id|nct_id|group_type|title|description
61978811|NCT04667663|EXPERIMENTAL|CPD-DARA|"Drug: Daratumumab Other Name: Darzalex~Drug: Cyclophosphamide~Drug: Pomalidomide Other Name: Pomalyst/ Imnovid~Drug: Dexamethasone"
61978812|NCT00969150|PLACEBO_COMPARATOR|2|Matching placebo capsules, oral administration, once daily dosing.
61978813|NCT00969150|EXPERIMENTAL|1|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing.
61978814|NCT04244279|EXPERIMENTAL|Intervention group|The intervention group will participate in a workshop regarding ergonomic principles in baby care. Finally, a brochure will be distributed summarizing the main contents of the workshop. One month and two months after the intervention, the intervention group will receive a videotaped reminder of the principles presented at the workshop via an email or WhatsApp message.
61978815|NCT04244279|NO_INTERVENTION|Control group|The control group will not receive any intervention during the data collection period. The intervention will be given three months after the beginning of the research, in the format of the brochure and videos sent via email or WhatsApp.
61978816|NCT05336955|EXPERIMENTAL|Telemental health START|Telemental health START will deliver two components via telephonic or other communication technology (e.g., Zoom). This includes component #2 (consultation and coping skills coaching) and component #4 (service linkages, referrals, outreach, \& training). START components #1 (intake and quarterly assessment) and #3 (24-hour urgent crisis response and intervention) will continue to be provided in-person.
61978817|NCT05336955|ACTIVE_COMPARATOR|In-person START|In-person START will deliver all model components in-person. This is the established model.
61978818|NCT04540757||Surgery|Surgery and systemic anti-cancer therapy (with or without radiotherapy) given in any order
61978819|NCT04540757||No surgery|Radiotherapy and systemic anti-cancer treatment given in any order (with or without adjuvant immunotherapy if indicated).
61978820|NCT03958799|EXPERIMENTAL|Group 1: Investigational Product (IP) Formulation A|IP Formulation A administration, participation in Stage 1 and Stage 2
61978821|NCT03958799|EXPERIMENTAL|Group 2: IP Formulation A|IP Formulation A administration, participation in Stage 1
61978822|NCT03958799|EXPERIMENTAL|Group 3: IP Formulation B|IP Formulation B administration, participation in Stage 1 and Stage 2
62359493|NCT05168176|EXPERIMENTAL|Dotilavir sodium tablet|
62359494|NCT05168176|ACTIVE_COMPARATOR|Dotilavir sodium tablet(Tivicay@)|
62739107|NCT06402526|EXPERIMENTAL|Mobile Epilepsy Education Package|"The Mobile Epilepsy Education Package (MEEP) consists of 2 parts. The first part entails the delivery of the MEEP education, and the second part consists of the Parental Monitoring Section. The intervention group will use MEEP for 4 weeks."
62739108|NCT06402526|OTHER|Standard care consisting of epilepsy education|Standard care consisting of epilepsy education and support offered at the study setting by members of the Pediatric Neurology Clinic was chosen as the comparator and serves as the control group.
62739109|NCT05076773|PLACEBO_COMPARATOR|Control Group (D)|Patient will receive opioid only for management of their perioperative pain
62739110|NCT05076773|ACTIVE_COMPARATOR|Paravertebral block Group (A)|Will receive thoracic paravertebral block
62739111|NCT05076773|ACTIVE_COMPARATOR|Pectoral block Group (B)|Will receive pectoral 1 and 2 block
62739112|NCT05076773|ACTIVE_COMPARATOR|Erector spinae block Group (C)|Will receive erector spinae block
62739113|NCT04636840|NO_INTERVENTION|Control Group|Access to a self-help version of Space From Body and Eating Concerns Program on SilverCloud Health App
62739114|NCT04636840|EXPERIMENTAL|Experimental Group A- Mobile App with Social Networking Feature|Access to a coached Space From Body and Eating Concerns program on SilverCloud Health App with private social media group for social networking support.
62739115|NCT04636840|EXPERIMENTAL|Experimental Group B- Mobile App Only|Access to a coached Space From Body and Eating Concerns program on SilverCloud Health App.
62739116|NCT00700882|EXPERIMENTAL|Dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62739117|NCT02572505|EXPERIMENTAL|HIV-Discordant Couple|A couple in which the man is HIV-seropositive and the woman is HIV-seronegative who wish to have a biologically related child. Couple will use condoms for all sexual acts except one act of unprotected intercourse during the fertile period when the woman will be taking the drug Truvada.
62739118|NCT01195376|EXPERIMENTAL|BEZ235 Dose Escalation once daily|oral BEZ235 once daily (q.d.)
62739119|NCT01195376|EXPERIMENTAL|BEZ Dose escalation twice daily|oral BEZ235 twice daily (b.i.d.)
62739120|NCT06515574|EXPERIMENTAL|Developmental care|In stage 1, participant in this arm will receive the developmental care
62739121|NCT06515574|NO_INTERVENTION|Usual care|Participant in this arm will receive the usual care
62739122|NCT02371460|EXPERIMENTAL|DHA-rich algal oil|1200mg DHA per day
62739123|NCT02371460|PLACEBO_COMPARATOR|Placebo|No supplementation in DHA
62739124|NCT03932773|SHAM_COMPARATOR|Sham rTMS + CPT|30 minutes of sham repetitive transcranial magnetic stimulation (rTMS) to the right dorsolateral prefrontal cortex (rDLPFC) prior to each Cognitive Processing Therapy (CPT) session
62739125|NCT03932773|ACTIVE_COMPARATOR|Active rTMS + CPT|30 minutes of 1 Hz rTMS to rDLPFC prior to each CPT session
62739126|NCT03932773|ACTIVE_COMPARATOR|Active rTMS Alone|30 minutes of 1 Hz rTMS to rDLPFC at 1 session per week over 12 weeks
62739127|NCT06370923|EXPERIMENTAL|Peer Distribution|In intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic.
62739128|NCT06370923|ACTIVE_COMPARATOR|Community Health Worker Distribution|This will be the Standard of Care, HIVST kits distributed by Community health workers in the Control clusters.
61978823|NCT03958799|EXPERIMENTAL|Group 4: IP Formulation B|IP Formulation B administration, participation in Stage 1
62359495|NCT06166888|EXPERIMENTAL|AK131|Subjects will receive AK131 via intravenously (IV) Q2W or Q3W, up to 2 years
62549902|NCT01867463|EXPERIMENTAL|Group 1|Group 1: n=20, randomized to receive 16 g Pfs25-EPA/Alhydrogel (n=10) or the comparator (EuvaxB, n=10) on D0, D56
62739129|NCT05538377|EXPERIMENTAL|Focal Vibration|
62739130|NCT05538377|ACTIVE_COMPARATOR|Control Group|
61978824|NCT03958799|EXPERIMENTAL|Group 5: IP Formulation C|IP Formulation C administration, participation in Stage 1 and Stage 2
61978825|NCT03958799|EXPERIMENTAL|Group 6: IP Formulation C|IP Formulation C administration, participation in Stage 1 and Stage 2
61978826|NCT03958799|EXPERIMENTAL|Group 7: IP Formulation D|IP Formulation D administration, participation in Stage 1 and Stage 2
61978827|NCT03958799|ACTIVE_COMPARATOR|Group 8: Tdap|TdaP administration, participation in Stage 1 and Stage 2
61978828|NCT03958799|ACTIVE_COMPARATOR|Group 9: Tdap|TdaP administration, participation in Stage 1
61978829|NCT01702454|EXPERIMENTAL|Fluarix Quadrivalent Primed Group|Subjects in this group were previously primed with 2 doses of Fluarix Quadrivalent vaccine in the primary study 115345 (NCT01439360) and received 1 dose of Fluarix Quadrivalent vaccine at Day 0 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.
61978830|NCT01702454|EXPERIMENTAL|Fluarix Quadrivalent Unprimed Group|Subjects in this group were unprimed in the primary study 115345 (NCT01439360) and received 2 doses of Fluarix Quadrivalent vaccine at Days 0 and 28 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.
61978831|NCT05163353|EXPERIMENTAL|Treatment with diluted Radiesse|Injection of Décolleté Wrinkles with diluted Radiesse
61978832|NCT05163353|OTHER|Delayed treatment with diluted Radiesse|Delayed injection of Décolleté Wrinkles with diluted Radiesse
61978833|NCT03012412|EXPERIMENTAL|Mindfulness Based Program for Infertility|"Behavioral: MBPI~The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 15 participants)."
61978834|NCT03012412|NO_INTERVENTION|Treatment As Usual (TAU)|Standard infertility medical treatment provided by IVF clinics (public and private) - no psychological intervention being pursued.
61978835|NCT00774150|EXPERIMENTAL|1. Cognitive Behavioral Therapy|
61978836|NCT00774150|ACTIVE_COMPARATOR|2. Client Centered Therapy|
61978837|NCT05725850|EXPERIMENTAL|EG (Experimental A. Oleracea extract gel)|The EG group received the application of experimental gel of A. Oleracea extract for post tooth bleaching sensitivity.
61978838|NCT05725850|PLACEBO_COMPARATOR|GP (Gel placebo)|The GP group received the application of a placebo gel.
62359496|NCT01153893|EXPERIMENTAL|Synflorix/Infanrix primed Group|Subjects previously primed with the Synflorix™ vaccine in the primary study 110521 (NCT00678301) received a booster dose of the Synflorix™ vaccine co-administered with a booster dose of the Infanrix™ vaccine at 15-21 months of age. Synflorix™ vaccine was administered intramuscularly in the right thigh or deltoid muscle of the arm. Infanrix™ vaccine was administered intramuscularly in the left thigh or deltoid muscle of the arm.
62549903|NCT01867463|EXPERIMENTAL|Group 2|Group 2: n=30, randomized to receive 47 g Pfs25-EPA/Alhydrogel (n=15) or the comparator (EuvaxB and Menactra , n=15) on D0, D56, D112, D480
61978839|NCT02786316|EXPERIMENTAL|intervention group|Hit program for the rehabilitation of persons with nonspecific chronic low backpain
61978840|NCT02786316|ACTIVE_COMPARATOR|Control group|a conventional rehabilitation program for persons with nonspecific chronic low backpain
61978841|NCT03643094|EXPERIMENTAL|Golden Black Seed|Golden Black Seed, 1 capsule per day for 8 weeks.
61978842|NCT01496547|EXPERIMENTAL|intensive chemo - RIC preparation|The intensive chemotherapy is composed of Fludarabine 35mg/m2 D1-5, high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
61978843|NCT03535870|EXPERIMENTAL|Fluticasone propionate/salmeterol|fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) twice a day by inhalation throughout the study
61978844|NCT03535870|ACTIVE_COMPARATOR|Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder|Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study
61978845|NCT03535870|PLACEBO_COMPARATOR|Placebo|placebo inhaled powder twice a day by inhalation throughout the study
61978846|NCT05625009|EXPERIMENTAL|Experimental: Transversus Abdominis Plane Block (TAPB)|patients received TAPB postoperatively
61978847|NCT05625009|EXPERIMENTAL|Experimental: Erector Spinae Plane Block (ESPB)|patients received ESPB postoperatively
61978848|NCT04804410|EXPERIMENTAL|Dielectric Properties of Tissue Samples from Thoracic Malignancies and Corresponding Normal Tissues|Our plan is to analyze 3-5 tissue probes acquired from 30 patients with a variety of thoracic malignancies. The investigators will plan to acquire tissue from each type of malignancy including: lung cancer, esophageal cancer and pleural based tumors. Tissue will be acquired in the operating room. Impedance measurements will be collected on multiple sections of excised tissue and will be translated into dielectric properties. After acquisition of data, the investigators will assess the data and continue to acquire patients to obtain significant estimates of overall tissue properties in each type of tumor. After undergoing an informed consent process in accordance with IRB approval, patients with be formally enrolled. All tumor electric property data will be stored securely and remain anonymous of patient identifying data.
61978849|NCT01341964|EXPERIMENTAL|Higher dose aspirin group|Clopidogrel 600 mg plus aspirin 325mg
62549904|NCT01867463|EXPERIMENTAL|Group 3|Group 3: n=70 randomized to receive 47 g Pfs25-EPA/Alhydrogel (n=35) or the comparator (EuvaxB and Menactra , n=35) on D0, D56, D112, D480
61978850|NCT01341964|ACTIVE_COMPARATOR|Low dose aspirin group|Clopidogrel 600mg plus aspirin 81mg
61978851|NCT03704454|EXPERIMENTAL|Group A - PYC & Placebo|50 mg of PYC for the first 4 weeks and then switch over to receive placebo for the following 4 weeks
62169184|NCT04634812|EXPERIMENTAL|[14C]-KBP-5074|
62549905|NCT01288404|PLACEBO_COMPARATOR|Control|topical 0.1% fluorometholone eye drops
62549906|NCT01288404|ACTIVE_COMPARATOR|Bevacizumab group 1|Bevacizumab 1.25 mg/0.05mL
62549907|NCT01288404|ACTIVE_COMPARATOR|Bevacizumab group 2|Bevacizumab 2.5 mg/0.1mL
62549908|NCT01288404|ACTIVE_COMPARATOR|bevacizumab group 3|bevacizumab 3.75 mg/0.15mL
61978852|NCT03704454|EXPERIMENTAL|Group B - PYC & Placebo|100 mg of PYC for the first 4 weeks and then switch over to receive placebo for the following 4 weeks
61978853|NCT03704454|EXPERIMENTAL|Group C - Placebo & PYC|Placebo for the first 4 weeks and then switch over to 50 mg PYC for the following 4 weeks
62359497|NCT01153893|EXPERIMENTAL|Synflorix/Infanrix unprimed Group|Unprimed subjects from the primary study 110521 (NCT00678301), not previously vaccinated with any pneumococcal vaccine, received a 2-dose catch-up vaccination of Synflorix™ vaccine at 15-21 and 17-23 months of age and a booster dose of Infanrix™ vaccine co-administered with the first dose of Synflorix™ vaccine at 15-21 months of age. Synflorix™ vaccine was administered intramuscularly in the right thigh or deltoid muscle of the arm. Infanrix™ vaccine was administered intramuscularly in the left thigh or deltoid muscle of the arm.
61978854|NCT03704454|EXPERIMENTAL|Group D - Placebo & PYC|Placebo for the first 4 weeks and then switch over to 100mg PYC for the following 4 weeks
62359498|NCT06508775|EXPERIMENTAL|Long-term follow-up of CAR T cell therapy|Assessment of long-term safety and efficacy of Miltenyi CAR T treatment.
62359499|NCT06297798|EXPERIMENTAL|Telerehabilitation Group|"In the telerehabilitation group, posture and stabilization exercises will be performed using Whatsapp and Zoom applications for 40 minutes, 5 days a week. Exercises will be applied for 10 weeks.~Posture and Stabilization Exercise Program:~1. Stretching of neck flexor, extensor, and lateral flexor muscles (30 seconds each)~2. Pectoral muscle stretching (30 seconds, 3 repetitions)~3. Isometric neck exercises (10 seconds, 10 repetitions)~4. Rhomboid strengthening exercise (bringing shoulder blades closer together against resistance using a TheraBand) (10 seconds, 10 repetitions)~5. Stretching of hamstring, lumbar lordosis and gastrocnemius muscles (sitting and standing) (30 seconds, 3 repetitions)~6. Pelvic posterior tilt exercise (10 seconds, 10 repetitions)~7. Bridge exercise (20 seconds, 10 repetitions)~8. Single-leg bridge exercise (Right-Left) (10 seconds, 10 repetitions)~9. Plank (starting with 60 seconds, increasing by 10 seconds each week)"
62359500|NCT06297798|NO_INTERVENTION|Control Group|The control group will not be given any exercise program; instead, general posture recommendations will be given.
61978855|NCT04533308|EXPERIMENTAL|VR intervention|Participants will have a session in VR for 20-30 minutes each working day. They can choose natural 360-degrees scenes from different locations in the world with or without interactions with animals. The equipment will include HTC Vive (HTC Corporation).
61978856|NCT04533308|NO_INTERVENTION|Control|Patients in the control group will not receive any psychological interventions.
62359501|NCT02268136|EXPERIMENTAL|BIII 890 CL|single increasing doses
62359502|NCT02268136|PLACEBO_COMPARATOR|Placebo|
62359503|NCT01022645||Levonorgestrel IUD|
62359504|NCT01022645||Copper IUD or Tubal Ligation|
62359505|NCT03916029|ACTIVE_COMPARATOR|Facilitator|120 hours training for local community members delivered on-country face-to-face during 6 4-day weeks and over a 3-6 month period. Certificate II modules in Aboriginal Primary Health Care, ear and hearing health skills development (otoscopy, tympanometry, and hearScreen) and employment as Ear Health Facilitators to the end of the trial.
62359506|NCT03916029|NO_INTERVENTION|Control|No Facilitator. Brief 6-monthly 2 to 3 hour in-service training via zoom for health professionals.
62359507|NCT05818384|EXPERIMENTAL|Wait List Control|Participants in the Wait List group will be randomly assigned to start the intervention 3 months later in the Summer.
62549909|NCT03475992|EXPERIMENTAL|Pre-diagnosed breast cancer|"Low-power microwave breast imaging system.~Core needle biopsy performed ≥14 days before the microwave breast investigation"
62549910|NCT03475992|EXPERIMENTAL|Pre-diagnosed breast cyst|"Low-power microwave breast imaging system.~No prior biopsy"
61978857|NCT02416440||screening for diabetes prevalence|blood samples
61978858|NCT06120816|EXPERIMENTAL|Nitric Oxide Releasing Mouthwash|Nitric Oxide Releasing Mouthwash (NORM) liquid producing NO at 266 ppm\*min in 20mL
61978859|NCT05376969|EXPERIMENTAL|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
62549911|NCT03475992|EXPERIMENTAL|Pre-diagnosed benign lesion|"Low-power microwave breast imaging system.~Core needle biopsy performed ≥14 days before the microwave breast investigation"
61978860|NCT02821481|EXPERIMENTAL|Beta-alanine and muscular endurance exercise|Receive 3.2 g/day beta-alanine and 3 days per week of endurance resistance training for 12 weeks
61978861|NCT02821481|EXPERIMENTAL|Beta-alanine without muscular endurance training|Receive 3.2 g/day beta-alanine with no endurance resistance training for 12 weeks
61978862|NCT02821481|PLACEBO_COMPARATOR|Placebo and muscular endurance exercise|Receive similar dextrose placebo and 3 days per week of endurance resistance training for 12 weeks
61978863|NCT02821481|PLACEBO_COMPARATOR|Placebo without muscular endurance training|Receive similar dextrose placebo with no endurance resistance training for 12 weeks
61978864|NCT05416320|EXPERIMENTAL|Calcipotriol Group|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
61978865|NCT05416320|SHAM_COMPARATOR|Control Group|Subjects will continue to use their primary physician prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
61978866|NCT03168308|ACTIVE_COMPARATOR|Neostigmine & Glycopyrrolate|Patients randomized to receive Neostigmine w/ Glycopyrrolate
61978867|NCT03168308|ACTIVE_COMPARATOR|Sugammadex|Patients randomized to receive Sugammadex
61978868|NCT03194555|EXPERIMENTAL|Low-Dose Naltrexone and Acetaminophen Combination|
62359508|NCT05818384|EXPERIMENTAL|Wakaya (Immediate Group)|Participants in the immediate group will be randomly assigned to start the intervention immediately in the Spring.
62359509|NCT05651841|EXPERIMENTAL|Placebo / Tezepelumab|"After 6-months of treatment, patients initially receiving placebo will switch to Tezepelumab for an additional 6 months.~For 6 months of treatment, six subcutaneous (injections in accessorized pre-filled syringes (APFS)) are performed every 4 weeks. Each subcutaneous injection corresponds to 210 mg of Tezepelumab or analogous placebo."
62359510|NCT05651841|EXPERIMENTAL|Tezepelumab / Tezepelumab|After 6-months of treatment, patients receiving Tezepelumab will continue Tezepelumab for an additional 6 months. For 6 months of treatment, six subcutaneous (injections in accessorized pre-filled syringes (APFS)) are performed every 4 weeks.Each subcutaneous injection corresponds to 210 mg of Tezepelumab.
62567048|NCT05008744||Patients presenting with TTTS|Pregnant persons between 16 and 36 weeks of pregnancy with a diagnosis of twin to twin transfusion syndrome
62567049|NCT01313897|EXPERIMENTAL|Velcade for Anti-MM therapy|Day(s) -9,-6,-2 3 doses of Bortezomib at 1.0 mg/m2, i.v.
61978869|NCT03194555|PLACEBO_COMPARATOR|Placebo|
61978870|NCT01040533||Failed / complicated jejunoileal bypass|
61978871|NCT00816231|EXPERIMENTAL|Alcohol and Nicotine Group|Alcohol and Nicotine Drug/Cue Interactions
61978872|NCT00816231|ACTIVE_COMPARATOR|Alcohol Only Group|Alcohol Only Drug/Cue Interactions
61978873|NCT00816231|ACTIVE_COMPARATOR|Nicotine Only Group|Nicotine Only Drug/Cue Interactions
61978874|NCT00816231|PLACEBO_COMPARATOR|Placebo and Placebo Group|Placebo Only Drug/Cue Interactions
62549912|NCT04634006|ACTIVE_COMPARATOR|active tDCS 1|Anodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the cathode will be placed over the the vertex (Cz), using square saline-soaked sponge pads 25 cm2. The current intensity of 1 mA will be used for 20 mins for a session. (N=25)
62549913|NCT04634006|ACTIVE_COMPARATOR|active tDCS 2|Anodal tDCS will be applied over the right IFG (1/3 of the distance between F8 and C6) according to the 10-20 EEG electrode systems and the cathode will be placed posterior to left mastoid, using square saline-soaked sponge pads 25 cm2. The current intensity of 1 mA will be used for 20 mins for a session. (N=25)
61978875|NCT06120920|ACTIVE_COMPARATOR|Conventional Physical Therapy and Routine Knee Exercises with Core Stability Exercises.|Patient will receive Conventional physical therapy include hot pack, Tens and routine knee strengthening exercises with core stability exercises.
62359511|NCT05651841|EXPERIMENTAL|Tezepelumab / Placebo|"After 6-months of treatment, patients receiving Tezepelumab will be switched to a placebo for an additional 6 months.~For 6 months of treatment, six subcutaneous (injections in accessorized pre-filled syringes (APFS)) are performed every 4 weeks. Each subcutaneous injection corresponds to 210 mg of Tezepelumab or analogous placebo."
61978876|NCT06120920|EXPERIMENTAL|Conventional Physical Therapy and Routine Knee Exercises with Hip Strengthening Exercises.|In this group, patient will receive conventional physical therapy include hot pack, Tens and routine knee exercises with hip strengthening exercises
61978877|NCT00909116||Chronic constipation - ODS|Adult Patients with ODS
62359512|NCT04466787|EXPERIMENTAL|Spectral Photon Counting Computed Tomography (SPCCT)|The randomized SPCCT patient will have this CT scan and an MRI before surgery. The plaque carotid will be collected for histological analysis
61978878|NCT03018509|EXPERIMENTAL|JTE-451 Dose 1|JTE-451 dose 1 for 28 days
61978879|NCT03018509|EXPERIMENTAL|JTE-451 Dose 2|JTE-451 dose 2 for 28 days
62359513|NCT04466787|ACTIVE_COMPARATOR|Dual Energy CT (DECT)|The randomized DECT patient will have this CT scan and an MRI before surgery. The plaque carotid will be collected for histological analysis
62359514|NCT01920438|EXPERIMENTAL|PEG|Percutaneous Endoscopic Gastrostomy
61978880|NCT03018509|EXPERIMENTAL|JTE-451 Dose 3|JTE-451 dose 3 for 28 days
61978881|NCT03018509|EXPERIMENTAL|JTE-451 Dose 4|JTE-451 dose 4 for 28 days
61978882|NCT03018509|EXPERIMENTAL|Placebo|Placebo for 28 days
61978883|NCT06443970|EXPERIMENTAL|Exsalta Device suctioning|
61978884|NCT06443970|ACTIVE_COMPARATOR|Coventional wall suctioning|
61978885|NCT02743650|EXPERIMENTAL|Sodium Bicarbonate|"All participants will receive oral sodium bicarbonate for 6 weeks (On-treatment period). After the 6 week visit, participants will stop taking sodium bicarbonate and return for a final visit 4 weeks later (Off-treatment period).~The initial dose of sodium bicarbonate prescribed is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d. Half the dose will be taken by mouth in the morning and the other half in the evening."
61978886|NCT02201186|EXPERIMENTAL|manuka honey enema treatment|Study patients diagnosed with acute pouchitis after bowel surgery for ulcerative colitis will perform manuka honey enemas twice a day for 30 days.
61978887|NCT01396707|EXPERIMENTAL|Herceptin+XELOX|
61978888|NCT00362115|EXPERIMENTAL|Azilsartan Medoxomil 5 mg QD|
61978889|NCT00362115|EXPERIMENTAL|Azilsartan Medoxomil 10 mg QD|
61978890|NCT00362115|EXPERIMENTAL|Azilsartan Medoxomil 20 mg QD|
61978891|NCT00362115|EXPERIMENTAL|Azilsartan Medoxomil 40 mg QD|
61978892|NCT00362115|EXPERIMENTAL|Azilsartan Medoxomil 80 mg QD|
61978893|NCT00362115|ACTIVE_COMPARATOR|Olmesartan 20 mg QD|
61978894|NCT00362115|PLACEBO_COMPARATOR|Placebo QD|
61978895|NCT01905384|ACTIVE_COMPARATOR|U-SEMS group|Patients undergoing routine care ERCP and randomized to 10 mm diameter Uncovered Self-expanding metal biliary stents (U-SEMS) (Wallflex, Boston Scientific).
61978896|NCT01905384|ACTIVE_COMPARATOR|C-SEMS Group|Patients undergoing routine care ERCP and randomized to a 10 mm diameter Covered Self-Expanding metal biliary stents (C-SEMS) (Wallflex, Boston Scientific)
61978897|NCT03415750|EXPERIMENTAL|Everolimus arm|Patients will be converted from Tacrolimus + Mycophenolate mofetil to Everolimus + Tacrolimus 'Conversion from Mycophenolate mofetil to Everolimus'
61978898|NCT03415750|ACTIVE_COMPARATOR|Mycophenolate arm|Patients will remain in Tacrolimus + Mycophenolate mofetil combination
61978899|NCT02904512|ACTIVE_COMPARATOR|Continuous glucose Monitoring and Point of Care blood glucose|Hospitalized patients with Diabetes Mellitus type 2 (DM2) managed with Continuous glucose monitoring (CGM) and Point of Care (POC) Finger sticks blood glucose
61978900|NCT02904512|PLACEBO_COMPARATOR|Point of Care (POC) blood glucose|Hospitalized Diabetes Mellitus type 2 (DM2) patients managed with Point of Care (POC) blood glucose only
62359515|NCT01920438|EXPERIMENTAL|RIG|Radiologically-guided Insertion of Gastrostomy
62359516|NCT05103241|EXPERIMENTAL|[14C]GP681|Subject will receive single dose of orally \[14C\] GP681 .
62359517|NCT03949621|ACTIVE_COMPARATOR|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
62359518|NCT03949621|EXPERIMENTAL|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
62359519|NCT03636308|EXPERIMENTAL|AS：Nanoparticle albumin-bound paclitaxel，S-1|"Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle.~S-1 is orally administered (BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle."
62567050|NCT04608396|EXPERIMENTAL|AXS-05|
62567051|NCT04608396|PLACEBO_COMPARATOR|Placebo|
62567052|NCT00529087|PLACEBO_COMPARATOR|1|
61978901|NCT00514033||Group A|PoliorixTM will be administered according to a 3-dose schedule at 2, 4, 6 months for primary vaccination followed by a booster dose between 4 to 6 years. For the primary vaccination course, 1 to 3 doses of the vaccine will be given depending on previous vaccination history with poliomyelitis vaccine.
61978902|NCT00806325||AML|Adult patients with AML admitted for treatment of the same
61978903|NCT02499250|EXPERIMENTAL|RIPC arm|The subjects will be interviewed and have their baseline frequency and severity of angina pectoris recorded, then they will receive daily remote ischemic conditioning plus optimal medical treatment over 30 days.
61978904|NCT02499250|ACTIVE_COMPARATOR|Control arm|The subjects will be interviewed and have their baseline frequency and severity of angina pectoris recorded, then they will receive optimal medical treatment over 30 days.
61978905|NCT01822405|ACTIVE_COMPARATOR|Pentoxifylline + Tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Tocopherol 1000 mg/day oral during 6 months
61978906|NCT01822405|EXPERIMENTAL|pentoxifylline + tocopherol + Hyperbaric Oxygen Therapy|
61978907|NCT05692765|NO_INTERVENTION|Control group|Adolescents in the control group were not exposed to the smartphone application and did not receive any advice to promote their F\&V consumption, which may have affected their F\&V consumption. Instead, they were only asked to complete the pre- and post-questionnaires.
61978908|NCT05692765|EXPERIMENTAL|Intervention group|Adolescents in the intervention group were divided into 11 smaller groups, each containing five participants to explain the application. The researcher provided a brief presentation about the health benefits and appropriate serving sizes of F\&Vs and explained how to use the smartphone application. An instructional brochure was provided in Arabic to all adolescents in the intervention group. The research team was available to assist participants at any time during the study period. After choosing six goals (three for fruit and three for vegetables), the participants were required to mark the goal that they chose daily and were requested to adhere to their chosen goals until the end of the study. The intervention period was 6 weeks.
61978909|NCT05670366|OTHER|Physically active participants|There is only one study arm, namely all participants are subjected to the same interventions.
61978910|NCT05133947||CIPN patient|Patient with CIPN symptom
61978911|NCT05133947||Healthy subject|Healthy subject
62359520|NCT03636308|ACTIVE_COMPARATOR|AG：Nanoparticle albumin-bound paclitaxel，Gemcitabine|"Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 and 8 of each 21 day cycle.~Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21 day cycle."
61978912|NCT03892109|ACTIVE_COMPARATOR|Gingitrac|The gingitrac cartridge was attached to the automixing gun and then the mixing syringe with intraoral tip was placed into the gingival sulcus and gingival retraction material was applied all around the selected abutment. After injecting the retraction material ,the corresponding comprecap was placed on to the abutment to push the material deep into the gingival sulcus. After 4 min, the comprecap with the set retraction material attached to it was removed from the patient mouth.
61978913|NCT03892109|ACTIVE_COMPARATOR|traxodent|The traxodent cartridge was attached to the automixing gun and then the mixing syringe with intraoral tip was placed into the gingival sulcus and gingival retraction material was applied all around the tooth. After injecting the retraction material ,the corresponding comprecap was placed on to the abutment to push the material deep into the gingival sulcus. After 4 min, the comprecap with the set retraction material attached to it was removed from the patient mouth.
61978914|NCT03892109|EXPERIMENTAL|Ultrapk cord|the cord packed into the gingival sulcus around the tooth
62359521|NCT05970978|EXPERIMENTAL|Response to previous biologic therapy|Participants with sPGA0 or 1 score and the body surface area affected with psoriasis lesions \<3% at baseline; or PASI-75 was achieved after treated with the previous biologics. 200mg of IBI112 will be administered subcutaneously at week 0, 12, 24 and 36.
62359522|NCT05970978|EXPERIMENTAL|Poor response to previous biologic therapy|Participants with sPGA score ≥2 at baseline, or body surface area affected with psoriasis lesions ≥3% at baseline, o PASI-75 was not reached after treated with previous biologics. 200mg of IBI112 will be administered subcutaneously at week 0, 4, 8, 20 and 32.
61978915|NCT03892109|PLACEBO_COMPARATOR|nocord|used directly in the tray
61978916|NCT00965588|EXPERIMENTAL|Vaccine (UB 311)|
61978917|NCT04861155|EXPERIMENTAL|Intervention Arm|The experimental intervention uses the SIVA-P3 system, the prototype of a digital solution aiming to support the diagnostic process in cases of chronic cough. The SIVA-P3 system primarily consists of a wearable audio and movement recorder and a smartphone app for the patient.
62391367|NCT04495166|ACTIVE_COMPARATOR|Educational app (Active control)|Participants in this arm will have access to a psychoeducational app (active control) which delivers content about gestation, maternal health and mental health, and child development. In addition, they will undergo will undergo brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation.
62549914|NCT04634006|SHAM_COMPARATOR|sham tDCS|Anodal tDCS will be applied over the left DLPFC (N=13) or right IFG (N=12) according to the 10-20 EEG electrode systems and the cathode will be placed over vertex or posterior to left mastoid, respectively, using square saline-soaked sponge pads 25 cm2. Sham stimulation will be maintained for 19 min without current flow by increasing current for 30 s followed by a decrease for 30 s.
62567053|NCT00529087|EXPERIMENTAL|2|
62567054|NCT00529087|EXPERIMENTAL|3|
61978918|NCT00825045|EXPERIMENTAL|Treatment with risperidone|Gradual titration of risperidone according to clinical response
61978919|NCT01951742|PLACEBO_COMPARATOR|Vehicle|vehicle without ANT-1401
61978920|NCT01951742|EXPERIMENTAL|Dose 1|lowest dose
61978921|NCT01951742|EXPERIMENTAL|Dose 2|second lowest dose
61978922|NCT01951742|EXPERIMENTAL|Dose 3|mid-level dose
61978923|NCT01951742|EXPERIMENTAL|Dose 4|second highest dose
61978924|NCT01951742|EXPERIMENTAL|Dose 5|highest dose
61978925|NCT05081011|EXPERIMENTAL|Voice Assistant Device|Subjects have their insulin titrated by a voice assistant device for 8 weeks. The Voice Assistant Device software algorithm is used to provide daily insulin dose and titration instructions.
61978926|NCT05081011|ACTIVE_COMPARATOR|Control|Subjects have their insulin titrated via standard of care for 8 weeks. The Voice Assistant Device is limited to providing a daily reminder to take medication.
61978927|NCT00362908|ACTIVE_COMPARATOR|Group 1|"Subjects consume study diets in the following order:~1. Diet 1 (20% fat diet) for 1 month with all food provided,~2. American Heart Association Step I Diet for 1 month at home, and~3. Diet 2 (40% fat diet) for 1 month with all food provided and then continue to follow this diet for an additional 4 months at home."
61978928|NCT00362908|ACTIVE_COMPARATOR|Group 2|"Subjects consume study diets in the following order:~1. Diet 2 (40% fat diet) for 1 month with all food provided,~2. American Heart Association Step I Diet for 1 month at home, and~3. Diet 1 (20% fat diet) for 1 month with all food provided and then continue to follow this diet for an additional 4 months at home."
61978929|NCT02041403||Renal resistive Index|
61978930|NCT01053364|EXPERIMENTAL|Implant|
61978931|NCT03992157|EXPERIMENTAL|holter-ECG|Implementation of an ECG Holter during hospitalisation patient.
62359523|NCT02620735|ACTIVE_COMPARATOR|Exercise Only|Participants receive 12-weeks PA training (1x/week - 60 min) group sessions with a CEP/RKin, and a progressively structured home-based exercise program based on the American College of Sports Medicine (ACSM) guidelines.It combines aerobic-resistance exercise with flexibility training, and progresses towards increased in intensity and improved fitness. The goal is at least 150 min/week of moderate-intensity aerobic activity. Participants are also asked to complete 3-5 additional home-based sessions of aerobic, and resistance activities each week. Initial intensity is based on the performance of the exercises during a group session and is self-monitored via the 10-point rating of perceived exertion, with a prescribed training zone of 4-7.
62391368|NCT02062385|EXPERIMENTAL|V260 with staggered EPI|V260 administered as a 2 mL oral solution at age \~2, 3, and 4 months, and staggered China Expanded Program on Immunizations (EPI) as follows: Oral poliovirus vaccine (OPV) administered as a 1 g oral solution at age \~2.5, 3.5, and 4.5 months, and diphtheria, tetanus, acellular pertussis vaccine (DTaP) administered as a 0.5 mL intramuscular injection at age \~3.5, 4.5, and 5.5 months
62739131|NCT06405438||Peloid therapy group|Patients in this group have already received peloid therapy for their carpal tunnel syndrome. Peloid therapy involves the application of natural mud, typically rich in minerals, to the affected area. The sessions will also last approximately 20-30 minutes per day, administered consecutively for 5 days a week, totaling 10 sessions for 2 weeks.
61978932|NCT03992157|NO_INTERVENTION|Crontrole|No implementation of an ECG Holter
61978933|NCT05611047|EXPERIMENTAL|Active cognitive rehabilitation|
61978934|NCT05611047|ACTIVE_COMPARATOR|Sham cognitive rehabilitation|
61978935|NCT04051047|EXPERIMENTAL|Gemcitabine|Gemcitabine will be given at 2100 mg/m2 IV over 30 minutes within 4 hours of planned surgical procedure. The surgical procedure is standard of care.
61978936|NCT04896320|EXPERIMENTAL|Gemcitabine + Tucatinib + Trastuzumab|Gemcitabine (1000 mg/m2) will be administered intravenously on Days 1 and 8 of each 21-day cycle. The investigational study drug (tucatinib) will be administered as 300mg by mouth taken twice a day of every day in each cycle. Trastuzumab will be administered per package insert on Day 1 of each cycle.
61978937|NCT04896320|EXPERIMENTAL|Vinorelbine + Tucatinib + Trastuzumab|Vinorelbine (25 mg/m2) will be administered intravenously on Days 1 and 8 of each 21-day cycle. The investigational study drug (tucatinib) will be administered as 300mg by mouth taken twice a day of every day in each cycle. Trastuzumab will be administered per package insert on Day 1 of each cycle.
61978938|NCT02968251|EXPERIMENTAL|Hand Washing Program (HWP)|Clusters in this arm will be given a Hand Washing Program (HWP) which will consist of: integrating hand washing practice in the school health policy, setting up proper hand washing facilities in the intervention schools, training to school teachers, delivering of health talk to schoolchildren and their parents, developing reminders and posters of a simplified 5-step hand washing technique, peer briefing session, take home package (5-steps hand washing, commitment letter, poster, leaflet). The program will be delivered once every week.
61978939|NCT02968251|NO_INTERVENTION|No Hand Washing Program (NHWP)|Clusters in this arm will be allowed to continue with their usual practice regarding hand washing/hygiene
61978940|NCT05016973|EXPERIMENTAL|RC48-ADC+ Triplizumab|RC48-ADC on days 1 every 21 days plus triplizumab on days 1 every 21 days
61978941|NCT03641144|EXPERIMENTAL|Navigation laser|Navigation laser photocoagulation treatment to the macular area of retinal thickening with a focal pattern and/or grid pattern
61978942|NCT03641144|ACTIVE_COMPARATOR|Traditional laser|Traditional laser photocoagulation treatment to the macular area of retinal thickening with a focal pattern and/or grid pattern
61978943|NCT04138329|ACTIVE_COMPARATOR|Lichtenstein Technique|In this arm the inguinal hernia repair was made with the Lichtenstein technique by surgeons with experience in this kind of plasty using the conventional polypropylene mesh.
61978944|NCT04138329|EXPERIMENTAL|Onstep Technique|In this arm the inguinal hernia repair was made with the Onstep technique by one surgeon with experience using the Bard's 3DMAX mesh.
61978945|NCT04382573||CDK13|CDK13 intragenic pathogenic variant
61978946|NCT04461171|EXPERIMENTAL|ERAS|Administration of a perioperative non-narcotic, multimodal pain management pathway.
61978947|NCT04461171|NO_INTERVENTION|Non-ERAS (Conventional)|Administration of a conventional perioperative pain management pathway that consists of both narcotic and non-narcotic pain medications.
62169185|NCT06647264||experimental group|Group according to the characteristics of different cases (for example), collect the basic information of all included patients and clinical case data, and make descriptive statistical analysis: the basic information of patients, operation methods, operation time, etc
62739132|NCT06405438||Paraffin treatment group|In this group, patients have already received paraffin treatment for their carpal tunnel syndrome. Paraffin treatment involves immersing the affected hand or hands in a mixture of heated paraffin wax. The sessions will last approximately 20-30 minutes per day, 5 days a week, for a total of 15 sessions for 3 weeks.
62549915|NCT06499324|EXPERIMENTAL|BTA group|"This arm corresponds to patients presenting with midline anterior primary or recurrent IH (subxiphoidal to suprapubic) of width \>= 10 cm, without loss of domain, scheduled for IH repair with mesh.~Patients will be injected with 288 IU of BTA (XEOMIN® 100U) into the lateral muscles (18 injection sites, 16UI/8mL/injection site), 4 to 6 weeks before the treatment of the IH."
61978948|NCT03007381|EXPERIMENTAL|Ketorolac tromethamine|Each patient will undergo mastectomy(ies) if immediate reconstruction is being performed, followed by uni- or bilateral abdominally based free flap harvest, microsurgical anastomoses, and flap inset. If randomized to the ketorolac intervention group, then the participant will receive 30 mg of intravenous (IV) ketorolac tromethamine. The anaesthetist will give participants their first study drug intravenously at the conclusion of surgery. The participant will then continue to receive their assigned drug every 6 hours for 72 hours, for a total of 13 doses. Patients all receive 1:1 care from nursing staff in the early postoperative period, and their nurse will administer all drugs given on the surgical ward.
61978949|NCT03007381|SHAM_COMPARATOR|Normal Saline|Each patient will undergo mastectomy(ies) if immediate reconstruction is being performed, followed by uni- or bilateral abdominally based free flap harvest, microsurgical anastomoses, and flap inset. If randomized to the control group the patient will be given a sham IV medication. The sham medication will be normal saline at the same volume as ketorolac, which corresponds to 3 ccs. The anaesthetist will give participants their first study drug intravenously at the conclusion of surgery. The participant will then continue to receive their assigned drug every 6 hours for 72 hours, for a total of 13 doses. Patients all receive 1:1 care from nursing staff in the early postoperative period, and their nurse will administer all drugs given on the surgical ward.
61978950|NCT01843764||children with malaria|Tanzanian children between 6-59 months with an uncomplicated P.falciparum monoinfection, followed after arthemeter-lumefantrine treatment according to national treatment guidelines
61978951|NCT04813094|EXPERIMENTAL|Internet-Based integrated-management Program|The Internet-based integrated management Program system have five domains that included patient's information collection, AF knowledge area, instructions on anticoagulation medicine, self-monitoring of symptom area, and professional consultation. Participants will have their own account and passwords to log in to the system via mobile phones or computers. Everyone will have their own area to ensure the privacy of participants. The research nurse will have sent messages every day to care about the participant's condition.
61978952|NCT04813094|ACTIVE_COMPARATOR|Control group|Patients in the control group will receive standard nurse consultations and three-time telephone coaching.
61978953|NCT04210310|EXPERIMENTAL|high-dose intranasal oxytocin|Subjects will be asked to use one spray in one nostril 4 times daily (9AM, 1PM, 5PM and 9 PM). Subjects will take 4 sprays daily of oxytocin for the entire study.
61978954|NCT04210310|PLACEBO_COMPARATOR|Nasal spray|Subjects swill be asked to use one spray in one nostril 4 times daily (9AM, 1PM, 5PM and 9 PM). The spray can be taken with or without food. Subjects will take 4 sprays daily of the placebo for the entire study.
61978955|NCT06476457|EXPERIMENTAL|Facilitated STAIR Coach|STAIR (Skills Training in Affective and Interpersonal Regulation ) Coach is a brief, low-intensity mobile-based intervention targeting difficulties in affective and interpersonal regulation. STAIR Coach participants will complete 10 interventions modules. Every two week, the participant will meet with a facilitator to review the module materials.
61978956|NCT01737515||Main group|Consecutive patients undergoing colorectal surgery for benign or malignant colorectal disease without any diversion from the standard of care
61978957|NCT01374412||osteoporosis|patients with benign osteoporosis
61978958|NCT01457066|EXPERIMENTAL|Intervention|This group will receive the peer navigator intervention.
61978959|NCT01457066|NO_INTERVENTION|Control|This group will receive usual care.
61978960|NCT02567955|ACTIVE_COMPARATOR|Immunogenicity two doses of Gardasil-9|Subjects will receive two doses of Gardasil-9
61978961|NCT02567955|EXPERIMENTAL|Immunogenicity Cervarix and Gardasil-9|Subjects will receive a dose Cervarix and a dose Gardasil-9
61978962|NCT01712607|EXPERIMENTAL|Warm-Up|Surgery after warm-up task Preoperative Warm-Up training
61978963|NCT01712607|NO_INTERVENTION|No Warm-up|Surgery without warm-up exercise
61978964|NCT01069107|ACTIVE_COMPARATOR|Consume of health services|One year follow-up of patients randomized to two different levels of health care
61978965|NCT03954951|NO_INTERVENTION|Control group|The clinicians in the control group will continue usual care without intervention. They will not receive the online course or performance feedback reports.
61978966|NCT03954951|ACTIVE_COMPARATOR|Intervention group|The primary care physicians will receive access to an online course on hypertension management based on the ACC/AHA and ESC guidelines. They will also receive feedback reports on their performance on hypertension management for 16 weeks.
61978967|NCT01973647|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT-I)|Six weekly sessions of Cognitive Behavioral Therapy for Insomnia
61978968|NCT01973647|EXPERIMENTAL|CBT-I + COPD-ED|Six weekly sessions of Cognitive Behavioral Therapy for Insomnia plus COPD Education
61978969|NCT01973647|EXPERIMENTAL|COPD Education (COPD-ED)|Six weekly sessions of COPD education
61978970|NCT01973647|PLACEBO_COMPARATOR|Attention Control (AC)|Six weekly sessions of non-sleep, non-COPD health education
62549916|NCT06499324|PLACEBO_COMPARATOR|Placebo group|"This arm corresponds to patients presenting with midline anterior primary or recurrent IH (subxiphoidal to suprapubic) of width \>= 10 cm, without loss of domain, scheduled for IH repair with mesh.~Patients will be injected with placebo of BTA (XEOMIN® 100U matching placebo) into the lateral muscles (18 injection sites, 8mL/injection site), 4 to 6 weeks before the treatment of the IH."
61978971|NCT02845245|ACTIVE_COMPARATOR|Standard of Care|Standard of care imaging techniques (3D CT scan and plain film radiographs) will be obtained for the surgeon to pre-operatively plan the surgery.
61978972|NCT02845245|EXPERIMENTAL|Intervention|A 3D printed plastic model prototype will be developed for the surgeon to use, in addition to the standard of care imaging techniques (3D CT scan and plain film radiographs), to pre-operatively plan the surgery.
61978973|NCT02057198|ACTIVE_COMPARATOR|Fidaxomicin|200 mg. 2 times a day for 10 days
61978974|NCT02057198|ACTIVE_COMPARATOR|Metronidazole|500 mg.orally 3 times daily for 10 days
61978975|NCT02057198|ACTIVE_COMPARATOR|Vancomycin|125 mg. orally 4 times a day for 10 days
61978976|NCT02988921|EXPERIMENTAL|Esophageal or esophagogastric cancer|
61978977|NCT05989789|OTHER|Radioactive seed-guided resection of cholangiocellular carcinoma in cirrhotic patients|"Detection of cholangiocellular and hepatocellular carcinomas can be challenging in both radiologic imaging and during surgical resection. Therefore, radioactive seed-guided resection of these tumors, analogously to breast cancer, could be an interesting approach.~This report emphasizes the difficulties, which surgeons and radiologists may face in tumor entities that are difficult to identify both macroscopically, by palpation and intraoperative imaging techniques. It also highlights the successful adaption of a procedure commonly used for breast cancer surgery for liver surgery"
61978978|NCT04541056|EXPERIMENTAL|Goal Management Training (GMT)|"GMT will be administrated in a group-based format over 5 sessions (minimum three weeks between each session). Homework assignments between sessions are included. Following the fourth session, text messages reading Stop! (a key instruction in GMT) will be sent to all GMT participants every day to maximize adherence to training (approximately 12 per participant). Homework assignment will also include the logging of automatic thoughts and an examination of the relationship between situations, thoughts, and accompanying emotions."
61978979|NCT04541056|ACTIVE_COMPARATOR|Waitlist/Brain Health Workshop (BHW)|The adults participating in the control condition will approximately one year from waitlist, be offered a psycho-educative training program, the BHW, in groups aimed at providing a better understanding of cognitive sequelae after treatment for childhood ALL. BHW will be administrated in a group-based format over 5 sessions (minimum three weeks between each session). Homework assignments between sessions are included. Homework assignments between sessions are included.
61978980|NCT00778089|OTHER|Open Label Single Arm|All enrolled subjects will have a skin test composed of Bovine Collagen and Lidocaine.
61978981|NCT03578029|EXPERIMENTAL|RGN-137|It is formulated as a gel for topical administration.
62549917|NCT03511599|EXPERIMENTAL|D-Cycloserine|Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
61978982|NCT03578029|PLACEBO_COMPARATOR|Placebo|It is composed of the same excipients as RGN-137 formulation without the active ingredient.
61978983|NCT01326416|ACTIVE_COMPARATOR|S: Nutritional Supplementation alone|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g of L-Leucine and 9 g of L-arginine), to distribute during each of the 3 main meals.
61978984|NCT01326416|ACTIVE_COMPARATOR|A: Physical Reconditioning alone|Physical reconditioning sessions led by a trainer three times a week for 6 months.
61978985|NCT01326416|ACTIVE_COMPARATOR|AS: Physical Reconditioning + Nutritional Supplementation|Association for six months of a specific nutritional supplementation by 21 g of L-Leucine and 9 g of L-arginine per day (to distribute during each of the 3 main meals) and of physical reconditioning sessions three times a week.
61978986|NCT01326416|NO_INTERVENTION|C: Lifestyle counseling|Usual advice given in consultation on the need for a balanced diet and regular physical activity
61978987|NCT04888156||GAT IOP below 15 mmHg|Glaucoma patients with an IOP measured with GAT below 15 mmHg prior performance of self-tonometry with iCare Home
61978988|NCT04888156||GAT IOP equal or above 15 mmHg|Glaucoma patients with an IOP measured with GAT equal or above 15 mmHg prior performance of self-tonometry with iCare Home
61978989|NCT03834701|EXPERIMENTAL|EUS guided radiofrequency ablation|Radiofrequency ablation will be performed using a system that consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure.
61978990|NCT01248442|EXPERIMENTAL|Cholecalciferol|
61978991|NCT01248442|PLACEBO_COMPARATOR|Placebo|
61978992|NCT00954746||Follow-up|Subjects Previously Treated with AA4500
61978993|NCT01166178|EXPERIMENTAL|Zoledronic Acid|Participants received zoledronic acid infusion in addition to calcium and vitamin D
61978994|NCT01166178|PLACEBO_COMPARATOR|Placebo|Participants received placebo to zoledronic acid infusion in addition to calcium and vitamin D
61978995|NCT04830852||Recovery Group|Participants aged 21 years and younger and enrolled within 12 weeks after acute infection or positive test. These participants will attend study visits at baseline, every 3 months for the first 6 months, and subsequently every 6 months for a total of 3 years.
61978996|NCT04830852||Convalescent Group|Participants aged 21 years and younger and enrolled more than 12 weeks after acute infection or positive test. These participants will attend study visits at baseline and subsequently every 6 months for a total of 3 years.
61978997|NCT04830852||Healthy contacts|Individuals (aged ≤21 years) without a diagnosis of SARS-CoV-2 infection or current symptoms suggestive of COVID-19 will serve as a control group and will attend visits for evaluations and sample collection at baseline and every 12 months for a total of 3 years.
61978998|NCT04830852||Parents/guardians of participants|Parents or guardians of participants in all cohorts will also be enrolled for limited participation to complete questionnaires about how the family is impacted by the participant's health and SARS-CoV-2.
61978999|NCT03304574|NO_INTERVENTION|Control|Participants will complete the electronic health assessment only and will not receive integrated personalized feedback
61979000|NCT03304574|EXPERIMENTAL|Intervention|Participants will complete the electronic health assessment and will receive integrated personalized feedback
61979001|NCT01453114|EXPERIMENTAL|Psychotherapy|Cognitive Behavioral Therapy
61979002|NCT00829231|EXPERIMENTAL|Arm 1|
61979003|NCT00829231|EXPERIMENTAL|Arm 2|
61979004|NCT00829231|EXPERIMENTAL|Arm 3|
61979005|NCT00212030|ACTIVE_COMPARATOR|1|
61979006|NCT00212030|PLACEBO_COMPARATOR|2|
61979007|NCT05052385||ECP only (aGVHD patients)|Patients treated with ECP and other Standard Of Care treatments (SOC)
61979008|NCT05052385||ECP and Ruxolitinib (aGVHD patients)|Patients treated with ECP and Ruxolitinib
62567055|NCT02774941|ACTIVE_COMPARATOR|Control|Standard single patient-use small volume JN (AirLife™ Sidestream® High-Efficiency Nebulizer, CareFusion, Yorba Linda, CA)
61979009|NCT05052385||Ruxolitinib only (aGVHD patients)|Patients treated with Ruxolitinib and other Standard Of Care treatments (SOC)
61979010|NCT05052385||ECP only (cGVHD patients)|Patients treated with ECP and other Standard Of Care treatments (SOC)
62359524|NCT02620735|EXPERIMENTAL|Exercise + iMOVE|Participants will receive the same exercise program at the Exercise Only group + 1) one-on-one telephone-based counselling (10 x 30-minute telephone: weeks 1, 2, 3, 4, 5, 6, 8, and 12 (during the exercise program) and at weeks 20,28 (post-exercise program booster sessions)); 2) supportive software on smart-phone devices (the HealthCoach program), 3) use of Fit-bit and corresponding software. The iMOVE intervention was designed to enhance sustained behavior change. The theoretical constructs employed are based on promoting motivation and establishing: a) exercise self-efficacy, b) social support for exercise and c) positive exercise-induced feelings during the acute intervention (12 weeks) and post-exercise program period (6 months).
61979011|NCT05052385||ECP and treatment combination (cGVHD patients)|Patients treated with ECP and Ruxolitinib or Ibrutinib
62549918|NCT03511599|ACTIVE_COMPARATOR|Placebo|Participants will ingest a capsule identical to the study medication, however this capsule will contain a placebo.Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
62549919|NCT03280264|EXPERIMENTAL|KHK7580|oral administration
62359525|NCT06318221|EXPERIMENTAL|immunonutrition (intervention group)|Immunonutrition enteral products was given to the patients in the intervention group
62359526|NCT06318221|ACTIVE_COMPARATOR|standard (control group)|Standard enteral products was given to patients in the control group.
61979012|NCT05052385||Treatment combination only (cGVHD patients)|Patients treated with Ibrutinib and/or Ruxolitinib and other Standard Of Care treatments (SOC)
61979013|NCT03598192|EXPERIMENTAL|TAP group|"The TAP block is performed under the ultrasound guidance at four points: at subcostal and lateral abdominal wall at right-side and left-side.~Drug: ropivacaine 0.375% 40 ml (maximum dose \<= 3 mg/kg). Maintenance: ropivacaine 0.375% 8 ml/hour during 48 hours."
61979014|NCT03598192|EXPERIMENTAL|PVB group|The paravertebral block is performed under the ultrasound guidance at T7. Drug: ropivacaine 0.5% 20 ml (maximum dose \<= 3 mg/kg). Maintenance: ropivacaine 0.25% 8 ml/hour during 48 hours.
61979015|NCT00415103|EXPERIMENTAL|1|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days Palonosetrón: 0.25 mg iv every 48 horas starting day 1
62359527|NCT02918955|ACTIVE_COMPARATOR|Arm rA (randomized)|Concomitant chemo-radiotherapy with early salvage neck dissection if less than complete clinical response
62359528|NCT02918955|EXPERIMENTAL|Arm rB (randomized)|Up-front neck dissection followed by radiotherapy with concomitant chemotherapy based on the cT pN cM staging after surgery
62359529|NCT02918955|ACTIVE_COMPARATOR|Arm oA (non-randomized)|Concomitant chemo-radiotherapy with early salvage neck dissection if less than complete clinical response
62359530|NCT02918955|EXPERIMENTAL|Arm oB (non-randomized)|Up-front neck dissection followed by radiotherapy with concomitant chemotherapy based on the cT pN cM staging after surgery
62359531|NCT01817660|ACTIVE_COMPARATOR|Open Surgery|In this arm, patients randomized to open surgical repair of popliteal artery aneurysm (OPAR).
61979016|NCT00415103|ACTIVE_COMPARATOR|2|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment.
62739133|NCT04930861|EXPERIMENTAL|Covidir|Patient (adults aged ≥18 years) with mild or moderate COVID-19 and flu-symptoms onset within 72 hours prior to inclusion. Treatment begins at the hospital. On the 4th day, participants who are well will be discharged and continue treatment up to Day 10 at home. All participants will receive Codivir 20 mg SC 2 x daily.
61979017|NCT00468572|EXPERIMENTAL|1|Participants will receive treatment with affectionate writing
61979018|NCT00468572|ACTIVE_COMPARATOR|2|Participants will receive treatment with meaningless writing
61979019|NCT03715166|EXPERIMENTAL|Bumetanide/S95008|
61979020|NCT03715166|PLACEBO_COMPARATOR|Placebo|
62359532|NCT01817660|ACTIVE_COMPARATOR|Endovascular Surgical repair (EPAR)|In this arm, patients randomized to endovascular repair of popliteal artery aneurysm (EPAR).
62359533|NCT02178306|EXPERIMENTAL|Telmisartan|
62359534|NCT05895695|ACTIVE_COMPARATOR|1|evaluation of levator muscle resection on congenital ptosis
62359535|NCT05895695|ACTIVE_COMPARATOR|2|evaluation of levator muscle plication on congenital ptosis
62359536|NCT04583969|EXPERIMENTAL|Remdesivir + Lenzilumab|200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 600-mg IV lenzilumab infusion every 8 hours starting on Day 1 for a total of 3 doses. N=275.
62359537|NCT04583969|ACTIVE_COMPARATOR|Remdesivir + Placebo|200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 600-mg IV lenzilumab placebo infusion every 8 hours starting on Day 1 for a total of 3 doses. N=275.
62359538|NCT05246475|EXPERIMENTAL|PET-MRI|Simultaneous 18F-EF5 PET and DW-MRI
62359539|NCT05059704|EXPERIMENTAL|Circuit Class Training|Patients will participate in a total of 1.5hour/day for 8 weeks with a 1:3 (therapist to patient). The circuit will be divided into 5 specific stations, 5 to 10 minutes for warm-up tasks and 15 to 20 minutes on each station as tailored to the patient's activity level
62359540|NCT05059704|ACTIVE_COMPARATOR|Individual Task specific training|Patients will participate in a total of 1.5hour/day for 8 weeks with 1:1 (therapist to patient) ratio. During each session, all patients will perform 5 to 10 minutes warm-up tasks, then practiced the selected tasks for the rest of the time.
62359541|NCT04179019|EXPERIMENTAL|Amlodipine|Amlodipine (dose 10 mg, once daily)
62359542|NCT04848012|NO_INTERVENTION|Usual non-invasive ventilation|The usual therapy the participant is receiving via non-invasive ventilator.
61979021|NCT03113019|EXPERIMENTAL|Immunotherapy based on dendritic cells|Intravenous administration dendritic cell and activated mononuclear cells at least 3 times 20-30 million cells / injection
61979022|NCT01067456|NO_INTERVENTION|Dedicated CT arm|Subjects in this arm will continue to receive standard of care - that is the dedicated CT protocol to rule out either aortic dissection or acute coronary syndrome or pulmonary embolism.
61979023|NCT01067456|EXPERIMENTAL|Comprehensive Cardiothoracic CT arm|The intervention consisted in a change of the routine CT protocol (as in dedicated CT protocol) to a comprehensive cardiothoracic CT protocol which includes changes in contrast injection and coverage to enable evaluation of the presence of acute coronary syndrome/aortic dissection/pulmonary embolism in a single scan.
61979024|NCT05192551||Plenvu|A new type of low-volume bowel-prep recently approved and introduced in the Swedish market. The dose is 500 ml x 2, The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
61979025|NCT05192551||Laxabon|A standard high volume bowel-prep, used for a long time in Sweden. The dose is 2000 ml x 2. The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
61979026|NCT05192551||Vistaprep|A standard high volume bowel-prep, used for a long time in Sweden. The dose is 2000 ml x 2. The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
61979027|NCT05192551||Movprep|A standard median volume bowel-prep, used for a long time in Sweden. The dose is 1000 ml x 2. The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
61979028|NCT06320795|EXPERIMENTAL|Soundi|Soundi device compared to overnight polysomnography
62359543|NCT04848012|EXPERIMENTAL|Auto-titrating non-invasive ventilation|A novel auto-titrating non-invasive ventilator
62359544|NCT01697904|EXPERIMENTAL|Low Oxygen Strategy|"Resuscitation was initiated with room air (21% O2) for LOX infants. Supplemental oxygen was given if 1) the heart rate (HR) was less than 100 bpm after 30 seconds of effective ventilation, 2) the lower limits of goal saturations were not met. Targeted goal Pre-ductal saturations after birth were derived by approximation of the interquartile values for healthy term infants as reported by Kamlin et al and Dawson et al.FiO2 was increased or decreased by 10% in 30 second intervals as needed. If HR \< 60 bpm after 30 seconds of effective ventilation , FiO2 was increased to 100% until the heart rate was stabilized.~Targeted Pre-ductal SpO2 After birth~1. min 60%-65%~2. min 65%-70%~3. min 70%-75%~4. min 75%-80%~5. min 80%-85%~10 min 85%-94%"
62359545|NCT01697904|ACTIVE_COMPARATOR|Traditional Oxygen strategy ( TOX)|Resuscitation for TOX infants was started with 100% O2 and adjusted every 30 seconds by 10% to meet the target oxygen saturation range of 85-94%
61979029|NCT04495842|EXPERIMENTAL|Intervention|Participants receive an active essential oil blend to inhale for 15 minutes. The blend contains plant based oils sourced from flowers and citrus plants.
61979030|NCT04495842|PLACEBO_COMPARATOR|Control|Participants receive an inert comparison to inhale for 15 minutes.
61979031|NCT00861432|ACTIVE_COMPARATOR|additive homeopathic treatment|These patients receive additive homeopathic treatment during conventional cancer treatment.
61979032|NCT00861432|NO_INTERVENTION|no additive homeopathic treatment|These patients do not receive additive homeopathic treatment during conventional cancer treatment.
62359546|NCT03312361|EXPERIMENTAL|15% Oxygen|All participants will breath in 15% oxygen for 2 hours
61979033|NCT05821842|EXPERIMENTAL|Sonu Treatment Group|Patients will receive acoustic resonance therapy for 15 minutes, twice a day, for two weeks using Sonu.
61979034|NCT05821842|SHAM_COMPARATOR|Sham Control Group|Patients will receive non-resonant acoustic energy for 15 minutes, twice a day, for two weeks using Sonu.
61979035|NCT05331287|EXPERIMENTAL|snifing Position|Nasotracheal intubation via fiberoptic bronchoscope under snifing position.The snifing position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into Nasal cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB.
61979036|NCT05331287|EXPERIMENTAL|neutral position|Nasotracheal intubation via fiberoptic bronchoscope under snifing position.The Head Extension was obtained by the occiput of the patient close to the operating table. When the FOB was inserted into Nasal cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB.
62359547|NCT02784977||Obstructive Sleep Apnea (OSA)|Patients with apnea hypopnea index of at least 5 events per hour. Intervention with positive airway pressure, or intraoral device, or uvuloplasty, or conservative treatment.
62359548|NCT02784977||No-OSA|Patients with apnea hypopnea index less than 5 events per hour. No intervention.
62359549|NCT04737980|EXPERIMENTAL|Experimental Group: Interscalene block with liposomal bupivacaine combined with bupivacaine|Interscalene nerve block was performed utilizing ultrasound guidance with infiltration of 10 ml of liposomal bupivacaine 1.3% (133 mg) combined with 10 ml of 0.5% bupivacaine hydrochloride.
62359550|NCT04737980|ACTIVE_COMPARATOR|Control Group: Interscalene block with ropivacaine combined with dexamethasone|Interscalene nerve block was performed utilizing ultrasound guidance with infiltration of 30ml of 0.5% ropivacaine combined with a 2 ml volume of 8mg of dexamethasone.
62359551|NCT03819270|EXPERIMENTAL|LY3372689|Escalating doses of LY3372689 administered orally in healthy participants in two of three study periods
62359552|NCT03819270|PLACEBO_COMPARATOR|Placebo|Matching placebo administered orally in healthy participants in one of three study periods
61979037|NCT05331287|EXPERIMENTAL|Head Extension|Nasotracheal intubation via fiberoptic bronchoscope under snifing position.The extension position with a 7-cm pillow underneath the shoulder and the occiput close to the operating table. When the FOB was inserted into Nasal cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB.
61979038|NCT02442362|ACTIVE_COMPARATOR|TOF Group|"Patients in the TOF group received chemotherapy with paclitaxel+oxaliplatin+fluorouracil"
61979039|NCT02442362|EXPERIMENTAL|SOX Group|The patients in the SOX group received chemotherapy with 'oxaliplatin+S1'
61979040|NCT05399381|EXPERIMENTAL|Frontoparietal Slow Theta Stimulation|Participants will receive multi-electrode transcranial alternating current stimulation over the prefrontal and parietal brain regions that induces frontal-to-parietal traveling wave at the frequency of 4 Hz with the intensity of up to 2 mA and duration up to 20 min.
61979041|NCT05399381|EXPERIMENTAL|Frontoparietal Fast Theta Stimulation|Participants will receive multi-electrode transcranial alternating current stimulation over the prefrontal and parietal brain regions that induces frontal-to-parietal traveling wave at the frequency of 7 Hz with the intensity of up to 2 mA and duration up to 20 min.
61979042|NCT05399381|EXPERIMENTAL|Parietofrontal Slow Theta Stimulation|Participants will receive multi-electrode transcranial alternating current stimulation over the prefrontal and parietal brain regions that induces parietal-to-frontal traveling wave at the frequency of 4 Hz with the intensity of up to 2 mA and duration up to 20 min.
61979043|NCT05399381|EXPERIMENTAL|Parietofrontal Fast Theta Stimulation|Participants will receive multi-electrode transcranial alternating current stimulation over the prefrontal and parietal brain regions that induces parietal-to-frontal traveling wave at the frequency of 7 Hz with the intensity of up to 2 mA and duration up to 20 min.
61979044|NCT05252000|EXPERIMENTAL|mechanical debridement and adjunctive aPDT|
61979045|NCT05252000|ACTIVE_COMPARATOR|mechanical debridement and sham aPDT|
61979046|NCT04678154|ACTIVE_COMPARATOR|Control|Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
61979047|NCT04678154|EXPERIMENTAL|Treatment|The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
61979048|NCT01226446|EXPERIMENTAL|Addition of Vitamin D to Peg-interferon plus Ribavirin|
61979049|NCT03444714|EXPERIMENTAL|RiMO-301+Radiotherapy|3 dose levels (5%, 10%, and 15% of the total baseline tumor volume, respectively) will be tested in a 3 + 3 dose escalation study
61979050|NCT03781128|OTHER|LSD, Placebo|Lysergic acid diethylamide (3 x 100 µg LSD in three weeks, per os) followed by Placebo
61979051|NCT03781128|OTHER|Placebo, LSD|Placebo (3 x 1 vial looking like LSD in three weeks, per os) followed by Lysergic acid diethylamide
61979052|NCT04047433|EXPERIMENTAL|women with external anal sphincter injury|The study cohort will be composed of women undergoing vaginal delivery and diagnosed with external anal sphincter injury after a vaginal delivery.
62359553|NCT04378257|EXPERIMENTAL|Therapist Guided E-Therapy|"The participants in this group will be allocated weekly sessions with a trained aboard certified clinical psychologist via a web-based e-therapy platform. The sessions will be conducted in the Arabic or English languages.~Following sessions would focus on psychological first aid based on the following interventional tools:~Cognitive Behavior Therapy (CBT)~* Acknowledging emotions and normalizing current stress~* Differentiate dysfunction versus distress (identify any debilitating thoughts/emotions if applicable)~* Behavioral Activation Acceptance and Commitment Therapy (ACT)~* Grounding, Breathing, Acceptance of emotions, and de-fusion"
62359554|NCT04378257|ACTIVE_COMPARATOR|Self-Help Therapy|The participants in the control group will be supplied with an automatic weekly newsletter through E-mail containing self-help information and tips to cope with distress associated with COVID-19 in Oman. The information will mainly comprise of behavioral tips from principles of CBT and ACT focusing on positive cognitive reinforcement, strengthening relationships and mindfulness practice.
62359555|NCT00695513|EXPERIMENTAL|I|BENEO synergy1
62359556|NCT05034614|OTHER|Pap smears using the Papette|Papette brush used to collect a Pap smear sample as standard of care.
62359557|NCT05034614|OTHER|Pap smears using the traditional spatula/cytology brush|Spatula/cytology brush used to collect a Pap smear sample as standard of care.
62359558|NCT04445350|EXPERIMENTAL|External focus of attention training program|The intervention group receives a strength and neuromuscular training program. The training instructions have an external focus of attention.
61979053|NCT04047433|EXPERIMENTAL|women without external anal sphincter injury|The control group will be women who had a vaginal delivery without any clinically apparent perineal laceration
61979054|NCT06105151|EXPERIMENTAL|Part Ⅰ - Single Ascending Dose (SAD) study: Experimental|Subjects will receive VV119 orally for single dose.
61979055|NCT06105151|EXPERIMENTAL|Part Ⅰ - Single Ascending Dose (SAD) study: Placebo|Subjects will receive VV119 placebo orally for single dose.
61979056|NCT06105151|EXPERIMENTAL|Part Ⅱ - Food Effect (FE) study: Experimental|Subjects will receive VV119 orally for single dose.
61979057|NCT04998747|EXPERIMENTAL|AMG 701: dose exploration|Cohorts of 3 to 6 participants each will be administered AMG 701 at different doses to determine the RP2D based on occurence of dose-limiting toxicities (DLTs) and on emerging safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy data.
61979058|NCT04998747|EXPERIMENTAL|AMG 701: dose expansion|Participants will be administered AMG 701 at the RP2D determined from dose exploration stage to further assess the safety, PK, PD, and efficacy of the selected dose.
61979059|NCT03153228||Smokers of traditional cigarettes|29 healthy smokers of traditional cigarettes (min. 1 packyear)
61979060|NCT03153228||Smokers of e-cigarettes|29 healthy smokers of e-cigarettes (min. 1 packyear)
62359559|NCT04445350|ACTIVE_COMPARATOR|Internal focus of attention training program|The control group receives a strength and neuromuscular training program. The training instructions have an internal focus of attention.
62359560|NCT01248364|EXPERIMENTAL|BI 10773 Arm|BI 10773 high dose once daily
62359561|NCT00830804|EXPERIMENTAL|RAL + DRV/RTV|Raltegravir (400 mg BID) plus Darunavir/Ritonavir (800 mg/100 mg QD) for 52 weeks
61979061|NCT03153228||Control|29 healthy volunteers.
61979062|NCT05346341|EXPERIMENTAL|Minimally invasive techniques|
61979063|NCT04006249|OTHER|diagnostic test|
61979064|NCT03103919|ACTIVE_COMPARATOR|Rotigotine + Standard Care|Subjects will use the Kinesia-ONE™ wearable device in-clinic at Visit 1 and Visit 2 for recording of specific motor symptoms. The optimal dose of Neupro for any given subject will be determined by standard clinical practice.
61979065|NCT03103919|EXPERIMENTAL|Rotigotine + Standard Care + Kinesia-360™ wearable device|Subjects will use the Kinesia-ONE™ wearable device in-clinic at Visit 1 and Visit 2 for recording of specific motor symptoms, and additionally subjects will use the Kinesia-360™ wearable device at home while awake for continuous measurement of motor symptoms. The Investigator will use these symptom data to provide feedback to subjects on their motor symptoms and to supplement standard of care to titrate the optimal dose of Neupro for any given subject.
62359562|NCT04285372|EXPERIMENTAL|Test group|No intervention on the side branch in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
62359563|NCT04285372|ACTIVE_COMPARATOR|Control group|Side branch protection: Ballooning or Kissing Balloon Technique, in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
61979066|NCT01042327|EXPERIMENTAL|dialyzer comparison|"Stable chronic kidney dialysis patients, currently dialyzing on the main Royal Free hospital dialysis unit will be asked to participate in the study. It is aimed to recruit 15 patients currently dialysing using the Fresenius FX100 dialyzer, who have used Fresenius polysulphone membranes for \> 3 months.~During a mid week dialysis session, dialysis adequacy will be assessed by on line clearance, and samples of both blood and dialysate taken to assess, both clearances and bio-compatibility.~Thereafter patients would be switched to dialyse using the ELISIOTM-H dialyzer, but continue with the same dialysis prescription, and after 3 months, measurements repeated"
62549920|NCT06242080|ACTIVE_COMPARATOR|"MTIA intervention"|"The Mindfulness Training Instructor Administered (MTIA) intervention will incorporate the following elements: training in an 8-week, 90-minute per week, modified mindfulness program, which places additional emphasis on training which is feasible and relevant to race/ethnic groups, including: a) didactics on relevance to stress, coping and resilience, b) mindful compassion for self and others; c) mindful communication, including non-verbal mindfulness, mindful listening, and mindful speaking. The MTIA will be instructor led, internet-delivered (via Zoom), interactive, group-based mindfulness training intervention that will incorporate the training for approximately 9 persons in a group format, with outside-of session assignments."
61979067|NCT04506489||Psychological investigation|
61979068|NCT00350714|EXPERIMENTAL|MBT|C13 methacetin dissolved in water to be ingested after breath baseline collected. Metabolism to measured in real time.
61979069|NCT02100059|EXPERIMENTAL|Electrical Stimulation (TENS)|The TENS (transcutaneous electrical nerve stimulation) electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
61979070|NCT00276159|EXPERIMENTAL|852A Treatment|Patients receiving at least one dose of 852A.
61979071|NCT04864379|EXPERIMENTAL|RFA+PD-1+iNeo-Vac-P01|Patients will undergo radiofrequency ablation. At Week 3, patients will receive PD-1 at a dose of 200mg administered by intravenous infusion (IV) every 2 weeks. At Week 12,all patients,regardless of their disease status,iNeo-Vac-P01(300mcg per peptide)+ GM-CSF (40mcg) on days 1, 4, 8, 15, 22, 52, and 82 from week 12. Additional booster vaccines might be administered depending on ethics and patients' potential benefit.
61979072|NCT04864379|EXPERIMENTAL|RFA+iNeo-Vac-P01+PD-1|Patients will undergo radiofrequency ablation. At Week 12, patients will receive iNeo-Vac-P01(300mcg per peptide)+ GM-CSF (40mcg) on days 1, 4, 8, 15, 22, 52, and 82 from week 12. Additional booster vaccines might be administered depending on ethics and patients' potential benefit. At Week 16, patients,regard of their disease status,will receive PD-1 at a dose of 200mg administered by intravenous infusion (IV) every 2 weeks.
62567056|NCT02774941|EXPERIMENTAL|Study|Vibrating Mesh Nebulizer (Aerogen® Solo with Ultra adapter, Aerogen Ltd, Galway, Ireland)
62567057|NCT00449865|PLACEBO_COMPARATOR|Placebo|
61979073|NCT06235788|NO_INTERVENTION|Control Group Intelligent Continuous Expertise Monitoring System (ICEMS) only verbal feedback group|"43 participants. Individuals receive standard information. They perform 6 5-min practice scenario resections with a 5-min break between each one. The 7th attempt is the 13-min realistic scenario.~Participants receive no feedback during the first repetition. They will then receive feedback on 4 metrics, one metric a time: instrument tip separation, low bipolar force, high aspirator force, high bipolar force. Once an attempt is completed without receiving feedback, the next repetition will assess the next metric in the list above. During the 5-min break after an attempt is completed without receiving feedback, participants can watch an optional expert-level demonstration video corresponding to the next metric. Participants receive no feedback during the 6th repetition. They will have no feedback in their 7th repetition, the realistic scenario."
61979074|NCT06235788|EXPERIMENTAL|Experimental Group ICEMS verbal feedback with pause group|"43 participants. Individuals receive standard information. They perform 6 5-min practice scenario resections with a 5-min break between each one. The 7th attempt is the 13-min realistic scenario.~Participants receive no feedback during the first repetition. They will then receive feedback on 4 metrics, one metric a time: instrument tip separation, low bipolar force, high aspirator force, high bipolar force. Once an attempt is completed without receiving feedback, the next repetition will assess the next metric in the list above. During the 5-min break after an attempt is completed without receiving feedback, participants can watch an optional expert-level demonstration video corresponding to the next metric. Participants receive no feedback during the 6th repetition. They will have no feedback in their 7th repetition, the realistic scenario."
62169186|NCT03291899|EXPERIMENTAL|Experimental single arm|"Chemotherapy using the FOLFIRINOX regimen will be given every 2 weeks for a total of 12 cycles. FOLFIRINOX consist of:~1. Oxaliplatin-85 mg/m2 IV Day 1~2. Leucovorin-400 mg/m2 IV Day 1~3. Irinotecan-180 mg/m2 IV Day 1~4. Fluorouracil (FU)-400 mg/m2 IV bolus Day 1~5. Fluorouracil 2400 mg/m2 infused over 46 hours starting day 1"
62169187|NCT02065726|EXPERIMENTAL|Whey protein|Nutritional counseling + 20 g (2 x 10 g) of whey proteins (Prother® - Spepharm Italy)
62169188|NCT02065726|ACTIVE_COMPARATOR|Nutritional counseling|Nutritional counseling
62359564|NCT05972395||Localized CLBP|Chronic low back pain \>3 months with localized pressure pain hyperalgesia
62359565|NCT05972395||Widespread CLBP|Chronic low back pain \>3 months with widespread pressure pain hyperalgesia
62359566|NCT03872557|ACTIVE_COMPARATOR|Tyrosine (TYR) depletion, then oral TYR|"TYR supplementation: Subjects will be directed to avoid consumption of L-DOPA and TYR enriched foods for 48 hours before oral glucose tolerance test (OGTT). On the evening prior to OGTT, subjects will substitute normal meal and snack for three prepackaged tyrosine-phenylalanine-free liquid meals.~Visit 2. Placement of intravenous catheter for the collection of serial blood samples and an OGTT with supplementation with oral tyrosine supplement. To supplement the OGTT with Tyrosine, the contents of four (4) L-Tyrosine 500 mg capsule are given 45 minutes before the oral glucose solution is administered. The capsules are to be administered with less than eight ounces of water to minimize dilution of gastric acidity."
62567058|NCT00449865|ACTIVE_COMPARATOR|creatine|
62567059|NCT06471049|EXPERIMENTAL|Transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES)|
62567060|NCT06471049|ACTIVE_COMPARATOR|Conventional laparoscopy|
62567061|NCT06471049|ACTIVE_COMPARATOR|Robot-assisted laparoscopy|
62567062|NCT05428774|EXPERIMENTAL|Test Product 1|Participants will consume test product 1 during one experimental visit.
61979075|NCT06235788|EXPERIMENTAL|Experimental Group ICEMS verbal feedback with pause and expert-level video demonstration|"43 participants. Individuals receive standard information. They perform 6 5-min practice scenario resections with a 5-min break between each one. The 7th attempt is the 13-min realistic scenario.~Participants receive no feedback during the first repetition. They will then receive feedback on 4 metrics, one metric a time: instrument tip separation, low bipolar force, high aspirator force, high bipolar force. Once an attempt is completed without receiving feedback, the next repetition will assess the next metric in the list above. During the 5-min break after an attempt is completed without receiving feedback, participants can watch an optional expert-level demonstration video corresponding to the next metric. Participants receive no feedback during the 6th repetition. They will have no feedback in their 7th repetition, the realistic scenario."
61979076|NCT05870709||sacubitril/valsartan|patient with a first ambulatory sacubitril/valsartan prescription
61979077|NCT00866684|EXPERIMENTAL|1|Patients will receive Sirolimus in addition to their previous immunosuppressive therapy.
61979078|NCT00866684|ACTIVE_COMPARATOR|2|Patients will stay on their previous immunosuppressive regimen.
61979079|NCT03992820|EXPERIMENTAL|TENS arm (trial arm)|The trial group will have the TENS (transcutaneous electrical nerve stimulator) to the area planned for injection for at least 30 minutes before injection of the local anaesthetic solution.
61979080|NCT03992820|OTHER|EMLA arm (Control arm)|The control group will have EMLA (Eutatic mixture of local anaesthetic) applied on the site planned for local anaesthetic injection and after 1 hour, will be removed and immediately injected with the same anaesthetic solution.
61979081|NCT01425957|OTHER|MCI Patient with Lumbar puncture|PartB: Patients affected by amnestic Mild Cognitive Impairment (aMCI).
61979082|NCT03109301|EXPERIMENTAL|Arm 1|Patients \> 18 years of age
61979083|NCT03109301|EXPERIMENTAL|Arm 2|Patients \< 18 years of age
61979084|NCT06022380||Round 1|Participants will be asked to score each outcome domain on a 9 point scale proposed by the GRADE group \[http://www.gradeworkinggroup.org\], in which 1 to 3 signifies an outcome of 'limited importance', 4 to 6 'important but not critical', and 7 to 9 'critical'. Round 1 will also provide participants with the opportunity to add further outcomes which they think may be important. Any suggested outcomes deemed to represent a new outcome domain by the study group (following discussion within study advisory group and a majority decision) will be added to the list for consideration in round two. Round 1 will last for approximately 2 months.
61979085|NCT06022380||Round 2|All items (in addition to further new outcome domains identified by participants in round 1) will be carried forward for consideration in round 2. Descriptive statistics (graphs) will be used to summarize the scores from round 1 and presented to participants. Participants will see the results of their individual score for each outcome in addition to the median score of each stakeholder group. The rationale for showing participants the scores from other groups is that it may improve consensus between the stakeholder groups. In addition, by carrying all items forward from round 1, it may be possible to identify changes in scoring patterns as a result of viewing other scores. Participants will be asked to score all items once again using the 9-point scale. Round 2 will last for approximately 2 month
61979086|NCT02497950||HeartMate 3|This registry will include all patients that receive the HM3 LVAS in the post-market setting
61979087|NCT01142700|EXPERIMENTAL|BMS-824393 (10mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
61979088|NCT01142700|EXPERIMENTAL|BMS-824393 (30 mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
61979089|NCT01142700|EXPERIMENTAL|BMS-824393 (100 mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
61979090|NCT01142700|PLACEBO_COMPARATOR|Placebo|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
61979091|NCT01142700|OTHER|Peginterferon alfa-2a plus Ribavirin|Weeks 13 - 48
61979092|NCT01529840|EXPERIMENTAL|Low dose 33 mcg/kg/day|
61979093|NCT01529840|EXPERIMENTAL|High dose 66 mcg/kg/day|
61979094|NCT01036035|ACTIVE_COMPARATOR|Treatment B|Study drug
61979095|NCT01036035|ACTIVE_COMPARATOR|Treatment D|Study drug
62549921|NCT06242080|ACTIVE_COMPARATOR|"MAPP intervention"|"The MindfulnessAPP (MAPP) is a self-administered intervention developed by the SMILE study team. The MAPP is for individual use, with eight MAPP sessions composed of mindfulness exercises and didactics that correspond to the MTIA sessions. As the MTIA weekly class will be 90 minutes in length, the MAPP assignments will recommend spending approximately 90 minutes per week covering the assigned lesson, but in a flexible format convenient for the participant. In addition, each session will contain mindfulness-based practice assignments generally ranging from 10 to 30 minutes per day. The total number of suggested days for completion will be 49 days, comparable to the time from start to finish of a traditional 8 week MTIA session; however, there will be flexibility within this individualized program."
62549922|NCT06242080|NO_INTERVENTION|Wait-list Control|The Wait-list Control (WLC) group will participate in all research assessment sessions, but will not be offered the Mindfulness intervention until after their role in the research is complete.
61979096|NCT01036035|PLACEBO_COMPARATOR|Treatment E|Placebo
61979097|NCT01036035|ACTIVE_COMPARATOR|Treatment A|Study Drug
61979098|NCT01036035|ACTIVE_COMPARATOR|Treatment C|Study Drug
61979099|NCT05277701|EXPERIMENTAL|Lazertinib|
61979100|NCT05434182|EXPERIMENTAL|Intradermal Suture Group|Vascular surgery patients undergoing a femoral approach surgery and randomized to this group will have their skin closed with an intradermal suture using Monosyn® (Braun®) 4/0 absorbable monofilament.
61979101|NCT05434182|ACTIVE_COMPARATOR|Metallic Staples|Vascular surgery patients undergoing a femoral approach surgery and randomized to this group will have their skin closed with metallic stapling using Visistat® (Weck®) 35W skin stapler.
61979102|NCT04108520|EXPERIMENTAL|Intervention Group|Exercises on respiratory muscle, 3 times per week, 1 hour peer day
61979103|NCT02063009||patients scheduled for oncologic high-risk surgery|
61979104|NCT01829516|EXPERIMENTAL|Oxytocin|50 moderate to heavy social alcohol users will receive a single dose 40 IU of intranasal oxytocin.
61979105|NCT01829516|PLACEBO_COMPARATOR|Placebo|"50 moderate to heavy social alcohol users will receive a single dose 40 IU of intranasal placebo.~NOTE: This is a cross-over design and subjects will participate in both arms."
62169189|NCT00382408|EXPERIMENTAL|Vaccine|Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).
62359567|NCT03872557|NO_INTERVENTION|TYR depletion, then no oral TYR|"Subjects will be directed to avoid consumption of L-DOPA and TYR enriched foods for 48 hours before OGTT. On the evening prior to OGTT, subjects will substitute normal meal and snack for three prepackaged tyrosine-phenylalanine-free liquid meals.~Subsequent Visit 3. This visit will consist of placement of intravenous catheter for the collection of serial blood samples and an OGTT without supplementation with oral tyrosine supplement."
61979106|NCT03394092||STEMI|The study population consists of 50 patients with ST-elevated acute myocardial infarction (STEMI) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded. Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
61979107|NCT03394092||Control|50 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as control group.Quantitative changes of IgG glycosylation be measured only once on admission.
61979108|NCT02772081|EXPERIMENTAL|Curosurf LISA|"Single dose of poractant alfa 200 mg/kg via brief insertion of a thin catheter (CHF 6440) into the trachea in neonates with RDS.~A second surfactant dose at 100 mg/kg will be administered with the same technique as the first dosage administration if needed.~After the first and second surfactant administration, neonates could receive a third surfactant dose at 100 mg/kg through a standard technique if needed."
61979109|NCT02772081|ACTIVE_COMPARATOR|Curosurf Endotracheal Tube|"Single dose of poractant alfa 200 mg/kg via the conventional intubation with endotracheal tube in neonates with RDS.~A second surfactant dose at 100 mg/kg will be administered with the same technique as the first dosage administration if needed.~After the first and second surfactant administration, neonates could receive a third surfactant dose at 100 mg/kg through a standard technique if needed."
61979110|NCT05933512|EXPERIMENTAL|Group A:SCTV01E-2|one dose of SCTV01E-2 on D0
61979111|NCT05933512|ACTIVE_COMPARATOR|Group A:SCTV01E|one dose of SCTV01E on D0
61979112|NCT05933512|EXPERIMENTAL|Group B:SCTV01E-2|one dose of SCTV01E-2 on D0
61979113|NCT04900194|EXPERIMENTAL|MBSC group|counseling group
61979114|NCT04900194|NO_INTERVENTION|Control group|standard care group
61979115|NCT02835807|EXPERIMENTAL|Health Chat including Indoor Tanning|Facebook group, Health Chat, which provides information via posts within the private group about a wide variety of health topics (e.g. tobacco use, body image) with 25% of all of the content being about indoor tanning. Indoor tanning-related content was developed by the investigators and a social media marketing expert using information from published literature on IT risk factors, evidence-based intervention content from published trials targeting IT reduction, public health campaigns from major non-profit organizations (e.g., CDC, Skin Cancer Foundation, etc.), and investigator-developed video-recorded interviews of local mothers and professionals about the risks of indoor tanning, experiences with skin cancer, and mother-daughter communication role modeling.
61979116|NCT02835807|ACTIVE_COMPARATOR|Health Chat excluding Indoor Tanning|Facebook group, Health Chat, which provides information via posts within the private group about a wide variety of health topics (e.g. tobacco use, body image), but does not include any content about indoor tanning. The designated number of posts (25%) assigned to the indoor tanning content in the intervention group will be assigned to prescription drug use in the control arm. In order to keep number and frequency of posts standardized between the two groups, prescription drug use was selected to replace the indoor tanning content for the control arm.
61979117|NCT05130619|EXPERIMENTAL|Treatment order A-.B-C-D|A: 5g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice B:10g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice C: 8g Triacetin mixed into 250ml water with added aromas of gin and lime juice D: 250ml water with added aromas of gin and lime juice
61979118|NCT05130619|EXPERIMENTAL|Treatment order B-D-A-C|A: 5g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice B:10g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice C: 8g Triacetin mixed into 250ml water with added aromas of gin and lime juice D: 250ml water with added aromas of gin and lime juice
61979119|NCT05130619|EXPERIMENTAL|Treatment order C-A-D-B|A: 5g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice B:10g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice C: 8g Triacetin mixed into 250ml water with added aromas of gin and lime juice D: 250ml water with added aromas of gin and lime juice
62549923|NCT04766112|EXPERIMENTAL|Group I|Group I will receive yang style Tai chi exercises combined with mental imagery training which consist of 10 positions
62739134|NCT05592327|EXPERIMENTAL|Citric acid abutment|"Antimicrobial-coated abutments (citric acid) will be allocated to the test group.~Permanent Vega® (Klockner Implant System, Barcelona, Spain) will be used. The interface between implant and abutment is platform switching. The abutment height will be of 2 mm. It will be placed the day of the implant surgery and tighten to 25 N"
61979120|NCT05130619|EXPERIMENTAL|Treatment order D-C-B-A|A: 5g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice B:10g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice C: 8g Triacetin mixed into 250ml water with added aromas of gin and lime juice D: 250ml water with added aromas of gin and lime juice
62359568|NCT02505815||Regional Anesthesia|Patients with surgery in regional anesthesia.
62549924|NCT04766112|ACTIVE_COMPARATOR|Group II|Group B will receive yang style Tai chi exercise which consist of 10 positions
62549925|NCT01495078|EXPERIMENTAL|Telemonitoring|Patients with follow-up telemonitoring
62549926|NCT01495078|NO_INTERVENTION|Non - telemonitoring|Patients with usual face follow-up
62549927|NCT03127514|PLACEBO_COMPARATOR|Placebo|Placebo administered by mouth or via feeding tube for 24 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
62549928|NCT03127514|EXPERIMENTAL|AMX0035|AMX0035 administered by mouth or via feeding tube for 24 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
62549929|NCT00995774|EXPERIMENTAL|Robotic then Conventional|robotic arm therapy first, conventional therapy second
61979121|NCT04375137||Severe COVID|patients with positive PCR or compatible CT admitted in ICU or intubated
61979122|NCT04375137||Non-severe COVID-19|patients with positive PCR or compatible CT admitted in ward without hypoxia
61979123|NCT04375137||Healthy Controls|Healthy controls with negative IgM/IgG for COVID-19
61979124|NCT03867604|SHAM_COMPARATOR|Sham injection|Subcutaneous injection at upper trapezium muscle level
61979125|NCT03867604|EXPERIMENTAL|Fascia injection|Fascia injection, below upper trapezium muscle
61979126|NCT06188936|OTHER|Work Package 1: Survey for clinicians and scientists|Online survey of UK clinicians' and scientists' views on home semen analysis tests, including whether a randomised trial is needed to compare them to standard care, and their willingness to recruit to such a trial.
61979127|NCT06188936|OTHER|Work package 2: Survey for patients|Sample size: 100 patients. Survey of patients' views prior to undergoing routine laboratory semen analysis, including awareness of home testing.
61979128|NCT06188936|EXPERIMENTAL|Work package 3: Home testing with ExSeed home semen analysis test and post-test survey|Sample size: 25 patients. Assessment of patients' ability to complete home semen testing with the ExSeed® test, opinions on ease of test use, and views after undergoing both laboratory semen analysis and home testing. Results from the ExSeed® test will be compared to the participant's laboratory semen analysis result to assess the accuracy of the home test.
61979129|NCT04137003|EXPERIMENTAL|Rouge et Or program|Rouge et Or program group follow a detailed program that they do on their own. It is made of three cycles of four weeks each. Every cycle contains 3 training sessions by week with a minimum of 24 hours between sessions. The training volume is modulated for every cycle and every week. Each training sessions is made of 6 warm-up exercises followed by 6 training exercises. The exercises are a mix of strengthening, endurance, plyometric, neuromuscular control and dynamic stability. The exercises change every month with a progressively increasing difficulty towards the end to mimic return to sport demands.
61979130|NCT04137003|ACTIVE_COMPARATOR|CHU intervention guide|CHU intervention guide group follow the standard CHU protocol. At three months post-surgery, the protocol suggests progressing the exercises without precisely suggesting exercise, parameter or frequency.
61979131|NCT05283057|ACTIVE_COMPARATOR|Group 1: Empagliflozin|25 patients with glomerulonephritis and proteinuria who were treated with Empagliflozin
62359569|NCT02505815||General Anesthesia|Patients with surgery in general anesthesia.
61979132|NCT05283057|PLACEBO_COMPARATOR|Group 2:|25 patients with glomerulonephritis and proteinuria who were treated with standard treatment and placebo
61979133|NCT01132157|EXPERIMENTAL|Propofol group|
61979134|NCT01132157|ACTIVE_COMPARATOR|Desflurane group|
61979135|NCT04565431||Group 1: Multiple Sclerosis|"Individuals with RRMS who are going to be starting Tysabri as determined by Neurologist as part of clinical care.~Intervention: Drug: Tysabri"
61979136|NCT04565431||Group 2: Healthy Controls|Healthy individuals who are age, gender and education matched to the MS group.
61979137|NCT02781051|EXPERIMENTAL|Physical Activity Intervention|Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up.
61979138|NCT00617045|EXPERIMENTAL|Duloxetine|type of experimental agent
61979139|NCT01164956|EXPERIMENTAL|M-P, P-M, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants \> 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
61979140|NCT01164956|EXPERIMENTAL|P-M, P-M, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants \> 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
61979141|NCT01164956|EXPERIMENTAL|P-M, M-P, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants \> 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
61979142|NCT01164956|EXPERIMENTAL|M-P, M-P, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants \> 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
61979143|NCT01164956|EXPERIMENTAL|M-P, P-M, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants \> 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
61979144|NCT01164956|EXPERIMENTAL|M-P, M-P, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants \> 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
62169190|NCT00382408|PLACEBO_COMPARATOR|Placebo|Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).
62359570|NCT05073172|EXPERIMENTAL|Arm I (StrataXRT)|Patients apply StrataXRT topically to the affected area once or twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =\< 1.
62359571|NCT05073172|ACTIVE_COMPARATOR|Arm II (standard of care)|Patients receive standard of care including calendula and/or Aquaphor applied 2-6 times daily plus hydrogel or Silvadene or topical corticosteroids applied twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =\< 1.
62549930|NCT00995774|EXPERIMENTAL|Conventional then Robotic|conventional therapy first, robotic therapy second
61979145|NCT01164956|EXPERIMENTAL|P-M, P-M, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants \> 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
61979146|NCT01164956|EXPERIMENTAL|P-M, M-P, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants \> 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
61979147|NCT00622960|EXPERIMENTAL|High MUFA diet|Those subjects assigned to a high monounsaturated fat diet
61979148|NCT00622960|ACTIVE_COMPARATOR|High CHO diet|Those subjects assigned to a high carbohydrate diet
61979149|NCT04144556|EXPERIMENTAL|Nintendo Wii and conventional physical therapy|"This group of patients will receive, in addition to the exercise program described below, a virtual rehabilitation program through Nintendo Wii. This program will include upper limb training and lower limb balance training. Participants will choose the games they want to perform the session with. Wii Fit (balance games) will be used for the treatment of the lower limbs, and Wii Sports (bowling, golf and tennis games) will be used for the treatment of the upper limbs."
61979150|NCT04144556|ACTIVE_COMPARATOR|Conventional Physical therapy|A warm-up period using a stationary bicycle, mobility exercises in supine position, active-assisted/passive kinesiotherapy of the lower and upper limbs, strengthening exercises in sitting position, balance, stability and coordination exercises and walking re-education exercises.
61979151|NCT00805311|EXPERIMENTAL|CEA Group|Patients will undergo carotid endarterectomy (CEA) and receive medical treatment including medical therapy with statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.
61979152|NCT00805311|ACTIVE_COMPARATOR|OMT Group|Patients will receive conservative therapy - optimal medical treatment (OMT) including statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.
61979153|NCT03280290|EXPERIMENTAL|receivers|"* Eligible for allo-HSCs from peripheral blood stem cells from a compatible donor HLA family (Appendix 1, the pre-transplant assessment must be enabled)~* In a complete remission rate of leucocytes with ≥ 2G / L~* Affiliated to social security person or beneficiary of such a scheme."
61979154|NCT03280290|EXPERIMENTAL|Donors|"* Member of the siblings and HLA-matched A, B, Cw, DR, DQ~* Eligible to donate peripheral blood stem cells for allo-HSCs (Appendix 2, pre donation assessment must be enabled)~* Having a rate of circulating lymphocytes ≥ 1 G / L~* Having a proportion of CD4 + CCR7 + ≥ 80% of the total CD4 T population~* The statutes CMV and EBV are known (positive or negative).~* Affiliated to social security person or beneficiary"
61979155|NCT05266755|PLACEBO_COMPARATOR|Patiens who will receive stanrdar care after hip fracture|All the patients who will be on surgery after a hip fracture will receive after the hospital discharge the standar following we are doing now in our hospital
61979156|NCT05266755|ACTIVE_COMPARATOR|Patiens who will receive FLS following after the hip fracture|All the patients who will be on surgery after a hip fracture will receive after the hospital discharge a FLS following, multidisciplinary, with a web and mobile app aplication
61979157|NCT04648345|EXPERIMENTAL|Erector spinal plane block group (ESPB group)|After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block will be performed in the ESPB group.
61979158|NCT04648345|ACTIVE_COMPARATOR|Vertebral side block group (VSB group)|After induction of general anesthesia, pre-operative ultrasound-guided bilateral vertebral side block will be performed in the VSB group.
61979159|NCT04648345|PLACEBO_COMPARATOR|Local block group （LB group）|Local block will be performed at the surgical incisions after the surgery under general anesthesia.
61979160|NCT04961554||Adult patients presenting with limited mouth opening|Adult patients presenting with limited mouth opening not allowing intubation by videolaryngoscopy, on mandibular surgical pathology requiring general anesthesia.
61979161|NCT03472404|EXPERIMENTAL|Intervention Group|Internal Brace augmented ankle Ligament reconstruction
61979162|NCT03472404|ACTIVE_COMPARATOR|Control Group|Brostrom-Gould ankle Ligament reconstruction
62739135|NCT05592327|PLACEBO_COMPARATOR|Control non coated abutment|Non- coated abutments (citric acid) will be allocated to the control group. Permanent Vega® (Klockner Implant System, Barcelona, Spain) will be used. The interface between implant and abutment is platform switching. The abutment height will be of 2 mm. It will be placed the day of the implant surgery and tighten to 25 N
62739136|NCT04120883|EXPERIMENTAL|HCQ treatment 1|In treatment arm 1, the dose of study drug will be 4 mg/kg/day. The daily dose will not exceed 400 mg. In both groups, the dose will be rounded down to 100, 200, 300, or 400 mg/day.
61979163|NCT02608749|EXPERIMENTAL|IC|Integrated care (IC)
61979164|NCT02608749|EXPERIMENTAL|LEE|Lower extremity exercise (LEE)
61979165|NCT02608749|EXPERIMENTAL|HC|Home care (HC)
61979166|NCT05298332|EXPERIMENTAL|ATI-2173 50 mg Japanese|Healthy adult Japanese subjects will receive 50 mg of ATI-2173
61979167|NCT05298332|EXPERIMENTAL|ATI-2173 50 mg Chinese|Healthy adult Chinese subjects will receive 50 mg of ATI-2173
61979168|NCT05298332|EXPERIMENTAL|ATI-2173 50 mg Non-Asian|Healthy adult non-Asian subjects will receive 50 mg of ATI-2173
62169191|NCT00982371||Controls|female; \>65 years old; BMI \>25kg/m2; postmenopausal \>5 yrs; NO clinical diagnosis of type 2 diabetes for \>5 years (according to Canadian Diabetes Association criteria)
62169192|NCT00982371||Type 2 Diabetes|female; \>65 years old; BMI \>25kg/m2; postmenopausal \>5 yrs; clinical diagnosis of type 2 diabetes for \>5 years (according to Canadian Diabetes Association criteria)
62359572|NCT04863313|EXPERIMENTAL|Group receiving the probiotic capsules|Experimental group will consume one probiotic capsule every day during 12 weeks at breakfast.
62359573|NCT04863313|PLACEBO_COMPARATOR|Group receiving the placebo capsules|Placebo group will consume one placebo capsule every day during 12 weeks at breakfast.
61979169|NCT03103386|EXPERIMENTAL|Fermented Rye Bran group|Intake of food product with a patented fermented rye bran: A patented fermented rye bran ingredient for food purpose has been produced through a process where a specific Lactobacillus curvatis strain was incubated with rye bran by Kampffmayer Food Innovation GmbH, Germany. The dried fermented rye bran was incorporated into a whole grain rye crisp bread product (25% on weight basis) commercially available in Sweden and in a novel extruded whole grain rye product (20%) developed by Lantmännen.Two crisp rye bread pieces (2 x 12g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily. Rye puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily. Total energy: 518 kcal/day.
61979170|NCT03103386|PLACEBO_COMPARATOR|Refined Wheat group|Intake of food product with common refined wheat: Corresponding crisp bread and extruded product will be produced using refined wheat flour. Two crisp bread pieces (2 x 12 g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily.Wheat puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily.Total energy: 513 kcal/day.
61979171|NCT02305108|EXPERIMENTAL|fascial manipolation and standard|
61979172|NCT02305108|ACTIVE_COMPARATOR|standard treatment|
61979173|NCT05381467|ACTIVE_COMPARATOR|immediate implant placement with The Dual-Zone Therapeutic Concept|
61979174|NCT05381467|EXPERIMENTAL|Immediate implant placement with the bone shielding concept|
62739137|NCT04120883|EXPERIMENTAL|HCQ treatment 2|In treatment arm 2, the dose of the study drug will be 5 mg/kg/day. The daily dose will not exceed 400 mg. In both groups, the dose will be rounded down to 100, 200, 300, or 400 mg/day.
61979175|NCT06203847|EXPERIMENTAL|Intervention group|"Combined drug treatment: includes epinephrine (Adrenaline® 1mg/vial) every 3 minutes, vasopressin (Pitressin® 20Unints/vial) every 3 minutes up to 4 vials (a total of 80Units), methylprednisolone (Solu-Medrol® 40mg/vial).~The method of administration is as follows: after the first administration of epinephrine (Adrenaline® 1mg/vial) to patients with cardiac arrest before hospital arrival, vasopressin (Pitressin® 20Unints/vial) and methylprednisolone (Solu-Medrol® 40mg/vial) are given simultaneously; thereafter, every 3 minutes, 1 mg (1 dose) of (Adrenaline® 1mg/vial) is given, along with 20 Units (1 dose) of vasopressin (Pitressin® 20Unints/vial) up to a maximum of 4 doses (a total of 80 Units) of vasopressin can be given before hospital arrival."
61979176|NCT06203847|ACTIVE_COMPARATOR|Control group|Standard drug treatment: epinephrine (Adrenaline® 1mg/vial). According to international resuscitation guidelines ( Advanced Cardiac Life Support, ACLS), patients with cardiac arrest before hospital arrival are given 1 mg (1 dose) of epinephrine (Adrenaline® 1mg/vial) every 3 minutes.
61979177|NCT05882799|ACTIVE_COMPARATOR|Ultrasound-guided dry needling group|Patients in this group will receive dry needling for piriformis syndrome under real-time ultrasound guidance.
61979178|NCT05882799|ACTIVE_COMPARATOR|Blinded dry needling group|Patients in this group will receive dry needling for piriformis syndrome without ultrasound guidance.
61979179|NCT05003154|NO_INTERVENTION|Conventional management group|Received conventional management based on Guidelines for GDM in China
61979180|NCT05003154|EXPERIMENTAL|Digitalized management group|Reveived conventional management and digitalized management
61979181|NCT01219920|ACTIVE_COMPARATOR|FOLFIRI|Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
61979182|NCT01219920|EXPERIMENTAL|FOLFOXIRI|Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
61979183|NCT00473642|EXPERIMENTAL|1|Standard Fluence Photodynamic Therapy combined with ranibizumab
61979184|NCT00473642|EXPERIMENTAL|2|Verteporfin at 50% fluence photodynamic therapy combined with ranibizumab
61979185|NCT00473642|ACTIVE_COMPARATOR|3|Ranibizumab monotherapy
61979186|NCT02913547|EXPERIMENTAL|Treatment group|"Each subject will serve as his/her own control, while comparing results before treatment, and after 6 weeks of treatment.~Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual."
61979187|NCT00757744|EXPERIMENTAL|A|Methadone maintenance treatment with Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
61979188|NCT00757744|ACTIVE_COMPARATOR|B|Methadone maintenance treatment with standard drug counseling
61979189|NCT02155140|ACTIVE_COMPARATOR|Jejunal feeding|Nutritional supplementation via their jejunostomies for six weeks post hospital discharge, with continued assessment for a further 18 weeks.
62359574|NCT06445465|EXPERIMENTAL|Participants with α-synucleinopathies.|The study population will be composed of participants with α-synucleinopathies.
62359575|NCT06445465|ACTIVE_COMPARATOR|Healthy volunteers|The study population will be composed of health volunteers.
62359576|NCT02463422||San Diego, CA|Toddlers detected with ASD and other disorders based on the Get SET Early Model in San Diego.
62359577|NCT02463422||Phoenix, AZ|Toddlers detected with ASD and other disorders based on the Get SET Early Model in Phoenix.
62359578|NCT05982145||Patients who are 60 years old and over|Patients who are 60 years old and over had a questionary and a measure of their leg's length
62359579|NCT05982145||Patients with / or had venous leg ulcers|Patients with / or had venous leg ulcers actually have individual interviews
62359580|NCT05982145||Caregivers who treat patients with venous leg ulcers (except nursing homes)|Caregivers who treat patients with venous leg ulcers (except nursing homes) actually have individual interviews
62359581|NCT05982145||Caregivers in nursing homes for dependant elderly people and institutions like hospital|Caregivers in nursing homes for dependant elderly people and institutions like hospital actually have focus groups
62359582|NCT06272630|EXPERIMENTAL|DWJ1464|UCDA 100 mg, TID
62359583|NCT06272630|PLACEBO_COMPARATOR|Placebo of DWJ1464|Placebo of DWJ1464, TID
61979190|NCT02155140|NO_INTERVENTION|No jejunal feeding|No jejunal feeding of patients for six weeks following hospital discharge, with continued assessment for a further 18 weeks
61979191|NCT00237601||1|Women with the intention to give birth at home
61979192|NCT00237601||2|Women with the intention to give birth in a short-stay hospital setting
61979193|NCT06313931|EXPERIMENTAL|Experimental group|Experimental group
61979194|NCT06313931|ACTIVE_COMPARATOR|Control group|Control group
61979195|NCT01983852||1|Children during End of Life Care
61979196|NCT01488357||Early stage breast cancer patients receiving mastectomy|
61979197|NCT06176573|ACTIVE_COMPARATOR|First arm - Pre-operative vaginal cleansing with chlorhexidine|Had vaginal cleansing with chlorhexidine prior to cesarean section and were monitored for infectious morbidity.
61979198|NCT06176573|ACTIVE_COMPARATOR|Second arm - Post-operative vaginal cleansing with chlorhexidine|Had vaginal cleansing with chlorhexidine after cesarean section and were monitored for infectious morbidity.
61979199|NCT03874520|EXPERIMENTAL|Video triage|The sick child will be assessed on video by the operator at the call-center.
61979200|NCT03874520|NO_INTERVENTION|Telephone triage|The sick child will be assessed solely over the telephone by the operator at the call-center.
61979201|NCT06092489|ACTIVE_COMPARATOR|Traditional Physiotherapy Program|Self-stretching will encapsulate the upper trapezius, pectoralis minor, posterior. Each stretch will consist of 3 repetitions of 30 seconds with a 30 second break between repetitions. Strengthening exercises will be performed using elastic resistance bands (Theraband ®) with 4 levels of resistance (red, green, blue and grey). Sets can be easily changed (without the person reporting muscle fatigue) and progressed with resistance. The therapist will ask about the level of effort required for exercise exercises and whether it would be possible to increase the resistance level. The exercise consists of three sets of 10 repetitions and is completed with 1 rest between them. Strengthening exercises will include prone extension, prone external rotation with abduction, side lying external rotation and serratus anterior strengthening . These workouts and workouts are also arranged regularly. After exercise, ice will be applied to the shoulder for 15 minutes.
61979202|NCT06092489|EXPERIMENTAL|Traditional Physiotherapy Program and Graded Motor Imagery Therapy|The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.
61979203|NCT05289414|ACTIVE_COMPARATOR|Radiofrequency|first group of patients will be sujected to radiofrequency treatment
62391369|NCT02062385|PLACEBO_COMPARATOR|Placebo with staggered EPI|Placebo administered as a 2 mL oral solution at age \~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age \~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age \~3.5, 4.5, and 5.5 months
61979204|NCT05289414|ACTIVE_COMPARATOR|Greater occipital nerve vlock|second group of patients will be sujected to Greater occipital nerve block
61979205|NCT00562939|EXPERIMENTAL|A|1 mg CpG 7909 + pneumococcal vaccines
61979206|NCT00562939|PLACEBO_COMPARATOR|B|Pneumococcal vaccines
61979207|NCT06386133|EXPERIMENTAL|Boost Group|The Boost Group will have the MSCopilot Boost mobile application and follow personalized fatigue management advices and physical activity program
61979208|NCT06386133|ACTIVE_COMPARATOR|Control Group|The Control Group will follow standard of care with general fatigue advices
61979209|NCT02320149|EXPERIMENTAL|Sarecycline|Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
61979210|NCT02320149|PLACEBO_COMPARATOR|Placebo|Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.
61979211|NCT01526616|ACTIVE_COMPARATOR|Metformin|850 mg/day twice a day
61979212|NCT01526616|ACTIVE_COMPARATOR|Metformin plus spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
61979213|NCT06267950|EXPERIMENTAL|IOE group|IOE groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
61979214|NCT06267950|ACTIVE_COMPARATOR|PNG group|PNG groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
61979215|NCT04291391|EXPERIMENTAL|Individuals without obesity and normoglycemia (NG) (Lean-NG)|Those assigned to the Lean-NG group will receive a North American-type diet diet for 4 weeks.
61979216|NCT04291391|EXPERIMENTAL|Individuals with obesity and NG (Obese-NG)|Those assigned to the Obese-NG group will receive a North American-type diet diet for 4 weeks.
61979217|NCT04291391|EXPERIMENTAL|Individuals with obesity and glucose intolerance (GI) (Obese-GI)|Those assigned to the Obese-GI group will receive a North American-type diet diet for 4 weeks.
61979218|NCT04291391|EXPERIMENTAL|Individuals with obesity and type 2 diabetes (T2D) (Obese-T2D)|Those assigned to the Obese-T2D group will receive a North American-type diet diet for 4 weeks.
61979219|NCT00589914|ACTIVE_COMPARATOR|RISPERDAL CONSTA|RISPERDAL CONSTA 25-50 mg eq every 2 weeks
61979220|NCT00589914|EXPERIMENTAL|R092670|Paliperidone Palmitate 50-150 mg eq every 4 wks
61979221|NCT02746874|ACTIVE_COMPARATOR|Active Group|Radiofrequency ablation procedure of the three articular branches of the knee joint. The targets will be thermally lesioned for 2 minutes 30 seconds thereby causing neurolysis.
61979222|NCT02746874|SHAM_COMPARATOR|Placebo Group|Simulated Radiofrequency Ablation procedure of the three articular branches of the knee joint.The targets will be not be thermally lesioned for 2 minutes 30 seconds therefore not causing neurolysis.
61979223|NCT04138420||Patients receiving Bevacizumab|Bevacizumab, intravitreal injection, three monthly, dosage: 1.25 mg/0.05 mL.
61979224|NCT03705507|EXPERIMENTAL|Selumetinib + Dexamethasone - Group A (18 years and above)|Patients will receive the adult cohort specified dose of selumetinib by mouth, as a single dose on cycle 1 day 1, then twice daily continuously from cycle 1 day 4 onwards. Combined with pulsed doses of dexamethasone at 6mg/m2/day on days 2-4 and 8-11 then at 4mg/m2/day on days 15-18 and 22-25 divided into two doses (as per local practice) by mouth during cycle 1, then on days 1-4 at 4mg/m2/day at the start of cycle 2, then on days 1-5 at 6mg/m2/day during subsequent cycles.
62359584|NCT05537610|EXPERIMENTAL|Contingency-Discrimintation Training (CDT)|In this condition, the clinician will alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. According to RaC2, alternating periods of reinforcer availability and unavailability for the alternative response will teach the participant that the alternative response alone produces reinforcement but not always. The investigators predict that resurgence of problem behavior will lower, shorter lasting, and with fewer participants experiencing resurgence than those in the control group.
61979225|NCT03705507|EXPERIMENTAL|Selumetinib + Dexamethasone - Group P (under 18 years)|Patients will receive the paediatric cohort specified dose of selumetinib by mouth, as a single dose on cycle 1 day 1, then twice daily continuously from cycle 1 day 4 onwards. Combined with pulsed doses of dexamethasone at 6mg/m2/day on days 2-4 and 8-11 then at 4mg/m2/day on days 15-18 and 22-25 divided into two doses (as per local practice) by mouth during cycle 1, then on days 1-4 at 4mg/m2/day at the start of cycle 2, then on days 1-5 at 6mg/m2/day during subsequent cycles.
61979226|NCT00265954|EXPERIMENTAL|1|Individuals in this arm receive a 6 month behavioral weight loss intervention delivered on-line. Groups meet via a web chat weekly for 24 weeks and monthly for the following 12 months.
61979227|NCT00265954|EXPERIMENTAL|2|In-person; Individuals in the in-person condition attend weekly group behavioral weight loss sessions for 24 weeks and then monthly sessions for the following 12 months.
61979228|NCT00265954|EXPERIMENTAL|3|In-person+internet; Individuals in this condition receive a behavioral weight loss intervention over the internet weekly for 24 weeks and monthly for the following 12 months. Every month during the first 24 weeks and every third month during the following year they have an in-person meeting.
61979229|NCT01251549|EXPERIMENTAL|Experimental: A|A group of paraplegics.
61979230|NCT01879501|EXPERIMENTAL|Low Vision Self-Management Program|Intervention: The program will work with participants to choose a specific and achievable goal they wish to achieve, involve participants in the learning process, provide information, explore experiences with low vision, and solutions to develop problem solving skills to enhance self efficacy. Participants will learn new techniques to cope with their activities of daily living. In addition to this, local guest experts in the field will be sourced and invited to provide training in aspects of low vision care.
61979231|NCT01879501|NO_INTERVENTION|Usual Care|Usual care delivered at the Singapore National Eye Centre
61979232|NCT00202644|EXPERIMENTAL|A|
61979233|NCT00202644|ACTIVE_COMPARATOR|B|
62567063|NCT05428774|EXPERIMENTAL|Test Product 2|Participants will consume test product 2 during one experimental visit.
61979234|NCT05059067||Macintosh blade size 3|Patients intubated using Macintosh blade size 3
61979235|NCT05059067||Macintosh blade size 4|Patients intubated using Macintosh blade size 4
61979236|NCT03945396|EXPERIMENTAL|Multidisciplinary intervention + homeopathic medication|"Multidisciplinary intervention (diet, exercise program, motivational support) and Calcarea carbonica ostrearum 30c.~A single dose of Calcarea carbonica ostrearum 30C dissolved in a 30 ml bottle of 30% alcohol-distilled water. Patients will receive 8 drops PO three times per day prior agitation."
61979237|NCT03945396|ACTIVE_COMPARATOR|Multidisciplinary intervention + homeopathic placebo|"Multidisciplinary intervention (diet, exercise program, motivational support) and placebo.~Placebo will be prepared with 30% alcohol-distilled water only, in the same 30 ml bottle. Patients will receive 8 drops PO three times per day prior agitation."
61979238|NCT04782089|EXPERIMENTAL|Camrelizumab+Fluzoparib|
61979239|NCT06380842||Pancreatitis with sepsis patients' organ dysfunction progression after open necrosectomy|Acute necrotizing pancreatitis patients with sepsis undergoing open necrosectomy will be measured SOFA scores at a special time point to characterize organ dysfunction experience profiles.
61979240|NCT03010254|EXPERIMENTAL|DFT015|ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
61979241|NCT03010254|ACTIVE_COMPARATOR|SN60WF|ACRYSOF® IQ Monofocal IOL, bilateral implantation
61979242|NCT03178773|ACTIVE_COMPARATOR|TExT-MED only|Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes. A patient-identified family member receives a social support curriculum (FANS) in traditional booklet form.
61979243|NCT03178773|EXPERIMENTAL|TExT-MED+FANS|Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes. A patient-identified family member receives a social support curriculum (FANS) by SMS-text-message synchronized by time and content.
61979244|NCT04923087||Patient hospitalized in geriatrics or EHPAD|Subjects 65 years of age or older, hospitalized in geriatrics or EHPAD residents
61979245|NCT04493281|EXPERIMENTAL|MT-1186|Healthy subjects were administered a single dose of Edaravone oral suspension
61979246|NCT04493281|ACTIVE_COMPARATOR|MCI-186|Healthy subjects were administered a single dose of Edaravone intravenous formulation
61979247|NCT03480750|EXPERIMENTAL|trientine with chemotherapy|trientine dihydrochloride PO daily (in different dose levels) plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1
62169193|NCT00349713|EXPERIMENTAL|Cohort 1: 25ug FMP2.1 / AS02A|20 subject to receive 25ug of FMP2.1 vaccine in 0.25mL of GSK Biologicals' adjuvant AS02A
62567064|NCT05428774|PLACEBO_COMPARATOR|Placebo|Participants will consume placebo during one experimental visit.
62359585|NCT05537610|ACTIVE_COMPARATOR|Control|This condition emulates a traditional approach to treatment in which the clinician does not alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. The investigators predict that resurgence of problem behavior will higher, longer lasting, and with more participants experiencing resurgence than those in the CDT group.
62359586|NCT06460831|PLACEBO_COMPARATOR|OTW group|
62359587|NCT06460831|EXPERIMENTAL|Microcatheter group|
62359588|NCT00659126|EXPERIMENTAL|Diagnostic (Gd, ferumoxytol, 3T or 7T MRI)|Patients receive gadolinium IV on day 1 and ferumoxytol non-stoichiometric magnetite IV on day 2. Patients undergo anatomical MRI sequences with 3T or 7T at baseline and on days 1-3. Patients also undergo DSC MRI and DCE MRI on days 1-2. Day 1 and day 2 imaging sessions may be separated by up to 7 days.
62359589|NCT05730101|NO_INTERVENTION|No treatment waitlist group|Participants receive neither cognitive-behavioral nor imaginary pill treatment and are told that they are in the no treatment waitlist group. They are told that they can receive one of the treatments at the end of the study. The treatment they receive will be chosen based on study results.
62359590|NCT05730101|ACTIVE_COMPARATOR|Cognitive-behavioral treatment group (CBT)|"Participants receive two individual and six group sessions with a therapist following the treatment manual Prokrastination."
62359591|NCT05730101|ACTIVE_COMPARATOR|Imaginary pill treatment group (IP)|In accordance with the imaginary pill technique, participants are instructed to take an imaginary pill. This instruction consists of a procedure including five steps (i.e., 1) identifying the IP sensitive problem, 2) building trust/belief/reality of the IP, 3) constructing a personally meaningful IP, 4) taking the IP, 5) suggestions for self-administering the IP in real life and building adherence. The session is repeated with small modifications seven weeks later.
62359592|NCT01527110|EXPERIMENTAL|Intravenous (IV) zanamivir 600mg twice daily|600mg of IV zanamivir infusion twice daily
61979248|NCT03635957|EXPERIMENTAL|Pegloticase With Methotrexate (MTX)|"Run-In Period: oral MTX at a dose of 15 mg weekly for 4 weeks prior to the first dose of pegloticase.~Pegloticase + Immunomodulator (IMM) Period: pegloticase 8 mg administered intravenously (IV) every 2 weeks from Day 1 through the Week 50 Visit for a total of 26 infusions. MTX 15 mg weekly on the same day each week, within 1 to 3 days prior to each pegloticase infusion and one additional weekly dose after the last infusion."
61979249|NCT04476433|NO_INTERVENTION|Control Group|Patients and caregivers who receive the treatment program, will previously constitute their own control group (waiting list control group).
61979250|NCT04476433|EXPERIMENTAL|Experimental Group|Patients and caregivers who receive the treatment program, will previously constitute their own control group (waiting list control group). Thus, diagnostic measures will be obtained in all of them in an initial evaluation (T1), and after 6 months of this evaluation the treatment program will be started. In the first contact session at 6 months after T1 all subjects (patients and relatives) will be re-evaluated (T2) and after this the treatment program will be started (within an estimated time of 15 days maximum from this second pre-treatment evaluation, the estimated duration of treatment being 5 months). After the completion of the patient and family treatment sessions, a new diagnostic test pass will be performed (T3) (within an estimated maximum period of 15 days from the completion of treatment) in order to evaluate the post-treatment change. Thus, the estimated time between T2 and T3 will be equivalent to that between T1 and T2, being 6 months.
61979251|NCT03218007|EXPERIMENTAL|acute coronary syndrome|
61979252|NCT00913042||1|febrile neutropenia patient
61979253|NCT01486628|PLACEBO_COMPARATOR|levodopa and carbidopa|
61979254|NCT01486628|PLACEBO_COMPARATOR|Placebo|Saline solution for subcutaneous administration
62359593|NCT02621255|ACTIVE_COMPARATOR|General anesthesia|General Anesthesia: Effect of general anesthesia will compare with regional anesthesia without use of nonsteroid antiinflammatory drug usage. Propofol 2mg/kg and rocuronium will be administered to patients for anesthesia induction. Anesthesia maintenance will ensure with sevoflurane %2 and N2O/O2 %50/50 mixture.
62359594|NCT02621255|ACTIVE_COMPARATOR|bupivacaine|Regional Anesthesia: Effect of regional anesthesia will compare with general anesthesia without use of nonsteroid antiinflammatory drug usage. Combined epidural-spinal anesthesia will be performed to patients. %5 bupivacain and 20µg fentanyl will apply for spinal anesthesia. Anesthesia maintenance will ensure with bupivacain.
62359595|NCT04592848||Population study|"Female patients who undergone a cystectomy and/or urinary diversion for a non-malignant disease at Lyon Sud Hospital between January 2007 and December 2019."
62359596|NCT05117749|EXPERIMENTAL|Mild UC-Saffron 100|Mild UC patients, receiving 100 milligram (mg)/day saffron for 8 weeks (50 mg two times (BID)), n=10
62359597|NCT05117749|EXPERIMENTAL|Moderate UC-Saffron 100|Moderate UC patients, receiving100 mg/day saffron for 8 weeks (50 mg BID), n=10
62359598|NCT05117749|EXPERIMENTAL|Mild UC-Saffron 50|Mild UC patients, receiving 50 mg/day saffron for 8 weeks (25 mg BID), n=10
62359599|NCT05117749|EXPERIMENTAL|Moderate UC-Saffron 50|Moderate UC patients, receiving 50 mg/day saffron for 8 weeks (25 mg BID), n=10
62359600|NCT05117749|PLACEBO_COMPARATOR|Mild UC-placebo|Mild UC patients, receiving 2 tablets of placebo for 8 weeks, n=10
62359601|NCT05117749|PLACEBO_COMPARATOR|Moderate UC-placebo|Moderate UC patients, receiving 2 tablets of placebo for 8 weeks, n=10
61979255|NCT03493009|EXPERIMENTAL|10mg Magnesium citrate|subjects will be required to follow a specific bowel preparation instruction consisting of dietary restrictions (no dried fruit, seeds or nuts) starting 5 days prior to the colonoscopy, an low residue diet at the day before the procedure, followed by a split dose of 10 mg of Magnesium citrate, followed by colonoscopy procedure with Pure-Vu System
62169194|NCT00349713|EXPERIMENTAL|Cohort 2: 50ug FMP2.1 / AS02A|20 subjects to receive 50ug of FMP2.1 vaccine in 0.5mL of GSK Biologicals' adjuvant AS02A
62359602|NCT03326583|EXPERIMENTAL|Patiromer|"This arm is a 2 week observation period before the start of the Patiromer treatment phase, followed by a 12 week treatment phase, and 6 week no treatment observation phase.~Pre-Treatment (Wk 1-2): Observational period. Baseline sample collection of blood and stool. No medication.~Treatment (Wk 3-14): Participants will take 8.4 grams of Patiromer once daily for one week, during which serum potassium and gastrointestinal symptoms will be evaluated. If tolerated and in the absence of hypokalemia, the dose will be up-titrated to 16.8 grams once daily for the remaining 11 weeks. Blood and stool will be collected.~Post-Treatment (Wk 15-20): Observational period. No medication. Blood and stool will be collected."
61979256|NCT03493009|EXPERIMENTAL|15mg Magnesium citrate|subjects will be required to follow a specific bowel preparation instruction consisting of dietary restrictions (no dried fruit, seeds or nuts) starting 5 days prior to the colonoscopy, an low residue diet at the day before the procedure, followed by a split dose of 15 mg of Magnesium citrate, followed by colonoscopy procedure with Pure-Vu System
61979257|NCT02150096|ACTIVE_COMPARATOR|Continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
61979258|NCT02150096|ACTIVE_COMPARATOR|Pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
61979259|NCT02150096|ACTIVE_COMPARATOR|low level laser therapy group|the group will be treated with 3J during 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
61979260|NCT02150096|NO_INTERVENTION|control group|group of women no treated, only evaluated in two moments and this group will be compared with orthers: laser, pulsed ultrasound and continuous ultrasound.
61979261|NCT01811173|EXPERIMENTAL|Nurse-physician comprehensive care|Comprehensive self management support and care coordination by a nurse-primary care physician team
61979262|NCT01811173|NO_INTERVENTION|Usual care survey control group|Patients will receive usual primary care and asked to complete questionnaires on four time points throughout the study
61979263|NCT01811173|NO_INTERVENTION|Usual care blinded control group|Patients will receive usual primary care.
61979264|NCT01067014||iO-Flex|
61979265|NCT04834427|EXPERIMENTAL|S (+)-Ketamine group|Patients who undergo general anesthesia using S(+)-ketamine hydrochloride for anesthesia induction, maintenance or postoperative analgesia.
61979266|NCT04834427|ACTIVE_COMPARATOR|Control group|Patients who undergo conventional therapy without S (+)-Ketamine hydrochloride injection during perioperative period.
61979267|NCT06067386|EXPERIMENTAL|Intervention arm|For each E. coli positive urine culture analyzed by LabOuest, GPs will receive an antibiotic susceptibility testing report, with the list of antibiotics restricted according to four E. coli susceptibility profiles, with an emphasis on narrower-spectrum antibiotics. The selected antibiotic susceptibility testing was developed following a targeted literature review and consultation with a steering committee including GPs, biologists and infectiologists. At the GP's request, a full antibiogram can be provided.
61979268|NCT06067386|ACTIVE_COMPARATOR|Control arm|GPs will receive a standard antibiotic susceptibility testing report for each E. coli positive urine culture.
61979269|NCT04934345||FC administration|"* All the patients receive crystalloids at 4 ml/kg/hour as maintenance fluid during surgery, according to standard practice.~* After the first episode of hypotension (MAP \< 65 mmHg) the PPV is checked.~* PPV ≥ 13% - FC (4 ml/kg of crystalloids administered in 10')~* PPV \< 13% - start norepinephrine (starting dose - 0.05 mcg/kg/min). In this group, the FC will be administered during an episode of intraoperative hypotension during NE infusion."
61979270|NCT04062838|EXPERIMENTAL|Prolotherapy|Injection of 20% dextrose (50 % dextrose diluted with 0.5% lidocaine) into the rotator cuff tendinous insertions as well as into the tear. All injections are performed under ultrasound.
61979271|NCT06031454|EXPERIMENTAL|Experimental 1|"All participants will receive the following oral doses of study drugs following an overnight fast in the fixed-sequence below:~Period 1: 1 × 15-mg Midazolam tablet ,1 ×20-mg omeprazole tablet ,1×10-mg rosuvastatin tablet~Period 2: 6 × 400-mg Leritrelvir tablet+1 × 15-mg Midazolam tablet, 1 ×20-mg omeprazole tablet ,1×10-mg rosuvastatin tablet"
61979272|NCT06031454|EXPERIMENTAL|Experimental 2|"All participants will receive the following oral doses of study drugs following an overnight fast in the fixed-sequence below:~Period 1: 1 × 400-mg Leritrelvir tablet~Period 2: 5 × 240-mg verapamil tablet+1 × 400-mg Leritrelvir tablet~Period 3: 8 × 600-mg rifampin capsule +1 × 400-mg Leritrelvir tablet"
61979273|NCT04415788|EXPERIMENTAL|Test of Incremental Respiratory Endurance - IMT|Training will consist of six levels (A-F) with six inspirations at each level for up to 36 breaths per session. TIRE data will be stored in the tablet and automatically synced to account on cloud-based online platform for subsequent interrogation and data retrieval. Before every training session, subjects will be required to complete one maximal and sustained inspiratory effort from which the training is based on for that day.
61979274|NCT04415788|EXPERIMENTAL|Threshold - IMT|Subjects assigned to the Standard training regimen will receive a commonly used Threshold inspiratory muscle trainer. This device features a one-way spring-loaded valve at one end and a mouthpiece on the other through which subjects will be required to breathe in hard enough to overcome the resistance provided by the spring-loaded valve, allowing correct inspiration to happen. In other words, air flow is blocked until subjects generate sufficient inspiratory pressure to exceed the device pre-set pressure in cmH2O. The resistance will be set using the device's adjustable pressure setting which is fixed at 50% of the subject's MIP at the time of enrollment. The resistance will be readjusted as needed at week 4 to still reflect 50% of their inspiratory muscle strength at that time. Subjects will be coached to perform up to 36 breaths daily using the device. They will be also instructed to complete the training session within a 30-minute period.
62359603|NCT02334553|ACTIVE_COMPARATOR|S1226 (8%)|The drug S1226(8%), consists of Perflubron and 8% CO2 in a medical gas mixture. The dosage is 3ml delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer.
62359604|NCT02334553|PLACEBO_COMPARATOR|Placebo|The comparator is normal saline delivered as an aerosol with compressed medical air with a Circulaire nebulizer.
62567065|NCT00114075|EXPERIMENTAL|Gait analysis|Gait analysis report is available for treatment planning
61979275|NCT04415788|SHAM_COMPARATOR|Sham IMT (Low resistence)|The Sham (Low Resistance) training regimen will use the same methods described above for the Standard IMT, except for the amount of resistance applied within the device. Subjects will receive a Threshold which has been set to its minimal resistance, which is 9 cmH2O. Again, subjects will be instructed to perform up to 36 breaths daily using the device within a 30-minute period.
61979276|NCT02143440|OTHER|Newly diagnosed type 2 patients|The initial assessment of daily insulin dose.
61979277|NCT04372667|EXPERIMENTAL|Post intervention|Community score card approach
61979278|NCT05486468|EXPERIMENTAL|Treatment Arm|This group will receive two YUTIQ implants at day 1.
62359605|NCT00343109|EXPERIMENTAL|Arm I|Patients receive HER-2/neu intracellular domain peptide-based vaccine mixed with GM-CSF intradermally once monthly for 6 months in the absence of disease progression or unacceptable toxicity.
61979279|NCT05486468|SHAM_COMPARATOR|Control Arm|This group will receive two sham injections at day 1.
61979280|NCT05057442||Anterior Cruciate Ligament Reconstruction|
61979281|NCT02248194|EXPERIMENTAL|"Group 1Tactile electrosurgical ablation"|Endometrial ablation will be done by Tactile electrosurgical ablation probe.
61979282|NCT02248194|ACTIVE_COMPARATOR|"Group 2 Hysteroscopic endometrial ablation"|Hysteroscopic endometrial ablation will be done by trans-cervical resection of endometrium.
61979283|NCT04492995|ACTIVE_COMPARATOR|Radiotracer + TUMIR|TUMIR = transvaginal ultrsound-guided myometrial injection
61979284|NCT04492995|EXPERIMENTAL|(Radiotraces + ICG) + TUMIR|ICG =indocyanine green TUMIR = transvaginal ultrsound-guided myometrial injection
61979285|NCT05894421|EXPERIMENTAL|TQB2223 injection+ Penpulimab Injection|intravenous injection of TQB2223 injection and Penpulimab injection for one times every three weeks, 21 days as a treatment cycle.
61979286|NCT02645214|PLACEBO_COMPARATOR|Control scrubs (non-antiseptic)|subject will wear control scrubs for the duration of a 12-hour ICU shift
61979287|NCT02645214|ACTIVE_COMPARATOR|Antiseptic Impregnated Scrubs Type 1|subject will wear antiseptic impregnated scrubs-type 1 for the duration of a 12-hour ICU shift
61979288|NCT02645214|ACTIVE_COMPARATOR|Antiseptic Impregnated Scrubs Type 2|subject will wear antiseptic impregnated scrubs-type 2 for the duration of a 12-hour ICU shift
62169195|NCT00349713|ACTIVE_COMPARATOR|Cohorts 1 and 2: Rabies vaccine (RabAvert)|"20 subjects to receive Rabies vaccine (RabAvert). 10 subjects from Cohort 1 and 10 subjects from Cohort 2~Rabies vaccine (RabAvert): RabAvert Rabies vaccine"
62359606|NCT05678270|EXPERIMENTAL|ICP-192|
62359607|NCT00948038|ACTIVE_COMPARATOR|Soy|Soy-based supplement to normal diet
62359608|NCT00948038|EXPERIMENTAL|Milk|Milk-based supplement to normal diet
62359609|NCT05112484||Gilenya|Gilenya (fingolimod) - first registration 17 March 2011, last renewal 16 November 2020, selective immunosuppressant (ATC code L04AA27), sphingosine-1-phosphate receptor modulator
62359610|NCT05112484||Tecfidera|Tecfidera (dimethyl fumarate) - first registration 30 January 2014, last renewal 20 September 2018, cytostatic and immunomodulatory drug (ATC code L04AX07), an activator of the transcription pathway of nuclear factor Nrf2
62359611|NCT05112484||Mavenclad|Mavenclad (cladribine) - first registration 22/08/2017, selective immunosuppressant (ATC code L04AA40), nucleoside analogue of deoxyadenosine
62359612|NCT05112484||Aubagio|Aubagio (teriflunomide) - first registration on 26 August 2013, last renewal on 28 May 2018, selective immunosuppressant (ATC code L04AA31), an inhibitor of the mitochondrial enzyme dihydroorotate dehydrogenase
62549931|NCT05662956|EXPERIMENTAL|Treatment group|"Induction: Subjects who meet the enrollment conditions will receive Venetoclax plus Azacitidine and CAG(VA-CAG) . Participants will receive this induction Therapy as azacitidine on days 1-7, venetoclax aily on days 1-28, cytarabine q12h on days 1-7, aclacinomycin on days 1,3,5,7, and granulocyte colony-stimulating factor on days 0-8. Participants will receive second induction if not reach complete remission.~Consolidation: If patients are intermediate or poor risk and have plans for allogeneic hematopoietic stem-cell transplantation(allo-HSCT) , high dose cytarabine (3g/m2 q12h days 1-3) for 1-2 cycles and follow up with allo-HSCT. In other cases, high dose cytarabine for 4 cycles."
62567066|NCT00114075|ACTIVE_COMPARATOR|Control|Subject has gait analysis test, but report is not available for treatment planning
61979289|NCT00888251||Comprehensive weight management program|
61979290|NCT03522857||Teesside University|nursing, midwifery, physiotherapy, occupational therapy, diagnostic radiography, paramedics
61979291|NCT03522857||Glasgow Caledonian University|nursing, midwifery, physiotherapy, occupational therapy, diagnostic radiography, paramedics
61979292|NCT03522857||Northumbria University|nursing, midwifery, physiotherapy, occupational therapy
61979293|NCT03522857||University of Nottingham|Physiotherapy, nursing and midwifery
61979294|NCT03522857||Curtin University|Physiotherapy
61979295|NCT03522857||Notre Dame University|Physiotherapy
61979296|NCT03522857||University College Dublin|Physiotherapists
61979297|NCT03522857||Leeds Beckett University|Physiotherapists
61979298|NCT03522857||University College Cork|Physiotherapists
61979299|NCT03522857||Robert Gordon University|OT, Physio, Midwifery, Nursing, Diagnostic radiography
61979300|NCT03522857||University of Ulster|Physiotherapy
61979301|NCT03522857||University of Limerick|OT, Physio, Midwifery, Nursing, Diagnostic radiography, paramedic
61979302|NCT01686633|EXPERIMENTAL|Arm1: Fluticasone Furoate/ Vilanterol 200/25 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (\<=65% or \>65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF/ VI 200/25 mcg once daily in the evening for 84 days.
61979303|NCT01686633|EXPERIMENTAL|Arm 2: Fluticasone Furoate/ Vilanterol 100/25 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (\<=65% or \>65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF/ VI 100/25 mcg once daily in the evening for 84 days
61979304|NCT01686633|EXPERIMENTAL|Arm 3: Fluticasone Furoate 100 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (\<=65% or \>65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF 100 mcg once daily in the evening for 84 days
61979305|NCT04528654|EXPERIMENTAL|Intervention App Group|The intervention group will be instructed to download the chosen hypertension mobile health app (Sphygmo BP) via a link provided on the platform. The hypertension app has blood pressure tracking and monitoring features and they are instructed to use the app. They will also receive a link to the Heart and Stroke foundation website which includes information on hypertension management and measuring blood pressure.
62169196|NCT05852054|NO_INTERVENTION|Usual Care|Patients will receive the usual standard of care
62169197|NCT05852054|ACTIVE_COMPARATOR|STEP-UP|STEP-UP will promote linkage to primary care and ongoing chronic disease evaluation for postpartum women with prior GDM and/or HDP
62359613|NCT03774368|OTHER|Website about emergency contraception|Subjects are randomly assigned to view an existing website about emergency contraception. The website contains information about the three methods of emergency contraception: the copper IUD, ulipristal pill, and levonorgestrel pill. It includes information about their relative effectiveness and where to access emergency contraception.
62359614|NCT03774368|OTHER|Video about emergency contraception|Subjects are randomly assigned to view an existing video about emergency contraception. The video is two minutes in length and contains information about the three methods of emergency contraception: the copper IUD, ulipristal pill, and levonorgestrel pill. It includes information about their relative effectiveness and where to access emergency contraception.
62359615|NCT06508528|EXPERIMENTAL|Growth mindset intervention group|Internship nursing students received a 12-week growth mindset intervention.
61979306|NCT04528654|NO_INTERVENTION|Educational Control Group|The control will comprise usual care including any anti-hypertensive medication and lifestyle changes, and the link to the Heart and Stroke Foundation website which includes information on hypertension management and measuring blood pressure.
61979307|NCT01864447|EXPERIMENTAL|VTE REHABILITATION|"The exercise prescription emphasizes gradual progression to longer duration (45-60 minutes per session), lower intensity (60-70% peak heart rate (PHR) exercise. Subjects have an exercise expenditure goal of \>3000 kcal/wk, attained after 2 to 4 weeks of gradually lengthening exercise bouts. All exercise sessions will be performed onsite for the first two weeks, after which subjects will perform 2 additional sessions a week in the home environment. Exercise logs will be reviewed weekly.~The Dietary Behavioral Weight Loss Intervention(BWL) intervention consists primarily of 12 small group sessions led by a dietician emphasizing dietary records, itemization of food, and caloric content. Subjects will be given individualized daily caloric goals 500 kcal less than predicted maintenance calories based on their baseline body weight."
61979308|NCT01864447|NO_INTERVENTION|CONTROL|The 12-week program will consist of monthly phone contacts to check-in to capture physical activity done outside of the intervention setting.
61979309|NCT05687422|EXPERIMENTAL|100μm laser spot diameter group|
61979310|NCT05687422|ACTIVE_COMPARATOR|200μm laser spot diameter group|
61979311|NCT03703128||Informants of suicide victims|Partners, children, parents, siblings, other relatives, peers or other informants of adults (aged 45-60 years) who received a definitive verdict of suicide in the Dutch-speaking part of Belgium (Flanders). The suicide should have taken place more than 3 months ago and less than 5 years ago.
61979312|NCT03703128||Control group|Informants i.e., partners, children, parents, siblings, other relatives, peers or other informants of adults (aged 45-60 years) who have mental health problems.
61979313|NCT00653146|EXPERIMENTAL|Mindfulness-based stress reduction|The MBSR program includes meditation techniques, body scan, awareness of breathing, mindful yoga, eating meditation, and walking meditation, and meets for 2 hours, once weekly for 8 weeks.
61979314|NCT00653146|PLACEBO_COMPARATOR|Healthy Lifestyles Program|The Healthy Lifestyles Program includes information on nutrition and physical activity, and meets for 2 hours, once weekly for 8 weeks.
61979315|NCT02839915|EXPERIMENTAL|Folinic Acid|Subjects randomized to receive Folinic Acid will take Liquid levo-leucovorin via oral route. The target dose is 1 mg/kg/day with a maximum of 25 mg/day, divided in two daily doses. A two- to four-week supply of 15 ml vials will be dispensed in line with the visit schedule. With the exception of children in the lowest weight group (≥ 15 - \< 20 kg) from days 1-14, parents will administer the prescribed dose twice a day at the same time each day.
61979316|NCT02839915|PLACEBO_COMPARATOR|Placebo Control|Subjects randomized to receive placebo will take placebo twice a day (Exception: children in the lowest weight group ( ≥ 15 - \< 20 kg) will start once a day for Days1-13). The pattern of dose escalation will be the same as the active compound. After 12 weeks, the blind will not be broken and subjects will be offered treatment for a 12-week open-label extension phase.
61979317|NCT00643032|ACTIVE_COMPARATOR|I|
61979318|NCT00643032|ACTIVE_COMPARATOR|II|
61979319|NCT05770947|EXPERIMENTAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for adolescents with higher weight seeking treatment for bulimia nervosa (CBT-BNh).Designed for adolescents, CBT-BNh will include psychoeducation, cognitive restructuring, and relapse prevention planning. The focus of therapy will include reducing extreme/unhealthy weight-control behaviors (purging) as well as binge eating, and self-compassion coping skills will address weight stigma and self-directed weight criticism.
61979320|NCT05770947|ACTIVE_COMPARATOR|Mindfulness|Learning to Breathe (L2B) is an existing, evidence-based program for adolescents that teaches mindfulness skills each week, including time to practice and reflect. the skills are grouped into six themes: Body, Reflections, Emotions, Attention, Tenderness, Habits, and Empowerment.
62359616|NCT06508528|OTHER|Hospital Teaching Team|Controlled group will receive regular hospital teaching.
62359617|NCT04559412|EXPERIMENTAL|Sofusa Enbrel|Enbrel® administered by the Sofusa® DoseConnect™ delivery system
61979321|NCT00422591|EXPERIMENTAL|Idarubicin + Cytarabine|Idarubicin 12 mg/m2 IV over 1 hour daily x 3 (days 1-3). Cytarabine 1.5 g/m2 IV over 24 hours daily on day 1-4 (age \<60 years) or days 1-3 (age \> 60 years).
61979322|NCT03474120||IVF treatment group|Patients treated with IVF. IVF promotion process, ovulation, fertilization, embryo quality, transplantation and final outcome were collected after the treatment cycle was completed.
61979323|NCT03474120||No IVF treatment group|the patients who did not have received IVF treatment .Patients were followed up to collect hormone levels, ultrasound results.
61979324|NCT04659967|EXPERIMENTAL|Pre/Post Training (Within subject)|Participants will complete a baseline questionnaire followed by immediate virtual training, and complete a post-training questionnaire. Participants will also be asked to complete a questionnaire 1-month, 3-months, and 6-months post-training.
61979325|NCT01408914|NO_INTERVENTION|RIF 600|
61979326|NCT01408914|EXPERIMENTAL|RIF 900|
61979327|NCT01408914|EXPERIMENTAL|RIF 1200|
62549932|NCT04729816|EXPERIMENTAL|Dietary Intervention|All participants will stay weight stable while undergoing 5 phases of a dietary intervention that lasts 62 days.
61979328|NCT05036031||EASL-CLIF ACLF patients|
61979329|NCT05036031||APASL ACLF patients|
61979330|NCT05036031||Non-ACLF patients|
62169198|NCT03083600|ACTIVE_COMPARATOR|Plant-based Protein Hydrolysate (1) 5g|plant-based protein hydrolysate 1 (5g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times per day for 12-weeks
61979331|NCT06120556||Severe Insulin Resistant Diabetes (SIRD)|"Patients with SIRD are characterized by high BMI and high insulin resistance and low HbA1c. These patients likely develop diabetic kidney disease.~Defined according to the simplified algorithm proposed by Bello-Chavolla et al. requiring the following data: age at diabetes diagnosis, age, BMI, height, waist circumference, HbA1c, fasting blood glucose, fasting triglycerides, HDL cholesterol"
61979332|NCT06120556||Mild Age-Related Diabetes (MARD)|"Patients with MARD are characterized by late onset diabetes without extreme features.~Defined according to the simplified algorithm proposed by Bello-Chavolla et al. requiring the following data: age at diabetes diagnosis, age, BMI, height, waist circumference, HbA1c, fasting blood glucose, fasting triglycerides, HDL cholesterol"
61979333|NCT06120556||Mild Obesity-related Diabetes (MOD)|Patients with MOD are characterized by high BMI without insulin resistance. Defined according to the simplified algorithm proposed by Bello-Chavolla et al. requiring the following data: age at diabetes diagnosis, age, BMI, height, waist circumference, HbA1c, fasting blood glucose, fasting triglycerides, HDL cholesterol
61979334|NCT06120556||Severe Insulin Deficient Diabetes (SIDD)|"Patients with SIDD are characterized by high HbA1c and rapid progression to insulin therapy. These patients likely develop retinopathy, even in the first years after diagnosis.~Defined according to the simplified algorithm proposed by Bello-Chavolla et al. requiring the following data: age at diabetes diagnosis, age, BMI, height, waist circumference, HbA1c, fasting blood glucose, fasting triglycerides, HDL cholesterol"
61979335|NCT05913180|ACTIVE_COMPARATOR|Vitamin C|1000mg Ascorbic acid daily starting the day of elective gynecological surgery for 10 days
61979336|NCT05913180|PLACEBO_COMPARATOR|Placebo|Placebo daily starting the day of elective gynecological surgery for 10 days
61979337|NCT06380088|EXPERIMENTAL|Task with music|Endurance isometric exercise performed to selected music.
61979338|NCT06380088|EXPERIMENTAL|Task with verbal encouragement|Endurance isometric exercise performed with verbal encouragement.
61979339|NCT06380088|EXPERIMENTAL|Task without motivational feedback|Task without motivational feedback.
61979340|NCT00492115|ACTIVE_COMPARATOR|"therapeutic CPAP Treatment (6 weeks)"|Intervention - The active comparator is an intervention of nightly therapeutic CPAP (continuous positive airway pressure) treatment for 6 weeks. Patients will use CPAP every night for the full duration of the study, i.e., 6 weeks
61979341|NCT00492115|PLACEBO_COMPARATOR|"Sham CPAP/therapetuic CPAP (6 weeks)"|"The placebo comparator is an intervention of placebo CPAP (continuous positive airway pressure) nightly for 3 weeks followed by therapeutic CPAP treatment nightly for 3 weeks.~Patients will use a sham CPAP (no real pressure) for 3 weeks and then will be switched to real CPAP for 3 weeks."
61979342|NCT05603689|ACTIVE_COMPARATOR|Normal diet|no limitations on food consumption.
61979343|NCT05603689|EXPERIMENTAL|Isocaloric ketogenic diet|We defined ICKD as a daily CHOs ingestion \< 30 to 50 g.d-1, without any limitation in fat consumption.
61979344|NCT02192866||Peanut allergic|No intervention(s) to be administered.
61979345|NCT02192866||Other food allergic|No intervention(s) to be administered.
61979346|NCT02192866||Controls|No intervention(s) to be administered.
61979347|NCT01082965|EXPERIMENTAL|Treatment|
61979348|NCT01082965|PLACEBO_COMPARATOR|Placebo|
61979349|NCT04573907|EXPERIMENTAL|Test Formulation of Levothyroxine|Levothyroxine sodium tablets 100 mcg Single dose of 600 mcg administered in dosing period 1 or 2
61979350|NCT04573907|ACTIVE_COMPARATOR|Reference formulation of Levothyroxine|Eutirox 100 mcg Single dose of 600 mcg administered in dosing period 1 or 2
61979351|NCT03240796|EXPERIMENTAL|minimal invasive surgery and secondary IOL implantation|
61979352|NCT03240796|ACTIVE_COMPARATOR|traditional cataract surgery and secondary IOL implantation|
61979353|NCT05483179||Patients with colorectal cancer Patients with colorectal cancer who underwent elective surgery.|Diagnostic Test: Preoperative cardiopulmonary exercise tetsing Patients underwent a cardiopulmonary exercise test prior to surgery.
61979354|NCT00366145|ACTIVE_COMPARATOR|Prochymal®|Participants who receive standard of care plus treatment with ex vivo cultured adult human mesenchymal stem cells.
61979355|NCT00366145|PLACEBO_COMPARATOR|Placebo|Participants who receive standard of care and do not receive treatment with ex vivo cultured adult human mesenchymal stem cells.
62359618|NCT03931395|EXPERIMENTAL|Honey Plus Standard of Care|The Honey standard of care group will receive treatment as usual, alternating acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic, plus 1 tsp of honey with every dose of acetaminophen. The Honey standard of care group will receive the first dose of honey in the recovery room with the administration of acetaminophen and will be provided with honey upon discharge.
62359619|NCT03931395|ACTIVE_COMPARATOR|Standard of Care|The standard of care group will receive treatment as usual (alternating acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic).
61979356|NCT05819554||Acromegaly patients|
61979357|NCT05819554||Non-secreting pituitary tumors affected patients|
61979358|NCT05819554||Secreting pituitary tumors affected patients|
61979359|NCT05819554||Healthy patients|
61979360|NCT04489576|ACTIVE_COMPARATOR|Group (1): Treatment with keratin cure hair|Group (1): Patients will be treated with Keratin cure ® hair treatment. It will be applied once with use of a flat iron.
61979361|NCT04489576|ACTIVE_COMPARATOR|Group (2): Treatment with Qod max keratin hair|Group (2): Patients will be treated with QOD Max ® keratin hair treatment. It will be applied once with use of a flat iron.
61979362|NCT04489576|PLACEBO_COMPARATOR|Group (3): Treatment without keratin hair treatment|Group (3): Patients will be treated without keratin hair treatment, but the same steps of keratin application will be followed.
61979363|NCT00119002|ACTIVE_COMPARATOR|Dexamethasone|1mg of Dexamethasone/kg
61979364|NCT00119002|PLACEBO_COMPARATOR|Placebo|1mg/kg placebo
61979365|NCT01822873||Normal|
61979366|NCT01822873||Age-related macular degeneration|
61979367|NCT05725954|EXPERIMENTAL|GUT LINK SmartPath|physicians will use the interactive GUT LINK Smartpath tool in virtual hallway platform to guide their care and referral practices
61979368|NCT05725954|NO_INTERVENTION|control|physicians will provide care and refer as per their usual practices
62169199|NCT03083600|ACTIVE_COMPARATOR|Plant-based Protein Hydrolysate (1) 10g|Plant-based protein hydrolysate 1 (10 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
61979369|NCT03902535||Group I (geriatric and quality of life assessments)|Patients complete comprehensive geriatric and quality of life assessments within 1-4 weeks of treatment (either upfront surgery which may be followed by radiation with or without chemotherapy or upfront radiation which may include CRT) initiation (baseline), and at 1, 3, and 6 months following CRT completion.
61979370|NCT03902535||Group II (quality of life assessment)|Family caregivers complete quality of life assessment at baseline, and at 1, 3, and 6 months following patient radiation or CRT completion.
61979371|NCT01203046|ACTIVE_COMPARATOR|GROUP A: 7 DAYS ANTIBIOTIC THERAPY|Ertapenem will be administrated within the first 2 hours of Hospital´s admission and the during the next 7 days after surgery.
61979372|NCT01203046|EXPERIMENTAL|GROUP B - 3 DAYS ANTIBIOTIC THERAPY|Ertapenem will be administrated within the first 2 hours of Hospital´s admission and during the next 3 days after surgery.
61979373|NCT00773292|EXPERIMENTAL|ciclosporin|48 weeks treatment with ciclosporin
61979374|NCT02766062|ACTIVE_COMPARATOR|propofol group|Patients with metabolic syndrome were randomly assigned to receive propofol anesthesia
61979375|NCT02766062|ACTIVE_COMPARATOR|sevoflurane group|Patients with metabolic syndrome were randomly assigned to receive sevoflurane anesthesia
61979376|NCT00023543|EXPERIMENTAL|1|Participants will reduce total fat intake to 17 percent of calories, 1300 kilo calories, and increase moderate activity to 150-240 minutes per week to obtain a 10 percent reduction in weight.
61979377|NCT01657045|EXPERIMENTAL|Cohort 1|Subjects will be randomized to receive injections JVS-100 or placebo.
61979378|NCT01657045|EXPERIMENTAL|Cohort 2|Subjects will be randomized to receive injections JVS-100 or placebo.
61979379|NCT01657045|EXPERIMENTAL|Cohort 3|Subjects will be randomized to receive injections of JVS-100 or placebo.
61979380|NCT02755324|EXPERIMENTAL|Intervention|Volunteers will be exposed to escalating doses of male Schistosoma mansoni cercariae
61979381|NCT03437720|EXPERIMENTAL|SAR425899 (Low Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
61979382|NCT03437720|EXPERIMENTAL|SAR425899 (High Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
61979383|NCT03437720|PLACEBO_COMPARATOR|Placebo (Low Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
61979384|NCT03437720|PLACEBO_COMPARATOR|Placebo (High Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
61979385|NCT01942187|ACTIVE_COMPARATOR|Medication Augmentation|Medication augmentation with aripiprazole (Abilify) starting at 5mg/day, and increasing weekly in 5mg increments to a maximum of 15mg (10mg/day is the target dose). Under conditions of nonresponse after 6 weeks, aripiprazole will be switched for bupropion (Wellbutrin), starting at 150mg, and possibly increasing to 300mg after 2 weeks.
61979386|NCT01942187|ACTIVE_COMPARATOR|Problem Solving Therapy|Treatment for 12 weeks with weekly sessions of Problem Solving Therapy, with a trained therapist.
61979387|NCT03206645|EXPERIMENTAL|Carboplatin/Paclitaxel + PTC596|Carboplatin AUC 6mg/L IV on day 1; Paclitaxel 175mg/m2 IV on day 1; Unesbulin PO, twice a week, on day 1, 4, 8, 11, 15 and 18 per 21-day cycle for the first 3 cycles.
61979388|NCT04945785||control|Before switch Advagraf to Envarsus
61979389|NCT04945785||case|After switch Advagraf to Envarsus
61979390|NCT00115856|NO_INTERVENTION|Subjects studied|Single arm exploratory feasibility safety and efficacy study of MRI to image atherosclerosis in arteries
61979391|NCT01460420|EXPERIMENTAL|Bortezomib + Lenalidomide|After conditioning treatment and graft versus host disease prophylaxis with Bz 1.3 mg/m2 on days +1, +4 and +7 plus sirolimus/rapamycin at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL, a maintenance therapy with Bz 1.3 mg/m2 on days 1, 8 and 15 in cycles of 56 days up to 6 cycles post-transplant and on day +180 Len will be started at a dose of 5 mg and will be maintained until relapse.
61979392|NCT06242314|EXPERIMENTAL|L-PRF|L-PRF was laid directly on the palatal wound immediately after free gingival graft harvesting and stabilized with silk suture.
62359620|NCT01655745|EXPERIMENTAL|FDG PET/MR, No Chemotherapy Arm|Patients that are NOT receiving chemotherapy but are only completing surgical intervention.
62359621|NCT01655745|EXPERIMENTAL|FDG PET/MR, Chemotherapy Arm|Patients that are receiving chemotherapy prior to completing surgical intervention. These patients will receive a FDG PET/MR prior to chemotherapy and after completion of chemotherapy (at the time of pre-op, before surgical intervention).
62359622|NCT05852730|EXPERIMENTAL|DPI-386 Nasal Gel|DPI-386 Nasal Gel, 0.4 mg
61979393|NCT06242314|EXPERIMENTAL|A-PRF|A-PRF was laid directly on the palatal wound immediately after free gingival graft harvesting and stabilized with silk suture.
62169200|NCT03083600|ACTIVE_COMPARATOR|Plant-based Protein Hydrolysate (1) 15 g|Plant-based 1 protein hydrolysate (15 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
62169201|NCT03083600|PLACEBO_COMPARATOR|Placebo|Cellulose Placebo stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks.
61979394|NCT06242314|PLACEBO_COMPARATOR|Palatal stent|Palatal stent was prepared by taking impression of the palate before surgery. After FGG harvesting, periodontal paste (COE-PAK periodontal dressing, GC, Illinois, USA) was applied on the wound surface of the palatal stent and the palate was closed.
61979395|NCT02892760|EXPERIMENTAL|with C-brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
61979396|NCT05891509|EXPERIMENTAL|Minimally Invasive Hematoma Evacuation|Subjects randomized to this arm will receive the intervention of minimally invasive hematoma evacuation and best medical therapy
61979397|NCT05891509|ACTIVE_COMPARATOR|Best Medical Therapy|Subjects randomized to this arm will receive best medical therapy alone
61979398|NCT01738763|EXPERIMENTAL|Low dose (2.5 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
61979399|NCT01738763|EXPERIMENTAL|Intermediate dose (4.0 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
61979400|NCT01738763|EXPERIMENTAL|High dose (6.0 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
61979401|NCT00439426|EXPERIMENTAL|1|
61979402|NCT02345811|EXPERIMENTAL|Sapphire|Participants were randomized to wear the Sapphire lens pair for two weeks during the cross over study.
61979403|NCT02345811|ACTIVE_COMPARATOR|senofilcon A|Participants were randomized to wear the senofilcon A lens pair for two weeks during the cross over study.
61979404|NCT05735392|OTHER|Trastuzumab emtansine as per SmPC for liquid biopsy and tissue collection|"Patients will receive trastuzumab emtansine (T-DM1) at 3.6 mg/kg intravenously every 21 days, as perSummary of Product Characteristics (SmPC).~Peripheral blood samples will be taken by venipuncture prior to initiation of study therapy (T0), and at designated time-points after the first (T1) the second (T2), the third(T3)and after the sixth(T6), the ninth(T9), until the 12thcycle of T-DM1(see Fig.1) on-treatment and finally at progression."
61979405|NCT05479955|EXPERIMENTAL|5 minutes skin to skin contact|Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. Skin-to-skin contact was applied to the babies of the women in this group for 5 minutes immediately after birth. After the application, routine follow-up and care of the newborn was performed and kept under a radiant heater. When the woman became stable, her baby was given and breastfeeding was supported.
61979406|NCT05479955|EXPERIMENTAL|60 minutes skin to skin contact|Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. Skin-to-skin contact application was initiated to the babies of the women in this group immediately after birth and was applied continuously for 60 minutes as recommended by WHO. Follow-up and care of the newborn were done during the application. At the end of 60 minutes, the baby was dressed and given to its mother.
61979407|NCT00588848|EXPERIMENTAL|Autoadjusting CPAP (VPAP auto)|The intervention will be the use of an Autoadjusting CPAP unit that will be applied to the subject during the 8 hours overnight the first night after surgery (study night). During this time, they will undergo a full night attended polysomnogram in their hospital room.
61979408|NCT00588848|ACTIVE_COMPARATOR|CPAP arm (usual care)|The intervention will be the use of the subject's own CPAP machine and this will be applied to the subject during the 8 hours overnight the first after surgery (study night). During the study night, they will undergo full polysomnography in their hospital room.
61979409|NCT02335723|ACTIVE_COMPARATOR|Alteco LPS Adsorber|Hemoperfusion and Standard therapy
61979410|NCT02335723|PLACEBO_COMPARATOR|Placebo|Placebo and Standard therapy. The placebo comparator device differs from Alteco® LPS Adsorber only in that no peptide component (i.e. active component) has been attached to the matrix.
61979411|NCT03296657|EXPERIMENTAL|stannous fluoride toothpaste|0.454% stannous fluoride will be used twice a day, brushing for at least 1 minute for 2 weeks
61979412|NCT01917201|OTHER|IVUS-guided group|The coronary stenting under IVUS-control (with VH or i-MAP) is carried out: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS (with VH or i-MAP) is being used, the optimality of stent implantation is also being assessed.If criteria of optimal implantation guided by IVUS were not achieved, additional impact is being made. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. An additional impact based on OCT data is not being used.
61979413|NCT01917201|OTHER|Non-IVUS group|The coronary stenting under angiography control is carried out. After postdilatation control OCT is carried out. An additional impact based on OCT data is not being used.
61979414|NCT06005844|OTHER|Adults with a cerebellar damage|
61979415|NCT01806753|EXPERIMENTAL|midazolam/propofol injection|Intermittent midazolam/propofol injection controlled by endoscopist
61979416|NCT01806753|ACTIVE_COMPARATOR|propofol infusion|Continuous propofol infusion with opioid administration
61979417|NCT04474067||• Asymptomatic or Pre-symptomatic Infection|Individuals who test positive for SARS-CoV-2 by virologic testing using a molecular diagnostic (e.g., polymerase chain reaction) or antigen test, but have no symptoms.
61979418|NCT04474067||Mild COVID-19|"Individuals who have any of the various signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnea, or abnormal chest imaging.~According to NIH classification"
62359623|NCT05852730|EXPERIMENTAL|Control|Another form of preventative or treatment medication for motion sickness (e.g., promethazine or meclizine)
61979419|NCT04474067||Moderate COVID-19|COVID-19 patients who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (SpO2) ≥94% on room air at sea level.
61979420|NCT04474067||Severe COVID-19|COVID-19 patients who have respiratory frequency \>30 breaths per minute, SpO2 \<94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) \<300 mmHg, or lung infiltrates \>50%
61979421|NCT04474067||Critical COVID-19|COVID-19 patients who have respiratory failure, septic shock, and/or multiple organ dysfunction.
61979422|NCT04474067||Sepsis|A control group of patients with sepsis-related cytokine storm
61979423|NCT04474067||CAR-T CRS|A control group of patients with cytokine release syndrome due to CAR-T therapy
61979424|NCT01044940||Birth asphyxia|Babies suffering from birth asphyxia
61979425|NCT01044940||Blood transfusion|Babies who receives blood transfusion
61979426|NCT01044940||Heart Surgery|Babies who need heart surgery
62169202|NCT03083600|ACTIVE_COMPARATOR|Plant-based Protein Hydrolysate (2) 5g|Plant-based protein hydrolysate 2 (5 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
61979427|NCT05247645||Rare diseases with predominantly skeletal involvement|The group comprises all patients affected rare diseases with predominantly skeletal involvement
61979428|NCT04853979|EXPERIMENTAL|PRONE|Any combination of prone or side position for 3 hours, 3 times a day for 3 days.
61979429|NCT04853979|ACTIVE_COMPARATOR|NO PRONE|Usual care
61979430|NCT03053414|ACTIVE_COMPARATOR|Treatment Arm # 1|50,000 IU oral vitamin D2 per week for 12 weeks + Dietary counseling
61979431|NCT03053414|ACTIVE_COMPARATOR|Treatment Arm # 2|50,000 IU oral vitamin D2 per week x 12 weeks then 800 IU/day oral vitamin D3 for 6 months + Dietary counseling
61979432|NCT03053414|ACTIVE_COMPARATOR|Treatment Arm # 3|50,000 IU oral vitamin D2 per week x 12 weeks then 5,000 IU/day oral vitamin D3 for 6 months+ Dietary counseling
61979433|NCT03053414|ACTIVE_COMPARATOR|Treatment Arm # 4|5,000 IU oral daily vitamin D3 for 9 months + Dietary counseling
61979434|NCT00879281|NO_INTERVENTION|1 Care as usual|Regular care
61979435|NCT00879281|EXPERIMENTAL|2 Intervention|"Regular Care + individualized written action plan to enhance self-mananagement and early detection/treatment of an exacerbation."
61979436|NCT02673489|EXPERIMENTAL|Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV)|Oral dosing of DCV 60 mg tablet once daily + SOF 400 mg tablet once daily + RBV 1000-1200 mg tablet per day (weight based) for 24 weeks.
61979437|NCT04850690||Children with hemiparetic Cerebral palsy|15 children with CP, between 9-15 years old
61979438|NCT06521359||case|
61979439|NCT06521359||control|
61979440|NCT05218473|EXPERIMENTAL|Prolonged ECG monitoring group|Patients receive 14-day continuous electrocardiography patch monitoring
61979441|NCT05218473|ACTIVE_COMPARATOR|Conventional procedure group|Patients received serial 12-lead electrocardiograms once daily for five days or 24-hour Holter monitoring
61979442|NCT04092790|EXPERIMENTAL|Virtual Gate Device (VGD)|The Virtual Gait Device (VGD) is a technology that uses fussy-logic technology to stimulate calf muscles in synchrony with the patient's heartbeat, enabling a virtual gait in patients who have limited mobility. The stocking-like device is especially useful in older patients who are acutely hospitalized and thus at risk for sarcopenia. While physical activity and physical resistance training are well-documented as preventive measures for sarcopenia, active physical exercise is an unrealistic option for most acutely hospitalized, mobility-limited, older patients. The VGD is a practical alternative that is simple to operate. One pilot study in the orthopedics department in Hadassah Medical Center in Jerusalem, Israel was performed on patients with fractured ankles with the goal of muscle wasting prevention. The VGD will be provided by the manufacturer for use in this pilot clinical study.
61979443|NCT02396901|EXPERIMENTAL|GDT group|Patients randomized to the GDT Group will care from a protective strategy with the suspension of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) 48 hours before surgery and receive hydration with lactated Ringer's solution at the rate of 1 mL/kg/h in the night before the surgery until the surgical procedure and perioperative hemodynamic therapy.
61979444|NCT02396901|PLACEBO_COMPARATOR|Control group|Patients randomized to the control group will be treated in accordance with the care in the institution's routine.
61979445|NCT05998200|OTHER|Serum with low concentration AHA (1% Glycolic acid and Lactic acid) and PGA|This serum containing low concentration AHA (1% Glycolic acid and Lactic acid) and PGA.
61979446|NCT01529879|EXPERIMENTAL|New abutment connection implant|Implant with new abutment connection
61979447|NCT01529879|ACTIVE_COMPARATOR|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
61979448|NCT01779739|NO_INTERVENTION|No perineorrhaphy|Subjects will not have a perineorrhaphy procedure added to the vaginal prolapse repair
61979449|NCT01779739|ACTIVE_COMPARATOR|Perineorrhaphy|Subjects will have a perineorrhaphy added to the vaginal repair of prolapse
61979450|NCT00851812|OTHER|Arm 1|Usual Care: Standard care monitoring
61979451|NCT00851812|EXPERIMENTAL|Arm 2|Progressive walking and resistance exercise treatment
61979452|NCT03186833||Group A|males or females aged \> 70 years without major systemic comorbidities (resting blood pressure \<140/90 mmHg, no history diabetes mellitus according to WHO criteria).
62549933|NCT02069509||Control research participants|diagnosis of FRDA genetically excluded
62549934|NCT02069509||FRDA patients|with genetically confirmed diagnosis of FRDA
61979453|NCT03186833||Group B|males or females aged \>70 years with hypertension, defined as a documented blood pressure of Systolic Blood Pressure (SP \>140 mmHg or \>90mmHg Diastolic Blood Pressure) without diabetes mellitus and HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria b) need for diuretic therapy.
61979454|NCT03186833||Group C|male or female aged \> 70 years with diabetes mellitus (defined according to the World Health Organization (WHO)) AND hypertension, without HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria38 b) need for diuretic therapy.
61979455|NCT03186833||Group D|male or female aged \>70 years with HFPEF, defined as signs and symptoms of HF with LVEF\>50% and raised natriuretic peptides (BNP\>35pg/ml or NT-proBNP\>125pg/ml) along with one other criteria: i) structural heart disease (left atrial enlargement or left ventricular hypertrophy) on TTE, ii) evidence of LV diastolic dysfunction based on ESC Guidelines 2016, or iii) hospitalization with heart failure within 12 months prior to study entry.
61979456|NCT03186833||Group E|male or female aged \>70 years with HFREF, defined as HF with LVEF \<40% on TTE)
61979457|NCT01757054|EXPERIMENTAL|Probiotic group|
61979458|NCT01757054|NO_INTERVENTION|Control group|This is a non-supplemented control group that will follow the same dietary and medication restrictions. The purpose of this group is to ensure results are due to supplementation and not due to random dietary exposure.
61979459|NCT04629053||Patients with an acute febrile illness|Patients with acute febrile illness, 4,800 children and 2,400 adults, divided equally across four countries (Laos, Myanmar,Thailand (including the Thai-Myanmar border region), and Bangladesh) and three age groups: \>28 days to \<5 years; ≥5 years to \<15 years, and ≥15 years of age.
61979460|NCT05039242|ACTIVE_COMPARATOR|Control Group A(Conventional Physical Therapy)|Balanced resistive hand exercise with use of physio hand ball squeezes
61979461|NCT05039242|EXPERIMENTAL|Experimental Interventional Group B (I-Band Application of Kinesiotaping)|Participants will receive exercise interventions as group A along with that the Kinesiotape, by using I application technique from proximal to distal on dorsum of hand and forearm.
61979462|NCT05039242|EXPERIMENTAL|Experimental Interventional Group C (fan shaped Application of Kinesiotaping)|Participants will receive exercise interventions as group A along with that the Kinesiotape will be applied, by using fan cut application technique on MCP joints involving extensor tendons of fingers on dorsal surface of both hands of subjects
61979463|NCT05554757|EXPERIMENTAL|conventional rubber dam system|in the first 30 patients, the conventional rubber dam was used prior to the OptraDam For the first 30 patients, on the day of the first appointment, the stopwatch was set for recording the time taken for the application of the conventional rubber dam . Following this, the required dental treatment was carried out. Radiographs were taken as \& when necessary . At the end of the appointment, the questionnaires were filled by the patient as well as the operator regarding their experience of the conventional rubber dam
61979464|NCT05554757|ACTIVE_COMPARATOR|OPTRADAM|In second appoinment the optradam was applied. The stopwatch was set for the recording the time of application of the OptraDam. The required dental treatment was carried out. Radiographs were taken. At the end of the appointment, the questionnaires were again filled by the patient as well as the operator regarding their experience of the OptraDam.
61979465|NCT03899142|EXPERIMENTAL|human hepatitis B immunoglobulin|once, i.m.
61979466|NCT05893433|EXPERIMENTAL|Bedside cycling Group|"Participants (25 patients) that will receive bedside cycling:~* Intensity:~  1. RPE from 11 to 13 (scale 6-20)~ 2. Resting HR + 20-30 bpm (up to tolerance if non-symptomatic), from low intensity and progressed to medium intensity.~* Duration: Session duration: Total duration of 20 min, early morning.~* Frequency: once daily from medically stable until discharge. in addition the medical treatment and routinely physiotherapy protocol."
61979467|NCT05893433|PLACEBO_COMPARATOR|Routine physical therapy Group|participant that will receive only routine physiotherapy treatment protocol and the medical treatment.
61979468|NCT06207773|EXPERIMENTAL|Educator verbal feedback|During the study, the educator will hold one-on-one meetings with the students regarding their clinical internship for at least 20 minutes every week for a total of 6 weeks
61979469|NCT00405587|EXPERIMENTAL|PLX4032|Open-label, sequential dose escalation
61979470|NCT01394679|ACTIVE_COMPARATOR|18-F-FDG Imaging Agent|18 F FDG followed by PET/CT imaging
61979471|NCT01394679|EXPERIMENTAL|99m Tc-EC-DG imaging agent|99m Tc-EC-DG injection followed by SPECT/CT imaging (target of 20-30 mCi of Tc)and \< 1 mg EC-DG
61979472|NCT01900327|EXPERIMENTAL|neoadj. Treatment|Neoadjuvant CRT with weekly Gemcitabine neoadjuvant 300mg/m2 for 6 weeks combined with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions will be followed by classical or pylorus-preserving partial pancreato-duodenectomy (PD) and adjuvant chemotherapy (CTx), preferentially using Gemcitabine adjuvant (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle).
61979473|NCT01900327|ACTIVE_COMPARATOR|Upfront Surgery|Upfront PD followed by adjuvant CTx, preferentially with Gemcitabine adjuvant (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle).
61979474|NCT02062879|EXPERIMENTAL|Ketamine|Ketamine 90mg/30 mL PCA (3 mg/mL)
61979475|NCT02062879|ACTIVE_COMPARATOR|Hydromorphone|Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)
61979476|NCT05411679|EXPERIMENTAL|Arm 1|patients with ataxia-telangiectasia mutated protein (ATM)-negative relapsed, advanced GC.
61979477|NCT05411679|EXPERIMENTAL|Arm 2|patients with relapsed extensive stage SCLC.
61979478|NCT03485690||COPD|COPD patients with no restrictions. The study protocol does not consider ad-hoc different patient groups. Prospective follow-up will be equally done in all recruited patients
61979479|NCT00827983|EXPERIMENTAL|Progesterone SC|
61979480|NCT00827983|ACTIVE_COMPARATOR|Progesterone Vaginal gel|
61979481|NCT02175888|EXPERIMENTAL|Oral iron supplement every day for 14 days|Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days
61979482|NCT02175888|ACTIVE_COMPARATOR|Oral iron supplement every second day for 28 days|Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days
61979483|NCT01065233||alcoholic cirrhosis with viral infection|patient with alcoholic cirrhosis with viral infection (300 patients)
61979484|NCT01065233||alcoholic cirrhosis without viral infection|patient with alcoholic cirrhosis without viral infection
61979485|NCT01709851||Type 1 Diabetes - vMD and sMD|Patients will undergo vascular (vMD) and subcutaneous microdialysis (sMD) using the GMD-system (GlucoMen(R)Day-system)
62359624|NCT05242263|EXPERIMENTAL|Training group - ACT with feedback|At the beginning of each session participants will complete 45 standard dot-probe trials. During these trials, participants' ABV will be measured and set as their baseline. In the following trials, participants will receive feedback: a green screen background when their ABV will reach below their baseline or a red screen background when their baseline ABV score is surpassed.
62359625|NCT05242263|SHAM_COMPARATOR|Control group - ABV with yoked sham feedback|Participants in this group will receive sham feedback that is unrelated to their ABV during the task, this is by presenting a feedback given to another participant in the training group (i.e., yoked sham feedback).
61979486|NCT01709851||Type 1 diabetes - vMD|Patients will undergo vascular microdialysis (vMD) using the GMD-system (GlucoMen(R)Day-system)
62359626|NCT06162871|EXPERIMENTAL|active participation|
61979487|NCT00532584|EXPERIMENTAL|treatment with inhaled beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
61979488|NCT00532584|NO_INTERVENTION|Control - healthy smokers|Group B will act as control and include healthy smokers who receive no treatment.
62359627|NCT06162871|NO_INTERVENTION|non involved in active part|
62359628|NCT00669032|EXPERIMENTAL|hyaluronic acid|Cycles of 5 injections of hyaluronic acid at specified intervals
62359629|NCT00669032|PLACEBO_COMPARATOR|Placebo|Cycles of 5 injections of saline at specified intervals
62359630|NCT02719067||ASD group|Subjects have a clinical diagnosis of autistic disorder or Asperger disorder defined by the DSM-IV and ICD-10 criteria
62359631|NCT02719067||TD group|Typically developing controls without lifetime ASD or a family history of ASD
62359632|NCT02045056|EXPERIMENTAL|Gemfibrozil|Gemfibrozil 600 mg by mouth twice daily for 48 weeks
62359633|NCT02045056|PLACEBO_COMPARATOR|Sugar pill|Matching placebo capsule by mouth twice daily for 48 weeks
62359634|NCT00594087|ACTIVE_COMPARATOR|1|Lunesta 2 or 3 mg
61979489|NCT00532584|NO_INTERVENTION|control - healthy non-smokers|Group C will act as control and include healthy non-smokers who receive no treatment.
61979490|NCT02297269||group laparoscopic surgery|Participants undergo laparoscopic gastrointestinal malignancy surgery will be included in this group. The pressure of pneumoperitoneum maintain in 10-12mmHg.
61979491|NCT02297269||group open surgery|Participants undergo open gastrointestinal malignancy surgery will be included in this group.
61979492|NCT04347239|PLACEBO_COMPARATOR|Placebo|
61979493|NCT04347239|EXPERIMENTAL|700mg Leronlimab|
61979494|NCT01762631||Cohort 1|All participants enrolled between November 2012 and March 2013 under the original protocol.
61979495|NCT01762631||Cohort 2|After Cohort 1 was completed, the study investigators changed the protocol to eliminate the photograph/weight of the powdered formula alone in each bottle to reduce burden. All other protocol procedures remained the same. Cohort 2 participants enrolled between April 2013 and May 2014.
61979496|NCT03310554|EXPERIMENTAL|26cm suspended overlength biliary stents group|
61979497|NCT03310554|EXPERIMENTAL|30cm suspended overlength biliary stents group|
61979498|NCT03310554|OTHER|ordinary plastic biliary stents group|
61979499|NCT05453344|OTHER|Intervention - DexCom one|Provision of DexCom one for glucose monitoring
61979500|NCT03189758|EXPERIMENTAL|Intervention|Participants will follow a Observational Control Diet (CON) diet followed by an Controlled Dietary Sodium Restriction (INT) diet.
61979501|NCT04946292|EXPERIMENTAL|Theory-derived intervention|Questionnaire will be used including the scales for three dominant theoretical models, Health Belief Model (HBM), Theory of planned behaviour (TPB) and Social Cognitive Theory (SCT). The theoretical model that best explains the health behaviours of the selected participants will be selected for designing oral health intervention.The theory-derived intervention will address the constructs/domains of the selected model(s) in the context of the three target behaviours (diet, toothbrushing and dental flossing).
62567067|NCT04316338|EXPERIMENTAL|Active intermittent theta-burst stimulation (iTBS)|6 weeks of iTBS delivered at 80% resting motor threshold will be delivered to personalized regions in the prefrontal cortex based on each individual's functional connectivity.
61979502|NCT04946292|ACTIVE_COMPARATOR|Conventional health education|Participants will be randomly assigned to the control group, stratified by gender and education level. Allocation concealment will be ensured by using sealed opaque envelopes.
61979503|NCT04489329|EXPERIMENTAL|Single Arm|Participant swallows and retrieves capsule in stool before and after ingestion of a probiotic. Capsule and stool samples are analyzed for presence of probiotic strain and compared to baseline.
61979504|NCT05077709|EXPERIMENTAL|Arm A (NSCLC)|NSCLC patients (metastatic stage IV) treated with IO102-IO103 SC Q3W in combination with pembrolizumab IV 200mg Q3W
61979505|NCT05077709|EXPERIMENTAL|Arm B (SCCHN)|SCCHN patients (metastatic stage IV) treated with IO102-IO103 SC Q3W in combination with pembrolizumab IV 200mg Q3W
61979506|NCT05077709|EXPERIMENTAL|Arm C (mUBC)|mUBC patients (metastatic stage IV) treated with IO102-IO103 SC Q3W in combination with pembrolizumab IV 200mg Q3W
61979507|NCT05063747||COVID-19 ICU cohort|All patients admitted to a Swedish ICU with COVID-19 with at least one year of follow up. COVID-19 is defined by the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) diagnosis U07.1 in the nationwide Swedish intensive care registry.
61979508|NCT05063747||COVID-19 hospital admission control cohort|Four random control patients per ICU patient matched on age legal gender and region. Controls selected from all patients admitted to a Swedish hospital with COVID-19 with at least one year of follow up not including patients in the COVID-19 ICU cohort. COVID-19 is defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish national patient registry.
61979509|NCT05063747||General population control cohort|Four general population controls per ICU patient, matched on age, legal gender and region drawn from the total population register of Sweden. ICU and hospital admitted COVID-19 patients are not included.
61979510|NCT06220422||Standard Department procedure for managing direct-acting oral anticoagulants|Standard Department procedure for managing direct-acting oral anticoagulants (NACO \< 50 ng/mL) in the management of fractures before September 2021
61979511|NCT06220422||New Department procedure for managing direct-acting oral anticoagulants|Intervention Description New Department procedure for managing direct-acting oral anticoagulants (NACO \< 100 ng/mL) in the management of fractures after September 2021
61979512|NCT00974909|ACTIVE_COMPARATOR|Treatment group|Treatment group
61979513|NCT00974909|SHAM_COMPARATOR|sham group|Sham group
61979514|NCT03331679|EXPERIMENTAL|2 Wk HIIT|2 weeks of High Intensity Interval Training
61979515|NCT06149507|EXPERIMENTAL|Acetaminophen|Syrup 10-15 mg/kg/dosage every 6-8 hours as needed and do not exceed more than 5 doses in 24 hours Duration 1 week
61979516|NCT06149507|ACTIVE_COMPARATOR|ibuprofen|Syrup 4-10 mg/kg/dosage every 4-6 hours as needed and do not exceed more than 5 doses in 24 hours Duration 1 week
61979517|NCT02245074|OTHER|Acute exacerbation|Cell profiles Analysis after sputum induction in infants with Acute exacerbation
61979518|NCT02245074|OTHER|Uncontrolled asthma|Cell profiles Analysis after sputum induction in infants with Uncontrolled asthma
61979519|NCT02245074|OTHER|controlled asthma|Cell profiles Analysis after sputum induction in infants controlled asthma
61979520|NCT02615587||AF patients in Denmark / Cohort 1|"The base population of AF patients for diagnosis and health care utilization / resource use will be identified in the National Patient Registry. For a given period of time (2000-2013, both years inclusive) all patients with a hospital contact (admission, outpatient visit or ER visit) and for whom AF was the primary or secondary diagnosis code will be identified.~Further Data sources used:~Registry of Medicinal Product Statistics: for determining the individuals' use of prescription medicine DREAM database: for investigation of sickness benefit and productivity loss Statistics Denmark's databases: on social services from municipalities Cause of Death Registry: AF-patients or controls who died during the study period (2000-2013) Danish Civil Registry: used for identification of controls, holds information about age, gender"
61979521|NCT04117425|OTHER|Pregnant women|"40 Pregnant women and 10 Pregnant women that have a medical interruption of pregnancy who were already treated by levetiracetam.~Blood collection at each trimester of pregnancy, delivery and post partum visit or at medical interruption.~Collection of saliva at each trimester of pregnancy and post partum visit. Collection of cord blood and amniotic fluid at delivery or at medical interruption"
62359635|NCT00594087|PLACEBO_COMPARATOR|2|Placebo 2mg or 3 mg
61979522|NCT02046109|EXPERIMENTAL|Repair|Subjects in the Repair group will be given a local anesthetic only if required (i.e. for restorations extending gingivally or on exposed dentin surface) as per usual clinical protocol. The existing restoration will not be removed. The surface of the existing restoration will be roughened with a Brasseler 8856 bur without extending to the surrounding enamel (except is the defect being repaired is adjacent to enamel). No accessory groves/pits for retention will be prepared. To repair the restoration, the surface will be etched using 35% phosphoric acid, and then 3M ESPE Scotchbond Universal Adhesive System followed by 3M ESPE Filtek Supreme Ultra Universal Restorative composite will be used as per the manufacturer's instructions.
61979523|NCT02046109|ACTIVE_COMPARATOR|Replace|Subjects in the Replace group will be given local anesthetic (an injection of 2% lidocaine with 1:100 000 epinephrine). The type of injection and dosage of anesthetics will be dependent on the tooth being treated, and will follow the usual protocol used in the Dalhousie Dentistry undergraduate clinics. The existing composite restoration will then be removed and the peripheral enamel beveled if not already beveled. To restore the tooth, the surface will be etched using 35% phosphoric acid, and then 3M ESPE Scotchbond Universal Adhesive System followed by 3M ESPE Filtek Supreme Ultra Universal Restorative composite will be used as per the manufacturer's instructions.
61979524|NCT03863990||Patients with PAH|Adult male and female patients from Argentina diagnosed with pulmonary arterial hypertension (PAH) of WHO functional class I between 01-Jan-2012 and 31-Dec-2017 and with at least one year of follow-up.
61979525|NCT00480272|EXPERIMENTAL|group A|"* adalimumab 40 mg subcutaneous injections every other week from baseline to month 12~* methotrexate orally weekly at initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.~* prednisone orally 50 mg daily, gradually tapered up to 6.25 mg at week 7 and stopped at month 6"
61979526|NCT00480272|PLACEBO_COMPARATOR|group B|"* adalimumab 40 mg subcutaneous injections every other week from baseline to the end of month 12~* methotrexate orally oweekly at an initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.~* placebo orally, stopped at month 6"
61979527|NCT05944341|EXPERIMENTAL|Articaine|
61979528|NCT05944341|ACTIVE_COMPARATOR|Lidocaine|
61979529|NCT00003492|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
61979530|NCT01665066|ACTIVE_COMPARATOR|Own Brand cigarette|Smoke Own Brand cigarette, 15 puff of cigarette.
61979531|NCT01665066|EXPERIMENTAL|One High 2,4% nicotine|Smoke electronic cigarette One High 2,4% nicotine for a day, 15 puff of e-cigarette.
61979532|NCT01665066|EXPERIMENTAL|Original 7,4 mg nicotine|Smoke electronic cigarette Original 7,4 mg nicotine for a day. 15 puff of e-cigarette.
61979533|NCT01665066|PLACEBO_COMPARATOR|Nicotine Free|Smoke electronic cigarette nicotine free (15 puff)
61979534|NCT01665066|EXPERIMENTAL|EGO 9mg|Smoke electronic cigarette EGO for a day (15 puff)
61979535|NCT04597307||IN.PACT™ Admiral™ DCB Cohort|De novo patients not previously treated with a DCB who are successfully treated with the IN.PACT™ Admiral™ DCB (ability to cross the target lesion).
62359636|NCT05067712|ACTIVE_COMPARATOR|Open Surgical Exposure Technique|After randomization, the PDC allocated to this arm is surgically exposed with the Open Technique followed by the Orthodontic Treatment phase
62359637|NCT05067712|ACTIVE_COMPARATOR|Closed Surgical Exposure Technique|After randomization, the PDC allocated to this arm is surgically exposure with the Closed technique followed by the Orthodontic Treatment phase.
62567068|NCT03892642|EXPERIMENTAL|BCG + Avelumab|Combination of avelumab and intravesical BCG. One cycle = 12 weeks (84 days). A standard maintenance therapy regimen will be provided with BCG occurring at Month 3, 6, and 12. Avelumab treatment ends at the conclusion of Month 12 maintenance therapy.
61979536|NCT03730493|EXPERIMENTAL|Pictorial flashcard|In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). Time was noted and kept for observation till 72 hours or removal in between.
62567069|NCT00958958|OTHER|Quality improvement program|"There are multifaceted Interventions for the clinic hospital team Including~1. Distribution of educational materials~2. Case manager~3. Reminders~4. Practical training"
61979537|NCT03730493|NO_INTERVENTION|Comparison Group|In control group, standard care was given as per the hospital protocol.Time was noted and kept for observation till 72 hours or removal in between.
61979538|NCT04669392|EXPERIMENTAL|70% Ethanol|Using 70% Ethanol Alcohol as a root canal irrigating solution before obturating the lower primary second molar with Metapex
61979539|NCT04669392|NO_INTERVENTION|Normal Saline|Irrigating the canals with Normal Saline before obturating the lower primary second molar with Metapex
61979540|NCT03465241||Monitoring by NGS group|This group will accept the ctDNA dynamic monitoring on the following phase:the day before surgery,the 3rd to 7th day after surgery,3 to 4 weeks after adjuvant chemotherapy finished, then every 6 months in the following 2 years.
61979541|NCT00791466|EXPERIMENTAL|1|
62359638|NCT05308667|EXPERIMENTAL|iTBS + mCIMT group|
61979542|NCT00791466|PLACEBO_COMPARATOR|2|
61979543|NCT03933150|OTHER|ultrasoun guided caudal epidural injection|A. Ultrasound-Guided CESI (Group 1) All the injection procedures were performed as an outpatient clinic setting. We used Acuson P300 (Siemens, Italy) with a linear transducer at 6 to 12 MHz as the US instrument, another curved transducer at 2-5 MHz was available for obese patients.
61979544|NCT03933150|OTHER|fluoroscopy guided caudal epidural injection|B. Fluoroscopy-Guided CESI (Group 2) All the injection procedures were performed in a specialized room with a FL device in the radiology department. We used a FL device GS 1004 with ALLURA XPER FD 20 system (Philips, Holland) with X-ray tube housing assembly, X-ray tube, beam limiting device and image receptor
61979545|NCT06107712|EXPERIMENTAL|Online yoga exercise group|Online yoga practice was implemented in a calm and quiet environment in the individuals' own home or dormitory in a way that they could participate online.
62567070|NCT00958958|NO_INTERVENTION|Hospital standard treatment|Hospital standard treatment
61979546|NCT06107712|ACTIVE_COMPARATOR|Face-to-face yoga exercise group|Face-to-face yoga practice was carried out at therapeutic exercise laboratory at Marmara University Health Sciences Faculty.
61979547|NCT06107712|NO_INTERVENTION|control|Participants in the control group who continued their routine activities for six weeks after the initial evaluation and did not participate in any exercise, yoga, etc. program were included in the second evaluation.
61979548|NCT05025189|ACTIVE_COMPARATOR|Table Grape|Subjects will consume 4 weeks of (two servings) of standardized Freeze-Dried Whole Table Grape Powder
61979549|NCT05025189|PLACEBO_COMPARATOR|Beige Diet|Subjects will consume 4 weeks of a beige diet (low in fiber and low in polyphenols)
61979550|NCT02661542|EXPERIMENTAL|Phase 1: Lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
61979551|NCT02661542|EXPERIMENTAL|Phase 1: 1.5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
61979552|NCT02661542|EXPERIMENTAL|Phase 1: 2.25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
61979553|NCT02661542|EXPERIMENTAL|Phase 1: 3.375x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
61979554|NCT02661542|EXPERIMENTAL|Phase 1: 5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
62359639|NCT05308667|SHAM_COMPARATOR|Sham iTBS+ mCIMT group|
61979555|NCT02661542|EXPERIMENTAL|Phase 1: 7.5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
61979556|NCT02661542|EXPERIMENTAL|Phase 1: 11.25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
61979557|NCT02661542|EXPERIMENTAL|Phase 1: 16.875x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
61979558|NCT02661542|EXPERIMENTAL|Phase 1: 25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
61979559|NCT02661542|EXPERIMENTAL|Phase 2a: FF-10502-01 at MTD in Pancreatic Cancer|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
61979560|NCT02661542|EXPERIMENTAL|Phase 2a: FF-10502-01 at MTD in Solid Tumors|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
62169203|NCT03083600|ACTIVE_COMPARATOR|Plant-based Protein Hydrolysate (2) 10g|Plant-based protein hydrolysate 2 (10 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
62169204|NCT03083600|ACTIVE_COMPARATOR|Plant-based Protein Hydrolysate (2) 15g|Plant-based protein hydrolysate 2 (15 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
62359640|NCT05308667|ACTIVE_COMPARATOR|mCIMT group|
62359641|NCT04146051|EXPERIMENTAL|Phase 1b Dose-Escalation|Generalized Myasthenia Gravis
62359642|NCT04146051|EXPERIMENTAL|Phase IIa Expansion|Generalized Myasthenia Gravis
62359643|NCT04146051|PLACEBO_COMPARATOR|Phase IIb Randomized Control Trial|Generalized Myasthenia Gravis
62359644|NCT03518489|EXPERIMENTAL|Experimental|Lappaconitine Adhesive Patch Lappaconitine Adhesive Patch is administered every radiation day, until the end of radiotherapy.
62359645|NCT03518489|ACTIVE_COMPARATOR|Control|Patients will be given standard care when oral pain is reported
62359646|NCT03119272||Anorexia Nervosa Patients|Inpatient population at Eating Disorders Unit (EDU) at the University of North Carolina Neurosciences Hospital. Recruited upon intake into the unit.
62359647|NCT03119272||Age and Sex Matched Healthy Controls|University of North Carolina Psychiatry email listserv.
62359648|NCT02228824|EXPERIMENTAL|Very low nicotine content cigarettes|
62359649|NCT02228824|ACTIVE_COMPARATOR|Normal nicotine content cigarettes|
62567071|NCT06509633|EXPERIMENTAL|Pain Neuroscience education and Standard Rehabilitation regime|Patients will get standard treatment of CTS, which is nerve gliding, stretchings of forearm and wrist muscles and wrist mobilization along with pain neuroscience education.
62359650|NCT01414517|ACTIVE_COMPARATOR|FOS|Prebiotic (FructoOligoSaccharide-FOS.
62359651|NCT01414517|PLACEBO_COMPARATOR|Placebo|Maltodextrin (non-prebiotic carbohydrate).
62359652|NCT02915640|EXPERIMENTAL|Remote technology|Remote technology will be used for an initial patient assessment after being contacted by phone from the peripheral center to transfer an acutely ill pediatric patient as assessed by the referral centre care provider.
62567072|NCT06509633|ACTIVE_COMPARATOR|standard Rehabilitation regime|Patient will get only nerve gliding and wrist forearm muscle stretching exercises.
61979561|NCT02335099|ACTIVE_COMPARATOR|ticagrelor|90 mg of ticagrelor to be given orally twice a day for 6 months
61979562|NCT02335099|PLACEBO_COMPARATOR|Placebo|Placebo drug to be given twice a day for 6 months
61979563|NCT03021421|SHAM_COMPARATOR|Group USA|(Marcain Heavy 0.5%; AstraZeneca®, London, UK) using a 25-G Quincke spinal injector (B. Braun®, Melsungen, Germany).
61979564|NCT03021421|ACTIVE_COMPARATOR|Group PCS|"(Stimupleks A; B. Braun®, Melsungen AG, Germany) to lumbar plexus in psoas muscle compartment (injected material 20 ml local anaesthetic mixture5 ml of 2% lidocaine + 15 ml of 0.5% bupivacaine)~%2 Aritmal ampul (Osel İlaç,Turkey) and Marcaine %0.5 flacon (AstraZeneca®, London, UK)"
61979565|NCT02404376|ACTIVE_COMPARATOR|Remote Ischemic Conditioning|Remote Ischemic Conditioning + placebo
61979566|NCT02404376|ACTIVE_COMPARATOR|Combined treatment|Remote Ischemic Conditioning + exenatide
61979567|NCT02404376|PLACEBO_COMPARATOR|Placebo|Sham Remote Ischemic Conditioning + placebo
61979568|NCT02404376|ACTIVE_COMPARATOR|Exenatide|Sham Remote Ischemic Conditioning + exenatide
61979569|NCT02165020|EXPERIMENTAL|Rectal toxicities after prostate hypofractionated radiotherapy|Rectal toxicities after prostate hypofractionated radiotherapy with hyaluronic acid
62169205|NCT01372202|ACTIVE_COMPARATOR|Arm A|Paclitaxel with Cisplatin along with Radiotherapy and followed by Esophagectomy
61979570|NCT04202991||COPD with pain|People with COPD who also report pain more often than not over the previous 3 months
61979571|NCT04202991||COPD with no pain|People with COPD who do not report pain more often than not over the previous 3 months
61979572|NCT04506476|EXPERIMENTAL|Activity tracker with weekly goals|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. We suggest a daily step-count which should improve the patients physical activity during radiotherapy of breast cancer. Patients receive weekly feedback and a new goal with the aim to reach a total of 6000 daily steps, which should be then maintained during radiotherapy."
61979573|NCT04506476|EXPERIMENTAL|Activity tracker without Weekly goals|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy.~The patients self-document their daily step count during radiotherapy, there will be no recommendation for the daily count of steps."
62359653|NCT02915640|NO_INTERVENTION|Control|A Nurse Practitioner or General Practitioner from a remote site has a pediatric acute care referral and arranges a transportation. There is an initial call to obtain a patient history, to provide advice to the remote caregiver to initiate specific therapies and to mobilize the specialized team to the patient.
61979574|NCT04506476|NO_INTERVENTION|Control arm with no activity tracker|"Patients receive a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. A fitness tracker will not be provided."
61979575|NCT04751344|EXPERIMENTAL|Liposomal Bupivacaine|The liposomal bupivacaine study arm will receive 8cc (13.3 mg/mL) liposomal bupivacaine via intravenous route at the completion of the procedure.
61979576|NCT04751344|ACTIVE_COMPARATOR|Bupivacaine HCl|The Bupivacaine HCl study arm will receive 10cc (5mg/mL) of bupivacaine HCl via intravenous route at the completion of the procedure.
61979577|NCT01076946||TLVBS|patients with transient left ventricular ballooning
62169206|NCT01372202|ACTIVE_COMPARATOR|Arm B|Cisplatin or Oxaliplatin with 5-Fluorouracil along with Radiotherapy and followed by Esophagectomy
62359654|NCT01923571||Normoglycemia|patients with intraoperative BGC in the 80-180 mg/dl range
61979578|NCT02958150|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine according to the stablished protocol
62359655|NCT01923571||Hyperglycemia|patients with intraoperative BGC exceeding 180 mg/dl
61979579|NCT02958150|ACTIVE_COMPARATOR|Standard Clinical Practice|The physician in charge will decide the treatment to be administered (if deemed necessary) in accordance with the protocol established at the department
61979580|NCT03781609|ACTIVE_COMPARATOR|Roller system group (RG)|A group performing motor learning manual wheelchair propulsion repetitions on a roller system.
62359656|NCT05412212|EXPERIMENTAL|LTBI video intervention|Patients randomized to the intervention group will be sent an invitation with a link to watch a brief (\~3 minute video) about the importance of taking and completing LTBI treatment.
62359657|NCT05412212|NO_INTERVENTION|Standard care|Patients who are randomized to receive standard of care will not receive any messages or have any contact with the research team.
61979581|NCT03781609|ACTIVE_COMPARATOR|Overground group (OG)|A group performing motor learning manual wheelchair propulsion repetitions overground.
61979582|NCT03781609|PLACEBO_COMPARATOR|Placebo - Wheelchair skills group (WSG)|A group receiving conventional manual wheelchair skills training.
61979583|NCT05864508|EXPERIMENTAL|intranasal oxytocin|intranasal oxytocin treatment once a day during 6 weeks
61979584|NCT05780112|EXPERIMENTAL|Experimental group|"The pregnant women did the breathing exercise in accordance with the 'Practical Guideline on Breathing Exercise for Reducing Nausea and Vomiting in the Pregnant Women'. The breathing exercise training took on average 15-20 minutes for each pregnant woman. After the training, the pregnant women were asked to do the breathing exercise properly and effectively in accordance with the guideline for a minimum of five minutes at least twice a day for four weeks.~* Refresher training was given to the pregnant women through phone calls at the end of the first and third weeks and home visits at the end of the second week, and in each of these interviews, the pregnant women's breathing exercise practices were followed and the NVPI was applied to the pregnant women.~* At the end of the research, in other words, at the end of the fourth week, the NVPI and SF-36 were applied once again to the pregnant women in the maternity polyclinic, and hence, the follow-up process came to an end."
62169207|NCT01372202|ACTIVE_COMPARATOR|Arm C|Cisplatin with 5-Fluorouracil along with Radiotherapy and followed by Esophagectomy
62169208|NCT01343147|OTHER|Deep hyperthermia|Microwave diathermy
62169209|NCT01343147|OTHER|Superficial hyperthermia|Hot packs
62169210|NCT01083537|EXPERIMENTAL|Cisplatin|"Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~1. Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~2. Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour"
61979585|NCT05780112|NO_INTERVENTION|control group|"At the beginning of the research (pretest phase), without giving information about the breathing exercise practice to the pregnant women and making them practice the exercise, the researcher only asked pregnant women in the control group to fill in the Personal Information Form and applied the NVPI and SF-36 to the pregnant women.~* The pregnant women were called by phone at the end of the first and third weeks and their homes were visited at the end of the second week, and in each interview, information about their health status was received from them and the NVPI was applied to them.~* At the end of the research (post-test phase), in other words, at the end of the fourth week, the NVPI and SF-36 were applied once again to the pregnant women in the maternity polyclinic."
61979586|NCT03228589|EXPERIMENTAL|probiotic strain|Active arm treated with the probiotic strain for 8 weeks.
61979587|NCT03228589|PLACEBO_COMPARATOR|Placebo|Placebo arm treated with placebo capsules (identical to active product capsule besides the bacteria) for 8 weeks.
61979588|NCT05851781|EXPERIMENTAL|lacosamide arm|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive Lacosamide 50 mg twice daily for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
61979589|NCT05851781|EXPERIMENTAL|Propranolol group|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive propranolol 160 mg once daily for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
61979590|NCT03649711|EXPERIMENTAL|CKD-Ticagrelor|Ticagrelor 90 mg twice daily (double blind, random assignment) + aspirin 81 mg/d
61979591|NCT03649711|ACTIVE_COMPARATOR|CKD-Clopidogrel|Clopidogrel 75 mg/day in the morning and a matching placebo in the evening to conceal frequency (double blind, random assignment) + aspirin 81 mg/d
61979592|NCT03649711|ACTIVE_COMPARATOR|Control-ticagrelor|Open label ticagrelor, 90 mg twice daily + aspirin 81 mg/d
61979593|NCT05820308|EXPERIMENTAL|Intervention Group|Companion dog walking
61979594|NCT05820308|ACTIVE_COMPARATOR|Attention Control Group|Educational resources about dog health
61979595|NCT01375907|EXPERIMENTAL|Rotavin|Rotavin-M1 vaccine, 10e6.3FFU/dose, 2 doses, 1 month between doses
61979596|NCT01111149|PLACEBO_COMPARATOR|Sugar Pill|Sugar pill will be given to patients as a comparison group to the active varenicline group. In the fist week, one placebo pill will be given per patient, followed by 2 pills per day for the remaining 12 weeks of the study.
61979597|NCT01111149|EXPERIMENTAL|Varenicline|Varenicline has not previously been examined for its efficacy and safety in subjects with schizophrenia. Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study. This is an experimental group to be compared against both placebo and bupropion HCl.
61979598|NCT01111149|ACTIVE_COMPARATOR|Bupropion HCl|Bupropion HCl is an established smoking cessation agent and will be used to compare its efficacy and safety against varenicline. Subjects in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study.
61979599|NCT03430596|EXPERIMENTAL|pramipexole|pramipexole ,flexible dose (0.375mg/d-0.75mg/d)
61979600|NCT03430596|ACTIVE_COMPARATOR|Antan|Antan,flexible dose (2-4mg/d)
61979601|NCT04110093|EXPERIMENTAL|Immunotherapy Combination treatment|All colorectal cancer patients received regorafenib plus PD-1 inhibitor
61979602|NCT05461794|EXPERIMENTAL|Arm A: Sitravatinib + Tislelizumab|Sitravatinib administered orally and tislelizumab administered intravenously
61979603|NCT05461794|EXPERIMENTAL|Arm B: Sitravatinib|Sitravatinib administered orally
61979604|NCT05461794|EXPERIMENTAL|Arm C: Investigator-chosen Chemotherapy|Docetaxel or Irinotecan
61979605|NCT00831142||Prostate Cancer|Males with prostate cancer, referred for biopsy or radical prostatectomy
61979606|NCT05147493|EXPERIMENTAL|Single-arm|"Eligible patients will initially receive an induction phase of six 28-day cycles of Isatuximab in combination with Bortezomib, Cyclophosphamide, and Dexamethasone, followed by a maintenance phase with isatuximab and lenalidomide until disease progression, death, unacceptable adverse events (AEs), lost to follow up, or consent withdrawal, whichever occurs first.~Isatuximab will be given at a dose of 10 mg/kg once weekly (QW) on Days 1, 8, 15, and 22 in Cycle 1, on Days 1 and 15 during Cycles 2-6 and on Day 1 from Cycle 7 onwards.~Bortezomib will be given at 1.3 mg/m2 on Days 1, 4, 8, 11 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.~Cyclophosphamide will be given at 300 mg/m2 on Days 1, 8, 15 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.~Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) on Days 1-4 and 9-12 of Cycle 1 and Days 1, 8, 15 and 22 of Cycles 2-6.~Lenalidomide will be given at 10 mg (or according to renal function) daily from Cycle 7 onwards."
61979607|NCT03212612||2 groups , control and cases|"Groupe 1: (cases) 45 women who were found to have surgically and histolopathologically -confirmed endometriosis. Endometrial samples(1-2 gram) will be taken by laparoscopy which is the gold standard for definitive diagnosis of endometriosis.~Group2:(control) 45women who were free of endometriosis. Endometrial samples(1-2 gram) will be taken by punch biopsy."
61979608|NCT05969873|EXPERIMENTAL|Pilates Group|In this group patients will be treated with physical therapy treatment pilates exercise. Group A underwent 45 minutes of Pilates exercises in addition to the identical exercise programme as group A to improve the strength, coordination and flexibility of the lower limbs. Pilates movements were carried out ten times, with a two-minute break in between each repetition. For six weeks, both groups participated in the intervention programme three times per week. Starting the programme off with supine exercises of segmental motions that include using the trunk muscles to maintain a neutral posture is normal. To enhance shoulder girdle control, supine arm workouts were gradually added. The spine's ability to flex and extend was steadily increased.
62359658|NCT02416778|EXPERIMENTAL|Treatment Arm|Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion will be administered in patients with COPD
61979609|NCT05969873|ACTIVE_COMPARATOR|Balance training group|In this group patients will be treated with PT treatment with balance training. Exercises for stability of posture on numerous surfaces and positions were performed by Group B, including exercises for the flexors and adductors of hip, flexors and extensors of knee, and calf muscle (15-second hold and five repetitions) for improving their flexibility. The lower extremity and trunk muscles were the focus of Group B. The postural control exercise included walking in every direction, moving past the point of stability in various postures like half-kneeling, standing on hard and soft surfaces, stepping down and up, walking and standing at the same time, and one leg standing with eyes open and closed. Each session started with a 5-minute warm-up and ended with a 5-minute cool-down in between each phase.
61979610|NCT03234192|ACTIVE_COMPARATOR|Therapeutic ultra sound|
61979611|NCT03234192|ACTIVE_COMPARATOR|Astym Treatment Technique|
61979612|NCT03234192|ACTIVE_COMPARATOR|Graston Treatment Technique|
61979613|NCT01603459|EXPERIMENTAL|IncobotulinumtoxinA (Xeomin) (up to 800 Units)|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection"
61979614|NCT02228551|OTHER|ARC PPS|Augmented renal clearance Point prevalence study
61979615|NCT02310945||Knee osteoarthritis|People with moderate/severe symptomatic knee osteoarthritis referred for physiotherapy
61979616|NCT04840290|EXPERIMENTAL|Sintilimab Plus Platinum Doublet Chemotherapy|Specified dose on specified days Sintilimab
61979617|NCT01996709|EXPERIMENTAL|Clear Care|Hydrogen peroxide-based contact lens solution used with habitual contact lenses for 90 days
61979618|NCT01996709|ACTIVE_COMPARATOR|Habitual MPS|Habitual contact lens solution used with habitual contact lenses for 90 days
61979619|NCT02913079|EXPERIMENTAL|Sit-stand desk|During this condition, participants will sit or stand as much as they like throughout a workday.
61979620|NCT02913079|PLACEBO_COMPARATOR|Sitting|During this condition, participants will work in the sitting position only.
61979621|NCT01729754|EXPERIMENTAL|Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg subcutaneously (SC) on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo (PBO) twice weekly until Week 12 and once weekly from Week 12 to Week 28.
61979622|NCT01729754|EXPERIMENTAL|Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg SC on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo twice weekly until Week 12 and once weekly from Week 12 to Week 28.
61979623|NCT01729754|PLACEBO_COMPARATOR|Placebo|Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive tildrakizumab 200 mg or tildrakizumab 100 mg on Weeks 12, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244.
61979624|NCT01729754|ACTIVE_COMPARATOR|Etanercept 50 mg|Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants who don't achieve PASI-75, receive tildrakizumab 200 mg after Week 28 (Weeks 32, 36 and 48) and, optionally, every 12 weeks thereafter until Week 244.
62169211|NCT01083537|EXPERIMENTAL|Paclitaxel|"Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~1. Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~2. Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~3. Hydration: Infuse Paclitaxel in 250cc NS over 1 hour"
62359659|NCT04796025|EXPERIMENTAL|T-Double|TACE Combined With Sintilimab Plus Bevacizumab Biosimilar
62359660|NCT05405218|EXPERIMENTAL|Carpal Tunnel Release with Ultrasound Guidance (CTR-US)|
62359661|NCT05405218|ACTIVE_COMPARATOR|Mini Open Carpel Tunnel Release (mOCTR)|
61979625|NCT05704608|EXPERIMENTAL|Experimental Group|Aerobic training program was performed by participants.
61979626|NCT05704608|NO_INTERVENTION|Control group|No intervention was performed by the participants.
61979627|NCT00539409|NO_INTERVENTION|1|Diabetic patients will complete quality of life questionnaires at baseline and quarterly thereafter to monitor and assess progress with complications resulting from their diabetes. Comparisons will be performed on lab values performed at baseline and every six months and medication information collected at weekly Pulsatile Intravenous Insulin treatment sessions.
61979628|NCT00539409|ACTIVE_COMPARATOR|Pulsatile Intravenous Insulin Therapy|
61979629|NCT05710549|EXPERIMENTAL|neurophysiological measurements|40 cognitively-unimpaired healthy young adults (age 18-35 years old), 40 cognitively-unimpaired healthy older adults (age 55+ years old), and 40 age-matched patients with mild cognitive impairment (MCI) (age 55+ years old) will be assessed using high-density electroencephalography (hdEEG) to characterize the spatiotemporal dynamics of brain oscillations during personalized, autobiographical memory (ABM) tasks.
61979630|NCT05710549|EXPERIMENTAL|neuropsychological examination|40 MCI patients (age 55+ years old) will undergo 20min multi-channel protocols of transcranial alternating current stimulation; tACS (either gamma, beta, or ActiSham stimulation randomized across the three laboratory sessions) to modify cognitive functioning (MoCA score), and oscillatory brain activity during performing personalized, autobiographical memory (ABM) tasks and resting-state EEG.
61979631|NCT02461355|EXPERIMENTAL|Anodal tDCS|Anodal tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
61979632|NCT02461355|SHAM_COMPARATOR|Sham tDCS|Sham tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
61979633|NCT00227162|ACTIVE_COMPARATOR|Group 1|Positive affect
61979634|NCT00227162|ACTIVE_COMPARATOR|Group 2|Self-Affirmation
61979635|NCT00227162|ACTIVE_COMPARATOR|Group 3|Positive Affect and self-affirmation
61979636|NCT00227162|NO_INTERVENTION|Group 4|Control group
61979637|NCT04436185|NO_INTERVENTION|Characteristics of newborns included|Characteristics of newborns included in the randomized controll
61979638|NCT04436185|EXPERIMENTAL|Intraclass Correlation between the NIPS Score of Parent, Nurse|Intraclass Correlation between the NIPS Score of Parent, Nurse
61979639|NCT04436185|EXPERIMENTAL|Comparisons of procedural pain scores among groups|Comparisons of procedural pain scores among groups
61979640|NCT06540209|EXPERIMENTAL|Bacillus clausii + zinc+ ORS group|Patients received zinc supplementation with ORS and Bacillus clausii
61979641|NCT06540209|EXPERIMENTAL|Saccharomyces boulardii +zinc+ ORS group|Patients were given zinc with ORS and Saccharomyces boulardii
61979642|NCT00195676|OTHER|Adalimumab|
61979643|NCT04516590||autoimmune antigen negative|treated with anti-epilepsy drugs
61979644|NCT04516590||autoimmune antigen positive|whether the patients receive immune therapy or not will depend on the type and titter of the autoimmune antibody as well as the severity of the symptom
61979645|NCT00535223|EXPERIMENTAL|Group Based Exposure Therapy|"Behavioral:~GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking."
61979646|NCT00535223|EXPERIMENTAL|Present Centered Group Therapy|"Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus. This lasted for 16 weeks."
61979647|NCT02602860|EXPERIMENTAL|Levetiracetam|"Cohort 1: Half of the subjects will receive LEV as a 5 minute iv infusion during the second Positron Emission Tomography (PET) scan, 60 minutes after the start of \[11C\]UCB-J administration.~Cohort 2: Half of the subjects will receive LEV as a 5 minute iv infusion during the first PET scan, 60 minutes after the start of \[11C\]UCB-J administration. The dose of LEV (500 mg to 2500 mg) or BRV (50 mg to 200 mg) will be decided based on the data obtained in Cohort 1. Subjects will return for a second PET imaging session (Visit 4), 7 to 28 days after completion of their first session (Visit 3) to enter the BRV arm."
61979648|NCT02602860|EXPERIMENTAL|Brivaracetam|"Cohort 1:Half of the subjects will receive BRV as a 5 minute iv infusion during the second Positron Emission Tomography (PET) scan, 60 minutes after the start of \[11C\]UCB-J administration.~Cohort 2:Half of the subjects will receive BRV as a 5 minute iv infusion during the first PET scan, 60 minutes after the start of \[11C\]UCB-J administration. The dose of BRV (50-200 mg) will be decided based on the data obtained in Cohort 1. Subjects will return for a second PET imaging session,7 to 28 days after completion of their first session to enter the LEV arm.~Cohort 3:void Cohort 4:Subjects will take oral BRV (25-100 mg bid) for 4 days and a single dose of BRV on Day 5. Pre-/post-block scans will be obtained at the first dose, one post-block scan after the last dose. Additional post-block scans may be obtained 8-10 and 28h or later after last dose; if last scan not needed, subject will return 7 to 28 days later for a post-block scan. Dose range for LEV in Cohort 4 will be 250 to \<1500mg."
61979649|NCT01981291|ACTIVE_COMPARATOR|Perineural|Patients in this group will receive a perineural injection of mepivacaine for subgluteal sciatic nerve block, in addition to a femoral nerve block and patient-controlled postoperative analgesia.
61979650|NCT01981291|EXPERIMENTAL|Intraneural|Patients in this group will receive an intraneural injection of mepivacaine for subgluteal sciatic nerve block, in addition to a femoral nerve block and patient-controlled postoperative analgesia.
61979651|NCT04554329|ACTIVE_COMPARATOR|bandage contact lens|A bandage contact lens was applied on the eye at the end of the surgery, and the eye was not covered with a patch.
61979652|NCT04554329|ACTIVE_COMPARATOR|eye patching|Antibiotic eye ointment was applied on the eye, and the eye was covered with a patch at the end of the surgery.
61979653|NCT03735433|NO_INTERVENTION|81 mg daily aspirin dose|obese women \>30 BMI at risk for preeclampsia will receive recommended 81mg ASA
61979654|NCT03735433|ACTIVE_COMPARATOR|162mg daily aspirin dose|obese women \>30 BMI at risk for preeclampsia will receive increased dose of 162mg ASA
61979655|NCT04750720|EXPERIMENTAL|Group with biological samples|Collection of biological samples (M0, M3, M6, M9, M12, M15, M18, M24) with associated data for the study of the kinetics of antibodies anti COVID-19 in subjects with documented SARS-CoV-2 infection (PCR and/or positive specific serology). In the vaccine sub-study: additional blood and nasopharyngeal samples before and after vaccination, up to 6 months.
61979656|NCT01518010|EXPERIMENTAL|GamePlay|
61979657|NCT02138760|NO_INTERVENTION|MRI guided cognitive fusion biopsy|Men in this arm will undergo MRI followed by systematic biopsy and then additional cognitive (freehand) biopsies of MRI suspicious targets
61979658|NCT02138760|EXPERIMENTAL|UroNav fusion biopsy|Men in this arm will undergo MRI followed by systematic biopsy and then additional UroNav fusion biopsy of MRI suspicious targets
61979659|NCT05587920||Non-hormonal contraceptive users|Women not using any form of hormonal contraceptive.
61979660|NCT05587920||Combined oral contraceptive pill users|Women using the oral combined oral contraceptive pill.
61979661|NCT05587920||Hormonal IUS|Women using the hormonal intrauterine system contraceptive.
61979662|NCT05587920||Hormonal implant|Women using the hormonal contraceptive implant contraceptive.
61979663|NCT05587920||Hormonal injection|Women using the hormonal injection contraceptive.
61979664|NCT04969120|ACTIVE_COMPARATOR|(group 1) receiving intravenous metoclorpramide|this group receive 10mg intravenous metoclopramide
61979665|NCT04969120|PLACEBO_COMPARATOR|(group 2) receiving placebo|this group receive 10mg intravenous placebo(0.9 sodium chloride)
61979666|NCT03627754|EXPERIMENTAL|Moderate Hepatic Impairment Group|Subjects with Child-Pugh Classification B (score 7-9)
61979667|NCT03627754|EXPERIMENTAL|Severe Hepatic Impairment Group|Subjects with Child-Pugh Classification C (score 10-15)
62359662|NCT06532253|EXPERIMENTAL|NVDX3 implant|NVDX3 implant is a sterilized, dry powder. The total administered quantity of NVDX3 implant depends on the bone defect size/intervertebral disc space.
62567073|NCT03239249|EXPERIMENTAL|Intervention group: IKO-model (20 schools)|Schools randomized to experimental group will implement the IKO-drop-out prevention intervention. Each county have a project leader responsible for following up the implementation. The model is described in a manual, that schools should follow.
62359663|NCT01972594|NO_INTERVENTION|Control group.|Natural progession based on Step count is recorded with a pedometer for 12 weeks.
62567074|NCT03239249|ACTIVE_COMPARATOR|Treatment as usual (22 schools)|Schools randomized to control group will work as previously with their drop-out prevention. This include various activities, but they are not systematic as in the IKO-model.
61979668|NCT03627754|EXPERIMENTAL|Normal Hepatic Function Group|Healthy subjects with normal hepatic function
61979669|NCT03287505|EXPERIMENTAL|Abilify IM Depot 300mg by once|300 mg dose group: single-administration of Aripiprazole IM Depot (300 mg) in 12 subjects;
61979670|NCT03287505|EXPERIMENTAL|Abilify IM Depot 400mg by once|400 mg dose group: single-administration of Aripiprazole IM Depot (400 mg) in 12 subjects.
61979671|NCT02723032|OTHER|Healthy Subjects and patients|Validation of SpO2 sensor in healthy subjects as a first step. Validation of SpO2 sensor in patients as a second step.
61979672|NCT05383768|PLACEBO_COMPARATOR|Restoration with conventional no heated bulk-fill resin composite|Restoration with conventional no heated bulk-fill resin composite, X-tra fill (VOCO, GERMANY)
61979673|NCT05383768|ACTIVE_COMPARATOR|restoration with one-time preheated conventional bulk-fill resin composite|restoration with one-time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C
61979674|NCT05383768|ACTIVE_COMPARATOR|restoration with five-time preheated conventional bulk-fill resin composite|restoration with five-time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C
61979675|NCT05383768|ACTIVE_COMPARATOR|restoration with ten-time preheated conventional bulk-fill resin composite|restoration with ten-time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C
61979676|NCT03486795|EXPERIMENTAL|Dual stimulation|"1. anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex~2. anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area"
61979677|NCT03486795|EXPERIMENTAL|M1 stimulation|anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
62359664|NCT01972594|EXPERIMENTAL|Targeted protocol with Pedometer|A step based targeted protocol is given along with a pedometer for 12 weeks post surgery.
61979678|NCT03486795|EXPERIMENTAL|PMC stimulation|anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area
61979679|NCT03486795|SHAM_COMPARATOR|Sham stimulation|Sham stimulation
61979680|NCT02133027|EXPERIMENTAL|Rouviere's Sulcus|Rouviere's sulcus is a 2 to 5 cm sulcus running to the right of the liver hilum anterior to the caudate process and usually containing the right portal triad or its branches.Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
61979681|NCT02133027|OTHER|traditional anatomy method|Ratcheted grasper is inserted through the lateral 5-mm port to retract the gallbladder fundus in cephalad fashion. An atraumatic grasper is inserted through the middle 5-mm port to retract the gallbladder infundibulum laterally, exposing the anteromedial aspect of the triangle of Calot.
61979682|NCT01863225|EXPERIMENTAL|Group A|RVX000222 200 mg (100 mg b.i.d.) + Atorvastatin 40 mg
61979683|NCT01863225|EXPERIMENTAL|Group B|RVX000222 200 mg (100 mg b.i.d.) + Rosuvastatin 20 mg
62359665|NCT04821960|ACTIVE_COMPARATOR|Conventional Mindfulness Program|Routine mindfulness lessons and activities.
62359666|NCT04821960|EXPERIMENTAL|Tailored Mindfulness Program for Fear of Memory Loss|Tailored mindfulness lessons and activities for fear of memory loss.
62359667|NCT02269384|SHAM_COMPARATOR|No History of Significant Injury|Experimental Noxious Stimulus, Memory of Experimental Noxious Stimulus, Memory of Prior Significant Injury, Mental Challenge Test
61979684|NCT01863225|EXPERIMENTAL|Group C|RVX000222 200 mg (100 mg b.i.d.) + Atorvastatin 80 mg
61979685|NCT01863225|EXPERIMENTAL|Group D|RVX000222 200 mg (100 mg b.i.d.) + Rosuvastatin 40 mg
61979686|NCT02808520||Hodgkin-lymphoma|Children and adolescents aged 10-18 years
61979687|NCT02029950|EXPERIMENTAL|Treatment (combination chemotherapy, pomalidomide)|See Detailed Description
61979688|NCT01243879|ACTIVE_COMPARATOR|Fasting with stimuli|Fasting in the presence of food-related stimuli
61979689|NCT01243879|SHAM_COMPARATOR|Fasting without stimuli|Fasting in the absence of food-related stimuli
61979690|NCT02133287|EXPERIMENTAL|AVI® Arsenic trioxide drug eluting stent|Study group: Arsenic trioxide drug eluting stent delivery system (AVI®)
61979691|NCT02133287|ACTIVE_COMPARATOR|Firebird2® sirolimus eluting stent system|Control group: sirolimus eluting cobalt-chromium alloy stent system(Firebird 2®)
61979692|NCT00845169|EXPERIMENTAL|Diesel Exposure|1 hour exposure to diesel exhaust at 300 µg/m3 during intermittent exercise
61979693|NCT00845169|EXPERIMENTAL|Air Exposure|1 hour exposure to filtered air during intermittent exercise
61979694|NCT06268093|EXPERIMENTAL|Thalidomide|Oral Thalidomide
61979695|NCT06010940|ACTIVE_COMPARATOR|control group|Control group (A) was treated by nasogastric tube and oral care.
61979696|NCT06010940|EXPERIMENTAL|study group|Study group (B) was treated as the control group in addition to a designed physical therapy program consisting of neuromuscular electrical stimulation in addition to exercises for oropharyngeal muscles.
61979697|NCT00553150|EXPERIMENTAL|Everolimus (RAD001), Radiation (RT), Temozolomide (TMZ)|"Patients receive oral everolimus and oral temozolomide and 3D-conformal radiotherapy or IMRT as in phase I. Patients will undergo a 4-6 week rest period in course 2 and then proceed to adjuvant therapy.~Adjuvant therapy with everolimus and temozolomide (courses 3-8): Patients receive oral everolimus and oral temozolomide as in phase I.~Adjuvant therapy with everolimus alone (courses 9 and all subsequent courses): Patients receive oral everolimus as in phase I.~All patients undergo fludeoxyglucose (FDG)- or fluorothymidine-labeled PET/CT scans at baseline and periodically during treatment."
61979698|NCT04690088||Manual infusion (control) group|
61979699|NCT04690088||TCI (case) group|
62359668|NCT02269384|ACTIVE_COMPARATOR|History of Significant Injury|Experimental Noxious Stimulus, Memory of Experimental Noxious Stimulus, Memory of Prior Significant Injury, Mental Challenge Test
62359669|NCT01220713|EXPERIMENTAL|Treatment 1--1.5 atm abs|
62359670|NCT01220713|EXPERIMENTAL|Treatment 2--2.0 atm abs|
62359671|NCT01220713|SHAM_COMPARATOR|Placebo--equivalent to breathing air|
62359672|NCT00996593|EXPERIMENTAL|open-label, single arm|
62359673|NCT00023712|EXPERIMENTAL|Treatment (bortezomib)|Patients receive bortezomib IV twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62359674|NCT01611298|EXPERIMENTAL|Single arm: Tetanus Toxoid|SCT Donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest
61979700|NCT04890639|EXPERIMENTAL|AIH group|Hypoxia will be administered via a specialized face mask attached to a gas mixing device (HYP123, Hypoxico Inc.), which controls oxygen content in inhaled air. The hypoxia administering unit will be manually adjusted to supply O2 at the target level for a given session (approximately 21%-normal room air, 17%, 13%, and 9% respectively). Each session will include 15 cycles of hypoxia, each lasting up to 60 seconds, interspersed with up to 90-second normoxic episodes. An oxygen monitor will continuously measure and record the fraction of inspired oxygen delivered (MAX-250E, Maxtec Inc.).
61979701|NCT04446377|EXPERIMENTAL|LAM-002A|LAM-002A (Apilimod Dimesylate) 125mg in five 25-mg capsules BID for 10 days
61979702|NCT04446377|PLACEBO_COMPARATOR|Placebo|(microcrystalline cellulose) in 5 capsules BID for 10 days
61979703|NCT02188589|EXPERIMENTAL|Nasal implant group|Bilateral or unilateral INEX nasal implants
61979704|NCT06366867|EXPERIMENTAL|VibrantMinds + Standard Care|Older adults at long-term care facilities receive the VibrantMinds games in addition to routine standard care administered by the facility and staff.
61979705|NCT06366867|NO_INTERVENTION|Standard Care|Older adults at long-term care facilities receive routine standard care administered by the facility and staff.
61979706|NCT03945487|EXPERIMENTAL|Comprehensive treatment plus UC-MSC treatment|
61979707|NCT03945487|OTHER|Comprehensive treatment|
61979708|NCT03684954|OTHER|Used of PRF in clsed sinus lifting|Used of PRF in closed sinus lifting with implant placement
61979709|NCT03684954|NO_INTERVENTION|Closed sinus with xenograft|used of xenograft in closed sinus lift with implant placement.
62359675|NCT00638755|EXPERIMENTAL|1|The following treatment sequence: A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide), D (placebo)
62567075|NCT01598272|EXPERIMENTAL|Vitality product AM + Vitality product PM|"Dietary Supplement:~Proprietary blend of ginseng, cordyceps, and pomegranate + proprietary blend of broccoli seed, red orange, and grape seed taken twice a day for 8 weeks."
61979710|NCT00732615|PLACEBO_COMPARATOR|Placebo|Sterile water for injection
61979711|NCT00732615|EXPERIMENTAL|50, 75, 100 mcg NPSP558|Initial dose of 50mcg, to be titrated up to 75mcg and then 100mcg dependent upon response
61979712|NCT03736317|SHAM_COMPARATOR|control group|Sham TBS delivered on left dlPFC or medial prefrontal cortex of amphetamine-dependent patients. Stimulation pulses are the same as the real group.
61979713|NCT03736317|EXPERIMENTAL|real mPFC cTBS group|The real cTBS stimulation pattern will be delivered on the medial prefrontal cortex.
61979714|NCT03736317|EXPERIMENTAL|real dlPFC iTBS group|The real iTBS stimulation pattern will be delivered on the left dorsal prefrontal cortex.
61979715|NCT03736317|EXPERIMENTAL|real dlPFC iTBS + real mPFC cTBS group|Combination therapy of real iTBS stimulation delivered on the left dorsal prefrontal cortex and real cTBS stimulation delivered on the medial prefrontal cortex.
61979716|NCT02653807|EXPERIMENTAL|mobilization with movement|MWM at the talocrural joint during active weight bearing ankle dorsiflexion with the belt
61979717|NCT02653807|ACTIVE_COMPARATOR|osteopathic mobilization|passive mobilization of the talo-crural joint
61979718|NCT03274414|EXPERIMENTAL|Unresectable paranasal sinus/nasal cavity malignancy|
61979719|NCT03864211|ACTIVE_COMPARATOR|Toripalimab monotherapy|Toripalimab is administrated intravenously (240mg, Q3W) continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends.
61979720|NCT03864211|EXPERIMENTAL|Thermal ablation plus toripalimab|One to five target lesions will be ablated completely. Toripalimab therapy will be initiated on day 3 or day 14 after ablation ((240mg, Q3W) ). Toripalimab is administrated continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends.
61979721|NCT02074787||Adult burn injuries|Adult patients with burns injuries attending the regional burns unit at Chelsea \& Westminster hospital between 48 and 72 hours post burn will be invited to take part in the study at the time of presentation to the unit.
61979722|NCT01374620|EXPERIMENTAL|Paclitaxel Dose escalation|"A standard dose escalation strategy will be used including 3 to 6 patients at each dose level (Paclitaxel dose escalation + fixed dose of cyclophosphamide)~+ blood collection"
61979723|NCT01374620|EXPERIMENTAL|Cohort extension|"An additional 10 patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose~+ blood collection"
61979724|NCT01194479|ACTIVE_COMPARATOR|Type 1 Diabetics|The active group were participants with type 1 diabetes.
61979725|NCT01194479|OTHER|Healthy Volunteers|The control group were participants without diabetes, matched by sex, age and BMI to the active comparator group.
61979726|NCT02626637|EXPERIMENTAL|Physical activity coaching|Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
62359676|NCT00638755|EXPERIMENTAL|2|The following treatment sequence: B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide), D (placebo), A (Nasal Carbon Dioxide)
62359677|NCT00638755|EXPERIMENTAL|3|The following treatment sequence: C (Nasal Carbon Dioxide), D (placebo), A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide)
62567076|NCT01598272|PLACEBO_COMPARATOR|Placebo|Dietary Supplement: Placebo Placebo taken twice a day for 8 weeks
61979727|NCT03831347|EXPERIMENTAL|Hatha Yoga|12 weeks of modified Hatha Yoga specifically designed to be administered to teens with depression.
61979728|NCT05294172|EXPERIMENTAL|KL-A167+Gemcitabine+Cisplatin|subject will receive KL-A167 1200mg every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, 4-6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day,4-6 cycles
61979729|NCT05294172|PLACEBO_COMPARATOR|Placebo+Gemcitabine+Cisplatin|subject will receive placebo every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, 4-6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, 4-6 cycles
61979730|NCT03439020|EXPERIMENTAL|FCSEMS + Plastic|"Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture and insert an additional plastic stent to anchor the metal stent.~(Plastic stent anchoring)"
61979731|NCT03439020|ACTIVE_COMPARATOR|FCSEMS|Insert only a fully covered self expandable metal stent (FCSEMS) without a plastic stent for malignant biliary stricture.
61979732|NCT05487781|EXPERIMENTAL|Group 1|Tyrphostin AG-17 content 10 mg with 700 mg of L-Carnitine tartrate
62359678|NCT00638755|EXPERIMENTAL|4|The following treatment sequence: D (placebo), A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide)
61979733|NCT05487781|EXPERIMENTAL|Group 2|Tyrphostin AG-17 content 3.3 mg with 700 mg of L-Carnitine tartrate
61979734|NCT05487781|EXPERIMENTAL|Group 3|Tyrphostin AG-17 content 1 mg with 700 mg of L-Carnitine tartrate
61979735|NCT04890366|EXPERIMENTAL|Alteplase plus Dimethyl Fumarate|
61979736|NCT04890366|NO_INTERVENTION|Alteplase|
61979737|NCT05237908||TSPACE 3D|the 3D printed cage (TSPACE 3D) is defined as investigational product
61979738|NCT05237908||TSPACE XP|the titanium coated PEEK cage (TSPACE XP) is defined as reference product.
61979739|NCT01197053|EXPERIMENTAL|100 mcg DBV712 (active)|100 mcg DBV712 administered epicutaneously every 24 hours.
62359679|NCT00054236|EXPERIMENTAL|non-myeloablative conditioning regimen|
62359680|NCT05477446|EXPERIMENTAL|CD207 CAR-T cells|Cohort 1 will receive 1 x 10\^6 CAR+ T cells/kg. Cohort 2 will receive 3 x 10\^6 CAR+ T cells/kg. Cohort 3 will receive 5 x 10\^6 CAR+ T cells/kg. Cohort 4 will receive 1 x 10\^7 CAR+ T cells/kg.
61979740|NCT01197053|PLACEBO_COMPARATOR|Placebo|Placebo will be administered epicutaneously every 24 hours
61979741|NCT01404390|EXPERIMENTAL|Arm 1|
61979742|NCT01404390|EXPERIMENTAL|Arm 2|
61979743|NCT00267046|EXPERIMENTAL|Palifermin|"Palifermin + Chemotherapy (Adriamycin (Doxorubicin)+ Ifosfamide (AI) or Adriamycin (Doxorubicin) + Cisplatin (AP) Regimen); Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m\^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m\^2. Ifosfamide 2.5 g/m\^2 IV bolus Days 0-3 (total 10 g/m\^2); Vincristine 2 mg IV Day 0.~AP=Doxorubicin (Adriamycin) + Cisplatin:~Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m\^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m\^2); Cisplatin 120 mg/m\^2 on day 0."
61979744|NCT00267046|PLACEBO_COMPARATOR|Placebo|"Placebo + Chemotherapy (AI or AP Regimen);~AI = Doxorubicin (Adriamycin) + Ifosfamide:~A single dose placebo prior to chemotherapy; Adriamycin 30 mg/m\^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m\^2. Ifosfamide 2.5 g/m\^2 IV bolus Days 0-3 (total 10 g/m\^2); Vincristine 2 mg IV Day 0.~AP=Doxorubicin (Adriamycin) + Cisplatin:~A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m\^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m\^2); Cisplatin 120 mg/m\^2 on day 0."
61979745|NCT02709031|ACTIVE_COMPARATOR|Cicletanine|Patients will take escalating doses of cicletanine
61979746|NCT02709031|EXPERIMENTAL|Cicletanine + magnesium|Patients will take escalating doses of cicletanine; patients will in addition take magnesium
61979747|NCT06520852|EXPERIMENTAL|Intervention group|Group using artificial intelligence tools in addition to traditional tools in preparing educational materials
61979748|NCT06520852|NO_INTERVENTION|Control group|Group using traditional tools in preparing educational materials
61979749|NCT02771158|EXPERIMENTAL|midodrine|randomization to midodrine 20 mg every 8 hours to be increased to a maximum of 40 mg every 8 hours until intravenous vasopressor discontinuation
61979750|NCT02771158|PLACEBO_COMPARATOR|placebo|randomization to placebo control
61979751|NCT03792308|EXPERIMENTAL|SPR206|"SAD Cohorts: Subjects will receive single doses of SPR206 via IV infusion over one hour. Planned doses to be studied are: 10, 25, 50, 100, 200, 300, 350 and 400mg. If the 300 mg dose is not deemed safe and well-tolerated, a dose of 250 mg will be used.~MAD Cohorts: Subjects will receive SPR206 via IV infusion over one hour q8h for 7 consecutive days (Cohorts 9 - 12) and over one hour q8h for 14 consecutive days (Cohort 13). Up to five dose groups will be studied. Planned doses will be 25 mg, 50 mg, 100 mg and 150 mg with dosing occurring q8h for 7 consecutive days (Cohorts 9 - 12) and q8h for 14 consecutive days (Cohort 13). Cohort 13 participants will be dosed at a dose deemed safe and tolerable, not to exceed the maximum dose tested in previous MAD dose cohorts.~."
61979752|NCT03792308|PLACEBO_COMPARATOR|Placebo|"The placebo used during this study is normal saline (0.9% sodium chloride for injection).~SAD Cohorts: Subjects will receive single infusions of placebo (0.9% sodium chloride for injection) over one hour.~MAD Cohorts: Subjects will receive q8h infusions of placebo over 1 hour for 7 consecutive days (Cohorts 9 - 12) and q8h infusions of placebo over 1 hour for 14 consecutive days (Cohort 13)."
61979753|NCT00646529|EXPERIMENTAL|1|budesonide/formoterol
62359681|NCT06044129||Vaginal trial labor group|
62359682|NCT00786097|EXPERIMENTAL|1|Dermacyd PH_DETINLYN (Lactic Acid)
62359683|NCT05595551|EXPERIMENTAL|"The intervention Aan Tafel in 1, 2, 3 euro"|The participants use the intervention program: the recipe booklets and the provided price guarantee for their meals.
61979754|NCT00646529|ACTIVE_COMPARATOR|2|budesonide
61979755|NCT00775645|EXPERIMENTAL|Arm I|Patients receive oral acetyl-L-carnitine hydrochloride 3 times daily for 24 weeks.
61979756|NCT00775645|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo 3 times daily for 24 weeks.
61979757|NCT02314650|EXPERIMENTAL|Transcutaneous acupoint stimulation|Electrical stimulation was given through electrodes attached to skin at Ximen and Shenmen acupoint during anesthesia
61979758|NCT02314650|PLACEBO_COMPARATOR|Non-acupoint stimulation|Electrical stimulation was given through electrodes attached to skin at shoulder (non-acupoint) during anesthesia
61979759|NCT02314650|SHAM_COMPARATOR|Control|patients were with electrodes attached but no stimulation was given
61979760|NCT05212649||More-GDMT|Baseline guideline-directed medications therapy (GDMT), including angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blocker (ARB), beta-blockers, mineralocorticoid receptor antagonist (MRA), and angiotensin receptor neprilysin inhibitor (ARNI) were documented at discharge. More-GDMT group was defined as patient population received GDMT \>=2 kinds of above medications.
62359684|NCT05595551|NO_INTERVENTION|Control group|The participants are not registered to use the program and will be recruited in social organizations to match their sociodemographic profile as much as possible.
62359685|NCT04297293|EXPERIMENTAL|Ramosetron-ODT|
62359686|NCT04297293|NO_INTERVENTION|Control|
62359687|NCT04681924|EXPERIMENTAL|Low carb diet|Low carb diet (n=54)
62359688|NCT04681924|EXPERIMENTAL|Low fat diet|Low fat diet (n=40)
62359689|NCT02793089||First quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7).
62359690|NCT02793089||Second quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7).
61979761|NCT05212649||Few-GDMT group|Baseline guideline-directed medications therapy (GDMT), including angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blocker (ARB), beta-blockers, mineralocorticoid receptor antagonist (MRA), and angiotensin receptor neprilysin inhibitor (ARNI) were documented at discharge. Few GDMT-group was defined as patients who received GDMT \< 2 kinds of the above medications.
61979762|NCT00298545|PLACEBO_COMPARATOR|placebo and Calcitriol|placebo tablets together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
61979763|NCT00298545|ACTIVE_COMPARATOR|2|calcium together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
61979764|NCT00755287|ACTIVE_COMPARATOR|insulin glargine|insulin glargine starting dose 10 IU daily in addition to continued prestudy metformin treatment
61979765|NCT00755287|EXPERIMENTAL|taspoglutide 10 mg|taspoglutide 10 mg once weekly in addition to continued prestudy metformin treatment
61979766|NCT00755287|EXPERIMENTAL|taspoglutide 10 mg/20 mg|taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued prestudy metformin treatment
61979767|NCT05281185|ACTIVE_COMPARATOR|Severe haemophilia A patients with weight-based prophylaxis|Severe haemophilia A patients with low-dose standard half-life concentrates weight-based prophylaxis
61979768|NCT05281185|EXPERIMENTAL|Severe haemophilia A patients with low dose extended half-life PK-guided prophylaxis|Severe haemophilia A patients with low-dose extended half-life concentrates PK-guided prophylaxis
61979769|NCT04108936||Peritoneal Carcinomatosis|Patients suffering from Peritoneal carcinomatoses from either CRC, gastric cancer or primary peritoneal malignancies
61979770|NCT04108936||Control group|Patients suffering from CRC or gastric cancer without peritoneal carcinomatosis
61979771|NCT01279551|EXPERIMENTAL|GTN|In this arm the investigators administer local application of 0.4% nitroglycerin ointment and ketorolac tromethamine 10 mg
61979772|NCT01279551|ACTIVE_COMPARATOR|Control|In this arm the investigators administer local application of lidocaine cloridrato 2.5% and ketorolac tromethamine 10 mg.
61979773|NCT04053959|EXPERIMENTAL|AI Group|Artificial intelligence assisted insulin titration system group
61979774|NCT04053959|ACTIVE_COMPARATOR|Control Group|Physicians decided insulin titration group
61979775|NCT03282942|EXPERIMENTAL|Exercise training protocols|Participants will be randomized in one of TWO groups: aerobic training group (AT) or strength training group (ST). Each training protocol will last 12 weeks, being the initial two weeks designed to participants' gradual adaptations to respective training protocol, with sessions performed three times per week in non-consecutive days.
61979776|NCT03282942|NO_INTERVENTION|Control Group|The individuals who will be part of the control group will be instructed to follow their daily activities, avoiding any systematic exercise program and return to the end of the 12 weeks for reevaluation.
61979777|NCT02484729|EXPERIMENTAL|AZD9977 oral suspension, single doses|In Part A up to 10 cohorts with single ascending doses with AZD9977 as oral suspension. In Part B AZD9977 as oral suspension in IntelliCap® capsule
61979778|NCT02484729|PLACEBO_COMPARATOR|Placebo, oral suspension, single doses|In Part A up to 10 cohorts with single doses with matching placebo to AZD9977
61979779|NCT02484729|EXPERIMENTAL|AZD9977, oral solution, single dose|In Part B, of oral solution of AZD9977 will be used as reference
61979780|NCT04688307|EXPERIMENTAL|Lifestyle modification and smoking reduction failure|Obtaining ideal body weight by calorie restriction diet and programmed physical activity and the amount of cigarette smoking reduction is not more than 50% of the baseline
61979781|NCT04688307|EXPERIMENTAL|Lifestyle modification and smoking reduction|Obtaining ideal body weight by calorie restriction diet and programmed physical activity and the amount of cigarette smoking reduction is 50% of the baseline or more
61979782|NCT05744453|EXPERIMENTAL|Olive Leaf Extract|Olive leaf extract supplementation
61979783|NCT05744453|PLACEBO_COMPARATOR|Control|Cellulose Supplementation
61979784|NCT06180590||Vosevi Group|Patients are administrated with once-daily oral Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir: 400mg/100mg/100mg)
62359691|NCT02793089||Third quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
61979785|NCT06180590||Sofosbuvir/Velpatasvir combined with ribavirin Group|Patients are administrated with once-daily oral Sofosbuvir/Velpatasvir (400mg/100mg) combined with ribavirin（500mg）twice a day
61979786|NCT02786342||Advanced HCC patients treated with sorafenib|
61979787|NCT01549392|ACTIVE_COMPARATOR|DECT/MR Spectroscopy +Avastin|-15 Glioma Patients with progression will undergo DECT and MRS before Avastin (10 mg/kg iv q2 weeks until progression) and 3 months later
61979788|NCT01549392|ACTIVE_COMPARATOR|DECT/MR Spectroscopy no Avastin|15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1
61979789|NCT01494480|EXPERIMENTAL|stem cell transplantation|After stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
61979790|NCT06045026|OTHER|Anti-sensitivity toothpaste|Participants will use the anti-sensitivity toothpaste according to the instructions on the commercial pack and their normal oral healthcare habits for 24 weeks.
61979791|NCT01647633|EXPERIMENTAL|Calcium Glycerophosphate Nasal Wash|Nasal spray wash twice daily and up to four additional times per day as needed for nasal allergy symptoms
61979792|NCT06477614|EXPERIMENTAL|Placental gp96 induced DC cell Vaccine|
61979793|NCT06477614|EXPERIMENTAL|Tumor-derived gp96 induced DC cell Vaccine|
61979794|NCT02537340||EMVI-MR positive|Patients with primary rectal cancer and extramural vascular invasion detected by staging MR
61979795|NCT02537340||EMVI-MR negative|Patients with primary rectal cancer and without extramural vascular invasion detected by staging MR
61979796|NCT05643768|EXPERIMENTAL|High-resistance IMST|30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 5 days/week, 6 weeks
61979797|NCT05643768|ACTIVE_COMPARATOR|Low-resistance IMST|30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 5 days/week, 6 weeks
61979798|NCT04855097|EXPERIMENTAL|Standard care group|Blood Volume Analysis will be performed at admission, during inpatient stay if warranted, and prior to hospital discharge. Treating physicians will be blinded to the results and will choose between a low-moderate and high diuretic dose based on usual care clinical assessment of volume status.
61979799|NCT04855097|EXPERIMENTAL|BVA-guided treatment arm|Blood Volume Analysis will be performed at admission, during inpatient stay if warranted, and prior to hospital discharge. Treating physicians will receive the results and will choose between a low-moderate and high diuretic dose based on measured volume status.
61979800|NCT05520944||Retrospective Data Collection|
61979801|NCT01776775|ACTIVE_COMPARATOR|abdominal binder|use of postoperative abdominal binder 30 days after the hernia repair
61979802|NCT01776775|NO_INTERVENTION|No abdominal binder|No intervention
61979803|NCT04138134||Group 1|Patients subjected to saphenectomy due to chronic venous insufficiency or varicose veins
61979804|NCT04138134||Group 2|Patients with atherosclerotic obstructive disease of lower limbs
61979805|NCT05549206|EXPERIMENTAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine 50μg|Two doses were administered by intramuscular injection, 28 days apart
61979806|NCT05549206|EXPERIMENTAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine 100μg|Two doses were administered by intramuscular injection, 28 days apart
61979807|NCT05549206|PLACEBO_COMPARATOR|Placebo|Two doses were administered by intramuscular injection, 28 days apart
61979808|NCT04417920|ACTIVE_COMPARATOR|group I (Express implant)|conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva
61979809|NCT04417920|ACTIVE_COMPARATOR|group II (trabeculectomy)|"Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock.~conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of sclerectomy and peripheral iridectomy and closed scleral flab and conjunctiva by nylon 10/0 sutures"
61979810|NCT05003076|EXPERIMENTAL|Placebo Then Methamphetamine|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.
61979811|NCT05003076|EXPERIMENTAL|Methamphetamine Then Placebo|Participants first receive 20 mg methamphetamine at their first session in the laboratory Then will return to the laboratory 72 hours later and will receive placebo.
61979812|NCT02716103||Initial Cohort: feasibility|Bone marrow collection and peripheral blood collection from ten patients with untreated AL amyloidosis will be evaluated to determine feasibility of isolating a plasma cell clone. An additional three teaspoons of bone marrow and 4 teaspoons of blood will be collected at the time of standard blood draw and bone marrow biopsy before receiving any treatment. There will be no extra procedures or visits specifically for this research.
61979813|NCT02716103||2nd Cohort - pre-treatment|If feasibility is determined with initial cohort, bone marrow collection and peripheral blood collection from 20 patients with untreated AL amyloidosis who are scheduled to undergo antineoplastic therapy will be evaluated to isolate a plasma cell clone. An additional 3 teaspoons of bone marrow and 4 teaspoons of blood will be collected at the time of standard blood draw and bone marrow biopsy before receiving therapy. For those who complete therapy and achieve complete response or very good partial response, subsequent samples of bone marrow and peripheral blood will be sent for minimal residual disease detection (based on the previously identified cancer clone) at 6 to 12 months post treatment.
61979814|NCT01060930|EXPERIMENTAL|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust \~ 300 mcg/m3 - during intermittent exercise
61979815|NCT01060930|EXPERIMENTAL|Air exposure|1 hour exposure to filtered air during intermittent exercise
62359692|NCT02793089||Fourth quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
62359693|NCT00248105|EXPERIMENTAL|PAM|
61979816|NCT01416922||LSIL|Women 21 years of age or older with an LSIL diagnosis
61979817|NCT01499667|EXPERIMENTAL|8-week washout + Fingolimod (FTY720)|8-week washout (8 weeks no treatment) followed by 24 weeks of treatment with fingolimod 0.5mg once a day
61979818|NCT01499667|EXPERIMENTAL|12-week washout + Fingolimod (FTY720)|12-week washout (8 weeks no treatment and 4 weeks placebo) followed by 20 weeks of treatment with fingolimod 0.5mg once a day
61979819|NCT01499667|EXPERIMENTAL|16-week washout + Fingolimod (FTY720)|16-week washout (8 weeks no treatment and 8 weeks placebo) followed by 16 weeks of treatment with fingolimod 0.5mg once a day
61979820|NCT03630120|ACTIVE_COMPARATOR|Standard of Care: DTC|Standard of Care (SOC) TKI Therapy for Differentiated Thyroid Cancer (DTC): Lenvatinib + Sorafenib.
62359694|NCT00248105|NO_INTERVENTION|PC|Participants not in the PAM group will be in the PC (physician counseling) group and will receive advice on lifestyle physical activity from their rheumatologist or primary care physician.
62359695|NCT03854812|ACTIVE_COMPARATOR|Group M|magnesium sulphate as adjuvant to propofol
62359696|NCT03854812|ACTIVE_COMPARATOR|Group F|fentanyl as adjuvant to propofol
62359697|NCT00105560|EXPERIMENTAL|Radiation therapy|This is a single arm study of radiation therapy with protons to standard doses.
62359698|NCT04858503|EXPERIMENTAL|internet-based cardiac rehabilitation enhancement intervention|internet-based cardiac rehabilitation enhancement intervention
62359699|NCT04858503|NO_INTERVENTION|conventional cares as arranged by hospital or community centers|Participants will receive conventional cares as arranged by hospital or community centers
62359700|NCT05474755|EXPERIMENTAL|GP681 40mg|Patients in the GP681 40mg group will receive a single oral dose of GP681 tablet 40mg with 240mL water.
62359701|NCT05474755|PLACEBO_COMPARATOR|placebo group|Patients in the Placebo group will receive a single oral dose of GP681 Simulant 40mg with 240mL water.
62359702|NCT02206321||Navigation total knee arthroplasty|Navigation total knee arthroplasty
61979821|NCT03630120|EXPERIMENTAL|Adaptive Care: DTC|SOC followed by Adaptive Care TKI Therapy for DTC Participants with \>=50% drop: Lenvatinib + Sorafenib.
61979822|NCT03630120|ACTIVE_COMPARATOR|Standard of Care: MTC|Standard of Care (SOC) TKI Therapy for Medullary Thyroid Cancer: Cabozantinib + Vandetanib.
61979823|NCT03630120|EXPERIMENTAL|Adaptive Care: MTC|SOC followed by Adaptive Care TKI Therapy for MTC Participants with \>=50% drop: Cabozantinib + Vandetanib.
61979824|NCT06437899|ACTIVE_COMPARATOR|local anaesthesia|
61979825|NCT06437899|ACTIVE_COMPARATOR|sedoanalagesia|
61979826|NCT04411589|EXPERIMENTAL|Magnifying endoscopy with optical enhancement system group|Patients in this group go through gastroscopy under the magnifying endoscopy with optical enhancement system.
61979827|NCT04411589|ACTIVE_COMPARATOR|white light endoscopy group|Patients in this group go through gastroscopy under white light endoscopy.
61979828|NCT01031940|ACTIVE_COMPARATOR|macintosh|
61979829|NCT01031940|ACTIVE_COMPARATOR|C-MAC|
61979830|NCT01031940|ACTIVE_COMPARATOR|Airtraq|
61979831|NCT06226233|EXPERIMENTAL|Juniver intervention group|Immediate access to the Juniver program
61979832|NCT06226233|NO_INTERVENTION|Wait list control|Access to the Juniver program after 12 weeks
61979833|NCT01928329|PLACEBO_COMPARATOR|Placebo|2 mg, 1 per week via subcutaneous placebo self injection
61979834|NCT01928329|EXPERIMENTAL|Exenatide (Bydureon)|2 mg, of drug administration 1 per week via subcutaneous self injection
62359703|NCT02206321||Conventional total knee arthroplasty|Conventional total knee arthroplasty
61979835|NCT03938584|EXPERIMENTAL|Vitamin C|
61979836|NCT03938584|PLACEBO_COMPARATOR|Placebo|
62359704|NCT01332097|EXPERIMENTAL|Treatment A|Single 75mg oral dose of BCT197 capsules + single oral dose of prednisone placebo capsules
62359705|NCT01332097|PLACEBO_COMPARATOR|Treatment B/G/E/I|Matching placebo comparator arm
62567077|NCT04540744|EXPERIMENTAL|Treatment Sequence AB|Participants will receive a single oral dose of fixed dose combination (FDC) of macitentan/tadalafil (10 milligram \[mg\]/20 mg) in fasted conditions (test) (Treatment A) in treatment period 1 followed by a single oral dose of a free combination of 10 mg macitentan and 20 mg tadalafil in fasted conditions (reference) (Treatment B) in treatment period 2 on Day 1. Study drug intake in subsequent treatment periods in an individual participant will be separated by a washout period of at least 10 days.
61979837|NCT05605392|EXPERIMENTAL|Deinstitutionalization|
61979838|NCT00768807|SHAM_COMPARATOR|Sham CPAP|Patients submitted to SHAM CPAP use for 06 months
61979839|NCT00768807|ACTIVE_COMPARATOR|CPAP|OSA patients submitted to 06 months of CPAP treatment
61979840|NCT03087760|EXPERIMENTAL|Single Arm|Single Arm, Open Label
61979841|NCT02153112|EXPERIMENTAL|Cohort 1, Group 1: 1 Dose|Children 4 to \<9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.
61979842|NCT02153112|EXPERIMENTAL|Cohort 1, Group 1: 2 Doses|Children 4 to \<9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.
61979843|NCT02153112|EXPERIMENTAL|Cohort 1, Group 2: 1 Dose|Children 1 to \<4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.
61979844|NCT02153112|EXPERIMENTAL|Cohort 1, Group 2: 2 Doses|Children 1 to \<4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
61979845|NCT02153112|EXPERIMENTAL|Cohort 1, Group 2a: 1 Dose|Children 1 to \<4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.
61979846|NCT02153112|EXPERIMENTAL|Cohort 1, Group 2a: 2 Doses|Children 1 to \<4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
61979847|NCT02153112|EXPERIMENTAL|Cohort 1, Group 3: 1 Dose|Toddlers 6 months to \<1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.
61979848|NCT02153112|EXPERIMENTAL|Cohort 1, Group 3: 2 Doses|Toddlers 6 months to \<1 year of age will receive 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
62359706|NCT01332097|ACTIVE_COMPARATOR|Treatment C|Single oral dose of BCT 197 placebo capsules + single oral dose of 40mg prednisone capsules
62359707|NCT01332097|EXPERIMENTAL|Treatment D|Single oral dose of 20mg dose of BCT197 capsules
62359708|NCT01332097|EXPERIMENTAL|Treatment F|Single oral dose of 20 mg dose of BCT197 capsules on Day 1 and Day 6
62359709|NCT01332097|EXPERIMENTAL|Treatment H|Single oral dose of 75mg dose of BCT197 capsules on Day 1 and Day 6
62359710|NCT02929862|EXPERIMENTAL|Single Agent 55716|
62359711|NCT02426112|ACTIVE_COMPARATOR|Azithomycin|"Azithromycin tablets 250 mg, 30mg/kg/week by mouth, once a week for 12 months.~* 10-20 kg: 250 mg~* 20-29 kg: 500 mg~* 30-39 kg: 750 mg~* 40-49 kg: 1250 mg"
62359712|NCT02426112|PLACEBO_COMPARATOR|Placebo|"Placebo tablets 250 mg, 30 mg/kg/week by mouth, once a week for 12 months.~* 10-20 kg: 250 mg~* 20-29 kg: 500 mg~* 30-39 kg: 750 mg~* 40-49 kg: 1250 mg"
61979849|NCT02153112|EXPERIMENTAL|Cohort 2, Group 4: 2 Doses|Infants 6 weeks to \<6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.
61979850|NCT02153112|EXPERIMENTAL|Cohort 2, Group 4: 3 Doses|Infants 6 weeks to \<6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.
61979851|NCT03006744|EXPERIMENTAL|Phonological awareness training|Parents will be given specific training on how to improve phonological awareness using books provided by the investigator. Parents watch a video with examples of how to improve phonological awareness. Suggestions include placing emphasis on rhyme and alliteration, segmenting long words into syllables and talking about how words sound and what they mean.
61979852|NCT03006744|PLACEBO_COMPARATOR|Reading enjoyment training|Parents will be given general training on how to make reading fun. Parents watch a video with examples of how they can bring books to life with funny voices, actions, and so on. The training is of a similar duration to the intervention arm.
61979853|NCT02150954|ACTIVE_COMPARATOR|foley bulb induction with low dose pitocin|Subjects in this arm will receive a standard infusion protocol of pitocin starting at 1 milliunit/minute (mius/min) and increasing 2 milliunits per minute every 30 minutes.
61979854|NCT02150954|ACTIVE_COMPARATOR|foley bulb with standard incremental pitocin infusion protocol|Subjects in this arm will receive a fixed low dose pitocin infusion protocol of 2 mius/min.
61979855|NCT05673044|EXPERIMENTAL|modified Studer ileal neobladder|the segment of the iso-peristaltic segment is 8 cm and the total length of the ileum used is 40 cm instead of 60 cm.
61979856|NCT05673044|EXPERIMENTAL|modified spiral ileal neobladder|the chimney of the spiral neobladder will be an angled one instead of straight.
61979857|NCT00826020|EXPERIMENTAL|Omegaven™|This study will be a prospective, non-randomized, open-label study of Omegaven™ for provision of parenteral lipid calories. The study cohort, receiving the parenteral nutrition (PN) lipid at 1g/kg/day, will be compared to historical controls at University of Nebraska Medical Center (UNMC) where parenteral lipid calories were provided exclusively through soybean-based formulations. The study is planned to enroll 100 patients. The Intestinal Rehabilitation Program at UNMC sees between 20 and 30 new pediatric patients per year, with almost all being PN-dependent and over 75% presenting with a bilirubin ≥ 2mg/dL. Based on these calculations, we estimate 4-5 years to enroll 100 patients.
61979858|NCT06181097|EXPERIMENTAL|negative pressure wound therapy|Both groups will have layered closure with 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. For the NPWT group, the Smith \& Nephew PICO dressing will be chosen as it is versatile with various size options, and the small suction pump is would not causing much problems to patient mobility. For the standard dressing group, the same PICO dressing will be applied, but without the suction.
61979859|NCT06181097|ACTIVE_COMPARATOR|standard dressing|Both groups will have layered closure with 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. For the NPWT group, the Smith \& Nephew PICO dressing will be chosen as it is versatile with various size options, and the small suction pump is would not causing much problems to patient mobility. For the standard dressing group, the same PICO dressing will be applied, but without the suction.
61979860|NCT05332509|EXPERIMENTAL|C-BRACE/SCO|The patient is first fitted during 2 months with the C-BRACE orthosis, them, after 2 weeks wash-out period, the patient is fitted with its Stance Controlled Orthosis (SCO).
61979861|NCT05332509|OTHER|SCO/C-BRACE|The patient is using its Stance controlled orthosis (SCO) during 2 months, then, after 2 weeks wash-out period, the patient is fitted with the C-BRACE orthosis.
61979862|NCT05775315|EXPERIMENTAL|Action Observation Therapy|exercises of AO protocol
62359713|NCT01359852|EXPERIMENTAL|001|"\[11C\] JNJ-42491293 + JNJ-40411813 Part C:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan,\[11C\] JNJ-42491293 + JNJ-40411813 Part D:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain,\[11C\] JNJ-42491293 Part A: \[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.,\[11C\] JNJ-42491293 Part B:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection have a 90 minute PET scan and have arterial and venous blood sampling."
61979863|NCT05775315|ACTIVE_COMPARATOR|Visual feedback and Action Observation Therapy|Excercises of AO protocol infront of a mirror
61979864|NCT05457673|EXPERIMENTAL|AtaCor EV Temporary Pacing Lead System|Subjects implanted with the AtaCor StealthTrac Lead Model AC-1013
61979865|NCT04273217|EXPERIMENTAL|AV-1 30 mg|Participants received a single intravenous (IV) infusion (infusion duration: 1 hour) of AV-1 30 mg on Day 1.
61979866|NCT04273217|EXPERIMENTAL|AV-1 90 mg|Participants received a single IV infusion (infusion duration: 1 hour) of AV-1 90 mg on Day 1.
61979867|NCT04273217|EXPERIMENTAL|AV-1 250 mg|Participants received a single IV infusion (infusion duration: 1 hour) of AV-1 250 mg on Day 1.
61979868|NCT04273217|EXPERIMENTAL|AV-1 500 mg|Participants received a single IV infusion (infusion duration: 1 hour) of AV-1 500 mg on Day 1.
61979869|NCT04273217|EXPERIMENTAL|AV-1 1000 mg|Participants received a single IV infusion (infusion duration: 1 hour) of AV-1 1000 mg on Day 1.
61979870|NCT04273217|PLACEBO_COMPARATOR|Placebo|Participants received a single IV infusion (infusion duration: 1 hour) of placebo matched to AV-1 on Day 1.
62359714|NCT05751694|EXPERIMENTAL|Visceral manual treatment|The objective of this technique is to reduce the tension of the tissues of the epigastric area.
62359715|NCT05751694|ACTIVE_COMPARATOR|Respiratory listening|It is a maneuver to evaluate the mobility of the ribs during respiration.
61979871|NCT02500290||Acute coronary syndrome|
61979872|NCT05244408||SCI Subjects|"Patients who suffer a traumatic spinal cord injury who meet the following inclusion criteria are eligible for admission into the study as SCI subjects:"
61979873|NCT05244408||Non-SCI Spine Trauma Control Subjects.|"Patients who suffer a fracture or dislocation of their spinal column but without neurologic injury are eligible for admission into the study as Non-SCI Spine Trauma Control Subjects"
61979874|NCT04086290|EXPERIMENTAL|RARP + SBRT + ADT|Radical prostatectomy + extended pelvic lymph node dissection according to EAU guidelines followed by stereotactic body radiotherapy to osseous lesions with six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
61979875|NCT01270711||Cabergoline users|cohort of patients, who are treated with cabergoline during the study period ( from January 1st, 2006 to July 1st 2012)
61979876|NCT05747092|ACTIVE_COMPARATOR|Control group: free gingival graft for gingival recession|
61979877|NCT05747092|EXPERIMENTAL|Test group: connective tissue graft for gingival recession|
61979878|NCT02535845|EXPERIMENTAL|Self-persuasion group|HPV information plus self-persuasion intervention in a tablet-based application (Project Voice)
61979879|NCT02535845|ACTIVE_COMPARATOR|Information only group|HPV information only in a tablet-based application (HPV Informational Video)
61979880|NCT05100524|EXPERIMENTAL|Motivational interview|8 motivational interviews were conducted with the intervention group.
61979881|NCT05100524|ACTIVE_COMPARATOR|Control Group|No application was made to increase physical compliance and improve quality of life.
61979882|NCT01892501|OTHER|hypermetabolic mediastinal lymph nodes in PET,|hypermetabolic mediastinal lymph nodes in PET,in a context of New cancer or cancer recurrence.
62359716|NCT00094835|EXPERIMENTAL|Paclitaxel + Carboplatin + Motesanib|Chemotherapy naïve participants received paclitaxel 200 mg/m\^2 and carboplatin chemotherapy administered by intravenous (IV) infusion on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. The initial dose of motesanib was 50 mg once daily administered in the initial cohort and up to 125 mg once daily was used in subsequent cohorts. A cycle was defined as the 3 weeks plus the time to recover from toxicity, if encountered.
61979883|NCT01185457||Left interscalene block|Left shoulder surgery under left interscalene block and HRV
61979884|NCT01185457||Right interscalene block|Right shoulder surgery under right interscalene block and HRV
61979885|NCT01622972|EXPERIMENTAL|Group 1|Healthy volunteers in Group 1: To give sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2
61979886|NCT01622972|EXPERIMENTAL|Group 2|Healthy volunteers in group 2: To give 2x sachet's A and B made up to 2 litres with tap water on day 1.
61979887|NCT01622972|EXPERIMENTAL|Group 3|Patients with functional constipation and irritable bowel syndrome characterized by constipation: To give sachet's A and B made up to 1 litre with tap water once on day 1
61979888|NCT01114165|EXPERIMENTAL|SeptiFast Test|Pathogen detection by SeptiFast Test as an adjunct to traditional microbiological assessments including blood culture
61979889|NCT01114165|ACTIVE_COMPARATOR|Only Conventional Diagnostics|Pathogen detection only by conventional microbiological assessments, e.g. blood culture
61979890|NCT04860791||Multiple Sclerosis patients|
61979891|NCT04834947||Prone position in non-intubated COVID19 , before and after.|Patients with non-intubated COVID19 pneumoniae for whom the clinician has decided to try prone positioning to increase the PaO2 in a context of hypoxemia with O2 requirement.
61979892|NCT03218033|NO_INTERVENTION|Control|Participants visited the Facinglupustogether.com website and participated in consecutive weekly modules for 8 weeks. At the end of each module there were questions pertaining to the subject of each module. The control group answered the questions in provided journals and these were sent back to the investigator. All subjects completed surveys in REDCap prior to the study intervention and again 6 weeks after study completion to assess secondary outcome measures. Medication adherence was assessed by calculating a medication possession ratio by acquiring information on fill dates at the subjects' pharmacies.
61979893|NCT03218033|ACTIVE_COMPARATOR|Social Media (SM)|"The intervention phase was 8 weeks in duration. Participants visited the Facinglupustogether.com website and participated in consecutive weekly modules. 8 The SM group answered the questions at the end of each module on a blogging site with other SM participants. SM participants were encouraged to provide feedback or questions about the material or personal questions that arose in response to each module.~All subjects completed surveys in REDCap prior to the study intervention and again 6 weeks after study completion to assess secondary outcome measures. Medication adherence was assessed by calculating a medication possession ratio by acquiring information on fill dates at the subjects' pharmacies."
61979894|NCT01998633|EXPERIMENTAL|Hematopoietic Stem Cell Transplant|Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
62359717|NCT00094835|EXPERIMENTAL|Panitumumab + Motesanib|Participants with no more than one prior chemotherapy regimen for NSCLC received panitumumab administered by IV at 9.0 mg/kg on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. The initial dose of motesanib was 50 mg once daily administered in the initial cohort, up to 125 mg once daily was used in subsequent cohorts.
62359718|NCT00094835|EXPERIMENTAL|Panitumumab + Paclitaxel + Carboplatin + Motesanib|"Chemotherapy naïve participants received panitumumab administered by IV at 9.0 mg/kg on Day 1 of each 21-day cycle, paclitaxel 200 mg/m\^2 and carboplatin chemotherapy administered by IV infusion on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter.~Participants were enrolled in this arm once a safe and tolerable dose of motesanib was established."
62359719|NCT03222219||low implant stability quotient|dental implant insertion with low torque values
61979895|NCT01572909|ACTIVE_COMPARATOR|Bendavia™|Bendavia™ administered intravenously at 0.05 mg/kg/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.
61979896|NCT01572909|PLACEBO_COMPARATOR|Placebo|Placebo administered intravenously at 60 mL/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.
61979897|NCT00243789|ACTIVE_COMPARATOR|1|Pentoxifylline
61979898|NCT00243789|NO_INTERVENTION|2|Placebo
61979899|NCT05281445|EXPERIMENTAL|Tic suppression|Children with tics will undergo a tic suppression experimental paradigm.
61979900|NCT02657382|EXPERIMENTAL|Heart Rate Variability (HRV) Biofeedback (BF)|Participants with coronary artery disease randomized to this group will complete myocardial blood flow (MBF) imaging and mental stress tests. Participants in this group will also participate in heart rate variability (HRV) biofeedback (BF) during the first six weeks of the study.
61979901|NCT02657382|EXPERIMENTAL|Waitlist Control|Participants with coronary artery disease randomized to this group will complete myocardial blood flow (MBF) imaging and mental stress tests.Participants in this group will receive the heart rate variability (HRV) biofeedback (BF) intervention between the week 6 and week 12 study visits.
61979902|NCT05087095|EXPERIMENTAL|CALM|CALM therapy will be provided via telehealth. Participants will complete surveys (post-session, post-intervention, and 90-day follow-up) via secure email link. Exit interviews will be conducted by phone
61979903|NCT04741074|ACTIVE_COMPARATOR|Semaglutide|This arm will receive semaglutide.
61979904|NCT04741074|PLACEBO_COMPARATOR|Placebo|This arm will receive placebo.
61979905|NCT04237090|ACTIVE_COMPARATOR|Diphenhydramine + placebo|"Diphenhydramine 50 mg intravenous given in a 50 milliliters bag of sodium chloride 0.9 percent, with famotidine, 30 minutes before the paclitaxel infusion. 15 minutes infusion.~Lactose tablet 100 mg per os given 30 minutes before the paclitaxel infusion.with a 180 milliliters glass of water."
61979906|NCT04237090|EXPERIMENTAL|Cetirizine + placebo|"Cetirizine tablet 10 mg per os given 30 minutes before the paclitaxel infusion.with a 180 milliliters glass of water.~1 milliliter of sodium chloride 0,9 percent intravenous given in a 50 milliliters bag of sodium chloride 0.9 percent, with famotidine, 30 minutes before the paclitaxel infusion. 15 minutes infusion."
61979907|NCT03946904|EXPERIMENTAL|preconditioning|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG. The lesion in this case was prepared with low power setting to start and is aimed at applying low level laser therapy (LLLT) first before using high power.
61979908|NCT03946904|EXPERIMENTAL|no preconditioning|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG.the lesion in this case was prepared with high power laser setting first to ablate the enamel, dentin, and caries.
61979909|NCT04260542|ACTIVE_COMPARATOR|FAST Lean|Short-term fasting (FAST), comparator group of lean subjects
61979910|NCT04260542|EXPERIMENTAL|FAST Obese|Short-term fasting (FAST), experimental group of obese subjects
61979911|NCT04260542|EXPERIMENTAL|KETO Obese|Medium-term ketogenic diet intervention (KETO), experimental group of obese subjects
61979912|NCT00630279|PLACEBO_COMPARATOR|1|
61979913|NCT00630279|EXPERIMENTAL|2|
61979914|NCT00630279|EXPERIMENTAL|3|
62359720|NCT03222219||medium implant stability quotient|dental implant insertion with medium torque values
62359721|NCT03222219||high implant stability quotient|dental implant insertion with high torque values
62359722|NCT01990703|EXPERIMENTAL|Early IUD Insertion Group|Immediate post-placental placement of the levonorgestrel IUD
62567078|NCT04540744|EXPERIMENTAL|Treatment Sequence BA|Participants will receive Treatment B in treatment period 1 followed by Treatment A in treatment period 2 on Day 1. Study drug intake in subsequent treatment periods in an individual participant will be separated by a washout period of at least 10 days.
61979915|NCT00630279|EXPERIMENTAL|4|
61979916|NCT00597766|ACTIVE_COMPARATOR|Low Dose|"Drug: Lidocaine (Neer's Test)~Drug: 20 mg Triamcinolone + Lidocaine"
61979917|NCT00597766|ACTIVE_COMPARATOR|Standard Dose|"Drug: Lidocaine (Neer's Test)~Drug: 40 mg Triamcinolone + Lidocaine"
61979918|NCT00597766|EXPERIMENTAL|High Dose|"Drug: Lidocaine (Neer's Test)~Drug: 60 mg Triamcinolone + Lidocaine"
61979919|NCT02015650|ACTIVE_COMPARATOR|Cetuximab|Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
61979920|NCT02015650|ACTIVE_COMPARATOR|Mitomycin-C / 5-Fluorouracil|Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
62182274|NCT02715427|ACTIVE_COMPARATOR|Conventional care|"Preoperative consultation Information support conventional perioperative No bowel preparation~Day before surgery Normal diet until midnight No carbohydrate loading Premedication with anxiolytic~Operative day Conventional general anaesthesia Classic management perfused volumes Conventional use of drains at the operative site Standard nasogastric drainage Conventional analgesia protocol~Postoperative time Mobilization from J1 Progressive refeeding Progressive removal of venous, arterial and urinary catheters. Gradual recovery of the usual treatment from J1 Breathe physiotherapy depending on the clinical course No stimulation of intestinal transit"
62359723|NCT01990703|ACTIVE_COMPARATOR|Standard Postpartum Insertion Group|Placement of the levonorgestrel IUD 4-6 weeks postpartum
62359724|NCT00706394|EXPERIMENTAL|A|Powerlink 34mm cuff stent graft
62359725|NCT04644484|EXPERIMENTAL|Experimental Group: SYN023+Rabies Vaccine|"SYN023:~Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible SYN023 is an equal mass mixture of CTB011 and CTB012, two monoclonal antibodies that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.~Dosage form: 6mg/2mL, liquid; Dosage: 0.3 mg/kg of SYN023; Frequency/duration: at Day 1~Rabies vaccine :~Interventions: should be administered in deltoid muscle Dosage form: \>=2.5 IU, freeze-dried vaccine, reconstitute into 0.5 mL before use Dosage: 0.5 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29"
62359726|NCT04644484|ACTIVE_COMPARATOR|Control Group: Human Rabies Immune Globulin (HRIG)+Rabies Vaccine|"Human Rabies Immune Globulin (HRIG):~Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible Dosage form: 100 IU/mL, liquid; Dosage: 20 IU/kg; Frequency/duration: at Day 1~Rabies vaccine :~Interventions: should be administered in deltoid muscle Dosage form: \>=2.5 IU, freeze-dried vaccine, reconstitute into 0.5 mL before use; Dosage: 0.5 milliliters (mL) after reconstitution; Frequency/duration: at Day 1, 4, 8, 15, 29"
62359727|NCT05564676|EXPERIMENTAL|flaxseed oil and pomegranate extract|2g daily of flaxseed oil plus 1.2g daily pomegranate dry extract
62359728|NCT05564676|PLACEBO_COMPARATOR|sunflower oil and microcrystalline cellulose|2g daily of sunflower oil plus 1.2g daily microcrystalline cellulose
62359729|NCT05508295||COVID positive case with mAb treatment|
61979921|NCT06073353|EXPERIMENTAL|THRIVE-M|"Participants will be recruited from the Massachusetts General Hospital Cancer Center and randomized in a 1:1 fashion, stratified by diagnosis type (newly diagnosed versus maintenance versus relapsed), to THRIVE-M versus usual care.~Participants will use THRIVE-M following a diagnosis of multiple myeloma to learn how to cope with physical symptoms, articulate their needs and navigate relationships, and focus on self-care while living with multiple myeloma using an iPad provided by the study team or the participant's own iPad.~Questionnaires (in person, over the computer or telephone, or by mail) will be completed by participants at predetermined days per protocol days."
61979922|NCT06073353|NO_INTERVENTION|Usual Care|"Participants will be recruited from the Massachusetts General Hospital Cancer Center and randomized in a 1:1 fashion, stratified by diagnosis type (newly diagnosed versus maintenance versus relapsed), to THRIVE-M versus usual care.~Questionnaires (in person, over the computer or telephone, or by mail) will be completed by participants at predetermined days per protocol days.~Participants in the usual care arm will receive their usual care with the multiple myeloma team, including all routine supportive care resources (e.g., support from social work, psychology, or psychiatry) offered by the multiple myeloma team to all patients diagnosed with multiple myeloma.~Patients in both the usual care and THRIVE-M group are permitted to use all supportive care services per usual care. We will track referrals to supportive care services in both groups by reviewing the Electronic Health Record (EHR)."
61979923|NCT04803669|ACTIVE_COMPARATOR|Conventional Treatment Group|Includes Hotpack, TENS, Ultrasound and Exercise programs.
61979924|NCT04803669|EXPERIMENTAL|IASTM Group|Inludes Hotpack, TENS, Ultrasound, Exercise program and Instrument-assisted Soft Tissue Mobilization Technique
61979925|NCT04232072|ACTIVE_COMPARATOR|Group ESPB = Erector spinae plane block group|ESPB will be performed 30 min before induction of general anesthesia, with patients in the sitting position by using US. Under aseptic conditions, the high frequency linear probe will be covered with a sterile sheath and a 22G, 50 mm block needle will be used. Local anesthetic infiltration with 2% of lidocaine will be applied under the skin. US probe will be placed longitudinally 2-3 cm lateral to the T7 transvers process. The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block. The same procedure will be performed for the opposite site.
61979926|NCT04232072|ACTIVE_COMPARATOR|Group Ibuprofen = Ibuprofen|In Group Ibuprofen, a dose of 800 mg ibuprofen IV will be administrated 30 min before induction of general anesthesia.
61979927|NCT04232072|NO_INTERVENTION|Group C = Control group|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period.
61979928|NCT03513302|PLACEBO_COMPARATOR|placebo|
61979929|NCT03513302|ACTIVE_COMPARATOR|nitrate|
61979930|NCT04489212|EXPERIMENTAL|Treatment (follow-up, observation)|Patients who have recurrence or progression during treatment or observation have medical charts are reviewed every 6 months for 5 years. Patients who complete adjuvant treatment are followed for observation 3 days after radiation therapy, 1 month after radiation therapy, every 3 months after radiation therapy for 2 years, every 6 months for 1 year, and then annually for 2 years.
61979931|NCT04867681|EXPERIMENTAL|Administration of a short psycho-education programme|
61979932|NCT04867681|NO_INTERVENTION|Control group|
61979933|NCT01619683|EXPERIMENTAL|Androxal|
61979934|NCT01619683|PLACEBO_COMPARATOR|Placebo|
61979935|NCT01108601|OTHER|Ringer's Lactate|Each patient will act as their own control with one ear receiving treatment, and the contralateral ear acting as control.
61979936|NCT04787029|EXPERIMENTAL|prophylactic medical compression therapy group|"This study provides medical compression stockings from the start date of Docetaxel administration for patients who have undergone mastectomy and axillary lymphectomy for breast cancer, and who are planning to receive Docetaxel adjuvant chemotherapy. The intervention group wears medical compression stockings for upper limbs with a pressure level of 1 (15-21mmHg) during the day from the start of docetaxel administration to 3 months after the end of administration.~Basic education of upper limb exercises (joint motion range enhancement exercises and upper limb muscle pumping exercises) is provided to both the intervention group and the control group."
61979937|NCT04787029|NO_INTERVENTION|control group|"The control group proceeds as an observation, but interventions such as providing stockings in the event of lymphedema are performed.~Basic education of upper limb exercises (joint motion range enhancement exercises and upper limb muscle pumping exercises) is provided to both the intervention group and the control group."
62359730|NCT05508295||COVID positive case having not received mAb treatment|
62359731|NCT05508295||COVID negative cases|
62359732|NCT03684070|EXPERIMENTAL|Enhanced Walking|FitBit + Lifestyle counseling/education session(8 weeks) + WeChat motivational messages and peer interaction
62359733|NCT03684070|ACTIVE_COMPARATOR|Walking Only|FitBit + Lifestyle counseling/education session(8 weeks)
62359734|NCT02699853|EXPERIMENTAL|Arm I (RRC)|Patients undergo RRC at day 0.
62359735|NCT02699853|EXPERIMENTAL|Arm II (ORC)|Patients undergo ORC at day 0.
62359736|NCT04745468|EXPERIMENTAL|Apheresis Group|"20 patients receive 2 apheresis treatments at intervals of 24 ± 12 h (additionally to the standard therapy after bypass surgery). The first treatment starts within 24 h postoperatively. If the CRP concentration increases to at least 30 mg/L 6-18 h after the end of the second treatment, a third treatment is performed.~For each treatment the 1 - 2.5-fold plasma void is processed. The duration of each treatment is 4-6 h."
62359737|NCT04745468|NO_INTERVENTION|Control group|17 patients of the control group receive the standard therapy after bypass surgery.
62359738|NCT04661267|EXPERIMENTAL|Supplement formula|Patients randomized to the experimental group will receive daily 1-ounce doses of stem cell support formula for 60 days. Patients will complete patient-reported outcome questionnaires at 1 month and 2 months.
61979938|NCT04368988|PLACEBO_COMPARATOR|Placebo - Phase 1|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
62359739|NCT04661267|PLACEBO_COMPARATOR|Placebo formula|Patients randomized to the control group will receive a daily 1-ounce doses of placebo stem cell support formula for 60 days. Patients will complete patient-reported outcome questionnaires at 1 month and 2 months.
62359740|NCT06301594|EXPERIMENTAL|the observation group|The observation group is the only group of the participants.The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of systematic simple swallowing training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 15-30 minutes. Each training session will be conducted approximately one hour prior to meals. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
62359741|NCT00718523|PLACEBO_COMPARATOR|A|Placebo plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of placebo administered on Day 1 of each 21-day cycle.
62359742|NCT00718523|EXPERIMENTAL|B|AMG 479 plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of AMG 479 single agent administered on Day 1 of each 21-day cycle.
62359743|NCT05506696|EXPERIMENTAL|Vitamin D supplementation|3200IU cholecalciferol (Fultium) peri-operatively
62359744|NCT05506696|NO_INTERVENTION|Control|No treatment. Control arm.
62359745|NCT03387891||Cancer patients|Cancer patients admitted to hospital for treatment or monitoring of health condition
61979939|NCT04368988|EXPERIMENTAL|SARS-CoV-2 rS - 25 μg without Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 25 μg, 1 dose each on Days 0 and 21.
61979940|NCT04368988|EXPERIMENTAL|SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.
61979941|NCT04368988|EXPERIMENTAL|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.
61979942|NCT04368988|EXPERIMENTAL|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M then Placebo - Phase 1|1 dose of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (mixed together for injection), on Day 0 followed by 1 dose of Placebo on Day 21.
61979943|NCT04368988|PLACEBO_COMPARATOR|Placebo - Phase 2|3 doses of Placebo (Saline), 1 dose each on Days 0, 21, and 189.
61979944|NCT04368988|EXPERIMENTAL|SARS-CoV-2 rS - 5/5 μg + 50 μg Matrix-M - Phase 2|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.
61979945|NCT04368988|EXPERIMENTAL|SARS-CoV-2 rS - Alternating 5/5 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 1 dose of Placebo on Day 21 followed by 1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 189.
61979946|NCT04368988|EXPERIMENTAL|SARS-CoV-2 rS - 25/25 μg + 50 μg Matrix-M - Phase 2|2 doses of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.
61979947|NCT04368988|EXPERIMENTAL|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 2 doses of Placebo, 1 dose each on Days 21 and 189.
62359746|NCT05906667|EXPERIMENTAL|Intervention Group|All participants assigned to the experimental group (walking)
62359747|NCT05351905|EXPERIMENTAL|CBD oil|Participants will receive CBD (cannabidiol) oil for a total duration of 12 weeks.
62359748|NCT05351905|EXPERIMENTAL|CBD+THC oil|Participants will receive CBD (cannabidiol) oil in combination with THC (delta-9-tetrahydrocannabinol) for a total duration of 12 weeks.
62359749|NCT05351905|PLACEBO_COMPARATOR|Placebo oil|Participants will receive matching placebo oil for a total duration of 12 weeks.
62359750|NCT03578380|EXPERIMENTAL|Surgery|Lymphovenous anastomosis
62359751|NCT03578380|ACTIVE_COMPARATOR|Compression|Conservative treatment with physiotherapy and compression
62359752|NCT05428449|EXPERIMENTAL|GT20029|
62359753|NCT05428449|PLACEBO_COMPARATOR|GT20029 Placebo|
62359754|NCT01975038||A convenience sample|The characteristics of the sample will be monitored to assure that each category of skin type (I- VI) is accrued in sufficient size to support analysis. In addition, the sample will have equal representation from 4 ethnic groups within each skin type category: African American, Asian, Hispanic, or non-Hispanic White. Participants will self-identify as being Asian, Black, Hispanic Black, Hispanic White, or non-Hispanic White.
62359755|NCT05471206|EXPERIMENTAL|Milk intolerant volunteers|
62359756|NCT05471206|ACTIVE_COMPARATOR|Milk tolerant volunteers|
62359757|NCT02791360|OTHER|MRI evaluation|Patient pretreated for brain tumor and witness
62359758|NCT00033111|ACTIVE_COMPARATOR|Cabergoline|Subjects received one tablet of 0.5 mg of cabergoline tablet per week for 12 weeks.
62359759|NCT00033111|PLACEBO_COMPARATOR|Placebo|Subjects received one tablet of 0.5 mg of cabergoline matched placebo tablet per week for 12 weeks.
61979948|NCT04368988|EXPERIMENTAL|SARS-CoV-2 rS - 5/5/5 μg + 50 μg Matrix-M - Phase 2|3 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Day 0, Day 21, and Day 189.
61979949|NCT04368988|EXPERIMENTAL|SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 2 doses of Placebo, 1 dose each on Days 21 and 189.
61979950|NCT03906045|EXPERIMENTAL|All patients|10 patients with moderate COPD and 10 patients with severe/very severe COPD inhale BGF followed by a breath hold of up to 10 seconds.
61979951|NCT05633121||Patient suffering from uremic calciphylaxis treated with rheopheresis|
61979952|NCT05633121||Patient suffering from uremic calciphylaxis not treated with rheopheresis|
61979953|NCT06002347|EXPERIMENTAL|STAC Parent Module|
61979954|NCT03026608|EXPERIMENTAL|Intervention Group|Communities randomized to the intervention group receive the Veggie Van program shortly after randomization.
61979955|NCT03026608|ACTIVE_COMPARATOR|Delayed Intervention Control Group|This group will receive the Veggie Van intervention approximately 6 months after baseline data collection and randomization (after the collection of 6 months outcomes data).
62359760|NCT02953613||Cardiac Catheterization with NIRS/IVUS|Cardiac cathetirization with NIRS/IVUS assessment if with blockage of indeterminate severity (greater or equal to 20% to 70%). One day to one week after invasive catheterization a CCTA will be done to correlate result, then CCTA will be repeated at 24 months
61979956|NCT04358653|EXPERIMENTAL|fall prevention exercise program|The experimental group was designed to undergo supervised exercise 2 days a week for 8 consecutive weeks for 45-50 min/session. The intervention program was implemented at the nursing home facilities.
62359761|NCT05304598|ACTIVE_COMPARATOR|Dexmedetomidine Group|a single intravenous (i.v.) dose of dexmedetomidine, 0.2 mcg/kg over 10 minutes
62359762|NCT05304598|ACTIVE_COMPARATOR|Control Group|routine awake intubation as per current unit standard of care
62359763|NCT02305290||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Upper Gastrointestinal Lesions will be included in this cohort.
62359764|NCT00947934|EXPERIMENTAL|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation.
62359765|NCT06365372||PAH|
62359766|NCT06365372||Non-PAH|
61979957|NCT04358653|NO_INTERVENTION|Control Group|The control group did not receive any intervention during that period and were instructed to pursue their habitual daily life activities.
61979958|NCT00631566|EXPERIMENTAL|1|
61979959|NCT00631566|PLACEBO_COMPARATOR|2|
61979960|NCT00631566|NO_INTERVENTION|No MRSA colonization|
61979961|NCT04938557|EXPERIMENTAL|An Automated Closed-loop Insulin Delivery (AiD) System.|The intervention being evaluated in this trial is automated closed-loop insulin delivery (AiD). The closed-loop system comprises of three components: an insulin pump, a continuous glucose monitor (CGM) and a computer-based model predictive control (MPC) algorithm to compute information from the CGM into a recommended insulin dose.
61979962|NCT04938557|ACTIVE_COMPARATOR|A Standard Insulin Delivery System|This can include either: an insulin pump (Continuous Subcutaneous Insulin Infusion - CSII) or multiple daily injections (MDI) without closed-loop.
61979963|NCT03909295|EXPERIMENTAL|LCZ696|Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient
61979964|NCT05545566|EXPERIMENTAL|All patients|
61979965|NCT03793582||Study group|All subjects agreeing to participate and meeting inclusion criteria but not meeting exclusion criteria
62359767|NCT02398981|NO_INTERVENTION|Baseline|Baseline data collection ( 20 patients per ICU)
62359768|NCT02398981|EXPERIMENTAL|Checklist|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist 40 patients per ICU
62359769|NCT01302691|EXPERIMENTAL|L50/H12.5/A5|Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.
62359770|NCT01302691|ACTIVE_COMPARATOR|L50 + A5|Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.
62359771|NCT02382783|OTHER|FLARE Intervention Group|"In the FLARE Intervention Group, we ask that you participate in all of the following, over the course of two years:~* Baseline Study Visit~* Monthly: Complete FLARE Questionnaires, at home, and report results. The last question on this questionnaire will ask you if you feel you are having a flare of your disease.~* FLARE Study Visit (if applicable): We will schedule you to be seen when/if you feel you are having a flare of your disease.~* Follow-up Visits (minimum of every 6 months): These are done as the standard of care for your RA.~* At one time-point, during your first return visit after the baseline visit you will have an examination by ultrasound~* Patient Satisfaction Surveys at three time-points: Baseline, 1 year, 2 year~Also, your rheumatology health care provider (RHCP) will be asked to participate in the study by completing three satisfaction surveys over the course of two years."
61979966|NCT05589207||Invaded Group|Patients whose inferior vena cava vascular wall is invaded according to histopathological examination.
61979967|NCT05589207||Non-invaded group|Patients whose inferior vena cava vascular wall is not invaded according to histopathological examination.
61979968|NCT04102592|EXPERIMENTAL|Intervention Group|Participants in this arm receive Lesu (baby wrap) treated with 0.5% permethrin
61979969|NCT04102592|PLACEBO_COMPARATOR|Control Group|Participants in this arm receive Lesu (baby wrap) soaked with water only to mimic re-treatment and mask allotment
61979970|NCT02692599|EXPERIMENTAL|Experimental Group|"* Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~* Intervention: investigational live attenuated mumps vaccine;"
61979971|NCT02692599|ACTIVE_COMPARATOR|Control Group|"* Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;~* Intervention: control live attenuated mumps vaccine;"
61979972|NCT04733092|EXPERIMENTAL|Embolization|Embolization of the inflammatory hypervascularization with a lipiodol emulsion
61979973|NCT01950845|EXPERIMENTAL|Automated fluid management system (Closed-loop system)|cardiac output Vigileo® (Edwards Lifesciences) monitoring is connected to the closed loop system that will automatically provide per operative fluid bolus to optimize cardiac output by automated detection of fluid responsiveness state.
61979974|NCT01950845|SHAM_COMPARATOR|Current practice manual fluid management|cardiac output Vigileo® (Edwards Lifesciences) monitoring will be used to help the anesthesiologist team to detect fluid responsiveness state for the manual fluid management optimization
62359772|NCT02382783|NO_INTERVENTION|Standard of Care (SOC) Group|"If you are randomized to the SOC Group, your care will not be any different than your usual care of rheumatoid arthritis (RA). You will be seen by a rheumatologist at a minimum of every six months, which is the standard of care for RA.~Additionally (for research), we ask the following of you...~* At one time-point, during your first return visit after the baseline visit you will have an examination by ultrasound~* Patient Satisfaction Surveys at three time-points: Baseline, 1 year, 2 year~Also, your rheumatology health care provider (RHCP) will be asked to participate in the study by completing three satisfaction surveys over the course of two years."
62359773|NCT03867110|PLACEBO_COMPARATOR|Placebo|Placebo is to be taken orally once a day (QD) in the morning for 12 consecutive weeks.
62359774|NCT03867110|ACTIVE_COMPARATOR|Ezetimibe 10 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) is to be taken orally QD in the morning for 12 consecutive weeks.
61979975|NCT00751647|OTHER|A1|Population receiving the CF specific outpatient PT services.
61979976|NCT01641692|EXPERIMENTAL|GSK573719 15.6 mcg|GSK573719 (Umeclinidium bromide) 15.6 mcg once-daily
61979977|NCT01641692|EXPERIMENTAL|GSK573719 31.25 mcg|GSK573719 (Umeclinidium bromide) 31.25 mcg once-daily
61979978|NCT01641692|EXPERIMENTAL|GSK573719 62.5 mcg|GSK573719 (Umeclinidium bromide) 62.5 mcg once-daily
62359775|NCT03867110|ACTIVE_COMPARATOR|Atorvastatin 10 mg|Atorvastatin 10 mg is to be taken orally QD in the morning for 12 consecutive weeks.
62359776|NCT03867110|EXPERIMENTAL|Ezetimibe 10 mg + Atorvastatin 10 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 10 mg is to be taken orally QD in the morning for 12 consecutive weeks.
62359777|NCT03867110|ACTIVE_COMPARATOR|Atorvastatin 20 mg|Atorvastatin 20 mg is to be taken orally QD in the morning for 12 consecutive weeks.
62359778|NCT03867110|EXPERIMENTAL|Ezetimibe 10 mg + Atorvastatin 20 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 20 mg is to be taken orally QD in the morning for 12 consecutive weeks.
62359779|NCT03867110|ACTIVE_COMPARATOR|Atorvastatin 40 mg|Atorvastatin 40 mg is to be taken orally QD in the morning for 12 consecutive weeks.
62359780|NCT03867110|EXPERIMENTAL|Ezetimibe 10 mg + Atorvastatin 40 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 40 mg is to be taken orally QD in the morning for 12 consecutive weeks.
62359781|NCT03867110|ACTIVE_COMPARATOR|Atorvastatin 80 mg|Atorvastatin 80 mg is to be taken orally QD in the morning for 12 consecutive weeks.
62359782|NCT03867110|EXPERIMENTAL|Ezetimibe 10 mg + Atorvastatin 80 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 80 mg is to be taken orally QD in the morning for 12 consecutive weeks.
61979979|NCT01641692|EXPERIMENTAL|GSK573719 125 mcg|GSK573719 (Umeclinidium bromide) 125 mcg once-daily
61979980|NCT01641692|EXPERIMENTAL|GSK573719 250 mcg|GSK573719 (Umeclinidium bromide) 250 mcg once-daily
61979981|NCT01641692|EXPERIMENTAL|GSK573719 15.6 mcg twice-daily|GSK573719 (Umeclinidium bromide) 15.6 mcg twice-daily
62359783|NCT01832857|EXPERIMENTAL|CPI-613 Alone|This arm is for patients that have failed, or are not eligible for, all available therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing \[MTD\]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
62359784|NCT05457738|EXPERIMENTAL|patients randomized to using the smartphone app|
62359785|NCT05457738|ACTIVE_COMPARATOR|patients randomized to not using the smartphone app|
62359786|NCT04005807|EXPERIMENTAL|Cohort 1 (fasted condition)|10 mg BPN-14967 or placebo
62359787|NCT04005807|EXPERIMENTAL|Cohort 2 (fasted condition)|25 mg BPN-14967 or placebo
62359788|NCT04005807|EXPERIMENTAL|Cohort 3 (fasted condition)|50 mg BPN-14967 or placebo
62359789|NCT04005807|EXPERIMENTAL|Cohort 4 (fed condition)|10 mg BPN-14967 or placebo
62359790|NCT04005807|EXPERIMENTAL|Cohort 5 (high-fat fed condition)|10 mg BPN-14967 or placebo
61979982|NCT01641692|EXPERIMENTAL|GSK573719 31.25 mcg twice daily|Gsk573719 (Umeclinidium bromide) 31.25 mcg twice-daily
61979983|NCT01641692|PLACEBO_COMPARATOR|Matched Placebo|Matched Placebo arm
61979984|NCT06258655|NO_INTERVENTION|Pre-intervention|The sample collected before the intervention
61979985|NCT06258655|EXPERIMENTAL|Post-intervention|The sample collected after the intervention
61979986|NCT01189214|EXPERIMENTAL|Memantine|
61979987|NCT02055014|ACTIVE_COMPARATOR|Liraglutide alone|Liraglutide 1.8mg once daily subcutaneous injection
61979988|NCT02055014|EXPERIMENTAL|Endobarrier alone|Duodenal-jejunal bypass liner (Endobarrier) device implantation without additional GLP-1RA therapy
61979989|NCT02055014|EXPERIMENTAL|Endobarrier and Liraglutide|Duodenal-jejunal bypass liner (Endobarrier) device with combined liraglutide 1.2mg once daily subcutaneous injection
61979990|NCT02244489|EXPERIMENTAL|Momelotinib (MMB)+capecitabine|Participants will receive momelotinib (MMB)+capecitabine at varying dose levels to determine the MTD for momelotinib (MMB) and capecitabine.
61979991|NCT02244489|EXPERIMENTAL|Momelotinib (MMB)+capecitabine+oxaliplatin|Upon reaching the MTD for momelotinib (MMB) and capecitabine or if no MTD is reached, participants will receive momelotinib (MMB)+capecitabine at the MTD plus oxaliplatin at varying dose levels to determine the MTD of combination capecitabine, momelotinib (MMB), and oxaliplatin.
62567079|NCT05948150|EXPERIMENTAL|group not to use a breastfeeding pillow|In this arm, individuals are not provided with a breastfeeding pillow.
61979992|NCT00672789|EXPERIMENTAL|1|Blood Smear Education
61979993|NCT00672789|ACTIVE_COMPARATOR|2|Standard education
61979994|NCT02548494|PLACEBO_COMPARATOR|Control Group|The control group will receive all traditional methods of treatment for DKA including iv insulin, correction of fluid loss, and electrolyte correction, including a placebo subcutaneous injection.
61979995|NCT02548494|EXPERIMENTAL|Treatment Group|The study group will receive the same treatment including iv insulin, correction of fluid loss, and electrolyte correction, but will be supplemented with a subcutaneous glargine injection.
61979996|NCT01643811||Gastrectomy|Patients who underwent gastrectomy for early gastric cancer
61979997|NCT01643811||Endoscopic submucosal dissection|Patients who underwent endoscopic submucosal dissection for early gastric cancer
61979998|NCT01103284|EXPERIMENTAL|DiaPep277|Administration of 1 mg DiaPep277®, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.
62359791|NCT03625297|NO_INTERVENTION|Shelter cat adoption control group|Families of children with autism will complete a control period with no intervention, then adopt a shelter cat after completion of the control period
62359792|NCT03625297|EXPERIMENTAL|shelter cat adoption|Families of children with autism will adopt a shelter cat
62359793|NCT01902004|ACTIVE_COMPARATOR|Escitalopram and Memantine|Participants will take a combination of Escitalopram and Memantine for 12 months
62359794|NCT01902004|ACTIVE_COMPARATOR|Escitalopram and placebo|Participants will take a combination of Escitalopram and placebo for 12 months
62359795|NCT01562678|EXPERIMENTAL|Liraglutide|
62359796|NCT01562678|PLACEBO_COMPARATOR|Placebo|
62567080|NCT05948150|EXPERIMENTAL|breastfeeding pillow group|In this arm, breastfeeding pillows are used for individuals
61979999|NCT01103284|PLACEBO_COMPARATOR|Placebo|Administration of placebo, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.
61980000|NCT03721276|EXPERIMENTAL|Therapy|Individuals assigned to therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, that address minority stress mechanisms underlying SMW's depression, anxiety, and alcohol abuse.
61980001|NCT03721276|OTHER|Waitlist|Individuals assigned to waitlist will be put on a waitlist for 3 months after baseline assessment, after which they will also receive the same treatment as the therapy group.
61980002|NCT01977508||haemodialysis vascular access using ePTFE grafts|
61980003|NCT00737620|ACTIVE_COMPARATOR|propaten graft|
61980004|NCT00737620|ACTIVE_COMPARATOR|Standard graft|
61980005|NCT01388218||Arm 1 - Daily+Clinical|Order of assessment: Daily PRO + Clinical visit PRO
61980006|NCT01388218||Arm 2 - Clinical+Daily|Order of assessment: Clinical visit PRO + Daily PRO
61980007|NCT01058889|EXPERIMENTAL|Telemedical device|Patient will receive a blood glucose measurement device and a telemedical device to monitor blood glucose measurements.
61980008|NCT01058889|NO_INTERVENTION|Treatment as usual|
61980009|NCT00702013||1|
61980010|NCT00702013||2|
61980011|NCT00702013||3|
61980012|NCT00702013||4|
61980013|NCT00702013||5|
61980014|NCT00702013||6|
61980015|NCT00702013||7|
61980016|NCT00702013||8|
62359797|NCT05247125|EXPERIMENTAL|Blue light exposure + Melatonin treatment|The participants will receive the combination of blue light exposure according to the protocol described by Killgore et al. (2020) and 3 mg of melatonin 1 hour before going to sleep (approximately at 20:00) (Ramos et al 2020) for 14 days
62359798|NCT05247125|EXPERIMENTAL|Melatonin treatment|The participants will receive 3 mg of melatonin 1 hour before going to sleep (approximately at 20:00) (Ramos et al 2020) and the morning placebo-light exposure according to the protocol described by Killgore et al. (2020) for 14 days
62359799|NCT05247125|EXPERIMENTAL|Blue light exposure|The participants will receive the morning blue light exposure according to the protocol described by Killgore et al. (2020) for 14 days and placebo pill 1 hour before going to sleep (approximately at 20:00)
62567081|NCT03895008||Cardia gastric cancer|Cardiac gastric cancer is defined as a cancer center lies arising 2-5 cm from the gastric mucosa distal to the esophagogastric junction.
61980017|NCT05013567|EXPERIMENTAL|Ibuprofen gel 5%|
61980018|NCT05013567|PLACEBO_COMPARATOR|Placebo|
61980019|NCT06216145|EXPERIMENTAL|Experimental group|"Before the skills exam, the 'Self-Efficacy Survey in the Most Commonly Used Skill-Requiring Practices in Nursing' will be administered. Apart from the end-of-term skill exam, students will be given a different skill exam than the control group, in which they will not receive any grades. For applications requiring invasive interventions, a skill test will be administered in the laboratory.~For applications that do not require invasive intervention, a skill test will be administered in the clinical environment. At the end of the semester, students will be asked to fill out the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing'. At the end of the semester, students will be evaluated with 2 skill applications and skill exam scores to be selected by written exam and lottery method."
61980020|NCT06216145|PLACEBO_COMPARATOR|conrol group|At the end of the fall semester midterm exam, the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing' will be administered. At the end of the semester, students will be asked to fill out the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing'. This scale will measure self-efficacy. At the end of the semester, students will be evaluated with 2 skill applications and skill exam scores to be selected by written exam and lottery method. With these exams, skills and theoretical knowledge will be measured.
61980021|NCT04656145|EXPERIMENTAL|Chlorhexidine Gluconate Gel Dressing|All subjects are receiving two surgical drains during a single operative procedure. This arm will be randomized to receive the intervention.
61980022|NCT04656145|NO_INTERVENTION|Standard of Care|All subjects are receiving two surgical drains during a single operative procedure. This arm will be randomized to received standard drain care - gauze (no intervention).
61980023|NCT02756884|EXPERIMENTAL|LoFU and aADSC|Low Frequency Ultrasound LFUS will be delivered in a non-sterile manner using a custom modified LFUS combined imaging/therapy probe. Adipose derived stem cells from the patient will be harvested through lipoaspiration. This solution will be injected intra-venous, intra-adventitia and intramuscular in the affected vessel and area after the administration of the low frequency ultrasound
61980024|NCT02756884|ACTIVE_COMPARATOR|Adipose Derived Stem Cells|Adipose derived stem cells from the patient will be harvested through lipoaspiration. This solution will be injected intra-venous, intra-adventitia and intramuscular in the affected vessel and area without the administration of the low frequency ultrasound
62359800|NCT05247125|PLACEBO_COMPARATOR|Placebo group|The participants will receive placebo light exposure in the morning (lamp turned off) and placebo pill treatment in the evening for 14 days
61980025|NCT04577118|OTHER|iotaSOFT Insertion System|The iotaSOFT Insertion System is a surgical device that aids the surgeon in implanting cochlear electrode arrays by controlling the speed and distance of implant insertion. All subjects enrolled in the trial will have the iotaSOFT Insertion System used during surgery.
61980026|NCT05545254||Breast cancer patients and their family members who have undertaken genetic testing|In this study, 259 participants were recruited from November 2019 to March 2022. All participants originated from a genetic counseling clinic of a cancer center in Shanghai, China. 259 participants were contact, and among them, 158 participants finally agreed to participate and completed the survey.
61980027|NCT02278263|PLACEBO_COMPARATOR|Control|Application of 20ml of normal saline (NaCl 0.9%) topically after implantation of prosthesis and left to sit for two minutes, excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
61980028|NCT02278263|EXPERIMENTAL|Topical|Application of 1.5g in 20ml tranexamic acid topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
62567082|NCT03895008||Non-cardia gastric cancer|Non-cardia gastric cancer is defined as tumors originated from the gastric mucosa distal to the cardia.
62359801|NCT04518345|EXPERIMENTAL|Treatment (dubermatinib)|"FLT3 AML WITH RELAPSED/REFRACTORY DISEASE:~INDUCTION: Patients receive dubermatinib PO QD on days 1-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients with clinical or hematologic response and not transplant eligible may continue dubermatinib until loss of response/clinical benefit. Patients with clinical or hematologic response and transplant eligible may continue dubermatinib until one week prior to admission."
62359802|NCT01261598|OTHER|1|Patients treated with curative and exclusive radiotherapy (60 Gy minimum), with possibly prior chemotherapy
61980029|NCT02278263|EXPERIMENTAL|Systemic|Application of 20ml of normal saline topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; Application of tranexamic acid intravenously (1.5g/15ml) at the same time prior to release of tourniquet
61980030|NCT01926314|EXPERIMENTAL|device|Patients in this group will be offered pelvic floor muscle rehabilitation program using PHENIX Neuromuscular Stimulation Therapy System device. The participants will start therapy once a week 42 days after delivery, and last 8 weeks.
61980031|NCT01926314|ACTIVE_COMPARATOR|usual home care without device|Patients in this group will receive usual home care without device.
61980032|NCT00488345|EXPERIMENTAL|A|0.75 mg/kg (up to a maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Escalation to next dose cohort will occur only after safety and tolerability at preceding dose have been established by sponsor (after tigecycline LDOT data are received) and if at least 5 of 6 PK samples per patient have been received by central laboratory in acceptable condition for 10 to 12 patients in cohort. Treatment period of tigecycline will be a minimum of 3 days (unless patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
62359803|NCT01261598|OTHER|2|Patient treated with concomitant chemotherapy and radiotherapy (60 Gy minimum), with possibly prior chemotherapy chemotherapy Treatment
62359804|NCT05223699|EXPERIMENTAL|Single dose MGTA-117|Dosing of MGTA-117 prepared and administered by IV infusion.
62359805|NCT04182906|ACTIVE_COMPARATOR|No ACEs screen|Participants complete all measures except an ACEs screening tool
62359806|NCT04182906|EXPERIMENTAL|Identified ACEs screen with Anticipatory Guidance|Caregiver-completed screening tool about child's adverse experiences.In this version, specific ACEs items are reported, Pediatric medical provider offers anticipatory guidance about ACEs and toxic stress.
62359807|NCT04182906|EXPERIMENTAL|De-Identified ACEs screen with Anticipatory Guidance|Caregiver-completed screening tool about child's adverse experiences. In this version,total number of ACEs items are reported, only. Pediatric medical provider offers anticipatory guidance about ACEs and toxic stress.
62359808|NCT04864600|ACTIVE_COMPARATOR|Standard Stearin Candle|Several candles will be lit. We will be using realistic burning cycles i.e. burning candles which extinguish and new ones being lit.
62359809|NCT04864600|EXPERIMENTAL|Modified low emission candle|Several candles will be lit. We will be using realistic burning cycles i.e. burning candles which extinguish and new ones being lit.
62359810|NCT04864600|NO_INTERVENTION|Clean Air|No candles in the chamber.
62359811|NCT04492787|EXPERIMENTAL|Changkang Granules|Changkang Granules
62359812|NCT04492787|PLACEBO_COMPARATOR|Changkang Placebo Granules|Changkang Placebo Granules
62359813|NCT03037606|EXPERIMENTAL|Rabelis DDR 50 mg Capsules and 1 placebo tablet|Placebo as comparator group is not used. Since study is double-blind, one placebo capsule and tablet is added to treatment groups in order to remove the discrepancy between investigational products.
62359814|NCT03037606|ACTIVE_COMPARATOR|Pariet 20 mg Enteric Coated Tablets and 1 placebo capsule|Placebo as comparator group is not used. Since study is double-blind, one placebo capsule and tablet is added to treatment groups in order to remove the discrepancy between investigational products.
62359815|NCT03432117|EXPERIMENTAL|Fixed respiratory rehabilitation program(A)|respiratory rehabilitation program for 12 weeks
61980033|NCT00488345|EXPERIMENTAL|B|1 mg/kg (up to a maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Escalation to next dose cohort will occur only after safety and tolerability at preceding dose have been established by sponsor (after tigecycline LDOT data are received) and if at least 5 of 6 PK samples per patient have been received by the central laboratory in acceptable condition for 10 to 12 patients in the cohort. Treatment period of tigecycline will be a minimum of 3 days (unless the patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
62359816|NCT03432117|EXPERIMENTAL|Mixed respiratory rehabilitation program(B)|Fixed respiratory rehabilitation for 6 weeks, and then responsive respiratory rehabilitation for 6 weeks
62359817|NCT03432117|NO_INTERVENTION|Control(C)|Ordinary rehabilitation service of the site for 12 weeks
62359818|NCT02919410|ACTIVE_COMPARATOR|Surgery performed using iodophor-impregnated adhesive drapes|
62359819|NCT02919410|OTHER|Surgery performed without iodophor-impregnated adhesive drapes|
62359820|NCT01395355|EXPERIMENTAL|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
62567083|NCT01977755|ACTIVE_COMPARATOR|danegapetide high dose|7,5 mg bolus injection, followed by 22,5 mg infused over 6 hours
62359821|NCT01395355|ACTIVE_COMPARATOR|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral weight management techniques.
62359822|NCT00555568|EXPERIMENTAL|Peer-led Groups|Arm 1 is a 3-month recovery-focused mental health education and support group led by peer facilitators
62359823|NCT00555568|EXPERIMENTAL|Clinician-led Groups|Arm 2 is a 3-month recovery-focused mental health education and support group led by a mental health clinician
62359824|NCT00555568|NO_INTERVENTION|Treatment as Usual|Arm 3 is treatment as usual (no intervention)
62359825|NCT01712503|EXPERIMENTAL|Toric intraocular lens|TFlex Lens (623T)
62359826|NCT01712503|PLACEBO_COMPARATOR|Monofocal intraocular lens|Superflex Aspheric Lens (920H)/Cflex Aspheric Lens (970C)
62567084|NCT01977755|ACTIVE_COMPARATOR|danegaptide low dose|2,5 mg bolus injection, followed by 7,5 mg infused over 6 hours
61980034|NCT00488345|EXPERIMENTAL|C|1.25 mg/kg (up to maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Treatment period of tigecycline will be a minimum of 3 days (unless patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
62359827|NCT05221593|NO_INTERVENTION|control group|will receive chemotherapy regimen with placebo
61980035|NCT00740142|ACTIVE_COMPARATOR|1|Interventional arm: oral L-ornithine-L-aspartate and oral lactulose
61980036|NCT00740142|PLACEBO_COMPARATOR|2|Oral lactulose
62359828|NCT05221593|EXPERIMENTAL|study group|"will receive chemotherapy regimen with Lithium Carbonate in controlled release formula (400mg b.i.d).~In order to avoid the potential for bone marrow stimulation at the time chemotherapy was administered, the administration of lithium was started 24 hours after the administration of chemotherapy and continued for 18 days of every 21.the lithium serum level will be measured at specific times to ensure lithium serum level between 0.4-0.8 mmol\\L along the treatment course."
62359829|NCT05163834|EXPERIMENTAL|Efgartigimod-1|Weekly efgartigimod infusions and the pneumovax 23 vaccine on day 22
62359830|NCT05163834|EXPERIMENTAL|Efgartigimod-2|Weekly efgartigimod infusions and the pneumovax 23 vaccine on day 36
61980037|NCT01303887|ACTIVE_COMPARATOR|R-CVP|Repeated every 21 days for up to 8 cycles with response assessment after 4 cycles. Responders (PR/CR) after 8 cycles will receive Rituximab maintenance therapy for 2 years (12 bi-monthly cycles).
62359831|NCT05163834|PLACEBO_COMPARATOR|Placebo|Weekly placebo infusions and the pneumovax 23 vaccine on day 22
62359832|NCT03318601|EXPERIMENTAL|cirrhotic patients with ascites|cirrhotic patients with ascites requiring prolonged hospitalization
62359833|NCT00062647|EXPERIMENTAL|Telavancin|
62359834|NCT00062647|ACTIVE_COMPARATOR|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram/12 hours or nafcillin, oxacillin, or cloxacillin 2 Gram/6 hours (IV) intravenously
62359835|NCT04113512|EXPERIMENTAL|Yoga Nasal Irrigation Group|Saline nasal irrigation using neti pot was practiced.
61980038|NCT01303887|EXPERIMENTAL|R-FC|Repeated every 21 days for 4 cycles. Responders (PR/CR) after 4 cycles will receive 4 further cycles of Rituximab only. Responders after 8 cycles will receive Rituximab maintenance therapy for 2 years (12 bi-monthly cycles).
61980039|NCT03985514|ACTIVE_COMPARATOR|Antibiotic treatment|Patients will receive in-hospital intravenous antibiotics (Piperacillin/Tazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3). Surgery if no symptom relif occur.
61980040|NCT03985514|OTHER|Clinical observation|"Patients are followed by in-hospital Active observation (watchful waiting) according to clinical routine. Patients are observed until either, recovery and dismissal from hospital, or decision for intervention (surgery) is taken."
61980041|NCT01012518|ACTIVE_COMPARATOR|Conventional PCT|PCT performed without video guidance, as conventionally performed
62169212|NCT05580302||Laryngeal Dystonia|"The study will be performed on 10-15 (maximal 20) subjects with diagnosed laryngeal dystonia who meet the exclusion/ inclusion criteria.~Inclusion criteria: adults (18-65 years old) who have confirmed diagnosis of laryngeal dystonia, no implanted metals in body (e.g. pacemaker, metal prosthesis in skull and oral cavity).~Exclusion criteria: pregnancy, other neurological disorders, psychiatric disorders, epilepsy or history of previous epilepsy attack, using of brain affecting pharmaceuticals, traumatic, tumor, infectious, metabolic brain lesions, heart conditions (15 ).~The composition of the group is represented is both gender, various age gap, and different height.~Before the beginning of testing, all subjects with a confirmed diagnosis of laryngeal dystonia will be once again evaluated by a specialist otorhinolaryngologist at the University Hospital of Split. Medical documentation of the examination will be available for further analysis."
62169213|NCT05580302||Healthy subjects|"The study will be performed on 20 healthy volunteering subjects who meet the exclusion/ inclusion criteria.~Inclusion criteria: healthy adults (18-65 years old), no implanted metals in body (e.g. pacemaker, metal prosthesis in the skull and oral cavity) Exclusion criteria: pregnancy, neurological disorders, psychiatric disorders, epilepsy or history of previous epilepsy attack, using of the brain affecting pharmaceuticals, traumatic, tumor, infectious, metabolic brain lesions, heart conditions.~The composition of the group is represented is both gender, various age gap, and different height."
61980042|NCT01012518|EXPERIMENTAL|Video-assisted PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
61980043|NCT06246318|EXPERIMENTAL|virtual reality plus conventional occupational therapy|"Virtual reality will be given to the study group in addition to the conventional occupational therapy program.~Nintendo Wii Fit Plus will be used as the virtual reality method in the research."
62169214|NCT03149887|EXPERIMENTAL|Experimental|Injection of liposomal bupivacaine in surgical field at end of arthroscopic rotator cuff repair.
62169215|NCT03149887|ACTIVE_COMPARATOR|Control|Injection of inert placebo solution in surgical field at end of arthroscopic rotator cuff repair.
62169216|NCT00761618|EXPERIMENTAL|Arm 1 - Daily|Intrapleural Catheters (IPC) drained every day
62359836|NCT04113512|NO_INTERVENTION|Wait list Control group|Group was given usual pain medication. After trial period, they were offered the intervention.
62359837|NCT00545467|ACTIVE_COMPARATOR|1|fast tapering of the previous medication within 1 week after initiating aripiprazole for 2 weeks
62359838|NCT00545467|ACTIVE_COMPARATOR|2|slow tapering of the previous medication within 4 weeks after initiating aripiprazole for 2 weeks
62359839|NCT01676792|EXPERIMENTAL|Lesion reduction|
62359840|NCT06122246|ACTIVE_COMPARATOR|Remote Blood Pressure (BP) Management Program|Participants will receive a remote BP management program (RBPM) inclusive of home BP monitoring and telehealth visits with a nurse or pharmacist.
62359841|NCT06122246|EXPERIMENTAL|Remote Blood Pressure (BP) Management Program + Community Health Worker (CHW)|Participants will receive a remote BP management program (RBPM) inclusive of home BP monitoring and telehealth visits with a nurse or pharmacist plus a social model with a CHW.
62359842|NCT06122246|NO_INTERVENTION|Usual Care|Participants will be monitored prior to any RBPM intervention.
62391370|NCT02062385|EXPERIMENTAL|V260 with concomitant EPI|V260 administered as a 2 mL oral solution at age \~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age \~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age \~3, 4, and 5 months
62359843|NCT02738762|ACTIVE_COMPARATOR|intervention group|enteral glutamine supplementation guided by glutamine level Enteral glutamine supplementation is started (day 1) at a dose of 3 sachets per day given at 6.00, 14.00 and 22.00 hr. A sachet contains 9 grams of L-glutamine ( Glutaperos®, GLNP Life Sciences). Enteral glutamine supplementation will be given for a maximum of 10 days or until the patient is discharged from the ICU
62359844|NCT02738762|NO_INTERVENTION|control group|patients receive normal treatment, no glutamine supplementation
62169217|NCT00761618|EXPERIMENTAL|Arm 2 - 3 Times a Week|IPC drained 3 times a week
61980044|NCT06246318|OTHER|conventional occupational therapy|This is a control group. Sensory integration and gross motor training approaches are used in the conventional occupational therapy program.
62169218|NCT01693159|EXPERIMENTAL|ECA: Ethyl-2-cyanoacrate|Application of ethyl-2-cyanoacrylate (ECA) for painful cetuximab-induced rhagades
62359845|NCT06071390|EXPERIMENTAL|Children watching animated- assisted video before endoscopy procedure|Inclusion criteria were children and mothers who voluntarily participated, who were aged 6-12 years, who know Turkish, and who do not have a vision or mental problem at a level to watch the image.
61980045|NCT01005420|EXPERIMENTAL|Blueberry Powder|"A blueberry smoothie will be consumed at the breakfast and dinner meals.~Nutritional Value:(based on one 16oz smoothie and subjects had to consume two a day)~* 206.4 Kcals~* 40.3 g Carbohydrate~* 11.5 g Protein~* 0.08 g Fat~* 0.05 g Sat fat~* 4.2 g Fiber~Ingredients:~* 245.0 g Dannon Light \& Fit yogurt~* 105 .0 g Skim milk~* 22.5 g Freeze-dried blueberry powder~* 5.0 g Imitation vanilla flavor~* 1.0 g Splenda~* 16 oz plastic cup with lid~* Smoothie total weight - 378.5 g"
61980046|NCT01005420|PLACEBO_COMPARATOR|Placebo|"A placebo smoothie will be consumed at the breakfast and dinner meals.~Nutritional Value:(based on one 16oz smoothie and subjects had to consume two a day)~* 201.3 Kcals~* 40.3 g Carbohydrate~* 10.7 g Protein~* 0.08 g Fat~* 0.05 g Sat fat~* 4.3 g Fiber~Ingredients:~* 245.0 g Dannon Light \& Fit yogurt~* 105 .0 g Skim milk~* 5.0 g Benefiber~* 12.0 g Sugar~* 4.0 g Artificial blueberry flavor(liquid \& powder)~* 1.5 g Red food color~* 0.7 g Blue food color~* 16 oz plastic cup with lid~* Smoothie total weight - 373.2 g"
61980047|NCT03194698|EXPERIMENTAL|MGX and Intense Pulsed Light Treatment (IPL)|Treatment with 4 visits and 4 treatments of IPL and Meibomian Gland Expression (MGX)
62359846|NCT06071390|NO_INTERVENTION|Children not watching animated- assisted video before endoscopy procedure|Exclusion criteria were children and mothers who not voluntarily participated, who were not aged 6-12 years, who don't know Turkish, and who have a vision or mental problem at a level to watch the image.
62359847|NCT04593836|EXPERIMENTAL|L-menthol|20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
62359848|NCT04593836|PLACEBO_COMPARATOR|Placebo|20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
62169219|NCT01693159|ACTIVE_COMPARATOR|Standard treatment of the institution|Standard treatment of the institution to treat painful cetuximab-induced rhagades
62169220|NCT00910871|EXPERIMENTAL|TMC207|TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks in addition to Background Regimen (BR) for the treatment of multi-drug resistant tuberculosis (MDR-TB).
62359849|NCT04018157|ACTIVE_COMPARATOR|ketodex|ketamine dexmedetomidine mixture
62359850|NCT04018157|ACTIVE_COMPARATOR|ketofol|ketamine propofol mixture
61980048|NCT03194698|ACTIVE_COMPARATOR|Meibomian Gland Expression (MGX)|Treatment with 4 visits and 4 treatments of MGX only
61980049|NCT05670990|EXPERIMENTAL|Equine assisted therapy|"once a week during 10 weeks the children will come to Humlamaden which is a horse farm with special trained horses and employees with specialist education in psychiatric care. During the time at the farm the child will go through a structured program that starts at the first time with just resting on the horse back under blankets"
61980050|NCT05670990|NO_INTERVENTION|Control|This group will receive treatment as usual and consist of those who is randomized to control group.
61980051|NCT01254526|EXPERIMENTAL|A|
62169221|NCT01523678|EXPERIMENTAL|Filgrastim|
62169222|NCT02775214|NO_INTERVENTION|Conventional Direct Laryngoscopy|Endotracheal intubation will be performed by conventional direct laryngoscopy.
62169223|NCT02775214|ACTIVE_COMPARATOR|Video Laryngoscopy|Endotracheal intubation will be performed by video laryngoscopy with the C-MAC.
62359851|NCT04018157|PLACEBO_COMPARATOR|placebo|normal saline
62359852|NCT02040155|EXPERIMENTAL|Real time dosimetric monitoring of brachytherapy.|
62169224|NCT01554371|EXPERIMENTAL|Phase 1b: 1.1 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)|Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.1 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD
62169225|NCT01554371|EXPERIMENTAL|Phase 1b: 1.4 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)|Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.4 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/ m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD
62567085|NCT01977755|PLACEBO_COMPARATOR|Placebo|bolus injection, followed by infused over 6 hours
61980052|NCT01254526|EXPERIMENTAL|B|
61980053|NCT03263442|EXPERIMENTAL|Intervention|Thiamine 200 mg IV
62359853|NCT04720339|EXPERIMENTAL|Experimental arm|
62567086|NCT02682303|EXPERIMENTAL|elastic bandage|In this study, Idealplast C® (6cm\*2.5m) was used.
62567087|NCT02682303|PLACEBO_COMPARATOR|Non-standardized tape (NST)|In the NST group, Pretape Cramer® (100% cotton, 1.25cm\*10m) was used.
61980054|NCT03263442|PLACEBO_COMPARATOR|Control|Normal saline IV
61980055|NCT02890706|OTHER|Patients|Each patient undergo the same CT protocol. Theobservers will observe the detection of the perfusion defects in two different techniques.
61980056|NCT02775734|ACTIVE_COMPARATOR|N-acetyl-cysteine|N-acetyl-cysteine + Clomiphene citrate + LOD
61980057|NCT02775734|ACTIVE_COMPARATOR|NO N-acetyl-cysteine|Clomiphene citrate + LOD
61980058|NCT00523250|EXPERIMENTAL|AR-102 0.003% Ophthalmic Solution|q.d. ocular
61980059|NCT00523250|EXPERIMENTAL|AR-102 0.005% Ophthalmic Solution|q.d. ocular
61980060|NCT00523250|EXPERIMENTAL|AR-102 0.01% Ophthalmic Solution|q.d. ocular
61980061|NCT00523250|EXPERIMENTAL|AR-102 0.03% Ophthalmic Solution|q.d. ocular
61980062|NCT00523250|EXPERIMENTAL|AR-102 Vehicle Ophthalmic Solution|q.d. ocular
62359854|NCT01227304|EXPERIMENTAL|Test of volume responsiveness using crystalloids|
62359855|NCT03460288|EXPERIMENTAL|Intervention Group|The training-program includes ten pictures related to slot-machine gambling and 10 neutral pictures that need to be either pushed (i.e., avoidance) or pulled (i.e., approach) with the computer mouse or finger (when a tablet is used) according to a non-affective dimension (color of the frame). Pictures are presented in random order.
62359856|NCT03460288|NO_INTERVENTION|Wait-list control group|The participants of the wait-list control condition do not receive the retraining intervention during the intervention period of 8 weeks, but may continue any treatment that has already been started before, including pharmacological treatment. Participants in the wait-list control condition receive full access to the training program after completion of the post-assessment.
62359857|NCT02969967|EXPERIMENTAL|SaeboFlex|Use of the SaeboFlex orthosis for a set protocol of grasp-release activities
62359858|NCT02441192|EXPERIMENTAL|Training resistance|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
62359859|NCT02441192|EXPERIMENTAL|Training aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
62359860|NCT02441192|EXPERIMENTAL|Training resistance+aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
62169226|NCT01554371|EXPERIMENTAL|Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort)|Dose-expansion cohort will enroll patients with advanced breast cancer only after Phase Ib enrollment has been concluded. The MTD of Eribulin mesylate will be administered on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.
62169227|NCT05036499|EXPERIMENTAL|Personalized Feedback Intervention (PFI)|Personalized Feedback Intervention targeting pain-related anxiety for hazardous drinkers with chronic pain
62169228|NCT05036499|NO_INTERVENTION|Assessment Only|Assessment only, no active treatment elements
62169229|NCT01475370|EXPERIMENTAL|OCV-501|
62169230|NCT00346177|ACTIVE_COMPARATOR|1|Stem Cells
62169231|NCT00346177|PLACEBO_COMPARATOR|2|Placebo
62169232|NCT02762500|EXPERIMENTAL|LYC-30937-EC 25 mg PO QD|LYC-30937-EC 25 mg by mouth once daily for 8 weeks
62169233|NCT02762500|PLACEBO_COMPARATOR|Placebo PO QD|Matching placebo by mouth once daily for 8 weeks
62359861|NCT05103475|EXPERIMENTAL|Rage Against the Pain (RAP)|The sets of body positions used in the RAP program will mirror those used in the Hatha Yoga classes, but the RAP program will differ from this traditional yoga practice in a number of ways: (1) the classes will be set to rock/heavy metal music; (2) meditation will not be incorporated; (3) yoga terms will not be used to describe the body positions (rather, positions will be cued in plain descriptive English terms); (4) the culminating activity for the class will be called a 'cool down' (rather than the savasana exercise typically used in yoga practice).
62359862|NCT05103475|ACTIVE_COMPARATOR|Control|The control group will comprise a program akin to Hatha yoga with chair modifications available to all Veterans who choose/need to use them.
62359863|NCT03970018||Autosomal dominant polycystic kidney disease|Autosomal dominant polycystic kidney disease (ADPKD) patients starting peritoneal dialysis for end stage renal failure will be included in this study.
62567088|NCT03538860|OTHER|Method A first then Method B|Conventional in-person interview with a psychiatrist with a live human interpreter with crossover to asynchronous telepsychiatry
62169234|NCT06525753||SickKids|Patients recruited from the Hospital for Sick Children (SickKids), Toronto, Canada
62169235|NCT06525753||Erasmus|Patients recruited from the Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands
62169236|NCT06585683||Confirmed TB|Participants with confirmed TB will start treatment and have a follow-up visit soon after to check their TB symptoms again and collect blood samples. They will also have a second follow-up visit at week 26 to assess their treatment progress and TB status.
62169237|NCT06585683||no TB (control)|Participants without TB will have a single follow-up visit to reassess TB symptoms and collect blood samples.
62169238|NCT03512288|EXPERIMENTAL|Multivalent|Pneumococcal conjugate vaccines
62169239|NCT03512288|ACTIVE_COMPARATOR|Control|13vPnC
62169240|NCT01718613|ACTIVE_COMPARATOR|Norepinephrine|
62169241|NCT01718613|ACTIVE_COMPARATOR|Vasopressin|
62169242|NCT05112172|EXPERIMENTAL|Oxygen Therapy|Oxygen Therapy in patients developing an altitude related adverse health effect (ARAHE) during 30h exposure to 2500m of high altitude
62169243|NCT05006703|EXPERIMENTAL|Intervention group|Access to digital intervention
62169244|NCT05006703|NO_INTERVENTION|Control group|Usual care group
62169245|NCT04026074|EXPERIMENTAL|Fentanyl i.v. (intravenously)|Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
62169246|NCT04026074|EXPERIMENTAL|Remifentanil i.v.|Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
62169247|NCT04026074|EXPERIMENTAL|Clonidine i.v.|Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
62169248|NCT04026074|EXPERIMENTAL|EMLA salve|Patients will be administered the medication (salve) and additionally will be administered i.v. saline as placebo
62169249|NCT04026074|PLACEBO_COMPARATOR|Placebo|Patients will be administered i.v. placebo (0,9% NaCl) and placebo salve (skin protection salve)
62169250|NCT05789199||Cefiderocol Treated|Participants who have been treated with at least 72 hours of cefiderocol through the EAP in Spain.
62169251|NCT05381077|OTHER|Whole body MRI|There is only one cohort where each patient have the standard of care follow up (PET/CT) and Whole body MRI- ZTE sequence for the study
62359864|NCT03471104|EXPERIMENTAL|PAID in clinical diabetes consultations|Participants randomised to the intervention arm. Participants complete the Problem Area in Diabetes scale (PAID) and evaluation PROMs. Participants with specified PAID scores will be offered an empowerment-based follow-up by diabetes specialist nurses.
62359865|NCT03471104|NO_INTERVENTION|Control group|Participants randomised to the control group. Participants complete PROMs but the results/answers will not be available in the electronic patient records until the trial is finished. The participants will receive standard care.
62359866|NCT06140628|ACTIVE_COMPARATOR|Formulation containing MLYAAT-1002® Composition|After the Fotana4D Pro® treatment, daily use of the formulation for 28 days: apply one pump of the formulation to the treated side of the face in the morning and evening, respectively.
62359867|NCT06140628|PLACEBO_COMPARATOR|Blank formulation without MLYAAT-1002® Composition|After the Fotana4D Pro® treatment, daily use of the blank formulation for 28 days: apply one pump of the blank formulation to the control side of the face in the morning and evening, respectively.
62359868|NCT01734278||Asenapine|Patients prescribed asenapine for any indication.
62359869|NCT04451317||Experimental|Patients involved in a Sport-Health initiative Visit once by telephone and then ask to fill in 3 questionnaires on a digital platform within 48 hours after the telephone interview.
62359870|NCT04451317||Control|Healthy sport subjects. Visit once by telephone and then ask to fill in 3 questionnaires on a digital platform within 48 hours after the telephone interview.
62359871|NCT05793957|EXPERIMENTAL|Group 1 (VR)|Patients use VR during chemotherapy infusion on study.
62359872|NCT05793957|ACTIVE_COMPARATOR|Group 2 (Smartphone)|Patients use smartphone during chemotherapy infusion on study.
62359873|NCT04227067|ACTIVE_COMPARATOR|TENS|A TENS device consists of an electric pulse generator and pads that are attached to the skin on around the area of maximal pain. We will use the conventional mode, which provides nerve stimulation with a pulse width of 60 microseconds and a pulse rate of 60 pulses per second. The channel intensity will be gradually increased until the intensity is noticeable but not painful.
62359874|NCT04227067|SHAM_COMPARATOR|SHAM TENS|In the SHAM TENS group the TENS pads will be attached to the pulse generator and the patients skin around the painful area. The investigator will turn the knobs on but the batteries will be removed from the device.
62359875|NCT01576120|EXPERIMENTAL|bowel prep regimen first boost 6 oz. and second boost 3 oz.|4L of PEG split into two doses:1.on the evening before the exam 2.on the morning of exam day.Upon SB Detection 6 oz. SuPrep administered and 3hrs later 3 oz. SuPrep was administered if needed depends on the capsule progress in the GI
62359876|NCT01576120|EXPERIMENTAL|bowel prep regimen first boost 3 oz. and second boost 6 oz.|4L of PEG split into two doses:1.on the evening before the exam 2.on the morning of exam day.Upon SB Detection 3 oz. SuPrep administered and 3hrs later 6 oz. SuPrep was administered if needed depends on the capsule progress in the GI
61980063|NCT05737212|EXPERIMENTAL|Group 1|"Radiation dose: 9 Gy-Eq~* Investigational product, boronophenylalanine, DMX-101 500mg/kg/3hr~* Investigational Device, DM-BTPS, DM-BNCT - neutron irradiation to reach maximum BNCT dose in brain of 9 Gy-Eq"
62359877|NCT06162689||Exposed Group|Women at risk of postpartum psychosis during pregnancy
62359878|NCT06162689||Unexposed Group|Women with no current or past history of psychiatric disorders during pregnancy
62359879|NCT04926844|EXPERIMENTAL|Study group|Children receiving levetiracetam + midazolam
62359880|NCT04926844|PLACEBO_COMPARATOR|Control group|Children receiving placebo + midazolam
62359881|NCT04016103|EXPERIMENTAL|MY01 Device|Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure
62359882|NCT01280019|EXPERIMENTAL|FRC guided|Patients receive an alveolar recruitment manoeuvre if FRC falls below 94% of baseline FRC
62359883|NCT01280019|ACTIVE_COMPARATOR|Saturation guided|Patients receive an alveolar recruitment manoeuvre if peripheral oxygen saturation falls below 90%
62359884|NCT03470311|ACTIVE_COMPARATOR|Benralizumab|Benralizumab 30mg in 1mL subcutaneously
62359885|NCT03470311|PLACEBO_COMPARATOR|Placebo|Matched placebo (1mL) to active Benralizumab subcutaneously
62359886|NCT06054438|OTHER|Group A- having treatment at first stage|"110 long-COVID patients will be divided into 2 groups (55 individuals per group).~⚫ Group A: 55 long-COVID patients (NO. 1- NO.55) Group B: 55 long-COVID patients (NO. 56- NO.110)~Group distribution and treatment in a two-stage waitlist design: ⚫ First-stage clinical trial for 12 weeks:~Group A (patients NO.1-55 will have treatment) Group B (patients NO.56-110 will have no Cs4 treatment on the waiting list)~⚫ Second-stage clinical trial for 12 weeks (After finishing the first-stage study): Group A (patients NO.1-55 will have no Cs4 treatment) Group B (patients NO.56-110 will have Cs4 treatment)"
62359887|NCT06054438|OTHER|Group B- having treatment at secondstage|"110 long-COVID patients will be divided into 2 groups (55 individuals per group).~⚫ Group A: 55 long-COVID patients (NO. 1- NO.55) Group B: 55 long-COVID patients (NO. 56- NO.110)~Group distribution and treatment in a two-stage waitlist design: ⚫ First-stage clinical trial for 12 weeks:~Group A (patients NO.1-55 will have treatment) Group B (patients NO.56-110 will have no Cs4 treatment on the waiting list)~⚫ Second-stage clinical trial for 12 weeks (After finishing the first-stage study): Group A (patients NO.1-55 will have no Cs4 treatment) Group B (patients NO.56-110 will have Cs4 treatment)"
62359888|NCT03067844|EXPERIMENTAL|Alirocumab|Alirocumab 150 mg/mL, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.
62359889|NCT03067844|PLACEBO_COMPARATOR|Placebo|Placebo, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.
62359890|NCT03271060|ACTIVE_COMPARATOR|Lumbar spondylolisthesis1|
62359891|NCT03271060|ACTIVE_COMPARATOR|Lumbar spondylolisthesis 2|
61980064|NCT05737212|EXPERIMENTAL|Group 2|"Radiation dose: 11 Gy-Eq~* Investigational product, boronophenylalanine, DMX-101 500mg/kg/3hr~* Investigational Device, DM-BTPS, DM-BNCT - neutron irradiation to reach maximum BNCT dose in brain of 11 Gy-Eq"
62359892|NCT01089569|ACTIVE_COMPARATOR|Exenatide|5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
62359893|NCT01089569|ACTIVE_COMPARATOR|Insulin Glargine|.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
62567089|NCT03538860|OTHER|Method B first then Method A|Asynchronous telepsychiatry - that is, video-recorded interviews that are subsequently processed with automated speech recognition and machine translation technologies, with crossover to conventional in-person interview with a psychiatrist with a live human interpreter
62567090|NCT05541081|OTHER|Point-of-care STI testing|Provision of point-of-care testing for chlamydia, gonorrhoea, trichomoniasis, syphilis, HIV, and hepatitis B, with comprehensive case management including partner notification
61980065|NCT05737212|EXPERIMENTAL|Group 3|"Radiation dose: 13 Gy-Eq~* Investigational product, boronophenylalanine, DMX-101 500mg/kg/3hr~* Investigational Device, DM-BTPS, DM-BNCT - neutron irradiation to reach maximum BNCT dose in brain of 13Gy-Eq"
61980066|NCT04082325|EXPERIMENTAL|Part A Lu AF88434 or Placebo|6 cohorts (cohort A1 to A6) with 9 subjects in each cohort. In each cohort 6 subjects will receive single doses of Lu AF88434 and 3 subjects will receive placebo
61980067|NCT04082325|EXPERIMENTAL|Part B1 Lu AF88434 Fed-Fasting-Fasting|4 subjects will receive an identical oral dose of Lu AF88434 in Group B1. The treatment sequence for Group B1 is: Fed-Fasting-Fasting. 14C-spiked dose (Lu AF99723) will be given in the last treatment sequence.
61980068|NCT04082325|EXPERIMENTAL|Part B2 Lu AF88434 Fasting-Fed-Fasting|4 subjects will receive an identical oral dose of Lu AF88434 in Group B2. The treatment sequence for Group B2 is: Fasting-Fed-Fasting. 14C-spiked dose (Lu AF99722) will be given in the last treatment sequence.
61980069|NCT04082325|EXPERIMENTAL|Part B3 Lu AF88434 Fasting-Fasting-Fed|4 subjects will receive an identical oral dose of Lu AF88434 in Group B3. The treatment sequence for Group B3 is: Fasting-Fasting-Fed.
61980070|NCT03109587|ACTIVE_COMPARATOR|Vivomixx (Visbiome)|2 packets of probiotics by mouth/day for 12 weeks
61980071|NCT03109587|PLACEBO_COMPARATOR|Placebo|identical in appearance, but without probiotics.
61980072|NCT05874661|ACTIVE_COMPARATOR|Internal Focus of Attention Group|"Participants will be given instructions that make them think about their body's movements.~Participants assigned to this condition first will complete the external focus condition second in the cross over."
62359894|NCT01089569|ACTIVE_COMPARATOR|Exenatide + Insulin Glargine|"Exenatide: 5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study~+ Insulin Glargine: 0.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results"
62359895|NCT04274634||Conditions with predisposition to lens oscillations|Marfan Syndrome and Pseudoexfoliation
62359896|NCT04274634||Age-matched with normal axial lengths|
62359897|NCT04274634||Age-matched with extreme axial lengths|
62359898|NCT04274634||Intraocular lens|
62359899|NCT04274634||Pre- and post- cataract surgery|
62359900|NCT04274634||Normals|
62359901|NCT04655924|EXPERIMENTAL|Active Intervention|Intervention delivered to patients by digital health platform.
62359902|NCT04655924|ACTIVE_COMPARATOR|Active Control|Intervention delivered to patients by digital health platform.
62359903|NCT05168852|EXPERIMENTAL|Permanent Resin 1 week|1st week control
62359904|NCT05168852|EXPERIMENTAL|Permanent Resin 6 mouth|6th month control
62359905|NCT01945268|EXPERIMENTAL|influenza vaccine|Participants at high risk for adverse vascular events will be immunized with 0.5 ml dose of inactivated trivalent influenza vaccine
62359906|NCT01945268|PLACEBO_COMPARATOR|placebo vaccination|Participants at high risk for adverse vascular events will be immunized with a 0.5 ml dose of sterile saline inactivated during the influenza season.
62359907|NCT03148964||Follow-up Arm|Blood sampling only
61980073|NCT05874661|EXPERIMENTAL|Extneral Focus of Attention Group|"Participants will be given instructions that make them think about an outside target or outcome.~Participants assigned to this condition first will complete the internal focus condition second in the cross over."
62359908|NCT00500812|EXPERIMENTAL|0.3 mg|Subjects Receiving 0.3 mg Cethrin
61980074|NCT06130644||Patients with lymph node metastasis|T1/2N+ patients
61980075|NCT06130644||Patients without lymph node metastasis|T1/2N- patients
61980076|NCT04679792||operated|Patients Under 18 years of age who are operated for Chiari Malformation on the basis of routine neurosurgical assessment.
61980077|NCT04679792||non operated|Patients Under 18 years of age who are not operated for Chiari Malformation on the basis of routine neurosurgical assessment.
61980078|NCT06263751|NO_INTERVENTION|Usual Care (Control)|Patient is screened for food or financial insecurity, if positive, social worker will refer him/her to community service programs.
61980079|NCT06263751|EXPERIMENTAL|NutriConnect Credit|Patient is given $20 credit to their Schnucks (grocery) Reward account every other week for F\&V shopping.
61980080|NCT06263751|EXPERIMENTAL|NutriConnect Delivery|Patient receives produce (F\&V) box (with equivalent $20 value) delivered to home every other week.
61980081|NCT01441310|EXPERIMENTAL|Laparoscopic sentinel node navigation surgery|Laparoscopic sentinel node navigation surgery
62359909|NCT00500812|EXPERIMENTAL|1 mg|Subjects receiving 1 mg Cethrin
62359910|NCT00500812|EXPERIMENTAL|3 mg|Subjects receiving 3 mg Cethrin
62359911|NCT00500812|EXPERIMENTAL|6 mg|Subjects receiving 6 mg Cethrin
62359912|NCT00500812|EXPERIMENTAL|9 mg|Subjects receiving 9 mg Cethrin
62359913|NCT03672357|EXPERIMENTAL|Laparoscopic liver resection|Laparoscopic hepatectomy
62359914|NCT03672357|OTHER|Open liver resection|Open hepatectomy
62359915|NCT05071443|EXPERIMENTAL|Negative pressure wound therapy (NPWT)|Negative pressure wound therapy (NPWT): an NPWT device will be applied hermetically from randomization to skin grafting.
62359916|NCT05071443|ACTIVE_COMPARATOR|Conventional dressing|Conventional dressing will be performed from randomization to skin grafting. The dressings will be performed following usual procedures of investigating centers
62359917|NCT05621590|EXPERIMENTAL|mlc-901 group|
62359918|NCT05621590|PLACEBO_COMPARATOR|placebo group|
62359919|NCT03056729|EXPERIMENTAL|Cohort HV1|
62359920|NCT03056729|EXPERIMENTAL|Cohort HV2|
62359921|NCT03056729|EXPERIMENTAL|Cohort HV3|
62359922|NCT03056729|EXPERIMENTAL|Cohort HV4|
62359923|NCT03056729|EXPERIMENTAL|Cohort HV5|
62359924|NCT03056729|EXPERIMENTAL|Cohort AD1|
62359925|NCT01153308||Bariatric Surgery Patients|Bariatric Surgery patients at UMass Memorial Medical Center
62359926|NCT02186561|EXPERIMENTAL|Pipeline™ Embolization Device|treatment with Pipeline™ Embolization Device
62359927|NCT03584438|EXPERIMENTAL|Hanlon Real iTBS Protocol 1|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. 600 pulses of iTBS over the motor cortex (C3), 3600 pulses are delivered over 19 minutes.
62359928|NCT03584438|EXPERIMENTAL|Hanlon Real iTBS Protocol 2|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. 600 pulses of iTBS over the motor cortex (C3), 1800 pulses are delivered over 9 minutes and 30 seconds.
62359929|NCT03584438|EXPERIMENTAL|Huang Real iTBS Protocol|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. (2 sec trains of tbs every 10 sec) was applied over the left motor cortex (C3) for 190 seconds (a total of 600 TMS pulses).
61980082|NCT04855825|EXPERIMENTAL|Robotic Exoskeleton Therapy|Gait rehabilitation provided using a wearable robotic exoskeleton
61980083|NCT04855825|ACTIVE_COMPARATOR|Conventional Gait Therapy|Gait rehabilitation provided using traditional gait therapy under the supervision of a licensed PT
61980084|NCT05685082|EXPERIMENTAL|Standardized patient group|The standardized patient simulation participants will receive a simulation with standardized patients on how to identify social determinants of health in an individual
61980085|NCT05685082|EXPERIMENTAL|Manikin-based group|The manikin-based simulation participants will receive a simulation with manikins on how to identify social determinants of health in an individual
61980086|NCT03675802|ACTIVE_COMPARATOR|Arm number one ,misoprostol|
61980087|NCT03675802|ACTIVE_COMPARATOR|Arm number 2 dinoprostone|
61980088|NCT01095016|EXPERIMENTAL|Meptin swinghaler|
61980089|NCT01095016|ACTIVE_COMPARATOR|Berotec|
61980090|NCT01909154|EXPERIMENTAL|Mesenchymal stromal cell therapy|Autologous bone marrow adult mesenchymal stem cells expanded in vitro. Administered by Intrathecal injection (subarachnoid and intramedullary). Depending on centromedullary post-traumatic injury: bone marrow stromal stem cells administration (MSCs) at the minimum dose of 100x106 followed by subarachnoid administration of 30x106 MSCs,3 months later
61980091|NCT03527966|ACTIVE_COMPARATOR|Intervention group - 5cc Vivigen and local autograft|
61980092|NCT03527966|ACTIVE_COMPARATOR|Control group - small kit rhBMP-2 with local autograft|
62359930|NCT03584438|EXPERIMENTAL|Gamboa Real iTBS Protocol|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. (2 sec trains of tbs every 10 sec) was applied over the left motor cortex (C3) for 380 seconds (a total of 1200 TMS pulses).
62359931|NCT03584438|SHAM_COMPARATOR|Sham iTBS protocol|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin over the left motor cortex (C3) and beneath the coil.
62359932|NCT02641639|ACTIVE_COMPARATOR|Fosbretabulin tromethamine|Physician's choice chemotherapy (weekly Paclitaxel or Pegylated Liposomal Doxorubicin \[PLD\]) plus bevacizumab and CA4P
62359933|NCT02641639|PLACEBO_COMPARATOR|Placebo|Physician's choice chemotherapy (weekly Paclitaxel or Pegylated Liposomal Doxorubicin \[PLD\]) plus bevacizumab and placebo
61980093|NCT03746769|EXPERIMENTAL|Single Arm Study|
61980094|NCT00411645|EXPERIMENTAL|A|
61980095|NCT00411645|PLACEBO_COMPARATOR|B|
61980096|NCT03201289||Cardiac surgery|
61980097|NCT01477840|EXPERIMENTAL|Misoprostol|
61980098|NCT05306054||Intra-Articular Knee Injury|Forty men and women aged 18-45 years old who are 1-7 years following an intra-articular knee injury.
61980099|NCT05306054||Controls|Forty men and women aged 18-45 years old who are matched to the injured group by age, sex and body mass index.
61980100|NCT03182829||Factor Xa inhibitor|"Patients on treatment with Apixaban, Edoxaban or Rivaroxaban are included into the evaluation study at the outpatient care unit. Patients receive treatment for a specific clinical indication such as non-valvular atrial fibrillation or venous thromboembolism since one week or longer. During the study visit DOAC Dipstick test and liquid-chromatography mass-specrotmery are performed to identify absence or presence of Factor Xa inhibitor in urine.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. \[Epub ahead of print\]"
61980101|NCT03182829||Thrombin inhibitor|"Patients on treatment with Dabigatran are included included into the evaluation study at the outpatient care unit. Patients receive treatment for a specific clinical indication such as non-valvular atrial fibrillation or venous thromboembolism since one week or longer. During the study visit DOAC Dipstick test and liquid-chromatography mass-specrotmery are performed to identify absence or presence of Thrombin inhibitor in urine.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. \[Epub ahead of print\]"
61980102|NCT01132404|EXPERIMENTAL|TAK-448 Dose 1|
61980103|NCT01132404|EXPERIMENTAL|TAK-448 Dose 2|
61980104|NCT01132404|ACTIVE_COMPARATOR|Leuprorelin|
61980105|NCT03564847|EXPERIMENTAL|LTP Plus|LTP Plus Participants will receive the intervention over 4 months Weekly sessions for 2 months and fortnightly for next two months by trained non-specialists/community health workers.
62359934|NCT00753961|ACTIVE_COMPARATOR|1|fermented dairy product
62359935|NCT00753961|PLACEBO_COMPARATOR|2|non fermented acidified dairy product.
61980106|NCT03564847|NO_INTERVENTION|Treatment As Usual (TAU)|Treatment as Usual (TAU) group will receive routine care and their follow up will be done at 4th and 6th month post randomization.
61980107|NCT01607086|EXPERIMENTAL|Group 1|To receive the sequence of investigational products in the order of AB where A is cherry lamotrigine ODT and B is cherry placebo.
61980108|NCT01607086|EXPERIMENTAL|Group 2|To receive the sequence of investigational products in the order of BA where A is cherry lamotrigine ODT and B is cherry placebo.
61980109|NCT05919381|EXPERIMENTAL|Gentuximab Injection|Gentuximab Injection 8 mg/kg, D1, 15 intravenous drip, combined with Paclitaxel Injection 80 mg/m2/time, D1, 8, 15 intravenous drip, a cycle every 28 days.
61980110|NCT05919381|PLACEBO_COMPARATOR|Gentuximab Injection Placebo|Gentuximab Injection Placebo 8 mg/kg, D1, 15 intravenous drip, combined with Paclitaxel Injection 80 mg/m2/time, D1, 8, 15 intravenous drip, a cycle every 28 days.
61980111|NCT05212012|EXPERIMENTAL|D,L-methadonehydrochloride + mFOLFOX6|"Dose Level D,L-methadone hydrochloride (Methasan® 10 mg/ml) In dose level I a maximum of 30 mg/day (15 mg (1,5 ml) 1-0-1) In dose level II a maximum of 35 mg/ day (17.5 mg (1,75 ml) 1-0-1) In dose level III a maximum of 40 mg/day (20 mg (2,0 ml) 1-0-1)~Treatment with mFOLFOX6 every two weeks; will be administered:~Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1) LV at a dose of 400 mg/m² iv over two hours (day 1) 5-FU at a dose of 2400 mg/m² iv over 46 hours (day 1-3)"
61980112|NCT01973907|NO_INTERVENTION|Usual Care Resuscitation Strategy|Decisions regarding the IV/IO administration of isotonic fluid boluses and/or the initiation and escalation of vasoactive medication infusions are left to the discretion of the treating physician and medical team. We ask that vasoactive medications not be initiated until at least 60 mL/kg (3 litres for children ≥ 50 kg) of isotonic fluid bolus therapy has been administered. The treating physician and medical team are advised to follow ACCM guidelines for the resuscitation of neonatal and pediatric septic shock and to target ACCM recommended therapeutic endpoints.
61980113|NCT01973907|EXPERIMENTAL|Fluid Sparing Resuscitation Strategy|The treating physician and medical team are advised to follow the assigned Fluid Sparing Resuscitation Strategy to guide decisions regarding the IV/IO administration of further isotonic fluid boluses, and the timing of initiation and escalation of vasoactive medication infusions to target the therapeutic endpoints recommended in the ACCM guidelines for the resuscitation of neonatal and pediatric septic shock.
61980114|NCT01076881|EXPERIMENTAL|combined aerobic and resistance training|
62359936|NCT03432767||Women having a vaginal delivery|A non-invasive hemoglobin monitor will be attached to the patient's finger and kept on for 2 hours after she delivers. Heart rate and blood pressure will be measured every 10 minutes.
62359937|NCT01570309|ACTIVE_COMPARATOR|Ergocalciferol|50,000 units of ergocalciferol once a week for 12 weeks
62359938|NCT01570309|PLACEBO_COMPARATOR|Sugar pill|
62359939|NCT01476761|ACTIVE_COMPARATOR|MicroCutter Stapling Device|Patients undergoing surgical treatment with the MicroCutter Stapling Device
62359940|NCT06145659|EXPERIMENTAL|Linkage Model|Preschool and Me intervention
62359941|NCT06145659|NO_INTERVENTION|Treatment as Usual|Preschool and Me intervention is not used
61980115|NCT01076881|ACTIVE_COMPARATOR|resistance training alone|
61980116|NCT03348020|EXPERIMENTAL|Baseline Clinical Trial|Before blood donation, subjects will participate in a baseline clinical trial where the research team will perform a series of metabolic tests as described in the detailed study description.
61980117|NCT03348020|EXPERIMENTAL|Post-Blood Donation Clinical Trial|1 month after blood donation, subjects will participate in post-blood donation clinical trial where the research team will perform a series of metabolic tests as described in the detailed study description.
62359942|NCT03908580|EXPERIMENTAL|Meditoxin®|Botulinum toxin type A was intramuscularly injected up to 360U and up to 4 sites, depending on the muscle size.
61980118|NCT03437525|EXPERIMENTAL|Peer Support Intervention|The experimental group will receive the peer support intervention for 12 months.
61980119|NCT03437525|NO_INTERVENTION|Control|Usual care
62359943|NCT01433692|EXPERIMENTAL|intervention group|
62359944|NCT01433692|OTHER|control group|
62359945|NCT03127553|NO_INTERVENTION|A - control|Free diet with standard bread
62359946|NCT03127553|ACTIVE_COMPARATOR|B - low-salt diet with normal bread|Low-sodium diet with standard bread
62359947|NCT03127553|EXPERIMENTAL|C - low-salt diet with low-salt bread|Low-sodium diet with low-sodium bread
62359948|NCT01603212|EXPERIMENTAL|Vemurafenib + IL-2 + Interferon Alfa-2b|Starting dose of Vemurafenib 720 mg by mouth twice daily. Three dose levels of Vemurafenib evaluated in combination with interferon and IL-2. These doses are 480 mg, 720 mg and 960 mg. IL-2 given by continuous venous infusion at starting IL-2 dose of 7 million IU/m2 daily for 4 days (total of 96 hours, days 2-5) starting day 2. IL-2 dose levels are 5MU/m2/day, 7MU/m2/day and 9MU/m2 day. Doses of interferon remain constant at 5 MU/m2 subcutaneously daily for 5 days starting Day 1.
62359949|NCT01915017|EXPERIMENTAL|Cognitive Behavior Therapy for Psychosis|Cognitive behavior therapy for psychosis is a manual-driven collaborative talk-therapy designed to help the individual identify appraisal biases and cognitive distortion, identify alternative explanations for events, and find ways to cope with the distress caused by persistent psychotic symptoms.
62359950|NCT01915017|EXPERIMENTAL|Cognitive Adaptation Training|CAT is a manual driven treatment using environmental supports such as signs, alarms, checklists, electronic devices, and the organization of belongings to bypass cognitive and motivational impairments and to cue and sequence adaptive behavior.
62359951|NCT01915017|EXPERIMENTAL|Multi-modal Cognitive Therapy|Combines Cognitive Behavior Therapy for Psychosis and Cognitive Adaptation Training into one home-delivered intervention
62359952|NCT01915017|ACTIVE_COMPARATOR|Treatment as Usual|Medication follow up and limited case management provided by the local community mental health center
62359953|NCT01670812|EXPERIMENTAL|FFP+HDMP+Rituximab|Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5.
62359954|NCT02577367|EXPERIMENTAL|Levothyroxine on empty stomach|Levothyroxine will be given on empty stomach, by holding enteral feeding for 2 hours before and 2 hours after Levothyroxine administration
62359955|NCT02577367|ACTIVE_COMPARATOR|Levothyroxine during feeding|Levothyroxine will be given while the enteral feeding is running
61980120|NCT03359447|EXPERIMENTAL|Weekly Iron|Weekly ferrous sulfate: one dose (4mg/kg/week).
61980121|NCT03359447|ACTIVE_COMPARATOR|Daily Iron|Daily ferrous sulfate: one dose (1 mg/kg/day). Maximum daily dose: 40 mg
61980122|NCT02760667|EXPERIMENTAL|Induction Therapy with 3 cycles|Cisplatin 75mg/m2 IV and Taxotere 75mg/m2 every 3 weeks for 3 cycles (Induction Chemotherapy) followed by surgical treatment
61980123|NCT06430203|EXPERIMENTAL|Peer-mentoring|Peer-mentoring which will include land based activities, nutrition and physical activity teaching.
61980124|NCT03509025|EXPERIMENTAL|Long Term Follow-up after Jointstem Transplantation|
61980125|NCT00338689|EXPERIMENTAL|Lower protein formula|"Intervention: Infant formula with relatively low protein content (1.25 g/ 100 ml) during the first year of life; described as Lower protein formula"
61980126|NCT00338689|PLACEBO_COMPARATOR|Higher protein formula|"Intervention: Infant formula with a relatively high protein content (2.05 g/ 100 ml) during the first year of life; described as Higher protein formula"
61980127|NCT00338689|NO_INTERVENTION|Breastfed reference group|Non-randomized breastfed group of infants at least 3 months exclusively breastfed
62359956|NCT06418568|EXPERIMENTAL|Patients with chloasma|The intervention involves treating melasma using tranexamic acid (aminomethylbenzoic acid) delivered through ultra-pulsed shockwave therapy on one side of the face, while the other side receives topical application of tranexamic acid at the same concentration.
62359957|NCT00696397||A|adult men and women between 18 and 50 years of age with atopic dermatitis
62359958|NCT02524067|EXPERIMENTAL|Intervention|Intervention: Circadian lighting, systematic information, music, foreclosure of the individual patient
62391371|NCT02062385|PLACEBO_COMPARATOR|Placebo with concomitant EPI|Placebo administered as a 2 mL oral solution at age \~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age \~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age \~3, 4, and 5 months
62391372|NCT05863065|EXPERIMENTAL|Personalized Virtual Reality exposure|Participants are exposed to a personalized, relaxing VR scenario administered by the Oculus Quest 2 tool.
62359959|NCT04322955|EXPERIMENTAL|Treatment with cabozantinib and nivolumab with nephrectomy|"All study participants will receive the same study medications, cabozantinib and nivolumab. The study drug, nivolumab, will be administered through an IV infusion every 4 weeks and cabozantinib will be administered orally daily. Initially participants will receive study treatment for 12 weeks. The cabozantinib will then be stopped prior to the nephrectomy. Initially patients enrolled on the study will be assigned to cohort 1.~Patients who are assigned to cohort 1 will be treated with cabozantinib until 21 days prior to surgery. A patient in cohort 1 will be evaluable for assessment of the cabozantinib washout interval (evaluable patients) if they~1. complete at least 10 of the 14 scheduled cabozantinib doses in the two week period prior to stopping cabozantinib AND~2. have surgical resection of the primary tumor.~In cohort 2, subjects will receive cabozantinib until 14 days prior to nephrectomy."
62359960|NCT04399980|ACTIVE_COMPARATOR|Intervention|Treatment infusion
61980128|NCT03324854|EXPERIMENTAL|mosquito net mesh|The open ventral hernia repair were carried out with rives technique, followed by the placement of the mosquito net mesh, and left active-close drainage, 30 minutes before the incisión, prophylactic antibiotic 1gm of cefalotin was administered.
61980129|NCT03324854|ACTIVE_COMPARATOR|prolene mesh|The open ventral hernia repair were carried out with rives technique, followed by the placement of the prolene mesh, and left active-close drainage, 30 minutes before the incisión, prophylactic antibiotic 1gm of cefalotin was administered.
62359961|NCT04399980|PLACEBO_COMPARATOR|Control|Placebo infusion
62359962|NCT03934203|EXPERIMENTAL|H/L/P/P/M treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
61980130|NCT06346990|EXPERIMENTAL|The intervention group/ Holy Quran Recital|For the intervention group, after patients were (1) extubated, (2) hemodynamically stable, and (3) negatively rated on primary CAM-ICU, they received holy Quran recital for four days. Typically, the second, third, fourth- and fifth-days following CABG. The daily sessions were done at 2 PM and 8 PM for 20 minutes each. We choose these times based on the nurses' recommendations about the minimal interruptions from physician rounds and family visits. The selection of Surah Al-Rahman was based on the widespread belief that it is among the most melodic and calming passages in the Quran, especially when recited by the well-known reciter Qari AbdulBasit. 1,5,40 The listening was done using one-use headphones on an iPad. The intervention was discontinued if the participant developed delirium.
61980131|NCT06346990|NO_INTERVENTION|The control group|For the control group, routine post-operative care was done
62359963|NCT03934203|EXPERIMENTAL|H/M/P/P/L treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
62391373|NCT00310440|EXPERIMENTAL|Bone graft substitute|Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with P-15 synthetic osteoconductive bone substitute (investigational device).
61980132|NCT05113615|ACTIVE_COMPARATOR|tiotropium bromide|tiotropium bromide inhaler (Spiriva Respimat) will be used once daily (2 puffs) for a total of 8 days
61980133|NCT05113615|PLACEBO_COMPARATOR|Matching placebo|matching placebo inhaler will be used once daily (2 puffs) for a total of 8 days
61980134|NCT00955942|EXPERIMENTAL|Arm I|Patients consume flaxseed muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.
61980135|NCT00955942|PLACEBO_COMPARATOR|Arm II|Patients consume placebo muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.
61980136|NCT05821868|ACTIVE_COMPARATOR|Aerochamber Plus® Flow-Vu®|1. Inhaled space chamber commonly use in our lung function lab for Bronchodilator Testing
61980137|NCT05821868|EXPERIMENTAL|Dosivent|2. Newer and different inhaled space chamber for Bronchodilator Testing
61980138|NCT04181502|EXPERIMENTAL|Inflation of a pneumatic tourniquet|
61980139|NCT04181502|SHAM_COMPARATOR|No inflation|No inflation of the pneumatic tourniquet placed on the lower limb
61980140|NCT00810407||rifabutin|Patients administered Rifabutin.
61980141|NCT02566083|ACTIVE_COMPARATOR|non-toric intraocular lens|non-toric approved intraocular lens
61980142|NCT02566083|ACTIVE_COMPARATOR|toric intraocular lens|approved toric intraocular lens
61980143|NCT01637467|EXPERIMENTAL|EMS intervention|The experimental group will received EMS at a therapeutic level.
61980144|NCT01637467|SHAM_COMPARATOR|Sham|The sham group will receive EMS at a sub-therapeutic level.
62359964|NCT03934203|EXPERIMENTAL|H/P/P/M/L treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
62359965|NCT03934203|EXPERIMENTAL|L/M/H/P/P treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
62359966|NCT03934203|EXPERIMENTAL|L/P/H/M/P treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
62359967|NCT03934203|EXPERIMENTAL|L/P/M/H/P treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
61980145|NCT06276439||Positive lymph node detection with bioinspired sensor|"We will assess the effectiveness of our bioinspired sensor in identifying affected lymph nodes in ex vivo samples. This innovative sensor integrates spectral filters and vertically aligned photodiodes, mirroring the visual capabilities of the mantis shrimp, to simultaneously capture intrinsic UV fluorescence and externally introduced NIR fluorescence from ICG.~To minimize the potential harm from UV radiation, we employ a phased imaging approach. Initially, ICG is injected near the tumor area in the patient, utilizing its NIR fluorescence to accurately locate the lymph node and facilitate the removal of nearby fatty tissue as necessary. Following this, UV light is momentarily used to detect autofluorescence from amino acids frequently found in tumors, providing insights into the lymph node's condition. All resected samples will be analyzed by pathologist and provide ground truth."
61980146|NCT06276439||Positive lymph node detection with highly sensitive imaging sensor|"We will evaluate the performance of our sensor, characterized by low noise and high quantum efficiency, in detecting compromised lymph nodes in ex vivo samples. This advanced sensor combine spectral filters and low noise photodiodes, enabling the simultaneous detection of natural UV fluorescence and induced NIR fluorescence from ICG.~To minimize the potential harm from UV radiation, we employ a phased imaging approach. Initially, ICG is injected near the tumor area in the patient, utilizing its NIR fluorescence to accurately locate the lymph node and facilitate the removal of nearby fatty tissue as necessary. Following this, UV light is momentarily used to detect autofluorescence from amino acids frequently found in tumors, providing insights into the lymph node's condition. All resected samples will be analyzed by pathologist and provide ground truth."
61980147|NCT03663725|EXPERIMENTAL|Intensified protocol|Early Temozolomide (TMZ) Concomitant TMZ Adjuvant TMZ Prolonged TMZ
61980148|NCT03663725|ACTIVE_COMPARATOR|Stupp protocol|Concomitant Temozolomide (TMZ) Adjuvant TMZ
62391374|NCT00310440|ACTIVE_COMPARATOR|Autologous Bone|Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with local autologous bone.
61980149|NCT02172742|EXPERIMENTAL|BIA 2-093|"BIA 2-093 1200 mg (2 tablets 600 mg) ESL, Eslicarbazepine acetate~Concomitantly with a dose of digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day)."
61980150|NCT02172742|PLACEBO_COMPARATOR|Placebo|"Placebo (2 tablets matching BIA 2-093 600 mg tablets) PLC, Placebo~Concomitantly with a dose of digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day)."
61980151|NCT02810392|ACTIVE_COMPARATOR|Intranasal Insulin|Intranasal Insulin (20 IU BID): Humulin insulin packaged is in single-dose ampules and inserted into the VianaseTM chamber. Ampoules are dispensed in 3 week supplies per study visit. Patients/caregivers, investigators, and outcome assessors are masked to group assignment. Subjects will receive their first dose in clinic, and wait 2 hrs to determine any adverse effects of inhaled dose. Glucose levels will be measured to monitor for hypoglycemia and documented. All subjects will check peak dose blood sugar levels with glucometer, 3 times per week during insulin treatment.
61980152|NCT02810392|PLACEBO_COMPARATOR|Intranasal Saline|Intranasal saline: Saline is packaged in single-dose ampules and inserted into the VianaseTM chamber. Ampoules are dispensed in 3 week supplies per study visit. Patients/caregivers, investigators, and outcome assessors are masked to group assignment. Subjects will receive their first dose in clinic, and wait 2 hrs to determine any adverse effects of inhaled dose. Glucose levels will be measured to monitor for hypoglycemia and documented. All subjects will check peak dose blood sugar levels with glucometer, 3 times per week during insulin treatment.
62359968|NCT03934203|EXPERIMENTAL|M/H/P/L/P treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
62359969|NCT03934203|EXPERIMENTAL|M/L/P/H/P treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
62391375|NCT06435052|EXPERIMENTAL|Eye Movement Desensitization & Reprocessing Therapy|Eye Movement Desensitization and Reprocessing (EMDR) therapy will be administered face-to-face by a psychotherapist in a total of 12 sessions, with one session per week. The efficacy of EMDR therapy will be compared with Cognitive Behavioral Therapy (CBT) in the treatment of Post-Traumatic Stress Disorder (PTSD) in Pakistan.
62567091|NCT06035523|OTHER|Subjects with a Wagner Grade 1 or 2 diabetic foot ulcer|Arm receives application of Endoform™ Antibacterial, Endoform™ Natural and Symphony™ and appropriate Off - loading
61980153|NCT05922787|EXPERIMENTAL|Experimental|Personal Information Form, Female Sexual Distress Scale-Revised (FSD-R),Arizona Sexual Experiences Scale (ASEX),Sexual Self-Confidences Scale (SSS) were utilized for the collection of research data. First of all, FSD-R was applied to the women, and the women who obtained a score above11.5 points or more from the FSD-R were invited to the study.Then, the Personal Information Form, ASEX, and SSS were first applied to the women invited to the study. Women in the experimental group received Reiki once a week for four weeks. No initiative was applied to the pregnant women in the control group. The FSD-R, ASEX and SSS were applied to all participant women after four weeks following the first application. The application of the measurement tools took 10-15 minutes.
61980154|NCT05922787|NO_INTERVENTION|Control|The researchers applied no initiative to the control group, and the women in the control group solely had the routine checks. The women in the control group filled out all pretest forms(Personal Information Form, FSD-R, ASEX, SSS. The post-test forms (FSD-R, ASEX, SSS) were re-administered 4 weeks later to women who did not receive any intervention.
61980155|NCT04097093||Study 62005-STBSG patients treated with imatinib > 10 years|
61980156|NCT03838822|EXPERIMENTAL|Intervention|Oral administration of cofactors, 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
61980157|NCT03978585|EXPERIMENTAL|HTEMS Arm|High tone therapy (home based) daily for 30 minutes on at least 5 of 7 days per week
61980158|NCT03978585|ACTIVE_COMPARATOR|TENS Arm|TENS therapy (home based) daily for 30 minutes on at least 5 of 7 days per week
61980159|NCT04345263|ACTIVE_COMPARATOR|MTA pulpotomy|Tooth will receive MTA \& resin composite restoration
61980160|NCT04345263|ACTIVE_COMPARATOR|Biodentine pulpotomy|Tooth will receive Biodentine \& resin composite restoration
61980161|NCT04345263|ACTIVE_COMPARATOR|Bioceramic pulpotomy|Tooth will receive Bioceramic \& resin composite restoration
61980162|NCT00453544|EXPERIMENTAL|Enhanced consent - A|The intervention was an enhanced consent process, including a multimedia aid for a moderate risk hypothetical protocol
61980163|NCT00453544|EXPERIMENTAL|Enhanced consent - B|The intervention was an enhanced consent process, including multimedia aide for a higher risk hypothetical protocol
61980164|NCT00453544|ACTIVE_COMPARATOR|Routine consent - A|This was a comparison condition - a routine consent process, including a printed consent document, for a moderate risk hypothetical protocol
61980165|NCT00453544|ACTIVE_COMPARATOR|Routine consent - B|This was a comparison condition - a routine consent process, including a printed consent document, for a higher risk hypothetical protocol
61980166|NCT00670865|EXPERIMENTAL|eDischarge|The eDischarge arm will consist of two teams on the General Internal Medicine ward at St. Michael's Hospital who have been randomly assigned to use the electronic discharge summary program.
61980167|NCT00670865|NO_INTERVENTION|Traditional|"The traditional arm will consist of two teams on the General Internal Medicine ward at St. Michael's Hospital who have been randomly assigned to use traditional, dictated discharge summaries."
61980168|NCT05955950|EXPERIMENTAL|Gratitude List|Participants must to write 3-5 words a day for 14 days about aspects of their daily experience that they are grateful for.
61980169|NCT05955950|ACTIVE_COMPARATOR|List of any event|Participants must to write 3-5 words a day for 14 days about events of your own choosing that impressed the participant during the day, whether positive or negative.
61980170|NCT03472027|EXPERIMENTAL|BCD-145 Monotherapy Dose Level 1|
61980171|NCT03472027|EXPERIMENTAL|BCD-145 Monotherapy Dose Level 2|
61980172|NCT03472027|EXPERIMENTAL|BCD-145 Monotherapy Dose Level 3|
61980173|NCT03472027|EXPERIMENTAL|BCD-145 Monotherapy Dose Level 4|
61980174|NCT03472027|EXPERIMENTAL|BCD-145 Monotherapy Dose Level 5|
61980175|NCT05321732|EXPERIMENTAL|Intervention: DWP16001 A mg|
61980176|NCT05321732|EXPERIMENTAL|Intervention: DWC202010 B mg|
61980177|NCT05321732|EXPERIMENTAL|Intervention: DWP16001 A mg + DWC202010 B mg|
61980178|NCT02843932|EXPERIMENTAL|Psychogenic disorders|Psychogenic movement disorders and seizures
61980179|NCT02051829||All patients|Comparison of the four screening score
61980180|NCT05533450|EXPERIMENTAL|Multi-focal rigid scleral contact lens|During the study period, subjects will wear a multi-focal rigid scleral contact lens daily.
62359970|NCT03934203|EXPERIMENTAL|M/P/H/P/L treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
62359971|NCT03934203|EXPERIMENTAL|P/H/L/M/P treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
62567092|NCT01113892|ACTIVE_COMPARATOR|EXXCEL Soft|A vascular graft comprised of extruded, expanded polytetrafluroethylene (ePTFE), indicated for use as a vascular prosthesis for replacement or bypass of diseased peripheral arteries (510(k) K962433).
61980181|NCT05533450|ACTIVE_COMPARATOR|Rigid gas permeable contact lens|During the study period, the subjects will wear rigid contact lenses daily
61980182|NCT06489769||Patient sample|Adults outpatients who are treated with opioids due to cancer-related pain.
61980183|NCT03042247||Hodgkin lymphoma patients|Hodgkin lymphoma patients with confirmed histological diagnosis
61980184|NCT03042247||DLBC non Hodgkin lymphoma patients|DLBC non Hodgkin lymphoma patients with confirmed histological diagnosis
61980185|NCT00487851|ACTIVE_COMPARATOR|1|Endoscopic treatment strategy
61980186|NCT00487851|ACTIVE_COMPARATOR|2|Surgical treatment strategy
61980187|NCT06065033|EXPERIMENTAL|Exercise|"Patients will perform 5 days of supervised stationary cycling exercise (with EKG telemetry) per week over a period of 4 weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR).~* Of the 5 sessions, 3 will be HIIT sessions and 2 will be MOD sessions.~* Subjects exercising on the HIIT day will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~* Subjects exercising on the MOD days will perform uninterrupted for 40 minutes duration at 60-65% of PHR progressing to 40 minutes duration at 70-75% of PHR by the end of week 2.~* Each training session will begin with a 10-min warm-up at 50% PHR and end with a 5-min cool down at 50% PHR. Exercise progression may have to be modified according to individual subject exercise tolerance."
61980188|NCT06065033|NO_INTERVENTION|Control|The control protocol will include a combination of light stretching and controlled breathing.
61980189|NCT04217746|EXPERIMENTAL|High flow nasal cannula (HFNC) group|The HFNC group will receive heated (approximately 37 ⁰C) and humidified (100% relative humidity) oxygenated gas delivered at high flow at 50L/min. Flow could be decreased to as low as 30L/min and temperature to 31 ⁰C as per patient's tolerance.
61980190|NCT04217746|NO_INTERVENTION|Conventional flow nasal oxygen (CFNO) group|The conventional flow nasal oxygen (CFNO) group is the control group which will receive ambient temperature and non-humidified oxygen delivered at flow rates of up to 8L/min (standard care).
61980191|NCT02723669|EXPERIMENTAL|AR10|AR10 acetylcysteine effervescent tablets for oral solution (two 0.5 g and four 2.5 g)
61980192|NCT02723669|ACTIVE_COMPARATOR|acetylcysteine|acetylcysteine solution; oral 20% (200 mg/mL)
61980193|NCT00040937|EXPERIMENTAL|treatment arm|thalidomide/dexamethasone followed by tandem melphalan peripheral blood stem cell transplantation (with cyclophosphamide and filgrastim or sargramostim support) and prednisone/thalidomide maintenance
61980194|NCT05273424||no groups|A cohort of CKD patients on hemodialysis
61980195|NCT06461533||Susoctocog Alfa (Genetical Recombination)|Participants will receive Susoctocog Alfa (Genetical Recombination) intravenous injection.
61980196|NCT04226274|EXPERIMENTAL|REN001|Oral
61980197|NCT02939898|PLACEBO_COMPARATOR|Lactose Monohydrate|2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 International Units of recFSH
61980198|NCT02939898|ACTIVE_COMPARATOR|Letrozole|2 tablets of 2,5 mg Letrozole are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 International Units of recFSH
61980199|NCT04832685|ACTIVE_COMPARATOR|Active LIFUP|All participants will receive active modulation of the posterior cingulate cortex (PCC) during Visit 3 or 4 (order counterbalanced).
61980200|NCT04832685|SHAM_COMPARATOR|Sham LIFUP|All participants will receive sham modulation of the posterior cingulate cortex (PCC) during Visit 3 or 4 (order counterbalanced).
61980201|NCT04229615|EXPERIMENTAL|Safety Lead-in, Doublet Arm|Fluzoparib+Apatinib
61980202|NCT04229615|EXPERIMENTAL|Single Arm|Fluzoparib
61980203|NCT04229615|PLACEBO_COMPARATOR|Placebo|Placebo
61980204|NCT02890589|EXPERIMENTAL|SYNERGY Stent|The SYNERGY™ stent is a Device marked CE (European Conformity), platinum chromium coronary stent, currently developped by Boston Scientific™. This stent has been designed with the goal of providing optimal and rapid healing within the vessel using a bioabsorbable polymer to elute everolimus.
61980205|NCT02890589|EXPERIMENTAL|BVS device|The ABSORB Everolimus-eluting Bioresorbable Vascular Scaffold (BVS 1.1, Abbott Vascular, California, USA, CE approved) is Device marked CE, currently the most studied PLA (Polylactic acid) based scaffold. It consists of PLLA (Poly I-lactic acid) backbone with 1:1 PDLLA (Poly-DL Lactic Acid) drug surface coating and a total strut thickness of 156 μm.
61980206|NCT05301426|EXPERIMENTAL|Passive hamstring stretch.|Manual stretching of the hamstring muscles using the technique proposed by Henri Neiger.
61980207|NCT05301426|EXPERIMENTAL|Longitudinal slippage of the sciatic nerve.|Neurodynamic technique described by David Butler and Michael Shacklock.
61980208|NCT05301426|ACTIVE_COMPARATOR|Passive upper limb mobilisations.|Control group. Passive mobilisation of the upper limbs.
61980209|NCT01334268|ACTIVE_COMPARATOR|Taxus Liberte Paclitaxel-Eluting Coronary Stent System|Subjects will be randomized to be treated with Taxus Liberte Paclitaxel-Eluting Coronary Stent System by an interactive voice response system (IVRS).
61980210|NCT01334268|EXPERIMENTAL|Medtronic Resolute (Zotarolimus-eluting stent)|Subjects will be randomized to be treated with Medtronic Resolute (Zotarolimus-eluting stent) by an interactive voice response system (IVRS).
61980211|NCT04743427|EXPERIMENTAL|physical therapy inervention|"1. hot pack~2. Three active exercises"
61980212|NCT04743427|EXPERIMENTAL|Body-blade exercises in addition to physical therapy intervention|"1. Three Body-blade exercises will be performed in random order (Two sets of, 3-minute exercise and 5-minute break, for each exercise )~2. hot pack~3. Three active exercises"
61980213|NCT01867021|EXPERIMENTAL|Agriflu|A single 0.5 mL dose of Investigational vaccine TIV (Agriflu) at visit 1, administered intramuscularly
61980214|NCT01867021|ACTIVE_COMPARATOR|Fluvirin|A single 0.5 mL dose of control vaccine TIVf (Fluvirin) at visit 1, administered intramuscularly
61980215|NCT00475176|EXPERIMENTAL|S-Adenosyl Methionine|
61980216|NCT03442907|EXPERIMENTAL|Study group|"The intraoperative blood pressure target for all patients in the study group is the mean arterial pressure (+ 10mmHg maximum) derived from the prior 24-hour blood pressure measurement.~To achieve the blood pressure target, fluid or vasoactive substances will be used."
61980217|NCT03442907|ACTIVE_COMPARATOR|Control group|Study patients of the control group are treated according to the standard operating procedures (SOP) of the Department of Anaesthesiology, University Medical Centre Hamburg Eppendorf.
61980218|NCT05284851|EXPERIMENTAL|Experimental group 1|Healthy people in experimental group will receive a dose of Live Attenuated Influenza Vaccine (non freeze- dried)
61980219|NCT05284851|ACTIVE_COMPARATOR|Positive control group|Healthy people in Positive control group will receive a dose of Live Attenuated Influenza Vaccine ( freeze- dried)
61980220|NCT05284851|PLACEBO_COMPARATOR|Placebo group|Healthy people in placebo group will receive a dose of placebo
61980221|NCT01843751|ACTIVE_COMPARATOR|Physician Office|Buprenorphine/naloxone via physician office (B-PO) x 10 months
61980222|NCT01843751|EXPERIMENTAL|Specialist Center|Buprenorphine/naloxone via specialist center (B-SC) x 3 months followed by B-PO x 7 months. The specialist center in this trial will be a methadone clinic.
61980223|NCT03556189|EXPERIMENTAL|Experimental|case management consists adjusting AV delay of pacemaker to achieve best cardiac output measured by trans-thoracic echocardiogram
61980224|NCT03556189|NO_INTERVENTION|Control: Usual care|Usual care is provided with routine pacemaker interrogation.
61980225|NCT03594292|EXPERIMENTAL|FASTFORWARDTM Bunion|The participants are treated with FASTFORWARDTM Bunion Correction system. The FASTFORWARDTM Bunion Correction system employed 3D printed titanium bone tether plate at second metatarsal. Due to the merit of 3D printing technology, the plate is designed to broadly distribute forces across bone to secure mechanical integrity of the bone. The FASTFORWARDTM Bunion Correction system has been cleared by the United States Food and Drug Administration.
61980226|NCT03594292|ACTIVE_COMPARATOR|Conventional Surgery|The participants are treated with fusion surgery. This procedures is a standard treatment for 1st metatarsal hallux valgus by cutting, realigning and fusing the 1st metatarsal or fusing the metatarsal-cuneiform joint.
61980227|NCT04840238|EXPERIMENTAL|Cholecalciferol|Cholecalciferol 30,000IU weekly orally
61980228|NCT04840238|PLACEBO_COMPARATOR|Placebo|Placebo tablets weekly orally
61980229|NCT03494309|EXPERIMENTAL|ORIF|Open Reduction \& Internal Fixation
61980230|NCT03494309|ACTIVE_COMPARATOR|CREF|Closed Reduction \& External Fixation
61980231|NCT03564145|EXPERIMENTAL|S5G4T-1|Participants will topically apply S5G4T-1 cream, once daily to face for 40 weeks.
61980232|NCT01396460||bariatric patients|Bariatric post operative patients were compared with morbid obese population
61980233|NCT01396460||control group|morbid obese population
61980234|NCT01413191|EXPERIMENTAL|CixutumumabTreatment|Cixutumumab 10 mg/kg intravenous (IV) over 1 hour on days 1 and 15 for 4 week courses.
62391376|NCT06435052|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) will be delivered face-to-face by a psychotherapist in a total of 14 sessions, with one session per week. The efficacy of CBT will be compared with Eye Movement Desensitization and Reprocessing therapy in the treatment of Post-Traumatic Stress Disorder in Pakistan.
62391377|NCT03085160|EXPERIMENTAL|Learning to Breathe|Six-week mindfulness-based group program for adolescents
61980235|NCT04002531|OTHER|Single Visit|"1. General and neurological examination~2. Vital signs including height, weight, blood pressure, pulse, temperature~3. 12 lead ECG~4. 2 hour Holter monitor for heart rate variability~5. Echocardiogram~6. Renal function will be assessed by the eGFR. The eGFR will be calculated from serum creatinine using CKD-EPI equation.~7. CBC with differential~8. Complete metabolic panel~9. Urinalysis~10. Urine Albumin/creatinine ratio.~11. Urine and plasma samples for biomarkers (Gb3, lyso-Gb3) that will be stored in -80 freezer and assayed in our lab.~12. Brief Pain Inventory questionnaire.~13. Quality of Life Questionnaires (SF36)"
61980236|NCT00528086||1|Parkinson disease patients and their family members or caregivers randomly assigned to receive their PD care in group visit format.
61980237|NCT00528086||2|Parkinson disease patients and their family members or caregivers randomly assigned to receive their PD care in standard of care format (one-on-one physician-patient visits).
61980238|NCT03566251|EXPERIMENTAL|Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS, Expanded Sisability Status Scale range of 0.5-4 who are able to walk independently.
61980239|NCT03566251|NO_INTERVENTION|Healthy individuals|29 healthy volunteers with matching ages and genders
61980240|NCT02852109||experimental group|patients who was firstly diagnosed as diffuse axonal injury
61980241|NCT02852109||control group|patients negative for magnetic resonance examination with no trauma
61980242|NCT04765579||4in1|4in1 block will be applied in the operation room
61980243|NCT04765579||medical|medical analgesics will be applied in the service
61980244|NCT02461901||Fidaxomicin treatment|Patients being treat with fidaxomicin (on the decision of their treating physician)
61980245|NCT02461901||Metronidazole or vancomycin treatment|Patients being treated with metronidazole or vancomycin (on the decision of their treating physician)
61980246|NCT04520932|EXPERIMENTAL|RFA treatment efficacy|PNETs ablation by radiofrequency treatment (1 to 3 sessions)
61980247|NCT03642236|EXPERIMENTAL|BTK treatment|Ibrutinib 420mg day -3 to d14; Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.
61980248|NCT03642236|ACTIVE_COMPARATOR|BTK-free treatment|Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.
61980249|NCT06321965|EXPERIMENTAL|SMA patient treated with SRT|Patients aged 0-15 with SMA type 1, 2 or 3, treated with TRS (nusinersen/risdiplam/onasemnogene abeparvovec/other).
61980250|NCT02551731|EXPERIMENTAL|Cannabidiol Oral Solution: 20 or 40 mg/kg/day BID|The dose of Cannabidiol Oral Solution will begin at 20 mg/kg/day \[10 mg/kg twice per day (BID)\], will be adjusted at any time if the investigator feels the safety or well-being of the participant is at risk, and will be titrated up or down according to protocol-stipulated parameters and at the investigator's discretion after Day 14 to enhance efficacy. Dose will not exceed 40 mg/kg/day.
61980251|NCT02543008|EXPERIMENTAL|Physical activity plus thoracic mobilization|Subjects randomly allocated to this arm will be submitted to a 10 minutes anaerobic exercise (2 minutes warming up, 5 minutes of 75% to 85% maximal heat rate, 3 minutes slowdown), followed by 5 minutes of passive intervertebral thoracic mobilization (3 sets of 1 minute, grade III, and 1 minute rest between each set).
61980252|NCT02543008|ACTIVE_COMPARATOR|Physical activity|Subjects allocated to this arm will be submitted to the same anaerobic exercise protocol, without the thoracic mobilization.
61980253|NCT02543008|PLACEBO_COMPARATOR|Placebo|Subjects in this group will be conducted to a placebo thoracic mobilization, without anaerobic exercise protocol. The investigator will apply only a manual contact, to mimic the genuine thoracic mobilization. The same 5 minutes period will be respected, and the same position of therapist and subject.
61980254|NCT00598247|EXPERIMENTAL|A|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks. A
61980255|NCT00765375|EXPERIMENTAL|Botox and Placebo on each side of face|Botulinum Neurotoxin Type A (Botox, 1.5-3 units/lesion); Bacteriostatic saline solution (0.11 cc/lesion)
61980256|NCT05810792|EXPERIMENTAL|Patients receiving immunomodulating treatment|
61980257|NCT02859779|OTHER|mediterranean adolescents with type 1 diabetes|
61980258|NCT02675413|EXPERIMENTAL|Dimethyl Fumarate|Open label dimethyl fumarate (Tecfidera) at the US approved dose of 120mg BID for 7 days and then 240mg BID thereafter for 12 months.
61980259|NCT06391164|EXPERIMENTAL|XC243 25 mg|XC243 25 mg single
61980260|NCT06391164|EXPERIMENTAL|XC243 50 mg|XC243 50 mg single
61980261|NCT06391164|EXPERIMENTAL|XC243 75 mg|XC243 75 mg single
61980262|NCT06391164|PLACEBO_COMPARATOR|Placebo|
62391378|NCT03085160|ACTIVE_COMPARATOR|Health Education|Six-week health education group program for adolescents
61980263|NCT00749918|EXPERIMENTAL|1|Each subject was evaluated and data was collected before and after the intervention
61980264|NCT01593423|EXPERIMENTAL|Homestead Food Production plus small pond aquaculture|
61980265|NCT01593423|ACTIVE_COMPARATOR|plant-based Homestead Food Production|
61980266|NCT01593423|SHAM_COMPARATOR|Control|
61980267|NCT01717404|EXPERIMENTAL|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
61980268|NCT06033521||Women with menopausal hormone therapy|Subjects who were newly diagnosed menopausal symptoms between 01 Jan 2012 and 31 Dec 2019, and were followed up for 12 months at least in the HIRA claims database
61980269|NCT03658850|ACTIVE_COMPARATOR|Intervention|the experimental group will receive one tablet of hydrochlorothiazide in the presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally for 3 days.
61980270|NCT03658850|PLACEBO_COMPARATOR|Control|placebo group will receive one tablet or equivalent volume of enteral solution of inert substance
61980271|NCT01973166|EXPERIMENTAL|Picosecond Q-switched Laser Treatment|Picosecond Q-switched Nd:YAG (1064 nm and 532 nm) laser
61980272|NCT01973166|ACTIVE_COMPARATOR|Nanosecond Q-switched Laser Treatment|Nanosecond Q-switched Nd:YAG (1064 nm and 532 nm) laser
61980273|NCT05611034|EXPERIMENTAL|IVLP in single lung|
62391379|NCT03286114|EXPERIMENTAL|Pembrolizumab|
62391380|NCT00489216|EXPERIMENTAL|Efalizumab|All patients on study will receive a total of 8 injections of efalizumab
61980274|NCT01524510|EXPERIMENTAL|MRA|All OSAS patients will be asked to sleep two nights without MRA and, +/- 1 week later, two nights with MRA
61980275|NCT05713045||intramuscolar injection|intramuscolar injection of 1 mg vitamin K at birth
62359972|NCT03934203|EXPERIMENTAL|P/H/L/P/M treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
62359973|NCT03934203|EXPERIMENTAL|P/L/M/P/H treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
62359974|NCT03934203|EXPERIMENTAL|P/M/P/L/H treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
61980276|NCT05713045||intramuscolar injection following by oral low dose|intramuscolar injection of 1 mg vitamin K at birth followed by 50 μg/die orally from the second to the fourteenth week of life
61980277|NCT05713045||intramuscolar injection following by oral high dose|intramuscolar injection of 1 mg vitamin K at birth followed by 150 μg/die orally from the second to the fourteenth week of life
61980278|NCT05713045||oral administration|oral dose of 2 mg vitamin K at birth, followed by a second dose at 4 weeks, and a third dose at 12 weeks
61980279|NCT04941235|ACTIVE_COMPARATOR|NU group|Bth nerve stimulator and ultrasound guided interscalene brachial plexus block
61980280|NCT04941235|ACTIVE_COMPARATOR|U group|Ultrasound guided interscalene brachial plexus block
61980281|NCT04941235|ACTIVE_COMPARATOR|N group|Nerve stimulator guided interscalene brachial plexus block
61980282|NCT04941235|NO_INTERVENTION|C group|No block only IV analgesics
61980283|NCT00708643|ACTIVE_COMPARATOR|Habitual silicone hydrogel|Habitual contact lens wear.
61980284|NCT00708643|EXPERIMENTAL|narafilcon A|Silicone hydrogel daily disposable contact lens
61980285|NCT05766475|ACTIVE_COMPARATOR|In-Person Delivery of Group Preventative Intervention (ROSE)|The Reach Out, Stay Strong, Essentials for New Mothers Program (ROSE), is an established Interpersonal Therapy (IPT)-oriented group intervention for postpartum depression. ROSE is a brief (5-session) program and its content addresses social support, role transition to motherhood, communication skills, and psychoeducation on PPD. ROSE consists of four 90-minute, weekly in person group sessions and one individual booster session. The first four sessions of ROSE will be delivered in groups of 6 to 20, and conducted in both English and Spanish. For the in-person groups, transportation via Uber will be provided to Denver Health Medical Center to reduce barriers to attendance.
61980286|NCT05766475|EXPERIMENTAL|Virtual Delivery of Group Preventative Intervention (ROSE)|In parallel to ROSE delivered in person, virtual ROSE consists of four 90-minute, weekly group sessions conducted via Zoom and one individual booster session.
61980287|NCT05181423||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
61980288|NCT05181423||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is a external validation cohort.
61980289|NCT05178966|EXPERIMENTAL|Bp OneDay programm|The BP One-Day program is based on a single day of psychoeducation .
61980290|NCT05178966|NO_INTERVENTION|Waiting List|Patients assigned in control group will be placed in waiting list and will benefit from the program after their participation to this study. During study participation, they will receive treatment as usual.
61980291|NCT05335564|EXPERIMENTAL|General information about depression|Exposure to general information about depression
61980292|NCT03414424|EXPERIMENTAL|All subjects|All subjects undergo same full protocol, including CES at rest and CES plus active hand or wrist movements.
61980293|NCT02100501||Atkins diet group|pediatric patients diagnosed with intractable epilepsy. Their ages ranged between 1 to 18 years amd indicated to dietary therapy. the targeting number of patients was 53. enrolled patients are assigned to randomly in one of KD group or Atkins group.
61980294|NCT02100501||Ketogenic diet group|pediatric patients diagnosed with intractable epilepsy. Their ages ranged between 1 to 18 years amd indicated to dietary therapy. the targeting number of patients was 51. enrolled patients are assigned to randomly in one of KD group or Atkins group.
61980295|NCT01012856|ACTIVE_COMPARATOR|Cognitive-Behavioral Therapy for Depression (CBT)|
61980296|NCT01012856|EXPERIMENTAL|Exposure-Based Cognitive Therapy for Depression (EBCT)|
61980297|NCT04177342|ACTIVE_COMPARATOR|fentanyl|the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
61980298|NCT04177342|EXPERIMENTAL|oxycodone|the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group
61980299|NCT01411696||All Participants|Patients who received at least 2 injections of OZURDEX® (dexamethasone intravitreal implant) to treat Macular Edema.
61980300|NCT01174927|ACTIVE_COMPARATOR|Heroin-dependent patients_1|daily dose of diacetylmorphine (30 mg to 500 mg) in 5 ml
61980301|NCT01174927|PLACEBO_COMPARATOR|Heroin-dependent patients_2|5 ml saline
61980302|NCT02829463||osteoarthritis patients|3.0 Tesla Magnetic resonance imaging was analyzed. It's the documentation from the outpatients and inpatients with osteoarthritis. It's not the intervention the study applied, but the subjects' disease demands.
61980303|NCT02829463||healthy controls|3.0 Tesla Magnetic resonance imaging was analyzed. It's the documentation from the outpatients and inpatients without osteoarthritis. It's not the intervention the study applied, but the subjects' non-osteoarthritis knee symptom demands.
61980304|NCT03872219|PLACEBO_COMPARATOR|Placebo|The children will receive and they are exposed daily to harmless materials that look and feel like the biodiversity intervention materials.
61980305|NCT03872219|EXPERIMENTAL|intervention arm|The children will receive and they are exposed daily to materials of high microbiological biodiversity.
61980306|NCT00470639|EXPERIMENTAL|TMS|
61980307|NCT00470639|SHAM_COMPARATOR|Sham|
61980308|NCT02550548|EXPERIMENTAL|GIP infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP infused at 4 incremental dosages, (initial dose will be 2.0 ng/kg/min, followed by 4.0, 8.0, and 16.0 ng/kg/min). Each dose will be infused continuously for 30 minutes, followed immediately by the next higher dose. The total time of this procedure is 240 minutes.
61980309|NCT02550548|EXPERIMENTAL|GLP-1 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GLP-1 infused at 4 incremental dosages, (initial dose will be 1.0 ng/kg/min, followed by 2.0, 3.0, and 4.0 ng/kg/min). Each dose will be infused continuously for 30 minutes, followed immediately by the next higher dose. The total time of this procedure is 240 minutes.
61980310|NCT02550548|EXPERIMENTAL|GIP + GLP-1 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP + GLP-1 infused simultaneously at 4 incremental dosages (doses will be half the amounts described above). These doses will be infused continuously for 30 minutes, followed immediately by the next higher doses. The total time of this procedure is 240 minutes.
62391381|NCT06067373||patients with postponed surgery|patients with postponed surgery
61980311|NCT02550548|EXPERIMENTAL|GIP + Ex-9 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP infused at 4 incremental dosages (as described above) with Ex-9 infused at a steady dose of 2.5 mcg/kg/min starting 90 minutes before the GIP infusion and maintained throughout the clamp experiment. The total time of this procedure is 240 minutes.
61980312|NCT03502226|EXPERIMENTAL|Intervention group|Received tailored feedback regarding sexual health risks
61980313|NCT03502226|NO_INTERVENTION|Control group|Did not receive tailored feedback.
61980314|NCT03043027|EXPERIMENTAL|Liposomal bupivicaine|
62391382|NCT03724552|EXPERIMENTAL|Transcranial LED Therapy (Participants ages 9-17)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
62391383|NCT03724552|EXPERIMENTAL|Transcranial LED Therapy (Participants ages 18-59)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
62391384|NCT01874288|EXPERIMENTAL|DI-Leu16-IL2 0.5 mg/m^2|Participants will receive DI-Leu16-IL2 0.5 mg/m\^2 subcutaneously (SC) for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
61980315|NCT03043027|ACTIVE_COMPARATOR|bupivicaine|
61980316|NCT03043027|PLACEBO_COMPARATOR|saline|
61980317|NCT01601249|EXPERIMENTAL|Polscope based embryo grading|Embryos for transfer will be selected based on highest polscope scores, unless are not grade 1-2 by conventional morphology
61980318|NCT01601249|ACTIVE_COMPARATOR|Morphology based embryo grading|Conventional embryo grading and decision making
61980319|NCT06209645|EXPERIMENTAL|tDCS then tACS|This group is made up of adult patients with drug-resistant neuropathic pain, who started with tDCS stimulation, followed by tACS stimulation, in accordance with randomization. Each series of each modality comprises 6 sessions spaced 2 weeks apart, the first session being in placebo mode and the following 5 in active mode. Each session lasts 20 minutes. In placebo mode, a 2 miliampere (mA) current is delivered for 30 seconds at the start and at the end of the session, to prevent the patient noticing the difference between placebo and active stimulation. In active mode, the 2mA current is delivered for the duration of the session.
61980320|NCT06209645|EXPERIMENTAL|tACS then tDCS|This group is made up of adult patients with drug-resistant neuropathic pain, who started with tACS stimulation, followed by tDCS stimulation, in accordance with randomization. Each series of each modality comprises 6 sessions spaced 2 weeks apart, the first session being in placebo mode and the following 5 in active mode. Each session lasts 20 minutes. In placebo mode, a 2mA current is delivered for 30 seconds at the start and at the end of the session, to prevent the patient noticing the difference between placebo and active stimulation. In active mode, the 2mA current is delivered for the duration of the session.
61980321|NCT01967212|EXPERIMENTAL|Game-based swallow biofeedback|swallowing training combined with game-based biofeedback in stroke dysphagia patient.
61980322|NCT01967212|ACTIVE_COMPARATOR|Swallow training without biofeedback|
61980323|NCT02393547|EXPERIMENTAL|Varenicline + Lorcaserin|Open label all subjects receive both Varenicline and Lorcaserin
61980324|NCT03352323|EXPERIMENTAL|oxymetazoline cream|
61980325|NCT05202509|EXPERIMENTAL|obicetrapib 10mg|one 10mg tablet, once daily.
61980326|NCT05202509|PLACEBO_COMPARATOR|Placebo|one placebo tablet, once daily
61980327|NCT02953054|ACTIVE_COMPARATOR|DMTS|DMTS applied to the upper arm
61980328|NCT02953054|PLACEBO_COMPARATOR|Placebo|Placebo patches to match DMTS applied to the upper arm
61980329|NCT01991457|OTHER|Treatment|Fludarabine, Total Body Irradiation (TBI) Fludarabine: 40 mg/m2 X 4 days TBI: TBI 2 Gy 2 times a day X 3 days
61980330|NCT02884674|ACTIVE_COMPARATOR|active Transcranial Magnetic Stimulation|Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, Using theta burst stimulation and using Transcranial Magnetic Stimulation navigator and robot
61980331|NCT02884674|PLACEBO_COMPARATOR|Placebo|Placebo comparator, using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using Transcranial Magnetic Stimulation navigator and robot
61980332|NCT06418841|EXPERIMENTAL|Computer-Assisted Paramedian Approac Technique|The L3-4 inter-laminar space will be selected as the target for puncture, and in the longitudinal direction, 1.0-1.5cm will be opened beside the upper edge of the spinous process (tip) of the lower vertebra as the entry point. The lumbar puncture needle will be inserted vertically along the axis of the anesthesia needle. The puncture path will be maintained completely perpendicular to the skin until the needle reached the PLTLF (posterior layer of the thoracolumbar fascia), where some resistance will be felt. The puncture direction is adjusted as needed. The tip of the needle will be tilted 20±10° in the sagittal direction and 15±5° inward such that the tip will point at the midpoint of the spinal canal. After the needle reaches the PLTLF, it will be further inserted 3-7 cm.
61980333|NCT06418841|EXPERIMENTAL|Conventional Midline Approach Technique|Puncture will be performed on the posterior median line near the midpoint of the L3-4 Space of spinous process. The lumbar puncture needle will be inserted vertically along the axis of the anesthesia needle, or the tip of the needle will be tilted 15° in the sagittal direction toward the head, so that the needle path is parallel to the space of spinous process.
61980334|NCT06397898|EXPERIMENTAL|Intervention group (video)|group that viewed an educational video before Novasure treatment
61980335|NCT06397898|NO_INTERVENTION|Control group (no video)|group that did not view an educational video before Novasure treatment
62359975|NCT03934203|EXPERIMENTAL|P/P/L/H/M treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
62391385|NCT01874288|EXPERIMENTAL|DI-Leu16-IL2 1.0 mg/m^2|Participants will receive DI-Leu16-IL2 1.0 mg/m\^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
61980336|NCT02963207|EXPERIMENTAL|Modified Sano's Classification|Modified Sano's Classification as described by Singh et al. 2013
61980337|NCT02963207|ACTIVE_COMPARATOR|NICE classification|NBI International Colorectal Endoscopic Classification as described by Hewett et al. 2012
61980338|NCT05419323||Traditional clinical pathway for OSA|"After referral, patients will have an initial encounter with a sleep care provider which might include in-person visits, telephone clinics, or video conferencing.~Intervention/Treatment: Patients in Arm 1 will receive routine care for OSA at one of the participating VA Sleep Medicine clinics."
61980339|NCT05419323||DREAM clinical pathway for OSA|"After referral, patients will not have an initial encounter with a care provider. After a clinician conducts a chart review of medical records, patients in the DREAM pathway will be referred for sleep testing.~Intervention/Treatment: Patients in Arm 2 will receive routine care for OSA at one of the participating VA Sleep Medicine clinics."
61980340|NCT05419323||Negative predictive value of HSAT|"Results of sleep tests will be compared for patients who undergo both HSAT and polysomnographic (PSG) procedures.~Intervention/Treatment: Patients in Arm 3 will undergo~a) HSAT sleep testing followed by PSG testing, or b) simultaneous administration of PSG and HSAT sleep testing."
61980341|NCT02425150|EXPERIMENTAL|Corneal reshaping/crosslinking (CRXL)|Corneal crosslinking with compression of the cornea using a sutured rigid contact lens during the treatment.
61980342|NCT02425150|ACTIVE_COMPARATOR|Corneal crosslinking (CXL)|Standard corneal crosslinking using the Dresden protocol.
61980343|NCT02425150|NO_INTERVENTION|Control group to CRXL|Healthy subjects, age- and sex-matched to the CRXL group.
61980344|NCT02425150|NO_INTERVENTION|Control group to CXL|Healthy subjects, age- and sex-matched to the CXL group.
61980345|NCT00410553|EXPERIMENTAL|Treatment (combination chemotherapy)|Patients receive eribulin mesylate IV and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 OR on days 1 and 8. Courses repeat every 28 or 21 days\* in the absence of disease progression or unacceptable toxicity.
61980346|NCT05886608|OTHER|AI500 single-dose gel|Interventional study on AI500 1.5 mL will be topically administered twice: the first at T0 and the second 24h from T0
61980347|NCT02221284||Alogliptin|Alogliptin 25 milligram (mg), tablets, orally, once daily, up to 12 months, along with an insulin preparations, with a rapid-acting insulin secretagogue (Glinide), with a SGLT-2 inhibitor, or the other diabetic drugs within 3 months prior to the start of alogliptin treatment or during the alogliptin treatment period in routine medical care.
61980348|NCT03844360|EXPERIMENTAL|Antineoplastic Drugs and Anti-infective Drugs|Bortezomib;eltrombopag;imatinib;dasatinib, pegaspargase and anti-infective drugs administered at standard dose for children with hematological neoplasms.
61980349|NCT01512121||functional MRI testing|"fMRI scanning with SCS on and off at different settings."
61980350|NCT01192282||Genital Warts|All female patients with Genital Warts presenting to Groote Schuur Hospital
61980351|NCT01830660|EXPERIMENTAL|hetrombopag|hetrombopag either at 2.5,5,10,20,30 or 40mg, p.o. once daily
61980352|NCT01830660|PLACEBO_COMPARATOR|placebo|Subjects will be randomized (5:1 eltrombopag : placebo) to receive either eltrombopag or placebo.
61980353|NCT04461015|OTHER|0.4mU Insulin|During the euglycemic clamp insulin will be infused at 0.4mU/Kg/Min
61980354|NCT04461015|OTHER|0.8mU Insulin|During the euglycemic clamp insulin will be infused at 0.8mU/Kg/Min
61980355|NCT00421187|EXPERIMENTAL|1|AmBisome® will be given on day 0 (10 mg/kg), day 2 (5 mg/kg), and day 5 (5 mg/kg)
61980356|NCT00421187|ACTIVE_COMPARATOR|2|AmBisome as a constant daily dose of 3 mg/kg for a maximum of 14 days or until the resolution of fever and neutropenia
61980357|NCT05552768|ACTIVE_COMPARATOR|Bone level-driven placement (BL Group)|Implants will be placed at the bone level, they will receive a 1.5-2 mm long CONNECT abutment.
61980358|NCT05552768|EXPERIMENTAL|Biological width-driven placement guidelines (BW Group)|Implants will be placed 4 mm below the mucosal margin using a 2-3 mm long CONNECT abutment.
61980359|NCT04072211|OTHER|Vaccine arm|Engerix-B vaccine will be administered. This arm will include all those at risk of hepatitis B virus infection
61980360|NCT00627003|EXPERIMENTAL|1|
61980361|NCT00627003|EXPERIMENTAL|2|
61980362|NCT01238679|EXPERIMENTAL|Cohort 1|Participants received an oral solution of 0.03 milligrams (mg) of PF-04958242, every 12 hours for 14 days.
61980363|NCT01238679|EXPERIMENTAL|Cohort 2|Participants received an oral solution of 0.05 mg of PF-04958242, every 24 hours for 14 days.
61980364|NCT01238679|EXPERIMENTAL|Cohort 3|Participants received an oral solution of 0.10 mg of PF-04958242, every 24 hours for 14 days.
61980365|NCT01238679|EXPERIMENTAL|Cohort 4|Participants received an oral solution of 0.15 mg of PF-04958242, every 24 hours for 14 days.
61980366|NCT01238679|EXPERIMENTAL|Cohort 5|Participants received an oral solution of 0.20 mg of PF-04958242, every 24 hours for 14 days.
61980367|NCT01238679|EXPERIMENTAL|Cohort 6|Participants received an oral solution of 0.25 mg of PF-04958242, every 24 hours for 14 days.
61980368|NCT01238679|PLACEBO_COMPARATOR|Matching Placebo|Participants received an oral solution of matching placebo, every 12 or 24 hours for 14 days.
61980369|NCT06397352|EXPERIMENTAL|ShotBlocker® Group|The ShotBlocker® is a small, flexible, drug-free plastic device with several short, blunt skin contact points on the bottom and a hole in the center through which injections can be administered. It is positioned onto the skin before an injection is made. After positioning the ShotBlocker® and ensuring that the contacts were in contact with the children's skin, the injection was made through the central hole by the nurse. The ShotBlocker® was cleaned with 70% alcohol before use on another child.
61980370|NCT06397352|EXPERIMENTAL|Buzzy® Group|Buzzy is a small plastic device powered by a vibrating motor and an ice pack. Buzzy is attached to the skin using a tourniquet 3 to 5 cm above the injection site just before the injection. Vibrations started 30 seconds before the procedure and continued until it was completed. The device was cleaned with 70% alcohol before use on another child.
61980371|NCT01647412|ACTIVE_COMPARATOR|Growth Hormone, Exclusion Diet, and Nutraceutical therapy|The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered recombinant human growth hormone (rhGH) for the first 26 weeks. After 26 weeks this group will continue on the exclusion diet nutraceutical therapy for the remaining 26 weeks of the study.
61980372|NCT01647412|PLACEBO_COMPARATOR|rhGH placebo, Exclusion diet, and nutraceutical therapy|The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered placebo injections for the first 26 weeks. After 26 weeks this group will continue on the exclusion diet and nutraceutical therapy for the remaining 26 weeks of the study.
61980373|NCT06159712|OTHER|Ocrelizumab|Patients with active multiple sclerosis starting standard treatment with ocrelizumab
61980374|NCT06159712|OTHER|Rituximab|Patients with active multiple sclerosis starting standard treatment with rituximab
61980375|NCT06159712|OTHER|Ofatumumab|Patients with active multiple sclerosis starting standard treatment with ofatumumab
61980376|NCT06159712|OTHER|Natalizumab|Patients with active multiple sclerosis starting standard treatment with natalizumab
61980377|NCT06159712|OTHER|Healthy controls|An age and gender matched healthy control group
61980378|NCT01924312|PLACEBO_COMPARATOR|No Intervention|A placebo cohort of 40 subjects with MCI related to vascular risk factors (MCI-CVD) will be followed longitudinally with cognitive, imaging, blood and optional spinal fluid biomarkers providing insight into the natural disease course of MCI-CVD. This natural history group will serve as the control group for the treatment arm described below.
61980379|NCT01924312|EXPERIMENTAL|Treatment Group|A cohort of 40 subjects with MCI-CVD will be treated with a nursing-based educational program (Heart Health Intervention) including aggressive symptom monitoring and treatment of vascular risks in a 6 visit intervention block over 12 weeks after baseline and thereafter for every 6 months for the study duration of 3 years. These subjects will be followed identically to the subjects in the natural history arm described in the control group above with cognitive testing, imaging, blood, and optional spinal fluid testing.
61980380|NCT02282670|EXPERIMENTAL|DA-5204|DA-5204 administered two times daily for two weeks
61980381|NCT02282670|ACTIVE_COMPARATOR|Stillen tab.|Stillen tab. administered three times daily for two weeks
61980382|NCT04489667|OTHER|+STEP Implementation|All patients will receive +STEP as new standard of care at their clinic. This intervention will include staff training, PROs as part of routine care to screen for substance use and mental health disorders, and telemedicine for health care delivery.
61980383|NCT02964962|EXPERIMENTAL|29 mm LOTUS Edge™|
61980384|NCT06542120||0 ~ 18 years old children|"Age range: 0 to 18 years old, with no gender restriction. Children who have been diagnosed with congenital heart disease (CHD) or confirmed to be free of CHD through echocardiographic examinations.~Children who have been diagnosed with bronchopneumonia or confirmed to be free of bronchopneumonia through chest imaging examinations.~Children who have been diagnosed with abdominal diseases or confirmed to be free of abdominal diseases through abdominal imaging examinations."
61980385|NCT00723892||PegIntron/Rebetol and psychotherapy support program|Participants receiving a psychotherapy support program during PegIntron/Rebetol therapy for hepatitis C.
62359976|NCT03934203|EXPERIMENTAL|P/P/M/L/H treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
62359977|NCT00050622|PLACEBO_COMPARATOR|No Treatment|No Medication, No Behavior Modification (BMOD)
61980386|NCT00723892||PegIntron/Rebetol alone (no psychotherapy)|Participants receiving no psychotherapy support program during PegIntron/Rebetol therapy for hepatitis C.
61980387|NCT03864471|EXPERIMENTAL|HCOACDM|The intervention, the HCOACDM, involves case screening, comprehensive assessment, and care coordination, and will be given over a 6-month period.
61980388|NCT03864471|ACTIVE_COMPARATOR|Routine care|The routine care services include home visits, telephone checkups, meals on the wheel, and health promotion activities.
61980389|NCT02808026|EXPERIMENTAL|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast for 8 weeks
61980390|NCT04357392|EXPERIMENTAL|Glucocorticoid intervention group|prednisone
61980391|NCT04357392|PLACEBO_COMPARATOR|Placebo control group|placebo
61980392|NCT02969824|NO_INTERVENTION|Usual Care Group|Following a brief period of physical and cognitive rest (typically1-7 days, depending on symptom severity and timing of spontaneous symptom abatement), the physician advises participants to increase their activity levels gradually with minimal head movement (predominantly involving a stationary bike) and progressively increase levels of exertion while remaining under the threshold of symptom exacerbation. Subsequently, exercise progressed to include a progression of head movements, visual and cognitive burdens, sport-specific activities, and heavy resistance, in that order, all below the symptom exacerbation threshold.
61980393|NCT02969824|EXPERIMENTAL|Supervised Exercise Group|These individuals will begin to exercise at Day 3 post-injury. These participants will be asked to complete a total of eight exercise sessions over the course of 11 days, with one day of rest after two consecutive sessions. Two of the sessions (i.e., first and mid-point) will be an in-person exercise sessions at the lab with a member of the research team while the remaining six sessions will be home-based exercise sessions with remote communication by phone (i.e., call or text) with a member of the research team. Once individuals in this group achieve asymptomatic status, they will be directed through the existing return to play guidelines.
61980394|NCT03414723|EXPERIMENTAL|SAR439954 with or without ramipril|"* On Period 1, following an overnight fast, subjects will receive once daily single morning oral intake of sotagliflozin from Day 1 to Day 5 followed by the first meal that has to be started within 10 min after dosing.~* On Day 1 of the Period 2, study subjects will begin a 10-day ramipril regimen following an overnight fast. From Day 6 to Day 10, subjects will receive once daily single morning oral intake of ramipril concomitantly to the sotagliflozin dosing."
61980395|NCT05820555|EXPERIMENTAL|Group A: 1 hour of tablet use in the hour before bed|"During week 1, children will maintain a sleep schedule within 30 minutes +/- of their habitual bedtime. This bedtime will be maintained throughout the 3 weeks of the study except on nights when dim light melatonin onset is assessed in the lab.~During week 2, participants will be asked to reframe from screen use in the 3 hours before bed time for 6 evenings.~During week 3, participants will be exposed to 1 hour of tablet use (Standard bright setting), 1 hour before bedtime for 6 evenings."
61980396|NCT05820555|EXPERIMENTAL|Group B: 1 hour of tablet use 2 hours before bed|"During week 1, children will maintain a sleep schedule within 30 minutes +/- of their habitual bedtime. This bedtime will be maintained throughout the 3 weeks of the study except on nights when dim light melatonin onset is assessed in the lab.~During week 2, participants will be asked to reframe from screen use in the 3 hours before bedtime for 6 evenings.~During week 3, participants will be exposed to 1 hour of tablet use (Standard bright setting), 2 hours before bedtime (and no screen use in the hour before bed) for 6 evenings."
61980397|NCT05820555|ACTIVE_COMPARATOR|Control Condition|"During week 1, children will maintain a sleep schedule within 30 minutes +/- of their habitual bedtime. This bedtime will be maintained throughout the 3 weeks of the study except on nights when dim light melatonin onset is assessed in the lab.~During week 2, participants will engage no screen use for the 3 hours before bedtime for 6 evenings.~During week 3, participants will be asked to engage in no screen use in the 3 hours before bedtime for 6 evenings."
61980398|NCT04890327|NO_INTERVENTION|Standard of Care|Patient presents to new Gynecologic Oncology appointment, family health history is collected by the physician during the clinic visit. Both the subject and physician complete assessment survey at the completion of clinic visit. Subject's medical record reviewed 6 months following study enrollment to determine subject's diagnosis, whether or not subject underwent genetic counseling and/or genetic testing and review genetic testing results.
61980399|NCT04890327|EXPERIMENTAL|Office|Patient presents to new Gynecologic Oncology appointment, subject is given access to a desk top computer in office and instructed to complete web-based family health history tool. Physician reviews results of patients web-based family health history tool.Subject and physician complete assessment survey at the completion of clinic visit. Subject's medical record reviewed 6 months following study enrollment to determine subject's diagnosis, whether or not subject underwent genetic counseling and/or genetic testing and review genetic testing results.
62359978|NCT00050622|ACTIVE_COMPARATOR|Low Dose Medication Only|0.15 mg/kg methylphenidate (MPH), No BMOD
62359979|NCT00050622|ACTIVE_COMPARATOR|Medium Dose Medication Only|0.3 mg/kg MPH, No BMOD
62359980|NCT00050622|ACTIVE_COMPARATOR|Higher Dose Medication Only|0.6 mg/kg MPH, No BMOD
62359981|NCT00050622|ACTIVE_COMPARATOR|Low Intensity BMOD Only|Placebo, Low Intensity BMOD
62359982|NCT00050622|ACTIVE_COMPARATOR|Low Intensity BMOD + Low Dose Medication|0.15 mg/kg MPH, Low Intensity BMOD
62359983|NCT00050622|ACTIVE_COMPARATOR|Low Intensity BMOD + Medium Dose Medication|0.3 mg/kg MPH, Low Intensity BMOD
62359984|NCT00050622|ACTIVE_COMPARATOR|Low Intensity BMOD + Higher Dose Medication|0.6 mg/kg MPH, Low Intensity BMOD
62359985|NCT00050622|ACTIVE_COMPARATOR|High Intensity BMOD Only|Placebo, High Intensity BMOD
61980400|NCT04890327|EXPERIMENTAL|Home|Patient is emailed a link containing web-based family health history tool prior to presenting for new Gynecologic Oncology appointment. Physician reviews results of patients web-based family health history tool. Subject and physician complete assessment survey at the completion of clinic visit. Subject's medical record reviewed 6 months following study enrollment to determine subject's diagnosis, whether or not subject underwent genetic counseling and/or genetic testing and review genetic testing results.
61980401|NCT05575765||Patients with a clinical diagnosis of colorectal cancer, colorectal polyps, and colorectal adenomas|
61980402|NCT01166763|EXPERIMENTAL|high dose vitamin D3 (10,000 IU weekly)|Group/Cohort Label vitamin D3
61980403|NCT00651573|ACTIVE_COMPARATOR|Blood transfusion triggers of 24% hematocrit value|Red blood cell transfusion will be given when hematocrit values fall below the assigned group 1 value which is 24%. When the hematocrit value falls to less 24%, a 1 unit RBC transfusion will be administered. Following administration of the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to transfusion and is greater than or equal to 24%, no further transfusions will be administered.
61980404|NCT00651573|ACTIVE_COMPARATOR|Blood transfusion triggers of 28% hematocrit value|Red blood cell transfusion will be given when hematocrit values fall below the assigned group 1 value which is 28%. When the hematocrit value falls to less 28%, a 1 unit RBC transfusion will be administered. Following administration of the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to transfusion and is greater than or equal to 28%, no further transfusions will be administered.
61980405|NCT04994990|ACTIVE_COMPARATOR|Standard Dosing Group|
61980406|NCT04994990|EXPERIMENTAL|Half Standard Dosing Group|
62359986|NCT00050622|ACTIVE_COMPARATOR|High Intensity BMOD + Low Dose Medication|0.15 mg/kg MPH, High Intensity BMOD
61980407|NCT05216731|EXPERIMENTAL|Bypass group|Under general or local anesthesia: Use of the best vascular substitute (inverted saphenous vein or vascular prosthesis).
61980408|NCT05216731|ACTIVE_COMPARATOR|Endovascular procedure group|Under general anesthesia, local anesthesia or sedation: Performing a balloon angioplasty completed by preferred stent deployment or drug-coated balloon angioplasty.
61980409|NCT06126133|EXPERIMENTAL|Near İnfrared Spektroskopi (NIRS)|Peripheral oxygen saturation to be measured with NIRS device
61980410|NCT05571241||fast rehabilitation program|conventional rehabilitation
61980411|NCT00807807|PLACEBO_COMPARATOR|1|Participants will receive placebo folic acid.
61980412|NCT00807807|EXPERIMENTAL|2|Participants will receive 100 mcg of folic acid.
62359987|NCT00050622|ACTIVE_COMPARATOR|High Intensity BMOD + Medium Dose Medication|0.3 mg/kg MPH, High Intensity BMOD
61980413|NCT00807807|EXPERIMENTAL|3|Participants will receive 400 mcg of folic acid.
61980414|NCT00807807|EXPERIMENTAL|4|Participants will receive 1000 mcg of folic acid.
61980415|NCT00807807|EXPERIMENTAL|5|Participants will receive 2000 mcg of folic acid.
61980416|NCT05132829|OTHER|Cefazolin and Indomethacin|Control arm- perioperative cefazolin and indomethacin
61980417|NCT05132829|EXPERIMENTAL|Azithromycin + control|perioperative azithromycin, cefazolin and indomethacin
61980418|NCT06084546|NO_INTERVENTION|Standard care with geko™ W3 device|Current geko™ device incorporating hydrogel adhesive designated KM40A
61980419|NCT06084546|ACTIVE_COMPARATOR|Standard care with geko™ X-W3|Next generation geko™ device incorporating new hydrogel adhesive designated KM40C
61980420|NCT01730209|EXPERIMENTAL|Everolimus|Everolimus once daily for 1 year, titration to trough levels of 5-10 ng/ml
62359988|NCT00050622|ACTIVE_COMPARATOR|High Intensity BMOD + Higher Dose Medication|0.6 mg/kg MPH, High Intensity BMOD
62359989|NCT01191632|ACTIVE_COMPARATOR|Radiation 0,5Gy|"Radiation: one time Radiation with an intensity of 0.5 Gy Group A~Beginning on a weekday 48 hours before surgery"
62359990|NCT01191632|ACTIVE_COMPARATOR|No radiation|Control group with 0Gy radiation
61980421|NCT01730209|PLACEBO_COMPARATOR|Placebo|Placebo treatment for 1 year. Tablets will be identical to everolimus tablets.
61980422|NCT03473808|EXPERIMENTAL|therapy + vibration|Imperceptible vibration applied to the wrist during a standardized hand task practice therapy program.
61980423|NCT05986162|EXPERIMENTAL|Itolizumab Dose Level 1|Itolizumab of 25 mg administered by intravenous infusion every 2 weeks for a total of 7 doses.
62359991|NCT01191632|ACTIVE_COMPARATOR|Radiation 2Gy|"Radiation: one time Radiation with an intensity of~2.0 Gy Group B~Beginning on a weekday 48 hours before surgery"
62359992|NCT01191632|ACTIVE_COMPARATOR|Radiation 5Gy|"Radiation: one time Radiation with an intensity of~5 Gy Group C Beginning on a weekday 48 hours before surgery"
62359993|NCT03432611|EXPERIMENTAL|Complete app|198 women with primary dysmenorrhea who receive an app which includes a self-care information feature and a self-acupressure feature.
62359994|NCT03432611|ACTIVE_COMPARATOR|Control intervention I|198 women with primary dysmenorrhea who receive an app for menstrual pain which includes the self-care information feature, but not the self-acupressure feature.
62359995|NCT03432611|ACTIVE_COMPARATOR|Control intervention II|198 women with primary dysmenorrhea who receive an app for menstrual pain which includes the self-acupressure feature, but not the self-care information feature.
62391386|NCT01874288|EXPERIMENTAL|DI-Leu16-IL2 2.0 mg/m^2|Participants will receive DI-Leu16-IL2 2.0 mg/m\^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
61980424|NCT05986162|EXPERIMENTAL|Itolizumab Dose Level 2|Itolizumab of 50 mg administered by intravenous infusion every 2 weeks for a total of 7 doses.
61980425|NCT05986162|EXPERIMENTAL|Itolizumab Dose Level 3|Itolizumab of 100 mg administered by intravenous infusion every 2 weeks for a total of 7 doses.
61980426|NCT04262232|EXPERIMENTAL|Ca-HELP|This intervention arm will consist of six components: (1) Assessment of current knowledge, attitudes, and preferences; (2) clarification and correction of misconceptions about cancer pain control; (3) teaching of relevant concepts (education about cancer pain control); (4) planning (identifying goals of care, creating achievable goals of care, and creating strategies to communicate goals of care to providers and family members); (5) rehearsal of communication strategies using role play exercises; and (6) portrayal of learned skills (patient applies skills in visit with healthcare provider).
61980427|NCT06133192|ACTIVE_COMPARATOR|Steroids alone|Steroids 2 mg/kg/day
61980428|NCT06133192|EXPERIMENTAL|ECP + steroids|Steroids 2 mg/kg abd ECP x 2 per week for 1 months and once a week for 2 months
61980429|NCT02197507|EXPERIMENTAL|RA patients|
61980430|NCT06087783|EXPERIMENTAL|Muscle-targeted nutritional support|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
61980431|NCT06087783|OTHER|Standard of care|Control group receiving no nutritional intervention or on-demand non muscle-targeted nutritional intervention such as nutritional counseling with or without oral nutritional supplement
61980432|NCT02615054||treated with trastuzmab no cardiac effects|
61980433|NCT02615054||treated with trastuzmab with cardiac effects|
62359996|NCT04241172|EXPERIMENTAL|Immersive Virtual Reality (HIVR)|"The HIVR exercises will be performed using Nirvana system, a medical device based on virtual reality specifically designed to support motor rehabilitation, by projecting aquatic scenarios on the floor that simulates the movement and the noise of the water due to the motor exercise execution by the patient. In particular, the following virtual reality scenarios will be used:~* Swimming pool: the environment represents a swimming pool (water and edge). The patient must perform exercises by moving the lower limbs while sitting on a chair. The virtual environment gives the sensation of having the lower limbs immersed in water above the knees;~* Water metal: the environment gives the feeling of being immersed in water up to the waist. The subject interacts with the virtual water performing walking exercises and receiving visual and auditory biofeedback."
61980434|NCT02615054||healthy volunteers no cancer treatment|
61980435|NCT02132325|EXPERIMENTAL|Dignity Therapy|
61980436|NCT02097407|EXPERIMENTAL|Group D : Dexmedetomidine + propofol group|In Group D, DEX (1 µg kg-1) was intravenously loaded for 10 min before induction of anaesthesia.
61980437|NCT02097407|PLACEBO_COMPARATOR|Group C : Saline + propofol group|In Group C, 0.9% of normal saline (1 µg kg-1) was loaded 10 min before induction of anaeshtesia.
61980438|NCT01125839||Spondylitis|Patients who checked spine MRI for back pain
61980439|NCT00091351|EXPERIMENTAL|surgery|"Patients undergo surgery.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed at 28 days, 4 months, every 6 months for 5 years, and then annually for 5 years."
61980440|NCT00091351|EXPERIMENTAL|radiation + surgery|"Patients undergo preoperative radiotherapy once daily, 5 days a week, for 5.5 weeks. Within 28-63 days after the completion of radiotherapy, patients undergo surgery.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed at 28 days, 4 months, every 6 months for 5 years, and then annually for 5 years."
61980441|NCT00376350|EXPERIMENTAL|High dose manipulation|High dose spinal manipulation + ultrasound
62359997|NCT04241172|ACTIVE_COMPARATOR|Traditional Hydrotherapy (TH)|"The TH group exercises will be performed in a swimming pool suitable for hydrotherapy treatments. In particular, patients will perform:~* exercises with patients sitting on the swimming pool edge with lower limb immersed in the water;~* flexion-extension of the knee;~* leg and hip circling;~* flexion-extension of the ankle;~* triple flexion;~* water walking exercises."
62359998|NCT04241172|ACTIVE_COMPARATOR|Traditional Rehabilitation (TR)|"The TR group exercises will be performed in the gym with a physiotherapist. In particular, patients will perform:~* exercises with a patient sitting on a chair (3 minutes per exercise):~* flexion-extension of the knee;~* leg and hip circling;~* flexion-extension of the ankle;~* triple flexion;~* walking (with and without aids)."
62359999|NCT01482572||Gene profiling Success|
62360000|NCT02540876|EXPERIMENTAL|Treatment (ilorasertib)|Patients receive ilorasertib PO BID on days 1, 8, 15, 29, and 36. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62360001|NCT00809861|ACTIVE_COMPARATOR|1|volar locking plating of distal radius fractures
62360002|NCT00809861|ACTIVE_COMPARATOR|2|
62360003|NCT01966861|NO_INTERVENTION|usual care|Weaning as protcolised by the units' daily practice (SBT)
61980442|NCT00376350|EXPERIMENTAL|Moderate dose manipulation|Moderate dose manipulation + low dose massage + ultrasound
62360004|NCT01966861|EXPERIMENTAL|Weaning guided by lung ultrasound|Predictive early signs of respiratory distress are assessed by lung ultrasound and if found will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis)
62360005|NCT04009460|EXPERIMENTAL|Part A dose escalation|ES101 will be escalated in patients with advanced solid tumors.
62360006|NCT04009460|EXPERIMENTAL|Part B expansion|Subjects with solid tumors will be treated with single-agent ES101 at either specified dose levels or RP2D.
61980443|NCT00376350|EXPERIMENTAL|Low dose manipulation|low dose spinal manipulation + moderate dose massage + ultrasound
61980444|NCT00376350|OTHER|High dose masssage|high dose massage + ultrasound
61980445|NCT03941431|EXPERIMENTAL|Chinese medicine internal treatment group|Participants in Chinese medicine internal treatment group will receive Jueyin granule two times daily after meals and moving cupping placebo therapy three times per week for 8 weeks.
61980446|NCT03941431|EXPERIMENTAL|Chinese medicine external treatment group|Participants in Chinese medicine internal treatment group will receive Jueyin placebo granule two times daily after meals and moving cupping therapy three times per week for 8 weeks.
61980447|NCT03941431|EXPERIMENTAL|Chinese medicine treatment group|Participants in Chinese medicine treatment group will receive Jueyin granule two times daily after meals, moving cupping therapy and NB-UVB placebo therapy three times per week for 8 weeks.
61980448|NCT03941431|EXPERIMENTAL|Western medicine treatment group|Participants in Western medicine treatment group will receive Jueyin placebo granules two times daily after meals, moving cupping placebo therapy and NB-UVB therapy three times per week for 8 weeks.
61980449|NCT03941431|EXPERIMENTAL|Integrated Chinese and Western Medicine Treatment Group|Participants in Chinese and Western Medicine Treatment Group will receive Jueyin granules two times daily after meals, moving cupping therapy and NB-UVB therapy three times per week for 8 weeks.
61980450|NCT01425346||Normal Healthy|Normal, healthy males and females between the ages of 21 and 70 with healthy eyes as determined by a standard ophthalmic examination.
61980451|NCT02059057|EXPERIMENTAL|LVRC System|
61980452|NCT00356369|EXPERIMENTAL|Nimenrix Group|Subjects receiving GSK Biologicals' meningococcal vaccine 134612
61980453|NCT00356369|ACTIVE_COMPARATOR|Mencevax Group|Subjects receiving Mencevax™ ACWY
61980454|NCT06404606|ACTIVE_COMPARATOR|Group A (Black Cumin & Turmeric)|Participants will receive one capsule of black cumin and turmeric thrice per week (Alternate days) for 12 weeks.
61980455|NCT06404606|ACTIVE_COMPARATOR|Group B (Black Cumin & Turmeric along with Quantum Acoustic Waves)|Participants will receive one capsule of black cumin and turmeric along with Quantum Acoustic Waves (QAW) three days per week for 12 weeks
61980456|NCT06404606|ACTIVE_COMPARATOR|Group C (Quantum Acoustic Waves)|Participants will receive Quantum Acoustic Waves (QAW) three days per week for 12 weeks
61980457|NCT06340828|EXPERIMENTAL|Washing Microbiota Transplantation (WMT) group|After assessing the general condition and gastrointestinal symptoms of the patients upon admission, consecutive days of washing microbiota transplantation were conducted. The administration time was 3 p.m., administered via a nasogastric tube at a dosage of 50 ml per administration. A follow-up appointment at the hospital was scheduled for week 12 post-treatment to reinforce the therapeutic effect with a second treatment, following the same timing, dosage, and administration route as the first treatment.
61980458|NCT00817921||1|former premature children treated by ibuprofen
61980459|NCT00817921||2|former premature children not treated by ibuprofen
61980460|NCT00817921||3|former term children (control)
61980461|NCT04689295|OTHER|experiment group|Three dimensional scoliosis therapy method (Schroth) will be applied to the participants for 6 weeks. It consist of 15 different exercises combined with rotational breathing exercise.
61980462|NCT04689295|OTHER|control group|Traditional scoliosis exercises will be applied to the participants for 6 weeks. It consist of 6 different exercises
61980463|NCT04843774||COVID-negative Multiple Sclerosis patients treated with ocrelizumab|
61980464|NCT06101667|ACTIVE_COMPARATOR|Best medical management|Patients randomly assigned to the control group should receive the best medical management according to the guidelines.
61980465|NCT06101667|EXPERIMENTAL|Endovascular treatment|Stent retrievers, thromboaspiration, balloon angioplasty, stent deployment, intra-arterial thrombolysis (Recombinant tissue plasminogen activator (rt-PA) or urokinase), or the various combinations of these approaches.
61980466|NCT04329169|EXPERIMENTAL|Virtual Implant Planning|
61980467|NCT01155687||Psychosocial counseling|the group received annualized treatment of psychosocial counseling
61980468|NCT01155687||Medication|this group received medical treatment by the local medical doctor
61980469|NCT03900767|EXPERIMENTAL|Clinic-Level|"Clinics will receive the AAC intervention consisting of an EHR-based point of care alert that prompts clinic staff to Ask every patient about tobacco use, Advise tobacco using patients to quit, and Connect interested tobacco users to the Utah Tobacco Quit Line~Assigned Interventions = Electronic Health Record intervention AAC"
61980470|NCT03900767|EXPERIMENTAL|Phase I Group I (Continued EHR and text messages)|Patients receive a weekly text message for one month followed by a monthly text message over the next 5 months (i.e., 6 months of text messages following each tobacco users' clinic visit). All messages will include a motivational message, the Quit Line website, the Quit Line phone number, and simple two-touch response that directly connects interested tobacco users to the Quit Line.
61980471|NCT03900767|EXPERIMENTAL|Phase I Group II (Continued clinic-level EHR intervention only)|Patients receive continued clinic level EHR intervention only (CO).
61980472|NCT03900767|EXPERIMENTAL|Phase II Group I (Text messages, Counseling call)|Patients receive a monthly text message plus 2 brief telephone calls from patient navigators/health educators for 6-12 months following each tobacco user's clinic visit.
61980473|NCT03900767|EXPERIMENTAL|Phase II Group II (Text messages continued)|Patients receive a monthly text message for 6-12 months following each tobacco user's clinic visit that includes a simple one-touch response to directly connect to the Quitline.
61980474|NCT06441175|EXPERIMENTAL|D-V group|the group that performs direct laryngoscopy first and then videolaryngoscopy
61980475|NCT06441175|EXPERIMENTAL|V-D group|the group that performs videolaryngoscopy first and then directlaryngoscopy
61980476|NCT04247581|OTHER|Cohort 1|This will include subjects with no known history of AF and are in normal sinus rhythm at time of screening
61980477|NCT04247581|OTHER|Cohort 2|This will include subjects with known persistent or permanent AF who are in AF at the time of screening
61980478|NCT02697175|EXPERIMENTAL|Live Video-Colposcopy|Women are able to observe their colposcopic examination in real-time watching a flat screen in front of them
61980479|NCT02697175|ACTIVE_COMPARATOR|No Live Video-Colposcopy|Women are not able to observe their colposcopic examination in real-time
61980480|NCT03443284|EXPERIMENTAL|Intervention (Health Partner)|The mobile health (mHealth) product, Health Partner for Knees and Hips (Health Partner), is a combination of an iPhone or iPod Touch Operating System (iOS) mobile application (app) and a health care provider (HCP) portal.
61980481|NCT03443284|OTHER|Control|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Providence Health \& Services.
61980482|NCT02457910|EXPERIMENTAL|Taselisib 2 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
61980483|NCT02457910|ACTIVE_COMPARATOR|Enzalutamide|Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may crossover to receive Enzalutamide + Taselisib
61980484|NCT02457910|EXPERIMENTAL|Taselisib 4 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
61980485|NCT02457910|EXPERIMENTAL|Taselisib 6 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
61980486|NCT02457910|EXPERIMENTAL|Taselisib 8 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
62360007|NCT04190589|EXPERIMENTAL|Robotic CME|Robot-assisted extended right colectomy
61980487|NCT02457910|EXPERIMENTAL|Enzalutamide + Taselisib|Patients receive enzalutamide PO QD starting on day 1 of cycle 1, and will receive Taselisib PO QD starting on day 1 of cycle 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61980488|NCT02457910|EXPERIMENTAL|Cross-Over|Upon progression of disease, patients on the enzalutamide only arm will be allowed to crossover to enzalutamide + taselisib (must begin no later than 21 days after the clinic visit at which disease progression is determined) Enzalutamide and Taselisib will be taken PO QD
61980489|NCT03707314|OTHER|Group A: Immediate angiography|Immediate angiography with follow-on revascularisation if indicated
61980490|NCT03707314|OTHER|Group B: Standard of care angiography|Standard of care angiography with follow-on revascularisation if indicated (within 3-4 days, but will vary depending on recruiting centre)
61980491|NCT00745472||1|
61980492|NCT00745472||2|
61980493|NCT03341533|EXPERIMENTAL|Ice packs plus usual post-op analgesia|Ice pack applied to the abdomen and maintained continuously for the first 12 hours post-operatively. Standard standard post-operative analgesia orders will be followed in addition to use of ice.
61980494|NCT03341533|ACTIVE_COMPARATOR|Usual post-op analgesia|Standard post-operative analgesia only, no ice use.
61980495|NCT00867425|EXPERIMENTAL|Intervention|
61980496|NCT04425733|EXPERIMENTAL|Panel A MK-5475 180 µg|Participants receive 180 µg of MK-5475 once daily (QD) via inhalation from Days 1-7.
61980497|NCT04425733|PLACEBO_COMPARATOR|Panel A Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
61980498|NCT04425733|EXPERIMENTAL|Panel B MK-5475 360 µg|Participants receive 360 µg of MK-5475 QD via inhalation from Days 1-7.
61980499|NCT04425733|PLACEBO_COMPARATOR|Panel B Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
61980500|NCT04425733|EXPERIMENTAL|Panel C MK-5475 ≤360 µg|Participants receive ≤360 µg of MK-5475 QD via inhalation from Days 1-7.
61980501|NCT04425733|PLACEBO_COMPARATOR|Panel C Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
61980502|NCT00827879|EXPERIMENTAL|Strength at Home Couples Group|PTSD-Focused Cognitive Behavioral Therapy for Couples
61980503|NCT00827879|PLACEBO_COMPARATOR|Supportive Group Therapy|Supportive therapy for couples
61980504|NCT02180633||Fellow Eyes|Patients that suffer from unilateral idiopathic macular hole, and whose fellow eyes don't show any sign of retinal pathology.
61980505|NCT02180633||Controls|Healthy subjects age-matched to the other group, with no visible retinal pathologies.
61980506|NCT03060239|EXPERIMENTAL|Experimental arm|Patients with Parkinson's disease with severe REM sleep behaviour disorder according to International Classification of Sleep Disorders (ICSD2) criteria.
61980507|NCT05054959|EXPERIMENTAL|consolidation chemotherapy|"chemoradiation: intensity-modulated irradiation technique with simultaneous integrated boost to the tumor (IMRT-SIB) or with volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (VMAT-SIB) to the total tumor dose of 46.2 Gy in T1-3 tumors and 48.4 Gy in T4 tumors in 22 fractions with concomitant CT with capecitabine (dosage: 825 mg / m2 / 12 h per os continuously from the first to the last day of irradiation).~6 cycles of CAPOX chemotherapy. One cycle of CAPOX CT lasts 3 weeks and consists of capecitabine 1000 mg / m2 / 12h per os for 1-14 days and oxaliplatin 130 mg / m2 intravenously in a two-hour infusion on day 1."
61980508|NCT05054959|ACTIVE_COMPARATOR|induction chemotherapy|"4 cycles of induction CAPOX chemotherapy. One cycle of CAPOX CT lasts 3 weeks and consists of capecitabine 1000 mg / m2 / 12h per os for 1-14 days and oxaliplatin 130 mg / m2 intravenously in a two-hour infusion on day 1.~Chemoradiation:intensity-modulated irradiation technique with simultaneous integrated boost to the tumor (IMRT-SIB) or with volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (VMAT-SIB) to the total tumor dose of 46.2 Gy in T1-3 tumors and 48.4 Gy in T4 tumors in 22 fractions with concomitant CT with capecitabine (dosage: 825 mg / m2 / 12 h per os continuously from the first to the last day of irradiation).~2 cycles of consolidation CAPOX chemotherapy."
61980509|NCT01346839|EXPERIMENTAL|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
61980510|NCT01346839|NO_INTERVENTION|Usual Care Control|"The usual care at MEDVAMC consists of providers using an advanced EHR and its notification system (the View Alert system) that immediately alerts providers about clinically significant events. The system relies primarily on computerized notification (alerts) displayed prominently through a View Alert window that is displayed in the EHR every time a provider signs on or switches between patient records. The system does not require providers to read alerts, and providers do have an option of ignoring the View Alert window to bypass it. At SWHS there is a navigation program for patients who have received a cancer diagnosis by tissue biopsy. However, currently there is no routine tracking of patients if they do not show for their scheduled appointments and tests at SWHS."
61980511|NCT03506607|EXPERIMENTAL|Exercise in hypoxia 1500m|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 16%.
61980512|NCT03506607|EXPERIMENTAL|Exercise in hypoxia 2500m|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 14%.
61980513|NCT03506607|PLACEBO_COMPARATOR|Exercise in normoxia|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). For the exercise performed in normoxia conditions, subjects will breathe room air.
62360008|NCT01441518|EXPERIMENTAL|Home care|
61980514|NCT03775057|EXPERIMENTAL|MyDose Coach app intervention|The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
61980515|NCT04101903|EXPERIMENTAL|Diagnostic Aid|The experimental group will use the trial diagnostic aid for all 6-week infant hip checks
61980516|NCT04101903|NO_INTERVENTION|Standard of Care|The control group will assess infants according to standard practice, during the 6-week hip check.
61980517|NCT02557698|EXPERIMENTAL|Balneum oil bath|Balneum oil bath, bathing every other day for four weeks
61980518|NCT02557698|NO_INTERVENTION|standard skin cleanser|Usual skin cleanser (non-oil containing), bathing or showering every other day for four weeks
61980519|NCT01895660|EXPERIMENTAL|Group with continuous constraint and daily therapy|
61980520|NCT01895660|EXPERIMENTAL|Group with continuous constrainit and 3 days a week therapy|
61980521|NCT01895660|EXPERIMENTAL|Group with part-time constraint and daily therapy|
61980522|NCT01895660|EXPERIMENTAL|Group with part-time constraint and 3 days a week therapy|
61980523|NCT01895660|ACTIVE_COMPARATOR|Usual and customary treatment group|
61980524|NCT06407544|ACTIVE_COMPARATOR|Group (Q):|including 20 patients with hip fractures will undergo ultrasound guided anterior QLB, will be administered 0.3 ml/kg of 0.125% bupivacaine (containing 1 mic/ml of dexmedetomidine and 5 mg of dexamethasone).
61980525|NCT06407544|ACTIVE_COMPARATOR|Group (F):|including 20 patients with hip fractures will undergo ultrasound guided FIB, will be administered 0.3 ml/kg of 0.125% bupivacaine (containing 1 mic/ml of dexmedetomidine and 5 mg of dexamethasone).
61980526|NCT06407544|ACTIVE_COMPARATOR|Group (C):|including 20 patients with hip fractures will receive ultrasound scanning for QLB or FIB with saline injection \[26\].
61980527|NCT02939235|ACTIVE_COMPARATOR|Crushed ticagrelor followed by morphine|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously
61980528|NCT02939235|ACTIVE_COMPARATOR|Crushed ticagrelor, morphine,metoclopramide|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
61980529|NCT05587400|EXPERIMENTAL|patients with pulmonary artery hypertension and/or right ventricular dysfunction|
61980530|NCT05592782|EXPERIMENTAL|Study Arm|
61980531|NCT06201533|EXPERIMENTAL|Low-intensity, combined physical-cognitive exercise|The exercise program will be prescribed at low intensity for 50 minutes/session, 3 times /week for 12 consecutive weeks.
61980532|NCT06201533|NO_INTERVENTION|Control|Participants will be asked to maintain their routine lifestyle throughout the study period.
61980533|NCT00812370|EXPERIMENTAL|open label|
61980534|NCT00514540|EXPERIMENTAL|First-Line/Second-Line Chemotherapy|"First-Line (CD) Chemotherapy: Carboplatin area under the curve (AUC) = 5, intravenous (IV) over 30 minutes and Docetaxel 75 mg/m\^2 IV over 60 minutes, Day 1. Repeated every 3 weeks.~Second-Line (EP) Chemotherapy: Etoposide 120 mg/m\^2 daily for 3 days and Cisplatin 25 mg/m\^2 for 3 days with adequate intravenous hydration mannitol diuresis and supportive care (antiemetics). Repeated every 3 weeks."
61980535|NCT03407378|EXPERIMENTAL|Assessments ON regular PD treatment|IPT803 Questionnaires Motor assessments on regular PD treatment Optional pharmacogenetic assessments Optional Blood-Oxygen-level Dependent Functional-MRI
61980536|NCT03407378|EXPERIMENTAL|Assessments OFF regular PD treatment|IPT803 Questionnaires Motor assessments before taking regular PD treatment Optional pharmacogenetic assessments Optional Blood-Oxygen-level Dependent Functional-MRI
61980537|NCT02384707|EXPERIMENTAL|allergic food|"Reintroduction procedure for small doses :~* Administration of the first dose the first dose must be allergic food or placebo~* Clinical monitoring for 45 minutes~* Administration of the second dose"
61980538|NCT00665847|EXPERIMENTAL|Etravirine (TMC125)|
61980539|NCT03953573||Women post-delivery|
61980540|NCT03173599|EXPERIMENTAL|PNA 40mg|"Metacavir Enteric-coated Capsules,oral before meal~The beginning dose is 40mg,If no adverse effects were observed in 40 mg, the next dose group was started of 80mg."
61980541|NCT03173599|EXPERIMENTAL|PNA 80mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 80mg,If no adverse effects were observed in 80 mg, the next dose group was started of 160mg."
61980542|NCT03173599|EXPERIMENTAL|PNA 160mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 160mg,If no adverse effects were observed in 160 mg, the next dose group was started of 240mg."
61980543|NCT03173599|EXPERIMENTAL|PNA 240mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 240mg,If no adverse effects were observed in 240 mg, the next dose group was started of 360mg."
61980544|NCT03173599|EXPERIMENTAL|PNA 360mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 360mg,If no adverse effects were observed in 360 mg, the next dose group was started of 480mg."
61980545|NCT03173599|EXPERIMENTAL|PNA 480mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 480mg."
61980546|NCT03173599|PLACEBO_COMPARATOR|PNA Placebo|"Metacavir Enteric-coated Capsules Placebo,oral before meal~The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg"
61980547|NCT04187560|ACTIVE_COMPARATOR|Part A Cohort 1|LB-102 50 mg (n=6) or Matching Placebo (n=2) x 1 day
61980548|NCT04187560|ACTIVE_COMPARATOR|Part A Cohort 2|LB-102 15 mg (n=6) or Matching Placebo (n=2) x 1 day
61980549|NCT04187560|ACTIVE_COMPARATOR|Part A Cohort 3|LB-102 100 mg (n=6) or Matching Placebo (n=2) x 1 day
61980550|NCT04187560|ACTIVE_COMPARATOR|Part A Cohort 4|LB-102 200 mg (n=6) or Matching Placebo (n=2) x 1 day
61980551|NCT04187560|ACTIVE_COMPARATOR|Part A Cohort 5|LB-102 150 mg (n=6) or Matching Placebo (n-2) x 1 day
61980552|NCT04187560|ACTIVE_COMPARATOR|Part B Cohort 6|LB-102 50 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
61980553|NCT04187560|ACTIVE_COMPARATOR|Part B Cohort 7|LB-102 100 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
61980554|NCT04187560|ACTIVE_COMPARATOR|Part B Cohort 8|LB-102 75 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
61980555|NCT03657706|ACTIVE_COMPARATOR|group A|tunnel procedure with subepithelial connective tissue graft (sCTG)
61980556|NCT03657706|ACTIVE_COMPARATOR|group B|tunnel procedure with modified free gingival graft (mFGG)
61980557|NCT04517565|EXPERIMENTAL|Patients with SWS or high-risk facial port-wine birthmark|All patients with SWS brain involvement (based on previous imaging) or facial port-wine birthmark indicating a high risk for SWS brain involvement will undergo a brain MRI and neuro-psychology testing.
61980558|NCT05931250|EXPERIMENTAL|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) device using 50x70 mm electrodes that are placed bilaterally between EEG coordinates C3/C5 for left hemisphere and C4/C6 for right hemisphere (corresponding to S1 and M1 of the eye). The alternating current electrodes are in-phase and have the same peak to peak stimulation 3mA, for 30 minutes duration at 10Hz. An impedance value under 15 ohms is required at all times to ensure patient comfort and safety.
61980559|NCT05931250|EXPERIMENTAL|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) device using 50x70 mm electrodes that has the anodal electrode placed contralateral to most prominent ocular pain or, in the case of bilateral pain symptoms, contralateral to the dominant hand between EEG coordinates C3/C5 for left hemisphere and C4/C6 for right hemisphere (corresponding to S1 and M1 of the eye), and the cathode placed on the patient's upper arm. A current peaking at 3mA will ramp up for 20 secs and be delivered for a total of 20 minutes, thereafter, ramping down for 20s. An impedance value under 15 ohms is required at all times to ensure patient comfort and safety.
61980560|NCT01758783|PLACEBO_COMPARATOR|placebo group|
61980561|NCT01758783|EXPERIMENTAL|Glutamine group|
61980562|NCT03301142|EXPERIMENTAL|Device laser|treatment with application of Erbium Laser: YAG 2940nm, SMOOTH mode, one session per month for three months (n=20
61980563|NCT03301142|ACTIVE_COMPARATOR|kinesiotherapy|with supervision twice a week for three months (n=20)
61980564|NCT03522974|PLACEBO_COMPARATOR|Placebo|40 g/d placebo powder
62360009|NCT01441518|ACTIVE_COMPARATOR|Hospital care|
62360010|NCT06112067|EXPERIMENTAL|DBS intervention group|This is a single arm, prospective, open label clinical study, participants who fit inclusion standards, don't fit exclusion standards and fit surgical implantation standard will start DBS system stimulation and adjust parameters after 7-14 days of implantation. Then after stimulation for 8-24 weeks, they will be evaluated for treatment efficacies. This study is extendable, with agreements from participants, long term efficacy and safety follow-up study will be performed after 24 weeks ± 7 days, specific plan depends on different mental disorders.
61980565|NCT03522974|EXPERIMENTAL|Strawberry powder (high dose)|40 g/d freeze dried strawberry powder
62360011|NCT04134169||Rheumatoid arthritis|
61980566|NCT03522974|ACTIVE_COMPARATOR|Strawberry powder (low dose)|13 g/d freeze dried strawberry powder
61980567|NCT02945033|EXPERIMENTAL|Patient with aspirin intake|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines. Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece. If the mutation is detected, patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years. Blood intake will be done every 6 months to evaluate patient compliance to treatment
61980568|NCT02945033|PLACEBO_COMPARATOR|Patient with placebo intake|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines. Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece. If the mutation is detected, patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years. Blood intake will be done every 6 months to evaluate patient compliance to treatment
61980569|NCT03866343|ACTIVE_COMPARATOR|Low AGE diet|Subjects will be asked to consume a diet containing a low AGE content for 4 weeks.
61980570|NCT03866343|OTHER|High AGE diet|Subjects will be asked to consume a diet containing a high AGE content for 4 weeks.
61980571|NCT05324995|EXPERIMENTAL|Multimodal injection|The first group was treated using a preemptive periarticular injection of multimodal drugs. Therefore, a combination of drugs consisted of 50 mg bupivacaine hydrochloride 0.5% (AstraZeneca, Cenexi, France), 1 ml morphine sulfate 10 mg/ml (DarouPakhsh, Tehran, Iran), 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) and 30 mg ketorolac (Caspian Tamin, Rasht, Iran) diluted by 0.9% sodium chloride solution to make a total 100 ml of injection drug was injected in periarticular area. The injections were done within 15 minutes before the incision in seven areas of the joint as followed: 15 ml in posterolateral soft tissue and lateral femoral periosteum, 15 ml posteromedial soft tissue and medial femoral periosteum, 20 ml inferomedial capsule, 20 ml superomedial capsule, 10 ml lateral capsule, 10 ml medial subcutaneous tissues and 10 ml lateral subcutaneous tissue.
61980572|NCT05324995|EXPERIMENTAL|epinephrine group (placebo group)|The second group received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary, similar to the first group.
61980573|NCT05324995|EXPERIMENTAL|celecoxib group (control group)|The third group administered celecoxib (200 mg) orally immediately before the surgery initiation.
61980574|NCT02757742||Non-ischemic cardiomyopathy|Non-ischemic cardiomyopathy patients with baseline cardiac magnetic resonance LVEF≤35%
61980575|NCT05815472|EXPERIMENTAL|Patients affected by locally advanced non-small-cell lung cancer|"Patients affected by locally advanced non-small-cell lung cancer (staged III according to 8th TNM classification), undergoing induction therapy (IT) followed by either radical surgery or immunotherapy boost and treated in Fondazione Policlinico Universitario A. Gemelli IRCCS of Rome, Italy, will be enrolled in this study."
61980576|NCT05542264|ACTIVE_COMPARATOR|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|
61980577|NCT05542264|EXPERIMENTAL|SEP-363856|
61980578|NCT01045889|EXPERIMENTAL|R-CHOP + PBSCT|All patients will receive chemoimmunotherapy with Rituximab + CHOP regimen for 6 cycles followed by high dose cyclophosphamide and stem cell collection, then high dose therapy with BEAM conditioning regimen and peripheral blood stem cell transplantation
61980579|NCT03814291|EXPERIMENTAL|cohort 1 IBI302 treated with first dose level of IBI302|
61980580|NCT03814291|EXPERIMENTAL|cohort 2 IBI302 treated with second dose level of IBI302|
62360012|NCT05387213|EXPERIMENTAL|Huddle attendees|Participants in this arm participated in huddles
62360013|NCT05387213|NO_INTERVENTION|Huddle non-attendees|Participants in this arm did not participate in huddles
62360014|NCT03020264|EXPERIMENTAL|Patients older than 75 years|Collection of hypoglycaemia épisodes with the glycemic sensor FREESTYLE Libre Pro
62360015|NCT02062242|EXPERIMENTAL|Transvaginal electrical stimulation|Patients treated with transvaginal electrical stimulation.
62360016|NCT02062242|EXPERIMENTAL|Palpation|Patients treated with vaginal palpation.
62360017|NCT02062242|EXPERIMENTAL|Palpation with posterior pelvic tilt|Patients treated with vaginal palpation associated with posterior pelvic tilt and contraction of accessory muscles.
62360018|NCT02062242|EXPERIMENTAL|Control group|Patients receive verbal instructions related to the pelvic floor and its contraction.
61980581|NCT03814291|EXPERIMENTAL|cohort 3 IBI302 treated with third dose level of IBI302|
61980582|NCT03814291|EXPERIMENTAL|cohort 4 IBI302 treated with fourth dose level of IBI302|
61980583|NCT03814291|EXPERIMENTAL|cohort 5 IBI302 treated with fifth dose level of IBI302|
61980584|NCT03814291|EXPERIMENTAL|cohort 6 IBI302 treated with sixth dose level of IBI302|
62360019|NCT02479295|ACTIVE_COMPARATOR|Straight Tenckhoff catheter|Tenckhoff catheter with straight intra-abdominal part
62360020|NCT02479295|ACTIVE_COMPARATOR|Coiled Tenckhoff catheter|Tenckhoff catheter with coiled intra-abdominal part
62360021|NCT05134597||Group 1 - Patients with Chronic Venous Disease (CVD)|Patients with CVD at different stages, according to CEAP Classification of Chronic Venous Disorders, will be recruited.
62360022|NCT05134597||Group 2 - Healthy subjects without Chronic Venous Disease (CVD)|Voluntary healthy subjects without Chronic Venous Disease (CVD) will be recruited.
62360023|NCT04011319|NO_INTERVENTION|convention culture|Each droplet separate culturing an individual embryo.
62360024|NCT04011319|EXPERIMENTAL|group culture|Embryos were cultured in the same droplet.
61980585|NCT03512509|EXPERIMENTAL|A|Low glycaemic potato
61980586|NCT03512509|EXPERIMENTAL|B|High glycaemic potato
61980587|NCT06155331|PLACEBO_COMPARATOR|Placebo group|22 patients which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle is given every 21 day) plus placebo tablets once daily.
61980588|NCT06155331|ACTIVE_COMPARATOR|Fenofibrate group|22 patients which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle is given every 21 day) plus Fenofibrate 160 mg once daily.
61980589|NCT00744627|PLACEBO_COMPARATOR|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
61980590|NCT00744627|EXPERIMENTAL|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
61980591|NCT04853927|ACTIVE_COMPARATOR|Proxalutamide + Standard of Care|Proxalutamide + standard of care as determined by the PI
61980592|NCT04853927|PLACEBO_COMPARATOR|Placebo + Standard Care|Placebo + Standard of care as determined by the PI
61980593|NCT01382979|EXPERIMENTAL|Alcohol education and prevention|AlcoholEdu is an online course designed to prevent alcohol misuse and related problems among college freshmen.
61980594|NCT01382979|NO_INTERVENTION|Control|Control group.
61980595|NCT05153044|OTHER|sickle cell children group|sickle cell children group
61980596|NCT05153044|OTHER|sickle cell adult group|sickle cell adult group
61980597|NCT05153044|OTHER|control children group|control children group
61980598|NCT05153044|NO_INTERVENTION|Vaccinated patients|Vaccinated patients
61980599|NCT03627689|EXPERIMENTAL|Active air purifier arm|Active portable air purifier for 1 month at bedside
62360025|NCT05870670|EXPERIMENTAL|NNC0519-0130|Escalating multiple doses of NNC0519-0130 administered subcutaneously.
62360026|NCT05870670|PLACEBO_COMPARATOR|Placebo|Escalating multiple doses of NNC0519-0130 matching placebo administered subcutaneously.
62360027|NCT03385694||Assessment|All the patients operated on Van Nes Rotationplasty for bone tumors at IOR and long term surviving
62360028|NCT01693861||Patients|Patients with metastatic colorectal cancer treated with chemotherapy
62360029|NCT02104323|EXPERIMENTAL|Endostatin，treatment effect evaluation|Patients receive continuous intravenous Endostatin drug pumping during the course of treatment. The drug dosage is 7.5mg/m2/d. Every course of treatment lasts three months. Patients are designed to receive total three courses of treatment if there is no disease progression. The interval between two courses is one month.
62391387|NCT01874288|EXPERIMENTAL|DI-Leu16-IL2 4.0 mg/m^2|Participants will receive DI-Leu16-IL2 4.0 mg/m\^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles
62391388|NCT01874288|EXPERIMENTAL|DI-Leu16-IL2 6.0 mg/m^2|Participants will receive DI-Leu16-IL2 6.0 mg/m\^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
61980600|NCT03627689|SHAM_COMPARATOR|Sham air purifier arm|Placebo portable air purifier for 1 month at bedside
61980601|NCT04905173|EXPERIMENTAL|Hypertrophic Cardiomyopathy|Subjects with a documented diagnosis of hypertrophic cardiomyopathy (HCM) will have an echocardiogram at rest followed by an echocardiogram with Valsalva maneuver as part of regular care. If these tests show no severe obstruction, subjects will continue with both squat-to-stand and amyl nitrite.
61980602|NCT05501028||Patients scheduled for consult with gastroenterologist|
61980603|NCT05501028||Patients scheduled for diagnostic endoscopy|
61980604|NCT02734979|EXPERIMENTAL|Biobridge and lymph node transfer|The investigators will investigate whether addition of the Biobridge scaffold to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm. The investigators will perform lymph scans (lymphoscintigrams) before surgery and one year following surgery to determine the success of the surgery. In addition, the volume of the operated arm will be monitored by repeated measurement with a tape measure. The investigators will also track bioimpedance, a painless technique to detect fluid in the tissues. The investigators will obtain small skin biopsies and blood samples to detect the biological changes that may occur as a result of successful surgery.
61980605|NCT04567433||CHEST Study|Participants in the CHEST trial long term sepsis cohort
61980606|NCT04567433||ARISE Study|Participants in the ARISE study long term follow-up cohort
61980607|NCT04567433||ADRENAL study|Participants in the ADRENAL study
61980608|NCT00156533|PLACEBO_COMPARATOR|Placebo|QHS dosing with placebo (i.e. nightly dose)
61980609|NCT00156533|ACTIVE_COMPARATOR|QHS Zolpidem|QHS dosing with 10mg of zolpidem (i.e. nightly dose)
61980610|NCT00156533|EXPERIMENTAL|Intermittant Zolpidem|Intermittent dosing with 10mg of zolpidem (3-5 pills per week as needed
61980611|NCT00156533|NO_INTERVENTION|Control|Monitor only condition (no placebo, no drug).
61980612|NCT03755687|EXPERIMENTAL|Art Therapy Intervention|Standardized mixed media art therapy directives (e.g. drawing/painting/collaging within a circle)
61980613|NCT00310531|EXPERIMENTAL|Arm 1|
61980614|NCT00310531|ACTIVE_COMPARATOR|Arm 2|
61980615|NCT01525550|EXPERIMENTAL|sunitinib|
61980616|NCT03234751|ACTIVE_COMPARATOR|Obese nondiabetic insulin resistant subjects- Panel A|IV nesiritide 3 pmol/kg/min or placebo for nesiritide
61980617|NCT03234751|ACTIVE_COMPARATOR|Obese nondiabetic insulin resistant subjects- Panel B|IV nesiritide 2 pmol/kg/min or placebo for nesiritide
61980618|NCT03580317|EXPERIMENTAL|EA + Carbamazepine Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including electroacupuncture(EA) treatment and combined with Carbamazepine (0.1g each time, thrice daily). The follow-up period is 6 months.
61980619|NCT03580317|PLACEBO_COMPARATOR|EA + Placebo Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including EA treatment and combined with placebo of carbamazepine. The follow-up period is 6 months.
61980620|NCT03580317|ACTIVE_COMPARATOR|Sham EA+ Carbamazepine Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham electroacupuncture(sham EA) intervention and combined with carbamazepine. The follow-up period is 6 months.
61980621|NCT03580317|SHAM_COMPARATOR|Sham EA+ Placebo Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham EA intervention and combined with placebo took orally. The follow-up period is 6 months.
61980622|NCT03874897|EXPERIMENTAL|CAR-CLDN18.2 T-Cells|The subjects enrolled will be sequentially assigned to the corresponding dose level.
61980623|NCT03874897|EXPERIMENTAL|Cohort 1|CT041 monotherapy in patients with GI cancers who failed standard chemotherapy
61980624|NCT03874897|EXPERIMENTAL|Cohort 2|CT041 plus anti-PD1 therapy in patients with GI cancers who failed standard chemotherapy
61980625|NCT03874897|EXPERIMENTAL|Cohort 3|CT041 sequential treatment after first-line therapy in GC/GEJ
61980626|NCT03874897|EXPERIMENTAL|Cohort 4|prior treatment failure to anti-CLDN18.2 monoclonal antibody
61980627|NCT03527095|EXPERIMENTAL|Regimen A|FDL169 200 mg reference tablet
61980628|NCT03527095|EXPERIMENTAL|Regimen B|FDL169 200 mg testing tablet 1
61980629|NCT03527095|EXPERIMENTAL|Regimen C|FDL169 200 mg testing tablet 2
61980630|NCT03527095|EXPERIMENTAL|Regimen D|FDL169 200 mg testing tablet 1 or 2 with high fat diet
61980631|NCT03527095|EXPERIMENTAL|Regimen E|FDL169 200 mg testing tablet 1 or 2, fasted
61980632|NCT03527095|EXPERIMENTAL|Regimen F|FDL169 200 mg testing tablet 1 or 2, with standard diet
61980633|NCT06213168|EXPERIMENTAL|HFNC|Patients assigned to the control group will be continuously treated by HFNC. HFNC will be initiated within one hour following randomization.
61980634|NCT06213168|EXPERIMENTAL|HFNC with CPAP|Patients assigned to the intervention group will receive high flow nasal oxygen plus CPAP sessions
61980635|NCT03715218|EXPERIMENTAL|Mother Touch Program|Post natal care provided by trained carer after the birth. 6 weeks of care included massage, special diet, physical and mental relaxations.
62360030|NCT04285853|EXPERIMENTAL|Oxycodone Arm|"Patients in this opioid group will receive 15 oral opioid tablets (5 mg oxycodone) Patients will also receive 8 rescue medications, in the Oxycodone arm will be placebo rescue medications.~All participants will also receive the following as part of standard of care:~1. Oral non-opioid (1000 mg acetaminophen), every 8 hours.~2. Prescription of non-opioid non-steroidal anti-inflammatory medication (naproxen 500 mg) to be used 2x/day post-surgery.~3. Standardized multimodal intra- and post-operative protocols, including an adductor canal peripheral nerve block.~4. Intraoperative education on post-surgical pain management."
62391389|NCT02357108|ACTIVE_COMPARATOR|Group 1: Video/Doctor Sequence 1|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
61980636|NCT03715218|OTHER|Usual care Program|Usual care and supervision was provided as usual.
61980637|NCT05164042|EXPERIMENTAL|Treatment group|Subjects who meet the enrollment conditions will receive intravenous infusion of allogeneic CD19 CAR-T cells after pretreatment.
61980638|NCT01721187||Low disinhibition|fMRI during fed and fasted states
61980639|NCT01721187||High disinhibition|fMRI during fed and fasted states
61980640|NCT01214161|EXPERIMENTAL|lidocaine gel|This group will be those randomized to receiving the intervention with 2% lidocaine gel.
61980641|NCT01214161|PLACEBO_COMPARATOR|placebo gel (surgilube)|This group will be randomized to having the intervention with the placebo surgilube gel.
61980642|NCT00473460|EXPERIMENTAL|Arm 1|
61980643|NCT00473460|PLACEBO_COMPARATOR|Arm 2|
61980644|NCT03273790||NSCLC patients|Initiated Nivolumab treatment at least once from 01 Apr. 2016 through 31 Dec. 2016
61980645|NCT03637972|EXPERIMENTAL|Ventilated cigarettes only|Filters with approximately 30-36% filter ventilation
61980646|NCT03637972|EXPERIMENTAL|Unventilated cigarettes only|Filters with approximately 3.0-4.6% filter ventilation
61980647|NCT03637972|EXPERIMENTAL|Ventilated cigarettes + alternative nicotine delivery systems|Filters with approximately 30-36% filter ventilation and access to alternative nicotine delivery systems including e-cigarette/vaping device, medicinal nicotine (lozenge, gum and patch).
61980648|NCT03637972|EXPERIMENTAL|Unventilated cigarettes + ANDS|Filters with approximately 3.0-4.6% filter ventilation and access to alternative nicotine delivery systems including e-cigarette/vaping device, medicinal nicotine (lozenge, gum and patch).
61980649|NCT00500851|ACTIVE_COMPARATOR|1|In case of meeting clinical criteria for jejunal feeding, tubes are placed using CORTRAK (electromagnetic imaging).
61980650|NCT00500851|ACTIVE_COMPARATOR|2|Endoscopic placement of jejunal feeding tubes fulfilling clinical indication for jejunal feeding.
61980651|NCT00277433||Atopic Dermatitis|
61980652|NCT00277433||Non-atopic control|
61980653|NCT03063658|ACTIVE_COMPARATOR|Paracetamol|Paracetamol (Paracerol) 1 gram will be administered intravenously. The first dose will be infused for 10 minutes after the induction of anesthesia and before the first surgical incision. The remaining three doses will be administered every 6 hours for postoperative 24 hours.
61980654|NCT03063658|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen (Intrafen) 800 mg will be administered intravenously. The first dose will be infused for 10 minutes after the induction of anesthesia and before the first surgical incision. The remaining three doses will be administered every 6 hours for postoperative 24 hours.
61980655|NCT05844189|EXPERIMENTAL|Treatment Group|CRMRF and physical therapy modalities on pelvic floor.
61980656|NCT05844189|SHAM_COMPARATOR|Sham Group|Only physical therapy modalities on pelvic floor. In this Arm the CRMRF is off.
61980657|NCT04953221||M1 Test group|YJ001 for spray, topical application on the skin, drug concentration 100mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
61980658|NCT04953221||M1 control group|YJ001 simulant for spray, topical application on the skin, drug concentration 100mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
61980659|NCT04953221||M2 Test group:|YJ001 for spray, topical application on the skin, drug concentration 150mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
61980660|NCT04953221||M2 control group:|YJ001 simulant for spray, topical application on the skin, drug concentration 150mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
61980661|NCT04953221||M3 Test group|YJ001 for spray, topical application on the skin, drug concentration 200mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
61980662|NCT04953221||M3 control group|YJ001 simulant for spray, topical application on the skin, drug concentration 200mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
61980663|NCT00331279|ACTIVE_COMPARATOR|Cinnamon Extract|A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
61980664|NCT00331279|PLACEBO_COMPARATOR|Placebo|
61980665|NCT03032666|EXPERIMENTAL|sofosbuvir/velpatasvir|Epclusa
61980666|NCT01127412|ACTIVE_COMPARATOR|Physical activity stimulating program|Advices to stimulate motor activity and motor development at the age of two weeks, two months, four months, eight months and eleven months
62360031|NCT04285853|PLACEBO_COMPARATOR|Placebo Arm|"Patients in placebo group will receive 15 placebo tablets. All patients will also receive 8 rescue medications: Patients who randomize to the non-opioid arm will receive 5mg oxycodone rescue tablets.~All participants will also receive the following as part of standard of care:~1. Oral non-opioid (1000 mg acetaminophen), every 8 hours.~2. Prescription of non-opioid non-steroidal anti-inflammatory medication (naproxen 500 mg) to be used 2x/day post-surgery.~3. Standardized multimodal intra- and post-operative protocols, including an adductor canal peripheral nerve block.~4. Intraoperative education on post-surgical pain management."
61980667|NCT01127412|NO_INTERVENTION|Control|
61980668|NCT00390325|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity.
61980669|NCT02020395|PLACEBO_COMPARATOR|Test meal (500 kcal)_normal weight|ham sandwich chocolate cream orange juice
61980670|NCT02020395|ACTIVE_COMPARATOR|Test meal (500 kcal)_obese weight|ham sandwich chocolate cream orange juice
61980671|NCT01818154|EXPERIMENTAL|Minimal Erythema Dose LED|A 2 x 2 cm section of skin will be exposed to LED light.
61980672|NCT01818154|PLACEBO_COMPARATOR|Minimal Erythema Dose narrow band UVB|A 2 x 2 cm section of skin will be exposed to narrow band UVB light.
61980673|NCT05990543|EXPERIMENTAL|Group 1|Nelmastobart + Capecitabine
61980674|NCT03071575|ACTIVE_COMPARATOR|Group A:|Group A will receive a measles-rubella vaccine dose at 6 and 9 months
61980675|NCT03071575|ACTIVE_COMPARATOR|Group B:|Group B will receive a measles-rubella dose at 9 months only
61980676|NCT01019642|EXPERIMENTAL|Vitamin D|Cholecalciferol, 4,000 IU/d for 6 months
61980677|NCT01019642|PLACEBO_COMPARATOR|Placebo|placebo
61980678|NCT02979847|EXPERIMENTAL|Treated|hybrid approach (epicardial and subsequent endocardial mappings and ablations)
61980679|NCT02979847|ACTIVE_COMPARATOR|Control|conventional endocardial approach
61980680|NCT04351087|ACTIVE_COMPARATOR|Platelet Rich Plasma|157cc of whole blood will be harvested via standard venipuncture from the antecubital fossa and mixed with 24cc ACD-A (manufacturer recommends 8cc ACD-A per 52cc of whole blood). 156ml of whole blood will be processed in the FDA Cleared Angel cPRP system at 2% hematocrit. 1ml of whole blood and the resultant PRP will be analyzed in the Sysmex XN-350 for complete analysis (platelet, leukocyte, red blood cell counts). The remaining PRP will be injected under sterile technique using ultrasound-guidance through a superolateral approach. For patient comfort, 2cc of 1% lidocaine can be administered using a 26-gauge needle (into soft tissues only). PRP will then be injected using a 25-guage needle. A maximum of 6ml of PRP will be injected. Injection site will be cleaned and bandaged and patient will be dismissed with post-injection precautions and 1 month follow-up scheduled.
61980681|NCT04351087|ACTIVE_COMPARATOR|Microfragmented adipose tissue|Adipose is aspirated from the subcutaneous tissue of the buttock or abdomen. Aspiration site is injected with 10ml 1% lidocaine with epinephrine. A small poke incision is made with an 11-blade scalpel. Then 120ml of Klein solution is injected into the adipose tissue. Solution sits for 15 minutes to allow for adequate anesthesia. Aspiration cannula is inserted and moved in a back and forth motion for 2 minutes to allow for adipose aspiration. 30ml fat will be aspirated. Aspiration site is cleaned and bandaged. The aspirated fat is processed using the Lipogems system. 30ml of adipose is transferred to the device, saline is run through the device to remove oils and then approximately 5-7ml of adipose tissue is removed and ready for injection. The Microfragmented adipose tissue are then injected in identical fashion to the PRP above.
61980682|NCT02703909|EXPERIMENTAL|moderate NMB + 10 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate neuromuscular block (NMB) which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
61980683|NCT02703909|ACTIVE_COMPARATOR|moderate NMB + 15 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate NMB which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 15 mm Hg pressure. This arm represents the usual operating conditions for this type of surgery at the University hospital.
61980684|NCT02703909|EXPERIMENTAL|deep NMB + 10 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 10 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
61980685|NCT02703909|EXPERIMENTAL|deep NMB + 15 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 15 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
61980686|NCT05187793|EXPERIMENTAL|Olokizumab|"Subject randomized to receive intravenous infusion of 0,8 ml solution of Olokizumab, one (128 mg), or two (256 mg) doses, in addition to standard therapy in line with the current temporary guidelines Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) of the Ministry of Health of Russian Federation.~Standard therapy includes:~* Baricitinib, p.o., 4 mg once daily for 7 days~* Favipiravir, p.o.,~  * for patients weighing \<75 kg: 1600 mg twice daily on Day 1, then 600 mg twice daily from the 2nd to the 10th day;~ * for patients weighing ≥ 75 kg: 1800 mg twice daily on Day 1, then 800 mg twice daily from the 2nd to the 10th day; (Patients who have started etiotropic therapy with favipiravir or remdesivir prior to randomization will continue the initiated treatment.)~* dexamethasone at doses of 4 - 20 mg / day or methylprednisolone at a dose of 1 mg / kg / intravenous injection every 12 hours."
61980687|NCT05187793|ACTIVE_COMPARATOR|Standard therapy|"Standard therapy in line with the current temporary guidelines Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) of the Ministry of Health of Russian Federation including:~* Baricitinib, p.o., 4 mg once daily for 7 days~* Favipiravir, p.o.,~  * for patients weighing \<75 kg: 1600 mg twice daily on Day 1, then 600 mg twice daily from the 2nd to the 10th day;~ * for patients weighing ≥ 75 kg: 1800 mg twice daily on Day 1, then 800 mg twice daily from the 2nd to the 10th day; (Patients who have started etiotropic therapy with favipiravir or remdesivir prior to randomization will continue the initiated treatment.)~* dexamethasone at doses of 4 - 20 mg / day or methylprednisolone at a dose of 1 mg / kg / intravenous injection every 12 hours."
61980688|NCT01909479|EXPERIMENTAL|MOD-4023|
61980689|NCT01909479|PLACEBO_COMPARATOR|Placebo|
61980690|NCT02402309|EXPERIMENTAL|Active topical NS2 1% dermatologic cream|NS2 1% topical cream for dermal application
61980691|NCT02402309|PLACEBO_COMPARATOR|Topical vehicle dermatologic|Vehicle placebo for dermal application
61980692|NCT02188290||HAPLO group|Control group of all eligible patients who received an HSCT from a haploidentical donor without ATIR administration between 1 January 2006 and 30 June 2013
61980693|NCT02188290||MUD group|Control group of eligible patients who received an HSCT from a fully matched unrelated donor between 1 January 2010 and 31 December 2012
61980694|NCT02188290||MMUD group|Control group of eligible patients who received an HSCT from a 1-locus mismatched unrelated donor between 1 January 2010 and 31 December 2012
61980695|NCT02188290||UCB group|Control group of eligible patients who received a double umbilical cord blood transplantation between 1 January 2010 and 31 December 2012
61980696|NCT01364662|EXPERIMENTAL|1|
61980697|NCT01364662|EXPERIMENTAL|2|
61980698|NCT01364662|EXPERIMENTAL|3|
61980699|NCT01364662|EXPERIMENTAL|4|
61980700|NCT01453634|EXPERIMENTAL|Lunacalcipol 180|180 µg (n=4)Lunacalcipol Injection
61980701|NCT01453634|EXPERIMENTAL|Lunacalcipol 270|270 µg (n=8)Lunacalcipol Injection
62360032|NCT04653389|EXPERIMENTAL|Preoperative TACE+Sintilimab+/-Radiotherapy of vein tumor thrombus+postoperative Sintilimab|The first TACE and immunotherapy will be performed at the same time on the first day of treatment. Anti-PD-1 Injection will be administered every three weeks ,until the disease progresses according to mRECIST criteria or intolerable toxicity or the patients' request, or surgery.Hypofractionated radiation therapy will be adopted for Type Vp2, Vp3 PVTT or Type Vv2 HVTT about 2 weeks after the first TACE.If the imaging examination 4 weeks after the surgery confirm that there is no recurrence and no contraindications to receive immunotherapy, anti-PD-1 antibody adjuvant therapy can be started.Every 21 days is a course of treatment, and the longest medication duration lasts for 6 months.
62360033|NCT05452317||Chronic active AMR group|
62360034|NCT05452317||Non-Chronic active AMR group|
61980702|NCT02993068|EXPERIMENTAL|Arm A (online education)|Patients watch genetic testing online educational video and receive genetic testing online test results report.
61980703|NCT02993068|EXPERIMENTAL|Arm B (online education, post telephone counseling)|Patients watch genetic testing online educational video, receive genetic testing online test results report, and post-telephone genetic counseling.
61980704|NCT02993068|ACTIVE_COMPARATOR|Arm C (online education, pre- and post-telephone counselling)|Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, genetic testing online test results report, and post-telephone genetic counseling.
61980705|NCT02993068|EXPERIMENTAL|Arm D (online education, pre-telephone counseling)|Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, and genetic testing online test results report.
61980706|NCT05867472|EXPERIMENTAL|Inhaled sedation - volatile anesthetic|The ICU patient will receive either Isoflurane or Sevoflurane, whichever is available at the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
62360035|NCT03028467|EXPERIMENTAL|GSK3196165 Dose 1|Participants will receive GSK3196165 Dose 1 weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
62360036|NCT03028467|EXPERIMENTAL|GSK3196165 Dose 2|Participants will receive GSK3196165 Dose 2 weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
61980707|NCT05867472|NO_INTERVENTION|IV sedation - standard of care|The ICU patient will receive standard of care, which is IV sedation supplied by the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
61980708|NCT04034173|OTHER|RAS mutations frequency <= 7%|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion\* D1~\*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.~Followed by FOLFIRI regimen~* Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1~* Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1~* 5-FU 400 mg/m² BSA, bolus, D1~* 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2~q day 14"
61980709|NCT04034173|OTHER|RAS mutation frequency >7% to <=14%|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion\* D1~\*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.~Followed by FOLFIRI regimen~* Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1~* Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1~* 5-FU 400 mg/m² BSA, bolus, D1~* 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2~q day 14"
61980710|NCT04034173|OTHER|RAS mutation frequency >14% to <=20%|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion\* D1~\*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.~Followed by FOLFIRI regimen~* Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1~* Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1~* 5-FU 400 mg/m² BSA, bolus, D1~* 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2~q day 14"
61980711|NCT00519818|EXPERIMENTAL|Cortef and Chronocort|Cortef 3 times daily(total dose 30 mg)for minimum of 7 days followed by Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
61980712|NCT05742438|ACTIVE_COMPARATOR|Lidocaine group|A loading dose of 1.5mg/kg lidocaine will be infused for 10 minutes during anesthesia induction. During the surgery and post-anaesthesia care unit (PACU) stay, 1.5 mg/kg/h of lidocaine were continuously infused until the patient was transferred to the general ward.
61980713|NCT05742438|ACTIVE_COMPARATOR|Dexmedetomidine group|A loading dose of 0.3mcg/kg dexmedetomidine will be infused for 10 minutes during anesthesia induction. During the surgery and PACU stay, 0.3 mcg/kg/h of dexmedetomidine were continuously infused until the patient was transferred to the general ward.
61980714|NCT05742438|ACTIVE_COMPARATOR|Intrathecal Morphine group|200\~300mcg of Intrathecal morphine will be injected at the anesthesia induction for colorectal surgery.
61980715|NCT05766007||Risperidone|Pregnant or breastfeeding women receiving the long acting injectable form of Risperidone and their babies
61980716|NCT05766007||Paliperidone palmitate|Pregnant or breastfeeding women receiving Paliperidone palmitate and their babies
62360037|NCT03028467|EXPERIMENTAL|GSK3196165 Dose 3|Participants will receive GSK3196165 Dose 3 weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
61980717|NCT05766007||Flupentixol decanoate|Pregnant or breastfeeding women receiving the Flupentixol decanoate and their babies
61980718|NCT05766007||Zuclopenthixol decanoate|Pregnant or breastfeeding women receiving the Zuclopenthixol decanoate and their babies
61980719|NCT05766007||Fluphenazine decanoate|Pregnant or breastfeeding women receiving the Fluphenazine decanoate and their babies
61980720|NCT06221904|EXPERIMENTAL|The observation group|The observation group is the only group.The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Simple Gymnastics Training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 30 minutes. Each training session will be conducted approximately at 9.00 a.m. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
61980721|NCT02653560|EXPERIMENTAL|Potassium magnesium Citrate (KMgCit) arm|Potassium magnesium citrate will be prepared by mixing potassium citrate, magnesium citrate and/or citric acid by Meta Pharm Development. The content of each sachet will be dissolved in 250 ml water and will be drunk with breakfast and again with dinner during the KMgCit Phase, to deliver 40 meq K, 20 meq Mg and 74 meq citrate per day for 4 weeks
61980722|NCT02653560|EXPERIMENTAL|Potassium citrate arm|A special sachet formulation containing 20 meq K/sachet will be made for the study by Meta Pharm Development. The contents of a sachet will be added to 250 ml water and drunk with breakfast and dinner, to deliver 40 meq K (as citrate) per day during the Potassium Citrate Phase for 4 weeks.
62360038|NCT03028467|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
62739138|NCT05136222|EXPERIMENTAL|Intervention|"This trial of PSG-assisted commencement of non-invasive ventilation (NIV) in motor neurone disease (MND) follows the methodology of our previous single-site study (Hannan et al 2019 ERJ), with the addition of an open label cohort that extends until (the earlier of) 12 months or death.~After empirical NIV set-up and an acclimatisation period (3 weeks), participants will undergo single night in-laboratory polysomnography (PSG). The PSG will be performed and supervised by a sleep scientist. In the intervention group, the intervention PSG results will be used to adjust/titrate NIV settings to optimize ventilation and improve synchrony between the patient and the NIV device. Participants will be asked to continue to use NIV as prescribed for the subsequent 7 week intervention period."
62360039|NCT03295604|EXPERIMENTAL|test group|Miller class I-II gingival recession defects operated with sub epithelial connective tissue graft (SCTG) in addition with enamel matrix derivatives (EMD) (Emdogain ®, Switzerland ) in SCTG+EMD group.
61980723|NCT02653560|EXPERIMENTAL|Potassium chloride arm|Potassium chloride will contain 20 meq KCl per sachet. During the Potassium Chloride Phase, subjects will dissolve the content of each sachet in 250 ml water and ingest it with breakfast and again with dinner, to deliver 40 meq K (as chloride) per day for 4 weeks
61980724|NCT02653560|PLACEBO_COMPARATOR|Placebo|Placebo will comprise microcrystalline cellulose, equivalent in volume in each sachet as other test products. During the Placebo Phase, subjects will dissolve the entire content of a sachet in 250 ml water and drink it with breakfast and again with dinner for 4 weeks.
61980725|NCT02946047|EXPERIMENTAL|Ixazomib 1 mg|Cohort A: Patients will receive ixazomib 1mg 3 times monthly for 12 weeks, then weekly for 12 weeks.
61980726|NCT02946047|EXPERIMENTAL|Ixazomib 2 mg|Cohort B: Patients will receive ixazomib 2mg 3 times monthly for 12 weeks, then weekly for 12 weeks.
61980727|NCT02946047|EXPERIMENTAL|Ixazomib 3 mg|Cohort C: Patients will receive ixazomib 3 mg 3 times monthly for 12 weeks, then weekly for 12 weeks.
61980728|NCT02946047|EXPERIMENTAL|Ixazomib 4 mg|Cohort D: Patients will receive ixazomib 4mg 3 times monthly for 12 weeks, then weekly for 12 weeks.
62182275|NCT02715427|EXPERIMENTAL|Enhanced recovery|"Preoperative consultation Specific information about the enhanced rehabilitation No bowel preparation Immunonutrition for the 7 preoperative days~Day before surgery Minimal preoperative fasting No premedication Carbohydrate loading~Operative day Optimized general anesthesia Reduced volumes perfused Limiting use of drains at the operative site Reduced doses of morphine Local anesthetic usage No standard use of nasogastric drainage~Postoperative time Stimulation mobilization from D0 Refeeding on demand  from D0 Early removal of venous, arterial and urinary catheters. J1 recovery from the majority of the usual treatment Breathe physiotherapy from D0 to D5 Ileus prevention by chewing gum"
61980729|NCT02252198||Investigational|• Participants will be asked to provide a total of three sputum samples over Days 1 and 2. The intent is for all samples to be collected before the subject starts any form of TB treatment. The first specimen (S1) should be 2 ml or greater in volume, and the second and third specimens (S2 and S3) should each be 1 ml or greater in volume. On Day 1, each participant will be asked to submit one spot sputum (S1) after enrollment and a second spot sputum after at least 2 hours (S2). Participants will be instructed to come back the following day (Day 2) and provide a third spot sputum (S3). In the event that a participant fails to return on Day 2, S3 may be collected a maximum of 7 days after enrollment, provided that no TB treatment has been initiated.
61980730|NCT04501367|EXPERIMENTAL|DEXTENZA Group|Patients undergoing vitrectomy with internal limiting membrane peel
62360040|NCT03295604|EXPERIMENTAL|control group|Miller class I-II gingival recession defects operated with only sub epithelial connective tissue graft (SCTG). No drug or something else were used
61980731|NCT04501367|EXPERIMENTAL|Second DEXTENZA Group|Patients undergoing vitrectomy with internal limiting membrane peel
61980732|NCT04501367|EXPERIMENTAL|Topical Prednisolone Acetate 1% Group|Patients undergoing vitrectomy with internal limiting membrane peel
61980733|NCT00954850||Severe asthmatics|Main study group
61980734|NCT00954850||Mild-moderate asthmatics|Control group
62360041|NCT00740363|EXPERIMENTAL|A|Patients will receive 4 weeks of treatment with sitagliptin once daily
62739139|NCT05136222|PLACEBO_COMPARATOR|Control|"The participants allocated to the control group will also be asked to attend a single night in-laboratory PSG. The NIV settings will not be adjusted throughout the PSG (sham PSG). Participants in the control group will retain their original settings after the sham PSG, and will be asked to continue to use NIV in this manner for the subsequent 7 week intervention period."
61980735|NCT04895215|EXPERIMENTAL|AB-2004|
61980736|NCT04895215|PLACEBO_COMPARATOR|Placebo|
61980737|NCT01362374|EXPERIMENTAL|Arm A (Doc + Ipat 100mg)|Participants received ipatasertib at a dose of 100 milligrams (mg) once daily for 14 consecutive days (beginning on Day 2) in combination with docetaxel on Day 1, in 21-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
61980738|NCT01362374|EXPERIMENTAL|Arm A (Doc + Ipat 200mg)|Participants received ipatasertib at a dose of 200mg once daily for 14 consecutive days (beginning on Day 2) in combination with docetaxel on Day 1, in 21-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
61980739|NCT01362374|EXPERIMENTAL|Arm A (Doc + Ipat 400mg)|Participants received ipatasertib at a dose of 400mg once daily for 14 consecutive days (beginning on Day 2) in combination with docetaxel on Day 1, in 21-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
61980740|NCT01362374|EXPERIMENTAL|Arm A (Doc + Ipat 600mg)|Participants received ipatasertib at a dose of 600mg once daily for 14 consecutive days (beginning on Day 2) in combination with docetaxel on Day 1, in 21-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
61980741|NCT01362374|EXPERIMENTAL|Arm B (mFOLFOX + Ipat 100mg)|Participants received ipatasertib at a dose of 100mg once daily for 7 consecutive days (beginning on Day 1) in combination with mFOLFOX6 chemotherapy (comprising of oxaliplatin, leucovorin, and 5-FU) on Day 1, in 14-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
61980742|NCT01362374|EXPERIMENTAL|Arm B (mFOLFOX + Ipat 200mg)|Participants received ipatasertib at a dose of 200mg once daily for 7 consecutive days (beginning on Day 1) in combination with mFOLFOX6 chemotherapy (comprising of oxaliplatin, leucovorin, and 5-FU) on Day 1, in 14-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
61980743|NCT01362374|EXPERIMENTAL|Arm B (mFOLFOX + Ipat 400mg)|Participants received ipatasertib at a dose of 400mg once daily for 7 consecutive days (beginning on Day 1) in combination with mFOLFOX6 chemotherapy (comprising of oxaliplatin, leucovorin, and 5-FU) on Day 1, in 14-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
61980744|NCT01362374|EXPERIMENTAL|Arm B (mFOLFOX + Ipat 600mg)|Participants received ipatasertib at a dose of 600mg once daily for 7 consecutive days (beginning on Day 1) in combination with mFOLFOX6 chemotherapy (comprising of oxaliplatin, leucovorin, and 5-FU) on Day 1, in 14-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
61980745|NCT01362374|EXPERIMENTAL|Arm C (Pac + Ipat 400mg)|Participants received ipatasertib at a dose of 400mg once daily for 21 consecutive days (beginning on Day 1) in combination with paclitaxel on Days 1, 8, and 15, in 28-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
61980746|NCT01362374|EXPERIMENTAL|Arm C (Pac + Ipat 600mg)|Participants received ipatasertib at a dose of 600mg once daily for 21 consecutive days (beginning on Day 1) in combination with paclitaxel on Days 1, 8, and 15, in 28-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
62360042|NCT00740363|PLACEBO_COMPARATOR|B|No treatment for 4 weeks
62360043|NCT02157103|EXPERIMENTAL|Bevacizumab|Cycle 1 (each cycle is 3 weeks): Bevacizumab 25 mg in 1 ml subcutaneously daily.
62360044|NCT05034471|EXPERIMENTAL|Mitral Valve Repair with Novel Device Technologies|All study participants will undergo mitral valve repair by replacing the chordae tendinea with ePTFE single loop sutures using novel suturing devices.
62360045|NCT04725539|EXPERIMENTAL|Intermittent hypoxia (IH) pre-conditioning|"The IH pre-conditioning program will be performed in a sitting position by inhaling a gas mixture with reduced O2 content via face masks.The program will include five sessions per week for 3 weeks. Each session consists of three to five hypoxic (14-10% inspired fraction of oxygen) periods, each lasting 3-5 min with 3-min normoxic intervals.~The control setting includes breathing room air via face mask."
62360046|NCT04725539|EXPERIMENTAL|Hypoxia pre-adaptation|The hypoxia pre-adaptation program consists of sleeping 1 night at 1900m. The control setting includes sleeping 1 night close to sea level.
62360047|NCT01176188|EXPERIMENTAL|Comfort Care|Parental soothing, including tactile and auditory strategies, followed by a quiet period with the application of earmuffs to block auditory stimulation
62360048|NCT01176188|ACTIVE_COMPARATOR|Usual Care|
62360049|NCT04107116|EXPERIMENTAL|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: proactive symptom assessments for patients for up to 12-months.
61980747|NCT01362374|EXPERIMENTAL|Arm D (Enza + Ipat 400mg)|Participants received ipatasertib at a dose of 400mg once daily alone for 8 days, then from Day 9, ipatasertib will be administered in combination with enzalutamide once daily for 27 days (Cycle 1 duration = 35 days). Participants received both ipatasertib and enzalutamide once daily continuously in subsequent 28-days cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first. Higher (up to 600 mg) or lower dose of ipatasertib may be evaluated in subsequent cycles depending upon safety, tolerability, and pharmacokinetics of the first cycle.
61980748|NCT01362374|EXPERIMENTAL|Arm D (Enza + Ipat 600mg)|Participants received ipatasertib at a dose of 600mg once daily alone for 8 days, then from Day 9, ipatasertib will be administered in combination with enzalutamide once daily for 27 days (Cycle 1 duration = 35 days). Participants received both ipatasertib and enzalutamide once daily continuously in subsequent 28-days cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first. Higher (up to 600 mg) or lower dose of ipatasertib may be evaluated in subsequent cycles depending upon safety, tolerability, and pharmacokinetics of the first cycle.
61980749|NCT01362374|EXPERIMENTAL|Arm D (Enza + Ipat 400-600mg)|Participants received ipatasertib at a dose of 400-600mg once daily alone for 8 days, then from Day 9, ipatasertib will be administered in combination with enzalutamide once daily for 27 days (Cycle 1 duration = 35 days). Participants received both ipatasertib and enzalutamide once daily continuously in subsequent 28-days cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first. Higher (up to 600 mg) or lower dose of ipatasertib may be evaluated in subsequent cycles depending upon safety, tolerability, and pharmacokinetics of the first cycle.
61980750|NCT01102933||Unselected post-myocard infarct patients|Patients diagnosed with MI at Uppsala University Hospital
61980751|NCT04945902|ACTIVE_COMPARATOR|Asynchronous Group|The asynchronous intervention will provide access to information and resources for mental health support via Brightspace. The intervention will be six weeks long and each week will have a topic. The weekly topics include (1) identifying feelings; (2) biology of emotions; (3) mindfulness; (4) recognizing and responding to stress; (5) mental health stigma; and (6) self-care/self-advocacy. Each week, you will be required to complete four types of activities: education, reflective exercises, an activity, and a short assessment. All of these resources will be provided on Brightspace to be completed on your own time but the activities must be completed during the week they are assigned. You will not have to interact with other international students if you are in the asynchronous intervention group.
61980752|NCT04945902|EXPERIMENTAL|Synchronous Group|If you are assigned to the synchronous intervention group, you will be required to complete the asynchronous interventions on Brightspace AND attend a weekly one-hour support group. These support groups will meet virtually using a restricted WebEx channel and will be recorded. In this support group, students will discuss the weekly activities and build connections and support with each other. This group will be led by advanced doctoral students in counseling psychology and overseen by a counseling psychology faculty member, who is also a licensed psychologist.
61980753|NCT04945902|NO_INTERVENTION|Waitlist|If you are assigned to the wait-list group, you will not have access to the asynchronous or synchronous interventions during the course of this study. After this study is completed, you will have access to the asynchronous intervention on Brightspace.
61980754|NCT05482009||Strong exposure group of traditional Chinese medicine|receiving traditional Chinese medicine treatment + basic western medicine treatment, the cumulative time of traditional Chinese medicine treatment reaches more than 80% of the total course of treatment
61980755|NCT05482009||Moderate Chinese medicine exposure group|received Chinese medicine treatment + western medicine basic treatment, the cumulative time of Chinese medicine treatment reached 30%-79% of the total course of treatment
62360050|NCT04107116|ACTIVE_COMPARATOR|Control Group Arm|The control group arm will receive usual care as provided by their local oncologists.
62360051|NCT01678157||Documented symptomatic paraesophageal hernia|"1. Documented symptomatic paraesophageal hernia.~2. Greater than 5 cm hiatal hernia on upper gastrointestinal study.~3. Evidence that the stomach or other viscera is present in the hernia and does not spontaneously reduce from the mediastinum.~4. Significant symptoms or signs of a paraesophageal hernia including but not limited to heartburn,dysphagia, chest pain, shortness of breath, postprandial abdominal pain, early satiety, odynophagia, or chronic anemia.~5. Consenting adult 19 years of age or older~6. Must be able to participate in follow-up evaluation.~7. Free of cognitive impairment"
62360052|NCT02995941||Raters|No interventions will be administered. Raters will be state licensed as physical therapists working as outpatient physical therapists in the St. Luke's University Health Network.
61980756|NCT05482009||Weak exposure group of traditional Chinese medicine|receiving traditional Chinese medicine treatment + basic western medicine treatment, the cumulative time of traditional Chinese medicine treatment is less than 30% of the total course of treatment
61980757|NCT05482009||Western medicine group|receive basic western medicine treatment only
61980758|NCT02577211|EXPERIMENTAL|Hipocaloric enteral nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg.
61980759|NCT02577211|ACTIVE_COMPARATOR|Normocaloric enteral nutrition|25 kcal per kg of body weight and 1.7 grams of protein per kg.
61980760|NCT05724069|OTHER|Sequence A|"Eligible subjects will be treated for 4 periods with either velusetrag (2 periods) or placebo (2 periods), with a wash-out period of 2 weeks between treatment periods.~The progression order of the treatment periods varies in each sequence."
61980761|NCT05724069|OTHER|Sequence B|"Eligible subjects will be treated for 4 periods with either velusetrag (2 periods) or placebo (2 periods), with a wash-out period of 2 weeks between treatment periods.~The progression order of the treatment periods varies in each sequence."
62182276|NCT00820664|ACTIVE_COMPARATOR|17β-estradiol 2.0 milligrams|Estrace 2.0 mg tablet
62360053|NCT02995941||Patients|No interventions will be administered as a component of this study. Patients will be recruited from a convenience sample of consecutive patients presenting for physical therapy consultation for shoulder pain.
62360054|NCT01693497|EXPERIMENTAL|Dialogical exposure therapy|Psychotherapy based on a manual integrating Gestalt principles with cognitive-behavioral techniques.
62360055|NCT01693497|ACTIVE_COMPARATOR|Cognitive Processing Therapy|Cognitive Processing Therapy, a cognitive behavioral psychotherapy for PTSD patients. Based on a German manual adapted from Resick and Schnicke, 1993.
62360056|NCT02727517|ACTIVE_COMPARATOR|Early (≤ 60 seconds) cord clamping|Early (≤ 60 seconds) cord clamping
62360057|NCT02727517|ACTIVE_COMPARATOR|Delayed cord clamping|Delayed (≥ 180 seconds) cord clamping
62360058|NCT02439736||CT positive for acute intracranial lesion|
62360059|NCT02500277|ACTIVE_COMPARATOR|Cryobiopsy|Pleural biopsy with a flexible cryoprobe
62360060|NCT02500277|ACTIVE_COMPARATOR|Forceps biopsy|Pleural biopsy with a flexible forceps
62360061|NCT03355768|EXPERIMENTAL|Romidepsin Arm|Control Arm: Subjects will receive Romidepsin 14 mg/m2 on Days 1, 8, 15.
61980762|NCT05724069|OTHER|Sequence C|"Eligible subjects will be treated for 4 periods with either velusetrag (2 periods) or placebo (2 periods), with a wash-out period of 2 weeks between treatment periods.~The progression order of the treatment periods varies in each sequence."
61980763|NCT05724069|OTHER|Sequence D|"Eligible subjects will be treated for 4 periods with either velusetrag (2 periods) or placebo (2 periods), with a wash-out period of 2 weeks between treatment periods.~The progression order of the treatment periods varies in each sequence."
61980764|NCT02728895|EXPERIMENTAL|Cohort 1: Vedolizumab 75 mg|Vedolizumab 75 mg, injection, intravenously once on Days -1, 13 and 42.
61980765|NCT02728895|EXPERIMENTAL|Cohort 2: Vedolizumab 300 mg|Vedolizumab 300 mg, injection, intravenously once on Days -1, 13 and 42.
61980766|NCT02728895|EXPERIMENTAL|Cohort 3: Vedolizumab Dose 1|Vedolizumab first decided dose as determined from Cohort 1 or 2, injection, intravenously once on Days -1, 13 and 42.
61980767|NCT01830582|EXPERIMENTAL|1 A|The patients will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 24 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the second week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
61980768|NCT01830582|EXPERIMENTAL|1 B|The patient will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 48 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the third week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
61980769|NCT01830582|EXPERIMENTAL|1 C|The patient will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 72 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the fourth week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
61980770|NCT01830582|EXPERIMENTAL|2|The last patient patients that will undergo a standard pre-chemoradiation MRI scan, followed by a repeat research scan either 24, 48 or 72 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the second, third or fourth week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
61980771|NCT05736107|EXPERIMENTAL|CBL-514 Injection|Participant will receive CBL-514 2 mg/cm² administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to a maximum of 4 treatments.
61980772|NCT05736107|PLACEBO_COMPARATOR|0.9% Sodium Chloride|Participant will receive 0.9% Sodium Chloride administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to a maximum of 4 treatments.
61980773|NCT02725242|EXPERIMENTAL|Once-daily budesonide/formoterol (160/4.5 μg/d)|once-daily budesonide/formoterol (160/4.5 μg/d)
61980774|NCT02725242|ACTIVE_COMPARATOR|Twice-daily Budesonide (200μg)|twice-daily Budesonide (400μg/d)
61980775|NCT05454956|EXPERIMENTAL|BID Dosing|TP-03, lotilaner ophthalmic solution, 0.25% administered topically twice a day and TP-03 vehicle administered once a day to maintain masking for approximately 85 days
61980776|NCT05454956|EXPERIMENTAL|TID Dosing|TP-03, lotilaner ophthalmic solution, 0.25% administered topically three times a day for approximately 85 days
61980777|NCT01755884|EXPERIMENTAL|Wheat oral immunotherapy|Well-cooked wheat spaghetti is given daily to the patients starting from a minimal dosage (0,0003 g of wheat protein) and increasing the dosing in every 1-2 weeks until a dosage corresponding the size of one meal.
61980778|NCT04731168|NO_INTERVENTION|Control|
61980779|NCT04731168|EXPERIMENTAL|MAD|Patients will have a mandibular advancement device during the first postoperative night
61980780|NCT01927666|EXPERIMENTAL|dietary intervention|To measure the variation in extent of ITC excretion in urine from a capsule delivered dose of 100mg glucoraphanin
61980781|NCT02448654|ACTIVE_COMPARATOR|Tolcapone|100mg tolcapone three times a day for 7 days then 100mg once a day on day 8
62360062|NCT03355768|EXPERIMENTAL|Romidepsin + Pralatrexate Combination Arm|Combination Arm: Subjects will receive Romidepsin 12 mg/m2 and Pralatrexate 25 mg/m2.
61980782|NCT02448654|PLACEBO_COMPARATOR|Sugar Pill|Sugar pill
61980783|NCT02116244|EXPERIMENTAL|Civamide Nasal Spray|Civamide Nasal Spray 0.01% 20ug/dose (20ul), 10ul in each nostril, twice daily for 12 weeks
61980784|NCT05398601|ACTIVE_COMPARATOR|MOBILIZATION WITH MOVEMENT|"MOBILIZATION with MOVEMENT~TENS, MWM techniques for Knee"
62182277|NCT00820664|ACTIVE_COMPARATOR|17β-estradiol 0.5 milligrams|Estrace 0.5 mg tablet
62360063|NCT01363856||First ever acute stroke|Patients over 18 years and without prior stroke according to WHO criteria, displaying an ischemic stroke, onset within the last 7 days, language German
62360064|NCT05595603|EXPERIMENTAL|Zoledronic Acid loaded bone cement|4mg zoledronic acid-loaded gentamicin bone cement (PMMA)
62360065|NCT05595603|ACTIVE_COMPARATOR|conventional gentamicin bone cement|gentamicin bone cement (PMMA)
62360066|NCT01502358|EXPERIMENTAL|Tetravalent Dengue Vaccine (TVDV)|low dose (no adjuvant)
62360067|NCT01502358|EXPERIMENTAL|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|low dose (with adjuvant)
62360068|NCT01502358|EXPERIMENTAL|Tetravalent dengue Vaccine (TVDV) with Vaxfectin® (high-dose)|high dose (with adjuvant)
62391390|NCT02357108|ACTIVE_COMPARATOR|Group 2: Video/Doctor Sequence 2|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
61980785|NCT05398601|EXPERIMENTAL|periosteal electrical dry needling|TENS, periosteal electrical dry needling 4 point technique for Knee
62360069|NCT01729104|EXPERIMENTAL|Phase I: Carfilzomib + Lenalidomide + Rituximab|Phase I: Four primary dose levels of carfilzomib plus lenalidomide (carfilzomib 20 mg/27 mg + lenalidomide 20 mg, carfilzomib 20 mg/36 mg + lenalidomide 20 mg, carfilzomib 20mg/45 mg + lenalidomide 20 mg, carfilzomib 20 mg/56 mg + lenalidomide 20 mg,) evaluated with a fixed dose of rituximab (375 mg/m2 weekly for 4 weeks). Alternate dose levels using 15 mg of lenalidomide in combination with carfilzomib and rituximab evaluated if MTD is exceeded with 20 mg of lenalidomide.
62360070|NCT01729104|EXPERIMENTAL|Phase II: Mantle Cell Lymphoma Group|"Phase II: Patients enrolled at recommended dose level (MTD) of Carfilzomib established in Phase I of the study.~Phase II Lenalidomide Dose: 20 mg by vein on Days 1-21 of each cycle.~Phase II Rituximab Dose: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months."
61980786|NCT01172184||Severe mitral regurgitation|Patients with severe mitral regurgitation are admitted for pre-operation cardiac catheterization and are willing to participate in this study.
62391391|NCT02357108|ACTIVE_COMPARATOR|Group 3: Video/Doctor Sequence 3|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
61980787|NCT02234453|EXPERIMENTAL|Cancer patients|Adult patients with solid tumours receiving systemic anti-cancer therapy who are able to use the Minicare H-2000.
62739140|NCT02308592|PLACEBO_COMPARATOR|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
61980788|NCT05943145|EXPERIMENTAL|Group Dance and Movement Training|Group dance and movement sessions
61980789|NCT02861794|OTHER|GMK Sphere|Patients receive a GMK Sphere Total Knee Replacement.
61980790|NCT04422002||Surgical treatment|
61980791|NCT04422002||Palliative treatment|
61980792|NCT05406258|EXPERIMENTAL|Patients performing intermittent catheterization|
61980793|NCT02864251|EXPERIMENTAL|Nivolumab+Platinum doublet chemotherapy|
61980794|NCT02864251|EXPERIMENTAL|Nivolumab + Ipilimumab|Enrollment is closed for this arm
61980795|NCT02864251|ACTIVE_COMPARATOR|Platinum doublet chemotherapy|
61980796|NCT05814887|EXPERIMENTAL|ReLink|Medical device to be tested
61980797|NCT05814887|NO_INTERVENTION|Control|Control, no medical device
61980798|NCT06153511|EXPERIMENTAL|Patient with spinal condition who requires a transpedicular fixation intervention.|Patient with spinal condition (vertebral fractures, spinal stenosis, kyphosis, among others) who requires a intervention for spinal fusion with pedicle screws.
61980799|NCT01269424|ACTIVE_COMPARATOR|Cohort 1|LV gene transfer after concurrent chemo-radiotherapy
62391392|NCT02357108|ACTIVE_COMPARATOR|Group 4: Video/Doctor Sequence 4|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
61980800|NCT01269424|ACTIVE_COMPARATOR|Cohort 2|LV gene transfer prior to concurrent chemo-radiotherapy
61980801|NCT01269424|ACTIVE_COMPARATOR|Cohort 3|Intra patient dose escalation of TMZ in patients with evidence of P140K marked cells
61980802|NCT04659889||Patients with clinical features of Long Covid|Patients who have had COVID-19 (PCR proven and/or clinical features of COVID-19) who are currently displaying symptoms of long Covid
61980803|NCT04659889||Patients with no symptoms of Long Covid|Patients who have had COVID-19 (PCR proven and/or clinical features of COVID-19) who are not displaying symptoms of long Covid
61980804|NCT00721773|EXPERIMENTAL|ACE inhibitor, benazepril|Benazepril will be started at 10 mg/day and will be up-titrated to 20 mg/day according to BP control and tolerability.
61980805|NCT00721773|EXPERIMENTAL|Angiotensin receptor blocker, valsartan|Valsartan will be started at 80 mg/day and will be up-titrated to 160 mg/day according to BP control and tolerability.
61980806|NCT00721773|EXPERIMENTAL|RAS inhibitors, benazepril+valsartan|Benazepril will be started at 10 mg/day and will be up-titrated to 20 mg/day, and valsartan will be started at 80 mg/day and will be up-titrated to 160 mg/day according to BP control and tolerability.
61980807|NCT00721773|ACTIVE_COMPARATOR|non-RAS inhibitors, control|Drug: antihypertensive agents, except ACE inhibitors and ARBs. Administration of antihypertensive agents will select as follows: CCB→β-blocker→α-blocker.
61980808|NCT04900831||Group 1|
61980809|NCT00937443||Walking Exercise Group|Walking Exercise Group versus Control Group
61980810|NCT02063854|ACTIVE_COMPARATOR|NE-58095 IR 2.5 mg Once Daily on Awakening|NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
61980811|NCT02063854|EXPERIMENTAL|NE-58095 DR 25 mg Once Monthly on Awakening|NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
61980812|NCT02063854|EXPERIMENTAL|NE-58095 DR 25 mg Once Monthly Following Breakfast|NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
62182278|NCT00820664|PLACEBO_COMPARATOR|3|Placebo
61980813|NCT02063854|EXPERIMENTAL|NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast|NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
61980814|NCT02063854|EXPERIMENTAL|NE-58095 DR 37.5 mg Once Monthly on Awakening|NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
61980815|NCT02063854|EXPERIMENTAL|NE-58095 DR 37.5 mg Once Monthly Following Breakfast|NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
61980816|NCT02063854|EXPERIMENTAL|NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast|NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
61980817|NCT02697695||laparoscopic sleeve gastrectomy|patients who underwent laparoscopic sleeve gastrectomy (LSG) due to obesity and/or metabolic syndrome
62360071|NCT01729104|EXPERIMENTAL|Phase II: Follicular, Marginal Zone, DLBCL Group|"Group consists of : Patients with follicular lymphoma (FL) grade 1 - 3, marginal zone lymphoma (MZL), or non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL).~Phase II: Patients enrolled at recommended dose level (MTD) of Carfilzomib established in Phase I of the study.~Phase II Lenalidomide Dose: 20 mg by vein on Days 1-21 of each cycle.~Phase II Rituximab Dose: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months."
61980818|NCT02697695||laparoscopic Roux-en-Y- gastric bypass|patients who underwent laparoscopic Roux-en-Y- gastric bypass (LRYGB) due to obesity and/or metabolic syndrome
61980819|NCT02697695||laparoscopic omega-loop gastric bypass|patients who underwent laparoscopic omega-loop gastric bypass (LOLGB) due to obesity and/or metabolic syndrome
61980820|NCT02286505|EXPERIMENTAL|Brain Morphometry|Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.
61980821|NCT02286505|OTHER|Standard radiological assessment.|Standard neuroradiological report of the structural MRI only.
61980822|NCT02266745|EXPERIMENTAL|Arm 1: PT-112 injection|Arm 1: PT-112 Injection, administered by intravenous infusion, biweekly 360 mg/m2
61980823|NCT02266745|EXPERIMENTAL|Arm 2: PT-112 injection|Arm 2: PT-112 Injection, administered by intravenous infusion, biweekly 250 mg/m2
61980824|NCT02266745|EXPERIMENTAL|Arm 3: PT-112 injection|Arm 3: PT-112 Injection, administered by intravenous infusion, 360 mg/m2 for two doses, 250 mg/m2 for subsequent doses
61980825|NCT04630418|EXPERIMENTAL|NanoSilk Cosmo|Participants will receive a 30 mL jar of NanoSilk Cosmo
61980826|NCT05485298||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
61980827|NCT05485298||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
61980828|NCT01552252|PLACEBO_COMPARATOR|0% POs-Ca|
61980829|NCT01552252|ACTIVE_COMPARATOR|0.5% POs-Ca|
61980830|NCT01552252|ACTIVE_COMPARATOR|1% POs-Ca|
61980831|NCT01552252|ACTIVE_COMPARATOR|1.5% POs-Ca|
61980832|NCT01552252|ACTIVE_COMPARATOR|2% POs-Ca|
61980833|NCT06332846||study group|The study group consisted of 59 individuals subjects with a first ischemic stroke, with symptoms from the anterior cerebral artery (basin of the internal carotid artery), with a significant neurological deficit (minimum 3 points according to National Institute of Health Stroke Scale
61980834|NCT06332846||control group|The control group (59 individuals) matched for age and gender was selected among patients of the Department of Interdisciplinary Dentistry at Pomeranian Medical University in Szczecin.
61980835|NCT02269020|EXPERIMENTAL|3 patients cancer of the epi larynx|"3 patients with squamous cell carcinoma of the epi-larynx~Intervention: Neck Dissection"
61980836|NCT04983992||observation group|People suffered from excessive lateral pressure syndrome with extracapsular release of lateral retinaculum.
62360072|NCT04549415|ACTIVE_COMPARATOR|metformin|Metformin, 1000 mg b.i.d, 12 months
62360073|NCT04549415|ACTIVE_COMPARATOR|lifestyle modification|Lifestyle modification Standard Principles
61980837|NCT04983992||control group|People suffered from excessive lateral pressure syndrome with conservative treatment
61980838|NCT01829581||oral anticoagulation associated intracerebral hemorrhage|
61980839|NCT05204654|EXPERIMENTAL|In-office fabricated appliance|A customized in-office fabricated appliance using the printed digital model of the subject will be used for AP correction. AP correction will be completed following CMA protocol (see model description)
61980840|NCT05204654|ACTIVE_COMPARATOR|Carriere Motion Appliance|The appropriate length appliance will be placed as directed in the CMA handbook on the maxillary first molar and canine. AP correction will be completed following CMA protocol (see model description)
61980841|NCT02066740|EXPERIMENTAL|EverFlex™ stent with Entrust™ delivery system|
61980842|NCT01857232|OTHER|Control|OND + DEX + FOS followed by oral DEX
61980843|NCT01857232|PLACEBO_COMPARATOR|Placebo|OND + APD403 followed by oral PLACEBO
61980844|NCT01857232|EXPERIMENTAL|Low dose APD403|OND + APD403 followed by oral APD403 low dose
61980845|NCT01857232|EXPERIMENTAL|Mid dose APD403|OND + APD403 followed by oral APD403 mid dose
61980846|NCT01857232|EXPERIMENTAL|High dose APD403|OND + APD403 followed by oral APD403 high dose
61980847|NCT02649907|EXPERIMENTAL|Weight loss|3 months weight loss intervention by behavioral intervention
61980848|NCT04389567||Patients with COVID-19 taking Famotidine|Use of any dose of oral Famotidine during period of COVID-19
61980849|NCT00941018|EXPERIMENTAL|SAD cohort 1|Single ascending dose (SAD) cohort 1 will participate in three dosing periods separated by 2 weeks. Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control. The starting dose will be 300 mg. Subsequent doses will be determined by the pk and safety data from previous cohorts.
61980850|NCT00941018|EXPERIMENTAL|SAD cohort 2|SAD cohort 2 will participate in three dosing periods separated by 2 weeks. Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control. The doses to be administered will be determined by the pk and safety data from previous cohorts.
61980851|NCT00941018|EXPERIMENTAL|MAD cohort 1|Multiple ascending dose (MAD) cohort 1 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous SAD cohorts.
61980852|NCT00941018|EXPERIMENTAL|MAD cohort 2|MAD cohort 2 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.
61980853|NCT00941018|EXPERIMENTAL|MAD cohort 3|MAD cohort 3 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohorts.
62549935|NCT03885115|EXPERIMENTAL|Intervention|Participants randomly assigned to the experiential group (EG) will receive a 12-week structured exercise that will consist of two group fitness sessions (i.e. kickboxing, Zumba, fitness yoga, and other aerobic exercises) every week. Certified fitness instructors will lead each session and participants will learn strategies how to be more active during the daily routines at home. Parents or other relatives in the EG will participate in one 2-hour session every four weeks (total of 3 sessions) designed to help them support their children and entire family in being active and eat healthy at home. Parents will meet with a fitness instructor who will provide specific tips on how to increase physical activity at home as well as providing community resources to be active. A basic nutrition education and cooking demonstrations, and healthy recipes will be also provided to parents at these workshops. Data/assessments are collected, pre and post the 12 weeks intervention.
62549936|NCT03885115|NO_INTERVENTION|Control|Participants randomly assigned to the control group (CG) will receive once a week recreational structured group play/game sessions led by trained BOUNCE interns/staff. The control group will receive 60 minute of structured free play sessions (i.e. recreational games) once a week for 12 weeks. Every 4 weeks, parents will be given (either sent home with their child or via email or mail) basic nutrition information, healthy recipes, and tips to promote physical activity at home as well as community resources to be active. Data/assessments are collected, pre and post the 12 weeks intervention.
62549937|NCT03740373|EXPERIMENTAL|Treatment Sequence 1|Subjects will receive BGF MDI with 10 s breath hold during Treatment Period 1 and BGF MDI with 3 s breath hold during Treatment Period 2
61980854|NCT00941018|EXPERIMENTAL|MAD cohort 4|MAD cohort 4 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.
61980855|NCT01408030|PLACEBO_COMPARATOR|Placebo spray|sterile saline
61980856|NCT01408030|ACTIVE_COMPARATOR|Bevacizumab spray|bevacizumab 1%
62549938|NCT03740373|EXPERIMENTAL|Treatment Sequence 2|Subjects will receive BGF MDI with 3 s breath hold during Treatment Period 1 and BGF MDI with 10 s breath hold during Treatment Period 2
62549939|NCT04816071|EXPERIMENTAL|EAA - non-vaccinated|18 g/day
62549940|NCT04816071|PLACEBO_COMPARATOR|Placebo - non-vaccinated|18 g/day
61980857|NCT01408030|ACTIVE_COMPARATOR|Estriol spray|Estriol 0.1%
61980858|NCT01408030|ACTIVE_COMPARATOR|Tranexamic acid spray|tranexamic acid 10%
61980859|NCT04458545|PLACEBO_COMPARATOR|Placebo Vaccine|
61980860|NCT04458545|EXPERIMENTAL|Low Dose Vaccine (100 μg)|
61980861|NCT04458545|EXPERIMENTAL|High Dose Vaccine (400 μg)|
61980862|NCT04902456|EXPERIMENTAL|Power Chain and Crimpable hook for En-masse retraction|"Retraction will start on a 0.017x0.025 Stainless Steel wire using elastomeric chain ( force applied will be 212 g per side ) extending between the crimpable hooks and the miniscrew"
61980863|NCT04902456|EXPERIMENTAL|T-loop|"Closing retraction T-loops will be fabricated using 0.017x0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine."
61980864|NCT02401594|EXPERIMENTAL|Group 1: Rivaroxaban treatment|Rivaroxaban active substance plus a placebo of enoxaparin
61980865|NCT02401594|ACTIVE_COMPARATOR|Grouyp 2: Enoxaparine treatment|Enoxaparin active substance plus a placebo tablet of Rivaroxaban
61980866|NCT05681455|EXPERIMENTAL|Experimental group|"A two-phase microcurrent with a frequency between 1.14 Hertz and 14.29 Hertz and currents between 0.1 and 0.9 mA will be applied.~A total of 15 sessions in 7.5 weeks. Twice a week. The session time with microcurrents will last 60 minutes."
61980867|NCT05681455|PLACEBO_COMPARATOR|Placebo group|"Microcurrent machines shall be operated in such a way that they have a light signal but do not emit current. Neither the physical therapists who place them nor the subjects will be able to distinguish current-emitting machines from placebo machines.~A total of 15 sessions in 7.5 weeks. Twice a week. The session time with placebo will last 60 minutes."
61980868|NCT02829281|EXPERIMENTAL|Botulinum toxin group|Patients will receive a intervention with joint injection of 100 units of botulinum toxin
61980869|NCT02829281|ACTIVE_COMPARATOR|Corticosteroid group|Patients will receive a intervention with joint injection of 40mg of triamcinolone hexacetonide (corticosteroid)
62549941|NCT04816071|EXPERIMENTAL|EAA - vaccinated|18 g/day
62549942|NCT04816071|PLACEBO_COMPARATOR|Placebo - vaccinated|18 g/day
62739141|NCT02308592|ACTIVE_COMPARATOR|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
62549943|NCT00843661|EXPERIMENTAL|Ezetimibe and fenofibrate|
61980870|NCT02829281|PLACEBO_COMPARATOR|Saline Group|Patients will receive a joint injection of 2ml of normal saline
61980871|NCT01401868|EXPERIMENTAL|single arm|dose escalation
61980872|NCT03331549||Myocardial infarction|
61980873|NCT03331549||Control group|
61980874|NCT01430091|ACTIVE_COMPARATOR|Prasugrel clinical formulation|A single 5-milligram (mg) prasugrel tablet administered orally by swallowing it whole on 1 occasion.
61980875|NCT01430091|EXPERIMENTAL|Prasugrel (ODT) - on tongue|A single 5-mg prasugrel orally disintegrating tablet (ODT) administered orally by placing it on top of the tongue and keeping it there until it disintegrates.
61980876|NCT01430091|EXPERIMENTAL|Prasugrel (ODT) - apple juice|A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue followed by drinking approximately 180 milliliters (ml) apple juice within 1 minute after the tablet finishes disintegration.
61980877|NCT01430091|EXPERIMENTAL|Prasugrel (ODT) - chewed|A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue, but then chewed and swallowed rather than waiting for it to disintegrate.
61980878|NCT01430091|EXPERIMENTAL|Prasugrel (ODT) - under tongue|A single 5-mg prasugrel ODT administered orally by placing it under (rather than on top of) the tongue and keeping it there until it disintegrates.
61980879|NCT04995133|EXPERIMENTAL|Colistin Arm|Intravenous administration of 6.75 x 106 Units Colistin for 30 minutes
61980880|NCT00690092|ACTIVE_COMPARATOR|1|Volunteers with a history of pulmonary coccidioidomycosis verified by serology and/or histology or mycology.
61980881|NCT00690092|ACTIVE_COMPARATOR|2|Volunteers without a history of pulmonary coccidioidomycosis confirmed by serology (naive).
61980882|NCT00690092|ACTIVE_COMPARATOR|3|Volunteers with a history of pulmonary histoplasmosis but no history of coccidioidomycosis confirmed by serology.
61980883|NCT03597958||Hypercholesterolaemia|"Individuals attending Imperial College London Diabetes Centre (ICLDC) and with LDL-C ≥5.0 mmol/L, for children \<18 years LDL-C\>95th centile by age and gender for country, and possible evidence of known premature CHD.~Individuals with a high probability of disease according to the Dutch Lipid Network Criteria, score of ≥6 points, will be identified as possible probands (individual serving as our starting point for the genetic study of the family) and will be selected for further screening.~Patients will be tested for known and/or suspected FH genes, using next generation sequencing (NGS) panel, whole exome and/or whole genome sequencing (WES/WGS) in cases where FH is highly suspected despite negative results from panel testing, and transcriptomic analysis of RNA blood samples."
61980884|NCT02355119|ACTIVE_COMPARATOR|Gemcitabine|Gemcitabine 1000 mg/sqm on days 1,8,15 every 28 days
61980885|NCT02355119|EXPERIMENTAL|FOLFOXIRI|
61980886|NCT03035708|EXPERIMENTAL|varenicline|1 mg BID (2 capsules BID)
62360074|NCT00647946|EXPERIMENTAL|A|Stop zidovudine (ZDV) or stavudine (d4T) and start tenofovir DF 300mg once daily along with the other antiviral drugs that are used as part of their HAART regimen
62549944|NCT00843661|ACTIVE_COMPARATOR|Pravastatin|
62360075|NCT00647946|ACTIVE_COMPARATOR|B|Stop zidovudine (ZDV) or stavudine (d4T) and start abacavir 300mg twice daily along with the other antiviral drugs that are used as part of their HAART regimen
62360076|NCT01809197|EXPERIMENTAL|Air Optix/OFPM|Lotrafilcon B contact lenses (sphere, toric and multifocal), worn on a daily wear basis for 30 days, with OPTI-FREE MPDS lens care system
61980887|NCT03035708|PLACEBO_COMPARATOR|Placebo|1 mg BID (2 capsules BID)
61980888|NCT04728581|PLACEBO_COMPARATOR|Placebo|use of placebo during first 2 weeks after TKA surgery
61980889|NCT04728581|EXPERIMENTAL|Low dose Mirtazapine|Use of Mirtazapine 3.75mg before lights-out, allowed to increase medication to 7.5mg
61980890|NCT04728581|EXPERIMENTAL|Low dose Quetiapine|use of Quetiapine 3.125mg before lights-out, allowed to increase medication to 6.25mg
61980891|NCT05372328|OTHER|Desk1, Lap, Side, Desk2|"The order of arm positions for participants randomized to this arm will be:~Desk, Lap, Side, Desk"
61980892|NCT05372328|OTHER|Desk1, Side, Lap, Desk2|"The order of arm positions for participants randomized to this arm will be:~Desk, Side, Lap, Desk"
61980893|NCT05372328|OTHER|Lap, Desk1, Side, Desk2|"The order of arm positions for participants randomized to this arm will be:~Lap, Desk, Side, Desk"
61980894|NCT05372328|OTHER|Lap, Side, Desk1, Desk2|"The order of arm positions for participants randomized to this arm will be:~Lap, Side, Desk, Desk"
61980895|NCT05372328|OTHER|Side, Lap, Desk1, Desk2|"The order of arm positions for participants randomized to this arm will be:~Side, Lap, Desk, Desk"
61980896|NCT05372328|OTHER|Side, Desk1, Lap, Desk2|"The order of arm positions for participants randomized to this arm will be:~Side, Desk, Lap, Desk"
61980897|NCT01714154|EXPERIMENTAL|A: setrobuvir|
61980898|NCT01714154|EXPERIMENTAL|B: setrobuvir + DNV/r|
61980899|NCT02078609|EXPERIMENTAL|LGH447 monotherapy arm|LGH447 monotherapy in patients with AML or MDS
61980900|NCT02078609|EXPERIMENTAL|LGH447 + midostaurin combination arm|LGH447 + midostaurin in patients with AML
62182279|NCT04591262|EXPERIMENTAL|PF-06826647 600 mg PO>PF-06826647 600 mg PO+100 ug IV|PF-06826647 600 mg single dose in Period 1 followed by PF-06826647 600 mg PO and IV infusion of 100 ug of PF-06826647 in Period 2.
62182280|NCT02288364|ACTIVE_COMPARATOR|1% Lidocaine|1% Lidocaine alone.
62182281|NCT02288364|ACTIVE_COMPARATOR|1% Lidocaine plus sodium bicarbonate|1% Lidocaine plus 8.4% sodium bicarbonate
62182282|NCT03937245||HA-BSI|Patients with HA-BSI treated in an ICU
62549945|NCT06064305||Septic AKI patients|Septic AKI patients
62549946|NCT06064305||Non-septic post-cardiothoracic AKI patients|Non-septic post-cardiothoracic surgery AKI patients
62549947|NCT06064305||non-AKI patients undergoing routine nephrectomy|non-AKI patients undergoing routine nephrectomy
62549948|NCT02171871|EXPERIMENTAL|CONTROL GROUP|"Healthy non-smoking volunteers (18-40 years old) will be subject, after giving their brief medical history, to IOS and to the nitrogen washout test. The IOS will be conducted in four positions (standing, sitting, right and left lateral decubitus), whereas the nitrogen washout test in two (sitting and decubitus).~Then the subjects will be exposed to a smoking environment for 20 minutes."
61980901|NCT01333059|EXPERIMENTAL|Experimental Group|"In this arm Fentanyl and Midazolam was replaced with placebo (normal saline) during cycling.~At cycling time for midazolam, the continuous infusion of midazolam was stopped by the bedside nurse. The nurse started a pump containing a syringe labeled Study Drug M which contained the placebo drug (normal saline). The switch to Study Drug M occurred twice daily at 0800 and 2000 for a period of 3 hours each. At cycling time for fentanyl, the continuous infusion of fentanyl was stopped by the bedside nurse. The pump containing a syringe labeled Study Drug F, which contained the placebo drug (normal saline), was started. The switch Study Drug F occurred twice daily at 1400 and 0200 for a period of 3 hours each.~Dosing was done per standard of care and not prescribed per protocol"
61980902|NCT01333059|ACTIVE_COMPARATOR|Control Group|"In this arm, midazolam and fentanyl were administered during cycling.~At cycling time for midazolam, the continuous infusion of midazolam was stopped by the bedside nurse. The nurse started a pump containing a syringe labeled Study Drug M which contained the control drug (midazolam). The switch to Study Drug M occurred twice daily at 0800 and 2000 for a period of 3 hours each. At cycling time for fentanyl, the continuous infusion of fentanyl was stopped by the bedside nurse. The pump containing a syringe labeled Study Drug F, which contained the control drug (fentanyl), was started. The switch to Study Drug F occurred twice daily at 1400 and 0200 for a period of 3 hours each.~Dosing was done per standard of care and not prescribed per protocol."
61980903|NCT00727883||1|Post menopausal women treated with adjuvant TAM for breast cancer
61980904|NCT02416258|ACTIVE_COMPARATOR|LP0113 aerosol spray|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
61980905|NCT02416258|PLACEBO_COMPARATOR|Aerosol spray vehicle|No active ingredient, topical
61980906|NCT02416258|ACTIVE_COMPARATOR|LEO 90100 aerosol foam|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
61980907|NCT02416258|ACTIVE_COMPARATOR|Betamethasone dipropionate aerosol spray|Betamethasone (as dipropionate) 0.5 mg/g, topical
61980908|NCT02416258|ACTIVE_COMPARATOR|Calcipotriol aerosol spray|Calcipotriol (as monohydrate) 50 mcg/g, topical
61980909|NCT02416258|ACTIVE_COMPARATOR|Daivobet® gel|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
61980910|NCT05193864||Ambulatory CHF patients|Patients visiting an outpatient CHF clinic
62360077|NCT01809197|ACTIVE_COMPARATOR|Acuvue Oasys/Habitual MPS|Senofilcon A contact lenses (sphere, toric and multifocal), worn on a daily wear basis for 30 days, with habitual MPS lens care system
62549949|NCT02017015|EXPERIMENTAL|nab-paclitaxel with gemcitabine|nab-paclitaxel at 125 mg/m\^2, intravenous (IV) infusion over 30 to 40 minutes followed by gemcitabine at 1000 mg/ m\^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
61980911|NCT02637700|EXPERIMENTAL|Intravenous Immunoglobulin|Patients with skin biopsy proven idiopathic Small Fiber Neuropathy in this arm will receive intravenous immunoglobulin.
61980912|NCT02637700|PLACEBO_COMPARATOR|Placebo (Saline 0.9%)|Patients with skin biopsy proven idiopathic Small Fiber Neuropathy in this arm will receive placebo (saline 0.9%).
61980913|NCT01968668|EXPERIMENTAL|BAY94-8862 (1.25 mg)|
61980914|NCT01968668|EXPERIMENTAL|BAY94-8862 (2.5 mg)|
62360078|NCT01607294|EXPERIMENTAL|ETC-1002|ETC-1002 daily Weeks 1-2, 80 mg/day; Weeks 3-4, 120 mg/day
61980915|NCT01968668|EXPERIMENTAL|BAY94-8862 (5 mg )|
61980916|NCT01968668|EXPERIMENTAL|BAY94-8862 (7.5 mg)|
61980917|NCT01968668|EXPERIMENTAL|BAY94-8862 (10 mg)|
61980918|NCT01968668|PLACEBO_COMPARATOR|Placebo|
61980919|NCT01968668|EXPERIMENTAL|BAY 94-8862 (15 mg)|
61980920|NCT01968668|EXPERIMENTAL|BAY 94-8862 (20 mg)|
61980921|NCT03785665|EXPERIMENTAL|Participants|All study participants will be examined by the MD1 capsules, 2-5 capsules per person, one capsule at a time. Efforts will be made to maintain balanced numbers between men and women and even distribution of ages
61980922|NCT03125070|EXPERIMENTAL|Group I (INSPIRE, survivorship care plan)|Patients receive immediate access to the INSPIRE online program and personalized survivorship care plan.
62549950|NCT05123430|EXPERIMENTAL|MitraClip operated patients suffering from serious mitral insufficiency|
62549951|NCT06278480||MegaCarti®|Experimental: MegaCarti® application after microfracture The experimental group is applied with MegaCarti® and underwent high tibial osteotomy(HTO) after microfracture.
61980923|NCT03125070|ACTIVE_COMPARATOR|Group II (usual care)|Patients receive an online program linking to existing online survivor resources and a personalized survivorship care plan. Patients may receive access to the INSPIRE online program after 12 months.
61980924|NCT05682781|ACTIVE_COMPARATOR|Dietary Counseling|
61980925|NCT05682781|EXPERIMENTAL|Dietary Counseling + Oral Nutritional Supplement|
61980926|NCT04425265|EXPERIMENTAL|Plasma radiofrequency ablation arm|Plasma radiofrequency ablation at low temperature for localized recurrent nasopharyngeal carcinoma
61980927|NCT04425265|ACTIVE_COMPARATOR|Electrocautery block resection arm|Electrocautery block resection at high frequency for localized recurrent nasopharyngeal carcinoma
62360079|NCT01607294|PLACEBO_COMPARATOR|Placebo|Placebo daily 4 weeks
62360080|NCT03043846||Tight control and Treat to Target arm|For this group, the treating rheumatologist will agree to monitor very closely (at least every 4 weeks) and also to treat their patients in accordance with a pre-defined strategy.
61980928|NCT02414334|ACTIVE_COMPARATOR|Immediate SABR|Immediate stereotactic ablative radiotherapy (standard arm)
61980929|NCT02414334|EXPERIMENTAL|Delayed SABR|Delayed stereotactic ablative radiotherapy (delayed= treatment six months after randomisation or at disease progression) (experimental arm)
61980930|NCT00864149|EXPERIMENTAL|A|Carvedilol 12.5 mg Tablets, single dose
62549952|NCT06278480||Microfracture only|The control group underwent microfracture and high tibial osteotomy(HTO)
62549953|NCT05806892|EXPERIMENTAL|Experiment|Thera Pearl application will be explained to the woman in detail and the first application will be carried out together in the hospital.
62549954|NCT05806892|NO_INTERVENTION|Control|No intervention will be applied to the control group.
62360081|NCT03043846||Usual care arm|For this arm, the treating rheumatologists will continue to manage the enrolled patients in accordance to their usual care.
62360082|NCT01141218||Never-smokers with lung cancer|
62360083|NCT05946707|ACTIVE_COMPARATOR|high oxygen: decremental FiO2 titration|Five minutes before lung isolation fraction of inspired oxygen will be increased to 1.0, representing the standard procedure for one-lung ventilation. 10, 20 and 30 minutes after OLV initiation paO2 obtained from arterial blood gas analysis will be measured and FiO2 titrated to achieve a paO2 of 75-120 mmHg.
62360084|NCT05946707|EXPERIMENTAL|low oxygen: incremental FiO2 titration|Before lung isolation fraction of inspired oxygen will be maintained as previously set to guarantee normoxia (SpO2 \>92%). During OLV SpO2 will be continuously monitored and FiO2 adjusted to keep SpO2 \>92%. Additionally after 10, 20 and 30 minutes after OLV initiation paO2 obtained from arterial blood gas analysis will be measured and FiO2 more precisely titrated to achieve a paO2 of 75-120 mmHg.
62360085|NCT01288586||Device|Scandinavian Total Ankle Replacement System (STAR Ankle)
61980931|NCT00864149|ACTIVE_COMPARATOR|B|Coreg® 12.5 mg Tablets , single dose
62360086|NCT00418717|EXPERIMENTAL|1|Arm 1: Period A-25mg BW; Arm 1: Period B-50mg QW
62360087|NCT02120352|EXPERIMENTAL|CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)|On Day 1 of the Maintenance period, participants who successfully completed the Induction period, were randomized to receive following intramuscular (IM) doses: Day 1 only: CAB long acting (LA) 800 mg (loading dose delivered as two 400 mg IM injections) + RPV LA 900 mg IM; Week 4 only: CAB LA 600 mg IM (second loading dose, no RPV); and from Week 8: CAB LA 600 mg IM +RPV LA 900 mg IM every 8 Weeks (Q8W) for 96 weeks. Eligible participants had the option to continue study participation in the Extension Period.
62360088|NCT02120352|EXPERIMENTAL|CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)|On Day 1 of the Maintenance period, participants who successfully completed the Induction period, were randomized to receive following IM doses: Day 1 only: CAB LA 800 mg (loading dose delivered as two 400 mg IM injections) + RPV LA 600 mg IM; and from Week 4: CAB LA 400 mg IM + RPV LA 600 mg IM every 4 Weeks (Q4W) for 96 weeks. Eligible participants had the option to continue study participation in the Extension Period.
62360089|NCT02120352|ACTIVE_COMPARATOR|CAB 30 mg+ABC/3TC QD (Induction Period)|In induction period, all participants received an oral regimen of cabotegravir (CAB) 30 milligrams (mg) once daily (QD) plus abacavir/lamivudine (ABC/3TC) 600/300 mg QD for 20 weeks. They also received an oral dose of Rilpivirine (RPV) 25 mg tablet once daily in the last 4 weeks of the Induction Period.
61980932|NCT05028179|NO_INTERVENTION|Standard Care (comparator)|Patients will receive standard care
62360090|NCT02120352|ACTIVE_COMPARATOR|CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)|On Day 1 of the Maintenance period, participants who successfully completed the Induction period, were randomized to receive CAB and ABC/3TC QD for 96 weeks. Eligible participants had the option to continue study participation in Extension Period by switching to an optimized IM CAB LA+ RPV LA regimen of their choice (Q8W or Q4W).
62360091|NCT02120352|EXPERIMENTAL|Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period)|Participants who completed 96 weeks of CAB 30 mg + ABC/3TC QD regimen in Maintenance Period transitioned to Extension Period and received an optimized loading dose of CAB LA 600 mg+RPV LA 900 mg IM at Week 100 and Week 104 followed by CAB LA 600 mg+RPV LA 900 mg IM-Q8W in the Extension Phase. Participants were followed up until end of Extension Period.
62360092|NCT02120352|EXPERIMENTAL|Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period)|Participants who completed 96 weeks of CAB 30 mg + ABC/3TC QD regimen in Maintenance Period transitioned to Extension Period and received an optimized loading dose of CAB LA 400 mg+RPV LA 900 mg IM at Week 100 followed by CAB LA 400 mg+RPV LA 900 mg IM-Q8W in the Extension Phase. Participants were followed up until end of Extension Period.
62360093|NCT02120352|OTHER|Long-Term Follow-Up Group|This group included participants that were withdrawn from CAB LA+RPV LA IM regimens based on protocol criteria and were required to access Highly Active Antiretroviral Therapy (HAART) of choice. Participants were followed up for approximately 52 weeks.
62360094|NCT02316626|EXPERIMENTAL|Subcutaneous progesterone|Luteal phase support cycles will involve once-daily administration of 25 mg of SC P from the day after insemination for 14 days.
61980933|NCT05028179|EXPERIMENTAL|Standard Care plus AI platform (EchoGo)|Patients will receive standard care plus their Echocardiogram will be sent to Ultromics for AI assessment. The report from the assessment will be sent to the clinician, and utilised to inform the patients further care.
61980934|NCT02160158|EXPERIMENTAL|Cohort 1|
62360095|NCT02316626|ACTIVE_COMPARATOR|Vaginal Progesterone|Luteal phase support cycles will involve once-daily administration of 90 mg vaginal gel from the day after insemination for 14 days.
61980935|NCT02160158|EXPERIMENTAL|Cohort 2|
61980936|NCT04954547|EXPERIMENTAL|Subsidy Arm|Participants in the arm will receive $$50 if they reach the PBF goal and will be subsidized on approved health-improving expenses.
61980937|NCT04954547|EXPERIMENTAL|Cash Arm|Participants in the arm will receive S$350 if they reach the PBF goal.
61980938|NCT04954547|NO_INTERVENTION|Control|Other than the participation fees, no additional incentives will be provided.
61980939|NCT01399138|EXPERIMENTAL|Blueberry Powder|A blueberry smoothie will be consumed at the breakfast and dinner meals.
61980940|NCT01399138|PLACEBO_COMPARATOR|Placebo|A placebo smoothie will be consumed at the breakfast and dinner meals.
61980941|NCT06226766|EXPERIMENTAL|Dose escalation/expansion|"The dose escalation phase will utilize single patient accelerated dose titration (ADT) for dose level 1 (1.1 mg/kg , SC, QW) and dose level 2 (2.3 mg/kg, SC, QW), followed by dose level 3 (4.5 mg/kg, SC, QW), dose level 4 (5.6 mg/kg, SC, QW) and dose level 5 (6.7 mg/kg, SC,QW), which will all be enrolled and monitored using the 3+3 design, aimed at determining the MTD/RP2D of JSKN033.~After or during dose escalation, SMC will select 1-2 dose levels to expand with 10-30 additional patients with gastrointestinal tumor with HER2 expression each dose level for further exploration of the efficacy and safety of JSKN033."
62182283|NCT03106792|EXPERIMENTAL|Hairfinity #1|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
62360096|NCT01324427|EXPERIMENTAL|virtual medical visit|"This is a pilot trial involving a maximum of 84 patients undergoing either allogeneic or autologous stem cell transplant aimed at determining the feasibility and acceptance of a virtual medical visit by patients and health care personnel. During this pilot trial we expect to perform 84 virtual medical visits using telemedicine."
62360097|NCT01656811|EXPERIMENTAL|levalbuterol 90 mcg|levalbuterol 90 mcg delivered via metered dose inhaler (MDI)
62360098|NCT01656811|EXPERIMENTAL|levalbuterol 180 mcg|levalbuterol 180 mcg delivered via MDI
61980942|NCT03312933||Duration of boot >2 weeks|All patients who were placed into a CAM walker boot for \>2 weeks were prospectively enrolled. Patients were placed by an orthopedic cast technician into either a tall or short CAM walker boot, based upon the appropriate boot type needed for treatment. Inclusion criteria included anticipated boot wear for at least two weeks, and weightbearing as tolerated weightbearing restrictions. Exclusion criteria included transitioning into a CAM walker boot as part of a postoperative protocol, injury requiring restricted weightbearing, or an additional acute injury to the lower back or lower extremity. Those who subsequently reported wearing the boot for less than two weeks or had a treatment plan change were removed from the study.
61980943|NCT05160831|EXPERIMENTAL|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells injection is applied for knee OA patients.
62360099|NCT01656811|ACTIVE_COMPARATOR|racemic albuterol 180 mcg|racemic albuterol 180 mcg delivered via MDI
62360100|NCT01656811|PLACEBO_COMPARATOR|Placebo|Placebo delivered via MDI
62360101|NCT04459494|EXPERIMENTAL|Test group|Patients undergoing dental implant treatment without flap removal (Test Group)
61980944|NCT06297733||Physiotherapy Students|The population of the research consists of undergraduate students of the physiotherapy and rehabilitation department.
61980945|NCT03358901|EXPERIMENTAL|YC-6|6 volunteers in each level will be infused 100, 200, 400, or 600 mg of YC-6 over 7 consecutive days: BID within 30 minutes for the first 6 days and QD on the 7th day.
62360102|NCT04459494|ACTIVE_COMPARATOR|Control group|Patients who will receive dental implants by removing conventional full thickness flaps (Control group)
62360103|NCT01451151|EXPERIMENTAL|Treated|
62360104|NCT04648618||OSA + DME +|Patients with OSA and DME
61980946|NCT03358901|PLACEBO_COMPARATOR|Vehicle|2 volunteers in each level will be infused 2, 4, 8, or 12 g of vehicle over 7 consecutive days: BID within 30 minutes for the first 6 days and QD on the 7th day.
61980947|NCT00759863|EXPERIMENTAL|Lifezig|Subjects watch personalized reminiscence video channels developed by program staff with the help of family members/caregivers (using the LifeZig system)
62360105|NCT04648618||OSA - DME +|Patients with DME, but no evidence of OSA
62360106|NCT00759083|EXPERIMENTAL|1|Patients with HIT/HITTS who require anticoagulation for PCI
62360107|NCT00640146|EXPERIMENTAL|MNTX|Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) subcutaneously (SC) once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.
62360108|NCT00640146|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to MNTX SC once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.
62360109|NCT04454138||Targeted supratenon's placement of XEN 45|Placement of Xen-45 gelatin microstent in the supra-tenon's space to maximize aqueous outflow, while preventing obstruction, limiting fibrosis of the bleb, and promoting long-term patency.
62360110|NCT04454138||Non-targeted placement of XEN 45|Implantation of the XEN-45 gelatin microstent within the subconjunctival space, avoiding intra-tenon's placement.
62360111|NCT06507761|SHAM_COMPARATOR|Sham Group|
62360112|NCT06507761|ACTIVE_COMPARATOR|Hot Pack Group|
62360113|NCT06507761|ACTIVE_COMPARATOR|Cold Pack Group|
62360114|NCT05134168|ACTIVE_COMPARATOR|LIFT|Patients underwent LIFT proecdure
62360115|NCT05134168|ACTIVE_COMPARATOR|LIFT+bone marrow mononuclear cell injection|Patients underwent LIFT with bone marrow mononuclear cell injection
62360116|NCT06076772||1|cases developed neutropenia Grade 0-2 with palbociclib administration
62360117|NCT06076772||2|cases developed neutropenia Grade 3-4 with palbociclib administration
61980948|NCT00759863|NO_INTERVENTION|Usual Care|Subjects follow routine activities applied by nurses or caregivers, such as traditional reminiscence, crafts, singing, recreational activities, and other activities.
61980949|NCT02987400|EXPERIMENTAL|Treatment|Obinutuzumab is given in a 21 day cycle intravenously starting at 1000 mg on day 1, 8 and 15 in cycle 1 and on day 1 of each following cycle Venetoclax is given orally at a dose of 800mg daily from day 1 of the first cycle.
61980950|NCT02394847|OTHER|propofol|dose of propofol according to the number of therapies
61980951|NCT02389088|NO_INTERVENTION|Phase I|"9 PCOS women will be studied. On study day one, r-FSH will be administered I.V. at a dose of 150 IU (FSH stimulation test). Blood samples will be obtained before and after FSH administration. After the FSH stimulation test, each subject will receive an I.M. injection of Lupron 3.75 mg. This dose has a duration effect of one month.~The FSH stimulation test will be repeated, as described above, at 5 weeks (early resumption of ovarian function) and 6 weeks (moderate resumption of ovarian function)."
62182284|NCT03106792|EXPERIMENTAL|Hairfinity #2|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
62182285|NCT03106792|EXPERIMENTAL|Hairfinity #3|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
62360118|NCT01843634|EXPERIMENTAL|ODSH|
62360119|NCT02580838|EXPERIMENTAL|early OnabotulinumtoxinA group|OnabotulinumtoxinA will be injected immediately when spasticity develop in early OnabotulinumtoxinA group.
62360120|NCT02580838|ACTIVE_COMPARATOR|late OnabotulinumtoxinA group|OnabotulinumtoxinA will be injected at 6 months after emergence of spasticity in late OnabotulinumtoxinA group.
62360121|NCT02580838|NO_INTERVENTION|no OnabotulinumtoxinA group|OnabotulinumtoxinA will not be injected for this group.
62360122|NCT06103019|ACTIVE_COMPARATOR|Conventional (complete denture)|Each patient received two prostheses: 1) Conventional Maxillary and mandibular complete denture. 2) 3D printed complete Maxillary and mandibular complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing denture then the other type of denture was delivered and used for another 3 months.
62360123|NCT06103019|ACTIVE_COMPARATOR|3D printed complete denture|Each patient received two prostheses: 1) Conventional Maxillary and mandibular complete denture. 2) 3D printed complete Maxillary and mandibular complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing denture then the other type of denture was delivered and used for another 3 months.
61980952|NCT02389088|ACTIVE_COMPARATOR|Phase II|"Women that participated in Phase I will be studied again after a washout of 2 months. On study day one, an FSH stimulation test will be performed as described above.~After the FSH stimulation test, each subject will receive an I.M. injection of Lupron 3.75 mg. This dose has a duration effect of one month. Four weeks after administration of Lupron, each subject will receive Letrozole 5mg for 14 days. The FSH stimulation test will be repeated at 5 weeks (early resumption of ovarian function) and 6 weeks (moderate resumption of ovarian function)."
62360124|NCT05343585|EXPERIMENTAL|Experimental|"* Training and use of Openfit~* Using the app to estimate food intake from simulated meals in a laboratory at PBRC or LSU (participants will not eat food during the meals)~* Rating the usability and satisfaction of the app"
62360125|NCT04537754|EXPERIMENTAL|clinician|Comparison of LED and diode laser
62360126|NCT02709109|EXPERIMENTAL|Sequence 1: VX-371 + Hypertonic Saline (HS), then HS|Participants received 85 microgram (mcg) VX-371 diluted in 3 milliliter (mL) 4.2 percent (%) HS through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 milligram (mg)/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their cystic fibrosis (CF) standard of care.
61980953|NCT03848273||Ischemic|questionnaire, physical-neurological examination, labor investigations, EEG
62360127|NCT02709109|EXPERIMENTAL|Sequence 2: HS, then VX-371 + HS|Participants received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
61980954|NCT03848273||Hemorrhagic|questionnaire, physical-neurological examination, labor investigations, EEG
62360128|NCT02709109|EXPERIMENTAL|Sequence 3: VX-371 + Placebo, then Placebo|Participants received 85 mcg VX-371 diluted in 3 mL 0.17% Saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
62360129|NCT02709109|EXPERIMENTAL|Sequence 4: Placebo, then VX-371 + Placebo|Participants received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
62360130|NCT04281017|EXPERIMENTAL|TIVA anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg) to limit any discomfort caused by the propofol injection. After endotracheal intubation, intravenous infusion of propofol, lidocaine, ketamine or narcotic as deemed appropriate by anesthesiologist. There will be no inhalation anesthetic used. Ventilation with oxygen and air mixture (50%/50%) and titrated to keep the mean arterial pressure within 20% of its preinduction value. Muscle relaxation maintain using Aliquots of rocuronium to 0 to 1 train-of-4 twitch response of adductor pollicis. During surgery, mechanical ventilation using pressure-controlled mode (peak inspiratory pressure 30 cm H2O). We aim for Tidal volume of 5-7 ml/Kg of ideal body weight with a positive end-expiratory pressure of 5 cm H2O, and a respiratory rate to maintain end-tidal carbon dioxide between 30 to 40 mm Hg.
62360131|NCT04281017|ACTIVE_COMPARATOR|Balanced anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg) to limit any discomfort caused by the propofol injection. After endotracheal intubation, the depth of anesthesia will be maintained at a minimum alveolar concentration of 1 to 1.25 using isoflurane in oxygen and air mixture (50%/50%) and titrated to keep the mean arterial pressure within 20% of its preinduction value. Muscle relaxation maintain using Aliquots of rocuronium to 0 to 1 train-of-4 twitch response of adductor pollicis. During the surgery, subjects will be mechanically ventilated using pressure-controlled mode (peak inspiratory pressure 30 cm H2O). We aim for Tidal volume of 5-7 ml/Kg of ideal body weight with a positive end-expiratory pressure of 5 cm H2O, and a respiratory rate to maintain end-tidal carbon dioxide between 30 to 40 mm Hg.
62391393|NCT02715635|ACTIVE_COMPARATOR|Nitrate-rich beetroot juice|"Biological: Typhoid vaccine The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution Other Name: Typhim Vi®~Dietary Supplement: Concentrate beetroot Juice 140 ml containing \~8 mmol of inorganic nitrate"
62549955|NCT03237338|EXPERIMENTAL|Insomnia-ture acupuncture|"True acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints will be administered on CID patients Intervention: Procedure: true acupuncture"
62549956|NCT03237338|SHAM_COMPARATOR|Insomnia-sham acupuncture|"Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints will be administered on CID patients Intervention: Procedure: true acupuncture"
61980955|NCT03848273||Control|questionnaire, physical-neurological examination, labor investigations, EEG
61980956|NCT01759030|ACTIVE_COMPARATOR|MabThera (F. Hoffmann-La Roche Ltd.)|"Stage 1 (week 1 - week 24) MabThera will be administered at a dose of 1000 mg, IV (on day 1 and day 15).~Stage 2 (week 24 - 48) If the disease activity remains on Week 24 the patient will undergo the second randomization (1:1 ratio): if he/she randomised into group A then he/she recieves BCD-020 at a dose f 1000 mg, IV, once in 2 weeks, 2 infusions per course (on day 1 and day 15); if he/she if he/she randomised into group B then he/she continues to recieve MabThera at a dose f 1000 mg, IV, once in 2 weeks, 2 infusions per course (on day 1 and day 15).~MabThera/BCD-020 will be used in combination with methotrexate (irrespectively to study stage)."
62182286|NCT03106792|PLACEBO_COMPARATOR|Placebo|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
62360132|NCT04835571|EXPERIMENTAL|CARMA study participants|All patients in the study are in the same treatment arm: all were treated for 12 months according to routine care and international guidelines for cardiovascular disease prevention in patients with very high cardiovascular risk. Through study physicians patients received an individual assessment and optimized cardiovascular risk management, including life style advice and adjustments in their medical preventive treatment, based on drugs used in standard care (eg. lipid lowering medication, anti-hypertensive-treatment, anti-thrombotic treatment). All treatment goals were set in accordance with current guidelines at the time for study participation.
61980957|NCT01759030|EXPERIMENTAL|BCD-020 (CJSC BIOCAD)|"Stage 1 (week 1-week 24) BCD-020 will be administered at a dose of 1000 mg, IV (on day 1 and day 15).~Stage 2 (week 24-48) If the disease activity remains on Week 24 the patient will undergo the second randomization (1:1 ratio): if he/she randomised into group A then he/she recieves MabThera at a dose f 1000 mg, IV, on day 1 and day 15; if he/she if he/she randomised into group B then he/she continues to recieve BCD-020 at a dose f 1000 mg, IV, on day 1 and day 15.~MabThera/BCD-020 will be used in combination with methotrexate (irrespectively to study stage)."
61980958|NCT01761656|EXPERIMENTAL|loading dose atorvastatin|For the arm of loading dose atorvastatin, patients will be treated with 80 mg atorvastatin 12 hours before PCI and 40 mg atorvastatin 2 hours before PCI and then 20mg/d after PCI.
61980959|NCT01761656|ACTIVE_COMPARATOR|conventional dose atorvastatin|For the arm of conventional dose atorvastatin, patients will be treated with 20 mg atorvastatin 12 hours before PCI and then 20mg/d after PCI.
61980960|NCT04460547||Completed Interventional studies|Interventional studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.
62360133|NCT02455388|EXPERIMENTAL|Low, then high added sugar diet|Participants will consume a low added sugar (5% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a high added sugar (25% total energy) diet for 7 consecutive days.
61980961|NCT04460547||Completed Observational studies|Observational studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.
62360134|NCT02455388|EXPERIMENTAL|High, then low added sugar diet|Participants will consume a high added sugar (25% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a low added sugar (5% total energy) diet for 7 consecutive days
62360135|NCT02455388|NO_INTERVENTION|Dietary recall and fingerstick|Participants will complete 4 in-person 24-hr dietary recalls and 2 fingerstick blood samples at Visit 1 and 3 within 3 weeks.
62360136|NCT05410899||Pelvic Floor Health Education|Education will compose presentation about women health, urinary incontinence, teaching anatomy of the pelvic floor and bladder training
61980962|NCT01471106|EXPERIMENTAL|Group 1: Dasatinib 40 mg|Dasatinib 40 mg by mouth once a day for 3 months (+/- 7 days), At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
61980963|NCT01471106|NO_INTERVENTION|Group 3: No Dasatinib|No treatment control group. At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
61980964|NCT01471106|EXPERIMENTAL|Group 2: Dasatinib 80 mg|Dasatinib 80 mg by mouth once a day for 3 months (+/- 7 days). At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
62360137|NCT05410899||Pelvic Floor Health Education and Exercise Program|pelvic floor health education and exercise of pelvic floor muscles for 12 weeks
61980965|NCT00677157||screening|participants evaluated for possible inclusion in a natural history or intervention protocol
61980966|NCT01271660|ACTIVE_COMPARATOR|Pregabalin|"30 randomly allocated patients after a 4-week run-in period, who will take part in a 6-week treatment period with pregabalin.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as standard dose period + 75mg twice a day for a week as tapering period."
61980967|NCT01271660|PLACEBO_COMPARATOR|Placebo|"30 randomly allocated patients after a 4-week run-in period, who will take part in a 6-week treatment period with placebo.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as standard dose period + 75mg twice a day for a week as tapering period."
61980968|NCT05003453|EXPERIMENTAL|1.5% Palmitoylethanolamide (PEA) sold as Levagen+|Investigational product will be provided as a topical cream containing 1.5% PEA and participants will be asked to apply to their affected site 2 times daily for 4 weeks. Cream should be applied liberally (as you would a moisturiser cream) such to coat the affected area and absorb into the skin.
61980969|NCT05003453|PLACEBO_COMPARATOR|Placebo comparator|A comparator placebo moisturiser cream (an unscented moisturizing base cream) will be provided and applied in the same manner as the active ingredient group. Participants will be asked to apply to their affected site 2 times daily for 4 weeks. Cream should be applied liberally (as you would a moisturiser cream) such to coat the affected area and absorb into the skin.
61980970|NCT05651633|EXPERIMENTAL|Lidocaine ear drops with usual care|usual care: oral analgesic with/without antibiotics
61980971|NCT05651633|NO_INTERVENTION|usual care|usual care: oral analgesic with/without antibiotics
61980972|NCT01918904|EXPERIMENTAL|Sodium Thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
61980973|NCT01918904|PLACEBO_COMPARATOR|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
61980974|NCT01356966|EXPERIMENTAL|Tetrahydrobiopterin + Folate|Male subjects with hypertension and chronic kidney disease stage 2 or 3 will receive Tetrahydrobiopterin (6R-BH4) 200 mg twice daily and folic acid 1 mg daily
61980975|NCT01356966|PLACEBO_COMPARATOR|Placebo + Folate|Male subjects with hypertension and chronic kidney disease stage 2 or 3 will receive 2 placebo pills twice daily and folic acid 1 mg daily
61980976|NCT06241079||ypT0N0|
61980977|NCT06241079||ypT0N+|
62360138|NCT05410899||Control|This goup will continue routine treatment such as medication usage
62360139|NCT05410197|EXPERIMENTAL|Envofolimab + Lenvatinib + Gemcitabine + Cisplatin|Single-arm trial whereby all consented, enrolled, eligible patients receive Envofolimab, Lenvatinib, Gemcitabine and Cisplatin
61980978|NCT06241079||ypT+N0|
61980979|NCT06241079||ypT+N+|
61980980|NCT01454869|ACTIVE_COMPARATOR|Standard care|nac + salotamul
61980981|NCT01454869|EXPERIMENTAL|heparin group|heparin group
62549957|NCT04269525|EXPERIMENTAL|pneumonia|According to Diagnosis and Clinical Management of Pneumonia caused by 2019-nCoV Infection(Trial Version 4), patients enrolled will be divided to serious pneumonia group or critical pneumonia group. All subjects will receive UC-MSCs 3.3 \* 107 cell number / 50ml / bag, 3 bags each time. And UC-MSCs will be infused intravenously on the 1st, 3rd, 5th, and 7th days after enrollment, 1 time each day. The efficacy and safety of the treatment, patients' adverse reactions will be monitored.
61980982|NCT02862613|EXPERIMENTAL|Precision Cells|"Precision Cells combined with Transcatheter Arterial Chemoembolization:~Transcatheter Arterial Chemoembolization:~patients will receive MMC,EADM hepatic arterial infusion,6 cycles. Precision Cells：After accepting concurrent TACE treatment,patients will receive 3 cycles of Precision Cells treatment"
61980983|NCT02862613|ACTIVE_COMPARATOR|Transcatheter Arterial Chemoembolization|patients will receive MMC,EADM hepatic arterial infusion,6 cycles.
62739142|NCT02882061|EXPERIMENTAL|CTDT positive|All subjects with a positive cervicothoracic differentiation test will be assigned to this arm. All subjects will then receive thoracic spinal manipulation to a level between T1 and T4.
61980984|NCT03727490|ACTIVE_COMPARATOR|Control|This group will have the subscapularis left un-repaired, which is the standard of care for our institution for reverse shoulder arthroplasty.
61980985|NCT03727490|EXPERIMENTAL|Study|This group will have the subscapularis tendon repaired through a bone to bone repair that will add approximately 5 minutes to the surgical procedure.
62360140|NCT01665872|EXPERIMENTAL|Cognitive-Behavioral Group Therapy|8-session Cognitive-Behavioral intervention based on Munoz et al's Mother Baby Manual, modified to meet the needs of mothers of children of all ages residing in public housing in New Haven, CT. Intervention co-facilitated by mental health clinician and a Community Mental Health Ambassador (peer).
62360141|NCT01665872|ACTIVE_COMPARATOR|Standard of care - Cognitive-Behavioral Group Therapy|8-session Cognitive-Behavioral intervention based on Munoz et al's Mother Baby Manual, modified to meet the needs of mothers of children of all ages residing in public housing in New Haven, CT. Intervention administered by mental health clinician.
62360142|NCT04615780|EXPERIMENTAL|mouthwash with green tea group|The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily.
62360143|NCT04615780|PLACEBO_COMPARATOR|mouthwash with tap water group|The control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.
62360144|NCT03934541|EXPERIMENTAL|Group 1 (Treatment 1): MPER-656 Liposome Vaccine|Participants will receive 500 mcg of MPER-656 liposomes, admixed with Aluminum Hydroxide Suspension, to be administered as two 0.5 mL doses at Months 0, 2, and 6.
62360145|NCT03934541|PLACEBO_COMPARATOR|Group 1 (Control 1): Placebo for MPER-656 Liposome Vaccine|Participants will receive placebo to be administered as two 0.5 mL doses at Months 0, 2, and 6.
62360146|NCT03934541|EXPERIMENTAL|Group 2 (Treatment 2): MPER-656 Liposome Vaccine|Participants will receive 2000 mcg of MPER-656 liposomes, admixed with Aluminum Hydroxide Suspension, to be administered as two 0.5 mL doses at Months 0, 2, and 6.
61980986|NCT00087581|EXPERIMENTAL|Group A: Monitored MMF + Reduced CNI|Group A will receive concentration-controlled/monitored MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or intravenous (IV) form. The initial dose will be at least 1 gram twice a day (BID) in adults and 600 milligrams per meter-squared (mg/m\^2) in pediatrics. Subsequent doses will be adjusted to maintain blood mycophenolic acid (MPA) levels greater than or equal to (≥) 1.3 micrograms per milliliter (μg/mL) with cyclosporine or ≥1.9 μg/mL with tacrolimus. The selected CNI will be dosed to maintain reduced blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 nanograms per milliliter (ng/mL); Days 30-90, 125-165 ng/mL; Days 90 through end of study, 95-145 ng/mL. Tacrolimus target concentrations areas follows: Days 1-30, 8-12 ng/mL; Days 30-90, 4-6 ng/mL; Days 90 through end of study, 3-5 ng/mL.
61980987|NCT00087581|EXPERIMENTAL|Group B: Monitored MMF + Full CNI|Group B will receive concentration-controlled/monitored MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The initial dose will be at least 1 gram BID in adults and 600 mg/m\^2 in pediatrics. Subsequent doses will be adjusted to maintain blood MPA levels ≥1.3 μg/mL with cyclosporine or ≥1.9 μg/mL with tacrolimus. The selected CNI will be dosed to maintain standard/full blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 250-270 ng/mL; Days 90 through end of study, 190-220 ng/mL. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 8-10 ng/mL; Days 90 through end of study, 6-8 ng/mL.
62182287|NCT01447862|ACTIVE_COMPARATOR|Vernakalant|Initially, patients will be given 3mg/kg Vernakalant in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of Vernakalant (2mg/kg), again over 10 minutes. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.
62360147|NCT03934541|PLACEBO_COMPARATOR|Group 2 (Control 2): Placebo for MPER-656 Liposome Vaccine|Participants will receive placebo to be administered as two 0.5 mL doses at Months 0, 2, and 6.
62360148|NCT01742533|EXPERIMENTAL|Group1 : HRT plus hUCMSCs treatment:|Participants will be given HRT plus human cord mesenchymal stem cells transplantation with a 12 menstrual Cycle follow-up.
62360149|NCT01742533|EXPERIMENTAL|Group 2: HRT plus hCBMNCs and hUCMSCs therapy|Participants will be given HRT plus combination of hCBMNCs together with hUCMSCs transplantation with a 12 menstrual Cycle follow-up.
62360150|NCT01742533|EXPERIMENTAL|Group3 : HRT plus hCBMNCs treatment:|Participants will be given HRT plus human cord blood mononuclear cells transplantation with a 12 menstrual Cycle follow-up.
62360151|NCT01742533|EXPERIMENTAL|Group 4:Hormone Replacement Therapy|Participants will be given conventional therapy only with a 12 menstrual Cycle follow-up.
62360152|NCT04225390|EXPERIMENTAL|Dacarbazine|Dacarbazine (day1 and day21) 850 mg/m² i.v. followed by re-exposure to the previous immunotherapy
62739143|NCT02882061|ACTIVE_COMPARATOR|CTDT negative|All subjects with a negative cervicothoracic differentiation test will be assigned to this arm. All subjects will then receive thoracic spinal manipulation to a level between T1 and T4.
62739144|NCT04603495|EXPERIMENTAL|Pelabresib + ruxolitinib|Pelabresib monohydrate tablets + ruxolitinib phosphate tablets
62739145|NCT04603495|ACTIVE_COMPARATOR|Placebo + ruxolitinib|Matching placebo tablets + ruxolitinib phosphate tablets
62360153|NCT01407848|EXPERIMENTAL|Furosemide|1 mg/kg/Ed
62549958|NCT04603326||Non-manifesting LRRK2 mutation carriers|Patients must have confirmed LRRK2 G2019S mutation Age 30 years or older at date of informed consent.
61980988|NCT00087581|EXPERIMENTAL|Group C: Fixed MMF + Full CNI|Group C will receive fixed-dose MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The dose will be at least 1 gram BID in adults and 600 mg/m\^2 in pediatrics. Subsequent doses are not to be adjusted, except in the case of unacceptable toxicity. The selected CNI will be dosed to maintain standard/full blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 250-270 ng/mL; Days 90 through end of study, 190-220 ng/mL. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 8-10 ng/mL; Days 90 through end of study, 6-8 ng/mL.
61980989|NCT03744923|ACTIVE_COMPARATOR|Transmuscular QLB group|Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall Then, scan dorsally keeping the transverse orientation until observing that the transverse abdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia The needle (20G spinal needle) is inserted in-plane from posterior to anterior and the tip of the needle is advanced towards then through the QL muscle, penetrating the ventral proper fascia of the QL muscle. The target site for injection is the plane between quadratus lumborum and psoas major. This will be followed by injection of Bupivacaine 0.5 % (0.25ml/kg) and lidocaine 2% (0.15ml/kg) mixed together.
61980990|NCT03744923|ACTIVE_COMPARATOR|unilateral posterior TAP block group|"under ultrasonographic guidance,the probe will be positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid-axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, the block was performed with the 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydro visualization of needle-tip position and confirming its correct positioning. This will be followed by injection of Bupivacaine 0.5 % (0.25ml/kg) and lidocaine 2% (0.15ml/kg) mixed together."
61980991|NCT03744923|NO_INTERVENTION|control group|the patients will not receive any blocks
61980992|NCT01729507|ACTIVE_COMPARATOR|Treatment with tDCS|This group will receive 7x verum treatment with tDSC. All participants receive standardised behavioural therapy ('The smoke-free programme')
61980993|NCT01729507|PLACEBO_COMPARATOR|7x sham treatment|This group will receive 7x sham treatment. All participants will receive standardised behavioural therapy ('The smoke-free programme')
62360154|NCT01407848|ACTIVE_COMPARATOR|Saline 0,9%|1ml/kg/Ed
62360155|NCT02360371|PLACEBO_COMPARATOR|Placebo (oral)|Within-subject double-blind, administration of placebo oral capsule. Order of dose randomized session days 3-5.
62360156|NCT02360371|EXPERIMENTAL|Hydromorphone (oral) 2mg|Within-subject double-blind, administration of hydromorphone via oral capsule. Order of dose randomized session days 3-5.
61980994|NCT02158338||Asthma|Mothers of children thought to have asthma
61980995|NCT02158338||Non-asthma|Mothers of children without diagnosed respiratory problems
61980996|NCT00166088|EXPERIMENTAL|Mediterranean Diet Arm|
61980997|NCT00166088|ACTIVE_COMPARATOR|Mediterranean Dietary Supplement Arm|
62360157|NCT02360371|EXPERIMENTAL|Hydromorphone (oral) 4mg|Hydromorphone oral capsule administered in double-blind manner on Day 2 as first study drug administration. Hydromorphone 4mg dosing day was set for safety purposes and non-randomized.
62360158|NCT02360371|EXPERIMENTAL|Hydromorphone (oral) 8mg|Within-subject double-blind, administration of hydromorphone via oral capsule. Order of dose randomized session days 3-5.
61980998|NCT00166088|NO_INTERVENTION|Control Arm|
62182288|NCT01447862|ACTIVE_COMPARATOR|Ibutilide|Patients will be given 1mg of ibutilide in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide, again over 10min. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.
62182289|NCT00906217||elderly patients|patients older than 70 years with normal renal function
62360159|NCT05210972||Diabetes|"Patients with level of HbA1c ≥ 6.5%, or Fasting blood glucose (FBG) ≥126 mg/dL, or a random plasma glucose (RBG) ≥ 200 mg/dL in a patient with classic symptoms of hyperglycemia.~In the absence of unequivocal hyperglycemia, diagnosis will be based on two abnormal test results, for FBG or RBG and HbA1c, from the same sample or in two separate test samples."
62360160|NCT05210972||Prediabetes|HbA1c 5.7-6.4% or FBG 110 mg/dL to 125 mg/dL The diagnosis will be based on two abnormal test results, for FBG or RBG and HbA1c, from the same sample or in two separate test samples.
62360161|NCT05210972||Normal glycemia|HbA1c \<5.7% and FBG 110 mg/dL
62360162|NCT04854577|EXPERIMENTAL|"Intervention group: Opioid Free Anesthesia with a pecto-intercostal fascial plane block"|Patients to whom a standardized opioid free anesthesia consisting of esketamine, lidocaine and dexmedetomidine will be administered with a pre-incisional pecto-intercostal fascial plane block.
62360163|NCT04854577|ACTIVE_COMPARATOR|"Control group: Traditional Opioid-based Anesthetic Regimen"|Patients who will receive a traditional opioid based anesthetic regimen. The administered dose of opioids is at the discretion of the attending anesthesiologist.
62391394|NCT02715635|PLACEBO_COMPARATOR|Nitrate-deplete beetroot juice|"Biological: Typhoid vaccine The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution Other Name: Typhim Vi®~Dietary Supplement: Concentrate beetroot Juice 140 ml which is nitrate-depleted"
62391395|NCT02986321|EXPERIMENTAL|CHF6001 DOSE1|DOSE1
62391396|NCT02986321|EXPERIMENTAL|CHF6001 DOSE2|DOSE2
62549959|NCT04603326||LRRK2 Parkinson Disease (PD) Participants:|Patients must have confirmed LRRK2 G2019S mutation Patients must meet the MDS criteria for Parkinson's disease Disease duration: any Age 30 years or older at time of PD diagnosis.
62360164|NCT02865265||Pecs II and parasternal blocks|"Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.~An ultrasound-guided ipsilateral PaB was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib."
62360165|NCT01909609|SHAM_COMPARATOR|Parent Survival Guide|This arm of the study will focus on the document that is normally given to all parents of newborn infants. It contains information on newborn care such as feeding, cleaning of the baby's penis, etc.
62360166|NCT01909609|EXPERIMENTAL|AAP Documents + Parent Survival Guide.|This arm of the study will focus on documents created based off of the American Academy of Pediatrics 2012 policy statement. They contain information on the potential risks and benefits of neonatal circumcision. The Parent Survival Guide contains information on newborn care such as feeding, cleaning of the baby's penis, etc.
62360167|NCT05474872||BIS monitoring|Patients in this group will be subjected to Bispectral index-guided general anesthesia.
62360168|NCT05474872||PRST score monitoring|Patients in this group will be subjected PRST score-guided general anesthesia.
62360169|NCT05239884|EXPERIMENTAL|Product usage order EFDGCHBA|Subjects will use each of the 8 products (EFDGCHBA) during an evaluation period, followed by a 4 hour Test Session
61980999|NCT05321433||The Swedish Cohort|Swedish data comes from a historical cohort of 424,386 clients of public dental clinics aged 23 and older in the Stockholm region with inception between October 2015 and January 2020, with follow-up from February 2020 to December 2020. In Sweden, the public dental clinics (Folktandvården, FTV) provide routine preventive visits (oral check-ups) to all residents who choose to receive care in these clinics. At each health check-up smoking and snus use are ascertained as past use, current use, and amount of current use. The national personal numbers assigned to every resident in Sweden at birth or at immigration will be used to obtain information on diagnoses of COVID-19 and of other diseases through record-linkage with regional health care registers. Demographic information will be extracted through record-linkage with the register of the total population of the Stockholm region held by Statistics Sweden.
62360170|NCT05239884|EXPERIMENTAL|Product usage order HAGBFCED|Subjects will use each of the 8 products (HAGBFCED) during an evaluation period, followed by a 4 hour Test Session
62360171|NCT05239884|EXPERIMENTAL|Product usage order CDBEAFHG|Subjects will use each of the 8 products (CDBEAFHG) during an evaluation period, followed by a 4 hour Test Session
62360172|NCT05239884|EXPERIMENTAL|Product usage order DECFBGAH|Subjects will use each of the 8 products (DECFBGAH) during an evaluation period, followed by a 4 hour Test Session
62360173|NCT05239884|EXPERIMENTAL|Product usage order FGEHDACB|Subjects will use each of the 8 products (FGEHDACB) during an evaluation period, followed by a 4 hour Test Session
62360174|NCT05239884|EXPERIMENTAL|Product usage order BCADHEGF|Subjects will use each of the 8 products (BCADHEGF) during an evaluation period, followed by a 4 hour Test Session
62360175|NCT05239884|EXPERIMENTAL|Product usage order ABHCGDFE|Subjects will use each of the 8 products (ABHCGDFE) during an evaluation period, followed by a 4 hour Test Session
62360176|NCT05239884|EXPERIMENTAL|Product usage order GHFAEBDC|Subjects will use each of the 8 products (GHFAEBDC) during an evaluation period, followed by a 4 hour Test Session
62360177|NCT03006796||group 1 (AZL/C)|Group 1 - patients receiving azilsartan medoxomil/chlorthalidone 40/12.5 mg or 40/25 mg per os once a day for 6 months.
62360178|NCT03006796||group 2 (IRB/H)|Group 2 - patients receiving irbesartan/hydrochlorothiazide 150/12.5 mg or 300/25 mg per once a day for 6 months.
62360179|NCT04494958|EXPERIMENTAL|Palbociclib + Binimetinib|
62360180|NCT03228706|EXPERIMENTAL|Intervention Group|All the participants who are randomly assigned to the intervention group will be undergoing the Know Your Medicine-Take it for Health (KYM-TIFH) program, which is a one-off structured group-based intervention (SGBI).
62360181|NCT03228706|NO_INTERVENTION|Control Group|All the participants who are randomly assigned to the control group will not be given any information related to KYM-TIFH. However, they will be assigned to the venue for the control group and will be asked to fill in questionnaires with the assistance of four facilitators. A briefing on how to answer the questionnaire will be given by the main facilitator and all facilitators are allowed to answer any questions raised by respondents related to the questionnaire. However, they are not allowed to answer on behalf of the respondents. After the completion of the questionnaire, they will be informed about the subsequent follow-up measurement after three, six and twelve months. After that, they will be dismissed and having usual care provided by the health clinic as before without any changes.
62360182|NCT03483116|EXPERIMENTAL|High dose RV3-BB neonatal schedule|High dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
62360183|NCT03483116|EXPERIMENTAL|Mid dose RV3-BB neonatal schedule|Mid dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
62360184|NCT03483116|EXPERIMENTAL|Low dose RV3-BB neonatal schedule|Low dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
62360185|NCT03483116|EXPERIMENTAL|High dose RV3-BB infant schedule|High dose infant RV3-BB vaccine schedule. Placebo for Investigational product dose 1 (0-5 days) and RV3-BB Vaccine for Investigational product doses 2 (week 6) 3 (week 10) and dose 4 (week 14)
62360186|NCT00493480|ACTIVE_COMPARATOR|carvedilol|
62360187|NCT00493480|ACTIVE_COMPARATOR|propranolol|Cirrhotic patients treated with propranolol
62360188|NCT03339401|EXPERIMENTAL|Brincidofovir|"Brincidofovir (BCV) for the treatment of adenovirs (AdV) infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.~Brincidofovir (BCV) treatment began no later than 100 days post-transplant and was to continue for a maximum of 16 weeks. Brincidofovir (BCV) was discontinued once AdV viremia was confirmed undetectable.~Subjects who did NOT receive concurrent cyclosporine on Day 1:~* If ≥48kg body weight, one 100mg oral tablet BIW (or 10mL of 10mg/mL oral suspension if unable to take tablets).~* If \<48kg body weight, 2mg/kg oral volume of 10mg/mL oral suspension BIW.~Subjects who received cyclosporine on Day 1 (or initiated cyclosporine at any time):~* 1.4mg/kg (maximum of 70mg) oral volume of 10mg/mL oral suspension BIW.~* 2mg/kg (maximum of 100mg) oral volume of 10mg/mL oral suspension BIW if discontinued cyclosporine."
62360189|NCT03339401|OTHER|Standard of Care|"Local institutional standard of care (SoC) (i.e., investigator-assigned therapy) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.~Management of these subjects was prescribed by the investigator as being in the best interests of the subject and may have included a watch-and-wait approach, with or without decreased immunosuppression (ergo, no treatment), or treatment administration with other available antivirals, most commonly cidofovir intravenously.~Decisions regarding SoC, including administration of therapy, dose and regimen of therapy, modification of immunosuppression, and monitoring was the responsibility of the clinical team caring for the subject, according to institutional guidelines, local practices, and applicable guidelines for the management of AdV infection."
62360190|NCT00088972|EXPERIMENTAL|Arm I - Celecoxib|Patients receive oral celecoxib twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.
62360191|NCT00088972|PLACEBO_COMPARATOR|Arm II - Placebo|Patients receive oral placebo twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.
62360192|NCT01369225|EXPERIMENTAL|0.5 mg/kg AAB-003|
62360193|NCT01369225|EXPERIMENTAL|1 mg/kg AAB-003|
62360194|NCT01369225|EXPERIMENTAL|2 mg/kg AAB-003|
62360195|NCT01369225|EXPERIMENTAL|4 mg/kg AAB-003|
62360196|NCT01369225|EXPERIMENTAL|8 mg/kg AAB-003|
62360197|NCT05531968|EXPERIMENTAL|BMI2006 100Units|Patients were intramuscularly injected (IM) with a total of 20U of BMI2006 in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line.
62360198|NCT05531968|ACTIVE_COMPARATOR|Botox®|Patients were intramuscularly injected (IM) with a total of 20U of Botox® in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line.
62360199|NCT02866734|ACTIVE_COMPARATOR|Free screening group|Subjects in this group receive free diabetic retinopathy screening.
62360200|NCT02866734|ACTIVE_COMPARATOR|Pay screening group ($150)|Subjects in this group receiving diabetic retinopathy screening will be charged HK$150.
62360201|NCT02866734|ACTIVE_COMPARATOR|Pay screening group ($300)|Subjects in this group receiving diabetic retinopathy screening will be charged HK$300.
62360202|NCT05833555|ACTIVE_COMPARATOR|Education and Resources|Education and Resources (E\&R) involves online training through the E-Hub on delivery of basic MH task-shifting skills, such as screening, psychoeducation, and referral to MH care. A community directory along with training on community resources will be made available to all participants. Specifically, we will recommend that those identified to have common MH problems (PHQ-4≥3) are offered a single two-hour zoom-based group psychoeducation session about depression and anxiety, COVID-19 impact on MH, wellness and self-care skills, and directory of Harlem-based MH services and other community resources. Participants exhibiting higher level needs are referred to MH specialists.
62360203|NCT05833555|EXPERIMENTAL|Multisector Collaborative Care|Multisector Collaborative Care (MCC) Model will consist of all resources offered in E\&R and additional trainings on skills related to working in a multisectoral team, care navigation, syndemic risks and coordination of services related to MH, social services, and health care.
62360204|NCT05833555|EXPERIMENTAL|Multisector Collaborative Care and Technology|MCC sites will be randomized to receive an additional technology-based implementation tool to evaluate impact on implementation and consumer outcomes.
62360205|NCT03370198|EXPERIMENTAL|Dose-level 1|The dose-level 1 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
62182290|NCT04959500|EXPERIMENTAL|Experimental group|Experimental: Radiation therapy, Temozolomide and anlotinib Patients will receive standard radiation therapy plus temozolomide (Stupp regimen). Anlotinib hydrochloride will be given with a daily dose of 10 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
62360206|NCT03370198|EXPERIMENTAL|Dose-level 2|The dose-level 2 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
62360207|NCT03370198|EXPERIMENTAL|Dose-level 3|The dose-level 3 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
62360208|NCT01018693|EXPERIMENTAL|VAK694 AND Immunotherapy (alutard)|
62360209|NCT01018693|EXPERIMENTAL|: VAK694 placebo AND Immunotherapy (alutard)|
62360210|NCT01018693|EXPERIMENTAL|VAK694 placebo AND Immunotherapy (alutard) placebo|
62360211|NCT00525226||1|Women who have experienced symptoms of depression or anxiety during pregnancy.
62360212|NCT00602771|EXPERIMENTAL|Arm I|Patients receive 600 mg of oral tipifarnib twice daily on days 1-14 and 100 mg of oral etoposide once daily on days 1-3 and 8-10.
62360213|NCT00602771|EXPERIMENTAL|Arm II (closed to accrual as of November 2008)|Patients receive 400 mg of oral tipifarnib twice daily on days 1-14 and 200 mg of oral etoposide once daily on days 1-3 and 8-10.
62360214|NCT00002657|EXPERIMENTAL|Immumosuppression, IFN-a, ProMACE-CytaBOM|Doses and schedules of immunosuppressive drugs (cyclosporin (or FK506), prednisone, and acyclovir) will depend on whether patients are judged to have clinically urgent disease or not. Patients who do not have a CR after initial immunosuppression will receive 3 cycles (28 days each) Interferon alpha 2b at 3.0 x 10\^6 IU/m\^2 on days 1-28. Patients who have a CR will then receive 6 additional cycles with 3 doses per week, then go onto observation. Patients who do not have a CR will then receive a maximum of 6 21-day cycles of chemotherapy, consisting of: cyclophosphamide 650 mg/m\^2 on day 1, adriamycin 25 mg/m\^2 on day 1, etoposide 120 mg/m\^2 on day 1, prednisone 60 mg/m\^2 on days 1-14, cytosine arabinoside 300 mg/m\^2 on day 8, bleomycin 5 mg/m\^2 on day 8, vincristine 1.4 mg/m\^2 on day 8, methotrexate 120 mg/m\^2 on day 8, leucovorin 25 mg/m\^2 q 6 hours on days 8-9, G-CSF 5 ug/kg/day on days 2-14, and one double strength tablet trimethoprim-sulfamethoxazole 3 times per week.
62360215|NCT02822651|EXPERIMENTAL|Vitamin D status|The 2500 subjects included in this unique arm will complete a self-administered questionnaire and will have a blood sampling to measure vitamin D blood concentration.
62360216|NCT06423105||false negative|This article defines cases that preoperative ultrasound indicates no suspicious malignant enlargement of central lymph nodes and postoperative paraffin pathology indicates the presence of metastatic cancer in central lymph nodes as false-negative cases.
62391397|NCT02986321|EXPERIMENTAL|CHF6001 DOSE3|DOSE3
62360217|NCT02910219|EXPERIMENTAL|Crofelemer|Patients on the treatment arm will take one tablet of crofelemer twice a day (each tablet is 125 mg), to be swallowed whole without chewing or crushing, during cycles 1-2 of chemotherapy with THP or TCHP. Patient will be monitored off crofelemer during cycle 3 of chemotherapy.
62360218|NCT02910219|NO_INTERVENTION|Control|Patients on the control arm will be on the study for cycles 1-3 of THP or TCHP. Patients on the control arm will not receive crofelemer at any time on this study.
62360219|NCT01297946|PLACEBO_COMPARATOR|Open-loop|Conventional continuous subcutaneous insulin infusion (CSII) therapy
62360220|NCT01297946|EXPERIMENTAL|Dual-hormone closed-loop|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. The infusion rates are based on continuous glucose sensor reading and a control algorithm.
62360221|NCT05401591|ACTIVE_COMPARATOR|Milk protein|
62360222|NCT05401591|EXPERIMENTAL|Whole cell chlorella|
61981000|NCT05321433||The Finnish Cohort|The Finnish data will come from three pooled cross-sectional national health surveys in Finland (FinSote 2018-2020) of 44,199 participants aged 20 and older. The study samples included permanent residents in Finland from the FinSote surveys 2018, 2019, and 2020. The unique personal identifier assigned to all Finnish residents will be linked to the Communicable Diseases Registry to obtain information on diagnoses of COVID-19, to the Care Register for Health Care (HILMO) to obtain information on hospital admissions due to COVID-19, and to Statistics Finland Mortality Data to obtain information on deaths. Data on some sociodemographic characteristics will be also obtained from the Digital and Population Data Services Agency.
62360223|NCT05401591|EXPERIMENTAL|Cracked cell chlorella|
62360224|NCT05401591|EXPERIMENTAL|Spirulina|
62360225|NCT01631045||15 min|Subjects post-meal brain MRI will be 15 minutes after breakfast.
62360226|NCT01631045||30 min|Subjects post-meal brain MRI will be 30 minutes after breakfast.
62360227|NCT01631045||60|Subjects post-meal brain MRI will be 60 minutes after breakfast.
62360228|NCT01631045||120|Subjects post-meal brain MRI will be 120 minutes after breakfast.
62360229|NCT01631045||180|Subjects post-meal brain MRI will be 180 minutes after breakfast.
62360230|NCT01631045||240|Subjects post-meal brain MRI will be 240 minutes after breakfast.
62360231|NCT01631045||300|Subjects post-meal brain MRI will be 300 minutes after breakfast.
62360232|NCT03915106||Bracing|AIS patients undergoing bracing to control the spinal curve progression
62360233|NCT03915106||Surgical|Severe AIS patients requiring surgical intervention to correct the spinal curve
62360234|NCT01458496|EXPERIMENTAL|Health Coaching|
62360235|NCT01458496|NO_INTERVENTION|Usual Care -Control|Patients assigned to the control (usual care) group will be advised to seek standard lifestyle counselling from their primary care physician.
62360236|NCT05300646|EXPERIMENTAL|Intervention|The prenatal MBSR program is an adaptation of MBSR. Details on the adaptation process is described in Skovbjerg S et al. Pilot and feasibility studies, 2021 Jun 3; 7 (1):118. Prenatal MBSR include nine weekly two-hour classes and is delivered in a combination between physical attendance and live-online teaching. The recommended time for daily mindfulness training between sessions is 15 minutes a day with options for longer practice. Audio recordings with guided meditations and a video with yoga programs for pregnancy is provided for home practice.
62360237|NCT05300646|NO_INTERVENTION|Treatment as usual|Standard clinical practice, usual care (TAU), consists of an average of six routine pregnancy visits to the outpatient antenatal clinic at Copenhagen University Hospital, Hvidovre and to a General Practitioner. Routine pregnancy visits involves primarily preventive counselling by midwifes, and in some cases consultations with a physician or social worker throughout pregnancy and the early post-partum period. In some cases, usual care may include consultations with a psychologist, although usually limited to a few sessions, and in more severe cases referral to psychiatric treatment.
62182291|NCT04959500|PLACEBO_COMPARATOR|control group|Experimental: Radiation therapy, Temozolomide and Placebo Patients will receive standard radiation therapy plus temozolomide (Stupp regimen). Placebo will be given with a daily dose of 0 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
62182292|NCT01637285|EXPERIMENTAL|PF-04856883 Treatment Arm 1|
62360238|NCT02840513|EXPERIMENTAL|Smartphone app/CO self-monitoring|The app offers a coaching function where users receive personalized messages to encourage smoking cessation and advice for behavioural changes. For the first 4 weeks of the intervention, individuals will also be asked to blow daily into a breath carbon monoxide monitor before going to sleep. Depending on the results of the breath test, individualized messages will be delivered by the Smokelyzer feedback app to either enhance maintenance of abstinence or increase the motivation to quit. After the first 4 weeks, participants will use the breath carbon monoxide monitor at least twice a week until the end of the 6-month study. The app will react with positive feedback in individuals doing well with smoking cessation and messages to encourage individuals with difficulties quitting to smoke.
62360239|NCT02840513|NO_INTERVENTION|Control|Participants in the control group will be managed according to usual care as regularly provided by their SHCS physicians. Physicians will motivate patients to quit, emphasise the advantage of quitting, and provide patients with an information card that contains short advices how to quit and addresses of stop smoking clinics. The Swiss HIV Cohort Study study nurse will enter past or current use as well as of nicotine replacement therapy or use of other pharmaceutical support to quit smoking in the online study form
62360240|NCT01630798|EXPERIMENTAL|Application of peptide|
62360241|NCT01647425||head and neck or lung cancer|patient with a first head and neck cancer or first lung cancer
62360242|NCT03636113||ICU nurses -manual|Standard method of Urine Output monitoring
62360243|NCT03636113||ICU nurses -automated|Device- Clarity RMS Electronic sensor
62360244|NCT04776915||Study Group|Infertile patients due to polycystic ovarian syndrome
62360245|NCT04776915||Control Group|Infertile patients due to unexplained infertility
62360246|NCT06045143||Apical pacing|Study LV strain with speckle Echo when lead of pacemaker on apical site
62360247|NCT06045143||Septal pacing|Study LV strain with speckle Echo when lead of pacemaker on septal site
62360248|NCT06057649|NO_INTERVENTION|control|participants of control group will receive no intervention. they will be instructed to continue with their routine practices
62391398|NCT02986321|EXPERIMENTAL|CHF6001 DOSE4|DOSE4
62360249|NCT06057649|EXPERIMENTAL|experimental|Participants of experimental group will perform effleurage abdominal massage
62360250|NCT02157012|EXPERIMENTAL|The condition of rheumatoid arthritis|
62360251|NCT00407550|EXPERIMENTAL|Gemzar x2|Treat subjects with 2 dosings/cycle of Gemzar x6 cycles.
62360252|NCT00407550|EXPERIMENTAL|Gemzar x1|Treat subjects with 1 dosing/cycle of Gemzar x9 cycles.
62360253|NCT00856986|EXPERIMENTAL|Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%
61981001|NCT05321433||The Norwegian Cohort|The Norwegian data will be based on the Norwegian Mother, Father and Child Cohort Study (MoBa) (Magnus et al., 2016), and the Norwegian Influenza Pregnancy Cohort (NorFlu) (Laake, 2018), with linkages to the Norwegian Surveillance System for Communicable Diseases (MSIS), the Norwegian Immunisation Registry (SYSVAK), and the Norwegian Population Registry. MoBa is a nation-wide population-based cohort consisting of 280 000 participants, where parents were recruited during pregnancy from 1999 to 2008, while NorFlu is a pregnancy cohort consisting of 9 000 participants recruited in Oslo and Bergen during the swine flu pandemic in 2009-2010. Demographic information is extracted from the registries via linkage to the existing cohort databases. For the purpose of this study, all subjects who died before the onset of the pandemic (February 2020) in the three countries will be excluded from the analysis.
62360254|NCT00856986|EXPERIMENTAL|Insulin detemir + Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%
62360255|NCT00856986|EXPERIMENTAL|Non-Randomised Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%
62360256|NCT00856986|OTHER|Early Withdrawals Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial
61981002|NCT00249444|ACTIVE_COMPARATOR|Mirtazapine|Mirtazapine will be administered on a fixed-flexible schedule, with dose titrated up to 60 mg per day or the maximum tolerated dose.
62360257|NCT00856986|OTHER|Intensified group|Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c ≥ 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group.
62360258|NCT03170258|EXPERIMENTAL|Reward-related Brain Region Feedback|Participants in this group will receive neurofeedback from a reward-related brain area (e.g., VTA, PFC) using EEG and/or fMRI during the experiment.
62360259|NCT03170258|SHAM_COMPARATOR|Noise Control|Participants in this group will receive sham neurofeedback. Participants will be debriefed at the end of the study.
62360260|NCT05171881|EXPERIMENTAL|Interventional Arm|All infants will undergo non-invasive NIRS monitoring of cerebral oxygen saturation and will have algorithm-driven clinical interventions to maintain cerebral saturation within target range during the first 72 hours of life.
62360261|NCT02925208||Cochlear Implant|Patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
62360262|NCT06195098|OTHER|Nosy Mitsio Population|Women of childbearing age from 14 to 49 years, pregnant or not and lactating or not, and their children and adolescent form 2 to 18 years old.
61981003|NCT00249444|PLACEBO_COMPARATOR|Placebo|placebo
61981004|NCT02889887||preterm|infants who born before 37 completed weeks
61981005|NCT03559465|EXPERIMENTAL|patient with Scs|patients with SSc, (10 diffuse forms and 20 limited forms)
61981006|NCT03559465|SHAM_COMPARATOR|healthy subject|
61981007|NCT03193931|EXPERIMENTAL|Arm A|Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
61981008|NCT03193931|ACTIVE_COMPARATOR|Arm B|Arm B: Methotrexate (MTX) 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
61981009|NCT01354847||cardiac surgery patients|cardiac surgery patients scheduled for elective complex cardiac surgery
61981010|NCT03738891|EXPERIMENTAL|Fat Reduction|The treatments are designed to see if the fat can be reduced in the abdomen.
62360263|NCT00609804|EXPERIMENTAL|Sorafenib+Erlotinib|Sorafenib 400 mg twice daily by mouth Erlotinib 150 mg once daily by mouth
62360264|NCT00609804|ACTIVE_COMPARATOR|Sorafenib|Sorafenib 400 mg twice daily by mouth.
62360265|NCT02145832|EXPERIMENTAL|Fluconazole|"Fluconazole Kabi, Fresenius 2mg/ml~Fluconazole will be administered at a loading dose of 25 mg/kg on the first day and followed by a maintenance dose of 12 mg/kg or 20 mg/kg once daily, depending of corrected gestational age (GA) at the beginning of treatment:~* 12 mg/kg/day for neonates corrected GA (GA + postnatal age) \< 30 weeks~* 20 mg/kg/day for neonates corrected GA (GA + postnatal age) ≥ 30 weeks~The infusion will last two hours."
62360266|NCT02145832|EXPERIMENTAL|Micafungin|"Mycamine 50mg - 10 mg/mL of micafungin~Micafungin will be administered as a loading dose of 15 mg/kg on the first day of treatment and followed by a maintenance dose of 10 mg/kg once daily.~The infusion will last two hours."
62360267|NCT05729269||Chronic liver disease|non-alcohol liver disease, alcohol liver disease, liver cirrhosis
62360268|NCT01101243|ACTIVE_COMPARATOR|Group 1|Body surface area: 88 %
62360269|NCT01101243|ACTIVE_COMPARATOR|Group 2|Body surface area: 22 %
62360270|NCT01101243|ACTIVE_COMPARATOR|Group 3|Body surface area: 88 %
62360271|NCT01101243|ACTIVE_COMPARATOR|Group 4|Body surface area: 88 %
62360272|NCT01101243|NO_INTERVENTION|Group 5|Body surface area: 0 %
62360273|NCT04149847|EXPERIMENTAL|Nylon darn repair|a nylon #1 suture to be used to reconstruct the posterior inguinal wall
62360274|NCT04149847|EXPERIMENTAL|polypropylene mesh repair|a commercially available 7.5cm x 15cm sheet of polypropylene mesh to be trimmed to fit the posterior inguinal wall
62360275|NCT02905825|EXPERIMENTAL|Indication for Helicobacter pylori testing|Walk in basis: any pediatric subjects with indication for Helicobacter pylori testing will be enrolled if they meet study eligibility criteria and will perform stool test and urea breath test within a week of each other.
62360276|NCT05211258|EXPERIMENTAL|a novel portable upper gastrointestinal endoscopy system|
62360277|NCT03914534|EXPERIMENTAL|Test Formulation of Valproic Acid|Valproic Acid tablets 500 mg Single dose administered in dosing period 1 or 2
62360278|NCT03914534|ACTIVE_COMPARATOR|Reference Formulation of Valproic Acid|Valcote tablets 500 mg Single dose administered in dosing period 1 or 2
62360279|NCT00418899||GLIOGENE|International Multi-Center, Multidisciplinary Study Consortium
62360280|NCT03136484|EXPERIMENTAL|Semaglutide + canagliflozin placebo|
62360281|NCT03136484|ACTIVE_COMPARATOR|Canagliflozin + semaglutide placebo|
62360282|NCT00704431|EXPERIMENTAL|darapladib|darapladib
62360283|NCT05954364||Psoriatic Arthritis|Patients with a rheumatologist-confirmed diagnosis of psoriatic arthritis who are initiating advanced therapy for peripheral musculoskeletal manifestations of psoriatic arthritis
62360284|NCT02658981|EXPERIMENTAL|A1 Anti-LAG-3|"Patients receive Anti-LAG-3 monoclonal antibody BMS-986016 IV over 60 minutes and on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Pharmacological Study~Laboratory Biomarker Analysis"
62360285|NCT02658981|EXPERIMENTAL|A2 Anti-CD137 (Urelumab)|"Patients receive Anti-CD137 (Urelumab) IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity~Pharmacological Study~Laboratory Biomarker Analysis"
62360286|NCT02658981|EXPERIMENTAL|B1 Anti-LAG3 + Anti-PD-1 (nivolumab)|"Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes and anti-LAG-3 monoclonal antibody BMS-986016 IV on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Pharmacological Study~Laboratory Biomarker Analysis"
62360287|NCT02658981|EXPERIMENTAL|B2 Anti-CD137 + Anti-PD-1|"Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes on days 1 and 15 and Anti-CD137 (urelumab) IV on day 1. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~(2pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program. Subjects currently on treatment may continue.)~Pharmacological Study~Laboratory Biomarker Analysis"
62360288|NCT02658981|EXPERIMENTAL|Intratumoral Studies|"Patients pre-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 (Arm A1), or urelumab (Arm A2), or nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B (B1)), or nivolumab and urelumab as in Part B (B2). Within 45 days of surgical resection, patients post-operatively receive drug from one of the four arms.~(3pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program. Subjects currently on treatment may continue.)"
61981011|NCT01631877|EXPERIMENTAL|enoxaparin with acenocoumarol|Patients will receive enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg with titration of dose to maintain a target INR of 2-3.intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR.After achieving the target INR this is to be repeated every 4th weekly. The Doppler Ultra Sonography screening will be done every 3monthly to assess the recanalization of portal vein thrombus but the medications will be continue for one year irrespective of recanalization.
61981012|NCT01631877|PLACEBO_COMPARATOR|Placebo|Injection placebo will be given for 5 days along with placebo tablets.
62360289|NCT03186261|EXPERIMENTAL|Nano silver fluoride solution|Nano silver fluoride solution (Prepared in Nanotech Co., Egypt) based on silver nanoparticles, chitosan and fluoride. Each tooth will receive two drops of NSF with a micro brush, equivalent to a dose of 10 mg of the solution.
62360290|NCT03186261|ACTIVE_COMPARATOR|Cavity Cleanser|Chlorhexidine digluconate 2 % solution (Cavity Cleanser, Bisco, USA). Each tooth will receive two drops of cavity cleanser with a micro brush, equivalent to a dose of 10 mg of the solution.
62360291|NCT01854671|NO_INTERVENTION|standard care|
62360292|NCT01854671|EXPERIMENTAL|family planning counseling led by community health worker|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
62360293|NCT04994704|EXPERIMENTAL|Propofol group|Propofol based total intravenous anesthesia
62360294|NCT04994704|ACTIVE_COMPARATOR|Remimazolam group|Remimazolam based total intravenous anesthesia
62360295|NCT05428553|EXPERIMENTAL|CSP/p-CSP|Prospective allocation
62360296|NCT05428553|ACTIVE_COMPARATOR|EMR/EPMR|Historical control
61981013|NCT01304745|EXPERIMENTAL|Physical traning in group|
61981014|NCT01304745|EXPERIMENTAL|Educational and counselling group|
61981015|NCT01304745|NO_INTERVENTION|Control group|
61981016|NCT03480659||Breast Cancer|Early stage luminal A and triple negative breast cancer \[TNBC\] (estrogen receptor-negative (ER-), progesterone receptor-negative (PR-) and HER2-negative (HER2-)
61981017|NCT03480659||Control|Age matched control females
61981018|NCT02218710||Growth hormone deficiency|
61981019|NCT02218710||healthy controls|
62360297|NCT05022472|EXPERIMENTAL|Intervention|We will use a 2-armed randomized controlled trial (RCT) where Latino and AA adults \>18 years or older from six participating communities and surrounding community health centers (CHC) will be assigned to the 2 VIDA! intervention (n=3 CHC; N=500 participants) or to the control site (e.g., standard of care) (n=3 CHC; N=500 participants). The two major components of the 2VIDA! intervention are: COVID-19 Individual Awareness and Education, COVID-19 Community Outreach and Health Promotion, COVID-19 Individual Health Education and Linkages to Medical and Supportive Services, and pop-up vaccination stations in Latino and AA communities.
62360298|NCT05022472|NO_INTERVENTION|Standard of care|The standard of care for vaccine delivery at the control sites. This includes individuals who make an appointment on their own or receive the vaccine at a health center and may receive information about the vaccine from their primary healthcare provider.
62360299|NCT03717636|EXPERIMENTAL|Hospital Day|Patients in the Hospital-Day group will return for medical evaluation 7-14 days in the specific unit.
62360300|NCT03717636|OTHER|Outpatient clinic|The patients in control group will return for medical evaluation 30 days at the outpatient clinic.
62360301|NCT02666690|EXPERIMENTAL|Patients with metastatic cancer treated with anti angiogenics|
62360302|NCT02569021||Biphasic DBS stimulations|Subjects in this group will have Biphasic DBS stimulation setting performed, Unified Parkinson's Disease Rating Scale (UPDRS), Tremor Rating Scale (TRS), kinesia accelerometer assessment, Trigno wireless system (EMG) assessment and GaitRite walking assessment performed.
62360303|NCT05110599|ACTIVE_COMPARATOR|Bryophyllum 50%|Participants of the verum group take Bryophyllum 50% chewable tablets starting the day after study inclusion. Participants take 2 tablets, four times a day for 2 weeks. If the birth takes place before the end of the 2 weeks, the study participation is terminated early.
62360304|NCT05110599|PLACEBO_COMPARATOR|Placebo|Participants of the control group take Placebo chewable tablets starting the day after study inclusion. Participants take 2 tablets, four times a day for 2 weeks. If the birth takes place before the end of the 2 weeks, the study participation is terminated early.
62360305|NCT06211127|EXPERIMENTAL|Cold laser plaque ablation group|The disposable cold laser plaque ablation catheter (hereinafter referred to as the ablation catheter) is used in conjunction with the cold laser plaque ablation System), which is suitable for the treatment of arteriosclerosis stenosis and occlusive lesions of the lower limbs.
62360306|NCT06211127|ACTIVE_COMPARATOR|The excimer laser group|Excimer laser uses 308nm wavelength excimer laser to conduct atherosclerotic plaques through the intertwined optical fibers in the catheter, using three action mechanisms of photothermal energy, photochemical energy and acoustic mechanical energy.
62360307|NCT03706820||normal rest and exercise hemodynamics|
62360308|NCT03706820||normal rest and abnormal exercise hemodynamics|
62360309|NCT03706820||resting pulmonary hypertension|
62360310|NCT03706820||abnormal wedge pressure at exercise|
62360311|NCT01062828||Gestational age < 32 weeks|Premature infants with gestational age between \<32 weeks regardless of birth weight
62360312|NCT03135288|EXPERIMENTAL|Cell-phone assisted|will be advised that they are going to receive a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits. They will be also provided with a cell phone number working 7 days a week to answer any query or questions regarding her family planning program.
62360313|NCT03135288|NO_INTERVENTION|control group|will receive the same above adequate counseling with referral card but without any phone assistance
62360314|NCT01157546|PLACEBO_COMPARATOR|Control|group A (control) will receive a bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side) via both TAP catheters.The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
62360315|NCT01157546|EXPERIMENTAL|TAP|group B (TAP) will receive a bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side) via TAP catheters. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
61981020|NCT04826146||CONOX|Patients are monitored with BIS and CONOX
62360316|NCT01763983|EXPERIMENTAL|Aerobic Exercise|12-week structured and monitored aerobic exercise program
62360317|NCT01763983|EXPERIMENTAL|CBT and Aerobic Exercise|Combined 12-week individual Cognitive Behavioural Therapy and Exercise Program
62360318|NCT01763983|NO_INTERVENTION|Waitlist Condition|12-week waitlist control condition, after which participants will have the chance to receive CBT group treatment.
62360319|NCT00239356|EXPERIMENTAL|AI|
62360320|NCT02458677|EXPERIMENTAL|PRX003|
62360321|NCT02458677|PLACEBO_COMPARATOR|Placebo|
62360322|NCT00647257|ACTIVE_COMPARATOR|A|
62360323|NCT00647257|PLACEBO_COMPARATOR|B|
62360324|NCT02571972|EXPERIMENTAL|Dorzolamide-timolol|"* On enrollment, eligible patients will have visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan and will then receive the same intravitreal pharmacologic agent administered at prior visit.~* Subsequent follow-up visits will be at an identical interval to pre-enrollment visit intervals (4, 5, or 6 week intervals) for the study duration.~* Each subsequent visit will consist of visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan, and intravitreal injection of same pharmacologic agent as prior visits~* At study conclusion, mean central macular thickness, maximum subretinal fluid height, and maximum pigment epithelial detachment height will be measured over the study period for all patients"
62360325|NCT00587301|EXPERIMENTAL|Lap-Band|Lap-band surgery in treatment of morbidly obese adolescents
62360326|NCT01978600|EXPERIMENTAL|SIMBRINZA™|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension, 1 drop 3 times a day (8AM, 3PM, 10PM) in each eye for 4 weeks
61981021|NCT05313074|PLACEBO_COMPARATOR|Healthy volunteers|Healthcare workers at National Cancer Institute
61981022|NCT05313074|ACTIVE_COMPARATOR|Cancer patients|"Cancer patients were divided into 3 groups based on treatment status including~1. active cancer on treatment~2. Planned to start treatment~3. Post-treatment (\<6 months)"
61981023|NCT01710033|PLACEBO_COMPARATOR|Placebo|
61981024|NCT01710033|EXPERIMENTAL|CP-690,550 5 mg BID|
61981025|NCT01710033|EXPERIMENTAL|CP-690,550 15 mg BID|
62360327|NCT01978600|ACTIVE_COMPARATOR|Timolol Maleate 0.5%|Timolol Maleate 0.5%, 1 drop twice a day (8AM, 8PM) in each eye for 4 weeks
62360328|NCT04019457|EXPERIMENTAL|Dietary fiber 1|Participants receive cereal flakes 1 to include it in their normal diet.
62360329|NCT04019457|EXPERIMENTAL|Dietary fiber 2|Participants receive cereal flakes 2 to include it in their normal diet.
62360330|NCT03023241|EXPERIMENTAL|all study patients|Same intervention for all subjects: anamnesis, questionnaires and biological samples (bladder biopsy, bladder washing, blood and urine) are collected at one single visit.
62360331|NCT00961116|EXPERIMENTAL|Fenofibric Acid (Fibricor™)|1 x 105 mg fenofibric acid (Fibricor™)tablet administered after an overnight fast of at least 10 hours
62360332|NCT00961116|EXPERIMENTAL|Fenofibrate (Tricor®)|1 x 145 mg fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
62360333|NCT04424316|EXPERIMENTAL|RSVpreF vaccine|RSVpreF
62360334|NCT04424316|PLACEBO_COMPARATOR|Placebo dose|Placebo
62360335|NCT00636441|ACTIVE_COMPARATOR|Guided Arm|"Genomically-guided treatment allocation.~This arm has the following cohorts:~* AC sensitive patients \[\>60% probability of response to AC\]~* TC sensitive patients \[\>60% probability of response to TC\]~* Patients sensitive to neither AC nor TC; randomized to AC or TC"
62360336|NCT00636441|ACTIVE_COMPARATOR|Non-Guided Arm|"Non-genomically-guided treatment allocation.~This arm has the following cohorts:~* In patients randomly assigned to AC:~  * Patients sensitive to AC~ * Patients sensitive to TC~ * Patients sensitive to neither AC nor TC~* In patients randomly assigned to TC:~  * Patients sensitive to AC~ * Patients sensitive to TC~ * Patients sensitive to neither AC nor TC"
62360337|NCT00323310|EXPERIMENTAL|Gadobenate Dimeglumine|
62360338|NCT06362447|EXPERIMENTAL|Gentamicin|Gentamicin injection
62360339|NCT04204798|EXPERIMENTAL|Dexmedetomidine group|Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.
62360340|NCT04204798|PLACEBO_COMPARATOR|Placebo group|Normal saline is infused for the same duration as in the dexmedetomidine group.
62360341|NCT01045434|EXPERIMENTAL|Omeprazole Magnesium DR 20 mg Capsules|Omeprazole Magnesium DR 20 mg Capsules of Dr Reddys Laboratories Limited
62360342|NCT01045434|ACTIVE_COMPARATOR|Prilosec 20 mg Tablets|Prilosec 20 mg Tablets of Procter and Gamble
62360343|NCT06269718|EXPERIMENTAL|The IOPI group|tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength
62360344|NCT06269718|ACTIVE_COMPARATOR|The general swallowing group|oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
62360345|NCT01444508|ACTIVE_COMPARATOR|crystalloid|
62360346|NCT01444508|PLACEBO_COMPARATOR|colloid|
62360347|NCT01203722|ACTIVE_COMPARATOR|REGIMEN B|"Pre-BMT :~* Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV~* Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV~* Day -1: 400 cGy total body irradiation (TBI) administered in a single fraction~Day 0: Allogeneic blood or marrow transplantation (BMT)~Post-Transplantation Immunosuppression Consisting of:~* Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV~* Day 5: Sirolimus loading dose 6 mg PO once~* Day 5 thru Day 35: Mycophenolate Mofetil (MMF) 15 mg/kg PO TID (maximum daily dose 3 g/day)~* Day 6 thru Day 180: Sirolimus maintenance dose 2 mg PO QD with dose adjustments to maintain trough of 3 - 12 ng/mL"
62360348|NCT01203722|ACTIVE_COMPARATOR|REGIMEN C|"Pre-BMT:~* Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV~* Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV~* Day -1: 400 cGy TBI administered in a single fraction~Day 0: BMT~Post-Transplantation Immunosuppression Consisting of:~* Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV~* Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day)~* Day 5 thru Day 180: Tacrolimus 1 mg administered IV QD"
62360349|NCT01203722|ACTIVE_COMPARATOR|REGIMEN B2|"Pre-PBSCT:~* Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV~* Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV~* Day -1: 400 cGy TBI administered in a single fraction~Day 0: Peripheral Blood Stem Cell Transplant (PBSCT)~Post-Transplantation Immunosuppression Consisting of:~* Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV~* Day 5: Sirolimus loading dose 6 mg PO once~* Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day)~* Day 6 thru Day 180: Sirolimus maintenance dose 2 mg PO QD with dose adjustments to maintain trough of 3 - 12 ng/mL"
62360350|NCT01203722|ACTIVE_COMPARATOR|REGIMEN B3: HIV patients with CCRd32 homozygous donors|"Pre-PBSCT:~* Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV~* Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV~* Day -1: 400 cGy TBI administered in a single fraction~Day 0: Peripheral Blood Stem Cell Transplant (PBSCT)~Post-Transplantation Immunosuppression Consisting of:~* Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV~* Day 5: Sirolimus loading dose 6 mg PO once~* Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day)~* Day 6 thru Day 180: Sirolimus maintenance dose 2 mg PO QD with dose adjustments to maintain trough of 3 - 12 ng/mL"
62360351|NCT05739357|ACTIVE_COMPARATOR|Cerebral perfusion monitoring|Multimodal monitoring includes cerebral oxygenation (with NIRS) and EEG (with SEDLINE). During the carotic clamp, if cerebral oxygenation decreased for more than 12 % on the operating side from the baseline value, simple interventions as, increasing arterial blood pressure, increasing arterial carbon dioxide tension or increasing oxygen inspiration concentration will be performed.
62360352|NCT05739357|NO_INTERVENTION|Control|The control arm does not have any monitor of cerebral perfusion and oxygenation, during the carotic clamp only intervention is regulating arterial blood pressure values.
62360353|NCT06070636|EXPERIMENTAL|bTAE-HAIC combined with Lenvatinib and Sintilimab|bTAE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin every 4 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Sintilimab, 200 mg intravenously every 3 weeks.
62360354|NCT05823870|EXPERIMENTAL|Sequence A|Period 1: Empagliflozin and Metformin Period 2: DW6014
62360355|NCT05823870|EXPERIMENTAL|Sequence B|Period 1: DW6014 Period 2: Empagliflozin and Metformin
61981026|NCT01710033|EXPERIMENTAL|CP-690,550 30 mg BID|
61981027|NCT03456674|EXPERIMENTAL|LaseMD System|Subjects will receive LaseMD System treatment(s) for treatment of melasma.
61981028|NCT00403793|ACTIVE_COMPARATOR|Arm 1|etonogestrel with testosterone undecanoate
61981029|NCT00403793|PLACEBO_COMPARATOR|Arm 2|Placebo
61981030|NCT01673451|PLACEBO_COMPARATOR|Placebo comparator|
61981031|NCT01673451|EXPERIMENTAL|E2006|
62182293|NCT01637285|EXPERIMENTAL|PF-04856883 Treatment Arm 2|
62360356|NCT05073913|ACTIVE_COMPARATOR|Living kidney donors|complete vascular exploration before and one year after nephrectomy
62360357|NCT05073913|SHAM_COMPARATOR|potential living kidney donors|complete vascular exploration before and one year after the first exploration (for patients with medical contraindication to donation or who have declined donation after the first exploration)
62360358|NCT05307341|ACTIVE_COMPARATOR|Treatment|One dose of sufentanil 30 mcg sublingual will be given pre-operatively when entering the operating room and one dose post-operatively in the PACU in addition to standard of care pain management.
62360359|NCT05307341|NO_INTERVENTION|Control|A multimodal approach to analgesia will be used in all subjects in the perioperative setting and will be used in both the control and treatment groups. Intraoperative dosing of opioids will be based on the anesthesiologist's clinical judgement related to the pain and hemodynamic response to surgical stimuli and on an as needed basis in the PACU. Administration of opioids in the PACU will be in response to moderate-to-severe pain.
62360360|NCT06363123||Multi-cancer group|Patients diagnosed with cancer, including lung cancer，breast cancer，colorectal cancer，thyroid cancer，gastric cancer，cervical cancer，liver cancer，pancreatic cancer，cholangiocarcinoma，prostate cancer，esophageal cancer，ovarian cancer，renal cell carcinoma.
62360361|NCT06363123||control group|Healthy controls
62360362|NCT05668026|EXPERIMENTAL|Immediate start|Study participants will receive venetoclax daily for 14 days followed by 14 days off defined as one cycle. This dosing will then be repeated for two additional cycles.
62360363|NCT05668026|ACTIVE_COMPARATOR|14-days lead-in|Study participants will receive placebo for 28 days, and then start venetoclax daily for 14 days followed by 14 days off defined as one cycle. This dosing will then be repeated for two additional cycles.
62360364|NCT00700063|EXPERIMENTAL|1|
62360365|NCT00700063|EXPERIMENTAL|2|
62360366|NCT00700063|EXPERIMENTAL|3|
61981032|NCT01669915|ACTIVE_COMPARATOR|ACTIVE Vitamin D + ACTIVE Omega-3 Fatty Acids|ACTIVE Vitamin D = Vitamin D3, one 2000 IU capsule/day; ACTIVE Omega-3 Fatty Acids = Omacor, one 1-gram capsule/day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
62360367|NCT00700063|PLACEBO_COMPARATOR|4|
62360368|NCT00700063|EXPERIMENTAL|5|
62360369|NCT00700063|EXPERIMENTAL|6|
62360370|NCT00700063|EXPERIMENTAL|7|
62360371|NCT00700063|PLACEBO_COMPARATOR|8|
62360372|NCT04472637|EXPERIMENTAL|Atorvastatin|They will receive atorvastatin 10 mg, as one tablet /day for 24 weeks.
62360373|NCT04472637|PLACEBO_COMPARATOR|placebo|They will receive a placebo in the form of multivitamin tablets similar to the experimental drug with the same regimen, as one tablet /day for 24 weeks.
62360374|NCT04253808|EXPERIMENTAL|Arm A|The experimental arm (N=6) were provided a CRHF diet with enough calories to maintain body weight for appoximately 2 weeks neoadjuvantly (during radiotherapy preparation) and adjuvantly during primary oncology treatment for \~6.5 weeks. The CRHF diet was composed of 45% fats (mostly) unsaturated fats, 25% proteins, and 30% carbohydrates.
62360375|NCT04253808|ACTIVE_COMPARATOR|Arm B|"Arm B (N=7) were provided a regular composition diet prescribed with enough calories to maintain body weight for approximately 2 weeks neoadjuvantly (during radiotherapy preparation) and adjuvantly during primary oncology treatment for \~6.5 weeks.~The regular composition diet was composed of \~50-52% carbohydrates, \~30% fats, and 18-20% proteins,"
62360376|NCT04253808|NO_INTERVENTION|Control group|The control group (N=26) followed applicable eligibility criteria but did not receive any intervention.
62360377|NCT04625985|EXPERIMENTAL|Metformin glycinate|620 mg bid (PO) for 14 days plus standard treatment
62360378|NCT04625985|PLACEBO_COMPARATOR|Placebo|Placebo tablet bid (PO) for 14 days plus standard treatment
62360379|NCT05755022|EXPERIMENTAL|Maxillary segment repositioning by utilizing reverse engineering using the 3D photogrammetry.|"* The printed stereolithographic model with the adapted miniplates will be scanned using 3D photogrammetry technique and a specific software dedicated for image acquisition will be used.~* A guide will be designed on the reproduced virtual model. This guide will be used intraoperative as a locating and positioning guide for the maxilla and the plates."
62360380|NCT05755022|ACTIVE_COMPARATOR|Maxillary segment repositioning by utilizing reverse engineering using the commercial scanners.|• The printed stereolithographic model with the adapted miniplates will be scanned using the commercial scanners and imported for virtual designing of the positioning and locating guide that will be used intraoperative for positioning the maxilla.
62360381|NCT05979155|EXPERIMENTAL|Study arm (multiple doses of NWY001)|Part 1: dose-escalation of monotherapy NWY001
62360382|NCT05979155|EXPERIMENTAL|Study arm (RP2D of NWY001)|Part 2: dose-expansion of monotherapy NWY001
62360383|NCT04124055|EXPERIMENTAL|Therapeutic drug monitoring (TDM)|Therapeutic drug monitoring (TDM) based on Saliva and Dried blood spot samples
62360384|NCT06177171|EXPERIMENTAL|Phase 1: Olaparib, ASTX727 (D1,D3)-Starting Dose|Participants enrolled in the starting dose cohort will receive 300 mg Olaparib orally, twice a day (BID) on day 1 and day 14 for each 28-day cycle. Participants will also receive 35/100mg ASTX727 on days 1, and 3 of the 28-day cycle. Participants may continue study treatment indefinitely until disease progression unacceptable toxicity, withdrawal, or study closure; whichever comes first. If no DLTs are reported for the first 3 participants, an additional dose escalation cohort may open at the next dose level.
62360385|NCT06177171|EXPERIMENTAL|Phase 1: Olaparib + ASTX727 (D1,D3,D5)|If no DLTs are reported in the previous dose level, participants enrolled in this cohort will receive 300 mg olaparib orally, twice a day (BID) on day 1 and day 14 for each 28-day cycle. Participants will also receive 35/100mg ASTX727 on days 1, 3 and 5 of the 28-day cycle. Participants may continue study treatment indefinitely until disease progression unacceptable toxicity, withdrawal, or study closure; whichever comes first.
62360386|NCT06177171|EXPERIMENTAL|Phase 1b: RP2D (Olaparib, ASTX727) - Dose Expansion|Participants enrolled in this cohort will receive the RP2D based on the safety and efficacy profile determined in the Phase 1 cohorts. Participants will receive the RP2D dose of olaparib orally, twice a day (BID) on day 1 and day 14 for each 28-day cycle. Participants will also receive 35/100mg ASTX727 at the RP2D for the 28-day cycle. Participants may continue study treatment indefinitely until disease progression unacceptable toxicity, withdrawal, or study closure; whichever comes first.
62182294|NCT01637285|EXPERIMENTAL|PF-04856883 Treatment Arm 3|
62360387|NCT02140892|EXPERIMENTAL|respiratory physical therapy manual technique|respiratory physical therapy manual technique- Autogenic Drainage
62360388|NCT02140892|EXPERIMENTAL|respiratory physical therapy technique- IPV|respiratory physical therapy technique- Intrapulmonary Percussive Ventilation
62360389|NCT02140892|NO_INTERVENTION|standart medical care|standard medical care
62360390|NCT04867200|EXPERIMENTAL|Group A|"1. Period 1: Reference drug(Lixiana 60 mg)~2. Period 2: Test drug(CKD-344 60 mg)"
62360391|NCT04867200|EXPERIMENTAL|Group B|"1. Period 1: Test drug(CKD-344 60 mg)~2. Period 2: Reference drug(Lixiana 60 mg)"
62360392|NCT00054184|EXPERIMENTAL|Study drug|
62360393|NCT02854670|EXPERIMENTAL|Capsaicin patch|Cuttable capsaicin patch. 2 patches of 4 cm² (2 x 2cm), for a total of 2.5 mg of capsaicin.
62360394|NCT04203017|EXPERIMENTAL|AutoHSCT + FMT|AutoHSCT with reduced intensity condition regimen (RIC). FMT starting D+60 up to D+120 via po capsules: 30 capsules with fecal transplant divided in two consecutive days (more accurate capsules amount is according to patients body weight)
62360395|NCT01521806|EXPERIMENTAL|Low dose|15 g of fiber per day will be added to snack foods
62360396|NCT01521806|EXPERIMENTAL|High dose|30 g of fiber per day will be added to snack foods
62549960|NCT04603326||Idiopathic PD (iPD) Particpants:|Patients must meet the MDS criteria for Parkinson's disease. Disease duration: any Age 30 years or older at time of PD diagnosis.
61981033|NCT01669915|ACTIVE_COMPARATOR|ACTIVE Vitamin D + PLACEBO Omega-3 Fatty Acids|ACTIVE Vitamin D = Vitamin D3, one 2000 IU capsule/day; PLACEBO Omega-3 Fatty Acids, one capsule/day
61981034|NCT01669915|ACTIVE_COMPARATOR|PLACEBO Vitamin D + ACTIVE Omega-3 Fatty Acids|PLACEBO Vitamin D, one capsule/day; ACTIVE Omega-3 Fatty Acids = Omacor, one 1-gram capsule/day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
61981035|NCT01669915|PLACEBO_COMPARATOR|PLACEBO Vitamin D + PLACEBO Omega-3 Fatty Acids|PLACEBO Vitamin D, one capsule/day; PLACEBO Omega-3 Fatty Acids, one capsule/day
61981036|NCT04234321|EXPERIMENTAL|basic fibroblast growth factor|Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.
61981037|NCT04234321|EXPERIMENTAL|Kangfuxin Liquid|Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.
61981038|NCT04234321|PLACEBO_COMPARATOR|0.9% Normal saline|0.9% Normal saline,20ml / 100cm2 / time,three times a day.
61981039|NCT02370979|EXPERIMENTAL|Dolutegravir|
61981040|NCT04486781|EXPERIMENTAL|Combination Therapy|All study participants will receive Pembrolizumab + sEphB4-HSA through a needle in a vein in their arm for an hour in an outpatient clinic. Pembrolizumab will be given at Day 1 of each 3 week cycle. The study drug (sEphB4-HSA) will be given at Day 1, 8, and 15 of each 3 week cycle.
61981041|NCT00716118||1|IVF patients.
61981042|NCT01264978|EXPERIMENTAL|repetitive neuromuscular stimulation|repetitive neuromuscular stimulation of the quadriceps arm are patients actively stimulated at increasing intensity to afford maximal contraction during training sessions
62360397|NCT01521806|PLACEBO_COMPARATOR|No fiber|Snack foods without fiber will be given
62360398|NCT01719016||Cardiac PET, Coronary catheterization|"Cardiac PET scan:~1. Injection of N-13 Ammonia radionuclide. 2 doses of 10 milliCuries and 20 milliCuries each.~2. Injection of Lexiscan.~Coronary catheterization:~1. Pressure and flow readings using Combowire~2. Injection of Adenosine."
62360399|NCT06275997|NO_INTERVENTION|Parallel arm 1|patients will undergo standard high-definition and high-quality upper-GI endoscopy for the detection of gastric lesions with histological mapping according to Sydney system
62360400|NCT06275997|ACTIVE_COMPARATOR|Parallel arm 2|patients will undergo high-definition and high quality upper-GI endoscopy with real-time assistance by real-time artificial intelligence for the detection of early gastric cancer and gastric dysplasia.
62360401|NCT06275997|OTHER|Cross-over arm 1 (control)|patients will undergo two standard high-definition and high-quality upper-GI endoscopies in tandem: the first will be without Artificial Intelligence assistance, and the second with Artificial Intelligence in order to define the miss rate for standard unassisted upper-GI endoscopy.
62360402|NCT06275997|ACTIVE_COMPARATOR|Cross-over arm 2|patients will undergo two standard high-definition and high-quality upper-GI endoscopies in tandem: the first will be with Artificial Intelligence assistance, and the second without Artificial Intelligence in order to define the decrease of miss rate when assistance by Artificial Intelligence is implemented.
62360403|NCT04709913|ACTIVE_COMPARATOR|Active Treatment: HU6 Planned doses of HU6; N = 32|Drug = HU6 HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
62360404|NCT04709913|PLACEBO_COMPARATOR|Placebo Comparator Non-active study drug N = 8|Placebo Comparator, non-active study drug.
62360405|NCT01960829|EXPERIMENTAL|Everolimus|
62360406|NCT02019017|EXPERIMENTAL|Botulinum Toxin Type A 25 IU|The first five patients will be injected 25 IU of Botulinum Toxin Type A
62360407|NCT02019017|EXPERIMENTAL|Botulinum Toxin Type A 50 IU|the next five patients will receive 50 IU of Botulinum Toxin Type A
62360408|NCT01915680||Glaucoma|
62360409|NCT01915680||Control|
62360410|NCT05525312|OTHER|"Standard protective ventilation"|Patients receiving a positive-end expiratory pressure (PEEP) of 5 cmH2O
62360411|NCT05525312|EXPERIMENTAL|"Open lung protective ventilation protocol"|Patients with a titrated positive-end expiratory pressure (PEEP) corresponding to the best lung compliance calculated with transpulmonary pressure.
62360412|NCT04066699||Localization|Electromagnetic navigation (EMN) guided percutaneous localization of suspicious lung lesion(s).
62360413|NCT01838421||Children under 12 years of age|Children under 12 years of age who underwent surgery in the Charité - University Medicine Berlin, Campus Virchow - Klinikum in the years 2011/12
62360414|NCT04616404|ACTIVE_COMPARATOR|Intervention Group|
62182295|NCT01637285|EXPERIMENTAL|PF-04856883 Treatment Arm 4|
62360415|NCT04616404|PLACEBO_COMPARATOR|Control Group|
62360416|NCT00259038|EXPERIMENTAL|Experimental Drug|
62360417|NCT00259038|PLACEBO_COMPARATOR|Placebo|
62360418|NCT04252261|EXPERIMENTAL|sulforaphane|To evaluate the effect of sulforaphane treatment on the cognitive deficits of patients with frontal brain damage
62549961|NCT04603326||Control (C) Participants:|Age 30 years or older at date of informed consent.
62360419|NCT04252261|PLACEBO_COMPARATOR|placebo|To evaluate the effect of sulforaphane treatment on the cognitive deficits of patients with frontal brain damage
62360420|NCT00927329|EXPERIMENTAL|dust mite|
62360421|NCT03209362|EXPERIMENTAL|SI-613|
62360422|NCT03209362|PLACEBO_COMPARATOR|Placebo|
62360423|NCT03643016|EXPERIMENTAL|Group with Virtual Epileptic Patient brain access data|
62360424|NCT03643016|NO_INTERVENTION|Group without Virtual Epileptic Patient brain access data|
62360425|NCT05999149|EXPERIMENTAL|Arm A|Camrelizumab Plus Chemotherapy and Famitinib
62360426|NCT05999149|ACTIVE_COMPARATOR|Arm B|Camrelizumab Plus Chemotherapy
62360427|NCT05767372|EXPERIMENTAL|Coherent breathing group|The participants will receive Inspiratory muscle trainer and Coherent breathing exercise three times per week for 12 weeks.
62360428|NCT05767372|EXPERIMENTAL|Inspiratory muscle training group|The participants will receive Inspiratory muscle training three times per week for 12 weeks.
62360429|NCT02899806|PLACEBO_COMPARATOR|Paper|Information about epidural analgesia by oral and paper sheep given by anesthesist in programed consultation
62360430|NCT02899806|EXPERIMENTAL|Video|Video information in addition to oral and written information gave by anesthesist in programed consultation
62360431|NCT01854489|ACTIVE_COMPARATOR|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
61981043|NCT05200520|EXPERIMENTAL|Appetite Self-Regulation|Participants will attend 12-weekly classes, delivered through virtual small group sessions (via zoom), self-monitor the participant's episodes of hunger and satiety with digital eating behavior website, weigh daily with a wireless Wi-Fi enabled scale, and use a FitBit to track physical activity. Participants will also receive weekly tailored feedback on eating, physical activity, and weight trends. Assessments will be conducted at 0, 3, and 6 months.
62360432|NCT01854489|PLACEBO_COMPARATOR|Placebo|The volunteers will be given oral placebo at 20.00 for 7 days
62360433|NCT01854489|ACTIVE_COMPARATOR|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
62360434|NCT06112912||REA Group|Students enrolled in schools receiving REA during Spring 2022 or Fall 2022
62360435|NCT04199546|OTHER|A child with Coffin-Lowry Syndrome|A boy with a known CLS diagnosis with a history of coughing during eating, long-lasting wheezing, sputum and inability to intake solid food will be included.
62360436|NCT01385319|ACTIVE_COMPARATOR|bare metal stent|
62360437|NCT01385319|EXPERIMENTAL|Endeavor sprint stent|
62360438|NCT02657876|EXPERIMENTAL|ExpressGraft-C9T1 Skin Tissue|Enrolled participants receive one application of ExpressGraft-C9T1 skin tissue
62360439|NCT06516458||Observation|Gait quality observation
62360440|NCT04503850||Group A Mirabegron|50 patients receiving Mirabegron 50 mg once daily \& alpha blocker
62360441|NCT04503850||Group B alpha blocker only|50 patients receiving alpha blocker only
62360442|NCT06211452|ACTIVE_COMPARATOR|ARM A: Conventional Consolidation|Conventional consolidation (CONS) (active comparator) (6-thioguanine 60 mg/m2/d, on days 1 to 43 orally; prednisone 40 mg/m2/d, on days 1 to 28 orally; vincristine 1.5 mg/m2/d, on days 1, 8, 15, 22; idarubicin 7 mg/m2/d, on days 1, 8, 15, 22; cytarabine 75 mg/m2/d, on days 3-6, 10-13, 17-20, 24-27, 31-34, 38-41; intrathecal cytarabine on days 1, 15, 29, 43 \[age-dependent dose\]; cyclophosphamide 500 mg/m2/d, on days 29, 43)
62360443|NCT06211452|EXPERIMENTAL|ARM B: Blocks Therapy|Block Therapy: AI block (randomized; cytarabine 500 mg/m2 as continuous infusion ×4 days and idarubicin 7 mg/m2 on days 3 and 5; intrathecal cytarabine on days 0 and 6), haM block (high-dose cytarabine 1 g/m2 every 12 hours for 3 days and mitoxantrone 10 mg/m2 on days 4 and 5, intrathecal cytarabine days 6 and 15)
62360444|NCT00005092|EXPERIMENTAL|Chemo, RT + PSCT|Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation
62360445|NCT05063617|NO_INTERVENTION|Wait-List Control|The wait-list control group will be instructed to maintain their current health habits and not to engage in any new physical activity or health programs for the next 8-weeks. The wait-list control group will be invited to access the intervention after 8-weeks.
62360446|NCT05063617|EXPERIMENTAL|mHealth Intervention|Intervention participants will be directed to the App store to download the Stronger Together app to proceed with app registration. Participants will then be connected with the community coach who is a 'real live person' who monitors in-app activity (this will be the program lead, SL). Other in-app features include peer discussion groups, behavioural support, and educational modules to support strategies to increase the quantity and quality of physical activity.
62360447|NCT01525303|EXPERIMENTAL|Exercise-Start (ES)|The ES group will receive standard behavioral treatment in the Self-Management Training Program for Chronic Headaches. In addition to this material, participants in this group will receive an exercise prescription for 20 minutes of moderate-intensity aerobic activity at the beginning of Week 1. The exercise prescription will increase to 25 minutes in Week 2, and 30 minutes in Week 3. They are asked to maintain 30 minutes per day of exercise through Week 8. Participants choose the type of exercise, and have the option to break it up into 10-minute increments throughout the day.
62360448|NCT01525303|EXPERIMENTAL|Exercise-Middle (EM)|The EM group will receive standard behavioral treatment in the Self-Management Training Program for Chronic Headaches.In addition to this material, participants in this group will receive an exercise prescription for 20 minutes of moderate-intensity aerobic activity at the beginning of Week 5. The exercise prescription will increase to 25 minutes in Week 6, and 30 minutes in Week 7. They are asked to maintain 30 minutes per day of exercise through Week 8. Participants choose the type of exercise, and have the option to break it up into 10-minute increments throughout the day.
62360449|NCT01759160|ACTIVE_COMPARATOR|Marsh|Marsh Plasma TCI with high initial target
62360450|NCT01759160|ACTIVE_COMPARATOR|Schnider|Schnider Plasma TCI with high initial target
62360451|NCT02053519|ACTIVE_COMPARATOR|Vigantol Oil, (Vitamin D3)|Oral Vigantol Oil 5 mls, (100 000 iu of Vitamin D). First dose at randomisation, 7 -28 days prior to commencing standard Hepatitis C treatment for Hepatitis C Genotypes 1 or 3 . Thereafter monthly with concurrent Hepatitis C treatment.
62360452|NCT02053519|PLACEBO_COMPARATOR|MyGliol Oil|Matched placebo. Subjects randomised to this arm will take 5 mls of active Placebo, (Mygliol oil), 7 - 28 days prior to commencing active Hepatitis C treatment and thereafter 5 mls monthly concurrent with Hepatitis C treatment for the duration of the study
62391399|NCT02986321|PLACEBO_COMPARATOR|Matched placebo|placebo control
62360453|NCT04397315|ACTIVE_COMPARATOR|Complete Pulpotomy|In case of complete pulpotomy procedure the exposed pulp tissue will be amputated using sterile bur in high speed hand piece to the level of canal orifices.
62360454|NCT04397315|ACTIVE_COMPARATOR|Partial Pulpotomy|In case of partial pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece to a depth of 2-3 mm.
61981044|NCT03362073|EXPERIMENTAL|Ketamine|continuous intravenous infusion of ketamine
61981045|NCT04650802|EXPERIMENTAL|Gait training|Participants receive five weeks individual robotic gait training in LOPES II, targeting paretic propulsion (60 minutes, two time a week). The robotic gait training is complemented with daily home exercises (15 minutes/day) focusing on increasing strength and practice of learned strategies in daily life.
61981046|NCT05877794|EXPERIMENTAL|wing group|
62360455|NCT04042012|EXPERIMENTAL|Eccentric group|The dancers of this group wil perform a soleus eccentric exercise
62360456|NCT04042012|EXPERIMENTAL|PNE group|"The dancers of this group will receive a PNE treatment, consisting of the application of galvanic current, by ultrasound.~The approach will be performed with a transverse axis with a needle orientation that will depend on the location of the target tissue. The parameters will be 3 mA, 3 seconds, 3 impacts (3: 3: 3). The periodicity will be 1day/7day/21day"
62360457|NCT04042012|EXPERIMENTAL|Combined group|The dancers of this group will receive a combined treatment and will be carried out in the same way as the other two groups.
62360458|NCT03030183|EXPERIMENTAL|Zilucoplan (RA101495)|Subjects will receive RA101495 at the dose of 0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
62360459|NCT03057912|EXPERIMENTAL|TALEN|TALEN (TALEN-HPV16 E6/E7 or TALEN-HPV18 E6/E7) plasmid in gel, administered twice one week for 4 weeks.
62360460|NCT03057912|EXPERIMENTAL|CRISPR/Cas9|CRISPR/Cas9 (CRISPR/Cas9-HPV16 E6/E7T1 or CRISPR/Cas9-HPV18 E6/E7T2 ）plasmid in gel, administered twice one week for 4 weeks.
61981047|NCT03305198|EXPERIMENTAL|Patients undergoing exercise oximetry|Patients with PAD referred for treadmill testing and exercise oximetry will have a capillary blood sampling from the earlobe
62360461|NCT03057912|NO_INTERVENTION|Control group|Observation
61981048|NCT00750711|EXPERIMENTAL|KT,2|There are two arms in this study: KT2 arm and KT4 arm. Patients in KT2 arm will be ablated with the 2 mm irrigated catheter and patients in KT4 mm will be ablated with the 4 mm irrigated catheter.
61981049|NCT04959942|EXPERIMENTAL|scapular stabilization exercise|the subjects will receive scapular stabilization exercise + postural correction exercise and advice three times per week for 10 weeks
61981050|NCT04959942|EXPERIMENTAL|postural correction exercise|the subjects will receive postural correction exercise and advice three times per week for 10 weeks
61981051|NCT04959942|ACTIVE_COMPARATOR|advice|the subjects will receive advice three times per week for 10 weeks
61981052|NCT01750099|EXPERIMENTAL|Combined spinal-epidural|After verification of being in the intrathecal space with free-flow of cerebral spinal fluid, 1 mL of 0.25% bupivicaine along with 20 mcg of fentanyl will be injected into the intrathecal space. Subsequently, a B/Braun Perifix FX closed tip multiorifice flexible epidural catheter will be threaded 4 cm into the epidural space. After obtaining a T6 dermatomal level of sensory blockade, a standard solution consisting of 0.125% bupivicaine with 2 mcg of fentanyl/mL of solution will be started at 10 mL/hour with a patient controlled epidural analgesia (PCEA) option of 8 mL every 45 minutes. If a patient requires redosing, 5-10 mL of 0.25% bupivicaine will be injected slowly through epidural catheter with a goal dermatome level of T6. No systemic opioids will be given.
61981053|NCT01750099|PLACEBO_COMPARATOR|Continuous lumbar epidural|After identifying the epidural space with the loss of resistance technique, a standard flexible epidural catheter will be threaded 4 cm into the epidural space. A standard test dose of 3 mL of 1.5% lidocaine with epinephrine 1:200,000 will be given through the catheter. If positive for vascular or intrathecal placement, procedure to be repeated at different interspace. If negative, catheter will be secured and slowly dosed with 5-10 mL of 0.25% bupivicaine through epidural catheter with a goal dermatome level of T6. After obtaining the dermatome level of sensory blockade, a standard solution consisting of 0.125% bupivicaine with 2 mcg of fentanyl/mL of solution will be started at 10 mL/hour with a PCEA option of 8 mL every 45 minutes. If a patient requires redosing, 5-10 mL of 0.25% bupivicaine will be injected slowly through epidural catheter with a goal dermatome level of T6. No systemic opioids will be given.
61981054|NCT05629390|EXPERIMENTAL|Lotilaner Ophthalmic Solution (TP-03)|Lotilaner Ophthalmic Solution (TP-03)
61981055|NCT05629390|PLACEBO_COMPARATOR|Vehicle Control|Vehicle Control
61981056|NCT01170754|EXPERIMENTAL|PEG-3350 and Gatorade|255 miralax with 64 oz gatorade.
61981057|NCT01170754|ACTIVE_COMPARATOR|Golytely 4 Liters|Golytely 4 Liters
61981058|NCT00907985|EXPERIMENTAL|Treatment sequence A|Subjects on sequence A will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
61981059|NCT00907985|EXPERIMENTAL|Treatment sequence B|Subjects on sequence B will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
61981060|NCT00907985|EXPERIMENTAL|Treatment sequence C|Subjects on sequence C will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
61981061|NCT00907985|EXPERIMENTAL|Treatment sequence D|Subjects on sequence D will receive single dose of placebo in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
62360462|NCT04517227|EXPERIMENTAL|single arm|All patients enrolled with receive the sequential therapy of TACE, ablation and durvalumab.
62360463|NCT05463172|EXPERIMENTAL|pelvic floor muscles strengthening exercises|pelvic floor muscles strengthening exercises
62360464|NCT05463172|EXPERIMENTAL|abdominal strengthening exercises|abdominal strengthening exercises
62360465|NCT05387798|EXPERIMENTAL|RAD011|
62360466|NCT00993304|EXPERIMENTAL|A|
62360467|NCT00993304|PLACEBO_COMPARATOR|B|
62360468|NCT04503512|ACTIVE_COMPARATOR|Non removal of fat pad|Non removal of fat pad
62360469|NCT04503512|ACTIVE_COMPARATOR|Removal of fat pad|Removal of fat pad
62360470|NCT01605201|EXPERIMENTAL|Implantation of cartilage graft|
62360471|NCT02883920||workers of Champagne vineyard|
62360472|NCT03472963|NO_INTERVENTION|Pre- drug|Participants will not receive any drug. They will be asked to return 1-6 weeks after the screening visit for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, rectal swabs, urine sample, and rectal biopsy via rigid sigmoidoscopy.
61981062|NCT00907985|EXPERIMENTAL|Treatment sequence E|Subjects on sequence E will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + placebo in session B of part 2.
61981063|NCT00907985|EXPERIMENTAL|Treatment sequence F|Subjects on sequence F will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
61981064|NCT00907985|EXPERIMENTAL|Treatment sequence G|Subjects on sequence G will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + placebo in session B of part 2.
61981065|NCT00907985|EXPERIMENTAL|Treatment sequence H|Subjects on sequence H will receive single dose of placebo part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
61981066|NCT00907985|EXPERIMENTAL|Treatment sequence I|Subjects on sequence I will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
61981067|NCT00907985|EXPERIMENTAL|Treatment sequence J|Subjects on sequence J will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
61981068|NCT00907985|EXPERIMENTAL|Treatment sequence K|Subjects on sequence K will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
61981069|NCT00907985|EXPERIMENTAL|Treatment sequence L|Subjects on sequence L will receive single dose of placebo in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
61981070|NCT00907985|EXPERIMENTAL|Treatment sequence M|Subjects on sequence M will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + placebo in session B of part 2.
61981071|NCT00907985|EXPERIMENTAL|Treatment sequence N|Subjects on sequence N will receive single dose of vofopitant 10 milligrams capsule in part 1, placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
61981072|NCT00907985|EXPERIMENTAL|Treatment sequence O|Subjects on sequence O will receive placebo in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + placebo in session B of part 2.
61981073|NCT00907985|EXPERIMENTAL|Treatment sequence P|Subjects on sequence P will receive placebo in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
61981074|NCT00907985|EXPERIMENTAL|Treatment sequence Q|Subjects on sequence Q will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session A of part 2 and placebo + placebo in session B of part 2.
61981075|NCT00907985|EXPERIMENTAL|Treatment sequence R|Subjects on sequence R will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session B of part 2.
61981076|NCT00907985|EXPERIMENTAL|Treatment sequence S|Subjects on sequence S will receive placebo in part 1, single doses of lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session A of part 2 and placebo + placebo in session B of part 2.
61981077|NCT00907985|EXPERIMENTAL|Treatment sequence T|Subjects on sequence T will receive placebo in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session B of part 2.
61981078|NCT05280067|EXPERIMENTAL|Investigational Device The ZetaFuse™ Bone Graft|The ZetaFuse™ Bone Graft is percutaneously implanted into the bone defect created by the metastatic tumor in a spinal vertebral body. The ZetaFuse™ Bone Graft is only for implantation into the vertebral body.
62360473|NCT03472963|EXPERIMENTAL|Group A.1|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 2 hours after dosing.
62360474|NCT03472963|EXPERIMENTAL|Group A.2|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 24 hours after dosing.
62360475|NCT03472963|EXPERIMENTAL|Group A.3|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 72 hours after dosing.
61981079|NCT05289011||Patients with spondyloarthritis without Inflammatory bowel disease|
62182296|NCT01702870||Suspected myositis|Participants with suspected myositis based on clinical criteria (Bohan and Peters criteria) referred for Magnetic resonance imaging
62391400|NCT02986321|ACTIVE_COMPARATOR|Budesonide|Budesonide DPI 800µg
62391401|NCT00265109|OTHER|open label|Open-label trial; all participants received levetiracetam
62549962|NCT04406077|EXPERIMENTAL|Intervention|Patients suffering from hydrocele, underwent treatment using Ligasure device.
61981080|NCT00410046|EXPERIMENTAL|Etanercept (ETN)|Patients received ETN dose 50 mg once weekly or Sulphasalazine dose 3 g daily in study 402 for 16 weeks. Upon enrollment into study 405, all received subcutaneous injections of etanercept 50 mg once weekly for 36 weeks.
61981081|NCT04834635|EXPERIMENTAL|FundoRingOAGB group|laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part (and suture cruroplasty if present hiatal hernia).
61981082|NCT04834635|ACTIVE_COMPARATOR|OAGB group|laparoscopic one anastomosis gastric bypass (and suture cruroplasty if present hiatal hernia).
61981083|NCT02438254||FH+|Young adults with at least one parent with an alcohol or other drug use disorder history.
61981084|NCT02438254||FH-|Young adults with no histories of alcohol or other drug use disorders in any parents or grandparents.
62360476|NCT03472963|EXPERIMENTAL|Group B.1|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 4 hours after dosing.
61981085|NCT03367481|ACTIVE_COMPARATOR|Control toothbrush|The participants will use a toothbrush with soft bristles.
62360477|NCT03472963|EXPERIMENTAL|Group B.2|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 48 hours after dosing.
62360478|NCT03472963|EXPERIMENTAL|Group B.3|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 96 hours after dosing.
62360479|NCT03472963|EXPERIMENTAL|Group C|Participants will be given a one- day supply of with Genvoya and Darunavir®. Participants return 8 hours (+/- 30min window), 24 hours (+/- 1 hr), and 48 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 8 hours after taking the medication.
62360480|NCT05228756|OTHER|Resistance Band exercise for Sickle Cell Disease|Participants will complete 16 exercise session at home wearing an accelerometer
61981086|NCT03367481|EXPERIMENTAL|Test toothbrush|The participants will use a toothbrush with medium bristles.
61981087|NCT01034462|EXPERIMENTAL|1|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing.
61981088|NCT01034462|PLACEBO_COMPARATOR|2|Matching placebo capsules, oral administration, once daily dosing.
61981089|NCT02225990|ACTIVE_COMPARATOR|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
61981090|NCT02225990|ACTIVE_COMPARATOR|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
61981091|NCT02225990|EXPERIMENTAL|Experimental Group, Sub-Acute|This group consists of sub-acute stroke patients who are between three weeks and six months post-stroke and will receive the QualPro protocol. If the participant is an inpatient at Shands Rehabilitation Hospital at the beginning of the study, his/her first three weeks of research therapy sessions will take place at the Shands Rehabilitation Hospital. After being discharged, the remainder of the study sessions will take place at either UF Health Rehab Center- Magnolia Parke or in the North Tower (6th floor) physical therapy department of Shands Hospital.
61981092|NCT02225990|EXPERIMENTAL|Experimental Group, Chronic|This group consists of chronic stroke patients who are greater than six months post-stroke and will receive the QualPro protocol. The study sessions will take place at either UF Health Rehab Center-Magnolia Parke or in the North Tower (6th floor) physical therapy department of Shands Hospital.
61981093|NCT00314015|EXPERIMENTAL|Patients with immediately loaded implants.|
61981094|NCT02980887||Controls|Healthy controls No intervention as this is an observational study
62360481|NCT06114030|OTHER|Deep margin elevation followed by crowns|Teeth restored with DME and crowns
62360482|NCT01842646|EXPERIMENTAL|PF-04449913 Treatment|Treatment will be administered on an outpatient basis. All patients will be treated with an oral dose PF-04449913 at 100 mg daily in 4-week cycles for a total of 4 cycles. Patients who demonstrate no evidence of progressive disease (i.e. stable disease or better) may continue on treatment until disease progression or loss of response, limiting toxicity, or death.
62360483|NCT01604096|EXPERIMENTAL|Intervention areas|Provinces of Modena and Parma (about 1.100.000 inhabitants - campaign targeted to the general population), in Northern Italy (Emilia-Romagna Region)
61981095|NCT02980887||Pulmonary Vascular Disease|Pulmonary Vascular Disease at risk for pulmonary hypertension
61981096|NCT02980887||Pulmonary Hypertension|Those meeting WSPH/WHO group classifications 1-5 of pulmonary hypertension
62360484|NCT01604096|NO_INTERVENTION|Control|All the other provinces in the Emilia-Romagna Region (where the information campaign has not been implemented)
61981097|NCT02049307|ACTIVE_COMPARATOR|Treatment|Losartan 100mg daily
61981098|NCT02049307|PLACEBO_COMPARATOR|Placebo|Matching placebo
61981099|NCT05423652|EXPERIMENTAL|POCUS-PRESUNA|Daily home hospital care will be enhanced by lung POCUS acquired remotely by community paramedics or in-person by physicians, and interpreted by physicians. They will then document their findings on PRESUNA to obtain a longitudinal record that enables monitoring of trends to support clinical decision-making.
61981100|NCT05423652|NO_INTERVENTION|Standard Care|Standard home hospital care
61981101|NCT04122898|EXPERIMENTAL|Intervention Group|Three months home-based PFM training program with weekly follow-up by a physiotherapist
61981102|NCT04122898|NO_INTERVENTION|Control Group|No intervention
61981103|NCT02045706|EXPERIMENTAL|Community Health Worker Trainings|Trained community health workers (CHW) (one per 25 households), conducted a focus group and four quarterly meetings. CHWs were then responsible for 25 households where they would teach preventive health, track health data for the Ministry, and refer sick cases (700 households total). Staff and volunteers also conducted home visits and handed out printed summaries. We also worked with the local villagers and community health workers to construct 3 protected water sources in the Intervention areas.
62360485|NCT00438022||1|Group 1 will include participants with AD, EH, and recurrent herpes simplex virus (HSV)
62360486|NCT00438022||2|Group 2 will include participants with AD and recurring HSV infections but without EH
61981104|NCT02045706|NO_INTERVENTION|Control Group|The Control Group was comprised of similar households to the Intervention Group (n = 700). In these villages, however, we did not instill the community health worker program until after the trial was completed.
61981105|NCT02588833|EXPERIMENTAL|Cohort 1|180 mg pegcetacoplan/day
61981106|NCT02588833|EXPERIMENTAL|Cohort 2|270 mg pegcetacoplan/day
61981107|NCT01820481|EXPERIMENTAL|Treatment 1|
61981108|NCT01820481|EXPERIMENTAL|Treatment 2|
61981109|NCT01820481|EXPERIMENTAL|Treatment 3|
61981110|NCT01820481|PLACEBO_COMPARATOR|Placebo|
61981111|NCT03032367|OTHER|Sequence 1|Bedaquiline 4 x 100mg administered in a whole tablet form, followed by bedaquiline 4 x 100mg administered in crushed form as a once only oral dose
61981112|NCT03032367|OTHER|Sequence 2|Bedaquiline 4x 100mg administered in crushed form, followed by bedaquiline 4 x 100mg administered in a whole tablet form, as a once only oral dose
61981113|NCT03742154|EXPERIMENTAL|Varenicline Group|50 participants will be enrolled in this group. They will receive a sample of varenicline to use for up to 4-weeks. They are receiving 40 - 0.5mg pills of varenicline, with instructions for titration.
61981114|NCT03742154|NO_INTERVENTION|Control Group|49 participants will be enrolled in this group.
61981115|NCT01843985||1. Eligible RCT/Elect RCT|Eligible for regular chemotherapy, elects and receives regular chemotherapy
61981116|NCT01843985||2. Eligible RCT/Elect LDC|Eligible for regular chemotherapy, elects and receives low-dose chemotherapy
61981117|NCT01843985||3. Eligible RCT/Elect PCO|Eligible for regular chemotherapy, elects and receives palliative care only
61981118|NCT01843985||4. Ineligible RCT/Elect LDC|Ineligible for regular chemotherapy, elects and receives low-dose chemotherapy
61981119|NCT01843985||5. Ineligible RCT/Elect PCO|Ineligible for regular chemotherapy, elects and receives palliative care only
61981120|NCT01834014|EXPERIMENTAL|mFOLFOX + Bmab|mFOLFOX plus bevacizumab
61981121|NCT01834014|ACTIVE_COMPARATOR|mFOLFOX + Cmab|mFOLFOX plus cetuximab
61981122|NCT02318511|EXPERIMENTAL|ReNu amniotic allograft|Knee injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
61981123|NCT02318511|PLACEBO_COMPARATOR|Saline|Knee injection with saline. Injectable saline will be used as the placebo control.
61981124|NCT02318511|ACTIVE_COMPARATOR|HA injection|Knee injection with HA. HA will be used as a viscosupplementation injection consisting of cross linked HA.
61981125|NCT01768481|EXPERIMENTAL|Statin|Atorvastatin 10 mg every day for one year
61981126|NCT01768481|PLACEBO_COMPARATOR|Sugar pill|Same size, taste and size placebo tablet (manufactured by sponsor) given every day for one year.
61981127|NCT05871268|EXPERIMENTAL|Physician Awareness|The physician will have access to the pre-visit Control Preference Scale survey results for women assigned to this group.
61981128|NCT05871268|ACTIVE_COMPARATOR|Usual Care|The physician will not have access to the pre-visit Control Preference Scale survey results for women assigned to this group.
61981129|NCT03539874||Confirmed paternity|Sperm sample from men with confirmed paternity
61981130|NCT03539874||Intrauterine insemination|Sperm sample from men in intrauterine insemination process
61981131|NCT03539874||In vitro fertilization|Sperm sample from men in in vitro fertilization process
62360487|NCT00438022||3|Group 3 will include participants with AD but without EH or HSV infection
61981132|NCT03600974||Endoscopy-E(+)|Subjects with positive endoscopy finding:erosive esophagitis or Barrett esophagus.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.
61981133|NCT03600974||Endoscopy-E(-)|Subjects with negative endoscopy finding:NERD.
61981134|NCT03600974||Acid-A(+)|Subjects with DeMeester scores\>14.72.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.
61981135|NCT03600974||Acid-A(-)|Subjects with DeMeester scores\<14.72
61981136|NCT03600974||impedance-I（+）W/S|Subjects with total reflux number \> 80 in 24h pH-impedance monitoring. W means weakly acid reflux account for above 50% in total reflux number. G means gas reflux account for above 50% in total reflux number.For subjects of this group,probiotic agent is considered.
61981137|NCT03600974||impedance-I（-）|Subjects with total reflux number \< 80 in 24h pH-impedance monitoring.
61981138|NCT03600974||Reflux-symptom association-S(+)|Subjects with positive reflux-symptom association.For subjects of this group, PPIs, Stretta, neuromodulators are considered.
61981139|NCT03600974||Reflux-symptom association-S(-)|Subjects with negative reflux-symptom association
61981140|NCT03600974||motility-M(+)|Subjects with motility disorders according to Chicago v3.0.For subjects of this group, prokinetic motility agents are considered.
61981141|NCT03600974||motility-M(-)|Subjects without motility disorders according to Chicago v3.0
61981142|NCT03600974||lower oesophageal sphincter-L(+)|Subjects with abnormal LES pressure or EGJ type III or hiatus hernia.For subjects of this group, Stretta,Laparoscopic Nissen fundoplication is considered.
61981143|NCT03600974||lower oesophageal sphincter-L(-)|Subjects with normal LES pressure and EGJ type I\~II
62360488|NCT00438022||4|Group 4 will include participants in good general health without AD, EH, or HSV infection
62360489|NCT04391088||hospitalized people living with diabetes|hospitalized people living with diabetes
62360490|NCT04724681|ACTIVE_COMPARATOR|Monitoring arm|Patients in this arm will have their vital signs monitored with continuous wireless devices and patients in this arm will be monitored with standard Early Warning Score
62360491|NCT04724681|NO_INTERVENTION|standard Early Warning Score arm|Patients in this arm will be monitored with standard Early Warning Score
62360492|NCT00100646|EXPERIMENTAL|1|Highly active antiretroviral therapy (HAART) consisting of lamivudine, lopinavir/ritonovir, and stavudine for 16 weeks with three structured treatment interruptions for 2, 4, and 8 weeks each; rabies vaccine at Weeks 16, 17, 22 and 92.
62360493|NCT00100646|ACTIVE_COMPARATOR|2|Continuous HAART consisting of lamivudine, lopinavir/ritonovir, and stavudine throughout the study; rabies vaccine at Weeks 16, 17, 22 and 92.
62360494|NCT05986825||Experimental|Patients with Verneuil disease
62360495|NCT05201482|EXPERIMENTAL|25 patients aged 8-16 years with moderate or severe visual impairment|25 patients aged 8-16 years with moderate or severe visual impairment will test the impact of a head-mounted augmented reality low vision aid (SightPlus) on vision and quality of life
62360496|NCT04605159|EXPERIMENTAL|RSV MAT Group - Mother|Maternal participants received a single dose of the RSV MAT vaccine administered at Day 1 in this study.
62360497|NCT04605159|PLACEBO_COMPARATOR|Placebo Group - Mother|Maternal participants received a single dose of placebo administered at Day 1 in this study.
62549963|NCT01733810|EXPERIMENTAL|Reflux Patients|Patients with reflux and a prior history of reflux esophagitis are being enrolled. The intervention is cessation of acid-suppressing medications.
61981144|NCT03600974||psychology-P(+)|Subjects with normal psychology condition.For subjects of this group,neuromodulators are considered.
61981145|NCT03600974||psychology-P(-)|Subjects with abnormal psychology condition
61981146|NCT01018368|EXPERIMENTAL|VX-770|
61981147|NCT01018368|EXPERIMENTAL|Rifampin|
61981148|NCT00319917|EXPERIMENTAL|1|
61981149|NCT00319917|PLACEBO_COMPARATOR|2|
61981150|NCT04356274|EXPERIMENTAL|Participatory System Dynamics (PSD)|12 clinics assigned to PSD
61981151|NCT04356274|EXPERIMENTAL|Audit and Feedback (AF)|12 clinics assigned to AF
61981152|NCT00075582|EXPERIMENTAL|Regimen I (chemotherapy, radiotherapy)|Patients receive VAC chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 1-9 and dactinomycin IV over 1 minute and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, and 10; VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, and 22 (dactinomycin is omitted during radiation therapy); and radiation therapy, 5 days a week, beginning on week 13 and continuing for 4-7 weeks, depending on prescribed dose. Some patients do not receive radiation therapy; some start it at week 24. (closed to accrual as of 08/13/2010)
61981153|NCT00075582|EXPERIMENTAL|Regimen II (chemotherapy, radiotherapy, surgery)|Patients receive VAC chemotherapy and radiation therapy as in regimen I and VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21, 25-33, and 37-45 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, and 46 (dactinomycin is omitted during radiation therapy). Some patients do not receive radiation therapy; some start it at week 13 and some at week 24. Some patients have conventional surgery (second-look) at Week 13 (closed to accrual as of 9/23/2011).
62360498|NCT04605159|NO_INTERVENTION|RSV MAT Group - Infant|This group consisted of infants born to mothers (from RSV MAT Group - Mother) who received a single dose of RSV MAT vaccine during pregnancy.
62360499|NCT04605159|NO_INTERVENTION|Placebo Group - Infant|This group consisted of infants born to mothers (from Placebo Group - Mother) who received a single dose of placebo during pregnancy.
61981154|NCT04371887|EXPERIMENTAL|Local Tailoring|The intervention arm will consist of six KPSC service areas randomly assigned to the intervention arm. Immediately after primary HPV screening opens at KPSC, the intervention arm will receive the local tailoring interventions. All providers (physicians, nurses and medical assistants) and department administrator from the primary care departments (family medicine and internal medicine) and the department of obstetrics and gynecology at these six service areas randomized to this arm will be included in the study, as well as female patients at these service areas between age 30-65 who received cervical cancer screening during the data collection period.
61981155|NCT04371887|NO_INTERVENTION|Hybrid Usual Care|The hybrid-usual care arm will consist of six KPSC service areas randomly assigned to this arm. The hybrid usual care arm will receive regional educational activities for the transition (as will the intervention arm) before the roll out of primary HPV testing. However, they will not receive any research-led intervention or adaptation guidance after primary HPV screening opens at KPSC. All providers (physicians, nurses and medical assistants) and department administrator from the primary care departments (family medicine and internal medicine) and the department of obstetrics and gynecology at these six service areas randomized to this arm will be included in the study, as well as female patients at these service areas between age 30-65 who received cervical cancer screening during the data collection period.
61981156|NCT03733691|EXPERIMENTAL|Ixazomib Only|The prescribed dose administration of ixazomib in this study is 3mg orally on Days 1, 8, and 15 of a 28-day cycle.
62182297|NCT01702870||Controls|Normal volunteers without myositis, who will undergo MR imaging to establish normal ranges of MR signal in health muscle
62549964|NCT03051477|EXPERIMENTAL|Helixor® M|Advanced solid tumors
62549965|NCT03395457|ACTIVE_COMPARATOR|Care as usual|This is the care provided by the neurologist for chronic migraine.
62360500|NCT04415190||cholangiocarcinoma with early palliative care|
62360501|NCT04415190||cholangiocarcinoma without early palliative care|
62360502|NCT05446974|EXPERIMENTAL|Nursing intervention|Nurses randomly assigned by applying a random selection method
62360503|NCT05446974|NO_INTERVENTION|Non-intervention|Nurses randomly assigned by applying a random selection method
62360504|NCT01754285|EXPERIMENTAL|LF-PB 10 mg|2 IM injections = placebo + 10 mg
62360505|NCT01754285|EXPERIMENTAL|LF-PB 20 mg|2 IM injections = placebo + 20 mg
62360506|NCT01754285|EXPERIMENTAL|LF-PB 30 mg|2 IM injections = 10 mg + 20 mg
62360507|NCT01754285|PLACEBO_COMPARATOR|Placebo|2 IM injections of placebo
62360508|NCT03341234|ACTIVE_COMPARATOR|Group SPB|Ultrasound guided serratus plane block with 30 ml %0,25 bupivacaine
62360509|NCT03341234|ACTIVE_COMPARATOR|Group Control|Ultrasound guided sham block with 2 ml saline subcutaneously
62360510|NCT06192667|EXPERIMENTAL|Geanial Injectable Composite Resin|"It contains 31% methacrylate monomer in the resin matrix and 69% silica and barium glass as fillers. A1, A2, A3, A3.5, A4, B1, B2, B3, C3, CV, BW, AO2, AO3, JE, AE colors are available. Due to their high durability, they can be used in places where recyclable composite resins are used. Apart from this, they are used as fissure sealants, sealants, repair of indirect restorations, blocking of undercuts and liner, like flowable composites.~After completing the cavity, the enamel surface was selectively roughened using 37% orthophosphoric acid for 15 seconds. Subsequently, G2 Bond Universal adhesive agent (GC Corp., Tokyo, Japan) was utilized. It was applied in 2mm layers in accordance with the composite manufacturer's instructions. Each layer was polymerized for 20 seconds."
62549966|NCT03395457|EXPERIMENTAL|Care as usual plus manual therapy|Other
61981157|NCT03733691|EXPERIMENTAL|Ixazomib + Lenalidomide|"The prescribed dose administration of ixazomib in this study is 3mg orally on Days 1, 8, and 15 of a 28-day cycle.~The prescribed dose administration of lenalidomide in this study is the same as the dose of the patient's front-line treatment taken in the last treatment cycle unless otherwise clinically indicated per investigator's discretion, taken orally on days 1-28 of a 28-day cycle. If patient was receiving lenalidomide at a higher dose than 10 mg, then the dose of lenalidomide on this study will be adjusted to 10 mg daily on days 1-28 of a 28-day cycle"
61981158|NCT03770390|OTHER|The study population|"Patients included in this study have pectus excavatum. The have either already undergone corrective surgery during the four years prior to the inclusion period, or are scheduled for surgery during the inclusion period.~Intervention: Surgical correction of pectus excavatum"
61981159|NCT05251545|ACTIVE_COMPARATOR|High power - short duration|Pulmonary vein isolation with high power settings of 45 Watts
61981160|NCT05251545|ACTIVE_COMPARATOR|Standard energy|Pulmonary vein isolation with standard power settings (30 Watts)
62360511|NCT06192667|EXPERIMENTAL|3M Filtek Z250 Universal Restorative|"It is designed to be used in both anterior and posterior restorations. The filler in the Filtek Z250 restorative is zirconia/silica. The inorganic filler is 60 vol% (without silane treatment) with a particle size of 0.01 to 3.5 μm. Filtek Z250 restorative contains BIS-GMA, UDMA and BIS-EMA monomers. Various restorative color options are available. It is packaged in conventional syringes and single-dose capsules.~After completing the cavity, the enamel surface was selectively roughened using 37% orthophosphoric acid for 15 seconds. Subsequently, G2 Bond Universal adhesive agent (GC Corp., Tokyo, Japan) was utilized. It was applied in 2mm layers in accordance with the composite manufacturer's instructions. Each layer was polymerized for 20 seconds."
62360512|NCT05702970|ACTIVE_COMPARATOR|Ferric Carboxymaltose|Control Group
62360513|NCT05702970|EXPERIMENTAL|Sucrosomial iron|Experimental arm 1
62360514|NCT05702970|EXPERIMENTAL|Sucrosomial iron and vitamin D|Experimental arm 2
61981161|NCT04342039|PLACEBO_COMPARATOR|Placebo|Participants will use a placebo nasal spray before being exposed to a series of allergen and pollution challenges.
61981162|NCT04342039|ACTIVE_COMPARATOR|Budesonide nasal|Participants will use budesonide nasal spray before being exposed to a series of allergen and pollution challenges.
61981163|NCT01124136|EXPERIMENTAL|Neurostimulation + Medication management|Investigational nerve stimulator device implanted to heart plus standard medication therapy.
61981164|NCT01124136|OTHER|Standard of Care (Control)|Standard of Care treatment is medication management only. Heart failure medications control symptoms and comorbidities, i.e. blood thinners, lipid lowering, and diuretics, and manage heart function, i.e. heart rhythm, rate, and pumping strength.
61981165|NCT05547074||The training cohort|To develop the prognostic model, 302 cases of postoperative PDAC were included in the final analysis and divided into the training and validation cohort by stratified sampling with 7:3 ratio (The training cohort: n=212; The validation cohort: n=90).
62360515|NCT02566616|EXPERIMENTAL|Intervention|"Cubital Tunnel Release with stimulator for nerve location~1 hour of Ulnar nerve stimulation"
62360516|NCT02566616|ACTIVE_COMPARATOR|Non-Intervention|Cubital Tunnel Release with stimulator for nerve location NO prolonged ulnar nerve stimulation
61981166|NCT05547074||The validation cohort|To develop the prognostic model, 302 cases of postoperative PDAC were included in the final analysis and divided into the training and validation cohort by stratified sampling with 7:3 ratio (The training cohort: n=212; The validation cohort: n=90).
61981167|NCT02068586|EXPERIMENTAL|Sunitinib- (Cohort 1, Arm I)|"Patients receive sunitinib malate PO daily for 6 months in the absence of disease progression or unacceptable toxicity~Quality-of-Life Assessment-Ancillary studies~- Laboratory Biomarker Analysis-Correlative studies"
61981168|NCT02068586|EXPERIMENTAL|Valproic acid- (Cohort 1, Arm II)|"Patients receive valproic acid PO daily for 6 months in the absence of disease progression or unacceptable toxicity~Quality-of-Life Assessment-Ancillary studies~Laboratory Biomarker Analysis-Correlative studies"
62360517|NCT00791804|EXPERIMENTAL|Single Arm|
62549967|NCT03016273|EXPERIMENTAL|Bladder flap|The bladder flap is made by superficially incising and dissecting the peritoneal lining to separate the urinary bladder from the lower uterine segment.
61981169|NCT02068586|EXPERIMENTAL|Sunitinib Malate (Cohort 2)|"Patients receive sunitinib malate PO daily for 12 months in the absence of disease progression or unacceptable toxicity~Quality-of-Life Assessment-Ancillary studies~Laboratory Biomarker Analysis-Correlative studies"
61981170|NCT02068586|ACTIVE_COMPARATOR|Sunitinib Malate + Valproic Acid (Cohort 3)|"Patients receive sunitinib malate PO daily and valproic acid PO daily for 12 months in the absence of disease progression or unacceptable toxicity.~Quality-of-Life Assessment-Ancillary studies~Laboratory Biomarker Analysis-Correlative studies"
61981171|NCT06024057|EXPERIMENTAL|LX101|
61981172|NCT01685996|EXPERIMENTAL|zonisamide|participants will receive zonisamide capsules (up to 300 mg) to take once a day.
61981173|NCT01685996|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo capsules to take once a day
61981174|NCT02069743|EXPERIMENTAL|Intervention|The intervention group will use the study's mobile application during the 8-week study.
61981175|NCT02069743|NO_INTERVENTION|Control|The control group will not use the study's mobile application during the study.
62360518|NCT03418272||Ventilated Pediatric Intensive Care Unit patient Group|This will be a prospective descriptive case series where tracheal cultures and PCR results will be analyzed at initial intubation and again several days into the ICU stay.
62360519|NCT03418272||Intubated OR patient Control Group|For the healthy operating room children, also a case series where a single set of studies will be obtained. tracheal cultures and PCR results will be analyzed after intubation These two groups will be compared, non-randomized.
62360520|NCT03347617|EXPERIMENTAL|Diagnostic (Ferumoxytol MRI, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 2 years or 35 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive ferumoxytol IV and undergo MRI scans at baseline, 4 weeks after the last day of standard of care stereotactic radiosurgery or chemoradiotherapy, every 9 weeks thereafter until suspected radiographic progression, and then within 4 weeks from suspected radiographic progression.
62360521|NCT03167541|EXPERIMENTAL|1|Treatment Order: Test, Reference
62360522|NCT03167541|EXPERIMENTAL|2|Treatment Order: Reference, Test
62360523|NCT04925947|EXPERIMENTAL|KN046|KN046 will be given intravenously every 2 weeks.
62360524|NCT06014957|EXPERIMENTAL|spinal group|12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF),immediately positioned supine with one pillow supporting the head and shoulders.
62360525|NCT06014957|EXPERIMENTAL|saddle block group|12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF),placed in the sitting position for ten minutes and then supine with one pillow supporting the head and shoulders.
62360526|NCT06053970|OTHER|Random order of virtual scenes|"Eight measurements on a stabilometry platform will be performed for each of the VR signals, in random order:~Signal A Direction: anteroposterior Speed: 5 m/s~Signal B Direction: anterior-posterior Speed: 5 m/s~Signal C Direction: Oblique forward and downward Speed: 5 m/s~Signal D Direction: Oblique forwards and upwards Speed: 5 m/s~Signal E Direction: Oblique forwards and to the right Speed: 5 m/s~Signal F Direction: Oblique forward and left Speed: 5 m/s~Signal G Direction: antero-posterior + Clockwise tunnel rotation at 10°/s Speed: 5 m/s~Signal H Direction: antero-posterior + Counter-clockwise tunnel rotation at 10°/s Speed: 5 m/s"
62360527|NCT02677623|EXPERIMENTAL|A- Pyridium|"* Method of administration: oral~* Dose: 200 mg PO with small sip of water~* Known adverse events: yellow discoloration of skin or sclera, 1-10% central nervous system effects including headache and dizziness, GI effect of cramping, \< 1% acute renal failure, methemoglobinemia, hemolytic anemia, hepatitis, rash, skin pigmentation, vertigo, stomach cramps~* Contraindications: to be used in caution in patients with renal impairment Cr Cl \< 50ml/minute and in patients who are receiving nitric oxide, prilocaine and sodium nitrite as it can cause methemoglobinemia"
62360528|NCT02677623|EXPERIMENTAL|B- Sodium Fluorescein|"* Method of administration: intravenous~* Dose: 25 mg~* Known adverse events: nausea, vomiting, flushing or rash, hypersensitivity and anaphylactic reactions can occur following injection and immediate treatment with epinephrine should be available, skin and urine discoloration (urine may appear bright yellow for 24-36 hours), extravasation may cause skin sloughing, toxic neuritis and phlebitis, nausea, rare cardiac arrest and seizure,~* Contraindications: use with caution in patients with history of hypersensitivity, allergies or asthma"
62360529|NCT02677623|EXPERIMENTAL|C- Mannitol|"* Method of administration: irrigant during cystoscopy~* Dose: 300cc during cystoscopy to visualize the ureters~* Known adverse events: dysuria, polyuria, hyponatremia with excess absorption, potential increased risk of urinary tract infection~* Contraindications when used as a genitourinary irrigation solution: anuria"
61981176|NCT05581758|EXPERIMENTAL|Treatment Sequence AB|"Participants will be administered AMG 510 orally in the following order:~Period 1 (treatment A) - AMG 510 under fasted conditions. Period 2 (treatment B) - AMG 510 under fed conditions."
62360530|NCT02677623|EXPERIMENTAL|Control- Normal saline|"* Method of administration: irrigant during cystoscopy~* Dose: 300cc~* Known adverse events: no known significant adverse events~* Contraindications: none"
62360531|NCT03520205|ACTIVE_COMPARATOR|Quadratus Lumborum Block|Patient will receive quadratus lumborum block
62360532|NCT03520205|ACTIVE_COMPARATOR|Continuous Epidural|Patient will receive epidural anesthesia
62360533|NCT01264068|NO_INTERVENTION|Insomnia control|
62360534|NCT01264068|EXPERIMENTAL|Suan Tsao Jen Tang|
62360535|NCT01264068|EXPERIMENTAL|Jia-Wey Shiau-Yau San|
62360536|NCT00377104|EXPERIMENTAL|Treatment (chemotherapy)|Patients receive alvocidib IV over 30 minutes (loading dose), followed by alvocidib IV over 4 hours on days 1, 8, and 15. Treatment repeats every 5 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62360537|NCT05957848|EXPERIMENTAL|Guanfacine extended-release|Guanfacine extended-release (target dose 4 mg), once daily for approximately 12 weeks plus treatment as usual
62360538|NCT05957848|PLACEBO_COMPARATOR|Placebo|Placebo once daily for approximately 12 weeks plus treatment as usual
62360539|NCT02391974|EXPERIMENTAL|PERIOSYAL FILL|n=15
62360540|NCT02391974|NO_INTERVENTION|No treatment (untreated control)|n=15
62360541|NCT01778270|OTHER|non invasive sensor pleural drainage|feasibility data will be collected with thorax impedance measurements via body bioimpedance sensor in Ohm before and after pleura drainage, via impedance cardiography stroke volume and cardiac output will be calculated and also respiratory parameters determined via capnograph as carbon dioxide (CO2) in %/ml exhaled volume before and after pleura drainage. Additionally heart sound analysis via electronic stethoscope will be compared to standard methods.
62360542|NCT01778270|OTHER|non invasive sensor healthy control|"the same measurements as in arm 1: feasibility data will be collected with thorax impedance measurements via body bioimpedance sensor before and after pleura drainage in Ohm, via impedance cardiography stroke volume and cardiac output will be calculated and also respiratory parameters determined via capnograph as carbon dioxide (CO2) in %/ml exhaled volume once in 25 healthy controls.~Additionally heart sound analysis via electronic stethoscope will be compared to standard methods."
62360543|NCT06276842|EXPERIMENTAL|Patient of Group A given Inferior Alveolar Nerve Block|The intervention involved approaching the nerve from the contralateral side of the oral cavity over the contralateral premolars. The needle was inserted into the mandibular tissue along the average boundary of the mandibular ramus within the pterygomandibular space and lateral to the pterygomandibular fold. If bony contact was not achieved within 27-29 mm of needle insertion, the needle was slightly withdrawn and repositioned more distally toward the premolars. After achieving bony contact, the needle was withdrawn by 1-2 mm, aspiration was performed, and then 1.8 ml of anesthetic solution was deposited.
62391402|NCT01932528|EXPERIMENTAL|500 mg LX606|All subjects will receive a single oral 500 mg dose of \[14C\]-LX1606.
62391403|NCT00000829|EXPERIMENTAL|1|Patients receiving intramuscular heptavalent pneumococcal conjugate vaccine
61981177|NCT05581758|EXPERIMENTAL|Treatment Sequence BA|"Participants will be administered AMG 510 orally in the following order:~Period 1 (treatment B) - AMG 510 under fed conditions. Period 2 (treatment A) - AMG 510 under fasted conditions."
61981178|NCT03078647|EXPERIMENTAL|Profound treatment to small areas|Single Profound treatment with the Dermal and/or SubQ cartridges to bra bulge, above the knees or upper arms
62182298|NCT01226836|EXPERIMENTAL|Living Well with COPD for Pulmonary Rehabilitation|
62391404|NCT00000829|PLACEBO_COMPARATOR|2|Patients receiving placebo vaccine
62391405|NCT06410833|EXPERIMENTAL|sequential use of rituximab and belimumab|
62549968|NCT03016273|NO_INTERVENTION|Non bladder flap|
62182299|NCT05199857|EXPERIMENTAL|Wellness education and Home exercise programs|
62360544|NCT06276842|EXPERIMENTAL|Group B-buccal infiltration-supplementary injection technique to Inferior Alveolar Nerve block|The intervention began by penetrating the needle into the buccal mucosa adjacent to the mandibular first molar. After aspiration, 1.8 ml of anesthetic solution (2% lignocaine with 1:100,000 epinephrine) was administered over approximately 2 minutes. Following a 15-minute period post-injection, each patient was asked about the level of numbness in their lip. Patients who did not experience significant lip numbness within this 15-minute timeframe were excluded from the study. For patients who reported positive lip numbness, the affected tooth was isolated using a rubber dam, and a traditional access opening procedure was initiated.
62360545|NCT01511991|EXPERIMENTAL|sevoflurane|10 min exposure to sevoflurane 1.0, 2.0 and 3.0 inspiratory vol% at sevoflurane dosage titration
62360546|NCT03530618|EXPERIMENTAL|Flexible tip straight guidewire|
62360547|NCT03530618|EXPERIMENTAL|J-tip guidewire|
62360548|NCT02089724||vemurafenib/other BRAF inhibitors|
62360549|NCT03402269||Adolescents with displaced clavicle fractures|Adolescents (11 to 17 years old) with displaced clavicle fractures will be enrolled in this study.
62360550|NCT04985240|EXPERIMENTAL|No Intervention: (control group)|The control group was assigned to crop lettuce without any biofortification but with the same characteristic of bioforticated lettuce(soil, water, harvesting time).
62360551|NCT04985240|EXPERIMENTAL|Experimental: intervention group|The intervention group was assigned to biofortificated Molibdenum crop lettuce.
62360552|NCT04957680|EXPERIMENTAL|computer-based cognitive behavioral therapy|
62360553|NCT04957680|ACTIVE_COMPARATOR|online stress management program|
62360554|NCT04957680|NO_INTERVENTION|waitlist|
62360555|NCT02167113||study population|
62360556|NCT06051656||Case group|Any adult patient with severe hand and wrist spasticity or contracture who suffers from a refractory pain, and is already candidate for cryoneurolysis.
62360557|NCT04307901||Incomplete colonoscopy|Individuals referred to colon capsule endoscopy due to incomplete colonoscopy investigation.
62360558|NCT04307901||Colonoscopy general anesthesia|Individuals referred to colon capsule endoscopy as alternative to colonoscopy under general anesthesia.
62360559|NCT04307901||Colonoscopy declined|Individuals referred to colon capsule endoscopy after completion of bowel preparation for colonoscopy, but who have declined colonoscopy to be carried out.
61981179|NCT05667038|PLACEBO_COMPARATOR|Placebo arm|The placebo sachets containing only the excipients, i.e., maize starch and maltodextrins, weights 3g. The placebo was indistinguishable in color, smell, and taste from the probiotic formulation.
61981180|NCT05667038|EXPERIMENTAL|Probiotic arm|Drug being used is Hexbio sachet containing 3g / 90 billion CFU. this drug is a formulation containing six microorganism strains (Lactobacillus acidophilus BCMC®12130, Lactobacillus casei subsp BCMC®12313, Lactobacillus lactis BCMC®12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium infantis BCMC®02129, and Bifidobacterium longum BCMC®02120).
61981181|NCT02970409|ACTIVE_COMPARATOR|heparin|Catheter Lock Therapy with Heparin
61981182|NCT02970409|EXPERIMENTAL|saline|Catheter Lock Therapy with saline
61981183|NCT04915833|EXPERIMENTAL|Patients for CRC screening and diagnostic colonoscopy|Consecutive patients \>45 years of age submitted for diagnostic colonoscopy
62360560|NCT06397534|EXPERIMENTAL|Flipped Learning|"In the experimental group, students will be administered the Introduction Characteristics Form, Stoma Care Knowledge Assessment Form (pre-test), and the General Self-Efficacy Scale (pre-test). Subsequently, digital materials (such as stoma care presentation materials and stoma care demonstration videos) will be prepared by the researchers. The video content will be uploaded to the 'Edpuzzle' program, which is accessible via internet connection or downloadable to devices. The video content in the 'Edpuzzle' program will consist of stoma care procedural steps. Following this, students will apply the stoma care skill in the skills laboratory under the supervision of instructors. To reinforce the implementation in the experimental group, online activities such as word clouds and quizzes will be sent. After the implementation and 4 weeks later, the 'Stoma Care Knowledge Assessment Form (post-test)' and the 'General Self-Efficacy Scale (post-test)' will be administered online."
62360561|NCT06397534|NO_INTERVENTION|Control|All students in the control group will be administered the 'Introductory Characteristics Form,' the 'Stoma Care Knowledge Assessment Form (pre-test),' and the 'General Self-Efficacy Scale (pre-test).' Subsequently, stoma care will be provided to the control group solely through traditional teaching methods. No additional resources will be provided. The stoma care topic will be taught to the control group for 2 hours theoretically and for 4 hours practically. Teaching in the control group will be conducted through PowerPoint presentations, question-and-answer sessions, demonstrations, and discussions. After the lesson, students will practice 'stoma care' in the skills laboratory under the supervision of instructors. After the implementation and 4 weeks later, the 'Stoma Care Knowledge Assessment Form (post-test)' and the 'General Self-Efficacy Scale (post-test)' will be administered online.
62360562|NCT05640700||Controls|Healthy women without HPV in their cervical and vaginal sample
62360563|NCT05640700||Women with HPV|Women with HPV, with or without cervical intraepithelial neoplasia or carcinoma
62360564|NCT02987244|EXPERIMENTAL|C-CHOEP|experimental arm will be treated by Chidamide combined CHOEP ( cyclophosphamide, epirubicine, vindesine, etoposide and prednisone) regimen for 6 cycles.
62739146|NCT02224443|EXPERIMENTAL|Group A, dexmedetomidine , 0.3µg.kg-1.h-1|Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed Continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
62739147|NCT02224443|EXPERIMENTAL|Group B,dexmedetomidine , 0.5µg.kg-1.h-1|Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
61981184|NCT01411709|ACTIVE_COMPARATOR|Vitano|
61981185|NCT01411709|NO_INTERVENTION|Control|No tablets - control group
61981186|NCT04250571|EXPERIMENTAL|No treatment group|Participants will receive no pills and will be told that they are in the no treatment group
61981187|NCT04250571|EXPERIMENTAL|Imaginary pill (IP) group|Participants will be instructed to take an imagined pill. This instruction consists of a procedure including five steps (i.e., identifying the IP sensitive problem, building trust/belief/reality of the IP, constructing a personally meaningful IP, taking the IP, suggestions for self-administering the IP in real life, and building adherence)
61981188|NCT04250571|EXPERIMENTAL|Open label placebo group|"Participants will have the information that they are receiving inert pills (i.e. P-Dragees, containing Placebo)"
62360565|NCT03313804|EXPERIMENTAL|Immune Checkpoint Inhibitor + Radiation|Immune checkpoint inhibitor (Nivolumab OR Pembrolizumab OR Atezolizumab) PLUS Radiation Therapy (Stereotactic Body Radiation Therapy OR fractionated radiation therapy)
62360566|NCT03091699|EXPERIMENTAL|Moderate intensity exercise|The Exercise intervention will persist of a 20-minute bout of moderate intensity aerobic exercise which by definition is 40-65% of Maximum Heart Rate. Exercise consisted of a 2-minute warm-up, followed by 15 min of walking at a rate, which will allow you to reach 2/3 of your max heart rate, and then a 3-minute cool down on a treadmill equaling 20 minutes. Heart Rate will be examined with Polar Wearlink coded Heart Rate monitors to attain the specific exercise intensity.
62360567|NCT03091699|ACTIVE_COMPARATOR|Nicotine Inhalation|The nicotine inhalation group will smoke a cigarette to completion of their choice, in the 20 minute time period allocated in the Exercise and Health Psychology Lab psychological assessment room (the room will be equipped with windows that allow for ventilation and an air purifier. During this time the participant will refrain from conversation.
62360568|NCT01080612|EXPERIMENTAL|330 mg pregabalin controlled release: 400 to 500 calories|
62360569|NCT01080612|EXPERIMENTAL|330 mg pregabalin controlled release: 600 to 750 calories|
62360570|NCT01080612|EXPERIMENTAL|330 mg pregabalin controlled release: 800 to 1000 calories|
62360571|NCT01080612|OTHER|300 mg pregabalin immediate release|
62360572|NCT04807101|NO_INTERVENTION|midazolam and fentanyl|Patients in this arm will receive standard conscious sedation with midazolam and fentanyl
62360573|NCT04807101|EXPERIMENTAL|midazolam alone|Patients in this arm will receive conscious sedation with medazepam alone
62360574|NCT00133172|EXPERIMENTAL|1|Steroid rapid 5-day withdrawal
62360575|NCT00133172|ACTIVE_COMPARATOR|2|Standard steroid maintenance
62360576|NCT03889964||patients with stable COPD|
62360577|NCT01360229|SHAM_COMPARATOR|Randomized Subjects receive a sham acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
62360578|NCT01360229|ACTIVE_COMPARATOR|Randomized Subjects receive real acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
61981189|NCT03761381||Early Dementia|This group will consist of adults with suspected dementia/Alzheimer's Disease. OCTA and NRAI data will be gathered in one study visit.
61981190|NCT03761381||Dementia-Free Controls|This group will consist of adults without suspected dementia/Alzheimer's Disease. OCTA and NRAI data will be gathered in one study visit.
62360579|NCT04569084|EXPERIMENTAL|MT-1186|
62360580|NCT04569084|EXPERIMENTAL|MT-1186 and Placebo|
62360581|NCT04055467|OTHER|[F18]-ASEM + Contingency Management|PET radiopharmaceutical 3-(1,4-diazabicyclo\[3.2.2\]nonan-4-yl)-6 \[18F\]fluorodibenzo\[b,d\]thiophene 5,5-dioxide with incentive payments.
62360582|NCT02403141||Normal glucose tolerance|Patients with normal fasting glucose. Blood glucose less than 5.6mmol/L
62360583|NCT02403141||Impaired fasting glycaemia|Patients with blood glucose between 5.6mmol/L - 7mmol/L
62360584|NCT02403141||Type 2 diabetes|Patients with blood glucose higher than 7mmol/L and negative IA2 and GAD antibodies.
62360585|NCT02403141||Type 1 diabetes|Patients on insulin and with positive IA2 and/or GAD antibodies.
62360586|NCT05307627||Long-term (>5 years) LDN users|Participants who have been using LDN for over 5 years
62360587|NCT05307627||intermediate-term (1-5 years) LDN users|Participants who have been using LDN for at least 1 year, but shorter than 5 years.
61981191|NCT03158051|EXPERIMENTAL|Intervention|Telephone health coaching, home blood pressure monitoring, individualized goal setting, and tailored educational materials
61981192|NCT03158051|NO_INTERVENTION|Usual clinical care|Usual care arm participants will receive routine hypertension clinical care per their primary care provider.
61981193|NCT04600674|EXPERIMENTAL|delayed cord clamping|DCC performed at 60 sec after birth
61981194|NCT04600674|EXPERIMENTAL|early cord clamping|ECC performed at 15 sec after birth
61981195|NCT06527131|EXPERIMENTAL|Group A (Study group)|PEMF group who recieves pulsed electromagnetic field therapy and electrical stimulation
61981196|NCT06527131|ACTIVE_COMPARATOR|Group B(control group)|who recieves standard wound care , electrical stimulation and medical treatment
62360588|NCT05307627||short-term (<12 months) LDN users|Participants who have been using LDN for less than a year. This group will serve as the control group.
62360589|NCT06294041|OTHER|Sleep Restriction Therapy (SRT)|
62360590|NCT06294041|OTHER|Sleep Hygiene Education|
62360591|NCT01109069|EXPERIMENTAL|PCI-32765|
61981197|NCT04585022|ACTIVE_COMPARATOR|Magnum|A metal-on-metal large diameter head total hip arthroplasty
61981198|NCT04585022|ACTIVE_COMPARATOR|Recap|A metal-on-metal hip resurfacing arthroplasty
61981199|NCT01862562|ACTIVE_COMPARATOR|Open surgery|Conventional procedure
61981200|NCT01862562|EXPERIMENTAL|Laparoscopic surgery|Minimum invasive procedure
61981201|NCT06155942|OTHER|Patients with Parkinson Disease|
61981202|NCT06155942|OTHER|Patients with Progressive Supranuclear Palsy|
61981203|NCT06155942|OTHER|Healthy volunteers|
61981204|NCT06131242||According to age, the group was divided into 18-45, 45-65, and > 65 years old.|
62360592|NCT01174888|EXPERIMENTAL|GROUP I (Dose levels 1-2):|Patients receive midostaurin orally (PO) twice daily on days 1-14 and bortezomib intravenously (IV) on days 1, 4, 8, and 11. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62360593|NCT01174888|EXPERIMENTAL|GROUP II (Dose levels 3-6)|Patients receive mitoxantrone hydrochloride IV over 10 minutes, etoposide IV over 1 hour, and cytarabine IV over 6 hours on days 1-6. Patients also receive midostaurin PO twice daily on days 8-21 and bortezomib IV on days 8, 11, 15, and 18. Treatment continues in the absence of disease progression or unacceptable toxicity.
62360594|NCT03649516|EXPERIMENTAL|iCKD APP Group|Use iCKD APP
62360595|NCT03649516|NO_INTERVENTION|Traditional Care Group|Accept traditional care
62391406|NCT06088511|EXPERIMENTAL|The Experimental Group|Participants in the Experimental Group will attend an implementation program guided by the Self-Determination Theory (SDT). The 12-week intervention consists of a 4-week, group-based, face-to-face supervised sessions conducted by a well-trained Research Assistant, plus an 8-week self-management phase.
62360596|NCT05369624|EXPERIMENTAL|Pulmonary rehabilitation home-based program intervention group (PRHP)(IG)|Participants were given two hospital sessions: in the first session the physiotherapist explained the exercises to be performed at home and there was a reminder session at 4 weeks. Reminder call was carried out weekly for 8 weeks. The patients were advised to do the exercises at least 3 times a week. The number of times they performed physical activity and its duration were recorded in a questionnaire
62360597|NCT05369624|NO_INTERVENTION|Control group|Participants received general written advice and recommendations for physical activity
62360598|NCT03027388|EXPERIMENTAL|1/LB100 Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma|Treatment with LB100
62360599|NCT01500941|ACTIVE_COMPARATOR|probiotics|
62360600|NCT01500941|PLACEBO_COMPARATOR|maltodextrin|
62360601|NCT02733679|EXPERIMENTAL|Ataxia Telangiectasia|Participants will receive two treatments - metformin and pioglitazone for eight weeks each, separated by a one week washout period.
62360602|NCT02733679|ACTIVE_COMPARATOR|Healthy controls|Participants will receive two treatments - metformin and pioglitazone for eight weeks each, separated by a one week washout period.
62360603|NCT00149383|PLACEBO_COMPARATOR|2|
62360604|NCT00149383|EXPERIMENTAL|1|
62360605|NCT01495364|EXPERIMENTAL|NBS10|active treatment - CD34+ cells
62360606|NCT01495364|PLACEBO_COMPARATOR|placebo|matching placebo
62360607|NCT05674604||Participants|Adult inpatients who are referred to Victoria General Hospital for rehabilitation with the chief complaint of an acute neurological disorder such as stroke, within next 16 weeks, and suffer from shoulder and/or knee pain. All potential participants are already candidate for cryoneurolysis to mange their shoulder or knee pain.
62360608|NCT01547013||COHORT 1|"Critical Controls: Twenty five (25) critically injured subjects with NO severe traumatic lower extremity traumatic injuries to provide control data for critically injured physiological status, a state which may induce systemic, vs. regional hypoperfusion. (Critical CONTROLS)"
62360609|NCT01547013||COHORT 2|"Ninety five (95) total (35 Cohort 2A; 35 Cohort 2B; 25 Cohort 2C) subjects with severe leg injuries presenting to a participating level 1 trauma center within 12 hours of their injury, to provide data on the acute post-injury phase. (STUDY COHORT)"
62360610|NCT01547013||COHORT 2A|"Subjects meeting COHORT 2 inclusion criteria, who have UNILATERAL severe leg injuries. Unilateral injuries include patients who meet the inclusion criteria for a severe lower extremity injury for ONE lower extremity, with no more than a simple soft tissue injury (eg, simple laceration) on the contralateral leg."
62360611|NCT01547013||COHORT 2B:|"Subjects meeting COHORT 2 inclusion criteria, who have BILATERAL lower extremity injuries, with at least one being a severe leg injury. Bilateral injury patients include patients with at least one lower extremity injury classified as severe based on Cohort 2 inclusion criteria, with a contralateral injury greater than a simple soft tissue injury, including femur, foot, and crush injuries. Note that it is not necessary for both lower extremity injuries to meet the inclusion criteria to be enrolled in this cohort."
62360612|NCT01547013||COHORT 2C|Subjects meeting COHORT 2 inclusion criteria, clinically diagnosed by the treating provider using that treating provider's standards of diagnosing ACS, and in addition to being diagnosed with ACS, the subject undergoes four-compartment leg fasciotomy. data collection to start BEFORE fasciotomy and continue AFTER fasciotomy.
62360613|NCT02894489|EXPERIMENTAL|corneal lenses|patients that wear corneal lenses ( Hiclear Rigid Gas Permeable Lenses)
62360614|NCT02894489|EXPERIMENTAL|large diameter lenses|patients that wear scleral lenses (Paragon Normaleyes)
62360615|NCT01976169|EXPERIMENTAL|PD-0332991 and T-DM1|"The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.~A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.~Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)"
62360616|NCT00638417|EXPERIMENTAL|maximal strength training|maximal dynamic strength training
62360617|NCT00638417|OTHER|conventional rehabilitation|rehabilitation as usual
62360618|NCT02394327|ACTIVE_COMPARATOR|Endoscopic nasogallbladder drainage|If GB cannulation was achieved and the wire was coiled in the GB, 5 to 7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA) was placed into the GB
62360619|NCT02394327|ACTIVE_COMPARATOR|Endoscopic gallbladder stenting|If GB cannulation was achieved and the wire was coiled in the GB, 7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA) was placed into the GB
62360620|NCT05825092|ACTIVE_COMPARATOR|AndroGel® 1.62%|"AndroGel® will be applied daily to the upper arms/shoulders. AndroGel® will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge.~For patients discharged from ICU before day 28, AndroGel® will be administered in hospital wards to complete the 28 days of treatment or until hospital discharge"
62360621|NCT05825092|PLACEBO_COMPARATOR|Placebo gel will be the same gel without testosterone|Placebo gel will be applied daily to the upper arms/shoulders. Placebo gel will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, Placebo gel will be administered in hospital wards to complete the 28 days of treatment or until hospital discharge
62360622|NCT03949543|EXPERIMENTAL|Healthy Adult Participants A|Participants who will get two interventional diets, for 7 days each, but allocated to start with large lunch intervention
62360623|NCT03949543|EXPERIMENTAL|Healthy Adult Participants B|Participants who will get two interventional diets, for 7 days each, but allocated to start with large dinner intervention
62360624|NCT05488912||Healthy BMI (20-25 kg/m2, n=30)|A group of 30 Hispanic/Latino adults who are NH residents residing in SNAP-eligible households, and have a BMI between 20 and 25 kg/m2.
62360625|NCT05488912||Overweight/Obese BMI (>28 kg/m2, n=30)|A group of 30 Hispanic/Latino adults who are NH residents residing in SNAP-eligible households, and have a BMI greater than or equal to 28 kg/m2.
62391407|NCT06088511|NO_INTERVENTION|The Control Group|Participants in The Control Group will attend 4-weekly, group-based, regular face-to-face health talks about managing sarcopenia with the exact dosage provided to the intervention group.
62182300|NCT04200404|EXPERIMENTAL|Phase Ib arm|arms 1. Phase Ib: advanced or refractory solid tumors;
62360626|NCT03514238|EXPERIMENTAL|Adults (BMI: ≥30 kg/m2)|"Obese individuals will participate to three conditions:~Control Sitting Condition (C), Sitting for 35 minutes Acute Bout of Continuous Moderate Aerobic Exercise (MOD) 50-55% of heart rate reserve Acute Bout of High Intensity Interval Aerobic Exercise (HIIT) 85-90% heart rate reserve"
61981205|NCT05149846|OTHER|Pre-conditioning|Pre-conditioning by three consecutive 60 seconds balloon inflations, spaced 120 seconds apart followed by 10 minutes rest prior to PCI
62360627|NCT03514238|EXPERIMENTAL|Adults (BMI: 18.5-24.9 kg/m2)|"Normal weight individuals will participate to three conditions:~Control Sitting Condition (C), Sitting for 35 minutes Acute Bout of Continuous Moderate Aerobic Exercise (MOD) 50-55% of heart rate reserve Acute Bout of High Intensity Interval Aerobic Exercise (HIIT) 85-90% heart rate reserve"
62360628|NCT00360685|OTHER|TAC + MMF|Tacrolimus and Mycophenolate
62360629|NCT00360685|OTHER|TAC+MTX|Tacrolimus and Methotrexate
62360630|NCT02539914|EXPERIMENTAL|VR motor-cognitive task|The VR motor-cognitive task group will perform a virtual reality motor and cognitive attention/memory task customized to each user in terms of the positive content.
62360631|NCT02539914|ACTIVE_COMPARATOR|Standard rehabilitation|The standard rehabilitation group will perform conventional motor and cognitive rehabilitation tasks.
62360632|NCT02655406|ACTIVE_COMPARATOR|Compression stockings|Patients randomised to group A will be asked to wear compression stockings for 1 week
62360633|NCT02655406|NO_INTERVENTION|No compression|Patients randomised to group B will be provided with bandages to wear for 24 hours only, with no further compression afterwards
62360634|NCT03073343|ACTIVE_COMPARATOR|diabetic patients with NAFLD|Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks.
62360635|NCT03073343|ACTIVE_COMPARATOR|non-diabetics with NAFLD|Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks.
62360636|NCT03305757|ACTIVE_COMPARATOR|conventional wound closure|The skin flaps will not undergo further treatment in this group.
62360637|NCT03305757|EXPERIMENTAL|flap fixation with vicryl sutures|The skin flaps will be sutured on to the pectoral muscle after having performed the mastectomy.
62360638|NCT03305757|EXPERIMENTAL|Artiss tissue glue|ARTISS tissue glue will be applied to the skin flaps after mastectomy
62360639|NCT05022043|ACTIVE_COMPARATOR|EOS|
62360640|NCT05022043|NO_INTERVENTION|NO-EOS|
62360641|NCT03771807|PLACEBO_COMPARATOR|Placebo & facial cleansing|"Maltodextrin and food coloring~Subjects will clean the right side of their face with a cosmetic instrument daily"
62360642|NCT03771807|ACTIVE_COMPARATOR|Beauty From Within & facial cleansing|"Study Product contains collagen hydrolysate, ceramide wheat extract oil and lutein~Subjects will clean the right side of their face with a cosmetic instrument daily"
62360643|NCT01525667|EXPERIMENTAL|150M PLX-PAD|Single course, multiple IM injections
61981206|NCT05149846|NO_INTERVENTION|Controll|No pre-conditioning, standard care
61981207|NCT02069990|ACTIVE_COMPARATOR|30000 IU cholecalcipherol once a week|30000 IU cholecalcipherol once a week oral
62360644|NCT01525667|EXPERIMENTAL|300M PLX-PAD|Single course, multiple IM injections
62360645|NCT01525667|PLACEBO_COMPARATOR|Placebo|Single course, multiple IM injections
61981208|NCT02069990|EXPERIMENTAL|7000 IU cholecalcipherol once a week|7000 IU cholecalcipherol once a week oral
62360646|NCT03807245|EXPERIMENTAL|GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® 25 mcg intramuscular 2 times with 4 weeks apart
62360647|NCT03807245|PLACEBO_COMPARATOR|Placebo GBS-NN/NN2 with Alhydrogel® 25|Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart
61981209|NCT02069990|EXPERIMENTAL|30000IU cholecalcipherol once a month|30000IU cholecalcipherol once a month oral
61981210|NCT02069990|ACTIVE_COMPARATOR|1000 IU cholecalciferol once a day|1000 IU cholecalciferol once a day
61981211|NCT01669733|EXPERIMENTAL|Live/Recorded Music Group|The music therapist will prepare a preferred song to be performed live in the preoperative room. Subjects in the live music group will listen to recorded music intraoperatively.
61981212|NCT01669733|EXPERIMENTAL|Recorded Music Group|Recorded music group will be given an iPod and headphones and will listen to a recorded version of a preferred song.
61981213|NCT01669733|ACTIVE_COMPARATOR|No Music (Standard of care)|The control group will receive standard of care and no music.
61981214|NCT06428344||Control group|Dentist specializing in endodontics with over five years of experience independently reviewed the participants' oral panoramic radiographs in a random order.
62360648|NCT03807245|EXPERIMENTAL|GBS-NN/NN2 with Alhydrogel® 50|Intramuscular GBS-NN/NN2 with Alhydrogel® injection 50 mcg 2 times with 4 weeks apart
62360649|NCT03807245|PLACEBO_COMPARATOR|Placebo GBS-NN/NN2 with Alhydrogel® 50|Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart
62360650|NCT00964600|EXPERIMENTAL|TAP blockade|bilateral TAP blockade at the end of cesarean delivery
62360651|NCT00964600|NO_INTERVENTION|No TAP|These patients would have usual analgesic drugs after cesarean
62360652|NCT03621189|ACTIVE_COMPARATOR|Active-Active|"Participants received the real intervention of TBS (iTBS 1200) over the posterior superior temporal sulcus for 8 weeks (2 days/week).~\*iTBS = intermittent theta burst stimulation"
62360653|NCT03621189|SHAM_COMPARATOR|Sham-Active|"Participants received the sham intervention of TBS (coil tilted one-wing 90° off the head) over the posterior superior temporal sulcus for 4 weeks (2 days/week) and then received the real intervention of TBS (iTBS 1200) over the posterior superior temporal sulcus for 4 weeks (2 days/week).~\*iTBS = intermittent theta burst stimulation"
62182301|NCT04200404|EXPERIMENTAL|Phase II arm|arms 2.Phase II: subjects with tumor of specific types
62360654|NCT05151367|EXPERIMENTAL|Text message reminders|Text message reminders
62360655|NCT05151367|NO_INTERVENTION|Usual Care|No reminders
62360656|NCT00116987|OTHER|1|Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
62360657|NCT00116987|OTHER|2|Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
62549969|NCT02452476|EXPERIMENTAL|CHF5633|Single dose within 24 hours from birth
62360658|NCT01068717|OTHER|Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fasted state
62360659|NCT01068717|OTHER|Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fasted state)|Single oral dose of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet administered in the fasted state
62360660|NCT01068717|OTHER|Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fed state
62360661|NCT01068717|OTHER|Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fed state)|Single oral dose of saxagliptin, 2.5 mg/metformin, 500 mg, FDC tablet administered in the fed state
62360662|NCT01136213||Multiple system atrophy|
62360663|NCT01136213||Idiopathic Parkinson Disease|
62360664|NCT01136213||Volunteers without neuropsychiatric disorder (Control)|
62360665|NCT03182153||Enrolled subjects|Subjects who are diagnosed with HCM and require routine extended cardiac monitoring for risk stratification of sudden cardiac death. All subjects will receive 28 days of external cardiac monitoring.
62360666|NCT01661309|PLACEBO_COMPARATOR|Inactive lozenge|Inactive lozenge containing 2mg sucrose dissolved in the mouth taken after a meal every other day for 16 weeks
62360667|NCT01661309|EXPERIMENTAL|Methylcobalamin|Methylcobalamin 1mg lozenge dissolved in the mouth following a meal taken every other day for 16 weeks.
62360668|NCT06167278|EXPERIMENTAL|Shell tray group|
62360669|NCT06167278|EXPERIMENTAL|Bar tray group|
62360670|NCT04088565|EXPERIMENTAL|PAS+VNS|Paired-associative stimulation (PAS) targeting primary motor cortex will be administered with VNS in individuals with hemiparesis secondary to stroke and neurologically-intact, age-matched controls.
62360671|NCT04088565|SHAM_COMPARATOR|PAS+Sham|Paired-associative stimulation (PAS) targeting primary motor cortex will be administered with sham stimulation in individuals with hemiparesis secondary to stroke and neurologically-intact, age-matched controls.
62360672|NCT00212212|EXPERIMENTAL|1|200 µg selenium as selenate
62360673|NCT00212212|EXPERIMENTAL|2|400 µg selenium as selenate
62360674|NCT00212212|EXPERIMENTAL|3|200 µg selenium as selenomethionine
62360675|NCT00212212|PLACEBO_COMPARATOR|4|placebo tablet
61981215|NCT06428344||Trial group|The diagnoses of caries on oral panoramic radiographs were made with the assistance of an artificial intelligence-aided oral panoramic diagnostic system.
61981216|NCT00674453|EXPERIMENTAL|Lasofoxifene 0.25 mg/d|
61981217|NCT00674453|PLACEBO_COMPARATOR|Placebo|
61981218|NCT06447727||SIRT with Yttrium-90 Microspheres combined with FOLFIRI and Bevacizumab|Selective Internal Radiation Therapy (SIRT) with Yttrium-90 \[90Y\] Microspheres Injection combined with FOLFIRI and Bevacizumab
61981219|NCT02618174|PLACEBO_COMPARATOR|Neutral Control Condition|Message about age of University of Birmingham
62169252|NCT06646523|EXPERIMENTAL|High-speed bodyweight resistance training|"The participants of the experimental group (high-speed bodyweight resistance training) will receive a home-based intervention that will include 5 minutes of warm-up (free active movements of trunk and lower limbs), followed by 50 min of exercises more targeted to the lower limb muscles, and by 5 minutes of cool-down (lower limb muscle stretching and relaxation breathing exercise).~The experimental intervention will be performed at maximum speed. During the initial home visit, the speed at which the participant can perform one set of each exercise at maximum speed will be timed. Speed-based progression will be determined every four weeks by increasing the number of repetitions in each set of exercises performed during subsequent home visits."
62360676|NCT03350971|EXPERIMENTAL|Virtual reality training|Training with ergometer associated with training on wii videogame during 4 days
62360677|NCT03350971|ACTIVE_COMPARATOR|Control|chest physical therapy
62360678|NCT03790540|EXPERIMENTAL|Injection with the aid of DentalVibe|"1 mL of Mepivacaine HCl 2%, 1/20000 Levonordefrin will be injected using a 27 gauge dental needle.~DentalVibe is a small, handheld cordless device that has a charging docking station. A demonstration of DentalVibe (DV) will be performed by putting it into direct contact with the children's nails before applying the device intraorally. Then, the device will be placed on the oral mucosa to enclose the injection site before administering local anesthesia and Potential subject-expectancy effects and pressure from the placement of DV will be controlled. The device will be turned on to stimulate the area of needle penetration. After 5 seconds of vibration, the needle will be inserted. The device will continue vibrating during needle insertion and anesthetic injection."
62360679|NCT03790540|ACTIVE_COMPARATOR|Injection with topical benzocaine 20%|Topical anesthesia -Benzocaine gel 20%. Tissues will be dried using (2 X 2) gauze to enhance the absorption of the benzocaine gel 20% around the site of the needle penetration and will be left in contact with the soft tissue for one minute. Then the local anesthetic solution (1 ml Mepivacaine HCl 2%, 1/20000 Levonordefrin) will be injected using a 27 gauge dental needle.
61981220|NCT02618174|PLACEBO_COMPARATOR|Food-based Control Condition|Message about variety of vegetables in the world
61981221|NCT02618174|ACTIVE_COMPARATOR|Health Condition|Message about the health benefits of eating vegetables
61981222|NCT02618174|ACTIVE_COMPARATOR|Descriptive Social Norm|Message suggesting most people eat plenty of vegetables
61981223|NCT02618174|EXPERIMENTAL|Liking Social Norm|Message suggesting most people like eating vegetables
61981224|NCT04299204|EXPERIMENTAL|Years 1997-2007|Group-1, PCNL was performed in the first 10 years period (Years 1997-2007);
61981225|NCT04299204|EXPERIMENTAL|2008- to the present|The PCNL was performed in the second ten years period from 2008 to the present.
62360680|NCT05477225|EXPERIMENTAL|NovoSorb® BTM|
62360681|NCT05477225|ACTIVE_COMPARATOR|Human Cadaver Allograft|
62360682|NCT00175071|EXPERIMENTAL|Comparison of cooking oils|Postmenopausal women (50-85 y) with LDL cholesterol 120 mg/dL.
62360683|NCT02612883||Esophagus|Measuring of tissue perfusion of the esophagus
62360684|NCT02612883||Liver|Measuring of tissue perfusion of the liver
62360685|NCT02612883||Stomach|Measuring of tissue perfusion of the stomach
62360686|NCT02612883||Pancreas|Measuring of tissue perfusion of the pancreas
62360687|NCT02612883||Colon|Measuring of tissue perfusion of the colon
62360688|NCT00505804|EXPERIMENTAL|1|
62360689|NCT00505804|ACTIVE_COMPARATOR|2|
62391408|NCT05845554||Biliary tract carcinoma patients|Biliary tract carcinoma patients will be the experimental group to determine the sensitivity of BileCAD analysis.
62360690|NCT05670249|ACTIVE_COMPARATOR|surgical plus medical treatment|Decompressive surgery protocol was kept constant throughout the study period and defined the following surgical interventions: (1) extensive bilateral suboccipital decompresive craniectomy with duraplasty, optional resection of the posterior arch of atlas, (2) preceding insertion of an external ventricular drainage (EVD) in all cases, and (3) evacuation of necrotic tissue.
61981226|NCT02614430|ACTIVE_COMPARATOR|Vocational training|Participants are randomized into the intervention group (training) where they are offered a training course of 4-9 weeks of physical training three times a week with a physiotherapist.
62360691|NCT05670249|NO_INTERVENTION|conservative medical treatment|Control group (conservative medical) was treated equally aggressive with regard to intensive care measures. Medical management generally followed the Turkish and European guidelines on acute stroke care valid at the time of patient admission.
62360692|NCT03380507|EXPERIMENTAL|Triple therapy group|"Experimental group will receive usual care according to Hamad Medical Corporation Adult Sepsis Care Pathway (CPW 10311, May 2017) PLUS triple therapy.~Triple therapy regimen:~Intravenous vitamin C (1.5 gm q 6 hourly for 4 days or until ICU discharge, whichever is earlier), hydrocortisone (50 mg q 6 hourly for 7 days or until ICU discharge, whichever is earlier, followed by a taper over 3 days) as well as intravenous thiamine (200 mg q 12 hourly for 4 days or until ICU discharge, whichever is earlier)."
62360693|NCT03380507|NO_INTERVENTION|Control group|Control group will receive usual care only according to Hamad Medical Corporation Adult Sepsis Care Pathway (CPW 10311, May 2017).
62360694|NCT01807949|PLACEBO_COMPARATOR|Placebo|Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.
62360695|NCT01807949|EXPERIMENTAL|LUM 600 mg qd/IVA 250 mg q12h|LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.
62360696|NCT01807949|EXPERIMENTAL|LUM 400 mg q12h/ IVA 250 mg q12h|LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.
62360697|NCT02639923||Minor head injury CCT pos. group|Tbi patients with acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.
62360698|NCT02639923||Minor head injury CCT neg. group|Tbi patients without acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.
61981227|NCT02614430|NO_INTERVENTION|Control|Participants are randomized into the control group where they are offered the standard treatment.
62360699|NCT02639923||Control Group (healthy volunteers)|Volunteers without history, signs or symptoms of acute traumatic injuries. Volunteers consent to have 7ml peripheral blood to be drawn.
62360700|NCT01392742||Cohort|
61981228|NCT04720846|ACTIVE_COMPARATOR|Control|Patients will receive standard-of-care physical therapy.
62360701|NCT01590667|ACTIVE_COMPARATOR|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
61981229|NCT04720846|EXPERIMENTAL|Matrix-Based PT|Patients will receive matrix-based physical therapy, in addition to standard-of-care physical therapy.
61981230|NCT03794557|EXPERIMENTAL|PUL-042|PUL-042 Inhalation Solution
61981231|NCT03794557|PLACEBO_COMPARATOR|Placebo|Sterile Water for injection
61981232|NCT05358171|EXPERIMENTAL|HIgh UPF (Ultra-processed foods)|Participants will consume a diet containing 81% total energy from UPF for 6 weeks
62360702|NCT01590667|PLACEBO_COMPARATOR|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
61981233|NCT05358171|ACTIVE_COMPARATOR|No UPF|Participants will consume a diet containing 0% total energy from UPF for 6 weeks
62360703|NCT01421069|EXPERIMENTAL|1|
62360704|NCT01855113||INVISALIGN®|those with an Invisalign® Treatment for orthodontic correction
62360705|NCT01855113||braces|those with braces for orthodontic correction.
62360706|NCT01930240|PLACEBO_COMPARATOR|TRIA-662 Placebo|Single dose of nine placebo capsules matching TRIA-662 drug capsules
62360707|NCT01930240|EXPERIMENTAL|TRIA-662 Low Dose|Single-dose of TRIA-662 administered as three 30 mg TRIA-662 capsules and six matching placebo capsules
62360708|NCT01930240|EXPERIMENTAL|TRIA-662 High Dose|Single dose of TRIA-662 administered as nine 30mg TRIA-662 capsules
62360709|NCT02653313|EXPERIMENTAL|ParvOryx|ParvOryx given intravenously on four consecutive days (day 1 to 4) and intrametastatic six to thirteen days thereafter (day 7, 10 or 14).
62360710|NCT04683172|EXPERIMENTAL|Active tDCS|Active tDCS will be delivered daily for 5 consecutive days with the patient either sitting or lying down.A tDCS session generally lasts 20 minutes.
62360711|NCT04683172|SHAM_COMPARATOR|Sham tDCS|Sham tDCS will be delivered daily for 5 consecutive days with the patient either sitting or lying down.A tDCS session generally lasts 20 minutes.
61981234|NCT04249037|ACTIVE_COMPARATOR|Arm A: Rapid Start Group|Same day antiretroviral therapy (ART) with bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + new diagnosis package with laboratory evaluations and social work referral.
61981235|NCT04249037|PLACEBO_COMPARATOR|Arm B: Standard Group|Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
61981236|NCT02116400||Suicidal|"Patients in this group have had suicidal behaviour according to the C-SSRS score.~Intervention: Interview Intervention: Neuropsychological testing Intervention: Serum concentration of lithium or sodium divalproate."
61981237|NCT02116400||Not suicidal|"Patients in this group have not had suicidal behaviour according to the C-SSRS score.~Intervention: Interview Intervention: Neuropsychological testing Intervention: Serum concentration of lithium or sodium divalproate."
61981238|NCT02962804|EXPERIMENTAL|Nivolumab plus radiation|Nivolumab plus radiation
61981239|NCT01141439||IPDI HFA-BDP MDI|Patients who commenced inhaled corticosteroid therapy as HFA-BDP via MDI
61981240|NCT01141439||IPDI FP MDI|Patients who commenced inhaled corticosteroid therapy as FP via MDI
61981241|NCT01141439||IPDA FP MDI|Patients who had a step up in inhaled corticosteroid therapy as FP via MDI
61981242|NCT01141439||IPDA HFA-BDP MDI|Patients who had a step up in inhaled corticosteroid therapy as HFA-BDP via MDI
62360712|NCT00260195|EXPERIMENTAL|School-based cognitive behavioral support group|Ten group lessons facilitated by a teacher or school counselor that focuses on psycho-education, development of a trauma narrative, approaching trauma-related situations, social problem solving, and cognitive skills.
62360713|NCT00260195|NO_INTERVENTION|Wait-list control group|Waiting list
62360714|NCT00002941|EXPERIMENTAL|Reinduction Therapy|Two courses of reinduction chemotherapy followed by bone marrow biopsy and aspirate prior to peripheral blood stem cell (PBSC) harvest. If marrow involvement is still present at harvest, then 2 additional courses of induction chemotherapy are given. The PBSC transplantation preparative regimen should begin within 2 weeks of completing reinduction therapy course, consisting of the following: Carmustine IV over 3 hours on days -8, -7, and -6, Etoposide continuous IV over days -8, -7, and -6, Cyclophosphamide IV over 1 hour daily on days -5, -4, -3, and -2, Mesna as a 15 min infusion before each dose of cyclophosphamide then at 3, 6, 9, and 12 hours after initiation of each cyclophosphamide dose Methylprednisolone IV is given to protect lungs from the toxic effects of carmustine.
62360715|NCT03025152|EXPERIMENTAL|Hou Gu Mi Xi|Patients in this arm receive Hou Gu Mi Xi, with an oral dose of 10 g/day during entire follow up period (2 years).
62360716|NCT03025152|PLACEBO_COMPARATOR|placebo|Patients in this arm receive placebo, with an oral dose of 10 g/day during entire follow up period (2 years).
62360717|NCT02565446|EXPERIMENTAL|Bariatric|Obese adult subjects who are scheduled to undergo bariatric surgery
62360718|NCT02565446|EXPERIMENTAL|Clinical|Subjects who received abdominal surgery for non-liver related indications (cholecystectomy, pancreatic cyst resection)
62360719|NCT02559557|EXPERIMENTAL|Supportive care (Spanish-adapted skills training)|"PHASE I (FOCUS GROUPS): Parents undergo a semi-structured interview with bilingual research assistants over 120 minutes. The content and purpose of the intervention is explained, and the focus group discussions elicit feedback on the intervention components and content of the sessions, and whether the material is culturally and linguistically appropriate. Following the focus group discussion, parents receive a copy of the educational handouts that they may choose to use with their child if they like.~PHASE II (PILOT TESTING): Parents of children age 5 to 17 years, 11 months old undergo adapted skills training in Spanish over 60 minutes (8 training sessions total) or 80 minutes (6 training sessions total). The adapted skills training sessions focus on parenting strategies and learning techniques. Sessions include homework assignments and techniques for parents to apply with their child for at least 30 minutes, 3 times a week at home."
62360720|NCT00293241|OTHER|MVP ON|Managed Ventricular Pacing programmed on
61981243|NCT01141439||IPDI CFC-BDP MDI|Patients who commenced inhaled corticosteroid therapy as CFC-BDP via MDI
61981244|NCT01141439||IPDA CFC-BDP MDI|Patients who had a step up in inhaled corticosteroid therapy as CFC-BDP via MDI
62360721|NCT00293241|OTHER|MVP OFF|Managed Ventricular Pacing programmed off: conventional pacing
62360722|NCT05779800|EXPERIMENTAL|Flowable resin composite stent group|Flowable resin composite is a bio compatible material used in dental field many years ago.
62360723|NCT05779800|ACTIVE_COMPARATOR|Periodontal pack group|"Non eugenol containing periodontal pack used in periodontal surgeries to protect the wound.~Other name :COE_PAK"
62360724|NCT00646438|ACTIVE_COMPARATOR|1|strict glucose control (study arm)
61981245|NCT03130842|ACTIVE_COMPARATOR|Sublingual alprazolam|
61981246|NCT03130842|ACTIVE_COMPARATOR|Oral midazolam|
62360725|NCT00646438|NO_INTERVENTION|2|standard insulin treatment (control arm)
62360726|NCT00430898|PLACEBO_COMPARATOR|1. Placebo|Placebo to mimic 40 mg of Simulect
62360727|NCT00430898|EXPERIMENTAL|2. 40 mg Simulect|40 mg of Simulect
62360728|NCT01967472|ACTIVE_COMPARATOR|co-formulated Amodiaquine-Artesunate|"Sanofi Coarsucam Infant dose (2-12 months/4.5-8kg), amodiaquine:67.5mg/artesunate 25mg; 1 tablet once a day for 3 days.~Sanofi Coarsucam Young Child (13-59 months/9-17kg), amodiaquine: 136mg/artesunate 50mg; 1 tablet once a day for 3 days."
62360729|NCT01967472|ACTIVE_COMPARATOR|artemether-lumefantrine|"Novartis coartem infant dose (2-11 months/5-14kg), artemether 20mg/lumefantrine 120mg; 1 tablet twice a day for 3 days.~Novartis coartem child dose (12-59 months/15-24kg), artemether 20mg/lumefantrine 120mg; 2 tablets twice a day for 3 days"
62360730|NCT04822311|EXPERIMENTAL|Investigate the effects of an exercise intervention on retired APF players|20 retired APF players (≥ 18 years of age), who suffer from chronic pain, will be enrolled.
62360731|NCT04362813|EXPERIMENTAL|Canakinumab|Canakinumab 450 mg for body weight 40-\<60 kg, 600 mg for 60-80 kg or 750 mg for \>80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
62360732|NCT04362813|PLACEBO_COMPARATOR|Placebo|250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
62360733|NCT04983810|EXPERIMENTAL|Phase I Dose escalation|"Phase I = Fadraciclib administered orally in escalating doses starting at 50mg bid MWF for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved.~Phase 2 = Recommended Fadraciclib phase 2 dose and schedule administered orally in 28 day cycles."
62360734|NCT01578538|ACTIVE_COMPARATOR|mesh used repair|mesh used hernia repair will be perform
62360735|NCT01578538|ACTIVE_COMPARATOR|nonmesh|nonmesh hernia repair techniques will be used
62360736|NCT01402024|EXPERIMENTAL|Aprepitant|It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy. Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm. The patient on aprepitant arm will receive the study drug (aprepitant)along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
61981247|NCT05634460|ACTIVE_COMPARATOR|Group A|patients in group A treated with 5% potassium hydroxide on every lesion once daily via cotton-tipped applicator for at least two weeks or till inflammatory manifestations
61981248|NCT05634460|ACTIVE_COMPARATOR|group B|patients in group B treated with10% potassium hydroxide on every lesion once daily via cotton-tipped applicator for at least two weeks or till inflammatory manifestations
62182302|NCT02444351|ACTIVE_COMPARATOR|control group|
62182303|NCT02444351|EXPERIMENTAL|botox group|
62182304|NCT03588819|EXPERIMENTAL|2-fraction SABR|
62182305|NCT02637856|EXPERIMENTAL|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
62182306|NCT02637856|EXPERIMENTAL|Ocrelizumab (substudy)|Participants with no serious IRR throughout the main study will be eligible to enroll in an optional substudy and receive one additional shorter infusion of ocrelizumab at the Week 96 visit. Ocrelizumab will be administered IV as a single 600-mg dose at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
62360737|NCT01402024|PLACEBO_COMPARATOR|Control|It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy. Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm. The patient on the control arm will receive the placebo along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
62360738|NCT05875389|EXPERIMENTAL|Virtual assessment|virtual assessment with a stroke neurologist/advanced practice nurse, with interdisciplinary support, to facilitate the care of patients admitted to primary stroke centres using existing tools for remote evaluation and review.
62360739|NCT03948451|EXPERIMENTAL|[14C]AZD5718 Oral Suspension|One 200 mg dose of \[14C\]AZD5718 Oral Suspension
62360740|NCT01692834|ACTIVE_COMPARATOR|Cyclosporine in Cremophor EL®|Dosing 5 mg/kg infused at a constant rate over 4 h with a syringe pump.
62360741|NCT01692834|ACTIVE_COMPARATOR|Cyclosporine in lipid emulsion|Dosing 5 mg/kg infused at a constant rate over 4 h with a syringe pump.
62360742|NCT00052936|EXPERIMENTAL|S6|6x CHOP-14
62360743|NCT00052936|EXPERIMENTAL|R6|6x CHOP-14 + 8x Rituximab
61981249|NCT06069960|EXPERIMENTAL|Surgical group|SALT operation plan for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
61981250|NCT02232633|EXPERIMENTAL|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily
62360744|NCT00052936|EXPERIMENTAL|S8|8x CHOP-14
62360745|NCT00052936|EXPERIMENTAL|R8|8x CHOP-14 + 8x Rituximab
62360746|NCT06189248|EXPERIMENTAL|Intervention group|"6 group activities designed with resourcefulness skills will be performed in the intervention group.~1. Introduction of Resourcefulness~2. Issue of the Interpersonal Competence: Applications of both personal and social resourcefulness strategies~3. Issues of the Interpersonal Competence \& Relationship Adjustment: Applications of both personal and social resourcefulness strategies~4. Issue of the Relationship Adjustment: Applications of both personal and social resourcefulness strategies~5. Issue of the Negative Emotion: Applications of both personal and social resourcefulness strategies~6. Conclusion"
62360747|NCT06189248|NO_INTERVENTION|Observation group|No intervention for the observation group.
62360748|NCT00683007|ACTIVE_COMPARATOR|1|Crystalloid
62360749|NCT00683007|ACTIVE_COMPARATOR|2|Hypertonic Saline
61981251|NCT00739544|OTHER|1|Quantitative sensory testing (QST) of healthy women to create reference values for QST evaluation of women treated for breast cancer
61981252|NCT01685931|EXPERIMENTAL|Paliperidone Palmitate|
62360750|NCT02992873|EXPERIMENTAL|Layperson allocated to fetch an AED and start CPR|In the intervention group mobile lifesavers will be directed to fetch the nearest AED and then attach it to the victim of OHCA. At least 1 volunteer will be directed to start CPR only
62360751|NCT02992873|ACTIVE_COMPARATOR|Layperson allocated to start CPR|In the control group all mobile lifesavers will be directed to the patient to start CPR.
62360752|NCT01924741||ALPPS|ALPPS is the most recent modification of the techniques developed for Two-stage hepatectomies. ALPPS allows to remove an extensive part of the liver in two steps. In the first step the liver parenchyma is transected along the intended line of resection and the future liver remnant cleaned by partial resections from all tumor tissue in the case of bilobar tumors. To this a portal ligation of the larger liver lobe that will have to be removed is added. After a waiting period of 1-2 weeks the second step is performed in which the deportalized liver is removed to render the patient completely tumor-free. (Ann Surg 2012; 255(3):405-14.)
62360753|NCT05521971|OTHER|Before group|In the usual care cohort, there was no systematic clinical pharmacist involvement regarding deprescribing of hypnotics.
62360754|NCT05521971|EXPERIMENTAL|After group|In the intervention cohort a pharmacist-led intervention was implemented comprising the four following components: 1) education of health care personnel; 2) access to standardized discontinuation regimens; 3) patient education; 4) support of transitional care.
62360755|NCT00194727|EXPERIMENTAL|1|Vinorelbine (20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle) and capecitabine (825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle). Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
62360756|NCT00912340|EXPERIMENTAL|Trastuzumab|Patients receive trastuzumab IV over 30 minutes once every 3 weeks and continue to receive their most recent hormone therapy. Patients achieving disease progression receive everolimus PO daily in combination with trastuzumab and hormone therapy.
62360757|NCT00912340|EXPERIMENTAL|Everolimus|Patients receive everolimus PO daily and continue their most recent hormone therapy. Patients achieving disease progression receive trastuzumab IV over 30-90 minutes once every 3 weeks in combination with everolimus and hormone therapy.
62360758|NCT00912340|EXPERIMENTAL|Trastuzumab and everolimus (ARM REMOVED)|Patients receive trastuzumab IV over 30 minutes once every 3 weeks and everolimus PO daily while continuing to receive their most recent hormone therapy.
62360759|NCT06212206|EXPERIMENTAL|PillBot|Patient will swallow the PillBot and be assessed with EGD after two hours of the examination
62360760|NCT01906476|EXPERIMENTAL|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
62360761|NCT01906476|ACTIVE_COMPARATOR|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
61981253|NCT05791266|EXPERIMENTAL|Sticker pads containing lavender and ylang ylang oil|Sticker pads , size 160 mm2, were produced by a certified ISO 9001 manufacturer and contained 0.3% lavender oil and 0.7% ylang ylang oil. The sticker pad was attached to the shirts of healthy volunteers for 2 hours. The outcomes were evaluated before, during and 30 minutes after removal of the pad.
61981254|NCT02075658|OTHER|Conventional Insufflation and Trocars|Subjects enrolled in this study arm will have their procedure performed using either the conventional insufflator and trocars. This system have been cleared for use by the FDA's 510 (k)process and are currently employed in clinical practice, including at UC Irvine Medical Center.
62182307|NCT06483685||Adverse Events with Radiopharmaceuticals drugs|Cases reported in the World Health Organization (WHO) of patients treated by Radiopharmaceuticals drugs with reported toxicity
62360762|NCT04535505||pertussis test population|People with clinical diagnosis of suspected pertussis in outpatient and ward in the Children's Hospital of Fudan University will be collected as study subjects. Their nasopharyngeal swabs will be collected. Bordetella isolation culture and identification method is the gold standard, and the new CPA platform based on CRISPR technology is the method to be tested. Diagnostic values of this research platform would be detected.
62360763|NCT00109005|EXPERIMENTAL|Cohort 1 - 25 mg lenalidomide (Revlimid)|oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks
62360764|NCT00109005|EXPERIMENTAL|Cohort 2 - 5 mg lenalidomide (Revlimid)|oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks
62360765|NCT00178698|OTHER|1|Thermochemotherapy
62360766|NCT04486989|EXPERIMENTAL|Cardiovascular Conditioning Protocol|Participants will complete a sub maximal cardiovascular training program twice per week for a period of 4 weeks.
62360767|NCT04486989|ACTIVE_COMPARATOR|Voice Production Exercises|Participants will complete voice production exercises twice per week for a period of 4 weeks.
62360768|NCT01320813|EXPERIMENTAL|Robot arm|Patients in this arm will have a thyroidectomy performed using a robot-assisted endoscopic technique.
62360769|NCT01320813|ACTIVE_COMPARATOR|Open surgery|Patients in this arm will have a thyroidectomy using an open surgical technique.
61981255|NCT02075658|ACTIVE_COMPARATOR|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port).
62360770|NCT01907555||- Patients presenting Cohen syndrome and two VPS13B mutations|
62360771|NCT01907555||Patients presenting Cohen syndrome without a VPS13B mutation|
62360772|NCT01907555||Patients presenting neutropenia|
61981256|NCT04299412||Melioidosis cases|serum samples collected from patients with B. pseudomallei positive cultures
62360773|NCT03134612|ACTIVE_COMPARATOR|Ondansetron|Ondansetron 8mg (2mg/cc) was given intravenously via a 20 G vein canula
62360774|NCT03134612|ACTIVE_COMPARATOR|Lidocain|Lidocain 40mg (20mg/cc + 2cc of normal saline) was given intravenously via a 20 G vein canula
62360775|NCT06376188|NO_INTERVENTION|Control|no communication training prior to simulation scenario
62360776|NCT06376188|OTHER|Communication-Trained|communication training prior to simulation scenario
61981257|NCT04299412||Non-melioidosis cases|serum samples collected from patients with B. pseudomallei negative cultures
61981258|NCT04877470||Newly referred patients visiting the spine-centre|Newly referred patients visiting the spine-centre at Zuyderland Medical Centre Heerlen in 2019, from 01.01.2019 until 31.12.2019.
61981259|NCT02546557||OPTICABG|Patients undergoing a coronary artery bypass graft surgery for the repair of a multi-vessel disease or left main-coronary disease.
61981260|NCT05318599||IPF patients (group 1)|Consenting adult patients \>18 years old with with already-diagnosed IPF
61981261|NCT05318599||NSIP patients (group 2)|Consenting adult patients \>18 years old with with already-diagnosed non-specific interstitial pneumonia (NSIP)
62360777|NCT00813917|ACTIVE_COMPARATOR|varenicline|
62360778|NCT00813917|PLACEBO_COMPARATOR|Placebo|
62360779|NCT00696098|EXPERIMENTAL|1|sodium butyrate
62360780|NCT00696098|PLACEBO_COMPARATOR|2|
62360781|NCT01753700|EXPERIMENTAL|UHT treated milk|1,5 L of 1,5% UHT milk pr day for 3 weeks (21days)
62360782|NCT01753700|PLACEBO_COMPARATOR|Paseurised milk|1,5 L 1,5% pasteurised milk pr day for 3 weeks (21 days)
62360783|NCT03512470|EXPERIMENTAL|Sistema Prevena ™ (TVAC)|Negative topical pressure system (Sistema Prevena ™).
62360784|NCT03512470|ACTIVE_COMPARATOR|Standard medication|Standard medication with sterile gauzes and a TNT patch or medicated patch
62360785|NCT06055049|EXPERIMENTAL|Kinesio Taping (n=28)|"Kinesio taping certified researcher Y.S. It will be implemented by. Kinesio Taping will be applied to the study group participants during three menstrual cycles. Kinesio taping will be done face to face by the researcher in the laboratory. The participants were given the Mcgill Pain Scale Short Form, Menstruation Symptom Scale, Perceived Stress Scale, Pittsburgh Sleep Quality Index and World Health Organization Quality of Life Scale-Short Form (WHOQOL-BREF-TR)  immediately after the third cycle and the fourth cycle without treatment. will be applied. The follow-up of the implementation process will be recorded with the MSF and KBIF prepared by the researcher.~Kinesio tapes will be applied to the sacral area with 100% tension twice a week, starting from the first start of menstruation. It will continue like this until the end of the 3rd period of menstruation."
62360786|NCT06055049|PLACEBO_COMPARATOR|Sham Taping (n=28)|"Sham taping (fake or tensionless kinesio taping) will be applied to students in the placebo group. The quality of the kinesio tape used in sham taping will be the same. Mcgill Pain Scale Short Form, Menstruation Symptom Scale, Perceived Stress Scale, Pittsburgh Sleep Quality Index and World Health Organization Quality of Life Scale-Short Form (WHOQOL-BREF-TR) administered to participants in the placebo group before the first session ) will be refilled at the end of the third cycle and at the end of the fourth cycle without treatment. In order to eliminate the ethical problems that may occur in the control group, kinesio taping will be applied to the participants in this group after the data collection process of the research is completed.~Kinesio tapes will be applied to the sacral area without tension, twice a week, starting from the first start of menstruation. This situation will continue until the end of the 3rd menstrual period."
62360787|NCT05245994|EXPERIMENTAL|Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib|
62360788|NCT02920229|EXPERIMENTAL|68Ga- PSMA PET/CT|100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
62360789|NCT04569617|ACTIVE_COMPARATOR|upper limb endurance protocol|UL endurance protocol - elbow flexion
61981262|NCT05318599||COPD patients (group 3)|Consenting adult patients \>18 years old with with already-diagnosed chronic obstructive pulmonary disease (COPD)
62182308|NCT05079906|OTHER|Main study arm|All subjects will have their SFA lesion assessed with FFR measurement.
62182309|NCT05079906|OTHER|Sub-study|Last 50 enrolled subjects will have HD-IVUS in addition to FFR.
62182310|NCT03671239|OTHER|Product Sequence A|Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period.
62360790|NCT04569617|ACTIVE_COMPARATOR|upper limb strength protocol|UL strength protocol - elbow flexion
61981263|NCT05318599||Control subjects (group 4)|"Consenting age-matched (+/- 2.5 years) never smokers patients with normal lung function (spirometry, lung volume and Transfer Factor for Carbon Monoxide (TLCO)) followed in the pulmonology outpatient clinic with similar quality of electronic medical records but for diseases other than the outcome of interest, namely:~1. patients with obstructive sleep apnea.~2. patients followed-up for occupational lung diseases (miners, chemical workers, etc.).~3. patients followed-up for pulmonary nodules (considered benign after 2 years)."
62360791|NCT04569617|ACTIVE_COMPARATOR|lower limb endurance protocol|LL endurance protocol - knee extension
62360792|NCT04569617|ACTIVE_COMPARATOR|lower limb strength protocol|LL strength protocol - knee extension
61981264|NCT03417453|ACTIVE_COMPARATOR|Eye Drop Dispenser TYPE Opticare|subject will assess TYPE 1 dispenser
61981265|NCT03417453|ACTIVE_COMPARATOR|Eye Drop Dispenser Autodrop|subject will assess Autodrop dispenser
61981266|NCT03386942|EXPERIMENTAL|Farletuzumab Ecteribulin|"Part 1 (Dose-escalation): The initial dose level of farletuzumab ecteribulin will be 0.3 milligrams per kilogram (mg/kg) every 3 weeks in the first cohort with 1 participant for dose-limiting toxicity (DLT) evaluation. DLTs will be evaluated in successive dose level cohorts with a single participant until a drug-related Grade 2 or higher toxicity is observed. If such a toxicity is observed, the cohort will be expanded to enroll a total of 3 participants.~Part 2 (Treatment Phase): farletuzumab ecteribulin will be administered every 3 weeks during the treatment phase at the dose determined in Part 1 until participants meet any of the criteria for discontinuation. Criteria for discontinuation include: withdrawal of consent, major protocol violations, unable to continue due to adverse events, pregnancy, progressive disease, Investigator decision, or infusion reactions."
62360793|NCT00732641|EXPERIMENTAL|Peginterferon α-2b|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
61981267|NCT03245008|EXPERIMENTAL|MT-5547 dosing regimen 1|MT-5547 Subcutaneous (SC) dosing regimen 1. Naproxen-matching placebo oral after Week 16.
61981268|NCT03245008|EXPERIMENTAL|MT-5547 dosing regimen 2|MT-5547 SC dosing regimen 2. Naproxen-matching placebo oral after Week 16.
61981269|NCT03245008|PLACEBO_COMPARATOR|MT-5547-matching placebo|MT-5547-matching placebo SC dosing. Naproxen oral after Week 16.
61981270|NCT03251508|EXPERIMENTAL|Peanut OIT/dietary peanut|Single arm study with all subjects receiving peanut OIT study drug for the initial 6 months. This is followed by daily ingestion of common dietary foods containing approximately 300 mg of peanut protein for an additional 6 months.
62360794|NCT00732641|NO_INTERVENTION|No Treatment|Participants will be observed and will receive no treatment.
61981271|NCT02694237|ACTIVE_COMPARATOR|Verbal|This group will only receive a verbal discussion based on the same script used for all three groups. This is the control group.
61981272|NCT02694237|ACTIVE_COMPARATOR|Verbal + Model|This group will receive a verbal discussion aided with an anatomic model intervention that group participants will be able to touch throughout the discussion.
61981273|NCT02694237|ACTIVE_COMPARATOR|Verbal + Video|This group will receive a verbal discussion aided with a knee anatomy video intervention that will be played on silent an orated by an interviewer.
61981274|NCT01391390|EXPERIMENTAL|Melatonin, antioxidant, oxidative stress|Melatonin is an active treatment for TD.
61981275|NCT01391390|PLACEBO_COMPARATOR|Placebo|Placebo look like the active drug, and same dose.
62360795|NCT04373707|ACTIVE_COMPARATOR|Low Prophylactic Dose of Low Molecular Weight Heparin|Enoxaparin, Tinzaparin, Nadroparin, Dalteparin
62360796|NCT04373707|EXPERIMENTAL|Weight-Adjusted Prophylactic Dose Low Molecular Weight Heparin|Enoxaparin, Tinzaparin, Nadroparin, Dalteparin
62360797|NCT02320240||SNRI Exposure Group|Patients who received a new prescription for an SNRI (duloxetine, venlafaxine, or desvenlafaxine at any dosage) with no prescriptions for either SNRI or SSRI in the prior year.
62360798|NCT02320240||SSRI Exposure Group|Patients who received a new prescription for an SSRI (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, or sertraline at any dosage) with no prescriptions for either SSRI or SNRI in the prior year.
62360799|NCT04663542|EXPERIMENTAL|0-week immobilization|0-week brace immobilization after the surgery will be conducted.
62360800|NCT04663542|EXPERIMENTAL|2-week immobilization|2-week brace immobilization after the surgery will be conducted.
62360801|NCT04663542|OTHER|4-week immobilization|4-week brace immobilization after the surgery will be conducted.
61981276|NCT01324388|EXPERIMENTAL|LY2189265 + Lisinopril|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Days 1, 8, 15, and 22 of Part 1 of the study.~Lisinopril: Dose as prescribed by participant's established course of therapy, oral, daily dosing throughout Part 1 of the study."
61981277|NCT01324388|PLACEBO_COMPARATOR|Placebo + Lisinopril|"Placebo: 1.5 milligrams (mg), subcutaneous (SC), on Days 1, 8, 15, and 22 of Part 1 of the study.~Lisinopril: Dose as prescribed by participant's established course of therapy, oral, daily dosing throughout Part 1 of the study."
62360802|NCT04663542|OTHER|6-week immobilization|6-week brace immobilization after the surgery will be conducted.
62360803|NCT05467488|NO_INTERVENTION|Non irradiated implants (group A)|
62360804|NCT05467488|ACTIVE_COMPARATOR|UVA irradiated group (group B)|
62360805|NCT05467488|ACTIVE_COMPARATOR|UVC irradiated group (group C)|
62182311|NCT03671239|OTHER|Product Sequence B|Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period.
62360806|NCT03577951|EXPERIMENTAL|high position space group|The left and right Trocar meet at the level of the sternum angle and begin to establish the operating space.
62360807|NCT03577951|EXPERIMENTAL|low position space group|The left and right Trocar meet under the sternum angle and begin to establish the operating space.
62360808|NCT00154193|ACTIVE_COMPARATOR|Cyclosporine|
62360809|NCT00908622|EXPERIMENTAL|Skeletal myoblasts|Percutaneous autologous myoblast implantation
62360810|NCT00908622|PLACEBO_COMPARATOR|No cells|Percutaneous culture medium without cells implantation
62360811|NCT00953225|EXPERIMENTAL|Vitamin D3|4,000 IU vitamin D3 daily for one year
62360812|NCT00953225|PLACEBO_COMPARATOR|Placebo|Placebo daily for one year
62391409|NCT05845554||Non-cancer participants Patients|Non-cancer participants Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the specificity of BileCAD analysis.
61981278|NCT01324388|EXPERIMENTAL|LY2189265 (Treatment 1)/Metoprolol + LY2189265 (Treatment 2)|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Day 1 of Treatment 1 and on Day 5 of Treatment 2 in Part 2 of the study.~Metoprolol: 100 mg, oral, on Days 1 through 7 of Treatment 2 in Part 2 of the study.~There was a washout period of at least 21 days between the LY2189265 and metoprolol doses of each treatment period (Day 1 of Treatment 1 to Day 1 of Treatment 2 in Part 2 of the study)."
61981279|NCT01324388|EXPERIMENTAL|Metoprolol + LY2189265 (Treatment 2)/LY2189265 (Treatment 1)|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Day 5 of Treatment 2 and on Day 1 of Treatment 1 in Part 2 of the study.~Metoprolol: 100 mg, oral, on Days 1 through 7 of Treatment 2 in Part 2 of the study.~There was a washout period of at least 21 days between the LY2189265 and metoprolol doses of each treatment period (Day 7 of Treatment 2 to Day 1 of Treatment 1 in Part 2 of the study)."
61981280|NCT04853342|EXPERIMENTAL|Furmonertinib|Furmonertinib (80 mg orally, once daily), in accordance with the randomization schedule.
61981281|NCT04853342|PLACEBO_COMPARATOR|Placebo Furmonertinib|Matching placebo for Furmonertinib (80 mg orally, once daily), in accordance with the randomization schedule.
61981282|NCT01335555||Patients Pre and Post-chemotherapy|
62360813|NCT02471209||Biliary Atresia Infants|Twenty-five infants diagnosed with Biliary Atresia and undergoing surgery were included in the study (age range 1-3 months). Inclusion criteria were persistent yellow skin or sclera, pale stool (in severe cases, clay-like), and hepatomegaly; increased serum bilirubin (progressively or no decline after increase), increased total bilirubin (TBil) dominated by increased direct bilirubin (DBil) (\>60%); elevated liver enzymes; ultrasound confirmation of poor gallbladder filling and signs of liver fibrosis; with radionuclide imaging confirmation of obstructed biliary excretion. Infants were excluded if they had concomitant cardiovascular or abdominal organ malformations.
61981283|NCT03190655|EXPERIMENTAL|Aluminaid|Treatment group: Aluminaid wound dressing
62360814|NCT02288039|EXPERIMENTAL|Social Identity Goal-Based Intervention|Participants will receive collaborative goal-setting
62360815|NCT02288039|NO_INTERVENTION|Standard Care|Participants will receive usual standard treatment
62360816|NCT04907162||Neuromuscular disease (NMD) Patients|"The patient has one of the following neuromuscular diagnoses:~1. histologically (muscle biopsy) confirmed inclusion body myositis (IBM), or~2. genetically confirmed late-onset Pompe disease (LOPD), or~3. genetically confirmed spinal muscular atrophy type 3 (SMA3), or~4. genetically confirmed myotonic dystrophy type 1, or~5. genetically confirmed myotonic dystrophy type 2, or~6. genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD)."
62360817|NCT04907162||Healthy control|no known neuromuscular disorder
61981284|NCT03190655|ACTIVE_COMPARATOR|Hydrogel|Hydrogel wound dressing (Trademark: Burnshield)
62360818|NCT04122586|NO_INTERVENTION|health control group|
62360819|NCT04122586|EXPERIMENTAL|Tongxieyaofang granule group|
62360820|NCT01256320|NO_INTERVENTION|Control Group|no shell egg consumption and usual dietary practices
61981285|NCT01966640|EXPERIMENTAL|Child food allergy suspicion|Basophil Activation Test realized in case of Child food egg and peanut allergy suspicion
61981286|NCT01618552|EXPERIMENTAL|SEE IT training (interviewing skills)|Intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) with patients who have coexisting depression and diabetes
61981287|NCT01618552|ACTIVE_COMPARATOR|Control (knowledge enhancement)|Brief video clip designed to increase primary care physician awareness of new medication treatments for patients with diabetes
61981288|NCT06320730||Group 110 < REP BG < 180|Those with blood glucose levels over 110 and under 180 after reperfusion in liver transplantation recipients.
62360821|NCT01256320|ACTIVE_COMPARATOR|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
62739148|NCT02224443|PLACEBO_COMPARATOR|Group C ,normal saline|Normal saline infusion will be given with the same infusion volume as group A and B
61981289|NCT06320730||Group REP BG ≤110 or ≥180|Those with blood glucose levels below 110 or above 180 after reperfusion in liver transplantation recipients.
61981290|NCT05298280|ACTIVE_COMPARATOR|Pendulum Group (PG)|In the PG, all patients received a pendulum appliance as described by Angelieri et al. The Nance button was anchored to the first and second premolars with removable wires.
61981291|NCT05298280|ACTIVE_COMPARATOR|Clear Aligner Group (CAG)|The treatment of sequential upper arch distalization was performed by the same board-certified orthodontists as proposed by Align Technology and described by Ravera et al.
61981292|NCT04937296|PLACEBO_COMPARATOR|Usual care|
61981293|NCT04937296|EXPERIMENTAL|Physical activity|
62360822|NCT01256320|ACTIVE_COMPARATOR|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
62360823|NCT03693404|EXPERIMENTAL|Spinal Anesthesia|Injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
62360824|NCT03693404|ACTIVE_COMPARATOR|General Anesthesia|The control group will receive no injection into area surrounding the fracture site
61981294|NCT03198533|ACTIVE_COMPARATOR|Triathlon PA|Triathlon PA (HA-surface) versus Triathlon Pressfit design: The goal with the un-cemented technique is to reach a full integration between the bone and the prosthesis. During the last years the usage of prosthesis with hydroxyapatite surface within tooth-, mandibular-surgery, hips- and knee-joints, have increased significantly. It has been shown that a thin layer of hydroxyapatite stimulates the anchorage of the implant. The goal with this sub study is to compare the stability of the fixation when using two different types of Triathlon un-cemented prosthesis designs. PA (HA-surface) versus Pressfit.
62360825|NCT02438046|EXPERIMENTAL|Palatal wound bandage by PRF|Intervention: In the test group (n=20 patients) the palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes
62360826|NCT02438046|PLACEBO_COMPARATOR|Palatal wound bandage by gelatin sponge|Intervention: The control group patients (n=20) will have their palatal wound medicated by absorbable gelatin sponge.
62360827|NCT00633802|PLACEBO_COMPARATOR|2|
62360828|NCT00633802|EXPERIMENTAL|1|
62739149|NCT05090163|ACTIVE_COMPARATOR|PREP group|Control group
62739150|NCT05090163|EXPERIMENTAL|PREP Plus group|Intervention group
61981295|NCT03198533|ACTIVE_COMPARATOR|Triathlon Pressfit|Triathlon PA (HA-surface) versus Triathlon Pressfit design: The goal with the un-cemented technique is to reach a full integration between the bone and the prosthesis. During the last years the usage of prosthesis with hydroxyapatite surface within tooth-, mandibular-surgery, hips- and knee-joints, have increased significantly. It has been shown that a thin layer of hydroxyapatite stimulates the anchorage of the implant. The goal with this sub study is to compare the stability of the fixation when using two different types of Triathlon un-cemented prosthesis designs. PA (HA-surface) versus Pressfit.
61981296|NCT04061096|ACTIVE_COMPARATOR|MIH-effected carious first permanent molar teeth|MIH-effected carious permanent first molar teeth were well-demarcated white/yellow or brown/yellow enamel opacities which is a sign for hypomineralization and asymptomatic which meant to be without any spontaneous pain or pain during eating or drinking, percussion or palpation tenderness, formation of abcess or fistula.
61981297|NCT04061096|ACTIVE_COMPARATOR|not MIH-effected carious first permanent molar teeth|The carious not MIH-effected teeth were only carious without any hypomineralize areas and asymptomatic which meant to be without any spontaneous pain or pain during eating or drinking, percussion or palpation tenderness, formation of abcess or fistula.
62360829|NCT01053572|ACTIVE_COMPARATOR|Celestone|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
62360830|NCT01053572|ACTIVE_COMPARATOR|sodium chloride solution|Group II will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and 0.9% sodium chloride solution to substitute for non-particulate Celestone
62360831|NCT01053572|ACTIVE_COMPARATOR|sodium choride solution|Group III will receive adhesiolysis, local anesthetic, normal sodium chloride solution instead of 10% hypertonic sodium chloride solution and non-particulate Celestone;
62360832|NCT01053572|ACTIVE_COMPARATOR|Double substitutes|Group IV will receive adhesiolysis, local anesthetic, and 0.9% sodium chloride solution to substitute for the 10% hypertonic sodium chloride, and 0.9% sodium chloride solution to substitute for non-particulate Celestone
61981298|NCT04061096|PLACEBO_COMPARATOR|MIH-effected non-carious first permanent molar teeth|MIH-effected teeth were carious permanent first molar teeth with well-demarcated white/yellow or brown/yellow enamel opacities which is a sign for hypomineralization and did not have any sign of caries.
62360833|NCT05373316|EXPERIMENTAL|MR-guided hypofractionated focal boost radiotherapy|External beam MR-guided (MR-linac) radiotherapy to the prostate and seminal vesicles of 5x7Gy (once weekly) with an isotoxic integrated focal boost up to 50Gy to the intraprostatic tumor as visible on multiparametric MR
62360834|NCT01072448|EXPERIMENTAL|Indacaterol 75 μg|Patients inhaled indacaterol 75 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
61981299|NCT04061096|PLACEBO_COMPARATOR|not MIH-effected non-carious first permanent molar teeth|not any signs of being caries or hypomineralization.
62360835|NCT01072448|PLACEBO_COMPARATOR|Placebo to indacaterol|Patients inhaled placebo to indacaterol once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62360836|NCT05878691|EXPERIMENTAL|GRC 54276|
61981300|NCT01782664|EXPERIMENTAL|100 mg GSK2586184|Subjects will be randomized to 100 mg GSK2586184 twice daily for up to 84 days
61981301|NCT01782664|EXPERIMENTAL|200 mg GSK2586184|Subjects will be randomized to 200 mg GSK2586184 twice daily for up to 84 days
61981302|NCT01782664|EXPERIMENTAL|400 mg GSK2586184|Subjects will be randomized to 400 mg GSK2586184 twice daily for up to 84 days
61981303|NCT01782664|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to receive Placebo twice daily for up to 84 days
62360837|NCT05878691|EXPERIMENTAL|GRC 54276 with pembrolizumab|
62360838|NCT05878691|EXPERIMENTAL|GRC 54276 with atezolizumab|
62360839|NCT00603850||1|Intermediate AMD Patients
62360840|NCT02284945|EXPERIMENTAL|Posterior percutaneous instrumentations|
62360841|NCT02284945|OTHER|Traditional open surgery with pedicle screw fixation|
62739151|NCT05961241|ACTIVE_COMPARATOR|running group|women who run on a regular basis
62182312|NCT03671239|OTHER|Product Sequence C|Participants will use rectal suppositories during the first 4-week product use period, rectal inserts during the second 4-week product use period, and rectal douches during the third and final 4-week product use period.
62739152|NCT05961241|EXPERIMENTAL|control|women who do not run
62739153|NCT05940857||OCS Liver Transplant Recipients|The US National OLP Registry will enroll all liver transplant recipients who are transplanted with an OCS-perfused donor liver in the Registry.
62739154|NCT05940857||Non-OCS Liver Transplant Recipients|Patients transplanted using other preservation modalities for clinical outcomes.
62182313|NCT03671239|OTHER|Product Sequence D|Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal douches during the third and final 4-week product use period.
62360842|NCT04090983|ACTIVE_COMPARATOR|Cognitive-behavioral therapy (Hesslinger protocol)|
62360843|NCT04090983|EXPERIMENTAL|Cognitive-behavioral therapy (CADDI protocol)|
62360844|NCT04614350|EXPERIMENTAL|A-Active|Markman Biologics microsurfaced ADM
62360845|NCT04614350|ACTIVE_COMPARATOR|B-Control|AlloDerm ADM
62360846|NCT02841917||Transcatheter Aortic Valve Replacement|ROS Post TAVR
62360847|NCT02841917||Surgical Aortic Valve Replacement|ROS Post SAVR
62360848|NCT03536923|EXPERIMENTAL|Leva Arm|Subjects will use the leva device twice daily to perform pelvic floor muscle exercises
62360849|NCT02121444||Cohort 1|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect auto-injector
62360850|NCT04194515||YH1 group|
62360851|NCT04194515||Metformin group|
62360852|NCT04956081|EXPERIMENTAL|virtual neuro-navigation|The specific area within the L-DLPFC will be identified by a software using MR images. TMS will be administered to the identified area.
61981304|NCT01782664|EXPERIMENTAL|400 mg GSK2586184 (Cohort B)|Subjects will take 400 mg GSK2586184 twice daily for up to 84 days
61981305|NCT01599871|EXPERIMENTAL|Intervention|Inhaled corticosteroids and long-acting beta agonist + theophylline (Slophylline capsules 100 mg/Theo-dur Retard 100 mg b.i.d.)
61981306|NCT01599871|PLACEBO_COMPARATOR|Control|inhaled corticosteroids and long-acting beta agonist + Placebo
61981307|NCT02450110|EXPERIMENTAL|Intervention|Spinal cord stimulation on top of standard treatment
62169253|NCT06646523|SHAM_COMPARATOR|Control group (Bodyweight intervention, usual speed)|"The participants of the control group (Bodyweight intervention, usual speed) will also receive a home-based intervention that will include 5 minutes of warm-up (free active movements of trunk and lower limbs), followed by 50 min of exercises more targeted to the lower limb muscles, and by 5 minutes of cool-down (lower limb muscle stretching and relaxation breathing exercise).~The control intervention will be performed at the usual speed. The same procedures that will be carried out to determine the maximum speed in the experimental group will be used to determine the usual speed in the control group. There will be no progression in the speed of performing the exercises. However, participants in the control group will also receive a home visit from the main researcher every four weeks to avoid bias related to the amount of attention given to participants in the experimental group."
62169254|NCT01751451|EXPERIMENTAL|Abiraterone acetate|"Group 1~* Abiraterone acetate 1000 mg daily x 8 months~* Prednisone 5 mg once daily x 8 months"
61981308|NCT02450110|NO_INTERVENTION|Control|Standard treatment
62169255|NCT01751451|EXPERIMENTAL|Abiraterone acetate and Degarelix|"Group 2~Abiraterone acetate 1000 mg daily x 8 months~* Prednisone 5 mg once daily x 8 months~* Degarelix subcutaneous depot injection q 1 month x 8 months"
62360853|NCT04956081|EXPERIMENTAL|on-line neuro-navigation|The specific area within the L-DLPFC will be identified by a person using MR images. TMS will be administered to the identified area.
62169256|NCT01751451|EXPERIMENTAL|Degarelix|"Group 3~• Degarelix subcutaneous depot injection q 1 month x 8 months"
62169257|NCT01329419||adefovir dipivoxil|Patients administrated adefovir at the site
62169258|NCT02794441|EXPERIMENTAL|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
62169259|NCT02794441|PLACEBO_COMPARATOR|Placebo|Matched oral solution in same volume per kg as dexamethasone
62360854|NCT03343782|EXPERIMENTAL|Stem cell transplantation|Intervention: 30 patients will be transplanted autologous bone marrow-derived mesenchymal stem cells and undergoing 2 treatment with 6 months interval
62739155|NCT03222362||patients 85 years and above|120 consecutive patients (male and female), aged 85 years and above, who underwent pars plana vitrecromy in the Tel Aviv Medical Center during the years 01/01/2006 - 31/12/2013, and were followed by physicians in the ophthalmology department in the center until December 2015.
62169260|NCT03638401|NO_INTERVENTION|Standard treatment|
62169261|NCT03638401|ACTIVE_COMPARATOR|Intervention arm|
62169262|NCT04906707|EXPERIMENTAL|EaseVRx Group|Participants will be asked to complete the 8-week program with assigned modules each week. Each week, participants will be asked to complete 7 modules, averaging 5 minutes in duration and ranging from 2 to 16 minutes in duration, for a total of 56 modules across the program. Participants will be instructed not to use the device while ambulating, and that they should use the headset a maximum of 3 times per 24-hour period (morning, noon, and evening) for not more than 30 minutes consecutively.
62169263|NCT04906707|ACTIVE_COMPARATOR|Active control Group|Participants in the control group will be asked to use the audio-only version of EaseVRx that excludes references to visual content. They will receive an electronic link to the audio recordings on SoundCloud (a music streaming platform) where they can choose to stream or download the audio recordings on their smartphone, laptop, or desktop computer. Each week, participants will be asked to complete 7 audio sessions.
62169264|NCT01149499|EXPERIMENTAL|Valacyclovir|Test 1000 mg Valacyclovir Tablet
62169265|NCT01149499|ACTIVE_COMPARATOR|Valtrex|Reference Listed 1000 mg Valtrex Tablet
62169266|NCT00184496|ACTIVE_COMPARATOR|methadon|Morphine methadone stop and go switch
62169267|NCT00184496|ACTIVE_COMPARATOR|Methadone|Methadon morphine overlap switch
61981309|NCT04057079|EXPERIMENTAL|Anugel|"In this arm, after the surgery a hydrogel impregnated sponge will be placed in the rectum.~The patient is evaluated after the operation and the following day when the sponge is removed.~A hydrogel impregnated foam pad is applied on the surface of the wound the following 5 days.~The patient is evaluated on post op, on day 1 (usually before discharge) and day 5~The pain of the patients are evaluated according to the VAS scale and the use of analgesics and opioids is monitored."
61981310|NCT04057079|ACTIVE_COMPARATOR|Sponge|"Currently used treatment method i.e. insertion of gelatine sponge in to the rectum post operation.~The patient is evaluated on post op, on day 1 (usually before discharge) and day 5~The pain of the patients are evaluated according to the VAS scale and the use of analgesics and opioids is monitored."
62169268|NCT02214836|EXPERIMENTAL|Kidney stones|"Device: Verasonics Data Acquisition System (VDAS)~Other Names:~Verasonics Data Acquisition System (VDAS) Verasonics Ultrasound Engine Subjects will be imaged the Verasonics Data Acquisition System (VDAS) using conventional clinical outputs within FDA limits. The image processing has been modified.~Subjects in this arm will be imaged by ultrasound by the VDAS. Stone location and size will be determined and compared to clinical determination of stone location and size."
62169269|NCT01368055|EXPERIMENTAL|Low Risk|70 Gy/CGE
61981311|NCT00732147|PLACEBO_COMPARATOR|2|Type 2 diabetes patients will receive placebo with 3 meals in experimental period.
62169270|NCT01368055|EXPERIMENTAL|Intermediate Risk|72.5 Gy/CGE
61981312|NCT00732147|EXPERIMENTAL|1|Type 2 Diabetes patient will receive Pramlintide with 3 meals in experimental period.
62182314|NCT03671239|OTHER|Product Sequence E|Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal inserts during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period.
62360855|NCT00660075|EXPERIMENTAL|1|Sitagliptin 100 mg/d for 6 weeks
62360856|NCT00660075|PLACEBO_COMPARATOR|2|Placebo for 6 weeks
62391410|NCT04797572|OTHER|Treated group|Patients in whom the free margin cusp sizer will be used to measure the free margin of the three leaflets of the aortic valve during aortic valve repair.
62549970|NCT02452476|ACTIVE_COMPARATOR|Poractant alfa|Single dose within 24 hours from birth
62169271|NCT05937971|EXPERIMENTAL|plantar sensitivity training group|Conventional exercises (with the addition of warm-up and cool-down periods) will be applied to all multiple sclerosis patients participating in the study; In addition, aerobic exercise training will be given. In addition to these exercises, plantar sensory training will be given to the sensory training group. Exercises and plantar sensory training will be given to the participants at intervals of three weeks, with progressively progressive sessions, 2 days a week for 12 weeks. Patients will be evaluated twice, before treatment and at the end of treatment 12 weeks later. Within the scope of the evaluation, balance, functional capacity, gait, proprioception and plantar sensory parameters will be measured in patients.
62169272|NCT05937971|ACTIVE_COMPARATOR|aerobic exercise training group|Conventional exercises (with the addition of warm-up and cool-down periods) will be applied to all multiple sclerosis patients participating in the study; In addition, aerobic exercise training will be given. In addition to these exercises, plantar sensory training will be given to the sensory training group. Exercises and plantar sensory training will be given to the participants at intervals of three weeks, with progressively progressive sessions, 2 days a week for 12 weeks. Patients will be evaluated twice, before treatment and at the end of treatment 12 weeks later. Within the scope of the evaluation, balance, functional capacity, gait, proprioception and plantar sensory parameters will be measured in patients.
62360857|NCT06149689|EXPERIMENTAL|mFOLFIRINOX plus radiotherapy|Patients with advanced pancreatic adenocarcinoma will receive a modified FOLFIRINOX regimen (oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 4\~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline.
61981313|NCT05652998|ACTIVE_COMPARATOR|Candida antigen|patients will be injected with intralesional C.albicans antigen
62169273|NCT01514864|EXPERIMENTAL|Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation)|Participants with nonsmall-cell lung cancer (NSCLC) and an inactivating B-RAF mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred
62169274|NCT01514864|EXPERIMENTAL|Dasatinib, 140 mg (NSCLC With DDR2 Mutation)|Participants with NSCLC and a discoidin domain receptor 2 (DDR2) mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred
62169275|NCT01072396|ACTIVE_COMPARATOR|18 mcg tiotropium|Patient to receive 1 tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
62169276|NCT01072396|PLACEBO_COMPARATOR|Placebo|Patient to receive 1 placebo inhalation powder capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler
62169277|NCT01072396|NO_INTERVENTION|Control|Age and gender matched control subjects to conduct incremental and constant work rate exercise tests for comparison to subjects with early stage COPD
62169278|NCT05644041|EXPERIMENTAL|Gemcitabine induction|Patients will receive Gemcitabine once weekly for 6 weeks.
62169279|NCT01601639|ACTIVE_COMPARATOR|Argon Plasma Coagulation|Patients with GAVE and/or chronic anemia, active GI bleeding, blood transfusion requirements
62169280|NCT01601639|ACTIVE_COMPARATOR|Endoscopic Band Ligation|Patients with GAVE and/or chronic anemia, active GI bleeding, blood transfusion requirements
62169281|NCT02078297||Scalp psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
62169282|NCT02078297||pustular palmo-plantar psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
62169283|NCT02078297||non-pustular palmo-plantar psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
62169284|NCT02078297||elbow psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
62169285|NCT02078297||leg psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
62360858|NCT02334085||HOW study participants|
62360859|NCT02595268|EXPERIMENTAL|Pitavastatin Then JNJ-63623872|Participants will sequentially receive single oral dose of pitavastatin 1 milligram (mg) on Day 1, followed by JNJ-63623872 600 mg twice daily on Days 4 through 12 with a single oral dose of pitavastatin 1 mg administered in the morning of Day 9. All study drug intakes will be taken orally, under fed conditions (within approximately 10 minutes after completion of a meal).
62360860|NCT01351311|EXPERIMENTAL|Exercise Group|Resistance exercise with swiss ball and drug treatment
61981314|NCT05652998|ACTIVE_COMPARATOR|Autologous platelets rich plasma|patients will receive intralesional autologous PRP injection
61981315|NCT05652998|PLACEBO_COMPARATOR|Saline|patients will receive intralesional saline
61981316|NCT02089633|EXPERIMENTAL|PACOX|Pegylated human arginase (PA) in combination with Capecitabine (C) and Oxaliplatin (OX)
61981317|NCT00385242|ACTIVE_COMPARATOR|PET guided Therapy|Patients will be randomized to undergo positron emission tomography aspart of their clinical work up
61981318|NCT00385242|ACTIVE_COMPARATOR|Standard care|Patients will be randomized to standard care will under go other types of imaging or work up for revascularization without PET imaging.
62169286|NCT02078297||Healthy subjects|
62169287|NCT04620733|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo to match seladelpar, orally, once daily, for a duration of up to 12 months.
62360861|NCT01351311|OTHER|Control Group|Drug treatment
62360862|NCT02747407||Basic Science Group II (vaccination at 9 months)|Patients undergo standard of care treatment and collection of blood samples as in Group I. Patients then receive hepatitis A and tetanus toxoid vaccinations at month 9.
62360863|NCT02747407||Basic Science Groups I (vaccination pre-treatment)|Patients receive standard of care hepatitis A or B vaccine, tetanus toxoid vaccine, and trivalent influenza vaccine and then undergo standard of care treatment external beam radiation therapy and receive standard of care temozolomide. Patients also undergo collection of blood Samples monthly for the first 8 months and then bimonthly for up to 12 months for analysis via flow cytometry, (CFSE) assay, live cell/dead cell distinction assay, and determination of naïve and memory immune response.
62360864|NCT01757587|ACTIVE_COMPARATOR|Vildagliptin|
62360865|NCT01757587|PLACEBO_COMPARATOR|Placebo|
62360866|NCT02025803|EXPERIMENTAL|TAS-114/capecitabine|See intervention description
62360867|NCT01082341|EXPERIMENTAL|Fy(+)|14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites
62360868|NCT01082341|ACTIVE_COMPARATOR|Fy(+) control|Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites.
62360869|NCT01082341|ACTIVE_COMPARATOR|Fy(-)|Six Fy(-) volunteers will be exposed to infective mosquito bites.
62360870|NCT05863702|NO_INTERVENTION|Usual Care|
62360871|NCT05863702|EXPERIMENTAL|Penny text-messaging program|
62360872|NCT03029949|EXPERIMENTAL|ACT with VR|acceptance and commitment therapy with vestibular rehabilitation in addition to clinical management
62360873|NCT03029949|ACTIVE_COMPARATOR|Self-treatment VR|self-treatment vestibular rehabilitation in addition to clinical management
62360874|NCT03081598|PLACEBO_COMPARATOR|Placebo|Daily dose of 6 capsules of placebo
62360875|NCT03081598|ACTIVE_COMPARATOR|PBI-4050 400 mg|Daily dose of 2 capsules of PBI-4050 and 4 capsules of placebo
62360876|NCT03081598|ACTIVE_COMPARATOR|PBI-4050 800 mg|Daily dose of 4 capsules of PBI-4050 and 2 capsules of placebo
62360877|NCT03081598|ACTIVE_COMPARATOR|PBI-4050 1200 mg|Daily dose of 6 capsules of PBI-4050
62360878|NCT03068936|EXPERIMENTAL|IMRT group|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
62360879|NCT03068936|OTHER|IMRT plus cisplatin group|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy),plus synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
62360880|NCT03622541|EXPERIMENTAL|sorafenib|
62360881|NCT05462405|EXPERIMENTAL|Experimental group|All subjects enrolled will be in the same experimental group.
62360882|NCT02254551|EXPERIMENTAL|LDE225 Plus Bortezomib|"Lead-In Portion: The lead-in portion of this study will investigate the safety and tolerability, and determine the MTD of LDE225, in combination with bortezomib in this patient population.~Expansion Portion: Eligible patients will receive LDE225 orally once daily for 21 days with the dose-level determined in the lead-in portion of the study. Eligible patients will also receive a standard regimen of bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of each 21 day cycle.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
62360883|NCT01700881|EXPERIMENTAL|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
62360884|NCT01700881|PLACEBO_COMPARATOR|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
61981319|NCT01566461|EXPERIMENTAL|Drug-Coated Balloon (DCB)|IN.PACT Admiral: Balloon Angioplasty
61981320|NCT01566461|ACTIVE_COMPARATOR|Standard PTA|Standard Percutaneous Balloon Angioplasty (PTA) Balloon: Balloon Angioplasty
62360885|NCT02679794|EXPERIMENTAL|Egg consumption|Consuming sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
62360886|NCT02679794|PLACEBO_COMPARATOR|Control|Consuming sautéed vegetables and 3g canola oil without eggs
62360887|NCT04504461||Laparoscopic Inguinal Hernioplasty. Ambulatory|Laparoscopic Inguinal Hernioplasty performed in ambulatory surgery center
62360888|NCT04504461||Laparoscopic Inguinal Hernioplasty. Hospital Stay|Laparoscopic Inguinal Hernioplasty that have to stay at least 24 hours at the hospital
62360889|NCT01766544|ACTIVE_COMPARATOR|Standard practice group (SPG)|Send a copy of the latest Canadian asthma and COPD guidelines to all PCPs.
62360890|NCT01766544|ACTIVE_COMPARATOR|Targeted Intervention Strategy (TISG)|interactive educational intervention, expert mentorship, practice-based tools. Consisting of 3 interactive sessions, 2 of which would be live meetings of 3h each and the third a one-hour teleconference.
62169288|NCT04620733|EXPERIMENTAL|Seladelpar|Participants will receive seladelpar 10 mg (or 5 mg down-titrated, for those participants who met specific safety monitoring criteria or had tolerability issues), orally, once daily, for a duration of up to 12 months.
62169289|NCT02198716|OTHER|Drug eluting stent|Percutaneous coronary intervention
62169290|NCT02198716|OTHER|Bare Metal Stent|Percutaneous Coronary Intervention
62360891|NCT05698108|ACTIVE_COMPARATOR|Conventional Physcial Therapy Group|All participants received treatment 2 times a week for 4 weeks. Pre-treatment included a Moist hot pack for 10 minutes and traditional physical therapy included Cyriax Deep Friction Massage (DFM), Ultrasound therapy as well as strengthening and stretching exercises
62360892|NCT05698108|EXPERIMENTAL|IASTM Group|Participants received Instrument Assisted Soft Tissue Mobilization Treatment 2 times a week for 4 weeks using Ergon IASTM tools.
62360893|NCT05933798|EXPERIMENTAL|Intervention Group|"Participants who were actively followed up during the study period with a personalized integrated care plan developed following the ICOPE screening and assessment, identified as at-risk for loss in intrinsic capacity."
62360894|NCT05933798|ACTIVE_COMPARATOR|Control Group|Pariticpants who continued receiving usual care during the study period.
62360895|NCT04054102|EXPERIMENTAL|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot
62360896|NCT04054102|SHAM_COMPARATOR|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot
62360897|NCT04415619|EXPERIMENTAL|Intervention group|10 patients will have immediate implant placement with buccal pad of fat free tissue
62360898|NCT01574261|ACTIVE_COMPARATOR|Inositol|Patients will be randomized to receive Inositol 4 g/die per os for four months of treatment
62360899|NCT01574261|PLACEBO_COMPARATOR|Placebo|Patients will be randomized to receive placebo for four months
62360900|NCT06043245|ACTIVE_COMPARATOR|Duodenal switch|The restrictive portion of the surgery involves removing approximately 70% of the stomach (along the greater curvature) and most of the duodenum. The malabsorptive portion of the surgery reroutes a lengthy portion of the small intestine, creating two separate pathways and one common channel.The common channel is 200 cm and 100m the alimentary limb.
62360901|NCT06043245|ACTIVE_COMPARATOR|SADI-S|Creation of a sleeve gastrectomy (SG) and a duodenal-ileal anastomosis with preservation of the pylorus, jejunal exclusion and a total common-alimentary limb, originally measuring 200 cm and later standardized to 300 cm to reduce the risk of nutritional deficiencies.
62360902|NCT06043245|ACTIVE_COMPARATOR|Minigastric bypass|Creation of a gastric pouch similar to Sleeve gastrectomy and the small bowel is run to 200 cm distal to Treitz' ligament and then anastomosed antecolic end-to-side to the gastric pouch.
62360903|NCT00045591|EXPERIMENTAL|Celecoxib 100 mg|
62360904|NCT00045591|EXPERIMENTAL|Celecoxib 400 mg|
61981321|NCT00882193|EXPERIMENTAL|Safety & Efficacy of Betaine Combined with Standard Anti-viral Therapy|"The primary objective is to examine safety \& efficacy of betaine when combined with standard anti-viral therapy in previously treated adult subjects with chronic hepatitis C infected with genotype 1. Efficacy will be determined through comparison of the sustained viral response (SVR) to our protocol three-drug regimen (Betaine, Peginterferon plus Ribavirin) to that historically seen in relapsers and non-responders when retreated with standard therapy (Peginterferon and Ribavirin alone).~Betaine (trimethylglycine) dose is 10 gm twice a day for 48 weeks. Pegasys (peginterferon alpha 2a) dose is 180mcg/0.5 ml subcutaneous injection for 48 weeks. Coegus (ribavirin) dose is 200mg - weight based, 1000 - 1200 mg/day for body weight or 75mg in 2 divided doses."
61981322|NCT03572140||group A|RAVS IN resistent cases after daclatasvir plus sofosbuvir treatment
61981323|NCT03572140||group B|RAVS IN relapsed cases after daclatasvir plus sofosbuvir treatment
62360905|NCT02682160|OTHER|Use of Protein Assistant|patients can use the Protein Assistant during 2 months to evaluate the quantity of protein's intake.
62360906|NCT04158310||Standard treatment only|Standard treatment only such as antiasthmatic, expectorant and antipyretic
62360907|NCT04158310||Standard treatment+Xiyanping injection|Standard Treatment such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection intravenous administration of 0.2-0.4mL/kg/day ,QD.
61981324|NCT02627430|EXPERIMENTAL|Treatment (talazoparib and Hsp90 inhibitor AT13387)|Patients receive talazoparib PO QD on days 1-7 (course 0). Beginning in course 1, patients receive talazoparib PO QD on days 1-28 and HSP90 inhibitor AT13387 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61981325|NCT03056391|EXPERIMENTAL|Paracetamol|"\>50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~\<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine."
62360908|NCT04414527|OTHER|Standard counseling|Pregnant women in the control group will receive the standard education package as per the Ethiopian guidelines. In the standard health care, pregnant women receive a minimum of four ante-natal care visits at the health centers during which they also receive iron and folic acid supplementation. They participate in monthly forums facilitated by nurses to answer questions and concerns regarding nutritional care.
62360909|NCT04414527|EXPERIMENTAL|Health-Video|Women in the Health-Video group will receive home visits for delivery of healthy nutrition messages using prepared video-based messages every two weeks. They will also participate in monthly forums facilitated by nurses using also videos for demonstration of nutritional care. During the monthly forums (six in total during the pregnancy and the post-partum periods), the messages will all be given as a video show coordinated by a nurse/ health professional for any questions. During postnatal period, two counseling sessions will be delivered within two weeks of birth, and 12 sessions or twice every month till 6 months.
61981326|NCT03056391|NO_INTERVENTION|No Paracetamol|"No Paracetamol plus IV artesunate or oral artemether/lumefantrine.~If temperature \>39.5°C, tepid sponging and mechanical antipyresis will be performed by research staff and/or relatives."
62360910|NCT01789892|EXPERIMENTAL|Diagnostic (methylprednisolone and FDG PET/CT scan)|Within 1-14 days of undergoing standard FDG PET/CT scan, patients receive methylprednisolone IV and then undergo a second FDG PET/CT scan.
62360911|NCT02996955|EXPERIMENTAL|SoSup group|usual care will be provided and social support and treatment of illness perceptions and activity advice and wearing the activ8
62360912|NCT02996955|ACTIVE_COMPARATOR|C group|usual care will be provided and treatment of illness perceptions and activity advice and wearing the Activ8
62360913|NCT02072694|EXPERIMENTAL|75 grams of glucose plus water solution|"In the group with 10 volunteers with obesity, some of them are submitted first to the 75 grams of glucose plus water solution (meal challenge) and in another time to only water.~Also, in the group with 10 volunteers without obesity, some of them are submitted first to the 75 grams of glucose plus water solution (meal challenge) and in another time to only water."
62360914|NCT02072694|PLACEBO_COMPARATOR|Pure water.|"In the same group with 10 volunteers with obesity, some of them are submitted first to only water (control) and in another time to the 75 grams of glucose plus water solution (meal challenge).~Also, in the same group with 10 volunteers without obesity, some of them are submitted first to only water (control) and in another time to the 75 grams of glucose plus water solution (meal challenge)."
62360915|NCT01397045|ACTIVE_COMPARATOR|Video-assisted lung segmentectomy|Patients undergoing VATS segmentectomy
62360916|NCT01397045|OTHER|Mini thoracotomy|Patients undergoing lung segmentectomy through a mini thoracotomy
62360917|NCT05462340|EXPERIMENTAL|Healthy Volunteers|Visit 3: (ASEM/AZAN) Blood draw for DNA, PET scan/art line Visit 3: (ASEM only) Blood draw for DNA, PET scan/art line Visit 4: (ASEM only) PET scan/art line
62360918|NCT05462340|EXPERIMENTAL|Schizophrenia (ari, brex, risp)|Visit 3: (ASEM/AZAN) Blood draw for DNA, PET scan/art line Visit 3: (ASEM only) Blood draw for DNA, PET scan/art line Visit 4: (ASEM only) PET scan/art line
62360919|NCT05462340|EXPERIMENTAL|Schizophrenia (olanz)|Visit 3: (ASEM/AZAN) Blood draw for DNA, PET scan/art line Visit 3: (ASEM only) Blood draw for DNA, PET scan/art line Visit 4: (ASEM only) PET scan/art line 2-wk Titration, 3-wk steady state
62360920|NCT05462340|EXPERIMENTAL|Schizophrenia (no med)|Visit 3: (ASEM/AZAN) Blood draw for DNA, PET scan/art line Visit 3: (ASEM only) Blood draw for DNA, PET scan/art line Visit 4: (ASEM only) PET scan/art line 2-wk Titration, 3-wk steady state
62360921|NCT04251624|EXPERIMENTAL|Goal Management Therapy|"Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors.~The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments.~Phase 1: Inpatients will attend group sessions twice per week for 3 weeks, each session being 2 hours in length.~Phase 2: Outpatients from the community will attend 1 session per week for 9 weeks, each session being 2 hours in length.~Phase 3: Outpatients from the community will attend 1 session per week for 9 weeks, each session being 2 hours in length."
62360922|NCT04251624|ACTIVE_COMPARATOR|Psychosocial Education|"Psychosocial education will provide participants with educational materials (e.g., brain function, neuroplasticity) and lifestyle interventions (e.g., sleep hygiene, stress, exercise).~They will be matched for length and for amount of facilitator contact with the Goal Management Therapy sessions.~Phase 1: Inpatients will attend group sessions twice per week for 3 weeks, each session being 2 hours in length.~Phase 2: Outpatients from the community will attend 1 session per week for 9 weeks, each session being 2 hours in length.~Phase 3: Outpatients from the community will attend 1 session per week for 9 weeks, each session being 2 hours in length."
62360923|NCT02560480||groin injury (group A)|magnetic resonance imaging performed in all athletes with acute or subacute groin injury
62360924|NCT02560480||control (group B)|magnetic resonance imaging performed in selected asymptomatic control athletes
62360925|NCT03267407||CrAg(+) and CM(-)|(1) Patients with CrAg positive without meningitis results will receive preemptive high-dose fluconazole to prevent developing meningitis.
62360926|NCT03267407||CrAg(+) and CM(+)|(2) Patients with CrAg positive and meningitis results will receive standard treatment for cryptococcal meningitis, following national guidelines.
62360927|NCT03267407||CrAg(-)|(3) Patients with CrAg negative results will be managed as other HIV infected patients with the standard of care, following national guidelines.
62360928|NCT03175874|OTHER|osteoporosis and alzheimer|patient with osteoporosis and alzheimer hospitalized for total hip prosthesis.
62360929|NCT03175874|OTHER|osteoporosis without alzheimer|Patient with osteoporosis without alzheimer hospitalized for total hip prosthesis.
62360930|NCT03175874|OTHER|Patient with arthrosis without alzheimer|Patient with arthrosis without alzheimer hospitalized for total hip prosthesis.
61981327|NCT04264637|EXPERIMENTAL|Azelastine hydrochloride 0.15% + Placebo|Each participant will receive a single dose (two sprays per nostril) of study intervention Azelastine hydrochloride 0.15% and Placebo at treatment period 1 and 2 respectively.
61981328|NCT04264637|EXPERIMENTAL|Placebo + Azelastine hydrochloride 0.15%|Each participant will receive a single dose (two sprays per nostril) of study intervention Placebo and Azelastine hydrochloride 0.15% at treatment period 1 and 2 respectively.
62360931|NCT01242254|EXPERIMENTAL|Group A|Patients will receive an intravitreal injection of KH902 0.5mg/eye/time monthly, after 3-time treatment patients will go on an as needed (PRN) dosing phase till week 52
62360932|NCT01242254|EXPERIMENTAL|Group B|Patients will receive an intravitreal injection of KH902 2.0mg/eye/time monthly, after 3-time treatment patients will go on an as needed (PRN) dosing phase till week 52
62360933|NCT02077504|EXPERIMENTAL|CONDUCTOME|MEG and MRI
62360934|NCT02051738|EXPERIMENTAL|Treatment Sequence AB|A single 500 mg dose of mebendazole fast-disintegrating chewable tablet will be administrated under fasted condition (Treatment A) in Treatment Period 1; In Treatment Period 2, the same medication will be administrated under fed condition (Treatment B).
61981329|NCT05153031||lithiasic acute cholecystitis|Acute cholecystitis with the presence of one or more calculi (gallstones) in the gallbladder.
61981330|NCT05153031||alithiasic acute cholecystitis|Acute cholecystitis without the presence of one or more calculi (gallstones) in the gallbladder.
61981331|NCT05153031||elective cholecystectomy|Elective surgery is surgery that is scheduled in advance because it does not involve a medical emergency.
61981332|NCT05153031||emergency cholecystectomy|Emergence surgery
61981333|NCT05153031||management with percutaneous cholecystostomy alone|Patients that didnt recieve cholecystectomy during de whole study
62360935|NCT02051738|EXPERIMENTAL|Treatment Sequence BA|A single 500 mg dose of mebendazole fast-disintegrating chewable tablet will be administrated under fed condition (Treatment B) in Treatment Period 1; In Treatment Period 2, the same medication will be administrated under fasted condition (Treatment A).
62360936|NCT01806285||Patients with Respiratory Symptoms|
62360937|NCT05264480|EXPERIMENTAL|Test group|Test patients receive bone augmentation and selective decorticalisation (corticotomy) and 1 week postop. OTM.
62360938|NCT05264480|ACTIVE_COMPARATOR|Control group|Control subjects receive bone augmentation without decorticalisation (corticotomy) and 1 week postop. OTM.
62360939|NCT04589338|EXPERIMENTAL|Endurance training group|
62360940|NCT04589338|EXPERIMENTAL|Resistance training group|
62360941|NCT04589338|NO_INTERVENTION|Control group|
62391411|NCT00689728|EXPERIMENTAL|30 milligram (mg) LY2127399|"Double-blind Treatment: 30 mg LY2127399 administered as a single intravenous (IV) infusion over 30 minutes at 0, 3, and 6 weeks.~Rescue: At Week 16 primary endpoint, participants without at least 20% improvement in either tender or swollen joint counts based on 28 joints, could receive an additional (unblinded) 30 minute infusion of LY2127399 80 mg or remain on initial randomized treatment up to Week 24.~Follow-up: Optional visits beyond Week 24, if needed, to assess safety including B cell count recovery."
61981334|NCT05153031||managemente with surgery|Patients that recieve cholecystectomy during de whole study
61981335|NCT06420440|EXPERIMENTAL|Neoadjuvant therapy group|Patients in the neoadjuvant group received neoadjuvant therapy prior to surgery (two cycles of HAIC combined with Tislelizumab and Lenvatinib), and adjuvant therapy (Tislelizumab for 8 cycles) after surgery.
61981336|NCT06420440|ACTIVE_COMPARATOR|Direct liver resection group|Patients in the control group underwent liver resection directly and received adjuvant therapy (Tislelizumab for 8 cycles) after surgery.
62360942|NCT05004519|EXPERIMENTAL|Opioid free anesthesia|"Dexmedetomidine 0,5 microgrammes/kg of ideal body weight (IBW) + magnesium 40 mg/kg of total body weight (TBW) in 10 minutes~* Dexmedetomidine 0,4- 0,8 microgrammes/kg of IBW/h;Lidocaine 2% 49ml+ Ketamine 50mg: 1ml/10kg of IBW/ hour;Ketamine 25 mg;lidocaïne 1,5 mg/kg IBW;Propofol 2mg/kgTBW;Rocuronium 1,2 mg/kg IBW;Cefazoline 2g if \>120 kg, 3g if \>120Kg;Paracetamol 15 mg/ KgTBW;Diclofenac 75 mg;Dexamethasone 10 mg;Ondansetron 4 mg;Sevorane;dexmedetomidine: 0,4-0,8 microgramme/kg/h;Rocuronium 0,1 mg/kg of IBW if posttetanic count\>1/10;Atropine 0,5 mg if heart rate \< 40/min;Ephedrine 5mg in Arterial mean pressure \< 20% of basal value;Nicardipine 0,5 mg if Arterial mean pressure \> 20% of basal value Emergence~* Stop dexmedetomidine;Stop sevorane;1 ml of NaCL 0,9%;Suggamadex 4 mg/ kg of IBW+ 4mg/kg of 40% ABW Post-anesthesia:Lidocaïne 2% 49ml + Ketamine 50 mg: 0,5 ml/ 10 kg IBW;Paracetamol 1g/6h;Diclofenac 75mg/12h;Morphine patient controlled analgesia: 1 mg/5 min, maximum 20mg/ 4 hours"
62360943|NCT05004519|EXPERIMENTAL|Multimodal anesthesia|"magnesium 40 mg/kg of total body weight (TBW) in 10 minutes~* Remifentanil 0,2-0,4 microgrammes/kg/min of ideal body weight; Saline 0,9%: Infusion at 1ml/10kg of ideal body weight/ hour;Ketamine 25 mg;lidocaïne 1,5 mg/kg IBW;Propofol 2mg/kgTBW;Rocuronium 1,2 mg/kg IBW;Cefazoline 2g if \>120 kg, 3g if \>120Kg;Paracetamol 15 mg/ Kg TBW;Diclofenac 75 mg;Dexamethasone 10 mg;Ondansetron 4 mg;Sevorane;remifentanil 0,2-0,4 microgrammes/kg/min;Rocuronium 0,1 mg/kg of IBW if posttetanic count\>1/10;Atropine 0,5 mg if heart rate \< 40/min;Ephedrine 5mg in Arterial mean pressure \< 20% of basal value;Nicardipine 0,5 mg if Arterial mean pressure \> 20% of basal value Emergence~* Stop remifentanil;Stop sevorane;1 ml of morphine 10mg/ml;Suggamadex 4 mg/ kg of IBW+ 4mg/kg of 40% ABW Post-anesthesia:Salne 50ml: 0,5 ml/ 10 kg IBW;Paracetamol 1g/6h;Diclofenac 75mg/12h;Morphine patient controlled analgesia: 1 mg/5 min, maximum 20mg/ 4 hours"
62360944|NCT01428440|OTHER|no treatment|
62360945|NCT00967226|EXPERIMENTAL|propranolol for treatment of hemangiomas|Assessing efficacy and tolerability of propranolol in management of symptomatic hemangiomas
62360946|NCT00967226|ACTIVE_COMPARATOR|Prednisolone|Assessing efficacy and tolerability of prednisolone in management of symptomatic hemangiomas and comparing to propranolol.
62360947|NCT00825149|EXPERIMENTAL|A: R/R FL: Obinutuzumab Low Dose + CHOP|Participants with Relapsed/Refractory (R/R) FL will receive obinutuzumab 400 milligrams (mg) intravenous (IV) infusion on Days 1 and 8 of Cycle 1 and every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 milligrams per square-meter (mg/m\^2), vincristine 1.4 mg/m\^2 capped at 2 mg, and cyclophosphamide 750 mg/m\^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 400 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
62360948|NCT00825149|EXPERIMENTAL|B: R/R FL: Obinutuzumab High Dose + CHOP|Participants with R/R FL will receive obinutuzumab 1600 mg IV infusion on Days 1 and 8 of Cycle 1 and 800 mg IV infusion every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 mg/m\^2, vincristine 1.4 mg/m\^2 capped at 2 mg, and cyclophosphamide 750 mg/m\^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 800 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
61981337|NCT05433961|EXPERIMENTAL|Hyperpolarized Xenon MRI assessment of lung function in endobronchial valve treated COPD patients|Volunteer patients scheduled for receiving endobronchial valve treatment as part of clinical care will be imaged with hyperpolarized xenon prior and post EBV for assessing lung function and improvement.
61981338|NCT03261947|EXPERIMENTAL|Western Safety Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, once daily (QD) for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 20 cycles. Participants with locally advanced or metastatic solid tumors with no standard therapeutic alternative in the United States were included in this cohort.
62360949|NCT00825149|EXPERIMENTAL|C: R/R FL: Obinutuzumab Low Dose + FC|Participants with R/R FL will receive obinutuzumab 400 mg IV infusion on Days 1 and 8 of Cycle 1 and every 4 weeks on Day 1 of subsequent cycles (for 46 cycles) in the induction period; Fludarabine 25 mg/m\^2/day and cyclophosphamide 250 mg/m\^2/day IV infusion every 4 weeks on Days 13 of each cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 400 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
62391412|NCT00689728|EXPERIMENTAL|80 mg LY2127399|"Double-blind Treatment: 80 mg LY2127399 administered as a single IV infusion over 30 minutes at 0, 3, and 6 weeks.~Rescue: At Week 16 primary endpoint, participants without at least 20% improvement in either tender or swollen joint counts based on 28 joints, could receive an additional (unblinded) 30 minute infusion of LY2127399 80 mg or remain on initial randomized treatment up to Week 24.~Follow-up: Optional visits beyond Week 24, if needed, to assess safety including B cell count recovery."
61981339|NCT03261947|EXPERIMENTAL|Pancreatic Cancer Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 4 cycles. Participants with metastatic pancreatic cancer who had progressed after at least 1 line of standard chemotherapy were included in this cohort.
61981340|NCT03261947|EXPERIMENTAL|Metastatic CRC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 12 cycles. Participants with metastatic CRC who had progressed after at least 2 lines of previous standard chemotherapy were included in this cohort.
61981341|NCT03261947|EXPERIMENTAL|sqEC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 8 cycles. Participants with metastatic sqEC who had progressed after at least 1 line of standard chemotherapy were included in this cohort.
61981342|NCT03261947|EXPERIMENTAL|sqNSCLC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 18 cycles. Participants with metastatic sqNSCLC who had progressed after at least 2 lines of standard treatment were included in this cohort.
62360950|NCT00825149|EXPERIMENTAL|D: R/R FL: Obinutuzumab High Dose + FC|Participants with R/R FL will receive obinutuzumab 1600 mg IV infusion on Days 1 and 8 of Cycle 1 and 800 mg IV infusion every 4 weeks on Days 1 of subsequent cycles (for 46 cycles) in the induction period; Fludarabine 25 mg/m\^2/day and cyclophosphamide 250 mg/m\^2/day IV infusion every 4 weeks on Days 13 of each cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 800 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
62360951|NCT00825149|EXPERIMENTAL|E: First-Line FL: Obinutuzumab + Bendamustine|Participants with first-line FL will receive obinutuzumab 1000 mg IV infusion on Days 1 and 8 of Cycle 1 and every 4 weeks on Day 1 of subsequent cycles (for 46 cycles) in the induction period; Bendamustine 90 mg/m\^2 IV infusion on Days 2 and 3 of Cycle 1 and every 4 weeks on Days 1 and 2 of each subsequent cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 1000 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
61981343|NCT02378701||Quality of Life in Myelodysplasia Scale (QUALMS-1)|Participants complete the Quality of Life in Myelodysplasia Scale (QUALMS-1) and the Anemia Subset of FACT (FACT-An), instrument twice: at the start of treatment, and after four cycles or discontinuation of treatment, whichever comes first.
61981344|NCT04779489|EXPERIMENTAL|PULSAR|Eligible patients will receive next-generation stereotactic radiotherapy (PULSAR) 30-36 Gy in 3 fractions to the bladder and targetable, pathologically enlarged lymph nodes
61981345|NCT02140788|ACTIVE_COMPARATOR|Metformin|Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added metformin will receive metformin 250 mg BID days 1-3, 500 mg BID days 4-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate a dose escalation will have the metformin dose reduced to the previously tolerated lower dose.
61981346|NCT02140788|ACTIVE_COMPARATOR|Fish Oil|Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added fish oil will receive OmegaBrite 500 mg gel cap BID days 1-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate the dose escalation to 1000 mg BID will have the fish oil dose reduce to 500 mg BID.
62360952|NCT00825149|EXPERIMENTAL|F: First-Line FL: Obinutuzumab + CHOP|Participants with first-line FL will receive obinutuzumab 1000 mg IV infusion on Days 1 and 8 of Cycle 1 and every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 mg/m\^2, vincristine 1.4 mg/m\^2 capped at 2 mg, cyclophosphamide 750 mg/m\^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 1000 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
62360953|NCT02135900|EXPERIMENTAL|Heliox|Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.
62360954|NCT02703142||Patients after esophagectomy|Endoscopic examinations are performed at 1, 8, and 15 postoperative days. Endoscopic examination is added when abnormal findings are demonstrated.
61981347|NCT02140788|ACTIVE_COMPARATOR|Metformin and Fish Oil|Subjects will continue to take the clozapine prescribed as standard of care. Subjects will receive Metformin and Fish Oil as part of the study.
62360955|NCT03215667|EXPERIMENTAL|Device treatment|easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane
62360956|NCT02692118||sepsis|Patients with septic shock admitted to ICU
62360957|NCT01154738|EXPERIMENTAL|Lidocaine|Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Lidocaine
61981348|NCT02140788|NO_INTERVENTION|No medication added|Subjects will continue to take the clozapine prescribed as standard of care. Subjects will not receive Metformin or Fish Oil.
62360958|NCT01154738|PLACEBO_COMPARATOR|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
62360959|NCT05606380|EXPERIMENTAL|HLX60 Group|The initial dose of HLX60 is 0.5mg/kg, and 5 dose levels are designed: 2mg/kg, 5mg/kg, 15mg/kg and 25mg/kg (Q3W). Patients will receive the treatment until without any clinical benefit, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first)
62360960|NCT00763243|EXPERIMENTAL|Cogmed Working Memory Training|Cogmed Working Memory Training Program
62360961|NCT03836352|EXPERIMENTAL|Arm 1 (All cohorts)|DPX-Survivac, Cyclophosphamide, Pembrolizumab
61981349|NCT04790760|EXPERIMENTAL|Continuous Glucose Monitoring|Participants will wear a CGM device on the back of both their left and right arm for 6 weeks.
61981350|NCT03138395||Experimental: Specimen Collection|Collection of peripheral blood and bone marrow samples will occur during routine care procedures. Collection of finger stick and saliva specimens will occur on the same day as the peripheral blood and bone marrow procedure, or during routine clinical procedures.
61981351|NCT05890807|EXPERIMENTAL|Patients whose oral cavity will be photographed in the diabetology department|The patient is seated in the chair. The trained staff member positions the mouth guard and takes a frontal photograph of the patient's oral cavity using the photo sensor (smart-phone). Only the oral cavity will be visible in the photograph and there will be no possibility for an external assessor to recognize the patient's face.
61981352|NCT03054545|EXPERIMENTAL|Iguratimod treating group|Iguratimod 25mg twice a day, oral administrated.
61981353|NCT02040454|ACTIVE_COMPARATOR|Standard Therapy Plus Paclitaxel|"Standard Therapy - heparin, angioplasty, stent~Paclitaxel - single intravascular dose up to 20 mg"
61981354|NCT02040454|SHAM_COMPARATOR|Standard Therapy Alone|heparin, angioplasty, stent
62360962|NCT03836352|EXPERIMENTAL|Arm 2 (Ovarian cohort only)|DPX-Survivac, Pembrolizumab
62360963|NCT00953004|EXPERIMENTAL|fiber drink|
62360964|NCT00953004|EXPERIMENTAL|fiber bread|
62360965|NCT00953004|EXPERIMENTAL|placebo|
62360966|NCT01911208|EXPERIMENTAL|RECRUIT intervention|Clinical sites will work with the RECRUIT team to enhance and individualize their recruitment methods.
61981355|NCT03638024||Study group|Maternal plasma cell free fetal DNA levels will be measured in 25 women with one or more previous cesarean section and placenta previa anterior only or with ultrasound finding suggestive of placental adhesion or invasion (accreta , increta or percreta).
62360967|NCT01911208|EXPERIMENTAL|Control|Clinical sites can use which ever recruitment methods they prefer.
61981356|NCT03638024||Control group|Maternal plasma cell free fetal DNA levels will be measured in 25 matched control with normally situated placenta without ultrasound finding suggestive of placental adhesion or invasion.
62360968|NCT01072903||IBS|Subjects with IBS
61981357|NCT04032041||Group 1: Healthy Able-bodied Individuals (Completed)|Healthy able-bodied individuals with no history of lower extremity trauma.
61981358|NCT04032041||Group 2: Individuals Requiring AFO Use (Recruiting)|Individuals with unilateral, below knee functional deficits that require an AFO for daily activities (e.g. fracture, muscle and/or nerve injury, ankle arthritis, or peripheral neurologic disease).
61981359|NCT04659850|OTHER|Group 1|Group 1 participants in the young 18 - 30 age group
61981360|NCT04659850|OTHER|Group 2|Group 2 participants in the older 55 - 75 age group
62360969|NCT01072903||Healthy|Healthy Controls
62360970|NCT03609489|EXPERIMENTAL|Test Group|Apatinib combined with Capetabine
62360971|NCT03609489|ACTIVE_COMPARATOR|Control Group|Capecitabine
62360972|NCT02023918|EXPERIMENTAL|Pegvisomant arm|Pegvisomant 20 mg subcutaneously Qday x 28 days will be administered by the study subject.
62360973|NCT02280486|ACTIVE_COMPARATOR|Saxagliptin|The treatment of saxagliptin will be initiated and maintained at 5mg every morning until the completion of the test.Meanwhile,subjects will be instructed to take stable doses of metformin (1500mg/d) through the whole trial.
61981361|NCT04234035|EXPERIMENTAL|Shared Decision-Making (via Decision Aid)|The intervention is a decision aid, which both encourages and facilitates a shared decision-making conversation between the clinician and the patient. The decision aid educates patients regarding evidence-based approaches to the management of suspected kidney stones in the ED. Clinicians will receive training specific to this decision aid, though the decision aid is designed to be used with no additional training.
61981362|NCT04234035|ACTIVE_COMPARATOR|standardized educational intervention (pamphlet +usual care)|The control arm will receive Usual Care and a standardized educational intervention (pamphlet). This intervention (pamphlet) contains information about kidney stones. Usual care for this clinical scenario generally involves the clinician choosing the management plan. Clinicians of subjects assigned to the usual care group will be asked to practice usual, evidence-based medical care, without shared decision-making.
62360974|NCT02280486|ACTIVE_COMPARATOR|Glimepiride|Glimepiride will be initially treated with 1 mg every morning to a dose of 6 mg/day.a.m. Every 4-week the subjects will be evaluated whether reach the target fasting plasma glucose (assayed by finger-stick ≦6.1 mmol/l ). If the fasting blood glucose not achieved the target at the maximum dose, maintain the maximum dose(6mg/d) until the completion of the test.Meanwhile,subjects will be instructed to take stable doses of metformin (1500mg/d) through the whole trial.
62360975|NCT05150795|ACTIVE_COMPARATOR|Group Pregabalin|Patients will receive oral pregabalin capsule (150 mg) 90 min before induction of anesthesia, and will receive a bolus injection of 10 ml saline at induction of anesthesia
62360976|NCT05150795|ACTIVE_COMPARATOR|Group Fentanyl|Patients will receive oral placebo capsule identical to the trial drug in size, shape and color, 90 min before induction of anesthesia and will receive a bolus injection of 10 ml of 1µg /kg fentanyl at induction of anesthesia
62360977|NCT04812860|EXPERIMENTAL|HR18042 100mg|
62360978|NCT04812860|EXPERIMENTAL|HR18042 125mg|
62360979|NCT04812860|EXPERIMENTAL|HR18042 200mg|
62360980|NCT04812860|ACTIVE_COMPARATOR|Tramadol hydrochloride ER 100mg|
62360981|NCT04812860|PLACEBO_COMPARATOR|Placebo to match HR18042 and Tramadol hydrochloride ER|
61981363|NCT00614315|EXPERIMENTAL|FLAIR Endovascular Stent Graft and Delivery System|
62360982|NCT00396305|EXPERIMENTAL|Group 2, Control Double Dose|12 elderly and 6 young participants. This group will be vaccinated with a double dose of vaccine without booster on Day 0. These subjects will receive a double-dose of vaccine administered as 2 consecutive injections (2 injections of 0.5 mL) in the same deltoid. The control group for Group 2 is group 1, Cohort 2.
62360983|NCT00396305|EXPERIMENTAL|Group 3-Control late booster|12 elderly and 6 young participants. This group will be vaccinated with the standard dose of vaccine (0.5 mL) on Day 0 and with a booster dose of vaccine (0.5 mL) on Day 21. The control for Group 3 is Group 1, Cohort 3.
62360984|NCT00396305|ACTIVE_COMPARATOR|Group 1, Control|12 elderly and 8 young participants. Group 1 will be further divided into 4 equal cohorts (each containing 3 elderly and 2 young adults). Cohorts 2, 3, and 4 will receive the standard dose of vaccine and placebo (0.5 mL saline) on Day 0, 21, or 7 respectively. Cohort 1 will be vaccinated with the standard dose of vaccine without placebo/vaccine booster.
62360985|NCT00396305|EXPERIMENTAL|Group 4-Control early booster|12 elderly and 6 young participants. This group will be vaccinated with the standard dose of vaccine (0.5 mL) on Day 0 and with a booster dose of vaccine (0.5 mL) on Day 7. The control for Group 4 is Group 1, Cohort 4.
61981364|NCT04246060||Cohort 1|Patients on extended release cysteamine treatment at study enrollment
61981365|NCT04246060||Cohort 2|Patients switching from immediate release cysteamine to extended release cysteamine during the study
61981366|NCT04246060||Cohort 3|Patients remaining on immediate release cysteamine treatment
61981367|NCT00289315|EXPERIMENTAL|Arm 1|Primary (Environmental) Prevention of Weight Gain
61981368|NCT00289315|EXPERIMENTAL|Arm 2|Primary (Envrironmental) and Secondary (Behavioral) Weight Gain Prevention Program
61981369|NCT00289315|EXPERIMENTAL|Arm 3|Control - no Environmental or Behavioral Program intervention
62360986|NCT06231914|EXPERIMENTAL|Fractional 1064-nm Picosecond laser|Fractional 1064-nm Picosecond laser for 3 sessions, at 4-week interval
62360987|NCT02532569|OTHER|Japanese encephalitis vaccine|After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose,SC
62360988|NCT02536157|ACTIVE_COMPARATOR|Dorsal block splint|Thermoplastic splint in 20 degrees flexion applied to the dorsum of the PIPJ.
62360989|NCT02536157|EXPERIMENTAL|Volar gutter splint|Thermoplastic splint in 0 degrees flexion applied to the volar surface of the finger.
61981370|NCT05047679|EXPERIMENTAL|Perioperative Pain Neuroscience Education|Patients in the experimental treatment group will receive Perioperative Pain Neuroscience Education, including a preoperative session 3 days before the surgery, access to an educational web application and a postoperative session 2 days following the surgery. Both education sessions will be face-to-face and will last approximately 60 minutes.
61981371|NCT05047679|ACTIVE_COMPARATOR|Perioperative Biomedical Education|Patients in the control treatment group will receive Perioperative Biomedical Education, including a preoperative session 3 days before the surgery, access to an educational web application and a postoperative session 2 days following the surgery. Both education sessions will be face-to-face and will last approximately 60 minutes.
61981372|NCT05127889|EXPERIMENTAL|Self-assembling peptide P11-4 varnish (study group)|"* Test lesions will be wiped with NaOCl to remove pellicle,~* Etched for 20 s with 35% H3PO4 Etching Gel to remove mineral deposits on the tooth surface and rinsed with water in accordance with the manufacturer's instructions.~* The lesions will be dried and isolated with cotton rolls.~* The varnish will be applied and left undisturbed for 5minutes (till disappearance) to allow diffusion of self-assembly."
61981373|NCT05127889|EXPERIMENTAL|Arginine-enriched Sodium Fluoride varnish (study group)|"* The Arginine powder will be suspended at 2%.~* A 10 mL of 5% sodium fluoride varnish tube dispensed in a sterile container.~* 200 mg of Arginine will be vigorously mixed with the varnish matrix for 60 sec using a sterile microbrush.~* After dryness of the white spot lesion, the prepared varnish will be applied evenly using the micro brush.~* After application the patient will be instructed to avoid rinsing, eating soft diet and avoid hot drinks for 2 hrs."
62360990|NCT06556667|ACTIVE_COMPARATOR|200J|biphasic defibrillator with maximum energy of 200J (® Zoll)
61981374|NCT05127889|ACTIVE_COMPARATOR|Tri Calcium Phosphate Fluoride varnish (positive control group)|"* To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.~* The varnish will be mixed with the brush to avoid separation of the material during storage~* However, to guarantee the best results suction will be used during application of the varnish.~* A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush~* The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.~* After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs.~All patients will be encouraged to maintain good oral hygiene through regular brushing."
61981375|NCT06412939||Patients in pediatric age (> 18 month and < 18 years) at the time of surgery|The full analysis set includes all paediatric patients who that have been treated for femoral shaft and subtrochanteric fractures or have performed prophylactic nailing of impending pathologic fractures or have undergone fixation of femurs that have been surgically prepared for deformity correction with the Agile nail, that will be systematically consecutive screened at the centers.
61981376|NCT01881230|EXPERIMENTAL|nab-Paclitaxel plus Gemcitabine|Treatment Arm A: nab-Paclitaxel 125 mg/m\^2 by intravenous (IV) administration over 30 minutes, followed by gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day cycle by IV administration over 30 minutes
62549971|NCT03514966|NO_INTERVENTION|Conventional group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the conventional group will receive no intervention. Thirty and 40 min after dimethicone administration, subjects will additionally take 200 ml and 800 ml water, respectively, and undergo MCE examination.
61981377|NCT01881230|EXPERIMENTAL|nab-Paclitaxel plus Carboplatin|Treatment Arm B: nab-Paclitaxel 125 mg/m\^2 on Days 1 and 8 by IV administration followed by carboplatin at an Area Under the Curve (AUC) of 2 on Days 1 and 8 of each 21-day cycle by IV administration
61981378|NCT01881230|ACTIVE_COMPARATOR|Gemcitabine plus Carboplatin|Treatment Arm C: Gemcitabine 1000 mg/m\^2 on Days 1 and 8 by IV administration followed by carboplatin AUC 2 on Days 1 and 8 of each 21-day cycle by IV administration
61981379|NCT02154581|ACTIVE_COMPARATOR|Type 1 implant and thin biotype|In this group, immediate implant placement (SLActive implant) is performed in patients with thin tissue biotype. In addition to implant placement bone grafting of the void between the implant and the fresh extraction socket, bone grafting the buccal aspect of the buccal plate (overcontouring) and soft tissue grafting (connective tissue) are performed.
61981380|NCT02154581|ACTIVE_COMPARATOR|Type 1 implant and thick biotype|In this group, immediate implant placement (SLActive implant) is performed including bone grafting of the void between the implant and the fresh extraction socket.
62360991|NCT06556667|ACTIVE_COMPARATOR|360J|biphasic defibrillator with maximum energy of 360J (® Physio-Control)
62360992|NCT01200160||Lipid abnormalities|Niacin
62360993|NCT04657354|ACTIVE_COMPARATOR|Fast track|Study subjects in Fast Track arm will get an MRI done on the same day. If the MRI shows concordant findings of herniated disc, the subject will be referred to a spine surgeon to be seen within one week. If the surgeon and subject decide on discectomy, the surgery is scheduled within the same week. Total timespan from first interview to surgery will be no longer than 2 weeks.
62360994|NCT04657354|NO_INTERVENTION|Usual care|"Study subjects in Usual Care will be treated following the Danish National Guidelines in which a conservative approach for the first 4-6 weeks with focus on pain relief by pain-relief medication, exercises and encouragement to resume normal activities as much as possible. Patients in this arm will be scheduled 2 and 4 week follow-up appointments as per national guidelines.~If the symptoms have not resolved after this period, then a referral to a multidisciplinary spine care department is made. However, if symptoms are still present at 8-12 weeks first then a referral for a spine surgeon assesment can be done."
62360995|NCT05459207|EXPERIMENTAL|Moderate Fat Meal, Followed by High Fat Meal Group|Participants will receive a moderate fat meal, followed by a high fat meal approximately seven days apart.
62549972|NCT03514966|EXPERIMENTAL|Position change group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
62549973|NCT02827734||interstitial lung disease|patients with known or suspected ILD such as idiopathic pulmonary fibrosis, non-specific interstitial pneumonia, sarcoidosis, granulomatosis with polyangiitis
62549974|NCT02827734||pulmonary healthy controls|patients without known or suspected pulmonary disease
62360996|NCT05459207|EXPERIMENTAL|High Fat Meal, Followed by Moderate Fat Meal Group|Participants will receive a high fat meal, followed by a moderate fat meal approximately seven days apart.
62360997|NCT02678728|EXPERIMENTAL|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion until 12hr of aortic cross clamp off
61981381|NCT06493708|EXPERIMENTAL|EMDR intervention|14 sessions of psychotherapy with EMDR will be carried out with patients. One session per week, lasting 90 minutes. The first two sessions will be used for the description of the EMDR method and for stabilization, then there will be treatment sessions.
61981382|NCT06493708|NO_INTERVENTION|Waiting List|Treatment as usual
62360998|NCT02678728|PLACEBO_COMPARATOR|Normal saline|IV loading and infusion of same volume of normal saline after induction until 12hr of aortic cross clamp off
62360999|NCT01631292|PLACEBO_COMPARATOR|600 IU D3|
62361000|NCT01631292|ACTIVE_COMPARATOR|2000 IU D3|
62361001|NCT01631292|ACTIVE_COMPARATOR|4000 IU D3|
62361002|NCT00582699||1|Patients with pancreatic cancer who meet DSMIV criteria for a current diagnosis of a Major Depressive Episode (N=25).
62361003|NCT00582699||2|Patients with pancreatic cancer who do not meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25)
61981383|NCT01053689|EXPERIMENTAL|Glimepiride|Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited
62361004|NCT00582699||3|Healthy controls who meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25).
62361005|NCT00582699||4|Healthy controls who do not meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25).
62361006|NCT04013165|ACTIVE_COMPARATOR|Active control|Usual care of the Community Mental Health Service
62361007|NCT04013165|EXPERIMENTAL|Village-based intervention|Individual-based case management + group-based program
62361008|NCT01386892||Healthy Volunteer|Healthy Volunteer without lung disease
62361009|NCT05018637|EXPERIMENTAL|WJ-MSC group|intramedullary injection of 4 x 107 WJ-MSCs (direct injection into the recently fractured vertebra) at baseline (day 0). subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
62361010|NCT05018637|ACTIVE_COMPARATOR|Teriparatide group|subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
62361011|NCT03127579|EXPERIMENTAL|Longer meal duration|Families eat longer as they usually do
62361012|NCT03127579|NO_INTERVENTION|Usual meal duration|Families eat as long as they usually do
62549975|NCT01707017|ACTIVE_COMPARATOR|High-load strength training|
61981384|NCT01053689|ACTIVE_COMPARATOR|Amaryl|Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc
61981385|NCT01893073|ACTIVE_COMPARATOR|Mindful walking|A weekly 60 minutes walking group exercise program consisting of a combination of walking and mindfulness over 8 weeks.
61981386|NCT01893073|NO_INTERVENTION|Waiting group|
61981387|NCT02502539|EXPERIMENTAL|autoimmune disease|to identify the mechanisms through which physical activity is liable to mediate inflammatory balance in autoimmune disease settings, and specifically in JIA patients.
61981388|NCT00842712|EXPERIMENTAL|Safety run-in part: Cil (1000 mg) + Cetuximab + Cis + Gem|
61981389|NCT00842712|EXPERIMENTAL|Safety run-in part: Cil (1000 mg) + Cetuximab + Cis + Vin|
61981390|NCT00842712|EXPERIMENTAL|Safety run-in part: Cil (2000 mg) + Cetuximab + Cis + Gem|
62361013|NCT00537680|EXPERIMENTAL|Arm 1 - 900 mg/day Idebenone|mid dose Idebenone
62361014|NCT00537680|EXPERIMENTAL|Arm 2 - up to 2250 mg/day Idebenone|high dose Idebenone
62361015|NCT00537680|PLACEBO_COMPARATOR|Arm 3 - Placebo|Placebo
62361016|NCT01432457|EXPERIMENTAL|desvenlafaxine succinate sustained-release 50 mg/day|
62361017|NCT01432457|EXPERIMENTAL|desvenlafaxine succinate sustained-release 100 mg/day|
62361018|NCT01432457|PLACEBO_COMPARATOR|Placebo|
62361019|NCT05599113|EXPERIMENTAL|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is an expedient remedy that is used in various joint and muscle pain treatments, is non-invasive, is well tolerated by patients, and has few side effects.
62361020|NCT04194957|EXPERIMENTAL|Wild type for DPYD|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD\*2A, c.2846A\>T, c.1236G\>A/HapB3 and DPYD\*13) that are found to be wild type for these SNPs
62549976|NCT01707017|ACTIVE_COMPARATOR|Low-load strength training|
61981391|NCT00842712|EXPERIMENTAL|Safety run-in part: Cil (2000 mg) + Cetuximab + Cis + Vin|
61981392|NCT00842712|EXPERIMENTAL|Randomized part: Cil (Once Weekly) + Cetuximab + Chemotherapy|
61981393|NCT00842712|EXPERIMENTAL|Randomized part: Cil (Twice Weekly) + Cetuximab + Chemotherapy|
61981394|NCT00842712|ACTIVE_COMPARATOR|Randomized part: Cetuximab + Chemotherapy|
61981395|NCT03556007|EXPERIMENTAL|Cohort 1 - 3 μg/kg LY3471851|Participants received 3 microgram per kilogram (μg/kg) of LY3471851 or placebo on days 1, 15 and 29 by subcutaneous (SC) injection.
62361021|NCT04194957|EXPERIMENTAL|heterozygous carrier of c.1236G>A or c.2846A>T DPYD variant|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD\*2A, c.2846A\>T, c.1236G\>A/HapB3 and DPYD\*13) that are found to be heterozygous for c.1236G\>A or c.2846A\>T of these SNPs
62361022|NCT04194957|EXPERIMENTAL|Homozygous or compound heterozygous carrier of DPYD variants|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD\*2A, c.2846A\>T, c.1236G\>A/HapB3 and DPYD\*13) that are found to be homozygous or compound heterozygous for these SNPs
62361023|NCT01291849|EXPERIMENTAL|remifentanil for intranasal surgery|
62361024|NCT01020032|EXPERIMENTAL|Music therapy|"Individual receptive music therapy by U sequence method"
62361025|NCT04797312|EXPERIMENTAL|Opioid free anesthesia (OFA) protocol|
62549977|NCT01707017|ACTIVE_COMPARATOR|Low-load + moderate-load strength training|
61981396|NCT03556007|EXPERIMENTAL|Cohort 1 - 6 μg/kg LY3471851|Participants received 6 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
62361026|NCT04797312|SHAM_COMPARATOR|standard practice protocol based on the use of opioids (sufentanil or remifentanil)|
62549978|NCT04914169||Indoor cycling training|8 subjects were asked to complete indoor cycling training, 3 times a week for 4 weeks. Each session of training consisted of 30-minute stationary biking (5 minutes of warm-up, 20 minutes of training and 5 minutes of cooldown).
62549979|NCT05717660|ACTIVE_COMPARATOR|Control|Androgen Deprivation therapy and Apalutamide
62361027|NCT02370550|EXPERIMENTAL|Cyclosporin A(CsA)+glucocorticoid|A. The efficacy/safety are evaluated at V3, V4, V5 and V6, and the treatment is adjusted accordingly. Patients who experienced treatment failure (FVC absolute decrease \>15% of predicted values after 4 weeks of treatment) are suggested to switch to intravenous glucocorticoid + cyclophosphamide(CYC) 0.5-1 g/m2 every 4 weeks as the rescue therapy after unblinding, and continue to complete the subsequent follow-up. Each patient can only have one chance to be rescued. Patients who experience a second treatment failure should be withdrawn from the trial and be given empirical treatment. Patients who did not experience treatment failure continued to receive current treatment. B. For subjects with aggravated shortness of breath and dyspnea in between of two consecutive visits, the investigators should decide whether a visit should be increased to complete subsequent examinations.
62361028|NCT02370550|PLACEBO_COMPARATOR|placebo+glucocorticoid|A. The efficacy/safety are evaluated at V3, V4, V5 and V6, and the treatment is adjusted accordingly. Patients who experienced treatment failure are suggested to switch to glucocorticoid + CsA 2-3mg/kg/d, BID as the rescue therapy, and continue to complete the subsequent follow-up. Each patient can only have one chance to be rescued. Patients who did not experience treatment failure continued to receive current treatment. B. For subjects with aggravated shortness of breath and dyspnea in between of two consecutive visits, the investigators in each center should decide whether a visit should be increased.
61981397|NCT03556007|EXPERIMENTAL|Cohort 1 - 12 μg/kg LY3471851|Participants received 12 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
62361029|NCT00014170|EXPERIMENTAL|Treatment (gefitinib)|Patients receive oral gefitinib daily. Courses repeat every 8 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
62361030|NCT00409916|PLACEBO_COMPARATOR|Standard Care Arm|In the Standard Care Arm, the treating clinician will adjust therapy according only to the clinical assessment of signs and symptoms of heart failure since the ICG information is blinded to the treating clinician.
61981398|NCT03556007|EXPERIMENTAL|Cohort 1 - 24 μg/kg LY3471851|Participants received 24 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
62361031|NCT00409916|ACTIVE_COMPARATOR|ICG Arm|In the ICG Arm, the treating clinician will adjust therapy according to the clinical assessment of signs and symptoms of heart failure, in addition to the ICG hemodynamic information obtained from the printed report.
62361032|NCT04383613|EXPERIMENTAL|PRONE POSITIONING|Patients in this arm will be instructed to lie on their stomach while they are in bed for 7 days or until the first of study hospital discharge or not requiring supplemental oxygen for \>24 hours or study outcome.
62361033|NCT04383613|NO_INTERVENTION|STANDARD OF CARE|Patients in this arm are not specifically instructed to lie on their stomach while they are in bed.
62361034|NCT03879629|EXPERIMENTAL|Pre-Emptive Strategy|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated one week before start of therapy and continued until end of therapy
62361035|NCT03879629|EXPERIMENTAL|Reactive Strategy|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated after documentation of subclinical cardiotoxicity, defined by an abnormal global longitudinal strain (GLS) or high-sensitive cardiac troponin (hsTnI) elevation and continued until end of therapy
62361036|NCT03879629|ACTIVE_COMPARATOR|Standard of Care|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated after documentation of a drop in LVEF by \>10% to a value less than 53% and continued until end of therapy
61981399|NCT04919278|EXPERIMENTAL|Intervention group|Participants will be evaluated for any health contraindication. Once reviewed they will received full spine chiropractic treatment for 4 weeks, at the rate of one adjustment per week. After three visits they will complete the outcome measures
62361037|NCT03770676|EXPERIMENTAL|Flavour 1|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 1. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
62361038|NCT03770676|EXPERIMENTAL|Flavour 2|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 2. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits biscuit for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
62361039|NCT03770676|EXPERIMENTAL|Flavour 3|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 3. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
62361040|NCT04173039|OTHER|Controls|Patients with psoriasis and without psoriatic arthritis.
61981400|NCT04919278|NO_INTERVENTION|Control group|Paticipants will be selected amongst thse attending predelivery sessions. They receive no chiropracti care. They will complete the outcomes at the same time as the Intervention group and then 4 weeks later.
62361041|NCT04173039|OTHER|Cases|Patients with psoriatic arthritis and with personal or familial psoriasis.
62361042|NCT03769337||Infected|Serum biomarkers in patients with diagnosis of prosthetic joint infection
62549980|NCT05717660|EXPERIMENTAL|Treatment|Androgen Deprivation therapy and Apalutamide and SBRT on all sites of metastatic disease
61981401|NCT04816279||First Audit cycle|
61981402|NCT04816279||Second Audit cycle|
61981403|NCT03175510||patients group|Patients with low back pain (18-65 years)
61981404|NCT04996888|EXPERIMENTAL|with AI preoperative automatic reminder system|After receiving regular instructions at the time of their appointment to discuss colonoscopy and education about colonoscopy provided by one nurse, including the importance of bowel preparation, the side effects of the agents used, and the exact preparation instructions, the patients in the experimental group will be sent a message and a phone call by AI system on the day before colonoscopy, which will emphasize the importance of bowel preparation, the directions for use and side effects of purgatives, the proper food type, and the start time.
62169291|NCT01395706|EXPERIMENTAL|ICG flourescence technique|This is an uncontrolled, non-randomised, open-label, monocenter clinical trial. A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.
62169292|NCT00312845|EXPERIMENTAL|Bortezomib + Rituximab|
62169293|NCT00312845|ACTIVE_COMPARATOR|Rituximab|
62361043|NCT03769337||Not Infected|Serum biomarkers in patients with implant failure not caused by infection
62361044|NCT01933321|EXPERIMENTAL|Intrathecal autologous stem cells|Intrathecal stem cells will be administered to patients that fulfill the inclusion criteria.
62361045|NCT02726334|EXPERIMENTAL|Group/Stream 1 - Monotherapy|"Patient group: Patients who have failed at least two lines of chemotherapy for metastatic disease.~Treatment: BNC101 administered via intravenous infusion over 60 minutes weekly.~Patients with stable disease or a response at or after day 56 (2 cycles) will be allowed to continue to receive weekly doses of BNC101 until disease progression."
62361046|NCT02726334|EXPERIMENTAL|Group/Stream 2 - Combination Chemo|"Patient Group: Patients who have failed at least one line of chemotherapy for metastatic disease.~Treatment: BNC101 administered in combination with FOLFIRI~Participants will be treated until disease progression, intolerable toxicity, withdrawal of consent, or study termination by the Sponsor, whichever occurs first."
62361047|NCT06099353|NO_INTERVENTION|Arm 1: Usual Care|"* General practitioners' (GPs) usual care for patients.~* GPs will direct patient participants to a publicly available webpage about managing CVD risk on the Health Promotion Board website."
62361048|NCT06099353|EXPERIMENTAL|Arm 2: Heart Age only|"* General practitioners' (GPs) usual care for patients.~* GPs will direct patient participants to a publicly available webpage about managing CVD risk on the Health Promotion Board website.~* GPs will also show patient participants how to access Heart Age, a risk assessment tool available online and communicate with them their respective Heart Age value."
62361049|NCT06099353|EXPERIMENTAL|Arm 3: Heart Age and Heart Age-HOPE-CVD app|"* General practitioners' (GPs) usual care for patients.~* GPs will direct patient participants to a publicly available webpage about managing CVD risk on the Health Promotion Board website.~* GPs will show patient participants how to access Heart Age, a risk assessment tool available online and communicate with them their respective Heart Age value.~* GPs will also direct patient participants to download the Heart Age-HOPE- CVD mobile app, an evidence-based behaviour change digital platform."
62361050|NCT06099353|EXPERIMENTAL|Arm 4: Heart Age, HOPE-CVD app, and genetic risk communication|"* General practitioners' (GPs) usual care for patients.~* GPs will direct patient participants to a publicly available webpage about managing CVD risk on the Health Promotion Board website.~* GPs will show patient participants how to access Heart Age, a risk assessment tool available online and communicate with them their respective Heart Age value.~* GPs will direct patient participants to download the Heart Age-HOPE- CVD mobile app, an evidence-based behaviour change digital platform.~* Patient participants will undergo genetic testing from which a genetic risk score for CVD will be estimated. They will be informed which quartile of genetic risk they are at in comparison to the rest of the population. The report also contains information on what this risk means for their chances of developing cardiovascular disease in the future."
62361051|NCT05941676||Head and neck carcinoma patients|Head and neck carcinoma patients will be enrolled in this study group.
62361052|NCT02469727|EXPERIMENTAL|Fitbit + Facebook|Participants will use the Fitbit device and join the Facebook group.
62361053|NCT02469727|NO_INTERVENTION|Usual care control|No intervention provided.
62361054|NCT00708747|EXPERIMENTAL|B|Patients were randomised to receive a commercially available standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) containing all important transport and inhibitor proteins as well as immunoglobulins
62361055|NCT00708747|ACTIVE_COMPARATOR|A|Patients were randomised to receive a 5% albumin solution
62361056|NCT04933409|EXPERIMENTAL|3D printed replica of Donor tooth|3D printed replica of Donor tooth
62361057|NCT04933409|ACTIVE_COMPARATOR|Conventional|Conventional method of autotransplantation.
62361058|NCT05609851||experimental group|A physical performance test will be applied to the group and Questionnaires related to occupation will be made to individuals.
62361059|NCT05023850|ACTIVE_COMPARATOR|Group TLIP|"Patients will receive a Thoracolumbar Plane Block (TLIPB) under ultrasound guidance while under general anesthesia.~Intervention: Patients will receive a TLIPB with 20mls 0.25% Bupivicaine bilaterally."
62361060|NCT05023850|EXPERIMENTAL|Group ESP|"Patients will receive an Erector Spinae Plane Block (ESPB) under ultrasound guidance while under general anesthesia.~Intervention: Procedure: Patients will receive an ESPB with 20 ml 0.25% Bupivacaine bilaterally."
62361061|NCT02158455|EXPERIMENTAL|NT SVG grafts|NT SVG randomized for revascularization of left or right coronary territory
62361062|NCT02158455|ACTIVE_COMPARATOR|RA grafts|RA grafts randomized for revascularization of left or right coronary territory
62361063|NCT00601679|EXPERIMENTAL|NT-proBNP|Surveillance NT-proBNP levels disclosed to physicians. Intervention (e.g. Diuretic management) based on NT-proBNP results.
62361064|NCT00601679|NO_INTERVENTION|Usual Care|Surveillance NT-proBNP levels blinded. Intervention (e.g. Diuretic management) based on clinical judgments.
62361065|NCT02821091|NO_INTERVENTION|Control young adults|Healthy adults, age between 20 to 59 yeas old
62549981|NCT06513689||Enrolment|All samples were collect at patient enrolment for the PILOT study (PMID: 32675200, ISRCTN 50236700)
62182315|NCT03671239|OTHER|Product Sequence F|Participants will use placebo rectal suppositories during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period.
62361066|NCT02821091|NO_INTERVENTION|Control old adults|Healthy adults, age between 60 to 80 yeas old
62361067|NCT02821091|EXPERIMENTAL|Exercise old adults|Healthy adults, age between 60 to 80 yeas old received interactive dynamic balance training
62361068|NCT03446612|EXPERIMENTAL|Participants receiving Daprodustat|Participants will receive 2 milligram (mg) daprodustat tablets once daily via oral route for a period of 41 days.
62361069|NCT03446612|ACTIVE_COMPARATOR|Participants receiving Darbepoetin alfa|Participants will receive Darbepoetin alfa solution for injection, administered as a single subcutaneous injection, once every two weeks (Days 1, 14 and 28).
62361070|NCT00642967|EXPERIMENTAL|Methoxy Polyethylene Glycol-epoetin Beta|Participants will receive subcutaneous methoxy polyethylene glycol-epoetin beta every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 micrograms (mcg) will be determined based on the previous dose of epoetin or darbepoetin received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
62361071|NCT04410081|EXPERIMENTAL|14C-lazertinib|Participants will receive a single oral dose of 14C-lazertinib on Day 1.
62361072|NCT02143960|ACTIVE_COMPARATOR|Velashape III device|Controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation
62361073|NCT02143960|ACTIVE_COMPARATOR|Noninvasive Cryolipolysis Device|A noninvasive device that reduces fat by freezing fat cells
62361074|NCT03608046|EXPERIMENTAL|Avelumab, Cetuximab, Irinotecan|"Avelumab : administrated at a fixed dose of 10 mg/kg once every 2- week. Cetuximab: administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3.~Irinotecan: administrated every 2 weeks (180 mg/m2)."
62361075|NCT06149754||Acute ischemic stroke with large vessel occlusion|Patients between 18 and 85 years old who have and acute cerebral stroke due to a demonstrated occlusion in the anterior circulation (M1 or M2 segment of middle cerebral artery with or without ipsilateral internal carotid artery (ICA), that undergo endovascular acute therapy fulfilling all inclusion criteria and with non exclusion criteria for that treatment. We also exclude patient with well-documented history of neuromuscular disorders, stroke or central nervous system tumors that could interfere in the SEPs assessment.
62361076|NCT05466981|EXPERIMENTAL|Current smokers with an HCV infection|Persons who currently smoke cigarettes and are also HCV RNA+
62361077|NCT05754801|EXPERIMENTAL|Active treatment (Yunzhi Essence)|Subjects will take 2 Yunzhi capsules, 4 times daily, for 6 months.
62361078|NCT05754801|PLACEBO_COMPARATOR|Placebo|Subjects will take 2 placebo capsules, 4 times daily, for 6 months
62361079|NCT03777085|EXPERIMENTAL|TQB2303|
62739156|NCT06660810|EXPERIMENTAL|Expansion Pilot|Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec. Weekly injections of talimogene laherparepvec will be continued until surgery. Surgery will be performed 4-6 weeks from the end of radiation therapy to allow for resolution of acute toxicities per current standard of care
61981405|NCT04996888|NO_INTERVENTION|without AI preoperative automatic reminder system|The patients in the control group accept colonoscopy routinely without AI based preoperative automatic reminder system. All patients will receive regular instructions at the time of their appointment to discuss colonoscopy and education about colonoscopy provided by one nurse, including the importance of bowel preparation, the side effects of the agents used, and the exact preparation instructions.
61981406|NCT00840294|NO_INTERVENTION|Observation|Observation only for 2 weeks
62361080|NCT03777085|ACTIVE_COMPARATOR|Rituximab|
62361081|NCT05483660|EXPERIMENTAL|Lactobacillus plantarum|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
62361082|NCT05483660|EXPERIMENTAL|Bacillus coagulans|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
62361083|NCT05483660|EXPERIMENTAL|Lactobacillus plantarum + Bacillus coagulans|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
62361084|NCT05483660|PLACEBO_COMPARATOR|Placebo|Adult milk powder 15 g per time, three times daily and half an hour before meal.
61981407|NCT00840294|ACTIVE_COMPARATOR|Antibiotic|Ciprofloxacin 500 mg twice daily for 2 weeks
62182316|NCT02711813|PLACEBO_COMPARATOR|Placebo|Placebo to TAB08
62361085|NCT00677560||3|"Mild-moderate asthma.~Within the asthma group, there were two sub-groups; mild-moderate asthma and severe asthma distinguished using the Global Initiative for Asthma (GINA) guidelines (GINA, 2009)."
62361086|NCT00677560||4|"Severe Asthma~Within the asthma group, there were two sub-groups; mild-moderate asthma and severe asthma distinguished using the Global Initiative for Asthma (GINA) guidelines (GINA, 2009)."
62361087|NCT00677560||1|"Normal subjects~Normal subjects were a group made up of healthy subjects, with normal lung function, non-smokers at the time of the screening."
62361088|NCT00677560||2|"Healthy smokers~Healthy smokers were comprised of people who were current smokers and had normal lung function at the time of screening."
62361089|NCT00677560||5|"COPD (Gold stage I - III)~The COPD group included stage I to III patients, classified according to severity of airflow limitation (post bronchodilator FEV1), from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (GOLD, 2011)."
62361090|NCT00565812|ACTIVE_COMPARATOR|200 mg|High dose active comparator
62361091|NCT00565812|ACTIVE_COMPARATOR|50 mg|Low dose active comparator
62361092|NCT00565812|PLACEBO_COMPARATOR|Placebo|Placebo comparator to be used for control purposes
62361093|NCT04026945|OTHER|Active Treatment (ST-CP) Group|"This study uses a dose-escalating approach in the active treatment arm. There is no comparator product. All qualifying patients receive the active treatment ST-CP as an injection in the region around the spermatic cord. The following dosing cohorts will be used:~I: 1 x 2 mL of 140 mg/mL ST-CP (= 280 mg lidocaine) II: 1 x 3 mL of 140 mg/mL ST-CP (= 420 mg lidocaine) III: 1 x 4 mL of 140 mg/mL ST-CP (= 560 mg lidocaine)"
62361094|NCT04510402|EXPERIMENTAL|Safety Analysis|Evaluate safety of PVP-I nasal swabs single daily application
62361095|NCT04510402|EXPERIMENTAL|Tolerability analysis|Investigate the dosing of PVP-I nasal swabs daily single dosing versus double dosing
62361096|NCT01804257|EXPERIMENTAL|Digital Health Feedback System (DHFS)|Ingestion Sensor, Wearable Sensor
62361097|NCT04037007|ACTIVE_COMPARATOR|Fistulotomy - High experienced|Fistulotomy precut with a needle knife, ERBE Endocut I, Effect 2; as the primary cannulation technique in high experienced endoscopists.
62361098|NCT04037007|ACTIVE_COMPARATOR|Fistulotomy - Low experienced|Fistulotomy precut with a needle knife, ERBE Endocut I, Effect 2; as the primary cannulation technique in low experienced endoscopists.
61981408|NCT06136923|EXPERIMENTAL|Multiple Sclerosis with Mobility Limitations Study App A|Cognitive Training App CT-100-D-004-A uses implicit training with audiovisual stimuli to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for multiple sclerosis with mobility limitations.
62182317|NCT02711813|EXPERIMENTAL|TAB08 Dose 1|
62182318|NCT02711813|EXPERIMENTAL|TAB08 Dose 2|
62182319|NCT01795729|EXPERIMENTAL|1: Coronary stent+optimal medical therapy|Coronary stent on top of optimal medical therapy
62182320|NCT01795729|ACTIVE_COMPARATOR|2: Optimal medical therapy|Optimal medical therapy
62361099|NCT04037007|ACTIVE_COMPARATOR|Conventional (guidewire) cannulation- High experience|Conventional cannulation with an sphincterotome and 0.035 inch hydrophilic tip guidewire as the primary cannulation technique in high experienced endoscopists.
62361100|NCT04037007|ACTIVE_COMPARATOR|Conventional (guidewire) cannulation - Low experienced.|Conventional cannulation with an sphincterotome and 0.035 inch hydrophilic tip guidewire as the primary cannulation technique in low experienced endoscopists.
62361101|NCT00217009|ACTIVE_COMPARATOR|Narrowband Ultraviolet B (TL-01UVB) Therapy|treatments - 3x weekly for 15 months
62361102|NCT00217009|ACTIVE_COMPARATOR|Topical Psoralen plus ultraviolet A (PUVA)|Treatments - 3x weekly for 15 months
62361103|NCT03948269|EXPERIMENTAL|Internet- and mobile-based group treatment|the therapy consists of 10 modules (15 hours in total) in groups of 8 participants each over a period of 10 weeks and one follow-up meeting (2 hours) 12 weeks after the 10th module (week 22). Each module is adapted from the previous literature on CBT rationale and will be conducted online on WeChat, a mobile social networking software with 1 billion users in 2018. First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging.
62361104|NCT03948269|ACTIVE_COMPARATOR|Face-to-face group treatment|10 modules will be conducted every weekend in the psychological counseling room of The Affiliated Obstetrics and Gynaecology Hospital of Nanjing Medical University.
62361105|NCT03930303|ACTIVE_COMPARATOR|Multimedia Arm|
62361106|NCT03930303|NO_INTERVENTION|Control|
62361107|NCT02057367|EXPERIMENTAL|Scalp block with 0.5% plain marcaine|Anterior scalp block with 0.5% plain Marcaine 20 ml.
62361108|NCT02057367|PLACEBO_COMPARATOR|Scalp block with 0.9% normal saline|Anterior scalp block with 0.9% normal saline 20 ml.
62361109|NCT05548257||All patients were reviewed|
62361110|NCT03929523|EXPERIMENTAL|HOPE group|hypothermic oxygenated perfusion
62361111|NCT03929523|ACTIVE_COMPARATOR|Control group|classic static cold storage
62361112|NCT06248463||Woman with hypertension risk related to gestation|SBP readings above 130 mmHg in office or the presence of a risk factor for eclampsia: (hypertensive disease in previous pregnancy, chronic hypertension, chronic renal disease, diabetes mellitus, or autoimmune disease) or any two moderate-risk factors (nulliparity, age ≥40 years, BMI ≥35 kg/m2, family history of PE, or interpregnancy interval \>10 years)
62361113|NCT02866604|ACTIVE_COMPARATOR|Strerofundin|Days of intervention: 3 days
62361114|NCT02866604|ACTIVE_COMPARATOR|0.9% saline|Days of intervention: 3 days
62361115|NCT01774292|ACTIVE_COMPARATOR|Alkalized lidocaine|160 mg of 4% lidocaine (4 ml) in the endotracheal cuff and add bicarbonate 8,4% until appropriate seal.
61981409|NCT06136923|OTHER|Multiple Sclerosis with Mobility Limitations Study App B|Cognitive Training App CT-100-D-004-B uses implicit training with verbal processing exercises to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for multiple sclerosis with mobility limitations.
61981410|NCT06136923|EXPERIMENTAL|Multiple Sclerosis without Mobility Limitations Study App A|Cognitive Training App CT-100-D-004-A uses implicit training with audiovisual stimuli to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for multiple sclerosis without mobility limitations.
61981411|NCT06136923|OTHER|Multiple Sclerosis without Mobility Limitations Study App B|Cognitive Training App CT-100-D-004-B uses implicit training with verbal processing exercises to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for multiple sclerosis without mobility limitations.
62549982|NCT05492643|EXPERIMENTAL|Group A：2 doses of inactivated SARS-CoV-2 vaccine|Group A: will enrol 500 participants who have received 2 doses of inactivated SARS-CoV-2 vaccine according to national immunization planning, whose last dose was given at least 6 months ago. They will be given one dose of the study vaccine (SYS6006) after enrolment.
62361116|NCT01774292|PLACEBO_COMPARATOR|Sterile saline|4 mL of sterile saline in the endotracheal cuff and add bicarbonate 8,4% until appropriate seal.
62549983|NCT05492643|EXPERIMENTAL|Group B：3 doses of inactivated SARS-CoV-2 vaccine|Group B: will enrol 500 participants who have received 3 doses of inactivated SARS-CoV-2 vaccine according to national immunization planning, whose last dose was given at least 6 months ago. They will be given one dose of the study vaccine (SYS6006) after enrolment.
62549984|NCT04539392||Infertile couple|
62361117|NCT02337686|EXPERIMENTAL|Treatment (pembrolizumab, surgery)|Patients receive pembrolizumab IV over 30 minutes on day -21 and day -1, and then undergo surgery on day 0. After 2-3 weeks or recovery from surgery, patients continue to receive pembrolizumab IV over 30 minutes every 3 weeks. Courses repeat every 42 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
62361118|NCT03497611||Patients with aortic stenosis|Patients receiving Edwards SAPIEN 3 Transcatheter aortic valve implantation
62361119|NCT05286268||Study group|Patients with confirmed COVID-19 disease
62361120|NCT05286268||Control group|Healthy volunteers without any of the exclusion criteria
62361121|NCT00707538|EXPERIMENTAL|1|
62361122|NCT01660230|ACTIVE_COMPARATOR|6 µg/kg 3K3A-APC, single-dose|Cohort 1: 6 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 20 mL IV infusion over 15 minutes
62361123|NCT01660230|ACTIVE_COMPARATOR|30 µg/kg 3K3A-APC, single-dose|Cohort 2: 30 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
62361124|NCT01660230|ACTIVE_COMPARATOR|90 µg/kg 3K3A-APC, single-dose|Cohort 3: 90 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
62361125|NCT01660230|ACTIVE_COMPARATOR|180 µg/kg 3K3A-APC, single-dose|Cohort 4: 180 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
62361126|NCT01660230|ACTIVE_COMPARATOR|360 µg/kg 3K3A-APC, single-dose|Cohort 5: 360 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
61981412|NCT06136923|EXPERIMENTAL|Oncology Breast Cancer Study App A|Cognitive Training App CT-100-D-004-A uses implicit training with audiovisual stimuli to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for breast cancer.
62361127|NCT01660230|ACTIVE_COMPARATOR|TBD µg/kg 3K3A-APC, single-dose|Cohort 6: TBD (not to exceed 720) µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
62361128|NCT01660230|ACTIVE_COMPARATOR|90 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 7: 90 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
62361129|NCT01660230|ACTIVE_COMPARATOR|180 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 8: 180 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
62361130|NCT01660230|ACTIVE_COMPARATOR|360 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 9: 360 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
62361131|NCT01660230|ACTIVE_COMPARATOR|TBD µg/kg 3K3A-APC, q12h for 5 doses|Cohort 10: TBD (not to exceed 720) µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
62361132|NCT01660230|PLACEBO_COMPARATOR|Matching Placebo, 0.9% NaCl in water|Cohorts 1-10: 0.9% sodium chloride in water and administered as either 20 mL IV infusion over 15 minutes (Cohort 1), or 100 mL IV infusion over 15 minutes (Cohorts 2-10)
62361133|NCT04208217|EXPERIMENTAL|Modeling to Learn (MTL)|12 clinics randomly assigned to MTL
62361134|NCT04208217|EXPERIMENTAL|Usual quality improvement (QI)|12 clinics randomly assigned to usual QI
62361135|NCT04423757|EXPERIMENTAL|BI 1358894|125 milligram (mg) BI 1358894 taken orally as three film-coated tablets (1x 25mg and 2x 50mg) once a day in the morning for six weeks.
62361136|NCT04423757|PLACEBO_COMPARATOR|Placebo|Placebo matching BI 1358894 taken orally as three film-coated tablets once a day in the morning for six weeks.
62361137|NCT00198458|EXPERIMENTAL|Vitrase|A single intradermal dose of 4.5 USP units of Vitrase at one site and the same volume of saline at a distant site for comparative control.
62361138|NCT03254862|EXPERIMENTAL|Group A: CSS & AsynS|"Electrical stimulation training on both legs:~Conventional synchronous stimulation (CSS) and Asynchronous Sequential Stimulation (ASynS) - CSS/ASynS"
62361139|NCT03254862|EXPERIMENTAL|Group B: CSS & AsynR|"Electrical stimulation training on both legs:~Conventional synchronous stimulation (CSS) and Asynchronous Random Stimulation (ASynR) - CSS/ASynR"
62361140|NCT05316493|EXPERIMENTAL|overweight MA+ILI|enrolled overweight (24kg/m2≤BMI\<28kg/m2) patients will receive megestrol acetate 160mg po qd plus weight management
62361141|NCT05316493|EXPERIMENTAL|overweight LNG-IUS+ILI|enrolled overweight (24kg/m2≤BMI\<28kg/m2) patients will be treated with LNG-IUS plus weight management
62361142|NCT05316493|EXPERIMENTAL|obese MA+ILI|enrolled obese (BMI≥28kg/m2) patients will receive megestrol acetate 160mg po qd plus weight management
62361143|NCT05316493|EXPERIMENTAL|obese LNG-IUS+ILI|enrolled obese (BMI≥28kg/m2) patients will be treated with LNG-IUS plus weight management
61981413|NCT06136923|OTHER|Oncology Breast Cancer Study App B|Cognitive Training App CT-100-D-004-B uses implicit training with verbal processing exercises to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for breast cancer.
62361144|NCT00424346|EXPERIMENTAL|Canakinumab 600 mg IV + 300 mg q2wk|Participants received canakinumab 600 mg intravenous (IV) loading dose on Day 1 and 300 mg subcutaneous injections every 2 weeks (q2wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg every 4 weeks.
62361145|NCT00424346|EXPERIMENTAL|Canakinumab 300 mg q2wk|Participants received canakinumab 300 mg subcutaneous injections every 2 weeks (q2wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
62361146|NCT00424346|EXPERIMENTAL|Canakinumab 150 mg q4wk|Participants received canakinumab 150 mg subcutaneous injections every 4 weeks (q4wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
62361147|NCT00424346|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injections every 2 weeks for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
62361148|NCT02846857|ACTIVE_COMPARATOR|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
62361149|NCT02846857|ACTIVE_COMPARATOR|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
61981414|NCT06136923|EXPERIMENTAL|Oncology Lung Cancer Study App A|Cognitive Training App CT-100-D-004-A uses implicit training with audiovisual stimuli to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for lung cancer.
61981415|NCT06136923|OTHER|Oncology Lung Cancer Study App B|Cognitive Training App CT-100-D-004-B uses implicit training with verbal processing exercises to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for lung cancer.
62361150|NCT02846857|ACTIVE_COMPARATOR|Dual-hormone closed-loop strategy|Variable subcutaneous insulin and glucagon mini-boluses will be infused using two separate subcutaneous infusion pumps to regulate glucose levels (MiniMed® Paradigm® Veo™, Medtronic). Participant's usual fast-acting insulin analog and Glucagon (Eli Lilly) will be used. Every 10 minutes, the glucose level as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. Newly reconstituted glucagon will be used every 24 hours.
62361151|NCT01431651|EXPERIMENTAL|probiotic, lifestyle counseling|
62361152|NCT05812768|EXPERIMENTAL|Suture-Tight|Subjects meeting all inclusion and exclusion criteria will receive graft anchoring utilizing the Suture-Tight Suture Delivery System.
62361153|NCT03010722||Regorafenib|"160 mg orally (po) od for 3 weeks of every 4-week cycle~All patients will be required to have pre-treatment dynamic contrast enhance computed tomography (DECT) scan pre-treatment and at 8 weeks. Suitable patients will also be required to have dynamic contrast enhanced magnetic resonance imaging (DEC-MRI) and diffusion weighted (DW)-MRI, pre-treatment and at 2 weeks. All patients will also be required to have an Ultrasound (USS) or CT-guided biopsy of suitable metastatic lesion."
62361154|NCT00720824|ACTIVE_COMPARATOR|1|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions
62361155|NCT00720824|PLACEBO_COMPARATOR|2|Office routine
62361156|NCT00640276|ACTIVE_COMPARATOR|T|Lifestyle modification + active drug(Pitavastatin)
62361157|NCT00640276|OTHER|C|Lifestyle Modification
62361158|NCT00035477|PLACEBO_COMPARATOR|1|placebo tablets in hospital and placebo tablets outpatient
62361159|NCT00035477|EXPERIMENTAL|2|Azimilide tablets in hospital and azimilide tablets outpatient
62361160|NCT00779298||Healthy subjects|Healthy subjects, without symptoms or a prior history of gastrointestinal disease, abdominal surgery or diabetes mellitus
62361161|NCT05750888|EXPERIMENTAL|Experimental group 1|A novel-designed intrinsic foot muscle-strengthening exerciser using 3D printing techniques will be used in the experimental group.
62361162|NCT05750888|SHAM_COMPARATOR|Experimental group 2|A regular exercise program will be provided in this group.
62361163|NCT05750888|NO_INTERVENTION|Control group|There is no exercise or other intervention in this group.
62361164|NCT01146951|EXPERIMENTAL|Rufinamide (E2080)|
61981416|NCT02607891|EXPERIMENTAL|STP + GWP42003-P|"Administered orally, twice daily (morning and evening; immediately after the participant's STP dose), commencing with up-titration of 100 mg/mL GWP42003-P to a maintenance dose of 20 mg/kg/day over 11 days.~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the open-label-extension (OLE) phase or who withdraw early.~STP Arm: Last patient completion October 2018"
61981417|NCT02607891|PLACEBO_COMPARATOR|STP + Placebo|"Administered orally, twice daily (morning and evening; immediately after the participant's STP dose), commencing with up-titration of placebo to an equivalent maintenance dose of 20 mg/kg/day over 11 days.~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.~STP Arm: Last patient completion February 2018"
61981418|NCT02607891|EXPERIMENTAL|VPA + GWP42003-P|"Administered orally, twice daily (morning and evening; immediately after the participant's VPA dose), commencing with up-titration of 100 mg/mL GWP42003-P to a maintenance dose of 20 mg/kg/day over 11 days.~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.~VPA Arm: Last patient completion February 2018"
62361165|NCT01146951|PLACEBO_COMPARATOR|Placebo|
62361166|NCT04089436||patients with encephalitis|children above 28days and adults with suspected encephalitis Hospitalized in 4 different Hospitals, Kantha Bopha IV children's Hospital, Phnom Penh, Cambodia, National paediatrics Hospital, Hanoi, Vietnam and Mahosot Hospital, Vientiane, Lao PDR, and Yangon Children Hospital, Yangon, Myanmar
62361167|NCT05885048||Cancer female participants|Fertility status before and after gonadotoxic treatment
62361168|NCT05885048||Cancer male participants|Fertility status before and after gonadotoxic treatment
62361169|NCT06120959|ACTIVE_COMPARATOR|Control group A|They received exercise program in the form of Bridging, Seated Marching Twist, Quadruped pelvic tilts, Modified Side Plank, and Bird dog for 6 successive weeks.
62361170|NCT06120959|EXPERIMENTAL|Study group B|They received the same stabilization exercise program plus Pelvic floor exercise for 6 successive weeks.
62361171|NCT00833807|EXPERIMENTAL|Nab-paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
62361172|NCT04432740|ACTIVE_COMPARATOR|Below Arm Cast Group|All the patients were prepared in the supine position at the emergency department. For analgesia, we used the hematoma block technique with 3 cc of 2% prilocaine hydrochloride®. In this group, after traction was applied using a finger-trap traction with a 4.5 kg weight for 5 minutes, the standard below arm cast was applied. Patients were encouraged to actively move their fingers, ipsilateral shoulder, and elbow in all the groups. Both treatments lasted 5 or 6 weeks after at our clinic
62361173|NCT04432740|ACTIVE_COMPARATOR|Reverse Sugar Tong Group|In this group, after traction was applied using a finger-trap traction with a 4.5 kg weight for 5 minutes, sugar tong splint made of 12 layers of plaster was performed by one person. The reverse sugar tong splint succeeds as a classic sugar tong splint by stabilizing the volar and dorsal aspects of the wrist and forearm, maintaining the same degree of immobilization. The splint fold is located distally at the first web space of the hand, which does not immobilize the elbow. In all the groups, the wrist immobilization position was the same; pronated forearm, 15-20° wrist flexion, ulnar deviation, and care was taken not to immobilize the metacarpophalangeal joints. Patients were encouraged to actively move their fingers, ipsilateral shoulder, and elbow in all the groups. Both treatments lasted 5 or 6 weeks after at our clinic
62361174|NCT00241878|EXPERIMENTAL|1|Teacher-Delivered Weight Control Intervention
62361175|NCT00241878|OTHER|2|Teacher-Delivered General Health Intervention
62361176|NCT02171819|EXPERIMENTAL|IVACFLU-A/H5N1, 7.5 mcg|IVACFLU-A/H5N1, 7.5 mcg HA per dose
62361177|NCT02171819|EXPERIMENTAL|IVACFLU-A/H5N1, 15 mcg|IVACFLU-A/H5N1, 15 mcg HA per dose.
62361178|NCT02171819|PLACEBO_COMPARATOR|Placebo|Phosphate buffered saline
61981419|NCT02607891|PLACEBO_COMPARATOR|VPA + Placebo|"Administered orally, twice daily (morning and evening; immediately after the participant's VPA dose), commencing with up-titration of placebo to an equivalent maintenance dose of 20 mg/kg/day over 11 days.~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.~VPA Arm: Last patient completion January 2018"
61981420|NCT04597996|EXPERIMENTAL|Web Based Education|A pre-test will be applied. Web-based education will be conducted. The post-test will be applied twice, the first one to be performed 4 weeks after Web-based education is completed and the second one 3 months after Web-based education is completed.
62361179|NCT05448989|EXPERIMENTAL|1% atropine 5+3|Put the 1% atropine eye drops into the conjunctival sac, then close the eyes and press the nasolacrimal duct used for 5 consecutive nights in the first week of each month, one night per week in the 2nd, 3rd, and 4th weeks; after 3 months of monocular application, change to the contralateral eye Total treatment time 1 year
62361180|NCT05448989|PLACEBO_COMPARATOR|1% atropine weekly|Put the 1% atropine eye drops into the conjunctival sac, then close the eyes and press the nasolacrimal duct once a week in both eyes Total treatment time 1 year
62361181|NCT03064347|ACTIVE_COMPARATOR|Coated Sucrose plus Whole Milk|200kcal sucrose plus whole milk powder in enteric coating as single dose
62361182|NCT03064347|PLACEBO_COMPARATOR|Non Coated Sucrose plus Whole Milk|200kcal sucrose plus whole milk powder with separate enteric coating materials as single dose
61981421|NCT04597996|NO_INTERVENTION|No Intervention Group|The control group will not have any intervention during the study.
61981422|NCT01358591|SHAM_COMPARATOR|Control Breakfast|Normal calcium breakfast.
62361183|NCT03064347|ACTIVE_COMPARATOR|Enteric Coated Sucrose|200kcal sucrose in enteric coating as single dose
62361184|NCT03064347|PLACEBO_COMPARATOR|Non-Enteric Coated Sucrose|200kcal sucrose with separate enteric coating materials as single dose
61981423|NCT01358591|EXPERIMENTAL|High calcium breakfast|High calcium breakfast.
61981424|NCT04814576|EXPERIMENTAL|Group 1|Collaborative nursing care
62361185|NCT03064347|ACTIVE_COMPARATOR|Enteric Coated Whey Protein|200kcal whey protein in enteric coating as single dose
61981425|NCT04814576|NO_INTERVENTION|Group 2|Traditional nusing care
62361186|NCT03064347|PLACEBO_COMPARATOR|Non-Enteric Coated Whey Protein|200kcal whey protein with separate enteric coating materials as single dose
62361187|NCT03064347|ACTIVE_COMPARATOR|Enteric Coated Pea Protein|200kcal pea protein in enteric coating as single dose
62361188|NCT03064347|PLACEBO_COMPARATOR|Non-Enteric Coated Pea Protein|200kcal pea protein with separate enteric coating materials as single dose
62361189|NCT02988219|ACTIVE_COMPARATOR|General anesthesia (G)|Holter ECG monitor General anesthesia Open kidney cancer surgery
62361190|NCT02988219|EXPERIMENTAL|Combined general/epidural (G/E)|Holter ECG monitor Epidural anesthesia General anesthesia Open kidney cancer surgery
62361191|NCT02314871|ACTIVE_COMPARATOR|Epidural|Patients will receive perioperative epidural analgesia. Drugs: bupivacaine 1.25 mg/ml and sufentanil 0.5 mcg/ml Form and frequency: continuous infusion Dosage: 4 - 14 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
62549985|NCT05347329|PLACEBO_COMPARATOR|Control Arm 1|Placebo (starch) in 3 capsules size 1 (0 mg of active ingredient), administered orally once daily on empty stomach with plenty of water.
61981426|NCT04251598|EXPERIMENTAL|Education group|"Only I am Protecting my Child From the Sun program was given."
61981427|NCT04251598|EXPERIMENTAL|Education + SMS group|"The I am Protecting my Child From the Sun program was given. After the program, an SMS message was sent on Wednesday and Saturday for 12 weeks. A total of 25 SMS messages were sent to remind the subject and applications."
61981428|NCT04251598|NO_INTERVENTION|Control group|"No attempt was made by the researcher during the study. Only data collection was carried out. At the end of the research, the I am Protecting my Child From the Sun program was given.."
61981429|NCT01499550|EXPERIMENTAL|TNI application|In this study arm the patient is treated with humidified transnasal high flow (TNI) plus oxygen (result flow: 20 L/min).
61981430|NCT01499550|ACTIVE_COMPARATOR|Oxygen treatment|Long term oxygen treatment (LOT) is the routine treatment in patients suffering from COPD. In this study arm the patient is treated with his individual oxygen flow rate.
61981431|NCT05796765|EXPERIMENTAL|Micronized DHACM 40 mg|Injection of 40 mg allogeneic micronized dehydrated human amnion chorion membrane (DHACM) suspended in 2.5 mL, 0.9% Sodium Chloride, USP
61981432|NCT05796765|EXPERIMENTAL|Micronized DHACM 100 mg|Injection of 100 mg allogeneic micronized dehydrated human amnion chorion membrane (DHACM) suspended in 2.5 mL, 0.9% Sodium Chloride, USP
61981433|NCT05796765|PLACEBO_COMPARATOR|Saline|Injection of 2.5 ml, 0.9% Sodium Chloride, USP
61981434|NCT03396614||EEG, ECG, CT, MRI|
61981435|NCT01375985|EXPERIMENTAL|AVI-7100|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
61981436|NCT01375985|EXPERIMENTAL|Placebo|Vehicle
61981437|NCT06489652|EXPERIMENTAL|Single-dose group|89Zr-Oxine-RY_SW01 Cell Injection 2.0 x 10\^6 cells/kg treatment
61981438|NCT00423150|EXPERIMENTAL|Temozolomide|
61981439|NCT03184350|OTHER|Adjuvant pelvic proton radiation|
62361192|NCT02314871|ACTIVE_COMPARATOR|Piritramide|Patients will receive postoperative analgesia with piritramide. Drugs: piritramide 1.0 mg/ml Form and frequency: continuous infusion Dosage: 0 - 4 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
62361193|NCT02314871|ACTIVE_COMPARATOR|Morphine|Patients will receive postoperative analgesia with morphine. Drugs: morphine 1.0 mg/ml Form and frequency: continuous infusion Dosage: 0 - 4 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
62361194|NCT03528824|EXPERIMENTAL|Fenugreek wraps|Daily application of fenugreek wraps for 1/2-2 hours per day, 4 weeks application
62361195|NCT03528824|ACTIVE_COMPARATOR|Diclofenac gel|Daily application of diclofenac gel, 4 weeks application
62361196|NCT03528824|NO_INTERVENTION|Usual care|no specific intervention
62361197|NCT05215678||INKA participants|Individuals eligible and accepting participation in the INKA trial (NCT05172843)
62361198|NCT05215678||n-INKA participants|Individuals eligible and declining participation in the INKA trial (NCT05172843)
62361199|NCT06443749|ACTIVE_COMPARATOR|group1|the appendiceal stump will be closed with a polyper homologous clip
62361200|NCT06443749|ACTIVE_COMPARATOR|group|the stump will be closed with an intracorporial node with a single instrument in
62361201|NCT01664156|EXPERIMENTAL|Korean red ginseng|The patients will receive Korean red ginseng(Korean Red Ginseng Powder Capsule®; Korea Ginseng Corporation, Daejeon, Korea). Patients will be requested to take 6 capsules 2 times a day (1h after breakfast and dinner).
62361202|NCT01664156|PLACEBO_COMPARATOR|placebo|Placebo Korean red ginseng capsule contain cornstarch powder with the same color and taste as Korean red ginseng. Patients will be requested to take 6 capsules 2 times a day (1h after breakfast and dinner).
61981440|NCT04322747||Participants scheduled to undergo skull-based surgery|Participants scheduled to undergo skull-based or mastoid surgery as part of their standard care will receive Audiometry for extended high frequencies, DPOAE, ECochG before and after the procedure in the non operated ear.
61981441|NCT03988192|EXPERIMENTAL|VOC analysis|VOC analysis in exhaled air and sweat in patients treated by immunotherapy for lung cancer.
61981442|NCT03060447|EXPERIMENTAL|Vesatolimod|Participants in Period 1 will receive 10 doses of vesatolimod (4 mg to 8 mg) once every 14 days over a 20-week period along with their prescribed ART. Participants in Period 2 (ATI) will discontinue ART and vesatolimod and will be monitored for rebound in HIV-1 plasma viremia for 24 weeks. Participants who restart ART during Period 2 due to virologic rebound will complete the ART Re-Initiation Visits, and then Post-ART Re-suppression Visits monthly for 6 additional months. Participants who complete 24 Weeks of ATI without restarting ART will move onto Period 3 and have 2 options. They can remain off ART for up to an additional 24 weeks. Those who restart ART at the start of Period 3 will complete ART Re-initiation Visits and then Post-ART Re-suppression Visits monthly for 6 additional months.
62169294|NCT00009789|EXPERIMENTAL|Radiotherapy|"Patients receive accelerated 3-dimensional (3-D) conformal radiotherapy daily 5 days a week for 3.5-6 weeks.~Cohorts of 8 patients receive escalating fractions of accelerated 3-D conformal radiotherapy until the maximum tolerated course is determined. The maximum tolerated course is defined as the course at which no more than 2 patients develop at least grade 3 dose-limiting toxicity and no more than 1 patient develops at least grade 4 dose-limiting toxicity.~Patients are followed at 3 weeks, 6 weeks, 3 months, every 3 months for 2 years, and then every 6 months for 3 years."
62361203|NCT03515213|ACTIVE_COMPARATOR|Active|
62361204|NCT03515213|PLACEBO_COMPARATOR|Placebo|
62361205|NCT01614912|EXPERIMENTAL|SM-13496|
62361206|NCT02293941|EXPERIMENTAL|JKB-122 5mg|5mg, oral, once daily
62361207|NCT02293941|EXPERIMENTAL|JKB-122 15 mg|15mg, oral, once daily
62361208|NCT02293941|EXPERIMENTAL|JKB-122 35 mg|35mg, oral, once daily
62361209|NCT02293941|PLACEBO_COMPARATOR|placebo|comparable capsule, oral, once daily
62361210|NCT05145803||College Students|"Collegiate students tested positive for SARS-CoV-2 by a molecular reference test (PCR test or antigen test) (index patients).~Collegiate students known to be contacts of the index patients."
62361211|NCT01374191|ACTIVE_COMPARATOR|onabotulinum toxin type-A|1 injection of Btx-A, or up to 4 injections of Btx-A during the 1-year study period if pain recurs
62361212|NCT01374191|PLACEBO_COMPARATOR|placebo|saline
62361213|NCT01374191|ACTIVE_COMPARATOR|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
62361214|NCT00430885|PLACEBO_COMPARATOR|Saline|
62361215|NCT00430885|EXPERIMENTAL|Octagam (IVIG)|Octagam (IVIg) is intravenous immunglobulin
62361216|NCT02003118|EXPERIMENTAL|AKR 202|
62549986|NCT05347329|EXPERIMENTAL|400 mg Tongkat Ali+ 200 mg Maca (Experimental Arm 2)|The content of 2 capsules of Tongkat Ali Maca (600 mg of active ingredient), Plus is equally distributed and inserted into 3 capsules size 1 (low dose), administered orally once daily with plenty of water.
62549987|NCT05347329|EXPERIMENTAL|600 mg Tongkat Ali+ 300 mg Maca ( Experimental Arm 3)|The content of 3 capsules of Tongkat Ali Maca Plus (900 mg of active ingredient), is equally distributed and inserted into 3 capsules size 1 (high dose), administered orally once daily with plenty of water.
62549988|NCT00775619|ACTIVE_COMPARATOR|2|Coreg® 12.5 mg tablets
62549989|NCT00775619|EXPERIMENTAL|1|Carvedilol 12.5 mg tablets
62361217|NCT02003118|PLACEBO_COMPARATOR|Placebo|
62361218|NCT06328660|EXPERIMENTAL|Lens 1|All participants will wear Lens 1 for 14 ± 3 days (Period 1)
62361219|NCT06328660|EXPERIMENTAL|Lens 2|All participants will wear Lens 2 for 14 ± 3 days (Period 2)
62361220|NCT01000025|ACTIVE_COMPARATOR|PF-00299804|Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62361221|NCT01000025|PLACEBO_COMPARATOR|Placebo|Patients receive oral placebo once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62361222|NCT01590212|NO_INTERVENTION|Care as usual|Participants received care in line with local guidelines
62361223|NCT01590212|ACTIVE_COMPARATOR|Mellow Bumps + care as usual|MB is a six week group-based antenatal programme designed to support families with additional health and social care needs. MB is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation.
62361224|NCT01590212|ACTIVE_COMPARATOR|Chill-out in Pregnancy + care as usual|CHiP is a relaxation programme that includes all the mother-centred components of Mellow Bumps but none of the baby or mother-baby relationship components. It runs for six weeks at two hours per week. It aims to decrease maternal stress levels.
62361225|NCT01449955|PLACEBO_COMPARATOR|Placebo (e.g., sugar pill)|15 mg Placebo will be administered once, in pill form.
62361226|NCT01449955|ACTIVE_COMPARATOR|Rapamycin|15 mg of Rapamycin will be administered once, in pill form.
62361227|NCT04157075|PLACEBO_COMPARATOR|No injection|No injection will be performed
62361228|NCT04157075|SHAM_COMPARATOR|Normal Saline Injection|Normal saline will be injected into the uterosacral ligaments prior to colpotomy
62549990|NCT06581380|EXPERIMENTAL|JK-1201I|Participants will receive JK-1201I as an intravenous (IV) infusion at dose of 180mg/m2 on Day 1 of each 21-day cycle until a treatment discontinuation criterion is met as specified in the protocol.
62361229|NCT04157075|ACTIVE_COMPARATOR|Bupivacaine Injection|Bupivacaine will be injected into the uterosacral ligaments prior to colpotomy
62361230|NCT05250518|NO_INTERVENTION|the control group|The control group will receive no prophylaxis of post-procedure bleeding.
62361231|NCT05250518|EXPERIMENTAL|APC group|The APC group will receive prophylaxis of post-procedure bleeding with argon plasma coagulation.
62361232|NCT05250518|EXPERIMENTAL|Clip group|The Clip group will receive prophylaxis of post-procedure bleeding with clip closure.
62361233|NCT06221072|EXPERIMENTAL|Group 1-JMT103|Participants will receive JMT103 and zoledronic acid placebo.
62361234|NCT06221072|EXPERIMENTAL|Group 2-zoledronic acid|Participants will receive zoledronic acid and JMT103 placebo.
61981443|NCT03060447|EXPERIMENTAL|Placebo|Participants in Period 1 will receive 10 doses of placebo matched to vesatolimod once every 14 days over a 20-week period along with their prescribed ART. Participants in Period 2 (ATI) will discontinue ART and placebo and will be monitored for rebound in HIV-1 plasma viremia for 24 weeks. Participants who restart ART during Period 2 due to virologic rebound will complete the ART Re-Initiation Visits, and then Post-ART Re-suppression Visits monthly for 6 additional months. Participants who complete 24 Weeks of ATI without restarting ART will move onto Period 3 and have 2 options. They can remain off ART for up to an additional 24 weeks. Those who restart ART at the start of Period 3 will complete ART Re-initiation Visits and then Post-ART Re-suppression Visits monthly for 6 additional months.
61981444|NCT03510520|EXPERIMENTAL|Medium Cut-Off Haemodialysis (Theranova)|Participants will receive medium cut-off haemodialysis treatment for 6 months in total (3 times per week treatment).
62361235|NCT01372644|EXPERIMENTAL|ADH, ALH, LCIS, SOM 230|Women who meet eligibility criteria.
62361236|NCT04144049|EXPERIMENTAL|MT921|1% or 1.5%, subcutaneously administered at most 50 injections per treatment.
62361237|NCT04144049|PLACEBO_COMPARATOR|Placebo|Subcutaneously administered at most 50 injections per treatment.
62361238|NCT05808023|ACTIVE_COMPARATOR|Mannitol|Mannitol belongs to the group of polyols within the FODMAPs.
62361239|NCT05808023|ACTIVE_COMPARATOR|Fructans|Fructans belong to the group of oligosaccharides, specifically the fructose-oligosaccharides (FOS), within the FODMAPs.
62361240|NCT06104722|EXPERIMENTAL|high intensity copenhagen adduction exercise group|Athletes in the high-intensity copenhagen adduction exercise group will perform classic copenhagen adduction exercise protocol.
62361241|NCT06104722|EXPERIMENTAL|low intensity copenhagen adduction exercise group|Athletes in the low-intensity copenhagen adduction exercise group will perform a modified copenhagen adduction exercise protocol.
62361242|NCT01156532||Adalimumab Treatment in Participants with Psoriasis|Participants with moderate to severe chronic plaque psoriasis defined as Psoriasis Area and Severity Index (PASI) ≥ 10 and body surface area ≥ 10% with or without psoriatic arthritis, who have an adalimumab therapy indication because they are candidates for systemic therapy or phototherapy and other systemic therapies are medically less appropriate.
62361243|NCT01300585|OTHER|MRI|All patients on study will undergo an MRI of the breast(s).
61981445|NCT03510520|ACTIVE_COMPARATOR|On-Line Haemodiafiltration|Participant will remain on their usual on-line haemodiafiltration (HDF) treatment for the 6 month study duration (3 times per week treatment).
61981446|NCT02591147|ACTIVE_COMPARATOR|Silver Diamine Fluoride 38%|Group 1 (SDF 38%) will receive the application of silver diammine fluoride (38% SDF solution) in addition to 5% sodium fluoride varnish to each approximal carious lesion (scores RA1,RA2,RA3) in a posterior tooth (premolar or molar) that is in contact with an adjacent tooth, using super floss, for a duration of 3 minutes under rubber dam isolation.
61981447|NCT02591147|PLACEBO_COMPARATOR|Placebo (Sterile water)|Group 2 Placebo (control) will receive the application of sterile water (placebo) in addition to 5% sodium fluoride varnish to each approximal carious lesion (scores RA1,RA2,RA3) in a posterior tooth (premolar or molar) that is in contact with an adjacent tooth, using super floss, for a duration of 3 minutes under rubber dam isolation.
61981448|NCT02806310||Prospective|Group A: Patients with known BAV who are scheduled to have a cardiac MRI.
62361244|NCT01176240|EXPERIMENTAL|Droxidopa|droxidopa active drug
62361245|NCT01176240|PLACEBO_COMPARATOR|Placebo|Placebo matched control
61981449|NCT02806310||Historic|Group B: Patients with known BAV who have already had an MRI within the past year
61981450|NCT00694213|EXPERIMENTAL|1|
61981451|NCT00694213|EXPERIMENTAL|2|
61981452|NCT00694213|EXPERIMENTAL|3|
61981453|NCT00694213|PLACEBO_COMPARATOR|4|
61981454|NCT03038633|EXPERIMENTAL|Cohort 1|"900 mg novel medical food containing 22.2mg iron~* receive 900 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~* receive a phone call from coordinator between Day 5-9 to assess side effects and medications~* return to General Clinical Research Center, (GCRC) for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
61981455|NCT03038633|EXPERIMENTAL|Cohort 2|"1800 mg novel medical food containing 44.4 mg of iron~* receive 1800 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~* receive a phone call from coordinator between Day 5-9 to assess side effects and medications~* return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
61981456|NCT03038633|EXPERIMENTAL|Cohort 3|"2700 mg novel medical food containing 66.6 mg of iron~* receive 2700 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~* receive a phone call from coordinator between Day 5-9 to assess side effects and medications~* return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
62361246|NCT06479434|EXPERIMENTAL|Metformin Treated PCO|After taking informed consent demographic data like name, age, anthropometric measurements (blood pressure, BMI, weight, height)will be recorded by researcher Body mass index (BMI), waist circumference, waist to hip ratio will be evaluated. Blood samples will be collected after an overnight fast of 8 to 10 hours. Then metformin will be given to subjects a dose of 500 mg three times a day for 8 weeks. Serum biomarkers and inflammatory markers will be assessed at day 0 and after 8 weeks post metformin administration.
62361247|NCT06479434|NO_INTERVENTION|PCO without Metformin|After taking informed consent demographic data like name, age, anthropometric measurements (blood pressure, BMI, weight, height)will be recorded by researcher Body mass index (BMI), waist circumference, waist to hip ratio will be evaluated. Blood samples will be collected after an overnight fast of 8 to 10 hours. . Serum biomarkers and inflammatory markers will be assessed at day 0 only.
62361248|NCT01522560|PLACEBO_COMPARATOR|Control Group|Residents will be randomly assigned to a feedback group or to the control group. Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a MSF evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation. Only the group assigned to feedback is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the MSF.
62361249|NCT01522560|ACTIVE_COMPARATOR|Feedback group|Residents will be randomly assigned to a feedback group or to the control group. Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a MSF evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation. Only the group assigned to feedback is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the MSF.
62361250|NCT01215669|EXPERIMENTAL|Group 1: Adult Intradermal (ID) Vaccine|Participants aged 18 to 59 years will be vaccinated with IDflu™ influenza vaccine
62361251|NCT01215669|ACTIVE_COMPARATOR|Group 2: Adult Intramuscular (IM) Vaccine|Participants aged 18 to 59 years will be vaccinated with Vaxigrip® Influenza vaccine
62361252|NCT01215669|EXPERIMENTAL|Group 3: Elderly Intradermal (ID) Vaccine|Participants aged 60 years or older will be vaccinated with IDflu™ Influenza vaccine
62361253|NCT01215669|ACTIVE_COMPARATOR|Group 4: Elderly Intramuscular (IM) Vaccine|Participants aged 60 years or older will be vaccinated with Vaxigrip® Influenza vaccine
62361254|NCT02529670|EXPERIMENTAL|Laser|15 patients will be positioned in a prone horizontal position under anesthetic monitoring. The intervertebral foramen between the second and third lumbar vertebrae will be accessed by percutaneous puncture guided by fluoroscopy. Laser Photon III® (DCM) will be applied through fiber optics crossing G18 cannulas, during 84 seconds.
62361255|NCT02529670|ACTIVE_COMPARATOR|Radiofrequency|15 patients will receive radiofrequency in the second dorsal root ganglion through tubes G20, 150 mm long and 5 mm active tip in contact with the target, neuromodulation will be held for 300 seconds at 42oC.
62361256|NCT02529670|ACTIVE_COMPARATOR|Drug: Lidocaine|In the local anesthetic group, 15 patients will receive the injection of 1 ml lidocaine without vasoconstrictor will be applied in the tubes G18, 150 mm long to block the second dorsal root ganglion.
62361257|NCT01915095|ACTIVE_COMPARATOR|Motor task+ Magnetic stimulation|Participants will be asked to complete a precision grip with the index and thumb finger at the same time as flexing or extending the wrist. magnetic stimulation to the brain will be administered and measurements will be taken during movement.
62361258|NCT01915095|ACTIVE_COMPARATOR|rTMS/sham rTMS|Participant will be randomly assigned to one of 3 groups: repetitive transcranial magnetic stimulation (rTMS), sham (fake) rTMS, or sham (fake) rTMS over control brain area will be administered to the brain. the stimulation will be targeting finger and wrist muscles during movement.
62361259|NCT01915095|ACTIVE_COMPARATOR|Training + rTMS/ Sham rTMS|Participants will be asked to follow a target line on the computer as accurately as possible while performing precision grips or foot movement . Magnetic stimulation will be given during rest and movement.
61981457|NCT03038633|EXPERIMENTAL|Cohort 4|"3600 mg novel medical food containing 88.8 mg of iron~* receive 3600 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~* receive a phone call from coordinator between Day 5-9 to assess side effects and medications~* return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
62361260|NCT02680106|EXPERIMENTAL|SPINNER|All patients in this arm will be treated with the SPINNER .
62361261|NCT02680106|ACTIVE_COMPARATOR|JELONET or IBU-Biatain|All patients in this arm will be treated with JELONET/IBU Biatain dressing, regarded as the standard of current care for split-skin donor-site wounds.
62361262|NCT02151968|ACTIVE_COMPARATOR|Traditional blind peribulbar block|
62361263|NCT02151968|EXPERIMENTAL|Ultrasound-guided peribulbar block|
62361264|NCT04460040|EXPERIMENTAL|Intervention|Exercise in moderate intensity tailored individually to 20 kcal/kg/week (range 1500-2000 kcal/week) with a free choice to exercise at home/gym on a treadmill or outdoors.
61981458|NCT04020393||Block group|The patients that had received Sphenopalatine ganglion block(SPGB) before the surgery
61981459|NCT04020393||Control Group|The patients that had not received SPBG before the surgery
62361265|NCT06115057|EXPERIMENTAL|Intervention|Fiber
62361266|NCT03770780|EXPERIMENTAL|SAGE-718|
62361267|NCT03770780|PLACEBO_COMPARATOR|Placebo|
62361268|NCT04696978||PND group|patients occur neurocognitive disorders according to scores in this group
61981460|NCT03414619|EXPERIMENTAL|Intrusive Thoughts Group|Clinically significant intrusive thought in the domain of obsessions, worries, or depressive ruminations with a score above the clinical mean (≥ 37) on the trait repetitive negative thinking measure (Perseverative Thinking Questionnaire, PTQ). These participants will receive the Cognitive Control Tasks and Script Driven Imagery Intervention.
61981461|NCT03414619|EXPERIMENTAL|Non-psychiatric Control Group|A score 1 SD below the community mean (≤ 15) on the trait repetitive negative thinking measure (Perseverative Thinking Questionnaire, PTQ). These participants will also receive the Cognitive Control Tasks and Script Driven Imagery Intervention.
61981462|NCT04475679|EXPERIMENTAL|Adhese Universal DC|
61981463|NCT04475679|ACTIVE_COMPARATOR|Adhese Universal|
62361269|NCT04696978||NO PND group|patients do not occur neurocognitive disorders according to scores in this group
62361270|NCT03797508|OTHER|threatened miscarriage|ultrasound ,CA125,progesterone
62361271|NCT04965116|EXPERIMENTAL|Early Initiation d-POPs|Initiation of d-POPs 120-160 hours after delivery. Dosing is 4mg daily for 24 days followed by 4 daily inactive tablets for 2 months.
62361272|NCT04965116|EXPERIMENTAL|Early Initiation n-POPs|Initiation of n-POPs 120-160 hours after delivery. Dosing is 0.35mg daily for 28 days for 2 months.
62549991|NCT06581380|ACTIVE_COMPARATOR|Topotecan|Participants will receive topotecan until a treatment discontinuation criterion is met as specified in the protocol.
62549992|NCT05063474||PAD: Peripheral Artery Disease|People with Peripheral Artery Disease (PAD). No intervention given, observation and assessment only
61981464|NCT04881708|NO_INTERVENTION|Current Care Group|The current care group will receive the standard of care currently in place within the subspecialty practices in the Department of Surgery, Mayo Clinic Rochester. This includes postoperative inpatient care directed by the surgical team, including timing of discharge and follow-up.
62361273|NCT04965116|PLACEBO_COMPARATOR|Interval Initiation of d-POPs|Placebo starting 120-160 hours after delivery, continuing for 28 days. Followed by 24 days of 4mg daily of d-POPs and 4 daily inactive tablets.
61981465|NCT04881708|ACTIVE_COMPARATOR|Remote Care Group|Patients randomized to the remote monitoring arm will engage in a Connected Care Remote Patient Monitoring (RPM) Complex Care program. RPM Complex Care programs utilize established and standardized equipment, logistics/reverse logistic, engagement methods, and nursing clinical practice. Use of RPM Complex Care programs in this manner, is considered standard practice. Patients will be monitored for 30 days by the Connected Care nursing team as is standard for surgical RPM Complex Care programs.
61981466|NCT05773820|EXPERIMENTAL|WJB001 capsules|Once a day (QD).
61981467|NCT03325075|EXPERIMENTAL|VAL-181388|
62361274|NCT01457924|EXPERIMENTAL|Cohort 1|Placebo and one dose of Ofatumumab 3mg over 24 weeks
62361275|NCT01457924|EXPERIMENTAL|Cohort 2|Two doses of Ofatumumab 3mg over 24 weeks
62361276|NCT01457924|EXPERIMENTAL|Cohort 3.1|Two doses of Ofatumumab 30mg over 24 weeks
61981468|NCT03325075|PLACEBO_COMPARATOR|Placebo|
61981469|NCT00917709|EXPERIMENTAL|DLB with extrapyramidal syndrome|patients dementia with Lewy bodies with extrapyramidal syndrome
61981470|NCT00917709|OTHER|DLB without extrapyramidal syndrome|patients dementia with Lewy bodies without extrapyramidal syndrome
61981471|NCT00917709|SHAM_COMPARATOR|healthy volunteers|healthy volunteers
61981472|NCT04778579|EXPERIMENTAL|ARI-0001|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
62361277|NCT01457924|EXPERIMENTAL|Cohort 3.2|Conditioning dose of Ofatumumab 3mg at randomization, two doses of Ofatumumab 30mg over 24 weeks
62361278|NCT01457924|EXPERIMENTAL|Cohort 4.1|Two doses of Ofatumumab 60mg over 24 weeks
62361279|NCT01457924|EXPERIMENTAL|Cohort 4.2|Conditioning dose of Ofatumumab 3mg at randomization, two doses of Ofatumumab 60mg over 24 weeks
62361280|NCT01457924|EXPERIMENTAL|Cohort 5.1|Six doses of Ofatumumab 60mg over 24 weeks
62361281|NCT01457924|EXPERIMENTAL|Cohort 5.2|Conditioning dose of Ofatumumab 3mg at randomization, six doses of Ofatumumab 60mg over 24 weeks
61981473|NCT00507754||Latent Tuberculosis Infection|Patients with cancer at risk for developing active tuberculosis (TB).
61981474|NCT01988103|EXPERIMENTAL|Apremilast 20mg|Apremilast 20 mg tablets orally twice a day (BID)
61981475|NCT01988103|EXPERIMENTAL|Apremilast 30mg|Apremilast 30 mg tablets orally BID
61981476|NCT01988103|PLACEBO_COMPARATOR|Placebo|Identically-appearing placebo tablets BID for 16 weeks followed by participants being re-randomized in a blinded fasion to apremilast 20 mg or 30mg tablets BID for 52 weeks
62361282|NCT04163913|EXPERIMENTAL|Cirvo Device|The CirvoTM device (Figure 1) is a lightweight, mobile, active, intermittent leg compression device placed on the calf of the leg, using hook and loop (e.g. Velcro) straps in the similar manner as commercially available intermittent leg compression devices The system utilizes an electro-mechanical drive system to intermittently compress the calf from the ankle toward the knee for a duration and compression level prescribed by the physician. The level of compression delivered by the CirvoTM therapy will be in the same range as existing devices which corresponds to the type of pressure applied by a blood pressure cuff.
62361283|NCT04163913|ACTIVE_COMPARATOR|ActiveCare DVT|A commercially available device was previously used to assess patient satisfaction with compression therapy for DVT prophylaxis as per standard of care.
62361284|NCT00635440|ACTIVE_COMPARATOR|A|
62361285|NCT00635440|SHAM_COMPARATOR|B|
62361286|NCT03091426|EXPERIMENTAL|Omiganan 1%|
62361287|NCT03091426|EXPERIMENTAL|Omiganan 1.75%|
61981477|NCT02545790||Persistent hypertrophy|Elevated cardiac mass at follow-up time point as measured by Echocardiographic and Serologic evaluations.
61981478|NCT02545790||Normal geometry|Normal cardiac mass at follow-up time point as measured by Echocardiographic and Serologic evaluations.
61981479|NCT05008250|EXPERIMENTAL|study group|Metoprolol tartrate (25 mg twice per day, orally) plus TMYXP (40 pills twice per day, orally). the treatment duration is 8 weeks.
61981480|NCT05008250|PLACEBO_COMPARATOR|control group|Metoprolol tartrate (25 mg twice per day, orally) plus placebo (40 simulated pills twice per day, orally). The treatment is 8 weeks.
61981481|NCT00730912|EXPERIMENTAL|Pediatrics 3 to 6 years|Pediatrics 3 to 6 years
61981482|NCT00730912|EXPERIMENTAL|Pediatrics 7 to 15 years|Pediatrics 7 to 15 years
61981483|NCT00730912|EXPERIMENTAL|Adults 16 to 64 years|Adults 16 to 64 years
61981484|NCT01540656|ACTIVE_COMPARATOR|Group 1|This group will receive immediate TMNS treatment beginning at baseline and ending at the 6 week point of the study.
61981485|NCT01540656|ACTIVE_COMPARATOR|Group 2|This group will receive delayed TMNS treatment beginning at the 6 week point of the study and ending at 12 weeks.
62361288|NCT03091426|EXPERIMENTAL|Omiganan 2.5%|
62361289|NCT03091426|PLACEBO_COMPARATOR|Vehicle|
62361290|NCT06261476|EXPERIMENTAL|Ashwagandha (Withania somnifera) Root Extract|Participants will take two Ashwagandha capsules containing 500 mg standardized root extract twice daily after breakfast and dinner, for a duration of 12 weeks.
62361291|NCT02090465||all eligible patients|Treatment with Picato according to Summary of Product Characteristics (SmPC)
62361292|NCT02695576|EXPERIMENTAL|Surgery|Lumbar fusion surgery Physiotherapy Cognitive behavioral therapy
62361293|NCT02695576|ACTIVE_COMPARATOR|Non-surgery|Physiotherapy Cognitive behavioral therapy
62361294|NCT03708757|EXPERIMENTAL|Post isometric relaxation - Group I|"Group I will receive post isometric relaxation techniques in order to reduce hamstring spasticity. This technique induces relaxation and decreases spasticity in muscles~Post isometric relaxation (3 sets of 10 repetitions ,1 session in a day, 30 minutes, 4 days a week for 6 weeks.) Stretching Exercises (10 reps 3sets) hold for 2 sec"
62549993|NCT05063474||PLL+PAD: People with Limb Loss and Peripheral Artery Disease|People with Lower-Limb Loss (PLL) and Peripheral Artery Disease (PAD) No intervention given, observation and assessment only
62549994|NCT04327011|EXPERIMENTAL|Experimental|Single arm Toca 511 vector/5-FC prodrug
61981486|NCT01763424|ACTIVE_COMPARATOR|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
62361295|NCT03708757|ACTIVE_COMPARATOR|Eccentric Muscle contraction - Group II|"Eccentric Muscle contraction lengthens the spastic muscles and enhance joint flexibility.~Hot Pack for (10 MINTS) Eccentric stretching (3 sets of 10 repetitions ,1 session in a day, 30 minutes, 4 days a week for 6 weeks.) Stretching Exercise(10 reps 3sets) hold for 2 sec In both experimental groups PIR and Eccentric stretching is applied on hamstring to"
62361296|NCT05107518||children with physical disabilities|his study was designed to examine the validity and reliability of the Turkish version of the Children Participation Assessment Scale. While examining the validity of the scale in children, it was planned to use the Child Health Questionnaire-(CSA) scale, which had previously been shown to be reliable and valid in healthy children with different disability levels.
62361297|NCT06058884|ACTIVE_COMPARATOR|favourbale outcome group|Four hundred fifty-six acute ischemic stroke (AIS) patients who had modified Rankin scale (mRS) two or less after 90 days of ischemic stroke.
62361298|NCT06058884|ACTIVE_COMPARATOR|unfavourbale outcome group|One hundred thirty-six acute ischemic stroke (AIS) patients who had modified Rankin scale (mRS) three or more after 90 days of ischemic stroke.
62361299|NCT02321683|EXPERIMENTAL|Bonemaster|Cement-less femoral stems with electrochemical deposition of hydroxyapatite
61981487|NCT01763424|EXPERIMENTAL|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
62361300|NCT02321683|ACTIVE_COMPARATOR|Hydroxyapatite|Cement-less femoral stems with plasmasprayed hydroxyapatite
62361301|NCT02036268|ACTIVE_COMPARATOR|Standard|Subjects will receive standard ostomy education.
62361302|NCT02036268|EXPERIMENTAL|Pre-Operative Education|In addition to standard ostomy education, subjects will receive additional education pre-operatively.
61981488|NCT00487747|EXPERIMENTAL|Peginterferon Alfa-2a|
62361303|NCT02036268|EXPERIMENTAL|Two-week Post Operative Education|In addition to standard ostomy education, subjects will receive additional education two weeks following surgery.
62361304|NCT02480504|EXPERIMENTAL|intermittent energy restriction|dietary intervention, intermittent energy restriction. Participants in the experimental group will follow av 5:2 diet and consume a very low calorie diet providing 400 (females) to 600 (males) calories of energy to days a week and for an average male participant, this will reduce energy intake approximately 22%.
62361305|NCT02480504|ACTIVE_COMPARATOR|continuous energy restriction|dietary intervention, continuous energy restrictions.Participants in the active comparator group will be asked to reduce daily energy intake by 22-23%
61981489|NCT03318354|EXPERIMENTAL|Test|Torrent's Olmesartan Medoxomil Tablets 40 mg
61981490|NCT03318354|ACTIVE_COMPARATOR|Reference|Daiichi Sankyo Inc's Benicar Tablets 40 mg
61981491|NCT01137045|ACTIVE_COMPARATOR|SPEEDA with modified TRC-ID regimen|35 healthy volunteers
62361306|NCT05665660|EXPERIMENTAL|CARE - Intervention arm for mammography education|CARE is a culturally tailored mammography education module.
61981492|NCT01137045|ACTIVE_COMPARATOR|VERORAB with modified TRC-ID regimen|35 healthy volunteers
61981493|NCT01137045|ACTIVE_COMPARATOR|SPEEDA with modified TRC-ID regimen plus ERIG|35 healthy volunteers
61981494|NCT01137045|ACTIVE_COMPARATOR|VERORAB with modified TRC-ID regimen plus ERIG|35 WHO category III patients
62361307|NCT05665660|EXPERIMENTAL|CARE + COACH - Intervention arm for mammography education + a patient navigator|CARE + COACH is the CARE education module in addition to a COACH, which is access to an Apache paraprofessional women's health coach. The Coach functions like a patient navigator.
62361308|NCT03048357|ACTIVE_COMPARATOR|Freedom Bed|Freedom Bed Continuous Lateral Rotation Therapy System
62361309|NCT03048357|OTHER|Standard Hospital Bed & Protocol|Standard Hospital Bed with manual caregiver re-positioning every 2 hours
62361310|NCT01179867|EXPERIMENTAL|Electronic Medication Reconciliation|"Electronic medication reconciliation includes:~1. Electronic retrieval of the community drug list at admission~2. Generation of discharge prescription using the discharge reconciliation module at discharge~3. Transfer of information on discontinued and changed medication to respective dispensing pharmacies and prescribing physicians"
62361311|NCT01179867|NO_INTERVENTION|Usual practice medication reconciliation|Usual practice in dealing with medication reconciliation. This includes viewing the hospital medications through the hospital electronic pharmacy system, and viewing the community drugs in the patient's chart, if it was collected at admission (not always the case). However not all physicians view the community drugs before writing the discharge prescription. The physician will write a paper discharge prescription to be given to the patient, but communications are generally not made directly to the community pharmacist or previous prescribing physicians.
62361312|NCT00853541||heart failure with renal impairment|Heart Failure patients with renal impairment
62361313|NCT00865046|EXPERIMENTAL|PST + PST boosters|PST once a week for 10 weeks, then tapering over 6 months
62361314|NCT00865046|ACTIVE_COMPARATOR|PST + control-PST boosters|PST once a week for 10 weeks, then control-PST tapering over 6 months
62361315|NCT00865046|PLACEBO_COMPARATOR|Control-PST|control-PST for 10 weeks
62549995|NCT03066258|EXPERIMENTAL|Cohort 1|3E9 GC (genome copies)/eye of RGX-314 (E means the exponential constant)
62549996|NCT03066258|EXPERIMENTAL|Cohort 2|1E10 GC/eye of RGX-314
62549997|NCT03066258|EXPERIMENTAL|Cohort 3|6E10 GC/eye of RGX-314
62549998|NCT03066258|EXPERIMENTAL|Cohort 4|1.6E11 GC/eye of RGX-314
62549999|NCT03066258|EXPERIMENTAL|Cohort 5|2.5E11 GC/eye of RGX-314
62550000|NCT05775029||Study group 1|Short term compliance group
62550001|NCT05775029||Study group 2|Long term compliance group
61981495|NCT01137045|ACTIVE_COMPARATOR|SPEEDA with ESSEN IM regimen plus ERIG|35 healthy volunteers
61981496|NCT01137045|ACTIVE_COMPARATOR|TRCS SPEEDA with modified TRC-ID regimen plus ERIG|35 healthy volunteers
62169295|NCT02652299||Early Rheumatoid Arthritis group|Following informed written consent, 20 patients with early RA will be enrolled from Odense University Hospital (OUH) during a 12 month period
62361316|NCT02715804|EXPERIMENTAL|PAG: PEGPH20 + nab-Paclitaxel + Gemcitabine|Participants will receive 3.0 micrograms/kilogram (μg/kg) PEGPH20 as an intravenous (IV) infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks \[Week 4 of every cycle will be a rest week with no treatment\]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 milligrams/square meter (mg/m\^2) nab-paclitaxel as an IV infusion and 1000 mg/m\^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.
62361317|NCT02715804|PLACEBO_COMPARATOR|AG: Placebo + nab-Paclitaxel + Gemcitabine|Participants will receive placebo matching to PEGPH20 as an IV infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks \[Week 4 of every cycle will be a rest week with no treatment\]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 mg/m\^2 nab-paclitaxel as an IV infusion and 1000 mg/m\^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.
62361318|NCT01784003||Non-amputee|People without an amputation will be recruited to participate in the study.
62361319|NCT01784003||Below the knee amputee|People with a unilateral transtibial amputation will be recruited to participate in the study.
62361320|NCT06153069|EXPERIMENTAL|Short-Course Regimen|The short-course regimen consists of two periods of 8-17 weeks. During the first 8 weeks, the regimen consists of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E). Then based on the presence of radiological manifestations, patients will be in divided into two sub-groups: with-radiological-lesions patients (with_R) and without-radiological-lesions patients (without_R). The regimen for with_R patients consists of rifampicin and isoniazid for an additional 9 weeks. Without_R patients will not undergo further continuation treatment, with a total treatment duration of 8 weeks. The regimen will be extended to 26 weeks if no culture conversion at the end of 8 weeks or the tuberculosis cavity is not closed at the end of treatment.
62361321|NCT06153069|ACTIVE_COMPARATOR|Standardized Regimen|The standard treatment regimen consists of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E) for 8 weeks, followed by rifampicin and isoniazid for an additional 18 weeks.
62361322|NCT00568607|EXPERIMENTAL|IFO, VP-16, DDP, DXM|
62361323|NCT04637191|EXPERIMENTAL|MentalPlus®|This group performed the task in the digital game for 25 minutes and later will be evaluated with standardized and validated neuropsychological tests for the studied population.
62361324|NCT04295707|EXPERIMENTAL|Monthly replacement orthokeratology without protein removal|Subjects will be required to perform daily cleaning for the monthly replacement orthokeratology lenses
62361325|NCT04295707|ACTIVE_COMPARATOR|Monthly replacement lenses with weekly protein removal|Subjects will be required to perform both daily cleaning and weekly protein removal for the monthly replacement orthokeratology lenses
62361326|NCT04295707|ACTIVE_COMPARATOR|Yearly replacement lenses with weekly protein removal|Subjects will be prescribed with orthokeratology lenses which will be replaced at least every 12 months during the study period. They will be required to perform both daily cleaning and weekly protein removal for their lenses.
62361327|NCT01624610|ACTIVE_COMPARATOR|Diet 1|Patients randomized to this arm will receive both written and face-to-face advice about how the components of Diet 1 can be used to control their IBS symptoms.
62361328|NCT01624610|ACTIVE_COMPARATOR|Diet 2|Patients randomized to this arm will receive both written and face-to-face advice about how the components of Diet 2 can be used to control their IBS symptoms.
62361329|NCT01234909||Atopic dermatitis|Pediatric patients ages 1-18 years old with atopic dermatitis
61981497|NCT06343194|ACTIVE_COMPARATOR|bruxism patients assessed with Bruxoff ®|"Subjects classified as bruxists based on the diagnostic criteria for sleep bruxism described by the American Academy of Sleeping Medicine, i.e. if they have at least one of the following two points:~1. The subject reports or is aware of noises of grinding or clamping during sleep.~2. One or more of the following signs are present:~   * Abnormal wear of teeth;~  * Discomfort, fatigue or pain in the muscles of the face;~  * Hypertrophy of muscles during voluntary clamping;~  * Any abnormalities in the mandibular muscle activity cannot be expressed by other sleep disorders, medical, neurological, drug use or substance abuse;~  * Bruxoff ® cut-off more than 4."
61981498|NCT06343194|ACTIVE_COMPARATOR|non-bruxism patients assessed with Bruxoff ®|Subjects with good health, with no evidence of bruxism symptoms or signs. Bruxoff ® cut-off equal or less than 4.
61981499|NCT00082355|EXPERIMENTAL|Alteplase (r-tPA)|Patients with DVT of lower extremity will receive up to 4 treatments low dose (\<10 mg/day) intraclot injections of alteplase. Intention is to evaluate safety and efficacy of this treatment, and durability of outcomes (for 6 months)in 25 patients.
61981500|NCT02441608|EXPERIMENTAL|Experimental group|This study is designed as a single group assignment, because the 4 dressings (3 placebos and 1 containing the product) will be applied in all volunteers. This means that the region in which the tested product will be applied will be compared with the other placebo regions in the same volunteer.
62361330|NCT02583516|EXPERIMENTAL|A - Continuous Administration|960 mg of vemurafenib po, bid, days 1 to 28 and 60 mg of cobimetinib po, od, days 1 to 21, for each 28-days' cycle.
62361331|NCT02583516|EXPERIMENTAL|B - Intermittent Administration|960 mg of vemurafenib po, bid, days 1 to 28 and 60 mg of cobimetinib po, od, days 1 to 21, for each 28-days' cycle, during 12 weeks. After that period, patients will be treated with both drugs at the same doses indicated previously, but with an intermittent pattern: vemurafenib days 1 to 28 followed by 14 days off (4 weeks on and 2 weeks off) and cobimetinib days 1 to 21 followed by 21 days off (3 weeks on and 3 weeks off)
62550002|NCT04731571||Adaptive Radiotherapy|Patients treated using adaptive radiotherapy on the Varian Ethos linear accelerator
62550003|NCT04731571||Conventional Radiotherapy|Patients treated using conventional, non-adaptive radiotherapy on the Varian Truebeam linear accelerator
61981501|NCT01207765|EXPERIMENTAL|Zevalin|1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging on study day +1. 90Y Zevalin will be administered seven to nine days after 111In Zevalin administration. The dose of 90Y Zevalin will be 0.4 mCi/kg, capped at a maximum dose of 32 mCi.
61981502|NCT02432534|EXPERIMENTAL|UVB + treatement|The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months.
61981503|NCT02432534|OTHER|UVB|The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
62361332|NCT02755025||Prospective cohort|This group will include ICU patients for the two month period after the automated SOFA score has been activated within the electronic patient care dashboard.
62361333|NCT03481569|EXPERIMENTAL|Pharmacokinetic sample|Plasma and cerebrospinal fluid samples performed at different timepoint during administration of antibiotic prescribed in routine use
62361334|NCT01632072|EXPERIMENTAL|Nutritional counseling|Dietary supplement
62361335|NCT01632072|NO_INTERVENTION|No nutritional counceling|
62361336|NCT02539719|EXPERIMENTAL|SC-003|Phase 1a (Escalation) - IV infusion Phase 1b (Expansion) - IV infusion
62361337|NCT02539719|EXPERIMENTAL|SC-003 in combination with ABBV-181|Phase 1a (Escalation) - IV infusion of SC-003 followed by IV infusion of ABBV-181 Phase 1b (Expansion) - IV Infusion of SC-003 followed by IV infusion of ABBV-181
61981504|NCT04990414|EXPERIMENTAL|CBT for voices and dissociation|24 sessions of Cognitive Behavioural Therapy (CBT) over a 6-month period treatment window.
61981505|NCT05482633|EXPERIMENTAL|Intervention Group|Experimental group is going to perform inspiratory muscle training exercises everyday for 8 weeks.
61981506|NCT05482633|NO_INTERVENTION|Control Group|No new interventions will be given to control group.
61981507|NCT02223273|EXPERIMENTAL|Multifaceted Strategy|"Multifaceted Intervention~1. Simulation Based Team Training~2. Case Manager~3. Check lists~4. Reminders~5. Educational Materials"
62361338|NCT06047990|EXPERIMENTAL|Cryobiopsy|In randomised patients in experimental arm was initially performed cryobiopsy (3 samples) and cosequently forceps biopsy (6 samples) with 5.2F or 7.5F forceps. Both sampling techniques were performed during one procedure of percutaneous transhepatic drainage under fluoroscopic control.
62361339|NCT06047990|ACTIVE_COMPARATOR|Forceps biopsy|In randomised patients in control arm was initially performed forceps biopsy (6 samples) with 5.2F or 7.5F forceps and cosequently cryobiopsy (3 samples). Both sampling techniques were performed during one procedure of percutaneous transhepatic drainage under fluoroscopic control.
61981508|NCT02223273|NO_INTERVENTION|Usual Care|Hospital Standard Treatment
61981509|NCT00494832|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine infusion
62361340|NCT05721560|EXPERIMENTAL|SINEFIX|Rotator cuff repair with the SINEFIX implant, using the SINEFIX instruments
62361341|NCT01180764|EXPERIMENTAL|Lovaza|Lovaza 4g po qd
62361342|NCT01180764|PLACEBO_COMPARATOR|Placebo|Matching placebo
62361343|NCT02081560|OTHER|colistin pharmacokinetics|Intravenous colistin 9 million units loading dose and 3 million units q8h maintenance dose as long as treatment of infection is required
61981510|NCT00494832|PLACEBO_COMPARATOR|Placebo|Normal Saline infusion
61981511|NCT05479682||EORTC QLQ-C30 first, EORTC QLQ-F17 second|Intervention relates to the order of questionnaires to be completed. In this cohort, the EORTC QLQ-C30 will be completed first and after a short interim task the QLQ-F17 second.
62361344|NCT01931150|EXPERIMENTAL|Dapsone LEFT, Moisturizer RIGHT|Dapsone 5% gel to LEFT side of face and chest BID (morning and evening) Moisturizer to RIGHT side of face and chest BID (morning and evening) AND oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)
62361345|NCT01931150|EXPERIMENTAL|Dapsone RIGHT, Moisturizer LEFT|Moisturizer to LEFT side of face and chest BID (morning and evening) Dapsone 5% gel to RIGHT side of face and chest BID (morning and evening) AND oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)
62361346|NCT01821404|PLACEBO_COMPARATOR|Placebo|Similar capsules as in the atorvastatin arm, but including no active ingredient. Used daily for 3-5 weeks before prostatectomy
62361347|NCT01821404|EXPERIMENTAL|Atorvastatin|Atorvastatin capsules orally, 80 mg daily for 3-5 weeks before prostatectomy
62361348|NCT00577915|EXPERIMENTAL|Breast MR Spectroscopy|Conventional images will be taken with standard pulse sequences. These images will be used for the diagnostic examination for which the patient will have been scheduled. Following the diagnostic study, a pulse sequence designed to obtain spectroscopy data will be used.This will be used on the existing magnets 1.5T and 3T. Memorial Sloan-Kettering Cancer Center has 1.5T and 3T magnets. The patient will have only one injection of contrast (gadolinium-DTPA) for the initial diagnostic study. No additional contrast will be administered. The additional sequence should take about 10 minutes, depending on breast size.
62361349|NCT01726816|EXPERIMENTAL|Probucol 250mg/day|Probucol 250mg group: probucol 250mg 2 tablets, 16 weeks
62361350|NCT01726816|EXPERIMENTAL|Probucol 500mg/day|Probucol 500mg group: probucol 250mg 2 tablets, 16 weeks
62361351|NCT01726816|PLACEBO_COMPARATOR|Placebo|Placebo group: placebo 2 tablets, 16 weeks
62361352|NCT05766423|NO_INTERVENTION|Usual Care|"Usual care includes:~1. The normal standard clinical practices at the participating practice.~2. No specific materials to promote PATTERN, and no additional materials that include adherence assessments or care alert notifications."
62361353|NCT05766423|ACTIVE_COMPARATOR|The PATTERN Intervention|"The intervention components include:~1. An adherence assessment completed by participants ahead of a regularly scheduled clinic visit.~2. Care alert notifications directed to a nurse pool and/or member of the clinical care team."
62361354|NCT04705610|EXPERIMENTAL|Radiologically Isolated Syndrome (RIS)|
62361355|NCT04705610|EXPERIMENTAL|Clinically Isolated Syndrome (CIS)|
62361356|NCT04705610|EXPERIMENTAL|Relapsing-Remitting MS (RRMS)|
62361357|NCT04705610|EXPERIMENTAL|Secondary Progressive MS (SPMS)|
62361358|NCT04705610|EXPERIMENTAL|Primary Progressive MS (PPMS)|
62361359|NCT04705610|EXPERIMENTAL|Healthy volunteer|
62550004|NCT06578273|EXPERIMENTAL|single arm|Subjects in the study will use NeuroGlove 60 minutes twice per day, 30 minutes to each hand. Subjects will be instructed on coordinating their breathing with device on/off periods to maximize relaxation. Subjects who complete less than 45 minutes of treatment per day will be considered noncompliant and may be replaced.
61981512|NCT05479682||EORTC QLQ-F17 first, EORTC QLQ-C30 second|Intervention relates to the order of questionnaires to be completed. In this cohort, the order of questionnaires is reversed: EORTC QLQ-F17 will be completed first and after a short interim task the QLQ-C30 second.
61981513|NCT00350636|EXPERIMENTAL|Oxybutynin topical gel|Oxybutynin topical gel
61981514|NCT00350636|PLACEBO_COMPARATOR|Placebo topical gel|placebo topical gel
62169296|NCT02652299||Longstanding Rheumatoid Arthritis group|Following informed written consent, 20 patients with longstanding RA will be enrolled from Odense University Hospital (OUH) during a 12 month period
62361360|NCT02896192|EXPERIMENTAL|Setmelanotide|Participants received titrated doses of setmelanotide once daily, by subcutaneous (SC) injection during titration period for 2 - 12 weeks. Thereafter, participants continued setmelanotide at their specific therapeutic dose for an additional 10 weeks during the open label treatment period. Participants who achieved at least a 5 kilograms (kg) weight loss (or at least 5% weight loss if baseline body weight was \<100 kg) at the end of the open label treatment period, continued into the 8-week double-blind withdrawal period and received 4 weeks setmelanotide and 4 weeks placebo. Following the withdrawal period, participants entered open label treatment period and received setmelanotide to complete approximately 52 weeks (\~1 year) of treatment at a therapeutic dose.
62361361|NCT01646853|EXPERIMENTAL|Concurrent radiochemotherapy|
62361362|NCT00484276|EXPERIMENTAL|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every 3 weeks or weekly
62361363|NCT00436020|ACTIVE_COMPARATOR|1|Active
62361364|NCT00436020|PLACEBO_COMPARATOR|2|Sham TMS
62361365|NCT02352532|EXPERIMENTAL|Low Back Pain - Dry Needling|
62361366|NCT02352532|SHAM_COMPARATOR|Low Back Pain - Sham|
62361367|NCT02352532|ACTIVE_COMPARATOR|Asymmptomatic - Dry Needling|
62361368|NCT05960136|ACTIVE_COMPARATOR|Sinus lift in patients with previous COVID-19 infection|Sinus floor augmentation in the posterior atrophic maxilla with delayed implant placement in patients with positive history of previous COVID-19 infection.
62361369|NCT05960136|ACTIVE_COMPARATOR|Sinus lift in patients with negative history of previous COVID|Sinus floor augmentation in the posterior atrophic maxilla with delayed implant placement in patients with negative history of COVID-19 infection.
62361370|NCT04023136|OTHER|only one arm (resected patients)|liver resection group
62361371|NCT00049504|EXPERIMENTAL|Treatment (nonmyeloablative HSCT)|"NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total body irradiation on day -1.~TRANSPLANTATION: Patients undergo BMT, from an HLA-haploidentical donor, on day 0.~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3.~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV over 1-2 hours and then tacrolimus PO, once tolerated, on days 4-180, with taper on day 86 in the absence of graft-versus-host disease. Patients also receive mycophenolate mofetil PO three times daily on days 4-35."
62361372|NCT06338007||Complications (No)|Patients who did not experience any postoperative complications within 90 days.
62361373|NCT06338007||Complications (Yes)|Patients who experienced any complications within 90 days after surgery.
62361374|NCT04246125||Therapeutic interventional radiology|Patients undergoing an interventional radiology procedure, at risk for developing radiation-induced skin lesions, including acts of therapeutic interventional neuroradiology (angioplasties, embolization of aneurysms, embolization of arteriovenous malformations , etc...), embolizations and ablations of thoracic tumors, therapeutic cardiac acts (transluminal angioplasties and chronic coronary occlusions) and abdominal embolizations.
62361375|NCT04478110|EXPERIMENTAL|Interactive education with linkage to care|Main intervention components included interactive group education, navigation services and engagement of health care providers for referrals, and linkage to care
62361376|NCT04478110|ACTIVE_COMPARATOR|general health education|Receive a group education session focused on general health education and primary prevention issues.
62361377|NCT01131442||The patient group|
62361378|NCT01131442||healthy control group|
62361379|NCT04556448|EXPERIMENTAL|Aligners|Invisalign treatment
62361380|NCT04556448|ACTIVE_COMPARATOR|Traditional braces|Clear braces
62361381|NCT01171014|EXPERIMENTAL|High dose probiotic|Bifidobacterium lactis HN019, 10 billion cfu/day
62361382|NCT01171014|EXPERIMENTAL|Low dose probiotic|Bifidobacterium lactis HN019, 1 billion cfu/day
62361383|NCT01171014|PLACEBO_COMPARATOR|Placebo|Placebo
62361384|NCT03027193|EXPERIMENTAL|Group 1|Group 1 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 5 x 10\^9 vp through intramuscular route.
62361385|NCT03027193|EXPERIMENTAL|Group 2|Group 2 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 2.5 x 10\^10 vp through intramuscular route.
62361386|NCT03027193|EXPERIMENTAL|Group 3|Group 3 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 5 x 10\^10 vp through intramuscular route.
62361387|NCT03027193|EXPERIMENTAL|Group 4|Group 4 volunteers (n= 3) will be administered MVA HAV, 5 x 10\^7 pfu through intramuscular route.
62361388|NCT03027193|EXPERIMENTAL|Group 5|Group 5 volunteers (n= 3) will be administered MVA HAV, 2 x 10\^8 pfu through intramuscular route.
62361389|NCT03027193|EXPERIMENTAL|Group 6|Group 6 volunteers (n= 10) will be administered ChAdOx2 HAV, 5 x 10\^10 vp followed by MVA HAV, 2 x 10\^8 pfu (8 weeks apart) through intramuscular route.
62361390|NCT02967484|EXPERIMENTAL|Treatment Group|"Participants will recieve the therapy as follows: Huo Xue San Feng acupuncture method+Routine care for ischemic stroke+One type of antihypertensive medication.~Intervention:Acupuncture(choosing the bilatral acupoint: Renying(ST9),Hegu(L14), Taichong(LR3),Quchi(LI11),Zusanli(ST36))+Drugs(one type of antihypertensive medicine)"
62361391|NCT02967484|NO_INTERVENTION|Control Group|"Participants recieve the therapy as follows:Routine care for ischemic stroke +One type of antihypertensive medication.~Intervention:Acupuncture(choosing the acupoint: Neiguan(PC6),Renzhong(10), Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).)+Drugs(one type of antihypertensive medicine)"
62361392|NCT03210064|EXPERIMENTAL|Apatinib and 5-Fluorouracil|Apatinib 500 mg qd po.5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
62361393|NCT03210064|ACTIVE_COMPARATOR|5-Fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
62361394|NCT06249022|EXPERIMENTAL|The observation group|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy.Based on this, the patients in the observation group were given enteral nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University).
62361395|NCT06249022|ACTIVE_COMPARATOR|The control group|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy. The patients in the control group were provided nutrition support with Nasogastric tube feeding , while the feeding process strictly followed the relevant guideline
62361396|NCT02152449|NO_INTERVENTION|Control group|"Control group: systematic advice on swallowing, plus:~* If no weight loss compared to usual weight: no intervention~* if weight loss \<5%: advice on a fat- and protein-enriched diet~* if weight loss ≥5%: advice on a fat- and protein-enriched diet + 1 unit of ONS/day per os"
62361397|NCT02152449|EXPERIMENTAL|oral nutritional supplementation|"Experimental ONS Group: systematic advice on swallowing + systematic advice on a fat- and protein-enriched diet, plus:~* if no weight loss compared to usual weight: 1 ONS/day per os~* if weight loss \<5% compared to usual weight: 2 ONS/day per os~* if weight loss ≥5% compared to usual weight: 3 ONS/day per os"
62361398|NCT04764968|NO_INTERVENTION|Usual care|During the 'usual care' period, participants will manage episodes of manifest or impending hypoglycemia as usual, e.g. through carbohydrate consumption or manual insulin pump suspension.
62361399|NCT04764968|EXPERIMENTAL|Dasiglucagon|During the 'dasiglucagon' period, participants will use pen-administered low-dose (80 µg) dasiglucagon to treat or prevent episodes of hypoglycemia.
62361400|NCT04327050|EXPERIMENTAL|Magnetic-ESD|Patients in MAG arm will be treated using magnetic anchored guided endoscopic submucosal dissection.
62361401|NCT00901589|ACTIVE_COMPARATOR|Premenopausal women-fishoil|
62361402|NCT00901589|PLACEBO_COMPARATOR|Premenopausal-placebo|
62361403|NCT00901589|ACTIVE_COMPARATOR|Postmenopausal women-fishoil|
62361404|NCT00901589|PLACEBO_COMPARATOR|Postmenopausal-placebo|
61981515|NCT02631850|ACTIVE_COMPARATOR|Traditional CI Therapy|"Participants will receive a 35-hour dose of CI therapy. Treatment will consist of 35 therapist/client contact hours in the clinic, 10 weekdays, over 3 weeks. To promote carry-over of motor gains to daily activities, participants will complete: (1) a treatment contract, (2) daily self-report of arm use, and (3) problem-solving to overcome barriers to use of the more affected upper extremity. In addition, the client will agree to wear a padded restraint mitt on the less affected hand for the majority of waking hours to encourage use of the weaker hand for daily activities. Finally, the participant will agree to 30 minutes per day of individualized task-practice outside the clinic (in addition to training in the clinic) focused on functional activities catered towards accomplishing the person's therapeutic goals."
61981516|NCT02631850|ACTIVE_COMPARATOR|Gaming CI Therapy|15 hours of progressive massed motor practice will occur through in-home video game play over 15 consecutive weekdays. Participants will play the game during times of their choosing. The participant will wear an activity monitor biofeedback device for the majority of waking hours. As with traditional CI therapy, the client will agree to an additional 30 minutes per day of individualized task-practice. Five therapist/client contact hours will occur in the clinic on approximate treatment days 1, 3, 6, and 11 and will focus on treatment elements that cannot be readily addressed through the game, such as problem-solving to help the participant carry over motor gains to daily life.
62361405|NCT04903704|OTHER|Sit to Stand testing|"Participants will undergo an ISWT in the hospital setting. This test is a standard of clinical care and it is essential to the patient assessment on their clinical visit. This test will therefore be conducted first in all cases.~They will be allowed a 30 minute rest before undertaking the 1MSTS test.~Clinical observations (heart rate, blood pressure, oxygen saturations) will be taken before and after both tests. Heart rate and oxygen saturations will be monitored during both tests.~Patient reported measures of dyspnoea and perceived exertion will be recorded on completion of both tests.~Adverse events e.g. dizziness, syncope or the participant becoming unwell be recorded.~Descriptive and inferential statistical analysis will be used to determine the safety of 1MSTS in the hospital setting and comparability between 1MSTS and ISWT for participants. We will also examine comparability between 1MSTS outcomes and other available routinely collected clinical data."
61981517|NCT02631850|ACTIVE_COMPARATOR|Gaming CI Therapy with Additional Contact via Video Conference|This group will receive treatment that is identical to Group 2, but will receive an additional 2.6 hours video conference consultation throughout the treatment period.
62169297|NCT02652299||Control group: Synovial tissue and peripheral blood|20 Non-RA patients who are referred to arthroscopy in a joint of the hand at OUH Department of Orthopedics, Section of hand surgery, are asked to participate by the surgeon at the first ambulatory consultation. Following informed written consent, MRI of hand, a blood sample and synovial biopsies, will be used as control for synovial and plasma fibrocyte levels. The synovial biopsies will be obtained during the planned arthroscopy.
62361406|NCT03249753|EXPERIMENTAL|SPH3127 200mg Panel A|Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.
62361407|NCT03249753|EXPERIMENTAL|SPH3127 200mg Panel B|Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
62361408|NCT01719679|EXPERIMENTAL|School Located Vaccine (SLV) Program|A vaccine program carried out by a community vaccinator will be conducted in a limited number of participating schools. The program will be open to the students enrolled at the participating schools
62361409|NCT01719679|NO_INTERVENTION|no School Located Vaccine (SLV) Program|Schools that are part of the non-intervention arm of the study will not have a school-located vaccine program.
62361410|NCT00361218|OTHER|open-label selective serotonin reuptake inhibitor (SSRI)|citalopram or escitalopram
62361411|NCT01674738|EXPERIMENTAL|Pemetrexed, Cisplatin, Bevacizumab|Stratum A
62361412|NCT01674738|EXPERIMENTAL|Pemetrexed, Cisplatin, Bevazizumab|Stratum B:
62361413|NCT03382197|EXPERIMENTAL|Nebulization|control intervention, will only perform nebulization;
62361414|NCT03382197|EXPERIMENTAL|Positive expiratory pressure valve|Intervention, will perform nebulization associated with positive expiratory pressure valve in the airways (EPAP)
62361415|NCT03382197|EXPERIMENTAL|Nonivasive ventilation|intervention, will perform nebulization associated with non-invasive ventilation Bi-level mode;
61981518|NCT02631850|ACTIVE_COMPARATOR|Traditional Occupational Therapy/Physical Therapy|Five therapist/client contact hours will occur on approximate treatment days 1, 3, 6, and 11 (same schedule as gaming CI therapy). 1 hour progressive resistance exercise to establish and progress an upper extremity home exercise program, 2 hours of neuromuscular reeducation, and 2 hours functional practice on activities of daily living (ADLs) with verbal encouragement to use the more affected upper extremity to the largest extent possible. Home practice consists of strengthening exercises, designed to increase range of motion, prescribed twice daily. After completing their participation in the standard OT condition (6 months), participants will be crossed-over to a CI therapy gaming only condition. This condition will be identical to that described above, excluding therapist contact throughout the intervention. Rather, participants will receive a DVD explaining the intervention and guiding them through use of the system.
61981519|NCT01517269|EXPERIMENTAL|Education with simulator|Parent randomized to this group will be taught diabetes management with vignette and simulator
62361416|NCT03658798|EXPERIMENTAL|FES-Garment|All participants will take part in 40 sessions of 1 hour of Functional Electrical Stimulation
62361417|NCT02820558|EXPERIMENTAL|Substance P - 1nmol/kg|Substance P 1nmol/kg intra-celiac artery, single treatment
61981520|NCT01517269|ACTIVE_COMPARATOR|Control arm: standard diabetes education|Parents will receive standard diabetes education with a diabetes educator
62361418|NCT02820558|EXPERIMENTAL|Substance P - 5nmol/kg|Substance P 5nmol/kg intra-celiac artery, single treatment
62361419|NCT02820558|EXPERIMENTAL|Substance P - 15nmol/kg|Substance P 15nmol/kg intra-celiac artery, single treatment
62361420|NCT02820558|EXPERIMENTAL|Substance P - 45nmol/kg|Substance P 45nmol/kg intra-celiac artery, single treatment
61981521|NCT01133054|EXPERIMENTAL|low FFR|FFR\<0.75
62361421|NCT06178094|EXPERIMENTAL|Video Diabetes Training group|"The data collection tools will apply in the first and second interviews and metabolic control variables will record.~Diabetes training videos will sent to the Training Group through smartphones after the first meeting as two episodes a week."
62361422|NCT06178094|NO_INTERVENTION|control group|The data collection tools will apply in the first and second interviews and metabolic control variables will record.
62361423|NCT06122753|ACTIVE_COMPARATOR|Standard Therapy|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic hemostasis according to the center protocol.~Standard combined endoscopic and pharmacological therapy as secondary prophylaxis (carvedilol + repeated endoscopic variceal ligation until the eradication of the esophageal varices)."
62361424|NCT06122753|EXPERIMENTAL|Preemptive TIPS|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic hemostasis according to the center protocol.~Performance of TIPS in the first 72 hours following initial endoscopic hemostasis."
62361425|NCT01956994|EXPERIMENTAL|Whey protein supplement|Subjects will be instructed to consume 40 g whey protein each day for 12 weeks.
62361426|NCT01956994|ACTIVE_COMPARATOR|Carbohydrate supplement|Subjects will be instructed to consume a carbohydrate supplement (iso-caloric to the whey supplement) each day for 12 weeks.
62361427|NCT01478178|EXPERIMENTAL|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
62361428|NCT02331641||Major hepatectomy (MH)|Patients who underwent MH for CLM instead of multiple minor hepatectomy (MMH)
62361429|NCT02331641||Multiple minor hepatectomy (MMH)|Patients who underwent MMH for CLM instead of MH
62361430|NCT00567957|PLACEBO_COMPARATOR|C|Saline starting before induction till entry to abdominal cavity
62361431|NCT00567957|ACTIVE_COMPARATOR|R|Remifentanil starting before induction till entry to abdominal cavity
62361432|NCT00611988|EXPERIMENTAL|1|The intervention includes individual therapy, group reinforcement, and follow-up phone contact
62361433|NCT00611988|ACTIVE_COMPARATOR|2|Attention control group will receive routine follow-up phone calls
62361434|NCT06095544|EXPERIMENTAL|ERAS group|ERAS group was consisted of evidenced-based systematic optimization approaches
62361435|NCT06095544|NO_INTERVENTION|Traditional group|The control group received routine care
62361436|NCT04493593|EXPERIMENTAL|Space for Sleep Group|SilverCloud internet-delivered CBT intervention for Insomnia
61981522|NCT01133054|NO_INTERVENTION|high FFR|FFR \> 0.75
61981523|NCT00768300|EXPERIMENTAL|Ambrisentan|
61981524|NCT00768300|PLACEBO_COMPARATOR|Placebo|
62361437|NCT03374813|EXPERIMENTAL|MimetikOss|Ridge preservation bone grafting after tooth extraction
62361438|NCT03374813|ACTIVE_COMPARATOR|Bio-Oss|Ridge preservation bone grafting after tooth extraction
62361439|NCT05194111|EXPERIMENTAL|Arm 1: Sacubitril-valsartan|Sacubitril-valsartan administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).
62361440|NCT05194111|EXPERIMENTAL|Arm 2: Valsartan|Valsartan administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)
62361441|NCT05380960||copd in acute excerbtion|(1) The first group (COPD group) in acute exacerbaction: We plan to include COPD patients who will be admitted to the Chest Diseases Department with severe exacerbation requiring admission to the RICU (severe dyspnea that responds inadequately to initial emergency therapy, changes in mental status, persistent or worsening hypoxemia, persistent or worsening respiratory acidosis, the need for ventilatory support, and/or hemodynamic instability.
62361442|NCT05380960||(2) The second group (non-COPD lung diseases group).|We plan to include patients admitted at the RICU with bronchial asthma, bronchiectasis, pneumonia, and interstitial lung disease.
62361443|NCT05380960||normal persons|have no diseases
62361444|NCT02077803|EXPERIMENTAL|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 100 mg, and 4 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
62361445|NCT02077803|EXPERIMENTAL|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
62361446|NCT02077803|EXPERIMENTAL|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
62361447|NCT03669406|EXPERIMENTAL|Autograft fat|Paraplegic patients with healed pelvic eschar
62361448|NCT05857007||Libre 2.0 CGM in patients taking EndoTool IV insulin|Ten patients with Hyperglycemia or/and Diabetes in the neuro ICU requires IV insulin through EndoTool algorithm will wear Libre 2.0 CGM for either 14 days or their stay in the neuro ICU
62361449|NCT04584931|EXPERIMENTAL|Treatment of gingival recession with colored composite|Composite restoration will be applied to the gingival recession defect
62361450|NCT04584931|ACTIVE_COMPARATOR|Treatment of gingival recession with coronally advanced flap|coronally advanced flap at the gingival defect
62361451|NCT04218604|EXPERIMENTAL|Personalized AF ablation using MDCT-derived LAWT|Pre-procedural MDCT images will be analysed in Teknon Medical Center (core-lab), using ADAS-3D™ (Galgo Medical, Barcelona, Spain) to obtain 3D atrial wall thickness maps that will be introduced into CARTO® navigation system (Biosense Webster, Diamond Bar, California, US). PVI will be performed point-by-point, aiming to complete a RF circle around the PV ostia (nephroid shape) on the 3D geometry using a ThermoCool® SmartTouch® 3.5-mm irrigated tip contact force-sensing RF ablation catheter (Biosense Webster, Inc.). AI targets will be defined by LAWT on the thickness color map, as follows: Thickness \< 1 mm (red): 300; 1-2 mm (yellow): 350; 2-3 mm (green): 400; 3-4 mm (blue): 450; \> 4 mm (purple): 500. The recommended power settings to reach these AI values will be, in general, 35 W for the posterior wall and 40 W for the anterior wall. Wherever local AWT is \> 3 mm (green and blue colors), an increased RF power (50 W) will be permitted.
62361452|NCT03442504|OTHER|FES PET/CT|"The images will be made immediately after the injection of the FES in a dynamic acquisition, of 30 minutes, centered on a positive FDG lesion. The imaging will then be completed 1 hour after the injection, after obtaining a urination, by an acquisition whole body (from the top of the skull to the root of the thighs or more if element on FDG or conventional imaging) which will be performed in the supine position with arms around the body. During the PET / CT scan, patients will breathe spontaneously. The acquisition will last 30 minutes."
62361453|NCT03550365|EXPERIMENTAL|Rye bran bread intervention|4 week rye bran bread diet intervention with dietary fibre intake of 30g
62361454|NCT03550365|EXPERIMENTAL|Rye bread intervention|4 week rye bread diet intervention with dietary fibre intake of 30g
62361455|NCT03550365|ACTIVE_COMPARATOR|Wheat bread intervention|4 week wheat bread diet intervention with dietary fibre intake of 5-20g prior to two other arms
62361456|NCT03269136|EXPERIMENTAL|PF-06863135|BCMA-CD3 bispecific antibody
62361457|NCT03269136|EXPERIMENTAL|PF-06863135 + dexamethasone|BCMA-CD3 bispecific antibody + dexamethasone
62361458|NCT03269136|EXPERIMENTAL|PF-06863135 + lenalidomide|BCMA-CD3 bispecific antibody + lenalidomide
62361459|NCT03269136|EXPERIMENTAL|PF-06863135 + pomalidomide|BCMA-CD3 bispecific antibody + pomalidomide
62361460|NCT03499769|EXPERIMENTAL|natural orifice|Patients who underwent laparoscopic surgery and removed the specimen from the natural orifice will be gathered. demographic data and perioperative results will be compiled
62361461|NCT03499769|NO_INTERVENTION|conventional|patients who underwent laparoscopic surgery and removed specimen with conventional will be gathered. demographic data and perioperative results will be compiled. (conventional extraction is suprapubic or median incision)
62361462|NCT00129740|EXPERIMENTAL|Nilotinib|400 mg orally twice daily
62361463|NCT06452368|ACTIVE_COMPARATOR|Palatal protraction|Palatal plate assisted with facemask
62361464|NCT06452368|ACTIVE_COMPARATOR|Buccal protraction|Buccal plate assisted with facemask
62361465|NCT01041469||with abnormalities|Down syndrome patients presenting with at least one sign of auto immune abnormality
62361466|NCT01041469||without abnormality|Down syndrome patients without any sign of recognized auto immune condition
62361467|NCT06207071|ACTIVE_COMPARATOR|Intervention|A DHA/ARA supplement will be added to expressed human milk or donor human milk administered during the first 3 weeks after birth.
62361468|NCT06207071|NO_INTERVENTION|Control|No DHA/ARA supplement will be added to expressed human milk or donor human milk administered during the first 3 weeks after birth.
62361469|NCT04516733|OTHER|single arm|patient with glioblastoma
62361470|NCT03182621|EXPERIMENTAL|THINK|The Translational Health in Nutrition and Kinesiology (THINK) program will have education and fitness sessions lasting two hours, five times a week for a total of 10 weeks. Sessions will include theory, clinical laboratory activities, and physically active games to facilitate a fun environment to enhance physical and health-related fitness, improve nutrition and exercise knowledge and behaviors, and exercise enjoyment and self-confidence.
61981525|NCT06290713|EXPERIMENTAL|Tadalafil and Exercise Arm|Participants receive tadalafil weight-dependent dosage to take daily for 6 months (26 weeks).
61981526|NCT06290713|PLACEBO_COMPARATOR|Placebo and Exercise Arm|Participants receive a tadalafil placebo tablet matching the tadalafil weight-dependent dosage to take daily for 6 months (26 weeks).
61981527|NCT03680950|EXPERIMENTAL|Upper Gastrointestinal Monitoring System|Participants who meet criteria of enrollment and is willing to join in this study will wear a real-time upper gastrointestinal monitoring system for checking whether upper gastrointestinal rebleeding occurs continuously for 3 days.
61981528|NCT05240560|EXPERIMENTAL|BP1.3656|1 tablet of 30 microgram (µg), 60µg or 90µg of BP1.3656 per day
61981529|NCT05240560|PLACEBO_COMPARATOR|Placebo|1 tablet of matching placebo per day
61981530|NCT00868075|EXPERIMENTAL|Chest Physiotherapy|Twice daily chest physiotherapy
62361471|NCT03182621|ACTIVE_COMPARATOR|SPARK|This The Sports, Play, and Active Recreation for Kids (SPARK) group will receive the traditional YMCA SPARK after-school program. They will undergo the same pre and post testing protocol as the intervention group, but will not receive the THINK program.
62361472|NCT03261570|ACTIVE_COMPARATOR|Pyridostigmine and Placebo|Pyridostigmine 60mg by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
62361473|NCT03261570|ACTIVE_COMPARATOR|Digoxin and Placebo|Digoxin 0.5mg (500mcg) by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
61981531|NCT00868075|EXPERIMENTAL|Chest Physiotherapy + Exercise Program|Chest Physiotherapy + Exercise Program
61981532|NCT03566823|EXPERIMENTAL|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
61981533|NCT03566823|EXPERIMENTAL|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
62169298|NCT06363409|EXPERIMENTAL|Cereal bar arm|weight lifting exercise and post-exercise cereal bar consumption
62361474|NCT04961879|ACTIVE_COMPARATOR|Reversed Cross Finger Flap group 1|
62361475|NCT04961879|ACTIVE_COMPARATOR|Reversed island Homo-digital Flap group 2|
62361476|NCT04447118|EXPERIMENTAL|Study treatment Arm|Pyrotinib maleate tablet, 400 mg, once daily (QD)
62361477|NCT04447118|ACTIVE_COMPARATOR|Control Arm|Docetaxel injection, 75 mg/m2, once every 3 weeks (Q3W)
62361478|NCT02074904|EXPERIMENTAL|Topiramate|up to 200mg/day orally (over 8 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
62361479|NCT02074904|PLACEBO_COMPARATOR|Placebo|placebo
61981534|NCT03566823|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching with ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
61981535|NCT01482039|NO_INTERVENTION|Standard Ultrasound|Current standard of care - one abdominal view of the cervix to rule out placenta previa
62361480|NCT04917120|EXPERIMENTAL|VRH (virtual reality hypnosis)|
62361481|NCT03371927|NO_INTERVENTION|Standard Feeding Method|The control group consisted of prescribed volumes of oral and/or gavage feedings at two or three hour intervals per feeding.
62361482|NCT03371927|EXPERIMENTAL|SINC Feeding Protocol|Safe individualized nipple-feeding competence (SINC) protocol
62361483|NCT01901978|EXPERIMENTAL|Weight Loss|Caloric restrictive diet
62361484|NCT02319408|NO_INTERVENTION|No radiation|Lobectomy for lung cancer without preoperative radiation
62361485|NCT02319408|EXPERIMENTAL|Preoperative radiation|Lobectomy for lung cancer with preoperative radiation
62361486|NCT04907864|EXPERIMENTAL|MIC|Multi-modal intervention
62361487|NCT04907864|NO_INTERVENTION|CPC|Conventional Palliative Care
62361488|NCT01279980|ACTIVE_COMPARATOR|Epidural|Subjects will have an epidural catheter placed to provide postoperative pain relief. This is standard care for those undergoing an enhanced recovery program.
61981536|NCT01482039|EXPERIMENTAL|Sequential Screen|Start with 3 abdominal views of the cervix with measurement. If 3 adequate views cannot be obtained, or if measurement is less than 3cm, then will perform transvaginal scan for measurement.
61981537|NCT01482039|EXPERIMENTAL|Screening Transvaginal Ultrasound|Obtain 3 adequate cervical length measurements using transvaginal ultrasound
62361489|NCT01279980|ACTIVE_COMPARATOR|Painbuster|Subjects will have a local anaesthetic wound catheter inserted into the wound at time of surgery rather than an epidural for the provision of postoperative pain relief.
61981538|NCT04899414|EXPERIMENTAL|Stage III/IV or Stage I/II NUAT- NKTCL or Relapsed or Refractory NK/T- cell lymphoma|4-6 cycles of induction DAPT followed by Auto HSCT as consolidation for CR/PR fit patients ,then by PD-1 as maintenance treatment (up to 16 cycles) for received Auto-HSCT
61981539|NCT03752112|EXPERIMENTAL|Cefixime|cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection.
62361490|NCT00047008|OTHER|Standard fractionation RT + cisplatin|Standard fractionation radiation therapy with concurrent cisplatin followed by conventional surgery for select patients.
62361491|NCT00047008|EXPERIMENTAL|Accelerated fractionation RT + cisplatin|Accelerated fractionation radiation therapy by concomitant boost with concurrent cisplatin followed by conventional surgery for select patients.
62361492|NCT01985919||Bone marrow aspirate/biopsy and blood specimens|Collection of blood and bone marrow specimens for research purposes and increase the successful acquisition of correlative bone marrow samples to improve translational research in bone marrow diseases
62361493|NCT02720250|EXPERIMENTAL|Omega-3|Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.
62361494|NCT02720250|EXPERIMENTAL|Regular|Intake of 3 regular chicken eggs per day for three weeks.
62361495|NCT03114098|EXPERIMENTAL|CYP2D6 gene abnormalities|"* A salivary sample (2 ml sample) which will allow the investigation of an anomaly of the metabolism of psychotropic drug.~* Blood sampling will be performed to assess treatment tolerance (6 ml). A sample (4 ml) will be kept for possible future analyzes in relation to the objectives of this study for the recruiting center of Nice.~* Electrocardiogram~* Clinical exam~* Clinical Global Impression Scale (CGI-S)~* Children's Global Assessment Scale (CGAS)~* Sheehan Disability Scale (SDS)~* Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III )~* Wechsler Intelligence Scale for Children - 4 (WISC-4)~* Wechsler Adult Intelligence Scale 4 (WAIS 4)~* Diagnostic and Statistical Manual of Mental Disorders (DSM)~* Autism Diagnostic Interview (ADI)"
62361496|NCT02989311|ACTIVE_COMPARATOR|Study 1:Morning test meal+Iron+MNP|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g). Iron compound added to the morning test meal A:12 mg of iron as ferrous sulfate given as 2 mg of 57Fe and 10mg of 56Fe.~Intervention: Dietary supplement: Fortified maize porridge (MNP + Iron)"
62361497|NCT02989311|ACTIVE_COMPARATOR|Study 1:Afternoon test meal+Iron+MNP|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g). Iron compound added to the afternoon test meal B:12 mg of iron as ferrous sulfate given as 2 mg of 58Fe and 10mg of 56Fe.~Intervention: Dietary supplement: Fortified maize porridge (MNP + Iron)"
62391413|NCT00689728|PLACEBO_COMPARATOR|Placebo|"Double-blind Treatment: Placebo comparator administered as a single IV infusion over 30 minutes at 0, 3, and 6 weeks.~Rescue: At Week 16 primary endpoint, participants without at least 20% improvement in either tender or swollen joint counts based on 28 joints could receive an additional (unblinded) 30 minute infusion of LY2127399 80 mg or remain on same initial randomized treatment up to Week 24.~Follow-Up: Optional visits beyond Week 24, if needed, to assess safety including B cell count recovery."
62169299|NCT06363409|EXPERIMENTAL|Almond arm|weight lifting exercise and post-exercise almond consumption
62169300|NCT03149432|ACTIVE_COMPARATOR|Reference analgesic|Gabapentin Rehabilitation Local care
62169301|NCT03149432|EXPERIMENTAL|reference analgesic and mirror therapy|Mirror Therapy Gabapentin Rehabilitation Local care
62361498|NCT02989311|ACTIVE_COMPARATOR|Study 2: Consecutive meals+Iron+MNP+GOS|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g) Iron compound added to the test meals:Test meal A will contain 12mg of ferrous sulphate given as 2mg 54Fe and 10mg 56Fe. Test meal B will contain 12mg of ferrous sulphate given as 2mg 57Fe and 10mg 56Fe.~Intervention: Dietary supplement: Fortified maize porridge (MNP+ Iron + GOS)"
62361499|NCT02989311|ACTIVE_COMPARATOR|Study 2:Alternate meal+Iron+MNP+GOS|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g) Iron compound added to the test meal C: 12mg of ferrous sulphate given as 2mg 58Fe and 10mg.~Intervention: Dietary supplement: Fortified maize porridge (MNP+ Iron + GOS)"
62361500|NCT02929628|EXPERIMENTAL|Patients with Various Frequency Stimulation|Patients are in the condition of Various Frequency Stimulation
62361501|NCT02929628|SHAM_COMPARATOR|Patients With Traditional Frequency Stimulation|Patients in the condition of Sham Comparator are Traditional Frequency Stimulation
62361502|NCT03616262|ACTIVE_COMPARATOR|Phase 1|In Phase 1, subjects will receive either Treatment A (Lidocaine alone) or Treatment B (Botox+Lidocaine )
62361503|NCT03616262|ACTIVE_COMPARATOR|Phase 2|In Phase 2, subjects will receive either Treatment B (Botox+Lidocaine) or Treatment A (Lidocaine alone) -- the opposite of what was administered in Phase 1
62361504|NCT03572153|EXPERIMENTAL|Self-Administered Hypnosis|Self-administered hypnosis will be practiced daily using different audio recordings using the researcher's voice. Participants will practice hypnosis at home after completing the two study sessions.
62361505|NCT03572153|ACTIVE_COMPARATOR|Self-Administered White Noise Hypnosis|Self-administered white noise hypnosis will be practiced daily using a white noise recording. Participants will practice hypnosis at home after completing the two consent and education sessions.
62361506|NCT04121689|EXPERIMENTAL|Milk Protein Concentrate|Seven young men (age: 22±1 y) will undergo repeated blood and biopsy sampling during primed continuous L-\[ring-2H5\]phenylalanine and L-\[1-13C\]leucine tracer infusions, and ingested 38 g of L-\[1-13C\]phenylalanine- and L-\[1-13C\]leucine-labeled milk protein concentrate
62361507|NCT01181141|EXPERIMENTAL|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery
62361508|NCT01181141|ACTIVE_COMPARATOR|Enoxaparin sodium|Enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery
62361509|NCT05823792||Patients aged 3-36 months with suspected ileocolic intussusception|Patients aged 3-36 months with suspected ileocolic intussusception
62361510|NCT01598207|EXPERIMENTAL|Marinol|
62361511|NCT01598207|PLACEBO_COMPARATOR|Placebo|
62361512|NCT03932019|EXPERIMENTAL|Jitongning tablet High dose group|Jitongning tablet,3tablets,bid,po
62361513|NCT03932019|EXPERIMENTAL|Jitongning tablet Low dose group|Jitongning tablet,2tablets,bid,po Jitongning tablet placebo,1tablet,bid,po
62361514|NCT03932019|PLACEBO_COMPARATOR|Placebo Comparator controlled group|Placebo Comparator: Jitongning tablet placebo,3tablets,bid,po
62361515|NCT04397926|EXPERIMENTAL|neoantigen vaccine|Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks
62361516|NCT05300893|NO_INTERVENTION|Treatment with night splint after percutaneous needle fasciotomy|
61981540|NCT03752112|OTHER|Benzathine penicillin|To benchmark the performance of benzathine penicillin in the study population being used for cefixime, the investigators will include a contemporary arm of participants that will receive standard of care treatment with benzathine penicillin according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.
62169302|NCT04931199|ACTIVE_COMPARATOR|CBT|
62361517|NCT05300893|EXPERIMENTAL|No treatment with night splint after percutaneous needle fasciotomy|
62361518|NCT04186663|EXPERIMENTAL|Advantage Arrest|38% silver diamine fluoride, topical, 1 drop, single application
62361519|NCT02967770|EXPERIMENTAL|Molecularly Tailored Therapy|Patients will be treated according to their molecular profile and accordingly, the 29 evaluable patients enrolled may receive one of a dozen, or dozens of treatment regimens.
62361520|NCT02967770|ACTIVE_COMPARATOR|Physician's Discretion Standard of Care|Patients will be treated according to physician discretion standard of care regimen.
62361521|NCT02608372|EXPERIMENTAL|Sequence A|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence LD-UP-CTR
62361522|NCT02608372|EXPERIMENTAL|Sequence B|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence LD-CTR-UP
62361523|NCT02608372|EXPERIMENTAL|Sequence C|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence UP-LD-CTR
62361524|NCT02608372|EXPERIMENTAL|Sequence D|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence UP-CTR-LD
62361525|NCT02608372|EXPERIMENTAL|Sequence E|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence CTR-LD-UP
62361526|NCT02608372|EXPERIMENTAL|Sequence F|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence CTR-UP-LD
62169303|NCT04931199|EXPERIMENTAL|CBT+App|
62361527|NCT01960426|ACTIVE_COMPARATOR|Empiric Dose Intensification|Intensify treatment with the existing drug
62361528|NCT01960426|ACTIVE_COMPARATOR|Testing based strategy|Measurement of drug (Adalimumab/Infliximab) Testing-based strategy for the management of secondary loss of response that is based on drug/ ADA measurement
62361529|NCT05263349||COPD patients|Arm with patients with respiratory disease in whom we study dreams
61981541|NCT01488721||General Newborn Population-Prospective|Specimens prospectively collected in the course of routine newborn screening originating from hospitals, birthing centers, and/or clinics.
61981542|NCT01488721||Newborn Specimens-Confirmed Positive|Banked confirmed positive specimens that were originally collected as part of the newborn screening program, but when found to screen positive for a disease, were followed up clinically to definitively diagnose the subject with the disease (CF, CAH or CH). Follow up results were reported to the sites by the treating clinicians.
62361530|NCT05263349||healthy subject|Arm with healthy subjects whose dream analysis will be used as a basis to compare them to the dreams of COPD patients and see if the disease (COPD) has an influence on the patients' dreams
62361531|NCT03340311|OTHER|Pre-Post|"(Phase one): Each participant will receive usual care (four weeks). Four weeks of glucose logs will be collected at patient's provider visits and completeness recorded.~(Phase two): Each participant will receive a BG5 wireless glucose meter with supplies enough for four weeks. Each participant will download the iGluco application to their smartphone. Education will be given on the monitor and iGluco application use. Four weeks of glucose logs will be collected at patient's provider visits and completeness recorded.~At the conclusion of phase 2, the participants will be asked to complete a satisfaction survey about the care received and their preference of monitors."
62361532|NCT03345368|EXPERIMENTAL|rTMS treated group|A Magstim Rapid2 Stimulator equipped with a double 70mm alpha coil P/N 3191-00 (Magstim, Wales, UK) will be used to stimulate the motor cortex. Transcranial magnetic stimulation will be applied through a coil at 10 Hz, a field intensity of 90% of the motor threshold. Stimuli will be provided in 10 trains of 100 pulses, followed by a 28 s rest period.
62361533|NCT03345368|SHAM_COMPARATOR|sham rTMS group|Sham rTMS will be administered with the coil held in contact with the head but a 180 degrees from scalp, and the power parameter will be reduced by half to avoid stimulation.b
62361534|NCT02957474|EXPERIMENTAL|Treatment A = single oral dose GED 0301, fasted|Subjects will receive a single oral 160 mg dose of GED-0301 after a 10 hour overnight fast
62361535|NCT02957474|EXPERIMENTAL|Treatment B = single oral dose GED 0301, fed|Subjects will receive a single oral 160 mg dose of GED-0301 after a 10 hour overnight fast, and within 30 minutes of completely consuming a high fat meal.
62361536|NCT02957474|EXPERIMENTAL|Treatment C = single oral dose GED 0301 fasted|Subjects will receive an oral dose of 160 mg of GED-0301 given as 4 tablets of 40 mg, after a 10 hour overnight fast
62361537|NCT02957474|EXPERIMENTAL|Treatment D = oral omeprazole and GED-0301|Subjects will receive one oral dose of 40 mg omeprazole once a day for 6 days. On the 5th day, a single oral 160 mg dose of GED-0301 will be given together with omeprazole.
62361538|NCT02851368|OTHER|Near Infrared Fluorescence Imaging with Indocyanine Green|Patients will receive an injection of indocyanine green (ICG) 1 day prior to surgery. Near infrared fluorescence imaging (NIFI) will be used to identify pulmonary nodules during the surgical biopsy and/or resection procedure.
62361539|NCT02894255|EXPERIMENTAL|PCI and CABG|
62361540|NCT05440487||Iron chelator|Patients prescribed with Iron Chelators
62361541|NCT00410904|EXPERIMENTAL|Arm I|Patients receive oral AZD2171 once daily on days 1-28 in course 1 and on days 1-21 in course 2 and all subsequent courses. Patients also receive pemetrexed disodium IV over 10 minutes on day 8 in course 1 and on day 1 in course 2 and all subsequent courses. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
62361542|NCT05680818|EXPERIMENTAL|Encaleret|Participants will receive encaleret at a dose as needed based on calcium levels.
62361543|NCT05680818|OTHER|Standard of Care (SoC)|Participants will continue receiving calcium supplements and/or active Vitamin D (calcitriol, alfacalcidol, falecalcitriol, etc.)
62361544|NCT05885490||Group 1|Patients undergoing treatment for histologically proven or suspected recurrent cancer of the head and neck - clinical data only
62361545|NCT05885490||Group 2|Patients undergoing treatment for histologically proven or suspected recurrent cancer of the head and neck - clinical data and optional biobank sampling
62361546|NCT05885490||Group 3|Patients undergoing treatment for histologically proven or suspected recurrent cancer of the head and neck - clinical data and optional quality of life data
62361547|NCT05885490||Group 4|Patients undergoing treatment for histologically proven or suspected recurrent cancer of the head and neck - clinical data and optional quality of life data and optional biobank sampling
62361548|NCT04446299|EXPERIMENTAL|BLI4900|Experimental bowel preparation solution for oral ingestion
62361549|NCT04446299|ACTIVE_COMPARATOR|FDA Approved Control|FDA approved bowel preparation solution for oral ingestion
61981543|NCT04025307|EXPERIMENTAL|bacTRL-IL-12|single-dose, 1 mL IV infusion of bacTRL-IL-12
61981544|NCT03541018|EXPERIMENTAL|Posterior canalolithiasis|Type of repositional maneuvre
61981545|NCT03541018|EXPERIMENTAL|Lateral cupulolithiasis|Type of repositional maneuvre
61981546|NCT03471195||CP|A total of 20 children with cerebral palsy and dental decay will undergothe following Collection of Saliva Total Salivary Cytokine Profile
62169304|NCT05264311|EXPERIMENTAL|EG: Exercise Group|Pilates exercise program (1 h x 2 sessions per week x 2 months)
62361550|NCT00105183|ACTIVE_COMPARATOR|EZ-2053|Anti-human-T-lymphocyte Immune Globulin, Rabbit (EZ-2053)
61981547|NCT03471195||Control|A total of 20 verbal children without cerebral palsy matched for age and extent of dental decay will undergo the following Collection of Saliva Total Salivary Cytokine Profile
61981548|NCT03540966|EXPERIMENTAL|Group A|complete Chinese version of the vitiligo life quality index, VLQI-C, conventional therapies plus CapulinTM on-demand treatment period
61981549|NCT03540966|PLACEBO_COMPARATOR|Group B|complete Chinese version of the vitiligo life quality index, VLQI-C, conventional therapies on-demand treatment period
61981550|NCT02677922|EXPERIMENTAL|AG-120 + Azacitidine|
61981551|NCT02677922|EXPERIMENTAL|AG-221 + Azacitidine|
62169305|NCT05264311|NO_INTERVENTION|CG: Control Group|Usual lifestyle
62361551|NCT00105183|PLACEBO_COMPARATOR|Placebo|USP 0.9% sodium chloride solution
62361552|NCT00105183|ACTIVE_COMPARATOR|EZ-2053 5mg/kg|Anti-human-T-Lymphocyte Immune Globulin, Rabbit
62361553|NCT01512472|ACTIVE_COMPARATOR|10 month degarelix therapy|
62361554|NCT01512472|ACTIVE_COMPARATOR|4 month degarelix therapy arm|
62361555|NCT02638272|OTHER|spine surgery|The objective was to compare the outcomes of radical debridement versus no debridement under different surgical procedures for the treatment of thoracic and lumbar tuberculosis.
62361556|NCT06274268|EXPERIMENTAL|Interventionnal|"Hand Grip Dynamometer Chair rise test measurement of impedance SEFI Nutritional Intake Assessment Questionnaire GPAQ questionnaire SARC-F questionnaire"
62361557|NCT00608842|EXPERIMENTAL|Deoxycholic Acid 1%|Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
62361558|NCT00608842|EXPERIMENTAL|Deoxycholic Acid 2%|Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
62361559|NCT00608842|EXPERIMENTAL|Deoxycholic Acid 4%|Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
62361560|NCT00608842|PLACEBO_COMPARATOR|Placebo|Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
62361561|NCT03180242|EXPERIMENTAL|EG12014|EG12014
62361562|NCT03180242|ACTIVE_COMPARATOR|EU-sourced Herceptin|EU-sourced Herceptin
62361563|NCT03180242|ACTIVE_COMPARATOR|US-sourced Herceptin|US-sourced Herceptin
62361564|NCT04914871|EXPERIMENTAL|The experimental protocol UN Lifeguard Kids in the Tunja version|Group to which the experimental protocol will be offered.
62361565|NCT04914871|PLACEBO_COMPARATOR|Educational session, accident prevention and wound management.|The control group will be offered the Educational session.
62361566|NCT04436783|EXPERIMENTAL|Virtual Reality Epley Maneuver System - VREMS|Patients in the VREMS cohort will be provided with the VREMS device, which will help guide them through the Epley maneuver in a virtual reality environment. All participants will be asked to rate the severity of their symptoms before undergoing the Epley maneuver. Subsequently, patients will be supervised as they perform the Epley maneuver - VREMS assisted. In both groups, once the patient has performed the Epley maneuver (whether with VREMS assistance or with the IH), they will be asked to rate their symptom severity after undergoing the Epley maneuver
62361567|NCT04436783|ACTIVE_COMPARATOR|Instructional Handout (IH)|Those in the control cohort will be provided an instructional handout (IH) to help them perform the Epley maneuver. They will be given a chance to review the IH, and then they will have a chance to perform the Epley maneuver.
62361568|NCT01521572|EXPERIMENTAL|Salbutamol|Short-acting bronchodilator for use in humans released by the Ministry of Health, widely used worldwide for the treatment of chronic obstructive pulmonary disease.
62361569|NCT05308160|ACTIVE_COMPARATOR|Dapagliflozin|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease.
61981552|NCT02677922|EXPERIMENTAL|Azacitidine|
62361570|NCT05308160|PLACEBO_COMPARATOR|Non-used drug|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease.
62361571|NCT01579149|EXPERIMENTAL|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg)
61981553|NCT03376854|EXPERIMENTAL|Hypothermia + Neuromuscular blockade|Deep sedation and Neuromuscular blockade (NMB) and surface temperature management to maintain core temperature between 34 and 35°C for 48h, then rewarm to 36°C at 0.33°C per h and NMB discontinued when core temp reaches 35.5°C.
61981554|NCT03376854|ACTIVE_COMPARATOR|Standard of care|Acetaminophen and surface temperature management to maintain core temperature between 37°C and 38°C. Rewarming to 37°C for hypothermia ≤36°C with continuous renal replacement therapy.
61981555|NCT04639609|EXPERIMENTAL|Group 1 : Patients|
61981556|NCT04639609|OTHER|Group 2 : healthy volunteers|
62361572|NCT01579149|PLACEBO_COMPARATOR|Placebo|
62361573|NCT00905372|EXPERIMENTAL|LY2062430|
61981557|NCT04739631|EXPERIMENTAL|acupuncture group|The acupuncture group and the sham-controlled group will receive three therapeutic sessions each week for four weeks, and another two sessions each week for four weeks (a total of 20 sessions at eight weeks). Each group will be followed-up for four weeks, to evaluate the persistent efficacy of acupuncture.The needle set for the sham acupuncture group and the real acupuncture group will use the CASOON Acupuncture Needle (Wuxi Jiajian Medical Instrument Company, limited), which needle size is 0.3 mm×30 mm. The depth of needling varied based on the patient's body sizes. After insertion, the needles were manually manipulated to obtain the De Qi sensation, which was defined as the acupuncturist feeling a tugging or grasping sensation from the needle manipulation and the patient feeling soreness, fullness, heaviness, or local distension at local needling sites.
62169306|NCT02261545|ACTIVE_COMPARATOR|n-3 Fatty Acid Supplemetation|patients with Type II Diabetes who receive 3 cap omega3, 3 times a day, for 10 weeks.
62361574|NCT00905372|PLACEBO_COMPARATOR|Placebo|
62361575|NCT02791867|ACTIVE_COMPARATOR|Active|AphoelineBrake administration
62361576|NCT02791867|PLACEBO_COMPARATOR|Placebo|Placebo Administration
62361577|NCT04992637|EXPERIMENTAL|ClockWork|Participants who are randomized to treatment will receive the ClockWork intervention
62361578|NCT04992637|ACTIVE_COMPARATOR|Usual Care|Participants will receive usual care during the postpartum period.
62361579|NCT02998255|EXPERIMENTAL|Single dose of 2L PEG|2 L of PEG solution was used on the day of colonoscopy.
62361580|NCT02998255|ACTIVE_COMPARATOR|Split-dose of 4L PEG|Split-dose of 4l PEG was used before and on the day of colonoscopy
62361581|NCT03245502||Transfused|Patients who have blood transfusion during cardiac surgery
62361582|NCT03245502||Not-Transfused|Patients who don't have blood transfusion during cardiac surgery
62361583|NCT05881512|EXPERIMENTAL|TUAS|Transcutaneous upper airway stimulation
62361584|NCT03966495||PRisM program|"Pluriprofessional primary care offices with the PRiSM RM program:~* Nine of the pluriprofessional primary care offices which implemented the RM program tested in the PRiSM study (2015-2017). The program consisted in: 1) Training on RM in the context of primary care; 2) The appointment of a RM referent in the office; 3) The conduct of six incident review meetings.~* All participating offices had to declare adverse events that occurred during the time frame of the PRiSM study.~* All participating offices had to fill in the safety climate survey MOSPS at the beginning and at the end of the PRiSM study."
62361585|NCT03966495||Control|"Pluriprofessional primary care offices without the PRiSM RM program:~* Nine of the offices pluriprofessional primary care offices which didn't implement the RM program tested in the PRiSM study (2015-2017). They belonged to the PRisM study control group.~* All participating offices had to declare adverse events that occurred during the time frame of the PRiSM study.~* All participating offices had to fill in the safety climate survey MOSPS at the beginning and at the end of the PRiSM study."
62361586|NCT01969513|EXPERIMENTAL|INTERVENTION ARM|Patients meeting the inclusion criteria will be randomly assigned to the experimental group. They will receive Epley's manoeuvre plus betahistine 8mg three times a day until they no longer have symptoms. The Epley's manoeuvre will be performed only on the first visit.
62361587|NCT01969513|SHAM_COMPARATOR|CONTROL GROUP|Patients meeting the inclusion criteria will be randomly assigned to the control group. These patients will receive sham manoeuvre (simulated Epley manoeuvre) plus betahistine 8mg three times a day until they no longer have symptoms. Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
62361588|NCT04675736|EXPERIMENTAL|brushing force|
61981558|NCT04739631|PLACEBO_COMPARATOR|sham-controlled group|The sham acupuncture group will be performed by superficial needling with less than 4mm depth. The needling location is about 0.5 cm away from the acupoints. Both the real acupuncture group and the sham acupuncture group received the same treatment protocol.
61981559|NCT04739631|NO_INTERVENTION|waitlist-control group|As an waitlist-control group, no acupuncture will be performed.
62361589|NCT06067750||Patients referred to Clinical Neurophysiology for Cerebral Function Analysing Monitoring (CFAM)|Patients referred from both adult and paediatric intensive care units
61981560|NCT00323518|PLACEBO_COMPARATOR|1|placebo
61981561|NCT00323518|EXPERIMENTAL|2|30 mcg/kg velafermin
62361590|NCT02162459||whey beverage|consumption of 52 grams of whey protein supplement following resistance exercise
62361591|NCT02162459||chocolate milk beverage|consumption of chocolate flavored milk following resistance exercise
62361592|NCT04368897||COVID-19 Male Patients|Males with laboratory confirmed SARS-CoV-2 infection
62361593|NCT01949857|EXPERIMENTAL|Attenuated HAV Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\\6.50 lgCCID50/ml in children aged 3-15 years \\6.50 lgCCID50/ml in adults aged 16 up to 65 years old
62361594|NCT01949857|EXPERIMENTAL|Attenuated HAV Vaccine, L-A-1 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
62361595|NCT01949857|EXPERIMENTAL|Inactivated HAV Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months\\320EU/Vial in children aged 3-15 years \\640EU/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose
61981562|NCT00323518|EXPERIMENTAL|3|10 mcg/kg velafermin
61981563|NCT00323518|EXPERIMENTAL|4|60 mcg/kg velafermin
61981564|NCT02689401|EXPERIMENTAL|Ferumoxtyol (Feraheme) with MRI|Patients will undergo a pre-contrast MRI followed by a pre determined dose of of IV Ferumoxyto. Post-contrast MRI imaging will be performed immediately following Ferumoxytol infusion and 48 hours after Ferumoxytol administration with subsequent image analysis.
61981565|NCT00886392||diabetic macular edema|Type 2 diabetes patients who had clinically significant macular edema by the criterion of the ETDRS
62361596|NCT01949857|EXPERIMENTAL|Inactivated HAV Vaccine, TZ84 Strain|250U/Vial in babies aged 18-35 months\\250U/Vial in children aged 3-15 years \\500U/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose
62361597|NCT00977717||FOLFOX|Stage III colorectal cancer patients who are treated with adjuvant FOLFOX chemotherapy
62361598|NCT03633591|EXPERIMENTAL|Modified Release Prototypes of Tolcapone|
62361599|NCT01128881|EXPERIMENTAL|IMMUNINE|
62361600|NCT01311895|EXPERIMENTAL|H2O|2 mg IV hydromorphone administered over 2-3 minutes as initial dose
62361601|NCT01311895|EXPERIMENTAL|1+1|"1 mg IV hydromorphone followed by an additional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the following question: Do you want more pain medication?"
62739157|NCT04171635||Patients with transfusional iron overload|The subject population of patients with transfusional iron overload awaiting liver transplant has been chosen because of the clinical indication for MRI examination every three months and the availability of liver explants for analysis after transplant. Explants will receive QSM or R2\* MRI to provide a quantitative biophysical connection to liver iron concentration (LIC).
61981566|NCT05405192|EXPERIMENTAL|Dostarlimab Group|Participants will receive a total of up to 20 cycles of Dostarlimab: 4 cycles of Dostarlimab at a dose of 500 mg on day 1 of each of the 21-day cycle and 16 cycles of Dostarlimab at a dose of 1000 mg on day 1 of each of the 42-day cycle.
61981567|NCT03893422|EXPERIMENTAL|WB-010|3 capsules administered twice daily with morning and evening meal for 12 weeks
61981568|NCT03893422|EXPERIMENTAL|WB-011|3 capsules administered twice daily with morning and evening meal for 12 weeks
61981569|NCT03893422|PLACEBO_COMPARATOR|Placebo|3 capsules administered twice daily with morning and evening meal for 12 weeks
61981570|NCT04123288|EXPERIMENTAL|Test drug formulation|Test drug 60 mg single dose
61981571|NCT04123288|ACTIVE_COMPARATOR|Reference drug formulation|60 mg single dose
61981572|NCT05594914|EXPERIMENTAL|AK104 plus concurrent chemoradiation therapy|AK104 10mg/kg plus TC regimen(paclitaxel liposome 135mg/m2, carboplatin AUC=5), once every 3 weeks (Q3W), induction treatment for 2 cycles; Subsequently, AK104 10 mg/kg plus TC regimen(paclitaxel liposome 135mg/m2, carboplatin AUC=5) is combined with radiotherapy(50Gy/25F) for 2 cycles.
62361602|NCT03597503|EXPERIMENTAL|Flexible dose of SPN-810|Subjects treated with flexible dose of SPN-810
62361603|NCT03597503|PLACEBO_COMPARATOR|Placebo|Subjects treated with Placebo
62361604|NCT04787926||Duralock-C 4%|DuraLock-C 4.0%: Pouch Contains: (2) 3 mL Syringes w/ 2.5 mL Trisodium Citrate Dihydrate 40 mg/mL Solution Contains: Trisodium Citrate Dihydrate, Citric Acid Anhydrous, Water
62361605|NCT04787926||Duralock-C 30%|DuraLock-C 30.0%: Pouch Contains: (2) 3 mL Syringes w/ 2.5 mL Trisodium Citrate Dihydrate 300 mg/mL Solution Contains: Trisodium Citrate Dihydrate, Citric Acid Anhydrous, Water
62361606|NCT04787926||Duralock-C 46.7%|DuraLock-C 46.7%: Pouch Contains: (2) 3 mL Syringes w/ 2.5 mL Trisodium Citrate Dihydrate 467 mg/mL Solution Contains: Trisodium Citrate Dihydrate, Citric Acid Anhydrous, Water
62361607|NCT03499613||Chronic low back pain|Patients with chronic low back pain participating to a 3 weeks Multidisciplinary rehabilitation program
62550005|NCT04552860|EXPERIMENTAL|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
62550006|NCT01696760|EXPERIMENTAL|Arm I (acetylsalicylic acid and PCD)|Patients receive acetylsalicylic acid orally PO BID and wear PCD on days 1-28 after surgery.
61981573|NCT03736291|ACTIVE_COMPARATOR|active rTMS|"The Active rTMS: The magnetic head uses the Magro X100's 8-shaped coil, and the intervention site is the cerebellar vermis (1 cm below the occipital carina). The stimulation intensity is gradually increased by the 80%-100% exercise threshold according to the patient's tolerance. The total number of stimulation pulses per day is 600, the basic frequency is 5 Hz, and one short burst stimulus is given every 200 milliseconds. In each short array, three single pulses with a frequency of 50 Hz are buried, and every 10 short bursts are stimulated for 8 s. A total of 200 short bursts of stimulation. Intervention once a day, 5 times a week, intervention for 2 weeks, a total of 10 times."
61981574|NCT03736291|SHAM_COMPARATOR|sham rTMS|"The sham rTMS: The sham stimulation method was to invert the 8 shaped coil, which was 180° to the scalp, and other intervention parameters were consistent with the study group."
62550007|NCT01696760|EXPERIMENTAL|Arm II (enoxaparin and PCD)|Patients receive enoxaparin subcutaneously SC QD and wear PCD on days 1-28 after surgery.
61981575|NCT03925740|EXPERIMENTAL|MI Varnish Group|The teeth will be cleaned, plaque will be removed, placement of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental probe following ICDAS score. Remineralization protocol, group one will be treated with MI varnish according to the manufacture instructions in first visit and each follow up visits.
62550008|NCT00711035|EXPERIMENTAL|Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection|If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line.
62550009|NCT00611546|PLACEBO_COMPARATOR|1|Perenteral nutrition bottle and tubing are not protected from light
62550010|NCT00611546|ACTIVE_COMPARATOR|2|Perenteral nutrition bottle and tubing are protected from light
62567093|NCT01113892|EXPERIMENTAL|FUSION Bioline|A synthetic vascular graft constructed of two layers. The inner layer is comprised of extruded, ePTFE. The outer layer is comprised of knit polyester textile. These two layers are fused together with a proprietary polycarbonate-urethane adhesive. The vascular graft also has a heparin coating on the graft's luminal surface. The Bioline coating is a bioactive surface coating consisting of a covalent Heparin Sodium coupled to immobilized recombinant human albumin.
62567094|NCT02933385|EXPERIMENTAL|Full lifestyle program|Participants receive all the intervention tools that aimed to enhance lifestyle profile.
62567095|NCT02933385|EXPERIMENTAL|High lifestyle program|Participants receive most of the intervention tools that aimed to enhance lifestyle profile.
62361608|NCT03919006|ACTIVE_COMPARATOR|Periodontitis|"GCF, saliva and serum samples were taken before and after treatment from periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
62361609|NCT03919006|ACTIVE_COMPARATOR|Gingivitis|"GCF, saliva and serum samples were taken before and after treatment from gingivitis patients.~Intervention: Non- surgical periodontal treatment (Scaling and oral hygiene instructions)"
62361610|NCT03919006|PLACEBO_COMPARATOR|Periodontally healthy|GCF, saliva and serum samples were taken at baseline from periodontally healthy individuals.
62361611|NCT05817981||Adolescent and Young Adult Cancer Survivors|Adolescent and young adult cancer survivors who aged range from 15 to 39, having been diagnosed with cancer and completed cancer treatment for at least 6 months.
62361612|NCT05817981||Clinical oncology medical staff|Medical staff who routinely work in the oncology ward.
62361613|NCT03012594|EXPERIMENTAL|Lanreotide|Open label
62361614|NCT05799209|EXPERIMENTAL|Reduced Environmental Stimulation Pool|floating supine in a pool for a prescribed amount of time (1 total session lasting 1 hour)
61981576|NCT03925740|EXPERIMENTAL|PreviDent Varnish Group|The teeth will be cleaned, plaque will be removed, placement of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental probe following ICDAS score. Group two will receive PreviDent varnish according to the manufacture instructions in the first visit and each follow up visits.
62361615|NCT05799209|ACTIVE_COMPARATOR|Zero Gravity Chair|floating supine in a zero-gravity chair for a prescribed amount of time (1 total session lasting 1 hour)
62361616|NCT04334772|EXPERIMENTAL|Muscle belly Microelectrolysis|"Group to receive direct current application percutaneously using an acupuncture needle with intensities in microamps (µA) at hamstring muscular belly. The acupuncture needle will correspond to the negative electrode or cathode.~The group will also receive a passive stretching exercise treatment by a physical therapist."
62361617|NCT04334772|EXPERIMENTAL|Tendon Microelectrolysis|"Group to receive direct current application percutaneously using an acupuncture needle with intensities in microamps (µA) at the hamstring tendon. The acupuncture needle will correspond to the negative electrode or cathode.~The group will also receive a passive stretching exercise treatment by a physical therapist."
62361618|NCT04334772|ACTIVE_COMPARATOR|Control|Group to receive treatment by assisted passive stretching performed by a physical therapist on tightness hamstrings.
62361619|NCT00005969|EXPERIMENTAL|Liposomal Tretinoin|Liposome by vein (IV) over 30 minutes every other day for 28 days and Chemotherapy.
62361620|NCT05218304|NO_INTERVENTION|Sample|questionnaires physical measurements (height, weight, perimeter abdominal and blood pressure)
62361621|NCT05218304|EXPERIMENTAL|Sub-sample - blood test|questionnaires physical measurements (height, weight, perimeter abdominal and blood pressure) Blood samples
62361622|NCT02687932|EXPERIMENTAL|LCZ696|LCZ696 for 12 months
62361623|NCT02687932|ACTIVE_COMPARATOR|Valsartan|Valsartan for 12 months
62361624|NCT01913743||MINDSETS|overweight/obese
62361625|NCT04648228|EXPERIMENTAL|ACT + MBRP|Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP) group will follow a manualized clinical protocol. Treatment will include 12 weekly group-based sessions, each lasting 90 minutes. Group sizes will range from 3 to 8. ACT + MBRP will be delivered via the VA Video Connect telehealth platform.
62361626|NCT04648228|ACTIVE_COMPARATOR|Education Control (EC)|The EC group will follow a protocol that combines opioid education sessions and psychology-led pain education sessions that are offered as part of the interdisciplinary pain program. Specifically, education will include 12 group-based sessions, each lasting 60 to 90 minutes. Group sizes will range from 3 to 8. EC will be delivered via the VA Video Connect telehealth platform.
62361627|NCT04675697|EXPERIMENTAL|Anlotinib+EP|
62361628|NCT00838695|EXPERIMENTAL|African Americans|Subjects' hand veins will be measured for maximum constriction while being infused with phenylephrine, and then mental stress and cold pressor testing
62361629|NCT00838695|EXPERIMENTAL|Caucasians|Subjects' hand veins will be measured for maximum constriction while being infused with phenylephrine, and then mental stress and cold pressor testing
62361630|NCT02654275|ACTIVE_COMPARATOR|Proprioceptive Intervention|Strength training on a non-stable surface
62361631|NCT02654275|NO_INTERVENTION|No Proprioceptive Intervention|Conventional strength training
62361632|NCT01667055||Patients with suspected drug allergy|Patients with a history of hypersensitivity reaction to beta-lactam antibiotics
62361633|NCT06031376||Fruquintinib plus PD-1 inhibitors|In fruquintinib plus PD-1 inhibitors group,The patients were treated orally with Fruquintinib (5mg once daily for 14 days on/7 days off, over a 21-day cycle), combined with 1 of the 5 anti-PD-1 antibodies (i.e., nivolumab, pembrolizumab, camrelizumab, sintilimab, or toripalimab). The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks.
62361634|NCT06031376||TAS-102 plus bevacizumab|In TAS-102 plus BEV group, Patients received TAS-102 (35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days) and bevacizumab (5 mg /kg, intravenously, on days 1 and 15, every 28 days). Bevacizumab was approved to be a 30-minute intravenous infusion before TAS-102.
62361635|NCT01939093|EXPERIMENTAL|Quetiapine|Quetiapine 100 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.
62361636|NCT01939093|ACTIVE_COMPARATOR|Haloperidol|Haloperidol 2 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.
62361637|NCT06158282|EXPERIMENTAL|Walking apnea at High Lung Volume|Participants walk at 5,5 km/h on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 15 seconds, followed by a normal breath of 10 seconds (15 cycles of 15s apnea - 10s normal breathing, until completing the 6 minutes)
62361638|NCT06158282|NO_INTERVENTION|Walking at normal breathing|Participants walk at 5,5 km/h on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
62361639|NCT01471639|EXPERIMENTAL|Intranasal ketorolac (Sprix)|FDA approved drug used in single arm study
62361640|NCT00954928||Anticoagulated patients|Those patients taking Coumadin, Plavix, Aspirin, Lovenox.
62361641|NCT00954928||Control patients|Those patients having hand or wrist surgery who do not take any anticoagulant medication.
62361642|NCT00931060|EXPERIMENTAL|Branched chain amino acids|Patients with cirrhosis. Healthy subjects age and sex matched
62361643|NCT04233710|EXPERIMENTAL|Robot + tDCS|10 sessions of 1.5 hrs of robotic therapy within a 3 week period, with 20 minutes of 1mA cathodal tDCS applied to the contralesional M1 area during first 20 minutes of robotic therapy. Robotic therapy will be conducted using the Kinarm Exoskeleton robot and use games to target unilateral and bilateral motor and sensory impairments.
62361644|NCT04233710|SHAM_COMPARATOR|Robot + sham tDCS|10 sessions of 1.5 hrs of robotic therapy within a 3 week period with 20 minutes of SHAM tDCS applied during the first 20 minutes of the robotic therapy. As with experimental arm, electrode will be placed on contralesional M1. Current will ramp up and then immediately ramp down to simulate the cutaneous sensations felt with actual tDCS. Robotic therapy will be delivered with Kinarm Exoskeleton robot and use games to target unilateral and bilateral motor and sensory impairments.
62361645|NCT03320889|OTHER|Pamphlets plus Review with Expert Educator|Educational Intervention includes Pamphlets plus Review with Expert Educator
62361646|NCT03320889|OTHER|Pamphlets only|Educational Intervention includes Pamphlets only
62361647|NCT03154177|NO_INTERVENTION|Standard ANC and PNC care only|Standard care offered following national guidelines of ANC and PNC.
62361648|NCT03154177|OTHER|Standard Care + Ultrasound+Pregnancy Testing|Standard care in combination with early pregnancy testing and ultrasound.
62361649|NCT03154177|EXPERIMENTAL|Group ANC and PNC only|Health facilities randomized to provide group ANC/PNC.
61981577|NCT03925740|ACTIVE_COMPARATOR|1.23% APF Control Group|Regular application of APF for 4 minutes with high volume suction to the whole mouth.
61981578|NCT00811473|EXPERIMENTAL|Quetiapine XR|
62361650|NCT03154177|EXPERIMENTAL|Group Care + Ultrasound+Pregnancy Testing|Group ANC and PNC care, in combination with early pregnancy testing and ultrasound.
62567096|NCT02933385|EXPERIMENTAL|Moderate lifestyle program|Participants receive some intervention tools that aimed to enhance lifestyle profile.
62567097|NCT02933385|EXPERIMENTAL|Light lifestyle program|Participants receive little intervention tools that aimed to enhance lifestyle profile.
62567098|NCT02933385|NO_INTERVENTION|Control group|Participants receive none of the intervention tools that aimed to enhance lifestyle profile.
62567099|NCT04767841|EXPERIMENTAL|Metformin|Metformin 1000 mg daily plus Celecoxib 200mg capsule
62567100|NCT04767841|EXPERIMENTAL|Placebo|Placebo tablet daily plus Celecoxib 200mg capsule
62169307|NCT02261545|PLACEBO_COMPARATOR|Placebo|patients with Type II Diabetes who receive 3 cap of placebo/ for 10 weeks.
62361651|NCT06285188||Cohort of patients with mold invasive fungal infection|Patients \>18 y, with a diagnosis of proven or probable mold invasive fungal infection (Aspergillus, Mucorales, Fusarium or Scedosporium), according to modified 2019 EORTC/MGS criteria, at diagnosis or at a refractory state after a first-line antifungal treatment
62361652|NCT01405378|EXPERIMENTAL|Robot Therapy and Real Transcranial Direct Current Stimulation|This group will involve carrying out robot therapy and real transcranial Direct Current Stimulation (tDCS).
62361653|NCT01405378|PLACEBO_COMPARATOR|Robot Therapy and sham tDCS|Participants will be randomised to group 2 whereby they will carry out the same robot therapy programme however, receiving sham stimulation.
62567101|NCT00758901||1 ROCC Knee prosthesis|Consecutive series of patients with ROCC Knee prosthesis.
62361654|NCT03450993|EXPERIMENTAL|Immediate SMART Program Intervention|Subjects will receive the SMART-3RP intervention following study enrollment.
61981579|NCT00811473|PLACEBO_COMPARATOR|Placebo|
62361655|NCT03450993|OTHER|Delayed SMART Program Intervention|Subjects will record symptoms following enrollment and receive the SMART-3RP intervention approximately 3 months following study enrollment.
62361656|NCT01819441|SHAM_COMPARATOR|Normal Azelnidipine/Perindopril|Systole blood pressure controlled between 130 mmHg\~140 mmHg(with or without hydrochlorothiazide).
62361657|NCT01819441|EXPERIMENTAL|Intensive Azelnidipine/Perindopril|Systole blood pressure controlled below 130 mmHg(with or without hydrochlorothiazide).
62361658|NCT02019745||LAIV (FluMist)|All subjects will receive a 0.2 mL dose of LAIV (FluMist) once during the study.
62361659|NCT03253133|EXPERIMENTAL|Oxaliplatin|"IP neoadjuvant chemotherapy protocol:~Oxaliplatine will be administered in IP in a total solution of 2L of serum G5%. A continuous infusion pump of Oxycodone would be administered for the entire duration of the intraperitoneal chemotherapy. Perfusion time for the intraperitoneal chemotherapy is estimated but not limited to one and a half hour.~Intravenous chemotherapy protocol:~Associated Intravenous (systemic) chemotherapy is administered during IP chemotherapy including at least LVFU2 (5FU-Leucovorin) or FOLFIRI (5FU-Irinotecan) regimens and targeted therapy if needed."
62361660|NCT03476434|NO_INTERVENTION|group A (HR-WLE)|Two tandem colonoscopies: first inspection was on high-resolution white-light endoscopy from the cecum/ileo-colonic anastomosis to the rectum, followed by a second inspection also on HR-WLE.
62361661|NCT03476434|EXPERIMENTAL|group B (HR_CE)|two tandem colonoscopies: first inspection was on HR-WLE from the cecum/ileo-colonic anastomosis to the rectum, followed by a second inspection with panchromoendoscopy on indigo carmine.
61981580|NCT02755766||Clubfeet|Babies, ages 0-1, with a diagnosis with clubfoot or clubfeet who are beginning treatment with foot abduction bracing following casting treatment.
61981581|NCT02755766||Adolescent Idiopathic Scoliosis|Patients, ages 10-14, with a diagnosis of AIS who are beginning treatment with TLSO (initial bracing).
61981582|NCT02755766||Guardians (CF babies)|Clubfoot patients' guardians.
61981583|NCT03849859|ACTIVE_COMPARATOR|Single plastic stent|Deployment of single plastic stent
61981584|NCT03849859|ACTIVE_COMPARATOR|Multiple plastic stents|Deployment of multiple plastic stent
61981585|NCT02684266|EXPERIMENTAL|SHR6390|Each subject will receive a single dose of SHR6390 and then repeat doses following a 3 week/1 week off regimen
61981586|NCT02254928|OTHER|Group 1|First stimulation cycle with corifollitropin alfa (experimental) Second stimulation cycle with rFSH and HMG (active comparator)
61981587|NCT02254928|OTHER|Group 2|First stimulation cycle with rFSH and HMG (active comparator) Second stimulation cycle with corifollitropin alfa (experimental)
61981588|NCT01578395|EXPERIMENTAL|N-acetylcysteine|This arm consists of 30 patients who will receive 1200mg n-acetylcysteine dissolved in 50ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
61981589|NCT01578395|EXPERIMENTAL|Ascorbic acid|This arm consists of 30 patients who will receive 3000 mg ascorbic acid dissolved in 50 ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
61981590|NCT01578395|PLACEBO_COMPARATOR|Sodium Chloride (NaCl)|This arm consists of 30 patients who will receive 50 ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
61981591|NCT00571987|OTHER|1|This is a non-randomized one arm study, all subjects receive treatment (radiofrequency ablation).
61981592|NCT05157490|EXPERIMENTAL|Mindfulness training|Completion of guided meditations in the preoperative time period, at least 3 sessions per week, leading up to surgery
61981593|NCT05157490|NO_INTERVENTION|Control|
61981594|NCT03303079|EXPERIMENTAL|TEV-48125 (675/225/225 mg) group|TEV-48125 will be subcutaneously administered once monthly for 3 months (675/225/225 mg).
62361662|NCT01263444|EXPERIMENTAL|Azarga|Brinzolamide 1% / timolol 0.5% Fixed Combination administered as 1 drop in study eye(s) twice a day (8:00 AM and 8:00 PM) for 12 weeks, at a 5 minute interval from the habitual prostaglandin monotherapy.
62361663|NCT05235100|EXPERIMENTAL|Apatinib arm|Apatinib 500mg QD, used 2 weeks prior to IMRT, concurrent with pre-operative IMRT, and 1 month after end of IMRT
62361664|NCT03392441|EXPERIMENTAL|Insulin Deprivation|Insulin Deprivation in Type 1 Diabetic Patients will be performed for a short time period (4-6 hours). Changes to Age, Sex, and Gender matched controls will be compared.
62361665|NCT02452749|EXPERIMENTAL|Cardiovascular Health Dietary Supplement|The cardiovascular health dietary supplement will be administered at a dosage of 1 caplet po per day for a period of 6 months
62361666|NCT03012542|EXPERIMENTAL|Diet 1|Administered for 8 weeks.
62361667|NCT03012542|EXPERIMENTAL|Diet 2|Administered for 8 weeks.
62361668|NCT00033592|EXPERIMENTAL|Arm I: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day. Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm I who continue to smoke are randomized to one of two treatment arms Arm IV or Arm V. Participants randomized to arm I who are smoke-free are randomized to one of two treatment arms Arm VIII or Arm IX."
62361669|NCT00033592|EXPERIMENTAL|Arm II: bupropion|"Participants receive oral bupropion 1-2 times daily.~Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm II who continue to smoke are randomized to one of two treatment arms Arm VI or Arm VII. Participants randomized to arm II who are smoke-free are randomized to one of two treatment arms Arm Arm X or Arm XI."
62361670|NCT00033592|EXPERIMENTAL|Arm III: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral bupropion 1-2 times daily. Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm III who continue to smoke do not receive any further therapy. Participants randomized to arm III who are smoke-free are randomized to one of four treatment arms Arm XII, Arm XIII, Arm XIV or Arm XV."
62361671|NCT00033592|EXPERIMENTAL|Arm IV: bupropion|"Participants receive oral bupropion 1-2 times daily for 12 weeks.~All participants are followed every month for 6 months."
62361672|NCT00033592|PLACEBO_COMPARATOR|Arm V: placebo|"Participants receive oral placebo 1-2 times daily for 12 weeks.~All participants are followed every month for 6 months."
62361673|NCT00033592|EXPERIMENTAL|Arm VI: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day for 12 weeks.~All participants are followed every month for 6 months."
62361674|NCT00033592|PLACEBO_COMPARATOR|Arm VII: placebo inhaler|"Participants receive 6-16 placebo inhaler cartridges per day for 12 weeks.~All participants are followed every month for 6 months."
62361675|NCT00033592|EXPERIMENTAL|Arm VIII: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day for 40 weeks.~All participants are followed every month for 6 months."
62361676|NCT00033592|PLACEBO_COMPARATOR|Arm IX: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day for 40 weeks.~All participants are followed every month for 6 months."
62361677|NCT00033592|EXPERIMENTAL|Arm X: bupropion|"Participants receive oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
62361678|NCT00033592|PLACEBO_COMPARATOR|Arm XI: placebo|"Participants receive oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
62361679|NCT00033592|EXPERIMENTAL|Arm XII: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
62361680|NCT00033592|PLACEBO_COMPARATOR|Arm XIII: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day and oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
61981595|NCT03303079|EXPERIMENTAL|TEV-48125 (675 mg/placebo/placebo) group|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/ placebo/placebo).
61981596|NCT03303079|PLACEBO_COMPARATOR|Placebo group|Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).
61981597|NCT05487326|ACTIVE_COMPARATOR|high thoracic ESPB group|Group where ESPB is performed at T2 with local anesthetic mixture 20 ml
61981598|NCT05487326|ACTIVE_COMPARATOR|cervical epidural group|Group where cervical epidural injection is performed at C6-7 or C7-T1 level
61981599|NCT01982747|OTHER|MGN - Placebo|Subjects of the MGN-Placebo arm will receive 60mg MGN1703 as 2 s.c. injections of 2 ml each during period 1 and physiological saline solution as Placebo as 2 s.c. injections of 2 ml each during period 2
61981600|NCT01982747|OTHER|Placebo-MGN|Subjects of the Placebo-MGN arm will receive physiological saline solution as Placebo as 2 s.c. injections of 2 ml each during period 1 and 60mg MGN1703 as 2 s.c. injections of 2 ml each during period 2
62361681|NCT00033592|EXPERIMENTAL|Arm XIV: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
62361682|NCT00033592|PLACEBO_COMPARATOR|Arm XV: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
61981601|NCT04039412|ACTIVE_COMPARATOR|(1) Hybrid regimen|omeprazole 20mg bid, and amoxicillin 1gm bid in the 1st week, then clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid in the 2nd week.
61981602|NCT04039412|ACTIVE_COMPARATOR|(2) Reverse hybrid regimen|clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid for 1 week, followed by omeprazole 20mg bid, and amoxicillin 1gm bid in the 2nd week.
61981603|NCT04039412|ACTIVE_COMPARATOR|(3) Levofloxacin quadruple regimen|levofloxacin 250mg QD, omeprazole 40mg QD, nitazoxanide 500mg bid, and doxycycline 100mg QD for 10 days. (LOAD)
62361683|NCT06233214|EXPERIMENTAL|vein imaging device|"During the PIC application attempt, the parents of the children in the experimental group will be ensured to be with their children throughout the procedure.~PIC placement attempt will be performed on the experimental group with the help of a vein imaging device."
61981604|NCT03070379|EXPERIMENTAL|Experimental group|Topical lidocaine pharyngeal anesthesia was performed.
61981605|NCT03070379|NO_INTERVENTION|Control group|No topical lidocaine pharyngeal anesthesia was performed.
61981606|NCT03192943|EXPERIMENTAL|Dose Escalation|monotherapy and combination therapy
61981607|NCT06459843|EXPERIMENTAL|pursed lip breathing techniques|Pursed lip breathing with aerobic exercise for 4 times per week for 4 week and duration will be 45-60 min. Relax your neck and shoulder muscles. For the use of PLB exercise, the intervention will be given every day till the patient discharged from hospital. Patient will perform 5 sets
61981608|NCT06459843|ACTIVE_COMPARATOR|coordinated breathing technique|The intervention will be given un every day till the patient discharge from hospital. Coordinated breathing with aerobic exercise for 4 times per week for 4 weeks. And duration will be 45-60 min
61981609|NCT04124289||Pain post surgery|Patients who have completed surgery will be assessed with three types of pain scales. A new pain scale, a functional pain scale (FPS), will be compared to two pain scales that are routinely used: the FACES pain scale and the numeric rating scale (NRS).
61981610|NCT00680745|EXPERIMENTAL|1|dapagliflozin 2.5mg + Glimepiride
61981611|NCT00680745|EXPERIMENTAL|2|dapagliflozin 5mg + Glimepiride
61981612|NCT00680745|EXPERIMENTAL|3|dapagliflozin 10mg + Glimepiride
61981613|NCT00680745|PLACEBO_COMPARATOR|4|Placebo + Glimepiride
61981614|NCT04814225|EXPERIMENTAL|Pea Protein Powder|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
62361684|NCT06233214|NO_INTERVENTION|control group|PIC placement attempt will be performed in the control group using the traditional application method without device support.
62361685|NCT02566109|OTHER|Fast MRI|All patients who agree to participate in this study will have a 10 minute fast MRI scan and Baseline and 6 month time periods. The fast MRI will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
62361686|NCT00651313|ACTIVE_COMPARATOR|Active|Lidocaine 10% (150mg) vaginal gel
62361687|NCT00651313|PLACEBO_COMPARATOR|Placebo|Placebo vaginal gel
62361688|NCT04798846|ACTIVE_COMPARATOR|External fixator|patient treated by external fixator
62361689|NCT04798846|ACTIVE_COMPARATOR|Dorsal plate|patient treated by dorsal spanning plate
62739158|NCT04171635||Healthy subjects|Healthy control subjects over the age of 21 with no known hematological or liver disease and no contraindications for MRI
62739159|NCT01419379||1|
62361690|NCT01955395|ACTIVE_COMPARATOR|Immediate Group|If the participant is assigned to the Immediate Group, the participant will immediately receive the Relaxation Response Resiliency Program (3RP) intervention (3 months), followed by 3 months of continuing to practice what the participant learned during the intervention.
62361691|NCT01955395|ACTIVE_COMPARATOR|Waitlist Group|If the participant is assigned to the Waitlist Group, the participant will wait for 3 months and then receive the full Relaxation Response Resiliency Program (3RP) intervention (3 months).
62361692|NCT01106391|EXPERIMENTAL|AAA stent graft system|"Cordis AAA stent graft system INCRAFT TM"
62361693|NCT02880462|ACTIVE_COMPARATOR|high dose sulforaphane|The goal of the study is to investigate whether adding high doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia.
62361694|NCT02880462|ACTIVE_COMPARATOR|low dose sulforaphane|The goal of the study is to investigate whether adding low doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia.
62361695|NCT02880462|PLACEBO_COMPARATOR|placebo|The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
61981615|NCT04814225|EXPERIMENTAL|Pea & Oat Protein Powder|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
62361696|NCT05625880|EXPERIMENTAL|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|There is only one arm in this study which is to enable high qualitative estimation of bilirubin levels in the blood of new-borns using Picterus JP.
62361697|NCT02561780|ACTIVE_COMPARATOR|Curriculum|"The curriculum is a mental health literacy resource designed to inform high school curricula and contains six distinct modules: 1) stigma of mental illness; 2) understanding mental health and mental illness; 3) information on specific mental illnesses; 4) experiences of mental illness; 5) seeking help and finding support; and 6) the importance of positive mental health.~A research assistant trained teachers on The Curriculum Guide content in a half-day session. Teachers implemented The Curriculum Guide, which requires approximately 6 hours of classroom time, during regular instruction of the Healthy Living course."
62361698|NCT02561780|ACTIVE_COMPARATOR|Curriculum +eLearning Follow-up|"The curriculum is a mental health literacy resource designed to inform high school curricula and contains six distinct modules: 1) stigma of mental illness; 2) understanding mental health and mental illness; 3) information on specific mental illnesses; 4) experiences of mental illness; 5) seeking help and finding support; and 6) the importance of positive mental health.~A research assistant trained teachers on The Curriculum Guide content in a half-day session. Teachers implemented The Curriculum Guide, which requires approximately 6 hours of classroom time, during regular instruction of the Healthy Living course. Students are asked to complete follow-up modules online. These modules are only accessible after completion of the Healthy Living course."
62361699|NCT02561780|NO_INTERVENTION|Teaching As Usual (Control)|Schools randomized to this arm of the study received the unadulterated Healthy Living course, taught as usual.
61981616|NCT04814225|EXPERIMENTAL|Oat Protein Powder|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
61981617|NCT04814225|ACTIVE_COMPARATOR|Whey Protein Isolate|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
61981618|NCT04615923|EXPERIMENTAL|Pridopidine|Pridopidine is administered orally twice daily for 24 weeks.
61981619|NCT04615923|PLACEBO_COMPARATOR|Matching Placebo|Matching placebo is administered orally twice daily for 24 weeks.
61981620|NCT01305850|ACTIVE_COMPARATOR|Aliskiren|
61981621|NCT01305850|ACTIVE_COMPARATOR|Aliskiren plus Losartan|
61981622|NCT01305850|ACTIVE_COMPARATOR|Enalapril plus Losartan|
61981623|NCT01305850|PLACEBO_COMPARATOR|placebo|
61981624|NCT05254457|NO_INTERVENTION|Observation Only Group|
61981625|NCT05254457|EXPERIMENTAL|Treated or Retreated Group|
61981626|NCT04829565|EXPERIMENTAL|botulinum toxin|50 IU of botulinum toxin
61981627|NCT04829565|PLACEBO_COMPARATOR|placebo|50 IU of placebo
61981628|NCT05400954||Reconstruction with silicone breast implant|The cohort will be composed of women who underwent surgery for first invasive breast cancer or ductal carcinoma in situ (DCIS) in the years 2000 to 2015 in the collaborating centres. Eligible for inclusion in the exposed group are all women who underwent (i) mastectomy followed by immediate implant-based reconstruction, (ii) mastectomy followed by implant-based reconstruction at a later stage and (iii) latissimus dorsi flap reconstruction with a silicone breast implant
61981629|NCT05400954||Breast cancer surgery without silicone breast implant|. Eligible for inclusion in the comparison group are women who underwent (i) simple mastectomy without reconstruction, (ii) autologous reconstruction and (iii) breast conserving surgery. From the latter group a frequency-matched sample will be selected based on age at breast cancer diagnosis and calendar year of diagnosis.
61981630|NCT05400954||cosmetic breast augmentation|. Women who underwent cosmetic augmentation in the years 2000 to 2015 constitute a second comparison group. From this group a frequency-matched sample will be selected based on age and year of surgery.
61981631|NCT02173912|EXPERIMENTAL|Sequence 1|"Single-dose crossover~1. Test: CJ-30059~2. Reference: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg~Once daily Oral administration with at least 14 days of washout period"
61981632|NCT02173912|EXPERIMENTAL|Sequence 2|"Single-dose crossover~1. Reference: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg~2. Test: CJ-30059~Once daily Oral administration with at least 14 days of washout period"
61981633|NCT00179400|ACTIVE_COMPARATOR|Pioglitazone|
61981634|NCT00179400|PLACEBO_COMPARATOR|Placebo|
61981635|NCT02794103|EXPERIMENTAL|Virtual Reality Distraction|The child will visualize and interact with the virtual environment throughout the hydrotherapy session.
61981636|NCT03448822||sentinel node procedure|a robot-assisted laparoscopic sentinel node procedure.
61981637|NCT04090645|OTHER|TheraShere in treatment of primary & secondary liver carcinoma|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with a relatively limited concurrent injury to surrounding normal tissue.
61981638|NCT01537029|EXPERIMENTAL|Doxorubicin and cyclophosphamide|
61981639|NCT01996826|ACTIVE_COMPARATOR|Avastin® (bevacizumab)|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
61981640|NCT01996826|PLACEBO_COMPARATOR|0.9% NaCl & Refresh Liquigel|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% NaCl. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
61981641|NCT04447079||'Before' and 'After' Arm|"Before Arm - This refers to the rate of Emergency Department visits in the pre-intervention period (12 months).~After Arm - This refers to the rate of Emergency Department visits in the post-intervention period (12 months) following the START of intervention."
61981642|NCT00196716|EXPERIMENTAL|Fabrazyme|Open-label study. Patients received 1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months.
61981643|NCT05390944|EXPERIMENTAL|IMP4297 first 5*20mg then 10*10mg|Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
61981644|NCT05390944|EXPERIMENTAL|IMP4297 first 10*10mg then 5*20mg|Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
61981645|NCT03582020|PLACEBO_COMPARATOR|Traditional Western Diet|Intervention: Menu plans and recommendations for persons who consume a traditional Western diet (daily consumption of meat and sausage)
61981646|NCT03582020|ACTIVE_COMPARATOR|Flexitarians|Intervention: Menu plans and recommendations for persons, who rarely consume meat and meat products (predominantly high-quality products; ≤ 2 times / week) = flexitarians
61981647|NCT03582020|ACTIVE_COMPARATOR|Vegetarians|Intervention: Menu plans and recommendations for persons who do not eat meat and sausage (vegetarians)
61981648|NCT03582020|ACTIVE_COMPARATOR|Vegans|Intervention: Menu plans and recommendations for persons who do not eat products from animal origin (vegans)
61981649|NCT04830787||hypertrophic cardiomyopathy|patients with hypertrophic cardiomyopathy
61981650|NCT04830787||control without hypertrophic cardiomyopathy|controls without hypertrophic cardiomyopathy
61981651|NCT06064474|EXPERIMENTAL|High ventilation breathwork with retention (HVBR)|Guided audio of HVBR pre-recorded by a trained breathwork facilitator for \~20min/day over 21 days (three weeks). Delivered remotely through audio link, comprising evocative music and four rounds of hyperventilation with four separate retentions (breath holds), progressively increasing in length (from \~45seconds up to \~90 seconds).
61981652|NCT06064474|PLACEBO_COMPARATOR|Placebo HVBR|Guided audio of placebo HVBR pre-recorded by a trained breathwork facilitator for \~20min/day over 21 days (three weeks). Delivered remotely through audio link, comprising music and four rounds of paced breathing at 15b/min (equal inhale:exhale) with four separate brief retentions, progressively increasing in length (from \~10secs to \~25secs).
61981653|NCT02621411||Substance abuser group|After preoperative screen by application of ICG test cassette, this group of patients are found current use of the certain substance(s).
61981654|NCT02621411||Non-substance abuser group|After preoperative screen by application of ICG test cassette, this group of patients are not found use of any substance.
61981655|NCT01974583||the treatment group A|The people in treatment group were regrafted with thin split-thickness skin graft
61981656|NCT01974583||the control group B|The group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith \& Nephew)
61981657|NCT01974583||the control group C|Group C were covered with paraffin gauze
61981658|NCT03109574|OTHER|Standard of Care Device|Current standard of care polyurethane catheter used at the hospital
62567102|NCT02360969||healthy subjects waiting for surgery|patients for whom surgery under general anesthesia with administration of curare is planned will be offered an examination of the eyes before and during surgery
61981659|NCT03109574|OTHER|Study Device|BioFlo DuraMax Chronic Hemodialysis Catheter
61981660|NCT06228040|ACTIVE_COMPARATOR|Before preanaesthetic teleconsultation implementation|
61981661|NCT06228040|EXPERIMENTAL|After preanaesthetic teleconsultation implementation|
61981662|NCT03747432|EXPERIMENTAL|Propofol|Procedural sedation with propofol during the TAVR procedure (anticipated around 2 hours), dosage: 0,5-2,5 mg/kg/h for appropriate level of sedation - Ramsay sedation score 3-4)
61981663|NCT03747432|EXPERIMENTAL|Dexmedetomidine|Procedural sedation with dexmedetomidine during the TAVR procedure (anticipated around 2 hours), dosage: bolus of 0,5 mcg/kg during 10 minutes, then continuous infusion of 0,2-1 mcg/kg/h for appropriate level of sedation - Ramsay sedation score 3-4)
61981664|NCT02391155|ACTIVE_COMPARATOR|single lumen|Single lumen needle in oocyte retrieval
61981665|NCT02391155|ACTIVE_COMPARATOR|double lumen|Double lumen needle with follicle flushing during oocyte retrieval
61981666|NCT05397665|ACTIVE_COMPARATOR|AT-007|AT-007 is an Aldose reductase inhibitor
61981667|NCT05397665|SHAM_COMPARATOR|Placebo|Is an non-active control
62169308|NCT04330261||SARS-CoV-2 Positive Children|All children screened for SARS-CoV-2 and presenting to participating sites will be enrolled in this study. Children who are eventually test-positive for SARS-CoV-2 will be considered the exposed group in this study. These children will have exactly the same prospective follow-up as the other group.
62169309|NCT04330261||SARS-CoV-2 Negative Children|All children screened for SARS-CoV-2 and presenting to participating sites will be enrolled in this study. Children who are eventually test-negative for SARS-CoV-2 will be considered the unexposed (control) group in this study. These children will have exactly the same prospective follow-up as the other group.
62567103|NCT01237171||Sub-lobar resection with Cesium-131|All enrolled patients will undergo sub-lobar resection and brachytherapy implant with Cesium-131 in an effort to study and quantify recurrence/control patterns.
62567104|NCT01026519|EXPERIMENTAL|Dose 1|Active dose
61981668|NCT02529618||Football Athlete Group|"All football athlete participants in this arm will take the integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT) test. Participants who sustain a concussion during the football season will complete the iDETECT test and a standing balance test (BESS assessment) four times after injury. Participants in this arm are eligible to receive the Riddell High Impact Technology (HIT) System or the i1 Biometrics Vector Mouth Guard.~NOTE: Football athletes who sustain a concussion during the football season will be evaluated and managed according to standard concussion screening and return-to-play (RTP) protocols. Performance on iDETECT or other study related tasks will NOT be used to make diagnosis, management, or return to play decisions. Study staff will not assist with or influence diagnosis, management, or return-to-play decision making by teams' medical personnel."
62361700|NCT03648463|EXPERIMENTAL|arthroscopy with removal of calcified cartilage|This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) along with removal of the calcified cartilage layer. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
62361701|NCT03648463|ACTIVE_COMPARATOR|arthroscopy without removal of calcified cartilage|This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) but with retention of the calcified cartilage cap. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
62361702|NCT04374201||2 zirconia FDPs|11 patients received 2 zirconia fixed dental prostheses
62361703|NCT04374201||1 zirconia FDP|26 patients received 1 zirconia FDP
61981669|NCT02529618||Non-Collision Sport Athlete Group|"Non-collision sport athletes who are active in a school's Fall athletic program will be take the integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT) test, standing balance test (BESS assessment), and complete a questionnaire at the beginning of the sport season. Participants will be asked to take the iDETCT test up to 5 more times during the season. Participants who sustain a concussion during the athletic season will be asked to take additional iDETECT tests four times after the injury.~NOTE: Non-collision sport athletes who sustain a concussion during the season will be evaluated and managed according to standard concussion screening and return-to-play (RTP) protocols. Performance on iDETECT or other study related tasks will NOT be used to make diagnosis, management, or return to play decisions. Study staff will not assist with or influence diagnosis, management, or return-to-play decision making by teams' medical personnel."
61981670|NCT05195463|EXPERIMENTAL|First group|Core stabilization exercises
61981671|NCT05195463|EXPERIMENTAL|Second group|Combination of core stabilization and abdominal corset
61981672|NCT05195463|EXPERIMENTAL|Third group|Only abdominal corset
61981673|NCT03195088|PLACEBO_COMPARATOR|Placebo|Healthy participants were administered a single dose of placebo matching BI 473494 solution via subcutaneous injection.
61981674|NCT03195088|EXPERIMENTAL|BI 473494 35 μg|Healthy participants were administered a single dose of 35 micrograms (μg) BI 473494 solution via subcutaneous injection.
61981675|NCT03195088|EXPERIMENTAL|BI 473494 75 μg|Healthy participants were administered a single dose of 75 micrograms (μg) BI 473494 solution via subcutaneous injection.
61981676|NCT02169739|NO_INTERVENTION|Medical therapy only|Intensive standard medical secondary prevention stroke treatment as per the recommendations of the American Heart Association/American Stroke Association national guidelines.
61981677|NCT02169739|ACTIVE_COMPARATOR|Ischemic Preconditioning + Medical|Patients will receive treatment with Cell Aegis remote ischemic preconditioning device once or twice daily for one year. The procedure will consist of up to four 5-minute cycles of bilateral upper extremity ischemia separated by five minutes of reperfusion. Patients will also receive intensive standard medical secondary prevention stroke treatment as per the American Heart Association/American Stroke Association national guidelines.
61981678|NCT03446742||Cardiovascular rehabilitation group|Initially all patients will have their charts analyzed, from which data will be extracted for characterization of the population, and anthropometric data will be measured for calculation of body mass index. Afterwards, patients will have their clinical, physical and biochemical parameters. They will be followed up for a period of 2 months during the routines of the cardiovascular rehabilitation sessions for assessment of signs and symptoms. In the second stage the patients will perform the normal routines of their cardiovascular rehabilitation program for a period of 6 months. In the third stage, patients will have their clinical, physical and biochemical parameters and then followed up for another 2 months during the routines of the sessions of the cardiovascular rehabilitation program to evaluate signs and symptoms, which will allow to evaluate if gains/losses in the physical parameters can exert influences in the appearance of signs and symptoms during the sessions.
61981679|NCT02135146|ACTIVE_COMPARATOR|Plasmalyte 3ml/kg/hr group|
61981680|NCT02135146|ACTIVE_COMPARATOR|Plasmalyte 6ml/kg/hr group|
61981681|NCT04139187|EXPERIMENTAL|Experimental|Individuals randomized to experimental group.
61981682|NCT04139187|NO_INTERVENTION|No Intervention Control|Individuals without quadriceps dominance randomized to no intervention group.
61981683|NCT00746642|EXPERIMENTAL|A|"Glucose measurements using Mellitor device."
61981684|NCT00746642|ACTIVE_COMPARATOR|B|"Glucose measurements conducted by using gold standard, Yellow Springs glucose analyzer"
62567105|NCT01026519|EXPERIMENTAL|Dose 2|Active dose
61981685|NCT00434655|ACTIVE_COMPARATOR|1 LAP BAND|
61981686|NCT00434655|EXPERIMENTAL|2 Sleeve gastrectomy|
62361704|NCT03261141||study group sixty three children|"1. severity and character of dysphonia APA using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~2. Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~3. the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
62567106|NCT01026519|EXPERIMENTAL|Dose 3|Active 3
62567107|NCT01026519|PLACEBO_COMPARATOR|Dose 4|Placebo dose
62739160|NCT04296305|EXPERIMENTAL|Group A (hydromorphone, placebo)|"TREATMENT PHASE I: Patients receive hydromorphone IV over 2 minutes and placebo IV over 15 minutes.~TREATMENT PHASE II: Patients receive hydromorphone IV over 15 minutes and placebo IV over 2 minutes."
62739161|NCT04296305|EXPERIMENTAL|Group B (hydromorphone, placebo)|"TREATMENT PHASE I: Patients receive hydromorphone IV over 15 minutes and placebo IV over 2 minutes.~TREATMENT PHASE II: Patients receive hydromorphone IV over 2 minutes and placebo IV over 15 minutes."
61981687|NCT06182826|EXPERIMENTAL|Group A|Patients in this group will receive Core Stability Protocol with Routine Exercise Protocol. A total of 3 sessions per week for 6 weeks will be given.
61981688|NCT06182826|ACTIVE_COMPARATOR|Group B|Patients will receive Routine Exercise Protocol. A total of 3 sessions per week for 6 weeks will be given.
61981689|NCT01953341|EXPERIMENTAL|AMG 333|Subjects will receive a single oral dose of AMG 333 .
61981690|NCT01953341|PLACEBO_COMPARATOR|Placebo|Subjects will receive a single oral dose of placebo.
61981691|NCT00067366|EXPERIMENTAL|Coping Skills Training|manualized coping skills training delivered along with conservative care
61981692|NCT00067366|ACTIVE_COMPARATOR|Standard Care|Attention and life counseling added to Standard conservative care
61981693|NCT03621852||Endoultrasound guided FNB|Patients with tumors of the pancreas, submucosal tumors or lymphnode disease of the upper gastrointestinal tract, which have to undergo EUS guided FNB.
61981694|NCT04130126|NO_INTERVENTION|Warm showers|Participants in the warm showers condition are instructed to continue their normal warm showers throughout the study
61981695|NCT04130126|EXPERIMENTAL|Cold showers|Participants in the cold showers condition will be asked to take cold showers over a time period of 3 months
61981696|NCT05973383||Intervention group- Basic|Subjects with behavioral support from the app LongLife Active®
61981697|NCT05973383||Intervention group- Standard|Subjects with behavioral support from the app LongLife Active® + social support
61981698|NCT05973383||Intervention group- Premium|Subjects with behavioral support from the app LongLife Active® + social support + individual coaching
61981699|NCT05973383||Control group|No exposure
61981700|NCT04899804||Validity and Reliability Group|This study will be completed in two phases. In the first phase, the participants included in the study will be evaluated first by tele-assessment. One hour later, all assessments will be repeated face-to-face procedures by the researchers; thus, the validity of the tele-assessment method will be determined. Before the tele-assessment, participants will be informed about having a chair whose floor-to-seat height is 48 cm and tape measure. In the second phase of the study, to determine the reliability of the tele-assessment method, all tests will be applied to the previously tested participant by the same researcher one week later and at the same time of the day using only the tele-assessment method.
61981701|NCT01463319|EXPERIMENTAL|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
61981702|NCT01463319|EXPERIMENTAL|air insufflation|air insufflation during insertion phase of colonoscopy
61981703|NCT02671591|EXPERIMENTAL|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP. The control condition is a one-hour, theory-based, one-to-one session that will help YBMSM think more about using condoms consistently and correctly with every sex partner.
61981704|NCT02671591|ACTIVE_COMPARATOR|control|"This condition will include the provision of free condoms and lubricants - selected from a buffet of condoms and lubricants designed to offer men a broad selection of high quality products that can optimize the fit and feel of condoms during sex."
61981705|NCT06027853|EXPERIMENTAL|CAR-NK cell therapy in Adult subjects with r/r AML|CAR-NK cell therapy in Adult subjects with r/r AML
61981706|NCT06317155||Young People|Young people who have a history of self-harm who have received an occupational therapy informed interventions from a Tier 4 CAMHS service within the last 12 months.
61981707|NCT06317155||Carers|The carers of a young person who has a history of self-harm, and who has received an occupational therapy informed interventions from a Tier 4 CAMHS service in the last 12 months.
61981708|NCT06317155||Healthcare Practitioners|Healthcare practitioners who have delivered or helped to facilitate an occupational therapy informed intervention whilst working for a Tier 4 CAMHS service, in the last 12 months.
61981709|NCT03477227|EXPERIMENTAL|Short stocking|After radiofrequency ablation of the GSF and phlebectomy varicose tributaries, patients will wear compression socks without foot for four weeks
61981710|NCT03477227|ACTIVE_COMPARATOR|Usual stocking|After radiofrequency ablation of the GSF and phlebectomy varicose tributaries, patients will wear usual compression socks for four weeks (usual care)
61981711|NCT02792556||patient having a drug abortion|Urine pregnancy test for adult women having a drug abortion until 8 weeks of amenorrhea, presenting to the control visit between the 14th and 21th day after drug intake.
61981712|NCT01519960|EXPERIMENTAL|A Pegasys|
61981713|NCT01519960|NO_INTERVENTION|B Untreated Control|
61981714|NCT01519960|EXPERIMENTAL|C Fibrosis non-randomized|
62169310|NCT05430607|EXPERIMENTAL|Intervention group|The intervention group will participate in a 9-week running program and will also continue their routine treatment program at the psychiatric ward.
62739162|NCT02904850||group of patients|Plasma dosage of erlotinib and OSI-420
61981715|NCT01519960|EXPERIMENTAL|Switch|
61981716|NCT04015245|EXPERIMENTAL|SNMC|
61981717|NCT04015245|NO_INTERVENTION|non-SNMC|
61981718|NCT01608659||botulinum toxin Type A|Previous treatment with botulinum toxin Type A for treatment of facial lines
61981719|NCT00878527|EXPERIMENTAL|Treatment with the pump|Treatment with the CircuLite Synergy Pocket Circulatory Assist Device
62169311|NCT05430607|NO_INTERVENTION|Control group|The control group will continue their routine treatment program at the psychiatric ward.
62169312|NCT06538727|EXPERIMENTAL|Group 1 - One session of OMT Intervention|Participants in the experimental condition will have one OMT treatment (Scapular Release) done to the upper back.
62739163|NCT05880849|EXPERIMENTAL|Choline|2.2 g of choline, given as choline bitartrate, for a total of 180 days.
62739164|NCT03981094|EXPERIMENTAL|BMS-986278|
61981720|NCT00484211|EXPERIMENTAL|A|
61981721|NCT05217329|EXPERIMENTAL|smart phone intervention group|smart phone intervention group stroke subjects completed smart phone App tasks with affected arm or bilateral arm movement
61981722|NCT05217329|ACTIVE_COMPARATOR|conventional group|stroke subjects receive conventional rehabilitation home program
61981723|NCT05526612|ACTIVE_COMPARATOR|Group 1|Motor imagery and Bobath Therapeutic Approach (BTA+MI)
61981724|NCT05526612|EXPERIMENTAL|Group 2|Motor imagery, Bobath Therapeutic Approach and Physical practice (BTA+MI+PP)
61981725|NCT03179995|EXPERIMENTAL|Octreotide treatment arm|Octreotide will be administered post-operatively until day 5
62739165|NCT03981094|EXPERIMENTAL|Pirfenidone|
62739166|NCT03981094|EXPERIMENTAL|BMS-986278 + Pirfenidone|
61981726|NCT03179995|PLACEBO_COMPARATOR|Placebo Arm|Normal saline will be administered post-operatively until day 5
61981727|NCT01541774|EXPERIMENTAL|Phoenix Atherectomy System|
61981728|NCT01165554|EXPERIMENTAL|[18F] Flutemetamol|
61981729|NCT01525043|ACTIVE_COMPARATOR|Naproxen|
61981730|NCT01525043|EXPERIMENTAL|Synera single patch applied for 12 hrs/day|
61981731|NCT01525043|EXPERIMENTAL|Synera sinlgle patch applied for 4hrs twice daily|
62361705|NCT03261141||control group sixty three children|"1. severity and character of dysphonia (APA using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~2. Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~3. the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
61981732|NCT03649685|ACTIVE_COMPARATOR|Group1: rTMS(bilateral SMA)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
61981733|NCT03649685|EXPERIMENTAL|Group2: rTMS(right DLPFC)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right DLPFC once a day, 5 days/week, for 4 weeks.
61981734|NCT03649685|EXPERIMENTAL|Group3: rTMS(right DLPFC+bilateral SMA)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right DLPFC and bilateral SMA once a day, 5 days/week, for 4 weeks.
61981735|NCT03649685|SHAM_COMPARATOR|Group4: shame rTMS|The sham rTMS will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
61981736|NCT00016146|EXPERIMENTAL|vaccine|"This is a dose-escalation study of GPI-0100.~Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant GPI-0100 subcutaneously weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity or disease progression.~Cohorts of 5 patients receive escalating doses of GPI-0100 until the optimal dose, based on antibody response, is reached.~Patients are followed every 3 months."
61981737|NCT05089227|EXPERIMENTAL|"intervention group"|
61981738|NCT05089227|ACTIVE_COMPARATOR|"standard group"|
61981739|NCT06096220|EXPERIMENTAL|Experimental group|Enucleation of OKC followed by local application of 5% 5-fluorouracil cream. Drug will be applied on the gauze left in the enucleation defect for 24 hours, after which the gauze will be removed.
61981740|NCT06096220|ACTIVE_COMPARATOR|Control group|Enucleation of OKC followed by local application Carnoy solution. Carnoy solution will be applied into the cystic cavity for 5 minutes and bone defect will be treated by Carnoy solution for 3 minutes immediately after the enucleation.
61981741|NCT02935322|ACTIVE_COMPARATOR|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|A mouthrinse combining chlorhexidine and NaF
61981742|NCT02935322|ACTIVE_COMPARATOR|0.2 % NaF mouthrinse|A mouthrinse containing NaF
61981743|NCT02935322|ACTIVE_COMPARATOR|0.12% chlorhexidine mouthrinse|A mouthrinse containing chlorhexidine
61981744|NCT02935322|PLACEBO_COMPARATOR|Placebo mouthrinse|A mouthrinse containing all basic ingredients as the other three mouth rinses compared but without chlorhexidine and fluoride
61981745|NCT04634747|EXPERIMENTAL|PVX-410/pembrolizumab/chemotherapy|
61981746|NCT04859712||Trial group: 45 patients with lumbar disc herniation|"The Pulse Detection System of Sound Waves  was used to collect three parts and five layers of pulsed sound waves from the hands of 45 patients with lumbar disc herniation."
61981747|NCT04859712||Control group :45 relatively healthy people|"The Pulse Detection System of Sound Waves  was used to collect the three-parts and five-layers pulse sound waves of the hands of 45 relatively healthy people."
61981748|NCT02985229|EXPERIMENTAL|All participants|All participants in the study will be given the option of home administration of 200 mg oral mifepristone and 800 μg buccal misoprostol for medical abortion.
61981749|NCT02478801|EXPERIMENTAL|Endurance trained|subjects will receive different levels of amino acids intakes varying from 0.2 to 2.8 g/kg/day.
61981750|NCT03973840|EXPERIMENTAL|healthy men treatment arm|Subjects were given 15 doses over 8 days, and then blood was drawn into several types of collection tubes at different storage conditions.
61981751|NCT03611790|EXPERIMENTAL|Intervention|NeVa VS
61981752|NCT00438087|PLACEBO_COMPARATOR|2|placebo versus methylprednisolone
61981753|NCT00438087|EXPERIMENTAL|1|placebo versus methylprednisolone
61981754|NCT04111679|EXPERIMENTAL|Music|During laparoscopic task performance; participants will wear a noise cancelling headphone that plays music that is chosen by the participant.
61981755|NCT04111679|NO_INTERVENTION|No music|During laparoscopic task performance; participants will wear a noise cancelling headphone that does not play music.
61981756|NCT02732509||Lean|Body mass index less than 25 kg/m2
61981757|NCT02732509||Overweight/obese|Body mass index 25-45 kg/m2
61981758|NCT01963403|ACTIVE_COMPARATOR|EE 30mcg/LNG 150mcg|combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)
61981759|NCT01963403|PLACEBO_COMPARATOR|Placebo|Placebo
61981760|NCT02400502|EXPERIMENTAL|I-CAT Therapy|Integrated Coping and Awareness Therapy is a six-month intervention designed to examine the physiological, biological, and psychological effects of meditation and mindfulness practice on individuals diagnosed with a psychotic disorder.
61981761|NCT01106898|EXPERIMENTAL|Treatment (chemotherapy with or without maintenance therapy)|"SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity."
62169313|NCT06538727|NO_INTERVENTION|Group 2 - No intervention|Participants in the control condition will receive no treatment.
62361706|NCT04445012||Aortic Valve Stenosis (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mitral regurgitation, using the BSE gradings \[Wharton 2014\].
62361707|NCT04445012||Mitral Valve Regurgitation (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mitral regurgitation, using the BSE gradings \[Wharton 2014\].
61981762|NCT01857466|EXPERIMENTAL|Floseal|In the Floseal group, the sites of bleeding were covered with Floseal under direct vision with a laparoscopic applicator and ovarian cortex was closed on itself and waited for 2 minutes for Floseal to act. Then, subsequently bleeding sites were reexamined with irrigation.
61981763|NCT01857466|ACTIVE_COMPARATOR|Bipolar coagulation|In the bipolar group, hemostasis of the ovarian parenchyma was achieved with selective minimal (20-30 watt current) bipolar coagulation without excessive coagulation of surgical defect to avoid damaging the ovary.
61981764|NCT05022784||Idiopathic Pulmonary Fibrosis Patients|Medicare beneficiaries with IPF who newly initiated treatment with nintedanib
61981765|NCT03300479|EXPERIMENTAL|Clevidipine|The treatment starts at admission to the ICU for 24 hours with 2 mg to a maximum of 16 mg Clevidipine per hour infused intravenously and continuously to reach the systolic target pressure \< 160 mmHg (\>120 mmHg).
61981766|NCT03300479|ACTIVE_COMPARATOR|Urapidil|The treatment starts at admission to the ICU for 24 hours with 5 mg to a maximum of 40 mg Urapidil per hour infused intravenously and continuously to reach the systolic target pressure \< 160 mmHg (\>120 mmHg).
61981767|NCT01894854|NO_INTERVENTION|Stem collar|The stem has two versions, one with and one without a collar. This arm will have stems with a collar. The classical Furlong HAC had a collar.
61981768|NCT01894854|ACTIVE_COMPARATOR|No Stem collar|The stem has two versions, one with and one without a collar. This arm will have stems without a collar. The classical Furlong HAC had a collar.
61981769|NCT05749445||Nirmatrelvir-Ritonavir|Hospitalized patients receiving at least one dose Nirmatrelvir-Ritonavir
61981770|NCT02029833|EXPERIMENTAL|Regular Canola Oil|60% oleic acid
61981771|NCT02029833|EXPERIMENTAL|High Oleic Canola Oil|70% oleic acid
61981772|NCT02029833|ACTIVE_COMPARATOR|Western Type Diet - Common Dietary Oils|Ghee, Safflower oil, Coconut oil, \& flax oil
61981773|NCT02875860|OTHER|Standardized postnatal care (Expectant)|Mothers will be expectantly managed during pregnancies and babies receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website.
61981774|NCT02875860|EXPERIMENTAL|Prenatal Intervention (FETO)|Patients will undergo fetoscopic endoluminal tracheal occlusion and ideally prenatal reversal of the occlusion followed by standardized postnatal care as in the expectant . In this study FETO (where GoldBal2 detachable balloon and Baltaccidbpe100 Delivery Catheter are used) is to be done between 30 weeks plus 0 day and 31 weeks plus 6 days and removal of the balloon at 34 weeks plus 0 day to 34 weeks plus 6 days.
61981775|NCT03696914||Eosinophilic|Asthmatic patients showing 3% or more sputum eosinophils
61981776|NCT03696914||Non-eosinophilic|Asthmatic patients showing less than 3% sputum eosinophils
62361708|NCT04445012||Aortic Regurgitation (Adults)|30 patients with mild, 30 with moderate, and 30 with severe aortic regurgitation, using the BSE gradings \[Wharton 2014\].
62361709|NCT04445012||Mitral Stenosis (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mitral stenosis, using the BSE gradings \[Wharton 2014\].
61981777|NCT00602147||Retrospective sample|People who have been diagnosed with multiple myeloma and have received high-dose melphalan.
61981778|NCT00602147||Prospective sample|People who have been diagnosed with multiple myeloma and will be receiving high-dose melphalan.
61981779|NCT01053819|EXPERIMENTAL|Etanercept|open label treatment(50 mg SQ)per Food and Drug Administration approval for 24 weeks
61981780|NCT03945474|EXPERIMENTAL|OMT|Patients will receive a standardized protocol of: condylar decompression, Still's technique for the sternocleidomastoid, hyoid rebalancing and thoracic inlet myofascial release.
61981781|NCT03945474|SHAM_COMPARATOR|Sham|Patient will be treated in the supine position, with hands gently applied without pressure to the four areas: occiput, lateral cervical spine, hyoid area and thoracic inlet.
61981782|NCT04109755|EXPERIMENTAL|Experimental|Short Course Radiation Therapy (5 x 5 Gy in 1 week, SCRT) with 4 injections of Pembrolizumab starting on the first day of radiotherapy and surgery
61981783|NCT03092531|EXPERIMENTAL|Positive STEPS|"Step 1) all participants randomized to the experimental condition will receive low-intensity, daily two-way SMS texts of personalized reminders to take medications as prescribed (social-cognitive cues). If a participants demonstrates \>90% adherence they will remain on step one. Participants who continue to have difficulty adhering to their HIV medications at one month after baseline or anytime up to the end of month three (weeks five through twelve) will progress to Step 2) Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes."
61981784|NCT03092531|NO_INTERVENTION|Standard of Care|The standard health services offered at each site (e.g., mental health services, case management) and a brief adherence educational session. This will consist of a review of medications and recommended dosing (i.e., to understand regimen), adherence expectations, toxicity expectations and medication misperceptions.The participant will then view a 20-minute animated tutorial which explains the importance of adherence to antiretroviral medication effectiveness.
61981785|NCT02601950|EXPERIMENTAL|Open-label Tazemetostat|All cohorts will receive 800 mg oral Tazemetostat twice a day in continuous 28-day cycles.
61981786|NCT06313970|EXPERIMENTAL|QL1706+chemotherapy|"QL1706 administered by intravenous infusion, 5 mg/kg, administered once every 3 weeks, every 3 weeks as a cycle; Albumin paclitaxel administered by intravenous infusion, 125 mg/m2, administered on Days 1 and 8, 1 treatment cycle every 3 weeks; Gemcitabine IV infusion over 30 min, 1000 mg/m2, administered on Days 1 and 8, 1 treatment cycle every 3 weeks; On day 1 of each cycle, drugs were administered in the following order: ql1706 → albumin paclitaxel → gemcitabine.~The first dose was administered within 2 days of randomization, and subjects used the study drug until protocol-specified criteria for treatment termination were present."
62169314|NCT04486742|EXPERIMENTAL|Itch CBT Arm|Participants randomized to the Itch CBT Arm will participate in 4 weekly telehealth sessions with a therapist to address common areas of anxiety related to atopic dermatitis.
62361710|NCT04445012||Mixed Valve Disease (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mixed valve disease. Overall classification based on the most severe disease using the BSE gradings \[Wharton 2014\].
62361711|NCT04445012||Ventricular Septal Defects (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe ventricular septal defects, using gradings from \[Samaan 1970\].
62361712|NCT04445012||Aortic Stenosis (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe aortic stenosis
61981787|NCT06313970|EXPERIMENTAL|QL1706+chemotherapy+ bevacizumab|"QL1706 administered by intravenous infusion, 5 mg/kg, administered once every 3 weeks, every 3 weeks as a cycle; Bevacizumab administered by intravenous infusion, 7.5 mg/kg, administered once every 3 weeks, every 3 weeks as a treatment cycle; Albumin paclitaxel administered by intravenous infusion, 125 mg/m2, administered on Days 1 and 8, 1 treatment cycle every 3 weeks; Gemcitabine IV infusion over 30 min, 1000 mg/m2, administered on Days 1 and 8, 1 treatment cycle every 3 weeks; On day 1 of each cycle, drugs were administered in the following order: ql1706 → bevacizumab → albumin paclitaxel → gemcitabine.~The first dose was administered within 2 days of randomization, and subjects used the study drug until protocol-specified criteria for treatment termination were present."
61981788|NCT00605670||1|Postoperative Breast Surgery Patients
62361713|NCT04445012||Pulmonary Stenosis (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe pulmonary stenosis.
61981789|NCT00605670||2|Preoperative Breast Surgery Patients
61981790|NCT02533037|ACTIVE_COMPARATOR|Traditional Instability Tools|Participants will use traditional instability tools during the impairment-based rehabilitation intervention.
61981791|NCT02533037|EXPERIMENTAL|Ankle destabilization shoes|Participants will use ankle destabilization shoes during the impairment-based rehabilitation intervention.
61981792|NCT04465851|ACTIVE_COMPARATOR|FS65_Curc|Ferrous Sulphate (65 mg/day elemental iron) and Curcumin 500 mg/day
61981793|NCT04465851|PLACEBO_COMPARATOR|FS65_Plac|Ferrous Sulphate (65 mg/day elemental iron) and Placebo (Curcumin placebo \[cellulose\])
62361714|NCT04445012||Patent Ductus Arteriosus (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe patent ductus arteriosus, graded using ductal size \[Arlettaz 2017\].
62739167|NCT04188067|EXPERIMENTAL|PPA patients|All study participants will carry a diagnosis of Primary Progressive Aphasia (PPA), either the logopenic, the non-fluent variant or the semantic variant. All participants will receive the same study interventions in a within-subject crossover design.
61981794|NCT04465851|PLACEBO_COMPARATOR|FS0_Plac|Placebo (Ferrous Sulphate placebo \[cellulose\]) and Placebo (Curcumin placebo \[cellulose\])
61981795|NCT04465851|PLACEBO_COMPARATOR|FS18_Plac|Ferrous Sulphate (18 mg/day elemental iron) and Placebo (Curcumin placebo \[cellulose\])
61981796|NCT04465851|ACTIVE_COMPARATOR|FS18_Curc|Ferrous Sulphate (18 mg/day elemental iron) and Curcumin 500 mg/day
61981797|NCT05846906|EXPERIMENTAL|Sildenafil and clomiphene citrate|Oral Clomiphene citrate (Tecnovula®) 50 mg was taken twice daily by the experimental group from day 2 through day 7 of the cycle, and oral sildenafil (Respatio® 20mg for 5 days) was taken from the last day of menstruation until reaching ovulation.
61981798|NCT05846906|OTHER|clomiphene citrate alone|Oral Clomiphene citrate (Tecnovula®) 50 mg was taken twice daily by the control group from day 2 through day 7 of the cycle in addition to a placebo tablet.
61981799|NCT04416464||Pneumonia due to SARS-CoV-2 infection|Adult hospitalized patients with pneumonia due to proven or suspected SARS-Cov-2 infection.
61981800|NCT04905095|EXPERIMENTAL|EWS|Early Warning Score will be implemented in the computer system of the nursing station
61981801|NCT04905095|ACTIVE_COMPARATOR|Control|Nursing supervision will be carried out in the usual way.
61981802|NCT00830843|ACTIVE_COMPARATOR|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
61981803|NCT00830843|EXPERIMENTAL|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
61981804|NCT01116297|EXPERIMENTAL|Imaging with S-FLARE imaging system|3 patients to be imaged by S-FLARE imaging system.
61981805|NCT05805982|EXPERIMENTAL|Educational Video|"The patient will watch a 15-minute video on an electronic tablet that includes the following items:~* What is hereditary cancer?~* Inheritance risk~* Who are candidates for a genetic test?~* What is a genetic testing and how can it help?~* What types of results can be expected from genetic testing?~* Reactions to the result of the genetic test~* Clinical care according to the results~* Any common questions? When the patient finish watching the video, he/she would have the opportunity to resolve any doubts."
61981806|NCT05805982|ACTIVE_COMPARATOR|In-Person genetic counseling|"Patients will receive pre-test genetic counseling in person with a specialist using the usual protocols existing at the Institute and systematically includes the following:~Family history of cancer Personal cancer risk assessment Education on inheritance and disease expression Types of tests and results (positive, negative and variants of uncertain significance).~Limitations of the genetic study Preparation of possible outcomes according to results Risks Additional information: confidentiality of the results, costs and test options. Opportunity will be given to resolve doubts"
61981807|NCT05126784|EXPERIMENTAL|AVT03 Arm|AVT03 (denosumab) is the proposed biosimilar for Prolia (denosumab). Subjects in this arm will receive a single 60mg dose of AVT03 (denosumab) as a subcutaneous injection.
61981808|NCT05126784|ACTIVE_COMPARATOR|Prolia Arm|Prolia(denosumab) is the proposed comparator for AVT03 (denosumab). Subjects in this arm will receive a single 60mg dose of Prolia (denosumab) as a subcutaneous injection.
61981809|NCT05503147|EXPERIMENTAL|Sativex first (blinded) (3 dose of spray)|Trial day 1: Sativex (3 dose of spray x 2) Trial day 2: Placebo (3 dose of spray x 2) Trial day 3: Voluntary
61981810|NCT05503147|EXPERIMENTAL|Placebo first (blinded) (3 dose of spray)|Trial day 1: Placebo (3 dose of spray x 2) Trial day 2: Sativex (3 dose of spray x 2) Trial day 3: Voluntary
62361715|NCT04445012||No Disease (Paediatric Patients)|264 paediatric patients with no heart disease. Note that we are only taking recordings from those who have been referred for an echocardiogram with a suspected heart condition but are subsequently found to have no heart disease.
62361716|NCT03858296|EXPERIMENTAL|Emotional awareness|4 modules of emotional awareness training
62361717|NCT03858296|EXPERIMENTAL|Cognitive reappraisal|4 modules cognitive reappraisal training
62361718|NCT03858296|EXPERIMENTAL|Awareness + reappraisal|4 modules emotional awareness and cognitive reappraisal training
62361719|NCT01363258|EXPERIMENTAL|Care-resistant mouth care (MOUTh)|These nursing home residents with dementia receive mouth care from study personnel who use strategies to reduce care-resistant behavior (Managing Oral Hygiene Using Threat Reduction or MOUTh) while providing evidence-based mouth care.
62739168|NCT06095934|EXPERIMENTAL|Evaluate the efficacy and safety of neo-antigen peptide vaccine in the treatment of advanced NSCLC|
62739169|NCT00543933|EXPERIMENTAL|iNO administered|iNO administered at 40 ppm via a non-rebreather mask
62739170|NCT02812264|EXPERIMENTAL|API App|use of API weight loss mobile application for 12 months, plus fitness tracker and scale.
61981811|NCT02834533|ACTIVE_COMPARATOR|column heading in tables.|The group 1 (G1, n=20) underwent Lokomat-Nanos training. Each patient underwent 40 1h-training sessions (for 3 times a week). Both the study groups were treated by Lokomat (Hocoma Inc., Zurich, Switzerland), which includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . The overall duration of Lokomat therapy, including the time to get on and off, was 60min, while the robotic gait training lasted around 40min.
61981812|NCT02834533|ACTIVE_COMPARATOR|row and column in table|The group 2 (G2, n=20) underwent Lokomat-Pro training, with the same G1 sessions. The Pro device offers instead a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
61981813|NCT05878054|OTHER|Control period 2 months|2 months control period, followed by 12 months intervention, followed by 8 months observation
61981814|NCT05878054|OTHER|Control period 4 months|4 months control period, followed by 12 months intervention, followed by 6 months observation
61981815|NCT05878054|OTHER|Control period 6 months|6 months control period, followed by 12 months intervention, followed by 4 months observation
61981816|NCT05878054|OTHER|Control period 8 months|8 months control period, followed by 12 months intervention, followed by 2 months observation
61981817|NCT02278250|EXPERIMENTAL|Part A: M4344 10 mg BIW|Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981818|NCT02278250|EXPERIMENTAL|Part A: M4344 20 mg BIW|Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981819|NCT02278250|EXPERIMENTAL|Part A: M4344 40 mg BIW|Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981820|NCT02278250|EXPERIMENTAL|Part A: M4344 80 mg BIW|Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981821|NCT02278250|EXPERIMENTAL|Part A: M4344 160 mg BIW|Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981822|NCT02278250|EXPERIMENTAL|Part A: M4344 300 mg BIW|Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981823|NCT02278250|EXPERIMENTAL|Part A: M4344 450 mg BIW|Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981824|NCT02278250|EXPERIMENTAL|Part A: M4344 700 mg BIW|Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981825|NCT02278250|EXPERIMENTAL|Part A: M4344 1050 mg BIW|Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981826|NCT02278250|EXPERIMENTAL|Part A: M4344 1200 mg BIW|Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981827|NCT02278250|EXPERIMENTAL|Part A2: M4344 100 mg BID|Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981828|NCT02278250|EXPERIMENTAL|Part A2: M4344 150 mg QD|Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981829|NCT02278250|EXPERIMENTAL|Part A2: M4344 250 mg QD|Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981830|NCT02278250|EXPERIMENTAL|Part A2: M4344 350 mg QD|Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981831|NCT02278250|EXPERIMENTAL|Part B1: M4344 350 mg + Carboplatin|Participants received M4344 at a dose of 350 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of Area under the concentration versus time curve 5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981832|NCT02278250|EXPERIMENTAL|Part B1: M4344 400 mg + Carboplatin|Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of AUC5 on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981833|NCT02278250|EXPERIMENTAL|Part B1: M4344 500 mg + Carboplatin|Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of AUC5 on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981834|NCT02278250|EXPERIMENTAL|Part C: M4344 250 mg QD|Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
61981835|NCT01372501|EXPERIMENTAL|Experimental: Device|All patients will be implanted with the Endobarrier Liner device
61981836|NCT04557657|EXPERIMENTAL|Control Group Resin cement|Control group Using resin cement
61981837|NCT04557657|ACTIVE_COMPARATOR|Intervention Group Active Cement|Intervention Group Using active cement bio activa
61981838|NCT00483379|EXPERIMENTAL|alglucosidase alfa 20 mg/kg every week|Participants were treated with alglucosidase alfa 20 mg/kg every week for 52 weeks. This was the 'frequent dose' arm.
62169315|NCT04486742|NO_INTERVENTION|Usual Care Arm|Participants randomized to the Usual Care Arm of the study will receive standard of care eczema educational materials that are typically provided by their health care provider after a clinic (or telehealth) visit.
62169316|NCT00803335|ACTIVE_COMPARATOR|Premarin cream 0.5gm|Application of 0.5gm of vaginal estrogen cream nightly until surgery.
61981839|NCT00483379|EXPERIMENTAL|alglucosidase alfa 40 mg/kg every other week|Participants were treated with alglucosidase alfa 40 mg/kg every other week for 52 weeks. This was the 'high dose' arm.
61981840|NCT03028831|ACTIVE_COMPARATOR|Resistant Starch|70g high-amylose maize starch which contains 42g of type 2 resistant starch
61981841|NCT03028831|PLACEBO_COMPARATOR|Digestible Starch|70g of fully digestible starch comprised of amylopectin corn starch.
61981842|NCT00674661|ACTIVE_COMPARATOR|Corneal Collagen Cross-linking (CXL) Treatment Group|riboflavin ophthalmic solution and UVA irradiation
61981843|NCT00674661|SHAM_COMPARATOR|Control Group|riboflavin opthalmic solution without UVA irradiation
61981844|NCT01481233|EXPERIMENTAL|Single arm|Colchicine 0.5 mg BID x 21 days
61981845|NCT01852942|EXPERIMENTAL|Losartan|
61981846|NCT01852942|PLACEBO_COMPARATOR|Sugar Pill|
61981847|NCT03583138||Buprenorphine|Participants are eligible for the study if they are 18 years of age or older, HIV+, meet DSM-IV criteria for opioid dependence, have health insurance accepted at Lab Corp, are able to read and understand English, and live in Washington, DC and plan to remain in DC. The intervention is to provide buprenorphine for 12 months for those who are interested in receiving it.
62361720|NCT01363258|ACTIVE_COMPARATOR|Evidence Base Mouth Care|Nursing home residents with dementia received mouth care from study personnel who were trained in evidence-based mouth care only.
62361721|NCT00977587|ACTIVE_COMPARATOR|Saccharomyces Cerevisiae CNCM I-3856|2 weeks of treatment with Saccharomyces Cerevisiae CNCM I-3856 1 capsule twice a day, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).
62361722|NCT00977587|PLACEBO_COMPARATOR|placebo|"Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~* Calcium phosphate, Dibasic 472.0 mg~* Maltodextrin DE14 112.1 mg~* Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day"
61981848|NCT03583138||No buprenorphine|No buprenorphine
61981849|NCT01462084|EXPERIMENTAL|Adaptive Servo-Ventilation (ASV) then BiLevel PAP|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual. ASV adjusts to the breathing events the individual is experiencing and provides enough PAP to resolve the breathing event. This is a crossover study, so all patients enter both treatment groups.
61981850|NCT01462084|EXPERIMENTAL|Bi-Level PAP then Adaptive Servo-Ventilation (ASV)|Bi-level pressure delivers two pressures, IPAP and EPAP. Both pressures are fixed and do not adjust based on the individuals breathing events. This is a crossover study, so all patients enter both treatment groups.
61981851|NCT05507255|ACTIVE_COMPARATOR|Relaxation training|Females will receive relaxation training, in the form of deep breathing, 3 days per week, for 8 weeks.
61981852|NCT05507255|EXPERIMENTAL|The same relaxation training plus an aerobic exercise program|Females will receive the same relaxation training, in addition to 30 minutes of a moderate aerobic exercise program on a treadmill, 3 days per week, for 8 weeks.
61981853|NCT01403246|EXPERIMENTAL|Lenalidomide with Chlorambucil|
61981854|NCT03512314|EXPERIMENTAL|Tadekinig alfa|Active drug treatment during 26 weeks
61981855|NCT03799497||Patients suffering from Anorexia Nervosa|Subjects with a diagnostic of anorexia nervosa disorder
61981856|NCT03799497||Control group|Healthy subjects with no psychiatric disorder
61981857|NCT01912287|EXPERIMENTAL|Yoga|The yoga intervention will apply Kundalini Yoga practices as taught by Yogi Bhajan. This is a well-known, accessible style of practice in the U.S. that incorporates all of the traditional components of yoga including physical postures and exercises, breathing techniques, relaxation exercises and meditation practices. It is a safe style of yoga that is registered with the Yoga Alliance that is readily and routinely adapted for therapeutic purposes. The 12-week yoga intervention will consist of 12 group classes and assigned daily home practice led by qualified and certified yoga instructors. Each group yoga session will include physical postures/exercises, breathing techniques, meditation and deep relaxation practice that are all easy to learn and do not require extensive practice or athletic ability to perform.
62361723|NCT01822223|EXPERIMENTAL|Laser-ablated dental implant-abutments|Laser-ablated dental implant abutments will be attached to surgically placed dental implants.
62361724|NCT01822223|ACTIVE_COMPARATOR|Smooth implant-abutments|Smooth dental implant-abutments will be attached to surgically placed dental implants.
62361725|NCT05200728|EXPERIMENTAL|SIM1910-09|"This trial includes of 2 parts, Part A-single ascending doses and Part B- multiple ascending doses.~Part A, there are 4 dose cohorts and each cohort will enroll 6 subjects to receive SIM1910-09.~Part B, there are 4 dose cohorts and each cohort will enroll 6 subjects to receive SIM1910-09.~The dose ascending will be determined by independent third party clinical physician. The next higher dose cohort could be initiated only if the stopping rules is not met."
61981858|NCT01912287|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT)|"The 12 session CBT treatment will be based on the standardized protocol developed at one of our centers (CARD) and widely available \[88\]. This protocol is comprised of four primary treatment modules including cognitive restructuring, progressive muscle relaxation, worry exposures, and in vivo exposure exercises. The initial sessions describe the cognitive behavioral model of worry and GAD. Each session consists of a different lesson. These lessons initially cover basic information about the nature of the anxiety and worry, the possible function and negative consequences of worrying, the maladaptive and paradoxical effects of attempting to control and suppress one's thoughts, the basic cognitive errors of probability overestimation and catastrophic thinking, adaptive strategies to deal with worries, such as problem solving, worry exposure, which may involve exploring and exposing the patient to negative images and scenarios that might be behind some of the worrisome thoughts."
62169317|NCT00803335|ACTIVE_COMPARATOR|Premarin cream 1.0gm|Application of 1.0gm of vaginal estrogen cream nightly until surgery.
62169318|NCT00803335|NO_INTERVENTION|No intervention|Women in this arm will not apply any cream or moisturizers to the vagina until surgery, ie no intervention.
62169319|NCT01134718|EXPERIMENTAL|001|TMC435 (F021) one morning dose of 150 mg
62169320|NCT01134718|EXPERIMENTAL|002|TMC435 (G006) one morning dose of 150 mg
62739171|NCT02812264|ACTIVE_COMPARATOR|Attention Control|use of non-API app for weight loss over 12 months, plus fitness tracker and scale.
62739172|NCT03049358|EXPERIMENTAL|Arm I (olfactory training)|Patients undergo olfactory training by smelling 4 essential oils in vials (rose, lemon, clove, and eucalyptus) over 15 seconds each, twice daily for 12 weeks.
61981859|NCT01912287|SHAM_COMPARATOR|Stress Education|SE will also include 12 weeks of group and home practice sessions. SE will control for attention from instructors, expectancy effects, and group support effects, Stress Education (SE) will be employed as an active control intervention. SE is currently used in NIH-funded protocols at the Benson-Henry Institute for Mind-Body Medicine at MGH. In this condition, participants will be provided with detailed and extensive information about stress and health, but will not receive any CBT, yoga, or other mind-body training techniques.
61981860|NCT05505357|EXPERIMENTAL|Patients with pCR predicted by MRI and vacuum-assisted biopsy (VAB) after neoadjuvant chemotherapy|When there is no residual tumor cells on the vacuum-assisted biopsy specimen, breast surgery will be omitted. In the case of clinical N0 AND MRI size ≤ 0.5cm AND lesion-to-background signal enhancement ratio ≤1.6, sentinel lymph node biopsy will be omitted. Otherwise, sentinel lymph node biopsy will be performed. If necessary, axillary lymph node dissection will be performed.
61981861|NCT02044744|EXPERIMENTAL|Referral|Physical activity referral
61981862|NCT02044744|NO_INTERVENTION|Wait-list control|Wait-list controls receive no intervention until after they provide follow-up measurements.
61981863|NCT03314155|EXPERIMENTAL|Cerebral neuroinflammation evaluation|The density of TSPO (which is an inflammation maker) is evaluated by the tracer's brain distribution volume (\[18F\] DPA-714).
61981864|NCT04028206|NO_INTERVENTION|Control Group|No intervention on sarcopenic subjects screened (based on the AWGS definition).
61981865|NCT04028206|ACTIVE_COMPARATOR|Exercise + HMB Group|Sarcopenic subjects on combined treatment of elastic-band exercise and HMB supplementation
61981866|NCT04028206|ACTIVE_COMPARATOR|Vibration Treatment + HMB Group|Sarcopenic subjects on combined treatment of vibration treatment and HMB supplementation
61981867|NCT04818281|EXPERIMENTAL|Low-Dose Group (Group A)|12 participants will receive 10 µg VLP vaccine (adjuvanted with alum and CpGODN-K3)
61981868|NCT04818281|EXPERIMENTAL|High-Dose Group (Group B)|12 participants will receive 40 µg VLP vaccine (adjuvanted with alum and CpGODN-K3)
61981869|NCT04818281|PLACEBO_COMPARATOR|Placebo Group|12 participants will receive 1 ml of 0.9% sodium chloride (NaCl)
61981870|NCT05505019|EXPERIMENTAL|Parkinson's Disease with apathy - Music-listening|"Participants in this arm will receive a YouTube account app to use. Prior to the start of the intervention, a research team member will guide participants in this group in constructing a playlist of music that they find rewarding or motivating."
61981871|NCT05505019|EXPERIMENTAL|Parkinson's Disease with apathy - Podcast-listening|"Participants in this arm will receive a YouTube account app to use. Prior to the start of the intervention, a research team member will guide participants in this group in choosing a podcast that they find rewarding or motivating."
61981872|NCT01475331|ACTIVE_COMPARATOR|Control Group|Cyst will be lavaged for 3-5 minutes with Ethanol (alcohol 80%). Following lavage with Ethanol (alcohol 80%), The cyst will be infused with an admixture of chemotherapy drugs (Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
61981873|NCT01475331|EXPERIMENTAL|Study Group|Cyst will be lavaged for 3-5 minutes with Normal Saline .. Following lavage with Normal Saline, The cyst will be infused with an admixture of chemotherapy drugs (Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
61981874|NCT01837979||DBS screening test|cell-free fetal DNA for Dried blood spots samples in high risk pregnant women.
61981875|NCT01837979||maternal serum screening test|cell-free fetal DNA for maternal serum screening test samples in high risk pregnant women.
61981876|NCT00255047|EXPERIMENTAL|Study Group 1: DAPTACEL®, ActHIB®, and IPOL®|Participants will receive 3 doses of DAPTACEL®, ActHIB®, and IPOL® at Months 2, 4, and 6, respectively
61981877|NCT00255047|EXPERIMENTAL|Study Group 2: Pentacel®|Participants will receive 3 doses of Pentacel® at Months 2, 4, and 6, respectively
61981878|NCT00255047|EXPERIMENTAL|Study Group 3: DTaP-IPV and ActHIB®|Participants will receive 3 doses of DTaP-IPV and ActHIB® at Months 2, 4, and 6, respectively
61981879|NCT00255047|EXPERIMENTAL|Study Group 4: Pentacel®|Participants will receive 3 doses of Pentacel® at Months 2, 4, and 6, respectively
61981880|NCT05325450|EXPERIMENTAL|Training A|Training A in Unilaterally postlingually-deafened adult cochlear implanted candidates
61981881|NCT05325450|EXPERIMENTAL|Training B|Training B in Unilaterally postlingually-deafened adult cochlear implanted candidates
61981882|NCT05325450|ACTIVE_COMPARATOR|Control|Training in bilaterally postlingually-deafened adult cochlear implanted candidates
61981883|NCT00772772|EXPERIMENTAL|Vitamin D3|Vitamin D3 30,000 international units orally per week for 8 weeks
61981884|NCT05413707|EXPERIMENTAL|Fixation group|"Patients are placed in a prone position on the operating table. Fixation of the posterior malleolus fracture. Posterior, and/or lateral and medial malleolus fractures will be treated with open reduction and internal fixation. ORIF of the posteromedial fragment in Mason and Molloy type 2B with one or more screws, or plate, if it is displaced more than 2 mm. Deltoid ligament injuries are repaired if incarcerated between medial malleolus and talus. The posteromedial fragment in Mason and Molloy type 2B will be fixed with one or more screws, or plate, if this fragment is displaced more than 2 mm. A Tillaux-Chaput or Wagstaffe fragment is fixed with suture anchor, plate, screw or pin if displaced \>2 mm depending on size and comminution of the fragment.~The syndesmosis is tested under fluoroscopy by lateralizing and then externally rotating the talus. If unstable it is fixed with one or two 3.5 mm cortical screws or a suture button."
61981885|NCT05413707|ACTIVE_COMPARATOR|Non-fixation group|"Patients are placed in a supine position on the operating table. No fixation of the PMF. The PMF is reduced by ligamentotaxis. Lateral and/or medial malleolus fractures will be treated with ORIF if present.~ORIF of the posteromedial fragment in Mason and Molloy type 2B with one or more screws, or plate, if it is displaced more than 2 mm.~Deltoid ligament injuries are repaired if incarcerated between medial malleolus and talus.~A Tillaux-Chaput or Wagstaffe fragment is fixed with suture anchor, plate, screw or pin if displaced \>2 mm depending on size and comminution of the fragment.~The syndesmosis is tested under fluoroscopy by lateralizing and then externally rotating the talus. If unstable it is fixed with one or two 3.5 mm cortical screws or a suturebutton."
61981886|NCT00819351|EXPERIMENTAL|PEG-asparaginase 6 weeks intervals|"PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (from week 13 after diagnosis to week 33).~All additional therapy (High Dose Methotrexate, Vincristin, Dexamethasone, 6-Mercaptopurine, doxorubicin, intrathecal chemotherapy) is the same in both arms."
62169321|NCT01134718|EXPERIMENTAL|003|TMC435 (G007) one morning dose of 150 mg
61981887|NCT00819351|ACTIVE_COMPARATOR|PEG-Asparaginase 2 weeks intervals|"PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (from week 13 after diagnosis to week 33).~All additional therapy (High Dose Methotrexate, Vincristin, Dexamethasone, 6-Mercaptopurine, doxorubicin, intrathecal chemotherapy) is the same in both arms."
62361726|NCT05200728|PLACEBO_COMPARATOR|Placebo|"This trial Includes of 2 parts, Part A-single ascending dose and Part B- multiple ascending dose.~Part A, there are 4 dose cohorts and each cohort will enroll 2 subjects to receive placebo.~Part B, there are 4 dose cohorts and each cohort will enroll 2 subjects to receive placebo.~The dose ascending will be determined by independent third party clinical physician. The next higher dose cohort could be initiated only if the stopping rules is not met."
61981888|NCT05366244||Patient with COVID-19|Mild to moderate COVID-19 patient with at least one risk factor for serve COVID-19 illness or death.
61981889|NCT01388608||RA patients receiving etanercept|Patients with active rheumatoid arthritis (RA) who are eligible to a treatment with etanercept.
61981890|NCT06196333||Diabetes|Diabetes patients above 40 years
61981891|NCT06196333||Controls|Healthy controlled human beings have no medical histories
61981892|NCT01167647||bronchoscopy patients|
61981893|NCT05941923|EXPERIMENTAL|Intervention group|The experimental group, who will receive specialized respiratory care from RCCN from the time they arrive in the emergency room until their discharge from the hospital
61981894|NCT05941923|NO_INTERVENTION|Control group|No intervention group, who will receive only routine care without any intervention.
61981895|NCT04572074|ACTIVE_COMPARATOR|Arm 1 (Guided imagery)|10 minutes of guided imagery experience
61981896|NCT04572074|EXPERIMENTAL|Arm 2 (Virtual reality)|10 minutes of virtual reality experience
61981897|NCT01073709|EXPERIMENTAL|Test|Acetaminophen extended release gelcaps 650 mg of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
61981898|NCT01073709|ACTIVE_COMPARATOR|Reference|Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)of McNeil Consumer \& Specialty Pharmaceuticals, Division of MCNEIL-PPC, Inc. Fort Washington, PA 19034 USA
61981899|NCT05938933|EXPERIMENTAL|Cohort|Cohort
61981900|NCT01168531|PLACEBO_COMPARATOR|placebo arm|
61981901|NCT01168531|ACTIVE_COMPARATOR|pregabalin arm|
61981902|NCT01168531|EXPERIMENTAL|dexamethasone with pregabalin arm|
61981903|NCT01649531|ACTIVE_COMPARATOR|Test group|1 Implant, to be placed in the position with greater vertical bone height with a mesial or distal cantilever.
61981904|NCT01649531|ACTIVE_COMPARATOR|Control group|2 Implants
61981905|NCT05793320|EXPERIMENTAL|Carpal Tunnel Release|
61981906|NCT05048628|ACTIVE_COMPARATOR|İce Pieces İmpregnated Group|Impregnation of pieces of ice was delivered to us; one ice cube is planned after wearing and movements automatically by the throat purchase to exit use and sound program, and move with one ice cube after movement. It can be used after extubation. It is in sound class with Visual Analogue Scale (VAS) for the use of customers before and after the application. Extubation is in the last 0. hours, no small application is made, only in sound class with VAS. Evaluated by Stout's Hoarseness Scale
61981907|NCT05048628|ACTIVE_COMPARATOR|Green Tea Gargle Solution Group|To the patients included in the gargle group with green tea; four after, six after eigth after hours after extubation, the patients of the intervention group were asked to gargle 30 cc of green tea and before the application and after the patient's oral intake was requested by the physician to prevent sore throat and hoarseness afterwards, patients' sore throat is measured with Visual Analogue Scale (VAS) and hoarseness is measured with Stout's Hoarseness Scale. At the 0. th hour after extubation, no treatment is applied to the patients, only sore throat is evaluated with VAS and hoarseness is evaluated with Stout's Hoarseness Scale.0
61981908|NCT05048628|ACTIVE_COMPARATOR|Arnica Montana Tea Gargle Solution Group|To the patients included in the gargle group with arnica montana tea; four after, six after eigth after hours after extubation, the patients of the intervention group were asked to gargle 30 cc of arnica montana tea and before the application and after the patient's oral intake was requested by the physician to prevent sore throat and hoarseness afterwards, patients' sore throat is measured with Visual Analogue Scale (VAS) and hoarseness is measured with Stout's Hoarseness Scale. At the 0th hour after extubation, no treatment is applied to the patients, only sore throat is evaluated with VAS and hoarseness is evaluated with Stout's Hoarseness Scale.
61981909|NCT05048628|NO_INTERVENTION|Control Group|Patients in the control group; sore throat and hoarseness scores at 0 hour immediately after extubation,to collect at 4, 6 and 8 hours after extubation, sore throat (Visual Analogue Scale) VAS; Stout s Voice if hoarseness It is evaluated with the Slightness Scale.
61981910|NCT06072950||Patient with NRS pain at rest being 4 or higher|Patient with NRS pain at rest being 4 or higher, primarily treated by emergency physician, internist, or surgeon. All patients receive usual care, no interventions are administered.
61981911|NCT06231212|EXPERIMENTAL|ECa groups|Intervention group takes capsules containing of ECa 233, an active substance composed of Madecassoside and Asiaticoside
61981912|NCT06231212|ACTIVE_COMPARATOR|NSAID group|Active-controlled group was given capsules containing 200 mg of ibuprofen
62361727|NCT00742846|ACTIVE_COMPARATOR|Group 1|The patient receives intra-articular steroid and local anesthetic injection under fluoroscopy.
62361728|NCT00742846|ACTIVE_COMPARATOR|Group 2|The patient receives subacromial steroid and local anesthetic injection under fluoroscopy.
61981913|NCT06231212|PLACEBO_COMPARATOR|Placebo group|Placebo-controlled group received capsules containing 250 mg of lactose
61981914|NCT01077804||Varivax vaccinated children|Children who are members of Kaiser Permanente Medical Care Program (KPMCP) and who received a first dose of the varicella vaccine, Varivax, in 1995 between the ages of 12 and 23 months.
61981915|NCT04216654||Group(A)|52 cases of type 2 diabetic patients.They have +ve Serum antibody and Stool antigen specific for Helicobacter pylori.
61981916|NCT04216654||Group(B)|36 cases of type 2 diabetic patients. They have +ve Serum antibody and -ve Stool antigen-specific for Helicobacter pylori.
61981917|NCT04216654||Group(C)|112 cases of type 2 diabetic patients. They have -ve Serum antibody and Stool antigen-specific for Helicobacter pylori.
61981918|NCT04052269|EXPERIMENTAL|eyes with glaucoma|patients with glaucoma will have imaging of retina post administration of Sildenafil or Tadalafil.
61981919|NCT04052269|OTHER|Healthy (unaffected) eyes|patients with healthy eyes who are already taking Sildenafil or Tadalafil have their imaging of retina post administration of Sildenafil or Tadalafil.
61981920|NCT05394441||Healthy adults (16+)|Healthy students, faculty and staff of ITMO University older than 16 years
61981921|NCT05114785||HFpEF group|Suspected HFpEF group: 80 patients will be recruited with history of dyspnoea, LV ejection fraction ≥ 50%, raised NTproBNP
61981922|NCT05114785||Control group|20 patients with suspected CAD but with no dyspnoea and normal echocardiogram.
61981923|NCT03604640|NO_INTERVENTION|standard care|
61981924|NCT03604640|EXPERIMENTAL|Physical and educational program|
61981925|NCT05485766|EXPERIMENTAL|Pembrolizumab+ Paclitaxel + Carboplatin Followed by Pembrolizumab + Olaparib|"1. Neoadjuvant phase; Treatment 1: Pembrolizumab+ Paclitaxel + Carboplatin (Cycles 1-4) Treatment 2: Pembrolizumab + Olaparib (Cycles 1-4)~2. Definitive Surgery~3. Adjuvant phase; Pembrolizumab + Olaparib (1-9 cycles)~Note: each cycle = 3 weeks (Neoadjuvant Treatment 1 and 2, and Adjuvant Treatment)"
61981926|NCT01550796|ACTIVE_COMPARATOR|d-cycloserine|d-cycloserine 250 mg two days per week one hour prior to(cognitive training)
61981927|NCT01550796|PLACEBO_COMPARATOR|Placebo|Placebo pill two days per week 1 hour prior to cognitive training
61981928|NCT04099927|EXPERIMENTAL|SHR0410|Experimental: SHR0410 dose escalation.
61981929|NCT01035203|ACTIVE_COMPARATOR|Cognitive behavioural therapy|
62361729|NCT00742846|ACTIVE_COMPARATOR|Group 3|The patient receives intra-articular local anesthetic injection under fluoroscopy.
61981930|NCT01035203|EXPERIMENTAL|Exercise|Endurance training (walking on a treadmill) 3 x weekly for 4 weeks
61981931|NCT04716387||Chlorfenapyr ITN|These study districts will receive Interceptor G2 ITNs during the mass distribution campaign.
61981932|NCT04716387||Piperonyl butoxide ITN|This study district will receive piperonyl butoxide ITN during the mass distribution campaign.
61981933|NCT04716387||Standard LLIN|These study districts will receive standard ITNs during the mass distribution campaign.
62361730|NCT00742846|ACTIVE_COMPARATOR|Group 4|The patient receives subacromial local anesthetic injection under fluoroscopy.
61981934|NCT04716387||Pyriproxyfen ITN|This study district will receive Royal Guard ITNs during the mass distribution campaign.
61981935|NCT03099447|EXPERIMENTAL|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
61981936|NCT03099447|EXPERIMENTAL|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
61981937|NCT03099447|SHAM_COMPARATOR|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
62361731|NCT00102934|EXPERIMENTAL|1|Participants will receive enfuvirtide for 6 months
62361732|NCT04896762||Extrapulmonary presentation for COVID-19|patients with confirmed covid 19 disease who primarily presented with extrapulmonary system affection
62361733|NCT04896762||pulmonary presentation for COVID-19|patients with confirmed covid 19 disease who primarily presented with pulmonary disease
62361734|NCT06453863|ACTIVE_COMPARATOR|Barefoot|Participants will berform gait, postural and functional evaluations without wearing any shoes
61981938|NCT03652844|ACTIVE_COMPARATOR|Allograft Adipose Matrix (AAM) 1.0|
62361735|NCT06453863|SHAM_COMPARATOR|Neutral gym shoes|Participants will be provided with appropriately sized neutral gym shoes, both for the acute evaluations and for assessment of one month longitudinal changes
62361736|NCT06453863|ACTIVE_COMPARATOR|Greater plantar feedback shoes|Participants will be provided with appropriately sized plantar shoes, both for the acute evaluations and for assessment of one month longitudinal changes
62361737|NCT01709968|EXPERIMENTAL|MAGNOX 520®|MAGNOX 520® (un-organic granular magnesium complex, composed of Magnesium Oxide \& Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks.
62361738|NCT01709968|PLACEBO_COMPARATOR|Similarly looking placebo.|Similarly looking placebo. Oral administration once daily for 4 weeks.
62739173|NCT03049358|SHAM_COMPARATOR|Arm II (sham training)|Patients undergo sham training by smelling canola oil in 4 vials over 15 seconds each, twice daily for 12 weeks.
61981939|NCT03652844|ACTIVE_COMPARATOR|Allograft Adipose Matrix (AAM) Diluted|
61981940|NCT02451839||Crohn's Disease|Participants with Crohn's disease. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
61981941|NCT02451839||Rheumatoid Arthritis|Participants with rheumatoid arthritis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
61981942|NCT02451839||Psoriasis|Participants with psoriasis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
61981943|NCT05783362|EXPERIMENTAL|High Exposure (HE)|Participants will receive five sessions total: four sessions of the Intervention, questionnaires, quantitative sensory testing, and CPM as an outcome in the first and fifth sessions.
61981944|NCT05783362|EXPERIMENTAL|Low Exposure (LE)|Participants will receive only two sessions in total: questionnaires, quantitative sensory testing, and CPM as an outcome at both sessions.
61981945|NCT05783362|NO_INTERVENTION|No Exposure (NE)|This group controls for natural history response, and participants will receive two sessions of questionnaires, and CPM as an outcome, and quantitative sensory testing for one session (last session).
62169322|NCT00098514|EXPERIMENTAL|Dose Level 1a|10 mg/m2 dose of PT523 administered day 1 of a 28-day cycle as a 5 minute IV infusion (IV bolus)
62169323|NCT00098514|EXPERIMENTAL|Dose Level 1b|5 mg/m2 dose of PT523 administered days 1 and 8 of a 28-day cycle as a 5 minute IV infusion
61981946|NCT02619292|EXPERIMENTAL|Mindful Movement Program|"Mindfulness is moment-to-moment, present-centered, purposive non-judgmental awareness; Dance/movement therapy is a multidimensional approach that integrates body awareness, expression and acceptance to facilitate physical, emotional, cognitive, social and spiritual integration of individuals"
61981947|NCT03978429|EXPERIMENTAL|Intervention Arm|"1. Community-based Pre-eclampsia/Eclampsia Detection and Management~2. Strengthened Referral Network from Community to Referral hospital levels~3. Antenatal Care Nurses will receive training on best practices for PE detection and management per Tanzanian Standard Treatment Guidelines.~4. Antenatal Care Nurses will be given smartphones and will be trained to complete Case Report Forms (CRF) to log key indicators and activities at each ANC visit, delivery and Postnatal Care visits of enrolled participants.~5. Antenatal Care Nurses will receive bluetooth blood pressure monitors.~6. Community Health Workers within the intervention arm facilities will receive training in pre-eclampsia features and will be provided with smart phones and access to a smart phone application that will prompt them to initiate follow ups with pregnant women within the community and they will receive SMS/text messages reminders about pregnant women within the community who require follow up."
61981948|NCT03978429|NO_INTERVENTION|Enhanced Usual Care|"1. Antenatal Care Nurses will receive training on best practices for PE detection and management per Tanzanian Standard Treatment Guidelines.~2. Antenatal Care Nurses will be given smartphones and will be trained to complete Case Report Forms (CRF) to log key indicators and activities at each ANC visit, delivery and Postnatal Care visits of enrolled participants.~3. Antenatal Care Nurses will receive bluetooth blood pressure monitors."
61981949|NCT04532866|EXPERIMENTAL|Isolation and Confinement|Six crew members will spend 8 months isolated and confined in the spaceflight analog NEK in Moscow.
61981950|NCT04532866|NO_INTERVENTION|Control Group|Up to ten participants matched for age, gender, and educational background undergo the same test protocol as the experimental group at identical points in time but without being isolated and confined in the NEK facility.
61981951|NCT03296254|EXPERIMENTAL|Course A|Body Mindfulness Exercised followed by Sitting Mindfulness Exercises. Written material and sound recordings will be offered as support elements.
61981952|NCT03296254|EXPERIMENTAL|Course B|Sitting Mindfulness Exercises followed by Body Mindfulness Exercises. Written material and sound recordings will be offered as support elements.
61981953|NCT06415409|PLACEBO_COMPARATOR|Water|rehydration with Plain water
61981954|NCT06415409|ACTIVE_COMPARATOR|Gatorade|rehydration with Gatorade drink
61981955|NCT06415409|ACTIVE_COMPARATOR|BodyArmor|Rehydration with Body Armor Drink
61981956|NCT06415409|EXPERIMENTAL|GoodSport|Rehydration with Good Sport drink
61981957|NCT01013701|ACTIVE_COMPARATOR|Fluticasone Furoate|nasal steroid
61981958|NCT01013701|PLACEBO_COMPARATOR|Placebo|nasal spray vehicle without drug
61981959|NCT00956904|EXPERIMENTAL|3-D TRUS navigation software during T-RALP|
61981960|NCT03375918|OTHER|Healthcare Trainees - Cluster 1|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
61981961|NCT03375918|OTHER|Healthcare Trainees - Cluster 2|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
61981962|NCT03375918|OTHER|Healthcare Trainees - Cluster 3|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
61981963|NCT03375918|OTHER|Healthcare Trainees - Cluster 4|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
61981964|NCT03375918|OTHER|Healthcare Trainees - Cluster 5|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
61981965|NCT01404325|EXPERIMENTAL|Quadruple low level IS regimen|quadruple immunosuppressive (IS) regimen consisting of everolimus, CNI, MPA and steroids
61981966|NCT01404325|EXPERIMENTAL|Centre specific triple IS regimen|centre specific CNI-based triple drug immunosuppression (IS)
61981967|NCT04028596|ACTIVE_COMPARATOR|Acetaminophen|Trade name: Paracetamol Pharmaceutical form: Tablet (oral use) Once 1000 mg 2h before the ECT-session. Total maximum of five times over the course of weeks
61981968|NCT04028596|ACTIVE_COMPARATOR|Nimodipine|Trade name: Nimotop Pharmaceutical form: Film-coated tablet (oral use) Once 60mg 2h before the ECT-session. Total maximum of five times over the course of weeks.
61981969|NCT04028596|NO_INTERVENTION|Control|Glass of water (50cc) only. Once 2h before the ECT-session. Total maximum of five times over the course of weeks.
61981970|NCT04142554|EXPERIMENTAL|Single Arm: Parsaclisib ( Dose De-Escalation )|Prior to their scheduled standard of care surgery or research biopsy, subjects (n = 5 per dosing cohort) will be given oral doses of parsaclisib (10, 3.0 or 1.0 mg) once daily over 14 consecutive days.
61981971|NCT03475966|EXPERIMENTAL|Prehabilitation|Exercise, nutrition and relaxation techniques all beginning four weeks prior to surgery date.
61981972|NCT03475966|ACTIVE_COMPARATOR|Rehabilitation|Exercise, nutrition and relaxation techniques all beginning immediately after surgery.
61981973|NCT02140567||Syncope Prediction|All enrolled patients that performed the tilt table test
61981974|NCT03879382|EXPERIMENTAL|anti-CD19/BCMA CAR-T cells|Administration with anti-CD19/BCMA CAR-T cells in the relapsed and refractory POMES Syndrome patients
61981975|NCT03006159|EXPERIMENTAL|Cohort 1|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 5 mg SHR0534 or matching placebo.
61981976|NCT03006159|EXPERIMENTAL|Cohort 2|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 10 mg SHR0534 or matching placebo.
62361739|NCT03549468|EXPERIMENTAL|low level tragus stimulation (LLTS)|Patients with ischemic cardiomyopathy (left ventricular ejection fraction \<35%) and heart failure who already have an implantable device with an atrial lead (dual chamber defibrillator or biventricular defibrillator) will undergo sequentially 1. Sham LLTS (5min), 2. Active LLTS at 5Hz (15min) and 20Hz (15min) and 3. Active LLTS group with atrial pacing at 100bpm at 5Hz (15min) and 20Hz (15min).
61981977|NCT03006159|EXPERIMENTAL|Cohort 3|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 25 mg SHR0534 or matching placebo.
61981978|NCT02166554|PLACEBO_COMPARATOR|Control Arm|Standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with saline placebo following surgery
61981979|NCT02166554|EXPERIMENTAL|Cross-linked Hyaluronan Hydrogel Arm|HyaRegen
62361740|NCT02715050|EXPERIMENTAL|Group A - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group A, received program 1 before strength training, and the same program 1 after training."
62361741|NCT02715050|EXPERIMENTAL|Group B - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 1 before strength training, and program 2 after training."
61981980|NCT04336982|EXPERIMENTAL|CC-90009 in combination with venetoclax and azacitidine|"CC-90009 will be administered intravenously per dosing schedule in a 28-day cycle. Venetoclax will be administered orally QD.~Azacitidine will be administered intravenously or subcutaneously on planned dosing days for each cycle."
61981981|NCT04336982|EXPERIMENTAL|CC-90009 in combination with gilteritinib|CC-90009 will be administered intravenously per dosing schedule in a 28-day cycle. Gilteritinib will be administered orally QD.
61981982|NCT00358566|ACTIVE_COMPARATOR|Gemcitabine|Gemcitabine alone treatment.
61981983|NCT00358566|EXPERIMENTAL|GV1001|GV1001 in sequential combination with Gemcitabine
62739174|NCT03574376|ACTIVE_COMPARATOR|Bupivacaine Liposome Injection [Exparel]|Patients will receive a nerve block with a medication called liposomal bupivacaine, also called Exparel. Once assigned, a University of Illinois surgeon, or resident surgeon, will administer the nerve block. The nerve block is expected to provide pain relief from 72 to 96 hours. During this time, patients may request oral or intravenous pain medication for breakthrough pain. Patients will remain in the hospital until discharged by the attending physician.
61981984|NCT01805024|EXPERIMENTAL|Omigapil|Omigapil treatment oral administration once per day after breakfast Cohort 1 Cohort 1 0.02 mg/kg/day Cohort 2 0.08 mg/kg/day Cohort 3a 0.04 mg/kg/day Cohort 3b 0.06 mg/kg/day
61981985|NCT06482476||Med students|Medical students in whom Lp(a) levels will be measured
61981986|NCT01259154||RFITT+UPPP|
61981987|NCT01259154||UPPP|
61981988|NCT03095391||Cohort 1|GFR: ≥ 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: none Comparator dose: none
61981989|NCT03095391||Cohort 2|GFR: ≥ 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 2 Comparator: Iohexol 5 mL Comparator dose: 1
61981990|NCT03095391||Cohort 3|GFR: ≥ 30 and \< 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: Iohexol 5 mL Comparator dose: 1
61981991|NCT03095391||Cohort 4|GFR: ≥ 15 and \< 30 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: Iohexol 5 mL Comparator dose: 1
61981992|NCT06318793||Group without POC|
61981993|NCT06318793||Group with POC and major POC|
61981994|NCT04429737|EXPERIMENTAL|Experimental|The prediabetes patients in this arm will receive Clam protein capsules or Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months.
61981995|NCT04429737|PLACEBO_COMPARATOR|placebo|The prediabetes patients in this arm will receive placebo with similar appearance of Clam protein capsules or Clam peptide plus Chlorella capsules.
61981996|NCT03465592|EXPERIMENTAL|Nivolumab|"Adults: 240 mg IV over 30 minutes every 2 weeks OR 480 mg IV over 30 minutes every 4 weeks. Children and Adolescents weighing 40 kg or more: 240 mg IV over 30 minutes every 2 weeks OR 480 mg IV over 30 minutes every 4 weeks.~Children and Adolescents weighing less than 40 kg: 3 mg/kg IV over 30 minutes every 2 weeks.A maximum of 24 cycles will be given on study."
61981997|NCT02409459|EXPERIMENTAL|Injectafer|15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
61981998|NCT02409459|PLACEBO_COMPARATOR|Placebo|15 cc of Normal Saline IV push at 2 ml/minute
61981999|NCT05683054|ACTIVE_COMPARATOR|Standard dosing group|In the standard based arm, patients will continue to receive adalimumab according to the standard dosing schedule of 40 mg every other week (maintenance phase).
61982000|NCT05683054|ACTIVE_COMPARATOR|Dose tapering group|In the dose tapering arm, adalimumab dosing frequency will be lowered to 40 mg every 3 weeks in patients who have supratherapeutic serum trough levels of adalimumab at three consecutive measurements.
61982001|NCT03972280|EXPERIMENTAL|Dose Level 1 (HS)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS
61982002|NCT03972280|EXPERIMENTAL|Dose Level 1 (PPP)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with PPP
62361742|NCT02715050|EXPERIMENTAL|Group C - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group C, received program 2 before strength training, and program 1 after training."
62739175|NCT03574376|ACTIVE_COMPARATOR|Epidural 0.125% bupivicaine|"Patients will receive pain relief through a 0.125% bupivacaine epidural in the upper back by an assigned anesthesiologist. This epidural will remain in place for an uncertain amount of time. The decision to remove the epidural will be determined by the physicians and will be based on level of pain and injury.~However, pain data will only be recorded by the research team for no longer than 96 hours after the epidural is placed. Patients are able to request intravenous and oral pain medications for breakthrough pain. After the epidural is removed, they will remain in the hospital until discharged by the attending physician."
61982003|NCT03972280|EXPERIMENTAL|Dose Level 1 (Total)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS or PPP
61982004|NCT03972280|EXPERIMENTAL|Dose Level 2 (HS)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS
61982005|NCT03972280|EXPERIMENTAL|Dose Level 2 (PPP)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with PPP
61982006|NCT03972280|EXPERIMENTAL|Dose Level 2 (Total)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS or PPP
62361743|NCT02715050|EXPERIMENTAL|Group D - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group D, received program 2 before strength training, and program 2 after training."
61982007|NCT01505868|EXPERIMENTAL|Arm I (cabazitaxel)|Patients receive cabazitaxel IV over 60-90 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
61982008|NCT01505868|EXPERIMENTAL|Arm II (cabazitaxel and carboplatin)|Patients receive cabazitaxel IV over 60-90 minutes and carboplatin IV over 60-90 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
62361744|NCT04504019|EXPERIMENTAL|USCTR Procedure|Participants will undergo the USCTR procedure with SX-One MicroKnife®, also known as UltraGuideCTR
61982009|NCT03441633||Group 1. Apixaban|"Patients who are on treatment with apixaban.~1a. patients who have initiated with apixaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~1b. patients who previously have been treated with VKA in the 12 months before index date."
61982010|NCT03441633||Group 2. VKA|"Patients who are on treatment with VKA.~2a. patients who have initiated with VKA as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~2b. patients who previously have been treated with VKA in the 12 months before index date."
61982011|NCT03441633||Group 3. Dabigatran|"Patients who are on treatment with dabigatran.~3a. patients who have initiated with dabigatran as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~3b. patients who previously have been treated with VKA in the 12 months before index date."
61982012|NCT03441633||Group 4. Rivaroxaban|"Patients who are on treatment with rivaroxaban.~4a. patients who have initiated with rivaroxaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~4b. patients who previously have been treated with VKA in the 12 months before index date."
61982013|NCT06346873|EXPERIMENTAL|JOGO for the Treatment of Tremor|Subjects with a diagnosis of essential tremor (ET) or functional tremor (FT) involving one or more of the upper extremities will undergo a 12-week JOGO treatment program.
61982014|NCT06297109|EXPERIMENTAL|Intervention|Participants treated with patient-specific implants for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
61982015|NCT06297109|ACTIVE_COMPARATOR|Control|Participants treated with conventional mini-plates for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
61982016|NCT03045081|NO_INTERVENTION|Usual care|Patients receive outcome tracking tool, PainTracker, but no additional web-based support for self-management
61982017|NCT03045081|EXPERIMENTAL|PainTracker Self-Manager|Patients are invited to complete the web-based PainTracker Self-Manager and interact with a nurse care manager who supports chronic pain self-management
61982018|NCT02965274|EXPERIMENTAL|Test|Torrent's Fluoxetine Tablets 20 mg
61982019|NCT02965274|ACTIVE_COMPARATOR|Reference|Warner Chilcott LLC, USA
61982020|NCT05874076|ACTIVE_COMPARATOR|Covid-19 group|This group underwent physiotherapy consisting of mobilization, normal range of motion, and a respiratory exercise program.
61982021|NCT05874076|EXPERIMENTAL|Mutation group|This group underwent physiotherapy consisting of mobilization, normal range of motion, and a respiratory exercise program.
61982022|NCT04424017||Healthcare workers (HCWs)|
61982023|NCT04424017||Healthy blood donors and healthy subjects in blood bank|
61982024|NCT04424017||Convalescents|
61982025|NCT00947479|OTHER|continuous positive airway pressure (CPAP)|CPAP will be applied in all patients
61982026|NCT04946357|EXPERIMENTAL|Arm A: Protons, 39 Gy (RBE) in 13 fractions (single dose 3.0 Gy(RBE))|Arm A: Protons, 39 Gy (RBE) in 13 fractions (single dose 3.0 Gy(RBE))
61982027|NCT04946357|EXPERIMENTAL|Arm B: Carbon ions, 39 Gy(RBE) in 13 fractions (single dose 3.0 Gy(RBE))|Arm B: Carbon ions, 39 Gy(RBE) in 13 fractions (single dose 3.0 Gy(RBE))
62739176|NCT04615234||Experimental: Treated with Genetic Test Guide (TGTG)|Antidepressant monotherapy treatments according to good clinical practice for major depressive disorder guided with the pharmacogenomic test (PGs)
62739177|NCT04615234||Control: Treated as Usual (TAU)|Antidepressant monotherapy treatments according to good clinical practice for major depressive disorder.
61982028|NCT01326767|ACTIVE_COMPARATOR|Paclitaxel dosing according to SmPC|
61982029|NCT01326767|EXPERIMENTAL|Individualized pharmacokinetically driven paclitaxel dosing|In the first treatment cycle, the Paclitaxel dose is adapted depending on the age and the gender of the patient. In the treatment cycles 2-6 the Paclitaxel dose is adapted based on individual PK data and toxicities.
61982030|NCT01466348|EXPERIMENTAL|Paracetamol and Caffeine|Paracetamol and caffeine
61982031|NCT01466348|ACTIVE_COMPARATOR|Paracetamol|Paracetamol
61982032|NCT03876431|ACTIVE_COMPARATOR|Traditional Exercise Group|Only traditional exercises will be performed in the early post-op period.
61982033|NCT03876431|EXPERIMENTAL|Easy-Flex Group|Easy-Flex group will be treated with the Easy-Flex device in addition to the traditional exercise program.
61982034|NCT06399588|EXPERIMENTAL|Intervention group|The intervention consists of three 40-minute sessions, delivered over three successive days, including knowledge and skill-based lectures, interactive activities, and materials targeting tobacco prevention and health promotion.
61982035|NCT06399588|NO_INTERVENTION|Control group|Participating schools in the control group will maintain their regular ongoing activities without introducing the IATIP. Students in the control group will not receive any specific anti-tobacco or health and well-being promotion materials beyond their standard school curriculum.
61982036|NCT03016286|EXPERIMENTAL|WBV group|whole-body vibration (WBV) group
61982037|NCT04299308|EXPERIMENTAL|Moderate Intensity Aerobic Exercise|45-55% of heart rat reserve (HHR) Low range = ((Max HR from Visit 1) - Resting HR ) \* 0.45 + Resting HR High range = ((Max HR from Visit 1) - Resting HR) \* 0.55 + Resting HR
62361745|NCT04504019|ACTIVE_COMPARATOR|mOCTR Procedure|Participants will undergo the traditional mOCTR procedure.
62361746|NCT02251067|ACTIVE_COMPARATOR|VPI-2690B low dose|6 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
62361747|NCT02251067|ACTIVE_COMPARATOR|VPI-2690B medium dose|18 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
62361748|NCT02251067|PLACEBO_COMPARATOR|Placebo|6 or 18 mg Placebo, administered subcutaneously every 2 weeks for 48 weeks
62361749|NCT02251067|ACTIVE_COMPARATOR|VPI-2690B high dose|48 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
62361750|NCT01268904||Pediatric status epilepticus|
62361751|NCT04743271|EXPERIMENTAL|High-Fat Diet|50% fat, 35% carbohydrate and 15% protein; 33% of each mono, poly and saturated fat
62361752|NCT04743271|ACTIVE_COMPARATOR|Low-Fat Diet|30% fat, 55% carbohydrate and 15% protein
62361753|NCT01079195||Single Patient group with Hypertension|Single Patient group with Hypertension
62361754|NCT00289861|ACTIVE_COMPARATOR|risperdone|
62361755|NCT00289861|PLACEBO_COMPARATOR|placebo|
62361756|NCT01620697||Perirenal fat|
62361757|NCT01251822|EXPERIMENTAL|PEG 3350|PEG 3350 plus electrolytes in solution plus placebo tablets
62361758|NCT01251822|ACTIVE_COMPARATOR|Prucalopride|Prucalopride tablets plus placebo solution
62361759|NCT02766907|ACTIVE_COMPARATOR|Study|prospective arm receiving cryopreserved amniotic membrane
62361760|NCT02766907|NO_INTERVENTION|Control|Retrospective review of debridement without cryopreserved amniotic membrane
62361761|NCT02312011|EXPERIMENTAL|IONIS-DMPKRx|"IONIS DMPKRx is administered subcutaneously over the course of 6 weeks for dose levels 1, 2, 3, 4, and 5.~IONIS DMPKRx is administered subcutaneously over the course of 12 weeks for dose levels 4 or 5."
61982038|NCT04299308|EXPERIMENTAL|High Intensity Aerobic Exercise|65-75% of heart rat reserve (HHR) Low range = ((Max HR from Visit 1) - Resting HR ) \* 0.65 + Resting HR High range = ((Max HR from Visit 1) - Resting HR) \* 0.75 + Resting HR
61982039|NCT00645073|ACTIVE_COMPARATOR|A|
61982040|NCT00645073|ACTIVE_COMPARATOR|B|
62361762|NCT02312011|PLACEBO_COMPARATOR|Placebo|A placebo is administered subcutaneously over the course of 6 weeks. A placebo is administered subcutaneously over the course of 12 weeks.
61982041|NCT03623360||Patients with liver cirrhosis|"The cohort includes patients who encompass the full clinical spectrum of liver function within cirrhosis.~The participants will undergo a full MRI protocol for liver screening including morphological imaging, fibrosis scoring tests based on relaxometry and diffusion maps, and our novel functional technique based on free breathing DCE-MRI."
62169324|NCT00098514|EXPERIMENTAL|Dose Level 1c|3.33 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
62169325|NCT00098514|EXPERIMENTAL|Dose Level 2|5 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
62361763|NCT05620069|EXPERIMENTAL|Music listening at bed time|
62361764|NCT05620069|NO_INTERVENTION|Treatment as usual|
62361765|NCT06339606||Abnormal Placentation|Women with a singleton or multiple pregnancy that are known or suspected of having abnormal placentation
62361766|NCT06339606||Control|Women with a singleton or multiple pregnancy with a low-risk pregnancy.
62361767|NCT00606177|EXPERIMENTAL|1|
62361768|NCT00606177|PLACEBO_COMPARATOR|2|
62361769|NCT00631618|EXPERIMENTAL|Suntinib|Suntinib
62361770|NCT02679781|ACTIVE_COMPARATOR|oral sedation|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
62361771|NCT02679781|ACTIVE_COMPARATOR|nasal sedation|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
62361772|NCT01609725|EXPERIMENTAL|Comprehensive treatment|Test treatment group
62361773|NCT01609725|OTHER|Community treatment|Control treatment group
62361774|NCT01311739|EXPERIMENTAL|10 mg Eligen® B12 (Cyanocobalamin/SNAC)|A single oral dose of Eligen® B12, cyanocobalamin/SNAC (5 mg cyanocobalamin/100 mg SNAC) administered in the fasted state as 2 tablets taken with 50 mL of water resulting in a total dose of 10 mg cyanocobalamin and 200 mg SNAC.
62361775|NCT01311739|EXPERIMENTAL|5 mg Eligen® B12 (Cyanocobalamin/SNAC)|A single oral dose of Eligen® B12, cyanocobalamin/SNAC (5 mg cyanocobalamin/100 mg SNAC) administered in the fasted state as a tablet taken with 50 mL of water resulting in a total dose of 5 mg cyanocobalamin and 100 mg SNAC.
62361776|NCT01311739|ACTIVE_COMPARATOR|5 mg Oral Cyanocobalamin|A single oral dose of cyanocobalamin alone (5 mg cyanocobalamin, commercial: VITALABS, INC) administered in the fasted state as a tablet taken with 50 mL of water resulting in a total dose of 5 mg cyanocobalamin.
62361777|NCT01311739|ACTIVE_COMPARATOR|1 mg Intravenous Cyanocobalamin|A single intravenous (IV) dose of cyanocobalamin (1 mg cyanocobalamin) administered in the fasted state. Each subject will receive a 1 mL IV injection of a 1 mg/mL (1000 μg/mL) solution resulting in a total dose of 1 mg cyanocobalamin.
62361778|NCT03147599|ACTIVE_COMPARATOR|Mebeverine|Coloverin (Mebeverine hydrochloride 135 mg)
62361779|NCT03147599|PLACEBO_COMPARATOR|Placebo|Placebo
62361780|NCT04919772||Stroke survivors|Chronic stroke, generally speaking chronic stroke refers to the period of recovery that takes place at least six months after the initial stroke event
62361781|NCT04633031||Group 1|Cheneau brace
62361782|NCT04633031||Group 2|Boston brace
62361783|NCT05678088|EXPERIMENTAL|Supervised Oropharyngeal Exercises|The participant will perform the oropharyngeal exercises that strengthen the tongue and pharyngeal muscles. The protocol will be delivered via a tablet-based app. The speech language pathologist will call or conduct videoconference visits with participants 1, 3, 5, 7 and 9 weeks after the baseline assessment to provide re-training (if needed) and to troubleshoot technical issues related to the use of the app.
62361784|NCT05678088|ACTIVE_COMPARATOR|Unsupervised Oropharyngeal Exercises|The participant will perform the oropharyngeal exercises that strengthen the tongue and pharyngeal muscles. The protocol will be delivered via a tablet-based app. After the initial training there will be no further scheduled interactions with the study staff except during the follow-up telephone calls and study visits.
62361785|NCT05678088|SHAM_COMPARATOR|Supervised Sham Exercises|The participant will perform sham control exercises that have no impact on oropharyngeal (e.g., base of the tongue) muscle strength. The speech language pathologist will call or conduct videoconference visits with participants 1, 3, 5, 7 and 9 weeks after the baseline assessment to provide re-training (if needed) and to troubleshoot technical issues related to the use of the app.
62361786|NCT03598127||sepsis group|patients of sepsis group are diagnosed with sepsis according to International Pediatric Sepsis Consensus Conference:Definitions for sepsis and organ dysfunction in pediatrics.
61982042|NCT02042248|EXPERIMENTAL|Arm A: ART initiated during AHI|Arm A will enroll approximately 6 participants who initiated ART during AHI (acute HIV infection). The target dose of AGS -004 is delivered in three ID (intradermal) injections of 0.2 mL of AGS-004 (0.6 mL total volume) for a total of 1.2 x 107 viable cells. AGS-004 is administered every 4 weeks at weeks 0, 4, 8, and 12 for a total of 4 doses.
62361787|NCT03598127||control group|A gender- and age- matched control group are recruited from among non-sepsis children from Pediatric Intensive Care Unit of West China Hospital.
62361788|NCT02357888|EXPERIMENTAL|Sequence 1|Treatment group sequence: Test Product on Day 1 and Placebo on Day 2
62361789|NCT02357888|EXPERIMENTAL|Sequence 2|Treatment group sequence: Placebo on Day 1 and Test Product on Day 2
62361790|NCT00753623|ACTIVE_COMPARATOR|Ramelteon first, placebo second|"In a crossover design, a subject will be first assigned to the ramelteon arm and then switched over to the placebo arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night.The ramelteon and placebo will be blinded by the central pharmacy.~The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long."
62361791|NCT00753623|PLACEBO_COMPARATOR|Placebo first, ramelteon second|"In a crossover design, a subject will be first assigned to the placebo arm and then switched over to the ramelteon arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night. The ramelteon and placebo will be blinded by the central pharmacy.~The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long."
62361792|NCT03765710|EXPERIMENTAL|Recommended protein intake|Subjects consumed a mixed meal with a macronutrient distribution of 13% protein, 54% carbohydrate, and 33% fat.
62361793|NCT03765710|EXPERIMENTAL|Elevated protein intake|Subjects consumed a mixed meal with a macronutrient distribution of 26% protein, 44% carbohydrate, and 30% fat.
62361794|NCT05263687|EXPERIMENTAL|Exercise Test|maximal and anaerobic threshold cardiopulmonary parameters
62361795|NCT01983878|EXPERIMENTAL|Ramucirumab|Ramucirumab 8 milligrams per kilogram (mg/kg) administered intravenously (IV) once every 2 weeks. Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance or withdrawal of consent.
62361796|NCT00820807|EXPERIMENTAL|1|3g/day
62361797|NCT00820807|EXPERIMENTAL|2|6g/day
62361798|NCT00820807|PLACEBO_COMPARATOR|Placebo beverage|0g/day
62361799|NCT01917890|EXPERIMENTAL|Curcumin Group|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of curcumin (as 6 capsules 500 mg)"
62361800|NCT01917890|PLACEBO_COMPARATOR|Placebo|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of placebo (as 6 capsules 500 mg)"
62361801|NCT05117593|EXPERIMENTAL|FBL-MTX|"A single dose of FBL-MTX will be administered by slow intravenous injection in the morning, under fasted conditions.~A maximum of 4 dose levels (0.1 mg, 0.33 mg, 1 mg and 2.5 mg) are pre-planned."
62361802|NCT05117593|PLACEBO_COMPARATOR|Placebo|A single dose of placebo will be administered by slow injection in the morning, under fasted conditions.
62361803|NCT03954990|PLACEBO_COMPARATOR|Control Arm|Placebo tablets oral, 4 tablets once.
61982043|NCT02042248|EXPERIMENTAL|Arm B: ART initiated during CHI|Arm B will enroll approximately 6 participants who initiated ART during CHI (chronic HIV infection). The target dose of AGS -004 is delivered in three ID (intradermal) injections of 0.2 mL of AGS-004 (0.6 mL total volume) for a total of 1.2 x 107 viable cells. AGS-004 is administered every 4 weeks at weeks 0, 4, 8, and 12 for a total of 4 doses.
61982044|NCT03959020||Patients, undergoing anti-reflux surgery|Patients having undergone anti-reflux surgery at the Department of Surgery, Kolding Hospital, a part of Hospital Lillebaelt, from 1th January 2002 - 31th December 2013
61982045|NCT02692781|EXPERIMENTAL|Dose Cohort 1|20mg MOD-6031 / Placebo
61982046|NCT02692781|EXPERIMENTAL|Dose Cohort 2|50mg MOD-6031 / Placebo
61982047|NCT02692781|EXPERIMENTAL|Dose Cohort 3|100mg MOD-6031 / Placebo
61982048|NCT02692781|EXPERIMENTAL|Dose Cohort 4|150mg MOD-6031 / Placebo
61982049|NCT02692781|EXPERIMENTAL|Dose Cohort 5|200mg MOD-6031 / Placebo
62361804|NCT03954990|ACTIVE_COMPARATOR|Treatment Arm|Will receive 4 tablets (2g) of metronidazole oral once.
62361805|NCT01501669|NO_INTERVENTION|Capecitabine alone arm|X arm
62361806|NCT01501669|EXPERIMENTAL|Irinotecan plus capecitabine arm|
62361807|NCT02645071|EXPERIMENTAL|Physical activity|The experimental arm is a 15-20 min interactive session, which aims to reduce participants' sedentary behavior and increase physical activity by increasing their motivation, self-efficacy, and knowledge of different types of easy exercises.
62361808|NCT04397692|EXPERIMENTAL|Inhaled NO delivered using LungFit™ in addition to SST|Patients will receive 80 ppm iNO for 40 min 4 times a day using LungFit™ device in addition to the standard of care.
62361809|NCT04397692|NO_INTERVENTION|Standard of care|Control - Standard of care
62361810|NCT05965206||Intervention group|Participants receive a follow-up phone call from a pharmacist approximately 7 business days after receiving intravenous chemotherapy infusion
61982050|NCT03351179||AMI patients with HFpEF|
62361811|NCT05965206||Control group|Participants do not receive a follow-up phone call from a pharmacist after receiving intravenous chemotherapy infusion
62361812|NCT03364491|EXPERIMENTAL|Tranexamic Acid|Tranexamic Acid for intravenous administration
62361813|NCT03364491|PLACEBO_COMPARATOR|Placebo|Normal saline for intravenous administration
62361814|NCT05619003|EXPERIMENTAL|Single-arm|The clinical investigation is an open-labelled, non-comparative, single-arm, prospective, multi-center investigation
62361815|NCT00829218|ACTIVE_COMPARATOR|1 - Glutamate challenge|Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 1 is the 5 grams of glutamate which will be given in a mixed juice.
62361816|NCT00829218|PLACEBO_COMPARATOR|2- Placebo|Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 2 is the placebo arm, which will be juice with nothing added.
62361817|NCT01082003|OTHER|Permanent Implant|Trental and Vitamin E for 6 months
62361818|NCT01082003|OTHER|Tissue Expander|Trental and Vitamin E for 6 months
62361819|NCT06268483|ACTIVE_COMPARATOR|Oral supplementation of hyaluronic acid + anti-inflammatory|Group I: an oral preparation (capsule) of HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg once a day in the morning plus an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months
62361820|NCT06268483|ACTIVE_COMPARATOR|Anti-inflammatori|Group C: an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.
62361821|NCT00921427|ACTIVE_COMPARATOR|VRT and active tDCS|Patients will receive tDCS (noninvasive brain stimulation) concurrently with vision restoration therapy. TDCS is delivered using a small battery-operated device. Electrical leads from the device are connected to saline soaked sponges that are placed at strategic locations on the skull corresponding to areas of the brain that need to be stimulated (in this case, the visual cortex). The dosage will be set to 2 mA/min for 30 minutes, twice a day for 3 days a week for 12 weeks.
62361822|NCT00921427|SHAM_COMPARATOR|VRT combined with sham tDCS|Patients will receive sham tDCS concurrently with vision restoration therapy. Electrical leads from the tDCS device will be connected to saline soaked sponges placed at strategic locations on the skull, in a similar maner as in the active tDCS group. Current will be turned on for 30 seconds but will be slowly ramped down and turned off. Treatment will continue for 3 days a week for 12 weeks.
62361823|NCT03275415|ACTIVE_COMPARATOR|Experimental|Curosurf + budesonide
62361824|NCT03275415|PLACEBO_COMPARATOR|Placebo|Curosurf + saline
62361825|NCT02275520|OTHER|IO access|Performed intraosseus access device during simulated cardiopulmonary resuscitation
62361826|NCT01582867|EXPERIMENTAL|HD and HDF|During one part of the study (study phase A) patients will undergo hemodialysis (HD) treatments with Hemoscan over 2 weeks (Run-In period), followed by 12 HD sessions with HemoControl during the following 4 to 6 weeks. Separated by a one week wash out period, the same patients will be switched to On-Line Hemodiafiltration (HDF) treatments (study phase B), for a Run-In period of 2 weeks with Hemoscan, followed by 12 On-Line HDF sessions with HemoControl over the last 4 to 6 weeks of the study period.
61982051|NCT03351179||AMI patients without HF|
62739178|NCT03027440||CPP Cohort|offspring born to historic CPP cohort participant mothers between 1959 and 1966 who were known to be alive at age 7 (if still alive at the time of NDI search, ages 50 to 57 years old)
62739179|NCT02441153||Group 1(Extended Timing)|Surgery will be performed at 10-11 weeks after the completion of chemoradiotherapy.
61982052|NCT01829750|SHAM_COMPARATOR|Control|"(Stage 1) No active intervention after standard surgical treatment~(Stage 2) Rescuing transplantation by cardiac progenitor cell infusion is applicable in patients, along with their written consent, 4 months after palliations who were assigned as control group in stage 1."
61982053|NCT01829750|ACTIVE_COMPARATOR|Cardiac progenitor cell infusion|(Stage 1) single dose, intracoronary infusion of 0.3 million cells/kg cardiac progenitor cells
61982054|NCT01832870|EXPERIMENTAL|Treatment|Patients enrolled will receive the standard 3-dose treatment of sipuleucel-T, followed by treatment(s) of ipilimumab.
61982055|NCT03559946|SHAM_COMPARATOR|Standard Protocol (SP) group|The patients in the SP group will receive one PTNS treatment and one sham treatment per week for 12 weeks
61982056|NCT03559946|EXPERIMENTAL|Condensed Protocol (CP) group|The patients in the CP group will receive 2 PTNS treatments per week for 12 weeks.
61982057|NCT01969240|ACTIVE_COMPARATOR|Chest Pain Choice Decision Aid|Patients randomized to the decision aid arm.
61982058|NCT01969240|NO_INTERVENTION|Usual Care|Patients randomized to the usual care arm (no decision aid used)
61982059|NCT03571074||Hypoxia|"Defined as a group of patients with oxygen saturation \<94 % irrespective of supplemental oxygen.~If COPD, defined as oxygen saturation \<88 % irrespective of supplemental oxygen."
61982060|NCT03571074||Normoxia|"Defined as a group of patients with oxygen saturation 94 % - 98 % in combination of supplemental oxygen, or oxygen saturation \>94 % without supplemental oxygen.~If COPD, defined as oxygen saturation 88 % - 92 % in combination of supplemental oxygen, or oxygen saturation \>88 % without supplemental oxygen."
61982061|NCT03571074||Hyperoxia|"Defined as a group of patients with oxygen saturation \>98 % in combination of supplemental oxygen.~If COPD, defined as oxygen saturation \>92 % in combination of supplemental oxygen."
61982062|NCT06144346|ACTIVE_COMPARATOR|Standard of Care|systemic and palliative treatment according to physician discretion
62169326|NCT00098514|EXPERIMENTAL|Dose Level 3|7.5 mg/m2 dose (or 6.7 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
61982063|NCT06144346|EXPERIMENTAL|Metastases Directed Therapy|SABR for all metastatic sites followed by systemic treatment for 6 months
61982064|NCT06144346|EXPERIMENTAL|Locoregional Treatment of the Primary|patients who respond to MDT and ST will be randomized to undergo loco-regional treatment or not
61982065|NCT00957073|EXPERIMENTAL|Device|Rheos® system
61982066|NCT00957073|NO_INTERVENTION|Medical Management|Medical Management Therapy
61982067|NCT01274390||Shorter-storage red blood cell units|Red blood cell units stored \<= 10 days
61982068|NCT01274390||Longer-storage red blood cell units|Red blood cell units stored \>= 21 days
61982069|NCT06250985|EXPERIMENTAL|Immediate reimplantation|Reimplantation in same procedure as removal of device or shortly thereafter.
61982070|NCT06250985|ACTIVE_COMPARATOR|Standart care|Reimplantation of device in a second procedure at a later date, after infection has been stabilized/cleared
62169327|NCT00098514|EXPERIMENTAL|Dose Level 4|11.25 mg/m2 dose (or 9 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
62361827|NCT01582867|EXPERIMENTAL|HDF and HD|patients will be treated vice versa, starting with On-Line Hemodiafiltration (HDF) followed by hemodialysis (HD) with the same respective Run-In periods and a washout period as patients in Arm hemodialysis (HD) and Hemodiafiltration (HDF) .
62361828|NCT05482555||Intervention/treatment Surgical cut-down and arterial puncture under direct vision|Surgical cut-down and arterial puncture under direct vision.
61982071|NCT05823623|EXPERIMENTAL|Inetetamab combined with Pyrotinib plus Oral Vinorelbine|Inetetamab: 8mg/kg for the first dose, 6mg/kg for the following doses, intravenous, every 3 weeks for one cycle. Pyrotinib: 400mg, oral, every day. Vinorelbine: 60mg/m2, oral, every week.
61982072|NCT04265781|EXPERIMENTAL|Dose escalation BAY1817080|Participants receive dose 1 to 3 of BAY1817080 as a single dose on Day 1.
61982073|NCT04265781|EXPERIMENTAL|Dose expansion BAY1817080|Participants receive the highest dose 3 of BAY1817080 twice daily (BID) from Day 1 until Day 13 and a single dose on Day 14.
62361829|NCT05482555||Percutaneous arteriotomy closed with closure device|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
62361830|NCT02533401|EXPERIMENTAL|Rituximab + Fludarabine + Cyclophosphamide|Participants will receive rituximab (375 milligrams per meter-squared \[mg/m\^2\] intravenously \[IV\]) on Cycle 1 Day 1, followed by fludarabine (25 mg/m\^2 once daily IV) and cyclophosphamide (250 mg/m\^2 once daily IV) for Days 2 to 4 of Cycle 1. Then rituximab (500 mg/m\^2 IV) will be administered on Day 1 of Cycles 2 to 6, followed by IV fludarabine (25 mg/m\^2 once daily IV) and cyclophosphamide (250 mg/m\^2 once daily IV) on Days 1 to 3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length, and the overall duration of treatment will be approximately 6 months.
62361831|NCT05062551|EXPERIMENTAL|intervetion group|50 patients complained of post-menstrual bleeding with confirmed presence of isthmocele. After written consent, the patient will be subjected to three steps hysteroscopic resection of an isthmocele by removing the distal edge of the niche then the proximal edge and lastly ball cauterization of the floor of the pouch of the isthmocele. Post-operative trans vaginal ultrasound and follow up for 2 menstrual cycles.
62361832|NCT04705987|EXPERIMENTAL|Experimental|Colchicine 0.5 mg
62361833|NCT04705987|PLACEBO_COMPARATOR|Placebo|Placebo
62361834|NCT01067651|ACTIVE_COMPARATOR|Plaster of Paris (POP)|
62361835|NCT01067651|ACTIVE_COMPARATOR|semi-rigid fiberglass softcast (SRF, 3M Scotchcast)|
62361836|NCT01060098||Rheumatoid arthritis|Participants with Rheumatoid arthritis
62361837|NCT01060098||Ankylosing spondylitis|Participants with Ankylosing spondylitis
62361838|NCT01060098||Psoriatic arthritis|Participants with Psoriatic arthritis
62361839|NCT03006081|EXPERIMENTAL|2mg intravitreal aflibercept injection|2mg intravitreal aflibercept (Eylea) injection at baseline, 1M, 2M, 3M, 4M, and 5M
62361840|NCT01487291||Psychotic patients|Inpatients and outpatients followed at Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro, Brazil
62361841|NCT04814524|EXPERIMENTAL|Group 1 (VR, Fitbit)|Beginning postoperative day 1, patients use VR over 30 minutes up to 4 times daily on weekdays and 2 times daily on weekends, and wear Fitbit daily with a goal of 2,000 steps until the day of discharge, or until 14 days after surgery. Pre and post-VR pain scores will be obtained for each VR use. Sleep data may also be evaluated from Fitbit devices.
62361842|NCT04814524|EXPERIMENTAL|Group 2 (VR)|Beginning postoperative day 1, patients use VR over 30 minutes up to 4 times daily on weekdays and 2 times daily on weekends until the day of discharge or until 14 days after surgery. Pre and post-VR pain scores will be obtained for each VR use.
62361843|NCT04814524|EXPERIMENTAL|Group 3 (Fitbit)|Beginning postoperative day 1, patients wear Fitbit daily with a goal of 2,000 steps until the day of discharge or until 14 days after surgery. Sleep data may also be evaluated from Fitbit devices.
61982074|NCT04265781|PLACEBO_COMPARATOR|Dose escalation Placebo|Participants receive placebo tablets orally as a single dose on Day 1.
61982075|NCT04265781|PLACEBO_COMPARATOR|Dose expansion Placebo|Participants receive placebo tablets as BID multiple doses from Day 1 until Day 13 and as a single dose on Day 14.
61982076|NCT06406192|NO_INTERVENTION|No Intervention Group|This group does not specifically encourage or interfere with physicians' original methods of inquiry or patients providing bodily examination data.
62361844|NCT04814524|ACTIVE_COMPARATOR|Group 4 (questionnaire)|Patients do not use VR or wear Fitbit.
62361845|NCT06262594|PLACEBO_COMPARATOR|Placebo First|0mg
62361846|NCT06262594|ACTIVE_COMPARATOR|Investigational Product First|10mg qhs
61982077|NCT06406192|EXPERIMENTAL|Intervention Group|This group encourages physicians to actively inquire or patients to voluntarily provide physical examination data during consultations.
61982078|NCT00130221|EXPERIMENTAL|chlorhexidine gluconate (CHG)|daily skin cleansing with no-rinse, 2% CHG-impregnated cloths (Sage)
61982079|NCT00130221|ACTIVE_COMPARATOR|Soap & Water|bathing daily with bar soap (Dial Corp., Scottsdale, AZ) warm water, and cotton washcloths
62361847|NCT03284021|OTHER|Fraxel laser|
62361848|NCT03223207||Control Group|The control group will include CIED patients who have been evaluated in the ED at The Heart Hospital Baylor Plano and Baylor Regional Medical Center at Plano. A minimum of 50 devices not compatible with the CareLink Express® system will be prospectively interrogated in the traditional evaluation method using the device manufacturer representative.
62361849|NCT03223207||CareLink Express|The study group will include CIED patients who present to the ED and receive a device evaluation using the CareLink Express® system. A minimum of 50 devices will be prospectively evaluated using CareLink Express®.
62361850|NCT02578355||Coronary CT Angiography (CCTA)|Patients included in the OPeRA Registry are those that have previously undergone clinically-indicated CCTA as part of their standard of care.
62361851|NCT04771546|EXPERIMENTAL|Intervention (Colpofix)|Intravaginal gel with Carboxymethyl-β-glucan and Polycarbophil
62361852|NCT04771546|NO_INTERVENTION|Control|No intervention (standard of care)
61982080|NCT01754844|EXPERIMENTAL|Group 1-5, single ascending dose AZD7624|Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo.
61982081|NCT01754844|PLACEBO_COMPARATOR|Placebo|Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo.
62169328|NCT00098514|EXPERIMENTAL|Dose Level 5|17 mg/m2 dose (or 12 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
62361853|NCT00550277|OTHER|Treatment|LBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring, all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles. Patients with objective response or stable disease after re-evaluation at week 8 will continue LBH589 at the same dose until disease progression, unacceptable toxicity and/or at the discretion of the investigator.
62361854|NCT00821860|EXPERIMENTAL|Arm I|Patients undergo video-assisted thoracoscopic cytoreductive pleurectomy either at the time of biopsy or after confirmation of biopsy results.
62361855|NCT00821860|ACTIVE_COMPARATOR|Arm II|Patients undergo talc pleurodesis via an indwelling intercostal chest drain or via thoracoscopy either at the time of biopsy or after confirmation of biopsy results.
62361856|NCT02238782|EXPERIMENTAL|selumetinib 75mg single dose|3 capsules of 25 mg administered orally
62361857|NCT02448914|EXPERIMENTAL|TRIGEL first, then Duodopa|"First Intervention (Day 1): TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).~Second Intervention (Day 2): Duodopa, intestinal gel (20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate).~Both TRIGEL and Duodopa treatment consists of 3 individually adjusted and pre-defined doses: a morning dose, a continuous 14 h infusion, and extra bolus doses (if required).~All TRIGEL doses correspond to 80% of the pre-study individually optimised doses of Duodopa. All Duodopa doses correspond to 100% of the pre-study individually optimized doses of Duodopa.~Administration is done through duodenal or upper jejunal infusion via the patient's permanently inserted gastrojejunostomy tube by means of an ambulatory infusion pump."
62361858|NCT02448914|EXPERIMENTAL|Duodopa first, then TRIGEL|"First Intervention (Day 1): Duodopa, intestinal gel (20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate).~Second Intervention (Day 2): TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).~Both TRIGEL and Duodopa treatment consists of 3 individually adjusted and pre-defined doses: a morning dose, a continuous 14 h infusion, and extra bolus doses (if required).~All TRIGEL doses correspond to 80% of the pre-study individually optimised doses of Duodopa. All Duodopa doses correspond to 100% of the pre-study individually optimized doses of Duodopa.~Administration is done through duodenal or upper jejunal infusion via the patient's permanently inserted gastrojejunostomy tube by means of an ambulatory infusion pump."
62361859|NCT02025049|EXPERIMENTAL|DP-b99|Intravenous DP-b99, 1.0 mg/kg twice daily for 2 consecutive days
62361860|NCT02025049|PLACEBO_COMPARATOR|Placebo|Intravenous placebo (mannitol based, DP-b99 look-alike) twice daily for 2 consecutive days
62361861|NCT04587921|EXPERIMENTAL|Patients monitored with oximeter|The first 45 patients will be monitored but the results will not be displayed. The second half of the patients the oximeter will have their monitoring data available online in the ward.
62361862|NCT03758872||historical comparaison whithout cuff|517 patients included in 2017 without CUFF and 517 patients will be included in 2018 with CUFF for polyp detection
62361863|NCT04767295|EXPERIMENTAL|Camrelizumab, Albumin Paclitaxel, Carboplatin|"ESCC participants in this study will be given intravenous administration of Camrelizumab (200mg/3w) combined with albumin paclitaxel (260 mg/m2) plus carboplatin chemotherapy. Every three weeks for a cycle of treatment, which will be conducted twice, and minimally invasive surgery within 5-8 weeks after the last administration.~Treatments will be administrated until disease progression, unacceptable adverse events (AE), concomitant diseases that hinder continued treatment."
62361864|NCT02843750|EXPERIMENTAL|Inspiratory Muscle Training-Rehabilitation|Patients will start the IMT-R, following their consent and within 2 weeks of their scheduled surgery: 10 sessions lasting about 90 minutes. Participants who completed their initial IMT greater than 2 weeks prior to surgery will have an additional visit prior to surgery. Participants will receive a Participant Manual demonstrating and explaining the rehabilitation process. Participants will also receive a log for recording their efforts and notes. A DVD of the rehabilitation is available to the participant. Participants will complete questionnaires at baseline and 3 months.
62361865|NCT06201169|ACTIVE_COMPARATOR|group I (control)|The bars are fabricated from titanium. the participants received implant supported hybrid prosthesis with CAD/CAM fabricated titanium bars
62361866|NCT06201169|EXPERIMENTAL|group II|The bars are fabricated from PEEK . the participants received implant supported hybrid prosthesis with CAD/CAM fabricated PEEK bars
62361867|NCT02156752|EXPERIMENTAL|ACT|Behavioral weight loss plus techniques from Acceptance and Commitment Therapy
62361868|NCT02156752|ACTIVE_COMPARATOR|SR|Behavioral weight loss plus self-regulation techniques
61982082|NCT05884047|OTHER|Virtual reality glasses|"In the research, Samsung Gear VR SM-R323 brand and model SG glasses provided by the researcher were used. Patients were offered four different options to watch as Forest of Serenity, Calm Place, Happy Place, Gala 360 Travel \& Relax. Forest of Serenity is a nature video consisting of bird sounds, colorful trees and flowers, and a clear lake where fish can be seen swimming in it. Calm Place is a relaxing video where cycles are shown 24 hours a day, where a person finds himself by the lake in the forest in snowy, rainy sunny weather. In Happy Place, one finds himself in a virtual camp environment where natural events such as dynamically changing weather, day-night cycles, and falling stars are experienced. Gala 360 Travel \& Relax is a Paris-Notre Dame museum tour video."
61982083|NCT05884047|OTHER|Scales|Spielberger State Anxiety Inventory Vital Signs Follow-up Form
61982084|NCT03219294|ACTIVE_COMPARATOR|Moderate Neuromuscular Blockade (NMB)|Intubating dose of Vecuronium 0.1 mg/kg (IBW) and re-dosing with 0.0125 to 0.05 mg/kg as needed to achieve and maintain 1 to 2 train-of-four (TOF) contractions. Redosing in this manner is a current clinical practice.
61982085|NCT03219294|ACTIVE_COMPARATOR|Deep NMB|Deep NMB: Intubating dose of Vecuronium 0.2 mg/kg (IBW) and re-dosing with 0.025 to 0.1 mg/kg to achieve and maintain zero twitches in the TOF, and post tetanic count (PTC) of 1 to 2 contractions. This level of blockade is new to the practice since approval of the drug for use at Maine Medical Center (MMC) but is in common use since the advent of Sugammadex.
62169329|NCT02423252|EXPERIMENTAL|Intervention group|Intervention: Massage, Relaxation, imagery, music. Patients in Intervention group will receive standard care plus massage, relaxation, guided imagery and music listening
62361869|NCT02156752|ACTIVE_COMPARATOR|WLO|Behavioral weight loss plus cooking tips and demonstrations
62169330|NCT02423252|NO_INTERVENTION|Control|Patients in control group will receive standard care only. Same records and outcome measures with intervention group will apply for control group as well.
61982086|NCT05220163|EXPERIMENTAL|CAD + POC Xpert|CAD followed by Xpert in CAD-positive participants (performed at POC) employing a low-cost panel van that is staffed by three health care workers. CAD-negative participants will be followed up, while CAD-positive participants will be offered POC Xpert. Xpert-positive participants will be referred for TB treatment initiation, while Xpert-negative (but CAD-positive) participants will undergo a clinical review. Thus, the active case finding (ACF) interventional package is one of CAD + POC Xpert (only in CAD positive participants).
61982087|NCT05220163|ACTIVE_COMPARATOR|POC Xpert only|Participants who are Xpert-positive will be referred for TB treatment initiation while Xpert-negative participants will be followed up. Thus, the active case finding (ACF) standard of care package is POC Xpert.
61982088|NCT00299013|ACTIVE_COMPARATOR|1|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
61982089|NCT00299013|EXPERIMENTAL|2|COLAL-PRED 40mg oral capsule, once daily for 8 weeks.
61982090|NCT00299013|EXPERIMENTAL|3|COLAL-PRED 60mg oral capsule, once daily for 8 weeks.
61982091|NCT00299013|EXPERIMENTAL|4|COLAL-PRED 80mg oral capsule, once daily for 8 weeks.
61982092|NCT04843644|EXPERIMENTAL|honey|"Honey, 10 grams per pack, calories 33.4 calories, protein 0.05 grams, fat 0.07 grams, fructose + glucose 7.0 grams, sodium 0 mg.~Usage is three times a day after three meals. After oral care is required before use, use 10 grams of longan honey, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink, or gargle within 30 minutes of use."
61982093|NCT04843644|EXPERIMENTAL|propolis|"Oil-soluble green propolis, propolis 100 mg / mL, dilute green propolis 200 times with edible oil, drink 0.5 mL each time, 3 times a day (a total of 50 mg).~Usage: three times a day, after three meals. After oral care is required before use, draw about 0.5ml of green propolis into the mouth, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink or gargle within 30 minutes of use."
61982094|NCT04843644|PLACEBO_COMPARATOR|control|Routine care to encourage oral care three times a day.
61982095|NCT01897142|EXPERIMENTAL|PF-05230907 and Placebo Cohort 1|
61982096|NCT01897142|EXPERIMENTAL|PF-05230907 and Placebo Cohort 2|
61982097|NCT01897142|EXPERIMENTAL|PF-05230907 and Placebo Cohort 3|
62361870|NCT02420795|EXPERIMENTAL|Treatment (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO on day 1 of every cycle or day 1 of every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62361871|NCT02776852|EXPERIMENTAL|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
61982098|NCT01897142|EXPERIMENTAL|PF-05230907 and Placebo Cohort 4|
61982099|NCT01897142|EXPERIMENTAL|PF-05230907 and Placebo Cohort 5|
61982100|NCT01897142|EXPERIMENTAL|PF-05230907 and Placebo Cohort 6|
62361872|NCT00150345|EXPERIMENTAL|Early treatment|Voriconazole starts within 18 hours of onset of fever intravenously with a loading dose of 6 mg/kg q12h for the first two doses followed by 4 mg/kg q12h (maintenance dose). Switched to oral treatment (200 mg BID) is possible after at least four days. Treatment will be ended if the patient is afebrile (\< 38.0 °C) for 7 days with neutrophil counts \< 500/µL, or if the patient is afebrile (\< 38.0 °C) for 2 days with neutrophil counts \> 500/µL.
62739180|NCT02441153||Group 2 (Non-extended timing)|Surgery will be performed at 6-7 weeks after completion of chemoradiotherapy.
62739181|NCT05388383||free-hand|spine surgery without robot
61982101|NCT00713154|PLACEBO_COMPARATOR|1|Placebo group
61982102|NCT00713154|ACTIVE_COMPARATOR|2|Control Group
61982103|NCT04880967||Standard Group|"Cohort of n=20 intensive care unit patients from the ages of 18 years will be collected.~Participants of this cohort will not use the ICU Feel Better App."
61982104|NCT04880967||Experimental Group|Cohort of n=20 intensive care unit patients from the ages of 18 years will be collected. Participants of this cohort will have the opportunity to use the ICU Feel Better App every day from the second day after admission to the ICU until the day of discharge from ICU.
61982105|NCT01738854|EXPERIMENTAL|intra-cuff pressure 40 cmH2O|
61982106|NCT01738854|ACTIVE_COMPARATOR|intra-cuff pressure 60 cmH2O|
61982107|NCT01738854|ACTIVE_COMPARATOR|intra-cuff pressure 80 cmH2O|
61982108|NCT03128346|EXPERIMENTAL|The nerve block group|TTP block under dynamic ultrasound guidance plus the standard care (hydromorphone, fentanyl, aspirin, acetaminophen)
61982109|NCT03128346|ACTIVE_COMPARATOR|The standard of care group|Patients in the standard care group will receive pain medications, such as hydromorphone, fentanyl, aspirin and acetaminophen.
61982110|NCT02085733||Possible Septic Arhtritis Patients|
61982111|NCT05573984||Vision Cohort 1|Score of ≥ 54 ETDRS letters read and a VF diameter ≥ 10 degrees in every meridian of the central field
61982112|NCT05573984||Vision Cohort 2|Score of ≥ 35 ETDRS letters read and a VF diameter \< 10 degrees in any meridian of the central field
61982113|NCT05573984||Vision Cohort 3|Score of \< 35 ETDRS letters read
61982114|NCT03195543||Patients with PAH|Diagnostic tests will be performed on patients with Pulmonary Artery Hypertension in order to assess any blood coagulation disorders. Platelet function, coagulation and fibrinolysis will be evaluated by platelet function analyzer-100 (PFA-100), light transmission aggregometry, rotational thromboelastometry (ROTEM) and endogenous thrombin potential.
61982115|NCT03195543||Patients with CTEPH|Diagnostic tests will be performed on patients with Chronic Thromboembolic Pulmonary Hypertension in order to assess any blood coagulation disorders. Platelet function, coagulation and fibrinolysis will be evaluated by platelet function analyzer-100 (PFA-100), light transmission aggregometry, rotational thromboelastometry (ROTEM) and endogenous thrombin potential.
61982116|NCT01619345|EXPERIMENTAL|Period 1: NN9924 with 50 mL water|
61982117|NCT01619345|EXPERIMENTAL|Period 2: NN9924 with 240 mL water|
61982118|NCT02655042||RCT-01|Participants in previous clinical trial that received blinded injection of RCT-01
61982119|NCT02655042||Placebo|Participants in previous clinical trial that received blinded injection of placebo
61982120|NCT02964468|EXPERIMENTAL|Treatment with IMRT Dose Escalation|Dose Escalation Intensity Modulated Radiotherapy treatment
61982121|NCT02964468|ACTIVE_COMPARATOR|Treatment with 3DCRT|3DCRT treatment (sequential boost)
62169331|NCT06108596|EXPERIMENTAL|Experimental group|Sintilimab with Interleukin-2+CAPOX
62361873|NCT00150345|OTHER|Deferred treatment|"Treatment with voriconazole (for dosage see early treatment arm) is initiated only if a patient is persistently febrile on day 5 after the onset of fever despite antibiotic treatment."
62361874|NCT04708769|EXPERIMENTAL|Smartphone App Participants (APP)|Smartphone application, diet and activity goals, online lessons, brief remote sessions with a Health Promotionist
62361875|NCT04708769|EXPERIMENTAL|Diabetes Prevention Program Participants (DPP)|Participant program manual, diet and activity logs, hour long remote sessions with a Health Promotionist
62361876|NCT01386567|EXPERIMENTAL|Androxal|Androxal (enclomiphene citrate)12.5 mg or 25 mg
62361877|NCT01386567|ACTIVE_COMPARATOR|Testim (topical testosterone)|
62361878|NCT05843305|EXPERIMENTAL|Dose Escalation|Oral tablets taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with BPI-452080 administered once daily.
62361879|NCT05843305|EXPERIMENTAL|Dose Expansion|"Oral tablets administered at MTD/RP2D defined dose. Each treatment cycle will be 21 days in duration with BPI-452080 administered once daily.~Cohort 1: Locally Advanced or Metastatic ccRCC Cohort 2: VHL disease associated RCC Cohort 3: Other Advanced Solid Tumors"
62361880|NCT04159922||Type 2 diabetic patients with foot wounds|
62361881|NCT04342429|EXPERIMENTAL|Prospective Study of Intensity-Modulated Proton Therapy (IMPT)|This is the first prospective study to investigate the safety and efficacy of IMPT for the treatment of SCLC. We will utilize adaptive planning throughout the radiation course. In addition, we will study the dosimetric parameters of IMPT and their correlation with treatment-related toxicities, particularly cardiac events.
62361882|NCT03384004|EXPERIMENTAL|Irrigation Technique 1|Patients randomized into this group will be treated using EndoVac Pure followed by Ultrasonic Irrigation.
62361883|NCT03384004|EXPERIMENTAL|Irrigation Technique 2|Patients randomized into this group will be treated using EndoVac Pure only.
62361884|NCT02484898||SEEQ™ MCT/ECM System|SEEQ™ MCT/ECM monitoring for the detection of non-lethal cardiac arrhythmias.
62361885|NCT03355404|EXPERIMENTAL|"Standing Patient"|
62361886|NCT03355404|NO_INTERVENTION|"Standardized management in stretcher"|
62361887|NCT04434105|EXPERIMENTAL|PRP group|patients received ultrasound-guided injection of 2 mL PRP into the affected carpal tunnel.patients will be injected twice with 2 weeks intervals
61982122|NCT05417945|EXPERIMENTAL|JensClip transcatheter valve repair system|Using the JensClip transcatheter valve repair system for the treatment of patients with moderate-severe or severe degenerative mitral regurgitation who are at high surgical risk.
62361888|NCT04434105|ACTIVE_COMPARATOR|Steroid group|patients received ultrasound-guided injection of 2 mL steroids (40 mg triamcinolone acetonide). into the affected carpal tunnel. patients will be injected twice with 2 weeks intervals
62361889|NCT04434105|PLACEBO_COMPARATOR|Control group|patients received ultrasound-guided injection of 2 mL saline patients will be injected twice with 2 weeks intervals
62361890|NCT03759028|EXPERIMENTAL|Ibuprofen|This group is given acetaminophen (liquid oral medication, 15mg/kg/dose every 6 hours as needed, max 90mg/kg/day) as the first-line pain medication, and as needed ibuprofen for breakthrough pain (liquid oral medication, 10mg/kg/dose every 8 hours as needed, max dose 40mg/kg/day).
62361891|NCT03759028|ACTIVE_COMPARATOR|Oxycodone|This group is given acetaminophen (liquid oral medication, 15mg/kg/dose every 6 hours as needed, max 90mg/kg/day) as the first-line pain medication, and as needed oxycodone for breakthrough pain (liquid oral medication, 0.1mg/kg/dose every 6 hours as needed).
62361892|NCT01947894||Adult Growth Hormone deficient Patients|Patients with GHD on Genotropin® replacement therapy.
62361893|NCT05586815|ACTIVE_COMPARATOR|Colistin plus Placebo|Colistin alone, 150 mg every 8 hours intravenously or according to renal function, plus Placebo
61982123|NCT01622361|ACTIVE_COMPARATOR|Chemotherapy Group|Chemotherapy Adriamycin+Cyclophosphamide\>Docetaxel
61982124|NCT01622361|EXPERIMENTAL|Endocrine therapy group|Endocrine therapy(GnRHa with Tamoxifen) group
61982125|NCT05435079|EXPERIMENTAL|new type of tracheotomy high-flow oxygen therapy (NTHF)|NTHF (connect the oxygen suction tube, Venturi, Fisher \& Paykel MR850 heated humidifier, RT308 breathing tube with humidification tank, airtight suction tube and tracheotomy in sequence from the output end of the automatic pressure-adjustable oxygen flow meter Catheter), adjust the MR850 to invasive automatic transmission, the temperature sensor automatically adjusts and maintains the gas temperature at the inlet of the tracheostomy catheter at 37°C according to the feedback temperature, and adjusts according to the gas outflow from the exhalation port of the patient's inspiratory phase. The gas flow rate of the oxygen therapy device is 40-60L/min. According to the monitored pulse oxygen saturation (SpO 2 ), the concentration of the venturi valve and the corresponding oxygen flow rate are adjusted to maintain the SpO 2 between 94% and 100%.
61982126|NCT05435079|ACTIVE_COMPARATOR|Respiratory Humidification Treatment（ AIRVO TM 2）|AIRVOTM 2 (Fisher \& Paykel, Auckland, New Zealand), connect the special breathing circuit, tracheostomy joint and tracheostomy tube in sequence from the output end of the oxygen flow meter. The gas outflow from the mouth is the standard, adjust the output gas flow rate of the therapy device to 40-60L/min, adjust the oxygen concentration according to the monitored pulse oxygen saturation (SpO 2 ), and maintain the SpO 2 between 94% and 100%. .
62361894|NCT05586815|EXPERIMENTAL|Colistin plus Minocycline|Colistin, 150 mg every 8 hours intravenously or according to renal function, plus Minocycline, 200 mg every 12 hours orally
62361895|NCT04399252|EXPERIMENTAL|LGG Arm|Participants in this arm will be given LGG for 28 days.
62361896|NCT04399252|PLACEBO_COMPARATOR|Placebo|Participants in this arm will be given a placebo for 28 days.
62361897|NCT04827810|EXPERIMENTAL|Dose -1|Accelerated Phase: - Standard Phase: 5 mg
62361898|NCT04827810|EXPERIMENTAL|Dose 1|Accelerated Phase: 10 mg Standard Phase: 10 mg
62361899|NCT04827810|EXPERIMENTAL|Dose 2|Accelerated Phase: 20 mg Standard Phase: 20 mg
62361900|NCT04827810|EXPERIMENTAL|Dose 3|Accelerated Phase: 40 mg Standard Phase: 35 mg
62361901|NCT04827810|EXPERIMENTAL|Dose 4|Accelerated Phase: 80 mg Standard Phase: 50 mg
62361902|NCT04827810|EXPERIMENTAL|Dose 5|Accelerated Phase: 160 mg Standard Phase: 65 mg
62361903|NCT04827810|EXPERIMENTAL|Dose 6|Accelerated Phase: 320 mg Standard Phase: 85 mg
62361904|NCT02575989|ACTIVE_COMPARATOR|1: control group|Classic - current management of trauma patients by French medical teams
62739182|NCT05388383||robot-assisted|Robot-assisted open surgery
62739183|NCT05388383||mi|Robot-assisted minimally invasive surgery
62361905|NCT02575989|EXPERIMENTAL|2: interventional group|"Intervention Name : monitoring, treatment, control and prevention of hypothermia~* Continuous monitoring of body temperature~* Ambulance warming (target : 30°C)~* Patient warming with dedicated blanket~* Infusion fluid warming (and temperature control)"
62361906|NCT04513405|OTHER|subjects with skin tears (Group A)|"A sample of peripheral venous blood will be taken to measure the levels of estrone and estradiol.~A skin biopsy on the intact skin area near the skin tear will be performed."
62361907|NCT04513405|OTHER|subjects without skin tears (Group B)|"A sample of peripheral venous blood will be taken to measure the levels of estrogen.~A skin biopsy (thin layer) on the intact skin area of the arm will be performed in order to evaluate skin estrogen receptors."
62361908|NCT05359679|EXPERIMENTAL|Value Champion Training Program|Intervention arm.
62361909|NCT05359679|ACTIVE_COMPARATOR|Standard Care|Control group.
62361910|NCT03698422||Healthy controls|"Estimated glomerular filtration rate (eGFR) \> 60 mL/min for \> 3 months and no known current or chronic medical or surgical conditions.~Blood and urine samples are collected for every 3rd hour during 24 hours"
62361911|NCT03698422||Predialysis CKD subjects|"Estimated glomerular filtration rate (eGFR) between 30 and 15 mL/min for \> 3 months (i.e. CKD stage 4).~Blood and urine samples are collected for every 3rd hour during 24 hours"
62361912|NCT03698422||ESKD subjects|"Maintenance haemodialysis treatment for \> 3 months for ESKD and with anuria (urine excretion \< 100 mL/day).~Blood and urine samples are collected for every 3rd hour during 24 hours"
62361913|NCT03380026|EXPERIMENTAL|Valchlor 0.016% Topical Gel|0.016% w/w topical mechlorethamine gel applied over a minimum of 8 cm2, nightly, over a period of 4 months.
62361914|NCT03380026|ACTIVE_COMPARATOR|Valchlor plus Triamcinolone|0.016% w/w topical mechlorethamine gel (once, nightly) and Triamcinolone acetonide 0.1% ointment (up to three times daily) applied in over a minimum of 8 cm2, over a period of 4 months.
62361915|NCT04679389|EXPERIMENTAL|Acetazolamide|Acetazolamide administered via capsule or liquid suspension. Capsule would be 250 mg oral capsules encapsulated by gelatin capsule and filled with lactose to match placebo. Liquid suspension would be 25 mg/mL oral suspension but adding 125 mg Acetazolamide tablets to suspending agent Ora-blend
62361916|NCT04679389|PLACEBO_COMPARATOR|Placebo|Placebo administered via capsule or liquid suspension. Capsule would be a gelatin capsule filled with lactose powder to match Acetazolamide. Liquid suspension would be Ora-blend.
62361917|NCT02691481|ACTIVE_COMPARATOR|Oatmeal breakfast|consuming 200 kcal of plain cooked oatmeal for breakfast
62361918|NCT02691481|ACTIVE_COMPARATOR|Glucerna formula|consuming 200 kcal of Glucerna shake for breakfast
62361919|NCT02691481|ACTIVE_COMPARATOR|Ultra Glucose Control formula|consuming 200 kcal of Ultra Glucose Control shake for breakfast
62361920|NCT03683004||CRC patients (Ctx+ group)|Postoperative CRC patients scheduled to begin CTX
62361921|NCT03683004||CRC patients (CT- group)|Postoperative CRC patients who do not receive CTX
62361922|NCT03683004||Healthy control group|Study participants that are demographically matched to CRC study patients and meet all inclusion criteria
62361923|NCT04547998|EXPERIMENTAL|All Participants (within patient control)|Each participant will serve as their own Control, receiving both Control and Investigational Interventions randomly allocated to treatment of a portion of a depigmented vitiligo lesion.
62361924|NCT04795492|EXPERIMENTAL|Intervention group|Remote intervention
62361925|NCT04795492|ACTIVE_COMPARATOR|Control group|Routine outpatient follow-up
62361926|NCT04238611|EXPERIMENTAL|Lactate microneedle|Measurement of lactate through microneedle
62361927|NCT05225480|EXPERIMENTAL|intervention arm|"The illness perception conversation will be delivered in one session during around 15 minutes. The conversation will be based on responses to the eight item Brief illness perception questionnaire and a rating of the most relevant item made by the patient on the same day.~The aim of the conversation will be to get an overview of the patient's illness perceptions concerning their knee OA and what is deemed the most maladaptive perceptions by the participant. Participants will be invited to elaborate on their thoughts concerning these perceptions.Although any maladaptive perceptions will be corrected if natural during the conversation, the conversation will not lead to any active attempts of changing illness perceptions. Rather, the conversation focusses on giving patients time and opportunity to express knee pain related perceptions and worries concerning their knee pain."
62361928|NCT05225480|ACTIVE_COMPARATOR|control arm|"The control conversation will be delivered in one session during around 15 minutes. In order to create two similar conversational settings where the only difference is the actual content of the conversations. The conversation will be based on responses to an eight item questionnaire concerning motivation for research participation and - similar to the illnes perception conversation - a rating of the most relevant item made by the patient.~The aim of the conversation will be to get an overview of the patient's motivation for research participation and let them elaborate on their thoughts concerning their motivation."
62361929|NCT01454024||Total study population|
62361930|NCT05557097||Group ultrasound + vaginal examination|Patients submitted to instrumental delivery by clinicians who routinely perform intrapartum sonography as an adjunct to clinical examination prior to vacuum delivery
62361931|NCT05557097||Group vaginal examination|Patients submitted to instrumental delivery by clinicians not performing intrapartum sonography prior to vacuum delivery
62361932|NCT01918267||Cohort|
62361933|NCT01270724|EXPERIMENTAL|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)|Two to four cycles of induction therapy with open label GemPOx followed by consolidation and autologous stem cell transplant (ASCT).
61982127|NCT04922983|SHAM_COMPARATOR|Group I: Placebo isometric measure, no injection|Group I: no isometric yoga-like exercise, no injection given.
61982128|NCT04922983|PLACEBO_COMPARATOR|Group II Isometric yoga-like exercise, placebo injection given|Group II isometric yoga-like exercise, injection of preservative-free normal saline.
61982129|NCT04922983|ACTIVE_COMPARATOR|Group III: True isometric exercise, botulinum injection|Group III: Isometric yoga-like exercise, botulinum injection given
62361934|NCT04010162||Group-1: King's College Hospital|Doctors in King's College Hospital, London, The United Kingdom (Excluding Urology and Gynecology)
62361935|NCT04010162||Group-2: Uludag University Hospital|Doctors in Uludag University Hospital, Bursa, Turkey (Excluding Urology and Gynecology)
62361936|NCT04010162||Group-3: The United States|Doctors from The United States (Excluding Urology and Gynecology)
62361937|NCT04010162||Group-4: The World|Doctors from all over the world (Excluding Urology and Gynecology)
62361938|NCT05825313|EXPERIMENTAL|Podcast Group|Podcast was applied to the experimental group.
62361939|NCT05825313|NO_INTERVENTION|Control Group|No intervention was applied to the control group.No intervention was applied to the control group.
61982130|NCT04922983|ACTIVE_COMPARATOR|Crossover|After the three months, Arm I and Arm II patients will be given botulinum injections, and Group I will be given the proper yoga-like exercise. These two arms will constitute a further comparator with their own performances in the first 3 months of the study.
62361940|NCT04853199|EXPERIMENTAL|Quercetin group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal
62361941|NCT04853199|PLACEBO_COMPARATOR|Placebo Group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal
62361942|NCT04220138|OTHER|cataract patients with poor red reflex|included cataract patients with poor red reflex
62361943|NCT00524043|EXPERIMENTAL|001|Paliperidone ER 1.5 mg tablet once daily for 6 weeks
62361944|NCT00524043|ACTIVE_COMPARATOR|002|Paliperidone ER 6 mg tablet once daily for 6 weeks
62361945|NCT00524043|PLACEBO_COMPARATOR|003|Placebo Once daily for 6 weeks
62361946|NCT04632745|OTHER|Cast Group|participant with distal radius fracture will be treated with short arm fiberglass cast
62361947|NCT04632745|OTHER|Splint Group|participant with distal radius fracture will be treated with short arm velcro wrist splint
62361948|NCT04988321|ACTIVE_COMPARATOR|Primary motor cortex (M1)|Stimulation of the M1
62361949|NCT04988321|ACTIVE_COMPARATOR|Dorsolateral prefrontal cortex (DLPFC)|Stimulation of the DLPFC
62361950|NCT01708538|ACTIVE_COMPARATOR|Epithelium on|Epi not removed during CXL treatment
62361951|NCT01708538|ACTIVE_COMPARATOR|Epithelium off|Epi removed before CXL treatment
62361952|NCT00932009||Human papillomavirus|Tanzanian men with HPV and Tanzanian men without
62361953|NCT01577355|EXPERIMENTAL|[C14]-LY2784544|Single 30 mg oral dose containing 100 micro curies of LY2784544
62361954|NCT05263544||Patients with displaced IUD|
62739184|NCT01020409||cardiac surgery with CPB use|Adult patients, who signed the informed consent, intervention: first-time scheduled heart surgery with CPB use.
61982131|NCT04718467|EXPERIMENTAL|adults group (aged 18-59 years) & vaccine|three doses of 40μg Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21, 42.
61982132|NCT04718467|PLACEBO_COMPARATOR|adults group (aged 18-59 years) & placebo|three doses of placebo at the schedule of day 0, 21, 42.
61982133|NCT04718467|EXPERIMENTAL|elderly adults group (aged 60-85 years) & vaccine|three doses of 40μg Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21, 42.
61982134|NCT04718467|PLACEBO_COMPARATOR|elderly adults group (aged 60-85 years) & placebo|three doses of placebo at the schedule of day 0, 21, 42.
61982135|NCT01910090|EXPERIMENTAL|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|FLURBIPROFEN, FAMOTIDINE 100/20 mg MULTI-LAYER TABLET one tablet, once
61982136|NCT01910090|ACTIVE_COMPARATOR|ANTADYS® and PEPCID®|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
61982137|NCT04718142|EXPERIMENTAL|vNEP with various shapes and sizes and overnight PSG|Administer vNEP therapy to study participants on the throat's anterior surface with a variable negative pressure ranging from -20 cmH2O up to -35 cmH2O. Assess participants for a reduction in Apnea-Hypopnea Index (AHI) for at least 120 minutes using polysomnography (PSG) and treatment tolerance compared to CPAP.
61982138|NCT01041560||Stoke|Hemiplegia with unilateral changes in tone and muscle strength
61982139|NCT00525174|ACTIVE_COMPARATOR|Patching|2 hours daily patching of the sound eye plus one hour near activities while patching
61982140|NCT00525174|ACTIVE_COMPARATOR|Bangerter filters|Bangerter filter worn on sound eye spectacles lens full time plus at least one hour near activities
62361955|NCT05263544||Patients without displaced IUD|
62361956|NCT05693688|EXPERIMENTAL|atosiban|Atosiban: bolus injection of 6.75 mg/0.9 ml atosiban in one minute followed by a continuous infusion of 18 mg/hour (=24ml/hour) for 3 hours followed by a continuous infusion of 6 mg/hour (=8 ml/hour) for the remaining 45 hours.
62361957|NCT05693688|PLACEBO_COMPARATOR|placebo|Placebo: injection of 0.9 ml saline in one minute followed by a saline infusion for 3 hours (24 ml/hour) followed by a continuous infusion (8 ml/hour) for the remaining 45 hours.
62361958|NCT02345044|EXPERIMENTAL|CS-3150 1.25 mg|One CS-3150 1.25 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
62361959|NCT02345044|EXPERIMENTAL|CS-3150 2.5 mg|Two CS-3150 1.25 mg tablets administered orally, once daily after breakfast.
62361960|NCT02345044|EXPERIMENTAL|CS-3150 5 mg|Two CS-3150 2.5 mg tablets administered orally, once daily after breakfast.
62361961|NCT02345044|PLACEBO_COMPARATOR|Placebo|Two placebo tablets to match CS-3150 tablet, administered orally, once daily after breakfast.
62361962|NCT02345044|ACTIVE_COMPARATOR|Eplerenone, 50-100 mg (Open Label)|One or two 50mg eplerenone tablet(s) administered orally, once daily after breakfast.
62361963|NCT01920971|ACTIVE_COMPARATOR|inferared therapy|hot pack therapy combined active infrared therapy over the low back (wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2) followed by 20-min supervised therapeutic exercise, for 3 times per week for a 4-week duration. Patients will be assessed at before treatment and follow-up assessments, including after 2 week of treatment; after 4 weeks of treatment; and 1 and 3 months, respectively, after treatment is terminated.
62361964|NCT01920971|PLACEBO_COMPARATOR|placebo infrared therapy|hot pack therapy combined placebo infrared therapy over the low back (wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2) followed by 20-min supervised therapeutic exercise, for 3 times per week for a 4-week duration. Patients will be assessed at before treatment and follow-up assessments, including after 2 week of treatment; after 4 weeks of treatment; and 1 and 3 months, respectively, after treatment is terminated.
62739185|NCT01375127||Subjects from Study A3921009|
62739186|NCT01375127||Subjects from Study A3921030|
62739187|NCT01091558||Colonoscopy|Healthy volunteer who is having a screening colonoscopy
62739188|NCT01091558||Ulcerative Colitis|Patients with confirmed ulcerative colitis who are scheduled for endoscopy for medical reasons.
62739189|NCT01153711|EXPERIMENTAL|BI 1744 10 mcg|solution for oral inhalation
62361965|NCT04209400|EXPERIMENTAL|Sci-B-Vac®|The 3-antigen HepB vaccine, Sci-B-Vac® contains three recombinant proteins of HBV viral envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac® was supplied in 1.0 ml vials.
62361966|NCT04209400|ACTIVE_COMPARATOR|Engerix-B®|The single-antigen HepB vaccine, Engerix-B® (GSK), contains the small S recombinant protein. Engerix-B® was supplied in 1.0 ml vials.
62361967|NCT04262908||Patients implanted with hip or knee prostheses|Patients who had hip or knee arthroplasty will be followed and asked at 3-months visit if they resumed their job or not. In both cases, further informations will be gathered
62361968|NCT05441943|EXPERIMENTAL|Lymphovenous anastomosis surgery|Lymphovenous anastomosis surgery with pre-operative planning using ICG lymphography and ultra high frequency ultrasound.
62361969|NCT02925559|EXPERIMENTAL|Dapagliflozin|The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
62361970|NCT02925559|ACTIVE_COMPARATOR|Gliclazide MR|As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
62361971|NCT02078661|ACTIVE_COMPARATOR|PG101 0.25%|Topical application of drug
62361972|NCT02078661|ACTIVE_COMPARATOR|PG101 1.0%|Topical application of drug
62361973|NCT02078661|PLACEBO_COMPARATOR|Placebo|Topical application of placebo
62361974|NCT03936478|EXPERIMENTAL|8.2 Gy Radiation Therapy|Accelerated partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm PTV margin. Treatment duration will be 5-6 days and treatments will be on alternative weekdays, with a minimum interval of 40 hours between subsequent fractions.
62361975|NCT04438304|EXPERIMENTAL|Intervention|64Cu-SARTATE will be administered at a fixed administration dose of 200 MBq (5.4 mCi) given as a single bolus intravenous injection.
62361976|NCT03152396|OTHER|Patients with inflammatory arthritis|All patients enrolled have a form of inflammatory arthritis and at least one uncontrolled CV risk factor (i.e. blood pressure, LDL-cholesterol, HbA1C, or current tobacco use). Pharmacist will assess each participants CV risk score using the validated RxEACH CV risk calculator. Over the 6 month intervention period, pharmacists will assist patients to modify a contributing risk factor thru treatment recommendations, prescription adaptation, and prescribing where necessary to meet treatment targets.
62361977|NCT00028119||Cohort 1|HIV-uninfected non-sex worker women
62361978|NCT00028119||Cohort 2|HIV-discordant heterosexual couples attending STD clinics
61982141|NCT01646515|PLACEBO_COMPARATOR|placebo arm|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
62361979|NCT03043261|EXPERIMENTAL|Psycho-Behavioral Intervention|"Williams LifeSkills modules which cover 10 core skills designed to improve coping skills, stress management and interpersonal relationships: 1) being aware of negative thoughts and feelings, 2) making a decision, 3) deflection skills, 4) problem solving or action skills, 5) assertion, 6) saying no, in addition to the following preventive skills: 7) speaking up, 8) listening, 9) empathy and 10) increasing positives"
61982142|NCT01646515|ACTIVE_COMPARATOR|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
61982143|NCT05540301|EXPERIMENTAL|Modified Sleeper Stretch Group|Modified sleeper stretch was performed for four weeks.
61982144|NCT05540301|ACTIVE_COMPARATOR|Modified Cross-Body Adduction Stretch Group|Modified cross-body adduction stretch was performed for four weeks.
61982145|NCT01356745|EXPERIMENTAL|premixed 50% nitrous oxide and oxygen|
61982146|NCT01356745|PLACEBO_COMPARATOR|medical air|
62361980|NCT02468960|OTHER|OPN strategy (study group)|"Interventions planned in this arm are as follows:~* Predilatation with OPN NC balloon catheter.~* Absorb BVS implantation.~* Treated segment visualization by OCT.~* Clinical FU at 12 months."
62361981|NCT02468960|OTHER|Standard strategy (control group)|"Interventions planned in this arm are as follows:~* Predilatation with standard compliant balloon.~* Absorb BVS implantation.~* Treated segment visualization by OCT.~* Clinical FU at 12 months."
62361982|NCT01329341|EXPERIMENTAL|Arm 1|Service Dogs
62361983|NCT05152667||Arm 1|Women with adenomyosis pretreated with levonorgestrel-releasing intrauterine device (LNG-IUS) and proceeding with the ICSI
62361984|NCT05152667||Arm 2|"Women with adenomyosis pretreated with oral progestin Dienogest and proceeding with the ICSI"
62361985|NCT06178757|ACTIVE_COMPARATOR|Group TAPB = Transversus abdominis plane block group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 0,5 mg/kg meperidin will be performed for rescue analgesia
62361986|NCT06178757|ACTIVE_COMPARATOR|Group EOIB = External oblique intercostal plane block group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 0,5 mg/kg meperidin will be performed for rescue analgesia
62361987|NCT00848770|ACTIVE_COMPARATOR|1, 140 to 160 mmHg|Esmolol, NPS or NOR
62361988|NCT00848770|ACTIVE_COMPARATOR|2, 161 to 180 mmHg|Esmolol, NPS or NOR
62361989|NCT00848770|ACTIVE_COMPARATOR|3, 181 to 200 mmHg|Esmolol, NPS or NOR
62361990|NCT02829008|EXPERIMENTAL|low-dose-bevacizumab/Pemetrexed|Low-dose-bevacizumab is given at a dose of 2 mg/kg once weekly by intravenous transfusion, which is on day 1, 8 and 15, and every three weeks are a treatment cycle .Pemetrexed is given at a dose of 500mg/m2 once on the first day by intravenous transfusion, and repeated every three weeks, too. The pretreatment of pemetrexed should be conducted within the study.
62361991|NCT02829008|ACTIVE_COMPARATOR|Treatment of physician' choice|Treatment of physician's choice can be any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. It can be drugs like taxanes,capecitabine, gemcitabine, cisplatin, everolimus or even nutrient solution,et al.
62361992|NCT00586638|EXPERIMENTAL|1|Video Game play with training strategy
62739190|NCT01153711|EXPERIMENTAL|Ketoconazole 400 mg|tablet
61982147|NCT02671994|EXPERIMENTAL|A (experimental group)|Oncologic treatment decision based on G8 screening followed by geriatric assessment and subsequent MDT, if needed, in addition to standard assessment (ECOG Performance Status + clinical assessment).
61982148|NCT02671994|NO_INTERVENTION|B (control group)|Oncologic treatment decision based on standard assessment (ECOG Performance Status + clinical assessment).
62361993|NCT00586638|ACTIVE_COMPARATOR|2|Video game play without training strategy
61982149|NCT00969176|NO_INTERVENTION|paracetamol|not applicable, since all included cases will receive intravenous paracetamol
62361994|NCT00586638|NO_INTERVENTION|3|Minimal contact control
62361995|NCT00854438|EXPERIMENTAL|Active treatment arm|Reduction of anticholinergic drug effects by pharmacist review
62361996|NCT00854438|NO_INTERVENTION|Control|No intervention
62361997|NCT02213549|PLACEBO_COMPARATOR|Placebo|3 placebo capsules/day for 12 weeks
61982150|NCT03089606|OTHER|Single Arm|This is a single arm study. All participants completed the study interventions which are pembrolizumab treatment, FDG PET, C11-AMT PET and CT scans.
61982151|NCT02750592|EXPERIMENTAL|secukinumab 150mg|A screening (SCR) epoch running 4-10 weeks before baseline (BSL) was used to assess eligibility followed by 52 weeks of treatment. The treatment periods consist of Treatment period 1 (BSL to Week 24) and Treatment period 2 (Week 24 to Week 52). After Week 52 follows a post-treatment follow-up until Week 60. A follow-up visit was done at 12 weeks after last study treatment administration for all patients, regardless of whether they completed the entire study as planned (Week 60) or discontinue prematurely.
61982152|NCT00982514||Standard dose asparaginase|Children who according to the protocol NOPHO ALL 2008 receive standard dose asparaginase
61982153|NCT00982514||Reduced dose asparaginase|Children who receive reduced dose asparaginase according to NOPHO ALL 2008
61982154|NCT01798199|EXPERIMENTAL|Alzheimer disease|
61982155|NCT05543122||Breastfeeding women|Either of the following drugs at steady state (Atenolol, Bupropion, Brivaracetam, Escitalopram, Fluconazole, Lacosamide, Lamotrigine, Levetiracetam, Methotrexate or Ezetimibe).
61982156|NCT04269980|ACTIVE_COMPARATOR|Group (PHN)|Group (PHN) (n=15): will receive hypotensive anesthesia with phentolamine infusion (Rogitamine, Egypharma) via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure
62361998|NCT02213549|EXPERIMENTAL|Ume paste and ginger powder|3 experimental capsules/day for 12 weeks.
61982157|NCT04269980|ACTIVE_COMPARATOR|Group MG|Group MG (n=15): will receive hypotensive anesthesia with 40 mg/kg Magnesium sulphate as bolus in 15 min with infusion later on till end of surgery at the rate of 10 mg/kg/hr .
61982158|NCT02420054|ACTIVE_COMPARATOR|Intermittent fasting|Intermittent fasting conducted by a group of subjects with type 2 diabetes mellitus and an age- and BMI matched control group.
61982159|NCT02420054|ACTIVE_COMPARATOR|Time control|A time control period.
61982160|NCT03523975|EXPERIMENTAL|Venetoclax, Lenalidomide, Rituximab|Rituximab 375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12 Lenalidomide 10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12. Venetoclax PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
61982161|NCT00488163|ACTIVE_COMPARATOR|Atomoxetine|Atomoxetine 40 mg compounded into capsules.
62361999|NCT01085019|EXPERIMENTAL|Dietary supplement: Cinnamon|
62362000|NCT01085019|EXPERIMENTAL|Dietary supplement: Oregano|
62362001|NCT01085019|EXPERIMENTAL|Dietary supplement: Ginger|
62362002|NCT01085019|EXPERIMENTAL|Dietary supplement: Rosemary|
62362003|NCT01085019|EXPERIMENTAL|Dietary supplement: Black pepper|
62362004|NCT01085019|PLACEBO_COMPARATOR|Dietary supplement: Placebo|
62362005|NCT03117309|EXPERIMENTAL|PART A: Nivolumab|Nivolumab 240mg; Nivolumab 360mg
62362006|NCT03117309|EXPERIMENTAL|PART B: Nivolumab + Ipilimumab|Nivolumab 3mg/kg and Ipilimumab 1mg/kg; Nivolumab 360mg
62362007|NCT03125018|EXPERIMENTAL|Test Subject|All subjects are enrolled into the test group and receive the LNCS ADTX Sensor.
62362008|NCT01586650|EXPERIMENTAL|Aerobic training|The patients in this arm perform a 50-minute-walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
62362009|NCT01586650|PLACEBO_COMPARATOR|Stretching exercises|The control group perform global stretching exercises for approximately 20 minutes 3 times a week for 12 weeks.
62362010|NCT00224783|ACTIVE_COMPARATOR|CAIV-T|CAIV-T contains 3 cold-adapted influenza virus strains (A/H1N1, A/H3N2, B) concentrated and refined by centrifugal separation from the chorioallantoic membrane of specific pathogen-free (SPF) eggs, containing SPG (sucrose-phosphate-glutamate), arginine, and acid hydrolyzed pig gelatin as stabilizers. Subjects were inoculated once with about 0.1 mL of investigational vaccine in each nasal cavity (a total of 0.2 mL) using a nebulizer.
61982162|NCT00488163|PLACEBO_COMPARATOR|Placebo|Inactive matching compounding of placebo capsules
61982163|NCT00536796||Patients at very high risk|
61982164|NCT00536796||Patients at high risk|
61982165|NCT00536796||Patients at medium risk|
61982166|NCT00536796||Patients at low risk|
62362011|NCT00224783|PLACEBO_COMPARATOR|Placebo|Placebo contained 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2). Subjects received about 0.1 mL (a total 0.2 mL) of the control drug using a nebulizer.
62362012|NCT00964262|EXPERIMENTAL|SR Exenatide (PT302)|Intervention: Drug: SR Exenatide (PT302)
62362013|NCT03241589||Rural Veterans|Originally the aim was to include VA sites who received the direct to patient facing app from OCC. Due to a lack of enrollment, the first arm or group has been redefined as Veterans living in rural areas receiving a request to use the patient facing app.
62362014|NCT03241589||Nonrural Veterans|Originally the comparison group consisted of VA sites to eventually receive the direct to patient facing apps. Since our enrollment at the facility level was low, this arm now consists of Veterans receiving a request to use the patient facing app, living in nonrural areas.
62362015|NCT01514006||Study Cohort|Patients, aged 65 or above, undergoing elective primary unilateral hip arthroplasty in a fast-track setting.
62362016|NCT00535444|ACTIVE_COMPARATOR|Control|assisted appointment with physician
62362017|NCT02134067|EXPERIMENTAL|TAS-119|"TAS-119 tablets, oral, dose-escalating, 28-day cycle.~Paclitaxel (90mg/m2) is administered IV in combination with TAS-119 in each of the arms."
62362018|NCT02327156|NO_INTERVENTION|group L|receive 4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU diluted with 1mL normal saline
62362019|NCT02327156|ACTIVE_COMPARATOR|group LD|4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU and dexmedetomidine 20 μg diluted with 1mL normal saline
62362020|NCT03969836||NeurOS Group|All patients will have both INVOS and NeurOS systems placed before and during cardiac surgery for monitoring cerebral oxygenation and brain blood volume.
62362021|NCT02687360|ACTIVE_COMPARATOR|Active rTMS stimulation|This arm will receive high-frequency rTMS pulses directed at the medial prefrontal and anterior cingulate cortices.
62362022|NCT02687360|SHAM_COMPARATOR|Sham rTMS stimulation|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil and to produce activation of facial muscles similar to the effect of active rTMS without stimulating the brain itself.
62362023|NCT00415545|EXPERIMENTAL|1|Fluid Watchers LITE program
62362024|NCT00415545|EXPERIMENTAL|2|Fluid Watchers PLUS program
62362025|NCT00415545|NO_INTERVENTION|3|Usual care control group
61982167|NCT02468869|EXPERIMENTAL|Information structuring skills training|Physicians received a communication skills training focusing on information structuring with the so-called book metaphor for a structured discharge communication with the patient.
62362026|NCT02945306|EXPERIMENTAL|Adenotonsillectomy|Removal of tonsils and adenoids under a general anaesthetic
62362027|NCT02945306|ACTIVE_COMPARATOR|Watchful waiting with supportive care|Reassurance with active medical treatment of conditions associated with Sleep Disordered Breathing such as otitis media with effusion and allergic rhinitis
62362028|NCT02583997|ACTIVE_COMPARATOR|Routine third molar extraction|"Patients randomized to this arm will have all four wisdom teeth removed according to usual, standard care (i.e. with suturing of the lower alveoli).~Intervention: Suturing of lower alveoli"
62362029|NCT02583997|EXPERIMENTAL|Third molar extraction without suturing|"Patients randomized to this arm will have all four wisdom teeth removed according to usual, standard care, except that the resulting alveoli will not be sutured.~Intervention: Non suturing of lower alveoli"
62362030|NCT05952960|OTHER|TAU Rationale|Rationale based on prior OLP studies (e.g. Kaptchuk et al., 2010)
62362031|NCT05952960|OTHER|Mindfulness Rationale|Rationale based on mindfulness meditation
62362032|NCT05952960|OTHER|Suspension of Disbelief Rationale|Rationale based on suspending disbelief about the placebo
62362033|NCT05676827||Study group|Participants with masticatory muscle pain lasting for over 3 months.
61982168|NCT02468869|ACTIVE_COMPARATOR|Empathy skills training|Physicians received a communication skills training focusing on empathy skills with the acronym NURSE for an empathetic discharge communication with the patient.
61982169|NCT04407000|EXPERIMENTAL|Test Drug|Loqular 200 mg Film Tablet containing 200 mg favipiravir (World Medicine İlaç-Turkey)
62362034|NCT05676827||Control group|Participants without masticatory muscle pain in last 6 months.
62362035|NCT04959604|EXPERIMENTAL|ICG-marked Colon Carcinoma|The participants will receive an endoscopic marking via ICG preoperatively
62362036|NCT06196619||Stage 1 lipedema patients|It is the stage where normal skin surface, enlarged subcutaneous fat tissue, and many small nodules are present upon palpation.
62362037|NCT06196619||Stage 2 lipedema patients|It is the stage with rough skin surface, large nodules of palpable subcutaneous fat tissue
62362038|NCT06196619||Stage 3 lipedema patients|It is the stage in which lobular deformation of the skin surface occurs with enlarged fatty tissue.
62362039|NCT00838370|EXPERIMENTAL|DPYD*2A|Patients are screened for a DPD-deficiency. Patients with a DPYD\*2A mutation are eligible for intervention with capecitabine/5-FU .
62362040|NCT05263921|ACTIVE_COMPARATOR|Treatment A: PF-07321332/ritonavir|PF-07321332 ritonavir
62362041|NCT05263921|EXPERIMENTAL|Treatment B: PF-07321332/ritonavir|PF-07321332/ritonavir mixed with water
62362042|NCT05263921|EXPERIMENTAL|Treatment C: PF-07321332/ritonavir|PF-07321332/ritonavir mixed with applesauce
62362043|NCT05263921|EXPERIMENTAL|Treatment D: PF-07321332/ritonavir|PF-07321332/ritonavir mixed with vanilla pudding
62362044|NCT03767998|EXPERIMENTAL|IMST group|Interventions: Respiratory muscle training for IMST. Inspiratory muscle training for patients with inspiratory muscle weakness (MIP less than 70% of normal range). IMT will commence from 30% to 60 % of MIP and then adjust one level of training loading according to the tolerance of continuously breathing through a respiratory trainer for two sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week.
62362045|NCT03767998|ACTIVE_COMPARATOR|Control group|Intervention: Non-training group, receive regular rehabilitation. All participants will receive usual rehabilitation care including body positioning instruction, postural correction, breathing control, cough maneuver, respiratory muscle stretch, chest wall mobility exercise and ventilation, fatigue management.
62362046|NCT03767998|EXPERIMENTAL|EMST group|Intervention: Respiratory muscle training for EMST. For patients with only swallowing disturbance. Training resistance will be adjusted accordingly. The loading will be performed with the previous resistance setting or even lower if training load is not tolerated or not completed.
62362047|NCT02031198|EXPERIMENTAL|AADvac1|"Patients who have received 6 doses in the previous trial will be administered 1-2 booster doses of AADvac1 (2 if their antibody titers decline below those achieved in the previous trial).~Patients who have received 3 doses in the previous trial will be administered another 3 doses, then vaccinated with booster doses as above."
62362048|NCT01871272||Meniscus Injury Patients|Patients having surgery for a meniscal tear.
62362049|NCT03356808|EXPERIMENTAL|Lung cancer-specific T cells|Peripheral blood mononuclear cells (PBMCs) of patients, who have cancer antigen identified lung cancer, will be obtained through apheresis, and T cells will be activated and ex vivo engineered.
62362050|NCT02295800||Mothers|HIV Infected mothers
62739191|NCT00520702|ACTIVE_COMPARATOR|3D CRT|3-Dimensional Conformal Radiation Therapy (3D CRT)
62739192|NCT00520702|ACTIVE_COMPARATOR|IMRT|Intensity-Modulated Radiation Therapy (IMRT)
62739193|NCT00624468|EXPERIMENTAL|Atacicept|
61982170|NCT04407000|ACTIVE_COMPARATOR|Reference drug|Avigan 200 mg Film Tablet containing 200 mg favipiravir (Toyama Chemical Industry Co.Ltd./Japan)
62362051|NCT02295800||Infants|HIV exposed infants
62362052|NCT02295800||Healthcare workers|Facility based healthcare workers
62739194|NCT00624468|PLACEBO_COMPARATOR|Placebo|
62739195|NCT05914077|EXPERIMENTAL|Duodenopancreatic aspiration after secretin stimulation + EUS-FNA|Duodenopancreatic aspiration after secretin stimulation will be performed followed by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA)
62362053|NCT01350011|ACTIVE_COMPARATOR|Innovative System (IS)|The innovative intervention uses the treatment system to support motivational counseling treatment entrance and treatment utilization. It has two components, a Motivational Intervention component via Expert System Counseling, and a Treatment Component that incorporates both pharmacological and behavioral long-term components. An innovative aspect of the IS is the use of the pharmacist as an intervention agent, who queries participants on their readiness to quit smoking, encourages involvement in the motivational intervention and in treatment, and who, along with the counselors, is available to answer medication questions.
62362054|NCT01350011|ACTIVE_COMPARATOR|Standard Treatment Control|After a baseline interview, patients in this condition will be given a packet of brochures on quitting, including descriptions of self-quitting and help-lines. Participants in this condition will continue to have access to their primary care providers, and through that system have access to pharmacotherapy for smoking cessation, if they wish to receive it. They will receive written instructions on how to approach their primary care provider about smoking cessation medication, and a written description of the medications used in smoking cessation and a list of those that are available to them through the public health system. At each assessment, patients will be queried about their use of these resources.
62362055|NCT05817955|EXPERIMENTAL|Azacitidine (AZA) with Ruxolitinib|"The treatment phase of each course of treatment is based on Azacitidine (AZA)+Ruxolitinib. Specific scheme: (1) Azacitidine+Ruxolitinib scheme: Azacitidine (AZA) 75mg · m-2 · D-1, D1 to D7, subcutaneous injection; Ruxolitinib, D1 to D28, orally, select Ruxolitinib initial dose according to platelet level: ① PLT\> 100X10\*9/L: 20mg BID orally; ② PLT (50-100) X10\*9/L: 15mg BID orally; ③ PLT \<50X10\*9/L: 10mg Bid orally.~The above schemes are all 28 days of treatment. If the patient has serious adverse reactions (such as infection and bone marrow suppression), appropriately delay the next course of treatment or adjust the amount of RUXOLITINIB. Termination of the scheme treatment."
62362056|NCT02587858||PKAN|This group consists of individuals diagnosed with PKAN using a combination of MRI, other clinical findings, and PANK2 gene sequencing.
61982171|NCT02838563||Patient living in nursing home|Patient with an Alzheimer Disease or related disorder living in nursing home.
62362057|NCT02587858||PLAN|This group consists of individuals diagnosed with PLAN using a combination of MRI, other clinical findings and PLA2G6 gene sequencing.
62362058|NCT02587858||BPAN|This group consists of individuals diagnosed with BPAN using a combinatino of MRI, other clinical findings, and WDR45 gene sequencing.
62362059|NCT04080492||Hypertrophic Cardiomyopathy|Patients being seen for the first time at the Cleveland Clinic for Hypertrophic Cardiomyopathy.
62362060|NCT04080492||Thoracic Aortic Dilatation|Patients being seen for the first time at the Cleveland Clinic for Thoracic Aortic Dilatation.
62362061|NCT04080492||Radiation Induced Heart Disease|Patients being seen for the first time at the Cleveland Clinic for Radiation-Induced Heart Disease.
62362062|NCT01668381||HCC patients|Hepatocellular carcinoma patients treated by radiofrequency ablation
62362063|NCT03620604||Stress urinary incontinence surgery|This is a single observational study were all patients had stress urinary incontinence. All of them underwent surgery performing a single incision sling type ALTIS
62362064|NCT00136838|EXPERIMENTAL|Neutral Cue first, then Active Cue|"Each participant receives two consecutive interventions.~1. Neutral Cue: during this phase of treatment participants were presented with neutral (sham) cue~2. Cigarette cue: during this phase of treatment participants were presented with active cigarette cue."
62362065|NCT00136838|EXPERIMENTAL|Active Cue first, then Neutral Cue|"Each participant receives two consecutive interventions.~1. Cigarette cue: during this phase of treatment participants were presented with active cigarette cue.~2. Neutral Cue: during this phase of treatment participants were presented with neutral (sham) cue"
62362066|NCT02884271||cardiac arrest group|patients who develop intraoperative cardiac arrest
62362067|NCT02884271||without cardiac arrest group|patients who don't develop intraoperative cardiac arrest
62362068|NCT01191281|EXPERIMENTAL|Diet/nutrition counsel+food aid|Intervention. Patients enrolled in the intervention group will receive a multi-component intervention that includes dietary and nutritional counseling and food assistance (food aid basket)
61982172|NCT05311332|EXPERIMENTAL|Anterior maxillary bone augmentation using computer guided autogenous cortical shell technique.|a patient-specific guide was used to harvest a chin cortical shell which was also prepared and positioned at the (anterior horizontally atrophied maxilla) recipient site using another patient-specific positioning guide.
62362069|NCT01191281|ACTIVE_COMPARATOR|dietary/nutritional counseling|Patients enrolled in the comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
62362070|NCT05480241|EXPERIMENTAL|Pancreatic Enzyme Replacement Therapy|Pancreatic Enzyme Replacement Therapy (PERT) 50000 Ph.U./meal + 25000 Ph.U./snack + Omeprazole 20mg once daily on fasting
62362071|NCT05480241|PLACEBO_COMPARATOR|Placebo|Placebo + Omeprazole 20mg once daily on fasting
62739196|NCT05914077|EXPERIMENTAL|EUS-FNA + duodenopancreatic aspiration after secretin stimulation|Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) will be performed followed by duodenopancreatic aspiration after secretin stimulation
62739197|NCT00858728|EXPERIMENTAL|1|5 portions fruit and vegetables/day
62739198|NCT00858728|OTHER|2|2 portions fruit and vegetables/day
61982173|NCT05311332|ACTIVE_COMPARATOR|Anterior maxilla bone augmentation using free hand autogenous cortical shell technique.|the horizontally atrophic anterior maxilla was augmented with a cortical shell technique the bone was harvested from the chin without a patient-specific guide.
61982174|NCT01184625|EXPERIMENTAL|Exercise|
61982175|NCT01184625|NO_INTERVENTION|No intervention|12 weeks of stable physical exercise level.
61982176|NCT03418298|EXPERIMENTAL|Prehabilitation group|Subjects will carry out a preoperative internet-based program including aerobic and resistance training three sessions per week
61982177|NCT03633487|EXPERIMENTAL|Mucinex® 1200 mg|Mucinex® 1200 mg Extended-Release (ER) Bi-Layer tablet (single dose)
61982178|NCT01895855|EXPERIMENTAL|PXVX0200|Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10\^8 CFU
61982179|NCT01895855|PLACEBO_COMPARATOR|Placebo|Biological: Placebo physiological saline
61982180|NCT02730325|ACTIVE_COMPARATOR|SBI 10 g BID|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10.0 grams twice per day
61982181|NCT02730325|PLACEBO_COMPARATOR|Placebo BID|Placebo
62362072|NCT02281968|EXPERIMENTAL|NSAID cohort|Patients who have had surgical management of ankle fracture will be given a standing regimen (scheduled doses) of 500 mg naproxen twice a day and will have received one intraoperative dose of ketorolac. Patients will have a prescription for opioids for breakthrough pain.
62362073|NCT02281968|PLACEBO_COMPARATOR|Placebo cohort|Patients who have had surgical management of ankle fracture will be given a standing regimen (scheduled doses) of placebo twice a day and will have received one intraoperative dose of saline solution. Patients will have a prescription for opioids for pain.
61982182|NCT00495170|EXPERIMENTAL|Concurrent proton and Chemotherapy|Proton Radiotherapy + Carboplatin + Paclitaxel
61982183|NCT00671307|PLACEBO_COMPARATOR|Placebo|Placebo
62362074|NCT04631614|EXPERIMENTAL|Manual therapy plus muscle strengthening exercises|The procedures to be performed with participants in the experimental group are as follows: (1) warm up with a walk or exercise bike for 5 minutes; (2) two ankle manual therapy techniques - \[a\] passive calf muscle stretching and \[b\] ankle joint mobilization; (3) five muscle strengthening exercises focusing on quadriceps and posterolateral hip complex - \[a\] clam exercise, \[b\] hip abduction exercise in side lying, \[c\] knee extension exercise in a sitting position, \[d\] squat exercise and \[e\] forward lunge exercise.
62362075|NCT04631614|ACTIVE_COMPARATOR|Muscle strengthening exercises|The procedures to be performed with participants in the control group are as follows: (1) warm up with a walk or exercise bike for 5 minutes; (2) five muscle strengthening exercises focusing on quadriceps and posterolateral hip complex - \[a\] clam exercise, \[b\] hip abduction exercise in side lying, \[c\] knee extension exercise in a sitting position, \[d\] squat exercise and \[e\] forward lunge exercise.
62362076|NCT02448017|ACTIVE_COMPARATOR|The Herbst appliance|Orthodontic functional appliance
61982184|NCT00671307|EXPERIMENTAL|Low dose|3 mg/kg of rhu-pGelsolin given as an IV infusion over 1 hour
61982185|NCT00671307|EXPERIMENTAL|Mid-dose|6 mg/kg of rhu-pGelsolin given as an IV infusion over 1 hour
62362077|NCT02448017|ACTIVE_COMPARATOR|Twin block appliance|Orthodontic functional appliance
62362078|NCT02182089||Dialysis patients with greater than 20% IDH|"Study Population:~The sample will be enriched for subjects prone to IDH, defined as patients who experience IDH for greater than 20% of HD treatments in the past 2 months. The study population will consist of 48 patients total, 75% of patients (n=36) prone to IDH and 25% of patients with less than 10% of IDH during the last two months (n=12)."
61982186|NCT00671307|EXPERIMENTAL|High dose|6 mg/kg of rhu-pGelsolin given a an IV infusion over 1 hour once a day for 3 days
61982187|NCT06081127|EXPERIMENTAL|Intervention|Patients assigned to the intervention arm will receive the intervention named Moving On After Breast Cancer (MOve-ABC).
61982188|NCT06081127|EXPERIMENTAL|Enhanced Usual Care (EUC)|All patients will receive EUC. However, participants assigned to this arm will have only EUC.
62362079|NCT02182089||Patients with less than 10% IDH|"Study Population:~The sample will be enriched for subjects prone to IDH, defined as patients who experience IDH for greater than 20% of HD treatments in the past 2 months. The study population will consist of 48 patients total, 75% of patients (n=36) prone to IDH and 25% of patients with less than 10% of IDH during the last two months (n=12)."
62362080|NCT00254163|ACTIVE_COMPARATOR|Fludarabine, Cyclophosphamide, and Rituximab|Fludarabine, Cyclophosphamide, and Rituximab (dosage based on day in cycle)
62362081|NCT00254163|EXPERIMENTAL|Pentostatin, Cyclophosphamide, and Rituximab|Pentostatin, Cyclophosphamide, and Rituximab (dosage depends on day in cycle)
62362082|NCT06337162|EXPERIMENTAL|INCB099280|Study participants will receive the recommended phase II dose (400mg/kg) of INCB099280 orally on days 1 through 28 of each 28-day cycle until liver transplant.
62362083|NCT03349580|EXPERIMENTAL|The training group|The training group performed rehabilitation program twice per week over 9 weeks. The group commenced rehabilitation 3 weeks after the surgery. During the phase one training (week 1 to week 5), the isometric exercises were preformed on the trunk extension, flexion and lateral flexion muscles. During the phase 2 (week 6 to week 9), the exercises were performed on the strength machines and duration of the exercises were maintained and prolonged to 30 seconds. The leg adduction and hip extension exercises were added. The patients were instructed to perform abdominal bracing (IAP) and maintain the neutral position of their lumbar spine before and during the exercises.
61982189|NCT03904433|EXPERIMENTAL|1. Sunflower oil|Sunflower oil (30 g)
61982190|NCT03904433|EXPERIMENTAL|2. Caprylic acid|Caprylic acid (20 g) + Sunflower oil (10 g)
61982191|NCT03904433|EXPERIMENTAL|3. Caprylic acid + Glucose|Caprylic acid (20 g) + Sunflower oil (10 g) + Glucose (50 g)
61982192|NCT03904433|EXPERIMENTAL|4. Coconut oil|Coconut oil (30 g)
61982193|NCT03904433|EXPERIMENTAL|5. Coconut oil + Glucose|Coconut oil (30 g) + Glucose (50 g)
61982194|NCT03904433|EXPERIMENTAL|6. Coconut oil + Caprylic acid|Coconut oil (30 g) + Caprylic acid (20 g)
61982195|NCT05302544|EXPERIMENTAL|"with mixed reality training group"|2 Mixed Reality sessions per week for 8 weeks in addition to motor activities usually performed
61982196|NCT05302544|ACTIVE_COMPARATOR|"without mixed reality training group"|group: only motor activities usually performed
61982197|NCT05757531|EXPERIMENTAL|[¹⁴C]-LY3437943|Single dose of \[¹⁴C\]-LY3437943 administered subcutaneously (SC).
61982198|NCT06163261|OTHER|Intervention group|This group will receive an individualized and person-centred prescription of physical activity and exercise in addition to standard care.
61982199|NCT06163261|NO_INTERVENTION|Control group|This group will receive standard care.
61982200|NCT03644745|EXPERIMENTAL|VM @ Home Usability|We will pilot our customer engagement and physical exercise system in the homes of up to 20 participants for 3 months. Participants will interact with the system on their own computers, smart phones, and/or televisions and wear an activity tracker throughout the study. Interactions include physical exercise, system usage, and video conferencing.
61982201|NCT01660607|EXPERIMENTAL|Dose escalation|For the Phase I arm of the study the addition of planned numbers and ratios of Treg compared to Tcon will occur at defined time points after hematopoietic cell infusion. Each cohort will have 3 patients per group. The initial doses and ratios utilized will be 1 x 10\^6/kg of T reg cells to 3x10\^6/kg of Tcon cells at a 1:3 ratio. In order to progress to the next dose level, there must be no evidence of grade 3 or 4 acute GVHD.
61982202|NCT05863910||Epilepsy Cohort|"For children with epilepsy, the following tools will be added for data collection at each time point:~* Side effects: Pediatric Epilepsy Side Effects Questionnaire \[PESQ\]~* Seizure frequency/severity: Seizure Diary Data Questionnaire"
62362084|NCT03349580|NO_INTERVENTION|The control group|The control group followed the hospital's standard protocol. These do not include exercises or physiotherapy before 3 months after surgery.
62362085|NCT04815538||industrial workers|Active workers more than 1 year in petrochemical plant, fertilizer factory , electrical station and food industry
62362086|NCT04815538||control group|office work unexposed
62362087|NCT01997281|EXPERIMENTAL|DF-cereal|"* dietary fiber-enriched cereal is provided with milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~* amount of cereal: 79 g (285.7 kcal) for dinner and breakfast, 38.5g (142.9 kcal) for night snack (10 p.m.)~* one serving (40g) of steamed egg is added for dinner and breakfast"
62362088|NCT01997281|OTHER|conventional cereal|"* conventional cereal is provided with milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~* amount of cereal: 80g (285.7 kcal) for dinner and breakfast, 40g (142.9 kcal) for night snack (10 p.m.)~* one serving (40g) of steamed egg is added for dinner and breakfast"
62362089|NCT00790530|EXPERIMENTAL|ATO-SR|Automated Telephone Outreach with Speech Recognition
62362090|NCT00790530|NO_INTERVENTION|Usual Care|Usual Care
62362091|NCT04690712|NO_INTERVENTION|Socio-Demographic Characteristics of Students|When the socio-demographic characteristics of the students are examined according to the pre-test findings; It was seen that 27% were in the first grade, 20.9% in the second grade, and 25.7% in the third grade. When the age groups were evaluated, it was determined that 47.8% were in the 7-8 age group, 51.5% were in the 9-10 age group and 50% of them were female students and 50% were male students. It was observed that 27.6% of the students had a bad income and 59.3% had a medium level of income. When the father's education status was questioned, it was determined that 17.6% of them did not finish primary school, 55.4% of them were primary school graduates, 2.6% of them were high school graduates. On the other hand, 55% of their mothers did not complete primary school, 43.5% were primary school graduates and 1.5% were secondary school graduates
62362092|NCT04690712|EXPERIMENTAL|Comparison of Students' Pretest and Posttest Development Screening Average|According to the results of height and weight screening at the pre-test stage; the average height of the students is 127.0 ± 9.11; It was determined that the average weight was 26.1 ± 6.19, the average height was 130.61 ± 8.83 and the average weight was 29.92 ± 6.39 in the final test stage. A significant difference was found between pre-test and post-test screening results
62362093|NCT04690712|EXPERIMENTAL|Comparison of Pre-Test and Post-Test Screening Results of Students|In the statistical evaluation, it was found that there was no significant difference between pre-test and post-test screening results
62362094|NCT02299804|EXPERIMENTAL|High dose arm|Have included the Levophencynonate Hydrochloric 1.5mg bid.
62362095|NCT02299804|EXPERIMENTAL|Low dose arm|Have included the Levophencynonate Hydrochloric 1.0mg bid.
61982203|NCT05863910||Cancer Cohort|"For children with cancer, the following tools will be added for data collection at each time point:~* Cancer symptom burden: Symptom Screening in Pediatrics Tool \[SSPedi\]~* Cachexia: Pediatric Functional Assessment of Anorexia/ Cachexia Treatment \[peds-FAACT\]"
62362096|NCT02299804|PLACEBO_COMPARATOR|Placebo arm|Have no any active component
62362097|NCT04297345|EXPERIMENTAL|hemodialysis group|"The active group will include patients with acute ischemic stroke who, in addition to conventional treatment (best possible medical treatment in patients admitted to a stroke unit), will undergo two hemodialysis sessions for a period of about 3 hours each session in the acute phase of stroke.~The investigators will perform a conventional and heparin-free hemodialysis using high-flow dialyzers to avoid possible adverse (allergic) reactions with polysulfones containing other dialyzers."
62362098|NCT04297345|NO_INTERVENTION|control group|The control group will be composed of patients with similar clinical and demographic characteristics to whom only conventional medical treatment will be applied.
62362099|NCT03191812|SHAM_COMPARATOR|Sham Stimulation|The Sham stimulation intervention will consist of one, twenty-minute session of transcranial direct current stimulation (tDCS) that does not target a cortical area but instead, provides just enough current to create tingling sensations across the scalp to mimic the feeling of receiving the real stimulation. The sham stimulation will use the same number and placement of electrodes as the real stimulation but with a much smaller total current intensity of 0.5 milliamps (mA).
62362100|NCT03191812|EXPERIMENTAL|M1 Stimulation|The M1 stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex at a total current intensity of 1.5 mA.
62362101|NCT03191812|EXPERIMENTAL|DLPFC Stimulation|The DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex at a total current intensity of 1.5 mA.
62362102|NCT03191812|EXPERIMENTAL|M1+DLPFC Stimulation|The M1+DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex and the dorsolateral prefrontal cortex simultaneously at a total current intensity of 3.0 mA.
62362103|NCT03511300|PLACEBO_COMPARATOR|Standard Instructions|Participants will receive standard instructions for cognitive tasks.
62362104|NCT03511300|EXPERIMENTAL|Goal Setting Instructions|Participants will receive goal-setting instructions for cognitive tasks.
62362105|NCT04514588|OTHER|caffeine consumption and metabolism|Participants will take part in two trials. Each trial will last one day at least one week apart. During the first trial half of the participants will consume caffeine (5mgr/kgr) and the rest only water. During the second trial a crossover design will be applied
62362106|NCT04514588|OTHER|control|Control group will consume only water (not coffee) and the same parameters will be recorded as previously
62362107|NCT00430391|EXPERIMENTAL|DVD patient high risk|Patients with a diagnosis of schizophrenia/schizoaffective disorder randomized to the DVD, high risk version
62362108|NCT00430391|EXPERIMENTAL|DVD patient low risk|Patient with a diagnosis of schizophrenia/schizoaffective disorder randomized to DVD consent, low risk version
62362109|NCT00430391|EXPERIMENTAL|DVD normal high risk|Participants with no psychiatric diagnosis randomized to DVD consent, high risk version
62739199|NCT06661642||Surgery patients|Patients undergoing various elective and sub-acute surgical procedures including thoracic, cardiac, abdominal, vascular, plastic, spinal neurosurgery, and orthopaedic procedures.
61982204|NCT05863910||General Pediatrics Cohort|There are no specific outcome scales added for this cohort.
62169332|NCT03090893|EXPERIMENTAL|Infusion group|Subjects will receive ATryn continuous infusion for maintaining serum antithrombin III levels between 80 - 100
61982205|NCT06237595|ACTIVE_COMPARATOR|1 Vagus nerve stimulation|The first group will receive cervical transcutaneous vagus nerve stimulation that will be carried out with a TENS device, using a small self-adhesive surface electrodes (1 cm diameter). The electrodes will be positioned on the surface of the neck that corresponds to the position of the left cervical branch of the vagus nerve, over the carotid pulse just medial to the sternocleidomastoid muscle (Molero-Chamizo et al., 2022) using a biphasic, asymmetrical waveform with a pulse duration that is less than 250 microseconds and a frequency of 20 hertz. Intensity is adjusted according to the sensory threshold level of each patient, each session lasts for 30 minutes (Kutlu et al., 2020). All patients will receive 3 sessions per week for a total of 12 sessions, The sessions will be carried on at Department of Rheumatology and Rehabilitation, Cairo University Hospital
61982206|NCT06237595|ACTIVE_COMPARATOR|2 Medical treatment|This group will receive medical treatment in the form of: Gabapentin 300 mg capsule once at night, and Duloxetine 30 mg cap once daily for 30 days.
61982207|NCT06237595|ACTIVE_COMPARATOR|3 Combined vagus nerve stimulation and medical treatment|This group will receive cervical t-VNS in the same protocol like the vagus nerve stimulation group, in addition to medical treatment in the form of: Gabapentin 300 mg capsule once at night, and Duloxetine 30 mg cap once daily for 30 days.
61982208|NCT03410940||Subjects who received a CLS Brevius Kinectiv stem|Subjects in need of a total hip arthroplasty who met the inclusion/exclusion criteria and received the CLS Brevius Kinectiv stem.
61982209|NCT02375191|ACTIVE_COMPARATOR|fentanyl|0.2% ropivacaine+ 1 mcg/kg fentanyl
62362110|NCT00430391|EXPERIMENTAL|DVD normal low risk|Participants with no psychiatric diagnosis randomized to DVD consent, low risk version
62362111|NCT00430391|EXPERIMENTAL|Routine control high risk|Participants with no psychiatric diagnosis randomized to routine consent, high risk version
62362112|NCT00430391|EXPERIMENTAL|Routine control low risk|Participants with no psychiatric diagnosis randomized to routine consent, low risk version
62362113|NCT00430391|EXPERIMENTAL|Routine patient low risk|Participants with schizophrenia/schizoaffective disorder randomized to routine consent, low risk version
62362114|NCT00430391|EXPERIMENTAL|Routine patient high risk|Participants with schizophrenia/schizoaffective disorder randomized to routine consent, high risk version
62362115|NCT05660889||Study group|Five patients with strong clinical suspicion of adrenocortical carcinoma
62362116|NCT05660889||Control group|Twenty patients without suspicion of adrenal malignancy. These patients should undergo an adrenal vein sampling as part of their routine diagnostics.
61982210|NCT02375191|EXPERIMENTAL|dexmedetomidine|0.2% ropivacaine+1 mcg/kg dexmedetomidine
62362117|NCT04783714|EXPERIMENTAL|Active Group|"Active treatment comprises of 3 soft gel capsules daily (with food) of Swisse Nutra+ Cholesterol Balance, a novel combination nutraceutical containing bergamot juice extract, artichoke leaf extract, hydroxytyrosol and plant sterols, totaling a daily dose of 375 mg bergamot juice extract, 150 mg artichoke leaf extract, 50 mg hydroxytyrosol and 1.8 g sunflower phytosterols.~Each capsule contains 125mg of bergamot juice extract, 50mg artichoke leaf extract, 16.67mg hydroxytyrosol and 600mg plant sterols.~The intervention will be administered for 4 months (112 days)."
62362118|NCT04783714|PLACEBO_COMPARATOR|Placebo|3 soft gel capsules of matching placebo daily (total daily dose of 696 mg palm olein and 232 mg olive oil).
62362119|NCT02033850|EXPERIMENTAL|APT-II group|"Intervention: rehabilitation of attention using the Attention Process Training-II.~Participants in the APT-II group will receive overall up to 40 hours of individual attention process training. Therapy will be administered in one two-hour session each week over a total of 20 weeks."
62362120|NCT02033850|NO_INTERVENTION|standard care group|Participants in the standard care group will not receive cognitive training or rehabilitation interventions, will be instructed to have an usual lifestyle, and will be conventionally provided of medication and clinic consultations
62362121|NCT02936336|NO_INTERVENTION|Control|without exercise intervention
61982211|NCT05418192|EXPERIMENTAL|Group A|Intervention Given: Enriched Environment (age-appropriate) + NDT + Therapeutic Dosing
61982212|NCT05418192|OTHER|Group B|Traditional Physical Therapy consisting of NDT
61982213|NCT05202418|EXPERIMENTAL|Biofeedback Enhanced Treatment|Participants in this group will participate in biofeedback enhanced cognitive behaviorally based coping skills treatment. Treatment will consist of a 6-visit group intervention conducted online, via Emory zoom. Groups will include 5-8 patients each. Sessions will include brief, daily homework to facilitate mastery that is developmentally tailored to youth (e.g., practice skills with support from phone or tablet apps). Groups will meet approximately every week for 6 weeks. Advanced Ph.D. students in clinical psychology and Principal Investigator will deliver the treatment protocol. They will complete questionnaires before and after each session to measure autonomic reactivity in response to stress induction and coping strategies.
61982214|NCT05202418|NO_INTERVENTION|Wait-list control|Participants randomized to the wait-list control group will complete the same measures of lifetime stress, autonomic reactivity, depression, anxiety. The identical treatment will be offered to control participants after the 6-week time point.
62169333|NCT03058237|EXPERIMENTAL|Part 1: Regimen A|"One low dose Arbaclofen Placarbil MR Prototype A tablet taken under fasting conditions.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
62362122|NCT02936336|EXPERIMENTAL|Exercise|Subjects with circuit exercise, aerobic dance, or Tai Chi exercise intervention.
62362123|NCT00822562|ACTIVE_COMPARATOR|Procedure/Surgery|surgery
62362124|NCT00822562|EXPERIMENTAL|Procedure|PRFA or PMCT
62362125|NCT01153672|EXPERIMENTAL|Treatment (enzyme inhibitor therapy, AI sensitization therapy)|Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD, letrozole PO QD, OR exemestane PO QD for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
62362126|NCT02783209|OTHER|Cataract surgery|Patient acts as his own control
62362127|NCT03309904|EXPERIMENTAL|Knee Control training program|The Knee Control program is a neuromuscular training program that consists of 6 different exercises, with 4 levels of progression and one pair-exercise, for each exercise. The Knee Control program takes about 10 minute to complete after familiarization. In addition, a 5-minute running warm-up is instructed to coaches. Coaches are to perform the Knee Control program + the 5 minute warm-up at all training sessions during the season, and the 5 minute warm-up before all matches.
62739200|NCT01149005|EXPERIMENTAL|insulin|patients who will get insulin with main meals during Intravenous (IV) antibiotic therapy due to pulmonary exacerbation
62362128|NCT03309904|NO_INTERVENTION|Control group - usual training|The control group teams receive no intervention, and coaches are instructed to carry out their normal training and warm-up practice throughout the season.
62362129|NCT02622438|OTHER|Course and follow up of patients affected by FSHD|
62362130|NCT03363165|ACTIVE_COMPARATOR|VM202|Participants will receive injections of VM202 (4 mgs) in calf skeletal muscle every 14 days for a total of four treatment days.
62362131|NCT03363165|PLACEBO_COMPARATOR|Placebo|Participants will receive injections of placebo in calf skeletal muscle every 14 days for a total of four treatment days.
62362132|NCT06109077|EXPERIMENTAL|Levator ani release|Participants will receive levator ani release exercise
62362133|NCT06109077|EXPERIMENTAL|Post isometric relaxion|Participants will receive post isometric relaxion exercise
62362134|NCT01313078|EXPERIMENTAL|Pegaspargase in women with cancer|Pegaspargase 2000 IU/m\^2 intramuscular or intravenously every 2 weeks
62362135|NCT05236660|EXPERIMENTAL|Multimodal care|Multimodal personalised treatment
62362136|NCT05236660|NO_INTERVENTION|Usual care|Usual care as offered to high-risk patients as offered in the Netherlands
62362137|NCT04865445|EXPERIMENTAL|AT-527 550 mg + midazolam (simultaneous)|n=12
62362138|NCT04865445|EXPERIMENTAL|AT-527 mg + midazolam (staggered)|n=12
62362139|NCT03375723|EXPERIMENTAL|Information on anatomy and physiology, and breathing technique|"Information on anatomy and physiology, and breathing technique~* Information about anatomy~* Information about physiology~* Breathing technique"
62362140|NCT03375723|ACTIVE_COMPARATOR|Usual care treatment|Usual care treatment given to patients with respiratory associated pain in acute PE, which is treatment with analgesics. The information on anatomy and physiology in acute PE is the usual information given by the physician at the ward that the patient is treated.
62362141|NCT01175590|EXPERIMENTAL|Besivance|besifloxacin ophthalmic suspension 0.6%
62362142|NCT01175590|PLACEBO_COMPARATOR|Vehicle|Vehicle of Besivance
62362143|NCT02076334|ACTIVE_COMPARATOR|Compression + normal garment|Far Infrared Fabric during exercise + Spandex at night
61982215|NCT06363006|EXPERIMENTAL|TKI+Cardonilizumab|"TKI:Tyrosine kinase inhibitors can serve as competitive inhibitors of adenosine triphosphate (ATP) binding to tyrosine kinase, as well as analogues of tyrosine, blocking the activity of tyrosine kinase and inhibiting cell proliferation.~Cardonilizumab:It can block the interaction between PD-1, CTLA-4 and their ligands PD-L1/PD-L2, B7.1/B7.2, thereby blocking the immunosuppressive response of the PD-1 and CTLA-4 signaling pathways, promoting tumor specific T cell immune activation, and inhibiting tumor cell growth."
61982216|NCT03573895|EXPERIMENTAL|Foam-Roller|
62169334|NCT03058237|EXPERIMENTAL|Part 1: Regimen B|"One low dose Arbaclofen Placarbil MR Prototype B tablet taken under fasting conditions.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
62362144|NCT02076334|ACTIVE_COMPARATOR|Normal Garment + Test garment at night|Spandex during exercise + Far Infrared Fabric at night
62362145|NCT02076334|SHAM_COMPARATOR|Normal Garment + normal garment|Spandex during exercise + Spandex at night
62362146|NCT02076334|ACTIVE_COMPARATOR|Test garment + Test garment|Far Infrared Fabric during exercise + Far Infrared Fabric at night
62362147|NCT05765552|ACTIVE_COMPARATOR|Control Group|Participants in control group will receive an exercise program consisted of upper and lower range of motion exercises.The exercises will be started as 8-10 repetitions and 1 set and the number of sets will be increased according to the progression of the patient. Exercises will be applied for 8 weeks, 2 days a week, each session will last for 30 minutes.
62362148|NCT05765552|EXPERIMENTAL|Dual-Task Training Group|Participants in the dual-task training group will receive exercises involving both motor and cognitive functions.Dual-task training sessions will begin with 10 minutes of stretching and proceed with 20 minutes of motor-cognitive dual-task exercises (counting backwards from 30 on double stance, naming the months and singing when standing on soft surfaces, finding words that starts with a given letter etc.) and sessions will end with 10 minutes of cooling.Exercises will be applied for 8 weeks 2 days a week each session will last for 30 minutes.
62362149|NCT01181440|EXPERIMENTAL|Dermagraft(R) and conventional care|
62362150|NCT01181440|OTHER|Conventional care only|
62362151|NCT00519883|ACTIVE_COMPARATOR|A|Arm A: Standard Supportive Care (no supervised exercise)
62362152|NCT00519883|EXPERIMENTAL|B|Arm B: Exercise Intervention
62362153|NCT00612339|EXPERIMENTAL|Avastin and Temozolomide|Avastin administered at 10 mg/kg every 2 weeks beginning a minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide dosed at 200 mg/m2 daily for 5 days in a 28-day cycle.
62362154|NCT01349296|EXPERIMENTAL|BIBF 1120 + RAD001|
62362155|NCT00005808|EXPERIMENTAL|Part 1 (lutetium texaphyrin, LEEP)|Patients receive lutetium texaphyrin IV over 5-20 minutes. Patients undergo in vivo tissue assessment by spectrometer at 0, 1, 3, 5, 12, and 24 hours and loop electrical excision procedure (LEEP) at 24 hours after lutetium texaphyrin infusion.
62362156|NCT00005808|EXPERIMENTAL|Part 2 (lutetium texaphyrin, laser therapy, LEEP)|Patients receive lutetium texaphyrin IV over 5-20 minutes. A laser delivers 730 nm of light to the cervix for 4, 8, or 16 minutes. Patients undergo LEEP at 4, 8, or 12 hours after exposure of the cervix to the light source.
62362157|NCT00773851|OTHER|A|transfacial sutures
62362158|NCT00773851|OTHER|B|staples
62362159|NCT02443805|ACTIVE_COMPARATOR|300 IR|300 IR tablet of HDM Allergen Extracts
62362160|NCT02443805|PLACEBO_COMPARATOR|Placebo|Placebo tablet
61982217|NCT03573895|EXPERIMENTAL|Neuromuscular Stretching|
61982218|NCT03573895|EXPERIMENTAL|Pasive stretching|
61982219|NCT03573895|NO_INTERVENTION|Control|
61982220|NCT05715008|EXPERIMENTAL|Kefir consumption|Kefir consumption (300ml/day) for 2 weeks in a counterbalanced manner to 16 adult subjects
61982221|NCT05715008|PLACEBO_COMPARATOR|Placebo (cow milk)|Placebo administration for 2 weeks in a counterbalanced manner to 16 adult subjects
61982222|NCT04672447|EXPERIMENTAL|L-Citrulline + Glutathione|Citrulline: 2 grams/day, Glutathione: 200mg/day for 4 weeks
61982223|NCT04672447|EXPERIMENTAL|L-Citrulline|Citrulline: 6 grams/day
61982224|NCT04672447|PLACEBO_COMPARATOR|Placebo|Maltodextrin: 6 grams/day
62362161|NCT02324738|EXPERIMENTAL|Healthy Volunteer|All subjects will receive Mefloquine and Dihydroartemisinin-piperaquine, wash out then will receive Mefloquine
62362162|NCT05628402||exhibitionist patients|
62362163|NCT00688545||Celecoxib|Patients treated with celecoxib as per treating physician's judgement
62362164|NCT00688545||nsNSAIDs (nonselective nonsteroidal anti-inflammatory drugs)|Patients treated with nsNSAIDs as per treating physician's judgement
62362165|NCT03402282|EXPERIMENTAL|embolization|upper rectal artery embolization
62362166|NCT03402282|ACTIVE_COMPARATOR|surgical treatment|surgical repair through the classic technique (Milligan and Morgan technique)
62362167|NCT03496441||Group 1|Colorectal cancer patients who will undergo a surgical resection with digestive anastomosis. Fecal sample collection for analysis before and after surgery (2 samples).
62362168|NCT03496441||Group 2|Patients having undergone surgical resection with digestive anastomosis for colorectal cancer or inflammatory bowel disease, complicated by anastomotic leakage. Fecal sample collection for analysis after surgery, once the leak is confirmed.
62362169|NCT03496441||Group 3|Patients with uncomplicated hernia pathology, without gastrointestinal comorbidity to undergo a surgery to heal this hernia without involving a gastrointestinal resection. Fecal sample collection for analysis before surgery (1 sample).
62362170|NCT03496441||Group 4|Inflammatory bowel disease patients waiting for elective surgery involving gastrointestinal resection. Fecal sample collection for analysis during surgery, directly from the bowel content (1 sample).
61982225|NCT02989740||Group A|Patients with negative FFR (\> 0.80) in the target lesion \& decided on OCT (Optical Coherence Tomography) imaging findings with NO thin-cap fibroatheroma
61982226|NCT02989740||Group B|Patients with negative FFR (\> 0.80) in the target lesion \& decided on OCT (Optical Coherence Tomography) imaging findings presence of ≥ thin-cap fibroatheroma
61982227|NCT02989740||Group C|Patients hosting FFR-positive target lesions that have been treated with PCI as per standard care and have further no TCFA lesions.
62362171|NCT01600794||male/female, immunity or others factor infertility, IVF|
62362172|NCT02657434|EXPERIMENTAL|Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed|Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
62362173|NCT02657434|ACTIVE_COMPARATOR|Arm B (Carboplatin or Cisplatin + Pemetrexed)|Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
62362174|NCT04213118|EXPERIMENTAL|Group A|Administration anlotinib and it should be continued until relapse of HCC or intolerable toxicity or patients withdrawal of consent.
62362175|NCT00546507|PLACEBO_COMPARATOR|A|placebo
62362176|NCT00546507|ACTIVE_COMPARATOR|B|celecoxib 200 mg qd p.o.
61982228|NCT01817933|EXPERIMENTAL|Physical therapy|
61982229|NCT04251221|EXPERIMENTAL|Moderate Drinkers|"Aim 1:~A baseline PET scan with \[11C\]PBR28, a TSPO-specific radioligand, will be conducted with moderate drinkers. Next, subjects will drink a fixed alcohol dose, followed a post-alcohol \[11C\]PBR28 PET scan timed to capture acute neuroimmune response. \[11C\]PBR28 distribution volumes (VT), which are proportional to TSPO number, will be measured throughout the brain. We will test the hypothesis that acute alcohol robustly increases \[11C\]PBR28 VT, consistent with microglial activation. The percent change in \[11C\]PBR28 VT (ΔVT) from baseline will quantify the magnitude of neuroimmune response."
61982230|NCT04251221|EXPERIMENTAL|Alcohol Use Disorder (AUD)|"Aim 2:~AUD subjects will participate in the study design described in Aim 1 (a baseline \[11C\]PBR28 PET scan, drink a fixed alcohol dose, followed by a post-alcohol \[11C\]PBR28 PET scans). The magnitude of neuroimmune response, quantified by ΔVT, will be compared between moderate drinkers and individuals with AUD to test the hypothesis that the neuroimmune response to alcohol is greater in those with AUD compared to moderate drinkers, consistent with the concept of alcohol 'priming microglia'."
61982231|NCT04511793|EXPERIMENTAL|Hepatic Artery Infusion (HAI)|The Medtronic Synchromed II pump with the Codman® Catheter will be used to create the investigational device. The Medtronic Synchromed II pump is a surgically implantable device that allows for the delivery of high doses of chemotherapy directly to the liver, in order to treat cancer. The device is surgically implanted into a subcutaneous pocket in the abdominal wall, and the catheter is inserted into the arterial system of the liver, allowing for chemotherapeutic delivery.
61982232|NCT05985655|EXPERIMENTAL|GTAEXS617|GTAEXS617 tablet for oral administration
61982233|NCT01998737||Women under osteoporosis suspicion|
61982234|NCT01998737||Healthy women|
62169335|NCT03058237|ACTIVE_COMPARATOR|Part 1: Regimen C|"One low dose Arbaclofen Placarbil SR tablet taken under fasting conditions as the reference product.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
62169336|NCT03058237|EXPERIMENTAL|Part 1: Regimen D|"One low dose tablet of the selected Arbaclofen Placarbil MR Prototype administered with 0.6 g/kg of beverage in orange juice.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
61982235|NCT02734446|ACTIVE_COMPARATOR|Reuterin D3 drops|Lactobacillus reuteri DSM 17938 (108 CFU) + Vitamin D3 (400 IU) 5 drops/day for 3 months (Reuterin D3 drops)
61982236|NCT02734446|PLACEBO_COMPARATOR|Placebo|The patients will receive 5 drops/day of placebo for 3 months
62362177|NCT00546507|EXPERIMENTAL|C|TDS-943 40 mg bid topically
62362178|NCT03753724||Group 1|On review of the scans by an expert, no further follow up or investigation is required, as the nodule(s) has been categorised as benign. As the patient was unaware the scan was being reviewed and no further investigations are required. Patient is invited to take part in the study (by telephone).
62169337|NCT03058237|EXPERIMENTAL|Part 1: Regimen E|"An optional regimen of one low dose tablet of the selected Arbaclofen Placarbil MR Prototype administered with 0.6 g/kg of beverage in orange juice.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
61982237|NCT06350292|EXPERIMENTAL|SLEEP: COPE|Content includes both standard CBT-I techniques \[sleep hygiene, stimulus control, sleep restriction, cognitive therapy\] as well as those targeting children with ODD and their parents. Active child participation is a goal but may be limited due to age/abilities. Parents will work with children to implement behavioral strategies.
61982238|NCT01042236|EXPERIMENTAL|Arm 1|
62362179|NCT03753724||Group 2|On review, the nodule is indeterminate and further scanning at a later date is required. The patient is informed of this, usually via a telephone call from either the doctor or nurse specialist working in the Lung Nodule Clinic (LNC) or site equivalent. This LNC is usually a virtual clinic - no physical interaction with the patient - and the follow up scan is reviewed and the patient contacted again via the virtual clinic. Patient is invited to take part in the study (by telephone, by post or in clinic if appropriate).
62362180|NCT03753724||Group 3|On review, the nodule is regarded as potentially malignant and further scans and a clinic appointment is made for the patient. Patient is invited to take part in the study (in clinic if appropriate).
62362181|NCT01999712||LVAD recipients|Patients who are scheduled for LVAD implantation will undergo preoperative echocardiography
62362182|NCT05400538|EXPERIMENTAL|Trial group|Biorepair Toothpaste + Mousse domiciliary use
62362183|NCT05400538|ACTIVE_COMPARATOR|Control group|Biorepair Toothpaste domiciliary use.
62362184|NCT01937013|EXPERIMENTAL|Intranasal Oxytocin|Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3
62362185|NCT01937013|PLACEBO_COMPARATOR|Saline Nasal Mist|Participants will be randomized to receive intranasal saline mist (placebo) on opposite visits from the interventional drug visit 2 or 3
62362186|NCT04572893|EXPERIMENTAL|MYK-491|Primary DCM due to MYH7 or TTN Variant or due to other causalities not related to MYH7 or TTN variants
62362187|NCT05156333|PLACEBO_COMPARATOR|Placebo|Daily oral administration of 1 capusle of placebo, composed of: hydroxypropylmethylcellulose; Anti-caking agent: Magnesium salts of fatty acids, Dioxide of silicon; Dye: E171.
61982239|NCT02625155|OTHER|Standard of Care (SOC Arm)|Standard of Care UDT
61982240|NCT02625155|OTHER|Selective PGx Testing (Test Arm)|Standard of Care UDT with selective PGx testing
61982241|NCT04976166|ACTIVE_COMPARATOR|Conventional group|Videos and leaflets will be provided. Patients will have education using leaflets for 5 minutes in each hospital at months 0 and 2, respectively.
61982242|NCT04976166|EXPERIMENTAL|Extensive Informed Decision Making group|Videos, leaflets, and intensive learning materials will be provided. Patients in the EIDM group will receive more informed and detailed education than those in the conventional group. Patients will have education for more than 10 minutes at months 0 and 2, respectively.
61982243|NCT04976166|EXPERIMENTAL|Shared Decision Making group|Videos, leaflets, and intensive learning materials will be provided. Patients will check self-assessment items, and then have education according to the patients' preference using a self-developed counseling calendar. Patients will have education for more than 10 minutes at months 0 and 2, respectively.
61982244|NCT02418507|ACTIVE_COMPARATOR|Proprietary Probiotic Blend|A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
62169338|NCT03058237|EXPERIMENTAL|Part 2: Regimen F|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
62362188|NCT05156333|ACTIVE_COMPARATOR|Probiotic|Daily oral administration of 1 capsule of mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).
62362189|NCT03132441|EXPERIMENTAL|Cardiac Rehabilitation|"Strength Training for Frailty:~All patients enrolled will be enrolled in 6 weeks of cardiac rehabilitation for the pilot study."
62362190|NCT05103072||testing all the plots|"the investigator chose the best plot of the leads for stimulation by a procedure long and exhausting for the patient and the examinator ( plot by plot )"
62362191|NCT05103072||Guide X Software|the investigator can chose the plot using a software (Guide Xt), which can delete the exhausting test
62362192|NCT03127436||Acarovac Hausstaubmilbe|"This prospective open multi-centre non-interventional study was initiated to document the tolerability and the safety profile of the subcutaneous allergen-specific immunotherapy with Acarovac in house dust mite allergic patients (children and adults) in routine medical care.~During the up-dosing phase with Acarovac, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.~Data on tolerability are documented by the physicians."
62362193|NCT02574481|EXPERIMENTAL|ELUVIA Stent Implantation|Percutaneous stent placement in the SFA/PPA
62362194|NCT02574481|ACTIVE_COMPARATOR|Zilver PTX Stent Implantation|Percutaneous stent placement in the SFA/PPA
62739201|NCT02931643|PLACEBO_COMPARATOR|High fat challenge breakfast|High fat breakfast without mixed-spices (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
62739202|NCT02931643|EXPERIMENTAL|High fat challenge breakfast with mixed-spices|High fat breakfast with mixed-spices (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
62739203|NCT00684710|EXPERIMENTAL|PAZ-417|
62739204|NCT00684710|PLACEBO_COMPARATOR|Placebo|
61982245|NCT02418507|PLACEBO_COMPARATOR|Placebo|The placebo is administered to randomized healthy participants
61982246|NCT05901779|EXPERIMENTAL|Probiotic Group|PG (probiotic group) patients received probiotic capsules containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. The intervention begins from the completion of preoperative chemotherapy to the seventh day after surgery.
61982247|NCT05901779|NO_INTERVENTION|Control Group|CG (Control Group) patients receive blank control management.
61982248|NCT05569200|EXPERIMENTAL|Haifu Focused Ultrasound tumor therapeutic System|
61982249|NCT03301038|EXPERIMENTAL|All Subjects|SingleArm: Escalating doses of rifampin (5 and 10 mg/kg/day) (SingleArm)
61982250|NCT03233906|ACTIVE_COMPARATOR|Chia Seeds|10% of a participants total kcal estimated needs given in chia seeds everyday for 8 weeks.
61982251|NCT03233906|NO_INTERVENTION|Control|Habitual diet with avoidance of high fiber and high omega-3 fatty acid foods.
62362195|NCT05419947|EXPERIMENTAL|Fixed dose 3 hours|Fixed dose 2.5 mg with IV administration at a time greater than 3 hours before surgery.
62362196|NCT05419947|EXPERIMENTAL|Fixed dose 30 min|Fixed dose 2.5 mg with IV administration during the immediate preoperative period (15-30 minutes before surgery).
62362197|NCT05419947|EXPERIMENTAL|Weight-adjusted dose 3 hour|Weight-adjusted dose (0.05 mg/kg of total body weight) with IV administration greater than 3 hours before surgery.
62362198|NCT05419947|EXPERIMENTAL|Weight-adjusted dose 30 min|Weight-adjusted dose (0.05 mg/kg of total body weight) with IV administration during the immediate preoperative period (15-30 minutes before surgery).
62362199|NCT03219801|EXPERIMENTAL|mesenchymal stem cells|Selected SLE patients were randomly divided into treated group and control group. In the treated group, 100-300 million allogeneic human umbilical cord derived mesenchymal stem cells were infused intravenously for one SLE patient. The possible adverse events, including immediately after mesenchymal stem cells infusions, as well as the long-term safety profiles were observed.
62362200|NCT03942146|NO_INTERVENTION|Control group|No information on smoking cessation
62362201|NCT03942146|ACTIVE_COMPARATOR|Written information, GynOp|"When reporting being a current smoker in the health declaration on-line the participant receives the following written recommendation in the web-based health declaration You have increased risks due to smoking. Smoking cessation 6 weeks before surgery and 6 weeks after surgery is recommended"
62362202|NCT03942146|ACTIVE_COMPARATOR|Doctor informed|"The smoking status of the participant is alerted to the surgeon when filling in the preoperative form with the text  the patient smokes, recommend smoking cessation"
62362203|NCT03942146|ACTIVE_COMPARATOR|Written information, GynOp + doctor informed|A combination of Group 2 and 3, i.e. a written recommendation is included in the web-based health declaration as in group 2 and in addition the surgeon is alerted that the participant is a smoker and instructed to recommend smoking cessation as in group 3.
62362204|NCT02320214|EXPERIMENTAL|Miami w/ frag Personal lubricant|Healthy subjects use Novel lubricant Miami w/ frag Personal lubricant at least 4 times per week for 2 weeks.
62362205|NCT01320969|EXPERIMENTAL|Mindfulness-Based Stress Reduction course|an eight week mindfulness-based stress reduction course
62362206|NCT01320969|NO_INTERVENTION|Waitlist group|waitlist group
62362207|NCT01952288|EXPERIMENTAL|simvastatin|simvastatin 40 mg/day
62362208|NCT01952288|PLACEBO_COMPARATOR|placebo|placebo
62362209|NCT05243719|EXPERIMENTAL|Treatment Options 1, 2, 3, 4, 5|Participants will fall into 1 of 5 treatment options dependent on the treatment received (ADP101 or placebo) during the parent study and their tolerance of the treatment regimen during the parent study.
62739205|NCT02547246|EXPERIMENTAL|rTMS session|Patients will have a 20 minute session of rTMS at a frequency of 10 Hz.
62739206|NCT02547246|PLACEBO_COMPARATOR|rTMS placebo (SHAM) session|Patients will have a 20 minute session of placebo rTMS
61982252|NCT04063956|EXPERIMENTAL|Cognitive training group|Multi-domain adaptive internet-based training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. 4 x 40 minutes per week, for 12 weeks.
61982253|NCT04063956|ACTIVE_COMPARATOR|Active-control group|Fixed, primary difficulty level tasks. 4 x 40 minutes per week, for 12 weeks.
61982254|NCT04602832|EXPERIMENTAL|ENHANCE Treatment Group|The ENHANCE program was tailored to address the current health and well-being challenges faced by individuals living in the COVID-19 pandemic. The contents of each week will focus on a new evidenced-based principle that has been shown in research to decrease negative thinking and emotions, as well as increase positive thinking, emotions, and overall physical and mental health and well-being. Each week participants will focus on the skills and methods of implementing happiness and well-being into their daily routine.
62362210|NCT02844673|ACTIVE_COMPARATOR|Standard monitoring (SM) arm|Participants will receive fixed dose hydroxyurea therapy (15 mg/Kg/day) with standard monitoring. Standard monitoring is defined as a follow-up visit two weeks after initiation of therapy and monthly follow-ups thereafter
62362211|NCT02844673|EXPERIMENTAL|mDOT arm|Participants will receive fixed dose hydroxyurea therapy (15 mg/Kg/day) and Mobile Directly Observed Therapy (mDOT) consisting of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Participants will receive alerts on their cell phone at pre-arranged times to remind them to take their medications. Participants will be followed-up at two weeks after initiation of therapy and monthly thereafter.
62362212|NCT00634465||1|
62362213|NCT02925312|EXPERIMENTAL|Intervention|Patients receive the full diabetes pathway intervention consisting of: individualized diabetes self-management education and support; T2DM meds management by clinician-supervised diabetes educators using an evidence-based algorithm and FDA approved anti-hyperglycemic agents; near, real-time blood glucose monitoring, delivered via a combination of two in-person and weekly remote (telephone/text) visits.
62362214|NCT02925312|NO_INTERVENTION|Matched controls|Patients receive standard of care from their primary care provider. Usual care visits are typically conducted quarterly per national guidelines for management of T2DM in adults, or more frequently as needed.
62362215|NCT04826120|ACTIVE_COMPARATOR|PCEA group|Patients of this group had intermittent epidural analgesia via PCEA associated to systematic 8 ml boluses every 60 min during the second stage of labor.
62362216|NCT04826120|EXPERIMENTAL|CEI Group|Patients of this group had continuous epidural infusion at the rate of 8 ml/h during the second stage of labor.
62362217|NCT02067572|EXPERIMENTAL|Salvia|Salvia mouthwash used 4 times per day for 4 days
62362218|NCT02067572|ACTIVE_COMPARATOR|Saline|Saline mouthwash used 4 times per day for 4 days.
62362219|NCT02690168||Healthy Men|
62362220|NCT05316818|EXPERIMENTAL|Triplet regimen (FOLFOXIRI)|The treatment planned consisted of irinotecan 160 mg/m² in 250 ml of NaCl 0.9% over 1 hr, followed by 85 mg/m² oxaliplatin in 250 ml dextrose 5% given concurrently with a 400 mg/m² leucovorin intra venous infusion in 250 ml dextrose 5% for 120 min, followed by 2400 mg/m² for 44-hr continuous infusion
62362221|NCT05316818|ACTIVE_COMPARATOR|standard duplet regimen (FOLFOX or FOLFIRI)|Regimen consisted of 180 mg/m² intravenous infusion of irinotecan for 60 min OR 85 mg/m² oxaliplatin day 1 only followed by a 200 mg/m² intra venous infusion of leucovorin for 120 min, a 400 mg/m² intravenous bolus of fluorouracil, and a 600 mg/m² continuous infusion of fluorouracil for 22 hr to be repeated on day 2
62362222|NCT04975490||SAPIENT = Sepsis ACLF patients|
62362223|NCT04975490||PROACT = Portal mediators as ACLF Targets|
62362224|NCT04975490||ELITE = prEdictors of beneficial LIver Tx in ACFL patiEnts|
62362225|NCT06396260|ACTIVE_COMPARATOR|Control|Sex- and age matched, healthy control. Will only have baseline DKI and MEG performed.
62362226|NCT06396260|ACTIVE_COMPARATOR|ALS without PBA|ALS patient without PBA, either at baseline and 6 month follow-up
62362227|NCT06396260|ACTIVE_COMPARATOR|ALS with PBA|ALS patient with PBA, either at baseline or follow-up
62362228|NCT05267418|ACTIVE_COMPARATOR|automated nasal oxygen titration with FreeO2 alone|The participant received automated nasal oxygen titration administered by a closed loop system (FreeO2) during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT). The objective of this system is maintain SpO2 a the pre-specified target level (94% in this study) with an automatic adjustment of oxygen flow second by second.
62362229|NCT05267418|ACTIVE_COMPARATOR|automated nasal oxygen titration with FreeO2 with high-flow nasal O2 therapy|In addition to nasal oxygen titration administered by a closed loop system (FreeO2), the participant received high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula during the 3-min CSST and endurance shuttle walking test.
62362230|NCT05267418|ACTIVE_COMPARATOR|Fixed-flow oxygen therapy|The participant received oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT). In patients already on home oxygen, the O2 flow during exercise was set at 1 L/min above the usual flow used at home .
62362231|NCT04006704|EXPERIMENTAL|D/C/F/TAF (Whole Placebo Tablet then Split Placebo Tablet)|Participants will receive scored film-coated 10 milligram (mg) FDC matching placebo tablets (Intake period 1) swallowed whole followed by FDC of scored film-coated D/C/F/TAF 675/150/200/10 mg matching placebo tablets (Intake period 2) swallowed as a split tablet on Day 1. Both the intakes will be separated by at least 15 minutes.
62362232|NCT04006704|EXPERIMENTAL|D/C/F/TAF (Split Placebo Tablet then Whole Placebo Tablet)|Participants will receive scored film-coated 10 mg FDC matching placebo tablets (Intake period 1) swallowed as a split tablet followed by FDC of scored film-coated D/C/F/TAF 675/150/200/10 mg matching placebo tablets (Intake period 2) swallowed whole on Day 1. Both the intakes will be separated by at least 15 minutes.
62362233|NCT01670682|ACTIVE_COMPARATOR|fascia fixation group|procedure: ischia spinous fascia fixation
62362234|NCT01670682|ACTIVE_COMPARATOR|mesh group|Procedure: Modified Pelvic Floor Reconstruction Surgery with mesh
62362235|NCT01107704|EXPERIMENTAL|Family Support Intervention|
62362236|NCT01107704|NO_INTERVENTION|Control Group|
62362237|NCT00517413|EXPERIMENTAL|C.E.R.A|Participants with chronic renal anaemia who were on dialysis and previously treated with intravenous (IV) or subcutaneous (SC) epoetin alfa, epoetin beta or darbepoetin alfa received monthly treatment with Continuous Erythropoietin Receptor Activator (C.E.R.A.) (methoxy polyethylene glycol-epoetin beta \[Mircera\]). The initial dose of C.E.R.A. was based on the last dose of the previous Erythropoiesis Stimulating Agent (ESA); 120, 200, or 360 micrograms (mcg) C.E.R.A., IV or SC, every 4 weeks for 48 weeks.
62362238|NCT02099760||STD testing (GC/Ct/trich)|
62362239|NCT00469872|ACTIVE_COMPARATOR|Child Focused|Occupational and physical therapy focused on improving child's skills and abilities through rehabilitation to improve child functioning
62362240|NCT00469872|EXPERIMENTAL|Context Focused|Occupational and physical therapy focused on improving child's skills and abilities through rehabilitation to change the task or environment around a child
62362241|NCT05872256|OTHER|Active Arm|0.045% Tazarotene/0.01% Habetasol Lotion apply once daily at bedtime to the scalp afflicted with psoriasis
62362242|NCT01056419|ACTIVE_COMPARATOR|Total thyroidectomy|
62362243|NCT01056419|ACTIVE_COMPARATOR|Anti-thyroid drug|
62362244|NCT00342004||Healthy Volunteers|Healthy female urban residents in Shanghai between ages of 40-70.
62362245|NCT06020833|EXPERIMENTAL|Roxadustat combined with retinoic acid group|
62362246|NCT04371185|EXPERIMENTAL|BAT2206 injection|45mg; subcutaneous injection
62362247|NCT04371185|ACTIVE_COMPARATOR|Stelara(US-licensed)|45mg; subcutaneous injection
62362248|NCT04371185|ACTIVE_COMPARATOR|Stelara(EU-licensed)|45mg; subcutaneous injection
62362249|NCT05027113|EXPERIMENTAL|Mind-Us|"Use of the 10% Happier app to complete at least one meditation daily -with the possibility of exceeding this goal by choosing additional meditations- for 4 weeks. Participants will be asked to complete The Basics and The Basics II courses to familiarize themselves with the principles of mindfulness meditation. Each audio-recorded session begins with a short video providing psychoeducation around mindfulness meditation and teaching specific techniques (e.g., using the breath as an anchor, redirecting attention, noting thoughts and emotions). For the last two weeks of the program, participants will be invited to complete the Essential Advice course. This additional course is composed of 14 sessions ranging in length from 15 to 18 minutes."
62362250|NCT05027113|NO_INTERVENTION|Assessments First|Wait-list control group. Individuals in this group will complete baseline, mid-, and post-treatment assessments before receiving the intervention (i.e., 4 weeks after randomization).
62362251|NCT05795868|EXPERIMENTAL|Compression stockings group|Pregnant women in the compression stockings group will wear the socks given for 3 weeks.
62362252|NCT05795868|PLACEBO_COMPARATOR|Placebo sock group|Pregnant women in the placebo socks group will wear the socks given for 3 weeks.
62362253|NCT01496274|EXPERIMENTAL|Prophylaxis|"Routine weekly prophylaxis and episodic treatment for bleeding episodes. An individualized dosing interval may be tested in sub-group subjects during the 2nd part of the trial.~Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention."
62362254|NCT01496274|EXPERIMENTAL|On-demand|Episodic treatment for bleeding episodes during the first 6 months then switch to routine weekly prophylaxis for a further 6 months Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention.
62362255|NCT01333098|EXPERIMENTAL|mifepristone|1 week mifepristone or placebo (followed by 3 weeks open label mifepristone)
62362256|NCT00778713|EXPERIMENTAL|1|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets of Ranbaxy laboratories Limited
62362257|NCT00778713|ACTIVE_COMPARATOR|2|Monopril ® - HCT 20-12.5 mg tablets by Bristol Meyers Squibb following a single oral dose (1 x 20/12.5 mg tablet)
62362258|NCT02068950|OTHER|Progressive resistance training|12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand).
62362259|NCT04359225|ACTIVE_COMPARATOR|3D telemedicine|3D telemedicine system
62362260|NCT04359225|PLACEBO_COMPARATOR|2D telemedicine|2D telemedicine system (standard care)
62362261|NCT01890317|EXPERIMENTAL|Mild hypothermia|Induction of mild hypothermia for 24 hr with invasive cooling in addition to primary percutaneous coronary intervention and optimal medical therapy
62362262|NCT01890317|NO_INTERVENTION|Control|Percutaneous coronary intervention and optimal medical therapy according to current guidelines
62362263|NCT02990559||Iron Repletion|Subjects participating in the associated study under the Iron Repletion arm will also undergo MRI (Magnetic Resonance Imaging) scan/fMRI (functional Magnetic Resonance Imaging) scan on two occasions, while performing cognitive tasks.
62362264|NCT02990559||Placebo|Subjects participating in the associated study under the Placebo arm will also undergo MRI/fMRI scans on two occasions, while performing cognitive tasks.
62362265|NCT03736668|EXPERIMENTAL|Patients with Type 2 diabetes|"One year after patient's inclusion, during the additional cardiology consultation, an echocardiography will be performed by the investigator to evaluate any changes.~Two years after the patient's inclusion, an investigator will contact by phone the general practitioner, cardiologist and / or diabetologist treating the patient to find out if any cardiovascular events occurred."
62362266|NCT02327312|EXPERIMENTAL|Surgical|Implantation of two Trabecular Meshwork stents into the study eye
62362267|NCT02327312|ACTIVE_COMPARATOR|Laser|Laser Trabeculoplasty
62362268|NCT05247983||experimental group|"Tension-free repair of inguinal hernia with Undissociate Spermatic cord"
62362269|NCT05247983||control group|Tension-free repair of inguinal hernia with traditional method
62362270|NCT02580240|PLACEBO_COMPARATOR|Placebo|Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
62362271|NCT02580240|EXPERIMENTAL|hydrocortisone|Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
62362272|NCT01587274|ACTIVE_COMPARATOR|Opioid|Naproxen + opioid
62362273|NCT01587274|ACTIVE_COMPARATOR|Skeletal muscle relaxant|Naproxen + skeletal muscle relaxant
62362274|NCT01587274|ACTIVE_COMPARATOR|Naproxen alone|Naproxen + placebo
62362275|NCT03073213|EXPERIMENTAL|Ixekizumab single dose|Participants received single dose of 80mg Ixekizumab by subcutaneous injection.
62362276|NCT03073213|EXPERIMENTAL|Ixekizumab Multiple Regimen 1 (80mg Q2W)|Participants received multiple doses of Ixekizumab starting with 160mg initial dose followed by 80mg every two weeks (Q2W) by subcutaneous injection.
62362277|NCT03073213|EXPERIMENTAL|Ixekizumab Multiple Regimen 2 (80mg Q4W)|Participants received multiple doses of 80mg Ixekizumab starting with 160mg initial dose followed by 80mg every four weeks (Q4W) by subcutaneous injection.
62362278|NCT06340672|ACTIVE_COMPARATOR|Standard Patient Pre-operative Counseling|These patients will undergo standard preoperative counseling. A standardized checklist will designate the mandatory information patients must receive during counseling including a description of the normal elements of the anatomy and abnormal elements of the anatomy relevant to each patient, a description of the basic steps of the surgical procedure and how it addresses each patient's individual problem, and a description of the potential risks, complications, and benefits of the procedure. Surgeons may augment the verbal descriptions of the preoperative counseling procedure with patient 2D MRI or CT imaging or generic 3D models or drawings. However, customized patient specific 3D printed models are not allowed.
62362279|NCT06340672|EXPERIMENTAL|Augmented Reality Enhanced Patient Pre-operative Counseling|This group of patients will undergo AR enhanced preoperative counseling. Surgeons will be provided with the same checklist of mandatory minimum information patients must receive during counseling as the control group. Both the patient and physician will wear an AR-headset. Medivis AnatomyX, a generic holographic anatomy visualization available on all AR-headset devices, will first be used to introduce the patient to normal anatomy and describe the steps of the procedure. Using Surgical AR, the patients specific imaging will then be accessed through the Medivis mobile workstation and projected into a 3D interactive model. The surgeon will use this model to highlight the patients pathology, explain how it is causing their symptoms, and review possible complications. The surgeon may refer back to the generic model in AnatomyX at any point during counseling.
62362280|NCT02999815|ACTIVE_COMPARATOR|Human tetanus immunoglobulin|Human tetanus immunoglobulin (Tetagam-P): Injection (prefilled syringe) 250 IU in 1 ml - Intrathecal 500 IU
62362281|NCT02999815|SHAM_COMPARATOR|Intramuscular antitoxin|Human tetanus immunoglobulin (Tetagam-P): Injection (prefilled syringe) 250 IU in 1 ml - Intramuscular 3000 IU OR Equine antiserum - 21,000 units
62362282|NCT01006213|EXPERIMENTAL|Lifestyle counseling vs motivational intervention|
62362283|NCT02089503||induction phase + intravitreal inj.|Group of patients who received Lucentis ® with induction phase
62362284|NCT02089503||intravitreal inj. without induction|Group of patients who received Lucentis ® without induction phase
62362285|NCT02089503||intravitreal inj. + monthly follow-up|group of patients who were monthly monitored (+/- 1 week)
61982255|NCT04602832|NO_INTERVENTION|Wait-List Control Group|Over the course of the study, participants will be asked to refrain from accessing the ENHANCE program materials to ensure the integrity of the research design. At the end of the study duration, participants will receive the full ENHANCE program.
62362286|NCT02089503||intravitreal inj. + follow-up :> 1 month|group of patients with Follow up visits intervals\> 1 month (+/- 1 week)
62362287|NCT02089503||intravitreal inj +induction+ month. FU|Group of patients who received Lucentis with induction phase and who were monthly monitored (+/- 1 week)
62362288|NCT02089503||date Lucentis® 1st intravitreal Inj.|Group of patients selected in accordance with the date of Lucentis® treatment start.
62362289|NCT01052636|NO_INTERVENTION|Control group|Patients receive only routine hospital care
62362290|NCT01052636|EXPERIMENTAL|Experimental group|Patients receive regular hospital routine care and interdisciplinary intervention program
61982256|NCT01988259|ACTIVE_COMPARATOR|Bilateral approach for laminoplasty|Open approach for laminoplasty
61982257|NCT01988259|ACTIVE_COMPARATOR|Unilateral approach for laminoplasty|Minimally invasive approach for laminoplasty
61982258|NCT01988259|ACTIVE_COMPARATOR|Subperiosteal approach for foraminotomy|Open approach for foraminotomy
61982259|NCT01988259|ACTIVE_COMPARATOR|Transmuscular approach for foraminotomy|Minimally invasive approach for foraminotomy
62362291|NCT05752240|EXPERIMENTAL|Active stimulation|Ten sessions of cathodic transcranial direct current stimulation over primary motor cortex
62362292|NCT05752240|SHAM_COMPARATOR|Sham stimulation|Ten sessions of sham stimulation over primary motor cortex
62362293|NCT02608125|EXPERIMENTAL|PRN1371|Drug: PRN1371
62362294|NCT06502145|EXPERIMENTAL|Dose level -1|Dose level -1 will be considered only if there are dose-limiting toxicities at dose level 0. This is a regimen of azacitidine and iadademstat.
62362295|NCT06502145|EXPERIMENTAL|Dose level 0|This is a regimen of azacitidine and iadademstat.
62362296|NCT06502145|EXPERIMENTAL|Dose level 1|This is a regimen of azacitidine and iadademstat.
62362297|NCT06502145|EXPERIMENTAL|Maximum Tolerated Dose (MTD)|The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a dose-limiting toxicity.
62362298|NCT00412113|ACTIVE_COMPARATOR|Norvasc 5 mg|Blinded amlodipine 5 mg and amlodipine/atorvastatin single pill combination 5/20 mg placebo dosed once daily for 6 weeks.
62362299|NCT00412113|EXPERIMENTAL|Caduet 10/20mg|Blinded amlodipine/atorvastatin single pill combination 10/20 mg dosed once daily for 6 weeks and amlodipine besylate 10 mg placebo.
62362300|NCT00412113|ACTIVE_COMPARATOR|Norvasc 10 mg|Blinded amlodipine 19 mg and amlodipine/atorvastatin single pill combination 10/20 mg placebo dosed once daily for 6 weeks.
62362301|NCT00412113|EXPERIMENTAL|Caduet 5/20mg|Blinded amlodipine/atorvastatin single pill combination 5/20 mg and amlodipine besylate 5 mg placebo dosed once daily for 6 weeks .
62362302|NCT01482455|PLACEBO_COMPARATOR|Clamp/Glycerol|"Glycerol infusion (glycerol in 0.9% saline provided by the pharmacy of the Vienna General Hospital, will be applied at a rate of 0.7 mg.kg-1.min-1) in order to match the lipid-induced rise in serum glycerol concentrations in the same experimental setting. 0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1. After two hours, a hyperinsulinemic-euglycemic clamp (Actrapid, Novo Nordisk, Bagsvaerd, Denmark; 40 mU.m-2 body surface area min-1) test will be commenced (120-240 min)."
61982260|NCT02724306|EXPERIMENTAL|Active Lifestyle Programme|ALP will receive supervised exercise sessions twice per week for three months and once per week for the following three months. Participants will also take part in biweekly physical activity workshops for the period of the intervention. Each session consists of a warm-up (5-10min), aerobic (20-30min) and resistance exercises (15-20), and cool-down (5-10)stretches lasting in total 60min. The intensity of exercises will be at 65-85% of maximum heart rate as determined by maximal fitness test. Exercise will take place in small groups of two to five people. Behaviour change workshops to aid the uptake and maintenance of physical activity will be delivered every fortnight throughout the whole intervention period totalling 12 workshops. Workshops will also take place in small groups.
61982261|NCT02724306|NO_INTERVENTION|Standard Care|The standard care group will not be offered the intervention until the end of the study at 12 months. Participants in this group will be encouraged to continue with their usual lifestyle.
61982262|NCT03337074||Sperm Epigenome arm/healthy men|Men with no significant health problems.
61982263|NCT03337074||Sperm Epigenome arm/cholestatic men|Men with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis.
62362303|NCT01482455|ACTIVE_COMPARATOR|OGTT/Lipid|On study-day 1, four hours after start of a triglyceride/heparin infusion an oral glucose tolerance test (OGTT, 75g glucose dissolved in 300ml flavoured water) will be performed (240-420 min).
62362304|NCT01482455|PLACEBO_COMPARATOR|OGTT/Glycerol|On study-day 2, four hours after start of a glycerol infusion an oral glucose tolerance test (OGTT, 75g glucose dissolved in 300ml flavoured water) will be performed (240-420 min).
62362305|NCT01482455|ACTIVE_COMPARATOR|Clamp/Lipid|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1. After two hours, a hyperinsulinemic-euglycemic clamp (Actrapid, Novo Nordisk, Bagsvaerd, Denmark; 40 mU.m-2 body surface area min-1) test will be commenced (120-240 min)."
62362306|NCT01759355||Surgery|Participants undergoing surgical intervention will receive a PET/MR scan prior and following surgery for a total of two (2) scans.
62362307|NCT01759355||Chemoradiation|Participants undergoing chemoradiation intervention will receive a PET/MR scan prior, during, and following chemoradiation for a total of three (3) scans.
62739207|NCT02840188||Radius tilt angle|Children 0-16 years of age positive for distal forearm fracture and positive history of goalkeeper's fracture (to catch a ball).
62739208|NCT02840188||Normal control group|Children 0-16 years of age without radius fracture and no history of catching a ball.
61982264|NCT03337074||Outcomes arm/Cholestatic fathers|Fathers who were diagnosed with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis either before or after the conception of their child who is now aged 16 - 25 years of age.
61982265|NCT03337074||Outcomes arm/Children of cholestatic fathers|16 - 25 years-old children of fathers who were diagnosed with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis either before or after their conception.
61982266|NCT04962009|EXPERIMENTAL|Travoprost Evolute® (Travoprost Punctal Plug Delivery System, T-PPDS), 166 ug|Each subject will have his/her lower puncta of each eye inserted with a Travoprost Evolute®. Each study subject will be instructed to return to the investigator's office the next day, 7, 28, 60 and 90-days after the insertion of their plugs for follow-up examinations.
61982267|NCT01648907||SPONDYLARTHRITIS COHORT|
61982268|NCT04798547|PLACEBO_COMPARATOR|Standard Length Myotomy|Patients randomized to received 8 cm standard length myotomy in Per-Oral Endoscopic Myotomy (POEM) for achalasia
61982269|NCT04798547|EXPERIMENTAL|Short Length Myotomy|Patients randomized to received 4 cm standard length myotomy in Per-Oral Endoscopic Myotomy (POEM) for achalasia
62739209|NCT02253290||Neuromuscular disease|Children and adolescents with Neuromuscular disease children according to neuromuscular convention UZL
61982270|NCT02333695|EXPERIMENTAL|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
62362308|NCT02758119|EXPERIMENTAL|Serious Game|"Participants in the serious game group will be pre-trained before the hands-on sessions with the serious game Staying Alive, available at http://www.stayingalive.fr/index_us.html This game aims at teaching the management of an out-of-hospital cardiac arrest to the general public and health professionals. In this game, the player faces a man who has experienced sudden cardiac arrest and learns the appropriate behavior, movements and techniques that can contribute to saving his life. The first level of the game lasts 4-5 minutes, depending on the skills of the player. It is a point and click game, displayed on a PC computer."
61982271|NCT02588170|EXPERIMENTAL|Surufatinib|Surufatinib 300 mg, orally, once daily (QD)
61982272|NCT02588170|PLACEBO_COMPARATOR|Placebo|Placebo 300 mg, orally, once daily (QD)
61982273|NCT06403735|EXPERIMENTAL|QLC1101|patients with advanced solid tumors harboring a KRAS G12D mutation were administrated with QLC1101 orally in a total of 6 dose groups at 100,200,400,600,900, and 1200 mg BID
61982274|NCT05972265|EXPERIMENTAL|Acute Exercise Moderate first|Day 1 Assessments, Day 8 Moderate Intensity Exercise (followed by symptom measures and neuropsychological tests), Day 15 Light Intensity Exercise (symptom measures and neuropsychological tests)
61982275|NCT05972265|ACTIVE_COMPARATOR|Acute Exercise Light first|Control Day 1 Assessments (symptom measures, neuropsychological tests, and cognitive complaints interview), Day 8 Light Intensity Exercise (followed by symptom measures and neuropsychological tests), Day 15 Moderate Intensity Exercise (symptom measures and neuropsychological tests)
61982276|NCT05972265|EXPERIMENTAL|Chronic Exercise Moderate|9-weeks Moderate Intensity Exercise Day 36 (at 3 weeks) Assessments Day 57 (at 6 weeks) Assessments Day 78 (at 9 weeks) Assessments
61982277|NCT05972265|NO_INTERVENTION|Activity as Usual|9-week activity as usual Day 36 (at 3 weeks) Assessments Day 57 (at 6 weeks) Assessments Day 78 (at 9 weeks) Assessments
62362309|NCT02758119|ACTIVE_COMPARATOR|Online course|Participants in the lecture group will watch individually a 4-min video of a PowerPoint presentation with voiceover narration, given in the medical school of Paris Descartes University. The video is edited to contain the same informations on out-of-hospital cardiac management than the serious game, with the same duration.
62362310|NCT04827615|OTHER|High Risk|"Group 2: Of all adults in (1), those at high risk of diabetes and hypertension, defined as having a score \>4 based on the following criteria:~* Age 40-49 years (+1), age ≥50 years (+2)~* Used to smoke or use smokeless tobacco products or sometimes currently use (+1), currently use daily (+2)~* Currently consume alcohol daily (+1)~* Waist circumference 81-90 cm (women)/91-100 cm (men) (+1), \>90 cm (women)/\>100cm (men) (+2)~* Physical activity \<150 minutes per week (+1)~* Parent and/or sibling with high blood pressure, diabetes, or heart disease (+2)"
62362311|NCT04827615|OTHER|Eligible adults|Group 1: All adults ≥30 years old living in the 12 target villages who meet eligibility criteria and provide informed consent
62362312|NCT01787955|EXPERIMENTAL|Braun anastomosis group|
62362313|NCT01787955|ACTIVE_COMPARATOR|conventional group|conventional Pylorus preserving pancreaticoduodenectomy
61982278|NCT00604331|ACTIVE_COMPARATOR|A|Pyruvate
61982279|NCT05304156||Standard of Care in patients with AML|"Standard of Care including a first course containing one of the following backbones without addition of third agent before day 8 of induction (approved drugs such as midostaurine or investigational agents administered beyond day 8 are allowed) :~* 7+3 induction 3+7 with daunorubicin (or idarubicin) and cytarabine~* CPX-351 induction"
61982280|NCT01873001|EXPERIMENTAL|Abiraterone acetate + pioglitazone HCl|Participants will receive 15 mg pioglitazone on Day 1 (Period 1). On Day 8 (Period 2), participants will receive 1000 mg abiraterone acetate followed by 15 mg of pioglitazone one hour later.
61982281|NCT05009940|EXPERIMENTAL|Gradusox then Sigvaris compression stockings|"This arm refers to the order of interventions received by the participant. The first intervention received by participants in this arm are Gradusox compression stockings applied to both legs.~After a washout period, the second intervention received are Sigvaris compression stockings applied to both legs."
62362314|NCT03970824|EXPERIMENTAL|CT-P17|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
62362315|NCT03970824|ACTIVE_COMPARATOR|US-licensed Humira|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
62362316|NCT03970824|ACTIVE_COMPARATOR|EU-approved Humira|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
62362317|NCT01635036||Women undergoing IVF treatment|Women undergoing IVF treatment
61982282|NCT05009940|EXPERIMENTAL|Sigvaris then Gradusox compression stockings|"This arm refers to the order of interventions received by the participant. The first intervention received by participants in this arm are Sigvaris compression stockings applied to both legs.~After a washout period, the second intervention received are Gradusox compression stockings applied to both legs."
61982283|NCT02208947|ACTIVE_COMPARATOR|PREPARE|"Partnership HealthPlan of California (PHC) pays primary care physicians (PCPs) to discuss and document ACP with Medi-Cal beneficiaries aged 65 and older and those younger than 65 with a life-limiting illness (usual care). The control condition, or enhanced usual care, adds a packet of educational information about ACP and access to the PREPARE website and verbal encouragement by their PCP delivered during a routine clinic visit to usual care."
61982284|NCT02208947|EXPERIMENTAL|PREPARE + consumer financial incentive|The experimental condition adds a consumer-directed financial incentive to enhanced usual care (provider-directed financial incentive and educational packet with information about the PREPARE website). Specifically, subjects will receive an immediate financial reward upon completing self-directed ACP (e.g., PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
62362318|NCT04258007|PLACEBO_COMPARATOR|Reversal Neostigmine|Patients undergoing cardiac catheterization will receive a combination of 0.02 mg/ kg atropine and 0.04 mg/ kg neostigmine following observing the second response on stimulating the ulnar nerve on the TOF watch
62362319|NCT04258007|ACTIVE_COMPARATOR|Reversal Sugammadex|Patients undergoing cardiac catheterization will receive sugammadex 4 mg/ kg when the T2 is observed on the TOF watch
62362320|NCT05534152|PLACEBO_COMPARATOR|Soup with no sumac|150 g butternut squash soup with no added sumac
61982285|NCT05657678|EXPERIMENTAL|Interventional Arm|a single administration of 750,000 IU of vitamin D3 via the enteral route (through a gastric tube) in ICU patients with severe vitamin D3 deficiency (measured plasma 25(OH)D3 levels ≤12.5 ng/ml) undergoing continuous renal replacement therapy with CVVHDF or CVVHF
62362321|NCT05534152|EXPERIMENTAL|Sumac added to soup at the end of cooking|150 g butternut squash soup with 1% sumac added at the end of cooking
62362322|NCT05534152|EXPERIMENTAL|Sumac added to the sumac during cooking|150 g butternut squash soup with 1% sumac added during cooking
62362323|NCT04194411||Valve surgery|Patients older than 65 years and undergoing elective valvular heart surgery
62362324|NCT01010269|ACTIVE_COMPARATOR|Vanguard Complete Knee|Vanguard Completed Knee with Microplasty Tibial Tray is designed to hold the tibial knee bearings in a microplsty knee procedure. The Co-Cro-Mo trays are designed with a shorter stem.
62362325|NCT01010269|ACTIVE_COMPARATOR|Vanguard High Flex RP|VGRD High Flex RP knee is an extension to the exsting Vanguard Knee and has been specifically desinged to facilitate greather than 135 degrees of knee flextion as required by certain patients.
62362326|NCT04898127|EXPERIMENTAL|Rapid test and concert|Participants in this arm will be offered access to a concert, after a negative rapid test.
62362327|NCT04898127|NO_INTERVENTION|Control|Participants in this are will not be offered access to a concert during the study period.
62362328|NCT02667522|EXPERIMENTAL|Parenting Intervention|Parenting Intervention: Parent-Child Interaction Therapy (PCIT)
62362329|NCT02667522|NO_INTERVENTION|Waitlist Control|Waitlist Control Condition
62362330|NCT03785444||Intensive Care Patients|Postoperative patients who have been admitted to intensive care
62362331|NCT03785444||Non-Intensive Care Patients|Postoperative patients who have not been admitted to intensive care but to the normal ward
62362332|NCT00425074|EXPERIMENTAL|SR-ASA|slow release acetylsalicylic acid 150 mg
62362333|NCT00425074|ACTIVE_COMPARATOR|ASA|normal release acetylsalicylic acid
62362334|NCT00617617|EXPERIMENTAL|A|Dietary Supplement: Prevastein HC®
62362335|NCT00617617|PLACEBO_COMPARATOR|B|Placebo
62362336|NCT00493467|EXPERIMENTAL|Zevalin|Ibritumomab Tiuxetan (Zevalin) + Rituximab
62362337|NCT01437267|EXPERIMENTAL|Vi-CRM, Older infants|Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
62362338|NCT01437267|ACTIVE_COMPARATOR|PNC13, Older infants|Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
62362339|NCT01437267|EXPERIMENTAL|Vi-CRM, Infants|Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
61982286|NCT05657678|ACTIVE_COMPARATOR|Control Arm|a single administration of 500,000 IU of vitamin D3 via the enteral route (through a gastric tube) in ICU patients with severe vitamin D3 deficiency (measured plasma 25(OH)D3 levels ≤12.5 ng/ml) undergoing continuous renal replacement therapy with CVVHDF or CVVHF
62362340|NCT01437267|ACTIVE_COMPARATOR|PNC13, Infants|Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine
62362341|NCT01437267|EXPERIMENTAL|Vi-CRM, Children|Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
62362342|NCT01437267|ACTIVE_COMPARATOR|Vi-PS, Children|Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine
62362343|NCT02556671||Moderate CKD Patients Undergoing PCI|
62362344|NCT02556671||Normal renal function Patients Undergoing PCI|
61982287|NCT01710956|EXPERIMENTAL|Arm 1(with twice-daily TRT)|
61982288|NCT01710956|EXPERIMENTAL|Arm 2 (with once-daily TRT)|
61982289|NCT01831154|EXPERIMENTAL|Tight Glycemic Group|The tight glycemic group received a continuous intravenous infusion of regular insulin in the intraoperative period titrated per a modified Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial bolus of insulin and insulin infusion was initiated prior to induction of anesthesia if the morning blood glucose was greater than 149 mg/dl or any time intraoperatively the blood glucose elevated above 149 mg/dl.The titration of insulin for the tight glycemic group maintained blood glucose levels between 110-149 mg/dl throughout the intraoperative period. The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes.Upon transfer to the intensive care unit the protocol ended and all subjects received the same glycemic control.
62362345|NCT04206670|EXPERIMENTAL|In-Home Technology System|Participants will receive and install the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) in their homes. Remote assistance will be provided to help with the installation. Sensors, warnings, messaging, and social networking features will be activated remotely. Participation will extend over a six month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter).
62362346|NCT04206670|OTHER|Waiting Control|Participants will be assigned a date for receiving and installing the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) six months after they enter the study. During that six-month period, questionnaires (e.g., health and well-being) will be administered 3 times (at the start of the study and every 3 months thereafter). At the end of the six-month period, participants will receive and install the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) in their homes. Remote assistance will be provided to help with the installation. Sensors, warnings, messaging, and social networking features will be activated remotely. Participation will extend over an additional six-month period with questionnaires (e.g., health and well-being) administered 2 times (every 3 months following installation).
62362347|NCT02938507|EXPERIMENTAL|Formulation 1 solabegron|Subjects will receive formulation 1 solabegron doses in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
62362348|NCT02938507|EXPERIMENTAL|Formulation 2 solabegron|Subjects will receive formulation 2 in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
62362349|NCT00915538|OTHER|Group 1 / use of pMDI as approved|The intervention in this group will use inhalation from the pMDI containing budesonide/formoterol pMDI 160/4.5 2 inhalations as approved. (FDA approved product information) without a spacer. The pulmonary function tests (PFTs) will be collected at baseline and for a period of 12 hours post inhalation of 2 inhalation of budesonide /formoterol; pMDI160/5.
62739210|NCT02048644|PLACEBO_COMPARATOR|placebo inhaler|matched placebo inhaler, to be taken 2 puffs, twice a day for 28 days
62739211|NCT02048644|EXPERIMENTAL|fostair|fostair 100mcg/6mcg 2pufss, twice a day.
61982290|NCT01831154|EXPERIMENTAL|Conventional Glycemic Group|The conventional glycemic group received a continuous intravenous infusion of regular insulin in the intraoperative period titrated per a modified Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial insulin bolus and infusion was initiated prior to induction of anesthesia if the morning blood glucose was greater than 180 mg/dl or any time intraoperatively that the blood glucose elevated above 180 mg/dl. The insulin infusion was titrated throughout the intraoperative period to maintain blood glucose levels between 150-180 mg/dl.The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes. Upon transfer to the ICU the intraoperative protocol ended and all subjects received the standardized glycemic control for the ICU.
61982291|NCT01831154|EXPERIMENTAL|Standard Glycemic Group|The standard glycemic group received intravenous injections of regular insulin in the intraoperative period titrated per the usual care protocol utilized at the study site. The initial bolus of insulin was initiated prior to induction of anesthesia if the morning blood glucose is greater than 180 mg/dl or any time intraoperatively that the blood glucose rises above 180 mg/dl. The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes.Upon transfer to the ICU the intraoperative protocol ended and all subjects received the standardized glycemic control for the ICU.
61982292|NCT04696952|EXPERIMENTAL|TS-142 10 mg|Period in which subjects received TS-142 10 mg
61982293|NCT04696952|EXPERIMENTAL|TS-142 20 mg|Period in which subjects received TS-142 20 mg
61982294|NCT04696952|EXPERIMENTAL|Zopiclone 7.5 mg|Period in which subjects received Zopiclone 7.5 mg
61982295|NCT04696952|EXPERIMENTAL|Placebo|Period in which subjects received placebo
61982296|NCT01428453|EXPERIMENTAL|250mg rilapladib|Experimental drug
62362350|NCT00915538|EXPERIMENTAL|Group 2 / pMDI with Aerochamber Plus|The intervention in this group will use the pMDI budesonide/formoterol 160/4.5 with a valve holding chamber spacer device, Aerochamber Plus which is the intervention being studied The PFTs will be collected at baseline and for a period of 12 hours post inhalation of 2 inhalation of Symbicort 160/5. This is the intervention to be studied for comparison to the non-spacer inhalations..
62362351|NCT00501462|OTHER|Mild renal impairmnent|
62362352|NCT00501462|OTHER|moderate renal impairment|
62362353|NCT00501462|OTHER|Normal renal function|
62362354|NCT00004467|PLACEBO_COMPARATOR|Placebo|
62362355|NCT00004467|EXPERIMENTAL|N-acetylcysteine (NAC)|
62362356|NCT03878225|ACTIVE_COMPARATOR|Ketone Mono Ester|"The ketone mono ester is commercially available dietary supplement beverage named H.V.M.N. Ketone Ester, marketed by HVMN Inc®. The KME beverage consists of water, D-β-hydroxybutyrate ester, stevia leaf extract, natural flavors, malic acid, potassium sorbate and potassium benzoate. The active ingredient is the D-β-hydroxybutyrate ester, with each dose containing 25g. Participants will be asked to ingest this 5 times daily for 3 days (72 hours), to a total of 15 doses during the study."
62362357|NCT03878225|PLACEBO_COMPARATOR|Placebo|The placebo beverage will consist of water added with a colorless, bitter flavor enhancer and a sweetening agent (Stevia) to approximate the taste of the KME beverage as closely as possible. The bitter flavor enhancer used is denatonium benzoate (Bitrex®). The placebo beverage will be delivered to patients in bottles identical to those used in the active arm. Patients, investigators and other caregivers will be blinded to treatment allocation until time of database unlock.
62362358|NCT05425303||Healthy athletes|Healthy professorial team sports athletes will be monitored for the occurrence of an acute lower extremity injury during a competitive season. After the end of the season, the cohort will be divided into a healthy athlete group, athletes injured in the hamstring muscles, and athletes with other types of lower extremity injuries.
62362359|NCT02527564|EXPERIMENTAL|Suvorexant|"50% of enrolled participants will be randomly assigned to receive double-blind suvorexant for one week, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the last 4 nights.~Following the one-week double-blind, placebo-controlled phase, 100% of participants will receive open-label suvorexant for 3 months, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the remainder of 3 months."
61982297|NCT01428453|PLACEBO_COMPARATOR|placebo|Placebo comparator
61982298|NCT01359449|EXPERIMENTAL|Menactra® Vaccine Group|Meningococcal vaccine naive participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate vaccine (Menactra®) at 12 months of age and at 18 months of age concomitantly with routine vaccines administered as per provincial schedule
61982299|NCT01359449|ACTIVE_COMPARATOR|Menjugate® Vaccine Group|Meningococcal vaccine naive participants will receive MenC vaccine (Menjugate) given concomitantly at 12 months of age with routine vaccines administered as per provincial schedule.
61982300|NCT04576130|EXPERIMENTAL|ICD-implantation|Implantation of an ICD either during admission or within 4 weeks after discharge from index event.
62362360|NCT02527564|PLACEBO_COMPARATOR|Placebo|50% of enrolled participants will be randomly assigned to receive double-blind placebo pill for one week, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the last 4 nights.
61982301|NCT04576130|NO_INTERVENTION|Standard care|Guideline directed medical therapy
61982302|NCT04408482|ACTIVE_COMPARATOR|Pancreatic sphincterotomy|Pancreatic sphincterotomy performed in difficult cannulation
61982303|NCT04408482|ACTIVE_COMPARATOR|Pancreatic sphincterotomy + pancreatic stent|Pancreatic sphincterotomy performed in difficult cannulation + pancreatic stent placement
62362361|NCT00455936|EXPERIMENTAL|study arm|Gefitinib 250mg table/QD, daily every 3 weeks
62362362|NCT00455936|ACTIVE_COMPARATOR|control arm|gemcitabine 1250mg/m2 iv on D1 \& D8 every 3 weeks Cisplatin 80mg/m2 iv on D1 every 3 weeks
62362363|NCT04824105|EXPERIMENTAL|Neurostimulation Group|"On one study day, participants will complete experimental tasks during functional magnetic resonance imaging. On two other study days, participants will complete tasks before and after receiving repetitive transcranial magnetic stimulation (rTMS). All participants will receive rTMS to ventromedial prefrontal cortex on one study day, and to pre-supplementary motor area on another study day.~Two stimulation procedures will be used, one for ventromedial prefrontal cortex and one for pre-supplementary motor area. For both targets, 3 sessions of 600 pulses at 110% of resting motor threshold will be presented over 30 minutes. For ventromedial cortex, a session will involve intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds. For pre-supplementary motor area, a session will involve continuous theta burst presented in 3-pulse bursts with 15 pulses/ sec."
62362364|NCT02048358|EXPERIMENTAL|2B3-201 150mg|2B3-201 150mg, once, IV infusion in 1000ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 1000ml 5% dextrose/ Placebo, once, IV infusion 1000ml 5% dextrose
62362365|NCT02048358|EXPERIMENTAL|2B3-201 300mg|2B3-201 300mg, once, IV infusion in 1500ml 5% dextrose/ Methylprednisolone hemisuccinate 300mg, once, IV infusion in 1500ml 5% dextrose/ Placebo, once, IV infusion 1500ml 5% dextrose
62362366|NCT02048358|EXPERIMENTAL|2B3-201 450mg|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 2500ml 5% dextrose/ Placebo, once, IV infusion 2500ml 5% dextrose
62362367|NCT02048358|EXPERIMENTAL|450mg 2B3-201|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose
62362368|NCT02048358|EXPERIMENTAL|300mg 2B3-201|2B3-201 300mg, once, IV infusion in 1500ml 5% dextrose
62362369|NCT02048358|EXPERIMENTAL|2B3-201 450mg male volunteers|2B3-201 450mg, once, IV infusion in 1500ml 5% dextrose
62362370|NCT02048358|EXPERIMENTAL|2B3-201 300mg or 450mg female volunteers|2B3-201 300mg or 450mg, once, IV infusion in 1500 or 2500ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 1500 or 2500ml 5% dextrose
62362371|NCT02048358|EXPERIMENTAL|Relapsing MS patients; 2B3-201 450 mg|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose
62362372|NCT02048358|EXPERIMENTAL|Relapsing MS patients; 2B3-201 dose tbd|2B3-201 (dose to be determined), once, IV infusion in 5% dextrose
62362373|NCT05671237|EXPERIMENTAL|bilateral infraorbital+infratrochlear block group|For this group we will perform bilateral infraorbital+infratrochlear block before surgery
62362374|NCT05671237|NO_INTERVENTION|non-block group|For this group we will start the surgery without performing a block
62362375|NCT04814511|OTHER|Standard therapy with InfectoScab 5 % Creme|
62362376|NCT04814511|EXPERIMENTAL|Escalated therapy with InfectoScab 5 % Creme (arm E5)|
62362377|NCT04814511|EXPERIMENTAL|Escalated therapy with Permethrin 10 % Creme (arm E10)|
62362378|NCT04814511|EXPERIMENTAL|Escalated therapy with InfectoScab 5 % Creme in combination with Driponin 3 mg Tabletten (arm EK)|
62362379|NCT04432467|EXPERIMENTAL|mesenchymal stem cells|Patients with impending caesarean section or with chronic inflammation in the mucosa of the uterus and fallopian tubes receiving standard treatment and mesenchymal stem cells
62362380|NCT04432467|ACTIVE_COMPARATOR|control|Patients with impending caesarean section or with chronic inflammation in the mucosa of the uterus and fallopian tubes receiving standard treatment
62362381|NCT05950555|ACTIVE_COMPARATOR|Patients given saline|10 cc/hour isotonic is given throughout the operation.
62362382|NCT05950555|ACTIVE_COMPARATOR|Patients given dexmedetomidine.|Dexmedetomidine 0.1 µg/kg IV bolus followed by 0.2 µg/kg/hr infusion throughout surgery.
62362383|NCT05950555|ACTIVE_COMPARATOR|Patients given ketamine.|Ketamine 0.2 mg/kg bolus followed by 0.1 mg/kg/hr infusion throughout surgery.
62362384|NCT00805012|ACTIVE_COMPARATOR|1|docetaxel+CDDP
62362385|NCT00805012|EXPERIMENTAL|2|docetaxel+S-1
62362386|NCT04134299|EXPERIMENTAL|AXA4010|AXA4010
62362387|NCT05255341|EXPERIMENTAL|roll pedicle connective tissue graft with bovine bone|"1. sulcular incisions were performed on the buccal and lingual aspects of the teeth to be extracted~2. Atraumatic extraction was made by periotome.~3. After tooth extraction the soft tissue was reflected at least 4 mm beyond the alveolar crest margin and the socket was filled with bovine derived xenograft and covered with roll pedicle connective tissue graft as a barrier membrane.~4. This pedicle is rolled under the buccal mucosa.The palatal connective tissue pedicle graft was outlined by full thickness incision along the oblique incision line, and parallel incision given from the mesial line angle of target place and reflected coronally up to the crest of the ridge defect. then a partial thickness incision was made extending beyond the line angles of adjacent incisors and mucogingival junction, leaving the periosteum on the bone.~5. the pedicle graft was rolled from the apical end and secured with interrupted sutures to the labial flap."
62362388|NCT02425436|ACTIVE_COMPARATOR|Ginkgo Biloba Extract group|This group received Ginko Biloba, two tablets per day
62169339|NCT03058237|ACTIVE_COMPARATOR|Part 2: Regimen G|"One low dose Arbaclofen Placarbil IR capsule taken under fasting conditions as the reference product.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
62362389|NCT02425436|PLACEBO_COMPARATOR|Placebo group|This group received placebo two tablets per day .
62362390|NCT03066297||Lobectomy|Lobectomy will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
62362391|NCT03066297||Segmentectomy|Segmentectomy will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
62362392|NCT03066297||Wide wedge resection|Wide wedge resection will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
62362393|NCT03002285|EXPERIMENTAL|Cerebral Palsy group|Group with Cerebral Palsy that performed the Fitts law in a computer task
62362394|NCT03002285|ACTIVE_COMPARATOR|Control group|Group with typical development that performed the Fitts law in a computer task
62362395|NCT02672618||chronic heart failure|18-85years old,having symptoms of heart failure,New York Heart Association（NYHA） class II or above American College of Cardiology/American Heart Association（ACC/AHA） class B, C, including hypertensive heart disease, rheumatic heart disease, ischemic cardiomyopathy and idiopathic cardiomyopathy
62362396|NCT02672618||normalCardiac function|18-85years old,no symptoms of heart failure,NYHA class I or above ACC/AHA class A, including controled hypertension,stability coronary heart disease and rheumatic heart disease
62362397|NCT02672618||healthy volunteers|18-85years old,Without basic cardiovascular diseases
62362398|NCT04163367|ACTIVE_COMPARATOR|Intervention as usual|The social services standard process for families reported for violence or abuse towards children. The standard process always includes a formal investigation of the suspected violence/abuse. The investigation may or may not result in voluntary or mandatory interventions, such as family support or parent training.
62362399|NCT04163367|EXPERIMENTAL|Intervention as usual + Safer Kids|The procedure in this arm is exactly the same as in the active comparator arm (i.e., investigation that may be followed by interventions). In addition, the general parent training program Safer Kids is offered during the investigation to all participants in this arm.
62362400|NCT00701246|EXPERIMENTAL|I|I Treatment: a daily dose (5 times a week) of either 4,2 mg/kg/day of ferrous sulfate + folic acid (50 mcg)
62362401|NCT00701246|PLACEBO_COMPARATOR|II|II Treatment of anemic children with 4,2 mg/kg/day of ferrous sulfate and folic acid placebo.
62362402|NCT00701246|EXPERIMENTAL|III|Prevention of anemia in non-anemic children ( 5 times a week)- 1,4 mg/kg/day of ferrous sulfate and folic acid
62362403|NCT00701246|PLACEBO_COMPARATOR|IV|1,4 mg/kg/day of ferrous sulfate plus folic acid placebo, five days a week.
62362404|NCT01135745|EXPERIMENTAL|Deep Brain Stimulation Therapy for OCD|Reclaim® DBS Therapy uses thin wires to deliver electric current (stimulation) to a very specific target in the brain. These wires are implanted surgically. They are attached to internal neurostimulators implanted under the skin of the chest below the collarbone, similar to cardiac pacemakers, or in the abdominal wall. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
62362405|NCT00981682|EXPERIMENTAL|SER120 (desmopressin)|
62362406|NCT03927911|ACTIVE_COMPARATOR|Open or mini-open surgical technique cohort|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
62362407|NCT03927911|ACTIVE_COMPARATOR|Tubular or Percutaneous cohort (Minimally Invasive Cohort)|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
62362408|NCT03927911|ACTIVE_COMPARATOR|Lumbar decompression without fusion (Outpatient Cohort)|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
62362409|NCT04616092|EXPERIMENTAL|FERINJECT Group|Patients with FERINJECT injection
62362410|NCT04616092|NO_INTERVENTION|Observation Group|Patients without FERINJECT injection
62362411|NCT01917552|EXPERIMENTAL|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
62362412|NCT01917552|NO_INTERVENTION|observation|
62362413|NCT04126603|PLACEBO_COMPARATOR|Group A Placebo|Metformin + Placebo.
62362414|NCT04126603|ACTIVE_COMPARATOR|Group B Active|Metformin + Placebo
62362415|NCT01852916|ACTIVE_COMPARATOR|Nasal CPAP|Nasal CPAP using Infant flow
62362416|NCT01852916|EXPERIMENTAL|NHFOV|Nasal High Frequency Oscillatory Ventilation using Dräger Babylog® VN500 ventilator machine
62362417|NCT05452824|EXPERIMENTAL|Tai Chi Prehabilitation|8 weeks Tai Chi prehabilitation prior to radical prostatectomy
62362418|NCT05452824|PLACEBO_COMPARATOR|Usual Care|Usual care
62362419|NCT03412123|EXPERIMENTAL|gLiFE pilot group|
62362420|NCT06135389||blood sampling scheme1|3 strata of 10 children and adolescents - normal weight, overweight and obese Titration of paracetamol (acetaminophen) - scheme 1
62362421|NCT06135389||blood sampling scheme2|3 strata of 10 children and adolescents - normal weight, overweight and obese Titration of paracetamol (acetaminophen) - scheme 2
62362422|NCT00800475|ACTIVE_COMPARATOR|Test Drug|
61982304|NCT03541265|EXPERIMENTAL|Adductor block protocol|An ultrasound-guided injection of Subsartorial saphenous nerve using Exparel 266 mg (20 cc vial) via a 21-gauge 4-inch Stimuplex A needle (B. Braun Medical Inc., Melsungen, Germany) was performed at mid-thigh level with a high-frequency linear ultrasound transducer. All regional anesthesia was performed by a trained anesthesiologist. Ultrasound pictures (pre-injection and post-injection) was obtained to verify proper local anesthetic placement.
62362423|NCT00800475|ACTIVE_COMPARATOR|Reference Drug|
62362424|NCT00968708|EXPERIMENTAL|Placebo|Alogliptin placebo matching tablets, orally, once daily. Participants continued to receive standard of care for cardiovascular disease and diabetes according to regional guidelines.
62362425|NCT00968708|EXPERIMENTAL|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for participants with normal or mildly impaired renal function as defined by estimated glomerular filtration rate (eGFR) ≥ 60 mL/min). Alogliptin 12.5 mg, tablets, orally, once daily for participants with moderately impaired renal function (eGFR ≥30 and \<60 mL/min). Alogliptin 6.25 mg, tablets, orally, once daily for participants with severely impaired renal function or end stage renal disease (eGFR \<30 mL/min). Participants continued to receive standard of care for cardiovascular disease and diabetes according to regional guidelines.
62362426|NCT04971369|EXPERIMENTAL|89Zr-NY001 injection|Patients will receive a tracer (5 mg, IV) dose of Zr-89 (1.5-2 mCi) labeled NY001 (89Zr-NY001)
62362427|NCT00134017|EXPERIMENTAL|Bone marrow transplant|Myeloablative bone marrow transplant with a busulfan (Bu), cyclophosphamide (Cy), preparative regimen and post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis
62362428|NCT04511936|ACTIVE_COMPARATOR|i-Lumen AMD Active|
62362429|NCT04511936|SHAM_COMPARATOR|i-Lumen AMD Sham|
62362430|NCT00643799|EXPERIMENTAL|A|
62362431|NCT00643799|ACTIVE_COMPARATOR|B|
62362432|NCT00643799|PLACEBO_COMPARATOR|C|
62362433|NCT05967208|EXPERIMENTAL|CONSORT referrals + Card referrals|Intervention arm
62362434|NCT05967208|ACTIVE_COMPARATOR|Card referrals alone|Control arm
62362435|NCT05459480|EXPERIMENTAL|Intervention Group|"Online training was continued according to the jigsaw technique for a total of 6 weeks, two hours a week. In the first week, 6 subgroups of 6 people were created.~Sub-topics of the physical examination course were shared according to the systems to these groups, called the main group.~In the first week, it was aimed for the groups to get to know each other and the first lesson was used for that. In the second week, the students in the main group researched the sub-topics of the unit given to them and formed a new group by coming together with students who were researching the same subject. This group was called the expert group. In the third and fourth weeks, expert groups continued their studies to reinforce the subject.~In the fifth and sixth group the students returned to their main groups and explained the subjects they had learned in the expert groups to their main group. Students were expected to teach each other all parts of the unit in their main groups."
62362436|NCT05459480|NO_INTERVENTION|Control Group|The subjects were explained by the instructor with the traditional e-teaching method and as in the intervention group, the lectures were conducted online for two hours a week for 6 weeks. At the end of each week, the relevant course documents were shared with the students. At the end of the sixth week, the post-tests of the learning motivation and self-confidence scales were applied in the control group simultaneously with the intervention group. In addition, an academic achievement test was applied.
62362437|NCT05367713||patients having had an osteitis of the cranial flap after craniectomy|
62739212|NCT02830854|EXPERIMENTAL|Molecular Hydrogen|Molecular hydrogen: 20 min per day of 3% H2 during 4 weeks
62362438|NCT04269837|EXPERIMENTAL|Supportive Care (sexual health counseling)|Patients receive sexual health counseling prior to starting and at the completion of radiation.
62362439|NCT01827241||Colonoscopy Outcomes|Data collected from endoscopy reports to complete a descriptive analysis of demographics, colonoscopy procedure performance, and assess type of benign colon polyps detected during screening and surveillance from 02/01/2009 - 12/31/2020.
62362440|NCT03940456||Inception cohort, former Elsinore pupils|640 former Elsinore pupils (330 female, 310 male). Aged 14 in 1965. Two earlier cross-sectional studies have been done in this group (in 1990 and 2000).
61982305|NCT03541265|ACTIVE_COMPARATOR|peri-articular injection|Peri-articular injection included combination of Exparel 266 mg (20 ml vial) with 20 ml of 0.5% bupivacaine, and normal saline to a total volume of 120 ml. The injection was meticulously administered prior and after cementation in the posterior capsule, posteromedial structures, the periarticular synovium, extensor apparatus, pes anserinus, anteromedial capsule, periosteum, iliotibial band, and subcutaneous plane. Injections were performed using 20-mL syringes with 22-gauge needle, minimal leakage. Visible tissue expansion was achieved.
62362441|NCT02444936|ACTIVE_COMPARATOR|ZOSTAVAX|ZOSTAVAX shingles vaccine Zoster vaccine live Single 0.65mL subcutaneous injection
62362442|NCT02444936|NO_INTERVENTION|Control|There is no drug given in this arm.
62362443|NCT02788591|OTHER|Proton Pump Inhibitor (PPI) Therapy|2x daily Proton Pump Inhibitor (PPI) Therapy for 8 weeks
62362444|NCT02788591|OTHER|Sucralfate|4x daily Sucralfate slurry, 1g, for 8 weeks
62362445|NCT03639922|ACTIVE_COMPARATOR|Imatinib|Imatinib 400mg (2 tablets of 400mg) per day for 6 days
62362446|NCT03639922|PLACEBO_COMPARATOR|Placebo|2 placebo tablets per day for 6 days
62362447|NCT05560152|EXPERIMENTAL|Experimental group|"Experimental: Experimental group Subjects will receive Yiqihuayu Decotion, combined with guidelines-based standard care.~Interventions:~Drugs: Yiqihuayu Decotion Other: Standard care (e.g. antiplatelet drugs and statins)"
62362448|NCT05560152|NO_INTERVENTION|Control group|"No Intervention: Control group Subjects will receive guidelines-based standard care.~Interventions:~Other: Standard care (e.g. antiplatelet drugs and statins)"
61982306|NCT05023187|EXPERIMENTAL|Social and Cognitive Online Training Group (SCOT)|A group of participants randomly assigned to a social-cognitive online training through individual cognitive training sessions and group sessions to improve social functioning.
62362449|NCT04030468|EXPERIMENTAL|General practitioners|Educational intervention
62362450|NCT04030468|EXPERIMENTAL|Patients|Informative intervention
62362451|NCT04030468|EXPERIMENTAL|General practitioners and patients|Combined strategy
62362452|NCT04030468|NO_INTERVENTION|Control|No intervention
62362453|NCT00615459|EXPERIMENTAL|Sequence 1: Placebo,Tiotropium, Indacaterol 150 μg|In period I, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. In period II, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via single dose dry powder inhaler (SDDPI). In period III, indacaterol 150 μg once daily delivered via SDDPI and placebo to tiotropium was delivered once daily via the tiotropium inhalation device. Daily inhaled corticosteroid (ICS) monotherapy (where applicable) was provided to remain stable throughout study. The Short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
61982307|NCT05023187|ACTIVE_COMPARATOR|Control Group (CON)|A group of participants randomly assigned to receive an active control intervention to compare performances with the experimental group.
61982308|NCT05835609|EXPERIMENTAL|PM534|Patients will be included in cohorts of a minimum of three or six patients to receive PM534 at successively increasing dose levels.
61982309|NCT02047747|EXPERIMENTAL|dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
61982310|NCT02699554||Orthopaedic surgery|
62169340|NCT03058237|EXPERIMENTAL|Part 2: Regimen H|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
62362454|NCT00615459|EXPERIMENTAL|Sequence 2: Indacaterol 300 μg, Indacaterol 150 μg, Tiotropium|In period I,indacaterol 300 μg once daily delivered via single dose dry powder inhaler (SDDPI)and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period II, indacaterol 150 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period III, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via SDDPI. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
62362455|NCT00615459|EXPERIMENTAL|Sequence 3: Indacaterol 150 μg, Indacaterol 300 μg, Placebo|In period I, indacaterol 150 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period II, indacaterol 300 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period III, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
62567108|NCT01812460|EXPERIMENTAL|Intervention-training-group|"The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times) The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every session of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoe as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.~The weight cuffs are handed over to the patients for self guided exercise during weekends"
61982311|NCT01601782|EXPERIMENTAL|Volume Imaging scan|New type of ultrasound scan using General Electric US scanner, Model is a GE Logiq E9.
61982312|NCT02631954|EXPERIMENTAL|TR Group|Test drug: Vorico Injection 200mg(Voriconazole) Wash out: 7 days Reference drug: Vfend® IV 200mg
61982313|NCT02631954|EXPERIMENTAL|RT group|Reference drug: Vfend® IV 200mg Wash out: 7 days Test drug: Vorico Injection 200mg(Voriconazole)
62362456|NCT00615459|EXPERIMENTAL|Sequence 4: Tiotropium, Placebo, Indacaterol 300 μg|In period I, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via SDDPI. In period II, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. In period III, indacaterol 300 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
62362457|NCT00718250|EXPERIMENTAL|cohort 1|AML Cell Vaccine alone
62362458|NCT00718250|EXPERIMENTAL|cohort 2|Donor leukocytes alone
61982314|NCT02493608|ACTIVE_COMPARATOR|scalpel group|Scalpel is the device used to make abdominal wall incision in this group of patient.
62362459|NCT00718250|EXPERIMENTAL|cohort 3|AML cell vaccine and Donor Leukocyte Infusion (1x107/kg)
62362460|NCT00718250|EXPERIMENTAL|cohort 4|AML cell vaccine and Donor Leukocyte Infusion (1x108/kg)
62362461|NCT01769638|EXPERIMENTAL|SPO1101|
61982315|NCT02493608|ACTIVE_COMPARATOR|Diathermy group|In this study group, abdominal wall incisions are made with diathermy which is a electrosurgical instrument.
61982316|NCT05175417||Case|Patients being considered for functional neurosurgical procedures, such as deep brain stimulation (DBS), radiofrequency ablation (RFA), gamma knife radiosurgery (GKR), or magnetic resonance-guided focused ultrasound (MRgFUS).
62362462|NCT01769638|EXPERIMENTAL|SPO1101D|
62362463|NCT03984812|EXPERIMENTAL|Part 1,Cohort 1:Subjects receiving blinded GSK3732394 10mg/PBO|GSK3732394 10 milligram (mg) or PBO will be administered by subcutaneous (SC) injection to the subjects.
62362464|NCT03984812|EXPERIMENTAL|Part 1,Cohort 2:Subjects receiving blinded GSK3732394 40mg/PBO|GSK3732394 40 mg or PBO will be administered by SC injection to the subjects. This is projected dose, dose will be based on PK/PD results from preceding dosing cohorts.
62362465|NCT03984812|EXPERIMENTAL|Part1,Cohort 3:Subjects receiving blinded GSK3732394 130mg/PBO|GSK3732394 130 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 3 will be based on PK/PD results from preceding dosing cohorts.
62362466|NCT03984812|EXPERIMENTAL|Part1,Cohort 4:Subjects receiving blinded GSK3732394 350mg/PBO|GSK3732394 350 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 4 will be based on PK/PD results from preceding dosing cohorts.
62362467|NCT03984812|EXPERIMENTAL|Part1,Cohort5: Subjects receiving blinded GSK3732394 600mg/PBO|GSK3732394 600 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 5 will be based on PK/PD results from preceding dosing cohorts.
62362468|NCT03984812|EXPERIMENTAL|Part1,Cohort6: Subjects receiving blinded GSK3732394 800mg/PBO|GSK3732394 800 mg or PBO will be administered by SC injection to the subjects. This is a projected dose and will be given if necessary. The dose administered in Part 1, Cohort 6 (if necessary) will be based on PK/PD results from preceding dosing cohorts.
62362469|NCT03984812|EXPERIMENTAL|Part2,Cohort1: Subjects receiving blinded GSK3732394 130mg/PBO|GSK3732394 130 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The dose administered in Part 2, Cohort 1 will be based on PK/PD results from preceding dosing cohorts.
62362470|NCT03984812|EXPERIMENTAL|Part2,Cohort2: Subjects receiving blinded GSK3732394 400mg/PBO|GSK3732394 400 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The administered dose in Part 2, Cohort 2 will be based on PK/PD results from preceding dosing cohorts.
62362471|NCT03984812|EXPERIMENTAL|Part2,Cohort3: Subjects receiving blinded GSK3732394 600mg/PBO|GSK3732394 600 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The administered dose in Part 2, Cohort 3 will be based on PK/PD results from preceding dosing cohorts and will not exceed the maximum exposure observed in SAD (Part 1).
61982317|NCT05175417||Control|Healthy control volunteers.
61982318|NCT05422677||single arm, single group(No interventional)|Observational
61982319|NCT04128384|OTHER|EPS arm|Limited electrophysiologic study including measurements of HV- and AH-intervals pre- and post-TAVR
61982320|NCT00074087|EXPERIMENTAL|Caelyx|doxorubicin HCl liposome IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses.
61982321|NCT05951010|EXPERIMENTAL|Transcranial direct current stimulation (tDCS)|Participants underwent anodal stimulation delivered by a battery-driven stimulator (Neuroelectrics, Barcellona, Spain) through a pair of saline-soaked surface sponge electrodes (7 x 5 cm2) producing a constant current of 2 mA for 20 min.
62362472|NCT05914740|EXPERIMENTAL|Venous valve remodeling|Venous valve function was remodeled under ultrasound guidance
62362473|NCT06349850||HbA1c level group|"* well controlled diabetic group : HBA1c less than 7%~* poorly controlled diabetic group : HBA1c equal to ore more than 7%"
62362474|NCT06349850||UHR level group|"median levels of UHR will be used to dichotomize the patients into groups of :~* low UHR group~* high UHR group"
62362475|NCT06349850||DKI group|"study population will be grouped into another two groups according to the presence of DKI:~* patients with DKI~* patients without DKI"
62362476|NCT06306352|EXPERIMENTAL|Vibrotactile feedback|Participants will receive vibrotactile feedback in the ABLE Exoskeleton.
61982322|NCT04453033|ACTIVE_COMPARATOR|Investigational Device|The Celeste device resembles a large tablet. It has a protective cover that folds into a stand and is magnetically attached to the back of the device. It produces a low intensity of specific bandwidths of light believed to be responsible for circadian and alerting responses in humans. The overall emission produces a pleasing soft glow of light.
61982323|NCT04453033|SHAM_COMPARATOR|Control Device|The Control device is identical in appearance to Celeste. When turned on, the device emits a soft diffused light that is indistinguishable in color from the Active Device. However, this device produces a different amount of the specific wavelengths thought to be effective in the Active Device. It is impossible to tell the difference between the sham device and the active device by looking at them.
62362477|NCT00987610|ACTIVE_COMPARATOR|slender guidewire|Percutaneous coronary intervention (PCI) using guidewires with small distal tip equal to 0.010 inch or less
62362478|NCT00987610|ACTIVE_COMPARATOR|normal guidewire|Percutaneous coronary intervention (PCI) using guidewires with normal distal tip equal to 0.014 inch
62362479|NCT01855425|OTHER|Investigational CBCT|Radiation
62362480|NCT05131529|NO_INTERVENTION|Control|The 3 dining halls allocated to this arm will receive none of the three interventions during the 3 semesters of the project.
62362481|NCT05131529|EXPERIMENTAL|Treatment|The 3 dining halls allocated to this arm will receive one intervention during each of the 3 semesters of the project (only one intervention per semester).
62362482|NCT03431142|EXPERIMENTAL|Clopidogrel monotherapy|On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue clopidogrel monotherapy in the following 9 months.
62362483|NCT03431142|ACTIVE_COMPARATOR|Clopidogrel plus aspirin|On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue DAPT (aspirin+clopidogrel) in the following 9 months.
62362484|NCT03431506|ACTIVE_COMPARATOR|non-training group|
62362485|NCT03431506|EXPERIMENTAL|training group|
62362486|NCT05767229|EXPERIMENTAL|Carvedilol for 1.5 hrs|Carvedilol 0.2 mg/kg for 1.52 hrs
62362487|NCT02884128|EXPERIMENTAL|PEP02 + 5-FU/LV|The initial starting dose of PEP02 is 60 mg/m2, and was escalated by increments of 20 mg/m2 between dose levels. 5-FU and LV were given as 24-hour infusion via an implanted central venous catheter, with dose fixed at 2000 mg/m2 and 200 mg/m2, respectively. PEP02 was administered on Day 1; 5-FU/LV was started after the end of PEP02 infusion on Day 1 and also on Day 8.
62362488|NCT04814407||Lung cancer patients|Patients age over 20, with suspected or confirmed diagnosis of lung cancer.
61982324|NCT06249425|EXPERIMENTAL|The experimental group|The patients are randomly assigned to either the experimental group or the placebo group. All patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using Intermittent Oro-esophageal Tube. In addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.
61982325|NCT06249425|PLACEBO_COMPARATOR|The placebo group|The patients are randomly assigned to either the experimental group or the placebo group. All patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using Intermittent Oro-esophageal Tube. In addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.
61982326|NCT01826487|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to ataluren orally 3 times a day (TID) at morning, midday, and evening for 48 weeks.
61982327|NCT01826487|EXPERIMENTAL|Ataluren|Participants will receive ataluren suspension orally TID, 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 48 weeks.
61982328|NCT03366402||Influenza A|
62362489|NCT04814407||Indeterminate subjects|Subjects who had indeterminate sub-centimeter pulmonary nodules or ground glass opacities discovered by computed tomography.
61982329|NCT03366402||Influenza B|
61982330|NCT03711487|EXPERIMENTAL|Ironing therapy|Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, 4 times daily from 12 hours after surgery and last for 2 days. The medicine bag can be heated and reused after it cool down.
62362490|NCT04814407||Control subjects|Non-cancer patients including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.
62362491|NCT00081328|EXPERIMENTAL|1|Metformin alone
62362492|NCT00081328|EXPERIMENTAL|2|Metformin + Rosiglitazone
61982331|NCT03711487|NO_INTERVENTION|No intervention|No intervention.
62362493|NCT00081328|EXPERIMENTAL|3|Metformin + Lifestyle Program
62362494|NCT04152746||Adenoid group|Periostin levels in the adenoid group
62362495|NCT04152746||Control Group|Periostin levels in the control group
62362496|NCT05968625|EXPERIMENTAL|Thermoformed retainers (TFR)|Thermoformed retainers are constructed from an Erkodur blank (ERKODENT® Erich Kopp GmbH, Pfalzgrafenweiler, Germany) with 1.0 mm in thickness, following the manufacturer's instructions.
62362497|NCT05968625|EXPERIMENTAL|Direct 3-D printed retainers (3DPR)|Private dental laboratories directly print the retainers using a NextDent 3D printer and NextDent ortho Flex resin. Thickness of 0.80mm
62739213|NCT02860208||3 years follow-up|all patients who received surgical treatment for peri-implantitis during a Randomized and Controlled Trial registered in ClinicalTrials.gov NCT NCT01857804
61982332|NCT06137404|ACTIVE_COMPARATOR|Splint M|Metacarpophalangeal joint blocking splint
61982333|NCT06137404|EXPERIMENTAL|Splint R|Relative motion extension splint
62362498|NCT00639262|EXPERIMENTAL|Cohort 1 - Brain Metastasis|Sorafenib and Radiotherapy
62362499|NCT00639262|EXPERIMENTAL|Cohort 2 - Gliomas|Sorafenib and Radiotherapy, plus Temozolomide
62362500|NCT02149472||Pregnant women with PPH|All pregnant women in participating hospitals are asked for their informed consent (n = 9.500). All women will complete a bleeding score generating questionnaire during their pregnancy. Only from women developing postpartum haemorrhage \> 1000 cc blood samples will be drawn (n = 600).
62362501|NCT05851092|EXPERIMENTAL|HRS-2189 Tablets|
62362502|NCT01661946|ACTIVE_COMPARATOR|Ranibizumab|intravitreal injection of 0.5mg ranibizumab in usual fashion
62362503|NCT01661946|ACTIVE_COMPARATOR|Bevacizumab|intravitreal injection of 1.25mg bevacizumab in usual fashion
62362504|NCT03907592|EXPERIMENTAL|L-carnitine Group|Group participated in the training protocol and supplemented by 1000 mg L-carnitine-L-tartrate in combination with 3000 mg L-leucine per day throughout 24 weeks.
62362505|NCT03907592|EXPERIMENTAL|Leucine Group|Group participated in the training protocol and supplemented by 4000mg of L-leucine per day throughout 24 weeks.
62362506|NCT03907592|EXPERIMENTAL|Control Group|Group participated in the training protocol without any supplementation throughout 24 weeks.
62362507|NCT06240624||Patients with Parkinson's disease and Levodopa-induced dyskinesia|"Inclusion criteria:~* Aged 18 or more~* Clinically established or probable PD according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease~* Peak-of-dose levodopa-induced dyskinesia~* Stable antiparkinsonian medicine for 4 weeks~* Signed informed consent~Exclusion criteria:~* Pregnancy or breastfeeding~* History of other neurologic or psychiatric disease~* Pacemaker or other implanted metallic or electronic devices which contraindicate MRI or TMS of the brain~* Claustrophobia"
62362508|NCT06240624||Patients with Parkinson's disease without Levodopa-induced dyskinesia|"Inclusion criteria:~* Aged 18 or more~* Clinically established or probable PD according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease~* No levodopa-induced dyskinesia~* Stable antiparkinsonian medicine for 4 weeks~* Signed informed consent~Exclusion criteria:~* Pregnancy or breastfeeding~* History of other neurologic or psychiatric disease~* Pacemaker or other implanted metallic or electronic devices which contraindicate MRI or TMS of the brain~* Claustrophobia"
61982334|NCT01894581|EXPERIMENTAL|Obese Women|Women with a BMI of greater than or equal to 30 kg/m2 underwent all study interventions, including taking 5 g daily of LOVAZA. Women underwent 8 hours of frequent blood sampling every 10 minutes both at baseline and after LOVAZA supplementation. Each frequent blood sampling included IV administration of GnRH at 6 hours.
61982335|NCT01894581|ACTIVE_COMPARATOR|Normal Weight|Women with a BMI of between 18-25 kg/m2 underwent all study interventions, including taking 5 g daily of LOVAZA for one cycle. Women underwent 8 hours of frequent blood sampling every 10 minutes both at baseline and after LOVAZA supplementation. Each frequent blood sampling included IV administration of GnRH at 6 hours.
62362509|NCT06240624||Healthy controls|"Inclusion criteria:~* Aged 18 or more~* Age- and sex-matched the PD groups~* Signed informed consent~Exclusion criteria:~* Pregnancy or breastfeeding~* History of other neurologic or psychiatric disease~* Pacemaker or other implanted metallic or electronic devices which contraindicate MRI or TMS of the brain~* Claustrophobia"
61982336|NCT04225351|EXPERIMENTAL|MCAF+CM|Modified coronally advanced flap + collagen matrix
61982337|NCT04225351|ACTIVE_COMPARATOR|MCAT+CM|Modified coronally advanced tunnel technique + collagen matrix
62362510|NCT04786730|EXPERIMENTAL|Open-label centanafadine|There will be multiple cohorts dosed with open-label centanafadine.
62362511|NCT05191849|OTHER|Small Cell Lung Cancer receiving chemotherapy|
61982338|NCT01394523|ACTIVE_COMPARATOR|Caudal epidural|The caudal epidural block will be delivered with 1.5ml/kg of 0.25% Bupivacaine up to a maximum of 30 mL.
61982339|NCT01394523|ACTIVE_COMPARATOR|Rectus sheath|The rectus sheath block will be performed with 0.1ml/kg of 0.25% Bupivacaine on each side at the T9-T10 distribution under ultrasound guidance.
61982340|NCT01394523|ACTIVE_COMPARATOR|Local|The surgeon will inject either 0.5% Bupivicaine 0.5ml/kg or 0.25% Bupivicaine 1ml/kg at the surgeon's discretion.
61982341|NCT01002950|EXPERIMENTAL|ACU-4429 tablet|
61982342|NCT01002950|PLACEBO_COMPARATOR|Matching placebo tablet|
61982343|NCT06507449|EXPERIMENTAL|High-pressure non-compliant balloon|The SIS Medical OPN NC® super high-pressure coronary balloon will be used for balloon angioplasty vessel preparation prior to implantation of a drug-eluting stent.
61982344|NCT06507449|EXPERIMENTAL|Orbital atherectomy|The Diamondback 360® Coronary Orbital Atherectomy System (OAS) will be used for orbital atherectomy (OA) vessel preparation prior to implantation of a drug-eluting stent.
61982345|NCT06507449|EXPERIMENTAL|Lithotripsy|The Shockwave® Medical system will be used for intravascular lithotripsy (IVL) vessel preparation prior to implantation of a drug-eluting stent.
61982346|NCT00114465|EXPERIMENTAL|VSL#3|Probiotic
61982347|NCT00114465|PLACEBO_COMPARATOR|Placebo|Placebo
62362512|NCT02613091|EXPERIMENTAL|Clemastine|This group will receive 8mg of clemastine daily.
61982348|NCT05959330|EXPERIMENTAL|Neural Tension Technique(ulnar, median, radial)|Neural Tension Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
61982349|NCT05959330|EXPERIMENTAL|Neural Slider Technique (ulnar, median, radial)|Neural Slider Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
62362513|NCT02137707||Gilenya treatment|Gilenya oral form once a day
62362514|NCT05254652|EXPERIMENTAL|Experimental: Duloxetine and Pregabalin|Experimental group will take medicine for 10 weeks from 2 weeks before surgery to 8 weeks after surgery. The group takes one pill of duloxetine 30 mg, one pill of pregabalin 150mg after breakfast and one pill of pregabalin 150 mg after dinner.
62362515|NCT05254652|ACTIVE_COMPARATOR|Active Comparator: Duloxetine|Active comparator group will take medicine for 10 weeks from 2 weeks before surgery to 8 weeks after surgery. The group takes only one pill of duloxetine 30 mg after breakfast.
62362516|NCT01712776|ACTIVE_COMPARATOR|Vapocoolant (Pain Ease Medium Stream )|Application of Vapocoolant (Pain Ease Medium Stream) for 4-10 seconds onto venipuncture site.
61982350|NCT05959330|EXPERIMENTAL|Neural Tension Technique and Neural Sliding Technique(ulnar, median, radial)|Neural Tension and Sliding Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
61982351|NCT02024347||LSSM arm|Intervention: upper endoscopy only performed to patients with high LSM (≥12.0kPa) or SSM (≥41.3kPa) values
61982352|NCT02024347||Control arm|Intervention: upper endoscopy performed to all patients in this group.
61982353|NCT02062320||PRE-PCAPS|Parturients who underwent delivery by Caesarean Section in the period October 2009 - September 2010
61982354|NCT02062320||POST-PCAPS|Parturients who underwent delivery by Caesarean Section in the period November 2010 - October 2011.
61982355|NCT05428488|EXPERIMENTAL|Experimental|"All included patients will receive TNF inhibitors subcutaneous for 12 weeks. In the experimental arm, a therapeutic sequential strategy will be proposed from W12 visit.~At 12 weeks (W12), patients who have at least a moderate EULAR response (delta DAS28-CRP between W0 and W12\>0.6 and DAS28-CRP≤5.1 at W12) will be randomized with a 1:1 ratio in the sequential strategy arm or the control arm.~In the sequential strategy (experimental) arm, the 88 randomized RA patients will be switched to abatacept subcutaneous for 36 weeks."
61982356|NCT05428488|ACTIVE_COMPARATOR|Control|"All included patients will receive TNF inhibitors subcutaneous for 12 weeks. In the control group, the 88 randomized RA patients will be treated with TNF inhibitor subcutaneous for another 36 weeks (from W12 visit).~In case of insufficient response to a first TNF inhibitor at 24 or 36 weeks, a second TNF inhibitor will be proposed."
61982357|NCT01859754||Octagam 5%|Primary Immune Deficiency Syndrome patients receiving Octagam 5% by infusion who have been treated with a marketed IVIG product for at least 6 months.
61982358|NCT01859754||Other marketed IVIG product|Primary Immune Deficiency Syndrome patients receiving marketed IVIG product other than Octagam 5% by infusion as treatment for at least 6 months.
61982359|NCT02742987|EXPERIMENTAL|Ticagrelor group|Ticagrelor 90 mg twice daily + standard medical therapy
61982360|NCT02742987|EXPERIMENTAL|Clopidogrel group|Clopidogrel 150 mg once daily + standard medical therapy
61982361|NCT03946384||patients|Hemophilia B with p.Ile112Thr mutation on factor IX gene
61982362|NCT04390945|EXPERIMENTAL|Camrelizumab Combined With Concurrent Radiotherapy and Chemotherapy|Camrelizumab (200mg Q2W, continuous medication until disease progression, intolerable toxicity, or withdrawal due to other reasons) Simultaneous radiotherapy (50-50.4Gy / 1.8-2Gy / 25-28F) Chemotherapy (Capecitabine, 625mg/m2, bid, oral, d1-5, qw, total 5 weeks).
61982363|NCT00378209|EXPERIMENTAL|lenalidomide, dexamethasone, bortezomib combination|Participants took the study medication in the clinic on Cycle 1 day 1. Each treatment cycle lasted three weeks. They took the lenalidomide (capsules) every day for the first two weeks only (days 1-14). They took the dexamethasone (tablets) on Day 1, 2, 4, 5, 8, 9, 11 and 12 and came to the outpatient treatment center for intravenous bortezomib on Day 1, 4, 8 and 11. The third week of the cycle was a rest period and the participant did not take any study medication.
61982364|NCT00320099|ACTIVE_COMPARATOR|1|Hydrocortisone and convention glycemic control
62362517|NCT01712776|PLACEBO_COMPARATOR|Nature's Tears Sterile Water|Application of sterile water stream (nature's tears) for 4-10 seconds onto the venipuncture site.
62362518|NCT03947255|EXPERIMENTAL|Brentuximab vedotin|
62362519|NCT05924126||septic patients who recieved appropriate empiric antibiotics|
62362520|NCT05924126||septic patients who recieved inappropriate empiric antibiotics|
61982365|NCT00320099|EXPERIMENTAL|2|Hydrocortisone and fludrocortisone and conventional glucose control
61982366|NCT00320099|EXPERIMENTAL|3|Hydrocortisone and intensive insulin therapy
61982367|NCT00320099|EXPERIMENTAL|4|hydrocortisone, fludrocortisone and intensive insulin therapy
61982368|NCT06063577|ACTIVE_COMPARATOR|Stratafix Group|Stratafix
61982369|NCT06063577|PLACEBO_COMPARATOR|Control Group|Standard of care
61982370|NCT02181439|OTHER|Right irradiated sector|"The low-energy laser (LLLT Low Level Laser Therapy) SIROLaser Advance: laser diode (970nm) is applied twice at day 0 and at M1. For each patient, randomized in this arm, only the right maxillary canine is actually irradiated. Irradiation is performed by scanning an area from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction and the cement enamel junction (CEJ) to the bottom of the vestibule in the vertical direction as well in buccally as in Palatine.~The same procedure will be applied to the left non-irradiated area, the only difference being that the laser will not be activated (placebo, laser inactive). Indeed, only the beam director will be lit and a beep start and end will be heard by the patient. In addition, the practitioner evaluating obtention or not of the class I will not know either which area has been irradiated or not."
61982371|NCT02181439|OTHER|Left irradiated sector|"The low-energy laser (LLLT Low Level Laser Therapy) SIROLaser Advance: laser diode (970nm) is applied twice at day 0 and at M1. For each patient, randomized in this arm, only the left maxillary canine is actually irradiated. Irradiation is performed by scanning an area from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction and the cement enamel junction (CEJ) to the bottom of the vestibule in the vertical direction as well in buccally as in Palatine.~The same procedure will be applied to the right non-irradiated area, the only difference being that the laser will not be activated (placebo, laser inactive). Indeed, only the beam director will be lit and a beep start and end will be heard by the patient. In addition, the practitioner evaluating obtention or not of the class I will not know either which area has been irradiated or not."
61982372|NCT04105933|EXPERIMENTAL|CS-CBT|Culturally sensitive-CBT intervention was comprised of 16 sessions of cognitive behavioral therapy focused on culturally-specific beliefs and attitude.
61982373|NCT04105933|ACTIVE_COMPARATOR|CBT|CBT intervention was comprised of 16 sessions of cognitive behavioral therapy.
61982374|NCT04482842|EXPERIMENTAL|Gene-guided Warfarin|
61982375|NCT04482842|OTHER|Routine use|
61982376|NCT04218227||Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
61982377|NCT04218227||Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
61982378|NCT04218227||Self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life.
61982379|NCT04218227||Psycho-education|It is a 7-months 2 hours-session (1 session per month) of psycho-education training. Psycho-education aims to empower and encourage the patient to become an actor in his therapeutic management, while offering a comprehensive model of the mechanisms of pain, the benefits of pharmacological treatments at a physical and psychological level as well as ways to change the way one lives every day.
62362521|NCT01570205|EXPERIMENTAL|XG-102 10 µg/kg|
62362522|NCT01570205|EXPERIMENTAL|XG-102 40 µg/kg|
62362523|NCT01570205|EXPERIMENTAL|XG-102 80 µg/kg|
62362524|NCT01570205|PLACEBO_COMPARATOR|placebo|
62362525|NCT06423872|EXPERIMENTAL|ZT002|Participants will be randomized to receive ZT002 injection or Placebo in 1 of 6 dose cohorts.
62362526|NCT06423872|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive ZT002 injection or Placebo in 1 of 6 dose cohorts.
62362527|NCT01886404||Efavirenz Group|Participants will be taking efavirenz as part of their antiretroviral regimen.
62362528|NCT01002898|EXPERIMENTAL|lopinavir/ritonavir|
61982380|NCT04218227||Self-hypnosis/self-care motivation|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
61982381|NCT00463346|EXPERIMENTAL|Acamprosate|Acamprosate
61982382|NCT00463346|PLACEBO_COMPARATOR|placebo|placebo
61982383|NCT05248841|EXPERIMENTAL|HEC-Glargine Treatment A (Test)|Subjects will receive single doses of Test Formulation HEC-Glargine on Day 1 of Treatment periods 1 and 2 followed by at least 7-21 days washout.
61982384|NCT05248841|ACTIVE_COMPARATOR|US-Lantus Treatment B (Reference)|Subjects will receive single doses of Reference Formulation Lantus on Day 1 followed of Treatment periods 1 and 2 by at least 7-21 days washout.
61982385|NCT02951156|EXPERIMENTAL|Phase 1b Arm A|avelumab/utomilumab/rituximab
61982386|NCT02951156|EXPERIMENTAL|Phase 1b Arm B|avelumab/utomilumab/azacitidine
61982387|NCT02951156|EXPERIMENTAL|Phase 1b Arm C|avelumab/rituximab/bendamustine
61982388|NCT02951156|EXPERIMENTAL|Phase 3 Arm D (selected from Phase 1b)|Selected regimen from Phase 1b component which may be i) avelumab/utomilumab/rituximab OR ii) avelumab/rituximab/azacitidine OR iii) avelumab/rituximab/bendamustine
62362529|NCT02517268|ACTIVE_COMPARATOR|Standard 7-Day Pathway|Patients follow the standard 7-day pathway following pancreaticoduodenectomy
62362530|NCT02517268|EXPERIMENTAL|Accelerated 5-Day Pathway|Patients follow the Whipple accelerated 5-day pathway following pancreaticoduodenectomy. The accelerated pathway includes more rapidly leaving the ICU setting, early mobilization and enhanced physical therapy, multimodal pain control, dietary modifications, and increased and standardized phone contact by a nurse practitioner during the first week following hospital discharge.
61982389|NCT02951156|ACTIVE_COMPARATOR|Phase 3 Arm E|Investigator's Choice of either rituximab/bendamustine or rituximab/gemcitabine/oxaliplatin
62362531|NCT01985165|EXPERIMENTAL|Imrecoxib|0.1g,BID,po
61982390|NCT04745598||Control group: Dental model|Patients diagnosed with periodontal disease stage I/II/III
61982391|NCT04745598||Computer-assisted teaching format group|Patients diagnosed with periodontal disease stage I/II/III
61982392|NCT04745598||Plaque-disclosing group|Patients diagnosed with periodontal disease stage I/II/III
61982393|NCT04745598||Intra-oral Camera group|Patients diagnosed with periodontal disease stage I/II/III
61982394|NCT03016247|ACTIVE_COMPARATOR|Enhanced Usual Care|Group will receive a single visit with a Nutritionist for dietary and physical activity counseling
61982395|NCT03016247|EXPERIMENTAL|TRUST intervention|Group will receive parent-adolescent trust-building and weight self-management training.
61982396|NCT02299986||Single arm Ultrasound measurement|Ultrasound measurement
61982397|NCT06422260||Porcelin fused to metal (PFM) group|Evaluation of biological response and clinical performance of the fixed partial denture anterior bridge constructed from PFM
61982398|NCT06422260||Zirconia group|Evaluation of biological response and clinical performance of the fixed partial denture anterior bridge constructed from ceramics
61982399|NCT06422260||Polyetheretherketone (PEEK) group|Evaluation of biological response and clinical performance of the fixed partial denture anterior bridge constructed from PEEK
61982400|NCT00660530|ACTIVE_COMPARATOR|1|One week before the administration of crushed or chewed lanthanum, the subjects were instructed to discontinue their P-binding agents, if prescribed previously. At the end of the 1-week washout period, subjects whose serum P exceeded 5.5 mg/dL were randomized to receive, in a crossover fashion, lanthanum 1000 mg (Fosrenol, Shire US Inc., Wayne, PA, USA) 3 times daily to be chewed with meals (chewed LAN) or lanthanum 1000 mg crushed into a ﬁne powder and taken with meals 3 times daily (crushed LAN), for 4 weeks each. The lanthanum tablets were crushed into a ﬁne powder using a mortar and pestle by the investigators, individually wrapped in powder packets and dispensed to the subjects on a weekly basis. The subjects were instructed to empty the powder into a small plastic cup provided, mix with 2 tablespoonfuls of applesauce and take it with meals. After each treatment (chewed or crushed LAN), there was a 1-week washout period.
61982401|NCT00660530|EXPERIMENTAL|2|After the one-week washout period, the subject received the other lanthanum treatment (chewed or crushed) that they did not receive in the initial treatment period.
61982402|NCT00368654|ACTIVE_COMPARATOR|A|Monotherapy with Raptiva alone
61982403|NCT00368654|EXPERIMENTAL|B|Combination therapy with both Raptiva and Methotrexate
61982404|NCT00368654|EXPERIMENTAL|C|Continue Raptiva, discontinue methotrexate
61982405|NCT00368654|EXPERIMENTAL|D|Continue combination therapy with both Raptiva and Methotrexate
61982406|NCT02060604|EXPERIMENTAL|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed plus ketorolac eyedrops TID
61982407|NCT02060604|ACTIVE_COMPARATOR|Ranibizumab Alone|3 monthly ranibizumab, then as needed
61982408|NCT05264077|EXPERIMENTAL|Dexmedetomidine|Inj.Dexmedetomidine(precidex ) 200mcg/2ml Given to participants in infusion form for 24 hours
61982409|NCT05264077|EXPERIMENTAL|Midazolam|Inj.midazolam 5mg/ml given to participants in infusion form for 24 hrs
61982410|NCT01693406||Normal Weight|Normal weight and normoglycemic women: Pre-pregnancy BMI between 18.5 - 24.9 kg/m2.
62362532|NCT01324128|EXPERIMENTAL|PA21 (2.5 g tablet)|
62362533|NCT01324128|ACTIVE_COMPARATOR|Sevelamer carbonate|
61982411|NCT01693406||Overweight/Obese|Overweight and normoglycemic women: Pre-pregnancy BMI between \> 25 kg/m2.
61982412|NCT01693406||Gestational Diabetes|Women who develop gestational diabetes and return to normal glucose control after delivery.
61982413|NCT01693406||Type 2 Diabetes|Women who are overweight and have Type 2 Diabetes that was diagnosed before pregnancy: Pre-pregnancy BMI \> 25 kg/m2.
61982414|NCT04368819|ACTIVE_COMPARATOR|Allopurinol|Allopurinol 300mg P.O. once daily for four weeks followed by allopurinol 300mg P.O. twice daily for 12 weeks.
61982415|NCT04368819|PLACEBO_COMPARATOR|Placebo|Placebo pills indistinguishable from the active comparator given P.O. once daily for four weeks, followed by twice daily for 12 weeks.
61982416|NCT04208399|EXPERIMENTAL|Part A: Group 1|Participants with liver cirrhosis with moderate hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.
62362534|NCT01324128|OTHER|PA21-1 (1.25 g tablet)|
62362535|NCT02873208|EXPERIMENTAL|ALKS 3831|Oral tablet, daily dosing
62362536|NCT06481020|EXPERIMENTAL|Dietary Supplement|PS-containing dietary supplement Sachet containing a powdered microencapsulated free plant sterols (2 g ingredient/day)
62362537|NCT06481020|PLACEBO_COMPARATOR|Placebo|Sachet containing the powdered excipients of the dietary supplement
61982417|NCT04208399|EXPERIMENTAL|Part A: Group 2|Participants with normal liver function with no liver cirrhosis will receive a single oral dose of JNJ-56136379 in fed condition.
61982418|NCT04208399|EXPERIMENTAL|Part B: Group 3 (optional)|Participants with liver cirrhosis with mild hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.
61982419|NCT04208399|EXPERIMENTAL|Part B: Group 4 (optional)|Participants with liver cirrhosis with severe hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.
61982420|NCT02053467|EXPERIMENTAL|eConsult|Physicians randomized to the intervention will have access to the Champlain BASE eConsult service right away (pending completion of an orientation session)
62739214|NCT04157153|EXPERIMENTAL|Treatment|All subjects will be implanted with the Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) and followed up until 60 months.
61982421|NCT02053467|NO_INTERVENTION|Control|Physicians randomized to the control group will use their standard referral practices for one year after randomization and only then will be given the option to use eConsult.
61982422|NCT04018833||ranibizumab|Patients nonresponsive to bevacizumab that were switched to ranibizumab
61982423|NCT04018833||aflibercept|Patients nonresponsive to bevacizumab that were switched to aflibercept
61982424|NCT01541969|EXPERIMENTAL|CR Neuromodulation|Adaptive NeuroModulation (ANM) T30 CR® Neurostimulator device. Participants receive the intervention according to the manufacturer/funder training given to the study team.
61982425|NCT01541969|ACTIVE_COMPARATOR|Tinnitus masking|Participants will receive the same Adaptive NeuroModulation (ANM) T30 CR® Neurostimulator device, but it will NOT be programmed according to the therapeutic algorithm (0-12 weeks).
61982426|NCT03610022|EXPERIMENTAL|Patients with BCC and annexial carcinoma|Patients with BCC and annexial carcinoma histologically proven under treatment or new patients under vismodegib
61982427|NCT01280214|EXPERIMENTAL|Triamcinolone|
62362538|NCT06082375|EXPERIMENTAL|Vitamin D|"Individually adapted to each participant based on BMI, dose of vitamin D3 in drops.~1. BMI 19-25 - 4000 IU~2. BMI 25-29,9- 6000 IU~3. BMI \>30- 8000 IU"
61982428|NCT01290640||TC3 TKA|Subjects implanted with a DePuy fixed-bearing Total Condylar III (TC3) TKA
61982429|NCT01290640||PFC RP TC3 TKA|Subjects implanted with a DePuy PFC Rotating Platform TC3 TKA
61982430|NCT03949205|EXPERIMENTAL|Leg Extension Isometric Training|Experimental group will perform leg extension isometric exercise.
61982431|NCT03949205|NO_INTERVENTION|Control Group|Control group will be advised to maintain their work habits and not to change their routine activities, especially diet and physical activities.
61982432|NCT05303207|OTHER|Your Super Detox|Dietary supplement
61982433|NCT04311996|EXPERIMENTAL|Friend and Target Both|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
61982434|NCT04311996|EXPERIMENTAL|Friend Provides Support|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
61982435|NCT04311996|EXPERIMENTAL|Unfamiliar Peer and Target|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
61982436|NCT04311996|EXPERIMENTAL|Alone|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
61982437|NCT06417242||HF index disease|Patients with no history of atrial fibrillation at the time of first diagnosis of heart failure
61982438|NCT06417242||Unclear index disease|Patients in whom the index disease is unknown or in whom atrial fibrillation is the index disease
62362539|NCT06082375|PLACEBO_COMPARATOR|Placebo|The placebo group will receive drops containing vegetable oil in the same bottles as vitamin D3.
61982439|NCT05333393|EXPERIMENTAL|Experimental group|Children in the experimental group will be informed about the diabot application and how they will use the application to manage their disease processes. Children/adolescents in the study group and their parents will be evaluated 5 times, once every 3 months, through data collection tools. Data will be collected from the children/adolescents in the control group and their parents by means of pre-test and data collection tools 5 times, once every 3 months.
61982440|NCT05333393|NO_INTERVENTION|Control group|The control group will recieve standard diabetes treatment without any training intervention
61982441|NCT03538158|EXPERIMENTAL|Intervention condition - Fittle Senior|Participants will have access to the Fittle Senior System which will provide guided exercises and social support.
61982442|NCT03538158|PLACEBO_COMPARATOR|Control condition - paper and pencil|Participants will have a written booklet with exercises that they may do it on their own.
61982443|NCT01547000|PLACEBO_COMPARATOR|Inactive placebo|
61982444|NCT01547000|EXPERIMENTAL|Extended-release Guanfacine|
62362540|NCT01210755|EXPERIMENTAL|Rivaroxaban then Dabigatran|Cross-over study with 15 days between administration of Rivaroxaban and Dabigatran
62362541|NCT01210755|EXPERIMENTAL|Dabigatran then Rivaroxaban|Cross-over study with 15 days between administration of Dabigatran and Rivaroxaban
61982445|NCT06293885|EXPERIMENTAL|D50|A solution of 50% glucose will be injected into the pleural space on the first and possibly the second day after surgery. The injection will be administered through the chest tube, which is already in place.
61982446|NCT06293885|ACTIVE_COMPARATOR|Standard of care|monitor air leak, if the air leak continues on post-operative day #5, a talc pleurodesis may be given.
62362542|NCT01582958|EXPERIMENTAL|Treatment|This arm will receive the usual Pulmonary Rehabilitation Program plus OMT, the intervention.
62362543|NCT01582958|PLACEBO_COMPARATOR|placebo|Receives normal pulmonary rehabilitation care plus positioned to receive OMT but OMT is not provided.
62362544|NCT01582958|NO_INTERVENTION|Control|This arm receives only pulmonary rehabilitation care.
61982447|NCT03232281|EXPERIMENTAL|Triptorelin pamoate PR 3-month|Subjects received 15 mg triptorelin pamoate per injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections, at baseline and Week 12).
61982448|NCT03232281|ACTIVE_COMPARATOR|Triptorelin acetate PR 1-month|Subjects received 3.75 mg triptorelin acetate per injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections, at baseline and Weeks 4, 8, 12, 16 and 20).
61982449|NCT01154218|EXPERIMENTAL|1|"All subjects will receive four treatments in one of the indicated orders:~A-B-C-D, B-D-A-C, C-A-D-B, D-C-B-A"
61982450|NCT02508454||Greater Miami Area Community|Members of the Miami area who qualify for the study, are not an employee of BHSF, and enroll.
61982451|NCT02508454||Baptist Health South Florida Employees|Employees of BHSF who qualify for the study and enroll.
61982452|NCT00380978|ACTIVE_COMPARATOR|early analgesia:combined-spinal epidural|
61982453|NCT00380978|ACTIVE_COMPARATOR|late analgesia (systemic)|
62362545|NCT06094114||Patients with Micra Av|Only patients who were previously implanted with a Micra MC1AVR01 can be enrolled in the study. Patients need to be able to perform an exercise test. All subjects provide signed and dated consent that he/she is willing and able to comply with the protocol.
62362546|NCT00095719|ACTIVE_COMPARATOR|A1|
62362547|NCT00095719|PLACEBO_COMPARATOR|B1|
61982454|NCT05826886|ACTIVE_COMPARATOR|Control video|Video of a woman describing basic information about psychotherapy and how it is embedded in the insurance system in Germany. Personal experience with therapy are not provided. 'Emotional writing' is introduced as a type of intervention used in depression treatment and basic information about it is provided.
61982455|NCT05826886|EXPERIMENTAL|Testimonials|Video of a patient and a therapist, who both describe their personal experience of depression therapy in a positive but realistic way. Emphasis is on the personal experience protagonist. 'Emotional writing' is described as a helpful technique from a first person perspective.
61982456|NCT03287440|ACTIVE_COMPARATOR|COPD Wellness With Health Advocate|This arm will be given low-intensity pulmonary rehabilitation, COPD Wellness, for individuals with moderate-to-severe COPD with an additional assignment of a health advocate to address unmet social needs as an adherence strategy.
61982457|NCT03287440|ACTIVE_COMPARATOR|COPD Wellness|This arm will only be given low-intensity pulmonary rehabilitation, COPD Wellness, for individuals with moderate-to-severe COPD.
62362548|NCT03255304|EXPERIMENTAL|health prime|
62362549|NCT03255304|EXPERIMENTAL|palatability prime|
62362550|NCT02438761|EXPERIMENTAL|PF-05212384|150 mg Intra-venous every week
62362551|NCT02291445|EXPERIMENTAL|Tempocol-ColoPulse®|Tempocol-ColoPulse® is a colon-targeted-delivery peppermint oil capsule that will deliver peppermint oil in the (ileo-) colonic region specifically.
62362552|NCT02291445|ACTIVE_COMPARATOR|Tempocol®|Tempocol® is an enteric-coated peppermint oil capsule that delivers peppermint oil in the upper small intestine.
62362553|NCT06206707|EXPERIMENTAL|Faecal microbiota transplantation (FMT)|Patients receive two applications of capsule FMT with 3-7 days between applications.
62362554|NCT06206707|PLACEBO_COMPARATOR|Placebo|Patients receive two applications of placebo capsules with 3-7 days between applications.
62362555|NCT04511988|EXPERIMENTAL|Experimental|blood sample (20 ml) and biopsy
62362556|NCT04019392|ACTIVE_COMPARATOR|Wetted ice with elastic wrap|A standard ice bag filled with 2000 mL of cubed ice and 300 mL of 5˚C water will be applied to each participants' lower leg for 30 minutes using an elastic wrap. The elastic wrap will be applied at approximately 75% percent tension starting distal to the treatment area and moving proximally overlapping by half. The elastic wrap application will consist of pulling the wrap to its full tension, measuring the length of the wrap, and calculating 75% of the total length to apply to the body part.
62362557|NCT04019392|ACTIVE_COMPARATOR|Game Ready|The half leg boot sleeve of the Game Ready® device (CoolSystems, Inc., Alamda, CA) will be applied to each participants' lower leg and ankle for 30 minutes set on the medium pressure setting (5-50 mmHG).
62362558|NCT05286567|EXPERIMENTAL|RGRN-305|1 tablet of 250mg RGRN-305 once daily for 16 weeks
62362559|NCT05286567|PLACEBO_COMPARATOR|Placebo|1 tablet of placebo once daily for 16 weeks
62362560|NCT04425460|EXPERIMENTAL|Favipiravir|Favipiravir Tablets, 200 mg/tablet Favipiravir combined with supportive care recommended in the current National/Local guidelines. Favipiravir dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.
61982458|NCT04183920|ACTIVE_COMPARATOR|Group A|Participants in this arm will be provided cranberry juice to consume for 42 days in total. After a 10-21-day washout period participants will receive placebo juice for 42 days.
61982459|NCT04183920|ACTIVE_COMPARATOR|Group B|Participants in this arm will be provided placebo juice to consume for 42 days in total. After a 10-21-day washout period participants will receive cranberry juice to consume for 42 days
61982460|NCT01978587|EXPERIMENTAL|Dose 1 JTZ-951|Tablets, 1 dose on Day 1 before hemodialysis
61982461|NCT01978587|EXPERIMENTAL|Dose 2 JTZ-951|Tablets, 1 dose on Day 8 after hemodialysis
62362561|NCT04425460|PLACEBO_COMPARATOR|Placebo|Placebo control group Favipiravir combined with supportive care recommended in the current National/Local guidelines
62362562|NCT04825249|EXPERIMENTAL|The traditional suture bridge technique group|For the TSB group, if the tear type is confirmed to be medium-sized during the operation, TSB technique will be performed
62567109|NCT01812460|NO_INTERVENTION|Control group|The patients randomized to the control group receive lung physiotherapy from day two of admittance. Lung physiotherapy consists of help to bring up sputum from the bronchi and lungs. The patients are instructed in breath exercises, use of Positiv Ekspiratory Pressure, breathing exercises, cough and pursed lip breathing. The patients are encouraged to spend as little time in bed as possible.
62739215|NCT02468687|OTHER|N-methyl-pyrrolidone|NMP dose escalation in accelerated phase and standard phase
61982462|NCT01986855|EXPERIMENTAL|Ertugliflozin (5 mg)|Ertugliflozin, 5 mg, oral, one 5 mg ertugliflozin tablet and one placebo tablet, once daily for 52 weeks
61982463|NCT01986855|EXPERIMENTAL|Ertugliflozin (15 mg)|Ertugliflozin, 15 mg, oral, one 5 mg and one 10 mg tablet, once daily for 52 weeks
61982464|NCT01986855|PLACEBO_COMPARATOR|Placebo|Matching placebo
61982465|NCT01278485||Sulphonylurea (SU) Monotherapy or SU + Metformin|Participants with Type 2 diabetes that have been treated with SU monotherapy for at least 6 months by a cardiologist, nephrologist, or family practice doctor.
62362563|NCT04825249|EXPERIMENTAL|The modified suture bridge technique group|For the MSB group, if the tear type is confirmed to be medium-sized during the operation, TSB technique will be performed
61982466|NCT02934906||Control Group|Pregnant women with anti-HPA antibody negative from the same hospital, the same race, and the same gravidity and parity, who are admitted at the same time.
62362564|NCT03357770|EXPERIMENTAL|low dose of mesenchymal stem cells|Three groups of patients were enrolled in this study. Every group includes three patients. The three groups of patients were treated with high, medium and low dose of cytokine.The low-dose is 1 × 10\^7cells / 3mL
62362565|NCT03357770|EXPERIMENTAL|medium dose of mesenchymal stem cells|the medium-dose is 5 × 10\^7cells / 3mL
62362566|NCT03357770|EXPERIMENTAL|high dose of mesenchymal stem cells|the high dose is 1 × 10\^8cells / 3mL
62362567|NCT01528995|ACTIVE_COMPARATOR|sacral nerve modulation|Implantation of Interstim II-3058 impulse generator after positive PNE test. Randomized controlled trial.
62362568|NCT01528995|ACTIVE_COMPARATOR|anal bulking agents|anal injection with Permacol after positive PNE test. Randomized controlled trial.
61982467|NCT02934906||Experimental Group|pregnant women with anti-HPA antibody positive
61982468|NCT04070391|EXPERIMENTAL|vitamin B6|One pill (100 mg) ingested daily for 4 weeks.
61982469|NCT04070391|PLACEBO_COMPARATOR|control|One vinegar pill ingested daily for 4 weeks
61982470|NCT02905682|EXPERIMENTAL|Desmopressin|Desmopressin ODT
61982471|NCT02905682|PLACEBO_COMPARATOR|Placebo|Placebo ODT
61982472|NCT02824250|EXPERIMENTAL|MBSR + Usual Care|8-week standard Mindfulness-Based Stress Reduction (MBSR) course + standard of care
61982473|NCT02824250|NO_INTERVENTION|Usual Care|Standard of care
61982474|NCT00992082|ACTIVE_COMPARATOR|Group LIA|Local Infiltration Analgesia
61982475|NCT00992082|ACTIVE_COMPARATOR|Group M|Intrathecal morphine
62362569|NCT01528995|ACTIVE_COMPARATOR|Anal bulking agents|Anal injection with Permacol after negative PNE test. cohort study.
61982476|NCT01715311|EXPERIMENTAL|Indacaterol|Indacaterol once daily
61982477|NCT01715311|PLACEBO_COMPARATOR|Placebo|Placebo for indacaterol and placebo for tiotropium once daily
61982478|NCT01715311|ACTIVE_COMPARATOR|Tiotropium|Tiotropium
61982479|NCT02024620|EXPERIMENTAL|Behavioral activation plus mobile app|Standard behavioral activation protocol with the addition of the Mood Coach mobile app to replace the paper and pencil forms used in the standard protocol.
61982480|NCT02024620|ACTIVE_COMPARATOR|Standard behavioral activation|Standard behavioral activation protocol using paper and pencil forms for treatment delivery and homework completion.
61982481|NCT01883414|ACTIVE_COMPARATOR|Group A|Subjects randomized to Group A will receive Ultherapy™ treatment on the superior or lateral half of the scar.
61982482|NCT01883414|ACTIVE_COMPARATOR|Group B|Subjects randomized to Group B will receive Ultherapy™ treatment on the inferior or medial half of the scar.
61982483|NCT06120036|ACTIVE_COMPARATOR|Kybella Injection|
61982484|NCT06120036|ACTIVE_COMPARATOR|Asclera Injection|
61982485|NCT03674918||persons with arterial hypertension|patients referred to consultation cardiology for hypertension. They get a 24 h blood pressure monitoring to define the exact mean arterial blood pressure
61982486|NCT03826979|EXPERIMENTAL|Pilates treatment|The participants undergo to a physical therapy rehabilitation program through the Pilates Method for 2 months.
61982487|NCT00574509|EXPERIMENTAL|131I-Anti-B1|BEAM + 131Iodine-Anti-B1 radioimmunotherapy and autologous HSCT
61982488|NCT05855031|EXPERIMENTAL|Intervention|An invitation to a liver stiffness measurement (Transient Elastography), to blood sampling and a leaflet on alcohol-related disease.
61982489|NCT05855031|NO_INTERVENTION|Control|An invitation to screening by blood sampling with Fib-4
61982490|NCT00455429|PLACEBO_COMPARATOR|Placebo|
61982491|NCT00455429|EXPERIMENTAL|JNJ-26113100 (50 mg) once daily|
61982492|NCT00455429|EXPERIMENTAL|JNJ-26113100 (100 mg) once daily|
61982493|NCT00455429|EXPERIMENTAL|JNJ-26113100 (100 mg) twice daily|
61982494|NCT00455429|EXPERIMENTAL|JNJ-26113100 (250 mg) twice daily|
61982495|NCT02592174|OTHER|HIV subjects|"* Evaluation of health-related quality of life and collection of social and demographic informations at the inclusion visit.~* Neurocognitive assessment with neuropsychologist and walking speed, grasp force and one leg stand assessments at the neurocognitive visit.~* Two substudies will be proposed:~  * cerebral images sub-study (80 patients in the centers of Montpellier and the centers of Nîmes)~ * sub-study on immune activating markers with sample's collection (plasma), 85 patients in the centers of Montpellier and the centers of Nîmes."
61982496|NCT04091373|EXPERIMENTAL|Sequence 1|100ug SC injection cotadutide in the upper arm on Day 1, in the lower abdomen on Day 8, and in the thigh on Day 15
61982497|NCT04091373|EXPERIMENTAL|Sequence 2|100ug SC injection cotadutide in the thigh on Day 1, in the upper arm on Day 8, and in the lower abdomen on Day 15
61982498|NCT04091373|EXPERIMENTAL|Sequence 3|100ug SC injection cotadutide in the lower abdomen on Day 1, in the thigh on Day 8, and in the upper arm on Day 15
61982499|NCT04091373|EXPERIMENTAL|Sequence 4|100ug SC injection cotadutide in the thigh on Day 1, in the lower abdomen on Day 8, and in the upper arm on Day 15
62362570|NCT02593461|EXPERIMENTAL|Diafert|The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
62362571|NCT02593461|OTHER|Control Group|The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
62362572|NCT05276427||Non clinical procedure|Completion of consent form and interview session
62362573|NCT04785937|EXPERIMENTAL|Imaging and Biopsy|All patients undergo both liver biopsy and liver imaging (US and MR) to assess the diagnostic performance of imaging compared to histopathological examination in the diagnosis of NASH and fibrosis.
62362574|NCT00661284||Ⅰ|Subject who have participated in previous studies and achieved DAS28 of \< 3.2 at the last observation and at least one time point among the two previous assessment time points in a previous studies.
62567110|NCT02059512|ACTIVE_COMPARATOR|Group 1|Intramyocardial administration of autologous bone marrow mononuclear cells during the operation coronary artery bypass grafting 0.2 ml - 10 injection in the zone of blood supply LAD.
61982500|NCT04091373|EXPERIMENTAL|Sequence 5|100ug SC injection cotadutide in the lower abdomen on Day 1, in the upper arm on Day 8, and in the thigh on Day 15
61982501|NCT04091373|EXPERIMENTAL|Sequence 6|100ug SC injection cotadutide in the upper arm on Day 1, in the thigh on Day 8, and in the lower abdomen on Day 15
61982502|NCT00324324|ACTIVE_COMPARATOR|moxifloxacin hydrochloride|Moxifloxacin 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
61982503|NCT00324324|PLACEBO_COMPARATOR|Sugar pill|Placebo 1 capsule orally once a day through D+100 after bone marrow transplant, then discontinue
61982504|NCT05347550|NO_INTERVENTION|Control - No graduated compression stockings|In those centres randomised to the control arm, participants will not receive Graduated Compression Stockings (GCS).
61982505|NCT05347550|EXPERIMENTAL|Intervention - The provision of graduated compression stockings|Centres randomised to the intervention arm, which is the current standard of care, will consist of participants receiving Graduated Compression Stockings (GCS). Clinical staff (e.g. theatre support workers) will issue stockings to all patients who are scheduled to undergo short-stay surgery. Participants will be instructed to wear their stockings just before undergoing the surgical procedure and to remove the stockings as soon as they are ambulant (i.e. after the procedure).
61982506|NCT00914862|EXPERIMENTAL|Children Ramelteon 4 mg|Children 6 to 11 years of age who had insomnia associated with ADHD received a single 4 mg oral dose of ramelteon.
61982507|NCT00914862|EXPERIMENTAL|Children Ramelteon 8 mg|Children 6 to 11 years of age who had insomnia associated with ADHD received a single oral 8 mg dose of ramelteon.
61982508|NCT00914862|EXPERIMENTAL|Adolescents Ramelteon 4 mg|Adolescents 12 to 17 years of age with insomnia received a single oral dose of 4 mg ramelteon.
61982509|NCT00914862|EXPERIMENTAL|Adolescents Ramelteon 8 mg|Adolescents 12 to 17 years of age with insomnia received a single oral dose of 8 mg ramelteon.
61982510|NCT00914862|ACTIVE_COMPARATOR|Healthy Adult Ramelteon 8 mg|Healthy adults (18 to 50 years old) received a single oral dose of 8 mg ramelteon.
61982511|NCT00437099|EXPERIMENTAL|1|subjects with BPD receiving Omacor 1.680 mg/d
61982512|NCT00437099|EXPERIMENTAL|2|BPD patients randomized to Omacor 3.360 mg/d
61982513|NCT00437099|PLACEBO_COMPARATOR|3|patients with BPD randomized to Placebo
61982514|NCT04611750|EXPERIMENTAL|Active Medication (AD036)|Participants will take AD036 QHS for 14 days.
61982515|NCT04611750|PLACEBO_COMPARATOR|Placebo Medication|Participants will take placebo QHS for 14 days.
61982516|NCT01438918|ACTIVE_COMPARATOR|200 mg|High dose active comparator
61982517|NCT01438918|ACTIVE_COMPARATOR|50 mg|Low dose active comparator
61982518|NCT01438918|PLACEBO_COMPARATOR|Placebo|Placebo comparator to be used for control purposes
61982519|NCT02741882||Cases|Mothers who delivered a baby with microcephaly at Nossa Senhora de Lourdes maternity hospital located in Aracaju, state of Sergipe, Brazil from September 1, 2015 through January 5, 2016. The intervention will be a questionary.
61982520|NCT02741882||Controls|Mothers who delivered a baby without microcephaly at Nossa Senhora de Lourdes maternity hospital located in Aracaju, state of Sergipe, Brazil from September 1, 2015 through January 5, 2016. The intervention will be a questionary.
61982521|NCT03403816|ACTIVE_COMPARATOR|Intervention|"Students in grades K-6 at 7 schools in two communities participating in a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions.~."
61982522|NCT03403816|NO_INTERVENTION|Comparison|Students in grades K-6 at the same 7 schools in two communities as the intervention participants, but who did not participate in the before school physical activity program.
61982523|NCT03559153|NO_INTERVENTION|Control group|All workers will receive ergonomics instructions. Instruction for rest break.
61982524|NCT03559153|EXPERIMENTAL|Passive rest break - Shiatsu massage|"All workers will receive ergonomics instructions. The workers will be receive quick massage using shiatsu techniques."
61982525|NCT03559153|ACTIVE_COMPARATOR|Active rest break - Physical Exercise Program|All workers will receive ergonomics instructions. The workers will be receive exercises during the rest break.
61982526|NCT04220008|EXPERIMENTAL|Treatment (busulfan, vorinostat, gemcitabine, clofarabine)|"Patients receive a low-level test dose of busulfan IV over up to 1 hour on days -15 to -9, vorinostat PO QD on days -8 to -4, gemcitabine IV over about 90 minutes on days -7 and -5, clofarabine IV over about 1 hour and high-dose busulfan IV over 3 hours on days -7 to -4. Patients with CD20 positive (+) lymphoma also receive rituximab IV over 3 to 6 hours on days -15, -8, 1, and 8. Patients undergo HSCT on day 0. Patients then receive cyclophosphamide IV over 2 hours on days 3 and 4. Beginning day 5, patients receive standard of care tacrolimus IV over 24 hours and mycophenolate mofetil IV over 2 hours TID until they can be tolerated PO. Once tolerated PO, patients receive tacrolimus PO BID for 6 months and mycophenolate mofetil PO TID for up to 30 days in the absence of disease progression or unacceptable toxicity. After 30 days, patients who develop GVHD continue treatment with mycophenolate mofetil at physician's discretion"
61982527|NCT03566368||Study Group|Isolated Traumatic Brain Injury Patients requiring emergency surgical intervention.
61982528|NCT04760912|EXPERIMENTAL|Experimental group general anesthesia without rocuronium|30 patient ASA classification 1-2 for general anesthesia. Standard anesthesia monitoring. After induction with Propofol and Sufentanil ( doses adjusted according to weight and age) anesthesia was maintained with sevorane. Muscle strength measured on three occasions with Yamar dinamometar for hand grip strength, before induciran to anesthesia and immediate after Salingeru from anesthesia, then again measured in first 24 hours.
61982529|NCT04760912|ACTIVE_COMPARATOR|Active comparator: general anesthesia with rocuronium|30 patient ASA classification 1-2 for general anesthesia. Standard anesthesia monitoring with train-of-four (TOF). After induction with Propofol and Sufentanil (doses adjusted according to weight and age) and rocuronium 0,6 mg per kg, anesthesia maintained with sevorane. Muscle strength neasured with Yamar dinamometar for hand grip strength before induction to anesthesia and immediate after awakening from anesthesia, then again measured in first 24 hours.
61982530|NCT00874523|ACTIVE_COMPARATOR|Arm A|
61982531|NCT00874523|ACTIVE_COMPARATOR|Arm B|
61982532|NCT03877289|EXPERIMENTAL|Oxybutynin|Children aged 4 - 6 years: Oxybutynin 2.5 mg (2.5ml) po TID Children aged 7 - 16 years: Oxybutynin 5 mg (5ml) po TID
62550011|NCT04263181||Cohort 0|"-A technical run-in of 5 patients with any of the following:~* Standard cytarabine/idarubicin induction, includes cytarabine 200 mg/m2 CIVI in 0.9% normal saline over 24 hours for 7 consecutive days (Days 1-7) \& idarubicin 12 mg/m2 per day for 3 consecutive days (Days 1-3). Other standard cytarabine-based induction protocols are allowed~* Decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 of each 28-day cycle.~* Azacitidine 75 mg/m2/day as a subcutaneous injection on Days 1-7 or on day 1-5 and 8-9 of each 28-day cycle~* Decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter.~* Azacitidine 75 mg/m2/day as a 1-hour infusion or by subcutaneous injection on consecutive Days 1-7 or on day 1-5 and 8-9 of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter."
61982533|NCT03877289|PLACEBO_COMPARATOR|Placebo|Orasweet liquid placebo
61982534|NCT03159481|EXPERIMENTAL|Usual Care + Health Promotion Intervention|Usual glaucoma care along with telehealth-based brief culturally informed health promotion intervention
61982535|NCT03159481|NO_INTERVENTION|Usual Care Only|Usual glaucoma management only, no intervention.
61982536|NCT04396990|EXPERIMENTAL|Group A Dextenza|Will receive Dextenza post-operative
61982537|NCT04396990|ACTIVE_COMPARATOR|Group B Topical Prednisolone|Will receive standard of care prednisolone acetate 1% QID for 1 week, BID for 1 week
61982538|NCT02268812||Ziconotide|"No drug will be provided by the sponsor. Treatment decisions will be made by physicians independent of participation in the registry.~IT analgesia may consist of ziconotide or any other drug used in IT therapy, including those used off-label as part of local clinical practice."
61982539|NCT06530342||Fencing Sword Branch Athletes|20 volunteer sword fencing athletes who are licensed by the Anatolian Archery and Fencing Club and meet our inclusion criteria.
61982540|NCT03863223|EXPERIMENTAL|A|Pyrotinib Plus trastuzumab and docetaxel
61982541|NCT03863223|PLACEBO_COMPARATOR|B|Placebo plus trastuzumab and docetaxel
61982542|NCT03984604|ACTIVE_COMPARATOR|CHI-921|During the double-blind treatment period (9 weeks), subjects will take 0.5 mL of their randomized treatment (CHI-921) for 3 weeks, followed by another 3 weeks of treatment at 1.0 mL for and another 3 weeks of treatment at 2.0 mL.
61982543|NCT03984604|PLACEBO_COMPARATOR|Placebo|During the double-blind treatment period (9 weeks), subjects will take 0.5 mL of their randomized treatment (placebo) for 3 weeks, followed by another 3 weeks of placebo treatment at 1.0 mL for and another 3 weeks of placebo treatment at 2.0 mL.
61982544|NCT05602987|EXPERIMENTAL|Study Group: enema|receiving enema at the night before anal surgery
61982545|NCT05602987|ACTIVE_COMPARATOR|Control Group: no enema|no enema before anal surgery
61982546|NCT03895996|EXPERIMENTAL|AVT001 (Treatment)|Infusion of AVT001 (treatment)
61982547|NCT03895996|PLACEBO_COMPARATOR|Matched placebo|Infusion of AVT001-matched placebo
61982548|NCT02338960|EXPERIMENTAL|Bremelanotide (BMT/BMT)|"(Main Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 24 weeks~(OLE Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
61982549|NCT02338960|PLACEBO_COMPARATOR|Placebo (PBO/BMT)|"(Main Study) PBO administered SC on an as-desired basis for 24 weeks~(OLE Study) subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
61982550|NCT05476341|EXPERIMENTAL|Bevacizumab injection|On the first day, bevacizumab injection was given, 3mg/kg each time, diluted to 100ml of 0.9% sodium chloride injection, mixed evenly, and then intravenous infusion for 90 minutes (±15 minutes).
61982551|NCT05476341|ACTIVE_COMPARATOR|Bevacizumab injection（Avastin）|On the first day, Avastin injection was given, 3mg/kg of which was diluted to 100ml of 0.9% sodium chloride injection. After mixing evenly, it was infused intravenously for 90 minutes (±15 minutes).
62169341|NCT03058237|EXPERIMENTAL|Part 2: Regimen I|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
62550012|NCT04263181||Cohort 1|"* Patients treated with cytarabine/idarubicin induction therapy~* Patients will receive a standard cytarabine/idarubicin induction, which includes cytarabine 200 mg/m2 CIVI in 0.9% normal saline over 24 hours for 7 consecutive days (Days 1-7) and idarubicin 12 mg/m2 per day in 0.9% normal saline over 15-30 minutes for 3 consecutive days (Days 1-3). Other standard cytarabine-based induction protocols are allowed (e.g. cytarabine/daunorubicin or Vyxeos)."
61982552|NCT00640445|EXPERIMENTAL|Expressive Writing|Participants assigned to the Expressive Writing (EW) condition will write about their deepest thoughts and feelings associated with their experience transitioning from being a soldier to being a civilian for 20 minutes a day for 4 days within a week.
61982553|NCT00640445|ACTIVE_COMPARATOR|Control Writing|Those assigned to control writing condition will write factually about the information needs of veterans transitioning from active duty to civilian status for 20 minutes on 4 days within one week.
61982554|NCT00640445|NO_INTERVENTION|No Writing Control|Treatment As Usual
62550013|NCT04263181||Cohort 2|"* Patients treated with decitabine~* Patients will receive decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 (per treating physician discretion) of each 28-day cycle."
61982555|NCT04234282|NO_INTERVENTION|Control Group|The control group will receive a 30-minute class on knee osteoarthritis diagnosis, prognosis, various treatment options, and will conclude with a question and answer session. This will account for the 30 minute face to face time provided in the treatment group
61982556|NCT04234282|EXPERIMENTAL|Manual Physical Therapy|The treatment group will receive one 30-minute session of orthopedic manual physical therapy targeting the knee joint and soft tissues with complementary exercises targeted at their impairment. The manual therapy and exercises are tailored to the individual based on their limitations and restrictions.
61982557|NCT05478447|EXPERIMENTAL|Vibration group|Vibration (WBV, and tendon vibration) and sympathetic activation maneuvers will be applied to participants
61982558|NCT03284164|EXPERIMENTAL|Healthy Subjects|Healthy Subjects matched to RI subjects Tenofovir Exalidex (TXL)
61982559|NCT03284164|EXPERIMENTAL|Severe RI|Severe Renal Impairment subjects Tenofovir Exalidex (TXL)
61982560|NCT02632552|EXPERIMENTAL|Technology-assisted care transition arm|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
61982561|NCT02632552|ACTIVE_COMPARATOR|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
61982562|NCT04565301|PLACEBO_COMPARATOR|Group C|The patients in this group will be administered 2 ml isotonic saline + 20 ml bupivacaine 0.50 % in the adductor canal block (control group).
62550014|NCT04263181||Cohort 3|"* Patients treated with azacitidine~* Patients will receive azacitidine 75 mg/m2/day as a subcutaneous injection on Days 1-7 or on day 1-5 and 8-9 (per treating physician discretion) of each 28-day cycle"
62567111|NCT02059512|PLACEBO_COMPARATOR|Group 0|Intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD during the operation coronary artery bypass grafting.
62362575|NCT02378493||Exposure: Concordance between tests|"The study population is composed of diabetic patients with foot wounds (at least stage \>=2) that are infected by at least 1 strain of S. aureus. Patients whose antibiogrammes and Antibiofilmogrammes are concordant will fall into this group (the exposed group).~Upon inclusion, 1) all patients' wounds will be sampled, and 2) the associated bacterial strains identified via Vitek and 3) antibiograms performed; the latter are all part of routine procedure. 4) S. aureus isolates will be further analysed via an antiobiofilmogramme, which is an experimental element added by this research. At the end of the 1st regimen of antibiotics prescribed, if the treatment failed steps 1 to 4 can be repeated. 30 days after the end of the 1st regimen of antibiotics prescribed, steps 1 to 4 are systematically performed."
61982563|NCT04565301|ACTIVE_COMPARATOR|Group D|The patients in this group will be administered 8 mg dexamethasone (2 ml) (23) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.
61982564|NCT04565301|ACTIVE_COMPARATOR|Group N|The patients in this group will be administered 500 mcg neostigmine (1 ml) + 1 ml isotonic saline (22) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.
62362576|NCT02378493||Non exposure: Not concordance between tests.|"The study population is composed of diabetic patients with foot wounds (at least stage \>=2) that are infected by at least 1 strain of S. aureus. Patients who do not fall into the concordance (exposure) group, will fall into the non exposure group. The latter includes semi-concordance or discordance between antibiogrammes and Antiobiofilmogrammes.~Upon inclusion, 1) all patients' wounds will be sampled, and 2) the associated bacterial strains identified via Vitek and 3) antibiograms performed; the latter are all part of routine procedure. 4) S. aureus isolates will be further analysed via an antiobiofilmogramme, which is an experimental element added by this research. At the end of the 1st regimen of antibiotics prescribed, if the treatment failed steps 1 to 4 can be repeated. 30 days after the end of the 1st regimen of antibiotics prescribed, steps 1 to 4 are systematically performed."
62362577|NCT01400139|EXPERIMENTAL|Hydrocodone bitartrate|Hydrocodone bitartrate (HYD) once daily (q24h) tablets
61982565|NCT00129493|OTHER|Arm 1|
61982566|NCT01014429|EXPERIMENTAL|1|
61982567|NCT03014323|EXPERIMENTAL|Galantamine then Placebo, WW|4 mg (1 capsule) galantamine twice a day for 4 weeks then placebo (1 capsule) twice a day for 4 weeks in white women (WW)
61982568|NCT03014323|PLACEBO_COMPARATOR|Placebo then Galantamine, WW|Placebo (1 capsule) twice a day for 4 weeks then 4 mg (1 capsule) galantamine twice a day for 4 weeks in white women (WW)
61982569|NCT03014323|EXPERIMENTAL|Galantamine then Placebo, AAW|4 mg (1 capsule) galantamine twice a day for 4 weeks then placebo (1 capsule) twice a day for 4 weeks in African American Women (AAW)
61982570|NCT03014323|PLACEBO_COMPARATOR|Placebo then Galantamine, AAW|Placebo (1 capsule) twice a day for 4 weeks then 4 mg (1 capsule) galantamine twice a day for 4 weeks African American Women (AAW)
61982571|NCT02268786|EXPERIMENTAL|Group A|Intent to transfer single euploid embryo based on NGS testing (VeriSeq™ PGS) of biopsied blastocysts
61982572|NCT02268786|NO_INTERVENTION|Group B|Intent to transfer single embryo based on morphological assessment according to the Gardner scoring system (no PGS)
61982573|NCT02484742|NO_INTERVENTION|Sleep control condition|8 hours of sleep throughout the 18-day stay in the Clinical Research Center
61982574|NCT02484742|EXPERIMENTAL|Insomnia symptom induction condition|4 4-day cycles, each consisting of 3 nights with sleep disruption followed by one night of recovery sleep.
61982575|NCT04341142|EXPERIMENTAL|Serological tests will be applied on patients blood sampling|Serological tests will be applied on patients blood sampling
61982576|NCT00560950|EXPERIMENTAL|1st Revaccination Group|
61982577|NCT00560950|EXPERIMENTAL|2nd Revaccination Group|
61982578|NCT01395160||Adult ADHD|
61982579|NCT01395160||Bipolar Disorder|
61982580|NCT01395160||Healthy control|
61982581|NCT05581537|EXPERIMENTAL|Study group (GA)|receive systematic desensitization in addition to goal directed paradigm for eight weeks, Three sessions per week (1hour and half)
61982582|NCT05581537|EXPERIMENTAL|Control group (GB)|receive goal directed paradigm for eight weeks, Three sessions per week (45 minutes)
61982583|NCT01163487|EXPERIMENTAL|Dichloroacetate (DCA)|25 mg/kg/day, 37.5 mg/kg, or 50 mg/kg/day oral DCA.
61982584|NCT00456131|EXPERIMENTAL|Intervention|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
61982585|NCT02386904|EXPERIMENTAL|Phosphate Enema|Phosphate Enema consisting on Monobasic Sodium Phosphate (USP) 19.2 gm /120 ml and Dibasic Sodium Phosphate (USP) 7.2 gm/120 ml Dosage Form: Enema Frequency: One time; 30 minutes before Sigmoidoscopy
61982586|NCT05383300|OTHER|Violent offenders with psychopathy|Violent offenders with psychopathy
61982587|NCT05383300|OTHER|Violent offenders without psychopathy|Violent offenders without psychopathy
61982588|NCT05383300|OTHER|Healthy non-offenders|Healthy non-offenders
61982589|NCT00565968|EXPERIMENTAL|Sorafenib dose escalation|
61982590|NCT02085187|EXPERIMENTAL|Telemedicine training and counselling|
61982591|NCT05744947||Recruited patient .|Patient previsouly recruited in the DISCO Registry (Study of the Prevalence Fibromuscular Dysplasia in Patient With Haematoma or Spontaneous Coronary Artery Dissection. (DISCO trial - NCT02799186)) with cardiac rehabilitation following the management of acute coronary syndrome
61982592|NCT03208842||women with previous cesarean scar|"the patient will be examined son graphically at 3 visits~1. The first visit at less than 10 weeks gestation :trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~   ---the site of the intrauterine gestational sac in relation to the endometrial cavity .~   -----doppler assessment of the retro chorionic blood flow in the area behind the maximum chorionic tissue to detect sensitivity index (RI),in cases of low gestational sac Doppler assessment of peri trophoplastic blood flow will be assessed.~2. then the patient will be enrolled during routine ANC till delivery and data collected at32-34 weeks gestation regarding placental site will be correlated with 1st data and data at delivery ."
62362578|NCT04192760|ACTIVE_COMPARATOR|Culotte Technique|Both vessels have to be wired. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference. After lesion preparation, the side branch has to be stented first. The first stent is placed from main branch into the side branch, covering the entire diseased segment with a wire jailed in the main vessel. The main vessel is rewired through the stent struts, and after removal of the jailed wire, is dilated with a balloon to separate stent struts. The side branch wire is then removed and the main vessel is stented covering the proximal and distal segment. The side-branch is re-wired and high pressure individual inflations are made in each vessel at the bifurcation point to ensure good stent strut separation. Afterwards, a lower pressure kissing inflation is made. Balloon sizing should be in accordance with the diameter of the vessel itself. Finally, a proximal optimization (POT) procedure is performed.
61982593|NCT03208842||women without previous cesarean scar|"the patient will be examined son graphically at 3 visits~1. The first visit at less than 10 weeks gestation :trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~   ---the site of the intrauterine gestational sac in relation to the endometrial cavity .~   -----doppler assessment of the retro chorionic blood flow in the area behind the maximum chorionic tissue to detect sensitivity index (RI),in cases of low gestational sac Doppler assessment of peri trophoplastic blood flow will be assessed.~2. then the patient will be enrolled during routine ANC till delivery and data collected at32-34 weeks gestation regarding placental site will be correlated with 1st data and data at delivery ."
61982594|NCT03667365|EXPERIMENTAL|aortic valve replacement|
62362579|NCT04192760|ACTIVE_COMPARATOR|DK-Crush Technique|"Both vessels have to be wired first. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference (rotablation, if needed).~After lesion preparation, the side branch is stented first. Side branch stent should have a small protrusion into the main branch. Before stent implantation in the side branch, an adequately sized balloon should be placed in the main branch, just opposite to the side branch ostium. After stent implantation in the side branch, stent balloon and wire are removed and the balloon in the main branch must be inflated, to crush the struts into the vessel wall. In next step, the new wire should be crossed into the ostium of the side branch and first kissing balloon dilatation will follow. The next step is to implant the second stent into the main branch, followed by second re-wiring, a second kissing balloon-dilatation and final proximal optimization (POT) procedure (single short balloon inflation in proximal segment)."
62362580|NCT02920450|EXPERIMENTAL|Treatment Arm (Phase 1b; Gedatolisib Dose Level 1[110 mg])|
61982595|NCT03667365|ACTIVE_COMPARATOR|strict clinical surveillance|
61982596|NCT00855998||1|With BRCA1 or BRCA2 mutations
61982597|NCT00855998||2|Without BRCA1 or BRCA2 mutations
61982598|NCT02428946|ACTIVE_COMPARATOR|Morning bromocriptine|Bromocriptine is taken in the morning
62550015|NCT04263181||Cohort 4|"* Patients treated with decitabine + venetoclax~* Patients will receive decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 (per treating physician discretion) of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter."
61982599|NCT02428946|ACTIVE_COMPARATOR|Evening bromocriptine|Bromocriptine is taken in te evening
61982600|NCT00534274|EXPERIMENTAL|TEP FLT|
61982601|NCT05566990|EXPERIMENTAL|LIV-GAMMA SN Inj.10%|
61982602|NCT03071627|ACTIVE_COMPARATOR|News with Spin|News items reporting results of animal studies with spin.
61982603|NCT03071627|EXPERIMENTAL|News without spin|News items reporting results of animal studies without spin.
61982604|NCT02429895|EXPERIMENTAL|All subjects (open-label extension)|All subjects will start treatment with ABT-122
61982605|NCT03384550|ACTIVE_COMPARATOR|Control|"Participants in this arm receive no incentives.~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
61982606|NCT03384550|EXPERIMENTAL|Financial Incentives|"Participants in this arm receive financial incentives.~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
61982607|NCT03384550|EXPERIMENTAL|Charity Incentives|"Participants in this receive charity incentives.~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
61982608|NCT00254540|EXPERIMENTAL|SU-011248 capsule|
61982609|NCT04712773|OTHER|Cardiac surgery patients|Patients scheduled for elective cardiac surgery (CABG or valve surgery).
61982610|NCT05156879|EXPERIMENTAL|Aspirin|Aspirin Enteric-coated Tablets，75mg/day，24 weeks
62362581|NCT02920450|EXPERIMENTAL|Treatment Arm (Phase 1b; Gedatolisib Dose Level 2[150 mg])|
61982611|NCT05156879|ACTIVE_COMPARATOR|Drospirenone ethinyl estradiol|Drospirenone ethinyl estradiol，one tablet/day for 21 consecutive days, 28 days as a cycle of use，24 weeks
61982612|NCT02093481|EXPERIMENTAL|+ ind. CHO + prim|Test meal: ate intrinsic indigestible carbohydrates 3 days prior to measurements of variables (priming)
61982613|NCT02093481|EXPERIMENTAL|- ind. CHO + prim|Reference:ate no intrinsic indigestible carbohydrates 3 days prior to measurements of variables (priming)
61982614|NCT02093481|EXPERIMENTAL|+ ind. CHO - prim|Test meal: ate intrinsic indigestible carbohydrates 1 day prior to measurements of variables (no priming)
61982615|NCT02093481|EXPERIMENTAL|- ind. CHO - prim|Reference: ate no indigestible carbohydrates the day prior to measurements of variables (no priming).
61982616|NCT02848157|EXPERIMENTAL|DR|dexmedetomidine 0.3mcg/kg and 0.25% ropivacaine 0.3ml/kg
61982617|NCT02848157|PLACEBO_COMPARATOR|PR|0.25% ropivacaine 0.3ml/kg
62362582|NCT02920450|EXPERIMENTAL|Treatment Arm (Phase 1b; Gedatolisib Dose Level 3[180 mg])|
62362583|NCT02920450|EXPERIMENTAL|Treatment Arm (Phase 2; MTD of Gedatolisib from Phase Ib)|
61982618|NCT01395433|ACTIVE_COMPARATOR|Treatment A|Conventional escitalopram
61982619|NCT01395433|EXPERIMENTAL|Treatment B|Escitalopram test treatment B
61982620|NCT01395433|EXPERIMENTAL|Treatment C|Escitalopram test treatment C
61982621|NCT00569296|EXPERIMENTAL|T-cells|EGFRBi-armed autologous activated T cells
61982622|NCT04699708||Preterm infants ≤ 32 weeks|All preterm infants ≤ 32 weeks born in two study centers receiving resuscitative measures at the time of birth either in the form of face mask ventilation or intubation.
61982623|NCT06019637||Spinal Muscular Atrophy Patients|Brazilian pediatric patients with a confirmed diagnosis of Spinal Muscular Atrophy treated with Onasemnogene Abeparvovec
61982624|NCT04136925||"runner participating of the Grand Raid"|
61982625|NCT05830487|EXPERIMENTAL|Low AGE diet with reduced energy and fat|Low advanced glycation end products diet with reduced energy and fat
61982626|NCT05830487|EXPERIMENTAL|Energy and fat-reduced normal diet|only energy and fat-reduced diet, advanced glycation end products intake will not be interfered with.
62362584|NCT01301755||1|
62362585|NCT03177746|EXPERIMENTAL|Dapoxetine/Tadalafil 30/20 mg film coated tablet|
62362586|NCT01802541|EXPERIMENTAL|DAG oil|
62362587|NCT01802541|PLACEBO_COMPARATOR|TAG oil|
62362588|NCT06348758||Dental Students in Egyptian Dental schools|Students should be in Egyptian Dental faculties. 1st year students will be excluded
62362589|NCT02046382|EXPERIMENTAL|IV Acetaminophen|Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
62362590|NCT02046382|PLACEBO_COMPARATOR|Normal Saline|Subjects will receive a 100mL dose of saline every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
62362591|NCT03771495|EXPERIMENTAL|Hip Joint Mobilization|passive accessory movement on femur in anterior/posterior direction, grade III for four minutes and passive physiological movement of the most restricted hip joint movement, grade III for one minute (without pain), and a verbal education of hypothesized underlying effect mechanisms.
62362592|NCT03771495|SHAM_COMPARATOR|Laying on of Hands|grade I, very small amplitude without encountering any tissue resistance for five minutes, thus effectively a Laying on of Hands, with a verbal education of hypothesized underlying effect mechanisms.
62362593|NCT03725449|EXPERIMENTAL|Phase I (user testing)|Participants complete telephone-based usability testing of the online program. Participants complete between 1-5 user testing sessions of the mySmartCheck program (about 45-60 minutes per session) to provide feedback on acceptability, satisfaction, comprehension, and usability.
62362594|NCT03725449|EXPERIMENTAL|Phase II Group I (mySmartCheck)|Participants are asked to complete a baseline survey. After completing the baseline survey, participants receive access to mySmartCheck program, and continue to receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline.
62362595|NCT03725449|EXPERIMENTAL|Phase II Group II (standard of care)|Participants are asked to complete a baseline survey. After completing the baseline survey, participants receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline.
61982627|NCT06000254|EXPERIMENTAL|physiotherapy and high-PEMF|The patient receives physiotherapy and high-PEMF therapy twice weekly, over a period of three weeks.
61982628|NCT06000254|SHAM_COMPARATOR|physiotherapy and sham high-PEMF|The patient receives physiotherapy and sham high-PEMF therapy twice weekly, over a period of three weeks.
61982629|NCT03438812|EXPERIMENTAL|Poor ovarian responders with DHEA|Women who meet the Bologna criteria receive dehydroepiandrosterone (DHEA, 90 mg daily for two months at least) supplementation prior to the IVF cycle.
61982630|NCT03438812|NO_INTERVENTION|Poor ovarian responders|Women who meet the Bologna criteria undergo the IVF cycle without pretreatment with DHEA
61982631|NCT03438812|NO_INTERVENTION|Normal ovarian responders|Women who do not meet the Bologna criteria and have normal ovarian response to ovarian stimulation.
61982632|NCT02204787|EXPERIMENTAL|active tDCS|Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a 2 mA intensity during 20 minutes.
61982633|NCT02204787|SHAM_COMPARATOR|Sham tDCS|Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a sham stimulation during 20 minutes. Initial stimulation followed by turning off the device as to ensure blinding.
61982634|NCT01239706|EXPERIMENTAL|NTx 265|
61982635|NCT01846611|EXPERIMENTAL|Arm A: trabectedin + DOXIL|Participants will receive DOXIL 30 millgram per meter square (mg/m\^2) administered as an intravenous (IV) infusion over approximately 90 minutes followed by trabectedin 1.1 mg/m\^2 administered as an IV infusion over approximately 3hours, every 3 weeks. Participants will be pretreated with 20 mg dexamethasone IV (or the IV equivalent) approximately 30 minutes before DOXIL study drug. As of Amendment 6, treatment with trabectedin will be discontinued for participants on treatment with trabectedin and no new participants will receive trabectedin. Participants who, in the opinion of the investigator, are deriving clinical benefit may continue treatment with single-agent DOXIL as per the local standard of care.
61982636|NCT01846611|ACTIVE_COMPARATOR|Arm B: DOXIL|Participants will receive DOXIL, 50 mg/m\^2 administered as an IV infusion over approximately 90 minutes every 4 weeks.
62362596|NCT03336060||Healthy Control|Age matched healthy subjects. Inclusion criteria for healthy controls are: male (18 - 40 years, right-handed); sportive (preferably ball game sports, e.g. soccer); no acute injury or life-quality impairing diseases; no medication
62362597|NCT03336060||Subjects with ACL reconstruction|"Unilateral, primary anterior cruciate ligament tear and reconstruction (1 to 10 years ago); no serious concomitant injuries, e.g. unhappy triad); no kinesiophobia; symmetric single leg jump performance (\>85 %); male (18 - 40 years, right-handed); sportive (preferably ball game sports, e.g. soccer); no acute injury or life-quality impairing diseases; no medication"
62362598|NCT01452724|EXPERIMENTAL|TAK-438 20 mg QD|
61982637|NCT03106155|EXPERIMENTAL|vistusertib (AZD2014)|vistusertib (AZD2014), 50 mg,BID, per os, every 12 hours
61982638|NCT04136054|EXPERIMENTAL|Adjusted group CBT-i for Depression, Anxiety and PTSD|Cognitive Behavioral group intervention for sleep problems in patients with Depression, Anxiety and PTSD, based on Cognitive Behavioral Therapy for insomnia
62362599|NCT01452724|ACTIVE_COMPARATOR|Lansoprazole 30 mg QD|
61982639|NCT04136054|ACTIVE_COMPARATOR|Care as usual wait-list control group|Treatment as Usual. (After about five months, participants in this condition are offered the experimental group treatment.)
62362600|NCT03465046|EXPERIMENTAL|low performance group 1|Protocol 1 will be the intervention administered with 80 h modified constraint induced movement therapy and 20 h bimanual intensive therapy
61982640|NCT02976623|OTHER|feedback group|"this group will receive the intervention metric-based feedback training on their performance. this will be based on validated metrics and errors, a trained investigator will deliver this feedback. It will be accompanied by deliberate practice"
62362601|NCT03465046|EXPERIMENTAL|low performance group 2|Protocol 2 will be the intervention administered with 80h bimanual intensive therapy and 20h modified constraint induced movement therapy
61982641|NCT02976623|NO_INTERVENTION|control group|"this control group will receive a standard type feedback on their performance no intervention. It will be delivered by a consultant anaesthetist who will be instructed to deliver feedback as they ordinarily do during their clinical practice"
62362602|NCT03465046|EXPERIMENTAL|moderate-high performance group1|Protocol 1 will be the intervention administered with 80 h modified constraint induced movement therapy and 20 h bimanual intensive therapy
62362603|NCT03465046|EXPERIMENTAL|moderate-high performance group 2|Protocol 2 will be the intervention administered with 80h bimanual intensive therapy and 20h modified constraint induced movement therapy
61982642|NCT06537154|ACTIVE_COMPARATOR|cCR, Standard of care|"Participants found to have a clinical complete response following NAT randomized to standard of care, described as definitive bladder treatment, which consists of either radical cystectomy, or chemo-radiation of the bladder"
61982643|NCT06537154|EXPERIMENTAL|cCR, Active surveillance|Participants found to have a clinical complete response following NAT randomized to the investigational arm consisting of active surveillance. They will have have no local treatment to their bladder and will be monitored with cystoscopy, cytology and imaging (active surveillance)
61982644|NCT06537154|NO_INTERVENTION|non-cCR, standard of care|Participants found to have residual urothelial carcinoma (not cCR) will received the standard of care definitive bladder treatment. They will received either radical cystectomy or chemo-radiation of the bladder.
61982645|NCT03774953|EXPERIMENTAL|Intervention group|protein and vitamin supplementation
62362604|NCT02563925|EXPERIMENTAL|Radiation and Tremelimumab|Subjects will get either whole brain radiation treatment (WBRT) or stereotactic radiosurgery (SRS), as per standard of care, with tremelimumab administered every 28 days. Patients, for whom concurrent HER2 directed therapy trastuzumab is indicated, as determined by the treating investigator, will be enrolled in a parallel HER2 directed therapy trastuzumab safety cohort. Protocol Expansion: Dose 1 of tremelimumab \& durvalumab (75 mg \& 1500 mg, respectively) will ideally be administered 2 days prior to initiation of brain radiotherapy (or between 5 days prior \& 3 days after initiation of radiotherapy). Subjects will get either WBRT or SRS, depending on the number \& size of their brain metastases. Following the 1st dose, tremelimumab \& duvralumab will be administered q28 days from the date of 1st tremelimumab \& durvalumab administration, plus or minus 1 week, for 4 cycles. After the 4th cycle, durvalumab will be administered alone until progression of disease or unacceptable toxicity.
61982646|NCT03774953|NO_INTERVENTION|Control group|No supplementations
61982647|NCT06478160|EXPERIMENTAL|CBSD-experimental group|blood collection with Closed-Blood Sampling System (CBSD)
61982648|NCT06478160|ACTIVE_COMPARATOR|Waste discard volume, control group|Blood collection without CBSD, usual practice, need to waste discard volume
61982649|NCT00944450|ACTIVE_COMPARATOR|1|Sitagliptin anhydrous formulation
61982650|NCT00944450|ACTIVE_COMPARATOR|2|Sitagliptin monohydrate FMI formulation
61982651|NCT05092685|EXPERIMENTAL|AAVLK03hOTC (also known as ssAAV-LK03.hAAT.hcoOTC)|Dose escalation in three groups from 6x10\^11vg/kg (low dose), 2x10\^12vg/kg (intermediate dose) to 6x10\^12vg/kg (high dose). Dose expansion in a fourth group with the best acceptable safety:efficacy ratio
61982652|NCT04886050|ACTIVE_COMPARATOR|LC350189 Formulation A (Tablet)|Each subject will be administered a single LC350189 200mg (QD) Tablet on Day 1 and Day 5, respectively.
61982653|NCT04886050|ACTIVE_COMPARATOR|LC350189 Formulation B (Capsule)|Each subject will be administered two LC350189 100mg (QD) Capsules (2 x 100-mg capsules) on Day 1 or Day 5, respectively.
61982654|NCT01589445|EXPERIMENTAL|Pioglitazone (001 group)|The patients received pioglitazone hydrochloride tablet 30 mg (001 drug)once daily for first three months
61982655|NCT01589445|EXPERIMENTAL|Metformin (002 group)|The patients received metformin hydrochloride tablet 850 mg (002 drug)once daily for next three months.
62362605|NCT01464814|EXPERIMENTAL|Probiotic|Lactobacillus casei in fish oil capsule
62362606|NCT01464814|PLACEBO_COMPARATOR|Placebo|Fish oil capsule
62362607|NCT05663476|EXPERIMENTAL|Control group|Periodontally and systemically healthy participants
62362608|NCT05663476|EXPERIMENTAL|Periodontitis without coronary artery disease|Periodontitis participants without coronary artery disease
62362609|NCT05663476|EXPERIMENTAL|Periodontitis with coronary artery disease|Periodontitis participants with coronary artery disease
62550016|NCT04263181||Cohort 5|"* Patients treated with azacitidine + venetoclax~* Patients will receive azacitidine 75 mg/m2/day as a 1-hour infusion or by subcutaneous injection on consecutive Days 1-7 or on day 1-5 and 8-9 (per treating physician discretion) of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter."
61982656|NCT03475381||Orkambi treated patients|All patients with CF who started ivacaftor+lumacaftor outside of a clinical trial between January 22nd 2016 and January 22nd 2017.
61982657|NCT00038207|EXPERIMENTAL|Liposomal Vincristine|
61982658|NCT01272609|EXPERIMENTAL|LCP + Timolol|Three sessions of LCP in 595 nm (diameter of spot 7mm; duration of shooting 1,5 ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
61982659|NCT01272609|ACTIVE_COMPARATOR|LCP|Three sessions of LCP in 595 nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure © spaced out of 1 month.
61982660|NCT01656590|OTHER|High Protein and Exercise therapy along-with Nocturnal Enteral|
61982661|NCT02145728|EXPERIMENTAL|Individual Cognitive Functional Therapy|The intervention being tested has four main components: (1) a cognitive component, for each patient, their vicious cycle of pain will outlined in a diagram based on their findings from the examination and the Orebro Musculoskeletal Pain Screening Questionnaire; (2) specific movement exercises designed to normalize maladaptive movement behaviours; (3) targeted functional integration of activities in their daily life previously, reported to be avoided or provocative by the patient; and (4) a physical activity and lifestyle programme.
61982662|NCT02145728|ACTIVE_COMPARATOR|Group Exercise Classes|6 classes will take place in total. The class has 3 components each week. First, a 30 minute talk and discussion on chronic pain, and some tips for participants. Second, a 40 minute exercise circuit, involving aerobic exercise, and gentle stretching and strengthening exercises. Finally, a 5 minute relaxation/mindfulness session will take place at the end. The total time involved is approximately 1 hour and 15 minutes.
61982663|NCT02390401|EXPERIMENTAL|Vacuum-assisted closure (VAC)|Prevena (VAC) device
61982664|NCT02390401|ACTIVE_COMPARATOR|Standard sterile dressing|Standard sterile dressing
61982665|NCT02436356|ACTIVE_COMPARATOR|Distal Radius Fracture Operative Group|Fracture group patients will undergo DXA and MRI scans, along with Osteoprobe indentation.
61982666|NCT02436356|ACTIVE_COMPARATOR|Healthy Volunteers (Non Fracture Group)|Healthy volunteers will undergo DXA and MRI scans.
61982667|NCT02436356|ACTIVE_COMPARATOR|Distal Radius Fracture Non-operative Group|Fracture group patients will undergo DXA and MRI scans, but will not undergo Osteoprobe indentation.
61982668|NCT00469092|EXPERIMENTAL|BIAsp 30|
62550017|NCT03093701|EXPERIMENTAL|Group 1|TLC399 (ProDex) 0.36mg DSP with 100 mM PL
61982669|NCT00469092|ACTIVE_COMPARATOR|Glargine|
61982670|NCT04343599|EXPERIMENTAL|Hypopressive exercises|Patients completed 10 weeks of abdominal hypopressive exercises with two sessions of 30 minutes per week.
61982671|NCT04343599|NO_INTERVENTION|Control group|Patients allocated to the control group did not receive any treatment.
61982672|NCT06124612||Atrial fibrillation|Patients already enrolled in main OCEANIC-AF study.
61982673|NCT06384716|EXPERIMENTAL|Experimental Group 1|"The intervention group will come to receive the treatment focused on training the motor control of the CORE. This intervention will consist of two sessions per week in which different levels of intervention will be established:~1. - First week: Sensitisation and voluntary work of the pelvic floor musculature without increasing the increase in intra-abdominal pressure.~2. - Second week: Work on respiratory motor control and activation of the pelvic floor.~3. - Third and fourth week: Motor control work with progressive increase in intra-abdominal pressure.~4. - Fifth and sixth week: Work on dynamic motor control in dual-task situations.~5. - Seventh and eighth week: Core motor control work in functional activities."
61982674|NCT06384716|NO_INTERVENTION|Control group|The control group will be evaluated before and after 8 weeks and will continue with their usual treatment.
62550018|NCT03093701|EXPERIMENTAL|Group 2|TLC399 (ProDex) 0.6 mg DSP with 100 mM PL
62550019|NCT03093701|EXPERIMENTAL|Group 3|TLC399 (ProDex) 0.6 mg DSP with 50 mM PL
61982675|NCT02337907|PLACEBO_COMPARATOR|Placebo comparator|
61982676|NCT02337907|EXPERIMENTAL|BI 409306 dose 1|
61982677|NCT02337907|EXPERIMENTAL|BI 409306 dose 2|
61982678|NCT02337907|EXPERIMENTAL|BI 409306 dose 3|
61982679|NCT02337907|ACTIVE_COMPARATOR|Active Comparator Donepezil|
61982680|NCT02337907|EXPERIMENTAL|BI 409306 dose 4|
61982681|NCT05718895|EXPERIMENTAL|ATG-022|"Dose Escalation Phase:~for subjects with solid tumors,approximately 16-36 subjects will be enrolled .~Dose Expansion Phase:~The tumor types in the Dose Expansion Phase may involve other tumor types based on the signals from the Dose Escalation Phase. The total number of patients in dose expansion will be up to approximately 120 patients."
61982682|NCT02947529|PLACEBO_COMPARATOR|Hemiarthroplasty - Placebo|Patients are placed into this arm based on the type of surgery performed and are randomized to receive placebo
61982683|NCT02947529|EXPERIMENTAL|Intramedullary nail - Tranexamic Acid|Patients are placed into this arm based on the type of surgery performed and are randomized to receive tranexamic acid
61982684|NCT02947529|EXPERIMENTAL|Hemiarthroplasty - Tranexamic Acid|Patients are placed into this arm based on the type of surgery performed and are randomized to receive tranexamic acid
61982685|NCT02947529|PLACEBO_COMPARATOR|Intramedullary nail - Placebo|Patients are placed into this arm based on the type of surgery performed and are randomized to receive placebo
61982686|NCT00567892|EXPERIMENTAL|1. rTMS|"Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
61982687|NCT00567892|SHAM_COMPARATOR|2. Sham rTMS|Sham rTMS appears identical to and mimics sounds and sensations of active magnet.
61982688|NCT01519453|EXPERIMENTAL|Home Based Asthma Education|Families will receive 4 home based and 3 phone based asthma education sessions with a community asthma outreach worker
61982689|NCT01519453|NO_INTERVENTION|Control|There is no control arm specific intervention
61982690|NCT03514784|ACTIVE_COMPARATOR|BB-12 with LGG (Lower Dose)|BB-12 with LGG (Multistrain probiotic; lower dose): 1 billion CFUs
61982691|NCT03514784|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62550020|NCT03093701|EXPERIMENTAL|Group 4|TLC399 (ProDex) 0.84 mg DSP with 50 mM PL
62550021|NCT01845688|EXPERIMENTAL|Losartan Tablets & QingReMoShen Granule|Losartan Tablets: 50mg, qd, po. QingReMoShen Granule: 12g, tid, po.
61982692|NCT03514784|ACTIVE_COMPARATOR|BB-12 with LGG (Higher Dose)|BB-12 with LGG (Multistrain probiotic: higher dose): 10 billion CFUs
61982693|NCT00695396|EXPERIMENTAL|001|Epoetin alfa 40 000 IU subcutaneously once every week (1 mL dose) for 48 weeks
61982694|NCT00695396|EXPERIMENTAL|002|Epoetin alfa 80 000 IU subcutaneously once every week (2 mL dose) for 48 weeks
61982695|NCT00695396|PLACEBO_COMPARATOR|003|Placebo Matching volume 1 mL for 48 weeks
61982696|NCT00695396|PLACEBO_COMPARATOR|004|Placebo Matching volume 2 mLfor 48 weeks
61982697|NCT04212247|EXPERIMENTAL|Well-being therapy|WBT will be used as the only non-pharmacological therapeutic strategy and 8 sessions will be delivered every other week with a duration of 60 minutes each. The manualized WBT will be used (Fava, 2016). Thus, the initial phase will be concerned with self-observation of psychological well-being. Once the instances of well-being will be properly recognized, the patient will be encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of well-being (intermediate phase). The final part will involve cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
61982698|NCT04212247|PLACEBO_COMPARATOR|Control condition|The control condition will include 8 every other week sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) guidelines (https://www.nice.org.uk/guidance/lifestyle-andwellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/ health-topics/disease-prevention/nutrition/a-healthylifestyle). These sessions will inform participants about well-being and lifestyles which can influence it.
61982699|NCT03913884|EXPERIMENTAL|Concentrated growth factor Group|Group I (test); in which CGF fibrin matrix was applied to the extraction socket
61982700|NCT03913884|EXPERIMENTAL|Non-Concentrated growth factor Group|Group II (control); in which CGF was not applied to the extraction socket
61982701|NCT00503308|EXPERIMENTAL|Abbreviated Consenting|
61982702|NCT00503308|NO_INTERVENTION|Standard Consenting|
61982703|NCT01136850|ACTIVE_COMPARATOR|SP, chloroquine treatment; bed net|Treatment course of sulphadoxine pyrimethamine and chloroquine on enrolment. Long lasting insecticide treated bed net
61982704|NCT01136850|EXPERIMENTAL|3 x SP plus azithromycin; bed nets|Three x monthly courses of azithromycin and sulphadoxine pyrimethamine plus long lasting insecticide treated bed net.
61982705|NCT04021589|EXPERIMENTAL|WLS-intervention group|chemotherapy + WLS
61982706|NCT04021589|ACTIVE_COMPARATOR|the control group|chemotherapy
61982707|NCT06202391|EXPERIMENTAL|Group A (Autogenic inhibition muscle energy technique)|12 sessions will be conducted over a period of 4 weeks with 3 days per week Frequency: 12 sessions, four times a week for 3 consecutive weeks Time duration: apporx. 8 to 10 minutes
61982708|NCT06202391|EXPERIMENTAL|Group B (Reciprocal inhibition muscle energy technique)|"12 sessions will be conducted over a period of 3 weeks with 4 days per week~Frequency: 12 sessions, four times a week for 3 consecutive weeks Time duration: apporx. 8 to 10 minutes"
61982709|NCT02284711|ACTIVE_COMPARATOR|Bipolar|Coagulation during salpingectomy using conventional bipolar electric energy
61982710|NCT02284711|ACTIVE_COMPARATOR|Ultrasound|Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
61982711|NCT06490263|EXPERIMENTAL|chewing or swallowing with single dose of WH006 in healthy subjects(Part One)|Administered by chewing with meals or swallowing after meals, with a dosage of 126 milligrams, given as a single dose only in healthy subjects.
61982712|NCT06490263|EXPERIMENTAL|single dose ascending of WH006 in healthy subjects (Part Two)|Administered by swallowing after meals with a single dose, four dose groups were performed sequentially in healthy subjects.
61982713|NCT06490263|EXPERIMENTAL|multiple dose ascending of WH006 in healthy subjects (Part Three)|Administered by swallowing after meals, taken three times daily; two dose groups were performed sequentially in healthy subjects.
61982714|NCT06490263|EXPERIMENTAL|multiple dose ascending of WH006 in overweight or obese subjects(Part Three)|Administered by swallowing after meals, taken three times daily; two dose groups were performed sequentially in overweight or obese subjects.
61982715|NCT03163550|EXPERIMENTAL|Cohort 1|Healthy volunteers
61982716|NCT03163550|EXPERIMENTAL|Cohort 2|Healthy volunteers
61982717|NCT03163550|EXPERIMENTAL|Cohort 3|Healthy volunteers
61982718|NCT03163550|EXPERIMENTAL|Cohort 4|Healthy volunteers
61982719|NCT03163550|EXPERIMENTAL|Cohort 5|Healthy volunteers
61982720|NCT00753558|PLACEBO_COMPARATOR|2|Oral solution of 0.45% saline and oral solution of H2O \& saccharine. Oral gel composed of mineral oil, gelatine powder, pectin, sodium carboxymethylcellulose, polyethylene
61982721|NCT00753558|ACTIVE_COMPARATOR|1|Oral solution and buccal gel of gentamicin and polymyxin E
61982722|NCT04711473|ACTIVE_COMPARATOR|Colonoscopy Only|Participants in this arm will receive a letter from their provider informing them they are overdue for colon cancer screening and requesting their participation in colonoscopy, and including a referral for the procedure at a local endoscopy center. Participants will be provided a phone number if interested in navigated colonoscopy scheduling.
61982723|NCT04711473|EXPERIMENTAL|Choice|Participants in this arm will receive a letter from their provider informing them they are overdue for colon cancer screening and requesting their participation in their choice of either colonoscopy or mailed fecal immunochemical testing (FIT). The letter will include both a referral for the colonoscopy at a local endoscopy enter and a FIT kit with a lab requisition and instructions for completion.
61982724|NCT04711473|EXPERIMENTAL|FIT Only|Participants in this arm will receive a letter from their provider informing them they are overdue for colon cancer screening and requesting their participation in FIT testing. The letter will include a FIT kit with lab requisition and instructions for completion.
61982725|NCT05451147|EXPERIMENTAL|Group A|DRUG: Chhinnavahni Kashaya Vati FORM: Tablet DOSE: 1 g TDS (2 Tab. of 500 mg each), Before Meals MODE OF ADMINISTRATION: Oral ANUPAAN: 20 ml of Agnimantha Kwatha DURATION: 3 Months
61982726|NCT05451147|ACTIVE_COMPARATOR|GROUP B|DRUG: Metformin FORM: Tablet DOSE: 500mg BID/TDS, Before Meals MODE OF ADMINISTRATION: Oral ANUPAAN:: Plain Water DURATION 3 Months
61982727|NCT05701410|EXPERIMENTAL|Study group|Patients with a history of lumbar spinal stenosis.
61982728|NCT06018259|EXPERIMENTAL|healthy volunteers|One blood sample will be taken from healthy volunteers in order to isolate PBMC and to assess the effect of the lipid of interest on them
62362610|NCT02450500|EXPERIMENTAL|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging.
62362611|NCT02155244||Common bile duct stones|Common bile duct stones traeted with ERCP
61982729|NCT02152579|EXPERIMENTAL|Isosorbide-5-mononitrate, tablet|Single treatment arm.
62362612|NCT02155244||CBDS|treated with ERCP combined with surgery
61982730|NCT05020392|EXPERIMENTAL|Effective of CAR-T-CD19 cells with concurrent BTK inhibitor|After enrollment, all subjects will receive oral BTK inhibitor immediately and BTK inhibitor treatment will continue for up to 90 days (or longer for who are benefiting from BTK inhibitor) after CAR-T-CD19 infusion. Eligible patients will undergo leukapheresis to obtain peripheral blood mononuclear cells (PBMCs) for CAR T-cell production. Upon successful generation CAR-T-CD19 product, participants will receive fludarabine-based lymphodepletion chemotherapy, followed by infusion of CAR-T-CD19 cells (2\*10\^6 cells/kg) on day 0 and day 1 respectively.
61982731|NCT05020392|ACTIVE_COMPARATOR|Effective of CAR-T-CD19 cells monotherapy|Eligible patients will undergo leukapheresis to obtain peripheral blood mononuclear cells (PBMCs) for CAR T-cell production. Upon successful generation CAR-T-CD19 product, participants will receive fludarabine-based lymphodepletion chemotherapy, followed by infusion of CAR-T-CD19 cells (2\*10\^6 cells/kg) on day 0 and day 1 respectively.
61982732|NCT06421779|EXPERIMENTAL|Experimental: VR|Children in the VR group put on VR glasses for approximately two minutes before the skin prick test and watched a VR underwater experience video throughout the procedure.
62362613|NCT04322240|EXPERIMENTAL|type 2 DM with peripheral neuropathy|Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication, antidiabetic drugs, or medications used for managing arterial hypertension or dyslipidaemia during the study.
62362614|NCT02686892||Group|Spanish territory population of 46,439,864 inhabitants
61982733|NCT06421779|NO_INTERVENTION|No Intervention: Control|Children in the control group underwent a routine skin prick test procedure. Control group children did not receive any distraction techniques.
61982734|NCT05757661|EXPERIMENTAL|Focal Vibration Group|
61982735|NCT05757661|SHAM_COMPARATOR|Sham Group|
62362615|NCT02686892||Cohort|Incident cases diagnosed with IBD over 12 months in the Spanish territory
62362616|NCT02318745|EXPERIMENTAL|Culturally Informed Family Treatment for Adolescents|CIFTA focuses on improving parenting practices, parent-adolescent attachment, adolescent ability to meet developmental challenges, increasing family support and decreasing family conflict/negativity, increasing knowledge of drug effects and triggers to use. Parents are taught general parenting and how to help a son or daughter with depression, conduct problems, and/or ADHD. Psycho-educational modules complement the family therapy and culturally relevant information is infused throughout the treatment. In family therapy sessions family members practice the skills and psycho-educational material they have learned. Treatment last approximately 4 months and includes approximately 6 session per month. Session may be family therapy sessions, individual sessions, or psycho-educational modules.
62362617|NCT02318745|ACTIVE_COMPARATOR|Individual Treatment As Usual|The active comparison condition reflects the typical individually-oriented services that behavior problem youth receive in the community. It was designed to isolate the effects of the CIFTA family interventions. A community agency helped us to standardize the individually-oriented services that were normally provided and a therapist trained by that agency was hired to work on the study to provide continuity to the services. The adolescent individual sessions addressed depression, ADHD, and/or conduct disorder through Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, and assertiveness training. The ITAU therapists were expected to hold 6 sessions per month with the youth.
62362618|NCT04016987|EXPERIMENTAL|Automated, Individualized Education|Subjects will be given instructions to install the patient-end App, which includes the following functions: diabetes education, patient-doctor communication, diabetes diary, peer support, reminder for blood sugar test and related abnormal results. They receive push notifications that provides recommended education materials which meet the needs of the patient by considering his/her baseline diabetes-related knowledge.
62550022|NCT01845688|PLACEBO_COMPARATOR|Losartan Tablets & Placebo Granule|Losartan Tablets: 50mg, qd, po. Placebo Granule: 12g, tid, po.
61982736|NCT03577743|EXPERIMENTAL|experimental arm|bevacizumab and chemotherapy given every 21 day untill disease progression or unacceptable toxicity
61982737|NCT04563169|EXPERIMENTAL|Video consultation|Patients in the video consultation group will receive video consultations.
61982738|NCT04563169|NO_INTERVENTION|Face-to-Face consultation|Patients in the usual care group will receive face-to-face consultations.
61982739|NCT05888246|EXPERIMENTAL|Diagnostic test|Diagnostic test: magnetocardiogram.
61982740|NCT02984189|EXPERIMENTAL|Inspiratory Critical Pressure Group|Inspiratory Critical Pressure will be used for training and will be determined, from a progressive inspiratory threshold-loading test will start with 50%MIP followed by 10%MIP increments, every 3min until subjects reached a load that there were unable to sustain for at least 1min (PThMAX). On another day, the subjects will perform a constant inspiratory loading test against a resistance of 95%, 100% and 105%PThMAX, for as long as they could tolerate. The intensity loads will be applied according the results of block randomization. The time elapsed until task failure was defined as inspiratory muscle endurance time, and will use to set the PThC. The respiratory work done (inspiratory pressure values) will be plotted in abscissa and the time-to-exhaustion in ordinate, and a linear regression going through the 3 points will be applied using the pressure-1/t relationship. The slope of the parallel line displaced downward projecting to the origin produce the PThC value.
61982741|NCT02984189|ACTIVE_COMPARATOR|60% Maximal Inspiratory Pressure Group|60% of maximal inspiratory pressure will be used for training.
61982742|NCT02984189|SHAM_COMPARATOR|Sham Group|6 cmH20 will be used for training.
61982743|NCT03951740|EXPERIMENTAL|Group of cardiac patients|All patients completed the study wearing two wrist-worn activity trackers and the Oxycon mobile as reference method during a laboratory activity protocol.
61982744|NCT01287897|PLACEBO_COMPARATOR|Placebo- SC injection|
61982745|NCT01287897|EXPERIMENTAL|Drug Dose level 1 - SC injection|
61982746|NCT01287897|EXPERIMENTAL|Drug Dose level 2 - SC injection|
61982747|NCT02081079|EXPERIMENTAL|Genotype 4|LDV/SOF for up to 12 weeks in treatment-naive and treatment-experienced participants with genotype 4 hepatitis C virus (HCV) infection
61982748|NCT02081079|EXPERIMENTAL|Genotype 5|LDV/SOF for up to 12 weeks in treatment-naive and treatment-experienced participants with genotype 5 hepatitis C virus (HCV) infection
61982749|NCT00003147|EXPERIMENTAL|Arm I|Patients receive adenovirus p53 construct by percutaneous injection to a maximum of two lesions on day 1. Treatment is repeated every 28 days for up to 6 courses. In the absence of dose-limiting toxicity (DLT) in the first cohort of 6 patients treated, subsequent cohorts of 6 patients each receive escalating doses of the drug on the same schedule. If DLT occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and that dose is declared the maximum tolerated dose. Study treatment may continue in the absence of disease progression and unacceptable adverse events.
62362619|NCT04016987|NO_INTERVENTION|Routine care|Subjects only receive the education provided by health-care professionals in the outpatient department
62362620|NCT05184127|EXPERIMENTAL|MIR 19 ®|Study participants from experimental groups, in addition to standard COVID-19 therapy, received the MIR 19 ® (2 inhalations per day with a single dose of 1.85 or 5.55 mg at intervals of 7-8 hours for 14 days).The standard therapy in this group included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
62362621|NCT05184127|ACTIVE_COMPARATOR|Standard COVID-19 therapy|In the comparison group, therapy was carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection.The standard therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.
62362622|NCT00843557||all ICU admissions|patients admitted to the ICU for greater then 72hrs
61982750|NCT00225251|EXPERIMENTAL|bupropion XL|Treatment with active medication (bupropion XL) dose ranging from 150 to 450 mg/day
62362623|NCT04301193|OTHER|Pregnant Women|All subjects will have the same intervention. Samples will be taken and manipulated in the laboratory for use of the Hemosonic Qauntra Analyzer
61982751|NCT00225251|PLACEBO_COMPARATOR|Placebo|Placebo comparator, matching appearance with active medication, taken from 1 to 3 tablets per day
61982752|NCT03375801|NO_INTERVENTION|control group/pre intervention|the first 164 patients will receive care as usual and will make the decision together with their clinician without support of the decision aid. They will be asked to fill out the questionnaires.
62362624|NCT00829660|ACTIVE_COMPARATOR|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
62550023|NCT05470608|EXPERIMENTAL|SL-1002|SL-1002 injectable solution, single dose
61982753|NCT03375801|EXPERIMENTAL|intervention arm|another 164 patients will receive the decision aid as support for the decision making process with their clinician.
61982754|NCT00602576|EXPERIMENTAL|Arm A|Patients who were temozolomide naive and had no brain metastases received oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.
61982755|NCT00602576|EXPERIMENTAL|Arm B|Patients who were temozolomide naive and had no brain metastases received sorafenib tosylate as in arm A and oral TMZ once daily on days 1-5 and 29-33.
61982756|NCT00602576|EXPERIMENTAL|Arm C|Patient with or without treated brain metastases who were treated with prior temozolomide and progressed were treated with oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.
61982757|NCT00602576|EXPERIMENTAL|Arm D|Patients with treated brain metastases were treated with sorafenib tosylate as in arm B and oral TMZ once daily on days 1-5 and 29-33.
61982758|NCT05245760|EXPERIMENTAL|All patient|All patients receive Tislelizumab, q3week; chemotherapy with carboplatin and paclitaxel weekly concurrently for 5 weeks before surgery. Tislelizumab is continued q3week in all patients after surgery for a total of one year from the start of study.
61982759|NCT03065244|ACTIVE_COMPARATOR|IVIG|Patient will be randomly assigned to receive a second IVIG infusion: 2 g/kg IV over 8-10 hours single infusion
61982760|NCT03065244|ACTIVE_COMPARATOR|Infliximab|Patient will be randomly assigned to receive Infliximab 10 mg/kg IV over 2 hours
61982761|NCT05431959|EXPERIMENTAL|Self-controlled|"The skin microbiome was collected by swabbing method from the crook of the arm (normal skin) and the nearest plaque's surface.~Balneotherapy in Lake Hévíz, 36℃ sulphur, carbonate, calcium, magnesium, hydrogen carbonate and very light radon-content thermal-mineral water 15 times in 3 weeks 30-minute therapy sessions. The total mineral substance of the water is 754 mg/l."
62550024|NCT05470608|PLACEBO_COMPARATOR|Matching placebo|Matching placebo injectable solution
61982762|NCT05387655||BCG vaccination|People who received a BCG vaccination in the prior BCG-CORONA-ELDERLY or BCG-PRIME study
61982763|NCT05387655||Placebo vaccination|People who received a placebo vaccination in the prior BCG-CORONA-ELDERLY or BCG-PRIME study
61982764|NCT01650038|ACTIVE_COMPARATOR|faecal transplantation; donor faeces|2 times treatment with faecal transplantation: faeces from a healthy donor processed for duodenal tube infusion. after bowel lavage with macrogol.
61982765|NCT01650038|PLACEBO_COMPARATOR|faecal transplantation; placebo|2 times treatment with (own) faecal transplantation: faeces from the patient processed for duodenal tube infusion. after bowel lavage with macrogol.
61982766|NCT03679780|ACTIVE_COMPARATOR|Control|This site will serve as the control site and will receive lactated Ringer's (saline solution) (2 µl/min) throughout the entire duration of the protocol. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
62362625|NCT00829660|PLACEBO_COMPARATOR|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
62362626|NCT04344704||DX devices with SMART headset detection enabled|The SMART detection algorithm is designed to, with the aid of atrial rhythm assessment, discriminate between ventricular tachycardias and a variety of supraventricular tachyarrhythmias for which device intervention is not required or desired
61982767|NCT03679780|EXPERIMENTAL|Inhibitor of Endothelin Type B Receptor|This site will receive 300 nM BQ-788, an inhibitor of the endothelin type B receptors. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
62362627|NCT04344704||DX device programmed in single chamber mode|"with the activation of one of the available discrimination criteria:~* Onset: distinguishes slow onset or onset tachycardias from sudden onset~* Stability: distinguishes between irregularly transmitted supraventricular tachycardias and ventricular tachycardias requiring therapy by continuous interval monitoring.~* Morphmatch: helps to distinguish between supra and ventricular signals through analysis of episode QRS width"
61982768|NCT03679780|EXPERIMENTAL|Inhibition of Endothelin Type A Receptor|This site will receive 500 nM aBQ-123, an inhibitor of endothelin type A receptors. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
61982769|NCT03679780|EXPERIMENTAL|L-Arginine|This site will receive 10 mM L-Arginine to supplement the substrate for endothelial nitric oxide synthase. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
61982770|NCT02814123|ACTIVE_COMPARATOR|Rapid Insulin-alone closed-loop delivery|Rapid Insulin will be delivered by subcutaneous infusion. Interventions: 24-hour inpatient intervention Drug: Rapid acting Insulin (aspart, lispro, glulisine)
61982771|NCT02814123|EXPERIMENTAL|Rapid Insulin-plus-pramlintide closed-loop delivery|"Rapid insulin and pramlintide will be delivered by subcutaneous infusion using a fixed ratio (6 µg pramlintide/unit insulin).~Interventions: 24-hour inpatient intervention Drug: Rapid acting Insulin (aspart, lispro, glulisine) Drug: Pramlintide"
62362628|NCT04606368|EXPERIMENTAL|Interventional cohort|Each subject will serve as their own control. Left side of lower jaw and submental area is control side. Right side of subject's lower jaw and submentum area will receive treatment.
62362629|NCT04242459|NO_INTERVENTION|Feasibility Study|This is a radiotherapy planning study to evaluate the feasibility to acquire longitudinal MRI scans during radiotherapy (prior to the main study) thus, participants will receive standard-of-care chemoradiation therapy (CRT) as per departmental protocol without any treatment adaptation.
62362630|NCT04242459|EXPERIMENTAL|HPV associated OPC Participants|"Participants will be treated initially with the standard radiotherapy dose of:~* 65 grays (Gy) in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.~* 54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease~In the 2nd week and 4th week of treatment, the participants will undergo Adaptive Radiotherapy to account for anatomical changes."
62362631|NCT04242459|EXPERIMENTAL|HPV negative OPC Participants - Radiotherapy dose escalation|"Participants will be treated initially with the standard radiotherapy dose of:~* 65Gy in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.~* 54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease~After 10 fractions the participants will be stratified into either responders or non-responders categories based on Apparent Diffusion Coefficients (ADC) response at week 2 of CRT.~Participants classified as responders will complete treatment without any radiotherapy dose changes. Their radiotherapy treatment target volumes will be adapted at weeks 2 and 4 of CRT to account for volume changes to the tumour.~The non-responders will undergo an increase in dose per fraction to Clinical Target Volume-1 (CTV-1) primary for fractions 11 to 30."
61982772|NCT02814123|EXPERIMENTAL|Regular Insulin-plus-pramlintide closed-loop delivery|"Regular insulin and pramlintide will be delivered by subcutaneous infusion using a fixed ratio (6 µg pramlintide/unit insulin).~Interventions: 24-hour inpatient intervention Drug: Regular Insulin (humulin R) Drug: Pramlintide"
61982773|NCT04846660|EXPERIMENTAL|Production pressured environment|Participants in this group were exposed to 4 audio recordings applying standardized pressure. Unlimited time.
62362632|NCT04242459|EXPERIMENTAL|Base of Skull HNC Participants|"Participants will be treated initially with the standard radiotherapy dose of:~* 65Gy in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.~* 54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease~Participants will undergo standard treatment with 3 cycles of induction chemotherapy followed by chemo-radiotherapy dose. Their radiotherapy treatment will be adapted at weeks 2 and 4 of CRT to account for volume changes to the tumour."
62362633|NCT01688999|EXPERIMENTAL|Cabozantinib|Administered orally at a dose of 60 mg once daily on each day of a 28-day cycle.
62362634|NCT05409846||Group A|Idiopathic hypertrophic cardiomyopathy
62362635|NCT05409846||Group B|Idiopathic left ventricle hypertrophy
62362636|NCT05409846||Group C|Idiopathic burned-out hypertrophic cardiomyopathy
62362637|NCT05409846||Group D|Idiopathic dilated cardiomyopathy
61982774|NCT04846660|NO_INTERVENTION|Regular environment|The control group was asked to complete the same task also with unlimited time. They were not exposed to the audio recordings.
61982775|NCT00333866|EXPERIMENTAL|1|
61982776|NCT00333866|EXPERIMENTAL|2|
61982777|NCT00333866|EXPERIMENTAL|3|
61982778|NCT00333866|PLACEBO_COMPARATOR|4|
61982779|NCT06032247|EXPERIMENTAL|Unilateral strength training|Resistance training three times per week for 8-weeks on one leg at a time per exercise.
61982780|NCT06032247|ACTIVE_COMPARATOR|Bilateral strength training|Resistance training three times per week for 8-weeks on both legs at a time per exercise.
61982781|NCT03272607|NO_INTERVENTION|Control|All participants in the control arm will receive medication reconciliation at admission and discharge, and identical follow up, but no prioritized deprescribing list will be generated.
61982782|NCT03272607|EXPERIMENTAL|Intervention|"Participants in the intervention arm will be electronically screened using an electronic software MedSafer which will generate output of PIMs that will be brought to the attention of the CTU team via the unit pharmacist as deprescribing opportunities. (Note that in the case of multiple recommendations, they will be limited and prioritized so as to avoid overwhelming the treating team.) Based on their own expert medical judgement, in collaboration with the patient/caregiver and other relevant clinicians, a decision will be made to deprescribe if appropriate by the patient's in-hospital doctors."
61982783|NCT02838680|EXPERIMENTAL|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
61982784|NCT04435015|EXPERIMENTAL|Camostat mesylate 200 mg|Participants will be given Camostat mesylate three times daily.
61982785|NCT04435015|PLACEBO_COMPARATOR|Microcrystalline Cellulose|Participants will be given placebo three times daily.
61982786|NCT03020407|EXPERIMENTAL|IVC Ultrasound-guided|The treating physician will promptly assess the IVC diameter to obtain the collapsibility index (IVCCI) (or distensibility index, IVCDI) of an eligible patient. A previous study showed that IVCCI \> 40% were strongly associated with fluid responsiveness. Accordingly, the patient will be given 10 ml/kg of bolus of 0.9% normal saline solution (NSS) each time when the IVCCI \> 40% is discovered and serial measurements will be done after each intravenous bolus is achieved until the IVCCI \< 40 % during our protocol. Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
61982787|NCT03020407|NO_INTERVENTION|Usual care|Patients will be promptly and empirically treated by 30 ml/kg loading of NSS in this treatment arm. After the NSS bolus, treatment with either the additional intravenous fluid or a vasopressor is given depended on physicians' discretion during the 6-hour study period. Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
61982788|NCT01161914|ACTIVE_COMPARATOR|Cerezyme®|60 U/kg infusion (every 2 weeks for 24 weeks)
61982789|NCT01161914|EXPERIMENTAL|ISU302|60 U/kg infusion (every 2 weeks for 24 weeks)
61982790|NCT03295253|EXPERIMENTAL|Female patients with Stress Incontinence|Female patients who will undergo autologous adipose tissue harvesting/grafting using Lipogems and grafting in urethra/bladder neck
61982791|NCT01746927||cricoid pressure|
61982792|NCT05771233|EXPERIMENTAL|Prevention|The group will consist of 20 participants (6 classical dancers, 4 Spanish dancers, 5 flamenco dancers and 5 contemporary dancers) who will be divided into groups according to their specialties, with a one-hour session per week for 7 weeks of physical exercise to strengthen core muscles and lumbo-pelvic stability.
61982793|NCT05771233|NO_INTERVENTION|Control|The experimental group will consist of 20 participants (4 classical dancers, 6 Spanish dancers, 5 flamenco dancers and 5 contemporary dancers) who will not receive any strength training. They will be evaluated at the beginning and at the end of the study to compare the physical conditions of the participants of this group with those of the experimental group.
61982794|NCT03659591|ACTIVE_COMPARATOR|Cognitive Behaviour Therapy|10 week, manual-based group CBT treatment for depression and anxiety, followed by optional booster sessions
61982795|NCT03659591|ACTIVE_COMPARATOR|Adaptive Psychological Training|5 week, manual-based group APT treatment for depression and anxiety, followed by optional booster sessions
61982796|NCT03019939|EXPERIMENTAL|Prevention (isavuconazole)|Patients receive isavuconazole PO every 8 hours for 6 doses and then Once a day (QD) or IV over 1 hour every 8 hours for 6 doses and then QD for up to 4 days for 12 weeks in the absence of disease progression or unacceptable toxicity.
61982797|NCT04725760|EXPERIMENTAL|Single Group Assisgnment|
61982798|NCT03359044||Sedation + topical anesthesia|midazolam 0.1～0.2 mg/kg for sedation, 2%lidocaine for topical anesthesia
61982799|NCT03359044||General anesthesia+ topical anesthesia|propofol 4～5mg/kg、Remifentanil2～3μg/kg for induction ,insert Laryngeal Mask Airway(LMA) , 2%lidocaine for topical anesthesia
61982800|NCT00417807|EXPERIMENTAL|Gleevec/Glivec|
61982801|NCT00555607|ACTIVE_COMPARATOR|steroid|Group receiving oral prednisolone (0.5 mg/kg bodyweight per day) during 14 days.
61982802|NCT00555607|PLACEBO_COMPARATOR|placebo|Group receiving placebo tablets during 14 days, followed by an open prednisolone treatment (0.5 mg/kg bodyweight per day) during a following 14 days.
61982803|NCT05325879|ACTIVE_COMPARATOR|Asymptomatic Individuals|Individuals aged between 18-50 who volunteered to participate in the study, will form the control group.
61982804|NCT05325879|EXPERIMENTAL|Individuals with neck pain|Individuals with neck pain aged between 18-50 who volunteered to participate in the study, will form the study group.
61982805|NCT00530933|SHAM_COMPARATOR|1|Sham tibial nerve stimulation
61982806|NCT00530933|EXPERIMENTAL|2|Percutaneous tibial nerve stimulation
61982807|NCT00530933|EXPERIMENTAL|3|Transcutaneous tibial nerve stimulation
62362638|NCT02477306|EXPERIMENTAL|Study group|60 subjects will receive a single oral dose of idiazole 20mg DR tabs under fasting condition in one period. And the subjects will receive a single dose of PARIET 20 mg DR tabs under fasting condition in the second period. A 7 days washout interval is in between the 2 periods
61982808|NCT05387733|EXPERIMENTAL|CBL-514 Group 1|Eligible participants will be enrolled and randomized into one of 2 dose groups. Group 1 with 10 mg CBL-514 per injection.
61982809|NCT05387733|EXPERIMENTAL|CBL-514 Group 2|Eligible participants will be enrolled and randomized to one of 2 dose groups. Group 2 with 15 mg CBL-514 per injection.
61982810|NCT02401880|ACTIVE_COMPARATOR|Empagliflozin plus Linagliptin|Linagliptin 5mg to be adminstered for 30 days in T2DM patients on stable metformin and Empagliflozin
61982811|NCT02401880|PLACEBO_COMPARATOR|Empagliflozin plus Placebo|Placebo to be adminstered for 30 days in T2DM patients on stable metformin and Empagliflozin
61982812|NCT02401880|OTHER|Empagliflozin|Empagliflozin 25mg will be adminstered for 30 days in T2DM patients
61982813|NCT01799616|EXPERIMENTAL|Pamidronate|In total, 48 patients will need to be recruited. These patients will be randomly assigned to one of the two groups, with each group comprising 24 patients: one group will be given pamidronate and the other placebo
61982814|NCT01799616|OTHER|Placebo|In total, 48 patients will need to be recruited. These patients will be randomly assigned to one of the two groups, with each group comprising 24 patients: one group will be given pamidronate and the other placebo
61982815|NCT00390533|EXPERIMENTAL|Saredutant 30 mg|Saredutant 30 mg once daily for a maximum of 8 weeks
61982816|NCT00390533|EXPERIMENTAL|Saredutant 100 mg|Saredutant 100 mg once daily for a maximum of 8 weeks
61982817|NCT00390533|PLACEBO_COMPARATOR|Placebo|Placebo for saredutant once daily for one week during the screening phase and for a maximum of 8 weeks during the acute phase
61982818|NCT00772707|EXPERIMENTAL|Opti-Free Replenish|Multi-purpose contact lens solution for cleaning and disinfecting study contact lenses used on a daily basis for 30 days.
61982819|NCT03629821|EXPERIMENTAL|Ballet|Subjects who will receive the experimental protocol.
61982820|NCT03629821|NO_INTERVENTION|Control|Subjects who will not receive the experimental protocol, only will be on a wait list.
61982821|NCT00999557|EXPERIMENTAL|Arm I|Patients apply topical bimatoprost ophthalmic solution to base of upper eyelid margins OR to eyebrow region once daily for 4 months in the absence of unacceptable toxicity.
61982822|NCT00999557|PLACEBO_COMPARATOR|Arm II|Patients apply topical placebo solution to base of upper eyelid margins OR to eyebrow region once daily for 4 months in the absence of unacceptable toxicity.
61982823|NCT04017273||Observational|The participants of this study will be seen at Emergency Department, and a nurse will perform a test called ER2 ( Emergency Room Evaluation and Recommendation).
61982824|NCT05087147|EXPERIMENTAL|Bonded space maintainer|Wire bonded with composite to abutment teeth
61982825|NCT05087147|ACTIVE_COMPARATOR|Banded space maintainer|Band and loop space maintainer
61982826|NCT05779878|EXPERIMENTAL|Interventional Group A|This group will be given Post isometric relaxation technique. Total intervention protocol will be given for four weeks of duration 3 sessions per week with total 12 sessions.
61982827|NCT05779878|EXPERIMENTAL|Interventional Group B|This Group will be given myofascial arm pull technique . Total intervention protocol will be given for four weeks of duration 3 sessions per week with total 12 sessions.
61982828|NCT05688241|EXPERIMENTAL|Group A: patients who undergo allogeneic HCT|Patients with EBV driven lymphomas (e.g., natural killer (NK)/T-cell lymphoma), with EBV complications (e.g. haemophagocytic lymphohistiocytosis (HLH), CAEBV) or patients with primary immunodeficiency disorders with high risk for EBV complications (e.g. SCID) with planned allogeneic HCT.
61982829|NCT05688241|EXPERIMENTAL|Group B: patients after HCT or SOT|EBV-driven PTLD that develop after a HCT or solid organ transplantation (SOT) and show decreased response to rituximab.
61982830|NCT03742609|NO_INTERVENTION|Information only|provision of written information regarding consequences of using a hearing aid and not using a hearing. For example using a hearing aid will improve ability to hear others.
61982831|NCT03742609|ACTIVE_COMPARATOR|Physical reminder only|provision of written information regarding consequences of using a hearing aid and not using a hearing and physical reminder to use a hearing aid. For example, a hearing aid box as a physical reminder to use the hearing aids.
61982832|NCT03742609|ACTIVE_COMPARATOR|Behaviour Plan only|provision of written information regarding consequences of using a hearing aid and not using a hearing and creation of behaviour plan to use a hearing aid. For example, when and where to use the hearing aids.
61982833|NCT03742609|EXPERIMENTAL|Info, Reminder and Plan|provision of written information regarding consequences of using a hearing aid and not using a hearing, physical reminder and creation of behaviour plan to use a hearing aid
62362639|NCT03955055|EXPERIMENTAL|Early Capsule Group|The intervention for subjects in this arm will be to have a video capsule deployed as soon as possible after presentation to the clinical decision unit. Information from the video capsule will be obtained and reviewed to determine location of bleeding. Once that information has been obtained a decision will be made on which endoscopic test is most pertinent in finding and treating the source of bleeding.
62550025|NCT01574690||Heart failure patients|50 subjects (both male and female) Heart failure patients already receiving RHC as part of their usual care
62567112|NCT02059512|ACTIVE_COMPARATOR|Group 2|Intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells during coronary artery bypass grafting intramyocardial 0.2 ml - 10 injection in the zone of blood supply LAD.
61982834|NCT01046734||Adult Community|
61982835|NCT01046734||Adult Hospital|
61982836|NCT01046734||Children Hospital|
61982837|NCT01046734||Children Community|
61982838|NCT03012347|EXPERIMENTAL|Sunscreen Users|Subjects will participate in a 2-Day study involving three applications of a single test article each day. The first application will be followed by an exposure of 30 minutes in a hot room.
61982839|NCT02959645||Cervical Dystonia|patients will have Cervical Dystonia
61982840|NCT02959645||Healthy control|Healthy Volunteers
61982841|NCT01144442|EXPERIMENTAL|HIPC Treatment|
61982842|NCT02105610|EXPERIMENTAL|volatile anesthetics (desflurane, isoflurane, sevoflurane)|
61982843|NCT02105610|ACTIVE_COMPARATOR|total intravenous anesthesia|
61982844|NCT05451862|OTHER|166Ho-TARE treatment|Patients with unresectable HCC with a single nodule ≤ 8 cm or up to three nodules with a diameter of ≤ 5 cm (each). Those patients who fulfil the initial selection criteria will undergo a work-up procedure for further screening of 166Ho-TARE eligibility. If a patient is deemed eligible for 166Ho-TARE, the patient will be included in the study.
61982845|NCT02576561|EXPERIMENTAL|TVGV-1 (cohort 1)|Antigen + Adjuvant - 0.6 mg lyophilized PEK fusion protein + 0.6 ml\* GPI- 0100 (1:1 ratio)
61982846|NCT02576561|ACTIVE_COMPARATOR|GPI-0100 (cohort 1)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein. 0.6 mg lyophilized placebo cake + 0.6 ml\* GPI- 0100 (1:1 ratio)
61982847|NCT02576561|PLACEBO_COMPARATOR|Placebo (cohort 1)|Placebo- 0 mg lyophilized PEK fusion protein. 0.6 mg lyophilized placebo cake + 0.6 ml placebo-diluent (1:1 ratio)
61982848|NCT02576561|EXPERIMENTAL|TVGV-1 (cohort 2)|Antigen + Adjuvant - 0.9 mg lyophilized PEK fusion protein + 0.9 ml\* GPI- 0100 (1:1 ratio)
61982849|NCT02576561|ACTIVE_COMPARATOR|GPI-0100 (cohort 2)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein. 0.9 mg lyophilized placebo cake + 0.9 ml\* GPI- 0100 (1:1 ratio)
61982850|NCT02576561|PLACEBO_COMPARATOR|Placebo (cohort 2)|Placebo - 0 mg lyophilized PEK fusion protein. 0.9 mg lyophilized placebo cake + 0.9 ml placebo diluent (1:1 ratio)
61982851|NCT02576561|EXPERIMENTAL|TVGV-1 (cohort 3)|Antigen + Adjuvant - 1.2 mg lyophilized PEK fusion protein + 1.2 ml\* GPI- 0100 (1:1 ratio)
61982852|NCT02576561|ACTIVE_COMPARATOR|GPI-0100 (cohort 3)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein + 1.2 mg lyophilized placebo cake 1.2 ml\* GPI- 0100 (1:1 ratio)
61982853|NCT02576561|PLACEBO_COMPARATOR|Placebo (cohort 3)|Placebo - 0 mg lyophilized PEK fusion protein. 1.2 mg lyophilized placebo cake + 1.2 ml placebo-diluent (1:1 ratio)
62362640|NCT03955055|NO_INTERVENTION|Standard of Care Work-up|"In this arm, patients will receive standard of care workup for non-hematemesis gastrointestinal bleeding. This could include upper endoscopy, colonoscopy, and additional capsule or small bowel enteroscopy depending on the subject's presentation and the results of the workup performed by the gastroenterology team. For patients requiring a video capsule endoscopy as part of standard of care workup the patients will be given the same Olympus video capsule that is used in the Early Capsule group."
62362641|NCT05688293|ACTIVE_COMPARATOR|Connective tissue graft|Patients will receive non-surgical periodontal treatment and connective tissue graft using tunneling technique
61982854|NCT02068443|ACTIVE_COMPARATOR|Alogliptin Alone|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride placebo-matching, tablets, orally, 2 tablets after breakfast and 1 tablet after dinner for 24 weeks.
61982855|NCT02068443|EXPERIMENTAL|Alogliptin + Metformin Hydrochloride QD|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 500 mg QD (250 mg x 2 tablets, once daily), tablets, orally, once, daily, after breakfast and 1 metformin hydrochloride placebo-matching, tablet, orally, once, daily, after dinner for 24 weeks.
61982856|NCT02068443|ACTIVE_COMPARATOR|Alogliptin + Metformin Hydrochloride BID|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 250 mg BID (twice daily), tablets, orally, 1 tablet after breakfast and 1 tablet after dinner and 1 metformin hydrochloride placebo-matching, tablet, orally, once, daily, after breakfast for 24 weeks.
62362642|NCT05688293|ACTIVE_COMPARATOR|Free gingival Graft|Patients will receive non-surgical periodontal treatment and partially de-epithelized free gingival graft
61982857|NCT02174055||Cancer Patients|This protocol aims to design, develop and pilot test a psychometric assessment for depression in older cancer patients. The study is divided in three phases. In Phase 1, approximately 15 depressed patients (as determined clinically) and approximately 15 non-depressed patients will undergo individual interviews. In Phase 2, the team will use the themes and subthemes obtained in Phase 1 to write a set of indicators into questionnaire form. In Phase 3, the newly developed questionnaire will be given to a sample of approximately 150 cancer patients who meet the eligibility criteria. Survey results obtained from this sample of 150 patients will be used to assess internal consistency, conduct item analysis, and determine the unique content of the proposed instrument.
61982858|NCT02492620|ACTIVE_COMPARATOR|Ferric Citrate|Ferric citrate (FC) will be supplied as tablets containing 210mg of ferric iron (as 1g ferric citrate) to those subjects randomized to FC. These participants will be initiated on study drug with a fixed dose of FC beginning with 2 tablet per meal.
61982859|NCT02492620|NO_INTERVENTION|Standard of Care (SOC)|Participants may receive open-label, non-FC phosphate binders at the discretion of their treating physician. During the Dialysis Period, dose of phosphate binders, use of ESA, intravenous iron and blood transfusions will be at the discretion of the primary treating nephrologist. Participants assigned to the SOC treatment arm may not receive FC at any point during the study.
61982860|NCT01802528||Obturator externus muscle injection|patients were treated with obturator externus injection
61982861|NCT03307720|ACTIVE_COMPARATOR|Poor responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.~Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment."
61982862|NCT03307720|EXPERIMENTAL|Poor responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)~Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment."
61982863|NCT03307720|ACTIVE_COMPARATOR|Normo responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.~Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment."
61982864|NCT03307720|EXPERIMENTAL|Normo responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)~Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment."
61982865|NCT03307720|ACTIVE_COMPARATOR|High responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.~Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment."
61982866|NCT03307720|EXPERIMENTAL|High responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)~Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment."
61982867|NCT02711046|EXPERIMENTAL|single stage nasolabial flap|single staged nasolabial flap as an interpositional material after surgical resection of fibrous band in oral submucous fibrosis
61982868|NCT05750355|EXPERIMENTAL|TPN171H|Subjects will receive TPN171H orally for single dose
62362643|NCT05688293|ACTIVE_COMPARATOR|Non surgical procedure|Patients will receive non-surgical periodontal treatment only
62362644|NCT04816045|ACTIVE_COMPARATOR|Intervention|Electrochemotherapy with bleomycin
62362645|NCT04816045|ACTIVE_COMPARATOR|Control|Electroporation with saline
62362646|NCT04085042|NO_INTERVENTION|Usual Care|Usual care during peripheral venous catheterization. Nurses will continue with the normal routine practice, by preparing all needed material individually.
62362647|NCT04085042|EXPERIMENTAL|PIVC pack|Nurses will use a sterile pack that includes all needed devices for peripheral intravenous catheterization according to the latest evidence (eg, cannula, swabs, disposable tourniquet, antiseptic).
62362648|NCT02314598||No treatment|
62362649|NCT01117025|ACTIVE_COMPARATOR|Circumferential PVI|
61982869|NCT05750355|PLACEBO_COMPARATOR|Placebo|Subjects will receive Placebo orally for single dose
61982870|NCT01002469|EXPERIMENTAL|sodium [1-13C] acetate|
61982871|NCT00856895||Hispanic|
62362650|NCT01117025|ACTIVE_COMPARATOR|Circumferential PVI+renal denervation|
62362651|NCT04107428|ACTIVE_COMPARATOR|Somatostatin|
62362652|NCT04107428|PLACEBO_COMPARATOR|Placebo|
62362653|NCT03487315|EXPERIMENTAL|specific IgE|Different level of specific IgE and immunoblot
62362654|NCT02944513|EXPERIMENTAL|Experimental|Subjects will receive the Quell device
62362655|NCT02944513|NO_INTERVENTION|Control|Subjects will not receive the Quell device
62362656|NCT00371540|NO_INTERVENTION|I|Routine care in the clinic
62362657|NCT00371540|EXPERIMENTAL|II|Follow-up in clinic every 3 months, home visits monthly
61982872|NCT00856895||Non-Hispanic|
61982873|NCT01328821|PLACEBO_COMPARATOR|Part A|"Single ascending dose administration of four doses of CTP-499 as tablets under fasting condition.~8 subjects per dose group will be enrolled with a 3:1 randomization of active drug to placebo.~Dose levels: 600mg -\> 1200mg -\> 1800mg -\> 2400mg"
61982874|NCT01328821|ACTIVE_COMPARATOR|Part B|Part B will consist of a single 400 mg dose of an immediate release capsule of CTP-499 administered under fasting conditions. In Part B 6 subjects will be enrolled.
61982875|NCT04016376|EXPERIMENTAL|PVB|Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
61982876|NCT04016376|EXPERIMENTAL|PVB + PECS-1|"Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.~For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor."
61982877|NCT04016376|EXPERIMENTAL|Serratus + PECS-1|"For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor.~For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior."
61982878|NCT01382446|ACTIVE_COMPARATOR|Standard Oral Care Regimen|Current oral care protocol includes the use of 1.5% H2O2-coated swabs every four hours, toothbrushing with toothpaste every 12 hours, and use of continuous subglottic suction apparatus.
61982879|NCT01382446|EXPERIMENTAL|Chlorhexidine Oral Care Regimen|This study will compare our current oral care practice with the use of Chlorhexidine Gluconate 0.12% (Peridex, 3M Corporation) Twice daily in addition to regularly scheduled oral care as a means to decrease the incidence of VAP utilizing evidence-based strategies.
61982880|NCT04171973|OTHER|Driving an electric wheelchair in real condition|In order to be able to evaluate the feasibility of virtual reality driving training, the driving performance will be evaluated on the same 3 standardized circuits: for the control group, 3 circuits of test of pipes in real condition of increasing difficulty are tested. Patients perform 2 passes in this condition.
61982881|NCT04171973|EXPERIMENTAL|Driving an electric wheelchair in virtual condition|In order to be able to evaluate the feasibility of driving training in virtual reality, the driving performance will be evaluated on the same 3 standardized circuits: for the virtual reality group, the circuits have been digitized. Patients perform 2 passes in this condition.
61982882|NCT04698031|EXPERIMENTAL|Clopidogrel|"After randomization, patients will receive clopidogrel mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking pills (using a dummy pill) with Arm 2 to ensure the double-blind nature of the intervention. Clopidogrel is FDA approved for secondary prevention of stroke. Patients will be followed for 24 months with repeat brain MRI scans obtained at 24 months."
61982883|NCT04698031|EXPERIMENTAL|Aspirin|"After randomization, patients will receive aspirin daily for the duration of the study. The VA Research Pharmacy will dispense similar looking pills (using a dummy pill) with Arm 1 to ensure the double-blind nature of the intervention. Aspirin is FDA approved for secondary prevention of stroke. Patients will be followed for 24 months with repeat brain MRI scans obtained at 24 months."
61982884|NCT02084147|EXPERIMENTAL|PET-CT and PET-MRI|Patients undergo PET-CT over approximately 30 minutes and PET-MRI over approximately 45-90 minutes.
61982885|NCT00641862|ACTIVE_COMPARATOR|Vitamin B12|Vitamin B12
61982886|NCT00641862|PLACEBO_COMPARATOR|Placebo|Placebo
61982887|NCT06160973|ACTIVE_COMPARATOR|Feed the household; Dedicated driver|Medically tailored meals will be provided for the enrolled individual, with additional meals provided as needed for others living the same household; Medically tailored meals will be delivered each week by a driver who is an employee of Community Servings
61982888|NCT06160973|ACTIVE_COMPARATOR|Feed the individual; Dedicated driver|Medically tailored meals will be provided for the enrolled individual; Medically tailored meals will be delivered each week by a driver who is an employee of Community Servings
61982889|NCT06160973|ACTIVE_COMPARATOR|Feed the individual; Commercial shipper|Medically tailored meals will be provided for the enrolled individual; Meals will be delivered by a commercial shipping organization
61982890|NCT06160973|ACTIVE_COMPARATOR|Feed the household; Commercial shipper|Medically tailored meals will be provided for the enrolled individual, with additional meals provided as needed for others living the same household; Meals will be delivered by a commercial shipping organization
61982891|NCT03558243|ACTIVE_COMPARATOR|Patent Hemostasis Arm|The TR Band (Terumo medical) will be placed on the sheath entry site, the air bladder of the TR Band will be filled with 18 mL of air to achieve initial hemostasis. The sheath will be removed, air will be withdrawn slowly until a pulsatile bleeding is observed through the sheath's orifice, once this phenomenon occurs, 2 ml of air will be added to the air bladder and the absence of bleeding will be corroborated, immediately afterwards a pulse oximeter will be placed on the index finger of the patient and transient manual compression of the ipsilateral ulnar artery will be performed, patency of the radial artery will be corroborated by means of oxygen saturation and adequate pulse curve (Barbeau reverse test), if it is not possible to achieve patent hemostasis, it will be retried deflating 1-2 ml of the TR Band every 15 minutes until a positive reverse Barbeau test with absence of bleeding is achieved. TR Band removal will be attempted 2 hours after the procedure.
62362658|NCT01659359|EXPERIMENTAL|virtual reality glasses and Lidocaine|virtual reality glasses and 5 ml Lidocaine 2%
62362659|NCT01659359|EXPERIMENTAL|Lidocaine|5 cc Lidocaine2%
62567113|NCT03855657||Inflammatory Bowel Disease Patient|Patient with confirmed diagnosis of Inflammatory Bowel Disease
61982892|NCT03558243|EXPERIMENTAL|ULTRA Arm|The TR Band will be placed at the sheath entry site, the ipsilateral ulnar artery will be compressed at the Guyon's canal by placing a cylindrical composite made by wrapping 4 inch x 4 inch gauze around a 1-inch plastic needle cap, and compressing it using a circumferentially applied Hemoband. After occlusive compression of ulnar artery is confirmed by means of plethysmography, patent hemostasis protocol will be used for radial artery hemostasis as described at the patent hemostasis arm. The needle cap and hemoband that compresses the ulnar artery will be removed 1 hour after the procedure. TR Band removal will be attempted 2 hours after the procedure.
61982893|NCT03558243|EXPERIMENTAL|Hemostatic Disc Arm|The StatSeal hemostatic disc will be placed above sheath entry site, the TR Band will be placed above the disc, according to the manufacturer's specifications the air bladder will be filled with 8 ml of air, the sheath will be then removed, corroborating the absence of bleeding, 20 minutes later 3 ml of air will be removed, 20 minutes after that 5 ml of air will be removed, finally the investigators will try to remove the deflated TR Band 60 minutes after the procedure.
61982894|NCT02127567|EXPERIMENTAL|Online writing tool|Participants will be provided the corresponding CONSORT item(s), key elements from the explanation and elaboration of the CONSORT 2010 and NPT extension along with examples of good reporting
61982895|NCT02127567|OTHER|writing with no specific support.|The control intervention will only consist of the title of the domain and a large text box where the participant will be asked to describe this part of the study for their study protocol. The participant will also have the option to indicate any important or necessary information that is not available in the provided study protocol.
61982896|NCT01465022|ACTIVE_COMPARATOR|Study Arm A|Study Arm A is one of two interventions (Combined estrogen-progestin pill)
61982897|NCT01465022|ACTIVE_COMPARATOR|Study Arm B|Study Arm B is one of two interventions (Progestin-only pill)
62362660|NCT02951897|ACTIVE_COMPARATOR|IA-CTC-High-enhance|IA lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy\&lymphadenectomy plus adjuvant chemotherapy. Postoperative CTC monitoring will be conducted.
62567114|NCT03855657||Healthy control|Controls (non-IBD) will comprise individuals undergoing colonoscopy for polyp or colorectal cancer screening, or investigations of gastrointestinal symptoms, and friends and spouses or partners of patients at Prince of Wales Hospital or Alice Ho Miu Ling Nethersole Hospital, or any individuals who are interested to participate in this study.
61982898|NCT01228357|EXPERIMENTAL|SSRI treated group|SSRI treated group is patients treated with fluoxetine, paroxetine, or sertraline
61982899|NCT01228357|ACTIVE_COMPARATOR|non-SSRI treated group|non-SSRI treated group is patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine
61982900|NCT05461651|SHAM_COMPARATOR|Knee arthroplasty|Knee arthroplasty without addition of antibiotic wash oraz antibitiotic powder to the surgery site
61982901|NCT05461651|ACTIVE_COMPARATOR|Knee arthroplasty + vancomycin|Knee arthroplasty with addition of vancomysin powder to the surgery site
61982902|NCT00171223|EXPERIMENTAL|All Participants With Chronic Myeloid Leukemia|Participants received STI571, capsules or tablets, orally, once a day at a dose of 400 mg. During the Core Phase of the study, participants received STI571 daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase of the study, and they continued STI571 for as long as the therapy was beneficial or until death, intolerable toxicity or the decision to discontinue by the investigator, whichever came first. (Maximum duration on study was approximately 14 years).
61982903|NCT04751825|EXPERIMENTAL|I-EAET|Internet administrated Emotional and Awareness and Expression Therapy (I-EAET). 10 weeks. Self-help treatment with therapist contact via text messages at least once a week.
61982904|NCT04751825|NO_INTERVENTION|WL|Wait-list.
61982905|NCT03287804|EXPERIMENTAL|AUTO2|Relapsed or refractory Myeloma patients
61982906|NCT03101137|ACTIVE_COMPARATOR|Caudal block with dexmedetomedine|Caudal Dexmedetomidine block group (DEXM) (n= 16) will receive caudal block using the bupivacaine 0.25% and Dexmedetomidine 1 μg/kg with the conventional general anesthesia,
61982907|NCT03101137|ACTIVE_COMPARATOR|Caudal block with dexamethasone|caudal Dexamethasone Block group (DEXA) (n =16) will receive caudal block using the bupivacaine 0.25% and Dexamethasone 0.1 mg/kg with the conventional general anesthesia,
61982908|NCT03101137|PLACEBO_COMPARATOR|Control (caudal block with bupivacaine)|caudal with bubivacaine (CONTROL) group (n = 16) will receive caudal block using the bupivacaine 0.25% and general anesthesia.
61982909|NCT04846790|NO_INTERVENTION|Control|The control group will complete the first three assessments similar to the two treatment groups but will not participate in the nature-based or virtual mindfulness interventions. At the end of their study participation (\~week 3), they will be offered the opportunity to partake in the nature-based and virtual mindfulness interventions.
61982910|NCT04846790|ACTIVE_COMPARATOR|Nature Only|The nature-based intervention is three days long, is offered at various locations throughout the United States, and includes activities such as hiking, mountain-biking, and kayaking. The healthcare workers can participate in the programs that are offered locally pending availability. Each program will enroll between 15 and 30 healthcare workers. All First Descents nature-based interventions have been intentionally designed with input from more than 450 hospital partners nationwide to improve psychosocial health, nurture supportive peer relationships, and better position healthcare workers to carry out their critical mission. There is no cost to attend, and meals and lodging are included. Special precautions against SARS-CoV-2 transmission are implemented.
61982911|NCT04846790|EXPERIMENTAL|Nature+Mindfulness|In the combined nature-based and virtual mindfulness intervention, participants will complete the nature intervention followed by the mindfulness intervention. The virtual mindfulness intervention is 10 days long and offered online. Each day the participant will receive a notification that a new mindfulness audio is ready for viewing, which is from 10 to 25 minutes long. Mindfulness exercises include mindful breathing, body scan, and loving-kindness meditation. Participants can view the daily audio as many times as they wish but cannot view the next day's content to maintain treatment fidelity. At the end of each day, participants will be asked to indicate if they viewed the mindfulness audio to track adherence.
61982912|NCT02747706|EXPERIMENTAL|Parent Mentoring|1-on-1, phone, SMS/text, and smartphone-based parent-to-parent mentoring.
61982913|NCT02747706|NO_INTERVENTION|Usual Care|No intervention through study.
61982914|NCT03533452|ACTIVE_COMPARATOR|PRE-GA|10 mL of 0.5% ropivacaine injection before the start of surgery and 10 ml of normal saline (0.9%) injection at the end of surgery through the interscalene catheter
61982915|NCT03533452|SHAM_COMPARATOR|POST-GA|10 ml of normal saline (0.9%) injection before the start of surgery and 0.5% ropivacaine injection at the end of surgery through the interscalene catheter
61982916|NCT02074995|EXPERIMENTAL|BVS857 Grp 1A open label|0.03 mg/kg of BVS857intravenously in open label manner
61982917|NCT02074995|EXPERIMENTAL|BVS857 Group 1B/1C, 2, 3, 4 Double Blind|
61982918|NCT02074995|PLACEBO_COMPARATOR|Placebo Group 1B/1C, 2, 3, 4|
61982919|NCT03238404|EXPERIMENTAL|NAC group|Patients will receive neoadjuvant chemotherapy (NAC) before the gastrectomy and ERAS.
61982920|NCT03238404|ACTIVE_COMPARATOR|Surgery alone group|Patients will not receive NAC before the gastrectomy and ERAS.
61982921|NCT01340144||PFC Sigma PS TKA|one group received primary TKA using the PFC Sigma PS TKA
61982922|NCT01340144||PFC Sigma HP PS TKA|One group received primary TKA using the PFC Sigma HP PS TKA.
61982923|NCT05339503|EXPERIMENTAL|GROUP A (HYDROCHLORIC ACID)|Total 30 teeth in each group were included. Preoperatively shade was checked with VITA classical A1-D4® shade guide. The mixture (hydrochloric acid pumice compound) was applied 10 times or more during the same session. Total treatment time was around 30 minutes. Every patient received entire microabrasion treatment. At the end of the treatment, neutral sodium fluoride gel was applied. Then change in shade was checked again with VITA classical A1-D4® shade guide.
61982924|NCT05339503|EXPERIMENTAL|GROUP B ( SODIUM HYPOCHLORITE)|"Total 30 teeth in each group were included. Preoperatively shade was checked with VITA classical A1-D4® shade guide.The mixture (sodium hypochlorite pumice compound) was applied 10 times or more during the same session. Total treatment time was around 30 minutes. Every patient received entire microabrasion treatment. At the end of the treatment, neutral sodium fluoride gel was applied. Then change in shade was checked again with VITA classical A1-D4® shade guide.~."
61982925|NCT02758015|ACTIVE_COMPARATOR|Standardized Meal|Standardized meal given to patients.
61982926|NCT02758015|EXPERIMENTAL|Beatine PO (by mouth) 1500mg|Betaine (natural supplement)
61982927|NCT02758015|EXPERIMENTAL|Betaine PO (by mouth) 3000mg|Betaine (natural supplement)
61982928|NCT02758015|EXPERIMENTAL|Betaine PO (by mouth) 4500mg|Betaine (natural supplement)
61982929|NCT02794662|EXPERIMENTAL|Oxygen Environment|Blended oxygen delivered by servo-controlled incubator
61982930|NCT02794662|ACTIVE_COMPARATOR|Nasal cannula oxygen|Blended oxygen delivered by nasal cannula
61982931|NCT00878007|EXPERIMENTAL|1|"Intermittent screening and treatment (IST) for malaria.~This intervention is a change from a previous intervention based on intermittent preventive treatment for malaria owning to the withdrawal of amodiaquine (one of the previous IPT drugs) in Kenya in 2009."
61982932|NCT00878007|EXPERIMENTAL|2|Enhanced teacher training on literacy instruction.
61982933|NCT00878007|EXPERIMENTAL|3|Intermittent screening and treatment (IST) for malaria and enhanced teacher training on literacy instruction
61982934|NCT00878007|NO_INTERVENTION|4|
61982935|NCT03318250|ACTIVE_COMPARATOR|Burst3D|"This is a device progamme setting which is being compared against DR6-LF.~Intervention for this arm is the dorsal root ganglion neurostimulation device implant which will occur at trial implant. Once device is implanted participants are assigned progammes in a randomized manner."
61982936|NCT03318250|ACTIVE_COMPARATOR|DRG-LF|"This is a device progamme setting which is being compared against Burst3D.~Intervention for this arm is the dorsal root ganglion neurostimulation device implant which will occur at trial implant.Once device is implanted participants are assigned progammes in a randomized manner."
61982937|NCT02306629|EXPERIMENTAL|Epratuzumab dose 1 sc|This group of Caucasian and Japanese subjects will receive one single dose 1 of epratuzumab subcutaneous
61982938|NCT02306629|EXPERIMENTAL|Epratuzumab dose 2 sc|This group of Caucasian and Japanese subjects will receive one single dose 2 of epratuzumab subcutaneous
61982939|NCT02306629|EXPERIMENTAL|Epratuzumab dose 3 sc|This group of Caucasian subjects will receive one single dose 3 of epratuzumab subcutaneous
61982940|NCT02306629|ACTIVE_COMPARATOR|Epratuzumab dose 2 iv|This group of Caucasian and Japanese subjects will receive one single dose 2 of epratuzumab as an intra venous infusion
61982941|NCT05352893|EXPERIMENTAL|IV high dose Imsidolimab, other name ANB019|ANB019 Biological Humanized Monoclonal Antibody High Dose
61982942|NCT05352893|EXPERIMENTAL|IV low dose Imsidolimab, other name ANB019|ANB019 Biological Humanized Monoclonal Antibody Low Dose
61982943|NCT05352893|PLACEBO_COMPARATOR|IV Placebo|Placebo Solution
62169342|NCT03058237|EXPERIMENTAL|Part 2: Regimen J|One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions, or a previously dosed MR prototype in the fed state. Part 2 participants receive Regimens F, G, H, I and J in a sequential manner.
61982944|NCT01218191||Subarachnoid hemorrhage|Patients presenting a SAH
61982945|NCT03885713|ACTIVE_COMPARATOR|Patients with treatment|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice, or adalimumab (Subcutaneus 40 mg milligram(s)) per clinical practice, or golimumab (subcutaneus 50 mg milligram(s)) per clinical practice, or vedolizumab (infusion 300 mg milligram(s)) per clinical practice or ustekinumab (subcutaneous 90 mg milligram(s)) per clinical practice or tofacitinib (oral 5mg bid oral) per clinical practice
61982946|NCT03885713|NO_INTERVENTION|healthy control|Patients without treatment
61982947|NCT02429518||Miltefosine|Miltefosine: target of 2.5 mg/kg/day for 28 days
61982948|NCT00336713|EXPERIMENTAL|Saredutant 100 mg|Saredutant 100 mg once daily in the morning for a maximum of 64 weeks
61982949|NCT00336713|PLACEBO_COMPARATOR|Placebo|Placebo for Saredutant once daily in the morning during the maintenance phase for a maximum of 52 weeks
61982950|NCT02208856|PLACEBO_COMPARATOR|Placebo|
61982951|NCT02208856|EXPERIMENTAL|BIBR 796 BS food effect|
61982952|NCT02208856|EXPERIMENTAL|BIBR 796 BS|
61982953|NCT00311623|ACTIVE_COMPARATOR|Control group|"Men \>18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.~Receive no intervention on Days 1-14. Surgery performed on Day 15."
62362661|NCT02951897|PLACEBO_COMPARATOR|IA-CTC-High-controls|IA lung adenocarcinoma cases with high abundant CTCs prior to operation will only undergo lobectomy\&lymphadenectomy. Postoperative CTC monitoring will be conducted.
61982954|NCT00311623|EXPERIMENTAL|Low-dose Rapamycin (3mg)|"Men \>18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.~Must have adequate hepatic, renal and bone marrow function, no allergy to rapamycins, avoid medications interfering with rapamycin metabolism, no active infection, no prior therapies for prostate cancer.~Will receive rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) oral (PO) once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15)."
61982955|NCT00311623|EXPERIMENTAL|High-dose Rapamycin (6mg)|"Men \>18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.~Must have adequate hepatic, renal and bone marrow function, no allergy to rapamycins, avoid medications interfering with rapamycin metabolism, no active infection, no prior therapies for prostate cancer.~Will receive rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) oral (PO) once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15)."
61982956|NCT00847457|EXPERIMENTAL|Aerobic exercise|Participants will perform aerobic exercise regularly for 12 weeks.
62169343|NCT03058237|EXPERIMENTAL|Part 3: Regimen K|"One low dose selected Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 2) taken under fasting conditions.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
61982957|NCT00847457|ACTIVE_COMPARATOR|Stretch|Participants will stretch regularly for 12 weeks.
61982958|NCT01748981|OTHER|Physical training|Exercise intervention.
61982959|NCT01748981|OTHER|As usual|Controls
61982960|NCT04171687|ACTIVE_COMPARATOR|Clopidogrel 75 mg|Oral administration of clopidogrel 75 mg tablet once daily for 7 days
61982961|NCT04171687|EXPERIMENTAL|Clopidogrel 75 mg + Tegoprazan 50 mg|Oral administration of clopidogrel 75 mg tablet and Tegoprazan 50mg tablet once daily for 7 days
62362662|NCT02951897|PLACEBO_COMPARATOR|IA-CTC-low-controls|IA lung adenocarcinoma cases with low abundant CTCs prior to operation will only undergo segmentectomy. Postoperative CTC monitoring will be conducted.
62362663|NCT02951897|ACTIVE_COMPARATOR|IB-CTC-High-enhance|IB lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy\&lymphadenectomy plus adjuvant chemotherapy. Postoperative CTC monitoring will be conducted.
62362664|NCT02951897|PLACEBO_COMPARATOR|IB-CTC-High-controls|IB lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy\&lymphadenectomy. Postoperative CTC monitoring will be conducted.
62362665|NCT02951897|PLACEBO_COMPARATOR|IB-CTC-low-controls|IB lung adenocarcinoma cases with low abundant CTCs prior to operation will undergo lobectomy\&lymphadenectomy. Postoperative CTC monitoring will be conducted.
62362666|NCT02732249|ACTIVE_COMPARATOR|Triple regimen group|Esomeprazole 20mg bid, clarithromycin 500mg bid and metronidazole 400mg qid for 14 days
61982962|NCT04171687|EXPERIMENTAL|Clopidogrel 75 mg + RAPA113|Oral administration of clopidogrel 75 mg tablet and RAPA113 tablet once daily for 7 days
61982963|NCT02167607|ACTIVE_COMPARATOR|Purple Potato|Active Comparator
61982964|NCT02167607|PLACEBO_COMPARATOR|White Potato|Placebo Comparator
61982965|NCT00894322|EXPERIMENTAL|Cohort 1: Healthy Participants|A single 10-mg dose of exenatide once weekly suspension given to healthy participants via 3 subcutaneous (SC) injections at Day 1.
61982966|NCT00894322|EXPERIMENTAL|Cohort 2: Diabetes Participants|On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, thiazolidinedione (TZD), or a combination of metformin or TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks.
61982967|NCT00894322|PLACEBO_COMPARATOR|Cohort 2: Diabetes Participants Placebo|On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, thiazolidinedione (TZD), or a combination of metformin or TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks.
61982968|NCT01275833|EXPERIMENTAL|Device programming modifies AV timing|DDD-40-BiV
61982969|NCT01275833|NO_INTERVENTION|Device programming allows intrinsic AV timing.|VVI-40-RV
61982970|NCT01266460|EXPERIMENTAL|Treatment (ADXS11-001)|Patients receive live-attenuated Listeria monocytogenes cancer vaccine ADXS11-001 IV over 30 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61982971|NCT03160534|EXPERIMENTAL|Intervention|Preoperative exercise intervention
61982972|NCT03160534|NO_INTERVENTION|Control|Only measurements
61982973|NCT02937779|EXPERIMENTAL|HBs Ag positive|"tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for positive Hbe Ag women.~No treatment for negative HBe Ag women"
61982974|NCT00002670|ACTIVE_COMPARATOR|Radiation therapy|Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week)
61982975|NCT00002670|EXPERIMENTAL|Radiation therapy plus cisplatin|Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week) plus Cisplatin-100 mg/m2 i.v. on days 1,22 and 43 with radiation therapy.
61982976|NCT06288412|EXPERIMENTAL|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin degludec once daily in the run-in period and insulin icodec once weekly in the treatment period.
62362667|NCT02732249|EXPERIMENTAL|Low metronidazole group|Esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, clarithromycin 500mg bid and metronidazole 400mg bid for 14 days
61982977|NCT00644280|ACTIVE_COMPARATOR|Ranibizumab|Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at 3 time points: 9 days before Ahmed tube insertion for open-angle glaucoma, 1 month post-surgery, and 2 months post-surgery
61982978|NCT00644280|NO_INTERVENTION|Usual care|Standard of care Ahmed tube insertion for open-angle glaucoma without injections of Ranibizumab
61982979|NCT05494450|OTHER|ExufiberAG+02|using ExufiberAG as the primary dressing on medium to high exuding chronic wounds.
62362668|NCT02732249|EXPERIMENTAL|High metronidazole group|Esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, clarithromycin 500mg bid and metronidazole 400mg qid for 14 days
62362669|NCT04581798||OSA|Patients with OSA confirmed by polysomnography, aged 35-65
62362670|NCT04581798||Non-OSA|Patients without OSA aged 35-65
61982980|NCT00637507|NO_INTERVENTION|2|Patients treated solely with a pressure- and volume-limited ventilatory strategy (target plateau pressure of 30 cm H2O) aimed at minimizing lung stress and strain, and thus, ventilator-induced lung injury.
61982981|NCT00637507|EXPERIMENTAL|1|Intermittent application of High-frequency Oscillation (HFO) and Tracheal Gas Insufflation (TGI) according to pre-specified criteria described in the Detailed Description. HFO-TGI sessions are interspersed with lung protective conventional mechanical ventilation until the PaO2/FiO2 ratio stabilizes at \>150 mm Hg.
61982982|NCT01782261|EXPERIMENTAL|Liraglutide|Liraglutide subcutaneous injection every day. first week 0.6mg, week 2-4 1.2mg.
61982983|NCT01782261|ACTIVE_COMPARATOR|Saxagliptin|Saxagliptin 5mg tablet by mouth every day for 4 weeks
61982984|NCT02246673|EXPERIMENTAL|RDEA3170 10 mg|Once daily (qd) with febuxostat 40mg (qd) for 7 days, and with febuxostat 80 mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
61982985|NCT02246673|EXPERIMENTAL|RDEA3170 15 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
61982986|NCT02246673|EXPERIMENTAL|RDEA3170 5 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
61982987|NCT02246673|EXPERIMENTAL|RDEA3170 2.5 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
61982988|NCT05271955|EXPERIMENTAL|Experimental|Children receiving the usual care plus intensive use of e-GOLIAH (experimental group)
61982989|NCT05271955|ACTIVE_COMPARATOR|Control|Children receiving only the usual treatment (control group).
61982990|NCT05194618|EXPERIMENTAL|Valerian/Lavender arm|Participants in this arm will receive actives products : 420 mg per tablet of Valerian root extract and 40 mg per tablet of essential oil of Lavender
61982991|NCT05194618|PLACEBO_COMPARATOR|Placebo arm|Participants in this arm will receive placebo (no active product)
61982992|NCT05383560|EXPERIMENTAL|mRNA-1273.214 + mRNA-1273.214|Fourth \& Fifth doses of an investigational mRNA vaccine, 56 days apart N ≈ 60 Under protocol versions 1.01-1.06
61982993|NCT05383560|EXPERIMENTAL|mRNA-1273.214 + Placebo|Fourth dose of an investigational mRNA vaccine followed by a fifth dose of placebo, 56 days apart N ≈ 60 Under protocol versions 1.01-1.06
61982994|NCT05383560|ACTIVE_COMPARATOR|mRNA-1273 + Placebo|Fourth dose of the commercial mRNA vaccine, followed by a fifth dose of placebo, 56 days apart N ≈ 30 Under protocol versions 1.01-1.06
61982995|NCT05383560|EXPERIMENTAL|mRNA-1273.214|A booster dose of an investigational mRNA vaccine at Visit 1 (Day 1). N ≈ 30 Under protocol versions 1.07
61982996|NCT05383560|ACTIVE_COMPARATOR|mRNA-1273.222|A booster dose of the commercial mRNA vaccine at Visit 1 (Day 1). N ≈ 30 Under protocol versions 1.07
61982997|NCT04208594|ACTIVE_COMPARATOR|GROUP (P):|will receive oral propranolol (INDERAL® -propranolol hydrochloride Ph. Eur. 10mg manufactured by AstraZeneca Egypt under license of AstraZeneca UK), 10 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 10 mg tablet one hour before the induction of anesthesia.
61982998|NCT04208594|EXPERIMENTAL|GROUP (I):|will receive oral ivabradine (Procoralan® 5mg manufactured by Servier laboratories, France), 5 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 5 mg tablet one hour before the induction of anesthesia.
61982999|NCT03326973||online or telephone survey|This is a cross-sectional survey. Our main method of communication with patients will be email. Participants will complete a single online or telephone survey at a minimum of 12 months post initial treatment of checkpoint inhibitors and remain on maintenance therapy.
61983000|NCT06120621|ACTIVE_COMPARATOR|Arm 1|Visco-Circumferential-Suture-Trabeculotomy followed by Phacoemulsification
62362671|NCT02693691|EXPERIMENTAL|CardioMEMS HF System|Subjects will collect pulmonary artery pressure measurements daily which will be used by health care professionals to adjust cardiac medications.
62362672|NCT05825989|EXPERIMENTAL|Healthy Beat Acupunch Regimen|The intervention group will receive the instructor-led HBA regimen 3 times/week for first 6 months, followed by the DVD-led HBA regimen for another 6 months.
62362673|NCT05825989|NO_INTERVENTION|Control group|The control group will continue their daily activities.
61983001|NCT06120621|ACTIVE_COMPARATOR|Arm 2|phacoemulsification alone
61983002|NCT01537510|ACTIVE_COMPARATOR|Usual Care|
61983003|NCT01537510|EXPERIMENTAL|Clinician intervention only|This arm will entail the development and deployment of alerts and access to a SmartSet at the time of a well child visit with a child between the ages of 6-12 years with a BMI ≥ 95th percentile.
62362674|NCT02839811|EXPERIMENTAL|immediate hypersensitivity to BLC|immediate hypersensitivity to BLC by In vitro diagnosis
62362675|NCT00513994|ACTIVE_COMPARATOR|1|
62362676|NCT03345992|PLACEBO_COMPARATOR|Placebo|After enrollment, the placebo arm will receive water for injection at a volume of 20ml diluted to a final volume of 250 ml dextrose in water 5%, infused once daily through intravenous route, within 1 hour, for a duration of four consecutive days.
61983004|NCT01537510|EXPERIMENTAL|Clinician intervention plus Direct-to-parent communication|Parents of children enrolled in this intervention arm will receive mailings, text messages and a series of 4 calls with a health coach to encourage behavior change in addition to the intervention received by the clinicians.
61983005|NCT02063490|EXPERIMENTAL|Adherence support|"One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)~+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions"
61983006|NCT02063490|NO_INTERVENTION|Control arm|Standard care
61983007|NCT05217420|EXPERIMENTAL|Moving Well|Participants will receive weekly calls for 12 weeks (7 weeks before total knee arthroplasty surgery and 5 weeks after surgery) from a peer coach, an exercise program, and mental preparation (through positive thinking) for surgery. Participants will also receive the standard of care for patients undergoing total knee arthroplasty.
61983008|NCT05217420|ACTIVE_COMPARATOR|Staying Well|Participants will receive weekly calls for 12 weeks (7 weeks before total knee arthroplasty surgery and 5 weeks after surgery) from a research assistant. The calls will be similar in length to those in the experimental arm and will cover various health topics not related to total knee arthroplasty. Participants will also receive the standard of care for patients undergoing total knee arthroplasty.
61983009|NCT05754515||target controlled infusion (TCI) group|Propofol and remifentanil will be used in TCI anesthesia, and while the patient is under adequate sedation (BIS40-60), muscle relaxation will be provided with 0.6 mg/kg rocurium bromide. While applying TCI anesthesia, the device will use the Minto model for Remifentanil infusion and the Schnider model for Propofol infusion.
61983010|NCT05754515||inhalation anesthesia (IA) groups|During anesthesia induction of patients receiving inhalation anesthesia, 60 mg 2% lidocaine, 2 mg/kg propofol, 0.6 mg/kg rocuronium bromide and 1 mcg/kg fentanyl will be used. Desflurane will be used with a minimum alveolar concentration of 1 and for additional intraoperative sedation. remifentanil will be given between 0.05 and 0.2mcg/kg/min according to the patient's needs.
62567115|NCT03855657||Healthy relatives of Inflammatory Bowel Disease patient|Relatives or household members of both patients with IBD or other diseases and controls will be recruited.
61983011|NCT06099977|EXPERIMENTAL|I (Binaural)|Binaural sound using headphone will be applied.
61983012|NCT06099977|PLACEBO_COMPARATOR|II (Placebo)|Only headphone without sound will be applied.
61983013|NCT02024867|ACTIVE_COMPARATOR|10 days of Trimethoprim-Sulfamethoxazole|Oral Trimethoprim-Sulfamethoxazole dosed at 10 mg Trimethoprim/kg/day divided twice a day, to a maximum of 640 mg Trimethoprim/day
61983014|NCT02024867|EXPERIMENTAL|3 days of Trimethoprim-Sulfamethoxazole|Oral Trimethoprim-Sulfamethoxazole dosed at 10 mg Trimethoprim/kg/day divided twice a day, to a maximum of 640 mg Trimethoprim/day
61983015|NCT05389345|EXPERIMENTAL|Actual tDCs + ET|All interventions will involve 4 weeks of group intervention consisting of two 1-hour group sessions per week and additional practice between sessions. Half of study participants will be randomized to receive 30 minutes of transcranial direct current stimulation (tDCS) prior to beginning each ET session. ET session will begin immediately after tDCS.
61983016|NCT05389345|SHAM_COMPARATOR|Sham tDCs + ET|All interventions will involve 4 weeks of group intervention consisting of two 1-hour group sessions per week and additional practice between sessions. Half of study participants will be randomized to receive 30 minutes of sham transcranial direct current stimulation (tDCS) prior to beginning each ET session. ET session will begin immediately after tDCS. During the sham tDCS, the procedures will be exactly the same as the real tDCS (e.g., application of electrodes), however, no stimulation will be provided when the device turned on.
61983017|NCT00339937||Cases|Adults in Italy with Kaposi's sarcoma
61983018|NCT00339937||Controls|Adults in Italy without Kaposi's sarcoma
61983019|NCT02922907|EXPERIMENTAL|Arabinoxylan Rice Bran|BRM4 two 500mg capsules thrice daily p.o. for 12 weeks
61983020|NCT02922907|PLACEBO_COMPARATOR|Placebo|Placebo for BRM4 two 500mg capsules thrice daily p.o. for 12 weeks
61983021|NCT04999150|ACTIVE_COMPARATOR|Corticotomy|"1. A full-thickness labial mucoperiosteal flap was reflected.~2. Two vertical corticotomies (1 mesial and 1 distal to the canine) were performed . The cortical bone was cut 2 to 3 mm below the alveolar crest towards the apex until bone marrow was exposed.~3. Cortical-cancellous bone grafts (0.5cc; PuraGraft, Kingwood, TX) were placed at the corticotomy sites.~4. The mini-screws were placed.~5. A nickel-titanium (NiTi) closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge (Orthopli Corp., Philadelphia, PA) was used to measure the force (150g)."
61983022|NCT04999150|EXPERIMENTAL|Micro-Osteoperforation|"1. MOPs were performed with a stainless-steel manual drill tip that had 1.6mm diameter with an adjustable depth set to 5mm (Excellerator® RT; Propel Orthodontics, Milpitas, CA).~2. Six perforations were made along 2 parallel vertical lines (each line with 3 holes spaced \~2mm apart) distal to the canine and perpendicular to the buccal cortical bone.~3. The mini-screws were placed.~4. A NiTi closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge was used to measure the force (150g)."
61983023|NCT01675128|EXPERIMENTAL|Phase I Dose Level I|Irinotecan 160 mg/m\^2 every other week; ISIS 183750 started 800 mg/every week will be administered intravenously on Cycle 1 Days 1, 3, 5, 8, 15 and 22 of a 28 day cycle, restaged every 8 weeks.
61983024|NCT01675128|EXPERIMENTAL|Phase I Dose Level II|Irinotecan 180 mg/m\^2 every other week; ISIS 183750 1000 mg/every week will be administered intravenously on Cycle 1 Days 1, 3, 5, 8, 15 and 22 of a 28 day cycle, restaged every 8 weeks.
61983025|NCT01675128|EXPERIMENTAL|Phase II Dose Level I|Irinotecan 160 mg/m\^2 every other week; ISIS 183750 1000mg every week will be administered as an intravenous infusion every week without break, i.e. Days 1, 8, 15 and 22 of a 28-day cycle. Patients will be re-staged every 8 weeks.
61983026|NCT03401983|EXPERIMENTAL|PFMT + AT|Pelvic Floor Muscle Training and Abdominal Training
61983027|NCT03401983|ACTIVE_COMPARATOR|PFMT|Pelvic Floor Muscle Training
61983028|NCT02877082|EXPERIMENTAL|Tacrolimus, bortezomib, thymoglobulin|Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctor's discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.
61983029|NCT03550703|EXPERIMENTAL|Single arm receiving V3-Myoma|A single oral pill of V3-Myoma therapeutic vaccine containing pooled antigens circulating in peripheral blood and within myoma tissues
61983030|NCT03753347|EXPERIMENTAL|influenza vaccine recipients|Participants of an earlier clinical trial (TITRE I) to receive one dose of the 2018-19 quadrivalent inactivated influenza vaccine
61983031|NCT04695925|ACTIVE_COMPARATOR|osimertinib monotherapy|osimertinib 80 mg po qd.
61983032|NCT04695925|EXPERIMENTAL|combination of osimertinib and chemotherapy|osimertinib 80 mg po qd plus pemetrexed 500 mg/m2 and carboplatin area under curve 5 intravenously every 3 weeks for four cycles, followed by maintenance osimertinib and pemetrexed until disease progression
61983033|NCT06021015|EXPERIMENTAL|Experimental group|Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）
61983034|NCT06021015|ACTIVE_COMPARATOR|Control group|Irinotecan and HepaSphere Microspheres
61983035|NCT01593488|EXPERIMENTAL|Intrathecal liposomal cytarabine|
61983036|NCT06245590|EXPERIMENTAL|Albumin + Midodrine|Albumin + Midodrine (5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (\>75 mm and \<90).
61983037|NCT06245590|ACTIVE_COMPARATOR|Midodrine +standard of care|Midodrine alone titrated based on MAP.
61983038|NCT02013648|ACTIVE_COMPARATOR|Standard arm|"Patients will receive induction therapy with daunorubicin 60 mg/m2/day administered on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 12mg²/day on days 1,3,5) and cytarabine 200 mg/m2/day administered by continuous IV infusion on days 1-7.~Patients achieving PR only at the end of cycle 1 will receive a second induction cycle with daunorubicin 50 mg/m2/day (when daunorubicin is not available due to supply shortage: Idarubicin 10 mg²/day on days 1 and 3) administered on days 1-3 and cytarabine 200 mg/m2/day administered by cont. IV infusion daily on days 1-5.~Patients will receive 4 cycles of consolidation therapy. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (\>60 years: 1 g/m2) q12h, days 1-3 administered intravenously over three hours.~Follow-up period: There is no maintenance therapy in the standard arm. Patients will be closely followed, in particular for molecular disease persistence or molecular relapse."
61983039|NCT02013648|EXPERIMENTAL|Investigational arm|"Patients will receive induction therapy with daunorubicin 60 mg/m2/day on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 12mg²/day on days 1,3,5) and cytarabine 200 mg/m2/day by cont. IV infusion on days 1-7. Patients will receive dasatinib 100 mg QD on days 8-21. Patients achieving PR only at the end of cycle 1 will receive a 2nd induction cycle with daunorubicin 50 mg/m2/day on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 10 mg²/day on days 1 and 3) and cytarabine 200 mg/m2/day by cont. IV infusion on days 1-5. Patients will receive dasatinib 100 mg QD on days 6-21.~Consolidation therapy (4 cycles). Treatment consists of high-dose cytarabine 3 g/m2 (\>60 years: 1 g/m2) q12h, days 1-3 iv over 3 hours. Patients will receive dasatinib 100 mg QD on days 4-21. Maintenance therapy: Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
61983040|NCT04525508||Normal glucose tolerance (NGT)|Those of the study population with one normal Oral glucose tolerance test (OGTT)
61983041|NCT04525508||Dysglycemia|Those of the study population with one dysglycemia (IFG and/or IGT)
61983042|NCT04525508||Diabetic OGTT|Those of the study population with one Diabetic OGTT
61983043|NCT01782859|PLACEBO_COMPARATOR|Placebo|Control group
61983044|NCT01782859|ACTIVE_COMPARATOR|Prednisone/hydrocortisone|"Steroid group will receive the following:~1. 20 mg prednisone pill to be taken in the morning of surgery prior to arrival to the hospital~2. 100 mg hydrocortisone IV 8 hours after first dose of prednisone followed by 3. Second and last dose of 100 mg hydrocortisone IV"
61983045|NCT00916747|EXPERIMENTAL|Treatment arm|All patients will receive zoledronic acid, pravastatin and lonafarnib
61983046|NCT00244946|EXPERIMENTAL|Autologous lymphocytes,carmustine,etoposide, melphalan, PBSCT|"* minus Day 8 ADMIT for Hydration~* minus Day 7 Carmustine 300 mg/m2 x 1 dose~* minus Day 6 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~* minus Day 5 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~* minus Day 4 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~* minus Day 3 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~* minus Day 2 Melphalan 140 mg/m2 x 1 dose~* minus Day 1 Day of Rest~* Day 0 Transplant"
61983047|NCT01794806|EXPERIMENTAL|Tooth extraction and grafting|Tooth extraction and grafting with allograft
61983048|NCT01794806|SHAM_COMPARATOR|Tooth extraction|Tooth extraction
61983049|NCT03066674|EXPERIMENTAL|McKenzie group|This group will receive Hand-on technique on the lumbar spine.
61983050|NCT03066674|EXPERIMENTAL|Control group|The Group will not receive Hand-on technique on the lumbar spine.
61983051|NCT03659981|EXPERIMENTAL|MS Patients|Multiple sclerosis patients MRI 7T will be performed
61983052|NCT05647473|EXPERIMENTAL|add-on low dose Astragalus|
61983053|NCT05647473|EXPERIMENTAL|Routine treatment|
61983054|NCT05647473|EXPERIMENTAL|add-on high dose Astragalus|
61983055|NCT00887354|EXPERIMENTAL|Teriparatide|"20 micrograms (mcg) a day by subcutaneous injection throughout study.~Placebo oral tablets once a week, to match the active comparator weekly dose, during the double-blind, double-dummy phase only."
62362677|NCT03345992|ACTIVE_COMPARATOR|Clarithromycin|After enrollment, the active drug arm will receive 1g of clarithromycin (500 mg powder for concentrate for solution for infusion per vial), dissolved into 20 ml water for injection and then diluted to a final volume of 250 ml dextrose in water 5%. This will be infused through intravenous route, once daily within 1 hour, for a duration of four consecutive days.
61983056|NCT00887354|ACTIVE_COMPARATOR|Risedronate|"35 milligrams (mg) risedronate sodium orally once weekly throughout study.~Daily placebo injection, to match the daily experimental drug dose, during the double-blind, double-dummy phase only."
61983057|NCT01374087|EXPERIMENTAL|Brachytherapy + Triptorelin 22.5 mg|Brachytherapy: Low or high dose rate. Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
61983058|NCT01374087|ACTIVE_COMPARATOR|Brachytherapy|Brachytherapy: Low or high dose rate.
61983059|NCT02594839|EXPERIMENTAL|MSCs|2 intravenous infusions of suspension of 200 000 000 MSCs each at interval of 7 days. Infusions will be repeated every 3 months for 1 year.
61983060|NCT02594839|PLACEBO_COMPARATOR|placebo|2 intravenous infusions of 400 mL saline each at interval of 7 days. Infusions will be repeated every 3 months for 1 year.
61983061|NCT01662518|EXPERIMENTAL|DDS-25|Intravitreal injection of DDS-25(Dexamethasone drug delivery system )
61983062|NCT02201706|EXPERIMENTAL|Multi-electrocoagulation retinectomy|Retinal re-detachment in eyes with silicone oil filled,a modified surgery named Multi-electrocoagulation retinectomy will be used to re-attach the retina.
61983063|NCT06443840|NO_INTERVENTION|Control group|Participants will be randomised into a control group, undergoing conventional in-centre rehabilitation.
61983064|NCT06443840|EXPERIMENTAL|Experimental group|The experimental group will have to carry out the programme of self-rehabilitation and tele-rehabilitation with the AutonHome® device in addition to conventional rehabilitation.
61983065|NCT02785107|EXPERIMENTAL|Intervention|Those who were randomized into the intervention group attended a workshop where the PI delivered a presentation that focused on establishing a preparatory exercise habit by using the M-PAC approach and proposed habit model. Participants were then provided with instructions on completing their exercise plan sheet.
62362678|NCT02251171|EXPERIMENTAL|TPV/RTV - Rifabutin|"Day 1: single dose Rifabutin~Days 8-20: morning and evening doses of Tipranavir/Ritonavir~Day 15: single dose Rifabutin"
61983066|NCT02785107|NO_INTERVENTION|Control|Participants exercised on their own without receiving any instructions.
61983067|NCT00452491|EXPERIMENTAL|1|
61983068|NCT00452491|ACTIVE_COMPARATOR|2|
61983069|NCT04599374||high TSH and high FT4|patients with high TSH and high FT4
61983070|NCT04599374||high TSH and low FT4|patients with high TSH and low FT4
61983071|NCT04599374||high TSH and high FT3|patients with high TSH and high FT3
61983072|NCT04599374||high TSH and low FT3|patients with high TSH and low FT3
61983073|NCT05282173|NO_INTERVENTION|Treatment As Usual (TAU)|Monitoring of treatment as usual (i.e., routine interactions between community health workers (CHWs) and their patients).
61983074|NCT05282173|EXPERIMENTAL|Siyakhana CHW Training|The Siyakhana CHW Training is a multi-day group training that aims to reduce stigma around mental health and substance use among CHWs. It integrates psychoeducation around TB/HIV, stigma, depression, and substance use, including countering myths and stereotypes around mental health and substance use; skills for CHW self-care; evidence-based skills for working with patients living with depression and substance use, such as components of motivational interviewing and problem-solving therapy; and exposure to individuals with lived experience of mental health and substance use. The training is a combination of informative presentations, discussions, worksheets/activities, and role-plays aimed at increasing awareness of mental health and substance use, reducing stigma, and improving interactions when working with patients with HIV/TB and mental health and substance use concerns.
61983075|NCT01857349|ACTIVE_COMPARATOR|Chlora Prep|Food and Drug Administration (FDA)-approved, surgical skin preparation solution: ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol; Enturia, El Paso, Texas)
61983076|NCT01857349|ACTIVE_COMPARATOR|Dura Prep|Food and Drug Administration (FDA)-approved, surgical skin preparation solution:DuraPrep (0.7% available iodine and 74% isopropyl alcohol; 3MHealthcare, St. Paul, Minnesota).
61983077|NCT00999583|EXPERIMENTAL|EPO|five injections maximum of 40000 UI EPO
61983078|NCT00999583|ACTIVE_COMPARATOR|Control|Classical take care
61983079|NCT06113432|EXPERIMENTAL|Helmet-CPAP then Mask-CPAP|CPAP via Helmet 40 minutes, then CPAP via full face mask 40 minutes
61983080|NCT06113432|EXPERIMENTAL|Mask-CPAP then Helmet-CPAP|CPAP via full face mask 40 minutes, then CPAP via helmet 40 minutes
61983081|NCT03366376|EXPERIMENTAL|Experimental|WBRT with hippocampus-sparing and SIB
61983082|NCT01620710|OTHER|prostate bed|"irradiation of the prostatic bed only (no higher risk of lymph node recurrence); helical IMRT of the prostate bed (18 x 3 Gy)~This arm has already finished recruitment"
61983083|NCT01620710|OTHER|prostate bed & lymph nodes|irradiation of the prostatic bed and the pelvic lymphatic drainage (in patients with higher risk of lymph node recurrence); helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
61983084|NCT04342845|EXPERIMENTAL|Motivational interviewing|The intervention group received an education program in small groups that included no more than ten members. The content was designed based on MI theory and the theory of patient empowerment. Program content was further informed by the Hospital Authority Patient Empowerment Program in Hong Kong. The education program consisted of four modules, held once a week, that each lasted approximately 1½ to 2 hours. They were grouped under the following four broad headings: Knowing Diabetes, Diabetes Self-Care, Healthy Diet and Physical Exercise. Each module started with a brief introduction to relevant background knowledge, which was followed by small-group discussions about personal barriers and techniques for overcoming challenges. During the small group discussions, educators acted as MI facilitators, using group MI techniques to strengthen participants' motivation.
61983085|NCT04342845|PLACEBO_COMPARATOR|Traditional lectures|The control group received traditional lectures that consisted solely of conveying healthcare information to patients. In order to minimize intervention bias, the control group lectures were standardized and adapted into four modules, namely knowing diabetes, healthy diet, physical exercises, and how to use medication correctly, which were similar topic headings, durations and frequencies to those of the intervention group. Each lecture was 1 hour and was provided by one of four health professionals (a pharmacist, dietician, endocrinologist or nurse) who had never received any prior training in MI.
61983086|NCT00841087|EXPERIMENTAL|SIBA|
62739216|NCT05504187|EXPERIMENTAL|Part 1: Dose Optimization Cohort 1, Dose 1|Participants will be administered with KP104 as a weekly maintenance dose for 24 Weeks. After the last participant completes 6 weeks of treatment, all available data, including safety, PK, PD, and modeling results, will be reviewed by the Internal Data Review Committee (IDRC) to determine Dosing Regimen 2
61983087|NCT00841087|ACTIVE_COMPARATOR|Insulin Detemir|
61983088|NCT05359666|EXPERIMENTAL|Irrisept|Irrisept® was used for surgical irrigation in subjects with abdominal trauma or acute surgical abdomen for study protocol IRR-CT-901-2013-01.
61983089|NCT05359666|ACTIVE_COMPARATOR|Standard of Care (SoC)|Institution determined the type of SoC used for surgical irrigation in subjects with abdominal trauma or acute surgical abdomen for study protocol IRR-CT-901-2013-01.
61983090|NCT01561820|ACTIVE_COMPARATOR|Buddy|Participant will be assigned a buddy that will meet with them at the gym for each of their exercise sessions. This person will serve as a source of support and motivation for them and will also help them remember and stick to the goals set for you. This person will also help them maintain their exercise logs and ensure they are correct. The buddy will not be exercising with them, but will just be there with them while you exercise.
61983091|NCT01561820|PLACEBO_COMPARATOR|Non Buddy|Participants will not be assigned a buddy (and are not allowed to bring someone with them as a buddy). They will be asked to exercise on their own and remember the goals set for them. They will also be responsible for filling out their own exercise logs and ensuring they are correct.
62169344|NCT03058237|EXPERIMENTAL|Part 3: Regimen L|"One low dose selected Arbaclofen Placarbil MR prototype tablet administered with 0.6 g/kg of beverage in orange juice or in the fed state, or one mid-low dose of the selected Arbaclofen Placarbil MR prototype tablet.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
62169345|NCT03058237|EXPERIMENTAL|Part 3: Regimen M|"An optional regimen of one mid-low dose of the selected Arbaclofen Placarbil MR prototype tablet (if not previously dosed in Regimen L) or one mid-high dose of the selected Arbaclofen Placarbil MR prototype tablet taken under fasting conditions.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
62567116|NCT05238727|ACTIVE_COMPARATOR|1.8 ml mepivacaine IANB|
61983092|NCT02659527|ACTIVE_COMPARATOR|standardized needle biopsy|"All enrolled patients are examined by means of dual tracer PET / MRI. Images will be interpreted by 4 designated readers. The readers are blinded of the respective results among each other. A consensus of the two principal readers of nuclear medicine and radiology will serve as reference for the guided needle biopsy. Additionally the readers are blinded to any result of the pathological workout until the recruitment of the last patient is finished.~According to the randomization, the standardized 12 core TRUS (TransRectal UltraSound)-guided biopsy is performed without knowledge of imaging findings by the urologist. If the biopsy is negative patients will have an additional image-guided biopsy with 4 more cores samples. After a positive biopsy the subjects be treated according to normal clinical practice."
61983093|NCT02659527|EXPERIMENTAL|image-guided biopsy|"All enrolled patients are examined by means of dual tracer PET / MRI. Images will be interpreted by 4 designated readers. The readers are blinded of the respective results among each other. A consensus of the two principal readers of nuclear medicine and radiology will serve as reference for the guided needle biopsy. Additionally the readers are blinded to any result of the pathological workout until the recruitment of the last patient is finished.~Patients will have a standardized 12 core TRUS-guided biopsy without knowledge of imaging findings by the urologist. Patients randomized in this arm will have an additional image-guided biopsy with 4 more cores samples. After a positive biopsy the subjects be treated according to normal clinical practice."
61983094|NCT03394482|EXPERIMENTAL|Lu AF35700 5 mg clinical formulation|
61983095|NCT03394482|EXPERIMENTAL|Lu AF35700 5 mg commercial formulation|
61983096|NCT03394482|EXPERIMENTAL|Lu AF35700 10 mg clinical formulation|
61983097|NCT03394482|EXPERIMENTAL|Lu AF35700 10 mg commercial formulation|
61983098|NCT03394482|EXPERIMENTAL|Lu AF35700 20 mg clinical formulation|
61983099|NCT03394482|EXPERIMENTAL|Lu AF35700 20 mg commercial formulation|
61983100|NCT05576493|EXPERIMENTAL|A:phaco+MP-TSCPC|22 patients with primary angle closure glaucoma will undergo phacoemulsification and micropulse cyclophotocoagulation
61983101|NCT05576493|EXPERIMENTAL|B:phaco+TSCPC|22 patients with primary angle closure glaucoma will undergo phaco and transscleral cyclophotocoagulation
61983102|NCT05576493|EXPERIMENTAL|C:phaco+endocyclophotocoagulation|22 patients with primary angle closure glaucoma will undergo phaco and endocyclophotocoagulation after cataract removal
61983103|NCT05576493|EXPERIMENTAL|D:phaco GSL|22 patients with primary angle closure glaucoma will undergo phaco and goniosynechiolysis
61983104|NCT00726076|EXPERIMENTAL|Treatment|The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment.
61983105|NCT00726076|EXPERIMENTAL|Control|Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
61983106|NCT03130166|EXPERIMENTAL|Intracorporeal anastomosis|Patients undergo robotic right colectomy with intracorporeal anastomosis.
61983107|NCT03130166|ACTIVE_COMPARATOR|Extracorporeal anastomosis|Patients undergo robotic right colectomy with extracorporeal anastomosis.
61983108|NCT03556579|EXPERIMENTAL|Test/Control|For Visit 1, subjects will be randomly assigned to 1 of 2 contralateral lens sequences (Right: Test, Left: Control) OR (Right: Control, Left: Test). Then for visit 2, subjects will be randomly assigned to the same 1 of 2 contralateral lens sequences again.
61983109|NCT03556579|EXPERIMENTAL|Control/Test|For Visit 1, subjects will be randomly assigned to 1 of 2 contralateral lens sequences (Right: Test, Left: Control) OR (Right: Control, Left: Test). Then for visit 2, subjects will be randomly assigned to the same 1 of 2 contralateral lens sequences again.
61983110|NCT04484233||Control Group|Anesthesiologists would have to respond to an online questionnaire about 10 hypotheticals clinical situations regarding patient blood management.
61983111|NCT04484233||Clinical Decision Support Group|Anesthesiologists would have to respond to an online questionnaire about 10 hypotheticals clinical situations regarding patient blood management helped by dedicated clinical decision support systems for patient blood management (iAnemia, Intelligence Anesthesia).
61983112|NCT05124951|EXPERIMENTAL|iGCTS|"Stratum I (Germinoma) Patients who achieved complete response after induction chemotherapy will receive WVI 2400cGy/15f plus primary boost 640cGy/4f.~Stratum II (NGGCTs) At the time of response evaluation before radiotherapy, those with complete response or residue disease \<1.5cm will receive WVI 3060cGy/17f plus primary boost 2340cGy/13f."
61983113|NCT01912846|SHAM_COMPARATOR|Attention usual care intervention|"Interventions includes prognosis disclosure and discussions of EOL care as needed as in current clinical practices.~Interventions of the attention usual care arm include a consistent master prepared nurse on the study team will provide the attention portion of the care and a workbook and a video with educational materials. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department."
61983114|NCT01912846|EXPERIMENTAL|Interactive advance care planning|The intervention aims at facilitating patients, families, and primary physicians to discuss the patient's wishes for EOL care by clarifying a terminally ill cancer patient's understanding of his/her prognosis and treatment options and her/his readiness for engagement in ACP, appropriately weighting the benefits and burdens of medical treatments at EOL, and clearly defining and documenting the patient's preferences so as to be readily available later for the patient's primary physician to guide EOL care decision-making which will honor the patient's preferences for EOL care.
61983115|NCT03664947|EXPERIMENTAL|exercise|The exergaming training programs have included recent daily living activities in games. In our study we have planned the Nintendo Wii Fit Plus Game Console in the therapy training.
61983116|NCT03664947|NO_INTERVENTION|control|No exercise training applied for the control group.
61983117|NCT02340598|EXPERIMENTAL|cold vest|Participants are given a cold vest that the pre-cool in a freezer. They are encouraged to use it daily to activate metabolism through brown adipose tissue and shivering.
61983118|NCT02340598|NO_INTERVENTION|control|No intervention, just recording of risk factors and basal metabolic rate.
62182321|NCT03749499|NO_INTERVENTION|Usual Care|Participants randomized to usual care will receive preprinted discharge instructions on HTN and a 48-72-hour referral to our FQHC (or other community health center if pre-assigned though Illinois Medicaid) to schedule their follow-up appointment (current standard of care)
61983119|NCT03577704|EXPERIMENTAL|HLX07+Gemcitabine+Cisplatin arm|"HLX07 is given on D1,D8,D15 combine with Gemcitabine (1000 mg/m2) and Cisplatin (75 mg/m2) in 3 weeks- cycles for 4-6 cycles .Gemcitabine was administered on the D1 and D8 and cisplatin 75 mg/m2 was administered on the D1. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
61983120|NCT03577704|EXPERIMENTAL|HLX07+Paclitaxel+Carboplatin arm|"HLX07 is given on D1,D8,D15 combine with Paclitaxel (80 mg/m2) and carboplatin (AUC=2) in 3 weeks-cycle for 4-6 cycles .Paclitaxel and carboplatin were administered on D1, D8 and D15. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
61983121|NCT03577704|EXPERIMENTAL|HLX07+mFOLFOX6 arm|"HLX07 is given on D1,D8 combine with mFOLFOX6 ( oxaliplatin (85 mg/m2), leucovorin (400 mg/m2), and 5-FU (400 mg/m2, followed by 2400 mg/m2) in 2 weeks-cycles for 6-12 cycles . Oxaliplatin, leucovorin and 5-FU were administered on D1. After 6-12 cycles of combination therapy,once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
61983122|NCT05854589|ACTIVE_COMPARATOR|Active Group - Sodium Chloride Crystal Topical|Each patient of the Active group will have their Melanoma covered by 2 drops of water, followed by applying Sodium Chloride granules to saturate the melanoma surface then add 2 more drops of water, then cover the NaCl-granules-covered Melanoma with a bandage. The bandage will stay in place for 12 hours daily and the procedure will be repeated daily for a total of 7 consecutive days, in addition to their standard treatments they receive from their health care providers, if any.
61983123|NCT05854589|PLACEBO_COMPARATOR|Control Group - Plain Water topical application|Each patient of the Control group will have their Melanoma covered by 4 drops of water, then covered by a bandage. The bandage will stay in place for 12 hours daily and the procedure will be repeated daily for a total of 7 consecutive days, in addition to their standard treatments they receive from their health care providers, if any.
61983124|NCT05569850|EXPERIMENTAL|Recently introduced toothpaste|Brushing twice a day with a recently introduced toothpaste.
61983125|NCT05569850|ACTIVE_COMPARATOR|Commercial toothpaste|Brushing twice a day with a commercially available toothpaste.
61983126|NCT06199102|EXPERIMENTAL|monitored group|Infants in the monitored group will receive an initial dose of 1000 IU of vit D (cholecalciferol/ Devikap; Polpharma, Starogard Gdański, Poland).
61983127|NCT06199102|ACTIVE_COMPARATOR|controlled group|Infants in the controlled group will receive 250 IU (cholecalciferol/ Devikap; Polpharma, Starogard Gdański, Poland) for very low birth weight infants and 500 IU (cholecalciferol/ Devikap; Polpharma, Starogard Gdański, Poland) for infants weighing above 1000 g.
61983128|NCT05718258|EXPERIMENTAL|Participants with mild hepatic impairment|Venglustat single dose on Day 1
61983129|NCT05718258|EXPERIMENTAL|Participants with normal hepatic function|Venglustat single dose on Day 1
61983130|NCT05718258|EXPERIMENTAL|Participants with moderate hepatic impairment|Venglustat single dose on Day 1
61983131|NCT05718258|EXPERIMENTAL|Participants with severe hepatic impairment|Venglustat single dose on Day 1
61983132|NCT05985850|EXPERIMENTAL|Aurora 1:1 Drops (Indica)|"Aurora 1:1 Drops (Indica)~Balanced 1:1 ratio of THC and CBD packaged in a 30 mL bottle:~THC: 16.8 mg/g (+/- 15%) CBD: 16.8 mg/g (+/- 15%)~Induction and dosing will be ad libitum and sublingually self-administered. Initial dose will be 5 mg (equivalent to 0.25 mL)/day and participants will be able to titrate in increments of 2.5mg (0.125 mL)/day up to a maximum of 40 mg (2 mL)/day, in consultation with a study physician."
61983133|NCT05985850|PLACEBO_COMPARATOR|Placebo|"Formulated using the same medium chain triglyceride (MCT) oil as Aurora 1:1 Drops (Indica)~Induction and dosing will be ad libitum and sublingually self-administered. Initial dose will be 5 mg (equivalent to 0.25 mL)/day and participants will be able to titrate in increments of 2.5mg (0.125 mL)/day up to a maximum of 40 mg (2 mL)/day, in consultation with a study physician."
61983134|NCT00084981|EXPERIMENTAL|Treatment (decitabine, valproic acid)|"Patients receive decitabine IV over 1 hour on days 1-10 and oral valproic acid three times daily on days 5-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine and valproic acid until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. After the MTD is determined, an additional 6 patients are treated at that dose."
61983135|NCT01297140|EXPERIMENTAL|questionary|
61983136|NCT03136679||Group 1 Normal|Spouse or Subject's caregiver. Blood and urine samples will be collected.
61983137|NCT03136679||Mild Cognitive Impairment|Subjects with MCI: Blood and urine samples will be collected.
61983138|NCT03136679||Alzheimer's disease|Subjects with Alzheimer's disease A. Mild B. Moderate C. Severe Blood and urine samples will be collected from these three sub-groups.
61983139|NCT02542878|EXPERIMENTAL|FOAM ROLLER|"Treatment with foam roller will be applied for 60 seconds to this group. Subjetc lye in supine position over the foam roller placed on back muscle extensors. Then, they must slide the body on the device, from postero-superior iliac spine to the dorsal zone.~A brief explanation of this self-application will be showed prior the intervention."
61983140|NCT02542878|PLACEBO_COMPARATOR|PLACEBO|An intervention similar (position and time) to the experimental group will be done, but the used device will be a very soft roller not compressing the contact zone.
61983141|NCT06419387|EXPERIMENTAL|Self-Therapy App|EMDR Flash Technique protocol will be administered via Self-Therapy App.
61983142|NCT06419387|ACTIVE_COMPARATOR|Psycho-Education|Psycho-Education will be administered via videos of a psychology professor.
61983143|NCT05849181|ACTIVE_COMPARATOR|Moona Active Group|Participants in the Moona Active Group will placed the device between the pillow and the pillow cover, under their head and neck.
61983144|NCT05849181|SHAM_COMPARATOR|Moona Inactive Group|Participants in the Moona Inactive Group will placed the device between the pillow and the pillow cover, under their head and neck.
62567117|NCT05238727|EXPERIMENTAL|3.6 ml mepivacaine IANB|
61983145|NCT05104034|EXPERIMENTAL|Screening group|Inform the elderly about the results of the screening and recommend those with moderate to high risk of fracture to receive active examination and treatment.
61983146|NCT05104034|EXPERIMENTAL|Multi-component integrated intervention|Introduce integrated services of health education, nutrition, rehabilitation, pharmaceutical care, and other multi-specialties to assist study participants with health promotion
61983147|NCT05104034|PLACEBO_COMPARATOR|Delayed intervention|receive general care after collecting basic information, and provide health education related information such as osteoporosis sarcopenia. After two year's follow-up, multi-disciplinary team intervention service will be implemented.
61983148|NCT03336775|EXPERIMENTAL|acupuncture|Patients receive acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks). These patients also received corticosteroid for 4 weeks, methylprednisolone 80mg ivdrip. for 3 days, 60mg ivdrip. for 3 days, 40mg ivdrip. for 3 days, 30mg po. for 7 days, 20mg po. for 7 days, 10mg po. for 5 days and maintain.
61983149|NCT03336775|NO_INTERVENTION|control|Patients receive no acupuncture. The use of corticosteroid is the same with Arm I.
61983150|NCT00795522|EXPERIMENTAL|Arm 1|Desloratadine
61983151|NCT05326477|OTHER|Standard-of-care behavioral weight loss treatment|6-months of group-based behavioral weight loss treatment following the Centers for Disease Control and Prevention Prevent T2 curriculum.
62362679|NCT03437629|ACTIVE_COMPARATOR|Calcium Hydroxide temporary cement|Cementation of a temporary crown with cement based on calcium hydroxide.
62362680|NCT03437629|ACTIVE_COMPARATOR|MTA temporary cement|Cementation of a temporary crown with cement based on Mineral trioxide aggregate .
61983152|NCT02532647|EXPERIMENTAL|Remimazolam|"Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
61983153|NCT02532647|ACTIVE_COMPARATOR|Midazolam|"Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
61983154|NCT02532647|PLACEBO_COMPARATOR|Placebo|"Placebo administered in double-blind manner.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
61983155|NCT04377477|EXPERIMENTAL|Lung low dose radiotherapy|Irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy
61983156|NCT02941445|EXPERIMENTAL|COMBO (sitagliptin and metformin)|metformin 1000 mg BID and sitagliptin 50mg BID for 12 weeks
61983157|NCT02941445|EXPERIMENTAL|MET (metformin)|metformin 1000 mg BID
61983158|NCT00946426||Diagnostic|Hyperinsulinemic euglycemic clamp
61983159|NCT01528254|ACTIVE_COMPARATOR|Vilda 50mg bid + metformin|Metformin + vildagliptin
61983160|NCT01528254|EXPERIMENTAL|Placebo + metformin|Metformin + Placebo of vildagliptin
61983161|NCT00654407|EXPERIMENTAL|1|Rosuvastatin
61983162|NCT00654407|ACTIVE_COMPARATOR|2|Atorvastatin
61983163|NCT00654407|ACTIVE_COMPARATOR|3|Simvastatin
61983164|NCT03804944|ACTIVE_COMPARATOR|ARM 1|Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
61983165|NCT03804944|ACTIVE_COMPARATOR|ARM 2|Focal hypo-fractionated radiation therapy - 8 Gy x 3 fractions starting day 8, every other day (M/W/F or W/F/M or F/M/W). + Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
61983166|NCT03804944|ACTIVE_COMPARATOR|ARM 3|Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days + Focal hypo-fractionated radiation therapy - 8 Gy x 3 fractions starting day 8, (every other day (M/W/F or W/F/M or F/M/W).
61983167|NCT03804944|ACTIVE_COMPARATOR|ARM 4|Ftl-3 ligand, self administered subcutaneous injections at day 1 for 5 consecutive days+ Focal hypo-fractionated Radiation therapy starting day 8, - 8 Gy x 3 fractions, every other day (M/W/F or W/F/M or F/M/W). + Pembrolizumab, on day 12 (last day of radiotherapy), 200mg IV infused over 30 minutes then repeated every 3 weeks until disease progression or unacceptable toxicity.
61983168|NCT04810676|EXPERIMENTAL|Sequence 1|"Peroid 1: CKD-501, D745, D150 -PO~Peroid 2: CKD-383- PO"
61983169|NCT04810676|EXPERIMENTAL|Sequence 2|"Peroid 1: CKD-383- PO~Peroid 2: CKD-501, D745, D150 -PO"
61983170|NCT03731884||Elapsed time of onset-of-pain-to-PCI <3 hours|Patients with AMI undergoing percutaneous coronary intervention (PCI) prior to 3 hours from the onset of symptoms
61983171|NCT03731884||Elapsed time of onset-of-pain-to-PCI >3 hours|Patients with AMI undergoing percutaneous coronary intervention (PCI) after at least 3 hours from the onset of symptoms
61983172|NCT01622699|EXPERIMENTAL|Transcutaneous bilirubin measurements|In this intervention group, the initial visual assessment of jaundice wille be followed by measurement by transcutaneous bilirubinometer
61983173|NCT01622699|ACTIVE_COMPARATOR|Visual assessment of neonatal jaundice|In this control group (standard of care) the visual assessment will be followed by measurement of blood bilirubin as indicated by the physician
61983174|NCT01948128|EXPERIMENTAL|Vitamin D3|Vitamin D3 40,000 iu per day by mouth
61983175|NCT01948128|PLACEBO_COMPARATOR|Placebo|Placebo taken daily by mouth
61983176|NCT02378363||Student 9 to 12 years|Students aged 9 to 12 years and enrolled in classes CM1, CM2 and 6th
61983177|NCT01983358|EXPERIMENTAL|JPI-289|Each cohort, volunteers will be infused JPI-289 through I.V for 30 min.(6 volunteers per each cohort, total 7 cohort)
61983178|NCT01983358|PLACEBO_COMPARATOR|Placebo|Each cohort, volunteer will be infused placebo through I.V for 30 min.(2 volunteers per each cohort, total 7 cohort)
62362681|NCT02244008|EXPERIMENTAL|joint mobilization|Anteroposterior mobilization of the talus (Maitland mobilization grade III)
62362682|NCT02244008|PLACEBO_COMPARATOR|manual contact|
62362683|NCT06238011|ACTIVE_COMPARATOR|Dexmedetomidine|Patient in this arm will receive dexmedetomidine loading 60ml/hour before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass
62362684|NCT06238011|PLACEBO_COMPARATOR|Normal Saline|Patient in this arm will receive normal saline loading 60ml/hour before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary artery bypass
62362685|NCT02533856|NO_INTERVENTION|Usual Care|Discharge from emergency department by usual care
62362686|NCT02533856|EXPERIMENTAL|ETOC|Discharge from emergency department with increased support services provided by BoardRounds after ED discharge
61983179|NCT01813539|EXPERIMENTAL|Dose Escalation: Cohort 1|Participants will receive ARGX-110 as an intravenous infusion (IV) at dose level 1.
61983180|NCT01813539|EXPERIMENTAL|Dose Escalation: Cohort 2|Participants will receive ARGX-110 as an IV infusion at dose level 2.
61983181|NCT01813539|EXPERIMENTAL|Dose Escalation: Cohort 3|Participants will receive ARGX-110 as an IV infusion at dose level 3.
61983182|NCT01813539|EXPERIMENTAL|Dose Escalation: Cohort 4|Participants will receive ARGX-110 as an IV infusion at dose level 4.
61983183|NCT01813539|EXPERIMENTAL|Dose Escalation: Cohort 5|Participants will receive ARGX-110 as an IV infusion at intermediate dose level at the conclusion of Cohort 4 prior to opening the safety expansion cohorts to participants enrolment.
61983184|NCT01813539|EXPERIMENTAL|Safety Expansion: Cohort 1|Participants with solid tumors will receive ARGX-110 as an IV infusion at a dose based on the safety, PD, and PK profiles of ARGX-110 as per the dose escalation part of the trial.
61983185|NCT01813539|EXPERIMENTAL|Safety Expansion: Cohort 2|Participants with hematological malignancies (all etiologies) will receive ARGX-110 as an IV infusion at a dose based on the safety, PD, and PK profiles of ARGX-110 as per the dose escalation part of the trial.
61983186|NCT01813539|EXPERIMENTAL|Safety Expansion: Cohort 3|Participants with cutaneous T-cell lymphoma (CTCL) will receive ARGX-110 as an IV infusion at dose level 2 followed by a maintenance therapy at dose level 2 or 3.
61983187|NCT01813539|EXPERIMENTAL|Safety Expansion: Cohort 4|Participants with peripheral T-cell lymphoma (PTCL) will receive ARGX-110 as an IV infusion at dose level 2 followed by a maintenance therapy at dose level 2 or 3.
61983188|NCT01813539|EXPERIMENTAL|Exploratory Efficacy: Cohort 5|Participants with relapsed/refractory CTCL will receive ARGX-110 as an IV infusion followed by a maintenance therapy at dose level 3.
61983189|NCT05376696|EXPERIMENTAL|Set for Variability|"Students in the experimental group will receive an average of 10-12 hrs. of small group intervention. All lessons will include (i) a focus on blending and segmenting phonemes within a synthetic phonics model, (ii) teaching common, vocabulary words (iii)shared book reading, and (iv) Set-for-variability component (SfV). This component will focus on teaching students how to find the sound variation of a grapheme-phoneme rule. For example when to use the sound /k/in /ch/ to read words such as stomach"
61983190|NCT05376696|ACTIVE_COMPARATOR|Current best practices|The control group will receive current-best practices (CBP). The participants will receive a similar approach as in the intervention group without Set-for-Variability. The participants will receive (i) a focus on blending and segmenting phonemes within a synthetic phonics model, (ii) vocabulary, (iii) shared book reading, and (iv) the absence of teaching Set-for-Variability. Instead of Set-for-variability, the participants will receive sight word reading of frequent words. They will learn the most frequent pronunciation of vowels: ee, ea, oo, ou, oa, ai, ay
61983191|NCT02933710||IMOJEV® Vaccine Group|Participants who are 12 months and older and who are given a first dose of IMOJEV® during a routine health care visit
61983192|NCT04969549|OTHER|Theta-burst stimulation (TBS)|Receive active iTBS, 1800 pulses, 100% MT over dlPFC.
62739217|NCT05504187|EXPERIMENTAL|Part 1: Dose Optimization Cohort 2, Dose 2|Participants will be administered with KP104 dose regimen 2 for 24 Weeks. After the last participant completes 6 weeks of treatment, all available data, including safety, PK, PD, and modeling results, will be reviewed by the IDRC to determine Dosing Regimen 3.
62739218|NCT05504187|EXPERIMENTAL|Part 1: Dose Optimization Cohort 3, Dose 3|Participants will be administered with KP104 dose regimen 3 for 24 Weeks. After the last participant completes 6 weeks of treatment, all available data, including safety, PK, PD, and modeling results, will be reviewed by IDRC to determine the Optimal biologic dose (OBD) for Part 2.
62739219|NCT05504187|EXPERIMENTAL|Part 2: OBD Cohort, Dose 4|Participants will be administered with KP104 OBD for 24 Weeks.
61983193|NCT00579956|EXPERIMENTAL|Meropenem|Meropenem
61983194|NCT00579956|ACTIVE_COMPARATOR|Ceftazidime|Ceftazidime
61983195|NCT02604524|EXPERIMENTAL|Closed-Loop Control (CLC) System|Subjects will use the Closed-Loop Control system in an attempt to maintain blood glucose in a certain range during the day and at night during the trial.
61983196|NCT02604524|PLACEBO_COMPARATOR|Sensor Augmented Pump Therapy Group|Subjects will manage their own glucose levels during the trial.
61983197|NCT05894733|OTHER|1|1: The first group was called by phone on the 15th day to ask if there were any complaints or problems with the device. Sequentially, they were called for controls at the end of the first, third, and sixth months.
61983198|NCT05894733|OTHER|2|2:The second group was accepted as the control group, following our clinic's standard procedure in the first and sixth months
61983199|NCT04264598|EXPERIMENTAL|Experimental Adult Group - Medium dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of medium dosage investigational sIPV Intervention: Biological: one-dose regimen of medium dosage investigational sIPV
61983200|NCT04264598|EXPERIMENTAL|Experimental Children Group - Medium dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of medium dosage investigational sIPV Intervention: Biological: one-dose regimen of medium dosage investigational sIPV
61983201|NCT04264598|EXPERIMENTAL|Experimental Infant Group - Medium dosage|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of medium dosage investigational sIPV Intervention: Biological: Three-dose regimen of medium dosage investigational sIPV
62362687|NCT04319640|EXPERIMENTAL|CBTI|N= 80 participants are offered Cognitive behaviour therapy for insomnia (CBT-I)
62739220|NCT02209558|NO_INTERVENTION|Standard Written Sternal Precautions|"Patients will receive education that is the standard of care at North Shore Long Island Jewish Health Systems in their post-operative sternal precautions."
62739221|NCT02209558|EXPERIMENTAL|Visual Sternal Precautions|"Patients will receive both standard of care written sternal precautions, as well as visual sternal precautions."
62739222|NCT02370316|EXPERIMENTAL|MIT - SA|Metacognitive Interpersonal Therapy -standard approach (MIT-SA) is a cognitive behavior-based psychotherapeutic approach that works to increase metacognitive abilities and to improve interpersonal relationships
62739223|NCT02370316|ACTIVE_COMPARATOR|Clinical Structured Treatment (CST)|Clinical Structured Treatment (CST) is a structured case management and symptom-targeted medication
61983202|NCT04264598|ACTIVE_COMPARATOR|Control Infant Group - commercialized sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized sIPV Intervention: Biological: Three-dose regimen of commercialized sIPV
61983203|NCT04264598|ACTIVE_COMPARATOR|Control Infant Group - commercialized IPV|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized IPV Intervention: Biological: Three-dose regimen of commercialized IPV
61983204|NCT00823927||1|Alveolar macrophage proteomes from HIV-seropositive smokers with emphysema
62362688|NCT04319640|ACTIVE_COMPARATOR|psychoeducation|N= 80 participants are offered psychoeducation about information on ASD
61983205|NCT00823927||2|Alveolar macrophages proteomes of both HIV+ smokers without emphysema and HIV- smokers.
61983206|NCT01974375|EXPERIMENTAL|micafungin|micafungin sodium IV (Mycamine®)
61983207|NCT01974375|ACTIVE_COMPARATOR|Fluconazole|Fluconazole IV (use same brand in each hospital)
61983208|NCT05058248|ACTIVE_COMPARATOR|Pudendal block|Ultrasound-guided bilateral pudendal block at the start of surgery, in gynecological position: injection of 15 mL of 0.475% Naropein in each ischiorectal fossa.
61983209|NCT05058248|OTHER|the standard method|Operated and anesthetized patients according to the standard method within the department
61983210|NCT03619187|EXPERIMENTAL|Single Arm|Study Product
61983211|NCT02263755||chronic hepatitis B subjects|Subjects who have been diagnosed with chronic hepatitis B.
61983212|NCT00926874||1|patients who presented an ischaemic stroke(full stroke or TIA)
61983213|NCT00926874||2|patients who present an acute coronary syndrome (ACS).
61983214|NCT03935373||Sjögren's syndrome|Sjögren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) primary or secondary SS; (2) aged between 20 and 75 years; (3) fulfilled the 2002 American-European Consensus Criteria for SS (AECG); (4) had no abnormal findings of immune, liver, kidney, or blood function evaluations. And the exclusion criteria were: (1) a history of alcohol abuse, diabetes mellitus, or major life-threatening condition; (2) pregnancy or breastfeeding; or (3) steroid pulse therapy within three months prior to the commencement of our study.
61983215|NCT03935373||Health subjects|Health subjects were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 41 and 63 years (which the age could match the SS patients enrolling in the SS-1 trial); (2) had no chronic inflammatory illness. And the exclusion criteria were: (1) a history of alcohol abuse, diabetes mellitus, or major life-threatening condition; (2) pregnancy or breastfeeding; (3) abnormal findings of immune, liver, kidney, or blood function evaluations; (4) total sleeping time insufficiency less than 6 hours before one day of enrollment; (5) ever took the conventional medicine or hormone within one month; (6) ever encountered the acute illness, allergy reaction, immune, or rheumatic disease within one month.
61983216|NCT03370354||Control group|First questionnaire (spiegel questionnaire) will allow a score on 30. If the score is \> 18, the patient will be in the control group.
61983217|NCT03370354||troubled sleeping patterns group|First questionnaire (spiegel questionnaire) will allow a score on 30. If the score is \< 18, the patient will be in the troubled patterns group.
61983218|NCT06053073|EXPERIMENTAL|At home patients group|After insertion of the Cervical Rippening Balloon and checking fetal and maternal well-being, the patient will go home between 6 and 8 hours to complete the cervical rippening process. The patient will remove autonomously the balloon and will go to the hospital one hour later, where the induction will continue.
61983219|NCT06053073|ACTIVE_COMPARATOR|Hospitalized patients group|After the insertion of the Cervical Rippening Balloon and verifications of the fetal and materna well-being, the patient will undergo the cervical rippening process for between 6 and 8 hours in the hospital and will remain hospitalized until the time of the delivery.
61983220|NCT01109251|OTHER|Intervention group|Group of patients presenting a non controlled AHT or a masked AHT, benefiting from an optimised caring at visit 0.
61983221|NCT01109251|OTHER|Control group|Patients presenting a non controlled AHT(persistent AHT, AHT necessiting an adaptation of the treatment by the generalist) with information of the generalist on the necessity of obtaining the tensional control according the HAS recommendations
61983222|NCT02165436|PLACEBO_COMPARATOR|Control|No gum
62362689|NCT02589743|ACTIVE_COMPARATOR|Fluroshield - F (Sealant)|Pit and fissure sealing using only sealant
62362690|NCT02589743|EXPERIMENTAL|Single Bond and F (Adhesive and Sealant)|Pit and fissure sealing using adhesive and sealant
61983223|NCT02165436|ACTIVE_COMPARATOR|Chewing Gum|Bubble gum-flavored sugar-free gum - chew for 15-30 minutes 5 times/day
61983224|NCT05643365||Hypothyroidism|decreased hormone levels (FT3 \< 3.5 pmol/L, FT4 \< 11.5 pmol/L, TSH \> 4.78 μU/mL) and symptoms of hypothyroidism within 6 months' follow-up.
61983225|NCT05643365||Euthyroidism|normal hormone levels (FT3 3.5 to 6.5 pmol/L, FT4 11.5 to 22.7 pmol/L, TSH 0.55 to 4.78 μU/mL), and no symptoms of hyperthyroidism after 6 months' follow-up
61983226|NCT05643365||Hyperthyroidism|increased hormone levels (FT3 \> 6.5 pmol/L, FT4 \> 22.7 pmol/L, TSH \< 0.55 μU/mL) and symptoms of hyperthyroidism after 6 months' follow-up
61983227|NCT02605707|EXPERIMENTAL|Intravenous stem cell transplantation|Intravenous transplantation of autologous endothelial progenitor cells plus conventional treatment include rehabilitation
61983228|NCT02605707|NO_INTERVENTION|Conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
61983229|NCT01456104|EXPERIMENTAL|vaccine|This is a single-arm phase I trial in patients with AJCC stage IIB, IIC, III, and IV (MIa) melanoma in which autologous human Langerhans-type dendritic cells (CD34+hematopoietic progenitor cell (HPC)-derived Langerhans cells, or LCs) will be electroporated with mRNA encoding full-length murine tyrosinase-related peptide 2 (TRP2). LCs will also be loaded with control antigens (HLA-A\*0201-restricted flu matrix peptide).
61983230|NCT01879241|EXPERIMENTAL|Rasagiline|"Rasagiline~1 mg/day; 18 months"
61983231|NCT01879241|PLACEBO_COMPARATOR|Placebo|once daily, 18 months
62362691|NCT02589743|ACTIVE_COMPARATOR|Helioseal Clear Chroma - H (Sealant)|Pit and fissure sealing using only sealant
62362692|NCT02589743|EXPERIMENTAL|Excite and H (Adhesive and Sealant)|Pit and fissure sealing using adhesive and sealant
61983232|NCT03986320|EXPERIMENTAL|Keeogo™ Dermoskeleton|Keeogo™ Dermoskeleton is a low-profile, assistive exoskeleton (or 'dermoskeleton') that orthotically fits to the lower limbs. Keeogo™ is worn on the user's lower body using a belt and contact areas attached around the thighs and calves.
61983233|NCT05436847|EXPERIMENTAL|Group A|NDT- age appropriate Transitions (age appropriate) Milestones training (age appropriate) Proprioceptive Input- age appropriate (Pushups Static quadruped, squat sitting, trampoline, hopping etc. With weights and splints for joint to joint approximation)
61983234|NCT05436847|ACTIVE_COMPARATOR|Group B|NDT- age appropriate Transitions (age appropriate) Milestones training (age appropriate)
61983235|NCT05409144|EXPERIMENTAL|Thoracic epidural infusion group|Patients will receive thoracic epidural preoperative
61983236|NCT05409144|EXPERIMENTAL|Erector Spinae Plane Block group|Patients will receive Ultrasound-guided Erector Spinae Plane Block preoperative with an injection of 30 ml levobupivacaine 0.25% and insertion of a catheter
61983237|NCT05409144|EXPERIMENTAL|Serratus Anterior Plane Block group|Patients will receive Ultrasound-guided Serratus Anterior Plane Block preoperative with an injection of 30 ml levobupivacaine 0.25%.
61983238|NCT00843583||resistant hypertension subjects|subjects with resistant hypertension
61983239|NCT03630575|EXPERIMENTAL|Newborns exposed in-utero to psychoactive substances|
61983240|NCT06186531|EXPERIMENTAL|PhytoSERM|Active intervention group
61983241|NCT06186531|PLACEBO_COMPARATOR|Placebo group|Control group
61983242|NCT01365507|EXPERIMENTAL|IDegAsp Simple|
61983243|NCT01365507|EXPERIMENTAL|IDegAsp Step wise|
61983244|NCT02553850||Ibandronate|Patients receiving ibandronate will be evaluated for bone turnover markers for 12 months. Ibandronate is not an investigational medicinal product (IMP) in this study.
61983245|NCT04760366|EXPERIMENTAL|Group A (Experimental)|Patients in this group will receive interventional therapy through fascial- muscular lengthening therapy .Patients in this group will also receive the conventional therapy
61983246|NCT04760366|OTHER|Group B: Conventional treatment|Patients in this group will receive the conventional therapy
61983247|NCT01531374|EXPERIMENTAL|Extreme Risk: TAVI Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Iliofemoral Access
61983248|NCT01531374|EXPERIMENTAL|Extreme Risk: TAVI Non-Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Non-Iliofemoral Access
61983249|NCT01531374|EXPERIMENTAL|High Risk: TAVI|High Risk Surgical Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
61983250|NCT03077802|EXPERIMENTAL|Modified Seldinger technique, Experienced group|Under ultrasound-guide, we will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by experienced practitioner who were defined as board-certified anesthesiologist staffs and had experience of more than 50 central venous catheterizations in both techniques.
61983251|NCT03077802|ACTIVE_COMPARATOR|Seldinger technique, Experienced group|Under ultrasound-guide, the desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by experienced practitioner who were defined as board-certified anesthesiologist staffs and had experience of more than 50 central venous catheterizations in both techniques.
61983252|NCT03077802|EXPERIMENTAL|Modified Seldinger technique, Inexperienced group|Under ultrasound-guide, we will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by inexperienced practitioner who were junior residents and had experience of less than 50 central venous catheterizations in both techniques.
61983253|NCT03077802|ACTIVE_COMPARATOR|Seldinger technique, Inexperienced group|Under ultrasound-guide, the desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by inexperienced practitioner who were junior residents and had experience of less than 50 central venous catheterizations in both techniques.
62362693|NCT03037567|EXPERIMENTAL|Modified Weight Watchers plan|Modified Weight Watchers Plan which includes a food plan, activity plan, group support and cognitive behavior modification. Weekly study-specific group meetings; electronic tools through iPhone app for 24 weeks.
61983254|NCT03851042|EXPERIMENTAL|Virtual Reality Head set in PACU|Use of VR Headset in PACU post hysterectomy for up to 4 hours.
61983255|NCT03851042|ACTIVE_COMPARATOR|No intervention|Routine PACU care post hysterectomy for up to 4 hours
61983256|NCT01802723|EXPERIMENTAL|LIPO-202, Low|Drug: salmeterol xinafoate
62362694|NCT01024101|EXPERIMENTAL|Paclitaxel|
62567118|NCT05238727|EXPERIMENTAL|1.8 ml mepivacaine IANB plus 1.8 ml articaine BI|
62567119|NCT01598064|EXPERIMENTAL|GK#10|GK#10 1 pk tid for 8 weeks
62567120|NCT01598064|PLACEBO_COMPARATOR|Placebo|Placebo 1 pack tid for 8 weeks
61983257|NCT01802723|EXPERIMENTAL|LIPO-202, Mid|Drug: salmeterol xinafoate
61983258|NCT01802723|EXPERIMENTAL|LIPO-202, High|Drug: salmeterol xinafoate
61983259|NCT01802723|EXPERIMENTAL|LIPO-202, Placebo|Drug: Placebo
61983260|NCT00499018|EXPERIMENTAL|1|R-MegaCHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT
61983261|NCT00499018|EXPERIMENTAL|1 BIS|R-CHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT
61983262|NCT00499018|EXPERIMENTAL|2|R-MegaCHOP14 x 4 Restaging + R-MegaCHOP x 2
61983263|NCT00499018|EXPERIMENTAL|2 BIS|R-CHOP14 x 4 Restaging + R-CHOP14 x 4
61983264|NCT05175690||Trial Population|The trial population will be enrolled from adults presenting for elective, outpatient COVID-19 testing at a single center, potentially with multiple testing locations (subject to local needs at the time of the trial). The investigational device will be provided to Participants via a cell phone preloaded with Common off-the-shelf original equipment manufacturer (COTS OEM) software and the investigational Dx SaMD. The investigational device will be evaluated during a single encounter in which an FCV-SDS will be collected. No follow-up visits or participant contacts will be involved in this trial.
61983265|NCT05741515|EXPERIMENTAL|VBP Intervention Group|Children coded as abnormal on functional tests (FT) (n=12) will participate in an 8-week 5X/week home-based VBT program. At the initial visit (T0), the PI will instruct the participants (caregiver and child) in the program and provide all materials. The exercises will be led by the caregiver, with weekly in person checks by the PI to progress and provide coaching. The child/caregiver will complete a daily log to report activities and level of enjoyment. VBT will be done 5 days/week and will include 4 key categories of exercises, each lasting 5 minutes (20 minutes total of exercise per day). The 4 categories, explained below, include: 1) Times 1 (X1) Viewing, 2) Gaze Shifting, 3) Static Balance, 4) Dynamic Balance. The proposed VBT home program will include 10 minutes of gaze stabilization exercises, and 10 minutes of balance training.
61983266|NCT05741515|SHAM_COMPARATOR|Sham Intervention|"Sham Intervention (not to be compared to intervention - for feasibility only):~Aim 1 is to establish the feasibility of a control intervention to be used in future studies. Therefore, 3 participants who score above the set criterion for the Functional Tests (FT) (i.e., they do not need VBT) will participate in an 8-week sham intervention. At T0, the PI will instruct the participants to do the sham intervention, led by the caregiver with weekly checks to control for attention bias. The sham intervention will be done for 20 minutes per day and will consist of 10 minutes of focused reading a book of the child's choice and 10 minutes of active play. The child and caregiver will complete a daily activity log documenting the activity and level of enjoyment."
61983267|NCT03453684|EXPERIMENTAL|Administration of Vancomycin|Administration of Vancomycin 15 mg/kg over 1 hour prior to surgical incision
61983268|NCT02201654|OTHER|EBUS patients|All patients in our study are in the same arm, as each patient serves as their own internal control. More specifically, each enrolled patient will receive both traditional EBUS (with the usage of stylet) and experimental EBUS (EBUS without a stylet) at each lymph node that is included in the experimental analysis.
61983269|NCT01481142|EXPERIMENTAL|Adacolumn|
61983270|NCT05635227|EXPERIMENTAL|Dexamethasone|The dexamethasone kit will contain 20 mg of dexamethasonphosfat (Dexavit®,Vital Pharma Nordic), 4mg/mL, i.e. 5 mL, which corresponds to 16.67 mg of dexamethasone. Dexamethasone will be administered as an intravenous bolus infusion over 2 minutes after induction of anaesthesia.
61983271|NCT05635227|PLACEBO_COMPARATOR|Placebo (for Dexamethasone)|The placebo kit will contain 5 mL of isotonic (0.9%) normal saline. Placebo will be administered as an intravenous bolus infusion over 2 minutes after induction of anaesthesia.
61983272|NCT05635227|EXPERIMENTAL|Olanzapine|The olanzapine kit will consist of two capsules each containing two 2.5 mg tablets of olanzapine (Olanzapine Stada®, STADA Nordic); i.e. total dose 10mg. The capsules will be delivered to the patient with instruction to take the capsule orally along with other standardized pre-procedure medicine. Patient intake will be recorded.
61983273|NCT05635227|PLACEBO_COMPARATOR|Placebo (for Olanzapine)|The placebo kit will consist of two placebo capsules identical to the capsules containing the olanzapine tablet. The capsules will be delivered to the patient with instruction to take the capsule orally along with other standardized pre-procedure medicine. Patient intake will be recorded.
61983274|NCT05635227|EXPERIMENTAL|Flow-targeted hemodynamic management|In the 'flow group', an arterial oxygen delivery (DO2) above 274 mL/min/m2 BSA AND a central venous oxygen saturation (ScvO2) above 70% will be targeted. CPB pump flow will be initiated at a flow rate of 2.4 L/min/m2. If DO2 or ScvO2 are below target, CPB pump flow will be gradually increased until targets are reached up to a maximum CPB pump flow of 3.2 L/min/m2. If DO2 or ScvO2 are below targets despite a maximum CPB pump flow, PaO2 will be gradually increased from an initial target of 15-20 kPa to a maximum of 40 kPa. A haematocrit level equal to or above 21% will be targeted, however, if DO2 or ScvO2 are below target despite a CPB pump flow of 3.2 L/min/m2, the haematocrit target level will be increased to equal to or above 25%. A MAP down to 35 mmHg will be tolerated throughout. The MAP target will be achieved by administration of boluses of phenylephrine up to a total of 2.0 mg, which can be followed by a continuous infusion of norepinephrine up to 0.6 μg per kg per min.
61983275|NCT05635227|ACTIVE_COMPARATOR|Pressure-targeted hemodynamic management|In the 'pressure group' a MAP between 70 to 80 mmHg will be targeted. The assigned MAP target will be achieved by administration of boluses of phenylephrine up to a total of 2.0 mg, which can be followed by a continuous infusion of norepinephrine up to 0.6 μg per kg per min. CPB pump flow will be fixed at a flow rate of 2.4 L per minute per square meter body surface area. A haematocrit level equal to or above 21% will be targeted throughout. A PaO2 of 15-20 kPa will be targeted throughout.
61983276|NCT05635227|EXPERIMENTAL|Low tidal-volume ventilation|"During initiation of CPB, the 'ventilation' group will receive a tidal volume at 3ml/kg and a set PEEP of 3 cm H2O. The respiratory frequency (RF) will be set at 10, and the inspiratory: expiratory (I:E) ratio will be set to 5:1. Peak pressures (Pmax) will be limited to \< 25 cm H2O. FiO2 will be set at 50%. The ventilation strategy will be maintained during CPB.~Any recruitment manoeuvres will be initiated solely at the discretion of the attending anaesthesiologist, and only if the patient's oxygen saturation drops below 88%. All recruitment manoeuvres will be completed by increasing the inspiratory pressure to 20 cmH2O for 10 seconds. The manoeuvre will be repeated three times."
62362695|NCT04287439|EXPERIMENTAL|Relaxation|"Patients will receive a training session for progressive muscle relaxation exercise.~They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence."
61983277|NCT05635227|ACTIVE_COMPARATOR|No ventilation|"The 'no-ventilation' group will receive no ventilation or PEEP. The ventilation strategy will be maintained during CPB.~Any recruitment manoeuvres will be initiated solely at the discretion of the attending anaesthesiologist, and only if the patient's oxygen saturation drops below 88%. All recruitment manoeuvres will be completed by increasing the inspiratory pressure to 20 cmH2O for 10 seconds. The manoeuvre will be repeated three times."
61983278|NCT01735643|EXPERIMENTAL|interactive videogame intervention|
61983279|NCT01735643|EXPERIMENTAL|waiting group|
61983280|NCT01754233|EXPERIMENTAL|755nm Alexandrite Laser|755nm Alexandrite Laser
61983281|NCT03914040|EXPERIMENTAL|IPSE program|IPSE is conceptually divided in two phases: 1) pre-immersion preparation, 2) immersion.
61983282|NCT03914040|NO_INTERVENTION|Traditional course|Participants in the control group will receive the current face-to-face course.
62362696|NCT04287439|EXPERIMENTAL|Meditation|Patients will receive a training session for minfullness meditation They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
61983283|NCT01522755||Patients implanted with the CapsureFix MRI pacing lead|Patients implanted with the CapsureFix MRI pacing lead model 5086
61983284|NCT01786954|EXPERIMENTAL|Icare then Goldmann then Tonopen|Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation. Patients receive Icare first and then are randomized to receive Tonopen followed by Goldmann OR Goldmann followed by Tonopen. This arm is Icare then Goldmann then Tonopen.
61983285|NCT01786954|EXPERIMENTAL|Icare then Tonopen then Goldmann|Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation. Patients receive Icare first and then are randomized to receive Tonopen followed by Goldmann OR Goldmann followed by Tonopen. This arm is Icare then Tonopen then Goldmann.
61983286|NCT01331954|EXPERIMENTAL|HIFU|
61983287|NCT01764009|EXPERIMENTAL|Plasmid AMEP electrotransfer in muscle|
61983288|NCT02910076|EXPERIMENTAL|Healthy volunteers|
61983289|NCT02910076|EXPERIMENTAL|Diabetes patients|
61983290|NCT05214482|EXPERIMENTAL|Phase Ib|Subjects receive AK112 plus AK117 until progression
61983291|NCT05214482|EXPERIMENTAL|Phase II|AK112 + chemotherapy± AK117 until progression; AK117 + chemotherapy;
61983292|NCT01080690|ACTIVE_COMPARATOR|EGD|In this arm EGD will be performed before EUS
61983293|NCT01080690|ACTIVE_COMPARATOR|EUS|In this arm, EUS will be performed before EGD.
61983294|NCT05568147|EXPERIMENTAL|Aspirin 100 mg daily|Once enrolled, patients will receive aspirin 100mg orally once per day
61983295|NCT05568147|PLACEBO_COMPARATOR|Placebo|Once enrolled, patients will receive placebo orally once per day
61983296|NCT05492331|EXPERIMENTAL|Music Therapy during the IUI procedure|Subjects undergoing an intrauterine insemination (IUI) procedure will experience music therapy during the procedure.
61983297|NCT05492331|NO_INTERVENTION|Standard of Care|Subjects will receive standard of care for intrauterine insemination (IUI) procedure.
61983298|NCT01684631||Hip arthroplasty|Patients implanted with a PINNACLE® ULTAMET™ Metal-on-Metal implant for conventional total hip arthroplasty for the treatment of a severe hip disease or true femoral cervical fracture.
61983299|NCT04588987|EXPERIMENTAL|Neoadjuvant group|Patients need to treat with PD-1 and apatinib before surgery. Sequential therapy with PD-1 and apatinib when patients accepted surgery.
61983300|NCT04588987|EXPERIMENTAL|Adjuvant group|Before surgery, patients no need to treat with PD-1 and apatinib. Sequential therapy with PD-1 and apatinib when patients accepted surgery.
61983301|NCT00368056|EXPERIMENTAL|1|eszopiclone 3 mg
61983302|NCT00368056|PLACEBO_COMPARATOR|2|Placebo tablet
61983303|NCT04416087|EXPERIMENTAL|Experimental group|The experiment consists of a supine bicycle exercise in a positron emission tomography (PET) scanner. Each subject will perform the experiment as well as serve as their own control (tumor blood flow at rest vs. blood flow during exercise).
61983304|NCT02489344|EXPERIMENTAL|GZ/SAR402671|Participants received GZ/SAR402671 15 milligrams (mg) once daily orally for 30 months in this extension study (LTS14116).
61983305|NCT01092533|EXPERIMENTAL|Mycophenolate sodium + Prednisolone|Mycophenolate sodium 1440 mg/day Prednisolone: initial dose 1 mg/kg/day, maintenance dose 5 mg/day
61983306|NCT01092533|ACTIVE_COMPARATOR|Prednisolone|Prednisolone: initial dose 1 mg/kg/day, maintenance dose 5 mg/day
61983307|NCT04416503|EXPERIMENTAL|Intervention group|Foot reflexology was performed for 12 week in the intervention group, whereas the control group continued their routine treatment and follow-up.
61983308|NCT04416503|NO_INTERVENTION|Control group|Usual follow-up was done to the control group.
61983309|NCT06536803|ACTIVE_COMPARATOR|high-load strength training with tisssue specific plantar fascia stretching exercise|Experimental group will receive high load strength training and Tissue-specific plantar fascia stretching exercise and routine physiotherapy. Pain, range of motion and functional disability will be measured before session, immediate effect after first session,then after 06 weeks (18 session) with high load strength training maximum repetition 12 RM with 3 sets in alternative days in each set minimum 2 mint rest interval and tissue specific plantar fascia stretching exercise perform for 10 times for 10 sec, after 12 weeks (36 sessions) with high load strength training maximum repetition 10 RM with 4 sets in alternative days in each set minimum 2 mint rest interval tissue specific plantar fascia stretching exercise perform for 10times
61983310|NCT06536803|ACTIVE_COMPARATOR|high-load strength training with routine physiotherapy|active compator group will then receive high load strength training and routine physiotherapy ultrasonic therapy
62362697|NCT04287439|ACTIVE_COMPARATOR|Attention matched control group|Patients will receive a training session focusing on the anatomy and physiological functions of the pancreas, general information about type 2 diabetes including signs, complication, and treatment methods.
61983311|NCT03878745|EXPERIMENTAL|BD Nano™ PRO 32G pen needle|Participants are to perform 6 pairs of injections.
61983312|NCT03878745|ACTIVE_COMPARATOR|Terumo Nanopass® 34G pen needle|Participants are to perform 6 pairs of injections.
61983313|NCT01919060||lesions in colon|
61983314|NCT01919060||lesions in extra-colon|
61983315|NCT04628676|EXPERIMENTAL|TXA group|tranexamic acid added to irrigation solution
61983316|NCT04628676|EXPERIMENTAL|EPN group|epinephrine added to irrigation solution
61983317|NCT03200496|EXPERIMENTAL|TALION®|
61983318|NCT03200496|EXPERIMENTAL|DA-5206(Fasting)|
61983319|NCT03200496|EXPERIMENTAL|DA-5206(Fed)|
61983320|NCT04022720|EXPERIMENTAL|Platelet Rich Fibrin (PRF) Group|Patients randomized to this group will receive treatment with a PRF graft.
61983321|NCT04022720|NO_INTERVENTION|No Platelet Rich Fibrin Group|Participants in the observational control group will be managed at the time of the complication by standard of care methods.
61983322|NCT00584142|EXPERIMENTAL|1|
61983323|NCT00584142|NO_INTERVENTION|2|
61983324|NCT06388863|EXPERIMENTAL|FMT capsule group|Participants will be given 6 FMT capsules twice a week for 24 weeks. The FMT capsules derived from healthy donors.
61983325|NCT06388863|PLACEBO_COMPARATOR|Placebo capsule group|Participants will be given 6 placebo capsules twice a week for 24 weeks. Placebo capsules are identical in appearance and smell as FMT capsules but contain milk powder.
62362698|NCT03419845|EXPERIMENTAL|Step Right Buddy arm|To use modified walking frame using the Step Right Buddy
62362699|NCT00435149|ACTIVE_COMPARATOR|1|
62362700|NCT00435149|ACTIVE_COMPARATOR|2|
61983326|NCT06208059|ACTIVE_COMPARATOR|manual acupuncture group|In the manual acupuncture group, participants will be needled in the scalp motor area on the lesion side and left in place for 30 minutes after obtaining qi. During needle retention, the needles will be intermittently twisted for 2min twice, with a frequency of about 200 r/min. Participants will receive treatment once daily, with six consecutive days of treatment followed by one day of rest each week, for three weeks.
61983327|NCT06208059|EXPERIMENTAL|electroacupuncture group|The same acupoint was selected as the manual acupuncture group in the electroacupuncture group. After obtaining qi, electroacupuncture stimulation will be applied using a continuous wave at a frequency of 2 Hz. The stimulation intensity will be adjusted based on the patient's tolerance, and each treatment will be lasted for 30 minutes. Participants will receive treatment once daily, with six consecutive days of treatment followed by one day of rest each week, for three weeks.
61983328|NCT02085785|EXPERIMENTAL|Coached|Participants randomized to the coached arm will receive the same educational and self-monitoring materials as the self-directed group. In addition, participants in the coached arm will receive 11 calls from a health coach and a single visit to their home by an exercise specialist.
61983329|NCT02085785|ACTIVE_COMPARATOR|Self-directed|Participants randomized to the self-directed arm will receive the same educational and self-monitoring materials as the coached group, but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.
61983330|NCT02085785|OTHER|Screened|Individuals who were contacted to inform them about the study or who contacted study personnel to express an interest in participating. This group is presented in order to present statistics on feasibility regarding recruitment
61983331|NCT02444260|SHAM_COMPARATOR|Intravenous Normal Saline|Intravenous Normal Saline plus Lignocaine HCl (1%) - administered by wound infiltration to a maximum dose of 4.5mg/kg ; Bupivocaine HCl (0.25%) - administered by wound infiltration to a maximum dose of 2 mg/kg plus i
61983332|NCT02444260|ACTIVE_COMPARATOR|Midazolam|Lignocaine HCl (1%) - administered by wound infiltration to a maximum dose of 4.5mg/kg Bupivocaine HCl (0.25%) - administered by wound infiltration to a maximum dose of 2 mg/kg plus Midazolam - administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg.
61983333|NCT02561637|EXPERIMENTAL|Case management|Before admission the spouse-patient dyads will take part in an interview with the case manager assessing the spouses' needs during admission through an individual care plan. During admission the case manager will follow-up and assess the goals and actions of the individual care plan and coordinate with other health professionals. During the discharge meeting the case manager will provide additional information to the spouse according to needs assessed in the care plan. After discharge the case manager will conduct a follow-up telephone call for the spouse 3-4 days and 10 days after the patient's discharge consisting of information similar to that provided at the discharge meeting.
61983334|NCT02561637|OTHER|Control group|Spouses and patients in the control group will receive usual care and written and oral information about the fast-track program and principles in general from the nursing staff. The usual care and information is provided before admission in the out-patient facilities and during admission
61983335|NCT01813084|EXPERIMENTAL|Part A: single dose escalation|
61983336|NCT01813084|EXPERIMENTAL|Part B: 14 day repeat dose escalation (healthy volunteers)|
61983337|NCT01813084|EXPERIMENTAL|Part C: 14 day repeat dose (asthma patients)|
61983338|NCT02133248||kidney recipient waitlist|Subjects on waitlist for Kidney transplant who are sensitized
61983339|NCT02133248||chronic antibody mediated rejection|Kidney transplant recipient who are diagnosed with chronic antibody mediated rejection
61983340|NCT02133248||control|Normal subjects-no kidney transplant or chronic rejection
61983341|NCT05098860|ACTIVE_COMPARATOR|Home Exercise Program|"The home exercise program includes a general educational training program. The program includes active stretching, strengthening, and stabilization exercises of neck muscles, head and neck posture exercises as well as relaxation and diaphragmatic breathing exercises.~Patients will be asked to do home exercises for 30-45 minutes once a day, 5 days a week for 8 weeks."
61983342|NCT05098860|ACTIVE_COMPARATOR|Manual Therapy Combined with Home Exercise Program|"Manual Therapy includes soft tissue and joint mobilizations of the cervical vertebrae, scapula and thoracic vertebrae. MT will be applied to the patients 2 days a week for 8 weeks.~The home exercise program includes active stretching, strengthening, and stabilization exercises of neck muscles, head and neck posture exercises as well as relaxation and diaphragmatic breathing exercises."
61983343|NCT05098860|ACTIVE_COMPARATOR|Tele-rehabilitation Assisted Program|Tele-rehabilitation assisted program will be given in the on-line environment. During 8 weeks, regularly planned exercises will be done via online applications for 30-45 minutes 2 days a week, accompanied by a physiotherapist. These patients will apply active cervical and thoracic region mobilizations called self-mobilization. Patients will be taught active mobilization applications with the help of a towel for the cervical region, with the assistance of a foam-roller for active mobilization of the thoracic region.
61983344|NCT04426331|NO_INTERVENTION|No Voucher|"Individuals being referred from screening events randomized to no intervention received the standard approach to offering free follow-up examinations (patient education, standard counseling, appointment information packet, reminder phone calls)."
61983345|NCT04426331|EXPERIMENTAL|Voucher Without Value Information|"In addition to receiving the standard approach above, individuals being referred from screening events randomized to Voucher Without Value Information received a personal voucher."
61983346|NCT04426331|EXPERIMENTAL|Voucher With Value Information|"In addition to receiving the standard approach above, individuals being referred from screening events randomized to Voucher With Value Information received a personal voucher, which differed from the voucher in the second arm since it included a statement of value."
61983347|NCT02367677||Clinical measurements|Measurements are made with a paper ruler
61983348|NCT02367677||Smartphone|Measurements are made with ImageJ from pictures taken with an iPhone 6
61983349|NCT02367677||Digital camera|Measurements are made with ImageJ from pictures taken with a Nikon D700
61983350|NCT00469560|EXPERIMENTAL|Deferasirox|
62362701|NCT02024945||Propiverine|Participants with symptoms of OAB, prescribed propiverine in accordance with the summary of product characteristics (SPC).
62362702|NCT03199742|ACTIVE_COMPARATOR|PTSD Coach with no Coaching|Participants will receive the PTSD coach mobile app.
61983351|NCT05372848|OTHER|Group 1|Group 1 includes volunteers who used to use manual toothbrushes and started to use an electric toothbrush for 1 month with the same daily brushing routine. Fifteen healthy individuals between the ages of 20 and 30 years with no systemic disease, restoration or caries, and whom have the criteria for using a manual toothbrush for at least 2 years included in Group 1.
61983352|NCT05372848|OTHER|Group 2|Group 2 includes volunteers who used to use an electric toothbrush and started to use a manual toothbrush for 1 month with the same daily brushing routines. Fifteen healthy individuals between the ages of 20 and 30 years with no systemic disease, restoration or caries, and whom have the criteria for using an electric toothbrush for at least 2 years included in Group 2.
61983353|NCT05847231|EXPERIMENTAL|mandala app|mandala will be aplicated
61983354|NCT05847231|NO_INTERVENTION|routine maintenance practice|Routine maintenance will be applied.
61983355|NCT02848014|EXPERIMENTAL|Expectation|Participants are asked to think and write about ways how they can positively influence/control the stress during stress induction. They also can think of strategies they used in their past. The purpose of this arm is to improve participants' personal control expectations.
61983356|NCT02848014|EXPERIMENTAL|Emotion|Participants in this group are asked to write a gratitude-letter to a person they want to thank. The purpose of this arm is to foster positive emotions.
61983357|NCT02848014|ACTIVE_COMPARATOR|Control|Participants in this group are asked to do a neutral writing task. The task is to write a protocol of yesterday's to-dos.
61983358|NCT06543069|EXPERIMENTAL|single arm|Sintilimab and Bevacizumab Combined with Pemetrexed and Cisplatin
61983359|NCT01558752|EXPERIMENTAL|Titanium Shell with CORAIL stem|Patients in Group 1 will receive a total hip replacement with titanium shell and CORAIL stem.
61983360|NCT01558752|ACTIVE_COMPARATOR|Modular Titanium Femoral Stem (Tri-Lock)|Patients in Group 2 will receive a total hip replacement with Modular Titanium Femoral Stem (Tri-lock).
61983361|NCT05663307|ACTIVE_COMPARATOR|Ginkgo diterpene lactone meglumine injection|Intravenous injections of Ginkgo diterpene lactone meglumine injection at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days ;Aspirin at a dose of 100 mg per day for 90 days.
61983362|NCT05663307|PLACEBO_COMPARATOR|Ginkgo diterpene lactone meglumine injection simulation|Intravenous injections of Ginkgo diterpene lactone meglumine injection simulation at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days ;Aspirin at a dose of 100 mg per day for 90 days.
61983363|NCT01068119|EXPERIMENTAL|Same-day discharge|Same-day discharge following PCI
61983364|NCT00505843|OTHER|1|7mg MK0657 capsules + \>/=1.0 mg/kg/hr dose of levodopa.
61983365|NCT00505843|OTHER|2|7mg MK0657 Pbo capsules + \>/=1.0 mg/kg/hr dose of levodopa.
61983366|NCT02087527|EXPERIMENTAL|CORTICOSTEROID|In addition to standard care for cellulitis, subject will receive intravenous Dexamethasone (8mg/2ml) 0.15 mg/kg/dose every 6 hours for the first 48 hours
62362703|NCT03199742|EXPERIMENTAL|PTSD Coach with Peer Coaching|Participants will receive the PTSD Coach + mobile app which will provide routine, personalized coaching for 8 weeks from a Veteran peer.
61983367|NCT02087527|PLACEBO_COMPARATOR|NORMAL SALINE|In addition to standard care for cellulitis, subject will receive normal saline solution administered intravenously using the same volume as the active drug group every 6 hours for the first 48 hours
61983368|NCT02045576|EXPERIMENTAL|Sleep position trainer|Nightbalance
61983369|NCT02045576|ACTIVE_COMPARATOR|Oral Appliance Therapy|Somnodent
61983370|NCT02496832|EXPERIMENTAL|FAZA PET-CT scan|"FAZA PET-CT imaging within 14 days of treatment from the EMR200592-001 study.~FAZA PET-CT imaging about 5 weeks after start of treatment from the EMR200592-001 study."
61983371|NCT00628992|OTHER|1|
61983372|NCT00628992|ACTIVE_COMPARATOR|2|
61983373|NCT00628992|ACTIVE_COMPARATOR|3|
61983374|NCT00628992|ACTIVE_COMPARATOR|4|
61983375|NCT06201117|EXPERIMENTAL|Preparatory information|In the experimental group, the participants will rate their anxiety before receiving the 12-minute preparation information video in addition to the usual preparation information on the day they gave consent to participate in the study. The participants will rate their anxiety again 30 minutes after the intervention. The experimental group will receive the preparation video again the second time on the day before surgery. Anxiety and treatment adherence will be measured in the ICU, 48 hours after the surgery.
61983376|NCT06201117|ACTIVE_COMPARATOR|Usual information|In the comparison group, the participants will rate their anxiety before receiving the usual preoperative information on the day they gave consent to participate in the study. The participants will rate their anxiety again 30 minutes after the usual information. Anxiety and treatment adherence will be measured in the ICU, 48 hours after the surgery.
61983377|NCT02444286||standard care group|optimal standard of care therapy
61983378|NCT02444286||device group|Follow-up of MitraClip device implantation plus optimal standard of care therapy
61983379|NCT04681170|OTHER|Age 5-10 years|Age 5-10 years Lomitapide dosing will commence with 2mg at week 1 for 8 Weeks,then increase to 5mg Week 8±3 days, 10 mg at Week 12±3 days to the maximum allowable dose of 20 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
61983380|NCT04681170|OTHER|Age11-15years|Lomitapide dosing will commence with 2mg at week 1 for 4 Weeks, then increase to 5mg Week 4±3 days, 10 mg at Week 8±3 days,20mgs at week, 12±3 days to the maximum allowable dose of 40 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
61983381|NCT04681170|OTHER|16 to ≤17 years|Lomitapide dosing will commence with 5mg at week 1 for 4 Weeks, then increase to 10mg Week 4±3 days,20 mg at Week 8±3 days,40mgs at week, 12±3 days to the maximum allowable dose of 60 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
62169346|NCT03058237|EXPERIMENTAL|Part 3: Regimen N|"An optional regimen of one mid-high dose of the selected Arbaclofen Placarbil MR prototype tablet (if not previously dosed in Regimen M) or two mid-low dose of the selected Arbaclofen Placarbil MR prototype tablets.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
62169347|NCT06477562||Proximal gastrectomy with double tract reconstruction group|
62362704|NCT03199742|EXPERIMENTAL|PTSD Coach with Clinician coaching|Participants will receive the PTSD Coach + mobile app which will provide routine, personalized coaching for 8 weeks from a clinical psychologist.
61983382|NCT02410954|EXPERIMENTAL|tDCS electrode configuration|Three rounds of tDCS using NeuroConn Direct Current stimulator Multiple Channel -4, Rogue Resolutions treatment optimization where each round includes identifying a promising electrode configuration based on electric field modeling using a realistic head model and capitalizing on the experience with the prior round (for rounds 2 and 3) and testing that electrode placement by administering a series of electrical doses of tDCS with that tDCS electrode configuration (carrying out a dose titration) in a cohort of 10 healthy control subjects to see if we can find an electrical dose which is well-tolerated, safe, suppresses the AOT pupil response and is below recommended current density safety limits (the safety limit in terms of Amperage varies depending on the electrode configuration)
61983383|NCT02410954|PLACEBO_COMPARATOR|Using tDCS to reduce acute fear|Administration of 7.5% CO2 to see if this elicits symptoms of Acute Fear and activates LC and whether tDCS safely inhibits the LC response to 7.5% CO2 compared with sham in a pilot cross-over trial (N=10). A 3-year double-blind, randomized, controlled trial where clinical symptoms of Acute Fear, the primary outcome are elicited with 7.5% CO2 in healthy volunteers is the final study component.
61983384|NCT00227903|EXPERIMENTAL|MI-CBT|Motivationally-enhanced cognitive behavioral skills counseling
61983385|NCT00227903|ACTIVE_COMPARATOR|Brief Advice|Advice and education
61983386|NCT04380259|EXPERIMENTAL|MBTR-R (Mindfulness-Based Trauma Recovery for Refugees)|Mindfulness-based group intervention consisting of nine 2.5-hour weekly sessions.
61983387|NCT04380259|NO_INTERVENTION|Waitlist-Control|Following the 9-week waitlist period and 1-week post-intervention assessment, participants randomized to waitlist-control were offered an equivalent group intervention (i.e., 22.5 total hours, group instructor and cultural mediator, psychoeducation and low-intensity cognitive behavior therapy skill training, relaxation techniques).
61983388|NCT04061811||HF (heart failure)|Patients with end stage renal disease requiring dialysis with reduced or preserved ejection fraction.
61983389|NCT04061811||Control|Patients with end stage renal disease requiring dialysis without HF.
61983390|NCT05608044|EXPERIMENTAL|Combination Botensilimab Dose 1 plus Balstilimab|Participants will receive botensilimab at dose 1 given IV and balstilimab given IV.
61983391|NCT05608044|EXPERIMENTAL|Combination Botensilimab Dose 2 plus Balstilimab|Participants will receive botensilimab at dose 2 given IV and balstilimab given IV.
61983392|NCT05608044|EXPERIMENTAL|Monotherapy Botensilimab Dose 1|Participants will receive botensilimab dose 1 given IV.
61983393|NCT05608044|EXPERIMENTAL|Monotherapy Botensilimab Dose 2|Participants will receive botensilimab dose 2 given IV.
61983394|NCT05608044|ACTIVE_COMPARATOR|Standard of Care|Participants will receive select standard of care as determined by the investigator.
61983395|NCT02307955|EXPERIMENTAL|firefly|participants treated with firefly device
61983396|NCT02307955|OTHER|Control|Standard of care
61983397|NCT03657758|ACTIVE_COMPARATOR|EPA and statin therapy group|After randomization, patients with combination therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
61983398|NCT03657758|ACTIVE_COMPARATOR|High dose statin therapy group|After randomization, patients with high dose statin therapy start high dose rosuvastatin (10mg/day) for ９ months.
61983399|NCT03657758|NO_INTERVENTION|low dose statin therapy group|After randomization, patients with low dose statin therapy take low dose rosuvastatin (5mg/day) for ９ months.
61983400|NCT03099044|ACTIVE_COMPARATOR|Single Active Dose|Subjects are assigned to receive a single Active beverage and a single placebo beverage.
61983401|NCT03099044|ACTIVE_COMPARATOR|Double Active Dose|Subjects are assigned to receive 2 doses of Active beverage.
61983402|NCT03099044|PLACEBO_COMPARATOR|Placebo comparator|Subjects are assigned to receive 2 doses of a placebo beverage.
61983403|NCT05970757|OTHER|Extended MRI group|The MRI-scan time is extended with 15-20 minutes.
61983404|NCT01462721|OTHER|SVG + eSVS Mesh vs Control SVG|Either the Circumflex Coronary Artery (Cx) or the Right Coronary Artery (RCA) will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
61983405|NCT01882374|EXPERIMENTAL|TXA127, blood draws, physical exams|Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of hematologic malignancies. Treatment dose is 300 mcg/kg/day TXA127.
61983406|NCT05040854||Healthy Subjects|Blood donors
61983407|NCT05040854||IBD patients - under biological therapy|Patients with IBD followed up in consultation on biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23.
61983408|NCT05040854||IBD patients - naive|Patients newly diagnosed with IBD and need for biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23,
61983409|NCT06423144||Group LS|Logical therapy combined with systemic therapy
61983410|NCT06423144||Group S|Systemic therapy alone（PD-1/PD-L1 inhibits and anti-angiogenic agents）
61983411|NCT01408979|EXPERIMENTAL|12 hours of magnesium sulfate|Patients in this group will have magnesium sulfate administered for 12 hours after delivery
61983412|NCT01408979|ACTIVE_COMPARATOR|24 hours of magnesium sulfate|Patients in this group will have magnesium sulfate administered for 24 hours after delivery
61983413|NCT02474992|EXPERIMENTAL|Intervention|This arm is eligible for participation in the Microclinic intervention, a social network-based educational program.
61983414|NCT02474992|NO_INTERVENTION|Comparison|This arm is not eligible for participation in the intervention during the first twelve months of the study. Following collection of the primary study endpoints, this arm will also be invited to participate in a Microclinic group. Participants in this arm will still have access to standard HIV care at the facility of their choice. At time of recruitment into the study, prior to randomization, all eligible participants will be counseled on the importance of returning to their clinic for ongoing HIV care.
61983415|NCT00875225|ACTIVE_COMPARATOR|Control DVD|Control DVD with usual care information
61983416|NCT00875225|ACTIVE_COMPARATOR|Intervention DVD|Intervention group will receive DVD with patient stories and information from health care professionals
61983417|NCT01314833|EXPERIMENTAL|TC*6|6 cycles of (Docetaxel 75mg/m2 ivgtt d1+ Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) .
61983418|NCT01314833|EXPERIMENTAL|CEF*3-T*3|3 cycles of CEF (Epirubicin 100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
61983419|NCT01314833|EXPERIMENTAL|EC*4-wP*12|4 cycles of EC (Epirubicin 90 mg/m2 ivgtt d1+Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) followed by 4 cycles of Paclitaxel (Paclitaxel 80mg/m2, ivgtt d1,8,15, 21days per cycle)
61983420|NCT03036787||moderate-early preterm infants|infant who births in 32 weeks to 37 weeks with family based intervention
61983421|NCT03036787||extremely-very preterm infants|infant who births in 27 weeks to 32 weeks with family based intervention
61983422|NCT03989999|EXPERIMENTAL|TCD Group|Transcranial Doppler within 8 hours of traumatic injury
61983423|NCT03989999|NO_INTERVENTION|CONTROL Group|Mild TBI management with SFMU recommandations
61983424|NCT01243970|ACTIVE_COMPARATOR|phenylephrine infusion|
61983425|NCT01243970|ACTIVE_COMPARATOR|Ephedrine infusion|
61983426|NCT03021850|ACTIVE_COMPARATOR|Stretching associated with shortwave heating|Applying deep heat through the shortwave equipment for 20 minutes, in coplanar application to the posterior part of the thigh associated with flexibility training of the hamstrings in the last 10 minutes of the session, performed by passive static stretching of the hamstring muscles in 10 repetitions of 30 seconds, with a 10 second pause between each repetition.
61983427|NCT03021850|ACTIVE_COMPARATOR|Stretching associated with cryotherapy|Cryotherapy application for 20 minutes, applied to the posterior part of the thigh associated with flexibility training of the hamstring muscles in the last 10 minutes of the session, performed by passive static stretching of the hamstring muscles, in 10 repetitions of 30 seconds , with a 10 second pause between each repetition.
61983428|NCT03021850|OTHER|Stretching isolated|The flexibility training of the hamstring muscles will be by passive static stretching of the hamstring muscles in 10 repetitions of 30-second , with a 10-second pause between each repetition.
61983429|NCT04052984|EXPERIMENTAL|Intervention group|Twenty four pares of healthy mothers-newborns, with delayed clamping and immediate skin-to-skin contact after birth by caesarean section
61983430|NCT04052984|NO_INTERVENTION|Control group|Twenty four pares of healthy mothers-newborns, with early clamping without skin-to-skin contact after birth by caesarean section and newborn attended in radiant warm table
61983431|NCT06366321|OTHER|conventionally constructed denture|construction of complete dentures by conventional (lost wax casting) technique
61983432|NCT06366321|OTHER|digitally constructed denture|construction of complete dentures by digital (CAD/CAM milling) technique
61983433|NCT04662047||Adults and children living in the 11 principal cities of Cataluña, Spain.|Adults and children living in the 11 principal cities of Cataluña, Spain: Barcelona, Hospitalet de Llobregat, Tarrasa, Badalona, Sabadell, Lérida, Tarragona, Mataró, Santa Coloma de Gramanet, Reus, Girona.
61983434|NCT04188522||Minor Stroke|"We will enroll a cohort of 15 adult patients previously admitted to Johns Hopkins Bayview Medical Center with small/minor acute ischemic stroke visible on neuroimaging. Patients will follow-up in clinic 4-6 weeks following hospital discharge. To be eligible for the study, patients must have a minor stroke, defined as NIH Stroke Scale score at follow-up of less than or equal to 8, modified Rankin score of 0-2, be competent speakers of English, and have no prior history of stroke, dementia, or untreated psychiatric disease. Those with proximal large vessel (M1) or branch (M2) occlusions will be excluded.~\*Based on preliminary results we have expanded our trial and will continue to recruit up to 40 patients with minor stroke."
61983435|NCT04188522||Controls|For comparison, we will recruit a group of age-similar controls (n=15) without neurologic disease or prior clinical history of stroke.
61983436|NCT04723381|EXPERIMENTAL|Experimental|Partivipants recieved web based genital hygiene education for seven week
61983437|NCT04723381|NO_INTERVENTION|Control|No intervention was applied to the women in the control group
61983438|NCT02680743|EXPERIMENTAL|Intervention Group|"Patients who fail newborn hearing screen will be screened for CMV by saliva PCR. If positive they will be referred for early hearing screen follow-up and early intervention.~They will also receive a consult with PEdiatric Infectious Disease to evaluate need for treatment.~Intervention:Education of parents to pursue prompt hearing screening."
61983439|NCT01968590|ACTIVE_COMPARATOR|cholecalciferol 600 IU|cholecalciferol in Ddrops form at either 600 International units per day versus 4,000 IU per day
61983440|NCT01968590|ACTIVE_COMPARATOR|cholecalciferol 4,000 IU|Cholecalciferol at 4,000 IU per day in the form of liquid Ddrops
61983441|NCT03103997|ACTIVE_COMPARATOR|New Needle|EUS-guided liver biopsy with needle and suction, no preparation
61983442|NCT03103997|EXPERIMENTAL|Dry Heparin|EUS-guided liver biopsy with needle flushed with heparin, then flushed with air, suction then attached
61983443|NCT03103997|EXPERIMENTAL|Wet Heparin|EUS-guided liver biopsy with needle flushed with heparin, 2 cc of liquid added to suction then attached.
61983444|NCT03294733|OTHER|Ultrasound|Ultrasound wrists to determine carpal tunnel size
61983445|NCT04323280|ACTIVE_COMPARATOR|Conventional Therapy|Ibuprofen 600mg every 8 hours for one week followed by tapering of dose by 200mg every week (3 weeks of therapy), in addition to Colchicine 0.5mg daily (\<70kg) or 0.5mg twice daily (\>70kg) for 3 months
61983446|NCT04323280|EXPERIMENTAL|Dexamethasone therapy|Dexamethasone therapy 20 mg once daily per os for 4 day in addition to colchicine therapy for 3 months 0.5mg daily (\<70kg) or 0.5mg twice daily (\>70kg)
61983447|NCT00862446|EXPERIMENTAL|Treatment|All infants will receive Omegaven
61983448|NCT03019107|EXPERIMENTAL|VentFree Stimulation|Breath synchronized abdominal NMES
61983449|NCT03019107|SHAM_COMPARATOR|Sham Stimulation|Sham breath synchronized abdominal NMES
61983450|NCT01570374|EXPERIMENTAL|iCBT|Receives treatment.
61983451|NCT01570374|NO_INTERVENTION|Waiting list control group|The waiting list control group initially receives no treatment, but do weekly screenings. After 9 weeks, the control group receives the same treatment as the other study arm.
62362705|NCT03199742|EXPERIMENTAL|PTSD Coach with Automated Coaching|Participants will receive the PTSD Coach + mobile app which will provide automated, personalized coaching for 8 weeks.
61983452|NCT02406651|EXPERIMENTAL|F-652 and systemic coritcosteroids|Subjects will be dosed once a week for four weeks with Recombinant Human Interleukin-22 IgG2-Fc (F-652). Dosing will be concurrent with systemic corticosteroids.
61983453|NCT06300242|EXPERIMENTAL|Message Only|Patients sent an email or SMS reminding them to get vaccinated against the flu.
61983454|NCT06300242|EXPERIMENTAL|Message + Financial Incentive|Patients sent an email or SMS reminding them to get vaccinated against the flu and offering them a $50 financial incentive if they are vaccinated within 1-week.
61983455|NCT06300242|ACTIVE_COMPARATOR|Active Control|Patients not sent any reminder message.
61983456|NCT00293644|EXPERIMENTAL|Pre-emptive Treatment Group|As soon as a patient becomes aware of the pregnancy, and before the Nausea and Vomiting of Pregnancy (NVP) starts, she will begin taking Diclectin®. When NVP starts, the dose will be adjusted to match symptoms.
61983457|NCT00293644|ACTIVE_COMPARATOR|Standard Treatment Group|Women randomised to this arm will not receive any Diclectin® before symptoms appear, and will be advised to commence treatment only at first sign of nausea. The starting dose of Diclectin® will be 20mg (2 tablets) at bedtime.
61983458|NCT00293644|NO_INTERVENTION|Natural Course Group|A third group will be randomly matched from Motherisk NVP callers who did not participate in our pre-emptive intervention and experienced severe Nausea and Vomiting of Pregnancy/Hyperemesis Gravidarum (NVP/HG) in their previous pregnancy. This group will serve as a control group for the potential effect of the early counselling. (These women will have called for the first time after NVP symptoms (of any degree) started in the current pregnancy).
61983459|NCT05487482|EXPERIMENTAL|Intervention Group- Receiving intervention by educating, training and homevisit|For the intervention groups, planning will be done to provide education and training. Families will be given modules on Safety Culture in the Elderly and will also receive home visits to check and monitoring the condition of the elderly at home related to adverse events and the home environment.
61983460|NCT05487482|NO_INTERVENTION|Control group|Thisi control group will only monitoring every 4 weeks by home visit. After 16 weeks, researchers will evaluate perceptions of the elderly's safety culture at home and adverse events at home
61983461|NCT00910312|EXPERIMENTAL|Breast Fibroadenoma|
61983462|NCT05945654||Anastomotic leak|Patients who had an Ivor Lewis Oesophagectomy and suffered an anastomotic leak (AL) postoperatively. AL, as defined according to ECCG (Esophagectomy Complication Consensus Group) criteria 1-3.
61983463|NCT05945654||No anastomotic leak|Patients who had an Ivor Lewis Oesophagectomy and had no AL postoperatively, ECCG 0.
61983464|NCT03410355|EXPERIMENTAL|BMAC/PRP Injection Group|This group will receive an injection of BMAC/PRP for treatment of OA
61983465|NCT03410355|ACTIVE_COMPARATOR|Cortisone Injection Group|This group will receive an injection of cortisone for treatment of OA
61983466|NCT05704504|EXPERIMENTAL|Group-based exercise intervention with EMA and personalized telephone support (SUP)|Participants in the SUP group will receive a 6-week group-based exercise intervention with ecological momentary assessment (EMA)and personalized telephone support.
61983467|NCT05704504|ACTIVE_COMPARATOR|Group-based exercise intervention (EXE)|Participants in the EXE group will receive a 6-week group-based exercise intervention.
61983468|NCT05704504|NO_INTERVENTION|No intervention control group (CON)|Participants in the CON group will not be given any intervention during the study period but will be advised to remain their typical lifestyle throughout the trial period.
61983469|NCT01518920|EXPERIMENTAL|PF-04958242|
61983470|NCT01518920|PLACEBO_COMPARATOR|Placebo|
61983471|NCT00999791|ACTIVE_COMPARATOR|Avastin|
61983472|NCT00999791|ACTIVE_COMPARATOR|Diclofenac|
61983473|NCT04566354|OTHER|Sprint exercise|Three bouts of 30-s sprint exercise with 20 min rest in between. Three fat biopsies obtained ar rest before first sprint, 15 min after and 120 min after third sprint Blood samples from stomach vein and arteria during the whole experiment
61983474|NCT03902912|EXPERIMENTAL|prednisolone|prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH plus 7. Women will be then given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
61983475|NCT01195428|ACTIVE_COMPARATOR|Simvastatin|Simvastatin 40 mg daily.
61983476|NCT01195428|PLACEBO_COMPARATOR|Placebo|Placebo
61983477|NCT05483855||Objective 1: Telehealth Visit|Any rheumatology patient, seen and treated by a participating physician, who is 19 years and older, with the target condition(s) of interest, and is already scheduled for a telehealth visit.
61983478|NCT05483855||Objective 2: ArthritisPower App|Patients diagnosed with Rheumatoid Arthritis who already have a pre-scheduled in-office visit.
61983479|NCT02074631|ACTIVE_COMPARATOR|Control group|Subjects will receive a standard recommended dose of calcium and vitamin D.
61983480|NCT02074631|EXPERIMENTAL|Pamidronate Group|Subjects randomized to pamidronate treatment will receive infusions approximately 100, 180, and 270 days after HCT along with calcium and vitamin D.
61983481|NCT05774158||Adult Congenital Heart Diseases|
61983482|NCT03586856|ACTIVE_COMPARATOR|Nasal mask interface|The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
61983483|NCT03586856|ACTIVE_COMPARATOR|Nasal prongs interface|The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
61983484|NCT04666233|EXPERIMENTAL|Resuscitation with PPE for prevention of SARS-Cov-2 infection|
62567121|NCT03458585||Group 1: patients attending for a 99mTc-MDP bone scan.|Group 1: Patients will be approached after they had their injection for the bone scan procedure. Completion of questionnaire will take place during the three hour uptake period, before they have the scan.
61983485|NCT04666233|ACTIVE_COMPARATOR|Resuscitation without PPE for prevention of SARS-Cov-2 infection|
61983486|NCT04152603|NO_INTERVENTION|Control Arm|Enrollment rates, parent/LAR-reported trust in research, and parent/LAR-reported experiences of respect during research recruitment before implementation of the BRIEF intervention.
61983487|NCT04152603|EXPERIMENTAL|BRIEF Arm|Enrollment rates, parent/LAR-reported trust in research, and parent/LAR-reported experiences of respect during research recruitment after implementation of the BRIEF intervention.
61983488|NCT01375387|EXPERIMENTAL|Lacosamide 100 mg, Japanese|1 Lacosamide 100 mg tablet plus 3 placebo tablets
61983489|NCT01375387|EXPERIMENTAL|Lacosamide 100 mg, Chinese|1 Lacosamide 100 mg tablet plus 3 placebo tablets
61983490|NCT01375387|EXPERIMENTAL|Lacosamide 200 mg, Japanese|2 Lacosamide 100 mg tablets plus 2 placebo tablets
61983491|NCT01375387|EXPERIMENTAL|Lacosamide 200 mg, Chinese|2 Lacosamide 100 mg tablets plus 2 placebo tablets
61983492|NCT01375387|EXPERIMENTAL|Lacosamide 400 mg, Japanese|4 Lacosamide 100 mg tablets
61983493|NCT01375387|EXPERIMENTAL|Lacosamide 400 mg, Chinese|4 Lacosamide 100 mg tablets
61983494|NCT01375387|PLACEBO_COMPARATOR|Placebo Comparator, Japanese|4 placebo tablets
61983495|NCT01375387|PLACEBO_COMPARATOR|Placebo Comparator, Chinese|4 placebo tablets
61983496|NCT04275440|EXPERIMENTAL|Exercise group|Participants would be required to take part in an exercise plan, under the instruction and guidance of professional sports teachers.
61983497|NCT04275440|EXPERIMENTAL|Caloric restriction group|The caloric restriction plan will be designed based on individual basal metabolic rate.
61983498|NCT04275440|EXPERIMENTAL|Combined intervention group|Participants will receive both exercise and caloric restriction intervention at the same time.
61983499|NCT05020496|NO_INTERVENTION|Group 1 (Negative Control, 20 participants)|"At the first visit, various doses of diphenylcyclopropenone (DPCP) are applied in acetone to give the required dose range, increasing by 60% increments. Elicitation patch is applied on the upper inner arm skin and removed by patients themselves exactly 6 hours after the application.~The second visit will be 48 hours after the DPCP treatment. At this visit, the bi-fold skin thickness will be measured using a Medical Skinfold Caliper.~The group1 will have only one treatment with DPCP and serve as negative controls for DPCP induced cutaneous immune responses in comparison to Group 2 and 3, which require two treatments with DPCP (sensitization and challenge) as described in the following group 2 and 3. The first reading of skin thickness prior to DPCP application serves as the baseline and the second reading after DPCP indicates an increase in skin thickness, which represents a quantitative parameter of DPCP induced immune responses."
61983500|NCT05020496|OTHER|Group 2 (Positive Control, 20 participants)|"This group of the study will take approximately 5 weeks and requires 3 visits. At the first visit, skin sites on the right upper buttock will be topically treated with a patch of the contact sensitizer (DPCP) for sensitization on the upper buttock for 48 hours. The skin patches will be removed by patients themselves after the application.~The second visit will be four weeks after the DPCP sensitization, participants will have a DPCP treatment again on the right upper inner arm with the same agent. At the visit, the bi-fold skin thickness will be measured prior to the application of DPCP skin patch by using a Medical Skinfold Caliper. Various DPCP doses are applied increasing by 60% increments. The patches are applied on the upper inner arm skin and removed by patients themselves exactly 6 hours after application.~The third and final visit will be 48 hours after the second DPCP treatment. At this visit, bi-fold skin thickness will be measured using a Caliper."
61983501|NCT05020496|EXPERIMENTAL|Group 3 (UVB & Biopsy 30 participants)|"This group of the study will take approximately 10 weeks and requires 10 visits.~At the first visit, blood will be collected and MED will be determined. The second visit will be 24h after UV when MED will be measured. Blood will be collected from patients at this time. The third visit will be on the 8th day. The two marked skin sites will be UV exposed at 2MED on 4 consecutive days.~Days 9-11 make up the fourth, fifth, and sixth visits. Following the last UV exposure blood will be collected. A single dose of DPCP will be placed on the upper buttock for 48 hours. The seventh visit will be on the 12th day when two skin biopsies will be taken. The ninth visit will be four weeks after the sensitization with DPCP, when the upper inner arm will be treated with DPCP. Bi-fold skin thickness will be measured prior to the application of DPCP. Various DPCP doses are applied. The tenth visit will be 48 hours after the DPCP treatment. At this visit, bi-fold skin thickness will be measured."
61983502|NCT04907539|EXPERIMENTAL|Arm A: RXC004 monotherapy|"Patients will receive RXC004 (2 mg once daily \[QD\], orally).~Patients in Arm A may crossover to Arm B treatment if they have progressive disease on the first Response Evaluation Criteria in Solid Tumours, (RECIST) scan (if Arm B is open at the time of progression)."
61983503|NCT04907539|EXPERIMENTAL|Arm B: RXC004 + nivolumab|"Patients will receive RXC004 (1.5 mg QD, orally) in combination with nivolumab (480 mg every 4 weeks \[q4w\], intravenous \[IV\] infusion).~Arm B will be opened once a RP2D for RXC004 in combination with nivolumab is established in the phase I dose escalation study (NCT03447470). RXC004 dose to be used in combination with nivolumab will be based on data from the phase 1 study (NCT03447470)."
61983504|NCT02994901||Group 1|Geriatric patient with Sarcopenia
61983505|NCT02994901||Group 2|Geriatric Patient without Sarcopenia
61983506|NCT02994901||Group 3|healthy control group
61983507|NCT01842256|EXPERIMENTAL|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|
61983508|NCT01842256|ACTIVE_COMPARATOR|Atorvastatin 40mg|
61983509|NCT02461108|EXPERIMENTAL|Price difference|Introduce a 10% price difference between foods labeled as nutritious and foods labeled as less nutritious and frame the price difference as either a Subsidy, Tax, or combination of a Tax and Subsidy.
61983510|NCT02461108|NO_INTERVENTION|No price difference|No price difference between nutritious and less nutritious foods.
61983511|NCT03605303|ACTIVE_COMPARATOR|CONTROL- etafilcon A current molding|1-Day ACUVUE® MOIST
61983512|NCT03605303|EXPERIMENTAL|TEST- etafilcon A novel molding|Investigational Contact Lens
61983513|NCT04777708|EXPERIMENTAL|Treatment (pembrolizumab, BO-112)|Patients receive pembrolizumab IV over 30 minutes on day 1 of odd number cycles. Patients also receive BO-112 by intratumoral injection on day 1, 8, and 15 of cycle 1, and day 15 of subsequent cycles. Treatment repeats every 3 weeks for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
61983514|NCT04237441||MDT conference|participants evaluated at MDT conference
61983515|NCT04237441||no MDT conference|participants not evaluated at MDT conference
61983516|NCT03495323|EXPERIMENTAL|Prexasertib + LY3300054|"* Prexasertib is administered intravenously twice per cycle~* LY3300054 is administered intravenously twice per cycle"
61983517|NCT00735787|PLACEBO_COMPARATOR|Placebo/Adalimumab|"Loading dose of 2 placebo injections at Week 0 and placebo injections every other week (eow) from Week 1 through Week 15.~In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27."
61983518|NCT00735787|ACTIVE_COMPARATOR|Adalimumab|80 mg adalimumab loading dose at Week 0 and 40 mg adalimumab eow from Weeks 1 through 15. For subjects who continued in the second period of the study, subjects received 2 placebo injections at Week 16 to maintain the blind. Open-label 40 mg adalimumab eow was administered from Week 17 through Week 27.
61983519|NCT05855005|EXPERIMENTAL|DTC Hearing Aid|
61983520|NCT01870583|ACTIVE_COMPARATOR|Combination iodine and chlorhexidine|The combincation skin preparation will utilize the iodine based preparation first followed by the chlorhexidine based skin preparation prior to cesarean delivery.
61983521|NCT01870583|ACTIVE_COMPARATOR|Chlorhexidine|Chlorhexidine based skin preparation solution applied to skin prior to cesarean delivery
61983522|NCT01870583|ACTIVE_COMPARATOR|Iodine povidone|Iodine povidone based skin preparation solution applied to skin prior to cesarean delivery
61983523|NCT06219850||HIIT+Diet|High-Intensity Interval Training (HIIT) and Nutritional education
61983524|NCT06219850||MICT+Diet|Moderate-Intensity Continuous Training (MICT) and Nutritional education
61983525|NCT06219850||HIIT+NoDiet|High-Intensity Interval Training (HIIT) without Nutritional education. The HIIT training consisted of 3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program consisted of 10 series of 1 min duration at 90% of peak power output, with 60 seconds of rest between sets (estimated total time of the session: 25 minutes).
61983526|NCT06219850||MICT+NoDiet|Moderate-Intensity Continuous Training (MICT) without Nutritional education. The MICT training consisted of 3 sessions per week in a cycle ergometer during 50 min at moderate intensity, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer.
61983527|NCT06219850||Diet+NoExercise|Nutritional education without Exercise. The education intervention consisted of individual nutritional counselling. The nutritional education program was conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants were provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods were provided.
61983528|NCT06219850||Control group|Neither exercise nor nutritional education
61983529|NCT01482754|EXPERIMENTAL|Rituximab Infusion at 90-minutes|
61983530|NCT00226954|EXPERIMENTAL|Zoledronic Acid with Intermittent Hormonal Therapy|
61983531|NCT01797003|ACTIVE_COMPARATOR|Opening wedge HTO|Opening wedge high tibial osteotomy using Puddu plate
61983532|NCT01797003|ACTIVE_COMPARATOR|Closing wedge HTO|Closing wedge high tibial osteotomy using cramp fixation
61983533|NCT03459742|EXPERIMENTAL|Intervention|Gamification strategy. In 2018, the intervention group are 15 schools from Municipality of Santiago. In 2019, the intervention will cover all eligible schools in the Municipality of Santiago.
61983534|NCT03459742|NO_INTERVENTION|Control|In 2018, the control group will be 5 randomly selected schools from Municipality of Santiago and 4 schools from Municipality of Estación Central. In 2019, the control group will be 4000 participants chosen from neighboring municipalities
61983535|NCT01011660|ACTIVE_COMPARATOR|A,1,IV|A means active; 1 means Amlodipine+Amiloride Compound; IV means phase IV
61983536|NCT01011660|ACTIVE_COMPARATOR|A,2,IV|A means active; 2 means Amlodipine+Telmisartan; IV means phase IV
61983537|NCT01011660|ACTIVE_COMPARATOR|A,3,IV|A means active; 3 means Amlodipine+Amiloride Compound with or no Simvastatin; IV means phase IV
61983538|NCT01011660|ACTIVE_COMPARATOR|A,4,IV|A means active; 4 means Amlodipine+Telmisartan with or no Simvastatin; IV means phase IV
61983539|NCT05939375|EXPERIMENTAL|FCC educational training|"The administration of the pre-tests, the planning of the educational process, including the development of e-learning modules and video lectures, was shared with the nurses.Each week, the topics were delivered to the nurses through online interactive methods, with each session lasting approximately 45-60 minutes. Six weeks after the completion of the six-week educational training, the nurses were administered the FCCAS post test via an online form.~The PedsQL HCPSS was utilized to assess the level of healthcare satisfaction among parents whose children received care in pediatric clinics. To assess parental healthcare satisfaction before the training, the mean scores of the PedsQL HCPSS from the institutional data of the hospital in January 2021 were used. Post training parental data were collected in May-June 2021 using the PedsQL HCPSS from parents whose children received care in pediatric clinics."
61983540|NCT04308837|EXPERIMENTAL|Patients With Local Regional Advanced Gastric Cancer|Patients with local regional advanced gastric cancer after at least 4 weeks post diagnostic laparoscopy and HIPEC, will receive all of the treatments described in the study protocol.
61983541|NCT00679263|EXPERIMENTAL|MN-221|
61983542|NCT00679263|PLACEBO_COMPARATOR|PLACEBO|Placebo intravenous infusion with dosing volume equivalent to active treatment.
61983543|NCT02255721|EXPERIMENTAL|SHIP Intervention|SHIP is a health behavior change intervention to give parents the knowledge, motivation, and skills necessary to set goals, problem-solve, and improve their child's sleep.
61983544|NCT02255721|ACTIVE_COMPARATOR|SHIP Control Arm|The active control arm uses the same strategies as the SHIP intervention arm, but for child health topics unrelated to sleep or outcome measures.
61983545|NCT04127331|ACTIVE_COMPARATOR|Routine|Patients who are scheduled for routine outpatient surgery.
61983546|NCT04127331|ACTIVE_COMPARATOR|Urgent|Patients who are scheduled for urgent surgery.
61983547|NCT04127331|ACTIVE_COMPARATOR|Emergent|Patients who are scheduled for emergency surgery.
61983548|NCT04612556||late-onset severe eosinophilic asthma and fixed obstruction|Patients with late-onset severe eosinophilic asthma and fixed obstruction will be administered Mepolizumab (100 MG), subcutaneusly every 30 days
61983549|NCT01066247|ACTIVE_COMPARATOR|Midazolam|intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
61983550|NCT01066247|ACTIVE_COMPARATOR|Morphine|intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
61983551|NCT00642239|PLACEBO_COMPARATOR|2|Concurrent radiochemotherapy and placebo
61983552|NCT00642239|EXPERIMENTAL|1|concurrent radiochemotherapy and Sodium Glycididazole
61983553|NCT06368960|EXPERIMENTAL|Radiotherapy|Radiation：Hypofractionated radiotherapy
61983554|NCT06368960|EXPERIMENTAL|BM201 injection combined with radiotherapy|BM201 injection：Intratumoral injection Radiation：Hypofractionated radiotherapy
61983555|NCT05494242|EXPERIMENTAL|single superior flap technique to secure macular hole closure.|"The patients are divided into two groups:~For the first group, the flap will be carried out under the effect of perfluorocarbon.~For the second group, the flap stabilized with methylcellulose."
61983556|NCT05494242|ACTIVE_COMPARATOR|Double flap technique to secure macular hole closure.|This arm is NCT05269563, we utilize the results as a comparator to the superior single flap technique.
61983557|NCT05787691|EXPERIMENTAL|Individualised Pain Management|"In the intervention group, patients will be followed by the team of the transitional pain service of the HUG, and depending on individual risk factors, contraindications and following discussion with the patient (shared decision-making) the bundle of individually targeted measures will be applied."
61983558|NCT05787691|NO_INTERVENTION|Standard care|In the control group, no specific measures will be applied, and patients are followed by their surgeon and general practitioner. In addition, during the hospitalization the Acute Pain Team may be requested. In case of persistent pain, it may happen that the surgeon or the general practitioner refers a patient to a chronic pain specialist.
61983559|NCT01435109|NO_INTERVENTION|Usual Care|
61983560|NCT01435109|EXPERIMENTAL|Patient Behavioral Intervention|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
61983561|NCT01435109|EXPERIMENTAL|Provider Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
61983562|NCT01435109|EXPERIMENTAL|Patient and Provider Interventions|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
61983563|NCT05839522||Persons in custody in Australia|Representative sample of 2400 people in prison from 25 representative prisons in Australia will participate in a biobehavioural survey involving point-of-care testing for HCV antibodies and RNA (if antibody positive), HBV surface antigens and antibodies, and HIV antibodies, and an interview-style survey.
61983564|NCT01866514|EXPERIMENTAL|Anesthesia Arm|proximal humerus intraosseous vascular access will be established bilaterally in the proximal humerus using the anesthesia approach in which the arm is abducted from the body.
61983565|NCT04345575|EXPERIMENTAL|VR Group|VR group participants were mailed an Oculus Go Virtual Reality headset preloaded with VR software developed by AppliedVR. Treatment content consisted of a variety of 21 sessions to support participants in learning cognitive and behavioral self-management skills based on evidence-based CBT principles and skills, biofeedback and mindfulness strategies used in pain management. The program was designed to improve self-regulation of cognitive, emotion, and physiological response to stress and pain.
61983566|NCT04345575|ACTIVE_COMPARATOR|Audio Group|The audio program consisted of the majority of the same narrative content contained in the VR program. Owing to VR having a visual and auditory media form, about one-third of the Audio program included didactic and experiential content that was not identifical but was closely matched to the VR content (sans references to visual imagery that would be confusing in the absence of visual content). Participants accessed 21 audio recordings on SoundCloud and asked to complete one session each day.
61983567|NCT02250755|EXPERIMENTAL|MRI T1 T2 sequences|comparison of perfusion sequences T1 T2 in patients with brain metastase cancer
61983568|NCT04146025|EXPERIMENTAL|Nature Coach Intervention|The Nature Coach Intervention consists of 3 components - home visit, text message follow up, and goal feedback.
61983569|NCT04146025|NO_INTERVENTION|Control Group|Education only
61983570|NCT03163082|ACTIVE_COMPARATOR|Cognitive Intervention|The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
61983571|NCT03163082|ACTIVE_COMPARATOR|Behavioral Intervention|The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
61983572|NCT03163082|ACTIVE_COMPARATOR|Interpretation Bias|"The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
62362706|NCT03907813|EXPERIMENTAL|liposomal bupivacaine infiltration|Local infiltration of all wound layers with liposomal bupivacaine (Exparel(R)) 20 ml diluted with 70 ml of normal saline to 90 ml for patient with a BMI of 39 and under. If BMI is 40 or more the 20 ml of liposomal bupivicaine will be diluted to 150 ml by adding 130 ml of normal saline
61983573|NCT03163082|ACTIVE_COMPARATOR|Evaluative Conditioning|The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
61983574|NCT04877379|EXPERIMENTAL|Part 1|Subjects will receive single doses of VNRX-7145 or VNRX-5024 alone and in combination. All subjects will receive study drug in the sequence specified by the randomization schedule.
61983575|NCT04877379|EXPERIMENTAL|Part 2A|Multiple dose administration of VNRX-7145 q8h for 10 days
61983576|NCT04877379|PLACEBO_COMPARATOR|Part 2B|Multiple dose administration of placebo q8h for 10 days
61983577|NCT04877379|EXPERIMENTAL|Part 3A|Multiple dose administration of low dose VNRX-7145 + VNRX-5024
61983578|NCT04877379|EXPERIMENTAL|Part 3B|Multiple dose administration of high dose VNRX-7145 + VNRX-5024
61983579|NCT04877379|PLACEBO_COMPARATOR|Part 3C|Multiple dose administration of Placebo (matching VNRX-7145 + VNRX-5024)
61983580|NCT04422054||Open Surgery Repair Group|In the open surgery repair group, preoperative patient characteristics, comorbid conditions, aneurysm anatomy and diameters will be matched with outcomes and complications, in the postoperative period, during follow up.
61983581|NCT04422054||Endovascular Repair Group|In the endovascular surgery repair group, preoperative patient characteristics, comorbid conditions, aneurysm anatomy and diameters will be matched with outcomes and complications in the postoperative period, during follow up.
61983582|NCT00993291|NO_INTERVENTION|Baseline frequency|Baseline DBS frequency
61983583|NCT01472250||chemotherapy|Eligible patients will accept generalized chemotherapy according to the investigator's assessment.
61983584|NCT01926873||Healthy volunteers|
61983585|NCT01199289|PLACEBO_COMPARATOR|Placebo|Participants will receive the matching placebo administered as subcutaneous (SC) injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
61983586|NCT01199289|EXPERIMENTAL|AMG 827 140 mg|Participants will receive AMG 140 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
61983587|NCT01199289|EXPERIMENTAL|AMG 827 210 mg|Participants will receive AMG 210 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
61983588|NCT01199289|EXPERIMENTAL|AMG 827 280 mg|Participants will receive AMG 280 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
61983589|NCT06064890|EXPERIMENTAL|Cohort 1 (dose 1)|Initial dose, delivered as a one-time only, intrathalamic administration.
61983590|NCT06064890|EXPERIMENTAL|Cohort 2 (dose 2)|Escalated dose, delivered as a one-time only, intrathalamic administration.
61983591|NCT03442621|EXPERIMENTAL|Relacorilant Fasted|Relacorilant Fasted
61983592|NCT03442621|EXPERIMENTAL|Relacorilant with a high fat breakfast|Relacorilant with a high fat breakfast
61983593|NCT03442621|EXPERIMENTAL|Relacorilant with a moderate breakfast|Relacorilant with a moderate breakfast
61983594|NCT04349618|ACTIVE_COMPARATOR|PROTECTIVE VENTILATION|Protective ventilation with tidal volume 6 mL/kg of predicted body weight
61983595|NCT04349618|EXPERIMENTAL|ULTRAPROTECTIVE VENTILATION|Ultraprotective ventilation with tidal volume reduction down to 4 mL/kg further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20
61983596|NCT03330522|EXPERIMENTAL|Intervention|"The active intervention is Love, Sex, \& Choices, a 12-episode, online HIV prevention intervention video series accessed on study provided smartphones. Each episode is up to 20 minutes in length. Study participants receive one episode per week for 12 weeks on study provided smartphones."
61983597|NCT03330522|ACTIVE_COMPARATOR|Control Comparison Group|The control comparison intervention is twelve messages in text that promote HIV prevention behaviors and open communication with male sex partners. Study participants receive one message per week for 12 weeks on study provided smartphones.
61983598|NCT02426073||HE|Healthy elderlies
61983599|NCT02426073||DM|Elderlies with type 2 diabetes
61983600|NCT02426073||SA|Elderlies with sarcopenia
61983601|NCT02426073||DS|Elderlies with both type 2 diabetes and sarcopenia
61983602|NCT01319812|EXPERIMENTAL|Astron Stent Group|"Participants indicated for stenting in iliac atherosclerotic lesions.~Intervention: Device: Astron Stents"
62362707|NCT03907813|PLACEBO_COMPARATOR|Saline infiltration|Local infiltration of all wound layers with saline, using to match the amount. The amount of total fluid is divided into 4 and instilled with 1-2 ml at a time in between fascial layers after fascial closure. Each 1/4 will be instilled laterally (2) and on each side of the incision(2)- extra fluid is placed subcutaneously.
61983603|NCT01319812|EXPERIMENTAL|Pulsar Stent Group|"Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.~Intervention: Device: Pulsar Stents"
61983604|NCT00966602|EXPERIMENTAL|Treatment Period 1|
61983605|NCT00966602|EXPERIMENTAL|Treatment Period 2|
61983606|NCT00966602|EXPERIMENTAL|Treatment Period 3|
61983607|NCT02493673|ACTIVE_COMPARATOR|CPAP therapy|Continuous positive airway pressure therapy
61983608|NCT02493673|SHAM_COMPARATOR|Sham CPAP|Sham- Continuous positive airway pressure
61983609|NCT03931421|EXPERIMENTAL|experiment group|In this arm, patients are treated with B Cell Maturation Antigen (BMCA)-targeted CAR-T cells and the safety and efficacy will be observed.
61983610|NCT05275764||optic capture group|IOL optic was captured through the posterior continuous curvilinear capsulorhexis
61983611|NCT05275764||endocapsular group|IOL was placed in the bag
61983612|NCT06210490|EXPERIMENTAL|Adjuvant therapy group|
61983613|NCT06210490|ACTIVE_COMPARATOR|Non-adjuvant therapy group|
61983614|NCT03508817|EXPERIMENTAL|Atropine Sulfate 0.01% Eye Drops Group|Intervention group will receive atropine sulphate eye drops 0.01% once nightly for 2 years.
61983615|NCT03508817|NO_INTERVENTION|Control group|Control group will not receive any medication.
61983616|NCT01687322||total hip replacement, quality of life, functioning|
61983617|NCT06309212||Pre-COVID period|January 2016 to January 2020
61983618|NCT06309212||Post-COVID period|January 2021 to September 2023
61983619|NCT04028076|EXPERIMENTAL|Peers LEAD|8-week educational behavioral intervention
61983620|NCT04443504|EXPERIMENTAL|Intervention Group|
61983621|NCT04443504|NO_INTERVENTION|Waitlist Group|The waitlist group will receive the intervention 3 months after the intervention group.
61983622|NCT04450147|EXPERIMENTAL|Tai Chi and Qigong|50mins x 12 weeks of virtually-delivered group tai chi/qigong
61983623|NCT04450147|ACTIVE_COMPARATOR|Walking and Stretching|50mins x 12 weeks of virtually-delivered group walking and stretching
61983624|NCT03209427|ACTIVE_COMPARATOR|Group I|intrathecal injection of 100 μg morphine
61983625|NCT03209427|ACTIVE_COMPARATOR|Group II|iIntrathecal injection of 200 μg morphine
61983626|NCT00888576||1|Non-intervention
61983627|NCT03071978|EXPERIMENTAL|LV-fusion pacing|Left Ventricular pacing (without Right Ventricular pacing)
61983628|NCT03071978|ACTIVE_COMPARATOR|BV pacing|Bi-Ventricular pacing
61983629|NCT00121550|EXPERIMENTAL|Clarithromycin|Clarithromycin is a lipophilic semi-synthetic macrolide antibiotic. The lipophilic nature of the drug allows it to easily penetrate into body fluids and tissues and accumulate intracellularly. Side effects are few, apart from trivial gastrointestinal complaints, and severe side effects are rarely observed during standard treatment.
61983630|NCT00121550|PLACEBO_COMPARATOR|Placebo|Placebo comparator
61983631|NCT00483808|EXPERIMENTAL|Denervation|Renal denervation using the Symplicty Catheter
61983632|NCT00874354|EXPERIMENTAL|Autologous bone marrow stem cells|Patients within 3 to 14 days from percutaneous coronary intervention (PCI) and stent implantation for Acute Myocardial Infarction (AMI) will receive either 50 cc's or 100 cc's of autologous bone marrow mononuclear cells through an intracoronary tranplantation of stem cells into the infarct-related coronary artery.
61983633|NCT00837655|EXPERIMENTAL|1|Sevelamer intervention
61983634|NCT00837655|ACTIVE_COMPARATOR|2|Calcium carbonate
61983635|NCT03518333|EXPERIMENTAL|ARM 1|Injection of adipose derived cells into penis followed six months later with sham control saline injection procedure
61983636|NCT03518333|EXPERIMENTAL|ARM 2|Sham control saline injection procedure followed six months later by injection of adipose derived cells into penis
61983637|NCT01761214|ACTIVE_COMPARATOR|Fluroquinolones|The fluroquinolones employed in the present study are referred to as oral levofloxacin (500mg q.d.), moxifloxacin (400mg, q.d.) and ciprofloxacin (500mg, b.i.d.). All medications are administered based on the bronchiectasis guideline issued by British Thoracic Society.
61983638|NCT01761214|ACTIVE_COMPARATOR|Beta-lactamase inhibitor|In the present study, amoxicillin and amoxicillin clavulanate potassium compound are employed, based on the British Thoracic Society guideline for bronchietasis, as mainly determined by sputum microbiology during steady-state bronchiectasis.
61983639|NCT03531307||Lactate and Ki 67 levels|Neurosurgical patients between June 2017 and February 2018 for tumoral and non-tumoral craniectomy with lactate levels at the beginning of surgery and Ki-67 index in biopsies.
61983640|NCT03034421|ACTIVE_COMPARATOR|Modified medical care|Patients will undergo 48-hours bed rest after endoscopic valve implantation.
61983641|NCT03034421|NO_INTERVENTION|Standard medical care|Patients will be treated with standard medical care without restriction to bed rest after endoscopic valve implantation.
61983642|NCT01829555|EXPERIMENTAL|contingency management|The intervention will provide escalating financial reinforcement for self-monitored blood glucose testing.
61983643|NCT00862810|OTHER|Received HPV vaccine first|
61983644|NCT00862810|OTHER|Received concomitant vaccines first|
61983645|NCT04490720|PLACEBO_COMPARATOR|Placebo|consume 1 sachet per day for 2 months
61983646|NCT04490720|EXPERIMENTAL|Buckwheat husk extract|consume 1 sachet per day for 2 months
61983647|NCT01264146|ACTIVE_COMPARATOR|calcaneal plating HBOT|Open reduction and internal fixation of calcaneal fracture + HBOT
61983648|NCT01264146|PLACEBO_COMPARATOR|calcaneal plating|Open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
61983649|NCT05890612||Participants receiving PAXLOVID|Participants receiving PAXLOVID according to locally approved label.
61983650|NCT02802592|ACTIVE_COMPARATOR|Epogen|1000 IU/kg Epogen in 250 ml of normal saline infused over 1 hr
61983651|NCT02802592|PLACEBO_COMPARATOR|Normal Saline|250 ml normal saline infused over 1 hr
61983652|NCT03185728|EXPERIMENTAL|iLookOut|Online, interactive learning program developed by study team.
61983653|NCT03185728|ACTIVE_COMPARATOR|Standard|Online mandated reporter training developed by the state of Maine during Y1, then recruited to complete iLookOut during Y2 and Y3.
61983654|NCT03185728|NO_INTERVENTION|Control|No active recruitment or incentivizing of participants to complete any training on mandated reporting during Y1 and Y2, then recruited to complete iLookOut during Y3.
61983655|NCT00728130|EXPERIMENTAL|A|A neck dissection of at least the ipsilateral sub-level 1B will be performed in all patients
61983656|NCT03893136||Control group|The control group mainly consists of healthy volunteers. The whole blood is obtained and frozen to detect the corresponding biochemical markers in the futures. The vascular tissues are obtained from the deserted and free abdominal aorta conjugated to the renal artery in the kidney transplantation.
61983657|NCT03893136||sham TA group|In the TA cohort, patients are divided into two groups mainly, sham TA group and scramble TA group. The sham TA group is the TA group who is given the traditional and classical intervention or treatment and so on.
62362708|NCT05330624|EXPERIMENTAL|the D0- M1-M6 regimen|Adults receive three doses of 1.0 ml plague vaccine at day 0, month 1, and month 6 (referred as the D0-M1-M6 regimen).
61983658|NCT03893136||scramble TA group|Compared to sham TA group in the cohort, scramble TA group refers to TA patients who are given novel drugs or new drugs which are safe to treat other autoimmune diseases but have not been used to treat TA yet, or some new interventions and so on.
61983659|NCT02956486|EXPERIMENTAL|Core Study: Elenbecestat 50 mg|Participants will receive one 50 milligram (mg) elenbecestat tablet, orally, once a day in the morning. The core study will be double blinded.
61983660|NCT02956486|PLACEBO_COMPARATOR|Core Study: Placebo|Participants will receive one matching placebo tablet, orally, once a day in the morning. The core study will be double blinded.
61983661|NCT02956486|EXPERIMENTAL|Open-label Extension Phase: Elenbecestat 50 mg|Participants completing the core study will receive one 50 mg elenbecestat tablet, orally, once a day in the morning.
61983662|NCT03247075|EXPERIMENTAL|Internet-delivered Cognitive Behavior Therapy|10 weeks of guided Internet-delivered Cognitive Behavior Therapy
61983663|NCT03247075|ACTIVE_COMPARATOR|Internet-delivered Support and Counseling|10 weeks of guided Internet-delivered support and counseling
62362709|NCT05330624|EXPERIMENTAL|the D0- M2-M6 regimen|Adults receive three doses of 1.0 ml plague vaccine at day 0, month 2, and month 6 (referred as the D0-M2-M6 regimen).
62362710|NCT00587834|EXPERIMENTAL|1|Within-subject design: one side of the mouth receives Gintuit
62362711|NCT00587834|ACTIVE_COMPARATOR|2|Within-subject control: one side of mouth receives tissue harvested from the palate
62362712|NCT01933204|EXPERIMENTAL|Acupuncture|Using basic points combined with additional points. Basic points are fixed, while additional points will be selected from a list of points categorized by syndrome differentiation.
61983664|NCT04011501|EXPERIMENTAL|Continuous unilateral ESP block|Erector spine block and catheter placement will be performed for continuous analgesia on this group of patients undergoing minimally invasive cardiac surgery. Initially a volume of 20 ml of Levobupivacaine 0.25% will be administered and subsequently a 22G catheter will be introduced and fixed 10-12 cm from the skin. At the end of the surgery, an elastomeric pump will be installed at a flow rate of 7 ml / hr with a 1.3% Ropivacaine solution.
61983665|NCT02368795|PLACEBO_COMPARATOR|Pharmacological Prevention|Combination of rectal indomethacin, sublingual isosorbide dinitrate and intravenous hydration with Ringer's lactate serum without pancreatic stenting
61983666|NCT02368795|ACTIVE_COMPARATOR|Pancreatic Stent|Pancreatic Stent PLUS Pharmacological Prevention
61983667|NCT02556268|EXPERIMENTAL|Riociguat and ATRIPLA|
61983668|NCT02556268|EXPERIMENTAL|Riociguat and COMPLERA|
61983669|NCT02556268|EXPERIMENTAL|Riociguat and STRIBILD|
61983670|NCT02556268|EXPERIMENTAL|Riociguat and TRIUMEQ|
61983671|NCT02556268|EXPERIMENTAL|Riociguat and antiretroviral protease inhibitor with TRIUMEQ|
61983672|NCT00664742|EXPERIMENTAL|Fluvastatin XL® Treatment|80 mg once daily, at bedtime.
61983673|NCT01446692||Patients with suboptimal response|
61983674|NCT01446692||Patients with symptomatic remission|
61983675|NCT04698720|EXPERIMENTAL|Muscle Relaxation with Guided Imagery|Participants in the Experimental Group 1 will receive four individual 45-minute sessions, every two weeks, of progressive muscle relaxation intervention with guided imagery focused on ulcer healing, carried out by the Psychologist responsible for implementing the project, on the day of the Diabetic Foot appointments.
61983676|NCT04698720|EXPERIMENTAL|Hypnosis with Guided imagery|Participants in the Experimental Group 2 will receive a four individual 45-minute sessions, every two weeks, of hypnosis intervention with guided imagery focused on ulcer healing, carried out by the qualified Hypnotherapists external to the research study, on the day of the Diabetic Foot appointments.
61983677|NCT04698720|PLACEBO_COMPARATOR|Active Control Group|Participants in the ACG will receive four individual 45-minute sessions of neutral guided imagery placebo focused on the patient's life before the foot ulcer, carried out by the Psychologist responsible for implementing the project, on the day of the Diabetic Foot appointments.
61983678|NCT04698720|NO_INTERVENTION|Passive Control Group|Participants in the PCG will not receive any intervention or placebo session.
61983679|NCT00070187|EXPERIMENTAL|Hyperfractionated Involved-Field Radiotion-immunotherapy|"Completed prior salvage induction therapy and have not received full tissue tolerance from prior radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily for 7 days.~HIGH-DOSE PREPARATIVE REGIMEN: Beginning within 7 days after radiotherapy, carmustine IV over 3 hours on day -6; etoposide IV over 1 hour and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes on day -1.~ASCT: Autologous bone marrow or peripheral blood stem cell transplantation on day 0. Filgrastim (oral or IV) beginning on day 1 and continuing until blood counts recover.~IMMUNOTHERAPY: Cyclosporine IV twice daily beginning on day 0 and continuing until the completion of the course of recombinant interferon gamma and interleukin-2. When sufficiently recovered, Aldesleukin once daily for 18 days."
61983680|NCT00070187|EXPERIMENTAL|Hyperfractionated Involved-Field Radiotion-no immunotherapy|"Completed prior salvage induction therapy and have not received full tissue tolerance from prior radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily for 7 days.~HIGH-DOSE PREPARATIVE REGIMEN: Beginning within 7 days after radiotherapy, carmustine IV over 3 hours on day -6; etoposide IV over 1 hour and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes on day -1.~ASCT: Autologous bone marrow or peripheral blood stem cell transplantation on day 0. Filgrastim (oral or IV) beginning on day 1 and continuing until blood counts recover."
61983681|NCT00705107||All Treated Patients|All patients participating in the study
61983682|NCT04007523|NO_INTERVENTION|Usual Care Group|Usual care per surgical ward standards
61983683|NCT04007523|EXPERIMENTAL|HELP Support System|This arm will receive the HELP Support System intervention only
61983684|NCT04007523|EXPERIMENTAL|Family Support System|This arm will receive the Family Support system intervention only
61983685|NCT04007523|EXPERIMENTAL|Combined Support Systems|Participants randomized to this arm will receive both HELP- and family-based support system interventions
61983686|NCT06219447|EXPERIMENTAL|Experimental group|Children will be immediately trained through the TABLET TOSCANA technologies (VRRS Home Tablet or Medico Amico Kids APP) for a cycle of 3 months.
61983687|NCT06219447|NO_INTERVENTION|Waitlist group|Children will continue standard care for 3 months and after that they will be guaranteed to be enrolled for the next 3-month cycle through the TABLET TOSCANA technologies (VRRS Home Tablet or Medico Amico Kids APP).
61983688|NCT03505944|EXPERIMENTAL|Treatment|Venetoclax+lenalidomide+rituximab
61983689|NCT06200077|SHAM_COMPARATOR|Conventional Ridge-Splitting Group|Six dental implant sites were prepared in three patients initially through ridge splitting technique associated with bone grafting followed by implants insertion after 4 months later.
61983690|NCT06200077|ACTIVE_COMPARATOR|Modified 3-Staged Ridge-Splitting Group|Six dental implant sites were prepared in four patients through mucogingival and bony incision initially then after 3-4 weeks ridge splitting with bone grafting were done, followed by implants insertion after 4 months later.
61983691|NCT06200077|EXPERIMENTAL|Modified 2-Staged Ridge-Splitting Group|Six dental implant sites were prepared in three patients initially through mucogingival, and bony incision followed by ridge splitting technique, bone grafting and implants insertion at the same time after 4 weeks from the bony incision.
61983692|NCT04554277|NO_INTERVENTION|Control|Usual management of heart failure. The sST-2 level will be blunted.
61983693|NCT04554277|EXPERIMENTAL|Biomarker guided therapy|Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.
61983694|NCT02248610||Rivaroxaban|All participants will be treated with rivaroxaban.
61983695|NCT06325358||Subjects with Multiple sclerosis|"Age ≥ 18 years~* Diagnosis of MS according to 2017 McDonald criteria~* Relapsing-remitting (RR) MS~* Residence in the provinces of Pavia or Milan (Italy)~* Informed consent form signed"
61983696|NCT05846061||Prevalence study population|prevalence study population
62362713|NCT01933204|ACTIVE_COMPARATOR|Climen 21 Tablets|COMPOSITION 11 white tablets each containing estradiol-17-valerate 2 mg, plus 10 pink tablets each containing estradiol-17-valerate 2 mg and cyproterone acetate 1 mg.
61983697|NCT02710045|ACTIVE_COMPARATOR|MV at 9 months|"Measles Vaccine at 9 months of age. Measles Vaccine at 18 months of age. All vaccines given as per normal Gambia schedule until 9 months of age, including third dose of diphtheria-tetanus-whole cell pertussis (DTP3), hepatitis B vaccine (HBV) and oral polio vaccine (OPV) at four months of age.~At 9 months of age given a single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid. Yellow fever vaccine (YF) and OPV administered at 11 months of age. Given a standard MV challenge at 18 months of age."
61983698|NCT02710045|ACTIVE_COMPARATOR|DTP + MV at 9 months|Measles Vaccine at 9 months of age. DTP Vaccine at 9 months of age. Measles Vaccine at 18 months of age. DTP3 dose withheld and given HBV and OPV at four months of age. At 9 months of age given a single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid, and i.m. DTP (Serum Institute of India Ltd.) in the thigh. Yellow fever vaccine (YF) and OPV administered at 11 months of age. Given a standard MV challenge at 18 months of age.
61983699|NCT02710045|ACTIVE_COMPARATOR|DTP at 9 months|DTP Vaccine at 9 months of age. Measles Vaccine at 18 months of age. DTP3 dose withheld and given HBV and OPV at four months of age. At 9 months of age given i.m. DTP (Serum Institute of India Ltd.) in the thigh. MV, OPV and YF administered at 11 months of age. Given a standard MV challenge at 18 months of age.
61983700|NCT00309842|EXPERIMENTAL|Unrelated UCBT for Blood Cancers|Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.
61983701|NCT03821298|EXPERIMENTAL|Standard of Care|short thumb orthoses during ADL, joint reeducation for hand used, radial nerve gliding exercises and thumb proprioception exercises
61983702|NCT03970733|EXPERIMENTAL|VLA15 with Alum lower dose|Main Study Phase: VLA15 with Alum lower dose - Booster Phase: arm discontinued
61983703|NCT03970733|EXPERIMENTAL|VLA15 with Alum higher dose|Main Study Phase: VLA15 with Alum higher dose - Booster Phase: VLA15 higher dose or placebo
61983704|NCT03970733|PLACEBO_COMPARATOR|Placebo|Main Study Phase: placebo - Booster Phase: arm discontinued
61983705|NCT02904473|EXPERIMENTAL|GROWell|GROWell incorporates 4 elements: phone coaching, goal setting, self-monitoring of behavior and skills training. These interactions take place on a study subject's cell phone, through text messaging, and phone calls with a dietician coach. At study initiation, the subject takes a short survey, after which the intervention algorithm assigns up to 4 tailored behavior change goals from the GROWell library. Goals are tailored to the subject's needs as indicated by the initial survey. Subjects self-monitor adherence weekly via text, responding to prompts from the system regarding their level of success with a given goal. Via text they receive immediate tailored feedback regarding their current adherence and long-term progress.
61983706|NCT02904473|NO_INTERVENTION|Attention Support Control (ASC)|The ASC control arm of the study involves one coaching call at baseline, regarding prenatal diet. Weekly text or IVR messages will focus on pregnancy, labor, delivery, and early infancy education.
61983707|NCT02904473|NO_INTERVENTION|Usual Care (USC)|The USC will receive no intervention. They will simply complete baseline and follow-up CASI and blood draw.
61983708|NCT01371474||Patients prescribed PAXIL|Patients with depression or in a depressed state starting PAXIL at 20 mg/day during study period
61983709|NCT02039674|EXPERIMENTAL|Part 1 Cohort A2 (Pembro2mg/kg+Paclitaxel [Pa]+Carboplatin [C])|Cohort A participants receive pembrolizumab (2 mg/kg) via intravenous (IV) infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m\^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (Aare Under the Curve \[AUC\] 6 \[6 mg/mL/min\]) via IV infusion on Day 1 of each 3-week cycle.
61983710|NCT02039674|EXPERIMENTAL|Part 1 Cohort B2 (Pembro 2mg/kg+Pa+C+Bevacizumab [B])|Cohort B2 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m\^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 \[6 mg/mL/min\]) via IV infusion on Day 1 of each 3-week cycle PLUS bevacizumab (15 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
61983711|NCT02039674|EXPERIMENTAL|Part 1 Cohort C2 (Pembro 2mg/kg+Pemetrexed [Pe]+C)|Cohort C2 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m\^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 \[5 mg/mL/min\]) via IV infusion on Day 1 of each 3-week cycle.
61983712|NCT02039674|EXPERIMENTAL|Part 1 Cohort D1 (Pembro 10mg/kg+Ipilimumab [I])|Cohort D1 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
61983713|NCT02039674|EXPERIMENTAL|Part 1 Cohort E (Pembro 2mg/kg+Erlotinib)|Cohort E participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS erlotinib (150 mg) via oral tablet once a day on every day of each 3-week cycle.
61983714|NCT02039674|EXPERIMENTAL|Part 1 Cohort F (Pembro 2mg/kg+Gefitinib)|Cohort F participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS gefitinib (250 mg) via oral tablet once a day on every day of each 3-week cycle.
61983715|NCT02039674|EXPERIMENTAL|Part 2 Cohort G+ (Pembro 200mg+C+Pe)|Cohort G+ participants receive pembrolizumab (200 mg) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 \[5 mg/mL/min\]) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m\^2) via IV infusion on Day 1 of each 3-week cycle.
61983716|NCT02039674|EXPERIMENTAL|Part 2 Cohort H (Pembro+I)|Cohort H participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle (at the recommended Phase II dose determined in Cohort D).
62362714|NCT02082028|EXPERIMENTAL|A (BGStar)|Patients will be educated within the context of the SINERGIA educational program to understand how to manage their own diabetes on the basis of their Self Monitoring of Blood Glucose values obtained with BGStar. Patients will be requested two 6-points profiles monthly.
62362715|NCT02082028|ACTIVE_COMPARATOR|B (traditional approach)|Usual approach for the disease management. Patients in Group B will receive usual education and, at any time during the study duration, if needed, will be instructed on Self Monitoring of Blood Glucose, performed with any glucose meter.
62362716|NCT03391076|EXPERIMENTAL|FilmArray group|Patients in this group will use FilmArray Respiratory Panel to test potential viral pathogens.
62362717|NCT03391076|NO_INTERVENTION|Routine test group|Patients in this group will use clinical routine methods to test potential viral pathogens.
61983717|NCT02039674|EXPERIMENTAL|Part 1 Cohort A10 (Pembro+Paclitaxel [Pa]+Carboplatin [C])|Cohort A10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m\^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 \[mg/mL/min\]) via IV infusion on Day 1 of each 3-week cycle.
61983718|NCT02039674|EXPERIMENTAL|Part 1 Cohort B10 (Pembro+Pa+C+Bevacizumab [B])|Cohort B10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m\^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 \[6 mg/mL/min\]) via IV infusion on Day 1 of each 3-week cycle PLUS bevacizumab (15 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
61983719|NCT02039674|EXPERIMENTAL|Part 1 Cohort C10 (Pembro 10mg/kg+Pemetrexed [Pe]+C)|Cohort C10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m\^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 \[5 mg/mL/min\]) via IV infusion on Day 1 of each 3-week cycle.
61983720|NCT02039674|EXPERIMENTAL|Part 2 Cohort G- (Placebo+C+Pe)|Cohort G- participants receive placebo (normal saline solution) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 \[5 mg/mL/min\]) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m\^2) via IV infusion on Day 1 of each 3-week cycle PLUS.
61983721|NCT02039674|EXPERIMENTAL|Part 1 Cohort D2 (Pembro 10mg/kg+Ipilimumab [I])|Cohort D2 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (3 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
61983722|NCT02039674|EXPERIMENTAL|Part 1 Cohort D4 (Pembro 2mg/kg+Ipilimumab [I])|Cohort D1 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
61983723|NCT05747729|EXPERIMENTAL|Surufatinib/Serplulimab/Platinum/Etoposide|
61983724|NCT02189473|EXPERIMENTAL|5 x 4 Gy in 1 week|radiotherapy with 5 x 4 Gy in 1 week (5 x 4 Gy per week)
61983725|NCT02189473|ACTIVE_COMPARATOR|10 x 3 Gy in 2 weeks|radiotherapy with 10 x 3 Gy in 2 weeks (5 x 3 Gy per week)
61983726|NCT01358357|EXPERIMENTAL|Lurasidone 20-80 mg flexible dose|
61983727|NCT01358357|PLACEBO_COMPARATOR|Placebo|
61983728|NCT02882854|EXPERIMENTAL|Guanfacine|Guanfacine 1 mg capsule by mouth, one time prior to surgery.
61983729|NCT02882854|PLACEBO_COMPARATOR|Placebo|Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
61983730|NCT01871246||People with COPD & recent exacerbation|The group consists of people with COPD who have had an exacerbation in the last year.
61983731|NCT06473259||ADT + docetaxel|mHSPC patients treated with ADT + docetaxel
61983732|NCT06473259||ADT + ARPI|mHSPC patients treated with ADT + ARPI
61983733|NCT06473259||ADT + ARPI + docetaxel|mHSPC patients treated with ADT + docetaxel + ARPI
61983734|NCT06473259||ADT + radiotherapy on primary tumor|mHSPC patients treated with ADT + radiotherapy on primary tumor
61983735|NCT05623267|EXPERIMENTAL|Experimental arm|Intravenous infusion (IV) of Sugemalimab 1200 mg at least 60 minutes on Day 1 of each treatment cycle, every 3 weeks (21 days), for 1 year or until disease progression or intolerable toxicity.
61983736|NCT05623267|PLACEBO_COMPARATOR|Control arm|Intravenous infusion (IV) of placebo at least 60 minutes on Day 1 of each treatment cycle, every 3 weeks (21 days), for 1 year or until disease progression or intolerable toxicity.
61983737|NCT04889339|EXPERIMENTAL|Test group: Braces designed with growth modulation simulation|The braces will be designed using a growth modulation method.
61983738|NCT04889339|ACTIVE_COMPARATOR|Control group: Conventional method|The braces will be designed by an orthotist without growth modulation simulation.
61983739|NCT06069973||Delayed cerebral ischemia|Definition by Vergouwen et al. Verified by computed tomography
61983740|NCT06069973||Non-delayed cerebral ischemia|No signs of cerebral ischemia clinically or by computed tomography.
61983741|NCT02505620||Surgical|Surgical correction of OSAS disease
61983742|NCT02505620||Conservative|Conservative treatment of OSAS disease
62362718|NCT04992377|EXPERIMENTAL|R-EPOCH plus IBR for RT|
62362719|NCT01115517|EXPERIMENTAL|Bevacizumab|
61983743|NCT00620828|PLACEBO_COMPARATOR|Block Negative|Subjects receive intra-op saline injection per protocol
61983744|NCT00620828|EXPERIMENTAL|Block Positive|Subjects receive intra-op Ropivicaine 0.5% injection per protocol
61983745|NCT04996459||Tislelizumab group|
61983746|NCT04352114|EXPERIMENTAL|LY3461767 - Subcutaneous (SC)|LY3461767 administered SC.
61983747|NCT04352114|PLACEBO_COMPARATOR|Placebo - SC|Placebo administered SC.
61983748|NCT04352114|EXPERIMENTAL|LY3461767 - Intravenous (IV)|LY3461767 administered IV.
61983749|NCT03929718|ACTIVE_COMPARATOR|Standard Therapy|subjects undergoing CTI ablation
61983750|NCT03929718|EXPERIMENTAL|Interventional Therapy|subjects treated with an aldosterone antagonist after CTI ablation
61983751|NCT03689803|ACTIVE_COMPARATOR|Lipidemia|
61983752|NCT00638313|PLACEBO_COMPARATOR|Placebo|
61983753|NCT00638313|EXPERIMENTAL|PF-04603629|
61983754|NCT06209892|NO_INTERVENTION|Conventional anticoagulation group|
61983755|NCT06209892|EXPERIMENTAL|Extended anticoagulation group|
61983756|NCT01901718||Subsys|Cancer patients experiencing breakthrough pain.
61983757|NCT00501293|EXPERIMENTAL|1|Methylphenidate Transdermal System
61983758|NCT03454750|EXPERIMENTAL|177Lu-PSMA|177Lu PSMA
61983759|NCT02197806|EXPERIMENTAL|AGN-199201|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
61983760|NCT02197806|EXPERIMENTAL|AGN-190584|1 drop of AGN-190584 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
61983761|NCT02197806|EXPERIMENTAL|AGN-199201 + AGN-190584 in One Eye|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
62362720|NCT01115517|ACTIVE_COMPARATOR|Mitomycin C|
62362721|NCT00228189|ACTIVE_COMPARATOR|A|Dendritic cells pulsed with CEA-peptide
62362722|NCT00228189|EXPERIMENTAL|B|Dendritic cells electroporated with CEA-mRNA
61983762|NCT02197806|EXPERIMENTAL|AGN-199201 + AGN-190584 in Both Eyes|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in both eyes, once and twice daily for 3 days each.
61983763|NCT06547866|EXPERIMENTAL|Zanubrutinb + BGB-11417|cf intervention
61983764|NCT05590065|EXPERIMENTAL|Arm 1 - Treatment|Participants with SCI will undergo a training programme with the ABLE Exoskeleton device two times a week for five weeks for a total of 10 sessions.
61983765|NCT01059474|EXPERIMENTAL|DMPS|We will recruit 10 healthy adult volunteers, over 18 years of age, who eat at least three servings of fish per week (since this diet is associated with detectable levels of mercury in the urine which may rise following chelation). Patients with known allergies to DMPS or sulfa drugs or history of neurologic or renal disease will be excluded. We will also control for number of mercury containing dental amalgams. History will be obtained regarding any potential mercury exposures or recent vaccinations.
62362723|NCT00228189|EXPERIMENTAL|C|Dendritic cells pulsed with CEA-peptide, in combination with oxaliplatin/capecitabine
61983766|NCT06536777|ACTIVE_COMPARATOR|Plyometric Training|Ballistic six exercises (Elastic ER, Elastic 90/90 ER, Overhead throw, 90/90 flexion ER Decel Throw, 90/90 Abduction ER Decel Throw, Internal Rotation). Ballistic Six plyometric training, done 2 days a week for 8 weeks, was given to the bowlers for rotator cuff muscles of their dominant shoulders. Exercises were performed using 3 sets of 10-20 repetitions, with 30 s of rest between each set. The progression of the training protocol. The equipment utilized in the Ballistic Six exercises included medicine balls (2-lb for single arm exercises and 6-lb for the 2-handed exercises). Subjects continued their strength and conditioning activities in off-season along with the Ballistic Six exercises. Following 8 weeks of training, post-readings for the bowling velocity, identical to that described in the pretesting protocol, were obtained and documented.
61983767|NCT06536777|EXPERIMENTAL|Plyometric Training with Blood Flow Resistance Training|Experiment group received Ballistic six exercises with Blood Flow Restriction (BFR) training. Regularly monitor and supervise the training sessions. BFR training is a method that mimics the effects of high intensity training by combining low intensity exercise with blood flow obstruction. A pneumatic cuff, often known as a tourniquet, is applied proximally to the muscle that is being trained. It can be used on the lower or upper extremity. The next step is to inflate the cuff to a certain pressure in order to achieve both total and partial venous blockage. The patient is then instructed to conduct resistance exercises with high repetitions (15-30) and short rest periods (30 sec) at a low intensity of 20-30% of 1 repetition maximum (1RM).
61983768|NCT06279689|EXPERIMENTAL|Healthy subjects : Adult and pediatric populations|"Only ultrasound procedures will be performed using an investigational ultrasound system.~All subjects will be asked to undergo 1 on site visit (Study Visit) during which the eligibility assessment and the ultrasound scans will be performed is to evaluate the anatomical characteristics of both anterolateral thighs, one shoulder (deltoid) and one upper arm (biceps and triceps) before and while applying a force similar to the ZENEO® triggering force."
61983769|NCT04256785|EXPERIMENTAL|VSL#3|probiotic VSL#3, 2 sachets b.i.d for 3 months
62362724|NCT00261794|EXPERIMENTAL|1|computer-assisted cognitive remediation (CACR)
61983770|NCT04256785|PLACEBO_COMPARATOR|placebo|matched placebo, 2 sachets b.i.d for 3 months
61983771|NCT05633524||89 SS patients|The medical records were analyzed retrospectively about the 89 patients with first onset of SS (SS group)
61983772|NCT05633524||89 healthy control subjects|The medical records were analyzed retrospectively about the 89 age- and gender-matched individuals (Control group) who presented with normal control.
61983773|NCT03190161|EXPERIMENTAL|Schizophrenia Patients|Clinician verification diagnosis of Schizophrenia or Schizoaffective Disorder
61983774|NCT03076957|EXPERIMENTAL|Treat Regimen|CKD-516(investigational Drug) Irinotecan
61983775|NCT02308410||Tourniquet group|This group received a pneumatic tourniquet during total knee arthroplasty.
61983776|NCT02308410||Non-tourniquet group|This group received no tourniquet during total knee arthroplasty.
61983777|NCT03993431|EXPERIMENTAL|Bio-active cement|Bio-active cement dispensed into the crown, and the crown was properly positioned over the tooth, cement was allowed to self-set for 20 seconds while maintaining gentle pressure on the crown, then flash cured using a light curing unit to remove excess cement, buccal and lingual surfaces were light cured for extra 10 seconds each.
62362725|NCT00261794|ACTIVE_COMPARATOR|2|computer-based cognitive activity
62362726|NCT02283918||Participants with education less than bachelor's degree|Participants are further divided into three sub-groups based on their age group Group 1: Participants aged between 25 to 34 years Group 2: Participants aged between 35 to 44 years Group 3: Participants aged between 45 to 58 years
61983778|NCT03993431|ACTIVE_COMPARATOR|Packable glass ionomer|Dentin conditioner was applied to the prepared crown surfaces for 20 sec, then rinsed, and dried. Capsule was activated, mixed for 10 seconds in an amalgamator, then loaded into the capsule applier to extrude cement directly into the crown, the crown was properly positioned over the tooth, cement was allowed to self-set for 2 minutes while maintaining gentle pressure on the crown, excess cement was removed before complete setting of cement.
61983779|NCT00991055|EXPERIMENTAL|Pioglitazone|
61983780|NCT00991055|PLACEBO_COMPARATOR|Placebo|
61983781|NCT01950377||Healthy Adults|Healthy adults healthy adults - male and female
61983782|NCT06541015|EXPERIMENTAL|Post Stroke - individuals with history of single unilateral stroke (>6 months since onset)|Individuals, aged 18-80, male or female, with a history of single unilateral stroke with subsequent lower limb hemiparesis on either side (\>6 months since onset)
61983783|NCT04487054|NO_INTERVENTION|Usual care|Subjects in the ICU with a poor prognosis will receive usual care in time period one.
61983784|NCT04487054|EXPERIMENTAL|Usual care plus palliative care|Subjects in the ICU with a poor prognosis will receive usual care plus targeted pro-active palliative care intervention within 48 hours of ICU admission in time period two.
61983785|NCT04521465||NovaTears® + Omega-3|
61983786|NCT01650233|EXPERIMENTAL|Mindfulness-based stress reduction|The mindfulness-based stress reduction (MBSR) program was previously adapted for urban youth and here further adapted to 12 weekly 50-minute classes for use in school.
61983787|NCT01650233|PLACEBO_COMPARATOR|Healthy Topics|An age-appropriate health education curriculum was used as a non-specific group comparison for the MBSR program to control for the effects of: positive adult instruction, interactive peer group instruction, learning new material, group size and location, time, and attention.
61983788|NCT03933787|PLACEBO_COMPARATOR|mannitol in a tablet|two tablets containing mannitol in a blister: one tablet provided to each volunteer in a blister 16 hours before the trial and one tablet provided two hours before the clinical trial
61983789|NCT03933787|ACTIVE_COMPARATOR|Saxagliptin in a tablet|two tablets containing each 5 mg of Saxagliptin in a blister: one tablet provided to each volunteer in a blister 16 hours before the trial and one tablet provided two hours before the clinical trial
61983790|NCT03832582|EXPERIMENTAL|Annexin|All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
61983791|NCT02307357|EXPERIMENTAL|newcomball players|active newcomball women players will perform physical fitness tests
61983792|NCT02307357|EXPERIMENTAL|control|not physically active women will perform physical fitness tests
61983793|NCT02469454|EXPERIMENTAL|early insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum. The ENG implant will be inserted subdermally in the non-dominant arm of volunteers upon local anesthesia with 2% lidocaine with vasoconstrictor, according to the manufacturer's instructions.
61983794|NCT02469454|ACTIVE_COMPARATOR|conventional insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted after 6 week of the delivery. The ENG implant will be inserted subdermally in the non-dominant arm of volunteers upon local anesthesia with 2% lidocaine with vasoconstrictor, according to the manufacturer's instructions.
61983795|NCT02357901|EXPERIMENTAL|RBP-6000 300mg/100mg|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given RBP-6000 300 mg injections on Days 1 and 29. Injections 3-6 are separated by 28 days (Day 57-Day 141) and contain RBP-6000 100 mg.~In addition, participants received individual drug counseling (IDC) at least once a week."
61983796|NCT02357901|EXPERIMENTAL|RBP-6000 300mg/300mg|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given six RBP-6000 300 mg injections on Days 1 to 141 with injections separated by 28 days.~In addition, participants received individual drug counseling (IDC) at least once a week."
61983797|NCT02357901|PLACEBO_COMPARATOR|Placebo Matching 300 mg/100 mg RBP-6000|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given placebo injections on Days 1 and 29 (matching the RBP-6000 300 mg dose volume). Injections 3-6 are separated by 28 days (Day 57-Day 141) and also contain placebo (matching the RBP-6000 100 mg volume).~In addition, participants received individual drug counseling (IDC) at least once a week."
61983798|NCT02357901|PLACEBO_COMPARATOR|Placebo Matching 300 mg RBP-6000|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given six placebo injections (volume-matched to RBP-6000 300 mg dose) on Days 1 to 141 with injections separated by 28 days.~In addition, participants received individual drug counseling (IDC) at least once a week."
61983799|NCT01387347|ACTIVE_COMPARATOR|Thymosin Beta 4|RGN-259 is a preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4
61983800|NCT01387347|PLACEBO_COMPARATOR|Placebo|The placebo solution is composed of the same excipients as RGN-259 but does not contain Tβ4. The Placebo is identical to the RGN-259 eye drops in color, consistency, and odor.
61983801|NCT00616655|ACTIVE_COMPARATOR|1|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
61983802|NCT00616655|ACTIVE_COMPARATOR|2|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
61983803|NCT00616655|PLACEBO_COMPARATOR|3|Placebo total daily dose 0.9 mg
61983804|NCT03416257||WIHS|Women's Interagency HIV Study
61983805|NCT03416257||MACS|Multicenter AIDS Cohort Study
61983806|NCT02940847|ACTIVE_COMPARATOR|blind technique|Investigators will perform a medial brachial cutaneous nerve block and an intercostobrachial nerve block with either a blind technique or an ultrasound-guided technique to estimate the effectiveness of each technique. The blind technique consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
61983807|NCT02940847|ACTIVE_COMPARATOR|ultrasound-guided technique|Investigators will perform a medial brachial cutaneous nerve block and an intercostobrachial nerve block with either a blind technique or an ultrasound-guided technique to estimate the effectiveness of each technique. In the ultrasound-guided technique, ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
62362727|NCT02283918||Participants with bachelor's degree or equivalent|Participants are further divided into three sub-groups based on their age group Group 1: Participants aged between 25 to 34 years Group 2: Participants aged between 35 to 44 years Group 3: Participants aged between 45 to 58 years
62362728|NCT03994276|PLACEBO_COMPARATOR|Phase 1: Control|oral glucose tolerance test (OGTT): 58g Dextrose in 330ml water
62362729|NCT03994276|ACTIVE_COMPARATOR|Phase1: Chickpea Control|"sub-cellular Chickpea powder: 58g total available carbohydrate, provided as 50g from chickpea powder + 8g from chocolate flavouring"
62362730|NCT03994276|EXPERIMENTAL|Phase1: Chickpea Powder|Chickpea powder: 58g total available carbohydrate, provided as 50g from chickpea powder + 8g from chocolate flavouring
62362731|NCT03994276|ACTIVE_COMPARATOR|Phase 2: Control|Wheat bread: breakfast consisting of a 100% wheat bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
62362732|NCT03994276|EXPERIMENTAL|Phase 2: 30%Chickpea Powder|Wheat bread: breakfast consisting of a 70% wheat / 30% Chickpea powder bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
62362733|NCT03994276|EXPERIMENTAL|Phase 2: 60%Chickpea Powder|Wheat bread: breakfast consisting of a 40% wheat / 60% Chickpea powder bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
61983808|NCT00591942|ACTIVE_COMPARATOR|VivaGlass dental cement|36 subjects (TOTAL) received two crowns each and another group of 11 subjects received a three-unit fixed dental bridge. Cross over design. One dental crown cemented with VivaGlass Cement/subject. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
62362734|NCT05796349||healthy group|The healthy group included 16 individuals (male, age 40.25±11.18). No history of brain disease and no abnormalities were seen on plain CT scans of their brains.
61983809|NCT00591942|ACTIVE_COMPARATOR|MultiLink dental cement|36 subjects (TOTAL) received two crowns each and another group of 11 subjects received a three-unit fixed dental bridge. Cross Over design. One dental crown per subject was cemented with Multilink Dental Cement. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
61983810|NCT05982509|NO_INTERVENTION|No intervention|Control group: 10 people without treatment
61983811|NCT05982509|EXPERIMENTAL|Treatment|Study Group: 10 People Applying EasyDew Regen MD Cream
61983812|NCT01724060||Gastric bypass|Patients due for gastric bypass surgery
61983813|NCT01724060||Gastric banding|Patients due for gastric banding
61983814|NCT01724060||Sleeve gastrectomy|Patients due for sleeve gastrectomy
61983815|NCT01724060||Endobarrier|Patients due to undergo endoscopic Endobarrier insertion
61983816|NCT01724060||Exenatide|Patients due to be commenced on Exenatide
61983817|NCT01724060||Liraglutide|Patients due to be commenced on Liraglutide
61983818|NCT01724060||Lifestyle|Patients due to be commenced on a lifestyle intervention programme
61983819|NCT01724060||Elective surgery or endoscopy|Patients due to have non bariatric surgery (i.e. cholecystectomy) or an elective diagnostic endoscopy
61983820|NCT05876741||Participants|patient presented with hematemesis , coffee ground vomiting , melena and haematoectasia to gastroenterology department will be included.
61983821|NCT03233958||Workshop participants|Participants of systemic / family constellation workshops
61983822|NCT04951245|EXPERIMENTAL|UC group|Ultrasound-assisted CNSs guided SLN mapping
61983823|NCT04951245|ACTIVE_COMPARATOR|GC group|CNSs plus ICG dual-tracer-guided SLN mapping
61983824|NCT03454919|OTHER|Palbociclib|single arm
61983825|NCT05346159||turner syndrome group|
61983826|NCT05346159||control group|
61983827|NCT06392542|EXPERIMENTAL|Whole Selves|Participants assigned to this arm will receive the Whole Selves intervention and complete assessment surveys at baseline, 30 days, and 90 days.
61983828|NCT01679379|ACTIVE_COMPARATOR|Absorbable suture group|Include women who have their skin closed with subcuticular stitches using \[Polyglactin 910 absorbable, synthetic, braided suture\].
61983829|NCT01679379|ACTIVE_COMPARATOR|Non absorbable suture group|Include women who have their skin closed with subcuticular stitches using \[Polypropylene non absorbable monofilament suture\].
61983830|NCT05102383|EXPERIMENTAL|All participants|All participants have habitual Comfilcon A Toric lenses optimized for wear over 2 weeks. Then all participants are fit with the Verofilcon A study daily disposable lenses with water surface treatment for astigmatism.
61983831|NCT02492347|ACTIVE_COMPARATOR|Neonates exposed to AN SSRI use|A group of newborn babies who have been exposed to SSRIs in pregnancy will receive an Electrocardiogram at 48-72 hours of age.
61983832|NCT02492347|OTHER|Neonates not exposed to AN SSRI use|A group of newborn babies, who require treatment with intravenous antibiotics for at least 36 hours, having been identified as being at risk of having an infection within 12 hours of being born. They are subsequently confirmed as clinically well and will receive an Electrocardiogram at 48-72 hours of age.
61983833|NCT03352986||osteonecrosis|Sickle cell patients with osteonecrosis as a vascular main complication
61983834|NCT03352986||leg ulcer|Sickle cell patients with leg ulcer as a vascular main complication
61983835|NCT03352986||microalbuminuria|Sickle cell patients with microalbuminuria as a vascular main complication
61983836|NCT03352986||pulmonary hypertension|Sickle cell patients with pulmonary hypertension as a vascular main complication
61983837|NCT03352986||stroke|Sickle cell patients with strocke as a vascular main complication
61983838|NCT03352986||priapism|Sickle cell patients with priapism as a vascular main complication
61983839|NCT04102215|EXPERIMENTAL|ARCI25|Robot assited Cochlear implant surgery.
61983840|NCT04123847|EXPERIMENTAL|Stand, Step and Voluntary Training|
61983841|NCT00946712|EXPERIMENTAL|Arm I (chemo +/- bevacizumab)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes with or without bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients receiving bevacizumab may continue to receive bevacizumab (as above) in the absence of disease progression or unacceptable toxicity.
62362735|NCT05796349||patient group|The patient group included 8 patients with brain diseases (7 males, age 59±10.46). Obvious lesions were visible on the patients' CT or MRI images, including 6 patients with intracranial hemorrhage, 1 patient with cerebral ischemia, and 1 patient with cerebral edema
62362736|NCT01989572|EXPERIMENTAL|Arm I (sargramostim, peptide vaccine)|Patients receive sargramostim SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
62362737|NCT01989572|EXPERIMENTAL|Arm II (sargramostim placebo, peptide vaccine)|Patients receive sargramostim placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
61983842|NCT00946712|EXPERIMENTAL|Arm II (chemo, cetuximab, +/- bevacizumab)|Patients receive paclitaxel and carboplatin with or without bevacizumab as in Arm I. Patients also receive cetuximab IV over 1-2 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients may continue to receive cetuximab with or without bevacizumab (as above) in the absence of disease progression or unacceptable toxicity.
61983843|NCT05569187||Ribociclib in combination with non-steroidal aromatase inhibitors|Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year
61983844|NCT00749372|OTHER|1|Patients who meet eligibility will be sent for radiographic imaging to include T2\* cardiac and liver MRI to ascertain quantification of organ-specific iron concentrations as well as cardiac left ventricular ejection fraction.
61983845|NCT05195112|EXPERIMENTAL|MT921|"* Injection volume/interval: 0.2mL/1.0cm~* Number of Injection: Maximum 50 times~* Concentration per unit area: 3mg/cm2"
61983846|NCT05195112|PLACEBO_COMPARATOR|Placebo|"* Injection volume/interval: 0.2mL/1.0cm~* Number of Injection: Maximum 50 times~* Concentration per unit area: 0mg/cm2"
61983847|NCT05337592|EXPERIMENTAL|SRD part: BI 1815368|
61983848|NCT05337592|PLACEBO_COMPARATOR|SRD part: Placebo|
61983849|NCT05337592|EXPERIMENTAL|BA part: T1-R-T2|R: BI 1815368 formulation 1, fasted condition T1: BI 1815368 formulation 2, fasted condition T2: BI 1815368 formulation 2, fed condition
61983850|NCT05337592|EXPERIMENTAL|BA part: R-T2-T1|
61983851|NCT05337592|EXPERIMENTAL|BA part: T2-T1-R|
61983852|NCT05039008|EXPERIMENTAL|Blood flow restriction group|"The intervention will last 4 weeks, with a periodicity of 3 weekly sessions (34). In total there will be 12 sessions lasting between 15 and 30 minutes.~The exercises will be: squats, knee extension and heel elevation (performing 4 sets of 15 repetitions with 30 seconds of rest between sets)."
61983853|NCT05039008|NO_INTERVENTION|Control group|The patients included in the control group will not receive any Physiotherapy intervention and will continue with their usual routine, being evaluated in the same periods as the rest of the patients.
61983854|NCT01864733|EXPERIMENTAL|intervention group|"1) The 'intervention' group: 3-month multimodal approach associating exercise rehabilitation, ONS, n-3 PUFAs and androgen substitution:~* Physical rehabilitation including endurance and resistance exercises two to three times a week.~* Oral nutritional supplements: Fortimel max® (Nutricia®) (300 ml, 720 kcal, 29 g de proteins), once per day.~* n-3 polyunsaturated fatty acids : DHA phospholipids (GPL-DHA®), 240 mg/day.~* Testosterone: Testopatch® 2.4 mg in men and 1.2 mg in women; 2 patches renewed every two days."
61983855|NCT01864733|OTHER|control group|2) The 'control' group: no multimodal approach but the treatment currently recommended: heart rehabilitation and dietary counseling during 3 months.
61983856|NCT00827970|EXPERIMENTAL|1 Screening|Individuals receiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
61983857|NCT00827970|NO_INTERVENTION|2 Control|Control group receiving usual care
61983858|NCT01452607|EXPERIMENTAL|SPI-1005 Capsule 200mg Ebselen x1|Lowest Dose Evaluated, 200mg Ebselen Total, Delivered as a Single Dose
61983859|NCT01452607|EXPERIMENTAL|SPI-1005 Capsule 200mg Ebselen x2|2x Lowest Dose Evaluated, 400mg Ebselen Total, Delivered as a Single Dose
61983860|NCT01452607|EXPERIMENTAL|SPI-1005 Capsule 200mg Ebselen x4|4x Lowest Dose Evaluated, 800mg Ebselen Total, Delivered as a Single Dose
61983861|NCT01452607|EXPERIMENTAL|SPI-1005 Capsule 200mg Ebselen x8|8x Lowest Dose Evaluated, 1600mg Ebselen Total, Delivered as a Single Dose
61983862|NCT01452607|PLACEBO_COMPARATOR|SPI-1000 Capsule 0 mg Ebselen Placebo|Matching Placebo Capsule, 0mg Ebselen Total, Delivered as a Single Dose
61983863|NCT06197815|EXPERIMENTAL|Off-site assistance group|The trainer supervised the trainee's cannulation operation outside the procedure room through a high-definition screen displaying the endoscopic view. Trainees wear headphones, and trainers use intercom to provide the unlimited verbal instructions. The trainer was not allowed into the procedure room and touched the endoscope or accessories until the trainee ask for help or failed to achieve deep biliary cannulation. Then the trainer would then take over and continue with the cannulation. The trainer would halt and correct the trainee's inappropriate maneuvers immediately to avoid unnecessary papillary trauma and potential complications.
61983864|NCT06197815|ACTIVE_COMPARATOR|Hands-on assistance group|During trainees' attempted cannulation, the trainer gave unlimited verbal instructions with hands-on assistance limited to only adjustment of scope position if necessary. To avoid unintended cannulation, the trainer was not allowed to touch the control section of the scope or the sphincterotome used for cannulation. However, the trainer would correct any inappropriate maneuvers immediately to avoid unnecessary papillary trauma and potential complications. The trainees could ask for help or stop cannulation at any time if they were not comfortable continuing the procedure. The trainer would then take over and continue with the cannulation.
61983865|NCT05864560||AAA Subjects|Patient diagnosed with Abdominal Aortic Aneurysm, who needs endovascular aortic repair.
61983866|NCT00632255||1|Patients with CML who have been treated with Imatinib (Glivec) within 6 months of diagnosis as first line therapy. Initial therapy with Hydroxyurea is permitted
61983867|NCT04297137|EXPERIMENTAL|Mycoprotein|Ingestion of 30 g mycoprotein drink
61983868|NCT04297137|EXPERIMENTAL|Spirulina|Ingestion of 30 g spirulina protein drink
61983869|NCT04297137|EXPERIMENTAL|Chlorella|Ingestion of 30 g chlorella protein drink
61983870|NCT04297137|EXPERIMENTAL|Pea|Ingestion of 30 g pea protein drink
61983871|NCT04297137|EXPERIMENTAL|Lupin|Ingestion of 30 g lupin protein drink
61983872|NCT04297137|ACTIVE_COMPARATOR|Milk|Ingestion of 30 g milk protein
61983873|NCT02746211|EXPERIMENTAL|High Titre Influenza virus|High Titre Influenza virus
61983874|NCT02746211|EXPERIMENTAL|Medium - High Influenza virus|Medium - High Influenza virus
61983875|NCT02746211|EXPERIMENTAL|Medium Low Titre Influenza virus|Medium Low Titre Influenza virus
61983876|NCT02746211|EXPERIMENTAL|Low titre Influenza Vaccine|Low titre Influenza Vaccine
61983877|NCT03667560|EXPERIMENTAL|Dermacell ADM without basement membrane|Dermacell ADM without a basement membrane
61983878|NCT03667560|ACTIVE_COMPARATOR|FlexHD|FDA-approved FlexHD Pliable
61983879|NCT03332576|EXPERIMENTAL|Cohort 1|"6 Doses DPX-Survivac (2 prime q3w, 4 boost q8w)~Low dose cyclophosphamide"
61983880|NCT03332576|EXPERIMENTAL|Cohort 2|"6 Doses DPX-Survivac (2 prime q3w, 4 boost q8w)~Low dose cyclophosphamide"
61983881|NCT03332576|EXPERIMENTAL|Cohort 3|"3 Doses DPX-Survivac (1 prime, 2 boost q8w)~Low dose cyclophosphamide"
61983882|NCT03332576|EXPERIMENTAL|Cohort 4|"5 Doses DPX-Survivac (2 prime q6w, 3 boost q6w)~Low dose cyclophosphamide"
61983883|NCT03332576|EXPERIMENTAL|Cohort 5|"5 Doses DPX-Survivac/DPX-Survivac(Aqueous) (2 prime q4w, 3 boost q4w)~Low dose cyclophosphamide"
61983884|NCT00303498|EXPERIMENTAL|Sitaxsentan sodium|
61983885|NCT00303498|PLACEBO_COMPARATOR|Placebo|
61983886|NCT04019314|EXPERIMENTAL|Subjects with know chronic systolic heart failure|Subjects with know chronic systolic heart failure (LVEF\<50%) admitted to SMH Heart Failure Medical Service for decompensated HF with clinical findings of volume overload requiring advanced diuretic therapy intervention and management will receive daily blood draws and quantitative blood volume analysis
61983887|NCT06470230||Pediatric oncology patients/survivors|Children who have or had cancer
61983888|NCT06470230||Guardians/caregivers of pediatric oncology patients/survivors|Parents or caregivers of children who have or had cancer
61983889|NCT02986568|EXPERIMENTAL|Cervical cancer|"* Primary cervical cancer patients, FIGO stage IB1-IIB~* Refractory cervical cancer patients who do not respond to concurrent chemoradiotherapy or radiotherapy~* Recurrent cervical cancer after concurrent chemoradiotherapy or radiotherapy"
61983890|NCT02986568|EXPERIMENTAL|Uterine cancer|"* Primary uterine cancer patients, FIGO stage IA, grade3, IB-IVA~* Refractory uterine cancer who does not respond to concurrent chemoradiotherapy or radiotherapy~* Recurrent uterine cancer after concurrent chemoradiotherapy or radiotherapy"
61983891|NCT02986568|EXPERIMENTAL|Cervical cancer, pelvic sidewall invasion|"Cervical cancer patients showing pelvic sidewall invasion~* Primary cervical cancer~* Refractory cervical cancer patients who do not respond to concurrent chemoradiotherapy or radiotherapy~* Recurrent cervical cancer after concurrent chemoradiotherapy or radiotherapy"
61983892|NCT02986568|EXPERIMENTAL|Non-cervical cancer, pelvic sidewall invasion|"* Gynecologic cancer patients other than cerivcal cancer, showing pelvic sidewall invasion with or without distant metastasis~* Patients showing uncontrolled pelvic pain due to the tumor invasion"
61983893|NCT03345667||Anti-Vegf|Use intravitreous anti-vegf
61983894|NCT03256539|EXPERIMENTAL|Sleep Intervention|Sleep treatment program (to be developed) that incorporates modified cognitive behavioral therapy for insomnia (CBT-I) and bright light therapy (BLT)
61983895|NCT03256539|PLACEBO_COMPARATOR|Placebo intervention|Placebo (quasi-desensitization) intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration).
61983896|NCT03118154||Manual Physical Therapy, retrospective|Endometriosis subjects treated at Clear Passage with follow up to assess changes in pain and overall health in a retrospective chart review.
61983897|NCT03118154||Control, prospective|Endometriosis control subjects not treated at Clear Passage that complete two questionnaires, 30 days apart, to assess changes in their pain levels.
61983898|NCT00604292||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases
61983899|NCT00452829|EXPERIMENTAL|Study Group|5 mg folic acid (the standard UK supplement for pregnancies at high risk of NTD) and 1 g inositol,
61983900|NCT00452829|PLACEBO_COMPARATOR|Control Group|5 mg folic acid (the standard UK supplement for pregnancies at high risk of NTD)and 1 g placebo
61983901|NCT03434847|NO_INTERVENTION|Control|Standard preoperative assessment
61983902|NCT03434847|ACTIVE_COMPARATOR|Education|Pre-operative education regarding post-operative pain expectations
61983903|NCT03402685|NO_INTERVENTION|NIBP-Group|NIBP will be shown, ClearSight will be covered.
61983904|NCT03402685|EXPERIMENTAL|ClearSight-Group|ClearSight will be shown, NIBP will be covered.
62362738|NCT01989572|EXPERIMENTAL|Arm III (sargramostim, peptide placebo)|Patients receive sargramostim SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
61983905|NCT00829543|EXPERIMENTAL|sacroiliac injection|an open label study designed to evaluate the efficacy and safety of guide-free sacroiliac injection in refractory sacroiliac pain due to spondyloarthropathies
61983906|NCT03008083|ACTIVE_COMPARATOR|3 months DAPT Intervention|After implantation of Firehawk coronary stents, all subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and thienopyridines (clopidogrel or ticagrelor)for 3 months.
61983907|NCT03008083|ACTIVE_COMPARATOR|12 months DAPT Intervention|After implantation of Firehawk coronary stents, all subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and thienopyridines (clopidogrel or ticagrelor)for 12 months.
61983908|NCT05831761|EXPERIMENTAL|PCA|Postoperative intravenous infusion of piritramid patient controlled analgesia (PCA) (piritramide 0.5 mg/ml; infusion 1,5 mg/h, bolus 1,5 mg, lock out 30 minutes)
61983909|NCT05831761|EXPERIMENTAL|PCEA|Postoperative patient controlled epidural analgesia (epidural cathterer inserted into Th7-8 intervertebral space, 200 ml of 0.125% levobupivacaine, 4 mg of morphine, 0.075 mg of clonidine; infusion 5 ml/h, bolus 5 ml, lock out 30 minutes).
61983910|NCT05831761|EXPERIMENTAL|tramadol|Continous postoperative infusion of tramadol 300 mg and metamizole 2,5 g (in 500 ml 0.9% NaCl, rate of infusion 40 ml/h)
61983911|NCT05831761|EXPERIMENTAL|lidocaine|Postoperative topical lidocaine and PCA (piritramide 0.5 mg/ml; infusion 0.5 mg/h, bolus 1.5 mg, lock out 20 minutes)
61983912|NCT05241522|ACTIVE_COMPARATOR|Tilmanocept Dose - 0.050 mg|
61983913|NCT05241522|ACTIVE_COMPARATOR|Tilmanocept Dose - 0.20 mg|
61983914|NCT05241522|ACTIVE_COMPARATOR|Tilmanocept Dose - 0.40 mg|
61983915|NCT02195063||Pain management|patients undergoing transdermal treatment for pain
61983916|NCT02195063||Scar care|patients undergoing transdermal treatment for scars
61983917|NCT02195063||Wound care|patients undergoing transdermal treatment for wounds
61983918|NCT02195063||UDT|patients receiving urinary drug tests
61983919|NCT01821534||All Participants|Healthy volunteers. No treatment (intervention) was administered.
62362739|NCT01989572|PLACEBO_COMPARATOR|Arm IV (placebo, peptide placebo)|Patients receive placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
62362740|NCT01989572|EXPERIMENTAL|Arm V (sargramostim)|Patients receive sargramostim SC on days 1-14.
62362741|NCT01989572|PLACEBO_COMPARATOR|Arm VI (sargramostim placebo)|Patients receive sargramostim placebo SC on days 1-14.
61983920|NCT05284669|EXPERIMENTAL|Experimental e-learning|The experimental interactive intervention is based on international guidelines for the management of LBP and includes multiple interactions with the participant in a virtual environment. Metaphors and concrete clinical situations are presented to translate the knowledge (i.e. the management of low back pain from a biopsychosocial point of view) to clinical practice. Interactions consists of videos, open and closed questions and audio records.
61983921|NCT05284669|OTHER|Traditional e-learning|The traditional intervention consists of a traditional online lecture based on international guidelines for the management of LBP without any interaction. The focus is more fundamental (theoretical) without metaphors or clinical cases.
61983922|NCT05348161|OTHER|Anti-HER2 & Immunotherapy|Advancd gastric cancer patients received anti-HER2 \& immunotherapy ± chemotherapy
61983923|NCT05348161|OTHER|Anti-HER2|Advancd gastric cancer patients received anti-HER2 ± chemotherapy.
61983924|NCT01661192|EXPERIMENTAL|AAT( Alpha 1 Antitrypsin)|Subjects who maintained peak stimulated C-peptide secretion ≥ 0.2nmol/L will continue treatment with AAT according to the dosage group they were allocated to at the previous study(40mg/kg or 60mg/kg or 80mg/kg), intravenously, once a week for 6 consecutive weeks, at 24-week intervals for a duration of \~54 weeks.
61983925|NCT01661192|NO_INTERVENTION|Follow up group|Subjects who have not maintained peak stimulated C-peptide secretion ≥ 0.2nmol/L or subjects with peak stimulated C -peptide secretion ≥ 0.2nmol/L who are reluctant to receive additional study drug, will be followed up only with no administration of investigational product
61983926|NCT05106855|OTHER|Implants GM Acqua surface, with LLLT.|"Surgical protocol Periotomes will be used for atraumatic extraction and/or a stainless steel tooth extractor.~The implant, GM Acqua, will be placed in a flapless manner through the alveolus, manually or mechanically, and a minimum length of 2 mm longer than the root length. The implant placement site will be prepared following the manufacturer's protocol.~The minimum torque that to be employed to attain primary stability of the implant will have to be ≥ 30 Ncm measured with a manual torque wrench. (Neodent®).~After the implant has been placed, a healing abutment GM (Neodent®) will be placed, with a maximum torque of 10 N.cm.~LLLT protocol:~With a infrared diode laser, wavelength of 808 nm, continuous mode, a dose of 2J per spot, for 20 seconds per spot, the following irradiation protocol shall be applied: immediately after surgery and on days 3 and 7 after surgery, 4 spots (2 in the vestibular and 2 in lingual/palatal of the alveolus/implant)."
61983927|NCT05106855|OTHER|Implants GM Acqua surface, without LLLT.|"Surgical protocol Periotomes will be used for atraumatic extraction and/or a stainless steel tooth extractor.~The implant, GM Acqua, will be placed in a flapless manner through the alveolus, manually or mechanically, and a minimum length of 2 mm longer than the root length. The implant placement site will be prepared following the manufacturer's protocol.~The minimum torque that to be employed to attain primary stability of the implant will have to be ≥ 30 Ncm measured with a manual torque wrench. (Neodent®).~After the implant has been placed, a healing abutment GM (Neodent®) will be placed, with a maximum torque of 10 N.cm."
61983928|NCT05106855|OTHER|Implants GM NeoPoros surface, with LLLT.|"Surgical protocol Periotomes will be used for atraumatic extraction and/or a stainless steel tooth extractor.~The implant, GM NeoPoros, will be placed in a flapless manner through the alveolus, manually or mechanically, and a minimum length of 2 mm longer than the root length. The implant placement site will be prepared following the manufacturer's protocol.~The minimum torque that to be employed to attain primary stability of the implant will have to be ≥ 30 Ncm measured with a manual torque wrench. (Neodent®).~After the implant has been placed, a healing abutment GM (Neodent®) will be placed, with a maximum torque of 10 N.cm.~LLLT protocol:~With a infrared diode laser, wavelength of 808 nm, continuous mode, a dose of 2J per spot, for 20 seconds per spot, the following irradiation protocol shall be applied: immediately after surgery and on days 3 and 7 after surgery, 4 spots (2 in the vestibular and 2 in lingual/palatal of the alveolus/implant)."
61983929|NCT05106855|OTHER|Implants NeoPoros surface, without LLLT.|"Surgical protocol Periotomes will be used for atraumatic extraction and/or a stainless steel tooth extractor.~The implant, GM NeoPoros, will be placed in a flapless manner through the alveolus, manually or mechanically, and a minimum length of 2 mm longer than the root length. The implant placement site will be prepared following the manufacturer's protocol.~The minimum torque that to be employed to attain primary stability of the implant will have to be ≥ 30 Ncm measured with a manual torque wrench. (Neodent®).~After the implant has been placed, a healing abutment GM (Neodent®) will be placed, with a maximum torque of 10 N.cm."
61983930|NCT02005250||hyperthyroidism|61 pre- and postmenopausal women with hyperthyroidism
61983931|NCT02005250||hypothyroidism|32 pre- and postmenopausal women with hypothyroidism
61983932|NCT05195723|EXPERIMENTAL|WP1122|"Each study group consists of 10 volunteers randomized in a 4:1 ratio to receive WP1122 or placebo. In the first part of the study (Single Ascending Dose \[SAD\]) in each group (up to 4), 8 volunteers will receive WP1122 and 2 volunteers will receive placebo, one time orally. A total of up to 40 volunteers will be enrolled into the SAD portion of the study.~The second part of the study (Multiple Ascending Dose \[MAD\]) will begin when the third group in the SAD part of the study has completed dosing. In this part of the study (MAD) in each group (up to 4), 8 volunteers will receive WP1122 and 2 volunteers will receive placebo, 2 times per day (12 hours apart) orally for 7 days. A total of up to 40 volunteers will be enrolled into the MAD portion of the study.~Up to 80 volunteers will be enrolled into the study entirely."
61983933|NCT05195723|PLACEBO_COMPARATOR|Placebo|"Each study group consists of 10 volunteers randomized in a 4:1 ratio to receive WP1122 or placebo. In the first part of the study (Single Ascending Dose \[SAD\]) in each group (up to 4), 8 volunteers will receive WP1122 and 2 volunteers will receive placebo, one time orally. A total of up to 40 volunteers will be enrolled into the SAD portion of the study.~The second part of the study (Multiple Ascending Dose \[MAD\]) will begin when the third group in the SAD part of the study has completed dosing. In this part of the study (MAD) in each group (up to 4), 8 volunteers will receive WP1122 and 2 volunteers will receive placebo, 2 times per day (12 hours apart) orally for 7 days. A total of up to 40 volunteers will be enrolled into the MAD portion of the study.~Up to 80 volunteers will be enrolled into the study entirely."
61983934|NCT03297385|EXPERIMENTAL|Prostatectomy after enzalutamide|"This is a single-arm study. Patients will have biopsies, after which they will receive enzalutamide for 3 months.~After 3 months they will have a prostatectomy."
61983935|NCT06024421|EXPERIMENTAL|level 1: experimental|D1: 2400 mg BID; D2 to D13: 1600 mg BID and D14: 1600 mg in the morning
61983936|NCT06024421|EXPERIMENTAL|level 2: experimental|D1: 2400 mg BID; D2 to D13: 2000 mg BID and D14: 2000 mg in the morning
61983937|NCT06024421|EXPERIMENTAL|level 3: experimental|D1: 2400 mg BID; D2 to D13: 2400 mg BID andD14: 2400 mg in the morning
61983938|NCT06024421|PLACEBO_COMPARATOR|level 1: placebo|D1: 2400 mg BID; D2 to D13: 1600 mg BID and D14: 1600 mg in the morning
61983939|NCT06024421|PLACEBO_COMPARATOR|level 2: placebo|D1: 2400 mg BID; D2 to D13: 2000 mg BID and D14: 2000 mg in the morning
61983940|NCT06024421|PLACEBO_COMPARATOR|level 3: placebo|D1: 2400 mg BID; D2 to D13: 2400 mg BID andD14: 2400 mg in the morning
61983941|NCT01045642|ACTIVE_COMPARATOR|Prilosec 20 mg Tablets|
61983942|NCT01045642|EXPERIMENTAL|Omeprazole Magnesium DR 20 mg Capsules|
61983943|NCT03854617|EXPERIMENTAL|Oral NVB Metronomic|50mg three times weekly on Mondays (or Tuesdays), Wednesdays (or Thursdays) and Friday (or Saturdays). A cycle is a 3 weeks period.
61983944|NCT03854617|ACTIVE_COMPARATOR|Oral NVB Weekly|60mg/m2 weekly for cycle 1 and 80mg/m2 weekly for subsequent cycles in the absence of grade 3 or 4 toxicity. A cycle is a 3 weeks period.
61983945|NCT05892042|EXPERIMENTAL|intervention|patient will receive dual antiplatelet therapy, the choose of p2Y12 inhibitor is at the discretion of the clinician. in addition the patient will receive rivaroxaban 15mg daily in addition to the dual antiplatelet therapy.
61983946|NCT05892042|NO_INTERVENTION|control|patient will receive dual antiplatelet therapy, the choose of p2Y12 inhibitor is at the discretion of the clinician.
61983947|NCT06012201||low normal protein intake|the patient in this group will intake enteral protein feeding from 0.8- 1.5 gm /kg/day
61983948|NCT06012201||high normal protein intake|the patient in this group will intake enteral protein feeding from 1.6 - 2.2 gm /kg/day
61983949|NCT05019365||Participants with previous HER2 breast cancer|
61983950|NCT05019365||Healthy Volunteers|
61983951|NCT04728061|EXPERIMENTAL|Single Ascending Dose|
61983952|NCT04728061|EXPERIMENTAL|Multiple Ascending Dose|
61983953|NCT02977988|EXPERIMENTAL|Mindfulness Meditation|Mindfulness-Based Relapse Prevention-Women (MBRP-W)
61983954|NCT02977988|ACTIVE_COMPARATOR|Active Comparator|Brain and Recovery (B\&R)
62362742|NCT03905824|EXPERIMENTAL|Debridement and microfracture in LOC + Cells|Traditional debridement and microfracture treatment adding a platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord in patients with osteochondral lesions of the talus.
62362743|NCT03905824|ACTIVE_COMPARATOR|Debridement and microfracture in LOC|Traditional debridement and microfracture treatment in patients with osteochondral lesions of the talus.
62362744|NCT01499797|NO_INTERVENTION|regular medical care|Identified community dwelling frail elderly people receiving regular medical care in their primary care setting
62362745|NCT01499797|EXPERIMENTAL|The CareWell programme|Identified community dwelling frail elderly people receiving care in line with the CareWell programme
61983955|NCT01677975|EXPERIMENTAL|ultrasound, dynamic lymphscintigraphy|
61983956|NCT05864066||1|Women in preterm delivery with GA \< 36 weeks.
61983957|NCT05864066||2|Women not in labor undergoing elective C-section with GA between 36 and 40 weeks.
61983958|NCT05864066||3|Women following spontaneous labor (without being induced) with GA between 36 and 40 weeks.
61983959|NCT05546047|ACTIVE_COMPARATOR|Treatment with Acthar gel|Group 1 - (17 patients) Acthar gel 80 units 2 times a week alone for 12 months of therapy.
61983960|NCT05546047|ACTIVE_COMPARATOR|Treatment with combination Acthar gel and Tacrolimus therapy|Group 2 - (17 patients) Acthar get 80 units 2 times a week plus oral Tacrolimus 1.0 mg two times a day titrated to trough Tacrolimus levels between 4-6 ng/ml
61983961|NCT05711225|EXPERIMENTAL|Experimental group|"The behavior stage was determined by applying the Stages of Change Scale (SCS) form to the pregnant women in the experimental group. The pre-test data from the women in the experimental group were obtained through the website through the Participant Introduction Form,Behavior Change Process Scale (BCPS), Self-Efficacy Scale/Encouraging Factors Scale (SES/EFS) and Decision Balance Scale (DBS) before watching the videos. In addition, FNDT was applied to women who smoked during pregnancy. Post-test data from the women in the experimental group were collected by having them fill out the postpartum part of the Participant Identification Form at the 4th week postpartum after watching the animation videos, and FNDT, SCS, BCPS/EFS and DBS forms for those who still smoke, on the website."
61983962|NCT05711225|NO_INTERVENTION|Control group|"The behavior stage was determined by applying the Stages of Change Scale (SCS) form to the women participating in the control group. The pre-test data of the women participating in the control group were applied via the Participant Identification Form, FNDT, SCS, BCPS/EFS and DBS and the FNDT form to those who continued to smoke during pregnancy. Post-test data from women in the control group were collected with the postpartum part of the Participant Identification Form at 4 weeks postpartum, FNDT, SCS, BCPS/EFS and DBS for smokers."
61983963|NCT01185938|ACTIVE_COMPARATOR|Rosuvastatin|
61983964|NCT01185938|NO_INTERVENTION|Control|
61983965|NCT04515342||Participants|This is a cross-sectional study involving approximately 150 patients. They undergo a physical examination, fill out a questionnaire, have blood samples drawn, undergo a Dual Energy X-ray Absorptiometry (DXA) scan and different physical procedures to assess muscle strength and muscle function.
61983966|NCT01907672|EXPERIMENTAL|Rapid Diagnostic Test|Rapid Diagnostic Test for malaria to direct antimalarial dispensing decisions in Chemical Shops
61983967|NCT01907672|NO_INTERVENTION|No RDT|Chemical sellers dispense antimalarials as per their own decisions without the benefit of test results
61983968|NCT05803811|EXPERIMENTAL|Low dose|Daily dose of 1.4 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks
61983969|NCT05803811|EXPERIMENTAL|Mid dose|Daily dose of 10 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks
61983970|NCT05803811|EXPERIMENTAL|high dose|Daily dose of 75 mg Vitamin B2 (Riboflavin) once a day for 12 weeks
61983971|NCT05803811|PLACEBO_COMPARATOR|Placebo|One capsule of 570 mg (consisting of microcrystalline cellulose) once a day for 12 weeks
61983972|NCT04964154|NO_INTERVENTION|BRAVE Non-Intervention|Survey participants in the BRAVE non-intervention arm will not have received information (e.g., informational pamplets, flyers, townhalls) about COVID-19 testing and vaccination from the BRAVE project.
61983973|NCT04964154|ACTIVE_COMPARATOR|BRAVE Intervention|Survey participants in the BRAVE intervention arm will have received information (e.g., informational pamplets, flyers, townhalls) about COVID-19 testing and vaccination from the BRAVE project.
61983974|NCT04038515|EXPERIMENTAL|E-liquid Order 'A'|Order 'A' for E-liquid Self-Administration: All participants will be given all e-liquids (i.e., all 20 nicotine\*flavor combinations (4 nicotine\* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine\*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
61983975|NCT04038515|EXPERIMENTAL|E-liquid Order 'B'|Order 'B' for E-liquid Self-Administration: All participants will be given all e-liquids (i.e., all 20 nicotine\*flavor combinations (4 nicotine\* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine\*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
61983976|NCT04038515|EXPERIMENTAL|E-liquid Order 'C'|One nicotine level condition is a medium nicotine e-liquid (12 mg/mL nicotine). All participants will be given all e-liquids (i.e., all 20 nicotine\*flavor combinations (4 nicotine\* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine\*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
61983977|NCT04038515|EXPERIMENTAL|E-liquid Order 'D'|One nicotine level condition is a high nicotine e-liquid (24 mg/mL nicotine). All participants will be given all e-liquids (i.e., all 20 nicotine\*flavor combinations (4 nicotine\* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine\*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
61983978|NCT04444414|EXPERIMENTAL|Manual Therapy group|Bilateral manipulation lumbosacral, hip joint gapping, stretching the hip rotators with hip and knee flexion, femorotibial gapping, decompression of connective tissue of the patellofemoral region, internal and external joint line opening in laterality, mobilization of the base of the fibula, tibiofibular-talus gapping, and muscle strengthening.
61983979|NCT04444414|OTHER|Control group|They received no treatment, they just went to the evaluations.
61983980|NCT03192592|EXPERIMENTAL|Body moisturizer Apotech®|Instructions for use: Massage the product in the body twice a day (morning and evening) with gentle movements until completely absorption. Daily use for 28 days.
61983981|NCT02729974|EXPERIMENTAL|ROTEM|Participants randomized to this arm will have rapid testing of hematocrit and clotting function every 30 minutes during the hysterectomy portion of their surgery for placenta accreta, with transfusion of blood products based on defined abnormalities in these tests.
61983982|NCT02729974|ACTIVE_COMPARATOR|Standard treatment|Participants randomized to this arm will have standard visual assessment of blood loss and standard laboratory studies to assess blood count and clotting function when indicated during the hysterectomy portion of their surgery for placenta accreta. Transfusion of blood products will be based on abnormalities of these test results.
61983983|NCT02249533|EXPERIMENTAL|Spot Light and High School RIO|"A total of 200 youth football teams (100 high school and 100 middle school-aged teams) will be enrolled. Potential participating teams, all high schools eligible to report football data to High School RIO™ as well as all Pop Warner and Middle School sponsored football teams that have a valid e-mail contact, will be e-mailed a letter inviting them to participate (Appendix 3).~Intervention: Certified Athletic Trainers will be given access to report football injuries via High School RIO and will report potential concussions using the Spot Light Concussion app."
61983984|NCT02249533|NO_INTERVENTION|Control|Control: Certified Athletic Trainers will be given access to report football injuries via High School RIO.
61983985|NCT03899584|ACTIVE_COMPARATOR|Treatment with 4-aminopyridine|The 4-aminopyridine will be administered in the form of gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as excipient. The dose of 4-aminopyridine will increase 10 mg / every 2 to 4 weeks until reaching the maximum dose proposed by weight ( maximum 1 mg / kg / d).
61983986|NCT03899584|PLACEBO_COMPARATOR|Placebo oral capsule|Patients randomized to the placebo sequence will receive placebo in the same way as those who will take 4-AP. They will be blinded to the fact that they are taking placebo and the capsules will be identical in appearance to the intervention capsules.
61983987|NCT02751515|EXPERIMENTAL|Bain De Soliel - Solid|All subjects are patched with the same product
61983988|NCT00881933|EXPERIMENTAL|Fludarabine|
61983989|NCT03585439||Single cohort of operated patients|One group of patients: isthmic spondylolisthesis operated in our center using a double approach technique
61983990|NCT05476861||Having omit insulin|Patients with type 1 diabetes who responded to the BETTER survey that they intentionally forgot their insulin.
61983991|NCT05476861||Not intentionally omit insulin|Patients with type 1 diabetes who responded to the BETTER survey that they did not intentionally omit their insulin, but they did omit it.
61983992|NCT03535350|EXPERIMENTAL|Unmethylated MGMT Glioblastoma|Every patient gets ibrutinib + radiation over 6 weeks. Patients will undergo a 4-week break and then Ibrutinib treatment will continue until disease progression, intolerable toxicity, or death.
61983993|NCT03535350|EXPERIMENTAL|Methylated MGMT Glioblastoma|Every patient gets ibrutinib + radiation + daily Temozolomide (TMZ) (75mg/m2) for 6 weeks. Patients will undergo a 4-week break and patients will then receive daily ibrutinib and adjuvant Temozolomide for Days 1-5 of a 28-day cycle of temozolomide for 6 cycles. The temozolomide will continue until disease progression, intolerable toxicity, or death or maximum of 6 cycles. Ibrutinib treatment will continue until disease progression, intolerable toxicity, or death.
61983994|NCT06069687|EXPERIMENTAL|MELPIDA|A single intrathecal infusion of 10 mL at 1E14 vg/mL for a total dose of 1E15 vg (open-label)
62362746|NCT06239324|ACTIVE_COMPARATOR|Fractional Erbium laser Technique (Group A)|About 35 patients with alopecia areata will Subject to fractional Erbium (Er-YAG) laser (Fotona Xs dynamics,Slovenia) with energy of 600 mj in short pulse mode (MSP) with spot size of 7 mm diameter, frequency of 3 Hz and pixel 3. Latanoprost( xalatan 0.005% ) is applied to the treated area for all participants.
61983995|NCT03178747|ACTIVE_COMPARATOR|Case|Patients who clinically diagnosed as herpes simplex, herpes zoster or varicella zoster skin infection.
61983996|NCT03178747|SHAM_COMPARATOR|Negative control|Patients who develops vesicular lesion but not typically considered as herpesviral skin infection, such as acute eczema, Paederus dermatitis
61983997|NCT01874847|EXPERIMENTAL|Melatonin 10mg|Melatonin 10mg capsule(high dose arm), oral, once at night, given for 28 days
61983998|NCT01874847|PLACEBO_COMPARATOR|Sugar Pill|Sugar Pill, one capsule, once at night, 28 days
61983999|NCT01874847|EXPERIMENTAL|Melatonin 3mg|Melatonin 3mg capsule (low dose arm), once, at night, 28 days
61984000|NCT04962061|EXPERIMENTAL|Multidomain intervention|The multidomain intervention will combine a cognitive training with aerobic and resistance exercises training, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
61984001|NCT04962061|EXPERIMENTAL|Physical exercise intervention|The physical exercises intervention will include aerobic and resistance exercises training, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
61984002|NCT04962061|ACTIVE_COMPARATOR|Active control intervention|The active control intervention will include stretching and toning exercises, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
61984003|NCT05196542|EXPERIMENTAL|mersilene tape arm (ETHICON, polyester 5mm double needle)|Group 1: patients with apical prolapse who will do Sacro hysteropexy using mersilene tape (polyester 5mm tape with double needle)
61984004|NCT05196542|OTHER|polyproline mesh arm (ETHICON, polyprolene mesh)|Group 2: patients with apical prolapse who will do Sacro hysteropexy using poly-proline mesh
61984005|NCT04903249|EXPERIMENTAL|Affect-regulated exercise prescription|"Participants receive instructions to adjust their pace of exercise so that they feel fairly good or better (i.e., a rating of +1 or higher on the Feeling Scale) while exercising and to avoid any increases in intensity that promote feeling fairly bad or worse. If no intensity of exercise feels at least fairly good participants will be told to exercise at an intensity that feels as positive as possible."
61984006|NCT05414279|OTHER|Capillary and venous sodium|From each patient a capillary and venous blood sample will be taken in order to determine the sodium level
61984007|NCT04882228|EXPERIMENTAL|Entelon Tab.150mg|
61984008|NCT04882228|ACTIVE_COMPARATOR|Venitol tab.|
61984009|NCT00963287|EXPERIMENTAL|bascial prescription|Decoction ,two times a day,one bag of decoction one time
61984010|NCT00963287|PLACEBO_COMPARATOR|low does of bascial decoction|Decoction ,two times a day, one bag decoction of one time
61984011|NCT01239433||mechanically ventilated patients|ICU patients on mechanical ventilation. Daily endotracheal suctioning performed to reduce secretions. Data recorded during these therapeutic interventions.
61984012|NCT02941965|EXPERIMENTAL|ICSI without PGS|Selection of embryos are based on blastocyst morphology criteria on day 5. A maximum of 2 embryos will be transferred for each treatment cycle.
61984013|NCT02941965|EXPERIMENTAL|ICSI with PGS|"PGS will be applied to select embryos on day 5, only euploid embryos will be transferred.~A maximum of 2 embryos will be transferred for each treatment cycle."
61984014|NCT03896243||Uterine artery ligation (UAL)|"We would like toinvite the patients to the hospital at least 6 months after surgery who underwent only uterine artery ligation performed due to uterine atony during C-section.~They would be evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
62362747|NCT06239324|ACTIVE_COMPARATOR|Micro needling Technique (Group B)|About 35 patients with alopecia areata will Subject to micro needling using electronic dermapen device (Dr Pen Derma PenUltima A6) which has a disposable head personalized for each patient and sterilized after each session. the dermapen will penetrate the skin with depth 0.6 mm. It will pass vertically over the affected area in a circular pattern until pinpoint bleeding appears. Latanoprost ( xalatan 0.005% ) is applied to the treated area for all participants.
62362748|NCT02121314|ACTIVE_COMPARATOR|Fasting-Fed|blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE as iv therapy; on day 2, HRZE as oral therapy in fasting condition (2 hours before meals); and on day 3 HRZE as oral therapy in fed condition (after meals).
61984015|NCT03896243||Control Group:|"We would like to invite the patients to the hospital at least 6 months after C-section who delivered baby without any complication.~They would be also evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
61984016|NCT04463550||Patients GFAP-IgG positive in serum and/or CSF|Patients developing clinical autoimmune encephalitis or meningoencephalomyelitis with anti-GFAP antibodies, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis or the National Reference Center for Centre de référence for Neuro-inflammatory diseases of the brain and the spinal cord at the Neurological Hospital of Bron.
61984017|NCT01288794|ACTIVE_COMPARATOR|Standard medical treatment plus albumin|The patients will receive standard medical treatment (diuretics) plus weekly albumin infusion
61984018|NCT01288794|OTHER|Standard medical treatment|The patients will receive the standard medical treatment (diuretics), but non albumin for the therapy of ascites
61984019|NCT05954624|EXPERIMENTAL|Experimental 1|"All participants will receive the following oral doses of study drugs following an overnight fast in the fixed-sequence below:~Period 1: 1 × 0.25-mg digoxin tablet, 1 × 10-mg rosuvastatin tablet Period 2: 8 × 600-mg ZSP1273 tablet+1 × 0.25 mg digoxin tablet, 1 × 10-mg rosuvastatin tablet"
62362749|NCT02121314|ACTIVE_COMPARATOR|Fed-Fasting|blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE therapy as iv therapy; day 2, HRZE as oral therapy in fed condition, and on day 3, HRZE as oral therapy in fasting condition
62362750|NCT02019498|EXPERIMENTAL|relaxation|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
62362751|NCT02019498|ACTIVE_COMPARATOR|Usual care waiting list|Patients allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
62362752|NCT00334204|OTHER|Measure Platelet Function Analyser -100 (PFA-100)|measuring Platelet Function Analyser (PFA)-100 test (an in vitro platelet function test, in addition to the rest of the routine/uusal clinical care)
61984020|NCT05954624|EXPERIMENTAL|Experimental 2|"All participants will receive the following oral doses of study drugs following an overnight fast in the fixed-sequence below:~Period 1: 600-mg ZSP1273 tablet Period 2: 5× 500mg Probenecid tablet BID+600-mg ZSP1273 tablet Period3: （Day1）200mg Itraconazole Capsule BID，（Day2-7）200mg Itraconazole Capsule QD+600-mg ZSP1273 tablet"
61984021|NCT05899907|EXPERIMENTAL|Treatment group|Standard of care plus Telitacicept 160 mg sc per week; after week 12, the dose can be reduced to 80 mg per week due to safety considerations.
61984022|NCT05899907|OTHER|Control group|Standard of care
61984023|NCT03467113|EXPERIMENTAL|ZX008 0.2 to 0.8 mg/kg/day|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive open-label ZX008 (flexible dosing 0.2 mg/kg/day to 0.8 mg/kg/day)
61984024|NCT06046456|EXPERIMENTAL|PACT|Receive the intervention
61984025|NCT06046456|NO_INTERVENTION|CAU|Receive care as usual, i.e., the standard care provided to pregnant women without any additional experimental interventions. It typically involves routine prenatal care, which may include regular check-ups, medical assessments, and general support from healthcare professionals
61984026|NCT02788968|OTHER|Adolescents|MRI 11-15 years
62362753|NCT05912036|EXPERIMENTAL|CA-CRT|Computer-Assisted Cognitive Remediation Therapy
62362754|NCT05912036|NO_INTERVENTION|TAU|Treatment as Usual
61984027|NCT02788968|EXPERIMENTAL|Young adults|MRI 19-25 years
61984028|NCT04674384|ACTIVE_COMPARATOR|Intermittent Low Energy Diet (ILED)|
61984029|NCT04674384|ACTIVE_COMPARATOR|Continuous Low Energy Diet (CLED)|
62362755|NCT05603494|EXPERIMENTAL|home spirometry group|
62362756|NCT00628225|NO_INTERVENTION|1|Usual Care
62362757|NCT00628225|EXPERIMENTAL|2|Multifacetted smoking cessation intervention (aimed at professional (training and education) and at patients (counseling + nicotine replacement)
61984030|NCT02473354|OTHER|Resp Depression Sequence 1 - 3|"Sequence #1: breathe 21% through the facemask and increase ventilation to achieve a target hypocapnic ET CO2 of 25 - 30 mmHg. Subject will then breathe a gas mixture containing 6% CO2 / 30% O2 to achieve a target hypercapnic ET CO2 up to 60 mmHg or HCVR is terminated at the discretion of the PI.~Sequence #2: breathe 21% O2 (normoxia) before remifentanil administration Sequence #3: breathe 50% O2 (hyperoxia) before remifentanil administration"
61984031|NCT02176850||Micardis®|
61984032|NCT05837416|EXPERIMENTAL|Oxygen Releasing Oral Gel (blue®m) with Coe-Pak dressing|topical application of Oxygen Releasing Oral Gel (blue®m) on the surgical site followed by Coe-Pak immediately after gingival depigmentation surgery, then 1 week postoperatively
61984033|NCT05837416|EXPERIMENTAL|Nano-emulsion complex propolis and vitamin C (NBF GINGIVAL GEL®) with Coe-Pak dressing|topical application of Nano-emulsion complex propolis and vitamin C (NBF GINGIVAL GEL®) on surgical site followed by Coe-Pak immediately after surgery, then 1 week postoperatively
61984034|NCT05837416|ACTIVE_COMPARATOR|COE-PAK periodontal dressing only|Periodontal dressing (COE-PAK) will be applied on surgical site only .
61984035|NCT05323942|OTHER|Education and Exercise Therapy Group|Children and their parents were trained about bruxism, parafunctional oral habits, and sleep hygiene education. Therapeutic exercises about head-neck posture, breathing, and relaxation were given for 8 weeks.
61984036|NCT01985581|EXPERIMENTAL|Placebo first then GXR|patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine). In the first intervention period subject took placebo and second intervention period subject took GXR. GXR dose was optimized to between 1 and 4mg.
61984037|NCT01985581|PLACEBO_COMPARATOR|GXR first then Placebo|patient will continue to take stable dosage of usual stimulant(Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine). In the first intervention period subject took GXR and second intervention period subject took placebo. GXR dose was optimized to between 1 and 4mg.
61984038|NCT04949165|EXPERIMENTAL|Iron Supplementation|
61984039|NCT04949165|NO_INTERVENTION|Control|
61984040|NCT00947973|EXPERIMENTAL|Challenging Horizons Program after-school model|Participants will receive the CHP after-school model.
61984041|NCT00947973|EXPERIMENTAL|Challenging Horizons Program consultation model|Participants will receive the CHP consultation model.
61984042|NCT00947973|NO_INTERVENTION|Community care|Participants will have access to standard community care.
61984043|NCT03625791||radiation-induced sarcomas|
61984044|NCT03625791||radiotherapy for at least 5 years and without sarcomas|
61984045|NCT03625791||primary sarcomas|
61984046|NCT06319755||Post-surgical patients|Adults having had pancreatoduodenectomy (Whipple's) surgery for curative intent.
61984047|NCT06319755||Matched controls|Participants matched to each post-surgical participant by age, sex, body mass index (BMI), smoking status.
62362758|NCT00628225|EXPERIMENTAL|3|Multifacetted smoking cessation intervention (aimed at professional (training and education) and at patients (counseling + nicotine replacement + bupropion-SR)
62362759|NCT00519610||I|Patients will have charts reviewed for relevant medical information before and after surgery to assess patient outcome after placement of H-graft shunt for the treatment of portal hypertension.
62362760|NCT05229419||acute pediatric poisoning cases|All cases of acute pediatric poisoning of both sexes, in age group less than or equals to 18 years old will presenting to Assiut University Hospital with acute poisoning whose their adverse effects occurring following administration of single dose of a substance or multiple doses exposure within 24 hours.
62362761|NCT03862495|EXPERIMENTAL|Chlamydia Screening and Treatment|At the time of recruitment and prior to delivery, this group will have immediate testing for C. trachomatis and N. gonorrhoeae. Physicians will notify C. trachomatis positive results to pregnant women and suggest them and their spouses to get treated according to the national standard treatment plan for Chlamydia (Azithromycin 1g, single oral administration). Patients will be followed up to confirm cure of C. trachomatis in one month. Partner notification and treatment will be suggested for pregnant women who test positive for Chlamydia.
62567122|NCT03458585||Group 2: patients attending for a 18F- FDG PET/CT scan.|Group 2: Patients will be approached and consented after they had their injection and scan for 18F- FDG PET/CT. Completion of questionnaire will take place immediately after patients have changed and wait to leave the department, while they wait for their scan to be checked .
62567123|NCT05560568||Adult patients with type 1 diabetes|Adult patients with type 1 diabetes treated with insulin pumps according to current recommendations with an indication to switch to a hybrid closed-loop pump
61984048|NCT06221514|OTHER|Core Group|"Each session will begin with a 5-10-minute core dynamic warm-up exercise.~The participants then will perform approximately 30 minutes of core exercises using therapy resistance bands. All players will rest for a few seconds between the exercises. The core exercises will include: bicycle crunches with the band placed around the feet, standing knee tucks with the band placed around the feet (without shoulder rotations and while applying posterior pelvic tilts), flutter kicks with the band placed above the ankles, leg raises with knees flexed and no resistance band, and posterior pelvic tilts from a supine position with hold.~Lastly, the training session will end with a 5-10-minute cool-down."
61984049|NCT06221514|OTHER|Shoulder Group|"Each session will begin with a 5-10-minute shoulder dynamic warm-up exercise.~The participants then will perform approximately 30 minutes of shoulder exercises using therapy resistance bands. All players will rest for a few seconds between the exercises. The shoulder exercises will include: internal and external rotations with the elbow flexed and band wrapped around an object of appropriate height, shoulder abduction to 90˚ with band placed under feet for fixation, shoulder flexion to 90˚ with band placed under feet for fixation, and seated rowing with band held in hands while being placed around the feet were all performed in a sitting position to avoid activation of core muscles.~Lastly, the training session will end with a 5-10-minute cool-down."
61984050|NCT06029634||virologic breakthrough|CHB patients withdraw NAs with virologic breakthrough
61984051|NCT06029634||virologic response|CHB patients withdraw NAs with virologic response
61984052|NCT06029634||healthy group|The healthy (non-HBV infected) group completed a standard HBsAg vaccination scheduled before entering the study
61984053|NCT05446402|EXPERIMENTAL|Acne Treatment|
61984054|NCT01502111||Airway management|Patients receiving advanced airway management in physician manned helicopter emergency medical services over a 12-month period.
61984055|NCT02604212|PLACEBO_COMPARATOR|Placebo Low Dose Comparator|Placebo (low dose comparator) once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
61984056|NCT02604212|PLACEBO_COMPARATOR|Placebo High Dose Comparator|Placebo (high dose comparator) once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
61984057|NCT02604212|EXPERIMENTAL|ARC-520 1.0 mg/kg|Low dose (1.0 mg/kg) ARC-520 once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
61984058|NCT02604212|EXPERIMENTAL|ARC-520 2.0 mg/kg|High dose (2.0 mg/kg) ARC-520 once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
61984059|NCT03684512|EXPERIMENTAL|Adolescent Only|Remote based physical activity intervention delivered to adolescents only. Adolescents will be asked to attend weekly group exercise sessions, individual support sessions, and monitor their daily physical activity.
61984060|NCT03684512|ACTIVE_COMPARATOR|Adolescent and Parent|Remote based physical activity intervention delivered to adolescents and their parent. Adolescents and a parent will be asked to attend weekly group exercise sessions, individual support sessions, and monitor their daily physical activity. Parents will have access to a Parent Facebook group.
61984061|NCT05618964|EXPERIMENTAL|Group A: Deep Neck Flexors & Extensors exercises|"Group A Patients will receive:~Deep neck flexor exercises (2 set of 10 repetitions) that includes:~* Contraction of deep neck flexor muscle in supine~* Craniocervical flexion in supine~Deep Neck Extensor exercises (2 set of 10 repetitions) that includes:~* Contraction of deep neck extensors in quadruped position~* Segmented extension movement with the head bent down onto their chest in a horizontal direction,"
61984062|NCT05618964|NO_INTERVENTION|Group B: Standardized Physical Therapy|"Standardized Physiotherapy treatment will be:~* Hot pack for 10 minutes,~* SNAG manual therapy at Cervical spine 6 repetitions for 60 seconds.~* Superficial neck muscles (upper trapezius, Levator scapulae, Pect.Major) stretching for 3 times with 30 seconds and~* Neck isometrics 10 times with 6 seconds hold. Both groups will come thrice per week for a total of 4 weeks. Pre and post treatment values of both groups will be analyzed"
61984063|NCT02988791|EXPERIMENTAL|Probiotic (Bifidobacterium)|Active, Bifidobacterium BB12
61984064|NCT02988791|PLACEBO_COMPARATOR|Placebo|Placebo
61984065|NCT05780333|OTHER|tap block|"Tap block is one of the frequently used field blocks for analgesia management of abdominal surgery.~At the end of surgery and general anesthesia, transversus abdominis fascial plane will be detected with using lineer usg probe. With in-plane tecnique after placement of the needle in the transversus abdominis fascial plane, and careful aspiration to exclude vascular puncture, a test dose of 1 mL will be injected to determine resistance to flow, and confirm needle tip placement within the fascial plane. After this, 20 ml local anaestetic mixture will be injected through the needle. The TAP block will be then performed on the opposite side using an identical technique."
61984066|NCT05780333|ACTIVE_COMPARATOR|esp block|"The effectiveness of esp block is also evaluated in abdominal surgery after spinal surgery, thoracic and cardiovascular surgery.~At the end of surgery and general anesthesia, in the lateral decubitus position, the linear probe will be placed approximately 3 cm lateral to the T10 spinous process, in the parasagittal plane. With the in-plane technique, when the block needle rests on the transverse process (approximately 3cm in depth), the erector spina plan will be confirmed with a 0.5-1 mL 0.9% NaCl test dose. 20 ml of local anesthetic mixture will be applied to the confirmed area. The procedure will be applied bilaterally."
61984067|NCT02464345|EXPERIMENTAL|HAPIFED|HAPIFED therapy
61984068|NCT02464345|ACTIVE_COMPARATOR|CBT-E|CBT-E therapy
61984069|NCT03787628|ACTIVE_COMPARATOR|Cannabidiol (CBD) 600 mg|Thirty participants who meet all eligibility criteria will be randomized to receive CBD (ATL5; Ananda Scientific) at a dose of 600 mg.
61984070|NCT03787628|PLACEBO_COMPARATOR|Placebo|Thirty participants who meet all eligibility criteria will be randomized to receive placebo.
61984071|NCT05757921|EXPERIMENTAL|Non-surgical mechanical treatment with Perisolv® (A)|The test group will receive the following treatment: In the deepened pockets to be treated, Perisolv is initially applied according to the manufacturers recommendation.Then subgingival debridement is performed. This is performed with piezoelectric ultrasound (EMS) while rinsing water and completed with subgingival manual instrumentation. In addition an aliquot of Perisolv was left after final debridement.
62567124|NCT05109533|NO_INTERVENTION|Group 1 - ARM WITH STANDARD TREATMENT|Standard specific treatment for vaginal infections following latest version of CDC guidelines
61984072|NCT05757921|ACTIVE_COMPARATOR|Non-surgical mechanical treatment without Perisolv® (B)|The control group will receive the following treatment: In the deepened pockets to be treated, subgingival debridement is performed. This is performed with piezoelectric ultrasound (EMS) while rinsing water and completed with subgingival manual instrumentation.
61984073|NCT01730157|EXPERIMENTAL|Treatment (yttrium Y 90 glass microspheres, ipilimumab)|Patients undergo radioembolization with yttrium Y 90 glass microspheres via hepatic arterial infusion on day 1. Beginning on day 29, patients also receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
61984074|NCT06067542|EXPERIMENTAL|Study group using chlorhexidine toothpaste after wisdom tooth extraction|22 patients, 17 females and 5 males, 44 bilateral, similarly positioned fully impacted impacted lower third molars were extracted. Bilateral impacted wisdom teeth of the patients were randomly selected. After the operation, the experimental group received Dentasave 0.2% chlorhexidine toothpaste containing chlorhexidine
61984075|NCT06067542|PLACEBO_COMPARATOR|Control group using chlorhexidine-free toothpaste after wisdom tooth extraction|Bilateral impacted wisdom teeth of the patients were randomly selected. After the operation, the control group was given toothpaste with the same ingredients as the study group but without chlorhexidine.
61984076|NCT01736150|EXPERIMENTAL|Sevelamer carbonate|Subjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (\>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site.
61984077|NCT01736150|PLACEBO_COMPARATOR|Placebo|Subjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (\>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site.
62362762|NCT03862495|EXPERIMENTAL|Control|This group will have testing after delivery (immediately following childbirth) or in the event of an adverse pregnancy outcome for C. trachomatis and N. gonorrhoeae. In the event of a positive test, patients will be informed of the positive test results the same way as the intervention group. Specific treatment options will be the same as the intervention group. Physicians will ask patients to return to Nanhai Hospital one month after treatment for test of cure. Partner notification and treatment will be suggested for pregnant women who test positive for Chlamydia.
61984078|NCT06365801||Healthy Volunteers group|There are 50 healthy volunteers in the group.
62362763|NCT01232192|NO_INTERVENTION|Antenatal model|
61984079|NCT06365801||IBS group|There are 50 patients in the IBS group.
61984080|NCT04702867||Periodontal bone loss group|The cases with level of alveolar crest more than 2 mm from the CEJ as measured using CBCT scan on mesial and distal sides of all premolar and molar teeth.
61984081|NCT04702867||Healthy group|The cases with level of alveolar crest equal to or less than 2 mm from the CEJ as measured using CBCT scan on mesial and distal sides of all premolar and molar teeth.
61984082|NCT01947920|EXPERIMENTAL|1: Tramadol HCl 200 mg daily or placebo|Participants will receive one capsule of Tramadol hydrochloride (HCl) every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
61984083|NCT01947920|EXPERIMENTAL|2: Tramadol HCl 400 mg daily or placebo|Participants will recieve two capsules of Tramadol HCl every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
61984084|NCT01947920|EXPERIMENTAL|3: Tramadol HCl 600 mg daily or placebo|Participants will receive three capsules of Tramadol HCl every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
61984085|NCT03023969|ACTIVE_COMPARATOR|group A|percutaneous ozone intradiscal injection group A receive 10 ml of ozone oxygen mixture 40 ug O3/ ml O2
61984086|NCT03023969|ACTIVE_COMPARATOR|group B|percutaneous ozone intradiscal injection group receive 10 ml of ozone oxygen mixture 30 ug O3/ ml O2.
61984087|NCT06308120|ACTIVE_COMPARATOR|ION™ Endoluminal System|ION™ Endoluminal System Providers will utilize the ION™ Endoluminal System to perform a diagnostic bronchoscopy procedure
61984088|NCT06308120|ACTIVE_COMPARATOR|superDimension Navigation System and Accessories|Providers will utilize the superDimension Navigation System and Accessories to perform a diagnostic bronchoscopy procedure.
61984089|NCT04157608|ACTIVE_COMPARATOR|Habitual Prosthesis|Participant's existing baseline prescribed prosthesis
61984090|NCT04157608|EXPERIMENTAL|e-MIP|Experimental ankle-foot prosthesis
61984091|NCT00087711|EXPERIMENTAL|A|
61984092|NCT00087711|ACTIVE_COMPARATOR|B|
61984093|NCT06427811|EXPERIMENTAL|Asciminib 80 mg|80 mg once daily at approximately the same time each day or 40 mg twice daily per Investigator's discretion at approximately 12-hour intervals
61984094|NCT06427811|EXPERIMENTAL|Asciminib 200 mg|200 mg twice daily at approximately 12-hour intervals
61984095|NCT00994292|EXPERIMENTAL|1. YM150 Dose V, twice daily|
61984096|NCT00994292|EXPERIMENTAL|2. YM150 Dose W, once daily|
61984097|NCT00994292|EXPERIMENTAL|3. YM150 Dose X, twice daily|
61984098|NCT00994292|EXPERIMENTAL|4. YM150 Dose Y, once daily|
62362764|NCT01232192|EXPERIMENTAL|Antenatal Model|
62362765|NCT02155894|EXPERIMENTAL|Disease control, Telemedicine, doctor|Using an online platform for self assessment and with the Flare instrument as decision support, the patients are contacted over the telephone by a doctor at week 13, 26, 39.
62362766|NCT02155894|EXPERIMENTAL|Disease control, Telemedicine, nurse|Using an online platform for self assessment and with the Flare instrument as decision support, the patients are contacted over the telephone by a nurse at week 13, 26, 39.
61984099|NCT00994292|EXPERIMENTAL|5. YM150 Dose Y, twice daily|
61984100|NCT00994292|EXPERIMENTAL|6. YM150 Dose Z, once daily|
61984101|NCT00994292|PLACEBO_COMPARATOR|7. Placebo|
61984102|NCT00430560|ACTIVE_COMPARATOR|1|work therapy
61984103|NCT00430560|EXPERIMENTAL|2|work therapy plus cognitive remediation
61984104|NCT00832585|EXPERIMENTAL|Alefacept|"Amevive® has been shown to be a safe and effective agent in the treatment of psoriasis but may prove useful in treating atopic dermatitis at a dose of 15mg IM every week for 12 weeks. Unlike other biologics for the treatment of skin diseases, the use of alefacept is not associated with increased infection, congestive heart failure, demyelinating disorders or lupus- like syndromes."
61984105|NCT04166435|EXPERIMENTAL|Temozolomide + Olaparib|Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.
61984106|NCT00774228|EXPERIMENTAL|I-ZIP Ocular Bandage|I-Zip bandage application
61984107|NCT00774228|ACTIVE_COMPARATOR|Oasis 24 hour Soft Shield Collagen Corneal Shield|Oasis shield application
61984108|NCT01092182|EXPERIMENTAL|Group A - Burkitt lymphoma Low Risk Arm|Burkitt lymphoma Low Risk Arm Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
61984109|NCT01092182|EXPERIMENTAL|Group B - Burkitt lymphoma High Risk Arm|Burkitt lymphoma High Risk Arm Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
61984110|NCT01092182|EXPERIMENTAL|Group C - DLBCL high risk arm|Diffuse large B-cell lymphoma (DLBCL) high risk arm Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
61984111|NCT02071888|EXPERIMENTAL|CB-839|CB-839 is administered as oral capsules three times daily (TID) or twice daily with food (BIDf) in 21-day cycles until disease progression or unacceptable toxicity
61984112|NCT02071888|EXPERIMENTAL|CB-839 and low dose dexamethasone|CB-839 is administered as oral capsules twice daily with food (BIDf) in 28 day cycles in combination with dexamethasone until disease progression or unacceptable toxicity
61984113|NCT02071888|EXPERIMENTAL|CB-839, pomalidomide, and low dose dexamethasone|CB-839 is administered as oral capsules twice daily with food (BIDf) in 28 day cycles in combination with pomalidomide and dexamethasone until disease progression or unacceptable toxicity
61984114|NCT00450333|ACTIVE_COMPARATOR|1|Erythropoietin(EPO)-naive BIW
61984115|NCT00450333|ACTIVE_COMPARATOR|2|EPO-naive QW
61984116|NCT00450333|ACTIVE_COMPARATOR|3|EPO QW
61984117|NCT00450333|ACTIVE_COMPARATOR|4|EPO Q2W
61984118|NCT01760512|EXPERIMENTAL|Robot-assisted surgery|Robot-assisted (da Vinci surgical system) gastric bypass
61984119|NCT01760512|ACTIVE_COMPARATOR|Conventional laparoscopy|Laparoscopic gastric bypass
61984120|NCT04057014|ACTIVE_COMPARATOR|Extraction Only|Immediate extraction of infected tooth without antibiotic prescription.
62362767|NCT02155894|NO_INTERVENTION|Usual care|Usual care: control of disease activity with consultations in the outpatient clinic.
61984121|NCT04057014|EXPERIMENTAL|Average Dose Antibiotic|Average dose antibiotic therapy(25 mg/kg/day in divided doses every 12 hours (maximum 875 mg/dose)) for 10 days and receive tooth extraction on day 10 (25 patients). (\*given the average weight of a 12 year old is 45 kilos, we do not expect that we will reach the maximum dose in this group)
61984122|NCT04057014|EXPERIMENTAL|High Dose Antibiotic|High dose antibiotic therapy (45 mg/kg/day in divided doses every 12 hours (maximum 875 mg/dose)) for 5 days and receive tooth extraction on day 10 (25 patients)
61984123|NCT04262843|EXPERIMENTAL|Treatment (fludarabine, TMLI, HCT, cyclophosphamide)|"CONDITIONING: Patients receive fludarabine IV QD on days -7 to -5, and undergo TMLI BID on days -4 to 0 in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo hematopoietic cell transplantation on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV QD on days 3-4 in the absence of disease progression or unacceptable toxicity. Beginning on day 5, patients also receive granulocyte colony stimulating factor and tacrolimus/mycophenolate mofetil per institutional standard."
61984124|NCT03780868|ACTIVE_COMPARATOR|external DCR|"A curvilinear incision of 10-15 mm length was made along the anterior lacrimal crest .~The smaller end of the blunt dissector was used to fracture Lamina papyracea, the parchment like bone of the posterior half of the lacrimal fossa. the nasal mucosa was stripped from lacrimal bone with the help of Traquair's periosteal elevator, An osteotomy of approximately 12.5 x10mm was created with successive punching of bone by Cittelli's punch. Lacrimal sac and nasal mucosa were opened in a 'H' fashion with the no.11 Bard-Parker blade and Bowman's probe was in place, to form a large anterior and smaller posterior flap."
61984125|NCT03780868|ACTIVE_COMPARATOR|silicone intubation with MMC|"Bowman's probe was gently inserted into the inferior canalicular system, until a hard stop was felt in the lacrimal sac, after which it was rotated into the NLD to reach below the inferior concha. The probe was then withdrawn via the inferior punctum and the process was repeated for the upper canaliculus.~After irrigation with normal saline to confirm duct patency, irrigation was performed by introducing 1 ml of MMC (0.5 mg/ml) into the duct with a syringe, the ocular surface then irrigatedby normal saline. Intubation was done by a silicone tube connected by each of its end to a malleable steel guide. A grooved director was placed under the inferior turbinate to guide the probe out of the nose, after which the steel guide was cut from the silicone tube"
61984126|NCT00888095|EXPERIMENTAL|1|caudal Zona incerta (cZI)
61984127|NCT00888095|EXPERIMENTAL|2|Nucleus subthalamicus (STN)
61984128|NCT04213365|OTHER|cognitive stimulation and adapted physical activity|12 weeks of cognitive stimulation sessions coupled with APA (Adapted Physical Activity) sessions.
61984129|NCT05029986|EXPERIMENTAL|All participants|This is a single-arm trial. All participants will receive (1) a control condition (socialization phase, 2 weeks) and (2) an intervention condition (speech breathing intervention, 4 weeks). Group sessions will take place once a week, and participants will be instructed to practice their exercises every day at home during the study duration.
61984130|NCT06431854|EXPERIMENTAL|Patient group|This group comprises 60 patients aged 12 to 17 diagnosed with an eating disorder. They must have shown poor response to treatment, defined as having one of the two conditions: 1) undergoing over a year of treatment, including partial and total hospitalization, without symptom stabilization (needing high-intensive treatment units i.e. not being able to follow individual treatment in external consultations); 2) having more than three admissions without symptom stabilization in less than one year. They will be recruited from child/adolescent ED units in Catalonia. Exclusions will be acute ED pathology requiring urgent pediatric attention or admission to an acute psychiatric ward.
61984131|NCT02872493||RYGB|Roux-en-Y Gastric Bypass - these are patients that undergo a Roux-en-Y gastric bypass operation for their bariatric operation.
61984132|NCT02872493||VSG|Vertical Sleeve Gastrectomy - these are patients that undergo a vertical sleeve gastrectomy operation for their bariatric operation.
61984133|NCT03688477|EXPERIMENTAL|iovera°|Patients will receive iovera° prior to stand of care ACL
61984134|NCT03688477|NO_INTERVENTION|Standard of Care|Patients will receive standard of care ACL procedure without iovera° treatment.
62362768|NCT00832481|ACTIVE_COMPARATOR|Repaglinide,tablet|
61984135|NCT00985842|OTHER|Arm 1|Comparison of five different clinically used suspension and socket systems
61984136|NCT02456142|EXPERIMENTAL|caudal bupivacaine|1ml/kg of 0.125% caudal bupivacaine given over 2 minutes will be given at the end of surgery
61984137|NCT02456142|ACTIVE_COMPARATOR|intravenous morphine|0.05mg/kg intravenous morphine given over 5 minutes
62362769|NCT00832481|ACTIVE_COMPARATOR|Metformin, tablet|
61984138|NCT02110342|EXPERIMENTAL|Treatment|
61984139|NCT05678829|EXPERIMENTAL|Virtual Reality|Using a virtual reality application based on individuals in Virtual Reality creatures, it will be explained for an average of 20 minutes in a time period where they are appropriate, through extensive trainings according to what is given.
61984140|NCT05678829|EXPERIMENTAL|Face to face|By using the training room of the family health center specified for the individuals in the Face to face group, training content covering the subjects of reproductive and health and family planning methods will be prepared, and the days when women are suitable will be determined, and each training will be given for 40 minutes with face-to-face classical training method. Educational subjects will be continued in parallel with Virtual Reality group by using Ministry of Health hand brochures and training materials for Face to face group.
61984141|NCT05678829|NO_INTERVENTION|Control|No intervention will be made to the control group during the training.
62362770|NCT02232724|EXPERIMENTAL|Dual time point FDG PET/CT|Choline PET/CT and dual time point FDG PET/CT
62362771|NCT04227210|EXPERIMENTAL|RSV Vaccine: Dosage Group #1|Participants in this group will receive a single dose of the RSV vaccine at dosage #1
61984142|NCT02942446|EXPERIMENTAL|Headgear|Investigative Headgear with CPAP mask
61984143|NCT03959293|EXPERIMENTAL|FOLFIRI plus durvalumab|"* Durvalumab: 1500 mg by 1-hour IV infusion. Every 4 weeks until progression~* FOLFIRI (1 course every 2 weeks, until progression):~* Irinotecan: 180 mg/m² by 2-hour IV infusion,~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~* 5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~* Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
62362772|NCT04227210|EXPERIMENTAL|RSV Vaccine: Dosage Group #2|Participants in this group will receive a single dose of the RSV vaccine at dosage #2
61984144|NCT03959293|EXPERIMENTAL|FOLFIRI plus durvalumab plus tremelimumab|"* Durvalumab: 1500 mg by 1-hour IV infusion - Every 4 weeks.~* Tremelimumab: 75 mg by 1-hour IV infusion - Every 4 weeks (for only 4 cycles).~* FOLFIRI (1 course every 2 weeks, until progression):~* Irinotecan: 180 mg/m² by 2-hour IV infusion~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion~* 5-FU bolus: 400 mg/m² by 10-minutes IV bolus~* Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
61984145|NCT02278107|EXPERIMENTAL|Tidal Assist Ventilator System|Lightweight, portable, positive pressure ventilator system with proprietary nasal interface. Ventilator is powered by compressed oxygen delivered by cylinder, concentrator, or wall source.
61984146|NCT02278107|ACTIVE_COMPARATOR|Nasal Cannula Oxygen|Nasal Cannula Oxygen Standard nasal cannula oxygen at 2-5 liters per minute (LPM) based on patient requirement. Oxygen sources includes cylinder, concentrator, or wall source.
61984147|NCT03741660|EXPERIMENTAL|Konjac-mannan|Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet
61984148|NCT03741660|PLACEBO_COMPARATOR|Placebo|wheat bran fiber biscuits with NCEP Step II metabolically controlled diet
61984149|NCT04905212|EXPERIMENTAL|Telitacicept 160mg|Telitacicept 160mg subcutaneous injection once weekly, and a total of 24 doses
61984150|NCT04905212|EXPERIMENTAL|Telitacicept 240mg|Telitacicept 240mg subcutaneous injection once weekly, and a total of 24 doses
61984151|NCT04905212|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection once weekly, and a total of 24 doses
61984152|NCT04156776|EXPERIMENTAL|Group A (MET)|Muscle Energy Technique Conventional Treatment
61984153|NCT04156776|EXPERIMENTAL|Group B (AIS)|Active Isolated Stretching Conventional Treatment
61984154|NCT01089959|OTHER|Esomeprazole|Effect of PPI esomeprazole on acid reflux \& related arousals during sleep in patients with GERD.
61984155|NCT00228917|EXPERIMENTAL|ACAC_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study ( NCT00317187) are boosted in the current study with one dose of the same vaccines at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age
62362773|NCT03714061|EXPERIMENTAL|Pain Neuroscience Education (PNE)|The PNE will be administered following Explaining Pain concepts (Butler and Moseley, 2013), initially contextualizing the importance of the program. The program will be administered as interactive workshops lasting 50 minutes. In addition, the participants were oriented to perform at home a group o motor control exercises during three weeks, twice a week.
62362774|NCT03714061|ACTIVE_COMPARATOR|Self-Management Education (SME)|The SME education will be administered as an interactive workshop lasting 50 minutes. The program is based on the Back-book material (Roland et al, 2011), focusing on concepts targeting change of behavior and beliefs. In addition, the participants were oriented to perform at home a group o motor control exercises during three weeks, twice a week.
62362775|NCT01776944||Obese children|
62362776|NCT00403351||ARM-CAD 1|Cross-sectional analysis using coronary angiogram results
62362777|NCT00403351||ARM-CAD 2|Prospective cohort for incident cardiovascular events and mortality
62362778|NCT02882022|EXPERIMENTAL|CPAP|All participants will be included in this arm, and CPAP will be administered using a full face mask at incrementally increasing pressures. This will occur during a single session lasting no more than one hour.
61984156|NCT00228917|EXPERIMENTAL|ACHibPS_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
61984157|NCT00228917|EXPERIMENTAL|HibACPS_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of Trianrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
61984158|NCT00228917|EXPERIMENTAL|HibHibPS_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of the same vaccine at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
61984159|NCT00228917|EXPERIMENTAL|ACAC_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of the same vaccines at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age
61984160|NCT00228917|EXPERIMENTAL|ACHibPS_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
62362779|NCT03257618|EXPERIMENTAL|Temozolomide|"Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.~Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression."
61984161|NCT00228917|EXPERIMENTAL|HibACPS_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of Trianrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
61984162|NCT00228917|EXPERIMENTAL|HibHibPS_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of the same vaccine at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
61984163|NCT04150276|ACTIVE_COMPARATOR|ZEEP during awakening|ZEEP will be used during emergence preoxygenation and awakening.
61984164|NCT04150276|ACTIVE_COMPARATOR|PEEP during awakening|PEEP is maintained throughout emergence preoxygenation and awakening.
61984165|NCT01227772|EXPERIMENTAL|Weekly Cohort|The gastric cancer vaccine (OTSGC-A24) will be administered at a dose of 1 mg once a week
61984166|NCT01227772|EXPERIMENTAL|2-weekly cohort|The gastric cancer vaccine (OTSGC-A24) will be administered at the dose of 1 mg every 2 weeks.
61984167|NCT01227772|EXPERIMENTAL|3-weekly cohort|The gastric cancer vaccine (OTSGC-A24)will be administered at 1 mg very 3 weeks
61984168|NCT03762148|EXPERIMENTAL|ferrous fumarate|labelled iron as ferrous fumarate
61984169|NCT03762148|EXPERIMENTAL|ferrous sulphate|labelled iron as ferrous sulphate
62362780|NCT00499460|OTHER|Arm I|Two 30-day treatment periods separated by a washout of at least 4 weeks. In Period 1, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29. In Period 2, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
61984170|NCT03762148|EXPERIMENTAL|ferric pyrophosphate|labelled iron as ferric pyrophosphate
61984171|NCT03762148|EXPERIMENTAL|ferrous fumarate + 3.5 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 3.5 g GOS
61984172|NCT03762148|EXPERIMENTAL|ferrous fumarate + 7 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 7 g GOS
61984173|NCT03762148|EXPERIMENTAL|ferrous sulphate + 15 g GOS|labelled iron as ferrous sulphate + prebiotics in the form of 15 g GOS
61984174|NCT03762148|EXPERIMENTAL|ferrous fumarate + Vitamin C|labelled iron as ferrous fumarate + Vitamin C
61984175|NCT03762148|EXPERIMENTAL|ferric pyrophosphate + 15 g GOS|labelled iron as ferric pyrophosphate + prebiotics in the form of 15 g GOS
61984176|NCT03762148|EXPERIMENTAL|ferrous fumarate + 7 g GOS + Vitamin C|labelled iron as ferrous fumarate + prebiotics in the form of 7 g GOS + Vitamin C
61984177|NCT05190731|SHAM_COMPARATOR|Contact touch at occipital region, but no actual cranial manipulation|Each subject was treated with Sham by CSPOMM and NMM board-certified osteopathic physicians. The physician's finger pads of both hands were placed underneath the supine subject's head in contact on the occipital squama medial to the lambdoidal and occipitomastoid sutures. The subject's head rested passively on the finger pads for 3 minutes. No cranial manipulative forces were applied.
61984178|NCT05190731|ACTIVE_COMPARATOR|Osteopathic cranial manipulative medicine|Each subject was treated with CV4 technique by CSPOMM and NMM board-certified osteopathic physicians. All CV4 treatments were performed by one individual according to standardized protocol. The physician's hands were placed underneath the occiput with the thenar eminences in contact on the occipital squama medial to the lambdoidal and occipitomastoid sutures. Inherent cranial rhythmic motion was identified and thenar eminences followed occipital motion anteriorly during the extension phase until a still point was attained. This position was held until the still point released (usually about 3 minutes) and normal cranial motion ensued.
61984179|NCT04469114|EXPERIMENTAL|Tofacitinib|Tofacitinib 10mg twice daily for 14 days or until hospital discharge
61984180|NCT04469114|PLACEBO_COMPARATOR|Placebo|Placebo twice daily for 14 days or until hospital discharge
61984181|NCT06478537|EXPERIMENTAL|hetrombopag treatment|
61984182|NCT06280573|EXPERIMENTAL|intervention group|
61984183|NCT06280573|NO_INTERVENTION|control group|
61984184|NCT03327311||Bellafill 1 week post-injection|n=2. Histopathology conducted 1 week post-injection
61984185|NCT03327311||Bellafill 1 month post-injection|n=2. Histopathology conducted 1 month post-injection
61984186|NCT03327311||Bellafill 2 months post-injection|n=2. Histopathology conducted 2 months post-injection
61984187|NCT03327311||Bellafill 3 months post-injection|n=2. Histopathology conducted 3 months post-injection
61984188|NCT03327311||Bellafill 6 months post-injection|n=2. Histopathology conducted 6 months post-injection
61984189|NCT03540147|EXPERIMENTAL|Exercise with Hokanson cuffs|Participants will walk on the treadmill with Hokanson cuffs inflated.
61984190|NCT03540147|EXPERIMENTAL|Exercise with BStrong Bands|Participants will walk on the treadmill with BStrong bands inflated.
61984191|NCT03540147|SHAM_COMPARATOR|Exercise without inflated bands/cuffs|Participants will walk on the treadmill with non-inflated BStrong bands.
61984192|NCT03540147|EXPERIMENTAL|Yoga poses with BStrong bands inflated|Participants will perform 15-20 yoga poses with BStrong bands inflated.
61984193|NCT03540147|SHAM_COMPARATOR|Yoga poses with BStrong bands uninflated|Participants will perform 15-20 yoga poses with uninflated BStrong bands.
61984194|NCT05212714|EXPERIMENTAL|taVNS Treatment|n = 20
61984195|NCT05212714|SHAM_COMPARATOR|Sham Comparator|n = 10
61984196|NCT05322642|EXPERIMENTAL|Experimental: (UP-A)|The UP-A (Ehrenreich et al., 2008) is an emotion-focused, transdiagnostic CBT for adolescents A 10-session youth-focused programmed by adapting the core modules of UP-A, for indicated prevention and school settings.
61984197|NCT05322642|ACTIVE_COMPARATOR|Active control condition|"The active control condition will be based on the 10 session of Progressive Relaxation Training programme of Bernstein and Borkovec.~It follows a similar structure as the UP-A. A group format will be used."
61984198|NCT00629499|EXPERIMENTAL|Intervention|100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle) in combination with 600 mg/m2 of IV cyclophosphamide once every 3 weeks for 4 cycles (i.e., a total treatment period of 12 weeks \[84 days\]). Patients with fluorescence in situ hybridization (FISH) HER2+ or IHC3+ breast cancer will also receive treatment with trastuzumab in addition to the nab paclitaxel / cyclophosphamide combination therapy. Maintenance therapy with trastuzumab will continue (for the HER2+ patients who are receiving trastuzumab) after the 12-week treatment period with combination nab paclitaxel/cyclophosphamide/trastuzumab. The total treatment time for trastuzumab will be 52 weeks rather than only 12 weeks.
61984199|NCT04395209|EXPERIMENTAL|stroke individuals|
61984200|NCT04395209|ACTIVE_COMPARATOR|healthy individuals|
61984201|NCT03384979|PLACEBO_COMPARATOR|TBW protocol|Patients will receive a contrast agent dose based on their TBW as a standard clinic protocol.
61984202|NCT03384979|EXPERIMENTAL|LBW protocol|Patients will receive a contrast agent dose based on their calculated LBW.
61984203|NCT05085275|EXPERIMENTAL|Ferric citrate|Supplied as tablets for oral administration containing 1 gram ferric citrate (210 milligrams of ferric iron). Administered orally with meals or snacks.
61984204|NCT05085275|PLACEBO_COMPARATOR|Placebo|Tablets, matching in color and size to ferric citrate.
61984205|NCT02556333|EXPERIMENTAL|FTC/TAF|Emtricitabine 200mg/tenofovir alafenamide 25mg (FTC/TAF) tablet to be given orally once daily to be added to a failing regimen for 10 days. If HIV RNA decline by \>= 0.5 log copies/mL, patient will continue on FTC/TAF with a new antiretroviral regimen for 48 weeks. If \< 0.5 log copies/mL decline, patient will be taken off FTC/TAF.
61984206|NCT02389998|EXPERIMENTAL|Placebo|Arm 1: Subjects take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary for a period of three weeks. Subjects will also have access to hyoscyamine as a rescue medication.
61984207|NCT02389998|OTHER|No Treatment|Arm 2: Subjects receive no treatment but have access to hyoscyamine as a rescue medication.
61984208|NCT04023448|EXPERIMENTAL|coloplasty(CP)|After purse-string suture and ligation of the head of the stapler at the colonic end, 5cm away from the colonic end, 5cm longitudinal incision was made to the proximal end of the teniae coli in the anterior wall of the colon, transverse suture was performed, and the plasmomuscular layer was embedded, then end to end colon-rectum (or anal canal) anastomosis was performed
61984209|NCT04023448|NO_INTERVENTION|straight colorectal anastomosis (SCA)|End to end colon-rectum (or anal canal) anastomosis was performed routinely
61984210|NCT02155647|EXPERIMENTAL|Part A: Avelumab|Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
61984211|NCT02155647|EXPERIMENTAL|Part B: Avelumab|Participants received Avelumab as first-line treatment for metastatic or distally recurrent MCC at a dose of 10 mg/kg as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
61984212|NCT03011307|EXPERIMENTAL|Oxytocin|Oxytocin 100 micrograms administered intrathecally
61984213|NCT03011307|PLACEBO_COMPARATOR|Placebos|Placebo injection administered intrathecally
61984214|NCT04862845|ACTIVE_COMPARATOR|Patients in group I (PD group)|
61984215|NCT04862845|ACTIVE_COMPARATOR|patients in group II (P group)|
61984216|NCT04862845|SHAM_COMPARATOR|patients in group III (C groups)|
61984217|NCT05670392|ACTIVE_COMPARATOR|Arm 1: laser and HITS treatment|Laser and magnetic chair Treatment
61984218|NCT05670392|OTHER|Arm 2: laser (without HITS treatment)|Laser treatment
61984219|NCT01739582|EXPERIMENTAL|Androxal|Androxal (enclomiphene citrate) 12.5 mg, once daily, oral capsule. Subjects will be up-titrated to 25 mg if testosterone levels remain below 450 ng/dL at visit 2.
61984220|NCT01108133|EXPERIMENTAL|Hydrocortisone, fMRI, Intrusions|10 mg Hydrocortisone are administered one hour before the fMRI experiment. We use the script-driven imagery paradigm to induce intrusive memories during fMRI scanning.
61984221|NCT01108133|EXPERIMENTAL|Dexamethasone, fMRI, Intrusions|2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment. (DEX-Test). We use the script-driven imaging paradigm to induce intrusive memories during fMRI-scanning.
61984222|NCT01108133|EXPERIMENTAL|Placebo, fMRI, Intrusions|Placebo is administered one hour before the fMRI experiment. We use the script-driven imaging paradigm to induce intrusive memories during fMRI-scanning in patients with posttraumatic stress disorder.
61984223|NCT02225756|EXPERIMENTAL|Cyclosporine A dose 1|
61984224|NCT02225756|EXPERIMENTAL|Cyclosporine A dose 2|
61984225|NCT02225756|PLACEBO_COMPARATOR|Placebo|
62362781|NCT00499460|OTHER|Arm II|Two 30-day treatment periods separated by a washout of at least 4 weeks. In Period 1, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29. In Period 2, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
62362782|NCT04677049|EXPERIMENTAL|Niacin|"Niacin controlled release technology (CRT):~Niacin CRT™ is to be started 7 days before concurrent Radiation Therapy (RT)- Temozolomide (TMZ) treatment.~Chemo/Radiation Therapy:~For all patients, regardless of the phase of the study, concurrent RT and TMZ for 6 weeks followed by 6-12 cycles of monthly TMZ will be given.~Concurrent Temozolomide:~TMZ will be administered from the first to the last day of RT at 75 mg/m2 orally (PO) for a maximum of 49 days.~Monthly Temozolomide:~Cycles of chemotherapy Day 1 to Day 5 every 28 days will start 28 days (+/- 2 days) after the end of RT-TMZ. First cycle of TMZ is administered at 150 mg/m2 Day 1-Day 5 by mouth (PO) and increased to 200 mg/m2 Day 1-Day 5 PO from cycle 2 onwards if well tolerated. While 6 cycles are standard of care, the Neuro-Oncologist may continue up to 12 cycles if clinically appropriate."
62362783|NCT00300534|NO_INTERVENTION|Abbott Laboratories Determine test for syphilis|Abbott Laboratories Determine rapid test for syphilis
61984226|NCT03900000|OTHER|Short_Physiotherapy|one period of physiotherapy (8 weeks)
61984227|NCT03900000|OTHER|Long_Physiotherapy|two periods of physiotherapy (à 8 weeks)
61984228|NCT06243887|OTHER|Conventional group|patients of minimally invasive esophagectomy with standard of care approaches
61984229|NCT06243887|OTHER|ERAS group|patients of minimally invasive esophagectomy with enhanced recovery after surgery protocol
61984230|NCT03253887|EXPERIMENTAL|Ethanol-lock therapy (ELT) Group|This group received daily alcohol 70% (ethanol-lock) with intraluminal alcoholization of both lumens of the central venous catheters
61984231|NCT03253887|NO_INTERVENTION|Control Group|This group did not receive the ethanol-lock, being only followed daily and treated according to the standard protocol in operation at this healthcare unit.
61984232|NCT03038815|EXPERIMENTAL|Controll-VACOped-Ortho Tri|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed. For control, the participants are wearing Sport shoes.This group had the VACOped as the first intervention.
61984233|NCT03038815|EXPERIMENTAL|Controll-Ortho Tri-VACOped|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed. For control, the participants are wearing Sport shoes.This group had the Ortho Tri first intervention
61984234|NCT00961844|EXPERIMENTAL|DC vaccine + Temozolomide|Dendritic cell loaded with h-TERT mRNA, survivin mRNA and autologous tumor cell mRNA, lymphodepletion treatment and T cell expansion and reinfusion.
61984235|NCT02123355|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
61984236|NCT02123355|SHAM_COMPARATOR|Normal saline|Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
61984237|NCT00824044|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT)|CBT is a manualized therapeutic treatment for depression based on principles of cognitive restructuring and behavioral changes.
61984238|NCT00824044|ACTIVE_COMPARATOR|Escitalopram|Escitalopram or Lexapro is a Selective Serotonin Reuptake Inhibitor (SSRI) used to treat depression
61984239|NCT03854656|NO_INTERVENTION|Control|Control group for 13 weeks (n=50). Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.
61984240|NCT03854656|EXPERIMENTAL|Time-restricted eating|Time-restricted eating for 13 weeks (n=50). In addition to the intervention, participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.
61984241|NCT06209229|EXPERIMENTAL|natirium nucleonate|"* Calcitriol- 5000 units in the morning before meals every other day 21 days and the next 3 weeks after the end of therapy.~* Magnesium (in the form of lactate dihydrate) 470 mg + pyridoxine (in the form of hydrochloride) 5 mg - take orally 3 tablets per meter square of body surface area, in the evening 2 hours before bedtime, 21 days and the next 3 weeks after the end of therapy.~* Quercetin from onion juice - take orally 1000 mg in the morning before meals, 21 days, as well as the next 3 weeks after the end of therapy.~* sodium oligodinucleatide orally at the rate of 2 tablets under the tongue per meter square of body surface, in the morning 15 minutes before meals every other day, a total of 5 times (1, 3, 5, 7 , 9 day from the beginning of therapy), then after 21 days to repeat the course for 3 months.~* Spray natirium nucleonate 4 doses in the morning on the hyoid, suck, do not swallow for 3-5 minutes, once every 4 days for 21 days."
61984242|NCT02220933|EXPERIMENTAL|MD1003|MD1003 100mg capsules, 1 capsule tid for 24 months
61984243|NCT02220933|PLACEBO_COMPARATOR|Placebo|Placebo capsule, 1 capsule tid for 12 months, then switch to MD1003 100mg capsule, 1 capsule tid for 12 months
61984244|NCT04836728|EXPERIMENTAL|arm 1|IBI308 intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d2 or Albumin paclitaxel intravenous infusion 260mg/m2 d2; Carboplatin intravenous infusion AUC5 d2; CIK cells, 1x10\^10 (10 billion ), intravenous infusion,d14; Q3W.
61984245|NCT04836728|ACTIVE_COMPARATOR|arm 2|IBI308 intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d2 or Albumin paclitaxel intravenous infusion 260mg/m2 d2; Carboplatin intravenous infusion AUC5 d2;
61984246|NCT06430138|EXPERIMENTAL|Healthy participants|Participant will be given Orange Juice 300ml to drink
61984247|NCT06430138|ACTIVE_COMPARATOR|Ileostomy participants|Participant will be given orange Juice 300ml to drink
61984248|NCT05872711|EXPERIMENTAL|Low carbohydrate diet|The LCD will provide 50-80g of carbohydrate per day with no caloric restriction. The planned macronutrient compositions (percentages of the total calories) of the diet were: 15-20% carbohydrate (\<80 g/day), 33% protein and 58% total fat.
61984249|NCT05872711|ACTIVE_COMPARATOR|Mediterranean diet|The MED group was prescribed a moderate-fat MED, rich in vegetables and low in red meat, with poultry and fish preferred to beef and lamb. The primary sources of added fat were 30 to 45 g of olive oil and a handful of nuts (five to seven nuts \<20g) per day. The planned macronutrient compositions of the diet were 40-50% carbohydrate, 25% protein and 35% total fat. The diet is based on the recommendations of Willett and Skerrett
61984250|NCT05227794|EXPERIMENTAL|Compassion-Based Intervention|Participants in this condition are assigned to an empirically supported 8-week online compassion-based intervention protocol. The intervention includes a weekly 2-hour educational session and a recommendation of 15-30-mins of daily meditation, and real-world assignments to practice compassion.
61984251|NCT05227794|EXPERIMENTAL|Mindfulness-Based Intervention|Participants in this condition are assigned to an empirically supported 8-week online mindfulness-based intervention protocol. The intervention includes a weekly 2-hour educational session, a recommendation of 15-30 minutes of daily meditation, and an optional 6-hour one-day retreat.
61984252|NCT05227794|NO_INTERVENTION|Waitlist Control (WL)|The WL control group will complete all study assessments on the same schedule as the intervention arms. At the time of the final follow-up assessment, participants will be randomly assigned to one of the interventions (CCT or MBSR) with the same instructors.
61984253|NCT01761838|EXPERIMENTAL|SMT for low back pain patients|To investigate the effects of high velocity, low amplitude lumbopelvic spinal manipulative therapy on spinal stiffness and back muscle activity.
61984254|NCT01761838|OTHER|Asymptomatic arm|To investigate the sequential changes in spinal stiffness and back muscle activity of asymptomatic participants over time without any intervention. Participants of this arm can volunteer for an additional experimental pain protocol after their third visit (at 1 week) to investigate the effects of experimental pain on the changes of spinal stiffness and back muscle activity using a randomized crossover design (injecting 5% hypertonic saline or 0.9% isotonic saline to the interspinous ligaments at L3 to L5 levels in random order in two additional visits).
61984255|NCT01761838|OTHER|Low back pain participants without SMT|To investigate the temporal changes in lumbar disc diffusion within a 1-hour period without SMT
61984256|NCT05612633|OTHER|Oral zelavespib 100 mg|Oral zelavespib 100 mg will be administered once daily
61984257|NCT01447810|EXPERIMENTAL|Treatment|
61984258|NCT03043989|ACTIVE_COMPARATOR|Docetaxel and clarithromycin combination|"Docetaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2."
61984259|NCT03043989|ACTIVE_COMPARATOR|Cabazitaxel and clarithromycin combination|"Cabazitaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2."
61984260|NCT04503759||Foot and Ankle Surgery using NanoBone|All patients in the study will be drawn from the individual surgeons' practice. Patients will be among those already scheduled for foot and ankle surgery after having failed conservative treatment, or will have had foot and ankle surgery using NanoBone products but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient. The choice of a NanoBone product, as well as the surgery, is or was independent of this research project. Only patients who have had NanoBone implanted and consent to participate and meet the inclusion-exclusion criteria will be included in the registry.
62362784|NCT01375738|ACTIVE_COMPARATOR|Gastroduodenostomy|Arm 1: undergo gastroduodenostomy after distal gastrectomy for gastric cancer
62362785|NCT01375738|EXPERIMENTAL|Roux-en Y gastrojejunostomy|Arm 2: undergo Roux-en Y gastrojejunostomy after distal gastrectomy for gastric cancer
61984261|NCT00531024|EXPERIMENTAL|1|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
61984262|NCT00531024|PLACEBO_COMPARATOR|2|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
61984263|NCT06472908|EXPERIMENTAL|Colchicine 0.5 mg|Colchicine 0.5 mg, one pill a day, oral intake
61984264|NCT06472908|EXPERIMENTAL|Colchicine 0.375 mg|Colchicine 0.375 mg, one pill a day, oral intake
61984265|NCT06472908|PLACEBO_COMPARATOR|Placebo|Placebo, one pill a day, oral intake
61984266|NCT04309643|EXPERIMENTAL|CTP-543|In Period 1, participants will receive a single oral dose of the combination oral contraceptive (OC) on Day 1. There will be a washout period of 7 days between dosing in Period 1 and the first dose in Period 2. In Period 2, participants will receive twice daily oral doses of CTP-543 for 8 consecutive days with a single dose of the combination OC co-administered on Day 4.
61984267|NCT02158104||Latent trigger point in the upper trapezius muscle|
61984268|NCT04244513|EXPERIMENTAL|HD-DBS|This group will be routinely activated after surgery and then stimulated for 6 months.
61984269|NCT04244513|SHAM_COMPARATOR|HD-sham-DBS|This group of patients will be re-launched 3 months after surgery, continued stimulation for 3 months
61984270|NCT05506852|EXPERIMENTAL|Strategy Training|Participants will play the Breakfast Game with training strategy.
61984271|NCT05506852|ACTIVE_COMPARATOR|Regular Approach|Participants will play the Breakfast Game without training strategy.
61984272|NCT04768465||Combined Immunotherapy|"MG patients are treated with tacrolimus combined with low-dose prednisone (0.25mg/kg/d).~Symptomatic treatment like pyridostigmine bromide can be added to relieve symptoms (≤480mg/d)."
61984273|NCT04768465||Tacrolimus monotherapy|MG patients are treated with tacrolimus as initial immune monotherapy. Symptomatic treatment like pyridostigmine bromide can be added to relieve symptoms (≤480mg/d).
61984274|NCT03573479||Pre-implementation cohort|This is the pre-implementation phase where a baseline documentation will take place about usual clinical practice, perceptions and attitudes of PICU staff and clinicians
61984275|NCT03573479||PICU Liber8 bundle|After the implementation of the bundle (the PICU Liber8 components) same measurements will be captured and analyzed comparatively.
61984276|NCT02087475|EXPERIMENTAL|Neoadjuvant therapy arm|FOLFIRI \* 6 cycles +/- radiotherapy -\> surgery -\> FOLFIRI \* 6 cycles
61984277|NCT02087475|ACTIVE_COMPARATOR|Adjuvant therapy arm|Surgery -\> FOLFIRI \* 12 cycles +/- radiotherapy
61984278|NCT02587065|EXPERIMENTAL|peginterferon beta-1a|125 μg administered subcutaneously (SC) every 2 weeks
61984279|NCT05045976|EXPERIMENTAL|Experimental group|The experimental group will receive the web-based interactive self-management support intervention.
62362786|NCT06022172|EXPERIMENTAL|Experimental group|MOTIVATIONAL INTERVIEW BASED ON THE CALGARY FAMILY INTERVENTION MODEL IN PARENTS WITH A CHILD WITH CEREBRAL PALS.
62362787|NCT06022172|NO_INTERVENTION|CONTROL GROUP|no action will be taken
61984280|NCT05045976|NO_INTERVENTION|Control group|The control group will receive usual care and regular patients education.
61984281|NCT01909596|NO_INTERVENTION|Knee osteoarthritis patients - No insoles|Without orthoses
61984282|NCT01909596|ACTIVE_COMPARATOR|Knee osteoarthritis patients - Customised|Medial arch support without lateral wedge
61984283|NCT01909596|ACTIVE_COMPARATOR|Knee osteoarthritis patients - Customised + 6°|6° lateral wedge insoles + Medial arch support
61984284|NCT01909596|ACTIVE_COMPARATOR|Knee osteoarthritis patients - Customised + 10°|10° lateral wedge insoles + Medial arch support
61984285|NCT03253107||responder in palliative chemotherapy|After initial chemotherapy, responder (complete remission, partial remission)
61984286|NCT03253107||non-responder in palliative chemotherapy|After initial chemotherapy, disease progression
61984287|NCT03253107||responder in adjuvant chemotherapy|complete cure and no recurrence at least 1 year after treatment
61984288|NCT03253107||non-responder in adjuvant chemotherapy|non-complete cure or recurrence within 1 year after treatment
61984289|NCT02929823|EXPERIMENTAL|Low Dose SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0.0002% SJP-0035 ophthalmic solution in the affected eye(s) 4 times daily for 4 weeks.
61984290|NCT02929823|EXPERIMENTAL|High Dose SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0.001% SJP-0035 ophthalmic solution in the affected eye(s) 4 times daily for 4 weeks.
61984291|NCT02929823|PLACEBO_COMPARATOR|Vehicle of SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0% SJP-0035 ophthalmic solution (consisting of the vehicle for the solution) in the affected eye(s) 4 times daily for 4 weeks
61984292|NCT02617511|EXPERIMENTAL|Omega-3 Supplementation|This groups will supplement their regular diet with 2.97 grams of combined omega-3 fatty acid (EPA/DHA) supplement in soft gel form on a daily basis for 12 weeks. This group will also complete a whole body progressive resistance training program 3 days per week for 12 weeks.
61984293|NCT02617511|PLACEBO_COMPARATOR|Placebo|This group will supplement their regular diet with 3.0 grams of a combined omega-3-6-9 supplement in soft gel form on a daily basis for 12 weeks. This group will also complete a whole body progressive resistance training program 3 days per week for 12 weeks.
61984294|NCT00867451|EXPERIMENTAL|Immediate Treatment|Children will receive behavioral sleep interventions and, if needed, melatonin, to improve sleep functions.
61984295|NCT00867451|EXPERIMENTAL|Delayed Treatment|Children will only receive sleep behavior interventions for the first four weeks of the trial. Treatment with study drug will be delayed to the 5th week.
61984296|NCT04339296|EXPERIMENTAL|Intervention group|Intervention group included medication management with Spencer.
61984297|NCT04339296|NO_INTERVENTION|Control Group|The control group continued to use their current method of medication management, such as blister packs, strip packs, pill organizers and plastic prescription vials.
61984298|NCT05543941|EXPERIMENTAL|XPERIENCE Advanced Surgical Irrigation|Patients will receive the XPERIENCE Advanced Surgical Irrigation prior to wound closure.
61984299|NCT05543941|ACTIVE_COMPARATOR|Dilute Betadine|Patients will receive Dilute Betadine solution prior to wound closure.
61984300|NCT02127242|EXPERIMENTAL|air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
61984301|NCT02127242|NO_INTERVENTION|hepatectomy group|Hepatic resection using an open approach is performed for all segments affected by biliary stenosis and the affected bile duct drainage area.Hepaticojejunostomy is performed in patients with common bile duct stenosis and in those considered to be at high risk for recurrence.
61984302|NCT00159250|EXPERIMENTAL|Low dose|Low dose of AVI-4658
61984303|NCT00159250|EXPERIMENTAL|High dose|High dose of AVI-4658
61984304|NCT06519188|EXPERIMENTAL|NEBUL APPLICATION GROUP|The experimental group patients were taught the method of nebulization with 5 ml isotonic sodium chloride. Patients were asked to perform the application twice a day, in the morning and in the evening, for two months.
61984305|NCT06519188|NO_INTERVENTION|NON APLICATION GROUP|No intervention was performed on control group patients who volunteered for the study.
61984306|NCT03822247|EXPERIMENTAL|Multidisciplinary Recovery Program|"Two cohorts of patients will randomly be placed in either experimental od no intervention group.~Patients undergoing Multidisciplinary Recovery After Surgery Program will gain better preparation for early mobilization after surgery, nutritional support, individually modified analgesia and psychological support during inpatient treatment. Program includes preoperative, intraoperative and postoperative multidisciplinary comprehensive interventions."
61984307|NCT03822247|NO_INTERVENTION|Conventional Perioperative Care|Patients undergoing conventional care
61984308|NCT02258321|EXPERIMENTAL|PPI-668 tablet followed by capsule|On day 1, one 200 mg PPI-668 tablet will be administered. On day 6, two 100 mg PI-668 capsules will be administered.
61984309|NCT02258321|EXPERIMENTAL|PPI-668 capsule followed by tablet|On day 1, two 100 mg PI-668 capsules will be administered. On day 6, one 200 mg PPI-668 tablet will be administered.
61984310|NCT02981823|EXPERIMENTAL|hip replacement|The patients undergo total hip replacement with the collum femoris preserving stem suffered from periprosthetic fractures.
61984311|NCT00654173|EXPERIMENTAL|1|Rosuvastatin
61984312|NCT00654173|ACTIVE_COMPARATOR|2|Simvastatin
61984313|NCT00654173|ACTIVE_COMPARATOR|3|Atorvastatin
61984314|NCT01357408||REVEAL XT device|Subjects implanted at time of admission for HF or to be implanted within 14 days of discharge from HF hospitalization for clinical indications\>
61984315|NCT04011527||Patients with Coronary Artery Disease|Patients with Coronary Artery Disease undergoing a Rotational Atherectomy in Coronary Lesion/s
61984316|NCT04315337|EXPERIMENTAL|Virtual Training Arm|This is a within-participant study with two arms. All participants receive the Virtual Training with one target task and they are tested (after one day and one month) on the target task (arm 1) and as well as on a control task(arm 2). Assignment to the specific task that is trained is randomized across participants.
61984317|NCT04315337|NO_INTERVENTION|Control Arm|This is a within-participant study with two arms. All participants receive the Virtual Training with one target task and they are tested (after one day and one month) on the target task (arm 1) and as well as on a control task(arm 2). Assignment to the specific task that is trained is randomized across participants.
61984318|NCT00431210|EXPERIMENTAL|Biological/Vaccine|Epstein-Barr virus-specific adoptive T-cells immunotherapy given intravenously on Days 1 and 14
61984319|NCT03887000|EXPERIMENTAL|MAGNESIUM|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
61984320|NCT03887000|EXPERIMENTAL|PLACEBO|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
61984321|NCT03984591|ACTIVE_COMPARATOR|Spironolactone|Spironolactone used according to heart failure guidelines
61984322|NCT03984591|ACTIVE_COMPARATOR|Eplerenone|Eplerenone used according to heart failure guidelines
61984323|NCT04692428|EXPERIMENTAL|FIBSI group|ultrasound supra inguinal Fascia iliaca block
61984324|NCT04692428|EXPERIMENTAL|FNB group|ultrasound femoral nerve block
61984325|NCT00525733|ACTIVE_COMPARATOR|3-drug standard therapy|FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ +ritonavir 100 mg QD
61984326|NCT00525733|EXPERIMENTAL|5-drug experimental therapy|FTC 200 mg/TDF 300 mg QD + darunavir 800 mg + ritonavir 100 mg QD + Raltegravir 400 mg BID + Maraviroc 150 mg BID
61984327|NCT05434260|ACTIVE_COMPARATOR|Surgiphor: sterile povidone iodine irrigation solution|Surgiphor Wound Irrigation Solution, bottle consisting of sterile 0.5% PVP-I formulation with 0.9% saline, Potassium Iodide, Phosphate Buffer, Vitamin E TPGS
61984328|NCT05434260|PLACEBO_COMPARATOR|Sterile saline|
61984329|NCT06127992|EXPERIMENTAL|Typical ColdU|39 patients had typical ColdU confirmed by positive ICT and TempTest® CSTs.
61984330|NCT06127992|EXPERIMENTAL|Atypical ColdU|24 patients had atypical ColdU with negative ICT and TempTest® CSTs.
62567125|NCT05109533|EXPERIMENTAL|Group 2 - ARM WITH STANDARD TREATMENT PLUS PROBIOTICS IMPLEMENTATION|Standard specific treatment for vaginal infections plus long-lasting (9 months) vaginal and oral probiotics implementation (Lactobacillus rhamnosus BMX 54 vaginally and Lactobacillus reuteri RC-14/Lactobaciullus rhamnosus GR-1 combination orally)
61984331|NCT06127992|OTHER|Control group|15 healthy controls (HCs) who had no history of pathological reactions associated with cold exposure, and all of them had negative CSTs
61984332|NCT02192918|EXPERIMENTAL|Airbrush|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Participants will receive access to one of each of the following after the 6-month assessment at no cost: massage, pedicure, yoga class, and dance class. Participants will schedule these activities on their own and the study staff will arrange for payment for the appointment.
61984333|NCT02192918|EXPERIMENTAL|Airbrush Plus|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class. These activities are being given as healthy alternatives to the relaxation sensation of indoor tanning.
61984334|NCT02192918|ACTIVE_COMPARATOR|Delayed Airbrush Plus|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class.
61984335|NCT02686879|NO_INTERVENTION|Natural progession|Following the natural progression of axial growth and refractive error.
61984336|NCT02686879|EXPERIMENTAL|Anisohyperopes - intervention eye|The more hyperopic eye will be fitted with a centre-near multifocal contact lens
61984337|NCT02686879|EXPERIMENTAL|Hyperopes|Both eyes will be fitted with centre-near multifocal contact lenses.
61984338|NCT02686879|EXPERIMENTAL|Anisohyperopes - fellow eye|The less hyperopic eye will be fitted with a single vision contact lens if required.
61984339|NCT03642210|EXPERIMENTAL|Levonorgestrel 52 mg intrauterine system|Levonorgestrel 52 mg intrauterine system, inserted for use up to 6 months
61984340|NCT03975855||Suspicious axillary lymph nodes|All patients with histologically confirmed breast cancer or highly suspicious breast lesions presenting with suspicious axillary lymph nodes
61984341|NCT01628601||POAG or OHT|Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
61984342|NCT02283047|ACTIVE_COMPARATOR|CONTROL GROUP-DIET|Hypocaloric diet intervention with no supervised exercise intervention
61984343|NCT02283047|EXPERIMENTAL|DIET & MODERATE CONTINUOUS TRAINING|Intervention with hypocaloric diet and supervised moderate continuous exercise training (60-80%HRpeak). High volume training (45 minutes in progression from 20 min)
61984344|NCT02283047|EXPERIMENTAL|DIET & HIGH VOLUME HIIT|Intervention with hypocaloric diet and supervised high intensity interval training (85-95%HRpeak). High volume training (45 minutes in progression from 20 min)
61984345|NCT02283047|EXPERIMENTAL|DIET & LOW VOLUME HIIT|Intervention with hypocaloric diet and supervised high intensity interval training (85-95%HRpeak). Low volume training (20 min)
61984346|NCT05925023|EXPERIMENTAL|Sirolimus on refractory/relapsed wAIHA|A prospective research of the sirolimus efficiency on refractory/relapsed primary wAIHA patients. Sirolimus dosage: 1-3 mg/d with plasma concentration 4-15ng/mL. Medication time should last at least 6 months. After reaching the optimal response, responders continue to use sirolimus for 1 year, and then gradually reduce the dosage.
61984347|NCT02548247|EXPERIMENTAL|Orafti® Inulin|Daily consumption of 12g Orafti® Inulin (3x 4g/d) over a period of 4 weeks
61984348|NCT02548247|PLACEBO_COMPARATOR|Placebo|Daily consumption of 12g/ Maltodextrin (3x 4g/d) over a period of 4 weeks
61984349|NCT02576288|EXPERIMENTAL|Sitagliptin|100mg will be administered by mouth daily for 28days
61984350|NCT02576288|PLACEBO_COMPARATOR|Matching Placebo|One placebo will be administered by mouth daily for 28days
61984351|NCT05950789|EXPERIMENTAL|Virtual reality application group|During the preparation stage of the port catheter injection attempt, the intervention group was given a calming video and music concert using virtual reality glasses.
61984352|NCT05950789|NO_INTERVENTION|Control|In the control group, no intervention was made other than the routine application.
61984353|NCT01229423|EXPERIMENTAL|LATISSE®|bimatoprost 0.03% (LATISSE®)
61984354|NCT03016962|EXPERIMENTAL|Cap-assisted colonoscopy|cap-assisted colonoscopy
61984355|NCT03016962|ACTIVE_COMPARATOR|Standard colonoscopy|Standard colonoscopy
61984356|NCT01147705|ACTIVE_COMPARATOR|Allopurinol|Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks.
61984357|NCT01147705|PLACEBO_COMPARATOR|Placebo|Same number of tablets and appearance as active drug.
61984358|NCT00322842|EXPERIMENTAL|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
61984359|NCT00322842|EXPERIMENTAL|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
61984360|NCT02537054|EXPERIMENTAL|Aflibercept|2 mg/ dose (pro re nata, maximum 1 dose/ month), intravitreal use
61984361|NCT01376271||Subjects prescribed paroxetine tablets|Subjects with SAD prescribed paroxetine tablets during study period
61984362|NCT00326950|EXPERIMENTAL|1|
61984363|NCT02850809||patients|Treated by percutaneous image-guided radiofrequency for renal tumor
61984364|NCT00183092|EXPERIMENTAL|quinacrine|
61984365|NCT00183092|PLACEBO_COMPARATOR|placebo|
61984366|NCT06112951|EXPERIMENTAL|Treatment Group|Treatment group will receive extracorporeal photopheresis. First, a two-day treatment cycle will be performed once every second week for the first two months. Then, a two-day treatment cycle will be performed once a month for 6 months.
61984367|NCT06112951|NO_INTERVENTION|Control Group|Control group will be observed and no active treatment will be administered. This is our standard of care in the studied clinical situation.
61984368|NCT04908553|OTHER|low dose group|Remimazolam Tosilate for Injection 0.1mg/kg at induction
61984369|NCT04908553|OTHER|medium dose group|Remimazolam Tosilate for Injection 0.15mg/kg at induction
61984370|NCT04908553|OTHER|high dose group|Remimazolam Tosilate for Injection 0.2mg/kg at induction
61984371|NCT02016482|ACTIVE_COMPARATOR|Adalimumab (ADA)|Period A: ADA 40 mg subcutaneous every other week (sc eow) for 25 weeks starting 1 week after initial loading dose of 80 mg. Period B: Placebo at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
61984372|NCT02016482|PLACEBO_COMPARATOR|Placebo|Period A: Placebo sc eow for 25 weeks. Period B: ADA 80 mg sc at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
61984373|NCT05283798|EXPERIMENTAL|rate of missed threads in the first 6 weeks|To compare efficacy safety \& side effects of multiload 375 IUD versus copper T 380 IUD when inserted during elective CS
61984374|NCT05283798|OTHER|number of bleeding days in first 6 weeks|compare numbers of bleeding days in first 6 weeks and first 6 month
61984375|NCT02144441|EXPERIMENTAL|Patient self-administered insulin|The study's only arm
61984376|NCT00568750|EXPERIMENTAL|Dasatinib|
61984377|NCT01237535|EXPERIMENTAL|Luteal support with progesterone only|Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel)Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.
61984378|NCT01237535|EXPERIMENTAL|Luteal support with estrogen + progesterone|Luteal support with estrogen + progesterone \[(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg\].
61984379|NCT01237535|NO_INTERVENTION|No luteal support|
61984380|NCT02202642|EXPERIMENTAL|limbal stem cells|"Using collagenase to isolate limbal stem cells and improve the technique of ex vivo expansion of limbal stem cells for the treatment of patients suffering from unilateral limbal stem cell insufficiency based on the concept of limbal stem cells need special cell-cell contact and cell-extracellular matrix interaction to support their survival"
61984381|NCT03773887|OTHER|acute alcoholic hepatitis|collection of liver biopsies collection of blood samples in patients with acute alcoholic hepatitis (group A)
61984382|NCT03773887|OTHER|Alcoholic cirrhosis|collection of liver biopsies collection of blood samples in patients with alcoholic cirrhosis (group B1)
61984383|NCT03773887|OTHER|Without chronic liver disease|collection of liver biopsies collection of blood samples in patients without chronic liver disease (group B2)
61984384|NCT04814420|EXPERIMENTAL|Experimental group|The group will include 15 patients with OSA 5 with mild OSA 5 with moderate OSA 5 with severe OSA
61984385|NCT04814420|OTHER|Control group|This group will include 5 patients with no OSA
61984386|NCT04675294|EXPERIMENTAL|evorpacept (ALX148) + pembrolizumab|evorpacept (ALX148) 45 mg/kg IV and pembrolizumab 200 mg IV given every 3 weeks.
61984387|NCT04675294|ACTIVE_COMPARATOR|pembrolizumab|pembrolizumab 200 mg IV given every 3 weeks.
61984388|NCT04592029|EXPERIMENTAL|TACE-Sin-Bev|TACE combined with sintilimab and bevacizumab.
61984389|NCT02475551|EXPERIMENTAL|Treatment|IdeS as a single infusion
61984390|NCT03739112|EXPERIMENTAL|Quadrivalent VLP Vaccine|Participants received one intramuscular (IM) injection of 0.5 mL of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.
61984391|NCT03739112|ACTIVE_COMPARATOR|Fluarix Quadrivalent® Comparator Vaccine|Participants received one IM injection of 0.5 mL of 15 μg/strain of the Fluarix Quadrivalent® comparator vaccine on Day 0.
61984392|NCT04892043|EXPERIMENTAL|Part 1 Monotherapy Dose Escalation Phase|"In Part 1, SQZ-AAC-HPV as a monotherapy is administered every 3 weeks for up to a year.~There are 3 groups (Cohorts) in this Phase as follows:~* Cohort 1a: low dose SQZ-AAC-HPV~* Cohort 1b: high dose SQZ-AAC-HPV~* Cohort 1c: higher or lower dose SQZ-AAC-HPV"
61984393|NCT04892043|EXPERIMENTAL|Part 2 Combination Safety Phase|"In Part 2, SQZ-AAC-HPV in combination with immune checkpoint inhibitors (1) ipilimumab, (2) nivolumab, or (3) nivolumab plus ipilimumab is administered every 3 weeks up to a year, but the immune checkpoint inhibitors may be administered up to 2 years. There are 3 groups (Cohorts) in this Phase as follows:~* Cohort 2a: SQZ-AAC-HPV RP2D (Recommended Phase 2 Dose) plus ipilimumab~* Cohort 2b: SQZ-AAC-HPV RP2D plus nivolumab~* Cohort 2c: SQZ-AAC-HPV RP2D plus nivolumab and ipilimumab"
61984394|NCT03346499|EXPERIMENTAL|NK cells and IL-2|
61984395|NCT05762900|EXPERIMENTAL|Ultra-hypofractionated arm|The patients will be treated by Ultra-hypofractionated irradiation.
61984396|NCT00891644||1|HIV positive adolescents who never initiated care within 6 months of receipt of HIV positive results.
61984397|NCT00891644||2|HIV positive adolescents who initiated care, but did not follow up with care within 12 months of the initial care visit. Also included in this group are those who initiated and followed-up with care, but have dropped out of care for 12 or more months.
61984398|NCT00891644||3|HIV positive adolescents who initiated care and maintained care. These youth are currently in care.
61984399|NCT00590447|EXPERIMENTAL|A|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients achieving a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 further courses of single agent rituximab on days 50, 72, 94 and 116.
61984400|NCT00590447|EXPERIMENTAL|B|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients who do not achieve a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 courses of R-CHOP on days 50, 72, 94 and 116.
61984401|NCT06054087|EXPERIMENTAL|EA group|Subjects in this group received electroacupuncture along with the basic treatment at a frequency of 2 treatments per week for 6 weeks for a total of 12 interventions. The follow-up period is one month.
61984402|NCT06054087|OTHER|Waiting list group|The subjects in this group will receive only basal treatment with no additional therapies during the study period. After the end of the study period, patients were given 12 acupuncture treatments
61984403|NCT02657460|EXPERIMENTAL|MTX-ATMPs|methotrexate-autologous tumor derived microparticles
62169348|NCT03504371|ACTIVE_COMPARATOR|bilateral erector spinae block|The patient placed in a lateral position and ultrasound transducer placed 3 cm lateral to the T7 spinous process. Three muscles will be identified: trapezius, rhomboid major, and erector spinae. 8-cm 22-gauge block needle will be inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between rhomboid major and erector spinae muscles, as evidenced by visualization of local anesthetic spreading in a linear pattern between erector spinae and the bony shadows of the transverse processes. 20 mL of 0.25% bupivacaine will be injected then it will be repeated on the other side in the same way without changing the position of the patient to achieve sensory block T5-T10 .
62169349|NCT03504371|SHAM_COMPARATOR|Thoracic epidural anesthesia|an epidural catheter placed at the T7-8 interspace after proper sterilization and positioning of the patient in the sitting position then standard technique of application will be applied, then a test dose consists of 3 ml of 1.5% preservative free lidocaine will be injected followed by 5-6 ml of bupivacaine 0.25%
61984404|NCT02657460|SHAM_COMPARATOR|cisplatin|Cisplatin is a traditional treatment for lung cancer
61984405|NCT00918658||Patients with hematologic cancer|Patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma
61984406|NCT00918658||Patients without cancer|Patients who do not have cancer.
61984407|NCT06450626|EXPERIMENTAL|Listening Music Intervention|Participants listen to 30 minutes of a music playlist of their choice.
61984408|NCT02137733|ACTIVE_COMPARATOR|Bisoprolol group|Daily oral administration of bisoprolol 0.625 mg tablet once a day should be given (Step 1). If tolerability is confirmed by an investigator, the dose should be increased to 1.25 mg (bisoprolol 0.625 mg, 2 tablets; or bisoprolol 2.5 mg, half tablet; once daily) (Step 2). In the same manner, the doses should be increased to 2.5 mg (bisoprolol 2.5 mg, 1 tablet; or bisoprolol 5 mg, half tablet; once daily, Step 3), to 3.75 mg (bisoprolol 2.5 mg, 1.5 tablets once daily, Step 4), and to 5 mg (bisoprolol 2.5 mg, 2 tablets; or bisoprolol 5 mg, 1 tablet; once daily, Step 5).
62567126|NCT02231567|EXPERIMENTAL|Neurocognitive Rehabilitation|Rehabilitative approach based on exercises proposed as sensory-motor problems, whose solution involves the use of higher cognitive functions (attention, memory, language).
61984409|NCT02137733|ACTIVE_COMPARATOR|Carvedilol group|Daily oral administration of carvedilol 1.25 mg, 1 tablet twice a day (after breakfast and supper) should be given (Step 1). If tolerability is confirmed by an investigator after administering 2.5 mg/day of carvedilol, the dose should be increased to 5 mg (carvedilol 2.5 mg, 1 tablet twice daily) (Step 2). In the same manner, the dose should be increased to 10 mg (carvedilol 2.5 mg, 2 tablets twice daily, Step 3), to 15 mg (carvedilol 2.5 mg, 3 tablets twice daily, Step 4), and to 20 mg (carvedilol 10 mg, 1 tablet twice daily, Step 5).
61984410|NCT01291758||GWI|Veterans of the 1990-1991 Persian Gulf War who have autonomic, neurological and other symptoms
61984411|NCT01291758||HC|Healthy veterans of the 1990-1991 Persian Gulf War
61984412|NCT04564456|EXPERIMENTAL|Test Product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
61984413|NCT04564456|ACTIVE_COMPARATOR|Reference Product|ADVAIR DISKUS® 500/50
61984414|NCT04517214|EXPERIMENTAL|Toripalimab Combined with GP Arm|Systemic chemotherapy for 6 cycles: Toripalimab 240mg d1+Gemcitabine 1.0g/m2 d1, Cisplatin 80mg/m2 d1, q3w; Followed by Radiotherapy to the nasopharynx and neck; Then maintenance therapy of Toripalimab with Capecitabine: Toripalimab 240mg d1+Capecitabine 1000mg/m2 bid d1-14, q3w
61984415|NCT04517214|ACTIVE_COMPARATOR|GP Arm|Systemic chemotherapy for 6 cycles: Gemcitabine 1.0g/m2 d1, Cisplatin 80mg/m2 d1, q3w; Followed by Radiotherapy to the nasopharynx and neck; Then maintenance therapy of Capecitabine: Capecitabine 1000mg/m2 bid d1-14, q3w
61984416|NCT02583776|EXPERIMENTAL|Unblinded CGM|"CGM data will be unblinded, with Hypo/hyperglycemia alarms on. Data will be recorded from CGM every three hours and intervention to adequate glucose intake will be performed to keep glycemia in normal range (72-144mg/dl) if necessary."
61984417|NCT02583776|OTHER|Blinded CGM|Hypo/hyper alarms are off. CGM data will be blinded. Glucose intake will be adequate according to 2-3 capillary glycemic tests per day.
61984418|NCT03479788||DM|Observational study. NO intervention
61984419|NCT03479788||non-DM|Observational study. NO intervention
61984420|NCT06541288|EXPERIMENTAL|AI Prediction Model|
61984421|NCT06541288|ACTIVE_COMPARATOR|Conventional Imageing Assessment|
61984422|NCT00696852|ACTIVE_COMPARATOR|Mindfulness Meditation|
61984423|NCT00696852|ACTIVE_COMPARATOR|Yoga|
61984424|NCT00696852|ACTIVE_COMPARATOR|Conventional Stress Reduction|
61984425|NCT03585205||cognitive load with/ without stress induction|"Participants will engage in demanding cognitive load computerized tasks (such as N-back and Stroop tasks). They will engage in these tasks once in a non-stressful (neutral condition), and once in a stressful condition.~Psychological stress will be induced by the following methods:~1. Limiting time for task completion~2. Providing negative feedback on participants' performance in relation to others~3. Presentation of sudden, loud sounds during task"
62169350|NCT02061215||recipients aged 20-40|CMV viral load
62169351|NCT02061215||recipients older than 60|CMV viral load
62169352|NCT03965247|EXPERIMENTAL|Lithium|Increasing amounts of lithium for 11 plus or minus 1 day. Day 1: 400 mg at night Day 2: 600 mg at night Day 3-11: 800 mg at night. The lithium intervention was prepared from 200mg Priadel prolonged release tablets. The intervention was provided in blue and white gelatine capsules to be taken orally.
61984426|NCT06473870||Study population|"Adult subjects (40 years old or higher), smokers and non-smokers, both women and men who have the capacity to comply with the study follow-up and sign the informed consent, will be recruited from Servicio Andaluz de Salud (SAS), Osakidetza Servicio Vasco de Salud (OSA), Centre Hospitalier Universitaire de Liège (CHUL) and Centre for Tuberculosis and Lung Diseases (CTLD) of Riga East University Hospital (REUH)."
61984427|NCT03893604|EXPERIMENTAL|Anodal tDCS|Subjects will receive 20min anodal tDCS
61984428|NCT03893604|SHAM_COMPARATOR|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
61984429|NCT00343200|PLACEBO_COMPARATOR|Placebo|
61984430|NCT00343200|EXPERIMENTAL|Sildenafil|
61984431|NCT03787251|EXPERIMENTAL|experimental group|It is recommended that the initial dose of apatinib is 500mg po qd. Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks. If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
61984432|NCT03787251|ACTIVE_COMPARATOR|Control group|"The chemotherapeutic drug chosen by the investigator (if not used in the previous treatment regimen, it cannot be selected).~The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient.~In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient decease. If the adverse event grade 3 and above Or non-hematologic toxicity of grade II and above appeared, allowing the dose to be lowered twice."
61984433|NCT03980457|EXPERIMENTAL|Exo-group|Standard rehabilitation plus use of Exoskeleton
61984434|NCT03980457|PLACEBO_COMPARATOR|Control-Group|Standard rehabilitation
61984435|NCT04175769|EXPERIMENTAL|Experimental intervention|Standard intervention of immunotherapy or combination of immunotherapy and chemotherapy, plus the experimental intervention nutritional product.
61984436|NCT04175769|PLACEBO_COMPARATOR|Non-experimental intervention|Standard intervention of immunotherapy or combination of immunotherapy and chemotherapy, plus the non-experimental intervention placebo product.
61984437|NCT06520930|NO_INTERVENTION|Arms|"First Stage: As a pre-test, pulse, respiratory rate and saturation values will be checked, Descriptive Questionnaire and General Comfort Scale (GAS) will be applied to primiparous pregnant women in the control group.~Second Stage: As the final test, the heart rate, respiratory rate, blood pressure and saturation values will be checked again at the end of the 8th session for primiparous pregnant women, and the Descriptive Questionnaire and General Comfort Scale (GAS) will be applied."
62169353|NCT03965247|PLACEBO_COMPARATOR|Rayotabs|The placebo intervention was 200mg Rayotabs. The intervention was provided in blue and white gelatine capsules to be taken orally - same as the lithium intervention to maintain blinding.
62169354|NCT01638533|EXPERIMENTAL|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62169355|NCT03274206|EXPERIMENTAL|BLS-ILB-E710c|"* Drug: BLS-ILB-E710c 1,000mg~* Dosage and duration: 4 capsules per day for 5 consecutive days at week 1,2,4, and 8)"
62169356|NCT03274206|PLACEBO_COMPARATOR|BLS-ILB-E710c-placebo|"* Drug: BLS-ILB-E710c-placebo~* Dosage and duration: 4 capsules per day for 5 consecutive days at week 1,2,4, and 8)"
62169357|NCT03207620||smoker asthmatics|"* Asthma control questionnaire (ACQ) score~* Spirometry~* Sputum cytology"
62169358|NCT03207620||non-smoker asthmatics|"* Asthma control questionnaire (ACQ) score~* Spirometry~* Sputum cytology"
62169359|NCT02264717|ACTIVE_COMPARATOR|Cardiac MRi|A minimum of 150 patients will be randomized to Cardiac MRI followed by conventional angiography CCA-FFR, after detection of obstructive anatomic coronary artery stenoses on coronary Computed Tomography Angiography (cCTA)
62567127|NCT02231567|ACTIVE_COMPARATOR|Traditional Rehabilitation|It is a rehabilitative approach based on exercises for the recovery of hip's range of motion, muscle strengthening exercises, stretching exercises of the hamstring muscles, adductor and iliopsoas and proprioceptive exercises.
62567128|NCT00580151|EXPERIMENTAL|1|
62567129|NCT00580151|PLACEBO_COMPARATOR|2|
62169360|NCT02264717|ACTIVE_COMPARATOR|SPECT|A minimum 150 patients will be randomized to SPECT followed by conventional angiography CCA-FFR, after detection of obstructive anatomic coronary artery stenoses on coronary Computed Tomography Angiography (cCTA).
62169361|NCT03868618|EXPERIMENTAL|Genio Therapy|The Genio™ system is an implantable neurostimulation system comprised of one implanted device
62169362|NCT02375932|EXPERIMENTAL|Pre-Visit Tool|Patients whose primary care physicians are allocated to the intervention arm will receive a secure electronic message shortly after scheduling an appointment with their provider asking them to complete a pre-visit prioritization survey using the kp.org patient portal
62169363|NCT02375932|ACTIVE_COMPARATOR|Usual Care Control|Patients whose primary care physicians are allocated to the control arm will continue with usual care
62169364|NCT02411422|EXPERIMENTAL|Intubation using laryngoscope|"Intubation using Macintosh laryngoscope. we will check procedure time according to kind of endotracheal tube, separately.~Two kinds of endotracheal tube will be used~* Conventional endotracheal tube~* Reinforced endotracheal tube"
62169365|NCT02411422|EXPERIMENTAL|i-gel blind intubation|"i-gel blind intubation means that blind endotracheal intubation will be performed after i-gel insertion.~i-gel will be used as a conduit. we will check procedure time according to kind of endotracheal tube, separately.~Two kinds of endotracheal tube will be used~* Conventional endotracheal tube~* Reinforced endotracheal tube"
61984438|NCT06520930|EXPERIMENTAL|Intervention Group|As a pre-test, pulse, respiratory rate, blood pressure and saturation values will be checked, Descriptive Questionnaire and General Comfort Scale (GAS) will be applied to the primiparous pregnant women in the experimental groups. Breathing therapy exercises based on Kolcaba's comfort theory were designed as face-to-face training by the researcher himself, who received breathing therapy training for primiparous pregnant women once a week, for a total of 8 sessions. 6 pieces will be created within the session. Each session lasts approximately 45-60 minutes. As the final test, pulse, respiratory rates, blood pressure and saturation values will be checked again at the end of the 8th session/week to determine the change in primiparous pregnant women, and the Descriptive Questionnaire and General Comfort Scale (GAS) will be applied.
61984439|NCT03205410|EXPERIMENTAL|Patients with RIPC|intervention: remote ischemic preconditioning - three cycles of 5-min ischemia, achieved by inflation of blood-pressure cuff to 200 mmHg, followed by 5-min reperfusion while the cuff was deflated were applied to the upper left arm.
61984440|NCT03205410|SHAM_COMPARATOR|Patients without RIPC|intervention: no - remote ischemic preconditioning - in controls, the cuff was placed around the arm but not inflated.
62169366|NCT02411422|EXPERIMENTAL|i-gel bronchoscopic intubation|"i-gel bronchoscopic intubation means that bronchoscopic endotracheal intubation will be performed after i-gel insertion.~i-gel will be used as a conduit. we will check procedure time according to kind of endotracheal tube, separately.~Two kinds of endotracheal tube will be used~* Conventional endotracheal tube~* Reinforced endotracheal tube"
62169367|NCT02133183|EXPERIMENTAL|Arm I (sapanisertib before and after surgery)|Patients receive sapanisertib PO according to the results from Part I. Patients also undergo surgery on day 0. Within 45 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61984441|NCT05023811|EXPERIMENTAL|[14C]RIST4721|\[14C\]RIST4721 oral solution
61984442|NCT01271920|EXPERIMENTAL|AUY922 + Trastuzumab|
61984443|NCT02913391|EXPERIMENTAL|recruitment group (RG)|After extubation the patient who was randomized to the Recruitment Group (RG) used noninvasive ventilation (NIV) associated with recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV until 30 minutes with pressure support for a tidal volume of 6 mL/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen (FiO2) for a peripheral oxygen saturation (SpO2) ≥ 95%.
62169368|NCT02133183|EXPERIMENTAL|Arm II (sapanisertib after surgery)|Patients undergo surgery on day 0. Within 45 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62169369|NCT06646705|EXPERIMENTAL|Aligner|Full-mouth clinical periodontal measurements recorded and saliva obtained
61984444|NCT02913391|ACTIVE_COMPARATOR|control group (CG)|After extubation the patient who was randomized to the Control Group (CG) used noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, FiO2 for a SpO2 ≥ 95%.
61984445|NCT03691896|EXPERIMENTAL|Lower dose|cholecalciferol 400UNT, oral solution
61984446|NCT03691896|ACTIVE_COMPARATOR|Middle dose|cholecalciferol 800UNT, oral solution
61984447|NCT03691896|EXPERIMENTAL|Higher dose|cholecalciferol 1200UNT, oral solution,
61984448|NCT02902185|EXPERIMENTAL|Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.
61984449|NCT02902185|PLACEBO_COMPARATOR|Placebo-controlled|Placebo with the same taste and appearance like Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.
61984450|NCT03264287|EXPERIMENTAL|3 times per week therapeutic frequency|"1.Acupuncture: GV20, LU5, LI11, LI4,GV14,BL13, ST2, BL2,ST7,ST6 and ashi point on the face.~* Huatuo Brand needle (0.20\*13mm) will be used for GV14, BL13, ST2, BL2, ST7, ST6 and ashi point on the face. Huatuo Brand needle (0.3\*40mm) will be used for GV20, LU5, LI11 and LI4.~  2.Moving capping: Du Meridian (from GV14 to GV3) as well as the first (from BL11 to BL28) and second (from BL41 to BL53) side lines of the Urinary Bladder Meridian of Foot-Taiyang.~* Guoyiyan Brand cupping jar (size 4) will be used. 3.Ear point tapping: Lung (CO14), Heart (CO15), Stomach (CO4), Neifenmi (CO18), Pizhixia (AT4).~* Huatuo Brand, made by the seed of Vaccaria segetalis ( Neck.)Garcke."
62169370|NCT03037814|OTHER|Compomer|Adhesive agent+Compomer
61984451|NCT03264287|ACTIVE_COMPARATOR|1 time per week therapeutic frequency|"The acupoints and treating procedures will be the same as the 3 times per week group. Only treating frequency is different. The treating frequency is 1 time per week.~1. Acupuncture: GV20, LU5, LI11, LI4,GV14,BL13, ST2, BL2,ST7,ST6 and ashi point on the face.~2. Moving capping: Du Meridian (from GV14 to GV3) as well as the first (from BL11 to BL28) and second (from BL41 to BL53) side lines of the Urinary Bladder Meridian of Foot-Taiyang.~3. Ear point tapping: Lung (CO14), Heart (CO15), Stomach (CO4), Neifenmi (CO18), Pizhixia (AT4).~   * Use the seed of Vaccaria segetalis ( Neck.)Garcke."
61984452|NCT04746703|EXPERIMENTAL|MRI before and 6 months after bariatric surgery|"Recruitment of patient with planned bariatric surgery in Louis Mourier Hospital by the nutritionist, during the preoperative day hospitalisation (performed during the multidisciplinary preparation for bariatric surgery) when patients are deemed eligible for bariatric surgery according to HAS (High Authority of Health) criteria.~Programming of MRI in the month between preoperative visit and surgery. During this exam without injection of contrast agents in the radiology department of Louis Mourier Hospital, additional sequences with specific acquisitions as previously validated in humans will be performed for the study.~Bariatric surgery will be performed as in usual care in Louis Mourier hospital. The same MRI will be performed in day hospitalization scheduled 6 months after surgery."
61984453|NCT02559089||anti-NMDA receptor encephalitis|
61984454|NCT02559089||other autoimmune encephlitis|
61984455|NCT02559089||other encephalopathy|
61984456|NCT00949325|EXPERIMENTAL|temsirolimus plus liposomal doxorubicin|Single arm study: Dose escalation of temsirolimus plus constant dose of liposomal doxorubicin.
61984457|NCT02347267|EXPERIMENTAL|Caloric and non-caloric SSBS reduction|Sweetened beverages (SSBS) caloric and non-caloric were not permitted and allowed only plain water
61984458|NCT02347267|ACTIVE_COMPARATOR|Caloric SSBS reduction|Only plain water and non-caloric sweetened beverages (SSBS) were allowed
61984459|NCT02347267|NO_INTERVENTION|All beverages|Beverages were not restricted
61984460|NCT02972554|EXPERIMENTAL|Propanolol Hydrochloride|This is the experimental group given the beta-blocker
61984461|NCT02972554|PLACEBO_COMPARATOR|Placebo|This is the control group given a placebo.
62169371|NCT03037814|OTHER|RMGIC|Primer+RMGIC
61984462|NCT01563718|EXPERIMENTAL|PRE-release XR-NTX|Participants randomly assigned to the pre-release condition will receive one injection of XR-NTX 1-2 weeks prior to prison release plus up to five additional injections of XR-NTX in the community after release
61984463|NCT01563718|ACTIVE_COMPARATOR|POST-release XR-NTX|Participant randomly assigned to the post-release group will be referred to Rhode Island Hospital to receive up to six injections of XR-NTX immediately after release from prison
61984464|NCT01050257|EXPERIMENTAL|Oseltamivir (TAMIFLU®) 100 mg|Oseltamivir (TAMIFLU®) 100 mg intravenous (IV) infused over 2 hours, two times a day (every 12 hours) for 5 days. At the discretion of the investigator after 3 days of treatment (6 doses), participants could either continue IV treatment or switch to 75 mg oral oseltamivir twice daily to complete the 5 days of treatment. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug (IV or oral) for up to 5 days.
61984465|NCT01050257|EXPERIMENTAL|Oseltamivir (TAMIFLU®) 200 mg|Oseltamivir (TAMIFLU®) 200 mg intravenous (IV) infused over 2 hours, two times a day (every 12 hours) for 5 days. At the discretion of the investigator after 3 days of treatment (6 doses), participants could either continue IV treatment or switch to 150 mg oral oseltamivir twice daily for 5 days. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug (IV or oral) for up to 5 days.
62169372|NCT03037814|OTHER|Giomer|Adhesive Agent+ Giomer
61984466|NCT01050257|EXPERIMENTAL|Oseltamivir Open Label|Moderate/Severe renal impaired participants received open label oseltamivir IV or oseltamivir capsules at reduced doses for 5 days as per protocol. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug as per protocol.
61984467|NCT04289246|EXPERIMENTAL|Treatment Group (TG)|On the first day of the intervention phase, research assistants visited TG's participants to introduce the MAD in the presence of caregivers. After the training session, which lasted 40 min approximately, the MAD was personalized according to the participant's prescriptions and through discussions with them on an appropriate schedule for presenting the reminders. Research assistants used the MAD administrator sub-system to enter the medication names, health problems to address, timetables, and the frequency at which medications should be taken. Then, they attached and configured NFC tags to each of the pill containers, which included selecting the images that best represented the pills and their containers to be used to form the visual reminders. Afterward, the MAD was placed in the homes' area where participants reported taking medications. MAD was used for 5 weeks during which data on medication adherence and system adoption was collected from the TG.
61984468|NCT04289246|NO_INTERVENTION|Control Group (CG)|Participants in the CG followed their medication routine as usual. During 5 weeks data on medication adherence was collected.
61984469|NCT03784404|ACTIVE_COMPARATOR|Non surgicel group|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material
61984470|NCT03784404|ACTIVE_COMPARATOR|Surgicel group|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material follwed by insertion of 3-4 pieces of small surgicel inside the cyst cavity
61984471|NCT02542631|EXPERIMENTAL|Bolus Insulin Patch (Calibra Finesse)|Use of the wearable patch to deliver meal-related bolus insulin dose
61984472|NCT02542631|ACTIVE_COMPARATOR|Insulin Pen (Novo-Nordisk FlexPen®)|Use of the pen device to deliver meal-related bolus insulin dose
61984473|NCT00058604|EXPERIMENTAL|Treatment|Each patient will receive a Biological/Vaccine Intravenous injection of EBV specific CTLs
62169373|NCT03037814|OTHER|Amalgam|Amalgam
62169374|NCT04287816|EXPERIMENTAL|Zero hard-boiled egg at 0 h|No eggs will be consumed on the test day. Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone prior to the 72-h pharmacokinetics trial.
61984474|NCT05031533|EXPERIMENTAL|Assigned Interventions|"Radiation therapy: Dose-painting radiation~Systemic treatment: Choose a systemic treatment plan according to the patient's genetic testing status~(1) Chemotherapy~1. Squamous cell carcinoma: Paclitaxel 135mg/m2 D1 + Cisplatin 25mg/m2 D1-3, every 21 days, a total of 2-4 cycles.~2. Non-squamous cell carcinoma (adenocarcinoma, large cell carcinoma): Pemetrexed 500mg/m2 d1 + Cisplatin 75 mg/m2 d1-3, a total of 2-4 cycles.~(2) Targeted therapy: According to the patient's genetic testing status, molecular targeted therapy such as EGFR-TKI and ALK inhibitors can be selected; (3) Immunotherapy: According to the patient's genetic testing status, immunotherapy such as PD1/PD-L1 inhibitors can be selected;"
61984475|NCT01988831|PLACEBO_COMPARATOR|Placebo|"113 patients will be enrolled in the placebo group with respect to randomization.~Placebo group will be prescribed placebo pills in the same packaging as propranolol treated group.~The frequency and duration of the treatment is the same as propranolol arm. The placebo group will have the same cardiology consultation as propranolol treated group to ensure the respect of blindness."
62169375|NCT04287816|EXPERIMENTAL|One hard-boiled egg at 0 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 1 hard-boiled egg prior to the 72-h pharmacokinetics trial.
62169376|NCT04287816|EXPERIMENTAL|Two hard-boiled eggs at 0 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 2 hard-boiled eggs prior to the 72-h pharmacokinetics trial.
62169377|NCT04287816|EXPERIMENTAL|Three hard-boiled eggs at 0 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 3 hard-boiled eggs prior to the 72-h pharmacokinetics trial.
62169378|NCT04287816|EXPERIMENTAL|One hard-boiled egg at 3 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone at 0 h prior to the 72-h pharmacokinetics trial followed by 1 hard-boiled egg 3 hours after spinach consumption.
62169379|NCT04287816|EXPERIMENTAL|One hard-boiled egg at 0 h + One hard-boiled egg at 3 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 1 hard-boiled egg at 0 h prior to the 72-h pharmacokinetics trial followed by 1 egg 3 hours after spinach consumption.
62169380|NCT06344494|EXPERIMENTAL|Experimental group|Subjects will undergo planned intracardiac interventional procedures utilizing the Arch EchoTM Intracardiac Ultrasound catheter and combined ultrasound system.
61984476|NCT01988831|EXPERIMENTAL|Betablocker|"drug: 'Propranolol hydrochloride' 338 patients will be enrolled in the Propranolol Group and treated with propranolol.~The dosage will be determined by the cardiologist as the maximum tolerated dose to a maximum of 160mg/day.~One long acting pill a day until an evidence of disease progression or the end of the study."
61984477|NCT00606476|ACTIVE_COMPARATOR|1|0.15 mg/kg active bapineuzumab
61984478|NCT00606476|ACTIVE_COMPARATOR|2|0.5 mg/kg active bapineuzumab
61984479|NCT00606476|ACTIVE_COMPARATOR|3|1.0 mg/kg active bapineuzmab
61984480|NCT06161220|EXPERIMENTAL|Carbidopa capsule|Dose: 4x 100 mg
61984481|NCT06161220|ACTIVE_COMPARATOR|Moxifloxacin Tablets, USP|Dose: 400 mg
61984482|NCT06161220|PLACEBO_COMPARATOR|Placebo|
61984483|NCT01581307|EXPERIMENTAL|2nd Line Chemotherapy With Radiotherapy|"Administration of 2nd line chemotherapy will consist of a modified FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin) will take place at least 2 weeks after the completion of first-line chemotherapy. Generally, second-line chemotherapy is given every two weeks for 6-10 cycles.~The goal of treatment with TheraSpheres is to allow a large dose of radiation to be delivered directly to the tumor(s) with less risk of toxic effects from radiation to other parts of the body or to healthy liver tissue."
61984484|NCT04923724|ACTIVE_COMPARATOR|Tourniquet during surgery|Patients in this group get a tourniquet during surgery.
61984485|NCT04923724|ACTIVE_COMPARATOR|No Tourniquet during surgery|Patients in this group do not get a tourniquet during surgery.
61984486|NCT05916729|ACTIVE_COMPARATOR|Healthy subjects with acrylate dentures and oral Candida spp infection-Miconazole group|"These group includes systematically healthy patients wearing acrylate dentures and with microbiologically confirmed oral infection caused with Candida spp.~These patients were treated with Miconazole gel."
61984487|NCT05916729|EXPERIMENTAL|Healthy subjects with acrylate dentures and oral Candida spp infection-Candberrol-Miconazole group|"These group includes systematically healthy patients wearing acrylate dentures and with microbiologically confirmed oral infection caused with Candida spp.~These patients were treated with Miconazole gel and Candberrol lozenges."
61984488|NCT05916729|ACTIVE_COMPARATOR|Diabetic subjects without dentures and with oral Candida spp infection - Miconazole group|"These group includes diabetes mellitus patients without acrylate dentures and with microbiologically confirmed oral infection caused with Candida spp.~These patients were treated with Miconazole gel."
61984489|NCT05916729|EXPERIMENTAL|Diabetic subjects without dentures and with oral Candida spp infection - Miconazole-Candberrol group|"These group includes diabetes mellitus patients without acrylate dentures and with microbiologically confirmed oral infection caused with Candida spp.~These patients were treated with Miconazole gel and Candberrol lozenges."
61984490|NCT05916729|ACTIVE_COMPARATOR|Diabetic subjects with acrylate dentures and oral Candida spp - Miconazole group|"These group includes diabetes mellitus patients with acrylate dentures and microbiologically confirmed oral infection caused with Candida spp.~These patients were treated with Miconazole gel."
61984491|NCT05916729|EXPERIMENTAL|Diabetic subjects with acrylate dentures and oral Candida spp - Miconazole and Candberrol group|"These group includes diabetes mellitus patients with acrylate dentures and microbiologically confirmed oral infection caused with Candida spp.~These patients were treated with Miconazole gel and Candberrol lozenges."
61984492|NCT00786487|EXPERIMENTAL|lipid trained|20% lipid infusion in trained subjects
61984493|NCT00786487|ACTIVE_COMPARATOR|glycerol trained|glycerol infusion into trained subjects
61984494|NCT00786487|EXPERIMENTAL|lipid untrained|lipid infusion into untrained subjects
61984495|NCT00786487|ACTIVE_COMPARATOR|glycerol untrained|glycerol infusion into untrained subjects
61984496|NCT06238232|EXPERIMENTAL|68Ga-Pentixafor PET/CT group|Patients divided into 68Ga-Pentixafor PET/CT group need to undergo 68Ga-Pentixafor PET/CT examination and guide subsequent treatment based on the results
61984497|NCT06238232|NO_INTERVENTION|AVS group|Patients divided into AVS group need to undergo AVS to guide subsequent treatment based on the results
61984498|NCT05363384|EXPERIMENTAL|CT-L01 25/1,000 mg FDC Tablet|Alogliptin Benzoate 25 mg/Metformin HCl XR 1,000 mg, FDC Tablet
61984499|NCT05363384|ACTIVE_COMPARATOR|Alogliptin Benzoate 25 mg, Metformin HCl XR 1,000 mg|"1. Alogliptin Benzoate 25 mg~2. Metformin HCl XR 1,000 mg"
61984500|NCT04577937|EXPERIMENTAL|PSG in LAM patients|Patients affected by LAM underwent whole-night PSG
61984501|NCT01718847|EXPERIMENTAL|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
61984502|NCT01330485|EXPERIMENTAL|Affect Regulation Training|Affect Regulation Training as described in Berking \& Whitley, 2014.
61984503|NCT01330485|ACTIVE_COMPARATOR|Common Factor Control Condition (CFC)|Common factor based therapy control condition
61984504|NCT01330485|NO_INTERVENTION|Waitlist Control Condition|Wait List Control
61984505|NCT04738344|EXPERIMENTAL|Percutaneous coronary intervention and stent implantation using one long stent|Long coronary lesions will be treated percutaneously with a single long stent (more than 40 mm in length) and intravascular ultrasonography (IVUS) will be done immediately after stent deployment to record the baseline picture
61984506|NCT04738344|EXPERIMENTAL|Percutaneous coronary intervention and stent implantation using more than one overlapping stents|Long coronary lesions will be treated with more than one overlapping stents and intravascular ultrasonography (IVUS) will be done immediately after stent deployment to record the baseline picture
61984507|NCT05990101|EXPERIMENTAL|APP group|Awake prone position (APP) for 4 or more hours per day in addition to standard care for the first 72 hours from randomisation. After the initial period, use of APP is at discretion of the treating clinician. Awake prone can be discontinued earlier if patients meets pre-specified criteria of sustained improvement.
61984508|NCT05990101|NO_INTERVENTION|Control group|Standard care excluding APP
61984509|NCT03816085|EXPERIMENTAL|Shoe with 4 cm heel|Shoes with 4 cm heel will be applied to women. Tests to measure balance, muscular endurance and function will be done while they wear this shoe.
61984510|NCT03816085|EXPERIMENTAL|Shoe with 10 cm heel|Shoes with 10 cm heel will be applied to women. Tests to measure balance, muscular endurance and function will be done while they wear this shoe.
61984511|NCT03816085|NO_INTERVENTION|Without shoes|Women will be included in the tests to measure balance, muscular endurance and function without shoes.
61984512|NCT01123109|OTHER|nulliparous females|nulliparous women over the age of 18
61984513|NCT02360592|ACTIVE_COMPARATOR|1, conventional control group|Entecavir 0.5 mg po daily for 72 weeks
61984514|NCT02360592|EXPERIMENTAL|2, combination and sequential group|Interferon alfa-2b 600wIU qod iH for 48 weeks plus Entecavir 0.5mg qd po for 8 weeks
61984515|NCT02360592|EXPERIMENTAL|3, multitarget group|Interferon alfa-2b 600wIU qod iH for 48 weeks plus Entecavir 0.5mg qd po for 8 weeks plus interleukin 2 25 wIU qod iH for 12 weeks plus Hepatitis B Vaccine 60ug qm im for 48 weeks
61984516|NCT00739037|PLACEBO_COMPARATOR|A|
61984517|NCT00739037|EXPERIMENTAL|B|
61984518|NCT05351242|EXPERIMENTAL|Thermotherapy/sauna bath|Must go to a sauna (min. Temperature 85℃) min. 4 times a week for 6 months. Each sauna bath must last at least 7 minutes. The intervention patients receive a subscription card for a sauna during the period. Patients will still receive pre-existing treatment
61984519|NCT05351242|NO_INTERVENTION|No thermotherapy/sauna bath|"Not allowed to go to a sauna for 6 months. Patients who come to do so, by e.g. an oversight, however, remain in the study, to avoid introducing bias. It will be registered as a protocol violation, but the patient will be included in Intention To Treat analysis and modified Intention To Treat analysis. Patients will still receive pre-existing treatment."
61984520|NCT05700981|EXPERIMENTAL|Colon capsule endoscopy|Patients randomized to colon capsule endoscopy
61984521|NCT05700981|NO_INTERVENTION|Colonoscopy|Patients randomized to colonoscopy
61984522|NCT04318990|EXPERIMENTAL|Distal radial artery access|Wrist rests on a comfortable underground which brings the wrist in passive ulnar flexion. Patient is asked to bring the thumb under the other four fingers. After disinfection, patient is covered with a sterile drape. Brachial drape is applied to the hand exposing the anatomical snuff box and the proximal radial. Under ultrasound guidance, local anesthesia applied by SC injection of 5cc of lidocaine filling the radial fossa. Puncture performed at the point of maximal pulsation proximal in the anatomical snuffbox. If fails, a puncture more distal, can be attempted. After successful anterior wall puncture a radial sheath wire is advanced. Proper position verified by fluoroscopy or by ultrasound to ensure the wire didn't traverse the palmar arch, followed by introduction of a hydrophilic sheath. After administration of a spasmolytic cocktail containing 200-400 mcg of nitroglycerin and 5 mg of verapamil, the operator can take up a position at the level of the patient's knees.
61984523|NCT04318990|ACTIVE_COMPARATOR|Proximal radial artery access|Half of the patients enrolled in the study undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized proximal radial access for cardiac catheterization.
61984524|NCT01578889|EXPERIMENTAL|Group 1: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine administered as 0.5 mL by intramuscular (IM) injection in both the left and right deltoids using the Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
61984525|NCT01578889|PLACEBO_COMPARATOR|Group 1: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.5 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
61984526|NCT01578889|EXPERIMENTAL|Group 2: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 250 mcg IL-12 pDNA adjuvant, and divided into two 0.55 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
61984527|NCT01578889|PLACEBO_COMPARATOR|Group 2: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.55 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
61984528|NCT01578889|EXPERIMENTAL|Group 3: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 1,000 mcg of the IL-12 pDNA adjuvant and divided into two 0.75 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
62169381|NCT06344494|ACTIVE_COMPARATOR|Control group|Subjects will undergo planned intracardiac interventional procedures utilizing the SOUNDSTAR 3D Diagnostic Ultrasound catheter and ACUSON P500 system.
61984529|NCT01578889|PLACEBO_COMPARATOR|Group 3: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.75 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
61984530|NCT01578889|EXPERIMENTAL|Group 4: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 1500 mcg of the IL-12 pDNA adjuvant divided into two 0.9 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
61984531|NCT01578889|PLACEBO_COMPARATOR|Group 4: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.9 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
61984532|NCT01413555|EXPERIMENTAL|Blood Culture QI Program|
61984533|NCT05221333|OTHER|Healthy participants|Up to 25ml of saline administered through OBI
61984534|NCT01822184||No treatment|Observational non-treatment study
61984535|NCT01010906|EXPERIMENTAL|Mild Hepatic Insufficiency (HI)|Participants with mild hepatic insufficiency (HI) administered a single 300 mg oral tablet of vaniprevir
61984536|NCT01010906|EXPERIMENTAL|Healthy Control to Mild HI|Healthy, matched to mild HI, control participants administered a single 300 mg oral tablet of vaniprevir
61984537|NCT01010906|EXPERIMENTAL|Moderate HI|Participants with moderate HI administered a single 300 mg oral tablet of vaniprevir
61984538|NCT01010906|EXPERIMENTAL|Healthy Control to Moderate HI|Healthy, matched to moderate HI, control participants administered a single 300 mg oral tablet of vaniprevir
62169382|NCT05804526|EXPERIMENTAL|RC88+Sintilimab Injection|RC88+Sintilimab Injection Arm
61984539|NCT01010906|EXPERIMENTAL|Severe HI|Participants with severe HI administered a single 200 mg oral tablet of vaniprevir
61984540|NCT01010906|EXPERIMENTAL|Healthy Control to Severe HI|Healthy, matched to severe HI, control participants administered a single 200 mg oral tablet of vaniprevir
61984541|NCT04404075||Group 1 patients|"1. Age 18 and above~2. Eczema Area and Severity Index (EASI) score ≥ 10~3. Investigator Global Assessment (IGA) ≥ 3"
61984542|NCT04404075||Group 2 patients|"1. Age 18 and above~2. Eczema Area and Severity Index (EASI) score ≥ 1 but \< 10~3. Investigator Global Assessment (IGA) 1 or 2"
61984543|NCT04404075||Group 3 patients|"1. Age 12 to 17~2. Eczema Area and Severity Index (EASI) score ≥ 10~3. Investigator Global Assessment (IGA) ≥ 3"
62169383|NCT04748445||All participants|
62169384|NCT05046301||Diagnostic (contrast-enhanced mammography)|Patients complete a questionnaire and undergo collection of a blood sample. Patients undergo CEM.
62169385|NCT01093690|EXPERIMENTAL|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg orally four times a day on day 2-5
62169386|NCT01093690|PLACEBO_COMPARATOR|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
62169387|NCT02367742|OTHER|Endurance Activity (EA)|The subjects have followed a program of endurance (aerobic) activity (EA).
62169388|NCT02367742|OTHER|EA + Resistance Training (RT)|The subjects have followed a program of endurance activity (EA) and resistance training (RT).
62169389|NCT06143488|EXPERIMENTAL|EVT group|In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice.
61984544|NCT04404075||Group 4 patients|"1. Age 12 to 17~2. Eczema Area and Severity Index (EASI) score ≥ 1 but \< 10~3. Investigator Global Assessment (IGA) 1 or 2"
61984545|NCT03593265|EXPERIMENTAL|Healthy group|healthy subjects MUNIX will be performed
61984546|NCT03961607|EXPERIMENTAL|Painless Photodynamic Therapy(P-PDT) group|The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying 5% 5-aminolevulinic acid#ALA#cream for 30min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
61984547|NCT03961607|ACTIVE_COMPARATOR|Conventional Photodynamic Therapy(C-PDT) group|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 50 J/cm2) after applying 5% 5-aminolevulinic acid cream for 1.5h.A repeat treatment was administered once weekly for a maximum of 3 weeks.
61984548|NCT01467947|EXPERIMENTAL|Berinert|
62169390|NCT06143488|ACTIVE_COMPARATOR|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
62169391|NCT01931683|EXPERIMENTAL|remifentanil|LMA removal was accomplished when remifentanil was maintained a predetermined concentration throughout the emergence periods.
62169392|NCT03579680|EXPERIMENTAL|ADT ORDER CHECK ATTESTATION (OR)|"Experimental: ADT ORDER CHECK ATTESTATION (OR) Order restrictions (Or) operate as an organizational constraint, widely perceived as a forcing function giving providers little leeway to exercise judgment but have a strong evidence-base for changing provider behavior. Study staff will place a health factor structured data element in the EMR of patients whose clinic visits study staff have confirmed to be targets for ADT de-implementation. This health factor combined with a low PSA level will trigger the ADT Order Check Attestation Intervention (Or) when the provider places an order for ADT."
62362788|NCT03964506|EXPERIMENTAL|Cohort 1- AML or MDS|Patients with will receive HBO therapy one time on day 0 of the transplant. The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber (Model 3200/3200R, Sechrist Industries, Inc., USA), breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes were spent during the compression and decompression phases and subjects had 10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.
62169393|NCT03579680|EXPERIMENTAL|PROVIDER SCRIPT (SC)|"Experimental: PROVIDER SCRIPT (SC) The provider script (Sc) is a communication aid to be used and documented as an accountable justification in the electronic medical record. This strategy also has a strong evidence-base for changing provider behavior. Study staff will enter a pre-populated CPRS EMR progress note 1 business day prior to a target clinic visit. The note includes talking points for the provider to help with a discussion. It can be edited and cosigned by the provider, giving a quick and simple way to document the discussion. The progress note template asks providers to indicate whether patient prefers to continue or discontinue low-value ADT. Appropriate documentation of the decision will be tracked for fidelity. We will also have a patient handout entitled: Living well with prostate cancer: Is hormone therapy still right for you? as a patient engagement and information resource."
62169394|NCT01012999|EXPERIMENTAL|Intranasal sufentanil, pain relief|Intranasal sufentanil administered at a dose of 0.5 mcg/kg times one dose at beginning of thirty minute period
62362789|NCT03964506|EXPERIMENTAL|Cohort 2- CMML, aCML, CML, CNL, MDS/MPN|Patients with will receive HBO therapy one time on day 0 of the transplant. The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber (Model 3200/3200R, Sechrist Industries, Inc., USA), breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes were spent during the compression and decompression phases and subjects had 10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.
62362790|NCT06118554|ACTIVE_COMPARATOR|Control group|The control group (CG) irrigated in the standard FDA consumer-recommended position, defined as leaning forward with a natural ear-to-shoulder head tilt.
61984549|NCT06320145|EXPERIMENTAL|Group A (Cryotherapy Group)|About 15 Women suffering from primary dysmenorrhoea who will receive cryotherapy sessions (3 days per week for 20 minutes), in addition to core stability exercise.
61984550|NCT06320145|EXPERIMENTAL|Group B (core stability Group)|About 15 Women suffering from primary dysmenorrhoea who will receive core stability exercises only
62169395|NCT04896502|EXPERIMENTAL|Telemedicine Arm|For the proposed study, participants will randomized to receive TM home assessments/interventions performed by a trained home visitor (HV) or standard of care asthma trigger education by the HV. Those who are randomized to TM home assessments/interventions will complete a baseline home assessment and two follow-up visits, 2 months apart. Visits will assess the presence of potential asthma triggers in the home and frequency of asthma symptoms/exacerbations. TM participants will be provided education and materials necessary to reduce asthma triggers in the home. Follow-up visits will assess the interval change in presence of asthma triggers, change in daily asthma symptoms/exacerbations, and participant/family retention of education.
62169396|NCT04896502|ACTIVE_COMPARATOR|Standard of Care Education|For subjects randomized to receive standard of care asthma education, written and verbal information will be provided regarding identification and removal of potential asthma triggers in the home but no formal assessment of the home will be performed, nor will participants in this arm receive trigger reduction materials.
61984551|NCT02083731|EXPERIMENTAL|MSCs|MSCs will be used to treat refractory CMV infection or CMV-associated diseases. MSCs will be intravenously infused at a dose of 1×10\^6 cells/kg. If anticipates do not attain the complete remission standards within 14d, a second course of the same treatment will be given.
61984552|NCT01721421|EXPERIMENTAL|Extended Treatment time|Extended treatment time of 6 hours
62169397|NCT00265096|EXPERIMENTAL|002|golimumab 50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
61984553|NCT01721421|ACTIVE_COMPARATOR|standard treatment time|Standard Treatment time of 4 hours
62169398|NCT00265096|EXPERIMENTAL|001|Placebo; golimumab SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
62362791|NCT06118554|EXPERIMENTAL|Backfill group|Backfill group (BG) subjects irrigated with a head tilt of 90 degrees ear-to-shoulder and used the nostril closest to the ground.
61984554|NCT01722240|ACTIVE_COMPARATOR|Liraglutide 1.8mg|Daily Injection
61984555|NCT01722240|PLACEBO_COMPARATOR|Placebo|Daily Injection
61984556|NCT03911414|EXPERIMENTAL|Omega-3 Fatty Acids + Inositol|Subjects will be treated with 1020mg QAM + 1020mg QPM of omega-3 fatty acids and inositol based on weight (subjects under 25kg: 1000mg QD; Subjects weighing 25kg or more: 2000mg QD).
61984557|NCT03911414|EXPERIMENTAL|N-acetylcysteine|Subjects will be treated with N-acetylcysteine capsules (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2400mg QD) or effervescent tablets (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2700mg QD) based on age .
61984558|NCT03533192|EXPERIMENTAL|Receipt of It's Your Game...Keep it Real|It's Your Game...Keep it Real is an HIV, STI, and teen pregnancy prevention program
61984559|NCT03533192|NO_INTERVENTION|Usual care|Students received their regular health education.
61984560|NCT04120974|EXPERIMENTAL|Optimal insulin injection|Study subjects will receive personal training from the Investigator on how to optimally inject insulin to treat their Diabetes Mellitus. In addition, each subject receives instruction how to use a web-based platform with online video training modules on optimal injection technique.
61984561|NCT01172847|ACTIVE_COMPARATOR|A|
61984562|NCT01172847|ACTIVE_COMPARATOR|B|
61984563|NCT01172847|EXPERIMENTAL|C|
61984564|NCT00574054|OTHER|1|
61984565|NCT00031889|ACTIVE_COMPARATOR|Arm I|Patients receive oral exemestane once daily
61984566|NCT00031889|ACTIVE_COMPARATOR|Arm II|Patients receive exemestane as in arm I and oral bicalutamide once daily
61984567|NCT00071760|EXPERIMENTAL|Arm A - 4weeks - less than 2 years old (FPV/RTV bid)|"Cohort 2A - 4weeks - less than 6 months old. Fosamprenavir (FPV) 50 mg/mL oral suspension/ritonavir (RTV) 80 mg/mL oral solution twice daily (BID)~Cohort 1A - 6 months - less than 2yrs old. Fosamprenavir (FPV) 50 mg/mL oral suspension/ritonavir (RTV) 80 mg/mL oral solution twice daily (BID)"
61984568|NCT00071760|EXPERIMENTAL|Arm B- 4weeks - less than 2 years old (FPV bid)|"Cohort 2B - 4weeks - less than 6 months old. Fosamprenavir (FPV) 50 mg/mL oral suspension twice daily (BID)~Cohort 1B - 6 months - less than 2yrs old. Fosamprenavir (FPV) 50 mg/mL oral suspension twice daily (BID)"
61984569|NCT04368286|EXPERIMENTAL|Rehabilitation group|To conduct a comprehensive pulmonary rehabilitation assessment and treatment
61984570|NCT04368286|NO_INTERVENTION|Conventional medical group|Conventional medical treatment
61984571|NCT01897012|EXPERIMENTAL|Treatment (alisertib, romidepsin)|Patients receive alisertib PO BID on days 1-7 (dose levels 1-4) or days 1-3, 8-10, and 15-17 (dose levels 5-8). Patients also receive romidepsin IV over 4 hours on days 1 and 8 (dose levels 1-4) or 2, 9, and 16 (dose levels 5-8). Treatment repeats every 21 days (dose levels 1-4) or 28 days (dose levels 5-8) for up to 8 courses in the absence of disease progression or unacceptable toxicity.
61984572|NCT02109120||carotid endarterectomy (CEA)|CEA patients with vein blood collection
61984573|NCT00951665|EXPERIMENTAL|Phase lb Regimen 1|Participants received trastuzumab emtansine (T-DM1) every three weeks (Q3W) + paclitaxel weekly (QW) intravenously.
61984574|NCT00951665|EXPERIMENTAL|Phase Ib Regimen 2|Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously.
61984575|NCT00951665|EXPERIMENTAL|Phase Ib Regimen 3|Participants received T-DM1 QW + paclitaxel QW intravenously.
61984576|NCT00951665|EXPERIMENTAL|Phase Ib Regimen 4|Participants received T-DM1 QW + paclitaxel QW + pertuzumab Q3W intravenously.
61984577|NCT00951665|EXPERIMENTAL|Phase IIa Group A|Participants received maximum tolerated dose (MTD) from Phase 1b i.e. T-DM1 3.6mg/kg Q3W + paclitaxel 80mg/m\^2 QW intravenously.
61984578|NCT00951665|EXPERIMENTAL|Phase IIa Group B|Participants received MTD from Phase 1b i.e. T-DM1 3.6mg/kg Q3W + paclitaxel 80mg/m\^2 QW + pertuzumab Q3W intravenously.
61984579|NCT00950547|ACTIVE_COMPARATOR|Control|Traditional Chest drains
61984580|NCT00950547|EXPERIMENTAL|CARDIOPAT|CARDIOPAT Cell Saver after Surgery
61984581|NCT01950533||Peanut allergic|Subjects allergic to peanuts by oral food challenge
61984582|NCT01950533||Milk allergic|Subjects allergic to milk by oral food challenge
61984583|NCT01950533||Egg allergic|Subjects allergic to egg by oral food challenge
61984584|NCT03890549||obstructive sleep apnea group|The patients were diagnosed by thoracic and ENT (Eye-Nose-Throat) specialist through polysomnography.
61984585|NCT01951339|EXPERIMENTAL|Sitagliptin plus placebo|100 mg sitagliptin plus 2 mg placebo once daily for three months
61984586|NCT01951339|ACTIVE_COMPARATOR|Glimepiride plus placebo|2 mg glimepiride plus 100 mg placebo once daily for three months
61984587|NCT05027412|EXPERIMENTAL|En Bloc TURBT with Collins Loop|"If the patient is randomized to the TURB group, it will be carried out with a Collins loop, with bipolar energy.~After randomization, demographic data (age, sex, exposure to tobacco, occupational risk), symptoms prior to randomization (micro or macrohematuria, LUTS) and laboratory data (urinary cytology, hemoglobin and serum creatinine) will be collected. Finally, the physical characteristics of the lesion will be noted in the cystoscopy immediately prior to the intervention: size, location (s) and appearance of the tumor. After the intervention, the type of procedure (TURB / TUB), the duration of the procedure from when the resector is inserted until the urinary catheter is placed, and complications according to the Clavien-Dindo scale will be recorded. In your first post-surgical check-up, the days of hospital stay and the time of bladder catheterization will be collected."
61984588|NCT05027412|ACTIVE_COMPARATOR|Conventional TURBT|The TURB will be carried out with bipolar current according to the traditional technique.
61984589|NCT04537000|NO_INTERVENTION|control group|The strategies of red blood cell transfusion for the pediatric patients in this group will be made by the attending doctors in charge based on the current transfusion guidelines. The attending doctors decide when to start blood red cell transfusion and order the volume of the blood red cell as the usual clinical practice.
61984590|NCT04537000|EXPERIMENTAL|study group|For study group, the clinical condition score must be identified every time red blood cell transfusion is considered. The strategies of red blood cell transfusion for the pediatric patients in this group, including the trigger and the volume, will be made based on the comparison between the clinical condition score and the Hb concentration.
61984591|NCT01351844|ACTIVE_COMPARATOR|Education and exercise intervention|"The intervention module will contain a brief series of slides with a voice-over. An occupational therapist will review recommended exercises."
61984592|NCT01351844|PLACEBO_COMPARATOR|Education and general exercise|"The control module will contain a brief series of slides with a voice-over. A physical therapist with experience in treating breast cancer patients will demonstrate a series of 4-5 general stretching and toning exercises."
61984593|NCT03239587||No Musical Intervention - Control Group|"Participants wait for 30 minutes in a standard pre-surgery waiting area without music.~Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.~Participants complete 2 questionnaires about anxiety and stress levels."
61984594|NCT03239587||Musical Intervention Group|"Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.~Blood drawn before, and about 30 minutes after participant in the waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.~Participants complete 2 questionnaires about anxiety and stress levels."
61984595|NCT01511523|ACTIVE_COMPARATOR|RGMA001|Proprietary blend of Vitamin E, Silymarin, and Carnitine.
61984596|NCT01511523|PLACEBO_COMPARATOR|Sugar Pill|No treatment.
61984597|NCT03997149|EXPERIMENTAL|Stress Condition|The stress condition involved the Trier Social Stress Test (TSST), a standardized laboratory stressor designed to elicit psychological stress and cortisol responses. Following the TSST, participants were brought to a separate room, instructed to rest and given the option to eat at their leisure. Books and magazines were included in the room for the participant to utilize.
61984598|NCT03997149|PLACEBO_COMPARATOR|Rest Condition|Participants completed a control condition on a separate day. This condition followed the same sequence of events as the stress condition with the exception that the 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
61984599|NCT01498718|EXPERIMENTAL|Group 1A (18-50 yrs): DNA vaccine + TIV|HA DNA Vaccine (VRC-FLUDNA061-00-VP) at Day 0 and licensed TIV at Week 36
61984600|NCT01498718|EXPERIMENTAL|Group 2A (51-70 yrs): DNA vaccine + TIV|HA DNA Vaccine (VRC-FLUDNA061-00-VP) at Day 0 and licensed TIV at Week 36
61984601|NCT01498718|PLACEBO_COMPARATOR|Group 1B (18-50 yrs): TIV only|Phosphate buffered saline (PBS) on Day 0 + TIV at Week 36
61984602|NCT01498718|PLACEBO_COMPARATOR|Group 2B (51-70 yrs): TIV only|Phosphate buffered saline (PBS) on Day 0 + TIV at Week 36
62169399|NCT00265096|EXPERIMENTAL|003|golimumab 100 mg sc injections every 4 wks from wk 0 up to 5 yrs
62169400|NCT02409121|EXPERIMENTAL|Open label|All participants will receive a tablet educational intervention (health IT platform) during the patient inpatient hospitalization for autologous or allogeneic transplant
62169401|NCT03777553|EXPERIMENTAL|VETNET|Narrative Exposure Therapy for Justice-Involved Veterans
62169402|NCT04568083||Ticagrelor cohort|Patients initiating ticagrelor 60 mg after an MI, with no prescription of ticagrelor 60 mg prior to their qualifying MI. The qualifying MI is defined as the most recent MI occurring before the first ticagrelor 60 mg prescription.
62169403|NCT04568083||Non-ticagrelor cohort|Patients not prescribed ticagrelor 60 mg at a comparable time point after an MI as matched patients in the ticagrelor cohort. Patients may be prescribed another P2Y12 inhibitor or aspirin alone.
62169404|NCT04739462|EXPERIMENTAL|Intervention|Participants in this arm will receive the study intervention.
62169405|NCT04739462|NO_INTERVENTION|Routine Antenatal Care|Participants in this arm will receive no intervention.
62169406|NCT05627583||Anorexia Nervosa (AN)|Anorexia Nervosa patients hospitalized for rehabilitation
62169407|NCT04036773|EXPERIMENTAL|Intervention Group|
62169408|NCT04036773|NO_INTERVENTION|Control Group|
62169409|NCT04991623|EXPERIMENTAL|Kinesiology taping|Apply a kinesiology taping on the abdominal muscles plus conventional physiotherapy
62169410|NCT04991623|ACTIVE_COMPARATOR|Physiotherapy Group|Apply a conventional physiotherapy
62169411|NCT00212862||Patients with chemotherapy induced anemia|
62169412|NCT03792893|EXPERIMENTAL|Higher Blood Pressure|BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure. Intervention: Ergometry H
62362792|NCT06118554|EXPERIMENTAL|Model group|Finally, the model group (MG) irrigated in an optimal position based on their 3D nasal replica. This patient-specific position was communicated to each MG patient with clear instructions during an in-person training session.
61984603|NCT04595513|EXPERIMENTAL|Stage 1 Open Label|Phase I/II, open-label PK and initial safety analysis. TAVT-18 administered orally twice/daily to achieve precision dosing target of 10 ng/ml. Whole blood sirolimus levels are assessed at defined intervals on days 1, 7, and 14. After day 14, participants can elect to continue open-label treatment with TAVT-18 until 12 months of age. Final developmental outcomes are assessed at 24 months of age.
61984604|NCT00196560|EXPERIMENTAL|exernal rotation|external rotation at 90 degrees
61984605|NCT05947682|OTHER|Adults who are planned to undergo plastic surgery|Adults who are planned to undergo plastic surgery for abdominal liposuction or lipoaspiration under general anaesthetic for their own care and who are voluntary for fat donation to contribute to the study
61984606|NCT05224674|ACTIVE_COMPARATOR|Large-Focused Extracorporeal Shock Wave Therapy|
61984607|NCT05224674|ACTIVE_COMPARATOR|Controlled-Unfocused Extracorporeal Shock Wave Therapy|
62362793|NCT00114218|EXPERIMENTAL|Treatment (gemcitabine hydrochloride, docetaxel)|Patients receive gemcitabine IV over 30 minutes followed by docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
61984608|NCT05224674|SHAM_COMPARATOR|Sham Extracorporeal Shock Wave Therapy|
61984609|NCT04532099|OTHER|LID018869, then AOHP (Part A)|Lehfilcon A contact lenses worn first, followed by senofilcon A contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) for approximately 30 days, with a scheduled visit at approximately Day 15 of each wear period. Lenses will be removed nightly for cleaning and disinfection with CLEAR CARE contact lens solution.
61984610|NCT04532099|OTHER|AOHP, then LID018869 (Part A)|Senofilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) for approximately 30 days, with a scheduled visit at approximately Day 15 of each wear period. Lenses will be removed nightly for cleaning and disinfection with CLEAR CARE contact lens solution.
61984611|NCT04532099|ACTIVE_COMPARATOR|Biofinity (Part B)|Comfilcon A contact lenses worn bilaterally (in both eyes) for approximately 30 days, with a scheduled visit at approximately Day 15 of the wear period. Lenses will be removed nightly for cleaning and disinfection with CLEAR CARE contact lens solution.
61984612|NCT03309358|EXPERIMENTAL|Inhaled SNSP113|
61984613|NCT03309358|PLACEBO_COMPARATOR|Inhaled Placebo|
61984614|NCT04244188||Patients treated for aortic arch aneurysms|Patients treated for aortic arch aneurysms by double branched endovascular repair (Bolton Medical) will be included.
61984615|NCT01591876|SHAM_COMPARATOR|Progressive muscle relaxation|As well as usual care participants in the control arm will receive instruction in progressive muscle relaxation.
61984616|NCT01591876|ACTIVE_COMPARATOR|Aerobic exercise|Intervention -moderate intensity aerobic exercise.
62169413|NCT03792893|EXPERIMENTAL|Lower Blood Pressure|BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure. Intervention: Ergometry L
62169414|NCT04778683|EXPERIMENTAL|VR Group|The investigator explained the use of VR glasses to the children in the VR group. The investigator selected two VR programs to be watched by the children. In the VR program named Amazon, the child perceives himself to be walking among the trees in the Amazon forests. The other VR program gives the child a feeling of water skiing.
61984617|NCT05095987|EXPERIMENTAL|One day discharge after laparoscopic Appendectomy|
61984618|NCT05447351||Treated|Counselling, personalized dietary strategy aimed at increasing the adherence to Mediterranean diet, personalized physical activity program with a personal trainer, use of digital tools (i.e., games, apps) aimed at improving the adherence to dietary/lifestyle indications.
61984619|NCT05447351||Control|generic dietary indications oriented to weight reduction; generic invitations to increase physical activity, routine monitoring
61984620|NCT05880810|EXPERIMENTAL|Continuous Glucose Monitoring|Subjects admitted to the Advanced Care at Home program (home hospital) will have the continuous glucose monitor sensor placed for up to 10 days to monitor and dose insulin.
61984621|NCT05880810|NO_INTERVENTION|Control Arm (Standard of Care)|Subjects admitted to the Advanced Care at Home program (home hospital) will continue with standard of care glucose monitoring (capillary glucose levels checked via glucometer), insulin dosing, and DM treatment during the 10 day period.
61984622|NCT03879655|EXPERIMENTAL|VTS-270|Eligible participants who transition into this study will receive treatment with VTS-270 at the last dose level administered in Study VTS301, administered IT via LP infusion every 2 weeks, for up to a total duration of 3 years or until the investigator considers VTS-270 to be no longer beneficial to the participant, VTS-270 receives marketing authorization, or the VTS-270 development program is discontinued.
61984623|NCT02007564|EXPERIMENTAL|LIFE Intervention|RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
62169415|NCT04778683|NO_INTERVENTION|Control Group|The same evaluations were performed in children in the control group who received routine clinical care.
62169416|NCT01439997|EXPERIMENTAL|Desmopressin Melt Therapy in Nocturnal Polyuria Patients|
62169417|NCT04990973|EXPERIMENTAL|Mediterranean Diet and then AAD|Healthy participants that are randomized to the MedDiet followed by a 4-week washout and a crossover to the AAD.
62169418|NCT04990973|EXPERIMENTAL|Average American Diet (AAD) and then Mediterranean Diet|Healthy participants that are randomized to AAD followed by a 4-week washout and a crossover to the Mediterranean Diet.
62169419|NCT01996397|OTHER|CRT implantation|Standard CRT indication. Assessment of acute response to CRT.
62362794|NCT04570969|NO_INTERVENTION|standard of care|Peri-operative analgesia by opioids
62362795|NCT04570969|EXPERIMENTAL|Peri operative regional analgesia|Peri-operative analgesia by Continuous bilateral Erector Spinae Catheters
62362796|NCT05635370||Pentoxifylline|Exposure group
62362797|NCT05635370||Cilostazol|Reference group
61984624|NCT02007564|NO_INTERVENTION|Supportive Telephone Contact Control|Patients and caregivers each received three separate, structured emotional support telephone calls with research staff (M duration = 13 minutes; SD = 6.5 minutes) to minimize differential drop-out with the RSV intervention group. Control callers asked questions of participants and then engaged in supportive conversations using empathic listening and reflection. Topics discussed included family, intergenerational ties, and important aspects of the patient's life, but structured reminiscence and the creative and therapeutic nature of legacy activities were not discussed.
61984625|NCT03388294|EXPERIMENTAL|PC followed by SR|Parents will be coached for 6 weekly sessions in the Parents and Infants Engaged (PIE) intervention pre-linguistic (PC) domain to identify their child's pre-linguistic communication bids during daily routines and respond to those bids in ways that optimize parent-child engagement. After posttest 1, they will be coached for 6 weekly sessions on sensory reactivity bids.
61984626|NCT03388294|EXPERIMENTAL|SR followed by PC|Parents will be coached for 6 weekly sessions in the Parents and Infants Engaged (PIE) intervention sensory reactions (SR) domain to identify their child's sensory reactions to daily activities and respond to those reactions or modify the environment in ways that optimize parent-child engagement. After posttest 1, they will be coached for 6 weekly sessions on pre-linguistic communication bids.
61984627|NCT02914652|EXPERIMENTAL|Operated VSD's|Through the use of Electronic Patient Journal (EPJ), the investigators have identified a total of 182 children who underwent surgical closure of a congenital VSD at Aarhus University Hospital, Denmark between 1990 and 1995. After thorough review of all charts, 117 patients were excluded from participation. Exclusion criteria were coexistence of other congenital heart defects (n=89), associated syndromes, e.g. Down's (n=14), operation through a ventricular approach (n=7), missing chart (n=6) and documented arrhythmia requiring pacemaker (n=1). The remaining 68 patients represent a homogeneous group comparing surgeons, anaesthetists, surgical procedure and post-surgical period. A fraction of this group will be randomly selected for this trial, and receives salbutamol or norflouran, blinded.
61984628|NCT02914652|EXPERIMENTAL|Un-operated VSD's|Using EPJ, this project identified a total of 481 children born between 1985 and 1998 who had a small VSD, confirmed through diagnosis codes, that was not closed, neither spontaneously nor surgically. Exclusion criteria were lack of medical record, suffering from coronary disease, other congenital cardiac abnormalities than VSD, spontaneous closure of the ventricular septal defect at inclusion date, magnetic implants, pregnancy, lack of Danish language skills, suffering from lung disease requiring continuous medical treatment. The remaining patients represent a homogenous group of patients with isolated persistent ventricular septal defects. A fraction of this group will be randomly selected for this trial, and receives salbutamol or norflouran, blinded.
61984629|NCT02914652|EXPERIMENTAL|Healthy controls|Will function as a control group. Controls will be recruited through www.forsoegsperson.dk and www.sundhed.dk. Current group receives salbutamol or norflouran, blinded.
61984630|NCT06018714|EXPERIMENTAL|Fruquintinib group|"Patients will receive Fruquintinib maintenance treatment for six months, or until tumor recurrence, metastasis, or intolerable drug toxicities occur within six months.~After achieving no evidence of disease (NED), a chest, abdomen, and pelvic CT scan with contrast or a chest CT scan with abdominal and pelvic MRI scan will be performed every 6 months within 2 years. Colonoscopy will be performed annually. CEA, CA19-9, and abdominal and pelvic ultrasound will be performed every 3 months. If abnormalities are found, further imaging studies and colonoscopy will be conducted, and if necessary, a PET/CT scan will be performed."
61984631|NCT02424383|EXPERIMENTAL|PTA (Lutonix® 035 DCB Catheter)|Treatment with the Lutonix 035 DCB will be per the investigational site's standard of care and adhering to the IFU.
61984632|NCT01216579|PLACEBO_COMPARATOR|Reference arm|Asthmatic patients managed as per British Thoracic Society guidelines by symptoms and lung function.
61984633|NCT01216579|ACTIVE_COMPARATOR|Mannitol managed arm|Group of asthmatic patients managed according to their mannitol challenge.
61984634|NCT03054870|OTHER|Xe-133 Followed by Technegas|Subjects first inhaled active comparator Xe-133, approximately 10 to 30 millicuries (mCi), and ventilation planar scintigraphy was performed per site standard of care procedures for subject medical need. On the same day, following completion of Xe-133 imaging, subjects inhaled experimental Technegas (Technetium-99m labeled carbon particles), approximately 1.1 mCi, and ventilation planar scintigraphy was performed.
61984635|NCT04002596|EXPERIMENTAL|ExAblate MRgFUS treatment|Ablation of Thalamus Vim nucleus with ExAblate 4000 Neuro MRgFUS for TDPD
61984636|NCT00101907|EXPERIMENTAL|Panitumumab + Gem/Cis|Panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.
62169420|NCT01234675|EXPERIMENTAL|milnacipran|Drug: milnacipran 7-day dose escalation, 28- day treatment with milnacipran 50 mg and 7-day taper period before or after crossover to placebo
62169421|NCT01234675|PLACEBO_COMPARATOR|placebo|Drug: placebo 45-day placebo treatment before or after crossover to milnacipran
62362798|NCT06145204||single-group|"Adult patients suffering from lymphoedema of one or both lower limbs, capable of expressing their wishes and cared for their pathology at the Godinne Lymphoedema Reference Center.~There is no intervention (observational study). Questionnaires will be given at the beginning (Day 0) and the end (Day 4) of the cure : Lymph-iCf-LL, OMSPQ, BPI-sf, DN4."
62362799|NCT00712933|EXPERIMENTAL|1|1 mg/kg dose of belimumab given IV every 28 days.
62169422|NCT02659384|EXPERIMENTAL|Bevacizumab|Bevacizumab monotherapy treatment in arm 1 will be discontinued upon RECIST documented progression or upon treatment withdrawal, whichever occurs first. Patients will cross-over to the combination of bevacizumab and atezolizumab upon progression as long as they meet cross-over criteria.
62362800|NCT00712933|EXPERIMENTAL|2.|10 mg/kg dose of belimumab given IV every 28 days.
62362801|NCT02951455|EXPERIMENTAL|CD-LC|Group behavioral intervention with 9 weekly sessions lasting 2 hours. Critical Dialogue (CD), Licensed Clinician (LC).
62362802|NCT02951455|EXPERIMENTAL|CBP- LC|Group community mobilizing intervention with 9 weekly sessions spread in 15 weeks. Capacity Building Project (CBP), Licensed Clinician (LC)
62362803|NCT02951455|EXPERIMENTAL|QLW- LC|Group intervention where participants learn to develop and implement personal goals that are measurable, attainable, realistic, and time bound. Intervention includes 9 sessions. Quality of Life Wheel, Licensed Clinician (LC)
62362804|NCT02951455|EXPERIMENTAL|CD & CBP- LC|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
62169423|NCT02659384|EXPERIMENTAL|atezolizumab + bevacizumab + placebo|The randomized treatment regimen (atezolizumab + bevacizumab + placebo) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients then go off protocol treatment and further treatment is left to the investigator's decision.
62362805|NCT02951455|EXPERIMENTAL|CD & QLW- LC|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
61984637|NCT00101907|EXPERIMENTAL|50 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 50 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.
61984638|NCT00101907|EXPERIMENTAL|75 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 75 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.
61984639|NCT00101907|EXPERIMENTAL|100 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 100 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.
61984640|NCT00101907|EXPERIMENTAL|125 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 125 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.
61984641|NCT00101907|EXPERIMENTAL|75 mg BID AMG 706 + panitumumab + Gem/Cis|AMG 706 75 mg administered orally twice daily (BID) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.
61984642|NCT02981342|EXPERIMENTAL|Abemaciclib|Abemaciclib given orally.
61984643|NCT02981342|EXPERIMENTAL|Abemaciclib + LY3023414|Abemaciclib given orally and LY3023414 given orally.
61984644|NCT02981342|EXPERIMENTAL|Standard of Care (Gemcitabine or Capecitabine)|Gemcitabine given intravenously (IV) OR capecitabine given orally.
61984645|NCT04418986|SHAM_COMPARATOR|Control (CCI Group)|The Participants will undergo phacoemulsification with on-axis incision
61984646|NCT04418986|ACTIVE_COMPARATOR|Study (OCCI Group)|The Participants will undergo phacoemulsification with opposite clear corneal incisions
61984647|NCT01982851|ACTIVE_COMPARATOR|Group E|Epidural de novo technique
61984648|NCT01982851|ACTIVE_COMPARATOR|Group BF|Combined spinal epidural (CSE) technique with intrathecal 0.5% Bupivicaine 2.5mg + Fentanyl 15mcg
61984649|NCT01982851|ACTIVE_COMPARATOR|Group F|Combined spinal epidural (CSE) technique with intrathecal fentanyl 25mcg
61984650|NCT03816059||Hospitalized - ACS|Hospitalized patients with acute coronary syndrome
61984651|NCT03816059||Hospitalized - stroke|Hospitalized patients with stroke
61984652|NCT03816059||Hospitalized - chronic lung disease|Hospitalized patients with exacerbation of chronic lung disease
61984653|NCT03816059||Outpatient|Outpatients
61984654|NCT05584644||Palbociclib plus hormonal treatment - first line treatment|Patients who initiated Palbociclib + hormonal therapy in the first line treatment
61984655|NCT05584644||Palbociclib plus hormonal treatment - second line treatment|Patients who initiated palbociclib plus hormonal treatment in the second line treatment
61984656|NCT03348345|EXPERIMENTAL|Eat Breathe Thrive Intervention|A manualized program designed to prevent eating disorders using psychoeducation, group work, and yoga.
61984657|NCT03348345|NO_INTERVENTION|Wait-List|Participants are placed on a wait-list receiving no intervention.
61984658|NCT03255382|EXPERIMENTAL|Risankizumab|Participants randomized to receive open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 4, and 16.
61984659|NCT03255382|ACTIVE_COMPARATOR|Fumaderm|Participants randomized to receive open-label Fumaderm 30 mg administered as a tablet orally once daily from Week 0 to Week 2 and then up to 240 mg, 3 times daily from Week 3 to Week 24 if 90% Improvement in Psoriasis Area and Severity Index (PASI90) is not achieved and if tolerability allows.
61984660|NCT04135833|EXPERIMENTAL|Itraconazole and BPI-7711|BPI-7711 alone followed by BPI-7711 +Itraconazole, followed by Itraconazole alone.
61984661|NCT04135833|EXPERIMENTAL|Rifampicin and BPI-7711|BPI-7711 alone followed by BPI-7711 +Rifampicin, followed by Rifampicin alone.
61984662|NCT03169582|ACTIVE_COMPARATOR|Avanafil|Clinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil).
61984663|NCT03169582|ACTIVE_COMPARATOR|Sildenafil|Clinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil)
61984664|NCT01062282||Group 1|
61984665|NCT02451228||Single-group|Observational opportunistic pharmacokinetic study of 300 pregnant women receiving Indomethacin therapy as standard of care for risk of preterm birth. Receive serial blood collection from IV.
61984666|NCT02245841|EXPERIMENTAL|H.P Acthar Gel|80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
61984667|NCT00484939|EXPERIMENTAL|Bevacizumab + capecitabine|Participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3-week treatment cycle. In addition, participants received capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 3-week treatment cycle.
61984668|NCT00484939|ACTIVE_COMPARATOR|Capecitabine|Participants received capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 3-week treatment cycle.
61984669|NCT03670303|EXPERIMENTAL|Intervention group|This group will include randomly selected two boys and two girls schools. Vision screening and refraction will be carried out at base line.Compliance will be assessed at 6 months follow-up after baseline assessment than educational intervention will be given. Six months after intervention compliance will be assessed again.
61984670|NCT03670303|NO_INTERVENTION|Control group|This group will also include randomly selected two boys and two girls schools. Vision screening and refraction will be carried out at base line.Compliance towards spectacle use will be assessed at 6 months after baseline assessment. No intervention will be given in this group. Compliance will be assessed again at the same time when assessed in intervention group 6 months after the intervention.
61984671|NCT03678532|EXPERIMENTAL|Daily interruption of sedation (control group)|Control group received daily interruption of sedation. After intubation, patients received IV infusion of midazolam. 1-2 mg / hour with increments 1-2 mg/hr gradually increasing dose till RASS reached -4 or -5. Infusion stopped at 7:00 AM. If the patient is awake no need for resuming infusion. If signs of discomfort occurred, infusion resumed at half of the prior dose, targeting conscious sedation (RASS 0: -3)
61984672|NCT03678532|EXPERIMENTAL|No sedation|Intervention group were managed by no-sedation strategy. Patients received bolus doses of midazolam (1-5 mg) only when needed, after atrial to control agitation by correcting the underlying cause. If the patient needed more than 3 bolus doses , IV infusion of midazolam was given by the daily interruption protocol as in the control group. No crossover was allowed between groups. Analysis was done by intension-to-treat principle.
61984673|NCT05783687||A - Newly diagnosed|Newly diagnosed (DPA/Trientine/Zinc for \< 28 days)
61984674|NCT05783687||B - D-penicillamine|D-penicillamine
61984675|NCT05783687||C - Zinc|Zinc
61984676|NCT05783687||D - Trientine (2HCl or 4HCl)|Trientine (2HCl or 4HCl)
61984677|NCT05755009|EXPERIMENTAL|High- and Low-dose radiotherapy combined with immunotherapy|High- and Low-dose radiotherapy combined with immunotherapy and maintain immunotherapy. Immunotherapy (Envafolimab) once every week (maintain total two years). Continuous high-(8Gy×5F) and low-dose (1.33Gy×5F) Radiotherapy starts at the second week after immunotherapy.
61984678|NCT01265849|EXPERIMENTAL|LI + CIZ + SOC|LI plus CIZ (cyclophosphamide, indomethacin and zinc-multivitamins) was given as neoadjuvant therapy prior to standard of care (SOC).
61984679|NCT01265849|ACTIVE_COMPARATOR|Standard of Care (SOC) only|SOC for previously untreated SCCHN patients is currently surgery (with curative intent) followed by either radiotherapy or combined radiochemotherapy depending on the patient's risk status for recurrence as determined at surgery.
61984680|NCT01265849|EXPERIMENTAL|LI + SOC|LI was administered without CIZ to determine the contribution of CIZ to the effects of LI.
61984681|NCT03081507|EXPERIMENTAL|LHW-led small media intervention arm (SM-LHW)|
61984682|NCT03081507|EXPERIMENTAL|LHW-led plus small media intervention arm (PN-LHW)|
61984683|NCT01978665|PLACEBO_COMPARATOR|prednisone and Solumedrol|placebo arm versus prednisone
61984684|NCT01978665|PLACEBO_COMPARATOR|solumedrol|placebo versus solu medrol
61984685|NCT01978665|OTHER|placebo|measurement of fitness
61984686|NCT05302154|ACTIVE_COMPARATOR|Standard treatment group|Dental treatment is carried out with tell-show-do technique as a behavioural guidance technique.
61984687|NCT05302154|EXPERIMENTAL|Cartoon movie- passive distraction group|Dental treatment is carried out with showing cartoon movie as a passive distraction during the treatment.
61984688|NCT05302154|EXPERIMENTAL|VR-active distraction group|The active distraction group is treated while wearing the VR headset and interacting with the designed application.
61984689|NCT02921776|EXPERIMENTAL|Aim 1- VidaTalk post-extubation|"Aim 1 is a two group iterative design preliminary to clinical trial. Group 1 and Group 2 will each consist of five previously mechanically ventilated patients who will be recruited from the ICUs at the OSUWMC (Ohio State University Wexner Medical Center), including discharged patients.~Group 1 will use an initial android prototype of VidaTalk tablet application to be assessed for functionality (ergonomics, ease of use, ease of learning, simplicity, effectiveness and user interface) and usability on customizable communication, picture symbols, and integration with mobile communication devices.~Group 2 will use an improved alpha prototype of VidaTalk tablet application version engineered from observations made during Group 1 sessions."
61984690|NCT02921776|EXPERIMENTAL|Aim 2 - VidaTalk intubated|"Usability testing preliminary to Clinical Trial (Aim 3). Mechanically Ventilated patients will provide feedback on acceptability, will perform test messages with minimal errors, and will rate VidaTalk an overall average score of 4.5 or higher (Likert-type scale; 1 to 7) on usability questions. Prior to implementing these procedures, the company will perform further iterative design assessments and engineer a Vidatalk tablet application prototype. This prototype will be used with a final group of ten (10) intubated patients receiving mechanical ventilation support to field-test the prototype for functionality (human-device interaction factors, feasibility, and usability) and acceptability.~Intervention is usability tasks with the VidaTalk app"
61984691|NCT02921776|EXPERIMENTAL|Aim 3 - VidaTalk tablet app|"Test the clinical efficacy of VidaTalk with MV patients by examining qualitative and quantitative endpoints in a clinical setting. 35 intubated patients (oral endotracheal tube or tracheostomy) will be randomized to the intervention arm and will receive a protocolized instruction in the use of the VidaTalk application including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.~Intervention will be receipt of VidaTalk tablet application."
61984692|NCT02921776|OTHER|Aim 3 - attention-control|"35 intubated patients (oral endotracheal tube or tracheostomy) will receive the standard of care, which may include primarily writing tools (paper and pen) and, occasionally, picture or alphabet communication charts.~Patients randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk application, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.~Interventions will be Aim 3 - attention-control with non-VidaTalk tablet."
61984693|NCT02921776|NO_INTERVENTION|Aim 5-VidaTalk Efficacy in Family caregivers|"Aim 5 will test the preliminary efficacy of VidaTalk compared to attention control (AC) on anxiety and depression symptoms in family caregivers during the ICU stay and post-discharge (1-mos; 3-mos; 6-mos) and PTSD-related symptoms post-discharge both qualitatively and quantitatively.~Aim 5.a.) Psychological outcomes (anxiety, depression, and PTSD-related symptoms) between the two groups will be compared at each time point and across time. Aim 5.b.) Family caregivers' perceived communication difficulty will be measured .Aim 5.c.) Family caregivers' experience of communication while they were visiting the patient who received the VidaTalk app in the ICU and their emotional reactions to communication with a patient will be measured."
61984694|NCT00555750|EXPERIMENTAL|eszopiclone (3mg)|active medication (eszopiclone 3mg tablet) by mouth nightly 30 min before bed
61984695|NCT00555750|PLACEBO_COMPARATOR|placebo|identical placebo tablet by mouth nightly 30 min before bed
61984696|NCT02838056|EXPERIMENTAL|epidural injection|epidural injection of 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
62169424|NCT02659384|EXPERIMENTAL|atezolizumab + bevacizumab + acetylsalicylic acid|The randomized treatment regimen (atezolizumab + bevacizumab + acetylsalicylic acid) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients then go off protocol treatment and further treatment is left to the investigator's decision.
61984697|NCT06258876||Patients with an indication for PrEP|"- Any patient presenting to a general medicine consultation for initial PrEP prescription or having previously received a hospital-initiated PrEP prescription, in a CEGGID (Centres gratuits d'information, de dépistage et de diagnostic), in a sexual health center, and not having had a PrEP prescription renewal for at least 4 months.~OR~- Any patient seen in a general medicine consultation with an indication for PrEP."
61984698|NCT02335164|EXPERIMENTAL|HA 45ug|recombinant influenza hemagglutinin (H5) 45ug, i.m. injection, 2 doses
61984699|NCT02335164|EXPERIMENTAL|HA 45ug+Advax1|recombinant influenza hemagglutinin(H5) 45ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
61984700|NCT02335164|EXPERIMENTAL|HA 45ug+Advax2|recombinant influenza hemagglutinin (H5) 45ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
61984701|NCT02335164|EXPERIMENTAL|HA 15ug+Advax1|recombinant influenza hemagglutinin (H5) 15ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
61984702|NCT02335164|EXPERIMENTAL|HA 15ug+Advax2|recombinant influenza hemagglutinin (H5) 15ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
61984703|NCT02335164|EXPERIMENTAL|HA 5ug+Advax1|recombinant influenza hemagglutinin (H5) 5ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
62169425|NCT01994135|ACTIVE_COMPARATOR|Reference food|The reference food is white bread
62169426|NCT01994135|EXPERIMENTAL|Test food dose 1|Test food dose 1 response will be compared to reference test food
62169427|NCT01994135|EXPERIMENTAL|Test food dose 2|Test food dose 2 response will be compared to reference test food as well as to test food dose 1
61984704|NCT02335164|EXPERIMENTAL|HA 5ug+Advax2|recombinant influenza hemagglutinin (H5) 5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
61984705|NCT02335164|EXPERIMENTAL|HA 2.5ug+Advax2|recombinant influenza hemagglutinin (H5) 2.5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
61984706|NCT02335164|EXPERIMENTAL|HA 15ug|recombinant influenza hemagglutinin (H5) 15ug, i.m. injection, 2 doses
61984707|NCT04780854|ACTIVE_COMPARATOR|Metformin group|1 gm metformin tablet administered twice daily for 3 months
61984708|NCT04780854|PLACEBO_COMPARATOR|Metformin-free|1 placebo tablet administered twice daily for 3 months
61984709|NCT03191760|EXPERIMENTAL|Behavioral Activation and Social Engagement|Participants will attend 6 in-person or phone-mediated therapy sessions lasting approximately 45 minutes per session, held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills. We have modified the standard Behavioral Activation intervention by reducing the number and length of sessions to accommodate the Primary Care setting. In addition, there will be a stronger emphasis on social engagement in BASE then in standard BA and social contact and support will be addressed during each treatment session.
61984710|NCT06482021|EXPERIMENTAL|Study group (A) Low-intensity shock wave group|Study group A will receive low-intensity extracorporeal shock wave therapy Li-ESWT (3 Hz, 0.09 mJ/mm2, 300 pulses), for two sessions per week for six weeks. Nitric oxide level and the electrophysiology (EMG) of peripheral nerves and muscles were measured pre and post-treatment.
61984711|NCT06482021|EXPERIMENTAL|Study group (B) Acetylcholine iontophoresis group|Study group (B) will receive iontophoresis by acetylcholine current intensity of 3 to 5 mA. Check skin every 3-5 minutes for signs of skin irritation with (15) min for three sessions per week for six weeks. Nitric oxide level and the electrophysiology (EMG) of peripheral nerves and muscles were measured pre and post-treatment.
61984712|NCT04508192|EXPERIMENTAL|Copenhagen Adduction|The CA is a high-intensity partner exercise where the player is lying on their side using the elbow of the lower forearm to support their body and the other arm placed along their body. The upper arm is supported by the partner who places their one hand under the knee and the other under the ankle, holding the leg approximately in the height of their hip. The player performs a 3-second concentric movement lifting their body until it reaches a straight line. At the same time, the other leg is adducted so that it touches the other leg. A 3-second eccentric adduction then follows with the body lowered halfway to the ground and the foot of the lower leg touching the ground without supporting the body.
61984713|NCT04508192|ACTIVE_COMPARATOR|Adductor Squeeze|The SQ exercise is an isometric hip adduction exercise with the player holding a ball between their knees. The player lies supine with the ball placed between the knees with the knees and hips flexed and the feet flat on the surface with the first toe is pointed straight forward.the player is asked to press against the ball as hard as they can The contraction is held for 10 seconds
62169428|NCT00764010|NO_INTERVENTION|1|No dietary counseling, placebo capsules for omega-3
61984714|NCT01838031|NO_INTERVENTION|the control group|The serum will be stored and the measurements will be obtained after the delivery
61984715|NCT01838031|ACTIVE_COMPARATOR|the thyroid screening group|The thyroid function and antibody will be measured during pregnancy. The subclinical hypothyroidism will be treated individually.
61984716|NCT02385084|EXPERIMENTAL|Part A: LY2409021 Capsule|Single oral dose of LY2409021 capsule in one of three study periods.
61984717|NCT02385084|EXPERIMENTAL|Part A: LY2409021 Tablet Pre-commercial|Single oral dose of LY2409021 tablet (pre-commercial formulation) in one of three study periods.
61984718|NCT02385084|EXPERIMENTAL|Part A: LY2409021 Tablet Commercial|Single oral dose of LY2409021 tablet (commercial formulation) in one of three study periods.
61984719|NCT02385084|EXPERIMENTAL|Part B: LY2409021 Capsule|Single oral dose of LY2409021 capsule in one of two study periods.
61984720|NCT02385084|EXPERIMENTAL|Part B: LY2409021 Tablet Commercial|Single oral dose of LY2409021 tablet (commercial formulation) in one of two study periods.
61984721|NCT00150839|ACTIVE_COMPARATOR|1|Probands receive mirtazapine and venlafaxine
61984722|NCT00150839|PLACEBO_COMPARATOR|2|Patients receive mirtazapine and placebo
61984723|NCT02411292|EXPERIMENTAL|Enoxaparin metabolism|Eligible patients will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
62169429|NCT00764010|ACTIVE_COMPARATOR|2|Dietary counseling, placebo capsules for omega-3
62169430|NCT00764010|ACTIVE_COMPARATOR|3|No dietary counseling, omega-3 capsules
61984724|NCT00507442|EXPERIMENTAL|VDR|VELCADE (bortezomib), dexamethasone, and Revlimid (lenalidomide)
61984725|NCT00507442|EXPERIMENTAL|VDCR|VELCADE (bortezomib), dexamethasone, cyclophosphamide, Revlimid (lenalidomide)
61984726|NCT00507442|EXPERIMENTAL|VDC|VELCADE (bortezomib), dexamethasone, cyclophosphamide
61984727|NCT00507442|EXPERIMENTAL|VDC-mod|Modified dosing of VELCADE (bortezomib), dexamethasone, cyclophosphamide
61984728|NCT04576611|EXPERIMENTAL|face-to-face|A 4-week intervention (8 sessions) will be carried out in a group of patients with non-specific chronic low back pain using face-to-face modality guided by a health professional.
61984729|NCT04576611|EXPERIMENTAL|self-managed|A 4-week intervention (8 sessions) will be carried out in a group of patients with non-specific chronic low back pain using self-managed modality through BackFit App.
61984730|NCT06397703|EXPERIMENTAL|ADT with SBRT|The ADT patients will be treated with monthly Degarelix, or Leuprolide injections or daily Relugolix pills. After three months have elapsed, these patients as per routine will undergo SBRT. SBRT comprises stereotactic, ultra-fractionated radiotherapy every other day for five total treatments.
62169431|NCT00764010|ACTIVE_COMPARATOR|4|Dietary counseling and omega-3 capsules
61984731|NCT06397703|ACTIVE_COMPARATOR|SBRT Alone|Participants treated with SBRT alone (standard of care) will be administered stereotactic, ultra-fractionated radiotherapy every other day for five total treatments.
62169432|NCT06512181|EXPERIMENTAL|Uterine preservation|Conservative management of PAS with the inclusion of antibiotics and uterine artery embolization, followed by close monitoring.
61984732|NCT05023746||Clinically diagnosed as non-small cell lung cancer samples|
61984733|NCT02569216|EXPERIMENTAL|Electrical Inhibition (EI) intervention|Electrical Inhibition (EI) uterine pacemaker is activated only when there is a preterm uterine contraction. The EI uterine pacemaker delivers a 1-15mA (20mA maximum) constant direct current for only 2 seconds only while there is a preterm uterine contraction.
62169433|NCT04054193|EXPERIMENTAL|Fosaprepitant Treatment|Participants received fosaprepitant dimeglumine once daily (QD) for 3 days and were followed for 14 days during the 17-day Cycle 1. Participants also optionally received dexamethasone as background therapy, and a serotonin (5-hydroxytryptamine \[5-HT3\]) receptor antagonist on Day 1 and optionally on Days 2-3 as background therapy. After completing Cycle 1, participants had the option to continue for up to 2 additional 17-day cycles of the same treatment regimen.
62169434|NCT05609721||Patients with antithromotic therapy|Data from medical records and radiology registry with mTBI in Sundsvall hospital between 2018-2020 in Sundsvall identified 2044 patients. Demographic data, pre-injury medications with antithrombotic treatment, state of consciousness at admission and the results of CT-scans of brain was investigated.
62169435|NCT05609721||Patients without antothrombotic therapy|Data from medical records and radiology registry with mTBI in Sundsvall hospital between 2018-2020 in Sundsvall identified 2044 patients. Demographic data, pre-injury medications with antithrombotic treatment, state of consciousness at admission and the results of CT-scans of brain was investigated.
62169436|NCT00574171|EXPERIMENTAL|1|
62362806|NCT02951455|EXPERIMENTAL|QLW & Capacity Building ProjectCBP- LC|Combination of goal development and implementation with community mobilization intervention including 9 weekly sessions spread across 15 weeks. Licensed Clinician (LC)
62362807|NCT02951455|EXPERIMENTAL|QLW & CD & CBP-LC|Combination of group behavioral intervention, goal development and implementation, and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
62362808|NCT02951455|EXPERIMENTAL|LC|This condition will include 3 core sessions that are not a part of the components being tested. These are support sessions to the components being tested and is hypothesized to have the smallest impact on substance use outcomes.Licensed Clinician (LC)
61984734|NCT03164343|EXPERIMENTAL|Pain Neuroscience Education for children|All participants within this study will receive Pain Neuroscience Education
61984735|NCT01291056|ACTIVE_COMPARATOR|Clomphine|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
61984736|NCT01291056|PLACEBO_COMPARATOR|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
61984737|NCT03668938|EXPERIMENTAL|intervention|The occupational therapy intervention provides a treatment aimed at improving autonomy in the activities chosen by the patient
61984738|NCT03668938|ACTIVE_COMPARATOR|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
61984739|NCT02432846|EXPERIMENTAL|Intuvax (INN: ilixadencel)+ Nephrectomy+Sunitinib|Two Intuvax (INN: ilixadencel) doses (10 million cells/dose) 14 days apart before nephrectomy, followed by Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
61984740|NCT02432846|ACTIVE_COMPARATOR|Nephrectomy+Sunitinib|Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
61984741|NCT06454409|EXPERIMENTAL|Treatment (regorafenib, venetoclax, azacitidine)|Patients receive regorafenib PO QD on days 1-21 of each cycle, venetoclax PO QD on days 1-21 of each cycle, and azacitidine IV over 10-40 minutes on days 1-7 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration during screening and on study as well as blood sample collection on study.
61984742|NCT01741181|ACTIVE_COMPARATOR|Vitamin D supplementation|Vitamin D3 tablets (cholecalciferol)
61984743|NCT01741181|PLACEBO_COMPARATOR|Placebo pill|Placebo pill
61984744|NCT00991666|EXPERIMENTAL|1|AMD Patients
61984745|NCT00991666|ACTIVE_COMPARATOR|2|healthy controls
61984746|NCT01930851||Gastric bypass|All gastric bypass operated patients in the Central Denmark Region 2006-2011
61984747|NCT04923503|EXPERIMENTAL|lean ramadan fasting|conduct ramadan fasting for 30 days
61984748|NCT04923503|EXPERIMENTAL|obese ramadan fasting|conduct ramadan fasting for 30 days
61984749|NCT04923503|EXPERIMENTAL|diabetics ramadan fasting|conduct ramadan fasting for 30 days
61984750|NCT03164928|OTHER|Placebo|SC Q6M placebo
61984751|NCT03164928|EXPERIMENTAL|Denosumab|1 mg/kg BW (up to a maximum of 60 mg) SC Q6M
61984752|NCT01460264||exposed|current daily smokers 100 cigarettes or more during lifetime
61984753|NCT01460264||unexposed|current non-smokers
61984754|NCT01400516|EXPERIMENTAL|Teriparatide|The participants who are in treatment arm received teriparatide 20 μg, subcutaneous injection, 1 injection per day, with a biologic for 12 months. A second year of teriparatide was offered to all interested participants. All participants received daily 1000 milligrams (mg) of calcium citrate, 800 IU of vitamin D and a Tumor Necrosis Factor (TNF) antagonist.
61984755|NCT01400516|OTHER|Control Arm|The participants randomized to the control arm had the same testing as those in the treatment arm and were offered teriparatide, if determined to be effective in healing bone erosions, after the first 12 months. All participants received daily 1000 mg of calcium citrate, 800 IU of vitamin D and a TNF antagonist.
61984756|NCT04731987|EXPERIMENTAL|Orange juice (A)|42 subjects between 40 and 65 years old with predisposition to cardiovascular disease will consume daily 330 ml of orange juice naturally rich in hesperidin (drink A) during 6 weeks
61984757|NCT04731987|PLACEBO_COMPARATOR|Control beverage (B)|42 subjects between 40 and 65 years old with predisposition to cardiovascular disease will consume daily 330 ml of control beverage (drink B)- a soft drink with sugar concentration identical to drink A - during 6 weeks
61984758|NCT04731987|EXPERIMENTAL|Control beverage supplemented with hesperidin formulation (B+HESP)|42 subjects between 40 and 65 years old with predisposition to cardiovascular disease will consume daily 330 ml of control beverage (identical to drink B but supplemented with hesperidin to reach level of drink A) during 6 weeks
61984759|NCT02308254|ACTIVE_COMPARATOR|Lixisenatide|Lixisenatide: 10 mcg, one subcutaneous injection dose
61984760|NCT02308254|PLACEBO_COMPARATOR|Placebo|Matching placebo: one subcutaneous injection dose
61984761|NCT02671279|OTHER|Low calorie diet|Dietary intervention group
61984762|NCT03375411|EXPERIMENTAL|INC1-Bare metal stent|Percutaneous coronary implantation of the device (Stent INC-1) following the standard procedure of stent placement
61984763|NCT06415422|OTHER|Daily Sampling in Platelet Function|The management of patients included in this study is not altered from the standard recommended care. The only exception is the daily blood draw into a dry tube for decentralized analysis using VeriFyNow until the normalization of platelet function, which is not part of routine care.
61984764|NCT01062321||Hepatitis-E, Pregnant & Non-pregnant|Pregnant,Acute Viral Hepatitis, Fulminant Hepatic Failure
61984765|NCT01950923|EXPERIMENTAL|Arm I (sildenafil citrate)|Patients receive sildenafil citrate PO before the initiation of standard robotic partial nephrectomy.
61984766|NCT01950923|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO before the initiation of standard robotic partial nephrectomy.
61984767|NCT01295515|EXPERIMENTAL|Interferon treatment|Interferon treatment The intervention is administration of Pegylated Interferon Alpha 2b (PEGINTRON) weekly for four weeks
61984768|NCT03057665||Pregnant Women|Measure magnetic field versus time for fetus, using atomic biomagnetometer.
61984769|NCT03609515|EXPERIMENTAL|Patients with contract about patient-controlled admissions|Patients have a contract about short self-referred inpatient admissions in mental health services without approval by clinicians, for a maximum of 5 days and with a minimum of three weeks between such stays
61984770|NCT01696994|NO_INTERVENTION|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
62169437|NCT03451994||Body odor|individuals self-reporting idiopathic body odor with or without bad breath
62169438|NCT03451994||Breath odor|individuals self-reporting idiopathic bad breath but no body odor
61984771|NCT01696994|ACTIVE_COMPARATOR|Ovarian Screening|Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.
61984772|NCT02447081||Subjects implanted with Amulet Device|All subjects who receive the Amulet device will be followed.
61984773|NCT05812976||PAH Patients|Pulmonary Index of Microcirculatory Resistance (PIMR) and Right Ventricle Index of Microcirculatory Resistance (RV-IMR) measurements during standard-of-care right +/- left heart catheterization at baseline and among those who undergo a standard-of-care right heart catheterization at 6 months.
61984774|NCT03797209||AXIOS Patient|
61984775|NCT01571414|EXPERIMENTAL|Arm 1A-EFV and PA-824|Participants will receive PA-824 on Days 1 to 7, no study medication on Days 8 to 21, EFV on Days 22 to 35, and EFV plus PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 7, 34, and 41 to 42.
61984776|NCT01571414|EXPERIMENTAL|Arm 1B-EFV and PA-824|Participants will receive EFV on Days 1 to 14, EFV plus PA-824 on Days 15 to 21, no study medication on Days 22 to 35, and PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 13, 20 to 21, and 42.
62362809|NCT02951455|EXPERIMENTAL|CD- PF|Group behavioral intervention with 9 weekly sessions lasting 2 hours. Critical Dialogue (CD), Peer Facilitator (PF)
61984777|NCT01571414|EXPERIMENTAL|Arm 2A-LPV/r and PA-824|Participants will receive PA-824 on Days 1 to 7, no study medication on Days 8 to 21, LPV/r on Days 22 to 35, and LPV/r plus PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 7, 35, and 42.
61984778|NCT01571414|EXPERIMENTAL|Arm 2B-LPV/r and PA-824|Participants will receive LPV/r on Days 1 to 14, LPV/r plus PA-824 on Days 15 to 21, no study medication on Days 22 to 35, and PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 14, 21, and 42.
61984779|NCT01571414|EXPERIMENTAL|Arm 3-RIF and PA-824|Participants will receive PA-824 on Days 1 to 7, RIF on Days 8 to 14, and RIF plus PA-824 on Days 15 to 21. Inpatient study visits will occur at Days 7 and 21.
61984780|NCT00803868|EXPERIMENTAL|1|Varenicline
62362810|NCT02951455|EXPERIMENTAL|CBP- PF|Group community mobilizing intervention with 9 weekly sessions spread in 15 weeks. Capacity Building Project (CBP), Peer Facilitator (PF)
62169439|NCT04727242|EXPERIMENTAL|Cytoreductive Surgery+HIPEC gemcitabine+dacarbazine|"* Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine followed by postoperative systemic chemotherapy with dacarbazine. Conceptually, HIPEC will be administered as a 60 minute heated intraperitoneal infusion (ie, intraperitoneal wash or lavage).~* HIPEC: Gemcitabine will be instilled at a dose of 1000 mg/m2 for 60 minutes at temperatures of 42° to 43°C.~* Systemic adjuvant chemotherapy starting 30 days ± 14 days post surgery. Dacarbazine 1000 mg/m2 IV every 3 weeks x 6 cycles"
62169440|NCT03228654|EXPERIMENTAL|Unipolar electrocautery|vaginal hysterectomy using Unipolar electrocautery
62169441|NCT03228654|ACTIVE_COMPARATOR|Purohit's technique|Vaginal hysterectomy using Purohit's technique
62169442|NCT05313529|EXPERIMENTAL|Liraglutide|"Liraglutide will be titrated from 0.6mg/day to a final dose 1.8mg/day during the first 2 weeks, if well tolerated.~Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 8-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but liraglutide could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study."
62169443|NCT05313529|EXPERIMENTAL|Empagliflozin|"Empagliflozin will be initiated and maintained at 10mg/ day every morning until the completion of the study.~Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 8-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but Empagliflozin could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study."
61984781|NCT00803868|PLACEBO_COMPARATOR|2|Placebo
61984782|NCT04407312|EXPERIMENTAL|CILO group|"Intervention:~Suspected patients with AMI were loaded with 600-mg clopidogrel and 300-mg aspirin in the emergency room.~After 3 to 5 days post-PCI (before discharge), patients were randomly allocated to the CILO group or the placebo group (1:1 fashion) based on a computer-generated randomization sequence.~For the CILO group, cilostazol-SR 200 mg daily was added to dual antiplatelet therapy with aspirin (100 mg daily) and clopidogrel (75 mg daily).~Study drug is maintained for 30 days. Double blinded, Randomized, Placebo controlled Trial.~Drug:~Cilostazol-SR, Tablet, 200mg, once daily. Astrix, Capsule, 100mg, once daily. Plavix, tablet, 75mg, once daily."
61984783|NCT04407312|PLACEBO_COMPARATOR|Placebo group|"Intervention:~Suspected patients with AMI were loaded with 600-mg clopidogrel and 300-mg aspirin in the emergency room.~After 3 to 5 days post-PCI (before discharge), patients were randomly allocated to the CILO group or the placebo group (1:1 fashion) based on a computer-generated randomization sequence.~In the Placebo group, placebo tablet was administered on top of dual antiplatelet therapy with aspirin (100 mg daily) and clopidogrel (75 mg daily).~Study drug is maintained for 30 days. Double blinded, Randomized, Placebo controlled Trial.~Drug:~Placebo, Tablet, 200mg, once daily. Astrix, Capsule, 100mg, once daily. Plavix, tablet, 75mg, once daily."
61984784|NCT03082599|ACTIVE_COMPARATOR|Emmetropia both eyes (OU) group|Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
61984785|NCT03082599|EXPERIMENTAL|Nanovision group|Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
61984786|NCT01620073|OTHER|Partner friendly arm|Proportion of males counseled and tested using routine standards of prenatal care
61984787|NCT01620073|EXPERIMENTAL|Home based arm|Proportion of male partners accepting HIV counseling and testing following home visits for couple HIV counseling and testing during pregnancy
61984788|NCT02507583|EXPERIMENTAL|Cohort 1|After protocol amendment dated 11 May 2017, all subjects enrolled into the trial will receive 20 chambers for 48 hours.
61984789|NCT02193373|ACTIVE_COMPARATOR|Sub-Occipital Release|Osteopathic Manual Medicine
61984790|NCT02193373|ACTIVE_COMPARATOR|Rib-Raising|Osteopathic Manual Medicine
61984791|NCT02193373|ACTIVE_COMPARATOR|Stellate Ganglion Release|Osteopathic Manual Medicine
61984792|NCT02193373|ACTIVE_COMPARATOR|All techniques|Osteopathic Manual Medicine
61984793|NCT02193373|SHAM_COMPARATOR|All Techniques-S|Sham Osteopathic Manual Medicine
61984794|NCT02193373|SHAM_COMPARATOR|Sub-Occipital Release-S|Sham Osteopathic Manual Medicine
61984795|NCT02193373|SHAM_COMPARATOR|Rib-Raising-S|Sham Osteopathic Manual Medicine
61984796|NCT02193373|SHAM_COMPARATOR|Stellate Ganglion Release -S|Sham Osteopathic Manual Medicine
61984797|NCT06146933|EXPERIMENTAL|Subject glucometer measurement|
61984798|NCT03698474|ACTIVE_COMPARATOR|SPMC-S|Natrium picosulfate /Magnesium citrate ( Picoprep™, oral solution) 2L in the evening before colonoscopy
61984799|NCT03698474|ACTIVE_COMPARATOR|SPMC-D|Natrium picosulfate/ Magnesium citrate ( Picoprep™, oral solution) 1L in the evening and 1L in the morning before colonoscopy
62169444|NCT05313529|EXPERIMENTAL|linagliptin|"linagliptin will be initiated at 5mg/ day every morning. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 8-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but linagliptin could not be adjusted.~If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study."
62169445|NCT03897049|EXPERIMENTAL|TWC App|The intervention is a mobile app delivered sexual health promotion program designed specifically for transgender women. The mobile app includes 42 interactive activities plus resource maps, opportunities for mentoring, and communication forums for connecting with other transgender women.
61984800|NCT03698474|ACTIVE_COMPARATOR|PEGA-S|Polyethylene glycol / Ascorbic acid ( Moviprep™, oral solution) 2L in the evening before colonoscopy
61984801|NCT03698474|ACTIVE_COMPARATOR|PEGA-D|Polyethylene glycol / Ascorbic acid (Moviprep™, oral solution) 1L in the evening and 1L in the morning before colonoscopy
61984802|NCT03698474|ACTIVE_COMPARATOR|SULF-S|Natrium/ Kalium/ Magnesium sulfate ( Eziclen™, oral solution) 1 L in the evening before colonoscopy
61984803|NCT03698474|ACTIVE_COMPARATOR|SULF-D|Natrium/ Kalium/ Magnesium sulfate ( Eziclen™, oral solution) 0,5 L in the evening and 0,5L in the morning before colonoscopy
61984804|NCT06187610|EXPERIMENTAL|Educational intervention group|
61984805|NCT06187610|NO_INTERVENTION|Control group|
61984806|NCT04542135|ACTIVE_COMPARATOR|Sulindac|sulindac 150 mg
61984807|NCT04542135|PLACEBO_COMPARATOR|Placebo|placebo pill
62169446|NCT03897049|ACTIVE_COMPARATOR|General Health App|An alternate mobile app (TWC COVID only) designed specifically for transgender women. The mobile app includes 7 interactive activities focused on COVID and COVID resources.
62169447|NCT02617667|EXPERIMENTAL|CyclASol Ophthalmic Solution 1|Cyclosporine A solution (dose-level 1) in vehicle
62169448|NCT02617667|EXPERIMENTAL|CyclASol Ophthalmic Solution 2|Cyclosporine A solution (dose-level 2) in vehicle
61984808|NCT04404647|EXPERIMENTAL|Intervention|Selected patients who choose to participate will undergo ablation of the target lesion using irreversible electroporation.
61984809|NCT00004984|EXPERIMENTAL|Parenteral Insulin|High risk participants randomized to intervention
62169449|NCT02617667|PLACEBO_COMPARATOR|Placebo Ophthalmic Solution|Vehicle only
62169450|NCT02617667|ACTIVE_COMPARATOR|Restasis|Cyclosporine A 0.05% ophthalmic emulsion
61984810|NCT00004984|ACTIVE_COMPARATOR|Close Observation|High risk participants randomized to observation
61984811|NCT00004984|EXPERIMENTAL|Oral Insulin|Intermediate risk participants randomized to intervention
62739224|NCT02584452|ACTIVE_COMPARATOR|Continuous Adductor Canal Nerve Catheter|Ultrasound guided femoral nerve block with 20cc of 2% mepivacaine \<20 minutes prior to in room time. Intraoperative patients will undergo initiation of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert this group will receive ultrasound guided adductor canal continuous nerve catheter using normal saline bolus followed by 1/8% bupivacaine infusion through catheter at 8cc/h.
62169451|NCT03386305|EXPERIMENTAL|EnvarsusXR arm|Patients are converted to once daily EnvarsusXR (study drug). The patients continue taking this medication for 9 months of the study. Initial dosage will be 0.8 times the total daily dose of tacro bid, due to higher bioavailability. All subsequent dose adjustments will be based on maintenance of target tacro trough levels within range of 5-12 ng/ml.
62169452|NCT03386305|ACTIVE_COMPARATOR|Standard of care arm|Post Liver Transplant patients take Tacrolimus twice daily as a part of standard of care. Those participating in the study will continue to take tacrolimus twice daily, as apart of their regular care. As a part of the study, they will complete the medication adherence and quality of life instruments.
62169453|NCT03353155|ACTIVE_COMPARATOR|Usual Care|Telephone and/or home visits at 1 week, and thereafter, monthly for 6 months, to check on medication compliance and/or medical social problems and/or physical therapy needs and/or health-related financial challenges by the relevant service departments as recommended by the discharging physician.
62169454|NCT03353155|ACTIVE_COMPARATOR|CareHub|Telephone follow-up by a nurse care coordinator acting as single point of contact for medication compliance and/or medical social problems and/or physical therapy needs and/or health-related financial challenges based on automatic enrollment using ACE score cut-off at admission.
62169455|NCT02503839|EXPERIMENTAL|Arm#1|"arm#1 (n=10) receiving etoricoxib from inclusion day 0 and in 140 days.~Step-wise inclusion starting with arm#1,arm#2 and arm#3 (first group) randomized (2:2:1) and if safety data are satisfactory proceeding with arm #4 and the rest of arm#3 randomized (2:2:1)."
62169456|NCT02503839|EXPERIMENTAL|Arm#2|arm#2 (n=10) receiving H56:IC31 vaccine at day 84 and 140 and no etoricoxib.
62169457|NCT02503839|NO_INTERVENTION|Arm#3|arm#3 (n=10), the first group (n=5) serving as control to arm#1 and arm#2, the next group (n=5) serving as control to arm#4.
61984812|NCT00004984|PLACEBO_COMPARATOR|Placebo|Intermediate risk participants randomized to placebo
61984813|NCT02478554|NO_INTERVENTION|Population-based|Participants will be randomly assigned to population-based fetal growth curves
61984814|NCT02478554|ACTIVE_COMPARATOR|Customized-based|Participants will be randomly assigned to customized-based fetal growth curves (intervention)
62169458|NCT02503839|EXPERIMENTAL|Arm#4|arm#4 (n=10) receiving etoricoxib from inclusion day 0 and in 140 days and H56:IC31 vaccine at day 84 and 140.
62169459|NCT05181891|EXPERIMENTAL|(CM+TAU) Contingency Management + Treatment as Usual|Varenicline (VC) will be supplied in .5 mg tablets once per week during the active treatment period. During the first week of treatment (Week 3) participants will be instructed to take .5 mg once per day for days 1-3, and 0.5 mg twice per day for days 4-7. The investigators will maintain a target dose of 1mg twice per day for the remaining active treatment period. Additionally, participants will also receive Take Control counseling via video. Participants in CM+TAU will receive reinforcement for submitting urine samples that test negative for recent alcohol use.
62362811|NCT02951455|EXPERIMENTAL|QLW-PF|Group intervention where participants learn to develop and implement personal goals that are measurable, attainable, realistic, and time bound. Intervention includes 9 sessions. Quality of Life wheel, Peer Facilitator (PF)
62362812|NCT02951455|EXPERIMENTAL|CD & CBP- PF|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions. Peer Facilitator (PF)
62362813|NCT02951455|EXPERIMENTAL|CD & QLW- PF|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Peer Facilitator (PF)
62362814|NCT02951455|EXPERIMENTAL|QLW & CBP- PF|Combination of goal development and implementation with community mobilization intervention including 9 weekly sessions spread across 15 weeks.Peer Facilitator (PF)
61984815|NCT03674242|EXPERIMENTAL|Eryaspase plus Chemotherapy|"eryaspase 100 U/kg dosed at Day 1 and Day 8 of each 3-week cycle in combination with~* Gemcitabine IV infusion 1000 mg/m2, Day 1 and Day 8.~* Carboplatin IV infusion at a calculated area under the curve (AUC) of 2.0 (AUC2), Day 1 and Day 8."
61984816|NCT03674242|ACTIVE_COMPARATOR|Chemotherapy alone|Gemcitabine plus carboplatin dosed at Day 1 and Day 8 of each 3-week cycle
61984817|NCT01488903||Premenopausal Women|600 health premenopausal Women
61984818|NCT01488903||Postmenopausal women|600 healthy postmenopausal women
61984819|NCT03345589|EXPERIMENTAL|18-22mg/kg/d Ursodeoxycholic group|
61984820|NCT03345589|PLACEBO_COMPARATOR|13-15mg/kg/d Ursodeoxycholic group|
61984821|NCT01173718|EXPERIMENTAL|GORE® ACUSEAL Vascular Graft|
61984822|NCT03888872|EXPERIMENTAL|Group I|Group I (Study): will consist of 20 patients with diabetic neuropathy and will receive High tone power therapy in addition to selected physical therapy program (Wobble board training, AROM exercises for both UL \& LL, gentle manual stretching exercises for both UL \& LL and graduated gait training). for 10 sessions every other day, each session for 1.45 hours (60 minutes for HiTop and 45 minutes for selected physical therapy program).
61984823|NCT03888872|EXPERIMENTAL|Group II|Group II (Control): will consist of 20 patients with diabetic neuropathy and will receive selected physical therapy program only same as group I. For 10 sessions every other day, each session for 45 minutes.
62169460|NCT05181891|ACTIVE_COMPARATOR|(NC+TAU) No Contingency + Treatment as Usual|Varenicline (VC) will be supplied in .5 mg tablets once per week during the active treatment period. During the first week of treatment (Week 3) participants will be instructed to take .5 mg once per day for days 1-3, and 0.5 mg twice per day for days 4-7. The investigators will maintain a target dose of 1mg twice per day for the remaining active treatment period. Additionally, participants will also receive Take Control counseling via video. NC+TAU will receive reinforcement for submitting any urine sample, regardless of test results.
62169461|NCT04949789|OTHER|Placebo without Exercise|"2 Capsules to be taken 30 minutes before breakfast.~* Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~* On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
62169462|NCT04949789|OTHER|Placebo with Exercise|"2 Capsules to be taken 30 minutes before breakfast.~* Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~* On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
62169463|NCT04949789|OTHER|IP I|"2 Capsules to be taken 30 minutes before breakfast.~* Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~* On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
62169464|NCT04949789|OTHER|IP II|"2 Capsules to be taken 30 minutes before breakfast.~* Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~* On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
62169465|NCT04949789|OTHER|IP III|"2 Capsules to be taken 30 minutes before breakfast.~* Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~* On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
61984824|NCT02555332||Women underwent screening for thyroid function|All these women underwent screening for thyroid function (TSH,FT4,TPOAb) at the first antenatal visit and the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation. The correlation between the combination of TSH level and TPOAb status and the risk of Gestational Diabetes Mellitus was analyzed.
61984825|NCT01379742|ACTIVE_COMPARATOR|Iodine-125 standard 18 g needle|Rapidstrand
61984826|NCT01379742|ACTIVE_COMPARATOR|20 g needle|Thin Strand
61984827|NCT04784221|EXPERIMENTAL|Radiation by protontherapy associated to nanoparticles injection|
61984828|NCT06391736|EXPERIMENTAL|Low dosage group|Single intravenous administration of GC301 at a dose of 3.0 x 10\^13 vector genomes per kilogram body weight
62169466|NCT01124656|EXPERIMENTAL|Pioglitazone-Azilsartan QD|(Dependent on glycosylated hemoglobin level at screening)
61984829|NCT06391736|EXPERIMENTAL|High dosage group|Single intravenous administration of GC301 at a dose of 6.0 x 10\^13 vector genomes per kilogram body weight
61984830|NCT05653544||Mitochondrial myopathy|Mitochondrial myopathy, confirmed genetically
62169467|NCT04999683|EXPERIMENTAL|ITIS diet|anti-inflammatory (ITIS) diet for 14 days
62169468|NCT05016778|EXPERIMENTAL|Treatment Group|This is a open label, single arm clinical trial.
62169469|NCT03039088||Fibromyalgia patients|
62169470|NCT03039088||Not fibromyalgia patients|
62169471|NCT00801450|EXPERIMENTAL|Intravitreal (IVI)|
62169472|NCT00801450|EXPERIMENTAL|SubTenon´s (STI)|
62169473|NCT04015128||T2 Alpha Femoral Nail GT|Subjects in the clinical investigation will undergo placement of the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System which allows for insertion through the tip of the greater trochanter, according to the approved Instructions for Use and Operative Technique Manual.
62169474|NCT02876302|EXPERIMENTAL|Paclitaxel (12weeks)|"Paclitaxel is administered weekly followed by standard Doxorubicin and Dyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively~* 16 patients will be randomized from the Run-In 7 days of Ruxolitinib~* The drug will be administered at a pre-determine dosage"
62169475|NCT02876302|EXPERIMENTAL|Ruxolitinib with Paclitaxel (12weeks)|"Paclitaxel is administered with daily Ruxolitinib, followed by standard Doxorubicin and Cyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively~* 16 patients will be randomized from the Run-In 7 days of Ruxolitinib~* The drug will be administered at a pre-determine dosage"
61984831|NCT02738333|EXPERIMENTAL|LDV/SOF (Cohort 1)|LDV/SOF FDC for 12 weeks
61984832|NCT02738333|EXPERIMENTAL|SOF+RBV (Cohort 1)|SOF+RBV for 12 weeks
61984833|NCT02738333|EXPERIMENTAL|LDV/SOF (Cohort 2)|Participants who are ineligible for or intolerant to RBV therapy will receive LDV/SOF FDC for 12 weeks.
61984834|NCT01288287||Week 12 Disease Activity Score (DAS) Responders|Patients achieving a reduction from Baseline in a Disease Activity Score 28-joint count (Erythrocyte Sedimentation Rate) \[DAS28(ESR)\] score of greater than 1.2 points at Week 12
61984835|NCT01288287||Week 12 Disease Activity Score (DAS) Non-Responders|Patients who fail to achieve a reduction from Baseline in a Disease Activity Score 28-joint count (Erythrocyte Sedimentation Rate) \[DAS28(ESR)\] score of greater than 1.2 points at Week 12
61984836|NCT02975219|EXPERIMENTAL|Treatment group|4.5mg Bevacizumab-800CW intravenously
61984837|NCT04571710|EXPERIMENTAL|Treatment group|Intervention: Drug: SHR1258 400mg
61984838|NCT04025658|ACTIVE_COMPARATOR|Oxytocin 0.5IU|Patient is given 0.5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
61984839|NCT04025658|ACTIVE_COMPARATOR|Oxytocin 1IU|Patient is given 1IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
61984840|NCT04025658|ACTIVE_COMPARATOR|Oxytocin 2IU|Patient is given 2IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
61984841|NCT04025658|ACTIVE_COMPARATOR|Oxytocin 3IU|Patient is given 3IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
62169476|NCT02876302|EXPERIMENTAL|Ruxolitinib and Paclitaxel (12weeks)|"Paclitaxel is administered with daily Ruxolitinib, followed by standard Doxorubicin and Cyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively~* 32 patients will be randomized from the Run-In 7 days of Ruxolitinib + Paclitaxel~* The drug will be administered at a pre-determine dosage"
62169477|NCT06011928|ACTIVE_COMPARATOR|Motor imagery focused pelvic floor exercise (MOPEXE)|"Internal imagery technique, one of the imagery techniques, will be applied to the participants.~Exercise program 8 weeks, 3 days a week, 3 sets of 10 repetitions of each movement and between sets It is planned to rest for 10 seconds."
62169478|NCT06011928|ACTIVE_COMPARATOR|Relaxation exercise (RE) group|One of the relaxation methods, Progressive Relaxation Exercises will be used.Exercises will be required to be applied 3 days a week, as 1 set of 10 repetitions per day.
62169479|NCT06011928|ACTIVE_COMPARATOR|Combined exercise group (CEG)|With the video home exercise program, the participants performed progressive relaxation exercises, respectively. then they will be provided with motor imagery focused pelvic floor exercises. A rest period of 5 minutes will be applied between two different exercise programs.
62169480|NCT03052283||Patients with CF|\>2000 in Germany, France, Italy, Spain, Denmark, Belgium, Portugal, GB, Ireland, USA, Australia, Canada, Brazil, Argentina...
61984842|NCT04025658|ACTIVE_COMPARATOR|Oxytocin 4IU|Patient is given 4IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
61984843|NCT04025658|ACTIVE_COMPARATOR|Oxytocin 5IU|Patient is given 5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
61984844|NCT02007265||TIA and SPC outpatients|All consecutive patients attending outpatient TIA and Stroke Prevention Clinics at three regional stroke centres will be eligible to be screened.
61984845|NCT05190380|EXPERIMENTAL|High intensity|"Intervention: Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.Routine physical therapy including TENS, Hot pack and Deep friction massage along with high intensity exercises will also be delivered along with Muscle Energy Technique. Experimental:High intensity will be treated with high intensity exercises in such a way that~1st and 2nd week; resistance training will be of 50% 1RM with 4 sets of 10 repetitions.~3rd and 4th week: resistance training will be of 70% 1RM with 4 sets of 10 repetitions.~5th and 6th week: the training will be of 80% 1RM with 4 sets of 10 repetitions~Last 4 sessions will be:~7th and 8th week: resistance training will be of 80% 1RM with 5 sets of 10 repetitions."
61984846|NCT05190380|EXPERIMENTAL|Low intensity|"Intervention: Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.Routine physical therapy including TENS, Hot pack and Deep friction massage along with Low intensity exercises will also be delivered along with Muscle Energy Technique. Experimental:Low intensity Group B will be treated with low intensity exercise in such a way that,~1st and 2nd week; Resistance training will be of 20% 1RM with 4 sets of 15 reps 3rd and 4th week Resistance training will be of 30% 1RM with 4 sets of 15 reps 5th and 6th week: the training will be of 40% 1RM with 4 sets of 15 reps~Last session will be:~7th and 8th week; Training of 40% 1RM with 5 sets of 15 reps"
61984847|NCT00403247|EXPERIMENTAL|A|vitamin capsule
61984848|NCT00403247|PLACEBO_COMPARATOR|B|placebo capsule
61984849|NCT00454987|EXPERIMENTAL|Menitorix Group|Previously primed in infancy with Menitorix™ and Infanrix-IPV™ and boosted with Menitorix™ (Priorix™ co-administered). All UK subjects received a booster dose of Infanrix-IPV™ at 40 to 43 months of age, intramuscularly in the deltoid region.
62169481|NCT03052283||Age-matched healthy controls|\>100 in Germany \>100 in each of the other participating countries
61984850|NCT00454987|ACTIVE_COMPARATOR|Meningitec Group|Previously primed in infancy with Meningitec™ and Pediacel™ and boosted with Menitorix™ (Priorix™ co-administered). All UK subjects received a booster dose of Infanrix-IPV™ at 40 to 43 months of age, intramuscularly in the deltoid region.
61984851|NCT00454987|ACTIVE_COMPARATOR|Meningitec+Hiberix Group|"Previously primed (according to the routine UK immunisation schedule) with 3 doses of a Meningitec™ conjugate vaccine and a Hiberix™ containing vaccine before the age of 8 months without booster dose at 12 months of age (only for UK). All subjects received a booster dose of Infanrix-IPV™ and Menitorix™ at 40 to 43 months of age, intramuscularly in the deltoid region.~This group was added only at year 2 in UK (Meningitec+Hiberix Group) to comply with UK Hib Catch-up vaccination programme."
62169482|NCT03425045|EXPERIMENTAL|Repetitive Transcranial Magnetic Stimulation|Patients in this study arm will undergo the rTMS stimulation as described above.
61984852|NCT00720057|EXPERIMENTAL|Naproxen sodium ER (BAYH6689)|single dose (1 tablet) ER Naproxen sodium 660 mg with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
61984853|NCT00720057|PLACEBO_COMPARATOR|Placebo|Single dose (1 tablet) of placebo with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
61984854|NCT05891483|EXPERIMENTAL|Treatment group A: SHR-1905 Injection（dose 1）|
61984855|NCT05891483|EXPERIMENTAL|Treatment group B: SHR-1905 Injection（dose 2）|
61984856|NCT05891483|EXPERIMENTAL|Treatment group C: SHR-1905 Injection（dose 3）|
61984857|NCT05891483|PLACEBO_COMPARATOR|Placebo Group|
62169483|NCT03425045|SHAM_COMPARATOR|Sham stimulation|Patients in this study arm will undergo the sham stimulation as described above.
62169484|NCT03425045|ACTIVE_COMPARATOR|Ginkgo Biloba Extract|Patients in this study arm will receive medication therapy as described above, without any rTMS or sham procedure.
62169485|NCT02511808|ACTIVE_COMPARATOR|Step-up Treatment: MI|After receiving one session of Brief Advice (BA), participants will be assessed at week 4 for response to this treatment. Those who are deemed non-responders to the BA will be randomly assigned to receive either Motivational Interviewing (MI) or more BA. In this arm, participants will receive two sessions of MI.
62169486|NCT02511808|OTHER|Control: BA|After receiving one session of Brief Advice (BA), participants will be assessed at week 4 for response to this treatment. Those who are deemed non-responders to the BA will be randomly assigned to receive either Motivational Interviewing (MI) or more BA. In this arm, participants will receive one additional session of BA.
62169487|NCT02511808|ACTIVE_COMPARATOR|Step-up Treatment: Specialist Care|After receiving one session of Brief Advice (BA) and two sessions of Motivational Interviewing (MI) or one session of BA over the first 8 weeks of the study, participants will be assessed at week 8 for response to this treatment. Those who are deemed non-responders will be randomly assigned to receive Behavioral Self-Control Training (BSCT) or more MI if they were randomized to MI at week 4 or five sessions of combined MI and BSCT or one more session of MI if they were randomized to BA at week 4. In this arm, participants will receive four sessions of BSCT if they received MI at the previous randomization or five sessions of combined MI and BSCT if they received BA at the previous randomization.
61984858|NCT04300595|ACTIVE_COMPARATOR|general anesthesia (Group G)|Patients receive general anesthesia with intravenous opioids and local infiltration of saline (Group G)
62362815|NCT02951455|EXPERIMENTAL|CD & QLW & CBP- PF|Combination of group behavioral intervention, goal development and implementation, and community mobilization intervention including 15 weekly sessions.Peer Facilitator (PF)
62362816|NCT02951455|EXPERIMENTAL|PF|This condition will include 3 core sessions that are not a part of the components being tested. These are support sessions to the components being tested and is hypothesized to have the smallest impact on substance use outcomes. Peer Facilitator (PF)
61984859|NCT04300595|ACTIVE_COMPARATOR|Local anesthesia (Group L)|Patients receive general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L).
61984860|NCT05855668|OTHER|Alcohol Use Disorder|Participants will be treated with 12 weeks of CBT for AUD (group therapy) and have the option to receive evidence-based pharmacotherapy for AUD guided by a pharmacotherapy algorithm.
61984861|NCT05855668|OTHER|Cannabis Use Disorder|Participants will be treated with 12 weeks of CBT + motivational enhancement therapy for CUD (group therapy).
61984862|NCT01524848|OTHER|Open label|Single arm pazopanib
61984863|NCT00355862|ACTIVE_COMPARATOR|1|Center specific immunosuppressive regimen (mTOR inhibitor free)
61984864|NCT00355862|EXPERIMENTAL|2|Sirolimus containing regimen
61984865|NCT02877823|EXPERIMENTAL|Treatment|"1. Home delivery of bottled water supplying 48 oz. /day for the child and 24 oz. /day per other household members (up to 6 family members).~2. Child pedometer use and activity tracking to encourage child physical activity/goal setting and engage parents in monitoring their child's health behavior.~3. Family Navigator Services by telephone with the parent to help engage and empower parents in child healthy lifestyle changes. They will also be able to assist with resource needs for the household (food/housing services).~4. Healthy Lifestyle Education based on the American Academy of Pediatrics Institute for the Healthiest Childhood Weight daily guidelines which are 5 fruit and vegetable servings, two hours or less screen time, one hour or more physical activity, no sugary drinks daily and limit fruit juice to one hundred percent real fruit juice."
61984866|NCT02877823|ACTIVE_COMPARATOR|Control|Healthy Lifestyle Education based on the American Academy of Pediatrics Institute for the Healthiest Childhood Weight daily guidelines which are 5 fruit and vegetable servings, two hours or less screen time, one hour or more physical activity, no sugary drinks and limit fruit juice to one hundred percent real fruit juice.
61984867|NCT05064033|EXPERIMENTAL|GROUP A|Pragmatic Set of intervention and posterior capsular stretch
61984868|NCT05064033|ACTIVE_COMPARATOR|GROUP B|Pragmatic Set of intervention and Sleeper Stretch
61984869|NCT00495833|NO_INTERVENTION|1|
61984870|NCT00495833|EXPERIMENTAL|2|photo and blood pressure personalization
61984871|NCT00495833|EXPERIMENTAL|3|photo personalization only
61984872|NCT00495833|EXPERIMENTAL|4|blood pressure personalization only
61984873|NCT00495833|EXPERIMENTAL|5|no personalization
61984874|NCT00495833|EXPERIMENTAL|A|receives gift card in blood pressure (BP) kit
61984875|NCT00495833|EXPERIMENTAL|B|does not receive gift card in BP kit
61984876|NCT06214650|EXPERIMENTAL|Radiofrequency group|"All participants will be receive two interventions:~1. A weekly session for 10 weeks with radiofrequency. It will be use the protocol of INDIBA. Each session will last 30 minutes.~2. Participants will do an homely exercise protocol. This protocol will practise for 3 days at week."
61984877|NCT06214650|ACTIVE_COMPARATOR|Control group|"All participants will be receive two interventions:~1. A weekly session for 10 weeks with radiofrequency. It will be use INDIBA without intensity such as a placebo. Each session will last 30 minutes.~2. Participants will do an homely exercise protocol. This protocol will practise for 3 days at week."
61984878|NCT00762242||1|Blood sampling and brachial artery ultrasound
61984879|NCT03784885|EXPERIMENTAL|30 μg of AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine in 30 μg of AD07010
61984880|NCT03784885|EXPERIMENTAL|45 μg of AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine in 45 μg of AD07010
61984881|NCT03784885|ACTIVE_COMPARATOR|AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine
61984882|NCT04432051|PLACEBO_COMPARATOR|GRUP Control|The daily respiratory system examination of COVID-19 patients who are hospitalized in the intensive care unit is performed and the necessary mechanical ventilation applications are performed by evaluating the arterial blood gas analysis.
61984883|NCT04432051|ACTIVE_COMPARATOR|GRUP Ultrasonography|The daily respiratory system examination of COVID-19 patients who are hospitalized in the intensive care unit is performed and the necessary mechanical ventilation applications are performed by evaluating the arterial blood gas analysis. However, the lung of the patient will be evaluated by ultrasound and the position to use the lung capacity most appropriately will be given.
61984884|NCT02522286|NO_INTERVENTION|Usual Care|Standard clinical care in primary care offices
61984885|NCT02522286|EXPERIMENTAL|Ask 3 Questions|Patients using 3 questions to their physicians when making medical decisions during the office visit.
61984886|NCT02522286|EXPERIMENTAL|Open Communication|This arm has three components: (1) Patients, physicians, and medical assistants watching a video aimed at encouraging open communication; (2) Patients fill out a Visit Companion Booklet about what are the most important issues they want to discuss with their physicians, record their next steps, and teach back on their next steps; (3) physicians receiving communication coaching from a Standardized Patient Instructor on patient-centered communication.
61984887|NCT02522286|EXPERIMENTAL|Ask 3 Questions + Open Communication|A combination of both the Ask 3 and Open Communication arms.
61984888|NCT06172764|EXPERIMENTAL|Group A|vitamin D Deficient group having initial caries
61984889|NCT06172764|ACTIVE_COMPARATOR|Group B|vitamin D deficient group having initial caries
61984890|NCT06172764|PLACEBO_COMPARATOR|Group C|vitamin D sufficient group having initial caries
61984891|NCT06429462||Healthy Controls (lab assessment)|"Participants will be asked to complete 8 questionnaires before the lab assessments: The data will be entered and saved onto REDCap by a member of the research team. The 8 questionnaires including baseline data are PROMIS-29 v2, Oxford Knee Score, IPAQ Short Last 7 Days, Numeric Rating Scale, Single Ease Question, Barthel Index for Activities of Daily Living and EQ-5D-5L.~Participants will be asked to complete the following:~2-minute walk on a treadmill 10 m walk (5 m x 2). Timed up and Go (TUG) Sit to stand test~At home:~TUG Sit to stand test"
61984892|NCT06429462||Participant post total knee replacement surgery (lab assessment)|"Participants will be asked to complete 8 questionnaires before the lab assessments: The data will be entered and saved onto REDCap by a member of the research team. The 8 questionnaires including baseline data are PROMIS-29 v2, Oxford Knee Score, IPAQ Short Last 7 Days, Numeric Rating Scale, Single Ease Question, Barthel Index for Activities of Daily Living and EQ-5D-5L.~Participants will be asked to complete the following:~2-minute walk on a treadmill 10 m walk (5 m x 2). Timed up and Go (TUG) Sit to stand test~At home:~TUG Sit to stand test"
61984893|NCT06429462||Healthcare professionals (focus group)|A member of the research team will conduct interviews to discuss how the knee4life project and how final tool can be deployed in clinics and services. These discussions will provide valuable insights into the future adoption and application of computer-vision technology. These will take place online.
61984894|NCT06429462||Stakeholders (focus group)|A member of the research team will conduct interviews to discuss how the knee4life project and how final tool can be deployed in clinics and services. These discussions will provide valuable insights into the future adoption and application of computer-vision technology. These will take place online.
61984895|NCT06429462||Participants post total knee replacement surgery|A member of the research team will conduct interviews to discuss how the knee4life project and how final tool can be deployed in clinics and services. These discussions will provide valuable insights into the future adoption and application of computer-vision technology. These will take place online.
61984896|NCT03806959|EXPERIMENTAL|Pan Capsule and colonoscopy|Every patient will have both Pan Capsule and colonoscopy examinations Descriptive study only
62362817|NCT05158179|EXPERIMENTAL|Spasmodic Dysphonia Patients|"Following appropriate nasal local anesthetic, the channeled laryngoscope was inserted through the nose. The 6-0 monofilament was pressed against the posterior nasopharyngeal wall and swiftly removed to establish a perceptual strength of 1, as an internal anchor. The lateral pyriform sinus (LPS) was presented with the planned stimulus, followed by the aryepiglottic fold (AEF) and the false vocal folds (FVF). Participants were instructed to raise their hand when the stimulus was detected, and then were asked by the study team to report a perceptual strength score, in comparison to the nasopharyngeal anchor strength of 1. LAR response was recorded by the study team. A negative response was defined as a lack of LAR to two appropriate stimuli. The LPS and AEF were tested in order of increasing stimulus: 6-0, 5-0, 4.5-0 and 4-0 monofilaments. The false vocal folds (FVF) were tested last. Testing of FVF terminated after the first observed LAR."
61984897|NCT04176900|EXPERIMENTAL|Alternating 3D boluses|Both rigid and flexible 3D printed boluses made for each patient. Each is used on alternate days during radiation therapy.
61984898|NCT04087252|EXPERIMENTAL|vaccinated group|Neoantigen vaccination will be performed with 6 doses in total, once per week
62362818|NCT05419115|NO_INTERVENTION|Usual Care|"Open label, 1:1 randomisation to usual care in hospital vs early supported discharge with SQIN-Furosemide administered via SQIN-Infusor.~Usual care: Usual care as per institutional practice (including IV diuretics)"
62362819|NCT05419115|EXPERIMENTAL|Early supported discharge|"Open label, 1:1 randomisation to usual care in hospital vs early supported discharge with SQIN-Furosemide administered via SQIN-Infusor.~Early supported discharge: with SQIN-Furosemide and SQIN-Infusor. SQIN-Furosemide: 80mg of SQIN-Furosemide in each cartridge; 5 hours running time; up to 2 applications in 24h (maximum dose of 160mg of SQIN-Furosemide in 24h). SQIN-Infusor: patient/carer administered."
62362820|NCT06119425|NO_INTERVENTION|Control|Patients judged to be at average risk of CRC will be engaged in a conversation about CRC risk factors and standard of care (SOC) screening options. Patients who express a desire to be screened using the SOC options will be considered part of the control group.
61984899|NCT01112852|ACTIVE_COMPARATOR|EVL + vasoconstrictor|Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
61984900|NCT01112852|EXPERIMENTAL|EVL + PPI|Pantoloc 40 mg intravenously per day was instituted on enrollment and continued for 5
61984901|NCT00687765|EXPERIMENTAL|1|
61984902|NCT00870896|EXPERIMENTAL|Tiotropium|Cough reflex measured by capsaicin Inhalation Challenge will follow Dicpinigaitis performed at 1 and 3 months. Solutions prepared to make a stock solution of 0.01 Mol diluted with physiologic saline to yield 11 doubling concentrations from 0.98 to 1,000 uMol/L. Final diluted capsaicin concentrations are: 0.98, 1.95, 3.9, 7.8, 15.6, 31.2, 62.5, 125, 250, 500, and 1000 uMol/L. Then, place 1 ml of the first concentration into nebulizer. Subjects inhale single breath of capsaicin aerosol. Single breaths are delivered in ascending order, with normal saline randomly interspersed to increase blindness, until two or more coughs (C2) and five or more coughs (C5) are reached. The different concentrations are delivered at 2 minute intervals.
61984903|NCT02294344|EXPERIMENTAL|DFPP&CTX|double filtration plasmapheresis(DFPP) combined with intravenous cyclophosphamide (IV-CTX) pulse therapy in addition(DFPP\&CTX)
61984904|NCT02294344|ACTIVE_COMPARATOR|cyclophosphamide|cyclophosphamide(CTX) pulse therapy
61984905|NCT01947439|EXPERIMENTAL|Biolimus A9 eluting stent|biolimus A9 stent( Biomatrix or Biomatrix Flex) will be placed in under Percutaneous Coronary Intervention.
61984906|NCT01947439|ACTIVE_COMPARATOR|Zotarolimus-eluting stent|zotarolimus eluting stent (Resolute Integrity) will be placed in under Percutaneous Coronary Intervention.
61984907|NCT00374881|ACTIVE_COMPARATOR|1|Morphine High Dose
61984908|NCT00374881|PLACEBO_COMPARATOR|2|Morphine Low Dose
62362821|NCT06119425|EXPERIMENTAL|Experimental|Patients judged to be at average risk of CRC will be engaged in a conversation about CRC risk factors and standard of care (SOC) screening options as well as the option to be screened with a blood-based test which is not currently standard of care. Patients who express a desire to be screened using the SOC options or the blood-based non-SOC option will be considered part of the experimental group.
62362822|NCT05031572|OTHER|conventional caloric restriction diet|(DCR protocol): lifestyle recommendations for a healthy Mediterranean diet under a continued daily caloric restriction diet
61984909|NCT00374881|PLACEBO_COMPARATOR|3|Sorbitol Phenylephrine
61984910|NCT00374881|EXPERIMENTAL|4|Sorbitol high concentration+Phenylephrine+Morphine
61984911|NCT00374881|EXPERIMENTAL|5|Sorbitol low concentration+Phenylephrine+Morphine
62362823|NCT05031572|OTHER|Intermitent fasting|Fasting for two days (non-consecutive) out of seven, with the fasting days separated by at least one day.
62362824|NCT04721938|OTHER|Intervention|Systematic weight loss intervention
62362825|NCT00959881|EXPERIMENTAL|Donepezil plus placebo|
62362826|NCT00959881|EXPERIMENTAL|Donepezil plus begacestat|
61984912|NCT00893750|EXPERIMENTAL|NET Truth Education|
61984913|NCT00893750|EXPERIMENTAL|Conflict Resolution Trainings|
61984914|NCT00893750|EXPERIMENTAL|Traditional Methods|
61984915|NCT06291142||Patient Participants|Patients with an SSc spectrum disorder, and healthy controls (objective 3)
61984916|NCT06291142||Healthcare Professional Participants|Healthcare Professionals taking part in the qualitative element of the study
62362827|NCT00676156|ACTIVE_COMPARATOR|A|This arm involves a 1-day pharmacokinetics study of three different formulations of oral lipoic acid.
61984917|NCT03504696||Patients with Advanced Melanoma|RIC-Mel patients with advanced (unresectable or metastatic) melanoma treated with nivolumab in the context of nivolumab ATU program (occurred from 12-Sep-2014 to 31-Aug-2015)
61984918|NCT04571580|PLACEBO_COMPARATOR|placebo|intracoronary infusion with saline
61984919|NCT04571580|EXPERIMENTAL|reteplase 9mg|intracoronary infusion with reteplase 9mg
61984920|NCT04571580|EXPERIMENTAL|reteplase 18mg|intracoronary infusion with reteplase 18mg
61984921|NCT00822068|EXPERIMENTAL|anodal tDCS|
61984922|NCT00822068|ACTIVE_COMPARATOR|2|cathodal tDCS
61984923|NCT00822068|PLACEBO_COMPARATOR|3|sham stimulation
61984924|NCT05371574|ACTIVE_COMPARATOR|Tranexamic acid|Each participant will receive 1gram of tranexamic acid
62362828|NCT00676156|ACTIVE_COMPARATOR|B|This arm will examine the pharmacokinetics of LA with and without fish oil supplement in a cross over design.
62362829|NCT00676156|ACTIVE_COMPARATOR|C|This arm will include the study of a single dose of R enantiomer lipoic acid.
62362830|NCT04127461|ACTIVE_COMPARATOR|Open vessel harvesting|Arm 1 is the conventional procedure
62362831|NCT04127461|EXPERIMENTAL|Medtronic endoscope|Arm 2 - is the minimally invasive procedure
62362832|NCT00653328|EXPERIMENTAL|Therapeutic Intervention|
61984925|NCT05371574|ACTIVE_COMPARATOR|clonidine|Each participant will receive 0.2mg of oral clonidine
61984926|NCT03887364|ACTIVE_COMPARATOR|Group A-Diaphragmatic breathing exercise|Diaphragmatic breathing exercise
61984927|NCT03887364|EXPERIMENTAL|Group B-Icing and Airflow Stimulation|Icing and Airflow Stimulation
61984928|NCT03432741|EXPERIMENTAL|Treatment (FDG-PET, direct tumor microinjection)|Patients undergo FDG-PET and receive saline intralesionally on day 1. Patients also receive up to five additional injections of gemcitabine hydrochloride, romidepsin, belinostat, carfilzomib, copanlisib hydrochloride, nivolumab, trastuzumab, daratumumab, obinutuzumab, pembrolizumab, or rituximab intralesionally per investigator on day 1. Beginning 5 days later, patients with nodal/extranodal mass undergo restaging FDG-PET and biopsy (if clinically feasible). Within 3-7 days, patients with cutaneous disease undergo restaging photography and biopsy.
61984929|NCT04249310||Tiotropium/Olodaterol|Combination of Tiotropium and Olodaterol
61984930|NCT04249310||Tiotropium|
61984931|NCT01482247|ACTIVE_COMPARATOR|L-arginine|
61984932|NCT01482247|PLACEBO_COMPARATOR|Placebo Supplement|
61984933|NCT03492216|NO_INTERVENTION|Control|All participants will receive brief alcohol and adherence counseling according to Uganda Ministry of Health guidelines.
61984934|NCT03492216|EXPERIMENTAL|Escalating incentives (EtG tests)|Escalating incentives for EtG negative urine test (Intervention: Incentives for negative EtG test).
61984935|NCT03492216|EXPERIMENTAL|Escalating incentives (IsoScreen tests)|Escalating incentives for IsoScreen positive urine tests (Intervention: Incentives for positive IsoScreen test).
61984936|NCT03492216|EXPERIMENTAL|Escalating incentives (EtG + IsoScreen)|Escalating incentives for EtG negative tests and for IsoScreen positive urine tests with the incentives rewarded separately (Interventions: Incentives for negative EtG test and Incentives for positive IsoScreen test).
61984937|NCT04400786|EXPERIMENTAL|On-demand treatment|This group of 98 ankylosing spondylitis patients is prescribed with intermittent Imrecoxib (100mg.prn.po) according to the feeling of pain till 24 weeks. The sulfasalazine (500mg.tid.po) is used.
61984938|NCT04400786|ACTIVE_COMPARATOR|Continuous treatment|This group of 98 ankylosing spondylitis patients is prescribed with continuous Imrecoxib (100mg.bid.po) for 24 weeks. The sulfasalazine (500mg.tid.po) is used.
61984939|NCT04178187|ACTIVE_COMPARATOR|Lactolevure|Patients will receive quadruple eradication therapy for Helicobacter Pylori infection with Amoxicillin, Clarithromycin, Metronidazole, Omeprazole and Probiotics
62362833|NCT01673269|EXPERIMENTAL|ERCP with direct examination of the CBD|
62362834|NCT02705443||Tissue w/ Thermographic Anomaly|"* Visibly undamaged tissue with anomaly identified by the thermographic image~* No intervention~* Standard of care"
62362835|NCT02705443||Tissue w/o Thermographic Anomaly|"* Visibly undamaged tissue with no anomaly identified by the thermographic image~* No intervention~* Standard of care"
62362836|NCT02705443||Tissue w/ Visible Anomaly|"* Visibly damaged tissue~* No intervention~* Standard of care"
62362837|NCT05531513|EXPERIMENTAL|Virtual Reality (VR) Meditation|The VR Meditation intervention will be administered in Arm 1.
61984940|NCT04178187|PLACEBO_COMPARATOR|Placebo|Patients will receive quadruple eradication therapy for Helicobacter Pylori infection with Amoxicillin, Clarithromycin, Metronidazole, Omeprazole and Placebo
61984941|NCT03534154||TBI - MRI / bloods / cognitive / clinical outcomes|Work package 1. In a large multi-centre cohort of adult moderate/severe TBI patients we aim to identify the most informative plasma biomarker(s) of the severity of axonal injury. We will characterise their time course, focusing on neurofilament light (NFL) and tau, and relate these to magnetic resonance imaging (MRI) measures of axonal injury. Using logistic regression we will then test whether these measures contribute to the prediction of clinical outcome at twelve months
61984942|NCT03534154||TBI - Advanced MRI / bloods / cognitive / clinical outcomes|Work package 2. In a subgroup of the patients recruited to WP1 we will use advanced MRI and longitudinal assessments to provide a more detailed description of the relationship between the plasma biomarkers and outcome after TBI. We will test whether advanced diffusion and myelin integrity measures correlate with plasma biomarkers and whether early plasma biomarker levels predict neurodegeneration measured by progressive atrophy after TBI.
61984943|NCT03534154||TBI - microdialysis / adv. MRI / cognitive / clinical|Work package 3. In a second subgroup of patients recruited to WP1 we will combine microdialysis, neuroimaging and plasma sampling of axonal proteins to provide a deeper understanding of the mechanisms of axonal injury progression and use this approach to investigate the axonal origin of the plasma biomarkers.
61984944|NCT03534154||Healthy volunteer|Single assessment using MRI, bloods and cognitive testing.
61984945|NCT02276729|EXPERIMENTAL|Mirror Box Treatment Group|Participants in the intervention group will be required to perform two 20 minute sessions of Mirror Box Therapy, five days/week for the duration of their in-patient stay carried out under the direction of members of the OT stroke team as well as receiving their standard OT treatment for upper limb rehabilitation for the duration of their in-patient stay, which is 3-5 sessions per week of approximately 45 minutes duration. This classic rehabilitation treatment is based upon neurodevelopmental theory using the Bobath approach of postural control and repetitive task training.
62362838|NCT05531513|ACTIVE_COMPARATOR|Psychoeducational Pamphlets|The Psychoeducation Pamphlet intervention will be administered in Arm 2.
62362839|NCT02744560|EXPERIMENTAL|patients|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
62362840|NCT03892707||NSAIDs group|Patients with acute non-specific low back pain prescribed with modern NSAIDs (preferential/selective COX-2 inhibitors)
62362841|NCT03892707||NSAIDs+Milgamma+Milgamma compositum group|Patients with acute non-specific low back pain prescribed with modern NSAIDs (preferential/selective COX-2 inhibitors) + Milgamma® / Milgamma® compositum
62362842|NCT04444492|EXPERIMENTAL|Ranibizumab+Laser-arm|Ranibizumab injections and additional targeted laser
61984946|NCT02276729|NO_INTERVENTION|Conventional Therapy Control Group|Participants in the control group shall receive their standard OT treatment for upper limb rehabilitation for the duration of their in-patient stay, which is 3-5 sessions per week of approximately 45 minutes duration. This classic rehabilitation treatment is based upon neurodevelopmental theory using the Bobath approach of postural control and repetitive task training.
61984947|NCT02760446|OTHER|CAM-ICU.fr|CAM-ICU and ICDSC evaluation proceed by two investigators and a Neuropsychologist (Speech \& language therapist specialized in neuropsychology)
61984948|NCT02211573|NO_INTERVENTION|Control group|Patients of this group don't performed physical training
61984949|NCT02211573|EXPERIMENTAL|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
61984950|NCT02616042|EXPERIMENTAL|Centella asiatica and bamboo salt|Participants received a dentifrice which contains Centella asiatica, bamboo salt, dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime). All participants used the assigned dentifrices for 4 days in each trial cycle.
61984951|NCT02616042|EXPERIMENTAL|Centella asiatica|Participants received a dentifrice which contains Centella asiatica, dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime).
61984952|NCT02616042|PLACEBO_COMPARATOR|Control dentifrice|Participants received a plain dentifrice which contains dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime).
61984953|NCT03849833|OTHER|Vitamin D3 supplementation|All participants will be selected for treatment with cholecalciferol, vitamin D3 supplementation and included in this single arm
61984954|NCT02825927|EXPERIMENTAL|Intervention group|Intensive training with oral screen for 5 weeks.
61984955|NCT02825927|NO_INTERVENTION|Control group|The control group is not offered any intervention.
62362843|NCT04444492|ACTIVE_COMPARATOR|Ranibizumab-arm|Only Ranibizumab injections
62362844|NCT01219491||Egg donor recipients|
62362845|NCT06360497|EXPERIMENTAL|mindfulness meditation group|participants in mindfulness meditation group would receive four weeks mindfulness meditation intervention.
62362846|NCT06360497|EXPERIMENTAL|loving-kindness and compassion meditation group|participants in loving-kindness and compassion meditation group would receive four weeks loving-kindness and compassion meditation meditation.
62362847|NCT06360497|NO_INTERVENTION|waitlist|participants in waitlist receive no intervention
62362848|NCT02715492|ACTIVE_COMPARATOR|Transarterial Chemoembolization|1st group: included 20 patients with HCC treated by TACE only.
62362849|NCT02715492|EXPERIMENTAL|TACE and LMWH|2nd group: included 20 patients with HCC treated by TACE and adjuvant dose of Low Molecular Weight Heparins (LMWH).
62362850|NCT03537092|EXPERIMENTAL|Vaginal Film|Each participant who inserted a single use placebo vaginal film (Day 0) is randomized to the timing of Visit 3 (Day 3, 7, 10, or 14)
61984956|NCT05654155|EXPERIMENTAL|Auricular acupressure group|The AAG participants received auricular acupressure three times a day for five days every week for three weeks. Using Dr. Huang's ear reflex theory, our AAG intervention included six acupoints (i.e., shenmen, subcortex, heart, kidney, anxious, and neurasthenia points) that have been demonstrated to be effective in improving sleep and emotional stability.
61984957|NCT05654155|SHAM_COMPARATOR|sham auricular acupressure group|Participants in SAG received the same protocol of auricular acupressure as the AAG, but six acupoints were used near the treated acupoints (e.g., sacroiliac, neck, stomach, wrist, tonsil, and tongue), which would have had no effects on participants' sleep and mood status.
61984958|NCT01574612|EXPERIMENTAL|topical cream acyclovir/hydrocortisone|topical cream acyclovir/hydrocortisone used
61984959|NCT06129721|EXPERIMENTAL|Emergent Stenting|Emergent Stenting In Acute Vertebrobasilar Occlusions
61984960|NCT03519347|EXPERIMENTAL|Potassium Removal Maximization Strategy|Dialysate potassium will be adjusted according to the results of point of care testing in order to maximize potassium removal and avoid hyperkalemia.
61984961|NCT03519347|EXPERIMENTAL|Potassium Gradient Minimization Strategy|Dialysate potassium will be adjusted according to the results of point of care testing in order to minimize the flux of potassium.
61984962|NCT03519347|EXPERIMENTAL|Alkalosis Avoidance Strategy|Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding alkalosis.
61984963|NCT03519347|EXPERIMENTAL|Acidosis Avoidance Strategy|Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding acidosis.
61984964|NCT05643040|EXPERIMENTAL|femoral nerve block|To evaluate the intraoperative analgesia effectiveness of femoral nerve block in patients who will have knee surgery.
61984965|NCT05643040|EXPERIMENTAL|adductor canal block|To evaluate the intraoperative analgesia effectiveness of adductor canal block in patients who will have knee surgery.
61984966|NCT05643040|EXPERIMENTAL|4in1 block|To evaluate the intraoperative analgesia effectiveness of 4in1 block in patients who will have knee surgery.
61984967|NCT04471389||Hanzhong adolescent hypertension cohort|A total of 4623 adolescents aged 6-15 years old in Hanzhong rural areas was recruited in 1987. During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
61984968|NCT04471389||Mei county adult salt-sensitive hypertension cohort|A total of 675 individuals from 126 families were recruited in this family-based dietary intervention study. A community-based BP screening was conducted among adults aged 18-60 years in the study villages. The probands who had a mean systolic BP (SBP) between 130-160 mmHg and/or a diastolic BP (DBP) between 85-100 mmHg and no use of antihypertensive medications and their parents, siblings, spouses, and offspring were recruited in this study. During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
61984969|NCT02192255|EXPERIMENTAL|Intervention phone call|The intervention arm consisted of one protocol-structured telephone call from an interventionist who was a nurse health manager (1 site), diabetes educator or diabetes educator trainee (1 site), or pharmacist (2 sites). Interventionists followed the same structured telephone interview protocol to ascertain whether the subject had started taking the new prescription. Those taking the new medication as prescribed received positive reinforcement. Those who either had not filled the prescription or were not taking the medication as directed, were asked about reasons for nonadherence and assisted in identifying and resolving barriers. The median call lasted \< than 5 minutes, and up to 3 call attempts were made. Most intervention calls occurred within 2 to 6 weeks after the prescription date.
61984970|NCT02192255|NO_INTERVENTION|Control arm - usual care|Those in the control arm received usual care.
61984971|NCT01629368|EXPERIMENTAL|Dosing Period 1|
61984972|NCT01629368|EXPERIMENTAL|Dosing Period 2|
61984973|NCT04098224|EXPERIMENTAL|Interventional Device - Treated|Subjects connected to the investigational device smART+
61984974|NCT04098224|NO_INTERVENTION|Control Group|treated according to local Standard of Care.
61984975|NCT03822208|ACTIVE_COMPARATOR|AL003 by intravenous (IV) infusion|Single-doses of AL003 in dose-escalating cohorts Multiple doses of AL003 in single cohort
61984976|NCT03822208|PLACEBO_COMPARATOR|Placebo by intravenous (IV) infusion|Matching saline solution will be administered for placebo subjects
61984977|NCT06419972|EXPERIMENTAL|Experimental|They will receive multimodal physiotherapy programme, which will combine therapeutic exercise based in general strength exercise combined with a pelvic floor education program.
61984978|NCT06419972|NO_INTERVENTION|Control|They will not receive any type of intervention
61984979|NCT05778786|EXPERIMENTAL|Test/Control|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to wear bilaterally two different study lenses, one at a time, for a minimum of 8 hours per day for at least 5 days during each wear period, over two wear periods (test then control) with a washout period of 7+/-2 days duration between wear periods.
61984980|NCT05778786|EXPERIMENTAL|Control/Test|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Control/Test sequence, to wear bilaterally two different study lenses, one at a time, for a minimum of 8 hours per day for at least 5 days during each wear period, over two wear periods (control then test) with a washout period of 7+/-2 days duration between wear periods.
61984981|NCT04352855||C/T|C/T cases: individuals fulfilling eligibility criteria and treated with ceftolozane-tazobactam
61984982|NCT04352855||C|C cases: individuals fulfilling eligibility criteria and treated with colomycine
61984983|NCT01801644|EXPERIMENTAL|gemcitabine plus cisplatin|gemcitabine plus cisplatin: 3 cycles of gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion and cisplatin 70 mg/m2 on day 1 as an 2 hour infusion will be applied
62362851|NCT02814448|ACTIVE_COMPARATOR|CO2 standard cryotherapy- double freeze|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
61984984|NCT03439670|EXPERIMENTAL|Treatment Group 1|Patients enrolled in Treatment Group 1 (experimental group) will receive vamorolone 2.0 mg/kg/day for the duration of the study.
62362852|NCT02814448|ACTIVE_COMPARATOR|CO2 standard cryotherapy- single freeze|Single freeze treatment consists of one five-minute freeze
62362853|NCT02814448|ACTIVE_COMPARATOR|CryoPen- double freeze|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
62362854|NCT02814448|ACTIVE_COMPARATOR|CryoPen- single freeze|Single freeze treatment consists of one five-minute freeze
61984985|NCT03439670|EXPERIMENTAL|Treatment Group 2|Patients enrolled in Treatment Group 2 (experimental group) will receive vamorolone at 6.0 mg/kg/day for the duration of the study.
61984986|NCT03439670|ACTIVE_COMPARATOR|Treatment Group 3|Patients enrolled in Treatment Group 3 (active comparator group) will receive prednisone 0.75 mg/kg/day for 24 weeks followed by 20 weeks of treatment with 2.0 mg/kg/day vamorolone.
61984987|NCT03439670|ACTIVE_COMPARATOR|Treatment Group 4|Patients enrolled in Treatment Group 4 (active comparator group) will receive prednisone 0.75 mg/kg/day for 24 weeks followed by 20 weeks treatment with 6.0 mg/kg/day vamorolone.
61984988|NCT03439670|PLACEBO_COMPARATOR|Treatment Group 5|Patients enrolled in Treatment Group 5 (placebo comparator group) will receive placebo daily for 24 weeks followed by 20 weeks treatment with 2.0 mg/kg/day vamorolone.
61984989|NCT03439670|PLACEBO_COMPARATOR|Treatment Group 6|Patients enrolled in Treatment Group 6 (placebo comparator group) will receive placebo daily for 24 weeks followed by 20 weeks treatment with 6.0 mg/kg/day vamorolone.
61984990|NCT05130931|EXPERIMENTAL|Multimodal Conservative Treatment|
61984991|NCT05130931|NO_INTERVENTION|Standard healthcare.|
61984992|NCT00302042|EXPERIMENTAL|1: Brief Counseling Plus Group Lifestyle|Brief counseling plus group diabetes prevention in community
61984993|NCT00302042|ACTIVE_COMPARATOR|2: Brief Counseling Alone|Brief Counseling for pre-diabetes alone
61984994|NCT00798538|ACTIVE_COMPARATOR|Integrated|Provision of buprenorphine induction and management, substance abuse counseling and HIV care at one clinic.
61984995|NCT00798538|PLACEBO_COMPARATOR|Non-integrated|Buprenorphine induction, substance abuse counseling and HIV care will be managed at multiple locations, respectively: the Community Health Care Van, the Yale AIDS Program, and individuals' HIV clinics.
61984996|NCT05749575|EXPERIMENTAL|Chidamide Plus Toripalimab Plus Paclitaxel|Cedaramine: 20mg, twice a week.Toripalimab: 240mg, once in 3 weeks,intravenous.Paclitaxel: 175mg / m2, once in 3 weeks, routine preventive anti-allergy treatment, surgery after 4 cycles of IV infusion.
61984997|NCT01687959|ACTIVE_COMPARATOR|activity of peritoneal fibrinolysis|measurements of peritoneal fibrinolysis using tissue-type plasminogen activator and its specific activity, urokinase-type plasminogen activator, and plasminogen activator inhibitor type 1
61984998|NCT01687959|ACTIVE_COMPARATOR|surgical outcomes|surgical outcomes of laparoscopic cholecystectomy
61984999|NCT02526888|EXPERIMENTAL|Sequence AB|During Period 1, subjects receive a single dose of ACT-541468 on Day 1. During Period 2, they receive Diltiazem from Day 1 to Day 7 and a single dose of ACT-541468 on Day 4
61985000|NCT02526888|EXPERIMENTAL|Sequence BA|During Period 1, subjects receive Diltiazem from Day 1 to Day 7 and a single dose of ACT-541468 on Day 4. During Period 2, they receive a single dose of ACT-541468 on Day 1
61985001|NCT02355691|EXPERIMENTAL|PREVENA Group|Patients will be treated with the PREVENA negative pressure device following total hip arthroplasty. This dressing will be used for a period of seven days.
61985002|NCT02355691|NO_INTERVENTION|Standard group|Patients will be treated with the standard absorptive dressing following total hip arthroplasty.
61985003|NCT02140099|EXPERIMENTAL|Healthy Relationships Education/Skills|The experimental intervention is the group-based, 15-session Healthy Relationships Plus Program (HRPP). In this study, the HRPP will be offered in a condensed 8-day format (July 8-11 and 14-17, 2014). On days 1 to 7, participants will attend the program for 2 hours, and on day 8, participants will attend the program for 1 hour. The program will be facilitated by high school teachers. Eight HRPP groups will run concurrently during the study period.
61985004|NCT02140099|OTHER|Classroom Activities|The control condition is a group-based, 15-session program focusing on typical Classroom Activities. The primary activity is to create a school welcome packet for incoming Grade 9 students, with other activities including reading and physical exercise. The control condition will be offered on 8 consecutive weekdays (July 8-11 and 14-17, 2014). On days 1 to 7, participants will attend the control program for 2 hours, and on day 8, participants will attend the control program for 1 hour. The control group will be facilitated by bachelor's level research assistants and pre-service teachers. Eight control groups will run concurrently during the study period.
61985005|NCT00496093|EXPERIMENTAL|Pneumococcal Vaccine, Polyvalent (23-valent)|Participants received one 0.5 mL dose of Pneumococcal Vaccine, Polyvalent (23-valent) by intramuscular (deltoid) injection on Day 1.
62362855|NCT02814448|EXPERIMENTAL|Thermocoagulator|Single heat application at 100 ºC for 40 seconds
61985006|NCT03553407|EXPERIMENTAL|Low Level Laser - Pulse|In this group the patient will receive the following laser protocol: 880nm, 30mW, 3.6 J / cm², 25 Hz
61985007|NCT03553407|EXPERIMENTAL|Low Level Laser - continuous|In this group the patient will receive the following laser protocol: 880nm, 30mW, 3.6 J / cm²
61985008|NCT03553407|PLACEBO_COMPARATOR|Low Level Laser - Placebo|In this group the patient will receive the protocol with the equipment turned off.
61985009|NCT01815125|EXPERIMENTAL|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
61985010|NCT01815125|PLACEBO_COMPARATOR|Placebo|The control group will receive a similar looking/ tasting pill of placebo.
61985011|NCT01352988|EXPERIMENTAL|Fumaric acid esters|
61985012|NCT01032876|EXPERIMENTAL|Deep Hypothermic Circulatory Arrest|
61985013|NCT01032876|EXPERIMENTAL|Antegrade Cerebral Perfusion|
61985014|NCT01848587|EXPERIMENTAL|acupuncture|5 acupuncture sessions over a 4 week period plus standard treatment
61985015|NCT01848587|ACTIVE_COMPARATOR|usual care|standard treatment (pregnancy belt, behavioral recommendations, exercises, pain killers as prescribed by usual health care professional)
61985016|NCT05128877|NO_INTERVENTION|Control group|No intervention was made in the control group.
61985017|NCT05128877|EXPERIMENTAL|intervention group|Progressive relaxation techniques were applied to the intervention group.
61985018|NCT03498625|OTHER|Clinical remission CD|
61985019|NCT05669560|NO_INTERVENTION|Control group|Will receive SRP alone.
61985020|NCT05669560|EXPERIMENTAL|Test group|Will receive SRP + PerioProtect ™.
61985021|NCT01616446||remission|Nephrotic patients in remission
61985022|NCT01616446||relapse|Nephrotic patients in recidive
61985023|NCT00945139|EXPERIMENTAL|Single Arm: Doxil and Avastin|Patients receive both agents, doxil and Avastin.
62362856|NCT00067626|EXPERIMENTAL|1|500/1000 mcg oral chromium taken daily or placebo (crossover)
61985024|NCT00598663|EXPERIMENTAL|Off/On|"6 month-Period Off: Continuous Subcutaneous Insulin Infusion (CSII) and Self Monitoring Blood Glucose \[Device: Paradigm® Real-Time pump with Sensor Off feature\]~4 month wash out period~6 month-Period On: Continuous Subcutaneous Insulin Infusion (CSII) + personal continuous glucose monitoring (personal CGM) \[Device: Paradigm® Real-Time pump with Sensor On feature continuously\]"
61985025|NCT00598663|EXPERIMENTAL|On/Off|"6 month-Period On: Continuous Subcutaneous Insulin Infusion (CSII) + personal continuous glucose monitoring (personal CGM) \[Device: Paradigm® Real-Time pump with Sensor On feature continuously\]~4 month wash out period~6 month-Period Off: Continuous Subcutaneous Insulin Infusion (CSII) and Self Monitoring Blood Glucose \[Device: Paradigm® Real-Time pump with Sensor Off feature\]"
61985026|NCT03712319|EXPERIMENTAL|Group 1: App.|"Participants use application REM Volver a casa on their cell phones during 8 weeks. Codes are provided to the students in order to unlock the different stages of the training free of charge. The application provides short videos and audios for training. Students practice on their own, in accordance with the instruction of completing a stage a week."
61985027|NCT03712319|ACTIVE_COMPARATOR|Group 2: MBSR.|Participants attend a presence-based training during 8 weeks. The Mindfulness-Based Stress Reduction program involves a session of two and a half hours each week.
61985028|NCT03712319|NO_INTERVENTION|Group 3: Waiting list.|Participants do not receive any intervention during the study. At the end of the study (16 weeks), they are provided with the codes so they can unlock the app and use it like participants from Group 1.
61985029|NCT03731520|EXPERIMENTAL|Assessing exercise behavior|determining exercise behaviour in patients with JIA by using specific scales
61985030|NCT04919577||RSS- Group|Patients without RSS after distal gastrectomy.
61985031|NCT04919577||RSS+ Group|Patients with RSS after distal gastrectomy.
61985032|NCT06376747|ACTIVE_COMPARATOR|Standard blood sampling technique|Blood withdrawal after catheter decontamination, blood draw for laboratory analysis, catheter flush
61985033|NCT06376747|EXPERIMENTAL|Closed technique blood sampling|In-line sampling: through 2 three-way stopcocks: blood withdrawal for catheter decontamination, blood draw for laboratory analysis, return of the withdrawn blood for catheter decontamination, catheter flush
61985034|NCT01014520|EXPERIMENTAL|Gabapentin|Neurontin
61985035|NCT01014520|EXPERIMENTAL|Amitriptyline|Elavil
61985036|NCT04819087|EXPERIMENTAL|Patients|Patients with Pelvic Floor Dysfunction Related Temporamandibular Joint Problems and Tinnitus
61985037|NCT04375189|NO_INTERVENTION|Standard Care|
61985038|NCT04375189|EXPERIMENTAL|Complex Clinic Arm|
61985039|NCT02051777|OTHER|ONS 1 and DA|Oral Nutritional Supplement 1 and Dietary Advice
61985040|NCT02051777|OTHER|ONS 2 and DA|Oral Nutritional Supplement 2 and Dietary Advice
61985041|NCT02051777|OTHER|DA Alone|Dietary Advice Alone
61985042|NCT06398054|PLACEBO_COMPARATOR|Ibuprofen|will receive one tablet of ibuprofen 400 mg and two tablets of placebo (similar in size, structure and colour to Hyoscine N-Butil Bromide)
61985043|NCT06398054|EXPERIMENTAL|Ibuprofen plus HHB|will assume one tablet of ibuprofen 400 mg plus two tablets of Hyoscine N-Butil Bromid 10 mg.
61985044|NCT00665353|EXPERIMENTAL|PIO (step 1) then PIO+PEG-INF+RBV (step 2)|All participants in this study will receive pioglitazone therapy for 24 to 28 weeks. Participants will continue pioglitazone and add peginterferon and ribavirin to their treatment regimen for up to 48 additional weeks.
61985045|NCT04415632|EXPERIMENTAL|LGI Diet|low glycemic index diet
61985046|NCT04415632|OTHER|HGI Diet|High glycemic index diet
61985047|NCT03889158|EXPERIMENTAL|Acute Inflammation|All participants will receive the typhoid vaccination (intramuscular injection, 0.5 mL, 1 time).
61985048|NCT03889158|EXPERIMENTAL|Ascorbic Acid|All participants will receive ascorbic acid (Vit C) on two occasions \[oral pill, 2g, 2x (baseline, during acute inflammation)\].
61985049|NCT04500210|PLACEBO_COMPARATOR|Placebo|one capsule daily
61985050|NCT04500210|ACTIVE_COMPARATOR|Turmeric extract|one capsule daily
61985051|NCT04324060|ACTIVE_COMPARATOR|TPO treatment group|Danazol 0.2g tid po+rhTPO (recombinant human thrombopoietin injection) 300U/kg/d×14d si every month (stop when PLT≥100×10e9/L or increased more than 50×10e9/L), total course 6 months
61985052|NCT04324060|PLACEBO_COMPARATOR|control|Danazol 0.2g tid po+ control (sodium chloride)×14d si every month, total course 6 months
61985053|NCT06502626|EXPERIMENTAL|Sprint Interval Training|Sprint interval training will be given for 4 weeks. Each week consisted of three training sessions, separated by at least one resting day. Participants will complete a 15-minutes warm up before training session. The Sprint interval training group consisted of 30 s sprints at near maximal effort, with three minutes of rest between each sprint. The training intensity of Sprint interval training sessions was evaluated subjectively during sessions. During the first week, the Sprint interval training group performed five sprints per session. The number of sprints then increased gradually, until a total of 10 sprints per session. When the number of sprints reached seven, subjects were given six minutes of rest midway through the training session
61985054|NCT06502626|OTHER|Regular Training|Regular training will be done.
61985055|NCT05268614|EXPERIMENTAL|Chemo-radiotherapy|Participants will receive chemo-radiotherapy.
61985056|NCT04001881||Hypotension group|spinal anesthesia in Hypotensive patients with low LV-EF Transthoracic echocardiography of IVC before spinal anaesthesia
61985057|NCT04001881||Normotension group|spinal anesthesia IN Normotensive patients with low LV-EF Transthoracic echocardiography of IVC before spinal anaesthesia
61985058|NCT02177279|OTHER|Visit A- 120g wheat bran cereals|A morning vist where volunteers consumed 120g of wheat bran cereals with 125ml semi-skimmed milk
61985059|NCT02177279|OTHER|Visit B-40g wheat bran cereals|A morning vist where volunteers consumed 40g of wheat bran cereals with 375 ml semi-skimmed milk
61985060|NCT02177279|OTHER|Follow up-40g (8days), 120g (1day) wheat bran cereals|Volunteers follow their normal diet but they were asked to consume 40g wheat bran cereals with 125 ml semi-skimmed milk for eight days and on day nine 120g wheat bran cereals with 375ml semi-skimmed milk
61985061|NCT05968807|EXPERIMENTAL|iParent2Parent Program|
61985062|NCT05968807|NO_INTERVENTION|Standard of Care Waitlist Control Group|
61985063|NCT01627821|ACTIVE_COMPARATOR|Jarvik 2000 Treatment|Jarvik 2000 VAS, Post-Auricular Cable
61985064|NCT01627821|ACTIVE_COMPARATOR|HeartMate II Control|HeartMate II VAS Control
61985065|NCT04699409|EXPERIMENTAL|FAST|stroke education: FAST
62739225|NCT02584452|ACTIVE_COMPARATOR|Long Acting Single Bolus Adductor Canal Nerve Block|Ultrasound guided femoral nerve block with 20cc of 2% mepivacaine \<20 minutes prior to in room time. Intraoperative patients will undergo initiation of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert this group will receive ultrasound guided adductor canal nerve block with 10cc of 0.5% ropivacaine and 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve.
61985066|NCT04699409|EXPERIMENTAL|STROKE 112|stroke education: STROKE 112
61985067|NCT05516433||Imipenem|Prescribing rules differ from one department to another: Imipenem is the preferred drug at Saint-Joseph Hospital.
61985068|NCT05516433||Meropenem|Prescribing rules differ from one department to another: Meropenem is the preferred carbapenem at Avicenne Hospital.
62362857|NCT00067626|EXPERIMENTAL|2|500/1000 mcg oral chromium taken daily or placebo (crossover)
62362858|NCT05438706|EXPERIMENTAL|Arm 1|chidamide in combination with camrelizumab and capecitabine
61985069|NCT00712829|EXPERIMENTAL|1|123-I-MIP-1072 administration followed by 123-I-MIP-1095 administration two weeks later.
61985070|NCT00712829|EXPERIMENTAL|2|123-I-MIP-1095 administration followed by 123-I-MIP-1072 administration two weeks later.
61985071|NCT01975909|ACTIVE_COMPARATOR|Transcranial Magnetic Stimulation (TMS)|A Magstim 200 (Magstim, UK) and 14cm circular coil positioned tangential to the head will be used to deliver stimuli at 100% of maximum stimulator output. Transcranial Magnetic Stimulation will be applied to three regions: 1) 4cm lateral to the right of the inion, 2) centered on the inion, 3) 4cm lateral to the left of the inion. Five pulses separated by 6 seconds will be delivered with a counter-clockwise current, followed by the same five pulses delivered with a clockwise current, for a total of 10 pulses per region, and 30 pulses per session.
61985072|NCT01975909|SHAM_COMPARATOR|Sham Transcranial Magnetic Stimulation|A sham condition of Transcranial Magnetic Stimulation will be used and follow the same protocol as the active stimulation; however no magnetic pulses will be delivered through the scalp.
61985073|NCT03852550|EXPERIMENTAL|Usual Care + MyREADYTransition[TM] BBD App|Participants in the experimental Intervention group continue to get the same care they have been getting (their usual care) and they receive the MyREADY Transition\[TM\] BBD App e-health application. There are 19 parts in the App with videos and games to help youth learn and practice ways to manage their health. There are approximately 5-7 hours of content in total. Participants will be asked to wait at least one day between the parts. There is a timer in the App to help to moderate pace and align with how young people learn and digest information. Participants can choose how much time they want to take to do the App. It is recommended that participants make their own routine for using it. The recommended shortest and longest intervention exposure times are: 1 part each day (this will take 19 days to do all of the App), 1 part each week (this will take 19 weeks to do all of the App).
61985074|NCT03852550|NO_INTERVENTION|Control Group: Usual Care|Participants in the no intervention Control group continue to get the same care they have been getting (their usual care). The researchers aim to supply the App to participants in both the intervention and control group for a limited time after participation in the study.
61985075|NCT02558712|OTHER|Face to face exam|Standard of clinical care, 8 point eye exam
61985076|NCT05955118||Open Angle Glaucoma|Subjects with mild to moderate open angle glaucoma undergoing bilateral combined cataract surgery \& Hydrus Microstent implantation.
61985077|NCT03809507||NC Clinicians|Qualtrics Survey of NC Clinicians with DEA registration
61985078|NCT02289976|ACTIVE_COMPARATOR|femoral condyle|Core decompression of the talar avascular necrosis followed by free microvascular femoral condyle grafting
61985079|NCT02289976|ACTIVE_COMPARATOR|core decompression|Core decompression and nonvascularized autograft from the iliac crest
61985080|NCT02672423|EXPERIMENTAL|Abemaciclib Part A|Reference formulation (R) = 3 x 50 mg abemaciclib capsules, Test formulation (T150) = 150 mg abemaciclib tablet administered orally on Day 1 in each of 2 periods.
61985081|NCT02672423|EXPERIMENTAL|Abemaciclib Part B|R = 3 x 50 mg abemaciclib capsules, T150 = 150 mg abemaciclib tablet, Test Formulation 50 (T50) = 3 x 50 mg abemaciclib tablets administered orally on Day 1 in each of 3 periods.
61985082|NCT02672423|EXPERIMENTAL|Abemaciclib Part C|T150 Fed and T150 Fasted = 150 mg abemaciclib tablet with a high-fat meal (T150 Fed) and then without a high-fat meal (T150 Fasted) on Day 1 in each of 2 periods administered orally.
61985083|NCT06523036|EXPERIMENTAL|Combined chiropractic care and Tai Chi|All participants will be enrolled in a 16-week intervention period during which time they will receive 10 chiropractic treatments in addition to weekly Tai Chi training.
61985084|NCT06001554|EXPERIMENTAL|ICC-T|5 days with 8 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
61985085|NCT06001554|NO_INTERVENTION|monitoring condition|No intervention
61985086|NCT05757947|ACTIVE_COMPARATOR|"no-touch saphenous vein as I-graft"|Coronary bypass surgery according to the I-graft method. Proximal anastomosis to RIMA.
61985087|NCT05757947|ACTIVE_COMPARATOR|"no-touch saphenous vein as conventional free graft"|Coronary artery bypass grafting using the free conduit technique. Proximal anastomosis to aorta.
61985088|NCT03388619|EXPERIMENTAL|Arm 1/Prostate Bed with Integrated Boost|Prostate bed with integrated boost.
61985089|NCT03388619|EXPERIMENTAL|Arm 2/Prostate Bed Irradiation Only|Prostate bed irradiation only.
61985090|NCT05353127||Patiënts who underwent a CPET prior to elective colorectal surgery investigate fitness level.|Patients considered for colorectal cancer surgery who were ≥18 years of age, had a score ≤7 metabolic equivalents of task on the veterans-specific activity questionnaire.
61985091|NCT00229255|ACTIVE_COMPARATOR|high frequency meals group|High carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
61985092|NCT00229255|ACTIVE_COMPARATOR|twice-a -day meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks
62362859|NCT05438706|EXPERIMENTAL|Arm 2|chidamide in combination with camrelizumab and carboplatin
61985093|NCT01287273||Group A|Transfer at the day of embryo thawing
61985094|NCT01287273||Group B|Transfer of thawed embryos 24-72 hours post thawing
61985095|NCT04734509|EXPERIMENTAL|Porter Brown Breathing system|"The Porter Brown has a double mask system that is characterized by a mask-within-a-mask scavenging system. The system includes easy to remove inner masks which vent into the outer mask. This helps in cleaning and sterilization. The soft inner part of the mask system provides a comfortable fit and an excellent seal around the patient's nose.~This mask is routinely used in inhalation sedation for children's dental treatment.~This is a sterilisable system."
61985096|NCT04734509|EXPERIMENTAL|Silhouette Breathing system|The Silhouette is a single-use nasal mask and breathing circuit with lightweight tubing and an adhesive strip across the bridge of the nose to secure the mask in place and create a good seal around the patient's nose.
61985097|NCT02563795||Group I|Pregnant with BMI\<30 and having spinal anesthesia with 10 mg hyperbaric bupivacaine
61985098|NCT02563795||Group II|Pregnant with BMI\<30 and having spinal anesthesia with 7,5 mg hyperbaric bupivacaine+25 mcg fentanyl
61985099|NCT02563795||Group III|Pregnant with BMI\>30 and having spinal anesthesia with 10 mg hyperbaric bupivacaine
61985100|NCT02563795||Group IV|Pregnant with BMI\>30 and having spinal anesthesia with 7,5 mg hyperbaric bupivacaine+25 mcg fentanyl
61985101|NCT01061242|NO_INTERVENTION|Baseline|Post-Intensive Care Unit (ICU) neurocognitive testing and sleep survey performed on patients exposed to ad-lib Medical ICU environment.
61985102|NCT01061242|EXPERIMENTAL|Sleep Promotion Group|Post-ICU neurocognitive testing and sleep survey performed on patients exposed to interventions in the pre-existing MICU sleep quality improvement project.
61985103|NCT06242587|ACTIVE_COMPARATOR|Group Pericoccygeal block|Patients undergoing pericoccygeal block
62362860|NCT03101527|EXPERIMENTAL|Supplementation|Subjects received Omega-3 PUFA supplementation
62362861|NCT00112684|EXPERIMENTAL|Treatment (chemotherapy, biological therapy)|Patients receive alvocidib IV over 4½ hours once weekly in weeks 1-4. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62362862|NCT05431712||DSA+|Patients with pre-transplantation detected donor-specific antibodies, with Luminex Single Antigen Bead analysis.
62362863|NCT05431712||PRA+|Immunized controls without DSAs pre-transplantation, with equal peak PRA levels and donor/recipient age as the DSA+ group.
62362864|NCT05431712||PRA-|Non-immunized controls without DSAs pre-transplantation, with a peak PRA of less than 6%, with equal donor/recipient age as the DSA+ group.
62567130|NCT06566131|EXPERIMENTAL|PuzzleWalk (Gamified mHealth)|"PuzzleWalk integrates gamification strategies and incentivization of walking behaviors to induce target behavior changes. Capitalizing on the distinctive attributes and preferences of autistic adults, PW emphasizes the advantages of visual learning while minimizing the need for undesired face-to-face social interactions. A novel feature is its conversion algorithm that translates daily step counts into playtime for spot the difference puzzle games, which leverages the psychological satisfactions of autonomy, relatedness, and competence."
61985104|NCT06242587|ACTIVE_COMPARATOR|Group Impar ganglion block|Patients undergoing impar ganglion block
61985105|NCT04327232|EXPERIMENTAL|Active|"For patients randomized to active experimental arm: Spironolactone~Patient will receive study drug for 18 months. Study drug dosages are 1 tablet alternate day, 1 tablet per day, or 2 tablets per day, with 1 tablet being 25mg spironolactone. Study drugs are titrated every 3 months based on patients' potassium and eGFR blood tests results."
61985106|NCT04327232|PLACEBO_COMPARATOR|Control|"For patients randomized to control arm: Placebo~Patient will receive placebo for 18 months. Placebo dosages are 1 tablet alternate day, 1 tablet per day, or 2 tablets per day. Placebo are titrated every 3 months based on patients' potassium and eGFR blood tests results."
61985107|NCT02280564|NO_INTERVENTION|Control|Standard diabetes care
61985108|NCT02280564|EXPERIMENTAL|Health coaching with technology support|Behavioral strategies including problem solving skills building, family communication counseling, technology support, motivational interviewing support.
61985109|NCT00383149|EXPERIMENTAL|Ixabepilone plus Cetuximab|All participants were administered ixabepilone at a starting dose of 32 mg/m\^2 as a 3-hour intravenous (IV) infusion every 3 weeks. In addition, all participants were administered an initial dose of cetuximab (400 mg/m\^2 IV over 2 hours) followed by a weekly lower dose (250 mg/m\^2 IV over 1 hour).
61985110|NCT00913367|ACTIVE_COMPARATOR|Amaryl group|
61985111|NCT00913367|EXPERIMENTAL|Amaryl M group|
61985112|NCT04225299|EXPERIMENTAL|TOOKAD®|TOOKAD® , lyophilized formulation, given at a dose of 4mg/Kg.
61985113|NCT04225299|NO_INTERVENTION|Active Surveillance|Active surveillance is one of the management strategy in men who have intermediate risk localised prostate cancer
61985114|NCT06253611|EXPERIMENTAL|Nivolumab Combined With FOLFOX and EXL01|Nivolumab 240 mg IV q2w and FOLFOX q2w plus EXL01 orally once daily
61985115|NCT06253611|ACTIVE_COMPARATOR|Nivolumab and FOLFOX|Nivolumab 240 mg IV q2w and FOLFOX q2w
61985116|NCT03176992|ACTIVE_COMPARATOR|Surgicel group|80 patients underwent formal curettage followed by insertion of 4 pieces of Surgicel inside the uterine cavity
61985117|NCT03176992|NO_INTERVENTION|Thermal balloon ablation group|80 patients underwent thermal balloon ablation using bipolar radiofrequency electrical energy (Novasure)
61985118|NCT03176992|NO_INTERVENTION|Endometrial resection group|80 patients underwent transcervical Hysteroscopic endometrial resection
61985119|NCT02045797|EXPERIMENTAL|Treatment Group A|Subject will receive GSK2140944 750mg IV every 12 hours (q12h; twice daily \[BID\]) on Day 1 and Day 2. Subject may switch to GSK2140944 1500mg orally (PO) q12h (BID) at investigator's decision or will continue to receive GSK2140944 750mg IV q12h (BID) from Day 3 to Day 10.
62362865|NCT05721196|EXPERIMENTAL|Culturally adapted Psychoeducation (CaPE)|
62362866|NCT05721196|ACTIVE_COMPARATOR|Treatment as Usual (TaU)|
62362867|NCT03712527|EXPERIMENTAL|Platelet-Rich Plasma|
62362868|NCT03712527|PLACEBO_COMPARATOR|Placebo|
62362869|NCT04685538|EXPERIMENTAL|Chloroprocaine 3%|All the eligible patients will be administrated by Chloroprocaine 3 % according to the randomization criteria.
62362870|NCT04685538|ACTIVE_COMPARATOR|Tetracaine 0.5%|All the eligible patients will be administrated by Tetracaine 0.5% according to the randomization criteria.
62362871|NCT05920200||Patients with groin and femoral hernia/IG|
62362872|NCT05920200||Patients with umbilical hernia/IG|
61985120|NCT02045797|EXPERIMENTAL|Treatment Group B|Subject will receive GSK2140944 1000mg IV q12h (BID) on Day 1 and Day 2 . Subject may switch to GSK2140944 2000mg PO q12h (BID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q12h (BID) from Day 3 to Day 10.
61985121|NCT02045797|EXPERIMENTAL|Treatment Group C|Subject will receive GSK2140944 1000mg IV q8h (TID) on Day 1 and Day 2. Subject may switch to GSK2140944 2000mg PO q8h (TID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q8h (TID) from Day 3 to Day 10.
61985122|NCT02681120||High risk/BMI > 30|Women at elevated risk for breast cancer will have imaging (MRI and mammogram) pre-bariatric surgery and 1 year post-bariatric surgery, and blood and tissue collection (blood draw and biopsy) pre-bariatric surgery, 2 weeks post-bariatric surgery, and 1 year post-bariatric surgery.
61985123|NCT02681120||Women with normal BMI|Deidentified samples that were donated to the IU Komen Tissue Bank will be used for comparison to the high risk/BMI \> 30 cohort.
61985124|NCT03525210|OTHER|HIV patients|All HIV patients will receive the study vaccines
61985125|NCT03525210|OTHER|SOT patients|All SOT patients will receive the study vaccines
62362873|NCT05920200||Patients with ventral and incisional hernia/InG|
62362874|NCT03054740|ACTIVE_COMPARATOR|Gebauer Ethyl Chloride|Device: Vapocoolant (Ethyl Chloride Mist Spray)
62362875|NCT03054740|PLACEBO_COMPARATOR|Nature's Tears|Device: Sterile Water
62362876|NCT03437291||Abnormal placental invasion|patients had placenta previa with histopathologically confirmed abnormal invasion with all three grades i.e. accreta, increta and percreta,
61985126|NCT05114616|EXPERIMENTAL|Sleep Study and Daytime MWT|Health volunteers completing one overnight sleep study followed by daytime MWT. The sleep study will include standard surface electrodes as well as EEGBuds. Participants will be asked to wear Ellcie Healthy glasses, concurrent with the EEGBuds, during each MWT trial.
61985127|NCT02596594|EXPERIMENTAL|Port intervention|"The subcutaneous intraumbilical port-system will be implanted in IUGR patients with the cerebroplacental ratio less than 1 (cerebroplacental ratio= PI in the middle cerebral artery / PI umbilical artery) between 24/0 and 30/0 weeks of gestation.~The fetuses will receive AAs and glucose supplementation via a subcutaneously implanted intraumbilical perinatal port system till the delivery. Control by doppler and cardiotocogram"
61985128|NCT02596594|NO_INTERVENTION|control|"IUGR patients with the cerebroplacental ratio less than 1 (CPR= PI middle cerebral artery / PI umbilical artery) between 24/0 and 30/0 weeks of gestation.~Control by doppler and cardiotocogram"
61985129|NCT02205333|EXPERIMENTAL|MEDI6469 6 mg/kg|Participants received MEDI6469 6 milligram/kilogram (mg/kg) as a single intravenous (IV) administration on Day 1
61985130|NCT02205333|EXPERIMENTAL|MEDI6469 10 mg/kg|Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1
62362877|NCT03437291||Normal placenta|patients had placenta previa with no abnormal invasion
62391414|NCT03437980|EXPERIMENTAL|propofol spinal acceptance|"The surgeon and the anesthetist will discuss the exclusion criteria. Then they will discuss the information's about spinal and general anesthesia with the illegible patients, also reply the patient's questions in a preoperative visit. The primary decision for the patient; either spinal or general anesthesia will be recorded.~The patients refusing spinal anesthesia will be discussed again to detect the rate of acceptance of spinal anesthesia if propofol sedation is ensured during the procedure to provide a painless spinal injection. The final decision will be applied; either spinal with procedural sedation, or general anesthesia."
62391415|NCT04035356||HAART 300|HAART 300 Aortic Annuloplasty Device
61985131|NCT02205333|EXPERIMENTAL|MEDI6469 2 mg/kg+Tremelimumab 3 mg/k|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 3 mg/kg as IV administration on Day 1 then every 4 weeks (Q4W) for 6 doses, after which every 12 weeks (Q12W) for 2 doses or until PD
61985132|NCT02205333|EXPERIMENTAL|MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 10 mg/kg as IV administration on Day 1 then Q4W for 6 doses after which Q12W for 2 doses or until progression of disease (PD)
61985133|NCT02205333|EXPERIMENTAL|MEDI6469 2 mg/kg+Durvalumab 3 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 3 mg/kg as IV administration on Day 1 then every 2 weeks (Q2W) for 12 months or until PD
61985134|NCT02205333|EXPERIMENTAL|MEDI6469 2 mg/kg+Durvalumab 10 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
61985135|NCT02205333|EXPERIMENTAL|MEDI6469 10 mg/kg+Durvalumab 10 mg/kg|Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
61985136|NCT02205333|EXPERIMENTAL|MEDI6469 2 mg/kg+Rituximab 375 mg/m^2|Participants received MEDI6469 2 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed complete response (CR) plus 1 cycle, or PD plus rituximab 375 mg/m\^2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
62391416|NCT04035356||HAART 200|HAART 200 Aortic Annuloplasty Device
62391417|NCT02082743|EXPERIMENTAL|Outdoor activity|Outdoor activity in recess time
62391418|NCT02082743|NO_INTERVENTION|Control|
62391419|NCT03723746|EXPERIMENTAL|Cohort 1: Dose 1 or Placebo (Part 1 - SD)|Participants will receive a single oral dose (single day \[SD\] Dose 1) of either JNJ-67670187 or placebo capsules after an overnight fast on Day 1 of Part 1.
62391420|NCT03723746|EXPERIMENTAL|Cohort 2: Dose 2 or Placebo (Part 1 - SD)|Participants will receive a single oral dose (Dose 2) of either JNJ-67670187 or placebo capsules after an overnight fast on Day 1 of Part 1.
62391421|NCT03723746|EXPERIMENTAL|Cohort 3: Dose 1 or Placebo (Part 2 - MD)|Participants will receive an oral dose (Multiple Day \[MD\] Dose 1) of either JNJ-67670187 or placebo capsules once daily for 14 days without antibiotic pretreatment after an overnight fast in Part 2.
62391422|NCT03723746|EXPERIMENTAL|Cohort 4:Antibiotic + Dose 1 or Placebo (Part 2 - MD)|Participants will receive pretreatment with an oral antibiotic, followed by an oral dose (Dose 1) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2.
62391423|NCT03723746|EXPERIMENTAL|Cohort 5: Dose 2 or Placebo (Part 2 - MD)|Participants will receive an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily without antibiotic pretreatment for 14 days after an overnight fast in Part 2.
62362878|NCT01727557|ACTIVE_COMPARATOR|Local anesthesia|
62362879|NCT01727557|ACTIVE_COMPARATOR|regional anesthesia|
62362880|NCT02887365|EXPERIMENTAL|tegafur-uracil|tegafur-uracil treatment in patients with stage II MSI-L or MSS colon cancer
62362881|NCT02887365|NO_INTERVENTION|Observation|Observation for one year
62362882|NCT04717895|EXPERIMENTAL|1st Situation|Subjects included will be identified with an even selection number will begin the virtual reality session by viewing a rocking environment followed by a translation environment
62362883|NCT04717895|ACTIVE_COMPARATOR|2nd Situation|Subjects included will be identified with an odd selection number will start the virtual reality session by viewing a translation environment followed by a rocking environment
62362884|NCT01244204|EXPERIMENTAL|Vitamin D|
62362885|NCT01244204|PLACEBO_COMPARATOR|Placebo|
62362886|NCT04390997|NO_INTERVENTION|Periodontally Healthy|20 participants with bleeding on probing less than 10%, probing depths less than 4mm, and no clinical attachment loss which was measured by six sites per tooth
61985137|NCT02205333|EXPERIMENTAL|MEDI6469 10 mg/kg+Rituximab 375 mg/m^2|Participants received MEDI6469 10 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed CR plus 1 cycle, or PD plus rituximab 375 mg/m2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
62362887|NCT04390997|NO_INTERVENTION|Gingivitis|20 participants with bleeding on probing greater than 10%, probing depths less than 4mm, and no clinical attachment loss which was measured by six sites per tooth
62362888|NCT04390997|OTHER|Periodontitis|20 participants with bleeding on probing greater than or equal to 30%, probing depths greater than or equal to 5mm at least non-adjacent two teeth in each quadrant of the dentition, and clinical attachment loss greater than or equal to 4mm which was measured by six sites per tooth, and radiographic bone loss on the coronal third of root or severe (vertical/ horizontal) bone loss.
62362889|NCT01983618|PLACEBO_COMPARATOR|Interscalene catheter|No block will be performed prior to surgery. An interscalene catheter will be inserted under ultrasound guidance by the anesthesiologist before the induction of anesthesia. Local anesthetics will only be administered once all TCD assessments are completed but prior to the end of surgery.
62362890|NCT01983618|EXPERIMENTAL|Interscalene nerve block and catheter|The anesthesiologist will perform the interscalene nerve block and insert an interscalene catheter under ultrasound guidance before induction of anesthesia. A standardized mixture of bupivacaine, lidocaine and epinephrine will be administered prior to surgery.
61985138|NCT00281684|EXPERIMENTAL|Placebo|Eligible participants received a single dose of SB705498 matching placebo capsules (4 placebo capsules) via oral route and were followed up to a maximum of 14 days.
62362891|NCT05725200|EXPERIMENTAL|Individualized treatment in patients with metastatic colorectal cancer|"Interventions with anti-cancer drugs having marketing authorisation in Norway will be used in this study.~The intervention will be study drugs as monotherapy or treatment with approved combinations.~This trial will facilitate access to potentially effective interventions to which they would otherwise not have access."
61985139|NCT00281684|EXPERIMENTAL|SB705498 400 mg|Eligible participants received a single dose of SB705498 400 milligram (mg) capsules (2 x 200 mg capsules plus 2 placebo capsules) via oral route and were followed up to a maximum of 14 days.
61985140|NCT00281684|EXPERIMENTAL|SB705498 1000 mg|Eligible participants received a single dose of SB705498 1000 mg capsules (2 x 200 mg capsules plus 2 x 300 mg capsules) via oral route and were followed up to a maximum of 14 days.
61985141|NCT00281684|EXPERIMENTAL|Co-Codamol|Eligible participants received a single dose of Co-codamol capsules (2 x Paracetamol Ph Eur 500 mg, codeine phosphate hemihydrate Ph Eur 12.8 mg plus two placebo capsules) via oral route and were followed up to a maximum of 14 days.
61985142|NCT05537077|ACTIVE_COMPARATOR|Group 1|%5 Dextrose prolotherapy, hotpack therapy and home based exercise program was applied to group 1.
61985143|NCT05537077|ACTIVE_COMPARATOR|Group 2|%10 Dextrose prolotherapy, hotpack therapy and home based exercise program was applied to group 2.
62362892|NCT02870257|EXPERIMENTAL|Progressive overload strengthening group|"Strengthening protocol with progressive load~Strengthening muscle exercises for the shoulder and scapular with progressive increase of load during 10 weeks (20 sessions)"
62362893|NCT02870257|ACTIVE_COMPARATOR|Strengthening group|"Strengthening protocol without progressive load~Strengthening muscle exercises for the shoulder and scapular without increase of load (minimal load) during 10 weeks (20 sessions)"
62362894|NCT01089218|NO_INTERVENTION|control|control without intervention
62362895|NCT01089218|ACTIVE_COMPARATOR|Amoxicillin/clavulanate|
62362896|NCT01138397|EXPERIMENTAL|Group 1|Participants at 18 to 59 years of age
62362897|NCT01138397|EXPERIMENTAL|Group 2|Participants at 60 years of age or older
62362898|NCT04717661||76 healthy early pregnant women in the trial group|The pulse sound waves of three parts and five layers of each of the two hands of 76 pregnant women will be collected by Pulse Detection System of Sound Waves.
61985144|NCT05537077|ACTIVE_COMPARATOR|Group 3|%20 Dextrose prolotherapy, hotpack therapy and home based exercise program was applied to group 3.
61985145|NCT05537077|ACTIVE_COMPARATOR|Group 4|Hotpack therapy and home based exercise program was applied to group 4.
61985146|NCT05693714||1|One group who have adenovirus infection
61985147|NCT03165110|EXPERIMENTAL|Users of the Onyx Blood Glucose Meter/ app System at home|Participants have a diagnosis of either type 1 or type 2 diabetes for at least 6 months and use insulin.
61985148|NCT05488691|EXPERIMENTAL|Eye Movement Desensitization and Reprocessing therapy|8 to 10 individual 60-minutes sessions over 2 months.
62362899|NCT04717661||76 relatively healthy non-pregnant women in the control group|The pulse sound waves of three parts and five layers of each of the two hands of 76 relatively healthy non-pregnant women will be collected by Pulse Detection System of Sound Waves.
62362900|NCT00225212|EXPERIMENTAL|Rituximab after ASCT|Rituximab 375 mg/m2 starting 6 weeks after ASCT transplant, and for the 5th and subsequent subjects, a second course at the same dose 6 months after ASCT.
62362901|NCT01390038|EXPERIMENTAL|Simpliciti™ Shoulder System|The Simpliciti™ Shoulder System is intended for Total Shoulder Arthroplasty of the shoulder.
62362902|NCT03251872|EXPERIMENTAL|Drug: Olaparib|Olaparib up to 400 mg BID (100 to 400 mg) for 16 weeks
62362903|NCT03924648||premature ovarian insufficiency|Idiopatic premature ovarian insufficiency (POI), defined as loss of ovarian function and subsequent amenorrhea before the age of 40.
62362904|NCT03924648||Control|The investigators compared patients with POI to a cohort of age matched healthy controls recruited among women who visited the gynecology clinic for routine examination or from hospital workers. All volunteers for the control group had regular menstrual cycles and no concomitant health problems.
62362905|NCT01351857|OTHER|Transition Coordinator|A Transition Coordinator, a Certified Diabetes Educator, will provide transition support and the link between pediatric and adult diabetes care. The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
62362906|NCT01351857|NO_INTERVENTION|Current Standard of Care|Subjects in the control group will transition to adult care equal to the intervention group and will differ only by exclusion of Transition Coordinator. Control group will receive the current standard of diabetes care otherwise unchanged. Three months following randomization, subjects in the control group will be referred to the adult endocrinologist in the same way as subjects in the intervention group
62362907|NCT03048409||Enteral tube fed adults|Enteral formula
62362908|NCT03658317|ACTIVE_COMPARATOR|cases|laboratory tests including (random blood glucose , serum urea and creatinine , lipogram , serum uric acid , HbA1c , urine analysis , 24 hours urinary proteins ) abdominal ultrasonography dupplex on the renal vessels
62362909|NCT03658317|ACTIVE_COMPARATOR|controls|laboratory tests including (random blood glucose , serum urea and creatinine , lipogram , serum uric acid , HbA1c , urine analysis , 24 hours urinary proteins ) abdominal ultrasonography dupplex on the renal vessels
62362910|NCT05212402|EXPERIMENTAL|Test Product|28 participants will be given the test product (TP)
62362911|NCT05212402|PLACEBO_COMPARATOR|Placebo|28 participants will be given the placebo product.
61985149|NCT05488691|ACTIVE_COMPARATOR|Treatment as usual|Same periodicity as the experimental group and at the same time range.
61985150|NCT04481633|OTHER|Patient treated with Hydroxy-chloroquine|patients treated with Hydroxy-Chloroquine (HC) with or without immunosuppressants (IS)(HC+ group, n=400)
61985151|NCT04481633|OTHER|Patient without treatment with Hydroxy-chloroquine|patients without treatment with Hydroxy-Chloroquine with or without immunosuppressants
61985152|NCT01165255||Infants born to women who were exposed to antidepressants|Women ages 12 through 49 (as of delivery date) who were dispensed an antidepressant between 01 January 1995 and 30 September 2004 from the original Bupropion study.
61985153|NCT01819454|EXPERIMENTAL|pH monitoring sinusitis no polyps|30 patients with chronic rhinosinusitis without nasal polyposis, without asthma bronchiale or ASA syndrome
61985154|NCT01819454|EXPERIMENTAL|pH monitoring sinusitis with polyp|30 patients with chronic rhinosinusitis with nasal polyposis, without asthma bronchiale or ASA syndrome
61985155|NCT01819454|EXPERIMENTAL|pH monitoring sinusitis, polyps, asthma|30 patients with chronic rhinosinusitis with nasal polyposis and with asthma bronchiale and/or ASA syndrome
61985156|NCT02164747||Control group before telemedicine|Residents of nursing homes without telemedicine before implementation of telemedicine in nursing homes with telemedicine
61985157|NCT02164747||Control group after telemedicine|Residents of nursing homes without telemedicine after implementation of telemedicine in nursing homes with telemedicine
61985158|NCT02164747||Exposed group, before telemedicine|Residents of nursing homes with telemedicine prior implementation of telemedicine
61985159|NCT02164747||Exposed group, after telemedicine|Residents of nursing homes with telemedicine after implementation of telemedicine
62362912|NCT04606407|EXPERIMENTAL|Treatment|Inhaled NO delivered using LungFit™ in addition to standard of care
62362913|NCT04606407|NO_INTERVENTION|Standard of care|Standard of care
62362914|NCT01020968|EXPERIMENTAL|Ixmyelocel-T|The treatment arm of the study will receive catheter-based injections of the study cellular product.
62362915|NCT01020968|PLACEBO_COMPARATOR|Vehicle Control|will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control.
62362916|NCT06216106||patients undergone prepectoral breast reconstruction|As the retrospective nature of this study, we have no exlusion criterias. We included all the patients with prepectoral breast reconstruction with polyurethane covered implants. We also included patients underwent postoperative radiation therapy (50 patients) and 20 patients with history of previous radiotherapy
62362917|NCT02574819|EXPERIMENTAL|Drug|Methylnaltrexone (MNTX) nearly 0.15mg/kg administered every other day for 2 weeks.
62362918|NCT02574819|PLACEBO_COMPARATOR|Placebo|Placebo administered every other day for 2 weeks.
62391424|NCT03723746|EXPERIMENTAL|Cohort 6:Antibiotic + Dose 2 or Placebo (Part 2 - MD)|Participants will receive pretreatment with an oral antibiotic, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2.
61985160|NCT03432546||ICU patients|Over 18-year old intensive care patients, non-interventional prospective observational study
61985161|NCT00636909|EXPERIMENTAL|1|Study treatment arm with G-CSF
61985162|NCT00003573|EXPERIMENTAL|Treatment 1, Etoposide, 50mg/m2/day|"Patients begin treatment within 1 month of surgery. Patients receive 6 weeks of radiation therapy to the head and spine, with boosts to the posterior fossa and to sites of metastasis. Patients also receive 2 courses of oral etoposide once daily for 3 weeks concurrent with and immediately following radiotherapy (weeks 1-3 and 5-7).~Patients then receive adjuvant chemotherapy consisting of cisplatin IV once every 4 weeks for 3 courses beginning on week 11, oral etoposide daily for 21 days every 4 weeks for 3 courses (weeks 11, 15, and 19), cyclophosphamide IV on days 1 and 2 with filgrastim (G-CSF) SQ daily for at least 10 days every 4 weeks for 8 courses (weeks 23-51), and vincristine IV on days 1, 8, and 15 every 4 weeks for 8 courses (weeks 23-51)."
62169488|NCT02511808|OTHER|Control: MI|After receiving one session of Brief Advice (BA) and two sessions of Motivational Interviewing (MI) or one session of BA over the first 8 weeks of the study, participants will be assessed at week 8 for response to this treatment. Those who are deemed non-responders will be randomly assigned to receive Behavioral Self-Control Training (BSCT) or more MI if they were randomized to MI at week 4 or five sessions of combined MI and BSCT or one more session of MI if they were randomized to BA at week 4. In this arm, participants will receive one session of MI if they received MI at the previous randomization or two sessions of MI if they received BA at the previous randomization.
62169489|NCT01081236||Compensated liver cirrhosis|
61985163|NCT00003573|EXPERIMENTAL|Treatment 2, Etoposide, 35mg/m2/day|"Patients begin treatment within 1 month of surgery. Patients receive 6 weeks of radiation therapy to the head and spine, with boosts to the posterior fossa and to sites of metastasis. Patients also receive 2 courses of oral etoposide once daily for 3 weeks concurrent with and immediately following radiotherapy (weeks 1-3 and 5-7).~Patients then receive adjuvant chemotherapy consisting of cisplatin IV once every 4 weeks for 3 courses beginning on week 11, oral etoposide daily for 21 days every 4 weeks for 3 courses (weeks 11, 15, and 19), cyclophosphamide IV on days 1 and 2 with filgrastim (G-CSF) SQ daily for at least 10 days every 4 weeks for 8 courses (weeks 23-51), and vincristine IV on days 1, 8, and 15 every 4 weeks for 8 courses (weeks 23-51)."
61985164|NCT03946033|OTHER|Single arm|All participants are included in the same arm. Immunoscore Colon Test is applied on a tumor sample and the result is kept secret. In the Multidisciplinary Meeting evaluating the adjuvant therapy of the participant, a first therapeutic decision is taken, then Immunoscore result will be disclosed and the Multidisciplinary Meeting will take a second decision.
61985165|NCT05132959||Patient Group|Patients with supraspinatus tendinosis
61985166|NCT05132959||Control Group|Patients without shoulder pain
61985167|NCT01565109|EXPERIMENTAL|Single arm study|"Docetaxel - Cisplatine - 5FU 2 cycles of Docetaxel - Cisplatine - 5 FU~Radiation: Radiation of 45 Grays on 5 weeks Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks"
61985168|NCT02207790|EXPERIMENTAL|E2609 low-dose and placebo in healthy Japanese subjects|Cohort 1 will consist of Japanese subjects randomized to a low-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
61985169|NCT02207790|EXPERIMENTAL|E2609 mid-dose and placebo in healthy Japanese subjects|Cohort 2 will consist of Japanese subjects randomized to a mid-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
61985170|NCT02207790|EXPERIMENTAL|E2609 high-dose and placebo in healthy Japanese subjects|Cohort 3 will consist of Japanese subjects randomized to a high-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
62362919|NCT02451488|EXPERIMENTAL|GM-CSF|Patients will be treated with 14 days of GM-CSF self-administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on the day of enrollment. Patients will be instructed in the self-administration of GM-CSF and after they have demonstrated competency with the procedure, they will self-administer the treatment at home. Patients will undergo surgery within 1 day to 5 days after cessation of the GM-CSF therapy.
62362920|NCT02451488|OTHER|Standard of Care|no neo-adjuvant therapy prior to surgical intervention
62362921|NCT03368352|NO_INTERVENTION|Normoxia|Sleep in normal room air with no drug
62362922|NCT03368352|PLACEBO_COMPARATOR|Hypoxia with Placebo|Sleep in hypoxic tent after taking Placebo 1 hour before bed.
62362923|NCT03368352|EXPERIMENTAL|Hypoxia with Melatonin|Sleep in hypoxic tent after taking 5 mg Melatonin before bed.
61985171|NCT02207790|EXPERIMENTAL|E2609 mid-dose and placebo in healthy White subjects|Cohort 4 will consist of White subjects randomized to a mid-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
61985172|NCT01254227|EXPERIMENTAL|Deferasirox|Deferoxamine combination followed by Deferasirox monotherapy
61985173|NCT04972084|EXPERIMENTAL|Powerscope group|Class II patients which will receive treatment using Powerscope appliance
62362924|NCT02003768|EXPERIMENTAL|TIVA|2% Propofol (Fresofol®), Remifentanil 20mcg/cc (Ultiva®)
62362925|NCT02003768|ACTIVE_COMPARATOR|Des|Desflurane (Suprane®), Remifentanil continuous infusion (20mcg/cc)
62362926|NCT04140539|EXPERIMENTAL|Gene Therapy|Infusion OTL-101
62362927|NCT00187850|EXPERIMENTAL|PP|Partial pulpotomy
62362928|NCT00187850|OTHER|DPC|Direct pulp capping
62362929|NCT05256316||Previously admitted COVID-19 patients in intensive care units|Infectious Diseases Physicians from participating hospitals will identify patients with COVID-19 admitted to their hospital who had an intensive care unit stay during the first 60 days after hospital admission.
62362930|NCT00528008|ACTIVE_COMPARATOR|A|povidone-iodine
61985174|NCT06110429|EXPERIMENTAL|lactate sodium|100 mL of Sodium lactate (Osmolality 2560 mOsm/L) in 15 mins of administration via a central venous catheter
61985175|NCT06110429|ACTIVE_COMPARATOR|Hypertonic Saline solution|single infusion of 100 mL of 7.5% saline (osmolarity, 2560 mOsm/L) (HSS group)in 15 mins of administration via a central venous catheter
62362931|NCT00528008|ACTIVE_COMPARATOR|B|chlorhexidine gluconate
61985176|NCT06371404||PTSD|Subjects with Post Traumatic Stress Disorder
61985177|NCT06371404||AUD|Subjects with Alcohol Use Disorder
61985178|NCT06371404||PTSD & AUD|Subjects with Post Traumatic Stress Disorder and Alcohol Use Disorder
61985179|NCT06371404||HC|Healthy Control Subjects
61985180|NCT06371404||TC|Trauma-exposed healthy control subjects.
61985181|NCT03852303|ACTIVE_COMPARATOR|ivermectin once a year|Ivermectin one dose per year and anti-epileptic treatment
62362932|NCT04546867|OTHER|Sonography arm|Sonography is being performed by expericenced investigators to visualize a pancreatic stent in the pancreatic duct. If the stent is being visualized, an endoscopy will be performed to remove the stent. Otherwise, x-ray will be needed to confirm the sonographic finding of a dislodged pancreatic stent with no further need of intervention. If x-ray finds a pancreatic stent in situ opposingly to ultrasound, an endoscopy will be performed to confirm the stents position and eventually remove it.
62362933|NCT05178290|EXPERIMENTAL|CHILD testing|One child and parent dyad will be tested for COVID-19 using the ASU saliva test as part of back-to-ECE safely programming. All sites will receive this condition.
62362934|NCT05178290|EXPERIMENTAL|CHILD+ personnel testing|This arm receives the CHILD condition plus ECE site personnel are screened biweekly for COVID-19 using the ASU saliva test.
62362935|NCT05178290|EXPERIMENTAL|SAGE garden|The SAGE arm is a garden-based curriculum that emphasizes outdoor learning opportunities such as active games, songs, and garden-activities. About half of the original 40 sites (roughly evenly divided by CHILD and CHILD+) will receive this in year one, and the remaining sites will receive this condition in year two.
62739226|NCT03718884|EXPERIMENTAL|Drug Cocktail|"Period 1:~Participants received a single dose of the following drug cocktail on Day 1: 1 mg midazolam, 10 mg warfarin, 10 mg vitamin K, 30 mg dextromethorphan, 20 mg omeprazole, 100 mg Caffeine administered orally"
62362936|NCT05178290|SHAM_COMPARATOR|Wait list|Those in the wait list condition will receive SAGE in year two.
62362937|NCT01769625|PLACEBO_COMPARATOR|placebo & cholecalciferol 400 IU|In this arm, the placebo is in place of celecoxib and the current RDA for cholecalciferol is used the control of the cholecalciferol higher dose.
61985182|NCT03852303|EXPERIMENTAL|ivermectin 2 times a year|Ivermectin one dose 2 times a year and anti-epileptic treatment
61985183|NCT03852303|EXPERIMENTAL|ivermectin 3 times a year|vermectin one dose 3 times a year and anti-epileptic treatment
62362938|NCT01769625|ACTIVE_COMPARATOR|placebo & cholecalciferol 2,000 IU|Placebo \& cholecalciferol 2,000 IU
62362939|NCT01769625|EXPERIMENTAL|celecoxib 400mg & cholecalciferol 2,000 IU|celecoxib 400 mg \& cholecalciferol2,000 IU
62362940|NCT04823546|EXPERIMENTAL|Activity based therapy|"Activity based training was done in 2 phases. exercise involve~1. Standing and reaching~2. Sit-to-stand~3. Stepping forward and backward Phase 2 Phase 2 started after 3 weeks. Phase 2 included the phase 1 exercise along with below exercise.~(10) Walking on a treadmill;"
62362941|NCT04823546|ACTIVE_COMPARATOR|strength training|Strength training for hip • flexor and extensors and abductors, knee extensors, and ankle dorsi flexors and plantar •flexors. Apart from using body weight, sandbag weights and Therabands of eight different resistances
62362942|NCT03674541|ACTIVE_COMPARATOR|Study Drug - Pyridostigmine|Pyridostigmine 60 mg by mouth as a one time dose
62362943|NCT03674541|PLACEBO_COMPARATOR|Placebo|Placebo by mouth as a one time dose
62362944|NCT03504267|EXPERIMENTAL|Physical Activity Group|The PAG (physical activity) group will receive evidence-based educational information as well as a list of local resources for pursuing physical activity.
62362945|NCT03504267|NO_INTERVENTION|Standard of Care Group|The SOC (standard of care) group will receive no additional information beyond standard-of-care brochures and information
62362946|NCT01026350|EXPERIMENTAL|study group|
62362947|NCT02408926|EXPERIMENTAL|Group A|Women will be vaccinated with an acellular pertussis containing vaccine (Boostrix) between 27 and 36 weeks of gestation. Children born from these mothers will be vaccinated according to the official recommendations in Thailand at 2, 4, 6 and 18 months with a hexavalent acellular pertussis containing vaccine (Infanrix hexa).
61985184|NCT04608786|EXPERIMENTAL|Combined the therapy using Capecitabine and PD-L1|PD-L1 antibody ZKAB001 D1 5mg/kg every three weeks,up to 16 cycles or 1 year of treatment or the patient has tumor recurrence or metastasis Capecitabine 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis
61985185|NCT02062333|ACTIVE_COMPARATOR|dexmedetomidine|0,4-0,8 µg./kg./h dexmedetomidine
61985186|NCT02062333|ACTIVE_COMPARATOR|esmolol|100- 300 µg./kg./min esmolol
61985187|NCT01962129||Patients affected by a syndrome OFD|
61985188|NCT01962129||Patients AFFECTED BY A SEVERE MENTAL RETARDATION SYNDROMIQUE|
61985189|NCT00101114|EXPERIMENTAL|Treatment (sorafenib tosylate, interferon alpha-2b)|Patients receive oral sorafenib twice daily on days 1-28 and interferon alfa subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61985190|NCT00631527|EXPERIMENTAL|Sunitinib Malate, Hormone Ablation + RT|Sunitinib Malate + Hormone Ablation (Leuprolide or Goserelin + Bicalutamide) + Radiation Therapy (RT)
62362948|NCT02408926|ACTIVE_COMPARATOR|Group B|Women will be vaccinated with an acellular pertussis containing vaccine (Boostrix) between 27 and 36 weeks of gestation. Children born from these mothers will be vaccinated according to the official recommendations in Thailand at 2, 4, 6 and 18 months with a pentavalent whole cell pertussis containing vaccine (Quinvaxem). OPV (oral poliovirus vaccine) will also be administered at 2, 4, 6 and 18 months.
62362949|NCT03105245|ACTIVE_COMPARATOR|Short time interval + Normal ventilation|
62362950|NCT03105245|ACTIVE_COMPARATOR|Short time interval + Hyperventilation|
62362951|NCT03105245|ACTIVE_COMPARATOR|Long time interval + Normal ventilation|
62362952|NCT03105245|ACTIVE_COMPARATOR|Long time interval + Hyperventilation|
62362953|NCT03835988|EXPERIMENTAL|Geniculate Artery Embolization|Patients undergoing geniculate artery embolization. Patients will be assessed and followed post-procedurally to detect changes in knee pain and function. Medication use, adverse events and performance based tests of physical function will also be recorded. A pre-procedural MRI will be compared to a 6 month post-procedure MRI to assess for changes in synovitis and assess for complications.
62362954|NCT02842541|EXPERIMENTAL|Single dose arm|Subjects will receive a single intravitreal dose of EBI-031
61985191|NCT05215301||Occupational Voice Users|Workers who uses voice extensively during work falls under occupational voice users (e.g. singers, actors, radio announcer, teacher, translator, lawyer). The grouping were made based on references from The Union of the European Phoniatricians
61985192|NCT05215301||Non-occupational Voice Users|Those who didn't use voice extensively during work falls under non-occupational voice users (motorcycle drivers, daily labor, administrative workers)
62362955|NCT02842541|EXPERIMENTAL|Repeat dose arm|Subjects will receive an intravitreal dose of EBI-031 monthly for 3 months
62362956|NCT05515445|EXPERIMENTAL|Normal Hepatic Function|Subjects with normal hepatic function will receive a single 48 mg oral dose of Chiglitazar
62362957|NCT05515445|EXPERIMENTAL|Mild Hepatic Impairment|Subjects with mild hepatic impairment will receive a single 48 mg oral dose of Chiglitazar
62362958|NCT05515445|EXPERIMENTAL|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment will receive a single 48 mg oral dose of Chiglitazar
61985193|NCT00954902|SHAM_COMPARATOR|No spice, no stress|Subject are given placebo capsules and told they contain an antioxidant concentrate
61985194|NCT00954902|SHAM_COMPARATOR|No Spice, Stress|Subjects are given placebo capsules and told they are receiving an equivalent amount of an antioxidant concentrate.
62169490|NCT01081236||Decompensated liver cirrhosis|
62169491|NCT03051529||combined spinal epidural|24 patients with dilated cardiomyopathy undergoing vascular surgery in the lower half of the body under combined spinal epidural anesthesia will be enrolled in the study
62169492|NCT03410095||Sleep apnea patients|80 patients recently diagnosed with severe sleep apnea will participate in the Brain Changes in Sleep Apnea Study.
61985195|NCT00954902|EXPERIMENTAL|Spice, no stress|
62362959|NCT05515445|EXPERIMENTAL|Severe Hepatic Impairment|Subjects with severe hepatic impairment will receive a single 48 mg oral dose of Chiglitazar
62362960|NCT04734977|EXPERIMENTAL|HILT+exercise|Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of four weeks, and one session per day for a total of 20 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist.
62362961|NCT04734977|SHAM_COMPARATOR|Sham HILT+exercise|Sham therapy was applied in five sessions a week for four weeks, with a total of 20 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist.
62362962|NCT04734977|ACTIVE_COMPARATOR|Exercise only|Exercise program was applied in five sessions a week for four weeks, with a total of 20 sessions a day.
62362963|NCT05065268|EXPERIMENTAL|Interventional|Immersive virtual-reality stimulation (IVR): 1 session of 3 blocks of 15 trials of 20 seconds each. Rest time is 1-2 minute(s) between blocks. 1 session lasts 19 minutes.1 session every 2 days for 4 weeks (15 sessions total).
62362964|NCT03874416|EXPERIMENTAL|Specific rehabilitation of working memory|Specific rehabilitation of working memory according to hierarchized rehabilitation.
62362965|NCT03874416|ACTIVE_COMPARATOR|Control group|Non-specific rehabilitation of working memory, usual therapy.
62362966|NCT00441480|ACTIVE_COMPARATOR|Plant sterol esters|plant sterols esterified to fish oil fatty acids
62362967|NCT00441480|PLACEBO_COMPARATOR|placebo|Corn oil
62362968|NCT03950960|EXPERIMENTAL|BMS-986256 +Itraconazole|
61985196|NCT00954902|EXPERIMENTAL|Spice and Stress|
62362969|NCT05338658|EXPERIMENTAL|Peptide Alarm Therapy + Pembrolizumab|"Participants receive pembrolizumab 200 mg every 3 weeks (Dose Finding Component) or a disease appropriate PD1/PD-L1 inhibitor (Dose Expansion Component) for 2 treatment courses per standard of care.~The first dose of PAT is given on Day 1 and on Day 3 (36 to 48 hours after the 1st PAT dose)~A second course of the PD1/PD-L1 inhibitor is given per standard of care on Day 22 (Cycle 2 Day 1)."
62362970|NCT01024920|EXPERIMENTAL|Nintedanib (BIBF 1120)|Non-marketed substance: Twice daily oral doses of 200mg BIBF 1120 given continuously.
62362971|NCT01024920|ACTIVE_COMPARATOR|sunitinib|Marketed substance: Once a day oral doses of 50mg sunitinib given in repeated 6 week cycles: 4 weeks active, 2 weeks rest.
62362972|NCT05612594|EXPERIMENTAL|Bexagliflozin|Bexagliflozin once daily for 6 months
62362973|NCT05612594|PLACEBO_COMPARATOR|Placebo|Placebo once daily for 6 months
62362974|NCT05653856|EXPERIMENTAL|Diagnostic Imaging with 64Cu-PSMA-I&T|64Cu-PSMA I\&T
62362975|NCT00814307|EXPERIMENTAL|Active 5mg|
62362976|NCT00814307|EXPERIMENTAL|Active 10 mg|
62362977|NCT00814307|PLACEBO_COMPARATOR|Placebo Sequence 1|
61985197|NCT03722550|ACTIVE_COMPARATOR|Control Group|Standard Starter Infant Formula, Standard Follow-up Formula, and Standard Growing-up Milk
62362978|NCT00814307|PLACEBO_COMPARATOR|Placebo Sequence 2|
62362979|NCT02666040|EXPERIMENTAL|U - ULTRAPRO|Inguinal Hernia Surgery with ULTRAPRO® meshes, a new ULTRAPRO® mesh will be implanted in patients in the group (AG). The surgery will be evaluated in terms of procedure, detecting the mode of admission to hospital, the duration of surgery, anesthesia volume and type used, composition of the surgical equipment.
62362980|NCT02666040|ACTIVE_COMPARATOR|P - Prolene|"Inguinal Hernia Surgery with Prolene® meshes, the conventional mesh in polypropylene Prolene® will be implanted in patients in the control group (CG). The surgery will be evaluated in terms of procedure, detecting the mode of admission to hospital, the duration of surgery, anesthesia volume and type used, composition of the surgical equipment."
62362981|NCT02104141||Operated Subjects|ROIA Interbody Cage with VerteBRIDGE plating
62362982|NCT04553367|PLACEBO_COMPARATOR|Group A|patients of group A Continue on the conventional way of ventilation and . Microbiological results collected from patients of group A through qualitative sputum.
62362983|NCT04553367|ACTIVE_COMPARATOR|Group B|had three times bronchoscopy one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period to confirm both clinical and bacteriological cure. Bronchoscopy done with the following precautions: we used flexible bronchoscopy Olympus BF-160 adult size, patients kept sedated with both midazolam and fentanyl, 4 syringe of normal isotonic saline used for wash every one 10 ml and suction done immediately after injection, suction of the fluid and small airway secretion after only the first injection of isotonic saline syringe used for BAL and sent for qualitative culture
62362984|NCT06507605|EXPERIMENTAL|Arm 1a (n=20)|6μg Pfs230D1-CRM197 + 5μg of R21 in 50μg Matrix-M
62362985|NCT06507605|EXPERIMENTAL|Arm 1b (n=20)|6μg Pfs230D1-CRM197 + 10μg of R21 in 50μg Matrix-M
62362986|NCT06507605|EXPERIMENTAL|Arm 1c (n=20)|12μg Pfs230D1-CRM197 + 5μg of R21 in 50μg Matrix-M
62362987|NCT06507605|EXPERIMENTAL|Arm 1d (n=20)|12μg Pfs230D1-CRM197 + 10μg of R21 in 50μg Matrix-M
62362988|NCT06507605|ACTIVE_COMPARATOR|Arm 1e (n=20)|5μg of R21 in 50μg Matrix-M
61985198|NCT03722550|EXPERIMENTAL|Test Group 1|Starter Infant Formula (same as Control Group) supplemented with 1.5g/L of Human Milk Oligosaccharides, Follow-up Formula (same as Control Group) supplemented with 0.5g/L of Human Milk Oligosaccharides, and Growing-up Milk (same as Control Group) supplemented with 0.4g/L of Human Milk Oligosaccharides
61985199|NCT03722550|EXPERIMENTAL|Test Group 2|Starter Infant Formula (same as Control Group) supplemented with 2.5g/L of Human Milk Oligosaccharides, Follow-up Formula (same as Control Group) supplemented with 0.5g/L of Human Milk Oligosaccharides, and Growing-up Milk (same as Control Group) supplemented with 0.4g/L of Human Milk Oligosaccharides
61985200|NCT03722550|ACTIVE_COMPARATOR|Breastfed Group|Non-randomized Breastfed reference group
62169493|NCT00703599|EXPERIMENTAL|1|This is the only arm and that is the treatment group.
62362989|NCT06507605|ACTIVE_COMPARATOR|Arm 1f (n=20)|10μg of R21 in 50μg Matrix-M
62362990|NCT06507605|EXPERIMENTAL|Arm 2a (n=20)|20μg Pfs230D1-CRM197 + 5μg of R21 in 50μg Matrix-M
62362991|NCT06507605|EXPERIMENTAL|Arm 2b (n=20)|20μg Pfs230D1-CRM197 + 10μg of R21 in 50μg Matrix-M
62362992|NCT06507605|EXPERIMENTAL|Arm 2c (n=20)|20μg Pfs230D1-CRM197 in 50μg Matrix-M
62362993|NCT06507605|EXPERIMENTAL|Arm 2d (n=20)|20μg Pfs230D1-EPA + 5μg of R21 in 50μg Matrix-M
62362994|NCT06507605|EXPERIMENTAL|Arm 3a (n=20)|40μg Pfs230D1-CRM197 + 5μg of R21 in 50μg Matrix-M
62362995|NCT06507605|EXPERIMENTAL|Arm 3b (n=20)|40μg Pfs230D1-CRM197 + 10μg of R21 in 50μg Matrix-M
62362996|NCT05375162|EXPERIMENTAL|Exp Condition 1|Research participant receives the Core Intervention + E-Coach + General Mindfulness Training + MVPA Specific Mindfulness Training + Buddy
62362997|NCT05375162|ACTIVE_COMPARATOR|Exp Condition 2|Research participant receives the Core Intervention + E-Coach + General Mindfulness Training + MVPA Specific Mindfulness Training
62362998|NCT05375162|ACTIVE_COMPARATOR|Exp Condition 3|Research participant receives the Core Intervention + E-Coach + Buddy
62362999|NCT05375162|ACTIVE_COMPARATOR|Exp Condition 4|Research participant receives the Core Intervention + E-Coach
62363000|NCT05375162|ACTIVE_COMPARATOR|Exp Condition 5|Research participant receives the Core Intervention + E-Coach + General Mindfulness Training + Buddy
62363001|NCT05375162|ACTIVE_COMPARATOR|Exp Condition 6|Research participant receives the Core Intervention + E-Coach + General Mindfulness Training
62363002|NCT05375162|ACTIVE_COMPARATOR|Exp Condition 7|Research participant receives the Core Intervention + E-Coach + MVPA Specific Mindfulness Training + Buddy
62363003|NCT05375162|ACTIVE_COMPARATOR|Exp Condition 8|Research participant receives the Core Intervention + E-Coach + MVPA Specific Mindfulness Training
61985201|NCT02786147||Patient Initiated|Patients randomized into this group will receive a standard handout explaining their result, which includes information on how to obtain cancer genetics services through Winship. However, neither the patient nor their ordering clinician will be directly contacted regarding the B-RST result.
61985202|NCT02786147||Physician Notification|Patients randomized into this group will also receive the standard handout explaining their result. In addition, their primary care physician or ordering physician will be notified via Emory Electronic Medical Record (EeMR) that the patient screened positive on the B-RST. The note will provide specific instructions on how to refer the patient for cancer genetic counseling services.
61985203|NCT02786147||Automatic Follow-Up By Genetic Counseling Staff|Patients randomized into this group will also receive the standard handout explaining their result. Within 1-2 weeks after their mammogram appointment, patients will receive a phone call from a genetics counseling staff person to explain their screening result and to offer to set up a genetics counseling appointment. This call may take up to 10 - 15 minutes.
61985204|NCT04853745||sodium bicarbonate group|Sodium bicarbonate-based powder (CLASSIC®, EMS SA, Nyon, Switzerland) was used for air polishing the samples belonging to this group. All surfaces were numbered and application was made to the mesial and distal surfaces of the root, buccal and lingual surfaces of the crown to avoid repeated instrumentations. After device and samples were fixed, a metal plate with a 5 mm diameter hole was placed on the sample to limit the application area. Surfaces one and three were air-polished using the with a medium power setting (9 LED power setting), and surfaces two and four were air-polished using the with a maximum power setting (17 LED power setting). The distance between the handpiece and the tooth surface was kept constant at 5 mm, and the treatment angulation was adjusted to 60 degrees. In all applications, the application time was 5 seconds and the water setting was medium (6 LED). The powder chambers of the device were filled to the maximum level in each application.
61985205|NCT04853745||glycine group|Glycine-based powder (PERIO®, EMS SA, Nyon, Switzerland) was used for air polishing the samples belonging to this group. All surfaces were numbered and application was made to the mesial and distal surfaces of the root, buccal and lingual surfaces of the crown to avoid repeated instrumentations. After device and samples were fixed, a metal plate with a 5 mm diameter hole was placed on the sample to limit the application area. Surfaces one and three were air-polished using the with a medium power setting (9 LED power setting), and surfaces two and four were air-polished using the with a maximum power setting (17 LED power setting). The distance between the handpiece and the tooth surface was kept constant at 5 mm, and the treatment angulation was adjusted to 60 degrees. In all applications, the application time was 5 seconds and the water setting was medium (6 LED). The powder chambers of the device were filled to the maximum level in each application.
61985206|NCT04853745||erythritol group|Erythritol-based powder (PLUS®, EMS SA, Nyon, Switzerland) was used for air polishing the samples belonging to this group. All surfaces were numbered and application was made to the mesial and distal surfaces of the root, buccal and lingual surfaces of the crown to avoid repeated instrumentations. After device and samples were fixed, a metal plate with a 5 mm diameter hole was placed on the sample to limit the application area. Surfaces one and three were air-polished using the with a medium power setting (9 LED power setting), and surfaces two and four were air-polished using the with a maximum power setting (17 LED power setting). The distance between the handpiece and the tooth surface was kept constant at 5 mm, and the treatment angulation was adjusted to 60 degrees. In all applications, the application time was 5 seconds and the water setting was medium (6 LED). The powder chambers of the device were filled to the maximum level in each application.
61985207|NCT00805623|NO_INTERVENTION|AW|no pacifier , no sucrose
61985208|NCT00805623|ACTIVE_COMPARATOR|AS|sucrose without pacifier
61985209|NCT00805623|NO_INTERVENTION|PW|
62363004|NCT05375162|ACTIVE_COMPARATOR|Exp Condition 9|Research participant receives the Core Intervention + General Mindfulness Training + Buddy
62363005|NCT05375162|ACTIVE_COMPARATOR|Exp Condition 10|Research participant receives the Core Intervention + General Mindfulness Training
62363006|NCT05375162|ACTIVE_COMPARATOR|Exp Condition 11|Research participant receives the Core Intervention + MVPA Specific Mindfulness Training + Buddy
62363007|NCT05375162|ACTIVE_COMPARATOR|Exp Condition 12|Research participant receives the Core Intervention + MVPA Specific Mindfulness Training
62363008|NCT05375162|ACTIVE_COMPARATOR|Exp Condition 13|Research participant receives the Core Intervention + General Mindfulness Training + MVPA Specific Mindfulness Training + Buddy
62363009|NCT05375162|ACTIVE_COMPARATOR|Exp Condition 14|Research participant receives the Core Intervention + General Mindfulness Training + MVPA Specific Mindfulness Training
62363010|NCT05375162|ACTIVE_COMPARATOR|Exp Condition 15|Research participant receives the Core Intervention + Buddy
62363011|NCT05375162|ACTIVE_COMPARATOR|Exp Condition 16|Research participant receives the Core Intervention
62363012|NCT01569087|EXPERIMENTAL|Empegfilgrastim 3 mg|Patients will receive a single administration of empegfilgrastim at a dose of 3 mg subcutaneously , 24 h after the chemotherapy
62363013|NCT01569087|EXPERIMENTAL|Empegfilgrastim 6 mg|Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy
62363014|NCT01569087|ACTIVE_COMPARATOR|Filgrastim|Patients will receive filgrastim subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy
61985210|NCT00805623|EXPERIMENTAL|PS|Pacifier and sucrose interventional
61985211|NCT01958775|EXPERIMENTAL|GLP=2|active treatment with a single dose of GLP-2 (1500mcg)
61985212|NCT01958775|PLACEBO_COMPARATOR|Placebo|placebo
61985213|NCT00103181|ACTIVE_COMPARATOR|Group 1: WBI|Patients undergo whole breast irradiation (WBI) once daily, 5 days a week for 5-7 weeks.
61985214|NCT00103181|EXPERIMENTAL|Group 2: PBI|Patients undergo partial-breast irradiation (PBI) twice daily on 5 days over a period of 5-10 days. This may be delivered by intracavitary brachytherapy, MammoSite or other single-entry intracavitary device, or 3-dimensional conformal accelerated partial breast irradiation.
61985215|NCT05077592|NO_INTERVENTION|Control|Direct Wound closure
61985216|NCT05077592|ACTIVE_COMPARATOR|Intervention|The use of 10% surgical povidone iodine to wash the wound directly after fascial closure and before wound closure
61985217|NCT01980355|EXPERIMENTAL|Tranexamic Acid|1000mg tranexamic acid; given over 15 minutes into the vein once prior to surgery.
61985218|NCT01980355|PLACEBO_COMPARATOR|Placebo|Placebo given over 15 minutes into the vein once prior to surgery.
61985219|NCT02144233|EXPERIMENTAL|Occlusal adjustment therapy|Occlusal adjustment therapy consists of the elimination of premature tooth contacts during retruded jaw closure, and the reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance). A resin-composite, placed mainly in the canine tooth, can be used to increases the flatter lateral guidance on the habitual chewing side; overcorrection is expected to compensate for a masticatory preference on the opposite side to the handedness.
61985220|NCT02144233|PLACEBO_COMPARATOR|Placebo occlusal adjustment therapy|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
61985221|NCT00994240|ACTIVE_COMPARATOR|ED&C times 3 cycles|
61985222|NCT00994240|ACTIVE_COMPARATOR|ED & C times 1 cycle|
62363015|NCT03582852|ACTIVE_COMPARATOR|promontory|Laparoscopic sacrocolpopexy, which consist in fixing a mesh between vaginal anterior wall
62363016|NCT03582852|ACTIVE_COMPARATOR|laparoscopic lateral suspension|The procedure consists in spreading out bilaterally, a subperitoneal T-shaped mesh in the anterior abdominal wall
62363017|NCT02414113||Low GNOS donors|
62363018|NCT02414113||High GNOS donors|
61985223|NCT06362187|EXPERIMENTAL|Gut Directed VR|
61985224|NCT06362187|SHAM_COMPARATOR|Sham VR|
61985225|NCT00134160|ACTIVE_COMPARATOR|1|High-dose ARB monotherapy
61985226|NCT00134160|ACTIVE_COMPARATOR|2|Combination therapy of ARB with Calcium Channel Blocker
61985227|NCT05384067|EXPERIMENTAL|Mindfulness-based intervention|Participants in this arm will wear a sleep-monitoring device, complete questionnaires and participate in an online mindfulness component each week for the duration of this study.
61985228|NCT05384067|NO_INTERVENTION|Control|Participants in this arm will only wear a sleep-monitoring device and complete questionnaires.
61985229|NCT04243187|EXPERIMENTAL|Clinical Study|"9 visits, once a week, for bean intake (80 grams of dried beans, soaked for 12 hours, cooked in new water for 1.5 - 2 hours. This is approximately 160 grams of cooked beans).~Four varieties of beans (3 native and 1 commercial) will be analyzed, which will be consumed in duplicate by participants (8 visits).~A ninth visit will be made to perform a exhaled hydrogen test with raffinose (5 grams), as a positive control."
61985230|NCT00727974||1|"Diagnostic Criteria for CVS:~3 or more different episodes of vomiting, normal health between episodes, no abnormal test results to account for vomiting \[such as endoscopic biopsies (looking at a body part with a lighted tube), hydronephrosis (water block kidney drainage), cholelithiasis (gallstones), pancreatitis (swelling of the pancreas), and hypoglycemia (too little sugar in the blood)\];"
61985231|NCT00727974||2|"Diagnostic Criteria for Migraine:~5 or more different headaches, complete return to health in between headaches, headaches last 2-48 hours and get in the way everyday activity, headache affects one side of head, with pounding moderate-to-severe pain, one of the following: nausea, vomiting, photophobia (fear of light), phonophobia (fear of sound)."
61985232|NCT03928847|OTHER|EGCG PK in healthy volunteers 450 mg|Healthy volunteers: 450 mg Epigallocatechin-3-gallate (EGCG) capsules administered once daily by mouth
61985233|NCT03928847|OTHER|EGCG PK in healthy volunteers 600 mg|Healthy volunteers: 600 mg Epigallocatechin-3-gallate (EGCG) capsules administered once daily by mouth
62169494|NCT05043688|EXPERIMENTAL|Neoadjuvant Chemotherapy With Camrelizumab|Chemotherapy: Paclitaxel（Albumin Bound）100mg/m2, Day 1,8,15，Carboplatin AUC=5mg/ml/min, Day 1； Camrelizumab: Day 1, every 3 weeks, 2 cycles; Postoperative adjuvant treatment: Camrelizumab maintenance
61985234|NCT03928847|OTHER|EGCG PK in healthy volunteers 750 mg|Healthy volunteers: 750 mg Epigallocatechin-3-gallate (EGCG) capsules administered once daily by mouth
61985235|NCT03928847|NO_INTERVENTION|No treatment control in ILD patients|Patients: not treated with EGCG
61985236|NCT03928847|EXPERIMENTAL|EGCG treatment in ILD patients|Patients: 600 mg EGCG capsules once daily by mouth for two weeks
61985237|NCT02440477||partial rotator cuff tears|50 subjects with shoulder pain who are diagnosed with partial rotator cuff degenrative tears by ultrasound. All patients will be measured for their body weight and height and their hand dominance will be notified. Following reliability trials on the first 10 subjects, all subjects will be tested for pain provocation and level of pain (VAS) in both shoulders with 3 commonly used clinical shoulder tests for the diagnosis of rotator cuff diseases Empty can ,Neer test and Hawkins-Kennedy test in 3 sitting postures; normal resting posture, slouched posture, and upright posture with scapular retraction. In addition, the rotator cuff muscle strength tests during shoulder abduction, internal rotation and external rotation will be measured for the 2 shoulders using a hand-held dynamometer.
62169495|NCT05043688|EXPERIMENTAL|Neoadjuvant Radiochemotherapy With Camrelizumab|Chemotherapy: Paclitaxel 50mg/m2, Day 1,8,15,22,29，Carboplatin AUC=2mg/ml/min，Day 1,8,15,22,29 Camrelizumab: 200mg，Day 1,22 Radiotherapy: 41.4 Gy , D1-5/W Postoperative adjuvant treatment：Camrelizumab maintenance
62363019|NCT05813613||Healthy Group|"* Will perform squatting exercise while reporting subjective muscle fatigue levels periodically, until maximal subjective fatigue is reached~* Will have sEMG for vastus lateralis and rectus femoris, chest expansion, goniometry for the knee recording using the Biopac."
61985238|NCT02440477||control group|50 volunteering subjects without any pain in the upper quadrant.All patients will be measured for their body weight and height and their hand dominance will be notified. Following reliability trials on the first 10 subjects, all subjects will be tested for pain provocation and level of pain (VAS) in both shoulders with 3 commonly used clinical shoulder tests for the diagnosis of rotator cuff diseases Empty can ,Neer test and Hawkins-Kennedy test in 3 sitting postures; normal resting posture, slouched posture, and upright posture with scapular retraction. In addition, the rotator cuff muscle strength tests during shoulder abduction, internal rotation and external rotation will be measured for the 2 shoulders using a hand-held dynamometer.
61985239|NCT01402674|ACTIVE_COMPARATOR|LPT|Subjects treated with phentermine for 2 years or more.
61985240|NCT01402674|NO_INTERVENTION|APT|Patients treated with phentermine for 7 to 14 days.
61985241|NCT05024058|EXPERIMENTAL|Ligelizumab low dose, symptomatic dermographism group|Ligelizumab low dose subcutaneous injection every 4 weeks in participants with symptomatic dermographism
61985242|NCT05024058|EXPERIMENTAL|Ligelizumab high dose, symptomatic dermographism|Ligelizumab high dose subcutaneous injection every 4 weeks in participants with symptomatic dermographism
61985243|NCT05024058|PLACEBO_COMPARATOR|Placebo SC q4W, symptomatic dermographism|Placebo subcutaneous injection every 4 weeks in participants with symptomatic dermographism
61985244|NCT05024058|EXPERIMENTAL|Ligelizumab low dose, cold urticaria|Ligelizumab low dose subcutaneous injection every 4 weeks in participants with cold urticaria
61985245|NCT05024058|EXPERIMENTAL|Ligelizumab high dose, cold urticaria|Ligelizumab high dose subcutaneous injections every 4 weeks in participants with cold urticaria
61985246|NCT05024058|PLACEBO_COMPARATOR|Placebo SC q4w, cold urticaria|Placebo subcutaneous injection every 4 weeks in participants with cold urticaria
61985247|NCT05024058|EXPERIMENTAL|Ligelizumab high dose, cholinergic urticaria|Ligelizumab high dose subcutaneous injections every 4 weeks in participants with cholinergic urticaria
61985248|NCT05024058|PLACEBO_COMPARATOR|Placebo SC q4w, cholinergic urticaria|Placebo subcutaneous injections every 4 weeks in participants with cholinergic urticaria
61985249|NCT04645407|EXPERIMENTAL|FZHY Group|conventional therapy plus Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time.)
61985250|NCT04645407|NO_INTERVENTION|Control Group|conventional therapy
61985251|NCT01908257|EXPERIMENTAL|Sequence 1 fasted|"Day 1: Lesinurad 400 mg once daily (qd)~Day 5: Ranitidine 150 mg twice daily (bid)~Day 6: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad.~Day 7: Ranitidine 150 mg (bid)"
61985252|NCT01908257|EXPERIMENTAL|Sequence 2 fasted|"Day 1: Ranitidine 150 mg (bid)~Day 2: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad~Day 3: Ranitidine 150 mg (bid)~Day 7: Lesinurad 400 mg (qd)"
61985253|NCT05306301|EXPERIMENTAL|Patients With BCR/ABL1-Like Acute Lymphoblastic Leukemia|"In the run-in phase, patients will receive a dosage of 15 mg of ICLUSIG (ponatinib). If there are no toxicities observed, 30 mg of ponatinib will be administered in the remaining patients. MRD of patients will be evaluated on weeks 4, 10, 16, and 22. If a donor is available, MRD-positive patients will proceed to an allogeneic transplant after cycle 3. If there is no donor available, they'll continue treatment with 5 additional consolidation/reinduction blocks, followed by 24 28-day cycles of maintenance.~Induction/consolidation cycles are administered at 28 (cycles 1-2) and 21(cycles 2-8) day intervals."
61985254|NCT04500834|EXPERIMENTAL|Positive reactions, Concordance with reference allergen|All subjects will be patch tested with 11 experimental and 11 reference allergens. Rates of positive reactions will be evaluated using Cohen's kappa calculation.
61985255|NCT05328128|EXPERIMENTAL|Study Group|Children and families included in the study group were directed to the child development unit to receive toilet training.
61985256|NCT05328128|NO_INTERVENTION|Control Group|The control group consisted of families who wanted to manage toilet training process themselves.
61985257|NCT03683758|EXPERIMENTAL|FIFA11+ / Intervention Group|This group will complete the FIFA11+ warm-up three times per week for eight weeks.
61985258|NCT03683758|ACTIVE_COMPARATOR|Typical Warm-up / Control Group|This group will complete their usual warm-up three times per week for eight weeks
61985259|NCT03756688|NO_INTERVENTION|Group 1: Control|No treatment will be administered for the entirety of the study (6 months)
61985260|NCT03756688|EXPERIMENTAL|Group 2: Treatment|PTT for 30 min 2x/ day x 3 months, followed by no treatment x 3 months
61985261|NCT03756688|EXPERIMENTAL|Group 3: Treatment|PTT for 30 min 2x/day x 3 months, followed by once weekly (30 minutes) x 3 months
61985262|NCT03756688|EXPERIMENTAL|Group 4: Treatment|PTT for 30 min 2x day x 6 months
61985263|NCT04804943|EXPERIMENTAL|NOA-001 group (ARDS caused by Non-COVID-19 cohort)|Patients will receive the standard and NOA-001 therapy.
61985264|NCT04804943|NO_INTERVENTION|Standard treatment group (ARDS caused by Non-COVID-19 cohort)|Patients will receive the standard therapy.
61985265|NCT04804943|EXPERIMENTAL|NOA-001 group (ARDS caused by COVID-19 cohort)|Patients will receive the standard and NOA-001 therapy.
61985266|NCT00561756|EXPERIMENTAL|Vaccine Therapy|This single arm, open-label, phase I clinical trial of xenogeneic CD20 DNA vaccination is designed to evaluate its safety in patients with B cell lymphoma. The study is a dose escalation study at three test doses, 0.5 mg, 2 mg and 4 mg of purified plasmid DNA per injection. There will be an initial cohort of three patients receiving a pre-level 1 dose of 0.1 mg/vaccination before proceeding to the three test doses.
61985267|NCT06071442|EXPERIMENTAL|Part 1: Vemircopan, Metformin and Rosuvastatin|"Participants will receive Vemircopan, Metformin and Rosuvastatin in a fixed sequence over 2 periods.~Period 1 (8 days): Participants will receive a single dose of metformin on day 1 and a single dose of rosuvastatin on day 4.~Period 2 (12 days): Participants will receive vemircopan twice daily from day 1 to day 11. On day 5, participants will receive metformin co-administered with vemircopan. On day 8, participants will receive rosuvastatin co-administered with vemircopan.~There will be a washout period of at least 4 days between the dose of rosuvastatin in Period 1 and the first dose of vemircopan in Period 2."
62169496|NCT05043688|ACTIVE_COMPARATOR|Neoadjuvant Radiochemotherapy|Chemotherapy: Paclitaxel 50mg/m2, Day 1,8,15,22,29，Carboplatin AUC=2mg/ml/min，Day 1,8,15,22,29 Radiotherapy：41.4 Gy , D1-5/W. Postoperative adjuvant treatment: non-pCR: Camrelizumab maintenance; PCR: surveillance
62169497|NCT02894359||CD patients|10 patients with a cervical dystonia
62169498|NCT02894359||control subjects|10 healthy patients
62363020|NCT05813613||Post Covid-19 Group|"* Will perform squatting exercise while reporting subjective muscle fatigue levels periodically, until maximal subjective fatigue is reached~* Will have sEMG for vastus lateralis and rectus femoris, chest expansion, goniometry for the knee recording using the Biopac."
62363021|NCT00845845|ACTIVE_COMPARATOR|Omega-3-acid ethyl esters (Lovaza)|Participants receive 4 milligrams (mg) daily of omega-3-acid ethyl esters (Lovaza) and dietary counseling for 24 weeks
62363022|NCT00845845|PLACEBO_COMPARATOR|Placebo|Participants receive daily placebo and dietary counseling for 24 weeks
62363023|NCT02911519|EXPERIMENTAL|Brief Group Psychoeducation|It was designed after a review of the literature on the subject; content and procedures will be written in a manual. They will be five sessions of two hours once a week. Each session will be conducted by a clinical psychologist and a general practitioner trained in group management.
62363024|NCT02911519|ACTIVE_COMPARATOR|Treatment as Usual Only|The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
62363025|NCT01016678|OTHER|Active, Active, Active, Placebo|One fifth of the 105 subjects will be randomized to this arm and treat their four migraines in this order. First three will be treated with Active Treximet and the last or 4th migraine will be treated with Placebo.
62363026|NCT01016678|OTHER|Active, Active, Placebo, Active|This is another of the five treatment arms. One fifth of the 105 subjects will be randomized to this group and will treat the first two migraines with Active drug, Treximet, and then the third migraine with placebo and the last (4th) migraine with Treximet.
62567131|NCT06328205|EXPERIMENTAL|Rehabilitation therapy+Glossopharyngeal Nerve Block|The study lasts 10d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. Based on this, the patients in the experimental group are provided with Stellate Ganglion Block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day.
61985268|NCT06071442|EXPERIMENTAL|Part 2: Vemircopan and LNG/EE-Containing OCs|"Participants will receive Vemircopan and LNG/EE-Containing OCs in a fixed sequence over 2 periods.~Period 1 (7 days): Participants will receive a single dose of OC, consisting of LNG and EE on day 1.~Period 2 (10 days): Participants will receive multiple doses of vemircopan from day 1 to day 9. On day 5, participants will receive a single dose of OC co-administered with vemircopan.~There will be a washout period of at least 7 days between the dose of OC in Period 1 and the first dose of vemircopan in Period 2."
61985269|NCT06071442|EXPERIMENTAL|Part 3: Vemircopan and Carbamazepine|"Participants will receive Vemircopan and Carbemazepine in a fixed sequence over 2 periods.~Period 1 (4 days): Participants will receive a single oral dose of vemircopan on day 1.~Period 2 (22 days): Participants will receive carbemazepine twice daily from day 1 to day 21. On day 19, participants will receive a single oral dose of vemircopan co-administered with carbamazepine.~There will be a washout period of at least 4 days between the dose of vemircopan in Period 1 and the first dose of carbamazepine in Period 2."
61985270|NCT05772936|EXPERIMENTAL|single arm non-randomized|all enrolled subjects will participate in the perturbation-induced step training, 1 or 6 sessions about 1-1.5 hour (30-90 trials) each session.
61985271|NCT01109199|EXPERIMENTAL|PolyGlycopleX (PGX)|
61985272|NCT01109199|PLACEBO_COMPARATOR|Rice Flour|
62363027|NCT01016678|OTHER|Active, Placebo, Active, Active|Approximately one fifth of the 105 subjects will be randomized to this group and treat their first migraine with Active Treximet and the second migraines with Placebo. The final two migraines treated will be with Active study drug.
62363028|NCT01016678|OTHER|Placebo, Active, Active, Active|One fifth of the 105 subjects will be randomized to this treatment arm, where they will treat the first headache with placebo and the remaining three migraines will be treated with Active treximet.
62363029|NCT01016678|OTHER|Active, Active, Active, Active|One fifth of the subject will treat all their migraines with Active Treximet.
62363030|NCT03381625|EXPERIMENTAL|BMX-010 0.03%|200 subjects will receive BMX-010 0.03% twice daily for 7-28 days applied to psoriasis or atopic dermatitis lesions.
62363031|NCT03381625|PLACEBO_COMPARATOR|Placebo|100 subjects will receive placebo twice daily for 7-28 days applied to psoriasis or atopic dermatitis lesions.
62363032|NCT04238689|EXPERIMENTAL|Group 1 - 0.1mg/kg TB31F|0.1 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. Subjects will be observed for the occurrence of any adverse events. There will be a minimum of 48 hours between TB31F administration to each subsequent volunteer. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
62363033|NCT04238689|EXPERIMENTAL|Group 2 - 1mg/kg TB31F|1 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
62363034|NCT04238689|EXPERIMENTAL|Group 3 - 3mg/kg TB31F|3 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
62391425|NCT03723746|EXPERIMENTAL|Cohort 7 (Optional): Laxative + Dose 2 or Placebo (Part 3)|Participants may receive pretreatment with an oral laxative, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. Cohort 7 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
62567132|NCT06328205|PLACEBO_COMPARATOR|Rehabilitation therapy+placebo injection|The study lasts 10d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy.
61985273|NCT05196009|EXPERIMENTAL|Mental Health and Substance Use support|Pilot Mental health and substance use peer navigation, ecological momentary assessments and virtual support group
61985274|NCT02397421|ACTIVE_COMPARATOR|Treatment|Dapagliflozin 10mg once daily
61985275|NCT02397421|PLACEBO_COMPARATOR|Control|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
61985276|NCT05501184|EXPERIMENTAL|Synchronous Telerehabilitation Group|The exercise program was applied to groups that include three participants of the synchronous group 3 days per week by video conference method on an online platform (Zoom) with the supervision of a physiotherapist. The time of the group session was organized according to the availability of participants in that group and the physiotherapist using shared calendar availability (Doodle). The physiotherapist sent a reminder to participants one hour prior to each session including the video conference meeting link. Each exercise session lasted approximately 40 minutes. For 8 weeks, a total of 24 exercise sessions were performed. The physiotherapist demonstrated the exercises as needed, supervised the group by giving real-time feedback, and progressed the exercise program according to the needs of each group.
61985277|NCT05501184|ACTIVE_COMPARATOR|Asynchronous Telerehabilitation Group|The exercise program was prescribed and followed up 3 days per week via the mobile application (FizyoTr). A notification was sent to participants' phones via mobile application prior to each session and attendance to the exercise program was recorded. For 8 weeks, a total of 24 exercise sessions were performed. The physiotherapist progressed the exercise program according to the assessment at 4 weeks and the needs of each participant.
61985278|NCT02115711|EXPERIMENTAL|Community health worker|Home visits by community health worker to deliver the multi-component behavioural intervention targeted at the individual's hypertension, diabetes or smoking.
61985279|NCT02115711|NO_INTERVENTION|Usual care|Patients will receive usual care in the community
61985280|NCT05180214|ACTIVE_COMPARATOR|bupivacaine|
62363035|NCT04238689|EXPERIMENTAL|Group 4 - 10mg/kg TB31F|10 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days.
62363036|NCT04238689|EXPERIMENTAL|Group 5 - 100mg TB31F|100mg of monoclonal antibody TB31F is administered subcutaneously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days.
62363037|NCT03136900|EXPERIMENTAL|Study Diet|Enteral diet made of Nutrilon without lactose® fortified by concentration
62363038|NCT03136900|ACTIVE_COMPARATOR|Control Diet|Enteral diet made of Nutrilon without lactose® fortified by Maltodextrin and oil supplementation.
61985281|NCT05180214|ACTIVE_COMPARATOR|bupivacaine and ketorolac|
61985282|NCT01558388|EXPERIMENTAL|Vaginal lactobacilli|
62739227|NCT03718884|EXPERIMENTAL|Mirikizumab + Drug Cocktail|"Period 2:~Participants received 250 mg mirikizumab subcutaneously (SC) once every 4 weeks (Q4W) for 16 weeks (Days 1 to Day 113)~Period 2:~Participants received the second dose of the drug cocktail: 1 mg midazolam, 10 mg warfarin, 10 mg vitamin K, 30 mg dextromethorphan, 20 mg omeprazole, 100 mg caffeine administered orally on Day 116."
62739228|NCT01207609|EXPERIMENTAL|Laparoscopic Gastric Plication|Collect data prospectively on the safety and efficacy of the Laparoscopic Gastric Plication operation for 50 patients with Severe or Morbid Obesity
61985283|NCT01558388|PLACEBO_COMPARATOR|Placebo|
61985284|NCT01701843|OTHER|Placebo (left) / Cromoglicate (right)|Placebo (on a lesion left bodyside), Cromoglicate (on a lesion on right bodyside)
61985285|NCT01701843|OTHER|Placebo (right) / Cromoglicate (left)|Placebo (on a lesion right bodyside), Cromoglicate (on a lesion on left bodyside)
61985286|NCT05135520|ACTIVE_COMPARATOR|Transabdominal specimen extraction|The outcomes of transabdominal specimen extraction in a classic way in patients who underwent multiport laparoscopic surgery for resection of kidney
61985287|NCT05135520|EXPERIMENTAL|Transvaginal natural orifice specimen extraction (NOSE)|The outcomes of transvaginal natural orifice specimen extraction (NOSE) in patients who underwent multiport laparoscopic surgery for resection of kidney
61985288|NCT05301296|NO_INTERVENTION|Control Arm|Standard of Care.
61985289|NCT05301296|ACTIVE_COMPARATOR|Intervention Arm|Clinical examination of the breast for early detection of Cancer.
61985290|NCT05016557|EXPERIMENTAL|Mycoprotein|Bolus ingestion of mycoprotein providing 25g protein
61985291|NCT05016557|EXPERIMENTAL|Spirulina|Bolus ingestion of spirulina providing 25g protein
62363039|NCT02150512|EXPERIMENTAL|Transpulmonary thermodilution (TPTD)|The intervention group (TPTD guided therapy) follows a fluid resuscitation protocol based on stroke volume variation (SVV) and extravascular lung water (EVLW). Initial trigger for fluid loading when circulatory insufficiency is present will be SVV.
62363040|NCT02150512|ACTIVE_COMPARATOR|Surviving Sepsis Guidelines (SSG)|The standard group (SSG guided therapy) follows a fluid resuscitation protocol based on the Surviving Sepsis Campaign recommendations. Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg).
62363041|NCT01152411|EXPERIMENTAL|Autologous bone marrow stem cells|
61985292|NCT05016557|EXPERIMENTAL|Chlorella|Bolus ingestion of chlorella providing 25g protein
62567133|NCT03268980||Patients group|All patients (over 18y) admitted to the Hospices Civils de Lyon the day of the study, whatever the reason, able to fullfill the questionnaire by themselves.
62739229|NCT01178944|EXPERIMENTAL|Treatment (pralatrexate, oxaliplatin)|Patients receive pralatrexate IV over 3-5 minutes and oxaliplatin IV over 2 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Oxaliplatin will be discontinued after 12 courses.
62363042|NCT03489070|ACTIVE_COMPARATOR|Traumastem®|Oxidized nonregenerated cellulose hemostatic agents.Traumastem® absorbable patches, applied topically, once, intraoperatively to stop bleeding.The patches are used on the wound surface of the liver.
61985293|NCT03921697||Parkinson Disease Patients|"Patients with PD will be recruited at Fondazione Policlinico Universitario Gemelli and Fondazione Don Gnocchi ONLUS in Rome. All included patients will be affected by idiopathic PD. Clinical data will be acquired by a trained neurologist.~We will remotely monitor 300 patients through wearable sensors. Subjects will be instructed to wear the sensor for 14 consecutive days."
62363043|NCT03489070|ACTIVE_COMPARATOR|Surgicel®|Oxidized regenerated cellulose hemostatic agents.Surgicle® absorbable patches, applied topically, once, intraoperatively to stop bleeding.The patches are used on the wound surface of the liver.
62363044|NCT00544804|EXPERIMENTAL|Lapatinib|Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer
61985294|NCT06287528|EXPERIMENTAL|Dose Level 1|0.5x106 CAR-T cell/kg without lymphodepleting chemotherapy (LDC)
61985295|NCT06287528|EXPERIMENTAL|Dose Level 2|0.5x106 cells/kg with lymphodepleting chemotherapy (LDC)
61985296|NCT06287528|EXPERIMENTAL|Dose Level 3|1x106 cells/kg with lymphodepleting chemotherapy (LDC)
61985297|NCT03294395|ACTIVE_COMPARATOR|Ceftriaxone im|Current standard treatment. Ceftriaxone 500mg (single intramuscular dose) + placebo (single oral dose)
62363045|NCT02949557|ACTIVE_COMPARATOR|Decortication +DFDBA|After phase 1 therapy patients were assigned for decortication+ DFDBA group. Mucoperiosteal flaps were reflected. After open flap debridement, decortication was performed and DFDBA graft was placed in the treatment of intrabony defects.
62363046|NCT02949557|ACTIVE_COMPARATOR|Decortication+ Xenograft (Cerabone)TM|After phase 1 therapy patients were assigned for decortication+ xenograft (Cerabone)TM group. Mucoperiosteal flaps were reflected. After open flap debridement, decortication was performed and DFDBA graft was placed in the treatment of intrabony defects.
62363047|NCT04437316|ACTIVE_COMPARATOR|Low Level Laser|therapeutic laser
62363048|NCT04437316|PLACEBO_COMPARATOR|Placebo Low Level Laser|non-therapeutic laser
62363049|NCT03907449||Symptoms of Strep Throat|"Any patient presenting with symptoms of pharyngitis~* Fever~* Sore throat~* Swollen lymph nodes in neck~* Redness of throat/tonsils~* White/yellow patches on tonsils~* Not currently on antibiotics"
62363050|NCT06422572||Population without stroke|"1. Control population in a case-controlled study of prior stroke ;~2. Control population in a case-controlled study of preexisting coronary heart disease;~3. Population in previous community cross-sectional studies ."
61985298|NCT03294395|EXPERIMENTAL|Ertapenem im|Ertapenem 1000mg (single intramuscular dose) + placebo (single oral dose)
61985299|NCT03294395|EXPERIMENTAL|Fosfomycin po|Fosfomycin oral suspension 6g (single oral dose) + placebo (single intramuscular dose)
61985300|NCT03294395|EXPERIMENTAL|Gentamicin im|Gentamicin sulfate, injectable 5mg/kg (single intramuscular dose) + placebo (single oral dose)
61985301|NCT01457885|EXPERIMENTAL|CloBu4 regimen|After pre-conditioning with CloBu4 (Clofarabine/Busulfan x 4), subjects will receive a peripheral blood stem cell transplant
61985302|NCT04390477|EXPERIMENTAL|Probiotic|1 pill od containing 1x10E9 cfu of the probiotic
61985303|NCT04390477|NO_INTERVENTION|Control|No treatment
61985304|NCT02290509|EXPERIMENTAL|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
61985305|NCT02290509|ACTIVE_COMPARATOR|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
61985306|NCT01199744||Influenza virus infection patients exposed to zanamivir|Safety of Influenza virus infection patients exposed to zanamivir
61985307|NCT00935844|EXPERIMENTAL|TAK-901 Arm|
61985308|NCT02002923|ACTIVE_COMPARATOR|PVI only|
61985309|NCT02002923|ACTIVE_COMPARATOR|PVI+BT injection|
62363051|NCT00776698|EXPERIMENTAL|1|
62363052|NCT00318370|EXPERIMENTAL|Far Only|Farletuzumab only (Far Only): farletuzumab, 100 milligrams (mg)/square meter (m2).
62567134|NCT03268980||Hospital staff group|Anyone, whatever age and trade, paid directly by the Hospices Civils de Lyon on the day of the survey, regardless of the duration of the employment contract, and present on one of the sites of the Hospices Civils de Lyon the day of the investigation.
61985310|NCT00877877|OTHER|Cervarix Group|Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.
61985311|NCT02963337||remifentanil PCA|The patients in the remifentanil group will receive remifentanil hydrochloride (Ultiva, GlaxoSmithKline, Oslo, Norway) diluted in physiologic saline to a concentration of 40µg/ml and administered using PCA pump with a bolus duration of 20 sec. A stepwise bolus doses from 15 to 30 µg, maximum 40 per 2 min will be applied with no background infusion.
61985312|NCT02963337||Combined spinal-epidural analgesia PCA|A 27-gauge needle will be placed via the shaft of the epidural needle inserted at the L2-3/L3-4 inter-space by the investigator. After confirming the CSF, 2,5 mg of bupivacaine with 20 µg of fentanyl will be injected. That will be followed by the placement of a 20-gauge multi-hole catheter into the epidural space which will be connected to the PCA pump with a possibility of injecting 6-10 ml 0,1% bupivacaine with 2 µg of fentanyl/ml every 20 min with no background infusion.
61985313|NCT02126956|EXPERIMENTAL|ACT-128800|Subjects received a single oral dose of 40 mg 14C-labeled ACT-128800 (one capsule)
61985314|NCT02461225|ACTIVE_COMPARATOR|Erchonia® FX-635™|The Erchonia® FX-635™ is made up of 3 independent 17 milliWatts (mW), 635 nanometers (nm) red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
61985315|NCT02461225|PLACEBO_COMPARATOR|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light.
61985316|NCT00930150|EXPERIMENTAL|Posit Science Intervention|Participants will receive targeted cognitive training and participate in a bridging group.
62363053|NCT00318370|EXPERIMENTAL|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
62363054|NCT03619837|EXPERIMENTAL|Treatment Arm|"Single Arm: Sofosbuvir/Velpatasvir~Dosage: 400mg/100mg. Once daily for 12 weeks."
61985317|NCT00930150|ACTIVE_COMPARATOR|Control|Participants will play commercially available computer games and participate in weekly groups to discuss health and wellness.
61985318|NCT04056442|EXPERIMENTAL|Cannabidiol|300 mg Cannabidiol (synthetic form) Olive Oil Solution, 5%
61985319|NCT04056442|PLACEBO_COMPARATOR|Placebo|Olive Oil Solution
61985320|NCT02287064|EXPERIMENTAL|Intravenous Immune Globulin (IVIG)|
62363055|NCT03063398||Patients after acute pancreatitis|Such patients will be followed and assessed for the development of Exocrine Pancreatic Insufficiency. 'No intervention, this is an observational study.
61985321|NCT04568980||Hormonal contraceptive users|Persons exposed to any hormonal method of birth control. This includes combined oral contraceptive pills, combined transdermal patch, combined vaginal ring, progestin-only pills, depo-medroxyacetate, levonorgestrel intrauterine system/device, hormonal subdermal implant
62363056|NCT02548741|ACTIVE_COMPARATOR|Treatment (Metformin)|Forty patients with elevated glycosylated hemoglobin A1c (HbA1c) \> 6.0% (patients with type 2 diabetes mellitus or prediabetes) but HbA1C \< 9.0%. They will receive the active comparator (metformin).
62363057|NCT02548741|PLACEBO_COMPARATOR|Placebo|Forty patients with elevated glycosylated hemoglobin A1c (HbA1c) \> 6.0% (patients with type 2 diabetes mellitus or prediabetes) but HbA1C \< 9.0%. They will receive the placebo comparator.
62363058|NCT02548741|OTHER|Non-diabetic|Forty matched non-diabetic patients with HbA1C ≤ 5.6%. They will not receive either treatment (metformin) or placebo.
61985322|NCT04568980||Non-hormonal contraceptive users|Persons exposed to any non-hormonal method of birth control. This includes male or female sterilization methods, Copper intrauterine device, internal/external condoms, diaphragm, cervical cap, withdrawal, sponge, fertility based methods, spermicide
61985323|NCT04568980||Non-contraceptive users|Persons who did not use any method of birth control
61985324|NCT04888871||Only Fundal Pressure (Kristeller Maneuver)|prolonged second stage phase and not prolonged second phase in pregnant women to singletons at the weeks between 37-42, applying Only Fundal Pressure (Kristeller Maneuver) and the postpartum evaluation of maternal episiotomy needs presence of second and third degree perineal tears, presence of postpartum hemorrhage and need for blood transfusion , cesarean rates and fetal first and fifth minute Apgar score , fetal blood gas parameters, presence of fetal trauma, need for neonatal intensive care will
61985325|NCT04888871||Only Vacuum Extraction|prolonged second stage phase and not prolonged second phase in pregnant women to singletons at the weeks between 37-42, applying only vacuum extraction and the postpartum evaluation of maternal episiotomy needs presence of second and third degree perineal tears, presence of postpartum hemorrhage and need for blood transfusion , cesarean rates and fetal first and fifth minute Apgar score , fetal blood gas parameters, presence of fetal trauma, need for neonatal intensive care will
61985326|NCT04888871||Both Fundal Pressure (Kristeller Maneuver) and Vacuum Extraction|prolonged second stage phase and not prolonged second phase in pregnant women to singletons at the weeks between 37-42, applying Both Fundal Pressure (Kristeller Maneuver) and Vacuum Extraction and the postpartum evaluation of maternal episiotomy needs presence of second and third degree perineal tears, presence of postpartum hemorrhage and need for blood transfusion , cesarean rates and fetal first and fifth minute Apgar score , fetal blood gas parameters, presence of fetal trauma, need for neonatal intensive care will
61985327|NCT00374296|NO_INTERVENTION|1|Elderly (≥65 years) untreated arm
61985328|NCT00374296|EXPERIMENTAL|2|Relapsed/Refractory Arm
61985329|NCT01380509|EXPERIMENTAL|A|Subjects received kali product under fasting conditions
61985330|NCT01380509|ACTIVE_COMPARATOR|B|Subjects received Searle product under fasting conditions
61985331|NCT02128633|PLACEBO_COMPARATOR|placebo|"Individuals that were randomized for treatment  A  . The product tested were always delivered in a transparent plastic syringe with 10 mls marking identified by the letters  A  . The syringes were given to individuals in an opaque plastic envelope sealed and delivered along with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (Placebo gel)."
62363059|NCT04826029|OTHER|Standard arm|
62363060|NCT04826029|EXPERIMENTAL|Interventional arm|
62363061|NCT05829395|EXPERIMENTAL|İntervention Group|Starting from the week following the pre-test application, online training will continue according to the Metaverse-based for a total of 3 weeks, two hours a week, for the intervention group. At the end of the 3 weeks, the Instructional Materials Motivation Scale and Academic Success Assessment (Quiz) will be re-administered as a post-test.
62363062|NCT05829395|NO_INTERVENTION|Control Group|The subjects were explained by the instructor with the traditional e-teaching method. The subjects will be explained by the instructor with the traditional e-teaching method and as in the intervention group, the lectures were conducted online for two hours a week for 3 weeks. At the end of the 3 week, the post-tests of the Instruvtional Materials Motivation Scale and Academic Success Assessment (Quiz) will be apply in the control group simultaneously with the intervention group.
62567135|NCT03268980||Students group|Everyone who is regularly enrolled in one of the schools or institutes of the Hospices Civils de Lyon or in one of the two faculties of medicine of the Université Lyon I, in any initial training and present on one of the sites of the faculties the day of the investigation
61985332|NCT02128633|EXPERIMENTAL|Experimental gel|"Individuals that were randomized for treatment  B  - The product was delivered in a transparent plastic syringe with 10 mls identified by the letter  B . The syringes were given to individuals in an opaque plastic envelope sealed and with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (5% sodium fluoride, potassium oxalate 5%, strontium chloride 10% ) ."
62363063|NCT02737176|EXPERIMENTAL|Tobacco cessation intervention|Tobacco cessation intervention is implemented for 12 weeks. The nicotine dependence status is evaluated by the FTND (Fagerstrom Test for Nicotine Dependence) test. The point 3 or more is regarded as a moderate or high tobacco dependence and determining a cessation intervention. During the tobacco cessation intervention for the subjects, attending doctors implement standard treatments for their oral diseases. Even if participants fail to abstain from smoking, the oral treatment is continued. In case of the use of the NRTs (nicotine patch and/or gum), the investigators supply it for 2 weeks as a free of charge, and later the subjects themselves purchase it as over the counter (OTC) drugs at a pharmacy.
62363064|NCT02737176|NO_INTERVENTION|Non-tobacco cessation intervention|Those who do not intention to abstinence from smoking strongly and/or having less than 3 points in FTND test are allocated to non-tobacco cessation intervention group. The same treatment as the tobacco cessation intervention group is carried out for their oral diseases.
62363065|NCT03619850|EXPERIMENTAL|Ferumoxytol|
62363066|NCT03619850|ACTIVE_COMPARATOR|Iron sucrose|
62363067|NCT04777123|ACTIVE_COMPARATOR|sitting position|patients will be left in the sitting position
62363068|NCT04777123|NO_INTERVENTION|supine position|patients will lie down immediately after injection
62363069|NCT01487707|EXPERIMENTAL|Voluntary Health Worker (VHW) Program|
62363070|NCT01487707|EXPERIMENTAL|VHW program plus Safe Birth Kit|
62363071|NCT01487707|EXPERIMENTAL|VHW program plus Folk Media Activities|
62363072|NCT04120727||Patient|patients with predominant osteoarthritis of the knees
62363073|NCT04120727||Health professionals|health professionals with a link to osteoarthritis (physical and rehabilitation doctor, Rheumatologist, Physiotherapist, family doctor, pharmacist, Adapted physical activity teacher)
62363074|NCT02366247|EXPERIMENTAL|PEG-Tα1|PEG-Tα1 (3.2 mg/ml, once a week, taken subcutaneously) and adefovir (10 mg, once daily, taken orally) for 48 weeks
62363075|NCT02366247|PLACEBO_COMPARATOR|Placebo to match PEG-Tα1|PEG-Tα1 placebo (1ml, once a week, taken subcutaneously) and adefovir (10 mg, once daily, taken orally) for 48 weeks
62363076|NCT01461824|ACTIVE_COMPARATOR|150 mg DMPA|Depot medroxyprogesterone acetate (DMPA) 150 mg every 12 weeks IM
62363077|NCT01461824|EXPERIMENTAL|104mg DMPA|Depot medroxyprogesterone acetate (DMPA) 104 mg every 12 weeks IM
62363078|NCT01461824|EXPERIMENTAL|75mg DMPA|Depot medroxyprogesterone acetate (DMPA) 75 mg every 12 weeks IM
61985333|NCT02128633|ACTIVE_COMPARATOR|Positive control|"Individuals that were randomized for treatment  C  . The product tested were always delivered in a transparent plastic syringe with 10 mls marking identified by the letters  C  . The syringes were given to individuals in an opaque plastic envelope sealed and delivered along with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (Fluoride neutral NaF gel 2 %)."
61985334|NCT05577585|ACTIVE_COMPARATOR|Ketamine|Participants will undergo one infusion of ketamine as active comparator. (R,S-ketamine 50mg/ml solution for injection, dose: 0,5 mg per kg bodyweight) Both medications will be diluted in 100 ml saline and will be adjusted for infusion over 40 minutes, administered with a syringe pump.
61985335|NCT05577585|PLACEBO_COMPARATOR|Midazolam|Participants will undergo one infusion of midazolam as comparator. (0,045 mg/kg bodyweight) Both medications will be diluted in 100 ml saline and will be adjusted for infusion over 40 minutes, administered with a syringe pump.
61985336|NCT02607436|EXPERIMENTAL|Sarpogrelate + Aspirin|Sarpogrelate as an active drug
61985337|NCT02607436|ACTIVE_COMPARATOR|Aspirin alone|Aspirin as an active comparator
61985338|NCT00536107|ACTIVE_COMPARATOR|Docetaxel|docetaxel
61985339|NCT00536107|EXPERIMENTAL|Gefitinib|Gefitinib (IRESSA)
62363079|NCT04378439|ACTIVE_COMPARATOR|intervention group|7 community health leaders; 56 social network members
62363080|NCT04378439|ACTIVE_COMPARATOR|delayed-intervention|7 community health leaders; 56 social network members
62363081|NCT01398228|OTHER|Group 1|Group 1 will receive quality improvement initiatives first, after 6 months of baseline initiation.
62363082|NCT01398228|OTHER|Group 2|Group 2 will receive quality improvement initiatives second, after 6 months of the intervention initiation for Group 1.
62363083|NCT01398228|OTHER|Group 3|Group 3 will receive quality improvement initiatives third, after 6 months of the intervention initiation for Group 2.
62363084|NCT01398228|OTHER|Group 4|Group 4 will receive quality improvement initiatives forth, after 6 months of the intervention initiation for Group 3.
62363085|NCT04281836|EXPERIMENTAL|Breathing awareness through use of virtual reality breathing|Healthy participants were recruited in this group.
62363086|NCT04281836|ACTIVE_COMPARATOR|Traditional breathing awareness|Healthy participants were recruited in this group.
62363087|NCT02411513|EXPERIMENTAL|Active|60 minutes of CEFALY stimulation as acute treatment of an on-going attack
62363088|NCT03949010|EXPERIMENTAL|Kinesiotaping with space correction technique|
62363089|NCT03949010|EXPERIMENTAL|Kinesiotaping with muscle inhibition technique|
62363090|NCT03949010|ACTIVE_COMPARATOR|Home exercise program|
62363091|NCT06227806|EXPERIMENTAL|Tibial Tubercle Transfer surgery|Tibial Tubercle Transfer surgery followed by a home exercise program.
62363092|NCT06227806|ACTIVE_COMPARATOR|Home Exercise Program|A home exercise program.
62363093|NCT03125993|EXPERIMENTAL|>10000 steps brisk walking|This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: \> 10000 steps, \> five days, per week. For individual follow-up, body components and metabolic risk factors will be tested before and after the study.
62363094|NCT03870906|EXPERIMENTAL|WhatsApp interaction|Individual and group chat interactions.
62363095|NCT03870906|PLACEBO_COMPARATOR|Text message|Regular text messages with similar frequency to those in the Intervention group.
62391426|NCT03723746|EXPERIMENTAL|Cohort 8 (Optional):Antibiotic+Laxative+Dose 2/Placebo(Part 3)|Participants may receive pretreatment with an oral antibiotic and oral laxative, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. Cohort 8 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
61985340|NCT03120546|EXPERIMENTAL|Group A|rigid video stylet intubation - video laryngoscope intubation
61985341|NCT03120546|EXPERIMENTAL|Group B|video laryngoscope intubation - rigid video stylet intubation
61985342|NCT05229120|EXPERIMENTAL|Episodic Future Thinking|Parents who are receiving residential substance use disorder (SUD) treatment will receive an adapted episodic future thinking focused condition. Parents will meet with peer recovery coaches (PRCs) who will administer the intervention, focused on generating future, pleasant events with their children. After the intervention session, parents will receive a daily postcard over the course of two weeks including a reminder cue generated as part of the episodic future thinking (EFT) intervention and a prompt to remember these episodes in vivid detail.
61985343|NCT03644199|OTHER|OGTT test|Comparison of responses to a OGTT between CF subjects and health control subjects
61985344|NCT03644199|OTHER|Mixed meal|Comparison of responses to a mixed meal through the day between CF subjects and health control subjects
61985345|NCT03594279|EXPERIMENTAL|Community Mobilization|This arm will receive specific messages regarding the prevention and management of childhood diarrhea and pneumonia. The investigators will form village committees (VC) consisting of prominent members of the community (6-8 in a group) to carry out awareness and motivational activities for the uptake of the identified interventions.
61985346|NCT03594279|EXPERIMENTAL|Community Mobilization and Community Incentive|In this arm, along with the interventions in the community mobilization arm, community based incentives will also be provided. The clusters which improve the practices for preventive and curative strategies for diarrhea and pneumonia will receive community-based incentive including structural benefits linked to health including tube wells, water supply, toilets in community/schools, water storage facility or any other incentive as decided with the respective village committees.
61985347|NCT03594279|NO_INTERVENTION|Control|This arm will receive the routine standard of care.
61985348|NCT05243368|EXPERIMENTAL|Nutritional Intervention (NI)|In addition to the usual treatment, will receive dietary advice and a nutritional supplement, according to the results of their evaluation in the Endocrinology Service
61985349|NCT05243368|NO_INTERVENTION|Control (C)|Who will continue with their usual treatments in the Diabetic Foot Unit and they will receive dietary advice
62363096|NCT02384993|EXPERIMENTAL|Enhanced Physical Activity|Those assigned to the enhanced physical activity group will train 3-4 days per week with the goal of attaining current public health recommendations of 150 minutes of moderate intensity exercise by the 7th week of training, and maintaining this level of exercise for the remainder of the 26-week intervention. A gradual increase in exercise intensity and duration will be used throughout this twenty-six week exercise intervention, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Training will occur in individual sessions supervised by exercise specialists with the appropriate education and experience. Each training session will begin with an appropriate warm-up, slowly build up, and end with an appropriate cool down period.
62363097|NCT02384993|NO_INTERVENTION|Usual Physical Activity|"All study participants randomized to the usual physical activity group will receive education from study staff about the importance of maintaining a healthy and active lifestyle. They will receive standardized literature such as Exercise \& Physical Activity: Your Everyday Guide from the National Institute on Aging. These booklets provide vetted and reliable information for older adults on how to exercise. Participants assigned to the usual physical activity group will not be provided additional support or guidance with an exercise program."
62363098|NCT03373318|EXPERIMENTAL|Experimental|Human Albumin
61985350|NCT05721833|EXPERIMENTAL|non-invasive high-frequency oscillatory ventilation|Patients were titrated for relevant parameters of non-invasive ventilation the day before the trial. In the non-invasive high-frequency oscillation ventilation mode, the support pressure is consistent with the non-invasive bi-level positive pressure mode, and the high frequency airway pressure oscillation driven by the solenoid valve is added during the expiratory phase. The amplitude is about 4cmH2O, and the oscillation frequency is about 8HZ.
61985351|NCT05721833|ACTIVE_COMPARATOR|Bilevel positive pressure ventilation|Patients were titrated for relevant parameters of non-invasive ventilation the day before the trial. Noninvasive bilevel positive pressure ventilation mode pressure titration follows previous studies.
61985352|NCT02255500|EXPERIMENTAL|Bupivacaine FNB + EXPAREL Infiltration|Femoral nerve block with bupivacaine HCl 0.5% with epinephrine 1:200,000 within 2 hours of the surgical procedure. Infiltration of EXPAREL 266 mg just prior to wound closure.
62363099|NCT03373318|ACTIVE_COMPARATOR|Control|Plasmalyte
61985353|NCT03503786|ACTIVE_COMPARATOR|Chemotherapy|Carboplatin AUC 5+Paclitaxel 175 mg/m2 q 21days for 6-8 cycles and Avelumab
61985354|NCT03503786|EXPERIMENTAL|Chemotherapy and avelumab|Carboplatin AUC 5+ Paclitaxel 175 mg/ m2+Avelumab 10 mg/kg q 21days for 6 -8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity
61985355|NCT03204305|ACTIVE_COMPARATOR|Cannabis users|Smoked Cannabis plant material (0 and 25 mg THC) will be administered to volunteers who are regular cannabis users. Cannabis users will also complete a PET scan where 20 millicurie of 11C-OMAR
61985356|NCT03204305|ACTIVE_COMPARATOR|Nonuser controls|No cannabis administration. Non-user controls will complete a PET scan where 20 millicuries of 11C-OMAR
61985357|NCT03888196|EXPERIMENTAL|Intervention Group|500 mg/day of Panax Ginseng. 2 weeks treatment
62363100|NCT00904176|ACTIVE_COMPARATOR|Dapagliflozin + Warfarin|
62363101|NCT00904176|ACTIVE_COMPARATOR|Warfarin|
62363102|NCT00904176|ACTIVE_COMPARATOR|Dapagliflozin + Digoxin|
62363103|NCT00904176|ACTIVE_COMPARATOR|Digoxin|
62363104|NCT04720690||Appropriately grown for age infants|40 appropriately grown for gestational age (AGA) infants. 20 will be \<32 weeks, and 20 will be ≥32 weeks gestational age at birth.
62363105|NCT04720690||Small for gestational age infants|40 small for gestational age (SGA) infants. 20 will be \<32 weeks, and 20 will be ≥32 weeks gestational age at birth.
62363106|NCT04720690||Fetal growth restricted infants|40 fetal growth restricted (FGR) infants. 20 will be \<32 weeks, and 20 will be ≥32 weeks gestational age at birth.
62567136|NCT02318446|PLACEBO_COMPARATOR|Control group|Will receive Oral saccharine tablet daily for 1month along with their existing antiepileptic therapy
62567137|NCT02318446|EXPERIMENTAL|Test group|Will receive Oral Folic acid 1mg tablet daily for 1month along with their existing antiepileptic therapy
62363107|NCT04366713|EXPERIMENTAL|Neratinib|Neratinib with loperamide prophylaxis, and capecitabine for participants treated for metastatic breast cancer
62363108|NCT01952093||Usual care program|VLBW preterm infants who received usual medical care during hospitalization after birth.(in the previous study)
62363109|NCT01952093||Clinic-based intervention program|VLBW preterm infants who received specific early intervention program delivered at clinic before 1 year of corrected age (in the previous study)
62363110|NCT01952093||Home-based intervention program|VLBW preterm infants who received specific early intervention program delivered at home before 1 year of corrected age (in the previous study)
62363111|NCT01952093||Term control group|Healthy term infants
62363112|NCT05826041|EXPERIMENTAL|INSPIRE Group|90-minute support group; 9 content sessions over 18 weeks; co-led by a professional facilitator and peer.
62363113|NCT05826041|ACTIVE_COMPARATOR|Intervention as Usual: Traditional Domestic Violence Support Group|75-minute support group; 18-weeks; led by a domestic violence service provider counselor or advocate
62363114|NCT06398444|EXPERIMENTAL|Lutetium[177Lu] Oxodotreotide Injection|
62363115|NCT00997555|EXPERIMENTAL|bronchoscopy intervention group|Group undergoing scheduled bronchoscopy.
62363116|NCT00997555|NO_INTERVENTION|Control group|Standard treatment without scheduled bronchoscopy.
62363117|NCT04745312|ACTIVE_COMPARATOR|Ambient light|Fluorescent ambient lighting
62363118|NCT04745312|EXPERIMENTAL|Ambient light plus task lamp|Fluorescent ambient lighting plus task lamp
62363119|NCT00368472|EXPERIMENTAL|Perampanel|Participants previously receiving placebo/perampanel in the double blind study, were titrated to receive perampanel 2 mg to 12 mg, once daily during the OLE study
62363120|NCT02833818|EXPERIMENTAL|CAKE-intervention|Increased nutrition and dietary consultations. Growth rate followed by clinical nutritionists that supply high protein and energy if growth rate deviates from 17g/kg/day
62363121|NCT02833818|ACTIVE_COMPARATOR|CAKE-control|nutrition according to established procedures in the neonatal intensive care unit (NICU)
61985358|NCT03888196|PLACEBO_COMPARATOR|Control Group|500 mg/day of Celulose. 2 weeks treatment
61985359|NCT05858346|EXPERIMENTAL|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
61985360|NCT05858346|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy for Social Anxiety Disorder|To provide an evidence-based comparison for the TBT condition, the research-supported psychological treatment of CBT for SAD will be used. CBT for SAD demonstrates efficacy in improving SAD symptoms and quality of life for patients with SAD, with durable improvements evidenced at follow-up assessments. CBT for SAD was used as a comparison to TBT in previous preliminary research. CBT for SAD involves several primary components, including: 1) psychoeducation, 2) training in cognitive restructuring, 3) exposures, 4) advanced cognitive restructuring, and 5) termination.
61985361|NCT06271252|EXPERIMENTAL|OriCAR-017|Single OriCAR-017 infusion
61985362|NCT03642223|ACTIVE_COMPARATOR|normal-weight|
61985363|NCT03642223|EXPERIMENTAL|peripheral adiposity|
61985364|NCT03642223|EXPERIMENTAL|central adiposity|
61985365|NCT03647865|EXPERIMENTAL|Patients need genioplasty|
61985366|NCT05544786|ACTIVE_COMPARATOR|Treatment A: Nirmatrelvir/ritonavir|Nirmatrelvir and ritonavir tablets
61985367|NCT05544786|EXPERIMENTAL|Treatment B: Nirmatrelvir/ ritonavir|Nirmatrelvir/ritonavir with water
61985368|NCT05544786|EXPERIMENTAL|Treatment C: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir with infant formula
61985369|NCT05544786|EXPERIMENTAL|Treatment D: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir with vanilla pudding
61985370|NCT05544786|EXPERIMENTAL|Treatment E: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir with food and vanilla pudding
61985371|NCT06449807|ACTIVE_COMPARATOR|crossover point intensity exercise|
61985372|NCT06449807|NO_INTERVENTION|No Intervention|
61985373|NCT01765153|EXPERIMENTAL|Endurance first|Participants to start with Endurance Training. Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training. Training was 5x/wk for 2 months, followed by a 2-month rest period. Participants then returned for training in the Precision Training 5x/wk for 2 months.Participants train to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto. This is followed by another 2-month rest. Measures of walking speed, distance, skill, confidence, as well as mood were obtained at least 3 times before any training, then monthly thereafter.
62363122|NCT00169806|OTHER|cohort|Subjects who are scheduled to undergo a percutaneous kidney stone removal who do not have complicated comorbidities
62363123|NCT03326661|ACTIVE_COMPARATOR|Needle aspiration|Patients treated with aspiration will receive standard antibiotic treatment according to clinical guidelines: Penicillin and metronidazole or Clindamycin alone in case of penicillin allergy. These patients will be treated in the outpatient clinic and will be examined again the day after inclusion. Aspiration will be done if necessary. At this first control visit the clinician will schedule the next visit based on findings.
62363124|NCT03326661|ACTIVE_COMPARATOR|Tonsillectomy a chaud|Patients treated with tonsillectomy a chaud are admitted for intra-venous treatment with penicillin and metronidazole until surgery. Antibiotic treatment is discontinued after surgery and the patient may be discharged from the hospital the day after surgery.
62363125|NCT01847079|OTHER|Intervention group, procalcitonin|procalcitonin to guid obtaining bloodcultures in the ICU
62363126|NCT01847079|NO_INTERVENTION|Control group, ICIS, procalcitonin|Measurement of PCT and ICIS.
62363127|NCT05757479|EXPERIMENTAL|Steroid-eluting stent implant|Subjects randomized to the experimental group will receive steroid-eluting stent implantation in the affected sinus and saline rinses.
62363128|NCT05757479|ACTIVE_COMPARATOR|Nasal steroid spray|Subjects randomized to the comparator group will receive nasal steroid spray and saline rinses.
62363129|NCT02229253||Degarelix|Treatment according to standard clinical practice.
62363130|NCT04334512|EXPERIMENTAL|Quintuple Therapy|Patients will be treated with quintuple therapy for 10 days.
62363131|NCT04334512|PLACEBO_COMPARATOR|Placebo|Patients will be treated with placebo.
61985374|NCT01765153|EXPERIMENTAL|Precision first|Participants to start with Precision Training. Participants train to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto. Training was 5x/wk for 2 months, followed by a 2-month rest period. Participants then returned for Endurance Training 5x/wk for 2 months. Participants are trained to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training. followed by another 2-month rest. Measures of walking speed, distance, skill, confidence, as well as mood were obtained at least 3 times before any training, then monthly thereafter.
61985375|NCT00366158|EXPERIMENTAL|1|Ventricular Instrinsic Preference (VIP) turned ON
61985376|NCT00366158|ACTIVE_COMPARATOR|2|Ventricular Instrinsic Preference (VIP) turned OFF
61985377|NCT02533947|EXPERIMENTAL|Exercise group|The exercise program will be developed through a pilot phase with 10 patients prior to the start of the main study.
61985378|NCT02533947|OTHER|Control group|A waitlist control group will get the intervention after 7 month of treatment as usual.
61985379|NCT04626232|EXPERIMENTAL|N SLEEVE|Monocentric, randomized, single-blind controlled trial, with 2 parallel arms (experimental technique versus surgical reference technique).
61985380|NCT04626232|OTHER|SLEEVE|The conventional sleeve gastrectomy technique consists of reducing the gastric capacity by removing 2/3 of the stomach by a vertical transection.
61985381|NCT02328560||Paramedical ad consultation|Monitoring will be the same in the 2 groups; That paramedical consultation announcement is made in current practice.
61985382|NCT02328560||No paramedical ad consultation|Monitoring will be the same in the 2 groups
61985383|NCT03777007|EXPERIMENTAL|Experimental|The application used is build upon the company's category-defining, SPARTA Platform and create a platform that streamlines the performance and management of post-acute care physical therapy. The rehab tool will provide us with functional outcome score.
61985384|NCT03916757|EXPERIMENTAL|V-Boost recipients|In this open label study all eligible participants will receive daily tablet of V-Boost
61985385|NCT02498457|ACTIVE_COMPARATOR|low calcium dialysis|patients in this group will be dialyzed using a dialysate with a calcium concentration 1.25mmol/L.
61985386|NCT02498457|OTHER|Routine dialysis|Patients in this groups will be dialyzed using routine dialysate with a calcium concentration 1.5mmol/L.
61985387|NCT00150072|EXPERIMENTAL|imatinib|
61985388|NCT03816098||elderly patients with dysphagia|
61985389|NCT03816098||elderly patients without dysphagia|
61985390|NCT00605475|EXPERIMENTAL|Canakinumab|"Eligible participants were assigned to receive canakinumab in one of four cohorts; 1) Single IV infusion of canakinumab 0.3 mg/kg; 2) Singe IV infusion of canakinumab 10 mg/kg; 3) single IV infusion of canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of canakinumab 0.03 mg/kg.~All participants were required to take a concomitant stable daily dose of metformin during the study."
61985391|NCT00605475|PLACEBO_COMPARATOR|Placebo|"Eligible participants were assigned to receive placebo to canakinumab in one of four cohorts; 1) Single IV infusion of placebo to canakinumab 0.3 mg/kg; 2) Singe IV infusion of placebo to canakinumab 10 mg/kg; 3) single IV infusion of placebo to canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of placebo to canakinumab 0.03 mg/kg.~All participants were required to take a concomitant stable daily dose of metformin during the study."
61985392|NCT03492099|EXPERIMENTAL|Buprenorphine Arm|This is the main and only arm of the study. All patients in this arm will undergo the steps outlined in the protocol to convert to buprenorphine treatment.
61985393|NCT01519440||blunt|Blunt expansion of the primary incision was derived by placing the index fingers of the operating surgeon into the incision and pulling the fingers apart laterally and cephalad.
61985394|NCT01519440||sharp|Sharp expansion of the primary incision was developed by cutting laterally and cephalad using bandage scissors
61985395|NCT01523886|ACTIVE_COMPARATOR|Deep neuromuscular blockade|
61985396|NCT01523886|PLACEBO_COMPARATOR|Moderate neuromuscular blockade|
61985397|NCT05383547|EXPERIMENTAL|Glomerular disease patients|
62169499|NCT06274892|EXPERIMENTAL|Remote monitoring PROs|All participants allocated to the interventional arm will receive the RT technique, dose and fractionation according to institutional standards. Once per week, participants will use a mobile phone 'app' to enter mPROs, and indicate a need for review for any other reason. The treatment Radiation Therapists will triage the participant to either attend or skip that week's on-treatment review based on this information and established criteria. After RT completion, Advanced Practice Radiation Therapists (apRTs) will triage the participant to receive a virtual follow-up visit when necessary. Participants will be seen once by a Radiation Oncologist 4 to 12 weeks after last radiation treatment. The participants will also complete the following questionnaires: 1) Baseline (patient factors); 2) 'During treatment' (review quality); 3) 'Post acute phase' (satisfaction with care). Circle-of-care HCP will comment on the impact of the PROMOTE process on the quality of care for that participant.
62169500|NCT06274892|NO_INTERVENTION|Standard of Care|All participants allocated to the standard of care arm will receive all RT treatment activities according to institutional standards. Participants will attend the weekly in-person review session with a Radiation Oncologist during treatment and will be seen once between 4 and 12 weeks after last RT treatment. Documentation of radiation-related toxicity will be performed by the radiation HCPs according to standard of care. Participants will be asked to complete the following study questionnaires: 1) Baseline evaluation (patient factors); 2) 'During treatment' evaluation (need/usefulness of review); 3) 'Post acute phase' evaluation (satisfaction with care).
62169501|NCT04879875|EXPERIMENTAL|Group 1|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed immediately after surgery.~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for CO2."
62363132|NCT04815733|ACTIVE_COMPARATOR|Mandatory ventilation|deep neuromuscular block and mandatory ventilation (PCV-VG);
62363133|NCT04815733|EXPERIMENTAL|Pressure support ventilation|partial neuromuscular block and pressure support ventilation (PSVpro).
61985398|NCT04941456|ACTIVE_COMPARATOR|Open Tracheostomy|Participants will perform the six-minute walk test each session to assess ambulation distance, alternating between the open tracheostomy (standard) versus the Passy-Muir Valve in place intervention on sequential days to compare results.
62363134|NCT01923649|EXPERIMENTAL|Lanreotide slow release 90 mg|Patients receive lanreatide slow release (Somatuline autogel) 90 mg every four weeks via a deep subcutaneous injection, three times. After a wash out period of 4 weeks they receive a similar placebo every for weeks, three times.
62363135|NCT01923649|PLACEBO_COMPARATOR|Placebo|Patients receive a deep subcutanous injection of placebo every four weeks, three times. After a wash out of three weeks, they will receive somatuline 90 mh via a deep subcutanous injection every four weeks, three times.
62363136|NCT03374436|EXPERIMENTAL|High-Carbohydrate Sedentary|Participants will remain seated for 9 hours (except for using the restroom) while consuming a high-carbohydrate diet (3 meals)
62363137|NCT03374436|EXPERIMENTAL|High-Carbohydrate Active|"Participants will remain seated for 9 hours (except for using the restroom) while consuming a high-carbohydrate diet (3 meals) but will complete 8 stair climbing sprint snacks once per hour involving ascending 3 flights of stairs at a vigorous pace (\~20 seconds each)."
62363138|NCT03374436|ACTIVE_COMPARATOR|Low-Carbohydrate Sedentary|Participants will remain seated for 9 hours (except for using the restroom) while consuming a low-carbohydrate diet (3 meals)
62169502|NCT04879875|EXPERIMENTAL|Group 2|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed 72 hours after surgery.~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for CO2."
62169503|NCT05632016|NO_INTERVENTION|group N|patients will not receive erector spinae block (ESP)
62169504|NCT05632016|ACTIVE_COMPARATOR|group E|patients will receive bilateral bilevel erector spinae block (ESP)
62169505|NCT04226183|NO_INTERVENTION|control group|pregnant women without pregnancy workout and consume guava juice
62169506|NCT04226183|EXPERIMENTAL|positive control group|prenatal pregnant women with pregnancy workout but not consume guava juice
62363139|NCT02871518|EXPERIMENTAL|Two cycle CCRT|Concurrent cisplatin(100mg/m2,D1,D22)combine with IMRT
62363140|NCT02871518|ACTIVE_COMPARATOR|Three cycle CCRT|Concurrent cisplatin(100mg/m2,D1,D22 and D43)combine with IMRT
62363141|NCT03627000||failure after reimplantation|description of the failure at the reimplantation
62567138|NCT04861727|NO_INTERVENTION|Group control|will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will make MRPA and will receive the report and general guidance on blood pressure control and pharmacotherapy assessment
62169507|NCT04226183|EXPERIMENTAL|treatment group|prenatal pregnant women with pregnancy workout and consume guava juice
62169508|NCT04318587|EXPERIMENTAL|Allosure Arm|All subjects will be in arm one and will have AlloSure blood draws at multiple time points.
62169509|NCT00158886|EXPERIMENTAL|Subjects with rectal cancer|Subjects will be administered topotecan along with concomitant radiation for five days per week for five weeks. Topotecan doses will start at 0.25 milligrams per square meter (mg/m˄2) and will be escalated 0.15 mg/m˄2 for subsequent cohorts. To advance to the next dose level of topotecan, at least two subjects will have to complete therapy with oral topotecan without experiencing grade 3 or 4 toxicity for three weeks after the oral topotecan treatment.
62169510|NCT04685018||HC|Mentally and medically healthy adults between 18 and 60 years, free from any current or previous medical or psychiatric condition.
62169511|NCT04685018||OCD|Adults between 18 and 60 years, with a diagnosis of Obsessive-Compulsive Disorder and medication-free or with stable medication regimen for at least 3 weeks prior to the study.
62169512|NCT04163835|EXPERIMENTAL|Low-dose Group|The intervention is half-dose of Wenxin Granules (1/2 normal dose).
62169513|NCT04163835|EXPERIMENTAL|Medium-dose Group|The intervention is medium-dose of Wenxin Granules (normal dose).
62169514|NCT04163835|EXPERIMENTAL|High-dose Group|The intervention is twice-dose of Wenxin Granules (twice normal dose).
62169515|NCT04163835|PLACEBO_COMPARATOR|Placebo Group|The intervention is a placebo.
62169516|NCT04542642|ACTIVE_COMPARATOR|reSET-O|Prescription Digital therapeutic
62169517|NCT04542642|EXPERIMENTAL|PEAR-008|Investigational Digital Therapeutic
62169518|NCT04098393|EXPERIMENTAL|patients hematologic malignancies other than multiple myeloma|A. Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels. B. Melphalan (70mg/m2/day) administered on days -6 and -5. C. Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2. All patients receiving matched related or unrelated donor allografts receive anti-thymocyte globulin (ATG) 2.5 mg/kg/day on days -3 and -2 to deplete chemotherapy resistant host T-cells that could hinder engraftment, and it may provide additional GVHD prophylaxis.
62169519|NCT04098393|EXPERIMENTAL|patients with multiple myeloma|A. Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels. B. Melphalan (70 mg/m2/day) administered on days -6 and -5. C. Fludarabine (25 mg/m2/day) administered on days -6, -5, -4, -3, -2. All patients receiving matched related or unrelated donor allografts receive anti-thymocyte globulin (ATG) 2.5 mg/kg/day on days -3 and -2 to deplete chemotherapy resistant host T-cells that could hinder engraftment, and it may provide additional GVHD prophylaxis.
62363142|NCT04587960|ACTIVE_COMPARATOR|Primary closure of Cesarean wound|Immediate closure of skin incision where healing occurs by primary intention
62363143|NCT04587960|EXPERIMENTAL|Delayed primary closure of Cesarean wound|Delayed closure of skin incision following regular wound dressing for 2 to 3 days.
62363144|NCT06238115|EXPERIMENTAL|Tirofiban group|After femoral artery puncture, initial infusion of 0.4μg/kg body weight/minute over 30 minutes, followed by a continuous infusion of 0.1μg/kg body weight/minute for 24 hours.
62363145|NCT06238115|PLACEBO_COMPARATOR|Standard medical care|Routine dual antiplatelet therapy (aspirin 100 mg/day, clopidogrel 75 mg/day)
62363146|NCT01515488|EXPERIMENTAL|Self-triage kiosk|Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
62363147|NCT01515488|EXPERIMENTAL|Nurse-initiated triage|Nurse-initiated triage for obtaining medical history and presenting problem(s)
62363148|NCT01715272|ACTIVE_COMPARATOR|Fleet enema|This group will receive Fleet enema as their treatment
62169520|NCT04701073|NO_INTERVENTION|"Control group usual care"|Promotion of physical activity and taking usual medicines for pain relief
62363149|NCT01715272|EXPERIMENTAL|TF037|This group will receive TF037 as their treatment
62363150|NCT01668134|EXPERIMENTAL|Stereotactic radiation|
62363151|NCT04880772|NO_INTERVENTION|Standard care|Standard Care: Surgery school as per ELHT pre-operative guidelines (includes generic pre-operative information, advice and optimisation e.g correction of anaemia)
62363152|NCT04880772|EXPERIMENTAL|Prehabilitation|Surgery School plus Moderate intensity exercise \& Forceval (multivitamin)
62363153|NCT06133985|EXPERIMENTAL|Costovertebral mobilizations + Conventional Physiotherapy|"Costovertebral mobilizations along conventional treatment patient would receive costovertebral mobilization in side lying position for 10th to 6th ribs, in sitting position for 10th to 2nd rib and in supine position for 1 rib.~Frequency: 5 times/week for 3 weeks. Intensity: moderate intensity (pain free) Time: 20 mins Type: costovertebral joint mobilization to improve respiratory function and chest tightness.~Conventional treatment diaphragmatic breathing exercises and pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 30 mins Type: breathing exercises to improve respiratory function and chest tightness."
62550026|NCT05930379|EXPERIMENTAL|LSVT-Loud delivered by telerehabilitation|F - Frequency: 7 times/week for 4 weeks according to a mixed model (4 days of synchronous sessions followed by independent practice + 3 asynchronous sessions); I - Intensity: sessions customized according to the patient's functional abilities to ensure the progression of difficulty in rehabilitation sessions; T- Time: each synchronous session will last about 60 minutes, each independent practice will last about 5-10 minutes, and each asynchronous session will last about 30 minutes; T- Type: Individual speech therapy sessions with the Lee Silverman Voice Treatment-Loud method delivered by telerehabilitation.
62363154|NCT06133985|OTHER|Conventional Physiotherapy|diaphragmatic breathing exercises and pursed-lip expiration exercises Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness.
62363155|NCT03314012|EXPERIMENTAL|Catheter-Based Carotid Body Ablation|All subjects undergo catheter-based ablation of the carotid body using the Cibiem Transvenous Ultrasound System (CTUS).
62363156|NCT04282876||Degarelix|Patients undergoing radiation therapy for bladder cancer while also being treated with Degarelix (androgen deprivation therapy)
62739230|NCT05003180|ACTIVE_COMPARATOR|Surgical|"Surgical stabilization. Brace treatment will not be used postoperative. Early ambulation after surgery is encouraged. Surgery is to be performed within 2 weeks from the injury. The choice of supplier and brand of implants are based on the preference of each participating center.~Physiotherapy and other measures of rehabilitation are prescribed on an individual basis."
62739231|NCT05003180|NO_INTERVENTION|Non-surgical treatment|"No surgical stabilization is performed. Early ambulation after treatment randomization is encouraged. Brace treatment is not required, but a standard three-point hyperextension brace may be offered up to 3 months for pain relief. The choice of supplier and brand of brace are based on the preference of each participating center. The brace will only be used upon mobilization. Brace use will be estimated by the patient at the 3-4 months follow-up.~Physiotherapy and other measures of rehabilitation are prescribed on an individual basis."
62550027|NCT05930379|ACTIVE_COMPARATOR|LSVT-Loud in the clinic|"The frequency, intensity, time of the rehabilitation sessions will be the same as the experimental group.~T- Type: Individual speech therapy sessions with the Lee Silverman Voice Treatment-Loud method delivered in the clinic."
62550028|NCT02301390|ACTIVE_COMPARATOR|Amiodarone only|The control group will receive amiodarone only.
62550029|NCT02301390|EXPERIMENTAL|Amiodarone + Catheter Ablation|The experimental group will receive amiodarone plus catheter VT ablation.
62550030|NCT04315506|EXPERIMENTAL|#EnufSnuff.TXT Intervention|Scheduled gradual reduction. Participants are asked to gradually reduce smokeless tobacco usage.
62739232|NCT04916353|EXPERIMENTAL|20% hypertonic dextrose water injection group|echo guide 20% dextrose water 3ml was injection in lesion site
62739233|NCT04916353|ACTIVE_COMPARATOR|Steroid injection group|Triamcinolone Acetonide 40mg/ml, 1ml, and Lidocaine 2ml as the active comparator group
62363157|NCT04282876||Control|Patients undergoing radiation therapy for bladder cancer with or without simultanous treatment with androgen deprivation therapy (not Degarelix)
62363158|NCT03700346|OTHER|survivors|survivor at ICU discharge muscle microdialysis
62363159|NCT03700346|OTHER|Non survivors|death before ICU discharge muscle microdialysis
62363160|NCT04229108|OTHER|Healthy volunteer|Will record traditional timed up and go followed by two digitised versions
62363161|NCT01643304||Group 1|
62169521|NCT04701073|EXPERIMENTAL|Intervention group : lumbar belt|wearing the LombaStab belt during 3 months in addition to usual care (promotion of physical activity and taking usual medicines for pain relief).
62169522|NCT04225078|EXPERIMENTAL|Treatment Sequence 1: Treatment ADBC|Participants will receive treatment A (Loperamide therapeutic dose) on Day 1 on treatment period 1, followed by Treatment D (Moxifloxacin) on Day 1 of treatment period 2 followed by Treatment B (Loperamide supratherapeutic dose) on Day 1 of treatment period 3 followed by Treatment C (placebo) on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
62363162|NCT02786836|EXPERIMENTAL|13C-Methacetin Testing|All patients enrolled into the ALFSG Registry with the duration of illness \<26 weeks with (1) severe acute liver injury; International Normalized Ratio (INR) ≥2.0) and not related to acetaminophen overdose, with no evidence of hepatic encephalopathy (HE); and (2) acute liver failure; INR ≥1.5 with presence of any degree of HE will perform the Breath Test.
62363163|NCT06267807|OTHER|MR lymphangiography contrast injection|"GBCM will be administered. Any routinely used macrocyclic GBCM can be used for MR lymphangiography, we generally use Dotarem® (Gadoteric acid- gadoterate meglumine). The dose used is the same standard dose of 0.1 mmol/kg of body weight used for routine intravenous injection. The guidelines and precautions used for intravenous injection of GBCM, should be followed for MR lymphangiography.~Subsequently, post-contrast imaging is performed (again, this will take around 20 minutes)"
62363164|NCT04798690||Growth hormone|Growtropin®-II
62363165|NCT01233180|ACTIVE_COMPARATOR|Gua Sha|Single Gua Sha treatment of the neck and shoulder region.
62363166|NCT01233180|ACTIVE_COMPARATOR|Thermotherapy|Single use of a mud heat pad on the neck and shoulder region.
62550031|NCT04315506|ACTIVE_COMPARATOR|Enough Snuff Intervention|Participants in this arm will be given the Enuff Snuff cessation manual.
62550032|NCT06583213|EXPERIMENTAL|Fractional Spinal Anaesthesia. Group A.|An intrathecal catheter 20 G will be then inserted 4-5 cm into the intrathecal space.This technique of SA will be performed on all patients , the needle should be inserted between L3 and L4 space or L4 and L5 space in order to avoid injury to the spinal cord. An intrathecal mixture (5mL) containing 3 mg/ml hyperbaric bupivacaine and 1 μg/ml dexmedetomidine will be prepared. Intrathecal anaesthesia will be induced by giving 2 mL (6 mg of hyperbaric bupivacaine and 2 μg of dexmedetomidine ) of the mixture, followed by a second 2 mL injection after 25 min.
62550033|NCT06583213|ACTIVE_COMPARATOR|Conventional Spinal Anaesthesia. Group B.|"Intrathecal anaesthesia will be induced by giving 12.5 mg Hyperbaric bupivacaine (2.5mL) and 4 μg of dexmedetomidine (1mL) (i.e., a total intrathecal dose (3.5 mL) of 12.5mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ).~Sensory level will be monitored by cold spray. Haemodynamic recordings will be documented every five minutes up until 45 minutes."
62550034|NCT06398379|EXPERIMENTAL|Fecal Virome Transplantation|Treatment with Fecal Virome Transplantation capsules (one treatment) following standard treatment of antiobiotics (Vancomycin)
62550035|NCT06398379|ACTIVE_COMPARATOR|Fecal Microbiota Transplantation|Treatment with Fecal Microbiota Transplantation capsules (one treatment) following standard treatment of antiobiotics (Vancomycin)
62550036|NCT03409354|EXPERIMENTAL|Tele-rehabilitation|Tele-rehabilitation via iPad.
62550037|NCT03409354|ACTIVE_COMPARATOR|Usual care|Usual rehabilitation care, prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
62550038|NCT01130493|OTHER|IPX066-CLE-OLE|Dose conversion from CLE to IPX066, IPX066 (Part 1 Period 1), Open-label IPX066, CLE (Part 1 Period 2), OLE (Part 2)
62550039|NCT01130493|OTHER|CLE-IPX066-OLE|Dose conversion from CLE to IPX066, CLE (Part 1 Period 1), Open-label IPX066, IPX066 (Part 1 Period 2), OLE (Part 2)
62550040|NCT01385774|ACTIVE_COMPARATOR|Intervention group: Angioplasty|Angioplasty with or without stent of the iliac artery
62550041|NCT01385774|ACTIVE_COMPARATOR|Control: Supervised Exercise Therapy|Supervised exercise therapy by a physiotherapist
62550042|NCT04932421|EXPERIMENTAL|Experimental group (UP-C intervention)|UP-C intervention 15 weekly sessions, for children and parents
62550043|NCT04932421|ACTIVE_COMPARATOR|Control group (ABC of emotions intervention)|ABC of emotions - a psychoeducational intervention 5 sessions every 3 weeks for children
62550044|NCT03392350|ACTIVE_COMPARATOR|Behavioral Intervention arm|"A behavioral intervention consisting of a physician body scan consultation with a radiologist which included viewing self imagery followed by an 18 month behavioral intervention which included educational modules covering:~Responding to Stress More Effectively Enhancing the effects of Relaxation Nourishing your immune system Energizing your Body Welcoming Others and Strengthening Relationships"
62550045|NCT03392350|ACTIVE_COMPARATOR|Control Group|No Intervention
62739234|NCT00641238||Early stage NSCLC|Early stage non-small cell lung cancer
62169523|NCT04225078|EXPERIMENTAL|Treatment Sequence 2: Treatment BACD|Participants will receive Treatment B on Day 1 of treatment period 1 followed by Treatment A on Day 1 of treatment period 2 then Treatment C on Day 1 of treatment period 3 and then Treatment D on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
61985399|NCT04941456|EXPERIMENTAL|PMV in place|Participants will perform the six-minute walk test each session to assess ambulation distance, alternating between the open tracheostomy (standard) versus the Passy-Muir Valve in place intervention on sequential days to compare results.
61985400|NCT02296385|EXPERIMENTAL|Supplementation|Supplementation
61985401|NCT04318236|EXPERIMENTAL|Online-Program + factors 1,2,3,4|"In this arm all four factors are set to active (i.e. yes):~* diagnostic interview~* motivational module~* guidance~* e-mail reminders"
61985402|NCT04318236|EXPERIMENTAL|Online-Program + factors 1,2,3|"In this arm three factors are set to active (i.e. yes):~* diagnostic interview~* motivational module~* guidance"
61985403|NCT04318236|EXPERIMENTAL|Online-Program + factors 1,2,4|"In this arm three factors are set to active (i.e. yes):~* diagnostic interview~* motivational module~* e-mail reminders"
61985404|NCT04318236|EXPERIMENTAL|Online-Program + factors 1,2|"In this arm two factors are set to active (i.e. yes):~* diagnostic interview~* motivational module"
61985405|NCT04318236|EXPERIMENTAL|Online-Program + factors 1,3,4|"In this arm three factors are set to active (i.e. yes):~* diagnostic interview~* guidance~* e-mail reminders"
61985406|NCT04318236|EXPERIMENTAL|Online-Program + factors 1,3|"In this arm two factors are set to active (i.e. yes):~* diagnostic interview~* guidance"
61985407|NCT04318236|EXPERIMENTAL|Online-Program + factors 1,4|"In this arm two factors are set to active (i.e. yes):~* diagnostic interview~* e-mail reminders"
61985408|NCT04318236|EXPERIMENTAL|Online-Program + factor 1|"In this arm one factor is set to active (i.e. yes):~- diagnostic interview"
61985409|NCT04318236|EXPERIMENTAL|Online-Program + factors 2,3,4|"In this arm three factors are set to active (i.e. yes):~* motivational module~* guidance~* e-mail reminders"
62363167|NCT05718661|EXPERIMENTAL|Virtual Reality Glasses Group|The intervention group will watch a virtual reality video with mobile virtual glasses by the researcher (SŞ) and the stress level on the smart wristband will be recorded. In addition, necessary variables will be recorded with the data collection form.
61985410|NCT04318236|EXPERIMENTAL|Online-Program + factors 2,3|"In this arm two factors are set to active (i.e. yes):~* motivational module~* guidance"
61985411|NCT04318236|EXPERIMENTAL|Online-Program + factors 2,4|"In this arm two factors are set to active (i.e. yes):~* motivational module~* e-mail reminders"
62550046|NCT00138008|ACTIVE_COMPARATOR|1|Drug: endocrine therapy
62550047|NCT00138008|EXPERIMENTAL|2|Procedure/Surgery: radiotherapy
62550048|NCT01044121|EXPERIMENTAL|Mattress Firmness|
62739235|NCT02748044|EXPERIMENTAL|Eligible patients for CC-Cruiser test|
62739236|NCT01770275||patients with esophageal cancer|Patients with esophageal cancer who underwent esophagectomy
62739237|NCT01210963||SENSIMED Triggerfish|
62739238|NCT02819258|OTHER|Endodontic treatment for a tooth with a periapical pathology|
61985412|NCT04318236|EXPERIMENTAL|Online-Program + factor 2|"In this arm one factor is set to active (i.e. yes):~- motivational module"
61985413|NCT04318236|EXPERIMENTAL|Online-Program + factors 3,4|"In this arm two factors are set to active (i.e. yes):~* guidance~* e-mail reminders"
62169524|NCT04225078|EXPERIMENTAL|Treatment Sequence 3: Treatment CBDA|Participants will receive Treatment C on Day 1 of treatment period 1 followed by Treatment B on Day 1 of treatment period 2 then Treatment D on Day 1 of treatment period 3 and then Treatment A on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
62363168|NCT05718661|PLACEBO_COMPARATOR|Non-Virtual Reality Glasses Group|The plain version of the video, which was shown to the intervention group by the researcher (SŞ) to the placebo group, will be watched over the phone with the naked eye and the stress level on the smart bracelet will be recorded. In addition, necessary variables will be recorded with the data collection form.
62550049|NCT06575582|NO_INTERVENTION|Exploratory preliminary study|General practitioners (n = 10), outpatient psychiatrists and psychologists (n = 10) and their patients (n = 20) will be involved. First, partly structured interviews will be conducted with the general practitioners and the psychiatric/psychological professionals as well as the patients they treat in order to record their perspectives on digital health services and the role of digital navigators. In parallel, focus groups will be organized with all three main groups to understand their opinions, concerns and expectations regarding the use of digital health applications and digital navigators. The data collection for the preliminary study extends over a period of 3 months (October - December 2024).
62550050|NCT06575582|EXPERIMENTAL|Training|Staff members (n = 6) of participating study cites will be trained to become Digital Navigators. The recruitment and training of the digital navigators will take place over a period of 4 months (October 2024 to January 2025).
62169525|NCT04225078|EXPERIMENTAL|Treatment Sequence 1: Treatment DCAB|Participants will receive Treatment D on Day 1 of treatment period 1 followed by Treatment C on Day 1 of treatment period 2 then Treatment A on Day 1 of treatment period 3 and then Treatment B on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
62363169|NCT05718661|NO_INTERVENTION|Control Group|Anxiety control will be done by the researcher (SU) for the control group.
62363170|NCT01820767|EXPERIMENTAL|Paricalcitol|SUBGROUP 1 (G1): Paricalcitol oral dosis triphosphoinositide mgc/100, 3 days a week.
62363171|NCT01820767|ACTIVE_COMPARATOR|Paricalcitol, Atorvastatin|SUBGROUP 2 (G2): Paricalcitol (same dosis than G1) + Atorvastatin (1 daily dosis 20 mg)
62550051|NCT06575582|EXPERIMENTAL|Treatment team and patient support|The Digital Navigators support the treatment teams in the study centers in the selection and integration of suitable apps and digital health applications (DiGAs). The selected patients (n = 48, 8 per center) are accompanied and supported by the trained navigators for 12 weeks to find a suitable app for them and integrate it into their treatment. A total period of 3 months is planned for both the recruitment of patients and the implementation off the intervention (December 2024 to February 2025).
62550052|NCT01993004||Healthy subjects|Self-explanatory
62363172|NCT01820767|ACTIVE_COMPARATOR|Atorvastatin|SUBGROUP 3 (G3): Atorvastatin (same G2 dosis)
61985414|NCT04318236|EXPERIMENTAL|Online-Program + factor 3|"In this arm one factor is set to active (i.e. yes):~- guidance"
62550053|NCT01993004||Untreated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are not on any disease-modifying treatment approved for MS
62550054|NCT01993004||Treated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who were prescribed Glatiramer acetate prior to enrollment
62550055|NCT04780178|EXPERIMENTAL|TACTICs|Our ACT intervention will include 6 weekly 1-hour telephone sessions and 1 booster session offered 1 month after session 6 designed to increase psychological flexibility through practice of one or more of the six skills in each session. Although these are ideally spaced 1 week apart, participants will have up to 12 weeks to complete the 6 sessions. Each session will include guided mindfulness practice that encourages non-judgmental awareness of the present moment to increase psychological flexibility; brief (10-minute) study-provided audio recordings will enable participants to practice mindfulness at home. Caregivers will also identify deeply-held values to serve as a guide when choosing how to spend limited time or energy and will set values-based action goals each week. A booster session will be provided one month after session 6 to reinforce skills learned.
62550056|NCT04780178|NO_INTERVENTION|Minimally Enhanced Usual Care|All caregivers randomized to the mEUC group will receive a mailed packet containing 1) a letter from the Co-PIs thanking them for participating, 2) printed selections from of the NIH Alzheimer's caregiving website (https://www.nia.nih.gov/health/alzheimers/caregiving), and 3) a listing of Alzheimer's Association sponsored support groups closest to the caregiver's home address. Caregivers will also receive a brief phone call from the research coordinator to verify receipt of the packet. Since this is a usual care group with a minimally-enhanced component, it will be up to the mEUC participants to decide whether or not to engage with these intervention materials.
62739239|NCT03574766|EXPERIMENTAL|Meditation Group|Twenty minutes of daily meditation for 7 days. Routine lactation support.
61985415|NCT04318236|EXPERIMENTAL|Online-Program + factor 4|"In this arm one factor is set to active (i.e. yes):~- e-mail reminders"
61985416|NCT04318236|EXPERIMENTAL|Online-Program + no factor|"In this arm no factor is set to active (i.e. yes):"
61985417|NCT02708147|SHAM_COMPARATOR|Conventional treatment|"Conventional treatment means that there will be only contact with physician/paediatrician and maybe drugs prescription.~Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after."
61985418|NCT02708147|EXPERIMENTAL|Physiotheraphy + Conventional treatment|Apart Conventional treatment a Physiotherapy protocol (techniques and education) will be performed on 5 sessions and evaluations will be made after each session as well as on baseline and on the 3th, 5th and 21st days and an interview 30 days after.
61985419|NCT00206414|EXPERIMENTAL|Iressa Day 1 with Arimidex and Faslodex|Subjects randomized to Iressa on Day 1 in combination with Arimidex and Faslodex.
61985420|NCT00206414|ACTIVE_COMPARATOR|Iressa Day 21 with Arimidex and Faslodex|Subjects randomized to Iressa Day 21 in combination with Arimidex and Faslodex
61985421|NCT01148745|OTHER|ferumoxytol|FDA approved drug
61985422|NCT01288950|EXPERIMENTAL|Vitamin D3|
61985423|NCT01288950|NO_INTERVENTION|Placebo|
61985424|NCT04147455|EXPERIMENTAL|RealConsent|Participants randomized to this study arm will receive an adapted program of RealConsent.
61985425|NCT04147455|ACTIVE_COMPARATOR|Health Education Control Condition|Participants in the control arm will receive a web-based health promotion program.
62550057|NCT02463773|EXPERIMENTAL|Ultrasound|Adults older than 18 years old who develop ARDS, as defined by the Berlin criteria, within 72 hours of ICU admission.
62550058|NCT00966472|EXPERIMENTAL|Erlotinib + Rosuvastatin|To determine the recommended phase II dose (RP2D) of rosuvastatin that can be given in combination with standard erlotinib treatment in patients with advanced incurable squamous cell cancer and NSCLC.
62550059|NCT06582485|EXPERIMENTAL|Active treatment iCM012 solution 2 mg/mL|iCM012 solution 2 mg/mL - 200 mL Investigational Medicinal Product (IMP) solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
62363173|NCT01082588|ACTIVE_COMPARATOR|pravastatin|pravastatin 40mg, once a day, shortly after baseline for 12 consecutive weeks
62363174|NCT01082588|PLACEBO_COMPARATOR|Placebo|placebo, once a day, shortly after baseline for 12 consecutive weeks
62363175|NCT06171815|EXPERIMENTAL|First Arm|Students in the first arm received simulation training under the leadership of a peer facilitator on the first day, and under the leadership of an instructor facilitator on the second day.
61985426|NCT02983383|ACTIVE_COMPARATOR|TAP block group (Group T)|At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
61985427|NCT02983383|ACTIVE_COMPARATOR|Group without TAP (Group P)|Patients in Group P will have adjuvant added to spinal anesthesia.
62363176|NCT06171815|EXPERIMENTAL|Second Arm|Students in the second arm received simulation training under the leadership of an instructor facilitator on the first day and under the leadership of a peer facilitator on the second day.
62363177|NCT00823160|ACTIVE_COMPARATOR|1: Sternotomy|Patients who are randomized to a sternotomy after the finding of blood in the pericardial sac.
62363178|NCT00823160|ACTIVE_COMPARATOR|2: Subxyphoid window|Patients who receive a subxyphoid window after the finding of blood in the pericardial sac.
62550060|NCT06582485|PLACEBO_COMPARATOR|Placebo|Placebo - 200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
62550061|NCT01821807||26 gauge quincke|Patients (n=150) will be treated with 26 gauge quincke spinal needle for spinal anesthesia for cesarean section.
62550062|NCT01821807||26 gauge atraucan|Patients (n=110) will be treated with 26 gauge atraucan spinal needle for spinal anesthesia for cesarean section.
62550063|NCT02855476||Early Pre-manifest HD|"Participants eligible are persons who meet the following criteria:~1. Are 18-75 years of age, inclusive, at the time of consent; and~2. Do not have clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score \< 4; and~3. Have CAG expansion ≥ 40; and~4. Have burden of pathology score, computed as (CAG - 35.5) × age, \< 250"
62550064|NCT02855476||Late Pre-manifest HD|"Participants eligible are persons who meet the following criteria:~1. Are 18-75 years of age, inclusive, at the time of consent; and~2. Do not have clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score \< 4; and~3. Have CAG expansion ≥ 40; and~4. Have burden of pathology score, computed as (CAG - 35.5) x age, ≥ 250"
62550065|NCT02855476||Early Manifest HD|"Participants eligible are persons who meet the following criteria:~1. Are 21-75 years of age, inclusive, at the time of consent; and~2. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and~3. Have CAG expansion ≥ 40; and~4. Have Stage I or Stage II HD, defined as UHDRS Total Functional Capacity (TFC) scores between 7 and 13 inclusive"
62550066|NCT02855476||Moderate Manifest HD|"Participants eligible are persons who meet the following criteria:~1. Are 21-75 years of age, inclusive, at the time of consent; and~2. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and~3. Have CAG expansion ≥ 40; and~4. Have Stage III HD, defined as UHDRS TFC scores between 3 and 6, inclusive"
62739240|NCT03574766|NO_INTERVENTION|Control Group|Routine lactation support.
62739241|NCT01877525||All patients in one cohort|Consecutive adult patients undergoing colonoscopy for colorectal cancer screening or routine surveillance indications were prospectively enrolled between October 2011 and October 2012.
61985428|NCT02015780|PLACEBO_COMPARATOR|Placebo|Fasiglifam placebo-matching tablets, once daily, and stable antihyperglycemic therapy for up to 16 weeks. Then Fasiglifam placebo-matching tablets, once daily and antihyperglycemic therapy, adjusted as necessary per the Investigator's discretion, for up to 36 weeks.
61985429|NCT02015780|EXPERIMENTAL|Fasiglifam|Fasiglifam 50 mg tablets, once daily and stable antihyperglycemic therapy for up to 16 weeks. Then Fasiglifam 50 mg tablets, once daily and antihyperglycemic therapy, adjusted as necessary per the Investigator's discretion, for up to 36 weeks.
61985430|NCT03404479|EXPERIMENTAL|Co-administration group|Co-administration of Diacerein 50mg, Celecoxib 100mg.
61985431|NCT03404479|ACTIVE_COMPARATOR|Single administration group 1|Single administration of Diacerein 50mg and placebo.
61985432|NCT03404479|ACTIVE_COMPARATOR|Single administration group 2|Single administration of Celecoxib 100mg and placebo.
61985433|NCT05394987|EXPERIMENTAL|Optical correction|Prescription of spectacles for full-time wear to correct refractive error
61985434|NCT02519530|EXPERIMENTAL|Intervention|Behavioral: Teen Outreach Program
62169526|NCT06536374|EXPERIMENTAL|Folate receptor blocker with Standard of Care|Administration of a dietary intervention to reduce folic acid at the time of standard of care androgen deprivation therapy.
62363179|NCT01913171|ACTIVE_COMPARATOR|Walking|WALK. The participants were instructed to walk daily, at first week 12minutes/day, week II 16mins/day, week III 20mins/day, week IV 24 mins/day, week V 28mins/day, week VI 32mins/day at a pace that would moderately increase heart rate and result in sweating
62363180|NCT01913171|ACTIVE_COMPARATOR|Hula-hooping|HULA. The participants were instructed to hula hoop daily, at first week 6minutes/day, week II 8mins/day, week III 10mins/day, week IV 12 mins/day, week V 14mins/day, week VI 16mins/day
62739242|NCT02146872||Very Premature CAD|Patients who have received a coronary intervention procedure on the basis of atherosclerosis before the age of 40
62550067|NCT02855476||Advanced Manifest HD|"Participants eligible are persons who meet the following criteria:~1. Are 21-75 years of age, inclusive, at the time of consent; and~2. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and~3. Have CAG expansion ≥ 40; and~4. Have Stage IV HD, defined as UHDRS TFC scores between 0 and 2, inclusive"
62363181|NCT03183960|EXPERIMENTAL|Mentor|An independent centralized randomization database will provide allocation concealed to the involved clinicians and assessors. A stratified block randomization of severity of impairment will be performed within each rehabilitation hospital
62363182|NCT03183960|ACTIVE_COMPARATOR|Traditional rehabilitation|An independent centralized randomization database will provide allocation concealed to the involved clinicians and assessors. A stratified block randomization of severity of impairment will be performed within each rehabilitation hospital
62550068|NCT02855476||Incomplete Penetrance HD|"Participants eligible are persons who meet the following criteria:~1. Are 18-75 years of age, inclusive, at the time of consent; and~2. Have CAG expansion of 36-39"
62169527|NCT06536374|NO_INTERVENTION|Standard of Care treatment|Standard of care treatment participants will have no intervention, only their prescribed androgen deprivation therapy (ex. intermediate/high risk localized prostate cancer starting ADT+ radiotherapy, metastatic hormone-sensitive prostate cancer (mHSPC) treated with or without androgen receptor pathway inhibitor (ARPI) as soon as able (within 2 weeks)
61985435|NCT02519530|NO_INTERVENTION|Comparison|This group did not receive TOP, they received business as usual health curriculum offered through the public school system
61985436|NCT01994629|EXPERIMENTAL|MenACWY-CRM|MenACWY-CRM
62550069|NCT02855476||Juvenile Manifest HD|"Participants eligible are persons who meet the following criteria:~1. Are ≥11 years of age at the time of consent; and~2. Have clinical diagnostic features of juvenile HD, defined as UHDRS Diagnostic Confidence Score = 4 aged ≤20 years; and~3. Have CAG expansion ≥ 40"
62363183|NCT03108300|EXPERIMENTAL|propranolol hydrochloride with Doxorubicin|The patients suffering from metastatic soft tissue sarcoma will receive doxorubicin 60mg per square meter of body surface area every 21 days combined with propranolol hydrochloride 40mg twice daily
62363184|NCT04039789|ACTIVE_COMPARATOR|Control|Usual Care: that consists of healing the wound (assessment, cleaning, disinfection, debridement and topical treatment) and compression therapy multilayer usual practice, according to the recommendations for the treatment of cutaneous ulcers of the Region of Madrid.
61985437|NCT01994629|ACTIVE_COMPARATOR|MenACWY-TT|MenACWY-TT
61985438|NCT04382833|EXPERIMENTAL|HOT APPLICATION GROUP|Thermoforming, one of the dry hot application methods, was performed on the sacral (S1-S4) vertebrae region of pregnant women in the hot application group while they were in sitting or left-side-lying position (during 4-5, 6-7, and 8-9 cm cervical dilation). Thermoforming was applied by wrapping it with a towel to protect pregnant women from the direct effect of its hot surface. The mean water temperature used in thermoforming was 50C. The water temperature was measured using a liquid thermometer. When 50°C water was subjected to hot application, the surface temperature reached around 40°C. The hot application was carried out continuously for 20 min.20 The body temperature of the pregnant women was evaluated before the application.
62550070|NCT02855476||Healthy Control|"Participants eligible are persons who meet the following criteria:~1. Are 18-75 years of age, inclusive, at the time of consent; and~2. Have no known family history of HD; or~3. Have known family history of HD but have been tested for the huntingtin gene CAG expansion and are not at genetic risk for HD (CAG \< 36)."
62550071|NCT04817618|EXPERIMENTAL|iptacopan 200mg|iptacopan 200 mg b.i.d.
62550072|NCT04817618|PLACEBO_COMPARATOR|Placebo to iptacopan 200mg|Placebo to iptacopan 200mg b.i.d.
62169528|NCT06447298||Parents accompanying children|Parents accompanying children aged 0 to 17 who have undergone laparoscopic surgery in the paediatric surgery department in Brest.
62550073|NCT02806115|EXPERIMENTAL|acetic acid-enhanced endoscopy|Acetic acid-enhanced endoscopy combines conventional endoscopy with the instillation of acetic acid.
62550074|NCT03155243||Participants receiving adalimumab (Humira®)|Participants with active non- infectious intermediate, posterior or panuveitis receiving adalimumab (Humira®).
62550075|NCT01159561|EXPERIMENTAL|Vaccinated|Western Equine Encephalitis Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, administered in 0.5 mL doses subcutaneously in the upper outer aspect of the triceps in a 3-dose primary series (Days 0, 7, and 28) with a mandatory boost (Day 180)
62550076|NCT00073346|EXPERIMENTAL|cognitive behavior therapy for hoarding disorder|Cognitive behavior therapy included 26 sessions of motivational enhancements; skills training for sorting, organizing and problem solving; direct practice not acquiring new items and discarding possessions to remove clutter and organize possessions; cognitive therapy to evaluate beliefs about possessions; and relapse prevention skills.
62550077|NCT00073346|NO_INTERVENTION|Wait list control|Participants waited to receive treatment for 12 weeks
62550078|NCT01205087|PLACEBO_COMPARATOR|Placebo|
62550079|NCT01205087|ACTIVE_COMPARATOR|OKT3 - 0.2|
62550080|NCT01205087|ACTIVE_COMPARATOR|OKT3 - 1|
62550081|NCT01205087|ACTIVE_COMPARATOR|OKT3 - 5|
62550082|NCT06582459||HFNC treatment|HFNC therapy. The initial flow rate of 50-60 L/min was subsequently adjusted to maintain an oxygen saturation (SpO2) ≥92%. The FiO2 was titrated to maintain the PaO2 between 60 and 80 mmHg.
62169529|NCT05662215|EXPERIMENTAL|CK-3828136 for SAD Cohort|Subjects will be assigned to one of approximately 8 planned dose cohorts and receive single doses of CK-3828136
62169530|NCT05662215|PLACEBO_COMPARATOR|Placebo for SAD Cohort|Subjects will be assigned to one of approximately 8 planned cohorts and receive single doses of placebo
62169531|NCT05662215|EXPERIMENTAL|CK-3828136 for MAD Cohort|Subjects will be assigned to one of approximately 8 planned dose cohorts and receive multiple doses of CK-3828136
62550083|NCT06582459||NIV treatment|A Mindray SV300 ventilator (Mindray Medical International Limited, Shenzhen, China) was used to deliver NIV via an oronasal mask. The initial inspiratory positive airway pressure (IPAP) was 12-15 cmH2O and adjusted later to achieve a tidal volume of 6-8 mL/kg of predicted body weight and a respiratory rate of \<30 breaths/min. The expiratory positive airway pressure (EPAP) was established at 5-8 cmH2O. Additional-ly, FiO2 was titrated to maintain a PaO2 between 60 and 80 mmHg.
62550084|NCT05137587|ACTIVE_COMPARATOR|Group P|Patients sedated with propofol
62550085|NCT05137587|ACTIVE_COMPARATOR|Group K|Patients sedated with ketamine
62550086|NCT00641628||1|
61985439|NCT04382833|EXPERIMENTAL|MASSAGE GROUP|Massage using effleurage and friction techniques was applied to the 4-5 cm right and left lateral parts of the midline on the sacral (S1-S4) vertebrae region of pregnant women in the massage application group while they were in sitting or left-side-lying position (during 4-5, 6-7, and 8-9 cm cervical dilation). The massage application was carried out continuously for only 10 min because it was thought to cause irritation to the area where it was practiced.
62169532|NCT05662215|PLACEBO_COMPARATOR|Placebo for MAD Cohort|Subjects will be assigned to one of approximately 8 planned cohorts and receive single doses of placebo
62550087|NCT05669235||Long covid|Women who present symptoms after suffering from COVID-19, consistent with long covid.
62550088|NCT05669235||Covid|Women who have passed COVID-19 without consequences.
62363185|NCT04039789|EXPERIMENTAL|Intervention|"ACTIVE LEGS: The usual care plus experimental intervention. It is a structured educational intervention, directed by nurses and carried out in the health center consultations. The intervention Active Legs has been designed based on the available evidence. It incorporates a program of lower limb exercise at home and daily walking patterns.~Home program of lower limb exercises. The nurse will instruct the patients in the performance of 4 exercises of lower limbs of progressive difficulty that must be performed at home 5 days a week, twice a day Daily walking program. In addition, patients must ambulate progressively until reaching the marked goal (150 min / week (30 minutes for 5 days a week)) .~At the start of the study, the Active Legs diary will be provided, showing the patterns of the exercise and walking program graphically and a pedometer."
62363186|NCT02126813|ACTIVE_COMPARATOR|500 ml.|A bladder volume of 500 ml. or more, and incapability of voluntary micturition, is used as interventional threshold for urinary bladder catheterization.
62169533|NCT05662215|EXPERIMENTAL|Food Effect|Healthy subjects will be administered CK-3828136 with and without food in a cross-over fashion.
62363187|NCT02126813|EXPERIMENTAL|800 ml|A bladder volume of 800 ml. or more, and incapability of voluntary micturition, is used as interventional threshold for urinary bladder catheterization.
62550089|NCT04289363||ED patients|Administrative and health record data will be examined to assess rates of screening, assessment, eligibility determination, etc.
62550090|NCT02756130|EXPERIMENTAL|Treatment (birinapant, carboplatin)|Patients receive birinapant IV over 30 minutes on days 1 and 8, and carboplatin IV over 30 minutes to 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62363188|NCT05571904|EXPERIMENTAL|the thick STSG group|For the patients in the thick STSG group, the surgeons harvested thick STSGs which were larger than recipient sites. The extra skin was punctured and stretched to cover the donor site (the novel technique).
62363189|NCT05571904|ACTIVE_COMPARATOR|the thin STSG group|For the patients in the thin STSG group, the surgeons harvested thick STSGs of the size of recipient sites. Their donor sites were covered with thin STSGs which were harvested from other parts of the patients.
62550091|NCT01843387|EXPERIMENTAL|Cohort 1|Mesenchymal Precursor Cells (MPCs) - Dose 1 or Placebo
62363190|NCT04246346|EXPERIMENTAL|Interactive chatbot|A chatbot embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
62363191|NCT04246346|ACTIVE_COMPARATOR|Senior ophthalmologists|Senior ophthalmologists would communicate with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
62363192|NCT04228107|EXPERIMENTAL|Cohort|"Participants will be enrolled in medication use monitoring. Their medication use patterns will be available to themselves and their guardians via a smartphone application, and to their asthma care providers via a portal. There will be no interventions to change medication use patterns. A portion of them will be asked to participate in a semistructured interview during which they will be asked questions about their perception of their asthma, health beliefs regarding medication use, and what they feel would be the most helpful to get them to take their asthma medicines.~Additionally a small group of healthcare providers will be asked to participate in a focus group to collect qualitative data on medication use barriers and facilitators"
62363193|NCT02299271|ACTIVE_COMPARATOR|ropivacaine block|Ropivacaine 0.375% as a one-time 60 milliliter injection.
62169534|NCT01963858|EXPERIMENTAL|Functional relaxation|Functional relaxation
62169535|NCT01963858|ACTIVE_COMPARATOR|No relaxation|No relaxation
62363194|NCT02299271|PLACEBO_COMPARATOR|saline block|Sodium chloride 0.9% as a one-time 60 milliliter injection.
62363195|NCT05097157|EXPERIMENTAL|Treatment with Device|Subjects received up to 5 treatments with the device, spaced 4 weeks apart.
62550092|NCT01843387|EXPERIMENTAL|Cohort 2|Mesenchymal Precursor Cells (MPCs) - Dose 2 or Placebo
62550093|NCT03624192|EXPERIMENTAL|RECELL® Autologous Cell Harvesting Device|RECELL + Telfa™ Clear and Xeroform™ dressings
62550094|NCT03624192|ACTIVE_COMPARATOR|Telfa™ Clear and Xeroform™ dressings|Telfa™ Clear and Xeroform™ dressings
62550095|NCT01056289|ACTIVE_COMPARATOR|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|
62550096|NCT01056289|ACTIVE_COMPARATOR|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|
62550097|NCT01056289|PLACEBO_COMPARATOR|Placebo|
62550098|NCT06397495|EXPERIMENTAL|Flipped Groups|
62550099|NCT06397495|NO_INTERVENTION|Traditional Learning Groups|
62550100|NCT03299582|EXPERIMENTAL|Healthy subjects (Hypothermia)|To investigate the safety and tolerability of limb hypothermia in subjects without cancer
62169536|NCT06026826|ACTIVE_COMPARATOR|real stimulation|Participants will receive active tACS twice daily for one week. The anode was placed over AF3 with return electrodes placed at the contralateral mastoid process. Fourteen 2-mA sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 20 minutes per session, twice daily over 7 consecutive days, and the stimulus frequency was set as 8 Hz.
62550101|NCT03299582|EXPERIMENTAL|Healthy subjects (Cryocompresion)|To investigate the safety and tolerability of cryocompression in subjects without cancer
62739243|NCT02146872||Healthy middle-aged 1st degree relatives|Healthy 1st degree relatives aged 30-65 years of patients with very premature CAD.
61985440|NCT04382833|NO_INTERVENTION|CONTROL GROUP|
61985441|NCT00625859|EXPERIMENTAL|Subjects receiving treatment sequence 1|Eligible subjects will receive treatment A in period 1, treatment B in period 2 and treatment C in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
62363196|NCT01113840|PLACEBO_COMPARATOR|Control|Control group continues with their daily activity as they were prior to randomization. Receive bi-weekly follow-up phone calls to assess health status and encourage adherence with protocol.
62363197|NCT01113840|ACTIVE_COMPARATOR|Exercise|Exercise classes three times per week in a controlled, supervised environment.
62550102|NCT03299582|EXPERIMENTAL|Cancer subjects (Hypothermia)|To investigate the safety and tolerability of limb hypothermia in subjects with breast cancer being treated with paclitaxel chemotherapy.
62550103|NCT03299582|EXPERIMENTAL|Cancer subjects (Cryocompresion)|To investigate the safety and tolerability of cryocompression in subjects with cancer being treated with taxane-based chemotherapy.
62550104|NCT04652778|EXPERIMENTAL|Treatment|
61985442|NCT00625859|EXPERIMENTAL|Subjects receiving treatment sequence 2|Eligible subjects will receive treatment B in period 1, treatment C in period 2 and treatment A in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
61985443|NCT00625859|EXPERIMENTAL|Subjects receiving treatment sequence 3|Eligible subjects will receive treatment C in period 1, treatment A in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
61985444|NCT00625859|EXPERIMENTAL|Subjects receiving treatment sequence 4|Eligible subjects will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
61985445|NCT00625859|EXPERIMENTAL|Subjects receiving treatment sequence 5|Eligible subjects will receive treatment B in period 1, treatment A in period 2 and treatment C in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
61985446|NCT00625859|EXPERIMENTAL|Subjects receiving treatment sequence 6|Eligible subjects will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
61985447|NCT00789893||Women with cervical, endometrial, rectal or anal cancer|Women seen in the radiation oncology clinic with cervical, endometrial, rectal or anal cancer who will receive external beam pelvic radiation or brachytherapy
62550105|NCT04328701|EXPERIMENTAL|Mindfulness-based CBT|All participants will receive four individual mindfulness-based CBT sessions.
62550106|NCT04328701|NO_INTERVENTION|Treatment as Usual|All participants will undergo surgery as usual, with no additional intervention.
62363198|NCT05024617||trigger finger stage 1-2-3|Volunteer patients between 35-65 years old diagnosed with Stage 1, Stage 2 and Stage 3 trigger finger based on the Froimson Classification were included in the study. Exclusion criteria include paediatric trigger finger, trigger thumb, concomitant de'Quervain tenosynovitis, carpal tunnel syndrome, or Dupuytren's contracture, neurological or rheumatological diseases, chronic pain syndromes, pregnancy and patients with treatment history of related finger/fingers
62363199|NCT00458367||001|Open label risperidone long acting injectable intramuscular injections every 2 weeks for 26 weeks flexible dose 25 to 50 mg
62550107|NCT01679652|EXPERIMENTAL|Nebivolol|Tablet Nebivolol 5 mg (oral use) for 5 days
62550108|NCT01679652|PLACEBO_COMPARATOR|Placebo|Inactive placebo given as tablet for 5 days
62550109|NCT05549505|EXPERIMENTAL|ARV-471 monotherapy|ARV-471 taken once daily until surgical resection
62550110|NCT05549505|ACTIVE_COMPARATOR|Anastrozole monotherapy|Anastrozole 1mg taken once daily until surgical resection
62550111|NCT00425763|EXPERIMENTAL|AQAS|
62550112|NCT06548425|EXPERIMENTAL|Smart Phone Based Cardiac Telerehabilitation|
61985448|NCT05034107|EXPERIMENTAL|Persons with dementia|Persons who have been diagnosed with dementia by their physicians and in nursing homes. Persons with dementia who have at least one symptom of BPSD and willing to participate in this study. These participants will be exposed to diffused Ylang-Ylang aromatherapy.
61985449|NCT03407573|ACTIVE_COMPARATOR|Restrictive|Restrictive transfused when Hb at or below 70
62550113|NCT06548425|ACTIVE_COMPARATOR|Center based cardiac Rehabilitation|
62550114|NCT04536376|EXPERIMENTAL|Resilience Program|a 4 week program focused on improving resilience
62550115|NCT04180865||Parkinson's disease patients|150 de novo treatment naive Parkinson's disease patients.
62550116|NCT04180865||Healthy control subjects|150 Healthy sex- and age-matched controls, also matched according to presence and severity of constipation, serving as a control group for microbiome composition analyses.
62550117|NCT05760248|EXPERIMENTAL|10XB-101 Solution for Injection, 6.0%|Participants receive 10XB-101 Solution for Injection, 6.0% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4 weeks for up to 6 treatments.
62550118|NCT05760248|PLACEBO_COMPARATOR|Placebo Solution for Injection|Participants receive Placebo Solution for Injection, via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4 weeks for up to 6 treatments.
61985450|NCT03407573|ACTIVE_COMPARATOR|Liberal|Will receive blood transfusion when Hb drops below or equal to 90
61985451|NCT02930551|ACTIVE_COMPARATOR|Lidocaine|Lidocaine 2 ml injection with 2% Adrenaline
61985452|NCT02930551|PLACEBO_COMPARATOR|Isotonic Saline|Isotonic Saline 2 ml Injection
61985453|NCT04665050|EXPERIMENTAL|V116|Participants receive a single 1.0 mL intramuscular (IM) injection of V116 on Day 1.
62169537|NCT06026826|SHAM_COMPARATOR|sham stimulation|Participants will receive sham tACS twice daily for one week. Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
62169538|NCT04494243|EXPERIMENTAL|AD-214/Rabeprazole|Period 1 : Test Drug(AD-214 10/600mg) Period 2 : Reference Drug(Rabeprazole 10mg)
62550119|NCT05549180|ACTIVE_COMPARATOR|Patients received DTG/3TC + BIC/FTC/TAF placebo|DTG 50 mg/3TC 300 mg 1 tablet per day + BIC 50 mg/ FTC 200 mg/ TAF 25 mg placebo 1 tablet per day
61985454|NCT04665050|ACTIVE_COMPARATOR|PNEUMOVAX™23|Participants receive a single 0.5 mL IM injection of PNEUMOVAX™23 on Day 1.
61985455|NCT05426226|ACTIVE_COMPARATOR|laser group|"Laser group use specific wavelength to light the sleep acupoints during.~If the laser group take light acupuncture in the first month, and then become the sham group in the next month, vice versa."
62550120|NCT05549180|EXPERIMENTAL|Patients received BIC/FTC/TAF + DTG/3TC placebo|BIC 50 mg/ FTC 200 mg/ TAF 25 mg per day + DTG 50 mg/3TC 300 mg placebo1 tablet per day
62550121|NCT02770378|EXPERIMENTAL|Temozolomide combined with 9 repurposed drugs|"After enrollment, the subject goes into the induction cycle, which lasts 35 days. The induction cycle consists of a drug-by-drug addition and up-dosing process.~Hereafter, the subject will enter the treatment cycles (up to 12). During the induction cycle and the first 2 treatment cycles, regimen adjustments (dropping of certain drugs, dose modification of certain drugs) may be executed to accommodate to the patients' individual toxicity reactions that may occur during this period."
62169539|NCT04494243|EXPERIMENTAL|Rabeprazole/AD-214|Period 1 : Reference Drug(Rabeprazole 10mg) Period 2 : Test Drug(AD-214 10/600mg)
62550122|NCT04197778|EXPERIMENTAL|group A|
62550123|NCT04197778|EXPERIMENTAL|group B|
62550124|NCT02808416|EXPERIMENTAL|Personalized cellular vaccine|Patients will undergo tumor resection or biopsy, and receive biweekly cellular vaccines consisting of mRNA-pulsed autologous DCs.
62550125|NCT02945189||Peri menopausal|Participants aged 41-55 years
62550126|NCT02945189||post menopausal|participants aged 56-65 years
62739244|NCT02146872||PCAD families|Families severely affected by premature CAD
62169540|NCT06646575||Patient participant|
62169541|NCT06646575||Informal carer participant|
62169542|NCT06646575||Healthcare professional participant|
62169543|NCT06549699|ACTIVE_COMPARATOR|Meal delivery program|Patients will receive 2 meals daily (21 meals weekly) of medically-tailored meals incorporating traditional Navajo foods, followed by a cooking class at the end of the meal program (meals provided for 30 days for phase I pilot feasibility and 60 days for phase II)
62550127|NCT01926574|EXPERIMENTAL|long rehabilitation|a 3.5-week, in-patient rehabilitation program, organized as a 7-hour workday with weekends off, simulating a close to normal summer work-week in Norway, and mainly group-based with maximum 8 participants per group. Focus on mental training (aimed at increasing motivation and self-efficacy), physical training and work-related problem solving.
61985456|NCT05426226|SHAM_COMPARATOR|sham group|"sham group use the same divce and acupointsas the laser group, but the light is just a regular light.~If the laser group take light acupuncture in the first month, and then become the sham group in the next month, vice versa."
61985457|NCT04100304|OTHER|patient under going liver resection|
61985458|NCT03420651|EXPERIMENTAL|PEFR Guided Management|Peak Expiratory Flow Rate (PEFR) Patients in this group will perform PEFR testing every 30 minutes and this data along with the National Asthma Prevention and Education Program guidelines will be considered by primary ED medical providers in the management of this group.
62550128|NCT01926574|EXPERIMENTAL|short rehabilitation|4+4 full days of rehabilitation at Hysnes Rehabilitation Center, separated by 2 weeks living at home. Group-based with 8 participants per group, focus on mental training (aimed at increasing motivation and self-efficacy), physical training and work-related problem solving. A workplace visit will be included in addition to the 4 + 4 rehabilitation days, if considered relevant.
62550129|NCT01926574|ACTIVE_COMPARATOR|Acceptance and commitment therapy|6 dynamic processes (committed action, self-as-context, presence in the moment, values, defusion and acceptance) are targeted both in group-sessions and individual meetings. Only the psychological part of the experimental interventions is applied, in an outpatient setting.
61985459|NCT03420651|EXPERIMENTAL|Non-PEFR Guided Management|Standard Clinical Judgement Patients in this group will receive management based on primary medical provider's clinical judgement.
61985460|NCT06189222|EXPERIMENTAL|virtual reality glasses|The sample of the research, which was carried out as a randomized controlled experimental study, consisted of 102 children, including 51 in the control group and 51 in the study group, who were aged between 7 and 12 and were on treatment in the emergency department. Research data were collected using a Descriptive Data Form for Children and the Children's Emotional Manifestation Scale. During the data collection phase, first, the Descriptive Data Form for Children was filled out for the control and study groups. No intervention was applied to the control group. After the tourniquet was tied in the study group, the children started watching a video of their choice through virtual reality glasses. When the process was completed, the video was stopped. During this period, the child was evaluated using the Children's Emotional Manifestation Scale.
61985461|NCT06189222|NO_INTERVENTION|standard care|Intervention during intravenous catheter insertion to the child
61985462|NCT04287712||Participants received surgery|Patients who underwent surgery at the Department of Thoracic Surgery of Peaking University People's Hospital, Jiangsu Cancer Hospital, and Beijing Haidian Hospital were enrolled with the following criteria: 1) pathologically confirmed lung cancer; 2) no history of other malignancies; 3) no anti-cancer treatment (chemotherapy, radiotherapy, targeted therapy, etc.) before surgery. Plasma samples were collected before surgery and plasma lipids were detected by mass spectrometry. Pathological diagnosis and clinical characteristics of enrolled participants were retrieved.
61985463|NCT05058300||Patients with Chest Pain|An unselected patient-population with chest pain in emergency department
61985464|NCT00696514|PLACEBO_COMPARATOR|2|placebo capsule, once per day
61985465|NCT00696514|EXPERIMENTAL|1|Vitamin B12 and folic acid capsule, once a day
61985466|NCT05601986|OTHER|Physiotherapy and Rehabilitation Program|Control Group
61985467|NCT05601986|EXPERIMENTAL|Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program|Intervention Group
62550130|NCT01926574|NO_INTERVENTION|Untouched|this group will be followed in registers at group level and not be aware of their participation in the study
61985468|NCT03343873|EXPERIMENTAL|Midarolam|midarolam sensation group
61985469|NCT03343873|EXPERIMENTAL|Propofol|propofol sensation group
61985470|NCT03343873|EXPERIMENTAL|dexmedetomidine|dexmedetomidine sensation group
61985471|NCT00798044|EXPERIMENTAL|Feedback to counselors|substance abuse counselors received feedback reports on their average performance and on the average performance of the clinic as a whole. Feedback reports contained information on average alliance, treatment satisfaction, and drug/alcohol use.
61985472|NCT00798044|NO_INTERVENTION|Treatment as Usual|No feedback reports were provided in this arm.
62550131|NCT05081986|EXPERIMENTAL|D-cycloserine|Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine one hour prior to receiving theta-burst stimulation (TBS; a patterned stimulation). Their baseline motor evoked potentials (MEP) will be recorded for 20 minutes prior to receiving the first TBS to the motor cortex and change in MEP amplitude will be measured following stimulation up to 60minutes later. They will then receive a second TBS to the motor cortex and change in MEP amplitude will again be measured following stimulation up to 60minutes later.
62550132|NCT05081986|PLACEBO_COMPARATOR|Placebo|Participants will ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule one hour prior to receiving theta-burst stimulation (TBS; a patterned stimulation). Their baseline motor evoked potentials (MEP) will be recorded for 20 minutes prior to receiving the first TBS to the motor cortex and change in MEP amplitude will be measured following stimulation up to 60minutes later. They will then receive a second TBS to the motor cortex and change in MEP amplitude will again be measured following stimulation up to 60minutes later.
61985473|NCT06488963|NO_INTERVENTION|Control group|"Children in the control group will receive standard care. VIPN is expected to follow at the end of the third cycle, nearly three months from the first VCR dose/application. Accordingly, no additional intervention will be performed to prevent peripheral neuropathy in children in the control group.~Standard care: The clinic uses no pharmacological or non-pharmacological method as standard care for preventing VIPN. For patients with VIPN in the pediatric oncology clinic, dose reduction or treatment interruption is performed. Children will be excluded from the study if such a situation occurs during the research time period."
62550133|NCT05721287|ACTIVE_COMPARATOR|SBS-1000|Investigational Product
62550134|NCT05721287|PLACEBO_COMPARATOR|Placebo|Normal saline (0.9% sodium chloride \[NaCl\])
62550135|NCT00550459|PLACEBO_COMPARATOR|1|Placebo tablet given once a day for 21 days
62550136|NCT00550459|ACTIVE_COMPARATOR|2|Tolvaptan 15 mg-60 mg tablet given once a day for 21 days.
62550137|NCT03555123|EXPERIMENTAL|SIMDAX|Levosimendan2.5mg/mL
62550138|NCT03555123|PLACEBO_COMPARATOR|SIMDAX Placebo|Water for injection
61985474|NCT06488963|EXPERIMENTAL|Cold Therapy/Intervention Group|In addition to standard care in the clinic, cold therapy will be applied to the children in the intervention group while they are receiving VCR in the inpatient pediatric oncology clinic. Children in the intervention group will wear cold therapy gloves and socks.To maintain the appropriate level of cold, the research assistant will replace the iced gel packs in the gloves and socks every 5 min during the treatment.
62363200|NCT01396746||People with Post Stroke Conditions|(a) having acquired stroke at least 1 year before testing. (b) Chronic weakness and/or spasticity of the affected side. (c) Independent stair-climbers (with hand-rail). (d) With cognitive level sufficient to comprehend instructions. (e) age range between 40-69. (f) Use of walking aid is permitted as long as the participant is able to walk on a treadmill with hand-rail. (g) No heart failure or other medical conditions that preclude participation in the study.
62363201|NCT03322397|EXPERIMENTAL|Kindness to Others|Participants will complete the 'Other-Focused Acts of Kindness Intervention' by performing acts of kindness for others. They be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
61985475|NCT05634551||Questionnaires (All Participants)|If participants are found to be eligible and agree to take part in the study, information about you (such as age, gender, race, ethnicity, marital status, education, employment status, religious beliefs, and information about your cancer diagnosis and history, current therapy and goal of cancer therapy) will be collected.
61985476|NCT05634551||Interview (Some Participants)|Not every participant will be asked to have an interview. It is expected that about 20-30 participants will take part in the interview part of the study.
62550139|NCT06099392|EXPERIMENTAL|TEA group|TEA at ST36 (Zusanli) combined with 2L Polyethylene Glycol Electrolytes Powder for bowel preparation
62550140|NCT06099392|NO_INTERVENTION|Sham-TEA group|2L Polyethylene Glycol Electrolytes Powder for bowel preparation
61985477|NCT02436551||Pregnant women in Tajikistan|
62550141|NCT04944524|EXPERIMENTAL|Tofactitinib|partcipants would be given one tablet of tofacitinib (5mg per tablet), twice per day, the treatment duration will last 12 months during the whole follow-up period.
62550142|NCT04944524|ACTIVE_COMPARATOR|Methotrexate|partcipants would be given tablets of methotrexate (2.5mg per tablet) from the initial dose of 15mg (6 tablets) and add to the maximal and optimal dose of 20mg (8 tablets), once per week, the treatment duration will last 12 months during the whole follow-up period.
62550143|NCT02671747|EXPERIMENTAL|Pilot workshop|Participants attend intervention. No control arm
62550144|NCT02412917|EXPERIMENTAL|FV-100 400 mg QD|FV-100 400mg QD
62550145|NCT02412917|EXPERIMENTAL|FV-100 400mg BID|FV-100 400mg BID(total daily dose of 800mg)
62550146|NCT02412917|ACTIVE_COMPARATOR|valacyclovir|valacyclovir 1000mg TID
61985478|NCT05044754||SCAP|Patients with recurrent prostate cancer undergoing SCAP
61985479|NCT05044754||HIFU|Patients with recurrent prostate cancer undergoing HIFU
61985480|NCT03669692|ACTIVE_COMPARATOR|Control|Patients in the control group will be assigned to a free diet (ad libitum), according to the Spanish Association of Urology lifestyle recommendations for patients with LUTS
62169544|NCT06549699|PLACEBO_COMPARATOR|Usual Care|Patients will receive usual care plus the recipes of the meals received by intervention group
62169545|NCT01497951|EXPERIMENTAL|Aminolaevulinic acid|
62169546|NCT01497951|PLACEBO_COMPARATOR|Placebo|
62169547|NCT02754310|ACTIVE_COMPARATOR|Repeated scenarios|Participants in the repeated scenario group will learn the management of a pediatric asthma exacerbation on the same scenario repeated three times. The scenario is a pediatric moderate asthma exacerbation not responding to treatment, .
62363202|NCT03322397|ACTIVE_COMPARATOR|Kindness to Self|Participants will complete the 'Self-Focused Acts of Kindness Intervention' by performing acts of kindness for themselves. They be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
62550147|NCT02304029|EXPERIMENTAL|assessment of a innovative MRI|Sodium MRI will be performed at CEMEREM, CHU Timone, the only site with this technique, with a Siemens Verio 3T MRI using a dedicated coil and a sequence already developed locally, in 90 patients with partial drug -resistant epilepsy
61985481|NCT03669692|EXPERIMENTAL|Caloric Restriction|"Patients in the experimental group will be assigned to intermittent caloric restriction, based on an early time restricted eating, with a 16/8 fasting/feeding scheme.~The patients in this group will have a RC progressive scheme until achieve a maximum of 5 days a week of fasting."
61985482|NCT04474860||Malignant Hyperthermia|Samples from Chinese whose malignant hyperthermia susceptibility had been confirmed after a positive clinical manifestation of malignant hyperthermia and samples from their blood relations will receive genetic testing.
61985483|NCT05665790|EXPERIMENTAL|radiotherapy|
62550148|NCT03493412|EXPERIMENTAL|BH4-Placebo|Subjects will be tested on two different days, first day will be baseline and Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin) and second day will be Placebo. Testing will take place one-hour after BH4/placebo intake. There will be a 2-week washout between testing days.
61985484|NCT05665790|EXPERIMENTAL|palliative surgery|
62550149|NCT03493412|EXPERIMENTAL|Placebo-BH4|Subjects will be tested on two different days, first day will be baseline and placebo and second day will be Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin). Testing will take place one-hour after BH4/placebo intake. There will be a 2-week washout between testing days.
62550150|NCT05298917|OTHER|extended contact lens wear|subjects wear silicone hydrogel contact lenses continuously for 7+/- 1 days - corneal sensitivity will be measured and compared at baseline versus after extended contact lens wear
62550151|NCT05854524|ACTIVE_COMPARATOR|Parkinson Disease|Participants diagnosed with Parkinson disease (PD) will the main arm of the study and will be compared to the control group.
61985485|NCT05665790|NO_INTERVENTION|no primary leison treatment|
61985486|NCT00703612|EXPERIMENTAL|Treatment Group|This is the only arm and that is the treatment group.
62550152|NCT05854524|ACTIVE_COMPARATOR|Control|Older, adults who are age- and sex-matched to the PD participants.
62550153|NCT01979991|EXPERIMENTAL|CT Imaging and Reconstruction|To develop a MBIR (model-based image reconstruction) method that will improve X-ray CT lung imaging by improving image quality and reducing dose.
62550154|NCT03182777|ACTIVE_COMPARATOR|Lidocaine with epinephrine|Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% with epinephrine 1:100.000 for dental restorative procedures in patients with cardiac channelopathies.
62550155|NCT03182777|ACTIVE_COMPARATOR|Lidocaine|Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% without vasoconstrictor for dental restorative procedures in patients with cardiac channelopathies.
62550156|NCT00531167|EXPERIMENTAL|A|combination therapy
61985487|NCT04778189|PLACEBO_COMPARATOR|normal saline group (NS)|patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes after spinal anesthesia
62169548|NCT02754310|EXPERIMENTAL|Varied scenarios|"Participants in the varied scenarios group will learn the management of a pediatric asthma exacerbation on three different scenarios: a moderate asthma exacerbation, a mild one, and a severe one, for the same length of time than the repeated scenarios group. In this group, there is a variation of scenarios."
62169549|NCT03596099|EXPERIMENTAL|Mizkan rice vinegar with acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.
62550157|NCT00531167|ACTIVE_COMPARATOR|B|entecavir
62550158|NCT04174625|EXPERIMENTAL|Omega3-FA group|Omega3-FA group 1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
62550159|NCT04174625|EXPERIMENTAL|Control group|VD3 group 50,000 IU/week
62550160|NCT01371747|EXPERIMENTAL|Stratum 1: 8.4 g/d patiromer|Participants with baseline serum potassium \> 5.0 to 5.5 mEq/L (milliequivalent)
61985488|NCT04778189|ACTIVE_COMPARATOR|dexamethasone group (SD)|patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline in 5-10 minutes after spinal anesthesia
61985489|NCT03826862|EXPERIMENTAL|intervention group|All patients receive CT three-dimensional reconstruction before surgery.
62169550|NCT03596099|PLACEBO_COMPARATOR|Mizkan rice vinegar without acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid
62169551|NCT05985109|EXPERIMENTAL|Non-liver metastasis cohort|Arm A will include microsatellite-stable metastatic colorectal cancer patients who have no active liver metastasis. Patients are required to have received prior 5-Fu， oxaliplatin, and irinotecan treatment before enrollment.
62169552|NCT05985109|EXPERIMENTAL|BRAF V600E mutant cohort|Arm B will include microsatellite-stable metastatic colorectal cancer patients who have BRAF V600E mutation. Patients are required to have received prior 5-Fu， oxaliplatin, and irinotecan treatment before enrollment.
62169553|NCT05985109|EXPERIMENTAL|Front-line therapy cohort|Arm C will include microsatellite-stable metastatic colorectal cancer patients who are unable or refuse to receive standard first-line or second-line treatment.
62169554|NCT04639076|ACTIVE_COMPARATOR|Behavioral Weight Loss Group|Participants in this arm will receive a standard behavioral weight loss approach that recommends a calorie deficit based on starting weight, a standard activity minute goal progression based on baseline activity and standard behavioral weekly counseling.
62169555|NCT04639076|EXPERIMENTAL|Personalized Behavioral Weight Loss Group|Participants in this arm will receive a personalized weight loss approach that recommends either a low carbohydrate or low fat calorie reduced diet; personalized activity plan with either daily or weekly bout-related goals; and eating frequency of either 3 times per day or 5-6 times per day.
62550161|NCT01371747|EXPERIMENTAL|Stratum 1: 16.8 g/d patiromer|Participants with baseline serum potassium \> 5.0 to 5.5 mEq/L
62550162|NCT01371747|EXPERIMENTAL|Stratum 1: 25.2 g/d patiromer|Participants with baseline serum potassium \> 5.0 to 5.5 mEq/L
62550163|NCT01371747|EXPERIMENTAL|Stratum 2: 16.8 g/d patiromer|Participants with baseline serum potassium \> 5.5 to \< 6.0 mEq/L
62169556|NCT04290416|EXPERIMENTAL|Microwire electrodes|Activity of individual neurons will be recorded via microwire contacts. These microwire electrodes do not interfere with the macrowire clinical recordings.
62169557|NCT04475016|EXPERIMENTAL|Neoadjuvant Therapy|TIP (Paclitaxel + Ifosfamide + Cisplatin) \& Nimotuzumab \& Triprilimab
62169558|NCT01033279|NO_INTERVENTION|Usual care|Patients followed by usual care at the hospital's anticoagulation clinic
62739245|NCT06376162|EXPERIMENTAL|Ziftomenib|"During Cycle 1 (49 days), participants will receive escalating doses of ziftomenib once daily (QD) on Days 8 to 49. Participants will also receive FLA chemotherapy consisting of fludarabine at a dose of 30 mg/m\^2 (1 mg/kg/dose in infants \<1 year of age or ≤10 kg) and cytarabine at a dose of 2000 mg/m\^2 (67 mg/kg/dose in infants \<1 year of age or ≤10 kg) QD on Day 1 to Day 5.~Participants with \<5% blasts will continue ziftomenib monotherapy until Day 49. Participants with a response and \>5% blasts will continue to Cycle 2. During Cycle 2 (28 days), participants will receive escalating doses of ziftomenib QD on Day 1 to Day 28 in combination with FLA chemotherapy on Day 1 to Day 5.~Participants who respond to treatment, but experience a delay prior to hematopoietic stem cell transplantation (HSCT), may receive up to 10 additional cycles (28 days) of ziftomenib monotherapy.~Participants may also receive intrathecal therapy prophylaxis, if needed, during all cycles."
62739246|NCT02820246||hospitalised patients|all patients present in a hospital ward during the morning shift
62739247|NCT01145001|ACTIVE_COMPARATOR|Active Nicotine Patch and Contingency Management|Subjects in this group will receive Contingency Management and active nicotine patch
62550164|NCT01371747|EXPERIMENTAL|Stratum 2: 25.2 g/d patiromer|Participants with baseline serum potassium \> 5.5 to \< 6.0 mEq/L
62550165|NCT01371747|EXPERIMENTAL|Stratum 2: 33.6 g/d patiromer|Participants with baseline serum potassium \> 5.5 to \< 6.0 mEq/L
62550166|NCT03972761|ACTIVE_COMPARATOR|Group exposed to cognitive remediation|Computerized cognitive remediation program. Program performed during inclusion in the EPIREMED patient study (Clinical trial number NCT02757794)
62550167|NCT03972761|PLACEBO_COMPARATOR|Group not exposed to cognitive remediation|Standard remediation performed during inclusion in the EPIREMED patient study (Clinical trial number NCT02757794)
62550168|NCT06106347||CVS group|positive CVS diagnosis
62550169|NCT06106347||control|participants with no-CVS diagnosis
62550170|NCT02017470|EXPERIMENTAL|Gender-tailored women's heart health outpatient programme|The programme consists of general cardiologist, advanced practice nurse, dietician, physiotherapist and occupational therapist. The participant will be asked to participate in one-on-one interviewing, focus group discussions, and the forthcoming health promotion strategies that are developed based on the data collected
62550171|NCT02017470|NO_INTERVENTION|Conventional general cardiology outpatient programme|
62169559|NCT01033279|EXPERIMENTAL|Self-management|Self-monitoring and self-adjustment of oral anticoagulation according to predefined algorithms
62550172|NCT01169792||Breast cancer patients|Breast cancer patients who underwent surgery with or without chemotherapy, endocrine therapy and/or radiation therapy. The patients are categorized according to the genetic polymorphisms or the activity score of the cytochrome P450 metabolism.
62550173|NCT01485822||TRAVATAN|As prescribed by physician for the treatment of open-angle glaucoma and dosed for at least two years
61985490|NCT03826862|NO_INTERVENTION|control group|All patients did not receive CT three-dimensional before surgery
61985491|NCT02749812|EXPERIMENTAL|Constant Continuous Positive Airway Pressure|
61985492|NCT02749812|EXPERIMENTAL|automatic Continuous Positive Airway Pressure|
61985493|NCT00379626|EXPERIMENTAL|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
61985494|NCT05749302|EXPERIMENTAL|Al18F-NOTA-FAPI PET/CT|Al18F-NOTA-FAPI PET/CT will be performed on patients with suspected or clearly diagnosed FAP positive-expressing tumors. The patients were injected with Al18F-NOTA-FAPI and underwent PET/CT scan 20\~40min after the injection.
61985495|NCT05938751|EXPERIMENTAL|Intervention group|Participants in this group received the TEAm_YOUNG ADULTS program, an intervention to promote and develop self-determination-related skills.
61985496|NCT05938751|NO_INTERVENTION|Waiting list group|Participants in this group were on the waiting list. That means they had to wait until the intervention group received the intervention and post-test evaluation to receive the intervention. They could keep their intervention as usual during the whole study.
61985497|NCT04165512|EXPERIMENTAL|stellate ganglion block in breast cancer related lymphedema|US-guided stellat ganglion block will be applied to the patients with breast cancer related lymphedema twice at two-week intervals.
61985498|NCT06341972|EXPERIMENTAL|Self-management intervention|Cognitive behavioral therapy based self-management intervention for anxiety
61985499|NCT06341972|NO_INTERVENTION|Usual Care|Usual hospital-based care
61985500|NCT05864300|ACTIVE_COMPARATOR|Hourly Neurochecks|Patients awakened for neurological exams every hour
61985501|NCT05864300|ACTIVE_COMPARATOR|Every-Other-Hour Neurochecks|Patients awakened for neurological exams every-other-hour
61985502|NCT02047357|EXPERIMENTAL|Intervention Arm|Learning Through Play Plus
61985503|NCT02047357|NO_INTERVENTION|Control|This arm will receive no intervention
62550174|NCT01485822||Treatment Naive|No prior exposure (or less than 1 month) to any topical, ocular prostaglandin analogue
62550175|NCT01553669|EXPERIMENTAL|reminiscence therapy|Reminiscence therapy is a method of using the memory to protect mental health and improve the quality of life.
62550176|NCT01553669|NO_INTERVENTION|Control group|The participants assigned to the waiting-list as the control group will be treated as before. After the intervention period, we will conduct reminiscence therapy on them if they ask for.
62550177|NCT00261950|EXPERIMENTAL|Cinacalcet|All subjects were enrolled into the single arm to receive Cinacalcet. There was no comparator arm.
62182322|NCT03749499|ACTIVE_COMPARATOR|Educational and Empowerment Intervention|"Participants receive:~1. HTN Educational Video about high BP, how it is diagnosed, and importance of treatment to prevent secondary complications.~2. Visual Echocardiogram Image Clips of age/gender-matched echocardiograms will be used to educate and motivate patients to change behavior and improve their BP.~3. Mobile Health and Remote BP monitoring- participants receive an FDA-approved home blood pressure monitoring (HBPM) kit that includes the Nokia wireless BPM+ monitor and Health Mate mobile app. The app automatically launches when the patient slips on the cuff. Synced data are automatically uploaded from the mobile app to the iCardia server of our study.~4. A Post-Acute Care HTN Transition consultation (PACHT-c) with a clinical pharmacist or advanced practice nurse (APN)."
62550178|NCT02819492||Routine colonoscopy Cohort|Patients receiving routine colonoscopy at the study site
62739248|NCT01145001|ACTIVE_COMPARATOR|Nicotine Patch with no Contingency Management|Subjects in this group will receive active nicotine patch without contingency management for abstinence
62169560|NCT04450771|EXPERIMENTAL|Family-based Treatment for ARFID(FBT-ARFID)|FBT-ARFID is a manualized treatment based on the model of FBT that employs the same interventions as standard FBT for AN and BN: externalization, agnosticism, parental empowerment, a behavioral focus on changing eating behavior. Early sessions focus on inciting parents to make changes and include a family meal that allows therapists to observe \& consult directly to mealtime behaviors. FBT-ARFID for children 12 and under is manualized and consists of 2 phases. The first phase is focused on parents taking charge \& changing the eating behaviors of their child that are maintaining ARFID. The second phase focuses on the child taking up in an age-appropriate way managing their eating consistent with the changes the parents have employed in phase 1. Fourteen 1-hour sessions will be conducted approximately weekly over 4 months. Throughout medical monitoring and weekly dietary consultation are available to the family.
61985504|NCT02467569|EXPERIMENTAL|Hemay020|"Part one: Dose Escalation Group Hemay020 capsules will be taken orally in doses of 25mg, 50mg, 100mg, 200mg or 300mg once daily for 28 days.~Part two: Extension Group Hemay020 capsules will be taken in two dose groups that assessed by Part one for 28 days."
61985505|NCT03104114|PLACEBO_COMPARATOR|Historical Control|Pharmacy care was standard, high-touch model where an institutional specialty pharmacy contact patients via telephone. Standard adherence and counseling was offered over the phone to patients.
62739249|NCT01145001|PLACEBO_COMPARATOR|Placebo patch and Contingency Management|Subjects in this group will receive a placebo transdermal patch and contingency management
61985506|NCT03104114|EXPERIMENTAL|Pharmacist-intervention|In-person counseling with a clinical pharmacist prior and during treatment with an oral oncology medication. Patients meet with a clinical pharmacist prior, at month 3 and month 6 during the study.
61985507|NCT00613015|EXPERIMENTAL|Modafinil/Stress|Participants received placebo for 2 days. modafinil on the third day and participated in the TRIER social stress task on the third day.
62739250|NCT01145001|PLACEBO_COMPARATOR|Placebo Patch and no Contingency Management|Subjects in this group will receive a placebo patch and will not receive contingency management
62739251|NCT03079934||Absorb-BVS|Bioresorbable vascular scaffold implantation
62739252|NCT03427814|EXPERIMENTAL|Pamiparib|Participants received pamiparib orally.
62550179|NCT04237272|ACTIVE_COMPARATOR|Pod System|Participants assigned to this intervention will try to pod system e-cigarette in the lab and receive a pod system e-cigarette to use for a three week sampling period.
62550180|NCT04237272|ACTIVE_COMPARATOR|Customizable Tank|Participants assigned to this intervention will try to customizable tank system e-cigarette in the lab and receive a customizable tank system e-cigarette to use for a three week sampling period.
62550181|NCT04237272|ACTIVE_COMPARATOR|Control|Participants assigned to this arm will not receive any e-cigarette
62550182|NCT06581185||Research|Patients who were diagnosed with PTC as children
62550183|NCT01799837|OTHER|Healthy Controls|Posttraumatic stress disorder (PTSD) is a potentially debilitating anxiety disorder triggered when a person is exposed to a traumatic event that is beyond what is experienced in everyday life. A traumatic event may include an interpersonal event like physical or sexual assault, exposure to a disaster or accidents, combat or witnessing a traumatic event. Some symptoms of PTSD include not being able to sleep, nightmares, flashbacks of the event and having problems with memory or not being able to focus. You are being asked to volunteer because you are either 1) a normal healthy volunteer or 2) a deployed veteran or non-deployed veteran who is diagnosed with PTSD. We anticipate enrolling 16 subjects; 8 veterans with PTSD and 8 healthy volunteers without PTSD.
62567139|NCT04861727|ACTIVE_COMPARATOR|Intervention group|will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will receive general guidance on blood pressure control and pharmacotherapy assessment, will also do MRPA whose result will guide pharmaceutical suggestions, when necessary, they will also receive a Referral Letter to the Prescriber containing pharmaceutical suggestions for optimization of pharmacotherapy, considering the current clinical protocols.
62182323|NCT00945113|EXPERIMENTAL|Treatment group|attendance at one-week speech therapy group
62182324|NCT04169997|EXPERIMENTAL|IMP4297|The starting dose is 100mg QD
62182325|NCT04169997|PLACEBO_COMPARATOR|Placebos|The starting dose is 100mg QD
62182326|NCT03740204|EXPERIMENTAL|17-β estradiol with cyclic progesterone|
62567140|NCT05399875|EXPERIMENTAL|Augmented reality virtual ruler|Patient's in this arm will have their physician use an augmented reality virtual ruler to measure catheter length during catheter placement.
62739253|NCT03427814|PLACEBO_COMPARATOR|Placebo|Participants received placebo orally.
62739254|NCT01000298|PLACEBO_COMPARATOR|Placebo|
62182327|NCT03740204|PLACEBO_COMPARATOR|Placebo|
61985508|NCT00613015|EXPERIMENTAL|Modafinil/no stress|Participants received placebo for 2 days. modafinil on the third day and did not participate in the TRIER social stress task on the third day.
62182328|NCT02447276|EXPERIMENTAL|Group A|Group A will receive REGN475 dosing regimen 1
61985509|NCT00613015|EXPERIMENTAL|Guanfacine/stress|Participants received guanfacine for 3 days and participated in the TRIER social stress task on the third day.
61985510|NCT00613015|EXPERIMENTAL|Guanfacine/no stress|Participants received guanfacine for 3 days and did not participate in the TRIER social stress task on the third day.
61985511|NCT00613015|PLACEBO_COMPARATOR|Placebo/Stress|Participants received placebo for 3 days and participated in the TRIER social stress task on the third day.
61985512|NCT00613015|PLACEBO_COMPARATOR|Placebo/no stress|Participants received placebo for 3 days and did not participate in the TRIER social stress task on the third day.
61985513|NCT05011864|EXPERIMENTAL|Tele-Behavioral Activation and Fall Prevention|Each subject will participate in five 1-hour, weekly Tele-BA sessions followed by four 1-1.5 hour, weekly in-home FP sessions with the same provider
61985514|NCT05011864|EXPERIMENTAL|Tele-Behavioral Activation|Each subject in this arm will participate in five 1-hour, weekly Tele-BA sessions followed by four weekly check-in (booster) calls of up to 30 minutes each.
62169561|NCT04450771|ACTIVE_COMPARATOR|Manualized Non-Specific Usual Care for ARFID(NSC)|A manualized non-specific psycho-educational and motivational enhancement approach that is based on a supportive non-directive psychotherapy model that has been used in other RCTs with eating disorders as a comparison. NSC consists of sessions with the child alone and 5 parent-only meetings. Sessions are 1-hour. NSC matches FBT-ARFID for time and therapist attention. The focus of the NSC intervention is psychoeducation about health \& social impacts of restrictive eating and supporting parent \& child exploration of motivation to change eating patterns \& choices they make about changes to eating. The therapist does not initiate behavioral or cognitive interventions. Feelings about eating and making changes are explored in both the child and parent sessions. Medical and dietary advice are provided weekly.
62169562|NCT05983328|EXPERIMENTAL|Healthy Volunteers dose 1|Evaluate tolerability, safety and pharmacokinetic properties of HUYPS-1 after 1 tablet oral administration in healthy subjects
61985515|NCT05011864|EXPERIMENTAL|Fall Prevention|Each subject will participate in four 1-1.5 hour, weekly in-home (or tele, if COVID continues) FP sessions followed by four weekly check-in (booster) calls of up to 30 minutes each.
61985516|NCT05011864|ACTIVE_COMPARATOR|Attention Control (Telephone Support Call)|AC participants in this study will receive five weekly telephone calls of up to 45 minutes each and four weekly check-in calls of up to 30 minutes each from a research assistant (RA) who will employ genuine regard and attentive listening and provide nonspecific support.
62169563|NCT05983328|EXPERIMENTAL|Healthy Volunteer dose 2|Evaluate tolerability, safety and pharmacokinetic properties of HUYPS-1 after 9 tablets oral administration in healthy subjects
62169564|NCT02273180|EXPERIMENTAL|SAR342434|SAR342434 before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
62169565|NCT02273180|ACTIVE_COMPARATOR|Humalog|Humalog before meals intake on top of QD Insulin Glargine, up to Week 52.
62550184|NCT01799837|OTHER|Veterans with PTSD|Posttraumatic stress disorder (PTSD) is a potentially debilitating anxiety disorder triggered when a person is exposed to a traumatic event that is beyond what is experienced in everyday life. A traumatic event may include an interpersonal event like physical or sexual assault, exposure to a disaster or accidents, combat or witnessing a traumatic event. Some symptoms of PTSD include not being able to sleep, nightmares, flashbacks of the event and having problems with memory or not being able to focus. You are being asked to volunteer because you are either 1) a normal healthy volunteer or 2) a deployed veteran or non-deployed veteran who is diagnosed with PTSD. We anticipate enrolling 16 subjects; 8 veterans with PTSD and 8 healthy volunteers without PTSD.
62550185|NCT06338722|EXPERIMENTAL|Intervention group|Complete questionnaires Attend one 2 hour weekly virtual meeting for 5 weeks and an individual meeting with an occupational therapist and with a vocational counselor
62550186|NCT06338722|NO_INTERVENTION|control group|Complete questionnaires
62550187|NCT01006681|EXPERIMENTAL|Monovalent MF59-Adjuvanted vaccine|
62550188|NCT02220517|EXPERIMENTAL|A: MR-guided in-bore prostate biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
62550189|NCT02220517|EXPERIMENTAL|B: MRI/US fusion-guided prostate biopsy|Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
62550190|NCT04455165||RVAo MITAVA|Patient operated since 2009 for aortic valve replacement through right anterior minithoracotomy approch in Dijon Burgundy University Hospital
62550191|NCT02892149|EXPERIMENTAL|Vadadustat|
61985517|NCT05155007|EXPERIMENTAL|Treatment Sequence ABC|Participants will receive a single oral dose of rilematovir (Treatment A) in Treatment Period 1, followed by a single oral dose of ciclosporin (Treatment B) in Treatment Period 2 and then single oral dose of ciclosporin plus single oral dose of rilematovir (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
61985518|NCT05155007|EXPERIMENTAL|Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
62169566|NCT04675671||Pregabalin group (Group P)|Group pregabalin patients will be received 75 mg of pregabalin twice daily for 2 days before surgery
61985519|NCT05155007|EXPERIMENTAL|Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
62169567|NCT04675671||Control group (Group C)|The Control group will be received plasebo capsule mg at the same point in time
62169568|NCT01024829|OTHER|Whole tumor boost|Patients in this arm will receive radiotherapy (66Gy) in 24 fractions of 2.75 Gy with an integrated boost to the primary tumor as a whole
62169569|NCT01024829|OTHER|Boost 50% SUV area|Patients in this arm receive radiotherapy (66Gy) in 24 fractions of 2.75Gy with an integrated boost to the 50% SUVmax area of the primary tumor (of the pre-treatment FDG-PET-CT scan)
62169570|NCT02669888|EXPERIMENTAL|Indigo naturalis ointment|"1. Form: ointment~2. Dose: each gram of ointment contains 200µg of indirubin~3. Dosing schedule: apply 0.5g of ointment per 10 x 10 dermatitis lesion twice daily"
62169571|NCT02669888|PLACEBO_COMPARATOR|Placebo|"1. Form: ointment~2. Dose: vehicle~3. Dosing schedule: apply 0.5g of ointment per 10 x 10 dermatitis lesion twice daily"
62169572|NCT05244226|ACTIVE_COMPARATOR|Short acting opioids: Fentanyl, Hydromorphone|
62550192|NCT02892149|ACTIVE_COMPARATOR|Darbepoetin alfa|
62550193|NCT00524420|EXPERIMENTAL|Active rTMS|Active rTMS involves administration of real rTMS to the patient.
62169573|NCT05244226|ACTIVE_COMPARATOR|Long Acting Opioid: Methadone|
62169574|NCT06268431|EXPERIMENTAL|60-minute oxytocin rest|
62169575|NCT06268431|NO_INTERVENTION|Usual care with continuous oxytocin infusion|
62550194|NCT00524420|SHAM_COMPARATOR|Sham rTMS|Sham rTMS is a placebo or inactive form of rTMS for study control and comparison purposes.
62739255|NCT01000298|EXPERIMENTAL|Amoxicillin|
62550195|NCT02479126||Interstitial Lung Disease|Patients will be identified from a specified 5 year period based on an International Classification of Diseases-9 (ICD-9) code diagnosis of Interstitial Lung disease (515) or Idiopathic Pulmonary Fibrosis (516.3). The patients will be obtained from the records of the Veterans Integrated Service Network (VISN) 6: VA Mid-Atlantic Health Care Network.
62550196|NCT04800640|NO_INTERVENTION|No Electroanalgesia|The sample will consist of 132 individuals, of both sexes, where they will be randomly included in two groups: 1) Intervention group composed of 66 patients who will effectively receive the treatment through electroanalgesia through TENS; and 2) Control Group, which will also consist of 66 individuals; however, they will not be subjected to electroanalgesia
62550197|NCT04800640|EXPERIMENTAL|Electroanalgesia|The sample will consist of 132 individuals, of both sexes, where they will be randomly included in two groups: 1) Intervention group composed of 66 patients who will effectively receive the treatment through electroanalgesia through TENS; and 2) Control Group, which will also consist of 66 individuals; however, they will not be subjected to electroanalgesia
62550198|NCT03872531||Cohort 1|Includes age group 3-5 with a cap at 20 subjects. This is a retrospective, observational study
62550199|NCT03872531||Cohort 2|Includes age group 6-10 with a cap at 30 subjects. This is a retrospective, observational study
62169576|NCT05675839|EXPERIMENTAL|Experimental|"Before the intervention, students filled the Nursing Professional Pride Scale. Nursing students watched a documentary and a movie about nursing profession. After the intervention, students filled the Nursing Professional Pride Scale."
62169577|NCT05675839|NO_INTERVENTION|Control|"First of all, Control group filled the Nursing Professional Pride Scale. The control group have no intervention. They filled the scale again, after 2 week."
62550200|NCT03872531||Cohort 3|Includes age group 11-15 with a cap of 30 subjects. This is a retrospective, observational study
62550201|NCT03872531||Cohort 4|Includes age group 16-20 with a cap of 20 subjects. This is a retrospective, observational study
62550202|NCT03872531||Cohort 5|Includes age group 21-30 with a cap at 20 subjects. This is a retrospective, observational study
62550203|NCT03872531||Cohort 6|Includes age group 31-40 with a cap at 20 subjects. This is a retrospective, observational study
62550204|NCT03872531||Cohort 7|Includes age group 41 and over with a cap at 35 subjects. This is a retrospective, observational study
62550205|NCT06469437|NO_INTERVENTION|Control|This group will be submitted to geriatric assessment through CFS and TaGA-10 tools only.
62169578|NCT00616486|EXPERIMENTAL|1|
62169579|NCT00616486|PLACEBO_COMPARATOR|2|
62169580|NCT05240482|PLACEBO_COMPARATOR|Conventional treatment group|Patients in the placebo group will receive bilateral ST36 injection with normal saline 1ml/point
61985520|NCT05155007|EXPERIMENTAL|Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
61985521|NCT05155007|EXPERIMENTAL|Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment C in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
61985522|NCT05155007|EXPERIMENTAL|Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
61985523|NCT01655979|EXPERIMENTAL|MEP-1|
61985524|NCT01655979|EXPERIMENTAL|MEP-2|
62169581|NCT05240482|EXPERIMENTAL|ST36 acupoint injection group|Patients in the experimental group will receive bilateral ST36 injection with anisodamine 1ml/point
62169582|NCT06370143||Participants with atrophic gastritis, intestinal metaplasia, and dysplasia|Participants with presence of atrophic gastritis, intestinal metaplasia, and dysplasia and risk of the progression of these lesions
62169583|NCT06370143||Control Group|Healthy controls
62169584|NCT06370143||Participants with gastric cancer|Participants with gastric cancer
62550206|NCT06469437|EXPERIMENTAL|Intervention|This group will be submitted to geriatric assessment through CFS and TaGA-10 tools, and the investigators will provide the physician with a short note with the proposed glycated hemoglobin target.
62550207|NCT01690702|ACTIVE_COMPARATOR|dtEC-dtD|Epirubicin and Cyclophosphamide with a tailored dose 4 cycles q2w followed by one additional week followed by Docetaxel with a tailored dose 4 cycles q2w.
62550208|NCT01690702|EXPERIMENTAL|EnPC|Epirubicin 150mg/qm 3 cycles q2w followed by nabPaclitaxel 260-330mg/qm (to be determined in run-in-phase) 3 cycles q2w followed by Cyclophosphamide 2000mg/qm 3 cycles q2w
62550209|NCT06581653|EXPERIMENTAL|PEI Intervention Group|"1. After enrollment, a fecal elastase-1 (FE-1) test will be conducted. If the FE-1 level is below 200ug/g, the patient will undergo a comprehensive 20-minute WWH medication health education session and complete a 2-week medication health assessment.~2. Following enrollment, patients will receive monthly regular telephone counseling sessions (total of 6) to monitor medication adherence, as well as a follow-up visit at 6 months. Additionally, the MMAS-8 score for medication adherence and SF36 score for quality of life will be assessed. Patients attending the follow-up visit will undergo PEI testing using the PEI test kit. For those unable to attend in person for any reason, PEI assessment can be completed by mailing in specimens.~3. After enrolling for 6 months, routine counseling services will cease and a follow-up visit at 12 months will take place. The MA score at 12 months will be recorded while observing the clinical course of the disease."
62567141|NCT03374865||Video-mediated consultation|Consultations using Facetalk videocommunication software
62169585|NCT03188809|ACTIVE_COMPARATOR|femoral nerve block|Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
62169586|NCT03188809|ACTIVE_COMPARATOR|adductor canal block|Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
62169587|NCT05987839|ACTIVE_COMPARATOR|intervention group|Total knee arthroplasty assisted by knee navigation and positioning system. Specification Model: OP-RKL22
62550210|NCT06581653|NO_INTERVENTION|PEI Control group|"1. After enrollment, a fecal elastase-1 (FE-1) test will be conducted. If the FE-1 level is below 200ug/g, the patient will undergo a comprehensive 20-minute WWH medication health education session and complete a 2-week medication health assessment.~2. After enrollment, patients were not frequently communicated by phone to supervise their medication, and were followed up once at the 6th and 12th month (2 times in total).Additionally, the MMAS-8 score for medication adherence and SF36 score for quality of life will be assessed."
62550211|NCT06581653|EXPERIMENTAL|non-PEI Intervention Group|"1. After enrollment, a fecal elastase-1 (FE-1) test will be conducted. If the FE-1 level is ≥ 200ug/g, the patient will undergo a comprehensive 20-minute WWH medication health education session and complete a 2-week medication health assessment.~2. Following enrollment, patients will receive monthly regular telephone counseling sessions (total of 6) to monitor medication adherence, as well as a follow-up visit at 6 months. Additionally, the MMAS-8 score for medication adherence and SF36 score for quality of life will be assessed. Patients attending the follow-up visit will undergo PEI testing using the PEI test kit. For those unable to attend in person for any reason, PEI assessment can be completed by mailing in specimens.~3. After enrolling for 6 months, routine counseling services will cease and a follow-up visit at 12 months will take place. The MA score at 12 months will be recorded while observing the clinical course of the disease."
62550212|NCT06581653|NO_INTERVENTION|non-PEI Control group|"1. After enrollment, a fecal elastase-1 (FE-1) test will be conducted. If the FE-1 level is ≥ 200ug/g, the patient will undergo a comprehensive 20-minute WWH medication health education session and complete a 2-week medication health assessment.~2. After enrollment, patients were not frequently communicated by phone to supervise their medication, and were followed up once at the 6th and 12th month (2 times in total).Additionally, the MMAS-8 score for medication adherence and SF36 score for quality of life will be assessed."
62550213|NCT02756208|EXPERIMENTAL|300 ug FLSC vaccine|Subjects will be vaccinated with 300 ug FLSC vaccine (highest vaccine dose) on study days 0, 28, 56 and 168.
62550214|NCT02756208|EXPERIMENTAL|150 ug FLSC vaccine|Subjects will be vaccinated with 150 ug FLSC vaccine (middle vaccine dose) on study days 0, 28, 56 and 168.
62550215|NCT02756208|EXPERIMENTAL|75 ug FLSC vaccine|Subjects will be vaccinated with 75 ug FLSC vaccine (lowest vaccine dose) on study days 0, 28, 56 and 168.
62550216|NCT02756208|PLACEBO_COMPARATOR|Placebo|Subjects will be vaccinated with placebo (control group) on study days 0, 28, 56 and 168.
62169588|NCT05987839|NO_INTERVENTION|control group|Total knee arthroplasty without knee navigation and positioning system
61985525|NCT04923204||Bipolar depression pharmacogenetics|Patients 18 years and older, with a diagnosis of bipolar disorder with an index episode of depression with or without associated psychotic symptoms (according to the Diagnostic Manual of Mental Disorder 4th Edition Text Revision, DSM-IV-TR), who attended the Bipolar Disorder Program of the Psychiatry Service of the Hospital Clínic de Barcelona (Spain).
62550217|NCT05965752|ACTIVE_COMPARATOR|BrainHQ Active Comparator|5 sessions/week at 30 min/session
62550218|NCT05965752|EXPERIMENTAL|BrainHQ|5 sessions/week at 30 min/session
61985526|NCT05163028|EXPERIMENTAL|Dose Escalation and Expansion|HBI-2376 will be given orally in ascending doses (escalation cohort), until the maximum tolerated dose or recommended Phase 2 dose is reached. Up to 6 patients will then be enrolled in the expansion cohort at the recommended dose.
61985527|NCT03409172|EXPERIMENTAL|Control group (CTr)|No counseling or nutritional therapy and no exercise
62550219|NCT05965752|EXPERIMENTAL|BrainHQ + PASC CoRE|BrainHQ plus 9 group sessions at 1.5 hr/session and 3 individual sessions at 1 hr/session
62550220|NCT05965752|EXPERIMENTAL|Brain HQ + tDCS-active|2.0 mA stimulation delivered for 30 min during each BrainHQ session
62550221|NCT05965752|PLACEBO_COMPARATOR|Brain HQ + tDCS-sham|Inactive stimulation delivered for 30 min during each BrainHQ session
62550222|NCT05477043||group of study|Patients ≥ 18 years old subjected to uterosacral ligaments suspension surgical procedures for pelvic organs prolapse.
61985528|NCT03409172|EXPERIMENTAL|Moderate intensity continuous training (MICT)|"Follow-up during a period of 8 weeks of supervised ergometer-based moderate-intensity continuous training based on HRmax (MICT).~MICT:~* 3 sessions per week~* intensity at 65-75% HRmax~* time-effort per session: 50 min"
61985529|NCT03409172|EXPERIMENTAL|High Intensity Interval Training (HIIT)|"Procedures: Follow-up during a period of 8 weeks of supervised ergometer-based high intensity interval training based on HRmax (HIIT).~HIIT:~* 3 sessions per week~* 10 bouts of one minute at 90% HRmax interspersed by one minute at 40% HRmax~* time-effort per session: 25 min"
61985530|NCT04812054|EXPERIMENTAL|Hypothermic oxygenated machine perfusion|Allografts will be subject to end-ischemic hypothermic oxygenated perfusion at 12 degrees Celsius through both hepatic artery and portal vein after a period of simple cold storage at 4 degrees Celsius and immediately prior to implantation. The perfusion will last at least 2 hours and the period will be prolonged in case of ongoing hepatectomy, in order to perform graft implantation immediately after perfusion.
61985531|NCT04812054|ACTIVE_COMPARATOR|Simple cold storage|Allografts will be stored in perfusate at 4 degrees Celsius from the procurement until implantation.
62169589|NCT06550297|ACTIVE_COMPARATOR|Arm 1: Cohort A (type 2 diabetes patients who currently qualify for MTMs) Active Comparator|Participants in this arm are type 2 diabetes patients with hypertension or elevated blood pressure who currently qualify for medically tailored meals (MTMs). This arm will receive God's Love We Deliver's current MTM program, which consists of 10 home-delivered MTMs per week and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period.
61985532|NCT03303378|EXPERIMENTAL|Melatonin group|Patients will receive a total intravenous melatonin dose of 11.61 mg (aproximately 166 μg/kg).
62567142|NCT03374865||Face-to-face consultation|Traditional face-to-face consultations
62567143|NCT01631539|OTHER|Chemoembolization|chemoembolization with DC Bead™ loaded with Irinotecan
61985533|NCT03303378|PLACEBO_COMPARATOR|Control group|Patients will receive the same dose of placebo.
61985534|NCT03169647|EXPERIMENTAL|Intervention|listening-based protocol (type A)
61985535|NCT03169647|PLACEBO_COMPARATOR|Control|listening-based protocol (type B)
62182329|NCT02447276|EXPERIMENTAL|Group B|Group B will receive REGN475 dosing regimen 2
62182330|NCT02447276|EXPERIMENTAL|Group C|Group C will receive REGN475 dosing regimen 3
62182331|NCT02447276|EXPERIMENTAL|Group D|Group D will receive REGN475 dosing regimen 4
62182332|NCT02447276|EXPERIMENTAL|Group E|Group E will receive matching placebo
62550223|NCT06278896|EXPERIMENTAL|Intervention Arm|Participants will stop empiric antibiotic therapy after their episode of fever if afebrile for 48 hours, no clinically documented source of bacterial infection, and no hemodynamic or respiratory decompensation.
62550224|NCT06278896|NO_INTERVENTION|Control Arm|Participants will continue antibiotic therapy until count recovery and/or standard of care as deemed by inpatient providers, which is the current guidelines recommended by the IDSA.
62550225|NCT03675061|OTHER|Control group|Current care : The management of the preterm delivery risk without biochemical test, with hospitalization of the patient, initiation of tocolysis and a complete corticosteroid treatment.
62363203|NCT03322397|SHAM_COMPARATOR|Daily Report|Participants will complete the 'Daily Reports' and be asked to report their daily activities throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will list activities from their day.
62363204|NCT05297799|EXPERIMENTAL|Lactating women|New mothers whose infants born after 28 weeks gestational age are unable to breastfeed will exclusively breast pump their breast milk with an Ameda Pearl breast pump for a minimum of the first 14 days postpartum.
62363205|NCT05009238|EXPERIMENTAL|Group (A)|Group (A): will receive lumbar stabilization exercises
62363206|NCT05009238|NO_INTERVENTION|Group (B)|Group (B): will be control group.
62363207|NCT00895778|EXPERIMENTAL|NMB|muscle relaxation (neuromuscular block) during laparoscopic cholecystectomy
62363208|NCT00895778|PLACEBO_COMPARATOR|no NMB|no muscle relaxation (neuromuscular block) during laparoscopic cholecystectomy
62363209|NCT00204412|EXPERIMENTAL|1|flax lignan
62363210|NCT00204412|PLACEBO_COMPARATOR|2|placebo
62363211|NCT05820646|EXPERIMENTAL|Patients with necrotic mandibular premolars will be treated with boswellia sacra|25-45 years old patients with necrotic single rooted mandibular premolar with single canal with periapical lesion will be treated with boswellia sacra as an intracanal medicament for 3 days
62363212|NCT05820646|EXPERIMENTAL|Patient with necrotic mandibular premolar will be treated with boswellia sacra|25-45 years old patients with necrotic single rooted mandibular premolar with single canal with periapical lesion will be treated with boswellia sacra as an intracanal medicament for 7 days
62363213|NCT05820646|ACTIVE_COMPARATOR|Patients with necrotic mandibular premolar will be treated with calcium hydroxide|25-45 years old patients with necrotic single rooted mandibular premolar with single canal with periapical lesion will be treated with calcium hydroxide as an intracanal medicament for 7 days
62363214|NCT03907969|EXPERIMENTAL|Core Module: AZD7648 Monotherapy|AZD7648 will be administered orally on an empty stomach
62363215|NCT03907969|EXPERIMENTAL|Combination Module 1: AZD7648 + PLD|AZD7648 will be administered in combination with Pegylated liposomal doxorubicin (PLD)
62363216|NCT01787851|ACTIVE_COMPARATOR|Triheptanoin oil|The standard dose of triheptanoin oil for adults is 1-2gm/kg/24 hours. For purposes of this study, we will administer 0.25mg/kg four-times per day. The liquid study drug will be mixed into sugar-free, low fat yogurt, pudding or nutritional supplement shake, depending on patient preference.
62363217|NCT01787851|PLACEBO_COMPARATOR|Simple sugar|0.25mg/kg of sugar syrup will be mixed into sugar-free, low fat yogurt, pudding or nutritional supplement shake four-times per day before meals.
62363218|NCT04890561|EXPERIMENTAL|Lemborexant 10 mg|Participants will receive a single dose of lemborexant 10 mg tablet, orally on Day 1.
62363219|NCT00383708|EXPERIMENTAL|1|
62363220|NCT00633048|EXPERIMENTAL|NSA-789|active drug
62363221|NCT00633048|PLACEBO_COMPARATOR|placebo|placebo
62363222|NCT01522768|EXPERIMENTAL|Afatinib and Paclitaxel|This is a multi-institution, open-label, non-randomized, Phase II evaluation of oral afatinib daily and intravenous paclitaxel (weekly, 3 weeks on, 1 week off) in patients with trastuzumab refractory HER2-positive metastatic or recurrent esophagogastric adenocarcinoma. An initial biopsy prior to the start of therapy is required for the correlative studies evaluating the biologic effects of afatinib. It will be obtained for all patients whose tumors are feasible to biopsy. At the site investigator's discretion, a second biopsy will also be obtained. At the discretion of the MSK Principal Investigator, select participants who show response on this study and then progress may be asked to have an optional third biopsy.
62363223|NCT02484950|EXPERIMENTAL|Rotator cuff repair with stem cells|Using clinically accepted methods, subjects will undergo bone marrow aspiration (from hip, proximal humerus or tibia) through a small incision prior to arthroscopy in the group undergoing MSC augmentation. They will then undergo arthroscopic full thickness rotator cuff repair using a double row, TOE anchor/suture technique with mesenchymal stem cell augmentation.
62363224|NCT02484950|PLACEBO_COMPARATOR|Rotator cuff repair without stem cells|Subjects will undergo arthroscopic full thickness rotator cuff repair using a double row, TOE anchor/suture technique, without augmentation of mesenchymal stem cells. To maintain patient blinding, all patients will receive a small incision around the site of expected bone marrow aspiration (hip, proximal humerus, or tibia), regardless of whether or not they receive bone marrow.
62363225|NCT02070341|EXPERIMENTAL|Split dose PEG|Patients randomized to the Polyethylene Glycol (PEG) group will be instructed to ingest 2L of bowel preparation the night before their colonoscopy (starting at 7PM), as well as 1.5-2L of carbohydrate-electrolyte rehydration solution. The following day they will be instructed to ingest the remaining 2L of bowel preparation and must finish ingesting the entire preparation at least 4 hours prior to the scheduled colonoscopy.
62363226|NCT02070341|EXPERIMENTAL|Split dose Picosalax|Patients randomized to the Picosalax (P/MC) group will be instructed to mix one sachet in 150mL of water and ingest the entire mixture at 7PM the night before their colonoscopy. In addition, they will be instructed to ingest 1.5-2L of carbohydrate-electrolyte rehydration solution after they consume the P/MC sachet. The following day they will mix the second sachet in 150mL of water and must finish ingesting the entire preparation at least 4 hours prior to the scheduled colonoscopy. They will also be instructed to drink additional carbohydrate-electrolyte rehydration solution after they ingest the P/MC sachet.
62550226|NCT03675061|OTHER|PartoSure group|"Each women have a biochemical test = PartoSure Test.~* PartoSure test negative : For a negative test, the patient will be able to benefit from a nifedipine tocolysis, if the uterine contractions require it, then she will return home with a control by a midwife at home twice a week up to 34 weeks of amenorrhea.~* PartoSure test positive : For a positive test, the patient will be hospitalized 7 days with a care identical to the control group."
62550227|NCT00512577|ACTIVE_COMPARATOR|A|Patients will not receive a pre-operative transfusion.
62363227|NCT04563572|EXPERIMENTAL|PPG Smartwatch|"The Preventicus Heartbeats algorithm ist a certified tool for detection of Atrial Fibrillation. It differentiates accurately between regular rhythm, single premature beats and the absolute arrhythmia concordant with AF. The Preventicus algorithm is device-agnostic, meaning that any wearable device capable of recording PPG-signals can be used for data collection.~CardioWatch 287 is a novel non-invasive monitoring device manufactured by the MMT company. The device monitors heart rhythm, heart rate (HR) and respiratory rate (RR) based on peripheral PPG signal.~In this arm, we will test the quality of the algorithm integrated into the smartwatch."
62363228|NCT04563572|EXPERIMENTAL|PPG Bracelet|"The Preventicus Heartbeats algorithm ist a certified tool for detection of Atrial Fibrillation. It differentiates accurately between regular rhythm, single premature beats and the absolute arrhythmia concordant with AF. The Preventicus algorithm is device-agnostic, meaning that any wearable device capable of recording PPG-signals can be used for data collection.~A PPG-sensor is also integrated into a bracelet Basler Band manufactured by the MMT company, which is a simplified multisensory device.~In this arm, we will test the quality of the algorithm integrated into the bracelet."
62169590|NCT06550297|EXPERIMENTAL|Arm 2: Cohort A (type 2 diabetes patients who currently qualify for MTMs) Intervention|Participants in this arm are type 2 diabetes patients with hypertension or elevated blood pressure who currently qualify for medically tailored meals (MTMs). This arm will receive God's Love We Deliver's current MTM program, which consists of 10 home-delivered MTMs per week and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period (same as Arm 1). In addition, they will receive a culturally and contextually tailored cardiovascular health promotion program that consists of didactic sessions focused on lifestyle change and the American Heart Association's Life's Essential 8 framework, setting weekly specific, measurable, attainable, realistic, and timely (S.M.A.R.T.) goals for health behavior modification, group coaching, cooking demonstrations, recipes and gift bags with healthy ingredients, and addressing social needs.
61985536|NCT00853723|EXPERIMENTAL|PTHrP 400 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months.
61985537|NCT00853723|EXPERIMENTAL|PTHrP 600 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months.
62363229|NCT03785470|EXPERIMENTAL|Fructose and physical inactivity|Subjects will consume 6 cans of soda per day and restrict their physical activity.
62363230|NCT00422669|ACTIVE_COMPARATOR|RV Mid-Septal Pacing|Pacing lead is placed in the right ventricle at the middle of the muscle separating the right and left sides of the heart
62363231|NCT00422669|ACTIVE_COMPARATOR|RV Apical Pacing|Pacing lead is placed at the bottom of the right ventricle of the heart, in the right ventricular apex
62363232|NCT05386849|EXPERIMENTAL|FUSION closed loop glucose control system|All subjects will be treated with the FUSION closed loop glucose control system for up to 24 hours
62363233|NCT03046563|EXPERIMENTAL|Acupressure and Abdominal Massage|Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail.
62363234|NCT03046563|SHAM_COMPARATOR|Pressing the sham points|Pressing the sham points for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail.
61985538|NCT00853723|ACTIVE_COMPARATOR|PTH 20 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months.
61985539|NCT05023265|EXPERIMENTAL|SBRT for Medically Inoperable RCC|35-40 Gy in five fractions (7-8 Gy/day)
61985540|NCT04528745||Patients with cancer receiving cytostatic treatment|Consecutive patients referred for cytostatic treatment or in treatment with cytostatic agents for colorectal or pancreatic cancer
61985541|NCT01004588|EXPERIMENTAL|Protein drink|protein drink
61985542|NCT01004588|PLACEBO_COMPARATOR|Placebo drink|Placebo drink
61985543|NCT02287558|EXPERIMENTAL|Pomalidomide|Pomalidomide will be supplied as 1.0 mg, 2.0 mg, 3.0 mg and 4.0 mg capsules for oral administration. The principal investigator will determine whether intrapatient dose escalation is indicated based on the response of the patient's bleeding during the first 30 days of therapy. If dose escalation is indicated, pomalidomide will be increased by 1 mg/month at the investigator's discretion to a maximal dose of 5 mg/day.
61985544|NCT00457782|EXPERIMENTAL|I|Intravenous KW-2478 (ascending dose cohorts)
61985545|NCT04777695||CICU Inpatients|This is a prospective observational study of all children admitted to the pediatric CICU during a one month period of time for patients aged 0 to less than or equal to 22 years of age, as per the World Health Organization definition of a pediatric patient.
61985546|NCT03411681|ACTIVE_COMPARATOR|Normal Weight|
61985547|NCT03411681|EXPERIMENTAL|Obese|
61985548|NCT05196841|EXPERIMENTAL|Experimental group|Anastatica Hierochuntica
62363235|NCT04368104||Group A|women using any form of minipills
62363236|NCT04368104||Group B|women subjected to office hysteroscopy for different indications but not using any form of hormones or systemic or local hormonal contraception.
62567144|NCT05089513|EXPERIMENTAL|Robotic surgery|Robotic surgery in both live donor and recipient
62739256|NCT01000298|EXPERIMENTAL|cefdinir|cefdinir
62739257|NCT06653803|ACTIVE_COMPARATOR|Group A (n=30)|Rhomboid Intercostal Block
61985549|NCT05196841|NO_INTERVENTION|Control group|routine care
61985550|NCT02687984|EXPERIMENTAL|RBP-7000 PLGH A|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 21 kDa PLGH polymer.
61985551|NCT02687984|EXPERIMENTAL|RBP-7000 PLGH B|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 29 kDa PLGH polymer.
61985552|NCT02687984|ACTIVE_COMPARATOR|RBP-7000 PLGH C|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 26 kDa PLGH polymer. This intermediate molecular weight treatment serves as the reference treatment.
61985553|NCT02662127|EXPERIMENTAL|SIGVARIS®. Class 2 - RAL: 23-32|Graduated elastic compression stockings
61985554|NCT03710226||cases|women with recurrent miscarriage (two or more consecutive miscarriages)
61985555|NCT03710226||controls|women without recurrent miscarriage and delivered at least once before
61985556|NCT01253759||1|Combined treatment of Transpupillary Thermotherapy and ICG-based photodynamic therapy (PDT)
62363237|NCT06042192|EXPERIMENTAL|TK-254RX applied to Lower Arm, Lower thigh or Ankle|"For Group1, TK-254RX will be applied to left and right side (total of two TK-254RX per day) of the following predetermined application site by subjects.~Day1: Lower Arm, Day2: Lower thigh, Day3: Ankle"
62363238|NCT06042192|EXPERIMENTAL|TK-254RX applied to Upper Arm, Upper thigh or Lower leg|"For Group2, TK-254RX will be applied to left and right side (total of two TK-254RX per day) of the following predetermined application site by subjects.~Day1: Upper Arm, Day2: Upper thigh, Day3: Lower leg"
62363239|NCT03322085|EXPERIMENTAL|paroxysmal AF with radiofrequency ablation|radiofrequency catheter ablation therapy
62363240|NCT03322085|EXPERIMENTAL|persistent AF with radiofrequency ablation group|radiofrequency catheter ablation therapy
62363241|NCT03322085|EXPERIMENTAL|paroxysmal AF with cryoballoon group|cryoballoon ablation therapy
62363242|NCT05300854|ACTIVE_COMPARATOR|Standard anesthesia in addition to serratus plane block|general anesthesia was given then ultrasound-guided serratus plane block
62363243|NCT05300854|ACTIVE_COMPARATOR|Standard anesthesia in addition to para-vertebral block|general anesthesia was given then ultrasound-guided para-vertebral block
62363244|NCT01239238||Care as usual|Therapy is guided based on symptoms and lung function. Assessments: home monitoring, symptoms, lung function, FeNO, asthma control, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
62363245|NCT04155125|EXPERIMENTAL|efepoetin alfa|"Route of administration: Subcutaneous Injection.~The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period."
62363246|NCT04155125|PLACEBO_COMPARATOR|Mircera|"Route of administration: Subcutaneous Injection.~The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL."
62363247|NCT02565953|EXPERIMENTAL|Paclitaxel-releasing PTA balloon catheter|Treatment of renal dialysis arteriovenous fistula stenosis with paclitaxel-releasing percutaneous transluminal angioplastic (PTA) balloon catheter.
62363248|NCT02565953|ACTIVE_COMPARATOR|PTA Balloon catheter|Treatment of renal dialysis arteriovenous fistula stenosis with percutaneous transluminal angioplastic (PTA) balloon catheter.
62363249|NCT04613271|EXPERIMENTAL|Group 1|"Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days."
62363250|NCT04613271|ACTIVE_COMPARATOR|Group 2|Administration Group 2: Azithromycin 500 mg once a day for 5 days.
62363251|NCT03010904|EXPERIMENTAL|pasteurized milk|milk that has undergone pasteurization treatment
62169591|NCT06550297|ACTIVE_COMPARATOR|Arm 3: Cohort B (type 2 diabetes patients who do not currently qualify for MTMs) Active Comparator|Participants in this arm are type 2 diabetes patients with hypertension or elevated blood pressure who do not currently qualify for medically tailored meals (MTM) programs. This arm will receive God's Love We Deliver's current MTM program, which consists of 10 home-delivered MTMs per week and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period. In addition, they will receive a culturally and contextually tailored cardiovascular health promotion program that consists of didactic sessions focused on lifestyle change and the American Heart Association's Life's Essential 8 framework, setting weekly specific, measurable, attainable, realistic, and timely (S.M.A.R.T.) goals for health behavior modification, group coaching, cooking demonstrations, recipes and gift bags with healthy ingredients, and addressing social needs.
62182333|NCT03866980|EXPERIMENTAL|AK105 plus Carboplatin and Pemetrexed|Subjects receive AK105 200 mg intravenously (IV) plus pemetrexed 500 mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV plus pemetrexed 500 mg/m\^2 IV Q3W until progression.
62363252|NCT03010904|EXPERIMENTAL|homogenized pasteurized milk|Milk that has undergone homogenization and pasteurization treatment
62363253|NCT03010904|EXPERIMENTAL|UHT milk|Milk that has undergone homogenization and ultra high temperature treatment
62363254|NCT05321693|ACTIVE_COMPARATOR|Active tPCS|
62363255|NCT05321693|SHAM_COMPARATOR|Sham tPCS|The currentwill only be applied forthe first 30 seconds. Patients may notice the same sensation of initial stimulation butwill not receive the current for the remaining time.
61985557|NCT01675687|EXPERIMENTAL|Internet|"Participants of this intervention group get follow up support via Internet.~They have access to new inputs biweekly consisting of~* Thematic inputs and instructions (e.g. advice on shopping, cooking, regular exercise on daily routine, motivation and more)~* assignments promoting self-awareness and introspection~* spreadsheets promoting self-monitoring~News and updates (e.g. recipes, gymnastic classes, meetings of self support groups and more) will be available each month.~Tailored feedback of their behaviour will be given by documentation on spreadsheets."
62363256|NCT04917250|EXPERIMENTAL|treatment arm|Treated with gemcitabine, pegaspargase, etoposide and dexamethasone
62363257|NCT06078891|EXPERIMENTAL|BCG vaccinated patients|A single arm experiment to examine the effect of 3 standard intradermal vaccinations with BCG (at times 0, 1 month and 12 months) on plasma biomarkers.
62363258|NCT01801761||develop group|previous COPD study
62363259|NCT01801761||validation group|consecutive COPD patients from outpatient clinics
62363260|NCT01015690||unexplained infertility|patients with unexplained infertility
62363261|NCT01015690||healthy controls|women who wish to conceive, no more tha 3 previous cycles, age above 18
62363262|NCT01015690||references|lesbian women with a regular cycle without use of anticonception and not at risk of becoming pregnant
62363263|NCT04714944|PLACEBO_COMPARATOR|Placebo|isocaloric placebo
62363264|NCT04714944|EXPERIMENTAL|whole fiber product|15 g for 2 weeks, followed by 30 g for 10 weeks
62363265|NCT06526598|EXPERIMENTAL|PMI-targeted group|The participants will be treated according to the standard of care for mechanical ventilation. During PSV, pressure support is set and adjusted according to the PMI target.
62363266|NCT06526598|ACTIVE_COMPARATOR|VT/RR-targeted group|The participants will be treated according to the standard of care for mechanical ventilation. During PSV, pressure support is set and adjusted according to the VT/RR target.
61985558|NCT01675687|EXPERIMENTAL|Printed Manual|"Participants of this intervention group get follow up support via a printed manual.~The manual consist of all the same inputs as are available to the Internet follow up group.~* Thematic inputs and instructions (e.g. advice on shopping, cooking, regular exercise on daily routine, motivation and more)~* assignments promoting self-awareness and introspection~* spreadsheets promoting self-monitoring~All inputs will be given at once at the beginning of the follow up intervention, only news and updates (e.g. recipes, gymnastic classes, meetings of self support groups and more) will be sent per mail each month.~There is no tailored feedback of their behaviour as the paper-pencil documentation on spreadsheets can't be monitored by the psychologists."
62169592|NCT06550297|EXPERIMENTAL|Arm 4: Cohort B (type 2 diabetes patients who do not currently qualify for MTMs) Intervention|Participants in this arm are type 2 diabetes patients with hypertension or elevated blood pressure who do not currently qualify for medically tailored meals (MTM) programs. This arm will receive the MTM program and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period but with a distinct MTM dosing schedule. They will receive the regular MTM schedule of 10 MTMs/week for the first 3 months of the intervention. After this initial period, MTM dosing will be gradually reduced by 1 MTM each month to a target schedule of 5 MTMs/week in the final month of the intervention. In addition, they will also receive the same culturally and contextually tailored cardiovascular health promotion program as Arms 2 and 3.
62169593|NCT00481156|EXPERIMENTAL|Patients: Cognitive Remediation|Patients in the cognitive REM condition attended up to 25 h of training in small groups over 4-6 weeks based on the approach to cognitive remediation described by Wexler and Bell (2005). Patients performed tasks designed to train attention and memory from the battery available within a computerized software package (CogPack Marker Software). This training protocol has been shown to improve memory and executive functioning in patients with schizophrenia (Sartory et al, 2005) and tasks chosen were designed to produce improved working memory and attention capacity in the treated group. In addition, patients in the REM group trained on the word N-back one to two times a week and on N-back tasks using a variety of other stimuli (such as faces) one to two times a week to support the generalization of working memory improvements.
62363267|NCT02187341|EXPERIMENTAL|5-HTP|200 mg 5-HTP capsule will be ingested 2h prior to reporting to the laboratory.
62363268|NCT02187341|PLACEBO_COMPARATOR|Placebo|For these visit subjects will ingest placebo (Sugar pill) capsule 2 hours before reporting to the laboratory.
62363269|NCT00928512|EXPERIMENTAL|Secukinumab 25mg|Secukinumab 25mg s.c. q4wk
62363270|NCT00928512|EXPERIMENTAL|Secukinumab 75mg|Secukinumab 75mg s.c. q4wk
62363271|NCT00928512|EXPERIMENTAL|Secukinumab 150mg|Secukinumab 150mg s. c. q4wk
62363272|NCT00928512|EXPERIMENTAL|Secukinumab 300mg|Secukinumab 300mg s.c. q4wk
62363273|NCT00928512|PLACEBO_COMPARATOR|Secukinumab Placebo|Secukinumab Placebo s.c. q4wk
62550228|NCT00512577|ACTIVE_COMPARATOR|B|Patients will receive a pre-operative blood transfusion. Those presenting with an admission Hb of less than 9g/dL will receive a simple (also called a 'top-up') transfusion, those presenting with an admission Hb of more than or equal to 9g/dL will undergo a partial exchange transfusion.
62739258|NCT06653803|ACTIVE_COMPARATOR|Group B (n=30)|Retrolaminar Block
62739259|NCT00443053|ACTIVE_COMPARATOR|Fondaparinux 2.5mg|
62739260|NCT00443053|PLACEBO_COMPARATOR|Placebo|
62739261|NCT04303013|ACTIVE_COMPARATOR|Standard of Care|
61985559|NCT04483908||Cohort 1|"Disease survivors with a positive polymerase chain reaction (PCR) test \> 12days (d) ago and no symptoms (\~250 participants).~Cohort 1 \& 2 are supposed to have an antibody response to different levels and should provide ability to deduce the detection limit, and estimate the true positive and false negative rates of both ELISA and POC assays."
61985560|NCT04483908||Cohort 2|"Disease survivors with a positive PCR test 7 - 12d ago and no symptoms (\~100 participants).~Cohort 1 \& 2 are supposed to have an antibody response to different levels and should provide ability to deduce the detection limit, and estimate the true positive and false negative rates of both ELISA and POC assays."
62739262|NCT04303013|EXPERIMENTAL|Meditation|
62739263|NCT05533307||nulliparous women with normal birth (not needed mediolateral episitomy)/1|group without mediolateral episiotomy
61985561|NCT04483908||Cohort 3|Subjects with PCR negative test \> 5d (\~100 participants). Cohort 3 \& 4 are the control groups. They are supposed to not have an antibody response for COVID-19 and should therefore help estimate the true negative and false positive rates.
61985562|NCT04483908||Cohort 4|"Anonymised blood sera from the Serumbank at the Kantonsspital Basel-Land (KSBL) taken during last years influenza period (\~100 participants).~Cohort 3 \& 4 are the control groups. They are supposed to not have an antibody response for COVID-19 and should therefore help estimate the true negative and false positive rates."
61985563|NCT04868279|EXPERIMENTAL|Interventional Gruop|"Web-based interactive nurse support program with the intervention group will continue for 3 months, the implementation will last 6 months in total. Individuals in the intervention group will be able to access the training content by accessing the website designated for the study from devices such as computers or mobile phones.~Data collection forms will be applied to the intervention group 3 times in total, before starting the Web-based interactive nurse support program, at the end of the Web-based interactive nurse support program (in the 3rd month) and in the 6th month."
61985564|NCT04868279|NO_INTERVENTION|Control Group|Web-based interactive nurse support program will not be opened to the control group, only access to data collection tools will be provided.
61985565|NCT02141282|EXPERIMENTAL|ABT-199 after ibrutinib therapy|Participants with ibrutinib-resistant or refractory chronic lymphocytic leukemia (CLL) received venetoclax tablets once daily (QD) until disease progression or study drug discontinuation; median time on treatment was 593 days. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
61985566|NCT02141282|EXPERIMENTAL|ABT-199 after idelalisib therapy|Participants with idelalisib-resistant or refractory chronic lymphocytic leukemia (CLL) received venetoclax tablets once daily (QD) until disease progression or study drug discontinuation; median time on treatment was 1023 days. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
62739264|NCT05533307||nulliparous women with normal birth (with mediaolateral episiotomy)/2|group with mediolateral episiotomy
62739265|NCT03800537|EXPERIMENTAL|All Participants|All participants will receive the investigational MR Fingerprinting sequence.
62739266|NCT05268692|ACTIVE_COMPARATOR|GS|gemcitabine plus S-1
62363274|NCT03960658|EXPERIMENTAL|Ketamine and PE|ketamine treatment followed by a standardized prolonged exposure session for the first 3 weeks; then, weekly prolonged exposure as usual.
62363275|NCT01553721|EXPERIMENTAL|udenafil|"1. Phase IIa Experimental : Udenafil Dose 1, Dose 2~2. Phase IIb Experimental : Udenafil"
62363276|NCT01553721|PLACEBO_COMPARATOR|placebo|"1. Phase IIa Placebo Comparator : Placebo~2. Phase IIb Placebo Comparator : Placebo"
62363277|NCT02763241|EXPERIMENTAL|Cleanoze®|"Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.~The patient will be instructed to use this isotonic solution for nasal irrigation daily."
62363278|NCT02763241|ACTIVE_COMPARATOR|Syringe irrigation|"Nasal irrigation using sterile 0.9% NaCl 250 ml by 20 ml syringe~The patient will be instructed to use this isotonic solution for nasal irrigation daily."
62363279|NCT02394990|EXPERIMENTAL|Violence Brief Intervention|Participants receive a standard of care brief motivational intervention (BMI) to address alcohol consumption (ABI) based on self reported use and their relationship between consumption and behavior, followed by an additional BMI to address how involvement in violence (VBI) impacts their life, relationship to social norms, and strategies to avoid violence.
62363280|NCT02394990|ACTIVE_COMPARATOR|Control|Participants receive only ABI
62363281|NCT04356924|EXPERIMENTAL|Psychological treatment|The psychological treatment consists of 11 sessions (55 minutes per occasion), where the patient meets a psychologist face-to-face (either licensed or under training to be licensed) once a week. In between sessions, patients are supposed to complete homework exercises that are related to the contiguous sessions (2 x 45 minutes per week).
62363282|NCT04356924|ACTIVE_COMPARATOR|Cognitive training|Like the experimental group, the active control group also consists of 11 sessions (55 minutes per occasion), once a week. At those occasions, the patient will meet a psychology student under training or a MSc in psychology that coaches the patients during the cognitive training. In between sessions, patients are supposed to take 2 walks (45 minutes per occasion to meaningfully match the home exercises in the experimental group).
62169594|NCT00481156|ACTIVE_COMPARATOR|Patients: Cognitive-Behavioral Social Skills Training|Patients in the CBSST group also attended up to 25 h of treatment but followed a manualized group therapy protocol (Granholm et al, 2005) using cognitive and behavioral therapy methods to increase patients' skills in symptom recognition, communication, problem solving, and relapse prevention. In both conditions, the facilitators interacted with the clients throughout small group (B4 patients) sessions: in the REM group, this mostly involved brief one-on-one discussions regarding task performance; in the CBSST condition, this interaction was in the context of the group milieu.
62169595|NCT00481156|OTHER|Controls: Retest control group|Estimate of normal brain functioning and retest effects
62169596|NCT01655992|EXPERIMENTAL|S1 generic|40mg／m2 bid four weeks on two weeks off
62169597|NCT01655992|ACTIVE_COMPARATOR|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
62169598|NCT06227442||Group A|will include 48 RA patients without renal affection.
62169599|NCT06227442||Group B|will include 48 RA patients with renal affection.
62169600|NCT06227442||Group C|will include 48 healthy control.
62169601|NCT04284722|ACTIVE_COMPARATOR|Metformin +|The study intervention involves the self-administration of metformin in the same dosage as the patient's regular dosage according to regular dosing schedule and randomization.
62169602|NCT04284722|NO_INTERVENTION|Metformin -|The control group involves no intervention, which means cessation of oral metformin therapy 24 hours prior to surgery according to the local guidelines of the anesthesia department and the national anesthesiology guidelines.
62169603|NCT05888558||Ocular myasthenia gravis group|Ocular myasthenia gravis,age between 18-50 years old
62169604|NCT05888558||General myasthenia gravis group|General myasthenia gravis,age between 18-50 years old
62169605|NCT05888558||Healthy control group|people who are healthy without any systemic diseases，18-50 years old
62169606|NCT04345783|EXPERIMENTAL|Camrelizumab+Apatinib Mesylate+Tegio|
62363283|NCT04356924|NO_INTERVENTION|Treatment as usual|This group receives no intervention. They receive regular health information that is given after the extended cognitive examination at the Cognitive Centers. However, after the finalization of the post-intervention evaluations, this group will be randomized to participate in one of the active interventions. We will conduct additional post-intervention assessments also for those individuals in this group that accept this offer to increase the power of the intervention evaluation.
62363284|NCT01721629|OTHER|Sudden wean of nasal CPAP|The CPAP is taken off at the morning ward round. If the discontinuation of the CPAP fails according to prespecified failure criteria, CPAP is recommenced and continued for at least 24 hours. Then a new evaluation takes place and if the infant again meets the inclusion criteria another attempt of sudden wean can be undertaken. Infants are considered successfully weaned if they are off CPAP for three days.
62363285|NCT01721629|OTHER|Gradual wean of nasal CPAP pressure|The reduction of the CPAP pressure begins at the morning ward round and the pressure is reduced in steps with 1 cmH2O maximum once a day. Each time the pressure is to be reduced the infant needs to be evaluated according to the inclusion criteria and only if these are still met, will the pressure be reduced. When a CPAP pressure at 4 cmH2O is reached the infant is treated with this pressure for 24 hours and then the CPAP is discontinued. Infants are considered successfully weaned if they are off CPAP for three days.
62363286|NCT03154034||Severe mitral regurgitation|
62363287|NCT02302755|EXPERIMENTAL|Screening/ Active Treatment Arm|"Screening Period: This includes diagnosis confirmation, consent, required tests and vaccinations.~Treatment Period: All patients will be enrolled through the University of Iowa. This study will follow a patient-specific TP10 dose-escalation scheme during the Induction Period and subsequent dose adjustments based on complement levels during the Maintenance Period"
62363288|NCT06165861|EXPERIMENTAL|Experimental (with VR-G)|The patients in this procedure watched video with using VR-G for approximately 6 minutes at the surgical clinic before going surgery.
62363289|NCT06165861|NO_INTERVENTION|Standard (No VR-G)|The patients took the standart protocol of the surgical clinic and didn't watch video with using VR-G
62363290|NCT00323427|EXPERIMENTAL|Arm 1|Group Aural Rehabilitation session, two hours in length, approximately 6 participants plus Group Facilitator
62363291|NCT00323427|ACTIVE_COMPARATOR|Arm 2|Veterans receive new VA issued digital hearing aids per Standard VA Audiology Hearing Aid services
62363292|NCT02421146|SHAM_COMPARATOR|Sham tDCS - Healthy Controls|The sham group session will contain 20 minute sessions of transcranial direct current stimulatio , but only the first minute will be with 2mA, then unbeknownst to the subject, the unblinded research assistant will turn off the stimulation.
62363293|NCT02421146|ACTIVE_COMPARATOR|tDCS - Healthy Controls|will receive real transcranial direct current stimulation. Real tDCS stimulation will involve ten 20 minute stimulations daily (at 2 mA anode over the left DLPFC while cathode over the right suborbital region) on 5 weekdays of two consecutive weeks
62363294|NCT02421146|SHAM_COMPARATOR|Sham tDCS - Patients|The sham group session will contain 20 minute sessions of transcranial direct current stimulation as well, but only the first minute will be with 2mA, then unbeknownst to the subject, the unblinded research assistant will turn off the stimulation.
62363295|NCT02421146|ACTIVE_COMPARATOR|tDCS - Patients|will receive real transcranial direct current stimulation . Real tDCS stimulation will involve ten 20 minute stimulations daily (at 2 mA anode over the left DLPFC while cathode over the right suborbital region) on 5 weekdays of two consecutive weeks
62363296|NCT00742040|EXPERIMENTAL|1|
62363297|NCT00742040|ACTIVE_COMPARATOR|2|
62363298|NCT00121680|EXPERIMENTAL|1|
62363299|NCT04199403||Single Group|
62363300|NCT05797298||cataract patients implanted with toric IOLs|Cataract patients who received the implantation of different toric IOLs with different haptic designs
62363301|NCT04716010|OTHER|Control|Products that contain red meat will not have warning labels or an increase in price.
62363302|NCT04716010|EXPERIMENTAL|Warning Labels|"The warning labels are black octagons with white text that appear next to images of products that contain red meat. One label says WARNING: Eating red meat contributes to colon and rectal cancer and the other label says WARNING: Eating red meat harms the environment."
62363303|NCT04716010|EXPERIMENTAL|Tax|The tax is a 30% increase in the price of products that contain red meat.
62363304|NCT04716010|EXPERIMENTAL|Combined Warning Labels and Tax|"The Combined Warning Labels and Tax arm features both the warning labels and tax. The warning labels are black octagons with white text that appear next to images of products that contain red meat. One label says WARNING: Eating red meat contributes to colon and rectal cancer and the other label says WARNING: Eating red meat harms the environment. The tax is a 30% increase in the price of red meat products."
62363305|NCT05177289|EXPERIMENTAL|Treatment group|Patients allocated to the treatment group will receive scalp cooling combined with thrice weekly PBM sessions during the CTx course and until one month after the end of CTx.
62363306|NCT05177289|ACTIVE_COMPARATOR|Control group|Patients allocated to the control group will receive scalp cooling during their CTx course.
62363307|NCT04128618|EXPERIMENTAL|Active NMES|
62363308|NCT04128618|SHAM_COMPARATOR|Modified NMES sham|
62363309|NCT02979028|EXPERIMENTAL|TEAS group|Electric stimulation was given through electrode attached to acupoints SP6 and ST36 .TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.
62169607|NCT03460496|EXPERIMENTAL|APN-led Intervention|"Intervention group being provided with the interventions described below.~* Advanced practice nurses' interventions~* Neonatologists: neonatal outpatient consultation~* psychological support~* lactation consultant~* physiotherapeutic interventions~* collaboration with social workers~* music therapy~* close collaboration with other health care professionals~* interprofessional roundtable meetings"
62363310|NCT02979028|SHAM_COMPARATOR|Sham group|Non-acupoint is located 2cm inward to the specific acupoints.TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.
62363311|NCT02979028|PLACEBO_COMPARATOR|Control group|Control patients will receive the same treatment without electrical stimulation.
62363312|NCT00468611|EXPERIMENTAL|1|
62169608|NCT03460496|NO_INTERVENTION|Control, Standard Care|Control group receiving standard care
62363313|NCT00468611|PLACEBO_COMPARATOR|2|
62363314|NCT04054739|EXPERIMENTAL|Robot-assisted gait training|experimental group that applied the end-effector robot-assisted gait training
62363315|NCT04054739|ACTIVE_COMPARATOR|Treadmill gait training|control group that applied the treadmill gait training
62363316|NCT00816608||type 2 diabetes|
62363317|NCT00004604|EXPERIMENTAL|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
62363318|NCT04062799||Study cohort|
62363319|NCT04598841|EXPERIMENTAL|intervention group|Intravenous nutrition or oral high-calorie diet 7-10 days before surgery
62363320|NCT04598841|NO_INTERVENTION|control group|normal diet before surgery
62363321|NCT01958554|EXPERIMENTAL|Intervention Group|The integrated intervention consisted of 12 week of program and group support, based on the freedom program by pet craven. The former component was provided covering beliefs held and tactics used by the domestic violence abusers and took about 45 minutes. It included protection and enhanced choice-making and problem-solving skills.
62363322|NCT01958554|NO_INTERVENTION|Wait list control group|The group was listed in wait list and were offered the same intervention and support on completion of study period.
62363323|NCT02699671||acute myocardial infarction|
62363324|NCT05333003|EXPERIMENTAL|Semaglutide|Semaglutide medication will be taken by participants on a weekly schedule, and adherence tracked
62363325|NCT05333003|PLACEBO_COMPARATOR|Placebo|Placebo will be taken by participants on a weekly schedule, and adherence tracked
62363326|NCT01413828|EXPERIMENTAL|concurrent|trastuzumab was administered concurrently with any anthracycline-containing adjuvant regimen
62739267|NCT05268692|ACTIVE_COMPARATOR|GnP|gemcitabine plus nab-paclitaxel
62363327|NCT01413828|ACTIVE_COMPARATOR|sequential|trastuzumab was administered sequentially to any anthracycline-containing adjuvant regimen
62363328|NCT04545034|EXPERIMENTAL|Water aerobic exercise protocol|Walter aerobic exercise session would be used to treat blood pressure in elderly hypertensive people.
62363329|NCT04545034|NO_INTERVENTION|Control Group|No exercise intervention would be used.
62363330|NCT02270099||Subjects with suspected HSV Lesions|
62363331|NCT02108834|ACTIVE_COMPARATOR|nerve block|cervical plexus block with ropivacaine
62363332|NCT02108834|PLACEBO_COMPARATOR|Placebo|placebo saline
62169609|NCT06295237|NO_INTERVENTION|Standard of Care|Optimized ventilator settings to control and reduce the number of asynchronies
62363333|NCT02820038|ACTIVE_COMPARATOR|Other CMI Only|Approximately 75 participants will be assigned to this study group. Participants will ONLY receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications.
62363334|NCT02820038|EXPERIMENTAL|Other CMI & SMART Program|Approximately 75 participants will be assigned to this study group. Participants will receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications AND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
62363335|NCT02820038|EXPERIMENTAL|Drug Facts Boxes Only|Approximately 75 participants will be assigned to this study group. Participants will ONLY receive Drug Facts Boxes for rheumatoid arthritis medications.
62363336|NCT02820038|EXPERIMENTAL|Drug Facts Boxes & SMART Program|Approximately 75 participants will be assigned to this study group. Participants will receive Drug Facts Boxes for rheumatoid arthritis medicationsAND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
62363337|NCT02713295||Subjects with Moderate to Severe Plaque Psoriasis|Subjects with Moderate to Severe Plaque Psoriasis in Greece
62363338|NCT04950660|ACTIVE_COMPARATOR|Caffeine arm|Experimental Group: patient group (n = 34) receiving a 100 mg dose of caffeine (1/2 of a 200mg tablet to be taken whole or crushed), taken twice daily. This will be an adjuvant to their standard pain control.
62363339|NCT04950660|PLACEBO_COMPARATOR|Placebo arm|Control group: patient group (n = 34) receiving placebo compounded to look similar to the caffeine treatment, taken twice daily. This will be an adjuvant to their standard pain control.
62363340|NCT04709874|EXPERIMENTAL|Paravertebral block|Patients will receive paravertebral block guided by a nerve stimulator.
62363341|NCT04709874|ACTIVE_COMPARATOR|Suprascapular block|Patients will receive suprascapular block
62363342|NCT01956058|EXPERIMENTAL|brachytherapy remedial|
62363343|NCT04594018|EXPERIMENTAL|FINLÂNDIA|"The study is double-dummy. The patient must take 1 pill and apply hair lotion as follow:~1 tablet finasteride placebo, oral, once a day.~1 mL Finlândia hair lotion, topical, twice a day."
62363344|NCT04594018|ACTIVE_COMPARATOR|Minoxidil + finasteride|"The study is double-dummy. The patient must take 1 pill and apply hair lotion as follow:~1 tablet finasteride, oral, once a day.~1 mL minoxidil hair lotion, topical, twice a day."
62363345|NCT06430645|EXPERIMENTAL|low dose of esketamine|Drug：esketamine (0.3mg/kg)
62363346|NCT06430645|EXPERIMENTAL|high dose of esketamine|Drug：esketamine(0.6mg/kg)
62169610|NCT06295237|ACTIVE_COMPARATOR|Activated automatic detection and adjustment of asynchronies|Active mode of a mechanical ventilator software automatically detecting and adjusting ventilator parameters to control or reduce the number of events.
62169611|NCT03769129|EXPERIMENTAL|Microwave ablation|Firstly, microwave ablation performed at our department by interventional radiologist, then Pembrolizumab will be administered at a dose of 2 mg/kg every three weeks.
62169612|NCT03769129|OTHER|Pembrolizumab|Firstly, pembrolizumab was administered intravenously at a dose of 2 mg/kg. Then microwave ablation will be performed if there is no immune-related adverse reactions. Pembrolizumab will also be continuously administered every three weeks until the imaging evaluation of the disease progress.
62169613|NCT03298347|EXPERIMENTAL|80mg/kg of caffeine|80mg/kg of caffeine is given to treat AOP.
62169614|NCT03298347|ACTIVE_COMPARATOR|20mg/kg of caffeine|20mg/kg of caffeine is given to treat AOP.
62363347|NCT06430645|EXPERIMENTAL|control group|Drug：0.9% saline
62363348|NCT01594346|PLACEBO_COMPARATOR|Sugar Pill|
62363349|NCT01594346|ACTIVE_COMPARATOR|Alpha-Tocopherol|
62363350|NCT00466661|EXPERIMENTAL|Acamprosate|666 mg p.o. TID
62363351|NCT00466661|PLACEBO_COMPARATOR|Placebo|Matching placebo
62169615|NCT01723332|EXPERIMENTAL|Intervention|Clinical based educational and self management intervention.
62363352|NCT03905876|OTHER|assessment of psychological experience|Questionnaire
62363353|NCT01844427|ACTIVE_COMPARATOR|Memantine HCl|Memantine administered in capsule form twice daily for 12 weeks and titrated up to a maximum daily dose of 20mg.
62363354|NCT01844427|PLACEBO_COMPARATOR|Placebo|Masked placebo administered in capsule form twice daily for 12 weeks. Placebo titration will be titrated according to the same procedure as active memantine.
62363355|NCT03591913|EXPERIMENTAL|study group|will receive sublingual misoprostol immediately after urinary catheterization and before skin incision
62363356|NCT03591913|ACTIVE_COMPARATOR|control group|will receive sublingual misoprostol immediately after skin closure
62363357|NCT01517906|EXPERIMENTAL|Cognitive behavioral counseling|
62363358|NCT01517906|ACTIVE_COMPARATOR|Supportive therapy|
62363359|NCT01507571|EXPERIMENTAL|Dignity Therapy|
62363360|NCT02130752|EXPERIMENTAL|Ultrasonic scalpel surgery group|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes; some great vessels can ligation by nylon, silk line or Hemolock.
62363361|NCT02130752|EXPERIMENTAL|Monopolar electrocautery surgery group|During the procedures of the abdominal approach D2 distal gastrectomy, use monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes; some great vessels can ligation by nylon, silk line or Hemolock.
62363362|NCT02676453|EXPERIMENTAL|Intervention|Dental hygienist support
62363363|NCT02676453|NO_INTERVENTION|control|Care as usal
62363364|NCT01617928|EXPERIMENTAL|veliparib (ABT-888)|
62363365|NCT05587608|ACTIVE_COMPARATOR|ultrasound-guided thoracic segmental spinal group|given ultrasound-guided thoracic segmental spinal heavy Marcaine plus 25 ug fentanyl at the level of T10 interlaminar space.
62169616|NCT01723332|NO_INTERVENTION|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies.
62169617|NCT02093897|EXPERIMENTAL|rVIII-SingleChain|Subjects will be assigned to either an on-demand or prophylaxis regimen and will receive rVIII-SingleChain as an intravenous (IV) infusion. Subjects assigned to a prophylaxis regimen will be treated with 15 to 50 IU/kg of rVIII-SingleChain every second day or 2 to 3 times per week, or at the investigator's discretion, based on available PK data, the FVIII treatment regimen used before enrollment and/or the subject's bleeding phenotype. The dose for on-demand treatment of a bleeding episode is based on the recommendations of the World Federation of Hemophilia (WFH), with a minimum dose of 15 IU/kg. All subjects were to be treated for a minimum of 50 EDs. For the PK evaluation, the subjects will receive a single IV dose of 50 IU/kg of rVIII-SingleChain on Day 1 at the start of the PK evaluation period.
62363366|NCT05587608|NO_INTERVENTION|General anesthesia group|General anesthesia (control)
62169618|NCT01694199|ACTIVE_COMPARATOR|Active study device with PRFE|This study arm receives pulsed radiofrequency energy (PRFE) from an active test device.
62169619|NCT01694199|SHAM_COMPARATOR|Sham study device with no PRFE|This study arm receives no pulsed radiofrequency energy (PRFE) from a sham test device.
62169620|NCT01626677|EXPERIMENTAL|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
62169621|NCT01626677|ACTIVE_COMPARATOR|Microfracture|conventional treatment method
62169622|NCT01314638||Single group|Single group, Identical investigations for all subjects
62169623|NCT00806741|ACTIVE_COMPARATOR|1|NG-monomethyl-L-arginine (L-NMMA)
62169624|NCT00806741|ACTIVE_COMPARATOR|2|Phenylephrine
62169625|NCT00806741|PLACEBO_COMPARATOR|3|Physiological saline solution
62169626|NCT00226746|EXPERIMENTAL|Paclitaxel and Gemcitabine|"Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions), Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36."
62169627|NCT03786003|EXPERIMENTAL|VATS|Video-assisted thoracoscopic surgery
62169628|NCT03786003|ACTIVE_COMPARATOR|Thoracotomy|Open surgery
61985567|NCT02141282|EXPERIMENTAL|ABT-199 after ibrutinib therapy: Expansion Cohort|Participants with ibrutinib-resistant or refractory chronic lymphocytic leukemia (CLL) received venetoclax tablets once daily (QD) until disease progression or study drug discontinuation; median time on treatment was 622 days. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg. Participants enrolled into the Expansion Cohort with bulky disease at study entry who were non-responders or those who showed signs of clinical progression after completing the ramp up to 400 mg either by clinical disease assessment or by CT/MRI scan between Week 6 to Week 12 may have been permitted to escalate venetoclax to a daily dose of 600 mg.
61985568|NCT02141282|EXPERIMENTAL|ABT-199 after idelalisib therapy: Expansion Cohort|Participants with idelalisib-resistant or refractory chronic lymphocytic leukemia (CLL) received venetoclax tablets once daily (QD) until disease progression or study drug discontinuation; median time on treatment was 1189 days. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg. Participants enrolled into the Expansion Cohort with bulky disease at study entry who were non-responders or those who showed signs of clinical progression after completing the ramp up to 400 mg either by clinical disease assessment or by CT/MRI scan between Week 6 to Week 12 may have been permitted to escalate venetoclax to a daily dose of 600 mg.
62169629|NCT05363098||Mechanically ventilated neurosurgical patients|Observational study in mechanically ventilated neurosurgical patients
62169630|NCT01037829||Pregnancy women|Comparison of pregnancy outcomes between (Novartis) H1N1 vaccinated women and (Novartis) H1N1 unvaccinated women.
62169631|NCT03269149|EXPERIMENTAL|Adapted Tango Dance|20 improvisational, 90-minute adapted tango dance sessions over a 12-week period.
62169632|NCT03269149|ACTIVE_COMPARATOR|Educational Control|Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks.
62169633|NCT02367378||MIS|Those who received minimally invasive surgical procedures
62363367|NCT00032006|EXPERIMENTAL|brachytherapy + radiation|"Within 4 weeks after completion of androgen suppression, patients are sequentially enrolled to 2 different cohorts of brachytherapy.~Cohort 1: Patients undergo initial-dose transperineal interstitial permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.~Cohort 2: After a minimum of 1-year follow-up for all patients in cohort 1, if tolerance is acceptable, additional patients undergo higher-dose transperineal interstitial permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.~Quality of life is assessed at baseline, within 2 weeks prior to brachytherapy, every 3 months for 1 year, and then every 6 months for 2 years.~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years."
62363368|NCT06374589|EXPERIMENTAL|Close-loop FiO2 Controller|Six hours period where the fraction of inspired oxygen (FiO2) delivered will be automatically titrated based on SpO2 values obtained from the patient.
62169634|NCT02367378||Control|Those who received treatments which include surgical resection, chemotherapy, and radiotherapy.
62169635|NCT00466622|EXPERIMENTAL|1|Metformin 1000mg x 2 daily. Orally. From Weifa
62169636|NCT00466622|PLACEBO_COMPARATOR|2|Placebo 2 tablets x 2 daily. Orally From Weifa
62169637|NCT03835403|NO_INTERVENTION|Usual Care (control arm)|These cardiac arrests will receive standard EMS response.
62169638|NCT03835403|EXPERIMENTAL|HeartRunner Activation|For these cardiac arrests, HeartRunners will be activated in addition to standard EMS response.
62169639|NCT00333554|EXPERIMENTAL|DHA Treatment Group|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
62169640|NCT00333554|PLACEBO_COMPARATOR|Control Group|Placebo for DHA given to nursing mother (breast milk), study formula, or capsules (removing content and mixing with food)depending on age of child.
62169641|NCT02284802|EXPERIMENTAL|Confocal endomicroscopy|Pts will be submitted to confocal endomicroscopy examination of the area of interest during endoscopy. A presumptive diagnosis will be made. This diagnosis will be compared to the definitive histologic diagnosis provided by endoscopic biopsies of the area of interest.
62169642|NCT00307671|OTHER|A|conventional treatment
62169643|NCT00307671|EXPERIMENTAL|B|reduction dose
62169644|NCT00984399|EXPERIMENTAL|vaginal 17β-estradiol, questionnaire , symptom checklist|This is a prospective longitudinal pilot study, and the targeted patient population is postmenopausal women with breast cancer being treated with adjuvant aromatase inhibitors who are initiated on vaginal 17β-estradiol to relieve symptoms of atrophic vaginitis.
61985569|NCT04571775|ACTIVE_COMPARATOR|Qi-Shield user group|
61985570|NCT04571775|SHAM_COMPARATOR|Sham Qi-Shield user group|
62363369|NCT06374589|ACTIVE_COMPARATOR|Conventional|Six hours period where the fraction of inspired oxygen (FiO2) delivered will be manually titrated by clinician based on SpO2 values obtained from the patient.
62169645|NCT05204771||Normal foetus|All pregnant women reffered for 3rd trimester routine ultrasound examination without any fetal abnormality
62169646|NCT04848116|EXPERIMENTAL|Cohort 1|Nivolumab (240 mg) + HuMax/BMS-986253 (2400 mg) will be administered as an IV infusion.
62169647|NCT04848116|EXPERIMENTAL|Cohort 2|Nivolumab (240 mg) + HuMax/BMS-986253 (3600 mg) will be administered as an IV infusion.
61985571|NCT04571775|NO_INTERVENTION|No Qi-Shield device group|
61985572|NCT02443012|EXPERIMENTAL|Nevanac|Patients with CSME treated with argon laser photocoagulation (focal/grid laser) and Topical Gutt Nepafenac 0.1% given 8 hourly interval for 3 months
61985573|NCT02443012|PLACEBO_COMPARATOR|Laser|Patients with CSME treated with argon laser photocoagulation (focal/grid laser)
61985574|NCT02258126|ACTIVE_COMPARATOR|Control group|healthy lifestyle education including healthy lifestyle education, supportive therapy and behavioral advice for both children and parents to improve nutrition and physical activity
61985575|NCT02258126|EXPERIMENTAL|Exercise group|multidisciplinary intervention program including healthy lifestyle education, supportive therapy and behavioral advice for for both children and parents to improve nutrition and physical activity and supervised exercise.
61985576|NCT01948973|ACTIVE_COMPARATOR|OFF, subsensory, suprasensory|Here the stimulator is turned OFF for the first 2 weeks, then set subsensory (90% of sensory threshold) for the next 2 weeks and finally set suprasensory for the last 2 weeks.
61985577|NCT01948973|ACTIVE_COMPARATOR|Subsensory, OFF, suprasensory|Here the stimulator is set subsensory (90% of sensory threshold), then turned OFF for the next 2 weeks and finally set suprasensory in the last 2 weeks.
61985578|NCT05147909|EXPERIMENTAL|Sodium Phosphate (NaPO4) then sodium chloride (NaCl)|Participants will be asked to take 2 capsules daily of Sodium Phosphate (containing a total of 500 mg of Pi, 372mg of sodium) ) for 4 weeks during the high Pi phase (total Pi intake 1,200 mg/d). Then, participants will be asked to take 2 capsules of Sodium Chloride (NaCl, containing a total of 372mg of sodium) to match Na content to Sodium Phosphate without extra Pi daily for 4 weeks during the low Pi phase (total Pi intake = 700 mg/d).
61985579|NCT05147909|EXPERIMENTAL|NaCl then NaPO4|Participants will be asked to take 2 capsules daily of Sodium Chloride (NaCl, containing a total of 372mg of sodium) for 4 weeks during the low Pi phase (total Pi intake = 700 mg/d). Then, participants will be asked to take 2 capsules of Sodium Phosphate daily for 4 weeks Sodium Phosphate (containing a total of 500 mg of Pi, 372mg of sodium) for 4 weeks during the high Pi phase (total Pi intake 1,200 mg/d).
61985580|NCT02402985|OTHER|High animal protein diet group AP|6-weeks diet intervention with high animal protein
61985581|NCT02402985|OTHER|High plant protein diet group PP|6-weeks diet intervention with high plant protein
61985582|NCT02653456|EXPERIMENTAL|RA-308 Excimer Laser and DABRA Catheter|Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions that cannot be crossed with standard guidewires. The catheter and laser are a system, and cannot be used separately.
61985583|NCT05375695|EXPERIMENTAL|Time-restricted eating|Time-restricted eating for 12 weeks (n=20).
61985584|NCT00529854||1|Observational evaluation of current billing and documentation practices
61985585|NCT00529854||2|Use of SIC-IR Billing Module
61985586|NCT03613051||age band one|age band one ( from 3 to 6 years ) we test manual dexterity by posting coins with prefered hand and non prefered hand test balance by jumping on mats
61985587|NCT03613051||age band two|age band two ( from 7 to 10 years ) test manual dexterity by threading lace
61985588|NCT03613051||age band three|age band three ( from 11 to 18 years ) test manual dexterity by turning pegs test balance by zigzag hopping
61985589|NCT00982488|OTHER|Dasatinib, 50 mg QD to 120 mg BID, Chronic phase|Participants with chronic phase disease continued on the previous study dose of dasatinib, ranging from 50 mg once daily (QD) to 120 mg twice daily (BID).
61985590|NCT00982488|OTHER|Imatinib, 400 mg BID, Chronic phase|Participants with chronic phase disease received 400 mg of imatinib twice BID.
61985591|NCT00982488|OTHER|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, AP|Participants with advanced phase disease, accelerated phase (AP), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
61985592|NCT00982488|OTHER|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, MBP|Participants with advanced phase disease, myeloid blast cell (MBP), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
61985593|NCT00982488|OTHER|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, Ph+ ALL|Participants with advanced phase disease, Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
62169648|NCT02676921||GROUP 1|Ten samples of sinus membrane where harvested from fifteen patients during a surgical nasal approach for treatment of chronic rhinosinusitis.
62169649|NCT02924181|ACTIVE_COMPARATOR|Lt PV CF guided/rt PV CF blinded|Fifteen patients will be allocated to this group. Left side pulmonary veins isolation will be performed with contact force information guidance. Then, right side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).
62363370|NCT05526781||Clareon® monofocal Intraocular lens (toric and non-toric models)|Bilateral implantation of the Clareon monofocal Intraocular lens (toric and non-toric models) with the Monarch IV inserter
62363371|NCT02376478||TNF-alpha inhibitors|TNF-alpha Inhibitors: patients with psoriasis or inflammatory bowel diseases under TNF-alpha inhibitor monotherapy
62739268|NCT06328270|ACTIVE_COMPARATOR|Study Group|The group received a 3-week intra-articular injection of 15 mg/ml ozone.
62739269|NCT06328270|ACTIVE_COMPARATOR|Control Group|The group received a 1 ml intra-articular injection of betamethasone
62169650|NCT02924181|ACTIVE_COMPARATOR|Lt PV CF blinded/rt PV CF guided|Fifteen patients will be allocated to this group. Left side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).Then, right side pulmonary veins isolation will be performed with contact force information guidance.
61985594|NCT04432311|EXPERIMENTAL|Binge Focused Therapy (BFT)|Guided self-help - Three online group sessions, homework, and self-guided check-ins to monitor continued progress and/or signs of relapse.
61985595|NCT04432311|ACTIVE_COMPARATOR|CBT Unguided Self Help (CBT USH)|Pure self-help - The use of the book Overcoming Binge Eating and its associated homework.
61985596|NCT05028439|EXPERIMENTAL|RAF combined with gemcitabine and S-1 group|Patients will receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement, and be treated with gemcitabine and S-1 within 1 month after RFA.
61985597|NCT05028439|PLACEBO_COMPARATOR|RFA-only gruop|Patients will only receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement
61985598|NCT02030379|EXPERIMENTAL|Online QPL-CT to Oncologist|Use the online QPL-CT to prioritize their questions and the prioritized list will be conveyed to their oncologist
61985599|NCT02030379|EXPERIMENTAL|Online QPL-CT|Use the online QPL-CT to prioritize their questions.
61985600|NCT02030379|EXPERIMENTAL|Pencil and Paper QPL-CT|Use pencil and paper QPL-CT to prioritize their questions
61985601|NCT02022098|EXPERIMENTAL|Debio 1143|In addition to Cisplatin and Radiotherapy, Debio 1143 in solution form will be administered orally or by feeding tube (while fasting) daily for 14 days every three weeks (on days 1-14, 22-35 and 43-56).
61985602|NCT02022098|PLACEBO_COMPARATOR|Placebo|In addition to Cisplatin and Radiotherapy, matching placebo in solution form will be administered orally or by feeding tube (while fasting) daily for 14 days every three weeks (on days 1-14, 22-35 and 43-56).
62169651|NCT02924181|ACTIVE_COMPARATOR|Rt PV CF guided/lt PV CF blinded|Fifteen patients will be allocated to this group. Right side pulmonary veins isolation will be performed with contact force information guidance. Then, left side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).
62169652|NCT02924181|ACTIVE_COMPARATOR|Rt PV CF blinded/lt PV CF guided|Fifteen patients will be allocated to this group. Right side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter). Then, left side pulmonary veins isolation will be performed with contact force information guidance.
61985603|NCT01020279|OTHER|Parallel Group A|Celecoxib 200 mg (Active Comparator) ; Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)
61985604|NCT01020279|OTHER|Parallel Group B|oral Placebo (Placebo Comparator); Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)
61985605|NCT05851950|EXPERIMENTAL|rumination-focused cognitive behavioural group therapy|1 individual in-take session, 11 sessions of rumination-focused cognitive behavioural group therapy, 1 individual closing session.
61985606|NCT05851950|ACTIVE_COMPARATOR|Treatment as usual|standard OPUS treatment. OPUS treatment is handled by an interdisciplinary OPUS team and consists primarily of medical treatment, psychoeducation, training in symptom management and social skills as well as family discussions. All patients in OPUS have a contact doctor and a contact person who is responsible for coordinating the treatment and collaborating with municipal bodies.
61985607|NCT03822676|EXPERIMENTAL|Stent|Prophylactic pancreatic stent before segmental pancreatic surgery
61985608|NCT03822676|NO_INTERVENTION|No stent|No prophylactic stent before surgery
61985609|NCT05158868||Post covid infected group|normal pregnant women infected by covid during 3rd trimester
61985610|NCT05158868||Control group|normal pregnant women
61985611|NCT05562973|EXPERIMENTAL|Dose Sequence 1 (15, 20, 25)|"Psilocybin dose sequence~Session 1: 15 mg Session 2: 20 mg Session 3: 25 mg"
61985612|NCT05562973|EXPERIMENTAL|Dose Sequence 2 (20, 25, 30)|"Psilocybin dose sequence~Session 1: 20 mg Session 2: 25 mg Session 3: 30 mg"
61985613|NCT05562973|EXPERIMENTAL|Dose Sequence 3 (25, 30, 35)|"Psilocybin dose sequence~Session 1: 25 mg Session 2: 30 mg Session 3: 35 mg"
62363372|NCT02376478||Purine/folic acid analogues|Purine/folic acid analogues: patients with psoriasis or inflammatory bowel diseases receiving monotherapy with purine or folic acid analogues, such as azathioprin, 6-mercaptopurine, or methotrexate
61985614|NCT05562973|EXPERIMENTAL|Dose Sequence 4 (30, 35, 40)|"Psilocybin dose sequence~Session 1: 30 mg Session 2: 35 mg Session 3: 40 mg"
61985615|NCT05562973|EXPERIMENTAL|Dose Sequence 5 (35, 40, 45)|"Psilocybin dose sequence~Session 1: 35 mg Session 2: 40 mg Session 3: 45 mg"
61985616|NCT04919954|EXPERIMENTAL|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 7 doses of tebipenem, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 8 hours following the last dose.
61985617|NCT04919954|ACTIVE_COMPARATOR|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 doses of tebipenem, followed by sampling of interstitial tissue fluid by a microdialysis probe inserted in a thigh over 8 hours following the last dose.
61985618|NCT05548842|EXPERIMENTAL|Combined group|This group takes the combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill for 12 weeks.
61985619|NCT05548842|PLACEBO_COMPARATOR|Placebo group|This group takes placebo for 12 weeks.
62169653|NCT04320810||mNGS diagnosis|Using mNGS to diagnosis infectious disease of this group
62363373|NCT02376478||Combination therapy|Combination therapy: patients with psoriasis or inflammatory bowel diseases receiving combination therapy with TNF-alpha blocker plus purine or folic acid analogues
62363374|NCT02376478||Alternative/no medication|Alternative/no medication: patients with psoriasis or inflammatory bowel diseases receiving alternate therapy, such as phototherapy, fumaric acid, mesalazine, or no medication
62363375|NCT02262676||Rivaroxaban|Patients with Atrial fibrillation treated with Rivaroxaban
62739270|NCT04264520|EXPERIMENTAL|PTSD Psychoeducation + Skills Intervention|
61985620|NCT06340646|NO_INTERVENTION|No Return of Genetic Results|"Participants will undergo germline genomic sequencing as part of consenting to the WU-PE-CGS program.~Participants will be given the option to receive the results from the genomic sequencing. After they consent to the study, the types of results available to them will be explained by research staff. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues. These choices will be presented to them via a discussion with study staff with accompanying paper information"
61985621|NCT06340646|EXPERIMENTAL|Return of Genetic Results|"Participants will undergo germline genomic sequencing as part of consenting to the WU-PE-CGS program.~Participants will be given the option to receive the results from the genomic sequencing. After they consent to the study, the types of results available to them will be explained by research staff. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues. These choices will be presented to them via a discussion with study staff with accompanying paper information"
62363376|NCT06156891|EXPERIMENTAL|Toxicities reduced treatment arm|"Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 70% Partial Response(PR) in HPV-related patients.~Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) combined with concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 70% Partial Response(PR) in HPV-urelated patients."
62363377|NCT06156891|ACTIVE_COMPARATOR|Conventional treatment arm|Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70.4Gy/32Fx) when responses to induction chemotherapy are less than 70% Partial Response (PR) regardless of HPV status.
61985622|NCT06215404|ACTIVE_COMPARATOR|Liberal group|stroke volume variation \< 10%
61985623|NCT06215404|EXPERIMENTAL|restrictive group|stroke volume variation \< 18%
61985624|NCT01887574|EXPERIMENTAL|Open|
62169654|NCT01761474||1. Carbon dioxide insufflation with BPS|Both midazolam (0.05 mg/kg body weight; 1 mg if age\[70 or ASA class III-IV) and fentanyl (50 lg; 25 lg if age\[70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, repeated doses of 10-20 mg propofol were administered to achieve a moderate level of sedation. Maintenance of sedation was also performed with repeated doses of 10-20 mg propofol.
62363378|NCT01489267|NO_INTERVENTION|Control group|Ten patients in the group only receive nerve functional evaluation and electrophysiology examination before and 1,3,6,12 months after recruit. They will not accept cell therapy.
61985625|NCT01166477|ACTIVE_COMPARATOR|Triple therapy|The patients who would be allocated to this arm will continue with their triple therapy treatment, based on any protease inhibitor boosted with ritonavir
61985626|NCT01166477|EXPERIMENTAL|Monotherapy|Those patients allocated to this arm will start to take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
62169655|NCT01761474||2. Carbon dioxide insufflation with Propofol|Sedation was induced by intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age\[70 or ASA class III-IV), followed by repeated doses of 10-20 mg propofol to induce sedation. Repeated doses of 10-20 mg propofol were then administered to maintain adequate sedation, according to the desired sedation depth and patient risk profile.
62169656|NCT01761474||3. Air insufflation with BPS|Both midazolam (0.05 mg/kg body weight; 1 mg if age\[70 or ASA class III-IV) and fentanyl (50 lg; 25 lg if age\[70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, repeated doses of 10-20 mg propofol were administered to achieve a moderate level of sedation. Maintenance of sedation was also performed with repeated doses of 10-20 mg propofol.
62169657|NCT01761474||4. Air insufflation with Propofol|Sedation was induced by intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age\[70 or ASA class III-IV), followed by repeated doses of 10-20 mg propofol to induce sedation. Repeated doses of 10-20 mg propofol were then administered to maintain adequate sedation, according to the desired sedation depth and patient risk profile.
62169658|NCT05330325|EXPERIMENTAL|Somapacitan|Participants will receive Somapacitan for 156 weeks
62169659|NCT05330325|ACTIVE_COMPARATOR|Norditropin®|Participants will receive Norditropin® for 52 weeks (main phase) and Somapacitan for 104 weeks (extension phase)
62169660|NCT06646432|EXPERIMENTAL|Test group: tunnel with connective tissue graft and injectable platelet rich fibrin|Tunneling will be performed at the recession defect sites with insertion of palatal connective tissue graft taken from the patient hard palate inside the prepared tunnel. The graft will be soaked ,before insertion inside the tunnel, in injectable platelet rich fibrin ,prepared from patient own blood for 15 minutes. The tunnel with the soaked graft inside will be advanced coronally.
62363379|NCT01489267|EXPERIMENTAL|Stem cell transplantation|10 patients in the group accept stem cell transplantation.
62363380|NCT01211119|EXPERIMENTAL|platelet-rich fibrin, PRF|
62363381|NCT01526005||Active agent (nicotine patch)|
62363382|NCT01526005||Placebo patch|
62363383|NCT00196807|EXPERIMENTAL|Information plus DA at home|
61985627|NCT05169723|EXPERIMENTAL|Respiratory Activity 1|
61985628|NCT05169723|EXPERIMENTAL|Respiratory Activity 2|
61985629|NCT05169723|EXPERIMENTAL|Respiratory Activity 3|
61985630|NCT05169723|EXPERIMENTAL|Respiratory Activity 4|
61985631|NCT05169723|EXPERIMENTAL|Respiratory Activity 5|
61985632|NCT05734079|ACTIVE_COMPARATOR|Standard of care|Standard of care includes a written paper sheet that summarizes information about the colonoscopy procedure and bowel preparation.
61997252|NCT03179085|EXPERIMENTAL|Home-Based Kidney Care Intervention|All subjects randomized to the HBKC arm will be visited by a CHR in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and participant preference will be incorporated into the HBKC intervention arm by allowing participants to prioritize the order in which curriculum topic areas will be emphasized by the CHRs. Topics from currently available NIDDK and IHS kidney education materials will include: (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
61985633|NCT05734079|EXPERIMENTAL|Standard of care + Video call|The video call will be performed at a designated time with a GE educated nurse. The purpose of the video call is (i) to clarify the patient in person about the colonoscopy procedure (ii) efficiently prepare the patient for bowel preparation by; asking the patient about her/his medical condition, the indication for colonoscopy, medical history, current medical status and medications currently taken. The patient will be inquired, whether she/he went through colonoscopy in the past, what preparation methods were undertaken and what the outcome of the examination was. Based on the information collected during the conversation, the designated nurse performing the interview will tailor the method of bowel preparation for the patient in terms of kind of relaxant, adjustment of medication intake and dietary adjustments before the examination.
61985634|NCT05734079|EXPERIMENTAL|Standard of care + Video call + Educational video film|The video film will explain the colonoscopy procedure and the bowel preparation procedure, in layman's terms and in the patient's preferred language (Hebrew or Arabic).
62169661|NCT06646432|ACTIVE_COMPARATOR|Control group: tunnel with connective tissue graft only|Tunnel preparation will be made in the recession defect sites with insertion of palatal connective tissue graft from the patient hard palate. The tunnel with the graft will be advanced coronally.
62169662|NCT01838447|NO_INTERVENTION|Usual care group|This group will receive daily cholecalciferol (vitamin D3) based on the Adequate Intake (AI) for infants and the Recommended Dietary Allowance (RDA) for children over 1 year. Specific dose amounts are 400 IU per day for infants (0-1 year), and 600 IU per day for children between 1-17 years. Infants under 12 months of age who are formula fed will be given a placebo solution.
62169663|NCT01838447|EXPERIMENTAL|High Dose Group|This group will receive cholecalciferol (vitamin D3) based on the age-specific tolerable daily upper intake level (UL). Specific dose amounts are 1600 IU per day for infants (0-1 year), and 2400 IU per day for children between 1-17 years. Infants under 12 months of age who are formula fed will be given a dose of 1200 IU per day to account for vitamin D in formula.
62169664|NCT02025985|EXPERIMENTAL|Part 1: Cohort A-Ovarian carcinoma: Selinexor up to 60 mg/m^2 BIW|Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 50 milligram per meter square (mg/m\^2) of selinexor oral tablets twice weekly (BIW) (doses at least 36 hours apart) with light meal and 120 milliliters (mL) of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m\^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m\^2 once weekly (QW). This treatment continued until progression of disease (PD) or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
62169665|NCT02025985|EXPERIMENTAL|Part 1: Cohort B-Endometrial carcinoma: Selinexor up to 60 mg/m^2 BIW|Participants with endometrial carcinoma who had received at least one line of chemotherapy for relapsed or advanced (Stage IVb, IIIc) disease received a dose of 50 mg/m\^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m\^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m\^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
62363384|NCT00196807|ACTIVE_COMPARATOR|UC Information at home|
62363385|NCT00196807|EXPERIMENTAL|Information plus decision aid at clinic|
62363386|NCT00196807|ACTIVE_COMPARATOR|UC Information at clinic|
62182334|NCT03866980|PLACEBO_COMPARATOR|Placebo plus Carboplatin and Pemetrexed|Subjects receive placebo intravenously (IV) plus pemetrexed 500 mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV plus pemetrexed 500 mg/m\^2 IV Q3W until progression.
62182335|NCT03866980|EXPERIMENTAL|AK105 plus anlotinib|Subjects receive AK105 200 mg intravenously (IV) plus Anlotinib 12mg/d PO D1-14, Q3W until progression.
62363387|NCT01095666|EXPERIMENTAL|Group 1|
62363388|NCT01095666|EXPERIMENTAL|Group 2|
62363389|NCT01095666|EXPERIMENTAL|Group 3|
62363390|NCT02143323|ACTIVE_COMPARATOR|Glutathione S-Transferase Theta1(GSTT1)/Mu1(GSTM1) wild/wild|Augmentin tablet
62363391|NCT02143323|ACTIVE_COMPARATOR|GSTT1/GSTM1 wild/null type|Augmentin tablet
62363392|NCT02143323|ACTIVE_COMPARATOR|GSTT1/GSTM1 null/wild type|Augmentin tablet
62363393|NCT02143323|ACTIVE_COMPARATOR|GSTT1/GSTM1 null/null type|Augmentin tablet
62363394|NCT01564602|EXPERIMENTAL|single port laparoscopic surgery|2-channel or multiple channel single port laparoscopic surgery in gynecologic disorders
62363395|NCT05146037|ACTIVE_COMPARATOR|Saline flushing|TAVI valves will be prepared according to instruction for use(IFU) with saline flushing only.
61985635|NCT00768144|EXPERIMENTAL|Sunitinib|Patients received oral Sunitinib at the daily dose of 37.5 mg continuously over a 28- day treatment cycle. Treatment continued until clinical or radiological evidence of progressive disease or excessive toxicity.
61985636|NCT04059679|ACTIVE_COMPARATOR|EC aspirin (81mg qd)|
62363396|NCT05146037|EXPERIMENTAL|CO2 and saline flushing|TAVI valves will be flushed with CO2 and then saline as per IFU
62363397|NCT03002740||NVAF patients newly prescribed apixaban|
62363398|NCT03002740||NVAF patients newly prescribed rivaroxaban|
62363399|NCT03002740||NVAF patients newly prescribed dabigatran|
62363400|NCT03002740||NVAF patients newly prescribed VKA|
61985637|NCT04059679|EXPERIMENTAL|EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)|
61985638|NCT00304564|EXPERIMENTAL|geriatric community|Subject will stand on a computerized posturography force plate and stability scores are measured
61985639|NCT01531712|EXPERIMENTAL|QT + QRT|"Chemotherapy (6 cycles x 14 days): Gemcitabine 1000 mg/m2 (day 1) + Oxaliplatin 100 mg/m2 (day 2) + Tarceva 100 mg/day.~Chemoradiotherapy (5,5 weeks): Gemcitabine 40 mg/m2 (2 days/week) + Tarceva 100 mg/day + Radiotherapy (1,8 Gy/day x 28 doses, total dose: 50,4 Gy)."
61985640|NCT01955161|PLACEBO_COMPARATOR|Placebo|Placebo adjunct to 10 mg Donepezil
62363401|NCT03892525|EXPERIMENTAL|treatment|
61985641|NCT01955161|EXPERIMENTAL|Idalopirdine 30 mg|Idalopirdine adjunct to 10 mg Donepezil
61985642|NCT01955161|EXPERIMENTAL|Idalopirdine 60 mg|Idalopirdine adjunct to 10 mg Donepezil
61985643|NCT02364544|OTHER|Health Technology Program|"The components of the treatment model include: 1) Prescriber Decision Assistant (PDA) 2) relapse prevention plan, 3) the daily support website 4) FOCUS, an interactive smart phone text-messaging application 5) a web-based, cognitive-behavioral therapy (CBT) program~All patients will be provided with pharmacological treatment (PDA), brief in-person relapse prevention counseling, and an Android mobile phone. The other program components will be provided to patients using a shared decision-making approach to assess need and preference."
61985644|NCT04652479|EXPERIMENTAL|Avexitide 45 mg twice daily then avexitide 90 mg once daily|Patients will receive one of the two dosing regimens of avexitide for 14 days followed by the other dosing regimen of avextide for 14 days
61985645|NCT04652479|EXPERIMENTAL|Avexitide 45 mg once daily then avexitide 90 mg twice daily|Patients will receive one of the two dosing regimens of avexitide for 14 days followed by the other dosing regimen of avextide for 14 days
61985646|NCT02408393|PLACEBO_COMPARATOR|Placebo|Saline (30 mL maximum)
61985647|NCT02408393|EXPERIMENTAL|Ropivacaine|Ropivacaine 7.5 mg/mL (0.35 mL/kg of solution)
61985648|NCT00775931|ACTIVE_COMPARATOR|marrow graft transplant conditioning|Pre-transplant conditioning using Campath-1H, Busulfan, Fludarabine monophosphate, and total lymphoid irradiation followed by unrelated or matched related donor marrow graft transplantation (both peripheral blood and marrow) and a second CD34 cell infusion on Day 42.
61985649|NCT00775931|ACTIVE_COMPARATOR|cord blood transplant conditioning|Pre-transplant conditioning using Campath-1H, Busulfan and Cyclophosphamide followed by unrelated umbilical cord blood transplantation and a second smaller portion cord blood graft infusion on Day 42.
61985650|NCT05958355|EXPERIMENTAL|Functional postural control training|The training includes (1) Maintaining a stationary posture in a standing position for a total of 10 minutes, (2) Posture control training involving unilateral lower limb stepping movements for a total of 10 minutes, and (3) Advanced walking task training, including sudden stops, turns, ball raises, and obstacle crossing during walking, for a total of 10 minutes.
61985651|NCT05958355|ACTIVE_COMPARATOR|Treadmill training|The subjects in the control group performed a 30-minute walking session on a treadmill at a self-selected speed.
61985652|NCT02032966|EXPERIMENTAL|Nonsurgical|"Randomized to nonsurgical: patient will receive surgical treatment of the inside portion (medial malleolus) of the tibia fracture only; the fibula fracture (and posterior malleolus fracture, if present) will be closed reduced (not repaired surgically)."
61985653|NCT02032966|ACTIVE_COMPARATOR|Surgical|"Randomized to surgical: patient will receive surgical treatment of both the inside portion (medial malleolus) of the tibia fracture, as well as the fibula fracture (lateral malleolus). Fixation of the posterior side of the tibia (posterior malleolus) may or may not be performed based upon intraoperative x-rays."
61985654|NCT02032966|OTHER|syndesmotic injury|"Non-randomized / syndesmotic injury: patients who have a positive ligament stress test (signifying a syndesmotic injury) during surgery will require surgical treatment of both the tibia and the fibula and cannot be randomized to either arm (nonsurgical versus surgical). Patients in this arm will still be included in the study for the collection of clinical and functional outcomes."
61985655|NCT04164615|EXPERIMENTAL|GB221+ Capecitabine tablets|test drug+capecitabine
61985656|NCT04164615|PLACEBO_COMPARATOR|Placebo control + capecitabine tablets|placebo+capecitabine
61985657|NCT00456547||Postpartum hysterectomy|Women that require postpartum hysterectomy for post-delivery bleeding.
62169666|NCT02025985|EXPERIMENTAL|Part 1: Cohort C-Cervical carcinoma: Selinexor up to 60 mg/m^2 BIW|Participants with cervical carcinoma who had received at least one line of chemotherapy for relapsed or advanced (Stage IV) disease received a dose of 50 mg/m\^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m\^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m\^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
62182336|NCT03381469|EXPERIMENTAL|Periodontitis patients undergoing NSPT|Case group participants will receive comprehensive periodontal treatment also known as non-surgical periodontal therapy (NSPT) that will be completed by the end of week 20-21 of gestation.
61985658|NCT00456547||Cesarean delivery case controls|Women that deliver by cesarean that presented with risk factors for bleeding but did not require post delivery hysterectomy
61985659|NCT01998698|ACTIVE_COMPARATOR|Monovision Group|Phacoemulsification surgery with intraocular lens implantation (monovision correction)
61985660|NCT01998698|ACTIVE_COMPARATOR|Multifocal Group|Phacoemulsification surgery with intraocular lens implantation (multifocal lens insertion)
61985661|NCT02081482|EXPERIMENTAL|subjects with refractory chronic cluster headache|Adult subjects with refractory chronic cluster headache and ONS indication
61985662|NCT04984993|EXPERIMENTAL|MED3000|MED3000 gel formulation topically applied to the glans penis
61985663|NCT04984993|EXPERIMENTAL|Tadalafil|Tadalafil (5 mg) tablets to be taken orally
61985664|NCT06063395||Patient undergoing open surgery on the abdominal aorta by laparotomy|
61985665|NCT00994955|EXPERIMENTAL|selective retina therapy (SRT)|Focal laser treatment with an SRT-Laser which selectively affects the retinal pigment epithelium while sparing the photoreceptor layer.
61985666|NCT05270954|ACTIVE_COMPARATOR|Group 1 (Phase 1)|All volunteers randomized to Group 1 will be administered the Betuvax-CoV-2 drug according to the following scheme: 20 μg + 5 μg, twice, within a 28-day period.
61985667|NCT05270954|ACTIVE_COMPARATOR|Group 2 (Phase 1)|All volunteers randomized to Group 2 will be administered the Betuvax-CoV-2 drug according to the following scheme: 20 μg + 20 μg, twice, within a 28-day period.
61985668|NCT05270954|ACTIVE_COMPARATOR|Group 3 (Phase 2)|All volunteers randomized to Group 3 will be administered the Betuvax-CoV-2 drug according to the following scheme: 20 μg + 5 μg, twice, within a 28-day period.
61985669|NCT05270954|ACTIVE_COMPARATOR|Group 4 (Phase 2)|All volunteers randomized to Group 4 will be administered the Betuvax-CoV-2 drug according to the following scheme: 20 μg + 20 μg, twice, within a 28-day period.
61985670|NCT05270954|PLACEBO_COMPARATOR|Group 5 (Phase 2)|Volunteers randomized to Group 5 will be administered a placebo reference drug (0.9% aqueous sodium chloride solution), twice, within a 28-day period.
61985671|NCT04478357|OTHER|Treatment A|4 mg fesoterodine ER tablet manufactured at Zwickau.
61985672|NCT04478357|OTHER|Treatment B|4 mg fesoterodine ER tablet manufactured at Freiburg
61985673|NCT04478357|OTHER|Treatment C|8 mg fesoterodine ER tablet manufactured at Zwickau
61985674|NCT04478357|OTHER|Treatment D|8 mg fesoterodine ER tablet manufactured at Freiburg.
61985675|NCT03626220||acupuncture group|acupuncture with de-chi sensation
61985676|NCT03626220||sham acupuncture group|skin-deep acupuncture without de-chi sensation
61985677|NCT00981955|ACTIVE_COMPARATOR|75mg caffeine|
62363402|NCT00660946||37 dialysis patients|37 chronic hemodialysis patients on warfarin requiring Laboratory INR monitoring for anticoagulation management.
61985678|NCT00981955|ACTIVE_COMPARATOR|50mg l-theanine|
61985679|NCT00981955|ACTIVE_COMPARATOR|75mg caffeine and 50mg l-theanine|
62363403|NCT03508544|ACTIVE_COMPARATOR|Lumbar ESP block|Ultrasound-guided lumbar Erector spinae plane (ESP) block performed at the begining of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
62363404|NCT03508544|ACTIVE_COMPARATOR|QLB Block|Ultrasound-guided transmuscular quadratus lumborum block (QLB) performed at the begining of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
62363405|NCT03508544|SHAM_COMPARATOR|Control|Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
62363406|NCT05135429|EXPERIMENTAL|Bathing group|Newborn bathing will be done by the same nurse for each newborn in the study group. Since the evening hours are thought to be calmer for the baby bath, the hours between 22:00-24:00 will be chosen. Each newborn will be disinfected with only water beforehand and showered in the sinks used to wash the baby in the clinic. Bath time will be limited to two minutes. Newborns will be dried and dressed immediately after bathing. Monitor probes for monitor follow-ups and blood pressure cuffs will be connected to prevent extra touching during measurements.
62363407|NCT05135429|NO_INTERVENTION|control group|Newborns in the control group will not receive any intervention. However, body temperature, pulse, respiration, systolic and diastolic blood pressure, saturation, oxygen demand and N-PASS scores will be evaluated and recorded in accordance with the measurement intervals of the newborns in the study group.
62363408|NCT05381675|EXPERIMENTAL|Intervention|Participants will receive a supervised tele-rehabilitation program 2 days a week for 6 weeks.
62363409|NCT05381675|OTHER|Control|Participants will receive the same rehabilitation program as prescribed.
62363410|NCT06120933|EXPERIMENTAL|Test population|"For the first 8 weeks, each participant will take both the Hair Nutra Growth and Hair Nutra Boost supplements daily.~For the remaining 4 weeks, participants will only take the Hair Nutra Growth supplement."
61985680|NCT00981955|PLACEBO_COMPARATOR|0mg caffeine/l-theanine|
61985681|NCT03679910||Group 1|pancreatic cancer patients (50 patients)
61985682|NCT03679910||Group2|A- Non-pancreatic cancer subjects with benign diseases will be 20 subjects. B- Healthy individuals (control): 20 apparently healthy volunteers after informed consent.
61985683|NCT03084588|ACTIVE_COMPARATOR|Methadone|Patients in the methadone group will receive a single dose of methadone 0.2 mg/kg at induction of anesthesia
61985684|NCT03084588|ACTIVE_COMPARATOR|Interscalene block|Patients in the intersclene block group will receive an interscalene block prior to induction of anesthesia
61985685|NCT04225169|EXPERIMENTAL|Exercises|diaphragmatic breathing exercises
61985686|NCT04225169|NO_INTERVENTION|Control|Patients in the control group received routine patient care consisting of cold therapy
61985687|NCT00783601|EXPERIMENTAL|1|Treatment Sequence 1: MK0524 + placebo, MK0524 + montelukast, placebo, placebo, placebo + montelukast
61985688|NCT00783601|EXPERIMENTAL|2|Treatment sequence 2: Placebo, montelukast, placebo, MK0524, MK0524 + montelukast
61985689|NCT05184114|ACTIVE_COMPARATOR|Recovered COVID-19 patients|Recovered COVID-19 Patients will undergo three CMR examinations. The scans will take place at (i) within 2 weeks of confirmed recovery, (ii) 3 months after recovery and (iii) 1 year after recovery. At time of CMR examinations, patients will have blood tests.
61985690|NCT05184114|EXPERIMENTAL|non-COVID-19 patients with viral respiratory infections|non-COVID-19 Patients will undergo three CMR examinations. The scans will take place at (i) within 2 weeks of confirmed recovery, (ii) 3 months after recovery and (iii) 1 year after recovery. At time of CMR examinations, patients will have blood tests.
61985691|NCT05184114|EXPERIMENTAL|Volunteers as age and gender matched controls.|Volunteer controls will undergo one CMR examination. At time of CMR examinations, patients will have blood tests.
61985692|NCT05184114|EXPERIMENTAL|Volunteers who planning to receive a 2-dose COVID-19 vaccine as vaccination controls|Vaccination controls will undergo two CMR examinations. The scans will take place (i) within 2 weeks before received 1st dose of COVID-19 vaccine and (ii) within 2 weeks (preferably 5-7 days) after receiving the 2nd dose of COVID-19 vaccine. At time of CMR examinations, patients will have blood tests.
61985693|NCT00893087|ACTIVE_COMPARATOR|1|Flow triggering
62363411|NCT04978480||Stroke patients|patients with suspected severe acute stroke
62363412|NCT05054231|EXPERIMENTAL|Patient treated with CAR-T cells|
62363413|NCT04883918|EXPERIMENTAL|ASC930|Experimental Arm
62363414|NCT02098005|ACTIVE_COMPARATOR|Usual care|usual care evidence-based physiotherapy
62363415|NCT02098005|EXPERIMENTAL|modern neuroscience approach|modern neuroscience approach
61985694|NCT00893087|ACTIVE_COMPARATOR|2|Pressure triggering
61985695|NCT00893087|ACTIVE_COMPARATOR|3|NAVA triggering
61985696|NCT01983527|EXPERIMENTAL|Arthrographic distention + intra-articular corticosteroid|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension), 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
61997253|NCT03325907|EXPERIMENTAL|template-guided biopsy|Participants receive transthoracic lung biopsy guided by navigational template.
61985697|NCT01983527|ACTIVE_COMPARATOR|Arthrographic distention|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
62363416|NCT04310865|EXPERIMENTAL|Yinhu Qingwen Granula Group|Based on the standard medical treatment, the patients will be given Yinhu Qingwen Granula for 10 days.
62363417|NCT04310865|PLACEBO_COMPARATOR|Yinhu Qingwen Granula Low-dose Group|Based on the standard medical treatment, the patients will be given 10% dose of Yinhu Qingwen Granula for 10 days.
62363418|NCT02366793|EXPERIMENTAL|Accessory joint mobilization|Humeral head slides, anterior, posterior and caudal slides.
62363419|NCT02366793|EXPERIMENTAL|Nerve mobilization|neural tissue longitudinal slide using the median neurodynamic test 1 (Butler).
62363420|NCT02983513|EXPERIMENTAL|Early Intervention|"The early intervention program is delivered during the NICU stay, according to the MITP and Premie Start Protocol, in order to train parents to: recognize signs of infant stress and alert-available behavior to promote mother-infant interaction; adopt principles of graded stimulation; optimize interactions and avoid overwhelming infants through facilitation strategies (for example, engage and support the visual attention of the newborn). The program is held in eight main sessions and one additional post-discharge session.~In addition parents are trained and invited to daily promote preterm baby massage therapy and visual attention according to a detailed protocol."
62363421|NCT02983513|NO_INTERVENTION|Standard Care|Standard Care according to NICU protocols including Kangaroo Mother Care, nesting and minimal handling
62363422|NCT03245710|EXPERIMENTAL|Zhibai Dihuang powder|Arm: Experimental: Zhibai Dihuang Formula powder Zhibai Dihuang Formula powder: Traditional Chinese medicine formula powder product 5g by mouth, after meal, 3 times in one day for 12 weeks
62363423|NCT03245710|PLACEBO_COMPARATOR|placebos|Arm: placebo Comparator placebos 5g by mouth after meal, 3 times in one day for 12 weeks
62363424|NCT00390429|EXPERIMENTAL|Phase I, Group I (completed)|Patients receive docetaxel IV over 1 hour on day 1 and oral erlotinib hydrochloride once on days 2, 9, and 16. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression. Patients may then continue to receive erlotinib hydrochloride alone in the absence of unacceptable toxicity or disease progression.
62363425|NCT00390429|EXPERIMENTAL|Phase I, Group II (completed)|Patients receive docetaxel as in group I and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression. Patients may then continue to receive erlotinib hydrochloride alone in the absence of unacceptable toxicity or disease progression.
62363426|NCT00390429|EXPERIMENTAL|Phase II|Patients receive docetaxel IV over 1 hour on day 1 and oral erlotinib hydrochloride at the MTD determined in group II of phase I once daily on days 2-16. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may then continue to receive erlotinib hydrochloride alone in the absence of disease progression or unacceptable toxicity.
62363427|NCT01277978||Carbetocin|Women undergoing elective caesarean sectio in regional anesthesia randomised to receive 100 ug Carbetocin (the clinical standard dose) following delivery of the baby.
62363428|NCT01277978||Oxytocin|Women undergoing elective caesarean sectio in regional anesthesia randomised to receive 5 IU oxytocin (the clinical standard dose) following delivery of the baby.
61985698|NCT01983527|ACTIVE_COMPARATOR|Intra-articular corticosteroid|Arthrographic pseudodistention of the glenohumeral joint with injection of 5 ml contrast and 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension).
61985699|NCT04682184|EXPERIMENTAL|Wearable Biosensor Patch Device + Propranolol|Participants will wear the biosensor patch device followed by propranolol administered orally in one of three study periods.
61985700|NCT04682184|EXPERIMENTAL|Wearable Biosensor Patch Device + Pseudoephedrine|Participants will wear the biosensor patch device followed by pseudoephedrine administered orally in one of three study periods.
62363429|NCT04862741|EXPERIMENTAL|NX-13 250mg IR|Oral
62363430|NCT04862741|EXPERIMENTAL|NX-13 500mg IR|Oral
62363431|NCT04862741|EXPERIMENTAL|NX-13 500mg MR|Oral
61985701|NCT04682184|EXPERIMENTAL|Wearable Biosensor Patch Device (Alone)|Participants will wear biosensor patch device (alone) during one of three study periods.
61985702|NCT01366339|EXPERIMENTAL|Arm 1|Oral methylnaltrexone
61985703|NCT01366339|EXPERIMENTAL|Arm 2|Oral methylnaltrexone
62363432|NCT04862741|PLACEBO_COMPARATOR|Placebo|Oral
62363433|NCT01136746|ACTIVE_COMPARATOR|Sliding scale regular insulin|
62363434|NCT01136746|EXPERIMENTAL|Basal-bolus therapy|
62363435|NCT04707378|ACTIVE_COMPARATOR|active left DLPFC navigated-rTMS|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC.
62363436|NCT04707378|SHAM_COMPARATOR|sham left DLPFC navigated-rTMS|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of sham stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (sham) over the left DLPFC.
61985704|NCT01366339|EXPERIMENTAL|Arm 3|Oral methylnaltrexone
61985705|NCT01366339|PLACEBO_COMPARATOR|Arm 4|Oral placebo
61985706|NCT04979169|NO_INTERVENTION|Non-adherent control|Subjects who are determined to be non-adherent to screening guidelines and are assigned to usual treatment via randomization in REDCap.
61985707|NCT04979169|EXPERIMENTAL|Non-adherent intervention|Subjects who are determined to be non-adherent to screening guidelines and are assigned to intervention treatment (text messaging) via randomization in REDCap.
61985708|NCT01798472|EXPERIMENTAL|uncemented hemiarthroplasty|Patients aged 80 or older with displaced femoral neck fracture treated with an uncemented hemiarthroplasty
61985709|NCT01798472|EXPERIMENTAL|reverse hybrid total hip arthroplasty|Patients aged between 65 and 79 years treated with an reverse hybrid arthroplasty.
61985710|NCT01798472|ACTIVE_COMPARATOR|cemented hemiarthroplasty|Patients aged 80 or older with displaced femoral neck fracture treated with an cemented hemiarthroplasty
61985711|NCT01798472|ACTIVE_COMPARATOR|cemented total hip arthroplasty|Patients aged between 65 and 79 years treated with an cemented total hip arthroplasty.
62363437|NCT01085656|EXPERIMENTAL|OXi4503|Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.
62363438|NCT00873145||1|Patients with major bone defects around the elbow.
61985712|NCT06229496|EXPERIMENTAL|GAS regimen-dose level 1|
62363439|NCT04790539|EXPERIMENTAL|SHR-1210+Paclitaxel-albumin+Carboplatin|SHR-1210 was given in the first day of each cycle, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first day of each cycle, with intravenous drip.
61985713|NCT06229496|EXPERIMENTAL|GAS regimen-dose level 2|
61985714|NCT06229496|EXPERIMENTAL|GAS regimen-dose level 3|
61985715|NCT03724812|EXPERIMENTAL|Portico valve and FlexNav™ Delivery System|Portico valve implantation with the second-generation FlexNav Delivery system
62363440|NCT03542149|EXPERIMENTAL|Cohort 1: Treatment Group A: 200mg of OZ439 and 480 mg PQP|200mg of OZ439 and 480 mg PQP. (OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension) and PQP.
62363441|NCT03542149|EXPERIMENTAL|Cohort 1:Treatment Group B: 200mg of OZ439 and 640 mg PQP|"200mg of OZ439 and 640 mg PQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension) and PQP."
62363442|NCT03542149|EXPERIMENTAL|Cohort 1:Treatment Group C: 400mg of OZ439 and 480 mg PQP|"400mg of OZ439 and 480 mg PQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension) and PQP."
62363443|NCT03542149|EXPERIMENTAL|Cohort 1Treatment Group D and Cohort 3 Treatment group A : 400mg of OZ439 and 640 mg PQP|"400mg of OZ439 and 640 mg PQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension) and PQP."
62363444|NCT03542149|EXPERIMENTAL|Cohort 2: Treatment Group A: 800mg of OZ439 and 960 mg PQP|800mg of OZ439 and 960 mg PQP.
62363445|NCT03542149|EXPERIMENTAL|Cohort 2: Treatment Group B: 200mg of OZ439 and 320 mg PQP|200mg of OZ439 and 320 mg PQP.
62363446|NCT03542149|EXPERIMENTAL|Cohort 3: Treatment Group B: 800mg of OZ439 and 640 mg PQP|800mg of OZ439 and 640 mg PQP
62363447|NCT03374761|EXPERIMENTAL|Families First Home Visiting Program|10 group sessions conducted weekly and 4 home visits for the duration of the program. Sessions and visits of the Families First Home Visiting Program cover child development, parenting skills, parent-child communications, and positive discipline practices. The intervention is delivered by para-professional community facilitators, trained in the program.
62363448|NCT03374761|NO_INTERVENTION|Control Group|The control group receives the standard, government run, services provided by community health workers in West Java. Once the evaluation of the intervention arm is completed, participants in the control arm will be offered the intervention.
62363449|NCT04019210|EXPERIMENTAL|MODIFIED TRABECULECTOMY|"Recta-angular scleral flap (one half the scleral thickness) is dissected,reaching 2 mm into the cornea. The dissection through the cornea is carried out with great care, leaving only thin corneal stroma over Descement's membrane.~Application of direct heat cautery using a prob Imm in size (the prob was heated for 45 seconds) the cautery was applied at 4 points two of them just in front of blue corneal line and the other two at 2 mm anterior to the blue line, the diameter of each point is 1 - 1.5 mm."
61985716|NCT01912417|EXPERIMENTAL|Hemodialysis session with exercise|Patients were included in a randomly crossover study design such that each patient received one HD session with exercise (intervention) and the next session without exercise (control), alternating for six consecutive HD sessions.
61985717|NCT01912417|NO_INTERVENTION|hemodialysis session without exercise|Each patient received one hemodialysis session without exercise
61985718|NCT03134482|EXPERIMENTAL|In vitro maturation (IVM)|"hCG primed in vitro maturation (IVM) procedure Gonadotropin is not used in this patient group If the endometrial thickness in 6mm or more and the mean diameter of largest follicle is 11 mm or less on menstrual cycle day 9 to 12 on ultrasonography, oocyte retrieval is planned two days later.~Recombinant hCG injection (priming) is given 36 hour before oocyte retrieval, followed by intracytoplasmic sperm injection (ICSI) for oocyte fertilization.~The biochemical pregnancy is confirmed by serum beta hCG 15 days later oocyte retrieval.~The clinical pregnancy is confirmed when gestational sac is detected by transvaginal ultrasonography 3 weeks later oocyte retrieval."
61985719|NCT03134482|ACTIVE_COMPARATOR|Minimal stimulation IVF|"minimal stimulation IVF procedure These patients are stimulated with 150 or less IU of recombinant Follicle-stimulating hormone (FSH) from menstrual cycle day 3 in GnRH antagonist protocol.~If the mean diameters of two or more follicles are 17mm or more, oocyte retrieval is planned two days later.~Recombinant hCG is triggered 36 hour before oocyte retrieval, followed by intracytoplasmic sperm injection (ICSI) for oocyte fertilization if needed.~The biochemical pregnancy is confirmed by serum beta hCG 14 days later oocyte retrieval.~The clinical pregnancy is confirmed when gestational sac is detected by transvaginal ultrasonography 3 weeks later oocyte retrieval."
61985720|NCT02174068|EXPERIMENTAL|paracetamol|drug interaction between paracetamol and nefopam in healthy volunteers.
62363450|NCT03438513||Problem Solving Therapy|This program is intended for caregivers to acquire techniques to manage stressful situations encountered in everyday life.
61985721|NCT06022120|OTHER|An integrated health literacy intervention|Intervention: A group of students at each school will develop and implement their own project activities at meetings two times during the intervention. Activities are implemented in schools for all students.
62363451|NCT03438513||Speaking group|The group will be led by a psychologist.
61985722|NCT06022120|NO_INTERVENTION|Reference|No intervention activities
62363452|NCT03438513||Standard medical care|Occupational Therapy Assessment Psychological assessment
61985723|NCT03747874|OTHER|past medical history of sudden hearing loss|sleep examination and ventilatory polygraphy device for 1 night
62363453|NCT01391468|PLACEBO_COMPARATOR|Placebo|cornstarch
61985724|NCT00385996|EXPERIMENTAL|Erlotinib|Erlotinib 150mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
62363454|NCT01391468|EXPERIMENTAL|Probiotics|probiotics
62363455|NCT04464577|EXPERIMENTAL|Arm A: BMS-986235+Fluconazole|
62363456|NCT04464577|EXPERIMENTAL|Arm B: BMS-986235+ Bupropion|
62363457|NCT04464577|EXPERIMENTAL|Arm C: BMS-986235+ Itraconazole|
61997254|NCT04213456|EXPERIMENTAL|Nutritional supplementation|Powder added to water,high protein and multi vitamin and minerals
61985725|NCT02659709||Glaucoma Patients and Caregivers|Glaucoma patients and caregivers will complete a 20 item questionnaire providing demographic information, glaucoma eye drop compliance, interest in medication reminders, availability to smartphone, tablet and social media technology and interest in using a glaucoma application on social media.
61985726|NCT04179695|EXPERIMENTAL|consultation with Parkinsun|
62363458|NCT02017704|ACTIVE_COMPARATOR|IMRT and Capecitabine|"Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications~Followed by:~* Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~* 5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions~* 5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus~Cycle length: 14 days (2 weeks)~Duration of treatment: 12 cycles~Then: Surgical Resection"
62363459|NCT02017704|EXPERIMENTAL|Endo-HDR|"Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy~Followed by:~* Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~* 5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions~* 5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus~Cycle length: 14 days (2 weeks)~Duration of treatment: 12 cycles~Then: Surgical Resection"
61985727|NCT04179695|ACTIVE_COMPARATOR|consultation as usual without Parkinsun|
62363460|NCT01671891||rectal cancer with stage II-IV|rectal cancer with stage II-IV intervention: pelvic radiotherapy (45-55Gy) concurrent chemotherapy using capecitabine and oxaliplatin
62363461|NCT04955509||Training|random splitting based on random sequences generated by engineers to train and optimize a machine learning model
61985728|NCT04248608|EXPERIMENTAL|erector spinae block|Ultrasound guided erector spinae block with will be done after induction of intravenous anesthesia. After identification of trapezius, rhomboid major, and erector spinae muscles. The needle will be inserted in a cephalad-to-caudal direction until the tip contact transverse process and the needle tip is visualized in the plane deep to the erector spinae muscle. The needle tip position is confirmed by visualizing linear spread of test dose between the muscles after injection. A total dose of 25 mL of 0.25% bupivacaine will be injected.
61985729|NCT04248608|EXPERIMENTAL|serratus anterior block|Ultrasound guided serratus anterior block will be done after induction of intravenous anesthesia. The serratus anterior, latissimus dorsi, and the intercostal muscles will be identified in the fourth and fifth intercostal level, an 18 G Tuohy needle will be advanced in the plane between the serratus anterior muscle and the intercostal muscles. A total dose of bupivacaine 25ml in a concentration of 0.25% will be administered under the serratus muscle after a test dose using an in-plane technique.
61985730|NCT04248608|ACTIVE_COMPARATOR|intravenous morphine|intravenous morphine will be administrated in a dose of 0.1 mg per kg after induction of general anesthesia
62363462|NCT04955509||Testing|random splitting based on random sequences generated by engineers to evaluate the performance of the model
61985731|NCT05069766|EXPERIMENTAL|BioXmark™|
62363463|NCT05051033|ACTIVE_COMPARATOR|Surgical mitral valve repair|Patients who are randomized to the surgical arm will undergo mitral surgery.
62363464|NCT05051033|ACTIVE_COMPARATOR|Transcatheter edge-to-edge repair|In the transcatheter edge-to-edge repair arm, patients will be treated with a commercially-approved edge-to-edge mitral repair device.
62363465|NCT04419662|EXPERIMENTAL|All patients included|
62363466|NCT03186872|NO_INTERVENTION|Care as usual|Participants randomized to this group will continue to see the IBD medical home team as usual
61985732|NCT02248350|EXPERIMENTAL|Exercise Group|8-weeks of supervised and home based exercise intervention, 3 times a week, 50-minutes a session for a total of 150/minutes a week
61985733|NCT02248350|ACTIVE_COMPARATOR|Stretching Control group|Informational booklet containing stretching exercises (20-minutes a day)
62363467|NCT03186872|EXPERIMENTAL|Digital behavioral program app|Participants randomized to this group will see the IBD medical home team and will utilize the cognitive behavioral app as the intervention.
62363468|NCT01634113|EXPERIMENTAL|tiotropium low dose|Once daily, delivered with Respimat® inhaler
62363469|NCT01634113|EXPERIMENTAL|tiotropium high dose|Once daily, delivered with Respimat® inhaler
62363470|NCT01634113|PLACEBO_COMPARATOR|placebo|Once daily, delivered with Respimat® inhaler
62363471|NCT03464890|EXPERIMENTAL|LICHTENA DermAD|"Comparison within subjects of P926 - LICHTENA DermAD CREMA VISO and P927 - LICHTENA DermAD CREMA CORPO versus placebo and versus untreated control area. Study products were applied once, on experimentally induced erythema by repeated tape stripping on 4 different adjacent skin areas of the forearms (volar surface - 2 areas on each side)"
61985734|NCT05880927|EXPERIMENTAL|Pyrotinib 400mg/day|High risk HER2 positive patients receive pyrotinib 400mg/day for half or one year
61985735|NCT04846803|EXPERIMENTAL|Patients prophylatic treated with ABU|Patients with prophylactic bladder flushing with an ABU strain.
61985736|NCT04846803|PLACEBO_COMPARATOR|Patients control group|The control group with bladder flushing with saline solution.
61985737|NCT02009046|EXPERIMENTAL|SEI Classroom Curriculum|Participants receive the SEI classroom curriculum.
61985738|NCT02009046|ACTIVE_COMPARATOR|Control Classroom Curriculum|Participants receive the control classroom curriculum.
61985739|NCT02009046|EXPERIMENTAL|SEI Curriculum + 3 School Components|Participants receive SEI classroom curriculum and three school wide components (peer advocacy and education, parent education, clinical services linkages).
61985740|NCT02009046|ACTIVE_COMPARATOR|Control Curriculum + 1 School Component|Participants receive control classroom curriculum and one of the three school wide components (clinical services linkages).
61985741|NCT01466387|ACTIVE_COMPARATOR|TF+YF|Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.
61985742|NCT01466387|ACTIVE_COMPARATOR|TF + YF + MenACWY-CRM197|Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.
61985743|NCT01466387|ACTIVE_COMPARATOR|JE + Rabies|Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies vaccine.
62363472|NCT04306757|EXPERIMENTAL|FCV|Artificial ventilation will be performed with individualized flow-controlled ventilation (Evone, Ventinova Medical B.V., Eindhoven, the Netherlands) during cardiac surgery until admission to postoperative ICU. Individualisation will be established by compliance guided end-expiratory and peak pressure setting, flow setting will be adjusted to secure normocapnia and I:E Ratio set to 1:1.
61985744|NCT01466387|ACTIVE_COMPARATOR|JE + Rab + MenACWY-CRM197|Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.
61985745|NCT01466387|ACTIVE_COMPARATOR|Rabies|Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine.
62363473|NCT04306757|ACTIVE_COMPARATOR|PCV|Artificial ventilation will be performed with low tidal volume pressure-controlled ventilation (Primus, Dräger, Lübeck, Germany) during cardiac surgery until admission to postoperative ICU. Peak pressure will be set to achieve a tidal volume of 7ml/kg predicted body weight at a compliance titrated positive end-expiratory pressure. Respiratory rate will be set to maintain normocapnia and I:E ratio set to 1:1.5 except extension of expiration is necessary in order to avoid air trapping.
62363474|NCT05097170||1|patients under the age of 65
61985746|NCT01466387|ACTIVE_COMPARATOR|MenACWY-CRM197 (Combined)|Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.
61985747|NCT01405963|PLACEBO_COMPARATOR|Placebo|Participants received placebo to tezepelumab administered by intravenous infusion on study days 1, 29, and 57.
62363475|NCT05097170||2|patients above the age of 65
62363476|NCT02178163|EXPERIMENTAL|Ancillary-Correlative (comprehensive genomic analysis)|Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray. Based on the results of the genomic analysis, patients may begin therapy.
62363477|NCT04425798||Patients with LEV application|LGG patients with GRE take levetiracetam less than 1 month preoperatively. These patients take levetiracetam tablets twice a day, and one tablet at a time. Each levetiracetam tablet contains 500mg levetiracetam.
62363478|NCT04425798||Patients without LEV application|LGG patients with GRE do not take any medicine or receive any treatment preoperatively.
62363479|NCT04799704||symptomatic patient|The first part of our study is to confirm the detectability of the SARS-nCoV-2 in the tear film of symptomatic patients.
62363480|NCT04506944||General population|Whole population of scrub typhus endemic villages
62363481|NCT04506944||hospital case population|cases recruited at study clinics who are not enrolled in general population cohort
62363482|NCT04506944||Serological cohort|random subset of 4000 participants above the age of 10 drawn from general population cohort
61985748|NCT01405963|EXPERIMENTAL|Tezepelumab 700 mg|Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57.
61985749|NCT05447754|EXPERIMENTAL|Combined RAGT and TBT|Participants will be treated with Lokomat for 40 minutes, twice a week for 5 weeks, and RAGT with a body weight support system and combined TBT for 40 minutes each session 3 times a week. During RAGT, 30-40% of each participant's body weight will be taken with the body weight support system. In patients without drop foot and knee instability in the sessions after the first session, the body weight will be reduced by 10% and progression will be achieved. The speed of the treadmill will be adjusted between 1.2-2.6 km/h and the maximum speed tolerated by the patient will be reached during the sessions. TBT exercises 3 times a week for 40 minutes (weight transfer to the paretic leg during sitting and standing, weight transfer during sitting and standing with or without an assistive device) will be personalized according to the patient. Progression of exercises will be provided by adding upper extremity and trunk activities in addition to exercises.
61985750|NCT05447754|ACTIVE_COMPARATOR|TBT Only|Participants were given balance exercises (weight transfer to the paretic leg during sitting and standing, weight transfer during sitting and standing without an assistive device, walking on a flat surface to the forward and sideways) for 5 weeks, 5 times a week and for 40 minutes in each session. lying down while sitting and standing) will be applied.
61985751|NCT02232425|EXPERIMENTAL|Drug: IX-01|Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
62363483|NCT00005945|EXPERIMENTAL|Induction Not Randomized|Standard Induction (28 Days). M3 Marrow at Day 28 and Off Protocol Therapy.
61985752|NCT02232425|PLACEBO_COMPARATOR|Placebo|Two to four capsules administered orally, 1-6 hours prior to sexual activity
62363484|NCT00005945|EXPERIMENTAL|Induction and Oral MTX, Double Delayed Intensification CNS|Patients with CNS disease at diagnosis, without other unfavorable characteristics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Cranial radiation therapy during the Consolidation phase.
61985753|NCT04748133|ACTIVE_COMPARATOR|acupuncture|"Patients in the acupuncture group will receive a standardised treatment with 12 needles (sharp tip, stainless steel needles, size 0.3 X 40 mm) at 7 acupuncture points Du 26 and Ren 17 (on the middle body line), and bilateral LI 4, HE 7, LV 3, ST 36 and PC 6). Application of the needles is performed by a licensed medical acupuncturist.~The needles will be inserted after endotracheal intubation and mechanical ventilation and will be removed immediately before patient extubation."
61985754|NCT04748133|PLACEBO_COMPARATOR|placebo|no treatment
61985755|NCT03721315|NO_INTERVENTION|Control|This group will receive the standard of care for this condition.
61985756|NCT03721315|EXPERIMENTAL|Intervention|This group will receive additional education along with their designated health support person prior to hospital discharge. This intervention does not include drugs/or devices.
61985757|NCT00708539|ACTIVE_COMPARATOR|1|Crinone vaginal gel 8% 90 mg once daily
61985758|NCT00708539|ACTIVE_COMPARATOR|2|Progesterone mic 400 mg three times daily
61985759|NCT03585179|EXPERIMENTAL|Oral tranexamic acid|250 mg of tranexamic acid bid orally
61985760|NCT03585179|EXPERIMENTAL|Topical tranexamic acid|5% topical tranexamic acid bid
62363485|NCT00005945|EXPERIMENTAL|Induction and Augmented regimen (IV MTX, Double DI)|Patients with unfavorable characteristics. Standard Induction (14 Days), Augmented Induction (Days 14-35), Consolidation (9 weeks), Interim Maintenance I (56 Days), Delayed Intensification I (2 months), Interim Maintenance II (2 months), Delayed Intensification II (2 months), then Maintenance (84 day courses).
62363486|NCT00005945|EXPERIMENTAL|Induction and Oral MTX, Single Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months) then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
62363487|NCT00005945|EXPERIMENTAL|Induction and Oral MTX, Double Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
61985761|NCT03585179|ACTIVE_COMPARATOR|Topical hydroquinone|4% hydroquinone once daily at night
62363488|NCT00005945|EXPERIMENTAL|Induction and IV MTX, Single Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months) then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
62363489|NCT00005945|EXPERIMENTAL|Induction and IV MTX, Double Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in event free remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
61985762|NCT02430675|EXPERIMENTAL|Group A|irreversible electroporation for Unresectable Laryngeal Neoplasms
61985763|NCT02430675|NO_INTERVENTION|Control|The patients without treatment
61985764|NCT04212260|EXPERIMENTAL|Oro-pharyngeal exercises|Use of oro-pharyngeal exercises
62363490|NCT02923050|NO_INTERVENTION|Waitlist control|
61985765|NCT04212260|SHAM_COMPARATOR|Sham control|Use of sham exercises.
62363491|NCT02923050|EXPERIMENTAL|10-week family meals program|
62363492|NCT06380348|EXPERIMENTAL|JMT101 combined with Osimertinib|
62363493|NCT06380348|ACTIVE_COMPARATOR|Cisplatin combined with pemetrexed|Participants randomized into chemotherapy arm can receive up to 4 cycles of pemetrexed + cisplatin (pemetrexed 500 mg/m\^2 + cisplatin 75mg/m\^2, IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
62363494|NCT01781663|EXPERIMENTAL|KAM2904 Face Cream and KAM3008 Body Lotion|A group treated with KAM2904 Face Cream and KAM3008 Body Lotion
61985766|NCT03144674|EXPERIMENTAL|Cohort 1- Closed to Further enrollment|Participants who have received prior ibrutinib.
61985767|NCT03144674|EXPERIMENTAL|Cohort 2|Participants who have not received a prior BTK inhibitor.
61985768|NCT00914355|EXPERIMENTAL|SBRT for Hepatocellular Carcinoma|
61985769|NCT02423538|EXPERIMENTAL|single ascending doses|single ascending doses, oral tablets
61985770|NCT02423538|PLACEBO_COMPARATOR|Placebo|Placebo Comparator, oral tablets
61985771|NCT04898257|OTHER|Lactibiane Tolerance®|30 consecutive patients with IBS-D and an increased intestinal permeability assessed by 51Cr-EDTA or 99mTc-DTPA will receive the multistrain probiotic Lactibiane Tolerance® 10 billion CFU 1 capsule twice a day (30 minutes before breakfast and 30 minutes before dinner) for 30 days treatment. At the end of treatment, patients will repeat intestinal permeability assessment by 51Cr-EDTA or 99mTc-DTPA.
61985772|NCT04267133|EXPERIMENTAL|All Participants|
61985773|NCT06200727|EXPERIMENTAL|PRF membrane in macular hole|To observe the healing and visual recovery of a macular hole, the macular hole was filled with a PRF membrane. Before the participant went into the operating theatre, a blood sample was taken from the anterior elbow vein using a 5 ml tube without anticoagulants. The middle layer of blood after centrifugation was PRF. After retrobulbar anesthesia and removal of the posterior vitreous cortex. In the PRF group, PRF membrane was utilized to fill the macular hole after the ILM was peeled. Then the eyeball was filled with sterile air after adequate air-liquid exchange. At the end of the operation, tobramycin dexamethasone ophthalmic ointment was applied to the operated eye with pressure, and the participant was instructed to maintain a prone position for 7 days after the operation.
61985774|NCT06200727|ACTIVE_COMPARATOR|Internal limmiting membrane(ILM) peeling in macular hole|"After retrobulbar anesthesia and removal of the posterior vitreous cortex, the control group underwent the procedure of peeling the ILM. The ILM was completely removed from the retina. Then the eyeballs were filled with sterile air after adequate air-liquid exchange.~At the end of the operation, tobramycin dexamethasone ophthalmic ointment was applied to the operated eye with pressure, and the participant was instructed to maintain a prone position for 7 days after the operation."
61985775|NCT06200727|EXPERIMENTAL|PRF membrane transplantation in pterygium|Following the removal of the pterygium, the prepared PRF was cut to match the size of the exposed scleral surface. It was then placed on the sclera and secured to the surrounding conjunctiva using 3-7 interrupted sutures of 10-0 nylon thread. This was done to ensure that the PRF implant was perfectly aligned with the conjunctiva.
61997255|NCT04213456|PLACEBO_COMPARATOR|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals.
61997256|NCT05281614|EXPERIMENTAL|Arm A|Arm A will receive 6 weeks of vedolizumab after 8 weeks of etanercept. Final study visit at 52 weeks.
61997257|NCT05281614|EXPERIMENTAL|Arm B|Arm B will receive 6 weeks of vedolizumab only. Final study visit at 52 weeks.
62363495|NCT01781663|SHAM_COMPARATOR|petrolatum-based moisturizer|control group
62363496|NCT04804904|EXPERIMENTAL|TQ-B3101: Fed + Fast|In each of the two study periods (separated by a washout period),a single dose of TQ-B3101 will be administered.Participants will receive TQ-B3101 in fed condition on Day 1 of treatment period 1 followed by a single oral dose of TQ-B3101 in fasted condition on Day 1 of treatment period 2.
61985776|NCT06200727|ACTIVE_COMPARATOR|Autologous conjunctival transplantation in pterygium|After the pterygium removal surgery, to restore the eye, participants need to undergo a corneal limbal stem cell transplant. The transplanted stem cells should be the same size as the exposed scleral surface above the temporal part of the eye. When transferring the transplant, ensured that the corneal edge of the grafted conjunctival flap was positioned opposite to the cornea. Closed the flap to the peripheral conjunctiva with 3-7 interrupted sutures using 10-0 nylon thread. Fixed the conjunctival flap to the surrounding conjunctiva with sutures, and covered the sclera with the surrounding bulbar conjunctiva.
61985777|NCT06200727|EXPERIMENTAL|PRF membrane transplantation in trabeculectomy for glaucoma|The surgical procedure involved the creation of a scleral flap and conjunctiva in the usual manner. The subflap tissue was rinsed with balanced saline and then a small piece of tissue (measuring 1.5mm x 2mm) was removed from the inferior trabecular tissue of the scleral flap. In the corresponding position, peripheral iris excision was performed and the iris was rinsed to remove lost pigment in the vicinity of the incision. Once the orientation was verified, the PRF membrane was placed under the scleral flap.
61985778|NCT06200727|ACTIVE_COMPARATOR|Amniotic membrane in trabeculectomy for glaucoma|The surgical procedure began with creating the scleral flap and conjunctiva in the usual manner. The sub flap tissue was then rinsed with balanced saline, and a piece of tissue measuring 1.5mm x 2mm was excised from the inferior trabecular tissue of the scleral flap. Next, peripheral iris excision was performed in the corresponding position and the iris was rinsed to remove pigment in the vicinity of the incision. To control the tension of the sutures, the amniotic membrane was placed under the scleral flap, followed by meticulous suturing of the conjunctival flap.
61985779|NCT06200727|EXPERIMENTAL|PRF membrane transplantation in corneal ulcer|The necrotic tissue of the corneal ulcer was cleared to expose the local fresh tissue, and the PRF group prepared PRF membrane and covered the surface of the test eye, and the autologous PRF membrane was continuously sutured to the corresponding surrounding tissues using 10-0 absorbable sutures so that the PRF membrane covered the entire portion of the lesion and was able to be anchored to it.
61985780|NCT06200727|ACTIVE_COMPARATOR|Amniotic membrane in corneal ulcer|The necrotic tissue of the corneal ulcer was removed to reveal the fresh tissue in the area. After that, the excess amniotic membrane was carefully extracted and placed over the affected eye's surface. The membrane was then attached securely to the surrounding tissue using 10-0 absorbable sutures, covering the entire lesion and holding it in place for proper healing.
61985781|NCT00605813||Sertraline hydrochloride.|Patients taking Sertraline hydrochloride.
61985782|NCT01682902|EXPERIMENTAL|Formulation 1|
61985783|NCT01682902|EXPERIMENTAL|Formulation 2|
61985784|NCT01682902|ACTIVE_COMPARATOR|Insulin aspart (NovoLog®)|
61985785|NCT04726345|EXPERIMENTAL|Fexofenadine|Participants in this arm will receive fexofenadine 180mg once daily, in addition to standard of care pain medications (NSAIDs).
61985786|NCT04726345|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive placebo once daily, in addition to standard of care pain medications (NSAIDs).
61985787|NCT01057017|EXPERIMENTAL|intervention|"Bevacizumab: 7.5mg/kg, IV over 30-90 minutes every 3 weeks until disease progression.~Panitumumab Dose Level 1: 6mg/kg over 60-120 minutes every 3 weeks until disease progression Dose Level 2: 9mg/kg over 60-120 minutes every 3 weeks until disease progression"
61985788|NCT03238638|EXPERIMENTAL|Acquired Resistance Cohort and Suboptimal Benefit Cohort|"Patients will be divided into two cohorts. Investigators anticipate 15 patients per cohort.~Cohort 1: Acquired Resistance Cohort~* Treat upon emergence of acquire resistance~* Prior benefit from an9-PD-1/PD-L1 therapy defined as a. preior response, and/or b. greater than or equal to 5 months of stable disease~* Progressive disease on recent scans~* Intercurrent therapy is allowed~Cohort 2: Suboptimal Benefit Cohort~* Treat subop. mal response/benefit, BEFORE emergence of acquired resistance~* Prolonged stable disease greater than or equal to 5 months OR Subop9mal response (greater than 10% and less than 50%)~* Ongoing stable disease on recent scans~Both cohorts will receive pembrolizumab and epacadostat."
61985789|NCT02182531|EXPERIMENTAL|Epinastine and Pseudoephedrine combination|
61985790|NCT02182531|ACTIVE_COMPARATOR|Epinastine|
61985791|NCT02182531|ACTIVE_COMPARATOR|Pseudoephedrine|
61985792|NCT02064166|EXPERIMENTAL|Insulin|40 IU of intranasal insulin daily
61985793|NCT02064166|PLACEBO_COMPARATOR|Placebo|Placebo arm using intranasal normal saline
61985794|NCT03329495|ACTIVE_COMPARATOR|SMA-orientated right hemicoloectomy|SMA-orientated right hemicoloectomy
61985795|NCT03329495|EXPERIMENTAL|SMV-orientated right hemicoloectomy|SMV-orientated right hemicoloectomy
61985796|NCT01393808|EXPERIMENTAL|Paricalcitol|
61985797|NCT01393808|PLACEBO_COMPARATOR|placebo|
61985798|NCT00478985|EXPERIMENTAL|1|Imatinib treatment ending
61985799|NCT03613935|PLACEBO_COMPARATOR|Product 1|Normal glucose, isosweet, homogeneous: 43 g glucose beverage, with a 43 g glucose equivalent sweetness homogenously delivered
61985800|NCT03613935|ACTIVE_COMPARATOR|Product 2|Low glucose, isosweet, heterogeneous: 30 g glucose beverage with 43 g glucose equivalent sweetness heterogeneously delivered
61985801|NCT03613935|ACTIVE_COMPARATOR|Product 3|Low glucose, less sweet, homogeneous: 30 g glucose beverage with a 30 g glucose equivalent sweetness homogenously delivered
61985802|NCT03613935|ACTIVE_COMPARATOR|Product 4|Low glucose+sucralose, isosweet, homogeneous: 30 g glucose + 18 mg sucralose beverage with a 43 g glucose equivalent sweetness homogenously delivered
61985803|NCT03515772||Amlodipine with Dolutegravir|"This is the control group regarding HIV drug interaction potential on amlodipine"
61985804|NCT03515772||Amlodipine with Darunavir|"This is the case group regarding HIV drug interaction potential on amlodipine"
61985805|NCT03515772||Atorvastatin with Dolutegravir|"This is the control group regarding HIV drug interaction potential on atorvastatin"
61985806|NCT03515772||Atorvastatin with Darunavir|"This is the case group regarding HIV drug interaction potential on atorvastatin"
61985807|NCT03515772||Rosuvastatin with Dolutegravir|"This is the control group regarding HIV drug interaction potential on rosuvastatin"
61985808|NCT03515772||Rosuvastatin with Darunavir|"This is the case group regarding HIV drug interaction potential on rosuvastatin"
61985809|NCT01304914||Healthy, term-delivered babies|
61997258|NCT01334658|ACTIVE_COMPARATOR|Balanced Salt Solution (BSS®)|Subjects who received Balanced Salt Solution.
61997259|NCT01334658|ACTIVE_COMPARATOR|Glucose-bicarbonate-Ringer Lactate (GBRL)|Subjects who received glucose-bicarbonate-Ringer Lactate.
61985810|NCT05799807|ACTIVE_COMPARATOR|Cohort 1 - Conservative|Negative weight-bearing CT (≤ 2mm between C1-M2, as opposed to the uninjured side) will be considered stable and treated conservatively with a prefabricated walker with weight-bearing as tolerated for six weeks. These patients will undergo bilateral radiographs after six weeks and combined CT and radiographs after twelve weeks to monitor the degree of stability
61985811|NCT05799807|ACTIVE_COMPARATOR|Cohort 2 - Surgical|Positive weight-bearing CT (\> 2mm between C1-M2, as opposed to the uninjured side) will be operated by minimally invasive stabilization (eg, isolated homerun screw)
61985812|NCT01277952|EXPERIMENTAL|DBS Surgery|Deep brain stimulation (DBS) will be the treatment option in this study along with behavioral interventions for participants with severe disability due to Traumatic Brain Injury (TBI) 24 months post their injury, the participants will have severe disabilities in behavioral and emotional self-regulation, cognitive impairments and somatic symptoms.
61985813|NCT05338892||Cohort 1|Participants with r/r DLBCL who were treated with at least 2 prior systemic therapies in the real-world setting
61985814|NCT06490029||A:Previously exposed to CISPLATIN with significant ATL damage|Groupe A
62363497|NCT04804904|EXPERIMENTAL|TQ-B3101: Fast+Fed|In each of the two study periods (separated by a washout period),a single dose of TQ-B3101 will be administered.Participants will receive TQ-B3101 in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of TQ-B3101 in fed condition on Day 1 of treatment period 2.
62363498|NCT04315597|EXPERIMENTAL|Hypericum extract STW 3-VI (Laif® 900, BAY98-7108)|
62363499|NCT04315597|PLACEBO_COMPARATOR|Placebo|
62363500|NCT05839639|ACTIVE_COMPARATOR|NrtIs|
62363501|NCT05839639|EXPERIMENTAL|HH-003|
62363502|NCT05839639|EXPERIMENTAL|HH-003+NrtIs|
62363503|NCT05616039|ACTIVE_COMPARATOR|Control Group (Standard liver surgery)|In this group, tumour/s, resection margin identification, and the type and number of liver resections will be based on naked eye examination, palpation, and intraoperative ultrasound. All the intra-operative findings will be recorded on a pre-designed proforma, and these details include the type of surgical approach (open, laparoscopic, and hand-assisted), if it is an open operation the type of incision, the location, number and size of tumour/s, relationship of the tumour/s to inflow and outflow of the liver, duration of surgery, and estimated blood loss. Post-operatively histology of the resected specimen including resection margin status will be recorded.
62363504|NCT05616039|EXPERIMENTAL|Intervention Group (I-FIGS)|Patients will receive intravenous indocyanine green(ICG) injection (0.03-0.05mg/kg) 2-4 hours before surgery. ICG comes in crystal form in 25mg dose. It will be diluted with 25ml of water, and the required dose as per the weight of the patient will be prepared freshly and given at least 2-4 hours before surgery. The surgical planning will be carried out as per the standard approach using the naked eye and IOUS. As for standard surgery, all intra-operative findings will be recorded on the proforma that contains the details that need to be collected. Once this is all recorded, ICG cameras will be switched on, and the additional findings (additional lesions detected, additional resections carried out) and change to surgical plan (change to the line of parenchymal transection) will be noted. Post-operatively histology of the resected specimen including resection margin status will be recorded.
61985815|NCT06490029||A:Previously exposed to CISPLATIN without significant ATL damage|Groupe A
61985816|NCT06490029||A:Previously exposed to cochlear RADIOTHERAPY with significant ATL damage|Groupe A
61985817|NCT06490029||A:Previously exposed to cochlear RADIOTHERAPY WITHOUT significant ATL damage|Groupe A
61985818|NCT06490029||A:Previously exposed to cochlear RADIOTHERAPY & CISPLATIN with significant ATL damage|Groupe A
61985819|NCT06490029||A:Previously exposed to cochlear RADIOTHERAPY & CISPLATIN WITHOUT significant ATL damage|Groupe A
61985820|NCT06490029||A:Previously exposed to OXALIPLATIN|Groupe A
61985821|NCT06490029||A:Previously exposed to CARBOPLATIN|Groupe A
61985822|NCT06490029||A:Previously exposed to TAXANES|Groupe A
61985823|NCT06490029||A:Previously exposed to VINCALCALOIDS|Groupe A
61985824|NCT06490029||A:Previously exposed to other neurotoxicant|Groupe A
62363505|NCT01810380|PLACEBO_COMPARATOR|Placebo|
62363506|NCT01810380|EXPERIMENTAL|Brexpiprazole|Patients randomised to brexpiprazole received 1mg/day on Day 1, 2mg/day on Day 2, 3mg/day on Day 3 (uptitration); the dose could be adjusted from Day 4 onwards to 2, 3, or 4mg/day to optimise the clinical effect and tolerability.
61985825|NCT06490029||B:Patients cured of cancer without ototoxic or neurotoxic exposure|Groupe B
61985826|NCT06490029||B:Companions without ototoxic or neurotoxic exposure|Groupe B
61985827|NCT06490029||A:Hyperacusic patients following cancer treatment|Groupe A
61985828|NCT06490029||A:Tinnitus patients following cancer treatment|Groupe A
61985829|NCT06490029||A:Patients with vestibular disorders following cancer treatment|Groupe A
61985830|NCT06490029||C:Patients with an indication for CISPLATIN recruited prior to any treatment|Groupe C
61985831|NCT06490029||C:Patients indicated for cochlear radiotherapy and recruited prior to treatmen|Groupe C
61985832|NCT06490029||C:Patients with indication for CISPLATIN and cochlear radiotherapy recruited prior any treatment|Groupe C
61985833|NCT06490029||C:Patients with an indication for OXALIPLATIN treatment recruited prior to any treatment|Groupe C
61985834|NCT06490029||C:Patients with indication for CARBOPLATIN recruited prior to any treatment|Groupe C
61985835|NCT06490029||C:Patients with indication for TAXANES therapy recruited prior to any treatment|Groupe C
61985836|NCT06490029||C:Patients with indication for VINCALCALOIDES or other neurotoxicant|Groupe C
61985837|NCT00941044|EXPERIMENTAL|non-invasive NAVA|application of non-invasive neurally adjusted ventilatory assist in healthy volunteers
61985838|NCT03069495||Healthy Control Adult Subjects|Healthy adult subjects between the ages of 19-50 years will be enrolled.
61985839|NCT03069495||Asthmatic Adult Subjects|Adult subjects between the ages of 19-50 years with mild-to-moderate asthma seen within the UNMC Allergy and Pulmonary Clinics will be invited to be enrolled.
61985840|NCT03069495||Chronic Urticaria Adult Subjects|Adult subjects between the ages of 19-50 years with chronic urticaria seen within the UNMC Allergy Clinics will be invited to be enrolled.
61985841|NCT01640483|ACTIVE_COMPARATOR|supportive|
61985842|NCT01640483|ACTIVE_COMPARATOR|interpretative|
61985843|NCT01640483|ACTIVE_COMPARATOR|mixed supportive/interpretative|
61985844|NCT01801150|NO_INTERVENTION|lifestyle and diabetes treatment|Counseil about lifestyle and current diabetes treatment
61985845|NCT01801150|EXPERIMENTAL|CPAP nasal treatment|Continuous positive airway pressure (CPAP) nasal during the night and current diabetes treatment. Device
61985846|NCT05264545|OTHER|Single Arm|There are no arms in the study, it is a non randomized, controlled study
61985847|NCT02154191|EXPERIMENTAL|Surgical Intervention Group|The Surgical Intervention Group will undergo the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
61985848|NCT02154191|NO_INTERVENTION|Non-Intervention Group (Control)|No Intervention.This group will consist of patients wait listed for surgery but further back in the queue.
61985849|NCT02949492|EXPERIMENTAL|IL-2 arm|Liver recipients \<50 years old and 2-6 years after transplantation will receive IL-2 and gradually discontinue their immunosuppressive medication
61985850|NCT00035464|PLACEBO_COMPARATOR|1|Placebo tablets
61985851|NCT00035464|EXPERIMENTAL|2|125 mg azimilide tablets
61985852|NCT00195182||1. No intervention|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to adhere to their medication goal.
61985853|NCT00195182||2. Experimental|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to engage adhere to their medication goal. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level.
61985854|NCT01700855|EXPERIMENTAL|Electroacupuncture|Patients received electroacupuncture stimulation
61985855|NCT01700855|SHAM_COMPARATOR|Non-electroacupuncture|Patients received sham electroacupuncture
61985856|NCT05297825|EXPERIMENTAL|Vegan|Participants will be asked to consume a healthy vegan diet.
61985857|NCT05297825|EXPERIMENTAL|Omnivore|Participants will be asked to consume a healthy omnivore diet.
61985858|NCT00628433|PLACEBO_COMPARATOR|1|Placebo
61985859|NCT00628433|EXPERIMENTAL|2|HE3286 5 mg daily
61985860|NCT00628433|EXPERIMENTAL|3|HE3286 10 mg daily
61985861|NCT00628433|EXPERIMENTAL|4|HE3286 20 mg daily
61985862|NCT00628433|EXPERIMENTAL|5|HE3286 4 mg daily
61985863|NCT02450032|EXPERIMENTAL|G17DT|Treatment with 500µg/ 0.4mL dose of G17DT administered by intramuscular injection at 0, 2, and 6 weeks.
61985864|NCT00148889|SHAM_COMPARATOR|2|Sham-stimulation
61985865|NCT00148889|ACTIVE_COMPARATOR|1|Active GPI-DBS
61985866|NCT01946997||Group 1: Non Diabetic|Normal retina
61985867|NCT01946997||Group 2: Diabetes with no retinopathy|Diabetic patients without diabetic retinopathy
61985868|NCT05903885|EXPERIMENTAL|Onsite group|"The on-site distribution group will receive the Fecal Immunochemical Test (FIT) kits directly while visiting the Department of Motor Vehicles (DMV) location at 4606 N 56th St Ste100, Omaha, NE 68104.~Participants in the on-site group will be guided through the process of receiving the FIT kits by trained research staff present at the designated location. They will be given instructions on collecting the stool sample and using the FIT kit properly.~They will also be given a culturally tailored educational brochure, a prepaid return envelope, and receive reminder text messages and phone calls within 3 weeks of the receipt of the FIT kit. Post-FIT navigation support will be provided for those with positive results or without a family doctor/insurance."
61985869|NCT05903885|ACTIVE_COMPARATOR|On-site with social media advertising group|"The onsite with social media advertising group participants will receive FIT kits directly at the DMV location, similar to the onsite group. Additionally, they will be exposed to targeted social media advertisements on Facebook, Instagram, and YouTube.~These participants will encounter ads featuring video content with community member testimonials, emphasizing the importance of colorectal cancer screening for African Americans aged 45-75. The campaign will run from August 19 to October 29, 2024.~Participants in this group will receive the FIT kits at the DMV along with detailed instructions on how to collect the stool sample and use the kit. They will also receive a culturally tailored educational brochure, prepaid return envelope, reminder text messages, and phone calls within three weeks of receipt of the FIT kit. Post-FIT navigation support will be provided for those with positive results or without a family doctor/insurance."
61985870|NCT01209884||Healthy Elderly sub-group|Healthy males between the age of 80-85 years old who have not experienced chronic disease during their lifetime.
61985871|NCT00876954|PLACEBO_COMPARATOR|Placebo|Warming without increase in core temperature
61985872|NCT00876954|ACTIVE_COMPARATOR|Hyperthermia|Hyperthermia for 2,5 hours (39 °C core temperature)
61985873|NCT04851886|ACTIVE_COMPARATOR|Individual robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will undergo 18 sessions of robot-assisted upper-limb rehabilitation. During the sessions, a therapist will administer one-on-one therapy (i.e. each study volunteer will work with a single therapist).
61985874|NCT04851886|EXPERIMENTAL|Group robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will also undergo 18 sessions of robot-assisted upper-limb rehabilitation. However, a therapist will administer the intervention as group therapy with up to three subjects participating in the session at the same time. To facilitate the deliver of the therapeutic intervention, the robot will be equipped with a camera system (called PostureCheck) designed to track the quality of the exercises.
61985875|NCT01631058|EXPERIMENTAL|Everolimus|"Number of patients: 45 Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.~Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.~Corticosteroids: as clinical practice."
61985876|NCT00741039|EXPERIMENTAL|1,|Patients \> or = to 65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23 valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly).
61985877|NCT00741039|EXPERIMENTAL|2|MSKCC employee volunteer controls \> or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly).
61985878|NCT04626947|OTHER|Open label|Single arm
61985879|NCT01096810|EXPERIMENTAL|TBL 12|TBL 12, sea cucumber, will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression
61985880|NCT05696912|OTHER|Ex-vivo and In-vitro approach|"Ex-vivo approach concerning 25 patients with blood sample in PAXgene tubes or skin biopsy and RNA-Seq analysis.~In-vitro approach concerning 25 patients without specific samples needed for analysis in minigene or luciferase assay"
61985881|NCT00945009|EXPERIMENTAL|Arm 1 (Bilateral Wilms Tumors)|Patients start with three drug chemotherapy (Regimen VAD; vincristine, dactinomycin and doxorubicin) and are evaluated and six and 12 weeks for feasibility of undergoing a partial nephrectomy/renal sparing surgery. At week 12 definitive surgery takes place followed by chemotherapy and radiation therapy based on histology and stage. Treatment continues for 25 or 31 weeks depending on histology. Patients are followed for up to 10 years following end of therapy.
61985882|NCT00945009|EXPERIMENTAL|Arm 2 (Unilateral High Risk tumors bilaterally predisposed)|Patients start with either 2 drug or three drug chemotherapy (Regimen VA, VAD) and are evaluated a 6 and 12 weeks for feasibility of undergoing a partial nephrectomy. At week 12 definitive surgery takes place followed by chemotherapy.
61985883|NCT00945009|EXPERIMENTAL|Arm 3 (DHPLN)|Patients with this rare disease are diagnosed based on cross-sectional imaging characteristics and undergo 2 drug chemotherapy (Regimen;VA). Patients are reassessed at 6 weeks and 12 weeks. If disease has responded or stayed stable chemotherapy is completed for 19 weeks (Regimen EE4A). If disease has progress a biopsy is performed to assess histology and adjust therapy based on the biopsy. This therapy may include, nephrectomy, chemotherapy or radiation therapy.
61985884|NCT06053294|EXPERIMENTAL|CS- First|Participants who receive the conditional stimulus (CS) - first.
61985885|NCT06053294|EXPERIMENTAL|CS+Fast First|Participants who receive the CS+Fast First
61985886|NCT06053294|EXPERIMENTAL|CS+Slow First|Participants who receive the CS+Slow First
61985887|NCT03047642||Malawi febrile patients|Children and adults with fever presenting at the outpatient department
61985888|NCT03047642||Brazil febrile patients|Children and adults with fever presenting at the outpatient department
61985889|NCT03047642||Gabon febrile patients|Children with fever or with a recent history of fever presenting at the outpatient department
61985890|NCT01718652|EXPERIMENTAL|Canagliflozin + cyclosporine|Each volunteer will receive canagliflozin (JNJ-28431754) once daily on Days 1 through 8 with a single dose of cyclosporine on Day 7.
61985891|NCT03013439|EXPERIMENTAL|cohort 1 iron isomaltoside|treated with first dose level of iron isomaltoside
61985892|NCT03013439|EXPERIMENTAL|cohort 2 iron isomaltoside|treated with second dose level of iron isomaltoside
61985893|NCT03013439|EXPERIMENTAL|cohort 3 iron isomaltoside|treated with third dose level of iron isomaltoside
61985894|NCT03013439|EXPERIMENTAL|cohort 4 iron isomaltoside|treated with fourth dose level of iron isomaltoside
61985895|NCT02295033|EXPERIMENTAL|Boost irradiation|
61985896|NCT02295033|NO_INTERVENTION|No boost irradiation|
61985897|NCT00790881|OTHER|Antiretroviral-naive|Antiretroviral-naive included as control group
61985898|NCT00790881|ACTIVE_COMPARATOR|Nevirapine-based antiretroviral therapy|Nevirapine-based antiretroviral therapy
61985899|NCT04723940|ACTIVE_COMPARATOR|Oral Antibiotics|Participant will receive 6 weeks of oral antibiotic therapy to treat their infection. The type of antibiotic given will be at the discretion of the infectious disease doctor.
61985900|NCT04723940|ACTIVE_COMPARATOR|Intravenous Antibiotics|Participant will receive 6 weeks of intravenous (IV) antibiotic therapy to treat their infection. The type of antibiotic given will be at the discretion of the infectious disease doctor.
61985901|NCT00199927|ACTIVE_COMPARATOR|standard therapy|Standard therapy
61985902|NCT00199927|ACTIVE_COMPARATOR|fluvastatin|40-80 mg/day
61985903|NCT02816892||Rupture group|Rupture was defined by direct visualisation of the discontinuity of the aortic wall by computed tomography, sonography, intraoperative findings or at autopsy with detection of blood in the pleural, pericardial or abdominal cavity.
61985904|NCT02816892||Covert rupture group|Covert rupture was defined as an intramural haematoma without detection of free blood in the body cavities.
61985905|NCT02816892||Acute dissection group|Acute dissection was defined when blood separating the layers of the aortic media was newly diagnosed.
61985906|NCT02816892||Chronic dissection group|Chronic dissection was defined as the absence of any visible propagation of a known dissection compared to preexisting examinations.
61985907|NCT02816892||Ectatic aneurysm group|Ectatic aneurysm was defined as a permanent localised dilatation of the aorta with a diameter of at least 50% greater than normal
61985908|NCT01203228|ACTIVE_COMPARATOR|A|Myeloablative conditioning
61985909|NCT01203228|EXPERIMENTAL|B|Reduced Intensity Conditioning
61985910|NCT02722447|ACTIVE_COMPARATOR|Rivaroxaban|Rivaroxaban 20 mg od for 6 weeks after an initial course of rivaroxaban for 6 weeks (15 mg bid for 3 weeks and 20 mg od for 3 weeks)
61985911|NCT02722447|EXPERIMENTAL|Placebo|Placebo for 6 weeks after an initial course of rivaroxaban for 6 weeks (15 mg bid for 3 weeks followed by 20 mg od for 3 weeks)
61985912|NCT00518323|EXPERIMENTAL|001|Paliperidone ER 1.5 mg tablet once daily for 6 weeks
61985913|NCT00518323|EXPERIMENTAL|002|Paliperidone ER 3 mg or 6 mg tablet once daily for 6 weeks
61985914|NCT00518323|EXPERIMENTAL|003|Paliperidone ER 6 mg or 12 mg tablet once daily for 6 weeks
61985915|NCT00518323|PLACEBO_COMPARATOR|004|Placebo Once daily for 6 weeks
61985916|NCT01916356|EXPERIMENTAL|educational video|Change in participant's infertility knowledge before and after watching the educational video covering the topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
61985917|NCT01185119|ACTIVE_COMPARATOR|GLP-1|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
61985918|NCT01185119|PLACEBO_COMPARATOR|placebo|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
61985919|NCT00885716|EXPERIMENTAL|communication skills training|group training in shared decision making.
61985920|NCT00885716|ACTIVE_COMPARATOR|cognitive training|standard group training of cognitive skills (Konzentrationstraining)
61985921|NCT00818428|ACTIVE_COMPARATOR|1|Speech Production Intervention + Articulation Parent Group
61985922|NCT00818428|EXPERIMENTAL|2|Speech Production Intervention + Dialogic Reading Parent Group
61985923|NCT00818428|EXPERIMENTAL|3|Speech Perception Intervention + Articulation Parent Group
61985924|NCT00818428|EXPERIMENTAL|4|Speech Perception Intervention + Dialogical Reading Parent Group
61985925|NCT05951387|ACTIVE_COMPARATOR|dexmedetomidine plus ketamine|starting intravenous infusion dose of dexmedetomidine 0.5 µg/kg/h mixed with ketamine 0.5 mg/kg/h to 30 mechanically ventilated ARDS patient
61985926|NCT05951387|ACTIVE_COMPARATOR|high dose dexmedetomidine|dexmedetomidine at 0.5 µg/kg/h intravenous infusion only to be titrated to achieve full sedation to 30 mechanically ventilated ARDS patient
61985927|NCT04835025||Control group (radiotherapy group)|In non-small cell lung cancer, patients with brain metastases received radiotherapy for brain lesion (without limitation of dose and treatment method for radiotherapy) , but not receiving immunotherapy. Those patients would enter the control group. After patients experiencing disease progression(PD) in this group, follow-up treatment does not include immunotherapy until tumor progression again or death.
61985928|NCT02258230|ACTIVE_COMPARATOR|2D mode LSC|2D mode of the 3D Laparoscopic Video System for the Laprascopic Sacral Colpopexy (LSC) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
61985929|NCT02258230|ACTIVE_COMPARATOR|3D mode LSC|3D mode of the 3D Laparoscopic Video System for the Laprascopic Sacral Colpopexy (LSC) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
61985930|NCT02258230|ACTIVE_COMPARATOR|2D mode PVR|2D mode of the 3D Laparoscopic Video System for the Paravaginal Repair (PVR) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
61985931|NCT02258230|ACTIVE_COMPARATOR|3D mode PVR|3D mode of the 3D Laparoscopic Video System for the Paravaginal Repair (PVR) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
61985932|NCT02099097|ACTIVE_COMPARATOR|Standard Care|"usual care, which consists of four (face-to-face or telephone) counseling sessions with a trained nurse who has expertise in helping cancer patients quit smoking. This is the same as the treatment an MSK patient who enrolls in the MSK smoking cessation program would receive.~To collect further data to improve the game intervention, the investigators will conduct semi-structured telephone interviews with patients who were randomized to the treatment arm but did not play the game during the one month intervention period. The purpose of the interviews is to elicit qualitative feedback on any barriers that may have prevented participants from playing. At the completion of the intervention period, patients will be asked if they would like to participate in a telephone interview. Telephone interviews will take about twenty minutes and will be held at a time that is convenient for the patient."
61985933|NCT02099097|EXPERIMENTAL|Smoking Cues Coping Skills Game (SC+SCCS/Quit IT).|Smokers randomly assigned to SC+SCCS/Quit IT will receive all the components of Standard Care. The patient will be oriented and trained face-to-face (during their hospitalization) on use of the game by study staff using an iPad. The orientation and training session will comprise: 1) Overview of the game and its objectives; 2) discussion of the rules of the game; 3) watching a 10 minute tutorial given by the game narrator (avatar); 4) answering all patient questions; and 5) evaluation of the patient's comprehension of game play via a 17 question survey. Once patients have access to QuitIT, they will also receive a set of Coping Cards
61985934|NCT05080933||COVID-19|
61985935|NCT05080933||H1N1|
61985936|NCT01613625|EXPERIMENTAL|Elastography|
61985937|NCT02974296|EXPERIMENTAL|new target TMS|new target transcranial magnetic stimulation guided by MRI
61985938|NCT02974296|ACTIVE_COMPARATOR|standard TMS|standard transcranial magnetic stimulation
61985939|NCT00838058|EXPERIMENTAL|Part1; controlled release formulation 4; 250 mg|one 250 mg controlled release tablet, once in the morning, in fasted state
61985940|NCT00838058|EXPERIMENTAL|Part1; controlled release formulation 4; 500 mg|2x250 mg, once in the morning, in fasted state
61985941|NCT00838058|EXPERIMENTAL|Part 1; controlled release formula 4; 1000 mg|4x250 mg tabs, once in the morning, in fasted state
61985942|NCT00838058|EXPERIMENTAL|Part 1; controlled release formulation 4; 500 mg FED|2x250 mg, once in the morning , in fed state
61985943|NCT00838058|EXPERIMENTAL|Part 2; IR formulation 500mg|4x125 mg tab of current formulation , once in the morning in the fasted state. This arm will occur as Part 2, only as needed, pending results of Part 1
61985944|NCT00838058|EXPERIMENTAL|Part 2; IR formulation, 500 mg FED|4x125 mg once in the morning in the fed state. This arm will occur as part of Part 2,only as needed, pending results of Part 1.
61985945|NCT00838058|EXPERIMENTAL|Part 2; controlled release formulation 5;500 mg, FASTED|2x250 controlled release formulation 5 tabs once in the morning in the fasted state. This arm will only occur as part of Part 2, pending results of Part 1.
61985946|NCT00838058|EXPERIMENTAL|Part 2; controlled release formulation 5;500 mg, FED|2x250 mg controlled release formulation 5 tabs once in the morning in the fed state. This arm will only occur as part of Part 2 pending results of Part 1
61985947|NCT01046682|ACTIVE_COMPARATOR|Salsalate|
61985948|NCT01046682|NO_INTERVENTION|Usual care|
61985949|NCT01141881|EXPERIMENTAL|TPA,IVB,F/U|
61985950|NCT00854945|EXPERIMENTAL|ON 01910.Na|1800 mg/day of ON 01910.Na administered as a 24-hour continuous intravenous infusion on days 1, 2 and 3 of 14-day cycle.
61985951|NCT04089059|OTHER|Treatment Arm|Pulmonary Artery Pressure Guided Heart Failure Management (PAPGHFM) and Guideline Directed Medical Therapy (GDMT) considering daily Pulmonary Artery Pressure (PAP) measurements and vital signs collected by Cordella Heart Failure System (CHFS).
61985952|NCT05321615|OTHER|Study arm|All patients will undergo a standard VATS pleuroscopy to visually search for the nodule and its position. Sequential assessment using a grasper, the Palpator, the VATS ultrasound probe, and then finger palpation will be done to detect the nodule.
61985953|NCT04355325|ACTIVE_COMPARATOR|Experimental|modified monolithic zirconia crowns At the time of the second optical impression, implants will be randomly allocated to either the test group (modified monolithic zirconia crowns) or the control group (metal ceramic crowns), using a computer-generated randomization list.
61985954|NCT04355325|PLACEBO_COMPARATOR|control|metal ceramic crowns At the time of the second optical impression, implants will be randomly allocated to either the test group (modified monolithic zirconia crowns) or the control group (metal ceramic crowns), using a computer-generated randomization list.
61985955|NCT05023525|EXPERIMENTAL|HSK31858, single dose|5 cohorts with single doses starting with 5 mg HSK31858 as tablet.
61985956|NCT05023525|PLACEBO_COMPARATOR|Placebe, single dose|5 cohorts with matching placebo to HSK31858 as tablet.
61985957|NCT04096625|EXPERIMENTAL|Active tDCS|Active tDCS will be delivered at 2mA for 20 minutes.
61985958|NCT04096625|SHAM_COMPARATOR|Sham tDCS|Sham tDCS: after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).
61985959|NCT02530450||Group 1|Initially blinded to continuous glucose monitoring (CGM) data after 1st use Not blinded to continuous glucose monitoring data after 2nd and 3rd use
61985960|NCT02530450||Group 2|Never blinded to continuous glucose monitoring (CGM) data
61985961|NCT00418132|EXPERIMENTAL|1|Participants will receive thalidomide.
61985962|NCT00418132|PLACEBO_COMPARATOR|2|Participants will receive placebo thalidomide.
61985963|NCT02867709|EXPERIMENTAL|Ubrogepant 25 mg|1 ubrogepant 25 milligram (mg) tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
61985964|NCT02867709|EXPERIMENTAL|Ubrogepant 50 mg|1 ubrogepant 50 mg tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
61985965|NCT02867709|PLACEBO_COMPARATOR|Placebo|1 placebo-matching ubrogepant tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
61985966|NCT04294511|EXPERIMENTAL|Experimental|camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate
61985967|NCT06523504|EXPERIMENTAL|The DIMS Group|wear DIMS ,and use placebo,once nightly, both eye
61985968|NCT06523504|EXPERIMENTAL|0.02% ATP|wear SP, and use 0.02%ATP eye drops, once nightly, both eye
61985969|NCT06523504|EXPERIMENTAL|0.04%ATP|wear SP, and use 0.04%ATP eye drops, once nightly, both eye
61985970|NCT06523504|EXPERIMENTAL|0.02%ATP+DIMS|wear DIMS, and use 0.02%ATP eye drops, once nightly, both eye
61985971|NCT06523504|EXPERIMENTAL|0.04%ATP+DIMS|wear DIMS, and use 0.04%ATP eye drops, once nightly, both eye
61985972|NCT05847075|EXPERIMENTAL|Sedentary Diabetic people|Sedentary people with Type 2 Diabetes.
61985973|NCT05847075|EXPERIMENTAL|Heat Therapy|Diabetic people allocated in Heat Therapy for 12 weeks.
61985974|NCT05847075|EXPERIMENTAL|StrengthTraining|Diabetic people allocated in Strength training for 12 weeks.
61985975|NCT02090647|ACTIVE_COMPARATOR|titanium 1|titanium abutment type 1
61985976|NCT02090647|ACTIVE_COMPARATOR|titanium 2|titanium abutment type 2
62169667|NCT02025985|EXPERIMENTAL|Part 2: Cohort A-Ovarian carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW|Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 35 mg/m\^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 6 weeks of treatment, a dose of 50 mg/m\^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m\^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
62169668|NCT02025985|EXPERIMENTAL|Part 2: Cohort A-Ovarian carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW|Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 50 mg/m\^2 of selinexor oral tablets QW (doses at least 5 days apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 6 weeks of treatment, a dose of 60 mg/m\^2 of selinexor oral tablets QW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m\^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
62169669|NCT01286870|OTHER|Reconstruction|"The study population will consist of women aged 18 or over who are undergoing primary breast reconstruction.~The Reconstruction cohort will include subjects with loss of breast tissue due to mastectomy, contralateral breast for post-reconstruction symmetry or subjects with deformities secondary to disease, malignancy, trauma, and congenital deformity. Subjects in this cohort cannot have been implanted with breast implants, but may have tissue expanders. A Becker implant is considered a tissue expander until the port and fill tube have been removed. Women who undergo surgery primarily for a mastopexy will not be part of the reconstruction cohort."
62169670|NCT03604289|EXPERIMENTAL|Angiotensin-(1-7)|Participants receive intravenous angiotensin-(1-7) at one study visit for 100 minutes total. Angiotensin-(1-7) will be given in escalating doses of 2ng/kg/min, 4ng/kg/min, and 8ng/kg/min. Each of these doses will be infused for 10 minutes. Following the dose escalation, angiotensin-(1-7) will be given at 8ng/kg/min for an additional 70 minutes. Infusion rates will be calculated for each patient based on body mass.
62169671|NCT03604289|PLACEBO_COMPARATOR|Saline|Participants receive intravenous saline at one study visit for 100 minutes total. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each patient based on body mass. Saline will be given in escalating doses for 10 minutes each and then held for 70 minutes at the highest dose.
61985977|NCT02090647|ACTIVE_COMPARATOR|zirconia 1|zirconia abutment type 1
61985978|NCT02090647|ACTIVE_COMPARATOR|zirconia 2|zirconia abutment type 2
61985979|NCT02090647|ACTIVE_COMPARATOR|titanium nitrate|titanium nitrate abutment
61985980|NCT01157884||Kidney Transplantation|
61985981|NCT06010225||ERAS group|Patients who met the inclusion criteria and consented were assigned to the ERAS group
61985982|NCT06010225||control group|Patients who met the inclusion criteria and did not consent were assigned to the ERAS group
61985983|NCT03013556|ACTIVE_COMPARATOR|Group A,TDF|The subjects in group A will be treated by TDF for 96 weeks
62169672|NCT04186117|EXPERIMENTAL|Biological collection|"For all the patients include in the study :~- Blood samples collected at before any treatment~In parallel to this biological collection, standardized clinical data will be entered into a database"
62169673|NCT06329011|EXPERIMENTAL|Comprehensive rehabilitation+Intermittent Oro-esophageal Tube+Transcranial stimulation|The patients are randomly assigned to either the experimental group or the placebo group. All patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using Intermittent Oro-esophageal Tube. In addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.
62169674|NCT06329011|PLACEBO_COMPARATOR|Comprehensive rehabilitation+Intermittent Oro-esophageal Tube|The patients are randomly assigned to either the experimental group or the placebo group. All patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using Intermittent Oro-esophageal Tube. In addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.
62169675|NCT06646731|ACTIVE_COMPARATOR|Cryoneurolysis|For participants randomized to active treatment, the probe placed in the research participant will be triggered and the nitrous oxide passed through the probe and then back into the machine, and finally vented out from the console. This will result in a freeze-thaw cycle. This may be repeated, as necessary, to ensure the entire cross-section of each nerve is fully treated.
62169676|NCT06646731|SHAM_COMPARATOR|Sham|Patients in this arm will also receive a diagnostic block with local anesthetic. If pain relief is satisfactory, the patients in this arm will undergo the procedure but the cryo probe will simply not be activated.
62169677|NCT05657613|EXPERIMENTAL|CYP450 Cocktail and Transporter Substrates with Pacritinib|This is the first part of the study which is an open-label, single-center, 1-way DDI study designed to assess the effect of pacritinib 200 mg BID at steady state on the systemic exposure of a cocktail of cytochrome P450 (caffeine, midazolam, and omeprazole) and transporter substrates (digoxin, rosuvastatin, and metformin) in 18 healthy male subjects.
62169678|NCT05657613|EXPERIMENTAL|CYP450 3A4 inducer (Bosentan) with Pacritinib|The second part of the study comprises of 2 arms. This is the first arm Days 1 through 14: An oral dose of pacritinib 200 mg (2 × 100 mg capsules) BID (approximately 12 hours apart) Days 8 through 14: An oral dose of bosentan 125 mg BID (approximately 12 hours apart) All the doses will be administered with approximately 240 mL of water.
62169679|NCT05657613|EXPERIMENTAL|CYP450 3A4 inhibitor (Fluconazole) with Pacritinib|"This is the second arm of Part 2 of the study:~Days 1 through 14: An oral dose of pacritinib 200 mg (2 × 100 mg capsules) BID (approximately 12 hours apart) Days 8 through 14: An oral dose of fluconazole 200 mg QD"
62169680|NCT05952908|EXPERIMENTAL|Proficiency-Based Progression training group|Trainees in this group will follow the simulation-based implant training curriculum (same content/tools in both study arms) and they will be required to demonstrate a quantitatively defined proficiency benchmark at each training stage to be able to advance to the next stage (proficiency-based progression \[PBP\] approach).
62169681|NCT05952908|ACTIVE_COMPARATOR|Traditional training group|Trainees in this group will follow the simulation-based implant training curriculum (same content/tools in both study arms) but they will not be required to demonstrate a quantitatively defined proficiency benchmark at each training stage to be able to advance to the next stage.
62169682|NCT06396923|SHAM_COMPARATOR|control group|Participants will complete a series of 3 x 15-second repeated Wingate Anaerobic Tests (WAnTs) on an electronically braked bicycle ergometer. Participants will warm up for 5 minutes at a no-load resistance. Resistance to the test will be calculated using 7.5% of the participant's body mass. Upon successful completion of each WAnT, performance variables, heart rate, rate of perceived exertion (RPE; Scale 1-10), and motivation rating will be obtained. Motivation will be achieved using a visual analogue scale with a 100 mm line. Participants will indicate how motivated they were to exercise during WAnT, from most motivated ever to least motivated. Scores will be obtained by measuring from zero to the point marked on the 100 mm line. All anaerobic performance measurements will be calculated during each 15-second WAnT period via Velotron Software (v4 1.0.6 Velotron, Racermate Inc., Seattle, WA, USA).
62169683|NCT06396923|EXPERIMENTAL|Music group|The same exercise protocol will be applied. However, participants in the music group will complete the test by listening to the music of their own choosing. (The same headphones will be used to play music with the same electronic device, and the device will be set to the same volume for all participants.)
62169684|NCT02578667|NO_INTERVENTION|Gorbly Compression not needed|
62169685|NCT02578667|EXPERIMENTAL|Gorbly Compression may benefit|the use of the Gorbly device with the consent of the patient
62169686|NCT00489489|EXPERIMENTAL|Teriflunomide 7 mg + IFN-β|Teriflunomide 7 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
62169687|NCT00489489|EXPERIMENTAL|Teriflunomide 14 mg + IFN-β|Teriflunomide 14 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
62169688|NCT00489489|PLACEBO_COMPARATOR|Placebo + IFN-β|Placebo (for Teriflunomide) once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
62169689|NCT01399502|ACTIVE_COMPARATOR|Self-help advice|Each email will contain a self-help strategy for coping with depressive symptoms. The email will contain information about why the strategy will be effective, tips for implementing the strategy and overcoming barriers, and how to set a goal to implement the strategy. Strategies are based on previous research published by the trial co-ordinators.
62169690|NCT01399502|PLACEBO_COMPARATOR|Depression information|Each email will contain different information about depression, such as symptoms, risk factors, prevalence.
62169691|NCT01364545|OTHER|Ketone ester drink Vs placebo drink|Ketone ester drink Vs placebo drink (cross over study - all patients will recieve both)
62169692|NCT03627351||Healthy Women and Men|Group of healthy women and men
62169693|NCT04714697|EXPERIMENTAL|Cohort 1(post nivolumab and ipilimumab combination)|the subject who failed one prior line by nivolumab and ipilimumab
62169694|NCT04714697|EXPERIMENTAL|Cohort 2 (post pembrolizumab plus axitinib, pembrolizumab plus lenvatinib, or avelumab and axitinib)|the subject who failed one prior line by PD-1/PD-L1 inhibitors in combination with VEGF TKI
62169695|NCT04714697|NO_INTERVENTION|Cohort 3 (post sequential immunotherapy after VEGFR TKI)|the subject who failed the second line by immunotherapy (PD-1 antibody or PD-L1 antibody) following the first line VEGFR TKI
62169696|NCT01979757|ACTIVE_COMPARATOR|Centrifugation|Patients recieved fatgraft processed by Centrifugation
62169697|NCT01979757|ACTIVE_COMPARATOR|Puregraft|Patients recieved fatgraft processed by Puregraft
62169698|NCT05876364|EXPERIMENTAL|Cohort 1|Injection in the muscle at 0day , 28 day
62169699|NCT05876364|EXPERIMENTAL|Cohort 2|Injection in the muscle at 0day , 28 day
62169700|NCT05876364|EXPERIMENTAL|Cohort 3|Injection in the muscle at 0day , 28 day
62169701|NCT04416321|OTHER|Device|All subjects who are entered into this trial will receive the Keos Lumbar Interbody Fusion Device.
62169702|NCT04557865|EXPERIMENTAL|Participants receving 18F-PMPBB3 (APN-1607) PET imaging|Single arm, open label
62169703|NCT00951574|PLACEBO_COMPARATOR|saline solution|Pre-filled syringes of 0.4 ml, 1 subcutaneous injection/day (every 24 hours).
62363507|NCT01810380|OTHER|Quetiapine extended release|Active Reference. Patients randomised to quetiapine received 300mg/day on Day 1, 600mg/day on Days 2 and 3 (uptitration); the dose could be adjusted from Day 4 onwards to 400, 600, or 800mg/day to optimise the clinical effect and tolerability.
62169704|NCT00951574|EXPERIMENTAL|nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
62169705|NCT00786721||Diffuse Optical Spectroscopy|muscle properties scanning
62169706|NCT05095233|EXPERIMENTAL|Young Adults Culturally Adapted Therapy for Suicidal Prevention|Young Adults Adapted Manual Assisted Psychological Therapy for Suicide Prevention
62169707|NCT05095233|ACTIVE_COMPARATOR|MINPLAN TOOL|Research has shown that user engagement, rather than the modality of therapy is the key to achieving successful outcomes and given that just 50% and 13% of patients currently have a choice of when and where they receive therapy, self-help tool apps Like MIN PLAN may not only be equally effective as some forms of traditional psychotherapy but also provide a flexible and pragmatic means of increasing patient access, through removing barriers to treatment that do not respond to financial impetus.
62169708|NCT03195127|EXPERIMENTAL|multimodal physical therapy|Multimodal physical therapy sessions three times a week, for four weeks, lasting one hour. Consist of limb strengthening exercises, endurance training, and balance/coordination drills.
62169709|NCT03195127|NO_INTERVENTION|Usual care|Subjects will receive the standard therapy program provided by University Specialty Hospital therapy services. To compliment the physical therapy regimen, an optimized nutritional program will be administered according accepted guidelines.
62169710|NCT04160000|ACTIVE_COMPARATOR|Phase 1 Catheter Ablation|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent. They randomly assigned to catheter ablation as one arm. They will undergo a catheter ablation procedure within 14 days of randomization. This procedure will include isolation of all four pulmonary veins in the antrum using catheter delivered radiofrequency current, cryothermal or laser ablation energy with standard FDA approved ablation catheter systems used in atrial fibrillation ablation. Patients will be monitored for a minimum period of 9 months after the catheter ablation intervention.
62169711|NCT04160000|ACTIVE_COMPARATOR|Phase 1 Antiarrhythmic drug therapy|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent. They will be randomly assigned to antiarrhythmic drug therapy for Rate or Rhythm control in this arm. They will undergo drug dose titration within 14 days of randomization. . Patients will be monitored for a minimum period of 9 months after the AAD therapy initiation
62169712|NCT04160000|ACTIVE_COMPARATOR|Phase 2 Guided Heart Failure Therapy|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent and completion of Phase 1. They will be randomly assigned to insertion of an implantable hemodynamic monitor in this arm and heart failure therapy guided by wireless hemodynamic monitoring. Patients will be monitored for a minimum period of 9 months after the implantable hemodynamic monitor insertion on guided drug therapy
62169713|NCT04160000|ACTIVE_COMPARATOR|Phase 2 Empiric Heart Failure Therapy|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent and completion of Phase 1. They will be randomly assigned to heart failure management with empirical selection of heart failure therapy. Patients will be monitored for a minimum period of 9 months after the initiation of empirically selected heart failure drug therapy
62169714|NCT01137123|ACTIVE_COMPARATOR|standard two field +follow-up|
62169715|NCT01137123|EXPERIMENTAL|standard two field +adjuvant chemotherapy|
62169716|NCT01137123|EXPERIMENTAL|total two field+follow-up|
62169717|NCT01137123|EXPERIMENTAL|total two field+adjuvant chemotherapy|
62169718|NCT01137123|EXPERIMENTAL|three field+follow-up|
62169719|NCT01137123|EXPERIMENTAL|three field+adjuvant chemotherapy|
62169720|NCT01052870|OTHER|androgen receptor gene polymorphism|Medication response will be assessed according to androgen receptor genotype
62169721|NCT01052870|ACTIVE_COMPARATOR|finasteride|medication for treating androgenetic alopecia in women
62169722|NCT00990821|EXPERIMENTAL|Part I, Panel A|100 mg MK-0517 (nonpolysorbate 80 formulation \[non-PS80\]) or placebo → 150 mg MK-0517 (non- PS80) or placebo → 125 mg aprepitant
62169723|NCT00990821|EXPERIMENTAL|Part I, Panel B|100 mg MK-0517 (PS80 formulation \[PS80\]) or placebo → 150 mg MK-0517 (PS80) or placebo → 125 mg aprepitant
62169724|NCT00990821|EXPERIMENTAL|Part I, Panel C|40 mg MK-0517 (non-PS80) or placebo → 40 mg aprepitant
62169725|NCT00990821|EXPERIMENTAL|Part II|2 mg midazolam → 100 mg MK-0517 (PS80) + 2 mg midazolam
62169726|NCT00990821|EXPERIMENTAL|Part III, Panel 1, Treatment Sequence 1|125 mg aprepitant → 90 mg MK-0517 (PS80)
62169727|NCT00990821|EXPERIMENTAL|Part III, Panel 1, Treatment Sequence 2|40 mg MK-0517 (non-PS80) → 125 mg aprepitant
62169728|NCT00990821|EXPERIMENTAL|Part III, Panel 2|40 mg MK-0517 (non-PS80)
62169729|NCT00990821|EXPERIMENTAL|Part IV|40 mg MK-0517 (non-PS80 formulation)
62363508|NCT02190630|ACTIVE_COMPARATOR|Part time (12hour) wear|the' Modified Clark Twin Block' will be worn part time
62363509|NCT02190630|ACTIVE_COMPARATOR|Full time (24hour) wear|the ' Modified Clark Twin Block' will be worn full time
62169730|NCT00990821|EXPERIMENTAL|Part V, Treatment Sequence 1|125 mg aprepitant → 100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80 formulation)
62169731|NCT00990821|EXPERIMENTAL|Part V, Treatment Sequence 2|100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80) → 125 mg aprepitant
62169732|NCT00990821|EXPERIMENTAL|Part V, Treatment Sequence 3|115 mg MK-0517 (PS80) → 125 mg aprepitant → 100 mg MK-0517 (PS80)
62169733|NCT00990821|EXPERIMENTAL|Part V, Treatment Sequence 4|125 mg aprepitant → 115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80)
62169734|NCT00990821|EXPERIMENTAL|Part V, Treatment Sequence 5|100 mg MK-0517 (PS80) → 125 mg aprepitant → 115 mg MK-0517 (PS80)
62169735|NCT00990821|EXPERIMENTAL|Part V, Treatment Sequence 6|115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80) → 125 mg aprepitant
62169736|NCT06472011|EXPERIMENTAL|Arm 1 (lean steak and potatoes)|lean steak and potatoes will be provided to subjects and primary and secondary outcomes will be measured at timelines explained under primary and secondary outcome measures.
62169737|NCT06472011|EXPERIMENTAL|Arm 2 (lentil and sweet potato chili )|lentil and sweet potato chili will be provided to subjects and primary and secondary outcomes will be measured at timelines explained under primary and secondary outcome measures.
62169738|NCT06472011|EXPERIMENTAL|Arm 3 (macaroni and cheese)|macaroni and cheese will be provided to subjects and primary and secondary outcomes will be measured at timelines explained under primary and secondary outcome measures.
62169739|NCT06472011|EXPERIMENTAL|Arm 4 (fish tacos)|fish tacos will be provided to subjects and primary and secondary outcomes will be measured at timelines explained under primary and secondary outcome measures.
62169740|NCT06472011|EXPERIMENTAL|Arm 5 (chicken and pea fried rice)|chicken and pea fried rice will be provided to subjects and primary and secondary outcomes will be measured at timelines explained under primary and secondary outcome measures.
62169741|NCT06472011|EXPERIMENTAL|Arm 6 (pita and hummus)|pita and hummus will be provided to subjects and primary and secondary outcomes will be measured at timelines explained under primary and secondary outcome measures.
62169742|NCT06472011|EXPERIMENTAL|Arm 7 (creamy pork pasta)|creamy pork pasta will be provided to subjects and primary and secondary outcomes will be measured at timelines explained under primary and secondary outcome measures.
62169743|NCT02599870|EXPERIMENTAL|NeuroIDgenetix Test Panel Intervention|The medical provider for the NeuroIDgenetix-guided group will make post-operative pain management recommendations based on test results. Patient outcomes, length of hospital stay and number of medical visits will be measured throughout the study.
62169744|NCT02599870|NO_INTERVENTION|Control|The medical provider for the control group will not receive the NeuroIDgenetix Test Panel results and will make post-operative pain management recommendations based as usual. Patient outcomes, length of hospital stay and number of medical visits will be measured throughout the study.
62169745|NCT00530049||questionnaires|"The purpose of this study is to develop a PRO instrument that measures quality of life as relates to facial appearance after head and neck cancer reconstruction surgery and after dermatologic surgery for patients with cutaneous skin cancers. . To develop this measure, we will adhere to the following sequential steps recommended by quality of life experts. Thus, the study will have three parts:~* Questionnaire content generation and development of preliminary instrument~* Field-testing the preliminary questionnaire with item reduction and development of final questionnaire~* Psychometric evaluation of final questionnaire"
62169746|NCT05340439|EXPERIMENTAL|Incobotulinumtoxin A treatment|The study will consist of three injection cycles. In each, an injection visit is followed by an observation period of 12 to 20 weeks.
62169747|NCT04753281|OTHER|Lifestyle counselling|Participants will receive an assessment appointment and up to 8 follow up sessions with a Health Psychologist to help them set goals and monitor changes of their own self management behaviour.
62169748|NCT04753281|NO_INTERVENTION|Treatment as usual|Treatment as usual
62169749|NCT01732627|EXPERIMENTAL|Group 1: MenACYW Conjugate Vaccine|Adult participants aged greater than or equal to (≥) 56 years received a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W 135) Tetanus Toxoid (MenACYW) Conjugate vaccine on Day 0.
62169750|NCT01732627|ACTIVE_COMPARATOR|Group 2: Menomune® A/C/Y/W 135 vaccine|Adult participants aged ≥56 years received a single dose of Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W 135 Combined (Menomune®) vaccine on Day 0.
62169751|NCT00888394|EXPERIMENTAL|1|
62169752|NCT00888394|EXPERIMENTAL|2|
62391427|NCT03723746|EXPERIMENTAL|Cohort 9 (Optional): Dose 2 or Placebo (Part 3) + Biopsy|Participants may receive an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. After final dosing collection of sigmoid biopsies will be performed. Cohort 9 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
62169753|NCT00888394|EXPERIMENTAL|3|
62169754|NCT00888394|EXPERIMENTAL|4|
62169755|NCT05191121|ACTIVE_COMPARATOR|FTP Alone|Functional Task Practice Alone - Participants allocated to this group will complete 40 minutes of training focused on improving functional tasks followed by 10 minutes of functional training/carryover in a relevant environment without functional electrical stimulation (FES).
62169756|NCT05191121|ACTIVE_COMPARATOR|FTP+Con-FES|Functional Task Practice + Conventional Functional Electrical Stimulation - Participants allocated to this group will complete 40 minutes of training focused on improving functional tasks supplemented with conventional parameter (200µs; 40Hz) functional electrical stimulation (FES). followed by 10 minutes of functional training/carryover in a relevant environment.
62169757|NCT05191121|ACTIVE_COMPARATOR|FTP+WPHF-FES|Functional Task Practice + Wide Pulse, High Frequency Functional Electrical Stimulation - Participants allocated to this group will complete 40 minutes of training focused on improving functional tasks supplemented with wide pulse, high frequency (1000µs; 100 Hz) functional electrical stimulation (FES) followed by 10 minutes of functional training/carryover in a relevant environment.
62169758|NCT04092959|EXPERIMENTAL|Walking group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
62169759|NCT04092959|EXPERIMENTAL|Chinese Square Dancing group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
62391428|NCT05737927|ACTIVE_COMPARATOR|SINGLE DOSE- TEST PRODUCT 1 (T1)|Oral coated beads 8 g glucose (content glucose/bead 47% w/w)
62169760|NCT04092959|EXPERIMENTAL|Control group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
62169761|NCT03899259|EXPERIMENTAL|4 Milligram (mg) Baricitinib|Participants received one 4 mg Baricitinib tablet administered orally, every day (QD) one placebo tablet administered orally QD to maintain blind.
62169762|NCT03899259|EXPERIMENTAL|2 mg Baricitinib|Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain blind.
62169763|NCT03899259|PLACEBO_COMPARATOR|Placebo|Participants received two placebo tablets administered orally QD to maintain the blind.
62169764|NCT03899259|EXPERIMENTAL|4 mg Baricitinib Maximum Extended Enrollment (MEE)|Participants received one 4 mg Baricitinib tablet administered orally, every day (QD) one placebo tablet administered orally QD to maintain blind.
62169765|NCT03899259|EXPERIMENTAL|2 mg Baricitinib MEE|Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain blind.
62363510|NCT05241938|EXPERIMENTAL|Pattern Selective Laser Trabeculoplasty|PSLT will be performed using the Pascal Streamline 577 laser (Topcon Inc., Tokyo, Japan). The laser spot is directed at the anterior chamber angle encompassing the pigmented and non-pigmented trabecular meshwork. Laser power is titrated by placing a laser mark in the lower quadrant with an exposure duration of 10 milliseconds (ms). The initial energy of 500 megawatts (mW) is selected and the power is reduced or increased until a slight whitening of the trabecular meshwork is minimally noticed. This power is then maintained and the pulse duration is automatically reduced to 5ms to produce invisible injury. The treatment is administered in 32 steps, each pattern consists of 36 stitches: 3 rows of 13 stitches each (total of 1152), with zero space between adjacent stitches.
62363511|NCT05241938|ACTIVE_COMPARATOR|Prostaglandin analogue eye drops|Prostaglandin analogue eye drops (latanoprost, bimatoprost or travoprost) will be prescribed
62169766|NCT03899259|PLACEBO_COMPARATOR|Placebo MEE|Participants received two placebo tablets administered orally QD to maintain the blind.
62169767|NCT01540071|EXPERIMENTAL|NRX 194204|This was a single arm open-label study. All patients enrolled received 20 mg of IRX4204 per day orally, for six months, or longer if the patient had disease stabilization and was tolerating the experimental treatment.
62169768|NCT00655668|EXPERIMENTAL|Lenalidomide|Open-label, oral lenalidomide monotherapy
62169769|NCT06231550|EXPERIMENTAL|FC084CSA|
62169770|NCT01954758|EXPERIMENTAL|Personalized embryo transfer (pET)|Patients will undergo a cycle of endometrial preparation following hormone replacement therapy (HRT) and an endometrial biopsy in a substituted cycle after 5 days (around 120 hours) of progesterone administration. The ERA test will determine the window of implantation (WOI) for each patient and will recommend the best time for embryo transfer thereby increasing the chances of a successful outcome. In some specific cases (≤ 10%) a second biopsy will be required to help the bioinformatic predictor to ensure the most appropriated moment for the embryo transfer. In a different cycle, patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI and vitrified. In a subsequent cycle, following the ERA result, a personalized embryo transfer (pET) will be carried out following the same conditions in which the ERA test was obtained, using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage)
62169771|NCT01954758|ACTIVE_COMPARATOR|Frozen embryo transfer (FET)|Patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI. In a subsequent cycle, following hormone replacement therapy (HRT), a frozen embryo transfer (FET) will be performed using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).
62169772|NCT01954758|ACTIVE_COMPARATOR|Fresh embryo transfer (ET)|Patients will undergo a controlled ovarian stimulation cycle (COS) to obtain oocytes which will be fertilized by IVF/ICSI. In the same cycle, a fresh embryo transfer will be performed using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).
62169773|NCT01766323|PLACEBO_COMPARATOR|Arm Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
62169774|NCT01766323|ACTIVE_COMPARATOR|Arm-Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
62169775|NCT06205407|ACTIVE_COMPARATOR|Treatment A|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets manufactured at Viatris.
62363512|NCT05287204||AKI-RRT|Adults admitted to the ICU with AKI requiring CRRT with study enrollment within 48 hours of CRRT initiation.
62169776|NCT06205407|EXPERIMENTAL|Treatment B|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets manufactured at Neolpharma.
62169777|NCT00825643||Insulin detemir|
62363513|NCT05287204||Historical Controls|The controls for the ICU phase will be 41 critically ill adults without AKI-RRT in whom similar measurements of muscle size, quality, and function were collected in a recent prior study \[PubMed ID: 33148301\]. The controls for the recovery phase will come from an ongoing prospective observational study being performed at the University of Kentucky, which will include outpatient functional assessments performed on 200 ICU survivors (NCT05537298).
62169778|NCT03964545|EXPERIMENTAL|EFP neurofeedback|Ten sessions of EFP neurofeedback training. EEG is picked up with scalp electrodes, processed in real-time and returned to patients. One session lasts 30 min.
62169779|NCT03964545|NO_INTERVENTION|Treatment as usual|Like patients from the treatment arm, these patients are on current residential treatment.
62169780|NCT04759118|NO_INTERVENTION|Control group|The participant in his group is a pregnant woman. The facilitators of the control groups were midwives who are already providing prenatal education classes at the clinics. The classes followed the government curriculum, which consists of three classes per month and does not invite husbands to participate. However, in this study, participants in the control group have four classes over a one-month period to better match the program of the intervention group. The material for the standard curriculum includes anatomical and physiological changes during pregnancy, pregnancy care, birth, and postpartum care. The classes also address family planning after giving birth, newborn care, preventing infectious disease, and procedures for obtaining a birth certificate. The midwives also discuss and debunk unhealthy local myths, beliefs, and cultural practices surrounding pregnancy, childbirth and the postpartum period
62169781|NCT04759118|EXPERIMENTAL|Experimental group|The modified childbirth education program was applied in the experimental group. the intervention covered modification of content material, learning methods, and involving husband or other relatives during the class.
62169782|NCT04627064|EXPERIMENTAL|Abemaciclib-Arm 1|"Arm 1~* Abemaciclib will be taken at a standard recommended starting dose 2X daily during 28 day study cycles and will be taken until radiographic progression, unacceptable toxicity or withdrawal.~* Imaging assessments will be performed every 8 weeks during the first six months of the study, then every 12 weeks, in both Arm 1 and Arm 2."
62169783|NCT04627064|EXPERIMENTAL|Abemaciclib and MK-6482-Arm 2|"Arm 2~* Arm 2 will start enrolling only after there is experience with Arm 1 to see what abemaciclib effects are when given alone,~* Dose escalation will occur following a 3+3 design.~* Abemaciclib will be taken 2X daily uring 28 day study cycle~* MK-6482 will be taken 1x daily during 28 day study cycle~* Imaging assessments will be performed every 8 weeks during the first six months of the study, then every 12 weeks, in both arms."
62169784|NCT05990283|EXPERIMENTAL|Socket shield technique with immediate implant placement|For the patients in the shield group, shields were prepared with the Root Membrane Kit. After the palatal part was removed, the buccal fragment was prepared at the crest level, and an internal bevel chamfer was formed on the fragment. Implants were placed 3-4 mm apical to the gingival margin of the adjacent teeth.
62169785|NCT05990283|EXPERIMENTAL|Guided bone regeneration with immediate implant placement|For the patients in the regeneration group, teeth were extracted atraumatically, implants were placed 3-4 mm to the gingival margin, and the space between the implant and buccal bone was filled with anorganic bovine bone graft at the time of implant placement. The graft particles were covered by a pericardium membrane. The membrane was fixed to the bone with titanium pins.
62169786|NCT03661008||Adolescents with paternal involvement|
62169787|NCT03661008||Adolescents without paternal involvement|
62169788|NCT01707498|EXPERIMENTAL|Tetraplegic patients|Scanning device RoBIK Brain-Computer Interface
62169789|NCT01707498|EXPERIMENTAL|Healthy volunteers|RoBIK Brain-Computer Interface
62169790|NCT01631318|EXPERIMENTAL|Diagnostic (3D contrast-enhanced ultrasound imaging)|Patients undergo 3D dynamic contrast-enhanced ultrasound imaging before initiation of chemotherapy and at 2 weeks.
62169791|NCT04440683||Antler plate group|Antler plate group
62169792|NCT04387916|EXPERIMENTAL|KC1036|Patients take a single dose of KC1036 for the pharmacokinetic study, then off for 5 days before the first cycle begins. In the subsequent treatment cycles, KC1036 are given orally once daily, 21 days as a cycle.
62169793|NCT03463538|ACTIVE_COMPARATOR|Arthroscopic capsular release|Surgical release performed under general anesthetic
62169794|NCT03463538|ACTIVE_COMPARATOR|Hydro-dilatation|injection of water under local anesthetic in to shoulder joint
62169795|NCT00400257||1|People at high risk of heart failure.
62169796|NCT00637325|EXPERIMENTAL|A|"In the maintenance study:~ARM A: maintenance of trastuzumab~In the 2nd line study:~ARM A: trastuzumab plus chemotherapy treatment"
62169797|NCT00637325|NO_INTERVENTION|B|"In the maintenance study:~ARM B: interruption of trastuzumab treatment~In the 2nd line study:~ARM B: chemotherapy alone"
62169798|NCT02449993||MammaTyper™|MammaTyper™ will be used to assess tumor material of patients treated with neo-adjuvant therapy.
62169799|NCT00940914|OTHER|pain disorders|patients with Parkinson's disease presenting pain disorders
62169800|NCT00940914|OTHER|without pain disorders|patients with Parkinson's disease without pain disorders
62169801|NCT01709643|OTHER|High fat breakfast lean subjects|Subjects will consume a high fat breakfast, containing of sausage rolls. Energy content of the breakfast will be set to 50 % of the recommended daily calorie intake (BMR times 1.3).
62169802|NCT01709643|OTHER|High fat breakfast,obese subjects|Subjects will consume a high fat breakfast, containing of sausage rolls. Energy content of the breakfast will be set to 50 % of the recommended daily calorie intake (BMR times 1.3).
62169803|NCT01709643|OTHER|HF breakfast with protein,lean subjects|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls. The amount of added proteins will be calculated to assure that the total energy content from proteins in the breakfast equals 20 %,
62169804|NCT01709643|OTHER|HF breakfast with protein,obese subjects|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls. The amount of added proteins will be calculated to assure that the total energy content from proteins in the breakfast equals 20 %,
62169805|NCT01291043|EXPERIMENTAL|Shiatsu Group|
62169806|NCT01291043|NO_INTERVENTION|Control Group|
62169807|NCT01643018|EXPERIMENTAL|laparoscopic surgery|-Laparoscopic surgery group describes the patients treated with laparoscopic surgery
62169808|NCT01643018|ACTIVE_COMPARATOR|Open Surgery|-open surgery group describes the patients treated with traditional open surgery
62169809|NCT01256372|EXPERIMENTAL|AP214; dose-level 1|AP214; dose-level 1
62169810|NCT01256372|EXPERIMENTAL|AP214; dose-level 2|AP214; dose-level 2
62169811|NCT01256372|PLACEBO_COMPARATOR|Placebo to AP214|Placebo
62169812|NCT05426655|EXPERIMENTAL|Self management|Intervention group: education in pain neuroscience + self-massage + exercises + advice and recommendations.
62169813|NCT00356213|EXPERIMENTAL|A|laparoscopic sleeve gastrectomy
62169814|NCT00356213|ACTIVE_COMPARATOR|B|laparoscopic gastric bypass
62169815|NCT02173249|EXPERIMENTAL|AC 170 0.24%|
62169816|NCT01643902|EXPERIMENTAL|IV tPA|Treatment will be initiated within 4.5 hours of awakening, for patients who meet inclusion criteria
62169817|NCT02657018|EXPERIMENTAL|Intervention|MOBIGAME group
62169818|NCT02657018|ACTIVE_COMPARATOR|Control|Lifestyle counseling group
62169819|NCT02860858|EXPERIMENTAL|Aflibercept|
62169820|NCT06446531|PLACEBO_COMPARATOR|Placebo|Randomization will occur 1:1:1:1 to this placebo group
62169821|NCT06446531|EXPERIMENTAL|SGLT2 inhibitor Group|Randomization will occur 1:1:1:1 to this SGLT2 inhibitor group
62169822|NCT06446531|EXPERIMENTAL|GLP-1 Receptor Agonist Group|Randomization will occur 1:1:1:1 to this GLP-1 receptor agonist group
62169823|NCT06446531|EXPERIMENTAL|Metformin with SGLT2 Inhibitor Group|Randomization will occur 1:1:1:1 to this metformin plus SGLT2 inhibitor group
62169824|NCT04090788|EXPERIMENTAL|dried bitter-gourd supplements|2.4 gram per day for 4 weeks
62169825|NCT04090788|ACTIVE_COMPARATOR|dried cucumber supplements|2.4 gram per day for 4 weeks
62169826|NCT01600261||eye exam|
62169827|NCT06012305|NO_INTERVENTION|Only Exercise Group|"They will be included in the exercise program that includes postural exercises after ischemic compression and stretching. Stretching exercises will be aimed at stretching the upper trapezius muscle. In the sitting position, the person whose head will be flexed and lateral flexed to the opposite side will stay in this position for 30 seconds and then come back to the same position.~This will be practiced 15 times a day, 3 days a week. Ischemic compression will then be applied. In ischemic compression, the therapist will apply pressure on the trigger points detected by palpation for 1 minute, and the application will be completed with a total of 5 repetitions at 1-minute intervals. It will continue to be applied 3 sets a day, 3 days a week. Posture exercises were determined as scapular retraction and chin tuck exercises. The exercises will be done in 3 sets of 15 repetitions per day, 3 days a week."
62169828|NCT06012305|ACTIVE_COMPARATOR|Taping Group with Muscle Technique|In addition to the exercise program in the first group, upper trapezius inhibition tape will be applied on the myofascial trigger points in the upper trapezius 3 times a week. The KT (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, USA) used in this study will be waterproof, porous and adhesive. 5 cm wide and 0.5 mm thick kinesio tape will be used. Before the application, the patient will be seated and asked to bring the neck to the opposite side lateral flexion and the head to the same side rotation. In this position, the Kinesiotape inhibition technique will be applied. The tape will be asked to stay on the person for 2 days, then it will be interrupted for 1 day and then the same application will be made. This practice will continue during the 4 weeks of treatment.
62169829|NCT06012305|EXPERIMENTAL|Taping Group with Epidermis Dermis Fascia Technique|In addition to the exercise program in the first group, kinesio taping will be applied with web cut cutting with EDF technique on myofascial trigger points in the upper trapezius. Before the application, the patient will be seated and asked to bring the neck to the opposite side lateral flexion and the head to the same side rotation. Tape will be applied with EDF technique. The band will be asked to stay on the person for 2 days, then a break for 1 day and then the same application will be made again. This practice will continue during the 4 weeks of treatment.
62169830|NCT02936739|EXPERIMENTAL|Elastic spine pad|Patients, who receive Elastic Spine Pad (TM) as cervical disc prosthesis after ventral discectomy.
62169831|NCT02936739|ACTIVE_COMPARATOR|Rotaio|Patients, who receive Rotaio (TM) as cervical disc prosthesis after ventral discectomy.
62169832|NCT04565392|EXPERIMENTAL|famotidine|A 20-milligram tablet of Pepcid in the morning and evening the first day, to be increased thereafter to one tablet every 8 hours if not improving
62169833|NCT04565392|PLACEBO_COMPARATOR|Placebo|A placebo tablet to match a 20-milligram (mg) tablet of Pepcid in the morning and evening the first day, to be increased thereafter to one tablet every 8 hours if not improving
62169834|NCT05615558|EXPERIMENTAL|Animal|Arm of the study consuming a high-protein diet from animal sources.
62169835|NCT05615558|EXPERIMENTAL|Non-animal|Arm of the study consuming a high-protein diet from non-animal sources.
62169836|NCT06065202|EXPERIMENTAL|SeND Home Pathway|Total parenteral nutrition (TPN) will begin within 72 hours of abdominal surgery. Calorie needs will be determined by indirect calorimetry. Nutritional shakes will begin when a liquid diet is started. These will be taken 3 times a day while in the hospital and for 4 weeks after discharge.
62169837|NCT06065202|NO_INTERVENTION|Standard Nutrition|Standard nutrition as determined by clinical providers.
62169838|NCT06645730||Metabolic syndrome combined with hypertension|Metabolic syndrome patients diagnosed with hypertension.
62169839|NCT06645730||Metabolic syndrome combined with diabetes|Metabolic syndrome patients diagnosed with diabetes.
62169840|NCT06645730||Metabolic syndrome combined with fatty liver|Metabolic syndrome patients diagnosed with fatty liver.
62169841|NCT02270463|EXPERIMENTAL|Tagraxofusp-erzs|Patients received tagraxofusp-erzs (SL-401) by IV infusion over 15 minutes for 5 consecutive days of a 28-day cycle in both stages.
62169842|NCT02312609|EXPERIMENTAL|Test|Minocycline hydrochloride extended release tablets 135 mg
62169843|NCT02312609|ACTIVE_COMPARATOR|Reference|Solodyn Extended Release Tablets 135 mg
62169844|NCT06255288|EXPERIMENTAL|Dialogue, patient information and protein supplement|"Patient will receive:~1. Structured nutritional dialogue during two visits to the clinic.~2. Written patient information (pamphlet) during their first visit to the clinic.~3. Protein supplement drink during two visits to the clinic.~4. Prescription of protein supplement drink during their first visit to the clinic."
62169845|NCT06339385||EDICU patients|All patients admitted to the participating EDICU during the on-site investigation.
62169846|NCT00577096|EXPERIMENTAL|Exercise|Study participants were computer randomized to an individualized exercise program. Participants were stratified within Arm according to whether or not they received thalidomide with heparin, and by age (60 and younger versus older than 60)
62169847|NCT00577096|ACTIVE_COMPARATOR|usual care|Study participants were asked to remain as active as possible but not prescribed an individualized exercise program. Participants were stratified within Arm according to whether or not they received thalidomide with heparin, and by age (60 and younger versus older than 60)
62169848|NCT01447251|EXPERIMENTAL|A: Newly Diagnosed/CPAP/NO DM/PreDx DRS|patients who have newly-diagnosed obstructive sleep apnea (OSA) requiring continuous positive airway pressure (CPAP) therapy without diabetes and are given the result of the diabetes risk score
62169849|NCT01447251|EXPERIMENTAL|B: Newly Diagnosed/CPAP/NO DM/NO PreDx DRS|patients who have newly-diagnosed OSA requiring CPAP therapy without diabetes and are not given the result of the diabetes risk score
62169850|NCT01447251|ACTIVE_COMPARATOR|C: Controls|age, sex, and BMI-matched controls without OSA or diabetes
62169851|NCT01447251|ACTIVE_COMPARATOR|D: Controls on CPAP|age, sex, BMI, and OSA severity matched patients on CPAP therapy for OSA
62363514|NCT06022146|EXPERIMENTAL|1H3P3 regimen of isoniazid and rifapentine 3 times a week for one month|12-dose ultra-short TPT 1H3P3 regimen of isoniazid and rifapentine 3 times a week for one month
62182337|NCT03381469|ACTIVE_COMPARATOR|Periodontitis Patients undergoing supragingival scaling|The control group participants with periodontitis will receive oral hygiene instruction and single visit supragingival scaling of all teeth at their baseline visit.
61985984|NCT03013556|EXPERIMENTAL|Group B,TDF+PEG|The subjects in group B will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks
62363515|NCT06022146|ACTIVE_COMPARATOR|3HR regimen of isoniazid and rifampicin once daily for three months|3HR regimen of isoniazid and rifampicin once daily for three months
62169852|NCT02368366|EXPERIMENTAL|Therapist Guided Face to Face FPST|Therapist Guided Face to Face Family Problem Solving Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
62169853|NCT02368366|EXPERIMENTAL|Therapist Guided Online FPST|Therapist Guided Online Family Problem Solving Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
62169854|NCT02368366|EXPERIMENTAL|Self-Guided Online FPST|Self-Guided Online Family Problem Solving Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
62169855|NCT02640807|EXPERIMENTAL|CYT107 high frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for 4 weeks
62169856|NCT02640807|EXPERIMENTAL|CYT107 low frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for the first week, followed by CYT107 and Placebo once a week for the three following weeks
62363516|NCT03037307|EXPERIMENTAL|Test product|Participants will topically apply the test product to clean wet denture (upper denture) fit surface in a pattern consistent with product label and application instructions.
62169857|NCT02640807|PLACEBO_COMPARATOR|Control|Patients will receive Placebo (NaCl 0.9%) twice a week for 4 weeks
62169858|NCT06435624|EXPERIMENTAL|Combined group|Intelligent rehabilitation robot training system under repetitive facilitative exercise (RFE)
62169859|NCT06435624|ACTIVE_COMPARATOR|RFE group|Repetitive facilitative exercise (RFE)
62169860|NCT06435624|ACTIVE_COMPARATOR|CT group|Conventional therapy (CT)
62169861|NCT05343819|EXPERIMENTAL|AON-D21|Multiple ascending doses by iv infusion
62169862|NCT05343819|PLACEBO_COMPARATOR|Placebo|Placebo medication identical in appearance to active
62169863|NCT04581772|EXPERIMENTAL|Cohort A|
62169864|NCT04581772|EXPERIMENTAL|Cohort B|
62169865|NCT04581772|EXPERIMENTAL|Cohort C|
62169866|NCT03104309|OTHER|Levonorgestrel intrauterine system|
62363517|NCT03037307|ACTIVE_COMPARATOR|Positive Control|Participants will topically apply the positive control to clean wet denture (upper denture) fit surface in a pattern consistent with product label and application instructions.
62363518|NCT03037307|OTHER|Negative Control|Participants of this group will not be assigned to any treatment.
62363519|NCT02914197|EXPERIMENTAL|Full information|"The intervention arm will receive full information on the risks and benefits of mammography through:~1. Decision aid~2. YouTube video~3. Group information session"
62363520|NCT02914197|NO_INTERVENTION|Control|Standard information leaflet for breast screening from Cancer Care Ontario
62169867|NCT01018576|EXPERIMENTAL|Delayed cord clamping|
62169868|NCT06016764|EXPERIMENTAL|Individuals with a diagnosis of autism|Individuals with an autism diagnosis
62169869|NCT03635437|EXPERIMENTAL|Low dose gamma-aminobutyric acid (GABA)|Oral GABA treatment 200 mg daily for 6 months
62169870|NCT03635437|EXPERIMENTAL|High dose gamma-aminobutyric acid (GABA)|Oral GABA treatment 600 mg daily for 6 months
62169871|NCT03635437|EXPERIMENTAL|High dose gamma-aminobutyric acid (GABA) + Alprazolam|Oral Alprazolam treatment 0.5 mg daily combined with oral GABA treatment 600 mg daily for 3 months. Alprazolam treatment thereafter ended, and study subjects will continue with oral GABA treatment 600 mg daily only for another 3 months.
62169872|NCT05630599||ILD|ILD, or lung fibrosis, is one of a spectrum of fibrotic diseases, associated with ageing, obesity, diabetes and pollution, that are responsible for \~45% of premature deaths in Western Europe. Of \>90,000 patients in the United Kingdom with ILD, \~30,000 have idiopathic pulmonary fibrosis, idiopathic pulmonary fibrosis, the most severe form. idiopathic pulmonary fibrosis is a disease of unknown aetiology that is more frequent in males presenting mainly in the sixth and seventh decades of life. There is no cure and median survival, just 3-5 years following diagnosis is worse than for many cancers.
62169873|NCT05630599||COPD|COPD is a common, long term condition of the lungs that is usually caused by cigarette smoking. In addition to daily symptoms and limitations in activities, patients are prone to developing chest infections called 'exacerbations'. Exacerbations are a significant problem: unpleasant for patients, and sometimes severe enough to cause hospital admission (and therefore National Health Service pressures) and death.
62182338|NCT03381469|ACTIVE_COMPARATOR|Without Periodontitis undergoing supragingival scaling|Placebo group participants without periodontitis will receive oral hygiene instruction and single visit supragingival scaling of all teeth at their baseline visit.
62363521|NCT03563261|ACTIVE_COMPARATOR|Collagen supplement group|Participants assigned in the collagen supplement group will drink the active product every morning before breakfast.
62363522|NCT03563261|PLACEBO_COMPARATOR|Placebo supplement group|Participants assigned in the placebo supplement group will drink the placebo every morning before breakfast.
62391429|NCT05737927|ACTIVE_COMPARATOR|SINGLE DOSE- TEST PRODUCT 2 (T2)|Oral coated beads 12 g glucose (content glucose/bead 47% w/w)
62169874|NCT05630599||COVID-19|Recovery from COVID19 has many unknowns, especially in the long term. Symptoms of COVID-19 have varied among those who have tested positive: some have displayed no symptoms, while others have developed severe pneumonia, progressing to lung injury and acute respiratory distress syndrome (ARDS) and, in the longer term, pulmonary fibrosis. Notably, the consequences of COVID-19 include effects on other organs including: heart, kidneys, and brain.
62169875|NCT01695525|EXPERIMENTAL|Yoga|Participants will be asked to practice Yoga 3 times per week at a minimum, and daily at a maximum. Participants will receive training in different Yoga techniques including breathing exercises, postures and meditation. Participants will be asked to practice 1 hour Yoga sessions comprised of breathing exercises, postures and meditation.
62169876|NCT04696926||patients who underwent an aortic valve replacement|
62169877|NCT02046057|EXPERIMENTAL|PNB of SLN|Percutaneous core biopsy of sentinel node prior to standard sentinel node dissection
62169878|NCT03742232|EXPERIMENTAL|PLENVU|PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.
62169879|NCT03742232|ACTIVE_COMPARATOR|SELG-ESSE|SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.
62169880|NCT02704026||Inflammatory Bowel Disease|Patients 6-18 of age at the time of enrolment who have IBD at any stage of disease activity, on any or no treatment
62169881|NCT02704026||Control|Age- and sex-matched healthy controls
62169882|NCT05041842|EXPERIMENTAL|Tucatinib plus systemic treatment with or without hormone therapy|Addition of tucatinib to the systemic treatment (pertuzumab and trastuzumab) with or without hormone therapy.
62169883|NCT05182827|EXPERIMENTAL|Euthymic patients with history of suicide attempt (suicide attempters)|Currently euthymic patients with at least one lifetime major depressive episode and a history of suicide attempts
62169884|NCT05182827|EXPERIMENTAL|Euthymic patients without any history of suicide attempt (affective controls)|Currently euthymic patients with at least one lifetime major depressive episode and with no history of suicide attempts
62169885|NCT05613504|ACTIVE_COMPARATOR|Treatment group A|Treatment group A was given endocrine and acupuncture treatment for 8 weeks (24 times in total, 3 times a week); followed up for 16 weeks, no acupuncture treatment.
62169886|NCT05613504|SHAM_COMPARATOR|Treatment group B|Treatment group B was given endocrine and sham acupuncture treatment for 8 weeks, followed up for 16 weeks, no acupuncture during the period, and after 16 weeks, received standardized acupuncture for 8 weeks (24 times in total, 3 times a week).
62169887|NCT05613504|NO_INTERVENTION|control|The control group was given conventional adjuvant endocrine therapy, premenopausal patients received tamoxifen therapy, and postmenopausal patients received aromatase inhibitor or tamoxifen therapy.
62169888|NCT06464614|EXPERIMENTAL|Adebrelimab＋Apatinib＋Radiotherapy＋Investigator chosen chemotherapy (ICC)|Adebrelimab（1200mg，d1 q3w, continuous medication until disease progression, intolerable toxicity, or withdrawal due to other reasons），Apatinib (250mg，d1-21，q3w), Radiotherapy， Investigator chosen chemotherapy (ICC)
62169889|NCT06464614|EXPERIMENTAL|Adebrelimab＋Apatinib＋Investigator chosen chemotherapy (ICC)|Adebrelimab（1200mg，d1 q3w, continuous medication until disease progression, intolerable toxicity, or withdrawal due to other reasons），Apatinib (250mg，d1-21，q3w), Investigator chosen chemotherapy (ICC)
62169890|NCT02892006|EXPERIMENTAL|Intervention|All participants in the study will participate a 6 week improv intervention.
62169891|NCT04024371||HV|Humans aged 20-55 without a diagnosis of a psychiatric and neurological disorder.
62169892|NCT04024371||SZ|Humans aged 20-55 with a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of Schizophrenia.
62169893|NCT04024371||MDD|Humans aged 20-55 with a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of MDD.
62169894|NCT04531852||At risk older adults|Home-dwelling older adults entitled to preventive home visit, who had a risk profile for loss of physical function and disability identified through a multi-domain screening instrument
62169895|NCT04950049|ACTIVE_COMPARATOR|2 ml dexamethasone (5 mg/ml)|50 patients receive 2 ml dexamethasone (5 mg/ml) , the injection time of dexamethasone was less than 2s.
62169896|NCT04950049|EXPERIMENTAL|5 ml dexamethasone (2mg/ml)|50 patients receive 5 ml dexamethasone (2mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.
62169897|NCT04950049|EXPERIMENTAL|10 ml dexamethasone (1mg/ml)|50 patients receive 10 ml dexamethasone (1mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.
62169898|NCT04950049|EXPERIMENTAL|20 ml dexamethasone (0.5mg/ml)|50 patients receive 20 ml dexamethasone (0.5mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.
62169899|NCT00006436|EXPERIMENTAL|Arm 1-Combination Chemo and Biological Therapy|Combination chemo and biological therapy
62169900|NCT06028399|EXPERIMENTAL|Concurrent Training|Concurrent training combines aerobic and resistance training within the same session for 30 - 60 minutes, comprising 3 sessions per week for 12 weeks.
62169901|NCT06028399|ACTIVE_COMPARATOR|Aerobic Training|Aerobic training for 30 - 60 minutes comprises 3 sessions per week for 12 weeks.
62169902|NCT02382406|EXPERIMENTAL|Arm A: Phase I Dose Finding Cohort|"Twelve subjects will be enrolled and treated with carboplatin AUC 6 IV on Day 1, nab-paclitaxel 100 mg/m\^2 IV on Day 1, Day 8, and Day 15, pembrolizumab 2\* mg/kg IV on Day 1 for 4 cycles. pembrolizumab (Phase I) treatment for Cohort 1 will continue for a maximum duration of 4 21-day cycles~Phase I, Cohort 1 Maintenance Therapy:~Participants who have confirmed CR, PR, or SD (non-progression) after 4 cycles, maintenance therapy with MK-3475 2\* mg/kg will continue on D1 of each 21-day cycle. Treatment will continue until progression of disease, unacceptable toxicity, or a maximum of 2 years from C1D1.~If unacceptable toxicity is seen in Phase I Cohort 1, 12 additional participants will be enrolled in Cohort 2 and treated with carboplatin AUC 6 IV on D1, nab-paclitaxel 100 mg/m2 IV on D1, D8, and D15, MK-3475 2\*mg/kg IV on D1 starting C2. MK-3475 (Phase 1) treatment for Cohort 2 will continue for a maximum duration of 3 21-day cycles (C2-4 only)."
62182339|NCT02003690|EXPERIMENTAL|Dialectical Behavior Therapy + Pharmacotherapy|Dialectical Behavior Therapy + Pharmacotherapy
62182340|NCT02003690|ACTIVE_COMPARATOR|Standard of Care Psychotherapy + Pharmacotherapy|Standard of Care Psychotherapy + Pharmacotherapy
62363523|NCT00615212|ACTIVE_COMPARATOR|Subjects receiving midazolam|Eligible subjects will receive midazolam oral syrup with a dose of 5 milligrams on Day 1.
62169903|NCT02382406|EXPERIMENTAL|Arm B: Phase II Investigational Treatment|"Subjects will be treated with carboplatin AUC 6 given IV on Day 1, nab-paclitaxel 100 mg/m\^2 given IV on Day 1, Day 8, and Day 15, and pembrolizumab 200mg IV on Day 1 of each cycle. Pembrolizumab Phase II treatment will continue for a maximum duration of 4 cycles (cycle = 21 days).~Maintenance Therapy For participants who have confirmed CR, PR, or SD (non-progression) after 4 cycles of induction therapy, maintenance therapy with MK-3475 2\* mg/kg will continue on Day 1 of each 21-day cycle. Treatment will continue until progression of disease, unacceptable toxicity, or for a maximum of 2 years from C1D1.~\*As additional data from ongoing trials becomes available, the dose of MK-3475 may be adjusted."
62169904|NCT05422859|OTHER|MobiDig|50 patients will have access to a mobile phone application for 3 months.
62169905|NCT05626478|ACTIVE_COMPARATOR|Arm 1 - Cataract surgery gtt regimen per SOC|Following cataract surgery (without Dextenza 0.4mg insert) patients will receive: Prednisolone Acetate 1% QID X 2 Weeks, then BID x 2 weeks and stop / Prolensa 0.07% QD X 4 Weeks and stop.
62169906|NCT05626478|EXPERIMENTAL|Arm 2 - Cataract surgery with Dextenza and less frequency of gtt regimen|Following cataract surgery with DEXTENZA 0.4mg insert, patients will receive: Prolensa 0.07% QD X 4 Weeks and stop
62169907|NCT04685759|ACTIVE_COMPARATOR|In-Person Exercise Protocol (IPEP)|This group will receive exercise instruction and monitoring in-person from the certified Cancer Exercise Trainer (CET) in the gym facility at Moncrief Cancer Institute (MCI). Study participants will be scheduled for exercise sessions twice a week with the oncology exercise trainer.
62169908|NCT04685759|EXPERIMENTAL|Virtual Exercise Protocol (VEP)|This group will receive exercise instruction and monitoring from the CET via telehealth sessions at home. Study participants will be scheduled for exercise sessions twice a week with the oncology exercise trainer.
62169909|NCT04258215|EXPERIMENTAL|Positive pressure achieved with PSA|Maximum airway inflation pressure achievable before a significant leak occurs.
62169910|NCT06646367|ACTIVE_COMPARATOR|Conventional therapy|It will include 36 lactating females suffering from neck pain who will receive conventional therapy in the form of moist heat for 30 min, 5 times per week for 5 weeks and transcutaneous electrical nerve stimulation (TENS) that will be applied for 25 min, 5 times per week for 5 weeks.
62169911|NCT06646367|EXPERIMENTAL|Conventional therapy + Alexander technique|It will include 36 lactating females suffering from neck pain who will receive the same conventional therapy in addition to the Alexander technique which will be applied for 60 min, 2 classes per week, for 5 weeks.
62169912|NCT01248143|EXPERIMENTAL|Green tea|
62169913|NCT01248143|EXPERIMENTAL|FPP|
62169914|NCT03928769||Control Group|Patients with traumatic vascular injury, ultimately corresponding to control patients
62169915|NCT03928769||Atheroma Group|"Patients will be included either in the atheromatous group (patients with atheromatous pathology) or in the control group (patients without atheromatous pathology), according to the clinical evaluation.~In the atheromatous group, subjects must have a clinically significant atheromatous pathology.~The investigator must specify the site (s) affected by the atheroma: carotid artery, coronary artery, aorta, renal artery, mesenteric artery or lower limb artery."
62169916|NCT03852875|EXPERIMENTAL|Education|Patients in the experimental arm will receive a 1-on-1 education session to review the their CR participation. As part of the discussion about their CR participation, these patients will also receive feedback on their intake exercise stress test.
62169917|NCT03852875|SHAM_COMPARATOR|Control|Patients in the Control arm will receive a 1-on-1 education session to review the their CR participation. As part of the discussion about their CR participation, these patients will NOT receive feedback on their intake exercise stress test.
62169918|NCT01886391|EXPERIMENTAL|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 \[5-min DBR\], 1 for week 2 \[10-min DBR\], 1 for weeks 3-8 \[15-min DBR\]), developed by the PI, to use to practice their deep breathing.
62169919|NCT04309006|EXPERIMENTAL|CTG and customized healing abutment|Customized healing abutment used with connective tissue graft
62169920|NCT04309006|EXPERIMENTAL|CTG and conventional healing abutment|Conventional healing abutment (same diameter of the implant) used with connective tissue graft
62169921|NCT04309006|ACTIVE_COMPARATOR|customized healing abutment|Customized healing abutment used without connective tissue graft
62169922|NCT04309006|ACTIVE_COMPARATOR|conventional healing abutment|Conventional healing abutment (same diameter of the implant) without connective tissue graft
62169923|NCT05651542|EXPERIMENTAL|Comprehensive Self-Management|The 8 week intervention is delivered online with a brief weekly check-in with a registered nurse.
62169924|NCT05651542|OTHER|Usual care group|The control group will receive standard care without the comprehensive self-management intervention.
62169925|NCT06132906|EXPERIMENTAL|(Study group) will be treated with locating guides to reposition the maxilla with pre-bent plates|After le fort 1 osteotomy, locating guides will be used to reposition the maxilla with pre-bent plates.
62169926|NCT06132906|ACTIVE_COMPARATOR|(Control group) will be treated with Intermediate wafer.|After le fort 1 osteotomy, Intermediate wafer will be used with intermaxillary fixation.
62169927|NCT02586389||Non-hematological Cancer Cohort|Eligible subjects will have been previously diagnosed with a non-hematological cancer with tumor present at baseline blood draw.
62363524|NCT00615212|ACTIVE_COMPARATOR|Subjects receiving rosiglitazone|Eligible subjects will receive rosiglitazone oral tablet with a dose of 4 milligrams on Day 2.
62363525|NCT00615212|ACTIVE_COMPARATOR|Subjects receiving flurbiprofen|Eligible subjects will receive flurbiprofen oral tablet with a dose of 50 milligrams on Day
62363526|NCT00615212|EXPERIMENTAL|Subjects receiving GSK376501|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams from Day 4 to Day 10.
62363527|NCT00615212|EXPERIMENTAL|Subjects receiving GSK376501+ midazolam|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with midazolam oral tablet of 5 milligrams on Day 11.
62391430|NCT05737927|ACTIVE_COMPARATOR|SINGLE DOSE- TEST PRODUCT 3 (T3)|Oral coated beads 16 g glucose (content glucose/bead 47% w/w)
62169928|NCT04092621|EXPERIMENTAL|Rhythm-control strategy|The patient will receive 1) amiodarone 150mg bolus over ten minutes followed by intravenous (IV) 1mg/min for 6 hours and then 0.5mg/min for 18hours, and 2) direct current cardioversion (DCC) at the completion of initial 6 hour IV bolus or within 24 hours of new onset of atrial fibrillation. Patient will be placed on by mouth amiodarone 400mg three times daily for seven days, then 400mg twice daily for seven days, then 400mg once daily for seven days, then 200mg daily until stop date which will be by provider discretion after discharge from ICU. If the patient does not convert to a normal sinus rhythm with routine DCC then they will remain in the rhythm-control strategy to receive amiodarone as directed. Amiodarone may be extended at discretion of provider for 30 days with discontinuation if adverse effects. If no contraindications, anticoagulation will be recommended prior to DCC with enoxaparin 1mg/kg every 12 hours.
62169929|NCT04092621|ACTIVE_COMPARATOR|Rate-control strategy|At treating physician's discretion, one of the following, or a combination of the following, will be administered to the patient: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin. The target heart rate is less than 120 beats per minute (bpm) or maintained hemodynamics. Patients in the rate-control arm who are hypotensive after new onset atrial fibrillation can undergo DCC at the provider's discretion and crossover into the rhythm-control arm.
62169930|NCT02619279|EXPERIMENTAL|Immediate treatment|Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
62169931|NCT02619279|NO_INTERVENTION|Delayed treatment|Participants' mothers will receive no intervention but will be placed on a waitlist to receive the intervention after a 12-month delay.
62363528|NCT00615212|EXPERIMENTAL|Subjects receiving GSK376501 + rosiglitazone|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with rosiglitazone oarl tablet of 4 milligrams on Day 12.
62169932|NCT02801747|EXPERIMENTAL|Condition 1|Receives a core intervention session and the navigation intervention component (long duration; that is, up to 6 months).
62169933|NCT02801747|EXPERIMENTAL|Condition 2|Receives a core intervention session, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
62169934|NCT02801747|EXPERIMENTAL|Condition 3|Receives a core intervention session, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
62169935|NCT02801747|EXPERIMENTAL|Condition 4|Receives a core intervention session, the peer mentorship component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
62169936|NCT02801747|EXPERIMENTAL|Condition 5|Receives a core intervention session, the pre-adherence preparation component, and the navigation intervention component (short duration, that is, up to 3 months).
62169937|NCT02801747|EXPERIMENTAL|Condition 6|Receives a core intervention session, the pre-adherence preparation component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
62169938|NCT02801747|EXPERIMENTAL|Condition 7|Receives a core intervention session, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (long duration, that is, up to 6 months).
62169939|NCT02801747|EXPERIMENTAL|Condition 8|Receives a core intervention session, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
62363529|NCT00615212|EXPERIMENTAL|Subjects receiving GSK376501 + flurbiprofen|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with flurbiprofen oral tablet of 50 milligrams on Day 13.
62169940|NCT02801747|EXPERIMENTAL|Condition 9|Receives a core intervention session, the Motivational Interviewing sessions component, and the navigation intervention component (short duration, that is, up to 3 months).
62363530|NCT06169995|EXPERIMENTAL|Remimazolam Tosilate for Injection|
62169941|NCT02801747|EXPERIMENTAL|Condition 10|Receives a core intervention session, the Motivational Interviewing sessions component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
62169942|NCT02801747|EXPERIMENTAL|Condition 11|Receives a core intervention session, the Motivational Interviewing sessions component, the peer mentorship component, and the navigation intervention component (long duration, that is, up to 6 months).
62169943|NCT02801747|EXPERIMENTAL|Condition 12|Receives a core intervention session, the Motivational Interviewing sessions component, the peer mentorship component, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
62169944|NCT02801747|EXPERIMENTAL|Condition 13|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, and the navigation intervention component (long duration, that is, up to 6 months).
62169945|NCT02801747|EXPERIMENTAL|Condition 14|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
62169946|NCT02801747|EXPERIMENTAL|Condition 15|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
62169947|NCT02801747|EXPERIMENTAL|Condition 16|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the peer mentorship component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
62182341|NCT05120154|EXPERIMENTAL|Intervention|Access to all the CAPACITI module materials, provided on a learning management system. The intervention group will also receive the CAPACITI program with module facilitation, namely high-facilitation and expert coaching in the coverage of module materials in four live webinars (bimonthly for the 2 month duration of the module = 4 webinars).
62363531|NCT05146934||Hormone sensitive group|Prednisone, 0.5mg/kgqd, 3-6months
62363532|NCT05146934||Hormone insensitivity group|Prednisone, 0.5mg/kgqd, 3-6months
62363533|NCT00880607|ACTIVE_COMPARATOR|Intrathecal morphine|Receives a single dose of intrathecal morphine
62363534|NCT00880607|EXPERIMENTAL|Extended Release Epidural Morphine|Receives DepoDur extended release epidural morphine for pain management
62169948|NCT01890798|EXPERIMENTAL|Drisapersen (DMD117402)|The protocol is open only to the subjects who completed GSK protocol DMD114876 and participated in protocol DMD115501, United States citizens who have completed protocol DMD114044, or United States citizens who are participating in protocol DMD114349 outside the United States and want to end their participation in the DMD114349 study. Eligible subjects will receive drisapersen 6 milligram (mg)/kilograms (kg) once a week via subcutaneous (SC) injection.
62169949|NCT05051696|EXPERIMENTAL|Oncorine (H101) with or without radiotherapy|The tumor mass was injected with H101 per day for 5 consecutive days, 3 weeks as one treatment cycle, and 1 to 4 cycles according to the condition of the patient, and the patient was treated with or without radiotherapy in sequential. The injection dose of H101 was determined by the tumor volume or maximum tumor diameter:5.0×10\^11 virus particles(VP) for if tumor diameter≤5cm; 1×10\^12 VP for the tumor diameter between 5cm and 10cm, and 1.5×10\^12 VP for the tumor diameter\>10cm.
62169950|NCT06646419||Intervention group|"Intervention is implemented at a hospital level and will change overall daily practice. The intervention is composed of 3 active components: 1) education on guideline led disease knowledge and transition bundle led management pathway, 2) standardized transition bundle implementation, 3) clinical audit.Education begins at nearly 4 weeks before first subject in and keep learning every 4 weeks.~Standardized transition bundle will be implemented once the first round education is completed. Clinical audit takes up after first subject enrolled and implemented every 12 weeks."
62169951|NCT06646419||Control group|The control group will maintain the current usual care practice.
62169952|NCT00166361|EXPERIMENTAL|Memokath 051 Ureteral Stent|Subjects assigned to this arm received a Memokath 051 Ureteral Stent.
62363535|NCT06332040|EXPERIMENTAL|Gentamicin|14.4 mg gentamicin dissolved in 30 mL 0f 0.9% saline administered BID
62169953|NCT00166361|ACTIVE_COMPARATOR|JJ Stent|Subjects assigned to this arm received a JJ stent.
62169954|NCT02391545|EXPERIMENTAL|Duvelisib and Rituximab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Duvelisib will be administered orally, twice daily, in 28-day cycles.~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26."
62169955|NCT02391545|EXPERIMENTAL|Duvelisib and Obinutuzumab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Duvelisib will be administered orally, twice daily, in 28-day cycles.~Obinutuzumab 1000 mg will be administered intravenously (IV) beginning at Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26."
62169956|NCT05598203|EXPERIMENTAL|Intervention|"The intervention group will receive four group meetings in addition to the usual care, specifically in the form of operative groups. Participants in these groups will actively participate in the sessions and will be given tasks to complete at home. There will be four sessions, which can be held weekly, fortnightly or monthly, depending on the availability of participants. Each participant will attend each meeting only once. These sessions, lasting one hour, will take place at the Hospital de Clínicas de Porto Alegre and approximately 20 participants will be invited to each group.~Topics covered in these sessions will include:~1. Let's go shopping = purchasing food through NOVA classification and nutritional labeling and food labels~2. Healthy Plate = Diabetes Plate Method.~3. Hunger and satiety = signs of hunger and satiety and eating mindfully~4. Empowering change = barriers and difficulties in the process of maintaining lifestyle changes"
62169957|NCT05598203|ACTIVE_COMPARATOR|Control (usual treatment)|"In the usual care provided, there will be a consultation with a dietitian every four months. This consultation will involve nutritional counseling, where up to five combinations of lifestyle changes will be agreed upon with the participant. The combinations will be tailored to individual needs and align with diabetes recommendations, emphasizing increased consumption of natural foods, organizing meals according to the Diabetes Plate method, and promoting a reduction in sedentary time. Subsequent visits will reassess the combinations of lifestyle changes, addressing barriers and motivations identified during the counseling process.~Patients will not be encouraged to implement caloric restrictions, but they will be motivated to adopt healthy eating patterns in accordance with the recommendations of the American Diabetes Association and the Sociedade Brasileira de Diabetes."
62169958|NCT03455569|EXPERIMENTAL|Behavioral sleep education|manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
62169959|NCT03455569|EXPERIMENTAL|Education only|education on sleep, aging, and dementia but without specific or individualized recommendations
62169960|NCT03472976|EXPERIMENTAL|Group 1|0.1 ml of influenza A/H5N1 IIV vaccine (9 mcg HA) intradermally 15 minutes after the application of approximately 250 mg of Imiquimod (Aldara) cream topically (deltoid) on Day 1 and Day 22. N=25
62169961|NCT03472976|EXPERIMENTAL|Group 2|0.1 ml of influenza A/H5N1 IIV vaccine (9 mcg HA) intradermally 15 minutes after the application of approximately 250 mg of Aqueous Cream B.P. (Control Cream) topically (deltoid) on Day 1 and Day 22. N=25
62169962|NCT01689285|ACTIVE_COMPARATOR|valacyclovir tablet|Administration of 500 mg once daily on day 1 (group A) or on day 8 (group B)
62169963|NCT01689285|EXPERIMENTAL|valacyclovir oral solution|Administration of 500 mg once daily on day 1 (group B) or on day 8 (group A)
62169964|NCT05674578|EXPERIMENTAL|Health services research (patient navigator)|Patients are assigned a Black patient navigator for racial concordance and receive coaching from patient navigator over 30 minutes every other week for 3 months and then monthly for 3 months.
62169965|NCT00789932|EXPERIMENTAL|CBT|
62169966|NCT00789932|ACTIVE_COMPARATOR|Usual Care|
62169967|NCT06326216||Observational (Cohort I)|Prostate cancer patients undergo blood and urine sample collection on study. Patients' medical records are also reviewed.
62169968|NCT06326216||Observational (Cohort II)|Female urology clinic patients and female volunteers undergo blood and urine sample collection on study.
62169969|NCT00761410|OTHER|P.F.C. Sigma RP-F Total Knee Replacement|An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
62363536|NCT06332040|PLACEBO_COMPARATOR|Placebo|30 mL of 0.9% saline administered BID
62391431|NCT05737927|ACTIVE_COMPARATOR|SINGLE DOSE- TEST PRODUCT 4 (T4)|Oral uncoated beads 12 g glucose
62391432|NCT05737927|ACTIVE_COMPARATOR|SINGLE DOSE- TEST PRODUCT 5 (T5)|Oral coated beads 12 g glucose (content glucose/bead 60% w/w)
62391433|NCT05737927|ACTIVE_COMPARATOR|MULTIPLE DOSE- TEST PRODUCT 2 (T2)|Oral coated beads 12 g glucose (content glucose/bead 47% w/w)
62169970|NCT04822337|EXPERIMENTAL|Phase I|Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
62169971|NCT04822337|EXPERIMENTAL|Phase II|Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
62169972|NCT05882344|ACTIVE_COMPARATOR|Deep Brain Stimulation|Patients who are implanted and receive intermittent stimulation daily for the first 12 months
62169973|NCT05655624|EXPERIMENTAL|Group A|Pursed lip Breathing along Mat Pilates Training
62169974|NCT05655624|ACTIVE_COMPARATOR|Group B|pursed lip breathing without Mat Pilates Training
62169975|NCT04263883|ACTIVE_COMPARATOR|Conventional treatment|Usual Care Group: Conventional treatment: moist hot pack. manual therapy, Therapeutic Exercise.Home program routine.
62363537|NCT00212758|ACTIVE_COMPARATOR|Low- Standard GH dose|This arm will receive Low dose of growth hormone (GH) (Nutropin AQ), for 7 days in a cross over design. Low dose GH will be 0.025 mg/kg/day. This will be followed by 2 weeks of wash out, then subjects will receive and the standard dose of Nutropin AQ (GH) at 0.05 mg/kg/dose given subcutaneously for another 7 days. IGF-I levels are measured after 7 days of the Low and the Standard dose of GH. After that all subjects will be treated with the standard dose of GH therapy of 0.05 mg/kg/day for 6 months and re-evaluated. If growth is adequate then subjects will continue on standard dose of GH for another 6 months for a total of 12 months.
62169976|NCT04263883|EXPERIMENTAL|Study or Experimental Group|"1. moist hot pack.~2. manual therapy.~3. Therapeutic Exercise.~4. Home program routine. 5.3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill. For 10 weeks(3Times/week for 20 minutes)."
62169977|NCT05102656||Group A (video call)|Patients receive standard of care via video call with treating physician.
62169978|NCT05102656||Group B (in-person)|Patients receive standard of care in-person physician visits.
62169979|NCT00475787|EXPERIMENTAL|Spinal Manipulative therapy|Spinal manipulation involves high velocity low amplitude manipulation and flexion distraction and mobilization.
62169980|NCT00475787|SHAM_COMPARATOR|Detuned Ultrasound|"Detuned Ultrasound involves utilizing an ultrasound machine that is set to 0 w/cm2 and US gel is applied to the spine for 11 minutes."
62169981|NCT04758156|EXPERIMENTAL|CleanViewAL|1L polyethylene glycol+ascorbic acid split dose
62169982|NCT04758156|PLACEBO_COMPARATOR|SUPREP|Oral sulfate solutiom
62169983|NCT03160755||Qualitative Interviews|Adult outpatients with metabolic syndrome.
62391434|NCT01730768|EXPERIMENTAL|AQW051 10 mg/day|Two 5mg AQW051 capsules will be taken orally daily by patients from Day 1 until Day 84.
62169984|NCT00111839|ACTIVE_COMPARATOR|Pemetrexed Alone|Participants will receive pemetrexed 50 milligrams per square meter (mg/m\^2) intravenous (IV) infusion every 3 weeks until disease progression (PD) or the occurrence of unacceptable toxicity.
62169985|NCT00111839|EXPERIMENTAL|Pemetrexed Plus Matuzumab 800 mg per Week|Participants will receive pemetrexed 50 mg/m\^2 IV infusion every 3 weeks in combination with matuzumab 800 milligrams (mg) IV infusion once every week. Treatment will continue until PD or the occurrence of unacceptable toxicity.
62169986|NCT00111839|EXPERIMENTAL|Pemetrexed Plus Matuzumab 1600 mg Every 3 Weeks|Participants will receive pemetrexed 50 mg/m\^2 IV infusion every 3 weeks in combination with matuzumab 1600 mg IV infusion every 3 weeks. Treatment will continue until PD or the occurrence of unacceptable toxicity.
62169987|NCT04402021|EXPERIMENTAL|Aerobic Exercise|Participants randomized to the aerobic exercise group will complete 30 minutes of outdoor walking at a moderate intensity, defined as 50% heart rate reserve from the American College of Sports Medicine (ACSM) exercise prescription recommendations. A 5-minute warm-up and cool-down will occur before and after the 30-minute bout. A Polar H10 heart rate monitor will continuously monitor exercise intensity during the session. Ratings of Perceived Exertion (RPE) will be assessed using the Borg scale (i.e., 6-20 rating system) to indicate perceived exercise effort every 5 minutes during the exercise session. Each session will last approximately 50 minutes.
62169988|NCT04402021|OTHER|Quiet Rest|Participants randomized to this condition will be instructed to watch a nature documentary void of topics related to sleep or exercise. A Polar H10 heart rate monitor will continuously monitor heart rate during the session to mimic the aerobic exercise condition. Participants will not be permitted to complete homework or work during the allotted time to reduce the chance of unintended stimuli. The quiet rest sessions will be 50 minutes in length.
62169989|NCT05005338|EXPERIMENTAL|Cohort A|
62169990|NCT03501888|ACTIVE_COMPARATOR|Cognitive Behavior Therapy (CBT)|CBT: individually, ca 18 weeks.
62169991|NCT03501888|ACTIVE_COMPARATOR|Acceptance and Commitment Therapy (ACT)|ACT: given in a group setting: ca 18 weeks.
62169992|NCT05153642|EXPERIMENTAL|Microsurgical intervention|Microsurgical intervention will be used for treatment of acute symptomatic occlusion of middle cerebral artery (in M1 or M2 segment) with or without intracranial ICA occlusion in patients who failed to reach recanalization using standard treatment
62169993|NCT05153642|NO_INTERVENTION|Standard treatment|Acute symptomatic occlusion of middle cerebral artery (in M1 or M2 segment) with or without intracranial ICA occlusion in patients who failed to reach recanalization using standard treatment - intravenous thrombolysis and/or mechanical thrombectomy
62169994|NCT04700397||Repeatability group 1|The patient with systolic blood pressure above 120 mmHg, who will receive a repeatability test with 200mcg, then another 100 mcg nitroglycerine injection, with a time interval of 3 minutes apart.
62169995|NCT04700397||Repeatability group 2|The patient with systolic blood pressure above 120 mmHg, who will receive a repeatability test with 200mcg, then another 200 mcg nitroglycerine injection, with a time interval of 3 minutes apart.
62169996|NCT04700397||Repeatability group 3|The patient with systolic blood pressure above 120 mmHg, who will receive a repeatability test with 200mcg, then another 300 mcg nitroglycerine injection, with a time interval of 3 minutes apart.
62169997|NCT04700397||pressure-recommended doses of NTG|The patient with systolic blood pressure above 100 mmHg, who will receive the nitroglycerine injection with the dose of recommendation, adjusted according to the blood pressure.
62169998|NCT00575900|EXPERIMENTAL|1|Low carbohydrate and low fat.
62169999|NCT00575900|EXPERIMENTAL|2|Low carbohydrate fat rich diet
62170000|NCT00575900|ACTIVE_COMPARATOR|3|A balanced low fat diet
62391435|NCT01730768|PLACEBO_COMPARATOR|Placebo to AQW051|Matching placebo administered orally.
62391436|NCT02730234|EXPERIMENTAL|JetStream XC with balloon angioplasty|The intervention consists of JetStream atherectomy of femoropopliteal in-stent restenosis using the JetStream XC device followed by adjunctive balloon angioplasty in all patients.
62363538|NCT00212758|ACTIVE_COMPARATOR|Standard-Low GH dose (7 Days)|This arm will receive Standard dose of growth hormone (GH) (Nutropin AQ), for 7 days in a cross over design. Standard dose GH will be 0.5 mg/kg/day. This will be followed by 2 weeks of wash out, then subjects will receive and the Low dose of Nutropin AQ (GH) at 0.025 mg/kg/dose given subcutaneously for another 7 days. IGF-I levels are measured after 7 days of the Low and the Standard dose of GH. After that all subjects will be treated with the standard dose of GH therapy of 0.05 mg/kg/day for 6 months and re-evaluated. If growth is adequate then subjects will continue on standard dose of GH for another 6 months for a total of 12 months.
62363539|NCT04273425||Study cohort (Confirmed myeloma patients)|"Patients with suspected multiple myeloma will be recruited. They will be asked to fill in questionnaires (regarding pain, quality of life, catastrophizing), donate serum samples and allow the research team to access their clinical data and their diagnostic bone biopsy.~Those who receive a positive diagnosis will be followed up upon completion of first-line treatment, and questionnaire data and blood samples collected again."
62363540|NCT04273425||Control cohort (non-confirmed myeloma patients)|"Patients with suspected multiple myeloma will be recruited. They will be asked to fill in questionnaires (regarding pain, quality of life, catastrophizing), donate serum samples and allow the research team to access their clinical data and their diagnostic bone biopsy.~Samples from patients who receive a negative myeloma diagnosis will be used as negative controls."
62363541|NCT03292341|EXPERIMENTAL|Patients|"Patients diagnosed with larynx cancer and ex-larynx cancer patients:~* Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~* Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~* Questionnaires"
62363542|NCT03292341|EXPERIMENTAL|Clinicians|"2.Clinicians Radiotherapy-oncologists, ENT(Ear-Nose-Throat)-specialists, General practitioners, Nurses~* Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~* Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~* Questionnaires"
62170001|NCT06646796|NO_INTERVENTION|Control group|Group used as comparison.
62170002|NCT06646796|EXPERIMENTAL|Intervention group|Yoga practioner group with a certified teacher, 3 times a week during 3 months.
62170003|NCT05768321|EXPERIMENTAL|GEC255 treatment|Oral tablet(s), once daily in 28-day cycles
62391437|NCT02160509||- The patients who undergo ultrasonography in the ED|
62170004|NCT03314233|EXPERIMENTAL|DING intervention|Delayed Cord Clamping
62170005|NCT03334799|OTHER|Sacroiliac belt on and off|Belt on and belt off
62170006|NCT00890214|ACTIVE_COMPARATOR|1 prostacyclin group|prostacyclin analogue (PGIA) used as circuit anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in acute kidney failure patients
62170007|NCT00890214|ACTIVE_COMPARATOR|2 heparin group|unfractionated heparin used as circuit anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in acute kidney failure patients
62170008|NCT02572999||Valvular heart disease|All patients aged 70 years or older, consecutively admitted for elective heart valve surgery or if admitted for elective transcatheter aortic valve implantation, or if a patient presents with symptomatic moderate to severe valvular heart disease on hospital admission as evidenced by moderate to severe valve regurgitation or stenosis will be included in this cohort. Participants will be observed up to 30 days post-hospital discharge
62170009|NCT03097458|EXPERIMENTAL|Counselling|short-term counselling for families
62170010|NCT03097458|NO_INTERVENTION|Wait-list control group|Wait-list control group
62170011|NCT02024399|OTHER|Exercise|Strength training x 20 sessions (10 weeks) Aerobic exercise core strengthening Running
62170012|NCT06538831|EXPERIMENTAL|Diet N-P-|
62170013|NCT06538831|EXPERIMENTAL|Diet N+P-|
62170014|NCT06538831|EXPERIMENTAL|Diet N-P+|
62170015|NCT06538831|EXPERIMENTAL|Diet N+P+|
62170016|NCT04859218|EXPERIMENTAL|ABO non-identical transfusion|All study patients will participate in the study for two consecutive transfusion episodes (a transfusion episode is defined as a clinic visit where 2 RBC units are transfused) and will receive an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. Randomization will dictate the order of the transfusion. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
62170017|NCT04859218|ACTIVE_COMPARATOR|ABO identical transfusion|All study patients will participate in the study for two consecutive transfusion episodes (a transfusion episode is defined as a clinic visit where 2 RBC units are transfused) and will receive an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. Randomization will dictate the order of the transfusion. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
62170018|NCT01661244|EXPERIMENTAL|Part A - Single dose escalation|
62170019|NCT01661244|EXPERIMENTAL|Part B - 14 day repeat dose escalation|
62170020|NCT04785742|EXPERIMENTAL|20 exon (20INS) mutation|
62170021|NCT04785742|EXPERIMENTAL|Rare mutations except for 20INS|
62170022|NCT01242033|EXPERIMENTAL|one cup red raspberries|treatment meal consists of one cup red raspberries
62170023|NCT01242033|EXPERIMENTAL|two cups red raspberries|treatment meal consists of two cups red raspberries
62170024|NCT01242033|EXPERIMENTAL|four cups red raspberries|treatment meal consists of four cups red raspberries
62170025|NCT01242033|PLACEBO_COMPARATOR|bread|treatment meal consists of two slices white bread
62170026|NCT01242033|ACTIVE_COMPARATOR|vitamin C|treatment meal consists of two slices white bread and 200 mg vitamin C in the form of supplemental ascorbic acid
62182342|NCT05120154|ACTIVE_COMPARATOR|Control|Access to all the CAPACITI module materials, provided on a learning management system. The control group will not receive module facilitation (i.e., will entail self-directed learning).
62182343|NCT00827775|NO_INTERVENTION|Control|Patients without intradialytic hypertension defined as average pre to post hemodialysis SBP falling \>10 mmhg for more than 4/6 of the last dialysis treatment sessions
62182344|NCT00827775|ACTIVE_COMPARATOR|Intervention|Patients with intradialytic hypertension defined as average pre to post hemodialysis SBP elevation of \>10 mmhg for more than 4/6 of the last dialysis treatment sessions
62182345|NCT05298293|EXPERIMENTAL|ONCOLAXY follow-up|patients will make a regular assessment of symptoms via an electronic questionnaire
62170027|NCT05584761|EXPERIMENTAL|experimental group|"unrelated umbilical cord blood stem cell microtransplantation combined with AZA/AZA+ based treatment.~A single unit of unrelated umbilical cord blood was reinfused within 24-72 hours after the end of AZA or chemotherapy, and the longest delay was 96 hours after the end of chemotherapy. The umbilical cord blood was matched at 0-3/10 locus.~Specific treatment options:~1. AZA monotherapy:~   Azacitidine 75mg·m-2·d-1, d1-d7, subcutaneous injection;~2. VA :~   Azacitidine 75mg·m-2·d-1, d1-d7, subcutaneous injection; Venetoclax (VEN) 100mg d1,200mg d2,400mg d3 to d14, orally.~3. VAH:~Azacitidine 75mg·m-2·d-1, d1-d7, subcutaneous injection; Venetoclax (VEN) 100mg d1, 200mg d2,400mg d3 to d14, orally. Homoharringtonine injection (HHT) 2-3mg d1 to d14 was intravenously injected. During the period, the medication time was adjusted according to the patient's blood condition and complications"
62363543|NCT03292341|EXPERIMENTAL|Other involved organizations|Patient Organizations and insurance companies Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid
62170028|NCT04148716||patients|recruitement of 9 patients
62170029|NCT04148716||control|recruitement of 9 control person
62170030|NCT01959607|ACTIVE_COMPARATOR|THS 2.2 then CC|"Each subject will follow the below study design:~* Day 0 = Wash-out (1 day)~* Day 1 = 1st intervention (single product use of THS 2.2)~* Day 2 = wash-out~* Day 3 = 2nd intervention (single product use of CC)."
62170031|NCT01959607|ACTIVE_COMPARATOR|CC then THS 2.2|"Each subject will follow the below study design:~* Day 0 = Wash-out (1 day)~* Day 1 = 1st intervention (single product use of CC)~* Day 2 = wash-out~* Day 3 = 2nd intervention (single product use of THS 2.2)."
62170032|NCT01959607|ACTIVE_COMPARATOR|THS 2.2 then NRT|"Each subject will follow the below study design:~* Day 0 = Wash-out (1 day)~* Day 1 = 1st intervention (single product use of THS 2.2)~* Day 2 = wash-out~* Day 3 = 2nd intervention (single administration of NRT gum \[Nicorette® 2mg\])."
62170033|NCT01959607|ACTIVE_COMPARATOR|NRT then THS 2.2|"Each subject will follow the below study design:~* Day 0 = Wash-out (1 day)~* Day 1 = 1st intervention (single administration of NRT gum \[Nicorette® 2mg\])~* Day 2 = wash-out~* Day 3 = 2nd intervention (single product use of THS 2.2)."
62170034|NCT04841811|ACTIVE_COMPARATOR|Group A (almonertinib continuous treatment)|Subjects will be randomly assigned to groups A and B after radical therapy (surgery or radiothrapy) and will receive 110 mg of almonertinib once a day for 2 years or until disease recurrence or metastasis.
62170035|NCT04841811|EXPERIMENTAL|Group B (ctDNA monitoring guided the almonertinib treatment)|Subjects will be randomly assigned to group B after radical therapy (surgery or radiothrapy) and will receive almonertinib guided by ctDNA dynamic monitoring (every 3 months test ctDNA once, if it is positive, continue to receive almonertinib 110 mg once a day, if it is negative, stop almonertinib until ctDNA turns positive and receive almonertinib treatment again).
62170036|NCT04491136|EXPERIMENTAL|ACEI/ARB treatment for 6 months/ARNI treatment the next 6 months|Patients received angiotensin-converting enzyme inhibitor/angiotensin receptor blockers treatment the first 6 months. The following 6 months patients received angiotensin receptor neprilysin inhibitor treatment.
62170037|NCT06647290|EXPERIMENTAL|Negative Pressure Wound Therapy|The wound is dressed using negative pressure wound therapy.
62170038|NCT06647290|ACTIVE_COMPARATOR|Standard Wound dressing|After the skin is closed, the wound is covered using sterile standard gauze dressing.
62170039|NCT02391571|EXPERIMENTAL|Oxycodone/Naltrexone|Oxycodone/Naltrexone Capsules (over-encapsulated), on days 6-10, every 6 hours (at 09:00, 15:00, 21:00)
62170040|NCT02391571|ACTIVE_COMPARATOR|Oxycodone|Oxycodone Tablets (Over-encapsulated), on Days 6-10, every 6 hours (at 09:00, 15:00, 21:00)
62170041|NCT02391571|OTHER|Placebo Lead-In|Placebo Lead-In: Placebo Capsules (matching to Active and Experimental) on days 4-5, every 6 hours (at 09:00, 15:00, 21:00)
62170042|NCT04238299||Main study cohort|Patients with CKD recruited from specialist nephrology clinics
62363544|NCT03498092|EXPERIMENTAL|Bupivacaine-Dexmedetomidine group|After general anesthesia, patients will receive a cocktail of isobaric bupivacaine 2.5 mg/ml plus 5 micrograms (mcg)/ml adrenaline and 1mcg/kg dexmedetomidine in a volume of 0.5 ml/kg injected superficial to serratus muscle between and below latissimus dorsi muscle.
62363545|NCT03498092|ACTIVE_COMPARATOR|Bupivacaine group|After general anesthesia, patients will receive a cocktail of isobaric bupivacaine 2.5 mg/ml plus 5 micrograms (mcg)/ml adrenaline in a volume of 0.5 ml/kg injected superficial to serratus muscle between and below latissimus dorsi muscle.
62170043|NCT01645358|EXPERIMENTAL|Helmet to deliver NIV|
62170044|NCT01645358|ACTIVE_COMPARATOR|Total Face to deliver NIV|
62170045|NCT05534802|SHAM_COMPARATOR|Conventional treatment group|Cardiac surgery patients undergoing cardiopulmonary bypass are not treated with ulinastatin
62170046|NCT05534802|EXPERIMENTAL|Ulinastatin|Cardiac surgery patients undergoing cardiopulmonary bypass are treated with ulinastatin
62170047|NCT03630458|EXPERIMENTAL|Pearl millet couscous - made in Senegal|Steamed pearl millet couscous - commercially produced in Senegal
62170048|NCT03630458|EXPERIMENTAL|Pearl millet couscous - made in USA|Steamed pearl millet couscous - pearl millet obtained from Senegal but processed and prepared in USA
62363546|NCT03498092|PLACEBO_COMPARATOR|Saline group|This group will serve as a control and blinding group and will receive saline infiltration in the same manner.
62363547|NCT03079557|EXPERIMENTAL|Intragastric botulinum toxin type A|Botulinum toxin A (Allergan) injected intragastrically in the antrum
62391438|NCT01099670|EXPERIMENTAL|7.5 mg NRL001|Nine subjects will receive 7.5 mg NRL001 in a 2 g suppository; three will receive matching placebo.
62170049|NCT03630458|EXPERIMENTAL|Pearl millet thick porridge|Thick porridge prepared according to traditional West African methods with pearl millet obtained from Senegal but processed and prepared in USA
62170050|NCT03630458|EXPERIMENTAL|Wheat couscous|Steamed wheat couscous - wheat flour processed and prepared in USA
62170051|NCT03630458|ACTIVE_COMPARATOR|White rice|White rice - medium-grain prepared using a rice cooker
62170052|NCT06016179|EXPERIMENTAL|Treatment Arm - intracavitary tocilizumab|Four incremental weekly intra-cavitary doses of tocilizumab starting at 0.5μg/mL and increasing to 1.6μg/mL, 5μg/mL and 50μg/mL once a week over four weeks.
62170053|NCT01298219|EXPERIMENTAL|Lubiprostone|24 mcg capsules twice daily (BID)
62170054|NCT01298219|PLACEBO_COMPARATOR|Placebo|0 mcg capsules twice daily (BID)
62363548|NCT05378776|EXPERIMENTAL|Sucrose|The experimental arm will receive 1.5 ml/kg of the sucrose solution at triage (once). The composition of the homemade sucrose solution used in our emergency department is 3.5 g of table sugar (sucrose) mixed with 10 ml of diluted juice (see standard arm description) to obtain a solution with the same appearance as the standard arm.
62170055|NCT01730118|EXPERIMENTAL|1/Part I dose escalation|Adenoviral Transduced Autologous Human epidermal growth factor receptor (AdHER) dendritic cell (DC) vaccine administered at escalating doses
62170056|NCT01730118|EXPERIMENTAL|2/Part I dose expansion|Adenoviral Transduced Autologous Human epidermal growth factor receptor (AdHER) dendritic cell (DC) vaccine administered at a next lower dose or the highest dose
62170057|NCT01730118|EXPERIMENTAL|3/Part 1 dose escalation|Adenoviral Transduced Autologous Human epidermal growth factor receptor (AdHER) dendritic cell (DC) vaccine administered at Dose Level 1
62170058|NCT01730118|EXPERIMENTAL|4/Part II dose escalation|Adenoviral Transduced Autologous Human epidermal growth factor receptor (AdHER) dendritic cell (DC) vaccine administered at Dose Level 1
62170059|NCT01730118|EXPERIMENTAL|5/Part II dose expansion|Adenoviral Transduced Autologous Human epidermal growth factor receptor (AdHER) dendritic cell (DC) vaccine administered at Arm 1 maximum tolerated dose (MTD)
62170060|NCT04688086||Women with no personal history of breast cancer|Women who came in for a breast mammography between ages 30 and 80 years were invited to take part in the study. All the women included in the study underwent breast cancer screening first by Thermalytix, the AI-based thermal imaging test, followed by mammography.
62170061|NCT06472882|EXPERIMENTAL|tDCS Targeting the Dorsolateral Prefrontal Cortex (DLPFC)|"Participants in this arm will receive transcranial Direct Current Stimulation (tDCS) targeting the DLPFC. The tDCS will be administered at an intensity of 2 mA for 20 minutes. This arm aims to evaluate the effects of DLPFC stimulation on performance during a maximal effort No Jump Burpee exercise."
61985985|NCT03013556|EXPERIMENTAL|Group C,TDF+PEG|The subjects in group C will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks
61985986|NCT02395718|EXPERIMENTAL|QDU|Patients will undergo a fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation. Patients will have immediate access to all diagnostic tests and treatments that will be carried out all day (24 hours) on demand from the responsible physician. The QDU is both organisationally and physically integrated in the ED. Point of care ultrasonography can be performed round the clock. Additionally the Department of Radiology provides the QDU with more advanced diagnostic procedures such as e.g. CT scans or MRI scans on a fast track basis. There is access to additional specialist evaluations from the ED staff or from various in house specialists, when needed. Simultaneously to the medical treatment, physical therapists and occupational therapists train and optimise patients' level of functioning, including prevention of loss of function.
61985987|NCT02395718|ACTIVE_COMPARATOR|DIM|Patients in the control group are treated as conventionally at one of seven wards at the DIM. After initial admission including initial diagnostics and treatment have been carried out in the ED, patients are transferred to the DIM. Usually patients are seen primarily by the on-call physician for evaluation of acute symptoms. The following day, a Chief physician will work out a plan for further diagnostics and treatment. Treatment by physiotherapists and occupational therapists is available on request from a physician. Analyses of blood samples are performed at the central laboratory and radiological procedures at the Department of Radiology.
61985988|NCT03229668|PLACEBO_COMPARATOR|Group I|Administration of a placebo capsule 1 hour prior to the surgical operation
61985989|NCT03229668|EXPERIMENTAL|Group II|Administration of 75mg of pregabalin 1 hour prior to the surgical operation
61985990|NCT03229668|EXPERIMENTAL|Group III|Administration of 150mg of pregabalin 1 hour prior to the surgical operation
61985991|NCT06387914|ACTIVE_COMPARATOR|Stimulation ON|"ON stimulation is a programme that on average provides pain relief to participants based on previous experience with DBS for pain. There will be some titration of stimulation, based on patient response. The setting with best acute pain relief will be the one chosen for the ON phase, with individual parameter settings up to a maximum of:~Frequency up to 80 Hertz(Hz), Amplitude 6.0 milliamps(mA) and or Pulse Width 500 microseconds(uS).~Duration of intervention: 1 month"
61985992|NCT06387914|SHAM_COMPARATOR|Stimulation Pseudo-ON|Pseudo-ON is a low power programme that provides sham stimulation (high frequency, low amplitude stimulation generally ineffective at providing pain relief) and drains battery over time, requiring the participant to recharge the device periodically: Frequency around 250 Hertz(Hz), Amplitude less than 0.5 milliamps(mA), Pulse Width 500 microseconds(uS Duration of intervention: 1 month
61985993|NCT05318183|EXPERIMENTAL|Whole Wheat Bread|Participants consuming 128 g of whole wheat bread (4 slices of bread) daily for two weeks
61985994|NCT05318183|PLACEBO_COMPARATOR|White Bread (control)|Participants consuming 128 g of white bread (4 slices of bread) daily for two weeks
61985995|NCT04915755|EXPERIMENTAL|Cohort1:Participants with tBRCAmut HER2-breast cancer(Independent of HR status,including HR+andTNBC)|Eligible participants will receive either Niraparib or Placebo.
61985996|NCT04915755|EXPERIMENTAL|Cohort 2: Participants with tBRCAwt TNBC|Eligible participants will receive either Niraparib or Placebo.
61985997|NCT00990496|EXPERIMENTAL|GBM Treatment|
61985998|NCT05211713|EXPERIMENTAL|Intervention group receiving Opp|The effectiveness study will be conducted as a randomized controlled trial with an intervention group and a waiting-list control group. Data will be collected at baseline (T1, pre intervention) and after about six weeks of intervention (T2, post intervention).
61985999|NCT05211713|NO_INTERVENTION|Control group|The waiting list control group will receive the intervention after study completion.
61986000|NCT04568057|ACTIVE_COMPARATOR|NIR Transcranial phototherapy device|The active transcranial phototherapy device. 1068 nm NIR Transcranial phototherapy PBM-T device An air-cooled LED helmet with a peak wavelength of 1068 nm, spectral width of 60 nm, and a 6-minute internal timer was used. The average optical power output of the combined arrays is circa 3.8 Watts, 12mw/sq. cm. The total energy to be delivered to the cranium is 1368J (3.8 x 360) per treatment session.
61986001|NCT04568057|PLACEBO_COMPARATOR|Placebo Device.|Placebo cranial device. The external appearance of the device is identical to that of the active device but no NIR light is emitted.
61986002|NCT03331146|PLACEBO_COMPARATOR|Control group|saline infusion will be administered after induction of general anesthesia
62170062|NCT06472882|EXPERIMENTAL|tDCS Targeting the Primary Motor Cortex (M1)|"Participants in this arm will receive transcranial Direct Current Stimulation (tDCS) targeting the primary motor cortex (M1). The tDCS will be administered at an intensity of 2 mA for 20 minutes. This arm aims to evaluate the effects of M1 stimulation on performance during a maximal effort No Jump Burpee exercise."
62170063|NCT06472882|SHAM_COMPARATOR|SHAM tDCS|Participants in this arm will receive a sham tDCS session, which simulates the experience of tDCS without actual stimulation. This arm serves as a control to ensure the blinding of participants and evaluators.
62170064|NCT01095809|EXPERIMENTAL|bevacizumab|intravitreous bevacizumab 2,5 mg at baseline, week 4 and 8. reinjection is required.
62170065|NCT01095809|EXPERIMENTAL|triamcinolone acetonide|intravitreous triamcinolone 2 mg, frequency: 3 months
62170066|NCT01679613|EXPERIMENTAL|1 Nintedanib (Reference)|single dose, oral with 240 ml water
62170067|NCT01679613|EXPERIMENTAL|2 Nintedanib + Ketoconazole (Test)|Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
62170068|NCT01679613|EXPERIMENTAL|3 Nintedanib (Reference)|single dose, oral with 240 ml water
62170069|NCT01679613|EXPERIMENTAL|4 Nintedanib + Ketoconazole (Test)|Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
62170070|NCT03331848|PLACEBO_COMPARATOR|PLACEBO|
62170071|NCT03331848|EXPERIMENTAL|PXT002331 - 20mg|
62170072|NCT05558761|NO_INTERVENTION|Control Group|this group will take mesalamine 1 g three times daily
62170073|NCT05558761|ACTIVE_COMPARATOR|Pentoxifylline group|his group will take mesalamine 1 g three times daily plus pentoxifylline 400 mg two times daily
62170074|NCT05756361|EXPERIMENTAL|20 Child-Parent Dyads|Family-Based Behavioral Treatment
62170075|NCT06158412|EXPERIMENTAL|ATRA in Combination with a KPD Regimen|All-trans Retinoic Acid plus the KPD Regimen
62170076|NCT02502721|EXPERIMENTAL|Part A|To study effect of DWC20151 on DWC20152 PK
62170077|NCT02502721|EXPERIMENTAL|Part B|To study effect of DWC20152 on DWC20151 PK
62170078|NCT00829647|EXPERIMENTAL|combination dasatinib plus lenalidomide|dasatinib 70 mg po daily plus lenalidomide 2.5 md po daily
62170079|NCT06645756|EXPERIMENTAL|Obese group|Test meal
62170080|NCT06645756|EXPERIMENTAL|Normal weight group|Test meal
62170081|NCT03489837|EXPERIMENTAL|Levotuss CR tab|oral taken
62170082|NCT03489837|ACTIVE_COMPARATOR|Levotuss syrup|oral taken
62170083|NCT04715919||Patients in ICU|ICU patients with COVID-19
62170084|NCT04715919||Patients in Hospital Ward|Patients with COVID-19 in hospital wards
62170085|NCT03390933|EXPERIMENTAL|Fluoxetine Group|Approximately 96 patients will be enrolled into the intervention (Phase II) over the duration of the entire study.
62170086|NCT06125639|EXPERIMENTAL|Sauna Group|
62170087|NCT06125639|NO_INTERVENTION|Control Group|
62170088|NCT04494425|EXPERIMENTAL|Trastuzumab deruxtecan|Trastuzumab deruxtecan (T-DXd; DS-8201a) arm
62170089|NCT04494425|ACTIVE_COMPARATOR|Standard of Care|Investigator's choice standard of care chemotherapy (capecitabine, paclitaxel, nab-paclitaxel) arm
62170090|NCT05771558|EXPERIMENTAL|Tailored Lighting Intervention (TLI)|"The TLI will be performed for 2 hours each day over an 8-week period~During the last week of the lighting, participants will be asked to wear the actigraph and light meter again for 7 days"
62170091|NCT01670747||ARDS|Sedated and mechanically ventilated patients admitted to ICU
62170092|NCT01600235|EXPERIMENTAL|Phenylephrine|Phenylephrine induced-hypertension arm
62170093|NCT01600235|NO_INTERVENTION|Conventional treatment|Control arm
62170094|NCT03084614||Controls|non exposed controls
62170095|NCT03084614||donors with naturally enriched antimicrobial blood samples and|Donors with naturally enriched antimicrobial blood samples an breast milk, Comparisons will be made with non exposed controls.
62170096|NCT02032420|EXPERIMENTAL|STAR|Introductory training by video depicting 4 sequential maneuvers for reacquisition of needle image in ultrasound: see, tilt, align, rotate.
62170097|NCT02032420|ACTIVE_COMPARATOR|ART|Introductory training with a video depicting 3 probe position aspects for reacquisition of needle image by ultrasound: alignment, rotation, tilt.
62170098|NCT05610319|EXPERIMENTAL|Treat and Extend|Participants randomized to the T\&E Arm will initially receive 6 milligrams (mg) faricimab intravitreal (IVT) injections monthly (28d +/-7 days), with treatment intervals increased/extended, reduced, or maintained based on CST assessments, until week 100.
62170099|NCT05610319|OTHER|Control/Usual Care Arm|Participants in the control arm will receive 6 milligrams (mg) faricimab intravitreal (IVT) injections monthly (28d +/-7 days), for 6 treatments. Afterwards, participants will continue to receive 6mg faricimab IVT every 8 weeks until week 100.
62170100|NCT02612363|EXPERIMENTAL|Early goal directed sedation group|"Dexmedetomidine for sedation in early goal directed sedation group~* Analgesia~* Dexmedetomidine start at 0.7ug/kg/hour~* Dose range: 0.2- 0.7 u/kg/hour~* Supplemental other sedatives at lowest effective dose Target Richmond Agitation-Sedation Scale score of -2 to +1 to achieve sedation goal in EGDS group"
62170101|NCT02612363|PLACEBO_COMPARATOR|Standard sedation|"Control drug for sedation in early goal directed sedation group~* Analgesia~* Control drug~* Supplemental other sedatives at lowest effective dose for standard sedation Target Richmond Agitation-Sedation Scale score of -2 to +1 to achieve sedation goal"
62170102|NCT06329531||Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS)|You will be asked to complete three questionnaires and a short interview about yourself and how well you are able to complete your daily tasks. The SOCS-OTS, which is a 20-item questionnaire.
62170103|NCT05051683|ACTIVE_COMPARATOR|group (1)|combined endoscopic \& radiologic intervention for management of acute perforated peptic ulcer
62170104|NCT05051683|NO_INTERVENTION|group (2)|surgical management of acute perforated peptic ulcer
62182346|NCT05298293|NO_INTERVENTION|Standard follow-up|patients will have the standard follow-up
62182347|NCT05153785|EXPERIMENTAL|Lidocaine arm|The experimental arm will receive a bolus of 1,5mg/kg Lidocaine before induction of anesthesia, immediately followed by an infusion of 1,5mg/kg/h until 1 hour post surgery.
62182348|NCT05153785|PLACEBO_COMPARATOR|Placebo arm|The placebo arm will receive the same amount of normal Saline.
62182349|NCT00721032|EXPERIMENTAL|1|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia.
62182350|NCT00721032|ACTIVE_COMPARATOR|2|Anti-arrhythmic group.
62363549|NCT05378776|PLACEBO_COMPARATOR|Control|This group will receive 1.5 mL/kg of diluted juice composed of juice (apple or orange) and water in equal proportion once at triage. This solution contains 0.05 g/ml of sucrose for a total of 0.075 g/kg of sucrose (eight times less than the intervention arm).
62363550|NCT00044525|EXPERIMENTAL|Arm 1|
62170105|NCT01287416|EXPERIMENTAL|Applied Suicide Intervention Skills Training (ASIST)|"ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The training is designed for anyone (especially those in a position of trust), from professionals and volunteers to members of the community. Participants range from those in caring roles to people concerned about family members or friends. The theory is that suicide can be pre¬vented with the help of prepared caregivers. ASIST is designed to help all caregivers become more willing, ready and able to help persons at risk. Just as CPR skills make physical first aid possible, training in suicide intervention develops the skills used in suicide first aid."
62170106|NCT01287416|ACTIVE_COMPARATOR|Resilience Retreat|The two days will be divided into cultural activities, sharing circles, small group discussions, story telling and dance. Two First Nations community leaders will be identified to lead each of the two retreats.
62170107|NCT03410953|EXPERIMENTAL|Fendrix|"The primary immunisation consists of 4 separate 0.5 ml doses of FENDRIX administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine"
62170108|NCT01063127||1|group A: 10 morbidly obese subjects who will undergo gastric banding will be studied basally, 1 week after low-calorie diet and 1 week after operation.
62363551|NCT01113190|ACTIVE_COMPARATOR|CBI in ED with AMET at 3 months|computer-delivered brief intervention (CBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
62170109|NCT01063127||2|group B: 10 morbidly obese subjects who will undergo gastric bypass will be studied basally, 1 week after low-calorie diet and 1 week after operation.
62363552|NCT01113190|ACTIVE_COMPARATOR|CBI in ED with EUC at 3 months|computer-delivered brief intervention (CBI) at baseline with enhanced usual care-EUC at 3 months
62363553|NCT01113190|ACTIVE_COMPARATOR|IBI in ED with AMET at 3 months|intervener-delivered brief intervention (IBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
62363554|NCT01113190|ACTIVE_COMPARATOR|IBI in ED with EUC at 3 months|intervener-delivered brief intervention (IBI) at baseline with enhanced usual care-EUC at 3 months
62363555|NCT01113190|ACTIVE_COMPARATOR|EUC in ED with AMET at 3 months|enhanced usual care (EUC) at baseline with adapted motivational enhancement therapy-AMET at 3 months
62363556|NCT01113190|ACTIVE_COMPARATOR|EUC in ED with EUC at 3 months|enhanced usual care (EUC) at baseline with EUC at 3 months
62363557|NCT03504462|EXPERIMENTAL|Distal tibial nerve block|Patient receiving a specific block of medial and lateral plantar nerves in order to preserve the calcaneal nerve
62363558|NCT05060198|ACTIVE_COMPARATOR|Artemether-lumefantrine (AL)|Participants will be randomized to receive a standard weight-based regimen of artemether-lumefantrine (Coartem®, Novartis Pharmaceuticals Corporation, Missouri, USA). Children in the AL arm received two daily doses (morning and evening) orally, over 3 days (6 doses total at 0, 8, 24, 36, 48, and 60 hours post initial dose, administered with food or milk at the clinic and at home). To promote and evaluate adherence, study staff called parents in the evening to remind them to give the AL dose to the child and to bring the blister pack to the clinic the next day for confirmation.
62363559|NCT05060198|ACTIVE_COMPARATOR|Dihydroartemisinin-piperaquine (DP)|Participants will be randomized to receive a standard weight-based regimen of dihydroartemisinin-piperaquine (DuoCotexin®; Holley-Cotec Pharmaceuticals, Beijing, China). DP was administered once a day for three days (at 0, 24, and 48 hours, orally).
62363560|NCT02408185|EXPERIMENTAL|Colistin 6 million units + 240mg/8h|Loading dose of 6 million units of colistin+ 240mg/8h maintenance
62363561|NCT02408185|EXPERIMENTAL|Colistin 6 million units + 360mg/12h|Loading dose of 6 million units of colistin+ 360mg/12h maintenance
62363562|NCT03121807|EXPERIMENTAL|Home parenteral nutrition|"Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.~Patients received 85 mg/m2 oxaliplatin and 200 mg/m2 leucovorin as a 2-h intravenous infusion on day 1, followed by 2400 mg/m2 5Fluorouracil as a 46-h continuous infusion. This regimen is repeated every 14 days as a cycle."
62363563|NCT00888212|EXPERIMENTAL|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
62363564|NCT05074862|EXPERIMENTAL|Ketone monoester (3-OHB)|Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US). Bolus of 300 mg/kg followed by a 2-hour continuous enteral infusion with a dosing of 100 mg/kg/hour (maximal total dose 50 grams). There is a 1-hour lag between the bolus and the continuous infusion.
62170110|NCT03731637||New-onset diabetes|Subjects with biochemically-defined new-onset diabetes
62363565|NCT05074862|PLACEBO_COMPARATOR|Placebo Treatment|Maltodextrin- and fatbased placebo in isocaloric, isovolemic dose to the experimental arm.
62363566|NCT04657445||home-quarantined patients|home-quarantined patients
62363567|NCT04657445||inhospitalized patients|inhospitalized patients
62363568|NCT02356328||NovaTears®|
62170111|NCT00794911|EXPERIMENTAL|QOLT|Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions.
62170112|NCT00794911|ACTIVE_COMPARATOR|ST|Supportive Therapy (ST) 8 weekly individual counseling sessions
62170113|NCT00794911|NO_INTERVENTION|Standard Care|
62170114|NCT06611800||Presence or absence of personalized advance prescriptions|collection of data for the purpose of know the benefit of personalized advance prescriptions for patients in palliative care at home, particularly in reducing the number of visits to the emergency room and their conditions of death
62363569|NCT03175016|EXPERIMENTAL|DEBIRI|Transcatheter arterial chemoembolization(TACE) with Irinotecan eluting-bead(DEBIRI)
62363570|NCT01489228|EXPERIMENTAL|High Dose E1224|High Dose (HD - 8weeks) Group
62363571|NCT01489228|EXPERIMENTAL|Low Dose E1224|Low Dose (LD - 8 weeks) Group
62363572|NCT01489228|EXPERIMENTAL|Short Dose E1224|Short Dose (SD - 4 weeks) Group
62363573|NCT01489228|PLACEBO_COMPARATOR|Placebo|Placebo (8 weeks) Group
62363574|NCT01489228|ACTIVE_COMPARATOR|Benznidazol|BZN (Laboratório do Estado de Pernambuco -LAFEPE, tablet 100mg), 5 mg/Kg/day PO divided in two daily doses, for 60 days
62363575|NCT02794025|EXPERIMENTAL|esmolol group|patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava.
62170115|NCT06254079|EXPERIMENTAL|Intervention group|A video containing information about the operating room environment and intraoperative care will be watched. The patients who watch the video will be questioned again about the points they do not understand, the issues they are curious about about the perioperative period, and the information they want to learn, and this information will be given verbally by the researchers.
62363576|NCT02794025|SHAM_COMPARATOR|control group|Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol.
62363577|NCT03582969|EXPERIMENTAL|Fecal transplantation|Fecal transplantation of feces from healthy donor via capsules. Oral application.
62363578|NCT03582969|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62170116|NCT06254079|NO_INTERVENTION|Control Group|Patients in this group will not be shown any videos and will continue to receive care according to their clinical routine.They will be asked to answer the questions in the patient introduction form the day before the surgical intervention. The surgical anxiety scale will be filled in when patients come from the ward to the preoperative waiting room on the day of surgery. Finally, patients will be asked to answer the questions on VAS and Quality of Recovery-15 (QoR-15) in the patient room at the 24th hour after surgery.
62170117|NCT05450705|EXPERIMENTAL|9 to 14 Years Old: Day 1 and Month 6|Chinese females 9 to 14 years old will receive a 0.5 mL intramuscular (IM) injection of 9-valent HPV (9vHPV) vaccine on Day 1 and Month 6
62170118|NCT05450705|EXPERIMENTAL|9 to 14 Years Old: Day 1 and Month 12|Chinese females 9 to 14 years old will receive a 0.5 mL iIM injection of 9-valent HPV (9vHPV) vaccine on Day 1 and Month 12
62170119|NCT05450705|EXPERIMENTAL|20 to 26 Years Old: Day 1, Month 2 and Month 6|Chinese females 20 to 26 years old will receive a 0.5 mL IM injection of 9-valent HPV (9vHPV) vaccine on Day 1, Month 2 and Month 6
62170120|NCT05262920|EXPERIMENTAL|The BSM Intervention|"Guided by the Individual and Family Self-Management Theory, the Lucas team developed the Breastfeeding and BNP Self-Management (BSM) intervention. The BSM intervention uses a cloud-based platform, links to educational modules, and daily journaling, to provide women uniform best practice knowledge and skills for BF and BNP self-management.~Strategies include guided imagery, therapeutic breathing, mindfulness, relaxation, non-pharmacological interventions that are integrated within the self-management process such as goal-setting, self-monitoring, problem-solving, and social support through texting."
62170121|NCT05262920|ACTIVE_COMPARATOR|Attention Control|Attention control participants will receive equivalent attention as the BSM group. The fourth-trimester care based on the CDC HEAR HER campaign and infant health information modules will be provided through the REDCap link.
62363579|NCT04379947||FFR-CABG|Patients with at least one intermediate stenosis that received a preoperative FFR evaluation before being referred for CABG
62170122|NCT06307964||Alcoholic hepatitis|Patients with histologically proven AH (after transjugular liver biopsy procedure and histological assessment).
62363580|NCT04379947||Angio-CABG|Patients with at least one intermediate stenosis that did not received a preoperative FFR evaluation before being referred for CABG
62363581|NCT05319223||Patient management group|patient blood management group
62363582|NCT05319223||Control|control
62170123|NCT06307964||No alcoholic hepatitis|"Patients with initially suspected AH (excessive alcohol consumption and modified Maddrey score \> 32) but no AH at the histological evaluation of liver biopsy.~It corresponds to patients with decompensated alcoholic liver disease but no AH."
62363583|NCT01831804|EXPERIMENTAL|Cohort 1 Part A|Healthy subjects in this arm will receive single applications of GSK1278863 or placebo (with 6:2 ratio) on intact skin in two escalating dosing periods each separated by 10 days. The first application will be with a single dose of 0.3 mg and second application will be single dose of 3 mg.
62363584|NCT01831804|EXPERIMENTAL|Cohort 2 Part A|Subjects with diabetic foot ulcer (DFU) will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on intact skin and second application directly on DFU. Dose will be based on wound area and review from previous cohort data.
62739271|NCT03158740|ACTIVE_COMPARATOR|DII-Based Counseling System|The DII-based counseling group will utilize our 12-week IMAGINE Counseling System curriculum.The DII-based counseling group will meet once a week for 12 weeks to cook, and to engage in exercise and stress-reduction activities. Along with the initial clinic, participants will meet one-on-one for a nutrition counseling session with a registered dietitian. Participants will have access to online material through our Imagine Healthy Online Portal and will be given take-home activities, referred to as IMAGINE actions. These homework assignments will focus on goal setting for nutrition, physical activity, and stress reduction. The nutrition components of this intervention will be based on the DII and will focus on anti-inflammatory foods and components.
62170124|NCT01842399|PLACEBO_COMPARATOR|Placebo Comparator|2x/day orally
62170125|NCT01842399|EXPERIMENTAL|Resveratrol 1|75 mg, 2x/day orally
62170126|NCT01842399|EXPERIMENTAL|Resveratrol 2|150 mg, 2x/day orally
62363585|NCT01831804|EXPERIMENTAL|Cohort 3 Part A|Subjects with DFU will receive single application of GSK1278863 or placebo directly on DFU. Dose will be based on wound area and review from previous cohort data.
62363586|NCT01831804|EXPERIMENTAL|Cohort 4 Part A|Subjects with DFU will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on DFU and second application on intact skin. Dose will be based on wound area and review from previous cohort data.
62391439|NCT01099670|EXPERIMENTAL|10 mg NRL001|Nine subjects will receive 10 mg NRL001 in a 2 g suppository; three will receive matching placebo.
62391440|NCT01099670|EXPERIMENTAL|12.5 mg NRL001|Nine subjects will receive 12.5 mg NRL001 in a 2 g suppository; three will receive matching placebo.
62363587|NCT01831804|EXPERIMENTAL|Cohort 5 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
62363588|NCT01831804|EXPERIMENTAL|Cohort 6 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
62363589|NCT01831804|EXPERIMENTAL|Cohort 7 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
62363590|NCT03530202|EXPERIMENTAL|HVRT + Creatine Monohydrate|Participants will perform 8-weeks of high-velocity resistance training, defined as performing the concentric phase of a lift as fast as possible and taking two seconds to perform the eccentric phase of the lift, on six exercises (bilateral legpress, leg extension, leg curl, chest press, triceps extension, and biceps curl) and consume creatine monohydrate powder. The load will be 80% of the participants one-repetition max (1RM; the maximum weight that can be successfully lifted one time with proper form).
62363591|NCT03530202|PLACEBO_COMPARATOR|HVRT + Maltodextrin Powder|Participants will perform 8-weeks of high-velocity resistance training, defined as performing the concentric phase of a lift as fast as possible and taking two seconds to perform the eccentric phase of the lift, on six exercises (bilateral legpress, leg extension, leg curl, chest press, triceps extension, and biceps curl) and consume maltodexterin powder. The load will be 80% of the participants one-repetition max (1RM; the maximum weight that can be successfully lifted one time with proper form).
62363592|NCT06203483|ACTIVE_COMPARATOR|Adductor canal block|Adductor canal block will be performed at the end of the surgery. Patients will be administered tenoxicam (Tilcotil 20 mg flakon) 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol (100 mg-Contramal ® ampul) will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine (Aldolan ampul 100 mg/2 ml) IV will be administered.
62363593|NCT06203483|ACTIVE_COMPARATOR|PENG block|PENG Block will be performed at the end of the surgery. Patients will be administered tenoxicam (Tilcotil 20 mg flakon) 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol (100 mg-Contramal ® ampul) will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine (Aldolan ampul 100 mg/2 ml) IV will be administered.
62170127|NCT06646302|EXPERIMENTAL|Low frequency burst sound stimulation group|"Low frequency burst sound stimulation is a frequency-specific sound stimulition that have the potential to interfere with thalamocortical rhythm disturbances.~Prior to agreeing to participate in the study, participants will be informed that they will receive two different acoustic stimulation treatments, with a 20-minute washout period between the two treatments. The order of which sound stimulation will be received will be determined according to a random number table and will be blinded to the investigator and the subject."
62363594|NCT00568204|EXPERIMENTAL|1|Mexyn-A
62363595|NCT06383819|EXPERIMENTAL|Longidaza®|Bovhyaluronidase azoximer, 3000 IU
62363596|NCT06383819|PLACEBO_COMPARATOR|Placebo|The placebo will contain no active pharmaceutical ingredients.
62363597|NCT00587444|OTHER|1|control standard dose heparin dose
62363598|NCT00587444|ACTIVE_COMPARATOR|2|high dose heparin dose
62363599|NCT00587444|ACTIVE_COMPARATOR|3|hepcon guided therapy
62363600|NCT06423170|EXPERIMENTAL|Camrelizumab plus GEMOX|Camrelizumab plus GEMOX was given as conversion therapy for unresectable gallbladder cancer
62170128|NCT06646302|ACTIVE_COMPARATOR|Tinnitus frequency-centered narrowband noise stimulation group|"Tinnitus frequency-centered narrowband noise stimulation is a traditional form of sound stimulation that is commonly used in the masking treatment of tinnitus.~Prior to agreeing to participate in the study, participants will be informed that they will receive two different acoustic stimulation treatments, with a 20-minute washout period between the two treatments. The order of which sound stimulation will be received will be determined according to a random number table and will be blinded to the investigator and the subject."
62170129|NCT00631098|EXPERIMENTAL|1|Cannulation of external jugular vein and cannulation of cubital vein
62170130|NCT05154539|EXPERIMENTAL|Test Group 1 (TG1)|"TG1 participants are testing the new digital assessment routine in a private setting.~Audiology assistants in private hearing clinics located in the Region of Northern Jutland in Denmark are performing the standardized examination packages. The private hearing clinics also conduct hearing aid treatment for TG1 participants with simple hearing loss.~TG21 participants with complicated hearing loss or ear-related diseases are referred to the Department of Audiology at Aalborg University Hospital for further examination prior to treatment initiation."
62182351|NCT05408819||Coplanar Template group|Paticipant will undergo coplanar template assisted CT-guided abdominal tumor biopsy or fiducial markers implantation and the prospective accuracy and safety data will record.
62363601|NCT01308294|EXPERIMENTAL|2 vaccine injections in 1 limb|9 patients initially planned: patients received peptides with IMP321/LAG-3Ig and Montanide in 2 injections sites at 5 cm distance from each other 2 vaccine injections in same limb (vaccine 1 : NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2 : Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)
62363602|NCT01308294|EXPERIMENTAL|2 vaccine injections in distinct limbs|Groupe2: 2 vaccine injections in different limb should include 9 patients that were initially planned: patients received the same vaccine in 2 syringes injected each in a distinct limb (vaccine 1: NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2: Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)
62363603|NCT01308294|EXPERIMENTAL|"2 vaccine injections in distinct limbs"|Groupe3: 2 vaccine injections in distinct limb should include 9 patients that were initially planned; due to premature trial termination, no patients could be enrolled. Patients of this group should have received the same vaccine but without the MHC class II peptide (MAGE-A3)
62170131|NCT05154539|EXPERIMENTAL|Test Group 2 (TG2)|"TG2 participants are testing the new digital assessment routine in a public setting.~Audiology assistants in public hearing clinics located in the Region of Northern Jutland in Denmark are performing the standardized examination packages. The public hearing clinics also conduct hearing aid treatment for TG2 participants with simple hearing loss.~TG2 participants with complicated hearing loss or ear-related diseases are referred to the Department of Audiology at Aalborg University Hospital for further examination prior to treatment initiation."
62170132|NCT05154539|ACTIVE_COMPARATOR|Control Group 3 (CG3)|"CG3 participants will be assessed conventionally by a private practicing ENT specialist in the Region of Northern Jutland in Denmark at physical consultation in accordance with current Danish practice. CG3 participants with simple hearing loss can choose whether hearing aid treatment should be conducted in either a private or a public hearing clinic.~CG3 participants with complicated hearing loss or ear-related diseases are referred to the Department of Audiology at Aalborg University Hospital for further examination prior to treatment initiation."
62363604|NCT03429764|ACTIVE_COMPARATOR|Control group (CG),CISS|continuous independent sling sutures (CISS) will be placed with minimum two intact contact points at the surgical site,
62363605|NCT03429764|EXPERIMENTAL|Test group (TG),VIMS|internal mattress suture (VIMS) will be placed with minimum two intact contact points at the surgical site,
62363606|NCT01894334|NO_INTERVENTION|Control group|no intervention
62363607|NCT01894334|EXPERIMENTAL|Tranexamic acid group|tranexamic acid ，intravenous 30mg/kg/d，Preoperative
62363608|NCT01894334|EXPERIMENTAL|Edaravone group|edaravone, iv, 1mg/kg/d,Preoperative
62363609|NCT01894334|EXPERIMENTAL|Ulinastatin group|Ulinastatin ,iv，20,000 U /kg/d，Preoperative
62170133|NCT00705614||Remicade Group|Particpiants with no prior exposure to Remicade, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who start on Remicade will constitute the Remicade Group, regardless of whether they continue with Remicade or switch to another treatment.
62363610|NCT02843178|EXPERIMENTAL|1: distributed, targeted vouchers|Participants receive four $5 vouchers each valid for a subsequent week of the month (i.e., one voucher valid for week 1 only, a second for week 2 only, a third for week 3 only, and a fourth for week 4 only), starting in month 1 and continuing every month through month 6. The voucher is restricted to pay for fruits and vegetables.
62363611|NCT02843178|ACTIVE_COMPARATOR|2: lump sum, targeted vouchers|Participants receive four $5 vouchers each valid for an entire month, starting in month 1 and continuing every month through month 6. The voucher is restricted to pay for fruits and vegetables.
62170134|NCT00705614||Standard Therapy Group|Participants who are being treated with standard therapy and are not adequately maintained and will be offered an alternative treatment that does not include Remicade. Standard therapy participants must not have previously received Remicade.
62363612|NCT02843178|ACTIVE_COMPARATOR|3: distributed, untargeted vouchers|Participants receive four $5 vouchers each valid for a subsequent week of the month (i.e., one voucher valid for week 1 only, a second for week 2 only, a third for week 3 only, and a fourth for week 4 only), starting in month 1 and continuing every month through month 6. The voucher can pay for any food but not tobacco, alcohol or prepared foods.
62363613|NCT02843178|ACTIVE_COMPARATOR|4: lump sum, untargeted vouchers|Participants receive four $5 vouchers each valid for an entire month, starting in month 1 and continuing every month through month 6. The voucher can pay for any food but not tobacco, alcohol or prepared foods.
62363614|NCT01001572|ACTIVE_COMPARATOR|Valsartan 160 mg|One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks
62170135|NCT00705614||Switched to Remicade Group|Participants who started in the Standard Therapy Group but switched over to Remicade sometime during the follow-up period. Participants who switch to Remicade are evaluated in the Standard Therapy group until the time of the switch and are evaluated in the Switched to Remicade group thereafter.
62170136|NCT04323332|EXPERIMENTAL|Traditional Chinese Medicine|TCM prescription and conventional treatments
62363615|NCT01001572|EXPERIMENTAL|Valsartan/amlodipine 160/5 mg|One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks
62170137|NCT04323332|NO_INTERVENTION|Control|conventional treatments
62170138|NCT01679457|EXPERIMENTAL|ACT-Focused ERP|One Session.
62170139|NCT01679457|ACTIVE_COMPARATOR|TAU-ERP|One Session.
62170140|NCT01367613|EXPERIMENTAL|Arm 1|
62170141|NCT02968121|EXPERIMENTAL|Part A: Single Dose Injection: Subcutaneous|Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous
62170142|NCT02968121|EXPERIMENTAL|Part A: Single Dose Injection: Intramuscular|Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous
62170143|NCT02968121|EXPERIMENTAL|Part B: Cohort 1|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
62170144|NCT02968121|EXPERIMENTAL|Part B: Cohort 2|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
62363616|NCT01001572|OTHER|Single-Blind Run-In Valsartan 160 mg|Single-Blind Run-In treatment with one capsule Valsartan 160 mg taken orally once daily at approximately 9:00 AM for 4 weeks.
62363617|NCT01197794|EXPERIMENTAL|AZD1981 10 mg|AZD1981 10 mg
62363618|NCT01197794|EXPERIMENTAL|AZD1981 40 mg|AZD1981 40 mg
62363619|NCT01197794|EXPERIMENTAL|AZD1981 100 mg|AZD1981 100 mg
62363620|NCT01197794|EXPERIMENTAL|AZD1981 400 mg|AZD1981 400 mg
62363621|NCT01197794|EXPERIMENTAL|AZD1981 80 mg|AZD1981 80 mg
62363622|NCT01197794|EXPERIMENTAL|AZD1981 200 mg|AZD1981 200 mg
62363623|NCT01197794|PLACEBO_COMPARATOR|Placebo|
62363624|NCT01415908|ACTIVE_COMPARATOR|Control Group|
62363625|NCT01415908|EXPERIMENTAL|Investigational Group|
62363626|NCT05437913|OTHER|Self compassion intervention|4 weeks group and online format self compassion intervention
62170145|NCT02968121|EXPERIMENTAL|Part B: Cohort 3|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
62170146|NCT03601949|EXPERIMENTAL|SInergy Cooled Radiofrequency|Halyard Health SInergy Cooled Radiofrequency in addition to standard medical management
62170147|NCT03601949|ACTIVE_COMPARATOR|Medical Management|Standard Medical Management
62170148|NCT05360290|ACTIVE_COMPARATOR|CTC positive|
62170149|NCT05360290|OTHER|CTC negative|
62363627|NCT01361880|OTHER|Reduce infant mortality|The overall purpose of this study is to develop and evaluate a systematic approach to improve African-American parental behaviors specifically with regards to the infant sleep environment
62363628|NCT03481504|EXPERIMENTAL|ACT-ETP|Cognitive behavioral treatment
62363629|NCT03481504|NO_INTERVENTION|Usual care|no intervention
62363630|NCT00591240||Multiplex pathogen identification.|Urine samples of patients at risk for urinary tract infections were collected. Biosensor based assays were used to detect the most common uropathogens in these samples. Analytical validity of the biosensor assays was examined by comparing biosensor results to those obtained using standard clinical microbiology laboratory methods. No interventions were performed.
62363631|NCT00591240||Antimicrobial susceptibility testing.|Urine samples of patients at risk of urinary tract infections were collected. Biosensor based antimicrobial susceptibility test, in concert with pathogen identification assay was directly performed on these samples. Analytical validity of the biosensor assays was examined by comparing biosensor results to those obtained using standard clinical microbiology laboratory methods. No interventions were performed.
62363632|NCT02285517|ACTIVE_COMPARATOR|modified Meek technique|Intervention: modified Meek skin grafting technique. Patients with third degree of burns without infected wounds are included and the modified Meek results are studied , measured and compared to other group which is operated lesions by mesh technique
62363633|NCT02285517|ACTIVE_COMPARATOR|mesh technique|Intervention: mesh skin grafting technique. patients with third degree of burns without infected wounds are included and the mesh skin grafting technique results are studied , measured and compared to other group which is operated lesions by modified Meek skin grafting technique
62363634|NCT00973180|EXPERIMENTAL|Enhanced Label|Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
62170150|NCT01797822|EXPERIMENTAL|Artificial tears first, then Dexamethasone|Artificial tears four times a day both eyes for two weeks, then Dexamethasone 0.01% four times a day both eyes for two weeks
62363635|NCT00973180|NO_INTERVENTION|Standard Label|Subjects in this arm will receive their prescriptions labeled with a standard label.
62363636|NCT01155960|ACTIVE_COMPARATOR|Arimidex|Arimidex® Tablets 1 mg
62363637|NCT01155960|EXPERIMENTAL|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
62170151|NCT04727190|EXPERIMENTAL|TBCB group|Specimens were obtained using 1.1 mm ultrathin cryoprobe with or without guide sheath by bronchoscope.
62170152|NCT04727190|ACTIVE_COMPARATOR|TBFB group|Specimens were obtained using 1.5 mm or 1.9 mm biopsy forceps with or without guide sheath by bronchoscope.
62170153|NCT03465670|ACTIVE_COMPARATOR|CHX|Post-surgery use of a 0.2% chlorhexidine (CHX) mouthrinse (10 ml for 1 minute, t.i.d. for 21 days)
62363638|NCT05214404||Ulcerative colitis group|Patients with ulcerative colitis as observation group
62363639|NCT05214404||Non-ulcerative colitis group|Non-ulcerative colitis as control group
62363640|NCT01187134|ACTIVE_COMPARATOR|Intervention group|
62363641|NCT01187134|NO_INTERVENTION|Conventional CME|Hospitals receive conventional continuing medical education in lecture style twice a year. They receive current publications and recommendations for national and international meetings regarding diagnosis and therapy of sepsis.
62363642|NCT04484051||Routine clinical care with Genotropin treatment|Data collection throughout routine clinical care with subcutaneous injections Genotropin, 0.6-0.8 mg/day. Participants start with 0.2 mg/day and the dose increases with 0.2 mg/day per month to a maximum dose of 0.6-0.8 mg/day.
62363643|NCT04955496||ERAS Group|Patients were treated by enhanced recovery after surgery
62363644|NCT04955496||Control Group|Patients were not treated by enhanced recovery after surgery
62363645|NCT04758741|EXPERIMENTAL|Acceptance and commitment treatment|The members of the intervention group receive one session of acceptance and commitment treatment per week according to Hayes (2006) approach in groups of 10 in 8 sessions of 90 minutes by a trained counselor (researcher) in Mashhadalkoubeh Health Center.
62391441|NCT01099670|EXPERIMENTAL|15 mg NRL001|Nine subjects will receive 15 mg NRL001 in a 2 g suppository; three will receive matching placebo.
62170154|NCT03465670|EXPERIMENTAL|CHX+HA+ADS|Post-surgery use of a 0.2% chlorhexidine (CHX) mouthrinse containing 0.2% hyaluronic acid (HA) and Anti-Discoloration System (ADS) (10 ml for 1 minute, t.i.d. for 21 days)
62170155|NCT02391116|EXPERIMENTAL|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib (Aliqopa, BAY80-6946) solution for IV infusion (test drug/investigational medicinal product)
62170156|NCT04369664|EXPERIMENTAL|Type 2 Diabetes group|All participants with type 2 diabetes will be given cholesterol-lowering medicine (evolocumab (PCSK9 inhibitor) plus atorvastatin (statin) or ezetimibe (zetia)) for 1 month with the same risk factors being measured following cholesterol reduction. They will be asked to undergo blood draw, to receive study medication, and to undergo additional optional vascular health testing including endothelial cell harvesting and glycocalyx (tongue probe).
62170157|NCT04369664|OTHER|Control group|The participants in the control group are subjects with elevated cholesterol who do not have diabetes. All participants will be given cholesterol-lowering medicines (evolocumab (PCSK9 inhibitor) plus atorvastatin (statin) or ezetimibe (zetia)) for 1 month with the same risk factors being measured following cholesterol reduction. They will be asked to undergo blood draw, to receive study medication, and to undergo additional optional vascular health testing including endothelial cell harvesting and glycocalyx (tongue probe).
62182352|NCT04053569|EXPERIMENTAL|Diet with table grape|Table grape (5g/Kg) administered for four weeks with dietary recommendations. A strict restriction of fruits and the limitation of other foods containing polyphenols will be necessary.
62363646|NCT04758741|SHAM_COMPARATOR|Health Education|This rct has one arm and health education is done only for the purpose of blinding the study so that the participant does not know which of the control or intervention groups it is in and has no comparative aspect and has nothing to do with resilience.
62363647|NCT05822648|EXPERIMENTAL|Intervention|Project Health will be delivered in six 1-hour group sessions that will be held weekly. In addition, participants will be asked to complete 30 mins of response inhibition and attention trainings once per week between the sessions. This program promotes to retain the gradual lifestyle modification designed to bring energy intake into balance with energy output and the food response inhibition and attention training, but will adapt the dissonance-induction activities to focus on the negative effects of developing T2D in addition to the negative effects of obesity, overeating, and a sedentary lifestyle.
62363648|NCT05822648|ACTIVE_COMPARATOR|Control|We selected a T2D management psychoeducational comparison condition. To match Project Health, the educational videos will be delivered in 6 1-hour blocks. The educational group will be instructed to watch videos on nutrition, exercise, and how to maintain general health during the lifespan
62363649|NCT00278863|ACTIVE_COMPARATOR|S-1|
62363650|NCT00278863|ACTIVE_COMPARATOR|Capecitabine|
62363651|NCT04616924|EXPERIMENTAL|RHB-204|Each capsule contains clarithromycin 158.3mg; rifabutin 40mg; clofazimine 13.3mg.
62363652|NCT04616924|PLACEBO_COMPARATOR|Placebo|Matching placebo will contain riboflavin, a type of B vitamin, which may discolor urine in a similar fashion as RHB-204.
62363653|NCT05481970|ACTIVE_COMPARATOR|Dexmedetomidine group|Group A , Induction of general anesthesia will be done using lidocaine (1.5 mg/kg), propofol (2-3 mg/kg), and atracurium (0.5 mg/kg). Dexmedetomidine 0.5 µg/kg over 10 min, started 10 min before induction. Following tracheal intubation, dexmedetomidine infusion generally will be initiated at 0.6 μg/kg/h and titrated between 0.2 and 1.0 μg/kg/h according to the heart rate maintaining bispectral index (BIS) between 40-60, lidocaine (1.5 mg/kg/h). ketamine will be given as a bolus dose of 0.3 mg/kg after induction and prior to skin incision then 0.2 mg/kg/h as an infusion. Patients will receive dexamethasone (8 mg i.v.) after induction.
62170158|NCT06434545|EXPERIMENTAL|Intervention group|The intervention group consists of 20 nursing team, each recruiting 20 clients with palliative care needs. This results in a total of 400 clients for the intervention group. A nursing team consists of nurse assistants, registered nurses and specialized nurses.
62170159|NCT06434545|NO_INTERVENTION|Control group|The control group consists of 20 nursing teams that will continue to provide care as previous to the start of the study. Contact persons also recruit 20 clients per nursing team, resulting in a total of 400 client for the control group.
62363654|NCT05481970|PLACEBO_COMPARATOR|Opioid group|In group (B) (OBA) for induction of anesthesia, patients will receive propofol 2-3mg/kg, fentanyl 1-2mcg/kg and atracurium 0.5 mg/kg as a muscle relaxant to facilitate intubation. Fentanyl bolus doses of 0.5-1 mcg/kg will be given to keep BIS score 40-60 during surgery.
62363655|NCT01750840||Stimulation Group|All patients will receive either the Biomet® EBI Bone Healing System, Biomet OrthoPak® Non-invasive Bone Growth Stimulator System or Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator Systems.
62363656|NCT00758407|ACTIVE_COMPARATOR|1|
62363657|NCT00758407|PLACEBO_COMPARATOR|2|
62363658|NCT05615038|EXPERIMENTAL|Contact aspiration first line thrombectomy|Patients will have the mechanical thrombectomy by first-line contact aspiration
62363659|NCT05615038|ACTIVE_COMPARATOR|Stent retriever first line thrombectomy|Patients will have the mechanical thrombectomy by first-line stent retriever
62363660|NCT06263244|EXPERIMENTAL|Ziltivekimab|15 mg ziltivekimab subcutaneously once per month for 5 months
62363661|NCT06263244|PLACEBO_COMPARATOR|Placebo|Placebo, subcutaneously, once per month for 5 months
62363662|NCT05953324|EXPERIMENTAL|Cases|consumed two medium-size kiwifruit group \[21\] (cases) 1 hour before bedtime every night for 6 weeks (42 days in total).Randomization was performed by giving participants a note identifying the condition to which they were randomized; the note was placed in a sealed envelope. Blindness was not applicable since cases received kiwifruit and controls did not receive. Total number of kiwis consumed should be (14 kiwis (number of kiwis in one week) x 6 (number of weeks) = 84 kiwis in total. Participants consuming the kiwifruit were asked to keep a diary to record if they consumed them every day. During the 6-week intervention period, participants received their kiwifruit every week on the first day of the week (Sunday) that is adequate for a week (14 kiwi fruits brand name: Sharbatly Co. Ltd, variety: Hayward, country of origin: Italy). The kiwifruits were supplied at optimum ripeness for consumption and were instructed to keep the kiwi in the fridge to prevent damage.
62363663|NCT05953324|NO_INTERVENTION|Controls|Had poor sleep quality however did not consume kiwifruit
62363664|NCT03290794||Decision to treat with intravitreal aflibercept for wet AMD|Adult patients with a diagnosis of wet AMD, as an indication approved by the local health authorities for use with intravitreal aflibercept.
62739272|NCT03158740|ACTIVE_COMPARATOR|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC.
62170160|NCT04131699||pediatric thoracoscopic group|record hemodynamic changes and cardiac output at different intrathoracic pressures ( insufflation pressures 4, 5, 6 mmHg)
62170161|NCT06045871|OTHER|Patients with anterior vertical maxillary excess (gummy smile)|
62170162|NCT01116453|EXPERIMENTAL|Acupuncture|
62170163|NCT01116453|ACTIVE_COMPARATOR|Usual Care|usual care followed by delayed acupuncture
62170164|NCT01189370|EXPERIMENTAL|Intra-Patient Dose Escalation: Sorafenib|All patients will receive a starting dose of sorafenib 400 mg by mouth twice daily. At four weeks, all patients who have not experienced Grade 3 or 4 toxicity will undergo dose escalation using a treatment schedule of days 1-5 days of each week. Doses will continue to be escalated every 4 weeks depending on tolerability and tumor response.
62170165|NCT05360199|NO_INTERVENTION|control group|no recall PROMs group ; without knowledge of previous PROMs scores
62170166|NCT05360199|ACTIVE_COMPARATOR|intervention group|recall PROMs group ; with knowledge of previous PROMs scores
62182353|NCT04053569|NO_INTERVENTION|Specific dietary advice|Dietary recommendations (such as limitation of alcohol, caffeine), and low consumption of fruits.
62363665|NCT02818270|EXPERIMENTAL|Drug depositions|Aerosol drug deposited delivered on the inhaled and exhaled filters and protective filters were evaluated. Salbutamol and Acetylcysteine were delivered by a jet nebulizer through a mechanical ventilator.
62363666|NCT00995267|EXPERIMENTAL|behavioral intervention|Behavioral intervention arm comprises 5 joint parent-child school-based nutritional activities in which nutritional information was combined with Adler's behavioral concepts. and a 5-session parental workshop.
62363667|NCT00995267|NO_INTERVENTION|control arm|
62363668|NCT04594356||Patients with COVID-19 infection|"As part of this research, existing clinical data of patients infected with COVID-19 is collected from the patients' computerized medical records.~During the hospitalization of the patients, in addition to the clinical and laboratory data collected, the dosage of IL-6, apparently playing a central role in the worsening of the symptoms of COVID-19, was performed. The remainder of the contents of the tube used to perform this assay will allow further research by assaying the DNA-myeloperoxidase (DNA-MPO) complexes. These complexes reflect a phenomenon called netosis, most likely involved in the widespread inflammation that patients have suffered from."
62170167|NCT02580981|EXPERIMENTAL|Genomic Testing|"Newly diagnosed ALL patients will undergo genomic studies listed in Primary Objective 1. Analyses will be performed on a bone marrow (BM) aspirate at initial diagnosis (patients with an absolute blast count of at least 1,000/μL, may submit 2 mL of peripheral blood at diagnosis for each 1 mL of required BM. In patients in whom the aspirate cannot be obtained, a core biopsy will be used).~In addition, flow cytometric analysis and deep sequencing will be used to characterize and monitor the molecular heterogeneity and clonal evolution of disease during front-line therapy. BM, blood, and buccal specimens will be collected on day 29 of induction treatment and possibly at a later time point if relapse occurs."
62170168|NCT04868981|EXPERIMENTAL|GST-HG141|GST-HG141 tablets at varying dosages by mouth for 28 days
62170169|NCT04868981|PLACEBO_COMPARATOR|Matching Placebo for GST-HG141|Placebos for GST-HG141 tablets at varying dosages by mouth for 28 days
62170170|NCT01278511|EXPERIMENTAL|Canadian C-Spine Rule|
62363669|NCT00509652|EXPERIMENTAL|Arm 1|Erythrocyte apheresis
62363670|NCT00509652|ACTIVE_COMPARATOR|Arm 2|Phlebotomy
62363671|NCT03150199|EXPERIMENTAL|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
62363672|NCT03150199|ACTIVE_COMPARATOR|MI-Based Health Education Intervention|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior related to diabetes health (physical activity, medication adherence, diet) and will use motivational interviewing techniques to facilitate the consideration of behavior change.
62170171|NCT01021202|EXPERIMENTAL|Early tracheostomy|Percutaneous dilation tracheostomy \< 72h on mechanical ventilation
62739273|NCT06440954|EXPERIMENTAL|Intrathecal pemetrexed|Intrathecal pemetrexed
62170172|NCT01021202|EXPERIMENTAL|Late tracheostomy|Percutaneous dilation tracheostomy \> 10 days on mechanical ventilation
62170173|NCT01138137|EXPERIMENTAL|All subjects|
62170174|NCT02266589|EXPERIMENTAL|Hydrocortisone|little doses of hydrocortisone
62170175|NCT02266589|NO_INTERVENTION|Placebo|Placebo
62170176|NCT01396733|ACTIVE_COMPARATOR|Low dose group|Patients who will receive 600 mg/day alpha-lipoic acid
62170177|NCT01396733|ACTIVE_COMPARATOR|High dose group|Patients who will receive 1,200 mg/day alpha-lipoic acid
62170178|NCT04398355|NO_INTERVENTION|control|basic treatment+Swallowing rehabilitation training
62170179|NCT04398355|EXPERIMENTAL|Combination treatment|basic treatment+Swallowing rehabilitation training+Chinese traditional rehabilitation
62170180|NCT04398355|EXPERIMENTAL|Liu-Zi-Jue treatment|basic treatment+Swallowing rehabilitation training+Liu-Zi-Jue
62170181|NCT04398355|EXPERIMENTAL|acupuncture treatment|basic treatment+Swallowing rehabilitation training+acupuncture
62363673|NCT01544478|EXPERIMENTAL|V501|Participants received a 0.5-mL vaccination of V501 by intramuscular injection on Day 1, Month 2, and Month 6
62363674|NCT04494529|PLACEBO_COMPARATOR|Single-Dose (12 mg betamethasone + placebo)|"The standard course of betamethasone consists of 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg. Before enrolment and randomization in the SNACS trial, all women will have received a first 12 mg injection of betamethasone according to local hospital protocols. After this first injection, randomization is performed.~Participants randomized to the experimental Single-Dose arm will receive a similar appearing placebo injection instead of the standard 2nd dose of 12 mg of betamethasone (i.e. they will receive the experimental single-dose regimen, total 12 mg of betamethasone only from the first injection)."
62739274|NCT03150745|OTHER|Colposcopic group|
62739275|NCT03150745|OTHER|office hysteroscopic group|
62170182|NCT06013982|EXPERIMENTAL|Patients discharged following acute care stroke|Participation will last 3 months from enrollment. Demographic data will be retrieved from the electronic health record and the Generalized Anxiety Disorder-7 (GAD-7) Anxiety Questionnaire will be administered at baseline. Participants will repeat the GAD-7 in 3 months and an additional qualitative survey on their experience including an evaluation of the structured anxiety reduction program.
62170183|NCT04864236|EXPERIMENTAL|Intervention group|This group will undergo airway management in the operating room as part of the anesthesia for surgery in the presence of the novel isolation device.
62170184|NCT04864236|NO_INTERVENTION|Control group|
62170185|NCT00460577|ACTIVE_COMPARATOR|Formoterol (Foradil®)|Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.
62170186|NCT00460577|ACTIVE_COMPARATOR|Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg|Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.
62182354|NCT03088189||Vitamin B12 group|Mothers in the group are receiving vitamin B12 2µg supplements daily
62391442|NCT01142011|EXPERIMENTAL|Belimumab|"The first cycle of Belimumab is a loading cycle of 3 doses over 28 days (days 1, 15, 29).~After the first cycle, additional cycles of belimumab will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles)."
62739276|NCT02731820|EXPERIMENTAL|Treatment group|Potassium citrate Calcium carbonate Vitamin D3
62739277|NCT02731820|PLACEBO_COMPARATOR|Control group, Placebo|Placebo (Excipients) Calcium carbonate Vitamin D3
62170187|NCT03267069||alcohol liver disease|Patients with alcohol liver disease consenting to participate in the study will be administered an initial survey at inclusion and then follow-up surveys at 3, 6, 9, 12, 15, and 18 month intervals and then 2, 5, and 10 years. There is no intervention cohort, all enrolled will complete the same surveys. Recidivism will be measured by responses to survey questions, clinical interviews documented in the chart, and urine ethnyl glucuronide or blood ethanol testing.
62363675|NCT04494529|ACTIVE_COMPARATOR|Double-Dose (12 mg betamethasone + 12 mg betamethasone)|"The standard course of betamethasone consists of 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg. Before enrolment and randomization in the SNACS trial, all women will have received a first 12 mg injection of betamethasone according to local hospital protocols. After this first injection, randomization is performed.~Participants randomized to the Double-Dose arm will receive the standard 2nd dose of 12 mg of betamethasone injected intramuscularly (i.e. they will receive the standard double-dose regimen, total 24 mg of betamethasone)."
62363676|NCT01728727|ACTIVE_COMPARATOR|conventional|conventional treatment \& antiviral treatment
62170188|NCT05990075|EXPERIMENTAL|Self-monitoring|This research study will evaluate a self-monitoring intervention to increase awareness, provide support, and promote motivation to initiate treatment after referral to mental health. The proposed intervention is a user-driven program delivered online and by mobile text. This will be initially piloted for acceptability among Veterans referred to mental health service for depression treatment.
62170189|NCT04104724|EXPERIMENTAL|Self-help|Immediate access to self-help materials
62170190|NCT04104724|NO_INTERVENTION|Control|Wait-list control - treatment as usual (no intervention)
62170191|NCT06584565||modeling queue|The modeling queue is used to manage and prioritize tasks related to the development and training of models.
62170192|NCT06584565||validation queue|The validation queue is designed to handle tasks related to the evaluation and validation of models.
62170193|NCT06645626||UHS Specialist Clinic population|All patients seen in regional clinic with this diagnosis
62170194|NCT06645626||Interested patients from non-specialty clinics around the country.|Interested patients who meet the inclusion criteria and are from any region in the country with no movement disorder specialist clinic.
62170195|NCT03377283|ACTIVE_COMPARATOR|AP-KTx/LTx|Transplant recipients receiving an rATG-perfused kidney or liver
62170196|NCT03377283|PLACEBO_COMPARATOR|CP-KTx/LTx|Transplant recipients receiving a control-perfused kidney or liver.
62170197|NCT03343288|EXPERIMENTAL|Silver HA coated implants|Silver doped hydroxyapatite coated implants
62170198|NCT06175182||cystic fibrosis|No intervention
62170199|NCT06175182||healthy volunteers|No intervention
62170200|NCT03152500|EXPERIMENTAL|FEMTIS IOL|The FEMTIS-IOL has a special haptic system that allows the lens to clamp into the capsulorrhexis.
62170201|NCT03152500|ACTIVE_COMPARATOR|Acrysof IOL|The Acrysof IOL has a flexible haptic design that keeps the IOL stable and centered in the capsular bag
62170202|NCT05160402|EXPERIMENTAL|Cohort 1 (SAD)|In Cohort 1, subjects will be randomized to receive a single intranasal and intraoral administration of 1 mg of IGM 6268 or placebo
62170203|NCT05160402|EXPERIMENTAL|Cohort 2 (SAD)|In Cohort 2, subjects will be randomized to receive a single intranasal and intraoral administration of 3.75 mg of IGM 6268 or placebo
62170204|NCT05160402|EXPERIMENTAL|Cohort 3 (SAD)|In Cohort 3, subjects will be randomized to receive a single intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo
62170205|NCT05160402|EXPERIMENTAL|Cohort 4 (MAD)|In Cohort 4, subjects will be randomized to receive a single intranasal and intraoral administration of 3.75 mg of IGM 6268 or placebo once a day for 5 days.
62170206|NCT05160402|EXPERIMENTAL|Cohort 5 (MAD)|In Cohort 5, subjects will be randomized to receive a single intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo once a day for 5 days.
62170207|NCT05160402|EXPERIMENTAL|Cohort 6 (MAD)|In Cohort 6, subjects will be randomized to receive a single intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo twice a day for 5 days.
62170208|NCT00556764|EXPERIMENTAL|2 cohorts|"In this observational study 2 cohorts will participate. Cohort 1 will include people with Parkinson disease and Cohort 2 will include healthy volunteers.~A subset of twelve subjects (8 PD and 4 HC) will be enrolled in the \[123I\] IBVM and SPECT imaging portion of this study"
62170209|NCT00884884|PLACEBO_COMPARATOR|Double Placebo|Placebo, Placebo
62170210|NCT00884884|EXPERIMENTAL|Aripiprazole 15, Placebo|15 mg Aripiprazole, Placebo
62170211|NCT00884884|EXPERIMENTAL|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
62170212|NCT00884884|EXPERIMENTAL|Topiramate 100mg, Placebo|Topiramate 100 mg daily plus Placebo daily
62170213|NCT00884884|EXPERIMENTAL|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
62170214|NCT00884884|EXPERIMENTAL|Topiramate 100, Aripiprazole 5|Topiramate 100 daily plus, Aripiprazole 5mg daily
62170215|NCT00884884|EXPERIMENTAL|Topiramate 200, Aripiprazole 15|Topiramate 200 mg daily plus Aripiprazole 15mg daily
62170216|NCT00884884|EXPERIMENTAL|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily, Aripiprazole 7.5 mg daily
62170217|NCT00884884|EXPERIMENTAL|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
62170218|NCT01924806|ACTIVE_COMPARATOR|WoundWand™ Debridement Device|Group I - Coblator IQTM Controller plus WoundWandTM Debridement Device. Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound.
62170219|NCT01924806|ACTIVE_COMPARATOR|Standard of Care sharp debridement|Group II - Standard of Care (SoC) surgical (sharp) debridement. Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound.
62170220|NCT02679079|PLACEBO_COMPARATOR|Placebo|Administered once daily for 6 weeks
62170221|NCT02679079|EXPERIMENTAL|Dose Group 1|Administered once daily for 6 weeks
62170222|NCT02679079|EXPERIMENTAL|Dose Group 2|Administered once daily for 6 weeks
62170223|NCT02581137|EXPERIMENTAL|Prevention (extended-release metformin hydrochloride)|Patients receive extended-release metformin hydrochloride PO QD for 2 weeks and then BID for 10-12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62170224|NCT01971424|EXPERIMENTAL|Mg oxide|Participants were supplemented for 12-weeks with 300 mg of daily oral magnesium oxide.
62363677|NCT01728727|EXPERIMENTAL|UC-MSC transplantation|Participants will receive umbilical cord derived mesenchymal stem cell treatment at day 1 and conventional treatment and antiviral treatment through the one year study visit. Participants will then be followed until one years study visit
62170225|NCT01971424|NO_INTERVENTION|Controls|The control group was educated by a trained dietician to follow a healthy diet.
62170226|NCT00759681|ACTIVE_COMPARATOR|Control|Gelfoam and Thrombin
62170227|NCT00759681|EXPERIMENTAL|Investigational Device|ArterX Surgical Sealant
62170228|NCT06646185|OTHER|TamponCupPad|Participants will adopt tampons during the first two menstrual cycles (first period of the trial), followed by adoption of cups during the next two menstrual cycles (second period), and lastly menstrual pads for the next two menstrual cycles (third crossover period).
62170229|NCT06646185|OTHER|TamponPadCup|Participants will adopt tampons during the first two menstrual cycles (first period of the trial), followed by adoption of pads during the next two menstrual cycles (second period), and lastly menstrual cups for the next two menstrual cycles (third crossover period).
62170230|NCT06646185|OTHER|CupTamponPad|Participants will adopt menstrual cups during the first two menstrual cycles (first period of the trial), followed by adoption of tampons during the next two menstrual cycles (second period), and lastly menstrual pads for the next two menstrual cycles (third crossover period).
62170231|NCT06646185|OTHER|CupPadTampon|Participants will adopt menstrual cups during the first two menstrual cycles (first period of the trial), followed by adoption of menstrual pads during the next two menstrual cycles (second period), and lastly tampons for the next two menstrual cycles (third crossover period).
62170232|NCT06646185|OTHER|PadTamponCup|Participants will adopt menstrual pads during the first two menstrual cycles (first period of the trial), followed by adoption of tampons during the next two menstrual cycles (second period), and lastly menstrual cups for the next two menstrual cycles (third crossover period).
62170233|NCT06646185|OTHER|PadCupTampon|Participants will adopt menstrual pads during the first two menstrual cycles (first period of the trial), followed by adoption of menstrual cups during the next two menstrual cycles (second period), and lastly tampons for the next two menstrual cycles (third crossover period).
62170234|NCT03157687||Healthy controls|"* Blood sampling for nutrition and inflammatory status~* Stool sampling before preventive gastroscopy and colonoscopy~* Questionnaires about general health, gastrointestinal symptoms and 3-day food record~* Collection of biopsies in duodenum during gastroscopy~* Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
62170235|NCT03157687||Inflammatory bowel disease (IBD)|"* Blood sampling for nutrition and inflammatory status~* Stool sampling before indicated gastroscopy and colonoscopy~* Questionnaires about general health, gastrointestinal symptoms and 3-day food record~* Collection of biopsies in duodenum during gastroscopy~* Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
62170236|NCT03157687||Liver transplantation recipient (LTX)|"* Blood sampling for nutrition and inflammatory status~* Stool sampling before indicated gastroscopy and colonoscopy for evaluation of liver transplantation (LTX)~* Questionnaires about general health, gastrointestinal symptoms and 3-day food record~* Collection of biopsies in duodenum during gastroscopy~* Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
62170237|NCT04088136|EXPERIMENTAL|Everyday Metacognitive Memory|Training in techniques for managing memory demands in everyday life
62170238|NCT04088136|ACTIVE_COMPARATOR|Memory Strategy Control|Trains the use of memory strategies for learning new associations and concepts
62170239|NCT01346826|ACTIVE_COMPARATOR|2 hours-infusion group|Number of patients: 57 (Standard 2 hours-infusion group)
62170240|NCT01346826|EXPERIMENTAL|1 hour-infusion group|Number of patients: 59 (1 hour-infusion group)
62170241|NCT01346826|EXPERIMENTAL|30 minutes-infusion group|Number of patients: 59 (30 minutes-infusion group)
62170242|NCT02389725|ACTIVE_COMPARATOR|disposable elastic tourniquet|
62170243|NCT02389725|ACTIVE_COMPARATOR|manual blood pressure cuff|manual blood pressure cuff inflated to 150 milliliters mercury (mmHg)
62170244|NCT00722488|EXPERIMENTAL|1|MLN4924
62170245|NCT03263104|EXPERIMENTAL|Lactobacillus plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402 equivalent to 2x10\^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed twice daily, before breakfast and dinner with 250mL of water.
62363678|NCT01779804||Patients with foot and ankle injury|After baseline data is obtained a cohort of patients with acute foot and ankle injuries will have OFAR applied
62170246|NCT03263104|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed twice daily, before breakfast and dinner with 250mL of water.
62170247|NCT05325658||Oropharyngeal dysphagia|Patients with oropharyngeal dysphagia. Patients will be examined before and after combination therapy.
62170248|NCT04833842|EXPERIMENTAL|Web-based birth preparation program supported by motivational interview|A web-based childbirth preparation program prepared based on the Health Belief Model and supported by motivational interviews will be applied to primigravida women in the initiative group.
62170249|NCT04833842|EXPERIMENTAL|web-based birth preparation program|A web-based birth preparation program based on the Health Belief Model will be applied to primigravida women in the control group.
62170250|NCT03364283||Sitting Position|Sitting and semi-sitting
62170251|NCT03364283||Horizontal Position|Prone, lateral and park bench.
62170252|NCT01202383|ACTIVE_COMPARATOR|NADCC tablets|
62170253|NCT01202383|PLACEBO_COMPARATOR|Placebo tablets|
62170254|NCT05521555||total knee arthroplasty under 55|Patient who had total knee arthroplasty before 55 between January 2010 and December 2019
62170255|NCT02944526|EXPERIMENTAL|Ropivacaine Suprascapular Nerve Block|"Suprascapular nerve block realized in sterile conditions under live ultrasound guidance: injection of 5ml of Ropivacaine monohydrochloride 2mg/ml.~3 successive blocks are realized at 1 week interval."
62170256|NCT02944526|PLACEBO_COMPARATOR|Placebo Suprascapular Nerve Block|"Suprascapular nerve block realized in sterile conditions under live ultrasound guidance: injection of 5ml of physiological /isotonic saline.~3 successive blocks are realized at 1 week interval."
62170257|NCT01048983|OTHER|Questionnaires and Phone Calls|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
62170258|NCT01048983|ACTIVE_COMPARATOR|Curcumin Only|
62170259|NCT01048983|ACTIVE_COMPARATOR|Armodafinil Only|
62170260|NCT01048983|ACTIVE_COMPARATOR|Minocycline Only|
62170261|NCT01048983|ACTIVE_COMPARATOR|Bupropion Only|
62170262|NCT01048983|ACTIVE_COMPARATOR|Curcumin + Armodafinil|
62170263|NCT01048983|ACTIVE_COMPARATOR|Curcumin + Minocycline|
62170264|NCT01048983|ACTIVE_COMPARATOR|Curcumin + Bupropion|
62170265|NCT01048983|ACTIVE_COMPARATOR|Armodafinil + Minocycline|
62170266|NCT01048983|ACTIVE_COMPARATOR|Armodafinil + Bupropion|
62170267|NCT01048983|ACTIVE_COMPARATOR|Minocycline + Buproprion|
62363679|NCT05499598|EXPERIMENTAL|Modified minimally invasive surgical technique with PRF and vitamins A and C|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. Ascorbic Acid will be added to the fresh blood to achieve a concentration of 250 μg/ml, Retinol will also be added to achieve a concentration of 20 μmol/L. The resultant PRF clot will be placed into the intra-osseous defect.
62363680|NCT05499598|ACTIVE_COMPARATOR|Modified minimally invasive surgical technique with PRF|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of whole blood is drawn by venipuncture of the antecubital vein and is collected into two blood collection tubes without anticoagulant for PRF preparation.The resultant PRF clot will be placed into the intra-osseous defect
62170268|NCT01048983|ACTIVE_COMPARATOR|Curcumin + Armodafinil + Minocycline|
62170269|NCT01048983|ACTIVE_COMPARATOR|Curcumin + Armodafinil + Bupropion|
62170270|NCT01048983|ACTIVE_COMPARATOR|Curcumin + Minocycline + Bupropion|
62170271|NCT01048983|ACTIVE_COMPARATOR|Armodafinil + Minocycline + Bupropion|
62170272|NCT01048983|ACTIVE_COMPARATOR|Curcumin + Armodafinil + Minocycline + Bupropion|
62170273|NCT06117761|EXPERIMENTAL|COMBAT-ICU|The COMBAT-ICU group will receive an intervention which will last for 8 weeks, with 3 sessions per week. A blended training platform with supervised in-person home visits and a real-time supervised online and unsupervised selfpractice approach will be used to deliver the intervention, with the platform gradually shifted from home visits to unsupervised self-practice according to participants' physical functioning level. Family caregivers will be involved in the intervention, so that they can facilitate home-based training. Each intervention session will last for 80 minutes and comprise 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training. Moreover, all participants in the COMBAT-ICU group will be invited to complete a satisfaction survey and semi-structured qualitative interview, which will focus on exploring the acceptability and perceived effects from participants' perspective.
62170274|NCT06117761|EXPERIMENTAL|Exercise Group|The exercise group will receive an 8-week, home-based, exercise intervention which is the same as that of the exercise component of the COMBAT-ICU intervention, 3 sessions per week, and 45 minutes per session, but will not receive any structured cognitive training.
62170275|NCT06117761|PLACEBO_COMPARATOR|Attention Placebo Group|The attention placebo group will receive a telephone call every 2 weeks, with the conversation focused on information provision and brief counselling relating to their health conditions, in order to reduce the potential bias from greater attention for the COMBAT-ICU and exercise groups. They will also receive the routine care provided by the healthcare system, including medical follow-ups with the clinical team, without structured out-patient rehabilitation services.
62170276|NCT04421118||standard portal pressure gradient measurement and CT scan|"Procedure/Surgery:~Portal pressure gradient measurement and CT imaging examination. Three-dimensional models reconstructing and fluid dynamics simulation."
62170277|NCT06182124|EXPERIMENTAL|Phase 1 (Stage 1): Multivalent Pneumococcal Vaccine - Formulation 1|Participants to receive a single injection of Multivalent Pneumococcal Vaccine - Formulation 1. This is a possible candidate for continuation in Phase 2 (Stage 2).
62170278|NCT06182124|EXPERIMENTAL|Phase 1 (Stage 1): Multivalent Pneumococcal Vaccine - Formulation 2|Participants to receive a single injection of Multivalent Pneumococcal Vaccine - Formulation 2. This is a possible candidate for continuation in Phase 2 (Stage 2).
62170279|NCT06182124|ACTIVE_COMPARATOR|Phase 1 (Stage 1) and Phase 2 (Stage 2): 20-valent pneumococcal conjugate vaccine (20vPnC)|Participants to receive a single injection of 20vPnC.
62170280|NCT03030053|EXPERIMENTAL|Active|Cocoa-Flavanol Supplements: 3 capsules per day each containing 300mg (total dose of 900mg daily) for 24 weeks
62170281|NCT03030053|PLACEBO_COMPARATOR|Control|Control Supplements: 0mg cocoa-flavanols per day for 24 weeks
62170282|NCT01789541||Atrial fibrillation|Patients with atrial fibrillation undergoing ablation
62170283|NCT01789541||AV-nodal reentry tachycardia|Patients with AV-Nodal Reentry Tachycardia undergoing ablation
62170284|NCT06643884|EXPERIMENTAL|80 micrograms of bel-sar|1 Cycle AU-011 with a dose of 80 micrograms
62170285|NCT06643884|EXPERIMENTAL|160 micrograms of bel-sar|1 Cycle AU-011 with a dose of 160 micrograms
62170286|NCT06643884|EXPERIMENTAL|200 micrograms of bel-sar with one cycle|1 Cycle AU-011 with a dose of 200 micrograms
62170287|NCT06643884|EXPERIMENTAL|200 micrograms of bel-sar with two cycles|2 Cycles AU-011 with a dose of 200 micrograms
62170288|NCT06643884|NO_INTERVENTION|Observational|Subjects that meet trial inclusion, but do not meet criteria for enrollment into the bel-sar treatment cohorts, may be enrolled in this cohort. The observational cohort will not receive bel-sar treatment.
62170289|NCT02824029|EXPERIMENTAL|Treatment (ibrutinib)|Patients receive ibrutinib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62170290|NCT02380885|EXPERIMENTAL|SCIT|Social Cognition and Interaction Training: psychosocial group intervention
62170291|NCT02380885|EXPERIMENTAL|TAFT|Therapeutic Alliance Focused Therapy
62170292|NCT02380885|NO_INTERVENTION|TAU|Treatment as Usual
62170293|NCT02373605|EXPERIMENTAL|Dry Needling,Thrust Manipulation|
62170294|NCT02373605|ACTIVE_COMPARATOR|Exercise,Non-thrust Mobilization|
62170295|NCT06127966|EXPERIMENTAL|Erector Spinae Plane Block group(EA group + EB group)|Conventional anesthesia induction, followed by ultrasound-guided erector spinae plane (ESPB) block with 0.5% ropivacaine (20 ml) after anesthesia induction.
62170296|NCT06127966|SHAM_COMPARATOR|Control group（CA group + CB group)|Conventional anesthesia induction, followed by ultrasound-guided injection of 0.9% saline (20 ml) into the erector spinae plane (ESPB) after anesthesia induction.
62170297|NCT03973047|PLACEBO_COMPARATOR|Group 1: BMT plus placebo|1 dose of BMT 1.75 mg via autoinjector plus placebo (dosed 30±5 minutes prior to BMT dosing) on Day 1.
62170298|NCT03973047|ACTIVE_COMPARATOR|Group 2: BMT plus Zofran|1 dose of BMT 1.75 mg via autoinjector plus Zofran 8 mg (dosed 30±5 minutes prior to BMT dosing) on Day 1.
62170299|NCT02990299|NO_INTERVENTION|Usual Care|Participants will receive their usual care for the first year of their enrollment in the study. They will receive a referral to a diabetes educator and a clinical pharmacist, a one-page sheet of contact information for their healthcare providers, and paper-based, low-literacy diabetes information. After one year, they will change to the mDAS intervention arm for one year.
62170300|NCT02990299|EXPERIMENTAL|mHealth for Diabetes Adherence Support|Participants will receive in-person support from a health coach and a clinical pharmacist with whom they will meet with regularly via videoconference. After one year, participants who have completed the mDAS intervention will be monitored for an additional year with usual care to evaluate maintenance.
62170301|NCT04501978|EXPERIMENTAL|ACTIV-3 Drug plus SOC|Participants in this study will be randomized to receive one of the ACTIV-3 drug treatments plus Standard of Care (SOC) or placebo plus SOC
62170302|NCT04501978|PLACEBO_COMPARATOR|Placebo plus SOC|The placebo arm may be pooled across more than one experimental arm if multiple investigational drugs are available to be tested at the same time. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
62170303|NCT04608006||Vaginal Delivery|Delivered both twins vaginally
62170304|NCT04608006||C-Section Delivery|Delivered both twins by Cesarean Section
62170305|NCT04608006||Vaginal/C-Section Delivery|Delivery first twin vaginally and second twin By C-Section.
62170306|NCT06575998|EXPERIMENTAL|Training with pro-active identification|For detailed description of the intervention, see the separate section on interventions.
62170307|NCT06575998|EXPERIMENTAL|Training without pro-active identification|For detailed description of the intervention, see the separate section on interventions.
62170308|NCT06575998|NO_INTERVENTION|Control|Care as usual according to national applicable primary guide guidelines.
62363681|NCT06145087|PLACEBO_COMPARATOR|Placebo|The placebo is provided together with the placebo by AgeLess Sciences LLC, a Public Benefit Corporation.
62170309|NCT01678898|EXPERIMENTAL|0.2 mg/kg|PRX-102 0.2 mg/kg every 2 weeks
62363682|NCT06145087|EXPERIMENTAL|"NOVOS Core supplement"|"The NOVOS Core supplement is a commercially available product and has 12 ingredients. It was developed and is provided together with the placebo by AgeLess Sciences LLC, a Public Benefit Corporation."
62363683|NCT05189704|EXPERIMENTAL|NSAID group|NSAID based patient-controlled analgesia will connected to intravenous line for pain control.
62363684|NCT05189704|ACTIVE_COMPARATOR|Opioid group|Opioid based patient-controlled analgesia will connected to intravenous line for pain control.
62363685|NCT05850013||Sub Protocol 1|Sub protocol 1 - Blood pressure measured in participants who are able to cooperate and are relatively still Within each study session, compliant participants will have their blood pressure measured using standard-of-care equipment and methods during the same 60 seconds that their other vital signs are measured
62391443|NCT04466592|EXPERIMENTAL|Supportive intervention|A research psychologist will support participants, promoting their competences in the recover of work and social activities, such as the compliance.
62391444|NCT03931928|NO_INTERVENTION|Control group (Group 1)|All patients receive Placebo
62739278|NCT03814382|EXPERIMENTAL|Acupuncture|All subjects will receive up to 10 needles for 20 minutes for 1 treatment using acupuncture needles.
62170310|NCT01678898|EXPERIMENTAL|1 mg/kg|PRX-102 1 mg/kg every 2 weeks
62170311|NCT01678898|EXPERIMENTAL|2 mg/kg|PRX-102 2 mg/kg every 2 weeks
62170312|NCT03327051|ACTIVE_COMPARATOR|Omeprazole and VSL #3|Participants will receive a proton pump inhibitor (Omeprazole) and VSL #3 Probiotics
62170313|NCT03327051|PLACEBO_COMPARATOR|Placebo and VSL #3|Participants will receive placebo and VSL #3 Probiotics
62170314|NCT03229096|EXPERIMENTAL|Apatinib plus XELOX|Patients will be given the perioperative chemotherapy of Apatinib plus XELOX once recruited
62170315|NCT04337034|EXPERIMENTAL|mobile phone supported and family-centred rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and family-centred rehabilitation intervention (F@ce 2.0)
62170316|NCT04337034|ACTIVE_COMPARATOR|Information and blood pressure measurement|Control group participants will be given information about stroke and their blood pressure will be measured
62170317|NCT02461719|EXPERIMENTAL|CYPORIN N EYE DROPS 0.05%(TJCS eye drop)|CYPORIN N EYE DROPS 0.05%(TJCS eye drop) 1 drop twice/day for 12 weeks to both eyes
62170318|NCT02461719|ACTIVE_COMPARATOR|Restasis eye drop|Restasis eye drop(Cyclosporine ophthalmic solution 0.05%) 1 drop twice/day for 12 weeks to both eyes
62170319|NCT03538223|EXPERIMENTAL|"Radioterapy+Melomics-Health Listening"|"The musical content is composed by an algorithm (named Melomics-Health) with the purpose of acting psychologically and physiologically on the person: the music follows a constant, melodic trend with a reduced musical density; time is unchanged and there are no significant dynamic and tonal variations. Patients will undergo to music listening for 15 minutes (5 tracks lasting 3 minutes each) before radiotherapy session. Appropriate earphones will be used in order to focus their attention on the musical-sound component and to isolate themselves from the external context."
62170320|NCT03538223|EXPERIMENTAL|Radiotherapy+Individualized Listening|The musical content is based on the patient's preferred music (chosen by patients with the support of the music therapist) with the purpose of acting psychologically and physiologically on the person. Patients will undergo to music listening for 15 minutes before radiotherapy session. Appropriate earphones will be used in order to focus their attention on the musical-sound component and to isolate themselves from the external context.
62170321|NCT03538223|OTHER|Radiotherapy+No Music Listening|Patients will undergo the standard treatment (radiotherapy) without music support.
62170322|NCT06645652|EXPERIMENTAL|Participatory Arts|Participants will develop drawing skills through learning specific techniques and deliberately engaging cognitive domains such as perception, visuospatial reasoning, attention, and processing speed. The intervention is completed in a hybrid format where lessons are completed online and practice is completed in a sketchbook and drawing things from life. Prompts are provided to guide daily practice sessions. Techniques learned include contour drawing, gesture drawing, negative space drawing.
62363686|NCT05850013||Sub protocol 2|OPTIONAL Sub protocol 2: Electrocardiogram (ECG) for measurement of Heart rate variability This sub-protocol is relevant for children who would benefit from having a 3-lead ECG to capture beat to beat variability. This will be done in a subset of the participants, and ideally on a subsequent that is representative of the full cohort of participants in terms of age profile, skin tone distribution and illness.
62170323|NCT06645652|ACTIVE_COMPARATOR|Receptive Arts|Participants will learn about different art periods and browse online galleries. The materials will be available online through a website through which participants will access and browse online galleries. Weekly topics include genres, subjects, or specific mediums. Prompts and vocabulary will accompany the galleries to guide their learning.
62170324|NCT05955365|EXPERIMENTAL|Monotherapy strategy|Patients randomized to the monotherapy treatment arm receive any of the commercially available oral P2Y12 inhibitors (clopidogrel, prasugrel oder ticagrelor) and immediately discontinue aspirin and DOAC (or will not re-start DOAC after PCI if treatment was temporarily stopped before). After 1 month, the P2Y12 inhibitor will be stopped and treatment with a commercially available DOAC (at investigator's discretion and dosed according to the instructions for use in patients with atrial fibrillation) will be initiated for the duration of 11 months. After completion of the 12-month study regimen (study visit), the patient will receive antithrombotic therapy according to routine care.
62170325|NCT05955365|ACTIVE_COMPARATOR|Standard of care strategy|Patients randomized to the standard of care, receive DOAC for at least 12 months. In addition, aspirin is administered for up to 1 month after PCI at investigator's discretion and one of the available P2Y12 inhibitors (clopidogrel, prasugrel oder ticagrelor at investigator's discretion) is administered for a minimum of 6 months and up to 12 months after PCI. After completion of the 12-month control arm regimen (study visit), the patients will be treated according to routine care.
62170326|NCT01075100|EXPERIMENTAL|Weekly Ixabepilone +carboplatin|Subjects will receive ixabepilone and carboplatin on Days 1 and 8 of each 21-day cycle.
62170327|NCT04332367|EXPERIMENTAL|Carboplatin, Taxane And Ramucirumab|Carboplatin AUC 5 IV every 3 wks, Paclitaxel 80 mg/m2 IV days 1 and 8 every 3 weeks, and Ramucirumab 10 mg/kg IV every 3 weeks
62170328|NCT02534129|EXPERIMENTAL|Single Arm|Radiation field is divided into two sections, one treated with Difinsa53 and the other with Aquaphor
62170329|NCT04127383|EXPERIMENTAL|ABCC-tool|The intervention group will use the ABCC-tool during consultation with their healthcare provider. Healthcare providers in the intervention group will receive a short instructional film about the ABCC-tool before the start of the study. Additionally, healthcare providers from 12 practices will be invited for interviews, evaluating the context and process of implementation.
62170330|NCT04127383|NO_INTERVENTION|Usual care|The control group will receive usual care, and healthcare providers will not be instructed
62170331|NCT05595369|EXPERIMENTAL|Experimental: Paxlovid 25 day dosing|Drug: Paxlovid 25 day dosing Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) bid x 25 days See NCT05965726 (Paxlovid Sub-study)
62170332|NCT05595369|EXPERIMENTAL|Experimental: Paxlovid 15 day dosing|Drug: Paxlovid 15 day Dosing Paxlovid (nirmatrelvir 300mg and ritonavir 100mg) bid x 15 days then ritonavir 100mg bid plus nirmatrelvir matching placebo bid x 10 days See NCT05965726 (Paxlovid Sub-study)
62170333|NCT05595369|PLACEBO_COMPARATOR|Placebo Comparator: Control|Drug: Control ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid bid x 25 days See NCT05965726 (Paxlovid Sub-study)
62170334|NCT03273283|EXPERIMENTAL|Intervention|Patients received a brief intervention on alcohol use. This brief intervention was a little chat based on motivational techniques to enhance motivation to reduce alcohol use or to initiate treatment. Patients were referred to specialized treatment when indicated.
62170335|NCT03273283|NO_INTERVENTION|Control|Informative leaflets regarding alcohol use
62170336|NCT04656860|EXPERIMENTAL|Juice Plus+|Participants will consume 6 capsules daily consisting of a combination of Juice Plus+ Garden Blend, Juice Plus+ Orchard Blend and Juice Plus+ Berry Blend. Participants will consume supplements for 24-months.
62170337|NCT04656860|PLACEBO_COMPARATOR|Placebo|Participants will consume 6 capsules daily consisting of microcrystalline cellulose, rice starch, vegetarian capsule (cellulose), and magnesium stearate. Participants in this condition will receive 1-year of supplements after the study is completed.
62170338|NCT05411471|EXPERIMENTAL|Arm 1 (1 dose Omicron Vaccine arm, mRNA vaccine group)|75 participants who have completed two/three doses of mRNA vaccine (prior to this study) will receive one dose COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain(1200 SOU).
62170339|NCT05411471|EXPERIMENTAL|Arm 2 (2 doses Omicron Vaccine arm, mRNA vaccine group)|75 participants who have completed two/three doses of mRNA vaccine (prior to this study) will receive two doses COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain (0,28 days)(1200 SOU).
62170340|NCT05411471|EXPERIMENTAL|Arm 3 (1 dose Omicron Vaccine arm, CoronaVac® group)|75 participants who have completed two/three doses of CoronaVac®(prior to this study) will receive one dose COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain (1200 SOU).
62170341|NCT05411471|EXPERIMENTAL|Arm 4 (2 doses Omicron Vaccine arm, CoronaVac® group)|75 participants who have completed two/three doses of CoronaVac®(prior to this study) will receive two doses COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain (0,28 days)(1200 SOU).
62170342|NCT01502202|ACTIVE_COMPARATOR|Study arm|Pemetrexed plus Cisplatin plus Gefitinib
62170343|NCT01502202|PLACEBO_COMPARATOR|Placebo arm|Pemetrexed plus Cisplatin plus Placebo
62170344|NCT04361916|EXPERIMENTAL|home care with active monitoring|home care with active monitoring conducted by health workers with daily visit to patients.
62170345|NCT05201170|EXPERIMENTAL|PL9643 Ophthalmic Solution|PL9643 ophthalmic solution bilaterally three times a day.
62170346|NCT05201170|ACTIVE_COMPARATOR|Vehicle Ophthalmic Solution|Vehicle ophthalmic solution bilaterally three times a day.
62170347|NCT02040545||Infertility|Patients undergoing ovulation induction and controlled ovarian hyperstimulation at a participating infertility center
62170348|NCT02238691|EXPERIMENTAL|Mask ventilation with PEEP|15 subjects will undergo anesthetic induction with application of PEEP of 10 cm H2O during mask ventilation.
62739279|NCT01761799|EXPERIMENTAL|P3 Vaccine Promotion Package|The 5 obstetric practices randomized to the intervention arm will receive and implement all components of the evidence-based P3 vaccine promotion package at the beginning of the study.
62170349|NCT02238691|NO_INTERVENTION|Mask ventilation without PEEP|15 subjects will undergo anesthetic induction without PEEP during mask ventilation.
62170350|NCT03806283||Cohort 1 no Preeclampsia|Cohort 1: 26 mothers with no diagnosis of preeclampsia during pregnancy (13 male, 13 female neonate) Omental Biopsy and placental collection will be performed
62170351|NCT03806283||Cohort 2 mild or severe Preeclampsia|Cohort 2: 26 mothers with diagnosis of mild or severe preeclampsia during pregnancy (13 male, 13 female neonate) Omental Biopsy and placental collection will be performed
62170352|NCT04230993|EXPERIMENTAL|Ocean Bio Actif-Fluid+|Moderate hypertonic seawater solution (15 g / L NaCl) with polysorbate 80. The use is 1 to 2 sprays per nostril 4 times a day until symptoms of cold disappear, according to the instructions for use of the products.
62170353|NCT04230993|EXPERIMENTAL|Ocean Bio Active-Stuffy nose|Moderate hypertonic seawater solution (15 g / L NaCl) without polysorbate 80. The use is 1 to 2 sprays per nostril 4 times a day until symptoms of cold disappear, according to the instructions for use of the products.
62170354|NCT04230993|ACTIVE_COMPARATOR|Ocean Bio Active-Hygiene of the nose|Isotonic seawater solution (9 g / L NaCl). The use is 1 to 2 sprays per nostril 4 times a day until symptoms of cold disappear, according to the instructions for use of the products.
62170355|NCT01789229||Malignant tumors|"Patients who have one of the Neoplasms stated above under conditions."
62170356|NCT01789229||Benign controls|Patients with a benign tumor or an inflammatory disease - to be matched by age.
62170357|NCT01789229||Healthy controls|People/patients who have no known disease at time of sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.
62170358|NCT03942783|ACTIVE_COMPARATOR|Control Group|"The control group will receive a written work self-help information pack plus usual care. The pack includes published arthritis patient information booklets about work; a decision-tree flowchart; information about the UK Equality Act. The self-help information pack is mailed to the participants by the CTU following randomisation.~Usual care consists of: prescribed medication; attending Rheumatology clinics; referral to rehabilitation, as and when deemed necessary from the Rheumatology clinic, but not including work advice. Any rehabilitation required will be provided as normal, e.g. provision of exercise, self-management education, activities of daily living advice, psychosocial support."
62170359|NCT03942783|EXPERIMENTAL|WORKWELL Group|The same as the Control Group (i.e. self-help information pack, plus usual care) PLUS the WORKWELL intervention. This consists of, on average, 4.5 hours contact, including: a structured work assessment; identification of work-related barriers and priority problems; collaborative treatment planning with the participant; a range of self-management, work advice and job modifications appropriate to the individual participant's problems; goal setting and action planning; and a 30 minute telephone review to identify progress with goals at the end of treatment.
62170360|NCT02660034|EXPERIMENTAL|Part A: Dose Escalation Phase|Participants received tislelizumab and pamiparib (dose escalation) until determination of the maximum tolerated dose/recommended Phase 2 dose.
62170361|NCT02660034|EXPERIMENTAL|Part B: Dose Expansion Phase|Participants received tislelizumab and pamiparib (dose expansion).
62170362|NCT05234645|EXPERIMENTAL|Younger group|Fifteen participants, between 18 and 35 years of age. Participants are not pregnant; are healthy and suffering from no chronic diseases with the potential to influence vascular function; non-smoker; sedentary (defined via the completion of the international physical activity questionnaire; IPAQ); and were not consuming regularly probiotic-containing products. Additionally, a medical questionnaire was completed to exclude anyone with overt chronic disease.
62170363|NCT05234645|EXPERIMENTAL|Older group|Fourteen participants, between 55 and 75 years of age. Participants are not pregnant; are healthy and suffering from no chronic diseases with the potential to influence vascular function; non-smoker; sedentary (defined via the completion of the international physical activity questionnaire; IPAQ); and were not consuming regularly probiotic-containing products. Additionally, a medical questionnaire was completed to exclude anyone with overt chronic disease.
62170364|NCT06159933|EXPERIMENTAL|Historic cohort (SUPINE POSITIONING)|According to our local protocol, until December 2021, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
62170365|NCT06159933|EXPERIMENTAL|Historic cohort (LATE PRONATION)|According to our local protocol, until December 2021, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
62170366|NCT06159933|EXPERIMENTAL|Prospective cohort (EARLY PRONATION)|On the contrary, starting from January 2022 our local protocol was updated and all LT recipients developing PGD \>1 were routinely turned prone within 24 hours after the diagnosis ('early PP').Patients were placed in PP for at least 16 hours before being turned back to the supine position when meeting predefined criteria previously published by Guèrin et al
62170367|NCT01992302||Rapid Cycling Group|Patients who develop a rapid cycling course during the follow-up period.
62170368|NCT01992302||Non Rapid Cycling Group|Patients who do not develop a rapid cycling course during the follow-up period.
62170369|NCT05335005|EXPERIMENTAL|MK-2060|Participants continued their established background therapy of daily 75 mg clopidogrel for 2 weeks (days -14 to 0). Participants then continued background therapy while receiving 25 mg MK-2060 intravenous (IV) infusion on days 1, 3, 5, and 8.
62170370|NCT02988245|EXPERIMENTAL|Genetically-Guided Treatment for HTN|Using a patient's genetic composition to guide BP prescribing for patients with hypertension, post diagnosis.
62170371|NCT02988245|ACTIVE_COMPARATOR|JNC-8-Guided Treatment|Using traditional (JNC-8) guidelines for BP prescribing for patients with hypertension, post diagnosis.
62170372|NCT05558098|ACTIVE_COMPARATOR|Standard of Care|Current standard of care for critically ill patients.
62170373|NCT05558098|ACTIVE_COMPARATOR|Standard of care plus dapagliflozin|Current standard of care for critically ill patients plus open-label dapagliflozin 10 mg per day for 14 days or until ICU discharge
62170374|NCT05009147|EXPERIMENTAL|experimental group|receive whole body manual massage
62170375|NCT05009147|NO_INTERVENTION|control group|After experiment, receive whole body manual massage
62170376|NCT04106336|NO_INTERVENTION|non cannabis addict|30 non cannabis addict will be control group
62170377|NCT04106336|ACTIVE_COMPARATOR|cannabis addict|30 cannabis addict will undergo rTMS
62170378|NCT06645899||Patients with hypoparathyroidism|"Male and female patients of any age who are affected by chronic hypoparathyroidism.~The observation study does not include any type of intervention."
62170379|NCT06645899||Patients with pseudohypoparathyroidism|"Male and female patients of any age who are affected by pseudohypoparathyroidism.~The observation study does not include any type of intervention."
62170380|NCT05698511|EXPERIMENTAL|Psilocybin|Healthy volunteers will receive up to four doses of psilocybin separated from each other by at least one week. The first dosing session will involve 10 mg psilocybin, the remaining three dosing sessions will receive up to 25mg psilocybin.
62170381|NCT04127578|EXPERIMENTAL|Dose Level 1|
62170382|NCT04127578|EXPERIMENTAL|Dose Level 2|
62182355|NCT03088189||Multiple micronutrient group|mothers in this group are receiving vitamin B12 2µg plus multiple micronutrients (MMN) plus 20g of milk powder
62739280|NCT01761799|NO_INTERVENTION|No P3 vaccine promotion package intervention|The 5 obstetric practices randomized to the control arm will not receive the comprehensive vaccine promotion package at the beginning of the study and will instead be instructed to continue their standard of care regarding influenza and Tdap vaccination of pregnant patients.
62739281|NCT02933424|NO_INTERVENTION|Control beverage with no protein powder|Standard breakfast drink with no protein powder added
61986003|NCT03331146|ACTIVE_COMPARATOR|Sodium Nitrite|sodium nitrite will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
61986004|NCT05133219|EXPERIMENTAL|Research Group|"Participants will be received Intensified sensory therapy.~Other: Occupational Therapy Activities of Daily Living Training~Intervention: Other: Occupational therapy intervention"
61986005|NCT05133219|EXPERIMENTAL|Control Group|"Participants will be received Occupational Therapy.~Other: Activities of Daily Living Training"
61986006|NCT05052099|EXPERIMENTAL|mFOLFOX6 combined with Atezolizumab and Bevacizumab|"Patients will receive mFOLFOX6 combined with Atezolizumab 840 mg and Bevacizumab 10 mg/kg in 14-day cycles.~Treatment will be continued until disease progression, unacceptable toxicity or voluntary withdrawal."
61986007|NCT03451149|EXPERIMENTAL|Intervention|Undergo transjugular intrahepatic portosystemic shunt creation using a radiofrequency wire (Powerwire) in lieu of a trocar needle to cut through liver parenchyma
61986008|NCT00652236||FCT|Patients passing a function- centred rehabilitation
61986009|NCT00652236||PCT|Patients passing a pain-centred rehabilitation
61986010|NCT03068273|EXPERIMENTAL|Intervention|For type 2 patients in the intervention group, CGM data will be viewed real-time.
61986011|NCT03068273|EXPERIMENTAL|Control|For type 2 patients in the control group, CGM data is blinded to all and only gathered for comparison purposes to intervention group.
61986012|NCT02400879|ACTIVE_COMPARATOR|Remifentanil|For anesthesia maintenance, TCI-remifentanil (fixed Cp of 20 ng/ml) and TCI-propofol (variable Ce \< 2.0 µg/ml) for maintaining BIS 40-60
61986013|NCT02400879|PLACEBO_COMPARATOR|sevoflurane and sufentanil|TCI-sufentnail (Cp of 0.4-0.8 ng/ml) and sevoflurane (\< 1.5 MAC) for maintaining 80-120 % of preoperative value and BIS \< 60
61986014|NCT05373420||All individuals tested for COVID-19 in Belgium|All individuals of 18 years old and over tested for COVID-19 at least once in Belgium until the 31st of August 2021
61986015|NCT00939276|EXPERIMENTAL|NEVANAC|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
61986016|NCT00939276|PLACEBO_COMPARATOR|Nepafenac Vehicle|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
61986017|NCT02004028|EXPERIMENTAL|VS-6063 (defactinib)|Administered orally (BID) for 12, 21 or 35 days (+/- 2 days)
61986018|NCT02341807|EXPERIMENTAL|Cohort 1: AAV2-hCHM Dose 1|Single, unilateral subretinal administration of a single low dose range of AAV2-hCHM.
61986019|NCT02341807|EXPERIMENTAL|Cohort 2: AAV2-hCHM Dose 2|Single, unilateral subretinal administration of a single high dose range of AAV2-hCHM.
61986020|NCT02341807|EXPERIMENTAL|Cohort 3 (Expansion Cohort): AAV2-hCHM Dose 2|Single, unilateral subretinal administration of a single high dose range of AAV2-hCHM.
61986021|NCT00921180|EXPERIMENTAL|Entecavir and peginterferon|Entecavir 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52
61986022|NCT00921180|ACTIVE_COMPARATOR|Placebo and peginterferon|Placebo 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52
61986023|NCT04926532|EXPERIMENTAL|Toripalimab + Sorafenib|Toripalimab was administered intravenously at a fixed dose of 240 mg, and the infusion time was 60 ± 5 min, once every 21 days. The cumulative longest medication period is 2 years. Sorafenib was taken orally after meals, twice a day.
61986024|NCT04852458|EXPERIMENTAL|Intravenous hydrocortisone|
61986025|NCT04852458|NO_INTERVENTION|Observational|Participants will complete assessments/surveys only.
61986026|NCT04366037|EXPERIMENTAL|Control group|This group performed their routine training
61986027|NCT04366037|EXPERIMENTAL|Experimental 1|This group performed their routine training plus proprioceptive exercises in the warm-up.
61986028|NCT04366037|EXPERIMENTAL|Experimental 2|This group performed their routine training plus proprioceptive exercises in the cool-down
61986029|NCT05782751|EXPERIMENTAL|(groupI)|10 recession sites treated by (GEM 21s) ® with free connective tissue graft
61986030|NCT05782751|ACTIVE_COMPARATOR|(groupII)|10 recession sites GEM 21s with collagen membrane
61986031|NCT05982054|OTHER|bone marrow injection|injection of autologous concentrated bone marrow cells under ultrasound and fluoroscopy guide after core decompression
61986032|NCT01976234|ACTIVE_COMPARATOR|Fresh group|Fresh group will receive RBC stored for less than 14 days
61986033|NCT01976234|ACTIVE_COMPARATOR|Old group|Old group will receive RBC stored for 14 days or more
61986034|NCT03498742||No SABA users|Asthmatic subjects that did not use short acting beta2 agonists in the last 3 months and being using none agent or ICS, systemic corticosteroids of combined ICS/LABA as relief symptoms agent.
62170383|NCT03967093|EXPERIMENTAL|Part 1 Dose Escalation: Safety and Tolerance|Sequential cohorts of patients with relapsed solid tumors, including malignant brain tumors, will be treated with escalating doses of BXQ-350 until the maximum tolerated dose (MTD) is established, or in the absence of a maximum administered dose (MAD), the highest planned dose level (3.2 mg/kg) is reached.
62170384|NCT03967093|EXPERIMENTAL|Part 2: Ependymoma Patients|Cohort of patients with recurrent ependymoma will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
62170385|NCT03967093|EXPERIMENTAL|Part 2: Brain Tumor Patients|Cohort of patients with recurrent malignant brain tumors will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
62170386|NCT03967093|EXPERIMENTAL|Part 2: DIPG Patients|Cohort of patients with recurrent diffuse intrinsic pontine glioma (DIPG) will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
62170387|NCT03967093|EXPERIMENTAL|Part 2: Other Solid Tumor Patients|Cohort of patients with relapsed non-central nervous system (CNS) solid tumors will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
62170388|NCT02375438||Cohort Group|Patients with a clinical presentation suggestive of mitochondrial cytopathy, in whom mitochondrial deletions above 20% have been found in muscle are considered eligible if they are older than 18 years and are willing and able to give written informed consent.
62170389|NCT02375438||Control Group|Twenty healthy individuals matched for age and gender will be included in the study and considered as controls.
62170390|NCT02005029|PLACEBO_COMPARATOR|Placebo|One time IV dose of placebo
62170391|NCT02005029|EXPERIMENTAL|Erythromycin|One time IV dose of 100 mg Erythromycin
62170392|NCT02982070|EXPERIMENTAL|Mental Toughness Training|Behavioral training in goal-building, mindfulness, and the growth mindset.
62170393|NCT02982070|NO_INTERVENTION|College as Usual|no training provided
62170394|NCT04410003|PLACEBO_COMPARATOR|Placebo|Cellulose capsules, cloxacillin, electrolyte purgative (Peglyte)
62170395|NCT04410003|ACTIVE_COMPARATOR|Active|Capsules of stool from Protected donors, cloxacillin, electrolyte purgative (Peglyte)
62170396|NCT01730261|EXPERIMENTAL|Online Emotional Regulation Treatment|Participants will receive 24 treatment sessions, with baseline, post-treatment screening and follow-up screening, and bi-weekly assessments
62170397|NCT04667442||EUA RT-PCR positive|
62170398|NCT04667442||EUA RT-PCR negative|
62170399|NCT06538142|EXPERIMENTAL|Photobiomodulation + Restoration with self-cure composite resin|The participants will receive photobiomodulation + self-cure composite resin restoration.
62170400|NCT06538142|EXPERIMENTAL|Restoration with Self-cure Composite Resin|The participants will receive self-cure composite resin restoration.
62170401|NCT06538142|EXPERIMENTAL|Photobiomodulation + Restoration with Photopolymerizable Bulk-fill Composite Resin|The participants will receive photobiomodulation + restoration in bulk-fill photopolymerizable composite resin restoration.
62170402|NCT05375383|ACTIVE_COMPARATOR|Streptococcus salivarius K12 lozenge|Streptococcus salivarius K12 lozenge
62170403|NCT05375383|ACTIVE_COMPARATOR|Probiotic S. salivarius K12 lozenges containing prebiotic A|Streptococcus salivarius K12 lozenge with prebiotic
62170404|NCT05375383|ACTIVE_COMPARATOR|Probiotic S. salivarius K12 lozenges containing prebiotic B|Streptococcus salivarius K12 lozenge with prebiotic
62170405|NCT05375383|ACTIVE_COMPARATOR|Probiotic S. salivarius K12 lozenges containing prebiotic A and B|Streptococcus salivarius K12
62170406|NCT05375383|ACTIVE_COMPARATOR|Probiotic S. salivarius K12 powder|Streptococcus salivarius K12 powder
61986035|NCT03498742||SABA users|Most of the asthmatic subjects usually inhale SABA as rescue medication and many times SABA is the only one prescribed treatment for asthma.
61986036|NCT01048021||Supraclavicular Block|
62170407|NCT05375383|ACTIVE_COMPARATOR|Probiotic S. salivarius K12 powder containing prebiotic A|Streptococcus salivarius K12 powder with prebiotic
62170408|NCT05375383|ACTIVE_COMPARATOR|Probiotic S. salivarius K12 powder containing prebiotic B|Streptococcus salivarius K12 powder with prebiotic
62170409|NCT05375383|ACTIVE_COMPARATOR|Probiotic S. salivarius K12 powder containing prebiotic A and B|Streptococcus salivarius K12 powder with prebiotic
62170410|NCT05375383|ACTIVE_COMPARATOR|Probiotic S. salivarius M18 lozenges|Streptococcus salivarius M18 lozenge
62170411|NCT05375383|ACTIVE_COMPARATOR|Probiotic S. salivarius M18 lozenges containing prebiotic A|Streptococcus salivarius M18 lozenge with prebiotic
62170412|NCT05375383|ACTIVE_COMPARATOR|Probiotic S. salivarius M18 lozenges der containing prebiotic B|Streptococcus salivarius M18 lozenge with prebiotic
62170413|NCT05375383|ACTIVE_COMPARATOR|Probiotic S. salivarius M18 + lozenges containing prebiotic A and B|Streptococcus salivarius M18 lozenge with prebiotic
62170414|NCT02411214||<12 years|children under 12 years diagnosed with cancer questionnaire survey
62170415|NCT02411214||12-18 years|adolescents diagnosed with cancer questionnaire survey
62170416|NCT02411214||parents|parents of children and adolescents diagnosed with cancer questionnaire survey
62170417|NCT04987034||Direct and indirect PPG measurements|Measuring the portalsystemic pressure gradient in patients directly using the EchoTip® Insight™ and indirectly through the HVPG procedure.
62170418|NCT06445361|OTHER|Study cohort|FibroScan measurement
62170419|NCT05267249|EXPERIMENTAL|Autotransplantation|Autotransplantation and apicoectomy of mature teeth
62170420|NCT03467997|NO_INTERVENTION|Filtered Air|Subjects sit in a room for two hours breathing in filtered air which resembles levels of air pollution found in the ambient environment
62170421|NCT03467997|ACTIVE_COMPARATOR|Diesel Exhaust|Subjects sit in a room for two hours breathing in diesel exhaust at 200 micrograms of meter cubed.
62170422|NCT03467997|ACTIVE_COMPARATOR|TSST/Stress only|Subjects undergo a mental stress test, known as the Trier Social Stress Test (TSST), which involves a public speaking and math task.
62170423|NCT03467997|ACTIVE_COMPARATOR|Diesel Exhaust and stress|Subjects sit in a room for two hours breathing in diesel exhaust at 200 micrograms of meter cubed and are subject to a mental stress test (TSST) which involves a public speaking and math task.
62182356|NCT03088189||Placebo|Mothers are receiving placebo
62391445|NCT03931928|EXPERIMENTAL|Group 2|"Patients will receive (Z)-endoxifen dosed according to CYP2D6 genotype"
62170424|NCT03135821|PLACEBO_COMPARATOR|10% active Placebo|"Placebo will constitute granules with 10% active core ingredients as below:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g~- 2 packets of sachets once before breakfast and once before dinner."
62170425|NCT03135821|ACTIVE_COMPARATOR|Traditional Chinese Medication (TCM) Drug A,B,C,D|"Traditional Chinese Medication (TCM) Drug A,B,C,D.~TCM Drug A:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome15g~TCM Drug B:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Liver stagnation with heaty transformation: add Scutellaria Root 5g、Prunella Spike 5g~TCM Drug C:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Prominent abdominal pain: White Peony Root to increase to 15g add Bupleurum Root 5g~TCM Drug D:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Hard stools: add Peach Kernel 5g、Areca Seed 5g"
62170426|NCT06457347|EXPERIMENTAL|Ultra early (<24 hours)|
62170427|NCT06457347|ACTIVE_COMPARATOR|Early (24-72 hours)|
62170428|NCT04063878|EXPERIMENTAL|Single tooth restorations using Acuris conometric concept|
62363687|NCT05850013||Sub protocol 3|The questionnaire will ask questions related to vital sign monitoring habits and preferences, or not, of Lifelight®-type technologies for measuring vital signs instead of standard-of-care methods.
62363688|NCT03483376|ACTIVE_COMPARATOR|Dental prophylaxis|Study volunteers with black plaque stained teeth will receive standard dental prophylactic cleaning to remove the stain. The prophylaxis will be carried out using an ultrasonic scaler, prophylaxis brush and abrasive paste.
62170429|NCT05744557|EXPERIMENTAL|num Vapocoolant|vapocoolant anesthetic spray (a spray that cools and numbs the skin) to control pain during minor surgical procedures (such as lancing boils, incisions, injections and IV placements) and minor sport injuries
62170430|NCT02404012|ACTIVE_COMPARATOR|Ferrous sulfate|Ferrous sulfate 65 mg. t.i.d is the standard of care for oral supplementation for iron deficiency
62363689|NCT03483376|EXPERIMENTAL|Dental prophylaxis + aPDT|"Study volunteers with black plaque stained teeth will receive standard dental prophylactic cleaning, followed by antimicrobial photodynamic therapy (aPDT) to remove the stain. The prophylaxis will be carried out using an ultrasonic scaler, prophylaxis brush and abrasive paste. The aPDT protocol is as follows:~* Patient will rinse the oral cavity with 20 ml of an aqueous solution of curcumin (photosensitizer; 1.5 g/L) for 30 seconds.~* Blue light from a Bluephase 20i curing lamp will be applied perpendicularly for 1 min per tooth (30 seconds on the vestibular side and 30 seconds on the palatal side).~* Remaining photosensitizer will be removed using the prophylaxis brush. The aPDT protocol is repeated following a rest period of 10 days."
62170431|NCT02404012|EXPERIMENTAL|AspironTM 65 mg t.i.d.|AspironTM, an organic formulation of iron, is the experimental treatment for oral supplementation of iron deficiency
62170432|NCT03939416|EXPERIMENTAL|POLD concept treatment|Patients treated with rhythmic mobilizations according to the POLD concept, in addition to the standart treatment
62170433|NCT03939416|ACTIVE_COMPARATOR|CONTROL|Patients treated with the standart treatment
62170434|NCT00527514|EXPERIMENTAL|1|
62363690|NCT00461240||acromegaly|
62363691|NCT00461240||growth hormone deficiency|
62170435|NCT06095518||Adult Intensive Care Unit, Queen Mary Hospital|
62170436|NCT06095518||Department of Intensive Care Unit, Tuen Mun Hospital|
62170437|NCT05354726||CKD group|"Inclusion Criteria for Volunteers (Inclusion Criteria):~* 6-18 age range,~* According to the Chronic Kidney Disease Assessment and Classification Guide prepared by the National Kidney Foundation- Kidney Disease Outcomes Quality Initiative (NKF-KDOQI); Stage 2, glomerular filtration rate 60-89 ml/min/1.73 m2, Stage 3, glomerular filtration rate 30-59 ml/min/1.73 m2, Stage 4, glomerular filtration rate 15-29 ml/min/1.73 m2,~* Presence of kidney transplantation was determined as inclusion criteria.~Exclusion Criteria for Volunteers:~* acute infection,~* Ongoing dialysis,~* Congenital heart disease,~* Hypertension that cannot be controlled with dual antihypertensive medication,~* Neurological and/or genetic musculoskeletal disease,~* The presence of orthopedic and cognitive problems that prevented the tests from being performed were determined as exclusion criteria."
62170438|NCT05354726||Control Group|"Inclusion Criteria for Control Volunteers:~* Not have cardiovascular, neurological and/or genetic musculoskeletal disease~* Not having orthopedic and cognitive problems that prevent testing~* The patient's and/or family's willingness to participate in the study"
62363692|NCT05281068|EXPERIMENTAL|Iguratimod and Danazol|Iguratimod is given at a dose of 25 mg bid. Danazol is given at 200mg bid for 12 weeks.
62363693|NCT05281068|ACTIVE_COMPARATOR|Danazol|Danazol is given at 200mg bid for 12 weeks.
62170439|NCT06258447|EXPERIMENTAL|Study (ABM MNC) Treatment|Left ventricular catheterization with treatment consisting of autologous bone marrow mononuclear cells (ABM MNC) processed and delivered using the CardiAMP cell therapy system
62170440|NCT06258447|SHAM_COMPARATOR|Control Treatment|Left ventricular (diagnostic) catheterization but no administration of ABM MNC
62170441|NCT05048407|EXPERIMENTAL|Gynaecological laparoscopic surgery|Eligible women aged 18 - 70 years, regardless of parity, who need laparoscopic gynaecological surgery and who provide informed consent prior to surgery
62363694|NCT06180876|EXPERIMENTAL|remimazolam|remimazolam continuous infusion is used for general anesthesia; dosage:0.7-1.5mg/kg/h; duration: from start of anesthesia induction to end of surgery
62363695|NCT06180876|ACTIVE_COMPARATOR|propofol|propofol continuous infusion is used for general anesthesia; dosage:4-8mg/kg/h; duration: from start of anesthesia induction to end of surgery
62363696|NCT01201304|EXPERIMENTAL|Interoceptive exposure|Repeated trials of voluntary hyperventilation intended to reduce fears of arousal-related body sensations.
62363697|NCT01201304|PLACEBO_COMPARATOR|Expressive writing|Expectancy control intervention.
62363698|NCT06397976||Eyes with normal anterior segment|
62363699|NCT06397976||Eyes with abnormal anterior segment|
62363700|NCT05774613|PLACEBO_COMPARATOR|Placebo|beverage with physical and sensory characteristics to the treatment beverage without the bioactive compounds corresponding to the study.
62363701|NCT05774613|EXPERIMENTAL|Hibiscus-based drink|beverage in patent process with application number MX/a/2022/010704
62363702|NCT04313101||Cases (ICUAW)|57 critically ill patients developing ICUAW during their stay in the intensive care unit will be included in the study as cases.
62739282|NCT02933424|EXPERIMENTAL|Beverage with Rice protein powder 25 grams|Standard breakfast drink with 25 grams of rice protein powder.
62363703|NCT04313101||Controls|A total of 57 Critically ill patients in the same period who did not develop ICU acquired weakness during their ICU stay will be included as controls.
62363704|NCT05379205|ACTIVE_COMPARATOR|Usual Care/Control Group|Usual care group will follow the usual institutional pre-surgery care..
62363705|NCT05379205|EXPERIMENTAL|Prehabilitation + Postoperative Programs (PPP) Group|PPP group will include 3 complementary modules: (i) supervised physical exercise, (ii) dietary behavior change, and (iii) psychological support.
62363706|NCT03198104||Liver disease|Paediatric patients (50-60 pts.) with liver disease who are scheduled for an ultrasound-guided liver biopsy as part of their standard care - these patients will be scanned using MRI and fibroscan, then will proceed through standard care pathway to receive blood tests and a liver biopsy. Findings from the fibroscan, blood tests and liver biopsy will be compared to the MRI data to determine it's accuracy in detecting and distinguishing different types of liver disease.
62363707|NCT03198104||Autoimmune Hepatitis Group (AIH)|Paediatric patients who have been diagnosed with autoimmune hepatitis and are about to initiate pharmacological treatment (15-30 pts.) will be scanned using MRI and fibroscan, then proceed through the standard care pathway to receive repeated blood tests and liver biopsies throughout treatment. MRI and fibroscan will be repeated before each liver biopsy. Findings from the fibroscan, blood tests and liver biopsy will be compared to MRI data to determine it's accuracy in monitoring liver disease.
62363708|NCT03198104||Healthy Volunteers|Healthy volunteers (20-30 children) will be scanned using MRI and fibroscan and used as healthy controls.
62363709|NCT05845008|EXPERIMENTAL|Acetaminophen/Naproxen Sodium Fixed Combination|Participants will self-administer a fixed combination of acetaminophen/naproxen sodium orally as multiple doses over a period of up to 10 days.
62363710|NCT04071171|ACTIVE_COMPARATOR|Phoxilium®|
62363711|NCT04071171|EXPERIMENTAL|Biphozyl®|
62363712|NCT03432572|EXPERIMENTAL|pyridium|Group A will take 200 mg of oral Pyridium 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
62363713|NCT03432572|ACTIVE_COMPARATOR|riboflavin|Group B will take 400 mg of riboflavin 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
62363714|NCT03432572|PLACEBO_COMPARATOR|thiamine|Group C will take the placebo (50 mg of thiamine) 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
62363715|NCT02395289|EXPERIMENTAL|Cognitive-Based Compassion Training (CBCT)|HIV-1 positive subjects on antiretroviral therapy (ART) will be randomized to receive an 8-week program of Cognitive-Based Compassion Training (CBCT).
62363716|NCT02395289|ACTIVE_COMPARATOR|Health Discussion Control|HIV-1 positive subjects on antiretroviral therapy (ART) will be randomized to attend a health discussion group for 8 weeks.
62363717|NCT03006900|EXPERIMENTAL|Pilates and massage|Pilates (twice per week for 50 minutes) and massage (once per week for one hour)
62363718|NCT03006900|ACTIVE_COMPARATOR|Massage|Massage (once per week for one hour)
62363719|NCT01255293|ACTIVE_COMPARATOR|1000 centistoke silicone oil|
62363720|NCT01255293|ACTIVE_COMPARATOR|5000 centistoke silicone oil|
62363721|NCT05480761|EXPERIMENTAL|Single Arm Open Labeled Commercial Sucraid|All subjects will complete a 7-day treatment period of open-labeled FDA approved commercial Sucraid.
62363722|NCT01085604||Low back pain|Individuals with current low back pain attributed to poor trunk neuromuscular control (clinical instability).
62363723|NCT02623387|ACTIVE_COMPARATOR|Standard Paravertebral Block|Patients receiving a conventional paravertebral block of dilute local anaesthetic (eg. 5ml of 0.5% bupivacaine or similar) administered using anatomical landmarks
62363724|NCT02623387|ACTIVE_COMPARATOR|Ultrasound Guided Paravertebral Block|Patients receiving paravertebral block of dilute local anaesthetic (eg. 5ml of 0.5% bupivacaine or similar) administered under ultrasound guidance
62363725|NCT04049812|ACTIVE_COMPARATOR|Pulsed electromagnetic field (PEMF) treatment Group|Group received routine hot pack, Transcutaneous electrical nerve stimulation (TENS) and PEMF treatment.
62363726|NCT04049812|SHAM_COMPARATOR|Sham PEMF treatment Group|Group received routine hot pack, TENS and sham PEMF treatment.
62363727|NCT04501172||Study group|People who use social networks, with permanent residence in Greece, aged above 18 years old and adequate literacy of Greek language
62363728|NCT00145197|EXPERIMENTAL|Improving the Delivery of Effective Care to Minorities|
62363729|NCT05666908|EXPERIMENTAL|HFNO group|Direct guidance and positioning of DLT intubation with FOB visualization, using HFNO during intubation asphyxia.
62363730|NCT05666908|NO_INTERVENTION|Control group|The DLT cannula was directly guided and positioned under FOB visualization, and no oxygen therapy equipment was used during intubation.
62363731|NCT00602069|EXPERIMENTAL|1|Participants will receive cognitive behavioral therapy through the Helping to Overcome PTSD through Empowerment program
62363732|NCT00602069|ACTIVE_COMPARATOR|2|Participants will receive standard shelter services
62363733|NCT01202760|EXPERIMENTAL|120 mg LY2127399|"LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240-mg (2 SC injections of 120 mg each) loading dose of LY2127399 when initiating treatment.~During the Treatment Period, for blinding purposes, participants alternated injections of LY2127399 and injections of Placebo every 2 weeks.~After 16 weeks, non-responders received 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
62363734|NCT01202760|EXPERIMENTAL|90 mg LY2127399|"LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180-mg (2 SC injections of 90 mg each) loading dose of LY2127399 when initiating treatment.~After 16 weeks, non-responders continued to receive 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
62363735|NCT01202760|PLACEBO_COMPARATOR|Placebo|"Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections of Placebo when initiating treatment.~After 16 weeks, non-responders received 90 milligrams (mg) of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
62363736|NCT01204307|EXPERIMENTAL|docetaxel/cisplatin|The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
62363737|NCT01204307|ACTIVE_COMPARATOR|Pemetrexed/cisplatin|The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
62363738|NCT05265962|EXPERIMENTAL|Decitabine plus Penpulimab|Pts received decitabine 10mg/d IV daily x5 every 3 weeks and penpulimab(AK-105) 200 mg intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
62363739|NCT05621018|ACTIVE_COMPARATOR|Intervention group|Patients will be introduced to Maze Out in an information meeting with the investigators and will afterwards receive a link with the game and a username. Each patient has to choose a code to start playing the game. The code will not be available for the investigators.
62363740|NCT05621018|ACTIVE_COMPARATOR|Control group|Patients will be introduced to Maze Out. 15 weeks later they will follow the same procedure as intervention group.
62170442|NCT00702338||corifollitropin alfa + recFSH Mothers|Eligible participants in Stage 1a of base study P05693 (NCT00697255) were administered injection(s) with subcutaneous (SC) corifollitropin alfa (15mcg) and daily SC injections with recFSH (50 IU) when the largest follicle reached a size of ≥12 mm. A bolus injection of hCG (5000 IU) was then administered if at least one follicle was ≥18 mm and in total no more than two follicles ≥15 mm were observed. Eligible mothers in this group with an ongoing pregnancy established in the base study (confirmed at ≥10 weeks after hCG bolus injection) were then to be followed for safety and efficacy on the current follow-up (FU) study (P05713) according to standard practice (no treatment administered).
62363741|NCT04628611|ACTIVE_COMPARATOR|Video laryngoscopy Group (V) using Storz c-mac laryngoscope|video laryngoscope without a channel used for endotracheal intubation, the device used to obtain a view of the larynx, and the endotracheal tube is passed through the vocal cords independent of the device. The device is connected to the monitor via connecting cable
62363742|NCT04628611|ACTIVE_COMPARATOR|The flexible intubating laryngoscopy Group (F) using Storz flexible intubation video endoscope set|The flexible intubating scope is used to locate the vocal cords and acts as a stylet for the endotracheal tube once the scope is placed into the trachea.This device consists of a flexible insertion cord that contains a small camera at the tip, used to transmit images to camera head. The cord includes a channel for a light source, a working channel for suction or administration of oxygen or local anesthetic, and a cable that allows the operator to flex the tip of the scope. The cord attaches to a handle with a light source,camera head control lever for flexion/extension of the tip, and a working channel port. The device is connected to the monitor via connecting table
62363743|NCT00671398|EXPERIMENTAL|Ramelteon 8 mg QD|
62363744|NCT00671398|EXPERIMENTAL|Ramelteon 16 mg QD|
62363745|NCT00671398|PLACEBO_COMPARATOR|Placebo|
62363746|NCT01205919|EXPERIMENTAL|Internet-based self-help|This self-help training is exclusively provided via Internet over a period of 10 weeks. The treatment is based on the cognitive-behavioral approach and consists of 18 modules with helpful strategies to cope with tinnitus (e.g., applied relaxation, positive imagery, attention shift exercises, cognitive restructuring, sleep management, concentration management,). All modules include an information text, detailed practice instructions, worksheets and homework assignments. At the end of each treatment week, there is an e-mail contact between the participants and their therapist. The participants report on their work with the modules and if they had encountered any problems. The therapist provides feedback, support and recommendations on how to proceed.
62363747|NCT01205919|ACTIVE_COMPARATOR|Discussion forum group|To the participants of the control group the internet-based self-help after waiting time of 10 weeks is offered. During the waiting period participants receive access to a tinnitus online discussion forum.
62170443|NCT00702338||corifollitropin alfa + hCG Mothers|Eligible participants in Stage 1b of base study P05693 (NCT00697255) were administered injection(s) with SC corifollitropin alfa (30 mcg) and daily SC injections with hCG (200 IU) when the largest follicle reached a size of ≥12 mm. A bolus injection of hCG (5000 IU) was then administered if at least one follicle was ≥18 mm and in total no more than two follicles ≥15 mm were observed. Eligible mothers in this group with an ongoing pregnancy established in the base study (confirmed at ≥10 weeks after hCG bolus injection) were then followed for safety and efficacy on the current FU study (P05713) according to standard practice (no treatment administered).
62363748|NCT03024385||Mothers of healthy infants|Mothers of young infants presenting for well child visits between the ages of 0-2 years of age
62363749|NCT05018169|EXPERIMENTAL|BA-A|Teens will participate in BA-A. BA-A is a 12-session manualized treatment that utilizes established BA strategies and incorporates common mental health treatment adaptations for young people with ASD.
62363750|NCT06110104|EXPERIMENTAL|control group|they recieve Routine physiotherapy program comprises a combination of closed kinetic chain and open kinetic chain exercises, including straight leg raising, isometric quadriceps, isometric hip adduction, terminal knee extension, semi-squat, and leg press for 6 weeks.
62363751|NCT06110104|EXPERIMENTAL|Retro-walking group|they recieve routine physiotherapy and Retro-walking program which is about 10 min of supervised retro walking training 3 days a week for 6 weeks at their comfortable walking speed . The participants will be instructed to gradually increase their walking time up to 30 min over the 6-week period.
62363752|NCT06110104|EXPERIMENTAL|whole body vibration group|they recieve routine physiotherapy and whole body vibration which is 3 days per week for 6 weeks. During the training, the participants will perform static squat training barefoot on the platform with bent knees (30° and 60°). The distance between the feet was consistent with the shoulders. the duration time, sets and total time will be increased progressively over the 6-week.
62363753|NCT02194517|NO_INTERVENTION|control (B)|Patients performing CHO and FP exchanges calculation with standard method.
62363754|NCT02194517|EXPERIMENTAL|ELKa (A)|Patients counting CHO and FP exchanges with ELKa toolset.
62363755|NCT05228080||acute ischemic stroke|
62739283|NCT02933424|EXPERIMENTAL|Beverage with Pea protein powder 25 grams|Standard breakfast drink with 25 grams of pea protein powder.
62739284|NCT02933424|EXPERIMENTAL|Beverage with Oats protein powder 25 grams|Standard breakfast drink with 25 grams of Oats protein powder.
62363756|NCT02822157|EXPERIMENTAL|Olaparib|olaparib 300mg oral tablets twice daily for 28 days in 28-day cycles
62363757|NCT02822157|ACTIVE_COMPARATOR|Chemotherapy|physician's choice chemotherapy
62363758|NCT04261881|ACTIVE_COMPARATOR|Nutraceutical intervention, 5 capsules twice daily.|Participants will consume the nutraceutical blend ATP-Fuel at 5 capsules twice daily.
62363759|NCT04261881|ACTIVE_COMPARATOR|Nutraceutical intervention, 3 capsules once daily.|Participants will consume the nutraceutical blend ATP-II at 3 capsules once daily.
62363760|NCT04261881|ACTIVE_COMPARATOR|Nutraceutical intervention, 3 capsules twice daily.|Participants will consume the nutraceutical blend ATP-II at 3 capsules twice daily.
62363761|NCT01492842||Youth with behaviorally-acquired HIV who enrolled in ATN 106|Behaviorally-acquired HIV-infected adolescents and young adults, ages 12-24, inclusive, who have enrolled in ATN 106.
62363762|NCT04499638||Non type 2 diabetic patient|Tracking the catheter from insertion to removal. Collection of any patients complication associated with these devices and what different treatments has been administered
61986037|NCT05109988|EXPERIMENTAL|Intervention|The intervention consists of four weekly 20-30 minutes telephone-administered counselling sessions on breastfeeding, delivered individually in the first month postpartum for mothers and fathers.
62170444|NCT00683514|OTHER|A|"* cycle 1 \& 2 (q 28 days) = chemotherapy : oral vinorelbine (50 mg/m2 d1, d8, d15) and cisplatin (20 mg/m2/d from d1 to d4) combined with radiotherapy~* cycle 3 \& 4 (q 21 days) = chemotherapy : oral vinorelbine (60 mg/m2 d1, d8 for cycle 1, 80 mg/m2 d1 \& d8 for cycle 2) and cisplatin (80 mg/m2 d1) plus Best Supportive Care"
62170445|NCT00683514|OTHER|B|"* cycle 1 \& 2 (q 28 days) = chemotherapy : oral vinorelbine (50 mg/m2 d1, d8, d15) and cisplatin (20 mg/m2/d from d1 to d4) combined with radiotherapy~* Best Supportive Care only"
62170446|NCT00348283|PLACEBO_COMPARATOR|Double Blind|Blinded study through Week 52. Adalimumab compared to placebo during blinded portion.
62170447|NCT00348283|OTHER|Open Label|Note: No comparator was used in Open-Label portion of study. From Week 8, subjects could have switched to open-label (OL) adalimumab 40mg administered subcutaneously (SC) every other week (eow)or OL adalimumab 40 mg SC every week (ew) dosing to treat disease flare or non-response. At Week 52, all remaining subjects were allowed to switch to the Open-Label portion of the study.
62170448|NCT05022927|EXPERIMENTAL|Dose escalation part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab after administering ERY974 as a single agent and to determine the MTD by evaluating DLTs of in patients with locally advanced or metastatic HCC.
62170449|NCT05022927|EXPERIMENTAL|Expansion part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab after administering ERY974 as a single agent To evaluate the anti-tumor effect.
62170450|NCT05022927|EXPERIMENTAL|Concomitant use part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab and to determine the MTD.
62170451|NCT05022927|EXPERIMENTAL|Biomarker part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab after administering ERY974 as a single agent and to evaluate the biomarkers.
62170452|NCT05022927|EXPERIMENTAL|Mono dose escalation part|Patients will receive ERY974 as a single agent and to determine the MTD by evaluating DLTs of in patients with locally advanced or metastatic HCC.
62170453|NCT03551197|EXPERIMENTAL|Budesonide and formoterol bid|At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.
62170454|NCT01316809|EXPERIMENTAL|A|Surgical arm
62170455|NCT01316809|EXPERIMENTAL|B|Non-surgical arm
62170456|NCT04934878||Referral information|first visit to our hospital/transfer from another hospital
62170457|NCT06645639||Audit Group|We will perform an audit of health records of all hospitalized patients at one selected study ward, one day of every other week, at each of the 3 study sites to track their routine nutrition care in phase 1 and changes in nutrition care post-implementation in phase 3.
62363763|NCT04499638||Diabetic type 2 patient|Tracking the catheter from insertion to removal.Collection of any patients complication associated with these devices and what different treatments has been administered
62363764|NCT04735809|PLACEBO_COMPARATOR|Placebo|Microcystalline Cellulose
62363765|NCT04735809|EXPERIMENTAL|Treatment|Whole Cell Algae Fermentate
61986038|NCT05109988|NO_INTERVENTION|Control|Standard postpartum care
62170458|NCT06645639||Detailed Patient Group|Patients will be recruited in this group from one selected study ward, one day of every other week, at each of the 3 study sites to track their routine nutrition care in phase 1 and changes in nutrition care post-implementation in phase 3. They will also be followed up over a phone call one month after discharge.
62363766|NCT00810251||MatrixRIB|
62363767|NCT01149772|EXPERIMENTAL|ACCESS|Medically ill patients received six-sessions of cognitive behavioral therapy tailored to their unique needs. Patients received 2 core modules and 3 elective modules. Elective modules focused on physical health, cognitive restructuring, behavioral activation, and relaxation. The six session was a wrap up that everyone received. Patients also had the option to receive 2 follow-up booster sessions to aid in maintenance of skills learned.
62363768|NCT01149772|NO_INTERVENTION|Enhanced Usual Care|Patients in this arm received feedback about their physical and emotional health functioning and were still able to receive usual primary care services.
62363769|NCT03870672|ACTIVE_COMPARATOR|CCFES + rTMS facilitating cHMC|"This rTMS paradigm is the New Approach. Facilitation of the intact hemisphere target (cHMC) will be achieved using 5Hz rTMS. After rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
62391446|NCT03931928|EXPERIMENTAL|Group 3|Patients will receive (Z)-endoxifen dosed according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening
62170459|NCT06645639||Healthcare Provider Group|A questionnaire assessing the knowledge, attitude, and self-perceived practices (KAP) amongst healthcare professionals will be conducted with staff, including trainees, at each site's study ward. Further, the workload of the study ward's Registered Dietitian will be assessed for 3 days.
62170460|NCT05773209|EXPERIMENTAL|RLRL of 100% intensity|Participants will be treated with RLRL treatment (100% intensity) twice per day with an interval of at least 4 hours, each treatment last 3 minutes. Cross over arms after one month of use and one month of washout period.
62170461|NCT05773209|SHAM_COMPARATOR|RLRL of 5% intensity|Participants will be treated with the sham device (5% intensity) twice per day with an interval of at least 4 hours, each treatment last 3 minutes. Cross over arms after one month of use and one month of washout period.
62170462|NCT05021965|EXPERIMENTAL|group 1: have two weeks of at-home tooth bleaching|Participants will receive two weeks of at-home tooth bleaching with 10% Carbamide peroxide(Opalescence PF 10%) for the maxillary anterior teeth.
62170463|NCT05021965|EXPERIMENTAL|group 2 : have two sessions of in-office tooth bleaching|Participants will receive two sessions（with a 1- week interval ） of in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%)for the maxillary anterior teeth.
62170464|NCT05021965|EXPERIMENTAL|group 3 : one week of at-home and then have one session of in-office tooth bleaching|Participants will receive one week of at-home tooth bleaching with 10% Carbamide peroxide(Opalescence PF 10%) and then receive one session of in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%)for the maxillary anterior teeth.
62170465|NCT05021965|EXPERIMENTAL|group 4 : one week of in-office and then have one session of at-home tooth bleaching|Participants will receive one session of in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) and a week later receive one week of at-home tooth bleaching with 10% Carbamide peroxide(Opalescence PF 10%)for the maxillary anterior teeth.
62170466|NCT06632834|EXPERIMENTAL|Simvastatin|Simvastatin added with baseline anti-congestive medication in dilated cardiomyopathy patient.
62170467|NCT05680415|EXPERIMENTAL|Treatment Group|"Mycobacterium vaccae for injection (Mica) :~Dosage form: injection. Main ingredients and contents:Mycobacterium protein 22.50μg/ bottle. Open the aluminum-plastic combination cap of the Xilin bottle, dilute it with 1.0ml sterilized water for injection, shake well, extract the liquid, and inject it deep into the buttocks muscle. Six times every two weeks."
62170468|NCT05680415|NO_INTERVENTION|Blank Group|Non-injection drug.
62170469|NCT01502371|EXPERIMENTAL|MF MDI 50 mcg BID|Participants receive MF MDI 25 mcg x 2 inhalations (50 mcg total dose) BID PLUS Placebo dry powder inhaler (DPI) x 1 inhalation once daily (QD) in the evening for 12 weeks.
62170470|NCT01502371|EXPERIMENTAL|MF MDI 100 mcg BID|Participants receive MF MDI 50 mcg x 2 inhalations (100 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
62170471|NCT01502371|EXPERIMENTAL|MF MDI 200 mcg BID|Participants receive MF MDI 100 mcg x 2 inhalations (200 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
62170472|NCT01502371|ACTIVE_COMPARATOR|MF DPI 100 mcg QD|Participants receive Placebo MDI x 2 inhalations BID PLUS MF DPI x 1 inhalation QD in the evening for 12 weeks.
62170473|NCT01502371|PLACEBO_COMPARATOR|Placebo|Participants receive Placebo MDI x 2 inhalations BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
62170474|NCT00678899|EXPERIMENTAL|Surgery|Implantation with the Nucleus Hybrid L24 Cochlear Implant
62170475|NCT02894385|EXPERIMENTAL|Part 1 - Subjects with severe renal impairment|Subjects with severe renal impairment received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
62170476|NCT02894385|EXPERIMENTAL|Part 1 - Subjects with moderate hepatic impairment|Subjects with moderate hepatic impairment received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
62170477|NCT02894385|EXPERIMENTAL|Part 1 - Healthy subjects|Healthy subjects received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
62170478|NCT06363877|EXPERIMENTAL|Povidone-Iodine Intraoperative Peritoneal Lavage and Intraoperative Wound Irrigation|Patients in this arm will undergo combined intraoperative peritoneal lavage and intraoperative wound irrigation with a diluted aqueous povidone-iodine solution.
62170479|NCT06363877|ACTIVE_COMPARATOR|Normal Saline Intraoperative Peritoneal Lavage and Intraoperative Wound Irrigation|Patients in this arm will undergo combined intraoperative peritoneal lavage and intraoperative wound irrigation with a normal saline solution.
62170480|NCT04457245|ACTIVE_COMPARATOR|Arm I (dRT)|150 Patients undergo standard dRT at the discretion of the treating radiation oncologist. Patient does not undergo PSMA PET for RT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. No other primary treatment can be given before dRT. If a patient assigned to the control arm undergo a PSMA PET scan at another institution he will be discontinued from the study.
62170481|NCT04457245|EXPERIMENTAL|Arm II (18F-DCFPyL, PET/CT, dRT)|162 Patient undergoes PSMA PET with 18F-DCFPyL for dRT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. Patients then undergo dRT at the discretion of the treating radiation oncologist, who receives PSMA PET results and images. No other primary treatment can be given before RT.
62170482|NCT02269033|EXPERIMENTAL|Patient Navigated Latinas|Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
62170483|NCT02269033|ACTIVE_COMPARATOR|Non Navigated Latinas|A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged \> 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
62170484|NCT06269796||Preschool Children|A prospective study was conducted, aiming at the early detection of neuromotor signs in preschool children with suspected Developmental Coordination Disorder (DCD) in Greece.The Little Developmental Coordination Disorder Questionnaire (LDCDQ) was used to evaluate motor skills of the children. Children with scores that indicated suspicion of DCD were offered the option to undergo the BOT-2 test.
62170485|NCT04795076|PLACEBO_COMPARATOR|Standard formula|Feeding the infant or child with the regular formula which is prepared with standard concentrations
62170486|NCT04795076|ACTIVE_COMPARATOR|Nutrient-dense formula|Feeding the infant or child with the nutrient-dense formula which is prepared by concentrating regular formula.
62170487|NCT06645496|EXPERIMENTAL|Study Arm|All patients undergoing radiotherapy at the Clinic for Radiotherapy (Campus Virchow Klinikum, Campus Benjamin Franklin) will be informed about the possibility of participating in the study. If written consent is given, patients will be asked to complete the established questionnaires (EORTC QLQ-C30 and eHEALS) and a questionnaire to collect epidemiological data at their next visit to the respective clinics.
62170488|NCT01249768||Cohort|The cohort will consist of 150 patients with a hypokinetic rigid syndrome and a disease duration of maximum 36 months
62170489|NCT02213224|EXPERIMENTAL|Perindopril|Perindopril 4mg qd taken in the morning;
62170490|NCT02213224|EXPERIMENTAL|Telmisartan|Telmisartan 80mg qd taken in the morning;
62170491|NCT02213224|PLACEBO_COMPARATOR|Amlodipine|Amlodipine；5mg qd taken in the morning.
62170492|NCT03282877|EXPERIMENTAL|iCST web-application|A computerised cognitive stimulation programme consisting of 21 sessions.
62170493|NCT03282877|NO_INTERVENTION|Treatment as usual (TAU)|The control group will consist of a treatment-as-usual group and will not receive any additional intervention.
62170494|NCT04979234|EXPERIMENTAL|Interventional|Endoscopic gastric reduction
62170495|NCT06222034|EXPERIMENTAL|Filgotinib Dose A|Dose A of filgotinib mini-tablet for participants with bodyweight (BW) 15-\<25 kg
62170496|NCT06222034|EXPERIMENTAL|Filgotinib Dose B|Dose B of filgotinib tablet for participants with BW ≥25-\<60 kg
62170497|NCT06222034|EXPERIMENTAL|Filgotinib Dose C|Dose C of filgotinib tablet for participants with BW ≥60 kg
62170498|NCT01841645|OTHER|CLA depletion-repletion|
62170499|NCT04883541|EXPERIMENTAL|The Study Group|Pregnant women participated in the applications, which lasted two days a week, for ten weeks, and for 60 minutes a day.
62170500|NCT04883541|PLACEBO_COMPARATOR|Control Group|The control group was only given delivery preparation training for 6 weeks, and the birth processes were followed by routine follow-ups.
62170501|NCT00411463|EXPERIMENTAL|Psychotherapy|Subjects randomized to the Psychotherapy arm will receive Interpersonal and Social Rhythm Therapy (IPSRT-BPII)
62170502|NCT00411463|EXPERIMENTAL|Medication|Subjects randomized to the medication arm will receive the FDA approved medication Seroquel (quetiapine)
62170503|NCT01740999|EXPERIMENTAL|silicone arthroplasty|silicone arthroplasty
62170504|NCT01740999|ACTIVE_COMPARATOR|arthrodesis|arthrodesis
62170505|NCT04188119|EXPERIMENTAL|(Arm A) Avelumab + Proto Pump Inhibitor (PPI)|21 patients into Arm A: Avelumab + Proton Pump Inhibitor (PPI)
62170506|NCT04188119|EXPERIMENTAL|(Arm B) Avelumab + Aspirin + PPI|21 patients into Arm B: Avelumab + Aspirin + PPI
62170507|NCT01509599|EXPERIMENTAL|Cryotherapy|"Cryotherapy is delivered via a cooling gel wrap applied to the affected lower leg using a dosing regimen, starting with daily cooling in month one to PRN in the last 3 months over the 9 month study."
62170508|NCT01509599|SHAM_COMPARATOR|Usual care|"The sham wrap, filled with cotton, is applied to the affected lower leg using a dosing regimen, starting with daily application in month one to PRN in the last 3 months over the 9 month study."
62170509|NCT04658771|EXPERIMENTAL|All patients|"Patients will undergo MR-HIFU ablation procedure of OO under general anesthesia. Patients will be monitored for disease status and adverse events for 12 months following procedure. Patients with incomplete or partial response at 28 days after MR-HIFU will be permitted a second MR-HIFU procedure.~If there is still incomplete pain relief without medication use by 28 days following the second MR-HIFU treatment, patients will be offered standard of care treatment with RFA and followed for one year."
62170510|NCT04158453|ACTIVE_COMPARATOR|AUT00201|
62170511|NCT04158453|PLACEBO_COMPARATOR|Placebo|
62170512|NCT00877188|EXPERIMENTAL|exercise|supervised combined aerobic and resistance training for 12 weeks
62170513|NCT00877188|NO_INTERVENTION|control|waist list control with usual care
62170514|NCT06141694|EXPERIMENTAL|Endovascular Robotic Navigation|
62739285|NCT03688334|ACTIVE_COMPARATOR|IPF patients|Supplementation of oxygen treatment (40% FiO2) during steady state cardiopulmonary exercise testing
62739286|NCT03688334|SHAM_COMPARATOR|IPF patients (crossover)|Supplementation of medical air (sham Oxygen) during steady state cardiopulmonary exercise testing
62739287|NCT04106258|EXPERIMENTAL|low light dose|PDT is applied to the patients at low light dose : power density of 60mW/cm2 for 20 minutes
62170515|NCT02328209|EXPERIMENTAL|ranibizumab|ranibizumab
62170516|NCT04769895|EXPERIMENTAL|MaaT013|"Route of administration: rectal (enema)~Study drug dose: 4 enemas in total:~Week 1:~* D0-D1: vancomycin pre-treatment (250mg per os, 4 times a day for 2 days)~* D2: 1 dose~* Between D3 to D5: 1 dose Week 2: 1 dose (7 +/- 2 days after the last dose) Week 3: 1 dose (7 +/- 2 days after the last dose) A supplementary dose can be prescribed in case of GvHD relapse or massive antibiotic use during the study."
62170517|NCT04183803|EXPERIMENTAL|rosa robot assistance|Patients with ACL rupture requiring surgical treatment will be included. The reconstruction will be performed with hamstring tendon graft or patellar tendon graft. The femoral and tibial tunnels placement will be guided by the Rosa robot (Zimmer®).
62170518|NCT01615107|EXPERIMENTAL|GROUP 1: Oxytocin infusion alone|GROUP 1: Oxytocin infusion alone
62170519|NCT01615107|EXPERIMENTAL|double balloonand oxytocin|insertion of the double balloon and oxytocin
62170520|NCT00730210|ACTIVE_COMPARATOR|a: PTH (1-84) 100 ug s.c.inj. once a day|PTH (1-84) 100 ug subcutaneous injections once a day
62170521|NCT00730210|PLACEBO_COMPARATOR|b: placebo 100 ug s.c. inj. once a day|placebo 100 ug sub cutaneous injection once a day
62170522|NCT04787718|EXPERIMENTAL|Almond|Participants will consume 2.0 oz of raw, shelled, unsalted almonds.
62170523|NCT04787718|ACTIVE_COMPARATOR|Control group|an isocaloric (2.0 oz raw almonds) amount of unsalted pretzels daily.
62170524|NCT00948103|PLACEBO_COMPARATOR|Oxygen|
62170525|NCT00948103|ACTIVE_COMPARATOR|Nitrous Oxide|
62170526|NCT02767596|EXPERIMENTAL|Lixisenatide|S.C. Lixisenatide 10 mcg for 2 weeks and then 10 mcg for 10 weeks
62170527|NCT01828476|EXPERIMENTAL|ARM A|Abiraterone with ABT-263
62739288|NCT04106258|EXPERIMENTAL|high light dose|PDT is applied to the patients at high light dose : power density of 75mW/cm2 for 20 minutes
61986039|NCT05161169|EXPERIMENTAL|Sequencing cohort|Infants receive genome sequencing with analysis of approximately 1000 genes associated with childhood-onset and highly actionable adult-onset disease risks. Pathogenic and likely pathogenic variants are reported to the child's parents and pediatrician. Participants also receive a detailed family history report and standard well-child care.
62170528|NCT01828476|EXPERIMENTAL|ARM B|Abiraterone with both ABT-263 and Hydroxychloroquine
62170529|NCT03666013||Young healthy subjects|20-30 years old, max 1h of exercise per week
62170530|NCT03666013||Elderly with a normal physical function|65-80 years old, max 1h of exercise per week
62363770|NCT03870672|ACTIVE_COMPARATOR|CCFES + rTMS facilitating iM1|"This rTMS paradigm is the Conventional Approach.Facilitation of M1 will be achieved using 5Hz rTMS. After rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
61986040|NCT05161169|NO_INTERVENTION|Control cohort|Infants receive a detailed family history report plus standard well-child care.
61986041|NCT00520975|ACTIVE_COMPARATOR|Arm A (chemotherapy and placebo)|"INDUCTION THERAPY: Patients receive trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22 and paclitaxel IV over 60 minutes with or without carboplatin IV over 60 minutes on days 1, 8, and 15. Patients also receive placebo IV over 30-90 minutes on day 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and placebo IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
61986042|NCT00520975|EXPERIMENTAL|Arm B (chemotherapy and bevacizumab)|"INDUCTION THERAPY: Patients receive trastuzumab and paclitaxel with or without carboplatin as in Arm A. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
61986043|NCT02002364|ACTIVE_COMPARATOR|Single use flexible optical scope|Single use flexible optical scope , Ambu aScope
61986044|NCT02002364|ACTIVE_COMPARATOR|Multiple use flexible optical scope|Multiple use flexible optical scope
61986045|NCT01818076|EXPERIMENTAL|Dose A|Dose A: Botulinum toxin type A
61986046|NCT02935608|EXPERIMENTAL|BIIB074 high dose|Administered twice daily (BID)
61986047|NCT02935608|EXPERIMENTAL|BIIB074 low dose|Administered BID
61986048|NCT02935608|PLACEBO_COMPARATOR|Placebo|Placebo administered BID
61986049|NCT03842384|EXPERIMENTAL|iENDURE|iENDURE involves two delivery modes: computer and text message. The intervention initially targets motivational processes in combination with introductory strategies for managing physical and emotional distress through a single, brief, computer-delivered session followed by eight weeks of theoretically-informed text messages intended to enhance motivation and promote distress tolerance (DT).
61986050|NCT03842384|NO_INTERVENTION|Treatment-as-Usual|Participants in the TAU comparison control group will engage in buprenorphine treatment as determined by their clinical team. This could include medication evaluations, individual or group counseling, case management or peer recovery. TAU was selected as the comparison condition as it represents a robust and evidence-based approach to the treatment of OUD.
61986051|NCT01334723||Acute Urinary Retention|This subset of the Integrated Health Care Information Solutions (ICHIS) benign prostate hyperplasia (BPH) study population was used to assess acute urinary retention as a clinical outcome.
61986052|NCT01334723||Prostate Surgery|This subset of the ICHIS BPH study population was used to assess surgery as a clinical outcome.
61986053|NCT02723084|EXPERIMENTAL|Arm A|Co-formulated ABT-493/ABT-530 (300 mg/120 mg) administered once daily (QD) for 8 weeks in HCV genotype (GT) 2 -infected, DAA treatment-naïve participants without cirrhosis.
61986054|NCT02723084|ACTIVE_COMPARATOR|Arm B|sofosbuvir (400 mg) QD co-administered with weight based ribavirin (RBV) 600-1000 mg divided twice daily (BID) for 12 weeks in HCV GT2 -infected, DAA treatment-naïve participants without cirrhosis.
61986055|NCT01107587|EXPERIMENTAL|HRV group|Subjects will receive GSK Biologicals' human rotavirus vaccine 444563.
61986056|NCT01107587|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive placebo.
61986057|NCT01030523|EXPERIMENTAL|Short Implants|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
61986058|NCT01030523|ACTIVE_COMPARATOR|Long Implants in combination with bone grafting|ASTRA TECH Implants System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting
61986059|NCT06325007|ACTIVE_COMPARATOR|group 1 - study group|Candidates will drink a mixture of 60 ml of castor oil and 140 ml of orange juice. 30 minutes later, A 22-French Foley catheter will be inserted above internal cervical os and will be filled with 60 mL of normal saline.
61986060|NCT06325007|ACTIVE_COMPARATOR|group 2- control|A foley catheter will be inserted into cervical canal as described above according to the department protocol without ingestion of castor oil.
61986061|NCT01045356||children less than 2 months old|
61986062|NCT01045356||children 2 months to 12 months old|
61986063|NCT01045356||Children > 2 months old and less than or equal to 20 kg|
61986064|NCT05690555|EXPERIMENTAL|Postoperative Pelvic Floor Physical Therapy (PFPT)|If patients were randomized into the Postoperative PFPT arm, they were further randomized into the following sub-arms: Postoperative PFPT alone and Preoperative and Postoperative PFPT
61986065|NCT05690555|ACTIVE_COMPARATOR|No Postoperative Pelvic Floor Physical Therapy (PFPT)|Patients will present to see the physical therapist 3 weeks postoperatively. The following interventions will be performed: Subjective assessment of bowel and bladder function. Visual and external palpation and assessment of external pelvic floor region. Intravaginal pelvic floor assessment. Pelvic floor muscle dynamics and coordination assessment. Review of pelvic floor anatomy and function.
61986066|NCT01338831|EXPERIMENTAL|Breast & Prostate Cancer Group|Dose Escalation
61986067|NCT01338831|EXPERIMENTAL|Breast Cancer Group|Dose Expansion
62170531|NCT03666013||Elderly with a decreased physical function|65-80 years old, max 1h of exercise per week, SPPB under 9 or frailty score lower then 10
61986068|NCT01338831|EXPERIMENTAL|Prostate Cancer Group|Dose Expansion
62170532|NCT03666013||Active elderly|65-80 years old, minimal 3h of exercise per week
62170533|NCT02504502|EXPERIMENTAL|Enhanced genomic report|routine clinical care for return of results per whole genome sequencing study with enhanced genetic test results report developed through phase 1 and 2 of this study
62170534|NCT02504502|OTHER|Control with delayed access|routine clinical care for return of results per whole genome sequencing study and no intervention through three months. This arm will crossover to receipt of enhanced report upon completion of baseline and 3 month post-baseline followup surveys. Participants in this arm will complete a third survey at 3 months post receipt of enhanced report
62170535|NCT04414254|EXPERIMENTAL|conference-Cefprozil for Suspension®|"Cefprozil for Suspension® (125mg/5ml, 50ml/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.)"
62170536|NCT04414254|EXPERIMENTAL|test-cefprozil granule|cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd)
62170537|NCT00692445|ACTIVE_COMPARATOR|citalopram + TC-5214|
62170538|NCT00692445|PLACEBO_COMPARATOR|citalopram + placebo|
62170539|NCT06285227|EXPERIMENTAL|Group 1|CM313, subcutaneous injection, once
62170540|NCT06285227|EXPERIMENTAL|Group 2|CM313, subcutaneous injection, once
62170541|NCT06285227|EXPERIMENTAL|Group 3|CM313, subcutaneous injection, once
62170542|NCT06285227|EXPERIMENTAL|Group 4|CM313, infusion, once
62170543|NCT03302871|EXPERIMENTAL|İntensive Therapy Group|Children who received Botulinum toxin type A to plegic upper limb would be treated by transcranial direct current stimulation and a hybrid training model of CIMT and BIT
62170544|NCT03302871|ACTIVE_COMPARATOR|Control Group|Children who received Botulinum toxin type A to plegic upper limb would continue their usual care
62170545|NCT06430671|EXPERIMENTAL|CLS12311 low|Low dose CLS12311
62170546|NCT06430671|EXPERIMENTAL|CLS12311 medium|Medium dose CLS12311
62170547|NCT06430671|EXPERIMENTAL|CLS12311 high|High dose CLS12311
62170548|NCT00433498|EXPERIMENTAL|Carboplatin/cisplatin and Etoposide with Pravastatin|
62170549|NCT00433498|PLACEBO_COMPARATOR|Carboplatin/cisplatin and Etoposide with Placebo|
62170550|NCT05433311|ACTIVE_COMPARATOR|Exercises|Neutral position training, transversus abdominis/multifidius/abdominal/back extensors strengthening exercise, bridge exercise, cat-camel exercise, lumbal extensor/hamstring/gastrosoleus/latissimus dorsi/gluteal stretching exercises
62170551|NCT05433311|NO_INTERVENTION|Routine|Only routine treatment
62170552|NCT05664126|EXPERIMENTAL|Cohort A|"Cohort A will include haploidentical donor who is identical to the stem cell donor.~The first 5 patients will be enrolled in Cohort A. If safety criteria are met, cohort B will be open for enrollment."
62170553|NCT05664126|EXPERIMENTAL|Cohort B|Cohort B will include haploidentical donor who is different from the stem cell donor
62170554|NCT05028153|ACTIVE_COMPARATOR|Antibiotics|Azithromycin (10mg/kg) administered via oral suspension for 3 consecutive days
62170555|NCT05028153|PLACEBO_COMPARATOR|Placebo|Placebo with no active substance administered via oral suspension for 3 consecutive days
62170556|NCT01704859|PLACEBO_COMPARATOR|Vitamin D placebo + fish oil placebo|
62170557|NCT01704859|ACTIVE_COMPARATOR|Vitamin D placebo + fish oil|
62170558|NCT01704859|ACTIVE_COMPARATOR|Vitamin D + fish oil placebo|
62170559|NCT01704859|ACTIVE_COMPARATOR|Vitamin D + fish oil|
62170560|NCT01424176|EXPERIMENTAL|Dexpramipexole (dose 1)|Subjects with mild or moderate renal impairment.
62170561|NCT01424176|EXPERIMENTAL|Dexpramipexole (dose 2)|Subjects with severe renal impairment and end stage renal disease (ESRD).
62170562|NCT06584942|EXPERIMENTAL|Open-Label Suvorexant|Participants will complete study visits at Day 0 (Baseline, V2), Day 7 (V3), and Day 14 (V4). After completing a baseline pre-treatment fMRI scan, participants will begin taking 20mg suvorexant daily for 14 days. On day 14, participants will complete a post-treatment fMRI scan.
62170563|NCT01812837|EXPERIMENTAL|20 minutes incubation - with pretreatment|
62170564|NCT01812837|EXPERIMENTAL|40 minutes incubation - with pretreatment|
62170565|NCT01812837|EXPERIMENTAL|60 minutes incubation - with pretreatment|
62170566|NCT01812837|SHAM_COMPARATOR|60 minutes incubation - no pretreatment|
61986069|NCT01338831|EXPERIMENTAL|Uterine Leiomyoma Group|Dose Expansion
61986070|NCT03839212|EXPERIMENTAL|Happy Older Latinos are Active (HOLA)|A 16-week multi-component, health promotion intervention
61986071|NCT01285245|EXPERIMENTAL|kineret|
61986072|NCT01788670|PLACEBO_COMPARATOR|Water|Lemon-flavoured water (150 ml)
61986073|NCT01788670|ACTIVE_COMPARATOR|Ethanol high dose|The high dose corresponds to 30 g of ethanol in pilot cohort 1, to 12 g of ethanol in pilot cohort 2 and to 42 g of ethanol in pilot cohort 3. For the definitive study the high dose corresponds to 30 g of ethanol. Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
62170567|NCT01369147|EXPERIMENTAL|Parenteral nutrition energy dose at 0.6 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake at 0.6 x REE for up to 28 days. The dose of parenteral nutrition (PN) will be adjusted taking into account any calories from propofol, clevidipine, dextrose-containing IV fluids surpassing 500 mL/day, and any enteral feedings, to obtain the energy dose that the participant was randomized to receive.
62170568|NCT01369147|ACTIVE_COMPARATOR|Parenteral nutrition energy dose at 1.0 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake at 1.0 x REE for up to 28 days. The dose of PN will be adjusted taking into account any calories from propofol, clevidipine, dextrose-containing IV fluids surpassing 500 mL/day, and any enteral feedings, to obtain the energy dose that the participant was randomized to receive.
62170569|NCT01369147|EXPERIMENTAL|Parenteral nutrition energy dose at 1.3 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake at 1.3 x REE for up to 28 days. The dose of PN will be adjusted taking into account any calories from propofol, clevidipine, dextrose-containing IV fluids surpassing 500 mL/day, and any enteral feedings, to obtain the energy dose that the participant was randomized to receive.
62170570|NCT02728947|ACTIVE_COMPARATOR|2mg|1 week on 2mg/24 hr patch
62170571|NCT02728947|ACTIVE_COMPARATOR|4mg|1 week on 4mg/24hr patch
62170572|NCT02728947|ACTIVE_COMPARATOR|6mg|1 week on 6mg/24hr patch
62363771|NCT03870672|SHAM_COMPARATOR|CCFES + Sham rTMS|"This rTMS paradigm is the Sham Approach. Immediately after sham rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
62363772|NCT03818711|EXPERIMENTAL|Communication & Coping Intervention|A cognitive behavioral intervention for mothers of adolescents with type 1 diabetes to improve coping and the quality of parental involvement.
62363773|NCT03818711|ACTIVE_COMPARATOR|Education & Check Ins|The comparison group receives educational materials on diabetes management and phone calls, as well as access to a secret Facebook group with daily posts on diabetes management.
62363774|NCT03483831|EXPERIMENTAL|Intervention group|Students of 5 secondary school classes aged 12-14
62363775|NCT03483831|NO_INTERVENTION|Control group|Students of 5 secondary school classes aged 12-14
62170573|NCT02728947|ACTIVE_COMPARATOR|8mg|1 week on 8mg/24hr patch
62363776|NCT05225506|EXPERIMENTAL|Exercise|In this single group design, all participants will be provided with 6 months of twice weekly supervised group exercise.
62363777|NCT02297646|EXPERIMENTAL|Carbohydrates|50 grams of carbohydrates 4 times a week for each training session
62550229|NCT01232452|EXPERIMENTAL|Pemetrexed + Cisplatin + Cixutumumab|"Induction Treatment: Pemetrexed 500 mg/m\^2 plus cisplatin 75 mg/m\^2 plus cixutumumab 20 mg/kg given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for patients with significant tumor size reduction, after sponsor approval.~Maintenance Therapy: Pemetrexed 500 mg/m\^2 plus cixutumumab 20 mg/kg given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met."
62170574|NCT03904888|OTHER|l-TAPP without local anesthetics|These patients will undergo a laparoscopic surgery without local anaesthetics.
62170575|NCT03904888|OTHER|l-TAPP with local anesthetics|These patients will undergo a laparoscopic surgery with local anaesthetics.
62170576|NCT03904888|OTHER|r-TAPP without local anesthetics|These patients will undergo a robot-assisted surgery without local anaesthetics.
62170577|NCT03904888|OTHER|r-TAPP with local anesthetics|These patients will undergo a robot-assisted surgery with local anaesthetics.
62170578|NCT03258099||wild genotype|Through next generation sequencing, distinguish wild genotype of capecitabine
62170579|NCT03258099||mutant genotype|Through next generation sequencing, distinguish mutant genotype of capecitabine
62170580|NCT04149587||Brodalumab 210 mg Q2W|Participants will receive brodalumab 210 milligrams (mg) administered as 1 subcutaneous injection at Day 1 and at Weeks 1 and 2 followed by 210 mg every 2 weeks (Q2W) thereafter until Week 26.
62170581|NCT00116584|OTHER|heliox|heliox-driven nebulizations for children with moderate to severe bronchiolitis
62170582|NCT00116584|OTHER|oxygen|oxygen-driven nebulizations for children with moderate to severe bronchiolitis
62170583|NCT02376322|EXPERIMENTAL|Radiotherapy in bone metastases|The purpose of this one armed, phase II trial is to determine the efficacy and safety profile of a hypofractionated radiotherapy regimen, 16 Gy in 2 fractions with an interval of one week, for the palliation of complicated bone metastases in patients with poor performance status.
62170584|NCT04611048|EXPERIMENTAL|Main study|Several electrophysiological and behavioural tests will be performed to properly diagnose the patients/check that the healthy controls do not suffer of neuropathy.
62170585|NCT02580019|NO_INTERVENTION|conventional stroke treatment|Control group without intervention, whereas they receive conventional stroke treatment that including rehabilitation
62170586|NCT02580019|EXPERIMENTAL|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation accompanied with conventional treatment including rehabilitation
62170587|NCT05834972||Landmark-guided percutaneous dilatational tracheostomy|All patients will be enrolled two times. First, an experienced anesthesiologist will examine the neck anatomy and mark the second or third tracheal ring using the traditional landmark-guided technique, and the duration will be recorded. Then, the same anesthesiologist will examine the neck anatomy and mark the second or third tracheal ring using the ultrasound (USG)-guided approach, and the duration will be recorded. The distance between these two aforementioned markings will be measured and recorded. The first marking determined by the landmark method will be looked at with USG and where it corresponds anatomically will be recorded. Also, the vascular and glandular structures of the area and potential complications will be noted.
62363778|NCT02297646|PLACEBO_COMPARATOR|Control|no carbohydrate intake
62363779|NCT01543113|OTHER|melanoma|melanoma
62363780|NCT01802268|ACTIVE_COMPARATOR|Sirolimus|Conversion from Tacrolimus to Sirolimus
62363781|NCT01802268|ACTIVE_COMPARATOR|Tacrolimus|Maintenance on tacrolimus
62363782|NCT04628598|EXPERIMENTAL|Home visiting pregnant women|The pregnant women in the experimental group will be given education and care with home visits.
62363783|NCT04628598|NO_INTERVENTION|Control Group|Home visits will not be made to the control group, only the primary care antenatal care will be followed.
62363784|NCT00971360||Conversion disorder|
62363785|NCT00971360||Healthy control|
62363786|NCT00770224|EXPERIMENTAL|R-CHOP, tositumomab and rituximab|"Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 IV Day 1 Prednisone 100 mg PO Days 1-5 Rituximab 375 mg/m2 IV Day 1 Q 21 Days x 6 Cycles~Patients are restaged by CT scan. Unlabeled tositumomab antibody 450 mg IV within 12 after Cycle 6 of CHOP. Dosimetric dose 35 mg IV after infusion of unlabeled tositumomab antibody. Unlabeled tositumomab antibody 450 mg IV 7-14 days after dosimetric dose. Therapeutic dose 35 mg IV after infusion of unlabeled tositumomab antibody.~Rituximab 375 mg/m2 IV q 3 months x 4 years beginning 1 year after registration."
62363787|NCT04364906|ACTIVE_COMPARATOR|Quadratus Lumborum Block 2|Quadratus Lumborum Block 2 (QLB 2) will be performed the patients in Group A after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively
62363788|NCT04364906|ACTIVE_COMPARATOR|Quadratus Lumborum Block 3|Quadratus Lumborum Block 3 (QLB 3) will be performed the patients in Group B after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively
62170588|NCT05834972||Ultrasound-guided percutaneous dilatational tracheostomy|All patients will be enrolled two times. First, an experienced anesthesiologist will examine the neck anatomy and mark the second or third tracheal ring using the traditional landmark-guided technique, and the duration will be recorded. Then, the same anesthesiologist will examine the neck anatomy and mark the second or third tracheal ring using the ultrasound (USG)-guided approach, and the duration will be recorded. The distance between these two aforementioned markings will be measured and recorded. The first marking determined by the landmark method will be looked at with USG and where it corresponds anatomically will be recorded. Also, the vascular and glandular structures of the area and potential complications will be noted.
62170589|NCT05904288||Arm 1|The study group will receive noninvasive, in-depth clinical assessments similar in frequency to monitoring pertinent to normal clinical practice aimed at people with Parkinson's disease. In addition, within the mobile application provided as a gateway for data collection from the wearable sensors, subjects will also have the ability to access a library of video-recorded exercises, the effect of which on symptom modification, however, is not the subject of this investigation.
62170590|NCT06641128|ACTIVE_COMPARATOR|MTX SC or IM - Empa tab|IM or SC Methotrexate plus Empa tablets 25 mg once dailyf or 3 months.
62170591|NCT06641128|PLACEBO_COMPARATOR|MTX SC or IM - placebo tab|IM or SC Methotrexate plus placebo tablet once daily for 3 months.
62170592|NCT05502861|EXPERIMENTAL|Intervention|The study's intervention is a prognostic-triggered EHR alert to nudge clinicians to provide generalist or specialist PC. The alert notifies the clinician that the patient is likely to benefit from PC, and requires clinicians to actively choose to provide generalist PC themselves, consult PC specialist, or to defer PC. If a clinician chooses to consult specialist PC, a second alert will fire that enables them to easily and quickly place the consult order. The alert will trigger for all patients with moderate or higher 6-month mortality risk on second full hospital day at 8AM.
62170593|NCT05502861|ACTIVE_COMPARATOR|Control/Usual Care|During the control phase, patients meeting eligibility criteria will be enrolled for study data collection but there will be no attempt to influence delivery of care. The length of the control phase will differ at each hospital dependent on the sequence in which hospitals are randomly assigned to switch to the intervention phase. All hospitals contribute a minimum of 15 weeks of outcomes data prior to adopting the intervention.
62170594|NCT01847599|OTHER|capecitabine|patients treated by capecitabine alone (n=100)
62170595|NCT01847599|OTHER|capecitabine + lapatinib|patients treated by capecitabine and lapatinib (n=100)
62170596|NCT00103116|EXPERIMENTAL|Autologous dendritic cell cancer vaccine|Open label nonrandomized
62170597|NCT03086070|EXPERIMENTAL|Treatment arm|omeprazole 20 mg capsule once daily for 8 weeks
62170598|NCT03086070|PLACEBO_COMPARATOR|Placebo arm|matching placebo capsules ones daily for 8 weeks
62170599|NCT03862105|EXPERIMENTAL|Health App with Provider Monitoring/Care|30 patients enrolled by the study team will receive notifications through a mobile health app (Twistle) before and after surgery. Patient Reported Outcome data will be collected through patient responses in this app and timely clinician feedback will be provided to patients to prevent complications and readmission.
62170600|NCT05472636||Patients|Patients under the age of 18 who were admitted to the dermatology outpatient clinic between 2008-2021 and diagnosed with granuloma annulare
62170601|NCT03016364|EXPERIMENTAL|APP in dosage adjustment|Through the guidance of APP software, clinical doctors try to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain.
62170602|NCT02341599|EXPERIMENTAL|Group A: Healthy|Healthy participants with normal renal function (Stage 1: eGFR ≥90 mL/min/1.73m\^2).
62170603|NCT02341599|EXPERIMENTAL|Group B: Mild RI|Participants with mild RI (Stage 2: eGFR ≥60 to \<90 mL/min/1.73m\^2).
62170604|NCT02341599|EXPERIMENTAL|Group C: Moderate RI|Participants with moderate RI (Stage 3: eGFR ≥30 to \<60 mL/min/1.73m\^2).
62170605|NCT02341599|EXPERIMENTAL|Group D: Severe RI|Participants with severe RI (Stage 4: eGFR \<30 mL/min/1.73m\^2) not receiving HD.
62170606|NCT02341599|EXPERIMENTAL|Group E: ESRD-HD|Participants with ESRD who are receiving HD for at least 3 months preceding the initial dose in this study (Stage 5).
62170607|NCT02908412|EXPERIMENTAL|Digital nerve block in left hand|Patients in this group will receive DNB in left hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
62170608|NCT02908412|EXPERIMENTAL|Digital nerve block in right hand|Patients in this group will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
62170609|NCT02706834|EXPERIMENTAL|Cohort 1, Sequence I|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
62170610|NCT02706834|EXPERIMENTAL|Cohort 1, Sequence II|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
62363789|NCT04884529|EXPERIMENTAL|Chair Yoga Treatment Group|The chair-yoga session will occur for 8-weeks (60 minutes/week) on Zoom. The chair-yoga intervention will include gentle seated postures, relaxation using breathing techniques, and a mindfulness component.
62550230|NCT01232452|ACTIVE_COMPARATOR|Pemetrexed + Cisplatin|"Induction Treatment: Pemetrexed 500 mg/m\^2 plus cisplatin 75 mg/m\^2 given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for patients with significant tumor size reduction, after sponsor approval.~Maintenance Therapy: Pemetrexed 500 mg/m\^2 given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met."
62170611|NCT02706834|EXPERIMENTAL|Cohort 1, Sequence III|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
62170612|NCT02706834|EXPERIMENTAL|Cohort 1, Sequence IV|Non-Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
62170613|NCT02706834|EXPERIMENTAL|Cohort 2, Sequence I|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
62170614|NCT02706834|EXPERIMENTAL|Cohort 2, Sequence II|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
62170615|NCT02706834|EXPERIMENTAL|Cohort 2, Sequence III|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
62170616|NCT02706834|EXPERIMENTAL|Cohort 2, Sequence IV|Non-Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. There was a 7-day washout period between each period. Each period lasted 4 days with a 7-day washout period between periods.
62170617|NCT02706834|EXPERIMENTAL|Cohort 3, Sequence I|Japanese participants. TAK-828 15 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
62170618|NCT02706834|EXPERIMENTAL|Cohort 3, Sequence II|Japanese participants. TAK-828 15 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 150 mg, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
62170619|NCT02706834|EXPERIMENTAL|Cohort 3, Sequence III|Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 150 mg, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
62170620|NCT05653609||Telemonitoring|Patients monitored by the Cureety digital platform
62170621|NCT01020487|EXPERIMENTAL|Part 1: Paricalcitol|Participants received a single 3 µg dose of paricalcitol capsules on Study Day 1.
62170622|NCT01020487|PLACEBO_COMPARATOR|Part 2: Placebo|Participants received placebo capsules three times a week (TIW) for 12 weeks during the double-blind treatment phase. From Weeks 12 to 24 participants received open-label paricalcitol at an initial dose of 1 µg three times a week. Doses could be increased in 1 μg increments every 4 weeks based on chemistry evaluations to target Kidney Disease Outcomes Quality Initiatives (KDOQI) target levels.
62170623|NCT01020487|EXPERIMENTAL|Part 2: Paricalcitol|Participants received paricalcitol three times a week for 12 weeks during the double-blind treatment period and during the open-label period (Weeks 12-24). The initial dose of paricalcitol was 1 µg TIW. Doses could be increased in 1 μg increments every 4 weeks based on chemistry evaluations to target KDOQI target levels.
62170624|NCT00776984|EXPERIMENTAL|tiotropium 5mcg/day|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
62170625|NCT00776984|EXPERIMENTAL|placebo|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
62170626|NCT05294328|EXPERIMENTAL|Combination ophthalmic solution (LNZ101) dosed bilaterally|LNZ101: Aceclidine/Brimonidine combination ophthalmic solution
62170627|NCT05294328|EXPERIMENTAL|Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally|LNZ100: Aceclidine ophthalmic solution
62170628|NCT05294328|EXPERIMENTAL|Vehicle Ophthalmic Solution dosed bilaterally|Proprietary Vehicle ophthalmic solution
62170629|NCT04021147|EXPERIMENTAL|Action Observation|
62170630|NCT04021147|EXPERIMENTAL|Motor Imagery|
62170631|NCT04021147|EXPERIMENTAL|Visual mirror feedback|
62170632|NCT04021147|ACTIVE_COMPARATOR|Orofacial exercise|
62170633|NCT05657275|EXPERIMENTAL|Intervention period|Patient management will be guided by a multimodal algorithm integrating the performance of biological and iconographic examinations
62170634|NCT05657275|NO_INTERVENTION|Control period|Patient management will be done according to the usual practices of centers and emergency physicians
62170635|NCT01605435|EXPERIMENTAL|Ghrelin Group 1|Dose finding with each of the first two participant coming to the CTRC for four visits greater than or equal to 72 hours apart and on each receiving subcutaneous injection of - placebo (first visit) and three escalating doses of ghrelin 2ug/kg (second visit) , 5 ug/kg (third visit), and 10 ug/kg (fourth visit).
62170636|NCT01605435|EXPERIMENTAL|Ghrelin Group 2|Dose finding with each of the final three participant coming to the CTRC for four visits greater than or equal to 72 hours apart and on each receiving subcutaneous injection of - placebo (first visit) and three escalating doses of ghrelin 5ug/kg (second visit) , 7.5 ug/kg (third visit), and 10 ug/kg (fourth visit).
62170637|NCT06146088|EXPERIMENTAL|Batch 1 (6-35 months old, 2 doses)|Inactivated Enterovirus 71 Vaccine (human diploid cell) in children aged 6-35 months old on Day 0 and Day 30 approved by the National Institute for Food and Drug Control
62170638|NCT06146088|EXPERIMENTAL|Batch 2 (6-35 months old, 2 doses)|Inactivated Enterovirus 71 Vaccine (human diploid cell) in children aged 6-35 months old on Day 0 and Day 30 approved by the National Institute for Food and Drug Control
62170639|NCT06146088|EXPERIMENTAL|Batch 3 (6-35 months old, 2 doses)|Inactivated Enterovirus 71 Vaccine (human diploid cell) in children aged 6-35 months old on Day 0 and Day 30 approved by the National Institute for Food and Drug Control
62170640|NCT05814679|EXPERIMENTAL|Intervention Group|The patient will relax with virtual reality in the hemodialysis center with the researcher.
62170641|NCT05814679|PLACEBO_COMPARATOR|Control Group|The patients in the control group will be given a training on the functions of the kidneys.
62170642|NCT06645769|EXPERIMENTAL|NaPB administration|
62170643|NCT06645769|PLACEBO_COMPARATOR|Placebo control|
62170644|NCT05942573|EXPERIMENTAL|continuation of Serplulimab plus chemotherapy after first progression|"Serplulimab+Paclitaxel+Apatinib~Paclitaxel±Ramucirumab"
62170645|NCT01436604|OTHER|LV dysfunction group|Cardiac MRI
62170646|NCT01436604|OTHER|Control group|Cardiac MRI
62170647|NCT03106337|EXPERIMENTAL|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
62170648|NCT06395909||Siponimod cohort|Patients who were at least 18 years old diagnosed with clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), or active secondary progressive multiple sclerosis and had received at least 3 months of siponimod treatment after the index date.
62170649|NCT03809806|OTHER|patients after hysterectomy|modified anterior transvaginal mesh surgery
62170650|NCT05208593|PLACEBO_COMPARATOR|Negative Event Only|Participants will be asked to think of a specific example of the most (or one of the most) negative, unpleasant event with alcohol they have experienced; the event they choose must have occurred at least a year ago. Or they will be asked to think of the most significant event that has occurred in the past year. After thinking of a specific event, they will be given three minutes to write about their experience. The writing prompt will ask that they express the event information in a few sentences. This writing prompt will help participants place themselves back into that moment and access salient emotions and cognition about it. Similar negative event prompts have been used in counterfactual thinking studies (McFarland \& Alvaro, 2000; White \& Lehman, 2005).
62170651|NCT05208593|ACTIVE_COMPARATOR|Negative Event + Factual Thinking Task|"Participants in this group, the event plus the factual thinking task condition, will be told the following after completing the negative event writing task, After disappointing and/or negative experiences like the one you described on the previous page, people often think about the details of the situation. For example, when it happened, who was involved, and what happened right before or after the incident occurred. In the space below please provide examples of some of these details.. There will be 10 blank boxes below the instructions and participants will be asked to provide some examples of details from their traumatic event. They will be asked to only list as many as they can naturally recall without repeating any. This procedure is derived from Kray and colleague's (2010) study on counterfactual thinking and meaning in life."
62170652|NCT05208593|EXPERIMENTAL|Negative Event + Counterfactual Task|"Participants will be told after completing the negative event writing task, After disappointing and/or negative experiences like the one you described, people sometimes cannot help thinking what if... or if only... and imagining how things might have gone differently. That is, if only I had done something differently, the negative drinking situation could have been avoided or turned out better. In the box below please identify things that, had they been different, would have improved the outcome of the negative drinking situation you described earlier and briefly describe how the outcome would have been better. Participants will be asked to list three counterfactuals about the event. Participants will also be asked to think of situations where these strategies could be used, to list out any obstacles that might prevent them from implementing these strategies and to indicate their intention to use each strategy over the next week."
62170653|NCT05208593|EXPERIMENTAL|Personalized Normative Feedback|Participants in this group, the personalized normative feedback, will be asked to rate the frequency and quantity of TAMU students that use PBS when drinking.
62170654|NCT02801500|EXPERIMENTAL|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis.
62170655|NCT02801500|ACTIVE_COMPARATOR|Traditional Manual Anastomosis|A handsewn technique will be used during bilioenteric anastomosis.
61986074|NCT01788670|ACTIVE_COMPARATOR|Ethanol low dose|The low dose corresponds to 18 g of ethanol in pilot cohort 1, to 6 g of ethanol in pilot cohort 2 and to 24 g of ethanol in pilot cohort 3. For the definitive study the low dose corresponds to 18 g of ethanol. Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
61986075|NCT02797847|ACTIVE_COMPARATOR|ALN-TTRSC02|
61986076|NCT02797847|PLACEBO_COMPARATOR|Sterile normal saline 0.9% for SC administration|
61986077|NCT02635828|EXPERIMENTAL|Triple therapy PONV prophylaxis|At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis.
61986078|NCT01750008|OTHER|Global Fibroid Ablation|Global Fibroid Ablation
61986079|NCT01750008|OTHER|Laparoscopic Myomectomy|Myomectomy via laparoscopy
61986080|NCT01103609|EXPERIMENTAL|1|twice daily on Day 1 to Day 10, with Warfarin on Day 4
61986081|NCT01103609|PLACEBO_COMPARATOR|2|twice daily on Day 1 to Day 10, with Warfarin on Day 4
61986082|NCT03817385|EXPERIMENTAL|repetitive TMS (Transcranial Magnetic Stimulation)|rTMS and physical / occupational therapy
62170656|NCT02768077|EXPERIMENTAL|Melatonin(Circadin®)|Melatonin(Circadin®) is taken orally, once daily before going to sleep for a period of 4 weeks.
62170657|NCT02768077|PLACEBO_COMPARATOR|Placebo|Placebo tablet is taken orally, once daily before going to sleep for a period of 4 weeks.
62170658|NCT04764864|ACTIVE_COMPARATOR|Angioembolization|
62170659|NCT04764864|ACTIVE_COMPARATOR|Preperitoneal Pelvic Packing|
62170660|NCT01440699|EXPERIMENTAL|Treatment|For ALLO-ASC 1xE7 cells/ml,3 patients are to be enrolled. If there is no safety issue, 3 more patients will be enrolled to be treated with ALLO-ASC 3xE7 cells/ml.
62363790|NCT04884529|NO_INTERVENTION|Waitlist Control Group|These participants will be on a waitlist to receive the chair yoga program after data collection has been completed (e.g., after 8-weeks).
61986083|NCT03817385|EXPERIMENTAL|robotic GT (Gait Training)|robotic gait training for 20 times and physical / occupational therapy
61986084|NCT03817385|NO_INTERVENTION|traditional rehabilitation|patient only received traditional rehabilitation program
61986085|NCT00967993||KRX-0502 (ferric citrate)|"KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate. All patients initiated on study drug will start with a fixed dose of KRX-0502 (ferric citrate) of 6 caplets per day.~Patients will be titrated at Visits 4, 5, and 6 based on serum phosphorus lab results. If serum phosphorus levels go below normal, there will be a decrease in pills; if serum phosphorus levels go above normal, there wil be an increase in pills. The maximum number of KRX-0502 (ferric citrate) caplets per day will be 12, or 12 g/day of ferric citrate.~Patients will take study drug orally with meals or snacks or within one hour after their meals or snacks."
61986086|NCT05239273|EXPERIMENTAL|Complex Decongestive Therapy (CDT) Group|Phase 1 of CDT will be applied to CDT group. This application consists of manual lymph drainage, skin care, compression bandage and exercises. This phase will continue 5 days a week for 3 weeks.
61986087|NCT05239273|OTHER|Control group|Waiting list will included in control group.
61986088|NCT03273881|ACTIVE_COMPARATOR|glucose solution and insulin|Participants will receive intravenous saline solution boosted with 5% glucose + 8 units regular insulin in a rate of 125 mL/h.
61986089|NCT03273881|ACTIVE_COMPARATOR|glucose solution only|Participants will receive intravenous saline solution boosted with 5% glucose in a rate of 125 mL/h.
61986090|NCT04263701|ACTIVE_COMPARATOR|Conventional Physiotherapy Group|45 minutes, 2 days in a week for 8 weeks
61986091|NCT04263701|EXPERIMENTAL|Dual Task Training Group|45 minutes, 2 days in a week for 8 weeks
61986092|NCT00056563|ACTIVE_COMPARATOR|1|Deep Brain Stimulation
61986093|NCT00056563|ACTIVE_COMPARATOR|2|Best Medical Therapy
61986094|NCT03927612|EXPERIMENTAL|Alternate Perspective|After experiencing VR scenarios, participants will experience the interactions again from the virtual counterpart's perspective within the VR system.
61986095|NCT03927612|PLACEBO_COMPARATOR|Control Perspective|After experiencing VR scenarios, participants will experience the interactions again from the same perspective in the VR system.
61986096|NCT01247610||ADHD group|
61986097|NCT01247610||Control group|
61986098|NCT05309109|EXPERIMENTAL|MCO-HD group|Hemodialysis sessions using the Theranova 500™ (Baxter healthcare Corporation Deerfield, USA; surface area 2 m², ultrafiltration coefficient: 59 ml/h/mmHg)
61986099|NCT05309109|EXPERIMENTAL|HF-HD group|Hemodialysis sessions using the Elisio 21H™ (Nipro Europe, Zaventen Belgium; surface area 2.1 m², ultrafiltration coefficient: 82 ml/h/mmHg)
61986100|NCT01353287||TAVI live case or video-taped transmission|
61986101|NCT01353287||TAVI without transmission|
61986102|NCT01618409|EXPERIMENTAL|PictureRx cards|Illustrated format of medication instructions that includes pictures of pills and icons to show their purpose
61986103|NCT01618409|NO_INTERVENTION|Control|Usual care
61986104|NCT02773927|EXPERIMENTAL|Agave inulin + Metformin|5 g of Agave inulin powder every 12 hrs + 500 mg tablet of metformin every 24 hrs
61986105|NCT02773927|ACTIVE_COMPARATOR|Metformin + Placebo of agave inulin|500 mg tablet of metformin every 24 hrs + 5 g every 12 hrs of calcinated magnesia powder
61986106|NCT02773927|ACTIVE_COMPARATOR|Agave Inulin+Placebo of Metformin|5 g of agave inulin powder every 12 hrs + 500 mg tablet of calcinated magnesia as metformin placebo every 24 hrs
61986107|NCT02773927|PLACEBO_COMPARATOR|Placebo of Inulin + Placebo of Metformin|5 g of calcinated magnesia powder every 12 hrs + 500 mg tablet of calcinated magnesia every 24 hrs
61986108|NCT01153243|ACTIVE_COMPARATOR|Ergocalciferol|The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)
62170661|NCT06468462|ACTIVE_COMPARATOR|WHO-recommended periodic presumptive treatment|Participants assigned to the STI PPT arm will be evaluated at baseline and every 3 months thereafter for STI PPT eligibility based on having had condomless anal sex and either multiple sex partners or a sex partner with an STI in the past 6 months. If eligible, they will be offered 400 mg po cefixime plus 1 gram azithromycin po under direct observation, using the same regimen as for syndromic treatment per the latest WHO recommendations.
62170662|NCT06468462|ACTIVE_COMPARATOR|Doxycycline post-exposure prophylaxis|Participants assigned to the doxyPEP arm will be provided with a 30-day supply of doxycycline hyclate at each quarterly visit, with refills as needed. They will have 1:1 counselling on the self-administration of 200 mg po doxycycline within 24-72 hours after condomless anal or vaginal sex as frequently as daily if indicated but not more than once daily, in accordance with the doxyPEP trial in the United States.
62363791|NCT00159380|EXPERIMENTAL|Healthy volunteers|8 non smokers non asthmatic
62363792|NCT00159380|EXPERIMENTAL|Asthma volunteers|8 asthmatic mild
62363793|NCT00520299|EXPERIMENTAL|Cohort 1|Subjects received ADI-PEG 20 at a dose of 40 IU/m\^2
62363794|NCT00520299|EXPERIMENTAL|Cohort 2|Subjects received ADI-PEG 20 at a dose of 80 IU/m\^2
62363795|NCT00520299|EXPERIMENTAL|Cohort 3|Subjects received ADI-PEG 20 at a dose of 160 IU/m\^2
62363796|NCT05204758|EXPERIMENTAL|Study arm|Patients receive afatinib and TCM. TCM recipe was chosen from three essential TCM formulas, including Bai He Gu Jin Tang (yin nourishing), Wen Dan Tang (phlegm reducing), and Qing Shang Fang Fen Tang (heat clearing). The packages contained 1.6 g TCM preparations, which were manufactured in powder form by Sun Ten Pharmaceutical (Taichung, Taiwan) according to the good manufacturing practice requirements. Patients were instructed to intake three packages of TCM preparations with each meal three times a day, for a total of nine packages per day. Administration of TCM was initiated at the same time as afatinib and continued for a total of three months.
62170663|NCT06468462|NO_INTERVENTION|Standard care|Participants assigned to the standard care arm will receive screening for STI symptoms at every scheduled visit and syndromic treatment with cefixime 400 mg po stat plus azithromycin 1 gram po stat under direct observation, in accordance with current Kenyan recommendations for genital and anorectal infections. This regimen will be updated if Kenyan recommendations change.
62170664|NCT05065164|EXPERIMENTAL|dnosumab|Desuzumab 60 mg subcutaneously /6 months, twice a year
62170665|NCT05065164|PLACEBO_COMPARATOR|placebo control|Placebo subcutaneous injection /6 months, twice a year
62170666|NCT01887418|EXPERIMENTAL|QuickShot™ - 100 mg Treatment A|QuickShot™Testosterone - Auto-injector device for SC use
62170667|NCT01887418|EXPERIMENTAL|QuickShot™ - 50 mg Treatment B|QuickShot™Testosterone- Auto-injector device for SC use
62170668|NCT01887418|ACTIVE_COMPARATOR|Delatestryl 200 mg IM Treatment C|Commercially available Testosterone enanthate 200 mg IM dosage - 'standard of care' arm for reference
62170669|NCT05923359|EXPERIMENTAL|Apple Watch Intervention Group|Participants will be asked to wear an Apple Watch and use the Mayo Clinic ECG Study App to collect and share data with the study team.
62170670|NCT05923359|NO_INTERVENTION|Control Group|Participants will receive usual care.
62170671|NCT04134455|ACTIVE_COMPARATOR|Onlay Mesh Reinforcement group|The midline fascia was closed with running, slowly absorbable sutures (PDS 1-0) with a recommended suture length to wound length ratio of 4:1. An anterior plane with a width of about 8 cm was created between the anterior fascia and the subcutis. A Lightweight polypropylene mesh was used and placed on the anterior rectus fascia with an overlap of 3 cm. The mesh was fitted in the dissected space and it was fixed with PDS 2-0 suture. Fixing points are placed taking the mesh and the anterior fascia of the rectus muscle, at a distance of 3 cm between each point until completing its circunference.
62170672|NCT04134455|EXPERIMENTAL|RTL reinforcement group|The RTL suture is placed parallel at a distance of 0.5 cm from the fascial margin. Ideally the thread should lie between the anterior and the posterior rectus muscle sheath; there should be no contact with the rectus muscle. A nonabsorbable monofilamental polypropylene thread and a 65-mm ½ needle are used. Around this longitudinal thread, the continuous suture for fascial closure is introduced immediately lateral to the thread; with running, slowly absorbable sutures (PDS 1-0) with a recommended suture length to wound length ratio of 4:1. An anterior plane with a width of about 8 cm was created between the anterior fascia and the subcutis
62170673|NCT05026242|EXPERIMENTAL|Almond intervention|Participants will follow their regular Western-style diet substituting unhealthy snacks by 2-daily servings of almonds
62170674|NCT05026242|ACTIVE_COMPARATOR|Control|Participants will be provided with isocaloric snacks
62170675|NCT03800264|ACTIVE_COMPARATOR|BISOPROLOL|BISOPROLOL 5mg per oral (P.O.) in the evening of the operation and then one dose (5 mg) every twenty four hours during the next two days.
62170676|NCT03800264|ACTIVE_COMPARATOR|hydrocortisone|hydrocortisone 100 mg intravenously is given in the evening of the operation and then 100 mg every eight hours during the next two days.
62170677|NCT03219476|EXPERIMENTAL|Neoadjuvant endocrine therapy treatment (physician's choice)|Once enrolled, patients would be treated with the current standard-of-care endocrine therapy. Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status. The patient would be treated with endocrine therapy in a neoadjuvant setting for four weeks, with dosing continuing until surgery.
62170678|NCT01516606|EXPERIMENTAL|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
62170679|NCT02864342|ACTIVE_COMPARATOR|BreatheMate device and application|BreatheMate Bluetooth device that attaches to Symbicort pressurized Metered Dose Inhaler (pMDI) and cell phone with application that sends medication and refill reminders and reminders to complete a COPD questionnaire
62363797|NCT05204758|PLACEBO_COMPARATOR|Control arm|Patients receive afatinib and placebo. Placebo without the medical ingredients was prepared to be similar to the weight, color, smell, taste, and packaging of the TCM formulas. The packages contained 1.6 g placebo preparations, which were manufactured in powder form by Sun Ten Pharmaceutical (Taichung, Taiwan) according to the good manufacturing practice requirements. Patients were instructed to intake three packages of placebo preparations with each meal three times a day, for a total of nine packages per day. Administration of placebo was initiated at the same time as afatinib and continued for a total of three months.
62170680|NCT02864342|PLACEBO_COMPARATOR|BreatheMate device without application|BreatheMate Bluetooth device that attaches to Symbicort pressurized Metered Dose Inhaler (pMDI) and cell phone without any reminders or alerts.
62170681|NCT05971147|EXPERIMENTAL|Fish Oil Group|All participants will be placed in this group
62170682|NCT02160561|EXPERIMENTAL|Intervention Arm|Experimental - Intervention Arm patients who are in critical illness with acute respiratory failure and are mechanically ventilated will be placed in an upright reverse trendelenburg position
62170683|NCT05800483|EXPERIMENTAL|Healium|Healium is a web-based platform that employs a user-centric design and aims to appeal to a low health literate population. It features a simple language and layout, a large font size, contrasting text and background colors, bright color palette, and use of short labels and headings to describe content.
62363798|NCT02839473|EXPERIMENTAL|Hydrosorb® arm|Hydrogel Hydrosorb®
62170684|NCT05800483|NO_INTERVENTION|Comparison (Healing Choices)|The Healing Choices program represents a virtual health center that patients visit to obtain disease and treatment-related information. The software was designed to be open to exploration with an intuitive layout, without restrictions in terms of order of access. Information is stored in virtual rooms, such as a library, a conference room showing videos by survivors who discuss their approach to treatment, and physician offices containing videos of physicians representing different treatment specialties. All information was extensively vetted by health education experts of the National Cancer Institute's Cancer Information Services (CIS).
62170685|NCT02028234|ACTIVE_COMPARATOR|pantoprazole|Patients were randomly assigned to omeprazole (20 mg day) or pantoprazole (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
62170686|NCT02028234|ACTIVE_COMPARATOR|Omeprazole|Patients were randomly assigned to omeprazole (20 mg day) or pantoprazole (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
62170687|NCT05144802|EXPERIMENTAL|group 1 : FreeStyle Libre 2 on right arm and Dexcom G6 on left arm|In this group, participants will be continuously monitored for their interstitial glucose level with 2 CGM devices : FreeStyle Libre 2 will be applied on right arm and Dexcom G6 will be applied on left arm.
62170688|NCT05144802|ACTIVE_COMPARATOR|group 2 : 2 FreeStyle Libre 2 on left arm and Dexcom G6 on right arm|In this group, participants will be continuously monitored for their interstitial glucose level with 2 CGM devices : Dexcom G6 will be applied on right arm and FreeStyle Libre 2 will be applied on left arm.
62170689|NCT06328725|ACTIVE_COMPARATOR|Phase 1 - Cohort 1|EN001 5.0x10\^5 cells/kg
62170690|NCT06328725|ACTIVE_COMPARATOR|Phase 1 - Cohort 2|EN001 2.5x10\^6 cells/kg
62170691|NCT06328725|PLACEBO_COMPARATOR|Phase 2 - Experimental Group|The recommended phase 2 dose (RP2D) of EN001
62170692|NCT06328725|PLACEBO_COMPARATOR|Phase 2 - Control Group|EN001 placebo
62170693|NCT03121729|EXPERIMENTAL|enhanced recovery after surgery|"enhanced recovery after surgery includes:~1. Multimodal analgesia~2. Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet~3. Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally B: Remove catheter early~4. Early activity~5. Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken"
62170694|NCT05620654|EXPERIMENTAL|Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin|Patients with ovarian cancer receive hyperthermic intraperitoneal paclitaxel combined with a fixed dose of cisplatin (75mg/m2)
62170695|NCT05098197|EXPERIMENTAL|Tumor Infiltrating Lymphocytes|1x10\^9-5x10\^10 in vitro expanded autologous TILs will be infused i.v. to patients with advanced hepatobiliary-pancreatic cancers after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
62170696|NCT00612716|EXPERIMENTAL|Allogeneic Transplantation|Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.
62170697|NCT05854056|ACTIVE_COMPARATOR|Accelerated rehabilitation protocol|Elements of physical therapy Group 1 Accelerated rehabilitation Antioedema knee, calf, leg Day 1 Knee brace, ROM limitations No Weight-bearing limitations No, crutches are recommended for 4 weeks. Active exercises. Functional exercises. 1 week Active dynamic strengthening exercises. 5 weeks Closed chain exercises for muscle strengthening. 8 weeks Muscle endurance and neuromuscular control, progress strengthening exercises, jogging 12 weeks
62170698|NCT05854056|ACTIVE_COMPARATOR|Conservative rehabilitation protocol|"Elements of physical therapy Group 2 Conservative rehabilitation Antioedema knee, calf, leg Day 1 Knee brace, ROM limitations 6 weeks Weight-bearing limitations 4 weeks limb weight, followed by half body weight till week 6~Active exercises. Functional exercises. 8 weeks Active dynamic strengthening exercises. 8 weeks Closed chain exercises for muscle strengthening. 8 weeks Muscle endurance and neuromuscular control, progress strengthening exercises, jogging 12 weeks"
62170699|NCT00273351|EXPERIMENTAL|[123I]B-CIT|\[123I\]B-CIT and SPECT imaging
62170700|NCT05562583|EXPERIMENTAL|Intervention (single arm)|5 session self-guided online delivered positive emotion regulation intervention with social components.
62170701|NCT03635775|EXPERIMENTAL|Anodal ipsilesional Active tDCS|Anodal tDCS (excitatory) applied to the lesioned hemisphere. Participant must have lesioned hemisphere MEP.
62170702|NCT03635775|EXPERIMENTAL|Cathodal contralesional Active tDCS|Cathodal tDCS (inhibitory) applied to the non-lesioned hemisphere. Participant must have lesioned hemisphere MEP.
62170703|NCT03635775|EXPERIMENTAL|Anodal contralesional Active tDCS|Anodal tDCS (excitatory) applied to the non-lesioned hemisphere. Participant must not have lesioned hemisphere MEP.
62170704|NCT03635775|SHAM_COMPARATOR|Sham tDCS|Sham tDCS applied in one of the above configurations
62170705|NCT00240097|EXPERIMENTAL|Irinotecan; Oxaliplatin; Neulasta|Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
62170706|NCT00240097|EXPERIMENTAL|Etoposide; Carboplatin; Neulasta|Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) area under the concentration curve (AUC) 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
62170707|NCT04774783|EXPERIMENTAL|Low-Level Laser Therapy|Over the course of the study, participants within this group will receive 12 sessions of Low-Level Laser Therapy (LLLT) treatment over a duration of 4 weeks using the Richmar TheraTouch LX2 device. Treatment location will be determined through assessment of each qualifying participant. Treatment sessions will be limited to a single area of the body associated with the qualifying participant's primary pain complaint.
62170708|NCT04958434|EXPERIMENTAL|Part A - Dose Escalation|Dosed every 3 weeks IV with TST005, starting dose is 1 mg/kg, and 5 dose levels will be tested.
62170709|NCT04958434|EXPERIMENTAL|Part B - Dose Expansion|Participants with any kind of advanced or HPV metastatic solid tumors dosed Q3W with the Part A Q3W recommended dose of TST005
62170710|NCT05879991|EXPERIMENTAL|Part A: BI 1810631 (C-14)|
62170711|NCT05879991|EXPERIMENTAL|Part B: BI 1810631 then BI 1810631 (C-14)|
62170712|NCT04747847|EXPERIMENTAL|Atorvastatin and anakinra|Anakinra up to 8 mg/kg/day and atorvastatin at 0.75 mg/kg/day
62170713|NCT05021757||Disrupt CAD III PAS Cohort|Patients in the CathPCI Registry who undergo a PCI procedure using a Shockwave C2 Coronary IVL catheter and meeting the eligibility criteria will be included in the PAS cohort.
62170714|NCT01657071|EXPERIMENTAL|Group A|
62170715|NCT01657071|ACTIVE_COMPARATOR|Group B|
62170716|NCT02411253|EXPERIMENTAL|rhIL-2|"* 0.5 MIU/m²/day of IL2 with a maximum of 1MIU/day in a volume of 1 ml for children and adolescents,~* 1MIU/day for adults.~Subcutaneous injection every day (5 days) then:~* Regimen A injection every two weeks between D15 and D351,~* Regimen B injections every week between D15 and D351"
62170717|NCT02411253|PLACEBO_COMPARATOR|Placebo|"Placebo with a identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 days) then:~* Regimen A injection every two weeks between D15 and D351~* Regimen B injections every week between D15 and D351"
62363799|NCT02839473|PLACEBO_COMPARATOR|Placebo arm|Castalie water spray
62170718|NCT04712786||Group|27 patients, Group 1 consisted of patients with pseudophakic rhegmatogoneous retinal detachment who underwent pars plana vitrectomy and 12% perflouropropane (C3F8) gas tamponade and 20 patients Group 2 consisted of patients with epiretinal membrane or vitreous hemorrhage who underwent PPV without any tamponade
62170719|NCT01523028|EXPERIMENTAL|Coffee, bread and honey|200 mL coffee + 2 bread rolls + honey
62170720|NCT01523028|EXPERIMENTAL|Coffee, bread and peanut butter|200 mL coffee + 1 bread roll + peanut butter
62170721|NCT01523028|EXPERIMENTAL|200 mL black coffee|
62170722|NCT03747159|EXPERIMENTAL|BLM+RTX treatment arm|"Intervention 1 Belimumab injection: subcutaneous weekly injections with 200mg belimumab (BML) for the duration of the entire study period of two years.~Intervention 2 Rituximab infusion: Two intravenously infusions of 1000mg rituximab (RTX) at week 4 and week 6 after the start of belimumab.~Intervention 3: Standard of care: induction therapy with three intravenously infusions methylprednisolone of 1000mg (or 500mg if weight is below 60kg), oral prednisolone 60mg with a quick tapering scheme to reach 5mg in 10 weeks and mycofenolate mofetil start dosis 500mg twice daily with maximum dosis of 2000mg twice daily depending on tolerance and area under curve (AUC) aimed at 60mg\*hour/L."
62170723|NCT03747159|NO_INTERVENTION|Standard of Care treatment arm|"Intervention 1: Standard of care: induction therapy with three intravenously infusions methylprednisolone of 1000mg (or 500mg if weight is below 60kg), oral prednisolone 60mg with a quick tapering scheme to reach 5mg in 10 weeks and mycofenolate mofetil start dosis 500mg twice daily with maximum dosis of 2000mg twice daily depending on tolerance and area under curve (AUC) aimed at 60mg\*hour/L.~Optional intervention: (if patients flare or are non-responders on mycofenolate mofetil + prednisolone) : Two intravenously infusions of 1000mg rituximab at week 4 and week 6 after the start of belimumab."
62170724|NCT05004805|EXPERIMENTAL|Methylene blue Arm|The intervention is carried out in addition to the standard treatment. Administered Intervention is topical application of 0.02% Methylene blue solution in the form of repeated nasopharyngeal irrigation. The investigational drug is equipped with a spray nozzle to perform three administrations into both lower nasal passages. After three administrations on each side, it is recommended to take a deep breath so that the injected solution is distributed along the nasopharynx and oropharynx every 4 hours (5-6 times a day with a break for sleep). Duration is the period of stay of the subject, as long as there is no need for non-invasive or invasive mechanical ventilation. If the subject refuses further treatment in a hospital but does not withdraw consent to participate in the study, they should continue to take study drug after discharge from hospital, but not later than the date of the follow-up visit.
62170725|NCT05004805|PLACEBO_COMPARATOR|Saline solution Arm|The intervention is carried out in addition to the standard treatment. Adminestered Intervention is saline solution in the form of repeated nasopharyngeal irrigation. Dosage form, dosage, frequency and duration of intervention are the same.
62170726|NCT06338254|EXPERIMENTAL|PMT Group|Pregnant women included in this group received a total of 12 sessions of percussion massage therapy, applied to their bilateral lower extremities for four weeks.
62170727|NCT06338254|NO_INTERVENTION|Control Group|No massage therapy was applied to the lower extremities of the pregnant women in this group.
62170728|NCT02895854|ACTIVE_COMPARATOR|LDR-brachytherapy with I125 seeds|Low-dose rate-brachytherapy with I125 permanent seeds in prostate cancer.
62170729|NCT02895854|ACTIVE_COMPARATOR|Hypofractionated RT 5 x 7,25 Gy|Hypofractionated stereotactic radiotherapy 5 x 7,25 Gy delivered every second day in prostate cancer.
62170730|NCT00001219||Patients undergoing MRI in the Clinical Center|All patients who, by virtue of the NIH protocol in which they are enrolled, who qualify for MRI will be eligible for participation in this protocol.
62170731|NCT03359187|ACTIVE_COMPARATOR|Normal saline with salt/Soda|Normal saline with salt/soda rinse 4 times a day/everyday and for each time 15 ml.
62170732|NCT03359187|EXPERIMENTAL|Clinacanthus nutans|Clinacanthus nutans in form of mouth wash rinse 4 times a day/everyday and for each time 15 ml.
62170733|NCT03359187|EXPERIMENTAL|Boesenbergia rotunda|Boesenbergia rotunda in form of mouth wash 4 times a day/everyday and for each time 15 ml.
62170734|NCT04362176|EXPERIMENTAL|pathogen reduced SARS-CoV-2 convalescent plasma|Transfusion of convalescent plasma will be administered by clinical or research personnel while the participant is hospitalized on Study Day 0. Plasma will be administered at a rate of 500 mL/hour and will be administered within 12 hours of randomization.
62170735|NCT04362176|PLACEBO_COMPARATOR|Placebo|Participants randomized to the control group will receive 250mL of Lactate Ringers containing multivitamins intravenously on Day 1 as a placebo.
62170736|NCT02802579|ACTIVE_COMPARATOR|A: standard protocol|Standard dual-source computed tomography coronary angiography protocol
62170737|NCT02802579|EXPERIMENTAL|B: enhanced protocol|enhanced dual-source computed tomography coronary angiography protocol
62170738|NCT02802579|EXPERIMENTAL|C: enhanced obesity protocol|enhanced obesity-mode dual-source computed tomography coronary angiography protocol
62170739|NCT01868516|PLACEBO_COMPARATOR|Placebo|One tablet of placebo to be administered orally twice a day.
62170740|NCT01868516|EXPERIMENTAL|0.5 mg dexmecamylamine (TC-5214)|One tablet of 0.5 mg dexmecamylamine to be administered orally twice a day.
62170741|NCT01868516|EXPERIMENTAL|1 mg dexmecamylamine (TC-5214)|One tablet of 1 mg dexmecamylamine to be administered orally twice a day.
62170742|NCT01868516|EXPERIMENTAL|2 mg dexmecamylamine (TC-5214)|One tablet of 2 mg dexmecamylamine to be administered orally twice a day.
62170743|NCT02302625|EXPERIMENTAL|Cognitive behavior therapy|Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
62170744|NCT03235401||Pulmonary Arterial Hypertension patients|
62170745|NCT01164371||Initial presentation of coronary disease - Stable angina|Patients whose initial symptomatic presentation of coronary disease is stable angina (either diagnosis or symptoms)
62170746|NCT01164371||Initial presentation of coronary disease - ACS|Patients whose initial symptomatic presentation of coronary disease is acute coronary syndrome (ST-elevation myocardial infarction \[STEMI\], non-STEMI \[nSTEMI\] or unstable angina) without prior stable angina or symptoms of stable angina
62170747|NCT01164371||Initial presentation of coronary disease - Coronary death|Patients whose initial symptomatic manifestation of coronary disease is coronary death with no prior diagnosis of stable angina (or symptoms of stable angina) or diagnosis of acute coronary syndrome
62170748|NCT01164371||Initial presentation of coronary disease - None|Patients without symptomatic presentation of coronary disease, either alive or dead from non-coronary cause
62170749|NCT02264353|EXPERIMENTAL|Donepezil|Sleep data with Donepezil given
62170750|NCT02264353|PLACEBO_COMPARATOR|Placebo|Sleep data with Placebo given
62170751|NCT04636099|EXPERIMENTAL|CTA Group|The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery
62170752|NCT04636099|NO_INTERVENTION|Non-CTA Group|The CTA group was routinely peformed upper abdomen enhenced without CT Angiography before surgery
62170753|NCT04834518||Negative result at the first autoantibodies screening test|Participants will be invited to repeat the screening test at the age of 2-5 years old
62170754|NCT04834518||Positive result at the first or second autoantibodies screening test|"* Participants will be monitored annually for risk of type 1 diabetes. (HbA1c, repeated OGTT, monitoring of urine and blood glucose where indicated)~* Families will attend diabetes-educational program emphasizing on DKA prevention~* Stress assessment for the families involved and stress alleviating interventions when required."
62170755|NCT00873678||1|Children or adult patients affected with JS/CORS
62170756|NCT00249847|EXPERIMENTAL|Paroxetine|Paroxetine controlled-release (2-12.5 mg tablets, orally, every day for 4 weeks)
62170757|NCT00249847|EXPERIMENTAL|Conjugated equine estrogen|Conjugated equine estrogen (0.625 mg tablet, orally, every day for 4 weeks)
62170758|NCT04693650|EXPERIMENTAL|Treatment group- UHF(+RF) stimulation|Patients implanted with leads and be administered with UHF stimulation
62170759|NCT04693650|NO_INTERVENTION|Control group|Patients implanted with lead receiving fake stimulation (no stimulation but same device procedure with test group)
62170760|NCT02537236|EXPERIMENTAL|Group one|20 subjects received Therapeutic Lifestyle Changes diet more 1.05 grams of fish oil omega 3 fatty acids
62170761|NCT02537236|ACTIVE_COMPARATOR|Group two|20 subjects received conventional diet more 1.05 grams of fish oil omega 3 fatty acids
62170762|NCT02537236|EXPERIMENTAL|Group three|20 subjects received Therapeutic Lifestyle Changes diet more 2.10 grams of fish oil omega 3 fatty acids.
62170763|NCT02537236|ACTIVE_COMPARATOR|Group four|20 subjects received conventional diet more 2.10 grams of fish oil omega 3 fatty acids
62170764|NCT02537236|PLACEBO_COMPARATOR|Group five|20 subjects, control group received conventional diet.
62170765|NCT01910922||Repeated exposure Group (RE)|Exposure to basic salsify puree during E1-E8
62170766|NCT01910922||Flavour-flavour learning-salt (FFL-S)|Exposure to salty salsify puree during E1-E8
62170767|NCT01910922||Flavour-flavour learning-nutmeg (FFL-N)|Exposure to nutmeg-flavored salsify puree during E1-E8
62170768|NCT05242913|ACTIVE_COMPARATOR|High Dose SolnulTM|7.0 g of Resistant Potato Starch administered daily for 4 weeks
62170769|NCT05242913|ACTIVE_COMPARATOR|Low Dose SolnulTM|3.5 g of Resistant Potato Starch (plus 3.5 g digestible corn starch for 7.0 g total carbohydrate) administered daily for 4 weeks
62170770|NCT05242913|PLACEBO_COMPARATOR|Placebo|7.0 g digestible corn starch administered daily for 4 weeks
62170771|NCT05873816|EXPERIMENTAL|ProtEmbo - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the ProtEmbo cerebral embolic protection device.
62170772|NCT05873816|ACTIVE_COMPARATOR|Sentinel - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the Sentinel cerebral embolic protection device.
62170773|NCT05873816|NO_INTERVENTION|Control Arm|Subjects will undergo TAVR without embolic protection.
62170774|NCT01905371|EXPERIMENTAL|Dextroamphetamine + Physical therapy (PT)|"Treatment with d-amphetamine + physical therapy administered under two regimens administered sequentially:~10 mg of d-amphetamine combined with 1 hr PT session beginning 1 hr after drug administration every 4 days, for a total of 6 or 10 sessions"
62170775|NCT01905371|PLACEBO_COMPARATOR|Placebo + Physical Therapy (PT)|"Treatment with placebo + physical therapy administered under two regimens administered sequentially:~Regimen 1: 10 mg of placebo combined with 1 hr PT session beginning 1 hr after placebo administration every 4 days, for a total of 6 or 10 sessions"
62170776|NCT04271514|EXPERIMENTAL|COMPLETED ENROLLMENT -- Single Dose Escalation Part A - active|Increasing doses of RPT193 will be administered to healthy volunteers
62170777|NCT04271514|PLACEBO_COMPARATOR|COMPLETED ENROLLMENT -- Single Dose Escalation Part A - placebo|Matching placebo will be administered to healthy volunteers
62170778|NCT04271514|EXPERIMENTAL|COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - active|Increasing doses of RPT193 will be administered once/day for 7 days to healthy volunteers
62170779|NCT04271514|PLACEBO_COMPARATOR|COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - placebo|Matching placebo will be administered once/day for 7 days to healthy volunteers
62170780|NCT04271514|EXPERIMENTAL|COMPLETED ENROLLMENT -- Expansion Part C - active|RPT193 will be administered daily for 28 days to patients with atopic dermatitis
62170781|NCT04271514|PLACEBO_COMPARATOR|COMPLETED ENROLLMENT -- Expansion Part C - placebo|Matching placebo will be administered daily for 28 days to patients with atopic dermatitis
62170782|NCT05129371|ACTIVE_COMPARATOR|Breathing Exercise Group|This group will be given breathing exercises in accordance with the determined protocol.
62170783|NCT05129371|PLACEBO_COMPARATOR|Placebo Breathing Group|Normal breathing of this group will be monitored.
62170784|NCT05129371|NO_INTERVENTION|Control Group|No application will be made to this group.
62170785|NCT03925519||non-obese|non-obese diabetic patients (n= 25, BMI ≤ 30 kg/m2) were subjected to supervised aerobic exercise
62170786|NCT03925519||obese group|obese diabetic group (n= 25, BMI ≥ 30 kg/m2)
62170787|NCT03207698|ACTIVE_COMPARATOR|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
62170788|NCT03207698|ACTIVE_COMPARATOR|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
62170789|NCT03207698|ACTIVE_COMPARATOR|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Metformin for treating furcation defect
62170790|NCT02513979|ACTIVE_COMPARATOR|angiotensin type II receptor antagonists|Hypertensive patients treated with angiotensin type II receptor antagonists
62170791|NCT02513979|NO_INTERVENTION|No treatment|Normotensive patients
62170792|NCT00640042|EXPERIMENTAL|1|
62170793|NCT04132388|ACTIVE_COMPARATOR|Standard-of-Care|Subjects will be instructed to take adalimumab according to the labeled dosing regimen. Subjects will return for evaluation at 12 \& 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit.
62170794|NCT04132388|EXPERIMENTAL|Electronic Reporting|"Subjects will be instructed to take adalimumab according to the labeled dosing regimen. The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter.~Subjects will return for evaluation at 12 \& 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit."
62170795|NCT04456049|EXPERIMENTAL|Enzalutamide (Xtandi®)|Interventional treatment
62170796|NCT04456049|ACTIVE_COMPARATOR|Standard of care (SOC)|Supportive treatment
62170797|NCT05107999|EXPERIMENTAL|Zhizhu Kuanzhong（ZZKZ） group|Patients in ZZKZ group were given ZZKZ (2 capsules tid) plus omeprazole (20 mg bid). ZZKZ was applied after each meal. Omeprazole was applied twice daily, before breakfast and supper.
62170798|NCT05107999|ACTIVE_COMPARATOR|Doxepin group|Patients in doxepin group were given doxepin (25 mg tid) plus omeprazole (20 mg bid). Doxepin was applied after each meal. Omeprazole was applied twice daily, before breakfast and supper.
62170799|NCT01083407|EXPERIMENTAL|0.12% Chlorhexidie Digluconate|Oral care included use of an oral gel containing chlorhexidine digluconate 0.12% as an active ingredient (chlorhexidine digluconate 0.12%; methylcellulose gel 2.12%, 25 g; gooseberry syrup, 4 drops; menthol solution 50%,3 drops; and distilled water, to 30 g).The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular,lingual, occlusal, and incisal). After each quadrant was cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto- anterior movements.
62170800|NCT01083407|PLACEBO_COMPARATOR|Toothbrushing|This group received the same oral care that experimental group with the use of a similarly formulated gel without the antiseptic agent.The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
62170801|NCT05834361|EXPERIMENTAL|early administration of carboprost methylate|Shortening the vaginal administration time of carboprost methylate, approximately 20 minutes before the surgery. Carboprost methylate was given when patients enter the operation room area.
62170802|NCT05834361|ACTIVE_COMPARATOR|delayed administration of carboprost methylate|Delay the vaginal administration time of carboprost methylate, approximately 2 hours before the surgery. Carboprost methylate was given when patients were in the ward.
62170803|NCT00585208|ACTIVE_COMPARATOR|Active drug|Ramelteon - this group receives active drug at a fixed dose of 8mg daily throughout study
62170804|NCT00585208|PLACEBO_COMPARATOR|Placebo (sugar pill)|placebo (sugar pill) - this arm receive the fake pill, also know as placebo or the sugar pill
62170805|NCT04204317||Autofluorescence|"The surgeon will perform the preplanned operation with FLUOBEAM XS. The following intraoperative variables will be recorded for all patients:~1. Surgery date~2. Duration of surgery~3. Operation performed~4. Procedure related comments~5. Number and location of the visualized glands~6. Intra-operative autofluorescence score (either 0 (no visualization or 1 visualization) for each gland"
62170806|NCT04204317||Control|"The surgeon will perform the preplanned operation without FLUOBEAM XS. The following intraoperative variables will be recorded for all patients:~1. Surgery date~2. Duration of surgery~3. Operation performed~4. Procedure related comments"
62170807|NCT05364541|OTHER|MyoVista wavECG|Single arm - subjects meeting the inclusion, exclusion and screening criteria will receive a MyoVista wavECG and a trans-thoracic echocardiogram.
62170808|NCT01359514|ACTIVE_COMPARATOR|Duloxetine|
62170809|NCT01359514|ACTIVE_COMPARATOR|Pregabalin|
62170810|NCT04545983|ACTIVE_COMPARATOR|ACD|In the previously conducted RCT 27 adult patients with an indication for ACD because of a monoradicular syndrome, corresponding to the C5-C6 or C6-C7 level, with corresponding pathology on MRI, were included and randomized to undergo ACD or ACDA.
62170811|NCT04545983|EXPERIMENTAL|ACDA|In the previously conducted RCT 27 adult patients with an indication for ACD because of a monoradicular syndrome, corresponding to the C5-C6 or C6-C7 level, with corresponding pathology on MRI, were included and randomized to undergo ACD or ACDA.
62170812|NCT05818137|EXPERIMENTAL|Sotatercept|Participants on background PAH therapy will receive sotatercept subcutaneous (SC) injections at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 3 weeks up to 24 weeks. Thereafter, participants may choose to continue receiving the treatment until approval of sotatercept in Japan.
62170813|NCT00797186|OTHER|Intensive therapy|There is one arm in this trial. All patients receive the same therapy. The goal is to compare a noninvasive and invasive imaging technique in the same population.
62170814|NCT01878253|EXPERIMENTAL|Investigational|This arm will include all subjects who are implanted with the investigational Sidus Stem-Free Total Shoulder Arthroplasty System.
62170815|NCT03887871|EXPERIMENTAL|Reference/Test|"1. Period 1: Harnal-D Tab. 1T~2. Period 2: Chong Kun Dang Tamsulosin HCl Tab. 1T"
62170816|NCT03887871|EXPERIMENTAL|Test/Reference|"1. Period 1: Chong Kun Dang Tamsulosin HCl Tab. 1T~2. Period 2: Harnal-D Tab. 1T"
62363800|NCT02959697|EXPERIMENTAL|Subcut. + Subconj. Injection|Patients will undergo standard blepharoptosis repair using an anterior approach, with an added injection of local anesthetic (Xylocaine) beneath the conjunctiva of the lid being operated on. They will still receive the standard subcutaneous local anesthetic given during blepharoptosis repair.
62170817|NCT04764877|NO_INTERVENTION|Standard Care|Standard teaching and physical exam for any patient that would be seen at our Hilltop Primary Care center asthma clinic. This included baseline PFTs. FOR THIS STUDY a second set of PFTs were obtained at the end of the visit
62170818|NCT04764877|EXPERIMENTAL|OMT arm|As above BUT with the addition of standardized OMT focusing on lung functionality. OMT provided by either our OMM attending at that time (Dr Wolf) or residents trained by her for this study (Drs. Regan, Jones, Pe and Bryant)
62170819|NCT06114511|EXPERIMENTAL|BL-M07D1|Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62170820|NCT02245464||Patients with essential hypertension|
62170821|NCT01384825||MS|Subjects with Multiple Sclerosis
62170822|NCT01384825||HC|Healthy Controls
62170823|NCT01384825||OND|"Subjects with Other Neurodegenerative Diseases, including both other non-inflammatory neurodegenerative diseases (OND) and other inflammatory neurodegenerative diseases (ONDi)"
62170824|NCT04380038|ACTIVE_COMPARATOR|Dupilumab|The dupilumab dose regimen selected for this study (300 mg q2w after an initial loading dose of 600 mg)
62170825|NCT04380038|PLACEBO_COMPARATOR|Placebo|A harmless substance that looks like the study drug, but which should have no effect. The placebo formulation used in this study contains all the ingredients present in the active drug, except the active ingredient (IL-4α antibody). Therefore, the risk related to this formulation should be no greater than the risk associated to the active drug.
62170826|NCT05545319|EXPERIMENTAL|Nirmatrelvir/ritonavir|Participants will receive nirmatrelvir/ ritonavir 300 mg/100 mg (or 150 mg/100 mg for participants with estimated glomerular filtration rate (eGFR) or estimated creatinine clearance (eCrCl) ≥30 to \<60 mL/min) every 12 hours from Day 1 through Day 15
62170827|NCT05545319|EXPERIMENTAL|Placebo/ritonavir|Participants will receive placebo 0 mg/ritonavir 100 mg every 12 hours for 15 days.
62170828|NCT04620122|EXPERIMENTAL|intervention group|Progressive Muscle Relaxation Training and Music Therapy are applied to the intervention group.
62170829|NCT04620122|NO_INTERVENTION|control group|No intervention is applied to the control group.
62170830|NCT06212934|EXPERIMENTAL|"Chou's Tiaoshen acupoints group"|"AcupuncturingChou's Tiaoshen acupoints,Chou's Tiaoshen acupoints is derived from the experience of Zhou Dean, anational famous traditional Chinese medicine doctor in our department."
62170831|NCT06212934|ACTIVE_COMPARATOR|Estazolam group|Estazolam is a drug commonly used in the treatment of insomnia
62170832|NCT01946529|ACTIVE_COMPARATOR|Group A (Standard Risk)|Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide. Doxorubicin will be omitted following a total cumulative dose of 375 mg/m\^2. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone, or surgery followed by radiation. Local control measures (surgery and/or radiation therapy) will be instituted after 6 courses of chemotherapy. Total duration of treatment is approximately 29 weeks.
62170833|NCT01946529|ACTIVE_COMPARATOR|Group B (High Risk)|Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, irinotecan, temozolomide, temsirolimus, bevacizumab, and sorafenib. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone or surgery followed by radiation.
62170834|NCT04382183|EXPERIMENTAL|Ketogenic weight loss maintenance diet|The ketogenic weight loss maintenance group will undergo in a ketogenic diet (50 g CHO/day) plant-based for 1 year.
62170835|NCT04382183|EXPERIMENTAL|Isocaloric balanced weight loss maintenance diet|The isocaloric balanced weight loss maintenance group will undergo in a diet following the standard Norwegian Health Directorate recommendations for 1 year.
62170836|NCT01961453|ACTIVE_COMPARATOR|Isosorbide Mononitrate, sustained release|One tablet containing 60 mg (Titration Stage 1) OR 120 mg (Titration Stage 2) of sustained-release ISMN administered at 8 AM.
62170837|NCT01961453|PLACEBO_COMPARATOR|Placebo capsule|One capsule of placebo administered once daily at 8 AM
62170838|NCT06212765|EXPERIMENTAL|Citrulline|The experimental product is 100% L-citrulline. Each pod will contain 10 grams of L-citrulline. Ten grams of L-citrulline provide 2.4 g of nitrogen.
62170839|NCT06212765|ACTIVE_COMPARATOR|Standard care|The active comparator is a mixture of the six non-essential amino acids. In order for the active comparator to be iso-nitrogenated compared with the experimental product, it will provide 2.4 g of nitrogen per pod. The active comparator will combine 13.2 % alanine, 19.8 % aspartate, 11.2 % glycine, 17.1 % proline, 15.6 % serine and 23.1 % histidine, for a total of 13 g of amino acids per pod.
62170840|NCT03358303|EXPERIMENTAL|Telemonitoring (Medly)|Medly is a smartphone application allows heart failure (HF) patients to measure and record their daily weight, blood pressure (BP), heart rate, and self-reported symptoms. This monitoring information is then transmitted wirelessly to a data server where an algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated self-care message based on their measurements and reported symptoms.
62170841|NCT03358303|NO_INTERVENTION|Control|Standard of care: Control groups will receive standard medical care when discharged from hospital, including discharge instructions, home medications as well as follow-up in a heart failure clinic or with a primary care doctor.
62170842|NCT05165303|EXPERIMENTAL|lidocaine with propofol|
62170843|NCT04770246|EXPERIMENTAL|TAS-117 Dose Escalation Daily Dose Regimen (Part A: safety lead-in)|Advanced or metastatic solid tumors irrespective of gene alterations
62170844|NCT04770246|EXPERIMENTAL|TAS-117 Dose Escalation Intermittent Dose Regimen (Part A: safety lead-in)|Advanced or metastatic solid tumors irrespective of gene alterations
62170845|NCT04770246|EXPERIMENTAL|TAS-117 Dose and Regimen Confirmation (Part A: safety lead-in)|Advanced or metastatic solid tumors with germline PTEN inactivating mutations
62170846|NCT04770246|EXPERIMENTAL|TAS-117 Phase 2 (Part B)|Advanced or metastatic solid tumors with germline PTEN inactivating mutations
62170847|NCT01024036|EXPERIMENTAL|Siltuximab+best supportive care (BSC)|Siltuximab 11 mg/kg will be administered as a 1-hour intravenous infusion every 3 weeks + BSC.
62170848|NCT01024036|PLACEBO_COMPARATOR|Placebo+BSC|Placebo will be administered as a 1-hour intravenous infusion every 3 weeks + BSC. Participants who do not respond to placebo during the blinded treatment period will have option to crossover and receive siltuximab 11 mg/kg which will be administered by 1-hour intravenous infusion every 3 weeks + BSC during the unblinded treatment period.
62170849|NCT05765890||Hepatologists|Recruited via email through online panel companies with which respondents have provided permission to be contacted for research purposes
62170850|NCT05765890||Metabolically-Focused HCPs|Recruited via email through online panel companies with which respondents have provided permission to be contacted for research purposes
62170851|NCT05914155|ACTIVE_COMPARATOR|Rituximab group in double-blind phase|
62170852|NCT05914155|PLACEBO_COMPARATOR|Placebo group in double-blind phase|
62170853|NCT05914155|OTHER|Rituximab group in open-label phase|
62170854|NCT00598858|EXPERIMENTAL|Treatment (docetaxel and prednisone)|Patients receive docetaxel IV over 60 minutes on days 1 and 2 and prednisone PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62170855|NCT03877952|EXPERIMENTAL|Study Participants|On Day 1, participants will receive a single oral dose of 14C-CORT125281 360 mg (6 X 60 mg capsules) after an overnight fast.
62170856|NCT02860559|EXPERIMENTAL|TBX-1400 treatment|Single intravenous infusion of TBX-1400
62170857|NCT06619210|EXPERIMENTAL|HL231 Dose 1（Part A）|single dose, oral inhalation by PARI BOY nebulizer
62170858|NCT06619210|EXPERIMENTAL|HL231 Dose 2（Part A）|single dose, oral inhalation by PARI BOY nebulizer
62170859|NCT06619210|EXPERIMENTAL|HL231 Dose 3（Part A）|single dose, oral inhalation by PARI BOY nebulizer
62170860|NCT06619210|ACTIVE_COMPARATOR|Ultibro （Part A）|Ultibro capsule for inhalation, consisting of a fixed dose combination of indacaterol 110µg and glycopyrronium 50µg, single dose, oral inhalation by Breezhaler
62170861|NCT06619210|PLACEBO_COMPARATOR|Placebo Solution for Inhalation (Part A)|Placebo Solution for Inhalation, single dose, oral inhalation by PARI BOY nebulizer
62170862|NCT06619210|EXPERIMENTAL|HL231 Dose 2（Part B）|single dose, oral inhalation by PARI BOY nebulizer
62170863|NCT06619210|EXPERIMENTAL|HL231 Dose 4（Part B）|single dose, oral inhalation by PARI BOY nebulizer
62170864|NCT06619210|ACTIVE_COMPARATOR|Active Comparator （Part B）|Ultibro capsule for inhalation, consisting of a fixed dose combination of indacaterol 110µg and glycopyrronium 50µg, single dose, oral inhalation by Breezhaler
62170865|NCT02222532|EXPERIMENTAL|Tetronine|Oral T3 (Tetronine) is given 1 mcg/kg every 6 hourly through naso-gastric tube since induction of anesthesia for 60 hours
62170866|NCT02222532|PLACEBO_COMPARATOR|Placebo|Placebo (saccharin lactic) is given every 6 hourly through naso-gastric tube since induction of anesthesia for 60 hours
62170867|NCT03474042|EXPERIMENTAL|GLPG2737|GLPG2737 will be provided as capsules for oral use.
62170868|NCT03474042|PLACEBO_COMPARATOR|Placebo|Placebo will be provided as capsules for oral use.
62170869|NCT02538471|EXPERIMENTAL|Arm 1 - Study Drug & Radiation therapy|"Study Drug: Enrolled patients will receive 300 mg/day of LY2157299. LY2157299 will be administered as an oral drug tablet.~The study drug will be administered orally on a 28-day cycle (1 cycle=28 days), every 2 weeks, or 14 days on / 14 days off. Blood samples will be obtained at baseline, and weeks 2, 6 and 15 for immune monitoring.~Radiation therapy : Patients will receive Radiation therapy to a metastatic site at a dose of 7.5 Gy, given consecutively on days 1, 3 and 5, during Week 1 of their treatment."
62170870|NCT01336387|EXPERIMENTAL|Arm I (retinoid 9cUAB30)|Participants receive retinoid 9cUAB30\* PO on days 1-28.
62170871|NCT01336387|PLACEBO_COMPARATOR|Arm II (placebo)|Participants receive placebo\* PO on days 1-28.
62170872|NCT03456830|EXPERIMENTAL|ALLN-177|ALLN-177 3,750 units per capsule
62170873|NCT03456830|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62170874|NCT01940692|ACTIVE_COMPARATOR|Intravenous tranexamic acid|Will receive 1.5g intravenous tranexamic acid preoperatively
62170875|NCT01940692|EXPERIMENTAL|Intra-articular tranexamic acid|Will receive 3g intra-articular tranexamic acid after wound closing
62170876|NCT03740737|EXPERIMENTAL|FE 999049 (Follitropin Delta)|
62170877|NCT03740737|PLACEBO_COMPARATOR|Placebo|
62170878|NCT06647342|ACTIVE_COMPARATOR|Standard dose|Patients in this arm will recieve the standard dose of bleomycin during treatment with electrochemotherapy
62170879|NCT06647342|EXPERIMENTAL|Dose reduction|Patients in this arm will recieve half the standard dose of bleomycin during treatment with electrochemotherapy
62170880|NCT06146790|EXPERIMENTAL|Endovascular treatment+ standard medical management|For the subjects randomized to endovascular treatment (EVT), treatment initiation is defined as the date and time of arterial puncture. Ideally, femoral artery puncture will occur within 30 minutes of randomization and no longer than 60 minutes after the completion of the qualifying imaging. Treatment initiation (arterial puncture) must occur before 24 hours since the subject was last known well. Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two (2) hours of arterial access. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
62170881|NCT06146790|ACTIVE_COMPARATOR|Standard medical management|Standard medical management
62170882|NCT06181929|EXPERIMENTAL|intervation group|LDCT screening exam
62170883|NCT01889771|EXPERIMENTAL|Nicotine Patch (4 weeks)|participants receive one 4-weeks supply of nicotine patches
62170884|NCT01889771|EXPERIMENTAL|Nicotine Patch (8 weeks)|participants receive up to 8 weeks of nicotine patches in up to two 4-week supplies
62170885|NCT01862614|EXPERIMENTAL|Buffered Articaine at 1st Appointment|Subjects received an infiltration injection of 1.8cc buffered 4% articaine.
62170886|NCT01862614|ACTIVE_COMPARATOR|Articaine at 1st Appointment|Subjects received an infiltration injection of 1.8cc 4% articaine (unbuffered).
62170887|NCT00660764||1|Patients eligible for the study were patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C ≥ 3.2 mmol/l. Patients were aged ≥ 18 years and ≤ 70 years (men) and ≤ 75 years (women), according to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention. The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation. Patient approved to place anonymous results at the disposal of AstraZeneca
62170888|NCT04140422|EXPERIMENTAL|Hyperosmolar Eye Drops|5% sodium chloride eye drops with 0,15% hyaluronic acid; one drop after waking up and one drop 30 min later on study day; investigator administered
62170889|NCT04140422|PLACEBO_COMPARATOR|Lubricating Eye Drops|Lubricating eye drops with 0,15% hyaluronic acid; one drop after waking up and one drop 30 min later on study day; investigator administered
62170890|NCT04364750|EXPERIMENTAL|Group A|"Participants in group A will undergo challenges in the order:~1. High-FODMAP beverage + placebo probiotic + L-Histidine~2. Low-FODMAP beverage + placebo probiotic + L-Histidine~3. High-FODMAP beverage + probiotic + L-Histidine~Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges."
62170891|NCT04364750|EXPERIMENTAL|Group B|"Participants in group A will undergo challenges in the order:~1. Low-FODMAP beverage + placebo probiotic + L-Histidine~2. High-FODMAP beverage + probiotic + L-Histidine~3. High-FODMAP beverage + placebo probiotic + L-Histidine.~Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges."
62170892|NCT04364750|EXPERIMENTAL|Group C|"Participants in group A will undergo challenges in the order:~1. High-FODMAP beverage + probiotic + L-Histidine~2. High-FODMAP beverage + placebo probiotic + L-Histidine~3. Low-FODMAP beverage + placebo probiotic + L-Histidine.~Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges."
62170893|NCT05488002|EXPERIMENTAL|Intervention|"This arm will receive pharmaceutical interventions.~Hypertensive patients will receive pharmacist recommendations on hypertension Diabetic patients will receive pharmacist recommendations on diabetes Obese patients will receive pharmacist recommendations on obesity"
62170894|NCT05488002|NO_INTERVENTION|Control|This arm will receive standard care
62170895|NCT02186587|OTHER|ConforMIS|Subjects who receive a ConforMIS custom total knee implant.
62170896|NCT01247870|EXPERIMENTAL|Metformin|Metformin 1 g twice daily for 28-35 days
62170897|NCT01247870|PLACEBO_COMPARATOR|Placebo|Matched placebo capsules
62170898|NCT02961777||Time 1|retrospective evaluation of patient record. no intervention
62170899|NCT02961777||Time 2|retrospective evaluation of patient record. no intervention
62170900|NCT02961777||Time 3|retrospective evaluation of patient record. no intervention
62170901|NCT01119534|EXPERIMENTAL|Transpulmin|Suppository composed by guaiacol, eucalyptol, menthol and camphor
62170902|NCT01119534|ACTIVE_COMPARATOR|Comparator 1|Suppository composed by guaiacol
62170903|NCT01119534|ACTIVE_COMPARATOR|Comparator 2|Syrup composed by guaifenesin
62170904|NCT03003884|EXPERIMENTAL|Remimazolam Tosilate 1|IV of Remimazolam Tosilate at 5mg for initial dose
62170905|NCT03003884|EXPERIMENTAL|Remimazolam Tosilate 2|IV of Remimazolam Tosilate at 7mg for initial dose
62170906|NCT03003884|EXPERIMENTAL|Remimazolam Tosilate 3|IV of Remimazolam Tosilate at 8mg for initial dose
62170907|NCT03003884|EXPERIMENTAL|Remimazolam Tosilate 4|IV of Remimazolam Tosilate at 5mg for initial dose.At the end of the endoscopy, flumazenil was injected.
62170908|NCT03003884|ACTIVE_COMPARATOR|Propofol|IV of Propofol at 1.5mg/kg for initial dose
62170909|NCT01545778||Tapentadol IR|
62170910|NCT01545778||Oxycodone IR|
62170911|NCT05582135|ACTIVE_COMPARATOR|group A|The parturients in group A were administered 2 mg morphine sulfate through the epidural catheter.
62170912|NCT05582135|ACTIVE_COMPARATOR|group B|The parturients in group B were administered 0.25mg/kg of esketamine.
62170913|NCT05582135|ACTIVE_COMPARATOR|group C|The parturients in group C were administered 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate.
62170914|NCT05582135|ACTIVE_COMPARATOR|group D|The parturients in group D were administered 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate.
62170915|NCT05083871||Learners of the European Trauma Course|Learners attending the European Trauma Course
62170916|NCT01655862||OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
62170917|NCT01618227|EXPERIMENTAL|Rehabilitation with static progressive splinting|Static progressive splinting is a well-established adjunct for restoring motion in stiff joints. Such splints apply a static stress relaxation force to the wrist and forearm tissues, which is sequentially increased as motion is achieved.
62170918|NCT01618227|EXPERIMENTAL|Rehabilitation without splinting|
62170919|NCT04509583|EXPERIMENTAL|PROFortil group|"Men with increased sperm DNA fragmentation (\>=30%) will be indicated for multi-micronutrient supplement (PROfortil™, twice daily) plus Vitamin E (Enat 400, once per day) in 3 months then checked again post-treatment for DF).~The IVF/ICSI cycles will then be analyzed for embryo quality, pregnancy outcomes including biochemical pregnancy rate, clinical pregnancy rate, on-going pregnancy, miscarriage."
62170920|NCT04509583|OTHER|Vitamin E group|"Any case with high DNA fragmentation index (DFI \>=30%) will be randomized indicated only Vitamin E (Enat 400 once per day) in 3 months then checked again post-treatment for (DFI).~The IVF/ICSI cycles will then be analyzed for embryo quality, pregnancy outcomes including biochemical pregnancy rate, clinical pregnancy rate, on-going pregnancy, miscarriage."
62170921|NCT01766414|ACTIVE_COMPARATOR|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion followed by administration of Endotoxin 2ng/kg
62170922|NCT01766414|PLACEBO_COMPARATOR|Placebo|Placebo (saline 0.9%) infusion followed by administration of Endotoxin 2ng/kg
62170923|NCT05904171|EXPERIMENTAL|Tangotherapy|2 hours of group-based Tangotherapy, weekly, for 6 weeks
62170924|NCT05904171|ACTIVE_COMPARATOR|Physical Activity|2 hours of group-based physical activity, weekly, for 6 weeks
62170925|NCT00936195|ACTIVE_COMPARATOR|Atripla (R)|
62170926|NCT00936195|ACTIVE_COMPARATOR|Combivir (R) + Kaletra (R) or Aluvia (R)|
62170927|NCT00128908|ACTIVE_COMPARATOR|Continuous triple-class therapy|Patients will be treated with a regimen containing antiretroviral agents from 3 different classes
62170928|NCT00128908|EXPERIMENTAL|Alternating therapy|Patients will be assigned to weekly alternating dual-class regimen
62170929|NCT00721019|EXPERIMENTAL|5-hour bedtime|
62170930|NCT00721019|EXPERIMENTAL|8.5-hour bedtime|
62363801|NCT02959697|SHAM_COMPARATOR|Subcut. + Sham Subconj. Injection|Patients will undergo standard blepharoptosis repair using an anterior approach, however they will not receive the additional subconjunctival Xylocaine injection. Instead, they will receive a sham injection of Normal Saline to prevent them from knowing which eye received the additional anesthetic.
62170931|NCT03425461|EXPERIMENTAL|Arm A (anti-SEMA4D VX15/2503, nivolumab)|ARM A: Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and nivolumab IV over 30 minutes every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
62170932|NCT03425461|EXPERIMENTAL|Arm B (anti-SEMA4D VX15/2503, ipilimumab)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and ipilimumab IV over 30 minutes every 21 days for courses 1-4, then receive anti-SEMA4D monoclonal antibody VX15/2503 every 28 days for subsequent courses for up to 12 months in the absence of disease progression or unacceptable toxicity.
62170933|NCT03809650|EXPERIMENTAL|Open-label treatment period|oral administration of macitentan 10 mg once daily
62170934|NCT05833399||Addicted patients on treatment with psychiatric medications.|Addicted patients receiving treatment with either quetiapine, olanzapine, mirtazapine, carbamazepine, sertraline, amitriptyline, chlorpromazine or risperidone as oral dosage forms of usual prescribed doses for psychiatric disorders.
62170935|NCT05833399||Healthy non-addicted controls.|Individuals who have never been addicted to any substance of use and did not receive any treatment with psychiatric medications.
62170936|NCT01145859|EXPERIMENTAL|Arm 1|
62170937|NCT05173259|ACTIVE_COMPARATOR|F-R/L-G05/G15/G25 or G25/G15/G05-L/R-F Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G05-G15-G25-G25-G15-G05).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G05-G15-G25-G25-G15-G05). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
62170938|NCT05173259|ACTIVE_COMPARATOR|F-R/L-G05/G25/G15 or G15/G25/G05-F-L/R Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G05-G25-G15-G15-G25-G05).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G05-G25-G15-G15-G25-G05). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
62170939|NCT05173259|ACTIVE_COMPARATOR|F-R/L-G15/G05/G25 or G25/G05/G15-F-L/R Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G05-G15-G25-G25-G15-G05).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G15-G05-G25-G25-G05-G15). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
62170940|NCT05173259|ACTIVE_COMPARATOR|F-R/L-G15/G25/G05 or G05/G25/G15-F-L/R Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G15-G25-G05-G05-G25-G15).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G15-G25-G05-G05-G25-G15). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
62170941|NCT05173259|ACTIVE_COMPARATOR|F-R/L-G25/G05/G15 or G15/G05/G25-F-L/R Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G25-G05-G15-G15-G05-G25).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G25-G05-G15-G15-G05-G25). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
62170942|NCT05173259|ACTIVE_COMPARATOR|F-R/L-G25/G15/G05 or G05/G15/G25-F-L/R Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G25-G15-G05-G05-G15-G25).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G25-G15-G05-G05-G15-G25). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
62170943|NCT01046071|EXPERIMENTAL|transversus abdominis plane block|transversus abdominis plane block with ropivacaine
62170944|NCT01046071|PLACEBO_COMPARATOR|block with saline|20 ml of isotonic saline bilateral
62170945|NCT02406040|EXPERIMENTAL|High Protein|2.4g protein/kg/d. The macronutrient composition will be 50:15:35 (carbohydrates:fat:protein) during Energy Restriction
62170946|NCT02406040|EXPERIMENTAL|Adequate Protein|1.2g protein/kg/d. The macronutrient composition will be 50:35:15 (carbohydrates:fat:protein) during Energy Restriction
62170947|NCT01334905|EXPERIMENTAL|Part A group|fasted condition then fed condition
62170948|NCT01334905|EXPERIMENTAL|Part B group|fed condition then fasted condition
62170949|NCT05253547|EXPERIMENTAL|Healthy climate-friendly dietary guidelines|Personalised healthy dietary recommendations aimed at reducing diet-related greenhouse gas emissions
62170950|NCT05253547|ACTIVE_COMPARATOR|Healthy eating guidelines|Personalised healthy dietary recommendations based on Ireland's Healthy Eating Guidelines
62170951|NCT00404547|ACTIVE_COMPARATOR|Alvesco|Alvesco 320mcg / Alvesco 640mcg
62170952|NCT00404547|ACTIVE_COMPARATOR|Usual Care|
62363802|NCT02661945|EXPERIMENTAL|Near focus with narrow band imaging|Near focus with narrow band imaging is used for marking the tumor margin.
62363803|NCT02661945|NO_INTERVENTION|Indigo carmin|After indigo carmine was sprayed over the lesion, marking is performed.
62170953|NCT01881100|EXPERIMENTAL|resin infiltration|The test group (41 children) had caries lesions treated with the infiltration technique using Icon (DMG, Hamburg, Germany) and fluoride varnish (Duraphat, Colgate Palmolive, Hamburg, Germany)at baseline evaluation. Fluoride varnish was applied every control visit every three months during 1 year.
62363804|NCT04961476||GrM0|GrM0 - without supplementation
62363805|NCT04961476||GrM1|GrM1 - with 1-MNA supplementation
62363806|NCT04368000|EXPERIMENTAL|Prone Positioning|
62363807|NCT04368000|ACTIVE_COMPARATOR|Usual care|
62363808|NCT05013294|EXPERIMENTAL|Intervention|The intervention group will receive a total of 43 text messages. Text messages were developed using the Behavior Chang Wheel (BCW) through a systematic process linked to specific behavior change techniques. The text messages will provide practical information or guidance to influence selection and eating healthy diet for type 2 diabetes care. The text messages were either loss- or gain-framed to increase influence on behavioral decisions. Additionally, the participants will receive a text message to rate their ability on selection of food and eating of healthy diet based on the messages received in the month. The combination of the one-way and two-way messages in this group are designed to increase engagement of the participants.
62363809|NCT05013294|PLACEBO_COMPARATOR|Control Arm|The control group will continue receiving standard care in the hospitals. The control group shall also receive a reminder text messages one day prior the routine clinic appointment. The clinic appointment dates shall be derived from the hospital where the participant receives routine diabetes care.
62363810|NCT01335490|EXPERIMENTAL|Biolite Cook Stove|Provision of two cook stoves to each subject. Each stove burns wood fuel, but more efficiently than a traditional three stone fire.
62363811|NCT01335490|EXPERIMENTAL|LPG Cook Stove|Provision of a two-burner liquified petroleum gas stove to each subject, along with fuel needed for the family during the follow up period.
62363812|NCT01335490|NO_INTERVENTION|Control|
62363813|NCT01505972|EXPERIMENTAL|Six and three time schedule|
62363814|NCT01505972|EXPERIMENTAL|Four and two time schedule|
62363815|NCT00972972|ACTIVE_COMPARATOR|dietary supplement|Extracts of bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.)
61986109|NCT01153243|PLACEBO_COMPARATOR|Placebo pill|The investigators will give intervention group 12 weeks of placebo pill (in pill every week)
61986110|NCT05434520||Preoperative biliary drainage|Patients who had undergone preoperative biliary drainage (ERC og PTC) prior to pancreatoduodenectomy
61986111|NCT05434520||No preoperative biliary drainage|Patients who had not undergone preoperative biliary drainage (ERC og PTC) prior to pancreatoduodenectomy
61986112|NCT00861146|EXPERIMENTAL|1 concurrent smoking cessation|smoking cessation delivered concurrent with intensive alcohol treatment
61986113|NCT00861146|ACTIVE_COMPARATOR|2 deferred smoking cessation|smoking cessation delivered 12 weeks after intensive alcohol treatment
61986114|NCT02196779||Patients undergoing abdominoplasty|Skin circulation to abdominal flap is evaluated during surgery using laser fluorescent imaging.
61986115|NCT05603559|EXPERIMENTAL|177Lu-P17-087 arm|All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-087 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
61986116|NCT05603559|EXPERIMENTAL|177Lu-P17-088 arm|All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-088 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
61986117|NCT03202147|ACTIVE_COMPARATOR|ALZT-OP1a|ALZT-OP1a: cromolyn (17.1 mg, capsule) for oral inhalation via dry powder inhaler, taken twice per day (morning and evening), 8-12 hours apart.
61986118|NCT03202147|PLACEBO_COMPARATOR|Placebo|ALZT-OP1a: placebo capsule for oral inhalation via dry powder inhaler, taken twice per day (morning and evening), 8-12 hours apart.
61986119|NCT00413192|EXPERIMENTAL|1|
61986120|NCT03382119||Patients having Fontan cardiac surgery|"This group includes pediatric patients, aged 2-5 years, who have had a Fontan operation. This surgery corrects a heart defect found at birth in which the heart has only one ventricle.~Patients will have an Ultrasound with ARFI imaging."
61986121|NCT03382119||Patients with Liver disease|"This group includes pediatric patients, aged 2-5 years, who have chronic liver disease caused by biliary atresia.~Patients will have an Ultrasound with ARFI imaging."
61986122|NCT06435533|EXPERIMENTAL|duodenal polyps <10 mm|low energy argonplasma coagulation
61986123|NCT02211001|EXPERIMENTAL|Pilates Group|The individuals were treated with Mat Pilates Method.
61986124|NCT02211001|EXPERIMENTAL|Segmented Dynamic Exercises Group|The individual were treated with ball exercises.
61986125|NCT02211001|EXPERIMENTAL|Global Postural Reeducation Group|The individuals were treated with postures of Souchard Method.
61986126|NCT04325958|OTHER|Age group 19 to 25|Participants will complete two sessions: one where they drive the simulator before and after smoking a placebo cannabis cigarette (\<1% THC), the other where they drive the simulator before and after smoking an active cannabis cigarette (15% ± 5% THC).
61986127|NCT04325958|OTHER|Age group 35 to 45|Participants will complete two sessions: one where they drive the simulator before and after smoking a placebo cannabis cigarette (\<1% THC), the other where they drive the simulator before and after smoking an active cannabis cigarette (15% ± 5% THC).
61986128|NCT02608268|EXPERIMENTAL|Phase I Dose escalation: MBG453 Q2W ROW|Sabatolimab every 2 weeks (Q2W) in Phase I Dose Escalation Part in rest of the world (ROW) patients
61986129|NCT02608268|EXPERIMENTAL|Phase I Dose escalation: MBG453 Q2W Japan|Sabatolimab Q2W in Phase I Dose Escalation Part in Japanese patients
61986130|NCT02608268|EXPERIMENTAL|Phase I Dose escalation: MBG453 Q4W ROW|Sabatolimab every 4 weeks (Q4W) in Phase I Dose Escalation Part in ROW patients
61986131|NCT02608268|EXPERIMENTAL|Phase I Dose escalation: MBG453 Q4W Japan|Sabatolimab Q4W in Phase I Dose Escalation Part in Japanese patients
61986132|NCT02608268|EXPERIMENTAL|Phase Ib Dose Escalation: MBG453 Q2W + PDR001 Q2W|Sabatolimab Q2W in combination with spartalizumab Q2W in Phase Ib Dose Escalation Part
62170954|NCT01881100|ACTIVE_COMPARATOR|fluoride varnish|The control group (40 children) had all tooth surfaces including WSL treated with fluoride varnish (Duraphat Colgate Palmolive, Hamburg, Germany)only at baseline evaluation and every control visit every three months during 1 year.
62363816|NCT00972972|PLACEBO_COMPARATOR|placebo dietary supplement|Placebo juice extracts
62170955|NCT06399640|EXPERIMENTAL|Eltanexor + Venetoclax|Participants receive eltanexor PO QD for 5 days per week for 14, 21, or 28 days every cycle, and venetoclax PO QD on days 1-14 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants undergo bone marrow aspiration and biopsy and blood sample collection throughout the study.
62170956|NCT04851145|EXPERIMENTAL|Experimental|
62170957|NCT01062854|EXPERIMENTAL|Earplugs|Subjects randomized to this arm of the study will wear earplugs during their baseline sleep study (polysomnogram).
62363817|NCT05739240|OTHER|no 3D model|
62170958|NCT01062854|NO_INTERVENTION|Comparison group|Subjects randomized to the comparison arm will not wear earplugs during their baseline sleep study.
62170959|NCT01628783|PLACEBO_COMPARATOR|Placebo|Microgranular cellulose in gelatine capsules.
62170960|NCT01628783|EXPERIMENTAL|Escitalopram 10 mg|Escitalopram in gelatine capsule
62170961|NCT01498445|EXPERIMENTAL|Phase I - Dasatinib 100 mg + Decitabine 10 mg/m2|Less Intensive, Schedule A1 Dasatinib 100 mg daily by mouth ; Decitabine 10 mg/m\^2 by vein over 1 hour daily for 10 days; 28 day cycle.
62170962|NCT01498445|EXPERIMENTAL|Phase I - Dasatinib 100 mg + Decitabine 20 mg/m2|More Intensive, Schedule A2: Dasatinib 100 mg daily by mouth ; Decitabine ose 20 mg/m\^2 by vein over 1 hour daily for 10 days; 28 day cycle.
62170963|NCT01498445|EXPERIMENTAL|Phase I - Dasatinib 140 mg + Decitabine 10 mg/m2|Less Intensive, Schedule B1 Dasatinib 140 mg daily by mouth ; Decitabine 10 mg/m\^2 by vein over 1 hour daily for 10 days; 28 day cycle.
62170964|NCT01498445|EXPERIMENTAL|Phase I - Dasatinib 140 mg + Decitabine 20 mg/m2|More Intensive, Schedule B2 Dasatinib 140 mg daily by mouth ; Decitabine 20 mg/m\^2 by vein over 1 hour daily for 10 days; 28 day cycle.
62170965|NCT01498445|EXPERIMENTAL|Phase II - Dasatinib 140 mg + Decitabine 10 mg/m2|Less Intensive, Schedule B1 Dasatinib 140 mg daily by mouth; Decitabine e 10 mg/m\^2 by vein over 1 hour daily for 10 days; 28 day cycle.
62170966|NCT01498445|EXPERIMENTAL|Phase II - Dasatinib 140 mg + Decitabine 20 mg/m2|More Intensive, Schedule B2 Dasatinib140 mg daily by mouth; Decitabine 20 mg/m\^2 by vein over 1 hour daily for 10 days; 28 day cycle.
62170967|NCT03585621|EXPERIMENTAL|SBRT to the Primary Breast Tumour|SBRT to the breast using 4 sequentially escalating dose levels from 9Gy to 12 Gy.
62170968|NCT03334773|EXPERIMENTAL|Intervention group|Nutrition education (group inclusive of education materials)
62170969|NCT03334773|NO_INTERVENTION|Control group|Only receives education materials
62170970|NCT00113880||1|5-8 years of age, estimated to be approximately 4,000 new FluMist vaccinees per season
62170971|NCT00113880||2|9-17 years of age, estimated to be approximately 5,000 new FluMist vaccinees per season
62170972|NCT00113880||3|18-49 years of age, estimated to be approximately 6,000 new FluMist vaccinees per season.
62170973|NCT00377312|EXPERIMENTAL|Group 1|Parathyroid Hormone (PTH) (1-34) 2 picomols/kg/hr for one week.
62170974|NCT00377312|EXPERIMENTAL|Group 2|Parathyroid Hormone (PTH) (1-34)4 picomols/kg/hr for one week.
62170975|NCT03117842|EXPERIMENTAL|Intervention Group|Participants in the intervention group will receive the 3 text or voice messages weekly. The messages will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support.
62170976|NCT03117842|NO_INTERVENTION|Control Group|"Those in the control group will get one check-in text or voice message between baseline and midline and another between midline and endline."
62170977|NCT01905293|EXPERIMENTAL|100% portion size|100% portion size condition
62170978|NCT01905293|EXPERIMENTAL|150% portion size|150% portion size condition
62363818|NCT05739240|OTHER|3D model|
62363819|NCT02172846|EXPERIMENTAL|Treatment (PBT, paclitaxel, and carboplatin)|"CHEMORADIATION THERAPY:~* PBT daily 5 days a week over 3 weeks for a total of 15 fractions~* Paclitaxel intravenously (IV) over 1 hour weekly for 3 weeks~* Carboplatin intravenously (IV) over 30 minutes weekly for 3 weeks.~CONSOLIDATION CHEMOTHERAPY (B=beginning 4-6 weeks after completion of radiation therapy, patients may receive):~* Paclitaxel IV over 1 hour on day 1~* Carboplatin IV over 30 minutes on day 1~* At the discretion of the treating physician~* Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
62170979|NCT01905293|EXPERIMENTAL|200% portion size|200% portion size condition
62170980|NCT03224689|EXPERIMENTAL|PEEK Femoral|Subjects with a primary diagnosis of end-stage symptomatic primary knee osteoarthritis who require a uni-lateral knee prosthesis and have been evaluated as appropriate candidates for a total knee arthroplasty by the Investigator will be invited to take part in this clinical investigation.
62170981|NCT01706393|EXPERIMENTAL|probiotics|"Probiotics supplementation group. Probiotics intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.~Probiotics is composed of Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium lactis, L. rhamnosus, B. longum and B. bifidum."
62170982|NCT01706393|PLACEBO_COMPARATOR|placebo|"Placebo group. Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.~Placebo is composed of starch.Probiotics and placebo were similar in appearance, taste."
62170983|NCT02200029|EXPERIMENTAL|Ademetionine IV|
62170984|NCT02200029|EXPERIMENTAL|Ademetionine oral|
62170985|NCT05166785|ACTIVE_COMPARATOR|In-person Diabetes Prevention Program (DPP)|Participants randomized to the in-person DPP intervention for 12 months
62170986|NCT05166785|ACTIVE_COMPARATOR|DPP program Tailored for Older Adults and delivered via Telehealth (DPP-TOAT arm)|Participants randomized to the DPP program Tailored for Older Adults and delivered via Telehealth (DPP-TOAT arm) intervention for 12 months.
62170987|NCT02521025|EXPERIMENTAL|Intermittent feeding|Intermittent feeding pattern throughout the bedrest period, with 4 boluses per day
62170988|NCT02521025|EXPERIMENTAL|Continuous feeding|Continuous feeding pattern throughout the bedrest period, with 4 boluses per day, without breaks in food supply.
62170989|NCT02933996|EXPERIMENTAL|TEAS+GA group|"The patients of TEAS+GA group will receive TEAS therapy in perioperative period.~GA: general anesthesia"
62170990|NCT02933996|SHAM_COMPARATOR|Sham TEAS+GA group|The patients of Sham TEAS+GA will receive none TEAS in perioperative period.
62170991|NCT02813447|ACTIVE_COMPARATOR|Pulmonary Rehab + Study Drug|Subjects randomized into this arm will be given active study drug (sertraline). Subjects will take 25mg tablets by mouth daily starting at visit 1 along with participating in the intensive pulmonary rehab program. Subjects will be assessed at one week intervals +/- 7 days for tolerability and side effects, and if tolerating study drug, the dose will be increased weekly by 25mg over the course of the first four weeks with maximum effective dose of 100mg daily by the end of week four. Subjects will continue this dose over the course of the remaining 8 weeks of the study, while participating in the graduate program of pulmonary rehab.
62170992|NCT02813447|PLACEBO_COMPARATOR|Pulmonary Rehab + Placebo|Subjects randomized to the placebo arm will have the same procedures as described above in the study drug arm with the exception that they will be receiving matched placebo drug.
62170993|NCT00674258|EXPERIMENTAL|B|
62170994|NCT05478720|EXPERIMENTAL|Dose escalation in healthy Malawian adults - 0.1 mg/kg IV DON|The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
62170995|NCT05478720|EXPERIMENTAL|Dose escalation in healthy Malawian adults - 1.0 mg/kg IV DON|The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
62170996|NCT05478720|EXPERIMENTAL|Dose escalation in healthy Malawian adults - 5.0 mg/kg IV DON|The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
62170997|NCT05478720|EXPERIMENTAL|Dose escalation in healthy Malawian adults - 10.0 mg/kg IV DON|The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
62170998|NCT05478720|EXPERIMENTAL|Dose escalation in Malawian adults with uncomplicated malaria - 0.1 mg/kg IV DON|The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
62170999|NCT05478720|EXPERIMENTAL|Dose escalation in Malawian adults with uncomplicated malaria - 1.0 mg/kg IV DON|The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
62171000|NCT05478720|EXPERIMENTAL|Dose escalation in Malawian adults with uncomplicated malaria - 5.0 mg/kg IV DON|The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
62363820|NCT02177812|EXPERIMENTAL|Dose Escalation Phase (Part 1)|The safety and PK/PD data will be reviewed prior to the dose decision, and the dose escalation will be guided by the Neuenschwander -continuous reassessment method (N-CRM).The dose escalation will complete when RP2D is determined. The RP2D will be the MTD or a lower dose that provides adequate PK exposure and biologic activity with superior tolerability.
62171001|NCT05478720|EXPERIMENTAL|Dose escalation in Malawian adults with uncomplicated malaria - 10.0 mg/kg IV DON|The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
62171002|NCT05478720|EXPERIMENTAL|Dose escalation in Malawian children with cerebral malaria - 0.1 mg/kg IV DON - Cohort 1|After adult doses are shown to be safe. The first 6 children with cerebral malaria enrolled will receive 0.1 mg/kg IV DON, and 2 will receive placebo.
62171003|NCT05478720|EXPERIMENTAL|Dose escalation in Malawian children with cerebral malaria - 0.1 mg/kg IV DON - Cohort 2|10 participants will receive 0.1 mg/kg IV DON, and 2 will receive placebo.
62363821|NCT02177812|EXPERIMENTAL|Expansion Phase (Part 2)|Once the MTD and/or RP2D has been determined in Part 1, an expansion cohort of up to 30 subjects will be enrolled in order to characterize the clinical activity and safety profile of the RP2D. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, or withdrawal of consent.
62363822|NCT00826488|OTHER|observational|Observational
62363823|NCT00650312|EXPERIMENTAL|1|Metformin Hydrochloride ER Tablets 500 mg
62363824|NCT00650312|ACTIVE_COMPARATOR|2|Glucophage® XR Tablets 500 mg
62363825|NCT05718453|ACTIVE_COMPARATOR|COPD patients|It is about 60 patients with Stable COPD
62363826|NCT05718453|ACTIVE_COMPARATOR|Acute exacerbation COPD|It is about 40 patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).
62363827|NCT05718453|PLACEBO_COMPARATOR|healthy controls|It is about 40 healthy controls were included in the study
62363828|NCT01160861|EXPERIMENTAL|A|
62363829|NCT01160861|EXPERIMENTAL|B|
62363830|NCT01160861|EXPERIMENTAL|C|
62363831|NCT05645653|EXPERIMENTAL|Educational treatment|The medication self-management intervention consists of three face-to-face education sessions and two weekly telephone follow-up over 6 weeks. Intervention components are derived from an extensive review of the literature, including the related theoretical framework and current practice. Based on the extended IMB model of medication adherence, this intervention is designed to offer information related to medication treatment, motivate patients to adhere, help build medication self-management skills, and develop adherence improvement plans. The face-to-face meeting will take place in the clinical nurse specialist counselling room in NCCCR.
62171004|NCT05478720|EXPERIMENTAL|Dose escalation in Malawian children with cerebral malaria - 1.0 mg/kg IV DON - Cohort 3|14 participants will receive 0.1 mg/kg IV DON, and 4 will receive placebo.
62171005|NCT05478720|EXPERIMENTAL|Dose escalation in Malawian children with cerebral malaria - 1.0 mg/kg IV DON - Cohort 4|28 participants will receive 0.1 mg/kg IV DON or1.0 mg/kg IV DON (n=TBD), and 8 will receive placebo.
62171006|NCT05478720|PLACEBO_COMPARATOR|Dose escalation in Malawian children with cerebral malaria - placebo|Cohort 1 will dose 2 participants to receive placebo Cohort 2 will dose 2 participants to receive placebo Cohort 3 will dose 4 participants to receive placebo Cohort 4 will dose 8 participants to receive placebo
62171007|NCT01126879|EXPERIMENTAL|Arm I|Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
62171008|NCT01126879|PLACEBO_COMPARATOR|Arm II|Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
62171009|NCT05724719||Unprovoked First Seizure (UFS)|Participants will undergo cognitive screening assessment, MRI imaging and EEG (if not already done) within 2-4 weeks of the initial First seizure clinic visit. Seizure recurrence will be monitored by a diary provided to each participant with details of the research team to contact in the event of a seizure. A researcher via perform telephone reminders at 3, 6, 9 and 12 months following the seizure. The primary outcome will be seizure recurrence at 12 months.
62171010|NCT05724719||Healthy Controls|Healthy control participants will complete the same neuropsychological battery, MRI scans and EEG protocols to evaluate baseline level of impairment in a healthy population and for the group comparisons of UFS to healthy controls to establish the changes already present at initial presentation with UFS.
62171011|NCT00515281|PLACEBO_COMPARATOR|INO Control (Short iNO)|INO will be given to infants in the control group for the first 7 days of the study gas, then O2 or room air, as clinically appropriate, on the 8th day, until 33 weeks corrected age
62171012|NCT00515281|EXPERIMENTAL|INO Treatment (Long iNO)|The treatment group will receive iNO, combined with O2 or room air, until 33 weeks corrected age.
62171013|NCT05144438||Pregnant women or woman in desire for conception|Towseek test : hair taking different questionnaires : environmental questionnaire, compliance questionnaire
62171014|NCT05693480|EXPERIMENTAL|Intervention Group|Older adults with zero time of falls in the past twelve months will be treated as the reference group. Older adults with at least one time of falls in the past twelve months will use the device to assess their balance ability by attending three rounds of the tests.
62171015|NCT03524547|EXPERIMENTAL|J-shaped|Endotracheal tube will be molded into a J-shape that is similar to that of Macintosh type blade of a McGrath MAC® videolaryngoscope.
62171016|NCT03524547|ACTIVE_COMPARATOR|60-degrees|Endotracheal tube will be bent 60 degrees.
62171017|NCT03341754|EXPERIMENTAL|Group 1 (D/ChAd63-CA)|"(2-antigen): 3 doses at 4 week intervals (Week 0, 4, and 8) of DNA prime with D-C + D-A at 2 mg total (1 mg per construct) per dose as two 1 mL IM injections of the blended D-CA, one in each arm, via Biojector 2000 needle-free injection device or an equivalent disposable syringe needle-free injection device. This will be followed after 16 weeks (Week 24) by 1 dose of ChAd63-C + ChAd63-A boost, at a total dose of 1 x 1011 virus particles (vp) (5 x 1010 vp/construct) as a single IM injection of 0.65mL, using a needle and syringe.~Week 0 = Prime with D-CA Week 4 = Prime with D-CA Week 8 = Prime with D-CA Week 24 = Boost with ChAd63-CA Week 28 = Controlled Human Malaria Infection (CHMI)"
62171018|NCT03341754|EXPERIMENTAL|Group 2 (D/ChAd63-CAT)|"(3-antigen): 3 doses at 4 week intervals (Week 0, 4, and 8) of DNA prime with D-C + D-A + D-T at 3 mg total (1 mg per construct) per dose as two 1 mL intramuscular (IM) injections of the blended D-CAT, one in each arm, via Biojector 2000 needle-free injection device or an equivalent disposable syringe needle-free injection device. This will be followed after 16 weeks (Week 24) by 1 dose of ChAd63-C + ChAd63-A + ChAd63-T boost, at a total dose of 1.5 x 1011 vp (5 x 1010 vp/construct) as a single IM injection of 1.0mL, using a needle and syringe.~Week 0 = Prime with D-CAT Week 4 = Prime with D-CAT Week 8 = Prime with D-CAT Week 24 = Boost with ChAd63-CAT Week 28 = Controlled Human Malaria Infection (CHMI)"
62171019|NCT03341754|ACTIVE_COMPARATOR|Infectivity Control (IC)|"Subjects will be exposed to the bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.~Week 28 = Controlled Human Malaria Infection (CHMI)"
62171020|NCT05065892|EXPERIMENTAL|Hypertension group|Hypertension group will enroll 330 subjects with hypertension (aged 60 years or older).
62171021|NCT05065892|EXPERIMENTAL|Diabetes Mellitus group|Diabetes group will enroll 330 subjects with diabetes (aged 60 years or older).
62171022|NCT05065892|EXPERIMENTAL|Combined Disease group|Combined Diseases group will enroll 300 subjects with both hypertension and diabetes (aged 60 years or older).
62171023|NCT05065892|ACTIVE_COMPARATOR|Healthy people group|Healthy people group will enroll 480 subjects with no medical history of hypertension or diabetes (aged 60 years or older).
62171024|NCT05240664|EXPERIMENTAL|ACP intervention|It is a theory-driven ACP programme specifically designed for PWEDs and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model.
62171025|NCT05240664|PLACEBO_COMPARATOR|Attention-control health talks|Dyads of participants in the control group will receive health talks. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants.
62171026|NCT05109117|EXPERIMENTAL|Test Arm|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg/centimeter\^2) of ChapStick Active Performance (CAP) Unscented will be applied to the assigned test site using a fingercot. The test product will be evenly spread over the test site using light pressure.
62171027|NCT05109117|NO_INTERVENTION|Control Arm|No treatment will be applied to the assigned control site.
62171028|NCT02832219|EXPERIMENTAL|Molecular hydrogen|Molecular hydrogen, tablet, 2 g/day, 4 weeks
62171029|NCT02832219|PLACEBO_COMPARATOR|Placebo|Cellulose, tablet, 2 g/day, 4 weeks
62171030|NCT06207084|EXPERIMENTAL|asynchronous exercise responder|Individuals only receiving asynchronous exercise content and are responding
62363832|NCT05645653|NO_INTERVENTION|Standard Care|Participants in the control group will continue to receive standard care from Physicians, nurses, and clinical pharmacists in the NCCCR. Physicians are the primary providers and coordinators of care for patients with chronic conditions. Physicians provide patients consultations and education regarding their diseases and treatments (typically clinician-centred) at each patient visit to the chronic disease clinic.
62171031|NCT06207084|EXPERIMENTAL|Asynchronous exercise and health coaching responder|Individuals receiving asynchronous exercise content and health coaching and are responding
62171032|NCT06207084|EXPERIMENTAL|Asynchronous exercise non-responder and 1 on 1 live training|Individuals receiving asynchronous exercise content and are not responding. The are receiving 1 on 1 live exercise sessions.
62171033|NCT06207084|EXPERIMENTAL|Asynchronous exercise and health coaching non-responder and 1 on 1 live training|Individuals receiving asynchronous exercise content and health coaching and are not responding. The are receiving 1 on 1 live exercise sessions.
62171034|NCT06207084|EXPERIMENTAL|Asynchronous exercise non-responder and group live training|Individuals receiving asynchronous exercise content and are not responding. The are receiving group live exercise sessions.
62171035|NCT06207084|EXPERIMENTAL|Asynchronous exercise and health coaching non-responder and group live training|Individuals receiving asynchronous exercise content and health coaching and are not responding. The are receiving group live exercise sessions.
62171036|NCT04402632|ACTIVE_COMPARATOR|Surgery Cohort: Control Arm|Control
62171037|NCT04402632|EXPERIMENTAL|Surgery Cohort: Treatment Arm|Treatment
62171038|NCT04402632|ACTIVE_COMPARATOR|Observational Cohort: Control Arm|Control
62171039|NCT04402632|EXPERIMENTAL|Observational Cohort: Treatment Arm|Treatment
62171040|NCT04973332|EXPERIMENTAL|Thrombectomy-SINOMED SR|Patients diagnosed with acute ischemic stroke within 24 hours from the onset of the stroke to the completion of femoral artery puncture, regardless of whether intravenous thrombolysis has been performed. Intracranial thrombectomy stents can be used to remove the thrombus in the large vessels of the brain in patients with ischemic stroke To restore blood flow.
62171041|NCT04973332|ACTIVE_COMPARATOR|Thrombectomy-Solitaire FR|Intracranial thrombectomy was performed with a control product（name:Solitaire FR）
62171042|NCT05765838|EXPERIMENTAL|Sequence for upper airway specimen collection (NPS right - Nasal swab left - OPS)|"1 NPS right - Nasal swab left - OPS~NPS = nasopharyngeal swab OPS = oropharyngeal swab"
62171043|NCT05765838|EXPERIMENTAL|Sequence for upper airway specimen collection (NPS left - Nasal swab right - OPS)|2 NPS left - Nasal swab right - OPS
62171044|NCT05765838|EXPERIMENTAL|Sequence for upper airway specimen collection (Nasal swab right - NPS left - OPS)|3 Nasal swab right - NPS left - OPS
62171045|NCT05765838|EXPERIMENTAL|Sequence for upper airway specimen collection (Nasal swab left - NPS right - OPS)|4 Nasal swab left - NPS right - OPS
62171046|NCT05765838|EXPERIMENTAL|Sequence for upper airway specimen collection (NPS right - OPS - Nasal swab left)|5 NPS right - OPS - Nasal swab left
62171047|NCT05765838|EXPERIMENTAL|Sequence for upper airway specimen collection (NPS left - OPS - Nasal swab right)|6 NPS left - OPS - Nasal swab right
62171048|NCT05765838|EXPERIMENTAL|Sequence for upper airway specimen collection (Nasal swab right - OPS - NPS left)|7 Nasal swab right - OPS - NPS left
62171049|NCT05765838|EXPERIMENTAL|Sequence for upper airway specimen collection (Nasal swab left - OPS - NPS right)|8 Nasal swab left - OPS - NPS right
62171050|NCT05765838|EXPERIMENTAL|Sequence for upper airway specimen collection (OPS - NPS right - Nasal swab left)|9 OPS - NPS right - Nasal swab left
62171051|NCT05765838|EXPERIMENTAL|Sequence for upper airway specimen collection (OPS - NPS left - Nasal swab right)|10 OPS - NPS left - Nasal swab right
62171052|NCT05765838|EXPERIMENTAL|Sequence for upper airway specimen collection (OPS - Nasal swab left - NPS right)|11 OPS - Nasal swab left - NPS right
62171053|NCT05765838|EXPERIMENTAL|Sequence for upper airway specimen collection (OPS - Nasal swab right - NPS left)|12 OPS - Nasal swab right - NPS left
62171054|NCT04449133|EXPERIMENTAL|Treatment Group 1|AD128 for 7 days, then, after a wash-out period of 7-10 days, placebo for 7 days
62171055|NCT04449133|EXPERIMENTAL|Treatment Group 2|Placebo for 7 days, then, after a wash-out period of 7-10 days, AD128 for 7 days
62171056|NCT01945255||HD-ABI|"1. Patients at National Taiwan University Hospital (NTUH)~2. Patients who have received PD more than 3 months~3. Patients who sign the informed consents~4. Patients who aged between 20-90 years"
62171057|NCT00793299|EXPERIMENTAL|Video Illness Narrative|single arm pilot study
62171058|NCT02871063||High altitude ARDS|ARDS diagnosed at altitudes greater than 1500 meters above sea level
62171059|NCT02871063||Sea level ARDS|ARDS diagnosed at altitudes below 1500 meters above sea level
62171060|NCT02503306|EXPERIMENTAL|Avanafil dose 1|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
62171061|NCT02503306|EXPERIMENTAL|Avanafil dose 2|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
62171062|NCT02503306|PLACEBO_COMPARATOR|Placebo|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
62171063|NCT02246634|EXPERIMENTAL|Diffusion Weighted MRI scan|Patients who are enrolled in the study will undergo an additional diffusion weighted MRI (T2W, DWI and ADC sequences) of the liver.
62171064|NCT03529084|EXPERIMENTAL|EGF816|Investigational treatment arm of EGF816 (nazartinib).
62171065|NCT03529084|ACTIVE_COMPARATOR|Investigator's Choice|Investigator's Choice (erlotinib or gefitinib).
62171066|NCT01567670|ACTIVE_COMPARATOR|Naloxone|nasal spray before binging, naloxone dose 2 mg, maximum daily dose 4 mg
62171067|NCT01567670|PLACEBO_COMPARATOR|nasal spray|nasal placebo (h2o) spray before binging, max sprays / day
62171068|NCT02924558|EXPERIMENTAL|Egg protein/unsaturated fatty acid|8% higher protein energy (from egg protein) and 8% higher fat energy (from unsaturated fatty acids); approximately 42/23/35% kcal from carbohydrate/protein/fat, respectively
62171069|NCT02924558|PLACEBO_COMPARATOR|Control|16% higher carbohydrate energy; approximately 58/15/27% kcal from carbohydrate/protein/fat, respectively
62171070|NCT03198416|EXPERIMENTAL|Investigational Device|Consented participants who meet eligibility will have a drug induced sleep endoscopy (DISE) with the Solar GI High Resolution pharyngeal Manometry system.
62171071|NCT03443752|EXPERIMENTAL|Shotokan-Karate|The protocol for Shotokan-karate training will involve a one hour training session which will be broken down into 3 major components. The training program will consist of warm-up exercises, katas (choreographed karate movements), and cool-down exercise.
62171072|NCT03443752|EXPERIMENTAL|Tai-Chi|The protocol for Tai Chi will involve a one-hour training session which will be conducted by an instructor at the Sun Life Financial Movement Disorders and Rehabilitation Centre.The following program will be held three times per week.
62171073|NCT04744688||48 cytoreductive surgery with HIPEC patients|48 patients with peritoneal metastases from colorectal cancer undergoing cytoreductive surgery with HIPEC (cytoreductive surgery with HIPEC patients)
62171074|NCT04744688||48 minimally invasive patients|48 rectal cancer patients undergoing minimally invasive rectal cancer resection
62171075|NCT06047379|EXPERIMENTAL|Phase 2a Safety Run-In - NEO212 and Ipilimumab|"- Unresectable or metastatic melanoma with uncontrolled metastases to the brain.~NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.~Ipilimumab - 3 mg/kg administered IV over 90 minutes every 3 weeks for a maximum of 3 doses per package insert."
62171076|NCT06047379|EXPERIMENTAL|Phase 2a Safety Run-In - NEO212 and Pembrolizumab|"The following primary cancers with uncontrolled metrastases to the brain:~* Unresectable or metastatic melanoma.~* NSCLC expressing PD-L1, with no EGFR or ALK genomic tumor aberrations.~* Metastatic NSCLC whose tumors express PD-L1.~* EGFR or ALK genomic tumor aberrations must have disease progression.~* SCLC.~* Unresectable, recurrent HNSCC whose tumors express PD-L1.~* HNSCC on or after platinum-containing chemotherapy.~* Urothelial carcinoma whose tumors express PD-L1.~* Urothelial carcinoma.~* Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).~* Microsatellite Instability-high or Mismatch Repair Deficient Colorectal Cancer (CRC).~* Gastric or gastroesophageal junction adenocarcinoma.~* Esophageal or gastroesophageal juncUon (GEJ).~* Cervical cancer.~* Merkel cell carcinoma.~NEO212 - Same as Arm 1.~Pembrolizumab - 200 mg administered every 3 weeks per package insert."
62171077|NCT06047379|EXPERIMENTAL|Phase 2a Safety Run-In - NEO212 and Nivolumab|"The following primary cancers with uncontrolled metrastases to the brain:~* Unresectable or metastatic melanoma.~* Metastatic non-small cell lung cancer.~* Advanced renal cell carcinoma.~* Squamous cell carcinoma of the head and neck.~* Urothelial carcinoma.~* Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.~* Unresectable esophageal squamous cell carcinoma (ESCC).~NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.~Nivolumab - 240 mg administered every 2 weeks per package insert"
62171078|NCT06047379|EXPERIMENTAL|Phase 2a Safety Run-In - NEO212 and Stivarga (Regorafenib)|"- Colorectal cancer (CRC) with uncontrolled metastases to the brain who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anU-EGFR therapy.~NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.~Stivarga - 160 mg orally, once daily for the first 21 days of each 28-day cycle per package insert"
62171079|NCT06047379|EXPERIMENTAL|Phase 2a Safety Run-In - NEO212 and CarbolaUn (ParaplaUn) + Paclitaxel (Taxol)|"- Colorectal cancer (CRC) with uncontrolled metastases to the brain.~NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.~Carboplatin - 300 mg/m2 IV on day 1 every 4 weeks for 6 cycles per package insert.~Paclitaxel - 135mg/m2 IV administered over 24 hours, every 3 weeks per package insert."
62171080|NCT06047379|EXPERIMENTAL|Phase 2a Safety Run-In - NEO212 and FOLFIRI (Zaltrap) + Bevacizumab (Avastin)|"- Metastatic colorectal cancer (mCRC) with uncontrolled metastases to the brain, that is resistant to or has progressed following an oxaliplatin-containing regimen~NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.~FOLFIRI - 4 mg/kg aIV over 1 hour every 2 weeks.~Bevacizumab - 10 mg/kg IV every 2 weeks."
62171081|NCT06047379|EXPERIMENTAL|Phase 2b efficacy - NEO212 for Astrocytoma IDH-mutant and Glioblastoma IDH-wildtype|"Patients receiving NEO212 alone for treatment of Astrocytoma IDH-mutant and Glioblastoma IDH-wildtype.~NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules."
62171082|NCT06047379|EXPERIMENTAL|Phase 2b efficacy - NEO212 & SOC for Uncontrolled Metastases to the Brain|"Patients receiving NEO212 in combination with select standard of care treatments for treatment of uncontrolled metastases to the brain.~NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.~SOC treatments established to be safe in Phase 2a of the study will be used in this arm of Phase 2b."
62171083|NCT02739490|NO_INTERVENTION|Group control|It does not perform any kind of guided exercise.
62171084|NCT02739490|EXPERIMENTAL|Core Training Group|The training was distributed in four positions defined ventral plank, side plank left, right side board and bridge semiflexion knees, respectively. With time isometric contraction of 30 seconds repeated four times with rest 30 seconds between repetitions. During 10 sessions distributed twice weekly.
62171085|NCT03053661||primary surgery + adj. C)RT|treatment naive patients to be treated by conventional primary surgery followed by adjuvant (chemo-)radiotherapy with curative intent
62171086|NCT03053661||primary chemoradiation|treatment naive patients to be treated by conventional primary chemoradiotherapy with curative intent
62171087|NCT02261285|EXPERIMENTAL|ONO-4538 1mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 1mg/kg, single dose
62171088|NCT02261285|EXPERIMENTAL|ONO-4538 3mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 3mg/kg, single dose
62171089|NCT02261285|EXPERIMENTAL|ONO-4538 10mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 10mg/kg, single dose
62363833|NCT03656666|ACTIVE_COMPARATOR|Apremilast|"Week 0-24: 21 patients will receive apremilast oral tablets with initial standard titration of dose day 1-6 followed by standard dose of 30 mg apremilast b.i.d.~Initial titration:~Day 1: 10 mg in morning. Day 2: 10 mg in morning and 10 mg in evening. Day 3: 10 mg in morning and 20 mg in evening. Day 4: 20 mg in morning and 20 mg in evening. Day 5: 20 mg in morning and 30 mg in evening. Day 6 and thereafter: 30 mg twice daily."
62363834|NCT03656666|PLACEBO_COMPARATOR|Placebo + Apremilast|Week 0-24: 21 patients will receive matching placebo oral tablets, with initial titration.
62171090|NCT06095154|EXPERIMENTAL|Experimental Group|GTVp (70Gy/33Fx): Gross tumor as seen on imaging and nasopharyngoscopy. CTVp1 (60Gy/33Fx): GTVp + 5 mm. CTVp2 (54Gy/33Fx): GTVp + 10 mm + entire nasopharyngeal mucosa. GTVn: Lymph nodes as seen on imaging. CTVn: Defined according to CACA/CMDA guidelines.
62171091|NCT06095154|NO_INTERVENTION|Control Group|GTVp (70Gy/33Fx): Gross tumor as seen on imaging and nasopharyngoscopy. CTVp1 (60Gy/33Fx): GTVp + 5 mm + entire nasopharyngeal mucosa. CTVp2 (54Gy/33Fx): GTVp + 10 mm + high-risk anatomical structures. GTVn: Lymph nodes as seen on imaging. CTVn: Defined according to CACA/CMDA guidelines.
62171092|NCT02825719|EXPERIMENTAL|Ulipristal|Patients will be prescribed Ulipristal acetate 5mg daily for 12 weeks before operation. If the patients have anaemia with haemoglobin less than 10g/dL, ferrous sulphate 300mg three times a day will be prescribed as well. Tranexamic Acid 500mg four times a day will be prescribed on request basis.
62171093|NCT02825719|PLACEBO_COMPARATOR|Placebo|Patients will be prescribed placebo pills daily for 12 weeks before operation. If the patients have anaemia with haemoglobin less than 10g/dL, ferrous sulphate 300mg three times a day will be prescribed as well. Tranexamic Acid 500mg four times a day will be prescribed on request basis.
62171094|NCT04893785|EXPERIMENTAL|Cabozantinib and Temozolomide|"All patients will receive:~* Cabozantinib 40 mg os QD~* Temozolomide 100 mg/m2/day seven days followed by seven days of stop (regimen one week on / one week off)."
62171095|NCT05970783|EXPERIMENTAL|Jincaopian Tablets group|Patients receive Jincaopian Tablets 0.6g/day for 12 weeks.
62171096|NCT05970783|PLACEBO_COMPARATOR|Placebo group|Patients receive a placebo 0.6g/day for 12 weeks.
62171097|NCT04031547|ACTIVE_COMPARATOR|Active tES-fMRI|
62171098|NCT04031547|SHAM_COMPARATOR|Inactive/Sham tES-fMRI|
62171099|NCT06135779|EXPERIMENTAL|A Lust for Life programme group|A Lust for Life programme will be delivered to participants by their class teachers in ten weekly sessions
61986133|NCT02608268|EXPERIMENTAL|Phase Ib Dose Escalation: MBG453 Q4W + PDR001 Q4W|Sabatolimab Q4W in combination with spartalizumab Q4W in Phase Ib Dose Escalation Part
61986134|NCT02608268|EXPERIMENTAL|Phase Ib Dose Escalation: MBG453 + Decitabine|Sabatolimab in combination with decitabine in Phase Ib Dose Escalation Part. This arm was not opened for enrollment.
61986135|NCT02608268|EXPERIMENTAL|Dose Ranging Part: MBG453 Q4W|Sabatolimab Q4W in Dose Ranging Part
61986136|NCT02608268|EXPERIMENTAL|Phase II: MBG453 + PDR001|Sabatolimab Q4W in combination with spartalizumab Q4W in non-small cell lung carcinoma (NSCLC) and melanoma
61986137|NCT02608268|EXPERIMENTAL|Phase II: MBG453|Sabatolimab alone in Phase II. This arm was not opened for enrollment.
62171100|NCT06135779|OTHER|Waiting list control group|Participants will receive curriculum as usual from their class teacher, and placed on a 12-week waiting list for the programme.
62171101|NCT05289375|ACTIVE_COMPARATOR|Test group (T)|Group formed by those patients who will receive the drug to be tested Vacucis
61986138|NCT05632549|PLACEBO_COMPARATOR|Placebo|Group 1 (n=22) which will receive traditional therapy plus placebo capsule twice daily for 3 months.
62171102|NCT05289375|PLACEBO_COMPARATOR|Placebo control group (P)|Group formed by those patients who will receive placebo, in the same dosage and duration
62171103|NCT06645873|EXPERIMENTAL|Continuous glucose monitoring|
62171104|NCT05517265||first-line therapy|Patients enrolled for first-line acalabrutinib (+/- obinutuzumab).
62171105|NCT05517265||later-line therapy|Pre-treated patients enrolled for later-line acalabrutinib therapy.
62171106|NCT04365738|EXPERIMENTAL|Pulmonary Rehabilitation|The patients who applied pulmonary rehabilitation were checked, motivated and followed-up regularly with video calls every day. Pulmonary rehabilitation program consists of patient education, breathing, in-house mobilization and range of motion exercises.
61986139|NCT05632549|EXPERIMENTAL|L-carnitine|Group 2 (n=22) which will receive traditional therapy plus L-carnitine capsules (500 mg twice daily) for 3 months.
61986140|NCT05632549|EXPERIMENTAL|Biotin|Group 3 (n=22) which will receive traditional therapy plus Biotin capsules (5 mg twice daily) for 3 months.
61986141|NCT05508763||PGx-guided dosing|This group will be genotyped for 14 pharmacogenes at the start of the study.
61986142|NCT05508763||Standard of care|This group will be genotyped for 14 pharmacogenes at the end of the study.
62171107|NCT04365738|PLACEBO_COMPARATOR|Control|As a patient education, information was given about the disease and treatment process, listening to the patient during this process and getting regular sleep, balanced nutrition and taking a break from smokers.
62171108|NCT04203199|EXPERIMENTAL|First H1 coil, then H7 coil|There will be 1 screening and 2 TMS visits. The procedures will be identical for each TMS visit, except for the type of TMS delivered (H1 or H7 coil). Each participant will be assigned to both coils, with TMS type. Participants assigned to this arm will receive the H1 coil at TMS visit 1, H7 coil at TMS visit 2
62171109|NCT04203199|EXPERIMENTAL|First H7 coil, then H1 coil|There will be 1 screening and 2 TMS visits. The procedures will be identical for each TMS visit, except for the type of TMS delivered (H1 or H7 coil). Each participant will be assigned to both coils, with TMS type. Participants assigned to this arm will receive the H7 coil at TMS visit 1, H1 coil at TMS visit 2.
61986143|NCT02434731|EXPERIMENTAL|Buzzy® device|The Buzzy® device will be applied just above the selected site of the venipuncture; a ice pack will be attached under the device; the device will be turned on and after 15 second the procedure will be carried out.
61986144|NCT02434731|NO_INTERVENTION|No intervention|No intervention for pain relief
61986145|NCT05338411||Early or precocious puberty who receive GH|Children with early or precocious puberty who receive exogenous growth hormone
61986146|NCT05338411||Early or precocious puberty who does not receive GH|Children with early or precocious puberty who does not receive exogenous growth hormone
61986147|NCT05338411||Healthy|Healthy children without any past medical history
62171110|NCT04030988|ACTIVE_COMPARATOR|Active|50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
62363835|NCT02069249|EXPERIMENTAL|Healthy Nutrition Intervention|Healthy Nutrition Intervention (HNI)
62363836|NCT02069249|EXPERIMENTAL|Healthy Sleep Intervention|Healthy Sleep Intervention (HSI)
62171111|NCT04030988|PLACEBO_COMPARATOR|Placebo|50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
62171112|NCT05056701|EXPERIMENTAL|patient with preeclampsia|Patient meeting the preeclampsia criteria or one of its complications (eclampsia, HELLP syndrome) according to the ISSHP 2018 definitions within the last 5 years
62171113|NCT02256488|EXPERIMENTAL|TIVc-Lot A|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot A
62363837|NCT02069249|NO_INTERVENTION|Waiting list control|Waiting list control group
62171114|NCT02256488|EXPERIMENTAL|TIVc-Lot B|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot B
62171115|NCT02256488|EXPERIMENTAL|TIVc-Lot C|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot C
62171116|NCT02256488|ACTIVE_COMPARATOR|TIVf|Subjects 18 to ≤ 49 years of age who received one vaccination of Control vaccine TIVf
62171117|NCT02517476|EXPERIMENTAL|Nutritional support|For the purpose of this study, we have developed nutritional guidelines by consensus and adapted to current guidelines (e.g., ESPEN, ASPEN). These guidelines specify a reinforced nutritional therapy strategy to cover nutritional requirements, focusing on nutritional targets based on the specific nutritional diagnoses defined by the IDNT. The nutritional guidelines may vary according to important medical diagnoses (i.e. renal failure). They specify not only nutritional targets, but also escalation of the route (i.e. food fortification, oral, enteral, parenteral) if targets cannot be achieved (≤75%) every 5 hours. Nutritional goals are being assessed daily in patients in the intervention group.
62171118|NCT02517476|NO_INTERVENTION|"Usual care (appetite-guided) controls"|"In control patients, we will use conventional nutrition according to the ability and desire of the patient to eat, using standard care food provided by the hospital kitchen (appetite-guided)."
62171119|NCT02878720|EXPERIMENTAL|Robotic therapy and real tVNS|This group receives REAL vagus nerve stimulation during robotic rehabilitation.
62171120|NCT02878720|ACTIVE_COMPARATOR|Robotic therapy and sham tVNS|This group receives SHAM VNS during robotic rehabilitation. Sham VNS is not effective. Both groups receive the same amount of robotic rehabilitation.
62171121|NCT02499835|EXPERIMENTAL|Arm I (pTVG-HP plasmid DNA vaccine, concurrent pembrolizumab)|Patients receive pTVG-HP plasmid DNA vaccine ID every other week on days 1, 15, 29, 43, 57, and 71 and pembrolizumab IV over 30 minutes every 3 weeks on days 1, 22, 43, and 64.
62171122|NCT02499835|EXPERIMENTAL|Arm II (pTVG-HP plasmid DNA vaccine, sequential pembrolizumab)|Patients receive pTVG-HP plasmid DNA vaccine ID as in Arm I and pembrolizumab IV over 30 minutes every 3 weeks on days 85, 106, 127, and 148.
62171123|NCT02499835|EXPERIMENTAL|Extended Treatment Arm III|pTVG-HP (100 μg) with rhGM-CSF (208 μg) administered intradermally (i.d.) every 3 weeks, for a maximum of 16 doses. Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 3 weeks, for a maximum of 16 doses, beginning on day 1 after the first pTVG-HP vaccination.
62171124|NCT02499835|EXPERIMENTAL|Extended Treatment Arm IV|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) every 2 weeks, for a maximum of 24 doses Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 4 weeks, for a maximum of 12 doses, beginning on day 1 after the first pTVG-HP vaccination
62171125|NCT06540248||61 patients evaluated|with IC/BPS (n=48), rUTI (n=6) and mixed /other diagnoses (including OAB; n= 7)
62171126|NCT05648136|EXPERIMENTAL|patients|"* Women aged 18 to 39 years~* with a history of RIF or unexplained RM~* with a negative diagnostic work-up (including pelvic ultrasound and hysteroscopy, parental karyotype, thyroid function test, and anti-thyroid and anti-phospholipid antibodies)~* with a basal FSH level \<10IU/l and AMH level \>1.5ng/ml~* with a regular menstrual cycle of 30+/-5 days~* receiving a new cycle of in vitro fertilization (IVF) +/- intracytoplasmic sperm injection (ICSI) for patients in the RIF group or a first cycle of IVF +/-ICSI for patients in the RM group~* received written and oral information and signed an informed consent"
62171127|NCT05648136|ACTIVE_COMPARATOR|control|"* Controls recruited in the Obstetrics and Gynecology Department with at least one live birth after a spontaneous pregnancy (with a time to conception of less than 12 months for each pregnancy) Voluntary oocyte donors recruited within the CECOS de Picardie (having presented at least one live birth with a delay necessary to conceive of less than 12 months)~* Controls recruited in the Reproductive Medicine and Biology Department having presented at least one live birth (spontaneous with a delay to conceive of less than 12 months for each pregnancy or after one or two MPA procedures) and benefiting from an IVF+/-ICSI procedure for secondary infertility~* Controls recruited in the department of Medicine and Reproductive Biology with a normal infertility assessment and benefiting from an IVF procedure with ICSI on male indication."
62171128|NCT05980975|EXPERIMENTAL|Coffee group (Group 1)|Then, at the 4th hour, 8th hour and 12th hour of the surgery, the patients in the coffee group received 10 gr. granulated coffee.
62171129|NCT05980975|EXPERIMENTAL|Hot water group (Group 2)|The patients in the hot water group were given 200 ml of 50-60 C0 sugar-free hot water at the 4th hour, 8th hour and 12th hour of the operation.
62171130|NCT05980975|NO_INTERVENTION|Control group (Group 3)|No application was made to the control group.
62171131|NCT05069844|EXPERIMENTAL|Gum chewing for 2 minutes|Patients will chew 1 piece of herbal sugar-free for 2 minutes and then spat it out.
62171132|NCT05069844|EXPERIMENTAL|Gum chewing for 4 minutes|Patients will chew 1 piece of herbal sugar-free for 4 minutes and then spat it out.
62171133|NCT05069844|NO_INTERVENTION|Control group|Patients will be asked to swallow 2 times only.
62171134|NCT02088723|EXPERIMENTAL|head of bed elevation|Compare the apnea hypopnea index with the patient in standard polysomnography and in elevated polysomnography (head of bed elevation)
62171135|NCT01405521|EXPERIMENTAL|M01ZH09 vaccine|
62171136|NCT01405521|PLACEBO_COMPARATOR|Vaccine placebo|
62363838|NCT03249701|EXPERIMENTAL|TEAS group|Transcutaneous Electrical Acupoint Stimulation on Neiguan, Quchi, Zusanli, Sanyinjiao. Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
62363839|NCT03249701|PLACEBO_COMPARATOR|Electroacupuncture group|Hand-needle on Neiguan, Quchi, Zusanli, Sanyinjiao.Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
62171137|NCT01405521|OTHER|Ty21a vaccine|Positive control
62171138|NCT03581253|EXPERIMENTAL|peripheral facial palsy patients|"peripheral facial palsy patients will performed questionnaires of quality of life (Facial disability Index (FDi) and Facial Clinimetric Evaluation (FaCE)"
62171139|NCT02801916|OTHER|Study subjects|Each healthy subject will receive each of the interventions in randomized order.
62363840|NCT03249701|SHAM_COMPARATOR|sham TEAS group|Sham transcutaneous electrical acupoint stimulation on Neiguan, Quchi, Zusanli, Sanyinjiao; Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
62171140|NCT06538220|EXPERIMENTAL|Obese patients|Patients suffering from obesity defined by a BMI ≥ 30 and following the Chronic Disease Unit care pathway
62171141|NCT04250181||Standard RF|ablation with RF power of 30 Watts (30W) and with 25 Watts (25W) on posterior wall
62171142|NCT04250181||High RF 40W (40 Watts)|ablation with RF power of 40 watts (40W)
62171143|NCT04250181||High RF 50W (50 Watts)|ablation with RF power of 50 watts (50W)
62171144|NCT05191186|ACTIVE_COMPARATOR|grass pollen extract treatment|participants receive 3 injections with Alutard phleum pratense, ALK, grass pollen extract
62171145|NCT05191186|PLACEBO_COMPARATOR|Placebo|Participants receive 3 injections with saline (NaCl 0.9%)
62171146|NCT04748497|OTHER|Parasportives of various disciplines|
62171147|NCT05269303|EXPERIMENTAL|Intervention group|Participants will receive a 3-month Live With Wearable Monitoring Device program.
62171148|NCT05269303|NO_INTERVENTION|Control group|Usual care. As with the participants in the intervention group, those in the control group can utilize the features in the Wearable Monitoring Device.
62171149|NCT05550077||Optical Coherence Tomography (OCT)|OCT and other classical imaging evaluation such as Transcranial Color Doppler (TCCD) and High resolution-MRI will be performed. The tailored treatment (such as anti-thrombotic management, post-dilation, et al) will be considered when specific plaque characteristics (including but not limited to in situ thrombus formation, macrocacilfication, et al), were observed under OCT.
62171150|NCT05550077||Non-Optical Coherence Tomography (N-OCT)|Classical imaging evaluation such as TCCD and High resolution-MRI will be performed, followed by standard percutaneous transluminal angioplasty and stenting.
62171151|NCT05123144|EXPERIMENTAL|Behavioral Health Screener + ORCHID Intervention (BHS+ORCHID)|"At the clinic level, sites randomized to implement BHS+ORCHID will receive training, materials, and other support to administer behavioral health screening and refer their clients with elevated depression symptoms to ORCHID.~At the individual level, those clients who are eligible and choose to enroll in ORCHID will receive self-guided training on 8 positive affect skills through weekly online sessions and daily practice exercises."
62171152|NCT05123144|NO_INTERVENTION|Standard of Care|usual care
62171153|NCT04185142||combined procedure group|patients underwent cryoballoon ablation and left atrial appendage closure
62171154|NCT03716583|EXPERIMENTAL|Melatonin/DMSO|25 mg melatonin in 1 g cream twice daily for the duration of the radiation therapy
62171155|NCT03716583|PLACEBO_COMPARATOR|Placebo|1 g of cream once daily
62363841|NCT02482740|EXPERIMENTAL|tamoxifen|tamoxifen 20 mg given everyday for 12 months
62363842|NCT02482740|ACTIVE_COMPARATOR|letrozole|letrozole 2.5 mg given everyday for 12 months
62171156|NCT02604342|EXPERIMENTAL|Alectinib|Participants will receive oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
62171157|NCT02604342|ACTIVE_COMPARATOR|Premetrexed/Docetaxel|Participants will receive chemotherapy with either pemetrexed (500 milligrams per square meter \[mg/m\^2\] of body surface area) or docetaxel (75 mg/m\^2) intravenously.
62171158|NCT04159051|EXPERIMENTAL|Combined regional hyperthermia and salvage radiotherapy|
62171159|NCT06575881||TTN-positive|Patients with a pathogenic or likely pathogenic variant in TTN on clinical genetic testing.
62171160|NCT06575881||Gene-positive|Patients with a pathogenic or likely pathogenic variant in a gene other than TTN on clinical genetic testing.
62171161|NCT06575881||Gene-negative|Patients without a pathogenic or likely pathogenic variant in a cardiomyopathy or arrhythmia gene on clinical genetic testing.
62171162|NCT00981071||A platoon with TB outbreak|
62171163|NCT01275417||adult|100 volunteers age ranged 18-80 years old
62171164|NCT01275417||children|60 children under 10 years old.
62363843|NCT04748770||patients with BMI≥30 kg/m2|
62363844|NCT04748770||patients with 25≤BMI≤30 kg/m2|
61986148|NCT04130230|EXPERIMENTAL|Neostigmine group|This arm will receive -in addition to standard therapy for sepsis and septic shock-Neostigmine methylsulfate ampoule diluted in normal saline, and administered as continuous infusion for five days. The rate of infusion is 0.2 mg/hr.
61986149|NCT04130230|PLACEBO_COMPARATOR|Standard group|This arm will receive the standard therapy for sepsis and septic shock only and followed for five days.
61986150|NCT02059850|EXPERIMENTAL|Treatment (cyclophosphamide, NY-ESO-1 specific T cells)|Patients receive cyclophosphamide IV on days -3 and -2 and NY-ESO-1 specific T cells IV over 60 minutes on day 0. Patients may receive additional infusions at the discretion of the PI.
61986151|NCT02034786|EXPERIMENTAL|Test|Adipose tissue collection and Transdermal injection of the filler agent, composed of mesenchymal stem cells derived from the autologous adipose tissue, associated with hyaluronic acid.
61986152|NCT02034786|ACTIVE_COMPARATOR|Control|Transdermal injection of hyaluronic acid only.
61986153|NCT03994692|EXPERIMENTAL|PEEK eminoplasty|"CT scan with bony window for facial bones and DICOM files on CD .then, Using cad cam software (mimics 15) , the virtual design and surgery will be done.~under general anathesia The TMJ will be exposed using the endural incision line and the articular eminence will be identified then blunt dissection so that the front wall of the articular capsule can be exposed completely.~* The patient specific PEEK eminence will be inserted and secured with two to three pre-planed screws .~* Functional mandibular movements were reproduced to confirm absence of subluxation and then closure"
61997260|NCT01194947||Study participants|patients 18 or older presenting to the Sheba Medical Center pigmented lesion clinic for skin cancer surveillance. Patients routinely undergo total skin examination that includes clinical and dermoscopic evaluation of skin lesions. Patients also routinely undergo annual total body digital photography that allows identification of new or changing lesions.
62171165|NCT06106789||Bronchiectasis|"1. Patients with a past medical history or a diagnosis of bronchiectasis in the current case;~2. Patients seen or admitted to the hospital from 1 January 2021 to 31 December 2023 (including outpatient, emergency, and inpatient);~3. Case record of at least 1 course of treatment (continuous administration for 28 days) with tobramycin inhalation solution or other antibiotic nebulisation;~4. Patients with a positive copper-green test at the first visit."
62171166|NCT06106789||Cystic fibrosis|"1. Patients with a past medical history or a diagnosis of cystic fibrosis in the current case;~2. Patients who were seen or admitted to the hospital from 1 January 2021 to 31 December 2023 (including outpatient, emergency, and inpatient);~3. Case record of at least 1 course of treatment (continuous administration for 28 days) with tobramycin inhalation solution or other antibiotic nebulisation;~4. Patients with a positive copper-green test at the first visit."
62171167|NCT06106789||Multidrug-resistant bacterial lung infections|"1. Patients with a diagnosis of pulmonary infection;~2. Patients admitted to the hospital from 1 January 2021 to 31 December 2023 (only inpatients were included);~3. Case records with completion of at least 3 days of treatment with tobramycin inhalation solution or other antibiotic nebulisation;~4. The patient tested positive for pathogens at least once during the period of medication."
62171168|NCT05204316|EXPERIMENTAL|Participants|Participants will provide spoken narratives on their headache disorder
62171169|NCT06643052||Before calculator|Newborn infants before assimilation of EOS calculator
62171170|NCT06643052||With calculator|Newborn infants after assimilation of EOS calculator
62171171|NCT02745314||>74 years|Older than 74 year-old patients
62171172|NCT04838145|ACTIVE_COMPARATOR|Active treatment|Pleconaril: 5 mg/kg x2 times a day for 26 weeks up to 40 kg. Max dose 300mg x2. Ribavirin:15 (7.5) mg/kg/day divided in two doses daily for 26 weeks: Max dose 1000mg/24h if body weight\<75kg and 1200mg if body weight\>75kg.
62171173|NCT04838145|PLACEBO_COMPARATOR|Placebo|Receives placebo, on a double blind basis
62171174|NCT05647109||Set of training|A total of 148 patients with endometrial cancer and atypical endometrial hyperplasia were included in the training set of the prediction model. They were divided into progesterone sensitive group and progesterone insensitive group.
62171175|NCT05647109||Set of verification|A verification set of the prediction model was established, consisting of 96 patients with endometrial cancer and atypical endometrial hyperplasia.
62171176|NCT03393065|EXPERIMENTAL|intervention group pulmonary congestion|in the intervention group pulmonary congestion, as assessed by the BLS will guide the diuretic and fluid management, with a target of below 15 BLS. Furthermore, in the active arm, in the patients who will require a renal replacement therapy (RRT), BLS will be used to further guide the dialysis fluid prescription.
62171177|NCT03393065|NO_INTERVENTION|Control group|control group the fluid management will not be LUS guided
62171178|NCT05087797|EXPERIMENTAL|nicorandil group|
62171179|NCT05087797|NO_INTERVENTION|control group|
62171180|NCT02467049|ACTIVE_COMPARATOR|ECG-guided insertion of PICC|Placement of the PICC (Peripherally Inserted Central Catheter ) ECG-guided insertion.
62171181|NCT02467049|EXPERIMENTAL|ULTRASOUND-guided insertion of PICC|Placement of the PICC (Peripherally Inserted Central Catheter ) ULTRASOUND-guided.
62171182|NCT04346433|EXPERIMENTAL|Adolescents with Normal Weight|This group will be comprised of 30 adolescents with normal weight (BMI equal to or greater than the 5th percentile but less than the 85th percentile). Participants will be asked to engage in the sleep manipulation intervention.
62171183|NCT04346433|EXPERIMENTAL|Adolescents with Overweight or Obesity|This group will be comprised of 30 adolescents with overweight or obesity (BMI equal to or above the 85th percentile). Participants will be asked to engage in the sleep manipulation intervention.
62171184|NCT03325608|EXPERIMENTAL|POISED Care|Dyads randomized to the POISED Care intervention will work with the POISED care management team - consisting of specially-trained nurses functioning as care managers (CMs) and para-professionals in the role of care manager assistants (CMAs) - to create an individualized care plan through the lens of cognitive impairment with an emphasis on coordinating care with the patient's primary care provider (PCP) and achieving relevance with the goals and capacity of the family care-giver and care-recipient.
62171185|NCT03325608|NO_INTERVENTION|Usual Care|Participants will receive referrals to services at the time of enrollment.
62171186|NCT05732922|NO_INTERVENTION|Control|Participants will be receiving their standard medical care.
62171187|NCT05732922|ACTIVE_COMPARATOR|Intervention|Participants will be receiving the intervention on top of their standard medical care.
62171188|NCT04389996||Patients with cancer|Survey
62171189|NCT04022603|EXPERIMENTAL|Optiflow nasal googles|Oxygen provided by means of high throughput nasal googles (Optiflow, Fisher\&Paykel- New Zealand).
62171190|NCT04022603|ACTIVE_COMPARATOR|Venturi mask|Oxygen provided by means of a Venturi mask.
62171191|NCT03526471|EXPERIMENTAL|Left Atrial Appendage (LAA) Occluder|Left Atrial Appendage (LAA) Occluder
62171192|NCT02896439|EXPERIMENTAL|Neurophysiological monitoring|
62171193|NCT05188547|NO_INTERVENTION|Control|No video education, only consultation by the anesthesiologist. No knowledge test before the consultation.
62171194|NCT05188547|NO_INTERVENTION|Baseline|No video education, only consultation by the anesthesiologist. Also a knowledge test before the consultation.
62171195|NCT05188547|EXPERIMENTAL|Video|Video education and a knowledge test directly afterwards. Consultation by the anesthesiologist after the knowledge test.
62171196|NCT05188547|EXPERIMENTAL|Video Augmented|Video education and consultation by the anesthesiologist directly afterwards. The knowledge test is taken after the consultation.
62171197|NCT03865862|EXPERIMENTAL|Experimental|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series.
62363845|NCT03582267|EXPERIMENTAL|Dietary Supplement|Docosahexaenoic Acid (DHA)
62363846|NCT03582267|NO_INTERVENTION|No Intervention|No Docosahexaenoic Acid supplementation
62171198|NCT03865862|ACTIVE_COMPARATOR|Control|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series.
62171199|NCT02358499|EXPERIMENTAL|Posaconazole Injection|We will give a single dose of intravenous posaconazole and collect blood samples for pharmacokinetics (PK). The study pool will be enriched by selecting participants with known sequence variations. Every effort will be made to balance age and disease state (HSCT vs. non-HSCT).
62171200|NCT04832815|EXPERIMENTAL|Equine Therapy|
62171201|NCT04832815|NO_INTERVENTION|Treatment as Usual (TAU)|
62171202|NCT04832815|EXPERIMENTAL|Therapeutic Horsemanship Program|
62171203|NCT02429232|EXPERIMENTAL|Pioglitazone|Pioglitazone 30 mg once daily will be administered orally for total 48 weeks.
62171204|NCT02429232|ACTIVE_COMPARATOR|Linagliptin|Linagliptin 5 mg once daily will be administered orally for total 48 weeks.
62171205|NCT05326633|NO_INTERVENTION|UC only|LTACH control group receiving usual care (UC) only.
62171206|NCT05326633|ACTIVE_COMPARATOR|MRP+HPRO+NMES+UC|LTACH group receiving mobility based rehabilitation (MRP) + neuromuscular electric stimulation (NMES) + high protein supplementation (HPRO) + usual care (UC)
62171207|NCT02668796|EXPERIMENTAL|Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
62171208|NCT02668796|ACTIVE_COMPARATOR|Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)|apply using the given applicator
62171209|NCT02668796|PLACEBO_COMPARATOR|Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
62171210|NCT05014906|ACTIVE_COMPARATOR|minocycline, azelaic acid|minocycline vs minocycline in comination with 15% azelaic acid for treatment of rosacea
62171211|NCT05014906|EXPERIMENTAL|azelaic acid|45 mg oral minocycline vs 45 mg oral minocycline plus 15% azelaic acid in the treatment of facial rosacea
62171212|NCT02788617||Non treatment group|This is a non-interventional study in which embryo selection is performed according to standard of care. The Diafert output, the granulocyte colony-stimulating factor (G-CSF) concentration in follicular fluid (FF), will be recorded but will not be used in patient management, ie, values will not be used for embryo selection in the assisted reproduction procedure.
62171213|NCT04858568||Hodgkin lymphoma|"Diagnoses:~Hodgkin lymphoma (classical Hodgkin lymphoma)"
62171214|NCT04858568||Aggressive B-NHL|"Diagnoses:~Aggressive B-NHL (E.g. Diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, Burkitt lymphoma, de novo transformed lymphoma, follicular lymphoma grade 3b)"
62171215|NCT04858568||Indolent B-NHL|"Diagnoses:~Indolent B-NHL (E.g.follicular lymphoma grades 1-3a, mantle cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukaemia/small lymphocytic lymphoma, lymphoplasmacytic lymphoma, nodular lymphocyte predominant Hodgkin lymphoma)"
62171216|NCT04858568||Peripheral T/NK-cell|"Diagnoses:~Peripheral T/NK-cell lymphomas (any mature T/NK cell malignancy)"
62171217|NCT01592383|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62171218|NCT05961618||Uninfected|Subjects who had recovered from SARS-CoV-2 infection
62171219|NCT05961618||Infected|Subjects who had not been infected with SARS-CoV-2.
62171220|NCT06645847|ACTIVE_COMPARATOR|Ketone ester|"Ketone ester (KE) (Chemical name: Bis-octanoyl-(R)-1,3-butanediol, Common name: C8 ketone di-ester) formulated in a tropical flavored beverage .~KE 12.5 g in 37.5 mL per day for 1 week KE 25 g/day in 75 mL per day for 1 week KE 37.5g/day in 112.5 mL per day for 1 week KE 50 g/day in 150 mL per day for 17 weeks (37.5 mL of study beverage contains 12.5 g of KE)"
62171221|NCT06645847|PLACEBO_COMPARATOR|Non-ketone placebo|"Placebo (non-ketogenic canola oil) formulated in a tropical flavored beverage~* 37.5 mL tropical flavored beverage containing 12.5 g/day of canola oil will be consumed for the first 7 days, with the first meal of the day.~* 75 mL tropical flavored beverage containing 25 g/day of canola oil will be consumed for week 2 (for 1 week) also with the first meal of the day.~* 112.5 mL tropical flavored beverage containing 37.5g/day of canola oil will be consumed from week 3 (for 1 week). 25g (75mL) with the first meal of the day and 12.5g (37.5mL) with the last meal of the day.~* 150 mL tropical flavored beverage containing 50g/day of canola oil will be consumed from week 4 (for 17 week). 25g (75mL) with the first meal of the day and 25g (75mL) with the last meal of the day."
62171222|NCT02155218|ACTIVE_COMPARATOR|Standard Injection Rate|Subjects will be given a small amount of contrast (approximately 1 cc test bolus) followed by administration of the remainder of the volume of contrast they are getting for their clinical study. This will be approximately 30-40 cc, depending on patient size, given at an injection rate of 2 - 2.5 cc/second.
62171223|NCT02155218|EXPERIMENTAL|Patient Tailored Injection Rate|"Subjects will be given a small amount of contrast (approximately 1 cc test bolus) followed by administration of the remainder of the volume of contrast they are getting for their clinical study. This will be approximately 30-40 cc, depending on patient size. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the contrast - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves. The injection rate will vary from 1 to 3 cc/second."
62171224|NCT06178198|EXPERIMENTAL|Ablative radioembolization for large HCC|Yttrium-90 resin microspheres (SIR-Sphere, SIRTEX) will be administered to cover the main tumor, satellite nodules, and margin.
62171225|NCT05452837|ACTIVE_COMPARATOR|Free Dermal Fat Graft|Free Dermal Fat Graft (FDFG) is applied to the superficial parotidectomy defect site
62171226|NCT05452837|ACTIVE_COMPARATOR|Superficial musculoaponeurotic system flap|Superficial musculoaponeurotic system (SMAS) Flap is dissected and tailored to fill the defect after superficial parotidectomy
62171227|NCT03053635|EXPERIMENTAL|0.35 mg/cm^2 TLD1433 Bladder Dose|"TLD1433 infusion and photodynamic therapy treatment (PDT):~TLD1433 is infused for 1 hour and photodynamic therapy treatment is performed after TLD1433 has been rinsed from the bladder. If treatment with the maximum recommended starting dose of 0.35mg/cm\^2 does not raise significant safety concerns as determined by the safety monitoring committee, the therapeutic dose of TLD1433 (0.70mg/cm\^2) will be used."
62171228|NCT01494298||T2DM|African-American men with type 2 diabetes who are not taking cholesterol-lowering medications.
62171229|NCT01494298||Control|African-American men without type 2 diabetes who are not taking cholesterol-lowering medications.
62171230|NCT02231814|EXPERIMENTAL|Group 1|Crohn's Disease Exclusion Diet+Partial Enteral Nutrition (PEN): Crohns Disease Exclusion Diet + PEN
62171231|NCT02231814|EXPERIMENTAL|Group 2|Crohn's Disease Exclusion Diet alone with a calcium supplement
62171232|NCT04775173|EXPERIMENTAL|Low dose of sirolimus|Sirolimus The plasma trough concentration of sirolimus is maintained within the range of 5-8 ng/ml by adjusting sirolimus dose, for 1 year.
62171233|NCT04775173|ACTIVE_COMPARATOR|High dose of sirolimus|Sirolimus The plasma trough concentration of sirolimus is maintained within the range of 10-15 ng/ml by adjusting sirolimus dose, for 1 year.
62171234|NCT06646757|NO_INTERVENTION|Arm 1|No resource provision
62171235|NCT06646757|EXPERIMENTAL|Arm 2|Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation
62171236|NCT06646757|EXPERIMENTAL|Arm 3|IBD Help Center (HELP) is a resource operated by the Crohn's and Colitis Foundation (CCF) for individuals to connect with an information specialist via email, call, or online live chat at no cost
62171237|NCT06646757|EXPERIMENTAL|Arm 4|IBD Help Center (HELP) is a resource operated by the Crohn's and Colitis Foundation (CCF) for individuals to connect with an information specialist via email, call, or online live chat at no cost Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation
62171238|NCT06646757|EXPERIMENTAL|Arm 5|"Coping with Crohn's and Colitis: A Patient and Clinician's Guide to CBT for IBD (CBT) is an IBD-specific cognitive behavioral therapy (CBT) workbook (e-book or hardcopy)"
62171239|NCT06646757|EXPERIMENTAL|Arm 6|"Coping with Crohn's and Colitis: A Patient and Clinician's Guide to CBT for IBD (CBT) is an IBD-specific cognitive behavioral therapy (CBT) workbook (e-book or hardcopy)~Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation"
62171240|NCT06646757|EXPERIMENTAL|Arm 7|"Coping with Crohn's and Colitis: A Patient and Clinician's Guide to CBT for IBD (CBT) is an IBD-specific cognitive behavioral therapy (CBT) workbook (e-book or hardcopy) IBD Help Center (HELP) is a resource operated by the Crohn's and Colitis Foundation (CCF) for individuals to connect with an information specialist via email, call, or online live chat at no cost"
62171241|NCT06646757|EXPERIMENTAL|Arm 8|"Coping with Crohn's and Colitis: A Patient and Clinician's Guide to CBT for IBD (CBT) is an IBD-specific cognitive behavioral therapy (CBT) workbook (e-book or hardcopy) IBD Help Center (HELP) is a resource operated by the Crohn's and Colitis Foundation (CCF) for individuals to connect with an information specialist via email, call, or online live chat at no cost Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation"
62171242|NCT06646757|EXPERIMENTAL|Arm 9|1) My IBD Care (APP) is a free smartapp that supports patients' tracking of symptoms, medical appointments, and medications; self-paced behavioral change programs
62171243|NCT06646757|EXPERIMENTAL|Arm 10|"My IBD Care (APP) is a free smartapp that supports patients' tracking of symptoms, medical appointments, and medications; self-paced behavioral change programs~Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation"
62171244|NCT06646757|EXPERIMENTAL|Arm 11|"My IBD Care (APP) is a free smartapp that supports patients' tracking of symptoms, medical appointments, and medications; self-paced behavioral change programs~IBD Help Center (HELP) is a resource operated by the Crohn's and Colitis Foundation (CCF) for individuals to connect with an information specialist via email, call, or online live chat at no cost"
62171245|NCT06646757|EXPERIMENTAL|Arm 12|"My IBD Care (APP) is a free smartapp that supports patients' tracking of symptoms, medical appointments, and medications; self-paced behavioral change programs~IBD Help Center (HELP) is a resource operated by the Crohn's and Colitis Foundation (CCF) for individuals to connect with an information specialist via email, call, or online live chat at no cost~Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation"
62171246|NCT06646757|EXPERIMENTAL|Arm 13|"My IBD Care (APP) is a free smartapp that supports patients' tracking of symptoms, medical appointments, and medications; self-paced behavioral change programs~Coping with Crohn's and Colitis: A Patient and Clinician's Guide to CBT for IBD (CBT) is an IBD-specific cognitive behavioral therapy (CBT) workbook (e-book or hardcopy)"
62171247|NCT06646757|EXPERIMENTAL|Arm 14|"My IBD Care (APP) is a free smartapp that supports patients' tracking of symptoms, medical appointments, and medications; self-paced behavioral change programs~Coping with Crohn's and Colitis: A Patient and Clinician's Guide to CBT for IBD (CBT) is an IBD-specific cognitive behavioral therapy (CBT) workbook (e-book or hardcopy)~Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation"
62171248|NCT06646757|EXPERIMENTAL|Arm 15|"My IBD Care (APP) is a free smartapp that supports patients' tracking of symptoms, medical appointments, and medications; self-paced behavioral change programs~Coping with Crohn's and Colitis: A Patient and Clinician's Guide to CBT for IBD (CBT) is an IBD-specific cognitive behavioral therapy (CBT) workbook (e-book or hardcopy)~IBD Help Center (HELP) is a resource operated by the Crohn's and Colitis Foundation (CCF) for individuals to connect with an information specialist via email, call, or online live chat at no cost"
62171249|NCT06646757|EXPERIMENTAL|Arm 16|"1. My IBD Care (APP) is a free smartapp that supports patients' tracking of symptoms, medical appointments, and medications; self-paced behavioral change programs~2. Coping with Crohn's and Colitis: A Patient and Clinician's Guide to CBT for IBD (CBT) is an IBD-specific cognitive behavioral therapy (CBT) workbook (e-book or hardcopy)~3. IBD Help Center (HELP) is a resource operated by the Crohn's and Colitis Foundation (CCF) for individuals to connect with an information specialist via email, call, or online live chat at no cost~4. Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation"
62171250|NCT06646393|EXPERIMENTAL|Paternal skin to skin contact group|Father-baby skin-to-skin contact was applied within the first hour immediately after the cesarean delivery. During the Father-Baby Skin-to-Skin Contact stage, the newborns were laid face down on their father's bare chest and covered with a blanket.
62363847|NCT06325540|EXPERIMENTAL|theracal pt|Teeth treated with indirect pulp capping with theracal pt
62363848|NCT06325540|EXPERIMENTAL|therabase|Teeth treated with indirect pulp capping with therabase
62363849|NCT06325540|ACTIVE_COMPARATOR|biodentine|Teeth treated with indirect pulp capping with biodentine
62171251|NCT06646393|NO_INTERVENTION|Control group|Routine care was given to the control group. After the mothers' procedures were completed, the breastfeeding process was started.
62171252|NCT03334071|ACTIVE_COMPARATOR|Exercise Intervention|Patients in the intervention arm will participate in a supervised in-hospital, exercise training program on a cycle ergometer before and during chemotherapy. At week 5-6 there will be a transition period of in-hospital to home-based exercise training (at this point we will perform the exercises that they will perform at home in the in-hospital environment to ensure that the patient understands the home-based exercise training programme) and then week 7-12 will be home-based exercise training only with telephone support.
62171253|NCT03334071|NO_INTERVENTION|Negative Control|Patients in the control arm will not undergo an exercise training program.
62171254|NCT03334071|NO_INTERVENTION|Observational|Patients who do not enrol in RCT will be enrolled in the observational arm
62171255|NCT06047041|ACTIVE_COMPARATOR|EIS Only|EIS Only (active comparator) condition schools involve technical assistance to support the implementation EIS.
62171256|NCT06047041|EXPERIMENTAL|EIS + ECHO|"EIS + ECHO (experimental) condition involves all of the activities included in the EIS Only condition and will include enhanced implementation supports. Enhanced implementation supports involve 1) monthly collaborative learning ECHO sessions for school student support team staff to support implementation of EIS and evidence-based mental and behavioral health practices and 2) individual school teams will also receive follow-up supports to promote the implementation strategies presented during ECHO sessions."
62171257|NCT04980755|EXPERIMENTAL|Phase one|"Participants will be asked to attend four weekly sessions of Body Reprogramming via group video call.~Each session will include up to 8 patients and will consist of a 25-30 minute live presentation"
62171258|NCT04980755|EXPERIMENTAL|Phase two|We anticipate that participant sin phase two will complete the same intervention, but it may be somewhat modified following participant feedback in phase one.
62171259|NCT03246256||Group 1|Patients with acute ischaemic stroke who were administered intavenous thrombolysis or patients with acute ischaemic stroke refusing intravenous thrombolysis; recall in both cases 60 to 90 minutes after the informed consent procedure
62171260|NCT03246256||Group 2|1st of 2nd degree relatives of patients with acute ischaemic stroke, who witnessed the informed consent procedure
62171261|NCT03246256||Group 3|Stroke patients with acute or subacute ischaemic stroke with a contraindication for intravenous thrombolysis
62171262|NCT03246256||Group 4|Patients without an ischaemic stroke but similiar risk factors (admitted to the Departement of Cardiology and Pneumology, Charité, Campus Benjamin Franklin, Berlin, Germany)
62171263|NCT03246256||Group 5|Patients with acute ischaemic stroke who were administered intavenous thrombolysis - recall 24 hours after the informed consent procedure
62171264|NCT03230071|PLACEBO_COMPARATOR|Placebo|placebo identified to TMBCZG,0.1g per pill which contains 0mg TMBCZG，3 pills per time, 2 times per day for 24 weeks.
62171265|NCT03230071|EXPERIMENTAL|TMBCZG-high dose|TMBCZG, 0.1g per pill which contains 14mg TMBCZG, 3 pills per time, 2 times per day for 24 weeks.
62171266|NCT03230071|EXPERIMENTAL|TMBCZG-medium dose|TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 2 TMBCZG pills and 1 placebo pill per time, 2 times per day for 24 weeks.
62171267|NCT03230071|EXPERIMENTAL|TMBCZG-low dose|TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 1 TMBCZG pills and 2 placebo pill per time, 2 times per day for 24 weeks.
62171268|NCT04186884||Observational (questionnaires)|Patients and caregivers visiting SCC for a consult or admitted to PCU complete questionnaires over 35 minutes.
62171269|NCT05934461||an open-label, multiinstitutional, single-arm retrospective study|Three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated conformal radiotherapy (IMRT) at a prescribed dose of 54-66 Gy/27-33 f. The combined TKI includes gefitinib, erlotinib, erlotinib, oseltinib, and ametinib. The specific uses are: gefitinib 250 mg orally once daily; erlotinib 125 mg orally three times daily; erlotinib 150 mg orally once daily; oseltinib 80 mg orally once daily; ametinib 110 mg orally once daily. TKI is taken until disease progression or intolerability.
62171270|NCT05934461||RT+C|Three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated conformal radiotherapy (IMRT) at a prescribed dose of 54-66 Gy/27-33 f. The combined TKI includes gefitinib, erlotinib, erlotinib, oseltinib, and ametinib. The specific uses are: gefitinib 250 mg orally once daily; erlotinib 125 mg orally three times daily; erlotinib 150 mg orally once daily; oseltinib 80 mg orally once daily; ametinib 110 mg orally once daily. TKI is taken until disease progression or intolerability.
62171271|NCT06646237||TBP|Patients with definite or probable tuberculous pleuritis
62171272|NCT06646237||Non-TBP|Patients without tuberculous pleuritis
62171273|NCT06209905|SHAM_COMPARATOR|Ti-PTFE|A mixture of autogenous bone (scrapped from the mandibular external oblique ridge) and bovine xenograft was administered on the atrophic recipient area after decortication by low-speed reducing drills, and covered with the Ti-PTFE membrane.
62171274|NCT06209905|ACTIVE_COMPARATOR|Khoury technique|A bone block was harvested from the mandibular external oblique ridge, then splitted into two plates; one fixated buccally and the other fixated occlusally by bone screws), and a mixture of autogenous bone (scrapped from the mandibular external oblique ridge) and bovine xenograft was administered on the atrophic recipient area after decortication by low-speed reducing drills.
62171275|NCT02072681||Mild and Rapidly Improving Ischemic Stroke|"Patients 18 years or older with mild or rapidly improving acute ischemic stroke defined clinically. .Absence of non-ischemic conditions neuro-imaging (i.e. absence of hemorrhage or a mass on brain imaging that arrived to the hospital within 4.5 hours after the onset of stroke symptoms.~All participants will have two follow up telephone calls: One at approximately 30 days after the stroke and one at approximately 90 days after the stroke to ask questions about how well participant can carry out usual duties after the stroke, how much assistance do he/she needs to perform your daily activities and how good or bad would he/she considers current health to be."
62171276|NCT06645561||Infants under one year|
62171277|NCT01779427|EXPERIMENTAL|AIM Intervention|
62171278|NCT01779427|EXPERIMENTAL|Wait List Control|Participants are in the Wait List Control group for 10 weeks and then they will participate in the AIM Intervention
62171279|NCT02642159|EXPERIMENTAL|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without other lipid modifying therapy (LMT) for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when non-high-density lipoprotein cholesterol (non-HDL-C) levels \>=100 mg/dL (2.59 mmol/L) at Week 8.
62171280|NCT02642159|ACTIVE_COMPARATOR|Usual Care|Participants on usual care continued on insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without additional LMT or with either ezetimibe, fenofibrate, omega-3 fatty acids or nicotinic acid as per Investigator's judgment for 24 weeks.
62171281|NCT02574897|EXPERIMENTAL|Electronic Symptom Survey|Patients randomized to the intervention arm will fill out the daily PRO-CTCAE electronic symptom survey. The intervention consists of sending the results of the surveys in the intervention arm to the clinical care team. The four symptom-specific PROMIS subsets (Anxiety, Depression, Fatigue, and Sleep Disturbance) will be filled out weekly while patients are admitted to the hospital. Patients will again complete the 6 minute walk distance testing, HRQoL surveys, and PASS assessment at the time of discharge. Patients in the intervention arm will complete a satisfaction survey at discharge. HRQoL (by mail) and PASS (by telephone) will be assessed for a third time 30 days after discharge.
62171282|NCT02574897|ACTIVE_COMPARATOR|Blinded Electronic Symptom Survey|Patients in the control arm will only fill out the symptom survey at the time of admission and days 7, 10, and 14. The results of symptom surveys from the patients in the control arm will not be sent to providers, but will be used for data analysis purposes only. The four symptom-specific PROMIS subsets (Anxiety, Depression, Fatigue, and Sleep Disturbance) will be filled out weekly while patients are admitted to the hospital. Patients will again complete the 6 minute walk distance testing, HRQoL surveys, and PASS assessment at the time of discharge. HRQoL (by mail) and PASS (by telephone) will be assessed for a third time 30 days after discharge.
62171283|NCT00105521|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to sarizotan tablet orally twice daily up to Week 12.
62171284|NCT00105521|EXPERIMENTAL|Sarizotan 2 milligrams per day (mg/day)|Participants will receive sarizotan 2 milligrams (mg) per day (given in 2 divided daily doses) up to Week 12.
62171285|NCT00105521|EXPERIMENTAL|Sarizotan 4 mg/day|Participants will receive sarizotan 4 mg/day (given in 2 divided daily doses) up to Week 12.
62171286|NCT00105521|EXPERIMENTAL|Sarizotan 10 mg/day|Participants will receive sarizotan 10 mg/day (given in 2 divided daily doses) up to Week 12.
62171287|NCT03198936|EXPERIMENTAL|Cognizin® SynapsaTM|Dose - 2 capsules twice a day with meals
62171288|NCT03198936|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules with microcrystalline cellulose with added colours Dose - 2 capsules twice a day with meals
62171289|NCT04113902|EXPERIMENTAL|intervention group|Health education is given intervention group and 12 weeks follow up.
62171290|NCT04113902|NO_INTERVENTION|control group|Control group takes standard health care and 12 weeks follow up.
62171291|NCT04072523||Observational Study Investigational Product NA|Patients : Type 2 Diabetic Patients
62171292|NCT06646471|OTHER|Real world cohort of NSCLC older adults patients|"Cohort of patients ≥70 years of age with NSCLC treated in first line therapy for thoracic tumors according to ESMO-referenced therapeutic standards or according to an innovative molecule and/or strategy.~An optional biobank based on blood samples taken during the screening phase prior to the first administration of systemic treatment will be collected. Sampling of tumoral materials will be collected prior to study participation and send for central reading.~Patients will be asked to come at the hospital for their regular visits as per site current practice and to complete three quality of life questionnaires (EORTC QLQ-F17; QLQ-LC13; QLQ-ELD14)."
62171293|NCT03979235||Heahlthy people|perform motor function assessment by using scales, sEMG, and inertia sensors
62171294|NCT03979235||People with motor deficits|perform motor function assessment by using scales, sEMG, and inertia sensors
62171295|NCT03979235||Patients with dysphagia|perform motor function assessment by using scales, sEMG, and inertia sensors
62171296|NCT05501483|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone is known to affect fat cells and is used as an active comparator. It reduces HbA1c but increase fat mass slightly. We hypothesize that pioglitazone may have particular benefits in individuals with a specific adipose cellularity.
62171297|NCT05501483|EXPERIMENTAL|Empagliflozin|Empagliflozin reduces HbA1c and increase lipolysis possibly due to increased glucagon secretion. It also reduces fat mass weight to a minor degree.
62171298|NCT05501483|EXPERIMENTAL|Semaglutide|Semaglutide reduces body weight, including fat mass, to a more significant degree than empagliflozin but has no known direct effects on adipose tissue.
62171299|NCT04320199|EXPERIMENTAL|Fermented Protaetia brevitarsis seulensis powder group|This group takes Fermented Protaetia brevitarsis seulensis powder for 8 weeks
62171300|NCT04320199|PLACEBO_COMPARATOR|Placebo group|This group takes placebo for 8 weeks
62171301|NCT01898442|ACTIVE_COMPARATOR|Ticagrelor 180|Standard ticagrelor 180mg loading dose
62171302|NCT01898442|EXPERIMENTAL|Ticagrelor 270mg|High ticagrelor 270mg loading dose
62171303|NCT01898442|EXPERIMENTAL|Ticagrelor 360mg|High ticagrelor 360mg loading dose
62171304|NCT00945763|PLACEBO_COMPARATOR|placebo|
62171305|NCT00945763|EXPERIMENTAL|N1539 15 mg|
62171306|NCT00945763|EXPERIMENTAL|N1539 30 mg|
62171307|NCT00945763|EXPERIMENTAL|N1539 60 mg|
62171308|NCT00945763|ACTIVE_COMPARATOR|Motrin|
62171309|NCT03802487|EXPERIMENTAL|Sotagliflozin|One treatment period includes a single oral dose of sotagliflozin + IV microdose 14C-sotagliflozin tracer plus charcoal. The other treatment period includes a single oral dose of sotagliflozin + IV microdose 14C-sotagliflozin tracer without charcoal.
62171310|NCT02727647|EXPERIMENTAL|Arm 1|FVIII concentration at 35-40 U/kg/dose 1 time/week for 5 months
62171311|NCT02727647|EXPERIMENTAL|Arm 2|FVIII concentration at 15-20 U/kg/dose 2 time/week for 5 months
62171312|NCT04163185|EXPERIMENTAL|AXS-07|Taken once upon migraine
62171313|NCT04163185|PLACEBO_COMPARATOR|Placebo|Taken once upon migraine
62171314|NCT03565302|PLACEBO_COMPARATOR|Control|Subjects receive placebo treatment
62171315|NCT03565302|EXPERIMENTAL|Long acting beta2-agonist|Subjects are treated with long-acting beta2-agonist formoterol
62171316|NCT03565302|EXPERIMENTAL|Short acting beta2-agonist|Subjects are treated with short-acting beta2-agonist terbutaline
62171317|NCT02544113|EXPERIMENTAL|Thymo|Subjects randomized to the (Delay CNI) group will be treated with Thymoglobulin® (total dose of 4.5 mg/kg) administered in three doses; (each dose being 1.5 mg/kg - administered Day 0 \[after transplant\], Day 2, and Day 4 post transplant), along with CNI delay for 10 days. CNI will be initiated on postoperative (post-transplant) Day 10. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
62171318|NCT02544113|PLACEBO_COMPARATOR|Control|Subjects randomized to the (Early CNI) group (Control group) will receive no antibody therapy for induction and will start CNI therapy on postoperative (post-transplant) Day 2. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
62171319|NCT06647459||Pathogenic variant in TTN|50 patients with a pathogenic variant in TTN
62171320|NCT06647459||Pathogenic variant in other cardiomyopathy genes|50 patients with a pathogenic variant in other cardiomyopathy genes
62171321|NCT06647459||Genotype-negativie controls|100 genotype-negative controls
62171322|NCT03254992|EXPERIMENTAL|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
62171323|NCT03254992|EXPERIMENTAL|ASD - Tangible task|Experimental group using Keyboard with more real activity.
62171324|NCT03254992|ACTIVE_COMPARATOR|TD - Abstract task|Control group using Kinect with more virtual activity.
62171325|NCT03254992|ACTIVE_COMPARATOR|TD - Tangible task|Control group using Keyboard with more real activity.
62171326|NCT04155333|EXPERIMENTAL|Active anodal stimulation|active anodal stimulation at F3, cathode placed on contralateral bicep
62171327|NCT04155333|EXPERIMENTAL|Active cathodal stimulation|active cathodal stimulation at F3, anode placed on contralateral bicep
62171328|NCT04155333|SHAM_COMPARATOR|Sham stimulation|sham stimulation that will be counterbalanced between subjects such that half will receive sham stimulation configured as condition 1 (anode F3, cathode bicep) and half will receive condition 2 (cathode F3, anode bicep)
62171329|NCT01914458|EXPERIMENTAL|Low-dose computed tomography (LDCT)|Patients will have one baseline LDCT scan.
62171330|NCT02946827|EXPERIMENTAL|Low FODMAPs /balanced gluten free diet|An expert in nutrition will give a balanced gluten free diet to patients, low in FODMAPs foods.
62171331|NCT02946827|ACTIVE_COMPARATOR|Balanced gluten free diet|An expert in nutrition will give a balanced gluten free diet to patients.
62171332|NCT00907517|EXPERIMENTAL|MK-8776 10 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 10 mg/m\^2 intravenously (IV) on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m\^2 IV via 72-hour continuous intravenous infusion (CIV) on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
62171333|NCT00907517|EXPERIMENTAL|MK-8776 20 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 20 mg/m\^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m\^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
62171334|NCT00907517|EXPERIMENTAL|MK-8776 40 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 40 mg/m\^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m\^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
62171335|NCT00907517|EXPERIMENTAL|MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 56 mg/m\^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m\^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
62171336|NCT00907517|EXPERIMENTAL|MK-8776 140 mg + Cytarabine 2 g/m^2|Participants received MK-8776 140 mg flat dose IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m\^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
62171337|NCT02473588|OTHER|LTIA Group|Patients in the LTIA Group (all patients) will have blood pressure recorded continuously. LTIA will be used to measure stroke volume and cardiac output after the completion of data collection
62171338|NCT04965090|EXPERIMENTAL|Patients with parenchymal brain metastases|All patients in both cohorts will receive both oral lazertinib and amivantamab by intravenous injection (IV). Lazertinib dosing will start at 240 mg daily. For patients who weigh \<80 kg, on C1D1 amivantamab 350 mg will be given IV via peripheral line for C1D1, D2 and D8, with 700 mg IV given on C1D2. For all other treatments, amivantamab 1050 mg IV will be given. For patients who weigh ≥ 80 kg, on C1D1 350mg IV amivantamab will be given and 1050 mg IV on C1D2, with 1400 mg IV given for all.
62171339|NCT04965090|EXPERIMENTAL|Patients with leptomeningeal (LM) disease with or without parenchymal brain metastases|All patients in both cohorts will receive both oral lazertinib and amivantamab by intravenous injection (IV). Lazertinib dosing will start at 240 mg daily. For patients who weigh \<80 kg, on C1D1 amivantamab 350 mg will be given IV via peripheral line for C1D1, D2 and D8, with 700 mg IV given on C1D2. For all other treatments, amivantamab 1050 mg IV will be given. For patients who weigh ≥ 80 kg, on C1D1 350mg IV amivantamab will be given and 1050 mg IV on C1D2, with 1400 mg IV given for all.
62171340|NCT02941432|OTHER|Black tea|Black tea compress treatment
62171341|NCT01968083|EXPERIMENTAL|RSV cps2 Vaccine|Participants will receive one dose of the RSV cps2 vaccine administered as nose drops at study entry.
62171342|NCT01968083|PLACEBO_COMPARATOR|Placebo|Participants will receive one dose of placebo administered as nose drops at study entry.
62171343|NCT00744796||DSAEK: Outcomes in patients with corneal edema|Best spectacle corrected visual acuity and anterior segment optical coherence tomography (OCT) at minimum will be performed in patients who have undergone DSAEK for corneal edema secondary to corneal endothelial dysfunction.
62171344|NCT00094497|ACTIVE_COMPARATOR|EDP-M|etopodide, doxorubicin, cisplatin and mitotane
62171345|NCT00094497|ACTIVE_COMPARATOR|Sz-M|streptozotocin and mitotane
62171346|NCT00919009|EXPERIMENTAL|Sorafeinb|Oral sorafenib (400 mg BID) will be start the 3 day after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination.
62171347|NCT02536885|EXPERIMENTAL|Liberal group|During the surgery, blood pressure of the patients will be maintained within ± 25% of the patient's normal blood pressure.
62171348|NCT02536885|EXPERIMENTAL|Restrictive group|During the surgery, blood pressure of the patients will be maintained within ± 10% of the patient's normal blood pressure.
62171349|NCT04596241|EXPERIMENTAL|Experimental|Subjects will be required to complete four (4) treatment visits and two follow-up visits. All of the study subjects will receive the treatment with the subject device.
62171350|NCT05577689||All patients|There is only one arm in the trial
62171351|NCT05576727||Unruptured Intracranial Aneurysm|
62171352|NCT03524950|NO_INTERVENTION|no dexmedetomidine|
62171353|NCT03524950|EXPERIMENTAL|high dose dexmedetomidine|
62171354|NCT03524950|EXPERIMENTAL|low dose dexmedetomidine|
62171355|NCT02245750|NO_INTERVENTION|Routine Invistigations|ICSI with long luteal phase protocol
62171356|NCT02245750|EXPERIMENTAL|Hysteroscopy|hysteroscopy will be done prior to the ICSI cycle
62171357|NCT01732926|EXPERIMENTAL|Rituximab + Bendamustine + Idelalisib|Participants will receive rituximab + bendamustine + idelalisib.
62171358|NCT01732926|EXPERIMENTAL|Rituximab + Bendamustine + Placebo|Participants will receive rituximab + bendamustine + placebo.
62171359|NCT01485991|EXPERIMENTAL|TMC435/PR|
62171360|NCT01485991|ACTIVE_COMPARATOR|TVR/PR|
62171361|NCT00424177|EXPERIMENTAL|eltrombopag|
62171362|NCT03525483|EXPERIMENTAL|Patients with ECMO|"Patients with circulatory assistance by ECMO Patients are included 48 hours after ECMO VA or VV therapy and after hemodynamic stabilization defined by blood pressure stability and cardiac output for at least 12 hours without significant changes in amine flow.~When stable they will have an Ultrasound for renal resistivity index measurement"
62171363|NCT00926952|EXPERIMENTAL|MAL-PDT 90 min incubation, no occlusion|Patients had 2-4 g of Methylaminolevulinate (MAL) spread on the entire face without occlusion and waited 90 minutes prior to photodynamic therapy (PDT) using red light.
62171364|NCT06297031|EXPERIMENTAL|heat application|women in the intervention group were treated with hot water application to the sacral region during the first stage of labor. When the cervical dilatation was 3-4 cm, 5-6 cm and 7-8 cm, heat application was applied a total of 3 times.
62171365|NCT06297031|NO_INTERVENTION|no heat application|No treatment was performed on women in the control group during the study. In the clinic, women's cervical dilatation is routinely checked by the midwife every 2-3 hours, and the progress of labor is monitored by fetal heart rate and fetal monitoring
62171366|NCT05913583||ICI group|Recipients with exposure to immune checkpoint inhibitors before liver transplantation
62171367|NCT05913583||non-ICI group|Recipients without exposure to immune checkpoint inhibitors before liver transplantation
62171368|NCT05915832|ACTIVE_COMPARATOR|RIC|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days.
62171369|NCT05915832|PLACEBO_COMPARATOR|Sham RIC|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days.
62171370|NCT01110161||Visceral fat mass|The study population will include Chinese adult men and women, over the age of 18 years. All subjects will be recruited at Fudan University. Subjects will represent a wide range of BMI values (18.5 - 40 kg/m2).
62171371|NCT06639698|EXPERIMENTAL|Treatment|Patients will take a tablet containing diosgenin (120 mg), alpha-lactalbumin (100 mg) and vitamin D (50 mcg) - two times per day for six months
62171372|NCT00988897|EXPERIMENTAL|1|"Patients will receive modified FOLFOX-6 regimen:~* oxaliplatin 85mg/m2, day 1 (given as a 2-hour infusion)~* LV 400mg/m2, day 1 (given as a 2-hour infusion simultaneous to oxaliplatin)~* 5-FU given as a bolus IV 400mg/m2 dose on day 1 followed by 2400mg/m2 continuous infusion over 46 hours (day 1 and 2)~A cycle is defined as 2 weeks. Patients will receive cycles of modified FOLFOX-6 regimen every 2 weeks up to a maximum of 8 cycles. Use of bevacizumab is at the discretion of the treating physician."
62171373|NCT01399684|EXPERIMENTAL|MEGF0444A + mFOLFOX-6 + Bevacizumab|Participants will receive MEGF0444A + mFOLFOX-6 (oxaliplatin, folinic acid, and 5-fluorouracil) regimen + bevacizumab. Participants will receive oxaliplatin for up to 8 cycles (Cycle = 14 days) and 5-fluorouracil, folinic acid, bevacizumab and MEGF0444A will be administered until disease progression or unacceptable toxicity for a maximum of up to 52 cycles.
62171374|NCT01399684|PLACEBO_COMPARATOR|Placebo + mFOLFOX-6 + Bevacizumab|Participants will receive MEGF0444A matching placebo + mFOLFOX-6 regimen + bevacizumab. Participants will receive oxaliplatin for up to 8 cycles and 5-fluorouracil, folinic acid, bevacizumab and placebo will be administered until disease progression or unacceptable toxicity for a maximum of up to 52 cycles.
62171375|NCT04461938|OTHER|Fasting|All study participants follow the same dietary intervention; thus, no randomization will take place.
62171376|NCT00067119|EXPERIMENTAL|Aggrenox|
62171377|NCT00067119|PLACEBO_COMPARATOR|Placebo|
62171378|NCT05192226|EXPERIMENTAL|Counterfactual Strategy Intervention|After participants finish describing past events where they were unable to participate or engage in physical activity and have identified barriers which impacted their events they just described, participants will be randomly assigned to conditions. Participants in the counterfactual strategy condition will engage in counterfactual strategies on barriers they believe they could have reasonably acted on to increase physical activity in their described event(s) that would have led to a better outcome. After identifying the counterfactual strategies, participants will then select three counterfactual strategies they just identified that they could use at some point in the upcoming week, any obstacles to using that counterfactual strategy, ways to overcome those obstacles, their intention to use the counterfactual strategy over the next week, and how likely they think the counterfactual strategy would have happened and led to the better outcome.
62171379|NCT05192226|NO_INTERVENTION|Control|Participants will be asked to describe past events where they were unable to participate or engage in physical activity. All participants will walk through the NIMHD framework with a researcher and be guided to identify barriers at various domains and levels of influence, which impacted their events they just described. After barrier identification, participants will be asked to select three barriers to talk aloud and list out additional details about the barriers identified.
62171380|NCT02580214|EXPERIMENTAL|Acerto|Preoperative immune nutrition for 5 days (Impact, Nestle) Preoperative fasting of 2h with a drink containing 12% maltodextrine No intravenous fluids postoperatively
62171381|NCT02580214|NO_INTERVENTION|Control|No immune nutrition Preoperative fasting of 6-8 h Crystalloid intravenous fluids until PO day 1
62171382|NCT00666835|EXPERIMENTAL|HX575 epoetin alfa Hexal AG|Eligible patients were switched from the comparator ERYPO®, to epoetin alfa HX575 Hexal AG in ratio 2:1 to be intravenously treated with HX575 in pre-filled syringes for 24 weeks (solution for injection i.v.). The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.
62171383|NCT00666835|ACTIVE_COMPARATOR|ERYPO®, Janssen-Cilag|Eligible patients were randomized and continued to be treated with ERYPO® Janssen-Cilag in pre-filled syringes intravenously (solution for injection i.v.) for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.
62171384|NCT02949622|EXPERIMENTAL|Multimodal intervention program|The intervention program will be in group format, with a size of 10 to 12 patients per group and with an extension of 12 sessions. The treatment program will feature sessions with psychoeducation of metabolic syndrome and treatment model, problem solving, stress management, anger management, social skills, self-efficacy and social support.
62171385|NCT02949622|ACTIVE_COMPARATOR|Lifestyle counseling|The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
62171386|NCT05971017|PLACEBO_COMPARATOR|Control group|To the control group was assigned lettuce without any biostimulation but with the same characteristic of biostimulated lettuce (soil, water, harvesting time)
62171387|NCT05971017|EXPERIMENTAL|Biostimulated Group|experimental: Biostimulated group: To the intervention group was assigned the biostimulated lettuce.
62171388|NCT00263783|EXPERIMENTAL|1|MEDI-522
62171389|NCT06140485|EXPERIMENTAL|NW Low-Glu®|"Patients in this arm will receive one placebo tablet plus two NW Low-Glu® capsules administered PO on empty stomach with plenty of water 2 hours after meals twice daily.~A total dose of four NW Low-Glu® capsules will be administered per day."
62171390|NCT06140485|ACTIVE_COMPARATOR|Metformin|"Patients in this arm will receive one metformin 1000 mg tablet plus two placebo capsules administered PO on an empty stomach with plenty of water 2 hours after meals twice daily.~A total dose of Metformin 2000 mg will be administered per day."
62171391|NCT05953818||Maintenance hemodialysis with diabetes group|The patients were given a quiet environment and completed the test within 10 minutes. The cognitive function of the two groups of patients was evaluated and analyzed using the Montreal Cognitive Assessment Scale (MoCA) in Chinese. The patients were given brain magnetic resonance high resolution structural imaging to observe changes in brain structure.
62171392|NCT05953818||Maintenance hemodialysis non diabetic group|The patients were given a quiet environment and completed the test within 10 minutes. The cognitive function of the two groups of patients was evaluated and analyzed using the Montreal Cognitive Assessment Scale (MoCA) in Chinese. The patients were given brain magnetic resonance high resolution structural imaging to observe changes in brain structure.
62171393|NCT04697641|EXPERIMENTAL|Helicobacter pylori eradication therapy Group|Patients with Functional Dyspepsia receiving two week course of triple drug regimen for H pylori eradication followed by six weeks of proton pump inhibitors
62171394|NCT04697641|ACTIVE_COMPARATOR|Symptomatic treatment group|Patients with Functional Dyspepsia receiving symptomatic therapy with proton pump inhibitors or gastric prokinetics
62171395|NCT03726125|EXPERIMENTAL|LY3374849 - SC (Part A)|Single subcutaneous (SC) dose of LY3374849
62171396|NCT03726125|EXPERIMENTAL|Insulin Degludec - SC (Part A)|Single SC dose of insulin degludec
62171397|NCT03726125|EXPERIMENTAL|LY3374849 - SC (Part B)|Single dose of LY3374849 administered SC in up to three of three study periods
62171398|NCT03726125|EXPERIMENTAL|LY3374849 - IV (Part B)|Single dose of LY3374849 administered intravenously (IV) in up to one of three study periods
62171399|NCT03726125|EXPERIMENTAL|LY3374849 - IV (Part C)|Single IV dose of LY3374849 in one of two study periods
62171400|NCT03726125|EXPERIMENTAL|Insulin Degludec - IV (Part C)|Single IV dose of insulin degludec in one of two study periods
62171401|NCT01116440|EXPERIMENTAL|BGS649 co-administered with Levora 28™|
62171402|NCT01116440|PLACEBO_COMPARATOR|Placebo co-administered with Levora 28™|
62171403|NCT02615834|NO_INTERVENTION|Control group|
62171404|NCT02615834|ACTIVE_COMPARATOR|Study group|
62171405|NCT04091919||ASD group|Isolated ostium Secundum ASD patients who are involving in this study have been already selected for intervention before the starting time of the study. The ASD patients who will be scheduled for transcatheter closure have either haemodynamically significant shunt fraction (Qp/Qs \> 1.5) or echocardiographic signs of right heart dilation or RV volume overload and pulmonary hypertension related symptoms. 2-D TTE derived Tissue Doppler and Strain Imaging will be done for all patients at baseline, 24 hours and 1-3 month post-procedure. Correlation between the device size and echocardiographic variables will be performed. Comparison between the results of the 2D-TTE derived Strain Imaging procedures will be done between baseline data and those obtained one day after the procedure and at one month follow up.
62171406|NCT04091919||Controlled group|Age matched controlled subjects without ASD
62171407|NCT02878590|EXPERIMENTAL|BONGO DEVICE|All participants that qualify will receive the intervention of the Bongo device
62171408|NCT05177770|EXPERIMENTAL|SRF617 in combination with etrumadenant and zimberelimab|All patients will receive SRF617 administered in combination with etrumadenant (AB928) and zimberelimab (AB122).
62171409|NCT03574493||Open laparotomy|A surgical procedure involving a large incision through the abdominal wall to gain access into the abdominal cavity.
62171410|NCT03574493||Laparoscopic surgery|A minimally-invasive technique in which operations are performed via small incisions (usually 0.5-1.5 cm) at a location distant to the site of interest.
62171411|NCT03574493||Robot-assisted surgery using the da Vinci® Surgical System|A minimally-invasive approach that allows good precision, flexibility, and control.
62171412|NCT03574493||Transanal surgery through the anus|Where the protectomy is performed down to up until the Douglas pouch
62171413|NCT02571283|EXPERIMENTAL|Randomized Group A [Cocktail Injection]|"COCKTAIL INJECTION:~Cocktail Injection Consists of:~Ropivacaine (Brand Name: Naropin) 5 mg/ml (49.25 ml) Ketorolac (Brand Names: Toradol, Sprix, Acuvail, Acular) 30 mg/ml (1 ml) Epinephrine (Brand Names: EpiPen, Adrenaclick, Medihaler-Epi, Twinject) 1 mg/ml (0.5 ml) Clonidine (Brand Names: Kapvay, Catapres, Duraclon, Nexiclon) 0.1 mg/ml (0.08 mg = 0.8 ml) Normal Saline added to total of 100 cc Dosage Form: Injection Dosage: See above Frequency: Single dose"
62171414|NCT02571283|EXPERIMENTAL|Randomized Group B [Cocktail Injection Plus Exparel]|"COCKTAIL INJECTION PLUS EXPAREL:~Cocktail Injection Consists of:~Ropivacaine (Brand Name: Naropin) 5 mg/ml (49.25 ml) Ketorolac (Brand Names: Toradol, Sprix, Acuvail, Acular) 30 mg/ml (1 ml) Epinephrine (Brand Names: EpiPen, Adrenaclick, Medihaler-Epi, Twinject) 1 mg/ml (0.5 ml) Clonidine (Brand Names: Kapvay, Catapres, Duraclon, Nexiclon) 0.1mg/ml (0.08 mg = 0.8 ml) Normal Saline added to total of 100 cc Dosage Form: Injection Dosage: See above Frequency: Single dose~Bupivacaine Liposome (Brand Name: Exparel) Dosage Form: Injection Dosage: 20 ml Single use vial, 1.3% (13.3 mg/ml) Frequency: Single dose"
62171415|NCT02571283|EXPERIMENTAL|Randomized Group C [Marcaine Plus Exparel]|"MARCAINE PLUS EXPAREL:~Bupivacaine Hydrochloride (Brand Name: Marcaine, Sensorcaine) Dosage Form: Injection Dosage: 3 ml vial, 0.5% solution Frequency: Single dose~Bupivacaine Liposome (Brand Name: Exparel) Dosage Form: Injection Dosage: 20 ml Single use vial, 1.3% (13.3 mg/ml) Frequency: Single dose"
62171416|NCT03078751|EXPERIMENTAL|Ribociclib + adjuvant endocrine therapy (ET)|"Patients in this arm took Ribociclib in combination with standard adjuvant endocrine therapy.~ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen (Tamoxifen no longer permitted after protocol amendment 2)"
62171417|NCT03078751|PLACEBO_COMPARATOR|Placebo + adjuvant endocrine therapy (ET)|Patients in this arm took Placebo in combination with standard adjuvant endocrine therapy. ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen
62171418|NCT05878990|ACTIVE_COMPARATOR|Culturally-tailored Tobacco Treatment Intervention|Upon consent, participants will complete a baseline survey, receive the home Carbon monoxide monitor and instructions on how to use, and be scheduled for weekly telephone calls with a certified tobacco treatment specialist (CTTS) for 6 weeks. The culturally-tailored tobacco intervention content by week via telephone call with the CTTS includes among others: Reasons and Motivations for Quitting, Benefits of Quitting, Stress Management and Discussion about Environmental Influences. Participants will also receive weekly Culturally-tailored Content Newsletters emailed after their weekly cessation counseling session.
62171419|NCT05878990|ACTIVE_COMPARATOR|Preference-Driven Culturally-tailored Tobacco Treatment Intervention|Upon consent, participants will complete a baseline survey, receive the home Carbon monoxide monitor and instructions on how to use, and be scheduled for weekly telephone calls with a certified tobacco treatment specialist (CTTS) for 6 weeks. The culturally-tailored tobacco intervention content by week via telephone call with the CTTS includes among others: Reasons and Motivations for Quitting, Benefits of Quitting, Stress Management and Discussion about Environmental Influences. Participants will complete the one-item Control Preference Scale and receive either an Active Content Newsletter or Passive Content Newsletter emailed after their weekly cessation counseling session.
62171420|NCT01748578|ACTIVE_COMPARATOR|EBI-005-1 5mg/mL|Healthy subjects will be randomized to EBI-005 5mg/mL vs. EBI-005-1 Placebo 3x/day
62171421|NCT01748578|ACTIVE_COMPARATOR|EBI-005-1 20 mg/mL|Healthy subjects will be randomized to EBI-005 20 mg/mL vs. EBI-005-1 Placebo 3x/day
62171422|NCT04461314|OTHER|Peer-led counselling|"1. About 50 university students trained as peer telephone counsellors through a structured training programme.~2. About 200 Drug-abusing youth and young adults received telephone-based, Peer-led Brief Motivational Interviewing (BMI)"
62171423|NCT05160597|EXPERIMENTAL|Diagnostic (68Ga-PSMA-11, image-guided prostate biopsy)|"SCREENING PROCEDURE: Patients receive 68Ga-PSMA-11 IV and 50-100 minutes later, undergo a PET/CT scan. Only patients with 68Ga-PSMA-11 uptake within the prostate proceed to image-guided biopsy.~IMAGE-GUIDED BIOPSY: Patients undergo experimental image-guided prostate biopsy using PET/CT images obtained during screening procedure during a standard of care TRUS."
62171424|NCT06423859|ACTIVE_COMPARATOR|Articaine alone|supraclavicular brachial plexus block will be performed in this group guided by ultrasound. A 30 ml volume local anesthetic will be injected in the form of (29 cc articaine 2% + 1 cc isotonic saline)
62171425|NCT06423859|EXPERIMENTAL|Articaine and Dexmedetomidine|supraclavicular brachial plexus block will be performed in this group guided by ultrasound. A 30 ml volume local anesthetic will be injected in the form of (29 cc articaine 2% + 1 cc volume of Dexmedetomidine 1 ug/kg)
62171426|NCT05000411|EXPERIMENTAL|Experimental group|
62171427|NCT05000411|PLACEBO_COMPARATOR|Control group|
62171428|NCT02212301|ACTIVE_COMPARATOR|senofilcon A / lotrafilcon B|Subjects were randomized to one of two lens wear sequences. Subjects randomized to this sequence first wore the senofilcon A contact lens and then wore the lotrafilcon B contact lens.
62171429|NCT02212301|ACTIVE_COMPARATOR|lotrafilon B/ senofilcon A|Subjects were randomized to one of two lens wear sequences. Subjects randomized to this sequence first wore the lotrafilcon B contact lens and then wore the senofilcon A contact lens
62171430|NCT04976283|ACTIVE_COMPARATOR|Pioglitazone|The starting dose would be 15mg/day for pioglitazone and 500 to 1500mg per day for metformin (depending on blood glucose levels). Starting dose for DPP4 inhibitors would be 50 to 100mg daily.
62171431|NCT04976283|ACTIVE_COMPARATOR|Empagliflozin|The starting dose would be 500-1500mg/day of metformin, plus 5/10/12.5mg empagliflozin (depending on blood glucose levels). Starting dose for DPP4 inhibitors would be 50 to 100mg daily.
62171432|NCT04976283|ACTIVE_COMPARATOR|Pioglitazone + Empagliflozin|The starting dose would be 15mg/day for pioglitazone and 500 to1500mg per day for metformin and 5/10/12.5mg/25mg/day empagliflozin and 50 to 100mg daily for DPP4 inhibitors depending on blood sugar levels.
62171433|NCT02899481|EXPERIMENTAL|Study group|The study group will be constituted by pregnant women in whom the operative delivery will be preceded by a transabdominal and transperineal ultrasound to evaluate fetal head position and fetal head station, by means of determination of the 'angle of progression'.
62171434|NCT02899481|NO_INTERVENTION|Control group|The control group will be constituted by pregnant women in whom the operative delivery will be carried out based solely on clinical criteria, namely transvaginal digital examination.
62171435|NCT02123277|EXPERIMENTAL|concept proof|Balloon catheter for the Eustachian tube
62171436|NCT02062281|ACTIVE_COMPARATOR|23-valent Pneumococcal Polysaccharide vaccine|"0.5ml 23-valent pneumococcal Polysaccharide vaccine made by Chengdu Institute of Biological Products Co.,Ltd.~lot number: 20130106-1, duration:JAN,17,2015."
62171437|NCT02062281|ACTIVE_COMPARATOR|Trivalent Influenza Vaccine|"0.5ml trivalent influenza vaccine made by Shanghai Institute of Biological Products Co.,Ltd.~lot number:20130713, duration:Jul,1,2014."
62171438|NCT02062281|EXPERIMENTAL|23vPPV+TIV|
62171439|NCT01965041|EXPERIMENTAL|Eyelea, ophthalmic exam, photgraphy|2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaCl
62171440|NCT02958475|EXPERIMENTAL|Attention Control|Participants in control arm will receive normal standard messages about infant injury prevention.
62171441|NCT02958475|ACTIVE_COMPARATOR|Breastfeeding Messages plus Social Support|Participant will receive between 5-7 text messages weekly through push notifications to their phone. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action. In addition they will be able to download the MMM app, which will store text messages received. Additionally, participants in this arm will be able to link within the app to a private Facebook page. Participants can access this page through their app or directly via Facebook where they can view, comment, and share in response to posts. The MMM app has three main elements: text messages via push notification are stored and searchable on the app, access to a breastfeeding social support group on Facebook, and access to videos and written material to facilitate knowledge acquisition and skills building.
62171442|NCT02958475|ACTIVE_COMPARATOR|Breastfeeding Messages only|Participant will receive between 5-7 text messages weekly through push notifications to their phone. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
62171443|NCT00579657|PLACEBO_COMPARATOR|1|"Intervention: 'control diet, supported by dietary supplement twice daily'~control diet \[carbohydrates 55(50 - 60)% , protein 15(10 - 20)% protein; fat ca. 30% of energy content; dietary fiber \< 15 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement daily)\]"
62171444|NCT00579657|EXPERIMENTAL|2|"Intervention: 'high cereal fiber diet, supported by dietary supplement twice daily'.~high cereal fiber diet \[carbohydrates 55(50 - 60)% , protein 15(10 - 20)% protein; fat ca. 30% of energy content; dietary fiber \> 20 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 15 g cereal fiber daily)\]"
62171445|NCT00579657|EXPERIMENTAL|3|"Intervention: 'high protein diet, supported by dietary supplement twice daily'~high protein diet \[carbohydrates 40 - 45% , protein \> 25 - 30%; fat ca. 30% of energy content; dietary fiber \< 15 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 25 g whey and plant protein daily)\]"
62171446|NCT00579657|EXPERIMENTAL|4|"Intervention: diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily.~high cereal fiber/high protein (MIX) moderately high cereal fiber/high protein diet (carbohydrates 45- 50)% , protein 20 - 25%; fat ca. 30% of energy content; dietary fiber 15 - 20 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 15 g cereal fiber and 2 x 25 g whey and plant protein daily)"
62171447|NCT05436145|EXPERIMENTAL|Within-participant micro-randomization|"Each day in the study, with probability .5 for each, a participant is randomized to receive a notification that day or no notification that day.~If a participant is assigned to receive a notification that day, 1 message set will be randomly selected from a pool of 60 message sets. There are 2 types of message sets: 1) Support and 2) Consequences.~If a participant is assigned to receive a Support message set, they will be randomized to receive either the Emotional or Practical Support version. If a participant is assigned to receive a Consequences message set, they will be randomized to receive either the Gain Framed or Loss Framed version."
62171448|NCT01031186|EXPERIMENTAL|Cohort 1, Session 1|In Dosing Session 1, the subjects will be administered 0.5 mg GSK356278 and placebo in a fasted state.
62171449|NCT01031186|EXPERIMENTAL|Cohort 1, Session 2|In Dosing Session 2, the subjects will be administered GSK356278 (0.5 mg and 1.5 mg) and placebo in a fasted state.
62171450|NCT01031186|EXPERIMENTAL|Cohort 1, Session 3|In Dosing Session 3, the subjects will be administered GSK356278 (1.5 mg and 4 mg) and placebo in a fasted state.
62171451|NCT01031186|EXPERIMENTAL|Cohort 1, Session 4|In Dosing Session 4, the subjects will be administered GSK356278 (4 mg and 8 mg) and placebo in a fasted state.
62171452|NCT01031186|EXPERIMENTAL|Cohort 1, Session 5|In Dosing Session 5, the subjects will be administered GSK356278 8 mg and placebo in a fasted state.
62171453|NCT01031186|EXPERIMENTAL|Cohort 2, Session 1|In Dosing Session 1, the subjects will be administered 8 mg GSK356278 and placebo in a fasted state.
62171454|NCT01031186|EXPERIMENTAL|Cohort 2, Session 2|In Dosing Session 2, the subjects will be administered GSK356278 (8 mg and 16 mg) and placebo in a fasted state.
62171455|NCT01031186|EXPERIMENTAL|Cohort 2, Session 3|In Dosing Session 3, the subjects will be administered GSK356278 (16 mg and 30 mg) and placebo in a fasted state.
62171456|NCT01031186|EXPERIMENTAL|Cohort 2, Session 4|In Dosing Session 4, the subjects will be administered GSK356278 (30 mg and 50 mg) and placebo in a fasted state.
62171457|NCT01031186|EXPERIMENTAL|Cohort 2, Session 5|In Dosing Session 5, the subjects will be administered GSK356278 50 mg and placebo in a fasted state. The subjects will undergo food assessment session in Session 5 incase they experience nausea. In food assessment session, the subjects will receive a dose of GSK356278 after a standard breakfast.
62171458|NCT02364609|EXPERIMENTAL|Arm I (afatinib dimaleate, pembrolizumab)|"DOSE DE-ESCALATION COHORT: Patients receive afatinib dimaleate PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days (for up to 2 years for pembrolizumab) in the absence of disease progression or unacceptable toxicity.~6 patients were enrolled into Dose Level 0 at 40 mg QD of afatinib, no de-escalation was needed prior to expansion."
62171459|NCT02364609|EXPERIMENTAL|Arm II (pembrolizumab, afatinib dimaleate)|"EXPANSION COHORT: Patients receive pembrolizumab IV over 30 minutes on day 1 for 2 courses. Beginning course 3, patients receive afatinib dimaleate PO and pembrolizumab IV as in Arm I. Courses repeat every 21 days (up to 2 years for pembrolizumab) in the absence of disease progression or unacceptable toxicity.~All five expansion patients were enrolled at the dose of 40 mg QD of Afatinib."
62171460|NCT00609323|EXPERIMENTAL|1|
62171461|NCT00609323|PLACEBO_COMPARATOR|2|
62171462|NCT02722122|EXPERIMENTAL|AIR DNase™ 2.5 mg|2.5 mg of AIR DNase™ administered once daily via inhalation for 28 days
62171463|NCT04741815|EXPERIMENTAL|Forced Air Warming Group|There is no intervention in patients before the operation. When he comes out of the operation and comes to the post-anesthesia care unit (PACU), he is warmed by forced air. When the body temperature of the patients reaches 36 ° C, they are transferred to the clinic with a cover and blanket.
62171464|NCT04741815|EXPERIMENTAL|Peripheral Carbon Fiber Warming Group|Gloves and socks developed by the researcher are applied half an hour before the operation. These materials, called environmental warming, have three layers. The first layer in contact with the patient is a thermal inner sheath made of 90% Polyester and 10% Polyamide and is used to maintain body temperature. The second layer consists of carbon fiber warmer and foil. The end of the carbon fiber warmer is USB connected. When the connection is plugged in, the warmer works. The third layer is again made of thermal fabric. A rubber bandage is made to separate the last layer from the external environment and to maintain the patient's body temperature. The USB connection is removed while patients are sent for surgery. After the operation, rewarming is started in the post-anesthesia care unit. When the patient's body temperature reaches 36 ° C, he is transferred to the clinic with a cover and blanket.
62171465|NCT04741815|NO_INTERVENTION|Control Group|A routine hospital procedure is applied. The patient is not warmed before going to surgery. A cover and blanket are used passively after being taken to the PACU from the operation.
62171466|NCT01333137|ACTIVE_COMPARATOR|Gemcitabine and Carboplatin|Gemcitabine 1000 mg/m2/day on Days 1 \& 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
62171467|NCT01333137|EXPERIMENTAL|P276-00 along with Gemcitabine and carboplatin|P276-00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 \& 8 every 21 days.In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
62171468|NCT06244030|EXPERIMENTAL|Core Stabilization Group|The athletes in the core stabilization group will be applied a 15-20 repetition core stabilization exercise program 3 days a week for 6 weeks by the researcher. The duration of the exercise program is planned not to exceed 30 minutes. The values before and after the exercise program will be recorded.
62171469|NCT06244030|NO_INTERVENTION|Control Group|The control group will not be given any exercise other than their own wrestling training program.
62171470|NCT03650244||Patients fitted with REMEEX|
62171471|NCT01971034|EXPERIMENTAL|Paclitaxel and Metformin|
62171472|NCT05744791|EXPERIMENTAL|Active Play Intervention|Preschool teachers will be asked to implement two active play activities each preschool day, one indoors and one outdoors. This is in addition to the current outdoor free play of 30 minutes each day. Each activity is 10-15 minutes for a total of 20-30 minutes per day.
62171473|NCT05744791|NO_INTERVENTION|Control|Preschool teachers will continue to implement their regular curriculum. This consists of one outdoor play opportunity for 30 minutes each day.
62171474|NCT04056117|EXPERIMENTAL|NA (Non-adjuvanted) - very low dose - infants|Infants receive 3 very low doses of the non-adjuvanted investigational product
62171475|NCT04056117|EXPERIMENTAL|A (adjuvanted) - very low dose - infants|Infants receive 3 very low doses of the adjuvanted investigational product
62171476|NCT04056117|EXPERIMENTAL|NA (Non-adjuvanted) - low dose -infants|Infants receive 3 low doses of the non-adjuvanted investigational product
62171477|NCT04056117|EXPERIMENTAL|A (adjuvanted) - low dose - infants|Infants receive 3 low doses of the adjuvanted investigational product
62171478|NCT04056117|EXPERIMENTAL|NA (non-adjuvanted) - medium dose - infants|Infants receive 3 medium doses of the non-adjuvanted investigational product
62171479|NCT04056117|EXPERIMENTAL|A (adjuvanted) - medium dose - infants|Infants receive 3 medium doses of the adjuvanted investigational product
62171480|NCT04056117|EXPERIMENTAL|NA (non-adjuvanted) - medium dose - children|Children receive 3 medium doses of the non-adjuvanted investigational product
62171481|NCT04056117|EXPERIMENTAL|A (adjuvanted) - medium dose - children|Children receive 3 medium doses of the adjuvanted investigational product
62171482|NCT04056117|EXPERIMENTAL|NA (non-adjuvanted) - medium dose-adults|Adults receive 2 medium doses of the non-adjuvanted investigational product
62171483|NCT04056117|EXPERIMENTAL|A (adjuvanted) - medium dose - adults|Adults receive 2 medium doses of the adjuvanted investigational product
62171484|NCT04056117|EXPERIMENTAL|NA (non-adjuvanted) - high dose - infants|Infants receive 3 high doses of the non-adjuvanted investigational product
62171485|NCT04056117|EXPERIMENTAL|A (adjuvanted) - high dose - infants|Infants receive 3 high doses of the adjuvanted investigational product
62171486|NCT04056117|EXPERIMENTAL|NA (non-adjuvanted) - high dose - children|Chilldren receive 3 high doses of the non-adjuvanted investigational product
62171487|NCT04056117|EXPERIMENTAL|A (adjuvanted) - high dose - children|Chilldren receive 3 high doses of the adjuvanted investigational product
62171488|NCT04056117|EXPERIMENTAL|NA (non-adjuvanted) - high dose - adults|Adults receive 2 high doses of the non-adjuvanted investigational product
62171489|NCT04056117|EXPERIMENTAL|A (adjuvanted) - high dose - adults|Adults receive 2 high doses of the adjuvanted investigational product
62171490|NCT04056117|EXPERIMENTAL|MenACWY-Placebo|Adults receive one administration of MenACWY followed by one placebo administration
62171491|NCT04056117|OTHER|Rabies|Children receive three administrations of Rabies
62171492|NCT04056117|OTHER|MenACWY-DTaP|Infants receive two administrations of MenACWY followed by DTaP administration
62171493|NCT05114902||PCV13 Non-vaccinated Settting|Pneumococcal vaccine-naïve children at the PCMC
62171494|NCT05114902||PCV13 Vaccinated Setting|Pneumococcal vaccine-exposed children at the SPMC
62171495|NCT04231266|ACTIVE_COMPARATOR|ManNAc|Oral ManNAc will be administered at a dose of 4 grams three times daily (total of 12 grams daily).
62171496|NCT04231266|PLACEBO_COMPARATOR|Placebo|Oral Placebo will be administered three times daily.
62171497|NCT00862485||StudyGroup|
62363850|NCT02512276|EXPERIMENTAL|Telepharmacist intervention|Patients diagnosed with diabetes, hypertension, or hyperlipidemia exhibiting sub-optimal adherence to their medications \[defined as combined (average of averages) proportion of days covered (PDC) \< 80%\] who also have poor or worsening disease control.
62171498|NCT02865759|EXPERIMENTAL|Mindfetalness|The pregnant woman will be informed about the possibility of practicing Mindfetalness verbally, in a brochure and at a website. The practice is described as spending 15 minutes every day from gestational week 28 to get to know the fetal movement pattern. The fetus must be awake when she practice Mindfetalness and the woman is suggested to lay on her left side when she observe the fetal movements. In the brochure as well at the website the woman can write down something about the nature, frequency or strength of the fetal movements. If the woman experiences decreased frequency of fetal movements or weaker movements she is instructed to seek health-care without unnecessary delay.
62171499|NCT02865759|NO_INTERVENTION|Routine Care|No activities will take place in the antenatal clinics randomized to routine care.
62171500|NCT04029792|EXPERIMENTAL|Combination of Plant Extracts (BSL_EP028)|Volunteers will take twice at day for 8 weeks a capsule containing the combination of a plant extracts (BSL_EP028)
62171501|NCT04029792|PLACEBO_COMPARATOR|Placebo|Volunteers will take twice at day for 8 weeks a capsule containing maltodextrin.
62171502|NCT05924048|EXPERIMENTAL|Group of 2% oxygen concentration.|Incubate human embryo at 2% oxygen concentration.
62171503|NCT05924048|NO_INTERVENTION|Group of 5% oxygen concentration.|Incubate human embryo at 5% oxygen concentration.
62171504|NCT06478056|OTHER|Surgery|patients operated on for pancreatic adenocarcinoma in the digestive surgery department of Rouen University Hospital
62171505|NCT03964038|ACTIVE_COMPARATOR|gilteritinib|Participants will receive a single dose of gilteritinib under fasting conditions.
62171506|NCT03964038|EXPERIMENTAL|gilteritinib mini-tablet oral suspension|Participants will receive a single dose of gilteritinib oral suspension with water under fasting conditions.
62171507|NCT03964038|EXPERIMENTAL|gilteritinib mini-tablet|Participants will receive a single dose of gilteritinib mini-tablets under fasting conditions.
62171508|NCT06288256||Adults Undergoing Spine Surgery|Adults Undergoing Spine Surgery on opiods
62171509|NCT05470218|ACTIVE_COMPARATOR|Standard protein meal|Participants will receive a standard protein meal, containing about 10% of energy as protein
62171510|NCT05470218|ACTIVE_COMPARATOR|High protein meal|Participants will receive a high protein meal, containing about 50% of energy as protein
62171511|NCT05470218|ACTIVE_COMPARATOR|Low protein meal + leucine|Participants will receive a standard protein meal, containing about 10% of energy as protein to which leucine has been added to match the total leucine content of the high protein meal
62171512|NCT06162637|OTHER|A|grup A with femoral neck fracture will be fixed by femoral neck locking plate
62171513|NCT06162637|OTHER|B|grup B with femoral neck fracture will be fixed by Multiple cannulated cancellous screws
62171514|NCT01547182|ACTIVE_COMPARATOR|Weight Loss|Caloric restriction
62171515|NCT01547182|EXPERIMENTAL|Weight Loss and Aerobic Training|Caloric restriction and walking
62171516|NCT01547182|EXPERIMENTAL|Weight Loss and Resistance Training|Caloric restriction and lifting weights
62171517|NCT04364022|ACTIVE_COMPARATOR|Lopinavir/Ritonavir|
62171518|NCT04364022|NO_INTERVENTION|Active surveillance|
62171519|NCT05699369|EXPERIMENTAL|Intervention arm|A comprehensive package of digital health interventions to connect patients, patient champions and public health providers to improve the management of non-communicable diseases (NCDs) during the pandemic will be implemented, including 1) providing training to health providers regarding an integrated NCD-COVID guideline; 2) using a smartphone app to improve NCD case management and linking with patient champions; and 3) employing telementoring platform to improve quality of care. Patient champions are experienced patients who can provide peer support.
62171520|NCT05699369|NO_INTERVENTION|Control arm|Usual care, which is routine hypertension and diabetes diagnosis and treatment under the World Diabetes Foundation (WDF) project will be implemented. The WDF project provides initial Zoom-based training of NCD care to rural health center (RHC) staff, but no tele-mentorship is offered. Under the usual care, patients with hypertension or diabetes are required to visit RHCs every month to renew their medications and measure their blood pressure. No other interventional components will be implemented in the control arm.
62171521|NCT06224335||sportwoman with high intensity of physical activity with stress urinary incontinence|High-intensity of regular physical activity at least three days per week, 90 minutes per day, for more than two years.
62171522|NCT06224335||sportwoman with high intensity of physical activity without stress urinary incontinence|High-intensity of regular physical activity at least three days per week, 90 minutes per day, for more than two years.
62171523|NCT04723888|EXPERIMENTAL|alpha-ketoglutarate Group|Take alpha-ketoglutarate supplements, alpha-ketoglutarate 300mg/d mixed with food or drink, for 1 years
62171524|NCT04723888|NO_INTERVENTION|Normal Control Group|Don't take alpha-ketoglutarate supplements
62171525|NCT02621502|EXPERIMENTAL|Quinoa variety 1|1 dose of Quinoa Variety 1 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
62171526|NCT02621502|EXPERIMENTAL|Quinoa variety 2|1 dose of Quinoa Variety 2 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
62171527|NCT02621502|EXPERIMENTAL|Quinoa variety 3|1 dose of Quinoa Variety 3 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
62171528|NCT02621502|EXPERIMENTAL|Quinoa variety 4|1 dose of Quinoa Variety 4 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
62363851|NCT02512276|NO_INTERVENTION|Usual care|Patients randomized to this arm will receive usual care.
62363852|NCT02382757||Children|
62363853|NCT05414513||Chronic Headache Group|Children with chronic headache
62363854|NCT05414513||Healthy Group|Children without pain
62171529|NCT02621502|ACTIVE_COMPARATOR|Anhydrous Glucose|1 dose of Anhydrous Glucose orally. . The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the control powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
62171530|NCT03714711||Total hip arthroplasty|Patient who are scheduled to undergo total hip replacement.
62171531|NCT03714711||Total knee arthroplasty|Patient who are scheduled to undergo total knee replacement.
62171532|NCT03597542|EXPERIMENTAL|Maltodextrin|Participants will consume 56g of maltodextrin dissolved in 500mL of water.
62171533|NCT03597542|EXPERIMENTAL|Egg|Participants will consume 36g of spray-dried egg powder (equivalent to 3 eggs) dissolved in 500mL of water.
62171534|NCT05758376|EXPERIMENTAL|Recovery Bridge|Open trial single arm pilot study
62171535|NCT00915785|EXPERIMENTAL|5 azacytidine|
62171536|NCT06363136||Study group|The group will include 14 children aged 7-16 who are voluntarily participating and being followed for bilateral isolated gastrocnemius tightness by the Department of Orthopedics and Traumatology at Bezmialem Vakif University.
62171537|NCT06363136||Control group|The group will consist 14 healthy children from the same age group.
62171538|NCT02513810|EXPERIMENTAL|Short-term DAPT after Biofreedom|
62171539|NCT02513810|ACTIVE_COMPARATOR|Long-term DAPT after BioMatrix or Ultimaster|
62171540|NCT04999956|EXPERIMENTAL|dynamic navigation|Dental implant placement using a dynamic navigation system
62171541|NCT04999956|SHAM_COMPARATOR|freehand|Dental implant placement using freehand technique
62171542|NCT05931289|ACTIVE_COMPARATOR|Enhanced Crisis Response Planning|Using supportive listening, a therapist conducts a brief interview to gather information about lifetime suicide attempt history and recent SI. The therapist then works with the client to identify a) warning signs for being in crisis, b) self-management/distraction strategies, c) reasons for living, d) sources of social support the client could contact in the event of a crisis, and e) crisis resources (e.g., veterans crisis line, contact information for current providers and local emergency resources). Steps for each of these, as well as specific contacts for social support and professional services are written on an index card provided to the patient and the patient is encouraged to keep the card in an accessible place (e.g., wallet) so it can be utilized in the event of a crisis.
62171543|NCT05931289|ACTIVE_COMPARATOR|Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT)|This weekly, 12-session intervention involves completion of an enhanced crisis response plan, as well as emotion regulation skills training, learning strategies to identify and challenge thinking patterns that contribute to suicide risk, and increased engagement in personally meaningful activities.
62171544|NCT05117879|OTHER|Cold snaring polypectomy|The sessile serrated adenoma size between 10-20mm would be resected by cold snaring polypectomy
62171545|NCT05117879|OTHER|Non-electrocautery Endoscopic Mucosal Resection (Cold EMR)|The sessile serrated adenoma size between 10-20mm would be resected by cold EMR
62171546|NCT05117879|OTHER|Electrocautery Endoscopic Mucosal Resection( Hot EMR)|The sessile serrated adenoma size between 10-20mm would be resected by Hot EMR
62171547|NCT03045302|EXPERIMENTAL|BIM23B065|
62171548|NCT06575699|EXPERIMENTAL|Rectus Sheath Block Group (Prospective arm)|Thirty subjects will be prospectively enrolled and will receive a bilateral rectus sheath block under ultrasound guidance using 133 mg liposomal bupivacaine and 20 ml bupivacaine 0.25% per side.
62171549|NCT06575699|ACTIVE_COMPARATOR|Thoracic Epidural Analgesia Group (retrospective arm)|60 patients who received thoracic epidural analgesia as part of our enhanced recovery after surgery protocol and stayed in hospital for at least 72 h.
62171550|NCT03081351|EXPERIMENTAL|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
62171551|NCT03081351|EXPERIMENTAL|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
62171552|NCT01158716|ACTIVE_COMPARATOR|Remote Ischemic Preconditioning|
62171553|NCT01158716|NO_INTERVENTION|Control|
62171554|NCT04471480|EXPERIMENTAL|group A，TCCA|paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w +anlotinib 10mg, PO, d1-14, q3w +camrelizumab 200 mg, IV, d1, q3w, after the treatment for 4-6 cycles, camrelizumab plus anlotinib for maintenance therapy until PD or intolerable toxicity
62171555|NCT04471480|EXPERIMENTAL|group B，TCC|paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w +camrelizumab 200 mg, IV, d1, q3w, after the treatment for 4-6 cycles, camrelizumab for maintenance therapy until PD or intolerable toxicity
62171556|NCT04471480|OTHER|group C，TC|paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w
62171557|NCT05738070||Patients with acute ischemic stroke|All the patients with stroke admitted to the hospital from July 2021 to July 2022 were included in this study. Patients with the following criteria were included in the study: (1) anterior circulation stroke established by diffusion-weighted imaging (DWI), (2) MRI performed within 72 hours of stroke onset, (3) Patient with occlusion of the vessel on MRA (Magnetic Resonance Angiography). (4) MRI performed before or during intravenous thrombolysis (IVT) or mechanical thrombectomy (MT). Infarcts with hemor¬rhagic transformation cases were not included in the study due to suboptimal SVS quantification
62171558|NCT04090216||Addict patients|patients with substance use disorders presented with STEMI \& undergoing Primary PCI
62171559|NCT04090216||Non Addict patients|patients without substance use disorders presented with STEMI \& undergoing Primary PCI
62171560|NCT03794128||1 - patient-specific neoantigen cancer vaccine production|
62171561|NCT03794128||2 - shared neoantigen cancer vaccine screening|
61986154|NCT03994692|ACTIVE_COMPARATOR|autogenous onlay grafting eminoplasty|"under general anesthesia , chin graft was taken Layered Endural approach to TMJ making wedge in eminence by mallet \& chisel (green stick fracture), then wedging piece of chin graft to increase the height of the eminence creating an obstacle to treat dislocation by manipulation of patient mandible intra operative.~- Functional mandibular movements were reproduced to confirm absence of subluxation then closure"
61986155|NCT04009421||High and low coronary artery plaque burden|Patients with high plaque burden defined as plaque in \>=4 segments of the coronary tree and low plaque burden as plaque in \<4 segments of the coronary tree assessed by postprocessing of CT coronary angiography images and cardiovascular events and mortality.
62171562|NCT06162806|ACTIVE_COMPARATOR|Group A|This group of patients will receive ultrasound guided caudal epidural block using 1ml/kg of Bupivacaine +0.5ulkg fentanyl
62171563|NCT06162806|EXPERIMENTAL|Group B|This group of patients will receive ultrasound guided caudal epidural block with 50 mg of magnesium added to (1ml/kg Bupivacaine+0.5ulkg fentanyl)bi-mixture
62171564|NCT06035003|EXPERIMENTAL|iMIED+TAU group|Internet-based Mindfulness Intervention for Emotional Distress (iMIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
62363855|NCT06391567||Control Group|The control group consisted of healthy subjects who were not diagnosed with Frozen Shoulder and did not have a chronic disease that would affect balance between the ages of 40-65.
61986156|NCT01536379|EXPERIMENTAL|Belimumab 10 mg|Subjects will receive belimumab 10 mg/ Kilogram (kg) infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care.
61986157|NCT01536379|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care
61986158|NCT04265274|EXPERIMENTAL|Disulfiram, vinorelbin, cisplatin, copper|Vinorelbine 25mg/m2 day 1 and 8, Cisplatin 75mg/m2 day 1, every 3 weeks, Disulifiram um 400mg daily and 2 mg of elementary Copper daily, continuously.
61986159|NCT04902716|EXPERIMENTAL|Precision Nursing, Frail women, Cognitive function, Sleep quality, Emotional state,|According to the characteristics of the elders in the community and making good use of health policies and local resources, a 12-week appropriate diversified curriculum is arranged as intervention measures.
61986160|NCT05300906|EXPERIMENTAL|Personalized|Participants in the personalized arm will receive the optimal combination of content, feedback and design, based on their baseline engagement scores.
61986161|NCT05300906|ACTIVE_COMPARATOR|non-personalized|Participants in the non-personalized arm will receive a randomly selected version of the 27 possible interventions, regardless of their baseline engagement scores.
61986162|NCT04698733|EXPERIMENTAL|Experimental: BEST™ Pro-Sport Ultra® microcurrent device|Participants will receive 2 treatments a week on nonconsecutive days for 6 weeks in the clinic with an active electrical stimulation device.
61986163|NCT06039423|ACTIVE_COMPARATOR|Group (M)|"The M-TAPA block will be combined with general anaesthesia.~:"
61986164|NCT06039423|PLACEBO_COMPARATOR|Group (C)|(control group) conventional general anaesthesia receiving multimodal analgesia.
61986165|NCT06291051|EXPERIMENTAL|Electrical spinal cord stimulation in Parkinson's patients presenting with painful camptocormia|
61986166|NCT01423487|EXPERIMENTAL|efficacy and safety|To investigate the efficacy and safety of Metformin in preventing patients with Risperidone from weight gain and amenorrhea.
61986167|NCT01423487|PLACEBO_COMPARATOR|placebo comparator|To investigate whether plcebo also could preventing patients with Risperidone from weight gain and amenorrhea.
61986168|NCT00661076|EXPERIMENTAL|1|
61986169|NCT00661076|EXPERIMENTAL|2|
61986170|NCT00661076|ACTIVE_COMPARATOR|3|
61986171|NCT01075204||Clarithromycin modified release|Patients with upper or lower respiratory tract infection were administered clarithromycin modified release 500 mg once daily for 7 days and then followed for a further 3 days, per routine clinical practice.
61986172|NCT03608514|ACTIVE_COMPARATOR|nor-epinephrine+/- epinephrine infusion|"Intravenous infusion of Nor-epinephrine in an initial dose of 0.01µg/kg/min. which can be increased every 15-30 minutes to maximum 3µg/kg/min. ± intravenous infusion of epinephrine with an initial dose 0.05µg/kg/min. \& can be titrated every 15-30 minutes up to 2µg/Kg/min.~The end point is to achieve mean arterial pressure ≥ 65 mmHg \& normalized lactate ≤ 2 mmol/L or lactate clearance ≥ 10% within 6 hours.~Patients will be followed for 48 hours."
61986173|NCT03608514|OTHER|Terlipressin infusion|"Intravenous infusion of terlipressin by rate 1-2µg/kg/min. The end point is to achieve mean arterial pressure ≥ 65 mmHg \& normalized lactate ≤ 2mmol/L or lactate clearance ≥ 10% within 6 hours.~Patients will be followed for 48 hours."
61986174|NCT04372680|EXPERIMENTAL|CTUS strategy group|CTUS examination will be performed until the day of patient extubation. CTUS examination will consist on a fully bedside ultrasonographic assessment of lung, cardiac and diaphragm functions
61986175|NCT04372680|NO_INTERVENTION|standard strategy group|from the day of patient's inclusion and beyond every day, the clinical team in charge of patients will decide to perform or not an SBT following current recommendations2. These criteria are mainly based on clinical data and do not include any specific ultrasound assessment.
61986176|NCT00713336|EXPERIMENTAL|1|ZD4054 + Moxifloxacin placebo
61986177|NCT00713336|ACTIVE_COMPARATOR|2|ZD4054 placebo + Moxifloxacin
61986178|NCT00713336|EXPERIMENTAL|3|ZD4054 + ZD4054 placebo + Moxifloxacin placebo
61986179|NCT00713336|PLACEBO_COMPARATOR|4|ZD4054 Placebo + Moxifloxacin placebo
61986180|NCT02955979||CT scan with iodinated contrast agents|Patients under 16 years old and must pass a CT scan with iodinated contrast agents. The following data will be collected in the medical record (creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern).
62171565|NCT06035003|NO_INTERVENTION|the TAU-only group|treatment as usual (TAU) group consisted of all medicinal and psychological treatments received between baseline and follow-up (about five months). Medicinal treatments included receiving Lorazepam, Olanzapine, Paroxetine Hydrochloride, Sertraline, etc. Psychological treatments included receiving cognitive behavior therapy or psychodynamic therapy.
62171566|NCT02835937|NO_INTERVENTION|Transfuse|Patients will receive a transfusion under standard care
62171567|NCT02835937|EXPERIMENTAL|No-Transfuse|Patients will not receive a transfusion
62171568|NCT05114161|NO_INTERVENTION|Standard care|All participants/caregivers will be asked for consent for point-of-care (POC) blood C-reactive protein (CRP), nasopharyngeal swab for virology/Mycoplasma testing, and urine for pneumococcal antigen (UAg) testing, but, since this testing will not affect care, these are optional (ie. refusal will not preclude enrolment). The RA will phone the caregiver at Day 2-5, Day 14-21, and Day 30 post-enrollment, for outcome ascertainment. Caregivers will be asked to fill out a daily diary (either electronically or on paper) to record the participant's symptoms, clinical progress, and possible drug adverse effects. Caregivers will also be instructed on how to take patient temperature. All participants whose symptoms do not progressively improve will be encouraged to return to the ED to be reassessed, as per standard of care.
62171569|NCT05114161|EXPERIMENTAL|Novel Care Pathway|Once a child is diagnosed with non-severe CAP (community-acquired pneumonia) in the ED, specific radiographic findings and point-of-care CRP testing will identify those who require antibiotic treatment immediately. The next day, results of multiplex respiratory pathogen and urine pneumococcal antigen (UAg, optional) testing will be integrated into the care plan, along with additional clinical information about the child gathered remotely, to ensure that only children at appreciable risk for bacterial infection receive antibiotics. Our care pathway uses already-available testing (NPS) in new ways, integrates newer diagnostics (point-of-care CRP, UAg), and includes properly-timed clinical follow up to change how children with non-severe CAP are managed.The research team will follow-up with the participant and caregiver the next day, 2-5 days, 7-21 days and day 30 post-enrolment to ensure clinical stability.
62171570|NCT04966936||Unilateral traumatic transfemoral amputee patients using C-Leg prosthesis|The activity levels of the patients will be evaluated by the Amputee Mobility Predictor, the mobility of the patients by the Locomotor Capacity Index, the prosthesis satisfaction in general with the visual analog scale (VAS), the walking ability and capacity with the prosthesis will be evaluated by the 2 min walking test, and the gait analysis will be evaluated in the motion analysis laboratory.
62171571|NCT04966936||Unilateral traumatic transfemoral amputee patients using Genium prosthesis|The activity levels of the patients will be evaluated by the Amputee Mobility Predictor, the mobility of the patients by the Locomotor Capacity Index, the prosthesis satisfaction in general with the visual analog scale (VAS), the walking ability and capacity with the prosthesis will be evaluated by the 2 min walking test, and the gait analysis will be evaluated in the motion analysis laboratory.
62171572|NCT04966936||Unilateral traumatic transfemoral amputee patients using Genium-X3 prosthesis|The activity levels of the patients will be evaluated by the Amputee Mobility Predictor, the mobility of the patients by the Locomotor Capacity Index, the prosthesis satisfaction in general with the visual analog scale (VAS), the walking ability and capacity with the prosthesis will be evaluated by the 2 min walking test, and the gait analysis will be evaluated in the motion analysis laboratory.
62171573|NCT03512587|EXPERIMENTAL|Personal quantum sonotherapy group|Patients who will listen through MP3 devices the personalized quantum sonotherapy previously created through a especialized software, before the application of regional anesthesia.
62171574|NCT03512587|PLACEBO_COMPARATOR|Control group|Patients will wear headphones but without playing the personalized quantum sonotherapy
62171575|NCT02123797||Multidisciplinary Clinic Patients|: 150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients
62171576|NCT02123797||Serial Care Patients|150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients = 450 patients Since Baptist Health Care System manages \>800 new cases each year, 300 of which are expected to be seen in multidisciplinary clinic, in practice, we conservatively expect to be able to recruit 150 cases from multidisciplinary clinic and 300 matched serial care controls (1:2 match) in 18 months.
62171577|NCT02123797||Multidisciplinary Caregivers|Consenting caregivers of consented multidisciplinary clinic patients (patients seen by multiple specialists at a single appointment time).
62171578|NCT02123797||Serial Care Caregivers|Consenting caregivers of consented serial care patients (patients who receive the current system of linear, sequential, referral-based care delivery).
62171579|NCT02123797||Clinical Providers|Clinical providers who referred at least 5 patients to the multidisciplinary program and consented to the study.
62171580|NCT05859009|ACTIVE_COMPARATOR|EUS-Guided Therapy of glue and coil + Non-selective Beta Blockers (Propanolol)|Participants in this arm will receive a daily oral dose of a non-selective beta blocker (Propanolol) and undergo EUS-guided therapy of glue and coil as described in Arms 1 and 2. Participants will be monitored for side effects, complications, and efficacy of both the medication and the procedure.
62171581|NCT05859009|ACTIVE_COMPARATOR|EUS-Guided Therapy of Glue and Coil|Participants in this arm will undergo endoscopic ultrasound (EUS) to identify and target gastric varices. Under EUS guidance, a combination of glue and coil will be used to occlude the gastric varices. Participants will be monitored for complications and efficacy of the procedure
62171582|NCT05859009|ACTIVE_COMPARATOR|Non-Selective Beta Blockers (Propanolol)|Participants in this arm will receive a daily oral dose of a non-selective beta blocker (such as propranolol) for the duration of the study. Participants will be monitored for side effects and efficacy of the medication.
62171583|NCT05017883|EXPERIMENTAL|TAA05 cell injection|TAA6 cell injection#Targeting FLT3 autologous chimeric antigen receptor T cells#
62171584|NCT04391218|EXPERIMENTAL|Multidisciplinary Approach Group|Multidisciplinary medication review and reconciliation during hospitalization involving geriatricians, nurses, pharmacists and supported by a Clinical Decision Support System, followed by an end-user App to support patients/caregivers in the correct drug intake after discharge.
62171585|NCT04391218|NO_INTERVENTION|Control Group|Medication review and reconciliation will be performed by geriatricians according to Good Clinical Practice and usual habits, that might also include digital and printed supports for medication appropriateness and drug interaction. Drug therapy will be listed and explained to the patient/caregiver at discharge. Patients/caregivers will be allowed to use any tools to support medication adherence, according to their habits and preferences (i.e. calendars, alarms, pill boxes).
62171586|NCT05830305|ACTIVE_COMPARATOR|Mobile health intervention|Subjects will enter their home BP measurements into a mobile stroke App (WeRISE) daily, and the study team will regularly review the BP measurements through a backend system. A protocol-based intervention via phone calls, which includes anti-hypertensive drug adjustment and reinforcement of lifestyle modification, will be implemented.
62171587|NCT05830305|NO_INTERVENTION|Usual care|Subjects will have their hypertension managed by their respective treating physicians.
62171588|NCT06149052|ACTIVE_COMPARATOR|Group A: warm up exercises with SMART training|For sensory stimulation planter massage was given, and it was applied to entire planter surface. Grade III anterior to posterior talocrural joint mobilization was given. For balance, single and double leg stance was performed. For functional training, lateral hops and SEBT was performed. And at the end, for resistance training, theraband was used with normal ankle joint movement. There is a progress in focus between the five domains over the 3weeks, as described below: The domains S and M are present across the whole intervention. In week 1, the main focus is on the A domain, in week 2 on the R domain, and in week 3 on the T domain. During the 3-week intervention period, 3 training sessions was held per week each lasting approximately 45 - 60 min, including 10 min warm up.
62171589|NCT06149052|ACTIVE_COMPARATOR|Group B: Warm up exercises with foot intensive rehabilitation(FIRE)|The FIRE intervention was included the progressive balance training, ankle and hip strengthening, range of motion exercises and foot massage. Plantar massage consisted of two, 1-min plantar massages with a 1-min rest between sets. Four previously established exercises were target the IFMs including the short-foot, toe-spread-out, hallux extension, and lesser-toe extension.
62171590|NCT04577586||Water|Patients who ingested only water as an oral contrast
62171591|NCT04577586||Milk|Patients who ingested milk as an oral contrast
62171592|NCT04577586||Mannitol|Patients who ingested mannitol as an oral contrast
62171593|NCT04722848|EXPERIMENTAL|Ponatinib+Blinatumomab|patients will receive induction with ponatinib followed by at least 2 cycles of blinatumomab
62171594|NCT04722848|ACTIVE_COMPARATOR|Chemotherapy+Imatinib|patients will receive a combination of imatinib and chemotherapy.
62171595|NCT03334747|EXPERIMENTAL|Treatment arm 1: KAE609 10 mg Single Dose (SD)|KAE609 10 mg once daily (QD) for 1 day
62171596|NCT03334747|EXPERIMENTAL|Treatment arm 2:KAE609 25 mg SD|KAE609 25 mg once daily (QD) for 1 day
62171597|NCT03334747|EXPERIMENTAL|Treatment arm 3:KAE609 10 mg 3 Days|KAE609 10 mg (QD) for 3 days
62171598|NCT03334747|EXPERIMENTAL|Treatment arm 4:KAE609 50 mg SD|KAE609 50 mg once daily (QD) for 1 day
62171599|NCT03334747|EXPERIMENTAL|Treatment arm 5:KAE609 25 mg 3 Days|KAE609 25 mg once daily (QD) for 3 days
62171600|NCT03334747|EXPERIMENTAL|Treatment arm 6:KAE609 75 mg SD|KAE609 75 mg once daily (QD) for 1 day
62171601|NCT03334747|EXPERIMENTAL|Treatment arm 7:KAE609 50 mg 3 Days|KAE609 50 mg once daily (QD) for 3 days
62171602|NCT03334747|EXPERIMENTAL|Treatment arm 8: KAE609 150 mg SD|KAE609 150 mg once daily (QD) for 1 day
62171603|NCT03334747|ACTIVE_COMPARATOR|Treatment arm 9: Coartem Control|Coartem® control
62171604|NCT02077153|EXPERIMENTAL|Group Reminescence|In the experimental condition, everything begins ensuring the participants that all the memories shared will not be spread out of the group. Every session will deal with a theme, recalling specific autobiographic experiences; they will be suggested following a chronological order. Participants are encouraged to bring photos or objects related to past themes: at the end of each meeting the theme of the following is revealed. The researchers can also bring materials as cues for reminiscence.
62171605|NCT02077153|ACTIVE_COMPARATOR|Group discussion|In the control condition, every meeting will offer topics for discussion taken from newspaper and newscasts: personal opinions are promoted, and links with the daily life of participants are welcome (everyday activities, personal preferences). The main goal is to stimulate the social interaction and the communication, without dealing with personal events from the past nor private memories.
62171606|NCT01930383||Arm A|HCC patients who receive curative surgery or radiofrequency ablation therapy
62171607|NCT01930383||Arm B|patients who receive trans-arterial chemoembolization
62171608|NCT01930383||Arm C|patients who receive systemic therapy
62171609|NCT05195905|EXPERIMENTAL|Physician-modified endografts|For this clinical protocol, endografts which are commercially available will be modified in a sterile fashion on a back-table in the operating room.
62171610|NCT06645808|EXPERIMENTAL|89Zr-F8scFv|"The first 3 patients of this arm will receive a single i.v. microsdose (1 mg) administration of 89Zr-F8scFv 15 MBq, followed by three whole-body PET/CT scans on day 1, 2 and 4. After the first three patients, an interim analysis will be conducted to determine the optimal scanning time point and radiation dose.~The following 13 patients will receive a single i.v. microsdose administration of 89Zr-F8scFv between 15 - 30 MBq, followed by one whole-body PET/CT scan on the optimal scanning day (day 1, 2 or 4). Each subject will have a follow-up visit approximately 28 days after IMP administration."
62171611|NCT06645808|EXPERIMENTAL|89Zr-C9scFv|"The first 3 patients of this arm will receive a single i.v. microsdose (1 mg) administration of 89Zr-C9scFv 15 MBq, followed by three whole-body PET/CT scans on day 1, 2 and 4. After the first three patients, an interim analysis will be conducted to determine the optimal scanning time point and radiation dose.~The following 13 patients will receive a single i.v. microsdose administration of 89Zr-C9scFv between 15 - 30 MBq, followed by one whole-body PET/CT scan on the optimal scanning day (day 1, 2 or 4). Each subject will have a follow-up visit approximately 28 days after IMP administration."
62171612|NCT03861585|EXPERIMENTAL|semantic group|"Half of the participants (named the semantic group) perform a semantic categorisation task."
62171613|NCT03861585|EXPERIMENTAL|emotional group|"Half of the participants (named the emotional group) perform an emotional evaluation task."
62171614|NCT05442424|EXPERIMENTAL|Produce Vouchers|Half of parent-child dyads will receive $60 per month for 6 months, to purchase fresh fruits and vegetables from a local farmers' market.
62171615|NCT05442424|ACTIVE_COMPARATOR|Wait-List Control|Half of parent-child dyads will be placed on a 6 month wait list and will receive $60 per month for 6 months, to purchase fresh fruits and vegetables from a local farmers' market, after completing the 6 month waiting period and follow up data collection.
62171616|NCT04282564|EXPERIMENTAL|CO-OP Arm (early phase A)|Patients will be integrated during the traditional day hospitalization follow-up, at the rate of 3 sessions per week. The patient will have 2 phases : phase A: CO-OP treatment during 6 week and phase B : without specific treatment during 3 weeks.
62171617|NCT04282564|EXPERIMENTAL|CO-OP Arm (mid phase A)|Patients will be integrated during the traditional day hospitalization follow-up, at the rate of 3 sessions per week. The patient will have 2 phases : phase A: CO-OP treatment during 6 week and phase B : without specific treatment during 2.5 weeks.
62171618|NCT04282564|EXPERIMENTAL|CO-OP Arm (late phase A)|Patients will be integrated during the traditional day hospitalization follow-up, at the rate of 3 sessions per week. The patient will have 2 phases : phase A: CO-OP treatment during 6 week and phase B : without specific treatment during 2 weeks.
62171619|NCT06584825|EXPERIMENTAL|Enhanced Vitals Monitoring|Enhanced (i.e. additional) monitoring using Health Canada approved devices in-hospital followed by thrice-daily monitoring at home 7 days after discharge (up to a maximum of 30 days postoperatively in total), with a protocol for clinical escalation if vital sign alert thresholds are exceeded.
62171620|NCT06584825|NO_INTERVENTION|Standard Care|Standard vitals monitoring in hospital and standard of care follow-up procedures once discharged home. The research team will administer a 30 day phone call and questionnaire.
62171621|NCT02177435|EXPERIMENTAL|Telmisartan plus Hydrochlorothiazide|
62171622|NCT02177435|EXPERIMENTAL|Telmisartan|
62171623|NCT01653171|NO_INTERVENTION|Control|Standard upper endoscopy withouth premedication
62171624|NCT01653171|PLACEBO_COMPARATOR|Water|100 mL of water, 20 minutes before upper endoscopy
62171625|NCT01653171|EXPERIMENTAL|Simethicone|Simethicone 200 mg, in water for up to 100 mL, to take 20 minutes prior to examination
62171626|NCT01653171|EXPERIMENTAL|N-acetylcysteine 500 mg + Simethicone|N-acetylcysteine 500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
62171627|NCT01653171|EXPERIMENTAL|N-acetylcysteine 1000 mg + Simethicone|N-acetylcysteine 1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
62171628|NCT05283525|PLACEBO_COMPARATOR|Placebo Group #1 (6.75 gms Once-A-Day)|Placebo Group #1 (1 Dose; 6.75 gms per day): A total of 25 subjects will be given 1 placebo sachet; To be taken one in the morning in an empty stomach over a period of 90 consecutive days
62171629|NCT05283525|PLACEBO_COMPARATOR|Placebo Group #2 (6.75 gms Twice-A-Day)|Placebo Group #2 (2 Doses; 13.5 gms in two divided doses per day): A total of 25 subjects will be given 2 placebo sachets; To be taken one in the morning in an empty stomach and the other in the afternoon in an empty stomach over a period of 90 consecutive days
62171630|NCT05283525|ACTIVE_COMPARATOR|TRCAP21 Group #1 (6.75 gms Once-A-Day)|TRCAP21 Group #1 (1 Dose; 6.75 gms per day): A total of 25 subjects will be given 1 TRCAP21 sachet; To be taken one in the morning in an empty stomach over a period of 90 consecutive days
62171631|NCT05283525|ACTIVE_COMPARATOR|TRCAP21 Group #2 (6.75 gms Twice-A-Day)|TRCAP21 Group #2 (2 Doses; 13.5 gms in two divided doses per day): A total of 25 subjects will be given 2 TRCAP21 sachets; To be taken one in the morning in empty stomach and the other in the afternoon in an empty stomach over a period of 90 consecutive days
62171632|NCT06290141|EXPERIMENTAL|Riliprubart Arm|Riliprubart + Placebo IVIg for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks
62171633|NCT06290141|ACTIVE_COMPARATOR|IVIg Arm|IVIg (IVIg continuation) + Placebo riliprubart for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks
62171634|NCT01475019|EXPERIMENTAL|PCOS obese Orlistat|Obese PCOS women treated with Orlistat, diet and physical exercise
62171635|NCT01475019|EXPERIMENTAL|Obese Orlistat|Obese women (non PCOS) treated with Orlistat, diet and physical exercise
62171636|NCT01475019|EXPERIMENTAL|PCOS obese diet|Obese PCOS women treated with diet and physical exercise
62171637|NCT01475019|EXPERIMENTAL|PCOS obese Sibutramine|Obese PCOS women treated with Sibutramine, diet and physical exercise
62171638|NCT04103905|EXPERIMENTAL|MIL62|
62171639|NCT04130958|EXPERIMENTAL|MDE and Active iTBS-TMS|This group will consist of patients diagnosed with MDE that are receiving active iTBS-TMS.
62171640|NCT04130958|EXPERIMENTAL|BPD and Active iTBS-TMS|This group will consist of patients diagnosed with BPD that are receiving active iTBS-TMS.
62171641|NCT04130958|SHAM_COMPARATOR|MDE and Sham iTBS-TMS|This group will consist of patients diagnosed with MDE that are receiving sham iTBS-TMS.
62171642|NCT04130958|SHAM_COMPARATOR|BPD and Sham iTBS-TMS|This group will consist of patients diagnosed with BPD that are receiving sham iTBS-TMS.
62171643|NCT06646861|EXPERIMENTAL|Exercise|Multi-modal exercise programme The 10-week multi-modal exercise programme will comprise of twice weekly online supervised group-based exercise sessions. Each exercise session will last approximately 1 hour and consist of a combination of aerobic, resistance and balance and flexibility exercises.
61986181|NCT05303584|EXPERIMENTAL|Group A|Approximately 70 subjects recruited from the prior clinical trial and newly enrolled 50 subjects will receive a booster dose of aerosolized Ad5-nCoV after three-dose priming with ICV
61986182|NCT05303584|EXPERIMENTAL|Group B|Approximately 70 subjects recruited from the prior clinical trial and newly enrolled 50 subjects will receive a booster dose of intramuscular Ad5-nCoV after three-dose priming with CoronaVac
61986183|NCT05303584|EXPERIMENTAL|Group C|Approximately 70 subjects recruited from the prior clinical trial and newly enrolled 50 subjects will receive homologous fourth dose of CoronaVac.
61986184|NCT01951157|ACTIVE_COMPARATOR|A - docetaxel|75 mg/m2 docetaxel day 1, 1-hour intravenous, every three weeks
61986185|NCT01951157|EXPERIMENTAL|B - lurbinectedin (PM01183)|3.2 mg/m2 PM01183, day 1, 1-hour intravenous, every three weeks
61986186|NCT01951157|EXPERIMENTAL|C - gemcitabine + lurbinectedin (PM01183)|800 mg/m2 gemcitabine / 1.6 mg/m2 PM01183 both on day 1 and day 8, 30-minutes gemcitabine/1-hour PM01183 intravenous, every three weeks
61986187|NCT04497077|EXPERIMENTAL|single dose tart cherry capsule|single dose tart cherry capsule
61986188|NCT04497077|EXPERIMENTAL|double dose tart cherry capsule|double dose tart cherry capsule
61986189|NCT04497077|EXPERIMENTAL|single dose tart cherry juice|single dose tart cherry juice
61986190|NCT04497077|EXPERIMENTAL|double dose tart cherry juice|double dose tart cherry juice
61986191|NCT04497077|EXPERIMENTAL|single placebo capsule|single placebo capsule
61986192|NCT04497077|EXPERIMENTAL|single placebo juice|single placebo juice
61986193|NCT00712231||phakic eyes|the cases did not accept any intraocular surgery
61986194|NCT00712231||pseudophakic eyes|tht cases did not accept any intraocular surgery expect for cataract surgery
62171644|NCT05930002|ACTIVE_COMPARATOR|Ivermectin group|received standard treatment plus Ivermectin in the form of oral tablets (0.2 mg/kg/day) single dose on an empty stomach for three successive days
62171645|NCT05930002|ACTIVE_COMPARATOR|Colchicine group|received standard treatment plus Colchicine 0.5mg tablets (3times/day after meal for 3 days then twice daily for 4 days)
62171646|NCT05930002|ACTIVE_COMPARATOR|Control group|received the standard treatment according to the protocol of the Egyptian Supreme Council of University Hospitals (http://scu.eg/pages/university_hospitals) (Vitamin C 500mg tablet twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75mg tablet once daily for two weeks and needed protocol of management according to case assessment and severity)
62171647|NCT01468025|ACTIVE_COMPARATOR|Theramine and naproxen|Patients in this group were randomly given active Theramine and active naproxen.
62171648|NCT01468025|ACTIVE_COMPARATOR|Theramine and placebo|Patients in this group were randomly given active Theramine with placebo representing naproxen.
62171649|NCT01468025|ACTIVE_COMPARATOR|Naproxen and placebo|Patients in this group were randomly given active naproxen and placebo to represent Theramine.
62171650|NCT04054596|EXPERIMENTAL|STEM|The treatment group (TX) will complete 8 sessions of STEM (2 sessions per week for 4 weeks), Sessions are approximately 30-45 minutes long.
62171651|NCT04054596|NO_INTERVENTION|Controlled|During weeks 2-5, one group will undergo a memory enhancement protocol, used to improve memory functioning in individuals with neurological injuries. The other group will serve as a control group and complete memory exercises with the researcher.
62171652|NCT01271036|EXPERIMENTAL|Formula PD-F-7716|Apply a dime-size amount on each application site as instructed during the 1-week study period
62171653|NCT05669287|EXPERIMENTAL|CT Perfusion|All patients will receive a baseline CT Perfusion scan. A subgroup of patients with chemotherapy treatment will receive a follow-up CT Perfusion after 3 months.
62171654|NCT00502983||Interview|AML Patients \& Healthy Controls
62171655|NCT06141772|EXPERIMENTAL|Kinetics of circulating tumor DNA|
62171656|NCT02229396|EXPERIMENTAL|Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg|
62171657|NCT02229396|EXPERIMENTAL|Exenatide Once Weekly 2 mg Alone|
62171658|NCT02229396|ACTIVE_COMPARATOR|Dapagliflozin Once Daily 10 mg Alone|
62171659|NCT05274100|EXPERIMENTAL|Group 1: Risankizumab Dose A|Participants will receive risankizumab dose A.
62171660|NCT05274100|EXPERIMENTAL|Group 2: Risankizumab Dose B|Participants will receive risankizumab dose B.
62171661|NCT05274100|EXPERIMENTAL|Group 3: Risankizumab Dose C|Participants will receive risankizumab dose C.
62171662|NCT05274100|EXPERIMENTAL|Group 4: Risankizumab Dose D|Participants will receive risankizumab dose D.
62171663|NCT05274100|EXPERIMENTAL|Group 5: Risankizumab Dose D|Participants will receive risankizumab dose D.
62171664|NCT00733564|ACTIVE_COMPARATOR|1|Paracervical block will be performed
62171665|NCT00733564|EXPERIMENTAL|2|Propofol anesthesia will be performed
62171666|NCT00733564|EXPERIMENTAL|3|Sevoflurane anesthesia will be performed
62171667|NCT01939821|EXPERIMENTAL|Educational and counselling program|In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach
62171668|NCT01939821|ACTIVE_COMPARATOR|Educational program|The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level.
62171669|NCT01939821|NO_INTERVENTION|Control group|The control group will not receive any educational program. It represents the present real life in nursing homes.
62171670|NCT01703988|EXPERIMENTAL|Nusinersen 3 mg|3 mg nusinersen on Days 1, 29, 85, intrathecal (IT) injection
62171671|NCT01703988|EXPERIMENTAL|Nusinersen 6 mg|6 mg nusinersen on Days 1, 29, 85, IT injection
62171672|NCT01703988|EXPERIMENTAL|Nusinersen 9 mg|9 mg nusinersen on Days 1 and 85, IT injection
62171673|NCT01703988|EXPERIMENTAL|Nusinersen 12 mg|12 mg nusinersen on Days 1, 29, 85, IT injection
62171674|NCT02661490|EXPERIMENTAL|Arm 1: NoV Vaccine Formulation A _1-Dose|Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.
62171675|NCT02661490|EXPERIMENTAL|Arm 2: NoV Vaccine Formulation A _2-Dose|Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.
62171676|NCT02661490|EXPERIMENTAL|Arm 3: NoV Vaccine Formulation B_1-Dose|Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.
62171677|NCT02661490|EXPERIMENTAL|Arm 4: NoV Vaccine Formulation B_2-Dose|Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.
62171678|NCT02661490|EXPERIMENTAL|Arm 5: NoV Vaccine Formulation A_1-Dose|Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.
62171679|NCT05269147|PLACEBO_COMPARATOR|SBGB with normal saline|patients will receive standardized general anesthesia + SBGB with normal saline.
62171680|NCT05269147|ACTIVE_COMPARATOR|SBGB with lidocaine 2%|patients will receive standardized general anesthesia + SBGB with lidocaine 2%
62171681|NCT05269147|ACTIVE_COMPARATOR|SBGB with bupivacaine 0.5%|patients will receive standardized general anesthesia+ SBGB with bupivacaine 0.5%
62171682|NCT00915460|EXPERIMENTAL|1|Patients previously enrolled in BIogen Idec study C95-812.
62171683|NCT00915460|EXPERIMENTAL|2|Patients previously enrolled in Biogen Idec study C96-823.
62171684|NCT00915460|EXPERIMENTAL|3|Patients previously enrolled in Biogen Idec study C97-830.
62171685|NCT00540384|EXPERIMENTAL|NESP - Schedule 1 Part A|Part A - 4.5, 6.75, 9.0 or 13.5 mcg/kg Q3W for 12 weeks
62171686|NCT00540384|EXPERIMENTAL|NESP - Schedule 2 Part A|NESP 9.0, 12.0, 15.0 or 18.0 mcg/kg Q4W for 12 weeks
62171687|NCT00540384|PLACEBO_COMPARATOR|Placebo - Schedule 1 Part A|Placebo Q3W for 12 weeks
62171688|NCT00540384|EXPERIMENTAL|NESP - Schedule 1 Part B|Open-label NESP at the dose of study drug administered at the end of Part A. Increase dose at week 19 if hgb \< 13.0g/dL and/or RBC transfusion in previous 2 weeks.
62171689|NCT00540384|PLACEBO_COMPARATOR|Placebo - Schedule 2 Part A|Placebo Q4W for 12 weeks
62171690|NCT00540384|EXPERIMENTAL|NESP - Schedule 2 Part B|Open-label NESP at the dose of study drug administered at the end of Part A
62171691|NCT04167085|EXPERIMENTAL|Doxycycline, then Placebo|Doxycycline for a period of 2 months followed by a 1-month washout period, and then placebo for a further 2 months period followed by a 1-month washout period.
62171692|NCT04167085|EXPERIMENTAL|Placebo, then Doxycycline|Placebo for a period of 2 months followed by a 1-month washout period, and then Doxycycline for a further 2 months period followed by a 1-month washout period.
62171693|NCT04685317|EXPERIMENTAL|Sentinel® Cerebral Protection System Group|Sentinel® Cerebral Protection System in patients undergoing AF catheter ablation
62171694|NCT04685317|ACTIVE_COMPARATOR|Standard of Care Group|Standard of care (no cerebral protection device) in patients undergoing AF catheter ablation
62171695|NCT06283563|EXPERIMENTAL|Experimental group|Participants will receive reminders regarding physical activity promotion via the social media group created.
62171696|NCT06283563|ACTIVE_COMPARATOR|Control group|Participants will be encouraged to continue their routine lives.
62171697|NCT06058117||children with invasive group A streptococcal disease|children with invasive group A streptococcal disease or other invasive or emergent infectious disease
62171698|NCT04385940|EXPERIMENTAL|High dose vitamin D|Ddrops® products,Vitamin D3, 50,000 IU, Oral
62171699|NCT04385940|ACTIVE_COMPARATOR|Low dose vitamin D|Vitamin D3 1000IU
62171700|NCT02515097|EXPERIMENTAL|IDP-122 Lotion|Participants will apply IDP-122 Lotion (halobetasol propionate \[HP\] 0.01%) topically once daily for 8 weeks.
62171701|NCT02515097|PLACEBO_COMPARATOR|IDP-122 Vehicle Lotion|Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.
62171702|NCT05262439|EXPERIMENTAL|New generation CPAP mask|The intended purpose of mask systems is to provide airflow from a CPAP device, through tubing, and to the patient. The air acts as a pneumatic splint to keep the airway open and prevent collapse during sleep. The masks to be used in this study are released masks approved and released.
62171703|NCT04177628|EXPERIMENTAL|Arm A: Shared decision making|Patients will be informed by a doctor randomized to practice shared decision making and use the in-consultation PtDA during the consultation on adjuvant radiotherapy.
61986195|NCT06005922|ACTIVE_COMPARATOR|conventional physiotherapy methods|conventional physiotherapy methods
61986196|NCT06005922|EXPERIMENTAL|temporomandibular joint (TMJ) group|conventional physiotherapy methods and temporomandibular joint mobilization and temporomandibular joint exercises
61986197|NCT03573947|EXPERIMENTAL|nivolumab, ipilimumab and paclitaxel|
61986198|NCT01369979||Patients with chronic liver disease|"Inclusion criteria~* Age between 40 and 70 years~* BMI between 20 and 26~Exclusion Criteria~* Diabetes mellitus~* Glucose intolerance~* Medical treatment of portal hypertension~* People who have undergone surgery for obesity~* Pregnancy"
61986199|NCT01369979||Healthy subjects|"Inclusion criteria~* Age between 40 and 70 years~* BMI between 20 and 26~Exclusion Criteria~* Diabetes mellitus~* Glucose intolerance~* Medical treatment of portal hypertension~* People who have undergone surgery for obesity~* Pregnancy"
61986200|NCT05270681|EXPERIMENTAL|Individuals with HD|Participants with a confirmed diagnosis of Huntington's disease
61986201|NCT05270681|EXPERIMENTAL|Care Partners|Participants' care partners
61986202|NCT06348992|EXPERIMENTAL|ACT-Y|Based on ACT and supplemented by Hatha Yoga exercise intervention, the intervention group used a combination of offline ACT psychological intervention and online Hatha Yoga training. ACT-Y intervention will be based on ACT combined with Yoga training and comprises a programme divided into eight 1-hour sessions conducted over 8 weeks
61986203|NCT06348992|ACTIVE_COMPARATOR|Mental Health Education Group|The control group also received 8 weeks of mental health education, including stress coping strategies, scientific parenting knowledge, and emotional management skills.
61986204|NCT02206425|EXPERIMENTAL|bortezomib + melphalan + prednisone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
61986205|NCT02206425|EXPERIMENTAL|bortezomib + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
61986206|NCT02206425|EXPERIMENTAL|carfilzomib + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
62171704|NCT04177628|NO_INTERVENTION|Arm B: Usual practice|Patients will be informed by a doctor randomized to inform about adjuvant radiotherapy according to usual practice.
62171705|NCT04284592|NO_INTERVENTION|Control group|Patients do not receive remote ischemic post-conditioning (RIP) after cardiopulmonary bypass
62171706|NCT04284592|EXPERIMENTAL|RIP group|Patients receive remote ischemic post-conditioning (RIP) after cardiopulmonary bypass
62171707|NCT06196229|ACTIVE_COMPARATOR|Action Observation Therapy|"During each training session, participants were asked to observe a specific object-directed daily action presented on a computer screen, and afterward they performed what they have observed, 5 repetitions of each task, time duration was noted.~16 motor tasks related to their daily living that were performed with their own hands which are following~1. Folding a towel~2. Cutting a toilet roll~3. Using scissors~4. Tightening shoelaces~5. Opening and closing a square airtight container~6. Opening a bottle top~7. Turning a faucet~8. Using a field of billfold~9. Drinking water~10. Setting a seal~11. Changing batteries~12. Opening and closing a zipper~13. Turning over pages of a book~14. Plugging the outlet~15. Spraying water with a sprayer~16. Sorting chopsticks and spoons and putting them in a box • The participants were advised to keep focusing on their affected arm/hand action observational tasks"
62171708|NCT06196229|EXPERIMENTAL|Action Observation Therapy combined with Virtual Reality|"In the VRT group, participants will execute VR-based activities conducted by the same therapist .~* 16 tasks will be assigned in each session. VR SHINECON 3D Glasses will be used~* The virtual environment was set in a 6 m2 physical space~* At the beginning of each session, the participant will sit in the center of the set zone and will be assisted to wear the VR glasses~* After the participant will confirm that the sight and sound is clear and comfortable, the tasks mentioned in action observation therapy will be done using virtual reality videos~* The Extrinsic feedback will be provided, including the time left, number of repetitions, and record number of repetitions"
62171709|NCT03074383|EXPERIMENTAL|Workshop|Self-Care Multidisciplinary Workshop for Diabetes consist in individual meetings with a multidisciplinary team (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) in which education and self-care topics will be approached. The workshop will be offered in 3 different modules with 2-4 weeks difference between them.
62171710|NCT03074383|ACTIVE_COMPARATOR|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
62171711|NCT03303521|EXPERIMENTAL|Sodium Zirconium Cyclosilicate (ZS)|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days.
62171712|NCT03303521|PLACEBO_COMPARATOR|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
62171713|NCT01086878|EXPERIMENTAL|Cotrimoxazole|
62171714|NCT04985747|EXPERIMENTAL|Polished palate|Participants will receive maxillary complete dentures with smooth palatal surfaces without modification.
62171715|NCT04985747|EXPERIMENTAL|Roughened palate|Participants will receive maxillary complete dentures with roughened palatal surfaces
62171716|NCT04985747|EXPERIMENTAL|Open palate|Participants will receive maxillary complete dentures with opened palatal surfaces
62171717|NCT04782505|EXPERIMENTAL|Cohort 1 (Part 1)|DWJ1248 100mg (100mg 1tab) PO
62171718|NCT04782505|EXPERIMENTAL|Cohort 2 (Part 1)|DWJ1248 200mg (100mg 2tab) PO
62171719|NCT04782505|EXPERIMENTAL|Cohort 3 (Part 1)|DWJ1248 300mg (100mg 3tab) PO
62171720|NCT04782505|EXPERIMENTAL|Group A (Part 2)|DWJ1248 100mg 2tab PO - Wash out - DWJ1248 200mg 1tab PO
62171721|NCT04782505|EXPERIMENTAL|Group B (Part 2)|DWJ1248 200mg 1tab PO - Wash out - DWJ1248 100mg 2tab PO
62171722|NCT01906658|EXPERIMENTAL|Acthar 80 U (1.0 mL) SC twice weekly|Acthar (Repository Corticotropin Injection) 80 U (1.0 mL) SC twice weekly
62171723|NCT01906658|EXPERIMENTAL|Acthar 24 U (0.3 mL) SC daily|Acthar (Repository Corticotropin Injection) 24 U (0.3 mL) SC daily
62171724|NCT01906658|EXPERIMENTAL|Acthar 56 U (0.7 mL) SC twice weekly|Acthar (Repository Corticotropin Injection) 56 U (0.7 mL) SC twice weekly
62171725|NCT01906658|EXPERIMENTAL|Acthar 16 U (0.2 mL) SC daily|Acthar (Repository Corticotropin Injection) 16 U (0.2 mL) SC daily
62171726|NCT02895698|ACTIVE_COMPARATOR|Treatment group|Dry cupping + active dorsiflexion exercise + stretching exercise
62171727|NCT02895698|OTHER|Control group|stretching exercise + active dorsiflexion without cupping
62171728|NCT02598934|EXPERIMENTAL|Ibandronate Group 1|Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly. Group 1 will receive a physician consultation after 4 months of treatment to review bone turnover test results.
62171729|NCT02598934|EXPERIMENTAL|Ibandronate Group 2|Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly. Group 2 will not receive a physician consultation.
62171730|NCT02772445|EXPERIMENTAL|STROKE-CARE Intervention|In STROKE-CARE, caregivers will learn a problem-solving strategy. Participants will receive approximately 10 sessions by an occupational therapist in the home over a 5 week process.
62171731|NCT02161185|OTHER|USL261|
62171732|NCT05648448|EXPERIMENTAL|Oseltamivir (TAMIFLU®)|
62171733|NCT05648448|EXPERIMENTAL|Favipiravir|
62171734|NCT05648448|EXPERIMENTAL|Zanamivir (RELENZA®) [Pending addition]|
62171735|NCT05648448|EXPERIMENTAL|Baloxavir (XOFLUZA®)|
62171736|NCT05648448|EXPERIMENTAL|Molnupiravir [Pending addition]|
62171737|NCT05648448|EXPERIMENTAL|Peramivir (RAPIVAB®) [Pending addition]|
62171738|NCT05648448|EXPERIMENTAL|Laninamivir (INAVIR®) [Pending addition]|
62171739|NCT05648448|EXPERIMENTAL|Oseltamivir and Baloxavir [Pending addition]|
62171740|NCT05648448|EXPERIMENTAL|Oseltamivir and Favipiravir [Pending addition]|
62171741|NCT05648448|EXPERIMENTAL|Favipiravir and Baloxavir [Pending addition]|
62171742|NCT05648448|NO_INTERVENTION|Negative control group|No treatment (except antipyretics- paracetamol)
62171743|NCT02528864||Normal endometrium|Control group (n=30) comprising surgical candidates with normal endometrial tissue will be collected for comparison.
62363856|NCT06391567||Patient Group|Patients who were diagnosed with Frozen Shoulder by physical examination, met the inclusion criteria, and agreed to participate in the study were selected for the patient group.
62171744|NCT02528864||Endometrial/uterine cancer|"1. 1st year: 50 eligible patients surgical candidates of endometrial cancer with pre-operative imaging and biological samples collected during operation.~2. 2nd year: Enroll another 50 surgical candidates and complete the data regarding clinical MRS/diffusion-weighted imaging and tissue high resolution MRS. Together with the 50 cancer subjects in the first year there will be in total 100 cancer subjects for analysis.~3. 3rd year: Collect enough positive events with any myometrial involvement (n=30), cervical stromal invasion (n=10) and nodal metastasis (n=10). Together with the 100 cancer subjects in the first and second years there will be in total 150 cancer subjects for analysis."
62171745|NCT05671744|OTHER|Blood samples from pregnant women|Samples of peripheral blood collected from pregnant women undergoing CVS or genetic amniocentesis
62171746|NCT03198351||Cohort I|Pregnant women with a confirmed diagnosis of multiple sclerosis (MS) and teriflunomide exposure during the current pregnancy
62171747|NCT03198351||Cohort II|Pregnant women with MS not exposed to teriflunomide during the current pregnancy
62171748|NCT03198351||Cohort III|Healthy pregnant women who do not have a known diagnosis of MS and have no known exposure to a known human teratogen
62171749|NCT03198351||"Registry group (not eligible for cohorts)"|Women who contact the OTIS registry study staff and who do not meet the criteria for the prospective study, for example, at time of contacting the study, having known prenatal diagnosis of congenital defect, or gestation weeks greater than 20 following a first trimester teriflunomide exposure, etc.; these participants will not be included in the primary analysis for the cohort study.
62171750|NCT01100268|EXPERIMENTAL|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
62171751|NCT03230110||Chronic Hypretension in Pregnancy|Pregnant subjects between 10-20 weeks gestation with chronic hypertension (on medication or hypertensive blood pressures documented at 2 clinic visits)
62171752|NCT03230110||Normotensive in Pregnancy|Pregnant subjects between 10-20 weeks gestation with normal blood pressure, and not on any treatment for chronic hypertension and no history of chronic hypertension, and matched for body mass index (+/- 3 kg/m2) with the chronic hypertension group.
62171753|NCT02037750|EXPERIMENTAL|LINKS|Foster parent and child participate in 16-week intervention
62171754|NCT02037750|NO_INTERVENTION|Services as Usual|Foster parent and child receive standard services through child welfare system
62171755|NCT01214499|ACTIVE_COMPARATOR|Treatment Control|Transmyocardial revascularization (TMR) with Holmium YAG (yttrium aluminium garnet) laser, according to habitual clinical practice in the Department of Cardiovascular Surgery.
62171756|NCT01214499|EXPERIMENTAL|Experimental Treatment|Transmyocardial revascularization (TMR) with Holmium YAG laser plus the patient's own stem cells extracted from bone marrow.
62171757|NCT00076063|EXPERIMENTAL|A|Participants in Groups A will receive four injections over 6 months of either LIPO-5 or a placebo.
62171758|NCT00076063|EXPERIMENTAL|B|Participants in Group B will receive four injections over 6 months of either the ALVAC-HIV (vCP1452) or a placebo.
62171759|NCT00076063|EXPERIMENTAL|C|Participants in Groups C will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
62171760|NCT00076063|EXPERIMENTAL|D|Participants in Group D will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
62171761|NCT00076063|EXPERIMENTAL|E|Participants in Group E will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
62171762|NCT05591378|EXPERIMENTAL|core stability exercises|improve balance and muscle strengthening
62171763|NCT05591378|EXPERIMENTAL|otago exercises|improve balance and quality of life
62171764|NCT05804981|OTHER|new screener group|this is the group that has annual wellness visits after the new screener is adopted by the UPMC health system
62171765|NCT05804981|NO_INTERVENTION|pre screener group|this is the group that has annual wellness visits before the new screener is adopted by the UPMC health system
62171766|NCT03570606||HA Paste in Spine|"Evaluation of HA Paste in spinal fusion procedures~o Spinal cage filling"
62171767|NCT03570606||HA Paste in long bone & extremities|"Evaluation of HA Paste in long bone and extremity group:~* Filling bone defects after cyst removal~* Filling distal radius fractures~* Filling defects such as tibial plateau fractures~* Filling defects created by osteotomy procedures"
62171768|NCT03570606||Granulated Paste in Spine|"Evaluation of Granulated Paste in spinal fusion procedures~o Spinal cage filling"
62171769|NCT03570606||Granulated Paste in long bone & extremities|"Evaluation of Granulated Paste in long bone and extremity group:~* Filling bone defects after cyst removal~* Filling distal radius fractures~* Filling defects such as tibial plateau fractures~* Filling defects created by osteotomy procedures"
62171770|NCT03570606||Granules in Spine|"Evaluation of Granules in spinal fusion procedures~o Spinal cage filling"
62171771|NCT03570606||Granules in long bone & extremities|"Evaluation of Granules in long bone and extremity group:~* Filling bone defects after cyst removal~* Filling distal radius fractures~* Filling defects such as tibial plateau fractures~* Filling defects created by osteotomy procedures"
62171772|NCT03570606||Block in long bone & extremities|"Evaluation of Blocks in long bone and extremity group:~o High tibial osteotomies with fixation"
62171773|NCT02782598||CRT+NAVH|Surface ECG and pressure-volume loop recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy and Negative Atrioventricular Hysteresis settings at the device implant procedure
62171774|NCT01365351||Growth hormone|Children with growth hormone deficiency
62171775|NCT01406171|EXPERIMENTAL|Isavuconazole and Midazolam|Isavuconazole three times per day (TID) for 2 days followed by once a day (QD) for 9 days. Midazolam single doses on days 1 and 12
62171776|NCT00830102|ACTIVE_COMPARATOR|1|"* Period 1 Treatment Regimen A: FlutiForm 100/10 ug~* Period 2 Treatment Regimen B: FlutiForm 250/10 ug~* Period 3 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug~* Period 4 Treatment Regimen D: Flixotide Evohaler 250 ug"
62171777|NCT00830102|ACTIVE_COMPARATOR|2|"* Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug~* Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug~* Period 3 Treatment Regimen B: FlutiForm 250/10 ug~* Period 4 Treatment Regimen A: FlutiForm 100/10 ug"
62171778|NCT00830102|ACTIVE_COMPARATOR|3|"* Period 1 Treatment Regimen B: FlutiForm 250/10 ug~* Period 2 Treatment Regimen A: FlutiForm 100/10 ug~* Period 3 Treatment Regimen F: Placebo~* Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug"
62171779|NCT00830102|ACTIVE_COMPARATOR|4|"* Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug~* Period 2 Treatment Regimen F: Placebo~* Period 3 Treatment Regimen A: FlutiForm 100/10 ug~* Period 4 Treatment Regimen B: FlutiForm 250/10 ug"
62171780|NCT00830102|ACTIVE_COMPARATOR|5|"* Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug~* Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug~* Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug~* Period 4 Treatment Regimen F: Placebo"
62171781|NCT00830102|ACTIVE_COMPARATOR|6|"* Period 1 Treatment Regimen F: Placebo~* Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug~* Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug~* Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug"
62171782|NCT04410354|ACTIVE_COMPARATOR|MMPD + remdesivir|Study subjects will receive MMPD oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).
62171783|NCT04410354|PLACEBO_COMPARATOR|Placebo + remdesivir|Study subjects will receive matching placebo oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).
62171784|NCT02248753|ACTIVE_COMPARATOR|Standard Care|Pharmacological cardioversion and/or electrical cardioversion
62171785|NCT02248753|EXPERIMENTAL|Wait-and-see Approach|Rate control drugs only (metoprolol, verapamil or digoxin)
62171786|NCT04604951|EXPERIMENTAL|Moderate|Group 1: Moderate 2 times per week transcutaneous spinal cord stimulation.
62171787|NCT04604951|EXPERIMENTAL|Intensive|Group 2: Intensive 5 times per week transcutaneous spinal cord stimulation.
62171788|NCT00529555|SHAM_COMPARATOR|Scaling and root planing + SHAM TX|sham treatment
62171789|NCT00529555|PLACEBO_COMPARATOR|Scaling and root planing + Vehicle|Placebo
62171790|NCT00529555|ACTIVE_COMPARATOR|Scaling & root planing + Periocline Gel|Minocycline HCL 2.1%
62171791|NCT03681002|OTHER|structured lifestyle program|individual counseling focusing on Lifestyle habits
62171792|NCT06646211|EXPERIMENTAL|Participant Group/Arm： Experimental: Methotrexate , Thiotepa and Zanubrutinib(MTZ)|
62171793|NCT02809677|OTHER|Non-Interventional Longitudinal Study|This is a 52 week non-placebo controlled and non-randomized clinical research study to see whether treating Major Depressive Disorder (MDD) in caregivers of children with asthma will improve asthma outcomes in children. Caregivers may choose to receive an antidepressant medication that is considered standard medical care for MDD, or may opt out of antidepressant treatment. No treatment is withheld from participants and no placebos are used, thus there is no active intervention in this study.
62171794|NCT01387776||study group|patients coming to clinique OVO in the 1st trimester of pregnancy to undergo prenatal screening
62171795|NCT03003832|EXPERIMENTAL|Intervention|"The intervention condition consists of a change to the electronic health record so that new opioid analgesic prescriptions automatically default to 10 pills (i.e., the quantity dispensed field is pre-populated). This value is modifiable by providers who can tailor the prescription based on clinical factors."
62171796|NCT03003832|NO_INTERVENTION|Standard of care|The control condition will be the usual electronic health record interface. The default number of pills varies by medication, most medications currently have either a blank default or a default of 30 pills.
62171797|NCT02592044|EXPERIMENTAL|Aromatherapy with lavender essential oil|The 2 drops of lavender essential oil will put on 5x5 cm gauze and the patient will inhale it for 5 minutes and during peripheral venous cannulation.
62171798|NCT02592044|PLACEBO_COMPARATOR|Placebo|The 2 drops water will put on 5x5 cm gauze ant the patient will inhale it for 5 minutes and during peripheral venous cannulation.
62171799|NCT03003923|EXPERIMENTAL|Taste Exposure|Children will be repeatedly offered the single vegetable which is unfamiliar to them over the 12 week period. Children will be in their natural setting at nursery and will be offered 40g of the vegetable by their usual nursery staff. The vegetable will be weighed before and after using a digital scale by the researcher.
62171800|NCT03003923|EXPERIMENTAL|Nutritional Education|Nursery staff will be trained by the PhunkyFoods team to deliver the nutritional education programme. Children will be taught Eat Well (learning about different food groups) and Strive for Five (learning about eating fruits and vegetables) components of the PhunkyFoods education programme by their usual nursery staff. Nurseries will be advised to deliver as much as possible of the two components over the 12 week period.
62171801|NCT03003923|EXPERIMENTAL|Taste Exposure and Nutritional Education|Children will be repeatedly offered a single unfamiliar vegetable over the 12 week period as well as receive the PhunkyFoods educational programme (Eat Well and Strive for Five components). Children will be in their natural setting at nursery and will be offered the vegetable and nutritional education by their usual nursery staff.
62171802|NCT03003923|NO_INTERVENTION|Control|Children will be offered single unfamiliar vegetable at the beginning, end and at the follow-up. There will be no repeated taste exposure or education during the study phase or follow-up; they will be offered the nutritional education after the study has completed.
62171803|NCT05358964|EXPERIMENTAL|African American Family Health History Education Program|The AAFHHEP arm is an intervention to increase utilization of FHH and increase preventative screening. This tool will be culturally tailored by African Americans for African Americans.
62171804|NCT05358964|ACTIVE_COMPARATOR|Genetic Alliance: Does it run in the family|The Genetic Alliance Does it run in the family is an existing family health history tool kit generalized to all racial groups. This tool is widely available via the internet.
62171805|NCT03377179|EXPERIMENTAL|ABC294640 +/- HCQ treatment|Part 1: All participants will be receiving ABC294640, 500 mg twice a day (BID), continuously in 28 day cycles Part 2: All participants will be receiving ABC294640, 500 mg twice a day (BID) and HCQ at a determined level, continuously in 28 day cycles
62171806|NCT05393388||PET/CT|PET.CT using the radiotracer \[18F\]AV-1451
62171807|NCT04135469|ACTIVE_COMPARATOR|Referral for tax preparation|Participants will be given contact information on financial services, including all the free tax preparation services in the city, including Boston Medical Center.
62171808|NCT04135469|EXPERIMENTAL|BMC tax preparation|A navigator will help the participants with using free tax preparation services located at Boston Medical Center or a service located elsewhere in the city.
62171809|NCT01553578|EXPERIMENTAL|Arm A (healing touch therapy)|Patients receive 30 minutes of healing touch therapy consisting of magnetic clearing, pain drains, hands in motion/hands still and mind clearing.
62171810|NCT01553578|EXPERIMENTAL|Arm B (guided imagery)|Patients listen to guided imagery audiotapes for 30 minutes.
62171811|NCT01553578|ACTIVE_COMPARATOR|Arm C (standard care)|Patients receive standard of care.
62171812|NCT02822040||Experimental group|All patients who have initial and final records qualify in the experimental group.
62171813|NCT02510404|EXPERIMENTAL|mCTLs against three viruss|The investigator will use 3 different dose levels starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. They will give the option of administering 2 additional doses (at the same level) of the same or different cell lines, 28 days after the first dose, in subjects that have limited or no improvement in viral count after one dose in the absence of any toxicities attributable to the infusion,or who receive other therapy that may affect the persistence or function of the infused mCTLs.
62171814|NCT00410423|EXPERIMENTAL|Bortezomib 0.7mg/m^2|Bortezomib in combination with mitoxantrone, etoposide and cytarabine
62171815|NCT00410423|EXPERIMENTAL|Bortezomib 1.0mg/m^2|
62171816|NCT00410423|EXPERIMENTAL|Bortezomib 1.3mg/m^2|
62171817|NCT06006832||maintenance steroid therapy group|Maintaining low-dose oral steroids
62171818|NCT06006832||immunosuppresants withdrawal group|Withdraw all immunosuppresants
62171819|NCT01189318|EXPERIMENTAL|Seroquel XR|Patients with MDD receives Seroquel XR.
62171820|NCT01189318|NO_INTERVENTION|healthy control|
62171821|NCT00230971|ACTIVE_COMPARATOR|A|
62171822|NCT00230971|ACTIVE_COMPARATOR|B|
62171823|NCT02539238|ACTIVE_COMPARATOR|control|Annual BLS training
62171824|NCT02539238|EXPERIMENTAL|intervention|Brief CPR training dispersed over a year period of time with real-time feedback during working hour
62171825|NCT01954771|ACTIVE_COMPARATOR|Control Group|Patients will receive conventional care and keep on their usual SMBG(Self-monitoring of blood glucose) methods. Additionally, each patient will also wear a CGMS(continous glucose monitoring system) device for 72h in the first week and the last week, respectively.
62171826|NCT01954771|ACTIVE_COMPARATOR|SMBG-4 Group|Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
62171827|NCT01954771|ACTIVE_COMPARATOR|SMBG-7 Group|Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
62171828|NCT03229525|ACTIVE_COMPARATOR|Trauma Related Expressive Writing|Participants randomized to this condition will complete six sessions during which they will write about their trauma for 20 minutes. The participant will receive instructions to write about the traumatic event that they feel affects them the most. For each session they will be instructed to write about the same event. For the first session, participants will complete psychoeducation and treatment rationale modules. The instructions for writing about the traumatic event will emphasize the importance of exploring their deepest emotions and thoughts at the time of the event, as well as providing detailed information about the event itself. For the remaining five writing sessions participants will be instructed to write about the same event and to focus on providing a detailed description of the part of the event that was most distressing to them, as well as how the event had affected their lives. A researcher will review the writing independently to ensure treatment compliance.
62171829|NCT03229525|SHAM_COMPARATOR|Neutral Expressive Writing|Participants randomized to this condition will complete six sessions during which they will write about their day, without describing emotions or opinions. Previous research has shown a significant reduction of symptoms with this type of control writing condition in participants with PTSD (Sloan et al., 2011). A researcher will review the writing to ensure compliance.
62171830|NCT01641627|EXPERIMENTAL|vibration|proprioceptive stimulation of the lower limb using vibration and plantar pressure boots
62171831|NCT04981184|OTHER|Gait and balance measurement|"Gait analysis with surface electromyography measurement: surface electromyography signals (of affected and non-affected legs), gait and stance parameters are collected while the patient walks for 30 seconds on the treadmill with integrated sensor equipment (for measuring the force distribution).~Balance analysis with Biodex balance system SD: measurements of postural stability, fall risk, limits of stability, sensory integration are collected."
62171832|NCT03293329|EXPERIMENTAL|Diaphragm manual therapy|3 diaphragm stretching techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position. 20 people are recruited in order to the inclusion criteria for the study. They have rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
62171833|NCT03293329|EXPERIMENTAL|Diaphragm hipopressive exercise|Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures. 20 people are recruited in order to the inclusion criteria for the study. They have rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
62171834|NCT03293329|ACTIVE_COMPARATOR|Shoulder myofascial trigger points treatment|A ischemic compression technique in infraespinatus and supraespinatus myofascial trigger points performed by a physical therapist is employed in this group. 20 people are recruited in order to the inclusion criteria for the study. They had rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
62171835|NCT02791126||Heart Failure|"Patients presented to hospital with a primary diagnosis of Heart Failure or are attending a hospital clinic for management of Heart Failure within 6 months of an episode of decompensated heart failure, which either resulted in a hospital admission (primary diagnosis) or was treated in out-patient clinic.~Cardiovascular Magnetic Resonance and Echocardiogram will be performed."
62171836|NCT03480919|EXPERIMENTAL|Shen Men acupuncture|Single acupuncture needles will be placed bilaterally onto the patient's Shen Men acupuncture point in the ear for a duration of 20 minutes.
62171837|NCT03480919|SHAM_COMPARATOR|Sham acupuncture|Single acupuncture needles will be placed bilaterally onto a sham location in the ear for a duration of 20 minutes.
62171838|NCT03480919|PLACEBO_COMPARATOR|Simulated acupuncture|Acupuncture will be simulated with a paper clip.
62171839|NCT00994396|PLACEBO_COMPARATOR|Placebo pill|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos
62171840|NCT00994396|EXPERIMENTAL|Vitamin D|4000 IU vitamin D3 (cholecalciferol) per day for 6 months.
62171841|NCT05249309||Treatment|The administration will be done subcutaneously, in the abdominal wall, using ketamine without dilution. The ketamine dose will be 0.5mg/kg, recommended for the first infusion. If there is no adequate response, according to psychiatric scales and clinical evaluation, the second infusion must be performed at least two days after the first, using 0.75mg/kg and the subsequent 1mg/kg. If the patient adequately responds to a dose (0.5 or 0.75mg/kg), it should be repeated after over twice weekly over a period of 4 weeks.
62171842|NCT05249309||Control|Will be checked weight, height and waist circumference and collected about 15 mL of peripheral blood.
62171843|NCT05563428|ACTIVE_COMPARATOR|Free gingival graft|Free gingival graft will be conducted.
62171844|NCT05563428|ACTIVE_COMPARATOR|Connective tissue graft|The recession will be treated with the pouch technique using a connective tissue graft.
62171845|NCT01520285|ACTIVE_COMPARATOR|Zanidip|tablets
62171846|NCT01520285|PLACEBO_COMPARATOR|Control Drug|Felodipine sustained-release tablet (5mg/tablet)
62171847|NCT04572997|EXPERIMENTAL|Full analysis set (FAS)|The full analysis set (FAS) consisted of all patients who received at least one dose of study drug.
62171848|NCT00448786|OTHER|Arm C|Arm C - AMG 706 75 mg BID 5-days on and 2-days off
62171849|NCT00448786|OTHER|Arm B|Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
62171850|NCT00448786|OTHER|Arm A|Arm A = AMG 706 125 mg PO daily continuously
62171851|NCT04299724|EXPERIMENTAL|Injection of Covid-19/aAPC vaccine|
62171852|NCT01557699|EXPERIMENTAL|PMV via Puffhaler® Device|The dry powder measles vaccine will be administered via a Puffhaler® device. A single dose of 10 mg will be used.
62171853|NCT01557699|EXPERIMENTAL|PMV via SoloventTM device|The dry powder measles vaccine will be administered via a SoloventTM device. A single dose of 10 mg will be used.
62171854|NCT01557699|ACTIVE_COMPARATOR|Licensed Subcutaneous Measles Vaccine|Licensed measles vaccine will be administered subcutaneously as single dose of 0.5 ml.
62171855|NCT04368533|EXPERIMENTAL|Livionex Dental Gel|Children assigned to this arm will brush/clean teeth with Livionex Dental Gel twice a day for up to 12 months.They will undergo a dental exam by a trained dentist including caries assessment (at baseline, 1, 3, 6, 9 or 12 months), dental plaque photograph, (at baseline, 1, 3, 6 and 9 or 12 months), and swab samples for dental plaque and saliva will be collected at all study visits. A questionnaire will be given to address dentifrice and brushing experience. Data on compliance and side-effects of toothpastes will be collected at each of the calls.
62171856|NCT04368533|ACTIVE_COMPARATOR|A standard children's toothpaste containing 1500 ppm fluoride|Children assigned to this arm will brush/clean teeth with a standard children's toothpaste containing 1500 ppm fluoride twice a day for up to 12 months. They will undergo a dental exam by a trained dentist including caries assessment (at baseline, 1, 3, 6, 9 or 12 months), dental plaque photograph, (at baseline, 1, 3, 6, 9 or 12 months), and swab samples for dental plaque and saliva will be collected at all study visits. A questionnaire will be given to address dentifrice and brushing experience at each study visit. A monthly phone call will be made to assess compliance with the study protocol, and to answer any questions or concerns. Data on compliance and side-effects of toothpastes will be collected at each of the calls.
62171857|NCT04482270|EXPERIMENTAL|Fezolinetant: Mild Hepatic Impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
62171858|NCT04482270|EXPERIMENTAL|Fezolinetant: Moderate Hepatic Impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
62171859|NCT04482270|EXPERIMENTAL|Fezolinetant: Normal Hepatic Function|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
62171860|NCT02112578|EXPERIMENTAL|Meclizine|Meclizine 25 mg, tablets
62171861|NCT02112578|ACTIVE_COMPARATOR|Dimenhydrinate|Dimenhydrinate 50 mg, soft Capsgel
62171862|NCT01654445|EXPERIMENTAL|TNK-tPA Tenecteplase|This is an open-label trial, all patients will receive tenecteplase.
62171863|NCT02292641|OTHER|Patients with pelvic recurrence from primary colorectal cancer|Implementation of imaging assessment proformas describing anatomic pelvic compartments and aetiology of disease recurrence for treatment planning.
62171864|NCT02206464|EXPERIMENTAL|Group 1|H7 DNA vaccine on Day 0 and H7N9 MIV at StudyWeek 16
62171865|NCT02206464|EXPERIMENTAL|Group 2|H7 DNA and H7N9 MIV administered on Day 0 and H7N9 MIV boost at Study Week 16
62171866|NCT02206464|EXPERIMENTAL|Group 3|H7N9 MIV on Day 0 and H7N9 MIV at Study Week 16
62171867|NCT04454489|EXPERIMENTAL|Quad-shot palliative radiotherapy and Immunotherapy|Systemic therapy (ICI) and radiotherapy will be administered according to the standard of care, according to the treating medical oncologist and radiation oncologist, respectively
62171868|NCT03657537|EXPERIMENTAL|Hyperketonemia - Placebo|Participants are randomly assigned to initially receive ketone infusion and then saline infusion
62171869|NCT03657537|EXPERIMENTAL|Placebo - Hyperketonemia|Participants are randomly assigned to initially receive saline infusion and then ketone infusion
62171870|NCT04137978|ACTIVE_COMPARATOR|ADV7103|"Patients receive ADV7103 twice a day at optimal dose. Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances.~Other Names:~• Potassium Citrate and Potassium Bicarbonate"
62171871|NCT04137978|ACTIVE_COMPARATOR|Standard of care comparator|Alkalinising treatment (SoC) taken at the usual dose and frequency
62171872|NCT05596149|ACTIVE_COMPARATOR|Toothpaste without fluoride|A group of participants that will be using toothpaste without fluoride.
62171873|NCT05596149|EXPERIMENTAL|Toothpaste with sodium fluoride|A group of participants that will be using toothpaste with sodium fluoride.
62171874|NCT05596149|EXPERIMENTAL|Toothpaste with sodium monofluorophosphate|A group of participants that will be using toothpaste with sodium monofluorophosphate.
62171875|NCT05596149|EXPERIMENTAL|Toothpaste with amine fluoride|A group of participants that will be using toothpaste with amine fluoride.
62171876|NCT06338293|EXPERIMENTAL|Inclisiran＋rosuvastatin group|Inclisiran sodium＋rosuvastatin 20mg group: Rosuvastatin was given 20mg daily for one year, and Inclisiran was given three times in total. After the first injection, 284mg(1.5ml solution) was injected subcutaneously, the second injection was 3 months after the first injection, and the third injection was in the ninth month.
62171877|NCT06338293|PLACEBO_COMPARATOR|Rosuvastatin group|Rosuvastatin group: Rosuvastatin 20mg daily for one year.
62171878|NCT04392297||Patients with CMV infection|
62171879|NCT04675762|EXPERIMENTAL|fingolimod with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with fingolimod.
62171880|NCT04675762|PLACEBO_COMPARATOR|Placebo with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with placebo.
62171881|NCT03738397|EXPERIMENTAL|Upadacitinib 30 mg QD|Participants will receive 30 mg upadacitinib orally once a day (QD) up to Week 24 and placebo to dupilumab by subcutaneous injection every other week from Baseline to Week 22.
62171882|NCT03738397|EXPERIMENTAL|Dupilumab 300 mg EOW|Participants will receive a loading dose of 600 mg dupilumab by subcutaneous (SC) injection on Day 1 followed by 300 mg dupilumab SC every other week (EOW) until Week 22 and placebo to upadacitinib orally QD up to Week 24.
62171883|NCT04937205||Cohort 2|This group of study participants started the 52-week parent randomized controlled trial (NCT03411356) on February 13, 2019.
62171884|NCT04937205||Cohort 3|This group of study participants started the 52-week parent randomized controlled trial (NCT03411356) on November 5, 2019.
62171885|NCT04937205||Cohort 4|This group of study participants started the 52-week parent randomized controlled trial (NCT03411356) on October 22, 2020.
62171886|NCT05295992|EXPERIMENTAL|Daily Adaptive External Beam Radiation Therapy|Daily adaptive radiation therapy delivered with Varian Ethos treatment system.
62171887|NCT05983068|EXPERIMENTAL|Pediatric AD participants|Participants will receive dupilumab IMP according to the approved prescribing label in the country/region where the study is conducted.
62171888|NCT00551187|EXPERIMENTAL|1|V504 + Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
62171889|NCT00551187|PLACEBO_COMPARATOR|2|Placebo + Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
62171890|NCT03739333|EXPERIMENTAL|patients with glioblastoma|implementation of 11C-Methionine PET-MRI
62171891|NCT03199261|EXPERIMENTAL|rE-4 Injection|10µg, rE-4 Injection, 30 minutes prior to the start time of a standard breakfast.
62171892|NCT03199261|ACTIVE_COMPARATOR|rE-4 Freeze-dried Powder|10µg, rE-4 Freeze-dried Powder, 30 minutes prior to the start time of a standard breakfast.
62171893|NCT00721825|ACTIVE_COMPARATOR|1|Neuroaid
62171894|NCT00721825|PLACEBO_COMPARATOR|2|Neuroaid matched placebo
62171895|NCT01532102|EXPERIMENTAL|AP611074 5% gel|Twice daily application of 100 mg dose of AP611074 5% gel for 41 days followed by a single morning application on Day 42
62171896|NCT01532102|PLACEBO_COMPARATOR|Placebo gel|Twice daily application of 100 mg dose of placebo gel for 41 days followed by a single morning application on Day 42
62171897|NCT06646224|EXPERIMENTAL|CorVad Percutaneous Ventricular Assist System|Subjects with cardiogenic shock caused by cardiomyopathy will be supported by the CorVad Percutaneous Ventricular Assist System
62171898|NCT02937051|ACTIVE_COMPARATOR|Own Brand Cigarette Condition|
62171899|NCT02937051|EXPERIMENTAL|Original-flavor Black&Mild cigar|
62171900|NCT02937051|EXPERIMENTAL|Apple-flavor Black&Mild cigar|
62171901|NCT02937051|EXPERIMENTAL|Cream-flavor Black&Mild cigar|
62171902|NCT02937051|EXPERIMENTAL|Wine-flavor Black&Mild cigar|
62171903|NCT03705988|EXPERIMENTAL|Intervention Arm|Participants will receive 40 sessions in 4 weeks, for twice daily on weekdays from Monday to Friday. Each session will be performed for 30 minutes. The current intensity will be adjusted continuously from 500 μA\~2mA.
62171904|NCT03705988|SHAM_COMPARATOR|Sham Arm|Participants will receive 40 sessions in 4 weeks, for twice daily on weekdays from Monday to Friday. Each session will be performed for 30 minutes. The current intensity will be adjusted lower than 100 μA.
62171905|NCT00452985||1|"* Injection of Docetaxel~* 3-hour gap~* Injection of carboplatin"
62171906|NCT02455284|EXPERIMENTAL|Healthy subjects|MRI and neuropsychological evaluation
62171907|NCT03292198|ACTIVE_COMPARATOR|Compression Group|"Subjects in the Compression Group will wear 20-30 mmHg sleeves and gauntlets daily for a maximum of 4 weeks. L-dex will be performed at the end of each week. If the L-dex score has reversed back into normal range, intervention (garment wearing) will be discontinued and the subject will resume the surveillance schedule of screenings. If the L-dex score is still abnormal, garment wearing continues. If L-dex score is abnormal even at the end of the 4 weeks, the subject will be removed from the study and referred to standard lymphedema therapy.~An abnormal L-dex is defined by 7 or more units change compared to the subject's pre-surgical baseline."
62363857|NCT05401903|EXPERIMENTAL|Chiropractic Maintenance Care|The intervention group will receive weekly chiropractic care, in the form of high-velocity, low amplitude (HVLA) chiropractic adjustments delivered to restricted vertebrae of the cervical, thoracic and lumbar spinal segments. The intervention duration is 8 weeks. Subjects in the intervention group who do not attend at least four (4) scheduled chiropractic visits will be withdrawn from the study.
62171908|NCT03292198|EXPERIMENTAL|Therapy Group|"Subjects in the Therapy Group will wear 20-30 mmHg sleeves and gauntlets daily and receive Manual Lymphatic Drainage 3x/week for a maximum of 4 weeks. L-dex will be performed at the end of each week. If the L-dex score has reversed back into normal range, intervention will be discontinued and the subject will resume the surveillance schedule of screenings. If the L-dex score is abnormal, intervention continues. If L-dex score is abnormal even at the end of the 4 weeks, the subject will be removed from the study and referred to standard lymphedema therapy.~An abnormal L-dex is defined by 7 or more units change compared to the subject's pre-surgical baseline."
62171909|NCT04672655|EXPERIMENTAL|ONBOARD Intervention Group|Those randomized to the ONBOARD group will receive 12 weeks of CGM supplies and provide hemoglobin A1c values, data downloads, and survey responses during various time points in the study. They will also receive the intervention which consists of four 60-minute sessions with study interventionist, held 2 weeks apart.
62171910|NCT04672655|NO_INTERVENTION|CGM Only Group|Those randomized to the CGM Only group will not receive the ONBOARD intervention during their 12-month participation in the study. There will only receive 12 weeks of CGM supplies and provide hemoglobin A1c values, data downloads, and survey responses during various time points in the study.
62171911|NCT01770314|EXPERIMENTAL|Experimental|Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
62171912|NCT01770314|NO_INTERVENTION|Control|The control group is a waitlist control. Participants will be given access to painACTION after the intervention period and follow up assessments are completed.
62171913|NCT05787171|EXPERIMENTAL|PDS group|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS. This is the group which received 2-0 PDS suture to sew up the incision.
62171914|NCT05787171|EXPERIMENTAL|Vicryl group|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.This is the group which received 2-0 Vicryl suture to sew up the incision.
62171915|NCT05787171|EXPERIMENTAL|Ethibond group|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.This is the group which received 2-0 Ethibond suture to sew up the incision.
62171916|NCT01902381|EXPERIMENTAL|Treatment (6, 8-bis(benzylthio) octanoic acid)|Patients receive treatment 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62171917|NCT05616832||Veterans with upper extremity impairment after stroke|Veterans with upper extremity impairment after stroke will be recruited for this study.
62171918|NCT01401036|ACTIVE_COMPARATOR|Nobori|subjects receiving Biolimus A9 eluting stent implantation
62171919|NCT01401036|SHAM_COMPARATOR|Uncoated stents|subjects receiving uncoated stent implantation
62171920|NCT05310344|EXPERIMENTAL|Patients with platinum-resistant recurrent epithelial ovarian cancer|
62171921|NCT03451526||Surgeries+adjuvant chemotherapies|Patients who received radical resection of lung cancer + adjuvant chemotherapies
62171922|NCT03451526||Perioperative chemotherapies|Patients who received perioperative chemotherapies
62171923|NCT04067206|EXPERIMENTAL|Recorded mothers' voice group.|The mothers of the babies were given voice recorders and asked to record their voice in a comfortable room saying whatever they wanted to their baby. Each mother recorded her voice for 3-5 minutes. The voice recorder was placed at the baby's foot five minutes before the procedure and then played to the baby during the procedure.The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups.
62171924|NCT04067206|EXPERIMENTAL|White Noise|"The white noise was started five minutes before the heel lance and was played to the baby during the procedure. Dr. Harvery Karp's The Happiest Baby, which consists of only intrauterine sounds, was used. The speakers were placed at a distance of about 30 cm from the foot of the neonate. The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups."
62171925|NCT04067206|EXPERIMENTAL|MiniMuffs|MiniMuffs placed on their ears five minutes before the procedure to reduce the environmental noise. Latus MiniMuffs - Neonatal Noise Attenuators have been developed for newborns and premature babies. MiniMuffs protect the sensitive ears of the premature and provide a safe environment for healthy development.
62171926|NCT04067206|NO_INTERVENTION|Control Group|The control group who were administered standard care.
62171927|NCT02625571|EXPERIMENTAL|Intervention|
62171928|NCT01951261|ACTIVE_COMPARATOR|telemonitoring and telephone control|Early discharge from hospital with telemonitoring, telephone control and three nurse scheduled visits.
62171929|NCT01951261|NO_INTERVENTION|home care|Early discharge from hospital with home care provided by hospital respiratory nurses and pulmonologists (daily visits).
62171930|NCT05383651||Adults|
62171931|NCT05383651||Pediatric/ Neonates|
62171932|NCT05218421||Participants|Patients with a carotid artery stenosis ≥50% according to clinically performed imaging (i.e. duplex, computed tomography angiography (CTA), or magnetic resonance angiography (MRA)) that are scheduled for a CEA.
62171933|NCT05990270|EXPERIMENTAL|EXPERIMENTAL GROUP|Cervical cancer education will be provided. (The training will be in three sessions, each session will last 20-30 minutes. In the training; ppt presentation for cervical cancer, HPV virus, question and answer method will be used. In addition, female pelvic anatomy, gynecological examination, how the Pap Test is done, and cervical exam on the gynecological examination model. will be explained by showing cancer pathologies ) After the training, the final test data will be obtained by applying the questionnaire again.
62171934|NCT05990270|NO_INTERVENTION|control group|
62171935|NCT02840175|EXPERIMENTAL|Experimental|"* Day 0 at Weeks 24 : Increase the interval between 2 doses of the biological agent (etanercept, adalimumab, tocilizumab, abatacept)~* Weeks 24 at Weeks 72: Stop the biological agent if inactive disease is maintained."
62171936|NCT02840175|ACTIVE_COMPARATOR|Control|"* Day 0 at Weeks 24: Maintain the biological agent (etanercept, adalimumab, tocilizumab, abatacept) at the same dose.~* Weeks 24 at Weeks 48 : Increase the interval between 2 doses of the biological agent.~* Weeks 48 at Weeks 72: Stop the biological agent if inactive disease is maintained."
62171937|NCT06645613|SHAM_COMPARATOR|Sham Transcranial Magnetic Stimulation|Sham TMS coils will be applied to stimulate the brain targets. No magnetic field will be generated using the sham coil. It will play sounds similar to the true TMS stimulations with the pulsed weak electric current applied to the scalp to generate a similar feeling as in true stimulations.
62171938|NCT06645613|EXPERIMENTAL|Transcranial Magnetic Stimulation|TMS with the intermittent theta burst stimulation protocol will be applied to the computed brain targets based on the MRI data of each participants.
62171939|NCT04281875|EXPERIMENTAL|NIRAF Detection Technology +|Parathyroid gland identification will be performed with PTeye using NIRAF detection technology as an adjunctive tool in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND).
62171940|NCT04281875|NO_INTERVENTION|NIRAF Detection Technology -|Parathyroid gland identification will be performed with the naked eye of the surgeon without using PTeye - NIRAF detection technology in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND).
62171941|NCT06141902|OTHER|NORMAL|daily diet
62171942|NCT06141902|NO_INTERVENTION|Take Jing Si Herbal Drink|Take Jing Si Herbal Drink daily
62171943|NCT01360294||Asthma with small airway disease|
62171944|NCT01360294||Asthma without small airway disease|
62171945|NCT01018797|EXPERIMENTAL|INTRASTROMAL CORNEAL RING SEGMENT|Eighteen eyes of 18 patients, 8 men and 10 women, with high levels (\> 5 diopters \[D\]) of postkeratoplasty astigmatism were studied in a nonrandomized, retrospective, observational case series. PK was performed to treat keratoconus in 15 patients, corneal scar after trauma in 2 patients, and Fuchs endothelial dystrophy in 1 patient.
62171946|NCT05319002|EXPERIMENTAL|Group EMDR|Participants in the experimental group will undergo a 3-week group EMDR intervention with weekly 60-minute group sessions.
62171947|NCT05319002|NO_INTERVENTION|Control|The control group will follow routine daily school activities
62171948|NCT01297452|EXPERIMENTAL|BKM120 (days 1 - 21) + paclitaxel + carboplatin|This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered with paclitaxel + carboplatin on both a 21-day cycle with growth factor support (Group 1)
62171949|NCT01297452|EXPERIMENTAL|BKM120 (days 1 - 28, ) + paclitaxel + carboplatin|This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered + paclitaxel with carboplatin on a 28-day cycle with growth factor support and a 28-day cycle (Group 2).
62171950|NCT01297452|EXPERIMENTAL|BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)|EXPANSION COHORT A BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT A.
62171951|NCT01297452|EXPERIMENTAL|BKM120 (days 1 - 21) + paclitaxel + carboplatin exp B|Expansion Cohort B will be restricted to patients with tumors known to harbor PTEN mutation or homozygous deletion. The regimen in Expansion Cohort B will be the same regimen established in Group 1 of the protocol, with BKM120 (now called buparlisib) at 100 mg/day per oral + paclitaxel (175 mg/m2) + carboplatin (AUC 5), both given intravenously (IV) on day 1 of a 21-day cycle
62171952|NCT04750213||Participants Receiving Humira (Adalimumab)|Participants receiving Adalimumab for Pyoderma Gangrenosum (PG).
62171953|NCT02705248||Group A|(Group A) case group: 40 pregnant females at 6- 13wks presenting with a history of recurrent pregnancy loss (two or more failed clinical pregnancies as documented by ultrasonography or histopathology examination according to the American Society of Reproductive Medicine) (ASRM, 2008).
62171954|NCT02705248||Group B|control group: 40 pregnant females at 6- 13wks with no history of abortion.
62171955|NCT00985621|EXPERIMENTAL|1|
62171956|NCT00985621|EXPERIMENTAL|2|
62171957|NCT00985621|ACTIVE_COMPARATOR|3|
62171958|NCT00985621|PLACEBO_COMPARATOR|4|
62171959|NCT02749175|EXPERIMENTAL|Cricoid force sensor monitor system|Nurse applied cricoid pressure with a sensor guided by monitoring Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons.
62171960|NCT02749175|SHAM_COMPARATOR|Sham cricoid force sensor monitor system|Nurse applied pressure on a sham sensor with no monitor input. Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons
62171961|NCT02749175|NO_INTERVENTION|Current standard|Nurse applied cricoid force according to memory. Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons
62171962|NCT06111443|EXPERIMENTAL|Dapagliflozin|Dapagliflozin (FORXIGA) 10 mg QD for 3 months
62171963|NCT06111443|NO_INTERVENTION|Usual care|guideline-direct usual care
62171964|NCT01238250||Copy Number Variants|Individuals with documented pathogenic or likely pathogenic copy number variants related to neurodevelopmental disorders.
62171965|NCT01238250||Gene Variants|Individuals with documented pathogenic or likely pathogenic variants in a gene related to neurodevelopmental disorders.
62171966|NCT03941769|EXPERIMENTAL|Supportive care (recombinant interleukin-7)|Within 60-180 days after CBT, patients receive recombinant interleukin-7 IM or SC once per week for 3 weeks.
62171967|NCT05761197||Children with history of OPC|Individuals in the non-OPC cohort will be age and sex-matched to individuals in the OPC cohort.
62171968|NCT05761197||Children without history of OPC|Individuals in the OPC cohort will be age and sex-matched to individuals in the non-OPC cohort.
62171969|NCT00209222|ACTIVE_COMPARATOR|1|induction: R-CHOP consoldiation : TBI/Cyclo
62171970|NCT00209222|EXPERIMENTAL|2|induction: R-CHOP/DHAP consolditaion: TBI/TAM
62171971|NCT05581589|EXPERIMENTAL|Treatment (sacituzumab govitecan)|Patients receive sacituzumab govitecan IV over 3 hours on days 1 and 8 of each cycle. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks after last dose, patients undergo radical cystectomy and pelvic lymph node dissection.
62171972|NCT01151878|EXPERIMENTAL|Glucomannan|glucomannan preparation in sachets: 1 saschet of 1.26g 2 times per day (daily dosage 2,52g); duration of intervention: 4 weeks
62171973|NCT01151878|PLACEBO_COMPARATOR|Placebo|maltodextrin prepared in sachets (1,3 g per sachet); 2 sachets per day; duration of intervention: 4 weeks
62171974|NCT02127814|EXPERIMENTAL|L. reuteri|
62171975|NCT02127814|PLACEBO_COMPARATOR|Identical Placebo|
62171976|NCT02998918|EXPERIMENTAL|PolyResveratrol Supplementation|Participants take 500 mg of PolyResveratrol (100 mg curcumin phytosome, 100 mg quercetin phytosome, 100 mg green tea phytosome, 100 mg trans-resveratrol, 100 mg trans-pterostilbene; Thorne Research) twice daily for one week. Two blood Draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.
62171977|NCT02998918|EXPERIMENTAL|Curcumin Supplementation|Participants take 500 mg of Curcumin phytosome twice daily for one week. Two blood draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.
62171978|NCT00509925|EXPERIMENTAL|Treatment period 1|Insulin detemir for 16 weeks (treatment period 1) followed by insulin NPH treatment for 16 weeks (treatment period 2) in addition to meal-time insulin aspart
62171979|NCT00509925|EXPERIMENTAL|Treatment period 2|Insulin NPH for 16 weeks (treatment period 1) followed by insulin detemir treatment for 16 weeks (treatment period 2) in addition to meal-time insulin aspart
62171980|NCT06194929|EXPERIMENTAL|Phase II, Defactinib and Avutometinib (Cohort A)|"Avutometinib will be administered at 3.2 mg biweekly orally (e.g., Monday/Thursday, Tuesday/Friday, or Wednesday/Saturday) for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle.~Defactinib will be administered at 200 mg twice a day orally for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle."
62171981|NCT06194929|EXPERIMENTAL|Phase Ib, Defactinib, Avutometinib, and Encorafenib (Cohort B)|"Avutometinib will be administered at 3.2 mg biweekly orally (e.g., Monday/Thursday, Tuesday/Friday, or Wednesday/Saturday) for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle.~Defactinib will be administered at 200 mg twice a day orally for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle.~Encorafenib will be administered orally to a small cohort to a limited dose escalation cohort using a Bayesian optimal interval (BOIN) design to evaluate safety, toxicity, and recommended phase II dose for dosage of encorafenib when combined with avutometinib and defactinib.~Dose escalation levels for Encorafenib:~Dose Level -1: 225 mg Daily (three 75mg capsules) Dose Level 0: 300 mg Daily (four 75mg capsules) Dose Level 1: 450 mg Daily (six 75mg capsules)"
62171982|NCT06194929|EXPERIMENTAL|Phase II, Defactinib, Avutometinib, and Encorafenib (Cohort B)|"Avutometinib will be administered at 3.2 mg biweekly orally (e.g., Monday/Thursday, Tuesday/Friday, or Wednesday/Saturday) for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle.~Defactinib will be administered at 200 mg twice a day orally for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle.~Encorafinib will be administered orally at doses defined in the dose escalation portion (225mg - 450mg) Daily continuously (days 1-28 of a 28 day cycle) for Cohort B."
62171983|NCT02581189||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
62171984|NCT01785797|NO_INTERVENTION|Control: burr hole drainage only|Burr hole drainage of chronic subdural hematoma under general or local anesthesia without the subsequent placement of a subdural drain.
62171985|NCT01785797|EXPERIMENTAL|Intervention: silicon subdural drain|Placement of a silicon subdural drain after burr hole drainage of a chronic subdural hematoma.
62171986|NCT01069406||presence of uterine artery notch|patients with uterine artery notch during the 2nd and 3rd trimester
62171987|NCT03255915|EXPERIMENTAL|Arm 1|Arm 1 will receive the Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) pod-IVR for Stage 2 followed by the placebo pod-IVR during Stage 3.
62171988|NCT03255915|EXPERIMENTAL|Arm 2|Arm 2 will receive the placebo pod-IVR for Stage 2 followed by the Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) pod-IVR during Stage 3.
62171989|NCT05087329|EXPERIMENTAL|Virtual Mindfulness intervention|Four weekly group Zoom webinars with a 15-20 minute pre-recorded meditation
62171990|NCT05087329|NO_INTERVENTION|Standard of Care|
62171991|NCT02737670|ACTIVE_COMPARATOR|Sulodexide|Sulodexide 25 mg twice per day for 40 days
62171992|NCT02737670|PLACEBO_COMPARATOR|Placebo|1 tablet twice per day for 40 days
62171993|NCT03643705|EXPERIMENTAL|Nurse Intervention|This multi-component intervention will consist of four evidence-based components delivered at 4 in-person visits (0, 4, 8, and 12 months) and by telephone contact: (1) nurse-led care coordination, (2) nurse-managed medication protocols and adherence support (3) home blood pressure monitoring, and (4) electronic medical records support tools.
62171994|NCT03643705|ACTIVE_COMPARATOR|Education Control|Participants in the education control arm will receive general prevention education delivered at 4 in-person visits (0, 4, 8, and 12 months), which will consist of evidence-based material on diet, exercise, smoking, sexually transmitted infections, and cancer prevention.
62171995|NCT04276636|EXPERIMENTAL|Caltrate|This group of patients are going to supplemented with Caltrate 0.6 g / d orally.
61997261|NCT01802775|EXPERIMENTAL|edoxaban/aspirin|Open label edoxaban will be provided. Subjects randomized to this treatment arm will receive edoxaban 60 mg once daily (QD) (two 30 mg tablets) for a total of approximately 3 months on a background of aspirin 100 mg QD.
62171996|NCT04276636|NO_INTERVENTION|Control|The other group do not interfere.
62171997|NCT03761407|EXPERIMENTAL|Group 1 (100 mg GRT0151Y)|"The dose of 100 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 100 mg. On Day 5 the last dose of 100 mg will be administered in the morning.~Matching placebo using the same dosing regimen as defined in the treatment group."
62363858|NCT05401903|NO_INTERVENTION|Control|The control group will not receive any chiropractic care during study protocol.
62363859|NCT02351739|OTHER|Pembrolizumab|Arm 1: pembrolizumab monotherapy
62363860|NCT02351739|OTHER|ACP-196 in combination with pembrolizumab|Arm 2: ACP-196 in combination with pembrolizumab
62363861|NCT01856803|ACTIVE_COMPARATOR|routine prophylaxis|In this group, CSA plus MMF and MTX adopted as prevention of GVHD.
62171998|NCT03761407|EXPERIMENTAL|Group 2 (125 mg GRT0151Y)|"The dose of 125 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 125 mg. On Day 5 the last dose of 125 mg will be administered in the morning.~Matching placebo using the same dosing regimen as defined in the treatment group"
62171999|NCT03761407|EXPERIMENTAL|Group 3 (150 mg GRT0151Y)|"The dose of 150 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 150 mg. On Day 5 the last dose of 150 mg will be administered in the morning.~Matching placebo using the same dosing regimen as defined in the treatment group"
62172000|NCT03761407|EXPERIMENTAL|Group 4 (225 mg GRT0151Y)|"The dose of 150 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the dose of 225 mg will be administered twice (b.i.d.). On Day 5 the last dose of 225 mg will be administered in the morning.~Matching placebo using the same dosing regimen as defined in the treatment group"
62172001|NCT00317603|EXPERIMENTAL|Vaccine|"Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately 1x10 7 , 4x10 6 ,~1x10 6 , or 1x10 5 depending on the final cell yield."
62172002|NCT02399683||Trichuris trichiura eggs|One healthy volunteer
62172003|NCT05818995||CKD G1|GFR ≥90 mL/(min·1.73m2)
62172004|NCT05818995||CKD G2|GFR 60\~89 mL/(min·1.73m2)
62172005|NCT05818995||CKD G3|GFR 30\~59 mL/(min·1.73m2)
62172006|NCT05818995||CKD G4|GFR 15\~29 mL/(min·1.73m2)
62172007|NCT05818995||CKD G5|GFR \<15 mL/(min·1.73m2)
62172008|NCT03857516||Recipients of cardiac resynchronization therapy|Consecutive patients with de novo implantation of a cardiac resynchronization defibrillator or pacemaker.
62172009|NCT03327688|ACTIVE_COMPARATOR|POCUS group|Point-of-care ultrasound
62172010|NCT03327688|NO_INTERVENTION|Radiologist group|Traditional diagnostic way
62172011|NCT03327688|ACTIVE_COMPARATOR|DVT POCUS group|DVT group after POCUS education
62172012|NCT03327688|NO_INTERVENTION|DVT traditional group|DVT group traditional diagnostic way before educational intervention
62172013|NCT02394509|EXPERIMENTAL|HOBSCOTCH-IP (in person)|Participants will receive the HOBSCOTCH intervention consisting of a first session conducted in-person, 3 weekly followed by 3 bi-weekly telephone coaching sessions, and a final session conducted in-person.
62172014|NCT02394509|EXPERIMENTAL|HOBSCOTCH-V (virtual)|Participants will receive the HOBSCOTCH intervention consisting of a first session conducted virtually, 3 weekly followed by 3 bi-weekly telephone coaching sessions, and a final session conducted virtually.
62172015|NCT02394509|OTHER|Control|Participants will be wait listed and given an option whether they prefer to enroll into HOBSCOTCH-IP or HOBSCOTCH-V. Subjects in Group 3 will receive HOBSCOTCH following a 6 month wait period.
62172016|NCT04691336|EXPERIMENTAL|PIMAGroup|All patients were summoned to the care center, being evaluated individually by a nurse, and based on the results, a care plan adapted to the specific needs and objectives was initiated. This care plan involved monitoring using different channels (face-to-face, telephone), with the main objective of monitoring the evolution of compliance, adherence and improving the quality of life of patients. The interventions that were carried out were educational and formative (using counseling communication skills), and technological (using monitoring tools in specific cases). The empowerment program was an educational session in which the nurse discussed content about dyspnea, the benefits of therapy, etc.
62172017|NCT05614024|EXPERIMENTAL|Real fNIRS Neurofeedback Arm|Participants assigned to the experimental arm will see their true, real-time brain activation (i.e., active real-time neurofeedback) during the neurofeedback session. This activation will be displayed to the participant as a thermometer that will increase as brain activation in the target region increases.
62172018|NCT05614024|SHAM_COMPARATOR|Sham-Control fNIRS Neurofeedback Arm|Participants assigned to the sham-control arm will see false feedback (or a fake signal) that is not connected to their right vlPFC activation during the neurofeedback session.
62172019|NCT04344756|EXPERIMENTAL|Active Coagulation|
62172020|NCT04344756|NO_INTERVENTION|Standard of Care|Control patients will receive the best standard of care and a subcutaneous preventive anticoagulation for at least 14 days with enoxaparin 4000 IU/24h, tinzaparin 3500 IU/24h or dalteparin 5000 IU/24h if creatinine clearance (Cockcroft) ≥ 30mL/min or unfractionated heparin 5000 IU/12h if creatinine clearance \< 30mL/min.
62172021|NCT02329223|EXPERIMENTAL|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 12 week treatment period.
62172022|NCT02329223|EXPERIMENTAL|Omalizumab 150 mg|Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 12 week treatment period.
62172023|NCT02329223|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo subcutaneously every 4 weeks during the 12 week treatment period.
62172024|NCT06646458|EXPERIMENTAL|Milk Powder (study product) usage group|Investigational Product Participants in this arm will need to take 2 times every day from baseline visit to 28 days.
62172025|NCT06647186|ACTIVE_COMPARATOR|Study group|Ten patients treated with Non-Incised Papillae Surgical Approach (NIPSA) plus Allograft bone substitute
62172026|NCT06647186|ACTIVE_COMPARATOR|Control group|Ten patients treated with Conventional Flap plus Allograft bone substitute
62172027|NCT01291550||Nerodegenerative diseases|Patients with parkinsonism and patients with dementia
62172028|NCT01291550||Controls|
62172029|NCT01291550||ADHD|Subjects diagnosed with ADHD
62172030|NCT06201715|EXPERIMENTAL|tofacitinib|
62172031|NCT06269393|PLACEBO_COMPARATOR|Placebo|Participants with TAO will be randomized to receive 4 intravenous infusions of placebo with an interval of 3 weeks, followed by 4 intravenous infusions of IBI311 with an interval of 3 weeks.
62172032|NCT06269393|ACTIVE_COMPARATOR|IBI311|Participants with TAO will be randomized to receive 8 intravenous infusions of IBI311 with an interval of 3 weeks.
62172033|NCT06537219||back pain group|participants with chronic back pain( pain duration at least 3 months) aged between 18 and 50 years , male and female participanst will be included in the study. Those with orthopaedic, neurological and systemic diseases will be excluded from the study.
62172034|NCT06537219||control group|healty male and female participants aged between 18 and 50 years
62172035|NCT00396214|EXPERIMENTAL|1|
62172036|NCT00396214|EXPERIMENTAL|2|
62172037|NCT00396214|ACTIVE_COMPARATOR|3|
62172038|NCT04051190|EXPERIMENTAL|VLED group|Participants will undergo a 10-week VLED.
62172039|NCT04051190|EXPERIMENTAL|Sleeve Gastrectomy group|Participants will undergo standard clinical practice prior to surgery.
62172040|NCT04051190|EXPERIMENTAL|Gatric Bypass group|Participants will undergo standard clinical practice prior to surgery.
62172041|NCT02003716||No treatment|
62172042|NCT00640185|PLACEBO_COMPARATOR|1|
62172043|NCT00640185|EXPERIMENTAL|2|
62172044|NCT00640185|EXPERIMENTAL|3|
62172045|NCT04531371|EXPERIMENTAL|dexemedetomidine|dexemedetomidine was administered intravenously after induction of general anesthesia.
62172046|NCT04531371|ACTIVE_COMPARATOR|magnesium sulphage|magnesium sulphate was infused through out the surgery after induction of general anaesthesia.
62172047|NCT04531371|PLACEBO_COMPARATOR|saline|nothing was given just saline during the operation.
62172048|NCT05686681|EXPERIMENTAL|Brief Behavioral Activation for Improving Social Connectedness|Active, 6 session Brief Behavioral Activation for Improving Social Connectedness
62172049|NCT03696732||Women undergoing cesarean section|Women undergoing cesarean section under spinal anesthesia with prophylactic phenylephrine drip.
62172050|NCT06512116|EXPERIMENTAL|SIBP-A17|SIBP-A17 is an Her2-ADC drug.
62172051|NCT04728217|EXPERIMENTAL|Patients receiving Efmoroctocog alfa|For long term prophylaxis, the recommended starting dose is 50 IU of factor VIII per kg body weight at intervals of 3 to 5 days. The dose may be adjusted based on patient response in the range of 25 to 65 IU/kg. In some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary.
62172052|NCT00743223||1|Study-group: The volunteers were selected on a randomized form among the individuals who went to the clinic of orofacial pain and temporomandibular disorders of São Paulo Hospital.
62172053|NCT00743223||2|Control-group: The volunteers were selected on a randomized form among the individuals who went to the dental offices of the researchers.
62172054|NCT01936298|EXPERIMENTAL|A-ROM Continuous Passive Rehabilitation|The group of patients with Active Range Of Motion (A-ROM) is subjected to two session per day in the morning and in the afternoon over a period of two weeks (5 days per week). Each session is composed by 30 min of continuous passive motion rehabilitation and 60 min of physical and occupational therapy.
62172055|NCT01936298|EXPERIMENTAL|P-ROM Continuous Passive Rehabilitation|The group of patients with Passive Range Of Motion (P-ROM), i.e. without active movements of the hand at the baseline, is subjected to two session per day in the morning and in the afternoon over a period of two weeks (5 days per week). Each session is composed by 30 min of continuous passive motion rehabilitation and 60 min of physical and occupational therapy.
62172056|NCT01785771|EXPERIMENTAL|ITCA 650|
62172057|NCT00287183|ACTIVE_COMPARATOR|PF-04494700 (TTP488)|
62172058|NCT00287183|PLACEBO_COMPARATOR|Placebo|
62172059|NCT01952106|EXPERIMENTAL|distraction|use the computer game to distract children's pain and anxiety during venepuncture
62172060|NCT05204472|EXPERIMENTAL|Burst DBS first, Tonic DBS second|10 days of Burst-stimulation followed by 10 days of active tonic stimulation (Burst-DBS -\> tonic-DBS)
62172061|NCT05204472|ACTIVE_COMPARATOR|Tonic DBS first, Burst DBS second|10 days of active tonic stimulation followed by 10 days of Burst-stimulation (tonic-DBS -\> Burst-DBS)
62172062|NCT06025877||Cohort A|One time clinician survey post-test following the receipt of the PrecivityAD2 blood test result
62172063|NCT06025877||Cohort B|Pre-test as well as post-test and close-out survey following the receipt of the PrecivityAD2 blood test result
62172064|NCT03410108|EXPERIMENTAL|Brigatinib 90 mg + Brigatinib 180 mg|Brigatinib 90 milligram (mg), tablets, orally, once daily (QD) for first 7 days followed by brigatinib, 180 mg, tablets, orally, QD in Cycle 1 of 28 days followed by brigatinib 180 mg, tablets, orally, QD in Cycle 2 and onward cycles of 28 days until investigator-assessed progressive disease (PD) or intolerable toxicity, withdrawal of consent, or discontinuation for any other reason, whichever comes first up to Cycle 34 of 28-day cycle, until data cut-off date 29 September 2020.
62172065|NCT00078858|EXPERIMENTAL|Treatment (prolonged MMF and truncated CSP)|"CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2, and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBMC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 150 and mycophenolate mofetil PO or IV TID on days 0-30, BID on days 31-150, and then taper to day 180. Treatment continues in the absence of unacceptable toxicity."
62172066|NCT03279536|EXPERIMENTAL|Oral Lactoferrin|Group A is 120 mg of Oral lactoferrin for 4 weeks Intervention: The participants 66 will receive oral Lactoferrin 120mg for 4 weeks
62172067|NCT03279536|ACTIVE_COMPARATOR|Total dose infusion (TDI) iron dextran|Group B is a parenteral total dose infusion (TDI) of LMW iron dextran 20mg/kg body weight for 4 weeks Intervention: The participants 33 will receive parental iron 20mg/kg body weight for 4 weeks
62172068|NCT04613622||Venetoclax|Adult patients (≥ 20 year-old) who have already initiated or are going to receive venetoclax treatment at National Taiwan University Hospital/National Taiwan University Cancer Center from August 2020 to December 2025.
62172069|NCT05752955|EXPERIMENTAL|SMARThealth Pregnancy|"SMART Health Pregnancy is a complex intervention designed to be delivered on top of usual care. It comprises three parts:~(i) A regular screening program focused on women's health during pregnancy and in the year following birth.~(ii) An electronic decision support system (EDSS) (iii) An short messaging service (SMS) appointment reminder system"
62363862|NCT01856803|EXPERIMENTAL|ATG prophylaxis|In this group,ATG+MMF+CsA+MTX was adopted as prevention of GVHD
62172070|NCT05752955|NO_INTERVENTION|Active Comparator: Usual Care|Usual antenatal and postnatal care. Women and health workers in the usual care clusters will not receive any additional support beyond that already offered under the local government programs
62172071|NCT00234221|ACTIVE_COMPARATOR|Strengths Based Case Management Model (SBCM)|The Strengths Based Case Management Model (SBCM) consists of 5 case-management sessions designed to promote linkage and engagement in assessment and treatment services, while assisting with the patient's perceived needs, as well as personal strengths and barriers to linkage and engagement.
62172072|NCT00234221|ACTIVE_COMPARATOR|Motivational Enhancement Therapy (MET)|The MET therapist will conduct 2 motivational enhancement sessions to work through the content of an educational workbook targeting the participant's alcohol use/abuse with the goal of negotiating a 'contract' to: 1) link to services, with the eventual goal of seeking and receiving specialized alcohol treatment; or 2) provide a strategy to self-monitor alcohol use, consider consequences, and later seek assessment.
62172073|NCT00234221|ACTIVE_COMPARATOR|Brief Informational Feedback (BIF) session|Subjects will receive brief informational feedback on the results of their alcohol screening and assessment and encouragement to seek treatment.
62172074|NCT05721378|EXPERIMENTAL|Permissive Weight Bearing group|Rehabilitation following the Permissive Weight Bearing (PWB) protocol
62172075|NCT05721378|ACTIVE_COMPARATOR|Restrictive Weight Bearing group|Rehabilitation following the Restrictive Weight Bearing (RWB) protocol
62172076|NCT04047680||SOF-based DAAs|Patients receiving sofosbuvir (SOF)-based direct acting antiviral agents (DAAs) for 12 weeks
62172077|NCT04047680||SOF-free DAAs|Patients receiving sofosbuvir (SOF)-free direct acting antiviral agents (DAAs) for 12 weeks
62172078|NCT06646744||Vaccinated children|Children between 5 and 12 years old vaccinated with 2 doses of an approved mRNA vaccione against COVID-19.
62172079|NCT03792789|EXPERIMENTAL|mCIMT with real rTMS|Modified Constraint Induced Movement Therapy (mCIMT) with real Repetitive Transcranial Magnetic Stimulation (rTMS). 10 sessions of mCIMT will be administered using physical rehabilitation protocol along with real rTMS over contralateral primary motor cortex.
62172080|NCT03792789|SHAM_COMPARATOR|mCIMT with sham rTMS|Modified Constraint Induced Movement Therapy with sham Repetitive Transcranial Magnetic Stimulation (using sham coil). 10 sessions of mCIMT will be administered using physical rehabilitation protocol along with sham rTMS over contralateral primary motor cortex using sham coil which simulated sound and touch of real coil but has no electro-magnetic waves.
62172081|NCT01572493|EXPERIMENTAL|Arm A1 (Dose Escalation, 10-day Dosing)|Maximum tolerated dose (MTD) determination in subjects with metastatic cancers receiving recombinant human Interleukin-15 (rhIL-15) intravenous (IV) for 10 consecutive days
62172082|NCT01572493|EXPERIMENTAL|Arm A2 (Dose Expansion, 10-day Dosing)|Clinical activity evaluation in subjects with metastatic cancers receiving recombinant human Interleukin-15 (rhIL-15) intravenous (IV) for 10 consecutive days
62172083|NCT01572493|EXPERIMENTAL|Arm B1 (Dose Escalation, 5-day Dosing)|Maximum tolerated dose (MTD) determination in subjects with metastatic unresectable cancers receiving recombinant human Interleukin-15 (rhIL-15) intravenous (IV) for 5 consecutive days
62172084|NCT01572493|EXPERIMENTAL|Arm B2 (Dose Expansion, 5-day Dosing)|Clinical activity evaluation in subjects with metastatic cancers receiving recombinant human Interleukin-15 (rhIL-15) intravenous (IV) for 5 consecutive days
62172085|NCT01956071|EXPERIMENTAL|WAPD|Participants were asked to complete three tasks while simultaneously pedaling at a sustainable and self-selected pace. The three tasks were: 1) compose and send an email; 2) search a topic on the internet, and 3) complete an on-line questionnaire.
62172086|NCT00835783||FUO|Patients with fever of unknown origin undergoing FDG-PET/CT as part of work-up.
62172087|NCT00835783||BUO|Patients with bacteremia of unknown origin undergoing FDG-PET/CT as part of work-up.
62172088|NCT00835783||VGI|Patients with vascular graft infections undergoing FDG-PET/CT as part of work-up.
62172089|NCT05683886|EXPERIMENTAL|KC1036|60mg QD
62172090|NCT03594266|EXPERIMENTAL|Therapy A Spinal Cord Stimulation Parameter Set|
62172091|NCT03594266|EXPERIMENTAL|Therapy B Spinal Cord Stimulation Parameter Set|
62172092|NCT02384083|EXPERIMENTAL|Filanesib, pomalidomide and dexamethasone|28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 \& 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 \& 22
62172093|NCT00837096|EXPERIMENTAL|V.A.C. Therapy|Negative Pressure Wound Therapy (NPWT) distrubtes negative pressre across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
62172094|NCT00837096|ACTIVE_COMPARATOR|Moist Wound Therapy (MWT)|t wound therapy (MWT) is a widely used treatment modality that demonstrates benefit through the facilitation of a moist wound environment, which is known to promote faster relative wound healing compared to wounds exposed to air.
62172095|NCT01561885|ACTIVE_COMPARATOR|Patients on Pathway Care|
62172096|NCT01561885|NO_INTERVENTION|Patients on Usual Care|
62172097|NCT03369652|EXPERIMENTAL|Intervention|Medication history by pharmaconomist. Medication review by pharmacist, patient interview, and conference with physician in hospital, telephone contact to general practitioner after discharge, medication report sent to primary care.
62172098|NCT03369652|NO_INTERVENTION|Control|Medication history by pharmaconomist. Usual care by physicians.
62172099|NCT04659278|PLACEBO_COMPARATOR|Group 1 Placebo|Placebo Isolate Placebo (Hemp seed oil and peppermint flavoring)
62172100|NCT04659278|ACTIVE_COMPARATOR|Group 2 Isolate Comparator|Isolate Placebo Isolate (CBD no terpenes Hemp seed oil \[slightly lower concentration of CBD ratio\])
62172101|NCT04659278|PLACEBO_COMPARATOR|Group 3 Placebo Comparator|Placebo OMD Endourage OMD (Full flower extract with a 1:1 ratio of cannabis terpenes, Hemp seed oil and peppermint flavoring)
62172102|NCT04659278|EXPERIMENTAL|Group 4 Experimental Placebo|OMD Placebo Endourage OMD (Full flower extract with a 1:1 ratio of cannabis terpenes, Hemp seed oil and peppermint flavoring)
62172103|NCT02584075|EXPERIMENTAL|Lifestyle intervention|
62172104|NCT05809245|EXPERIMENTAL|Corneal neurotization|Patients will undergo the corneal neurotization as described in the protocol. Their pre and post-procedure corneal sensation will be measured as a primary outcome measure. Secondary outcome measures will include visual acuity, corneal opacity, NEI VFQ, and confocal microscopy.
62172105|NCT06038383|EXPERIMENTAL|Group A - Intervention with Virtual Reality (VR)|Group of people with kidney disease that enrolled the intervention with VR during hemodialysis.
62172106|NCT06038383|ACTIVE_COMPARATOR|Group B - Intervention with Stationary Bike (SB)|Group of people with kidney disease that enrolled the intervention with SB during hemodialysis.
62172107|NCT06038383|EXPERIMENTAL|Group A - Intervention with Stationary Bike (SB) - Crossover|Group of people with kidney disease that enrolled the intervention with SB during hemodialysis, after the period of washout.
62172108|NCT06038383|ACTIVE_COMPARATOR|Group B - Intervention with Virtual Reality (VR) - Crossover|Group of people with kidney disease that enrolled the intervention with VR during hemodialysis, after the period of washout.
62172109|NCT02618785|EXPERIMENTAL|Hyoscine|The experiment group receive Hyoscine 10 mg 2 tablets by mouth before hysterosalpingography procedure
62172110|NCT02618785|PLACEBO_COMPARATOR|Placebo|The control group receive placebo by mouth before hysterosalpingography procedure
62172111|NCT03348969|EXPERIMENTAL|Intervention|Neoadjuvant Mitomycin C
62172112|NCT03348969|ACTIVE_COMPARATOR|Control|Adjuvant Mitomycin C
62172113|NCT03022045|EXPERIMENTAL|Risankizumab 75 mg|Participants randomized to receive risankizumab 75 mg at Week 0, Week 4, and every 12 weeks up to Week 172.
62172114|NCT03022045|EXPERIMENTAL|Risankizumab 150 mg|Participants randomized to receive risankizumab 150 mg at Week 0, Week 4, and every 12 weeks up to Week 172.
62172115|NCT05979402|EXPERIMENTAL|Training group|Face-to-face pressure ulcer training will be given to the relatives of the patients in the training group in the determined common time period. The presentation and pressure ulcer content prepared during the trainings will be conveyed by the researcher in two 30-minute sessions using lectures, example events and question-answer techniques.
62172116|NCT05979402|ACTIVE_COMPARATOR|Control group|Participants in the control group will not be interfered with by the researcher during the research. They will receive routine in-clinic training given by nurses.
62172117|NCT04665349|EXPERIMENTAL|Pre-op|Nutricia Pre-op, 400 milliliters, per os
62172118|NCT04665349|NO_INTERVENTION|Control|No intervention
62172119|NCT04781543|EXPERIMENTAL|HZN-825 300 mg once daily (QD)|One set of 2 HZN-825 150mg tablets in the morning and one set of 2 placebo tablets in the evening.
62172120|NCT04781543|EXPERIMENTAL|HZN-825 300 mg twice daily (BID)|One set of 2 HZN-825 150mg tablets in the morning and one set of 2 HZN-825 150mg tablets in the evening.
62172121|NCT04781543|PLACEBO_COMPARATOR|Placebo|One set of 2 placebo tablets in the morning and one set of 2 placebo tablets in the evening.
62172122|NCT05964270|ACTIVE_COMPARATOR|Intervention group (IG)|participants of the intervention group (IG) will get a login for the e-coach MM, and access to eight modules: medication, outpatient visit preparation, periodic assessment, messaging service, alerts, information, ad hoc complaint, personal care plan. IG participants information is collected on a web platform that automatically invites enrolled patients. The e-coach MM is available 24/7.
62172123|NCT05964270|NO_INTERVENTION|Control group (CG)|Participants in the CG (control group) will only get a login for a 'dummy version' without the modules, besides the periodic assessments (questionnaires), at the same time as the IG
62172124|NCT03692689|EXPERIMENTAL|SCT200|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
62172125|NCT05918289|EXPERIMENTAL|Intervention and control|Treatment group taken intervention of education program designed for elders and the control group did not take any intervention but at the end of the time duration they were taken the opportunity of 3 days class room intervention
62172126|NCT01939483|EXPERIMENTAL|Treatment (irinotecan hydrochloride)|"Patients receive irinotecan hydrochloride IV over 90 minutes on days 1, 8, 15, 22, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.~This arm also includes laboratory biomarker analysis as an intervention."
62172127|NCT06453174||Cohort one|A prospective sample of patients with a first episode psychosis referred over 18 months to the new early intervention in psychosis programme of Personalised Precision Psychiatry called PRINT - PRevention and early INTervention in mental health - at Salamanca University Healthcare Complex (CAUSA) in Salamanca, Spain.
62172128|NCT06453174||Cohort two|A retrospective, consecutive (in reverse chronological order as registered in CAUSA electronic health records) sample of patients who suffered a first-episode psychosis before the implementation of PRINT.
62172129|NCT06453174||Cohort three|For additional comparative purposes, we shall analyse environmental, clinical and pharmacogenetic information of patients with psychotic disorders of more than five years of evolution or with other mental disorders, whose data are currently stored, and ethically approved for research use, in our Unit of Pharmacogenetics and Precision Medicine at CAUSA.
62172130|NCT05095714|EXPERIMENTAL|Enhanced screening|Half-yearly liver ultrasound and fast-MRI
62172131|NCT05095714|ACTIVE_COMPARATOR|Screening recommendations|Half-yearly liver ultrasound
62172132|NCT05264298|EXPERIMENTAL|VIRTUAL Intervention (Treatment)|Participants assigned to intervention arm will have scheduled video telehealth appointments with a multidisciplinary team (Stroke provider, social worker, pharmacist) and remote telemonitoring of blood pressure with blood pressure medication adjustments biweekly as needed by pharmacists.
62172133|NCT05264298|ACTIVE_COMPARATOR|Standard Care|Participants assigned to standard care will follow-up with a stroke provider within 2 weeks of discharge and primary care as per usual recommendations. Participants will monitor their blood pressure on their own and pharmacists will contact participants monthly to review blood pressure. Pharmacists will make recommendations for blood pressure medication adjustment to participant primary care provider.
62172134|NCT03139383|PLACEBO_COMPARATOR|normal saline solution|The patients received normal saline solution as a maintenance fluid during surgery in dose of 2 ml/kg/hour.
62172135|NCT03139383|ACTIVE_COMPARATOR|dextrose solution|The patients received dextrose solution as a maintenance fluid during surgery in dose of 2 ml/kg/hour.
62172136|NCT00791102|ACTIVE_COMPARATOR|1|Topical ASP-1001
62172137|NCT00791102|PLACEBO_COMPARATOR|2|Placebo for Topical ASP-1001
62172138|NCT02186015|EXPERIMENTAL|Cholecalciferol|All participants will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
62172139|NCT02186015|NO_INTERVENTION|Vitamin D sufficient|All participants were ineligible for the intervention due to sufficient serum 25(OH)D levels at screening/baseline.
62172140|NCT05450640||Patients with haemophilia A with dispensing Emicizumab (HEMLIBRA®) in community pharmacy|This group of patients have chosen the dispensing of Emicizumab (HEMLIBRA®) in community pharmacy. This choice involves the contribution of the community pharmacist in the dispensing circuit who does not replace the hospital pharmacist but interact together for prescriptions renewals, emergency treatment or sharing information if necessary.
62172141|NCT05450640||Patients with haemophilia A with dispensing Emicizumab (HEMLIBRA®) in hospital pharmacy|This group of patients have kept the dispensing of Emicizumab (HEMLIBRA®) in hospital pharmacy
62172142|NCT04646135|EXPERIMENTAL|Sequence 1|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:~* Day 1: 6 Boluses at 0.1 mg/kg LZ every 4 hours~* Day 2: 6 Boluses at 0.2 mg/kg LZ every 4 hours~* Day 3: Continuous Infusion at 0.025 mg/kg/hour LZ"
62172143|NCT04646135|EXPERIMENTAL|Sequence 2|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:~* Day 1: 6 Boluses at 0.2 mg/kg LZ every 4 hours~* Day 2: 6 Boluses at 0.1 mg/kg LZ every 4 hours~* Day 3: Continuous Infusion at 0.03 mg/kg/hour LZ"
62172144|NCT04646135|EXPERIMENTAL|Sequence 3|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:~* Day 1: 6 Boluses at 0.3 mg/kg LZ every 4 hours~* Day 2: 6 Boluses at 0.1 mg/kg LZ every 4 hours~* Day 3: Continuous Infusion at 0.025 mg/kg/hour LZ"
62172145|NCT03721978|EXPERIMENTAL|VGX-3100 + EP|Participants received 3 IM injections of 6 mg (in 1 mL) VGX-3100 followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4, and Week 12.
62172146|NCT03721978|PLACEBO_COMPARATOR|Matched Placebo + EP|Participants received 3 IM injections of 1 mL VGX-3100 matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4, and Week 12.
62172147|NCT05307237|EXPERIMENTAL|Continuous Glucose Monitoring|Research Assistants (RAs) will verbally administer baseline survey and insert Dexcom G6 CGM, before unveiling the group assignment. CGM data will be transmitted from bedside iPhone to web-based platforms for: (1) Real-Time Management (via iPad-based FOLLOW app used by bedside RN and Digital Dashboard used by remote monitoring team) and (2) Clinical Optimization (via CLARITY, a Diabetes RN Coordinator will conduct remote clinical management of patients from a central, Scripps Diabetes Hub). A post-CGM satisfaction survey will be administered and compensation provided when CGM is removed prior to discharge or within 2 weeks following discharge. The CGM readings will be used to make recommendations for insulin adjustment and glucose management. After discharge, CGM data will be downloaded from a HIPPA-compliant, web-based CGM data management tool, and saved in Excel. The Data Analyst, blinded to condition, will routinely screen CGM data and merge individual spreadsheets for analysis.
62172148|NCT05307237|ACTIVE_COMPARATOR|Usual Care|RAs will verbally administer a baseline survey and insert the Dexcom G6 CGM. before unveiling the group assignment. CGM data will be blinded and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours if not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring, A post-CGM satisfaction survey will be administered and compensation provided when the CGM is removed prior to discharge or within 2 weeks following discharge. After discharge, CGM data will be downloaded from a HIPPA-compliant, web-based CGM data management tool, and saved in individual Excel spreadsheets. The study Data Analyst, blinded to study condition, will routinely screen CGM data and merge individual spreadsheets for analysis.
62172149|NCT03375697|EXPERIMENTAL|SAD (Part 1): Healthy Subjects|In Part 1, single ascending intravenous (IV) doses of JNJ-63733657 or placebo will be administered to sequential cohorts (Cohorts 1 to 5) of healthy subjects on Day 1. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. Here, SAD indicates single ascending dose.
62172150|NCT03375697|EXPERIMENTAL|MAD (Part 2): Subjects With Alzheimer's Disease (AD)|In Part 2, multiple ascending IV doses of JNJ-63733657 or placebo will be evaluated at three dose levels in sequential cohorts in subjects with prodromal or mild AD; 3 doses will be administered over a period of 8 weeks (Day 1, Day 29, Day 57). The starting dose will be decided based on the data from Part 1. Escalations will be done based on safety and tolerability similar to Part 1. Doses will not exceed those tested in Part 1. Here, MAD indicates multiple ascending dose.
62172151|NCT06183827|ACTIVE_COMPARATOR|the Oxygen Supply strategy|"During the 4-month period of control, the care teams will:~- Use Oxygen Supply by face mask (15Liters/minutes) from pre-hospital to intensive care unit admission until the 6th hour following the start of drowning care (Emergency Medical Service arrival at the scene).~Indeed, current concepts of advanced prehospital care include the use of oxygen by face mask (15Liters/minutes) and intubation-Mechanical Ventilation in case of failure. The requirement of intubation-Mechanical Ventilation by the Emergency Medical Service (pre-hospital phase) or Intensive Care Unit (hospital phase) practitioners during this first 6 hours period will be left to the discretion of the practitioners in charge of the patient;~- Continue this strategy in the Intensive Care Unit until the Acute Respiratory Failure resolution allows a reduction of Oxygen Supply. The Oxygen Supply will be reduced progressively litter by litter each 12 hours period with maintenance of capillary saturation up to 92%."
62172152|NCT06183827|EXPERIMENTAL|the 'Continuous Positive Airway Pressure strategy|"During the 4-month period of experimentation, the care teams will:~- Use Non-Invasive Ventilation by Continuous Positive Airway Pressure (set between 8 to 10 cm H2O) from pre-hospital setting to Intensive Care Unit admission until the 6th hour following the start of drowning care (Emergency Medical Service arrival at the scene).~The requirement of Mechanical Ventilation by the Emergency Medical Service (pre-hospital phase) or Intensive Care Unit (hospital phase) practitioners during this first 6 hours period will be left to the discretion of the practitioners in charge of the patient.~- Continue this strategy in the Intensive Care Unit until the Acute Respiratory Failure resolution allows a reduction of Non-Invasive Ventilation-Continuous Positive Airway Pressure. Non-Invasive Ventilation-Continuous Positive Airway Pressure support will be weaned progressively (left at practitioners' convenience) with maintenance of capillary O2 saturation up to 92%."
62172153|NCT06015620||Patients with morbid obesity undergoing metabolic surgery (Mini gastric bypass)|The patients undergoing mini gastric bypass surgery for morbid obesity and its different comorbidities like type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, hypothyroidism and chronic venous hypertension.
62172154|NCT06245499|EXPERIMENTAL|Intervention|Care Partners in the intervention group will be approached and offered care coordination through the Aging Brain Care Virtual program
62172155|NCT06245499|NO_INTERVENTION|Control|Care partners in the control group will not be approached, but outcomes data will be collected from the EMR for comparison with the intervention group.
62172156|NCT02722759|OTHER|hemoglobin measurement arm|"In this arm hemoglobin measurement is done by four different devices~* device Radical-7 for non-invasive measurement of SpHb~* device HemoCue for taking capillary and venous blood for measurement of HcHb~* device ABL 800 for measurement of BGAHb~* device Siemens ADVIA for measurement of labHb~For measurement of haemoglobin by the devices the following interventions have to be done:~* venous or arterial puncture (routine)~* capillary puncture~* placing of the Radical 7 sensor"
62172157|NCT03380221|EXPERIMENTAL|Watermelon|
62172158|NCT03380221|ACTIVE_COMPARATOR|Low fat cookies|
62172159|NCT01143298|EXPERIMENTAL|LEO 27847 oral solution 0.1 mg|LEO 27847 oral solution 0.1 mg
62172160|NCT01143298|EXPERIMENTAL|LEO 27847 tablet 0.10 mg|LEO 27847 tablet 0.10 mg
62172161|NCT01143298|EXPERIMENTAL|LEO 27847 tablet 0.01 mg|LEO 27847 tablet 0.01 mg
62172162|NCT04145089|ACTIVE_COMPARATOR|C-Mac intubation|Intubation with C-MAC video laryngoscopy
62172163|NCT04145089|ACTIVE_COMPARATOR|Glidescope intubation|Intubation with Glidescope video laryngoscopy
62172164|NCT04112355||6 months of age|"Visit 1~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :~* Draw a blood sample based on age groups below~* Provided a temperature diary to fill out for the next week Visit 2~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :~* Draw a blood sample based on age groups below~* Collect temperature diary if not already mailed in"
62172165|NCT04112355||12 months of age|"Visit 1~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :~* Draw a blood sample based on age groups below~* Provide a temperature diary to fill out for the next week Visit 2~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :~* Draw a blood sample based on age groups below~* Collect temperature diary if not already mailed in"
62172166|NCT04112355||5 years of age|"Visit 1~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :~* Draw a blood sample based on age groups below~* Provide a temperature diary to fill out for the next week Visit 2~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :~* Draw a blood sample based on age groups below~* Collect temperature diary if not already mailed in"
62172167|NCT04893902|ACTIVE_COMPARATOR|conventional ear impression|
62172168|NCT04893902|EXPERIMENTAL|digital auricular impression without marker using intra oral scanner|
62172169|NCT04893902|EXPERIMENTAL|digital auricular impression with marker using intra oral scanner|
62172170|NCT05317299|ACTIVE_COMPARATOR|Resistance Exercise Group|During 8 week progressive resistance exercises (three times a week)
62172171|NCT05317299|ACTIVE_COMPARATOR|Plyometric Exercise Group|During 8 week progressive plyometric exercises (three times a week)
62172172|NCT05317299|ACTIVE_COMPARATOR|High Intensity Interval Training Group|During 8 week progressive Hight Intensity Interval Training (three times a week)
62172173|NCT06479551|EXPERIMENTAL|Experimental Group: A|13 participants will be in experimental group giving them High intensity-low volume resistance training protocol of 4 reps and 2 sets comprising 90% of 1 RM parallel back squats for six weeks measure all values before giving them protocol and after protocol.
62172174|NCT06479551|EXPERIMENTAL|Control Group: B|13 participants will be in control group giving them moderate intensity-high volume resistance training training protocol of 8 reps and 3 sets comprising 80% of 1 RM parallel back squats for six weeks measure all values before giving them protocol and after protocol.
62172175|NCT06646380|EXPERIMENTAL|Multicomponent Training|Participants will be instructed to maintain normal daily life activities to prevent physical inactivity. Inclusion criteria will involve individuals over 65 years old, independent in daily activities, and without chronic diseases requiring pharmacological treatment affecting the experimental protocol, while exclusion criteria included failure to attend more than 25% of training sessions, failure to attend more than four consecutive sessions, or missing evaluation sessions. Participants will be randomly assigned to either the experimental group (EG ≈ 30) or control group (CG ≈ 30). Experimental group will be followed-up during the exercise sessions.
62172176|NCT06646380|PLACEBO_COMPARATOR|Control Group|The CG were instructed to maintain their daily life routines. However, the typical profile of this group was that the participants were regularly physically active people. Most participate in municipal activities like nature walking, physical activity sessions including dance (casually), board and card games, and traditional games (Bocce, Adapted Bowling, and darts).
62172177|NCT02203045|ACTIVE_COMPARATOR|Tourniquet|All lower extremities will be exsanguinated by elevation for 2 minutes. For lower extremities in the tourniquet group (TQT), a pneumatic tourniquet will be inflated according to standard practice (\>200 mmHg). For the NOTQT group, the tourniquet will only be inflated during component cementation. In both groups, tourniquet will be deflated after bone cement has set. In both groups, electrocautery will be used as needed throughout the procedure.
62172178|NCT02203045|EXPERIMENTAL|Non- tourniquet|All lower extremities will be exsanguinated by elevation for 2 minutes. For lower extremities in the tourniquet group (TQT), a pneumatic tourniquet will be inflated according to standard practice (\>200 mmHg). For the NOTQT group, the tourniquet will only be inflated during component cementation. In both groups, tourniquet will be deflated after bone cement has set. In both groups, electrocautery will be used as needed throughout the procedure.
62172179|NCT01903928|EXPERIMENTAL|ASP0113 group|Participants receive 1 mL of ASP0113 intramuscularly 5 times, on days -14 to -3, 14 to 40, 60 ± 5, 90 ± 10, and 180 ± 10, counting from the transplantation (stem cell transfusion) day (day 0)
62172180|NCT03746483|EXPERIMENTAL|MS1819 2240 mg/day (3 weeks) then PERT pre-study dose (3 weeks)|Patients in arm will further be randomized to receive either the sequence consisting of MS1819 2240 mg/day for 3 weeks followed by PERT for another 3 weeks. During the PERT treatment period the patients will take their stable pre-study PERT dose.
62172181|NCT03746483|EXPERIMENTAL|PERT pre-study dose(3 weeks) then MS1819 2240 mg/day (3 weeks)|Patients in arm will be randomized to receive PERT for 3 weeks followed by MS1819 2240 mg/day for another 3 weeks. During the PERT treatment period the patients will take their stable pre-study PERT dose.
62172182|NCT04303871|ACTIVE_COMPARATOR|patients|pregnant female with hypertension admitted in ICUfor control of BP invasive assessment of BP by radial cannulation was compared against non-invasive assessment of BP by an automated oscillometric BP device (Mobil-O-Graph )
62172183|NCT04303871|PLACEBO_COMPARATOR|control|matched control females of the same age but not pregnant invasive compared to non-invasive measurement of BP by same technique
62172184|NCT01249976|EXPERIMENTAL|catheter-spearing diagnostic methods|experimental
62172185|NCT02867371|EXPERIMENTAL|-Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System
62172186|NCT04414397|OTHER|No Treatment then JUVÉDERM® VOLUMA® XC|Participants received no treatment for 3 months during the Control Period. They either exited the study at Month 3 or received an optional treatment with JUVÉDERM® VOLUMA® XC injectable gel treatment in both temples during the Post-Control Period and an optional touch-up treatment 30 days later. Participants did not receive any treatment during the Maintenance Treatment Period.
62172187|NCT04414397|EXPERIMENTAL|JUVÉDERM® VOLUMA® XC|Participants received JUVÉDERM® VOLUMA® XC injectable gel treatment in both temples during the Control Period followed by an optional touch-up treatment 30 days later. Participants exited the study at Month 13 or received an optional maintenance treatment and were followed for 6 months during the Maintenance Treatment Period.
62172188|NCT05266157|ACTIVE_COMPARATOR|Usual care|"Skin care, exercise and compression stocking:~The patient has to wear custom-made compression thigh stocking(s) in case of unilateral/ bilateral swelling of the leg and has to wear a bermuda in case of swelling of the midline region. The patient continues the skin care and continues/ restarts exercise therapy with the home physical therapist 2 times a week. Frequency of exercises is gradually decreased: M1-3 2x/w, M4-6 1x/w, M7-9 1x/M; M10-12 only self-exercises."
62172189|NCT05266157|EXPERIMENTAL|Additional manual lymph drainage|"Usual care + manual lymph drainage. Manual lymph drainage is performed by the home physical therapist. Every session lasts for 30 minutes.~Frequency of manual lymph drainage is gradually decreased: M1-3 2x/w, M4-6 1x/w, M7-9 1x/M; M10-12 only self-MLD."
62172190|NCT03170947|EXPERIMENTAL|Custom insoles|Custom insoles will make with CAD-CAM using a laser scanning and casting for its construction. Custom insoles will make with direct adaptation technique (TAD) being of pvc resin.
62172191|NCT03170947|ACTIVE_COMPARATOR|Standardized insoles|Standardized insoles will be done by Ethylene-vinyl acetate (EVA) material.
62172192|NCT00511459|EXPERIMENTAL|A|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 10 mg/kg IV QW
62172193|NCT00511459|EXPERIMENTAL|D|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + Open Label AMG 386 10 mg/kg IV QW
62172194|NCT00511459|EXPERIMENTAL|B|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 3 mg/kg IV QW
62172195|NCT00511459|ACTIVE_COMPARATOR|C|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 placebo IV QW
62172196|NCT00550771|ACTIVE_COMPARATOR|Doxorubicin Based Regimen|
62172197|NCT00550771|EXPERIMENTAL|Pegylated Liposomal Doxorubicin (PLD) Based Regimen|
62172198|NCT06027697||Subchondroplasty|"AccuFill Porous Bone Substitute Material (BSM) will be administrated to the patient during a subchondroplasty procedure (treatment visit).~During the inclusion visit and the follow-up visits (Week 3, Week 6; Month 3, Month 6, Month 12, Month 24, Month 36, Month 48) the doctor will proceed the usual clinical exam and the patients will fulfil the validated questionnaires and scales to assess pain, functional impairments and subjective improvement."
62172199|NCT03986983|EXPERIMENTAL|Experimental group of Aerobic exercise|The participants perform the Aerobic exercise protocol - The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
62172200|NCT03986983|EXPERIMENTAL|Experimental group of Shockwave therapy and Aerobic Exercise|"The participants do the Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position.~In addition, the participants also perform the Aerobic exercise protocol - The entire protocol was monitored through the Polar® brand heart rate monitor and watch."
62363863|NCT02867384|ACTIVE_COMPARATOR|Obinutuzumab|"Obinutuzumab or will be administered at a pre- determine dose, intravenously, at 3, 6, 9 and 12 months from transplantation.~* Premedication with histamine blockers and acetaminophen will be provided~* All subjects will undergo allogeneic stem cell transplantation according to locally approved clinical trials"
62172201|NCT03986983|NO_INTERVENTION|Control group|The participants do not perform any type of intervention.
62172202|NCT03042858||Infants with PPV|During laparoscopy for pyloric stenosis, the surgeon will turn the camera downward to answer the first question, whether the inguinal canal is patent or closed. If a PPV is present, the subject will be followed for up to 18 years of age.
62172203|NCT03042858||Infants without PPV|During laparoscopy for pyloric stenosis, the surgeon will turn the camera downward to answer the first question, whether the inguinal canal is patent or closed. If there is no PPV, meaning they have normal anatomy, the patient demographic data will be recorded and this will terminate their participation.
62172204|NCT02486159|EXPERIMENTAL|Herbal plaster and Acupuncture|"In the first year: Acupoint herbal plaster applications every one week over a 4-week period for a total of 4 applications.~In the second year: Acupoint herbal plaster used as the same method as first year, and combined with Acupuncture treatment in the same time."
62182357|NCT04982627|EXPERIMENTAL|Brief Negotiation Interview Chatbot (BNI Chatbot)|Participants will receive a link to register for the chatbot. Following registration, they will complete the initial chat, which includes instructions for the entire study. The chatbot will then guide the participant through multiple BNIs focused on the goal of bup engagement, with the following steps: 1) Raise the Subject/Establish Rapport; 2) Enhance Motivation; 3) Provide \& Elicit Feedback; and 4) Negotiate a Plan. The chatbot then reminds the participant of their reasons why they might engage in OUD treatment based on their responses to Steps 2 \& 3, and their negotiated plan. The chatbot will electronically connect participants to a treatment provider of their choice, based on available options.
62363864|NCT02867384|SHAM_COMPARATOR|Placebo|"Placebo will be administered at a pre- determine dose, intravenously, at 3, 6, 9 and 12 months from transplantation.~* Premedication with histamine blockers and acetaminophen will be provided~* All subjects will undergo allogeneic stem cell transplantation according to locally approved clinical trials"
62363865|NCT03549819|EXPERIMENTAL|Cannabidiol (CBD) Oil Capsules|Pure CBD in sunflower lecithin oil, flexibly dosed at 200-800 mg per day
62363866|NCT03549819|PLACEBO_COMPARATOR|Sunflower Lecithin Oil in Capsule|1-4 capsules daily
62172205|NCT03047278|ACTIVE_COMPARATOR|Control Group|Adult patients (18 - 59 years old) with neuropathic pain of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting (phase I). To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10). In phase II, after 15 days (wash-out) from phase I, cetirizine hydrochloride (10 mg) was administered orally, twice a day, as pills, for five days. On the last day of cetirizine treatment, an oral single dose of gabapentin (300 mg), as capsule, was administered. Serial blood and urine samples were collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling.
62172206|NCT03047278|EXPERIMENTAL|Controlled Diabetes Group|Adult patients (18 - 59 years old) with controlled type 2 diabetes (glycated hemoglobin ≤ 8.0%) and diabetic neuropathy of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting. To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10).
62172207|NCT03047278|EXPERIMENTAL|Uncontrolled Diabetes Group|Adult patients (18 - 59 years old) with uncontrolled type 2 diabetes (glycated hemoglobin ≥ 8.0%) and diabetic neuropathy of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting. To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10).
62172208|NCT04385628||Relatives of patients hospitalized in the intensive care unit|Demographic data of the relative of the patient (age, proximity, educational background, patient co-existence, ethnicity, marital status, number of children, history of psychological treatment and the presence of an intensive care treatment history of any family member before) will be recorded. After the 3rd, 10th, and 30th days of patient admission, and once a month, the patient satisfaction survey will be filled face to face during informing the patient's relative. These three main data (Demographic data of the patient relatives, the most recent satisfaction questionnaire and emotional reactions observed while reporting death) will be evaluated and interpreted.
62172209|NCT05106816|EXPERIMENTAL|Vibrotactile Continuous stimulation|Continuous stimulation
62172210|NCT05106816|EXPERIMENTAL|Vibrotactile Intermittent stimulation|Intermittent stimulation
62172211|NCT05106816|SHAM_COMPARATOR|Vibrotactile Sham|Sham stimulation
62172212|NCT05360342|EXPERIMENTAL|Vitamin K supplement|Administration of a single dose vitamin K
62172213|NCT00002855|EXPERIMENTAL|Arm I|Arm I: Medical or surgical castration followed by an anti-androgen therapy with either flutamide, bicalutamide, or nilutamide.
62172214|NCT00002855|EXPERIMENTAL|Arm II|Arm II: Chemo/hormonal therapy for 3 x 8-week courses, followed by total androgen blockade. Each course consists of 6 weeks of cytotoxic therapy with doxorubicin, ketoconazole, vinblastine, and estramustine followed by 2 weeks rest. Maintained on hydrocortisone both during treatment and during rest.
62172215|NCT05354557|EXPERIMENTAL|Single prior autoHCT with melphalan|"Participants have not experienced disease progression since initiation of initial systemic anti-myeloma therapy, are within 12 months of frontline autoHCT with~\>/=140mg/m2 of melphalan, initiated lenalidomide maintenance at least 6 months ago, and have a very good partial response (VGPR) or less at time of enrollment. Cohort 1 will be initiated after evaluation of preliminary efficacy and safety data from Cohort 2."
62172216|NCT05354557|EXPERIMENTAL|2 to 3 prior lines of systemic anti-myeloma therapy +/- prior autoHCT|Participants have already received lenalidomide maintenance after a prior line of treatment, underwent a salvage autoHCT within the prior 2-6 months as consolidation therapy for relapsed disease after 2 to 3 prior therapies
62172217|NCT06195878|EXPERIMENTAL|CPAP Therapy|Participants who are diagnosed with moderate-to-severe sleep related breathing disorders (SRBDs) will undergo a 4-month trial of Continuous positive airway pressure (CPAP) therapy.
62172218|NCT04486833|EXPERIMENTAL|Investigational|In Phase 1, Phase 2a and the investigational arm of Phase 2b, patients will receive their assigned dose of quaratusugene ozeplasmid (intravenous administration once every 21 days) plus osimertinib (80 mg fixed dose oral tablet taken daily starting on Day 1 through Day 21 of every 21-day treatment cycle) until disease progression or unacceptable toxicity.
62172219|NCT04486833|ACTIVE_COMPARATOR|Control|In the control arm of Phase 2b, patients will receive platinum-based chemotherapy until disease progression or unacceptable toxicity.
62172220|NCT01437384|EXPERIMENTAL|E5501 plus minus verapamil; plus minus cyclosporine|
62363867|NCT04939532|ACTIVE_COMPARATOR|Text-Messaging (TM)|Population health management intervention that analyzes electronic health record data to automatically identify participants with high risk for either infection or severe disease and proactivity reaches those participants via text message for testing needs (as advised by state and/or federal guidelines) and testing recommendation when applicable. This is a bi-directional text messaging system.
62172221|NCT04086719|EXPERIMENTAL|BMS- 986185 + Pyrimethamine|
62172222|NCT04086719|EXPERIMENTAL|BMS-986185|
62172223|NCT01816100|EXPERIMENTAL|exercise session|"6 months weight resistance session, with before/after evaluations by MEG and DTI. Fifty minute exercise sessions, twice weekly will be done. Each session will rotate between 3 separate exercise protocols: Static weights, free weights and balance. Exercises will be done with each extremity independently. For consistency and convenience, the resistance training will be performed at Fast Forward Gym, Omaha, NE.~The primary outcome exercise data include strength and endurance"
62172224|NCT00658983|EXPERIMENTAL|1|Autologous Platelet Enriched Gel
62172225|NCT00658983|ACTIVE_COMPARATOR|2|Metalloproteinase Inhibitor (Promogran)
62172226|NCT05335668|EXPERIMENTAL|Patients with central poststroke pain|Patients with central poststroke pain
62363868|NCT04939532|ACTIVE_COMPARATOR|Text-Messaging plus Patient Navigation (TM+PN)|Population health management intervention that includes the same bi-directional text-messaging system as Arm 1 (the text messaging condition) with the addition of patient navigation. Patient navigation includes real-time assistance from a community health worker to address barriers, provide motivation, and assist with logistics of COIVD testing.
62172227|NCT05335668|EXPERIMENTAL|Patients without central poststroke pain|Patients without central poststroke pain
62172228|NCT05335668|ACTIVE_COMPARATOR|healthy controls|healthy volunteers
62172229|NCT01741636|EXPERIMENTAL|Supportive care (survivorship plan)|Patients undergo Survivorship Care Planning comprising disease surveillance, management of potential long-term and late effects, psycho-social-spiritual issues, and healthy living recommendations.
62172230|NCT02754752|EXPERIMENTAL|Group I (electroacupuncture therapy)|Patients undergo electroacupuncture therapy over 45 minutes 2-3 times per week over 4 weeks for a total of 10 sessions.
62172231|NCT02754752|PLACEBO_COMPARATOR|Group II (sham electroacupuncture therapy)|Patients undergo modified electroacupuncture therapy over 45 minutes 2-3 times per week over 4 weeks for a total of 10 sessions. Acupuncture needles are placed in different locations using a different technique than those used for Group I.
62172232|NCT02754752|ACTIVE_COMPARATOR|Group III (waitlist control)|Patients receive standard of care without any kind of acupuncture therapy.
62172233|NCT01599377|EXPERIMENTAL|Cohort 1|
62172234|NCT01599377|EXPERIMENTAL|Cohort 2|
62172235|NCT06584838||Allograft|Patients aged ≥ 40 y.o. that underwent ACL reconstruction using allograft tendons
62172236|NCT06584838||Autograft|Patients aged ≥ 40 y.o. that underwent ACL reconstruction using autograft tendons
62172237|NCT05811455|EXPERIMENTAL|Group A: aerobic exercises.|The first treatment group will be given aerobic exercises for six weeks at least three times per week. This group will include 14 participants. This study group will be assigned with basic treatment protocol with aerobic exercises along with 10 minutes of warm up period.
62172238|NCT05811455|ACTIVE_COMPARATOR|group b progressive muscle relaxation exercises.|"The intervention will be given three days per week for six weeks. Pre and post-treatment readings will be noted. Each total session will last for 45 minutes. The importance of the study will be explained, and consent will be taken from the people before the intervention will be applied.~* Breathe in, and tense the first muscle group (hard but not to the point of pain or cramping) for 4 to 10 seconds.~* Breathe out, and suddenly and completely relax the muscle group (do not relax it gradually) (20)"
62172239|NCT05811455|NO_INTERVENTION|Group C. Control group|No intervention was given
62172240|NCT04739293|EXPERIMENTAL|ON 123300|ON 123300 capsules at increasing doses per cohort, starting at 40 mg
62172241|NCT02864147|EXPERIMENTAL|imiquimod + 9-valent HPV vaccine|Participants randomized to the imiquimod + 9-valent HPV vaccine group will receive instruction on imiquimod self application (16 week course) at the baseline visit. In addition, all women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
62172242|NCT02864147|ACTIVE_COMPARATOR|imiquimod only|Participants randomized to the imiquimod only group will receive instruction on imiquimod self application (16 week course) at the baseline visit.
62172243|NCT02864147|NO_INTERVENTION|observation only (control)|Participants randomized to the control group will only be observed and will receive no intervention.
62172244|NCT04585737|EXPERIMENTAL|Treatment group 1|Treatment Group 1 (n=148): FDC of DTG/3TC (50mg/300mg) administered orally, once daily (QD), without regard to food.
62172245|NCT04585737|ACTIVE_COMPARATOR|Treatment group 2|Treatment Group 2 (n=74): Stay on baseline regimen consisting of FDC of B/F/TAF (50mg/200mg/ 25mg) (taken as prescribed) without regard to food.
62172246|NCT05065918|ACTIVE_COMPARATOR|Control - alcohol use reduction content|Alcohol use reduction content
62172247|NCT05065918|EXPERIMENTAL|Intervention - sexual violence and alcohol use harm reduction content|sexual violence and alcohol use harm reduction content
62172248|NCT03408821|EXPERIMENTAL|Problem Solving Therapy|All participants will attend 8 weekly sessions of Case Manager delivered Problem Solving Therapy.
62172249|NCT04804228|EXPERIMENTAL|Electrical dry needling|The experimental group consisting of 40 subjects will perform electrostimulation on the active myofascial trigger points of the following muscles: quadratus lumbar, multifidus and iliocostalis, following the PGM maps described by Travell and Simons. The electrostimulation of the PGM will be carried out using needle electrodes, the generated current will be produced by a TENS device with a frequency of 2 Hz and a pulse width of 250 μs, the application will be approximately 30 min. The therapeutic intervention will be 1 session per week for a total of 6 weeks.
62172250|NCT04804228|ACTIVE_COMPARATOR|Ischemic compression, analytical stretching and postural habits educational dossier|The control group consisting of 40 subjects will undergo an ischemic compression technique in active PGM with a time between 20 seconds and 1 minute until pain inhibition is achieved, and finally, analytical stretching will be carried out on the quadratus lumbar, multifid and iliocostal, 1 weekly session for 6 weeks providing a training dossier of postural education in their activities of daily life.
62172251|NCT02927899|EXPERIMENTAL|Prevention (dietary intervention, survey)|Patients receive 4 tomato-soy beverages and 3 labeled arugula seed powder portions. Patients add 1 arugula seed powder portion to each of 3 tomato-soy beverages immediately prior to consumption, and they consume 1 beverage without the powder. After each beverage tasting, patients complete a survey on the sensory acceptability of the sample.
62172252|NCT01811823|OTHER|TIV|"Trivalent Inactivated Influenza Vaccine The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~* A/California/7/2009 (H1N1)pdm-like virus~* A/Victoria/361/2011 (H3N2)-like virus~* B/Wisconsin/1/2010-like virus. (Yamagata lineage)"
62172253|NCT00130728|EXPERIMENTAL|erlotinib HCl + bevacizumab|oral erlotinib HCl 150 mg/day orally + intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
62172254|NCT00130728|PLACEBO_COMPARATOR|erlotinib HCl + placebo|oral erlotinib HCl 150 mg/day orally + intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
62363869|NCT00681122||1|Standard therapy
62363870|NCT00681122||2|Standard therapy + educational material
62172255|NCT06642363|EXPERIMENTAL|Drug|receiving ASX supplements
62172256|NCT06642363|PLACEBO_COMPARATOR|control|receiving placebo
62172257|NCT00604240||1|Parents / caregivers of any infant who has a length of stay of at least 1 week in the NICU at Christiana Hospital or Thomas Jefferson University Hospital.
62172258|NCT04133259|EXPERIMENTAL|HLX10, in patients with CHB|HLX10: 1 mg/kg at 0, 4th, 8th week (maximum 3 doses). Concomitant antiviral medications: take Nucleoside/nucleotide analogues (NAs) starting from at least 2 weeks before the first dose of HLX10 until 12 weeks after the last dose of HLX10 infusion.
62172259|NCT05571553|EXPERIMENTAL|Intervention group|"Phase 1~* Participants will assess their health status, at home, at recruitment (M0) and at 3 months (M3) with CARE© with the help of their family caregivers.~* The principal investigator or a representative will contact them by phone within 5 days of the CARE© assessment to complete ESOGER.~Phase 2~* Participants will assess their health status, at home, at recruitment (M0), at 3 months (M3), and at 6 months (M6) on the CARE© application with the help of their family caregivers. An additional assessment will take place over the phone by the principal investigator or one of his representatives.~* If their health status is considered fragile, then individuals will be contacted by phone by the PI or one of his representatives to complete the ESOGER© questionnaire (at M0, M3 and M6)."
62172260|NCT05571553|NO_INTERVENTION|Control group|"Phase 1~* Participants will assess their health status, by telephone, at recruitment (M0) and at 3 months (M3) with CARE© with the help of their family caregivers.~* The principal investigator or a representative will contact them by phone within 5 days of the CARE© assessment to complete ESOGER.~Phase 2~* Participants will assess their health status, at home, at recruitment (M0), at 3 months (M3), and at 6 months (M6) on the CARE© application with the help of their family caregivers. An additional assessment will take place over the phone by the principal investigator or one of his representatives.~* If their health status is considered fragile, then individuals will be contacted by phone by the PI or one of his representatives to complete the ESOGER© questionnaire (at M0, M3 and M6)."
62172261|NCT06647277|OTHER|PD patients|This is an open-label clinical trial to evaluate the Safety of fecal microbiota transplant following a 10 day treatment with Vancomycin in adult subjects with Parkinson's disease.
62172262|NCT04902196|EXPERIMENTAL|Group 1|persons with chronic low back pain of an non-specific origin
62172263|NCT04902196|ACTIVE_COMPARATOR|Group 2 (Control group)|"healthy persons (pain-free)"
62172264|NCT00935649|EXPERIMENTAL|Randomized great toe|Subjects with both great toes infected. Right/left randomized to treatment / no treatment
62172265|NCT00935649|NO_INTERVENTION|Untreated Toe|
62172266|NCT00733551|EXPERIMENTAL|Subjects receiving GSK962040 in cohort 1|Eligible subjects will receive repeat oral doses of GSK962040 given as 10 milligrams once daily tablet for 14 days.
62172267|NCT00733551|EXPERIMENTAL|Subjects receiving GSK962040 in cohort 2|Eligible subjects will receive repeat oral doses of GSK962040 given as 30 milligrams once daily tablet for 14 days.
62172268|NCT00733551|EXPERIMENTAL|Subjects receiving GSK962040 in cohort 3|Eligible subjects will receive repeat oral doses of GSK962040 given as 100 milligrams once daily tablet for 14 days.
62172269|NCT00733551|PLACEBO_COMPARATOR|Subjects receiving placebo in cohort 1, 2 and 3|Eligible subjects will receive repeat oral doses of placebo tablets given once daily for 14 days in cohort 1, 2 and 3.
62172270|NCT02396550|EXPERIMENTAL|Positive Expectations|Procedure/Surgery: Mobilization with movement in patients with lateral epicondylalgia with modification of its expectations into positive
62172271|NCT02396550|EXPERIMENTAL|Neutral Expectations|Procedure/Surgery: Mobilization with movement in patients with lateral epicondylalgia with modification of its expectations into neutral
62172272|NCT04872634|EXPERIMENTAL|SNK01 (4ⅹ10^9 cells) + GC|Administration of SNK01 4ⅹ10\^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks
62172273|NCT04872634|EXPERIMENTAL|SNK01 (4ⅹ10^9 cells) + GC + Cetuximab|Administration of SNK01 4ⅹ10\^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks + Weekly administration of Cetuximab until the disease progresses or unacceptable toxicity develops
62172274|NCT04872634|EXPERIMENTAL|SNK01 (6ⅹ10^9 cells) + GC|Administration of SNK01 6ⅹ10\^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks
62172275|NCT04872634|EXPERIMENTAL|SNK01 (6ⅹ10^9 cells) + GC + Cetuximab|Administration of SNK01 6ⅹ10\^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks + Weekly administration of Cetuximab until the disease progresses or unacceptable toxicity develops
62172276|NCT02250183|OTHER|Medihoney & Santyl|Each patient will receive both interventions simultaneously, but on non-contiguous parts of the body that each consist of partial thickness burn injuries of similar depth. For example, if a patient presents with bilateral second-degree burns to the lower extremities, one leg will be treated with MEDIHONEY® GEL with Active leptospermum honey dressing, while the other leg will be treated with SANTYL® ointment dressing. MEDIHONEY® is the target treatment for this study, while SANTYL® is standard care.
62172277|NCT03467789|EXPERIMENTAL|Group A: D3 prior to first PDT|"In both groups, one PDT session is preceded by neoadjuvant PDT while the other PDT session has no pretreatment.~Group A will take dietary D3 pills prior to the first PDT treatment (day 1), and placebo pills prior to the second PDT treatment (at 2 months). Both Group A and Group B will take continuous serum D3 prior to the third PDT visit (Month 4). A final assessment of lesion clearance will be performed at 6 months"
62172278|NCT03467789|EXPERIMENTAL|Group B: D3 prior to second PDT visit|"In both groups, one PDT session is preceded by neoadjuvant PDT while the other PDT session has no pretreatment.~Group B will receive placebo prior to their first PDT visit (day 1), and Vitamin D3 prior to their second PDT visit (at 2 months). Both Group A and Group B will take continuous D3 prior to the third PDT visit (Month 4). A final assessment of lesion clearance will be performed at 6 months"
62172279|NCT03688022|EXPERIMENTAL|MT-7117 BA and DDI (fasted)|MT-7117 lower content tablets, higher content tablets, higher content tablets with PPI (fasted), higher content tablets with PPI and acidic beverage (fasted)
62172280|NCT03688022|EXPERIMENTAL|MT-7117 food effect and DDI (fed)|MT-7117 higher content tablets (fasted and fed), higher content tablets with PPI (fed), higher content tablets with PPI and acidic beverage (fed)
62172281|NCT06247488|PLACEBO_COMPARATOR|Placebo|oral masked Placebo
62172282|NCT06247488|ACTIVE_COMPARATOR|Oxycodone 20 mg|oral active control
62172283|NCT06247488|EXPERIMENTAL|GE-IR 200mg|single oral dose
62172284|NCT06247488|EXPERIMENTAL|GE-IR 450 mg|single oral dose
62172285|NCT06247488|EXPERIMENTAL|GE-IR 200 mg + Oxycodone 20 mg|oral doses given together
62172286|NCT06247488|EXPERIMENTAL|GE-IR 450 mg + Oxycodone 20 mg|oral doses given together
62172287|NCT02811042|ACTIVE_COMPARATOR|Oropharyngeal leak pressure|Ambu AuraOnce
62172288|NCT02811042|EXPERIMENTAL|Fiberoptic position|Ambu AuraGain
62172289|NCT04912102|ACTIVE_COMPARATOR|Group H|Oxygen will be delvered via HFNO canula at 20 L/min, Fio2 0.4 and temperature of 37o c using Vapotherm Precision Flow.
62172290|NCT04912102|ACTIVE_COMPARATOR|Group M|Mask group will be provided with nasal CPAP (10cmH2O) at an oxygen flow rate of 15 L/min.
62172291|NCT04912102|ACTIVE_COMPARATOR|Group C|In the Control group, oxygen via a nasal cannula at a flow rate of 5 L/min will be delivered
62172292|NCT01963442|ACTIVE_COMPARATOR|Amoxicillin/Clavulanic acid treatment|after 3 day treatment of β-lactams, the subjects receive 5-day treatment of Amoxicillin/clavulanic acid. Chest X-ray performed at admission and Day 30 and replapses. 'blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
62172293|NCT01963442|PLACEBO_COMPARATOR|placebo treatment|after 3-day treatment of β-lactams, the subjects receive 5-day treatment of placebo. Chest X-ray performed at admission and Day 30 and replapse. blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
62172294|NCT02271737|EXPERIMENTAL|Experimental|Improve infection control in health centers; improve home hygiene; improve newborn danger signs recognition by the HC staff, VHSG, and mothers; and improve care coordination between community and health facilities. The above improvements will be through the training of health center staff and VHSG; HC staff and VHSG provide health education to mothers at the health centers and at home respectively; and provide supportive supervision to both HC and VHSG. VHSG will conduct three home visits to the mothers/newborns on the first 24 hours, the 3rd day, and the 7th day after delivery.
62172295|NCT02271737|NO_INTERVENTION|No Intervention|We do not make any interventions.
62172296|NCT00352391||Vanguard Study|Patients with Head and Neck or Non-Small Cell Lung Cancer who are Current or Former Smokers.
62172297|NCT03606850|EXPERIMENTAL|Treatment by citalopram|The patients will receive a treatment by citalopram at 20mg/day. If patients respond by at least 20% on the HAMD-21 scale at day 14 : continuation at 20 mg/day. If patients do not respond by at least 20% at day 14 : increase the dose at 40 mg/day. The patients who will not respond by at least 50% on the HAMD-21 scale at day 28 will be excluded of the study and will undergo a new treatment plan. The patients who will respond by at least 50% on HAMD-21 at day 28 will continue citalopram at the same dose and will be reappraised at day 60. The patients will be assessed for the markers of neuroexcitability at day 1, day 3, day 7, day 14, day 28 and day 60.
62172298|NCT05923398|EXPERIMENTAL|Experimental Group|During the duration of the study, all participants will use the Digital Intervention Suite (a web-based component, a VR platform, and wearable device) to measure passive and active data, such as: psychological variables (e.g., moral distress, anxiety, and depression) and physiological variables (e.g., heart rate and sleep).
62172299|NCT05153499|ACTIVE_COMPARATOR|CP101|
62172300|NCT05153499|PLACEBO_COMPARATOR|Placebo|
62172301|NCT04075097|EXPERIMENTAL|Aerobic exercise|44 minutes of moderate intensity walking on a treadmill.
62172302|NCT04075097|EXPERIMENTAL|Yoga|44 minutes of Iyengar yoga.
62172303|NCT03220659|PLACEBO_COMPARATOR|Standard settings|Usual pacing programming
62172304|NCT03220659|EXPERIMENTAL|Multi-point pacing|MPP programming
62172305|NCT04093466|EXPERIMENTAL|Treatment (CX1003)|Treatment will comprise 2 periods: a 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond).
62172306|NCT04161547|EXPERIMENTAL|Cohort A1: CSPCHA115 100 mg|"CSPCHA115 100 mg or placebo administered orally in the fasted state for 7 days.~* Eight subjects will receive CSPCHA115~* Two subjects will receive matching placebo"
62172307|NCT04161547|EXPERIMENTAL|Cohort A2: CSPCHA115 200 mg|"CSPCHA115 200 mg or placebo administered orally in the fasted state for 7 days.~* Eight subjects will receive CSPCHA115~* Two subjects will receive matching placebo"
62172308|NCT04161547|EXPERIMENTAL|Cohort A3: CSPCHA115 400 mg|"CSPCHA115 400 mg or placebo administered orally in the fasted state for 7 days.~* Eight subjects will receive CSPCHA115~* Two subjects will receive matching placebo"
62172309|NCT04161547|EXPERIMENTAL|Cohort A4: CSPCHA115 600 mg|"CSPCHA115 600 mg or placebo administered orally in the fasted state for 7 days.~* Eight subjects will receive CSPCHA115~* Two subjects will receive matching placebo"
62172310|NCT05729477|ACTIVE_COMPARATOR|Group 1 Phaco Subject Cohort|The Group 1 Phaco subject cohort will begin enrolling subjects sequentially in the first initial arm of the study with up to 250 eyes total.
62172311|NCT05729477|ACTIVE_COMPARATOR|Group 2 miCOR System Subject Cohort|The Group 2 MICOR System subject cohort, non-use of miLOOP will enroll subsequently with up to 250 eyes total.
62172312|NCT05729477|ACTIVE_COMPARATOR|Group 3 miCOR System Subject Cohort|The Group 3 MICOR System subject cohort, use of miLOOP optional will enroll subsequently with up to 250 eyes total.
62172313|NCT04321915|OTHER|Children with Autism spectrum disorder|"Patients will realised quesstionnaires, a blood sample will be collected, the feces will be collected too.~The analysis of intestinal microbiota and neuroinflammation markers will be processed."
62172314|NCT05262465|EXPERIMENTAL|MST for unfit|"Induction chemotherapy can use azacytidine combined with low-dose cytarabine, or azacytidine combined with BCL / 2 inhibitor, and infuse modified peripheral blood hematopoietic stem cells after chemotherapy.~Consolidation chemotherapy used azacytidine combined with low-dose cytarabine. After chemotherapy, modified peripheral blood hematopoietic stem cells were infused and repeated for 3 courses."
62172315|NCT01357447|EXPERIMENTAL|Dornase alfa (Pulmozyme)|Dornase alfa is a highly purified solution of recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.
62172316|NCT01357447|PLACEBO_COMPARATOR|Saline|Normal saline 0.9% solution
62172317|NCT04355052|ACTIVE_COMPARATOR|A - HCQ + AZT|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
62172318|NCT04355052|EXPERIMENTAL|B - HCQ + CAM|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Camostat mesylat 200 mg TID for 10 days
62172319|NCT04355052|NO_INTERVENTION|C - NI|No Intervention
62172320|NCT04066400|PLACEBO_COMPARATOR|wheat-based diet|The patients continue a wheat-based diet aiming at a reduction in bodyweight.
62172321|NCT04066400|EXPERIMENTAL|ATI reduced diet|Patients are counselled to reduce dietary gluten uptake.
62172322|NCT06462612|EXPERIMENTAL|Lumateperone 42 mg|Lumateperone 42 mg capsules
62172323|NCT06462612|PLACEBO_COMPARATOR|Placebo|Matching placebo
62172324|NCT00418418|ACTIVE_COMPARATOR|A|Patient group receiving the stem cell injections during the CABG
62172325|NCT00418418|PLACEBO_COMPARATOR|B|The patient group receiving autologous serum injections during the CAGB operation
62172326|NCT01192672|EXPERIMENTAL|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
62172327|NCT01192672|ACTIVE_COMPARATOR|Control Writing|The participants were instructed to write for 30-minute intervals for 4 consecutive days about all of the actions they performed that day for a 24 hour period. The subjects were asked not to write about their feelings or thoughts related to these actions.
62172328|NCT01192672|NO_INTERVENTION|Usual Care|Subjects in this group did not receive an intervention. They filled out measures at baseline, 1 month, and 3 month follow-up time periods.
62172329|NCT02117856|ACTIVE_COMPARATOR|1 implant|"Participants receive the following:~1 implant placed surgically in the mandibular midline; Soft reline of the existing complete lower denture; 2.25mm ball patrix placed on 1 healed implant; and Reline with 1 retentive matrix in the lower denture."
62172330|NCT02117856|ACTIVE_COMPARATOR|2 implants|"Participants receive the following:~2 implants placed surgically in the mandibular canine sites; Soft reline of the existing complete lower denture; 2.25mm ball patrices placed on 2 healed implants; and Reline with 2 retentive matrices in the lower denture."
62172331|NCT00953342|EXPERIMENTAL|Aerobic exercise|12 weeks of supervised aerobic exercise and standard care
62172332|NCT00953342|PLACEBO_COMPARATOR|Usual care|12 weeks of standard care
62172333|NCT05190224|EXPERIMENTAL|Experimental-|All participants will be included in this arm
62172334|NCT03750305|ACTIVE_COMPARATOR|psychoeducation/TAU|TAU consists of psycho-education for a period of 12 weeks, consisting of 6 2-hour sessions. Psycho-education is offered in groups,
62172335|NCT03750305|EXPERIMENTAL|imCT intervention|For a period of 12 weeks, 12 1-hour sessions of imagery-focused Cognitive Therapy delivered weekly by a trained therapists, divided in an in depth identification (4 sessions) of images followed by imagery interventions, (6 sessions) and a consolidation phase (2 sessions).
62172336|NCT06480851|EXPERIMENTAL|Neck Pain Group|
62172337|NCT06480851|ACTIVE_COMPARATOR|Non Neck Pain Group|
62172338|NCT06647225|OTHER|All active participants|All participants will undergo an AI-augmented ultrasound and there will be no active comparator
62172339|NCT02606487||CF pulmonary exacerbation group|Patients with cystic fibrosis admitted for inpatient treatment of a pulmonary exacerbation
62172340|NCT05958147|EXPERIMENTAL|Probing sites with SPR and C-PRF application|The test group received the C-PRF as adjunct to sacling and root planing
62172341|NCT05958147|NO_INTERVENTION|Probing sites with SPR alone|
62172342|NCT06431295|EXPERIMENTAL|Digital Visual Acuity Test|Subjects for an ophthalmological examination that includes a visual acuity examination at Mayo Clinic in Florida have a digital visual acuity test conducted with the FaceScan device.
62172343|NCT01870414|OTHER|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes \[2, 17\], temperature of 4º C \[22, 24\], water level at 20 cm.
62172344|NCT01857362|ACTIVE_COMPARATOR|Nitisinone 2 x 10 mg|Two nitisinone 10 mg capsules by mouth as a single dose
62172345|NCT01857362|EXPERIMENTAL|Nitisinone 1 x 20 mg capsule|One nitisinone 20 mg capsule by mouth as a single dose
62172346|NCT00038961|PLACEBO_COMPARATOR|Placebo + intermittent pneumatic compression (IPC)|
62172347|NCT00038961|EXPERIMENTAL|fondaparinux + intermittent pneumatic compression (IPC)|
62172348|NCT04705883|OTHER|Prasterone|10 patients will be treated using prasterone during 6 months.
62172349|NCT05350514||T1D|Young adults with youth-onset type 1 diabetes (n=5) from the SEARCH for Diabetes in Youth study cohort
62172350|NCT05350514||T2D|Young adults with youth-onset type 2 diabetes (n=5) from the SEARCH for Diabetes in Youth study cohort
62172351|NCT05350514||NDM|Age-similar group of young adults without diabetes (n=5)
62172352|NCT04627441|EXPERIMENTAL|TESS-EES|Transcutaneous Electrical Spinal Stimulation (TESS), used during the first month of training sessions, followed by Epidural Electrical Stimulation (EES) during the final 6-month training period.
62172353|NCT04462497|NO_INTERVENTION|Control Group|Participants will receive the existing method of head support (sponge and towel stack) intraoperatively.
62172354|NCT04462497|EXPERIMENTAL|Study Group|Participants will receive the prototype head and neck support device intraoperatively.
62172355|NCT02997397||tourniquet (+)|The cases in which the tourniquet technique is used
62172356|NCT02997397||tourniquet(-)|The cases in which the tourniquet technique is not used
62172357|NCT05823519||SINGLE Arm|Observational, Multicenter, Prospective, single arm registry study with consecutive, eligible patient enrollment at each site. Subjects will be followed procedurally to discharge, and as per institutional standard of care thereafter through to 3 years (total follow-up commitment), with follow up including Computed tomography angiography (CTA) study and Case Report Form data at 1 month, 6 months, 1 years, 2 years and 3 years, closing at this time the study primary endpoint.
62172358|NCT04017637|NO_INTERVENTION|Usual Care (UC)|Those randomized to the UC group will complete baseline and post-intervention assessments only. No intervention will be administered.
62172359|NCT04017637|EXPERIMENTAL|Resistance Training Intervention (RT)|Those randomized to the RT group will complete baseline and post-intervention assessments at weeks 0 and 12. For the intervention, they will complete resistance training for approximately 12 minutes 2x per week for 12 weeks.
62172360|NCT02934815|EXPERIMENTAL|Intervention group - SEGT|16 weekly sessions, 90 min of Supportive-expressive group therapy
62172361|NCT02934815|NO_INTERVENTION|Control group|No intervention
62172362|NCT06585748||Group L|Group L: Lidocaine spray. Lidocaine spray in our country is available in a 10% spray form, with each puff containing 10 mg of lidocaine. In Group L, 4 puffs of lidocaine spray were applied to the glans penis and urethral meatus, and after 5 minutes, the appropriate method and sterilization were used to apply a catheter gel, and a Foley catheter was placed in the bladder.
62172363|NCT06585748||Group P|Group P: Placebo In Group P, 4 puffs of isotonic saline (%0.09 NaCl) spray were applied to the glans penis and urethral meatus, followed by catheter gel application and Foley catheter placement.
62172364|NCT04087798|ACTIVE_COMPARATOR|Control|Eligible patients enrolled from the control group clinics will be given a Control-EDI which has information about kidney disease in general (not tailored to the patient) during their clinic visit.
62172365|NCT04087798|EXPERIMENTAL|Intervention|Eligible patients enrolled from the intervention group clinics will be given an Intervention-EDI which has personalized information about kidney disease. There will be space on this for the provider to type in any goals or key points they want the patient to remember. Additionally, patients in this group will also receive health coaching.
62172366|NCT00661323||1|Healthy volunteers will be recruited through the use of an approved study recruitment flyer.
62172367|NCT00661323||2|Chemotherapy patients will be approached at the time of their nuclear scan to rule out cardiac disease prior to chemotherapy. These patients will be referred to the study by their doctor for the assessment of heart function.
62172368|NCT06483269|OTHER|infiltrative procedure|
62172369|NCT04448821|EXPERIMENTAL|Sequence A|Period 1: metformin; Period 2: metformin + nilotinib
62172370|NCT04448821|EXPERIMENTAL|Sequence B|Period 1: metformin + nilotinib; Period 2: metformin
62172371|NCT04595526|ACTIVE_COMPARATOR|Tracheal suction|Uses the local standard procedure of tracheal suction to obtain secretions from the lower respiratory tract
62172372|NCT04595526|EXPERIMENTAL|Forced expiratory technique and induced sputum|This procedure is without suction. The patient's attempts to deliver a sputum sample after forced exhalation and coughing technique. Regardless of the result the patient then receives hypertonic saline by an inhalation mask to induce the sputum. If the patient cannot deliver a sample, tracheal suction will be performed in order to obtain a specimen for the analyses.
62172373|NCT05880459|ACTIVE_COMPARATOR|propofol and nalbuphine group|
62172374|NCT05880459|ACTIVE_COMPARATOR|Propofol and magnesium sulfate group|
62172375|NCT02600988|NO_INTERVENTION|Group 1: Control|Control group is composed by the first 50 patients included in the study. Those patients will not receive the treatment. Evaluations and follow-up will be the same as in the other groups.
62172376|NCT02600988|EXPERIMENTAL|Group 2: 1000IU/day of Vitamine D|It is composed by the following 50 patients joining the study. They will take 1000 IU of vitamin D once a day.
62172377|NCT02600988|EXPERIMENTAL|Group 3: 5000IU/day of Vitamine D|It is composed by the last 50 patients joining the study. They will take 5000 IU of vitamin D once a day.
62172378|NCT04928482|EXPERIMENTAL|27 session group|Participants in this arm will receive 27 sessions of backward walking training.
62172379|NCT04928482|ACTIVE_COMPARATOR|18 session group|Participants in this arm will receive 18 sessions of backward walking training.
62172380|NCT04176926||Group 1: SR|Group 1: Subjects in the sinus rhythm (SR) cohort should not have any history of atrial fibrillation and should not be in atrial fibrillation or other atrial arrhythmia at the time of enrollment based on the screening ECG.
62172381|NCT04176926||Group 2: AF|Group 2: Subjects in the atrial fibrillation (AF) cohort must have a known history of AF and must be in AF at the time of enrollment based on the screening ECG.
62172382|NCT02055053|EXPERIMENTAL|anesthetic intervention|After deployment of therapeutic mesh in the preperitoneal space of the abdomen wall during the procedure, the treatment group will receive infusion of 15 cc 0.5% Bupivicaine.
62172383|NCT02055053|PLACEBO_COMPARATOR|Saline intervention|After deployment of therapeutic mesh in the preperitoneal space of the abdomen wall during the procedure, the placebo group will receive the infusion of 15 cc 0.9% Saline.
62172384|NCT00420563|EXPERIMENTAL|CYCLOPHOSPHAMIDE|
62172385|NCT00420563|ACTIVE_COMPARATOR|MEGESTROL|
62172386|NCT03749148|ACTIVE_COMPARATOR|Dupilumab|Dupilumab, s.c. administration 2 injections (600mg) as loading dose, 1 injection (300mg) every 14 days for a total of 16 weeks
62172387|NCT03749148|PLACEBO_COMPARATOR|Placebo|matching Placebo, s.c. administration 2 injections as loading dose, 1 injection every 14 days for a total of 16 weeks
62172388|NCT02519829|ACTIVE_COMPARATOR|Monocryl closure|"The skin incision is closed with monocryl dissolvable sutures and a topical adhesive (glue) called Dermabond and covered with a Tegaderm dressing.~Intervention: Monocryl closure, Tegaderm dressing"
62172389|NCT02519829|ACTIVE_COMPARATOR|Vicryl and staple closure|"The skin incision is closed with vicryl and staples and covered with a gauze dressing.~Intervention: Vicryl and Staple closure, Gauze dressing"
62172390|NCT05353296|EXPERIMENTAL|Culturally adapted digital cognitive behavioral therapy for insomnia (CBT-I) (Somryst)|Somryst is an FDA-authorized digital cognitive behavioral therapy for insomnia (CBT-I) program that has been translated and culturally adapted for Spanish speakers. Group will have access to this culturally-adapted Somryst, along with the usual care provided by their primary care provider, and will be provided a sleep hygiene brochure during group assignment.
62172391|NCT05353296|ACTIVE_COMPARATOR|Minimally Enhanced Usual Care (mEUC)|Usual care by their primary care provider and a sleep hygiene brochure. Group will continue their typical standard care with their primary care provider, which may include pharmacotherapy. In addition, we will provide a sleep hygiene brochure during group assignment.
62172392|NCT04070183|OTHER|Attention Control (Home Safety Evaluation)|A nurse will complete a home visit with the patient and their surrogate decision maker or other family member (if they've designated one), in which he or she will provide suggestions on how to improve the safety of the patient's home.
62172393|NCT04070183|EXPERIMENTAL|Intervention (POST Facilitation)|A nurse will complete a home visit with the patient and their surrogate decision maker or other family (if they've designated one), in which he or she will provide education about the POST form. The POST facilitators will be nurses trained using the Respecting Choices Advanced Steps model.
62172394|NCT05746533||Participants Undergoing Hip Preservation/Surgical Interventions|Data will be prospectively collected on participants undergoing hip preservation at Yale-New Haven Hospital.
62172395|NCT04072198|EXPERIMENTAL|FOLFOXIRI/Bevacizumab + Nivolumab|Bevacizumab 5 mg/m2 Nivolumab 240 mg Irinotecan 165 mg/m2 iv (max 8 cycles) Oxaliplatin + leucovorin 200 mg/m2 (max 8 cycles) Fluorouracil 3200 mg/m2 (max 8 cycles)
62172396|NCT00413634|EXPERIMENTAL|Younger Participants (18-50 years)|
62172397|NCT00413634|EXPERIMENTAL|Elderly Participants (≥65 years)|
62172398|NCT02127983|EXPERIMENTAL|Early intervention|Early intervention arm engaging informal providers Received the intervention early in the first 12 months
62172399|NCT02127983|ACTIVE_COMPARATOR|Delayed intervention|Delayed intervention arm, engaging informal providers Received the intervention after one year
62172400|NCT04940780|ACTIVE_COMPARATOR|Patient Preference Arm|patients who specify their preference for either acupuncture or touch therapy
62172401|NCT04940780|ACTIVE_COMPARATOR|Randomized Treatment Arm|with no preference, to be randomly allocated to either the acupuncture or touch-therapy subgroup
62172402|NCT05261347|EXPERIMENTAL|intervention|mobilisation group
62172403|NCT05261347|SHAM_COMPARATOR|control|sham control group
62172404|NCT05668000|EXPERIMENTAL|AIDA/KT-app with devices|AIDA/KT-app with devices : with device link and with feedback
62172405|NCT05668000|PLACEBO_COMPARATOR|AIDA/KT-app only|AIDA/KT-app only : no device link or no feedback
62172406|NCT03795935|EXPERIMENTAL|Treatment|Patients who were previously implanted with a traditional DBS lead and have subsequently developed stimulation induced side effects will gain significantly more tremor control without side effects when re-implanted with a directional DBS lead. We expect these patients' quality of life will improve. These patients typically will have had significant tremor relief (greater than 75% reduction from preoperative tremor rating scale) without side effects at their one year post operative follow-up. With the expected disease progression they will have had to increase their DBS stimulation to the degree that their DBS now causes side effects in order to block their tremor
62172407|NCT01040403|EXPERIMENTAL|olodaterol (BI 1744) low and placebo|low dose inhaled olodaterol orally once daily from the Respimat inhaler
62172408|NCT01040403|EXPERIMENTAL|olodaterol (BI 1744) low and low tio|low dose inhaled olodaterol and low dose inhaled tiotropium, both from the Respimat inhaler and once daily
61997262|NCT01802775|ACTIVE_COMPARATOR|clopidogrel/aspirin|Open label clopidogrel will be provided. Subjects randomized to this treatment arm will receive clopidogrel 75 mg QD (one 75 mg tablet) for a total of approximately 3 months on a background of aspirin 100 mg QD. A loading dose of clopidogrel 300 mg (four 75mg tablets) will be given to subjects as the first dose as early as possible after adequate hemostasis (i.e., within 4 hours of hemostasis).
61997263|NCT02121587||Pain self-management course|This is a single group observational cohort study. Participants are adults with persistent musculoskeletal pain who choose to participate in an optional, six week pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment for individual patients.
61997264|NCT02214277|EXPERIMENTAL|Test Arm|
61997265|NCT02214277|ACTIVE_COMPARATOR|Control Arm|
61997266|NCT02214277|OTHER|Safety Arm|
61997267|NCT05854875|ACTIVE_COMPARATOR|RYGBP|Laparoscopic Roux en Y Gastric Bypass
61997268|NCT05854875|EXPERIMENTAL|RYGBP + FR|Laparoscopic Roux en Y Gastric Bypass with fundus resection
61997269|NCT04735497||Failed Weaning|Patients who failed to be liberated from mechanical ventillation
61997270|NCT04735497||Successful Weaning|Patients who were liberated from mechanical ventillation and needed no respiratory support
61997271|NCT00994448|EXPERIMENTAL|Bupropion|
61997272|NCT00994448|PLACEBO_COMPARATOR|Placebo (sugar pill)|
61997273|NCT03023566||Dotarem Enhanced MRI|All pediatric patients (\< 18 years) scheduled for clinically indicated contrast enhanced MRI (Brain MRI with/without contrast) will receive a single IV bolus injection of Dotarem at a dose of 0.1 mmol/kg bw at a flow rate of 1-2 mL/sec followed by saline flush (routine/ standard of care).
61997274|NCT05433454|EXPERIMENTAL|Outreach via Postcard|40 percent of the sample
61997275|NCT05433454|EXPERIMENTAL|Outreach via Postcard + Outbound Call|Outreach via postcard, plus placed an outbound phone call from navigators (20% of sample)
61997276|NCT05433454|EXPERIMENTAL|Outreach via Text Message Encouraging Call to Hotline|Outreach via text message encouraging a call to a hotline for assistance (15% of sample)
61997277|NCT05433454|EXPERIMENTAL|Outreach via Text Message Encouraging Call to Hotline + Outbound Call|Outreach via text message encouraging a call to a hotline for assistance, plus outbound phone call from navigators (7.5% of sample)
61997278|NCT05433454|EXPERIMENTAL|Outreach via Text Message Encouraging Text Reply To Connect with Navigators|Outreach via text message encouraging a text reply to connect with navigators via chatbot (15% of sample)
61997279|NCT05433454|EXPERIMENTAL|Outreach via Text Message Encouraging Text Reply To Connect with Navigators + Outbound Call|Outreach via text message encouraging a text reply to connect with navigators via chatbot, plus an outbound phone call from navigators (7.5% of sample)
61997280|NCT05433454|EXPERIMENTAL|Outreach via Text Message Encouraging a Call to a Hotline for Assistance + a Reminder Message|Outreach via text message encouraging a call to a hotline for assistance plus a similar reminder message two weeks later (15% of sample)
61997281|NCT05433454|EXPERIMENTAL|Outreach Text Message Encouraging Call a Hotline for Assistance + Reminder Message|Outreach via text message encouraging a call to a hotline for assistance plus a similar reminder message two weeks later + outbound call (7.5% of sample)
61997282|NCT05433454|EXPERIMENTAL|Outreach via Text Message Encouraging Text Reply To Connect with Navigators+ a Reminder Message|Outreach via text message encouraging a text reply to connect with navigators via chatbot plus a similar reminder message two weeks later (15% of sample)
61997283|NCT05433454|EXPERIMENTAL|Outreach via Text Message Encouraging Reply To Connect with Navigators + Reminder Message|Outreach via text message encouraging a text reply to connect with navigators via chatbot plus a similar reminder message two weeks later + outbound call (7.5% of sample)
61997284|NCT04306809|EXPERIMENTAL|Treatment|Internet delivered Acceptance and Commitment Therapy for PTSD and Chronic Pain, supported by a psychologist
61997285|NCT03616353|EXPERIMENTAL|Group 1: Corticosteroid Injection|Patients in this group will undergo an injection of corticosteroid into the carpal tunnel as per current treatment practices.
61997286|NCT03616353|EXPERIMENTAL|Group 2: Perineural Hydrodissection|Patients in this group will undergo a perineural hydrodissection plus an injection of corticosteroid into the carpal tunnel, as a novel technique.
61997287|NCT02499393|EXPERIMENTAL|TH+MgSO4|Therapeutic hypothermia plus magnesium sulphate intravenous infusion Neonates who were randomized to the study group (TH+MgSO4) received three 250 mg/kg doses of magnesium sulfate given as one - hour continuous infusion spaced 24 hours apart on three consecutive days. 20% Magnesium Sulfuricum (Polpharma), 2 g /10 ml were used.
61997288|NCT02499393|NO_INTERVENTION|TH- therapeutic hypothermia|therapeutic hypothermia without magnesium sulphate
61997289|NCT04892576|ACTIVE_COMPARATOR|Control group|Participants in this group received the standard physical rehabilitation program.
62172409|NCT01040403|EXPERIMENTAL|olodaterol (BI 1744) low and medium tio|low dose inhaled olodaterol and medium dose inhaled tiotropium, both from the Respimat inhaler and once daily
62172410|NCT01040403|EXPERIMENTAL|olodaterol (BI 1744) low and high tio|low dose inhaled olodaterol and high dose inhaled tiotropium, both from the Respimat inhaler and once daily
62172411|NCT01040403|EXPERIMENTAL|olodaterol (BI 1744) high and placebo|high dose inhaled olodaterol orally once daily from the Respimat inhaler
62172412|NCT01040403|EXPERIMENTAL|Olodaterol (BI 1744) high and low tio|high dose inhaled olodaterol and low dose inhaled tiotropium, both from the Respimat inhaler and once daily
62172413|NCT01040403|EXPERIMENTAL|Olodaterol (BI 1744) high and medium tio|high dose inhaled olodaterol and medium dose inhaled tiotropium, both from the Respimat inhaler and once daily
62172414|NCT01040403|EXPERIMENTAL|Olodaterol (BI 1744) high and high tio|high dose inhaled olodaterol and high dose inhaled tiotropium, both from the Respimat inhaler and once daily
62172415|NCT05532683|EXPERIMENTAL|Health Behavior Group|9- week health behavior promotion group intervention
62172416|NCT02773121|EXPERIMENTAL|Physical activity monitoring|"Participants will wear a physical activity sensor on the hip or waist with a belt. They will be instructed to increase their physical activity level to at least 150 min of moderate-intensity physical activity per week. They will be asked to follow guidelines in the Go4Life brochure, website, and/or videos by the National Institute on Aging. Participants will receive weekly phone calls to monitor their progress, to provide feedback, and to suggest example exercises."
62172417|NCT02773121|ACTIVE_COMPARATOR|Flexibility and balance|"Participants will wear a physical activity sensor on the hip or waist with a belt. They will be instructed to increase their balance and flexibility over the 12 week period of the intervention. They will be asked to follow guidelines in the Go4Life brochure, website, and/or videos by the National Institute on Aging. Participants will receive weekly phone calls to monitor their progress, to provide feedback, and to suggest example exercises."
62172418|NCT01880697|EXPERIMENTAL|TIVc (≥18 to ≤ 60 years) + TIVc (≥ 61 years)|Subjects in each age cohort received one dose of the cell-derived trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVc) formulation 2013/2014 Northern Hemisphere
62172419|NCT04800133|EXPERIMENTAL|BNT162b2 (adult/adolescent)|BNT162b2, tozinameran by Fosun/BioNTech Intramuscular injection (or intradermal for immunocompromised patients; or by graded challenge with history of non-severe allergy to PEG-containing drugs) 30ug/0.3ml per dose 3 doses, or 4 for immunocompromised patients; or 1/2 dose for patients with prior COVID-19
62172420|NCT04800133|EXPERIMENTAL|CoronaVac (intramuscular)|CoronaVac by SinoVac Intramuscular injection 3ug/0.5ml per dose 3 doses, or 4 for immunocompromised patients; or 1/2 dose for patients with prior COVID-19
62172421|NCT04800133|EXPERIMENTAL|CoronaVac (intradermal)|CoronaVac by SinoVac Intradermal injection 3ug/0.5ml per dose 3 doses, or 4 for immunocompromised patients; or 1/2 dose for patients with prior COVID-19
62172422|NCT04800133|EXPERIMENTAL|BNT162b2 (paediatric)|BNT162b2, tozinameran by Fosun/BioNTech Intramuscular injection (for immunocompromised patients only) 10ug/0.1ml per dose 4 doses for immunocompromised patients
62172423|NCT06642337|EXPERIMENTAL|Nutritional Education|"Participants in this arm will receive a Nutritional Educational Program designed specifically for caregivers of children diagnosed with iron deficiency anemia. This program includes a series of interactive sessions that focus on the following key components:~Understanding Iron Deficiency Anemia: Caregivers will learn about the causes, symptoms, and health implications of iron deficiency anemia in children.~Nutritional Education: The program will provide comprehensive information on identifying and incorporating iron-rich foods into the child's diet, including meats, leafy greens, legumes, and fortified cereals.~Enhancing Iron Absorption: Caregivers will be educated on dietary strategies to improve iron absorption, such as consuming vitamin C-rich foods alongside iron sources and avoiding inhibitors like calcium and certain beverages during meals.~Meal Planning and Preparation: Practical guidance will be given on how to effectively plan and prepare meals that are rich in iron and other"
62172424|NCT06642337|EXPERIMENTAL|Oral Iron Therapy|"Participants in this arm will receive oral iron therapy as the standard treatment for iron deficiency anemia. The intervention will include the following components:~Prescription of Oral Iron Supplement: Participants will be prescribed a specific oral iron formulation, such as ferrous sulfate, ferrous fumarate, or ferrous gluconate, according to established clinical guidelines tailored to the child's age and severity of anemia.~Dosage and Administration: Caregivers will receive clear instructions regarding the appropriate dosage, which will be determined based on the child's weight and medical needs. Administration guidelines will include taking the iron supplement on an empty stomach for optimal absorption, unless otherwise advised by a healthcare provider.~Monitoring of Adherence and Response: Caregivers will be instructed on the importance of adherence to the prescribed regimen, with scheduled follow-up visits to monitor hemoglobin levels and assess the child's overall health and r"
62172425|NCT01000571||H1N1 pandemic influenza vaccine recipient|Children and young adults between the ages of 6 months and 21 years and 13 kg or greater in body weight with underlying conditions of cancer, HIV, sickle cell disease or receipt of a stem cell transplant more than a year prior to study entry and who will receive inactivated H1N1 swine-origin monovalent influenza vaccine in the winter/fall of 2009-2010 as part of their routine clinical care.Target total accrual of up to 400 children and young adults stratified based on their underlying diagnosis as follows: 150 children or young adults with cancer, 100 with human immunodeficiency virus (HIV), 100 with sickle cell disease, and 50 with receipt of a stem cell transplant more than a year prior to study entry.
62172426|NCT02096809|EXPERIMENTAL|One week loading of Bone Anchored Hearing Aid (BAHA)|Bone Anchored Hearing Aid (BAHA) loading after one week
62172427|NCT01588171|ACTIVE_COMPARATOR|Bemiparin|A new second generation Low Molecular Weight Heparin
62363871|NCT03123484|EXPERIMENTAL|β-elemene+EGFR TKI|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) and β-elemene
62363872|NCT03123484|ACTIVE_COMPARATOR|EGFR TKI|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)
62363873|NCT03454945|EXPERIMENTAL|Doxycyline|Oral Vibramycin antibiotic100 mg capsule every 12 hours for 3 months
62363874|NCT03454945|ACTIVE_COMPARATOR|Phototherapy|UVA+ psoralen 3 sessions per week for 3 months
62363875|NCT05392049|EXPERIMENTAL|Bowen's therapy|Bowens therapy will be given to 12 patients of temporomandibular joint disorder .
62363876|NCT05392049|EXPERIMENTAL|Post isometric relaxation|post isometric relaxation technique will be given to12 patients of temporomandibular joint disorder.
62363877|NCT05380908||Patients with untreated non-small cell lung cancer|
62172428|NCT01588171|ACTIVE_COMPARATOR|Enoxaparin|A well known Low Molecular Weight Heparin
62172429|NCT01588171|NO_INTERVENTION|control group|Risky group patients for VTE, but they will not receive any thromboprophylactic drug.
62172430|NCT01845558|EXPERIMENTAL|Wobenzym® plus|Treatment with the licenced drug Wobenzym® plus (3x4 Capsules/ day)
62172431|NCT01845558|PLACEBO_COMPARATOR|Placebo equates Wobenzym® plus but without active ingredients|3x4 capsules/ day
62172432|NCT04963998|EXPERIMENTAL|Copper oxide dressings|Treatment of diabetic ulcers that were in a stagnated stage with copper oxide containing wound dressings
62172433|NCT01582412|EXPERIMENTAL|Isavuconazole and digoxin|Isavuconazole three times per day (TID) on Days 15 and 16, and once daily (QD) on Days 17 thru 26. Digoxin single dose on Days 1 and 19.
62172434|NCT03719118|EXPERIMENTAL|Genotyping group|The patients undergo pretreatment of genotyping for three genes (TPMT, NUDT15 and FTO)
62172435|NCT03719118|ACTIVE_COMPARATOR|Non-genotyping group|Patients receive standard doses of thiopurines based on the conventional regimen without pretreatment genotyping.
62172436|NCT02919397|EXPERIMENTAL|Intervention|If participants are allocated to the intervention group, participants will receive the wearable technology and access to the smartphone application. Motivational messages based on diabetes prevention programme content, and biofeedback messages based on physical activity data provided via the wearable technology, will be received by participants via the application. The diabetes prevention programme educational material will be available via the application.
62172437|NCT02919397|ACTIVE_COMPARATOR|Control|If participants are allocated to the control group, participants will receive the wearable technology and will be able to access their activity data via the smartphone application. Participants will also have have access to the diabetes prevention programme educational material via the application. Participants will not receive motivational messages related to the education content or activity data.
62172438|NCT00627523|EXPERIMENTAL|Active|The active treatment arm
62172439|NCT00627523|EXPERIMENTAL|Control|Control
62172440|NCT01742949|ACTIVE_COMPARATOR|Thermosmart|Subjects receive heated humidification
62172441|NCT01742949|PLACEBO_COMPARATOR|No humidification|Subjects use dry CPAP / APAP
62172442|NCT05994898||UHFUS|Pulmonary nodules were detected by UHFUS method.
62172443|NCT05994898||Palpation|Pulmonary nodules were detected by palpation method.
62172444|NCT02236702||Asymptomatic control|Asymptomatic control
62172445|NCT02236702||Mildly symptomatic with depressive symptoms|Mildly symptomatic with depressive symptoms
62172446|NCT02236702||Moderately symptomatic with depressive symptoms|Moderately symptomatic with depressive symptoms
62172447|NCT02236702||Severely symptomatic with depressive symptoms|Severely symptomatic with depressive symptoms
62172448|NCT05197153|EXPERIMENTAL|Half dose of MVC-COV1901|7.5 mcg of S-2P protein with adjuvant
62172449|NCT05197153|EXPERIMENTAL|Full dose of MVC-COV1901|15 mcg of S-2P protein with adjuvant
62172450|NCT05197153|EXPERIMENTAL|AZD1222|5\*10\^10 viral particles of AZD1222
62172451|NCT05197153|ACTIVE_COMPARATOR|Half dose of mRNA-1273|50 mcg mRNA encoding the pre-fusion stabilized S protein
62172452|NCT04847778|ACTIVE_COMPARATOR|Masked arm|"* Participants will be instructed on the correct installation and use of the Insulclock device and app on masked mode for recording insulin bolus information.~* Participants do not receive any other information and will not have access to the Insulclock 360 application from the Internet.~* Participants will keep administering insulin treatment as usual."
62172453|NCT04847778|ACTIVE_COMPARATOR|Active arm|"* Participants will receive detailed instructions on using the Insuclock 360 app and Insulclock device~* Participants will be instructed and motivated for full use of all system functions: alarms, messages to the caregivers and investigation team."
62363878|NCT05380908||Patients with non-small cell lung cancer after chemotherapy|
62363879|NCT05380908||Normal controls|
62172454|NCT03275402|EXPERIMENTAL|131I-omburtamab|One treatment cycle of 131I-omburtamab consists of one dosimetry dose (2 mCi ) (for subjects enrolled on Version 1-7 of Protocol 101) and one treatment dose (50 mCi) for up to 2 cycles of length 5 weeks (for subjects enrolled on Version 1-7 of Protocol 101) or 4 weeks (for subject enrolled after Version 7 of Protocol 101). For Japan only, the first cycle consisted of one dosimetry dose (2 mCi ) week 1 one treatment dose (50 mCi) week 2. If eligible a second cycle of 50 mCi 131I-omburtamab was given at week 6. For subjects below 3 and 1 years of age, the treatment dose was reduced by 33% and 50%, respectively.
61997290|NCT04892576|EXPERIMENTAL|SSC group|Participants in this group received the standard physical rehabilitation program as the control group in addition to the SSC exercise program
62172455|NCT06407583|NO_INTERVENTION|Control group|Participants receiving regular care in the 6 months period. They receive a brief education session at start about exercise and protein.
62172456|NCT06407583|EXPERIMENTAL|ProMIO2.0 intervention group|"Participants receiving regular care and our newly developed lifestyle intervention for 6 months period. The intervention is culture specific and contains of:~* Dietetic care focused on protein intake (protein counselling)~* Multicomponent exercise (physical therapy); a combination between group sessions and home-based exercise~The first 3 months are intensive phase, second 3 months guidance gradually decreases."
62172457|NCT00003926|EXPERIMENTAL|Solid/brain tumor patients (1-18 years)|Patients with solid tumor or brain tumor in the 1-18 years old stratum.
62172458|NCT00003926|EXPERIMENTAL|Solid/brain tumor patients (19-45 years)|Patients with solid tumor or brain tumor in the 19-45 years old stratum.
62172459|NCT04112875|ACTIVE_COMPARATOR|L-arginine|L-arginine supplementation: 5g/sachet with water 30 minutes before breakfast for 14 days.
62172460|NCT04112875|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin supplementation: 5g/sachet with water 30 minutes before breakfast for 14 days.
62363880|NCT02237794||Patients Without Acute Heart Conditions|Patients without acute heart conditions who were hospitalized for other medical indications.
62363881|NCT01465451|ACTIVE_COMPARATOR|ARM A- surgery alone|all cases will receive standard surgical procedures of curative resection for colorectal cancer, without intra-operative chemotherapy.
62363882|NCT01465451|EXPERIMENTAL|ARM B surgery plus chemotherapy|all cases will receive standard surgical procedures described as arm A. In addition, all cases will receive 5-FU chemotherapy during operation.
62363883|NCT00890669|EXPERIMENTAL|PD Group|Nine subjects with idiopathic PD, previously diagnosed by one specialist physician participated in this study.
62172461|NCT03329547|EXPERIMENTAL|Subjects receiving treatment sequence AB|Eligible subjects will receive treatment sequence AB; A= SKF101804 cefixime 400 mg test capsules and B= cefixime 400 mg reference capsules. Subjects will receive single oral dose of treatment A in treatment period 1 on Day 1 and treatment B in treatment period 2 on Day 1. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days.
62172462|NCT03329547|EXPERIMENTAL|Subjects receiving treatment sequence BA|Eligible subjects will receive treatment sequence BA; B= cefixime 400 mg reference capsules and A= SKF101804 cefixime 400 mg test capsules. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days. Subjects will receive single oral dose of treatment B in treatment period 1 on Day 1 and A in treatment period 2 on Day 1. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days.
62172463|NCT06381856||survey based needs assessment|cohort receiving survey based needs assessment
62172464|NCT06381856||Personal meeting based assessment|cohort receiving personal meeting based needs assessment
62172465|NCT03282799|ACTIVE_COMPARATOR|Standard Dose Etonogestrel Implant|Single 68 mg etonogestrel implant
62172466|NCT03282799|EXPERIMENTAL|Increased Dose Etonogestrel Implant|Two 68 mg (136 mg total) etonogestrel implants
62172467|NCT04290156|EXPERIMENTAL|Joint visits|Subjects in the intervention arm attend a total of four joint transition visits performed with the participation of both the adult and the pediatric gastroenterologist.
62172468|NCT04290156|NO_INTERVENTION|Usual care|Adolescents meet only the pediatric gastroenterologist, but there is a balanced consultation between the two gastroenterologists with respect the patient's treatment plan.
62172469|NCT06425094|EXPERIMENTAL|Microalgae extract capsules|Tetrasol extract, maltodextrin, vegetable magnesium stearate, dicalcium phosphate, hydrogenated rapeseed oil, hydroxypropylmethylcellulose
62172470|NCT06425094|PLACEBO_COMPARATOR|Placebo|maltodextrin, vegetable magnesium stearate
62172471|NCT05582590|EXPERIMENTAL|Cohort 1|2 x 10\^8 NEXI-003 T cells (derived from peripheral blood mononuclear cells \[PBMCs\] of the patient) administered by intravenous infusion on Day 1 of each cycle
62172472|NCT05582590|EXPERIMENTAL|Cohort 2|2 x 10\^8 NEXI-003 T cells (derived from peripheral blood mononuclear cells \[PBMCs\] of the patient) administered by intravenous infusion on Days 1 and 8 of each cycle
62172473|NCT05582590|EXPERIMENTAL|Cohort 3|2 x 10\^8 NEXI-003 T cells (derived from peripheral blood mononuclear cells \[PBMCs\] of the patient) administered by intravenous infusion on Days 1, 8, and 15 of each cycle
62172474|NCT05582590|EXPERIMENTAL|Cohort 4|4 x 10\^8 NEXI-003 T cells (derived from peripheral blood mononuclear cells \[PBMCs\] of the patient) administered by intravenous infusion on Day 1, and 2 x 10\^8 NEXI-003 T cells administered by intravenous infusion on Days 8 and 15 of each cycle
62172475|NCT05582590|EXPERIMENTAL|Dose Expansion Stage|Dose Expansion Stage to further define the safety and clinical activity, and to confirm the recommended Phase 2 dose of the NEXI- 003 T cell product at the dose established from the Dose Escalation Stage.
62172476|NCT05828602|ACTIVE_COMPARATOR|Conventional treatment|
62172477|NCT05828602|EXPERIMENTAL|TeleRehabilitation|
62172478|NCT03298555|EXPERIMENTAL|Mobile phone based intervention|This group will receive the smartphone app HealthyMoms between gestational week 14 and 37. The app will contain information and support to achieve a healthy weight gain and lifestyle during pregnancy. This group will also receive standard care.
62172479|NCT03298555|NO_INTERVENTION|Control|This group will only receive standard care.
62172480|NCT04187963|EXPERIMENTAL|Group physical therapy|Groups of 6 patients and 1 physical therapist for the 1.5 hour physical therapy session
62172481|NCT04187963|ACTIVE_COMPARATOR|Individual physical therapy|1.5 hour physical therapy session 1 on 1 (1 patient and 1 physical therapist)
62172482|NCT05615896|EXPERIMENTAL|P200TxE Device First|
62172483|NCT05615896|EXPERIMENTAL|P200TE Device First|
62172484|NCT06363513|EXPERIMENTAL|MPFF with aescin group|
62172485|NCT06363513|ACTIVE_COMPARATOR|MPFF group|
62172486|NCT04532008|NO_INTERVENTION|Control Group|No intervention
62172487|NCT04532008|EXPERIMENTAL|Treatment Group|Experimental group received 12 session of group based depression treatment, a matched savings program, financial literacy training, agricultural training, and a cash transfer.
62172488|NCT02091297|ACTIVE_COMPARATOR|TAP BLOCK|One unique regional technique for lower abdominal surgery, that has been shown effective for Cesarean Section in particular, is the transversus abdominis plane (TAP) block, which blocks T6-L1 sensory nerve branches and provides anesthesia to the anterior abdominal wall. The TAP block has been recommended and shown in case reports, but not clinically studied with trials, for patients on methadone or buprenorphine, to improve post-operative pain control. A long active local anesthetic, called ropivacaine, will be used to provide this anesthesia.
62172489|NCT02091297|ACTIVE_COMPARATOR|Common Care|Common care refers to the common way pain is treated after Cesarean Section: a long-acting spinal or epidural opioid such as morphine, plus oral and IV opioids and non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.
62172490|NCT02091297|ACTIVE_COMPARATOR|Patient Controlled Epidural Analgesia|For post-Cesarean analgesia, another regional technique that has been employed for superior pain control is continued epidural analgesia with local anesthesia and an opioid, either in addition or instead of long acting neuraxial opioids (Cohen). One study revealed equal analgesic efficiency, higher patient satisfaction scores, and less side effects with patient controlled epidural ropivacaine compared to epidural morphine (Chen). This is an especially attractive option for opioid dependent patients, but like the TAP block, has been not studied whether or not it lessens acute or chronic postoperative cesarean section, in the setting or in the absence of neuraxial opioids.
62172491|NCT05666063||Study Group|Patients who underwent ambulatory urodynamic studies due to lower urinary tract symptoms
62172492|NCT00721708|EXPERIMENTAL|1|Carnosine(450 mg)
62172493|NCT00721708|EXPERIMENTAL|2|Beef (150g)
62172494|NCT00721708|EXPERIMENTAL|3|chicken (150g)
62172495|NCT00721708|EXPERIMENTAL|4|Chicken broth (obtained from 150 g of chicken breast)
62172496|NCT03729544|EXPERIMENTAL|Alert|On-screen computerized decision support alert during the outpatient clinical encounter that notifies the provider that the patient should be screened for CTEPH
62172497|NCT03729544|NO_INTERVENTION|No Alert|No provider notification
62172498|NCT03441750|EXPERIMENTAL|metformin plus standard lifestyle intervention|Metformin starting dose is 850mg/d, it will be titrated to 850mg twice daily after 2 weeks and maintained until the last subject completes 2 years' intervention.
62172499|NCT03441750|OTHER|Standard lifestyle intervention|Standard lifestyle advice will be united for all subjects by providing special booklet.
62172500|NCT03096977|EXPERIMENTAL|CHUB-TST02 patients|All patients who participated in the NCT02805634 (CHUB-TST02) study.
62172501|NCT03122405|EXPERIMENTAL|Test group|The subjects will be enrolled in the test group and will simultaneously receive both RAM sensors.
62172502|NCT04584879|EXPERIMENTAL|Standard Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
62172503|NCT04584879|EXPERIMENTAL|Standard Group, Full Intervention|Participants in this group will receive 12 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
62172504|NCT04584879|EXPERIMENTAL|Capitalization Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
61997291|NCT03367143|EXPERIMENTAL|L-ICE|Lenalidomide 25mg/d po d1-10, Ifosfamide 1500mg/m2/d iv d1-3, Carboplatin 5\*\[GFR(ml/min)+25\]mg/d iv d2, Etoposide 100mg/m2/d iv d1-3, Frequency every 21 days, Total cycles 4
61997292|NCT03661814|EXPERIMENTAL|Prevena|This group will receive the negative pressure wound therapy device.
61997293|NCT03661814|NO_INTERVENTION|Standard of Care|This group will not receive the device and their surgery and clinical course will proceed as if they were not part of the study. They will receive the standard of care wound dressings.
61997294|NCT03204513|EXPERIMENTAL|Vanderbilt Powered Knee-Ankle Prosthesis|"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using the Vanderbilt Powered Knee-Ankle (PKA) Prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions using the Vanderbilt Powered Knee-Ankle (PKA) Prosthesis. The device participants begin with will be randomly selected but there will be an equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."
61997295|NCT03204513|ACTIVE_COMPARATOR|Microprocessor (MP) Knee Prosthesis|"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using their own Microprocessor (MP) Knee Prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions using the Microprocessor (MP) Knee Prosthesis. The device participants begin with will be randomly selected but there will be an equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."
61997296|NCT03859895||Observational (without bone scan)|Former Observational Arm participants of the ZiPP trial.
61997297|NCT03859895||Observational (with bone scan)|Former Interventional Arm participants of the ZiPP trial.
61997298|NCT06082466|ACTIVE_COMPARATOR|Conventional Autologous Bypass|
61997299|NCT06082466|ACTIVE_COMPARATOR|FRAMED Infrainguinal Venous Bypass|
61997300|NCT06167616||LADA|Classification of LADA based on age ≥35 years at diagnosis, GADA positivity (≥10 U/ml) and C-peptide concentrations of ≥0.2 nmol/L (IMMULITE) or ≥0.3 nmol/L (Cobas).
61997301|NCT06167616||Type 2 diabetes|≥35 years, GADA negative and C-peptide concentrations of \&gt;0.60 (IMMULITE)/\&gt;0.72 (Cobas) nmol/L.
61997302|NCT06167616||Controls|≥35 years, free of diabetes
61997303|NCT05819164|EXPERIMENTAL|88% SpO2 target|During this periods , oxygen will be administered in manual titration to reach 88% of SpO2.
61997304|NCT05819164|EXPERIMENTAL|90% SpO2 target|During this periods , oxygen will be administered in manual titration to reach 90% of SpO2.
61997305|NCT05819164|EXPERIMENTAL|92% SpO2 target|During this periods , oxygen will be administered in manual titration to reach 92% of SpO2.
61997306|NCT05819164|EXPERIMENTAL|94% SpO2 target|During this periods , oxygen will be administered in manual titration to reach 94% of SpO2.
61997307|NCT05819164|EXPERIMENTAL|96% SpO2 target|During this periods , oxygen will be administered in manual titration to reach 96% of SpO2.
61997308|NCT01489969|ACTIVE_COMPARATOR|20 mg|Neu-P11 dose of 20 mg
61997309|NCT01489969|ACTIVE_COMPARATOR|50 mg|Neu-P11 dose of 50 mg
61997310|NCT01489969|PLACEBO_COMPARATOR|placebo|matching placebo
61997311|NCT04010266|ACTIVE_COMPARATOR|Standard of care group|Receive standard of care for pain management, do not receive RelieVRx headset
61997312|NCT04010266|EXPERIMENTAL|Standard of care + RelieVRx group|Receive standard of care for pain management, plus RelieVRx headset
61997313|NCT02129803|EXPERIMENTAL|Experimental Therapy|High-Flow, 20 LPM (via Optiflow cannula) Heated (34C) Humidified Air
61997314|NCT02129803|PLACEBO_COMPARATOR|Control Therapy (Low Flow)|Low FLow, 5 LPM (via Optiflow cannula) Room Temperature (23-26C) Ambient Air
61997315|NCT00659867|EXPERIMENTAL|A|Chromoscopy-guided endomicroscopy with targeted biopsies
61997316|NCT00659867|ACTIVE_COMPARATOR|B|Standard endoscopy with random and targeted biopsies
61997317|NCT02751177|EXPERIMENTAL|OncoBEAM|KRAS, NRAS and BRAF mutations will be analyzed in circulating plasma DNA using ONCOBEAM technique.
61997318|NCT06447844|EXPERIMENTAL|OsteoGen Plug|OsteoGen® Plug (OGP) is a combination of bovine achilles tendon collagen matrix sourced from Australia or New Zealand and bioactive resorbable calcium apatite crystals intended for ARP. It is provided to clinicians in 3 different sizes to be placed in extraction socket.
61997319|NCT06447844|ACTIVE_COMPARATOR|BioGide|This product is SOC treatment and will be used per packaging instructions.
61997320|NCT00494572|SHAM_COMPARATOR|Sterile Water|Sterile water
61997321|NCT00494572|ACTIVE_COMPARATOR|Montelukast|10mg rapid dissolving granules in sterile water orally once
61997322|NCT00813358|EXPERIMENTAL|Endovascular repair|treatment
61997323|NCT01263548||Vyvanse|This is an open-label study which means that all study participants will be taking active study medication, Vyvanse.
62172505|NCT04584879|EXPERIMENTAL|Capitalization Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
62172506|NCT04584879|EXPERIMENTAL|Compensation Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
62172507|NCT04584879|EXPERIMENTAL|Compensation Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
62172508|NCT04021927|EXPERIMENTAL|Ring Phototherapy|The product will be an open-faced ring device with an angular reflective surface that redirects unused light sideways onto the neonate's body illuminating previously unexposed regions where treatable bilirubin exists while protecting the baby from head roll with an inner transparent corral. This device is superior to current PT devices because it converts existing waste light into treatment efficacy while integrating into existing single overhead lamp systems avoiding the purchase of secondary devices that are expensive and create hospital system complexity and inefficiency issues.
62172509|NCT04935918|EXPERIMENTAL|Study Arm 1|Children with bladder exstrophy or isolated epispadias
62172510|NCT00644735|EXPERIMENTAL|1|Nexium
62172511|NCT00644735|ACTIVE_COMPARATOR|2|Prevacid
62172512|NCT01529541|ACTIVE_COMPARATOR|Sitagliptin|Sitagliptin 100mg
62172513|NCT01529541|EXPERIMENTAL|CWP-0403|CWP-0403 100mg
62172514|NCT02137239|EXPERIMENTAL|Belatacept + Everolimus|Thymoglobulin (i.v. infusion) induction, daily (or less frequently, as tolerated) not to exceed 10 days, to reach a total cumulative dose between 3.0 and 5.5 mg/kg; belatacept (infusion) regimen of 10 mg/kg i.v. on Day 1, Weeks 1, 2, 4, 8 and 12 post transplant and then a maintenance dose of 5 mg/kg every 4 weeks after 12 weeks post transplant; everolimus (tablet) daily dosing at 3.0 mg/day, 2 divided doses, starting on Day 3 dosing adjusted based on blood sample tests; methylprednisolone (infusion) prior to each Thymoglobulin infusion and prednisone (tablet), once methylprednisolone is no longer needed. (Corticosteroids to be discontinued by Day 7 or as soon thereafter as thymoglobulin infusions are completed)
62172515|NCT02137239|EXPERIMENTAL|Tacrolimus + Mycophenolate mofetil|Thymoglobulin (i.v. infusion) induction, daily (or less frequently, as tolerated) not to exceed 10 days, to reach a total cumulative dose between 3.0 and 5.5 mg/kg; tacrolimus (tablet) daily dosing beginning at 0.1 mg/kg/day, then adjusted based on blood sample tests; MMF (tablet) daily dosing between 0.5 to 2.0 g/day divided in 2 doses (up to 3 g/day if African Americans/Blacks); methylprednisolone (infusion) prior to each Thymoglobulin infusion and prednisone (tablet), once methylprednisolone is no longer needed. (Corticosteroids to be discontinued by Day 7 or as soon thereafter as thymoglobulin infusions are completed)
62172516|NCT03448354|EXPERIMENTAL|NAC-IDS-HIPEC|Under the clinicians' decision, HIPEC procedures will be performed at the time of IDS.
62172517|NCT03448354|NO_INTERVENTION|NAC-IDS|Under the clinicians' decision, HIPEC procedures will not be performed at the time of IDS.
62172518|NCT02535962|EXPERIMENTAL|Corticosteriod + Probiotic Treatment|"Corticosteroid dosing of 1 mg/kg of body weight given once at the onset of the febrile period, repeated once within 24 hours if necessary, but no more than two doses per cycle. The second dose of corticosteroid treatment is only to be given within one day following the initial dosage if the fever persists.~Investigational drug (Intervention is Lactobacillus acidophilus and Bifidobacterium lactis): Patients will be instructed to take one sachet of the study product mixed into a 60 ml of water that is not hot. Each sachet will contain Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 at a dose of 5\*109 CFU of each strain. The investigational product will be taken daily for the duration of the study, which is a year."
62172519|NCT02535962|PLACEBO_COMPARATOR|Corticosteriod + PlaceboTreatment|"Corticosteroid dosing of 1 mg/kg of body weight given once at the onset of the febrile period, repeated once within 24 hours if necessary, but no more than two doses per cycle. The second dose of corticosteroid treatment is only to be given within one day following the initial dosage if the fever persists.~Placebo: will be taken daily and patients will be instructed to take one sachet of placebo mix into 60ml of water that is not to hot. The placebo will be taken daily for the duration of the study, which is one year. Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product."
62172520|NCT03327571||Group 1: cHL|Participants diagnosed with high-risk stage IIb-IV cHL, received frontline treatment with chemotherapy with or without radiotherapy between 01 January 2010 and 31 December 2013 from the 13 participating countries will be observed for various treatments received for cHL, associated adverse events and resources used from the date of cHL diagnosis until the date of first documented relapse or disease progression after frontline therapy. Participants will be continue to be observed for overall survival until the date of death or data collection, whichever occurs first.
62172521|NCT03327571||Group 2: RRHL|Participants diagnosed with RRHL, between 01 January 2010 and 31 December 2013 from the 13 participating countries will be observed for various treatments received for RRHL, detailed data on treatment pathways, clinical outcomes, associated adverse events and resources used from the date of RRHL diagnosis until the date death or data collection, whichever occurs first. Participants will be continue to be observed for overall survival until the date of death or data collection, whichever occurs first.
62172522|NCT06577649|ACTIVE_COMPARATOR|Active group|Continuous theta burst stimulation
62172523|NCT06577649|SHAM_COMPARATOR|Sham group|Sham repetitive transcranial magnetic stimulation (rTMS)
62172524|NCT03642288|EXPERIMENTAL|CRE-induced SBO|Patients with CRE-induced SBO received GG challenge.
62172525|NCT03642288|ACTIVE_COMPARATOR|ASBO|Patients with adhesive SBO (ASBO) received GG challenge.
62172526|NCT06140576|EXPERIMENTAL|Lenvatinib combined with Sindilimab and Nab-paclitaxel|The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
62172527|NCT01988883|PLACEBO_COMPARATOR|Placebo|Patients will receive two inactive placebo pills filled with microcrystalline cellulose on a randomized study day. Medications will be dummy blinded to the patient and investigators.
62172528|NCT01988883|EXPERIMENTAL|Modafinil|Patients will receive single doses of modafinil (200 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
62172529|NCT01988883|EXPERIMENTAL|Propranolol|Patients will receive single doses of propranolol (20 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
62172530|NCT01988883|EXPERIMENTAL|Modafinil plus Propranolol|Patients will receive single doses of modafinil (200 mg, oral) and propranolol (20 mg, oral) on a randomized study day. Medications will be dummy blinded to the patient and investigators.
62172531|NCT06262776|EXPERIMENTAL|Vaccination group|All participants will receive the assigned intervention, a 2-dose course of Zoster recombinant adjuvanted vaccine. Study participants will include kidney transplant recipients receiving specific immunosuppressive medications, and non-immunosuppressed household cohabitants, with comparisons made in magnitude of vaccine response.
62172532|NCT05607485|OTHER|Crowd workers|"Crowd workers watched 10 (oiut 45 possible) random videos and assessed with a standard assessment tool.~All participants were blinded to the identity and skill level of the surgeon"
62172533|NCT00847158|ACTIVE_COMPARATOR|1|phacoemulsification alone
62172534|NCT00847158|ACTIVE_COMPARATOR|2|phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
62172535|NCT00655369|EXPERIMENTAL|15 mg|
62172536|NCT00655369|EXPERIMENTAL|25 mg|
62172537|NCT00655369|EXPERIMENTAL|35 mg|
62172538|NCT00655369|EXPERIMENTAL|5 mg|
62172539|NCT00655369|EXPERIMENTAL|50 mg|
62172540|NCT00655369|PLACEBO_COMPARATOR|Placebo|
61997324|NCT02119546|EXPERIMENTAL|Exercise intervention|Aerobic exercise and dual-task training
61997325|NCT02119546|ACTIVE_COMPARATOR|Stretch exercise|Stretch exercise \& sitting balance
61997326|NCT05148858||Cases|Patients affected by COVID-19 infection
61997327|NCT05148858||Control|Normal subjects not affected by COVID-19 infection
61997328|NCT00472134|ACTIVE_COMPARATOR|Bupivicaine via Elastomeric pump|Bupivicaine via elastomeric pump
61997329|NCT00472134|PLACEBO_COMPARATOR|Placebo via elastomeric pump|Placebo via elastomeric pump
61997330|NCT01248858|EXPERIMENTAL|GSK2126458 and GSK1120212|The first combination schedule that will be tested involves giving both GSK2126458 and GSK1120212 continuously once a day in the morning until the subjects withdraw from the study. Other dosing schedules with both drugs will also be tested and these schedules are described below GSK2126458 will be dosed twice per day (morning and evening) continuously and GSK1120212 will be dosed once a day in the morning on a continuous schedule. Subjects will be treated with both drugs and remain in the study as long as they are benefiting from therapy. Another schedule that will be tested involves giving GSK2126458 twice each day (morning and evening) on an intermittent schedule (4 days of treatment, 10 days rest, then 4 days treatment, 10 days rest). GSK1120212 will be dosed once each day in the morning on a continuous schedule. Subjects will be treated with both drugs as long as they are benefiting from therapy.
61997331|NCT01381861|EXPERIMENTAL|Carotuximab (TRC105) alone|Single arm, open label Carotuximab (TRC105) alone therapy dosed at 10 mg/kg administered intravenously over 1 to 4 hours on days 1, 8, 15 and 22 of each 28 day cycle
61997332|NCT05596760|EXPERIMENTAL|Jumpstart Guide|The Jumpstart Guide is developed using automated methods. It summarizes the presence/absence of POLST, advance directives and DPOA documentation. The Jumpstart Guide also provides tips for conducting discussion about goals of care.
61997333|NCT05596760|NO_INTERVENTION|Usual Care|Clinicians of patients in the Usual Care arm will not receive a Jumpstart Guide.
61997334|NCT04906642|ACTIVE_COMPARATOR|Standard of Care|"Each of the following procedures will be conducted according to general or local site Standard of Care (SoC):~* Medication administration at surgery~* Surgical irrigation and wound debridement~* Surgical fracture preparation/fixation~* Surgical closure"
61997335|NCT04906642|EXPERIMENTAL|Standard of Care plus Next Science|In addition to the SoC, the blinded product will be applied in place of saline irrigation as the wound is closed (after bone fracture preparation/fixation), depending on the randomization.
61997336|NCT04917276||Training Group|The training cohort that used to built the response prediction model
61997337|NCT04917276||Validation Group|The validation cohort that used to validate the response prediction model
61997338|NCT05037838||Patient undergoing a liver transplantation|Patients undergoing a liver transplantation and able to have a transesopahageal ultrasound
61997339|NCT04566796|ACTIVE_COMPARATOR|(Group N)|patients in this group will receive 0.02 mg/kg atropine with neostigmine 0.05 mg/kg IV. to reverse the action of the neuromuscular blocker given.
61997340|NCT04566796|EXPERIMENTAL|(Group S)|the patients will receive Sugammadex 2mg/kg IV. As the reversal agent
61997341|NCT03769272||Echocardiographic targeting|
61997342|NCT03769272||Electrogram targeting|
61997343|NCT05937048|EXPERIMENTAL|Albumin|20% human albumin solution infusion, to raise and maintain serum albumin levels above 3.0 g/dl. Human albumin solution will be given to those enrolled in the study having serum albumin levels ≤ 3 g/dl to maintain the serum albumin levels above 3 g/dl.
61997344|NCT05937048|ACTIVE_COMPARATOR|Standard of Care|Standard treatment that the patient would receive had they not been included in the trial.
61997345|NCT03162601||Neurovascular|Patients to receive percutaneous neurovascular intervention
61997346|NCT01841814|EXPERIMENTAL|lymphoma|
61997347|NCT00654277|EXPERIMENTAL|A|Subjects received Kali formulated products under fasting conditions
61997348|NCT00654277|ACTIVE_COMPARATOR|B|Subjects received GlaxoSmithKine product under fasting conditions
61997349|NCT02397330|ACTIVE_COMPARATOR|group BIS|scheduled for ultrasound guided interscalene blockade with 30 ml of bupivacaine 0.25%
61997350|NCT02397330|EXPERIMENTAL|group BS|scheduled for selective blockade of the ultrasound guided suprascapular (15 ml bupivacaine 0.25%) and supraclavicular (15 ml bupivacaine 0.25%) nerves blocks
61997351|NCT01040585||Central America and the Caribbean|Panama, Costa Rica, Honduras, El Salvador and Nicaragua
61997352|NCT06497049|EXPERIMENTAL|GP40221|GP40221 is administered subcutaneously into the subcutaneous fat of the anterior abdominal wall at a dose of 0.5 mg using a pen injector.
62172541|NCT02847637|ACTIVE_COMPARATOR|Arm C (Control): No Prophylaxis, Then Emicizumab|Participants who had received episodic treatment with FVIII prior to study entry were randomized to continue episodic FVIII treatment when they started the trial. After completing 24 weeks of no prophylaxis (i.e., episodic FVIII treatment) on study, then they were given the opportunity to switch to emicizumab prophylaxis of 3 mg/kg subcutaneously (SC) once per week (QW) for 4 weeks, followed by maintenance dosing of 3 mg/kg emicizumab SC once every 2 weeks (Q2W). Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant was given the option to choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study.
62739289|NCT06659354|EXPERIMENTAL|Pregnant Body Project (PBP)|The Body Project is typically delivered as four 1-hour weekly sessions consisting of written, verbal, and behavioral exercises. The sessions aim to induce cognitive dissonance by encouraging participants to challenge the thin-ideal, a theoretically and empirically supported component of ED prevention. This adapted version of the Body Project (the Pregnant Body Project; PBP) consists of 6 1-hour, weekly group sessions delivered via Zoom. Since the target population consists of individuals with histories of an ED or disordered eating behaviors, PBP also includes elements from a treatment intervention (i.e., the Body Project Treatment 8.0 manual). PBP was adapted iteratively with a needs assessment, expert stakeholder input, and participant feedback following a mock trial with individuals with lived experience (i.e., individuals with histories of an ED who have given birth). This condition will be peer-delivered by facilitators with lived experience.
62172542|NCT02847637|EXPERIMENTAL|Arm A: Emicizumab 1.5 mg/kg QW|Participants who had received episodic treatment with FVIII prior to study entry were randomized to receive emicizumab prophylaxis at a dose of 3 milligrams per kilogram (mg/kg) subcutaneously (SC) once per week (QW) for 4 weeks, followed by maintenance dosing of 1.5 mg/kg emicizumab SC QW. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant was given the option to choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study.
62172543|NCT02847637|EXPERIMENTAL|Arm B: Emicizumab 3 mg/kg Q2W|Participants who had received episodic treatment with FVIII prior to study entry were randomized to receive emicizumab prophylaxis at a dose of 3 mg/kg subcutaneously (SC) once per week (QW) for 4 weeks, followed by maintenance dosing of 3 mg/kg emicizumab SC once every 2 weeks (Q2W). Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant was given the option to choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study.
62172544|NCT02847637|EXPERIMENTAL|Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)|Participants who had received FVIII prophylaxis prior to study entry were enrolled to receive emicizumab prophylaxis at a dose of 3 mg/kg subcutaneously (SC) once per week (QW) for 4 weeks, followed by maintenance dosing of 1.5 mg/kg emicizumab SC QW. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant was given the option to choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study.
62172545|NCT06505239|ACTIVE_COMPARATOR|FSD-F2R6-A-CP|
62172546|NCT06505239|PLACEBO_COMPARATOR|Placebo|
62172547|NCT01137552|EXPERIMENTAL|A|Dose Escalation
62172548|NCT01137552|EXPERIMENTAL|B|Dose Expansion
62172549|NCT01745718|OTHER|MRI and targeted biopsies|All patients receive the same level/number of diagnostic procedures. They all undergo targeted biopsies which are compared to the cytological imprints.
62172550|NCT01081730||001|ustekinumab as prescribed
62172551|NCT01081730||002|anti-TNF biologics as prescribed
62172552|NCT01081730||003|non-anti-TNF biologics as prescribed
62172553|NCT01081730||004|systemic non-biological treatments as prescribed
62172554|NCT01081730||005|general population non-treated cohort
62172555|NCT06395961|EXPERIMENTAL|HAB group|The superficial peroneal nerve, deep peroneal nerve, tibial nerve, gastrocnemius nerve, and saphenous nerve were sequentially blocked from one-third of the lower leg to the middle leg (about 15cm above the inner or outer ankle). 0.375% ropivacaine is used for the block and the total dose is 35ml. The ultrasound probe is placed vertical to the longitudinal axis of the body. On the lateral of tibia and fibula, 5ml of local anesthetic was injected to block the superficial peroneal nerve and 10ml for the deep peroneal nerve. On the posterior of the calf, 10ml of local anesthetic was injected to block the tibial nerve and 5ml for the sural nerve. On the inner side of the calf, 5ml of local anesthetic was injected to block the saphenous nerve.
62172556|NCT06395961|PLACEBO_COMPARATOR|GA group|No nerve block, only general anesthesia with tracheal intubation.
62172557|NCT01585688|EXPERIMENTAL|hLL1-DOX|
62172558|NCT04098497|EXPERIMENTAL|ACT-based microintervention delivered by mobile app|"At every time-point of the study, participants will complete self-reports of mania (as measured by the shortened YMRS), depression (as measured by the shortened SIGH-D ), medication adherence, and activity through the mobile app Lorevimo. After completing these assessments, participants will be randomly assigned to either receive one additional ACT-based microintervention question or receive no additional question.~The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action).~The ACT-based questions were developed by the research team as a unique intervention for the current study. They are based upon core themes of acceptance and commitment therapy: engagement, awareness, and openness."
62172559|NCT01552668|EXPERIMENTAL|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
62172560|NCT01552668|PLACEBO_COMPARATOR|Placebo|
62172561|NCT04872101|EXPERIMENTAL|Delgocitinib cream 20 mg/g|Twice-daily topical application for 16 weeks
62172562|NCT04872101|PLACEBO_COMPARATOR|Cream vehicle|Twice-daily topical application for 16 weeks
62172563|NCT01589380|PLACEBO_COMPARATOR|Placebo Arm|Placebo: Capsule that is containing lactate hydrate, identically appearing with fimasartan will be administered to patient in placebo group, once daily. Same placebo drug which was used in phase 3 clinical trial of fimasartan will be provided by Boryoung Phamaceutical company. Dose titration will be done with same criteria of fimasartan group. 30mg form and 60 mg form of placebo will be identical in its morphology.
62172564|NCT01589380|ACTIVE_COMPARATOR|Fimasartan|"Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP \< 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan."
62172565|NCT00729885|EXPERIMENTAL|1 Goggle I|Optimized Goggle
62172566|NCT00729885|SHAM_COMPARATOR|2 Google II|Goggle with 20 Degree error
62172567|NCT03761134|EXPERIMENTAL|Sotagliflozin dose 1|Sotagliflozin dose 1, given as two (2) dose 2 tablets, once daily, before the first meal of the day
62172568|NCT03761134|EXPERIMENTAL|Sotagliflozin dose 2|Sotagliflozin dose 2, given as 1 sotagliflozin dose 2 tablet and 1 sotagliflozin-matching placebo tablet (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
62172569|NCT03761134|PLACEBO_COMPARATOR|Placebo|Two sotagliflozin-matching placebo tablets (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
62172570|NCT00809783|EXPERIMENTAL|Tanezumab 10 mg|Tanezumab 10 mg
62172571|NCT00809783|EXPERIMENTAL|Tanezumab 5 mg|Tanezumab 5 mg
62172572|NCT00809783|EXPERIMENTAL|Tanezumab 2.5 mg|Tanezumab 2.5 mg
62172573|NCT06411210|EXPERIMENTAL|Semaglutide|Participants in this arm will receive semaglutide (escalated to 2.4mg or max tolerated dose) weekly for 12 months. Then a 4 week wean period plus 2 weeks as needed insulin titration.
62739290|NCT06659354|PLACEBO_COMPARATOR|Pregnancy Health Education (PHE)|This time- dose- and attention- matched control condition accounts for the potential effects of time spent and support from group members and facilitators. Participants assigned to the PHE group will also be asked to attend 6, 1-hour, weekly group sessions via Zoom. During the sessions participants receive psychoeducation on body image and disordered eating during pregnancy but will not engage in any dissonance-inducing exercises. Participants will also receive lifestyle education specific to pregnancy (e.g., proper nutrition, sleep, physical activity), tied back to body image and disordered eating.
62172574|NCT06411210|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive a matched placebo weekly for 12 months. Then a 4 week wean period plus 2 weeks as needed insulin titration.
62172575|NCT03130816|EXPERIMENTAL|allogeneic cord blood transplantation|"Intravenous(IV) infusion will be done by the following method A. After 4 hours of fasting, subjects will be sedated with chloral hydrate (Pocral®) syrup B. Intravenous infusion will be conducted in stem cell center, CHA Bundang Medical Center and the therapy will be performed by the Principal Investigator or a physician delegated from the Principal Investigator. The physician conducting the infusion will not participate in the efficacy and result analysis of this study.~C. Oxygen saturation will be monitored during therapy."
62172576|NCT03501524|EXPERIMENTAL|VATS evacuation|patients selected for VATS after failure of first thoracostomy tube drainage
62172577|NCT03501524|EXPERIMENTAL|thoracostomy tube|patients selected for thoracostomy tube reinsertion after failure of drainage with first thoracostomy tube
62172578|NCT05737797|EXPERIMENTAL|Endometrial cancer patients|Endometrial cancer patients Cervical cytology during surgical intervention.
62172579|NCT01507753|PLACEBO_COMPARATOR|Placebo Supplement and No PEP|Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
62172580|NCT01507753|EXPERIMENTAL|Omega-3 and PEP|"Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
62172581|NCT01507753|EXPERIMENTAL|Omega-3 and No PEP|Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
62172582|NCT01507753|EXPERIMENTAL|Placebo Supplement and PEP|"Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
62172583|NCT05367024|EXPERIMENTAL|Broccoli soup|The soup will be made with a commercially available dried vegetable soup supplemented with broccoli powder.
62172584|NCT05367024|SHAM_COMPARATOR|Courgette soup|The soup will be made with a commercially available dried vegetable soup supplemented with courgette powder.
62172585|NCT01933659|EXPERIMENTAL|group A: DSW group|ingesting DSW 200 cc four times a day (one hour before meal and bed time);
62172586|NCT01933659|PLACEBO_COMPARATOR|group B: non-DSW group|ingesting non-DSW drinking water 200 cc four times a day (one hour before meal and bed time).
62172587|NCT01290783|ACTIVE_COMPARATOR|FOLFIRI|
62172588|NCT01290783|EXPERIMENTAL|FOLF(HA)iri|
62172589|NCT05382871|EXPERIMENTAL|1: BIBP Inactivated COVID-19 vaccine (Omicron)|subjects will be blinded and receive two doses of BIBP Inactivated COVID-19 vaccine (Omicron) with 28 days apart more than 3 months after 2 or 3 doses of inactivated COVID-19 vaccine
62172590|NCT05382871|EXPERIMENTAL|2: WIBP Inactivated COVID-19 vaccine (Omicron)|subjects will be blinded and receive two doses of WIBP Inactivated COVID-19 vaccine (Omicron) with 28 days apart more than 3 months after 2 or 3 doses of inactivated COVID-19 vaccine
62172591|NCT05382871|EXPERIMENTAL|3：BIBP Inactivated COVID-19 vaccine (Omicron)|subjects will be blinded and receive two doses of BIBP Inactivated COVID-19 vaccine (Omicron) with 28 days apart more than 3 months after 2 or 3 doses of COVID-19 mRNA vaccine
62172592|NCT05382871|EXPERIMENTAL|4: WIBP Inactivated COVID-19 vaccine (Omicron)|subjects will be blinded and receive two doses of WIBP Inactivated COVID-19 vaccine (Omicron) with 28 days apart more than 3 months after 2 or 3 doses of COVID-19 mRNA vaccine
62172593|NCT05382871|ACTIVE_COMPARATOR|5：Inactivated COVID-19 Vaccine (prototype)|subjects will be blinded and receive two doses of Inactivated COVID-19 Vaccine (prototype) with 28 days apart more than 3 months after 2 or 3 doses of inactivated COVID-19 vaccine
62172594|NCT05382871|ACTIVE_COMPARATOR|6：Inactivated COVID-19 Vaccine (prototype)|subjects will be blinded and receive two doses of Inactivated COVID-19 Vaccine (prototype) with 28 days apart more than 3 months after 2 or 3 doses of COVID-19 mRNA vaccine
62172595|NCT05934084|NO_INTERVENTION|Control Arm (C)|Patients in the control arm will not receive any Survivorship Care Plan (SCP) or intervention and will be followed-up according to the best clinical practice, with questionnaires self-administration at 6 and 12 months from randomization.
62172596|NCT05934084|EXPERIMENTAL|Experimental Arm (E)|Patients in the experimental arm will follow the planned intervention (Survivorship Care Plan (SCP), nutritional plan, physical activity indication) for 6 months.
62172597|NCT01108484|EXPERIMENTAL|Supervised exercise|Cardiorespiratory and resistance training
62172598|NCT01108484|EXPERIMENTAL|Exercise + diet counseling|Cardiorespiratory and resistance training + Diet counseling to improve food intake(more fruit and vegetable and less fat food)
62172599|NCT01108484|EXPERIMENTAL|Exercise + diet counseling + psycho support|Cardiorespiratory and resistance training + Diet counseling to improve food intake(more fruit and vegetable and less fat food) + Weekly sessions to modify the behaviour
62739291|NCT03754127|EXPERIMENTAL|Active group|tDCS
62739292|NCT03754127|SHAM_COMPARATOR|Sham group|Sham tDCS
62172600|NCT01108484|NO_INTERVENTION|Control|They will keep their usual way of life
62172601|NCT04043806|EXPERIMENTAL|ELX/TEZ/IVA|"Part A: Participants received ELX 200 milligram (mg) once daily (qd),TEZ 100 mg qd, and IVA 150 mg every 12 hours (q12h) in the treatment period for 96 weeks.~Part B: Participants from certain countries participated in Part B and continued to received ELX 200 mg qd /TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 48 weeks."
62172602|NCT06008288|EXPERIMENTAL|JAB-21822|Monotherapy
62172603|NCT05138432|OTHER|Intervention Group|Monthly fruit and vegetable vouchers for 12 months, to start immediately after enrollment.
62172604|NCT05138432|OTHER|Delayed Intervention Group|Monthly fruit and vegetable vouchers for 12 months, to start after a 6-month waiting period.
62172605|NCT01533181|EXPERIMENTAL|Arm I: OS-906 (linsitinib)|OS-906 daily, continuously, every 3 weeks.
62363884|NCT01213290|ACTIVE_COMPARATOR|EUS-FNA with stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
62739293|NCT04674111|EXPERIMENTAL|Vortex Feasibility Study (Vortex FIH)|Vortex - First in Human Study to Evaluate the Feasibility, Safety, Clinical and Technical Success of the Vortex Temporary Percutaneous, Transvalvular Circulatory Support System (Vortex System)
62739294|NCT03620136|EXPERIMENTAL|locoregional analgesia by a block on the adductor channel|
62739295|NCT03620136|EXPERIMENTAL|locoregional analgesia by periarticular local infiltrations|
62739296|NCT03176862||CKD|40 patients per group of CKD from stage 2 to stage 5.
62739297|NCT03176862||Kidney transplant recipients|20 live-donor recipients will be studied pre-operatively and then followed up at 6 weeks and 1 years post-operatively.
62739298|NCT03176862||Controls|40 healthy controls and 40 hypertensive controls.
61997353|NCT06497049|ACTIVE_COMPARATOR|ozempic|Ozempic® is administered subcutaneously into the subcutaneous fat of the anterior abdominal wall at a dose of 0.5 mg using a pen injector
61997354|NCT02703636|OTHER|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
61997355|NCT04007172|EXPERIMENTAL|Neural Therapy & home exercise program|"Intracutaneous quaddle injections were performed using 1% lidocaine preparation as a local anesthetic for local application to painful points with palpation on the back and shoulders and for the segmental application, 2 cm lateral to the midline of the C1-T5 vertebrae and on spinous processes.~Both the groups received education about fibromyalgia and home exercise program, which included stretching, strengthening, and aerobic exercises."
61997356|NCT04007172|EXPERIMENTAL|Physical Therapy & home exercise program|"Physical therapy program was consist of transcutaneous electrical nerve stimulation- TENS (30-40 Hz, 20 minutes), hotpack (20 minutes) and continuous ultrasound (1mHz, 1.5w / cm2, 10 minutes) on painful points with palpation on the back and shoulders.~Both the groups received education about fibromyalgia and home exercise program, which included stretching, strengthening, and aerobic exercises."
61997357|NCT00024089|EXPERIMENTAL|Arm I|Patients receive oral gefitinib daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
61997358|NCT02284503|EXPERIMENTAL|40mg Rosuvastatin group|The subjects in this group will receive Rosuvastatin 40mg within 12±2h before PCI, follow 20mg post PCI for 30days.
61997359|NCT02284503|EXPERIMENTAL|20mg Rosuvastatin group|The subjects in this group will receive Rosuvastatin 20mg within 12±2h before PCI, follow 20mg post PCI for 30days.
61997360|NCT02284503|EXPERIMENTAL|no statin group|The subjects in this group will not receive Rosuvastatin before PCI, follow 10mg post PCI for 30days.
61997361|NCT01061086||1|Patients over 18 years old admitted to the hospital with Acute Coronary Syndrome.
61997362|NCT06190561|EXPERIMENTAL|Treatment A: PF-07940367 Product II|tablet by mouth
61997363|NCT06190561|EXPERIMENTAL|Treatment B: PF-07940367 Product I|tablet by mouth
61997364|NCT01737567|EXPERIMENTAL|Bright Narrow Band Imaging|Use of B-NBI to detect colonic adenomas.
61997365|NCT01737567|ACTIVE_COMPARATOR|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
61997366|NCT05855564|EXPERIMENTAL|School-based Mindfulness program|Eight session of mindfulness-based program based on Mindfulness Matters developed by Eline Snel
61997367|NCT04813770|EXPERIMENTAL|Theory-based messages|Theory-based health messages about COVID-19 and COVID-19 vaccination, the necessity of COVID-19 vaccination to oneself and others, and COVID-19 vaccine regulatory approval processes. These messages are based on publicly available information and are hypothesised to increase perceived necessity and reduce concerns about vaccination, and target known barriers to vaccine uptake.
61997368|NCT04813770|ACTIVE_COMPARATOR|General messages|General messages about the COVID-19 virus and the vaccination programme. These messages do not target necessity and concerns, but are anticipated to promote understanding of the pandemic.
61997369|NCT04060329|NO_INTERVENTION|Phase 1|Usual care
61997370|NCT04060329|EXPERIMENTAL|Phase 2|Usual care + coopeRATE Prompt intervention
62172606|NCT01533181|ACTIVE_COMPARATOR|Arm II (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes or PO QD on days 1-5. Patients may crossover to Arm I at the time of progressive disease.
62363885|NCT01213290|ACTIVE_COMPARATOR|EUS-FNA without stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
62172607|NCT02099149||Controls|Infants born to GBS colonized mother who do not develop GBS disease
62172608|NCT02099149||Cases|Infants with culture confirmed GBS disease
62172609|NCT06642922||group 1|normal weight group , 53 participants BMI , balance , and gross motor capacities were assessed for each participant
62172610|NCT06642922||group 2|overweight and obese group , 51 participants BMI , balance , and gross motor capacities were assessed for each participant
62172611|NCT06050226|EXPERIMENTAL|Arm1：low MY008211A dose|Participants will receive low MY008211A dose orally b.i.d
62172612|NCT06050226|EXPERIMENTAL|Arm2：high MY008211A dose|Participants will receive high MY008211A dose orally b.i.d
62172613|NCT02921152|OTHER|all|All patients with early breast cancer
62172614|NCT05589584|EXPERIMENTAL|intervention|NAC and weight reduction program
62172615|NCT05589584|NO_INTERVENTION|control|weight reduction program only
62172616|NCT01716923|EXPERIMENTAL|S-303 Treated Red Blood Cells|Patients receive S-303 treated red blood cells (RBCs).
62172617|NCT01716923|ACTIVE_COMPARATOR|Conventional, untreated Red Blood Cells|Patients receive conventional, untreated red blood cells (RBCs).
62172618|NCT04041024|EXPERIMENTAL|bulimia nervosa group|Patients with Bulimia Nervosa according to DSM 5 criteria aged between 18 and 35 years and specifically for participants attending MRI scans in the experiments: no counter indication to MRI scans and right handed.
62172619|NCT04041024|OTHER|Control group|healthy participants without any history of eating disorder aged between 18 and 35 years and specifically for participants attending MRI scans in the experiments: no counter indication to MRI scans and right
62172620|NCT03945851|EXPERIMENTAL|VNS + Rehabilitation|This study is only including subjects from the VNS-REHAB study (NCT03131960) who choose to participate in this fMRI sub-study. The experimental arm for that study includes subjects whose stroke treatment via Vagal Nerve Stimulation (VNS) delivered during rehabilitation.
62172621|NCT03945851|ACTIVE_COMPARATOR|Control VNS|This study is only including subjects from the VNS-REHAB study (NCT03131960) who choose to participate in this fMRI sub-study. The active control arm for that study included subject whose stroke treatment is rehabilitation (standard-of-care) with only a minimal amount of VNS at the start of each rehabilitation session.
62172622|NCT05716152||Psoriasis vulgaris participants|
62172623|NCT05716152||not diseased participants|
62172624|NCT05533645|EXPERIMENTAL|Experimental group|patients with high blood pressure or chronic kidney diseases stages 4-5
62172625|NCT03972137|EXPERIMENTAL|Heart Rate Variability Biofeedback-Smoking Cessation Therapy|All participants in this open trial received individualized cognitive-behavioral smoking cessation treatment (SCT), up to 8 weeks of the transdermal nicotine patch (NRT) and individualized heart rate variability biofeedback (HRVB).
62172626|NCT05012397|EXPERIMENTAL|Milademetan (RAIN-32)|260 mg once dailly orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
62172627|NCT00449488|NO_INTERVENTION|Control|
62172628|NCT00449488|ACTIVE_COMPARATOR|Epoetin alfa|i.v bolus 60.000 IU epoetin alfa
62172629|NCT01191450|ACTIVE_COMPARATOR|Higroton®|Chlorthalidone 25mg - one oral tablet a day in the morning
62172630|NCT01191450|EXPERIMENTAL|Diupress®|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning
62172631|NCT05947708|ACTIVE_COMPARATOR|High FLow Rate|Flow Rate of 500ml/min or higher
62172632|NCT05947708|ACTIVE_COMPARATOR|Low Flow Rate|Flow Rate of 300ml/min
62172633|NCT06371430|PLACEBO_COMPARATOR|Pain Scale|To assess the efficacy of the surgical procedure, pain scale evaluations were conducted on day 1,4 and 7, following the surgery. This evaluation involved a direct contact with the patients to gauge their subjective pain experience. A modified visual analog scale (VAS) was utilized, as described in reference \[34\]. No pain scale = 0, moderate pain scale = 5 and maximum pain scale = 10 \[21\]. In addition to efficacy measurements, safety measurements were also considered. The occurrence of adverse events (AEs) and serious adverse events (SAEs) was monitored throughout the duration of the study. These events were either detected by the investigator or reported by the patients themselves. The aim was to identify any potential complications or issues that arose because of the surgical procedure.
62172634|NCT06371430|PLACEBO_COMPARATOR|RFA and ISQ measurements|After the implants were fully seated, a Smartpeg specific to the implant system and restorative platform diameter was used for each implant. RFA was then performed using an OsstellMentor device from Ostell/Integration Diagnostics in Gothenburg, Sweden. This analysis was used to measure the ISQ values for all implant surfaces at days 0, 7 and 30 post-surgeries. For each implant, 4 readings were taken per lingual, mesial, distal, and vestibular direction. The average ISQ values of all the readings were recorded. Following the RFA measurements, new sterile healing abutments were inserted, and the incisions were sutured to close the wounds.
62172635|NCT06371430|EXPERIMENTAL|CBCT analysis|CBCTs were captured for implants from six patients with total of 24 implants, with 12 implants Galaxy TS (non-treated) on one side of the jaw and 12 implants Galaxy TSA (treated with BBL) on the other side of the jaw. All patients in this group had implants inserted in the upper jaw and each patient had 4 implants inserted (All on 4 technique). The CBCTs scans were conducted at days 1 and 60 post-surgeries using a 3D Accuitomo 170 scanner (J. MORITA EUROPE GMBH). The scans were performed with the following technical parameters: 90 kV, 5 mA, 87.5 mAs, voxel size ranging from 125-250 µm, 360° rotation, and scanning time of 17.5 s as previously described \[32\]. To ensure accuracy, a bite mark was utilized during CBCT scanning to correspond to the patients' midline. Consistency in bite mark placement was maintained to ensure that the same slice was obtained for each scan performed on the patient
62172636|NCT05982028|EXPERIMENTAL|Pit picking group|Minimally invasive pilonidal cyst surgery.
62172637|NCT05982028|EXPERIMENTAL|Excision group|Radical surgical pilonidal cyst excision without suturing
62172638|NCT02336113|NO_INTERVENTION|Control group|Standard care during hospital stay, without pharmacist involved
62172639|NCT02336113|EXPERIMENTAL|Pharmacist intervention|A pharmacist is included in the multidisciplinary treatment team during the hospital stay
62172640|NCT01093222|EXPERIMENTAL|Treatment (sorafenib tosylate and erlotinib hydrochloride)|Patients receive sorafenib tosylate PO twice daily and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62172641|NCT01266499|ACTIVE_COMPARATOR|Group 1: will receive PO Garamycin 80mg x 4/d|will receive PO Garamycin 80mg x 4/d
62172642|NCT01266499|ACTIVE_COMPARATOR|Group 2 : will receive PO Colistin (Polymyxin E) 100mg x 4/d|
62172643|NCT01266499|ACTIVE_COMPARATOR|Group 3: will receive both medications|
62172644|NCT01266499|PLACEBO_COMPARATOR|Group 4: will not receive PO treatment|
62172645|NCT03950596|ACTIVE_COMPARATOR|One acute resistance load exercise|One hundred volunteers will participate in one acute resistance load exercises to their quadriceps
62172646|NCT03950596|ACTIVE_COMPARATOR|Three acute resistance load exercises|One hundred volunteers will participate in three acute resistance load exercises to their quadriceps
62172647|NCT03950596|ACTIVE_COMPARATOR|Control Group|One hundred volunteers will participate in study as a control group
62172648|NCT01780363||controls|frequency of mevalonate kinase gene frequency
62172649|NCT01780363||Behçet patients|frequency of mevalonate kinase gene mutations
62172650|NCT04433949|ACTIVE_COMPARATOR|Arm I (physician choice)|Patients get best supportive care + physician choice of treatment
62172651|NCT04433949|EXPERIMENTAL|Arm II (LDRT)|Patients receive best supportive care + low dose RT (whole lung)
62172652|NCT01379261|ACTIVE_COMPARATOR|Hypothermia treatment|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
62172653|NCT01379261|NO_INTERVENTION|Standard treatment|Standard treatment
62172654|NCT01878188|EXPERIMENTAL|BC-819/PEI and BCG alternating|4 or 6 weekly treatments of BC-819/PEI alternating with 6 treatments of BCG
62172655|NCT01878188|EXPERIMENTAL|BC-819/PEI and BCG Vaccine sequential|4 weekly treatments of BC-819/PEI followed by 6 weekly treatments of BCG
62172656|NCT01878188|EXPERIMENTAL|twice-weekly treatments of BC-819 and BCG|6 twice-weekly treatments of BC-819/PEI and BCG
62172657|NCT04285476|EXPERIMENTAL|Signature of microRNA|Signature of miRNA in patients with Thyroid Cytologies of undetermined type and with a Bethesda classification 3, 4 or 5
62172658|NCT04968015|EXPERIMENTAL|VEN-CYTA|Venetoclax 600mg/day, Per Os (PO), D1 to D14 / 28 days cycle Cytarabine 50 mg/m2/12h Subcutaneous (SC), D1 to D5 / 28 days cycle
62172659|NCT04968015|ACTIVE_COMPARATOR|IDA-CYTA|Idarubicin 8mg/m2, Intravenous (IV), at D1 / 28 days cycle Cytarabine 50 mg/m2/12h, SC, D1 to D5 / 28 days cycle
62172660|NCT04297436|OTHER|Bexsero|Each participant is compared to baseline (before vaccination)
62172661|NCT00981929|ACTIVE_COMPARATOR|Tramadol|CYP2D6 metric
62172662|NCT00981929|ACTIVE_COMPARATOR|Omeprazole, losartan, caffeine|CYP2C19, CYP2C9 and CYP1A2 metrics
62172663|NCT00981929|ACTIVE_COMPARATOR|Tramadol, omeprazole, losartan and caffeine|CYP2D6, CYP2C19, CYP2C9 and CYP1A2 metrics
62172664|NCT04139239||Patients with disorders of consciousness|
62172665|NCT05422742|ACTIVE_COMPARATOR|SRP|Scaling and rooting planning
62172666|NCT05422742|EXPERIMENTAL|SRP + MM|Scaling and rooting planning in combination with minocycline microspheres
62172667|NCT05422742|NO_INTERVENTION|Periodontally-Healthy Subjects|No Intervention
62172668|NCT02686359|EXPERIMENTAL|Burning Mouth Syndrome Patients|saliva, blood and urinary samples
62172669|NCT02686359|ACTIVE_COMPARATOR|controls|saliva, blood and urinary samples
62172670|NCT00557349|ACTIVE_COMPARATOR|Omeprazole|40 mg Omeprazole daily
62172671|NCT00557349|ACTIVE_COMPARATOR|Famotidine|40 mg Famotidine daily
62172672|NCT04222335|OTHER|Blood sampling|Blood sampling
62172673|NCT05273177||CAI group|
62172674|NCT05273177||Control group|
62172675|NCT02429752|EXPERIMENTAL|Inspiratory Muscle Training|Subjects will receive 8 weeks of IMT
62172676|NCT02885883|ACTIVE_COMPARATOR|a control group|
62172677|NCT02885883|EXPERIMENTAL|patients with paroxysmal or persistent AF|
62172678|NCT02885883|EXPERIMENTAL|patients with permanent AF|
62172679|NCT06479252|ACTIVE_COMPARATOR|Centre-Based Condition|Participants will be asked travel to West Park Healthcare Centre to complete the sit-to-stand (STS) tests under the supervision of a trained research team member. Participants will be guided through the standardized protocol for the STS tests.
62172680|NCT06479252|EXPERIMENTAL|Remotely Supervised Condition|The sit-to-stand (STS) tests will be conducted in the patient's home and will be remotely monitored by a research staff member situated at the healthcare centre (via videoconference). The research team member will send a meeting invite to the participant who will independently join the videoconference from their home. At the onset of the study, participants will receive a handout to explain the materials they need to prepare for the session. Guidance will also be provided during the orientation meeting. Based on chair availability in participant's home, deviations will be noted by study staff. The testing procedure and instructions will be the same as the centre-based testing described.
62172681|NCT06479252|EXPERIMENTAL|Self-Administered Condition|The self-administered sit-to-stand (STS) tests will be conducted independently by the patient in their home setting. No supervision will be provided by study staff during the testing sessions. At the onset of the study, participants will receive a handout to explain the materials they need to prepare for the session. Detailed instructions for completing the STS tests independently will be provided to the participant (Appendix B). Guidance will also be provided during the orientation meeting. The instructions and guide to self-administer the test will be piloted at the start of the study, and the content may be refined to meet the needs of patients.
62172682|NCT06545721|EXPERIMENTAL|Normal weight group|18.5 kg/m2 ≤ BMI \< 24 kg/m2
62172683|NCT06545721|EXPERIMENTAL|Obese/Overweight Group|BMI ≥24 kg/m²
62172684|NCT05624697|OTHER|Augmented group|Patient Specific Sticky Bone /Implant Housing PEEK Shell in Anterior Atrophic Maxilla with simultaneous implant placement
62172685|NCT03448289|NO_INTERVENTION|Control|This group will not receive the RLPT.
62172686|NCT03448289|EXPERIMENTAL|Intervention|This group will receive the RLPT.
62172687|NCT02805036||30 cmH20 for 30 seconds|"plateau pressure is hold on at 30 cmH20 pour 30 seconds. The cardiac output and the lung aeration is assessed by ultrasound measures at 3 times: before, at the end of the recruitment and 30 minutes later.~echocardiography - arterial oximetry"
62363886|NCT02699125|EXPERIMENTAL|Placebo, Guanfacine, Hydrochlorothyazide|Sequence: Placebo, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
62363887|NCT02699125|EXPERIMENTAL|Placebo, Hydrochlorothyazide, Guanfacine|Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks.
61997371|NCT04060329|OTHER|Clinicians|After Phase 2, clinicians will be asked about their experiences with, and views about, the coopeRATE Prompt intervention.
61997372|NCT06481202|EXPERIMENTAL|"Complarate® (JSC GENERIUM, Russia)"|tocilizumab biosimilar
61997373|NCT06481202|ACTIVE_COMPARATOR|Actemra® (F. Hoffmann-La Roche Ltd., Switzerland)|tocilizumab
61997374|NCT00726570|EXPERIMENTAL|SCD + LMWH|This group will receive sequential compression device therapy to the lower limbs from their ICU admission until the morning after surgery.
61997375|NCT00726570|ACTIVE_COMPARATOR|LMWH only|Patients in this group will receive only standard LMWH therapy during their ICU stay.
61997376|NCT03139890|EXPERIMENTAL|High-fat milkshake|
61997377|NCT03139890|EXPERIMENTAL|High-carbohydrate milkshake|
61997378|NCT03139890|EXPERIMENTAL|High-protein milkshake|
61997379|NCT00544076|EXPERIMENTAL|Sildenafil Citrate/Mo+Aprostadil/day|Patients receive intraurethral alprostadil once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
61997380|NCT00544076|ACTIVE_COMPARATOR|Sildenafil Citrate Monthly|Patients receive 3 doses of oral sildenafil citrate on 3 separate occasions at least 48 hours apart monthly for 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
61997381|NCT00544076|EXPERIMENTAL|Daily Sildenafil Citrate|Patients receive oral sildenafil citrate once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
61997382|NCT01885091|EXPERIMENTAL|Kinerase|
61997383|NCT04784286|ACTIVE_COMPARATOR|Telemedicine 30-day follow-up visit|"The Center for Connected Care will arrange for 30-day post-op telemedicine visits via a secured video application. When there is a telemedicine visit, the Center of Connected Care will connect the patient and then page the midlevel provider and dietitian after the electronic rooming process is complete \& the patient is ready.~A survey about post-operative care visits within 7-14 days after that visit. The survey will focus on the following aspects: baseline familiarity with technology, patients' satisfaction with the post-op care they received, patients' preference of in-person vs telemedicine visits, patients' estimation of additional costs for care outside of the direct medical costs, along with an open question asking for comments \& feedback about their overall experience with their follow-up appointment."
61997384|NCT04784286|ACTIVE_COMPARATOR|In-person 30-day follow-up visit|"Standard practice of having bariatric surgery patients follow up with the bariatric surgery midlevel providers as well as with dietitians within 30-days after their bariatric procedure. The bariatric surgery midlevel providers are staffed and supported by our bariatric surgeons in case if they have questions or concerns.~Participants will be contacted via telephone and will be surveyed about their post-operative care visits within 7-14 days after that visit. The survey will focus on the following aspects: baseline familiarity with technology, patients' satisfaction with the post-operative care they received, patients' preference of in-person vs telemedicine visits, patients' estimation of additional costs for their care outside of the direct medical costs, along with an open question that will ask patients to provide comments and feedback about their overall experience with their follow-up appointment."
61997385|NCT02638142||Continuous Furosemide Infusion|continuous intravenous furosemide infusion
61997386|NCT02638142||Intermittent Furosemide Infusion|bolus intermittent intravenous furosemide infusion
61997387|NCT01223144|EXPERIMENTAL|Patients with essential tremor|Patients with essential tremor
61997388|NCT01223144|ACTIVE_COMPARATOR|age- and sex-matched control subjects|age- and sex-matched control subjects
61997389|NCT05210127|EXPERIMENTAL|After Scarf Osteotomy Group|30 participants after surgery
61997390|NCT05210127|EXPERIMENTAL|Without Scarf Osteotomy Group|30 participants without surgery
61997391|NCT02550457|NO_INTERVENTION|Control group|It will not apply any tape.
61997392|NCT02550457|EXPERIMENTAL|Experimental group 1|Apply the KT with tension in the erector spine muscles.
61997393|NCT02550457|EXPERIMENTAL|Experimental group 2|Apply the KT without tension in the erector spine muscles.
61997394|NCT02550457|PLACEBO_COMPARATOR|Placebo group|Apply Micropore tape in the erector spine muscles.
61997395|NCT02667483|EXPERIMENTAL|DS-5141b|"DS-5141b, Subcutaneous injection~Part 1: DS-5141b will be injected subcutaneously once a week for 2 weeks at the following dose levels. Dose escalation will be performed. DS-5141b will be administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.~* Level 1: 0.1 mg/kg~* Level 2: 0.5 mg/kg~* Level 3: 2.0 mg/kg~* Level 4: 6.0 mg/kg~Part 2: Two doses of DS-5141b will be selected based on the results obtained in Part 1. Each selected dose will be administered subcutaneously once a week for 12 weeks.~Part 2-Extension-2: Two doses, 2.0 mg/kg or 6.0 mg/kg, of DS-5141b will be administered subcutaneously once a week for 48 weeks."
61997396|NCT00916175|PLACEBO_COMPARATOR|P1&P2|Food product P1\&P2 is composed of: placebo1(mimic aloe vera gel) 30ml and placebo2 (mimic Cnidoscolus chayamansa infusion) 200ml;
61997397|NCT00916175|EXPERIMENTAL|P1&CC|Food Product P1\&CC contains: placebo1 (mimics liquified aloe vera gel) 30ml and Cnidoscolus Chayamansa infusion 200ml;
61997398|NCT00916175|EXPERIMENTAL|AG&P2|Food product AG\&P2 contains (liquified aloe vera gel) 30ml and placebo2 (mimic CC infusion) 200ml.
62172688|NCT02805036||10 cmH20 above|"plateau pressure is hold on at 10 cmH20 above. The cardiac output and the lung aeration is assessed by ultrasound measures at 3 times: before, at the end of the recruitment and 30 minutes later.~echocardiography - arterial oximetry"
62172689|NCT02218775|EXPERIMENTAL|LY2456302|LY2456302 dosed orally at 10 mg daily for 2 weeks in healthy volunteers
62172690|NCT02262364|EXPERIMENTAL|NStride APS|Subjects will receive an intra-articular injection of APS.
62172691|NCT06405516|ACTIVE_COMPARATOR|Patients undergoing cardiac surgery using the conventional cell saver device|
62172692|NCT06405516|EXPERIMENTAL|Patients undergoing cardiac surgery using the cell saver device|
62172693|NCT01462825|EXPERIMENTAL|tomato ketchup meal|
62172694|NCT01462825|PLACEBO_COMPARATOR|Placebo meal|
62172695|NCT05656807|ACTIVE_COMPARATOR|Go NAPSACC|Centers randomized to Go NAPSACC will receive the traditional Go NAPSACC program. This will include the center director leading the Go NAPSACC effort with support from a Go NAPSACC Implementation advisor. The advisor will orient each center to Go NAPSACC and its online tools and check in monthly with directors as they work through 2 cycles of Go NAPSACC over 6 months. Centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals.
62172696|NCT05656807|EXPERIMENTAL|Go NAPSACC Enhanced|Centers randomized to Go NAPSACC Enhanced will receive the traditional Go NAPSACC program as described in the Active Comparator arm. Additionally, child care providers will simultaneously receive a weight management program, Go NAPSACC Cares over 6 months. The health educator will orient providers with the website and its tools and resources. Providers will take a self-assessment and choose a goal of weight maintenance or weight loss. They will go through 18 lessons with accompanying resources. Within the website they will self-monitor their weight, physical activity, and red foods (diet quality). Providers will receive daily tips, weekly reminders via text message or email, and tailored weekly feedback based on their weight management goals and progress.
62172697|NCT00906659||diabetic macular edema|type 2 patients who had been treated with selective photocoagulation for clinically significant macular edema
62172698|NCT05512832||ISR|Patient developed in-stent restenosis 9-24 months after stenting
62172699|NCT05512832||no ISR|Patients were free of in-stent restenosis 9-24 months after stenting
62172700|NCT02915354|EXPERIMENTAL|Etanercept, AS|The patients were diagnosed with ankylosing spondylitis and obtained the ASAS20 response after etanercept treatment. Then they were discontinued to etanercept and received no treatment except DMARDs or NSAIDs which had used before.
62172701|NCT01960985|EXPERIMENTAL|Physicaltherapy|Exprerimental group I - motor training balance training Exprerimental group II - motor training associated with visual and auditory cues on the balance training Control group - recived general orientations.
62172702|NCT01960985|EXPERIMENTAL|physiotherapy|Exprerimental group I - motor training balance training Exprerimental group II - motor training associated with visual and auditory cues on the balance training Control group - recived general orientations.
62172703|NCT02150083|EXPERIMENTAL|OR retrograde fill|At completion of sling placement in the operating room, the bladder will be filled retrograde via a cystoscope with 300 mL sterile saline or water to inspect for bladder perforation. The cystoscope is removed and the foley catheter is NOT replaced for the duration of the surgery. The surgery is completed and the patient is transferred to the post-anesthesia care unit. Once she is able to ambulate, she will be instructed to void. The voided volume and residual volume will be recorded.
62172704|NCT02150083|NO_INTERVENTION|PACU retrograde fill|At completion of sling placement in the operating room, the bladder will be filled retrograde via a cystoscope with 300 mL sterile saline or water to inspect for bladder perforation. The cystoscope is removed and the foley catheter is replaced for the duration of the surgery and when complete the patient is transferred to the post-anesthesia care unit. Once she is able to ambulate, she will undergo a retrograde bladder fill with 300 mL of normal saline. The foley catheter will be removed and she will be instructed to void. The voided volume and residual volume will be recorded.
62172705|NCT05715502|EXPERIMENTAL|Experimental|Experimental: All recruited participants will be treated with salvage partial (focal) prostate brachytherapy for the lesion of recurrent prostate cancer with appropriate margin.
62172706|NCT02396498|PLACEBO_COMPARATOR|D2 radical gastrectomy+Systemic chemotherapy|8 cycles of systemic chemotherapy were performed for stage Ⅲ patients after D2 gastrectomy .Systemic chemotherapy(SP): Cisplatin: 60mg/m\^2, d1 , Intravenous infusion, every 3 weeks. S-1: 40-60mg/m\^2 bid, days 1-14, every 3 weeks .Subjects should be given maximum 8 cycles, or progression/intolerance.
62172707|NCT02396498|EXPERIMENTAL|D2 radical gastrectomy+HIPEC|8 cycles of hyperthermic intraperitoneal chemotherapy (cisplatin) and S-1(oral) were performed after D2 radical gastrectomy. HIPEC was conducted in d1 and d3: Normal saline 2000ml-5000ml, Cisplatin 60mg/m\^2, 43°C, 60min. every 3 weeks. S-1: 40-60mg/m\^2 bid, days 1-14, every 3 weeks.Subjects should be given maximum 8 cycles, or progression/intolerance.
62172708|NCT03930238|EXPERIMENTAL|VA MapTrek|Veterans in the intervention group receive a Fitbit and access to VA MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required to enroll). Each week, Veterans are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. Throughout each race, participants will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
62172709|NCT03930238|ACTIVE_COMPARATOR|Fitbit Only|Veterans randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to VA MapTrek or simply by giving the Veterans a Fitbit.
62172710|NCT05486871|ACTIVE_COMPARATOR|renal cell carcinoma stages T1|laparoscopic partial nephrectomy in renal cell carcinoma stage T1
62172711|NCT05486871|ACTIVE_COMPARATOR|renal cell carcinoma stages T2a|laparoscopic partial nephrectomy in renal cell carcinoma stage T2a
62172712|NCT00661466|EXPERIMENTAL|1|Either three or four 5x5-cm bupivacaine sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
62172713|NCT00661466|PLACEBO_COMPARATOR|2|Either three or four 5x5-cm placebo sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
62172714|NCT02359578|EXPERIMENTAL|Lymphatic occlusion pressure|injection of 100µg Indocyanine Green in the first interdigital space and application of increasing pressure around the arm to visualize at which pressure lymph flow is interrupted.
62172715|NCT06645548|NO_INTERVENTION|Control arm (standard care)|TBW, LBW and IBW will be estimated using standard care processes. All relevant medical care will be based on this weight for the first 72 hours
62172716|NCT06645548|EXPERIMENTAL|3D camera weight estimation|TBW, LBW and IBW will be automatically estimated using the 3D camera system. All relevant medical care will be based on this weight for the first 72 hours
62172717|NCT05672498|ACTIVE_COMPARATOR|TCM treatment|The patients are treated with traditional Chinese medicine. They take 150ml of liquid medicine every morning and evening for 7 days.
62172718|NCT05672498|PLACEBO_COMPARATOR|placebo treatment|The patients are treated with placebo. They take 150ml of liquid placebo every morning and evening for 7 days .
62172719|NCT01829685|ACTIVE_COMPARATOR|Group I|oral entecavir 1mg daily and adefovir 10mg daily for 144 weeks
62172720|NCT01829685|ACTIVE_COMPARATOR|Group II|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
62172721|NCT00748488|EXPERIMENTAL|A|Physical Therapy aimed to promote the level of physical activity
62172722|NCT00748488|ACTIVE_COMPARATOR|B|Physical Therapy aimed to move safely
62172723|NCT02683356|ACTIVE_COMPARATOR|OCT-guided PCI|OCT before and after Stent implantation
62172724|NCT02683356|ACTIVE_COMPARATOR|Angiography-guided PCI|OCT after Stent implantation
62172725|NCT04506359|NO_INTERVENTION|control group|Control Group: Usual care +case manager care, UC group or Control group
61986207|NCT02206425|EXPERIMENTAL|bortezomib + lenalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
62172726|NCT04506359|EXPERIMENTAL|experimental group|The experimental group is COPSCCP+ UC+ case manager care. In this group, a 6-month intervention providing for each time while subject visit their chest surgeon(s) in the OPD (from the first time before hospital discharge/T1) - usually patients visited hospital in 2 weeks, 1 month, 2 months, 3 months and 6 months (T2-6) after surgery. Patients will receive (a) nurse-guided touch-screen computer screening (assessment) for their psychological and physical distress and care needs during current week; (b) the screening /assessment results will immediately show as the outcome (we are developing a calculation system to sum those scores).
62172727|NCT01565239|EXPERIMENTAL|Fiix PT (Fiix-INR) monitoring and dosing of warfarin|The modified prothrombin time, sensitive only to factor II and X activity, will be used to monitor and dose warfarin.
62172728|NCT01565239|ACTIVE_COMPARATOR|PT (INR) monitoring and dosing of warfarin|The prothrombin time, sensitive to factors II, VII and X activity, will be used to monitor and dose warfarin.
62172729|NCT01811628||Questionnaire + Interview|Latinos and Hispanics who are smokers and recent quitters.
62172730|NCT04599387|ACTIVE_COMPARATOR|Supervised Exercise arm|
62172731|NCT04599387|PLACEBO_COMPARATOR|Usual care arm|
62172732|NCT03289416|OTHER|Platelet Rich Plasma (PRP)|Blood will be drawn from the patient using the Pure PRP II system into a syringe with anticoagulant (sodium citrate). 1 mL of blood will be separated and sent to a lab for analysis. Remaining blood will be separated into a single concentrating device and centrifuged to separate red blood cells from plasma and platelets. The plasma and platelets will be separated off with a syringe and re-centrifuged to separate the platelets from the plasma. 1 mL will be separated and sent to a lab for analysis leaving 6 mL for injection. Both the 1 mL of blood and the 1 mL of PRP will be sent to an independent lab to undergo analysis for CBC, TNC, human CD34+ hematopoietic stem/progenitor cell assay and CFU-F. Physician will then inject the PRP into the affected knee joint.
62172733|NCT03289416|OTHER|Bone Marrow Concentrate (BMC)|Bone marrow will be harvested from the posterior iliac crest using the PureBMC system. 50 mL of bone marrow will be drawn into one syringe containing 10 mL of sodium citrate. Marrow will be filtered and centrifuged for separation of the bone marrow concentrate. Plasma and cell concentrate will be separated off with two syringes and re-centrifuged to separate the cell concentrate from the plasma. After plasma is drawn off, BMC will be drawn into a syringe for injection into affected knee. BMC production procedure results in 7 mL of product and 1 mL will be separated and sent to a lab for analysis. Both 1 mL of BMA and 1 mL of BMC will be sent to an independent lab to undergo analysis for CBC, TNC, human CD34+ hematopoietic stem/progenitor cell assay and CFU-F.
62172734|NCT05615662|EXPERIMENTAL|Meru Health Program|This group of participants will receive the app-based 12-Week Meru Health Program as their study intervention.
62172735|NCT05615662|ACTIVE_COMPARATOR|Treatment as Usual|"This group of participants will receive Treatment as Usual mental health services under the direction and referral of their Primary Care Physician."
62172736|NCT04007848|EXPERIMENTAL|Cobimetinib|Experimental group : 36 histiocytoses's patients without or with BRAF V600E will be randomised in cobimetinib group
62172737|NCT04007848|PLACEBO_COMPARATOR|Placebo|Control group : 18 histiocytoses's patients without or with BRAF V600E will be randomised in the placebo group
62172738|NCT03849521||Asymptomatic group|Group with asymptomatic patients with carotid atherosclerosis.
62172739|NCT03849521||Symptomatic group|Group with symptomatic patients with carotid atherosclerosis.
62172740|NCT02345707|EXPERIMENTAL|Part A|Subjects will receive reference cabotegravir 30 mg current formulation (Treatment A), Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) and Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) in one of six sequences ABC, ACB, BCA, BAC, CAB, CBA in three treatment periods under fasting condition
62172741|NCT02345707|EXPERIMENTAL|Part B|Subjects will receive reference Cabotegravir 30 mg current formulation (Treatment A), Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) and Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) in one of six sequences ADE, AED, DAE, DEA, EAD, EDA in three treatment periods under fasting condition
62172742|NCT06155487|EXPERIMENTAL|(Part A) Single dose group 1|Oral dose of AJH-2947/placebo 100 mg, Korean Only\*
62172743|NCT06155487|EXPERIMENTAL|(Part A) Single dose group 2|Oral dose of AJH-2947/placebo 200 mg, Korean and Caucasian
62172744|NCT06155487|EXPERIMENTAL|(Part A) Single dose group 3|Oral dose of AJH-2947/placebo 300 mg, Korean and Caucasian
62172745|NCT06155487|EXPERIMENTAL|(Part A) Single dose group 4|Oral dose of AJH-2947/placebo 400 mg, Korean and Caucasian
62172746|NCT06155487|EXPERIMENTAL|(Part A) Single dose group 5|Oral dose of AJH-2947/placebo 600 mg, Korean and Caucasian
62172747|NCT06155487|EXPERIMENTAL|(Part A) Single dose group 6|Oral dose of AJH-2947/placebo 800 mg, Korean and Caucasian
62172748|NCT06155487|EXPERIMENTAL|(Part B) Multiple dose group 1|Oral dose of AJH-2947/placebo 200 mg, Korean and Caucasian
62172749|NCT06155487|EXPERIMENTAL|(Part B) Multiple dose group 2|Oral dose of AJH-2947/placebo 400 mg, Korean and Caucasian
62172750|NCT06155487|EXPERIMENTAL|(Part B) Multiple dose group 3|Oral dose of AJH-2947/placebo 600 mg, Korean and Caucasian
62172751|NCT04979156||SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors|SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
62172752|NCT01915992|OTHER|Volunteer healthy|
62172753|NCT01915992|ACTIVE_COMPARATOR|leukemia patient's|
62172754|NCT03154684|ACTIVE_COMPARATOR|STARK intervention|New care concept for hip fracture patients
62172755|NCT03154684|OTHER|Standard Care|Swiss standard of care for hip fracture patients
62172756|NCT01091844|ACTIVE_COMPARATOR|Spontaneous Fill Technique|"We allow the bladder to spontaneously fill, then allow the patient to void and afterward catheterize the patient to check a postvoid residual (spontaneous fill technique)."
62172757|NCT01091844|ACTIVE_COMPARATOR|Retrograde Fill Technique|"We assess bladder emptying by filling the bladder retrograde through the catheter already in place with 300 mL of saline and then removing the catheter and allowing the patient to void (retrograde-fill technique). We will determine postvoid residual indirectly by subtracting voided volume from the 300 mL infused volume. No catheterization will be performed with this technique unless they void less than 200 mL."
62172758|NCT02806817|EXPERIMENTAL|Bevacizumab + ME-344|"Bevacizumab single dose (15 mg/kg infused IV) on day 1. ME-344 will be administered at 10 mg/kg infused IV over 30 minutes on days 8, 15 and 22 (arm 1).~ME-344 will be suspended in 250 mL sterile saline."
62172759|NCT02806817|PLACEBO_COMPARATOR|Bevacizumab + normal saline|Bevacizumab single dose (15 mg/kg infused IV) on day 1. Placebo: will be administered normal saline 250 mL infused IV over 30 minutes on days 8, 15 and 22 (arm 2).
62172760|NCT02402699||Unresectable, recurrent or metastatic melanoma patients|All adult unresectable, recurrent, or metastatic melanoma patients with HBV or HCV treated with at least 1 dose of ipilimumab therapy in Taiwan
62172761|NCT03845335|EXPERIMENTAL|HA-coated hybrid implant|Patient allocated to this group will receive an iMAX® Hyaluronic Acid-coated hybrid dental implant for their dental implant-supported restoration.
62172762|NCT03845335|ACTIVE_COMPARATOR|Moderately rough implant|Patient allocated in this group will receive an iMAX® non-coated moderately rough dental implant with a machined neck their dental implant-supported restoration.
62172763|NCT02798276|EXPERIMENTAL|AGTP-treatment|Patients in which the non-revascularizable area will be covered by the adipose graft and the revascularizable area will be treated with the normal procedure.
62172764|NCT02798276|OTHER|Control|Patients in with the non-revascularizable area will be left untouched and the revascularizable area will be treated normally.
62172765|NCT04700488|EXPERIMENTAL|6D-MRI|Participants will undergo 6D-MRI imaging three times throughout the course of the study: once pre-NAT treatment, once during NAT treatment, and once post-NAT treatment.
62172766|NCT05561751|EXPERIMENTAL|GPC-100 in combination with propranolol;|"Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration.~Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm:~• GPC-100 in combination with propranolol; or"
62172767|NCT05561751|EXPERIMENTAL|GPC-100 in combination with propranolol and G-CSF|"Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration.~Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm:~• GPC-100 in combination with propranolol and G-CSF."
62172768|NCT01974661|EXPERIMENTAL|COMBIG-DC|COMBIG-DC (allogeneic dendritic cells) Cancer Vaccine 3 vaccinations: 5, 10 or 20 million cells per injection
62172769|NCT02274051|EXPERIMENTAL|Kinetin|"Kinetin titration phase to 30mg/kg dose or individual max dose taken once daily.~Patients will then proceed to steady state long-term phase at maximum individual dose of kinetin over a 3 year period."
62172770|NCT06410625|EXPERIMENTAL|Treatment arm|Patients who will receive standardized chemotherapy for pleural mesothelioma
62172771|NCT00033462|EXPERIMENTAL|Arm I|Patients receive oral erlotinib once daily. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
62172772|NCT02189122|ACTIVE_COMPARATOR|Group 1:Aspirin/placebo|Group 1 will be randomized to the order in which they receive rapid-release aspirin (ASA), 81 mg), ASA 162.5 mg, and identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
62172773|NCT02189122|ACTIVE_COMPARATOR|Group 2:NHP-544C/placebo|Group 2 will be randomized to the order in which they receive NHP-544C 81 mg, NPH-544C 162.5 mg and identical-appearing placebo for five days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
62172774|NCT02584218|EXPERIMENTAL|Non-invasive resin based caries sealing|Application of resin based sealant after acid etching of carious occlusal surface
62172775|NCT02584218|ACTIVE_COMPARATOR|Invasive resin based restoration|Application of resin based resin restoration after operative intervention of caries lesion, excavation and preparation on occlusal surface
62172776|NCT00981578|EXPERIMENTAL|ExAblate 2100 Treatment|ExAblate 2100 ablation for the treatment of painful bone metastases.
62172777|NCT03129971|EXPERIMENTAL|control group|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
62172778|NCT03129971|EXPERIMENTAL|experimental group|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
62172779|NCT03658694|EXPERIMENTAL|Conventional rTMS - study 1|In study 1 patients were randomly allocated to receive conventional repetitive transcranial magnetic stimulation (10Hz).
62172780|NCT03658694|EXPERIMENTAL|Sham rTMS - study 1|In study 1 patients were randomly allocated to receive sham repetitive transcranial magnetic stimulation.
62172781|NCT03658694|EXPERIMENTAL|Conventional rTMS - study 2|In study 2, after the end of the first trial will be allocated to receive conventional of repetitive transcranial magnetic stimulation (10Hz).
62172782|NCT03658694|EXPERIMENTAL|Patterned rTMS - study 2|In study 2, after the end of the first trial will be allocated to receive patterned of repetitive transcranial magnetic stimulation (Theta-burst).
62172783|NCT01883778||Emergency Department Patients|
62172784|NCT01883778||Emergency Medicine Physicians|
62172785|NCT06084455|EXPERIMENTAL|Aerobic exercise|30 minutes of aerobic exercise will be performed by the participants before and after cortical connectivity measurements.
62172786|NCT00273650|ACTIVE_COMPARATOR|A|Methyl-B12
62172787|NCT00273650|PLACEBO_COMPARATOR|B|Saline placebo
62172788|NCT03211897||Haloperidol 5mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
62172789|NCT03211897||Ziprasidone 20mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
62172790|NCT03211897||Olanzapine 10mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
62172791|NCT03211897||Midazolam 5mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
62172792|NCT05478681|EXPERIMENTAL|active tDCS|All participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with AD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down.
62172793|NCT05825547|EXPERIMENTAL|Cryotherapy|
62172794|NCT01685125|ACTIVE_COMPARATOR|Arm A (abiraterone acetate, prednisone)|Abiraterone acetate 1000 mg PO QD and Prednisone 5 mg PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62172795|NCT01685125|EXPERIMENTAL|Arm B (abiraterone acetate, prednisone, dasatinib)|Abiraterone acetate 1000 mg PO QD, Prednisone 5 mg PO BID, and dasatinib 100 mg PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62172796|NCT00411177|ACTIVE_COMPARATOR|Post-dilution on-line hemodiafiltration|Post-dilution on-line hemodiafiltration
62172797|NCT00411177|OTHER|High-flux hemodialysis|High-flux hemodialysis
62182358|NCT04982627|ACTIVE_COMPARATOR|Standard Care (OUD Education & Referral Resources)|• SC: The RA will provide participants with an electronic link, which provides OUD and bup education, and lists OUD treatment options and descriptions and locations, including bup prescribers. After reviewing, participants will be asked to choose from among the list of and a referral will be made based on the receiving treatment providers' procedures. These participants will not have access to the BNI chatbot. However, the referral facilitation, the electronic link will direct participants to a short Feasibility, Acceptability and Satisfaction (FAS) Assessment to obtain feedback on the process.
61997399|NCT00916175|EXPERIMENTAL|AG&CC|Food product AG\&CC is composed of: liquified aloe vera gel 30ml and Cnidoscolus Chayamansa infusion 200ml
61997400|NCT00916175|EXPERIMENTAL|TA (concentrated 5:1 aloe vera gel)|Food product TA contains concentrated 5:1 aloe vera gel by total process30 ml and purified water 200 ml.
61997401|NCT00916175|PLACEBO_COMPARATOR|P3|Food product Placebo 3 contains stabilizers and preservative used for TA 30 ml and purified water 200 ml.
61997402|NCT03382483||EXOGEN Treated|Patients prescribed EXOGEN and treatment initiated
61997403|NCT03382483||Non-EXOGEN Treated|Patients in insurance claims database who have not been treated with a bone growth stimulator; derived via propensity score subclassification
61997404|NCT05932186|ACTIVE_COMPARATOR|Interscalene block|Patients will receive inter scalene brachial plexus block combined with general anesthesia
61997405|NCT05932186|ACTIVE_COMPARATOR|Upper trunk block|Patients will receive upper trunk brachial plexus block combined with general anesthesia
61997406|NCT02296112|EXPERIMENTAL|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61997407|NCT06115928|EXPERIMENTAL|interventional group|Patients will undergo cardiac rehabilitation for 30-minute each sessions, twice a week for one month with virtual reality.
61997408|NCT06115928|NO_INTERVENTION|control group|Patients will undergo cardiac rehabilitation for 30-minute each sessions, twice a week for one month on standard care (without virtual reality)
61997409|NCT03926234||emergency triage patients|triage Level I triage Level II triage Level III triage Level IV
61997410|NCT02582853||Patients diagnosed with GBS|"Patients will undergo a lumbar puncture as a part of the diagnostic procedure as soon as they are suspected to be suffering from GBS on clinical grounds with blood test. The procedure and a blood test will be repeated after 6 months.~Lumbar puncture Blood sample"
61997411|NCT02582853||Symptomatic controls|Controls include patients with unspecified neurological symptoms or diseases who will undergo a lumbar puncture at the Department of Neurology at Aarhus University Hospital as part of their diagnostic work up irrespective of this study. We expect to include 40 symptomatic controls.
61997412|NCT02312726||Epidural group|Participants who elect to have an epidural anesthesia during labor, delivery and postplacental IUD insertion
61997413|NCT02312726||Non Epidural group|Participants who elect not to have epidural anesthesia during labor, delivery and postplacental IUD insertion
61997414|NCT03734471|ACTIVE_COMPARATOR|Traditional|
61997415|NCT03734471|EXPERIMENTAL|Reactor Device|
61997416|NCT02330796|EXPERIMENTAL|Arm A|Bucillamine (900 mg total dose over 7 days)
61997417|NCT02330796|EXPERIMENTAL|Arm B|Bucillamine (1,800 mg total dose over 7 days)
61997418|NCT02330796|ACTIVE_COMPARATOR|Arm C|Colchicine (1.8 mg total dose in 2 doses taken 1 hour apart)
62172798|NCT06231498||Overall Cohort|The study will include 300 adult (\>18yo) patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA). All patients will be recruited at Meyer Children's Hospital and Careggi University Hospital, which are referral centers for EGPA and have a large cohort of prevalent cases under long-term follow-up. They will represent the cases for the case-control epigenome-wide association study. Patients are expected to be untreated or under glucocorticoids at the time of sampling. A blood sample will be drawn for each participant. Among this cohort, 50 patients will be identified that will undergo treatment with Mepolizumab, and they will form the sub-cohort in which we will search for epigenetic predictors of the response to Mepolizumab treatment (predictive epigenomic study). These 50 patients will also be analyzed with regard to the transcriptomic and proteomic profile. Written informed consent from all participants and approval from the local ethical committees will be obtained.
62172799|NCT05310734|EXPERIMENTAL|PK and Safety|A Single 6-hour Treatment, Pharmacokinetic and Safety Study of Natroba (spinosad) Topical Suspension 0.9% w/w in Subjects 1 Month to 3 Years 11 Months of Age with an Active Scabies Infestation.
62172800|NCT00462202|EXPERIMENTAL|Sulodexide|Open label extension to original trial
62172801|NCT06646497|EXPERIMENTAL|Allogeneic hematopoietic stem cell transplantation Stem cell source only Bone Marrow|
62172802|NCT02067455|OTHER|LVAD patients|
62172803|NCT02640222||AC-naive treated with VKA|AC-naive treated with VKA
62172804|NCT02640222||AC-naive treated with apixaban|AC-naive treated with apixaban
62172805|NCT02640222||AC-naive treated with dabigatran|AC-naive treated with dabigatran
62172806|NCT02640222||AC-naive treated with rivaroxaban|AC-naive treated with rivaroxaban
62172807|NCT02640222||AC-experienced treated with VKA|AC-experienced treated with VKA
62172808|NCT02640222||AC-experienced treated with apixaban|AC-experienced treated with apixaban
62172809|NCT02640222||AC-experienced treated with dabigatran|AC-experienced treated with dabigatran
62172810|NCT02640222||AC-experienced treated with rivaroxaban|AC-experienced treated with rivaroxaban
62172811|NCT01092988|EXPERIMENTAL|Exablate 2100|MR Guided Focused Ultrasound treatment
62172812|NCT04168996|EXPERIMENTAL|rib fracture patients group|Individualized discharge planning in rib fracture patients with different severity of lung injury
62363888|NCT04260672|EXPERIMENTAL|Child-Centred Health Dialogue (CCHD)|The intervention CCHD consists of two parts 1) a universal Child Centred Health Dialog by the CHS-nurse directed in the first place to all 4-year-olds and their families (10 minutes) and 2) a targeted Family Guidance by the CHS-nurse to families where a child is identified with overweight at the age of 4 (60 minutes). All children invites to their regular 5-yrs health visit.
62550231|NCT04511260|EXPERIMENTAL|VRF Treatment|"A treatment of the vaginal canal using the NuEra Tight VRF small area handpiece. A treatment of the introitus and vestibule using the NuEra Tight VRF small area hand piece (optional).~Following screening visit, eligible subjects will be enrolled into the study. Each subject will receive 3 treatments, 4 weeks apart and 2 Follow Up (FU) visits, at 1, and 3 months following the last treatment."
62172813|NCT04168996|NO_INTERVENTION|Control group|Patients included in control group received standard conservative treatment during hospitalization
62172814|NCT02886234|EXPERIMENTAL|Mindfulness training (MT)|Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
62172815|NCT02886234|ACTIVE_COMPARATOR|Health Coaching (HC)|Eight, 30-minute phone delivered HC sessions once a week for 8 weeks
62172816|NCT03229356|NO_INTERVENTION|Waitlist Control|BPA will be rolled out to waitlist control sites after 6 months
62172817|NCT03229356|ACTIVE_COMPARATOR|Best Practices Advisory (BPA)|Clinicians will receive an email describing the BPA and order set, along with internet links to MD Quit Line without additional supplemental education.
62172818|NCT03229356|ACTIVE_COMPARATOR|BPA+ Enhanced Education|Clinicians will receive an email describing the new smoking BPA, educational materials offered, and a small tutorial on using the BPA and a new smoking cessation smart set in Epic. Education materials will include the educational hand out and academic detailing from Maryland Quit Line counselors.
62172819|NCT05441371|EXPERIMENTAL|Test; Parodontax toothpaste|1.st quadrant of subject
62172820|NCT05441371|PLACEBO_COMPARATOR|Control; Regular toothpaste|2.nd quadrant of subject
62172821|NCT04239157|EXPERIMENTAL|Treatment (canakinumab)|Patients receive canakinumab SC on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62172822|NCT01837719|EXPERIMENTAL|Treatment A: Atazanavir + Cobicistat coadministered|Participants received a single dose of atazanavir, 300 mg as capsule, coadministered with cobicistat,150 mg as tablet, following a light meal on Day 1 or 8
62172823|NCT01837719|EXPERIMENTAL|Treatment B: Atazanavir/Cobicistat FDC|Participants received a single fixed-dose combination (FDC) of atazanavir, 300 mg/cobicistat, 150 mg, following a light meal on Day 1 or 8
62172824|NCT01837719|EXPERIMENTAL|Treatment C: Atazanavir + Cobicistat coadministered|Participants received a single dose of atazanavir, 300 mg as capsule, coadministered with cobicistat,150 mg as tablet, in the fasted state on Day 15 or 22
62172825|NCT01837719|EXPERIMENTAL|Treatment D: Atazanavir/Cobicistat FDC|Participants received a single FDC dose of atazanavir, 300 mg/cobicistat, 150 mg, in the fasted state on Day 15 or 22
62172826|NCT01837719|EXPERIMENTAL|Treatment E: Atazanavir/Cobicistat FDC|Participants received a single FDC dose of atazanavir, 300 mg/cobicistat, 150 mg, following a high-fat meal on Day 29
62172827|NCT01894256|OTHER|Normal renal function|Patients with calculated serum creatinine clearance ≥81 mL/min (using Cockcroft-Gault equation).
62172828|NCT01894256|OTHER|Mild renal impairment|Patients with calculated serum creatinine clearance 51-80 mL/min (using Cockcroft-Gault equation).
62172829|NCT01894256|OTHER|Moderate renal impairment|Patients with calculated serum creatinine clearance 31-50 mL/min (using Cockcroft-Gault equation).
62172830|NCT05004688|EXPERIMENTAL|BCG|Active BCG immunization
62172831|NCT03113214|EXPERIMENTAL|radiochemotherapy 1|Patients will be treated with radiation therapy 57.2 Gy.
62172832|NCT03113214|EXPERIMENTAL|radiochemotherapy 2|Patients will be treated with radiation therapy 64.4 Gy.
62172833|NCT03113214|EXPERIMENTAL|radiochemotherapy 3|Patients will be treated with radiation therapy 71.6 Gy.
62172834|NCT03113214|EXPERIMENTAL|radiochemotherapy 4|Patients will be treated with radiation therapy 78.8 Gy.
62172835|NCT03113214|EXPERIMENTAL|radiochemotherapy 5|Patients will be treated with radiation therapy 86 Gy.
62172836|NCT03113214|EXPERIMENTAL|radiochemotherapy 6|Patients will be treated with radiation therapy 93.2 Gy.
62172837|NCT02311985|ACTIVE_COMPARATOR|Coagulogram-based protocol|Arm based on standard coagulation tests protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.
62172838|NCT02311985|EXPERIMENTAL|Thromboelastometry-based protocol|Arm based on rotational thromboelastometry (ROTEM(R)) protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.
62172839|NCT02311985|EXPERIMENTAL|Restrictive strategy|Arm based on a restrictive protocol strategy based on INR/PT and platelets count. The possible components to be used include fresh frozen plasma and/or platelets (random or aphaeresis).
62172840|NCT04725617|ACTIVE_COMPARATOR|Health Intervention Approach 1|Subjects randomized into Group 1 will be provided with approach 1, a behavioral health intervention administered by a Clinical Psychologist, in addition to administration of medication (Varenicline), and counseling, during 6 study visits.
62172841|NCT04725617|ACTIVE_COMPARATOR|Health Intervention Approach 2|Subjects randomized into Group 1 will be provided with approach 1, a behavioral health intervention administered by a Clinical Psychologist, in addition to administration of medication (Varenicline), and counseling, during 6 study visits.
62172842|NCT05869149|EXPERIMENTAL|Restaurants receiving FRESH intervention|Restaurants enrolled in the experimental arm of will FRESH undergo activities aimed to improve their healthy food offerings at their restaurants.
62172843|NCT05869149|NO_INTERVENTION|Restaurants not receiving FRESH intervention|Restaurants will be enrolled in the study, but not receive the FRESH intervention.
62172844|NCT05213117|EXPERIMENTAL|Co-localized Residents|Investigators plan to randomize 15 PGY-1 residents in internal medicine from the possible 74 PGY-1 incoming residents who agree to partake in the study, to one general medicine clinical floor for the academic year. These co-localized residents will complete 16-20 weeks of scheduled rotation time on White 9
62172845|NCT05213117|NO_INTERVENTION|Normally Schedule Residents|The control arm will consist of 18 PGY-1 residents who are scheduled by the residency program's algorithm in the usual fashion to complete general medicine rotations on 5 difference clinical floors. The 18 active comparator participants will be selected based on completing one of four general medicine rotation on the control floor White 8. These participants will then be followed while completing the remaining general medicine rotations on all clinical floors.
62172846|NCT05803902|EXPERIMENTAL|9MW1911 Dose 1|9MW1911 injection ( Dose 1) by intravenous injection once on the first day of treatment. 8 subjects will be enrolled, including 2 subjects for placebo administration.
62172847|NCT05803902|EXPERIMENTAL|9MW1911 Dose 2|9MW1911 injection (Dose 2) by intravenous injection once on the first day of treatment. 8 subjects will be enrolled, including 2 subjects for placebo administration.
62172848|NCT05803902|EXPERIMENTAL|9MW1911 Dose 3|9MW1911 injection (Dose 3) by intravenous injection once on the first day of treatment. 8 subjects will be enrolled, including 2 subjects for placebo administration.
62172849|NCT05803902|EXPERIMENTAL|9MW1911 Dose 4|9MW1911 injection (Dose 4) by intravenous injection once on the first day of treatment. 8 subjects will be enrolled, including 2 subjects for placebo administration.
62172850|NCT05803902|EXPERIMENTAL|9MW1911 Dose 5|9MW1911 injection (Dose 5) by intravenous injection once on the first day of treatment. 8 subjects will be enrolled, including 2 subjects for placebo administration.
62172851|NCT05803902|EXPERIMENTAL|9MW1911 Dose 6|9MW1911 injection (Dose 6) by intravenous injection once on the first day of treatment. 8 subjects will be enrolled, including 2 subjects for placebo administration.
62172852|NCT05803902|EXPERIMENTAL|9MW1911 Dose 7|9MW1911 injection (Dose 7) by intravenous injection once on the first day of treatment. 8 subjects will be enrolled, including 2 subjects for placebo administration.
62172853|NCT05803902|EXPERIMENTAL|9MW1911 Dose 8|9MW1911 injection (Dose 8) by intravenous injection once on the first day of treatment. 8 subjects will be enrolled, including 2 subjects for placebo administration.
62172854|NCT00711555|EXPERIMENTAL|Single arm study with Emend|"On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.~FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day."
62172855|NCT05372913|EXPERIMENTAL|W-GenZD Mobile Application Group|Participants assigned to the W-GenZD mobile application group will be asked to download and use the W-GenZD mobile application that will provide information and tools through a chatbot (a computer program designed to communicate with users). Participants will be invited to use the mobile application as often as they like during the 4-week treatment period - we will encourage 5 to 10 minutes of daily use.
62172856|NCT05372913|ACTIVE_COMPARATOR|CBT-Lite Teletherapy Group|Participants assigned to the CBT-lite teletherapy group will be asked to attend 1-hour teletherapy group sessions over Zoom once a week for 4 weeks. In this group, a study clinician will cover topics such as building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.
62172857|NCT02214771||1: CDI in patients treated with fidaxomicin|Diagnosed with a CDI and treated with fidaxomicin
62172858|NCT02214771||2: CDI in patients receiving treatment other than fidaxomicin|Diagnosed with a CDI, regardless of the prescribed treatment (not fidaxomicin)
62172859|NCT02413554|EXPERIMENTAL|Patch applied patients|"The investigators had enrolled consecutively the patients who were going to operation after femur neck fracture.~Participants were applied the 5 unit rivastigmine patches from 3 days before and 7 days after the femur neck operation."
62172860|NCT02413554|NO_INTERVENTION|Patch non-applied patients|The participants who were going to operation after femur neck fracture were not applied the rivastigmine patches.
62182359|NCT02742532|EXPERIMENTAL|Oxytocin|Intra-nasal oxytocin (40 IUs; 5 puffs in each nostril)
62182360|NCT02742532|PLACEBO_COMPARATOR|Placebo|Intra-nasal saline placebo (5 puffs in each nostril)
62182361|NCT06310083|ACTIVE_COMPARATOR|Submucosal Rescetion Turbinoplasty|participants in this group were applied for Endoscopic submucosal resection Turbinoplasty
62172861|NCT06153901|EXPERIMENTAL|endoloop mediated cardioplication (ECLC)|The ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.
62172862|NCT02720198|ACTIVE_COMPARATOR|Levomilnacipran|Levomilnacipran ER is switched from SSRI.
62172863|NCT02720198|ACTIVE_COMPARATOR|Quetiapine|Quetiapine XR is added in addition to current SSRI.
62172864|NCT04557332|EXPERIMENTAL|Mobile app|In this arm, participants received a mobile app to support ART medication adherence.
62172865|NCT04557332|NO_INTERVENTION|Control|In this arm, participants received care as usual.
62172866|NCT01424189|EXPERIMENTAL|ReSTOR Toric IOL|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
62172867|NCT01424189|ACTIVE_COMPARATOR|ReSTOR IOL|AcrySof® ReSTOR® Multifocal IOL Model SA60D3, bilateral implantation
62172868|NCT00993018|EXPERIMENTAL|JNJ-42160443 (1 mg)|JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
62172869|NCT00993018|EXPERIMENTAL|JNJ-42160443 (3 mg)|JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
62172870|NCT00993018|EXPERIMENTAL|JNJ-42160443 (10 mg)|JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
62172871|NCT00993018|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as a single, subcutaneous injection every 28 days for up to 52 weeks.
62172872|NCT06646445|EXPERIMENTAL|Experimental Arm|Pembrolizumab with a watch-and-wait approach
62172873|NCT06646445|ACTIVE_COMPARATOR|Control Arm|Surgical resection ±adjuvant chemotherapy:
62739299|NCT06659302|EXPERIMENTAL|Intro meeting|Participants will be sent baseline questionnaires online through REDCap (Research Electronic Data Capture; see Appendix 1-email templates), a secure web application, and housed on a secure server. Participants will access a unique REDCap survey link via email to complete questionnaire measures after consenting to the study. After completion of the baseline questionnaires, participants will be connected with an I-InTERACT-North therapist for an Introductory Meeting to conduct a baseline elevation session. If participants do not wish to enroll in the full program, post-intervention questionnaires will be administered online through REDCap post step 1. If they wish to proceed to the full program, they will complete the questionnaires after step 2 or 3.
62172874|NCT05783154|NO_INTERVENTION|Control Group (Group-1)|In control group: 42 patients with primary KOA will receive standard conventional care including rehabilitation for knee osteoarthritis.
62172875|NCT05783154|EXPERIMENTAL|Experimental Group (Group-2)|In the interventional group, another 42 patients with primary KOA will receive adipose tissue-derived mesenchymal stem cells (AT-MSCs) injection intra-articularly (Group-2). However, group-2 (Interventional group) will be subdivided into two sub-groups namely group-2a, and group-2b. A total of 21 Participants of group-2a will receive single doses of autologous adipose tissue-derived stem cell (AT-MSCs) and standard conservative care including rehabilitation for KOA. Whereas, group-2b, 21 respondents will receive two doses of autologous adipose tissue-derived stem cell (AT-MSCs) at 3 months intervals along with standard conservative care including rehabilitation for KOA.
62172876|NCT04673799|EXPERIMENTAL|MV088|MV088 injection (60mg) by subcutaneous injection once on the first day
62172877|NCT04673799|ACTIVE_COMPARATOR|Prolia®|Prolia® injection (60mg) by subcutaneous injection once on the first day
62172878|NCT01333683||Control|Normal subjects
62172879|NCT01333683||AH|Arterial hypertension patients
62172880|NCT01829828||Inpatients with cancer pain|Inpatients admitted for cancer pain management
62172881|NCT01451697|EXPERIMENTAL|Experimental: Cognitive Remediation|The remediation intervention will consist of a sequence of computerized cognitive exercises designed to improve a variety of aspects of attention, through repeated drill-and-practice (Bell, Bryson, Greig, Corcoran, \& Wexler, 2001; Bracy, 1995; Kurtz et al., 2007). Exercises will be started and continued at the highest level of difficulty, in order to best establish improvement over time. Components of the planned intervention produce performance gains on practiced tasks (e.g., Wexler et al., 1997) and generalization of improvement to other tasks (Kurtz et al., 2007). All training on computer exercises will be conducted with coaching from staff trained in these procedures.
62172882|NCT01451697|PLACEBO_COMPARATOR|Control (Placebo)|The placebo control condition will consist of structured relaxation training, which will involve viewing and participating with meditation and stress-reduction DVDs, and listening to and following a CD of Progressive Muscle Relaxation. Participants will benefit from learning stress reduction techniques in this condition, but will not exercise any of the cognitive domains of interest targeted in the treatment group.
62172883|NCT03168425|EXPERIMENTAL|Tailored|Participants will be prescribed an opioid based on a formula derived from inpatient opioid use
62172884|NCT03168425|OTHER|Control|Participants will be prescribed 30 tablets of oxycodone 5mg, which is the average prescription currently given to our population.
62172885|NCT04719819||Usual pratice|Assessment of usual practices
62182362|NCT06310083|PLACEBO_COMPARATOR|Partial Inferior Turbinectomy|participants in this group were applied for Partial Inferior Turbinectomy
62182363|NCT03989843||Frozen embryo transfer|Frozen embryo transfer
62182364|NCT03989843||Fresh embryo transfer|Fresh embryo transfer
62172886|NCT02996097|EXPERIMENTAL|CO2 ablative laser plus intralesional triamcinolone acetonide|A topical eutectic mixture of local anesthetics (EMLA) cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
62172887|NCT02996097|ACTIVE_COMPARATOR|Intralesional triamcinolone acetonide alone|A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. The other chosen lesion would be treated with intralesional triamcinolone acetonide alone at 4 week intervals.
62172888|NCT04721132|EXPERIMENTAL|Treatment (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery during week 12.
62172889|NCT00823004|ACTIVE_COMPARATOR|1|A/L: Poor responders who will receive letrozole and GnRH antagonist for ovarian stimulation
62172890|NCT00823004|ACTIVE_COMPARATOR|2|MF: In this arm poor responders are treated by microdose GnRH agonist flare protocol
62172891|NCT05453396|EXPERIMENTAL|Treatment (loncastuximab tesirine)|Patients receive loncastuximab tesirine IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
62172892|NCT03134976||Salvage Larynx|The first group includes subjects with cancer of the voice box (laryngeal squamous cell carcinoma) that has already been treated by either chemotherapy or radiation. This group will be treated using the standard of care, which includes starting thyroid hormone replacement therapy (levothyroxine) after surgery.
62172893|NCT03134976||Non-Salvage Larynx|The second group of subjects will consist of patients who have head and neck cancer of sites other than the voice box (larynx) without prior exposure to radiation or chemotherapy who are undergoing flap reconstruction surgery. This group will not be treated with levothyroxine so long as the subject has normal thyroid function. If a subject is hypothyroid, then thyroid hormone replacement will be given as a part of routine clinical care.
62172894|NCT01608958|ACTIVE_COMPARATOR|IV infusion|Oxytocin 10 IU will be administered IV infusion according to randomization assignment as soon as possible after delivery of the baby.
62172895|NCT01608958|ACTIVE_COMPARATOR|IM Injection|Oxytocin 10 IU will be administered IM according to randomization assignment as soon as possible after delivery of the baby.
62172896|NCT01129115|ACTIVE_COMPARATOR|Nonexercise control group|
62172897|NCT01129115|EXPERIMENTAL|Aerobic Exercise Group 1|
62172898|NCT01129115|EXPERIMENTAL|Aerobic Exercise Group 2|
62172899|NCT01129115|EXPERIMENTAL|Aerobic Exercise Group 3|
62172900|NCT02410317|EXPERIMENTAL|Continuous wound infusion group|Patients receive analgesia through a multiorifice wound catheter connected to ropivacaine infusion. Saline solution is given in the epidural bolus.
62172901|NCT02410317|ACTIVE_COMPARATOR|Epidural morphine group|Patients receive epidural analgesia through an epidural bolus of morphine. Saline solution is perfused through the wound catheter.
62172902|NCT00975364||blood sampling|Consented volunteers provide a one-off blood sample
62172903|NCT06646939|EXPERIMENTAL|Community Reintegration in Simulated Environment|
62172904|NCT04836338||Participants|Anesthesia and emergency medicine providers who perform pediatric orotracheal intubations
62172905|NCT04823117||Music therapy group|Music therapy lasted 30 minutes every day for a total of 20 days.
62172906|NCT04823117||Control group|No treatment given.
62172907|NCT05566002||Patients with pulmonary hypertension|A series of routine examinations, including chest X-ray, electrocardiography, echocardiography, etc, would be performed on consecutive patients at Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. An RHC with an mPAP of \>20 mmHg would confirm the diagnosis of PH. All these data will be collected as a source for machine learning or other artificial intelligence-assisted programs.
62172908|NCT05566002||Patients without pulmonary hypertension|A series of routine examinations, including chest X-ray, electrocardiography, echocardiography, etc, would be performed on consecutive patients at Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. An RHC with an mPAP of ≤20 mmHg would confirm the absence of PH. All these data will be collected as a source for machine learning or other artificial intelligence-assisted programs.
62172909|NCT01797705|EXPERIMENTAL|All subjects|All subjects underwent a sleep study with DeVilbiss AutoAdjust CPAP with revised algorithm simultaneously with hand-scored PSG.
62172910|NCT01213615||all patients eligible for implantation of a Hancock II Ultra|
62172911|NCT03268850|EXPERIMENTAL|LW-A|The Lost Wages A (LW-A) arm will be composed of kidney transplant patients meeting the inclusion criteria. This arm allows for possible wage reimbursement of living donor lost wages up to a certain amount. This will also include standard of care.
62172912|NCT03268850|EXPERIMENTAL|LW-B|The Lost Wages B (LW-B) arm will be composed of kidney transplant patients meeting the inclusion criteria. This arm allows for possible wage reimbursement of living donor lost wages up to a different amount. This will also include standard of care.
62172913|NCT06584643||case group|For every patient, a full history will be taken recording age, gender, education, residence, special habits, age at onset of vitiligo, duration of vitiligo, stability of vitiligo and family history. A detailed cutaneous examination will be performed including skin phototype, Koebner phenomenon, vitiligo clinical type, leukotrichia, Vitiligo Area Severity Index (VASI) and Vitiligo Disease Activity (VIDA) scores.
62172914|NCT06584643||healthy control|age and gender matched healthy volunteers as controls
62172915|NCT03189641|EXPERIMENTAL|Cilostazol eluting stent system (CES-1)|
62172916|NCT01363297|EXPERIMENTAL|Inotuzumab Ozogamicin|
62172917|NCT04547166|EXPERIMENTAL|Serplulima +Bevacizumab+XELOX|Serplulimab (HLX10) in Combination With Bevacizumab and chemotherapy (XELOX)
62172918|NCT04547166|PLACEBO_COMPARATOR|placebo + Bevacizumab+XELOX|placebo in combination with Bevacizumab and chemotherapy (XELOX)
62172919|NCT03659890|PLACEBO_COMPARATOR|Low nucleotide|2 week supplementation with a low nucleotide mycoprotein drink, with added dextrose
62172920|NCT03659890|EXPERIMENTAL|High nucleotide|2 week supplementation with a high nucleotide mycoprotein drink, with added dextrose
62172921|NCT03659890|EXPERIMENTAL|High nucletide + Ribose|2 week supplementation with a high nucleotide mycoprotein drink, with added ribose
62172922|NCT04238871||children or adults with Idiopathic Lung Disease|
62172923|NCT01414543|OTHER|providing information sheet|providing participants with information regarding the purpose of the research
62172924|NCT01414543|OTHER|Seeking consent|
62172925|NCT01414543|OTHER|Interview Participant|
62172926|NCT01414543|OTHER|Debrief|The Participants will be debriefed after the interview.
62172927|NCT06647316|EXPERIMENTAL|Intervention Group: Physiotherapy for Emotional Well-Being|The subjects will receive a minimum of four physiotherapy sessions in the various units where they are currently undergoing treatment. The treatment will be tailored to the specific pathology of each patient, in accordance with medical guidelines.
62172928|NCT03445507|EXPERIMENTAL|Intervention|Use of an evidence-based chat bot for smoking cessation
62172929|NCT03445507|ACTIVE_COMPARATOR|Control|Usual care (Madrid Health System Portfolio).
62172930|NCT02541799|EXPERIMENTAL|Telemedicine|Participants allocated to this arm will be approached the using a telemedicine medium to discuss study participation. The consent form will be administered while the investigator is on a telemedicine link.
62172931|NCT02541799|ACTIVE_COMPARATOR|Standard Care|Participants allocated to this arm will be approached in standard fashion where the investigator approaches the patient face to face. The consent form will be administered while the investigator is in the participant's room.
62172932|NCT00694564|EXPERIMENTAL|Treatment|This an open-labeled study. All participants will be part of the treatment group and receive SAM-e. S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
62172933|NCT04664985|ACTIVE_COMPARATOR|Mucogyne®|The dosage during the study will be 1 Mucogyne® ovule per day at bedtime for 10 days and then 1 ovule every 2 days until the end of the 3-month follow-up.
62172934|NCT04664985|NO_INTERVENTION|Control|No treatment for this arm.
62172935|NCT01733082||Cohort|
62172936|NCT05359705|EXPERIMENTAL|Healthy subjects|Healthy subjects who meet the Inclusion/Exclusion.
62172937|NCT05335239|EXPERIMENTAL|Intervention group|Every third month, a dental nurse will visit at home and deliver professional dental cleaning and delivery of one new toothbrush and fluoride toothpaste (\>4000ppm) (n:3) for the next three months. The visit is expected to take at the most 30 minutes.
62172938|NCT05335239|NO_INTERVENTION|Controll group|Continuous with oral care as usual, either by themselves or nursing assisted (help with oral hygiene procedure) during the whole study period. Home care aides working with the control study participants deliver a toothbrush and fluoride toothpaste (\> 4000 ppm) (n:3) every third month during the study period.
62172939|NCT03045055|EXPERIMENTAL|RIC group|RIC (remote ischemic conditioning) paired with endovascular treatment.
62172940|NCT03045055|SHAM_COMPARATOR|Sham group|Sham RIC (remote ischemic conditioning) paired with endovascular treatment.
62172941|NCT01276509|PLACEBO_COMPARATOR|Placebo-SC Injection|Placebo delivered SC, 3 doses separated by 4 weeks.
62172942|NCT01276509|EXPERIMENTAL|Drug Dose level 1- SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks.
62172943|NCT01276509|EXPERIMENTAL|Drug Dose level 2-SC injection|Drug dose level 2 delievered SC, 3 doses separated by 4 weeks.
62172944|NCT01276509|EXPERIMENTAL|Drug Dose level 3- SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks.
62172945|NCT00945178|EXPERIMENTAL|Part A: A|AZD1386
62172946|NCT00945178|EXPERIMENTAL|Part A: B|Placebo for AZD1386
62172947|NCT00945178|EXPERIMENTAL|Part B: A|Naproxen
62172948|NCT00945178|EXPERIMENTAL|Part B: B|Placebo for Naproxen
62172949|NCT01960114|EXPERIMENTAL|Acetaminophen ER|
62172950|NCT01960114|PLACEBO_COMPARATOR|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
62172951|NCT01184859|EXPERIMENTAL|Desmopressin 10µg|Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.
62172952|NCT01184859|EXPERIMENTAL|Desmopressin 25µg|Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.
62172953|NCT01184859|EXPERIMENTAL|Desmopressin 50µg|Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.
62172954|NCT01184859|EXPERIMENTAL|Desmopressin 100µg|Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.
62172955|NCT01184859|PLACEBO_COMPARATOR|Placebo|Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.
62172956|NCT02264418|EXPERIMENTAL|ODM 203|Oral capsules given once daily dosage 50-800mg
62172957|NCT02264418|EXPERIMENTAL|ODM-203|Oral tablets given once daily 200-1600mg
62172958|NCT04483791|OTHER|DynamX Novolimus Eluting Coronary Bioadaptor System|DynamX use in de novo coronary artery lesions
62172959|NCT02728375|EXPERIMENTAL|Computer gaming hand exercise regimen|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 45 minutes,three times per week for sixteen weeks
62172960|NCT02728375|ACTIVE_COMPARATOR|Conventional hand exercise program|Exercises targeted to improve finger range of motion and hand strength. The exercises will be performed 45 minutes, three times per week for sixteen weeks
62172961|NCT02646189|EXPERIMENTAL|REP 2139-Ca + immunotherapy|"REP 2139-Ca is the calcium chelate complex formulation of REP 2139.~Zadaxin is thymosin alpha 1~Pegasys is pegylated interferon alpha 2a~Patients initially receiving REP 2139-Ca with no Grade 3 adverse events at week 20 are eligible to transition to combination therapy with Zadaxin if serum HBV DNA is \> 2000 copies / ml.~After 10 weeks of REP 2139-Ca / Zadaxin combination therapy, patients not experiencing a measurable improvement in serum antiviral response can further transition to combination therapy with REP 2139-Ca and Pegasys."
62172962|NCT01073215|ACTIVE_COMPARATOR|Group Condition|
62172963|NCT01073215|EXPERIMENTAL|Self-Guided Condition|
62172964|NCT02966418|ACTIVE_COMPARATOR|Mild hypoxia preconditioning|Patients will be treated with mild hypoxia (Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%) before surgery.
62172965|NCT02966418|SHAM_COMPARATOR|Sham preconditioning|Patients will be treated with sham preconditioning (oxygen concentration: 21％) before surgery.
62172966|NCT04499014|EXPERIMENTAL|ultrasound|ultrasound : a frequency of 1 MHz and an intensity of 1 W/cm2, 5 days a week, a total of 10 sessions
62172967|NCT04499014|EXPERIMENTAL|phonophoresis|an intensity of 1 W/cm2 and a frequency of 1 MHz and phonophoresis with 0.1% dexamethasone pomade,5 days a week, a total of 10 sessions
62172968|NCT04499014|PLACEBO_COMPARATOR|placebo ultrasound|same ultrasound device as described above seemed to be working but without delivering any output, 5 days a week, a total of 10 sessions
62172969|NCT01393613|EXPERIMENTAL|Dose 3 OPC 34712|Higher dose, tablet, once daily, for six weeks
62172970|NCT01393613|EXPERIMENTAL|Dose 2 OPC 34712|Middle dose, tablet, once daily, for six weeks
62172971|NCT01393613|EXPERIMENTAL|Dose 1 OPC 34712|Lower dose, tablet, once daily, for six weeks
62172972|NCT01393613|PLACEBO_COMPARATOR|Placebo|Placebo, once daily, for six weeks
62172973|NCT01774461|NO_INTERVENTION|Sham RIC|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
62172974|NCT01774461|ACTIVE_COMPARATOR|Remote ischemic conditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
62172975|NCT00983424|EXPERIMENTAL|Treatment arm|Cyclosporine A + nab-paclitaxel
62172976|NCT01533064||Psychiatric Outpatients|
62172977|NCT05498077|EXPERIMENTAL|10 minute body scan meditation|Participants will be taken through a 10 minute body scan meditation by a physical therapist
62172978|NCT03326050|PLACEBO_COMPARATOR|gemifloxacin and Rifampicin|first group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once dailygroup will be given the usual regimen given for free by the Ministry of Health in Egypt; Rifampicin 300 mg twice daily for three months..
62172979|NCT03326050|PLACEBO_COMPARATOR|gemifloxacin and ciprofloxacin|. group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once daily group will be given a short course (four weeks) of oral Ciprofloxacin 750 mg twice daily
62172980|NCT03326050|PLACEBO_COMPARATOR|gemifloxacin and placipo|.group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once daily
62172981|NCT05317377|ACTIVE_COMPARATOR|Structured Exercise|Structured hand exercises will be applied in 45-minute sessions (16 sessions total), 2 days a week, over 8 weeks in addition to participants' routine physical activities.
62172982|NCT05317377|EXPERIMENTAL|Leap Motion Based Exergame (LMBE)|"ErgoActive and HandROM exercise apps focusing on hand exercises and fine motor skills will be applied in 45-minute session (16 sessions total), 2 days a week, over 8 weeks in addition to participants' routine physical activities."
62172983|NCT05067543||Tornier Perform Humeral System - Stem|Partial or total shoulder arthroplasty using the Tornier Perform Humeral Stem.
62172984|NCT04682340||Hashimoto's Group|Thyroid antibody positive and hypothyroidism
62172985|NCT04682340||Graves' Group|Thyroid antibody positive and hyperthyroidism
62172986|NCT04682340||Control Group|Thyroid antibody negative and euthyroidism
62172987|NCT05642247||CD patients who received Ustekinumab treatment|1. Inpatients with Crohn's disease diagnosed in the Sixth Affiliated Hospital of Sun Yat-Sen University from January 2020 to June 2022. 2.The patients were treated with Ustekinumab and followed up regularly for 20 weeks. 3. Complete pre-treatment cross-sectional imaging data (CTE/MRE and US)
62172988|NCT03974100|EXPERIMENTAL|GP2411|60 mg /mL subcutaneous injection every 6 months
62172989|NCT03974100|ACTIVE_COMPARATOR|EU authorized Prolia|60 mg /mL subcutaneous injection every 6 months
62172990|NCT05376787||Healthy Subjects|Participants must be willing to comply with all study procedures Participants must be willing to shave, or to have shaved, the sites where the neutral electrodes will be placed.
62391447|NCT05450380|EXPERIMENTAL|Experimental: LIFT001|"LIFT001 is composed by sodium hyaluronate at concentration of 2,5% (25 mg/ml) with 1,4-Butanediol diglycidyl ether (BDDE) acting as a cross-linking agent, in aqueous solution at physiological pH. The filler of 1ml is administered once or twice depending on the individual necessity.~The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face."
62391448|NCT02789566|EXPERIMENTAL|Regimen|Primaquine (PQ) 30 mg base single dose
62172991|NCT03412513|ACTIVE_COMPARATOR|Mirabegron|1:1 randomization to receive Mirabegron 50mg daily or placebo at visit 2. At visit 4 all subjects will receive Mirabegron 50mg.
62172992|NCT03412513|PLACEBO_COMPARATOR|Placebo|1:1 randomization to receive Mirabegron 50mg daily or placebo at visit 2. At visit 4 all subjects will receive Mirabegron 50mg.
62172993|NCT04064723|ACTIVE_COMPARATOR|Stem components|Randomization between two stem components. LCU or Corail stem.
62172994|NCT04064723|ACTIVE_COMPARATOR|Cup components|Randomization between two cup components. DeltaTT or Pinnacle cup.
62172995|NCT05590806|EXPERIMENTAL|Arm 1|Restoration
62172996|NCT05590806|EXPERIMENTAL|Arm 2|Evaluate
62172997|NCT01177137|EXPERIMENTAL|TRT|TRT includes treatment with a conventional sound generator (SG) and directive counseling (DC)
62172998|NCT01177137|OTHER|Partial TRT|Partial TRT includes treatment with a placebo sound generator (placebo SG) and directive counseling (DC).
62172999|NCT01177137|OTHER|Standard of Care (SC)|The standard of care arm includes care as typically delivered in US military medical centers
62173000|NCT05180487|EXPERIMENTAL|FCU Online + Coach|Parents in this arm will receive access to the FCU Online website and telehealth coaching/ support provided by a trained mental health provider. The FCU Online website includes a brief 5-minute assessment, feedback on parents' responses, and online tools to support parenting in areas that were identified as challenges by the assessment. These tools include animated videos, parenting tips, and interactives to help practice parenting skills. Telehealth coaching will focus on Wellness and Self-Care, Parenting and Substance Use, Positive Parenting, Proactive Parenting, and Supervision and Limit Setting.
62173001|NCT05180487|NO_INTERVENTION|Waitlist Control|Parents in this arm will initially serve as the control group but will receive access to the FCU Online website and telehealth coaching after completing four waves of data collection (baseline, 3-mo, 6-mo, and 12-mo follow-up).
62173002|NCT03578419|ACTIVE_COMPARATOR|Control Period|Standard-Volume Blood Collection Tubes
62173003|NCT03578419|EXPERIMENTAL|Intervention Period|"Small-Volume Blood Collection Tubes (soft-draw)"
62173004|NCT01930877|ACTIVE_COMPARATOR|Lidocaine|Intravenous Lidocaine bolus of 1.5 mg/kg followed by infusion of 1.5 mg/kg/hr
62173005|NCT01930877|PLACEBO_COMPARATOR|Placebo|Normal saline placebo infusion
62173006|NCT02971995|EXPERIMENTAL|Prostate cancer/TEP scan|
62173007|NCT02971995|ACTIVE_COMPARATOR|Prostate cancer/mpMRI|
62173008|NCT01537900|EXPERIMENTAL|Grazoprevir 100 mg|Participants received GZR 100 mg once daily (q.d.) for 7 days. Liver FNA was performed on Day 7.
62173009|NCT03440697||Aortopathy- Closed to external enrollment|Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography)
62173010|NCT03440697||Syndromic- Open to external enrollment|"Subjects with a genetic diagnosis of Marfan Syndrome (MFS), Loeys-Dietz Syndrome (LDS), Vascular Ehlers-Danlos Syndrome (EDS)~•positive genetic testing and/or a previous cardiac study required to be eligible"
62173011|NCT03440697||Aortopathy with Positive Genetic Results- Open to Enrollment|Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography) who also have positive genetic testing results related to aortopathy.
62173012|NCT03440697||Aortic Valve Disease- Closed to enrollment|Subjects with aortic valve disease (bicuspid, unicuspid, or tricuspid disease)
62173013|NCT03440697||Family Members- Open to external enrollment|"Family members of eligible subjects~•Only family members of subjects with syndromic diagnoses are eligible for external enrollment at this time"
62173014|NCT03440697||Controls- Closed to external enrollment|Control subjects having tissue removed during a surgical procedure (e.g. coronary artery bypass graft surgery (CABG), cardiac transplant, etc.)
62173015|NCT05833776|EXPERIMENTAL|group F|received spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with fentanyl (25ug)
62173016|NCT05833776|EXPERIMENTAL|group I|group I (30 patients) received spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with IPACK Block using plain bupivacaine 0.5% (15ml).
62173017|NCT03517059||PD patients|30 PD patients in ON and OFF levodopa conditions
62173018|NCT03517059||Healthy control subjects|30 age matched healthy control subjects
62173019|NCT03517059||Neurological control subjects|10 patients with defined supra nuclear palsy
62173020|NCT06194318|EXPERIMENTAL|group 1 (SCB-1019 90µg with Alum; young adults)|4 young adults (18-59 years old) will receive low dose SCB-1019 (90µg, with Alum) at Day 1
62173021|NCT06194318|PLACEBO_COMPARATOR|group 2 (Placebo; young adults)|2 young adults (18-59 years old) will receive Placebo at Day 1
62173022|NCT06194318|EXPERIMENTAL|group 3 (SCB-1019 360µg with Alum; young adults)|4 young adults (18-59 years old) will receive high dose SCB-1019 (360µg, with Alum) at Day 1
62363889|NCT04260672|NO_INTERVENTION|usual care|Usual care for preschool children identified with overweight and obesity Usual care is performed according to national guidelines that invites all 4-year-olds to a '4-years health visit' including a health conversation. A survey on usual care in the case of identified overweight initial to this study among almost all nurses working at the participating CHCs showed that two thirds of questioned CHS-nurses used to invite families in which the child is identified with overweight for 1 or 2 extra visits outside the usual program. The majority o referred children to a dietician, or to another caregiver. All children invites to their regular 5-yrs health visit.
62173023|NCT06194318|PLACEBO_COMPARATOR|group 4 (Placebo; young adults)|2 young adults (18-59 years old) will receive Placebo at Day 1
62173024|NCT06194318|EXPERIMENTAL|group 5 (SCB-1019 90µg without Alum; older adults)|10 older adults (60-85 years old) will receive low dose SCB-1019 (90µg, without Alum) at Day 1
62173025|NCT06194318|EXPERIMENTAL|group 6 (SCB-1019 90µg with Alum; older adults)|10 older adults (60-85 years old) will receive low dose SCB-1019 (90µg, with Alum) at Day 1
62173026|NCT06194318|PLACEBO_COMPARATOR|group 7 (Placebo; older adults)|4 older adults (60-85 years old) will receive Placebo at Day 1
62173027|NCT06194318|EXPERIMENTAL|group 8 (SCB-1019 360µg without Alum; older adults)|10 older adults (60-85 years old) will receive high dose SCB-1019 (360µg, without Alum) at Day 1
62173028|NCT06194318|EXPERIMENTAL|group 9 (SCB-1019 360µg with Alum; older adults)|10 older adults (60-85 years old) will receive high dose SCB-1019 (360µg, with Alum) at Day 1
62173029|NCT06194318|PLACEBO_COMPARATOR|group 10 (Placebo; older adults)|4 older adults (60-85 years old) will receive Placebo at Day 1
62173030|NCT05122052||Women with cancer|Patients with cancer of any site and stage defined as feminine both from the biological (female sex) and psychosocial point of view (feminine gender)
62173031|NCT05122052||Men with cancer|Patients with cancer of any site and stage defined as masculine both from the biological (male sex) and psychosocial point of view (masculine gender)
62173032|NCT02186496|EXPERIMENTAL|Candesartan and Amlodipine|Candesartan 8mg and Amlodipine 5mg, PO, 1days or 22days
62173033|NCT02186496|EXPERIMENTAL|CKD-330|CKD-330 8/5mg, PO, 1days or 22days
62173034|NCT03039647||Entry Point IR (SSPG, HOMA-IR)|All subjects will undergo baseline indirect (HOMA-IR) and direct (SSPG) measures of IR. The investigators hypothesize that a higher entry point IR will predict steeper decline in memory and executive function performance and hippocampal connectivity.
62173035|NCT03039647||Change in IR (HOMA-IR)|The investigators predict that change in IR (as measured by HOMA-IR) will predict the pattern of decline in memory and executive function performance and hippocampal connectivity.
62173036|NCT03528109|EXPERIMENTAL|patient-centered home CBT|60 minute office-based exposure therapy with a PhD psychologist once per month and a 90 minute community-based CBT with a mobile exposure coach three times per month for a total of four visits per month (once per week)
62173037|NCT03528109|ACTIVE_COMPARATOR|Provider-centered|60 minute office-based exposure therapy with a PhD psychologist four times per month (once per week)
62173038|NCT03528109|EXPERIMENTAL|patient-centered telehealth CBT|60 minute telehealth exposure therapy with a PhD psychologist once per month and a 90 minute telehealth CBT with a mobile exposure coach three times per month for a total of four visits per month (once per week). Patient-centered telehealth was closed when the recruitment goal was met in May 2021.
62173039|NCT03705533|OTHER|Sequence ABAB|Subjects assigned to sequence ABAB will receive a single 80 mg dose of the test product Telmisartan (1 x 80 mg tablet) marked as A in the sequence in Periods 1 and 3 and a single 80 mg dose of the reference product Micardis (1 x 80 mg tablet) marked as B in the sequence in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62173040|NCT03705533|OTHER|Sequence BABA|Subjects assigned to sequence BABA will receive a single 80 mg dose of the reference product Micardis (1 x 80 mg tablet) marked as B in the sequence in periods 1 and 3 and a single 80 mg dose of the test product Telmisartan (1 x 80 mg tablet) marked as A in the sequence in Periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62173041|NCT00141908|PLACEBO_COMPARATOR|Placebo progesterone injection|Placebo IM injections
62173042|NCT00141908|ACTIVE_COMPARATOR|Progesterone injections|17-hydroxyprogesterone caproate weekly injections
62173043|NCT04012099|EXPERIMENTAL|BMT101|BMT101 injection (treatment)
62173044|NCT04012099|NO_INTERVENTION|control|Un-treated control
62173045|NCT02004132|EXPERIMENTAL|Axiron|Axiron administered topically via metered dose pump to each underarm on Day 1
62173046|NCT00123435|ACTIVE_COMPARATOR|Arm 1|5-session nutritional counseling program
62173047|NCT00123435|EXPERIMENTAL|Arm 2|5-session nutritional counseling program + simple pedometer feedback
62173048|NCT00123435|EXPERIMENTAL|Arm 3|5-session nutritional counseling program + simple pedometer feedback + enhanced pedometer feedback web-based feedback
62173049|NCT01763346|ACTIVE_COMPARATOR|metformin|subjects receiving metformin
62173050|NCT01763346|EXPERIMENTAL|gastric banding|subjects receiving LAP-BAND
62173051|NCT02515526|ACTIVE_COMPARATOR|Reference|A cocktail of six different test substances to be administered orally followed by an I.V. dose of midzolam
62173052|NCT02515526|EXPERIMENTAL|Test|A cocktail of six different test substances to be administered orally followed by an I.V. dose of midzolam. In addition, ethanol will be administered at six different time points with of reaching a blood alcohol concentration of 1 per mille to see its effect on the activity of major cytochrome P450 enzymes, NAT-2 and P-glycoprotein.
62173053|NCT02735798|EXPERIMENTAL|Single Arm Study - Arm 1|10 patients will receive standard imaging at baseline, incl. FDG-PET/CT plus MR brain imaging. Patients will subsequently start protocol therapy with MM-302 and trastuzumab given on day 1 of an every 21-day dosing cycle, at recommended phase 2 dose of 30 mg/m2. Patients will receive 64Cu-labeled MM-302 (3-5 mg/m2 doxorubicin) 3 hours after unlabeled dose of MM-302. Integrated MR/PET imaging of brain and whole body will be performed at 2 time points following 64Cu-labeled MM-302 administration: (1) within 3 hours (+/- 1 hour) of labeled drug injection, and (2) 24 hours (+/- 6 hours) post-injection. Patients will continue to receive doses of unlabeled MM-302 plus trastuzumab every 3 weeks until clinical or radiographic disease progression (in brain or systemically) or unacceptable toxicity, whichever occurs soonest. MRI and FDG-PET/CT scans will be performed every 9 weeks to monitor for treatment response and disease progression.
62173054|NCT05211453|ACTIVE_COMPARATOR|Right sided atrioventricular node ablation|Right sided atrioventricular node ablation
62173055|NCT05211453|ACTIVE_COMPARATOR|Left sided atrioventricular node ablation|Left sided atrioventricular node ablation
62173056|NCT02452125|EXPERIMENTAL|Nicotine Gum|Nicotine chewing gum administered for 30 minutes
62173057|NCT01705951|EXPERIMENTAL|Group 1: Resistance Training/Nicotine Replacement|
62173058|NCT01705951|EXPERIMENTAL|Group 2: Resistance Training only|
62173059|NCT01705951|EXPERIMENTAL|Group 3: Nicotine Replacement Therapy only|
62173060|NCT01705951|NO_INTERVENTION|Group 4: Control; no RT and no NRT|
62173061|NCT04668534|EXPERIMENTAL|Treatment group 1|"Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi'an Bashui Health Technology Co., Ltd) at left tragus. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)."
62173062|NCT04668534|EXPERIMENTAL|Treatment group 2|"Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi'an Bashui Health Technology Co., Ltd) at left tragus. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)."
62173063|NCT04668534|ACTIVE_COMPARATOR|Control group|"Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi'an Bashui Health Technology Co., Ltd) at left earlobe. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)."
62173064|NCT01259440|ACTIVE_COMPARATOR|Video Teleconferencing Care|Video teleconferencing care
62173065|NCT01259440|PLACEBO_COMPARATOR|Usual Care|Usual Care
62173066|NCT01095601|OTHER|Treatment A|2x100 mg Formulation II avanafil tablet, fasted
62173067|NCT01095601|OTHER|Treatment B|2x100 mg Formulation II avanafil tablet, fed
62173068|NCT01095601|OTHER|Treatment C|2x100 mg Formulation I avanafil tablet, fasted
62173069|NCT01095601|OTHER|Treatment D|1x50 mg Formulation II avanafil tablet, fasted
62173070|NCT03565640|ACTIVE_COMPARATOR|Capio Slim Device|Participants will be randomized to the sacrospinous ligament fixation with use of Capio Slim Device
62173071|NCT03565640|EXPERIMENTAL|Anchorsure Device|Participants will be randomized to the sacrospinous ligament fixation with use of Anchorsure Device
62173072|NCT05655234|EXPERIMENTAL|Participants receiving the MB programme|"Participants receiving the MB programme:~meditative breathing; breathing while listening to music; drawing of a mental image while breathing; and processing and sharing of the experience. home practice"
62173073|NCT05655234|PLACEBO_COMPARATOR|Participants receiving the control condition|"Mental health education programme:~breathing exercise; stress reduction talk"
62173074|NCT04397614|EXPERIMENTAL|No Elevated Risk for COVID-19 Detected|Continue daily mHealth assessments
62173075|NCT04397614|EXPERIMENTAL|Elevated Risk for COVID-19 Detected|Daily mHealth assessments and telemedicine/nurse triage. If non-emergent intervention, enhanced symptom monitoring will occur.
62173076|NCT01995318|PLACEBO_COMPARATOR|Elastic bandage|Elastic bandage application as one of routine treatment choice of acute ankle sprains.
62173077|NCT01995318|OTHER|Kinesiotaping|Application of anti-edema kinesiotaping
62173078|NCT01260142|EXPERIMENTAL|Arm 1|
62173079|NCT01260142|EXPERIMENTAL|Arm 2|
62173080|NCT01260142|EXPERIMENTAL|Arm 3|
62173081|NCT00024102|ACTIVE_COMPARATOR|Standard Chemotherapy|"Patient/Physician choice of cyclophosphamide + MTX + 5-FU~OR~Cyclophosphamide + doxorubicin"
62173082|NCT00024102|EXPERIMENTAL|Capecitabine|Treatment with capecitabine
62173083|NCT06280118|NO_INTERVENTION|Pre-test (Control group)|
62173084|NCT06280118|NO_INTERVENTION|Post test (Control group)|
62173085|NCT06280118|NO_INTERVENTION|Pre test (experimental group)|
62173086|NCT06280118|EXPERIMENTAL|Post test (experimental group)|
62173087|NCT02702739|ACTIVE_COMPARATOR|Group I (<65 years)|Group I treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
62173088|NCT02702739|ACTIVE_COMPARATOR|Group II (>65 years)|Group II treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
62173089|NCT01880944||ER-spine trauma|patients with spinal trauma, who initially visits in emergency room
62173090|NCT01880944||OUT-spine trauma|patients with spinal trauma, who initially visits in outpatient clinic
62173091|NCT04168021|NO_INTERVENTION|Group 90 individuals, baseline assessment before intervention|Baseline Cognitive status assessment
62173092|NCT04168021|EXPERIMENTAL|Remote ischemic condition of the brain|Intermittent claudication induction on a daily basis for 1 month
62173093|NCT04168021|NO_INTERVENTION|Late cognitive assessment|Late cognitive status assessment 6 months later
62173094|NCT04679597||total neoadjuvant therapy|Total neoadjuvant therapy consisted of 12 weeks of induction chemotherapy with CAPOX or FOLFOX, chemoradiotherapy with capecitabine and six to eight weeks of consolidation chemotherapy with CAPOX or FOLFOX prior to surgery.
62173095|NCT04679597||standard therapy|Standard therapy (neoadjuvant chemoradiotherapy, surgery, adjuvant chemotherapy)
62173096|NCT01245803|EXPERIMENTAL|rosuvastatin,one month,lipid lowering|additional rosuvastatin(10mg) is given at 18hr and 4-6hr before PCI
62173097|NCT01245803|PLACEBO_COMPARATOR|sugar pill, one month|sugar pill is given 18-24hr and 4-6hr before PCI as control
62173098|NCT00553605|ACTIVE_COMPARATOR|I|Ketoprofen plus placebo parecoxib
62173099|NCT00553605|ACTIVE_COMPARATOR|II|Parecoxib plus placebo ketoprofen
62173100|NCT04486079|EXPERIMENTAL|Carbohyrate loading|Group A will receive 400ml of the carbohydrate rich drink, Nutricia preOp 2 hours before operation. This is the intervention group.
62173101|NCT04486079|NO_INTERVENTION|Fasting|Group B will be prepared before the operation with a 24-hour fasting. This is the current clinical standard.
62173102|NCT05130502|EXPERIMENTAL|Foam roller|Individuals perform Foam roller on bilateral legs and the muscles include Quadriceps, hamstring and gastrocnemius and soleus with a dynamic warm up program The investigators conduct the test for 2 sets and 60 seconds with 30 seconds rest period per muscle
62173103|NCT05130502|ACTIVE_COMPARATOR|Kinesiotape|Individuals perform Kinesiotape on bilateral legs and the muscles include Quadriceps, hamstring and gastrocnemius and soleus with a dynamic warm up program The investigators conduct the kinesiotape per muscle and will wait for 45 minutes for bring out the effects.
61997419|NCT03063996|OTHER|Standard of Care (peripheral IV access)|Patient with a history of difficult access or a patient that currently has difficult peripheral IV access.
62173104|NCT02759276||Resistant Hypertension (RH)|uncontrolled hypertension, with values ≥140/90 mmHg, using three or more antihypertensive drugs of different classes, including a diuretic, or controlled hypertension with four or more drugs.
62173105|NCT02759276||Stages 1 and 2 Hypertension (MMH)|According to the VI Brazilian Guidelines of hypertension, with blood pressure levels ranging from 140/90 mmHg to 179/109 mmHg, with up to two antihypertensive drugs of different classes and blood pressure levels controlled in the last two months.
62173106|NCT02759276||Normotensive (CG)|Blood Pressure \<140/90 mmHg and without comorbidities.
62173107|NCT04117906|EXPERIMENTAL|STAGE course|
62173108|NCT04117906|NO_INTERVENTION|Wait-list control|The wait-list control group will receive access to the STAGE course after the trial is complete.
62173109|NCT05501496|OTHER|Casting|Displaced fracture will be treated with closed reduction and long leg cast under general anesthesia
62173110|NCT05501496|ACTIVE_COMPARATOR|intramedullary nailing|Displaced fracture will be treated with closed or open reduction and flexible intramedullary nailing
62173111|NCT03965221|EXPERIMENTAL|LYNX|LYNX is developed using IMB model and engages youth through entering sexual diary data, earning badges, and calculating a personalized sexual protection (Sex Pro) score, which informs and motivates youth around HIV/STI testing and PrEP uptake. Behavioral skills are built through HIV/STI testing reminders, presenting options for home HIV testing and/or linkage to nearby testing services, and access to an online chat with support for HIV/STI testing and PrEP referral.
62173112|NCT03965221|EXPERIMENTAL|MyChoices|"MyChoices is adapted from an app for adult MSM, HealthMindr, developed using SCT. The app aims to increase HIV testing and PrEP uptake by increasing self- regulation, self-reflection, and self-efficacy around HIV testing and PrEP uptake. Brief surveys about sexual risk and protective health behaviors within the app are used to assist users in tracking and self-monitoring their behaviors and creating a personalized HIV testing plan. Quizzes, videos and infographics as well as Help me Choose, Ordering, and geofencing functions are used to maximize self-efficacy around HIV prevention and uptake of PrEP."
62173113|NCT03965221|NO_INTERVENTION|Standard of Care|Provision of referrals to local HIV/STI testing and PrEP resources.
62173114|NCT05753241||healthy group (HG)|Participants were grouped according to their basic conditions without any intervention
62173115|NCT05753241||allergen immunotherapy group (AIT)|Participants were grouped according to their basic conditions without any intervention
62173116|NCT05753241||allergic rhinitis group (ARG)|Participants were grouped according to their basic conditions without any intervention
62173117|NCT03436030|EXPERIMENTAL|Single arm, breathing manuevers|All subjects perform/undergo Valsalva, Muller, CPAP, hand grip, and passive leg raise, with ultrasound examination of heart recorded before and during the manoeuvre.
62173118|NCT02223507|EXPERIMENTAL|BIIR 561 CL|
62173119|NCT02223507|PLACEBO_COMPARATOR|Placebo|
62173120|NCT06645860|EXPERIMENTAL|Silver Diamine Fluoride+Potassium Iodide+Led Light|Following the silver diamine fluoride and potassium iodide application, LED light will be applied for 20 seconds.
62173121|NCT06645860|OTHER|Silver Diamine Fluoride(Control)|Only silver diamine fluoride and potassium iodide solution will be applied.
62173122|NCT04873297|EXPERIMENTAL|Metoclopramide Group|One group will be given metoclopramide 10mg TDS
62173123|NCT04873297|PLACEBO_COMPARATOR|Placebo Group|This group will be given placebo (normal saline 10ml via NG TDS)
62173124|NCT00613132|EXPERIMENTAL|1|Pts receiving EIACDs
62173125|NCT00613132|EXPERIMENTAL|2|Pts not receiving EIACDs
62173126|NCT00961610||Internet support group Intervention|
62173127|NCT00961610||Control group|
62173128|NCT00168714||Pregnant participants|Pregnant participants who were exposed to Avonex within approximately 1 week of conception or during the first trimester of pregnancy
62173129|NCT05610943|ACTIVE_COMPARATOR|quadratus lumborum nerve block|In Group Q; The patient was placed in the lateral position with the side to be blocked on top. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed transversely between the iliac crest and the costa edge. After imaging the external-internal oblique and transversus abdominis muscles, the probe was advanced posteriorly. Quadratus lumborum, Psoas Major and Erector Spina muscles were visualized. The needle was advanced towards the middle thoracolumbar fascia between the Quadratus lumborum muscle and the Erector Spina muscle with the in-plane technique, and the location was confirmed by injecting 1 ml of 0.9 saline. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
62173130|NCT05610943|ACTIVE_COMPARATOR|Ilioinguinal Iliohypogastric Nerve Block|In Group I; The patient was placed in the supine position. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed on the anterior abdominal wall parallel to the imaginary line between the umbilicus and the anterior superior iliac wing. After imaging the external-internal oblique and transversus abdominis muscles, the ilioinguinal-iliohypogastric nerve was visualized as two small hypoechoic areas between the internal oblique muscle and the transversus abdominis muscle. The location was confirmed by injecting 1 ml of 0.9 saline by advancing the needle with the in-plane technique close to the nerve structures. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
62173131|NCT04750577|PLACEBO_COMPARATOR|Placebo|
62173132|NCT04750577|EXPERIMENTAL|BI 685509 1 mg TID|
62173133|NCT04750577|EXPERIMENTAL|BI 685509 2 mg TID|Low dose followed by up-titration to medium dose.
62173134|NCT04750577|EXPERIMENTAL|BI 685509 3 mg TID|Low dose followed by up-titration to medium dose, followed by up-titration to high-dose.
62173135|NCT03415347|ACTIVE_COMPARATOR|Abscess de-roofing and curettage|Abscess de-roofing and curettage. The patient will be placed in the lateral position with the buttocks spread apart using tape. The cleft of the buttocks will be shaved prior to cleaning and preparation of the skin. A spindle-shaped (elliptical) excision will be performed to the lateral aspect of the abscess formation with a scalpel staying away from the midline. Once the pus has been drained through this lateral incision the wound cavity will then be curetted and washed out with hydrogen peroxide. The wound size will be measured by the operating surgeon who will record the maximal length and width of the wound. Once haemostasis (cessation of any bleeding) is achieved the wound will be packed with Kaltostat ribbon and the wound dressed with blue gauze and mefix tape. The wound is therefore left open.
62173136|NCT03415347|ACTIVE_COMPARATOR|Abscess wide local excision|Wide local excision. Patients will be placed in the prone position with the buttocks spread apart using tape. The cleft of the buttocks will be shaved prior to cleaning and preparation of the skin. Diluted methylene blue will be injected in all visible pits and a wide spindle-shaped (elliptical) midline excision of the skin and the underlying subcutaneous tissue down to the coccygeal (pre-sacral) fascia including all sinuses will be performed with electrocautery. The specimen will be sent for histology as per routine surgical practice. The wound will be washed with hydrogen peroxide. The wound size will be measured by the operating surgeon who will record the maximal length and width of the wound. Once haemostasis (cessation of any bleeding) is achieved the wound will be packed with Kaltostat ribbon and the wound dressed with blue gauze and mefix tape. The wound is therefore left open.
62173137|NCT02930837|EXPERIMENTAL|alteplase|
62173138|NCT04357496||Participants with SARS-COV-2|Participants tested positive for SARS-COV-2 aged 60 years or older
62173139|NCT05509283|NO_INTERVENTION|Passive control|Patients in the passive control arm will receive no additional pro-vaccination intervention beyond the health system's normal efforts. Although some patients are currently targeted for flu vaccination encouragement due to a conventional non-ML assessment that they are at high risk for complications, these patients are not told that they are at high risk or that they have been targeted.
62173140|NCT05509283|EXPERIMENTAL|Active control|Patients in the active control arm will receive messages reminding them to get a flu shot without being advised of their risk status.
62173141|NCT05509283|EXPERIMENTAL|High risk only|Patients in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications, without specifying how or why the health system believes this to be the case.
62173142|NCT05509283|EXPERIMENTAL|Risk based on medical records|Patients in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications via review of their medical records.
62173143|NCT05509283|EXPERIMENTAL|High risk based on algorithm|Patients in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records by a computer algorithm.
62173144|NCT03828877|NO_INTERVENTION|Group C|Arm: Group C control group. Non-acupuncture group. Gruop C will be Control group.
61997420|NCT03063996|ACTIVE_COMPARATOR|Peripheral IJ access|Patient with a history of difficult access or a patient that currently has difficult peripheral IV access and is randomized into the group that gets peripheral IJ access.
62173145|NCT03828877|ACTIVE_COMPARATOR|Group A|Arm: Group A, group of acupuncture Akupunktur will be done with Pres Needle (0.22x1.5 mm) Blood will be taken for the measurement of IL 17 and IL 23 from Group A (Acupuncture) patients 24 hours prior to endovenous ablation procedure. Then, with press needle (0.22x1.5) LU 9 (Taiyuan), LU7 (Lieque), SP 6 (Sanyinjiao) , ST 36 (Zusanli), LI 4 (Hegu) and LIV 3 (Taichong) points will be applied acupuncture.On the 3rd day, patients will be called for control. Blood will also be taken from the blood to measure IL 17, IL 23 values.
62173146|NCT06645535||HFpEF group|Patients with heart failure with preserved ejection fraction.
62173147|NCT06645535||HFrEF group|Patients with heart failure with reduced ejection fraction.
62173148|NCT06645535||Control group|Control participants without heart failure.
62173149|NCT05542914|EXPERIMENTAL|e-SBI|Electronic Screening and Brief Intervention for substance use and HIV risk reduction
62173150|NCT05542914|ACTIVE_COMPARATOR|Assessment Only|These individuals complete only the screening instruments, no brief intervention
62173151|NCT02815735|EXPERIMENTAL|comfilcon A|Participants wear comfilcon A lens for 4 weeks during the cross over study.
62173152|NCT02815735|ACTIVE_COMPARATOR|lotrafilcon B|Participants wear lotrafilcon B lens for 4 weeks during the cross over study.
62173153|NCT02920021|EXPERIMENTAL|Etokimab|Participants received a single dose of 300 milligrams (mg) etokimab administered by 1-hour intravenous (IV) infusion on Day 1.
62173154|NCT02920021|PLACEBO_COMPARATOR|Placebo|Participants received a single dose of placebo administered by 1-hour IV infusion on Day 1.
62173155|NCT05054283||Length of hospital Stay (normal)|The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and \> 7 days as prolonged LOS.
62173156|NCT05054283||Length of hospital Stay (prolonged)|The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and \> 7 days as prolonged LOS.
62173157|NCT03487341|ACTIVE_COMPARATOR|Cord drainage|
62173158|NCT03487341|ACTIVE_COMPARATOR|Cord clamping|
62173159|NCT03470103||Treatment naïve wAMD|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
62173160|NCT03470103||Treatment naïve DME|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
62173161|NCT03470103||Previously treated wAMD|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
62173162|NCT03470103||Previously treated DME|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
62173163|NCT03284593||intensive chemotherapy group|patients treated with intensive chemotherapy
62173164|NCT03284593||Azacitidine group|patients treated with azacitidine
62173165|NCT02542800|EXPERIMENTAL|Healthy participants|
62173166|NCT06477757|ACTIVE_COMPARATOR|Conventional Extracorporeal Circulation Arm (CCPB Arm)|Patients randomized into this group will be undergoing arrested-heart coronary artery bypass grafting with the use of conventional extracorporeal circulation.
62173167|NCT06477757|EXPERIMENTAL|Minimally Invasive Extracorporeal Circulation Arm (MiECC Arm)|Patients randomized into this group will be undergoing arrested-heart coronary artery bypass grafting with the use of minimally invasive extracorporeal circulation.
62173168|NCT05243342|EXPERIMENTAL|Dose escalation|Participants will receive escalating doses of XmAb24306 with daratumumab up to the maximum tolerated dose (MTD)
62173169|NCT05243342|EXPERIMENTAL|Dose expansion|Participants will receive XmAb24306 with daratumumab at the recommended phase 2 dose (RP2D)
62173170|NCT03363542|ACTIVE_COMPARATOR|Fruits and vegetables rich diet|dietary education to increase fruits and vegetable consumption
62173171|NCT03363542|ACTIVE_COMPARATOR|Whole grain fiber rich diet|dietary education to increase whole grain fiber consumption
62173172|NCT03363542|ACTIVE_COMPARATOR|Fruits and vegetables and whole grain fiber rich diet|dietary education to increase fruits and vegetable and whole grain fiber consumption
62173173|NCT03363542|NO_INTERVENTION|Control group|Routine care
62173174|NCT05164718|EXPERIMENTAL|Exercise group|
62173175|NCT05164718|OTHER|Control group|
62173176|NCT00385697|EXPERIMENTAL|Double-blind Herold Regimen|Full dose of teplizumab IV for 14 days, repeated at Week 26
62173177|NCT00385697|EXPERIMENTAL|Double-blind 33.3% Herold Regimen|One third full dose of teplizumab IV for 14 days, repeated at Week 26
62173178|NCT00385697|EXPERIMENTAL|Double-blind Curtailed Herold Regimen|Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26
62173179|NCT00385697|PLACEBO_COMPARATOR|Double-blind Placebo|Placebo IV dosing daily for 14 days repeated at Week 26
62173180|NCT00385697|EXPERIMENTAL|Open-label Herold Regimen|Full dose of teplizumab IV for 14 days, repeated at Week 26
62173181|NCT03069014|ACTIVE_COMPARATOR|400mg LM11A-31-BHS|400mg LM11A-31-BHS and 400mg Placebo per day
62173182|NCT03069014|ACTIVE_COMPARATOR|800mg LM11A-31-BHS|800mg LM11A-31-BHS
62173183|NCT03069014|PLACEBO_COMPARATOR|Placebos|800mg (microcrystalline cellulose with 0.5 - 1% magnesium stearate) per day
62173184|NCT01480440||Trabecular Metal Reverse Shoulder System|Patients requiring primary or revision reverse total shoulder arthroplasty who receive the Trabecular Metal Reverse Shoulder System
62173185|NCT02751645|NO_INTERVENTION|Standard of Care Control|This group will consist of all the participants that receive the standard of care treatment for elective surgical repair or palliation of their cardiac defect with the use of the cardiopulmonary bypass machine.
62173186|NCT02751645|EXPERIMENTAL|Acute Normovolemic Hemodilution|This group will consist of all the participants that receive the acute normovolemic hemodilution prior to their elective surgical repair or palliation of their cardiac defect with the use of the cardiopulmonary bypass machine.
62363890|NCT02225236|EXPERIMENTAL|Classroom Intervention|The intervention focuses on training executive functioning (e.g., working memory and inhibition) and metacognition (i.e., the ability to predict, check, monitor, coordinate and control cognitive operations) using play activities and structured language and reinforcement.
62363891|NCT02225236|NO_INTERVENTION|No treatment control|No intervention
62363892|NCT01941303||Advanced stage non-small cell lung cancer patients|
62173187|NCT00760877|EXPERIMENTAL|Nilotinib|Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.
62173188|NCT00760877|ACTIVE_COMPARATOR|Imatinib|Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.
62173189|NCT01002911|EXPERIMENTAL|Aggressive Antibiotic therapy|Patients receive preoperative intravenous antibiotics, intracavitary antibiotics during surgery and postoperative antibiotics.
62173190|NCT01002911|ACTIVE_COMPARATOR|Conventional Antibiotic Therapy|Preoperative intravenous antibiotics
62173191|NCT00825214|ACTIVE_COMPARATOR|1|Use of zapperclick on mosquito bite
62173192|NCT00825214|PLACEBO_COMPARATOR|2|use of inactivated zapperclick on mosquito bite
62173193|NCT00613223|EXPERIMENTAL|Vandetanib and Etoposide|Patients will be stratified based on whether they are receiving an enzyme-inducing anti-epileptic drug (EIAED). The dose level of vandetanib will be increased in successive cohorts of subjects. Etoposide will be given daily at a dose of 50 mg/ day for 21 days followed by 7 days with no etoposide.
62173194|NCT02946450||Not applicable-observational study|Not applicable-observational study
62173195|NCT06401785|EXPERIMENTAL|Hydrogen capsules|Hydrogen supplement
62173196|NCT06401785|PLACEBO_COMPARATOR|Placebo|Placebo supplement
62173197|NCT03510377|EXPERIMENTAL|Aquatic physical intervention|Aquatic physical intervention: Ai-Chi
62173198|NCT03510377|EXPERIMENTAL|On-land physical intervention|On-land physical intervention: Tai-Chi
62173199|NCT03510377|EXPERIMENTAL|Non physical intervention|Non physical intervention: Guided imagery
62173200|NCT04950387|EXPERIMENTAL|Experimental group|Participants took part in breathing exercises
62173201|NCT04950387|NO_INTERVENTION|Control group|Participant did not take part in intervention
62173202|NCT05117385|EXPERIMENTAL|Acerola|"dietary supplement : acerola extract self administrated by mouth for 28 days~1 capsule per day"
62173203|NCT05117385|EXPERIMENTAL|Panax ginseng extract|"dietary supplement : panax ginseng extract self administrated by mouth for 28 days~1 capsule per day"
62173204|NCT05117385|EXPERIMENTAL|Echinacea extract|"dietary supplement : echinacea extract self administrated by mouth for 28 days~1 capsule per day"
62173205|NCT05117385|EXPERIMENTAL|Quillaja extract|"dietary supplement : quillaja extract self administrated by mouth for 28 days~1 capsule per day"
62173206|NCT05117385|PLACEBO_COMPARATOR|Maltodextrin|"dietary supplement : maltodextrin supplement self administrated by mouth for 28 days~1 capsule per day"
62173207|NCT04998097|EXPERIMENTAL|experimental (iTBS group)|device: Magstim Rapid2 Stimulator
62173208|NCT04998097|SHAM_COMPARATOR|sham group|device shame Magstim Rapid2 Stimulator
62363893|NCT06089707|EXPERIMENTAL|4mg buprenorphine|4mg of buprenorphine will be given to a subset of participants immediately after naloxone administration.
62173209|NCT01705314|EXPERIMENTAL|vitamin D supplements|children and adolescents that are randomized to the intervention will receive 7 mls of D-drops (14,000U/week of vitamin D) for eight months
62173210|NCT01705314|PLACEBO_COMPARATOR|vitamin D placebo|children and adolescents that are randomized to placebo will receive 7 mls of placebo drops for eight months
62173211|NCT02475005|EXPERIMENTAL|Mobile self management app on smartphone|Mobile self management app on smartphone
62173212|NCT02475005|NO_INTERVENTION|Treatment as usual|Treatment as usual (control group)
62173213|NCT03974789||Suspected Cushing Disease|
62173214|NCT03868735|EXPERIMENTAL|CleanSweep Closed Suction System|Device that includes balloon sweeping technology
62173215|NCT03868735|NO_INTERVENTION|Standard in-line suction device|In-line suction device already in on intubated patients with an endotracheal tube
62173216|NCT02162914|ACTIVE_COMPARATOR|Regorafenib/active|Subjects randomized to be treated with Regorafenib (active product) will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off). Duration of one cycle is 28 days.
62173217|NCT02162914|PLACEBO_COMPARATOR|Regorafenib/placebo|Subjects randomized to be treated with Regorafenib (placebo) will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off). Duration of one cycle is 28 days.
62173218|NCT03698305|EXPERIMENTAL|ASP5354 Dose Escalation (5 Dose Levels)|Healthy male and female subjects will be assigned to Cohorts 1-5. In each cohort, 4 subjects will be randomized to receive escalated doses of ASP5354. Each subject will receive a single intravenous bolus injection under fasting conditions.
62173219|NCT03698305|PLACEBO_COMPARATOR|Placebo Dose Escalation (5 Dose Levels)|Healthy male and female subjects will be assigned to Cohorts 1-5. In each cohort, two subjects will be randomized to receive placebo.
62173220|NCT02168621|ACTIVE_COMPARATOR|Full-mouth ultrasonic debridement|Motivation and instruction in proper oral hygiene. Before initiation of the subgingival debridement the patient must show sufficient self-performed infection control (full-mouth plaque score \<30%). One session of full-mouth ultrasonic pocket/root debridement using a piezoceramic ultrasonic instrument. A follow-up visit after 2-4 weeks is scheduled for oral hygiene control and re-motivation/re-instruction if indicated. At 3 and 6 months re-evaluation is performed and re-instrumentation of all sites showing a remaining probing pocket depth of ≥5 mm carried out. Final evaluation at 18 months.
62173221|NCT02168621|ACTIVE_COMPARATOR|Section-wise scaling and root planing|Conventional treatment approach comprising motivation, oral hygiene instructions and section-wise scaling and root planing at required number of consecutive appointments with 1-2 week interval. Follow-up 2-4 weeks after the last session of SRP for oral hygiene control and re-instruction if indicated. At 3 and 6 months re-evaluation is performed and re-instrumentation of all sites showing a remaining pocket depth of ≥5 mm carried out. Final evaluation at 18 months.
62173222|NCT01372683|EXPERIMENTAL|Test cereal 1|Oat based breakfast cereal
62173223|NCT01372683|EXPERIMENTAL|Test cereal 2|2nd Oat based breakfast cereal
62173224|NCT01372683|EXPERIMENTAL|Leading oat based RTE cereal|3rd oat based breakfast cereal
62173225|NCT03922295|ACTIVE_COMPARATOR|endoscopic double flap group|
62173226|NCT03922295|ACTIVE_COMPARATOR|endoscopic single flap group|
62363894|NCT06089707|EXPERIMENTAL|8mg buprenorphine|8mg of buprenorphine will be given to a subset of participants immediately after naloxone administration.
62363895|NCT06089707|EXPERIMENTAL|16mg buprenorphine|16mg of buprenorphine will be given to a subset of participants immediately after naloxone administration.
62173227|NCT05463835|EXPERIMENTAL|RubusElite dairy beverage|The active treatment is a novel beverage, which has been formulated and developed by food Scientists at UCC. The RubusElite beverage is a science-led formulation of blackberry puree and high protein milk.
62173228|NCT05463835|ACTIVE_COMPARATOR|'Protein rich' dairy beverage|The high protein dairy beverage will be a commercially available high protein milk which is commercially produced.
62173229|NCT05463835|SHAM_COMPARATOR|'Low Protein' dairy beverage|The control beverage will be commercially available Taranis Dalia liquid commercially available low protein milk which will be purchased from the manufacturer for use in this study.
62173230|NCT02982096|ACTIVE_COMPARATOR|Cellutome treatment|Cellutome Device: Use of Cellutome on burn wounds
62173231|NCT02982096|OTHER|Standard of Care|Standard of Care: Acellular wound management
62173232|NCT01083446|ACTIVE_COMPARATOR|A|Nutritional intervention, standard Israeli breakfast
62173233|NCT01083446|ACTIVE_COMPARATOR|B|Nutritional Intervention, fast
62173234|NCT02168088||Index case|Subjects who have died of sudden unexplained death
62173235|NCT02168088||Biologically related family member|Biologically related family member of the deceased individual
62173236|NCT00639964|OTHER|type 1 diabetic pregnant women|type 1 diabetic pregnant women
62173237|NCT00639964|OTHER|type 2 diabetic pregnant women|type 2 diabetic pregnant women
62173238|NCT00639964|OTHER|healthy pregnant women|healthy pregnant women with normal glucose tolerance
62173239|NCT01705223|EXPERIMENTAL|group A|DNA vaccine prime at week 0,4,8 and rTV boost at week 16
62173240|NCT01705223|EXPERIMENTAL|group B|DNA vaccine prime at week 0,4,8 and rTV boost at week 24
62173241|NCT01705223|EXPERIMENTAL|group C|DNA vaccine prime at week 0,4,8 and rTV boost at week 32
62173242|NCT01705223|EXPERIMENTAL|group D|DNA vaccine prime with the addition of electroporation at week 0, 4, 8 and rTV boost at week 24
62173243|NCT06353919|EXPERIMENTAL|Yoga Nidra|Participants will practice 30 minutes of yoga nidra 3-5x's/week for 6 weeks
62173244|NCT06353919|ACTIVE_COMPARATOR|Sleep Hygiene, Anxiety, and Benzodiazepine Receptor Agonist Education|Participants will review education material for 30 minutes at a time, 3-5x's/week for 6 weeks
62173245|NCT05122793|EXPERIMENTAL|Prevention Group|In addition to the usual treatment (SoC), the prevention group receives an innovative prevention offer tailored to the severity of the heart failure (telemedical connection via health app as well as additional therapy recommendations).
62173246|NCT05122793|NO_INTERVENTION|Control Group|The control group receives the current standard treatment according to the valid guidelines (Standard of Care = SoC).
62363896|NCT06089707|EXPERIMENTAL|24mg buprenorphine|24mg of buprenorphine will be given to a subset of participants immediately after naloxone administration.
62173247|NCT04069429|EXPERIMENTAL|Healthy Controls|7 controls (subjects without GI symptoms and known GI disease), subjects will receive the radiopharmaceutical agent orally
62173248|NCT04069429|EXPERIMENTAL|Eosinophilic Esophagitis Patients|10 patients with diagnosed EoE (greater than 15 eosinophils per HPF) on esophageal biopsy will be included as the diseased population, subjects will receive the radiopharmaceutical agent orally
62173249|NCT00586742|ACTIVE_COMPARATOR|1|Labral repair with suture anchors
62173250|NCT00586742|ACTIVE_COMPARATOR|2|Biceps tenodesis with suture anchor
62173251|NCT00586742|SHAM_COMPARATOR|3|only a diagnostic arthroscopy performed
62173252|NCT06072963|EXPERIMENTAL|Group 1|Will receive intranasal insulin therapy as well as Oral Semaglutide.
62173253|NCT06072963|SHAM_COMPARATOR|Group 2|Will receive active intranasal insulin therapy and placebo Oral Semaglutide.
62173254|NCT06072963|SHAM_COMPARATOR|Group 3|Will receive intranasal insulin placebo and active Oral Semaglutide .
62173255|NCT06072963|PLACEBO_COMPARATOR|Group 4|Will receive intranasal insulin placebo and Oral Semaglutide placebo.
62173256|NCT05624086|EXPERIMENTAL|Exercised group|In this group, Hepatitis-C Men With Sexual Dysfunction (erectile dysfunction) Complaint (n=23) will receive exercise-training sessions (one hour walking on treadmill, for 3 months, three walking sessions per the week)
62173257|NCT05624086|NO_INTERVENTION|control group|in this group, Hepatitis-C Men With Sexual Dysfunction (erectile dysfunction) Complaint (n=23) will act as a control (waitlist) group that will receive no trainning
62173258|NCT04233333|ACTIVE_COMPARATOR|mustache fixation|
62173259|NCT04233333|EXPERIMENTAL|W.K fixation|
62173260|NCT05465486|EXPERIMENTAL|Complete injury at cervical spine|Patients from Greece, 14 y.o. or oder, suffering from chronic complete injury at the cervical spinal cord level (ASIA Impairment Scale A)
62173261|NCT05465486|EXPERIMENTAL|Incomplete Injury at cervical spine|Patients from Greece, 14 y.o. or oder, suffering from chronic complete injury at the cervical spinal cord level (ASIA Impairment Scale B, C, D, E)
62173262|NCT05465486|ACTIVE_COMPARATOR|Healthy participants|Healthy participants, age and sex matched to the participants in the other two arms
62173263|NCT01704014||α1-ARA Group|All patients on α1-ARA(α1-adrenergic receptor antagonists) medication who underwent cataract surgeries.
62173264|NCT01704014||Control Group|Age and sex-matched control subjects
62173265|NCT02115178||Lithotomy or Prone position|
62173266|NCT00584376|ACTIVE_COMPARATOR|1|Pregabalin
62173267|NCT00584376|PLACEBO_COMPARATOR|2|Placebo
62173268|NCT01284634|EXPERIMENTAL|GWP42003 200 milligrams (mg)/day Dose|Participants self-administered one x 100 mg GWP42003 capsule twice daily for 8 weeks (the first dose was 30 minutes before breakfast \[fasted\] and the second was 30 minutes before the evening meal \[typically 12 hours apart\]).
62173269|NCT01284634|EXPERIMENTAL|GWP42003 400 mg/day Dose|Participants self-administered two x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast \[fasted\] and the second was 30 minutes before the evening meal \[typically 12 hours apart\]).
62173270|NCT01284634|EXPERIMENTAL|GWP42003 800 mg/day Dose|Participants self-administered four x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast \[fasted\] and the second was 30 minutes before the evening meal \[typically 12 hours apart\]).
62363897|NCT02079519|EXPERIMENTAL|Bevacizumab 5 mg/kg|Participants received bevacizumab 5 mg/kg intravenously every 2 weeks for 6 months until disease progression or termination of the study. Participants showing a continuous benefit of therapy could receive treatment for a maximum of 12 months.
62173271|NCT01284634|EXPERIMENTAL|Placebo|Participants self-administered one, two or four placebo capsules twice daily, for 8 weeks (the first dose was 30 minutes before breakfast \[fasted\] and the second was 30 minutes before the evening meal \[typically 12 hours apart\]). Each capsule exactly matched the GWP42003 capsules in terms of appearance, size, smell and taste.
62173272|NCT05222009|EXPERIMENTAL|G-CSF arm1|PD-1 inhibitor resistance regimen+ G-CSF 3mg
62173273|NCT05222009|EXPERIMENTAL|G-CSF arm2|PD-1 inhibitor resistance regimen+ G-CSF 6mg
62173274|NCT03814278|EXPERIMENTAL|Complete bed rest|Participants on complete bed rest group kept antepartum confinement to bed with toileting restricted to bedpan use. Participants in this group received prophylactic subcutaneous enoxaparin (40mg/day).
62173275|NCT03814278|EXPERIMENTAL|Activity restriction group|Activity restriction group had motion limited to bathroom privileges and walks to the ward canteen four times per day.
62173276|NCT02806596|OTHER|sevoflurane|"* induction of anesthesia using sevoflurane administered with facial mask at inspired concentration of 6% (in a mixture of oxygen and nitrous oxyde)~* intervention : titration of inspired sevoflurane concentration until targeted bispectral index"
62173277|NCT05042713|ACTIVE_COMPARATOR|Wave One Gold|The Wave One Gold file will be used with the VDW endodontic motor (VDW) in accordance with the manufacturer's recommendations.
62173278|NCT05042713|ACTIVE_COMPARATOR|One Flare and Wave One Gold file system|The One Flare file will be used with a rotational speed of 300 rpm and 3 N/cm torque at a working length of 3 mm. After the Wave One Gold file will be used with the VDW endodontic motor (VDW) in accordance with the manufacturer's recommendations.
62173279|NCT05042713|ACTIVE_COMPARATOR|One Curve|The One Curve file (Size 25) will be used in the VDW endodontic motor (VDW) in continuous rotation at 300 rpm and 2.5 Ncm torque in accordance with the manufacturer's recommendations.
62173280|NCT05042713|ACTIVE_COMPARATOR|One Curve with One Flare|The One Flare file will be used with a rotational speed of 300 rpm and 3 N/cm torque at a working length of 3 mm. After the One Curve file (Size 25) will be used in the VDW endodontic motor (VDW) in continuous rotation at 300 rpm and 2.5 Ncm torque in accordance with the manufacturer's recommendations.
62173281|NCT02057302|PLACEBO_COMPARATOR|Group B|There are 538 patients recruited in this group. Patients in this group will take 2 capsules of placebo every time, twice every day, respectively after breakfast and supper.
62173282|NCT02057302|EXPERIMENTAL|Group A|There are 1614 patients recruited in this group. Patients in this group will take 2 capsules of Xuezhikang every time, twice every day, respectively after breakfast and supper.
62173283|NCT00021840||Homogen Hispanic pop/Cent Valley CRA|Homogeneous Hispanic population from the Central Valley of Costa Rica
62173284|NCT05135156|EXPERIMENTAL|Intervention|Access to an investigator-designed web-based educational resource with information about lung transplant for two weeks.
62173285|NCT05135156|ACTIVE_COMPARATOR|Control|Access to a publicly available web-based educational resource with information about transplant for two weeks.
62173286|NCT05017688|OTHER|Patient population|"The population of the study will be adult patients with GI-aGVHD grade III to IV undergoing MaaT013 treatment through named-patient use program ATUn (Early Access Program).~Blood and stool samples will be collected at each visit to analyse the gut microbiota and the immune cells."
62173287|NCT05586516|EXPERIMENTAL|IOA-289 in combination with gemcitabine/nab-paclitaxel|
62173288|NCT03696602||test with methacholine|
62173289|NCT03696602||test with exercise|
62173290|NCT06088355|EXPERIMENTAL|HV-PDAE: High Volume Partnered Dance Aerobic Exercise|HV-PDAE classes will meet 5 times a week for 90 minute sessions for 3 weeks at onset of trial and then every 4 weeks for a year. All participants will receive 112.5h of training. PDAE was adapted for older adults with balance impairments; modifications were made to the frame and steps of Argentine tango. People with PD partner an individual without PD, e.g., staff, caregiver, friend, or university student. The instructor, staff lead and assistants monitor participants for safety. Class sizes will consist of 6 or fewer pairs of participants with PD and partners. Participants with PD will dance with new partners (individuals without PD) every 15-20 minutes. Participants will learn new steps in each class. The class format includes practicing steps, warm-up, partnering and rhythmic exercises, learning new steps, combining old and new steps, cool down. PDAE classes follow a syllabus with new steps, rhythms and embellishments included in each class.
62173291|NCT06088355|ACTIVE_COMPARATOR|MV-PDAE: Moderate Volume Partnered Dance Aerobic Exercise|MV-PDAE: MV classes will meet biweekly for 52 weeks for 65-minute sessions. All participants will receive 112.5h of training. . PDAE was adapted for older adults with balance impairments; modifications were made to the frame and steps of Argentine tango. People with PD partner an individual without PD, e.g., staff, caregiver, friend, or university student. The instructor, staff lead and assistants monitor participants for safety. Class sizes will consist of 6 or fewer pairs of participants with PD and partners. Participants with PD will dance with new partners (individuals without PD) every 15-20 minutes. Participants will learn new steps in each class. The class format includes practicing steps, warm-up, partnering and rhythmic exercises, learning new steps, combining old and new steps, cool down. PDAE classes follow a syllabus with new steps, rhythms and embellishments included in each class.
62173292|NCT06088355|ACTIVE_COMPARATOR|MV-WALK: Moderate Volume Walking|MV-WALK (65-minute sessions): WALK will control for the walking that participants in PDAE do and will also take place in groups to control social effects of intervention. Walking for exercise expends 3 METS, like PDAE. (Knaggs et al., 2011) 65 minute sessions will consist of 15 minutes of warmup exercises, 45 minutes of walking with breaks ad libitum, and a 5-minute cool down. Setting will be a designated, safe, non-cluttered area for walking- indoors or outdoors. This protocol is in line with recommendations for gait training to improve gait parameters, i.e., 2-3 days per week, for 30-60 minutes and with evidence that light-moderate intensity walking programs can lead to gains in gait parameters.
62173293|NCT03487302||cCHD|
62173294|NCT03487302||CONTROLS|
62173295|NCT02201147|EXPERIMENTAL|cold biopsy polypectomy|
62173296|NCT02201147|EXPERIMENTAL|Cold snare polypectomy|
62173297|NCT04939324|OTHER|Blood samples at 2 sites: peripheral vein and tumor-draining vein|"D0: surgery (inclusion): oncological lung resection~* Blood samples at 2 sites: peripheral vein and tumor-draining vein~* Resected tumor analysis Standard clinical and radiological follow-up during 2 years (medical consultation or phone call)"
62173298|NCT04890886||Pre-existing Type 1 Diabetes and Type 2 Diabetes|Women with type 1 diabetes and type 2 diabetes diagnosed prior to pregnancy
62173299|NCT04890886||Gestational Diabetes|Women with gestational diabetes diagnosed in pregnancy by the oral glucose tolerance test
62173300|NCT04890886||Intrahepatic cholestasis of pregnancy|Women with intrahepatic cholestasis of pregnancy
62173301|NCT04890886||Control|Women without metabolic disease in pregnancy
62173302|NCT01203956|EXPERIMENTAL|SmartFlex|Use Continuous Airway Pressure device with SmartFlex engaged
62173303|NCT01203956|ACTIVE_COMPARATOR|Standard|Use Continuous Airway Pressure device without SmartFlex engaged
62173304|NCT06454071|OTHER|Interleukin6|Immunologic tests including Interleukin 6 were conducted before surgery, on the third day following surgery, and on the first outpatient visit day (approximately 21 days after surgery). The IL-6 tests were carried out in our hospital.
62173305|NCT06454071|OTHER|NK cell|Immunologic tests including Nk cell were conducted before surgery, on the third day following surgery, and on the first outpatient visit day (approximately 21 days after surgery). The NK cell tests were carried out in our hospital. Peripheral blood mononuclear cells were evaluated using flow cytometry via fluorochrome-conjugated antibodies against a number of NK cell receptors.
62173306|NCT02324088|ACTIVE_COMPARATOR|Arm A|4 cycles of high-dose EC (E150 mg/m² and C 4000 mg/m² every 3 weeks) then mastectomy with axillary lymph node dissection and radiotherapy
62173307|NCT02324088|EXPERIMENTAL|Arm B|4 cycles of high-dose EC (E150 mg/m² and C 4000 mg/m² every 3 weeks) then mastectomy with axillary lymph node dissection and radiotherapy followed by 4 cycles of D-5FU (D 85 mg/m², day 1 and 5FU 2500 mg/m²/day continuous infusion, days 1-5 every 3 weeks)
62173308|NCT02480244|EXPERIMENTAL|Behavioral intervention|Behavioral intervention consisting of 12 educational sessions promoting healthy diet and increased physical activity
62173309|NCT02480244|ACTIVE_COMPARATOR|Control|Control arm receives no health-related behavioral intervention
62173310|NCT05195450|EXPERIMENTAL|Tenofovir Alafenamide Fumarate|• TAF 25 mg OD vs no treatment x 5 years and beyond
62173311|NCT05195450|NO_INTERVENTION|No Treatment Arm|No treatment
62173312|NCT02241161|ACTIVE_COMPARATOR|plantaricin a - rejuvenating cream|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
62173313|NCT02241161|ACTIVE_COMPARATOR|plantaricin a - rejuvenating serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
62173314|NCT02241161|ACTIVE_COMPARATOR|plantaricin a - antioxidant serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
62173315|NCT02241161|ACTIVE_COMPARATOR|plantaricin a (rejuvenating cream +rejuvenating serum)|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
62173316|NCT02241161|ACTIVE_COMPARATOR|plantaricin a (rejuvenating cream + antioxidant serum)|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
62173317|NCT04685109|EXPERIMENTAL|Alocross|Cross-linked HA 0.2% + Aloe Vera 0.1% solution (N=40) Posology: One Drop in each eye 4 times daily for 84 days
62173318|NCT04685109|ACTIVE_COMPARATOR|Vismed|HA 0.18% hyaluronic solution (N40) Posology: One Drop in each eye 4 times daily for 84 days
62363898|NCT06450457|EXPERIMENTAL|High intensity stepping program|"The arm involves the use of the Polar heart rate monitor, the Therastride Treadmill System, OR the VECTOR Bioness~* The device utilized will be determine by how much assistance the participant needs.~* Some participants will not be utilizing any equipment other than a Polar heart rate monitor to collect heart rate data if they are already ambulating."
62173319|NCT02608697|EXPERIMENTAL|Group 1: CAT-2054 or Placebo Dose 1|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 250 mg CAT-2054 or placebo QD and open label 40 mg atorvastatin tablet administered daily.
62173320|NCT02608697|EXPERIMENTAL|Group 2: CAT-2054 or Placebo Dose 2|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 400 mg CAT-2054 or placebo QD and open label 40 mg atorvastatin tablet administered daily.
62173321|NCT02608697|EXPERIMENTAL|Group 3: CAT-2054 or Placebo Dose 3|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 250 mg CAT-2054 or placebo BID and open label 40 mg atorvastatin tablet administered daily.
62173322|NCT02608697|EXPERIMENTAL|Group 4: CAT-2054 or Placebo Dose 4|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 400 mg CAT-2054 or placebo BID and open label 40 mg atorvastatin tablet administered daily.
62173323|NCT05254834||Cancer Group|Collect Subject Data Collect Blood Specimen
62173324|NCT05254834||Non-cancer Group|Collect Subject Data Collect Blood Specimen One Year Follow Up On Cancer Status
62173325|NCT01215032|EXPERIMENTAL|Metformin|This is the only arm of this phase 2 open label study
62173326|NCT06197113|ACTIVE_COMPARATOR|10 Hz rTMS group|To the patients in the high frequency (10 Hz) rTMS (n:9) group, 110% resting motor threshold (rMT), 10 Hz frequency stimulation, 5-second stimulation, and then a total of 30 trains and 1500 pulses at 25-second intervals were applied for 15 minutes while targeting the lower extremity motor area.
62173327|NCT06197113|ACTIVE_COMPARATOR|iTBS group|To the patients in iTBS group (n:9), three bursts of stimulation at 50 Hz, repeated every 200 milliseconds, were delivered for 2 seconds every 10 seconds, totaling 600 stimuli at MT intensity, applied for a duration of 200 seconds.10 sessions was applied while targeting the lower extremity motor area.
62173328|NCT06197113|SHAM_COMPARATOR|Sham Group|The patients in the sham group (n:8) were given sham stimulation with a sham coil for 10 sessions.
62173329|NCT04701970|OTHER|changes in the occlusal load distribution|A crossover clinical study was carried out with previously constructed and used conventional complete dentures before relining with soft denture liners and then with the same dentures after relining with soft denture liners. patients were comfortably using their relined mandibular complete dentures for at least three months and the retention and stability of the conventional dentures were assessed before second recording of occlusal parameter. The evaluation of occlusal force distribution was carried out with the aid of T-Scan device
62363899|NCT06370949||bupivacaine|Ultrasonography (USG) guided bilateral TAP block:20 ml %0,25 concentration bupivacain
62173330|NCT03498885|EXPERIMENTAL|Low ligation|Left colic artery (LCA) is identified, tie the sigmoid artery and superior rectal artery,Apical lymph node dissection with the left colic artery preservation is performed.
62173331|NCT03498885|ACTIVE_COMPARATOR|High ligation|The IMA is ligated and divided at 2 cm from its origin. Apical lymph nodes dissection is performed.
62173332|NCT02954796|EXPERIMENTAL|(Dose Escalation) Cohort -1 - 6|SGN-CD352A will be given intravenously (into a vein; IV) every 28 days at increasing doses.
62173333|NCT03121040|EXPERIMENTAL|Subjects ingested VAAM® for 10 weeks|Ten young athletes ingested Vespa amino acid mixture (VAAM®) for 10 weeks, divided into different meter race including 1500-, 800- and 400-meter races.
62173334|NCT03121040|EXPERIMENTAL|Subjects ingested VAAM® for 6 weeks|Ten young athletes ingested Vespa amino acid mixture (VAAM®) for 6 weeks, divided into different meter race including 1500-, 800- and 400-meter races.
62173335|NCT03121040|NO_INTERVENTION|Subjects ingested nothing|Ten young athletes before ingesting Vespa amino acid mixture (VAAM®) , divided into different meter race including 1500-, 800- and 400-meter races.
62173336|NCT01394783|OTHER|Classic laryngoscope|Phase 1 and 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
62173337|NCT01394783|OTHER|Videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
62173338|NCT06500013|EXPERIMENTAL|Self-designed messages|This group of participants will design their own messages, and receive them via mobile messaging up to 3 times a week in the day and time of their choosing, for 16 weeks.
62173339|NCT06500013|ACTIVE_COMPARATOR|Standardized messages|This group of participants will receive messages designed by researchers based on behavioral change theories, up to 3 times a week in the day and time of their choosing, for 16 weeks.
62173340|NCT01911936|EXPERIMENTAL|LJM716|
62173341|NCT03185845|EXPERIMENTAL|Prolonged anticoagulation|3 months longer anticoagulation after regular treatment
62173342|NCT03185845|NO_INTERVENTION|Regular anticoagulation|stop anticoagulation after regular treatment
62173343|NCT04077775||Study group (group A):|"Study group (group ) Diagnostic Test: Study group (group A)24 women who have cyclic CPP~I) Pelvic tilt angle:~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately while the woman was in standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer"
62173344|NCT04077775||Study group(group B):|"included 20 women who have non-cyclic CPP and the other 16 women of the participants were normal I)~Pelvic tilt angle:~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately. In contrast, the woman was in a standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer~Diagnostic Test: Study group (group A)"
62173345|NCT04077775||Control group (group C):|"16 women of the participants were normal and considered the control group~I) Pelvic tilt angle:~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately while the woman was in standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer"
62173346|NCT01670188|ACTIVE_COMPARATOR|Pneumatic SCD|Use of pneumatic SCD (VenaFlow System - DJO Global) on upper extremity with PICC line inserted.
62173347|NCT01670188|NO_INTERVENTION|Non-SCD group|Standard care
62173348|NCT03695198|EXPERIMENTAL|LY3361237 - Subcutaneous (SC)|LY3361237 administered SC
62173349|NCT03695198|PLACEBO_COMPARATOR|Placebo - SC|Placebo administered SC
62173350|NCT03695198|EXPERIMENTAL|LY3361237 - Intravenous (IV)|LY3361237 administered IV
62173351|NCT03695198|PLACEBO_COMPARATOR|Placebo - IV|Placebo administered IV
62173352|NCT04151706|EXPERIMENTAL|fTBI/Thiotepa/fludarabine|Participants will be infused on Day 0 with donor derived CD34+ selected cells combined with CD8+CD45RA- T cells {CD Memory T Cells} following a standard myeloablative conditioning regimen that might consist of fTBI, Thiotepa, and Fludarabine or Busulfan and Cyclophosamide.
62173353|NCT00648206||1|drivers of motorised vehicles suspected of driving under the influence of psychoactive drugs or alcohol
62173354|NCT00648206||2|drivers stopped in police traffic controls and breathalysed positive for alcohol
62173355|NCT04373356|EXPERIMENTAL|Resin Infiltration|The interproximal surface with initial dental caries that are selected for this group will be treated using the resin infiltration ICON (DMG, Germany) and 5% Sodium Fluoride Varnish
62173356|NCT04373356|ACTIVE_COMPARATOR|Sodium Fluoride Varnish|The interproximal surface with initial dental caries that are selected for this group will be treated using topical application of 5% Sodium Fluoride Varnish.
62173357|NCT02731456|EXPERIMENTAL|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude.
62173358|NCT04574661|ACTIVE_COMPARATOR|Static stretching|Static stretching to lower limb muscles
62173359|NCT04574661|EXPERIMENTAL|Intermittent occlusion|Intermittent occlusion to lower limb
62173360|NCT01890499|EXPERIMENTAL|Low residue diet arm|"Two arm randomized controlled trial. First arm is the Clear feeds on postoperative day one arm.~The second arm (interventional arm) is the Low Residue diet on postoperative day one arm."
62173361|NCT01890499|ACTIVE_COMPARATOR|Clear feeds arm|Standard of care is to start clear feeds on postoperative day one for elective colorectal surgery patients.
62363900|NCT06370949||bupivacaine+dexmedetomidine|Ultrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine
62363901|NCT04203108|EXPERIMENTAL|ATG group|ATG group refers to treatment with a protocol including low-dose ATG, CsA, short-term MTX and MMF as GVHD prophylaxis.
62173362|NCT01093183|EXPERIMENTAL|Treatment (lenalidomide and cyclophosphamide)|Patients receive lenalidomide PO QD on days 1-21 and cyclophosphamide PO QD on days 1-28. Treatment repeats every 28 days for at least 4 courses in the absence of disease progression or unacceptable toxicity. Treatment modifications may apply according to response.
62173363|NCT01128140|EXPERIMENTAL|Motivational Enhancement Therapy|
62173364|NCT01128140|ACTIVE_COMPARATOR|Education|
62173365|NCT03306693|EXPERIMENTAL|Emotional skills|3 group sessions where patients are going to learn how to identify, express and regulate their emotions
62173366|NCT03306693|SHAM_COMPARATOR|Relaxation and talking group|3 group sessions where patients are going to follow relaxation instructions and after a non directive talking group about cancer
62173367|NCT04360642|OTHER|singing arm|"Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities: Newton Abbott and Torquay.~Lung function, frailty and health-related quality of life will be assessed by Spirometry, CRQ (chronic respiratory questionnaire), MRC breathlessness scale, Rockwood frailty and Warwick-Edinburgh Mental Well-being Scale (WEMWBS). Participants will be assessed at baseline and then again at completion of the 12-week course.~Written feedback from participants to capture qualitative experience using narrative and Patient Reported Outcome Measures (PROMs). The attrition and attendance rate will also be recorded for later review."
62173368|NCT00740298|ACTIVE_COMPARATOR|1|Sweet Taste
62173369|NCT00740298|ACTIVE_COMPARATOR|2|warmth
62173370|NCT01676883|EXPERIMENTAL|body composition assessment|Bioelectric impedance measurement pre- and post removal of calluses and corns (pedicure), then air-displacement plethysmography (gold standard)
62173371|NCT05578898|EXPERIMENTAL|CLEAR CC|Patients use CLEAR CC application with Smartphone or Tablet
62173372|NCT01105442||Bupivacaine|Patients who received bupivacaine + sufentanil
62173373|NCT01105442||Levobupivacaine|Patients who received levobupivacaine and morphine on demand
62173374|NCT00510783|ACTIVE_COMPARATOR|Phenytoin/Fosphenytoin|Patients in the control arm will receive either IV Dilantin (1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals) or IV Fosphenytoin (1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals).
62173375|NCT00510783|ACTIVE_COMPARATOR|Levetiracetam|Patients in the intervention arm will receive IV Keppra (1 gram of Keppra added to 100 mL diluent infused over 15 minutes).
62173376|NCT04514796|EXPERIMENTAL|40 mg/0.4 mL of SB5|100 mg/mL of SB5
62173377|NCT04514796|ACTIVE_COMPARATOR|40 mg/0.8 mL of SB5|50 mg/mL of SB5
62173378|NCT04136964||Patients group|Patients who have pain located in the anatomical region of the neck for more than three months due to mechanical causes; with or without radiation to the head, trunk, and upper limbs. Posteriorly, pain may be present in the neck region from the superior nuchal line to the spine of the scapula and the side region down to the superior border of the clavicle and the suprasternal notch.
62173379|NCT04899778|EXPERIMENTAL|Oral Contraceptive Pill|Oral contraceptive, 1/day, for one year
62173380|NCT04899778|NO_INTERVENTION|No Oral Contraceptive|No intervention
62173381|NCT00793377|EXPERIMENTAL|ADOC x 4 + Tam 20|Adriamycin will be given at a dose of 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles. Adriamycin will be administered as a short i.v. infusion over 15 minutes, followed immediately by a 1-hour infusion of docetaxel diluted in 250 mL NaCl. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
62173382|NCT00793377|EXPERIMENTAL|AC x 4 - Doc x 4 + Tam 20|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy
62173383|NCT03042559|ACTIVE_COMPARATOR|Protonics knee brace|All subjects were fitted with a regular-sized Protonics knee brace with resistive settings to resist knee flexion.
62173384|NCT03042559|EXPERIMENTAL|Sport cords|Resistive sports cord to resist knee flexion.
62173385|NCT02612805|EXPERIMENTAL|Aerobic training group|This group perform aerobic hydrogymnastics.
62173386|NCT02612805|ACTIVE_COMPARATOR|Combined training group|This group perform combined hydrogymnastics.
62173387|NCT02612805|PLACEBO_COMPARATOR|Training placebo|This group perform stretching and relaxation in aquatic environment.
62173388|NCT02643953|NO_INTERVENTION|Control Group|This arm includes women who are eligible and give birth (including cases of fetal or infant death) in the intervention period in comparative health wards, who will not receive the interventions and who will continue to receive their usual pattern of utilization of maternity care.
62173389|NCT02643953|EXPERIMENTAL|Other|The intervention will need to be multi-faceted, and will consist of provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; conditional cash transfers to promote uptake of services and targeted community health education and advocacy activities
62173390|NCT00741351|EXPERIMENTAL|IF|Sevoflurane (Inhalation)+Fentanyl
62173391|NCT00741351|EXPERIMENTAL|IR|Sevoflurane (Inhalation)+Remifentanyl
62173392|NCT00741351|EXPERIMENTAL|ER|Propofol (Endovenous)+ Remifentanyl
62173393|NCT03753750|EXPERIMENTAL|Actual stimulation|Subjects enrolled in the
62173394|NCT03753750|SHAM_COMPARATOR|Sham stimulation|
62173395|NCT04645953|EXPERIMENTAL|1mg AZ010|Single orally-inhaled dose
62173396|NCT04645953|EXPERIMENTAL|3mg AZ010|Single orally-inhaled dose
62173397|NCT04645953|EXPERIMENTAL|Placebo|Single orally-inhaled dose
62173398|NCT00802438|EXPERIMENTAL|Mepolizumab|up to 3 monthly doses of 750mg i.v. mepolizumab
62173399|NCT03193216|EXPERIMENTAL|Alginate group|Patients in this group will be taking the study medication -- alginate solution in addition to standard of care twice daily proton pump inhibitor therapy
62173400|NCT01933529|EXPERIMENTAL|ARA 290|ARA 290, 4.0 mg, injected subcutaneously once every morning during 28 days.
62173401|NCT01933529|PLACEBO_COMPARATOR|Placebo|Placebo, injected subcutaneously once every morning during 28 days,
62173402|NCT01675050|EXPERIMENTAL|Cyproheptadine first then Placebo|4 weeks of cyproheptadine or placebo with crossover to the other
62173403|NCT01675050|EXPERIMENTAL|Sugar Pill first then Cyprotheptadine|4 weeks of cyproheptadine or placebo with crossover to the other
62173404|NCT04244708|EXPERIMENTAL|Radiotherapy plus temozolomide|Undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week for a total dose of 54 Gy, plus continuous daily temozolomide (75 mg per square meter of body-surface area per day), followed by six cycles of adjuvant temozolomide.
62173405|NCT04244708|PLACEBO_COMPARATOR|Radiotherapy plus placebo|Radiotherapy treatment alone undergoing fractionated radiotherapy, total 54 Gy, 2GyX27, received placebo.
62173406|NCT03383029|EXPERIMENTAL|iEAT|Children with food refusal will participate in the iEAT program.
62173407|NCT04047225|EXPERIMENTAL|Analgesia Nociceptive Index (ANI)|Using ANI for guiding intraoperative opioid administration.
62173408|NCT04047225|NO_INTERVENTION|No Analgesia Nociceptive Index (ANI)|Do not use ANI
62173409|NCT01549249|NO_INTERVENTION|vitrectomy|
62173410|NCT00949221|OTHER|Group 1|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months
62173411|NCT00949221|OTHER|Group 2|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Intensive strategy using continuous glucose monitoring for 12 months
62173412|NCT00949221|OTHER|Group 3|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring).
62173413|NCT01879085|EXPERIMENTAL|Combination therapy|Dose Level\\Docetaxel IV\\ Gemcitabine IV\\Vorinostat PO\\Pegfilgrastim 1\\75 mg/m2\\900 mg/m2\\300 mg once daily\\6 mg on day 9 2\\75 mg/m2\\900 mg/m2\\200 mg twice daily\\6 mg on day 9 3\\75 mg/m2\\900 mg/m2\\300 mg twice daily\\6 mg on day 9 4\\75 mg/m2\\900 mg/m2\\400 mg twice daily\\6 mg on day 9
62173414|NCT02672137|EXPERIMENTAL|knowledge translation|knowledge translation 12-month multi-facet intensive knowledge translation measures that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
62173415|NCT02672137|NO_INTERVENTION|Usual care|no intervention
62173416|NCT05037721|EXPERIMENTAL|gargling with green tea of stroke patients|Use fresh green tea (package date less than one month) sourced from the local market and serve in the form of soaked tea bags. 0.5% green tea refers to a tea bag soaked in 0.5g green tea, soaked in 100ml warm water for 5 minutes and let cool. Then, put each bottle of 15ml mouthwash into a disposable opaque bottle, and give two bottles of mouthwash required daily at one time. Use 15ml twice a day, 30 minutes after breakfast and 30 minutes after lunch, each time for 30 seconds. Rinse mouth up and down for 30 seconds. Rinse mouth up and down, half sitting and lying down, and shake the head of bed for 30 degrees. After breakfast, the experimental group and the control group were instructed to clean their teeth according to routine procedures, and telephone reminders were provided to inform them to gargle.
62173417|NCT05037721|ACTIVE_COMPARATOR|gargling with water of stroke patients|Use water 15ml of mouthwash into a disposable opaque bottle, and give two bottles of mouthwash required daily at one time. Use 15ml twice a day, 30 minutes after breakfast and 30 minutes after lunch, each time for 30 seconds. Rinse mouth up and down for 30 seconds. Rinse mouth up and down, half sitting and lying down, and shake the head of bed for 30 degrees. After breakfast, the experimental group and the control group were instructed to clean their teeth according to routine procedures, and telephone reminders were provided to inform them to gargle.
62173418|NCT01562483|EXPERIMENTAL|delta-9-tetrahydrocannabinol (namisol)|
62173419|NCT01562483|PLACEBO_COMPARATOR|Placebo|
62173420|NCT03158818||HBV mono-infected (Standard of Care)|500 patients in Zambia
62173421|NCT04420741|EXPERIMENTAL|Iloprost|Patients randomized to active treatment (n=40 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
62173422|NCT04420741|PLACEBO_COMPARATOR|Isotonic saline|Patients randomized to placebo treatment (n=40 patients) will receive continuous infusion of placebo for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
62173423|NCT02152241||Patients with IBD|Adult patients with IBD diagnosed during childhood
62173424|NCT00560807|NO_INTERVENTION|A|Zero treatment/3 weeks
62173425|NCT00560807|ACTIVE_COMPARATOR|B|Frequency of Mobilization:1/week Duration of Mobilization Treatment: 3 weeks
62173426|NCT00560807|ACTIVE_COMPARATOR|C|Frequency of Mobilization: 1/week Duration of Mobilization Treatment: 6 weeks
62173427|NCT00560807|ACTIVE_COMPARATOR|D|Frequency of Mobilization: 1/week Duration of Mobilization Treatment: 12 weeks
62173428|NCT00560807|ACTIVE_COMPARATOR|F|Frequency of Mobilization: 2/week Duration of Mobilization Treatment: 3 weeks
62173429|NCT00560807|ACTIVE_COMPARATOR|G|Frequency of Mobilization: 2/week Duration of Mobilization Treatment:6 weeks
62173430|NCT00560807|ACTIVE_COMPARATOR|H|Frequency of Mobilization: 2/week Duration of Mobilization Treatment: 12 weeks
62173431|NCT00560807|ACTIVE_COMPARATOR|J|Frequency of Mobilization: 3/week Duration of Mobilization Treatment: 3 weeks
62173432|NCT00560807|ACTIVE_COMPARATOR|K|Frequency of Mobilization: 3/week Duration of Mobilization Treatment:6 weeks
62173433|NCT00560807|ACTIVE_COMPARATOR|L|Frequency of Mobilization: 3/week Duration of Mobilization Treatment:12 weeks
62173434|NCT00560807|NO_INTERVENTION|E|Zero treatment/6 weeks
62173435|NCT00560807|NO_INTERVENTION|I|Zero treatment/12 weeks
62173436|NCT02574351||obese asthmatic|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
62173437|NCT02574351||normal asthmatic|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group
62173438|NCT02574351||obese control|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
61997421|NCT02940171||Early surgery|Early Excision of full thickness burn First excision surgery of full -thickness burn performed within 48 hours from burn injury
62173439|NCT02574351||normal control|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
62363902|NCT04203108|ACTIVE_COMPARATOR|non-ATG group|Non-ATG group refers to treatment with a protocol including CsA, short-term MTX and MMF as GVHD prophylaxis.
62173440|NCT04059913|EXPERIMENTAL|Part 1: ESA-Naïve Participants - Low Weight Based Dosing|ESA-naïve participants will receive roxadustat 70 mg TIW for body weight 45 to \<60 kg or 100 mg TIW for body weight ≥60 kg.
62173441|NCT04059913|EXPERIMENTAL|Part 1: ESA-Naïve Participants - Standard Weight Based Dosing|ESA naïve participants will receive roxadustat 100 mg TIW for body weight 45 to \<60 kg or 120 mg TIW for body weight ≥60 kg.
62173442|NCT04059913|EXPERIMENTAL|Part 1: ESA-Treated Participants - Low Weight Based Dosing|ESA-treated participants will receive roxadustat 70 mg TIW for body weight 45 to \<60 kg or 100 mg TIW for body weight ≥60 kg.
62173443|NCT04059913|EXPERIMENTAL|Part 1: ESA-Treated Participants - Standard Weight Based Dosing|ESA treated participants will receive roxadustat 100 mg TIW for body weight 45 to \<60 kg or 120 mg TIW for body weight ≥60 kg.
62173444|NCT04059913|EXPERIMENTAL|Part 2: Roxadustat QW|Participants will receive roxadustat once a week (QW). Roxadustat dose will be 2-dose step increase from originally planned week 21 TIW per dose amount.
62173445|NCT04059913|EXPERIMENTAL|Part 2: Roxadustat BIW|Participants will receive roxadustat twice a week (BIW). Roxadustat dose will be 1-dose step increase from originally planned week 21 TIW per dose amount.
62173446|NCT04059913|EXPERIMENTAL|Part 2: Roxadustat TIW|Participants will receive roxadustat TIW. Roxadustat dose will continue per dose adjustment guideline.
62173447|NCT03600519||AMD Patients|OCT scan
62173448|NCT00945698|OTHER|ST-DI (Delayed intervention)|"* 1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
62173449|NCT00945698|EXPERIMENTAL|LNS-10gM|"* 140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
62173450|NCT00945698|EXPERIMENTAL|LNS-20gM|"* 280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
62173451|NCT00945698|EXPERIMENTAL|LNS-20gNoM|"* 280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
62173452|NCT00945698|EXPERIMENTAL|LNS-40gM|"* 560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
62173453|NCT00945698|EXPERIMENTAL|LNS-40gNoM|"* 560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
62173454|NCT05166798|EXPERIMENTAL|Intervention group|Cognitive control training: The adaptive Paced Auditory Serial Addition Task (aPASAT) is a Cognitive Control Training where participants need to click on the sum of the last two heard digits. Task difficulty is modified based on the participants' current task performance, allowing training of cognitive control. Five intervention groups will each receive a different amount of sessions.
62173455|NCT05166798|NO_INTERVENTION|Control group|Waitlist control group: Participants randomized to the control group will not perform the cognitive control training during the study, but will be given the opportunity to follow the training afterwards.
62173456|NCT04341415|EXPERIMENTAL|Auricular neuromodulation|
62173457|NCT04341415|SHAM_COMPARATOR|Control|
62173458|NCT00880152|EXPERIMENTAL|MBSR|An 8-week course in mindfulness-based stress reduction (MBSR)
62173459|NCT00880152|NO_INTERVENTION|2|Treatment as usual
62173460|NCT01763034|SHAM_COMPARATOR|limb ischemia|
62173461|NCT05028647|ACTIVE_COMPARATOR|VR treatment|5 subjects per country aged 13-16 treated with VR supported (Oculos) program, one hour a day for 5 days
62173462|NCT05028647|ACTIVE_COMPARATOR|AR treatment|5 subjects per country aged 10-13 treated with AR supported (tablet) program, one hour a day for 5 days
62173463|NCT05028647|NO_INTERVENTION|control age 13-16|dyslexic subjects aged 13-16 not randomized to active treatment
62173464|NCT05028647|NO_INTERVENTION|Control age 10-12|dyslexic subjects aged 10-12 not randomized to active treatment
62173465|NCT02162771|EXPERIMENTAL|CT-P10|"Patient treated with CT-P10 (375 mg/m2 IV) in combination with cyclophosphamide (750 mg/m2 IV), vincristine (1.4 mg/m2 \[max 2 mg\] IV), and prednisone 40 mg/m2 orally) up to 8 cycles every 3 weeks during the Core Study Period.~Patients having responses during Core Study Period treated with CT-P10 (375 mg/m2 IV) monotherapy up to 12 cycles every 2 months during the Maintenance Study Period."
62173466|NCT02162771|ACTIVE_COMPARATOR|Rituxan|"Patient treated with Rituxan (375 mg/m2 IV) in combination with cyclophosphamide (750 mg/m2 IV), vincristine (1.4 mg/m2 \[max 2 mg\] IV), and prednisone 40 mg/m2 orally) up to 8 cycles every 3 weeks during the Core Study Period.~Patients having responses during Core Study Period treated with Rituxan (375 mg/m2 IV) monotherapy up to 12 cycles every 2 months during the Maintenance Study Period."
62173467|NCT05215418|EXPERIMENTAL|VI-0521 Top Dose (Phentermine 15 mg + Topiramate 92 mg)|Week 1: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Week 2: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily; Week 3: VI-0521 (Phentermine 11.25 mg + Topiramate 69 mg) oral capsule, once daily; Weeks 4-8: VI-0521 (Phentermine 15 mg + Topiramate 92 mg) oral capsule, once daily
62173468|NCT05215418|ACTIVE_COMPARATOR|Phentermine 30mg|Weeks 1-8: Phentermine 30mg oral capsule, once daily
62173469|NCT05215418|PLACEBO_COMPARATOR|Placebo|Weeks 1-8: Placebo oral capsule, once daily
62173470|NCT04035863|EXPERIMENTAL|PBM + physiotherapy exercises|"will be submitted to active PBM and physiotherapeutic exercises.~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated at the lesion level with a wavelength of 808 nm, 25 J per point for 12 sessions. The same laser device (Laser DMC Therapy EC).~Physical therapy will occur twice per week after PBM for six weeks. Static balance exercises will be performed with the feet together and tandem on a variety of different surfaces (hard surface, foam rubber and carpets with different textures) and sensory inputs (eyes open and closed). Dynamic balance exercises will involve walking forward and backward on firm and foam surfaces and circumventing obstacles. Muscle strengthening exercises, squatting and changing postural positions will also be performed. All activities will be in the form of play to maintain the children's interest"
62173471|NCT04035863|SHAM_COMPARATOR|SHAM PBM + physiotherapy exercises|"will be submitted to sham PBM and physiotherapeutic exercises.~For irradiation sham, the individuals will be positioned comfortably in lateral decubitus on the examining table. The same laser device (Laser DMC Therapy EC) will be used but the device will emit sound but not light.~Physical therapy will occur twice per week after PBM for six weeks. Static balance exercises will be performed with the feet together and tandem on a variety of different surfaces (hard surface, foam rubber and carpets with different textures) and sensory inputs (eyes open and closed). Dynamic balance exercises will involve walking forward and backward on firm and foam surfaces and circumventing obstacles. Muscle strengthening exercises, squatting and changing postural positions will also be performed. All activities will be in the form of play to maintain the children's interest"
62173472|NCT06139159|EXPERIMENTAL|LHW as outreach agents/navigators|Conduct outreach activities with people in the community who are hard to reach and with limited access to health care, conduct screening for symptoms of mental illnesses, encourage and refer individuals at-risk, suspected of having, or affected by mental health issues for further triage.
62173473|NCT06139159|EXPERIMENTAL|LHW as navigators and auxiliary to care|"LHW continue conducting outreach and referral activities but in addition, LHW are more involved in their care. They arrange consultations, introduce the patient to the clinical team via a warm hand-off and assist in scheduling a follow -up visit, reviews the care plan with the patient and help reduce patient and system barriers impeding psychological well-being, support patients in achieving management goals; help patients address barriers through education, referral, and navigation to ancillary community services. They have frequent contact with the patient."
62173474|NCT06139159|EXPERIMENTAL|LHW stepped care and task shifting|LHW conduct activities of prior arms but in addition, they may provide specific components of mental health care (task-shifting), providing components of basic evidence-based treatments to patients with non-complex needs, and addressing other syndemic health and social conditions.
62173475|NCT04568356|EXPERIMENTAL|Antigen rapid test for COVID-19|The same group of patients participated in two arms of the study, one arm was for obtaining data on the rapid antigen test for COVID-19, the comparator arm was to obtain data from the RT-PCR
62173476|NCT03735641||postoperative|Expanded Pedicled Deltopectoral Flap is a type of surgical flap that has been cut away from surrounding areas for transplantation.The postoperative patients are studied . Tested sensory recovery,skin color and Skin elasticity
62173477|NCT00581009|EXPERIMENTAL|Chronobiological augmentation|chronobiological augmentation group
62173478|NCT00581009|EXPERIMENTAL|Medication only|medication only group
62173479|NCT00581009|EXPERIMENTAL|MDD Mechanism|
62173480|NCT06178055|EXPERIMENTAL|KUS121 high dose group|
62173481|NCT06178055|EXPERIMENTAL|KUS121 low dose group|
62173482|NCT06178055|SHAM_COMPARATOR|Control group|
62173483|NCT04493983|OTHER|Investigation|Unilateral oophorectomy was performed immediately after abdominal entry, and the remaining contralateral ovary was excised at the end of the hysterectomy in order to compare the effect of these surgical procedures on ovarian tissue.
62173484|NCT00478439|PLACEBO_COMPARATOR|Placebo Comparator|
62173485|NCT00223743|EXPERIMENTAL|Zonisamide|Zonisamide administration and tremor assessment to assess efficacy in reducing essential tremor
62173486|NCT05063981||CRSwNP|10 patients with severe refractory eosinophilic asthma plus CRSwNP
62173487|NCT05063981||No CRSwNP|10 patients with severe refractory eosinophilic asthma and no CRSwNP
62173488|NCT02174159|EXPERIMENTAL|Panel A: Ulonivirine 600 mg|Single oral dose of ulonivirine 600 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast
62173489|NCT02174159|EXPERIMENTAL|Panel B: Ulonivirine 150 mg|Single oral dose of ulonivirine 150 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast
62173490|NCT02174159|EXPERIMENTAL|Panel C: Ulonivirine <=600 mg|Single oral dose of ulonivirine \<=600 mg mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast. Inclusion of Panel C in the study, and the dose selected, will be decided pending evaluation of results for Panels A and B.
62173491|NCT00434577|EXPERIMENTAL|GSK1437173A _LD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) low dose (LD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by intramuscular injection (IM) in the upper deltoid site of the left arm.
62173492|NCT00434577|EXPERIMENTAL|GSK1437173A _MD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) medium dose (MD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
61997422|NCT02940171||Late surgery|Late Excision of full thickness burn First excision surgery of full -thickness burn performed after 48 hours from burn injury
62173493|NCT00434577|EXPERIMENTAL|GSK1437173A _HD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
62173494|NCT00434577|PLACEBO_COMPARATOR|Placebo + GSK1437173A _HD Group|Healthy male or female subjects aged 60 years or older, who received a 1st dose of saline solution and a 2nd dose of GSK1437173A high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
62173495|NCT00434577|ACTIVE_COMPARATOR|GSK1437173A_MODIFIED GROUP|Healthy male or female subjects aged 60 years or older, who received 2 doses of GSK1437173A modified formulation vaccine reconstituted with saline solution, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
62173496|NCT06263296|EXPERIMENTAL|Interventional Group|"For intervention group, principal investigator will assess subject health care needs prior to intervention. Two extra sessions, 20 minutes, face to face, individual self-management education with aid of computer, track log sheet will be provided to intervention group. Concept of motivational interviewing will be incorporated as complement teaching strategy to facilitate self-management learning. Principal investigator will be responsible to deliver burn self-management education upon discharge. Intervention group will receive Rehabilitation Booklet for Burn Patients upon discharge. After discharge, only intervention group subject receives two sessions, 10 minutes, telephone follow up calls and five personalized chat-based messaging follow up will be provided. Besides that, self-management education information will be delivered to intervention group via instant messaging service as well."
62173497|NCT06263296|NO_INTERVENTION|Control Group|For control group, participants will receive usual care by ward nurses (provide burn discharge pamphlet upon discharge + regular plastic surgeon follow up)
62173498|NCT03811834|EXPERIMENTAL|Mobocertinib 160 mg and [14C]-Mobocertinib 50 mcg + [14C]-Mobocertinib 160 mg|Mobocertinib 160 mg, capsule, orally, once under fasted state, followed by \[14C\]-mobocertinib 50 mcg (approximately 2 microcurie \[mcCi\]), infusion, intravenously, once on Day 1 of Period 1, further followed by a washout period of 9 days, followed by \[14C\]-mobocertinib 160 mg (approximately 100 mcCi), solution, orally, once under fasted state on Day 1 of Period 2.
62173499|NCT05892822||Amyotrophic Lateral Sclerosis|This study is an observational study without grouping.
62173500|NCT01547689|EXPERIMENTAL|Human Umbilical Cord Derived MSC|
62173501|NCT05753319||Physiotherapy group|Intervention group with assessment and early physiotherapy
62173502|NCT05753319||Control group|control group without assessment and physiotherapy in the emergency department
62173503|NCT02654457||Women with Breast Cancer #1|IVD Study
62173504|NCT02654457||Women with Breast Cancer #2|IVD Study
62173505|NCT02654457||Women with Breast Cancer #3|IVD Study
62173506|NCT02676440|OTHER|Treatment|Toothpaste containing 1.11% Fluoride as Sodium Monofluorophosphate and Zinc Citrate Trihydrate Serum containing 0.17% Fluoride as Sodium Monofluorophosphate and Zinc Sulphate Heptahydrate
62173507|NCT02676440|OTHER|Comparator|Silica toothpaste 1350ppm F as Sodium Fluoride
62173508|NCT06477237|EXPERIMENTAL|HB0017|Participants will receive HB0017 at week 0,1,2,4,8 followed by once every four weeks (Q4W) or once every eight weeks (Q8W) at Week 12.
62173509|NCT06477237|PLACEBO_COMPARATOR|placebo|Participants will receive placebo at week 0,1,2,4,8 followed by HB0017 once every four weeks (Q4W) at Week 12.
62173510|NCT04975932||Study group: TACE+ICIs|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE); ICIs: atezolizumab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, sintilimab or other ICIs
62173511|NCT04975932||Control group: TACE|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
61986208|NCT02206425|EXPERIMENTAL|carfilzomib + lenalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
62173512|NCT06197685|EXPERIMENTAL|Cognitive Rehabilitation + Aerobic Exercise with Virtual Reality (VR)|In the cognitive rehabilitation and aerobic exercise with VR condition, participants will complete a supervised, aerobic exercise training program (AET) integrated with virtual reality (Ideally Designed Exercise to Accelerate Learning/memory; IDEAL) three days per week over a 12 week period. For seven weeks, participants will only complete IDEAL. For weeks 8-12, participants will complete the Kessler Foundation modified story Memory Technique (KF-mSMT®), a memory retraining program on 2 of the 3 days per week.
62173513|NCT06197685|EXPERIMENTAL|Cognitive Rehabilitation + Stretching and Toning|In the cognitive rehabilitation and stretching and toning (S/T) exercise condition, participants will complete 12 weeks of supervised S/T activities 3 days per week over the 12 week period. For seven weeks, participants will only complete S/T. During weeks 8-12, participants will complete the Kessler Foundation modified story Memory Technique (KF-mSMT®), a memory retraining program on 2 of the 3 days per week.
62173514|NCT01065493|EXPERIMENTAL|Software Assisted Lifestyle Counseling|
62173515|NCT01065493|ACTIVE_COMPARATOR|Lifestyle Counseling|Status quo smoking cessation counseling.
62173516|NCT01688895||Participants with Protoporphyrias|Individuals with a documented diagnosis of Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
62173517|NCT02689752|EXPERIMENTAL|fruquintinib|fruquintinib suspension, 5 mg （100 mCi）oral taken once
62173518|NCT03698617|EXPERIMENTAL|HSK3486|"Dose Escalation Cohort:~0.1 mg/kg, 0.2 mg/kg, 0.3mg/kg 0.4 mg/kg 0.5 mg/kg, 0.6 mg/kg, 0.7mg/kg, 0.8 mg/kg Dose Expansion Cohort: 0.3 mg/kg and 0.5 mg/kg."
62173519|NCT03698617|ACTIVE_COMPARATOR|Propofol|Dose Escalation Cohorts:2.0mg/kg and 2.5mg/kg; Dose Expansion Cohorts: 2.0mg/kg
62173520|NCT01267058|EXPERIMENTAL|Group A|Subjects will receive the combined diphtheria, tetanus, acellular pertussis vaccine
61997423|NCT02259153|ACTIVE_COMPARATOR|Lean red meat diet|Participants were given 350 g per day of lean red meat to incorporate to their usual diet for ten days.
61997424|NCT02259153|ACTIVE_COMPARATOR|Fat red meat diet|Participants were given 350 g per day of fat red meat to incorporate to their usual diet for ten days.
62173521|NCT01267058|ACTIVE_COMPARATOR|Group B|Subjects will receive the acellular pertussis vaccine and one month later the combined diphtheria and tetanus vaccine
62173522|NCT01267058|ACTIVE_COMPARATOR|Group C|Subjects will receive the combined diphtheria and tetanus vaccine and one month later the acellular pertussis vaccine
62173523|NCT06390085|EXPERIMENTAL|Normal myofascial stiffness|Those participants with normal myofascial stiffness as assessed by palpation by a trained clinician.
62173524|NCT06390085|EXPERIMENTAL|Latent myofascial stiffness|Those participants with latent myofascial stiffness as assessed by palpation by a trained clinician.
62173525|NCT06390085|EXPERIMENTAL|Active myofascial stiffness|Those participants with active myofascial stiffness as assessed by palpation by a trained clinician.
62173526|NCT00902226|EXPERIMENTAL|Escitalopram|
62173527|NCT04814992|ACTIVE_COMPARATOR|Computer-Assisted Preoperative CBT Intervention|"Patients will receive the computer-assisted preoperative CBT intervention (n=75). A particularly promising internet-based CBT pain program for the population of interest, PAINTrainer, demonstrated improved pain, function, coping and global health in patients with chronic knee arthritic pain in comparison to an internet education control, with benefits persisting for up to 52 weeks. In addition to the PAINTrainer, there will be an integration of a motivational interviewing (MI) intervention delivered by a trained coach across the sessions about (1) the benefits of opioid tapering for post-operative pain control, (2) approaches for safely tapering, (3) identifying and managing withdrawal symptoms patients may experience."
62182365|NCT01093599|ACTIVE_COMPARATOR|Quit Line Only|Control Participants will call the Wisconsin Tobacco Quit Line intervention including phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
62173528|NCT04814992|NO_INTERVENTION|Treatment-as-usual (control)|Patients scheduled to undergo total joint arthroplasty at the study site are automatically enrolled in a mandatory 4-hour education class delivered by a nurse educator or physical therapist. Utilizing an in-person Powerpoint presentation format, patients are informed about pre-habilitation exercises to do prior to surgery; what to expect the day of surgery; the multimodal analgesia protocol used in the perioperative period; options for anesthesia and analgesia; and the expectation of physical therapy after surgery.
62173529|NCT01042145|ACTIVE_COMPARATOR|Prednisone|Prednisone, 2mg/kg for 3 days
62173530|NCT01042145|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone, 0.6mg/kg for one day, then placebo for 2 days
62173531|NCT04785573|ACTIVE_COMPARATOR|Intervention group|Participants with metabolic disorders will be subjected to nutritional counsel and the intake of 1 soft gel capsule daily for a total of 3 months.
62173532|NCT04785573|NO_INTERVENTION|Control group|Participants with metabolic disorders will be subjected to nutritional counsel for a total of 3 months.
62173533|NCT06344364||Non-Liver Related Event|Absence of any of the liver events described in the second group in the patient clinical follow-up.
62173534|NCT06344364||Liver Related Event|Liver-related events include liver-related death, hepatic decompensation events (variceal hemorrhage, ascites, hepatic encephalopathy), and hepatocellular carcinoma.
62173535|NCT02132598|EXPERIMENTAL|Cabozantinib (XL184)|"Patients will receive cabozantinib at 60 mg orally once daily and continue on treatment until disease progression, death or unacceptable adverse events.~Treatment cycles are 4 weeks in duration"
62173536|NCT00733577|EXPERIMENTAL|Cohort 1|15 mg SB756050 or placebo
62173537|NCT00733577|EXPERIMENTAL|Cohort 2|Planned dose for Cohorts 2 50mg SB756050 or placebo
62173538|NCT00733577|EXPERIMENTAL|Cohort 3|Planned dose for Cohort 3 150mg SB756050 or placebo
62173539|NCT00733577|EXPERIMENTAL|Cohort 4|Planned dose for Cohort 4 600mg SB756050 or placebo
62173540|NCT02137395|EXPERIMENTAL|Dexamethasone|Patients are received dexamethasone via intravenous (iv) route of 0.5 mg.kg-1 (maximum dose of 8 mg) in group D at the induction of anesthesia.
62173541|NCT02137395|PLACEBO_COMPARATOR|Placebo|An equal volume of saline iv in group S at the induction of anesthesia.
62173542|NCT05540418|EXPERIMENTAL|Experimental group|"Pre-procedural information form, state-trait anxiety scale, and comfort scale were applied to patients who had planned colonoscopy.~Two drops of lavender (2%) essential oil was dripped onto a 2 x 2 cm cotton gauze cloth attached to the front of the clothes of the experimental group patients, approximately 12 inches below their noses.~They were asked to inhale 2% lavender essential oil for 20 minutes. They were directed to breathe normally after inhalation.~Vital signs of the patients were checked before and after the procedure. After the process, the forms were filled again, the final test process was completed."
62173543|NCT05540418|NO_INTERVENTION|Control Group|"Pre-procedural information form, state-trait anxiety scale, and comfort scale were applied to patients who had planned colonoscopy. Lavender aromatherapy was not applied to the patients in this group, but routine care was applied.~After the process, the forms were filled again, the final test process was completed. The data took about 15-20 minutes with face-to-face interview method."
62173544|NCT06350370|EXPERIMENTAL|NOSES group|Patients with colorectal cancer underwent transanal or transvaginal specimen extraction
62173545|NCT06446999|EXPERIMENTAL|Yoga-Based Breathing Exercise|A protocol containing yoga-based breathing exercises will be used. The audio recording of this breathing exercise protocol will be uploaded to the video. After verbal information is given about how to do the exercise, the patient will be listened to the audio recording video and will be explained how to do it in practice. Then, the patient will be placed in a comfortable position by wearing headphones and will be allowed to exercise. The patient will be asked to do yoga-based exercise twice a day, the night before the surgery, once in the morning and once in the evening before going to bed for 3 days after the surgery.
62173546|NCT06446999|NO_INTERVENTION|Control|Continuity of routine treatment and care of the patients included in the control group will be ensured.
62173547|NCT05161143|EXPERIMENTAL|Experimental: Donafenib plus TACE|"Donafenib: 4-8 weeks after radical surgery,patients will take donafenib, 200mg Bid,at least 6 months.~TACE:4-8 weeks after radical surgery,Patients will receive TACE once."
62173548|NCT06407947|EXPERIMENTAL|Chimeric antigen receptor modified T cells Infusion|Chimeric antigen receptor modified T cells chimeric antigen receptor T cells
62173549|NCT04757519|EXPERIMENTAL|DPP-GLB Standard|Participants in this group will receive the standard Diabetes Prevention Program Group Lifestyle Balance (DPP-GLP) Intervention Program.
62173550|NCT04757519|EXPERIMENTAL|DPP-GLB Enhanced|Participants in this group will receive the enhanced Diabetes Prevention Program Group Lifestyle Balance (DPP-GLP) Intervention Program.
61997425|NCT01728493||Part 1|- newly diagnosed hypertensive patients in general practice
61997426|NCT01728493||Part 2:|"* newly diagnosed hypertensive patients with primary aldosteronism~* newly diagnosed hypertensive patients with essential hypertension"
61997427|NCT01728493||Part 3:|"* newly diagnosed hypertensive patients with normokalemic primary aldosteronism~* newly diagnosed hypertensive patients with essential hypertension"
62173551|NCT06348498|EXPERIMENTAL|Treatment Group|Jia Shen Tablet，4 tablets，take orally，2 times a day
62173552|NCT03180008|ACTIVE_COMPARATOR|Fit and Strong!|Fit \& Strong! is evidence-based group exercise and self-management program. Classes meet for 90 minutes and include 60 minutes of physical activity (stretching/flexibility, low impact aerobics, and lower-extremity strength training) and 30 minutes of health education that follows a structured, scripted curriculum that centers on physical activity and osteoarthritis and incorporates self-efficacy, social support, and self-regulation. Classes are held 3 days per week for 8 weeks (24 sessions total).
62363903|NCT01627223|EXPERIMENTAL|Lamivudine 100 mg p.o. q.d.|"To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.~* Cohort 1: Lamivudine 100 mg p.o. q.d.~* Cohort 2: Entecavir 0.5 mg p.o. q.d.~This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
61997428|NCT00587379|ACTIVE_COMPARATOR|1|Patients randomized to take 1 40mg Atorvastain pill per day for 6 week study period
61986209|NCT02206425|EXPERIMENTAL|bortezomib + cyclophosphamide + dexamethasone|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
62173553|NCT03180008|EXPERIMENTAL|Fit and Strong! Plus|Fit \& Strong! Plus differs from Fit \& Strong! only in that the 30 minutes of health education, while retaining the core physical activity and osteoarthritis components, has weight and diet-related topics added to the curriculum.
62173554|NCT06647329|EXPERIMENTAL|Treatment|CAR-T therapy
62173555|NCT01935193|EXPERIMENTAL|asa resistant|asa resistant patients receive endovenous infusion of lysine acetylsalicylate 288 mg and if asa resistance has been reversed they have been prescribed oral soluble salt of lysine acetylsalicylate.
62173556|NCT00812825|EXPERIMENTAL|PF-04173127|
62173557|NCT00812825|ACTIVE_COMPARATOR|Prednisolone|
62173558|NCT00812825|PLACEBO_COMPARATOR|Placebo|
62173559|NCT00812825|SHAM_COMPARATOR|Solution Placebo|
62173560|NCT00812825|EXPERIMENTAL|PF-04171327 Tablet|
62173561|NCT03690284|ACTIVE_COMPARATOR|Conventional Double Lumen Tube|Patient will be intubated with conventional double lumen endotracheal tube for single lung ventilation during thoracic surgery.
62173562|NCT03690284|EXPERIMENTAL|VivaSight Double Lumen Tube|Patient will be intubated with VivaSight double lumen endotracheal tube for single lung ventilation during thoracic surgery.
62173563|NCT06316778|EXPERIMENTAL|Pelvic floor muscle training|
62173564|NCT03540615|EXPERIMENTAL|BAY1830839|Single Dose escalations
62173565|NCT03540615|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62173566|NCT02827799|PLACEBO_COMPARATOR|Heart Failure Self-Management Education|This treatment includes participation in 4 one hour biweekly face-face sessions of education on heart failure self-management, as well as a 15 minute telephone call on intervening weeks. The total intervention is 8 weeks.
62173567|NCT02827799|EXPERIMENTAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This treatment includes participation in 4 one hour biweekly face-face sessions of cognitive behavioral therapy for insomnia, as well as a 15 minute telephone call on intervening weeks. The total intervention is 8 weeks.
62173568|NCT04101019|PLACEBO_COMPARATOR|Control|The patient will undergo the SPGB block with saline.
62173569|NCT04101019|ACTIVE_COMPARATOR|Active drug|The patient will undergo the SPGB block with the active drug which will include 10% lidocaine diluted to 5%.
62173570|NCT04957407||non-atrophic gastritis|OLGA-0 group；OLGA (Operative Link on Gastritis Assessment)
62173571|NCT04957407||mild-moderate atrophic gastritis|OLGA I-II group；OLGA (Operative Link on Gastritis Assessment)
62173572|NCT04957407||severe atrophic gastritis|OLGA III-IV group；OLGA (Operative Link on Gastritis Assessment)
62173573|NCT04957407||gastric cancer|gastric cancer
62173574|NCT02785575|ACTIVE_COMPARATOR|HeProCalc|This arm receives heparin and protamine doses according to the novel HeProCalc calculation model.
62173575|NCT02785575|NO_INTERVENTION|Traditional calculations|This arm receives heparin and protamine doses according to the standard protocol (using calculations with body weight and ACT)
62173576|NCT05951439|EXPERIMENTAL|Intervention Group 1|CRE-HMB mixture
62173577|NCT05951439|EXPERIMENTAL|Intervention Group 2|CRE-GGA mixture
62173578|NCT05951439|PLACEBO_COMPARATOR|Intervention Group 3|placebo
62173579|NCT05826405||Cashew Nut allergic|
62173580|NCT03375840|EXPERIMENTAL|Text-only PWL, immediate post|"Exposure to 9 FDA-mandated warning labels~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
62173581|NCT03375840|EXPERIMENTAL|Text-only PWL, delay posttest|"Exposure to 9 FDA-mandated warning labels~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
62391449|NCT02206230|EXPERIMENTAL|Hypofractionated radiation therapy|Hypofractionated radiation therapy of 60 Gy in 20 fractions (3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week. After a 4-week break, temozolomide days 1-5 every 28 days for 6-12 cycles(as per institutional standard)..
62391450|NCT02206230|ACTIVE_COMPARATOR|Standard radiation therapy|Standard radiation therapy of 60 Gy in 30 fractions (2 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week. After a 4-week break, temozolomide days 1-5 every 28 days for 6-12 cycles(as per institutional standard)..
62173582|NCT03375840|EXPERIMENTAL|Low-emot PWL, immediate posttest|"Exposure to 9 warning labels paired with image that elicited little emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
62173583|NCT03375840|EXPERIMENTAL|Low-emot PWL, delay posttest|"Exposure to 9 warning labels paired with image that elicited little emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
62173584|NCT03375840|EXPERIMENTAL|High-emot PWL, immediate posttest|"Exposure to 9 warning labels paired with image that elicited high emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
62173585|NCT03375840|EXPERIMENTAL|High-emot PWL, delay posttest|"Exposure to 9 warning labels paired with image that elicited high emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
62173586|NCT01961921|EXPERIMENTAL|ALN-TTR02 (patisiran)|
62173587|NCT04428983|EXPERIMENTAL|Hericium erinaceus mycelium|Hericium erinaceus capsules 1 table tid orally per day for 24 months
62173588|NCT04428983|PLACEBO_COMPARATOR|placebo|placebo capsules 1 table tid orally per day for 24 months
62173589|NCT00396097|ACTIVE_COMPARATOR|Standard|Standard daily HGH treatment
62173590|NCT00396097|ACTIVE_COMPARATOR|Formula-based|Formula-based dose regimen
62173591|NCT02950714|EXPERIMENTAL|LIN_NOW|Participants from CaNIOS centres randomized to the NOW group will be provided immediate access to the lupus interactive navigator (LIN), a web-based program developed to promote engagement and self-care in lupus.
62173592|NCT02950714|ACTIVE_COMPARATOR|LIN_WAIT|Participants from CaNIOS centres randomized to the WAIT group will have usual care for three months prior to crossing over to access to the LIN.
62173593|NCT01517490||Type 1 Insulin Pump|Patients with type 1 diabetes starting insulin pump treatment
62173594|NCT01517490||Type 1 conventional therapy|Patients with type 1 diabetes continuing treatment with multiple daily insulin injections.
62173595|NCT01517490||Type 2 Bariatric surgery|Patients with type 2 diabetes who are enrolled in pre-operative weight loss protocol prior to bariatric surgery.
62173596|NCT01517490||Type 2 conventional|Severely obese patients with type 2 diabetes who are to continue with non-surgical treatments of diabetes and obesity and with no planned bariatric surgery.
62173597|NCT01517490||Type 1 insulin pumpe follow-up|Patients with type 1 diabetes previously followed in an observational study with electrophysiological and psychophysical measures of retinal function.
62173598|NCT01517490||Healthy|Healthy volunteers.
62173599|NCT05481398|EXPERIMENTAL|Intervention group A|After the skin closed, negative pressure wound therapy will be applied.
62173600|NCT05481398|NO_INTERVENTION|Control group B|After the skin is closed, the wound is covered using sterile standard guaze dressing.
62173601|NCT03627130|ACTIVE_COMPARATOR|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
62173602|NCT03627130|PLACEBO_COMPARATOR|Potassium Chloride|Potassium Chloride
62173603|NCT04059497|EXPERIMENTAL|Exercise group|The exercise group will receive a 10-minute exercise intervention.
62173604|NCT04059497|EXPERIMENTAL|Healthy diet group|The healthy diet group (control) will receive a 10-minute healthy-diet intervention.
62173605|NCT06385314||Oral examination|remove of fixed partial denture for oral examination
62173606|NCT06385314||Denture renewal|remove of fixed partial denture for denture renewal
62173607|NCT06385314||Root canal treatment|remove of fixed partial denture for root canal treatment
62173608|NCT06385314||Tooth extraction|remove of fixed partial denture for tooth extraction
62173609|NCT06385314||Periodontal treatment|remove of fixed partial denture for periodontal treatment
62173610|NCT06385314||Composite filling restoration|remove of fixed partial denture for composite filling restoration
62173611|NCT03698071|EXPERIMENTAL|ANCA associated vasculitis|
62173612|NCT06205576|EXPERIMENTAL|DCB catheter|Using DCB catheter for the treatment of subjects with a de novo or non-stented restenotic obstructive lesion located in the native arteriovenous dialysis fistulae.
62173613|NCT05781841||patients with cutaneous warts|"Under complete sterile precautions, Skin biopsy will be taken from patients with wart lesion.~The specimen will be put in sterile plane tube containing saline and will be transferred immediately to the central research laboratory to be processed"
62173614|NCT05781841||healthy volunteers|"Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 2 mm disposable punches .~The specimen will be put in sterile plane tube containing saline and will be transferred immediately to the central research laboratory to be processed"
62173615|NCT06052345||CIPN group|Breast cancer patients that developed strong CIPN symptomatology at post-treatment evaluation (4 weeks after the end of therapy)
62173616|NCT06052345||No-CIPN group|Breast cancer patients that developed mild-to-no CIPN symptomatology at post-treatment evaluation (4 weeks after the end of therapy)
62173617|NCT06124183|EXPERIMENTAL|Experimental|A 12-session psychological program The intervention program consisted of 12 sessions of 80 minutes with a weekly frequency. The first session was diagnostic, and the following nine correspond to the following topics: perception (2), facilitation (2), labeling and understanding (2), emotional regulation, and management (3). The last session was evaluative. The intervention included practical tasks in context and supervision by clinical psychologist.
62173618|NCT06124183|PLACEBO_COMPARATOR|Control Group|Does not receive intervention
62173619|NCT03009877|ACTIVE_COMPARATOR|Preoxygenation with face mask|Standard preoxygenation with a mask will be performed for five minutes. Once preoxygenation is complete, patients will be induced with standard induction medications including lidocaine, midazolam, fentanyl and propofol. Once the patient is apneic, one breath will be given via facemask to confirm ventilation and then 0.6 mg/kg of rocuronium will be administered. The 5.5mm flexible intubation scope will be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope. Once the flexible intubation scope is in the trachea, the endotracheal tube (7.0 mm unless otherwise specified) will be advanced. Ventilation will not begin until the primary or secondary endpoints are reached.
62173620|NCT03009877|EXPERIMENTAL|Preoxygenation via hi flow nasal cannula|The high flow nasal cannula (Optiflow) will be applied as soon as the patient is in the operating room. The patient will be preoxygenated with high flow nasal cannula at 50 L/min for 5 minutes. After induction, general anesthesia will be maintained with a propofol infusion. One breath will be given via facemask to confirm ventilation and then 0.6 mg/kg of rocuronium will be administered. Upon apnea, the Optiflow™ flow will be increased to 70 L/min and jaw thrust will be performed until the patient is adequately relaxed. The video laryngoscope (C-MAC) will then be introduced into the oropharynx and the flexible intubation scope advanced into the trachea with the assistance of the C-MAC. Once the flexible intubation scope is in the trachea, the endotracheal tube will be advanced.
62173621|NCT02526771|EXPERIMENTAL|conventional lymph node dissection|conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
62173622|NCT02526771|ACTIVE_COMPARATOR|unconventional lymph node dissection|unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
62173623|NCT06408922|ACTIVE_COMPARATOR|Single prp injection|single intraarticular prp injection
62173624|NCT06408922|ACTIVE_COMPARATOR|triple prp injection|triple intraarticular prp injection
62173625|NCT02759887|OTHER|DS adult group|Consists of 15 DS subjects aged 21 and older who do not qualify for the diagnosis of dementia at the beginning of the study. Interventions include biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
61997429|NCT00587379|PLACEBO_COMPARATOR|2|Patients randomized to 1 40mg placebo pill per day for 6 week study
61997430|NCT06110988|EXPERIMENTAL|Pan-vascular interventional robotic system|Pan-vascular interventional robotic system assisted PCI
62173626|NCT02759887|OTHER|DS/AD group|Consists of 15 DS subjects aged 40 and older who do qualify for the diagnosis of dementia by DSM-IV criteria. Diagnoses will be by standard consensus review of all cases. Interventions include biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
62173627|NCT02759887|OTHER|NC adult|Consists of 10 cognitively normal, non-DS individuals, age-matched to the DS adult group. Interventions include biospecimen collection, cognitive assessments, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
62173628|NCT01876771|EXPERIMENTAL|[177]Lu-DOTA-TATE Therapy|"Nominal, induction stage dose of 150 mCi (5.55 GBq) \[177\]Lu-DOTA-TATE every 10 - 14 weeks for 4 treatments.~Nominal maintenance stage dose of 75 mCi (2.78 GBq) \[177\]Lu-DOTA-TATE every 22 - 40 weeks, up to a maximum of 8 treatments."
62173629|NCT03439397|EXPERIMENTAL|Ballon Technique group|Intervention：Ballon Technique
62173630|NCT03439397|ACTIVE_COMPARATOR|SOAI group|Intervention：Selective Ophthalmic Artery Infusion
62173631|NCT04136587|ACTIVE_COMPARATOR|Healthy Controls|"Inclusion criteria:~* Colonoscopy performed for the following indications: anemia, blood in stool, constipation, change in bowel habits, screening for colon cancer, follow up after polyps, weight loss~* Macroscopic normal colonoscopy except for diverticulosis (without any signs of inflammation), ≤ 3 polyps (except hyperplastic polyps of the colon and rectum), angiodysplasia~Exclusion criteria:~* Diagnosis of IBD or any other inflammatory condition of the small and large intestine~* Diagnosis of irritable bowel syndrome (IBS)~* Autoimmune disorders~* Obesity (BMI\> 30)~* Regular intake of NSAIDs (\> 2 tablets/ week), immunosuppressants~* Intake of antibiotics within the last 3 months~* Intestinal infection by enteric pathogens~* Probiotic therapy"
62173632|NCT04136587|ACTIVE_COMPARATOR|Crohn's disease|"2 Subgroups: inactive disease (10 patients) and active disease (10 patients)~Inclusion criteria:~* Colonoscopy indicated by routine clinical care~* Established diagnosis of Crohn´s disease (also if established by the study colonoscopy)~Exclusion criteria:~• Intestinal infection by enteric pathogens"
62173633|NCT04136587|ACTIVE_COMPARATOR|Ulcerative Colitis|"2 Subgroups: inactive disease (10 patients) and active disease (10 patients)~Inclusion criteria:~* Colonoscopy indicated by routine clinical care~* Established diagnosis of ulcerative colitis (also if established by the study colonoscopy)~Exclusion criteria:~• Intestinal infection by enteric pathogens"
62173634|NCT04136587|ACTIVE_COMPARATOR|Colorectal carcinoma|"Inclusion criteria:~• Diagnosis of a lesion with suspicion for colorectal cancer during endoscopy which is confirmed later by histology~Exclusion criteria:~• None"
62173635|NCT04136587|ACTIVE_COMPARATOR|Colitis/Enteritis of other origin|"Inclusion criteria:~* Diagnosis of intestinal inflammation at endoscopy or histology~* E.g.: Infectious colitis /enteritis; ischemic Colitis; microscopic colitis; graft versus host disease (GVHD); NSAID colitis; Colitis of unknown cause~Exclusion criteria:~• None"
62173636|NCT06350591|EXPERIMENTAL|Immobilization|Participants will undergo 10 days of unilateral immobilization whereby a leg will remain in 60 degrees of flexion with the use of a brace. All participants will complete this protocol.
62173637|NCT06350591|EXPERIMENTAL|Resistance Training|Participants will undergo 4 sessions of unilateral resistance training over a 10 day period (the resistance training protocol will include 3 sets of 8-12 reps of leg press and leg extension). All participants will complete this protocol. On day 0, participants will be asked to undergo a bout of unilateral resistance exercise, and the investigators will assess the acute response to exercise + protein feeding (via EAA supplement).
62173638|NCT03727997||AKI patients stage 3|
62173639|NCT02847819||Vocal cords movement assessment by airway USG.|Preoperatively patients undergoing thyroid surgery will be scanned by airway ultrasound and graded for vocal cord movement, the same group of patients will be again scanned and graded by airway ultrasound at 4th post operative hours.
62173640|NCT00895089|EXPERIMENTAL|A: Moxifloxacin|Moxifloxacin 400mg IV once daily for 14 days, then 400mg PO once daily for 7 days.
62173641|NCT00895089|ACTIVE_COMPARATOR|B: Ceftriaxone|Ceftriaxone 2gm IV every 12 hours for 14 days, then cephalexin 1gm PO every 6 hours for 7 days.
62173642|NCT00651937|ACTIVE_COMPARATOR|Standard Dose|Melphalan + Stem Cell Infusion (Standard Dose): Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10\^6 cluster of differentiation 34 (CD34)/kg on Day 0. Melphalan 100 mg/m\^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion. Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days. Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
62173643|NCT00651937|ACTIVE_COMPARATOR|High Dose|Melphalan + Stem Cell Infusion (High Dose): High Dose (Arm 2) = Stem cell dose of between 10-15 x 10\^6 CD34/kg On Day 0. Melphalan 100 mg/m\^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion. Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days. Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
61997431|NCT04366622|EXPERIMENTAL|Riociguat, Child Pugh A|Participants with liver cirrhosis and mild hepatic impairment received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
62173644|NCT05648318|EXPERIMENTAL|Lactulose oral solution (LOS)|
62173645|NCT05648318|ACTIVE_COMPARATOR|polyethylene glycol (PEG)|
62550232|NCT01955941||Cohort A|Patients with uveal melanoma for which brachytherapy is recommended will be considered and evaluated for enrollment into this study in order to describe the association between radiation treatment and changes in vision and blood flow within these treated eyes. Changes in vision and blood flow will be monitored at yearly intervals over a 5-year period. Up to 60 subjects will be recruited for this group.
61997432|NCT04366622|EXPERIMENTAL|Riociguat, Child Pugh B|Participants with liver cirrhosis and moderate hepatic impairment received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
61997433|NCT04366622|EXPERIMENTAL|Riociguat, control A|Healthy age-, weight-, and gender- matched participants to Child Pugh A group received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
61997434|NCT04366622|EXPERIMENTAL|Riociguat, control B|Healthy age-, weight-, and gender- matched participants to Child Pugh B group received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
62173646|NCT06331533|EXPERIMENTAL|Botulinum toxin A|30 points were marked on a randomly selected face half at 0.5 cm intervals. 0.5 U BoNT-A was injected into each point, making a total of 15 U BoNT-A.
62173647|NCT06331533|PLACEBO_COMPARATOR|Placebo|30 points were marked on a randomly selected face half at 0.5 cm intervals. 1.5 ml isotonic NaCl was injected intradermally into 30 points.
62173648|NCT04777097||healthy pregnant women|Healthy patients who receive a cesarean operation
62173649|NCT04777097||Pre-eclampsia|Patients with pre-eclampsia who receive a caesarean operation
62173650|NCT02621047|EXPERIMENTAL|Alectinib: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 milligrams (mg) on Day 1.
62173651|NCT02621047|EXPERIMENTAL|Alectinib: Severe Hepatic Impairment|Participants with severe hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 mg on Day 1.
62173652|NCT02621047|EXPERIMENTAL|Alectinib: Normal Hepatic Function|Participants with normal hepatic function will receive alectinib at a single oral dose of 300 mg on Day 1.
62173653|NCT00372255|EXPERIMENTAL|Influsplit SSW® 2005/2006 6-9 years Group|Subjects aged 6 to 9 years who received 2 doses of Influsplit SSW® 2005/2006 vaccine at an interval of 4 weeks (Day 0 and Day 28 ± 2).
62173654|NCT00372255|ACTIVE_COMPARATOR|Influsplit SSW® 2005/2006 10-13 years Group|Subjects aged 10 to 13 years who received 1 dose of Influsplit SSW® 2005/2006 vaccine at Day 0.
62173655|NCT04665778||high risk of hospitalization|
62173656|NCT04665778||not high risk of hospitalization|
62173657|NCT01428700||Non-Immune/Non-Viral (NINV)|Patients enrolled in ITN030ST transplanted for liver failure resulting from non-viral, non-immune causes
62173658|NCT01428700||Hepatitis C Virus (HCV) positive|Patients enrolled in ITN030ST transplanted for liver failure resulting from HCV genotype 1 infection
62173659|NCT03327077|NO_INTERVENTION|Control Group|
62173660|NCT03327077|EXPERIMENTAL|Intervention Group|Music group
62173661|NCT02810483|EXPERIMENTAL|Arm 1: Topiramate|Topiramate Arrow 50 mg hard capsules
62173662|NCT02810483|PLACEBO_COMPARATOR|Arm 2: Placebo Comparator|50 mg hard capsules with the same shape, color and taste than the active product
62173663|NCT04765813|EXPERIMENTAL|CBT and active smartphone mobile application|Participants receive a cognitive-behavioral treatment to quit smoking along with an App with active therapeutic components
62173664|NCT04765813|ACTIVE_COMPARATOR|CBT and control smartphone mobile application|Participants receive a cognitive-behavioral treatment to quit smoking along with a control App
62173665|NCT02303002|EXPERIMENTAL|Dose A|Dose A: Botulinum Toxin Type A
62173666|NCT02303002|EXPERIMENTAL|Dose B|Dose B: Botulinum Toxin Type A
62173667|NCT02303002|EXPERIMENTAL|Dose C|Dose C: Botulinum Toxin Type A
62173668|NCT02303002|ACTIVE_COMPARATOR|Dose D|Dose D: Botulinum Toxin Type A
61997435|NCT02242357||Patients with hypertension|
62173669|NCT02303002|PLACEBO_COMPARATOR|Dose E|Dose E: Placebo
62173670|NCT01861795||Preterm Neonates|Preterm neonates born at or above 27+0 weeks of gestational age sufficiently stable on nasal continuous positive airway pressure (CPAP) will be treated by standard of care.
62173671|NCT01724047|EXPERIMENTAL|Playground Intervention|Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed 2) Waitlist treatment, where the training will begin the following school year. The initial delivery will occur for 30 minutes three times for a period of two to three weeks, then 30 minutes two times for a period of two weeks, then 30 minutes once a week for up to 16 sessions, within a period of 3 months, then a 30 minute follow up will occur 3 months later. A systematic fading of intervention using performance feedback, coaching, and consultation. Outcome measures will be administered at entry, end of treatment, and 3-month follow-up. Entry diagnostic, exit and follow up assessments will last 1.5- 2 hours and participants will be assessed after school or in their homes.
62173672|NCT01724047|EXPERIMENTAL|STAT Intervention|Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. The intervention will be over a period of 6 weeks, with baseline, treatment, and a follow up visit totaling 18 weeks at the school site. Each visit is approximately 30 minutes. A systematic fading of intervention using performance feedback, coaching, and consultation. Outcome measures will be administered at entry, end of treatment. Entry diagnostic, exit and follow up assessments will last 1.5- 2 hours and participants will be assessed after school or in their homes.
62173673|NCT01724047|NO_INTERVENTION|Playground Waitlist Control|Waitlist Control
62173674|NCT01724047|NO_INTERVENTION|STAT Waitlist Control|Waitlist Control
61997436|NCT03118128|ACTIVE_COMPARATOR|metformin|Metformin 850mg PO three times a day, during the pre-induction with steroids, induction remission, consolidation and maintenance
62173675|NCT02435381|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo from days 2- 4.
62173676|NCT02435381|ACTIVE_COMPARATOR|Carisbamate|Participants will receive carisbamate 600mg qd from days 2- 4.
62173677|NCT01261455|ACTIVE_COMPARATOR|Superior Conjunctival Autograft|Conjunctival autograft following pterygium excision is taken from superior conjunctival tissue.
62173678|NCT01261455|EXPERIMENTAL|Inferior Conjunctival Autograft|Conjunctival autograft following pterygium excision is taken from inferior conjunctival tissue.
62173679|NCT05235997|EXPERIMENTAL|Hydrolized Collagen Peptide|This arm will be allocated randomly and receive 10 g hydrolized collagen peptide (Investigational Product) daily throughout the study.
61997437|NCT03118128|NO_INTERVENTION|No metformin|
61997438|NCT06251856|EXPERIMENTAL|lymphedema education|Participants will receive lymphedema education and educational brochures from the researcher on the 2nd day after gynecological cancer surgery.
62173680|NCT05235997|PLACEBO_COMPARATOR|Placebo|This arm will be allocated randomly and receive placebo throughout the study.
62173681|NCT03787238|EXPERIMENTAL|non-invasive Vagus Nerve Stimulation|nVNS (non-invasive vagus nerve stimulation) treatment with the gammaCore Sapphire device and standard of care
62173682|NCT03787238|NO_INTERVENTION|Standard of Care|Standard of Care treatment
62173683|NCT03790878|EXPERIMENTAL|Mindful Breathing|Participants receive training in a mindful breathing skill to regulate their emotional distress during a stressor task. They will then receive one week of reminders to use this skill, delivered through their mobile phones.
62173684|NCT03790878|ACTIVE_COMPARATOR|Habituation|Participants receive an exposure/habituation intervention to regulate their emotional distress during a stressor task. They will then receive one week of reminders, delivered through their mobile phones.
62173685|NCT03790878|PLACEBO_COMPARATOR|Control|Participants complete the stressor task with no emotion regulation training. Similar to the other conditions, they will then receive one week of reminders, delivered through their mobile phones to test for placebo effects.
62173686|NCT01325818|ACTIVE_COMPARATOR|1:pravastatin, 2:rosuvastatin|"1. Active Comparator Drug:pravastatin~2. Active Comparator Drug:rosuvastatin"
62173687|NCT06566209||Experimental FDG PET/CT|Patients will undergo PET/CT imaging as per clinical protocol, which includes 18F-FDG PET/CT, 13N-Amonia perfusion PET scan and CT imaging.
62173688|NCT06459037|EXPERIMENTAL|Healthy Periodontium|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
62173689|NCT06459037|EXPERIMENTAL|Gingivitis|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
62173690|NCT06459037|EXPERIMENTAL|non-smoker periodontitis|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
62173691|NCT06459037|EXPERIMENTAL|smoker periodontitis|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
62173692|NCT05189171||Metastatic colorectal cancer|Patients having a liver biopsy for suspected adenocarcinoma of the colon and/or rectum that is metastatic to the liver.
62173693|NCT04884490|EXPERIMENTAL|Intervention|"Eligible patients will be receiving either to oral co-trimoxazole + standard therapy.~Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally.~The following treatments are recommended as standard therapy:~1. Antibiotics for secondary bacterial infection as per institutional guidelines~2. Supplemental oxygen (to keep saturations between 92% to 96%)~3. Intravenous hydration (to maintain euvolumia)~4. Thrombo-prophylaxis as per local guidelines~5. Paracetamol (oral or I/V 1gram QDS as required or regular)~6. To consider steroids in appropriate cases.~7. Nasopharyngeal and throat swab to be sent for RT PCR to detect SARS-CoV-2 (if not already done) and blood culture Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally."
62173694|NCT04884490|PLACEBO_COMPARATOR|Standard|"Standard therapy along with placebo.~Placebo thrice (8 hourly) for 7 days.~The following treatments are recommended as standard therapy:~1. Antibiotics for secondary bacterial infection as per institutional guidelines~2. Supplemental oxygen (to keep saturations between 92% to 96%)~3. Intravenous hydration (to maintain euvolumia)~4. Thrombo-prophylaxis as per local guidelines~5. Paracetamol (oral or I/V 1gram QDS as required or regular)~6. To consider steroids in appropriate cases.~7. Nasopharyngeal and throat swab to be sent for RT PCR to detect SARS-CoV-2 (if not already done) and blood culture"
62173695|NCT03466229|ACTIVE_COMPARATOR|Antioxidant|Androferti - 1 twice per day
62173696|NCT03466229|PLACEBO_COMPARATOR|Placebo|Placebo - 1 twice per day
62173697|NCT03321656|ACTIVE_COMPARATOR|Tacrolimus|0.1 - 0.2 mg/kg/day in 2 divided doses every 12 hours orally
62173698|NCT03321656|EXPERIMENTAL|Envarsus XR|0.07-0.14 mg/kg/day every morning orally
62173699|NCT04770740|ACTIVE_COMPARATOR|Experimental: Vitamin K2|Patients with COVID-19 who get our dietary supplement vitamin K2, three tablets of 333mcg a day, for 14 days or until discharge, whichever occurs earlier.
62173700|NCT04770740|PLACEBO_COMPARATOR|Control: Placebo|Patients with COVID-19 who get placebo as control, three tablets a day, for 14 days or until discharge, whichever occurs earlier.
62173701|NCT00162552|ACTIVE_COMPARATOR|1|Patients with severe cirrhosis treated with Pentoxifylline
62173702|NCT00162552|PLACEBO_COMPARATOR|2|Patients with severe cirrhosis treated with a placebo
62173703|NCT04584359|EXPERIMENTAL|HVLA techiniques (G1)|Performed with thrust (also known as HVLA) in the sacroiliac joint and T10-L2 level
62173704|NCT04584359|EXPERIMENTAL|Global osteopathic protocol (G2)|Several elements were emphasized - myofascial, bone, and visceral.
62173705|NCT04584359|EXPERIMENTAL|Pelvic floor muscle training (G3)|Muscle Training for four weeks, with a weekly face-to-face visit lasting 10-20 minutes.
62173706|NCT04584359|NO_INTERVENTION|Control group (G4)|No intervention and was simply evaluated and re-evaluated.
62173707|NCT03650361|EXPERIMENTAL|Test Product|Adapalene Gel 0.3% manufactured by Aleor Dermaceuticals Limited, applied for 84 days
62173708|NCT03650361|ACTIVE_COMPARATOR|Reference Product|Adapalene Gel 0.3%, , applied for 84 days
62173709|NCT03650361|PLACEBO_COMPARATOR|Placebo Control|Vehicle of the test product, applied for 84 days
62550233|NCT01955941||Cohort B|Patients with uveal melanoma who have previously undergone I-125 plaque brachytherapy will be considered for enrollment into this study to evaluate blood flow in eyes with more advanced radiation-induced changes. This group will only undergo a one-time study session. Up to 40 subjects will be recruited for this group.
62173710|NCT04589390|OTHER|Selexipag|Selexipag will be up titrated for a period that will last 12 weeks (Phase 2). The initial dose will be 200 mcg of selexipag every 12 hours, with weekly dose increases of 200 mcg, up to the maximum dose of 1600 mcg every 12 hours or until the classic side effects of the prostacyclin pathway drugs (headache, mandibular pain), among others) arise. The dose will then be reduced by 200 mcg per dose, and this will be the maximum dose considered for that particular patient, maintained in Phase 3 (16 weeks).
62173711|NCT06336941|EXPERIMENTAL|Ultrasound group|The patients with a clinical diagnosis of oral squamous cell carcinoma will undergo intraoral ultrasonographic scan with a 70 MHz frequency probe to evaluate tumor depth of invasion and thickness
62173712|NCT04602039|EXPERIMENTAL|People without Diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
62173713|NCT04602039|EXPERIMENTAL|Participants with Pre-diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
62173714|NCT04602039|EXPERIMENTAL|Participants with Type 2 diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
62173715|NCT00514813|EXPERIMENTAL|Dynepo (Epoetin delta)|Subjects received Dynepo (Epoetin delta) either twice weekly (BIW), once weekly (QW), once every 2 weeks (Q2W) or once every 4 weeks (Q4W) based on what is appropriate for the subject
62173716|NCT05915013|EXPERIMENTAL|ketamine plus perampanel|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive 6 milligrams (mg) oral perampanel and intravenous ketamine. Participants will then undergo a 2-hour magnetic resonance imagining (MRI) scan. The following day, participants will return for an additional scan and symptom assessment.
62173717|NCT05915013|PLACEBO_COMPARATOR|ketamine plus placebo|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive an oral placebo (in lieu of 6 mg oral perampanel) and intravenous ketamine. Participants will then undergo a 2-hour MRI scan. The following day, participants will return for an additional scan and symptom assessment.
62173718|NCT03317678|EXPERIMENTAL|BioKefir (BKP)|BioKefir™ (Lifeway Foods) is a lactose-free fermented milk drink containing 12 different species of bacteria within the lactobacillus, bifidobacterium, and streptococcus generas totaling approximately 20 CFU per 3.5 ounce serving. The product also contains 2 g of fiber, including pectin and inulin. These fibers, especially inulin, are prebiotics that may function along with the probiotic species to support gastrointestinal health. The product is available commercially. Participants will be asked to consume 3.5 ounces twice daily, preferably at morning and nighttime. The probiotic will be provided in individual 3.5 ounce unlabeled containers. These quantities will be started on the first day of the intervention phase of the study (day 0, visit 0) and remain unchanged until the end of the intervention phase on day 56 (visit +4). Administration will be discontinued then.
62173719|NCT03317678|PLACEBO_COMPARATOR|Non-fermented Milk (NFM)|The NFM is dairy-based product ultra-filtered to remove lactose. In addition to being matched to lactose, the NFM contains similar energy, fat, and protein content as the probiotic. Participants will be asked to consume 3.5 ounces twice daily, preferably at morning and nighttime. The NFM control will be provided in 11.5 ounce unlabeled containers. These quantities will be started on the first day of the intervention phase of the study (day 0, visit 0) and remain unchanged until the end of the intervention phase on day 56 (visit +4). Administration will be discontinued then.
62173720|NCT02130271||Healthy|"Healthy subjects with no pain.~* Radioactive dye~* PET/MRI~* Blood draw"
62173721|NCT02130271||Sciatica|"Subjects with sciatica and scheduled for an epidural steroid injection (ESI).~* Radioactive dye~* PET/MRI~* Blood draw"
62173722|NCT05671133|EXPERIMENTAL|Experimental|Patient's clinician is given Clinician Decision Support Tool
62173723|NCT05671133|NO_INTERVENTION|Control|Patient's clinician is not given Clinician Decision Support Tool (care as usual)
62173724|NCT00603057||Lung Cancer Imaging Patients|Adult patients (\>18 years of age)with histologically confirmed or clinically diagnosed lung cancer who require radiation therapy, with or without surgery and with or without chemotherapy.
62173725|NCT02904161||first stage|For the first stage, 60 healthy volunteers, 10 patients with stage 4 breast cancer and 10 patients with other types of cancer will be recruited.
62173726|NCT02904161||second stage|For the second stage, approximately 65 breast cancer patients will be recruited.
62173727|NCT03284125||Facial paralysis|Patients affected by facial paralysis treated by LTM The aim is to evaluate the improvement of the swallowing disorders after surgery.
62173728|NCT04653207|OTHER|Control 1|Glucose 50g
62173729|NCT04653207|OTHER|Control 2|Glucose 50g
62173730|NCT04653207|OTHER|Control 3|Glucose 50g
62173731|NCT04653207|EXPERIMENTAL|Sucrose/Isomaltulose 100:0|A drink with 50g sucrose/isomaltulose 100:0
62173732|NCT04653207|EXPERIMENTAL|Sucrose/Isomaltulose 0:100|A drink with 50g sucrose/isomaltulose 0:100
62173733|NCT04653207|EXPERIMENTAL|Sucrose/Isomaltulose 50:50|A drink with 50g sucrose/isomaltulose 50:50
62173734|NCT04653207|EXPERIMENTAL|Sucrose/Isomaltulose 60:40|A drink with 50g sucrose/isomaltulose 60:40
62173735|NCT04653207|EXPERIMENTAL|Sucrose/Isomaltulose 70:30|A drink with 50g sucrose/isomaltulose 70:30
62173736|NCT04653207|EXPERIMENTAL|Sucrose/Isomaltulose 80:20|A drink with 50g sucrose/isomaltulose 80:20
62173737|NCT02254681|EXPERIMENTAL|Treatment|Four three-week treatment cycles. Gemcitabine (1000 gm/m\^2) and cisplatin (25 mg/m\^2) administered on days one and eight of each cycle. Whole liver and portal lymph node basin low dose radiotherapy on days one, two, eight, and nine of each cycle.
62173738|NCT03952728||ILI/ Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention, consented to administrative data linkages, and were successfully linked to Medicare databases.
62173739|NCT03952728||Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education control arm, consented to administrative data linkages, and were successfully linked to Medicare databases.
62173740|NCT04037306|ACTIVE_COMPARATOR|Rapid Feedback|Participants received daily feedback on both fiber intake and stool butyrate measurements.
62173741|NCT04037306|ACTIVE_COMPARATOR|Delayed Feedback|Participants received daily feedback on fiber intake and one-time feedback on stool butyrate measurements at the end of the study period.
62739300|NCT06659302|EXPERIMENTAL|Two sessions|Step 2: Parents who were identified as high stress/behaviour on the baseline questionnaires and/or based on the introduction meeting in Step 1, will be invited to participate in the initial two therapist-guided I-InTERACT-North sessions that focus on family stress and positive parenting strategies. Each session includes both an online psychoeducational module and a video conferencing session with a therapist. Session frequency is subject to change based on parent schedule preference and availability. Each session will last 60 minutes and will be video recorded (with consent from the participants). Sessions will be delivered to parents using Zoom, a secure online video conferencing platform (https://zoom.us/). If they wish to proceed to the full program, they will complete the questionnaires after step 3.
62173742|NCT02003664|ACTIVE_COMPARATOR|Baclofen ER versus Placebo|Baclofen ER versus Placebo (sugar pill)
62173743|NCT02003664|PLACEBO_COMPARATOR|Placebo versus Baclofen ER|Participants will receive either placebo (sugar pill) or Baclofen ER
62173744|NCT00747721|EXPERIMENTAL|1|Dexmedetomidine
62173745|NCT04151771|EXPERIMENTAL|LL-BFRT group|Participants randomised into intervention group are attending pulmonary rehabilitation in which strengthening exercises of the lower limb are performed using LL-BFRT.
62173746|NCT04151771|ACTIVE_COMPARATOR|Usual pulmonary rehabilitation group|Participants randomised into control group are attending usual pulmonary rehabilitation as established.
62173747|NCT01683643|EXPERIMENTAL|SBIRT Group|Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Experimental subjects, in addition to their risk score and informational materials, will also receive a brief intervention and a referral to treatment appropriate to their risk score from trained health educators. The health educators will be provided by Homeless Health Care, Los Angeles.
62173748|NCT01683643|ACTIVE_COMPARATOR|Control Group|Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
62173749|NCT00961298|EXPERIMENTAL|Duloxetine|Two weeks of placebo run in followed by 12 weeks of Duloxetine.
62173750|NCT00836914|ACTIVE_COMPARATOR|CAL-101|
62173751|NCT00836914|PLACEBO_COMPARATOR|Placebo|
62173752|NCT01808521|EXPERIMENTAL|N-acetylcysteine|IV administration of N-acetylcysteine (Acetadote) at 150mg/Kg loading bolus over 60 minutes followed by 150mg/Kg over 17 hours if loading dose was well tolerated.
62173753|NCT03630965|NO_INTERVENTION|Group A|No CPR video
62173754|NCT03630965|EXPERIMENTAL|Group B|CPR video
62173755|NCT01994538|ACTIVE_COMPARATOR|Longer (14 day) duration antimicrobial treatment|14 days of ciprofloxacin or trimethoprim/sulfamethoxazole
62173756|NCT01994538|PLACEBO_COMPARATOR|Shorter (7 day) duration antimicrobial treatment|7 days of ciprofloxacin or trimethoprim/sulfamethoxazole, followed by 7 days of placebo
62173757|NCT02212197|EXPERIMENTAL|CAM2032 3.75 mg|Single subcutaneous buttock injections of CAM2032 (leuprolide acetate FluidCrystal® injection depot) 3.75 mg on Days 0, 28 and 56.
62173758|NCT02212197|EXPERIMENTAL|CAM2032 7.5 mg|Single subcutaneous buttock injections of CAM2032 (leuprolide acetate FluidCrystal® injection depot) 7.5 mg on Days 0, 28 and 56.
62173759|NCT02212197|ACTIVE_COMPARATOR|Eligard 7.5 mg|Single subcutaneous buttock injections of Eligard® (leuprolide acetate) 7.5 mg on Days 0, 28 and 56.
62173760|NCT03022383||Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the DRI OCT Triton Plus device
62173761|NCT01713998|ACTIVE_COMPARATOR|Group A|Subjects will receive an increased density Ulthera System Treatment over the full face but with the energy turned down to the second highest level of four possible energy settings on one side of the face.
62173762|NCT01713998|ACTIVE_COMPARATOR|Group B|Subjects will receive an increased density guideline Ulthera System Treatment over the full face but with the energy turned down to the lowest level of four possible energy settings on one side of the face.
62173763|NCT01713998|ACTIVE_COMPARATOR|Group C|Subjects will receive an increased density guideline Ulthera System Treatment over the full face with the exception that a 4 MHz transducer will be used on the upper face in place of a7 MHz transducer, with the energy turned down to the lowest level of four possible energy settings.
62173764|NCT04313036|EXPERIMENTAL|Defibrotide|5 day course of defibrotide at standard dosing 25 mg/kg/day in 4 divided doses of 6.25 mg/kg. If not in CR by day 5, will be given for \>/= 21 days or per discretion of enrolling physician.
62173765|NCT04289714|EXPERIMENTAL|R-DOT|Remote Directly Observed Therapy
62173766|NCT04289714|EXPERIMENTAL|Haillie|Smartinhaler Haillie
62173767|NCT04289714|EXPERIMENTAL|Rafi-tone/INCA|Rafi-tone with Flo-tone /INCA
62173768|NCT03435614||Critically ill patients|Mechanically ventilated critically ill adults receiving regular opioids for more than 72 hours will be prospectively followed for the emergence of withdrawal symptoms upon weaning of opioids.
62173769|NCT02156388|EXPERIMENTAL|Ia-GW003 50μg/kg|2-3 subjects
62173770|NCT02156388|EXPERIMENTAL|Ia-GW003 150μg/kg|2-3 subjects
62173771|NCT02156388|EXPERIMENTAL|Ia-GW003 300μg/kg|3-6 subjects
62173772|NCT02156388|EXPERIMENTAL|Ia-GW003 400μg/kg|3-6 subjects
62173773|NCT02156388|EXPERIMENTAL|Ia-GW003 500μg/kg|3-6 subjects
62173774|NCT02156388|EXPERIMENTAL|Ia-GW003 600μg/kg|3-6 subjects
62173775|NCT02156388|EXPERIMENTAL|Ib-GW003 150μg/kg|6-8 subjects
62173776|NCT02156388|EXPERIMENTAL|Ib-GW003 300μg/kg|6-8 subjects
62173777|NCT04258488|EXPERIMENTAL|Oral Factor Xa inhibitor|
62173778|NCT04258488|ACTIVE_COMPARATOR|Vitamin K antagonist|
62173779|NCT04632797|ACTIVE_COMPARATOR|Cryocompression|Patients in this group receive cryocompression for the hands.
62173780|NCT04632797|ACTIVE_COMPARATOR|Cryotherapy|Patients in this group receive cryotherapy for the hands.
62173781|NCT04448925|EXPERIMENTAL|Recovery duration 15 seconds|Resting for 15 sec
62173782|NCT04448925|EXPERIMENTAL|Recovery duration 30 seconds|Resting for 30 sec
62173783|NCT04448925|EXPERIMENTAL|Recovery duration 45 seconds|Resting for 45 sec
62173784|NCT05345847|EXPERIMENTAL|1- Active Surveillance|Active surveillance with rescue corticosteroids
62173785|NCT05345847|ACTIVE_COMPARATOR|2- Early initiation of steroid (Standard)|Early intervention with high-dose steroids
62173786|NCT01494740|EXPERIMENTAL|split-virion, non-adjuvanted vaccine of 7.5 μg|split-virion, non-adjuvanted H1N1 vaccine of 7.5 μg.
62173787|NCT01494740|EXPERIMENTAL|split-virion, non-adjuvanted vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
62173788|NCT01494740|PLACEBO_COMPARATOR|split-virion, non-adjuvanted vaccine of seasonal influenza|split-virion, non-adjuvanted H1N1 vaccine of seasonal influenza.
62173789|NCT06337786|EXPERIMENTAL|Intervention arm|Patients diagnosed with rheumatoid arthritis receiving standard routine care and the digital app RB4.1.
62173790|NCT06337786|ACTIVE_COMPARATOR|Control arm|Matched controls from the DANBIO register receiving standard routine care. Up to 3 patients will be matched based on sex, age (+/-5 years), time at enrolment (\< 2 years prior to index date is allowed) and DAS28 scores (+/- 0.4).
62173791|NCT00817336|EXPERIMENTAL|D-serine|60 mg/kg/day
62173792|NCT00817336|PLACEBO_COMPARATOR|Placebo|
62173793|NCT02724163|ACTIVE_COMPARATOR|Mitoxantrone|"Course 1~* Mitoxantrone: 12 mg/m2 daily by IV infusion over 1 hour on days 1, 2, 3 and 4 (total 4 doses).~* Cytarabine:100 mg/m2 12 hourly by IV bolus on days 1-10 inclusive (total 20 doses).~Course 2~* Mitoxantrone: 12 mg/m2 daily by IV infusion over 1 hour on days 1, 2 and 3 (total 3 doses).~* Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-8 inclusive (total 16 doses)."
62173794|NCT02724163|EXPERIMENTAL|Liposomal daunorubicin|"Randomisation 1 (R1)) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug.~Course 1~* Liposomal daunorubicin: 80 mg/m2 daily by 1 hour IV infusion on days 1, 3 and 5 (total 3 doses).~* Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-10 inclusive (total 20 doses).~Course 2~* Liposomal daunorubicin: 60 mg/m2 daily by 1 hour IV infusion on days 1, 3 and 5 (total 3 doses).~* Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-8 inclusive (total 16 doses)."
62173795|NCT02724163|EXPERIMENTAL|Gemtuzumab Ozogamicin Dose Finding Study|"* Cohort 1: 1x3mg/m2 IV infusion over 2hours on day 4.~* Cohort 2: 2x3mg/m2 IV infusion over 2hours on day 4 and day 7.~* Cohort 3: 3x3mg/m2 IV infusion over 2hours on days 4, 7 and 10."
62173796|NCT02724163|ACTIVE_COMPARATOR|High dose cytarabine|Two courses of Cytarabine: 3 g/m2 12 hourly by IV infusion over 4 hours on days 1, 3 and 5 (total 6 doses).
62173797|NCT02724163|EXPERIMENTAL|Fludarabine & cytarabine|"Two courses of:~* Fludarabine: 30 mg/m2 daily by IV infusion over 30 minutes on days 1-5 inclusive (total 5 doses).~* Cytarabine: 2 g/m2 daily by IV infusion over 4 hours on days 1-5 inclusive (total 5 doses).The cytarabine infusion should be started 4 hours after the start of the fludarabine infusion"
62173798|NCT02724163|ACTIVE_COMPARATOR|Myeloablative conditioning|"* Busulfan Area Under the Curve (AUC) 70-100mg/L x hr by IV infusion over 3 hours, given 12 hourly on days -10 to -7 (8 doses).~* Cyclophosphamide 50mg/kg/day by IV infusion over 1 hour, on days -5 to -2 (4 doses)."
62173799|NCT02724163|EXPERIMENTAL|Reduced intensity conditioning|"* Busulfan AUC60-65mg/L X hr by IV infusion over 3 hours, given 12 hourly on days -5 to -2 (8 doses).~* Fludarabine 30mg/m2/day by IV infusion over 30 minutes on days -8 to -3 (6 doses)."
62173800|NCT03134937|OTHER|Study Arm|Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
62173801|NCT06478225|EXPERIMENTAL|BGT007H Cell Injection|"A modified 3+3 dose-escalation design is used, with BGT007H cells administered at five progressively increasing dose levels for treatment evaluation. The dose levels are (3.0×10\^7, 1.0×10\^8, 2.0×10\^8, 3.0×10\^8, 4.0×10\^8) BGT007H cells."
62173802|NCT05182970|ACTIVE_COMPARATOR|Metformin on top of standard care|Metformin will be prescribed by the Investigator at the study site and dispensed at pharmacy of choice by the patient. Metformin will be recommended to be gradually titrated to minimize gastrointestinal side effects with a start dose of 500 mg 1x1 for 1 week and thereafter 500 mg 1x2 with an individualised target dose of 2000 mg daily depending on tolerability. The goal is to a have minimal dose of 500 mg 1x2. Patients will be informed to stop medication in events of sever nausea, vomiting or dehydration according to standard practice. The threshold for metformin titration or adding another drug during follow-up is recommended to be assessed individually by the Investigator at the study site, responsible for the patient. Patients with eGFR \<60 cannot be included in the MIMET study. If GFR is between 30-45 ml/min during the study, metformin should be reduced to 1000 mg daily. Metformin is contraindicated if GFR \<30 ml/min. Standard care will be the same as in the control arm.
62173803|NCT05182970|NO_INTERVENTION|Standard care alone|Standard care according to national guidelines. In Sweden there is no pharmacological intervention recommended for individuals with prediabetes at present. Standard care includes diet and life-style advice, which will be given to both groups in the same manner according to local routines, based on the present guidelines. Secondary preventive treatment includes physical activity, participating in exercise program, dietary habits, BMI and or waist circumference, smoking and EQ-5D will be followed in accordance with the routinely reported SWEDEHEART-SEPHIA variables.
62173804|NCT00618384|ACTIVE_COMPARATOR|1|Patients with TACE therapy will be treated with Sorafenib (2 x 400 mg/day) until progressive disease
62173805|NCT05854771|ACTIVE_COMPARATOR|Single bout of yoga before eccentric exercise group|Yoga poses will be performed before the eccentric exercise of the four muscles group (elbow flexors and extensors, knee extensors and flexors) for a total time duration of 20-30 minutes. To induce delayed onset muscle soreness the participants will be asked to breathe and hold each yoga pose for 6-8 breaths. The participants will perform 6 sets of 10 repetitions of one repetition maximum eccentric drills of the elbow and knee with 3 minutes rest period between each set.
62173806|NCT05854771|ACTIVE_COMPARATOR|Single bout of yoga after eccentric exercise group|Yoga poses will be performed after the eccentric exercise of the four muscles group (elbow flexors and extensors, knee extensors and flexors) for a total time duration of 20-30 minutes. To induce delayed onset muscle soreness the participants will be asked to breathe and hold each yoga pose for 6-8 breaths. The participants will perform 6 sets of 10 repetitions of one repetition maximum eccentric drills of the elbow and knee with 3 minutes rest period between each set.
62550234|NCT00196326|EXPERIMENTAL|DR-1011|Participants were instructed to take, by mouth, one tablet daily for four 91-day cycles.
62550235|NCT04400162|ACTIVE_COMPARATOR|CCT (standard)|This arm consists of the CCT in a standard variant that provides the basic training experience without any added gaming elements.
62173807|NCT00543166|PLACEBO_COMPARATOR|2|180 patients divided to two separate groups (each containing 90 patients). This study has a cross-over, wash-out design, which consists of two 4 month treatment period separated by a one month long wash-out period. During one treatment period the patient gets placebo and during one of the treatment periods the patient gets 50mg of dehydroepiandrosterone (DHEA) in the morning.
62173808|NCT03212755|EXPERIMENTAL|group 1|25 diabetic patients without diabetic nephropathy
62363904|NCT01627223|EXPERIMENTAL|Entecavir 0.5 mg p.o. q.d|"To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.~* Cohort 1: Lamivudine 100 mg p.o. q.d.~* Cohort 2: Entecavir 0.5 mg p.o. q.d.~This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
62173809|NCT03212755|EXPERIMENTAL|group 2|25 type 2 diabetic patients with diabetic nephropathy
62173810|NCT03212755|SHAM_COMPARATOR|group 3|25 healthy subjects
62173811|NCT03005483|EXPERIMENTAL|Gabapentin|Gabapentin 10 mg/kg in children submitted unilateral limb surgery
62173812|NCT03005483|PLACEBO_COMPARATOR|Placebo|Placebo in children submitted unilateral limb surgery
62173813|NCT03840200|EXPERIMENTAL|Dose escalation-Cohort 1|Participants with advanced breast cancer, ovarian cancer, or prostate cancer will receive ipatasertib, 300 milligrams (mg), orally, once daily (QD) for 7 days in the run-in period. Participants will then receive ipatasertib, 300 mg, orally QD, and rucaparib, 400 mg, orally twice daily (BID) in each 28-day cycle until disease progression, unacceptable toxicity, death, or participant or investigator's decision to withdraw, whichever occurs first.
62173814|NCT03840200|EXPERIMENTAL|Dose escalation-Cohort 2a|Participants with advanced breast cancer, ovarian cancer, or prostate cancer will receive ipatasertib, 300 mg, orally, QD for 7 days in the run-in period. Participants will then receive ipatasertib, 300 mg, orally QD, and rucaparib, 600 mg, orally BID in each 28-day cycle until disease progression, unacceptable toxicity, death, or participant or investigator's decision to withdraw, whichever occurs first.
62173815|NCT03840200|EXPERIMENTAL|Dose escalation-Cohort 2b|Participants with advanced breast cancer, ovarian cancer, or prostate cancer will receive ipatasertib, 400 mg, orally, QD for 7 days in the run-in period. Participants will then receive ipatasertib, 400 mg, orally QD, and rucaparib, 400 mg, orally BID in each 28-day cycle until disease progression, unacceptable toxicity, death, or participant or investigator's decision to withdraw, whichever occurs first.
62173816|NCT03840200|EXPERIMENTAL|Dose escalation-Cohort 3|Participants with advanced breast cancer, ovarian cancer, or prostate cancer are planned to receive ipatasertib 400 mg orally QD for 7 days (run-in period prior to Cycle 1). Participants will then receive ipatasertib 400 mg orally QD and rucaparib 600 mg, orally BID in 28 days cycle until disease progression, unacceptable toxicity, death, or participant or investigator's decision to withdraw, whichever occurs first.
62173817|NCT03840200|EXPERIMENTAL|Dose Expansion|The recommended dose (ipatasertib and rucaparib) identified in Part 1 will be evaluated in participants with advanced prostate cancer who have had at least one line of prior therapy with second-generation androgen-receptor (AR)-targeted agents (e.g., abiraterone, enzalutamide, apalutamide).
62173818|NCT05625568|PLACEBO_COMPARATOR|Placebo|
62173819|NCT05625568|EXPERIMENTAL|5 mg VYNT-0126|
62173820|NCT05625568|EXPERIMENTAL|10 mg VYNT-0126|
62173821|NCT05878249|EXPERIMENTAL|wound lavage with normal saline|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of Normal saline for 30 seconds
62173822|NCT05878249|EXPERIMENTAL|wound lavage with sodium hypochlorite|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5% sodium hypochlorite (NaOCl) for 30 seconds
62173823|NCT05878249|EXPERIMENTAL|wound lavage with Ethylenediaminetetraacetic acid(EDTA)|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 12%Ethylenediaminetetraacetic acid(EDTA) for 5 minutes
62173824|NCT05878249|EXPERIMENTAL|wound lavage with sodium hypochlorite followed by Ethylenediaminetetraacetic acid|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5%sodium hypochlorite (NaOCl) for 30 seconds followed by 12%Ethylenediaminetetraacetic acid(EDTA) for 5 minutes
62173825|NCT02188277|EXPERIMENTAL|Xeomin®|4-8 Units per kg body weight. Single injection cycle.
62173826|NCT02188277|ACTIVE_COMPARATOR|Botox®|4-6(8) Units per kg body weight. Single injection cycle.
62173827|NCT02298855|NO_INTERVENTION|Conventional follow-up|Treatment as usual will involve: one post treatment appointment then 3 monthly appointments with a Dr. At appointments: medical history; investigations to monitor disease progression including CA125 tumour marker blood test if this were raised at diagnosis. A physical examination may be performed.
62173828|NCT02298855|EXPERIMENTAL|Individualised follow-up|Follow-up is delivered by a nurse and frequency and type (telephone or face-to-face) is negotiated to suit their individual situation. Assessment by holistic guide. The intervention is informed by a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to help patients manage symptoms and psychological discomfort.
62173829|NCT06080919|EXPERIMENTAL|DCB-PCI|Patients with coronary artery disease undergoing percutaneous coronary intervention will undergo DCB-PCI under IVUS guidance and angio-derived coronary phisiology assessment. Angiographic follow-up with IVUS evaluation will be performed 3 months after the index procedure.
62173830|NCT02656745|EXPERIMENTAL|Mobile Smoking Cessation Solution|Subjects download \& use the mobile application.
62173831|NCT03617458|ACTIVE_COMPARATOR|Metformin + mHealth Intervention|"Patients will receive active ingredient medicine with mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.~Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po twice a day (BID) x 5 days, 500mg by mouth (po) three times a day (TID) x 5 days,1000mg po BID x 69 days (12 weeks total)."
62363905|NCT00922519||1|
62173832|NCT03617458|PLACEBO_COMPARATOR|Placebo + Usual Care|Patient will receive non active medicine and routine medical care.
62173833|NCT03617458|ACTIVE_COMPARATOR|Metformin + Usual Care|"Patient will receive active ingredient medicine with routine medical care.~Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po BID x 5 days, 500mg po TID x 5 days,1000mg po BID x 69 days (12 weeks total)."
62173834|NCT03617458|PLACEBO_COMPARATOR|Placebo + mHealth Intervention|Patient will receive non active medicine and the mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
62173835|NCT02733835|EXPERIMENTAL|Remifentanil|Remifentanil Patient Controlled Analgesia
62173836|NCT01990664|EXPERIMENTAL|senofilcon A|Contact lenses to be worn in a daily wear modality
62173837|NCT01990664|EXPERIMENTAL|senofilcon A for Astigmatism|Contact lenses to be worn in a daily wear modality
62173838|NCT00816153|EXPERIMENTAL|PVI|PVI guided fluid management
62173839|NCT00816153|NO_INTERVENTION|Control|
62173840|NCT04147091|EXPERIMENTAL|domestic nanohydroxyapatite gel ApaCare & Repair|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
62173841|NCT04147091|EXPERIMENTAL|in-office ozone therapy OzonyTron|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
62173842|NCT04147091|EXPERIMENTAL|both remineralizing gel and ozone therapy|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
62173843|NCT00308919|EXPERIMENTAL|WST 09|Treatment with WST09 Vascular Photodynamic therapy
62173844|NCT04291703|EXPERIMENTAL|Antithymocyte globulin (ATG)|Antithymocyte globulin (ATG) will be intravenously administered over two days, with a total of 2 infusion periods. The first infusion is given at baseline visit (day 1), the second is given the next day at baseline visit (day 2). Body weight at baseline (Day 0- admission for the ATG/placebo infusion) will be used in calculating the doses for all infusions. The first dose (0.5mg/kg) will be infused over a minimum of 4 hours, and the second dose (2mg/kg) over a minimum of 4 hours with a maximum infusion time for each infusion of 10 hours. The second dose should be given no less than 12 and no more than 30 hours from the start of the first infusion. The final prepared product is to be labeled to protect the blind. Infusions may be administered either in a hospital or outpatient setting at the investigator's or institutions discretion.
62173845|NCT04291703|PLACEBO_COMPARATOR|Placebo|"0.9% Sodium Chloride Injection USP (Normal saline) is to be dispensed as the placebo for this study. The placebo is to be prepared dispensing an infusion bag of 0.9% Sodium Chloride Injection USP (Normal saline) with no additives (no ATG, no premedications) and label the product to protect the blind. The placebo will also be administered over a minimum of 4 hours for the first and second doses with a maximum infusion time of 10 hours. The second dose of the placebo arm should be given no less than 12 and no more than 30 hours from the start of the first infusion. Infusions may be administered either in a hospital or outpatient setting at the investigator's or institutions discretion."
62173846|NCT02874248|ACTIVE_COMPARATOR|Group 1: 15 mg E4/3 mg DRSP (n=10)|a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
62173847|NCT02874248|PLACEBO_COMPARATOR|Group1: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
62173848|NCT02874248|ACTIVE_COMPARATOR|Group 2: 30 mg E4/6 mg DRSP (n=10)|a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
62173849|NCT02874248|EXPERIMENTAL|Group 2: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
62173850|NCT02874248|ACTIVE_COMPARATOR|Group 3: 60 mg E4/12 mg DRSP (n=10)|a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days
62173851|NCT02874248|PLACEBO_COMPARATOR|Group 3: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
62173852|NCT02874248|ACTIVE_COMPARATOR|Group 4: 75 mg E4/15 mg DRSP (n=9)|a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
62173853|NCT02874248|PLACEBO_COMPARATOR|Group 4: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
62173854|NCT02207322|NO_INTERVENTION|Standard transplant care|"* Patient Enrollment and Caregiver Enrollment (within 72 hours of hospital)~  -- Complete baseline data collection, and registration~* Patient Randomization~* Standard transplant oncology care~  -- Palliative care consults only upon request~* Longitudinal Data Collection (patient \& family caregivers)~  * Week-2 of hospitalization~ * 3-months, and 6-months post HSCT"
62173855|NCT02207322|EXPERIMENTAL|transplant with early palliative care|"* Standard transplant oncology care with early palliative care~* Patient Enrollment and Caregiver Enrollment (within 72 hours of patient enrollment)~  --Complete baseline data collection, and registration Intervention description: Inpatient palliative care intervention description: 1st visit within 72 hours of randomization, At least twice weekly follow up visits~* Longitudinal Data Collection (patient \& family caregivers)~  * Week-2 of hospitalization~ * 3-months, and 6-months post HSCT"
62173856|NCT00757978|PLACEBO_COMPARATOR|1|Clozapine plus placebo
62173857|NCT00757978|ACTIVE_COMPARATOR|2|Clozapine plus memantine
62173858|NCT02223871|EXPERIMENTAL|ACT-451840 500 mg|All the participants were infected with Plasmodium falciparum parasites (malaria) using malaria-infected human erythrocytes. When the parasitemia reached 1000 counts/mL, all the participants received 500 mg of ACT-451840 as a single oral dose. Compulsory commencement of treatment with Riamet® (artemether-lumefantrine) to ensure complete clearance of any gametocytes, occurred 16 days after ACT-451840 administration (or earlier if required) for all participants. Primaquine was to be administered as a single dose only in participants for whom gametocytes were still identified after administration of Riamet® rescue medication
62173859|NCT01653093|EXPERIMENTAL|Diagnostic (3T MRI)|Patients undergo 3T MRI, including DCE-MRI, diffusion-weighted MRI, amide-proton-transfer MRI, and MR spectroscopy scans. Patients may undergo an additional 3T MRI scan at least 24 hours after the initial scan.
62173860|NCT03315988|EXPERIMENTAL|Vegan diet|"Intervention Description and Definition The participants will be asked to follow a diet that excludes foods hypothesised to support the syntheses of TMAO, particularly meat (any), eggs and fish (any). A number of studies suggest that dairy products may also have an effect in modulating TMAO production whereas other studies do not. Therefore, in order to avoid any potential contaminating or confounding effect, dairy products will also be avoided.~The diet employed in this study is broadly aligned to a vegan diet. The term vegan will be used to aid behaviour change and food choice. For example, an increasing array of products are now pack marked as vegan. The participants will be asked to keep their diet similar to their original and the Registered Dietitian involved in this study will plan their weekly menus accordingly."
62173861|NCT04778449||Observational (questionnaire, medical chart review)|Patients complete a maximum of 3 paper or electronic questionnaires over 30 minutes within 2 weeks of presentation to MD Anderson, new diagnosis of melanoma, and/or initiating a new treatment, within 2 weeks of first restaging, and within 2 weeks of the end of treatment. Patients may complete an additional paper or electronic dietary questionnaire over 10 minutes for 3 days (30 minutes total) or a phone-based dietary recall. Patients who start a new treatment of interest may repeat the questionnaires at the same time points. Patients' medical records are also reviewed.
62173862|NCT02747121|OTHER|Control before intervention|External inspection of health services. The intervention is external inspection of sepsis detection and treatment. The intervention is delivered on the organizational Level. Patient are not assigned to the intervention. The intervention is rolled out sequentially to 24 hospitals. We collect data at base line, before the inspections and 8 and 14 month after the inspections. The first arm is the Control period before the inspections.
62173863|NCT02747121|EXPERIMENTAL|Intervention|External inspection of health services. We compare the effect measures before and after the inspection. The intervention arm is data after the hospitals have received the inspection.
62173864|NCT01912183|ACTIVE_COMPARATOR|Monitoring device in PHR|Both groups will receive routine clinical care in the pediatric weight management program at McMaster Children's Hospital. Children/youth in both groups will receive a physical activity and sleep monitor and access to their PHR. The Active Comparator group will not receive any feedback or communication outside of clinic visits from the clinical team regarding their goal progress.
62173865|NCT01912183|EXPERIMENTAL|Communication through PHR outside clinic|Both groups will receive routine clinical care in the pediatric weight management program at McMaster Children's Hospital. Children/youth in both groups will receive a physical activity and sleep monitor and access to their PHR. The experimental group will receive regular communication with /access to the clinical team through a secure portal within the PHR(i.e. 2 way communication, weekly feedback to the families on their goal progress).
62173866|NCT02083679|EXPERIMENTAL|Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|
62173867|NCT02083679|EXPERIMENTAL|Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|
62173868|NCT02083679|EXPERIMENTAL|Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|
62173869|NCT02083679|EXPERIMENTAL|Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel|
62173870|NCT01602003|EXPERIMENTAL|LC15-0444 25 mg bid|LC15-0444 25 mg bid(twice daily)added on Metformin therapy
62173871|NCT01602003|EXPERIMENTAL|LC15-0444 50 mg qd|LC15-0444 50 mg qd(once daily) added on Metformin therapy
62173872|NCT01602003|ACTIVE_COMPARATOR|Sitagliptin 100mg qd|Sitagliptin 100 mg qd (once daily) added on the Metformin therapy
62173873|NCT05682885|EXPERIMENTAL|Axillary lymph node dissection with LBS|70 subjects will be needed for each group. A standard mastectomy or lumpectomy incision is made and ALND will be done in the same incision. The lymphatic vessels and lymph nodes will be resected using a near-infrared (NIR) camera. To locate lymphatic vessels, a microscope with ICG lymphography navigation is employed. LBS was performed by making intima-to-intima anastomosis between the afferent lymphatic vessels and the recipient's veins, or to the efferent lymphatic vessels. The anastomosis patency will be assessed by observing the ICG fluorescent flow. After surgery, follow-up will be done every 2 months and every 3 months in the second year. UEL index, ICG lymphography, and quality of life evaluation will be done. The cumulative incidence of BCRL, the free survival time of BCRL, and subclinical lymphedema (SCL) progression will be reported descriptively. BCRL risk factors and collateral lymphatic pathway will be observed as well.
62173874|NCT05682885|NO_INTERVENTION|Axillary lymph node dissection without LBS|70 subjects will be needed for each group. A standard mastectomy or lumpectomy incision is made and ALND will be done in the same incision. After primary breast cancer removal, a standard ALND level I, II, and if necessary, level III is performed. After surgery, follow-up will be done every 2 months and every 3 months in the second year. History taking, physical examination, radiology and histopathology examination, UEL index, and ICG lymphography evaluation will be done during follow-up. Each subject will complete the lymphedema quality of life questionnaire. The cumulative incidence of BCRL, the free survival time of BCRL, and SCL progression will be reported descriptively. BCRL risk factors and collateral lymphatic pathway will be observed as well.
62173875|NCT04313790|EXPERIMENTAL|Heparin Infusion|heparin infusion 500unit \\hour
62173876|NCT04313790|OTHER|Subcutaneus Heparin|subcutaneous heparin 5000unit \\ 8 hours
62173877|NCT04177732|OTHER|Healthy peri-implant status|Patient with healthy peri-implant status
62173878|NCT04177732|OTHER|Presence of peri-implant diseases|Patients with presence of peri-implant diseases
62173879|NCT06469814||Patients with chronic heart failure|
62173880|NCT06469814||Patients with acute heart failure|
62173881|NCT01421797|EXPERIMENTAL|Dexamethasone, Cortrosyn|Dexamethasone given 1 mg PO Cortrosyn given single IV bolus 0f 0.25 mg
62173882|NCT01778647|EXPERIMENTAL|Stimulants plus Lovaza|Usual dose of stimulant plus Lovaza (prescription Omega-3 fatty acids) at a dose of 1800 mg daily.
62173883|NCT01778647|PLACEBO_COMPARATOR|Stimulants plus placebo|Usual dose of stimulants plus placebo(corn oil), which will be given to the patients by MMC's pharmacy.
62363906|NCT03354572|ACTIVE_COMPARATOR|NAC|receive 150 mg/kg acetylcysteïne in 200 ml saline (NaCl0,9%) prior to surgery
62173884|NCT00451555|EXPERIMENTAL|Enzastaurin + Fulvestrant|"Participants received Enzastaurin loading dose of 1125 mg, on Day 1 of Cycle 1 only then received Enzastaurin 500 mg orally (QD) once daily in a 28-day cycle.~Participants received enzastaurin loading dose of 1125 mg, on Day 1 of Cycle 1 only then received Enzastaurin 250 mg orally (BID) twice daily in a 28-day cycle.~Fulvestrant was given intramuscularly at a loading dose of 500 mg on Day 1 and 250 mg on Day 15 in Cycle 1. Subsequent doses of Fulvestrant 250 mg were given on Day 1 of Cycle 2 and every 28 days thereafter."
62173885|NCT00451555|PLACEBO_COMPARATOR|Fulvestrant + Placebo|Participants received fulvestrant: 500 mg, IM, day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression. Then, participants received placebo, oral, daily.
62173886|NCT04225637|EXPERIMENTAL|Slow maxillary expansion|The miniscrew-supported maxillary expander is activated by turning the expansion screw once every other day.
62173887|NCT04225637|EXPERIMENTAL|Rapid maxillary expansion|The miniscrew-supported maxillary expander is activated by turning the expansion screw twice daily.
62173888|NCT03277586|EXPERIMENTAL|Probio'Stick|
62173889|NCT03277586|PLACEBO_COMPARATOR|Placebo|
62173890|NCT06401096||Control (C)|Patients in the control group who will undergo abdominal surgery will not be given any breathing exercises other than routine preoperative preparation. After appropriate anesthesia preparation, preoxygenation will begin.
62173891|NCT06401096||Triflo (T)|The patient group who receives breathing exercises will be given effective triflo exercise under the supervision of a nurse, starting with hospitalization at least 5 days before the operation and until the pre-operative period. Triflo working time will be planned to be minimum 5 minutes 4 times a day. Breathing exercise will be performed with both inhalation and exhalation. After appropriate anesthesia preparation, preoxygenation will begin.
62173892|NCT00804414|EXPERIMENTAL|1|
62173893|NCT00804414|PLACEBO_COMPARATOR|2|
62173894|NCT04108975|ACTIVE_COMPARATOR|Rectus muscle reapproximation group|Rectus muscle reapproximation by 3 interrupted simple sutures or 3 vertical mattress sutures
62173895|NCT04108975|ACTIVE_COMPARATOR|Rectus muscle non reapproximation group|No rectus muscle reapproximation will be done based on the fact that rectus muscle can regain its position
62173896|NCT01792583||Prospective Cohort|Prospective is defined per protocol: prospective data of pregnancy exposure are data acquired prior to the knowledge of the pregnancy outcome or prior to the detection of a congenital malformation at prenatal examination (e.g. fetal ultrasound, serum markers).
62173897|NCT01792583||Retrospective Cohort|Retrospective is defined per protocol: retrospective data of pregnancy exposure are data acquired after the outcome of the pregnancy is known or after the detection of a congenital malformation on prenatal examination.
62173898|NCT03322514|EXPERIMENTAL|experimental group|10 g of Inulin-Propionate Esters will be administered per day
62173899|NCT03322514|ACTIVE_COMPARATOR|Inulin|10 g of Inulin will be administered per day
62173900|NCT05645809|EXPERIMENTAL|MONOFIX® PGCL|An absorbable suture
62173901|NCT05645809|ACTIVE_COMPARATOR|Quill Monoderm™|An absorbable suture
62173902|NCT04748471|EXPERIMENTAL|18-45 years old|18 - 45 years old (60 volunteers), 2 injections of mRNA-1273, at day 1 and day 29
62173903|NCT04748471|EXPERIMENTAL|65-74 years old|65 - 74 years old (60 volunteers), 2 injections of mRNA-1273, at day 1 and day 29
62173904|NCT04748471|EXPERIMENTAL|At least 75 years old|At least 75 years old (60 volunteers), 2 injections of mRNA-1273, at day 1 and day 29
62173905|NCT05183477|EXPERIMENTAL|fast track|patients arriving at Emergency Department with suspected wrist or scaphoid fracture, randomly allocated to the fast track pathway (xray requested at triage by nurse)
62173906|NCT05183477|ACTIVE_COMPARATOR|normal pathway|patients arriving at Emergency Department with suspected wrist or scaphoid fracture, randomly allocated to waiting room and than medical examination before asking for xrays
62173907|NCT03644784||Yamaguchi University Hospital|
62173908|NCT03644784||Erasmus Medical Center|
62173909|NCT03644784||Academic Medical Center - Amsterdam|
62173910|NCT03644784||Segeberger Kliniken Gruppe|
62173911|NCT03644784||McGill University - Montreal|
62173912|NCT01801813||Neurosurgery for brain tumor patients|Collecting pre-operative and per-operative data, neuro-radiological data and post-operative complications
62173913|NCT03191214||No Warming|Patients undergoing brief surgical procedures of \>15 minutes for whom no warming devices are being employed.
62173914|NCT03191214||Forced Air Warming|Patients undergoing surgical procedures in which forced air warming, is being used
62173915|NCT03212183|EXPERIMENTAL|EPI-TAVIE|Patients assigned to this arm will be invited to complete a web-based nursing intervention called EPI-TAVIE.
62173916|NCT03212183|OTHER|Websites|Patients assigned to this arm will be invited to consult a validated list of predetermined conventional websites.
62173917|NCT02812628|ACTIVE_COMPARATOR|Conventional LAPR|Patients undergoing conventional laparoscopic abdominoperineal resection (LAPR).
62173918|NCT02812628|EXPERIMENTAL|LAPR-TILT|Patients undergoing LAPR with transabdominal individualized levator transection (TILT).
62173919|NCT04358068|EXPERIMENTAL|Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|"Hydroxychloroquine 400 mg (administered as two 200 mg capsules) orally twice daily for 2 doses starting on Day 0, followed by 200 mg (administered as one 200 mg capsule) orally twice daily for 12 doses (6 days), PLUS:~Azithromycin 500 mg (administered as two 250 mg capsules) orally as a single dose on Day 0, followed by 250 mg (administered as one 250 mg capsule) orally once daily for 4 doses (4 days)."
62173920|NCT04358068|PLACEBO_COMPARATOR|Arm B: Placebo for Hydroxychloroquine and Azithromycin|"Placebo for Hydroxychloroquine (administered as two matching placebo capsules) orally twice daily for 2 doses starting on Day 0, followed by Placebo for HCQ (administered as one 200 mg capsule) orally twice daily for 12 doses (6 days), PLUS:~Placebo for Azithromycin (administered as two matching placebo capsules) orally as a single dose on Day 0, followed by Placebo for Azithromycin (administered as one matching placebo capsule) orally once daily for 4 doses (4 days)."
62173921|NCT02947581|EXPERIMENTAL|Interventions|Albendazole and praziquantel. Albendazole: 15 mg/k/d up to 800 mg/d (days 1 to 20), followed by 15 mg/k/d up to 1200 mg/d (day 21 to 30) and prazicuantel (50 mg/k/d days 1 to 15).
62173922|NCT02947581|ACTIVE_COMPARATOR|Comparison regime|Albendazole and praziquantel placebo. Albendazole: 15 mg/k/d (days 1 to 30) and prazicuantel placebo in similar doses 50 mg/k/d (days 1 to 15).
62173923|NCT01414725|EXPERIMENTAL|Core Stability Training|
62173924|NCT01414725|PLACEBO_COMPARATOR|Relaxation|
62173925|NCT01414725|ACTIVE_COMPARATOR|Standard Physiotherapy Exercises|
62173926|NCT02134899|EXPERIMENTAL|Everolimus|everolimus based immunosuppression
62173927|NCT02134899|ACTIVE_COMPARATOR|Calcineurin|Calcineurin inhibitors maintenance
62173928|NCT02371161|EXPERIMENTAL|R-DHAP/R-ICE|High-dose myeloablative therapy (R-DHAP or R-ICE) and conditioning therapy (BEAM or FEAM) in elderly patients with relapsed NHL or resistant to firs line therapy
62173929|NCT04730076|ACTIVE_COMPARATOR|Standard Balloon Dilation|Patients in this group will receive standard balloon dilation therapy.
62173930|NCT04730076|EXPERIMENTAL|Progressive Balloon Dilation|Patients in this group will receive progressive balloon dilation therapy.
62173931|NCT02672514|ACTIVE_COMPARATOR|MiECC|"Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the minimally invasive extracorporeal circulation system (MiECC). MiECC has been developed based on the concept of a closed total CPB circuit. The basic elements are a centrifugal pump, a membrane oxygenator and an arterial filter. The priming volume compared to CECC could be reduced. The complete circuit is heparin-coated for maximizing the biocompatibility.~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation."
62173932|NCT02672514|ACTIVE_COMPARATOR|CECC|"Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the conventional extracorporeal circulation system (CECC). The CECC is an opened circulation system. The basic elements are a membrane oxygenator, a centrifugal pump, an open perfusion system containing the venous hard shell cardiotomy reservoir and the arterial line filter.~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation, leading to a reduction of the priming volume. The CECC flow was set as required in order to maintain a mean arterial pressure (MAP) between 50 and 75 mmHg."
62173933|NCT00930683|OTHER|1|MEDI-546
62173934|NCT00930683|OTHER|2|MEDI-546
62173935|NCT00930683|OTHER|3|MEDI-546
62173936|NCT00930683|OTHER|4|MEDI-546
62173937|NCT00930683|OTHER|5|MEDI-546
62173938|NCT00930683|OTHER|6|MEDI-546
62173939|NCT00930683|OTHER|7|MEDI-546
62173940|NCT00930683|OTHER|8|MEDI-546
62173941|NCT00930683|OTHER|9|MEDI-546
62173942|NCT02202148||alcohol withdrawal|
62173943|NCT00938132|EXPERIMENTAL|Fimasartan|
62173944|NCT03976778|OTHER|a pre-post interventional study|intervention consisted of 3 repeated workshops, every workshop had held for 2 days, one day per week, the number of attendants was appropriate/workshop (10 - 15).
62173945|NCT05284006||Mucopolysaccharidosis IVA|Patients affected by MPS IVA. The diagnosis of MPS will be confirmed by deficient enzyme activity of \< 5% of normal activity level as measured in plasma, leukocytes, or fibroblasts.
62173946|NCT01636830|ACTIVE_COMPARATOR|Toothbrush type - medium|This is a crossover study, where the person used either a soft brush (control) and the medium brush (test).
62363907|NCT03354572|PLACEBO_COMPARATOR|placebo|receive only NaCl 0.9% prior to surgery (volume identical to active comparator)
62173947|NCT01636830|ACTIVE_COMPARATOR|Toothbrush type - soft|This is a crossover study, where the person used either a soft brush (control)and the medium brush(test).
62173948|NCT03377959|EXPERIMENTAL|Pilates Group|Pilates Method Mat classes and Ballet Classes three times a week, totaling 24 session of each.
62173949|NCT03377959|OTHER|Ballet Group|Ballet Classes three times a week, totaling 24 sessions.
62173950|NCT06222775|ACTIVE_COMPARATOR|Control group|Control group receive activities on diabetes and obesity by Primary Care professionals on a care routine
62173951|NCT06222775|EXPERIMENTAL|Experimental group|"Experimental group receive multicomponent intervention based on:~De Cos AI, Gutiérrez Medina S, Luca B, Galdón A, Simon Chacín J, De Mingo ML, et al. Recommendations for clinical practice in diabetes and obesity. The Madrid Agreements. Document agreed by the working groups of the scientific societies: SENDIMAD, SOMAMFYC, SEMG Madrid, SEMERGEN Madrid and RedGDPS. Nutr Hosp \[Internet\]. 2018;35(4):971-8. Disponible en: http://dx.doi.org/10.20960/nh.1646 Kojdamanian Favetto V. Guía NICE 2022: actualización en el manejo de la diabetes mellitus tipo 2 en personas adultas. Evid actual pract ambul \[Internet\]. 2022;25(2):e007015. Disponible en: http://dx.doi.org/10.51987/evidencia.v25i3.7015"
62173952|NCT03293472|EXPERIMENTAL|Ropivacaine|"Experimental: 0.5% ropivacaine (isobaric) 4.5 ml for the patients \< 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml \> 180 cm.~supplementary bolus doses of ropivacaine as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period"
62173953|NCT03293472|ACTIVE_COMPARATOR|Bupivacaine|"0.5% v Bupivacaine mg (isobaric) loading dose of 0.5% bupivacaine, 3.0 ml for the patients \< 160 cm tall, 3.3 ml for 161-170 cm tall, 3.6 ml for 171-180 cm tall, and 4.0 ml \> 180 cm.~and supplementary bupivacaine bolus dose as required, followed by 0,12% bupivacaine 1 ml/h for the postoperative period"
62363908|NCT02500472|EXPERIMENTAL|Kava Supplement|See intervention description.
62363909|NCT02077491|ACTIVE_COMPARATOR|Intervention|High-protein diet and resistance training
62363910|NCT02077491|NO_INTERVENTION|Control|The control group recieves standard care during the study.
62363911|NCT02226419|EXPERIMENTAL|Break in L-carnitine treatment|Patients do not take their L-carnitine (Levocarnitine) treatment for 2-4 days until plasma carnitine and acylcarnitine have fallen. While patients abstain from taking the treatment, they are admitted for cardiac telemetry monitoring.
62363912|NCT03704805|EXPERIMENTAL|Problem-Solving Therapy|Participants in the intervention group receive the friendship bench intervention in addition to all services provided according to enhanced standard of care.
62363913|NCT03704805|ACTIVE_COMPARATOR|Enhanced Standard of Care|Participants in the control group receive enhanced standard of care.
62173954|NCT01011127||pravastatin|
62173955|NCT01011127||rosuvastatin|
62173956|NCT00900861||1|Asthmatic patients above 18 y, treated with ICS or bronchodilators
62363914|NCT01391455|NO_INTERVENTION|Spermatic Cord in contact with mesh|Where the spermatic cord has been allowed to remain in contact with the mesh.
62173957|NCT04701528|EXPERIMENTAL|Voclosporin (VCS)|"Prior to or at study entry, subjects are reduced in their standard immunosuppressive therapy to dual therapy with prednisone and tacrolimus according to current local guidelines.~In the experimental arm tacrolimus is switched to voclosporin 6 capsules (of 7.9 mg each) BID for a treatment period of minimal 56 days with a possible extension up to 1 year.~Safety drug monitoring will take place during the study to ensure that VCS trough levels are maintained between 30-60 ng/mL. If trough levels are not within these levels, dose adjustments will take place."
62173958|NCT04701528|ACTIVE_COMPARATOR|Tacrolimus (TAC)|"Prior to or at study entry, subjects are reduced in their standard immunosuppressive therapy to dual therapy with prednisone and tacrolimus according to current local guidelines.~In the Active comparator arm tacrolimus dosage is maintained.~Safety drug monitoring will take place during the study to ensure that TAC trough levels are maintained between 3-7 ng/ml. If trough levels are not within these levels, dose adjustments will take place."
62173959|NCT06079424||Level of vascular aging|community-based prospective longitudinal cohort
62173960|NCT06168513||Case group|The inclusion criteria for this study encompassed fecal specimens obtained from patients with a documented history of tumor, specifically those who received their primary or initial tumor diagnosis at our hospital.
62173961|NCT06168513||Healthy control|(1) Individuals who were in good health, devoid of evident diseases, and possessed normal physical examination reports; (2) Individuals who had not experienced significant chronic illnesses, such as hypertension, diabetes, chronic kidney disease, etc., in recent years, in order to exclude those who had been unwell but had normal physical examination reports; (3) Age and gender were matched with the case group.
62173962|NCT06398171|EXPERIMENTAL|Exercise|
62173963|NCT01659177|EXPERIMENTAL|LY2140023 fasting|Single oral dose of 80 mg LY2140023 given in fasted state
62173964|NCT01659177|EXPERIMENTAL|LY2140023 + food|Single oral dose of 80 mg LY2140023 given after standardized high-fat breakfast
62173965|NCT02968654|OTHER|Restrictive Transfusion Strategy|"Blood Transfusion will be given when hemoglobin concentration will be below 7 g/dL (as suggested by current guidelines in general ICU population)"
62173966|NCT02968654|OTHER|Liberal Transfusion Strategy|"Blood Transfusion will be given when hemoglobin concentration will be below 9 g/dL"
62173967|NCT00280709|ACTIVE_COMPARATOR|1|Covered metal stent
62173968|NCT00280709|ACTIVE_COMPARATOR|2|Uncovered metal stent
62173969|NCT05264064||Infants aged 0-18 months|Healthy infants aged 0-18 months, divided into four age groups: 0-3 months, 4-7 months, 8-11 months, and older than 12 months
62173970|NCT00060723||Adenotonsillectomy group|Children ages 5-12 who are scheduled for adenotonsillectomy for obstructive sleep apnea
62173971|NCT00060723||Comparison group|Children ages 5-12, scheduled for hernia repairs, other procedures not involving the head, chest or neck, or no procedures. Additional exclusions include children with a history of recurrent throat infections, large tonsils, history of or plans for adenoidectomy and/or tonsillectomy or who have been previously diagnosed with sleep-disordered breathing.
62173972|NCT03738254|ACTIVE_COMPARATOR|Paper PRO|Participants in the Paper PRO arm completed daily patient reported outcome diaries on paper
62173973|NCT03738254|ACTIVE_COMPARATOR|ePRO|Participants in the ePRO arm completed daily patient reported outcome diaries online via a smartphone app.
62173974|NCT03738254|EXPERIMENTAL|Game-Motivated ePRO|Participants in the Game-Motivated ePRO arm completed daily patient reported outcome diaries online via a smartphone app. These participants were also given access to a game that rewarded the participant with an in-game reward that helped the participant complete various in-game quests.
62173975|NCT06632340|OTHER|Group 1|tumor base size \<2 cm
62173976|NCT06632340|OTHER|Group 2|tumor base size \>2 cm
62173977|NCT01381458||COPD patients receiving pharmacotherapy|COPD patients age 40 years and older receiving pharmacotherapy to treat their COPD and an index event of COPD hospitalization or ER visit.
62173978|NCT03219255||Subjects receiving RELVAR 100 ELLIPTA|Subjects with a diagnosis of COPD, for which RELVAR is indicated, who are naive to RELVAR will be included.
62173979|NCT02854839|NO_INTERVENTION|The Control Group|Patients will be randomized 1:1 to the control group and the treatment group. Patients who had allocated control group will not receive adjuvant treatment.
62173980|NCT02854839|EXPERIMENTAL|The Treatment Group (MG4101)|Patients will be randomized 1:1 to the control group and the treatment group. The treatment group will receive 6 times of MG4101(allogeneic natural killer cells) on week 0, 1, 2, 5, 6, 7.
62173981|NCT06357936|EXPERIMENTAL|nano fat grafting group|
62173982|NCT06357936|SHAM_COMPARATOR|standard therapy group|
62173983|NCT01049984|EXPERIMENTAL|Rasagiline 1 mg|Participants took a 1 mg rasagiline tablet orally each day for 18 weeks.
62173984|NCT01049984|PLACEBO_COMPARATOR|Placebo|Participants took a matching placebo tablet once daily for 18 weeks.
62173985|NCT06646809|OTHER|Low inflammatory responder|Low inflammatory responder group - to receive standard care
62173986|NCT06646809|EXPERIMENTAL|High inflammatory responder - AKG|High inflammatory responder group - to receive AKG tablets (1g a day, once a day, taken orally)
62173987|NCT06646809|PLACEBO_COMPARATOR|High inflammatory responder - placebo|High inflammatory responder group - to receive placebo tablets (1g a day, once a day, taken orally)
62173988|NCT00359385|ACTIVE_COMPARATOR|Alendronate 70mg weekly|Alendronate 70mg weekly
62173989|NCT00359385|PLACEBO_COMPARATOR|placebo of alendronate 70mg weekly|placebo of Alendronate 70mg weekly
62173990|NCT06023888|EXPERIMENTAL|Periodicity-based|
62173991|NCT06023888|OTHER|Control|Standard ablation strategy as usual
62173992|NCT03998501|EXPERIMENTAL|Active|5-week CBTm
62173993|NCT03998501|NO_INTERVENTION|Waitlisted|Waitlisted (will receive 5-week CBTm 3 months after).
62173994|NCT00985530|EXPERIMENTAL|Arm 1|Tamibarotene + Arsenic Trioxide
62173995|NCT06625645|ACTIVE_COMPARATOR|Calcium Hydroxide mixed with saline as control intracanal medication|using calcium hydroxide with saline as control intracanal medication for necrotic primary molars
62173996|NCT06625645|EXPERIMENTAL|different types and combinations of intracanal medications for necrotic primary molars|
62173997|NCT05838976||Study Participants|This group will consist of at least 50 patients with carpal tunnel syndrome who are undergoing nonsurgical management. Participants will complete the shorter version of the CTQ-SSS and other functional measures, such as the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire and the Patient-Rated Wrist Evaluation (PRWE). The validity and reliability of the CTQ-SSS will be assessed in this group using test-retest reliability and internal consistency analyses, as well as construct validity analyses comparing CTQ-SSS scores with other functional measures.
62173998|NCT03955952||Bariatric Surgery|Patients with type 2 diabetes with BMI \>=30 that underwent bariatric surgery
62173999|NCT03955952||Non-Surgical Control|Matched non-surgical controls with type 2 diabetes and BMI \>=30
62174000|NCT05453877||subjects from Kailuan community|"1. Age from 18 to 90 years old; 2. Comes from the Kailuan Cohort, completed ≥1 visits which the medical history, physiological indicators were measured; 3. Without contraindications of CT and MR scan; 4. Can cooperate with the measurement of the medical history, physiological indicators and brain imaging.~Subjects with the following conditions should be excluded:~1. Known clinical history with congenital or acquired organic diseases (such as aortic stenosis); 2. Known history of drug abuse; 3. Pregnant and lactating women; 4. With clinical history of psychiatric diseases (such as schizophrenia)."
62174001|NCT01889277|EXPERIMENTAL|MT-3995-Low|MT-3995-Low Dose
62174002|NCT01889277|EXPERIMENTAL|MT-3995-High|MT-3995-High Dose
62174003|NCT01889277|PLACEBO_COMPARATOR|Placebo|Placebo
62174004|NCT00549042|EXPERIMENTAL|OROS hydromorphone|OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg
62739301|NCT06659302|EXPERIMENTAL|Full Program|Step 3: Families will be invited to participate in the full I-InTERACT-North program. The full program will provide an additional 5 online modules with live therapist videoconference coaching sessions. All sessions are strongly encouraged but for parents who do not complete the additional sessions, we will track what is completed and parents may still complete outcome measures. Based on previous work, average time of completion for the full program is 8-12 weeks. Each session will last 60 minutes and will be video recorded (with consent from the participants). Sessions will be delivered to parents using Zoom, a secure online video conferencing platform (https://zoom.us/). Before each session, parents will receive a meeting invitation link via email. After completing the program, participants will complete online questionnaires through REDCap. All participants will be invited to complete study follow-up questionnaires.
62174005|NCT00549042|PLACEBO_COMPARATOR|placebo|Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).
62174006|NCT02242799|EXPERIMENTAL|Study A Sequence 1|Artemether-lumefantrine combination alone for 3 days with PK sampling at steady state, then 21 day washout period followed by Dolutegravir 50mg od dosing to steady state (7 days) with PK sampling then a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, with PK sampling at steady state.
62174007|NCT02242799|EXPERIMENTAL|Study A Sequence 2|Dolutegravir 50mg od given for 7 days with PK sampling at steady state, followed immediately by a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, again with PK sampling at steady state. Following a 21 day washout period, the subject will then receive Artemether-lumefantrine combination alone for 3 days, with PK sampling at steady state.
62174008|NCT02242799|EXPERIMENTAL|Study B Sequence 1|Administration of artesunate-amodiaquine for 3 days with PK sampling at steady state
62174009|NCT02242799|EXPERIMENTAL|Study B Sequence 2|Dolutegravir alone for 7 days with PK sampling at steady state, followed immediately by administration of both artesunate-amodiaquine and dolutegravir together for a further 3 days with PK sampling at steady state
62174010|NCT03799354|EXPERIMENTAL|Treatment Group|Maximal strenght training (MST) plus endurance training (ET)
62174011|NCT03799354|ACTIVE_COMPARATOR|Control group|Endurance training (ET)
62174012|NCT06530498||Polycystic ovary syndrome (PCOS)|Women diagnosed with polycystic ovary syndrome based on International Evidence-based Guideline for the assessment and management of polycystic ovary syndrome (2023)
62174013|NCT06530498||Hypothalamic-pituitary-ovarian dysfunction (HPOD)|Women diagnosed with hypothalamic-pituitary-ovarian dysfunction based on The FIGO ovulatory disorders classification system (2022)
62174014|NCT03022110|ACTIVE_COMPARATOR|plastic stent|Endoscopic Ultrasound-guided Drainage with plastic stent
62174015|NCT03022110|EXPERIMENTAL|lumen-apposing metal stent (LAMS)|Endoscopic Ultrasound-guided Drainage with lumen-apposing metal stent
62174016|NCT01404377|ACTIVE_COMPARATOR|ropivacaine|treated group (ropivacaine infiltration)
62174017|NCT01404377|PLACEBO_COMPARATOR|placebo|placebo group : infiltration with saline solution
62174018|NCT04469452||Healthy Adults (19-99yrs)|Healthy adults already enrolled in separate studies using indirect calorimetry to measure RMR within our lab will be recruited for this study. Fifty participants (25 male, 25 female) will be heterogeneous in age, body composition, and physical activity based on the inclusion and exclusion of their respective studies. To test reliability, 25 of the 50 participants will repeat RMR measurements within 1 week of initial measurements.
62174019|NCT02926495|ACTIVE_COMPARATOR|Treatment (ON)|
62174020|NCT02926495|SHAM_COMPARATOR|Control (OFF)|
62182366|NCT01093599|ACTIVE_COMPARATOR|Quit Line plus MTS|Participants in the study group will receive the Quit Line intervention (talk to a Quit Line Counselor, receive quit smoking materials and get 4 weeks of nicotine patches) and also receive 4 weeks of training in mindfulness meditation through the mindfulness for smokers intervention.
62182367|NCT05187247|EXPERIMENTAL|VR group|"Women assigned to the VR group will use the virtual reality technology throughout the insertion procedure"
62182368|NCT05187247|NO_INTERVENTION|control group|control group for the intervention group
62182369|NCT01947153|EXPERIMENTAL|Fixed dose combination|Linagliptin/Metformin
62174021|NCT01940523|ACTIVE_COMPARATOR|Topical Tranexamic Acid|3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
62174022|NCT01940523|ACTIVE_COMPARATOR|Intravenous Tranexamic Acid|1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
62174023|NCT02402465|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray that is similar to Dymista in all respects except the active ingredient
62174024|NCT02402465|EXPERIMENTAL|Fluticasone propionate|Fluticasone propionate nasal spray provided in a bottle similar to placebo and dymista
62174025|NCT02402465|EXPERIMENTAL|Dymista (fluticasone/azelastine)|Dymista is also provided as a nasal spray in bottles similar to the other two agents
62174026|NCT05844033||Chronic Lymphocytic Leukemia and Multiple Myeloma Participants|"150 participants will be screened for an antigen-specific antibody profiling biomarker that is associated with an increased risk of any infections.~Study procedures include in-person or virtual appointments every 3 months for 2 years, some of which will also include bloodwork:~* In-person or virtual appointments with study staff for months 4, 10, 16, and 22 Day 1.~* In-person or virtual appointments with study staff for months 7, 13, 19, and 25 Day 1 with blood tests."
62174027|NCT00731588|EXPERIMENTAL|PPG1A - Adults|Phase I completed: Healthy male and post-menopausal female volunteers between the ages of 18 and 65. Volunteers must not have donated blood in the previous 8 weeks.
62174028|NCT00731588|EXPERIMENTAL|PPG1B - Infants|Phase II in progress: Newborns \>= 24 weeks gestation who are patients in the Neonatal Intensive Care Unit at the University of Iowa Hospitals and Clinics that are being treated with the expectation of survival.
62174029|NCT04236245|OTHER|Venclose RF System|Treatment of great saphenous vein (GSV) using Venclose RF System
62174030|NCT06158971|EXPERIMENTAL|Flexible Microwave Ablation|Soft tissue ablation will be performed using the phenoWave flexible Microwave Ablation System and Accessories on lesions in the peripheral lung. The image-guided ablation procedure may utilize a combination of the radial EBUS and conebeam CT to confirm the lesion, position of the device relative to lesion and monitor the ablation progress.
62174031|NCT03233087||Top third of subjects based levels of selected biomarker.|
62174032|NCT03233087||Middle third of subjects based levels of selected biomarker.|
62174033|NCT03233087||Bottom third ofsubjects based levels of selected biomarker.|
62174034|NCT05388149|EXPERIMENTAL|Neratinib Arm|Standard T-DM1 (3.6mg/kg) IV infusion every 3 weeks administered with Neratinib (160 mg) orally once daily up to 1 year.
62174035|NCT01873573|ACTIVE_COMPARATOR|EGD with Dilation|Standard of Care: Esophagogastroduodenoscopy (EGD) with dilation alone. If participants are assigned to Arm A and are not showing any clinical improvements as determined by their physician after the first three endoscopic dilation sessions, then they will be crossed over into Arm B.
62174036|NCT01873573|ACTIVE_COMPARATOR|EGD with Dilation, plus Triamcinolone|Standard of Care: EGD with dilation and Triamcinolone injection.
62174037|NCT04695314|EXPERIMENTAL|Glaucoma Group|Patients with glaucoma come in and get an intraocular pressure check at baseline. They get a 5 minute foot massage and then have their intraocular pressure checked every 30 minutes over 2 hour span.
62174038|NCT04695314|EXPERIMENTAL|Ocular Hypertension Group A|"Patients with OHTN come in and get an IOP check at baseline. They get a 5 minute foot massage and then have their IOP checked every 30 minutes over 2 hour span.~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received raised experimental shoe insert. Patients come back in the afternoon to have their IOP checked again.~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received sham flat shoe insert. Patients come back in the afternoon to have their IOP checked again."
62174039|NCT04695314|ACTIVE_COMPARATOR|Ocular Hypertension Group B|"Patients with OHTN come in and get an IOP check at baseline. They get a 5 minute foot massage and then have their IOP checked every 30 minutes over 2 hour span.~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received sham flat shoe insert. Patients come back in the afternoon to have their IOP checked again.~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received raised experimental shoe insert. Patients come back in the afternoon to have their IOP checked again."
62174040|NCT01514630|EXPERIMENTAL|Creatine monohydrate|14 female depressed methamphetamine users received 5 grams of creatine monohydrate daily for eight weeks.
62174041|NCT01424683||Endoscopic Vein Harvest (EVH)|A short saphenous vein segment is commonly used as a conduit for coronary artery bypass grafting (CABG), and clinicians must decide whether to obtain it by performing a traditional open vein harvest (OVH) or by performing an endoscopic vein harvest (EVH).
62174042|NCT01424683||Open Vein Harvest (OVH)|A short saphenous vein segment is commonly used as a conduit for coronary artery bypass grafting (CABG), and clinicians must decide whether to obtain it by performing a traditional open vein harvest (OVH) or by performing an endoscopic vein harvest (EVH).
62174043|NCT00030303|EXPERIMENTAL|vaccine|recombinant 70-kD heat-shock protein
62174044|NCT03709316|EXPERIMENTAL|ZL-2306 (Nirapairb)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
62174045|NCT03709316|PLACEBO_COMPARATOR|Placebo|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
62174046|NCT04615715|EXPERIMENTAL|CMV Risk-Reduction Intervention|One-on-one CMV prevention and education visit followed by 12 weeks of CMV prevention and education text messages
61997439|NCT06251856|NO_INTERVENTION|routine discharge education|Routine post-op discharge education is given to patients who undergo gynecological cancer surgery at the institution by nurses on the day of discharge.
62174047|NCT04615715|PLACEBO_COMPARATOR|Stress Reduction Messaging|One-on-one stress reduction messaging visit followed by 12 weeks of reducing stress text messages
62182370|NCT01947153|EXPERIMENTAL|Free combination|Linagliptin and Metformin
62174048|NCT04225039|EXPERIMENTAL|Cohort A|Subjects in this arm (N=16) receive a single priming dose of both INCMGA00012 (500mg) and INCAGN01876 (300mg) prior to stereotactic radiosurgery (SRS), then undergo SRS (8 Gy x 3 fractions). Following SRS, INCMGA00012 (500mg IV every 4 weeks) and INCAGN01876 (300mg IV every 2 weeks) are resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.
62174049|NCT04225039|EXPERIMENTAL|Cohort B sub-arm #1|Subjects in this arm (N=8) receive neoadjuvant immunotherapy INCMGA00012 (500mg) + INCAGN01876 (300mg) + SRS. Subjects then undergo surgery. Postoperatively, the immunotherapy combination of INCMGA00012 (500 mg IV every 4 weeks) and INCAGN01876 (300mg IV every 2 weeks) is resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.
62174050|NCT04225039|EXPERIMENTAL|Cohort B sub-arm #2|Subjects in this arm (N=8) receive neoadjuvant immunotherapy INCMGA00012 + INCAGN01876 (without SRS). Subjects then undergo surgery. Postoperatively, the immunotherapy combination of INCMGA00012 (IV every 4 weeks) and INCAGN01876 (IV every 2 weeks) is resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.
62174051|NCT04610645||Head and Neck Cancer Patients|Patients with adjuvant or definitve radiotherapy or radio-chemotherapy for head and neck cancer
62174052|NCT05870813||AI+OFS|adjuvant treatment with aromatase inhibitor + OFS (ovarian function suppression)
62174053|NCT05870813||TAM|Patients started the adjuvant treatment with Tamoxifen ± OFS
62174054|NCT04792255|EXPERIMENTAL|Group A: Reduced contrast media dose group|"Reduced contrast media protocol: extracranial carotid artery intervention (2-4 fps according to the institutional protocol).~Contrast administration with an automatic contrast injector: angiographic image acquisitions will be performed with 6 ml of 50% contrast media (3 ml iodined contrast media, 3 ml physiologic saline) with a 3 ml/s flow rate.~DSA and DVA images will be calculated; DVA images will be used for diagnosis and interventions."
62174055|NCT04792255|ACTIVE_COMPARATOR|Group B: Standard contrast media dose group|"Standard contrast media protocol: extracranial carotid artery intervention (2-4 fps according to the institutional protocol).~Contrast administration with an automatic contrast injector: angiographic image acquisitions will be performed with 6 ml iodined contrast media with a 3 ml/s flow rate.~DSA and DVA images will be calculated; DSA images will be used for diagnosis and interventions."
62174056|NCT00657475|EXPERIMENTAL|2|Cardiac surgery with Mini Extra Corporeal Circulation (MECC). Heparin low dose (150 UI/Kg).
62174057|NCT00657475|ACTIVE_COMPARATOR|1|Cardiac surgery with Mini Extra Corporeal Circulation (MECC). Heparin Full Dose (300 UI/Kg)
62174058|NCT00601471|EXPERIMENTAL|1|proximal tibiofibular manipulation
62174059|NCT00601471|EXPERIMENTAL|2|distal tibiofibular manipulation
62174060|NCT00601471|NO_INTERVENTION|3|no treatment
62174061|NCT06647251|ACTIVE_COMPARATOR|Q-MODE|Radiofrequency ablation with High Power - Short Duration (HPSD) up to 50W.
62174062|NCT06647251|ACTIVE_COMPARATOR|Q-MODE+|Radiofrequency ablation with High Power - Short Duration (HPSD) up to 90W.
62174063|NCT06647251|ACTIVE_COMPARATOR|Hybride Q-MODE/Q-MODE+|A combination of the two ablation methods.
62174064|NCT02773407|ACTIVE_COMPARATOR|Group A|Azithromycin tablets 20mg/kg/day for 7 days (Maximum dose 1000mg/day)
62174065|NCT02773407|ACTIVE_COMPARATOR|Group B|Co-trimoxazole tablets (Trimethoprim 10 mg/kg+Sulphamethoxazole 50 mg/kg) in two divided doses everyday for 7 days (maximum 3000mg/day)
62174066|NCT04491084|EXPERIMENTAL|FLT3 ligand (CDX-301), anti-CD40 antibody (CDX-1140), and SBRT|"Subjects on either study arm with limited disease will receive SBRT to all evident sites of active disease. Subjects on Arm 1 with extensive disease will initially receive SBRT to a single site of disease but may receive additional cycles of FLT3 ligand, anti-CD40 antibody, and SBRT at later time points."
62174067|NCT04491084|ACTIVE_COMPARATOR|Standard care|Subjects on either study arm with limited disease will receive SBRT to all evident sites of active disease.Subjects on Arm 2 with extensive disease are expected to receive some form of standard systemic therapy (e.g., docetaxel). Subjects on Arm 2 with limited disease may also receive standard systemic therapy following completion of SBRT to all sites of evident disease, at the discretion of the treating physicians.
62174068|NCT02652715|EXPERIMENTAL|Basic science (Salvia hispanica seed)|Patients receive Salvia hispanica seed PO QD for 12 weeks.
62174069|NCT01176136|EXPERIMENTAL|HOPS Intervention|Middle school age children who receive the Homework, Organization, and Planning Skills (HOPS) intervention.
62174070|NCT01176136|NO_INTERVENTION|Treatment As Usual|Middle school age children randomly assigned to receive treatment-as-usual services available through the school and community.
62174071|NCT00235014|ACTIVE_COMPARATOR|A-1, B-1|A-1 pertains to Phase 1; B-1 pertains to Phase 2
62174072|NCT00235014|ACTIVE_COMPARATOR|A-2, B-2|A2 pertains to Phase 1; B-2 pertains to Phase 2
62174073|NCT00235014|PLACEBO_COMPARATOR|A-3|
62174074|NCT00235014|ACTIVE_COMPARATOR|A-4|
62174075|NCT03209297|EXPERIMENTAL|Direct treatment|Patients receive the TMD treatment immediately
62174076|NCT03209297|EXPERIMENTAL|Delayed treatment|No intervention in the first 9 weeks of the study. Afterwards, the patients receive the same treatment as the other group
62174077|NCT05287698|EXPERIMENTAL|Cold vapor group|Cold vapor will be applied to the experimental group patients for 15 minutes in the recovery room. For the study, Nebtime UN600A Ultrasonic Nebulizer Device will be used to apply cold steam to the patients which used in the hospital and calibrated (https://elmaslarmedikal.com.tr/urunler/nebtime-un600a-ultrasonik-nebulizator/). The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5 (1-10), air blowing intensity 5 (1-10), heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service.
62174078|NCT05287698|NO_INTERVENTION|Control group|Patients in the control group will receive standard care that includes all medical and non-medical treatments in the hospital. Nursing care, which is routinely applied to patients in the postoperative period, both in the recovery room and in the service, will be continued within the standard care. The patients will be evaluated by the researchers in terms of sore throat and dysphagia when they come to the recovery room and at the 6th,12th, and 24th hours after the surgery in the postoperative service.
62174079|NCT01420900|ACTIVE_COMPARATOR|ABG II / Trident|
62174080|NCT01420900|ACTIVE_COMPARATOR|CLS / Trilogy|
62174081|NCT06306677||Subjects presenting for care at Hospitals|The group is formed by subjects reporting for care at one of the four participating hospitals (China, Hong Kong SAR, Italy) who required an OPG radiographs for their routine clinical care.
62174082|NCT01271153|ACTIVE_COMPARATOR|Dobutamine|Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours
62174083|NCT01271153|PLACEBO_COMPARATOR|Placebo|An equivalent infusion of placebo will be infused for 2.5 h
62174084|NCT06646081|ACTIVE_COMPARATOR|Greater Occipital Nerve Block Group|Greater Occipital Nerve Block for Chronic Headache
62174085|NCT06646081|ACTIVE_COMPARATOR|Stellate Ganglion Block Group|Stellate Ganglion Block for Chronic Headache
62174086|NCT06414681|EXPERIMENTAL|Tagrxofusp (IV) in combination with Pacritinib (Oral)|"Tagraxofusp Patients will receive 12 micrograms/kg of Tagraxofusp (TAG) by IV infusion once daily for 3 consecutive days.~Pacritinib Pacritinib (PAC) will be given orally, 200 mg twice per day starting at C2D4 and administered continuously (Subsequent cycles start on Day 1 of the Cycle)."
62174087|NCT00006099|EXPERIMENTAL|Intraperitoneal (IP) Infusion of 111In-hu3S193|"Hu3S193 was administered intraperitoneally at a dose of 5 mg radiolabeled with 5 millicurie (mCi) of 111In.~Patients received 10 mCi 99mTc-sulphur colloid IP administered in 500 ml of normal saline to assure the absence of any loculation or heterogeneous distribution of radioactivity in the peritoneal cavity. A paracentesis catheter was inserted and the hu3S193 was diluted in 100 mL of 5% human serum albumin and administered as a continuous intraperitoneal infusion over 30 minutes. This was followed immediately by 900 mL of normal saline."
62363915|NCT01391455|EXPERIMENTAL|Spermatic Cord is isolated from the mesh|The inguinal ligament is interposed between the cord and the mesh and then repaired. This isolates the cord from the mesh and the splinting function of the overlying inguinal ligament.
62174088|NCT00006099|EXPERIMENTAL|Intravenous Infusion of 111In-hu3S193|Hu3S193 was to be administered intravenously at a dose of 5 mg radiolabeled with 5 millicurie (mCi) of 111In, diluted in 100 mL of 5% human serum albumin and administered over a 30 minute period.
62174089|NCT02720081|EXPERIMENTAL|MK-1029 150 mg + Montelukast 10 mg|Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
62174090|NCT02720081|PLACEBO_COMPARATOR|MK-1029 Placebo + Montelukast 10 mg|Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
62174091|NCT05674383|EXPERIMENTAL|Intervention group|The intervention group will receive an axillary plexus nerve block as pain reduction before the fracture repositioning.
62174092|NCT05674383|ACTIVE_COMPARATOR|Control group|The control group will receive a fracture hematoma block as pain reduction before the fracture repositioning.
62174093|NCT00572351|ACTIVE_COMPARATOR|Red Wine|
62174094|NCT00572351|ACTIVE_COMPARATOR|White Wine|
62363916|NCT02687607||WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 80 years requiring treatment for single ruptured intracranial aneurysms.
62174095|NCT05858398|EXPERIMENTAL|Pharmocokinetics blood sample assessment|during first administration of docetaxel several pharmacokinetics samples will be assessed
62174096|NCT02115334|EXPERIMENTAL|professional-based group|professional therapists delivering the PHPA
62174097|NCT02115334|EXPERIMENTAL|parents-based group|parents executing the PHPA
62174098|NCT02115334|ACTIVE_COMPARATOR|control group|health education only
62174099|NCT02314169|EXPERIMENTAL|Part A (nivolumab)|Patients receive nivolumab IV over 60 minutes once every two weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI and blood sample collection throughout the study.
62174100|NCT02314169|EXPERIMENTAL|Part B Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes once every 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI and blood sample collection throughout the study.
62174101|NCT02314169|EXPERIMENTAL|Part B Arm II (nivolumab, ipilimumab)|Patients receive nivolumab as in Arm I. Patients also receive ipilimumab IV over 30 minutes once every 8 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI and blood sample collection throughout the study.
62174102|NCT05600998|EXPERIMENTAL|Camrelizumab+Anlotinib|Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks
62174103|NCT02068352|EXPERIMENTAL|0.3% OPA-15406|OPA-15406 0.3% ointment was applied topically twice daily (BID) to the selected treatment area(s) at approximately 12-hour intervals for 8 weeks.
62174104|NCT02068352|EXPERIMENTAL|1% OPA-15406|OPA-15406 1% ointment was applied topically BID to the selected treatment area(s) at approximately 12-hour intervals for 8 weeks.
62174105|NCT02068352|PLACEBO_COMPARATOR|Vehicle Ointment|OPA-15406 1%-matching placebo (vehicle ointment) was applied topically BID to the selected treatment area(s) at approximately 12-hour intervals for 8 weeks.
62174106|NCT02262390|ACTIVE_COMPARATOR|Standard of Care|Partner notification slip is given to the pregnant female participant on the day she receives her syphilis test results to give to their sexual partner encouraging them to come to the STI clinic and be screened for syphilis. The partner notification slip will have a code number, but no identifiable features (no names).
62182371|NCT05982080|EXPERIMENTAL|FP002 Injection|Dose escalation: FP002
62363917|NCT03082807|EXPERIMENTAL|Study group I|Study group I (18 participants) received the NCD with exercise (NCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
62363918|NCT03082807|EXPERIMENTAL|Study group II|Study group II (19 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
62363919|NCT00906906||1|Patient to receive CPB
62363920|NCT00910728|EXPERIMENTAL|1|AZD1480
62363921|NCT02658968|EXPERIMENTAL|Betalutin|10 MBq/kg b.w., in escalated doses with lilotomab pre-dosing
62174107|NCT02262390|ACTIVE_COMPARATOR|SMS reminders and notification slip for partner screening|Participants will receive weekly SMS reminders to encourage their partners to attend the STI clinic for syphilis testing for up to 8 weeks after initial positive syphilis test for the participant. The participant ID number will be written on both the notification paper which partners should bring in with them and on the SMS reminders.
62174108|NCT02262390|ACTIVE_COMPARATOR|Phone call reminders and notification slip for partner scree|Participants will receive weekly phone call reminders to encourage their partners to attend the STI clinic for syphilis testing for up to 8 weeks after initial positive syphilis test for the participant. The participant ID number will be written on both the notification paper which partners should bring in with them and be given to the participant when the nurse calls.
62174109|NCT04376242|EXPERIMENTAL|virtual reality then standard technology|patients randomized to this arm will first use virtual reality (VR) during and oral food challenge and then use standard technology during a second oral food challenge
62174110|NCT04376242|ACTIVE_COMPARATOR|standard technology then virtual reality|patients randomized to this arm will first use standard technology during and oral food challenge and then use virtual reality during a second oral food challenge
62174111|NCT01183013|ACTIVE_COMPARATOR|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily
62174112|NCT01183013|ACTIVE_COMPARATOR|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily
62174113|NCT01183013|ACTIVE_COMPARATOR|Pioglitazone 45 mg|Pioglitazone Capsules 45 mg once daily
62174114|NCT01183013|ACTIVE_COMPARATOR|Linagliptin 5mg|Linagliptin 5mg Tablets once daily
62174115|NCT01183013|EXPERIMENTAL|Linagliptin 5mg / Pioglitazone 15 mg|Linagliptin 5mg / Pioglitazone 15 mg Tablets once daily
62174116|NCT01183013|EXPERIMENTAL|Linagliptin 5mg / Pioglitazone 30 mg|Linagliptin 5mg / Pioglitazone 30 mg Tablets once daily
62174117|NCT01183013|EXPERIMENTAL|Linagliptin 5mg / Pioglitazone 45 mg|Linagliptin 5mg / Pioglitazone 45 mg Tablets once daily
62174118|NCT01872156|EXPERIMENTAL|Intervention GESTABAC|"Intervention based on the Clinician's Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth."
62174119|NCT01872156|OTHER|Control Group|The group control will act according to usual management.
62174120|NCT02960321||CAG without PCI|Diagnostic coronary angiography only
62174121|NCT02960321||CAG with PCI|Diagnostic coronary angiography and subsequent percutaneous coronary intervention (PCI)
62174122|NCT01560585|EXPERIMENTAL|Open label|All participants will receive Isotretinoin for 24 weeks
62174123|NCT00924599|EXPERIMENTAL|Intervention Group-English|Intervention Group will be learning how to lose weight through healthy eating and moderate exercise. The goal is to get participants to lose 7% of body weight and increase physical activity to 2 1/2 hours per week. This group will be meeting one time per week for twelve weeks, and then one time per month until conception.
62174124|NCT00924599|EXPERIMENTAL|Intervention Group-Spanish|Intervention Group will be learning how to lose weight through healthy eating and moderate exercise. The goal is to get participants to lose 7% of body weight and increase physical activity to 2 1/2 hours per week. This group will be meeting one time per week for twelve weeks, and then one time per month until conception.
62174125|NCT00924599|ACTIVE_COMPARATOR|Lifestyle education-English|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
62363922|NCT05944913|EXPERIMENTAL|Arm A : Surgery for STS and prevena|"The surgery for the STS lesion will be performed according to standard practices.~PREVENA™ Incision Management System should be applied immediately post-surgery to clean surgically closed wounds. It should be continuously applied for a minimum of 2 days and up to a maximum of 7 days (as per PREVENA user manual)"
62174126|NCT00924599|ACTIVE_COMPARATOR|Lifestyle education-Spanish|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
62174127|NCT05482256|EXPERIMENTAL|Toothpaste detergents with Eosinophilic Esophagitis Testing|Subjects will complete an esophageal string test prior to and after completing a high resolution esophageal manometry then brushing their teeth using Colgate toothpaste.
62174128|NCT03132753|EXPERIMENTAL|SUPPORT Group|Subjects enrolled in the intervention.
62174129|NCT03132753|NO_INTERVENTION|Treatment as Usual|Subjects enrolled in standard services.
62174130|NCT00672763|ACTIVE_COMPARATOR|A|Standard corticosteroid treatment PLUS Vitamin D3 (Colecalciferol).
62174131|NCT00672763|PLACEBO_COMPARATOR|B|Standard corticosteroid treatment PLUS placebo (Migliol Oil)
62174132|NCT04796389|EXPERIMENTAL|Recorded music|Recorded music intervention
62174133|NCT04796389|NO_INTERVENTION|Control|Standard of care
62174134|NCT02210611|ACTIVE_COMPARATOR|36 hours|Intrauterine insemination 36 hours after ovulation induction
62174135|NCT02210611|ACTIVE_COMPARATOR|42 hours|Intrauterine insemination 42 hours after ovulation induction
62174136|NCT00936754|EXPERIMENTAL|Treatment|Single administration of 500 mg of encapsulated brown seaweed powder, taken 30 minutes before test meal
62174137|NCT00936754|PLACEBO_COMPARATOR|Placebo|Single administration of encapsulated placebo, taken 30 minutes before test meal
62174138|NCT05131789|EXPERIMENTAL|Information System Group|The dementia case managers in the experiment group use information system to perform case management.
62174139|NCT03192202|EXPERIMENTAL|Cohort 1|1.5 mg/kg of AFM13 once weekly for weeks 1-8.
62174140|NCT03192202|EXPERIMENTAL|Cohort 2|7 mg/kg of AFM13 once weekly for weeks 1-8.
62174141|NCT03192202|EXPERIMENTAL|Cohort 3|7mg/kg CIVI for weeks 1-8.
62174142|NCT03192202|EXPERIMENTAL|Cohort 4|200mg flat dose once weekly for 8 weeks.
62174143|NCT04292925|EXPERIMENTAL|Experimental Group|Intervention with the new treatment protocol will include 18 treatment sessions of 45 minutes, between three to five times a week depending on the participant's state, over a period of four to six weeks.
62363923|NCT05944913|NO_INTERVENTION|Arm B : Surgery for STS and standard postoperative wound management|"The surgery for the STS lesion will be performed according to standard practices.~The dressing and drainage of the wound will be performed according to usual practices, with the exception of negative pressure dressings."
62174144|NCT04292925|ACTIVE_COMPARATOR|Control group|Intervention with conventional therapy will include 18 treatment sessions of 45 minutes, between three to five times a week depending on the participant's state, over a period of four to six weeks.
62174145|NCT05740969|ACTIVE_COMPARATOR|5-Fluorouracil|Patients will be asked apply a 40 mg/g creme containing 5-Fluorouracil once a day on their lesion for 10 days. A biopsy will be taken four days after last application. The patient will be refered to a dermatologist for further treatment, if necessary.
62174146|NCT05740969|ACTIVE_COMPARATOR|Imiquimod|Patients will be asked apply a 50 mg/g creme containing imiquimod thrice a week on their lesion for 10 days. A biopsy will be taken four days after last application. The patient will be refered to a dermatologist for further treatment, if necessary.
62174147|NCT05740969|EXPERIMENTAL|Melatonin|Patients will be asked apply a 25 mg/g creme containing melatonin once a day on their lesion for 10 days. A biopsy will be taken four days after last application. The patient will be refered to a dermatologist for further treatment, if necessary.
62174148|NCT05740969|NO_INTERVENTION|Control|A biopsy will be taken from the patient and the patient will be refered to a dermatologist for further treatment, if necessary.
62174149|NCT00660361||A|individuals co-infected with HIV-HBV and receiving tenofovir as aprt of their HAART regimen
62174150|NCT06221800||Treatment with PD1/L1 monotherapy|
62174151|NCT06221800||Treatment with PD1/L1 + chemotherapy|
62174152|NCT06221800||Treatment with Tyrosine Kinase Inhibitor|
62174153|NCT02364505|EXPERIMENTAL|Telemedicine mindfulness intervention|Participants are assigned to a telemedicine mindfulness intervention group. The protocol lasts 8 weeks and it is composed by one online course session each week and home exercises. The course sessions, with a synchronous communication, will be conducted by a trainer, through teleconferences, that will explain how to practice the exercises to develop mindfulness attitude, following the mindfulness-based intervention-multiple sclerosis protocol. Subjects will be able to take part of these sessions everywhere, through a computer, tablet o mobile. During these sessions, individuals will interact with the trainer with teleconference or textual communications.
62174154|NCT02364505|ACTIVE_COMPARATOR|Psycho-education control group|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
62174155|NCT03793140|EXPERIMENTAL|CPI-613|CPI-613 IV induction (Days 1-5 for first 2 Cycles \[14-day cycles\]), followed by CPI-613 IV maintenance (Days 1-5 for all Cycles thereafter \[21-day cycles\].
62174156|NCT00768209|EXPERIMENTAL|Treatment A|
62174157|NCT05885841|EXPERIMENTAL|XTR004|"In the resting stage, subjects will receive an IV bolus injection of XTR004 to assess myocardial perfusion and myocardial blood flow.~Under the pharmacological stress stage with adenosine, subjects will receive another IV bolus injection of XTR004 to assess myocardial perfusion and myocardial blood flow."
62174158|NCT05245084|EXPERIMENTAL|Sequence 1|"* Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~* Period 2: CKD-386(2)- A single oral dose of 1 tablet under fasting condition~* Period 3: D013, D326, D337- A single oral dose of 3tablet s under fasting condition~* Period 4: CKD-386(2)- A single oral dose of 1 tablet under fasting condition"
62174159|NCT05245084|EXPERIMENTAL|Sequence 2|"* Period 1: CKD-386(2)- A single oral dose of 1 tablet under fasting condition~* Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~* Period 3: CKD-386(2)- A single oral dose of 1 tablet under fasting condition~* Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition"
62174160|NCT03562897|EXPERIMENTAL|Ocoxin-Viusid®|Ocoxin-Viusid® before, during and after the Chemotherapy treatment.
62174161|NCT02969005|EXPERIMENTAL|surgery group|The dissection was continued into the deeper layers until the bone lesion was visualized, and the bone lesion was then thoroughly resected.
62174162|NCT01928407|EXPERIMENTAL|ATAZANAVIR|The patient included in this Group 1 will receive their first antiretroviral regimen included : ATV + TDF/FTC (or Abacavir/Lamivudine, \[ABC/3TC\], if contre indicated of TDF/FTC) The dose : atazanavir/ritonavir 300/100mg/day and TDF/FTC 245 /200 mg day, 3 pills once a day, during 48 weeks during a meal
62174163|NCT01928407|EXPERIMENTAL|DARUNAVIR|The patients included in this Group 2 will receive their first antiretroviral regimen included Group 2 : DRV+ TDF/FTC (or ABC/3TC if contre-indicated of TDF/FTC) The dose : darunavir/ritonavir 800/100mg/day and TDF/FTC 245 /200 mg day, 4 pills once a day, during 48 weeks during a meal
62174164|NCT05499247|EXPERIMENTAL|Single Arm|
62174165|NCT05381181|EXPERIMENTAL|CD19-UCART|All patients will be treated with at least 1 injection of CD19- UCART. A dose of 5x10\^6/kg BW of CD19-UCART will be evaluated. If \> 1/6 of DLT occurred, the dose would be reduced to 2.0x10\^6/kg BW.
62174166|NCT05056129|EXPERIMENTAL|Sensor-controlled digital game (SCDG)|The intervention group will receive a sensor-controlled digital game (SCDG) app and weight monitoring and physical activity sensors
62174167|NCT05056129|ACTIVE_COMPARATOR|Sensors-only|The control group will receive only the weight monitoring and physical activity sensors
62174168|NCT03652870|ACTIVE_COMPARATOR|Nortriptyline|25mg tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
62174169|NCT03652870|ACTIVE_COMPARATOR|Escitalopram|5mg tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
62174170|NCT03652870|PLACEBO_COMPARATOR|Placebo|The placebo tablet consists of lactose and magnesium stearate. One tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
62174171|NCT02176902|NO_INTERVENTION|Arm I (control)|Patients receive no intervention.
62174172|NCT02176902|EXPERIMENTAL|Arm II (fish oil)|Patients receive dietary counseling with research dietitian weekly for 1 month and then monthly for 11 months. Patients are given guidelines with recommended meals to follow a low omega-6, high omega-3 fat diet combined with fish oil. Patients also receive 4 fish oil capsules per day PO for 1 year.
62174173|NCT05518877|ACTIVE_COMPARATOR|Ketamine 15 Minutes|Participants receive 0.25mg/kg Ketamine dose intravenous for pain over 15 minutes.
62174174|NCT05518877|EXPERIMENTAL|Ketamine 30 Minutes|Participants receive 0.25mg/kg Ketamine dose intravenous for pain over 30 minutes.
62174175|NCT05809726|EXPERIMENTAL|Manual lymph drainage group|Manual lymph drainage; neck drainage, abdominal drainage, stimulation of axillary lymph nodes, and right arm drainage were performed by following a special technique and sequence. MLD was applied in a comfortable position while the patient was lying in the supine position. It took an average of 20 minutes.
62174176|NCT05809726|SHAM_COMPARATOR|Sham manual lymph drainage group|Sham manual lymph drainage; deep pressure was applied from distal to proximal with rapid movements to the right extremity to which the cold pressure test was applied. Fingers, dorsal and palmar surfaces of the hand, forearm, elbow, and upper arm were applied in order. The application was performed while the patient was lying in the supine position and lasted an average of 20 minutes.
62174177|NCT05809726|NO_INTERVENTION|Control Group|Participants in the control group were asked to lie on their backs for 10 minutes without speaking in a quiet, calm environment. At the end of 10 minutes, the patient was placed in a sitting position again and the third evaluation was performed.
62174178|NCT00524810|EXPERIMENTAL|Caelyx - Taxotere|
62174179|NCT01178281|EXPERIMENTAL|Pomalidomide 0.5 mg|"Participants received pomalidomide 0.5 mg/day by mouth for at least 168 days unless there were unacceptable side effects or disease progression.~Participants who were RBC-transfusion independent or experienced clinical benefit (defined as a reduction from Baseline of ≥ 50% in RBC-transfusion frequency during the prior 84-day interval) could continue to receive pomalidomide until loss of RBC-transfusion independence response or clinical benefit, or other criteria for treatment discontinuation applied."
62174180|NCT01178281|PLACEBO_COMPARATOR|Placebo|"Participants received placebo taken by mouth once daily for at least 168 days unless there were unacceptable side effects or disease progression.~Participants who were RBC-transfusion independent or experienced clinical benefit could continue to receive placebo until loss of RBC- transfusion independence response or clinical benefit, or other criteria for treatment discontinuation applied."
62174181|NCT01178281|EXPERIMENTAL|China Extension: Pomalidomide 0.5 mg|"Participants received pomalidomide 0.5 mg/day by mouth for at least 168 days unless there were unacceptable side effects, disease progression, or they received a RBC-transfusion.~Participants who experienced anemia response could continue treatment until the response was lost or other criteria for treatment discontinuation applied."
62174182|NCT00084747|EXPERIMENTAL|bortezomib|
62174183|NCT05524285|EXPERIMENTAL|experimental group|Intracranial Support Catheter
62174184|NCT05524285|ACTIVE_COMPARATOR|control group|Guide Catheter
62174185|NCT04522583||Troponin-positive ED patients|All patients admitted to the ED at the Hillel Yaffe Medical Center in Hadera, Israel, in the period 2016-2019 with cTn level higher than the 99th percentile of cTn concentration in the normal population (\>0.014 nanogram/milliliter).
62174186|NCT02450123|EXPERIMENTAL|sunitinib|sunitinib 50mg will be administered orally once a day 42 days.Study treatment will be continued until objective disease progression.
62174187|NCT06204614|EXPERIMENTAL|DRUG SCREENING USING IMD IN BLADDER CANCER|Study participants placed in arm 1 will be implanted with the microdevice.
62174188|NCT04787900|EXPERIMENTAL|iPhone measurement application|For the measurement, the participant was asked to lie on his side and flex the knee to 90 degrees. The examiner stabilized the patient from the pelvis with one hand, and with the other hand brought the flexed leg of the participant to abduction and extension. The Examiner 3 recorded the result by placing the device to be measured on the lateral projection of the midpoint of the femur.
62174189|NCT04787900|ACTIVE_COMPARATOR|Bubble inclinometer|measurement will be done by the same method. For the measurement, the participant was asked to lie on his side and flex the knee to 90 degrees. The examiner stabilized the patient from the pelvis with one hand, and with the other hand brought the flexed leg of the participant to abduction and extension. The Examiner 3 recorded the result by placing the device to be measured on the lateral projection of the midpoint of the femur.
62174190|NCT02179710||Motivational Interviewing|Review of adherence dashboard by the investigator with the patient to facilitate and engage intrinsic motivation within the client in order to change behavior.
62174191|NCT01107353|ACTIVE_COMPARATOR|First Imipramine Pamoate, then Tofranil-PM|First 75 mg imipramine pamoate capsule, then 75 mg Tofranil-PM capsule (after washout period)
62174192|NCT01107353|ACTIVE_COMPARATOR|First Tofranil PM, then imipramine pamoate|First 75 mg Tofranil-PM capsule, then 75 mg imipramine pamoate capsule (after washout period)
62174193|NCT00788047|OTHER|Regimen A (Reference)|
62174194|NCT00788047|EXPERIMENTAL|Regimen B (Test)|
62174195|NCT03854214|ACTIVE_COMPARATOR|Functional Electric Stimulation cycling|The Functional Electrical Stimulation (FES) cycling group will use RT300 ergometer (Restorative Therapies, Inc) with stimulation on.
62174196|NCT03854214|SHAM_COMPARATOR|Passive Cycling|The passive cycling group will use the same RT300 ergometer with stimulation off.
62174197|NCT02814097|EXPERIMENTAL|40 mg elamipretide|40 mg elamipretide once daily for 28 consecutive days
62174198|NCT02814097|PLACEBO_COMPARATOR|Placebo|Placebo once daily for 28 consecutive days
62174199|NCT06001827|EXPERIMENTAL|Treatment Arm|Treated with SelfWrap Bioabsorbable Perivascular Wrap during AVF creation surgery
62174200|NCT06001827|SHAM_COMPARATOR|Control Arm|AVF creation surgery without any intervention (untreated AVF control, or standard of care)
62174201|NCT04868318|EXPERIMENTAL|VHP(very-high protein) group|In VHP(very-high protein) group, we will provide pre-digested formula of 37% protein to the experimental group for at least 3 days to up to 7 days.
62174202|NCT04868318|ACTIVE_COMPARATOR|SHP(standard-high protein) group|SHP(standard-high protein) group is the control group, standard-high protein formula (16% of energy) would be given to the control group for at least 3 days to up to 7 days.
62174203|NCT03628456|EXPERIMENTAL|AffloVest Monarch Arm|Devices placed on highest intensity / highest frequency
62174204|NCT02512861|ACTIVE_COMPARATOR|Bupivacaine|Bupivacaine as a parasternal nerve block following pediatric cardiothoracic surgery
62174205|NCT02512861|PLACEBO_COMPARATOR|Placebo|Normal Saline
62174206|NCT06645925|EXPERIMENTAL|One Step Protocol|FGG simultaneous with delayed implant placement
62174207|NCT06645925|ACTIVE_COMPARATOR|Two Steps protocol|Conventional FGG protocol, prior to implant placement
62174208|NCT02895750|EXPERIMENTAL|normal to mild renal impairment|(12 subjects): eGFR ≥ 60 (normal renal function to mild renal impairment, CKD stages 1-2) METFORMIN
62174209|NCT02895750|EXPERIMENTAL|mild to moderate renal impairment|(12 subjects): eGFR 59-45 (mild to moderate renal impairment, CKD stage 3a) METFORMIN
62174210|NCT02895750|EXPERIMENTAL|moderate to severe renal impairment|(12 subjects): eGFR 44-30 (moderate to severe renal impairment, CKD stage 3b) METFORMIN
62182372|NCT00443898|EXPERIMENTAL|1|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks
62174211|NCT02986659|ACTIVE_COMPARATOR|Metformin then Placebo|Metformin dosing at 425, 850 and 1700 mg with GLUCOPHAGE® (metformin hydrochloride) Tablets. Treatment with metformin will be initiated at a dose of 425 mg (half pill) taken orally once a day at night for 7 days. After the week, the participant will be called to assess tolerance and will be asked to increase dose to one pill at night at a dose of 850 mg for one week. At the end of the second week, participants will be called again and if they tolerated the second dose, they will be asked to take two 850 mg pills, one in the morning and one at night, for a total dose of 1700 mg which is within the range of the usual effective dose of 1500 to 2000 mg/day for the remainder of the 3 months. Will then cross over to 3 months on placebo.
62174212|NCT02986659|PLACEBO_COMPARATOR|Placebo then Metormin|Dietary Supplement: Placebo with Methylcellulose capsules. Treatment with placebo will be initiated at a dose of a half pill taken orally once a day at night for 7 days. After the week, the participant will be called to assess tolerance and will be asked to increase dose to one pill at night for one week. At the end of the second week, participants will be called again and if they tolerated the second dose, they will be asked to take two pills, one in the morning and one at night for the remainder of the 3 months. After 3 months on placebo, participants will then cross over to 3 months of metformin as described in the other arm.
62174213|NCT05023941|ACTIVE_COMPARATOR|Medicine Group|Start orally take Acetazolamide 2 days before entering the hypoxic room.
62174214|NCT05023941|ACTIVE_COMPARATOR|RIPC Group|Start RIPC training twice daily, 6 days before entering the hypoxic room.
62174215|NCT05023941|EXPERIMENTAL|Rapid RIPC Group|Start RIPC training forth daily, 3 days before entering the hypoxic room.
62174216|NCT05023941|EXPERIMENTAL|Combined Group|Medicine + Rapid RIPC
62174217|NCT05023941|NO_INTERVENTION|Control Group|Subjects do not receive specific interventions before entering the hypoxic room.
62174218|NCT04794894||Telerehabilitation services|Physical therapy, occupational therapy, speech-language therapy, and/or counseling provided at home via telecommunication technologies.
62174219|NCT04794894||Clinic-based rehabilitation services|Physical therapy, occupational therapy, speech-language therapy, and/or counseling provided at a local facility.
62174220|NCT05313815|EXPERIMENTAL|Moderate Hypofracitonated Boost to the Prostate with Pelvic Radiation Therapy|External beam radiotherapy- 60 Gy in 20 fractions to the prostate, 48 Gy in 20 fractions to the pelvis, 68 Gy in 20 fraction optional boost to prostatic dominant intraprostatic lesion, 55 Gy in 20 fraction optional boost to involved pelvic lymph nodes
62174221|NCT03320642|EXPERIMENTAL|Itacitinib + Calcineurin Inhibitor (CNI) -Based Interventions|Itacitinib in combination with a CNI-based intervention.
62174222|NCT05163106|EXPERIMENTAL|Ribociclib and Letrozole Arm|Patients entered into this study will be given letrozole (FemarTM) in combination with ribociclib (KisqaliTM) for at least 6 months. Premenopausal women will also receive treatment with goserelin 3.6 mg s.c. every 4 weeks.
62174223|NCT04013932|EXPERIMENTAL|KUPAA Intervention + Standard of Care|Patients will be assigned to a KUPAA group composed of approximately 6 patients (joined by their 6 matched caregivers). Patients will first participate in 1-2 joining sessions with a provider, followed by a 1-day group educational workshop. Participants will then attend weekly family psychoeducation group sessions (\~1.5-2 hours) for 12 weeks.
62174224|NCT04013932|NO_INTERVENTION|Control - Standard of Care|Patients will receive the standard of care.
62174225|NCT00574626|EXPERIMENTAL|Peripheral Blood Stem Cell Transplant|Peripheral Blood Stem Cell Transplant
62174226|NCT00574626|ACTIVE_COMPARATOR|Bone Marrow Transplantation|Bone Marrow Transplantation
62174227|NCT01998997|ACTIVE_COMPARATOR|Family educational intervention|A family educational, non-pharmacologic intervention will be administered to educate family members on how to prevent delirium. Family members will be encouraged to actively participate in this non-pharmacologic intervention.
62174228|NCT01998997|PLACEBO_COMPARATOR|general health education|The placebo group will be given a brochure on good health habits
62174229|NCT02962063|EXPERIMENTAL|Esophageal Cancer|This is a phase Ib/II trial of durvalumab (MEDI4736), a monoclonal antibody against programmed death ligand-1 (PD-L1)), and tremelimumab, an anti-CTLA-4 antibody, in combination with chemoradiation for patients with locally advanced (TanyN+M0 or T3-4NanyM0) esophageal or gastroesophageal (GE) junction adenocarcinoma.
62174230|NCT04995406||Active TB ATB|Participants with active tuberculosis with diagnosis confirmed by GeneXpert and/or culture positivity
62174231|NCT04995406||Latent Tuberculosis Infections LTBI|Participants with presumed latent TB infection
62174232|NCT04995406||Healthy controls HC|Participants who do not have Active or Latent tuberculosis or other pathologies investigated in this study
62174233|NCT04995406||Non-tuberculous symptomatic participants|This cohort refers to participants who are known with chronic respiratory conditions and present with one or more signs and symptoms suggestive of TB, but in whom microbiological testing is negative.
62174234|NCT00785850|EXPERIMENTAL|1|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower
62174235|NCT06003738|ACTIVE_COMPARATOR|The fascia iliaca compartment block group|The first group 34 patients
62174236|NCT06003738|ACTIVE_COMPARATOR|The pericapsular nerve block group|The second group 34 patients
62174237|NCT01906645|NO_INTERVENTION|Usual Care|Usual care consists of 1) a routine nurse intake 2) medication reconciliation performed by treating physicians. Given resource constraints (routine medication reconciliation did not include corroborating medication histories with outpatient pharmacies, routine use of pill cards or pill boxes, or review of Medicaid formularies) Uninsured patients were financially responsible for most medications at discharge. 3) Discharge patient education was performed by inpatient nurses and treating physicians at the time of discharge. 4) Patients without a usual source of primary care were often given a list of the fourteen area safety-net clinics, which have limited capacity for uncompensated care.
62174238|NCT01906645|EXPERIMENTAL|C-TraIn|Care Transitions Innovation (C-TraIn) was delivered in addition to usual care, and includes (1) transitional nurse coaching and education, including post-discharge phone calls and home visits for highest risk patients; (2) pharmacy care that includes patient education, medication reconciliation, guidance to inpatient providers to encourage low-cost medications, and provision of 30 days of medications after discharge for those without prescription drug coverage; (3) post-hospital primary care linkages; (4) and explicit efforts at system integration through monthly quality improvement meetings.
62182373|NCT00443898|PLACEBO_COMPARATOR|2|vehicle (placebo) applied once daily for 48 weeks
62363924|NCT01000818|EXPERIMENTAL|Period 1|MK0518
62174239|NCT04201717|ACTIVE_COMPARATOR|laparoscopic assisted left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. The patients in the control group underwent with the traditional laparoscopic assisted technology. The free colon was taken out through a small incision in the middle of the abdomen or the outer edge of the left rectus abdominis. The mesentery was trimmed, the specimens were removed, and the anastomosis was completed.After the anastomosis, the whole surgical area was flushed and drainage tubes were left.
62174240|NCT04201717|EXPERIMENTAL|total laparoscopic left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion.In the experimental group, the mesentery was endoscopically trimmed, the specimens were excised and the anastomosis was completed under the laparoscope. The specimens were taken out through trocar incision in the navel or in the right lower abdomen. After the anastomosis, the whole surgical area was flushed and drainage tubes were left.
62174241|NCT05046652||One bag of convalescent plasma therapy|Four patients had been administered one dose of 200 mL CP with an antibody titer of 1:320.
62174242|NCT05046652||Two bags of convalescent plasma therapy|Four patients had been administered two doses of 200 mL CP with an antibody titer of 1:320.
62174243|NCT02865135|EXPERIMENTAL|DPX-E7 + Cyclophosphamide [Phase Ib Cohort]|Participants received: 1) 50 mg twice per day of cyclophosphamide orally 7 days before the vaccination, continuing for 7 days on and then 7 days off, throughout the treatment period; 2) two 0.25 mL priming doses of DPX-E7 3 weeks apart, followed by 0.1 mL booster dose every 8 weeks until clinical progression.
62174244|NCT02865135|EXPERIMENTAL|DPX-E7 + Cyclophosphamide [Phase II Cohort 1]|Participants were enrolled before amendment 10. Participants received: 1) 50 mg twice per day of cyclophosphamide orally 7 days before the vaccination, continuing for 7 days on and then 7 days off, throughout the treatment period; 2) two 0.25 mL priming doses of DPX-E7 3 weeks apart, followed by 0.1 mL booster dose every 8 weeks until clinical progression.
62174245|NCT02865135|EXPERIMENTAL|DPX-E7 [Phase II Cohort 2]|Participants were enrolled after amendment 10. Participants received two 0.50 mL priming doses of DPX-E7 3 weeks apart, followed by 0.2 mL booster dose every 8 weeks until clinical progression.
62174246|NCT01002547|PLACEBO_COMPARATOR|Arm 1|Diabetic with proven NASH by biopsy
62174247|NCT01002547|ACTIVE_COMPARATOR|Arm 2|Diabetic with proven NASH by biopsy
62174248|NCT01002547|OTHER|Arm 3|Diabetic with proven NASH by biopsy
62174249|NCT03038945|EXPERIMENTAL|2/0 barbed suture|Use barbed suture for the closure of the vaginal vault in patients with total Laparoscopic hysterectomy caused by a benign gynecologist pathology
62174250|NCT03038945|ACTIVE_COMPARATOR|Vicryl suture|Use VICRYL suture for the closure of the vaginal vault in patients with total Laparoscopic hysterectomy caused by a benign gynecologist pathology
62174251|NCT05501665|EXPERIMENTAL|Arm 1 (carboplatin, pemetrexed, pembrolizumab, radiation)|Patients receive carboplatin, pemetrexed, and pembrolizumab on day 1 of each cycle. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pemetrexed and pembrolizumab on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
62174252|NCT05501665|EXPERIMENTAL|Arm II (carboplatin, pemetrexed, cemiplimab, radiation)|Patients receive carboplatin, pemetrexed and cemiplimab-rwlc on day 1 of each cycle. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pemetrexed and cemiplimab-rwlc on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
62174253|NCT05501665|EXPERIMENTAL|Arm III (carboplatin, paclitaxel, cemiplimab-rwlc, radiation)|Patients receive carboplatin, paclitaxel and cemiplimab-rwlc on day 1 of each cycle. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pemetrexed and cemiplimab-rwlc on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
62174254|NCT05501665|EXPERIMENTAL|Arm IV (Carbo, pemetrexed, nivolumab, ipilimumab, radiation)|Patients receive carboplatin, pemetrexed and nivolumab on day 1 of each cycle and ipilimumab on day 1 of every other cycle. Treatment repeats for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive ipilmumab and nivolumab on the same schedule for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
62363925|NCT01000818|EXPERIMENTAL|Period 2|famotidine + MK0518
62363926|NCT01000818|EXPERIMENTAL|Period 3|omeprazole + MK0518
62363927|NCT05488418|EXPERIMENTAL|Patients exposed to a potentially traumatic event|
62363928|NCT04165005|EXPERIMENTAL|decentering group|"MBSR focused on a decentering component (i.e. individuals observe their feelings and thoughts as ephemeral events, with no reactivity, alongside with acceptance)."
62363929|NCT04165005|EXPERIMENTAL|guided imagery group|a group practicing in guided imagery sessions.
62363930|NCT04165005|NO_INTERVENTION|control group|usual care group
61997440|NCT02086929|EXPERIMENTAL|Trazodone|"300 mg/day for 8 weeks (including 1 week 150 mg/day of dose-titration). After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 450 mg/day.~Dosage form: capsule."
62174255|NCT05501665|EXPERIMENTAL|Arm V (Carboplatin, paclitaxel, pembrolizumab, radiation)|Patients receive carboplatin, paclitaxel, and pembrolizumab on day 1 of each cycle. Treatment repeats every 3 weeks for 4 up to cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. Patients then receive pembrolizumab on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
62174256|NCT05501665|EXPERIMENTAL|Arm VI (Carboplatin, paclitaxel, cemiplimab-rwlc, radiation)|Patients receive carboplatin, paclitaxel, and cemiplimab-rwlc on day 1 of each cycle. Treatment repeats every 3 weeks for 4 up to cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. Patients then receive cemiplimab-rwlc on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
62174257|NCT05501665|EXPERIMENTAL|Arm VII (carbo, paclitaxel, nivolumab, ipilimumab, radiation)|Patients receive carboplatin, paclitaxel, and cemiplimab-rwlc on day 1 of each cycle. Treatment repeats every 3 weeks for 4 up to cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. Patients then receive cemiplimab-rwlc on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
62174258|NCT05501665|EXPERIMENTAL|Arm VIII (pembrolizumab, radiation)|Patients receive pembrolizumab on day 1 of each cycle. Cycles repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
62174259|NCT05501665|EXPERIMENTAL|Arm IX (atezolizumab, radiation)|Patients receive atezolizumab on day 1 of each cycle. Cycles repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
62174260|NCT05501665|EXPERIMENTAL|Arm X (cemiplimab-rwlc, radiation)|"Patients receive cemiplimab-rwlc on day 1 of each cycle. Cycles repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions.~All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial."
62174261|NCT05501665|EXPERIMENTAL|Arm XI (nivolumab, ipilumumab, radiation)|Patients receive ipilmumab every 6 weeks and nivolumab every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
62174262|NCT05088447||Stable Disease|"15 control stable disease participants"
62174263|NCT05088447||Frequent Exacerbation Cohort|"15 experimental frequent exacerbation cohort"
62174264|NCT00788879|EXPERIMENTAL|1|This study arm is located in Brownsville, Texas. This community is exposed to the TSSC media messages as well as may be visited by the lay health workers and see the built environment changes
62174265|NCT00788879|NO_INTERVENTION|2|The control group is located in Laredo. This community is not exposed to the TSSC messages nor does the campaign work to actively change the built environment or use lay health workers to share physical activity and nutrition information.
62174266|NCT03669900|OTHER|a minimally invasive surgery (SERI)|The surgery consisted of varus traction, skin incision, metatarsal osteotomy and K- wire insertion. All the cases were done by the senior consultant orthopedic surgeon, including preoperative planning, the osteotomy itself and the follow up in the clinic. Another orthopedic surgeon was involved in collecting the data, doing all the measurements preoperative and postoperative and assisting the primary surgeon during the surgery.
62174267|NCT02497196|EXPERIMENTAL|Part 1:Active tPCS, Active tDCS|12 out of the 48 total health subjects will receive active tPCS and active tDCS. This will be done for 20 minutes simultaneously.
62174268|NCT02497196|EXPERIMENTAL|Part 1: Active tPCS, Sham tDCS|12 out of the 48 total health subjects will receive active tPCS and sham tDCS. This will be done for 20 minutes simultaneously.
62174269|NCT02497196|EXPERIMENTAL|Part 1:Sham tPCS, Active tDCS|12 out of the 48 total health subjects will receive sham tPCS and active tDCS. This will be done for 20 minutes simultaneously.
62174270|NCT02497196|SHAM_COMPARATOR|Part 1: Sham tDCS, Sham tDCS|12 out of the 48 total health subjects will receive sham tPCS and sham tDCS. This will be done for 20 minutes simultaneously.
62363931|NCT05587634|EXPERIMENTAL|Peer Health Coaching Intervention|Intervention Arm - these participants receive individualized peer health coaching (intervention group only) and an adaptive physical activity guide of local resources (both groups)
62363932|NCT05587634|NO_INTERVENTION|Control|Control arm - these participants receive only an adaptive physical activity local guide including information on local adaptive sports opportunities however no individualized peer health coaching
62363933|NCT01233570|EXPERIMENTAL|Topical tacrolimus|Once daily topical application
61997441|NCT02086929|ACTIVE_COMPARATOR|Venlafaxine XR|"75 mg/die for 8 weeks. After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 225 mg/day.~Dosage form: capsule."
62174271|NCT02497196|EXPERIMENTAL|Part 2: Active tPCS/Active tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving active tPCS and active tDCS (1/4 combinations all subjects will receive).
62174272|NCT02497196|EXPERIMENTAL|Part 2: Active tPCS/Sham tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving active tPCS and sham tDCS (1/4 combinations all subjects will receive).
62174273|NCT02497196|EXPERIMENTAL|Part 2: Sham tPCS/Active tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving sham tPCS and active tDCS (1/4 combinations all subjects will receive).
62174274|NCT02497196|SHAM_COMPARATOR|2: Sham tPCS/Sham tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving sham tPCS and sham tDCS (1/4 combinations all subjects will receive).
62174275|NCT02995733|ACTIVE_COMPARATOR|PARTICS|addition of PARTICS strategy - Patient Activated Reliever-Triggered Inhaled CorticoSteroid (PARTICS) using QVAR . Patient will use inhaled corticosteroid at time of rescue inhaler use
62174276|NCT02995733|NO_INTERVENTION|Usual Care|Provider-enhanced usual care arm; no change in asthma management
62174277|NCT02958813|EXPERIMENTAL|IMARA|IMARA blends three programs with the most relevance for AA women (SISTA) and girls (SiHLE) and families in psychiatric care (Project STYLE). Separate mother and daughter groups cover parallel content and run simultaneously, and joint activities enhance mothers' credibility as a resource for HIV/STI prevention, practice new communication skills, negotiate conflict, and strengthen the mother-daughter relationship. Activities reinforce the reciprocal impact of mothers and daughters, and enhance safe sex knowledge, attitudes, and skills. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
62174278|NCT02958813|PLACEBO_COMPARATOR|FUEL|FUEL Health Promotion Control combines two programs, FUEL and Project Balance Health Promotion. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. FUEL™ does not explicitly address HIV/STI prevention. Investigators will present information from Balance's session about HIV/AIDS, condoms, and other STIs. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
62174279|NCT00549861|NO_INTERVENTION|A1|CMR study for the assessment of irreversible tissue damage
62174280|NCT03416335|EXPERIMENTAL|Monotherapy Arm - Part A|Dose Escalation Drug DSP-0509
62174281|NCT03416335|EXPERIMENTAL|Combination arm - Part B|Dose Escalation Drug DSP-0509, Pembrolizumab
62174282|NCT03416335|EXPERIMENTAL|Combination arm - Part C|Dose Expansion, Drug DSP-0509, Pembrolizumab
62174283|NCT01292317|ACTIVE_COMPARATOR|intravenous hydration|intravenous application of 0.9% saline
62174284|NCT01292317|ACTIVE_COMPARATOR|oral hydration only|
62174285|NCT03684356|EXPERIMENTAL|experimental|immediate implant with socket shield technique
62174286|NCT03684356|ACTIVE_COMPARATOR|control|immediate implant placement with filling the buccal gap with xenograft
62174287|NCT02548754|EXPERIMENTAL|Active|Patients will receive 1 hour of active low level tragus stimulation daily for 6 months
62174288|NCT02548754|SHAM_COMPARATOR|Sham|Patients will receive 1 hour of sham low level tragus stimulation daily for 6 months
62174289|NCT00826371|EXPERIMENTAL|1|
62174290|NCT01623206|EXPERIMENTAL|Desmopressin|Four dose levels and two dosing schedules with 3 patients in each group.
62174291|NCT04491006|EXPERIMENTAL|Low Dose|Daily subcutaneous (SC) injection of Low Dose ATH-1017
62174292|NCT04491006|EXPERIMENTAL|High Dose|Daily subcutaneous (SC) injection of High Dose ATH-1017
62174293|NCT04491006|PLACEBO_COMPARATOR|Placebo|Daily subcutaneous (SC) injection of Placebo
62174294|NCT05347121||difficult airway|
62174295|NCT05460429|EXPERIMENTAL|Immunogenicity and safety group|360 subjects including 120 subjects aged 1-3 years with no history of varicella vaccination,240 subjects aged 4-6 years with a history of 1 dose of varicella vaccine will be enrolled to evaluate the immunogenicity and safety of varicella vaccine.All subjects will receive one dose of varicella vaccine.
62174296|NCT05460429|EXPERIMENTAL|Antibody level investigation study group|Immunization levels will be monitored among 2530 subjects aged 0-59 years old and will be collected venous blood to detect varicella antibody.
62174297|NCT05460429|EXPERIMENTAL|Safety group|30000 subjects aged 1-12 years old will be enrolled to conduct safety observation of mass vaccination of varicella vaccine.All subjects will receive one dose of varicella vaccine and all adverse events of all subjects will be collected.
62174298|NCT05460429|EXPERIMENTAL|Protective effect group|5000 subjects aged 1-12 years old will be enrolled to conduct protective effect study of varicella vaccine after exposure.
62174299|NCT05460429|EXPERIMENTAL|Etiology Group|30 varicella cases aged 1-12 years old from study 4 will be enrolled. Herpes fluid or pharyngeal swab samples of subjects will be collected to study the pathogenicity of varicella.
62174300|NCT01295788|EXPERIMENTAL|Simultaneous RT-CGM and Pump Initiation|The experimental group will initiate RT-CGM at the same time as they begin insulin pump therapy.
62174301|NCT01295788|ACTIVE_COMPARATOR|Delayed RT-CGM Initiation|The control group will use standard pump therapy until the 6 month study visit at which time RT-CGM will be initiated.
62174302|NCT02494453||Cardiac MRI|
62174303|NCT01304108|EXPERIMENTAL|Order Set|"Insertion of VTE-P Order Set tollgate in all active admission and transfer orders."
62174304|NCT01304108|EXPERIMENTAL|Clinical Decision Support Pop-up|Deploy rules-based pop-up that reminds ordering clinicians when patients do not have an active VTE-P plan.
62363934|NCT00778310|EXPERIMENTAL|Concerta|The subject will be administered their usual dose of Concerta the morning of the FMRI scan in a double blind fashion
62363935|NCT00778310|PLACEBO_COMPARATOR|Placebo|The subject will be administered a placebo the morning of the FMRI scan in a double blind fashion
62174305|NCT01304108|ACTIVE_COMPARATOR|Usual Care|Usual care, without the experimental additions
62174306|NCT01189617|EXPERIMENTAL|Formula PD-F-7619|At least twice per week for one week, massage about a dime-sized amount of the PD-F-7619 personal lubricant product to the application site as directed.
62174307|NCT03560414|EXPERIMENTAL|simple plasma exchange group|The mode is CVVH in CRRT machine, the treatment duration is 2h-3h, the application plasma volume is 40ml/Kg, the replacement fluid flow rate is 1000ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0ml/h.
62174308|NCT03560414|ACTIVE_COMPARATOR|conventional PDF treatment group|The mode of conventional PDF treatment group is CVVHDF in CRRT machine, and the duration of treatment is 3 hours. the application plasma volume 1500 ml . The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
62174309|NCT03560414|ACTIVE_COMPARATOR|less plasma PDF treatment group|The mode of conventional PDF treatment group is also CVVHDF in CRRT machine, and the duration of treatment is 3h. All patients are required to apply plasma 1000ml. Use plasma substitutes: 300ml NS+200ml 5% albumin. The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
62174310|NCT05540262|EXPERIMENTAL|Edaravone|
62174311|NCT04236622||Health|For each patient we evaluated the Probing Depth (PD), measured in mm, and the following dichotomous variables: plaque index (absent or present), gingival index (absent or present), occurrence of annual maintenance (absent or present), tooth position (anterior or posterior) and the patient's smoking habit (absent or present).
62174312|NCT04236622||Peri-implantitis|For each patient we evaluated the Probing Depth (PD), measured in mm, and the following dichotomous variables: plaque index (absent or present), gingival index (absent or present), occurrence of annual maintenance (absent or present), tooth position (anterior or posterior) and the patient's smoking habit (absent or present).
62174313|NCT06330233|SHAM_COMPARATOR|Conventional treatment group|mecobalamin tablets (0.5 mg/dose, 3 times/day) and epastat (0.5g/, 3 times/day, before meal) were administered orally for four weeks in conjunction with the patient's daily treatment (basal medication treatment for patients with combined hypertension and hyperlipidemia).
62174314|NCT06330233|EXPERIMENTAL|Moxibustion 15 minutes group|The selected acupoints of moxibustion are Zusanli(ST 36), Sanyinjiao(SP 6), Quchi(LI 11) and Kunlun(BL 60), moxa cones were pasted on the acupoints and moxibustion was applied by ignition, each time for 15 minutes at each acupoint, once every three days, twice a week, four consecutive weeks of treatment.
62174315|NCT06330233|EXPERIMENTAL|Moxibustion 15 minutes group of Part two|The selected acupoints of moxibustion are Zusanli(ST 36), Sanyinjiao(SP 6), Quchi(LI 11) and Kunlun(BL 60), moxa cones were pasted on the acupoints and moxibustion was applied by ignition, each time for 15 minutes at each acupoint, once every three days, twice a week, four consecutive weeks of treatment.
62174316|NCT06330233|EXPERIMENTAL|Moxibustion 30 minutes group|The selected acupoints of moxibustion are Zusanli(ST 36), Sanyinjiao(SP 6), Quchi(LI 11) and Kunlun(BL 60), moxa cones were pasted on the acupoints and moxibustion was applied by ignition, each time for 30 minutes at each acupoint, once every three days, twice a week, four consecutive weeks of treatment.
62174317|NCT06247618|EXPERIMENTAL|Virtual reality|
62174318|NCT03455218|EXPERIMENTAL|Nitric Oxide|20 ppm of Nitric Oxide delivered to the oxygenator via the INOmax device for the duration of the cardiopulmonary bypass time
62174319|NCT03455218|PLACEBO_COMPARATOR|Placebo|INOmax device attached to the oxygenator, but no gas is delivered through the device
62174320|NCT00397202|ACTIVE_COMPARATOR|The DivaCupTM|
62174321|NCT00507429|EXPERIMENTAL|Arm 1: CA4P + Carboplatin + paclitaxel|Six 21-day cycles: CA4P (60 mg/m2 on Days 1, 8, 15), carboplatin (AUC 6) + paclitaxel (200 mg/m2) on Day 2
62174322|NCT00507429|ACTIVE_COMPARATOR|Arm 2: Carboplatin + Paclitaxel|Six 21-day cycles of Carboplatin (AUC 6) + paclitaxel (200 mg/m2) given on Day 1
62174323|NCT00114543|ACTIVE_COMPARATOR|Aggressive ELBW|In Aggressive group 1, infants with birth weights 501-750g.
62174324|NCT00114543|ACTIVE_COMPARATOR|Aggressive VLBW|In the Aggressive group 2, infants with birth weights 751-1000g.
62174325|NCT00114543|ACTIVE_COMPARATOR|Conservative ELBW|In the Conservative group 1, infants with birth weights 501-750g.
62174326|NCT00114543|ACTIVE_COMPARATOR|Conservative VLBW|In the Conservative group 2, infants with birth weights 751-1000g.
62174327|NCT05047497||less than 10 years working|workers who work in cement factories in a period of time less than 10 years
62174328|NCT05047497||from 10-15 years working|workers who work in cement factories in a period of time from 10-15 years
62174329|NCT05047497||more than 15 years working|workers who work in cement factories in a period of time more than 15 years
62174330|NCT01990911|EXPERIMENTAL|Renal denervation|Renal denervation: both renal arteries are denervated by applying radio-frequency energy at application points moving in a helical fashion starting in the distal renal artery and moving to the proximal junction with the abdominal aorta.
62174331|NCT01990911|SHAM_COMPARATOR|Medical therapy|This group will not receive renal sympathetic denervation
62174332|NCT04212897|EXPERIMENTAL|Music Therapy|This group will be asked to practice a rhythmic auditory SFT intervention task at home.
62174333|NCT04212897|NO_INTERVENTION|No Music Therapy|This group will not engage in an intervention task at home and will be asked to continue their normal daily routine.
62174334|NCT00005797|OTHER|BuCy2|Busulfan \& Cyclophosphamide
62174335|NCT00005797|OTHER|VP16/TBI|Fractionated Total Body Irradiation + VP-16
62174336|NCT05842915||First Contact Practitioner (FCP)|"A continuous routine-data cohort study involving FCP primary care services aiming to recruit a minimum of 25patients per service from 10 FCP services, with complete data from at least 25 patients at baseline and 3-month follow up per service for each 12-month period. Data collection will involve:~Patient survey (to collect outcomes and experiences)~Organisational characteristics (collected via a survey to service leads and via publicly available national sources)~Electronic health record (EHR) data (collected via a standardised FCP template and search within EHR systems)"
62182374|NCT00443898|EXPERIMENTAL|3|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks
62182375|NCT00443898|PLACEBO_COMPARATOR|4|vehicle (placebo) applied once daily for 24 weeks
62174337|NCT05842915||MSK Community Services|"A continuous routine-data cohort study involving MSK Community Services, aiming to recruit a minimum of 250 patients per service from a minimum of 10 MSK services, with complete data from at least 250 patients at baseline and 3-month follow up per service for each 12-month period. Data collection will involve:~Patient survey (to collect outcomes and experiences)~Organisational characteristics (collected via a survey to service leads and via publicly available national sources)"
62174338|NCT04473768||NTS bloodstream infection|growth of NTS in blood culture
62174339|NCT04473768||NTS/Pf malaria co-infection|concurrence of current Pf malaria infection and NTS bloodstream infection
62174340|NCT04473768||Other pathogen bloodstream infections|growth of a pathogen other than NTS in blood culture
62174341|NCT04473768||Severe Pf malaria mono-infection|defined according to WHO-criteria
62174342|NCT04473768||Other causes of febrile illness requiring hospital admission|"* Current Pf malaria infection: see above~* Recent Pf malaria infection: see above~* Non-confirmed bloodstream infection without Pf malaria: no growth in blood culture and negative results in all Pf malaria tests~* If feasible, severe bacterial localized infections such as pneumonia, meningitis, osteomyelitis, complicated urinary tract infection, abscess, skin/soft tissue infection or abdominal infection, will be assessed and clinically defined"
62174343|NCT06397950||Patients with Schizophrenia|Patients are enrolled in a psychosocial rehabilitation program.
62174344|NCT01712698||Cervical spinal cord injury|Those patients with an acute cervical spinal cord injury evaluated with DTI MRI
62174345|NCT00676429|EXPERIMENTAL|1|Ziprasidone Hydrochloride oral solution with individual titration from 5 mg to 40 mg per day
62174346|NCT00676429|PLACEBO_COMPARATOR|2|Placebo oral solution
62174347|NCT02641106|EXPERIMENTAL|Video Directly Observed Therapy|VDOT arm participants use a smartphone to make a video recording of each weekly medication dose ingested using the VDOT mobile phone app. The VDOT app is programmed to send encrypted, time/date stamped videos to a HIPAA-compliant server as soon as the video recorder is stopped. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken. Dose 1 is observed in-person; doses 2-12 are observed via videos.
62174348|NCT02641106|ACTIVE_COMPARATOR|In-Person DOT|In-Person DOT arm participants follow standard-of-care procedures for monitoring ingestion of all medication doses. Participants take their first medication dose at the enrollment visit and return to the clinic once weekly to be observed taking the remaining 11 doses of medication until they complete the 12-dose regimen.
62174349|NCT06217497|EXPERIMENTAL|Experimental Group|After the patients in the experimental group were informed verbally and in writing and consented to participate in the study, the Patient Information Form, the Piper Fatigue Scale (PFS), and the Pittsburgh Sleep Quality Index (PSQI) were applied in the first interview and the initial readings were obtained. The researcher received training on a classical massage from an expert massage therapist before the foot massaging application. Patients in the experimental group were subjected to a foot massage with baby oil for 10 minutes during HD treatment three times a week for four weeks, 12 times in total. At the end of the second and fourth weeks after the foot massage, the second and third readings were recorded by repeating the PFS and PSQI.
62174350|NCT06217497|NO_INTERVENTION|Control Group|Patients in the control group were not subjected to any intervention other than routine HD treatment and nursing care. The first readings were obtained by applying the Patient Information Form, PFS and PSQI at the first interview, and the second and third measurement values were obtained by repeating the PFS and PSQI at the end of the second and fourth weeks.
62174351|NCT05583734|EXPERIMENTAL|Portomar(TM) Device|"Portomar(TM) Device for bone marrow biopsy~Subjects are self-controlled with one side having conventional biopsy and the other having the Portomar(TM) biopsy."
62174352|NCT00475735|EXPERIMENTAL|MK-0249|Total time in the study will be \~10 weeks.
62174353|NCT00475735|ACTIVE_COMPARATOR|Concerta|Total time in the study will be \~10 weeks.
62174354|NCT00475735|PLACEBO_COMPARATOR|Placebo|Total time in the study will be \~10 weeks.
62174355|NCT05011617|EXPERIMENTAL|MAC group|Electroacupuncture was performed for two consecutive days before surgery (2 daily 30-min sessions) by a licensed acupuncturist at 4.0 mA using an alternating frequency of 2 and 100 Hz (every 1.5 seconds) (LH-202, Huawei, Beijing, China). Acupoints included bilateral Yunmen (LU2), Zhongfu (LU1), Lieque (LU7), and Neiguan (PC6). On the day of surgery, electroacupuncture started upon the completion of a loading dose of dexmedetomidine, was suspended when CPB started (to avoid interference with electrocardiogram recording) and continued until the end of surgery.
62174356|NCT05011617|NO_INTERVENTION|IGA group|Anesthesia was induced with propofol (2.0-3.5 μg/mL) by target control infusion and 0.3-0.5 μg/kg sufentanil. Tracheal intubation was facilitated by rocuronium (1.0 mg/kg). Anesthesia was maintained using isoflurane at 0.7-1.0 minimal alveolar concentration in a gas mixture of oxygen and air and remifentanil (0.05-0.2 μg·kg-1·min-1) by intravenous injection pump. Sufentanil dose was totally 2.5-4.0 μg/kg. Muscle relaxation was achieved using 1/3-1/4 of the induction dose every 40-60 min based on a train of four. Mechanical ventilation with 80% O2 in air was used. Tidal volume (7-8 mL/kg) and respiratory rate (10-12/min) were adjusted according to PETCO2 to achieve normal ventilation (PETCO2 35-45 mmHg).
62174357|NCT04788277||Diagnostic (biospecimen collection)|Patients undergo collection of urine samples at baseline during standard of care office/clinic visit.
62174358|NCT02900222|EXPERIMENTAL|Choroid Plexus Coagulation|Patients with communicating hydrocephalus will be treated with endoscopic choroid plexus coagulation.
62174359|NCT06277024|EXPERIMENTAL|Treatment with combination of candenizumab, lenvatinib, and SOX regimen|
62174360|NCT04473118||Healthcare workers|All healthcare workers exposed directly or not to suspected or infected COVID-19 patients such as nurse; paramedic; senior physician; resident/ trainee physician; respiratory therapist; perfusionist; physiotherapist; dietitian; technician lab; technician imaging; pharmacist; occupational therapist; speech therapist
62174361|NCT03083093||CTEPH patients|the initial CTPA scan will be reviewed in patients diagnosed with CTEPH after an episode of an acute PE
62174362|NCT03083093||non CTEPH patients|the initial CTPA scan will be reviewed in patients after an episode of an acute PE in whom CTEPH was excluded
62182376|NCT00812721|PLACEBO_COMPARATOR|1|Preservative Free Saline
62182377|NCT00812721|ACTIVE_COMPARATOR|2|Optive (TM)
62182378|NCT00812721|ACTIVE_COMPARATOR|3|Refresh Moderate/Severe (TM)
62182379|NCT00812721|ACTIVE_COMPARATOR|4|Systane (TM)
62182380|NCT00812721|ACTIVE_COMPARATOR|5|Systane Ultra (TM)
62174363|NCT00282828|EXPERIMENTAL|Sertraline & Clonazepam|"Phase I non-responders randomized to this group remained on sertraline at the same dose level as at entry into Phase 2 with the addition of clonazepam up to 3.0mg per day.~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 0.5mg of clonazepam per day in order to remain in the study."
62174364|NCT00282828|EXPERIMENTAL|Venlafaxine|"Phase I non-responders randomized to this group switched to venlafaxine with flexible titration up to 225 mg per day.~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 75 mg venlafaxine per day in order to remain in the study."
62174365|NCT00282828|EXPERIMENTAL|Sertraline & Placebo|"Phase I non-responders randomized to this group remained on sertraline at the same dose level as at entry into Phase 2 with the addition of placebo.~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 1 capsule of placebo per day in order to remain in the study."
62174366|NCT04335695|OTHER|Vascular Rehabilitation and Follow Up|All subjects will be enrolled in a 6-12 Vascular Rehab Program (VRP) and then be followed for one year following discharge from the VRP.
62174367|NCT03371706|EXPERIMENTAL|Communication Bridge™|Participants receive Communication Bridge™, a multi-component, participation-focused, dyadic intervention in which both the person with PPA and their co-enrolled communication partner are intervention recipients. Communication Bridge™ is modelled on the Living with Aphasia: Framework for Outcome Measurement (A-FROM) and the Care Pathway Model that was developed for persons living with primary progressive aphasia. Consistent with participation-focused intervention models personally salient training stimuli are incorporated into all therapy activities in the Experimental arm.
62174368|NCT03371706|ACTIVE_COMPARATOR|Evidence-Based Impairment Focused|The Control arm includes a non-dyadic intervention in which the person with PPA is the active intervention recipient and their communication partner is in a supporting role. In the Control arm, participants receive a speech-language intervention designed to address impairment and functional limitations, comprised of activities that address word retrieval and 'automatic' speech production using fixed, non-personalized, stimuli across participants.
62174369|NCT06339814|EXPERIMENTAL|Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol|Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol will receive Eye Movement Desensitization and Reprocessing treatment plus the standard support
62174370|NCT06339814|ACTIVE_COMPARATOR|Treatment As Usual group|Treatment As Usual group will receive only standard support
62174371|NCT05610059|OTHER|Blood Pressure Technology System M|These participants will receive information about high blood pressure, medications and strategies that can be used to take medications and manage blood pressure. They will complete a mid-assessment at 3-months and a post-assessment at 6-months.
62174372|NCT05610059|OTHER|Blood Pressure Technology System E|These participants receive information about high blood pressure and medications. They will complete a mid-assessment at 3-months and a post-assessment at 6-months.
62174373|NCT04445519|EXPERIMENTAL|NCX 470 0.065%|NCX 470 Ophthalmic Solution, 0.065% dosed once daily to both eyes (initial phase of trial)
62174374|NCT04445519|EXPERIMENTAL|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes (initial phase of trial)
62174375|NCT04445519|ACTIVE_COMPARATOR|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes (initial phase of trial)
62174376|NCT04445519|EXPERIMENTAL|NCX 470 0.1% (remainder of trial)|NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes (chosen dose of NCX 470 to continue in remainder of trial)
62174377|NCT04445519|ACTIVE_COMPARATOR|Latanoprost 0.005% (remainder of trial)|Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes (active comparator for remainder of trial)
62174378|NCT06646718|EXPERIMENTAL|❖ Experimental Group: group A|Group A (study group): will include 33 children after selective dorsal rhizotomy surgery from both gender will be selected from the Outpatient Clinic. Able to attend physical therapy (PT) treatment at least three a week before and during this study. who will receive closed kinetic chain.
62174379|NCT06646718|OTHER|❖ Control Group:Group B|●Group B (control group): will include 33 children who will receive Traditional physiotherapy. will include 33 children after selective dorsal rhizotomy surgery from both gender
62174380|NCT01909947||Intubated extreme preterm infants|Infants with a birth weight ≤ 1250 grams and requiring endotracheal tube and mechanical ventilation
62174381|NCT00439348|EXPERIMENTAL|Electronic prescription|Patients receive a prescription for specific over-the-counter medications.
62174382|NCT00439348|ACTIVE_COMPARATOR|Verbal advice|
62174383|NCT05818436|EXPERIMENTAL|Experimental: Oral Functionalization Prosthesis repairment|Experimental: Oral Functionalization Prosthesis repairment: prosthetic reline and occlusal stabilization through repair of missing pieces and recovery of occlusal contacts and follow up with conventional prosthesis treatment
62174384|NCT05818436|ACTIVE_COMPARATOR|Active Comparator: control|Active Comparator: control conventional prosthetic treatment (new prosthesis)
62174385|NCT05303090|EXPERIMENTAL|H101 + Tislelizumab+ Lenvatinib|(Dose escalation and cohort expansion) H101 administered by intratumoral injection in combination with Tislelizumab administered intravenously (IV), and Lenvatinib administered orally.
62174386|NCT00535795|ACTIVE_COMPARATOR|1|Conventional Radiation Therapy (XRT), one fraction per day, from Sunday to Thursday every week.
62174387|NCT00535795|EXPERIMENTAL|2|Conventional Plus accelerated boost Radiation Therapy (XRT), from Sunday to Thursday every week.
62174388|NCT01282697|EXPERIMENTAL|rapamycin+irinotecan at a given dose|
62174389|NCT05579587||LPR Patients|Adults with a confirmed diagnosis of LPR with HEMII-pH (≥2 LPR events in 24 hr period), Esophageal manometry and Laryngoscopy undergoing endoscopic transoral incisionless fundoplication (TIF).
62174390|NCT00497198|EXPERIMENTAL|MCI-196|
62174391|NCT00497198|PLACEBO_COMPARATOR|Placebo|
62174392|NCT04056741|EXPERIMENTAL|Surfactant administered via supraglottic administration device|Patients in this group will have Calfactant at 3ml/kg administered via the supraglottic administration device.
62550236|NCT04400162|EXPERIMENTAL|CCT (game)|This arm consists of the same CCT as the standard version, however pre-defined gaming elements that are thought to increase usability as well as interest in the intervention have been added.
62550237|NCT05044702|EXPERIMENTAL|Retro walking|Retro walking
62174393|NCT06539416||Mixed Reality (MR) Assisted MitraClip Group|Patients undergoing MitraClip implantation with the assistance of MR technology, using Hololens 2.0 for three-dimensional visualization of DICOM images to enhance procedural precision and operator spatial awareness.
62174394|NCT06539416||Standard MitraClip Group|Patients undergoing MitraClip implantation using standard procedural methods without the assistance of MR technology.
62174395|NCT02611375|EXPERIMENTAL|tDCS + FTP group|This group of individuals with tetraplegia will receive transcranial direct current stimulation (tDCS) over the hand area of their primary motor cortex (M1). Stimulation at 2mA will be applied for 20 minutes while subjects complete a total of 1 hour of functional task practice (FTP) per session. (Only 20 minutes of functional task practice be be performed with stimulation on). 3 sessions will be completed per week for 4 weeks.
62174396|NCT02611375|ACTIVE_COMPARATOR|PNSS + FTP group|This group of individuals with tetraplegia will receive peripheral nerve somatosensory stimulation (PNSS) to the median nerve of the primary hand being trained. Stimulation will be set to elicit a sensory - not motor - response. Stimulation will be performed concurrently with the entire functional task practice (FTP) session. 3 sessions will be completed per week for 4 weeks.
62174397|NCT02611375|ACTIVE_COMPARATOR|sham tDCS + FTP group|This group of individuals with tetraplegia will receive sham transcranial direct current stimulation (tDCS) over the hand area of their primary motor cortex (M1) alongside functional task practice. Stimulation will be briefly turned on at the beginning of FTP and again after 20 minutes of practice in order to create a sham effect and maintain blinding of the participants. 3 sessions will be completed per week for 4 weeks.
62174398|NCT02277587|EXPERIMENTAL|Plenadren|Plenadren (modified release hydrocortison) 20-25 or 30 mg oral tablets will be administered once-daily at 8.00 AM in the fasting state The dose is kept the same as patients had before entering the trial.
62174399|NCT02277587|ACTIVE_COMPARATOR|Conventional glucocorticoid therapy|"Hydrocortisone (dose range 10 to 30) mg will be continued as before entering the study. Cortisone Acetate (dose 25 to 37.5 mg) will be continued as before entering the study. The morning dose will be administered in the fasting state.~The total daily dose and timing is not changed during the study period."
62174400|NCT02277587|NO_INTERVENTION|Healthy volunteers|Healthy volunteers will be enrolled as control group
62174401|NCT06210737|OTHER|2 months group|
62174402|NCT06210737|OTHER|7-11 months group|
62174403|NCT06210737|OTHER|12-23 months group|
62174404|NCT06210737|OTHER|2-5 years old group|
62174405|NCT02542085|ACTIVE_COMPARATOR|laparoscopic repair|patients who are randomized to have a laparoscopic mesh repair
62174406|NCT02542085|ACTIVE_COMPARATOR|hybrid repair|patients who are randomized to have a laparoscopic mesh repair and fascial closure
62174407|NCT01489462|EXPERIMENTAL|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
62174408|NCT01489462|EXPERIMENTAL|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
62174409|NCT01489462|ACTIVE_COMPARATOR|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
62174410|NCT03305471|EXPERIMENTAL|Part A: DS-2330b PIB, then Tablet|On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b PIB \[Treatment A1\] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b in tablet form \[Treatment A2\] right after breakfast.
62174411|NCT03305471|EXPERIMENTAL|Part A: DS-2330b Tablet, then PIB|On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b in tablet form \[Treatment A2\] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b PIB \[Treatment A1\] right after breakfast.
62174412|NCT03305471|PLACEBO_COMPARATOR|Part B: Placebo|Participants are given placebo three times daily \[Treatment B1\]
62174413|NCT03305471|EXPERIMENTAL|Part B: DS-2330b PIB|Participants are given 400 mg of DS-2330b PIB three times daily \[Treatment B2\]
62174414|NCT03305471|EXPERIMENTAL|Part B: DS-2330b PIB + Sevelamer|Participants are given 400 mg of DS-2330b PIB along with 1.6 grams of sevelamer three times daily \[Treatment B3\]
62174415|NCT03305471|EXPERIMENTAL|Part B: Placebo + Sevelamer|Participants are given placebo along with 1.6 grams of sevelamer three times daily \[Treatment B4\]
62174416|NCT03305471|EXPERIMENTAL|Part C: DS-2330b Tablet + Sevelamer|Participants are given one 250 mg dose of DS-2330b in tablet form along with 1.6 grams of sevelamer three times daily \[Treatment C\]
62174417|NCT01171885|PLACEBO_COMPARATOR|Placebo|Bilateral superficial cervical block.
62174418|NCT01171885|EXPERIMENTAL|Ropivacaine 0.25%|Bilateral superficial cervical block
62174419|NCT01171885|EXPERIMENTAL|Ropivacaine 0.5%|Bilateral superficial cervical block.
62174420|NCT01644825|EXPERIMENTAL|paclitaxel and pazopanib|
62174421|NCT01644825|ACTIVE_COMPARATOR|paclitaxel|
62174422|NCT04814615|EXPERIMENTAL|CD38-positive multiple myeloma|Patients with CD38 positive multiple myeloma with be enrolled. Patients will undergo pretreatment evaluation with standard of care diagnostic tests, as well as experimental 89Zr-daratumumab PET/CT. Patients will then undergo a course of standard of care therapy as defined by a medical oncologist. Following therapy, patients will repeat standard of care diagnostic tests, as well as experimental 89Zr-daratumumab PET/CT. Data analysis will be performed to evaluate 89Zr-daratumumab against standard of care diagnostic tests for the detection and localization of active disease before and after therapy.
62174423|NCT04457089|EXPERIMENTAL|Simvastatin|
62550238|NCT05044702|ACTIVE_COMPARATOR|conventional physical therapy|Conventional Physical therapy
62174424|NCT05056298|EXPERIMENTAL|Insole and Exercise group|will contain 17 patients, they will receive the custom made arch support insole in addition to the strengthening of foot muscles both intrinsic and extrinsic muscles.
62174425|NCT05056298|ACTIVE_COMPARATOR|Exercise group|will contain 17 patients, they will receive the standard insole in addition to the strengthening of foot muscles both intrinsic and extrinsic muscles.
62174426|NCT05512234|EXPERIMENTAL|L. reuteri|5 drops administered once daily for 21 days
62174427|NCT05512234|PLACEBO_COMPARATOR|Placebo|5 drops administered once daily for 21 days
62174428|NCT05210374|EXPERIMENTAL|DSF/Cu|"A 3+3 dose escalation design will be used to determine the recommended phase 2 dose (RP2D) of DSF/Cu in combination with liposomal doxorubicin. There will be a 7 day lead-in week of Disulfiram (DSF)/Copper Gluconate (Cu). The disulfiram and the copper gluconate will be dosed once a day. Disulfiram in the morning and copper gluconate in the evening. Same total daily dose every 4 week (28 days) administration of liposomal doxorubicin (Doxil) 30mg/m2/dose IV~Cycle length: 28 days Maximum 12 cycles"
62174429|NCT03568708|NO_INTERVENTION|Control Participants|The control group will reflect a comparison group similar to the POI patient group. As bone density, body composition, and cognitive domains continue to mature throughout the teenage years, this comparison group will provide an important metric of normal growth and development.
62174430|NCT03568708|EXPERIMENTAL|POI Participants|This group will be participants who have been recently diagnosed with POI. In an open-label fashion, participants with POI will receive Transdermal Estrogen(beginning at a dose of 25 μg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
62174431|NCT05451056|EXPERIMENTAL|sotorasib|Sotorasib will be given 960mg daily PO until disease progression or unacceptable toxicity .
62174432|NCT06645951||Patients with parathyroid carcinoma|Male and female patients of any age who developed parathyroid carcinoma. The study does not include any type of intervention
62174433|NCT06645951||Patients with atypical parathyroid adenoma|Male and female patients of any age who developed atypical parathyroid adenoma The study does not include any type of intervention
62174434|NCT06399003|EXPERIMENTAL|SIBP MMR vaccine group|Received a single dose of SIBP MMR vaccine alone at 1st dose on D1 and licensed Yellow Fever (YF) vaccine alone at 2nd dose on D43.
62174435|NCT06399003|ACTIVE_COMPARATOR|GSK MMR vaccine group|Received a single dose of GSK MMR vaccine alone at D1.
62174436|NCT06399003|EXPERIMENTAL|Joint vaccination group|Received a single dose of SIBP MMR vaccine co-administered with Yellow Fever vaccine on D1.
62174437|NCT03672383|EXPERIMENTAL|BAY987534 (Treated Arm)|Subjects with quiescent atopic dermatitis. Right or left volar forearm with test product applied.
62174438|NCT03672383|NO_INTERVENTION|Untreated Arm|Subjects with quiescent atopic dermatitis. Right or left volar forearm without test product applied.
62174439|NCT00727259||Patients with chronic hepatitis C|Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol.
62174440|NCT02108197|EXPERIMENTAL|CPAP Intervention|Continuous positive airway pressure (S9, ResMed)
62174441|NCT02108197|NO_INTERVENTION|Wait-list|Wait list controls
62174442|NCT05304221||Intervention group|Septic patients from 2 sites, who are hospitalized and require empiric antibiotic treatment, whose primary physician was assisted by the Shamir Resistance Calculator.
62174443|NCT05304221||Control group|Septic patients from 2 sites, who are hospitalized and require empiric antibiotic treatment, whose primary physician was not assisted by the Shamir Resistance Calculator.
62174444|NCT05633849|PLACEBO_COMPARATOR|Placebo group|In placebo group, participants were instructed to take two 500 mg olive oil placebo (placebo group) after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
62174445|NCT05633849|EXPERIMENTAL|Specialized pro-resolving mediators (SMP) group|In SPM group, Participants were instructed to take two 500 mg softgels of LIPINOVA after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
62174446|NCT03707418|ACTIVE_COMPARATOR|Bivalirudin Injection (Angiomax)|This arm will receive intravenous Bivalirudin for ECMO anticoagulation for the extent of ECMO support or 7 days whichever comes first
62174447|NCT03707418|ACTIVE_COMPARATOR|Heparin Sodium|This arm will receive intravenous Heparin Sodium for ECMO anticoagulation for the extent of ECMO support or 7 days whichever comes first
62174448|NCT00495261|EXPERIMENTAL|1|
62174449|NCT00495261|ACTIVE_COMPARATOR|2|
62174450|NCT03900715|EXPERIMENTAL|Luspatercept Administration|Luspatercept will be administered as a subcutaneous injection every 3 week (21 days; Q3W), at an initial dose level of 1.0 mg/kg. Doses may be titrated up starting at dosing visit Week 7 Day 1 (W7D1)
62174451|NCT02613143||Surgery|
62174452|NCT01501747|ACTIVE_COMPARATOR|overt drug|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving such medication.
62174453|NCT01501747|PLACEBO_COMPARATOR|Placebo (Covert drug)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
62174454|NCT03826147|ACTIVE_COMPARATOR|Nitrate-rich beetroot juice|Daily dose of nitrate-rich beetroot juice (70 mL) for 3 months.
62174455|NCT03826147|PLACEBO_COMPARATOR|Nitrate-depleted beetroot juice|Daily dose of nitrate-depleted beetroot juice (70 mL) for 3 months. The nitrate-depleted beetroot juice is identical in appearance, taste and caloric content to nitrate-rich beetroot juice, but with nitrate removed.
62174456|NCT04039555|ACTIVE_COMPARATOR|Active Arm - CO2 intimate|Patients will receive 2 sessions of CO2 laser treatment, spaced 4 to 6 weeks apart
62174457|NCT04039555|ACTIVE_COMPARATOR|Active Arm - Erbium-yag|Patients will receive 2 sessions of Erbium-Yag laser treatment, spaced 4 to 6 weeks apart
62174458|NCT04039555|SHAM_COMPARATOR|Sham Arm|Patients will receive 2 sessions of Erbium-Yag laser or CO2 laser treatment with non-therapeutic energy, spaced between 4 and 6 weeks apart
62174459|NCT02666170|EXPERIMENTAL|therapy with alpha-lipoic acid daily for six months|
62174460|NCT01630395|NO_INTERVENTION|conventional|Two-lung ventilation: tidal volume = 10 ml/kg, no PEEP. One-lung ventilation: tidal volume = 10 ml/kg, no PEEP
62174461|NCT01630395|ACTIVE_COMPARATOR|Protective|Two-lung ventilation: tidal volume 8 ml/kg, PEEP of 5 cmH2O. One-lung ventilation: tidal volume 6 ml/kg, PEEP of 5 cmH2O.
62174462|NCT01630395|ACTIVE_COMPARATOR|Recruitment|Two-lung ventilation: tidal volume 8 ml/kg, PEEP of 5 cmH2O. One-lung ventilation: tidal volume 6 ml/kg, PEEP of 5 cmH2O. Recruitment maneuver will be applied during one-lung ventilation.
62174463|NCT05221216||patients in Intensive Care unit|patients in Intensive Care unit with infection treated with cotrimoxazole will be included. Data will be collected of medical record.
62174464|NCT03519477|EXPERIMENTAL|Heart failure care with Sano test|Scheduled outpatient care for patients at high risk of admission for heart failure, supplemented with the Sano Patient Medication Profile
62174465|NCT03519477|NO_INTERVENTION|Heart failure care as-usual|Scheduled outpatient care for patients at high risk of admission for heart failure, care as-usual (i.e. without the Sano Patient Medication Profile).
62739302|NCT05962619|EXPERIMENTAL|Arthrocentesis alone|Arthrocentesis alone in management of temporomandibular joint dysfunction in the form of anterior disc displacement with reduction.by lavage by normal saline and during the lavage the mandible is moved through opening, excursive, and protrusive movements to facilitate lysis of adhesions.
62739303|NCT05962619|EXPERIMENTAL|arthrocentesis with hyaluronic acid injection|arthrocentesis with hyaluronic acid injection in management of temporomandibular joint dysfunction in the form of anterior disc displacement with reduction. after arthrocentesis is completed, lavage is done by hyaluronic acid injection
61997442|NCT05451771|EXPERIMENTAL|Phase 1: Venetoclax 200 mg|Cohort 1: Venetoclax 200 mg tablet, once daily for up to 2 cycles after achieving best response, for a maximum of 6 cycles (1 cycle = 28 days)
62174466|NCT03011554|EXPERIMENTAL|Implantable Miniature Telescope (IMT)|Intervention: Implanting the Implantable Miniature Telescope (IMT) in pseudophakic eyes of patients suffering from binocular end-stage AMD.
62174467|NCT05646589|EXPERIMENTAL|Person-centred care transition support|Person-centred dialogue intended to permeate all patient-provider communication, various pedagogical modes of information, a person-centred care and rehabilitation plan, and a bridging e-meeting to prepare patients for homecoming.
62174468|NCT05646589|ACTIVE_COMPARATOR|Regular care transition|Electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
62174469|NCT01591668|EXPERIMENTAL|0.3mg GS-9620|
62174470|NCT01591668|EXPERIMENTAL|1mg GS-9620|
62174471|NCT01591668|EXPERIMENTAL|2mg GS-9620|
62174472|NCT01591668|EXPERIMENTAL|4mg GS-9620|
62174473|NCT01591668|EXPERIMENTAL|0.3mg GS-9620 QW x 2 doses|
62174474|NCT01591668|EXPERIMENTAL|1mg GS-9620 QW x 2 doses|
62174475|NCT01591668|EXPERIMENTAL|2mg GS-9620 QW x 2 doses|
62174476|NCT01591668|EXPERIMENTAL|4mg GS-9620 QW x 2 doses|
62174477|NCT03888261|ACTIVE_COMPARATOR|Active Intervention:|Mind-body intervention (incl. Relaxation Response Resiliency Program \& the Open and Calm Program)
62174478|NCT03888261|NO_INTERVENTION|No Intervention|No intervention (Study participants will receive routine clinical practice)
62174479|NCT06588725|EXPERIMENTAL|Child behavior management - free resources|Two minutes of education about child behavior management coupled with free resources.
62174480|NCT06588725|EXPERIMENTAL|Child behavior management - handbook|Two minutes of education about child behavior management coupled with free resources and a handbook
62174481|NCT06588725|EXPERIMENTAL|Cavity Prevention|Two minutes of education about how to prevent cavities coupled with a 2 page handout.
62174482|NCT05335577||Preterm neonates with NEC|Preterm neonates with gestational age of 28-32 weeks and diagnosed with Necrotizing Enterocolitis based on Bell's modification criteria.
62174483|NCT05335577||Preterm neonates without NEC|Preterm neonates with gestational age of 28-32 weeks and without Necrotizing Enterocolitis based on Bell's modification criteria.
62174484|NCT05335577||Healthy term neonates|Term neonates with gestational age of 37-42 weeks without any comorbidities.
62174485|NCT06646874|NO_INTERVENTION|Control group|The control group completed the MoCA pre- and post-tests 20 minutes apart. A debriefing was conducted for the participants following the conclusion of the experiment.
62174486|NCT06646874|EXPERIMENTAL|VR group|Each participant in the VR group completed a five-minute familiarization session with the VR game before the experimental session. Following the familiarization session, participants in the VR group were instructed to complete the Montreal Cognitive Assessment (MoCA) Arabic version (pre-test: Arabic version 8.1 and post-test: Arabic version 8.2)
62174487|NCT03115229|NO_INTERVENTION|Control Group|The control group of the RCT was composed of 35 students randomly assigned to the control group who are BMI was between 25.0-29.9 or BMI was between 18.5-24.9 and they were in the risk group in terms of obesity according to the risk rating scales.
62174488|NCT03115229|EXPERIMENTAL|Intervention Group|The selected students were associated with obesity risk factors about obesity (owerveight or normal weight and they were in the risk group in terms of obesity according to the risk rating scales, and between 19-24 years old) and randomly assigned to the experimental group to Protective Nursing Interventions for Reduction Obesity Risk
62174489|NCT02053740|EXPERIMENTAL|R-S-Y-R-T|We added R-S-Y-R-T (500 mg 3 times per day) for 6 months
62174490|NCT02053740|OTHER|Routine western medicine|We kept routine western medicine only (as control group)
62174491|NCT04159805|PLACEBO_COMPARATOR|TAK-079 Placebo-matching|TAK-079 placebo-matching injection, subcutaneously (SC), once weekly in combination with standard background therapy for 8 weeks.
62174492|NCT04159805|EXPERIMENTAL|TAK-079 300 mg|TAK-079 300 mg injection, SC, once weekly in combination with standard background therapy for 8 weeks.
62174493|NCT04159805|EXPERIMENTAL|TAK-079 600 mg|TAK-079 600 mg injection, SC, once weekly in combination with standard background therapy for 8 weeks.
62174494|NCT06052683|ACTIVE_COMPARATOR|Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant|Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant to a total dose of 144 Gy.
62174495|NCT06052683|EXPERIMENTAL|Stereotactic Body Radiation Therapy to the prostate|Stereotactic Body Radiation Therapy to the prostate using 36.25 Gy in 5 fractions.
62174496|NCT00571558|EXPERIMENTAL|Treatment (aminolevulinin acid and photodynamic therapy)|Patients receive aminolevulinic acid PO 3-4 hours before undergoing photodynamic therapy using pulsed dye laser on day 1.
62174497|NCT03441919||Patients with type 1 diabetes, poor glycemic control|"* Diagnosis based on clinical criteria~* Duration of diabetes ≥10 years~* Age ≥20 years, ≤ 60 years~* HbA1c \>64 mmol/mol"
62174498|NCT03441919||Patients with type 1 diabetes, good glycemic control|"* Diagnosis based on clinical criteria~* Duration of diabetes ≥10 years~* Age ≥20 years, ≤ 60 years~* HbA1c \<64 mmol/mol"
62174499|NCT03441919||Healthy subjects|"* Absence of disease, no use of medication~* Matched for age, gender and BMI~* HbA1c \<42 mmol/mol"
62174500|NCT04617262|EXPERIMENTAL|Remote Problem Management Plus|Five individual sessions of low-intensity psychological intervention
62174501|NCT03732950|EXPERIMENTAL|Treatment (pembrolizumab)|Participants receive pembrolizumab intravenously IV on day 1. Courses repeat every 3 weeks for up to 35 courses (2 years) in the absence of disease progression or unacceptable toxicity.
62174502|NCT04227171||FSH only|GnRH agonist protocol \& GnRH antagonist protocol
62174503|NCT00427297|EXPERIMENTAL|NVP-containing|Infants randomized to this arm will receive nevirapine-containing HAART regimen
62174504|NCT00427297|ACTIVE_COMPARATOR|NVP-sparing|Infants randomized to this arm will receive nevirapine-sparing HAART
62174505|NCT04659200||Covid Disease Patient Group|Researchers evaluated serum thyrotropin, free triiodothyronine, free thyroxine hormones, thyroid peroxidase antibodies and anti-thyroglobulin antibodies in patients hospitalized for COVID-19 infection. The researchers evaluated the results of white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, D-dimer in Covid-9 patients.
62174506|NCT04659200||Covid-Free Control Group|Researchers evaluated the results of serum thyrotropin, free triiodothyronine, free thyroxine hormones, thyroid peroxidase antibodies and anti-thyroglobulin antibodies, white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, D-dimer in the non-patient control group.
62174507|NCT05135988||Children in vital distress|
62174508|NCT05135988||Health care givers|Experts in vital distress care Non experts in vital distress care
62174509|NCT02879539|EXPERIMENTAL|MP3000-ACE strategy|MP3000 sound coding strategy or ACE strategy with lower stimulation rate
62174510|NCT03187041|EXPERIMENTAL|Skin surface pressures under tourniquets and sensation|"Phase 1: Each phlebotomist will apply the tourniquet 10 separate times to the right arm of each subject. The tourniquet will remain on the arm for approximately ten seconds, to be able to allot enough time to collect an accurate pressure measurement. All 10 tourniquet skin pressure measurements will take place on the same day for a subject.~Phase 2: 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 1 hour. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use."
62174511|NCT01089387|EXPERIMENTAL|injection of bone marrow cells|
62174512|NCT04977297|EXPERIMENTAL|Move to Music Video Intervention|Participants in this arm will receive the Move to Music with Video (M2M-V) intervention. The participant will be asked to exercise twice daily for 5 consecutive days.
62174513|NCT04977297|ACTIVE_COMPARATOR|Move to Music Intervention|Participants in this arm will receive the Move to Music (M2M) only intervention without video. The participant will be asked to exercise twice daily for 5 consecutive days.
62174514|NCT05645744||Prior MB-102 CAR-T cell investigational product.|Patients previously treated with MB-102 CAR-T cell investigational product.
62363936|NCT03825445|EXPERIMENTAL|GnRHa trigger|Infertile patients underwent ovarian stimulation, started on cycle day eight with 75 IU Menogon (Ferring Pharm Co, Switzerland) daily. Ultrasound monitoring was required after every 2-3 days of stimulation and adjustments to dose and duration were tailed according the patient's response. Ovulation was triggered when at least one and no more than 3 follicles reached ≥18mm in diameter. Patients were then randomly assigned to receive two doses of GnRH-a (Fertipeptil 0.1mg x 2 vial; Ferring Pharm Co, Switzerland) for ovulation trigger.
62174515|NCT05645744||Prior MB-106 CAR-T cell investigational product.|Patients previously treated with MB-106 CAR-T cell investigational product.
62174516|NCT04420897||Normoxy: PaO2 = 80-120 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
62174517|NCT04420897||Moderate hyperoxemia: PaO2 =120-200 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
62174518|NCT04420897||Severe hyperoxemia: PaO2 >200 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
62174519|NCT02600897|EXPERIMENTAL|Dose-escalation Cohort: FL|Participants with R/R FL will receive 6 months of induction treatment with polatuzumab vedotin and lenalidomide at escalating doses to identify the recommended Phase 2 dose (RP2D) for polatuzumab vedotin and lenalidomide when combined with a fixed dose of obinutuzumab. Those who achieve CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 24-month maintenance regimen consisting of lenalidomide and obinutuzumab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).
62174520|NCT02600897|EXPERIMENTAL|Dose-escalation Cohort: DLBCL|Participants with R/R DLBCL will receive 6 months of induction treatment with fixed dose of polatuzumab vedotin and rituximab along with dose escalating lenalidomide. Lenalidomide will be administered at escalating doses to identify the recommended Phase 2 dose (RP2D) for lenalidomide. Those who achieve CR and PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 6-month consolidation regimen consisting of lenalidomide and rituximab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).
62174521|NCT02600897|EXPERIMENTAL|Expansion Cohort: FL|Participants with R/R FL who received induction treatment with polatuzumab vedotin and lenalidomide, in addition to obinutuzumab and achieved CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will receive a 24-months maintenance regimen consisting of lenalidomide and obinutuzumab for first 12 months followed by obinutuzumab treatment for next 12 months. Post-induction therapy will start 8 weeks after Cycle 6 Day 1.
62363937|NCT03825445|EXPERIMENTAL|hCG trigger|Infertile patients underwent ovarian stimulation, started on cycle day eight with 75 IU Menogon (Ferring Pharm Co, Switzerland) daily. Ultrasound monitoring was required after every 2-3 days of stimulation and adjustments to dose and duration were tailed according the patient's response. Ovulation was triggered when at least one and no more than 3 follicles reached ≥18mm in diameter. Patients were then randomly assigned to receive hCG (Pregnyl 5000IU; Organon Pharm Co, Nertheland) for ovulation trigger.
62363938|NCT02066545|PLACEBO_COMPARATOR|Vehicle Gel|
62363939|NCT02066545|EXPERIMENTAL|CLS001 topical gel 1%|Topical application once daily
62363940|NCT02066545|EXPERIMENTAL|CLS001 topical gel 1.75%|Topical application once daily
62363941|NCT02066545|EXPERIMENTAL|CLS001 topical gel 2.5%|Topical application once daily
62363942|NCT03009149|EXPERIMENTAL|AEROBIC EXERCISE|The effects of 12 week aerobic exercise will record
62363943|NCT06060704|EXPERIMENTAL|triplet combination therapy|Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab
62363944|NCT02629536|EXPERIMENTAL|Active-verum-NAC tablet|Intervention: Twice-daily administration of N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablets
62363945|NCT02629536|PLACEBO_COMPARATOR|Sham-placebo tablet|Intervention: Twice daily administration of sham/placebo tablet
62363946|NCT01591811|EXPERIMENTAL|Arm 1 Daily Boost of Radiation Therapy|Arm 1 of treatment, you will be receiving 15 daily radiation fractions of 2.7 Gy (measure of radiation dose) daily for three weeks to the entire breast with a daily concomitant boost of 0.5 Gy
62363947|NCT01591811|EXPERIMENTAL|Arm 2 Weekly Boost of Radiation Therapy|Arm 2 Weekly Boost will receive 15 daily radiation fractions of 2.7 Gy for three weeks to the entire breast with a weekly boost of 2.0 GY.
62363948|NCT02575300|EXPERIMENTAL|Ibrutinib Therapy|Ibrutinib Initial Dose 560 mg by mouth (PO) every day (QD)
62363949|NCT01052831|ACTIVE_COMPARATOR|Naltrexone|For the first four weeks of the study, participants were administered naltrexone at 50mg per day. Participants not in response at week 4 were increased to 100mg per day for the remaining four weeks of the study.
62363950|NCT01052831|PLACEBO_COMPARATOR|Placebo|Participants received the placebo treatment which looked identical to active study medication.
62363951|NCT02201667|EXPERIMENTAL|Ticagrelor group|Patients wil be given 180 mg loading dose of ticagrelor and 300mg loading dose of aspirin followed by PCI, then will receive 90 mg ticagrelor twice daily with aspirin maintenance dose to 30 days after randomization.
62363952|NCT02201667|ACTIVE_COMPARATOR|Clopidogrel group|Patients will be given clopidogrel 300mg loading dose and 300mg loading dose of aspirin followed by PCI, then will receive 75mg clopidogrel once with aspirin maintenance dose to 30 days after randomization.
62363953|NCT03853304|EXPERIMENTAL|Quadruple-Fortified Salt (QFS)|Salt fortified with iron, iodine, folic acid, and vitamin B12
62363954|NCT03853304|EXPERIMENTAL|DFS + Folic acid|Salt fortified with iron, iodine, and folic acid
62363955|NCT03853304|EXPERIMENTAL|DFS + Vitamin B12|Salt fortified with iron, iodine, and vitamin B12
62363956|NCT03853304|ACTIVE_COMPARATOR|Double-fortified salt (DFS)|Salt fortified with iron and iodine
62363957|NCT01170949|EXPERIMENTAL|Miltefosine|
62363958|NCT01170949|PLACEBO_COMPARATOR|Placebo|
62363959|NCT03912792||XLHED Patients|
62363960|NCT03912792||Healthy Controls|
62363961|NCT03713424|ACTIVE_COMPARATOR|Clav|4-day 125 bid oral capsule administration
62363962|NCT03713424|PLACEBO_COMPARATOR|Placebo|4-day, twice-daily oral capsule administration
62363963|NCT02716662|EXPERIMENTAL|Open Label|Axona
62363964|NCT04059471|ACTIVE_COMPARATOR|Standard Dose|Yellow fever vaccine, Institut Pasteur, standard dose as release by manufacturer will be administered subcutaneously once.
62363965|NCT04059471|EXPERIMENTAL|Fractional dose (1000 IU/dose)|Yellow fever vaccine, Institut Pasteur, will be titrated to about 1000IU/dose and administered subcutaneously once.
62363966|NCT04059471|EXPERIMENTAL|Fractional dose (500 IU/dose)|Yellow fever vaccine, Institut Pasteur, will be titrated to about 500IU/dose and administered once.
62363967|NCT04059471|EXPERIMENTAL|Fractional dose (250 IU/dose)|Yellow fever vaccine, Institut Pasteur, will be titrated to about 250IU/dose and administered once.
62363968|NCT02597192|ACTIVE_COMPARATOR|Active test group|probiotic oral hygiene products with Bacillus (PIP, Chrisal)
62363969|NCT02597192|PLACEBO_COMPARATOR|Placebo group|oral hygiene products without Bacillus
62363970|NCT05955872|EXPERIMENTAL|Sequence A: VX-147|Participants will receive VX-147 reference tablet under fasted condition in Treatment Period 1, then VX-147 test tablet under fed condition in Treatment Period 2, and VX-147 test tablet under fasted condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.
62363971|NCT05955872|EXPERIMENTAL|Sequence B: VX-147|Participants will receive VX-147 test tablet under fed condition in Treatment Period 1, then VX-147 test tablet under fasted condition in Treatment Period 2, and VX-147 reference tablet under fasted condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.
62363972|NCT05955872|EXPERIMENTAL|Sequence C: VX-147|Participants will receive VX-147 test tablet under fasted condition in Treatment Period 1, then VX-147 reference tablet under fasted condition in Treatment Period 2, and VX-147 test tablet under fed condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.
62174522|NCT02600897|EXPERIMENTAL|Expansion Cohort: DLBCL|Participants with R/R DLBCL who received induction treatment with polatuzumab vedotin and lenalidomide in addition to rituximab and achieved CR or PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will receive a 6-month consolidation regimen consisting of lenalidomide and rituximab. Post-induction therapy will start 8 weeks after Cycle 6 Day 1.
62363973|NCT02762708|ACTIVE_COMPARATOR|Roux-en-Y Gastric Bypass (RYGB)|Subjects between the ages of 20-65 years of age seen for weight management in the Nutrition Clinic at Mayo Clinic, who have been approved for RYGB.
62363974|NCT02762708|SHAM_COMPARATOR|Caloric restriction|Subjects between the ages of 20-65 years of age, with diagnosis of Type 2 diabetes mellitus or impaired fasting glucose. Subjects will undergo caloric restriction alone to mimic weight loss seen after gastric bypass surgery.
62363975|NCT02762708|ACTIVE_COMPARATOR|Exendin-9,39|Four subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of Exendin-9,39 or normal saline.
62363976|NCT02762708|PLACEBO_COMPARATOR|Normal Saline|Four subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of Exendin-9,39 or normal saline.
62363977|NCT02522078|ACTIVE_COMPARATOR|Dry Misoprostol|400 µg of dry misoprostol
62363978|NCT02522078|EXPERIMENTAL|Wet misoprostol|400 µg of wet misoprostol
62363979|NCT03647176|ACTIVE_COMPARATOR|small polyps|Cold snare polypectomy ; Polyp size will be measured using the tip of the snare catheter (2.5mm).Small (5-9 mm) colorectal polyps will be removed with a polypectomy snare. Following the resection, jet stream of water will be used to wash mucosal defect thoroughly. After endoscopist's attestation that polyp removal was complete by carefully observe the resection margins with near focus mode, biopsies were performed from two marginal sites located symmetrically on the left and right of the mucosal defects to confirm residual polyp tissue.
62363980|NCT03647176|EXPERIMENTAL|large polyps|Cold snare polypectomy; Polyp size will be measured using the tip of the snare catheter (2.5mm). Large (10-15 mm) colorectal polyps will be removed with a polypectomy snare. Following the resection, jet stream of water will be used to wash mucosal defect thoroughly. After endoscopist's attestation that polyp removal was complete by carefully observe the resection margins with near focus mode, 4 biopsies will be performed from all four quadrants of resection margins.
62363981|NCT02157168|NO_INTERVENTION|Control Group|Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker. Those not invited will constitute the usual care control group.
62363982|NCT02157168|OTHER|Intervention Group|"Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker in the intervention group.~The intervention group will be made up of two sub groups. The group of individuals who accept the invitation to participate (IG1) in the intervention and receive it, and those randomized to the intervention group but who reject the opportunity to participate (IG2)."
62363983|NCT01628393|EXPERIMENTAL|Ozanimod 0.5 mg|Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 0.5 mg weekly for another 96 weeks.
62363984|NCT01628393|EXPERIMENTAL|Ozanimod 1 mg|Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 1 mg weekly for another 96 weeks.
62363985|NCT01628393|PLACEBO_COMPARATOR|Placebo|Participants received placebo to ozanimod oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and were randomized to receive ozanimod 0.5 mg or 1 mg weekly for 96 weeks.
62363986|NCT01576666|EXPERIMENTAL|LDE225 and BKM120 in combination|LDE225 and BKM120 in combination
62363987|NCT01607073|OTHER|open label adjunctive add on|open label adjunctive add on of verapamil to existing medications. dosing begins at 1 mg/kg/d and increases weekly to target of 4 mg/kg/d in divided doses (three times/day)
62363988|NCT01761136|ACTIVE_COMPARATOR|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
62363989|NCT01761136|EXPERIMENTAL|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
62363990|NCT04834050|EXPERIMENTAL|Rheumatoid arthritis patients|
62363991|NCT04834050|EXPERIMENTAL|Knee Osteoarthritis patients|
62363992|NCT04834050|EXPERIMENTAL|Healthy patients|
62174523|NCT02146729|EXPERIMENTAL|Percutaneous Pedicle Screw Fixation|Percutaneous Pedicle Screw Fixation
62363993|NCT01943188|EXPERIMENTAL|Treatment (SBRT, autologous PBMC infusion)|"SBRT: Patients undergo standard of care SBRT over 1-2 weeks according to tumor volume and location.~LYMPHODEPLETION: Beginning 3 weeks later, patients receive cyclophosphamide PO BID for 3 days.~REINFUSION OF PBMC: Within 3-14 days of completing lymphodepletion with cyclophosphamide , patients undergo autologous PBMC infusion."
62363994|NCT05030597|EXPERIMENTAL|68Ga-DOTA-FAPI and 18F-FDG PET/CT|Investigators recruit patients whom are clinically highly suspected oral cancer or recurrence after treatment. Patients undergo 68Ga-DOTA-FAPI and 18F-FDG PET/CT imaging within one week.
62363995|NCT00763178|EXPERIMENTAL|PTSD|Duloxetine
62363996|NCT00437203|EXPERIMENTAL|1|
62363997|NCT01225276|EXPERIMENTAL|Dosage Arm 1|NewGam 10% 0.4 g/kg
62363998|NCT01225276|EXPERIMENTAL|Dosage Arm 2|NewGam 10% 1.0 g/kg
62363999|NCT01225276|EXPERIMENTAL|Dosage Arm 3|NewGam 10% 2.0 g/kg
62364000|NCT01225276|PLACEBO_COMPARATOR|Dosage Arm 4|Placebo 0.9% Saline
62364001|NCT02997774|ACTIVE_COMPARATOR|Standard Dialysis|Patient will undergo dialysis at 36.5 degrees Celsius to assess if this affects the liver function and perfusion
62364002|NCT02997774|EXPERIMENTAL|Cooler Dialysis|Patient will undergo dialysis at 35 degrees Celsius to assess if this affects the liver function and perfusion
62364003|NCT01617642||Control group|Healthy control group, matched for age and gender
62364004|NCT01617642||Acute intermittent porphyria|Patients with acute intermittent porphyria.
62364005|NCT04407624|EXPERIMENTAL|Intermittent Exercise Group|Warm-up, loading (walking, squat, sitting down on a chair, limb movements with weights, stepping on steps, walking on different floors), cooling and relaxation exercises
62364006|NCT04407624|ACTIVE_COMPARATOR|Control Group|Warm-up, loading (brisk walking at 60-85% of maximum heart rate), cooling and relaxation exercises
62364007|NCT01531361|EXPERIMENTAL|Arm I (vemurafenib and sorafenib tosylate)|Patients receive vemurafenib PO BID and sorafenib tosylate PO BID on days 1-28.
62364008|NCT01531361|EXPERIMENTAL|Arm II (vemurafenib and crizotinib)|Patients receive vemurafenib as in Arm I and crizotinib PO QD or BID on days 1-28.
62364009|NCT00527072|EXPERIMENTAL|001|infliximabOpen-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
62364010|NCT03459157|OTHER|HIV prevention package including PrEP|
62364011|NCT03507192|NO_INTERVENTION|Arm 1|30 subjects In arm 1, no intervention is performed.
62364012|NCT03507192|ACTIVE_COMPARATOR|Arm 2|30 patients In arm 2 , active comparators, Muscle relaxation using full body massage machine is performed every morning and evening for 30 minutes.
62364013|NCT02106572|EXPERIMENTAL|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900
62364014|NCT02106572|ACTIVE_COMPARATOR|Mitomycin C|intravesical instillation of Mitomycin C
62174524|NCT02146729|ACTIVE_COMPARATOR|Open Treatment|Midline posterior incision with instrumentation.
62174525|NCT04608032|EXPERIMENTAL|Ecological Cognitive training program for schizophrenia spectrum disorder [ECo-Sz]|To inform the patient about cognitive impairments and their repercussions ; to train the patient in problem-solving skills through exercices ; to implement strategies in daily life. Duration : two month. Frequency : Two one hour individual sessions and one hour of at-home training per week. Modalities : pen and papers exercices (tools, token, cards, maps and chessboard). Modules : Psychoeducation, Attention, Memory, Executive functions, Social cognition and metacognition, Functional impairments
62174526|NCT04608032|ACTIVE_COMPARATOR|[THoR] Recovery-Oriented Therapy|Individual psychotherapy sessions focussing on autonomy in daily life, management of mood disorders' and functional impact, social skills, motivation and the regulation of sleep and daily activities
62174527|NCT05310058|ACTIVE_COMPARATOR|12.5 g/d of C6 ketone di-ester|Low dose of ketone di-ester.
62174528|NCT05310058|ACTIVE_COMPARATOR|25 g/d of C6 ketone di-ester|Middle dose of ketone di-ester.
62174529|NCT05310058|ACTIVE_COMPARATOR|50 g/d of C6 ketone di-ester|Highest dose of ketone di-ester.
62174530|NCT01842919|OTHER|Huntington patient|This group will perform Magnetic Resonance Imaging (MRI), kinesthetic test and psychological questionnaires before and after 8 months of dance lessons
62174531|NCT01842919|OTHER|Assisting Person|This group will perform MRI, kinesthetic test and psychological questionnaires before and after 8 months of dance lessons
62174532|NCT01842919|OTHER|Pilot subject|Healthy volunteers to set up the kinesthetic test
62364015|NCT05597241|EXPERIMENTAL|Cohort 1, Apimostinel|Apimostinel, 25 mg IV single dose
62364016|NCT05597241|PLACEBO_COMPARATOR|Cohort 1, Placebo|Placebo, IV single Dose
62364017|NCT05597241|EXPERIMENTAL|Cohort 2, Apimostinel, 1 mg IV 8 consecutive daily doses|Apimostinel, 1 mg IV 8 consecutive daily doses
62364018|NCT05597241|PLACEBO_COMPARATOR|Cohort 2, Placebo IV 8 consecutive daily doses|Placebo IV 8 consecutive daily doses
62364019|NCT05597241|EXPERIMENTAL|Cohort 3, Apimostinel, 5 mg IV 8 consecutive daily doses|Apimostinel, 5 mg IV 8 consecutive daily doses
62364020|NCT05597241|PLACEBO_COMPARATOR|Cohort 3, Placebo 8 consecutive daily doses|Placebo IV 8 consecutive daily doses
62364021|NCT05597241|EXPERIMENTAL|Cohort 4, Apimostinel, 10 mg IV 8 consecutive daily doses|Apimostinel, 10 mg IV 8 consecutive daily doses
62364022|NCT05597241|PLACEBO_COMPARATOR|Cohort 4, Placebo 8 consecutive daily doses|Placebo IV 8 consecutive daily doses
62364023|NCT05597241|EXPERIMENTAL|Cohort 5, Apimostinel, 25 mg IV, 8 consecutive daily doses|Apimostinel, 25 mg IV 8 consecutive daily doses
62364024|NCT05597241|PLACEBO_COMPARATOR|Cohort 5, Placebo IV 8 consecutive daily doses|Placebo IV 8 consecutive daily doses
62364025|NCT01261260|PLACEBO_COMPARATOR|Uridine|1g BID
62364026|NCT03009903||P. acne subjects|14-50 year of age, P. acne diagnosed subjects
62364027|NCT03009903||None P. acne subjects|14-50 year of age, none P. acne diagnosed subjects
62364028|NCT01307371||Diabetes|Patients with diabetes.
62364029|NCT01307371||non-diabetes|Patients without diabetes.
62364030|NCT00614991|ACTIVE_COMPARATOR|Group A|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg BID Period 3-Fosamprenavir 1400mg BID + Raltegravir 400mg BID
62364031|NCT00614991|ACTIVE_COMPARATOR|Group B|Period 1-Raltegravir 400mg BID Period2-Fosamprenavir 1400mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg BID
62364032|NCT00614991|ACTIVE_COMPARATOR|Group C|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID
62364033|NCT00614991|ACTIVE_COMPARATOR|Group D|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 700mg BID + Raltegravir 100mg BID
62364034|NCT00614991|ACTIVE_COMPARATOR|Group E|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID
62364035|NCT00614991|ACTIVE_COMPARATOR|Group F|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
62364036|NCT04520308|EXPERIMENTAL|dupilumab|
62364037|NCT02244229|EXPERIMENTAL|Tamsulosin|
62364038|NCT02244229|ACTIVE_COMPARATOR|Finasteride|
62364039|NCT05007262|EXPERIMENTAL|Tangningtongluo tablets|Tangningtongluo tablets, 4 tablets one time,tid,po, taken after meals.The patients will receive drugs for 24 weeks continuously. After 24 weeks, the researchers will decide whether to continue depend on the patient condition and willingness. The maximum medication time is up to 48 weeks.Basic treatment: According to the comprehensive objectives of China Type 2 Diabetes Guidelines (2020 Edition) .The Angiotensin-Converting Enzyme（ACEI） and Angiotensin Receptor Blocker（ARB） drugs will be continued to use as the original treatment protocol.
62364040|NCT05007262|ACTIVE_COMPARATOR|Calcium dobesilate capsules|Calcium dobesilate capsules, 1 capsule at a time, tid,po.(morning, midday, and evening), used on an empty stomach.After 24 weeks, the researchers will decide whether to continue depend on the patient condition and willingness. The maximum medication time is up to 48 weeks.Basic treatment: According to the comprehensive objectives of China Type 2 Diabetes Guidelines (2020 Edition) .The Angiotensin-Converting Enzyme（ACEI ）and Angiotensin Receptor Blocker （ARB） drugs will be continued to use as the original treatment protocol.
62364041|NCT04490304|OTHER|posterior soft tissue repair durability|
62364042|NCT01944488|EXPERIMENTAL|GnRH intervention|All participating subjects are assigned to receive an intravenous GnRH agonist injection.
62364043|NCT05591651|EXPERIMENTAL|Preparation with hyaluronic acid|Treatment of damaged nipple skin: Preparation with hyaluronic acid. The hyaluronic acid preparation will contain white vaseline and 0.2% sodium hyaluronate in a 30 g container.
62364044|NCT05591651|EXPERIMENTAL|Neutral Preparation without hyaluronic acid|Treatment of damaged nipple skin: Neutral preparation without hyaluronic acid. The neutral preparation will contain white vaseline only, in a 30 g container, and wiil have the same appearance and fragrance as the active preparation.
62364045|NCT05589740|EXPERIMENTAL|Intervention|Intervention group consisting of culturally-tailored healthy eating advice through daily text messages for 2 months (delivery phase); a subsequent reinforcement phase of 2-months to repeat the text messages; and a subsequent maintenance phase of 2-months with no text messages.
62364046|NCT05589740|ACTIVE_COMPARATOR|Control|Control group consisting of general healthy eating advice through daily text messages for 2 months (delivery phase); a subsequent reinforcement phase of 2-months to repeat the text messages; and a subsequent maintenance phase of 2-months with no text messages.
62364047|NCT05272657|EXPERIMENTAL|low-carbohydrate diet|subjects in this arm are given detailed instructions and coaching in following a low-carbohydrate diet.
62364048|NCT05272657|EXPERIMENTAL|Mediterranean diet|subjects in this arm are given detailed instructions and coaching in following a Mediterranean diet.
62364049|NCT01250743|EXPERIMENTAL|Ascorbic Acid (Vitamin C)|
62364050|NCT01752075||REVLIMID|Taiwanese patients treated with REVLIMID
62364051|NCT01478061|ACTIVE_COMPARATOR|anastomoses in blood vessels and grafts|
62364052|NCT00761358|EXPERIMENTAL|Z-338|
62364053|NCT00761358|PLACEBO_COMPARATOR|placebo|
62364054|NCT01510223|EXPERIMENTAL|Dietary supplementation macademia oil|emia oil
62364055|NCT01510223|EXPERIMENTAL|Dietary supplementation olive oil|Olive oil
62364056|NCT01510223|EXPERIMENTAL|Dietary Supplementation fish oil|fish oil
62364057|NCT02872324|EXPERIMENTAL|Sessions of Mindfulness Based Cognitive Therapy (MBCT)|
62364058|NCT06090929|EXPERIMENTAL|Patients with STN-DBS|Patients accepted DBS implanted at the baseline
62364059|NCT06090929|NO_INTERVENTION|Patients without STN-DBS|Patients only accepted medication treatment before the end point
62364060|NCT01089166|EXPERIMENTAL|Torrent's Metformin tablets 500 mg|
62364061|NCT01089166|ACTIVE_COMPARATOR|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
62364062|NCT06409767|EXPERIMENTAL|Interventional arm|
62364063|NCT06409767|NO_INTERVENTION|Control arm|
62364064|NCT01120821|EXPERIMENTAL|Study drug|Gleevec treatment
62364065|NCT00201760|EXPERIMENTAL|Arm 1 Gemcitabine/Cisplatin/Trastuzumab|Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Cisplatin 30 mg/m2 iv over 90 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not administered within the past 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be given on the first day of cycle 1 only).
62364066|NCT00201760|ACTIVE_COMPARATOR|Arm 2 Gemcitabine / Trastuzumab|Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not administered within the past 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be given on the first day of cycle 1 only).
62364067|NCT02736396||Healthy Controls|Medical History, Neuropsychological tests, clinical assessments, fMRI
62364068|NCT02736396||Cognitive impairment|Medical History, Neuropsychological tests, clinical assessments, fMRI
62364069|NCT02228772|EXPERIMENTAL|MLN 9708|"* Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~* MLN 9708 will be given with standard multi-drug regimen for ALL . MLN 9708 will be administered on determined days during Induction therapy cycle and Consolidation cycle. If remission occurs and if eligible, the next stage with be either Stem Cell or Bone Marrow Transplant.~  * If not eligible to receive a transplant, the participant will continue on this study for the next 3 stages.~    * CNS Therapy~   * Consolidation 2~   * Continuation Therapy~No further MLN9708, the investigational drug, will be given after Consolidation 1 Standard chemotherapy -Vincristine, Cytarabine, Doxorubicin, Mercaptopurine, Cyclophosphamide, Methotrexate"
62364070|NCT06123741|EXPERIMENTAL|Parental Guidance+Virtual Reality Game|
62364071|NCT06123741|EXPERIMENTAL|Parental Guidance|
62364072|NCT06123741|EXPERIMENTAL|Virtual Reality Game|
62364073|NCT06123741|NO_INTERVENTION|Control Group|This group implement the rehabilitation plan drawn up in specialized medical care (treatment as usual).
62364074|NCT02176980|ACTIVE_COMPARATOR|Medical provider (MP) brief alcohol counseling & referral|"1. Screening of HCV-infected patients for alcohol use using the 10-item Alcohol Use Disorders Identification Test (AUDIT).~2. Patients self-administer the AUDIT.~3. HCV providers review the AUDIT with the patient.~4. If the patient is using any alcohol, the HCV provider conducts brief alcohol counseling using the FRAMES model, based on the evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) method.~5. Medical provider will explain the importance of alcohol abstinence in the presence of HCV infection.~6. Patient is referred to an alcohol treatment programs outside the liver clinic. Typical counseling will take the form of individual and group therapy."
62364075|NCT02176980|EXPERIMENTAL|Brief alcohol counseling & 6 months of HCV-alcohol treatment|"* Steps 1 through 5 as described in comparator arm above.~* 6 months of group therapy, offered weekly.~* 6 months of individual therapy, in person or by phone, offered every two weeks.~* Therapy content emphasizes interplay between alcohol use and liver health/HCV.~* Informal collaboration between HCV providers and addictions therapists.~* Shared EMR charting.~* Referral to study-provided psychiatry as needed."
62364076|NCT04750655|PLACEBO_COMPARATOR|Intraoperative antibiotics (Abx) only; no postoperative topical antibiotics|intraoperative/ intracameral antibiotic (moxifloxacin) only; no postoperative topical antibiotic drops
62364077|NCT04750655|ACTIVE_COMPARATOR|Intraoperative antibiotics (Abx); Postoperative topical antibiotics four times a day for 1 week|intraoperative/ intracameral antibiotic (moxifloxacin); postoperative topical antibiotic drops four times a day for 1 week
62364078|NCT04750655|ACTIVE_COMPARATOR|Intraoperative antibiotics (Abx); Postoperative topical antibiotics once a day for 1 week|intraoperative/ intracameral antibiotic (moxifloxacin); postoperative topical antibiotic drops once a day for 1 week
62364079|NCT02511275|OTHER|renal microdialysis|patient with renal microdialysis
62739304|NCT02023580|EXPERIMENTAL|Intervention|The Video Treatment arm will complete baseline, 3-, 6-, 9-, and 12-month online survey assessments. Between baseline and 3-month follow-up, men will view 6 video vignettes (participants will receive a link to view a video vignette once a week for 6 weeks). Based on our team's experience of attenuated intervention effects at 6 months, men will receive 4 video boosters, spaced 1 week apart, after the 6-month assessment survey. Spacing the dose over time can improve critical thinking. The additional videos will be a continuation of the dramatic series plus additional video scenes on disclosure and serodiscordant partnerships.
62174533|NCT05278065|EXPERIMENTAL|Electronic cigarette|Participants in this experimental condition will be provided with a 4th generation electronic cigarette device and disposable cartridges.
62174534|NCT05278065|NO_INTERVENTION|Smoking As Usual|Participants in this assessment-only condition will continue smoking as usual.
62174535|NCT00405002||1|ALI/ARDS patients
62174536|NCT00043407|EXPERIMENTAL|CPG 7909 Injection|
62174537|NCT01341444|EXPERIMENTAL|Prevena Incision Management System|Negative Pressure Therapy Device
62174538|NCT01341444|PLACEBO_COMPARATOR|Standard of Care for Surgical Incisions|Sterile gauze and a non-penetrable barrier
62174539|NCT05611489|OTHER|Open appendectomy|Appendectomy will be done through Mcberney incision.
62174540|NCT05611489|OTHER|Conventional lap appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic).
62174541|NCT01170923|EXPERIMENTAL|FDG-PET guided|Chemotherapy regimen will be changed depending on metabolic response.
62174542|NCT01170923|ACTIVE_COMPARATOR|CT guided|Chemotherapy regimen will be changed depending on CT findings (RECIST).
62174543|NCT00926302|EXPERIMENTAL|Test drug|Levetiracetam one period
62174544|NCT00926302|ACTIVE_COMPARATOR|Reference drug|Keppra one period
62174545|NCT02453802|ACTIVE_COMPARATOR|Topic TXA group|"Primary total knee replacement with intravenous 0.9% normal saline (20 ml) administration before deflation of the tourniquet and intraarticular application of Tranexamic Acid 5%,5ml/amp 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
62174546|NCT02453802|ACTIVE_COMPARATOR|IV TXA group|"Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously before deflection of the tourniquet and topical 160 ml 0.9% normal saline application after closure of joint capsule.~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
62174547|NCT02453802|PLACEBO_COMPARATOR|Control group|"Primary total knee replacement with 0.9% normal saline administration intravenously before deflation of the tourniquet and topical 160 ml 0.9% normal saline application after closure of joint capsule.~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
62174548|NCT01181583|EXPERIMENTAL|Tailored Internet-delivered CBT|
62174549|NCT01181583|EXPERIMENTAL|Non-tailored Internet-delivered CBT|
62174550|NCT01181583|ACTIVE_COMPARATOR|Online discussion group|
62174551|NCT03709056|EXPERIMENTAL|HSK3486 0.4/0.2mg/kg ，0.5mg/kg/0.15mg/kg|
62174552|NCT03709056|ACTIVE_COMPARATOR|Propofol 2.0/1.0mg/kg group|
62364080|NCT02613988|OTHER|MR imaging and standard treatment|Patients with glioblastoma undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and perfusion (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent) at pre-CCRT; 4 weeks after completion of the CCRT; and every 2 or 3 months during the adjuvant temozolomide therapy.
62364081|NCT04938089||ICS|Irregular compliant smoker
62364082|NCT04938089||RCS|Regular compliant smoker
62364083|NCT04938089||ICN|Irregular compliant non-smoker
62364084|NCT04938089||RCN|Regular compliant non-smoker
62364085|NCT01963780|EXPERIMENTAL|OCS Lung Tx.|A prospective, pivotal single arm trial.
62364086|NCT03793283||Continous Subcutaneous Insulin Infusion|"All T1DM adult patients attended in Ciudad Real General University Hospital and treated with CSII.~Forty-five patients are actually treated with CSII in our hospital."
62364087|NCT03793283||Multiple dose insulin injections (MDI):|"Forty-five T1DM adult patients attended in Ciudad Real General University Hospital and treated with MDI.~MDI patients will be selected through simple random sampling (1:1) from our T1DM patient database."
62364088|NCT02491827||Cellvizio mini laser probe|Cellvizio mini laser probe will be administered via the endoscopic device used for the neurosurgical procedure to provide confocal laser endomicroscopy in patients requiring neurosurgery due to glioma multiforme or subcranial tumors
62364089|NCT00645515|EXPERIMENTAL|Arm A|
62364090|NCT00645515|ACTIVE_COMPARATOR|Arm B|
62364091|NCT05826002|ACTIVE_COMPARATOR|Digital insomnia intervention|This group receives the following combination of treatment features: optimized graphical user interface (no), adaptive treatment strategy (no), daily prompts (no).
62364092|NCT05826002|ACTIVE_COMPARATOR|Digital insomnia intervention + optimized user interface|This group receives the following combination of treatment features: optimized graphical user interface (yes), adaptive treatment strategy (no), daily prompts (no).
62364093|NCT05826002|ACTIVE_COMPARATOR|Digital insomnia intervention + adaptive treatment strategy|This group receives the following combination of treatment features: optimized graphical user interface (no), adaptive treatment strategy (yes), daily prompts (no).
62364094|NCT05826002|ACTIVE_COMPARATOR|Digital insomnia intervention + optimized user interface, adaptive treatment strategy|This group receives the following combination of treatment features: optimized graphical user interface (yes), adaptive treatment strategy (yes), daily prompts (no).
62364095|NCT05826002|ACTIVE_COMPARATOR|Digital insomnia intervention + daily prompts|This group receives the following combination of treatment features: optimized graphical user interface (no), adaptive treatment strategy (no), daily prompts (yes).
62364096|NCT05826002|ACTIVE_COMPARATOR|Digital insomnia intervention + optimized user interface, daily prompts|This group receives the following combination of treatment features: optimized graphical user interface (yes), adaptive treatment strategy (no), daily prompts (yes).
62364097|NCT05826002|ACTIVE_COMPARATOR|Digital insomnia intervention + adaptive treatment strategy, daily prompts|This group receives the following combination of treatment features: optimized graphical user interface (no), adaptive treatment strategy (yes), daily prompts (yes).
62364098|NCT05826002|ACTIVE_COMPARATOR|Digital insomnia intervention + optimized user interface, adaptive treatment strategy, daily prompts|This group receives the following combination of treatment features: optimized graphical user interface (yes), adaptive treatment strategy (yes), daily prompts (yes).
62364099|NCT04839406|EXPERIMENTAL|Intervention|"Structured follow up at the ICU~* 1-3 days after admittance: Map caregivers' prioritized symptoms, needs and preferences with a digital assessment tool, followed by a meeting with a nurse to address these issues.~* Every 1-2 weeks: Repeat assessment of symptoms and needs with the assessment tool followed by a meeting with a nurse.~* At discharge: Structured conversation focusing on information and preparation for the transition to a regular ward or to another hospital including a card with information and support.~* Bereavement: Individualized support based on caregiver expressed needs, preferences and previous mapping, including a card with information and support.~* Follow up: Caregivers or bereaved will be contacted after 4-6 weeks, and will be offered a follow up conversation either on phone or at the unit."
62364100|NCT04839406|NO_INTERVENTION|Follow up as usual (Control)|Follow up as usual at the ICU
62364101|NCT02738580|ACTIVE_COMPARATOR|rFSH|Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
62364102|NCT02738580|ACTIVE_COMPARATOR|HP-HMG|Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG with normal ovarian function.
62364103|NCT00457756|ACTIVE_COMPARATOR|I|Cohort I subjects will take supplement for 12 weeks
62364104|NCT00457756|PLACEBO_COMPARATOR|II|Cohort II will take placebo for 12 weeks
62364105|NCT01666860||Anterior Lumbar Interbody Fusion procedure|
62364106|NCT06508151|EXPERIMENTAL|Arm 1|After neovaginoplasty, a vaginal mold spreaded with photoinduced-imine-crosslink hydrogel was placed in the neovagina.
62364107|NCT06508151|OTHER|Arm 2|After neovaginoplasty, a vaginal mold was placed in the neovagina directly without anything spreaded.
62174553|NCT02510222|EXPERIMENTAL|Oral Magnesium sulfate|Magnesium sulphate 4% concentration orally ( 65 mg per day for children one to three years of age; 110 mg per day for children four to eight years of age; 350 mg per day for children older than eight years) for 1 month
62174554|NCT02510222|PLACEBO_COMPARATOR|Control|Fifty children with cerebral palsy will be treated with conventional therapy as physiotherapy. They will receive placebo.
62364108|NCT02805062||Pleural Effusion|Malignant pleural effusion patients requiring investigation with thoracoscopy.
62364109|NCT00965549|EXPERIMENTAL|Lantus + Apidra basal plus one|"Before randomization (common with arm 2):~A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy.~8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued.~After randomization:~24 weeks of treatment period: Insulin (Lantus®) + metformin (if applicable) + a single injection of insulin glulisine (Apidra®), the latter administered at the patients largest meal of the day"
62364110|NCT00965549|ACTIVE_COMPARATOR|NovoMix 30 Biphasic|"Before randomization (common with arm 1):~A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy.~8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued.~After randomization:~24 weeks of treatment period: Insulin aspart/ insulin protamine crystallised insulin aspart (NovoMix® 30) + metformin (if applicable)"
62364111|NCT01267344|ACTIVE_COMPARATOR|GEMOX|Intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks.
62364112|NCT01267344|EXPERIMENTAL|E-GEMOX|Arm A will receive E-GEMOX with additional intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above.
62364113|NCT01057862|EXPERIMENTAL|Naltrexone|
62364114|NCT01057862|PLACEBO_COMPARATOR|Placebo|
62364115|NCT01996436|ACTIVE_COMPARATOR|Nicardipine|Group 1 : Nicardipine 5mg per circulation intra-arterial injection, Pharmacological angioplasty
62182381|NCT02828163|EXPERIMENTAL|Autologous Platelet rich plasma|Autologous platelet-rich plasma (PRP) is autologous plasma that has platelet concentration above the baseline. 1 millilitre of autologous platelet-rich plasma will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
62364116|NCT01996436|ACTIVE_COMPARATOR|Verapamil|Group 3: Verapamil 10mg per circulation intra-arterial injection, Pharmacological angioplasty
62364117|NCT01996436|ACTIVE_COMPARATOR|Nicardipine + Verapamil + Nitroglycerin|Group 4 : Nicardipine 5mg + Verapamil 10mg + Nitroglycerin 200mcg in 4cc 5 % dextrose in water , intra-arterial injection, Pharmacological angioplasty
62364118|NCT03685110||CoreHip|Clinical and Radiological Data of 300 patients of a Standard Patient Population, who are treated with CoreHip Total Hip Arthroplasty for Indications according to the Instructions for Use (IfU) with a five year follow Up
61997443|NCT05451771|EXPERIMENTAL|Phase 1: Venetoclax 400mg|Cohort 2: Venetoclax 400 mg tablet, once daily for up to 2 cycles after achieving best response, for a maximum of 6 cycles (1 cycle = 28 days)
62364119|NCT01469962||obese patients|
62364120|NCT05539872|EXPERIMENTAL|Insulin Aspart, I004|Participants who were dosed with I004
62364121|NCT05539872|ACTIVE_COMPARATOR|NovoLog|Participants who were dosed with NovoLog
62364122|NCT01128166||Patients implanted with a CRT-D (Cardiac Resynch. Therapy)|
62364123|NCT01011088||Early phase|Psychoses within the first 3 months after baby born
62364124|NCT01011088||Delayed phase|Psychoses \> 3 months to one year after baby born
62364125|NCT02201719||Hysterectomy Adenomyosis|Adenomyosis present
62364126|NCT02201719||Hysterectomy no adenomyosis|Adenomyosis not present
62364127|NCT01452360||Collection of CKD patient group|
62364128|NCT01452360||Collection of CKD high-risk group|
62364129|NCT01452360||Collection of healthy control group|
62364130|NCT01031199|EXPERIMENTAL|Arm 1|
62364131|NCT01031199|EXPERIMENTAL|Arm 2|
62364132|NCT05410808||Fibromyalgia patients|Patients diagnosed as having fibromyalgia according to the American College of Rheumatology 2016 classification criteria
62364133|NCT05410808||Healthy controls|Subjects not having fibromyalgia and who live in the same household as the fibromyalgia patients
62364134|NCT03174561|OTHER|Inuline, Choline and Silymarin + Diet|"Patients diagnosed with Irritable bowel syndrome who will follow diet restrictions together with a dietary supplement.~Intervention: Dietary Supplement, a combination of Inuline, Silymarin and Choline The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days"
62364135|NCT03174561|OTHER|Diet restriction|Patients diagnosed with Irritable bowel syndrome who will follow diet restrictions for 28 days. After the first month the patients are crossed between groups.
62364136|NCT04177875|EXPERIMENTAL|Chemoradiation and pd-1|Subjects in Arm A receive 2 cycles of Docetaxel /Albumin-bound Paclitaxel + Cisplatin, for neoadjuvant therapy Neoadjuvant radiotherapy for 40Gy/20F
62364137|NCT04824222|EXPERIMENTAL|A - SOC+IMP|The FMT (fecal microbiota transplantation) will be administered along with the standard COVID 19 pharmacological treatment (SOC- Standard of care). The FMT will be administered orally in one dose - in double cover, gastro-resistant, enteric release capsules in 60g dose (about 30-50 frozen capsules).
62364138|NCT04824222|PLACEBO_COMPARATOR|B - SOC+placebo|Using standard COVID 19 pharmacological treatment (SOC- Standard of care). The placebo will be administered orally in one dose - in double cover, gastro-resistant, enteric release capsules with lactose (about 30-50 frozen capsules).
62364139|NCT03642028|EXPERIMENTAL|Suvorexant|Suvorexant is a dual orexin receptor antagonist that is FDA approved to treat insomnia.
62364140|NCT03642028|PLACEBO_COMPARATOR|Identical Placebo|Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.
62364141|NCT05116891|EXPERIMENTAL|CAN04 and chemotherapy (mFOLFOX)|12 cycles for mFOLFOX/CAN04-Each cycle is 2 weeks.mFOLFOX/CAN04 treatment arm: CAN04 and mFOLFOX are administered on Day 1 with a mFOLFOX continuation of regime on Day 2. CAN04 is only administered on Day 1.
62364142|NCT05116891|EXPERIMENTAL|CAN04 and chemotherapy (DTX)|6 cycles for DTX/CAN04, Cycles are 3 weeks. DTX/CAN04 treatment arm: CAN04 and DTX are administered on Day 1 followed by CAN04 in monotherapy on Day 8.
62364143|NCT05116891|EXPERIMENTAL|CAN04 and chemotherapy (G/C)|8 cycles for G/C/CAN04, Cycles are 3 weeks. G/C/CAN04 treatment arm: CAN04 and G/C are administered on Day 1/Day 8.
62364144|NCT01186367|EXPERIMENTAL|Linear Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training, at 60% to 75 % of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at baseline.
62364145|NCT01186367|EXPERIMENTAL|Nonlinear Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at Baseline and as well as the CPET performed at Midpoint.
62364146|NCT01186367|EXPERIMENTAL|Progressive Stretching Group (Attention control)|The ultimate goal for the progressive stretching program is 3 to 4 individual stretching sessions/week for 10 to 50 minutes per session (+/- 10 minutes).
62364147|NCT05709314|EXPERIMENTAL|AMDX-2011P 100 mg|AMDX2011P 100mg (4ml) single bolus injection intravenous for diagnostic review
62364148|NCT02585076||Cohort 1|Patients aged 60 years or older regardless of gender and race with a documented diagnosis of hypertension will be enrolled into this study after the decision for electrocardiographic screening for AF has been made by the investigator
62364149|NCT06332612|ACTIVE_COMPARATOR|Standard|Group 1: Standard treatment with topical cream betamethasone and Pentoxifylline tablet.
62364150|NCT06332612|EXPERIMENTAL|MetforminO|Metformin 500 mg thrice daily.
62364151|NCT06332612|EXPERIMENTAL|MetforminT|Topical cream metformin thrice daily
62364152|NCT05936593|ACTIVE_COMPARATOR|Condylar Stabilizing (CS) insert|
62364153|NCT05936593|ACTIVE_COMPARATOR|Cruciate Retaining (CR) insert|
62364154|NCT00552994|ACTIVE_COMPARATOR|1|Cypher Select plus stent
62364155|NCT00552994|ACTIVE_COMPARATOR|2|Xience V stent
62364156|NCT05059847|NO_INTERVENTION|Standard Care Group|Each patient will receive the standard pharmacological treatment for patients with Acute Lymphoblastic Leukemia based on 3 cycles of chemotherapy (21 days duration per cycle); plus the World Health Organization recommendation that indicates at least 150 min a week of moderate physical activity, equivalent to walking 30 minutes a day for 5 days at an intensity between 60 and 70% of your maximum heart rate.
62364157|NCT05059847|ACTIVE_COMPARATOR|Resistance Training Group|Each patient will receive the standard pharmacological treatment for patients with Acute Lymphoblastic Leukemia based on 3 cycles of chemotherapy (21 days duration per cycle); plus a resistance exercise routine using weights. An individualized program with exercises supervised by a trainer and basic medical team will be developed for each patient during their hospital stay. Each training routine will have a monthly exercise progression based on intensity, frequency and / or duration.
62364158|NCT05059847|EXPERIMENTAL|Cross-training Group|Each patient will receive the standard pharmacological treatment for patients with Acute Lymphoblastic Leukemia based on 3 cycles of chemotherapy (21 days duration per cycle); plus a cross-training routine using implements without any extra weight to improve stability, joint mobility and general strength of the body. An individualized program with exercises supervised by a trainer and basic medical team will be developed for each patient during their hospital stay. Each training routine will have a monthly exercise progression based on intensity, frequency and / or duration.
62364159|NCT03044080|ACTIVE_COMPARATOR|IncobotulinumtoxinA|Injection of 200-300 units of IncobotulinumtoxinA (Xeomin ®)
62364160|NCT03044080|ACTIVE_COMPARATOR|OnabotulinumtoxinA|Injection of 200-300 units of onabotulinumtoxiA (Botox®)
62364161|NCT05592041|EXPERIMENTAL|Treatment group (Group I)|
62364162|NCT05592041|NO_INTERVENTION|Control group (Group II)|
62364163|NCT05265793|EXPERIMENTAL|Camrelizumab Combined With Apatinib|"Apatinib tablets: 250mg qd.po, 4 weeks as a cycle, continuous medication until disease progression, death or intolerable toxicity;~Camrelizumab: administered intravenously with a fixed dose of 200mg, administered intravenously (without preventive medication), each infusion for 30min (no less than 20min, no more than 60min), administered once every two weeks until disease progression, death or intolerable toxicity. The maximum period is 2 years.~The curative effect was evaluated every 8 weeks."
62739305|NCT02023580|ACTIVE_COMPARATOR|Control|The video control arm will complete baseline, 3-, 6-, 9-, and 12-month online survey assessments. The control arm will receive the same number (and timing of) video clips as the intervention arm, but from a non-theoretically driven gay-oriented show with videos that are similar in length in order to preserve dosing equality across both arms. As the video treatment arm will be provided efficacious theory-driven videos, investigators expect to find a significant decrease in sexual risk behaviors in the intervention arm, compared to the control arm. Should this occur by month 6, with agreement from the data safety monitoring board (DSMB), investigators will provide the control arm with the video treatments.
62174555|NCT01074437|OTHER|Group A: Corticosteroid with Placebo|Group A will receive oral, liquid Prednisolone, which is the standard corticosteroid that we use here at Seattle Children's, and oral liquid placebo. The dose of prednisolone that Group A will receive will be 1-2mg/kg/day for 7 days and then the dose will be slowly reduced and then stopped after 3 weeks. This is a standard dose for IH treatment. Gastric prophylaxis (Zantac) will be given to help prevent any stomach problems associated with prednisolone. This treatment will be given for two months, as is our standard practice.
62174556|NCT01074437|OTHER|Group B: Corticosteroid with Propranolol|Group B will receive oral liquid prednisolone, and oral propranolol. As in Group A, the dose of prednisolone will be 1-2mg/kg/day for 7 days and then the dose will be slowly reduced and then stopped after 3 weeks. Oral liquid propranolol will be dosed at 2 mg/kg/day, following initiation in the Cardiology Clinic. Gastric prophylaxis (Zantac) will be given to help prevent any stomach problems associated with prednisolone.
62364164|NCT05830526|OTHER|Escape Room|All of the participants were trained in the escape room.
62364165|NCT04029623|EXPERIMENTAL|Partnered Rhythmic Rehabilitation (PRR)|Participants in this study are will receive the PRR intervention. Participants will have two phases of intervention. In the three-month Training phase, participants will be assigned to 20, biweekly (90-minute) lessons over 12 weeks. In the nine-month Maintenance phase, participants will attend weekly lessons at least 3 times per month.
62364166|NCT04029623|ACTIVE_COMPARATOR|Group walking (WALK)|Participants in this study are will receive the WALK intervention. Participants will have two phases of intervention. In the three-month Training phase, participants will be assigned to 20, biweekly (90-minute) lessons over 12 weeks. In the nine-month Maintenance phase, participants will attend weekly lessons at least 3 times per month.
62364167|NCT00294684|EXPERIMENTAL|Corticosteroids|
62364168|NCT00294684|PLACEBO_COMPARATOR|Placebo|
62364169|NCT00909818|ACTIVE_COMPARATOR|standard fractionated radiotherapy|50 Gy/25 fractions, 2.00 Gy/fraction, 5 fractions per week
62364170|NCT00909818|EXPERIMENTAL|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
62364171|NCT01475318|EXPERIMENTAL|misoprostol + mifepristone + letrozole|
62364172|NCT01282567|OTHER|diabetic patients|
62364173|NCT02546310|EXPERIMENTAL|HTL0009936 high dose|high dose infusion
62364174|NCT02546310|EXPERIMENTAL|HTL0009936 low dose|low dose infusion
62364175|NCT02546310|PLACEBO_COMPARATOR|HTL0009936 matching placebo|matching infusion
62364176|NCT03842501|PLACEBO_COMPARATOR|Placebo|
62364177|NCT03842501|EXPERIMENTAL|Release supplement|
62364178|NCT02336048|ACTIVE_COMPARATOR|Placebo + Obinutuzumab + Chlorambucil|Participants will receive placebo and standard premedications on Days 1 and 2 of Cycle 1 (cycle length= 28 days) along with obinutuzumab and chlorambucil administered for 6 cycles.
62364179|NCT02336048|EXPERIMENTAL|Tocilizumab + Obinutuzumab + Chlorambucil|Participants will receive tocilizumab and standard premedications on Days 1 and 2 of Cycle 1 (cycle length= 28 days) along with obinutuzumab and chlorambucil administered for 6 cycles.
62174557|NCT01405534||Central venous catheter|All patients who require the placement of a central venous catheter
62364180|NCT03933280|ACTIVE_COMPARATOR|Group P|nalbuphine/propofol group
62364181|NCT03933280|ACTIVE_COMPARATOR|Droup D|Nalbuphine/dexmedetomidine group
62739306|NCT00615693|EXPERIMENTAL|1|
62739307|NCT00551434|EXPERIMENTAL|1|
62739308|NCT00551434|EXPERIMENTAL|2|
62739309|NCT00551434|EXPERIMENTAL|3|
62739310|NCT00551434|PLACEBO_COMPARATOR|4|
62364182|NCT05951543|EXPERIMENTAL|plyometric group|Experimental group will be given baseline exercises along with plyometric exercises such as Vertical jump, run and jump, drop jump (jump height between 40 and 50 cm) drop jump and horizontal jump with same height from 3rd week.particepents perform exercises carrying medicine balls. Participants will place their hands on the wall and performed foot stretches with the feet apart, 30 to 50 cm from the wall. Side row, biceps stretch and frontal row. Throwing and receiving, with a distance between 3 to 4 m.
62364183|NCT05951543|OTHER|dynamic balance group control group|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises
62364184|NCT06438965||Patient with neuromuscular disease|Muscle regions of the patients with neuromuscular diseases will be imaged using the MSOT device. Repeated measurements will be done after 6-12 months.
62364185|NCT04373018|ACTIVE_COMPARATOR|Sodium hypochlorite|Procedure/Surgery: Thirty mandibular molars treated with root canal treatment by using Sodium hypochlorite during biomechanical preparation.
62364186|NCT04373018|ACTIVE_COMPARATOR|Chlorhexidine|Procedure/Surgery: Thirty mandibular molars treated with root canal treatment by using Chlorhexidine during biomechanical preparation.
62364187|NCT04373018|EXPERIMENTAL|Chlorhexidine + Hydrogen peroxide|Procedure/Surgery: Thirty mandibular molars treated with root canal treatment by using a combination of Chlorhexidine + Hydrogen peroxide during biomechanical preparation.
62364188|NCT04134728|EXPERIMENTAL|GSK3196165 90 mg|Entire treatment period (24 Weeks): GSK3196165 90 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as standard of care (SoC).
62364189|NCT04134728|EXPERIMENTAL|GSK3196165 150 mg|Entire treatment period (24 Weeks): GSK3196165 150 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
62364190|NCT04134728|ACTIVE_COMPARATOR|Sarilumab 200 mg|Entire treatment period (24 Weeks): Sarilumab 200 mg SC injection every other week + placebo SC injection in the intervening weeks. Participants will also receive a stable dose of csDMARD(s) as SoC.
62364191|NCT04134728|PLACEBO_COMPARATOR|Placebo sequence 1|From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: GSK3196165 90 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
62364192|NCT04134728|PLACEBO_COMPARATOR|Placebo sequence 2|From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: GSK3196165 150 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
62364193|NCT04134728|PLACEBO_COMPARATOR|Placebo sequence 3|From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: Sarilumab 200 mg SC injection every other week + placebo SC injection in the intervening weeks. Participants will also receive a stable dose of csDMARD(s) as SoC.
62364194|NCT01482468|ACTIVE_COMPARATOR|continuous infusion|continuous infusion of palonosetron added to prophylactic single injection of palonosetron
62364195|NCT01482468|PLACEBO_COMPARATOR|singel injection|continuous infusion of normal saline added to prophylactic single injection of palonosetron
62364196|NCT02530099|NO_INTERVENTION|Control group|Receive no training.
62364197|NCT02530099|EXPERIMENTAL|CN-group|Receive basic camera navigation training.
62364198|NCT02530099|EXPERIMENTAL|Procedure-group|Receive training on a laparoscopic procedure.
62364199|NCT03780413|ACTIVE_COMPARATOR|PR-ESSENCE treatment|The treatment group receives PR-ESSENCE for 10 weeks. Outcome measures are collected pre- and post-treatment, and after 6 months and one year.
62364200|NCT03780413|ACTIVE_COMPARATOR|Control (TAU)|"The control group receives 10 weeks of treatment as usual (TAU) (that is the standard psychoeducation, support and treatment given to all youth after neuropsychiatric assessment at our clinic), followed by 10 weeks of PR-ESSENCE. Outcome measures were collected pre- and post-treatment, and after 6 months and one year."
62364201|NCT04393909|ACTIVE_COMPARATOR|Control group|Patients do not have access to the Patient Dx Questionnaire.
62364202|NCT04393909|ACTIVE_COMPARATOR|Patient Dx Questionnaire User group|Patient enrollees will be randomized to receive the Patient Dx Questionnaire administered by the research staff at the bedside.
62364203|NCT03373344|EXPERIMENTAL|Experimental Group|Participants in the experimental group will receive emotional processing training exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
62364204|NCT03373344|PLACEBO_COMPARATOR|Control Group|"Participants in the control group will meet with the examiner the same frequency and for the same duration as those in the experimental group.~They will receive placebo control exercises administered on a laptop computer."
62364205|NCT05883839||Student Group|"Three scales (knowledge, attitude, self-efficacy) in the Sexual Healthcare Questionnaire will be applied to 2nd and 3rd year nursing students. The scales will be re-administered to at least 30 students within 4 weeks."
62364206|NCT03983460|EXPERIMENTAL|Dupimulab arm|"At Day 0, patients will receive Dupilumab treatment. The recommended dose of Dupilumab for adult patients is an initial dose of 600mg followed by 300mg given every two weeks administered as subcutaneous injection. Dupilumab could be self-administered by subcutaneous injection into thigh or abdomen or injected in the upper arm in case of administration by the patient's caregiver. It is recommended to rotate the injection site with each injection.~At the end of treatment period, patient with AD IGA \>1 will stop the study and patient with AD IGA≤1 will enter in a 3 months-follow-up period. During this period, they will stop treatment initiated at Day 0 and apply rescue TCS if appearance of AD lesion within 3 months. Patients will note in their diary the applications of rescue TCS. The relapse is defined as the necessity to apply TCS rescues."
62550239|NCT04269473|EXPERIMENTAL|Experimental Group|Participants in the experimental group will receive a telehealth gait retraining intervention in addition to standard physical therapy rehabilitation for running-related knee pain, which includes: an at-home exercise program, a return to running protocol, and standard physical therapy evaluations.
62739311|NCT02488135|EXPERIMENTAL|Floseal Hemostatic Matrix|Patients will receive Floseal Hemostatic Matrix topically at the location of active bleeding. Floseal is a gel-like fibrin glue that is applied using a syringe and forms a hemostatic clot.
62364207|NCT03983460|ACTIVE_COMPARATOR|Optimized TCS treatment arm|"At Day 0, patients will receive topical corticosteroid treatment (TCS) adapted to the AD severity (potent and very potent TCS) with a personal therapeutic education for treatment optimization. It will be asked to perform, every day, an application of topical corticosteroid (TCS) (betamethasone valerate cream 0.1%, and if not active, clobetasol propionate cream 0.05%) on active lesions. Once the AD lesion is cleared, the patients will continue to apply TCS on healed lesions, twice a week until the end of the treatment period to prevent relapse.~At the end of treatment period, patient with AD IGA \>1 will stop the study and patient with AD IGA≤1 will enter in a 3 months-follow-up period. During this period, they will stop treatment initiated at Day 0 and apply rescue TCS if appearance of AD lesion within 3 months. Patients will note in their diary the applications of rescue TCS. The relapse is defined as the necessity to apply TCS rescues."
62364208|NCT03661372|ACTIVE_COMPARATOR|Face-to-Face|Face-to-Face Group: At the beginning of the session self-efficacy will be measured. This group will receive an instructor-led 45 minute long lecture on how to evaluate work, love, and play behavioral health form on a standardized patient. A face-to- face standardized patient scenario will test the participant on the application of work, love, and play assessment. In this scenario, the participant will meet a standardized patient in the exam room to discuss a behavioral health concern. At the end of each session (approximately 2 hours later), self-efficacy will be measured.
62364209|NCT03661372|ACTIVE_COMPARATOR|Robot|Robot Group: At the beginning of the session self-efficacy will be measured. This group will receive an instructor-led 45 minute long lecture on how to evaluate work, love, and play behavioral health form on a standardized patient. A robot (telesimulated) standardized patient scenario will test the participant on the application of work, love, and play assessment. In this scenario, the participant will meet a standardized patient in the exam room via a robot to discuss a behavioral health concern. At the end of each session (approximately 2 hours later), self-efficacy will be measured.
62364210|NCT03723408|OTHER|Single Arm post-approval study|Single Arm post-approval study.
62364211|NCT03706040|PLACEBO_COMPARATOR|Placebo|Participants randomized to receive placebo for 16 weeks in Period A followed by either risankizumab 150 mg or risankizumab 300 mg for 36 weeks in Period B.
62364212|NCT03706040|EXPERIMENTAL|Risankizumab 150 mg|Participants randomized to receive risankizumab 150 mg for 16 weeks in Period A followed by risankizumab 150 mg for 36 weeks in Period B.
62364213|NCT03706040|EXPERIMENTAL|Risankizumab 300 mg|Participants randomized to receive risankizumab 300 mg for 16 weeks in Period A followed by risankizumab 300 mg for 36 weeks in Period B.
62364214|NCT05128695||Covid-19 positive|Adults who tested Covid-19 positive
62364215|NCT05128695||Covid-19 negative|Adults who tested Covid-19 negative
62364216|NCT00655811|ACTIVE_COMPARATOR|Capsaicin|Capsaicin 0.1% cream application to the volar side of forearm.
62364217|NCT00655811|PLACEBO_COMPARATOR|Placebo moisturizing cream|Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.) to the opposite forearm.
62364218|NCT01444872|EXPERIMENTAL|TRV120027|TRV120027 administered as an IV infusion
62364219|NCT01444872|PLACEBO_COMPARATOR|Normal Saline|Normal Saline administered as an IV infusion
62364220|NCT01197092|ACTIVE_COMPARATOR|Verum|
62364221|NCT01197092|EXPERIMENTAL|Control|
62364222|NCT01614795|EXPERIMENTAL|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 1 hour and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.
62364223|NCT01614041|ACTIVE_COMPARATOR|Control Group|Patient randomized to control group is administrated with usual dose of tandospirone treatment, 30 mg/day
62364224|NCT01614041|EXPERIMENTAL|Study Group|Comparative high dose of tandospirone treatment, 60 mg/day
62364225|NCT03162094|EXPERIMENTAL|AVX-012 Opthalmic Solution Low dose|"Phase I: AVX-012 ophthalmic solution Low dose administration three times per day (TID) for 7 days~Phase II: If the low dose of AVX012 is selected on phase I, AVX-012 ophthalmic solution Low dose administration three times per day (TID) and two times per day (BID) for 28 days"
62364226|NCT03162094|EXPERIMENTAL|AVX-012 Opthalmic Solution High dose|"Phase I: AVX-012 ophthalmic solution High dose administration three times per day (TID) for 7 days~Phase II: If the high dose of AVX012 is selected on phase I, AVX-012 ophthalmic solution High dose administration three times per day (TID) and two times per day (BID) for 28 days"
62364227|NCT03162094|PLACEBO_COMPARATOR|Placebo (Vehicle) Opthalmic Solution|"Phase I: Placebo ophthalmic solution administration three times per day (TID) for 7 days~Phase II: Placebo ophthalmic solution administration three times per day (TID) and two times per day (BID) for 28 days"
62364228|NCT02475629|EXPERIMENTAL|Open-Label Ibalizumab plus OBR|2000 mg intravenous ibalizumab (loading dose) on Day 7 followed in 14 days (on Day 21) by 800 mg intravenous ibalizumab administered once every two weeks, plus an Optimized Background Regimen (OBR) beginning on Day 14.
62364229|NCT03571503||Integrative Korean medicine treatment|Herniated lumbar disc (HLD) patients with radiating leg pain in the integrative Korean medicine treatment group will be administered integrative Korean medicine treatment consisting of 2 sessions/day of acupuncture, and herbal medicine, Chuna manual therapy, bee venom pharmacopuncture and pharmacopuncture, electroacupuncture, cupping, and other interventions, as needed.
62364230|NCT03571503||Doin with integrative Korean medicine|Herniated lumbar disc (HLD) patients with radiating leg pain in the Doin (conduction exercise) with integrative Korean medicine treatment group will be administered integrative Korean medicine treatment consisting of 2 sessions/day of acupuncture, and herbal medicine, Chuna manual therapy, bee venom pharmacopuncture and pharmacopuncture, electroacupuncture, cupping, and other interventions, as needed, plus Doin (conduction exercise) for 1 session of the 2 sessions/day of acupuncture.
62364231|NCT04949828||Participants on CREON|
62364232|NCT03926637||Study Participants|Participants with MS, including CIS will complete the MSPT at their standard of care visits.
62550240|NCT04269473|ACTIVE_COMPARATOR|Control Group|Participants in the control group will receive standard physical therapy rehabilitation for running-related knee pain, which includes: an at-home exercise program, a return to running protocol, and standard physical therapy evaluations.
62550241|NCT04173325|EXPERIMENTAL|Nivolumab and Irinotecan|Drug: Nivolumab 360mg IV Day 1 of each 21 day cycle until disease progression or unacceptable toxicity + Drug: Irinotecan 500mg IV Day of each 21 day cycle for 2 cycles Followed by maintenance nivolumab (without irinotecan)
62364233|NCT03696446|EXPERIMENTAL|Virtual Cardiac Rehabilitation Program|This group will receive access to the NWC (NexJ Connected Wellness TM (NCW) and will be provided with a fitness tracker (Garmin Vivofit 3) to monitor their exercise, sedentary behaviours, and sleep patterns. The NWC platform includes components for education (health library, workbooks etc), collaboration (personal care plan, appointment scheduler, secure messaging system etc), and motivation (motivational messages on their homepage etc). With the Health Coach, participants will engage in: reviews of their risk factor profile and health priorities; goal setting and action planning; problem solving and skill building; and discussions of relapse prevention. Participants will receive a total of seven hours of health coaching delivered across nine sessions over a 26-week period
62364234|NCT03696446|OTHER|Case Managed Home Program|The Case Managed Home Program (CMHP) is delivered primarily via telephone. Following their CR intake, patients are linked with their CMHP Health Coach and attends their visit (in person or over the phone) which includes a comprehensive review of their health history, current symptoms, medications, activity, and individual concerns. Following this visit, participants will receive a total of 10 individualized telephone calls over a 26 week period. The program action plan is individually formulated based on the participant's goals and learning needs. Participants are provided with educational kits (exercise, nutrition, stress management or prevention) that are based on the principle of single point learning and incorporate behavioural change techniques.
62364235|NCT01674985|EXPERIMENTAL|Decitabine and cytarabine|induction therapy：decitabine 25mg/m2 daily for 4 days with cytarabine 150 mg/m2 daily for 7 days consolidation：decitabine 25mg/m2 daily for 4 days with cytarabine 2g/m2 q12h for 3 days
62364236|NCT06283225|EXPERIMENTAL|Intervention group|the intervention group has access to the dysmenorrhoea app and its functions in addition to normal regular care.
62364237|NCT06283225|NO_INTERVENTION|Control group|the intervention group has access to normal regular care only.
62364238|NCT05854797|ACTIVE_COMPARATOR|Normal Walking Group|Adhering to FITT method, normal walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 3.5 mph
62364239|NCT05854797|EXPERIMENTAL|Brisk Walking Group|Adhering to FITT method, brisk walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 4.5 mph.
62364240|NCT00844324|EXPERIMENTAL|A|Candesartan cilexetil 1mg/mL
62364241|NCT00844324|EXPERIMENTAL|B|Candesartan cilexetil 1.6mg/mL
62364242|NCT00630708|ACTIVE_COMPARATOR|1|Benazepril group
62364243|NCT00630708|ACTIVE_COMPARATOR|2|Losartan group
62364244|NCT00630708|ACTIVE_COMPARATOR|3|Benazepril+Losartan group
62364245|NCT05042557||Sun Yat-sen University Cancer Center|
62364246|NCT05042557||hanghai Chest Hospital|
62364247|NCT05042557||Tianjin Cancer Hospital|
62364248|NCT05042557||Fudan University Shanghai Cancer Center|
62364249|NCT05042557||Anhui Cancer Hospital|
62364250|NCT05042557||Shandong Cancer Hospital|
62739312|NCT02488135|ACTIVE_COMPARATOR|Traditional Nasal Packing|Patients will receive traditional nasal packing to try and abort bleeding. This includes either vaseline gauze or nasal merocels being inserted into the anterior nasal cavity using forceps. These expand upon contact with blood or liquid therefore creating a compression type hemostasis.
62739313|NCT03478254||Vaccination adherence|All type 1 diabetes adults patients attended in Ciudad Real General University Hospital willl be checked for Influenza Vaccination status, Pneumococcal Vaccination status and Hepatitis B Virus (HBV) status.
62739314|NCT06658314|ACTIVE_COMPARATOR|Experimental: interventional group 1(Kinesiotaping)|Kinesiotape will be applied by using two I-bands application technique. It will be applied once a week for 3 to 5 days and total time period of 3 weeks.
62739315|NCT06658314|EXPERIMENTAL|Experimental :interventional group II (Graded exposure therapy)|Graded exposure therapy consists of set of exercises, performed for 3 weeks with 3 sessions per week. Each exercise protocol has 5 to 10 repetitions per day.
62739316|NCT04224714|EXPERIMENTAL|Coronary heart disease patient|Quantitative coronary angiography (QCA) showed that there was a critical lesion in the proximal or middle segment of the coronary artery (diameter stenosis rate was 50% - 70%), and the diameter of the artery was more than 2.5mm
61997444|NCT05451771|EXPERIMENTAL|Phase 1: Venetoclax 400mg + Dexamethasone 10 mg|Cohort 3: Venetoclax 400 mg tablet, once daily and Dexamethasone 10 mg tablet once weekly, for up to 2 cycles after achieving best response, for a maximum of 6 cycles (1 cycle = 28 days)
62364251|NCT05042557||Hunan Cancer Hospital|
62364252|NCT05042557||Yunnan Cancer Hospital|
62364253|NCT05042557||Chinese Academy of Medical Sciences|
62364254|NCT00701441||Control group: healthy individuals without OSA|healthy individuals without OSA who are matched in weight and age to the participating OSA patients
62364255|NCT00701441||OSA group|Patients in the OSA group receive CPAP for 12 weeks as part of their care. patients with OSA provide measures at baseline and after 12 weeks of CPAP treatment.
62364256|NCT01936272|ACTIVE_COMPARATOR|Chhabra Shunt Placement|The shunting arm will comprise a standard frontal approach ventriculoperitoneal shunt using a silastic Chhabra system.
62364257|NCT01936272|ACTIVE_COMPARATOR|ETV/CPC|The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) arm will comprise a standard frontal approach with flexible endoscopy.
62364258|NCT05522296||Unvaccinated|Unvaccinated individuals who have risk factors for mpox infection and do not have a past history of mpox infection
62364259|NCT05522296||Vaccinated|Vaccinated individuals with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara) who have risk factors for monkeypox infection and do not have a past history of mpox infection.
62364260|NCT02754661|EXPERIMENTAL|COLON Capsule endoscopy|"Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the CCE procedure day. With the exception of Gastrografin, all colon preparation products will be standard colon cleansing products approved by the FDA.~Between 45 and 75 minutes after the final Polyethylene Glycol (PEG) ingestion, the subject will swallow the PillCam COLON Capsule with a cup of water.~If necessary, capsule position will be monitored to ensure adequate booster administration. Subjects will keep a timed diary of key preparation steps and bowel activity, including capsule excretion. Subjects will be allowed to leave the unit 10 hours after capsule ingestion if the capsule is not yet excreted. Subjects leaving before excretion will be instructed to disconnect the recorder at excretion or 12 hours after capsule ingestion (whichever comes first)."
62364261|NCT02754661|ACTIVE_COMPARATOR|Computed Tomographic Colonography|"Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the Computed Tomographic Colonography (CTC) procedure day.~The CTC procedure and study interpretation will be conducted in accordance with the ACR-SAR-SCBT-MR Practice Parameter for the Performance of CT Colonography in Adults. Colon insufflation will be performed with the subject in the lateral decubitus or supine position.With the subject in the supine position, a CT scout image will be taken to confirm adequate colon distention. If adequate bowel distention is not achieved, additional air will be insufflated into the colon. After scanning the subject in the supine position, the subject will be placed in the prone position, and additional CO2 will be administered. Subsequently, CT will be performed with the subject in the prone position. If a prone position is not possible for the subject, a left lateral decubitus position is preferred for optimal gas and fluid redistribution."
62364262|NCT04566757|EXPERIMENTAL|Umbilical Cord Plasma Infusion|Infusion of 50cc of Umbilical Cord Blood Plasma bi-monthly for 6 months
62364263|NCT05199883|EXPERIMENTAL|TI.VA group|The titration of Propofol and Remifentanil levels will be guided by TI.VA algorithm in the time between skin incision and completion of surgical resection.
62174558|NCT05255276|ACTIVE_COMPARATOR|Group 1 Treatment A|A single-dose administration of sitravatinib malate 50 mg on Day 1. Day 12, a single dose of sitravatinib malate 50 mg will be will be followed by a 72-hour PK sample collection period. Subjects will be discharged from the CRU on Day 4 after collection of 72-hour postdose PK sample and completion of all required study procedures.
62364264|NCT06343454|OTHER|Neutral Head Position|Neutral head position (PN), in which the head is positioned on the head-neck-spine plane.
62364265|NCT06343454|OTHER|Forward Head Position|Forward head position/active feeding position (PF), in which head is positioned 30° in front of head-neck-spine plane with forward head tilt.
62364266|NCT06343454|OTHER|Backward Head Position|Backward head position/drinking position (PB), in which the head is positioned 45° behind the head-neck-spine plane with backward head tilt.
62364267|NCT02255760|EXPERIMENTAL|MEDI3902 - Dose 1|Participants will receive a single intravenous (IV) dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
62364268|NCT02255760|EXPERIMENTAL|MEDI3902 - Dose 2|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
62364269|NCT02255760|EXPERIMENTAL|MEDI3902 - Dose 3|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
62364270|NCT02255760|EXPERIMENTAL|MEDI3902 - Dose 4|Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
62364271|NCT02255760|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
62364272|NCT04697160||Patients who received systemic therapies for R/R DLBCL|
62364273|NCT04477525|EXPERIMENTAL|ESP nerve block|
62364274|NCT04477525|NO_INTERVENTION|Standard of Care|Standard of care includes IV opioids, NSAIDs (commonly ketorolac), +/- acetaminophen. No regional anesthesia will be given to control patients.
62364275|NCT00510367|EXPERIMENTAL|Multimodality Treatment|"Multimodality (chemotherapy, surgery and radiation therapy) treatment:~5-Fluorouracil + Doxorubicin + Cyclophosphamide (FAC)"
62364276|NCT02030249|EXPERIMENTAL|High Protein / Low Glycaemic Index|A 10-month weight maintenance diet, administered from the 2-month to the 12-month time point, where protein intake is 25% of energy intake, carbohydrate intake is 45% of energy intake, dietary glycaemic index is \< 55. Please see parent study for further Arm details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview\&rank=1
62364277|NCT02030249|ACTIVE_COMPARATOR|Moderate Protein / High Glycaemic Index|A 10-month weight maintenance diet, administered from the 2-month to the 12-month time point, where protein intake is 15% of energy intake, carbohydrate intake is 55% of energy intake, dietary glycaemic index is \> 65. Please see parent study for further Arm details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview\&rank=1
62364278|NCT00516958|EXPERIMENTAL|1|Topical Dermacyn
62364279|NCT00516958|ACTIVE_COMPARATOR|2|Topical Dermacyn and levofloxacin
62364280|NCT00516958|ACTIVE_COMPARATOR|3|Topical saline and levofloxacin
62364281|NCT03301233|ACTIVE_COMPARATOR|estradiol valerate|oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma). One tablet every 12 hour from 2nd day of the cycle till the day of trigger of ovulation).
62364282|NCT03301233|EXPERIMENTAL|estradiol valerate and sildenafil|oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25 mg, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
62364283|NCT03636880|EXPERIMENTAL|Brief treatment for insomnia|Brief Behavioral Treatment for Insomnia (BBTI) is a manualized, individual intervention designed to modify sleep patterns to reduce insomnia and improve sleep quality and efficiency. Participants complete two in-person meetings and two booster telephone calls over a four-week period.
62364284|NCT03636880|ACTIVE_COMPARATOR|Sleep Monitoring|Sleep Monitoring is an active comparator condition where participants track their sleep patterns for two weeks prior to the baseline and post-intervention assessments. They receive no contact from study staff during the intervening four-week period, except for a reminder call to begin completing the second sleep diary and to schedule the post-intervention assessment.
62364285|NCT03690674|EXPERIMENTAL|Lifestyle Enhancement for ADHD Program|There is no comparison/control arm.
62364286|NCT00841672|EXPERIMENTAL|Aliskiren/amlodipine 300/10 mg tablet|Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg.
62364287|NCT00841672|ACTIVE_COMPARATOR|Amlodipine 10 mg capsule|Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg.
62364288|NCT03457636|EXPERIMENTAL|doxycycline anhydrous and adapalene/benzoyl peroxide|All subjects will receive at Baseline doxycycline anhydrous 40 mg (Oracea) to be taken once daily and Adapalene-Benzoyl Peroxide Gel .3-2.5% (Epiduo) to be applied once daily for 12 weeks
62364289|NCT02792049|EXPERIMENTAL|Modified Ambu Spur II bag valve mask|A health volunteer uses a modified Ambu Spur II bag valve mask with integrated internal handle (experimental device, not yet FDA approved) to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model).
62364290|NCT02792049|ACTIVE_COMPARATOR|Conventional Ambu Spur II bag valve mask|A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model).
62364291|NCT06183736|EXPERIMENTAL|Single-arm|This is a single-arm, open-label, multicenter, phase II study of CVL237 tablets in the treatment of advanced solid tumors with PTEN deficiency.All patients will be given CVL237 tablets, 200 mg, taken with food once daily for 28 consecutive days as a treatment cycle.
62364292|NCT05342142|ACTIVE_COMPARATOR|Exercise|Exercise program consisting of 12 weeks of aerobic and resistance exercises
62364293|NCT05342142|NO_INTERVENTION|Control|No intervention will be made
62364294|NCT04348435|EXPERIMENTAL|Allogeneic HB-adMSCs 200MM|Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 200 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.
62364295|NCT04348435|EXPERIMENTAL|Allogeneic HB-adMSCs 100MM|Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 100 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.
62364296|NCT04348435|EXPERIMENTAL|Allogeneic HB-adMSCs 50MM|Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 50 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.
62364297|NCT04348435|PLACEBO_COMPARATOR|Placebo|Subjects assigned to this arm will receive 5 intravenous infusions of placebo intervention (saline). Infusions will occur at weeks 0, 2, 6, 10, and 14.
62364298|NCT00876486|EXPERIMENTAL|Genexol®-PM|This is a open-labeled, randomized, parallel, phase III Trial. Up to 106 elgible patients will be enrolled in each treatment arm(Total 212 subjects will recruited) according to the trial design. Patients will be randomly allocated to arm A (Genexol-PM) or arm B (Paclitaxel).
62364299|NCT00876486|ACTIVE_COMPARATOR|Genexol®|This is a open-labeled, randomized, parallel, phase III Trial. Up to 106 elgible patients will be enrolled in each treatment arm(Total 212 subjects will recruited) according to the trial design. Patients will be randomly allocated to arm A (Genexol-PM) or arm B (Paclitaxel).
62364300|NCT02055170|EXPERIMENTAL|finasteride|finasteride 5mg po od from study entry to date of surgery
62364301|NCT04324086|EXPERIMENTAL|XP-endo Finisher file|removal of calcium hydroxide intracanal medication with XP-endo Finisher file
62364302|NCT04324086|EXPERIMENTAL|Irrisafe Ultrasonic tip|removal of calcium hydroxide intracanal medication with passive ultrasonic irrigation
62364303|NCT04324086|ACTIVE_COMPARATOR|side vented needle|removal of calcium hydroxide intracanal medication with conventional syringe irrigation
62364304|NCT05970068|EXPERIMENTAL|Group 1: Surgery + best medical treatment|The intervention group would receive the novel treatment of implantation of hydrophobic tubes for edema fluid drainage and the best medical treatment available.
62364305|NCT05970068|ACTIVE_COMPARATOR|Group 2: best medical treatment|This control group would receive only the best medical treatment available.
62364306|NCT00618813|EXPERIMENTAL|Treatment (combination chemotherapy)|See Detailed Description
62174559|NCT05255276|ACTIVE_COMPARATOR|Group 1 Treatment B|On Days 9 to 11, itraconazole 200 mg will be administered QD in the morning. On Day 12, a single dose of sitravatinib malate 50 mg will be coadministered with itraconazole. Itraconazole QD dosing will continue on Days 13 to 18 to maintain steady state during the PK sample collection period.
62174560|NCT05255276|ACTIVE_COMPARATOR|Group 2 Treatment A|A single-dose administration of sitravatinib malate 100 mg on Day 1 will be followed by a 72-hour PK sample collection period. Subjects will be discharged from the CRU on Day 4 after collection of 72-hour postdose PK sample and completion of all required study procedures.
62174561|NCT05255276|ACTIVE_COMPARATOR|Group 2 Treatment B|On Days 9 to 15, rifampin 600 mg will be administered QD in the morning. On Day 16, a single dose of sitravatinib malate 100 mg will be coadministered with rifampin followed by a 72 hour PK sample collection period. Rifampin QD dosing will continue on Days 17 to 22 to maintain steady state during the PK sample collection period.
62174562|NCT00694135|ACTIVE_COMPARATOR|EGP-437 1.6 mA-min at 0.4 mA|Ocular iontophoresis with EGP 437 1.6 mA-min at 0.4 mA
62174563|NCT00694135|ACTIVE_COMPARATOR|EGP-437 4.8 mA-min at 1.2 mA|Ocular iontophoresis with EGP-437 4.8 mA-min at 1.2 mA
62174564|NCT00694135|ACTIVE_COMPARATOR|EGP-437 10.0 mA-min at 2.5 mA|Ocular iontophoresis with EGP-437 10.0 mA-min at 2.5 mA
62174565|NCT00694135|ACTIVE_COMPARATOR|EGP-437 14.0 mA-min at 3.5 mA|Ocular iontophoresis with EGP-437 14.0 mA-min at 3.5 mA
62174566|NCT05317221||All patients|The is only 1 arm: all breast cancer patients undergoing surgery.
62174567|NCT06337240||Pelvic floor exercises on COPD patients|30 COPD female patients with urinary incontinence will receive pelvic floor exercises.
62174568|NCT05469763|EXPERIMENTAL|Circuit training exercise plus calcium tablets group|Study Group: they will receive circuit training exercise, 3 sessions per week for 12 weeks, in addition to calcium supplements.
62174569|NCT05469763|OTHER|Calcium tablets group|Control Group: they will receive daily dosage of calcium supplements 1-3 g/ day
62182382|NCT02828163|ACTIVE_COMPARATOR|Triamcinolone acetonide|Triamcinolone acetonide is an effective treatment for oral erosions of pemphigus vulgaris patients. 10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
62364307|NCT03568695|OTHER|Detected patients|If they agree to participate in the study, the patients detected for one or the other of the STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium) on one site, will have on day of result return, two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
62364308|NCT00064077|EXPERIMENTAL|Arm I (paclitaxel, cisplatin)|Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.
62364309|NCT00064077|EXPERIMENTAL|Arm II (vinorelbine, cisplatin)|Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.
62364310|NCT00064077|EXPERIMENTAL|Arm III (gemcitabine, cisplatin)|Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.
62364311|NCT00064077|EXPERIMENTAL|Arm IV (topotecan, cisplatin)|Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.
62364312|NCT01716988||Micafungin|
62364313|NCT03979872|ACTIVE_COMPARATOR|Arm 1: Skin Cancer Education Only|Participants will be randomized to receive education only.
62364314|NCT03979872|EXPERIMENTAL|Arm 2: Skin Cancer Education + UV Photo|Participants randomized to receive education + UV photo will have a UV light photo taken of their face to show UV damage in the skin that is invisible to the naked eye in addition to receiving skin cancer education.
62364315|NCT03979872|EXPERIMENTAL|Arm 3: Skin Cancer Education + MC1R Testing|Participants randomized to receive education + genetic testing will be asked to provide a saliva sample for MC1R testing in addition to receiving skin cancer education.
62364316|NCT03979872|EXPERIMENTAL|Arm 4: Skin Cancer Education + UV Photo + MC1R Testing|Participants randomized to receive education + UV photo + genetic testing will have a UV light photo taken of their face, Submit a saliva sample for MC1R testing, and receive skin cancer education.
62364317|NCT03581682|EXPERIMENTAL|Tele-Visit Using Parental Home Echo|All parents will have hands-on echo training. We will test if a tele-visit using parental home echo is clinically reliable compared to an on-site clinic visit, costs less, and improves parental sense of empowerment.
62364318|NCT02533661|EXPERIMENTAL|Family-centered intervention program|"The FCIP group received:~1. In-hospital intervention: modulation of the NICU, teaching of child development skills, feeding support,massage,parent support and education,transition home preparation.~2. After-discharge: clinic (1, 2, 4, 9 months) and home visits (0, 6, 12 months) for teaching of child development skills, feeding support, dyadic interaction activities, modulations of home environment, parent support and education."
62364319|NCT02533661|NO_INTERVENTION|Usual care program|"The UCP group received:~1. In-hospital intervention: environmental modulation and teaching of child development skills.~2. After-discharge:telephone calls (0, 1, 2, 4, 6, 9 and 12 months): consultation on general care concerns"
62364320|NCT05130268|EXPERIMENTAL|Dronedarone|In most patients, the investigators anticipate usual care to include an atrioventricular nodal blocking agent (beta-blocker, non-dihydropyridine calcium channel blocker, or digoxin) without an antiarrhythmic. As dronedarone has anti-adrenergic rate controlling properties, a low dose of beta-blocker or calcium-channel blocker is recommended in the United States Prescribing Information (USPI) when starting dronedarone. In the dronedarone arm concomitant digoxin use will be contraindicated due to P-gp interaction based upon data from the PALLAS trial. All patients will receive oral anticoagulation for stroke prevention according to current guideline recommendations.
62364321|NCT05130268|NO_INTERVENTION|Usual care|In most patients, the investigators anticipate usual care to include an atrioventricular nodal blocking agent (beta-blocker, non-dihydropyridine calcium channel blocker, or digoxin) without an antiarrhythmic. All patients will receive oral anticoagulation for stroke prevention according to current guideline recommendations.
62364322|NCT02509676|EXPERIMENTAL|dynamic stretching exercise|This group will perform dynamic stretching exercise to their left side gastrocnemius muscles for 5 weeks (5 days a week, 3 sets of exercise a day, each set including 5 repetitions of dynamic stretching lasting 45 seconds)
62364323|NCT02509676|NO_INTERVENTION|control|this group will not perform any stretching exercises for 5 weeks
62364324|NCT01003613|ACTIVE_COMPARATOR|Tranilast|CAT with FG and Tranilast and MMC 0.02%
62364325|NCT01003613|PLACEBO_COMPARATOR|Control|CAT with FG and MMC 0.02%
62364326|NCT05459766|EXPERIMENTAL|AO+MI|Video-clips observation representing motor contents, followed by motor imagery (12 minutes a day per 3 days).
62364327|NCT05459766|ACTIVE_COMPARATOR|CTRL|Usual care, consisting of preoperative education.
62174570|NCT04451031|EXPERIMENTAL|LiFT Program|LiFT is a two-module curriculum workshop for youth and their parenting adults. Topics for youth include communication skills, condom use, and skill building to access sexual healthcare resources. For parenting adults, topics include building a climate of trust and open communication with youth about sexual health. Trained and certified facilitators deliver each 2.5 hour module over one or two sessions. Youth and parents participated in simultaneous but separate programming in community locations such as schools or health care settings. They received participant guides that encourage communication between them. They could opt-in to receive 12 weekly texts that offered additional resources. Parenting adults received a phone call from the facilitator a month after the workshop to reinforce the skills learned during the program.
62174571|NCT04451031|NO_INTERVENTION|Comparison Group|The comparison group received business as usual. The youth and parents enrolled in the study could receive the existing services available within the broader community, which may have included sexual education delivered in the local school system. Study staff collected data throughout the study to track access to other TPP programming offered at the study sites.
62364328|NCT01589263|ACTIVE_COMPARATOR|ARM 1: onaBoNT-A + placebo|onaBoNT-A 200 U prostate injection and placebo oral capsule daily
62364329|NCT01589263|ACTIVE_COMPARATOR|ARM 2: Saline + Tamsulosin|Placebo prostate injection (saline) and tamsulosin 0.4 mg capsule daily.
62364330|NCT00568620|EXPERIMENTAL|1: Nasogastric feeding tube|
62364331|NCT00568620|EXPERIMENTAL|2: Placement of nasojejunal feeding tube|
62739317|NCT02408718|ACTIVE_COMPARATOR|Training group|Subjects randomized to this group will receive a 6 week Assistive Device Training program in the use of their assistive device. They will have mobility assessments taken at baseline, after the training program has been completed, and 3 months later. During this time, their falls will be recorded monthly using prospective falls calendars. Members of this group will also receive MRI scans at baseline and after the completion of the training program.
62364332|NCT04949425|EXPERIMENTAL|Patients with advanced solid tumours|Patients with advanced solid tumours will receive Adavosertib once daily for 5 days followed by 2 days off for 2 weeks out of a 21-day cycle.
62364333|NCT04568811|EXPERIMENTAL|Adenovirus Type-5 Vectored COVID-19 Vaccine|
62364334|NCT02445703|EXPERIMENTAL|Group 1 (HAV + HAV)|"Intervention: Inactivated Hepatitis A vaccine (HAV);~Subjects in this group each received 2 doses of inactivated HAV with a 6-month interval (day 0, month 6);~Route of administration: intramuscular injection in deltoid region;"
62364335|NCT02445703|EXPERIMENTAL|Group 2 (HAV + HABV)|"Intervention: Inactivated Hepatitis A vaccine (HAV) and Combined hepatitis A and hepatitis B vaccine (HABV);~Subjects in this group each received 1 dose of inactivated HAV at day 0, and 1 dose of HABV at month 6.~Route of administration: intramuscular injection in deltoid region;"
62174572|NCT05325476|EXPERIMENTAL|JomPrEP App Group|Participants in the TAU group will receive the JomPrEP app with major intervention features inactivated; information and resources for HIV testing, PrEP, and available mental health and addiction services will be available along with access to risk assessment tools. The Research Assistant will assist in downloading the app and provide a tutorial in using the assessment tool of the app.
62364336|NCT02445703|EXPERIMENTAL|Group 3 (HABV + HABV)|"Intervention: Combined hepatitis A and hepatitis B vaccine (HABV);~Subjects in this group each received 2 doses of HABV with a 6-month interval (day 0, month 6);~Route of administration: intramuscular injection in deltoid region;"
62364337|NCT03747536|EXPERIMENTAL|Intervention|ipratropium bromide administered via metered dose spray (21 micrograms per spray). 1-2 spray sublingual or to buccal mucosa every 6 hours up to 4 times a day
62364338|NCT03747536|PLACEBO_COMPARATOR|Placebo|normal saline administered via metered dose spray. 1-2 spray sublingual or to buccal mucosa every 6 hours up to 4 times a day
62364339|NCT03436147||Vaginal Assisted Laparoscopic Sacrohysteropexy(VALH)|Patients who were performed vaginal assisted laparoscopic sacrohysteropexy (VALH)
62364340|NCT03436147||Vaginal Hysterectomy and Vaginal vault suspension (VAH+VVS)|Patients who were performed vaginal hysterectomy and vaginal vault suspension(VAH+VVS)
62364341|NCT03498976|OTHER|Pulsed radiofrequency on SE nerve|Single technic
62364342|NCT03498976|OTHER|Pulsed radiofrequency on SE + CF nerves|Combinated technic
62364343|NCT04290403|EXPERIMENTAL|Pull ups|Pull-up continence products
62364344|NCT04290403|EXPERIMENTAL|Styled briefs with tapes|Styled briefs with tapes
62364345|NCT01455233|ACTIVE_COMPARATOR|besivance|ocular antibiotic
62364346|NCT01455233|ACTIVE_COMPARATOR|vigamox|ocular antibiotic
62364347|NCT01150760||Alvimopan Users|
62364348|NCT01150760||Matched controls|
62364349|NCT02175303|EXPERIMENTAL|Decidual stromal cell therapy for toxicity and inflammation|Patients with toxicity, inflammation or hemorrhages will receive decidual stromal cells at approximately 1x10\^6 cells/kg at one or more occasions at weekly intervals dependent on clinical response.
62364350|NCT00381719|EXPERIMENTAL|1|3 mg
62364351|NCT00381719|EXPERIMENTAL|2|20 mg
62364352|NCT00381719|EXPERIMENTAL|3|60 mg
62739318|NCT02408718|NO_INTERVENTION|Wait-list control|Subjects in this group will participate in the same mobility assessments and completion of the falls calendars, but will receive no intervention during this time. These subjects will have the opportunity to receive the training sessions when all assessment visits have been completed. These subjects will not receive MRI scans.
62364353|NCT00381719|PLACEBO_COMPARATOR|4|Placebo
62364354|NCT04153929|EXPERIMENTAL|BI 456906 0.3 mg|
62364355|NCT04153929|EXPERIMENTAL|BI 456906 0.9 mg|
62364356|NCT04153929|EXPERIMENTAL|BI 456906 1.8 mg|
62364357|NCT04153929|EXPERIMENTAL|BI 456906 2.7 mg|
62364358|NCT04153929|EXPERIMENTAL|BI 456906 1.2 twice weekly (2.4) mg|
62739319|NCT01825148||Type 1 Diabetes|patients with long standing T1D
62739320|NCT01825148||Healthy volunteer|healthy volunteers with normal glucose tolerance
62739321|NCT06045858|ACTIVE_COMPARATOR|Warfarin|Warfarin (Coumadine): INR target \[2.0-3.0\]
62174573|NCT05325476|ACTIVE_COMPARATOR|Treatment as usual|Participants in the JomPrEP group will be provided with full app access. The Research Assistant will use an onboarding checklist to orient participants to download the app and its use. Participants will be encouraged to explore and use all components of the app. Participants will be able to personalize the frequency, timing, and content for daily adherence support and weekly behavioral feedback messages and receive reminders for regular PrEP care. Participants can also contact the Research Assistant using the chat function for support and assistance with linkage to services.
62739322|NCT06045858|EXPERIMENTAL|Apixaban|Apixaban (Eliquis) at 2.5mg, per os, twice a day
62739323|NCT03637361|PLACEBO_COMPARATOR|Arm 1|100 mL Ocean Spray® Diet Cranberry Juice
62364359|NCT04153929|EXPERIMENTAL|BI 456906 1.8 twice weekly (3.6) mg|
62364360|NCT04153929|ACTIVE_COMPARATOR|Semaglutide|
62364361|NCT04153929|PLACEBO_COMPARATOR|Placebo|
62364362|NCT02731976|EXPERIMENTAL|GFD|After instruction of a dietician, participants adhered to a gluten-free diet for 4 weeks.
62364363|NCT02266004|EXPERIMENTAL|tDCS+ LT|Transcranial direct current stimulation(tDCS) plus locomotor training (LT) 3x per week for 3 consecutive weeks.
62364364|NCT03976518|EXPERIMENTAL|ATEZOLIZUMAB|Atezolizumab will be administered at a flat dose of 1200 mg by intravenous route. Atezolizumab will be delivered in 250-mL 0.9% NaCl (sodium chloride) intravenous (IV) infusion bags. The administration will be repeated every 3 weeks (21 \[± 3\] days). The initial dose will be delivered over 60 (± 15) minutes. In case the first infusion is tolerated without any infusion-associated AEs the second infusion may be delivered over 30 (± 10) minutes. If the second 30 minutes infusion is well tolerated all the subsequent infusions may be administered over 30 (± 10) minutes. The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
62364365|NCT01999348||Patients with POAG or OHT|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
62364366|NCT01107288|EXPERIMENTAL|Intervention group|Randomized to receive the intervention first
62364367|NCT01107288|OTHER|Delayed intervention control group|Randomized to wait-list control first
62364368|NCT05351190|OTHER|Treatment Arm|All participants will be given a rtCGM (Dexcom G6) to assess their glycemic control.
62364369|NCT05210621|OTHER|Patients with MS who have completed the CONSONANCE study|
62364370|NCT03064269|EXPERIMENTAL|Arm 1|CD19 CAR-T cells treated central nervous system B-cell acute lymphocytic leukemia.
62364371|NCT00198367|EXPERIMENTAL|Cisplatin-Gemzar|Cisplatin-Gemzar
62364372|NCT00198367|EXPERIMENTAL|Cisplatin-Navelbine-Radiotherapy|Cisplatin-Navelbine-Radiotherapy
62364373|NCT00198367|EXPERIMENTAL|Carboplatin-Taxol-Radiotherapy|Carboplatin-Taxol-Radiotherapy
62364374|NCT01489761|ACTIVE_COMPARATOR|zotarolimus-eluting stent|Resolute Integrity or Resolute Onyx stent
62364375|NCT01489761|EXPERIMENTAL|everolimus-eluting stent|Xience Prime or Xience Xpedition or Xience Alpine stent
62364376|NCT02180490|EXPERIMENTAL|UHAC 62 XX tablet|
62364377|NCT02180490|ACTIVE_COMPARATOR|UHAC 62 XX capsule|
62174574|NCT04760327|EXPERIMENTAL|Electrochemotherapy of gynecological cancers|
62364378|NCT01927887|EXPERIMENTAL|Nanoparticle MRI|Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
62364379|NCT02020291|EXPERIMENTAL|Foxy-5|Slow infusion of lyophilised and reconstituted Foxy-5 three times weekly on Monday, Wednesday and Friday for three weeks.
62364380|NCT00588523|EXPERIMENTAL|1|temozolomide followed by high dose busulfan and thiotepa
62364381|NCT05872698|ACTIVE_COMPARATOR|Carvedilol|Oral Carvedilol 6.25 mg to 12.5 mg OD/ or 6.25mg BD (maximum dose 12.5mg)
62364382|NCT05872698|PLACEBO_COMPARATOR|Placebo|Oral tablet (1 or 2 tablets)
62364383|NCT00889980||Melanoma|Patients with primary melanoma
62364384|NCT06043934|EXPERIMENTAL|Neural Mobilization with Intermittent Cervical Traction|Patients in this experimental group will receive neural mobilization with intermittent cervical traction and routine physical therapy.
62364385|NCT06043934|ACTIVE_COMPARATOR|Neural Mobilization|Patients in this control group will receive neural mobilization and routine physical therapy.
62364386|NCT02239367|EXPERIMENTAL|Depression Decision Aid protocol|The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention. Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower the elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
62364387|NCT06241820|OTHER|Lumbar Sympathetic Ganglion Block (LSGB)|FS-guided LSGB at L3 level.
62364388|NCT03678818|EXPERIMENTAL|Handling Medium Supplemented with Latrunculin A|
62364389|NCT03678818|NO_INTERVENTION|Handling Medium as it is.|
62364390|NCT04111653|EXPERIMENTAL|Single arm|Healthy volunteers
62364391|NCT04493463|EXPERIMENTAL|methylprednisolone + ropivacaine + saline|The local infiltration solution in the methylprednisolone plus ropivacaine with saline group (treatment group) will consist of 1 ml of 40 mg methylprednisolone plus 15ml of 1% ropivacaine and 14 ml saline.
62364392|NCT04493463|ACTIVE_COMPARATOR|ropivacaine + saline|The local infiltration solution in the ropivacaine plus saline group (control group) will consist of 15 ml of 1% ropivacaine and 15ml saline.
62364393|NCT05719077|EXPERIMENTAL|Intervention Group|Clinicians in intervention group will watch a series educational and instructional videos and use caregiver burden assessment tool up to four times during regular home visits with family caregivers of home hospice patients living with dementia. Clinicians will be assessed for changes in knowledge regarding dementia caregiving (secondary outcome). Family caregivers will be assessed for changes in caregiver burden (primary outcome) and preparedness and self-efficacy (exploratory outcomes).
62364394|NCT05719077|OTHER|Control Group|Clinicians in control group will listen to a presentation on outcomes for home hospice patients living with dementia. Clinicians will be assessed for changes in knowledge regarding dementia caregiving (secondary outcome). Family caregivers will be assessed for changes in caregiver burden (primary outcome) and preparedness and self-efficacy (exploratory outcomes).
62364395|NCT00084604|EXPERIMENTAL|Treatment (bevacizumab, cisplatin, irinotecan)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive cisplatin IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62364396|NCT03023605|NO_INTERVENTION|Pre-intervention PE Diagnosis|Patients visited in Emergency Department, with suspected Pulmonary Embolism, before the training intervention.
62364397|NCT03023605|EXPERIMENTAL|Post-intervention PE Diagnosis|"Patients visited in Emergency Department, with suspected Pulmonary Embolism, after the training intervention.~Training intervention centered on emergency department staff, regarding the application of clinical probability scores (Wells and Geneva scores) to guide the determination of D-dimer and the performance of pulmonary CT in patients with suspected pulmonary embolism."
62364398|NCT04984460||life-style counseling|"A sample of one or more of the following characteristics. Symptoms: vulva pruritus, burning pain, but also accompanied by pain in urine and sexual pain and other symptoms; Leucorrhea increased.~Physical signs: Vulva flushing, edema, visible scratches or chaps, white membrane attached to the inner side of the labia minora and the vaginal mucosa, more white bean residue like secretions can be seen in the vagina, which can be curd."
62364399|NCT03513289||Patient, Carer, and Clinician Interviews|This group/cohort consists of patients who experienced critical illness and were hospitalized in an ICU setting.
62364400|NCT01852630|EXPERIMENTAL|cefepime + Albumin|cefepime 1g iv 8 hourly + Albumin will be given for 2 days.
62364401|NCT01852630|ACTIVE_COMPARATOR|Imipenem + Albumin|Imipenem 1g iv 8 hourly + Albumin will be given for 2 days.
62739324|NCT03637361|EXPERIMENTAL|Arm 2|REL-1017 5 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
62739325|NCT03637361|EXPERIMENTAL|Arm 3|REL-1017 20 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
62174575|NCT03925662|ACTIVE_COMPARATOR|Folfox with avastin|Folfox with avastin only
62174576|NCT03925662|EXPERIMENTAL|Mebendazole|Folfox with avastin with mebendazole
62174577|NCT05168514|EXPERIMENTAL|Massage|"Massage begins with the patting (eflorage) maneuver. Massage is continued with petrissage, bearing, friction and percussion maneuvers.~Maneuvers are performed for 3-5 minutes. A patting motion is performed between maneuvers and at the end of the massage. During the massage, it is observed whether the integrity of the skin is impaired or in terms of redness."
62174578|NCT01747837|NO_INTERVENTION|standard ICD implantation alone|These subjects will undergo standard ICD implantation alone (if not already present)
62174579|NCT01747837|EXPERIMENTAL|Boston Scientific Vessix Renal Denervation System|"These subjects will undergo standard ICD implantation (if not already present) plus renal sympathetic denervation.~Ablation arm"
62174580|NCT03868098|ACTIVE_COMPARATOR|Crisaborole 2% (application rate A, B, C)|Crisaborole (Marketed drug)
62739326|NCT03637361|EXPERIMENTAL|Arm 4|REL-1017 60 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
62364402|NCT02499575|ACTIVE_COMPARATOR|Regional Block|Group A patients will receive only a pre-operative adductor canal block with 10 mL 0.5% ropivacaine plus a popliteal block with 30 mL 0.5% ropivacaine (total block 40 mL/200 mg).
62364403|NCT02499575|EXPERIMENTAL|Regional Block Plus Exparel|Group B patients will receive the standard of care pre-operative adductor and popliteal block as described (40 mL/200 mg of 0.5% ropivacaine) in addition to a postoperative pericapsular injection of Exparel using 106 mg (8 mL, equivalent to 120 mg bupivacaine HCl), per the same total dose as provided in manufacturer recommendations.
62364404|NCT00365768|EXPERIMENTAL|Arm I: Glutamine|Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.
62364405|NCT00365768|PLACEBO_COMPARATOR|Arm II: Placebo|Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.
62364406|NCT02435862|EXPERIMENTAL|1.0mg Luminate®|1.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
62364407|NCT02435862|EXPERIMENTAL|2.0mg Luminate®|2.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
62364408|NCT02435862|EXPERIMENTAL|3.0mg Luminate®|3.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
62364409|NCT02435862|PLACEBO_COMPARATOR|Balanced Salt Solution 0.10cc|Balanced Salt Solution 0.10cc injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
62364410|NCT03703960|EXPERIMENTAL|"Group 1 Hypnosis"|
62364411|NCT03703960|ACTIVE_COMPARATOR|"Group 2 music"|
62364412|NCT03703960|NO_INTERVENTION|Control group|
62364413|NCT00126672|EXPERIMENTAL|Ramaycin|Rapamycin treatment was initiated with a loading dose of 6 mg by mouth on day 1 followed by 2 mg by mouth daily. The dose was then adjusted to maintain a target blood level of 3-9 ng/ml for the first 16 weeks. After week 16, the dose of Rapamycin was increased to a target level of 9-15 ng/ml unless there was evidence for a partial response or complete response by kidney MRI. Trough Rapamycin levels were checked every 8-12 weeks (at 24 weeks, 32 weeks, 40 weeks, and 52 weeks) in all patients until the 12-month (week 52) study visit. If the Rapamycin dose was below target, the dose was increased by 1-2 mg until the target trough level was achieved. Rapamycin levels were checked every 2-3 weeks while the dose was adjusted. Amendment 20 (Jan 2009) permitted additional Rapamycin treatment during months 12-24 if the treating site investigator judged that this was in the best interest of the study participant.
62364414|NCT03420313|EXPERIMENTAL|Interim Buprenorphine Treatment|"Interim Buprenorphine Treatment includes (a) Maintenance treatment with Buprenorphine/ naloxone sublingual tablets with bi-monthly clinic visits for observed dosing and the remaining doses dispensed at home via a secure computerized portable device (Med-O-Wheel, Addoz, Finland).~(b) nightly calls from an automated Interactive Voice Response (IVR) phone system to assess any drug use, withdrawal and craving, (c) IVR-generated random call-backs for urinalysis and pill counts, and (d) HIV+Hepatitis education delivered via iPad. (e) monthly follow-up assessments"
62364415|NCT03420313|NO_INTERVENTION|Waitlist Control|Waitlist Control participants will remain on the waitlist for their treatment of choice but complete the same monthly assessments.
62364416|NCT00719524|EXPERIMENTAL|1|
62364417|NCT01462968|ACTIVE_COMPARATOR|Activated clotting time (ACT) group|heparinization measured as activated clotting time during surgery
62364418|NCT01462968|EXPERIMENTAL|Hepcon group|heparinization measured as heparin concentration in the blood during surgery
62364419|NCT04673669|EXPERIMENTAL|Single group|measuring the strength of the tendon of the posterior tibial muscle in healthy subjects with a hand-held dynamometer by two examiners and with an isometric dynamometer
62364420|NCT02338167||Advanced/metastatic breast cancer|3,500 patients with locally advanced, inoperable/metastatic breast cancer in any line of treatment (e.g. 1st, 2nd, 3rd, or ≥ 4th line).
62364421|NCT02338167||Early breast cancer|10,000 patients with breast cancer in the neoadjuvant and adjuvant (early breast cancer) setting independent of treatment regimen.
62364422|NCT04466813|EXPERIMENTAL|Deep Dry Needling|Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle
62364423|NCT04466813|SHAM_COMPARATOR|Sham Dry Needling|Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle
62364424|NCT01562145||Patients with rotator cuff tears|Patients with ultrasound verified rotator cuff tears
62174581|NCT03868098|PLACEBO_COMPARATOR|Placebo ointment (vehicle)|Placebo
62364425|NCT01562145||Healthy controls|Age and gender matched controls with ultrasound verified intact rotator cuff
62364426|NCT01143714|ACTIVE_COMPARATOR|A|
62364427|NCT01143714|PLACEBO_COMPARATOR|B|
62364428|NCT04572698|EXPERIMENTAL|LY09004|LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
62364429|NCT04572698|ACTIVE_COMPARATOR|EYLEA|EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
62364430|NCT04123431||ACE Acetabular Cup System with XLPE Liner|
62364431|NCT04123431||ACE Acetabular Cup System with Ceramic Liner|
62364432|NCT04123431||ACE Acetabular Cup System with Dual Mobility Insert|
62364433|NCT04229069|ACTIVE_COMPARATOR|Basica|4-week dietary supplementation with an alkaline salt (Basica)
62364434|NCT04229069|PLACEBO_COMPARATOR|Placebo|4-week dietary supplementation with a placebo
62364435|NCT01755741|EXPERIMENTAL|Placebo Vaginal Ring|Placebo vaginal ring with condom use
62364436|NCT01755741|OTHER|Condom|Male condoms during vaginal intercourse in presence and absence of the vaginal ring.
62364437|NCT05521646|EXPERIMENTAL|Intervention|QiC implemented
62364438|NCT05521646|NO_INTERVENTION|Control|
62364439|NCT03705260|ACTIVE_COMPARATOR|Comparator- High Risk|A high risk sub group of those assigned to the comparator arm will be identified by their most recent A1C \> 8. Patients in this group will receive usual care from their Primary Care Physician and dietitian.
62364440|NCT03705260|ACTIVE_COMPARATOR|Comparator- Well Controlled|The low risk sub group from the comparator arm (A1C \< 8) and those who are unlikely to benefit from an intensive behavioral intervention will get usual care by their Primary Care Physician and their dietitian.
62739327|NCT03637361|EXPERIMENTAL|Arm 5|REL-1017 100 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
62174582|NCT02775279||Acute coronary syndrome group|200 consecutive patients were recruited, who have diagnosed with acute coronary syndrom(ACS) by quantitative coronary angiography.
62364441|NCT03705260|EXPERIMENTAL|Enhanced Care- High Risk|A high risk sub group of those assigned to the enhanced care arm will be identified by their most recent A1C \> 8. Patients in this group will receive the intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
62364442|NCT03705260|EXPERIMENTAL|Enhanced Care- Well Controlled.|The low risk sub group from the enhanced care arm (A1C \< 8) and those who are unlikely to benefit from an intensive behavioral intervention will get usual care by their PCP and their dietitian. If they are found to be poorly controlled through monthly screening for risk, they may have the opportunity to move into the Enhanced Care High Risk group.
62364443|NCT00899678|ACTIVE_COMPARATOR|Maintenance High-Dose|Maintenance High-Dose group: 400 mg Certolizumab Pegol for subjects ≥ 40 kg or 200 mg Certolizumab Pegol for subjects 20 to \< 40 kg
62364444|NCT00899678|ACTIVE_COMPARATOR|Maintenance Low-Dose|Maintenance Low-Dose group: 200 mg Certolizumab Pegol for subjects ≥ 40 kg or 100 mg Certolizumab Pegol for subjects 20 to \< 40 kg
62364445|NCT05636904|EXPERIMENTAL|DLQ01 high dose|Twice daily application of DLQ01 high dose cutaneous solution in 30 subjects
62364446|NCT05636904|EXPERIMENTAL|DLQ01 low dose|Twice daily application of DLQ01 low dose cutaneous solution in 30 subjects
62364447|NCT05636904|PLACEBO_COMPARATOR|active ingredient-free vehicle solution to DLQ01|Twice daily application of DLQ01 vehicle cutaneous solution in 30 subjects
62364448|NCT05636904|ACTIVE_COMPARATOR|Minoxidil Solution 5%|Twice daily application of the comparator cutaneous solution in 30 subjects
62364449|NCT06245681||Transgender women|Transgender individuals assigned male at birth undergoing estrogen and antiandrogen hormone therapy
62364450|NCT06245681||Transgender men|Transgender individuals assigned female at birth undergoing testosterone hormone therapy
62364451|NCT01559701|EXPERIMENTAL|PF-00345439 (oxycodone)|PF-00345439 (oxycodone)
62364452|NCT05474989|EXPERIMENTAL|Verum|Subjects in the treatment arm will receive 150 μg LSD (first session) and 150 or 250 μg LSD (second session).
62364453|NCT05474989|ACTIVE_COMPARATOR|Active placebo|Subjects in the control arm will receive 10 µg LSD at the first session and 10 µg LSD at the second session.
62364454|NCT02928666|EXPERIMENTAL|DSS for recommendation interactions|participants may use the DSS for mitigating interactions between recommendations to detect interactions between guideline recommendations and find sets of non-conflicting recommendations. In addition, they may look at the relevant clinical guidelines and additional medical knowledge sources regarding drug-drug relationships, indications and contraindications.
62364455|NCT02928666|NO_INTERVENTION|No DSS|participants use only the relevant clinical guidelines and additional medical knowledge sources regarding drug-drug relationships, indications and contraindications to detect interactions between guideline recommendations and find sets of non-conflicting recommendations
62364456|NCT04913571|EXPERIMENTAL|TMB High group|
62364457|NCT04913571|EXPERIMENTAL|PD-L1 positive group|
62364458|NCT04913571|EXPERIMENTAL|Immunomodulatory (IM) group|
62364459|NCT04913571|EXPERIMENTAL|NanoString superiority group|
62364460|NCT04913571|EXPERIMENTAL|other types|
62364461|NCT05169736|EXPERIMENTAL|Internet-based Cognitive Behavior Therapy|ICBT, were participants receive 8 out of 15 possible modules, depending on their current problems and needs, 8 week long internet intervention for coping with mental health issues related to the climate crisis.
62364462|NCT05169736|NO_INTERVENTION|Wait-list control|Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention.
62364463|NCT00578422||Arm I: In Vitro IVUS Plaque studies|IVUS of Amputation Specimens
62364464|NCT00578422||Arm 2: Obserational Study|IVUS for patients undergoing standard lower extremity angiography for PAD.
62364465|NCT00475371|EXPERIMENTAL|1|MKC253 Inhalation Powder
62364466|NCT05904938|EXPERIMENTAL|Lenodiar Pediatric|Medical Device
62364467|NCT05904938|PLACEBO_COMPARATOR|Placebo|Placebo
62364468|NCT02539524|ACTIVE_COMPARATOR|Pulmonary Rehabilitation Group|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
62550242|NCT03435471|EXPERIMENTAL|G1 - Clinician-Directed Therapy|"Clinician-Directed Weekly Swallowing Therapy: Once weekly face-to-face meetings with a study speech pathologist for a total of six sessions, to participate in active swallowing exercises and review the home swallowing exercise program. Each session will last 30 minutes +/- ten minutes. Other assessments include:~* Clinician-Directed Prophylactic Swallowing Exercises~* Prophylactic Swallowing Home Exercise Program~* Penetration/Aspiration Scale (PAS)~* Functional Oral Intake Scale (FOIS)~* Eating Assessment Tool-10 (EAT-10)~* University of Washington Quality of Life (UW-QOL)~* Performance Status Scale for Head and Neck Cancer Patients (PSS-HN)~* DIGEST Safety Grade"
62364469|NCT02539524|EXPERIMENTAL|Yoga Group|Yoga Bhastrika Pranayama breathing exercises consisted of: 12-week pulmonary rehabilitation (two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs). After each pulmonary rehabilitation session, participants of this group performed 10 bhastrika pranayama breathing exercises (1 bhastrika is formed by 20 kapalabhati followed by 1 surya bedhana - described earlier).
62364470|NCT03087708|ACTIVE_COMPARATOR|Group I (lower dose naloxegol, placebo)|Patients receive lower dose naloxegol PO QD and placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
62364471|NCT03087708|ACTIVE_COMPARATOR|Group II (placebo, higher dose naloxegol)|Patients receive placebo PO QD and higher dose naloxegol PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
62364472|NCT03087708|PLACEBO_COMPARATOR|Group III (placebo)|Patients receive placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
62567145|NCT02044302|ACTIVE_COMPARATOR|standard analgesics|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Placebo application during surgery will be made to establish perfection in the study design in terms of randomization and blinding. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
62739328|NCT03637361|EXPERIMENTAL|Arm 6|REL-1017 150 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
62364473|NCT03208049|EXPERIMENTAL|Sleep Restriction Therapy|Sleep Restriction Therapy (SR). The initial Time in Bed (TIB) prescription is calculated on the average total sleep time (TST) reported in the baseline sleep logs. After one week, depending on subject's daily sleep logs and adherence to treatment, the therapist suggests a new TIB prescription. Napping is neither prescribed nor proscribed. However, if subjects find themselves having difficulty staying awake during the day, they are advised to take a brief (15 to 30 minutes) nap to ensure their safety.
62364474|NCT03208049|EXPERIMENTAL|Cognitive Therapy|Cognitive Therapy (CT). The CT treatment module is designed to meet three general goals: 1) identify dysfunctional sleep cognitions, 2) challenge their validity, and 3) replace them with more adaptive substitutes. Several specific techniques designed to meet these goals are discussed in materials distributed to subjects. Similar to SR, subjects in CT are provided with information about relevant elements of the science of sleep and healthy sleep practices.
62364475|NCT02758912|EXPERIMENTAL|arm 1, Cardionat®|oral intake of study drug capsules at a dose of 1 g per day for 3 weeks.
62364476|NCT02758912|EXPERIMENTAL|arm 2, Cardionat®|oral intake of study drug capsules at a dose of 2 g per day for 3 weeks.
62364477|NCT05446922|OTHER|MRI imaging of 10 healthy volunteers|10 healthy volunteers will proceed at an brain MRI imaging
62364478|NCT00735098|EXPERIMENTAL|1|KBA exercise protocol
62364479|NCT00735098|EXPERIMENTAL|2|strength training exercise protocol
62364480|NCT00735098|EXPERIMENTAL|3|KBA and strength training protocol
62364481|NCT00735098|SHAM_COMPARATOR|4|
62364482|NCT03940014||Pulmonary arteriovenous malformations|"Patients with hereditary haemorrhagic telangiectasia (HHT)-related Pulmonary Arteriovenous Malformations (PAVMs). For all patients, the final diagnosis of certain HHT the diagnosis can be made depending on the presence of four criteria known as the Curaçao criteria: 1) Spontaneous recurrent epistaxis 2) Multiple telangiectasias in typical locations 3) Proven visceral Arteriovenous Malformations (AVM) (lung, liver, brain, spine) 4) First-degree family member with HHT. If conditions three or four are met, a patient has definite HHT, while condition two is considered as possible HHT. All patients had a molecular diagnosis and all follow-up clinical assessments were available in the database."
62364483|NCT03688945|EXPERIMENTAL|Arm I (art sessions)|Participants attend at least 1 session of viewing art pieces over 15 minutes every day for 2 years.
62364484|NCT03688945|ACTIVE_COMPARATOR|Arm II (standard of care)|Participants receive standard of care for 2 years.
62364485|NCT02999191|EXPERIMENTAL|BI 1467335 (Treatment A)|Tablet under fasted conditions
62364486|NCT02999191|EXPERIMENTAL|BI 1467335 (Treatment B)|Oral solution under fasted conditions
62364487|NCT02999191|EXPERIMENTAL|BI 1467335 (Treatment C)|Tablet under fed conditions
62364488|NCT02095990|EXPERIMENTAL|Hydroquinone|"Hydroquinone 4% Cream will be applied in one side of the face while the other side of the face receives placebo.~Half of the patients will receive Hydroquinone on the right side of the face and the other half on the left side.~It will be applied daily, at night, during 8 weeks."
62364489|NCT02095990|PLACEBO_COMPARATOR|Placebo|"Placebo cream (vehicle of Hydroquinone 4% cream), will be applied in one side of the face, while the other side receives the active treatment.~Half of the patients will receive Hydroquinone on the right side of the face and the other half on the left side.~It will be applied daily, at night, during 8 weeks."
62364490|NCT06052189||Easy laryngoscopy|Laryngeal view grading according to the modified Cormack and Lehane grading scale where grades 1 and 2a are considered easy laryngoscopy and grades 2b, 3, and 4 are considered difficult laryngoscopy.
62364491|NCT06052189||Difficult laryngoscopy|Laryngeal view grading according to the modified Cormack and Lehane grading scale where grades 1 and 2a are considered easy laryngoscopy and grades 2b, 3, and 4 are considered difficult laryngoscopy.
62174583|NCT02775279||Control group|The 200 healthy controls without previous CHD history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
62364492|NCT00846469|EXPERIMENTAL|chest pain|CCTA (Coronary computed tomography angiography)
62364493|NCT01921452|EXPERIMENTAL|POC TSH Kits + Third Generation TSH Kit|
62364494|NCT00081939|EXPERIMENTAL|Study Treatment|Two cycles of VDTPACE induction (Velcade days 1, 4, 8, and 11; DTPACE days 4-7) with interim thalidomide (50 mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle. Induction followed by single or tandem MEL200 transplant (MEL140 mg/m2 for subjects \> 70 years of age) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each transplant. Transplants followed by two cycles of VDTPACE consolidation (Velcade days 1, 4, 8, and 11; DTPACE days 1-4) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle of VDTPACE. Consolidation followed by 3 years of maintenance therapy with VDT (velcade 1.0 mg/m2 days 1, 4, 8, 11 q 28 days; Thal 100 mg QD; and Dex 20mg days 1-4 and 8-11 q 28 days) during Year 1 and TD (Thal 100 mg QD and Dex 20 mg days 1-4, q 28 days) or VTD (velcade 1.0 mg/m2 weekly, Thal 100 mg QD, and Dex 20 mg weekly) during Years 2 and 3.
62364495|NCT01318668|EXPERIMENTAL|Nicotine vaccination|18 week treatment with Nicvax
62364496|NCT02645461|ACTIVE_COMPARATOR|Riluzole|Riluzole 50 mg twice daily in ALS patients
62364497|NCT02645461|EXPERIMENTAL|PEA plus Riluzole|Riluzole 50 mg twice daily plus Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily in ALS patients
62364498|NCT04516031|ACTIVE_COMPARATOR|Mesh-only repair|
62364499|NCT04516031|ACTIVE_COMPARATOR|Transversus Abdominis Muscl|
62364500|NCT01918683|OTHER|A -Tace alone|A - TACE alone (control group, current practice and treatment)
61997445|NCT05451771|EXPERIMENTAL|Phase 1: Venetoclax 400mg + Dexamethasone 20 mg|Cohort 4: Venetoclax 400 mg tablet, once daily and Dexamethasone 20 mg tablet once weekly, for up to 2 cycles after achieving best response, for a maximum of 6 cycles (1 cycle = 28 days)
61997446|NCT05451771|EXPERIMENTAL|Phase 2: Venetoclax MTD with Dexamethasone|Venetoclax MTD (200 mg or 400 mg) with Dexamethasone (10 mg or 20 mg) as determined by the phase I results
62174584|NCT01618071|ACTIVE_COMPARATOR|Oleic acid|75 g high oleic acid sunflower oil.
62174585|NCT01618071|ACTIVE_COMPARATOR|Linoleic acid|75 g high linoleic acid sunflower oil.
62174586|NCT01618071|EXPERIMENTAL|Eicosapentaenoic acid and docosahexaenoic acid|5 g EPA and DHA derived from fish oil, made up to a total of 75 g with high oleic sunflower oil.
62174587|NCT01618071|EXPERIMENTAL|Docosahexaenoic acid|5 g DHA derived from algal oil, made up to a total of 75 g with high oleic sunflower oil.
62364501|NCT01918683|EXPERIMENTAL|B - Tace combined with SBRT|B- TACE combined with SBRT (experimental group).
62364502|NCT05939271||persons with DM who underwent a lower extremity amputation|
62364503|NCT05939271||persons with DM who did not underwent a lower extremity amputation|
62364504|NCT05939271||persons without DM who underwent a lower extremity amputation|
62364505|NCT03718676|OTHER|Ferric sulphate|Group FS. Teeth in this goup will pulpotomized with ferris-sulphate.
62364506|NCT03718676|EXPERIMENTAL|Orto-mta|Group O-MTA.Teeth in this goup will pulpotomized with Ortho-mta.
62174588|NCT04095598||Syndesmotic injured group|The existing index test (ankle CT in neutral position), the new index tests (ankle CT in a stress position with extended-knee; ankle CT in a stress position with flexed-knee), and the reference test (MRI) will be applied. Foot and ankle ability measurement questionnaire (FAAM) will be applied with six months and one year after ankle CT.
62364507|NCT03718676|EXPERIMENTAL|Retro-mta|Group R-MTA. Teeth in this goup will pulpotomized with Retro-mta.
62364508|NCT05381207|ACTIVE_COMPARATOR|Montelukast|Montelukast, 10 mg, oraly Local corticosteriod nasal spary
62364509|NCT05381207|NO_INTERVENTION|No drug|No drug taking , only local corticosteriod nasal spray
62364510|NCT03460613|OTHER|FGID Patients|
62364511|NCT03460613|NO_INTERVENTION|Hepatology Control Group|
62364512|NCT03460613|NO_INTERVENTION|Healthy Volunteers|
62364513|NCT05906576|EXPERIMENTAL|Infliximab|Infliximab for the treatment of Crohn's disease in children
62364514|NCT00251589|EXPERIMENTAL|Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 200 mg twice a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the study and determined to be the MTD and therefore the recommended Phase II dose. Of the 16 patients treated at this dose level, 4 were assigned to the Phase I portion of the study and 12 were assigned to the Phase II portion
62364515|NCT00251589|EXPERIMENTAL|Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 300 mg once a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the amended study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.
62364516|NCT00251589|EXPERIMENTAL|Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 300 mg twice a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.
62364517|NCT00251589|EXPERIMENTAL|Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 400 mg once a day for 21 out of 28 days + erlotinib 150 mg once a day was evaluated in the Phase I portion of the original study and exceeded MTD. This cohort was then amended (Amendment 1) to identify a more tolerable once daily vorinostat dosing regimen. All patients treated at this dose level were assigned to the Phase I portion of the study.
62364518|NCT01733836|EXPERIMENTAL|Metformin|850mg BID
62364519|NCT01733836|PLACEBO_COMPARATOR|Placebo|
62364520|NCT01831778||all women|women receiving mammography at one of 6 mammography registries across the country.
62364521|NCT04571476|EXPERIMENTAL|UTB-VBN-EBUS group|Ultrathin bronchoscope with a 3.0-mm outer diameter and a 1.7-mm working channel was used in this group. Specimens were obtained using 1.5-mm biopsy forceps and 1.4-mm cytology brush with the guidance of VBN and EBUS.
62364522|NCT04571476|ACTIVE_COMPARATOR|TB-VBN-EBUS-GS group|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel was used in this group. Specimens were obtained using 1.5-mm biopsy forceps and 1.4-mm cytology brush with the guidance of VBN-EBUS and a 1.95-mm outer diameter guide sheath.
62174589|NCT04095598||Syndesmotic uninjured group|The existing index test (ankle CT in neutral position), the new index tests (ankle CT in a stress position with extended-knee; ankle CT in a stress position with flexed-knee), and the reference test (MRI) will be applied. Foot and ankle ability measurement questionnaire (FAAM) will be applied with six months and one year after ankle CT.
62174590|NCT04315129|OTHER|Single arm|A single arm will have biosensor (experimental) diagnoses compared to clinical (control, current standard of care). All participants in this group willl have a biosensor, with the data masked to patients, providers and clinical researchers
62174591|NCT05531734|EXPERIMENTAL|volunteers|Health volunteers
62174592|NCT04141722|EXPERIMENTAL|Sleep|
62174593|NCT04141722|EXPERIMENTAL|Wake|
62182383|NCT02550483|ACTIVE_COMPARATOR|Beta-Carotene Tomato Juice|Participants will receive high beta-carotene tomato juice daily as part of controlled diet (base diet + high beta-carotene tomato juice).
62364523|NCT04571476|ACTIVE_COMPARATOR|TB-VBN-EBUS-non-GS group|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel was used in this group. Specimens were obtained using conventional biopsy forceps and cytology brush with the guidance of VBN and EBUS, but without guide sheath.
62364524|NCT03370913|EXPERIMENTAL|valoctocogene roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg
62364525|NCT05176860|EXPERIMENTAL|High-performance CBCT imaging|Two additional study imaging sets are acquired.
62364526|NCT02420990|ACTIVE_COMPARATOR|Behavioral Only- Treatment|All participants will receive behavioral interventions (CASH-AA): family psycho-education in ADHD symptoms, executive functioning, and developmental impacts; family-based motivation and ADHD accommodation interventions; and academic training focused on home environment support and organizational skills.
62364527|NCT02420990|EXPERIMENTAL|Integrated Treatment|Half of the participants will also receive medication decision-making interventions (MIP): ADHD medication psychoeducation, family decision-making interventions, and (for those who elect to start medication) coordinated medication management.
62364528|NCT00692588||Placebo|Subjects who received placebo in DARAD Trial
62364529|NCT00692588||Doxycycline|Subjects who received doxycycline in DARAD Trial
62364530|NCT00692588||Rifampicin|Subjects who received rifampicin in DARAD Trial
62364531|NCT00692588||Doxycycline and Rifampicin|Subjects who received doxycycline and rifampicin in DARAD Trial
62364532|NCT00692588||Control|Normal controls
62364533|NCT05063968|EXPERIMENTAL|Part A - Single Ascending Dose (SAD) phase: Experimental|
62364534|NCT05063968|PLACEBO_COMPARATOR|Part A - Single Ascending Dose (SAD) phase:Placebo|
62364535|NCT05063968|EXPERIMENTAL|Part B - Food Effect (FE) phase: Experimental 1|
62364536|NCT05063968|EXPERIMENTAL|Part B - Food Effect (FE) phase: Experimental 2|
62364537|NCT05063968|EXPERIMENTAL|Part C - multiple ascending dose (MAD) phase: Experimental|
62364538|NCT05063968|PLACEBO_COMPARATOR|Part C - multiple ascending dose (MAD) phase:Placebo|
62364539|NCT01498588|EXPERIMENTAL|Eribulin+Doxorubicin+Cyclophosphamide|"Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide~Eribulin Day 1 and Day 8 of a 21 day cycle x 4 cycles:~Day 1: Eribulin 1.4mg/m² IV~Day 8: Eribulin 1.4mg/m² IV~Dose-dense doxorubicin and cyclophosphamide every 14 days x 4 cycles:~Day 1: Doxorubicin 60mg/m² IV~Day 1: Cyclophosphamide 600mg/m² IV~Day 2: Pegfilgrastim support 6mg sc at least 24 hours after chemotherapy at the discretion of the investigator."
62364540|NCT01689766|OTHER|Technetium Tc 99m EC20|
62364541|NCT06307977|NO_INTERVENTION|No Intervention: CHTC as usual|Participants complete the standard Couples HIV Testing and Counseling session (CHTC).
62364542|NCT06307977|ACTIVE_COMPARATOR|Behavioral: Couples Health Project|A three-session intervention for couples addressing couples communication skills, substance use, sexual agreements. The intervention also includes couples HIV testing and counseling in the final session.
62364543|NCT01675206|ACTIVE_COMPARATOR|360 µg Vit K2|Administration of 360 µg of Vitamin K2 thrice weekly
62364544|NCT01675206|ACTIVE_COMPARATOR|720 µg Vit K2|Administration of 720 µg of Vitamin K2 thrice weekly
62364545|NCT01675206|ACTIVE_COMPARATOR|1080 µg Vit K2|Administration of 1080 µg of Vitamin K2 thrice weekly
62364546|NCT06269757|EXPERIMENTAL|Individualized Exercise Program|"Patients with diagnosed ITB syndrome indicated for non-operative management who are assigned to an individualized exercise program.~Duration of therapy will be approximately 3 months. Patients will be followed for 6 months to assess longitudinal outcomes."
62364547|NCT06269757|ACTIVE_COMPARATOR|Standard Physical Therapy|"Patients with diagnosed ITB syndrome indicated for non-operative management who are assigned to receive standard physical therapy.~Duration of therapy will be approximately 3 months. Patients will be followed for 6 months to assess longitudinal outcomes."
62364548|NCT02409147|EXPERIMENTAL|Patients|Healthy female volunteers wishing to have a childbirth via uterine transplantation
62364549|NCT03381911|NO_INTERVENTION|E-Consent|This arm is the standard of care, where the consent form is presented to the subject on a computer screen and he/she can scroll ahead and back as needed. There is also an option to have each screen read aloud.
62364550|NCT03381911|EXPERIMENTAL|ECA Consent|"In this arm an Embodied Conversational Agent (ECA) which is a computer generated character reads the consent form aloud to the subject, and also describes each section using a pre-loaded script. In addition, the character performs teach-back, where she asks the subject a question about the section that was just described, and then repeats the section if the question is answered incorrectly."
62364551|NCT01112982|OTHER|Febuxostat Sub-Study|"To analyze the effect of urate-lowering therapy (specifically with febuxostat \[Uloric\]) on the synovial pannus in the index joint of a subgroup of patients. Subjects not currently on any urate-lowering therapy, or on a serum urate lowering drug other than febuxostat (Uloric) and who have a serum urate level of \> or = to 9.0, will be treated with febuxostat (Uloric) and their serum urate level will be followed at months 1, 3, 6, and 9. Magnetic Resonance Imaging (with and without gadolinium) of the same index joint will be repeated at month 9 to assess for the presence and degree of synovial pannus. Because initiation of urate-lowering therapy can induce acute attacks of gout, these subjects will also be started on colchicine as a prophylactic (and remain on colchicine for 6 months)."
62364552|NCT01112982|OTHER|MRI of index joint|"To analyze synovial pannus in the Magnetic Resonance Imaging (with and without gadolinium) of the index joint on Subjects not currently on any urate-lowering therapy, or on a serum urate lowering drug other than febuxostat (Uloric)."
62364553|NCT04337723|EXPERIMENTAL|Intervention|Clinic participants will be taught how to do ABI testing and WIfI scoring to identify patients with PAD/DM disease for early vascular referral.
62364554|NCT01314469||Patients with intermediate uveitis|
62174594|NCT02446379||EnLightTM and LightPathTM Imaging Systems arm|"Patients will first be injected intravenously with 2-5 MBq/kg, up to a maximum 300 MBq of the marketed product 18F-fluorodeoxyglucose (FDG) and after this undergo tumour excision surgery according to standard of care.~The surgical cavity will be imaged by the EnLightTM system and the tumour excision specimen will be imaged by both the EnLightTM and LightPathTM Imaging Systems. The EnLightTM and LightPathTM Imaging Systems results will not influence any surgical or clinical decision-making. The tumour excision specimen will be analysed according to standard of care pathology. Patients will be followed-up (Visit 3) 2-14 days after the end of surgery for adverse events (AEs)."
62174595|NCT05755217|ACTIVE_COMPARATOR|Dark chocolate|Single dose of 1g/kg of dark chocolate (70% cocoa, Lindt Excellence)
62174596|NCT05755217|PLACEBO_COMPARATOR|White chocolate|Single dose of 1g/kg of white chocolate (4% cocoa, Nestle Galak).
62174597|NCT04850859||group of scapulae bones|Human adult dry scapulae bones 40 of unknown sex and age will be collected.
62174598|NCT04850859||group of hip bones|Human adult dry hip bones 40 of unknown gender and age will be collected
62364555|NCT02715596|EXPERIMENTAL|Intervention A|2.7 g EPA supplementation in a 15 cc emulsion stick-pack
62364556|NCT02715596|PLACEBO_COMPARATOR|Intervention B|Placebo supplementation in a 15 cc emulsion stick-pack
62364557|NCT01620008|NO_INTERVENTION|Immediate Cord Clamping (ICC)|The infant will be placed on the maternal abdomen and the umbilical cord will be clamped immediately after birth (routine care).
62364558|NCT01620008|EXPERIMENTAL|Delayed Cord Clamping (DCC)|At birth, infants will be placed on the maternal abdomen and the cord clamping will be delayed for 5 minutes. If the provider is unable to delay the cord clamping, the cord will be milked 5 times.
62364559|NCT05070741|EXPERIMENTAL|Heat Therapy Treatment|This study will recruit subjects to participate in heat therapy treatment at the University of Kansas Medical Center (KUMC). After pre-screening, informed consent, and enrollment, all subjects will have baseline laboratory assessments as well as an examination for neuropathy and a lower distal leg biopsy (3mm). Subjects will complete 12 heat therapy treatments over the course of 4 weeks. Within 24-48 hours after the last heat therapy experience, post-treatment laboratory assessments as well as an examination for neuropathy and a lower distal leg biopsy (3mm) will be performed.
62739329|NCT01764269|OTHER|inactivated influenza vaccine (IIV)|Patients whose provider chooses to administer to them inactivated influenza vaccine (IIV)
62739330|NCT01764269|OTHER|Live attenuated influenza vaccine (LAIV)|Patients whose provider chooses to administer to them Live attenuated influenza vaccine (LAIV)
62739331|NCT00316706|EXPERIMENTAL|Cervarix Group|Subjects received 3 doses of GSK Biologicals' HPV-16/18 Vaccine (Cervarix™) during the primary study (NCT00196924). Subjects from this group continued the long-term follow-up study until Month 48.
62174599|NCT02605772|EXPERIMENTAL|metformin+Saxagliptin|metformin 0.5g tablet Saxagliptin 5mg tablet metformin 0.5g three times a day for three months Saxagliptin 5mg one time a day for three months
62174600|NCT02605772|EXPERIMENTAL|acarbose+Saxagliptin|acarbose 50mg tablet Saxagliptin 5mg tablet Saxagliptin 5mg one time a day for three months acarbose 100mg three times a day for three months
62364560|NCT06013319|EXPERIMENTAL|Esmolol group|Patients with ARDS who require mechanical ventilation after adequate disease assessment and whose heart rate continues to be ≥95 beats/min, but ≤120 beats/min within 24 hours after diagnosis, for at least 10 minutes without changing the dosage of catecholamine, were diagnosed as atrial fibrillation, atrial flutter or sinus tachycardia. The primary treatment is maintained while the esmolol load dose is administered and the maintenance dose is pumped continuously until the patient's heart rate is maintained between 80 and 94 beats per minute.
62364561|NCT06013319|NO_INTERVENTION|Control group|Patients with ARDS who need mechanical ventilation after adequate condition assessment and whose heart rate continues to be ≥95 beats /min but ≤120 beats /min after optimal hemodynamic treatment within 24 hours after diagnosis were randomly included in the control group. Routine mechanical ventilation, full sedation and analgesia, maintain RASS score 0-2 points; The target tidal volume is 6ml/kg, and the ventilator parameters should be adjusted in time according to the blood gas analysis. Hypotensive patients with sufficient blood volume should be pumped with pressor drugs. Timely sputum suction, airway management, eliminate fever, asthma, pain and other stimulation caused by the heart rate is too fast.
62364562|NCT04857892|EXPERIMENTAL|Part 1 : Treatment sequence ABC|Participants will receive a single oral dose of GSK3640254 25 milligrams (mg) (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A) in Period 1, followed by a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B) in Period 2. In Period 3, participants will receive a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C).
62364563|NCT04857892|EXPERIMENTAL|Part 1 : Treatment sequence BCA|Participants will receive a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B) in Period 1, followed by a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C) in Period 2. In Period 3 participants will receive a single oral dose of GSK3640254 25 mg (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A).
62364564|NCT04857892|EXPERIMENTAL|Part 1 : Treatment sequence CAB|Participants will receive a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C) in period 1, followed by a single oral dose of GSK3640254 25 mg (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A) in Period 2. In Period 3 participants will receive a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B).
62364565|NCT04857892|EXPERIMENTAL|Part 2 : Treatment sequence DE|Participants will receive a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions (Treatment D) in Period 1 followed by a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions (Treatment E) in Period 2.
62364566|NCT04857892|EXPERIMENTAL|Part 2 : Treatment sequence ED|Participants will receive a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions (Treatment E) in Period 1 followed by a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions (Treatment D) in Period 2.
62364567|NCT03551184|ACTIVE_COMPARATOR|Endotoxin|Endotoxin 0.6 ng/kg body weight injection
62364568|NCT03551184|PLACEBO_COMPARATOR|Placebo|Saline injection
62364569|NCT06394076|EXPERIMENTAL|Cross-linked sodium hyaluronate gel for injection containing lidocaine|Cross-linked sodium hyaluronate gel for injection containing lidocaine
62364570|NCT06394076|NO_INTERVENTION|No treatment control|No treatment control
62364571|NCT05544071|ACTIVE_COMPARATOR|rTMS Active|Blinded Active TMS coil. Active repetitive Transcranial Magnetic Stimulation (rTMS) and Sertraline (dosage form: pill, dosage: 50mg, frequency and duration: At the beginning of the treatment, the dose of 25mg/ was taken for 1-3 days and adjusted to 50mg/ days for 4-7 days. If there were no dose-limiting adverse events, the dose could be titrated to 100mg/ days in the second week. The dose could be flexibly adjusted within the range of 100\~150mg/ days until a satisfactory clinical response was achieved. After that, the drug dose was kept unchanged as far as possible. Take it once a day, after a meal at a relatively fixed time in the morning.)
62739332|NCT00316706|ACTIVE_COMPARATOR|Havrix Group|Subjects received 3 doses of Havrix™ (hepatitis A vaccine \[HAV\]) during the primary study (NCT00196924). Subjects from the this group completed the study at Month 24.
62739333|NCT02143856|EXPERIMENTAL|100 mg GLPG1205 fasted|Single dose of 100 mg GLPG1205 as two capsules of 50 mg after an overnight fast
62739334|NCT02143856|EXPERIMENTAL|100 mg GLPG1205 fed|Single dose of 100 mg GLPG1205 as two capsules of 50 mg exactly 30 minutes after the start of a high-fat, high-calorie breakfast
62739335|NCT04216472|EXPERIMENTAL|Treatment (alpelisib, nab-paclitaxel)|Patients receive alpelisib PO QD on days 1-21, and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may then undergo surgery to remove the tumor.
62739336|NCT04699032|EXPERIMENTAL|Severe Renal Impairment|eGFR (mL/min/1.73 m2): \<30 not on hemodialysis
62739337|NCT04699032|EXPERIMENTAL|Normal Healthy Match|eGFR (mL/min/1.73 m2): ≥90
62739338|NCT04699032|EXPERIMENTAL|Moderate Renal Impairment|eGFR (mL/min/1.73 m2): ≥30 to 60
62739339|NCT04699032|EXPERIMENTAL|Mild Renal Impairment|eGFR (mL/min/1.73 m2): ≥60 to 90
62364572|NCT05544071|SHAM_COMPARATOR|rTMS Sham|Blinded Sham TMS coil. Sham Transcranial Magnetic Stimulation (TMS) and Sertraline (dosage form: pill, dosage: 50mg, frequency and duration: At the beginning of the treatment, the dose of 25mg/ was taken for 1-3 days and adjusted to 50mg/ days for 4-7 days. If there were no dose-limiting adverse events, the dose could be titrated to 100mg/ days in the second week. The dose could be flexibly adjusted within the range of 100\~150mg/ days until a satisfactory clinical response was achieved. After that, the drug dose was kept unchanged as far as possible. Take it once a day, after a meal at a relatively fixed time in the morning.)
62364573|NCT05132595|PLACEBO_COMPARATOR|Normal saline in patients|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20 ml/h normal saline until starting skin suture.
62364574|NCT05132595|ACTIVE_COMPARATOR|Esketamine in patients|After the induction of anesthesia, esketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h esketamine until starting skin suture.
62364575|NCT05132595|ACTIVE_COMPARATOR|Ketorolac in patients|After the induction of anesthesia, ketorolac is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h ketorolac until starting skin suture.
62364576|NCT05132595|ACTIVE_COMPARATOR|Esketamine and Ketorolac in patients|After the induction of anesthesia, 0.2mg/kg esketamine and 0.2mg/kg ketorolac are intravenously injected, and then a continuous infusion of 0.2mg/kg/h esketamine and 0.2mg/kg/h ketorolac until starting skin suture.
62364577|NCT00643448|EXPERIMENTAL|AZD1305 loading dose 250 mg + 125 mg|Tablets
62364578|NCT00643448|EXPERIMENTAL|AZD1305 loading dose 500 mg + placebo|Tablets
62364579|NCT00643448|PLACEBO_COMPARATOR|Placebo corresponding to AZD1305 loading dose|Tablets
62364580|NCT02671760|EXPERIMENTAL|Treatment|SM-1
62364581|NCT02671760|ACTIVE_COMPARATOR|Comparator|2-drug combination
62364582|NCT02671760|PLACEBO_COMPARATOR|Placebo|Placebo
62364583|NCT01292525|ACTIVE_COMPARATOR|Tacrolimus|
62364584|NCT01292525|EXPERIMENTAL|Withdrawal of Tacrolimus|
62364585|NCT03429504||Obese breast cancer patients|Response to treatment and progression free survival in obese breast cancer patients
62364586|NCT03429504||non obese breast cancer patients|Response to treatment and progression free survival in non obese breast cancer patients
62364587|NCT03771989|ACTIVE_COMPARATOR|Intervention|Patients are treated with an intra articular injection with autologous, micro-fragmented adipose tissue.
62364588|NCT03771989|PLACEBO_COMPARATOR|Control|Patients are treated with an intra articular injection with saline (placebo).
62364589|NCT01616069|ACTIVE_COMPARATOR|epinephrine|Assessment of systolic and diastolic heart function during CABAG with CPB with levosimendan using TEE.
62364590|NCT01616069|ACTIVE_COMPARATOR|levosimendan|Assessment of systolic and diastolic heart function during CABAG with CPB with epinephrine using TEE.
62739340|NCT06024616|EXPERIMENTAL|TARANG arm|"Participants will participate in TARANG and receive the following a total of 14 sessions:~1. Navigating newly formed relationships (e.g. spousal communication, healthy relationships with in-laws, establishing peer network, and negotiation skills)~2. Improving women's awareness of sexual reproductive health~3. Challenging inequitable gender norms to reduce unintended pregnancies.~4. Life skills education to enable them to have improved social mobility, decision-making, and agency.~The TARANG intervention will be delivered by Vikalp (a registered non-governmental organization implementing the intervention)."
62174601|NCT05173506||Adolescent Depression Screening|"* \> 3 visits to clinic~* Diagnosis of epilepsy - International Classification of Diseases, Tenth Revision - Epilepsy and recurrent seizures (ICD-10:G40)~* Age \> 12 years at last visit (before CHICA-CN)~Computer assistant depression screening and management"
62364591|NCT04675801||Bridging therapy with LMWH (n=475)|Bridging therapy with LMWH was performed after discontinuation of oral antiplatelet agents prior to non-cardiac surgery
62364592|NCT04675801||Bridging therapy with tirofiban (n=475)|Bridging therapy with tirofiban was performed after discontinuation of oral antiplatelet agents prior to non-cardiac surgery
62364593|NCT06330090||Design|Behavioural or behavioural with imaging
62364594|NCT03273231|EXPERIMENTAL|ketamine group|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
62364595|NCT03273231|PLACEBO_COMPARATOR|control group|0.9% saline solution
62364596|NCT03489850|ACTIVE_COMPARATOR|Ibudilast|20mg BID Days 1-2 50mg BID Days 3-14
62364597|NCT03489850|PLACEBO_COMPARATOR|Placebo|Matched to active
62364598|NCT03990701|EXPERIMENTAL|Single Arm|All patients will undergo standard-of-care investigations (CT imaging of adrenals and AVS) and the research test (11C-metomidate PET-CT) with a dose of 150 - 300 Megabecquerel (MBq) (11C-metomidate) to identify functional unilateral adrenal disease.
62182384|NCT02550483|ACTIVE_COMPARATOR|Lycopene Tomato Juice|Participants will receive high lycopene tomato juice daily as part of controlled diet (base diet + high lycopene tomato juice).
62364599|NCT02792660|EXPERIMENTAL|Injeq IQ-Needle|Lumbar puncture is performed using Injeq IQ-Needle
62364600|NCT00255034|ACTIVE_COMPARATOR|24 weeks of therapy|Genotype 3 HCV subjects with high viral load (at least 2 million copies/mL) treated for 24 weeks
62364601|NCT00255034|EXPERIMENTAL|48 weeks of therapy|Genotype 3 HCV subjects with high viral load (at least 2 million copies/mL) treated for 48 weeks
62364602|NCT03294772|EXPERIMENTAL|Hand sanitizer group|DCCs received alcohol-based hand sanitizer and a program educational. Characteristics of the hydroalcoholic gel (Alco aloe gel): chlorhexidine digluconate at 0.2% solution, phenoxyethanol 1%, benzalkonium chloride 0.1%. aloe barbadensis 5%, ethyl alcohol 70%, excipients c.s.p. 100 ml. Alcohol of between 70%, ph = 7-7,5.
62364603|NCT03294772|EXPERIMENTAL|Liquid soap group|DCCs received soap and program educational. The liquid soaps used for handwashing in this study did not contain specific antibacterial component, ph= 5.5.
62364604|NCT03294772|NO_INTERVENTION|Control group|No hand sanitizer or educational program were used.
62364605|NCT06148350|EXPERIMENTAL|Group A: Frenkel's Exercise|"Frenkel's exercises spanned four weeks with distinct positions:~Week 1: Recumbent position, focusing on heel sliding, knee, and hip movements. Week 2: Seated exercises, emphasizing leg elevation and standing from a chair. Week 3: Erect posture activities, including forward, sideways, and backward walking with diverse steps and turns.~Week 4: Comprehensive exercises across all positions, emphasizing varied movements.~Each exercise set included 8-10 repetitions with 1-2 minutes of rest."
62174602|NCT05173506||Genetic Testing|"* \> 3 visits to clinic~* Diagnosis of global developmental delay - International Classification of Diseases, Tenth Revision - autistic disorder (ICD-10: F84)~* Age \< 6 years at last visit (before CHICA-CN)~Computer reminders to test for genetic disorders"
62364606|NCT06148350|ACTIVE_COMPARATOR|Group B: Conventional Balance Exercises|"Structured program with 8-10 reps and 1-2 min rest:~I. Strengthening: Targets hips, knees, and ankles-squats, lunges, leg presses. II. Weight-Shifting: Enhances balance with side-to-side, forward-backward steps.~III. Trunk Stabilization: Improves core control-planks, crunches, twists. IV. Proprioception: Balance board exercises challenge spatial awareness, performed under physiotherapist supervision."
62364607|NCT04250025|EXPERIMENTAL|EXPERIMENTAL GROUPE|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation
62364608|NCT04250025|NO_INTERVENTION|CONTRO GROUPE|60 patients benefit from standard treatment for 6 months i.e elastic compression and anticoagulation if needed. Notably, if patients were no longer on anticoagulant treatment at the time of screening and inclusion, this treatment will not be reintroduced.
62364609|NCT01628042|EXPERIMENTAL|Participants With Severe Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
62364610|NCT01628042|EXPERIMENTAL|Participants With Moderate Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
62364611|NCT01628042|EXPERIMENTAL|Participants With Mild Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
62364612|NCT01628042|EXPERIMENTAL|Healthy Matched Control Participants|Participants receive a single oral dose of vibegron 100 mg on Day 1.
62364613|NCT01234519|EXPERIMENTAL|Phase 1 - Cohort 1|"Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).~Patients will be enrolled in cohorts of 3 at a specified AEZS-108 dose beginning with 160mg/m\^2. Enrollment will be suspended until all members of a cohort have been observed for dose limiting toxicities (DLT) for a period of 3 weeks (1 cycle of AEZS-108) from initial treatment with AEZS-108. Dose escalation will proceed within each cohort according to a specific scheme where DLT is defined."
62364614|NCT01234519|EXPERIMENTAL|Phase 1 - Cohort 2|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
62364615|NCT01234519|EXPERIMENTAL|Phase 1 - Cohort 3|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
62364616|NCT01234519|EXPERIMENTAL|Phase 1 - Cohort 4|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
62364617|NCT01234519|EXPERIMENTAL|Phase 2|AEZS-108 at MTD to determine efficacy in up to 40 patients.
62364618|NCT05355818|EXPERIMENTAL|Delgocitinib cream|Delgocitinib cream 20 mg/g twice daily
62364619|NCT05355818|PLACEBO_COMPARATOR|Cream vehicle|Cream vehicle twice daily
62364620|NCT03466671|OTHER|Low dose once per day and placebo|"Four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.~After four weeks washout, four weeks administrations of placebo twice per day in morning and evening."
62364621|NCT03466671|OTHER|Low dose twice per day and placebo|Four weeks administrations of TTA-121 3U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.
62364622|NCT03466671|OTHER|High dose once per day and placebo|"Four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.~After four weeks washout, four weeks administrations of placebo twice per day in morning and evening."
62364623|NCT03466671|OTHER|High dose twice per day and placebo|Four weeks administrations of TTA-121 10U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.
62174603|NCT05173506||Rescue seizure therapy|"* \> 3 visits to clinic~* Diagnosis of epilepsy - International Classification of Diseases, Tenth Revision - Epilepsy and recurrent seizures (ICD-10: G40)~* Age \< 18 years at last visit (before CHICA-CN)~Computer reminders to prescribe and adjust rescue anti-seizure medications"
62364624|NCT03466671|OTHER|Placebo and low dose once per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.
62364625|NCT03466671|OTHER|Placebo and low dose twice per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U twice per day in morning and evening.
62364626|NCT03466671|OTHER|Placebo and high dose once per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.
62364627|NCT03466671|OTHER|Placebo and high dose twice per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U twice per day in morning and evening.
62364628|NCT00643097|EXPERIMENTAL|Arm I (ACTIVATE)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)-specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, every 2 weeks starting 4 weeks after the completion of radiation. Subsequent vaccinations were given once a month until clinical or radiographic evidence of progression or death.
62364629|NCT00643097|EXPERIMENTAL|Arm II (ACT II STD)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)- specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, biweekly starting within 6 weeks of completing radiation. Additional vaccinations were given until clinical or radiographic evidence of progression or death. Patients subsequently receive temozolomide at a targeted dose of 200 mg/m2 for the first 5 days of a 28 day cycle.
62567146|NCT02044302|EXPERIMENTAL|standard analgesics and bupivacaine|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into the chest 10 ml (about 2 teaspoons) of 0.5% bupivacaine during surgery. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
62364630|NCT00643097|EXPERIMENTAL|Arm III (ACT II DI)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)- specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, biweekly starting within 6 weeks of completing radiation. Additional vaccinations were given until clinical or radiographic evidence of progression or death. Patients subsequently receive temozolomide at a targeted dose of 100 mg/m2 for the first 21 days of a 28 day cycle.
62364631|NCT00836303|NO_INTERVENTION|Control|Patients of physicians randomly assigned to the control group received usual care
62364632|NCT00836303|EXPERIMENTAL|Intervention Group|This group will receive the behavioral intervention.
62364633|NCT05369533|ACTIVE_COMPARATOR|Telerehabilitation + Sinemet|Patients will receive 36 telerehabilitation sessions targeting arm motor function. TR consists of 70 minutes/day of activities targeting arm function, 6 days/week for 6-8 weeks. Half of these sessions are supervised by a licensed therapist, and the other half are done independently. Sinemet is taken one hour before starting TR, for the first 18 sessions.
62364634|NCT05369533|PLACEBO_COMPARATOR|Telerehabilitation + Placebo|Patients will receive 36 telerehabilitation sessions targeting arm motor function. TR consists of 70 minutes/day of activities targeting arm function, 6 days/week for 6-8 weeks. Half of these sessions are supervised by a licensed therapist, and the other half are done independently. Placebo is taken one hour before starting TR, for the first 18 sessions.
62364635|NCT05369533|NO_INTERVENTION|Usual care|Participants in the usual care group will receive no TR or study pill, but will continue with the recommendations made by their care team. All participants will be offered TR at the end of the study.
62364636|NCT01821885|EXPERIMENTAL|Spirometry and a brief advice to quit smoking|"Intervention group:~The intervention consists of completing a questionnaire and undergo spirometry with bronchodilator test by a trained nurse. Later, the patients receives a brief advice to quit smoking and a report of the spirometry results by their family doctor."
62364637|NCT01821885|ACTIVE_COMPARATOR|Brief advice to quit smoking|"Control group:~Patients in the control group complete a questionnaire by a nurse and then receive a brief advice to quit smoking by their family doctor."
62364638|NCT04125992|EXPERIMENTAL|Distal Radial|Patients who undergo coronary catheterization by accessing the distal radial artery in the snuff-box of the hand.
62364639|NCT04125992|ACTIVE_COMPARATOR|Forearm Radial|Patients who undergo conventional coronary catheterization by accessing the forearm radial artery.
62364640|NCT05045105||ICU physicians|Intensive Care physicians who will apply the method of invasive insertion of the intracerebral catheter for ICP monitoring
62364641|NCT05045105||Neurosurgeons|Neurosurgeons who will apply the method of invasive insertion of the intracerebral catheter for ICP monitoring
62364642|NCT05370079|OTHER|Control cohort|Patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.
62174604|NCT05173506||Adolescent Transition|"* \> 3 visits to clinic~* Age \> 13 years at last visit (before CHICA-CN)~Computer supported screening and counseling regarding transition to adult care"
62174605|NCT04707456|NO_INTERVENTION|MFM staff-level operator|
62174606|NCT04707456|OTHER|MFM fellowship trainee-level operator|
62174607|NCT04503837|EXPERIMENTAL|Intervention|Personalized Mobile Phone Video Recording in addition to Standard care
62174608|NCT04503837|NO_INTERVENTION|Control|Standard care alone
62174609|NCT02862652|EXPERIMENTAL|children with acute lymphoblastic leukemia|
62174610|NCT02551692|PLACEBO_COMPARATOR|NRT|
62174611|NCT02551692|PLACEBO_COMPARATOR|VAR|
62174612|NCT02551692|PLACEBO_COMPARATOR|PLAC|
62174613|NCT05183321|NO_INTERVENTION|Control Group|Group will not receive treatment: periodontal therapy
62174614|NCT05183321|EXPERIMENTAL|Periodontal therapy|Group will receive treatment: periodontal therapy
62174615|NCT04156178|EXPERIMENTAL|CD20-CD19 cCAR T cells|CD20-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD20 and CD19 CARs
62364643|NCT06231641|ACTIVE_COMPARATOR|Active treatment condition|Lemborexant at a 5mg dose is delivered in a film-coated tablet
62364644|NCT06231641|PLACEBO_COMPARATOR|Placebo condition|Placebo is delivered in a film-coated tablet
62364645|NCT00464711|OTHER|Escitalopram|single arm
62364646|NCT02011672|EXPERIMENTAL|nutrient-enriched milk|consumption of 250 ml three times per day
62364647|NCT02011672|PLACEBO_COMPARATOR|regular milk|consumption of 250 ml three times per day
62364648|NCT01847690|PLACEBO_COMPARATOR|Placebo|Treatment B is placebo (2 placebo tablets).
62364649|NCT01847690|ACTIVE_COMPARATOR|Hydrocortisone|Treatment A is 10 mg hydrocortisone (2 tablets Cortef, 5 mg each),Stress-dose will be taken per os one time 2 tablets 10 mg of Cortef 60 min before start of exercise. Cortef tablets 5 mg produced by Pharmacia and Upjohn . One day.
62364650|NCT02835898||Test Group|Patients with periodontal disease that need conventional periodontal treatment
62174616|NCT05579145|EXPERIMENTAL|5-Second Expiratory Pause|Closed system aspiration following by expiratory pause with mechanical ventilator for 5 seconds.
62174617|NCT05579145|EXPERIMENTAL|10-Second Expiratory Pause|Closed system aspiration following by expiratory pause with mechanical ventilator for 10 seconds.
62174618|NCT06646770|EXPERIMENTAL|Segmentectomy|Pulmonary anatomic segmentectomy with mediastinal nodal dissection
62174619|NCT06646770|ACTIVE_COMPARATOR|Lobectomy|Pulmonary lobectomy with mediastinal nodal dissection
62174620|NCT00770640|EXPERIMENTAL|Pioglitazone 30mg QD|(and variable insulin therapy)
62174621|NCT00770640|PLACEBO_COMPARATOR|Placebo QD|(and variable insulin therapy)
62174622|NCT03779321|OTHER|Lean panelists|Lean panelists or normal weight panelists with a BMI between 18.5 and 24.9 Acceptability was assessed
62174623|NCT03779321|OTHER|Obese panelists|Obese panelists with a BMI between 25 and 29.9 Acceptability was assessed
62174624|NCT00905814|OTHER|Sequence 1 (BABA)|Treatment A: One 5-mg FCIR tablet Treatment B: Five 1-mg FCIR tablets Subjects in this sequence will participate in 4 periods in the following order: B -\> A -\> B -\> A
62174625|NCT00905814|OTHER|Sequence 2 (ABAB)|Treatment A: One 5-mg FCIR tablet Treatment B: Five 1-mg FCIR tablets Subjects in this sequence will participate in 4 periods in the following order: A -\> B -\> A -\> B
62174626|NCT01422083|NO_INTERVENTION|Control group|This group of athletes do not perform a 6-week stretching program.
62364651|NCT02835898||Control Group|Periodontally-healthy individuals.
62364652|NCT06101316|EXPERIMENTAL|CB06-036 Cohort 1|1.5 mg Day1, orally taken in the morning, on an empty stomach.
62364653|NCT05183646|EXPERIMENTAL|DMX-200 (repagermanium)|"Patients will receive 120 mg immediate release capsules of DMX-200 twice daily during the treatment period (104 weeks)~OLE: Patients will receive 120 mg immediate release capsules of DMX-200 twice daily during the OLE period (108-212 weeks)"
62364654|NCT05183646|PLACEBO_COMPARATOR|Placebo|Patients will receive 120 mg immediate release capsules of Placebo twice daily
62364655|NCT03788616|ACTIVE_COMPARATOR|Group I|Group I : will consist of 30 teeth that will be restored by high-viscosity glass ionomer (Fuji IX Extra) with ART approach
62550243|NCT03435471|ACTIVE_COMPARATOR|G2 - Patient-Directed Home Therapy|"Patient-Directed Home Swallowing Therapy: One face-to-face meeting with a study speech pathologist prior to initiation of treatment. During that session, they will be encouraged to practice the given exercises independently on a specific daily schedule regime throughout their treatment. Other assessments include:~* Prophylactic Swallowing Home Exercise Program~* Penetration/Aspiration Scale (PAS)~* Functional Oral Intake Scale (FOIS)~* Eating Assessment Tool-10 (EAT-10)~* University of Washington Quality of Life (UW-QOL)~* Performance Status Scale for Head and Neck Cancer Patients (PSS-HN)~* DIGEST Safety Grade"
62550244|NCT04459741|EXPERIMENTAL|HIV+ Hypertensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
62550245|NCT04459741|OTHER|HIV+ Normotensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
62550246|NCT04459741|EXPERIMENTAL|HIV- Hypertensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
62550247|NCT04459741|OTHER|HIV- Normotensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
62550248|NCT05583825|EXPERIMENTAL|Rebozo Applied Group|"* Those who are in the latent phase (cervical opening 1-4 cm) will be provided to sign the informed consent form by making a statement regarding the research. The Personal Information Form will be filled and the anxiety levels of women with a cervical dilation of 3-4 cm will be determined with the State Anxiety Inventory and the pain level will be determined with the Visual Analog Scale, and rebozo techniques will be applied two or three times. After the application, the level of pain will be re-evaluated.~* When the cervical dilation is 6-7 cm (active phase), the pain level will be determined with the Visual Analog Scale, Rebozo Techniques will be applied two or three times and the pain level will be re-evaluated after the application.~* When the cervical opening is 8-9 cm (transition phase), the pain level will be determined, Rebozo Techniques will be applied two or three times, and anxiety and pain levels will be evaluated after the application."
62550249|NCT05583825|NO_INTERVENTION|Standard Care Group|"* Pregnant women who will not be subjected to any application other than routine hospital applications, who are in the latent phase (cervical opening 1-4 cm), will be provided to sign the informed consent form by making a statement about the research. Afterwards, by filling out the Personal Information Form, the anxiety levels of women with a cervical dilation of 3-4 cm will be determined with the State Anxiety Inventory, and their pain levels will be determined with the Visual Analog Scale.~* When the cervical opening is 6-7 cm (active phase), the level of pain will be determined.~* When the cervical dilation is 8-9 cm (transition phase), anxiety and pain levels will be determined.~* The Travay Follow-up Form will be used in the period from the admission of women to labor until the end of the action.~* Evaluation of birth experience will be done in the fourth stage of labor using the birth experience scale."
62550250|NCT01085760|EXPERIMENTAL|Vancomycin 125 mg orally 4 times a day|The patients will be randomized into four groups of ten patients: one group will receive low dose vancomycin, one group will receive high dose vancomycin, one group will receive low dose metronidazole and one group will receive high dose metronidazole.
62550251|NCT01085760|EXPERIMENTAL|Vancomycin 250 mg orally 4 times a day|
62550252|NCT01085760|EXPERIMENTAL|Metronidazole 250 mg orally 3 times a day|
62550253|NCT01085760|EXPERIMENTAL|Metronidazole 500 mg orally 3 times a day|
62550254|NCT01445704|EXPERIMENTAL|Probiotics|Patients treated with a probiotic (in capsule form) once daily for 12 weeks
62550255|NCT01445704|PLACEBO_COMPARATOR|Placebo|Patients treated with a placebo (in capsule form) identical to that of the probiotic capsule once daily for 12 weeks
62550256|NCT00070551|EXPERIMENTAL|Stratum I (GTI-2040, cytarabine)|Patients receive GTI-2040 IV continuously on days 1-6 and high-dose cytarabine IV over 2 hours twice daily on days 2, 4, and 6.
62550257|NCT00070551|EXPERIMENTAL|Stratum II (GTI-2040, cytarabine)|Patients receive GTI-2040 IV continuously on days 1-6 and high-dose cytarabine IV over 4 hours once daily on days 2-6. In both strata, treatment continues in the absence of unacceptable toxicity.
62550258|NCT02885402|EXPERIMENTAL|Osteoarthritis patient|
62550259|NCT02885402|PLACEBO_COMPARATOR|Healthy volunteers|
62550260|NCT06170216||iNHL|Different immunochemotherapies in small B-cell non-Hodgkin lymphoma
62550261|NCT03593395|ACTIVE_COMPARATOR|Program Structured Education Based Transition Program|Program Structured Education Based Transition Program \[STE\]
62550262|NCT03593395|EXPERIMENTAL|Structured Education Based Transition Program + Peer Mentoring|Structured Education Based Transition Program \[STE\] + Peer Mentoring \[PM\]
62550263|NCT02436226|ACTIVE_COMPARATOR|Clomiphene citrate-HCG group|Women will receive clomiphene citrate and human chorionic gonadotropin (HCG)
62550264|NCT02436226|ACTIVE_COMPARATOR|Clomiphene citrate group|Women will receive clomiphene citrate alone
62550265|NCT02251899|EXPERIMENTAL|Disease-Management intervention|Behavioral: Disease-Management intervention The participants in the intervention group receive a nurse-managed disease-management intervention that is regularly delivered by telephone or, when necessary, in person
62174627|NCT01422083|EXPERIMENTAL|Home stretching program|These athletes take on a home stretching program (sleeper's stretch).
62174628|NCT03461211|EXPERIMENTAL|Teprotumumab|Eight infusions of teprotumumab every 3 weeks (q3W) for a total of 21 weeks: teprotumumab 10 mg/kg administered on Day 1 and teprotumumab 20 mg/kg administered q3W for the remaining 7 infusions.
62364656|NCT03788616|ACTIVE_COMPARATOR|Group II|Group II : will consist of 30 teeth that will be restored by bioactive restorative material (ACTIVA KIDS bioactive restorative material) with ART approach.
62364657|NCT04409626||Cases|
62550266|NCT02251899|NO_INTERVENTION|No Intervention: Control arm|Control group not receiving any in
62550267|NCT04927234|EXPERIMENTAL|Standard of care + geko™ Therapy|In addition to their standard of care, for patients randomised to the intervention arm, geko™ therapy will be applied immediately post-surgery on the operated leg and administered for 24 hours / day whilst the patient remains in hospital, after which geko™ therapy will then be applied for 12hrs / day until the patient returns for their first post-operative follow-up visit (Day 14 ± 2 days post-surgery)
62364658|NCT04409626||Controls|Matched (5 controls per case) by date of birth +/- 180 days.
62364659|NCT02402621|ACTIVE_COMPARATOR|Conventional analgesic group|fentanyl
62364660|NCT02402621|EXPERIMENTAL|Model based analgesic group|fentanyl
62364661|NCT02802072|EXPERIMENTAL|Enterprise stent implantation group|Patients with atherosclerotic ischemic stroke will be randomly allocated to receive Enterprise stent implantation in combination with antiplatelet medication for carotid artery stenosis.
62550268|NCT04927234|NO_INTERVENTION|Standard of care|Patients will receive their standard of care as per hospital practice.
62550269|NCT04392895||Patients with locally advanced cervical cancer|Patients with locally advanced cervical cancer, who had undergone a PAL
62550270|NCT05963815||Degenerative spine disorder|Patients who are eligible for surgical treatment of the spine, including a lumbar herniated disk or lumbar spinal canal stenosis, discopathy and spondylolisthesis.
62550271|NCT05001646|EXPERIMENTAL|In-home EMF protection device|
62550272|NCT01491451|EXPERIMENTAL|rhBMP-2/ACS|
62550273|NCT01491451|ACTIVE_COMPARATOR|Autogenous bone|
62550274|NCT00919126|EXPERIMENTAL|Group A|Xenon 50% (45%-55%) in Oxygen (45%-55%),
62550275|NCT00919126|EXPERIMENTAL|Group B|Xenon 70% (65%-75%) in Oxygen (25%-35%)
62364662|NCT02802072|EXPERIMENTAL|Only aspirin medication group|Patients with atherosclerotic ischemic stroke will be randomly allocated to receive only antiplatelet medication for carotid artery stenosis.
62550276|NCT00919126|ACTIVE_COMPARATOR|Group C|Medical Air in Oxygen (45%-55%)
62550277|NCT05429892|EXPERIMENTAL|TRTsocialmot1 arm|"Smokers will receive real-time video-based motivational counseling and home-based food delivery.~Participants will receive educational material."
62550278|NCT05429892|ACTIVE_COMPARATOR|TRTmot3 arm|"Smokers will receive real-time video-based motivational counseling only.~Participants will receive educational material."
62174629|NCT02929706|EXPERIMENTAL|intervention group|Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
62550279|NCT05429892|ACTIVE_COMPARATOR|TRTsocial2 arm|"Smokers will receive home-based food delivery only.~Participants will receive educational material."
62550280|NCT01597778|EXPERIMENTAL|Haploidentical Bone Marrow Transplant|Participants will receive haploidentical bone marrow transplant using a reduced intensity conditioning regimen.
62550281|NCT01597778|EXPERIMENTAL|Double Umbilical Cord Blood Transplant|Participants will receive a double umbilical cord blood transplant using a reduced intensity conditioning regimen.
62550282|NCT01047514|EXPERIMENTAL|Online Chronic Disease Self-management|6 week, online, small group online self-management workshop
62550283|NCT02373449|EXPERIMENTAL|RS-fMRI|All subjects will be instructed to keep their eyes closed but to remain awake during the fMRI measurement. Resting State fMRI (RS-fMRI) will be performed within four weeks of planned infusion of ketamine, immediately after the end of infusion of ketamine on the fifth (last) day of infusion, and on the one month follow-up appointment after the infusion.
62550284|NCT02471040|EXPERIMENTAL|Type 1 diabetic subjects|Subjects will undergo a hyperinsulinemic-hypoglycemic clamp with a target glucose level of 55mg/dl. Once a stable glycemic state is reached, subjects will receive a bolus-continuous infusion beta-hydroxybutyrate (BHB) or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study. Throughout the BHB or saline infusion cognitive function will be tested via a standardized testing battery.
62739341|NCT06024616|NO_INTERVENTION|Control arm|Participants in the control arm receive standard of care--contraceptive access through community health workers and routine counseling by community health workers
62550285|NCT02471040|ACTIVE_COMPARATOR|Healthy Subjects|Healthy control subjects will undergo a hyperinsulinemic-hypoglycemic clamp with a target glucose level of 55mg/dl. Once a stable glycemic state is reached, subjects will receive a bolus-continuous infusion beta-hydroxybutyrate (BHB) or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study. Throughout the BHB or saline infusion cognitive function will be tested via a standardized testing battery.
62550286|NCT02471040|ACTIVE_COMPARATOR|Healthy Subjects CONTROL|Healthy control subjects will undergo a hyperinsulinemic-hypoglycemic clamp with a target glucose level of 55mg/dl. Once a stable glycemic state is reached, subjects will undergo an NMR test to characterize brain metabolism under hypoglycemia.
62550287|NCT03332810|EXPERIMENTAL|SME family based physical activity|Adults and family members will participate into one core session and one booster session
62550288|NCT03332810|ACTIVE_COMPARATOR|Gathering activity|Adults and family members will participate into two gathering activities
62550289|NCT02706444|ACTIVE_COMPARATOR|Conventional Balloon Angioplasty|Conventional balloon angioplasty. After fistulogram, full expansion of conventional balloon catheter under fluoroscopy guidance in \> 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram
62739342|NCT00648427|EXPERIMENTAL|1|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg
62739343|NCT00648427|ACTIVE_COMPARATOR|2|Paxil CR™ Tablets 25 mg
62174630|NCT02929706|NO_INTERVENTION|control group|optimize the thiopurine use by coventional strategy without konwing NUDT15 genotype
62174631|NCT02657954|EXPERIMENTAL|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training
62174632|NCT02657954|ACTIVE_COMPARATOR|Holistic Cognitive Education (HCE)|Holistic Cognitive Education
62174633|NCT01530659|EXPERIMENTAL|NT-501|Encapsulated cell therapy that delivers ciliary neurotrophic factor to the retina
62174634|NCT01530659|SHAM_COMPARATOR|Sham|Sham surgery
62550290|NCT02706444|ACTIVE_COMPARATOR|Drug-Coated Balloon Angioplasty|Drug-coated balloon angioplasty. After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in \> 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram
62550291|NCT01778634|PLACEBO_COMPARATOR|Placebo (5% dextrose)|Placebo
62550292|NCT01778634|EXPERIMENTAL|Azithromycin|Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
62550293|NCT03281018|EXPERIMENTAL|Interventional arm|Caregiver Accompaniment Time (CAT) + preoperative hypnosis session (experimental arm): The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
62550294|NCT03281018|NO_INTERVENTION|Control (CAT)|CAT is performed in routine care for all patients after the announcement of the illness by a trained nurse, if possible on the same day as the consultation or before the consultation of anesthesia. This is an interview of approximately 45 minutes to listen to the patient, to answer her questions and to re-explain the information delivered to her. The patient will tackle the history of the disease and then the treatment, this time dedicated evolves according to the desire of the patient and her ability to accept the disease. The patient can express her feelings, then the family circle is evoked talking about the resource persons and the future. The purpose of this interview is to obtain the autonomy of the patient by the setting up of supportive care
62550295|NCT00390208|OTHER|Group 1|Combination triple therapy of Lucentis, Dexamethasone and Visudyne Therapy
62550296|NCT00390208|OTHER|Group 2|Monotherapy: One 0.5 mg intravitreal Ranibizumab injection
62550297|NCT01959061|EXPERIMENTAL|Raltitrexed and Oxaliplatin|Raltitrexed and Oxaliplatin were mixed with 10-15 ml lipiodol by arterial chemoembolization on day 1 and during each 28-day cycle.
62739344|NCT02144402|ACTIVE_COMPARATOR|infant formula with DHASCO|standard infant formula with docosahexaenoic acid (DHA)
62550298|NCT01668914|EXPERIMENTAL|clinically positive axillary nodes|3\~18 hours before surgery, under ultrasonographic guidance, 0.5\~1.0 mCi 99mTc-SC in sterile saline (total volume 0.2\~2.0 mL) is injected intraparenchymally into 2 quadrants of breast. Subsequently, LSG is performed 0.5\~1.0 hour before surgery. Methylthioninium was injected intraparenchymally. IM-SLNB is performed during the surgery and the IMSLNs were sent to histologic examination
62550299|NCT02819089|ACTIVE_COMPARATOR|Dexmedetomidine|Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
62550300|NCT02819089|PLACEBO_COMPARATOR|NSS|NSS loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
62550301|NCT02836548|EXPERIMENTAL|vorinostat|Vorinostat 360 mg once daily
62550302|NCT01281605|ACTIVE_COMPARATOR|Active titration algorithm|titrate insulin dose by contacting with investigator by telephone weekly.
62550303|NCT01281605|EXPERIMENTAL|Usual titration algorithm|contact with investigator only at routine study visit.
62174635|NCT06646913|EXPERIMENTAL|Scleroderma Patients with Gastroparesis Symptoms|
62550304|NCT03897634|EXPERIMENTAL|Experiences Hearing Aid user|Single arm study, all participants in this arm. Participants will be experienced hearing aid users.
61997447|NCT05451771|ACTIVE_COMPARATOR|Phase 2: Control Arm (Investigator's Choice)|"Participants will receive one of the following as determined by the investigator:~Daratumumab, Pomalidomide, Bendamustine, or Ixazomib (+/- dexamethasone)"
62174636|NCT04845087|EXPERIMENTAL|Trial Group|Patients from this group will receive treatment with ozonized water.
62174637|NCT04845087|PLACEBO_COMPARATOR|Placebo Group|Patients from this group will receive placebo with water.
62174638|NCT06219161|ACTIVE_COMPARATOR|Test product (NAD3)|344 mg microcrystalline cellulose,156 mg of a proprietary blend of Wasabia japonica (freeze-dried rhizome) cultivar, standardized to NLT 12,000 ppm isothiocyanates, 97.0% Theacrine, Copper Nicotinic Acid chelated complex (17-20% Copper by ICP-Mass spectroscopy) per capsule
62174639|NCT06219161|PLACEBO_COMPARATOR|Placebo|500 mg of foodgrade mass, and color-matched microcrystalline cellulose per capsule
62550305|NCT05610423||Covid-19 vaccine associated myocarditis|No intervention
62550306|NCT05578599|OTHER|Experimental Treatment|Treatment with the Swiftsure CSS device in addition to standard oral care procedures
61997448|NCT01664572||Healthy subjects|
62174640|NCT01730742|EXPERIMENTAL|Sleep deprivation|Total sleep deprivation: participants were required to stay up for the entire night before a 'Blood Sample' was taken and the 'Neuroeconomics task' and 'Portion size task' were performed
62174641|NCT01730742|EXPERIMENTAL|Sleep|Sleep: participants had an 8-h sleep opportunity before a 'Blood Sample' was taken and the 'Neuroeconomics task' and 'Portion size task' were performed
62174642|NCT03036150|EXPERIMENTAL|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
62174643|NCT03036150|PLACEBO_COMPARATOR|Placebo|Placebo matching dapagliflozin.
62174644|NCT00509821|EXPERIMENTAL|Enzastaurin Once Daily (QD)|Enzastaurin given orally (PO) once daily (QD). 1125 mg loading dose D(-)7 then 500 mg PO,QD with concomitant radiotherapy.
62550307|NCT02376673|ACTIVE_COMPARATOR|Brochures|Mothers in this arm will receive safe sleep education from home visitors using standard brochures (including 1-page handouts and pamphlets) that are customarily used in this home visiting program.
62550308|NCT02376673|EXPERIMENTAL|Children's Book|Mothers in this arm will receive safe sleep education from home visitors using a specially-designed children's book incorporating American Academy of Pediatrics safe sleep guidelines.
62550309|NCT01458691|ACTIVE_COMPARATOR|Steroid group|Triamcinolone injection group
62550310|NCT01458691|EXPERIMENTAL|PRP group|Allogeneic PRP injection group
62550311|NCT03815461|EXPERIMENTAL|experiment group|Nab-paclitaxel+S-1
62550312|NCT04592146|ACTIVE_COMPARATOR|Control group|Participants randomized into the intervention group will receive care according to the current organizational model in each pilot site (managed by community care). Frailty care will consist in a multicomponent intervention.
62739345|NCT02144402|EXPERIMENTAL|infant formula with DHASCO-B|standard infant formula with DHA-B
62550313|NCT04592146|EXPERIMENTAL|Intervention group|"Participants randomized into the intervention group will receive the same intervention as those allocated into the control group, but this intervention will be supported by the POSITIVE technology.Informal caregivers will also receive an app to follow the evolution of the cared person.~As in the control group, participants allocated into the intervention group will be managed by community care; these professionals will have access to the evolution of the older persons so they can take promote actions in case early deterioration is detected."
62550314|NCT04110730|EXPERIMENTAL|3D Prostheses Users|Children with unilateral congenital upper-limb reductions
62550315|NCT04110730|ACTIVE_COMPARATOR|Typically Developing Children|Age- and sex-matched control group of typically developing children.
62550316|NCT06582121|EXPERIMENTAL|Participants|Study of the sleep with polysomnography during a 2-days stay in hospital. Other exam will be done during the 2 days.
62550317|NCT02010645|EXPERIMENTAL|Eltrombopag + Decitabine|"Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.~Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle."
62550318|NCT00714116|EXPERIMENTAL|SBI-087|
62550319|NCT05850364|EXPERIMENTAL|group C1|Co-administration of sIPV and routine infant vaccines at 6,10,14 weeks old (N=360)
62550320|NCT05850364|EXPERIMENTAL|group C2|Co-administration of sIPV and routine infant vaccines at 6, 10,14 weeks old
62550321|NCT05850364|EXPERIMENTAL|group S1|Administration of sIPV at 6,10,14 weeks old; Administration of routine infant vaccines at 8,12,16 weeks old
62550322|NCT05850364|EXPERIMENTAL|group S2|Administration of routine infant vaccines at 6,10,14 weeks old; Administration of sIPV at 8,12,16 weeks old
62550323|NCT04341324||Active arm: Subjects received hormonal therapy|"Study subject inclusion criteria~1. Male patients 18 years or older~2. Adenocarcinoma of the prostate either histologically or cytologically confirmed~3. Decided to be put on ADT -bilateral orchidectomy or luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist, with or without additional antiandrogen~4. After ADT performed, serum testosterone level should reach castrated level, i.e. \< 50 ng/dL after 6 weeks of treatment~5. Able to consent for the participate in the study"
62550324|NCT04341324||Control arm: Subjects do not plan to receive hormonal therapy|"Control subject:~1. Male patients 18 years or older~2. Adenocarcinoma of the prostate either histologically or cytologically confirmed~3. Able to consent for the participate in the study"
62550325|NCT00842192||A|
62550326|NCT03835273||Control group|Fifty control participants who have not received upper gastrointestinal surgery.
62550327|NCT03835273||Open surgery|Fifty patients who have undergone open removal of oesophagus more than one year ago.
62550328|NCT04449211|EXPERIMENTAL|Participants with massive bone defect|"Adult participants with health insurance regardless of sex having bone defect greater than 5cm due to trauma or tumour resection agree to participate the research.~The customised 3D-Printed implant is manufactured and undergoes post-processing treatment before being ready for implantation surgery."
62550329|NCT04235244|EXPERIMENTAL|left lower abdominal region|5 minutes before and after application to the right upper abdominal region. local cold application
62550330|NCT04235244|EXPERIMENTAL|right upper abdominal region|Thermomechanical-analgesia device will be operated 30 seconds before the injection in the right lower abdominal region and the device will be injected by sliding the device to the side of the selected region during the injection,
62550331|NCT04235244|EXPERIMENTAL|left upper abdominal region|Coolant spray will be applied to the upper left abdominal region for 15 sec.
62550332|NCT04235244|NO_INTERVENTION|right lower abdominal region|SC injection will be applied to the left lower abdominal region without any cold application.
62550333|NCT01023035|EXPERIMENTAL|Treated/Not Randomized|Participants received 4 weeks of PEG2b/RBV followed by 24 or 44 weeks of boceprevir plus PEG2b/RBV depending on Hepatitis C Virus RNA (HCV-RNA) levels. Participants continued with this treatment if their serum hemoglobin remained \>10 g/dL throughout the 28- or 48-week treatment period.
62550334|NCT01023035|EXPERIMENTAL|Ribavirin Dose Reduction|After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Ribavirin (RBV) Dose Reduction Arm received reduced doses of RBV for management of the anemia in combination with PEG2b and boceprevir therapies.
62550335|NCT01023035|EXPERIMENTAL|Erythropoietin Use|After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Erythropoietin Use Arm received erythropoietin for management of the anemia in addition to PEG2b/RBV and boceprevir therapies.
62550336|NCT04149652|OTHER|Patients with COPD or fibrosis|Subjects, enrolled on either an inpatient or outpatient basis, with stable COPD or fibrosis documented by anamnestic, imaging and functional tests. They will undergo lung function tests and bedside lung ultrasound integrated with lung elastosonography.
62550337|NCT04149652|OTHER|Smokers with no signs of COPD|Subjects with an active smoking habit or a personal history of hard smoking dating back to maximum 5 years before, without clinical and functional signs of COPD. They will undergo lung function tests and bedside lung ultrasound integrated with lung elastosonography.
62550338|NCT04149652|OTHER|Healthy non-smoking volunteers|Healthy volunteers who have never smoked and who have no clinical or functional sign of COPD or other respiratory diseases. They will undergo lung function tests and bedside lung ultrasound integrated with lung elastosonography.
62550339|NCT03068728|OTHER|All Study Participants|"Participants received hemostatic packing agent in one nasal cavity and no packing in the other.~Participants were randomized to one of three hemostatic packing agents (Arista, Nexfoam, Nasopore) through sealed envelope, chosen by surgeon prior to placement, with packing agent allocation and sidedness."
62174645|NCT00509821|EXPERIMENTAL|Enzastaurin Twice Daily (BID)|Enzastaurin 1125 mg loading dose D(-)7 then 250 mg twice daily (BID) PO, with concomitant radiotherapy.
62739346|NCT00596674|EXPERIMENTAL|Lifestyle Counts Intervention|A wellness intervention that includes 8 weeks of behavior change classes focused on acquiring the skills and knowledge to improve health behaviors (e.g., exercise, stress management), followed by 3 months of phone support.
62182385|NCT02550483|PLACEBO_COMPARATOR|Placebo Beverage|Participants will receive placebo beverage daily as part of controlled diet (base diet + placebo beverage).
62550340|NCT05209789|EXPERIMENTAL|HUGS therapy|A structured group intervention that aims to observe mother's behavior and responses with her baby, promote mother-baby interaction through play, and provide tools for positive interaction. This therapy involves cognitive and behavioral work. Therapists observe the mother-baby duo and share their observations from a perspective of encouragement and support. A playful and non-judgmental interaction is cultivated within the group. The main objective is to change the negative trajectory of mother-child interactions through tools from cognitive-behavioral therapies as well as using knowledge about child development.
62550341|NCT05209789|ACTIVE_COMPARATOR|Playtime|The participants assigned to the control group will also be in the presence of two therapists, allowing to reproduce the framework of the HUGS therapy. The difference will be the lack of direct therapeutic intervention from the therapists, but only classic psychoeducational guidance. The mothers are offered a time to play with their baby as well as the opportunity to discuss and share their experiences with other mothers, which is generally seen as supportive by them.
62550342|NCT02557763|EXPERIMENTAL|Severe PF arthritis|Oxford unicompartmental knee arthroplasty is partial knee replacement. Oxford unicompartmental knee arthroplasty is applied for medial compartmental of knee.
62550343|NCT02557763|EXPERIMENTAL|non severe PF arthritis|Oxford unicompartmental knee arthroplasty is partial knee replacement. Oxford unicompartmental knee arthroplasty is applied for medial compartmental of knee.
62550344|NCT04469504|EXPERIMENTAL|PREHAB|
62550345|NCT04469504|ACTIVE_COMPARATOR|control group|
62550346|NCT03567980|EXPERIMENTAL|topical crisaborole 2%|
62550347|NCT03716362||Neonates who will be admitted at Neonatal Intensive Care Unite|
62550348|NCT01757275|EXPERIMENTAL|Esomeprazole|
62550349|NCT01757275|ACTIVE_COMPARATOR|Cimetidine|
62550350|NCT04511585|EXPERIMENTAL|GLMC experimental arm|GLMC experimental arm receiving a 24-month (6 weeks each year) multilevel and TPB-based program aiming to promote PA practice
62550351|NCT04511585|NO_INTERVENTION|the control arm|the control arm that do not receive any intervention
62550352|NCT01739699|EXPERIMENTAL|Acetaminophen|Subjects will receive 1000mg of intravenous acetaminophen every 6 hours for 24 hours beginning with dural closure.
62550353|NCT01739699|OTHER|Placebo|Subjects will receive 100cc of normal saline every 6 hours for 24 hours beginning at dural closure.
62550354|NCT00770328|EXPERIMENTAL|Pentoxifylline|Patients receive Pentoxifylline 400 mg po TID for 8 weeks.
62550355|NCT00770328|PLACEBO_COMPARATOR|Placebo|Patients take a placebo TID for 8 weeks.
62550356|NCT01822106|ACTIVE_COMPARATOR|Omeprazole|Omeprazole at a rate of 20mg once per day
62550357|NCT01822106|EXPERIMENTAL|Wu-Chu-Yu Tang|Wu-Chu-Yu Tang at a rate of 3.0 g three times per day
62550358|NCT02573961|ACTIVE_COMPARATOR|laser|Subjects will receive 24 activated laser acupuncture group treatments. The laser will be applied for 10 seconds to each of the selected acupuncture points. In addition they will be instructed to take a tailored low caloric diet
62550359|NCT02573961|ACTIVE_COMPARATOR|high protein low carbohydrate diet|Subjects will be instructed to take a tailored high protein/low carbohydrate/low caloric diet.
62550360|NCT02573961|SHAM_COMPARATOR|control|Subjects in the control group will undergo sham laser acupuncture treatment with no laser power output. In addition they will be instructed to take a tailored low caloric diet .
62550361|NCT00356525|EXPERIMENTAL|Less Than One Year: Pemetrexed|Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
62550362|NCT00356525|EXPERIMENTAL|Less Than One Year: Pemetrexed + Gemcitabine|Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
62550363|NCT00356525|EXPERIMENTAL|One Year or Greater: Pemetrexed + Carboplatin|Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
62550364|NCT00356525|EXPERIMENTAL|One Year or Greater: Pemetrexed + Gemcitabine|Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
62550365|NCT02375165||Cohort with lymphedema|Participants with a history of acquired lymphedema of at least 6 months' duration, will have phlebotomy for serum and plasma.
62550366|NCT02375165||Cohort without lymphedema|Healthy volunteers; will have phlebotomy for serum and plasma.
62550367|NCT04944186|ACTIVE_COMPARATOR|Intervention Group|Patients in the experimental group will receive structured pressure injury patient education. It is consists of 2 sessions followed by biweekly follow-up for 8-week. The first session lasts for two days; the duration is 80 minutes (40 minutes /day for two days). Method of delivery is face to face, one to one with the aid of PowerPoint presentation and booklet. In the second session, the duration remains the same (80 minutes; 40 minutes/day for 2 days). The method of delivery also the same but teaching aid video presentation will be used. Three videos with a duration of approximately 2 - 3 minutes. In the second session, participants will be given a task to perform and document in the booklet given to monitoring its adherence. Upon completion of the two sessions, the patient will be follow-up biweekly and monitored their progress.
62550368|NCT04944186|OTHER|Control group|Patients in this group shall continue with the standard patient education in the ward. Standard patient education routinely delivers through an informal verbal method after wound dressing is done.
62550369|NCT03515512|EXPERIMENTAL|Enasidenib|Enasidenib will be administered orally once daily in 28-day cycles
62550370|NCT04805112|EXPERIMENTAL|Provision of multiple self-tests|Participants randomized to the intervention group will be given 2-3 HIV oral self-tests to offer to their sexual partner(s). The participant will be instructed to encourage their partner to test himself alone \[partner testing\] or with the participant \[couple testing\]; the partner will also be given a card with information on testing and a list of facilities where he can go for confirmatory testing. All participants will be encouraged to call a study helpline/hotline in the event of any adverse events that they or their sexual partners experience or if they need further instructions or information
62739347|NCT00596674|PLACEBO_COMPARATOR|Attention Countrol|8 weeks of general health classes followed by phone calls for 3 months
62739348|NCT03657134|EXPERIMENTAL|EP Procedure|Patient will continuously wear the CoVa-2 monitoring system until they are discharged. During this period, data from the sensor will be sent to the Gateway and Cloud-based System, and then analyzed retrospectively.
62739349|NCT05398029|EXPERIMENTAL|Part A: Single Ascending Dose Escalation/Adaptive Design|Participants will receive a single dose of VERVE-101 in multiple dose-escalation cohorts.
62739350|NCT05398029|EXPERIMENTAL|Part B: Single Dose Expansion|Participants will receive a single dose of VERVE-101 selected based on the doses studied in Part A.
62550371|NCT04805112|NO_INTERVENTION|Referral vouchers for clinic testing|Participants randomized to the control group will be given multiple referral coupons for HIV testing at pre-selected HIV testing services (HTS) sites. The participant will be instructed to give the coupon to their sexual partner(s) and encourage him to go for HIV testing at pre-selected HTS sites, either alone \[partner testing\] or together with the participant \[couple testing\]. The coupon will also have information on testing and a list of facilities where he can go for HTS. All participants will be encouraged to call a study helpline/hotline in the event of any adverse events that they or their sexual partners experience or if they need further instructions or information
62550372|NCT02688738|NO_INTERVENTION|Control|Standard of care
62550373|NCT02688738|ACTIVE_COMPARATOR|Treatment|Oral doxycycline
62550374|NCT03776149|EXPERIMENTAL|Beetroot juice (dietary nitrate)|Over the 7 days preceding each testing session, participants will consume 140 ml per day of beetroot juice (Beet It (HeartBeet Ltd.), Ipswich, UK). During this time participants will be asked to abstain from use of antiseptic mouthwash as this has been shown to temporarily kill the bacteria that facilitate the reduction of nitrate to nitrite. All participants will be asked to refrain from consuming any antioxidant (e.g., Vit E or Fish Oil) supplements during the course of the study as these may impact the study findings.
62550375|NCT03776149|PLACEBO_COMPARATOR|Black currant juice (placebo control)|Over the 7 days preceding each testing session, participants will consume 140 ml per day of a nitrate-depleted placebo. During this time participants will be asked to abstain from use of antiseptic mouthwash as this has been shown to temporarily kill the bacteria that facilitate the reduction of nitrate to nitrite. All participants will be asked to refrain from consuming any antioxidant (e.g., Vit E or Fish Oil) supplements during the course of the study as these may impact the study findings.
62550376|NCT04640415|NO_INTERVENTION|No alarms|Patients will be connected to monitoring equipment, registering vital sign data, but data will be blinded to clinical staff.
62550377|NCT04640415|ACTIVE_COMPARATOR|Active alarms|Patients will be connected to monitoring equipment, registering data, and data will be available to clinical staff, including alarms for vital sign deterioration.
62550378|NCT02172807|EXPERIMENTAL|Tiotropium low & Placebo|Tiotropium 18 µg inhalation capsule and Placebo MDI
62550379|NCT02172807|EXPERIMENTAL|Tiotropium high & Placebo|Tiotropium 36 µg inhalation capsule and Placebo MDI
62550380|NCT02172807|ACTIVE_COMPARATOR|Oxitropium & Placebo|Oxitropium MDI (100 µg/puff) and Placebo inhalation capsules
62550381|NCT06238453||Experimental group|Educational content will be sent to the experimental group once a week via the WhatsApp application, and individual counseling will be provided by answering their questions at the same time. A total of 8 weeks of intervention will be implemented, training will be given with training presentations in the first 6 weeks and training videos will be sent in the last 2 weeks.
62550382|NCT06238453||Control group|The control group will be invited to KETEM to have a mammogram without any intervention.
62550383|NCT01223391|EXPERIMENTAL|Abdominal binder|Standing with abdominal compression using elastic vs. non-elastic abdominal binders.
62550384|NCT01223391|PLACEBO_COMPARATOR|No abdominal binder|Standing without abdominal compression
62550385|NCT06485934||Observational Group|All of the outcomes will be applied to patients who come to the outpatient clinic due to shoulder problems. Then, 1 week later, participants will be recalled to apply the multidimensional kinesiophobia scale a second time.
62550386|NCT02941835|OTHER|radiation|intervention: pre-operative breast irradiation of 21 fx of 2.2Gy and boost 2.66Gy
62550387|NCT05560165|EXPERIMENTAL|PET/CT guided injection of combination of local anesthetic and steroids.|The F-18 Sodium fluoride (NaF) dose will be administered intravenously and the F-18 NaF PET/CT images will be reviewed, and the target nociceptive site will be determined on the basis of increased focal tracer uptake. The joint accessibility, location, and relation with the nearby vital organs will be assessed. The injection will be assisted using a dedicated automated robotic arm system. A combination of corticosteroids and local anesthetic will be injected.
62550388|NCT06301191||Semaglutide group|25 patients treated with semaglutide. Pulse wave velocity, aumentation index, SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of sublingual vessels using a high-resolution camera with Sideview Darkfield Imaging technique (Microscan, Glucockeck) will be evaluated. PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Liver steatosis and stiffness will be measured using Fibroscan® Mini+ 430 (Echosens, Paris, Île-de-France). CAP score will be used as an index of liver fat content, with normal values being \< 238 dB/m. E score will be used as an index of liver fibrosis, with normal values being 2- 6 kPa. Blood glucose, glycosylated hemoglobin (HbA1c) and a full lipidemic profile will be measured before and at 4 and 12 months of treatment.
62550389|NCT06301191||D-PP4 group|25 patients treated with D-PP4 inhibitors. Pulse wave velocity, augmentation index, SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of sublingual vessels using a high-resolution camera with Sideview Darkfield Imaging technique (Microscan, Glucockeck) will be evaluated. PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Liver steatosis and stiffness will be measured using Fibroscan® Mini+ 430 (Echosens, Paris, Île-de-France). CAP score will be used as an index of liver fat content, with normal values being \< 238 dB/m. E score will be used as an index of liver fibrosis, with normal values being 2- 6 kPa. Blood glucose, glycosylated hemoglobin (HbA1c) and a full lipidemic profile will be measured before and at 4 and 12 months of treatment
62550390|NCT01165489||Laryngomalacia|Patients with Laryngomalacia
62550391|NCT01165489||Control Group|Patients without Laryngomalacia
62550392|NCT02766335|EXPERIMENTAL|Arm I (MEDI4736 - closed to accrual 12/2015)|Patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
62739351|NCT02483091|EXPERIMENTAL|Multifaceted KT intervention|Webinars, online vignettes and e-module, copy of guideline recommendations
62739352|NCT02483091|NO_INTERVENTION|Control|Printed copy of guideline recommendations
62364663|NCT04262791|EXPERIMENTAL|Healthy Volunteers|Healthy participants will be monitored overnight for two consecutive nights at an inpatient setting to collect wrist actigraphy and videography data. Sleep headband (at sites where polysomnography (PSG) is available and performed) data will be collected on Night 2.
62364664|NCT04262791|EXPERIMENTAL|Participants With Atopic Dermatitis (AD)|Participants with AD will be monitored overnight for two consecutive nights at an inpatient setting to collect wrist actigraphy and videography data. Sleep headband (at sites where polysomnography (PSG) is available and performed) data will be collected on Night 2. Participants will also be monitored at home via wrist actigraphy, sleep headband when available in the outpatient setting for 7 consecutive nights.
62364665|NCT04181957|PLACEBO_COMPARATOR|Placebo|Participants receive placebo tablet composed of lactose.
62364666|NCT04181957|ACTIVE_COMPARATOR|Active|Participants receive a 50mg tablet of lisdexamfetamine dimesylate (LDX) once.
62364667|NCT00591162|ACTIVE_COMPARATOR|1|Compare bone density of severly burned children to normal non-burned population
62364668|NCT04989660|EXPERIMENTAL|Treatment Group|6% aqueous phenol, 1.5 mL per target site
62364669|NCT04989660|PLACEBO_COMPARATOR|Placebo Group|Isotonic saline, 1.5 mL per target site
62364670|NCT01709708|ACTIVE_COMPARATOR|Marcaine|Group A will receive treatment with 0.3 mL of 0.5% Marcaine delivered bilaterally with the Tx360™ device to the mucosa associated with the Sphenopalatine Ganglion (SPG)
62364671|NCT01709708|PLACEBO_COMPARATOR|Saline|Group B will receive saline placebo delivered bilaterally with the Tx360TM device to the mucosa associated with the SPG.
62364672|NCT05722977|EXPERIMENTAL|Surufatinib+envafolimab|
62364673|NCT04892680|EXPERIMENTAL|Online Diabetes Self-Management Education and Support (DSMES) Program|Participants will receive access to a 6-month online DSMES program that includes several components that are standard to DSMES. Participants receive online curriculum, access to a live Certified Diabetes Care and Education Specialist (CDCES), interactive group message forums, and connected devices for monitoring food intake, weight, physical activity and glucose levels.
62364674|NCT04892680|NO_INTERVENTION|Matched Control|A de-identified dataset of control subjects matched on baseline demographics and clinical characteristics will be cultivated for comparison to the active intervention arm.
62364675|NCT06034041|EXPERIMENTAL|Mediclore|After finish the operation, Mediclore group will be applied 1.5 CC of Mediclore at the surgical site. Mediclore is a Poloxamer-based thermosensitive anti-adhesive agent which is in a liquid solution and transform to a gel-state after being in a body temperature.
62364676|NCT06034041|PLACEBO_COMPARATOR|Control|After finish the operation, Control group will be applied 1.5 CC of normal saline at the surgical site.
62364677|NCT06033690|EXPERIMENTAL|multidisciplinary guide|Consultation and multidisciplinary guide with guidance on physical activity and healthy eating.
62364678|NCT06033690|NO_INTERVENTION|Control|Consultations with a multidisciplinary team
62364679|NCT05691712|EXPERIMENTAL|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
62364680|NCT05691712|EXPERIMENTAL|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
62364681|NCT05691712|EXPERIMENTAL|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
62364682|NCT05691712|PLACEBO_COMPARATOR|Placebo|Participants will receive a tirzepatide matched placebo.
62364683|NCT03538275||Unipolar depression cohort|Subjects with a known Dx of unipolar depression.
62364684|NCT03538275||Bipolar depression cohort|Subjects with a known Dx of bipolar disorder
62364685|NCT03538275||Healthy Control cohort|Subjects with no known unipolar or bipolar Dx.
62364686|NCT03208075|EXPERIMENTAL|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
62364687|NCT03208075|EXPERIMENTAL|Low-phosphorus Diet|Diet containing 500mg of phosphorus per day
62364688|NCT03208075|EXPERIMENTAL|High-phosphorus Die|Diet containing 2300mg of phosphorus per day
62364689|NCT03633994|EXPERIMENTAL|Heparin Bladder Instillation|At the completion of the scheduled benign hysterectomy, intravesicular bladder instillation containing 40,000U of heparin (40mL of 10,000U heparin/10mL) will be administered be introduced in a retrograde fashion by gravity via Foley catheter. The Foley catheter will be clamped for 30 minutes approximately 1cm from the vaginal opening.
62364690|NCT03633994|PLACEBO_COMPARATOR|Normal Saline Bladder Instillation|Patients randomized to the control group will undergo intravesical instillation with 40mL of normal saline. The Foley catheter will be clamped for 30 minutes approximately 1cm from the vaginal opening.
62364691|NCT04259060|ACTIVE_COMPARATOR|Hydroxocobalamin with Butyrate|Subjects enrolled will take hydroxocobalamin capsules twice daily for 4 weeks. All subjects will take an oral butyrate dose of 120 mg twice daily for 4 weeks.
62364692|NCT04259060|PLACEBO_COMPARATOR|Placebo with Butyrate|Subjects enrolled will take placebo capsules twice daily for 4 weeks. All subjects will take an oral butyrate dose of 120 mg twice daily for 4 weeks.
62364693|NCT04511338|EXPERIMENTAL|Sequence AB: circuit A follow by circuit B|Circuit (A) includes the dialyzer with Endexo and the CombiSet bloodline Circuit (B) includes dialyzer with Endexo and the Streamline bloodline
62364694|NCT04511338|EXPERIMENTAL|Sequence BA: circuit B follow by circuit A|Circuit (B) includes dialyzer with Endexo and the Streamline bloodline Circuit (A) includes the dialyzer with Endexo and the CombiSet bloodline
62364695|NCT00264095||001|
62364696|NCT03313856|PLACEBO_COMPARATOR|Placebo|The patients were randomly assigned to received placebo (calcinaned magnesia), 1 capsule before each meal for a period of 90 days.
62364697|NCT03313856|EXPERIMENTAL|Guazuma ulmifolia plus Tecoma stans|The patients were randomly assigned to received the herbarium mixture (GU/TS) , 1 capsule of 400mg, before each meal for a period of 90 days.
62364698|NCT04401410|EXPERIMENTAL|Dose Finding Phase|"This phase is designed to evaluate the maximum tolerated dose (MTD) of partially HLA-matched SARS-CoVSTs administered to hospitalized COVID19 patients with high risk of progression to mechanical ventilation.~The dose finding phase is a standard 3+3 safety study design. The 3 dose levels are:~DL1: 1x10\^7 cells (flat dose) DL2: 2x10\^7 cells (flat dose) DL3: 4x10\^7 cells (flat dose)"
62364699|NCT04401410|EXPERIMENTAL|Randomized Pilot - SARS-CoVSTs|Partially HLA-matched Virus Specific T cells (VSTs) will be given by intravenous injection.
62364700|NCT04401410|ACTIVE_COMPARATOR|Randomized Pilot - Routine Care|Hospitalized patients with COVID-19 will be treated per current institutional guidelines.
62364701|NCT02713945|EXPERIMENTAL|Simvastatin|Simvastatin administrated orally at 10 mg once a day in the morning during the first month Simvastatin administrated orally at 20 mg once a day in the morning during the second month During months 3 to 12, the dose will be fixed at 20 mg per day for children aged 12 years and younger and 40 mg for adolescent older than 12 years.
62364702|NCT02713945|PLACEBO_COMPARATOR|Control|Placebo administrated orally once daily in the morning
62364703|NCT01947647|EXPERIMENTAL|Transdiagnostic Behavior Therapy|A new transdiagnostic CBT protocol for the depressive/anxiety disorders was developed and revised through two demonstration studies and one focus group. The resulting protocol involves several primary components, including psychoeducation on the symptoms of depression and anxiety (session 1), assessment of motivation and setup of treatment plans (session 2), exposure therapy (sessions 3-15), and relapse prevention (final session). In addition to these primary components, optional modules are included to supplement exposure therapy later in treatment to address secondary symptoms (e.g., anger, sleep, hypervigilance, drinking to cope). The goal of these modules is to allow providers to tailor treatment to specific symptoms that may be present in any single or set of diagnoses that may be reducing the effects from the primary exposure approach. Session will be weekly for 45-60 minutes with homework assignments to be completed between sessions.
62364704|NCT01947647|ACTIVE_COMPARATOR|Behavioral Activation Therapy|To provide an evidence-based comparison for the transdiagnostic CBT condition, a second group of participants will receive manualized BAT. In general, BAT involves teaching patients to monitor their mood and daily activities with the goal of increasing pleasant, reinforcing activities and reducing unpleasant events. In the present study, the BAT condition will be manualized, following an existing protocol in the literature. BAT will be structurally equivalent to the transdiagnostic CBT with the same session length (45-60 minutes), frequency of sessions (weekly), duration of treatment (12-16 sessions), and amount of homework.
62364705|NCT02927184|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62364706|NCT02927184|EXPERIMENTAL|VK2809 (5mg)|5mg VK2809 capsule
62364707|NCT02927184|EXPERIMENTAL|VK2809 (10mg)|10mg VK2809 capsule
62364708|NCT02927184|EXPERIMENTAL|VK2809 (10mg QOD)|10mg VK2809 capsule
62364709|NCT03926260|EXPERIMENTAL|ctDNA analysis|additional blood sample of 20 ml
62364710|NCT02060968||IRIS PREMIER Cohort|Promus PREMIER
62364711|NCT04857086||Group1|About 1400 DTC patients with more than 5 years long-term follow-up from the date of signing the informed consent form (ICF) in DTCC 1st to signing ICF in DTCC 2nd will be collected data retrospectively.
62364712|NCT06050577|EXPERIMENTAL|oral Semaglutide/Rybelsus|oral Semaglutide 7-14 mg (or highest tolerated dose) once daily for 52 weeks (incl. titration)
62550393|NCT02766335|ACTIVE_COMPARATOR|Arm II (docetaxel - closed to accrual 4/2015)|Patients receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #2 4/22/15)
62550394|NCT02766335|EXPERIMENTAL|Arm III (MEDI4736 retreatment)|For patients assigned to Arm 1, MEDI4736: Upon evidence of progression following discontinuation of 12 months of treatment, patients may restart treatment with Arm 3, MEDI4736 for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period. Patients will only be able to restart treatment once; thus a maximum of two 12-month periods will be allowed. Patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
62550395|NCT06333704||SPIKEVAX BIVALENT or SPIKEVAX X|Participants receiving at least 1 dose of SPIKEVAX BIVALENT vaccine or SPIKEVAX X Injection are monitored for safety parameters up to 28 days post vaccination.
62550396|NCT04062292||Obstructive lung diseases group|"1. Having been diagnosed with obstructive pulmonary disease,~2. No acute exacerbation or infection in the past 1 week, Being between the ages of 18 and 65,"
62550397|NCT04062292||Healthy group|Age and sex matched healthy subjects without orthopedic and chronic diseases
62364713|NCT06050577|PLACEBO_COMPARATOR|oral Placebo|oral Placebo 7-14 mg (or highest tolerated dose) once daily for 52 weeks (incl. titration)
62364714|NCT01844791|EXPERIMENTAL|OCZ103-OS, Platinum, Gemcitabine|OCZ103-OS in combination with Platinum-Gemcitabine as standard of care
62364715|NCT05845411|EXPERIMENTAL|Intervention|A group of 30 people will participate in 8 fortnightly virtual group sessions for 4 months, where the subject of Mindful Eating will be addressed. Participants will be encouraged to share their eating experiences, reflect and discuss the above, and engage in formal and non-formal mindfulness eating practices (meditation, eating slowly, observing thoughts, and being present at meal times) between sessions.
62364716|NCT05845411|ACTIVE_COMPARATOR|Control|A group of 30 people will have 8 fortnightly, virtual, and individual consultations for 4 months. They will receive a hypocaloric diet (reduction of approximately 500kcal per day in total energy expenditure) and food and nutrition education. The food plan will be monitored in each meeting, and a theme of food and nutrition education will be worked on, based on the Food Guide for the Brazilian Population, through expository content. A virtual folder of all subjects taught will be provided.
62364717|NCT02205164|EXPERIMENTAL|Palonosetron + Aprepitant|Oral aprepitant will be given on days 1-3 (day 1, 125 mg 1 h before chemohterapy; days 2-3, 80 mg) multiple intravenous bolus of palonosetron 0.25 mg, 30 minutes before chemotherapy, every other single days, for a minimum of 2 administration (day 1, 3), in case of a 3 days chemotherapy regimen, and a maximum of 5 doses (day 1,3,5,7, 9) in case of a 10 days chemotherapy.
62364718|NCT02205164|ACTIVE_COMPARATOR|Palonosetron|multiple intravenous bolus of palonosetron 0.25 mg, 30 minutes before chemotherapy, every other single days, for a minimum of 2 administration (day 1, 3), in case of a 3 days chemotherapy regimen, and a maximum of 5 doses (day 1,3,5,7, 9) in case of a 10 days chemotherapy.
62364719|NCT03490019|EXPERIMENTAL|Metformin Therapy|Metformin therapy once daily for 24 weeks with a dose of 500, 850 or 1000 mg depending on body weight
62364720|NCT00453661||Intervention Group|Patient Navigator (PN) + Educational Materials + Annual Questionnaires
62364721|NCT00453661||Comparison Group|Educational Materials + Exit Questionnaire
62364722|NCT05108441|OTHER|Echo|Ultrasound and magnetic resonance imaging measurements of quadriceps femoris
62364723|NCT04774952|EXPERIMENTAL|RMC-5552|RMC-5552 for IV administration
62550398|NCT02033031|ACTIVE_COMPARATOR|Lucentis|PRN intravitreal injection of Lucentis
62550399|NCT02033031|ACTIVE_COMPARATOR|Avastin|PRN intravitreal injection of Lucentis
62550400|NCT02403258|EXPERIMENTAL|Plum-blossom needle group|Patients randomized into this group will receive plum-blossom needle as treatment. DU 20, DU 16, GB 20, EX-HN5, BL 15, BL 18, BL 23 will be selected as acupoints. Each point will be tapped gently one by one by plum blossom needle until the skin get slightly redness. The treatments will be given two sessions per week, consistently for 12weeks (24 sessions in all).
62364724|NCT03429608||patients with low thrombus burden|patients with the lower volume of aspirated thrombi, as measured using micro-CT
62364725|NCT03429608||patients with high thrombus burden|patients with the higher volume of aspirated thrombi, as measured using micro-CT
62364726|NCT00866060|ACTIVE_COMPARATOR|1|"10mg donepezil plus 20mg memantine~Participants in this arm will continue with their current donepezil 10mg/day regimen and immediately commence active memantine at a dose of 5mg per day, increasing in 5mg increments weekly until 20mg per day is achieved from week 4 onwards"
62364727|NCT00866060|PLACEBO_COMPARATOR|2|"Placebo donepezil plus 20mg memantine~Participants in this arm will immediately commence active memantine at a dose of 5mg per day, increasing in 5mg increments weekly until 20mg per day is achieved from week 4 onwards. Donepezil dose will be reduced to 5mg daily in weeks 1 to 4 and replaced with placebo donepezil in week 5."
62364728|NCT00866060|PLACEBO_COMPARATOR|3|"10mg donepezil plus placebo memantine~Participants in this arm will continue with their current donepezil 10mg/day regimen and immediately commence placebo memantine."
62364729|NCT00866060|PLACEBO_COMPARATOR|4|"Placebo donepezil plus placebo memantine~Participants in this arm will immediately commence placebo memantine dose escalation and will switch to donepezil 5mg daily in weeks 1 to 4, and replaced with placebo donepezil in week 5."
62364730|NCT02537223|EXPERIMENTAL|BYL719, Cisplatin, and Radiation Therapy|BYL719, orally, at a starting dose of 200-350 mg, once daily, for 7 weeks. Cisplatin, intravenously, at 100 mg/m2 over 1 hour, every 3 weeks for 3 doses. Radiation therapy, Monday to Friday, for 7 weeks.
62364731|NCT02021851|ACTIVE_COMPARATOR|Group DA: Dexamethasone and aprepitant|Group DA: Dexamethasone: 8 mg (intravenous), Aprepitant: 40 mg (oral)
62364732|NCT02021851|PLACEBO_COMPARATOR|Group DO: Dexamethasone and ondansetron|Group DO: Dexamethasone: 8 mg (intravenous), Ondansetron: 4 mg (intravenous)
62364733|NCT04220567|EXPERIMENTAL|Exercise and Patient-centred education|
62364734|NCT04220567|ACTIVE_COMPARATOR|Exercise|
62364735|NCT00565019|NO_INTERVENTION|Control|
62364736|NCT00565019|EXPERIMENTAL|Steroid|
62364737|NCT03401697||HIV/HCV Co-infected|Patients with HIV/HCV co-infection
62364738|NCT03401697||Type 2 Diabetes|Patients with Type 2 Diabetes
62364739|NCT02304419|EXPERIMENTAL|Galunisertib|150 milligrams galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
62364740|NCT01804660||25 healthy volunteers|No study treatments administered
62364741|NCT01686100|ACTIVE_COMPARATOR|No touch vein grafts|The grafts were harvested with there surrounding tissues.
62364742|NCT01686100|ACTIVE_COMPARATOR|Conventional vein grafts.|The grafts were stripped from surrounding tissue.
62364743|NCT02100202|PLACEBO_COMPARATOR|Placebo|Capsules containing 250 mg of placebo, two times a day
62364744|NCT02100202|EXPERIMENTAL|BioTurmin|Capsules containing 250 mg of BioTurmin (Curcuma longa rhizomes extract), two times a day
62364745|NCT02100202|EXPERIMENTAL|BioTurmin-WD|Capsules containing 250 mg of BioTurmin-WD (water dispersible curcuminoids), two times a day
62364746|NCT02100202|EXPERIMENTAL|MaQxan|Capsules containing 10 mg of MaQxan (Tagetes erecta flower extract), two times a day
62364747|NCT04673344|NO_INTERVENTION|Partial Rotator Cuff Repair|Routine partial rotator cuff repair
62364748|NCT04673344|ACTIVE_COMPARATOR|Partial Rotator Cuff Repair with Regeneten Scaffold|Routine partial rotator cuff repair with the addition of the Regeneten scaffolding patch
62364749|NCT01399255|EXPERIMENTAL|Listro™ Arm|Insulin Lispro (Listro™); 100 U/mL, DispoPen 3.0 mL.
62364750|NCT01399255|ACTIVE_COMPARATOR|Humalog® Arm|Insulin Lispro (Humalog®; 100 U/mL), Humalog® Kwik Pen™ 3.0 mL.
62364751|NCT04208880|EXPERIMENTAL|TBH Brain Workout 1.0|The TBH Brain Workout program will cover education topics that encourage engagement in interventions shown to impact cognitive performance, including those to enhance intellectual (e.g., how to focus attention), physical (e.g., how to eat healthy), and socio-emotional (e.g., how to stay socially engaged) well-being. The challenge activities will be easy to master.
62364752|NCT04208880|EXPERIMENTAL|TBH Brain Workout 2.0|The TBH Brain Workout program will cover education topics that encourage engagement in interventions shown to impact cognitive performance, including those to enhance intellectual (e.g., how to focus attention), physical (e.g., how to eat healthy), and socio-emotional (e.g., how to stay socially engaged) well-being. The challenge activities will be moderately difficult to master.
62364753|NCT04208880|EXPERIMENTAL|TBH Memory 1.0|The TBH Memory program will cover educational topics on how memory works, what environmental factors impact memory, and memory strategies. The challenge activities will be easy to master.
62550401|NCT02403258|ACTIVE_COMPARATOR|HRT group|Patients randomized into this group will receive habit reversal training (HRT) as treatment. Habit reversal training will consist of the following 4 parts: (1) self-monitoring, (2) competing responses, (3) relaxation training and (4) contingency management. The training will be given weekly in the 12 weeks (totally 12 sessions) by a special rehabilitation therapist, first two sessions 1.5 h, and remaining sessions 1 h for each treatment.
62550402|NCT05336032|ACTIVE_COMPARATOR|Oral glucose tolerance test|The volunteer will be performing the standardized oral glucose tolerance test with 75 gm of glucose. After an overnight fast of 10 hours the venous blood will be collected at fasting, 30, 60 and 120 minutes post-prandial and hunger-satiety scale recorded at the same interval.
62550403|NCT05336032|EXPERIMENTAL|Post prandial response to Rice|The participants will be served cooked basmati rice (70-gram available glucose). After an overnight fast of 10 hours the venous blood will be collected at fasting, 30, 60 and 120 minutes post-prandial and hunger-satiety scale recorded at the same interval.
62364754|NCT04208880|EXPERIMENTAL|TBH Memory 2.0|The TBH Memory program will cover educational topics on how memory works, what environmental factors impact memory, and memory strategies. The challenge activities will be moderately difficult to master.
62550404|NCT05149391|EXPERIMENTAL|C-CAR039|Autologous C-CAR039 administered by intravenous (IV) infusion
62550405|NCT02443740|EXPERIMENTAL|Single Ascending Dose-1 (Part A)|Single ascending doses of BIIB118 administered to healthy volunteers in a cross over study design
62550406|NCT02443740|EXPERIMENTAL|Single Ascending Dose-2 (Part A)|Single ascending doses of BIIB118 administered to healthy volunteers in a cross over study design
62174646|NCT00136175|EXPERIMENTAL|Arm I|Patients with clinical stage T2 with hydronephrosis or T3 bladder cancer will receive 3 cycles of chemotherapy (200mg/m\^2 paclitaxel on day 1, carboplatin on day 1, and 800 mg/m\^2 gemcitabine on days 1 and 8 of each 21 day cycle).
62550407|NCT02443740|EXPERIMENTAL|Single Dose Cerebrospinal Fluid (Part B)|Single maximum dose from Part A of BIIB118 administered to healthy volunteers to assess the PK of BIIB118 in CSF
62550408|NCT05296174|EXPERIMENTAL|cognitive-oriented intervention program|"The intervention group received a 40 mins social support intervention program once a week lasting for 6 weeks.~All participants were assessed by questionnaires before and after the intervention."
62550409|NCT05296174|ACTIVE_COMPARATOR|received health education program|"The control group received health education activities with the same frequency as the intervention group.~All participants were assessed by questionnaires before and after the intervention."
62550410|NCT02969421|ACTIVE_COMPARATOR|Slow Tenaculum Placement|This group will have their tenaculum placed using the slow method
62550411|NCT02969421|ACTIVE_COMPARATOR|Cough Method|This group will have their tenaculum placed using the cough method
62550412|NCT04488315|EXPERIMENTAL|The dexamethasone lipid microsphere plus ropivacaine group|
62550413|NCT04488315|ACTIVE_COMPARATOR|The ropivacaine alone group|
62550414|NCT01485133||Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
62550415|NCT01485133||Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered via a needle adaptor or the built-in scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
62364755|NCT04208880|ACTIVE_COMPARATOR|Book Club|The Book Club will be given a book to read on how to improve brain health and will discuss separate chapters across 8 sessions. These sessions will be led by the participants and no formal structure will be provided. No personal challenges will be asked of participants and no log will be required. All groups will have a sign-in sheet to record individual participation.
62364756|NCT04208880|NO_INTERVENTION|No Contact Wait List|The Wait List group will simply take the the surveys at each time point as the other groups.
62391451|NCT05183932||Surgery|"* Participants will have standard of care lobectomy/segmentectomy/wedge resection. Decision for treatment will be made at the discretion of the treating physician.~* PROMIS instruments include 8 domains and will be completed prior to treatment, 1 month post-treatment, 6 months post-treatment, 12 months post-treatment, 24 months post-treatment, and 36 months post-treatment~  * Bank 2.0 - Physical Function~ * Bank v1.1 - Pain Interference~ * Bank v1.0 - Fatigue~ * Bank v1.0 - Depression~ * Bank v1.0 - Anxiety~ * Bank v1.0 - Dyspnea Severity~ * Bank v2.0 - Ability to Participate in Social Roles and Activities~ * Bank v2.0 - Cognitive Function"
62550416|NCT00052598|EXPERIMENTAL|Treatment (adoptive immunotherapy)|Patients receive allogeneic CD8+ PR3-specific CTLs IV over 1-2 hours on days 0, 7, 14, 28, and 49 and aldesleukin SC twice daily on days 28-41 and 49-63 in the absence of unacceptable toxicity.
62550417|NCT03220854|EXPERIMENTAL|A: SBRT (body) irradiation only|Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations
62550418|NCT03220854|EXPERIMENTAL|B: Patients receiving SBRT and SRS (body and brain) irradiation|Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations
62550419|NCT03220854|EXPERIMENTAL|C: Patients receiving SRS (brain) irradiation only|Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations
62550420|NCT03240783|EXPERIMENTAL|Arm 1|Betamethasone OR Dexamethasone Injectable CT - fluoroscopic guided transforaminal lumbar epidural steroid
62550421|NCT03240783|EXPERIMENTAL|Arm 2|Normal Saline Flush, 0.9% Injectable Solution CT - fluoroscopic guided transforaminal lumbar epidural normal saline
62550422|NCT03240783|EXPERIMENTAL|Arm 3|"Dexamethasone Oral Tablet:~Oral dexamethasone 15 day tapered dosing is as follows: (i) days 1-5, 4 mg morning and evening, (ii) days 6-10, 2 mg morning and evening, and (iii) days 11-15, 1mg morning and evening."
62174647|NCT00136175|EXPERIMENTAL|Arm II|Patients with T4 or lymph node positive disease will receive up to 6 cycles of paclitaxel, carboplatin, and gemcitabine.
62550423|NCT03240783|OTHER|Arm 4|Sham Injection and/or oral placebo: CT/fluoroscopic guided (parameters set to zero) transforaminal lumbar sham (needle placement down to muscle and no injection of any fluid) AND placebo oral tablets taper.
62550424|NCT03678571|EXPERIMENTAL|Latrunculin A supplemented vitrification medium|
62550425|NCT03678571|NO_INTERVENTION|Vitrification medium with no supplementation|
62550426|NCT04983186|EXPERIMENTAL|Participants|Participants wear the Empatica E4 wearable sensor and use the smartphone applications developed by the research team.
62550427|NCT04874831|EXPERIMENTAL|domatinostat and avelumab|Single arm study of Domatinostat tablets in combination with avelumab infusion
62550428|NCT06550609|EXPERIMENTAL|Subjects treated|There is one treatment group. All patients will receive miltefosine TID for 28 days plus inhaled pentamidine on days 1,3,5,8,10,12,15,17,19,22.
62567147|NCT02044302|EXPERIMENTAL|standard analgesics and botulinum toxins|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during your operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
62550429|NCT04199052|NO_INTERVENTION|Standard of Care|Women assigned to the control arm will receive self-directed (non-Virtual Peer Navigator (PN) supported) treatment as usual at the HIV care service provider of choice following the Ryan White standard of care (i.e., referrals to physical, dental and mental health services; case management; and ancillary services. Annual assessments (e.g., updates on insurance, housing, referrals needed, behavioral assessment \[e.g., depression, substance use\]) are conducted by a case manager. For women who have fallen out of care and re-engage care, case management begins with an interview and assessment of current needs. Goals are set to create an individual care plan related to medical care, housing, and other resources, as needed. Referrals are made to appropriate services (e.g., primary care, housing, benefits counseling, food, support services) based on the intake assessment. It is important to note that the case management approach is self-guided versus intensive virtual PN assistance.
62550430|NCT04199052|EXPERIMENTAL|LinkPositively Intervention|Women assigned to the LinkPositively intervention arm will have access to all four components of the LinkPositively app. Women will be scheduled for a session with staff to inform them of their assigned virtual Peer Navigator (PN). Staff will train participants on how to download the app, explain the five components, using each component, and contacting their PN. Within the first week after, virtual PNs will complete a one-on-one, in-person or phone intake session with the participant, based on the participant's preference. During this intake session, the PN will conduct a participant needs assessment to connect her to HIV medical care via local health clinics and identify other areas of need, services of need, and assisted referrals (domestic violence services, mental health care, substance abuse treatment, housing and legal support, etc.). PNs will provide trauma-informed emotional and informational support, including guidance on accessing information about referred services.
62550431|NCT00637494|ACTIVE_COMPARATOR|1|Mifepristone followed by an antidepressant
62550432|NCT00637494|PLACEBO_COMPARATOR|2|Placebo followed by an antidepressant
62550433|NCT03830372|EXPERIMENTAL|VR Tier One|"Patients will receive:~* 10 sessions of 20 minutes of VR Tire One therapeutic game,~* 60 minutes of individual physiotherapy based on the Bobath and PNF concept with elements of manual therapy,~* 30 minutes individual aerobic training,~* 30 minutes balance exercises."
62550434|NCT03830372|ACTIVE_COMPARATOR|Control|"Patients will receive:~* 10 sessions of 20 minutes of Schultz Autogenic Training,~* 60 minutes of individual physiotherapy based on the Bobath and PNF concept with elements of manual therapy,~* 30 minutes individual aerobic training,~* 30 minutes balance exercises."
62550435|NCT01301729|EXPERIMENTAL|Trastuzumab|Participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams per meter square (mg/m\^2), every 3 weeks or paclitaxel 90 mg/m\^2 once a week until progression of disease, occurrence of intolerable toxicity, the participant discontinues the study or dies.
62550436|NCT01729949|ACTIVE_COMPARATOR|Active Treatment Beverage|Strawberry powder and Blackcurrent extract
62550437|NCT01729949|PLACEBO_COMPARATOR|Placebo Treatment Beverage|Placebo Beverage
62550438|NCT03498495|EXPERIMENTAL|SMART Intervention|
62550439|NCT03498495|NO_INTERVENTION|Usual Care|
62550440|NCT06329921|ACTIVE_COMPARATOR|Active Comparator: PTT protocol|Patients randomized to this arm will be monitored using the nurse-managed PTT guided protocol. This includes patients on both high- and low-dose heparin protocols.
62174648|NCT01078584||Hypertensive Participants|Hypertensive diabetics and non-diabetics, with or without isolated systemic hypertension and/or renal dysfunction, who were naïve to trandolapril or on trandolapril within past 30 days.
62174649|NCT03595137|EXPERIMENTAL|sono with simple needle guide device group (Group D)|sono with simple needle guide device Simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
62174650|NCT03595137|PLACEBO_COMPARATOR|sono only group (Group S)|sono only group After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
62174651|NCT02780739|EXPERIMENTAL|Cognitive Training - 48 sessions|56 hours of video game training with Mind Frontiers adaptive cognitive training software (48 70-min sessions distributed over 16 weeks)
62174652|NCT02780739|EXPERIMENTAL|Fitness, Cognitive Training, sham tDCS|32 hours and 40 min of high-intensity cardiorespiratory fitness training (28 70-min sessions distributed over 16 weeks); 23 hours and 20 min of video game training with Mind Frontiers adaptive cognitive training software with simultaneous sham tDCS (20 70-min sessions distributed over weeks 5-16)
62174653|NCT02780739|EXPERIMENTAL|Fitness, Cognitive Training, active tDCS|32 hours and 40 min of high-intensity cardiorespiratory fitness training (28 70-min sessions distributed over 16 weeks); 23 hours and 20 min of video game training with Mind Frontiers 1.0 adaptive cognitive training software with simultaneous active tDCS for a total of 10 hrs (20 70-min sessions distributed over weeks 5-16)
62174654|NCT02780739|ACTIVE_COMPARATOR|Active Control|56 hours of video game training with visual search and change detection tasks using open sesame software (48 70-min sessions distributed over 16 weeks)
62364757|NCT05975372|EXPERIMENTAL|Blossom tissue expander|"The intervention group involves the placement of the Mentor Spectrum tissue expander coupled with Blossom Syringe Assist device inserted above the pectoralis major muscle in the usual fashion. The nature of the surgery remains identical to that employed for conventional breast tissue expander insertion for reconstruction or augmentation.~Postoperative follow-up will occur within 1 week of surgery. Weekly follow-ups with documentation of clinical data throughout will also take place until completion of the expansion, stabilization of surgical scars, and removal of all percutaneous drains. Tissue expansion will be automatic via the Blossom device until appropriate volume is achieved. Thereafter, follow-ups will be scheduled as needed (monthly) according to usual clinical practice in implant-based breast reconstruction in preparation for the second stage expander to definitive implant exchange."
62364758|NCT05975372|ACTIVE_COMPARATOR|Standard tissue expansion|The standard tissue expansion group will undergo the same procedure with placement of the Mentor Spectrum tissue expander inserted above the pectoralis major muscle in the usual fashion. Postoperative follow-up will occur within 1 week of surgery. Weekly follow-ups with documentation of clinical data throughout will also take place until completion of the expansion, stabilization of surgical scars, and removal of all percutaneous drains. Tissue expansion will be achieved via serial injections of sterile saline into the tissue expander during postoperative follow up visits. Thereafter, follow-ups will be scheduled as needed (monthly) according to usual clinical practice in implant-based breast reconstruction in preparation for the second stage expander to definitive implant exchange. The postoperative follow-up and subsequent surgery to exchange the device to a permanent implant is normal part of standard care.
62364759|NCT01674660||volume status|volume status:group1 over volume status,group2 normal volume status,group3 low volume status
62364760|NCT01674660||night blood pressure|night blood pressure：group1 nondipper,group2 dipper,group3 extreme dipper,group4 riser
62364761|NCT01674660||interdialysis weight gain|interdialysis weight gain:group1 \>5% dry weight,group2 \<5% dry weight
62364762|NCT04443894|ACTIVE_COMPARATOR|PECS block|
62364763|NCT04443894|ACTIVE_COMPARATOR|local infiltration|
62364764|NCT03491969|EXPERIMENTAL|Alpha-Lipoic Acid(α-LA)|Double blind treatment period consisted of treatment with CHF standard treatments, followed by α-LA 200 mg tid over a total duration of 24 months.
62364765|NCT03491969|PLACEBO_COMPARATOR|Placebo|Double blind treatment period consisted of treatment with CHF standard treatments, followed by Placebo 200 mg tid over a total duration of 24 months.
62550441|NCT06329921|ACTIVE_COMPARATOR|Active Comparator: anti-Xa protocol|Patients randomized to this arm will be monitored using the pharmacy-managed anti-Xa protocol. This includes patients on both high- and low-dose heparin protocols.
62550442|NCT00934687|EXPERIMENTAL|clostridium botulinum toxin type A neurotoxin complex|A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.
62550443|NCT00934687|PLACEBO_COMPARATOR|0.9% sodium chloride NaCl solution|0.9% NaCl solution will be injected like the experimental compound
62550444|NCT05596656||allergic type 1 DM children|45 cases were considered allergic based on written questionnaire taken by the resident. Diagnosis of atopy was confirmed by skin prick testing
62550445|NCT05596656||Non-allergic type 1 DM children|Forty-five Non-allergic type 1 DM children were selected as age and sex matched control group.
62550446|NCT05088135|EXPERIMENTAL|Bilateral Auricular Vagus Nerve Stimulation|Vagus nerve stimulation is applied to this group from both ears.
62550447|NCT05088135|EXPERIMENTAL|Unilateral - Right Auricular Vagus Nerve Stimulation|In this group, vagus nerve stimulation is performed only from the right ear.
62550448|NCT05088135|EXPERIMENTAL|Unilateral - Left Auricular Vagus Nerve Stimulation|In this group, vagus nerve stimulation is performed only from the left ear.
62364766|NCT04564703|EXPERIMENTAL|cohort 1|Iberdomide will be given orally at 1.3 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
62364767|NCT04564703|EXPERIMENTAL|cohort 2|Iberdomide will be given orally at 1.0 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
62550449|NCT00866359|ACTIVE_COMPARATOR|A. Apremilast|
62550450|NCT00866359|PLACEBO_COMPARATOR|B. Placebo Comparator|
62550451|NCT00711880|EXPERIMENTAL|Sativex|
62550452|NCT00711880|PLACEBO_COMPARATOR|Placebo|
62174655|NCT02780739|NO_INTERVENTION|No Contact Control|Completed no study activities for 16 weeks after pre-assessment, then returned for post-assessment
62364768|NCT04564703|EXPERIMENTAL|cohort 3|Iberdomide will be given orally at 0.75 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
62364769|NCT05821036|EXPERIMENTAL|Intervention group|"Inclusion criteria:~* Having been diagnosed with FMS by a specialist physician,~* Being a woman between the ages of 18-64,~* To be literate,~* Having and actively using a smartphone or a computer~Exclusion criteria:~* Any disease accompanying FMS, the presence of psychiatric illness and endocrine disorders,~* Have previous activity management training,~* Currently and up to 4 weeks on psychotropic medication,~* Breastfeeding and pregnancy"
62364770|NCT05821036|NO_INTERVENTION|Control group|"Inclusion criteria:~* Having been diagnosed with FMS by a specialist physician,~* Being a woman between the ages of 18-64,~* To be literate,~* Having and actively using a smartphone or a computer~Exclusion criteria:~* Any disease accompanying FMS, the presence of psychiatric illness and endocrine disorders,~* Have previous activity management training,~* Currently and up to 4 weeks on psychotropic medication,~* Breastfeeding and pregnancy"
62364771|NCT01846689|EXPERIMENTAL|ESS|Prescription medical food erythropoietin stimulating system
62550453|NCT04509934|ACTIVE_COMPARATOR|Group 1|Connective Tissue Manipulation was performed to participants in Group 1, starting at the end of the menstrual cycle, 5 days a week and for 1 cycle (approximately 3 weeks) until the beginning of the next period.
62550454|NCT04509934|ACTIVE_COMPARATOR|Group 2|In Group 2, Connective Tissue Manipulation was started with the completion of menstrual cycle performed to participants for 5 days a week and until the other menstrual cycles. At the end of the menstrual cycle, it was restarted and a total of 2 cycles were applied until the second menstrual cycle started (approximately 6 weeks).
62550455|NCT05936515||Post-intervention group (Training course group)|The experimental group will be composed of patients aged 75 and over hospitalised in specialised departments after the establishment of geriatric correspondents trained in the specific care for the elderly.
62550456|NCT05936515||Pre-intervention group (Control group)|The control group will be composed of patients aged 75 years and over hospitalised in specialised departments before the introduction of geriatric correspondents trained in the specific care for the elderly. Their care will be conducted in accordance with usual practices.
62364772|NCT01960504|EXPERIMENTAL|Drug Eluting Absorbable Metal Scaffold|DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold
62364773|NCT02152072||medical students|
62550457|NCT04214197|OTHER|Crisaborole|Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
62550458|NCT05568667|EXPERIMENTAL|Risk sub-group|"1. st sub-grouup : Low risk to develop a CRC~2. nd sub-group : Moderate risk to develop a CRC~3. rd sub-group : High risk to develop a CRC"
62550459|NCT00972296||Persons with hemophilia with ankle pain|
62364774|NCT01927068|EXPERIMENTAL|Global Cohort 1|All subjects to be treated with the Stellarex 035 Drug Coated Balloon (DCB) for Percutaneous Transluminal Angioplasty (PTA).The drug coating is paclitaxel (PTX).
62550460|NCT00586534|ACTIVE_COMPARATOR|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
62550461|NCT00586534|EXPERIMENTAL|I/GDC + VR/CER|Second Arm:NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
62550462|NCT00797589|EXPERIMENTAL|Ringer lactate|Crystalloid solution
62550463|NCT00797589|EXPERIMENTAL|HES solution (Tetraspan®)|Balanced colloid solution
62550464|NCT00980031|PLACEBO_COMPARATOR|Lactose Tablet|Compounded capsule using Lactose Monohydrate Powder
62550465|NCT00980031|ACTIVE_COMPARATOR|Eplerenone|25 mg tablet placed in a capsule filled with Lactose Monohydrate Powder.
62550466|NCT05223140||Cases|Admission to NICU or early perinatal death
62550467|NCT05223140||Controls|No admission to NICU or early perinatal death
62550468|NCT03394469|OTHER|cohort|Collection of clinical and paraclinical data (biological and anthropometric) for evaluation of sarcopenic obesity in obese patients.
62550469|NCT01122186|EXPERIMENTAL|Intervention Condition|Eight sessions of Motivational Interviewing and Cognitive Behavioral Skills Training, adapted to target both MA use and medication adherence, as well as sexual risk behaviors and polydrug use.
62550470|NCT01122186|ACTIVE_COMPARATOR|Education Condition|Eight sessions of education with content designed to mirror the information covered in the intervention condition. The content will be as follows: 3 sessions focusing on medication adherence; 3 sessions focusing on the dangers of methamphetamine use; 1 session addressing sexual risk; and 1 session addressing poly-substance use.
62550471|NCT04160624|ACTIVE_COMPARATOR|Non-ECLS GROUP|For AS/R patients with normal EF, only TAVR was performed
62550472|NCT04160624|EXPERIMENTAL|ECLS GROUP|For AS/R patients with low EF, TAVR under ECLS-assisted was performed
62550473|NCT06490367|EXPERIMENTAL|Time-Restricted Eating|All participants are assigned to this arm.
62550474|NCT05707793||women suffering from vaginal laxity|self-reported perception of vaginal laxity on the Vaginal Laxity Questionnaire
62550475|NCT05707793||normal subjects without vaginal laxity|No self-reported perception of vaginal laxity on the Vaginal Laxity Questionnaire
62550476|NCT02208830|EXPERIMENTAL|conventional program|The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
62550477|NCT02208830|EXPERIMENTAL|pulmonary rehabilitation|Duration of 8 week, twice weekly exercise program with: lower limb strength training and aerobic training per 30 minutes.
62550478|NCT05961917|ACTIVE_COMPARATOR|Group low PEEP|Positive end-expiratory pressure will be set at 5 cmH2O during controlled mechanical ventilation.
62182386|NCT05955677|EXPERIMENTAL|[68Ga]Ga-PSMA-D5 and [68Ga]Ga-PSMA-11 PET/ CT scan|Subjects PET/CT imaging: On any two days for two consecutive weeks, each subject underwent a PET/ CT scan after intravenous injection of \[68Ga\]Ga-PSMA-D5 and \[68Ga\]Ga-PSMA-11.
62550479|NCT05961917|ACTIVE_COMPARATOR|Group high PEEP|Positive end-expiratory pressure will be set at 10 cmH2O during controlled mechanical ventilation.
62182387|NCT00962806|ACTIVE_COMPARATOR|Exercise|8 week intensive exercise group
62550480|NCT02547688|OTHER|Nasal High Flow|All subjects are in this group
62182388|NCT00962806|OTHER|Control Lifestyle counseling|Lifestyle counseling without intensive exercise
62364775|NCT01927068|EXPERIMENTAL|ISR Cohort 2|All subjects to be treated with the Stellarex 035 Drug Coated Balloon (DCB) for Percutaneous Transluminal Angioplasty (PTA).The drug coating is paclitaxel (PTX).
62364776|NCT00748865|EXPERIMENTAL|Systane Ultra|Systane Ultra 1 drop each eye one time
62364777|NCT00748865|ACTIVE_COMPARATOR|Systane|Systane 1 drop each eye one time
62364778|NCT02955771|EXPERIMENTAL|PDT-Deuteporfin（6 hour）plus stenting|Deuteporfin (7.5mg/kg) was injected intravenously 6 hours before intraluminal photoactivation (wavelength,630 nm;light dose, 180 J/cm(2)). After PDT, endoscopic or percutaneous stenting will be performed.The second treatment may be given after 3 months.
62364779|NCT02955771|EXPERIMENTAL|PDT-Deuteporfin（9 hour）plus stenting|Deuteporfin (7.5mg/kg) was injected intravenously 9 hours before intraluminal photoactivation (wavelength,630 nm;light dose, 180 J/cm(2)). After PDT, endoscopic or percutaneous stenting will be performed.The second treatment may be given after 3 months.
62364780|NCT02955771|OTHER|Stenting|Endoscopic or percutaneous stenting alone will be performed.
62550481|NCT01709929|EXPERIMENTAL|Insulin detemir|
62550482|NCT03672253|EXPERIMENTAL|CAR-T Re-treatment group|Patients will be treated with CAR-T cells targeting BCMA (Different epitope with the previous CAR-T cell treatment they had been used) with a escalation approach, 0.5x10\^6- 2.0x10\^6 CAR-T cells/kg.
62550483|NCT00641446|EXPERIMENTAL|1|Pulmicort
62550484|NCT00641446|ACTIVE_COMPARATOR|2|Varivax
62550485|NCT03242525||Emergency room|Twelve bleeding patients who are assigned to the emergency department receive a simultaneous blood analysis with POCT and central laboratory.
62550486|NCT03242525||Delivery room|Twelve bleeding patients who are assigned to the delivery room receive a simultaneous blood analysis with POCT and central laboratory.
62550487|NCT06194617||Patients with pulmonary embolism and using direct oral anticoagulants|Patients with pulmonary embolism and using direct oral anticoagulants
62550488|NCT01669187|ACTIVE_COMPARATOR|Education brochure|The control group will receive a standard education brochure which will be provided pre-operatively to the participants.
62739353|NCT00632827|EXPERIMENTAL|Treatment Plan|(1) Induction Chemo A; Two 21-day cycles of Gemcitabine 1000 mg/m2 days (D) 1, 8, Navelbine 20 mg/m2 D1, D8; Doxil 15 mg/m2 Days 1 and 8, G-CSF Days 4-6 and 10-15 (2) Induction Chemo B: Two 21-day cycles of Cyclophosphamide 2000 mg/m2 day 1; Doxorubicin 50 mg/m2 day 1; Vincristine 1.4 mg/m2 day 1; Prednisone 100 mg/m2 days 1-5; Methotrexate 3000 mg/m2 IV over 4h day 15; Leucovorin rescue (3) Disease Evaluation (4) High-dose Consolidation Chemo, high dose Ara-C, Denileukin diftitox (Ontak) and Stem Cell Collection (5) Consolidation Cytarabine 2000 mg/m2 IV over 2 h q 12h days 1-4, Etoposide 40 mg/m2 continuous intravenous infusion (CIVI), days 1-4, Denileukin Diftitox (Ontak) 9 mcg/kg/day days 6-10, G-CSF 10 mcg/kg/day day 14+, Stem cell collection day 22 (6) Autologous Stem Cell Transplant Carmustine 550 mg/m2 day -6, Etoposide 60 mg/kg IV over 4h day -4, Cyclophosphamide 100 mg/kg day -2, Stem cell infusion D0 (7) Post-transplant: Denileukin Diftitox (Ontak) 18 mcg/kg/day days 1- 5
62739354|NCT02406469|EXPERIMENTAL|Sequence A1-A2|Oral consumption of milk containing both A1 and A2 type beta casein in intervention phase 1 and milk containing only A2 type beta casein in intervention phase 2.
62739355|NCT02406469|PLACEBO_COMPARATOR|Sequence A2-A1|Oral consumption of milk containing only A2 type beta casein in intervention phase 1 and milk containing both A1 and A2 type beta casein in intervention phase 2.
62174656|NCT01585805|EXPERIMENTAL|Arm A (veliparib, gemcitabine hydrochloride, cisplatin)|Patients receive veliparib PO BID on days 1-12 or 1-21 of each cycle. Patients also receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 30 minutes on days 3 and 10 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout study. Patients also undergo tumor tissue and blood sample collection throughout the trial and undergo tumor biopsy during screening and on study.
62174657|NCT01585805|ACTIVE_COMPARATOR|Arm B (gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV and cisplatin IV as patients in arm A. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout study. Patients also undergo tumor tissue and blood sample collection throughout the trial and undergo tumor biopsy during screening and on study.
62174658|NCT01585805|EXPERIMENTAL|Arm C (veliparib)|Patients receive veliparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout study. Patients also undergo tumor tissue and blood sample collection throughout the trial.
62174659|NCT05139576||Pediatric Subjects and adults|Subjects were categorized into two age groups: \<18 years (pediatric) and ≥18 years (adult).
62174660|NCT05139576||Pediatrics and adults|Subjects were categorized into two age groups: \<18 years (pediatric) and ≥18 years (adult).
62174661|NCT02453516|EXPERIMENTAL|Serratus Block Group|Patients will receive a preoperative ultrasound-guided serratus block with 0.4ml/kg (max.30ml) of ropivacaine 0.5% with 1:4000,000 epinephrine injected between the serratus anterior (superficial) and external intercostal (deep) muscles followed by subsequent general anesthesia
62174662|NCT02453516|PLACEBO_COMPARATOR|Placebo Block - Control Group|Patients will receive a preoperative placebo injection with a subcutaneous injection of 1ml normal sterile saline solution in the midaxillary line and the ultrasound probe will be used to simulate the pressure and block duration associated with the serratus block. These patients will then receive general anesthesia.
62174663|NCT00392314|EXPERIMENTAL|Early favorable|patients with early favorable disease Ia IIA will have a PET/CT following 2 cycles of ABVD
62174664|NCT00392314|EXPERIMENTAL|Early Unfavorable|Patients with early favorable disease Ia or IIa with risk factors :large mediastinal mass extra nodal disease elevated esr, three or more involved areas, age equal or \>50 , lymphocytic depleted or mixed cellularity
62739356|NCT03213743|OTHER|before dexmedetomidine|We took blood samples before the administration of dexmedetomidine to determine exression level of microRNA in the subjects.
62739357|NCT04168164|EXPERIMENTAL|Ai Chi|Ai Chi aquatic therapy Dry land therapy
62174665|NCT00392314|EXPERIMENTAL|advanced disease|patients with advanced disease low IPS score 0-2 will start chemotherapy with ABVD for 2 cycles followed by PET/CT further therapy will be given according to PET/CT results
62174666|NCT00392314|EXPERIMENTAL|advanced disease IPS 3-7|Patients with advanced disease IPS score 3-7 will start chemotherapy with escalated beacopp. following 2 cycles PET/CT will be carried out and according to results further chemotherapy will be given
62174667|NCT01593436|ACTIVE_COMPARATOR|mindfulness training|mindfulness training for patients with insomnia
62174668|NCT01593436|NO_INTERVENTION|polysomnography and actigraphy|The intention is to assess the sleep architecture of meditators and non meditators women without menopausal insomnia by polysomnographic , actigraphy, and questionnaires to assess sleep quality and emotional state
62174669|NCT04392479|ACTIVE_COMPARATOR|Aflibercept-FOLFIRI (arm 1)|"* Aflibercept (D1) H0: 4mg/kg IV infusion over 60min (+ 2-minute window),~* Folinic acid (D1) H+1: 400mg/m² IV infusion over 120min (+ 2-minute window),~* Irinotecan (D1) H+1: 180mg/m² IV infusion over 60min (+ 2-minute window),~* 5-fluorouracile (D1) H+3: 400mg/m² IV infusion over 15min (+ 2-minute window),~* 5-fluorouracile (D1 to D3): H+3.5: 2400mg/m² IV infusion over 46 hours (+ 1hour window)~* H+49.5: End of treatment administration"
62174670|NCT04392479|EXPERIMENTAL|Aflibercept-mFOLFIRI3 (arm 2)|"* Aflibercept (D1) H0: 4mg/kg IV infusion over 60min (+ 2-minute window),~* Folinic acid (D1) H+1: 400mg/m² IV infusion over 120min (+ 2-minute window),~* Irinotecan (D1 and D3) H+1 and H+49: 75mg/m² IV infusion over 60min (+ 2-minute window) on cycles 1 and 2, then 90mg/m² at cycle 3 and furthers in absence of AEs grade ≥2,~* 5-fluorouracile (D1 to D3) H+3: 2400mg/m² IV infusion over 46 hours (+ 1hour window)~* H+50: End of treatment administration"
62174671|NCT01107106||Adolescents|250 postmenarcheal adolescent girls
62174672|NCT01107106||Adults|250 adult women
62174673|NCT04885426|EXPERIMENTAL|low-dose metformin group|low-dose metformin, 250mg/day
62174674|NCT04885426|EXPERIMENTAL|high-dose metformin group|high-dose metformin, 500mg/day
62174675|NCT04885426|PLACEBO_COMPARATOR|control group|placebo
62174676|NCT00255944|EXPERIMENTAL|Youthnet messages on Facebook|Participants will receive internet-based messages from the Youthnet program
62739358|NCT04002050|ACTIVE_COMPARATOR|CBTm Course Intervention|Participants placed in the intervention group will receive the CBTm Course. The CBTm Course consists of 5 classes, 90 minutes each, and held in-person on a weekly basis.
62174677|NCT00255944|ACTIVE_COMPARATOR|Messages on Facebook about current events|Participants will receive internet-based messages from the control program
62174678|NCT02966600|EXPERIMENTAL|Progressive resistance exercise (PRE)|Progressive resistance exercise (PRE) in akinetic-rigid Parkinson's disease patients. Intervention included sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.
62174679|NCT02966600|NO_INTERVENTION|Physical Activity|The control group followed its usual weekly physical activity routine
62550489|NCT01669187|EXPERIMENTAL|Live education and exercise instruction|The intervention group will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
62550490|NCT03637426|PLACEBO_COMPARATOR|GPLACEBO|In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
62550491|NCT03637426|EXPERIMENTAL|Gn-HAP|In this group a desensitizing gel containing 20% of nano-hydroxyapatite, 9000 ppm of sodium fluoride and 5% of potassium nitrate (Desensibilize Nano P, FGM®, Joinville, SC, Brazil) was applied to the hypersensitive dentin. The GnHAP volunteers will be submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications.
62550492|NCT03637426|EXPERIMENTAL|GLASER|"In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil) was applied in hypersensitive dentine.~GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours."
62364781|NCT01801189|EXPERIMENTAL|Pregabalin|Single, 300 mg pre-operative oral dose of Pregabalin.
62364782|NCT01801189|PLACEBO_COMPARATOR|Sugar Pill|Single, placebo pre-operative dose.
62364783|NCT03157843||Medical Patients|Medical patients who received, at admission and during all the length of recovery, antithrombotic drugs (low-molecular-weight heparin at prophylactic dosage ).
62364784|NCT03157843||Control Group|Medical patients not treated with antithrombotic drugs during the recovery. Subjects age, sex and comorbidities matched.
62364785|NCT01190020|ACTIVE_COMPARATOR|Lubiprostone|24mcg BID for 4 weeks, oral medication
62364786|NCT01190020|PLACEBO_COMPARATOR|Placebo|24mcg BID for 4 weeks (placebo), oral medication
62364787|NCT04220710||Marker selection group|Methalation detection of circulating free DNA and FFPF samples from pathologically confirmed patients with ovarian endometriosis(30 cases), ovarian cancer (30 cases)and other benign ovarian tumors (30 cases)will be performed to select markers for ovarian endometriosis diagnosis.
62364788|NCT04220710||Marker validation group|The selected markers will be validated in patients with ovarian cysts (300 cases )found by ultrasound. The diagnosis accuracy of the markers will be evaluated by comparing with the pathological diagnosis.
62550493|NCT03637426|EXPERIMENTAL|GLASERnHAP|In this group the laser + nano-hydroxyapatite was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, São Carlos, SP, Brazil) and a gel containing 20% nanohydroxyapatite, 9000 ppm sodium fluoride 5% potassium nitrate (Desensibilize Nano P, FGM®, Joinville, SC, Brazil) in hypersensitive dentin. GLASERnHAP first named a laser application and then an application of nanohydroxyapatite according to the manufacturer's recommendations.
62174680|NCT03715738|EXPERIMENTAL|arm 1 : Creaform3D + MyotonPRO|"A clinical questionnaire is completed by the investigator (chest circumference, thorax turn, breast measurements).~The breast density is assessed by the surgeon and scored from 1 to 5 (Likert scale) and then by the MyotonPRO The volumetric measurement of the breast is performed using the 3D digital camera. The patient is bent forward with hands resting on a chair during 30 seconds to 1 minute. The 3D digital camera rotates around the breast to capture the volume of the breast.~Intraoperatively, the weight of tissues removed is weighed (in grams), recorded in the observation notebook.~In post-operative (4 months), the possible long-term complications related to the intervention (mainly the dissatisfaction of the patient as for the aesthetic result) are collected then a new acquisition of the mammary volume is carried out with the digital camera 3D.~Once this measurement is completed, participation in the study is complete"
62174681|NCT03799289|EXPERIMENTAL|Iyengar Yoga|Participants randomized to the yoga intervention arm will receive 12 weeks of group-based yoga instruction, following a 12-week standard behavioral weight loss program. Group-based yoga instruction will occur twice per week and classes will be 60 minutes in duration. The yoga program will consist of breathing, postural, and meditation practices and home-based yoga practice will also be prescribed.
62182389|NCT04214275|EXPERIMENTAL|intervention group|standard care and participated in a pulmonary rehabilitation program
62364789|NCT04725201|EXPERIMENTAL|Intravenous unfractionated heparin|Administration of intravenous unfractionated heparin according to the Centre hospitalier de l'Université de Montréal (CHUM) deep vein thrombosis (DVT) protocol for 5 days after vascular anastomosis. A bolus will be administered intraoperatively based on the patient's weight. Dosages will be adjusted according to the activated partial thromboplastin time (aim for an APTT of 50-70), which will be measured 6 hours after the start of the protocol and after every dosage adjustment or every morning at 6 a.m. if no adjustments were made in the last 6 hours.
62364790|NCT04725201|SHAM_COMPARATOR|Control|"No administration of intravenous unfractionated heparin. These patients receive 5000 IU BID of heparin subcutaneously, as a standard post-operative protocol for all in-patients.~The control group receives sham bolus intraoperatively of normal saline and a post-operative normal saline infusion at a fixed dose through an infusion pump to mimic IV heparin infusion."
62364791|NCT01902693||HIV & chemotherapy|"Participants will be aged ≥ 18 years, aware of their HIV status and the diagnosis of malignancy, have a plasma viral load of \< 50 HIV-1 RNA copies/ml (on suppressive HAART) at enrolment and be designated to receive cytotoxic chemotherapy including one or more of the following agents: R-CHOP, ABVD, Liposomal doxorubicin (Caelyx) or liposomal daunorubicin (Daunoxome) or Paclitaxel.~There is no intervention for this study. Blood samples will be taken and if available from routine care surplus cerebrospinal fluid."
62364792|NCT02338856|EXPERIMENTAL|MB12066 200mg|
62739359|NCT04002050|NO_INTERVENTION|Comparison Group|Participants in the comparison group will not receive the intervention during the study, but will be offered intervention once the study has been completed (i.e. 3 month waiting-period). However, in the event that a stressful situation arises while a participant is placed in the comparison group, the participant may seek assistance from the usual mental health supports offered through their respective occupational organizations, EAP programs, and other programs in the community. Following completion of the study, participants in the comparison group will be invited to attend the CBTm Course.
62739360|NCT00709176|EXPERIMENTAL|Brief|Dyads randomized to BRIEF arm received the Brief FOCUS Program (two home visits and one phone call by a trained nurse) in addition to standard clinical care.
62174682|NCT03799289|ACTIVE_COMPARATOR|Cooking/dietary education|Participants randomized to the cooking/dietary education intervention arm will receive 12 weeks of group-based, cooking/dietary education instruction, following a 12-week standard behavioral weight loss program. This group-based instruction will occur twice per week and classes will be 60 minutes in duration. Classes will focus on providing basic nutrition knowledge and culinary skills, and will include cooking demonstrations.
62174683|NCT02166047|PLACEBO_COMPARATOR|Placebo 4 Weeks (Cohort A)|Placebo tablet once a week for 4 weeks
62174684|NCT02166047|EXPERIMENTAL|Vesatolimod 1 mg 4 Weeks (Cohort A)|Vesatolimod 1 mg tablet once a week for 4 weeks
62550494|NCT02764346|EXPERIMENTAL|iCanCope app|iCanCope app
62550495|NCT02764346|ACTIVE_COMPARATOR|Attention control app|Control group: iCanCope attention control app
62550496|NCT06191588|EXPERIMENTAL|infant cimt|"Other: Infant BIT Not use of unaffected hand containment. Both hand are use to improve the bimanual coordination~Other: Infant CIMT/BIT Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.~Other: Conventional therapy Following the usual therapy in the baby."
62550497|NCT06191588|ACTIVE_COMPARATOR|Infant BIT|"Other: Infant CIMT/BIT Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.~Other: Conventional therapy Following the usual therapy in the baby.~Other: infant cimt use of unaffected hand containment to improve the use of affected hand with unimanual activities"
62550498|NCT06191588|ACTIVE_COMPARATOR|Infant CIMT/BIT|"Other: Infant CIMT/BIT Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.~Other: Conventional therapy Following the usual therapy in the baby.~Other: infant cimt use of unaffected hand containment to improve the use of affected hand with unimanual activities"
62550499|NCT06191588|ACTIVE_COMPARATOR|Conventional Therapy|"Other: Infant BIT Not use of unaffected hand containment. Both hand are use to improve the bimanual coordination~Other: Infant CIMT/BIT Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.~Other: infant cimt use of unaffected hand containment to improve the use of affected hand with unimanual activities"
62550500|NCT02751671|EXPERIMENTAL|POCUS before clean catch sampling|The intervention of interest will be the use of emergency point-of-care ultrasound performed by a research assistant to evaluate bladder fullness before clean-catch stimulation manoeuvre. More specifically, following randomisation, children in the experimental group will have ePOCUS to measure the transversal bladder diameter. If the transversal bladder diameter is \> 2 cm, the CCU procedure will be started without a prior feeding period. If the diameter is \< 2 cm, the CCU will be postponed for a 20 minute feeding period and a new ePOCUS will be done. After the second ePOCUS, the CCU will be done if the transversal bladder diameter reaches \> 2cm. If not, the child will have another 20 minute feeding period and a third ePOCUS prior to proceeding to the CCU regardless the bladder diameter.
62364793|NCT02338856|PLACEBO_COMPARATOR|Placebo|
62364794|NCT00056550|EXPERIMENTAL|Recombinant Human Antithrombin (rhAT) infusion|Loading and continuous infusion dose of rhAT to target and maintain an AT activity level \> 80% and \< 120% of normal.
62174685|NCT02166047|EXPERIMENTAL|Vesatolimod 2 mg 4 Weeks (Cohort A)|Vesatolimod 2 mg tablet once a week for 4 weeks
62174686|NCT02166047|EXPERIMENTAL|Vesatolimod 4 mg 4 Weeks (Cohort A)|Vesatolimod 4 mg tablet once a week for 4 weeks
62739361|NCT00709176|EXPERIMENTAL|Extensive|Dyads randomized to EXTENSIVE arm received the Extensive FOCUS Program (4 home visits and two phone calls by a trained nurse) in addition to standard clinical care.
62739362|NCT00709176|NO_INTERVENTION|Control|Dyads randomized to CONTROL arm continued with standard clinical care.
62174687|NCT02166047|PLACEBO_COMPARATOR|Placebo 8 Weeks (Cohort B)|Placebo tablet once a week for 8 weeks
62739363|NCT05562206|EXPERIMENTAL|Study group|All subjects using the study device
62739364|NCT05558137||Elderly|patients aged 80 years or older
62174688|NCT02166047|EXPERIMENTAL|Vesatolimod 1 mg 8 Weeks (Cohort B)|Vesatolimod 1 mg tablet once a week for 8 weeks
62174689|NCT02166047|EXPERIMENTAL|Vesatolimod 2 mg 8 Weeks (Cohort B)|Vesatolimod 2 mg tablet once a week for 8 weeks
62174690|NCT02166047|EXPERIMENTAL|Vesatolimod 4 mg 8 Weeks (Cohort B)|Vesatolimod 4 mg tablet once a week for 8 weeks
62739365|NCT05558137||Young|patients aged 18-40 years
62739366|NCT06479291|EXPERIMENTAL|HCQ plus TPO-RA group|This group is experiment group. Participants will take eltrombopag for at least 24 weeks, the dose of eltrombopag is adjusted according to participants' platelet count, with HCQ twice a day for 1 year
62739367|NCT06479291|PLACEBO_COMPARATOR|TPO-RA group|This group is control group. Participants will take eltrombopag for at least 24 weeks, the dose of eltrombopag is adjusted according to participants' platelet count.
62739368|NCT04150237||Novices|Medical students
62739369|NCT04150237||Intermediates|Endoscopy (EGD) assisting nurses. No prior self-performed endoscopies
62739370|NCT04150237||Experienced|Medical doctors in medical Gastroenterology or surgery, who have self-performed more than 500 EGD
62174691|NCT02166047|PLACEBO_COMPARATOR|Placebo 12 Weeks (Cohort C)|Placebo tablet once a week for 12 weeks
62550501|NCT02751671|EXPERIMENTAL|Standard clean catch sampling|Patients allocated to this arm will have a 20 minute feeding period either being breastfed or provided with formula intake appropriate to the infant's age and weight. If possible, the genital areas of the infant will be cleaned with warm water and soap and dried with sterile gauze prior to the feeding. The parents will let the diaper opened and will be will be ready to collect urine if the child voids during the feeding period. After the feeding, the stimulated clean-catch procedure will be performed without prior ultrasound
62364795|NCT02569333|EXPERIMENTAL|Educational Video|Subjects to have access to educational video during hospital stay
62364796|NCT02569333|NO_INTERVENTION|Usual Care|Patients to receive usual care and will not have access to educational video.
62174692|NCT02166047|EXPERIMENTAL|Vesatolimod 1 mg 12 Weeks (Cohort C)|Vesatolimod 1 mg tablet once a week for 12 weeks
62739371|NCT05634785|EXPERIMENTAL|ATLCAR.CD30|Single Group Assignment: Subjects with Nonseminomatous Germ Cell Tumors who meet eligibility criteria for cellular therapy.
62174693|NCT02166047|EXPERIMENTAL|Vesatolimod 2 mg 12 Weeks (Cohort C)|Vesatolimod 2 mg tablet once a week for 12 weeks
62739372|NCT06238193||Early-onset colorectal cancer|Early-onset colorectal cancer
62739373|NCT06238193||Late-onset colorectal cancer|Late-onset colorectal cancer
62739374|NCT05889793|ACTIVE_COMPARATOR|Emetine|Participant takes Emetine 6mg for 10 consecutive days
62174694|NCT02166047|EXPERIMENTAL|Vesatolimod 4 mg 12 Weeks (Cohort C)|Vesatolimod 4 mg tablet once a week for 12 weeks
62174695|NCT05736302||Individuals without movement limitations|Individuals who are not classified as impaired or functionally limited per results of physical function testing.
62174696|NCT05736302||Individuals with impaired movement|Individuals who are classified as impaired, but not functionally limited per results of physical function testing.
62174697|NCT05736302||Individuals with impaired movement who are functionally impaired|Individuals who are classified as impaired and functionally limited per results of physical function testing.
62174698|NCT02312622|EXPERIMENTAL|Cohort A - Pegylated Irinotecan to treat NSCLC|Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
62174699|NCT02312622|EXPERIMENTAL|Cohort B - Pegylated Irinotecan to treat SCLC|Patients with small cell lung carinoma (SCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
62364797|NCT02005783|EXPERIMENTAL|DBD arm|Epirubicin: 90mg/m2, d1, q3w\*4 Cyclophosphamide: 600mg/m2, d1, q3w\*4 DBD: one dose of medicine twice per day, orally OR; Docetaxel: 75mg/m2, d1, q3w\*4 Cyclophosphamide: 600mg/m2, d1, q3w\*4 DBD: one dose of medicine twice per day, orally
62364798|NCT02005783|OTHER|EC/TC|Epirubicin: 90mg/m2, d1, q3w\*4 Cyclophosphamide: 600mg/m2, d1, q3w\*4 OR; Docetaxel: 75mg/m2, d1, q3w\*4 Cyclophosphamide: 600mg/m2, d1, q3w\*4
62739375|NCT05889793|PLACEBO_COMPARATOR|Placebo|Participant takes a placebo for 10 consecutive days
62739376|NCT02147210||1-Case|patients who developed CTG secondary to antibody-mediated kidney rejection (AMR), diagnosed by microscopic analysis.
62739377|NCT02147210||2-Control|patients with antibody-mediated kidney rejection (AMR) but without CTG
62739378|NCT04788485|ACTIVE_COMPARATOR|Neonates before adding smectite|neonates will receive diosmectite for treating of gastroesophageal reflux in neonates after MII-ph
62739379|NCT04788485|ACTIVE_COMPARATOR|neonates after adding smectite|neonates after they received diosmectite for treating of gastroesophageal reflux in neonates after MII-ph
62739380|NCT04967287|EXPERIMENTAL|MyopiaX|MyopiaX treatment
62739381|NCT04967287|ACTIVE_COMPARATOR|Myopia control spectacles|Clinically validated treatment to control myopia
62739382|NCT05612893||Influenza upper respiratory infection|This cohort aims to descirbe the nasal mucosal immune response in influenza patients. We will collect nasal mucosal cells from influenza patients using Nasal Cytology Curettes. Blood samples will also be obtained from the patient. All samples will be used for single cell sequencing.
62739383|NCT05612893||Viral Sepsis and Viral pneumonia|The purpose of this cohort is to characterize the immune pattern of patients with viral sepsis and find specific target for the treatment of viral sepsis. Blood samples will be obtained from the viral sepsis/pneumonia patients.All samples will be used for transcriptome sequencing.
62739384|NCT05612893||Bacterial Sepsis and Bacterial pneumonia|This cohort served as a control for the viral sepsis/pneumonia cohort.Blood samples will be obtained from the bacterial sepsis/pneumonia patients.All samples will be used for transcriptome sequencing.
62739385|NCT03423446|EXPERIMENTAL|Severe Hepatic Impairment|Up to 8 subjects with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15 points)
62739386|NCT03423446|EXPERIMENTAL|Healthy Control|Up to 8 healthy control subjects with normal hepatic function
62174700|NCT02312622|EXPERIMENTAL|Cohort C - Pegylated Irinotecan to treat mBC|Patients with metastatic breast cancer (MBC) to brain will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
62174701|NCT03756064|EXPERIMENTAL|Experimental group|Pyrotinib+Trastuzumab+Docetaxel +Carboplatin
62174702|NCT03756064|PLACEBO_COMPARATOR|Control group|Placebo Oral Tablet+Trastuzumab+Docetaxel +Carboplatin
62174703|NCT00778518|ACTIVE_COMPARATOR|1|low dose
62174704|NCT00778518|ACTIVE_COMPARATOR|2|Medium dose
62739387|NCT05740631|EXPERIMENTAL|Obeticholic acid|"FXR agonist, orally administration (10 mg)~Assignment of treatment (placebo and obeticholic acid) will be randomized before study visit 1. Either placebo or obeticholic acid will be administered orally in a single-blind fashion for 21 days. After a washout period of 28 days, either placebo or obeticholic acid will be administered as appropriate for an additional 21 days."
62739388|NCT05740631|PLACEBO_COMPARATOR|Placebo|Assignment of treatment (placebo and obeticholic acid) will be randomized before study visit 1. Either placebo or obeticholic acid will be administered orally in a single-blind fashion for 21 days. After a washout period of 28 days, either placebo or obeticholic acid will be administered as appropriate for an additional 21 days.
62174705|NCT00778518|ACTIVE_COMPARATOR|3|High Dose
62364799|NCT00093470|EXPERIMENTAL|Arm A (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62550502|NCT01525914||dutasteride, active surveillance|men with favorable risk prostate cancer on surveillance treated with dutasteride
62739389|NCT02501967|EXPERIMENTAL|COMET|The intervention consists of completion of the tool (COMET) by means of a 30 minute telephone interview prior to the primary care visit and provision of the tool's output to the patient and primary care physician. The COMET tool takes information about the patient's medications and chronic conditions from the electronic health record, and then supplements this with information obtained by a telephone interview assessing the patient's cognition, social supports, medication adherence, home medication regimen, medication side effects, and health status. In addition, there is a chart review screen to record renal function, blood pressure, and hemoglobin A1C. All of this information is run through a set of algorithms to identify medication reconciliation errors and potentially inappropriate medications.
62739390|NCT02501967|NO_INTERVENTION|Usual Care|
62364800|NCT00093470|OTHER|Arm B (clinical observation)|Patients undergo observation only.
62364801|NCT05229640|OTHER|Fibroscan|One study visit for fibroscan measurement of the liver.
62364802|NCT04356872|EXPERIMENTAL|treatment|The patients with metastatic and unresectable soft tissue sarcoma including undifferentiated pleomorphic sarcoma, synovial sarcoma, de-differentiated liposarcoma and myxoid liposarcoma will be enrolled and given sintilimab (PD-1) , doxorubicin and doxorubicin every three weeks for 6 cycles followed by sintilimab mono therapy till disease progression. The first enrolled six patients is safety run-in step for observing drug-limiting toxicity (DLTs). If the combinatory treatment is intolerable, the doses of chemo regimens will be reduced according to drug instruction.
62550503|NCT03959969|EXPERIMENTAL|Educational Video Recipients|Participants will be shown educational video on pain management after cesarean delivery on day of discharge. Upon discharge, participants will be given twenty tablets of oxycodone 5 mg by mouth every four hours as needed for pain and forty tablets of ibuprofen 600 mg by mouth every six hours as needed for pain.
62174706|NCT03690921|EXPERIMENTAL|Treatment (LET-IMPT, chemotherapy)|Patients undergo linear energy transfer-optimized intensity modulated proton therapy 5 times per week for 5-6 weeks. Patients also receive standard cisplatin and fluorouracil IV weekly for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
62174707|NCT06299956|OTHER|The intervention group|Supervised exercise therapy. Walking on a treadmill 3 times a week, for 12 weeks. Supervised by a physiotherapist.
62550504|NCT03959969|ACTIVE_COMPARATOR|Standard of Care Recipients|Participants will be given standard of care discharge instructions for pain management on day of discharge. Upon discharge, participants will be given twenty tablets of oxycodone 5 mg by mouth every four hours as needed for pain and forty tablets of ibuprofen 600 mg by mouth every six hours as needed for pain.
62550505|NCT02984371|EXPERIMENTAL|Group 1|Coronary artery bypass grafting + epicardial ganglionated plexi ablation
62550506|NCT02984371|ACTIVE_COMPARATOR|Group 2|Coronary artery bypass grafting
62739391|NCT00294671|ACTIVE_COMPARATOR|Diflunisal|Diflunisal 250 mg po bid
62550507|NCT02678208|ACTIVE_COMPARATOR|Tranexamic acid|received tranexamic acid containing 1 g/10mL tranexamic acid diluted with 20 mL of 5% glucose over a 5 minute period
62550508|NCT02678208|OTHER|placebo|received 30 mL of 5% glucose over the same period of time.
62550509|NCT01431365|EXPERIMENTAL|Moderate Exercise Group|The moderate exercise condition will involve participants walking briskly (equivalent to moderate intensity) on a treadmill for 10 minutes. Moderate intensity exercise will be defined as 40-68% of the resting heart rate reserve. Heart rate (HR) will be monitored in participants using a Polar RS100 Heart Rate monitor to serve as a guide for participants to attain the appropriate intensity.
62550510|NCT01431365|ACTIVE_COMPARATOR|Passive Sitting Group|The passive sitting condition will involve participants sitting passively for 10 minutes on a chair. Heart rate (HR) will be monitored in participants of the passive sitting group to help maintain group equivalency (with the moderate exercise condition) in regards to distraction effects and researcher contact.
62550511|NCT01238107|EXPERIMENTAL|High dose|
62550512|NCT01238107|EXPERIMENTAL|Low dose|
62739392|NCT00294671|PLACEBO_COMPARATOR|Placebo|Placebo 1 po bid
62739393|NCT03756051||Cohort|This study will collect prospective longitudinal data to characterize rates and identify correlates of a) physical harms due to follow-up tests, b) financial harms, and c) inappropriate screening using electronic medical record data and manual chart review. The study will also use surveys and semi-structured interviews to characterize rates and identify correlates of screening-related psychological harms, e.g. cancer specific worry, situational anxiety, mood disturbances, and decisional regret. Lastly, investigators will create and disseminate a balance sheet of benefits and harms to inform patients, providers, healthcare organizations, payers, and policymakers about the role of hepatocellular carcinoma screening in patients with cirrhosis.
62739394|NCT01996696|EXPERIMENTAL|Metformin|Metformin 500 mg PO TID x 30-36 months
62739395|NCT01996696|PLACEBO_COMPARATOR|Placebo|Identical placebo TID x 30-36 months
62174708|NCT04878575||ASD group|120 ASD patients (aged 5-18 years)
62550513|NCT01238107|PLACEBO_COMPARATOR|Placebo|
62174709|NCT04878575||ADHD group|120 ADHD patients (aged 5-18 years)
62174710|NCT04878575||TDC group|120 age-, and sex-matched typically developing controls (TDC) will be recruited from the same geographic areas of the ASD/ADHD groups via referral by teachers or the invitation of participants without any psychiatric disorders
62550514|NCT00805467|EXPERIMENTAL|1|R935788 50 mg tablet, orally, twice-a-day
62550515|NCT00805467|EXPERIMENTAL|2|R935788 100 mg tablet, orally, twice-a-day
62550516|NCT00805467|EXPERIMENTAL|3|R935788 100 mg tablet, orally, once-a-day
62550517|NCT00805467|EXPERIMENTAL|4|R935788 150 mg tablet, orally, once-a-day
62550518|NCT04233996|EXPERIMENTAL|Extended infusion|Piperacillin-tazobactam, cefepime or meropenem will be administered in half time of the dosing interval
62550519|NCT04233996|ACTIVE_COMPARATOR|Intermittent infusion|Piperacillin-tazobactam, cefepime or meropenem will be administered in 30 minutes
62550520|NCT05603325||Patient participants|Current inpatients within the acute mental health ward in which the study is taking place.
62550521|NCT05603325||Staff participants|Staff working within the acute mental health ward in which the study is taking place including nursing, mental, occupational therapy, estate and management team members
62550522|NCT05013008|EXPERIMENTAL|Finerenone|Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy in previous interventional Phase 3 trial FIGARO-DKD. No new intervention was administered in this biomarker study.
62550523|NCT05013008|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo once daily in addition to standard of care therapy in previous interventional Phase 3 trial FIGARO-DKD. No new intervention was administered in this biomarker study.
62739396|NCT05725226|ACTIVE_COMPARATOR|Group 1 : 6Fr|Procedure: RIRs/URSL Confirmation of Renal/ Ureteric Stone with CT Urography Preanesthetic Check up and SterileUrine Culture obtained prior to surgery Perioperative Care: Inj. Ceftriaxone 1gm IV stat dose , RIRS/ URSL performed using LASER Holmium lithotripsy 6Fr Double J stent is inserted to maintain the ureteric patency USSQ score obtained on Post operative Day 3, Day 7 and on the day of stone removal (Day 14) USG Abdomen and Pelvis is done on post operative Day 30 to confirm stone clearance.
62174711|NCT01248156||Intervention|Patients with persistent, long standing persistent and paroxysmal AF, who will receive ablation at sites that potentially maintain human AF.
62739397|NCT05725226|EXPERIMENTAL|Group 2: 4Fr|Procedure: RIRs/URSL Confirmation of Renal/ Ureteric Stone with CT Urography Preanesthetic Check up and SterileUrine Culture obtained prior to surgery Perioperative Care: Inj. Ceftriaxone 1gm IV stat dose , RIRS/ URSL performed using LASER Holmium lithotripsy 4Fr Double J stent is inserted to maintain the ureteric patency USSQ score obtained on Post operative Day 3, Day 7 and on the day of stone removal (Day 14) USG Abdomen and Pelvis is done on post operative Day 30 to confirm stone clearance.
62174712|NCT01248156||Control|Patients with persistent, long standing persistent and paroxysmal AF, who receive conventional ablation as determined by the operator at each site, and based upon Heart Rhythm Society guidelines.
62550524|NCT00269425|EXPERIMENTAL|Mediterranean diet,|
62550525|NCT00269425|EXPERIMENTAL|American Heart Association Step 2 diet|
62739398|NCT05849194|EXPERIMENTAL|POCUS group|Group that will undergo POCUS examination
62739399|NCT05849194|NO_INTERVENTION|Control group|The group that will not undergo POCUS examination
62739400|NCT00939289||Adults with T1DM|Adults (18+ years-old) diagnosed with type 1 diabetes mellitus; treated with multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy
62739401|NCT02860234||Group A:Clinical complete response (cCR)|Patients who achieve cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Nonoperative Management(NOM).
62739402|NCT02860234||Group B:Near-cCR|Patients who achieve near-cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Local Excision(LE) or Nonoperative Management(NOM).
62739403|NCT02860234||Group C:Residual tumor|Patients with residual tumor when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Total Mesorectal Excision(TME).
62739404|NCT06659796||Users of LifeVac device|Individuals who have used the LifeVac device during a choking emergency
62739405|NCT03625869|NO_INTERVENTION|Control|This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.
62739406|NCT03625869|EXPERIMENTAL|PICSO|This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).
62739407|NCT02547038|EXPERIMENTAL|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
62739408|NCT02547038|ACTIVE_COMPARATOR|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
62739409|NCT05447520|EXPERIMENTAL|Montelukast Group|Patients will receive conventional DMARDs plus montelukast 10 mg tablet once daily for 16 weeks.
62739410|NCT05447520|PLACEBO_COMPARATOR|Control Group|Patients will receive conventional DMARDs plus placebo tablet daily for 16 weeks
62739411|NCT05962684||ERAS|
62739412|NCT02498054|EXPERIMENTAL|Education with new meter feature.|Subjects experience a computer stimulation of a new meter feature ( colour range indicator) to help subjects interpret whether blood glucose results are low, in-range or high based on accepted guidance.
62739413|NCT00551343|OTHER|PWS|
62550526|NCT00269425|NO_INTERVENTION|Case controlled|
62739414|NCT00551343|OTHER|Controls|
62174713|NCT00135447||A|
62174714|NCT00685425|EXPERIMENTAL|A|Subjects randomized to the levalbuterol arm will complete 1 of 6 possible randomization sequences containing (a) levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
62739415|NCT00983333|EXPERIMENTAL|Web-based communication tool for health care professionals|
62174715|NCT00685425|ACTIVE_COMPARATOR|B|Subjects randomized to racemic albuterol will complete 1 of 6 possible randomization sequences containing (a) racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
62174716|NCT02217241|EXPERIMENTAL|Intervention|Students in the intervention group participated in a one-hour interactive, small-group handoff workshop facilitated by a study investigator. The workshop focused on the importance of specific handoff skills to patient safety.
62174717|NCT02217241|NO_INTERVENTION|Control|
62174718|NCT05721209|EXPERIMENTAL|VRTT With Feedback - Adults|"Adults aged 18-65 with TBI. At Week 1 after baseline, participants will begin study intervention on the C-Mill with augmented/virtual reality (AR/VR) guidance. Starting at Week 2, the study intervention on C-Mill will be repeated 3 sessions/week for 8 weeks.~Each one hour session will include about 15 minutes of standing balance training, about 5 minutes of stepping balance training and about 30 minutes of walking training on the C-Mill with AR/VR feedback."
61997449|NCT02979743|PLACEBO_COMPARATOR|Occupational therapy group|The children worked with an occupational therapist for 4 hours a day for 5 days per week (totaling 40 hours) and initially concentrated on unilateral activities with the hemiplegic hand,and added bilateral activities during the second week.
62182390|NCT04214275|NO_INTERVENTION|control group|received standard care after coronary artery bypass graft
62174719|NCT05721209|EXPERIMENTAL|VRTT With Feedback - Older Adults|"Adults aged 65 and older with TBI. At Week 1 after baseline, participants will begin study intervention on the C-Mill with augmented/virtual reality (AR/VR) guidance. Starting at Week 2, the study intervention on C-Mill will be repeated 3 sessions/week for 8 weeks.~Each one hour session will include about 15 minutes of standing balance training, about 5 minutes of stepping balance training and about 30 minutes of walking training on the C-Mill with AR/VR feedback."
62174720|NCT05721209|ACTIVE_COMPARATOR|VRTT Without Feedback - Adults|"Adults aged 18-65 with TBI. At Week 1 after baseline, participants will begin study intervention on the C-Mill without augmented/virtual reality (AR/VR) guidance. Starting at Week 2, the study intervention on C-Mill will be repeated 3 sessions/week for 8 weeks.~Each one hour session will include about 15 minutes of standing balance training, about 5 minutes of stepping balance training and about 30 minutes of walking training on the C-Mill without AR/VR feedback."
62174721|NCT05721209|ACTIVE_COMPARATOR|VRTT Without Feedback - Older Adults|"Adults aged 65 and older with TBI. At Week 1 after baseline, participants will begin study intervention on the C-Mill without augmented/virtual reality (AR/VR) guidance. Starting at Week 2, the study intervention on C-Mill will be repeated 3 sessions/week for 8 weeks.~Each one hour session will include about 15 minutes of standing balance training, about 5 minutes of stepping balance training and about 30 minutes of walking training on the C-Mill without AR/VR feedback."
62739416|NCT00983333|EXPERIMENTAL|Web-based communication training tool for patients|
62739417|NCT00983333|NO_INTERVENTION|Usual care for patient participants|
62739418|NCT01534351|EXPERIMENTAL|Finasteride|Finasteride 5 mg taken orally once daily and tamsulosin-matching placebo taken orally once daily for 12 months. The tamsulosin-matching placebo will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
62739419|NCT01534351|ACTIVE_COMPARATOR|Tamsulosin|Tamsulosin 0.2 mg taken orally once daily and finasteride-matching placebo taken orally once daily for 12 months. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
62739420|NCT01534351|EXPERIMENTAL|Finasteride and Tamsulosin|Finasteride 5 mg orally once daily and tamsulosin 0.2 mg orally once daily for 12 months, taken concomitantly. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
62739421|NCT00908323||A|Participants receiving the JS7 DNA and MVA/HIV62 vaccinations in HVTN 205
62739422|NCT00908323||B|Participants receiving the placebos of the JS7 DNA and MVA/HIV62 vaccines in HVTN 205
62739423|NCT05207033|ACTIVE_COMPARATOR|Unregulated ad condition|This arm will include exposure to unregulated e-cigarette ads or ads as they appear in modern media.
62739424|NCT05207033|EXPERIMENTAL|Regulated ad condition|This arm will include exposure to regulated e-cigarette ads or ads where we have taken out the appealing features.
62739425|NCT01058915|ACTIVE_COMPARATOR|Rosuvastatin 5mg|Rosuvastatin 5mg/day for one year
62739426|NCT01058915|ACTIVE_COMPARATOR|Rosuvaststin 40mg|Rosuvastatin 40mg/day
62739427|NCT00693537|EXPERIMENTAL|A|4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)
62739428|NCT00693537|NO_INTERVENTION|B|Control
62739429|NCT04452357|EXPERIMENTAL|PLDR Chemoradiation|"Patients will receive pulse-low-dose rate radiation, along with gemcitabine chemotherapy.~6 patients each will be accrued at two dose levels. PLDR radiation will be delivered as 10 fractions of 20 cGy, initiated once every 3 minutes. Dose levels will be selected as follows: Dose level 1: 56 Gy; Dose level 2: 66 Gy"
62739430|NCT03127917|EXPERIMENTAL|CitrullinePlacebo|Subjects allocated to the CitrullinePlacebo study arm received L-citrulline first, followed by placebo.
62739431|NCT03127917|EXPERIMENTAL|PlaceboCitrulline|Subjects allocated to the PlaceboCitrulline study arm received placebo first, followed by L-citrulline.
62174722|NCT06031870|ACTIVE_COMPARATOR|Standard care|
62174723|NCT06031870|ACTIVE_COMPARATOR|Pelvic floor muscle training|
62174724|NCT06031870|EXPERIMENTAL|Vaginal pessary|
62739432|NCT05727007|EXPERIMENTAL|MRI in colon cancer|All prospectively included patients with colon cancer will be preoperatively submitted to MRI for staging. The evaluation of the diagnostic accuracy will be based on the cross-examination with the CT scan and the pathology results
61997450|NCT02979743|ACTIVE_COMPARATOR|Occupational therapy puls acupuncture and massage methods|The patients receive occupational therapy puls acupuncture and massage methods.
61997451|NCT01514695|EXPERIMENTAL|Fentanyl|Fentanyl arm
62174725|NCT01792778|ACTIVE_COMPARATOR|ViaValve Safety IV Catheter|Catheter insertion using the ViaValve Safety IV Catheter.
62174726|NCT01792778|ACTIVE_COMPARATOR|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|Catheter insertion using the Insyte Autoguard BC Shielded IV Catheter
62174727|NCT00465907|EXPERIMENTAL|Paclitaxel, Carboplatin and Irinotecan|Study of Weekly Paclitaxel, Carboplatin and Irinotecan in patients with Non-Small Cell Lung Carcinoma
62174728|NCT05959811|EXPERIMENTAL|meridian yoga|60 minutes yoga ,twice a week for 8 weeks
62174729|NCT05959811|NO_INTERVENTION|usual care group|8 weeks of general care
62174730|NCT03905213|ACTIVE_COMPARATOR|conventional gauze|Device is a conventional gauze and the change will be to the day 2 and 4 of surgery
62174731|NCT03905213|EXPERIMENTAL|polyurethane dressing|Device is a polyurethane dressing and the change will be to the day 7 of surgery
62174732|NCT03905213|EXPERIMENTAL|vacuum therapy dressing|Device is a vacuum therapy dressing and the change will be to the day 7 of surgery
62182391|NCT03693040|EXPERIMENTAL|DHFS with IS-Truvada|Digital Health Feedback System (DHFS) with IS-Truvada 1 capsule daily for 12 weeks
61997452|NCT01514695|PLACEBO_COMPARATOR|Placebo|Placebo of identical appearance
61997453|NCT02657811|ACTIVE_COMPARATOR|Bench Incubation|These embryos will be randomized to the bench incubator.
61997454|NCT02657811|ACTIVE_COMPARATOR|Time Lapse Incubation|These embryos will be randomized to the Time Lapse Incubator.
62182392|NCT02275013||Early|Levosimendan administration within first hour of post-operative ICU admission
62739433|NCT04809766|EXPERIMENTAL|Cohorts I, II, and III (FH-TCR Tᴍsʟɴ)|"LYMPHODEPLETION CHEMOTHERAPY: Patients receive cyclophosphamide IV and fludarabine IV on days -5, -4 and -3 or may optionally receive bendamustine IV on days -4 and -3 prior to the 1st T cell infusion.~T-CELL THERAPY: Patients receive FH-TCR-Tᴍsʟɴ IV over 60-120 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity."
62739434|NCT04809766|EXPERIMENTAL|Cohort IV (FH-TCR Tᴍsʟɴ) (Discontinued with amendment 3/28/23)|"LYMPHODEPLETION CHEMOTHERAPY: Patients receive cyclophosphamide IV and fludarabine IV on days -3 to -1.~T-CELL THERAPY: Patients receive FH-TCR-Tᴍsʟɴ IV over 60-120 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity."
62739435|NCT03935867|EXPERIMENTAL|C-PROFET group|Community-dwelling, older adults participating in a home-based program -- C-PROFET, our adaptation of Prevention Of Falls in the Elderly Trial (PROFET).
62739436|NCT06658158|EXPERIMENTAL|Cognitive correction and stimulus control|
62739437|NCT06658158|ACTIVE_COMPARATOR|Sleep hygiene education|
62739438|NCT06387927|ACTIVE_COMPARATOR|Group A (control) received supervised conventional core stability exercise program Study|Group A (control) received supervised conventional core stability exercise program
62739439|NCT06387927|EXPERIMENTAL|group B received a home-based exercise program|Group B received a home-based exercise program.
62739440|NCT02123771||Helicobactor Pylori Infection|Comparison on the presence/absence of GGT antigen in the stool will be compared between H. pylori-positive and H. pylori-negative subjects. Rapid urease test result from the respective patients will be used as the golden standard. Should the GGT antigen in stool samples show promise in distinguishing between H. pylori-infected and uninfected individuals, sensitivity and specificity of the stool antigen test can then be established.
62739441|NCT06199375|EXPERIMENTAL|modified mirror therapy+Modified mirror therapy|The study lasted 30 days for each participant. The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy. Additionally, the patients in the experimental group were given modified mirror therapy.
62739442|NCT06199375|ACTIVE_COMPARATOR|routine rehabilitation therapy|The study lasted 30 days for each participant. The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy.
62739443|NCT03669666||control group|10 normal healthy subjects are conducted for cardiac magnetic resonance imaging examination
62739444|NCT03669666||case group|25 patients with valvular heart disease diagnosed clinically and by echocardiography are conducted for cardiac magnetic resonance imaging examination
62739445|NCT06488092||Pre-utilization of cesarean risk calculator|The time prior to the implementation of the cesarean risk calculator at the labor and delivery unit.
62739446|NCT06488092||Implementation of cesarean risk calculator|The cesarean risk calculator will be incorporated into routine care at the site
62739447|NCT04891718|EXPERIMENTAL|MVC-101 and Nivolumab|Patients with HNSCC who are scheduled for surgical biopsy or tumour resection surgery will be injected at least four hours to up to three days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline and solution stabilizer), a pre-cleaved/pre-activated drug control (cMVC-101), MVC-101 (the prodrug), or nivolumab as single agents or as combinations. Each drug will be delivered in subtherapeutic microdoses, and each microdose is simultaneously injected in a columnar fashion through each of 3, 5, or 8 needles (in a device configuration determined by tumour dimensions) into a single solid tumour or effaced metastatic lymph node.
62739448|NCT05483231|EXPERIMENTAL|Family integrated care intervention group|Provide Family integrated care for very low birth weight infants in the NICU.
62174733|NCT02236598|EXPERIMENTAL|K+ supplementation|K-supplement- Klor-Con® M10 is an immediately dispersing extended-release oral dosage form of potassium chloride containing 750 mg of microencapsulated potassium chloride, United States Pharmacopeia (USP) equivalent to 10 milliequivalent (mEq) of potassium in a tablet. Participants will be instructed to take two 10 mEq tablets twice daily in a blinded encapsulated form, for 3 months
62174734|NCT02236598|EXPERIMENTAL|Placebo|"Placebo - An inert powdered placebo will be identically encapsulated as the Klor-Con intervention tablets to maintain blinding. Participants will be instructed to take two tablets twice daily in a blinded encapsulated form, for 3 months~Subjects will be instructed to take the pills"
62550527|NCT05867043||Experience gastrointestinal dysfunction|"Gastrointestinal dysfunction is defined as acute gastrointestinal injury (AGI) score \>= 2 based on ESICM criteria, monitored within 72 hours according to early postoperative gastrointestinal dysfunction.~Experience gastrointestinal dysfunction = AGI score \>=2"
62739449|NCT05483231|OTHER|Routine nursing care group|Perform routine nursing care for very low birth weight infants in the NICU.
62739450|NCT05068323|OTHER|Epilepsy|Newly diagnosed epileptic patients
62739451|NCT05068323|SHAM_COMPARATOR|Control|healthy subjects
62739452|NCT04547634|EXPERIMENTAL|Experimental|The sample will receive of a Therapeutic Exercise and Education programme
62739453|NCT04547634|NO_INTERVENTION|Control|Subjects will be told to continue with their normal activity of daily living. After the intervention in the experimental group, the control group will be offered intervention.
61997455|NCT02657811|ACTIVE_COMPARATOR|Time Lapse Incubation - Modified|These embryos will be randomized to the bench incubator.
61997456|NCT00178191|EXPERIMENTAL|200 units Botox|200 units Botulinum-A toxin
61997457|NCT00178191|EXPERIMENTAL|300 units Botox|300 units Botulinum-A toxin
61997458|NCT00178191|PLACEBO_COMPARATOR|Placebo|Placebo
62739454|NCT05772455|EXPERIMENTAL|XZB-0004|
62739455|NCT06656052|EXPERIMENTAL|First Age Group|Participants with Age 21-30 years. All members of group number 1 who fall in the eligibility criteria will undergo three different types of cognitive loading. Three types of cognitive loading will be applied randomly to eliminate any bias. Each Method will be used three times with pre and post-recordings to ensure reliability.
62739456|NCT06656052|EXPERIMENTAL|Second Age Group|Participants with age 31-40 years. All members of group number 2 who fall in the eligibility criteria will undergo three different types of cognitive loading. Three types of cognitive loading will be applied randomly to eliminate any bias. Each Method will be used three times with pre and post-recordings to ensure reliability.
62739457|NCT06656052|EXPERIMENTAL|Third Age Group|Participants with Age 41-50 years. All members of group number 3 who fall in the eligibility criteria will undergo three different types of cognitive loading. Three types of cognitive loading will be applied randomly to eliminate any bias. Each Method will be used three times with pre and post-recordings to ensure reliability.
62739458|NCT06656052|EXPERIMENTAL|Fourth Age Group|Participants with age 51-60 years. All members of group number 4 who fall in the eligibility criteria will undergo three different types of cognitive loading. Three types of cognitive loading will be applied randomly to eliminate any bias. Each Method will be used three times with pre and post-recordings to ensure reliability.
62739459|NCT06656052|EXPERIMENTAL|Fifth Age Group|Participants with age 61-70 years. All members of group number 5 who fall in the eligibility criteria will undergo three different types of cognitive loading. Three types of cognitive loading will be applied randomly to eliminate any bias. Each Method will be used three times with pre and post-recordings to ensure reliability.
62174735|NCT05329649|EXPERIMENTAL|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive single infusion of CTX001 through central venous catheter.
62174736|NCT06048809|EXPERIMENTAL|Test Toothpaste|Participants will be instructed to brush their teeth with the test toothpaste (Sensodyne Repair and Protect containing 1100 parts per million \[ppm\] fluoride as SnF2) for 1-timed minute twice a day (morning and evening) in their usual manner for 6 weeks. Participants will record each brushing in the diary provided.
62739460|NCT03594747|EXPERIMENTAL|Tislelizumab + Paclitaxel + Carboplatin|Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)
62739461|NCT03594747|EXPERIMENTAL|Tislelizumab + Nab-paclitaxel + Carboplatin|Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)
62739462|NCT03594747|ACTIVE_COMPARATOR|Paclitaxel + Carboplatin|Paclitaxel 175 mg/m\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)
62739463|NCT04524715|EXPERIMENTAL|Active Treatment Group|LLLT Treatment using an UltraSlim red/IR LED device along with all standard treatment measures for COVID19.
62174737|NCT06048809|ACTIVE_COMPARATOR|Reference Toothpaste|Participants will be instructed to brush their teeth with the reference toothpaste (Colgate Cavity Protection containing 1100 ppm fluoride as sodium monofluorophosphate \[SMFP\]) for 1-timed minute twice a day (morning and evening) in their usual manner for 6 weeks. Participants will record each brushing in the diary provided.
62739464|NCT04524715|SHAM_COMPARATOR|Control Group|Treatment using a Sham comparator along with all standard treatment measures for COVID19.
62739465|NCT06270082|EXPERIMENTAL|IK-595|Dose Escalation and Dose Expansion
62739466|NCT04452058||Internal cohort|The internal cohort was retrospective enrolled in Guangdong Provincial People's hospital from March 1, 2015 to December 31,2019. Patients with single pulmonary lesion underwent preoperative chest CT scan and histologically confirmed precancerous lesions or early stage lung adenocarcinoma after thoracic surgery was included.
62550528|NCT05867043||Did not experience gastrointestinal dysfunction|Did not experience gastrointestinal dysfunction = AGI score \<2
62739467|NCT04452058||External cohort 1|The same inclusion/exclusion criteria were applied for another independent centers, Sun Yat-sen Memorial Hospital ,Guangdong Province, China, forming an external validation cohort of 73 patients
62739468|NCT04452058||External cohort 2|The same inclusion/exclusion criteria were applied for another independent centers, Zhoushan Lung Cancer Institution, Zhejiang Province, China, forming second external validation cohort of 30 patients
62739469|NCT04452058||Immune Cohort|The internal cohort was retrospective enrolled in Guangdong Provincial People's hospital from March 1, 2015 to May 31,2020. Patients with advanced lung cancer underwent preoperative chest CT scan and histologically confirmed NSCLC before receiving immunotherapy was included.
62739470|NCT00453037|ACTIVE_COMPARATOR|group I (early intervention)|"We refer to the results of the DAFNE-study. This study showed the merits of an educational program in diabetics. In accordance to the protocol of DAFNE, we developed a design as follows: For each participating center patients are randomly assigned to two groups. Group I receives an early educational intervention at time of randomization, which should lead to better control of blood pressure after 6 months compared to the control group. The protocol design was chosen for proving an independent effect of the educational program despite optimal management by the GP. Group II is designated to receive the educational intervention 6 months after enrollment into the study.~for further details please see brief description section"
62739471|NCT00453037|OTHER|delayed education|"delayed educational intervention~for further details please see brief description section"
62739472|NCT02690688||Pneumoperitoneum|Patients scheduled for laparoscopic (minimal invasive) abdominal surgery supported by pneumoperitoneum. Hemodynamic monitoring will be performed using Vigileo® monitor, Edwards Lifescience
62739473|NCT02690688||Open Surgery|Patients scheduled for conventional (open) abdominal surgery. Hemodynamic monitoring will be performed using Vigileo® monitor, Edwards Lifescience
62739474|NCT05129657|EXPERIMENTAL|Product usage order ABCDN|Subjects will use each of the 5 products sequentially (ABCDN) during an evaluation period, followed by a 4 hour Test Session.
62174738|NCT03857737|EXPERIMENTAL|ESD group|This group include patients who are going to undergo endoscopic submucosal dissection for early gastric cancer.
62739475|NCT05129657|EXPERIMENTAL|Product usage order ACBND|Subjects will use each of the 5 products sequentially (ACBND) during an evaluation period, followed by a 4 hour Test Session.
62174739|NCT03857737|ACTIVE_COMPARATOR|Surgery group|This group include patients who are going to undergo surgery for early gastric cancer.
62550529|NCT01795417|EXPERIMENTAL|XP200 device RF treatments|Every subject in the study will undergo 4 treatments and will be followed up for 6 months with photoraphic 3 evaluations: before treatment, 3 and 6 months follow-up. Photographs will be scored on a Fitzpatrick scale by 3 blinded evaluators.
62174740|NCT03594578|EXPERIMENTAL|Episodic future thinking|"Participants will complete a guided interview designed to elicit a number of personalized events that are likely to occur during various future time frames (e.g., 1 day, 1 week, 3 months, 1 year, etc.), as well as text cues designed to prompt episodic future thinking (e.g., In 3 months, I will be at my daughter's wedding). Text cues will be presented during subsequent behavioral tasks and participants will be asked to think vividly about these events."
62174741|NCT03594578|SHAM_COMPARATOR|Episodic recent thinking (control)|"Participants will complete a guided interview designed to elicit a number of personalized events that occurred in the recent past (e.g., earlier today, yesterday), as well as text cues designed to prompt episodic thinking (e.g., Earlier today, I was playing tennis with my wife.). Text cues will be presented during subsequent behavioral tasks and participants will be asked to think vividly about these events."
62739476|NCT05129657|EXPERIMENTAL|Product usage order BADCN|Subjects will use each of the 5 products sequentially (BADCN) during an evaluation period, followed by a 4 hour Test Session.
62739477|NCT05129657|EXPERIMENTAL|Product usage order BDANC|Subjects will use each of the 5 products sequentially (BDANC) during an evaluation period, followed by a 4 hour Test Session.
62174742|NCT06349317|EXPERIMENTAL|Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib|Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib
62174743|NCT05643898|EXPERIMENTAL|Mamá, te entiendo (Mom, I get you)|Participants assigned to this arm will receive a guided 8-week cognitive-behavioral app-based intervention for reducing postpartum depressive symptoms.
62174744|NCT05643898|NO_INTERVENTION|Waitlist|Participants in the WL condition will receive the same assessments as those in the intervention condition. Participants allocated to WL may access their local mental health services during their waiting period. In Chile, patients diagnosed with depression by a general practitioner have guaranteed access to treatment at low or no cost. Treatment varies according to depression severity, with group or individual therapy, alone or combined with pharmacotherapy. After the follow-up assessment, the WL group will be offered access to the intervention.
62174745|NCT05012943|EXPERIMENTAL|ARCT-154|Each participant is planned to receive a two-dose vaccination series of ARCT-154 at a dose of 5 µg with 28 day interval in the first vaccination series.
62739478|NCT05129657|EXPERIMENTAL|Product usage order CANBD|Subjects will use each of the 5 products sequentially (CANBD) during an evaluation period, followed by a 4 hour Test Session.
62174746|NCT05012943|PLACEBO_COMPARATOR|Placebo|Each participant is planned to receive a two-dose vaccination series of placebo (normal saline) with 28 day interval in the first vaccination series.
62739479|NCT05129657|EXPERIMENTAL|Product usage order CNADB|Subjects will use each of the 5 products sequentially (CNADB) during an evaluation period, followed by a 4 hour Test Session.
62174747|NCT05012943|ACTIVE_COMPARATOR|Astra Zeneca COVID-19 vaccine|Each participant is planned to receive a two-dose vaccination series of Astra Zeneca COVID-19 vaccine with 28 day interval in the first vaccination series.
62739480|NCT05129657|EXPERIMENTAL|Product usage order DBNAC|Subjects will use each of the 5 products sequentially (DBNAC) during an evaluation period, followed by a 4 hour Test Session.
62174748|NCT05286775|EXPERIMENTAL|Clinical treatment and Knee educational program|Medical knee treatment combined with knee educational educational program
62174749|NCT05286775|ACTIVE_COMPARATOR|Knee educational program|Knee educational program
62739481|NCT05129657|EXPERIMENTAL|Product usage order DNBCA|Subjects will use each of the 5 products sequentially (DNBCA) during an evaluation period, followed by a 4 hour Test Session.
62739482|NCT05129657|EXPERIMENTAL|Product usage order NCDAB|Subjects will use each of the 5 products sequentially (NCDAB) during an evaluation period, followed by a 4 hour Test Session.
62739483|NCT05129657|EXPERIMENTAL|Product usage order NDCBA|Subjects will use each of the 5 products sequentially (NDCBA) during an evaluation period, followed by a 4 hour Test Session.
62739484|NCT06381076|EXPERIMENTAL|Intervention|Participants will consume 38 g of high protein product with 7 mls of curcumin at the end of each dialysis session, 3 days a week for 8 weeks for a total of 24 treatments.
62739485|NCT06381076|PLACEBO_COMPARATOR|Control|Participants will consume 38 g of high protein product that contains an orange food colorant at the end of each dialysis session, 3 days a week for 8 weeks for a total of 24 treatments.
62174750|NCT01913288|EXPERIMENTAL|Biological Maternal Sounds|Daily Exposure to recorded mother's voice and heartbeat sounds via audio systems installed at the bedside
62739486|NCT02482428|EXPERIMENTAL|LFX453 0.1% NMC|LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks
62174751|NCT01913288|SHAM_COMPARATOR|Hospital Sounds|Exposure to standard hospital sounds; routine care.
62739487|NCT02482428|EXPERIMENTAL|LLFX453 0.15% LCC|LFX453 0.15% liquid crystal cream (LCC) Twice daily applications for a maximum of 12 weeks
62739488|NCT02482428|PLACEBO_COMPARATOR|Vehicle to NMC|Vehicle to nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks
61997459|NCT05325567|ACTIVE_COMPARATOR|1 incision technique|a mini-open incision that allows adequate exposure of the transverse carpal ligament (TCL), while staying distal to the distal wrist crease.
62739489|NCT02482428|PLACEBO_COMPARATOR|Vehicle to LCC|Vehicle to liquid crystal cream (LCC) Twice daily applications for a maximum of 12 weeks
62739490|NCT02482428|ACTIVE_COMPARATOR|Aldara|Aldara 5% cream 3 applications per week for a maximum of 16 weeks
62739491|NCT03778749|EXPERIMENTAL|electromyographic NMT monitoring at the hand|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
62739492|NCT03778749|EXPERIMENTAL|acceleromyographic NMT monitoring at the hand|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
62739493|NCT03778749|EXPERIMENTAL|acceleromyographic NMT monitoring at the eyebrow|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
62739494|NCT06281652|EXPERIMENTAL|Go classes|Subjects randomized to a group intervention with Go lessons once a week for 12 weeks
61997460|NCT05325567|ACTIVE_COMPARATOR|Two incision technique|A two-incision open carpal tunnel release techniques to ensure complete release both proximally and distally
61997461|NCT00885547|EXPERIMENTAL|immunosuppressor|
62174752|NCT02880969|EXPERIMENTAL|Patient with end stage renal disease undergoing dialysis|
62174753|NCT05472519|OTHER|Loeys-Dietz syndrome|Patients aged ≥ 5 years with Loeys-Dietz syndrome with a diagnosis confirmed by the presence of a TGF-βR 1 or R2 mutation.
62174754|NCT05472519|OTHER|Healthy Group|Subjects aged ≥ 5 years.
62174755|NCT00854152|EXPERIMENTAL|1|
62174756|NCT02538718|ACTIVE_COMPARATOR|YTP(ritodrine) arm|who randomly assigned to have Yutopar(ritodrine) as tocolytics
62174757|NCT02538718|EXPERIMENTAL|MgSO4 arm|who were randomised to have MgSO4 as tocolytics
62739495|NCT06281652|EXPERIMENTAL|Chess classes|Subjects randomized to a group intervention with Chess lessons once a week for 12 weeks
62174758|NCT06053047|EXPERIMENTAL|Use of Bluedrop Monitoring Service|"The BMS is made up of the Delta Foot Scanner (DFS) device, its accompanying Sentinel Review Interface (SRI) software and a Bluedrop virtual monitoring service.~The DFS is intended to be used for 30 seconds, once per day, by a person in their home. It is important that while using the device that the participant continues with their routine foot care as recommended by their doctor."
62174759|NCT06053047|NO_INTERVENTION|Standard of care|Participants continue with routine foot care as recommended by their doctor
62550530|NCT02361996||Coronary Bypass Surgery|"inclusion criteria:~* presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary bypass surgery.~* list of medication timely related to the procedure~* signed informed consent~exclusion criteria:~* intolerance to contrast agent~* multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection~* renal failure~* severe arrhythmia~* pregnancy~* reduction of cognitive capabilities to understand the purpose and the extent of the study~* participation in a medical-scientific study using X-rays in the last ten years~* lack of Russian knowledge to fill the forms~* lack of signed study agreement"
62739496|NCT06281652|EXPERIMENTAL|Go & Chess classes|Subjects randomized to a group intervention with Go and Chess lessons twice a week for 12 weeks
62174760|NCT01204593|EXPERIMENTAL|Insulin glargine + insulin glulisine|"Insulin glargine dosage will be individually titrated once a week to obtain FPG 80-120 mg/dL (4.5-6.7 mmol/L).~Insulin glulisine dosage will be individually titrated once a week to obtain a 2-hour postprandial plasma glucose (PPG) \< 180 mg/dL (\<10.0 mmol/L) and ideally around 140 mg/dL."
62174761|NCT02434523|EXPERIMENTAL|amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler)
62174762|NCT02434523|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
62174763|NCT04964609|EXPERIMENTAL|Single Arm|Comparison of EmbracePlus SpO2 readings with arterial blood saturation laboratory analysis in the same subject
62739497|NCT06281652|NO_INTERVENTION|Control|Subjects randomized to no intervention for 12 weeks
62174764|NCT00357318|EXPERIMENTAL|Treatment (sunitinib malate, bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29 and oral sunitinib malate (SU11248) once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
62174765|NCT02694588|ACTIVE_COMPARATOR|Infliximab|5 mg/kg body weight, week 0/2/6, then every 8 weeks
62174766|NCT02694588|ACTIVE_COMPARATOR|Vedolizumab|300 mg, week 0/2/6, then every 8 weeks
62174767|NCT01156402|EXPERIMENTAL|Active Intervention: Obesity Prevention|
62174768|NCT01156402|EXPERIMENTAL|Alternative Intervention/control: Oral Health|
62174769|NCT01395914|EXPERIMENTAL|100 mg QD|100 mg yellow coated, oval tablet; oral administration once daily
62174770|NCT01395914|PLACEBO_COMPARATOR|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
62174771|NCT04248036|OTHER|Circle Of Security Parenting, COS-P|Pilot study, assessing eligibility, outcome measures and compliance to Group intervention
62174772|NCT06640998|EXPERIMENTAL|Zone 1: Eyebrow Lift|Treatment of the upper face including treatment of forehead to mid cheek
62174773|NCT06640998|EXPERIMENTAL|Zone 2: Submentum and Neck|Treatment of the lower face including mid to low cheek, submentum, and neck
62174774|NCT05270473|ACTIVE_COMPARATOR|group A: b lynch|B lynch uterine compressive suture was done
62174775|NCT05270473|ACTIVE_COMPARATOR|group B : Nusicaa suture|Nusicaa uterine compressive suture was done
62174776|NCT02753764|NO_INTERVENTION|Normal control|Health volunteers will be recruited as an additional control group.
62174777|NCT02753764|OTHER|Corticosteroid sensitive (CS) asthmatics|After the initial visit, asthmatics will be given oral prednisone for 1 week and patients will return for the spirometer assessment. Patients will be defined as CR if \<10% improvement in FEV1 % predicted is observed and as CS in \>12% improvement in FEV1% predicted is observed.
62174778|NCT02753764|ACTIVE_COMPARATOR|Corticosteroid resistant (CR) asthmatics active|The study will have a 1 week oral corticosteroid (OSC) run-in period. Subjects unresponsive to OCS will be defined as corticosteroid resistant (CR) and randomized to two crossover treatment sequences consisting of 4 weeks of inhaled AZD7624 or placebo, followed by 4 weeks of a washout period, and another 4 weeks of placebo or ASD7624
62174779|NCT02753764|PLACEBO_COMPARATOR|Corticosteroid resistant (CR) asthmatics placebo|The study will have a 1 week oral corticosteroid (OSC) run-in period. Subjects unresponsive to OCS will be defined as corticosteroid resistant (CR) and randomized to two crossover treatment sequences consisting of 4 weeks of inhaled AZD7624 or placebo, followed by 4 weeks of a washout period, and another 4 weeks of placebo or ASD7624
62174780|NCT01111136|EXPERIMENTAL|stress intervention|Stress intervention.
62174781|NCT02056600|EXPERIMENTAL|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
62174782|NCT02056600|EXPERIMENTAL|C|Combination of gemigliptin50mg/metformin HCl sustained release 1000mg
62739498|NCT05730556|EXPERIMENTAL|Electrical Neuromodulation, Then Sham|Subjects will first have the Nerivio ® applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 12. Subjects will then have the sham device applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 24.
62739499|NCT05730556|EXPERIMENTAL|Sham, Then Electrical Neuromodulation|Subjects will first have the sham device applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 12. Subjects will then have the Nerivio ® applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 24.
62739500|NCT01804439||CALIBER Healthy Cohort|We will report findings from the CALIBER (CArdiovascular disease research using Linked BEspoke studies and Electronic Records) collaboration where we linked primary care data (from the General Practice Research Database \[GPRD\]) to three further sources of electronic health records: the Myocardial Ischemia National Audit Project registry (MINAP),cause specific discharge data from Hospital Episodes Statistics (HES) and cause specific mortality from the Office for National Statistics (ONS).
62739501|NCT03378544|EXPERIMENTAL|Experimental arm|Patients with suicidal ideation and depression will receive psychosocial interventions adapted from the WHO mental health Global Action Programme Intervention Guide (mhGAP-IG). The intervention will involve psycho-education to patients on the importance of maintaining interest in activities that they used to do, regular sleep cycles, physical activity and social activity.
62739502|NCT03378544|NO_INTERVENTION|Control group|Patients with suicidal ideation and depression will be trained on how to refer patients suffering from depression, using a referral note to the nearest health centre for further treatment
62739503|NCT02558036|ACTIVE_COMPARATOR|C-Mac D-Blade Neutral Position|C-Mac D-Blade videolaryngoscope with patients head and neck in neutral position.
62739504|NCT02558036|ACTIVE_COMPARATOR|C-Mac D-Blade Sniffing Position|C-Mac D-Blade videolaryngoscope with patients head and neck in sniffing position.
62739505|NCT02558036|ACTIVE_COMPARATOR|King Vision Neutral Position|King Vision videolaryngoscope with patients head and neck in neutral position.
62739506|NCT02558036|ACTIVE_COMPARATOR|King Vision Sniffing Position|King Vision videolaryngoscope with patients head and neck in sniffing position.
62739507|NCT02427139|EXPERIMENTAL|ANSiStim|"The ANSiStim device is designed to administer auricular point stimulation treatment over several days. The advantage of using the ear for this treatment is that it provides numerous points for stimulation within a small area. Stimulation is performed by electrical pulses emitted through strategically positioned needles.~Three zinc air batteries with 1.4 V provide the required stimulation energy for 96 hours. This constant current source guarantees equivalent stimulation energy regardless of the individual impedance of the skin. The treatment period varies based on the severity of the pain. To minimize the risk of adaption or tolerance to the electrical stimulation, it is applied for 3 hours, followed by a pause of 3 hours."
62739508|NCT05524857|EXPERIMENTAL|Fedratinib 300 mg|Cohort 1: 300 mg of Fedratinib by mouth, once daily during each 28-day cycle
62739509|NCT05524857|EXPERIMENTAL|Fedratinib 400 mg|Cohort 2: 400 mg of Fedratinib by mouth, once daily during each 28-day cycle
62739510|NCT02562300|ACTIVE_COMPARATOR|Sublingual misoprostol|The patients in this arm received 400 micrograms of sublingual misoprostol, immediately after delivery of the neonate.
62739511|NCT02562300|ACTIVE_COMPARATOR|oxytocin|The patients in this arm received 20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h , immediately after delivery of the neonate.
62739512|NCT02606123|EXPERIMENTAL|EPI-506|Part I: Ascending doses of EPI-506 administered orally to define the maximum tolerated dose.
62739513|NCT00969306|ACTIVE_COMPARATOR|Chloroquine|Patients receive Chloroquine
62739514|NCT05101265|EXPERIMENTAL|Normal Hepatic function cohort|"Patients in the control cohort must meet the following criteria:~* Total bilirubin ≤ 1.0 x upper limit of normal (ULN) and no clinical (or histological) evidence of liver disease.~* Aspartate aminotransferase (AST) ≤ 1.0 x ULN and alanine aminotransferase (ALT) ≤ 1.0 x ULN.~* Albumin ≥ 3.5 g/dL.~* The age, weight and CLcr should be within ±10 years, ±15 kg and ±20 mL/min of the mean of pooled HI cohort, respectively; and with a similar male/female ratio."
62550531|NCT02361996||Coronary Stenting|"inclusion criteria:~* presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary vessel dilatation/stenting.~* list of medication timely related to the procedure~* signed informed consent~exclusion criteria:~* intolerance to contrast agent~* multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection~* renal failure~* severe arrhythmia~* pregnancy~* reduction of cognitive capabilities to understand the purpose and the extant of the study~* participation in a medical-scientific study using X-rays in the last ten years~* lack of Russian knowledge to fill the forms~* lack of signed study agreement"
62550532|NCT02361996||Aortic Valve Replacement|"inclusion criteria:~* presence of aortic valve disease (stenosis) with clinical indication for aortic valve replacement without coronary vessel stenosis above 50%~* list of medication timely related to the procedure~* signed informed consent~exclusion criteria:~* intolerance to contrast agent~* multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection~* renal failure~* severe arrhythmia~* pregnancy~* reduction of cognitive capabilities to understand the purpose and the extent of the study~* participation in a medical-scientific study using X-rays in the last ten years~* lack of Russian knowledge to fill the forms~* lack of signed study agreement"
62174783|NCT04857775|EXPERIMENTAL|Intervention group|A quasi-experimental design was selected to more closely approximate service delivery models in agencies that do not typically employ control groups. Given promising findings (from seven ATTACH™ pilot studies), a randomized controlled trial design, even employing wait-list controls was deemed unacceptable and even unethical by patients, health care professionals and health system administrators in engagement activities surrounding the preparation of this proposal.
62174784|NCT02206087|EXPERIMENTAL|Cohort 1|100 mg PER977 or placebo administered following heparin sodium
62174785|NCT02206087|EXPERIMENTAL|Cohort 2|200 mg PER977 or placebo administered following heparin sodium
62550533|NCT00191126|OTHER|A|
62550534|NCT00191126|EXPERIMENTAL|B|
62739515|NCT05101265|EXPERIMENTAL|Mild Hepatic impairment cohort|"Patients with Mild Hepatic impairment must meet the following additional criteria~* Total bilirubin ≤ 1.0 x ULN and AST \> 1.0 x ULN, or~* Total bilirubin \> 1.0 - ≤ 1.5 x ULN and any AST, and~* Albumin ≥ 3.0 g/dL"
62739516|NCT05101265|EXPERIMENTAL|Moderate Hepatic impairment cohort|"Patients with Moderate Hepatic impairment must meet the following additional criteria~* Total bilirubin \>1.5 - ≤ 3.0 x ULN and any AST, and~* Albumin ≥ 2.8 g/dL"
62174786|NCT02206087|EXPERIMENTAL|Cohort 3|300 mg PER977 or placebo administered following heparin sodium
62174787|NCT02206087|EXPERIMENTAL|Cohort 4|400 mg PER977 or placebo administered as a single agent followed by 3-day wash-out. A second dose of 400 mg PER977 or placebo will be administered following heparin sodium injection
62174788|NCT02206087|EXPERIMENTAL|Cohort 5|500 mg PER977 or placebo will be administered following heparin sodium injection
62739517|NCT05101265|EXPERIMENTAL|Severe Hepatic impairment cohort|"Patients with Severe Hepatic impairment must meet the following additional criteria:~* Total bilirubin \>3.0 x ULN and any AST, and~* Albumin ≥ 2.5 g/dL"
62739518|NCT05107011|EXPERIMENTAL|LBL-015|Drug: LBL-015 for Injection，Initial dose - MTD; Q2W
62739519|NCT05864430|EXPERIMENTAL|Face-to-face Training Group|Students in this group will be given face-to-face training on SRH by the principal researcher accompanied by PowerPoint.
62739520|NCT05864430|EXPERIMENTAL|DataMatrix supported Face-to-face training group|Before starting the training, a QR code including PowerPoint on SRH will be given to the students in the group that receives training with QR code support (on the first slide). Students will be directed to the URL automatically determined by the researcher by scanning the QR code with the camera of their smartphones. Students will follow the lesson with the QR code given simultaneously with the training given during the education process.
62739521|NCT05864430|EXPERIMENTAL|Online training group|The students in the online training group will be given training on SRH/RES on an online platform accompanied by PowerPoint by the principal researcher.
62739522|NCT05151692|EXPERIMENTAL|Cohort 1: Nipocalimab|Participants will receive a single intravenous (IV) dose of nipocalimab Dose 1 on Day 1.
62739523|NCT05151692|EXPERIMENTAL|Cohort 2: Nipocalimab|Participants will receive a single IV dose of nipocalimab Dose 2 on Day 1.
62739524|NCT05151692|EXPERIMENTAL|Cohort 3: Nipocalimab|Participants will receive a single IV dose of nipocalimab Dose 3 on Day 1.
62739525|NCT04097275||Participants with an Inborn Error of Metabolism|
62739526|NCT04645680|EXPERIMENTAL|Arm I (isocaloric high-fiber diet)|Patients receive a whole foods diet that follows the recommended American Cancer Society guidelines but is higher in fiber for 11 weeks.
62739527|NCT04645680|ACTIVE_COMPARATOR|Arm II (isocaloric diet)|Patients receive a standard whole foods diet recommended by the American Cancer Society for 11 weeks.
62174789|NCT02206087|EXPERIMENTAL|Cohort 6|600 mg PER977 or placebo will be administered following heparin sodium injection
62550535|NCT01548105||Prolapse and Smoker|Patients in this arm have been determined to have more than stage 2 pelvic organ prolapse and have been smoking more than one pack per day Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
62550536|NCT01548105||Prolapse and non smoker|Patients in this arm have been determined to have more than stage 2 pelvic organ prolapse and non smoker for more than 7 years Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
62174790|NCT04270656|EXPERIMENTAL|Insulin pump therapy|
62174791|NCT04270656|ACTIVE_COMPARATOR|Multi-injection treatment ( MDI ).|
62550537|NCT01548105||No prolapse and smoker|Patients in this arm, have been determined not to have prolapse and smokes more than 1 pack per day Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
62739528|NCT04538118||Patient with a shoulder problem|Patients with shoulder problems between 18-65 years of age and being volunteered
62174792|NCT00683397||A|Patients with acute or previous venous thromboembolism \>18 years of age
62174793|NCT01849679||Post-Extubation Subjects|
62174794|NCT03664453|EXPERIMENTAL|Food Effect (Fasted)|"Subjects will be randomly assigned to one of the two treatment sequences. Two single doses of omaveloxolone 150 mg (taken in multiple 50 mg capsules) will be administered to the subjects beginning in the fasted state (Period 1) with a crossover and then in the fed state (Period 2).~Subjects will be confined beginning on Study Day -1 through the last PK blood draw on Study Day 6 during Period 1, and from Study Day 14 through the last PK blood draw on Study Day 20 during Period 2."
62182393|NCT02275013||Late|Levosimendan administration within 24 hours of post-operative ICU admission but after first hour
62182394|NCT01664923|EXPERIMENTAL|Enzalutamide|Enzalutamide 160 mg/day orally
62550538|NCT01548105||No prolapse and non smoker|Patients in this arm have been determined not to have prolapse and non smoker for more than 7 years Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
62550539|NCT01570114||covered metallic stent|Endoscopically insertion of fully covered metallic stent on benign colonic strictures
62739529|NCT06485713|EXPERIMENTAL|Experimental group|trifluridine/tipiracil combined with fufuquitinib
62739530|NCT06485713|ACTIVE_COMPARATOR|Control Group 1|Fufuquitinib
62550540|NCT02444910|EXPERIMENTAL|KDT501|Experimental drug, KDT501, is administered at 600mg for 10 consecutive days. On days 11 and 21 (+/- 1 day), based on the KDT501 drug exposure level, the subject will be provided instructions on dose adjustment of KDT501. Dose adjustments will be administered at 800mg for 10 consecutive days, determined at day 11; followed by 1,000mg for 8 consecutive days if determined at day 21.
62550541|NCT04449003||Adolescents with Tourette Syndrome|Adolescents (aged 13-17 years) with Tourette Syndrome
62739531|NCT06485713|ACTIVE_COMPARATOR|Control Group 2|Trifluridine/tipiracil
62739532|NCT00960401||cardiac counseling|10 left sided breast cancer patients 10 right sided breast cancer patients
62739533|NCT00960401||coronary artery evaluation|10 left sided breast cancer 10 right sided breast cancer
62739534|NCT06306196|EXPERIMENTAL|Group A1 (Three doses of Hecolin®; HIV negative adults aged 18-45 years)|Three doses of Hecolin® Recombinant Hepatitis E Vaccine administered at 0, 1 and 6 months to HIV negative participants, age 18-45 years old, 232 participants
62739535|NCT06306196|EXPERIMENTAL|Group A2 (Three doses of Hecolin®; HIV positive adults aged 18-45 years)|Three doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, 1 and 6 months, to HIV positive participants, age 18-45 years old, 178 participants
62739536|NCT06306196|EXPERIMENTAL|Group B1 (Three doses of Hecolin®; healthy adolescents aged 12-17 years)|Three doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, 1 and 6 months, to age 12-17 years old, 70 participants
62739537|NCT06306196|EXPERIMENTAL|Group B2 (Two doses of Hecolin®; healthy adolescents aged 12-17 years)|Two doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, 1 and 6 months) and one dose of Placebo, administered at 1-month timepoint, to age 12-17 years old, 70 participants
62739538|NCT06306196|PLACEBO_COMPARATOR|Group B3 (Placebo; healthy adolescents aged 12-17 years)|Three doses of Placebo, administered at 0, 1 and 6 months, to age 12-17 years old, 35 participants
62182395|NCT01664923|ACTIVE_COMPARATOR|Bicalutamide|50 mg/day orally
62364803|NCT00222248|EXPERIMENTAL|Pelvic floor muscle training|Weekly group session of education and exercise to music incorporating pelvic floor muscle training incorporating motor control, strength, endurance, power and functional training in a variety of different positions.
62739539|NCT06306196|EXPERIMENTAL|Group C1 (Three doses of Hecolin®; healthy children aged 6-11 years)|Three doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, 1 and 6 months, to age 6-11 years old, 70 participants
62739540|NCT06306196|EXPERIMENTAL|Group C2 (Two doses of Hecolin®; healthy children aged 6-11 years)|Two doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0 and 6 months and one dose of Placebo, administered at 1-month timepoint, to age 6-11 years old, 70 participants
62739541|NCT06306196|PLACEBO_COMPARATOR|Group C3 (Placebo; healthy children aged 6-11 years)|Three doses of Placebo, administered at 0, 1 and 6 months, to age 6-11 years old, 35 participants
62739542|NCT06306196|EXPERIMENTAL|Group D1 (Three doses of Hecolin®; healthy children aged 2-5 years)|Three doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, 1 and 6 months, to age 2-5 years old, 40 participants
62739543|NCT06306196|EXPERIMENTAL|Group D2 (Two doses of Hecolin®; healthy children aged 2-5 years)|Two doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0 and 6 months and of Placebo, administered at 1-month timepoint, to age 2-5 years old, 40 participants
62739544|NCT06306196|PLACEBO_COMPARATOR|Group D3 (Placebo; healthy children aged 2-5 years)|Three doses of Placebo, administered at 0, 1 and 6 months, to age 2-5 years old, 40 participants
62739545|NCT01391689|EXPERIMENTAL|Arm I (antineoplastic therapy)|Patients receive diindolylmethane (BioResponse) PO BID for approximately 18 months.
62739546|NCT01391689|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID for approximately 18 months.
62739547|NCT01933698|ACTIVE_COMPARATOR|Amoxi-Ped|Single dose of 500 mg amoxicillin - AMOXI-PED - was administered after a 12-hour overnight fast.
62739548|NCT01933698|ACTIVE_COMPARATOR|Amoxil|Single dose of 500 mg amoxicillin - AMOXIL - was administered after a 12-hour overnight fast.
62739549|NCT01599312|OTHER|Classic Macintosh laryngoscope|Classic Macintosh laryngoscope (Karl Storz, Tuttlingen, Germany)
62739550|NCT01599312|OTHER|McGrath®|McGrath® (Aircraft Medical Ltd, Edinburgh, UK)
62739551|NCT01599312|OTHER|C-MAC®|C-MAC® (Karl Storz, Tuttlingen, Germany)
62739552|NCT01599312|OTHER|GlideScope® Cobalt|GlideScope® Cobalt (Verathon Medical, Bothell, WA, USA)
62739553|NCT02579148|EXPERIMENTAL|HUCMSC injection|once intracavernous injection of 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells
62739554|NCT02579148|EXPERIMENTAL|collagen scaffolds/HUCMSC injection|once intracavernous injection of collagen scaffolds loaded with 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells
62739555|NCT00785590|EXPERIMENTAL|1|Dermacyd PH_DETINLYN (Lactic Acid)
62739556|NCT04097028|EXPERIMENTAL|Treatment (TAS-102, oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1 and trifluridine and tipiracil hydrochloride PO BID on days 1-5. Treatment repeats every 14 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care chemoradiation therapy followed by surgery.
62739557|NCT04145544|EXPERIMENTAL|Treatment arm|"Procedure will be performed under general anaesthesia. The patients will undergo a surgery that is identical to the one that was planned by the surgeon. At the end of the surgery, the investigator will use the ArtiFascia® patch. Implantation of the ArtiFascia® will be according to clinical discretion of the physician, and in compliance with ArtiFascia® instructions for use. Detailed instructions are in the instructions for use.~Post operation the subject will stay at the hospital according to site standards and physician discretion."
62739558|NCT04145544|ACTIVE_COMPARATOR|Control|"Same procedure as for the treatment arm but using a commercial suturable dural substitute.~Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use."
62739559|NCT03125031|EXPERIMENTAL|Group- Sensor 1|All subjects are enrolled into the test group and receive the Rainbow adhesive adult/pediatric sensors.
62739560|NCT03125031|EXPERIMENTAL|Group- Sensor 2|All subjects are enrolled into the test group and receive the Rainbow adhesive adult/neonatal sensors.
62739561|NCT01404143|ACTIVE_COMPARATOR|Subscapularis Tenotomy|"This treatment group will undergo a technique that involves division of the tendon to gain access to the shoulder.~After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity."
62739562|NCT01404143|EXPERIMENTAL|Subscapularis Peel|This treatment group will use a technique that involves elevation of the tendon off the bone in order to gain access to the shoulder.The subscapularis will be elevated from the lesser tuberosity.
62739563|NCT01120470|EXPERIMENTAL|OGX-427 and Prednisone|OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427
62739564|NCT01120470|ACTIVE_COMPARATOR|Prednisone|"Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization"
62739565|NCT02543073|EXPERIMENTAL|MSCs|MSCs will be given the patients in MSCs group. Besides, azithromycin (AZM) and glucocorticoid will also be administered.
62739566|NCT02543073|ACTIVE_COMPARATOR|Non-MSCs|AZM and glucocorticoid will be given for the patients in Non-MSCs group.
62739567|NCT05860257|EXPERIMENTAL|Implementation of PeerLearning.net|Teachers in implementation schools will be given access to training and resources to implement PeerLearning.net as a core component of instruction. Investigators will not create specific requirements of teachers but will ask that they deliver lessons with PeerLearning.net at least four times per month. Investigators will monitor all teacher usage and thus will be able to promote greater usage by (1) publicly acknowledging teachers that are using it frequently and experiencing success, and (2) targeting teachers who use it infrequently with additional resources and support to encourage more frequent use.
62739568|NCT05860257|NO_INTERVENTION|Pre-Intervention|Teachers in pre-intervention schools will continue with business as usual (i.e., typical instruction). Based upon previous experience in conducting research in school settings, teachers in pre-intervention schools will likely use CL very infrequently, and without the benefit of technology support.
62739569|NCT03560960|EXPERIMENTAL|Probable AD|Participants with probable AD with positive imaging AD pathology will receive the pramlintide challenge test.
62739570|NCT03560960|ACTIVE_COMPARATOR|Amnestic MCI|Participants with amnestic MCI with or without positive AD imaging pathology will receive the pramlintide challenge test.
62739571|NCT03560960|ACTIVE_COMPARATOR|Control- Normal Cognition|Participants with normal cognition without any memory complaints will receive the pramlintide challenge test.
62739572|NCT00348738|EXPERIMENTAL|1|Patients assigned to this group are receiving Erythropoietin medication
62739573|NCT00348738|NO_INTERVENTION|2|control group receiving no treatment
62739574|NCT01238991|EXPERIMENTAL|ACC-001 (3 micrograms) + QS-21|Active vaccine dose of 3 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
62739575|NCT01238991|EXPERIMENTAL|ACC-001 (10 micrograms) + QS-21|Active vaccine dose of 10 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
62739576|NCT01238991|EXPERIMENTAL|ACC-001 (30 micrograms) + QS-21|Active vaccine dose of 30 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
62739577|NCT03919084|ACTIVE_COMPARATOR|THRIVE-Basic|Screening-and-referral usual care model
62550542|NCT04449003||Adolescents without any neurologic or psychiatric diagnoses|Adolescents (aged 13-17 years) without any history of tics
62550543|NCT04767438||Pregnant women|All singleton pregnancies that present to the 12-week scan in the Obstetrics Unit of the participant hospitals. Singleton pregnancies; Gestational age less than 14 weeks, estimated according to Crown-Rump Length (CRL); Blood sample between 8 and 14 weeks of pregnancy; Patients who accept to participate in the study and sign the informed consent.
62739578|NCT03919084|EXPERIMENTAL|THRIVE+|Enhanced screening-and-referral with motivational interviewing and patient navigation services
62739579|NCT00718575|EXPERIMENTAL|1|Deceased liver donors that are randomized to this arm will receive the Glucose/Ischemic Preconditioning pre-treatment intra-operatively prior to starting cold preservation of the organ
62739580|NCT00718575|NO_INTERVENTION|2|Neither donors nor recipients receive any intervention. All procedures will be performed according to our institution's standard of care.
62739581|NCT02217423|EXPERIMENTAL|Obstructive increased AC|"Patient with obstructive respiratory disease with increased abdominal circumference.~chest physiotherapy. Chest physiotherapy airway clearance modality. The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest wall (compression, vibration) and cough."
62739582|NCT02217423|EXPERIMENTAL|Obstructive disfunction with normal AC|"Patients with obstructive respiratory disease with normal abdominal circumference.~Patient with obstructive respiratory disease with increased abdominal circumference.~chest physiotherapy. Chest physiotherapy airway clearance modality. The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest wall (compression, vibration) and cough."
62739583|NCT02217423|EXPERIMENTAL|Restrictive increased AC|"Patients with restrictive respiratory disease with increased abdominal circumference. chest physiotherapy chest wall expansion.~The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression) and incentive spirometry."
62739584|NCT02217423|EXPERIMENTAL|Restrictive disfunction with normal AC|"Patients with restrictive respiratory disease with normal abdominal circumference.~Chest physiotherapy chest wall expansion. The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression) and incentive spirometry."
62739585|NCT06499415|EXPERIMENTAL|topical 5FU-CAL, twice daily, during 4 or 6 consecutive days|Treatment duration is based on treatment location
62739586|NCT06499415|ACTIVE_COMPARATOR|topical 5FU, twice daily, 7 days a week, during 4 weeks|
62174795|NCT03664453|EXPERIMENTAL|Effect (Fed)|"Subjects will be randomly assigned to one of the two treatment sequences. Two single doses of omaveloxolone 150 mg (taken in multiple 50 mg capsules) will be administered to the subjects beginning in the fed state (Period 1) with a crossover and then in the fasted state (Period 2).~Subjects will be confined beginning on Study Day -1 through the last PK blood draw on Study Day 6 during Period 1, and from Study Day 14 through the last PK blood draw on Study Day 20 during Period 2."
62550544|NCT01080560|ACTIVE_COMPARATOR|NEORAL® Capsule 100 mg|
62739587|NCT05254990|EXPERIMENTAL|Reparixin + standard of care|"Reparixin will be administered orally at the dose of 1200 mg (2 x 600 mg tablets) TID (6 tablets daily) for up to 21 days.~The three daily doses will be administered maintaining an interval between doses of about 8 hours."
62739588|NCT05254990|PLACEBO_COMPARATOR|Placebo + standard of care|Placebo tablets are identical in appearance to the active formulation. Placebo will be administered with the same treatment schedule.
62739589|NCT02453152||Males with X-linked myotubular myopathy|History and physical, Tidal breathing, Maximal respiratory pressures, Peak cough flow, Pediatric Evaluation of Disability Inventory, PedsQL Multidimensional Fatigue Scale, Review of ventilation requirements
62739590|NCT03450343|EXPERIMENTAL|Oral azacitidine + R-ICE|Patients will receive 7 days of oral azacitidine (CC-486) leading into cycle 1 day 1 of R-ICE chemotherapy. R-ICE chemotherapy may be administered as an inpatient or as an outpatient . Oral azacitidine will be administered on days 8-21 of cycles 1 and cycle 2. R-ICE will be administered per standard of care.
62739591|NCT06662331|EXPERIMENTAL|Hunsuck-Epker Modification|A kind of ostoeotomy modification used during bilateral sagittal
62739592|NCT06662331|EXPERIMENTAL|Low and short medial osteotomy|A kind of ostoeotomy modification used during bilateral sagittal
62739593|NCT04757480|EXPERIMENTAL|Thoracolumbar Interfascial Plane Block (TLIP)|
62739594|NCT04757480|EXPERIMENTAL|Bilateral Erector Spinae plane Block (ESB)|
62550545|NCT01080560|EXPERIMENTAL|Cyclosporine 100 mg Capsule|
62550546|NCT03636178|OTHER|1st group|20 patients out of 40 will be enrolled into the study including males and females above 18 years old
62550547|NCT03636178|OTHER|2nd group|20 patients out of 40 will be enrolled in the study including males and females above 18 years old
62550548|NCT02631889|EXPERIMENTAL|Transcollation technology|the use of transcollation technology for hilium dissection during Lung surgery
62550549|NCT02631889|ACTIVE_COMPARATOR|Traditional Electrocautery|The use of electrocautery for hilium dissection during lung surgery
62550550|NCT06582394|EXPERIMENTAL|Exp Group|
62550551|NCT06582394|ACTIVE_COMPARATOR|Control Group|
62550552|NCT02514902|EXPERIMENTAL|Lateral Flow Device|Determine the feasibility of testing whole blood samples from patients with acute stroke (both ischemic and hemorrhagic) and traumatic brain injury being evaluated in the Emergency Department and Inpatient Services at University of Kentucky. No diagnostic or treatment decisions will be based on the results for any patient and the patient will not be told of the results.
62739595|NCT02030925|EXPERIMENTAL|IW-3718|Twice a day
61986210|NCT02206425|EXPERIMENTAL|bortezomib + cyclophosphamide + ascorbic acid|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib. Due to a potential drug-drug interaction between ixazomib and ascorbic acid, patients will receive ixazomib in the clinic in the morning and will be instructed to take ascorbic acid in the evening, followed by cyclophosphamide.
62174796|NCT03664453|EXPERIMENTAL|Dose Proportionality|"Subjects will be randomly assigned to one of two omaveloxolone dosages. A single dose of omaveloxolone (in either 50 mg or 100 mg) will be administered to the subjects in 50 mg capsules in a fasted state.~Subjects will be confined beginning on Study Day -1 through the last blood sample collection on Study Day 6."
62174797|NCT05434715|ACTIVE_COMPARATOR|conventional technique of thyroidectomy|"A standard transverse skin incision will be done two fingers above supra-sternal notch extend from the medial head of sternomastoid muscle at one side to the other one at the opposite side, incision of platysma along the whole length of skin incision.~Dissection of the thyroid gland will begin with securing the middle thyroid vein using ligation, bipolar diathermy, or harmonic scalpel.~Dissection of the upper pole with securing the superior thyroid vessel preserving the superior parathyroid glands and the external laryngeal nerve.~Severing the Berry's ligament with ligation of its artery and vein. The contralateral lobe of the thyroid gland will then be approached in a similar fashioon."
62174798|NCT05434715|ACTIVE_COMPARATOR|Minimal invasive technique|"The procedure will start by placing a small incision 2.5-3cm at the upper border of the cricoid cartilage at one of the natural creases of the neck, followed by an incision of the platysma along the length of the skin incision.~Identification of the midline of the neck and division of the strap muscles, followed by dissection of the plane between the muscles and the anterior surface of the thyroid gland.~Dissection of the lateral surface of the thyroid lobe with identification Cutting of sternothyroid muscle at its superior portion. Individual ligaton of branches of superior thyroid artery and vein near to the gland using haemostatic techniques (Harmonic or LigaSure scalpel), guarding the superior parathyroid glands.~Appropriate dissection will then be done. Dissection of the inferior pole and vessel securing using Harmonic or LigaSure scalpel will take place, then dissection of the undersurface of the thyroid gland will be done to separate the gland from its bed."
62739596|NCT02030925|PLACEBO_COMPARATOR|Matching Placebo|Twice a day
62739597|NCT06284460|EXPERIMENTAL|Cohort A: Single agent ASTX029|Participants will take ASTX029 daily on days 1-21 of each 28-day cycle. ASTX029 should be taken with water on an empty stomach, no food 2 hours before and 2 hours after dose.
62174799|NCT06460181|ACTIVE_COMPARATOR|Astaxanthin|Astaxanthin will be administered in a dosage of 12 mg/day orally by one soft gel capsule per day. the capsule consist of natural Astaxanthin and olive oil.
62174800|NCT06460181|PLACEBO_COMPARATOR|Placebo|The placebo will be administered orally by one soft gel capsule per day. The placebo contains olive oil and is color, order, and taste matched to the Astaxanthin soft gels.
62364804|NCT00222248|ACTIVE_COMPARATOR|Bladder training|Weekly group session of education regarding deferral techniques, timed voiding parameters and gentle exercise to music.
62550553|NCT03832205||Capaciflector monitoring group|Patients undergoing their pre-planned, routine cardiopulmonary exercise test (CPET). Additional, non-invasive capaciflector monitoring only - no therapeutic intervention.
62550554|NCT04371107|EXPERIMENTAL|azithromycin|azithromycin treatment 500 mg on day 1 then 250 mg the following 4 days from day 2 to day 5, per os.
62550555|NCT04371107|ACTIVE_COMPARATOR|symptomatic treatment|continuation of symptomatic treatment
62550556|NCT01570686|EXPERIMENTAL|Aliskiren: Fed|Aliskiren 300 mg once daily, taken 30 minutes after start of light breakfast
62739598|NCT06284460|EXPERIMENTAL|Cohorts B and C: Combination of ASTX727 + ASTX029|Participants will take ASTX029 daily on days 1-21 of each 28-day cycle. ASTX727 daily on days 1-5 of each 28-day cycle. Both ASTX029 and ASTX727 should be taken with water on an empty stomach, no food 2 hours before and 2 hours after dose.
62739599|NCT03447210|EXPERIMENTAL|Assisted Partner Services|All participants in this arm will be offered assisted partner services (APS) which involves outreach to sexual partners and to individuals with whom they use injection drugs. When partners are contacted they are offered HIV and HCV testing. There is no comparison arm.
62739600|NCT06269185||Infliximab|Bio-naive patients with ulcerative colitis who starts treatment with infliximab
62739601|NCT06269185||Adalimumab|Bio-naive patients with ulcerative colitis who starts treatment with adalimumab
62739602|NCT05049564|EXPERIMENTAL|keyhole group|patient harbored aneurysm who was treated by microsurgical clipping via keyhole approach.
62739603|NCT05049564|EXPERIMENTAL|conventional group|patient harbored aneurysm who was treated by microsurgical clipping via conventional craniotomy.
62739604|NCT05049564|EXPERIMENTAL|endovascular group|patient harbored aneurysm who was treated by endovascular coiling via femoral approach.
62739605|NCT04587830|EXPERIMENTAL|ADI-PEG 20 plus Radiotherapy and Temozolomide|"ADI-PEG 20 Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)~Radiotherapy Dose: 60 Gy in 30 daily (Monday-Friday) fractions of 2 Gy each; to start within 4 weeks of surgery (diagnostic and/or resection)~Temozolomide Dose: 75 mg/m2 daily during radiotherapy; 150-200 mg/m2 for 5 days every 4 weeks (1 cycle) x 6 cycles during maintenance period Route of Administration: oral or intravenous"
62739606|NCT04587830|PLACEBO_COMPARATOR|Placebo plus Radiotherapy and Temozolomide|"Placebo Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)~Radiotherapy Dose: 60 Gy in 30 daily (Monday-Friday) fractions of 2 Gy each; to start within 4 weeks of surgery (diagnostic and/or resection)~Temozolomide Dose: 75 mg/m2 daily during radiotherapy; 150-200 mg/m2 for 5 days every 4 weeks (1 cycle) x 6 cycles during maintenance period Route of Administration: oral or intravenous"
62739607|NCT04832789|NO_INTERVENTION|Best conventional ventilation|
62739608|NCT04832789|EXPERIMENTAL|Ultra-protective ventilation with ECMO|
62739609|NCT04528017|OTHER|PRECISION1, then Clariti 1-Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
62739610|NCT04528017|OTHER|Clariti 1-Day, then PRECISION1|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
62550557|NCT01570686|EXPERIMENTAL|Aliskiren: Fasting|Aliskiren 300 mg once daily taken after after an overnight fast
62174801|NCT03338257|EXPERIMENTAL|Husky Reads Intervention|The Husky Reads curriculum includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and sometimes food tasting to complement the learning objectives. Undergraduate students enrolled in the Husky Reads service-learning course at UCONN or college students participating in a paid summer internship deliver the program. Each team of 2-3 students is assigned 2-3 early care classrooms to visit and deliver Husky Reads on a weekly basis.
62174802|NCT03338257|NO_INTERVENTION|Wait list Control|Programs on the wait list for Husky Reads, participate in the pre and post intervention testing but do not receive the program.
62174803|NCT00984698|EXPERIMENTAL|Structured Therapy|Cognitive Behavioral Social Rhythm Group Therapy is designed to improve mood and sleep by stabilizing social rhythms, increasing exposure to ambient light, changing dysfunctional bed/bedtime associations, activating the imagery system by changing nightmare content, and challenging dysfunctional automatic thoughts that might contribute to behavioral inactivation and nonadherence to the therapy protocol. There is no discussion of past traumatic events.
62550558|NCT04077580|EXPERIMENTAL|Methenamine hippurate|Tablets containing 1 g methenamine hippurate, dosage 1 tablet morning and evening.
62550559|NCT04077580|PLACEBO_COMPARATOR|Placebo|Placebo tablets containing 1 g of lactose, with identical size, shape and stamps
62174804|NCT00984698|ACTIVE_COMPARATOR|Unstructured Therapy|Present Centered Group Therapy includes education about the typical symptoms and features associated with PTSD and MDD, with a focus on how these symptoms affect interpersonal relationships. It uses the group format to decrease isolation, normalize symptoms, and provide the experience of giving and receiving support. Some relaxation training is provided early in therapy. There is no discussion of past traumatic events.
62550560|NCT02608047||dengue patients|Dengue patients confirmed by Non-structural protein and RNA
62550561|NCT02608047||Healthy controls|Healthy population without any diseases
62174805|NCT01076322|EXPERIMENTAL|Treatment-A sequence|Meptin® Swinghaler / Ventolin® MDI
62174806|NCT01076322|EXPERIMENTAL|Treatment-B sequence|Ventolin® MDI / Meptin® Swinghaler
62174807|NCT05619900||Mucopolysaccharidosis I|Prenatally or postnatally diagnosed individuals
62550562|NCT00808951|EXPERIMENTAL|Artemether -lumefantrine|Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso
62550563|NCT00808951|EXPERIMENTAL|Artesunate-amodiaquine|Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso
62550564|NCT01662687|EXPERIMENTAL|Sancuso patch|
62550565|NCT01662687|ACTIVE_COMPARATOR|Kytril|
62550566|NCT04580264|EXPERIMENTAL|Experimental group|All participants will receive access to the same web-based lifestyle intervention (exercise and nutritional education)
62550567|NCT04340076|EXPERIMENTAL|Dose reduction|Dose reduction by interval prolongation in 2 steps to a maximum decrease of 50% of the original dose when disease activity (PASI) and quality of life index (DLQI) remain low.
62550568|NCT04340076|ACTIVE_COMPARATOR|Normal dose|Patients will continue treatment with the normal/maintenance dose of the biologicals.
62550569|NCT03524521|ACTIVE_COMPARATOR|Standard Walking|This arm is prescribed standard of care exercise prescription; 30 minutes of moderate intensity walking, 5 days/week.
62550570|NCT03524521|EXPERIMENTAL|Interval Training|This arm is prescribed body-weight based interval training 3 days per week with progressive increase in exercise intervals and sets.
62550571|NCT03228797|ACTIVE_COMPARATOR|Group I|( 20 patients) will receive an ultrasound guided rectus sheath block by the end of the surgery using 15 ml ropivacaine 0.5% on either side.
62550572|NCT03228797|ACTIVE_COMPARATOR|Group II|( 20 patients) multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer, a10 ml bolus of ropivacaine 0.2% will be administered through the catheter and then connected to an elastomeric pump delivering a continuous fixed -rate of ropivacaine 5ml/h.
62550573|NCT03228797|ACTIVE_COMPARATOR|Group III|( 20 patients) a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
62550574|NCT02649569||Observational (continuous activity monitoring, questionnaires)|Patients wear an activity monitor throughout and up 4 weeks after completion of radiation therapy. Patients who are willing may continue to wear the monitor through routine follow up appointments. Patients also complete questionnaires at evaluations, which take place prior to radiotherapy initiation, weekly during radiotherapy, and then 2 and 4 weeks after the completion of radiotherapy.
62550575|NCT01103492|EXPERIMENTAL|Ablation catheter|Procedure using the HALO90 Ablation catheter to heat a thin layer of rectal tissue using radiofrequency to reduce inflammation and bleeding in subjects with radiation proctitis.
62550576|NCT03358836||Group A|Episodic treatment with FIX concentrates for bleeding episodes
62550577|NCT03358836||Group B|Prophylaxis using any FIX concentrate with an intended trough of 1-5%
62550578|NCT03358836||Group C|Prophylaxis with an extended half-life (EHL) FIX with an intended trough of \>10%
62739611|NCT06219967|EXPERIMENTAL|Activated charcoal with cola|
62739612|NCT06219967|ACTIVE_COMPARATOR|Activated charcoal|
62739613|NCT02870517|EXPERIMENTAL|Relaxing Music|Participants will listen to relaxing music through noise-cancelling headphones during induction.
62739614|NCT02870517|ACTIVE_COMPARATOR|No Music|Participants will wear noise-cancelling headphones during induction but no music will be played through them.
62739615|NCT06440122||Patients with pheochromocytoma or paraganglioma and positive brown adipose tissue on FDG-PET|
62739616|NCT06440122||Patients with pheochromocytoma or paraganglioma and negative brown adipose tissue on FDG-PET|
62739617|NCT00956007|ACTIVE_COMPARATOR|Arm I: Intensity-Modulated Radiotherapy|Radiation therapy: 60 Gy intensity-modulated radiotherapy (IMRT), 2 Gy/day in 30 fractions (5 days a week for 6 weeks).
62550579|NCT04695769|EXPERIMENTAL|Group A: SOF/VEL/VOX with RBV|"Drug: Sofosbuvir/Velpatasvir/Voxilaprevir 400/100/100 mg tablets (single pill combination administered orally once daily) plus Ribavirin (weight-based dose 1000 or 1200 mg daily according to patient body weight: \< or \> 60 kg).~Another name: Vosevi, RBV"
62174808|NCT05619900||Mucopolysaccharidosis II|Prenatally or postnatally diagnosed individuals
62174809|NCT05619900||Mucopolysaccharidosis IV A|Prenatally or postnatally diagnosed individuals
62174810|NCT05619900||Mucopolysaccharidosis VI|Prenatally or postnatally diagnosed individuals
62174811|NCT05619900||Mucopolysaccharidosis VII|Prenatally or postnatally diagnosed individuals
62174812|NCT05619900||Infantile-Onset Pompe Disease|Prenatally or postnatally diagnosed individuals
62550580|NCT04695769|ACTIVE_COMPARATOR|Group B: SOF/VEL/VOX|"Drug: Sofosbuvir/Velpatasvir/Voxilaprevir 400/100/100 mg tablets (single pill combination administered orally once daily).~Another name: Vosevi"
62550581|NCT04102917||QFR group|915 patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, acute myocardial infarction with non-culprit stenosis who underwent FFR measurement and were able to analyze QFR.
62550582|NCT04405297||Hip Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected hip joint.
62739618|NCT00956007|EXPERIMENTAL|Arm II: IMRT plus cetuximab|"Radiation therapy (RT): 60 Gy IMRT, 2 Gy/day in 30 fractions (5 days a week for 6 weeks).~Cetuximab: 400 mg/m\^2 intravenously (IV) at least 5 days prior to IMRT; 250 mg/m\^2 IV once a week for 6 weeks during RT and continuing 4 weeks after RT."
62739619|NCT06659133|NO_INTERVENTION|Control|control group received routine care during pipelined endometrial biopsy.
62739620|NCT06659133|EXPERIMENTAL|Music|The experimental group listened to acemashiran maqam music during pipelined endometrial biopsy.
62739621|NCT05591859|OTHER|Restoration Anatomic Acetabular Shell|
62739622|NCT04982315|EXPERIMENTAL|Standard Acupuncture|Participants randomized to standard acupuncture will receive 8-15 acupuncture treatments over 3 months.
62739623|NCT04982315|EXPERIMENTAL|Enhanced Acupuncture|Participants randomized to enhanced acupuncture will receive 12-21 acupuncture treatments over 6 months.
62739624|NCT04982315|NO_INTERVENTION|Usual Care|Participants assigned to the usual care arm will not receive acupuncture and will be asked to not get acupuncture over the one-year course of the study.
62739625|NCT05155345|EXPERIMENTAL|Non-fractionated/Dose-finding|Participants will receive a single dose of mosunetuzumab.
62174813|NCT05619900||Neuronopathic Gaucher|Prenatally or postnatally diagnosed individuals
62174814|NCT05619900||Wolman Disease|Prenatally or postnatally diagnosed individuals
62174815|NCT03698630|EXPERIMENTAL|Dexamethasone|Single dose of 0.3 mg/kg dexamethasone (rounded off to the nearest 2 mg, max. 12 mg) prescribed on day 1
62174816|NCT03698630|ACTIVE_COMPARATOR|Prednisolone|1 mg/kg prednisolone (rounded off to the nearest 5 mg, max. 40 mg) prescribed daily for three days from day 1
62174817|NCT03910296||Acceptance & Commitment Therapy|"* Acceptance \& Commitment Therapy (ACT) use acceptance, mindfulness, commitment, and behavior change strategies to increase psychological flexibility.~* Each subject will participate for 6 sessions of Acceptance \& Commitment Therapy (ACT).~* ACT trains patients to reframe their unpleasant, negative, private events while encouraging personal values."
62174818|NCT00592735||1|
62174819|NCT03883698|EXPERIMENTAL|ESRD, alternate day dose|Participants with end stage renal disease (eGFR \<30 ml/min) and hepatitis C virus active infection and treated with sofosbuvir 400 mg on alternate days. Total duration of treatment will be 12 weeks
62174820|NCT03883698|EXPERIMENTAL|ESRD, daily dose|Participants with end stage renal disease (eGFR \<30 ml/min) and hepatitis C virus active infection and treated with sofosbuvir 200 mg daily doses. The total duration of treatment will be 12 weeks
62174821|NCT03883698|ACTIVE_COMPARATOR|Control|Participants with normal eGFR and hepatitis C virus infection and treated with sofosbuvir 400 mg daily dose. The total duration of treatment will be 12 weeks
62174822|NCT01654835|ACTIVE_COMPARATOR|low blood pressure alert|"A Low Blood Pressure condition as specified (SAP \<80 mmHg)will trigger an page to be sent to all anesthesia providers in \<1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support."
62174823|NCT01654835|PLACEBO_COMPARATOR|no low blood pressure alert|The Low Blood Pressure condition will be monitored by treatment team, but additional alert will not be sent to treatment team.
62550583|NCT04405297||Knee Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected knee joint.
62550584|NCT04405297||Ankle Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected ankle joint.
62550585|NCT04405297||Shoulder Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected shoulder joint.
62739626|NCT05155345|EXPERIMENTAL|Fractionated/Dose-escalation|Participants will receive a fractionated (divided) dose of mosunetuzumab on Days 1 and 8.
62739627|NCT04772625||PFA|The cohort consists of all patients operated with patellofemoral arthroplasty for isolated patellofemoral osteoarthritis in Denmark from Jan 1 2008 to Dec 31 2015. The number of patients is expected to be around 500. A patellofemoral arthroplasty is defined as an arthroplasty consisting of a metal trochlear component and a polyethylene patella component. The definition of isolated patellofemoral osteoarthritis in the study is pragmatic and given by the operating surgeon.
62739628|NCT00516906|PLACEBO_COMPARATOR|Transparent Adhesive Dressing|Standard of Care Non-Antimicrobial Transparent Adhesive Dressing
62174824|NCT02388932|EXPERIMENTAL|Treatment (SBRT)|"Participants undergo Stereotactic Body Radiation Therapy in 5 fractions at least 40 hours apart over 10-18 days.~Three dose levels: 40Gy and 45Gy all in 5 fractions. Each initial dose level will have 6 participants allocated to them. All participants are assessed at their 3 month post SBRT visit for Dose-Limiting Toxicities (DLTs). If ≤1 participant experiences a DLT, participants will be enrolled at the next dose level. If ≥3 participants experience a DLT, further accrual will be permanently halted and the study stopped. If 2 participants experience a DLT, then an additional 6 participants will be enrolled at the same dose level. In this setting, if ≤ 3/12 participants have a DLT, participants will be enrolled at the next dose level. If ≥ 4/12 participants have a DLT, further accrual will be permanently halted and the study stopped and 35 Gy will not be recommended as safe.~The dosing strategy for the 2nd (45Gy) cohort will be identical to the first."
62174825|NCT01702519|ACTIVE_COMPARATOR|Reference|nicotine transdermal patch with the existing polyisobutylene adhesive
62550586|NCT04405297||Wrist Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected wrist joint.
62550587|NCT05190705|EXPERIMENTAL|Loncastuximab Tesirine + Dexamethasone|"Participants will be given~* Loncastuximab Tesirine on Day 1 of every 28 day study cycle and continue for up to 6 cycles.~Participants will also receive pre-medications to reduce the chance of having a sensitivity reaction to the study treatment. Participants who tolerate the study treatment without a reaction may have pre-medications changed per determination of their doctor.~* Dexamethasone will be given prior to study treatment on Day -1 or up to 2 hours prior to loncastuximab tesirine and the day after treatment"
62550588|NCT03908437|EXPERIMENTAL|Rapid initiation|Rapid initiation of buprenorphine/naloxone, counseling, peer support and case management
62550589|NCT03908437|ACTIVE_COMPARATOR|Treatment as usual|Seeking treatment from the BAC/CRC (treatment as usual)
62174826|NCT01702519|ACTIVE_COMPARATOR|Treatement|nicotine transdermal patch with the alternate polyisobutylene adhesive
62174827|NCT02946749||Shanghai First Maternity and Infant Hospital|
62174828|NCT02946749||the Putuo District Maternity and Child Health Care Hospital|
62174829|NCT02946749||the Xinhua hospital affiliated to Shanghai jiaotong University|
62550590|NCT06529471|EXPERIMENTAL|Group receiving massage|In Postoperative 0, before the massage, the patient's sleep duration (with the Richard-Campbell Sleep Scale and smart watch) and cortisol level are measured (first test). In Postoperative 1, a back massage is applied three times (10:00-14:00-20:00). In Postoperative 2, sleep duration (with the Richard-Campbell Sleep Scale and smart watch) and cortisol level are measured (last test).
62174830|NCT02946749||The Sixth people's hospital of Shanghai|
62174831|NCT03675308|PLACEBO_COMPARATOR|Placebo|Participants randomized to receive double-blind placebo at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive 150 mg risankizumab followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.
62550591|NCT06529471|NO_INTERVENTION|Standard care group|The patients in this group are given routine care practices of the clinic. Sleep and cortisol measurements are made in parallel with the experimental group.
62550592|NCT01331993|EXPERIMENTAL|1|Treatment order : A, B, C
62550593|NCT01331993|EXPERIMENTAL|2|Treatment order : B, C, A
62550594|NCT01331993|EXPERIMENTAL|3|Treatment order : C, A, B
62550595|NCT01331993|EXPERIMENTAL|4|Treatment order : A, C, B
62174832|NCT03675308|EXPERIMENTAL|Risankizumab|Participants randomized to receive 150 mg risankizumab administered by subcutaneous injection at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive blinded placebo followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.
62174833|NCT03830515|EXPERIMENTAL|Closure of lacerations with microMend|Laceration closure with microMend
62174834|NCT03666208|EXPERIMENTAL|Thrombosed Arteriovenous Graft|Single arm pilot study to investigate effect of sirolimus coated balloon in thrombosed arteriovenous graft
62174835|NCT05113485|ACTIVE_COMPARATOR|Diabetes Prevention Program-based lifestyle change intervention (DPP)|The Diabetes Prevention Program-based lifestyle change intervention (DPP) is designed to help overweight breast cancer survivors to reduce their risk of breast cancer recurrence by reducing their excess body fat.
62174836|NCT05113485|EXPERIMENTAL|Highly Microbiota-Accessible Foods (HMAFs) intervention|The Highly Microbiota-Accessible Foods (HMAFs) lifestyle change intervention is designed to help overweight breast cancer survivors reduce their risk of breast cancer recurrence by reducing their elevated low-grade inflammation.
62174837|NCT03015181|EXPERIMENTAL|Group 1: 1 mg/kg IV Single Dose|Group 1 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 1 mg/kg.
62174838|NCT03015181|EXPERIMENTAL|Group 2: 5 mg/kg IV Single Dose|Group 2 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 5 mg/kg.
62174839|NCT03015181|EXPERIMENTAL|Group 3: 5 mg/kg SC Single Dose|Group 3 subjects received a single SC injection of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 5 mg/kg.
62174840|NCT03015181|EXPERIMENTAL|Group 4: 20 mg/kg IV Single Dose|Group 4 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 20 mg/kg.
62174841|NCT03015181|EXPERIMENTAL|Group 5: 40 mg/kg IV Single Dose|Group 5 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 40 mg/kg.
62174842|NCT03015181|EXPERIMENTAL|Group 6: 5 mg/kg SC Multiple Doses|Group 6 subjects received a SC injection of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0, Week 12 and Week 24 at a dose of 5 mg/kg.
62174843|NCT03015181|EXPERIMENTAL|Group 7: 20 mg/kg IV Multiple Doses|Group 7 subjects received an IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0, Week 12 and Week 24 at a dose of 20 mg/kg.
62174844|NCT00991029|ACTIVE_COMPARATOR|clopidogrel|Patients assigned to clopidogrel in addition to aspirin
62174845|NCT00991029|PLACEBO_COMPARATOR|placebo|Patients assigned to placebo in addition to aspirin
62550596|NCT01331993|EXPERIMENTAL|5|Treatment order : B, A, C
62550597|NCT01331993|EXPERIMENTAL|6|Treatment order : C, B, A
62550598|NCT04393714|EXPERIMENTAL|autogenous dentin graft treated with nitric acid|
62550599|NCT04393714|ACTIVE_COMPARATOR|autogenous dentin graft treated with hydrochloric acid|
62550600|NCT04721808||Patients with Rheumatoid Arthritis (RA)|Patients receiving tofacitinib from the Corrona RA Registry from November 2012 onward
62739629|NCT00516906|EXPERIMENTAL|CHG antimicrobial transparent dressing|Chlorhexidine gluconate antimicrobial transparent adhesive dressing
62174846|NCT03459521|EXPERIMENTAL|Fendrix HBV vaccine or HBVaxpro 40|"Drug: Fendrix Fendrix suspension for injection GlaxoSmithKline Route of administration, dose regimen: Intra-muscular Dose: 20mcg of Hepatitis B Surface Antigen per vaccination at baseline, 1, 2 and 6 months.~Drug: HBVaxpro 40 Sanofi Pasteur MSD Route of administration, dose regimen: Intra-muscular Dose: 40mcg of Hepatitis B Surface Antigen per vaccination at baseline, 1 and 6 months."
62739630|NCT05770635|EXPERIMENTAL|Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug|The experimental group received chemotherapy drug + polyvinyl alcohol embolized microspheres (Huihe Medical) for target lesion TACE (Trans-Arterial Chemoembolization)treatment.Experimental group and control group were selected to use iodide oil according to the condition of subjects.
62174847|NCT06646653|EXPERIMENTAL|Participant group|Woman who developed PPH after vaginal or caesarean delivery and first line interventions have been attempted and failed, and to which the Alma System was applied
62174848|NCT04549142||Pregnant women- high level pollution|Exposed to high levels of pollution (PM2.5)
62739631|NCT05770635|OTHER|Embosphere and chemotherapy drug|
62174849|NCT04549142||Pregnant women- low level pollution|Exposed to low levels of pollution (PM2.5)
62174850|NCT04549142||Non-pregnant women-high level pollution|Exposed to high levels of pollution (PM2.5)
62174851|NCT04549142||Non-pregnant women-low level pollution|exposed to low levels of pollution (PM2.5)
62174852|NCT05806164|ACTIVE_COMPARATOR|Beta-3 receptor agonist oral medication|Selective beta-3 receptor agonist oral medication approved for the treatment of urgency urinary incontinence including mirabegron or vibegron. Usual clinical care standards will be used for prescribing and dosing changes. For mirabegron, dosages are 25 mg and 50 mg as clinically indicated. For vibegron, dosage is 75 mg daily by mouth as clinically indicated.
62739632|NCT00143494|EXPERIMENTAL|1|Critically hill, mechanically ventilated patients
62739633|NCT04245306|EXPERIMENTAL|Children with Autism Spectrum Disorders|A group of 25 children with autism spectrum disorders (ASD)
62739634|NCT04245306|ACTIVE_COMPARATOR|Typically Developing children|A larger group of 150 typically developing children (TD)
62739635|NCT04245306|EXPERIMENTAL|Children with Developmental Language Disorders|A group of 25 children with developmental language disorders (DLD)
62739636|NCT04245306|EXPERIMENTAL|children with attention-deficit/hyperactivity disorder (ADHD group)|25 children with attention-deficit/hyperactivity disorder (ADHD group)
62739637|NCT03654040|EXPERIMENTAL|arTreg|"arTreg: alloantigen-reactive T regulatory cells~The investigational product is donor alloantigen-reactive regulatory T cells (arTreg). Supportive regimen for receipt of arTregs includes everolimus, leukapheresis, cyclophosphamide, and mesna.~Note: Participants who receive at least the minimum Treg product (arTreg) dose of 30 to \<90 x10\^6 total cells will be included in intent-to-treat analysis."
62739638|NCT00833963||Participants Treated With Trastuzumab|Participants who are being treated with trastuzumab during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
62739639|NCT00833963||Participants Treated With Trastuzumab and Pertuzumab|Participants who are being treated with the combination of trastuzumab and pertuzumab during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
62174853|NCT05806164|ACTIVE_COMPARATOR|Intradetrusor onabotulinumtoxinA|OnabotulinumtoxinA at a dose of 100 units will be injected into the bladder per usual care pathways.
62174854|NCT06255912|EXPERIMENTAL|LTC004 + MIL-97|
62174855|NCT06255912|EXPERIMENTAL|LTC004 + MIL-97+ chemotherapy|
62174856|NCT05143879|PLACEBO_COMPARATOR|Placebo|8 subjects took 3 g/kg/day of placebo during 9 weeks
62174857|NCT05143879|ACTIVE_COMPARATOR|Nitrate|8 subjects took 3 g/kg/day of nitrate during 9 weeks
62550601|NCT03657186|EXPERIMENTAL|ProbioSatys™|
62174858|NCT05143879|ACTIVE_COMPARATOR|Citrulline|8 subjects took 3 g/kg/day of citrulline during 9 weeks
62174859|NCT05143879|ACTIVE_COMPARATOR|Nitrate plus Citrulline|8 subjects took 3 g/kg/day of nitrate plus citrulline during 9 weeks
62174860|NCT06312995|EXPERIMENTAL|T3DDY01|Acquired a digital acquisition of the patient's forearm using the Intel RealSense D415. The arm of the patient' is placed on a support to allow the plaster nurse to position of the wrist at the correct angle to treat the fracture. The limb is temporarily immobilised in a plaster cast by the nurses of the practice. The patient is booked for a subsequent outpatient visit (which will be conducted within 72 hours of digital acquisition of the forearm) for the application of the device under investigation. The production of the device through a Stratasys F370 3D printer owned by the Meyer Children's Hospital IRCCS. The material used is ABS (Acrylonitrile butadiene styrene) supplied by Stratasys and specific to the machine. Placement of the device on the patient by the investigating nurses, after removal of the temporary device. Collection of data on the evaluation of study parameters.
62550602|NCT03657186|PLACEBO_COMPARATOR|Placebo|
62739640|NCT00833963||Participants Treated With Ado-Trastuzumab Emtansine|Participants who are being treated with ado-trastuzumab emtansine during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
62550603|NCT00538369|ACTIVE_COMPARATOR|standard-of-care|The standard-of-care group will receive sedation assessment and monitoring with the Ramsay scale, which is the accepted tool at this university
62739641|NCT04346173|EXPERIMENTAL|furlow z plasty with buccinator myomucosal flap|using furlow palatoplasty technique accompanied with addition of buccinator myomucosal flap for closure of primary unilateral cleft palate
62739642|NCT04523623|EXPERIMENTAL|Ibuprofen Group|To compare analgesia from ibuprofen to oxycodone in the initial treatment of acute pain in suspected isolated forearm fractures in children.
62739643|NCT04523623|EXPERIMENTAL|Oxycodone Group|To compare analgesia from ibuprofen to oxycodone in the initial treatment of acute pain in suspected isolated forearm fractures in children.
62739644|NCT04507048|ACTIVE_COMPARATOR|Passive intervention|"Administration of a booklet containing the explanation of 2 clinical rules for early detection of atypical melanocytic lesions: the ABCDE and the ugly duckling rules."
62739645|NCT04507048|EXPERIMENTAL|Active intervention|"A standardized oral explanation will be given to the patient by a dermatologist, together with the administration of a booklet containing written information of 2 clinical rules for detection of melanoma, as the ABCDE and the ugly duckling rules."
62739646|NCT02841007|EXPERIMENTAL|geko device arm|Patients consenting to take part will receive the geko device prior to surgery to internally fixate their fractured ankle, to reduce and prevent oedema
62739647|NCT03319459|EXPERIMENTAL|Regimen A|FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies.
62739648|NCT03319459|EXPERIMENTAL|Regimen B|FATE-NK100 in combination with trastuzumab in subjects with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, HER2+ advanced gastric cancer or other advanced HER2+ solid tumors.
62739649|NCT03319459|EXPERIMENTAL|Regimen C|Regimen C: FATE-NK100 in combination with cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC), or other epidermal growth factor receptor 1 positive (EGFR1+) advanced solid tumors.
62739650|NCT06660017|PLACEBO_COMPARATOR|Control Group|Topical unmedicated syrup base + any standard treatment for oral mucositis.
62739651|NCT06660017|EXPERIMENTAL|Intervention Group|Topical ketamine in syrup + any standard treatment for oral mucositis.
62739652|NCT01555073|ACTIVE_COMPARATOR|Pregabalin/celecoxib group|pregabalin/celecoxib twice a day for 13 days.
62739653|NCT01555073|ACTIVE_COMPARATOR|Pregabalin/placebo group|pregabalin/placebo twice a day for 13 days.
62739654|NCT01555073|ACTIVE_COMPARATOR|Celecoxib/placebo group|celecoxib/placebo twice a day for 13 days.
62739655|NCT01555073|PLACEBO_COMPARATOR|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
62739656|NCT02580123|EXPERIMENTAL|Experimental group|Received the intervention program.
62739657|NCT02580123|NO_INTERVENTION|Control group|received the standard care
62174861|NCT06312995|ACTIVE_COMPARATOR|PLASTER|Traditional device placement (antibrachio-metacarpal cast). Radiological check at 7 days after trauma to verify the angle of the stumps fracture angle, followed by radiological check at 14 days if necessary . Removal of the plaster cast 30 days after the trauma, radiological check to verify the formation of bone callus, clinical evaluation and data collection at the end of treatment
62550604|NCT00538369|EXPERIMENTAL|standard + BIS|Subjects in the standard-of-care + BIS group will receive sedation assessment and monitoring using the Ramsay scale and values from the bispectral index (BIS) monitor.
62739658|NCT03602157|EXPERIMENTAL|ATLCAR.CD30.CCR4 & ATLCAR.CD30|A 3+3 design in adult subjects. Subjects in the first dose level will receive ATLCAR.CD30.CCR4 cells alone, once safety has been established, the initial dose of ATLCAR.CD30.CCR4 will be combined with a fixed dose of ATLCAR.CD30 cells in the next dose level. Every time the dose of ATLCAR.CD30.CCR4 is escalated, subjects in that dose level will receive ATLCAR.CD30.CCR4 alone prior to subsequent dose level enrolling subjects to receive a combination of fixed dose ATLCAR.CD30 and the selected dose level of ATLCAR.CD30.CCR4. The six dose levels will consist of: dose level 1 = 2 × 10\^7 ATLCAR.CD30.CCR4 cells/m2; dose level 2 = 1 × 10\^8 ATLCAR.CD30 cells/m2 and 2 × 10\^7 ATLCAR.CD30.CCR4 cells/m2; dose level 3 = 5 × 10\^7/m2 ATLCAR.CD30.CCR4 cells/m2; dose level 4 = 1 × 10\^8 ATLCAR.CD30 cells/m2 and 5 × 10\^7 ATLCAR.CD30.CCR4 cells/m2; dose level 5 = 1 × 10\^8/m2 ATLCAR.CD30.CCR4 cells/m2; dose level 6 = 1 × 108 ATLCAR.CD30 cells/m2 and 1 × 108 ATLCAR.CD30.CCR4 cells/m2.
62739659|NCT03978598|EXPERIMENTAL|Immediate insertion group|Immediate insertion in the first 24 hours after delivery ENG implant insertion Intervention.
62550605|NCT05387187|EXPERIMENTAL|Pu Yang Wan Wu Tang plus Pentoxifylline|
62739660|NCT03978598|ACTIVE_COMPARATOR|Standard Postpartum Insertion Group|Insertion of the Etonogestrel implant 4-6 weeks postpartum Intervention.
62739661|NCT04081402|EXPERIMENTAL|HU-014 Inj|
62739662|NCT04081402|ACTIVE_COMPARATOR|Botox Inj|
62550606|NCT05387187|ACTIVE_COMPARATOR|Pentoxifylline|
62739663|NCT06264089|OTHER|No Arms have been specified for this study|No Arms have been specified for this study
62739664|NCT06660654|EXPERIMENTAL|Endometrial Cancer Cohort|Participants with endometrial cancer who will receive raludotatug deruxtecan (R-DXd) administered intravenously every 3 weeks (Q3W).
62739665|NCT06660654|EXPERIMENTAL|Cervical Cancer Cohort|Participants with cervical cancer who will receive R-DXd administered intravenously Q3W.
62739666|NCT06660654|EXPERIMENTAL|Non-high-grade Serous Ovarian Cancer|Participants with non-high-grade serous ovarian cancer who will receive R-DXd administered intravenously Q3W.
62739667|NCT06660654|EXPERIMENTAL|Urothelial Cancer Cohort|Participants with urothelial cancer who will receive R-DXd administered intravenously Q3W.
62739668|NCT06660654|EXPERIMENTAL|Clear Cell Renal Carcinoma (ccRCC) Cohort|Participants with clear cell renal carcinoma (ccRCC) who will receive R-DXd administered intravenously Q3W.
62739669|NCT02364115|EXPERIMENTAL|Stereotactic Body Radiotherapy|MRI-based, cone beam CT-guided SBRT delivery of a single dose of 18 Gray (Gy) on the visible metastasis, and 8 Gy on the bony compartment containing the metastasis (e.g. the affected vertebra or pedicle).
62739670|NCT02364115|NO_INTERVENTION|Conventional Radiotherapy|Delivery of a single fraction of 8 Gy using virtual simulation
62739671|NCT03861104|ACTIVE_COMPARATOR|group watched video|"patients will watch the medical video before filling out the spielberger state anxiety inventory at the time of nasal packing removal.~intervention is watching informative video."
62739672|NCT03861104|NO_INTERVENTION|group without video|patients will fill out the spielberger state anxiety inventory without watching the video at the time of nasal packing removal
62739673|NCT04410848||All patient with suspicion of choledocholithiasis|Patient with the suspect of common biliary duct stone for pain type colic in the right upper quadrant abdomen, the elevation of bilirubin, alkaline phosphatase, pancreatitis, dilated common bile duct and cholangitis. According to the criteria to assign the risk of choledocholithiasis. We are going to validate a scale based on intelligence artificial compared to the clinical predictor.
62739674|NCT06555978||Singaporean adults|Adults greater than 21 years of age living in Singapore of Chinese, Malay, or Indian ethnicity.
62550607|NCT06301906||Group 1|
62739675|NCT03944564|ACTIVE_COMPARATOR|Condition 1: sitting|Four hours of sitting condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
62739676|NCT03944564|ACTIVE_COMPARATOR|Condition 2: static standing|Four hours of static standing condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
62174862|NCT02953028|ACTIVE_COMPARATOR|Continuous Positive Airway Pressure|Patients treated With an auto-CPAP-machine which is a compressor Connected to a nose- or face mask which provides increased air pressure, opening the upper Airways during an apnea or hypopnea event.
62174863|NCT02953028|ACTIVE_COMPARATOR|Mandibular Advancing Splint|Patients treated With a twin block splint (oral appliance) advancing the mandible and thereby opening the upper Airways for easier passage of air during sleep preventing apnea and hypopnea events.
62739677|NCT03944564|ACTIVE_COMPARATOR|Condition 3: dynamic standing|Four hours of static standing condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
62739678|NCT04067973||patients|"Premature subjects benefit from the examinations described in the protocol, namely automated refractometry, intraocular air pressure, biometrics (with axial length and pachymetry (corneal thickness) performed by the same machine at the same time), a photo of the fundus (retinophotography) and an OCT RNFL. These examinations are necessary for the follow-up of premature children.~All children examined at Nantes University Hospital benefit systematically from: automated refractometry, intraocular pressure in the air and a photo of the fundus."
62739679|NCT04067973||control|"controls benefit from two additional tests: RNFL OCT and biometrics. The duration of the RNFL OCT is about 2 minutes, with a total of 10 seconds per eye, the rest being computer manipulation.~The biometrics take about 2 minutes to complete, with a total of 30 seconds per eye, the rest being computer manipulation.~These two reviews are conducted on the same day as the initial consultation and directly following the consultation."
62174864|NCT05856318||Pregnancy ~3000 participants|Actively planning to conceive within approximately 12 months of study registration. No previous pregnancies.
62739680|NCT06289426|EXPERIMENTAL|Yoga - Group S|The experimental group will participate in 8 weeks of live online yoga classes, 3 times a week for 60 minutes each session. The yoga program will be designed based on previous evidence and personal experience of yoga experts and researchers.
62739681|NCT06289426|NO_INTERVENTION|Control - Group L|The control group will be waitlisted and will continue with the usual routine for 8 weeks. They will participate in 8-week yoga classes after the completion of the study.
62739682|NCT02574884|OTHER|Recently infected subjects|Actual population of blood donors primo-infected with HCV with specific intervention for the study : one blood sample during the inclusion visit
62739683|NCT02574884|NO_INTERVENTION|Retrospective cases|Population of infected blood donors in 2007, 2008 and 2009 No blood sample
62739684|NCT02574884|OTHER|Individuals sources|Specific intervention for the study : one blood sample during the inclusion visit
62739685|NCT05064358|EXPERIMENTAL|Cohort 1: Participants receiving belantamab mafodotin at dose level (DL) 1|
62739686|NCT05064358|EXPERIMENTAL|Cohort 2: Participants receiving belantamab mafodotin at DL 2|
62174865|NCT05856318||Non-Pregnancy ~500 participants|Not planning to conceive within 18 months of study registration. No previous pregnancies.
62174866|NCT05334706|EXPERIMENTAL|Vaccination|Single arm, vaccination with 9vHPV in a 3-dose regimen (Day 1, Month 2, Month 6).
62739687|NCT05064358|EXPERIMENTAL|Cohort 3: Participants receiving belantamab mafodotin at DL 3|
62739688|NCT05064358|EXPERIMENTAL|Cohort 4: Participants receiving belantamab mafodotin at DL 4|
62739689|NCT05064358|EXPERIMENTAL|Cohort 5: Participants receiving belantamab mafodotin at DL4 with alternative dose modification|
62739690|NCT04227795|EXPERIMENTAL|Artificial intelligence-Assisted real time colonoscopy|AI assisted real-time detection of colonic lesions
62739691|NCT02382874|EXPERIMENTAL|AD-MSC|The patients with FSGS who underwent intravenous injection of AD-MSC.
62739692|NCT03367962|EXPERIMENTAL|Highly suspected to already have aGVHD|Patients highly suspected to have aGVHD. These patients will undergo a \[18F\]F-AraG PET-CT scan following a biopsy taken to confirm aGVHD.
62739693|NCT03367962|EXPERIMENTAL|High risk of developing aGVHD|Patients at high risk of developing aGVHD will undergo a \[18F\]F-AraG PET-CT scan on day 4 +/- 2 days post transplant. Additionally these patients will be scanned again between day 14-21 post transplant.
62739694|NCT03367962|EXPERIMENTAL|Healthy Subjects|Healthy subject volunteers will undergo preliminary evaluation to ensure eligibility, receive and sign an informed consent, be enrolled in the trial, and then have a \[18F\]F-AraG PET-CT scan.
62174867|NCT00932659||Hemodialysis patients|This is a single arm observational study. The single arm consists of adult hemodialysis patients without a prior history of cardiac arrhythmias who will be implanted with a continuous cardiac monitoring device (REVEAL, Medtronic) for an FDA approved indication.
62174868|NCT01732588|ACTIVE_COMPARATOR|Regimen A - 120mg OZ439 PIB|120mg single dose of OZ439 as powder in bottle (PIB) formulation
62174869|NCT01732588|EXPERIMENTAL|Regimen B - 120 mg OZ439 IR caplet|120 mg single dose of OZ439 immediate release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
62739695|NCT05332639|EXPERIMENTAL|Intervention Arm|Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool
62739696|NCT05332639|ACTIVE_COMPARATOR|Comparator arm|Standard Crohn's Disease Education
62739697|NCT06318273|EXPERIMENTAL|Part 1: ABBV-969 Dose Escalation|Participants will receive escalating doses of ABBV-969.
62739698|NCT06318273|EXPERIMENTAL|Part 2 A: ABBV-969 Dose Expansion|Participants will receive dose A of ABBV-969 from part 1.
62739699|NCT06318273|EXPERIMENTAL|Part 2 B: ABBV-969 Dose Expansion|Participants will receive dose B of ABBV-969 from part 1.
62739700|NCT06659809|EXPERIMENTAL|VPT infants and their caregivers randomly allocated to the intervention arm (VPT-VF)|Mother-infant dyads will partecipate in 6 weekly 1-hour sessions of Tele-care video-feedback intervention
62739701|NCT06659809|NO_INTERVENTION|VPT infants and their caregivers randomly allocated to the care as usual arm (VPT-CU)|Usual care; no VF intervention. This arm will act as a control group matched to preterm conditions of VPT-VF.
62739702|NCT06659809|NO_INTERVENTION|FT infants and their caregivers (FT-CG)|Usual care; no VF intervention. This arm will act as an additional control group unmatched to preterm conditions.
62174870|NCT01732588|EXPERIMENTAL|Regimen C - 120 mg OZ439 caplet via Enterion capsule|120 mg single dose of OZ439 caplet formulation containing nanoparticulate, administered orally via the Enterion capsule and delivered to the proximal small bowel
62174871|NCT03756025|EXPERIMENTAL|Vitro Molar® (DFL, Rio de Janeiro, Brazil)|ART restorations of a face with one of the two high-viscosity conventional glass ionomer cements-Vitro Molar® (DFL, Rio de Janeiro, Brazil).
62739703|NCT02644213|EXPERIMENTAL|research arm|"12 young, healthy civilian volunteers will participate in this study. The experiment will take place in a dome room.~The experiment will be performed according to the protocol of using CAREN and MOTEK systems:~1. CAREN high (Computer Assisted Rehabilitation Environment) which screens virtual scene in the dome.~2. MOTEK (Motek Medical©, the Netherlands) which is a two track treadmill (for each leg) placed on a rotatable platform.~each subject will undergo the same experiment protocol."
62739704|NCT04747054|EXPERIMENTAL|Radiotherapy added to systemic treatment|"Pembrolizumab 200mg every 3 weeks until disease progression or unacceptable toxicity.~Loco-regional radiotherapy(RT) depending on the RT timing :~* Before 3 cycles of pembrolizumab: RT could start at any time between one week after the first administration of pembrolizumab and the first day of the 3rd cycle.~* After 3 cycles of pembrolizumab: RT could start at any time after 3rd cycle and up to a maximum of 4 weeks after the 6th cycle of pembrolizumab.~If the investigator decides before randomization to add chemotherapy and depending on the RT timing:~* Start of RT planned before 3rd cycle: Chemotherapy could be delayed after the end of RT and start from cycle 3 or 4 of pembrolizumab.~* RT planned after 3rd cycle: Chemotherapy should start at the same time of pembrolizumab.~Chemotherapy will be composed of carboplatin AUC 5 mg/mL/min or cisplatin 100 mg/m² every 3 weeks with 5-fluorouracil (5-FU) 1000mg/m²/day during 4 days every 3 weeks for a maximum of 6 cycles"
62739705|NCT04747054|ACTIVE_COMPARATOR|Systemic treatment|"Pembrolizumab 200 mg every 3 weeks until disease progression or unacceptable toxicity.~If the investigator decides before randomization to add chemotherapy with pembrolizumab, the chemotherapy will be composed of carboplatin area under the curve (AUC) 5 mg/mL/min or cisplatin 100 mg/m² every 3 weeks with 5-FU 1000 mg/m²/day during 4 days every 3 weeks for a maximum of 6 cycles"
62739706|NCT04956640|EXPERIMENTAL|LY3537982 (Dose Escalation)|LY3537982 administered orally.
62174872|NCT03756025|ACTIVE_COMPARATOR|Ketac Molar Easy Mix® (3M ESPE, St Paul, MN, USA).|ART restorations of a face with one of the two high-viscosity conventional glass ionomer cements-Ketac Molar Easy Mix® (3M ESPE, St Paul, MN, USA).
62550608|NCT02756611|EXPERIMENTAL|Venetoclax|"Venetoclax will be administered orally once daily (QD) beginning with a dose-titration phase. The initial venetoclax dose is 20 mg QD. After 1 week of treatment at 20 mg QD, the dose will be escalated to 50 mg QD followed by subsequent increases, each after 1 week, to 100 mg QD, 200 mg QD and the maximum dose of 400 mg QD. Participants may continue to receive venetoclax for up to 2 years provided they continue to tolerate the drug, have no evidence of disease progression (based on investigator's assessment), do not have unacceptable toxicity, and do not meet any of the criteria for discontinuation.~In countries where venetoclax is not commercially available, participants who continue to derive benefit after 2 years of treatment may be able to extend their treatment for up to 2 additional years, plus one additional year until the venetoclax extension study was open, determined on a case by case basis."
62739707|NCT04956640|EXPERIMENTAL|LY3537982 (Dose Expansion)|LY3537982 administered orally either alone or with another investigational agent.
62739708|NCT04956640|EXPERIMENTAL|LY3537982 (Dose Optimization)|LY3537982 administered orally either alone or with another investigational agent
62739709|NCT03734016|EXPERIMENTAL|Zanubrutinib|Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy
62174873|NCT05532618|ACTIVE_COMPARATOR|Levobupivacaine|Intervention group; 10 ml of Levobupivacaine 0.25% will be added in the adductor canal using ultrasound
62174874|NCT05532618|PLACEBO_COMPARATOR|Placebo|Control group; 10 ml of sodium chloride 0.9% will be added in the adductor canal using ultrasound
62174875|NCT00962221||subclinical hypothyroidism|Patients with subclinical hypothyroidism
62174876|NCT03317899|EXPERIMENTAL|Group I (auto HSCT tbo-filgrastim)|Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days.
62174877|NCT03317899|EXPERIMENTAL|Group II (auto HSCT)|Patients undergo auto Hematopoietic Cell Transplantation (HSCT).
62174878|NCT01408875|EXPERIMENTAL|Rehabilitation and EMS Group|Patient Heart Failure who follows physical training and sessions of electrical quadricipital myostimulation.
62174879|NCT01408875|NO_INTERVENTION|Rehabilitation Group only|Patient Heart Failure who follows physical training
62174880|NCT06274450|EXPERIMENTAL|Drinks with active ingredients Rosa Roxburghii and Pomegranate|Take drinks with active ingredients such as Rosa Roxburghii and Pomegranate. Drink every morning on an empty stomach, 20ml/2 sachets/day.
62174881|NCT06274450|OTHER|Blank Group|Not taking drinks
62174882|NCT05750342|EXPERIMENTAL|Caqui|Subjects will consume two capsules daily. Each capsule will be taken before the two main meals.
62174883|NCT05750342|PLACEBO_COMPARATOR|Placebo|The product will have the same characteristics as the experimental product. They will consume two capsules per day, one before the two main meals.
62174884|NCT04068285|ACTIVE_COMPARATOR|High intensity interval exercise|"Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.~exercise"
62174885|NCT04068285|ACTIVE_COMPARATOR|Moderate intensity continuous exercise|"Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.~exercise"
62174886|NCT04068285|NO_INTERVENTION|No Intervention: Control group|The participants with type 2 Diabetes mellitus in the control group will make stretching exercise at home
62739710|NCT03734016|ACTIVE_COMPARATOR|Ibrutinib|Participants received Ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy
62739711|NCT05171309|EXPERIMENTAL|Camrelizumab in combination with apatinib plus NK cell|"Drug: Apatinib 250 mg once daily (QD) oral dosing.~Other Names:~• Apatinib Drug: Camrelizumab 200 mg intravenously every 2 weeks.~Other Names:~• Camrelizumab Drug: NK cell Cord blood derived NK cells 4 cycles, one cycle is defined as: total cells ≥1×109 per time, continuous intravenous infusion for 2 days every 14±2 days"
62739712|NCT05749666|EXPERIMENTAL|Tofacitinib group|Tofacitinib 5mg BID taken orally for 24 weeks and placebo of prednisolone taken daily according to preset tapering protocol during same period
62739713|NCT05749666|ACTIVE_COMPARATOR|Prednisolone group|Prednisolone taken daily according to preset tapering protocol and placebo of tofacitinib 5mg BID taken orally for 24 weeks
62174887|NCT02160678|ACTIVE_COMPARATOR|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G \& W Laboratories, Inc.) - test product
62174888|NCT02160678|OTHER|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
62739714|NCT06176690|EXPERIMENTAL|Treatment Phase|"Four dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells.~Cohorts of three patients will be enrolled at each dose level The dose is based on the number of CD.30 CAR-EBVT-expressing cells administered.~The total number of dose levels evaluated will depend upon toxicities experienced. Dose level cohorts will be numbered sequentially.~* Dose Level 1: 4 × 10\^7 C7R.CD30.CAR-EBVST cells~* Dose Level 2: 1 × 10\^8 C7R.CD30.CAR-EBVST cells~* Dose Level 3: 4 × 10\^8 C7R.CD30.CAR-EBVST cells~* Dose Level 4: 8 × 10\^8 C7R.CD30.CAR-EBVST cells"
62174889|NCT02160678|PLACEBO_COMPARATOR|Vehicle|Cream Vehicle (placebo) (G \& W Laboratories, Inc.)- vehicle
62550609|NCT03505086||cohort|All patients fulfilling the eligibility criteria who can be asked for consent. Basic register of only patient diagnosis, treatment and bleeding yes or no (without identifiable information).
62550610|NCT03505086||cases|Patient with clinically relevant bleeding, defined as major and clinically relevant non-major bleeding that leads to substantial additional medical care: WHO score 3-4 and part of the WHO score 2 bleedings (depending on the need for additional care).
62174890|NCT06138834|EXPERIMENTAL|Low-dose Y-6 sublingual tablet group|One Y-6 sublingual tablet (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), one placebo of Y-6 sublingual tablet (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol).
62174891|NCT06138834|EXPERIMENTAL|High-dose Y-6 sublingual tablet group|Two Y-6 sublingual tablets (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol).
62739715|NCT06657911||BAV patients underoging TAVR|Patients with bicuspid aortic valve undergoing TAVI for severe aortic stenosis with sizing performed
62739716|NCT05397041|EXPERIMENTAL|BMB-101|Participants receiving BMB-101 orally
62739717|NCT05397041|PLACEBO_COMPARATOR|Placebo|Participants receiving Matched Placebo orally
62739718|NCT00778375|EXPERIMENTAL|Clofarabine + Cytarabine + Decitabine|Clofarabine 20 mg/m\^2 by vein (IV) as a 1- to 2-hour intravenous infusion daily for 5 days. Cytarabine 20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions. Decitabine 20 mg/m\^2 as a 1- to 2-hour infusion daily for 5 days.
62739719|NCT00434447|EXPERIMENTAL|Zoledronic Acid|ZOL446
62739720|NCT06176430|ACTIVE_COMPARATOR|Daily Group|one group will receive ferrous sulphate 3mg/kg in the form of syrup daily
62739721|NCT06176430|SHAM_COMPARATOR|Twice Weekly Group|other group will receive ferrous sulphate 3mg/kg in the form of syrup twice weekly.
62739722|NCT04493541|EXPERIMENTAL|BMS-986256|
62739723|NCT04493541|PLACEBO_COMPARATOR|Placebo|
62739724|NCT06658509|EXPERIMENTAL|HIIT group|
62739725|NCT06658509|EXPERIMENTAL|SIT group|
62174892|NCT06138834|EXPERIMENTAL|Low-dose Cilostazol group|Two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), one half Cilostazol tablet (each tablet contains 50 mg Cilostazol), and one half Cilostazol mimicry tablet(each tablet contains 0 mg Cilostazol).
62550611|NCT03505086||controls|Patient without clinically relevant bleeding matched to a case patient based on diagnosis and therapy.
62739726|NCT06658509|NO_INTERVENTION|Control group|
62739727|NCT06655181|EXPERIMENTAL|Experimental Group|Participants in the experimental group will be taught a home-based chest physiotherapy program (breathing exercises, teaching relaxation positions, cough training, respiratory control, respiratory control, physical activity recommendation) to be applied for 30 minutes a day, 5 days a week for 8 weeks. In addition to this program, the participants in the experimental group will be given inspiratory and expiratory combined respiratory muscle training at 30% of MEP and MIP values for 8 weeks, 2 times a day for 20 minutes each, at least 5 days a week. The resistance setting of the participants in the experimental group will be adjusted to be calculated by measuring MIP-MEP again.
62174893|NCT06138834|EXPERIMENTAL|High-dose Cilostazol group|Two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol tablet (each tablet contains 50 mg Cilostazol).
62174894|NCT06138834|PLACEBO_COMPARATOR|Placebo group|Two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol).
62550612|NCT02478879|EXPERIMENTAL|ZP-PTH Patch|Intradermal microneedle patch coated with 40 mcg of PTH, applied intracutaneously to the abdomen daily for 30 minutes, 14 days of treatment
62550613|NCT02478879|ACTIVE_COMPARATOR|FORTEO(R) Pen|Marketed FORTEO 20 mcg, administered daily as a subcutaneous injection to the abdomen or thigh for 14 days of treatment.
62550614|NCT01605747|EXPERIMENTAL|Culturelle|
62550615|NCT01605747|PLACEBO_COMPARATOR|Placebo|
62739728|NCT06655181|SHAM_COMPARATOR|Control Group|Participants in the control group will be taught a home-based chest physiotherapy program (breathing exercises, teaching relaxation positions, cough training, respiratory control, respiratory control, physical activity recommendation) to be applied for 30 minutes a day, 5 days a week for 8 weeks. Patients in the control group will receive sham combined respiratory muscle training at the lowest constant load, twice a day for 20 minutes each, at least 5 days a week for a total of 8 weeks.
62739729|NCT05968495|EXPERIMENTAL|Renuvion APR System Treatment|Subjects are receiving treatment with the Renuvion APR system following power-assisted liposuction in the abdomen per investigator standard of care. Subjects may also have other body areas treated at the same time.
62174895|NCT00668330|ACTIVE_COMPARATOR|Ibandronate+alfacalcidol+calcium|Bonviva
62739730|NCT02483923|EXPERIMENTAL|Group S|
62739731|NCT02483923|PLACEBO_COMPARATOR|Group C|
62739732|NCT05359276||Cohort 1|Patients with a confirmed diagnosis of ASMD under early access to olipudase alfa in France
62739733|NCT06426693|EXPERIMENTAL|Neurofeedback|Three imaging (fMRI) sessions of experimental feedback.
62739734|NCT06426693|SHAM_COMPARATOR|Control neurofeedback|Three imaging (fMRI) sessions of sham feedback.
62739735|NCT00386217||Telephone Survey|90 minute Telephone survey of female cancer survivors
62739736|NCT06125236||Acute ischemic stroke with large- or medium-vessel occlusion|Acute ischemic stroke patients with large- or medium-vessel occlusion including all treatments.
62739737|NCT01133756|EXPERIMENTAL|Lenvatinib plus carboplatin + gemcitabine|Phase IB and Phase II
62174896|NCT00668330|ACTIVE_COMPARATOR|Placebo ibandronate+alfacalcidol+calcium|
62174897|NCT02440737|EXPERIMENTAL|NEST Intervention|Patients (PTs) and their caregivers (CGs) receive educational intervention, follow-up care, psychosocial assessment and care, and questionnaire administration interventions by completing psychosocial questionnaires and meeting with a nurse practitioner (NP) or nurse navigator (NN) for an initial survivorship care planning session to review the expected course of therapy and recovery, identify resources that may be needed and provide recommendations for follow-up. At the end of their treatment EOT), PTs and their CGs complete a 2nd set of questionnaires and meet with the NP/NN for a booster survivorship care planning session. They will receive an individualized final survivorship care plan and related materials. 2 months after EOT, PTs and their CGs complete a final set of questionnaires.
62739738|NCT01133756|ACTIVE_COMPARATOR|Carboplatin + gemcitabine|Phase II
62174898|NCT03907254|EXPERIMENTAL|National Capital Region (NCR)|10-week longitudinal pre-post study, in which each participant will serve as their own control. Each participant will train a service dog using methods that facilitate a relationship between the trainer and dog for the gradual shaping of desired behavior. Self-report measures of behavioral symptoms will be given weekly throughout participation in this study. Biological measures, including blood collection, HR, BP, etc. will be collected at baseline, during the three-week training follow-up, during the six-week training follow-up, and at a three-month post-training follow-up. The researchers will also be collecting self-report assessments from the participant, observational reports from an Occupational Therapist (OT) and electronic health records to track healthcare utilization and social skills (i.e. communication).
62739739|NCT05790018|EXPERIMENTAL|Experiment|First of all, questionnaire forms and scales will be applied to the pregnant women included in the experimental group in the pre-test (at 29-30 weeks). Then the pregnant pillow will be given and necessary explanations will be given about its use. Second follow-up 33-34. It will be done at the gestational week and the scales will be repeated. The final test is 37-38. It will be done at the gestational week (before birth) and the research will be completed.
62739740|NCT05790018|NO_INTERVENTION|Control|The researcher will apply the questionnaires and scales in the pre-test to the pregnant woman included in the control group, and no other intervention will be applied. 37-38 to the pregnant women in the control group. The final test will be done weekly.
62739741|NCT06215859|EXPERIMENTAL|MR-107A-02|15 mg Twice daily (BID) during in patient phase (0-48 hours following randomization) 15 mg BID dosing morning and evening, during out patient phase (5 days) .
62739742|NCT06215859|ACTIVE_COMPARATOR|Tramadol|"50 mg, administered every 6 hours (q6h) during the in patient phase (0-48 hours following randomization).~Placebo will be administered during out patient phase."
62174899|NCT05286086|SHAM_COMPARATOR|PREHAB-PREOP|PREHABILITATION BEFORE SURGERY
62174900|NCT05286086|EXPERIMENTAL|PREHAB-NEOADJ|PREHABILITATION DURING NEOADJUVANCY AND BEFORE SURGERY
62174901|NCT00598117||1|Group 1 (newly diagnosed patients) Initial assessment → first post op visit → 6 and 12 months post surgery
62174902|NCT00598117||2|Group 2 (post-treatment patients) A one-time assessment will be conducted at least 18 months following treatment
62174903|NCT04387422|EXPERIMENTAL|150 mg/dL|Hyperglycemia target of 150 mg/dL
62174904|NCT04387422|EXPERIMENTAL|225 mg/dL|Hyperglycemia target of 225 mg/dL
62174905|NCT04387422|EXPERIMENTAL|300 mg/dL|Hyperglycemia target of 300 mg/dL
62174906|NCT03231761|EXPERIMENTAL|Service user testimonial videos|Videos with service user testimonials about depression and psychosis
62739743|NCT06215859|PLACEBO_COMPARATOR|Placebo|Placebo is administered every 6 hours (q6h) during the in patient phase (0-48 hours following randomization) and twice daily during the out patient phase.
62739744|NCT00713778|EXPERIMENTAL|1|Laparoscopic ovarian cystectomy using bipolar
62174907|NCT03231761|ACTIVE_COMPARATOR|mhGAP didactic video|The intervention in the active comparator arm includes two didactic videos with instruction about depression and psychosis based on the World Health Organization mental health Gap Action Programme (mhGAP) modules for those conditions
62739745|NCT00713778|EXPERIMENTAL|2|Laparoscopic ovarian cystectomy using ultrasonic scalpel
62739746|NCT00713778|ACTIVE_COMPARATOR|3|Laparotomic ovarian cystectomy using suture
62739747|NCT04829682|EXPERIMENTAL|ACT for Life|ACT for Life + Treatment as Usual
62739748|NCT04829682|ACTIVE_COMPARATOR|Present Centered Therapy|Present Centered Therapy + Treatment as Usual
62739749|NCT01674049|EXPERIMENTAL|Exercise and Immediate Nutrition|40 min of circuit-style resistance exercise and 600g low-fat chocolate milk immediately after the exercise bout
62739750|NCT01674049|ACTIVE_COMPARATOR|Exercise and Nutrition 3 hours Post-Bout|40 min of circuit-style resistance exercise and 600g low-fat chocolate milk three hours after the exercise bout
62739751|NCT06482229|EXPERIMENTAL|m-tapa|
62739752|NCT06482229|EXPERIMENTAL|intraperitoneal bupivacain|
62739753|NCT06482229|EXPERIMENTAL|intraperitoneal bupivacain+dexmedetomidin|
62739754|NCT01519687|EXPERIMENTAL|Levotofisopam|All patients will receive a single dose of 50 mg on Day 1, 50 mg three times a day (TID) on Days 2 through 6, and a single dose of 50 mg on Day 7. Each dose of study drug will be administered by authorized site personnel throughout the 7-day inpatient treatment period.
62739755|NCT03650413|EXPERIMENTAL|UTTR1147A|All participants will have the opportunity to receive treatment with UTTR1147A until clinical remission is achieved. Participants will either receive treatment with UTTR1147A or undergo observation depending on disease status, as described in the protocol.
62739756|NCT05095727|EXPERIMENTAL|SAD: mRNA-3745|Participants will receive a single intravenous (IV) dose of mRNA-3745 on Day 1 in an inpatient setting. Participants that are/have been enrolled in the study and receive an administration of mRNA-3745 may also enroll in one of the MAD cohorts. The first MAD dose must occur at least 21 days after the SAD dose.
62739757|NCT05095727|EXPERIMENTAL|MAD: mRNA-3745|Participants will receive multiple IV doses of mRNA-3745 in an inpatient setting. Participants will have the option to continue treatment in the OLE.
62739758|NCT06464705|EXPERIMENTAL|PEMF treatment|Patient will receive a PEMF treatment. The involved leg will be exposed to PEMF for 10 minutes per session, and the treatment regime will run two times a week for eight weeks, summing up 16 sessions of PEMF exposure in total.
62174908|NCT03231761|NO_INTERVENTION|No video|Participants do not observe any videos prior to the assessment
62174909|NCT05427019|ACTIVE_COMPARATOR|Distal adductor canal block|Participants receiving continuous distal adductor canal block
62174910|NCT05427019|ACTIVE_COMPARATOR|Distal adductor canal block and Periarticular block|Participants receiving continuous distal adductor canal block and periarticular block
62174911|NCT04903847|NO_INTERVENTION|Dolutegravir/tenofovir disproxil/lamivudine|Continue dolutegravir 50 mg, tenofovir disproxil 245 mg, ,and lamivudine 300 mg once daily for 48 weeks.
62739759|NCT06464705|PLACEBO_COMPARATOR|Placebo treatment|Patient will receive a placebo treatment. The involved leg will be exposed to placebo treatment for 10 minutes per session, and the treatment regime will run two times a week for eight weeks, summing up 16 sessions of placebo exposure in total.
62739760|NCT06662344|EXPERIMENTAL|Intermittent Oral-esophageal Tube Feeding+comprehensive rehabilitation therapy|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition. The observation group receives Intermittent Oro-esophageal Tube Feeding for enteral nutrition support
62739761|NCT06662344|ACTIVE_COMPARATOR|Nasogastric Tube Feeding+comprehensive rehabilitation therapy|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition.The control group receives nasogastric tube for enteral nutrition support
62174912|NCT04903847|EXPERIMENTAL|dolutegravir/lamivudine|dolutegravir 50 mg/lamivudine 300 mg once daily for 48 weeks
62174913|NCT04903847|EXPERIMENTAL|doravirine/tenofovir disproxil/lamivudine|100 mg doravirin, 245 mg tenofovirdisoproxil and 300 mg lamivudine once daily for 48 weeks.
62174914|NCT05404126|NO_INTERVENTION|Control (Group 1)|Only assessments and scales will be applied to the participants in Group 1 at the beginning of the study and at the end of 12 weeks.
62550616|NCT06487247|EXPERIMENTAL|Arm 1: Access to home blood transfusions while enrolled in hospice (HEME-Hospice care)|Participants assigned to access to HEME-Hospice care who enroll in hospice will have at least once weekly assessment of symptoms of anemia and thrombocytopenia by the study team and will receive transfusions at home as indicated. Individualized care appointments with hospice care team providers, and frequency of visits are determined by individual participant need.
62739762|NCT03394651||Oral medication group|Patients in this group will receive oral medications to treat lower urinary tract symptoms
62739763|NCT03394651||Surgical treatment group|Patients in this group receive minimal invasive transurethral prostate procedures.
62739764|NCT03855787|ACTIVE_COMPARATOR|Ureteral stent group|A ureteral stent will be placed after ureteroscopy.
62174915|NCT05404126|EXPERIMENTAL|Conventional Exercise Balance (Group 2)|Group 2 will be included in the exercise program twice a week for 40 minutes for 12 weeks.
62174916|NCT05404126|EXPERIMENTAL|Dual Task-Oriented Stroboscopic Visual Training Group (Group 3)|Group 3 will be included in the exercise program twice a week for 40 minutes for 12 weeks. Trainings are planned with one-on-one therapist.
62739765|NCT03855787|ACTIVE_COMPARATOR|No ureteral stent group|A ureteral stent will not be placed after ureteroscopy.
62550617|NCT06487247|NO_INTERVENTION|Arm 2: Usual Care|Participants assigned to usual care will receive standard oncology care delivered by the hematologic oncologists. Participants will have access to regular/standard hospice care if they elect to enroll in hospice.
62739766|NCT05501080|EXPERIMENTAL|SAAE group|Subjects received super selective adrenal artery embolization treatment
62739767|NCT05501080|ACTIVE_COMPARATOR|Spironolactone group|Subjects received spironolactone treatment
62739768|NCT06040424|EXPERIMENTAL|Ipratropium / Levosalbutamol Fixed Dose Combination|"In this one-day study, patients will be administered 2 inhalation of İPRALEV 20 mcg/50 mcg aerosol inhalasyonu, süspansiyon at morning."
62550618|NCT00191191|EXPERIMENTAL|Pemetrexed 500 mg/m2|Pemetrexed 500 mg/m2
62550619|NCT00191191|EXPERIMENTAL|Pemetrexed 1000 mg/m2|Pemetrexed 1000 mg/m2
62174917|NCT05404126|NO_INTERVENTION|Healthy Control Group (Group 4)|Only assessments and scales will be applied to the participants in Group 4 at the beginning of the study and at the end of 12 weeks.
62174918|NCT06105996|EXPERIMENTAL|Interoceptive training|Participants will undergo 6 sessions of cardiac interoceptive training.
62174919|NCT06105996|NO_INTERVENTION|Treatment as usual arm|Participants will undergo treatment as usual.
62174920|NCT01800578||Bispectral Index Group|
62174921|NCT01165502|EXPERIMENTAL|CM3.1-AC100|Compound CM3.1-AC100 s.c.
62174922|NCT01165502|PLACEBO_COMPARATOR|Placebo|Placebo for compound CM3.1-AC100 s.c.
62174923|NCT02611921|EXPERIMENTAL|Crossover Group: Ketamine verses Placebo|"Phase 1: Two ascending doses of intranasal ketamine~Two week washout~Phase 2: Two doses of placebo"
62739769|NCT06040424|ACTIVE_COMPARATOR|Ipratropium + Levosalbutamol Free Dose Combination|"In this one-day study, patients will be administered 2 inhalations of VENTOLİN İnhaler 100 mcg and then 2 inhalations of ATROVENT MDI 0,02 mg/dose at morning."
62739770|NCT03420495|EXPERIMENTAL|OCD Group|Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for principal OCD. These participants will complete clinician interviews, self-report questionnaires, and receive the Decision-Making Tasks Intervention.
62739771|NCT03420495|EXPERIMENTAL|Non-psychiatric Control Group|No current DSM-5 diagnosis. These participants will also complete clinician interviews, self-report questionnaires, and receive the Decision-Making Tasks Intervention.
62739772|NCT04749628|PLACEBO_COMPARATOR|Ora-sweet SF|
62739773|NCT04749628|EXPERIMENTAL|400mg cannabidiol|
62174924|NCT02611921|EXPERIMENTAL|Crossover Group: Placebo verses Ketamine|"Phase 1: Two doses of placebo~Two week washout~Phase 2: Two ascending doses of intranasal ketamine"
62174925|NCT04672499|EXPERIMENTAL|Cohort 1: Miricorilant 900 mg (Regimen A1)|Participants will receive a single oral dose of miricorilant 900 mg (3 X 300 mg) after breakfast on Day 1. Cohort 1 treatment will be randomized and open label.
62174926|NCT04672499|EXPERIMENTAL|Cohort 1: Miricorilant 300 mg (Regimen A2)|Participants will receive a single oral dose of miricorilant 300 mg (2 X 150 mg) after breakfast on Day 1. Cohort 1 treatment will be randomized and open label.
62174927|NCT04672499|EXPERIMENTAL|Cohort 2: Miricorilant (Regimen B1 and B2)|Participants will receive a single oral dose of miricorilant 900 mg (6 X 150 mg) after breakfast on Day 1 (Regimen B1). After a minimum 7-day washout, participants will receive miricorilant 900 mg (6 X 150 mg) qd for 14 days (Regimen B2). Day 1 treatment in Regimen B2 will be in the fasted state; the remaining doses will follow breakfast. Cohort 2 treatments will be randomized and blinded.
62174928|NCT04672499|PLACEBO_COMPARATOR|Cohort 2: Placebo (Regimen B1 and B2)|Participants will receive a single oral dose of placebo matching miricorilant 900 mg (6 X 150 mg) after breakfast on Day 1 (Regimen B1). After a minimum 7-day washout, participants will receive placebo matching miricorilant 900 mg (6 X 150 mg) qd for 14 days (Regimen B2). Day 1 treatment in Regimen B2 will be in the fasted state; the remaining doses will follow breakfast. Cohort 2 treatments will be randomized and blinded.
62174929|NCT04672499|EXPERIMENTAL|Cohort 3: Miricorilant (Regimen C1 and C2)|Participants will receive two oral doses (morning and evening) of miricorilant 1350 mg (9 X 150 mg) after a meal on Day 1 (Regimen C1). After a minimum 7-day washout, participants will receive miricorilant 750 mg (5 X 150 mg) after breakfast for 14 days and miricorilant 600 mg (4 X 150 mg) in the evening after a meal for 13 days (Regimen C2). Cohort 3 treatments will be randomized and blinded.
62174930|NCT04672499|PLACEBO_COMPARATOR|Cohort 3: Placebo (Regimen C1 and C2)|Participants will receive two oral doses (morning and evening) of placebo matching miricorilant 1350 mg (9 X 150 mg) after a meal on Day 1 (Regimen C1). After a minimum 7-day washout, participants will receive placebo matching miricorilant 750 mg (5 X 150 mg) after breakfast for 14 days and placebo matching miricorilant 600 mg (4 X 150 mg) in the evening after a meal for 13 days (Regimen C2). Cohort 3 treatments will be randomized and blinded.
62174931|NCT00927550|EXPERIMENTAL|lithium plus usual care|
62174932|NCT00927550|ACTIVE_COMPARATOR|usual care without lithium therapy|
62174933|NCT06102798|EXPERIMENTAL|Acupuncture|"Hwato brand disposable acupuncture needles and adhesive pads will be used. The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted. There will be 18 treatment sessions with 3 times a week for continuous 6 weeks and a 30 min treatment per session."
62174934|NCT06102798|SHAM_COMPARATOR|Sham acupuncture|Hwato brand disposable placebo needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) and adhesive pads will be used. The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be selected. The treatment duration and frequency of sessions for participants in the SA group will be the same as in the acupuncture group.
62174935|NCT00344539|EXPERIMENTAL|B|80 mcg AMA1-C1/Alhydrogel® with 368 mcg Aluminum and 500 mg CPG 7909.
62174936|NCT00344539|EXPERIMENTAL|C|80 mcg AMA1-C1/Alhydrogel® with 368 mcg Aluminum alone.
62174937|NCT00344539|EXPERIMENTAL|A|20 mcg AMA1-C1/Alhydrogel® with 377 mcg Aluminum and 500 mg CPG 7909.
62174938|NCT00629317|ACTIVE_COMPARATOR|A|
62174939|NCT00629317|PLACEBO_COMPARATOR|B|
62550620|NCT04957238|EXPERIMENTAL|ARBORea decision-making tool|After a period of presentation and training on the dedicated decision-making tool (face-to-face, video and paper supports), nurses will be asked to use ARBORéa decision tree. This will be in the form of an electronic file and will give a suggestion of whether or not to use physical restraints. This is based on an algorithm based on specific and mandatory elements (neurological state : RASS (Richmond assessment sedation scale) and CAM-ICU (confusion assessment method-ICU) scores, modification of sedation dosage, equipment levels, presence and adhesion of the family) that will be completed online. ARBORea's suggestion will be collected as well as final caregiver's decision in order to evaluate relevance of the tool. Observations will also be made at least every 8 hours. This period will also be of random duration (stepped wedge)
62739774|NCT04749628|EXPERIMENTAL|800mg cannabidiol|
62739775|NCT03647345|EXPERIMENTAL|Experimental 1: Anodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of anodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
62174940|NCT01458756||liver transplant patients|Population of adult patients awaiting liver transplant, status on the waiting list in the transplant center of University Hospital of Lille.
62739776|NCT03647345|EXPERIMENTAL|Experimental 2: Cathodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of cathodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
62739777|NCT03647345|ACTIVE_COMPARATOR|Active Comparator: Single sham stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
62739778|NCT02709551|EXPERIMENTAL|HRV-Bfb|HRV biofeedback, training about 30 minutes/day
62739779|NCT02709551|EXPERIMENTAL|MBI|Mindfulness based intervention, training about 30 minutes/day
62739780|NCT02709551|OTHER|MBI_HRV-Bfb|Mindfulness based HRV biofeedback. Wait list control group for the interventions HRV-Bfb and MBI, after the main phase intervention with combined method.
62739781|NCT04630860|EXPERIMENTAL|56mg dose group|
62739782|NCT04630860|EXPERIMENTAL|84mg dose group|
62739783|NCT04630860|EXPERIMENTAL|112mg dose group|
62739784|NCT05509647||Covid-19 patients|Adult patients treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa level 0.3-0.7 iE/ml. All patients have Covid-19 proven by PCR or nose- or airway swab. Patients admitted to the ICU from the 15th of March 2020 until January 2022.
62739785|NCT05509647||non-COVID-19 patients|Adult patients treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa level 0.3-0.7 iE/ml. Patients admitted to the ICU between the 1st of January 2014 and the 1st of January 2020 are included.
62739786|NCT04458532|EXPERIMENTAL|(A) breast cancer after completion of chemo|300 min/wk for 16 weeks, followed by 16 weeks of usual care.
62739787|NCT04458532|EXPERIMENTAL|(B) breast cancer after completion of chemo|150 min/wk for 32 weeks.
62739788|NCT04458532|EXPERIMENTAL|(C) breast cancer after completion of chemo|300 min/wk for 32 weeks.
62739789|NCT04458532|ACTIVE_COMPARATOR|(D) breast cancer after completion of chemo|150 min/wk for 16 weeks, followed by 16 weeks of usual care.
62739790|NCT06025942|EXPERIMENTAL|Intervention|The Purrble intervention takes the form of an interactive plush toy, designed to be handed over to the young person and support in-the-moment soothing.
62174941|NCT02084355|EXPERIMENTAL|opioid rotation|"Patients who are randomized to opioid rotation are treated with strong opioid other than currently used strong opioid (Reduce the dose by 25%-50% to allow for incomplete cross-tolerance between different opioids).~* oral oxycodone : convert to oral hydromorphone or fentanyl patch~* oral hydromorphone : convert to oral oxycodone or fentanyl patch~* fentanyl patch : convert to oral oxycodone or oral hydromorphone"
62174942|NCT02084355|ACTIVE_COMPARATOR|opioid dose escalation|"Patients who are randomized to opioid dose escalation will be treated cancer pain by escalation dose of same strong opioid.~* oral oxycodone : maintain oral oxycodone and titrate the dose~* oral hydromorphone : maintain oral hydromorphone and titrate the dose~* fentanyl patch : maintain fentanyl patch and titrate the dose"
62739791|NCT06025942|NO_INTERVENTION|Control|Wait-list control (access to services as usual)
62739792|NCT01880294||Asian participants with chronic constipation|Asian participants diagnosed with chronic constipation using Asian Neurogastro-enterology and Motility Association (ANMA) diagnostic questionnaire.
62739793|NCT05614258|EXPERIMENTAL|ADG206 dose escalation|
62739794|NCT01594554||HCV Patients|A sample of 600 Han ethnic Chinese male or female who are ≥ 18 years old enrolled and completed in the study of AI452-009 (i.e., CCgenos cross sectional phase, ClinicalTrials.gov Identifier: NCT01293279).
62739795|NCT05327127|EXPERIMENTAL|K-001|K-877-ER and CSG452 Once daily (QD)
62739796|NCT05327127|EXPERIMENTAL|K-877-ER|K-877-ER and CSG452 Placebo QD
62739797|NCT05327127|EXPERIMENTAL|CSG452|CSG452 and K-877-ER Placebo QD
62739798|NCT05327127|PLACEBO_COMPARATOR|Placebo|
62739799|NCT03028415|EXPERIMENTAL|AMPLEX|
62174943|NCT05906901|PLACEBO_COMPARATOR|Control Group|The investigator will perform a cranial listening technique.
62739800|NCT03028415|ACTIVE_COMPARATOR|Autogenous Bone Graft (ABG)|
62739801|NCT04361136|EXPERIMENTAL|Delgocitinib cream 1 mg/g|Single topical occlusive administration
62739802|NCT04361136|EXPERIMENTAL|Delgocitinib cream 3 mg/g|Single topical occlusive administration
62739803|NCT04361136|EXPERIMENTAL|Delgocitinib cream 8 mg/g|Single topical occlusive administration
62739804|NCT04361136|EXPERIMENTAL|Delgocitinib cream 20 mg/g|Single topical occlusive administration
62739805|NCT04361136|PLACEBO_COMPARATOR|Delgocitinib cream vehicle|Single topical occlusive administration
62739806|NCT04697537|ACTIVE_COMPARATOR|Ultrasound guided regional anesthesia|Patient will be given a peripheral nerve block from their treating anesthesiologist before the operation (in the OR) with an conventional ultrasound guided femoral and sciatic block of each 15 ml ropivacaine 0,5% and 0,5 ml dexmedetomidine (100µg/ml).
62739807|NCT04697537|ACTIVE_COMPARATOR|Local infiltration analgesia|Patient will be given a local infiltration analgesia from their treating surgeon during the operation (in the OR) with 60 ml ropivacaine 0,5% and 1 ml dexmedetomidine (100µg/ml).
62739808|NCT05915195|ACTIVE_COMPARATOR|Routine Physical Therapy|routine physical therapy including range of motion exercises (Active assisted), stretching exercises, strengthening and positioning. Daily session was of 1 hour, 5 times weekly for 6 weeks.
62739809|NCT05915195|EXPERIMENTAL|Routine Physical Therapy and Postural and Kinesthetic Awareness|routine physical therapy and additionally postural and kinesthetic Awareness in front of mirror by emphasizing proper body positioning, movements \& balance in sitting and standing position by using interoceptive and exteroceptive reinforcement (verbal, tactile \& visual).
62739810|NCT02270528|EXPERIMENTAL|HIT1|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt, prior to the WCST, this group will perform a warm-up and the high intensity interval exercise. The second attempt, prior to the WCST, this group will perform a warm-up and 5-minute stationary period. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
62739811|NCT02270528|EXPERIMENTAL|HIT2|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt, prior to the WCST, this group will perform a warm-up and a 5-minute stationary period. The second attempt, prior to the WCST, this group will perform a warm-up and the high intensity interval exercise. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
62739812|NCT02270528|OTHER|CON|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt and second attempt, prior to the WCST, this group will participate in a 15-minute stationary period. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
62739813|NCT06352060||ICM|Patients who underwent ICM insertion
62739814|NCT06352060||Non-ICM|Patients with traditional monitoring methods
62739815|NCT00140907|PLACEBO_COMPARATOR|1|Placebo
62739816|NCT00140907|ACTIVE_COMPARATOR|2|Losartan
62739817|NCT01581021|ACTIVE_COMPARATOR|Thoracic Pedicle Screws|Group treated with pedicle screws in the thoracic spine
62739818|NCT01581021|ACTIVE_COMPARATOR|Laminar Hooks|Group treated with hooks in the thoracic spine
62739819|NCT00741897|EXPERIMENTAL|1|Fexofenadine
62739820|NCT01555034|ACTIVE_COMPARATOR|intervention plus therapy|
62739821|NCT01555034|ACTIVE_COMPARATOR|intervention no therapy|exercise and nutrition
62739822|NCT06454890|EXPERIMENTAL|Anti-Trop2 CAR-NK cell therapy group|chemotherapy followed by Trop2 CAR-NK infusion
62739823|NCT02771574|EXPERIMENTAL|Part A: Lyo avexitide 0.05 mg/kg|Participants will receive lyophilized avexitide (Lyo avexitide) twice daily for 3 days
62739824|NCT02771574|EXPERIMENTAL|Part A: Lyo avexitide 0.15 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
62739825|NCT02771574|EXPERIMENTAL|Part A: Lyo avexitide 0.35 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
62739826|NCT02771574|EXPERIMENTAL|Part A: Lyo avexitide 0.46 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
62739827|NCT02771574|EXPERIMENTAL|Part B: Liq avexitide 0.38 (±0.03) mg/kg|Participants will receive liquid avexitide (Liq avexitide) twice daily for 3 days
62739828|NCT06477393|SHAM_COMPARATOR|Control group|"The control group will receive placebo type procedures in addition to the usual medical rehabilitation procedures, i.e., heat treatments, so routine health care will not be lost. The typical procedures are assigned in accordance with the order of the Minister of Health of the Republic of Lithuania On the approval of descriptions of general and special requirements for the provision of medical rehabilitation and anti-recidivism sanatorium treatment services valid version dated 06.14.2023). In-resort sanatoriums, the mud and mineral water procedures are additionally paid services, which the sanatorium will provide free of charge for scientific development."
62739829|NCT06477393|ACTIVE_COMPARATOR|Experimental group|"Standard rehabilitation procedures will be applied (following the order of the Minister of Health of the Republic of Lithuania) supplemented by balneotherapy/peloid therapy. Rehabilitation procedures will be performed in the Lithuanian resort Birstonas sanatorium Versme. The standard rehabilitation procedures will be the same as those in the control group."
62739830|NCT03660865|EXPERIMENTAL|Light adjustable lens (LAL) and Light Delivery Device (LDD)|A pre-determined randomization scheme will be utilized to designate each of the patient's eyes as the primary eye (LAL) or the fellow eye (Control). Patient's primary eye will receive the light adjustable lens.
62739831|NCT03660865|ACTIVE_COMPARATOR|Control IOL|A pre-determined randomization scheme will be utilized to designate each of the patient's eyes as the primary eye (LAL) or the fellow eye (Control). Patient's fellow eye will receive the control IOL.
62174944|NCT05906901|EXPERIMENTAL|Suboccipital muscles inhibition|The investigator will perform a suboccipital muscles inhibition technique.
62182396|NCT01830062|EXPERIMENTAL|CACS and NIRS|All patients will undergo NIRS to at least 2 major epicardial vessels as a research related intervention. Patients will be considered to be enrolled in the trial upon completion NIRS evaluation. Patients who had a clinically indicated CT with CACS evaluation within 3 months prior to the cardiac catheterization with NIRS evaluation will not have any other research related interventions. Patients who have not had a clinically indicated CT with CACS within 3 months prior to the cardiac catheterization with NIRS evaluation will have the CACS after NIRS imaging prior to discharge from the hospital.
62182397|NCT04864717|ACTIVE_COMPARATOR|Doxycycline|Doxycycline 100mg po once daily x 6 months
62739832|NCT01835288|EXPERIMENTAL|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1-2 hours daily for up to 45 days. Patients achieving complete remission, receive arsenic trioxide IV over 1-2 hours daily 5 days a week for 4 weeks. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62739833|NCT00737217||Parkinson's disease|
62739834|NCT00737217||Normal Controls|
62739835|NCT00001244||General Population|MD referred or self-referred
62739836|NCT06637488|EXPERIMENTAL|Unilateral cleft lip repair using customized nasal conformer|
62739837|NCT06637488|ACTIVE_COMPARATOR|Unilateral cleft lip repair without using customized nasal conformer|
62567148|NCT02044302|EXPERIMENTAL|standard analgesics, bupivacaine and botulinum toxins|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 10 ml (about 2 teaspoons) of 0.5% bupivacaine and 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during the operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
62739838|NCT06614855|EXPERIMENTAL|Initial Treatment|Patients will undergo a contrasted MRI scan to determine the site for stereotactic biopsy. For dose #1, patients will be treated under monitored local anesthesia, or at the surgeon's discretion, under general anesthesia. Patients will then undergo stereotactic biopsy of their tumor. While evidence of radiation damage or necrosis may be present on the frozen section, inoculation with C134 will only proceed if viable, recurrent glioma is also present on the frozen section. The dose level of C134 will be 1 x 105 plaque forming units (pfu). Virus will be inoculated via catheters placed stereotactically in enhancing regions of tumor or immediately adjacent in non-enhancing tumor infiltrated regions at up to 5 different loci (each injection over 2 minutes). Catheters will be removed directly after administration for treatment 1.
62739839|NCT06614855|EXPERIMENTAL|2nd Treatment|"Before dose #2 administration, patients will undergo preoperative assessment of their disease status.~If they are deemed to have had a complete response (CR), no treatment will be undertaken until there is evidence of a possible recurrence. If this does not occur until after week 16, the patient's situation will be discussed with the DSMB and a decision made about possible second treatment.~If the patient has had a partial response or stable disease, and their tumor remains less than 5.5 cm in size, they wil lbe treated with stereotactic biopsy using the same technique described for dose #1~If the patient has suffered progression or peudoprogression, or if in the estimation of the surgeon it is not safe to perform inoculation alone, they will undergo craniotomy for resection of the tumor."
62174945|NCT02591914|EXPERIMENTAL|Altering regimens of Fovista™and Anti-VEGF Therapy|"All subjects will be treated with Fovista™ 1.5 mg/eye in combination with anti-VEGF therapy.~The following doses of Anti-VEGF therapy will be delivered based on the Investigator's discretion:~* Lucentis® 0.5 mg/eye~* Avastin® 1.25 mg/eye~* Eylea® 2 mg/eye~Subjects will be treated with Fovista™ and Anti-VEGF therapy every month for the first three months.~The regimen for administration of each intravitreal agent will be as follows:~Injection Day #1-Administration of Fovista™ 1.5mg/eye~Injection Day #2-Administration of Fovista™ 1.5mg/eye followed by anti-VEGF therapy after Fovista™ injection~The same regimen will be delivered monthly until the subject reaches maximum visual acuity benefit. Maximum visual acuity is defined as no increase in ETDRS visual acuity at two consecutive visits.~Subsequent re-treatment with the Anti-VEGF therapy will use a PRN (as-needed) regimen based on protocol specified retreatment criteria."
62174946|NCT04636879|EXPERIMENTAL|• Group 1. Positive expectation|"Dry needling is a very effective tool used in the treatment of nonspecific neck pain, which we hope will reduce your neck pain."
62174947|NCT04636879|ACTIVE_COMPARATOR|• Group 2. Neutral Expectation|"Dry needling is an indicated tool used in the treatment of nonspecific neck pain, but its efficacy is unknown."
62174948|NCT04636879|ACTIVE_COMPARATOR|• Group 3. Negative Expectation|"Dry needling is not a very effective treatment tool for nonspecific neck pain, so we expect your neck pain to increase a bit."
62567149|NCT00818350|EXPERIMENTAL|SUNITINIB|
62174949|NCT02178397|EXPERIMENTAL|EXPERIMENTAL ARM B|"INDUCTION chemotherapy: 4 cycles of~* pemetrexed with cisplatin or carboplatin~* or gemcitabine with cisplatin or carboplatin in combination with erlotinib~THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed in combination with erlotinib"
62174950|NCT02178397|ACTIVE_COMPARATOR|STANDARD ARM A|"INDUCTION chemotherapy: 4 cycles of~* pemetrexed with cisplatin or carboplatin~* or gemcitabine with cisplatin or carboplatin~THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed"
62174951|NCT01258296|ACTIVE_COMPARATOR|Active fentanyl patch|25 mcg/hr fentanyl patch
62174952|NCT01258296|PLACEBO_COMPARATOR|Placebo patch|Inactive patch that resembles treatment patch but contains no drug
62174953|NCT05558813|EXPERIMENTAL|DMD-CMP cohort|Minor (≥ 6 years) and major patients with genetically proven Duchenne myopathy
62174954|NCT01574014|ACTIVE_COMPARATOR|1: CBGT & Hydrocortisone|
62174955|NCT01574014|PLACEBO_COMPARATOR|2: CBGT & Placebo|
62174956|NCT00875615|EXPERIMENTAL|Cisplatin or Carboplatin + Sorafenib|
62174957|NCT05992662|EXPERIMENTAL|Intervention Group|"In this research, the training program was designed as an intervention.~Summary of the research's implementation plan:~Preparation of Mindfulness-based training program in bariatric surgery Inviting adult individuals to participate in the research before bariatric surgery and reaching the targeted number of participants Participants who agreed to participate in the study fill out the individual introduction form, complete the short story, and administer the Mindful Eating Questionnaire to the participants Conducting mindfulness-based 4-session training program Focus group discussion after the training Reminder of weekly practices Recording changes in mindful eating in participant experience diaries during the follow-up At the end of the monitoring phase (3rd-6th months), individual in-depth interviews and Mindful Eating Questionnaires are conducted with each participant in the action group"
62174958|NCT05992662|NO_INTERVENTION|Control Group|Mindful Eating Questionnaire will be applied before the surgery, at the 3rd and 6th months after the surgery. No intervention will be applied to the control group.
62174959|NCT05425173|ACTIVE_COMPARATOR|Conventional treatment|Chest Physical Therapy
62174960|NCT05425173|EXPERIMENTAL|Limb Range of Motion Exercises + Chest Physical Therapy|Limb Range of Motion Exercises + Chest Physical Therapy
62174961|NCT00985634|EXPERIMENTAL|LeGoo|Subjects in this arm, which is assigned at random, will receive the study device.
62174962|NCT00985634|ACTIVE_COMPARATOR|Control|Subjects in this arm will not receive the study device, but receive the standard of care for vessel occlusion (vessel loops.)
62174963|NCT04007146|EXPERIMENTAL|Cardiac Output Measurement|Subject will have a usual cardiac output
62174964|NCT05869383|PLACEBO_COMPARATOR|Placebo|Control group get placebo 2x5 grams a day for 14 days
62174965|NCT05869383|EXPERIMENTAL|Ophiochepalus striatus extract|Intervention group get Ophiochepalus striatus extract 2x5 grams a day for 14 days
62739840|NCT04742803|OTHER|Straberi Epistamp Needling Treatment|Non-Randomized treatment for patients who seek improvement for elastin, fine lines, deep wrinkles, and collagen production using Straberi Epistamp needling treatment
62739841|NCT04742803|OTHER|No Treatment|Non-Randomized patients who seek improvement for elastin, fine lines, deep wrinkles, and collagen production.
62739842|NCT02063867|NO_INTERVENTION|Arm 1: Usual Care|Routine policy for showering or bathing non-critical care patients
62739843|NCT02063867|ACTIVE_COMPARATOR|Arm 2: Decolonization|"Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen."
62739844|NCT04401800|EXPERIMENTAL|Part 1: Safety Run-in|Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
62739845|NCT04401800|EXPERIMENTAL|Part 2: Lenvatinib|Lenvatinib at the recommended phase 2 dose (RP2D) determined from Part 1 + tislelizumab in 21-day cycles for up to 12 months
62739846|NCT02557451|EXPERIMENTAL|surgery + antiangiogenic|surgery (vitrectomy - air - TPA) with injections of an antiangiogenic
62739847|NCT02557451|EXPERIMENTAL|intravitreal injection of gas/TPA + antiangiogenic|intravitreal injection of gas - TPA with injections of an antiangiogenic
62739848|NCT01925040|EXPERIMENTAL|Venus Pearl|Placement of restoration using Venus Pearl in carious teeth or as a replacement of a defective previous restoration.
62739849|NCT01925040|ACTIVE_COMPARATOR|control resin-based filling material|Placement of restoration using a control resin-based filling material in carious teeth or as a replacement of a defective previous restoration.
62739850|NCT05327660|ACTIVE_COMPARATOR|Quitline treatment as usual (TAU)|Quitline services provided by participating state quitlines
62739851|NCT05327660|EXPERIMENTAL|Quitline TAU plus remote CO monitoring|Quitline service plus daily CO monitoring via a smartphone app
62739852|NCT05327660|EXPERIMENTAL|Quitline TAU plus incentivized remote CO monitoring|Quitline TAU plus remote CO monitoring with small monetary incentives
62739853|NCT03730233|ACTIVE_COMPARATOR|Tension-free|Hiatal hernia repair by tension-free mesh closure
62739854|NCT03730233|ACTIVE_COMPARATOR|Suturing|Hiatal hernia repair by simple suturing of the diaphragmatic
62567150|NCT01182012|EXPERIMENTAL|Lifestyle counseling|Adjust drug treatment to control cardiovascular factor risks. A nurse will implement a lifestyle counseling in order to improve compliance of treatment and a healthy lifestyle.
62739855|NCT04964505|EXPERIMENTAL|Treatment (uproleselan, azacitidine, venetoclax)|Patients receive uproleselan IV over 1 hour Q12H on days 1-7, azacitidine IV or SC QD on days 1-7, and venetoclax PO QD on days 1-28. Beginning cycle 5, patients achieving MLFS or better response, may receive azacitidine IV or SC QD and uproleselan IV over 1 hour QD on days 1-6 and 8 or days 1-5 and 8-9 or days 1-5. Treatment with uproleselan repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Cycles with azacitidine and venetoclax repeat every 28 days in the absence of disease progression and unacceptable toxicity.
62739856|NCT02985918|EXPERIMENTAL|High-intensity NPPV|Patients will receive high-intensity NPPV.
62739857|NCT02985918|ACTIVE_COMPARATOR|Low-intensity NPPV|Patients will receive low-intensity NPPV.
62739858|NCT01400061||normal|body mass index: 19-24
62739859|NCT01400061||overweight|body mass index: 25-29
62739860|NCT01400061||obesity|body mass index: 30-40
62739861|NCT01400061||modbid obes|body mass index: over 40
62739862|NCT04861818|EXPERIMENTAL|Morning group|Participant are assigned to the morning group (7-9am) for 30-min exercise/rest interventions.
62739863|NCT04861818|EXPERIMENTAL|Afternoon group|Participant are assigned to the afternoon group (3-5pm) for 30-min exercise/rest interventions.
62739864|NCT02603237|OTHER|Glucose tolerance test|All participants will receive an oral standardized glucose tolerance test
62739865|NCT02603237|OTHER|Fat tolerance test|The same participants will receive an oral standardized fat load test
62174966|NCT01362283||Hypertension|Subject who meet eligible criteria
62174967|NCT06308731|EXPERIMENTAL|Caffeine-Based Energy Drink|12 oz Caffeine-based energy drink providing 200 mg caffeine
62567151|NCT05925647|EXPERIMENTAL|Messenchymal stem cell secretome|The hypoxic mesenchymal stem cell secretome has been developed up to chapter 7, stored at -196 C to -135 C in cryopreservation, and has passed quality tests.
62739866|NCT06542978|EXPERIMENTAL|40Hz stimulation group|After admission to AICU, the experimental group was stimulated at 40Hz for 6h;
62174968|NCT06308731|PLACEBO_COMPARATOR|Placebo|12 oz placebo void of all active ingredients
62174969|NCT01750177|EXPERIMENTAL|Television Viewing|Television viewing before mealtime
62174970|NCT01750177|EXPERIMENTAL|Video Game Playing|Video Game Playing before mealtime
62174971|NCT01750177|EXPERIMENTAL|Computer Use|Computer Use before mealtime
62174972|NCT01750177|EXPERIMENTAL|Sitting Quietly|Sitting Quietly before mealtime
62174973|NCT02108418|EXPERIMENTAL|TG-2349 as the original formulation|400 mg, 2 syringes
62567152|NCT05925647|PLACEBO_COMPARATOR|Placebo|Nacl 0,9% infusion
62567153|NCT01021462|EXPERIMENTAL|Period 1 + Period 2|graded infusion of intravenous glucose
62739867|NCT06542978|NO_INTERVENTION|Control group|After admission to AICU, the control group was not stimulated at 40Hz ;
62739868|NCT01429597||Observation|All Patients with a diagnosis of Fabry disease with N215S
62739869|NCT03799055||easy intubation|Cormack _Lehane : 1\&2
62739870|NCT03799055||difficult intubation|Cormack _Lehane : 3\&4
62739871|NCT03292549||Patients|Robotic partial surgery
62739872|NCT05219149||Patients with CNS Tumors|feasibility study of family interviews of those who are making decisions about treatment for newly diagnosed or relapsed CNS tumors. For patients 12 years of age and younger, caregivers only will be included in the interviews. For patients 13-17 years of age, caregivers will have the option to include the patient in the interviews. For patients 18 years of age and older, patients will have the option to include their caregivers in the interviews.
62739873|NCT04609592|EXPERIMENTAL|Lutathera|2 cycles of 177Lu Dotatate, followed by cytoreductive surgery, followed by additional 177Lu Dotatate (up to 2 cycles) for residual disease as determined by 68Ga DOTA TATE PET/CT
62739874|NCT01326884|OTHER|1|Endovascular Repair
62739875|NCT06306911|EXPERIMENTAL|Aronia Melanocarpa extract|a drink consisting of AME (Aronia Melanocarpa extract) and water.
62174974|NCT02108418|EXPERIMENTAL|TG-2349 as a new capsule formulation|400 mg, 4 capsules
62174975|NCT01772147|EXPERIMENTAL|Umeclidinium bromide|Long-acting muscarinic antagonist (LAMA)
62739876|NCT06152042|EXPERIMENTAL|Part 1|"Part 1 uses a randomized, open-label design with parallel assignment between 2 treatment arms in each cohort. The Part 1 Eligible participants will be randomly assigned by cohort to 1 of 2 treatment arms:~* Cohort 1: Participants with T1D diagnosed within 3 years with C-peptide concentration ≥0.2 nmol/L~* Arm A: BMF-219 100 mg QD for 12 weeks~* Arm B: BMF-219 200 mg QD for 12 weeks~* Cohort 2: Participants with T1D diagnosed between 3 to 15 years with C-peptide concentration ≥0.08 nmol/L.~* Arm A: BMF-219 100 mg QD for 12 weeks~* Arm B: BMF-219 200 mg QD for 12 weeks"
62739877|NCT06152042|EXPERIMENTAL|Part 2|"Part 2~Part 2 uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. Eligible participants will be randomly assigned to 1 of 3 arms using a 1:1:1 ratio:~* Arm A: BMF-219 100 mg QD for 12 weeks~* Arm B: BMF-219 200 mg QD for 12 weeks"
62739878|NCT06152042|PLACEBO_COMPARATOR|Placebo Comparator|Part 2 Study Double Blind Arm C matching placebo for 12 weeks.
62739879|NCT06125184|PLACEBO_COMPARATOR|Placebo group|Mean arterial pressure (MAP) will be increased from 65 mmHg to 85 mmHg with a blind drug (Placebo). If MAP does not increase norepinephrine will be titrated to reach the MAP target (85 mmHg).
62739880|NCT06125184|ACTIVE_COMPARATOR|Vasopressin group|Mean arterial pressure (MAP) will be increased from 65 mmHg to 85 mmHg with a blind drug (Vasopressin at 0.03 IU/min). If MAP does not increase norepinephrine will be titrated to reach the MAP target (85 mmHg).
62174976|NCT01772147|ACTIVE_COMPARATOR|Fluticasone propionate/Salmeterol|Inhaled corticosteroid (ICS)/Long-acting beta agonist (LABA)
62174977|NCT02716753|EXPERIMENTAL|Seminal plasma|Half of the amount of seminal plasma received after preparation of the spermatozoa used for IVF will be deposited around the external cervical opening
62174978|NCT02716753|PLACEBO_COMPARATOR|Physiological NaCL solution|An amount of physiological NaCL solution equal to half of the amount of seminal plasma received after preparation of the spermatozoa used for IVF will be deposited around the external cervical opening
62174979|NCT06190184|PLACEBO_COMPARATOR|Placebo|Participants who have mental health issues are randomized into this study arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
62174980|NCT06190184|EXPERIMENTAL|Viome's Precision Nutrition Program (VPNP)|Participants who have mental health issues are randomized into this study arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
62174981|NCT01993576|EXPERIMENTAL|indocyanine green|Indocyanine green is injected intravenously.
62174982|NCT00515697|EXPERIMENTAL|Ramucirumab|Intravenous infusion at 8 milligrams per kilogram (mg/kg) on day 1 of every 14-day cycle.
62174983|NCT02134847|EXPERIMENTAL|Intervention cohort|This cohort will work on the SCS intervention schedule
62174984|NCT02134847|NO_INTERVENTION|Control cohort|This group will work on a traditional schedule
62174985|NCT06048939|EXPERIMENTAL|aerobic and resistance training|moderate intensity aerobic and body weight resistance training on female adolescents.
62174986|NCT06048939|ACTIVE_COMPARATOR|aerobic training|moderate intensity aerobic and body weight resistance training on female adolescents.
62174987|NCT06006897||Post-COVID-19 group|This group will consist of individuals with idiopathic scoliosis who have had COVID-19.
62174988|NCT06006897||Control group|The control group will consist of individuals with idiopathic scoliosis without post-COVID-19.
62174989|NCT02534753|EXPERIMENTAL|Single Group|
62174990|NCT02679547||Appendicitis|The patients with appendicitis
62174991|NCT02679547||Control|The participants without appendicitis
62174992|NCT02301364|EXPERIMENTAL|Buparlisib (BKM120)|This is an open-label, phase II trial of the pan-PI3K inhibitor buparlisib (BKM120) for patients with recurrent or refractory primary central nervous lymphoma (PCNSL) and recurrent or refractory secondary central nervous lymphoma (SCNSL).
62174993|NCT06354192||Precision Nudging for Hypertension Management|All participants in this study will receive the digital health intervention.
62174994|NCT02508779|EXPERIMENTAL|Bump2Be|Blood Glucose Awareness Training for pregnancy or preconception
62174995|NCT02508779|ACTIVE_COMPARATOR|Routine Care|Routine care provided by subject's medical team
62174996|NCT04164498|EXPERIMENTAL|Music exposure|will be exposed to music to investigate effects on preventing noise Adverse effects
62174997|NCT04164498|NO_INTERVENTION|Control|no exposure to music
62174998|NCT04091464|EXPERIMENTAL|TRAIN-BW|1x/week for 8 weeks + home exercise program
62174999|NCT04091464|ACTIVE_COMPARATOR|TRAIN-FW|1x/week for 8 weeks + home exercise program
62175000|NCT02622464|EXPERIMENTAL|micro injection of SVF in vocal cords|micro injection of Stromal Vascular Fraction extracted from autologous adipose tissue in vocal cords
62175001|NCT04838964|EXPERIMENTAL|MRG003|MRG003 will be administrated via IV infusion at 2.0 mg/kg on Day 1 of every 3 weeks (21-day cycle).
62175002|NCT01723514|EXPERIMENTAL|Erenumab|Healthy participants and participants with migraine received subcutaneous doses of erenumab on days 1, 29 and 57.
62175003|NCT01723514|PLACEBO_COMPARATOR|Placebo|Healthy participants and participants with migraine received subcutaneous doses of placebo on days 1, 29 and 57.
62175004|NCT01456533||hospitalized patients|hospitalized patients with hyponatremia
62175005|NCT04863638|EXPERIMENTAL|A1 aged ≥ 71|300 subjects age ≥ 71 （A1）receive 3 doses of vaccine
62175006|NCT04863638|EXPERIMENTAL|A2 aged ≥ 71|200 subjects age ≥ 71 （A2）receive 3 doses of vaccine
62175007|NCT04863638|EXPERIMENTAL|A3 aged ≥ 71|200 subjects age ≥ 71 (A3) receive 3 doses of vaccine
62175008|NCT04863638|EXPERIMENTAL|B1 aged 60-70|300 subjects age 60-70 (B1) receive 3 doses of vaccine
62175009|NCT04863638|EXPERIMENTAL|B2 aged 60-70|200 subjects age 60-70 (B2) receive 3 doses of vaccine
62175010|NCT04863638|EXPERIMENTAL|B3 aged 60-70|200 subjects age 60-70 (B3) receive 3 doses of vaccine
62175011|NCT04863638|EXPERIMENTAL|C1 aged 18-59|300 subjects age 18-59 (C1) receive 3 doses of vaccine
62175012|NCT04863638|EXPERIMENTAL|C2 aged 18-59|200 subjects age 18-59 (C2) receive 3 doses of vaccine
62175013|NCT04863638|EXPERIMENTAL|C3 aged 18-59|200 subjects age 18-59 (C3) receive 3 doses of vaccine
62175014|NCT04863638|EXPERIMENTAL|C4 aged 18-59|300 subjects age 18-59 (C4) receive 2 doses of vaccine
62175015|NCT04863638|EXPERIMENTAL|D1 aged 9-17|300 subjects age 9-17 (D1) receive 3 doses of vaccine
62175016|NCT04863638|EXPERIMENTAL|D2 aged 9-17|200 subjects age 9-17 (D2) receive 3 doses of vaccine
62175017|NCT04863638|EXPERIMENTAL|D3 aged 9-17|200 subjects age 9-17 （D3）receive 3 doses of vaccine
62550621|NCT04957238|NO_INTERVENTION|Subjective physical restraints use|After study presentation and required data collection description, nurses will complete elements related to ARBORea's tool variables, and inform their actual practices of physical restraints use, at least every 8 hours. ARBORea data concern patient's neurological state (RASS and CAM-ICU scores) and changes in sedation doses. The conditioning will then be filled in to stratify the risk incurred. Pain management will be notified. Finally, the presence and involvement of the families will be collected. Other data, relating to working conditions of the nurses will be collected: nurse to patient ratio, special and time consuming events (new patient admission, in ICU emergencies, need to conduct a patient to CT-scan facility or operative room, change of patient's equipment). Nurse seniority in ICU will be specified. Incidents that have occurred (fall, self-injury, removal of a level C2 equipment). The random duration of this control period will be determined by stepped wedge sequencing.
62550622|NCT00347386|EXPERIMENTAL|Zinc|Administration of zinc sulphate every day during illness
62550623|NCT00347386|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62550624|NCT01407237||HIV-infected Individuals|
62550625|NCT01407237||non-HIV-infected Individuals|
62550626|NCT04725851|EXPERIMENTAL|High concentration Oxygen Therapy|12-15 Litre/min O2 delivery via Non-Rebreather Mask (NRM) consecutively for 24 hours.
62550627|NCT04725851|PLACEBO_COMPARATOR|Room air or low concentration oxygen|Room air or low concentration oxygen (0-2 Litre/min O2 ) consecutively for 24 hours.
62175018|NCT04863638|EXPERIMENTAL|D4 aged 9-17|300 subjects age 9-17 （D4）receive 2 doses of vaccine
62175019|NCT04863638|EXPERIMENTAL|E1 aged 3-8|300 subjects age 3-8 （E1） receive 3 doses of vaccine
62175020|NCT04863638|EXPERIMENTAL|E2 aged 3-8|200 subjects age 3-8 （E2）receive 3 doses of vaccine
62175021|NCT04863638|EXPERIMENTAL|E3 aged 3-8|200 subjects age 3-8 （E3）receive 3 doses of vaccine
62175022|NCT04863638|EXPERIMENTAL|E4 aged 3-8|300 subjects age 3-8 （E4）receive 2 doses of vaccine
62175023|NCT01823640|EXPERIMENTAL|Placebo-HRV|inoculation with placebo followed by inoculation with HRV
62175024|NCT01823640|EXPERIMENTAL|HRV-HRV|inoculation with HRV followed by a second inoculation with HRV
62175025|NCT02394925|EXPERIMENTAL|Multifocal Test Contact Lens|Subjects will wear the test lenses at least six hours per day, at least five days per week
62175026|NCT01201915|EXPERIMENTAL|Cohort 1: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 12 weeks.
62175027|NCT01201915|EXPERIMENTAL|Cohort 2: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 12 weeks.
62175028|NCT01201915|EXPERIMENTAL|Cohort 3: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 8 weeks, followed by 4 weeks with no treatment, followed by a second 8-week vismodegib treatment period.
62175029|NCT00978497|PLACEBO_COMPARATOR|1|Peginterferon and ribavirin + placebo BID for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
62175030|NCT00978497|EXPERIMENTAL|2|ANA598 200 mg BID + Peginterferon and ribavirin for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
62182398|NCT04864717|ACTIVE_COMPARATOR|Isotretinoin|Isotretinoin 40mg po once daily x 6 months
62550628|NCT04766645||Covid patients|Inpatients and outpatients admitted to the investigators' rehabilitation facility with covid symptoms
62550629|NCT05645549|EXPERIMENTAL|Centering Pregnancy with Care Navigation for pregnant Marshallese women|Forty pregnant Marshallese women will be enrolled in the group prenatal intervention, Centering Pregnancy, with care navigation to determine the feasibility of the intervention and the preliminary effectiveness to improve maternal and infant health care outcomes.
62550630|NCT05645549|NO_INTERVENTION|Pregnant Marshallese women enrolled in standard prenatal care|We will use a 1:1 propensity score matching with pregnant Marshallese women who completed standard prenatal care to compare their maternal and infant health care outcomes with those participants enrolled in the intervention.
62550631|NCT06360185||Asthmatics presenting to the emergency department in NNUH over 5 years|
62550632|NCT05845983|PLACEBO_COMPARATOR|Control group|The patient received conventional treatment and Maltodextrin treatment (placebo) for three months after surgery.
62550633|NCT05845983|EXPERIMENTAL|LA treatment group|The patient received conventional treatment and Lactobacillus acidophilus treatment for three months after surgery.
62550634|NCT01946932|ACTIVE_COMPARATOR|Cardiac Arrest 33°|survivors with temperature treatment 33°
62550635|NCT01946932|ACTIVE_COMPARATOR|Cardiac Arrest survivors 36°|survivors with temperature treatment 36°
62550636|NCT05975528|EXPERIMENTAL|SGLT2 inhibitor user|
62550637|NCT05975528|ACTIVE_COMPARATOR|Glimepiride user|
62550638|NCT03855267|PLACEBO_COMPARATOR|Group A|Propofol 20 mg/ml, recommended anesthesia induction dose of 0.1\~0.125 ml/kg, anesthesia maintenance pump speed of 0.2\~0.5ml/kg/h. keep bispectral index within 40 # 60
62550639|NCT03855267|ACTIVE_COMPARATOR|GroupB|EP1:3, that is, 10ml etomidate was mixed with 30ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
62550640|NCT03855267|ACTIVE_COMPARATOR|Group C|EP1:1, that is, 20ml etomidate was mixed with 20ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
62175031|NCT00978497|EXPERIMENTAL|3|ANA598 400mg BID + Peginterferon and ribavirin for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
62364805|NCT01042054|ACTIVE_COMPARATOR|Epidural|Patients will follow a standard optimised recovery protocol, including epidural analgesia for the first 48 hours postoperatively.
62364806|NCT01042054|EXPERIMENTAL|Wound catheter|Patients will follow a standard optimised recovery protocol, but analgesia in the first 48 hours will be delivered through local anaesthetic wound catheters and additional patient-controlled analgesia, instead of epidural analgesia.
62550641|NCT03855267|ACTIVE_COMPARATOR|Group D|EP3:1, that is, 30ml etomidate was mixed with 10ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
62550642|NCT03105518|EXPERIMENTAL|Analgesia options|Protocolized analgesia based on VAS degree of discomfort and time. Analgesic options include heating pad, acetaminophen, percocet (oxycodone), fentanyl 0.5-1 mcg/kg.
62550643|NCT05107648|EXPERIMENTAL|Gardner GOALS|Healthy lifestyle intervention by telehealth plus regular clinic visits
62175032|NCT02856841||optimum cytoreduction|without any gross tumor residue after surgery
62550644|NCT05107648|NO_INTERVENTION|Control|Regular clinic visits
62550645|NCT02301195|EXPERIMENTAL|Therapeutic Horseback Riding|Ten-weekly one-hour manualized small group Therapeutic Horseback Riding intervention led by certified THR instructor.THR intervention taught riding and horsemanship skills.
62364807|NCT01105936|EXPERIMENTAL|Paracetamol caplets|Two 665 mg sustained release paracetamol caplets administered orally with water.
62364808|NCT01105936|PLACEBO_COMPARATOR|Placebo caplets|Two placebo caplets administered orally with water.
62364809|NCT03997760|EXPERIMENTAL|TAK-755|Participants with SCD at their baseline health will receive a single intravenous (IV) infusion at one of the 3 dose levels of 40, 80 and 160 International units per kilogram (IU/kg) in a dose escalation manner.
62364810|NCT03997760|PLACEBO_COMPARATOR|Placebo|Participants with SCD at their baseline health will receive placebo matched to TAK-755 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.
62550646|NCT02301195|ACTIVE_COMPARATOR|Barn Activity Intervention|Ten-weekly one-hour manualized small group Barn Activity Intervention led by THR instructor, teaching horsemanship skills without horses present.
62550647|NCT02176954|EXPERIMENTAL|Test A, Test B, Comparator|The subjects first test Coloplast Test A followed by Coloplast Test B and finally Comparator.
62550648|NCT02176954|EXPERIMENTAL|Test A, Comparator, Test B|The subjects first test Coloplast Test A followed by Comparator and finally Coloplast Test B.
62550649|NCT02176954|EXPERIMENTAL|Test B, Test A, Comparator|The subjects first test Coloplast Test B followed by Coloplast Test A and finally Comparator.
62175033|NCT02856841||Suboptimum cytoreduction|with any gross tumor residue after surgery
62175034|NCT02723305||Testosterone Naive|Boys with Klinefelter syndrome age 12-17 who are Tanner 3, 4, or 5. No exogenous testosterone exposure in the past 5 years
62550650|NCT02176954|EXPERIMENTAL|Test B, Comparator, Test A|The subjects first test Coloplast Test B followed by Comparator and finally Coloplast Test B.
62550651|NCT02176954|EXPERIMENTAL|Comparator, Test A, Test B|The subjects first test Comparator followed by Coloplast Test A and then Coloplast Test B
62550652|NCT02176954|EXPERIMENTAL|Comparator, Test B, Test A|The subjects first test Comparator followed by Coloplast Test B and then Coloplast Test A.
62175035|NCT02723305||Testosterone exposed|"Boys with Klinefelter syndrome age 12-17 who are Tanner 3, 4, or 5.~+topical testosterone treatment for \>1 year"
62175036|NCT04097691||on subcutaneous glucose|this group was on subcutaneous glucose 0.5 ml per site around subcutaneous nerves in the foot region both on palm and sole.which is repeated every 2 weeks for 2 months.
62175037|NCT04097691||control(not receiving treatment)|the second group is considered as control.received no treatment.
62550653|NCT04639284||Combinational therapy|Participants who receive systemic treatment with an anti-angiogenic agent, including sorafenib, lenvatinib, apatinib, and bevacizumab, in combination with an anti-PD-1/PD-L1 antibody, including pembrolizumab, nivolumab, sintilimab, toripalimab, camrelizumab, tislelizumab, and atezolizumab.
62175038|NCT01828593|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62550654|NCT03400592|EXPERIMENTAL|irinotecan and nimotuzumab|Administration of irinotecan 180 mg/m2 IV once every 2 weeks and nimotuzumab 400 mg IV once weekly
62175039|NCT01828593|ACTIVE_COMPARATOR|SBI 2.5 g|Serum-derived bovine immunoglobulin protein isolate (SBI) 2.5 g
62175040|NCT01828593|ACTIVE_COMPARATOR|SBI 5.0g|Serum-derived bovine immunoglobulin protein isolate (SBI)5.0g
62175041|NCT06245161|EXPERIMENTAL|• Group IA|15 maxillary quadrants each have at least one primary molar indicated for restorative treatment or vital pulp therapy, allocated to Intra-osseous Anesthesia by QuickSleeper5.
62175042|NCT06245161|ACTIVE_COMPARATOR|• Group IB|15 maxillary quadrants each have at least one primary molar indicated for restorative treatment or vital pulp therapy, allocated to infiltration anesthesia
62175043|NCT06245161|EXPERIMENTAL|• Group IC|15 Mandibular quadrants each have at least one primary molar indicated for restorative treatment or vital pulp therapy, allocated to Intra-osseous Anesthesia by QuickSleeper5.
62550655|NCT06035835||Probiotic 1|Administration Lacticaseibacillus rhamnosus (L. Rhamnosus) ATCC 53103 (109 UFC/day) in very low birth weight since start at the first enteral feed until 35 week Postmenstrual age
62550656|NCT06035835||Probiotic 2|Administration Lactobacillus acidophilus (L. acidophilus) ATCC 4356 (109 UFC/12 h)+Bifidobacterium bifidum (B. bifidum) ATCC 15696 (109 UFC/12 h) in very low birth weight since start at the first enteral feed until 35 week Postmenstrual age
62550657|NCT06035835||No probiotic|No suplementation diet with probiotic
62550658|NCT00999817|OTHER|A|Single 30 mg dose of dextromethorphan
62550659|NCT00999817|EXPERIMENTAL|B|Single 45 mg dose of PF-00299804 plus a single 30 mg oral dose of dextromethorphan
62739881|NCT06112288|EXPERIMENTAL|Compressive myofascial release (cmr)|Participants in the CMR group were instructed to lie prone on the treatment table with their feet off the end of the table. The clinician began the treatment by bending the knee to 90° and shaking the muscle belly of the triceps surae group for 30 seconds. Next, the knee was fully extended, and CMR was performed on the medial and lateral sides of the Achilles tendon for 1 minute, followed by the musculotendinous junction for 2 minutes. Treatment consisted of broad strokes applied with the clinician's knuckles to release superficial restrictions, followed by more specific strokes applied with the clinician's thumb to any located restrictions. Strokes were applied at a contact point of 45° to the tissue, with pressure directed from distal to proximal. At the end of the intervention, the clinician shook the belly of the triceps surae complex for 30 seconds. The same examiner (T.S.) applied all CMR treatments.
62739882|NCT06112288|EXPERIMENTAL|ankle mobilization|The joint mobilization group received two sets of ankle joint mobilizations. Each set consisted of two-minutes of Grade III anterior-to-posterior talocrural joint mobilizations with a one-minute rest between sets with the patient in a long-sitting position. This mobilization was operationally defined as large-amplitude, one-second rhythmic oscillations from the mid- to end ROM with translation taken to tissue resistance
62739883|NCT06654856||Dong-A Opalmon® Tab|
62175044|NCT06245161|ACTIVE_COMPARATOR|• Group ID|15 mandibular quadrants each have at least one primary molar indicated for restorative treatment or vital pulp therapy, allocated to inferior alveolar nerve block (IANB) anesthesia
62550660|NCT03252743|EXPERIMENTAL|Internet-delivered CBT|Exposure-based internet-delivered CBT with ten weekly modules distributed over the internet during ten weeks, and weekly therapist support over the internet.
62550661|NCT00182325|EXPERIMENTAL|personalized web prenatal information|Personalized health information for pregnancy through personal health record
62175045|NCT06245161|EXPERIMENTAL|• Group IIA|15 maxillary primary molars indicated for extraction allocated to Intra-osseous Anesthesia by QuickSleeper5
62175046|NCT06245161|ACTIVE_COMPARATOR|• Group IIB|15 maxillary primary molars indicated for extraction allocated to Infiltration anesthesia
62739884|NCT04571424|EXPERIMENTAL|Cohort 1: BIIB133 Dose 1|Participants will receive single IV infusion of BIIB133 Dose 1.
62739885|NCT04571424|EXPERIMENTAL|Cohort 2: BIIB133 Dose 2|Participants will receive single IV infusion of BIIB133 Dose 2.
62175047|NCT06245161|EXPERIMENTAL|• Group IIC|15 Mandibular primary molars indicated for extraction, allocated to Intra-osseous Anesthesia by QuickSleeper5
62175048|NCT06245161|ACTIVE_COMPARATOR|• Group IID|15 Mandibular primary molars indicated for extraction, allocated to inferior alveolar nerve block (IANB) anesthesia.
62175049|NCT06176183|OTHER|Cohort I of patients|Individuals who undergo the conventional arthroscopic meniscus repair procedure
62175050|NCT06176183|OTHER|Cohort II of patients|Patients who receive the supplementary fibrin clot augmentation during the arthroscopic meniscus repair operation.
62175051|NCT02607345|ACTIVE_COMPARATOR|Glucomedics®|25gr Glucomedics®
62175052|NCT02607345|EXPERIMENTAL|Zusto®|25gr Zusto®
62175053|NCT00053768|ACTIVE_COMPARATOR|CHOEP-21|"CHOEP-21-Schema:~Cyclophosphamid (750 mg/m2 i.v. d1), Doxorubicin (50 mg/m2 i.v. d1), Vincristin (2 mg i.v. d1), Etoposid (100 mg/m² i.v. d1-3), Prednison (100 mg p.o. d1-5)"
62175054|NCT00053768|EXPERIMENTAL|high CHOEP-21|"High-CHOEP-21-Schema:~Cyclophosphamid (1400 mg/m2 i.v. d1), Doxorubicin (32,5 mg/m2 i.v. d1+2), Vincristin (2 mg i.v. d1), Etoposid (175 mg/m² i.v. d1-3), Prednison (100 mg p.o. d1-5)"
62175055|NCT06008106|EXPERIMENTAL|tunlametinib|Drug tunlametinib will be administered as 12mg BID
62175056|NCT06008106|ACTIVE_COMPARATOR|Assigned Interventions|combination chemotherapy
62175057|NCT02312362|EXPERIMENTAL|Combined sclerotomy ab interno and phaco|Combined sclerotomy ab interno and phacoemulsification with IOL implantation
62175058|NCT02312362|ACTIVE_COMPARATOR|Phacoemulsification with IOL implantation|Phacoemulsification with IOL implantation
62175059|NCT01364441|PLACEBO_COMPARATOR|P|
62175060|NCT01364441|EXPERIMENTAL|E|
62175061|NCT04939883|EXPERIMENTAL|Intervention Group|Patients allocated to the intervention group will receive carvedilol 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily according to the patients' tolerance; The dosis increments will occur every 5 days. If after the increment the patient develops bradycardia or hypotension, the dose will be reduced to the maximum tolerated dose. Carvedilol will ideally be maintained for up to 30 days after the end of chemotherapy.
62175062|NCT04939883|PLACEBO_COMPARATOR|Control Group|Patients allocated to this group will receive placebo in a presumably staggered and progressive manner similar to the group intervention. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.
62175063|NCT05739799|ACTIVE_COMPARATOR|Group A Intense pulse light laser|IPL laser Patients in Group A received intense pulse light (IPL) frequency of 690. A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by patients' were recorded
62175064|NCT05739799|ACTIVE_COMPARATOR|Group B Diode laser|Diode laser patients in Group B received diode laser treatment system. Diode laser was employed using triple wavelength (1064, 810 and 755 mm). A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by the patients were recorded.
62175065|NCT04024514|EXPERIMENTAL|Low dose|Low CT contrast media dose
62550662|NCT00182325|ACTIVE_COMPARATOR|general web prenatal information|General pregnancy health related websites
62550663|NCT03008759|PLACEBO_COMPARATOR|Placebo|Dentifrice without fluoride
62550664|NCT03008759|ACTIVE_COMPARATOR|Dentifrice standard|Dentifrice 1100 ppm sodium fluoride (NaF). Positive control
62550665|NCT03008759|EXPERIMENTAL|Dentifrice 50% Nano-F|Dentifrice experimental with Fluoride being half of fluoride Nanoencapsulated and other half freeform of NaF
62550666|NCT03008759|EXPERIMENTAL|Dentifrice 100% Nano-F|Dentifrice experimental with fluoride 100% Nanoencapsulated
62175066|NCT04024514|ACTIVE_COMPARATOR|Standard dose|Standard CT contrast media dose
62175067|NCT01842542|EXPERIMENTAL|Transcranial Magnetic Stimulation (TMS)|"Patients will receive NeuroStar Transcranial Magnetic Stimulation (TMS) therapy treatments 5 times a week for up to 8 weeks during the acute phase, 3 times during the first week, 2 times during the second week and 1 time during the third week of the taper phase.~Efficacy Assessments will be conducted throughout the acute and taper phase at protocol specific timepoints."
62739886|NCT04571424|PLACEBO_COMPARATOR|Cohort 1-2: Placebo|Participants will receive single IV infusion of matching placebo to BIIB133.
62739887|NCT03239951|EXPERIMENTAL|Device|Temporary implant (iTind)
62175068|NCT03285633|OTHER|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
62175069|NCT00702273||150 µg Corifollitropin Alfa|Participants from the base study P05787 (NCT00696800), received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa (Org 36286) on menstrual cycle Day 2/3 (Day 1); 7 daily SC injections from Days 1 to 7 with placebo-recombinant Follicle Stimulating Hormone (recFSH); followed by daily SC injections with 200 IU recFSH up to the day of human chorionogonadotropin (hCG). Daily SC injections of Ganirelix were given from Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles \>= 17 mm. On the day of oocyte pick up (OPU) daily doses of progesterone were started, for up to 6 weeks or menses. Eligible participants from the base study were enrolled in follow up study P05716, where no study treatments were given, and embryos obtained in the base study underwent FTET cycles.
62739888|NCT06084182|OTHER|Patient group|Patients with a definite diagnosis of MS according to McDonald diagnostic criteria
62739889|NCT06084182|NO_INTERVENTION|Control Group|Healthy individuals
62175070|NCT00702273||200 IU RecFSH|Participants from the base study P05787 (NCT00696800), received a single SC injection of placebo Corifollitropin Alfa on menstrual cycle day 2/3 (Day 1); 7 daily SC injections with 200 IU recFSH from Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Multiple daily SC injections of Ganirelix were given from Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles \>= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the base study were enrolled in follow up study P05716, where no study treatments were given, and embryos obtained in the base study underwent FTET cycles.
62175071|NCT03194854|EXPERIMENTAL|Fun For Wellness (FFW)|Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being.
62175072|NCT03194854|NO_INTERVENTION|Usual Care (UC)|The Usual Care (UC) group will conduct their lives as usual during the 30 day intervention period.
62739890|NCT02047773|PLACEBO_COMPARATOR|14 days Duration|14 days of antibiotics regardless of bacterial load.
62739891|NCT02047773|ACTIVE_COMPARATOR|Bacterial load guided duration|Antibiotics stopped early on day 8 or day 11 if the bacterial load when checked on day 7 and day 10 is less than 10\^6cfu/ml.
62182399|NCT01058525|ACTIVE_COMPARATOR|nerve block|median nerve block (6 ml lidocaine 1.5 % with adrenalin 1:200000)
62182400|NCT01058525|EXPERIMENTAL|median nerve block after hydro-dissection|median nerve block (6 ml lidocaine 1.5 % with adrenalin 1:200000) after hydro-dissection (glucose 5% solution)
62364811|NCT02235168|EXPERIMENTAL|With rollator|Six minutes walking test with rollator
62550667|NCT01720225|EXPERIMENTAL|Decitabine|Patients randomized to receive Decitabine 20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
62550668|NCT01720225|EXPERIMENTAL|Azacitidine|Patients randomized to receive Azacitidine 75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
62550669|NCT01436630||Stroke|"To accomplish the study it was assessed a group of 12 post-stroke patients who were admitted in the Rehabilitation Clinic inside the University. As inclusion criteria it was established to be able to walk alone without supervision and with no aids.~All the patients signed an informed consent before performing the tests. To characterize the sample it were used the Fugl-Meyer scale, Orpington test, Mini Exam of the Mental State and some other data regarding the age, gender, type of the lesion and side of the lesion."
62550670|NCT01385514||company A-Training Base No.1|
62550671|NCT01385514||company A-Training Base No.2|
62550672|NCT01385514||company A-Training Base No.3|
62550673|NCT06582836|EXPERIMENTAL|investigate the effect of prior engagement of tooth with orthodontic appliance on post extraction pa|In this randomized clinical trial, 44 patients were recruited who needed bilateral extractions of first premolars in upper arches. Patients were divided into two groups based on the timing of extractions. Group A needed extractions before alignment while Group B needed extractions for retraction of anterior teeth. Group A was sent for extractions first while Group B went for orthodontic bonding and banding procedures for orthodontic treatment. After series of aligning wires (0.014, 0.016, 17x25, 19x25 Heat activated NiTi and 19x25 SS) patients from group B were sent for extractions. For pain assessment, an 11-point numerical rating scale (NRS) were given to record pain intensity at 2, 4, 8, 12 and then 24 hours after extraction for the next 7 days.
62364812|NCT02235168|ACTIVE_COMPARATOR|Without rolator|Six minutes walking test without rollator
62364813|NCT04914819|ACTIVE_COMPARATOR|Online Behavioral Weight Loss|Participants will attend a virtual introduction to weight loss session and be enrolled in a 16-week online behavioral weight loss program. Participants will complete a virtual weigh-in at the start and end of the study.
62739892|NCT06312579|EXPERIMENTAL|12-week home based exercise|Consistent with current physical activity recommendations for older adults, participants randomized in this arm will be prescribed 5 days/week of exercise, with seated cycling exercise performed on 3 days a week (Monday, Wednesday and Friday), and strength/balance exercise performed 2 days a week (Tuesday and Thursday).
62364814|NCT04914819|ACTIVE_COMPARATOR|Usual Care|Participants will complete a virtual weigh-in at the start and end of the study. No additional intervention will be provided.
62364815|NCT04173390|EXPERIMENTAL|pregabalin|
62364816|NCT04173390|PLACEBO_COMPARATOR|placebo|
62550674|NCT00754650|EXPERIMENTAL|Bevacizumab 15 mg/kg|Participants received bevacizumab 15 mg/kg intravenously on Day 1 of each 3-week cycle for 8 cycles.
62550675|NCT03872973|EXPERIMENTAL|Training Group|Neuromuscular training will be performed in this group for 6 weeks.
62550676|NCT03872973|EXPERIMENTAL|Strobe Group|This group will perform neuromuscular training for 6 weeks with a strobe glasses.
62550677|NCT03872973|NO_INTERVENTION|Control Group|This group will not perform any neuromuscular training program.
62175073|NCT03096197|EXPERIMENTAL|EAW + TLS|The EAW+TLS training group will receive 60 minutes of exoskeleton-assisted walking overground per session, for a total of 80 sessions (3x/week, 28 wks.) with simultaneous transcutaneous lumbosacral stimulation (TLS) intervention followed by 15 minutes of over ground training without the exoskeleton. component is added to the exoskeleton assisted walking component in this group. TLS will involve placing self-adhesive stimulating electrodes bilaterally over the T11/T12 lumbar region. Correct placement will be confirmed by the elicitation of posterior root muscle reflexes in the lower limb muscles. A constant-voltage stimulator (RT 50 Sage stimulator) will deliver pulses of 2 ms width. TLS will be applied while the participant walks in the Exo-skeleton-assisted walking (EAW).
62175074|NCT03096197|EXPERIMENTAL|EAW without TLS|EAW, exoskeleton-assisted walking, an activity based therapy is a training which involves using the same exoskeleton device for all the participants. Each participant will undergo, 60 minutes of EAW as above. Each participant will undergo a stand evaluation and be instructed in proper use of the device. During the initial 3 sessions of training, the exoskeleton device will be tethered to an overhead pulley system during training to allow subjects to safely adapt to trunk, balance gait activities while walking in the exoskeleton. EAW overground walking will follow each training session with the 6-minute walk test, 10 meter walk test .
62175075|NCT05042362|EXPERIMENTAL|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily for 26 weeks.
62175076|NCT05042362|PLACEBO_COMPARATOR|Placebo + elinzanetant|Participants will receive matching placebo orally once daily for 12 weeks, followed by elinzanetant 120 mg for 14 weeks.
62550678|NCT02771288|OTHER|Kawasaki disease|
62175077|NCT05645900|EXPERIMENTAL|experimental vaccine 1|Subjects received 2 doses of 0.5 mL of quadrivalent influenza virus subunit vaccine, 28 days apart
62175078|NCT05645900|EXPERIMENTAL|experimental vaccine 2|Subjects received 2 doses of 0.25 mL of quadrivalent influenza virus subunit vaccine, 28 days apart
62175079|NCT05645900|ACTIVE_COMPARATOR|control vaccine|Subjects received 2 doses of 0.25 mL of Quadrivalent split influenza virus vaccine, 28 days apart
62364817|NCT00661167|EXPERIMENTAL|1|ABI-007
62364818|NCT01953367|EXPERIMENTAL|Vantobra; Treatment A|Vantobra, 170 mg tobramycin/1.7 mL nebulizer solution
62364819|NCT01953367|ACTIVE_COMPARATOR|TOBI; Treatment B|TOBI, 300 mg tobramycin/5 mL nebulizer solution
62550679|NCT04038138|EXPERIMENTAL|Patient with facioscapulohumeral muscular dystrophy|
62550680|NCT03953612|EXPERIMENTAL|PREG 300|Eligible participants will be randomly assigned to PREG 300 mg/day over 8 weeks with a) an inpatient-outpatient option where they will be admitted to the Clinical Neuroscience Research Unit (CNRU) at the Connecticut Mental Health Center (CMHC) for first two weeks and then outpatient at Yale Stress Center (YSC) for the remaining 6 weeks, or b) an outpatient option where they will participate in the entire study outpatient at YSC.
62550681|NCT03953612|PLACEBO_COMPARATOR|patients receiving placebo|Eligible participants will be randomly assigned to a placebo (PLA) treatment over 8 weeks with a) an inpatient-outpatient option where they will be admitted to the Clinical Neuroscience Research Unit (CNRU) at the Connecticut Mental Health Center (CMHC) for the first two weeks and then transition to outpatient at Yale Stress Center (YSC) for the remaining 6 weeks, or b) an outpatient only option where they will participate in the entire study outpatient at YSC.
62364820|NCT05865210|EXPERIMENTAL|Kegel Exercise with Myofascial release technique group:|Group A, we told patient to perform kegel exercise by hold and relax the pelvic floor muscles, initially 3-4 contractions for 3-5 seconds then we increase the repetition according to patient and apply myofascial release for trigger points. 4 session per week and post intervention assessment after 3 weeks follow-up
62550682|NCT03953612|EXPERIMENTAL|PREG 500|Eligible participants will be randomly assigned to PREG 500 mg/day over 8 weeks with a) an inpatient-outpatient option where they will be admitted to the Clinical Neuroscience Research Unit (CNRU) at the Connecticut Mental Health Center (CMHC) for first two weeks and then outpatient at Yale Stress Center (YSC) for the remaining 6 weeks, or b) an outpatient option where they will participate in the entire study outpatient at YSC.
62550683|NCT04205565|ACTIVE_COMPARATOR|L-oxiracetam|
62550684|NCT04205565|ACTIVE_COMPARATOR|Oxiracetam|
62550685|NCT04205565|PLACEBO_COMPARATOR|Plaecbo|
62550686|NCT03127111||Adjuvant chemotherapy|Samples from patients with stage III colorectal cancer who are going to receive fluorouracil-based adjuvant chemotherapy will be used for gene mutations analysis, gene methylation analysis, gene expression analysis, SNP analysis, and protein expression analysis.
62550687|NCT05088850||non-sepsis|
62550688|NCT05088850||sepsis|
62550689|NCT01401452||Participants with psoriasis and at least one co-morbid disease|Participants with moderate to severe plaque psoriasis with at least one co-morbid disease and/or symptom such as hypertension, psoriatic arthritis confirmed by a rheumatologist or other appropriate specialist, obesity, diabetes, metabolic syndrome or depression
62550690|NCT06581276|OTHER|OTP Intervention|Evidence-based behavioral pain treatment integrated into OTP model of care
62550691|NCT06552039|EXPERIMENTAL|Polyherbal Hair Oil|"Apply oil with the help of fingertips on your scalp and massage it gently enabling it to penetrate into the roots (follicle) of your hair. Don't apply with your palms and never rub it vigorously as it may uproot weak hair. Let the oil gradually seep into follicle of your hair \& nourish them for the whole night. The oil may be removed in the morning by washing of hair with Ayurvedic Shampoo.~Dosage form: Liquid Frequency: Three times a week Route of Administration: Topical"
62550692|NCT06552039|ACTIVE_COMPARATOR|Minoxidil Herbal Hair Oil + Minoxidil 5 (%) Hair Serum|First, apply the herbal hair oil generously to your scalp and hair, ensuring thorough coverage. Gently massage it in with your fingertips to promote circulation and absorption. After the oil application, follow the instructions provided for the application of the minoxidil hair serum. Apply the serum to the areas of your scalp where you desire hair growth, using the dropper provided or as directed. Massage it gently into your scalp to ensure even distribution and absorption. Leave the serum on without rinsing Frequency: For Minoxidil - Daily Night Application For Herbal Hair Oil- Thrice a week Route of Administration: Topical
62550693|NCT06552039|ACTIVE_COMPARATOR|Minoxidil Hair Serum|Apply the amount prescribed to the area of the scalp being treated, beginning in the center of the area. Frequency: Daily Night Application of Minoxidil Route of Administration: Topical
62739893|NCT06312579|PLACEBO_COMPARATOR|12-week standard of care|Participants in this group will be provided with guidance on the current standard of care. This includes guidance that these patients should slowly increase ambulation with appropriately fitted footwear.
62739894|NCT04611347|ACTIVE_COMPARATOR|Start with CBD|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of the CBD and then crossover to the other condition (Shea butter only ) for 2 additional weeks. Patients will apply the cream at the thumb base twice daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
62739895|NCT04611347|ACTIVE_COMPARATOR|Start with control (Shea butter)|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of Shea butter and then crossover to the other condition (CBD)for 2 additional weeks. Patients will apply the cream at the thumb base twice daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
62739896|NCT05803161|EXPERIMENTAL|Congrong Runtong oral liquid high-dose group|Congrong Runtong oral liquid, 2 bottles (1g herb content per bottle) per dose, three times a day
62739897|NCT05803161|EXPERIMENTAL|Congrong Runtong oral liquid low-dose group|Congrong Runtong oral liquid, 2 bottles (0.5g herb content per bottle) per dose, three times a day
62739898|NCT05803161|PLACEBO_COMPARATOR|Placebo group|Congrong Runtong oral liquid, 2 bottles (0g herb content per bottle) per dose, three times a day
62739899|NCT00814021|EXPERIMENTAL|sunitinib,|
62739900|NCT05294497|EXPERIMENTAL|Product usage order A B N C E D|Subjects will use each of the 6 products sequentially (A B N C E D) during an evaluation period, followed by a 4 hour Test Session.
62739901|NCT05294497|EXPERIMENTAL|Product usage order B C A D N E|Subjects will use each of the 6 products sequentially (B C A D N E) during an evaluation period, followed by a 4 hour Test Session.
62739902|NCT05294497|EXPERIMENTAL|Product usage order C D B E A N|Subjects will use each of the 6 products sequentially (C D B E A N) during an evaluation period, followed by a 4 hour Test Session.
62739903|NCT05294497|EXPERIMENTAL|Product usage order D E C N B A|Subjects will use each of the 6 products sequentially (D E C N B A) during an evaluation period, followed by a 4 hour Test Session.
62739904|NCT05294497|EXPERIMENTAL|Product usage order E N D A C B|Subjects will use each of the 6 products sequentially (E N D A C B) during an evaluation period, followed by a 4 hour Test Session.
62739905|NCT05294497|EXPERIMENTAL|Product usage order N A E B D C|Subjects will use each of the 6 products sequentially (N A E B D C) during an evaluation period, followed by a 4 hour Test Session.
62550694|NCT02079740|EXPERIMENTAL|Treatment (trametinib, navitoclax)|Patients receive trametinib PO QD and navitoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If unacceptable toxicity is observed, patients may receive trametinib PO QD on days 1-14.
62550695|NCT01924754||Standard intramuscular injection (NS-IM)|HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe (NS-IM)
62550696|NCT01924754||PharmaJet needle-free Stratis device (JI-IM)|HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device (JI-IM)
62550697|NCT01924754||PharmaJet needle-free Tropis device (JI-ID)|HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device (JI-ID)
62550698|NCT01943383||Diuretic|Patients who received a diuretic drug during the parent trial are eligible for participation.
62550699|NCT05783232|PLACEBO_COMPARATOR|Placebo Control 1 Capsules|Health Product Form 1 Capsules - control
62550700|NCT05783232|EXPERIMENTAL|Active Product 1.1 Capsules|Health Product Form 1 Capsules - active product 1
62550701|NCT05783232|EXPERIMENTAL|Active Product 1.2 Capsules|Health Product Form 1 Capsules - active product 2
62550702|NCT05783232|EXPERIMENTAL|Active Product 1.3 Capsules|Health Product Form 1 Capsules - active product 3
62550703|NCT03248427|EXPERIMENTAL|Ribociclib + Letrozol|Ribociclib: 600mg, 3-weeks-on/-week-off treatment Letrozole: 2.5mg daily; Six 28 days cycles
62550704|NCT03248427|OTHER|Chemotherapy|Chemotherapy treatment will consist of four cycles of AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days) followed by weekly paclitaxel during 12 weeks.
62550705|NCT05924412|EXPERIMENTAL|Parecoxib|This arm will receive intravenous parecoxib in the intraoperative period.
62550706|NCT05924412|PLACEBO_COMPARATOR|Placebo|This arm will receive a placebo intravenous injection containing saline solution in the same volume as the intervention group
62550707|NCT04134195|EXPERIMENTAL|Real transcranial direct current stimulation|Healthy adults and healthy seniors will undergo application of real transcranial direct current stimulation over two distinct brain areas.
62550708|NCT04134195|EXPERIMENTAL|Sham transcranial direct current stimulation|Healthy adults and healthy seniors will undergo application of sham transcranial direct current stimulation over two distinct brain areas.
62550709|NCT01322074||Total knee arthroplasty|Patients operated with elective, unilateral total knee arthroplasty.
62550710|NCT06387134|EXPERIMENTAL|trial group|The patients in the trial group received routine Western medicine treatments, and oral Lifei Xiaoji Wan (10 pills/time,3 times/day).
62550711|NCT06387134|PLACEBO_COMPARATOR|control group|The patients in the control group received routine Western medicine treatments.
62550712|NCT04201730|EXPERIMENTAL|ERAS|Perioperative intervention with individual Enhanced Recovery After Surgery （ERAS）
62739906|NCT06658223|EXPERIMENTAL|Exercise with virtual reality|The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person's condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
62739907|NCT06156176|EXPERIMENTAL|COVIDEx|This group will receive two 50-minute rehabilitation sessions per week for 8 weeks.
62739908|NCT06156176|NO_INTERVENTION|Standard of Care|This group will receive standard of care (no intervention) for the 8-week intervention period.
62739909|NCT03980743|ACTIVE_COMPARATOR|iOTA text messaging intervention|"There will be a 6 month active treatment phase consisting of monthly meetings with a study health coach to develop reasonable health goals and interactive text messaging to provide daily support and self-monitoring of behavior change goals between in-person visits. Participants may receive phone calls between visits from their health coach for additional support if needed. Following the active treatment phase, participants will receive daily health-related text messages for another 3 months."
62739910|NCT03980743|PLACEBO_COMPARATOR|Health Education text messaging intervention|"There will be a 6 month active treatment phase consisting of monthly in-person visits with a health coach to learn about healthy eating and activity behaviors, including developing readiness for health behavior change. Participants will not set specific health goals, but will receive weekly text messages about general health tips related to their in-person visits. Following the active treatment phase, participants will receive daily health-related text messages for another 3 months."
62739911|NCT02745678|EXPERIMENTAL|Thermosensitive gel formulation|Thermosensitive gel rectal formulation.
62739912|NCT04463563|ACTIVE_COMPARATOR|NIRS group. Brain oxygen saturations group.|A monitor by means of non-invasive stickers will display cerebral oximetry (brain oxygen saturations) throughout the heart surgery.This gives a direct reading of brain frontal lobe oxygen levels. The baseline is recorded before the patient goes to sleep (anaesthetised) and throughout the surgery and time on cardiopulmonary bypass if the brain oxygen levels fall below baseline then various physiological changes are made to restore oxygen to baseline.
62739913|NCT04463563|NO_INTERVENTION|Standard Patient Monitoring|No cerebral monitoring. Standard patient monitoring according to normal practice at Castle Hill Hospital apply.
62739914|NCT04655807|EXPERIMENTAL|Group 1- Standard of Care (SOC) Biological Therapy: Adalimumab|Participants will receive JNJ-64304500 Dose 1 or matching placebo subcutaneous (SC) injection as induction dose (Week 0) followed by JNJ-64304500 Dose 2 or matching placebo SC injection from Week 2 through Week 10 as maintenance dose in addition to adalimumab or its biosimilar as SOC therapy.
62739915|NCT04655807|EXPERIMENTAL|Group 2: SOC Biological Therapy: Ustekinumab|Participants will receive JNJ-64304500 Dose 1 or matching placebo SC injection as induction dose (Week 0) followed by JNJ-64304500 Dose 2 or matching placebo SC injection from Week 2 through Week 10 as maintenance dose in addition to ustekinumab as SOC therapy.
62739916|NCT01198210|PLACEBO_COMPARATOR|saline|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
62739917|NCT01198210|ACTIVE_COMPARATOR|ketamine|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
62739918|NCT01198210|ACTIVE_COMPARATOR|dexamethasone|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
62739919|NCT01198210|ACTIVE_COMPARATOR|dexamethasone-ketamine|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
62739920|NCT00799227|EXPERIMENTAL|700 µg Dexamethasone Implant|700 µg dexamethasone implant in the study eye at Day 1
62550713|NCT04252339|EXPERIMENTAL|RLY-1971 - Dose Escalation/Expansion|"Dose Escalation: Oral dose of RLY-1971 until Maximum Tolerated Dose (MTD), and Recommended Phase 2 dose (RP2D) are identified~Dose Expansion: Oral dose of RLY-1971 once Maximum Tolerated Dose (MTD), and Recommended Phase 2 Dose (RP2D) are identified."
62739921|NCT02963363|EXPERIMENTAL|Interventional|"Home-Based Adapted Physical Activity intervention during neoadjuvant chemotherapy :~150 minutes per week of aerobic and muscle strengthening exercises during 18 weeks"
62739922|NCT01834950|EXPERIMENTAL|Trastuzumab|The study is a single arm prospective study, aiming at identifying biomarkers of early response to trastuzumab
62364821|NCT05865210|ACTIVE_COMPARATOR|Kegel Exercise group|Group B, In this group we only perform kegel exercises to patients as hold and relax of pelvic floor muscle 3-4 contraction for 3-5 seconds.4 session per week and post intervention assessment after 3 weeks follow-up
62739923|NCT02791516|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injection once a month for 6 months.
62364822|NCT00748306|EXPERIMENTAL|GSK2190915|Intervention
62364823|NCT00748306|PLACEBO_COMPARATOR|Placebo|
62550714|NCT00956072|EXPERIMENTAL|Arm I|Patients undergo surgery of residual disease.
62550715|NCT00956072|ACTIVE_COMPARATOR|Arm II|Patients receive imatinib mesylate therapy according to standard of care.
62550716|NCT00369941|EXPERIMENTAL|MK-0518 400 mg b.i.d.|MK-0518 400 mg, which can be taken by mouth (PO) twice a day (b.i.d.) without regard to food, and placebo to efavirenz, which will be taken PO at bedtime (q.h.s.) on an empty stomach preferably at bedtime. All participants will take one tablet of TRUVADA® (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) with food, daily with the morning dose of MK-0518. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
62550717|NCT00369941|ACTIVE_COMPARATOR|Efavirenz 600 mg q.h.s.|Efavirenz 600 mg, which will be taken by mouth (PO) at bedtime (q.h.s.) on an empty stomach preferably at bedtime, and placebo to MK-0518, which will be taken PO twice a day (b.i.d.) without regard to food. All participants will take one tablet of TRUVADA® with food, daily with the morning dose of placebo. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
62550718|NCT03545542|EXPERIMENTAL|Neuroblastoma group|"10 children with neuroblastoma. Inclusion after verification of diagnosis and informed consent.~Sampling of fecal microbiome (Initial microbiome, microbiome under chemotherapy, final microbiome), fecal volatile organic compounds (initial fecal volatile organic compounds, fecal volatile organic compounds under chemotherapy and final fecal volatile organic compounds) and breath organic volatile compounds (initial breath organic compounds, breath volatile organic compounds under chemotherapy and final breath volatile organic compounds).~Samples will be taken after verifying diagnosis before initiation of chemotherapy, 1 week after completion of each cycle and 3 weeks after the end of chemotherapy."
62550719|NCT03545542|OTHER|Control group|"10 children without gastro-intestinal or pulmonary disease as age and sex matched controls to the neuroblastoma group. Patients will be recruited from paediatric surgery. Inclusion after informed consent.~Sampling of fecal microbiome (initial fecal microbiome), fecal volatile organic compounds (initial fecal volatile organic compounds) and breath organic volatile compounds (initial breath volatile organic compounds).~Samples will be taken as age and sex matched controls for the neuroblastoma group. Sampling will be done once after obtaining informed consent."
62550720|NCT01050465|ACTIVE_COMPARATOR|email|Patients randomized to this arm will receive an email health information prescription.
62550721|NCT01050465|ACTIVE_COMPARATOR|paper|Patients randomized to this arm will receive a paper health information prescription.
62550722|NCT02754765|EXPERIMENTAL|endTB regimen 1 (BeLiMoZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based. Subjects will undergo a linezoilid dose reduction randomization to either 300mg daily or 600mg three times a week after 16 weeks of treatment or after a linezolid-related AE requiring dose reduction, whichever is earlier.
62550723|NCT02754765|EXPERIMENTAL|endTB regimen 2 (BeLiCLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based. Subjects will undergo a linezoilid dose reduction randomization to either 300mg daily or 600mg three times a week after 16 weeks of treatment or after a linezolid-related AE requiring dose reduction, whichever is earlier.
62550724|NCT02754765|EXPERIMENTAL|endTB regimen 3 (BeDeLiLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based. Subjects will undergo a linezoilid dose reduction randomization to either 300mg daily or 600mg three times a week after 16 weeks of treatment or after a linezolid-related AE requiring dose reduction, whichever is earlier.
62550725|NCT02754765|EXPERIMENTAL|endTB regimen 4 (DeLiCLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based. Subjects will undergo a linezoilid dose reduction randomization to either 300mg daily or 600mg three times a week after 16 weeks of treatment or after a linezolid-related AE requiring dose reduction, whichever is earlier.
62550726|NCT02754765|EXPERIMENTAL|endTB regimen 5 (DeCMoZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based.
62550727|NCT02754765|ACTIVE_COMPARATOR|endTB regimen 6 (Control)|endTB regimen 6 is the control regimen.
62550728|NCT05349708|EXPERIMENTAL|Participant|Patients who were sent home with the intervention post-surgery
62550729|NCT05349708|NO_INTERVENTION|Historical controls|
62550730|NCT01609452|EXPERIMENTAL|Blisibimod|
62550731|NCT01609452|PLACEBO_COMPARATOR|Placebo|
62550732|NCT02322255||All Subjects|All subjects enrolled in the study.
62550733|NCT03086486|EXPERIMENTAL|1200mg L x 26 weeks + Pa + B|2 linezolid 600 mg active tablets once daily for 26 weeks plus 1 placebo linezolid 300 mg half tablet once daily for 26 weeks plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
62550734|NCT03086486|EXPERIMENTAL|1200 mg L x 9 weeks + Pa + B|2 linezolid 600 mg active tablets once daily for 9 weeks, 1 placebo linezolid 300 mg half tablet once daily for 9 weeks (for Weeks 1-9); 2 placebo linezolid 600 mg tablets once daily for 17 weeks, 1 placebo linezolid 300 mg half tablet once daily for 17 weeks (for Weeks 10-26) plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
62550735|NCT03086486|EXPERIMENTAL|600 mg L x 26 weeks + Pa + B|1 linezolid 600 mg active tablet once daily for 26 weeks, 1 placebo linezolid 600 mg tablet once daily for 26 weeks, 1 placebo linezolid 300 mg half tablet once daily for 26 weeks plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
62550736|NCT03086486|EXPERIMENTAL|600 mg L x 9 weeks + Pa + B|1 linezolid 600 mg active tablets once daily for 8 weeks, 1 placebo linezolid 600 mg half tablet once daily for 9 weeks, 1 placebo linezolid 300 mg half tablet once daily for 9 weeks (for Weeks 1-9); 2 placebo linezolid 600 mg tablets once daily for 17 weeks, 1 placebo linezolid 300 mg half tablet once daily for 17 weeks (for Weeks 10-26) plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
62550737|NCT00444587|EXPERIMENTAL|Trastuzumab + 2nd Line Chemotherapy|
62739924|NCT02791516|EXPERIMENTAL|Romosozumab|Participants received 210 mg romosozumab by subcutaneous injection once a month for 6 months.
62739925|NCT04458935||Participants|Participants with retinal hemangioblastoma (RH) managed with trans-scleral cryotherapy at the NIH.
62739926|NCT01241188|EXPERIMENTAL|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
62739927|NCT01241188|ACTIVE_COMPARATOR|2 TU Tuberculin PPD RT 23 SSI|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
62739928|NCT05713981|EXPERIMENTAL|non-invasive Meibomian gland (MG) expression|"Baseline testing of visual acuity, contrast sensitivity, color vision, and Innova, Inc. cone and B/W low contrast vision will be measured.~The intervention will be standard clinical expression of Meibomian superior and inferior glands (MG) using a sterile cotton tip applicator to apply gentle pressure in a rolling motion in the direction of the MGs along the upper and lower eyelid margins to allow oil secretion of the tested eye. One drop of sterile saline will be instilled following the intervention to remove debris. The subject's visual acuity, contrast sensitivity, color vision, and Innova, Inc. cone and B/W low contrast vision will be measured before and after this intervention."
62364824|NCT02566876|ACTIVE_COMPARATOR|Mixture of three Bifidobacteria|Patients were administered 1 sachet per day of a mixture of three Bifidobacteria (namely, 3 billions of Bifidobacterium longum BB536®, 1 billion of Bifidobacterium infantis M-63®, and 1 billion of Bifidobacterium breve M-16V®) for six weeks. Subsequently, no preparation was administered for a 2-week-''washout'' period. At each follow-up visit subjects underwent a complete physical examination, data recorded on the daily diaries were collected and compliance to treatment was verified.
62550738|NCT00444587|ACTIVE_COMPARATOR|Only Chemotherapy|
62550739|NCT02791451|EXPERIMENTAL|Telemonitoring|Exacerbation of COPD with wireless telemonitoring of respiratory rate, heart rate and sleep.
62550740|NCT05966415|EXPERIMENTAL|Endocalyx Pro|"Endocalyx is a food supplement that is distributed by Microvascular Health Solutions LLC in Alpine, Utah.~Patients will receive 4 capsules Endocalyx per day, for 8 consecutive weeks. The capsules are orally administered and can be taken with water, on an empty stomach or with food.~If possible, the patient will take 2 capsules in the morning, and 2 capsules in the afternoon. If preferred by the patient, the 4 capsules could also be taken once daily in the morning."
62550741|NCT05966415|PLACEBO_COMPARATOR|Placebo|"Placebo pills will be provided by Microvascular Health Solutions and are matched with the Endocalyx capsules. The placebo capsules contain no active pharmaceutical ingredients and contain solely widely used excipients.~Patients will receive 4 capsules of the placebo per day for 8 consecutive weeks. The capsules are orally administered and can be taken with water, on an empty stomach or with food. If possible, the patient will take 2 capsules in the morning, and 2 capsules in the afternoon. If preferred by the patient, the 4 capsules could also be taken once daily in the morning."
62550742|NCT06455813|ACTIVE_COMPARATOR|Macrogol 3350 and electrolytes.|Powder for oral solution in sachet Macrogol 3350 and electrolytes (ATC code A06AD65) which is administered orally as the content of 2 sachets daily (in the evening) during admission
62550743|NCT06455813|ACTIVE_COMPARATOR|Bisacodyl|Enteric coated tablet Bisacodyl (ATC code A06AB02) 5 mg, 2 tablets daily which is administered orally daily (in the evening) during admission
62550744|NCT06455813|ACTIVE_COMPARATOR|A combination of macrogol 3350 and electrolytes and bisacodyl|Powder for oral solution in sachet macrogol 3350 and electrolytes (ATC code A06AD65) which is administered orally daily (in the evening) as the content of 1 sachet given in combination with enteric coated tablet Bisacodyl (ATC code A06AB02) 5 mg, 1 tablet orally daily (in the evening) during admission
62550745|NCT05491486|EXPERIMENTAL|Mindfulness-based Group Therapy (MBGT+TAU)|Participants randomized into the experimental condition attend MBGT for four weeks in addition to regular university hospital outpatient treatment as usual (TAU). Overall, the core modules of the program are based on mindfulness-based cognitive therapy, taking into account both Chadwick's recommendations for implementing mindfulness in psychosis as well as patient feedback. Each week, a new topic is introduced to enhance the understanding of four core aspects of mindfulness (breath, senses, detachment, and body awareness). The therapy sessions will be held by a psychotherapist in training in cognitive behavioral therapy with over three years of experience in mindfulness practice and supervised by a psychotherapist with more than a decade of experience in mindfulness-based therapeutic approaches. Within the sessions, short periods of meditation are used to avoid prolonged periods of silence, and basic anchoring techniques and easy-to-understand language are used.
62550746|NCT05491486|NO_INTERVENTION|Treatment as Usual|All participants will be recruited from the outpatient facility at the Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin and therefore, the heterogeneity of the obtained treatment options can be limited. As the standard procedure in our outpatient facility, patients will be seen monthly by a psychiatrist as well as individual sessions by a psychotherapist or psychiatric nurse (1:2 ratio). Hence, regardless of the study condition, all participants will obtain high standard health care at a renowned university hospital outpatient facility according to official national and international treatment guidelines providing pharmacological therapy, psychological consultation, and, on-demand, psychosocial support by social workers. The amount of psychotherapy received and on-demand psychosocial support will be recorded during the study period.
62550747|NCT06552000|EXPERIMENTAL|Tumor Treatment Fields|"Duration: 2-4 week; target 18 hours/day (on average). Continuous between time of enrollment and date of surgery.~Cycle Length: 2-4 weeks"
62550748|NCT00584454|EXPERIMENTAL|Q Fever Vaccine (NDBR 105)|Volunteers will receive and intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase 1, MNLBR 110) in the volar aspect of the arm. Skin test will be evaluated; if erythema occurs after the skin test, it is medically contraindicated to vaccinate that volunteer. Volunteers with skin test reactions will not be vaccinated and withdrawn from the study.
62550749|NCT03081780|EXPERIMENTAL|FATE NK-100|
62364825|NCT02566876|PLACEBO_COMPARATOR|Placebo|Patients were administered 1 sachet per day of placebo for six weeks. Subsequently, no preparation was administered for a 2-week-''washout'' period. At each follow-up visit subjects underwent a complete physical examination, data recorded on the daily diaries were collected and compliance to treatment was verified.
62739929|NCT03005561|EXPERIMENTAL|Intervention|100 participants that will be participating in the Play Back meetings.
62739930|NCT03005561|NO_INTERVENTION|Control|100 participants that will not be participating in the Play Back meetings.
62739931|NCT03482648|EXPERIMENTAL|Single Ascending Doses|
62739932|NCT03482648|EXPERIMENTAL|Multiple Ascending Doses|
62739933|NCT06650228||Patients with ankylosing spondylitis|
62739934|NCT05128864|ACTIVE_COMPARATOR|HTO and Fulkerson|High Tibial Osteotomy with Antero-medialisation of Tibial Tubercle
62175080|NCT05212597|ACTIVE_COMPARATOR|Sacubitril-Valsartan Group|Participant start Sacubitril/Valsartan tablet 50mg twice a day and uptitrate to 100mg twice a day. Participants take the maximum dose considering blood pressure for a total of 48 weeks.
62175081|NCT05212597|PLACEBO_COMPARATOR|Amlodipine-Losartan group|Participant start amlodipine/losartan 25/2.5mg once a day and uptitrate to 5/100mg once a day. Participants take the maximum dose considering blood pressure for a total of 48 weeks.
62739935|NCT05128864|SHAM_COMPARATOR|HTO|Descending Hight Tibial Osteotomy
62175082|NCT04978012|EXPERIMENTAL|Combination of Fluzoparib and Camrelizumab|Fluzoparib,150mg bid po, d1-21, q3w Camrelizumab 200mg iv, d1, q3w
62739936|NCT06549166|EXPERIMENTAL|VR and exercise|virtual reality and neck exercises
62739937|NCT06549166|SHAM_COMPARATOR|exercise|only neck exercise
62739938|NCT04678986||ER2 participants|all participants of ER2 database will be included in the analysis
62175083|NCT06400264|EXPERIMENTAL|Treatment (nivolumab and BMS-986016 [relatlimab])|Patients receive nivolumab IV over 30 minutes on day 1 and BMS-986016 (relatlimab) over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo ECHO during screening as clinically indicated. Patients undergo a biopsy during screening and blood sample collection during screening and on study.
62175084|NCT05762081|EXPERIMENTAL|Intervention Group|Individuals who have undergone wiping bathing with disposable wipes
62175085|NCT05762081|SHAM_COMPARATOR|Control Group|Individualswho have undergone bathing with a traditional bath
62175086|NCT04087070||biosignal derived blood pressure|"Blood pressure is measured by an automated oscillometric device or arterial waveform from IntelliVue MX800 Bedside patient monitor (Philips Healthcare, Amsterdam, Netherlands).~Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.~1. PAT(time between R peak of ECG and beginning of the pulse of PPG)~2. PEP(time between R peak of ECG and peak of accelerometer signal)~3. PTT(PAT-PEP)"
62175087|NCT03944902|EXPERIMENTAL|Cohort 1: Dose Escalation using Niraparib and CB-839|The first phase will be a 3+3 design, 3 participants will be enrolled in the first cohort with a fixed dose of Niraparib and CB-839, 600 mg. If there are no dose limiting toxicities (DLT), 3 additional participants will be enrolled in the next cohort (CB-839, 800mg). If 1 of the 3 in the first cohort experiences DLT's, then the additional participants will be enrolled in the same cohort (CB-839, 600mg).
62175088|NCT03944902|EXPERIMENTAL|Cohort 2: Dose Escalation using Niraparib and CB-839|If there are no DLT's, 3 additional participants will be enrolled in the next cohort with a fixed dose of Niraparib and CB-839, 800mg.
62550750|NCT04832022||Vaccinated|Seronegative Chronic Inflammatory Rheumatism (CIR) who accepted vaccination against SARS-CoV2
62550751|NCT04832022||Non vaccinated|Seronegative Chronic Inflammatory Rheumatism (CIR) who refused vaccination against SARS-CoV2
62550752|NCT06178003|EXPERIMENTAL|intravitreal injection of Tpdelansbsalbac in malignant pleural and abdominal effusions|the safety and efficacy of intravitreal injection of Tpdelansbsalbac in the treatment of malignant pleural and abdominal effusions
62550753|NCT04233424|EXPERIMENTAL|D-PLEX+SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
62550754|NCT04233424|OTHER|Standard of care|The SoC for prophylactic antibiotic treatment is based on international guidelines
62550755|NCT04167111|ACTIVE_COMPARATOR|Vitamin D 4000|At baseline, if subjects 25(OH)D levels are 12-19.9, they will be started on 4000 IU per day.
62550756|NCT04167111|ACTIVE_COMPARATOR|Vitamin D 2400|At baseline, if subjects 25(OH)D levels are 20-30, they will be started on 2400 IU per day.
62550757|NCT02340481|EXPERIMENTAL|Loperamide Hydrochloride + Simethicone|Participant will take 2 loperamide hydrochloride and simethicone chewable tablets + 2 loperamide hydrochloride placebo capsules orally, as their first dose, and subsequently 1 loperamide hydrochloride and simethicone chewable tablet + 1 loperamide hydrochloride placebo capsule orally, in the event of unformed stool (provided that no more than 4 tablets/capsules are taken within a 24-hour period) up to 48 hours.
62550758|NCT02340481|ACTIVE_COMPARATOR|Loperamide Hydrochloride|Participant will take 2 loperamide hydrochloride capsules + 2 loperamide hydrochloride and simethicone chewable placebo tablets orally, as their first dose, and subsequently 1 loperamide hydrochloride capsule + 1 loperamide hydrochloride and simethicone chewable placebo tablet orally, in the event of unformed stool (provided that no more than 4 capsules/tablets are taken within a 24-hour period) up to 48 hours.
62550759|NCT03270969|EXPERIMENTAL|TDF/FTC|Tenofovir Disoproxil Fumarate/Emtricitabine group HIV-uninfected transgender women receiving feminizing hormone therapy plus tenofovir disoproxil fumarate/emtricitabine
62550760|NCT03354715|SHAM_COMPARATOR|Rapid prototyping Denture base|Complete Denture Using Rapid Prototyping method for fabrication of the complete denture depending on
62739939|NCT02422693|EXPERIMENTAL|Aquatic exercises|Warm-up, lumbar mobilization, stretching and relaxation. 3x-week (9 weeks), indoor pool, 32o.C/89.6o.F.
62739940|NCT02422693|ACTIVE_COMPARATOR|Aquatic exercises + Deep-water running|Same as AEG with addition of 20 minutes of running without touch the ground, 3x-week (9 weeks), indoor pool, 30o.C/86o.F.
62739941|NCT01837446|EXPERIMENTAL|Morphine mouthwash|The morphine group uses the mouthwash of 2% morphine solution (20 mg morphine sulfate diluted in 100 mL of water), 10 mL every three hours; six times a day. The morphine solution is prepared by the faculty of pharmacy under supervision of the Food and Drug Organization of the local Medical University.
62739942|NCT01837446|ACTIVE_COMPARATOR|Magic mouthwash|The magic group uses a mouthwash contained a mixture of 240 mL magnesium aluminum hydroxide (Alborz Co., Iran), 25 mL 2% viscous lidocaine (SinaDaru Co., Iran), and 60 mL diphenhydramine (Emad Co., Iran), 10 mL every three hours; six times a day.
62175089|NCT03944902|EXPERIMENTAL|Cohort 3: Expansion with Maximum Tolerated Dose (MTD)|Patients in this expansion cohort will continue study treatment with the MTD until they experience disease progression, unacceptable toxicity or withdraw consent. Patients who discontinue study treatment for reasons other than Progressive-Free Survival (PFS) will continue to have PFS follow-up visits every 2 months for the first 6 months after treatment, and every 3 months until disease progression, death, or start of another anticancer therapy.
62550761|NCT03354715|SHAM_COMPARATOR|Heat Cured Conventional Complete Denture|Complete Denture using heat cured Denture base using flasking and deflasking method
62550762|NCT00762112|EXPERIMENTAL|TAK-559 32 mg QD|
62550763|NCT02216500|EXPERIMENTAL|Ketogenic Therapy|Ketogenic Therapy will be administered.
62175090|NCT05236140|EXPERIMENTAL|Perineal electrical stimulation (Stimulation group)|Perineal electrical stimulation will be performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with perineal surface electrodes. Perineal electrical stimulation will be performed three days a week, 20 minutes a day, a total of 24 sessions for 8 weeks. The stimulation parameters are frequency at 50 Hz, a 5-10s work-rest cycle, and a 300ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100mA (according to the patient's discomfort level feedback). In this application, three surface electrodes which had 2 cm diameters were used; two electrodes symmetrically at the perianal region (medial to ischial tuberosity); and one electrode at the leg (ground-neutral electrode). Surface electrodes will be used individually for each patient. Perineal electrical stimulation sessions will be performed by an experienced urogynecology rehabilitation nurse.
62175091|NCT05236140|NO_INTERVENTION|Control group|Subjects in the control group will go through baseline assessment and will not receive treatment or instructions to perform pelvic floor exercises at home. After 8 weeks they will be submitted to the final assessment. After the final evaluation, they will be invited to start treatment in the urogynecological rehabilitation unit.
62175092|NCT01157377|EXPERIMENTAL|AGN-214868 total dose 500 ng|AGN-214868 injected into the bladder for total dose of 500 ng on Day 1.
62550764|NCT00004126|EXPERIMENTAL|Arm A|Paclitaxel 175 mg/m2 : administered by 1-hour constant rate IV infusion through a pump on day 1 of each cycle. Oxaliplatin 130 mg/m2 : On Day 1 of each 21-day treatment cycle, patients receive oxaliplatin diluted in 250-500 mL Dextrose 5% in Water infused intravenously over 2 hours.
62175093|NCT01157377|EXPERIMENTAL|AGN-214868 total dose 1000 ng|AGN-214868 injected into the bladder for total dose of 1000 ng on Day 1.
62175094|NCT01157377|EXPERIMENTAL|AGN-214868 total dose 2000 ng|AGN-214868 injected into the bladder for total dose of 2000 ng on Day 1.
62550765|NCT04851847|EXPERIMENTAL|MatrixflexTM resorbable collagen membrane|Experimental arm using the Matrixflex Resorbable Collagen Membrane for treatment of periodontal intrabony defects
62550766|NCT04851847|ACTIVE_COMPARATOR|control group membrane|Control arm using the Comparator Xenograft Resorbable Collagen Membrane or treatment of periodontal intrabony defects
62175095|NCT01157377|EXPERIMENTAL|AGN-214868 total dose 6000 ng|AGN-214868 injected into the bladder for total dose of 6000 ng on Day 1.
62175096|NCT01157377|EXPERIMENTAL|AGN-214868 total dose 18000 ng|AGN-214868 injected into the bladder for total dose of 18000 ng on Day 1.
62550767|NCT03955458|EXPERIMENTAL|FICB with EXPAREL|Group 1: Suprainguinal Fascia Iliaca Compartment Block (FICB) with EXPAREL and bupivacaine HCl
62550768|NCT03955458|ACTIVE_COMPARATOR|FICB with Standard of Care: ropivacaine|Suprainguinal FICB with continuous infusion of local anesthetic (ropivacaine) via catheter placed in the FIC.
62550769|NCT06277765|EXPERIMENTAL|CM310 group|
62550770|NCT06277765|PLACEBO_COMPARATOR|Placebo|
62550771|NCT06083519|SHAM_COMPARATOR|White Noise|Participants listened to white noise for 24 minutes
62175097|NCT01157377|EXPERIMENTAL|AGN-214868 total dose 60000 ng|AGN-214868 injected into the bladder for total dose of 60000 ng on Day 1.
62550772|NCT06083519|EXPERIMENTAL|LUCID Music|Participants listened to music chosen from the VIBE app with theta auditory beat stimulation for 24 minutes
62550773|NCT06357585|EXPERIMENTAL|web based education group|Parents in the experimental group will be given web-based training for 5 weeks.
62550774|NCT06357585|EXPERIMENTAL|control group|No intervention will be made to the parents in the control group, and the children will continue their routine care and treatment process.
62550775|NCT00504751|EXPERIMENTAL|Study Treatment|This is a single arm study
62550776|NCT05532033|EXPERIMENTAL|high flow nasal cannula|Two hours after extubation patients will received high flow nasal cannula oxygenation therapy for 24 hours
62550777|NCT05532033|ACTIVE_COMPARATOR|Standard oxygen therapy|Two hours after extubation patients will received standard oxygenation therapy for 24 hours
62550778|NCT03488082|EXPERIMENTAL|Measurement of the bold signal|
62550779|NCT04520126|ACTIVE_COMPARATOR|olive extract 1 - olivomed|15 patients will be randomized to receive two Olivomed soft capsules bid for one month (5 mg hydroxytyrosol po twice daily) and then they will be crossed over to treatment placebo for another one month.
62550780|NCT04520126|PLACEBO_COMPARATOR|placebo 1|15 patients will be randomized to receive two placebo soft capsules bid for one month. Then they will be crossed over to receive two Olivomed soft capsules bid for oen month (5 mg hydroxytyrosol po twice daily)
62550781|NCT04520126|ACTIVE_COMPARATOR|olive extract 2 - olivomedSmart|15 patients will be randomized to receive two soft capsules containing OL:HT:OC (2:1:3) bid for one month (5 mg hydroxytyrosol po twice daily) and then they will be crossed over to treatment placebo for another one month.
62550782|NCT04520126|PLACEBO_COMPARATOR|placebo2|15 patients will be randomized to receive two placebo soft capsules bid for one month. Then they will be crossed over to receive two soft capsules containing OL:HT:OC (2:1:3) bid for one month (5 mg hydroxytyrosol po twice daily) bid for one month.
62550783|NCT00869076|EXPERIMENTAL|Pharmacist Management|In this arm the Pharmacist managed the Diabetes in collaboration with the primary care physician
62550784|NCT00869076|ACTIVE_COMPARATOR|Usual Care|The patient was managed by the primary care physician
62739943|NCT00263042|EXPERIMENTAL|Rimonabant|Rimonabant 20 mg once daily
62739944|NCT00263042|PLACEBO_COMPARATOR|Placebo|Placebo (for Rimonabant) once daily.
62739945|NCT01027494||Treatment|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension, 4 drops in outer ear canal of infected ear(s) while awake 2 times per day for 7 days
62739946|NCT01027494||Healthy|No intervention
62739947|NCT00100256|EXPERIMENTAL|Arm 1|
62550785|NCT01259271|EXPERIMENTAL|Supra-threshold|Supra-threshold is defined as the nerve stimulation amplitude at which a subject can tolerate sensory responses (like tingling, tapping in the thumb, index or middle fingers) but will not cause pain or duress to the subject. The intervention (TAMS device), is stimulating through tyco extended wear electrodes that are placed directly on top of non dominant hand healthy median nerve fibers and they feel the paresthesia or tingling sensation.
62739948|NCT04789629|ACTIVE_COMPARATOR|low level laser , physiotherapy|Instrumentation Diode laser device will use for biostimulation of the muscle fiber . The device has a wavelength of 808 nm and a power output 0-250 mW. parameters of laser : Wavelength 808 nm Power output 100 mW Spot size 0.0314 cm2 Power density 3,18 W/cm2 Treatment time per point 40 s Energy density per point 4,77 J/cm2 Energy per point 4 J 12 sessions for one month with traditional physiotherapy ( stretching , strenghthing exercises , trunk control , balance training , standing exercises , gait training .)
62739949|NCT04789629|ACTIVE_COMPARATOR|physiotherapy|traditional physiotherapy ( stretching , strenghthing exercises , trunk control , balance training , standing exercises , gait training ) for one hour
62739950|NCT00328887|EXPERIMENTAL|CD40 Gene Transfer|Recruitment will be random from the referral base of the investigators from the popula¬tion of individuals with esophageal cancer defined by the protocol inclu¬sion/exclusion criteria.
62739951|NCT01339819|EXPERIMENTAL|Arm 1|Dabigatran Therapy
62739952|NCT01339819|ACTIVE_COMPARATOR|Arm 2|Phenprocoumon Therapy
62739953|NCT03082443|EXPERIMENTAL|Therapeutic group|
62550786|NCT01259271|EXPERIMENTAL|Sub-threshold|Sub-threshold is defined as the nerve stimulation amplitude just below the sensory perception of the subject. The intervention (TAMS device), is stimulating through tyco extended wear electrodes that are placed directly on top of non dominant hand healthy median nerve fibers. Subjects do not feel the paresthesia or tingling sensation despite there being a signal transmitted..
61986211|NCT02206425|EXPERIMENTAL|bortezomib + PLD + dexamethasone|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
62175098|NCT01157377|PLACEBO_COMPARATOR|Placebo to AGN-214868|Placebo to AGN-214868 injected into the bladder on Day 1.
62175099|NCT06294483||early onset SLE|group of patients diagnosed as SLE before age of fifty years old
62175100|NCT06294483||late onset SLE|Patients were diagnosed as SLE at age of fifty years old or more
62175101|NCT02109861|EXPERIMENTAL|Melphalan|A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan
62175102|NCT02109861|EXPERIMENTAL|Bortezomib|A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib
62175103|NCT02109861|EXPERIMENTAL|Dexamethasone|A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
62175104|NCT01379131||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
62567154|NCT05430750|ACTIVE_COMPARATOR|Conventional' - N2O carrier gas group|Ventilation will be initiated with 2% Sevoflurane in O2-N2O (60 % FiO2) @3L/min to MAC 0.5. Once MAC reaches 0.5, the FGF will be decreased to 1.0L/min (Low flow) and allowed to reach MAC 1.0 before incision is allowed. At 20-minutes time point post induction if MAC 1.0 is not achieved at 2% sevoflurane then the sevoflurane vaporizer concentration will be adjusted to achieve MAC 1.0, before incision is allowed. Anaesthesia will be maintained at MAC 1.0 throughout. After surgery is over, the N2O - Sevoflurane will be stopped and FGF increased to 3.0L with 100% O2.
62175105|NCT00012636|OTHER|Arm 1|
62175106|NCT02675998|EXPERIMENTAL|3mg BID|Tenapanor, 3mg BID (6mg total)
62739954|NCT03082443|NO_INTERVENTION|Control group|
62175107|NCT02675998|EXPERIMENTAL|10mg BID|Tenapanor, 10mg BID (20mg total)
62175108|NCT02675998|EXPERIMENTAL|Dose Titration|Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question
62175109|NCT02675998|PLACEBO_COMPARATOR|Placebo|Placebo
62175110|NCT02110225|EXPERIMENTAL|rhNGF 60µg/ml|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
62175111|NCT02110225|EXPERIMENTAL|rhNGF 180 µg/ml|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes.
62175112|NCT02110225|PLACEBO_COMPARATOR|Vehicle|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes.
62175113|NCT02125097|EXPERIMENTAL|Intracranial Aneurysm Treatment|Barrel™ Vascular Reconstruction Device (VRD) is Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio \< 2.
62175114|NCT02209727|EXPERIMENTAL|131I-Sibrotuzumab|single therapy dose administered over 60 minutes at week 4
62175115|NCT04560023|EXPERIMENTAL|Exposition to multimedia content|Ad hoc design multimedia content in a tablet (video with sound and subtitles).
62175116|NCT04560023|NO_INTERVENTION|Standard procedures|Standard procedures.
62550787|NCT01259271|SHAM_COMPARATOR|Sham Control|All subjects in the sham arm will go through the same process / experimental setup as in each of the active stimulation arms; however there will be no stimulation signal during the sham stimulation (output set and SNS box locked at 0 V). As this is the Sham control, there is no intervention but rather the intevention (TAMS device) setup (Tyco electrodes, wires and stimulator) are sent with the subject as if it were on (and just like Subthreshold arm the subjects cannot feel the stimulation). Audible alerts (to signify that the box is unplugged) will be disabled throughout the duration of the study. This sham arm will be used to assess the placebo effect caused by the stimulation and hence isolate the true effect of stimulation.
62550788|NCT03719651|EXPERIMENTAL|Intervention|"When clinics join the intervention arm, leaders will receive leadership training through the Leadership and Organizational Change for Implementation (LOCI) intervention.~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR, CT-PTSD, TF-CBT)"
62739955|NCT06544785|EXPERIMENTAL|Arm Zanubrutinib+early Obinutuzumab|"Patients will be treated with the combination of zanubrutinib 320 mg P.O qDay and obinutuzumab, starting obinutuzumab at cycle 2 to reduce infusion-related reactions. Intravenous obinutuzumab will be given on days 1 (100 mg), 2 (900 mg), 8 (1000 mg), and 15 (1000 mg) of cycle 2 and on day 1 (1000 mg) of cycles 3-7.~Response will be assessed after 20 cycles of treatment for the primary objective of the study. Patients that in the evaluation of cycle 20 who achieve uMRD will stop treatment with zanubrutinib, whereas the rest of patients will continue on treatment with zanubrutinib until progression, unacceptable toxicity or trial completion, whichever comes first. Patients who achieve an uMRD in bone marrow beyond C20, will also be allowed to stop the treatment, whereas the rest of patients will continue on treatment with zanubrutinib until progression, unacceptable toxicity, or trial completion, whichever comes first."
62550789|NCT03719651|ACTIVE_COMPARATOR|Control|"Clinics that are not yet included in the intervention arm, the leaders will not receive any leadership training (LOCI).~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR, CT-PTSD, TF-CBT)"
62550790|NCT04087915||High risk coronary artery disease|Participants with high risk coronary artery disease.
62739956|NCT06544785|EXPERIMENTAL|Arm Zanubutinib+late Obinutuzumab|"Patients will start treatment with zanubrutinib 320 mg P.O qDay in monotherapy. After 12 cycles of zanubrutinib patients will be treated with the combination of zanubrutinib and obitnutuzumab. Intravenous obinutuzumab will be given on days 1 (100 mg), 2 (900 mg), 8 (1000 mg), and 15 (1000 mg) of cycle 13 and on day 1 (1000 mg) of cycles 14-18.~Response will be assessed after 20 cycles of treatment for the primary objective of the study. Patients that in the evaluation of cycle 20 who achieve uMRD will stop treatment with zanubrutinib, whereas the rest of patients will continue on treatment with zanubrutinib until progression, unacceptable toxicity or trial completion, whichever comes first. Patients who achieve an uMRD in bone marrow beyond C20, will also be allowed to stop the treatment, whereas the rest of patients will continue on treatment with zanubrutinib until progression, unacceptable toxicity, or trial completion, whichever comes first."
62739957|NCT01320839||Stroke|People who have had a stroke and have an ankle-foot orthosis.
62550791|NCT04159246||Sovaldi group|patients with a documented diagnosis of chronic hepatitis C , normal renal functions And Rheumatoid factor tests (to exclude Purtscher like retinopathy as a rare presentation of cryoglobuinemia which considered one of extra hepatic manifestations of HCV)
62550792|NCT02206360||Individuals at elevated risk for pancreatic cancer|Individuals with an elevated risk of developing pancreatic cancer as either equal to or greater than five times the general population risk, or five times the average risk (1.5%) of developing pancreatic cancer by age 70; that is a 7.5% lifetime risk.
62739958|NCT05406739|EXPERIMENTAL|Spinal Cord Injury Group|Participants who have a spinal cord injury will receive two meals on two separate visits between five to seven days.
62739959|NCT05406739|ACTIVE_COMPARATOR|Control Group|Participants without a spinal cord injury will receive two meals on two separate visits between five to seven days.
62739960|NCT05734443|EXPERIMENTAL|non-treadmill trip training|Two training sessions per week will be completed for three consecutive weeks. Each training session will last 0.5-1 hour with an active training time of 30 minutes per participant. Training will involve repeated volitional and reactive stepping movements that mimic the movements necessary to recover balance after tripping while walking.
61986212|NCT02206425|EXPERIMENTAL|bortezomib + pomalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
62175117|NCT03582150|EXPERIMENTAL|Receiving Soberlink Device|
62550793|NCT03161977||Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
62550794|NCT01382888|ACTIVE_COMPARATOR|Heparin 2,400 IU /ml Cutaneous Spray|Patients are randomized to receive the active comparator heparin 2,400 IU/ml cutaneous spray for 24 weeks
62550795|NCT01382888|PLACEBO_COMPARATOR|Placebo Cutaneous Spray|Patients are randomized to receive placebo cutaneous spray for 24 weeks
62550796|NCT02419781|ACTIVE_COMPARATOR|Group with endovascular treatment|Group with additional endovascular treatment
62550797|NCT02419781|ACTIVE_COMPARATOR|Group without endovascular treatment|Group without additional endovascular treatment
62550798|NCT03166098||Diagnosis of Schizophrenia|
62550799|NCT03166098||Diagnosis of Bipolar Disorder|
62550800|NCT03166098||Unaffected siblings of the SZ groups|
62550801|NCT03166098||Unaffected siblings of the BP group|
62550802|NCT03166098||Healthy control (HC) comparison group|
62550803|NCT02509169|EXPERIMENTAL|TAE plus p53 gene|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
62550804|NCT02509169|ACTIVE_COMPARATOR|TAE|Trans-catheter embolization (TAE) will be given once per month
62550805|NCT03681249|EXPERIMENTAL|ShenqiDihuang Decoction|ShenqiDihuang Decoction 150ml by mouth, twice a day for 24 weeks
62550806|NCT03681249|PLACEBO_COMPARATOR|ShenqiDihuang Decoction placebo|ShenqiDihuang Decoction placebo 150ml by mouth, twice a day for 24 weeks
62550807|NCT04323943|EXPERIMENTAL|Carbon-AFO (C-AFO)|Manufactured carbon ankle foot orthosis (C-AFO) Sprystep (Thuasne) will be provided to patients. A familiarization with C-AFO will be performed before doing the tests.
62550808|NCT04323943|ACTIVE_COMPARATOR|Custom-made thermo-plastic orthosis (CM-AFO)|Own custom-made thermo-plastic orthosis (CM-AFO) of patients. A familiarization will be performed also before doing the tests.
62550809|NCT04323943|NO_INTERVENTION|Without orthosis (NO)|No orthosis - patient will wear only their shoes
62550810|NCT00852007|EXPERIMENTAL|DC-Tn-MUC|DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1. 1.2 x 10e7 dendritic cells per dose. 5 administrations (doses)may be given in total.
62550811|NCT06550557|EXPERIMENTAL|counseling group|"1. assessement of nomophobia score, mental health and self-esteem scores.~2. received 3 counselling sessions based on health belief model merged with smart phone action cues.~3. assessment of nomophobia score, mental health and self-esteem scores post intervention"
62550812|NCT06550557|NO_INTERVENTION|control group|assessment of nomophobia score, mental health and self-esteem scores at the same time interval of the intervention group, pre and post intervention
62550813|NCT04071834||Diabetes mellitus group|Diabetic patients undergoing spinal anesthesia for lower extremity surgery
62550814|NCT04071834||Non-diabetic group|Non-diabetic patients undergoing spinal anesthesia for lower extremity surgery
62550815|NCT01179386||methylphenidate|30 adolescents who are treated with Methylphenidate will perform the driving simulator and seat pressure mapping tests, in 2 different days : 1. with their regular methylphenidate medication and 2: without the methylphenidate medication after a 4 days washout period. Results will be recorded and statistical test will be performed.
62550816|NCT01179386||no medication|30 adolescents : control group , not suffering from ADHD and without methylphenidate medication will perform the driving simulator and seat pressure mapping tests. Results will be recorded and statistical test will be performed.
62550817|NCT02797171|EXPERIMENTAL|Group 1|Participants will receive 10 mg/kg of VRC01 at Months 0, 2, 4, and 6.
62550818|NCT02797171|EXPERIMENTAL|Group 2|Participants will receive 30 mg/kg of VRC01 at Months 0, 2, 4, and 6.
62550819|NCT02797171|EXPERIMENTAL|Group 3|Participants will receive 30 mg/kg of VRC01LS at Months 0, 3, and 6.
62550820|NCT02797171|EXPERIMENTAL|Group 4|Participants will receive 30 mg/kg of VRC01 at Month 0.
62550821|NCT02797171|EXPERIMENTAL|Group 5|Participants will receive 30 mg/kg of VRC01LS at Month 0.
62550822|NCT03632915||No study intervention|No study intervention
62550823|NCT02829645|OTHER|Eating disorders|
62550824|NCT05880329||Care home residents|100 care home residents will be recruited and followed up for 6 months.
62550825|NCT01954862|ACTIVE_COMPARATOR|Air insufflation method.|Colonoscopy performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
62550826|NCT01954862|EXPERIMENTAL|CO2 insufflation|Colonoscopy performed with CO2 insufflation using the insufflation unit, allowing for washing as needed.
62550827|NCT01954862|EXPERIMENTAL|Water Immersion/CO2|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Withdrawal phase done using CO2 insufflation.
62550828|NCT01954862|EXPERIMENTAL|Water Exchange/CO2|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using CO2 insufflation.
62550829|NCT01954862|EXPERIMENTAL|Water Immersion/AI|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Withdrawal phase done using room air insufflation.
62550830|NCT01954862|EXPERIMENTAL|Water Exchange/AI|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using room air insufflation.
62550831|NCT03171012|EXPERIMENTAL|Lower limbs CRT+ PNF|Lower Limbs Cardiorespiratory training associated with Proprioceptive Neuromuscular Facilitation
62550832|NCT03171012|ACTIVE_COMPARATOR|Lower limbs CRT + respiration|Lower limbs Cardiorespiratory training associated with respiration
62550833|NCT03171012|EXPERIMENTAL|Upper limbs CRT + PNF|Upper limbs Cardiorespiratory training associated with Proprioceptive Neuromuscular Facilitation
62550834|NCT03171012|ACTIVE_COMPARATOR|Upper limbs CRT + respiration|Upper limbs Cardiorespiratory training associated with respiration
62550835|NCT02281422|OTHER|Group 1 normal renal function|normal renal function (creatinine clearance \> 80 mL/min)
62550836|NCT02281422|OTHER|Group 2 mild renal impairment|mild renal impairment (creatinine clearance 50-80 mL/min)
62739961|NCT05734443|EXPERIMENTAL|treadmill trip training|Two training sessions per week will be completed for three consecutive weeks. Each training session will last 0.5-1 hour with an active training time of 30 minutes per participant. Training will involve repeated exposure to simulated trips on a treadmill. To simulate a trip, participants first stand on the stationary treadmill belt. A sudden and unexpected increase in backward treadmill belt speed induces a forward loss of balance similar to when tripping. Participants are then required to take steps to recover balance and establish a stable gait pattern before the trial ends. Trials are repeated using pseudo-random speeds that provide variability and are individualized to each participant's capabilities.
62739962|NCT05734443|NO_INTERVENTION|Control|
62739963|NCT00394043|EXPERIMENTAL|Osteopathic Manipulative Treatment|A protocol of specific osteopathic manipulative techniques was applied.
62739964|NCT00394043|PLACEBO_COMPARATOR|Placebo ultrasound|Sub-therapeutic ultrasound was applied.
62550837|NCT02281422|OTHER|Group 3 moderate renal impairment|moderate renal impairment (creatinine clearance 30-50 mL/min)
62550838|NCT02281422|OTHER|Group 4 severe renal impairment|severe renal impairment (creatinine clearance \<30 mL/min)
62550839|NCT02281422|OTHER|Group 5 end stage renal disease|end stage renal disease, requiring haemodialysis (ESRD)
62550840|NCT03167268|EXPERIMENTAL|Lycopene 20mg cpr/die|Lycopene is a compound belonging to carotenoid group, largely contained in tomatoes and their derivatives, which has an extreme antioxidant activity. In Dermatology, prolonged use of β-carotenoids in general and of lycopene in particular in the diet showed to be effective in skin protection from ageing, sunlight and radiotherapy damages because these compounds may accumulate in skin and thus contribute to reduce free radicals and inflammation effects.
62550841|NCT03167268|PLACEBO_COMPARATOR|Placebo|"Containing same excipients than the experimental Lycopene 20 mg but not active principle (Lycopene)"
62550842|NCT06583122|EXPERIMENTAL|Ultrasound Guided Approach|Ultrasound-guided approach to occipital nerve radiofrequency ablation
62550843|NCT04513392|ACTIVE_COMPARATOR|KTP laser treatment|All participants will complete a paper Voice Handicap Index-10 (VHI-10) questionnaire and laryngeal stroboscopy examination at baseline. Local anesthesia will be administered as per standard of care for in-office laryngeal procedures. KTP laser will be utilized to ablate the lesion of interest. Immediately following the procedure, participants will complete a VAS pain scale on paper. Participants will be asked to exercise 3 days of absolute voice rest following the procedure. All patients will have follow-up clinic appointments on POD 7, POD 30, and POD 90 after surgery. At each of the follow-up visit, the patients will fill out a paper VHI-10 questionnaire and undergo stroboscopic examination to assess vocal fold vibratory properties and closure, as well as residual lesions. During the first week post procedure, the participants will continue to complete a daily VAS at home for pain assessment.
62550844|NCT04513392|EXPERIMENTAL|BL laser treatment|The only difference in study procedures between the experimental arm and the control arm is that the experimental arm will use the BL laser. The post-operative instructions and follow-up schedule are identical.
62550845|NCT02647697|EXPERIMENTAL|Radiprodil|Subjects will receive a single dose of Radiprodil 30 mg in suspension form, orally via a syringe in the morning of Day 1.
62550846|NCT04259372||Primary Diagnosis|Analysis of patient blood at primary diagnosis of AML
62550847|NCT04259372||Relapse|Analysis of patient blood at time point of relapse after allo-HCT
62550848|NCT04259372||Remission|Analysis of patient blood during remission after allo-HCT
62550849|NCT03774407|OTHER|urogenital symptoms|To evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS.
62739965|NCT00394043|NO_INTERVENTION|Standard Medical care|Subjects did not receive either study treatment, but continued to receive standard medical care.
62739966|NCT04638413|EXPERIMENTAL|Walking regimen (W)|
62739967|NCT04638413|EXPERIMENTAL|Walking regimen + gamified inhibitory control training (W+PolyRules!)|
62739968|NCT02066831|EXPERIMENTAL|Telemedical Coaching|Patients will receive telemedical devices i.e. for the measurement of blood glucose, weight and physical activity. These devices will transfer the data to a data collector with a SIM card which sends the data to a data portal, which can be monitored by the participant and the coach. Health coaches which will have close phone contact to patients, supporting them to reduce weight and increase physical activity. In the first 12 weeks, patients will follow a formula diet (Almased) to achieve an initial weight reduction.
62739969|NCT02066831|ACTIVE_COMPARATOR|Telemedicine|Patients will receive telemedical devices i.e. for the measurement of blood glucose, weight and physical activity. These devices will transfer the data to a data collector with a SIM card which sends the data to a data portal which can be monitored by the participant.
62739970|NCT03101488|EXPERIMENTAL|KN035|KN035 is to be injected subcutaneously 0.1mg/kg or 0.3mg/kg or 1mg/kg or 2.5mg/kg or 5mg/kg or 10mg/kg weekly until disease progresses or unacceptable tolerability occurs.
62739971|NCT05541627|EXPERIMENTAL|Cohort 1|Low-dose of AB-1001
62739972|NCT05541627|EXPERIMENTAL|Cohort 2|High-dose of AB-1001
62739973|NCT05611645|EXPERIMENTAL|HSRT+Low-dose Bevacizumab|HSRT with low-dose bevacizumab every 2 weeks
62739974|NCT05611645|ACTIVE_COMPARATOR|Bevacizumab|Bevacizumab every 2 weeks
62739975|NCT02422641|EXPERIMENTAL|High-dose Methotrexate (8 gm/m2; HD-MTX)|Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (\~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
62550850|NCT03774407|EXPERIMENTAL|remyelination|To evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.
62739976|NCT02483793|ACTIVE_COMPARATOR|Oxybutynin group|This group will be prescribed oxybutynin as well as standard narcotic pain medications. Oxybutynin will be prescribed based off of standard dosing. Patients who are unable to swallow pills will be given oxybutynin elixir (0.5mg/kg/day, divided TID). Patients who are able to swallow pills will be given oxybutynin 5mg either BID or TID.
62175118|NCT00743496|EXPERIMENTAL|Group 1|Participants who consent to the study will receive Anti-GD2 antibody.
62550851|NCT05668702|EXPERIMENTAL|capillary blood glucose measurement|the researcher took venous blood sample in a tube from each patient and according to the list of order determined via randomization scheme formed on the computer, the patients' glucose levels were measured by taking a capillary blood sample from the side of the middle fingertip and palm of the dominant hand with the glucometer. Before the study, the patient's pain assessment at the end of each measurement was carried out by a nurse who was trained by the researcher about the use of Visual Analog Scale.
62550852|NCT06582862|EXPERIMENTAL|Pre aerobic exercise treatment|Subject will do aerobic exercise 3 times a week for 1 month. The training program includes the following: Week 1 consists of interval running (2 sets of 10 repetitions of 400 meters each) with 3 minutes of rest between repetitions and 10 minutes of rest between sets. Week 2 transitions to continuous running for 15-20 minutes. Week 3 involves 30 minutes of cross-country running. In Week 4, the program returns to interval running as in Week 1.
62550853|NCT06582862|EXPERIMENTAL|Pre anaerobic exercise treatment|Subject will do anerobic exercise 3 times a week for 1 month. The sprint training program includes the following: In Weeks 1 and 3, perform sprints of 20 m, 40 m, 60 m, and 80 m, with 2 sets of 5 repetitions each, allowing 5 minutes of rest between repetitions and 10 minutes of rest between sets. In Weeks 2 and 4, run 2 sets of 5 repetitions of 50 m sprints, with 5 minutes of rest between repetitions and 10 minutes between sets.
62550854|NCT02856802|EXPERIMENTAL|DFN-02|Participants self-administered a single-dose of DFN-02 (sumatriptan 10-mg/100 μL nasal spray) intranasally within one hour of an acute migraine pain episode.
62550855|NCT02856802|OTHER|Placebo|Participants self-administered a single-dose of DFN-02 placebo nasal spray matching DFN-02 intranasally within one hour of an acute migraine pain episode.
62550856|NCT02920671||Mitochondrial Disease|Clinical history consistent with the diagnosis of mitochondrial disease, and molecular genetic diagnosis.
62550857|NCT02920671||Obese|BMI \> 30 kg/m2. These will be matched with subjects with mitochondrial disease by age, sex, estrogen status (women), and usual self-reported physical activity.
62550858|NCT02920671||Normal Weight & Overweight|BMI 18.5 - \< 30 kg/m2. These will be matched with subjects with mitochondrial disease by age, sex, estrogen status (women), and usual self-reported physical activity.
62550859|NCT00698711|EXPERIMENTAL|1|"Three groups of 5 patients enrolled sequentially comprised from will receive MUC-2-KLH vaccines at the following g amounts of MUC-2-KLH per vaccination.~10 + 100 μg QS21 30 + 100 μg QS21 3 + 100 μg QS21"
62550860|NCT05209529|EXPERIMENTAL|Olaparib|Olaparib treatment for a total of 16 weeks
62550861|NCT05209529|EXPERIMENTAL|Olaparib and durvalumab|Olaparib and durvalumab treatment for a total of 16 weeks
62550862|NCT00626808||1|Children less than 24 months of age
62550863|NCT00626808||2|Children 24 to 59 months of age with a claim associated with a diagnosis of asthma
62550864|NCT00626808||3|Children 24 to 59 months of age without a claim associated with a diagnosis of asthma, but with dispensed medication for wheezing
62550865|NCT00626808||4|Children 24-59 months of age with immunosuppression
62175119|NCT05199441|EXPERIMENTAL|Dihydroxydibutylether group|This group takes dihydroxydibutylether for 8 weeks.
62550866|NCT06445621||Women in control program after ovarian/fallopian/primary peritoneal cancer|"Study population;~Inclusion criteria:~* ≥18 years of age~* Included in the control program for ovarian/fallopian/primary peritoneal cancer at Uppsala University Hospital, or in Norrlands University Hospital, Sweden~* Within 3 years after completed primary treatment for stage III-IV EOC, or after treatment for relapse~* No evidence of disease (normal CA 125 and no tumor detected on radiology or clinical examination).~* Patients on maintenance therapy (PARP-inhibitor, bevazicumab) can be included.~Exlusion: Other cancer diagnosis within 2 years (except squamous skin cancer or basalioma). Non-Swedish speaking. Not able to understand instructions."
62550867|NCT05509517|EXPERIMENTAL|Rhythm monitoring group|Patients randomized to the rhythm monitoring arm will assess their heart rhythm with a photoplethismography (PPG) based smartphone application (FibriCheck™). Measurements are performed three times daily and while experiencing symptoms. The patients start measuring immediately after discharge and continues until the scheduled postoperative consultation with the cardiologist or cardiac surgeon at 21-91days after discharge.
62550868|NCT05509517|NO_INTERVENTION|Usual care|Patients randomized to the rhythm monitoring arm will be discharged without protocol mandated rhythm monitoring. A postoperative consultation is scheduled with the cardiologist or cardiac surgeon at 21-91days after discharge.
62550869|NCT01245283|ACTIVE_COMPARATOR|Wait-list Non-exercise Control (CON)|Subjects will continue to participate in their normal activities and clinical care during the four month study period if assigned to this group.
62175120|NCT05199441|PLACEBO_COMPARATOR|Control group|This group takes placebo for 8 weeks.
62175121|NCT02624505|PLACEBO_COMPARATOR|Placebo Product|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
62175122|NCT02624505|ACTIVE_COMPARATOR|90 mcg Reference Product|Drug : 90 mcg Reference Product One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
62175123|NCT02624505|ACTIVE_COMPARATOR|180 mcg Reference Product|Drug: 180 mcg Reference Product One actuation each from two different Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
62175124|NCT02624505|EXPERIMENTAL|90 mcg Test Product|Drug: 90 mcg Test Product One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols
62175125|NCT06278753||Standard cystoscopy|Standard cystoscopy arm
62175126|NCT06278753||carbon dioxide cystoscopy|carbon dioxide cystoscopy arm
62175127|NCT02990364|ACTIVE_COMPARATOR|Control: EMLA Topical Product|"This represents the control group and it is the traditional analgesic used for circumcisions.~EMLA cream is a eutectic mixture of 2.5% lidocaine and 2.5% prilocaine, used as a topical anaesthetic to diminish pain from cutaneous procedures. Seventy minutes prior to circumcision, the newborn will be placed in the circumcision mold with the legs restrained, and attached to a monitor. 1 gram of EMLA cream will be applied by the nurse to the penis using a syringe and then wrapped with a dressing (Tegaderm). After sixty minutes the Tegaderm and drug will be removed, and the infant will be left to settle until the circumcision."
62739977|NCT02483793|ACTIVE_COMPARATOR|Tamsulosin group|This group will be prescribed tamsulosin and standard narcotic pain medication. Patients will be given tamsulosin 0.4mg at bedtime. This dosage has been used in other studies for children age ≥ 4.
62739978|NCT04556591|ACTIVE_COMPARATOR|Control|Participants will wear the Fitbit® and provide daily reports of health related quality of life (HRQOL) over a three-month (90 day) period (without the personalized feedback).
62739979|NCT04556591|EXPERIMENTAL|Just-in-time adaptive intervention (JITAI)|Participants will wear the Fitbit®, provide daily reports of health related quality of life (HRQOL) and receive personalized pushes over a three-month (90 day) period.
62739980|NCT04351399||patient with chronic painful inflammatory rheumatism|
62739981|NCT03926741|EXPERIMENTAL|GSNOR Challenge testing|patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
62739982|NCT01191736|EXPERIMENTAL|No training, assessed within 60 mins|Subjects receive no training
62739983|NCT01191736|EXPERIMENTAL|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
62739984|NCT01191736|EXPERIMENTAL|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
62739985|NCT01191736|EXPERIMENTAL|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
62739986|NCT01191736|EXPERIMENTAL|Ultra-brief video; assessed at 2 months|
62739987|NCT01191736|EXPERIMENTAL|Brief video; assessed 2 months later|
62739988|NCT01191736|EXPERIMENTAL|Brief video + hands-on; ass'd 2 ms later|
62739989|NCT02691520||Taiwan Participants with Treatment Resistant Depression|Taiwan participants with Depression will be followed up to 8 years for incidence and duration of treatment resistant depression.
62739990|NCT05081518|EXPERIMENTAL|Sequence 1: Lu AG06466-Placebo|Participants will receive Lu AG06466 capsules once daily (QD) at a low dose for 4 days (Days 1 to 4), medium dose for 4 days (Days 5 to 8), and high dose for 21 days (Days 9 to 29) in treatment period 1. Participants will receive matching placebo capsules from Day 1 to Day 29 in treatment period 2. Each treatment period will be separated by a washout period of 7 to 11 days.
62739991|NCT05081518|EXPERIMENTAL|Sequence 2: Placebo-Lu AG06466|Participants will receive matching placebo capsules QD from Day 1 to Day 29 in treatment period 1. Participants will receive Lu AG06466 capsules QD at a low dose for 4 days (Days 1 to 4), medium dose for 4 days (Days 5 to 8), and high dose for 21 days (Days 9 to 29) in treatment period 2. Each treatment period will be separated by a washout period of 7 to 11 days.
62739992|NCT05271253|ACTIVE_COMPARATOR|Group (C)|caudal group, where caudal anaesthesia was given using 1 mL/kg dose of 0.25% bupivacaine without epinephrine.
62739993|NCT05271253|ACTIVE_COMPARATOR|Group (D)|Dexmedetomidine (D) group, where Dex. (Precedex, hospira, Egypt) 0.8 μg/kg was given intravenously over 10 min as a loading dose, and then infused at a rate of 0.4 μg/kg/h
62739994|NCT05271253|PLACEBO_COMPARATOR|Group (P)|Placebo (P) group, where normal saline instead of Dex was given in volume (ml) and rate (ml/h) calculated related to the patient's body weight.
62175128|NCT02990364|ACTIVE_COMPARATOR|EMLA + Sucrose|"There is high-quality evidence for the beneficial effect of sucrose (24%) with non-nutritive sucking (pacifier dipped in sucrose) or 0.5 mL of sucrose orally in preterm and term infants. To assess this, 10 ml of sucrose (24%) will be given to the infant during the course of the circumcision.~In combination to the EMLA cream, the infant will be given sucrose during the circumcision to test the effects of sucrose and sucking on pain management."
62550870|NCT01245283|ACTIVE_COMPARATOR|Concentric Focused RX (CRX)|Training protocol for 1 set of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
62550871|NCT01245283|ACTIVE_COMPARATOR|Eccentric Focused RX (ERX)|"The Human Dynamics Laboratory features prototype equipment that increases resistance loads during the eccentric phase of the contraction while assistance is provided by the machine during the concentric phase. One set of each exercise - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press."
62550872|NCT05743010|EXPERIMENTAL|APL-1401|On Day 1, patients will be randomized to receive either APL-1401 or placebo in a 5:1 ratio. Patients will receive APL-1401 orally once daily (QD) during the 28-day treatment period.
62550873|NCT05743010|PLACEBO_COMPARATOR|Placebo|Identically matching placebo capsules once daily for 28 days
62550874|NCT06582329|NO_INTERVENTION|standard of care|Standard of care Prednisolon 40mg will be administered over 4 weeks
62739995|NCT06661551|EXPERIMENTAL|Group A (Generation X operator)|"Group A is going to be treated by operator number 1, an oral surgeon with more than 30 Years of experience, which belongs to Generation X"
62739996|NCT06661551|EXPERIMENTAL|Group B (Generation Y operator)|"Operator number 2 (MG) will treat Group B and is a dentist with 15 years of experience in oral surgery and belonged to Generation Y."
62739997|NCT06661551|EXPERIMENTAL|Group C (Generation Z operator)|"Group C will be treated by operator number 3 (DB), a final year dental student with no previous experience in oral surgery, that belonged to Generation Z."
62739998|NCT06427096|EXPERIMENTAL|Multifaceted intervention|Residents in this group will receive multifaceted intervention including low-sodium diet, weight management, physical exercise, BP monitoring and antihypertensive treatment.
62739999|NCT06427096|NO_INTERVENTION|Usual care|Residents in this group will receive usual lifestyle and health care management.
62740000|NCT01198704||HCC patients|Patients notified on the national waiting list for hepatic transplant
62740001|NCT05709561|ACTIVE_COMPARATOR|Acupressure Group|Acupressure was applied to the acupressure group twice a week in the first week by the researcher. Then, in the second week, it was observed that the students themselves applied this application twice this week under the supervision of the researcher.Then the acupressure group was asked to apply acupressure two days a week for 12 weeks, a total of 24 times.
62740002|NCT05709561|ACTIVE_COMPARATOR|Mindfulness Group|The researcher and students practiced mindfulness once a week for 8 weeks. Then the students were asked to do 3 cycles of application alone every day. mid-test was applied.
62740003|NCT05709561|PLACEBO_COMPARATOR|Plasebo Group|Acupressure and mindfulness practices were not applied to the control group and they continued their routine care.
62550875|NCT06582329|EXPERIMENTAL|Standard of care + Alpha 1 Antitrypsin|In the experimental arm the participants will receive Prolastin 120 mg/kg bodyweight and Prednisolon 40 mg over a time period of 4 weeks
62550876|NCT03852732|EXPERIMENTAL|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
62740004|NCT06352151|EXPERIMENTAL|1. Grup: Routine Physiotherapy Group|Children with Down Syndrome receive routine physiotherapy treatment in special education centers.
62740005|NCT06352151|EXPERIMENTAL|2.Group: Orofacial Treatment Group|The orofacial treatment group receives therapeutic orofacial treatment in addition to routine physiotherapy treatment. For orofacial therapy, sessions will be conducted twice a week for eight weeks, lasting 30-45 minutes, totaling 16 sessions.
62740006|NCT06352151|EXPERIMENTAL|3.Group: Therapeutic Yoga Group|The therapeutic yoga group receives therapeutic yoga treatment and routine physiotherapy treatment. Sixteen sessions were planned twice a week for eight weeks, each 30-45 minutes.
62740007|NCT00039780|ACTIVE_COMPARATOR|1|Tavocept (BNP7787)
62740008|NCT00039780|PLACEBO_COMPARATOR|2|0.9% Sodium Chloride Soln.
62740009|NCT04787549|EXPERIMENTAL|Virtual reality exergames|Cognitively challenging exergames using fully immersive virtual reality with a head-mounted display (HTC Vive; HTC Co., New Taipei City, Taiwan)
62740010|NCT06057935|EXPERIMENTAL|IVC arm|Pemetrexed and cisplatin will be administered intravenously for a total of 4 to 6 cycles. Participants will receive 4 cycles, but can receive up to 6 cycles based on clinician discretion. Substitution with carboplatin allowed for pre-existing impairment of hearing, renal function, or neuropathy.
62740011|NCT06057935|ACTIVE_COMPARATOR|NIPC arm|After completion of hyperthermic intraperitoneal chemotherapy/HIPEC, an intraperitoneal catheter with a subcutaneous reservoir will be inserted through the abdominal wall. When the participant's condition is considered stable by the physicians, the NIPC will be started. Pemetrexed and either cisplatin or carboplatin will be administered through the intraperitoneal port.
62740012|NCT01907321|EXPERIMENTAL|Expiratory muscle strength training (EMST)|Participants will complete 5 weeks of EMST training, 5 repetitions per set, 5 sets per day, 5 days per week.
62740013|NCT01907321|PLACEBO_COMPARATOR|Placebo expiratory training|Same look and feel of EMST with no resistance. Same protocol - 5 repetitions of 5 sets, 5 days per week
62550877|NCT04786847|EXPERIMENTAL|Single administration of 177Lu-DOTA-TLX591|Two single IV infusions of 76 mCi (2.8 GBq) each (equivalent to a 45 mCi/m2 administered activity in a standard 1.7m2 individual) of 177Lu-DOTA-TLX591, given 14 days apart. This therapy will be administered with the current standard of care treatment regimens.
62550878|NCT04622748||COVID-19|Recovered COVID-19 patients in Wuhan
62740014|NCT02749006|ACTIVE_COMPARATOR|Active iTBS rTMS|The active arm involves magnetic stimulation of the brain to the left dorsolateral prefrontal cortex (DLPFC) daily for four weeks. The active arm will be receiving intermittent Theta-Burst (iTBS) repetitive Transcranial Magnetic Stimulation (rTMS) to deliver magnetic pulses.
62740015|NCT02749006|SHAM_COMPARATOR|Sham rTMS|sham rTMS treatment involves scalp stimulation with no magnetic pulse daily for four weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
62740016|NCT06203392|EXPERIMENTAL|Very low carbohydrate ketogenic diet for six weeks|
62740017|NCT06203392|ACTIVE_COMPARATOR|Mediterranean diet for six weeks|
62550879|NCT04622748||Healthy Control|Uninfected people in Wuhan
62740018|NCT04693702||Age-related Macular Degeneration|
62740019|NCT04693702||Diabetic Macular Edema|
62740020|NCT03889340||Phase 1 cohort|Subjects resuscitated from cardiac arrest will undergo cooling per standard of care with the IQool device.
62740021|NCT05960643|EXPERIMENTAL|Breast self-examination group|This group was planned to consist of 51 female students studying at the university. First of all, students will be contacted through their electronically registered contact information. In the pre-test, the researchers will apply the 'Personal Information Form' and the 'Health Belief Model Scale' to the students with the self-report method. Afterwards, students will be given BSE training consisting of two 120-minute sessions. In the first session of the training, theoretical trainings about breast cancer and BSE will be given for 30 minutes. In the second session, BSE application will be shown on the wearable breast model and each student will practice on the model. The practice skills of the participants will be evaluated by the researchers using the 'BSE Practice Skill Evaluation Form'. At the end of the 'Health Belief Model Scale' application, face-to-face and 3 weeks later, online applications will be filled as a post-test.
62740022|NCT05960643|ACTIVE_COMPARATOR|Control group|No intervention will be made against people in this group.
62740023|NCT04837118|EXPERIMENTAL|Supportive care (resistance training)|SEE DETAILED DESCRIPTION.
62740024|NCT06658418|ACTIVE_COMPARATOR|dexmedetomidine combined with bupivacaine|use for Dexmedetomidine and bupivacain for erector spinae plane block
62740025|NCT06658418|EXPERIMENTAL|dexamethasone combined with bupivacaine|use of dexamethasone combined with bupivacaine for erector spinae plane block
62740026|NCT04679623|EXPERIMENTAL|Midazolam Injection|Midazolam injection, 10 mg
62740027|NCT04679623|ACTIVE_COMPARATOR|Seizalam™|Seizalam, 10 mg
62740028|NCT04521231|EXPERIMENTAL|Dose Escalation Phase: Blinatumomab Subcutaneous Formulation 1 (SC1)|Cohorts of at least 3 participants each will be treated with escalating doses of bilinatumomab to determine the maximum tolerated dose (MTD). The MTD will be defined as the dose for which the estimate of the toxicity rate from an isotonic regression (Yan et al, 2017) is closest to the target toxicity rate. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy will be assessed.
62550880|NCT02396719||LenSx|Phacoemulsification cataract surgery in at least 1 eye using LenSx® Laser technology
62550881|NCT00612092|EXPERIMENTAL|1|Standard spiral CT protocol
62550882|NCT00612092|ACTIVE_COMPARATOR|2|Sequential CT protocol
62550883|NCT01657435||Ceramax COC 28mm Acetabular Cup|The 28 mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper. The Pinnacle acetabular shell is a hemispherical type acetabulum replacement prosthesis, is available in a range of outer diameter (OD) sizes, and is used with a 28mm femoral head. Pinnacle 100 shells will be used in this study. The BIOLOX® delta ceramic femoral head components are manufactured from the same ceramic material as the acetabular bearing insert components. The femoral head is secured to the femoral stem component with an interlocking taper.
62550884|NCT00395161|EXPERIMENTAL|zinc selenium glutamine metoclopramide|metoclopramide, zinc, selenium, and glutamine
62550885|NCT00395161|PLACEBO_COMPARATOR|enteral whey protein and IV saline|saline, sterile water, whey protein
62740029|NCT04521231|EXPERIMENTAL|Dose Expansion Phase: Blinatumomab SC1|Up to 4 cohorts of participants with R/R B-ALL will be enrolled to the preliminary recommended phase 2 dose (RP2D) and schedule determined from dose escalation phase. Each cohort will aim to further assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy.
62740030|NCT04521231|EXPERIMENTAL|Ph-IIC: Clinical PK Evaluation of SC Blinatumomab Formulations|1 cohort of participants will be enrolled into the Ph-IIC arm. The clinical PK evaluation cohort (Ph-IIC) will be conducted to compare the PK of SC1 and SC2 formulations at the RP2D determined from the dose expansion phase, in participants with R/R B-ALL.
62550886|NCT03757312|EXPERIMENTAL|Fontan|Patients undergoing Fontan procedure to redirect blood flow from the lower body to the lungs.
62740031|NCT02569476|EXPERIMENTAL|Zanubrutinib and Obinutuzumab|In the dose-escalation part, dose levels and regimens were evaluated. In the indication-specific expansion cohorts, participants were assigned to different cohorts based on histology type.
62740032|NCT06586138||Maintenance of Wakefulness Test|Consecutive patients referred for Maintenance of Wakefulness test at the center for Sleep Medicine in Lyon University hospital (HCL - Croix Rousse Hospital)
62740033|NCT03286543|EXPERIMENTAL|Treatment Group (SPRINT Beta System)|Subjects in the treatment group will have up to 2 leads placed in their leg that underwent total knee replacement, will use the SPRINT Beta System, and will receive electrical stimulation in addition to the standard of care.
62740034|NCT03286543|NO_INTERVENTION|Control Group|Subjects in the control group will receive the standard of care.
62550887|NCT03757312|ACTIVE_COMPARATOR|Non-Fontan|Patients undergoing other cardiac surgeries requiring cardiopulmonary bypass.
62740035|NCT06484127||tertiary lymphoid structure positive patients|
62740036|NCT06484127||tertiary lymphoid structure negative patients|
62740037|NCT03870451|EXPERIMENTAL|Cohort 1 VascuTherm5 vascular compression device|VascuTherm5 vascular compression device Cohort 1 - Grade 2-3 neuropathy - Patients with established neuropathy (e.g. previously received bortezomib-based chemotherapy and have clinically documented CTCAE grade 2 or 3 neuropathies. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.
62740038|NCT03870451|EXPERIMENTAL|Cohort 2 VascuTherm5 vascular compression device|VascuTherm5 vascular compression device Cohort 2 Grade 1-2 Neuropathy - Patients with new-onset neuropathy (e.g. currently receiving bortezomib-based chemotherapy have clinically documented CTCAE grade 1 or grade 2 neuropathy to explore its role in preventing worsening of CIPN in patients receiving neurotoxic chemotherapy. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.
62740039|NCT05627232|EXPERIMENTAL|Part I (tazemetostat, CPX-351)|Patients receive tazemetostat PO BID on days -1 to 6, and CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients also undergo bone marrow aspiration and biopsy and blood sample collection during screening and on study.
62740040|NCT05627232|EXPERIMENTAL|Part II (palbociclib, CPX-351)|Patients receive palbociclib PO QD on days -3 to -1, and CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients also undergo bone marrow aspiration and biopsy and blood sample collection during screening and on study.
62740041|NCT06660693|ACTIVE_COMPARATOR|Upadacitinib (treatment arm)|Participants will receive Upadacitinib 45mg daily, once a day, for at least five days.
62740042|NCT06660693|NO_INTERVENTION|Infliximab (standard care)|Participants will receive standard care, which is Infliximab.
62740043|NCT05962645|EXPERIMENTAL|Group A|Healthy Participants (HP)
62740044|NCT05962645|EXPERIMENTAL|Group B|Participants with COPD
62175129|NCT02990364|ACTIVE_COMPARATOR|EMLA + Sucrose + Ring Block|"Ring block will be done with 1% lidocaine without epinephrine injected in a band around the penis halfway along the shaft. Ten minutes prior to circumcision, the newborn will be placed in the circumcision mold with the legs restrained, and attached to a monitor. A total of 2 mg/kg of 1% lidocaine without epinephrine will be used to perform the ring block and will be injected in a band around the penis. The block will be done by the circumciser.~In combination with the ring block, EMLA + sucrose will be given during the circumcision."
62550888|NCT04196881|EXPERIMENTAL|Training|group will receive training about ADHD
62550889|NCT04196881|NO_INTERVENTION|Control|group will not receive training about ADHD
62550890|NCT04238650|EXPERIMENTAL|MB02 (Bevacizumab Biosimilar)|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
62740045|NCT03935672|OTHER|All trial participants|"Baseline plasma and saliva tests for future translational analysis~Baseline planning FDG PET CT scan~Patients will start their 6 weeks of CCRT within two to three weeks following the planning scans. Cisplatin chemotherapy will be administered. 33 daily fractions of radiotherapy will be delivered over 6 weeks.~A second FDG-PET-CT scan (iPET) and repeat plasma and saliva tests will be carried out after 2 weeks of CCRT (on RT days 9 - 12) and the iPET assessed for residual FDG-avid disease. The biological GTV will be re-outlined based on the residual avid region of the tumour on the second PET-CT (bGTV_iP)~At the end of treatment, plasma and saliva tests will be carried out at 4 weeks post treatment and again at the 3 month post-treatment PET-CT~Swallowing and QoL assessments will be repeated 4 weeks (+/- 2 weeks) after treatment and will be repeated at 6, 12 and 24 months post-treatment. The plasma and saliva samples will be repeated at 12 and 24 months"
62740046|NCT03302884|EXPERIMENTAL|Biological sampling in ovarian carcinoma|Blood and tumor samples
62740047|NCT06661577||Healthy volunteers|Male and female healthy volunteers, aged 18 years or over, attending a study specific skin check appointment, without a diagnosis or histology of malignancies.
62550891|NCT04238650|ACTIVE_COMPARATOR|EU approved Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
62550892|NCT00792961|EXPERIMENTAL|Endomicroscopy|Endomicroscopy is performed in addition to the patient's indicated robot-assisted prostate surgery
62550893|NCT03685214|EXPERIMENTAL|0.9% saline|We use 0.9% saline for resuscitation fluid in ICU septic patients
62550894|NCT03685214|EXPERIMENTAL|Balanced Crystalloids|We use acetated Ringer's solution for resuscitation fluid in ICU septic patients
62740048|NCT06661577||SOC Patients|Participants attending a standard of care medical appointment at a skin clinic, a plastic surgery or a general practitioner for assessment, diagnosis and/or potential excision of a skin condition, With confirmatory medical practitioner diagnosis, and where appropriate confirmatory histological analysis of excised tissues
62550895|NCT01439256|EXPERIMENTAL|Computer Controlled Telephone Counseling|This arm intervenes with subjects and their treating physicians. The intervention is periodic medical adherence promotion counseling for subjects regarding their prescribed HTN medications through a computer-controlled telephone counseling program that has data on subject's recent BP values and their prescribed HTN medications. The subjects' treating physicians receive at regularly scheduled office visits information about subject's recent BP and medication adherence for each prescribed medication and also get physician information and management recommendations
62740049|NCT01545934|NO_INTERVENTION|Standard Care|
62740050|NCT01545934|EXPERIMENTAL|Lifestyle intervention|
62740051|NCT05647837|EXPERIMENTAL|patients wit IIH|"patient that complains of symptoms of chronic increase intracranial pressure especially visual with absent of organic cause through visual assessment, routine laboratory investigation and brain imaging.~these patients will undergo lumper puncture to assess CSF opening pressure and Neurofilament Light Chain (NFL) and HYpoxia Induced Factor (HIF) both in CSF and blood."
62175130|NCT02990364|ACTIVE_COMPARATOR|EMLA + Sucrose + DPNB|"Dorsal penile nerve block (DPNB) will be done with 1% lidocaine without epinephrine injected at two sites at the base of the penis (2 and 10 o'clock). Ten minutes prior to circumcision, the newborn will be placed in the circumcision mold with legs restrained, and attached to a monitor. A total of 2 mg/kg of 1% lidocaine without epinephrine will be used to perform the block, and equal aliquots in milliliters will be injected at the two sites at the base of the penis. The block will be done by the circumciser.~In combination with the DPNB, EMLA + sucrose will be given during the circumcision."
62550896|NCT01439256|NO_INTERVENTION|Usual Care|In this arm, patients with hypertension that is not adequately controlled receive usual care from their physicians. Usual care is defined as receiving regular care from the physician and no additional care or intervention from the study.
62550897|NCT03322644|EXPERIMENTAL|Internet-based CBT intervention|In addition to standard medical care, participants in the Internet-based CBT group will receive access to the Pancreatitis Pain Course and will be asked to complete all online modules over 2 months using their own smartphone or computer. A coach will guide participants through the weekly lessons.
62740052|NCT01604577|ACTIVE_COMPARATOR|interactive educational intervention|Physicians will use an interactive educational worksheet during the standard-of-care clinic visit.
62740053|NCT01604577|NO_INTERVENTION|control group|Physicians will conduct the standard-of-care clinic visit as usual.
62740054|NCT06382870|EXPERIMENTAL|education group|Firstly sociodemographic and pre-test scale will be applied to all nurses who meet the inclusion criteria. The simulation scenario will be applied on the second day of the research. The scenario, prepared using the literature on child abuse, takes 10 minutes. In the scenario, there will be a staff nurse, a charge nurse, a child skills model, and a facilitator researcher in the role of the mother.The other two researchers, as independent observers, will monitor the achievement of the scenario objectives from the checklists.
62740055|NCT04473274|EXPERIMENTAL|Pioglitazone group|Participants will receive pioglitazone 15mg to 30mg daily oral or enteral during hospitalization for up to 30 days in addition to standard of care
62740056|NCT04473274|NO_INTERVENTION|Matching cohort group|Participants will standard of care
62740057|NCT01741233|EXPERIMENTAL|UV-B irraditation|VitDgen
62740058|NCT06660797|ACTIVE_COMPARATOR|• Group 1: Manual dynamic agitation by matching gutta-percha master cones|matching gutta-percha master cones will be used in up and down motion 2mm amplitude at a frequency of 100 strokes during approximately 1 min in each prepared canal.
62740059|NCT06660797|ACTIVE_COMPARATOR|Group 3: Easy Clean system activation|EC instrument coupled to the countrangle handpiece and operated with a micromotor at approximately 20,000 rotations per minute in continuous rotation.
62175131|NCT06347029|EXPERIMENTAL|Chronic kidney disease at stage G3a|Renal clearance according to CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) between 60 and 45 ml/min/1.73m²
62175132|NCT06347029|EXPERIMENTAL|Chronic kidney disease at stage G3b|Renal clearance according to CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) between 45 and 30 ml/min/1.73m²
62550898|NCT03322644|NO_INTERVENTION|Wait list control group|Participants assigned to the Wait list control group will be asked to continue with any recommendations made by their clinic provider and will not be offered any internet-based content until after they complete the 5 month assessments (i.e. Months 5-7).
62550899|NCT04043455|EXPERIMENTAL|Olorinab low dose (Main Study)|
62550900|NCT04043455|EXPERIMENTAL|Olorinab medium dose (Main Study)|
62550901|NCT04043455|EXPERIMENTAL|Olorinab high dose (Main Study)|
62550902|NCT04043455|PLACEBO_COMPARATOR|Placebo (Main Study)|
62550903|NCT04043455|EXPERIMENTAL|Olorinab (Long-Term Extension)|Participants will receive olorinab based on their treatment assignment in the Main Study.
62550904|NCT03742193|EXPERIMENTAL|Apatinib + GD group|Apatinib + GD regimen. For unilateral metastases,3 cycles before metastasectomy, and 4 cycles after. For bilateral metastases, 3 cycles before first metastasectomy, 1 cycle inbetween, and then second metastasectomy followed by 4 cycles. Apatinib monotherapy is then maintained until 1 year following complete resection.
62740060|NCT06660797|ACTIVE_COMPARATOR|Group 2: XP-endo Finisher activation|XP-endo Finisher used in continuous rotation for 1 minute accompanied with in-and-out movements of approximately 7-mm amplitude will be applied to the instrument according to the manufacturer's recommendations⁸
62740061|NCT00540657|EXPERIMENTAL|1|
62740062|NCT00540657|PLACEBO_COMPARATOR|2|
62740063|NCT06539338|EXPERIMENTAL|INT2104 Dose Level 1|Single IV administration of INT2104
62740064|NCT06539338|EXPERIMENTAL|INT2104 Dose Level 2|Single IV administration of INT2104
62550905|NCT05628649|EXPERIMENTAL|Intervention|Participants in the intervention group will gather together in a 2-hour group setting once a week for the first 16 week intensive, then change to a once a month 2-hour gathering for the remaining 8 months of boosters of the intervention. Follow-up will occur 6 months after the final intervention class to assess long-term changes. The total time span of the study will be 18 months.
62550906|NCT05628649|NO_INTERVENTION|Control|The control group follows clinical care in the usual standard (i.e. continuing to receive usual care from one's primary care physician)
62550907|NCT00781807|EXPERIMENTAL|1|The prospective intervention group with nutrition management, home-based bicycle ergometer training program and psychosocial support
62740065|NCT06539338|EXPERIMENTAL|INT2104 Dose Level 3|Single IV administration of INT2104
62740066|NCT06539338|EXPERIMENTAL|INT2104 Recommended Dose|Single IV administration of INT2104
62740067|NCT06411327|NO_INTERVENTION|Control Arm|AHA Pocket Reference Card - all participants will have access to the AHA pocket reference card, which is the mostly commonly used cognitive aid during resuscitation.
62740068|NCT06411327|EXPERIMENTAL|Augmented Reality Only|Augmented Reality Devices - data collected from the Guiding-Pad app will be fed to two AR devices (i.e. team leader and medication nurse), which will provide role-specific decision support for these two providers.
62740069|NCT06411327|EXPERIMENTAL|LCD Screen Only|LCD Screen - data collected from the Guiding-Pad app will be fed to the LCD screen, which will be mounted on a wall, in clear view for the entire resuscitation team to see.
62740070|NCT06411327|EXPERIMENTAL|Augmented Reality + LCD Screen (Full InterFACE-AR System)|InterFACE-AR System - data collected from the Guiding-Pad app will be fed to the two AR devices (i.e. team leader and medication nurse) to provide role-specific decision support, and to the LCD screen, in clear view for the entire resuscitation team to see.
62740071|NCT06660719|EXPERIMENTAL|SP-8203|SP-8203 80 mg (40 mg/dose twice a day for three days)
62740072|NCT06660719|PLACEBO_COMPARATOR|Placebo|Placebo group: twice a day for three days
62740073|NCT00780143|EXPERIMENTAL|Arm 1|Plitidepsin in combination with Cytarabine
62740074|NCT06660303|EXPERIMENTAL|Study group|Patients who will receive comprehensive preoperative education tailored to their upcoming colorectal surgery. This education covers what to expect during the surgical process, postoperative care, pain management strategies, and guidelines to aid faster recovery.
62740075|NCT06660303|ACTIVE_COMPARATOR|Control Group|Participants which will receive routine hospital care. This means that participants in this group will go through the standard preoperative and postoperative procedures typically provided at the hospital without any additional specialized preoperative education or targeted nursing instructions
62740076|NCT05243121||Clinically symptomatic patients|Clinically symptomatic patients (defined as palpable masses, nipple discharge, asymmetric thickening or nodules, and abnormal skin changes according to the guidelines) should be examined by BMRI at the judgment of the clinician.
62740077|NCT04233398|EXPERIMENTAL|Test group HIFU treatment|Patients in the test group (120) will be treated with high intensity focused ultrasound (HIFU). The primary objective of this clinical trial is to evaluate the efficacy of the test device in the treatment of benign thyroid nodules, and the secondary objective is to evaluate the safety of the test device in the treatment of benign thyroid nodules and the improvement of symptoms (VAS score).
62175133|NCT06347029|EXPERIMENTAL|Chronic kidney disease at stage G4|Renal clearance according to CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) between 30 and 15 ml/min/1.73m²
62175134|NCT06347029|EXPERIMENTAL|Chronic kidney disease at stage G5 not dialyzed|Renal clearance according to CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) less than 15 ml/min/1.73m² but not dialyzed
62550908|NCT01832571|EXPERIMENTAL|Once daily Truvada®|One tablet of Truvada (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) daily
62550909|NCT03584087|PLACEBO_COMPARATOR|TG 0 (0Hr)|TG0 will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly in place of Terlipressin therapy after EVL.
62550910|NCT03584087|ACTIVE_COMPARATOR|TG 2 (48Hr)|TG2 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 48 hours after EVL .
62550911|NCT03584087|ACTIVE_COMPARATOR|TG 5 (120Hr)|TG5 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 120 hours after EVL .
62550912|NCT04555317|NO_INTERVENTION|Standard of Care|No intervention. Standard of care cancer pathway followed.
62550913|NCT04555317|ACTIVE_COMPARATOR|Musculoskeletal Health Package|3 month prehabilitation exercise program during radiotherapy and assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))
62550914|NCT03404674|EXPERIMENTAL|Group A1: CssBA 5 ug|Participants received an intramuscular injection of 5 ug CssBA on days 1, 22, and 43.
62740078|NCT04233398|NO_INTERVENTION|Control group|Patients in the control group (120) will be actively observed and followed up. The primary objective of this clinical trial is to evaluate the efficacy of the test device in the treatment of benign thyroid nodules, and the secondary objective is to evaluate the safety of the test device in the treatment of benign thyroid nodules and the improvement of symptoms (VAS score).
62740079|NCT01377909|EXPERIMENTAL|statin|
62175135|NCT06347029|EXPERIMENTAL|Chronic kidney disease at stage G5 with dialyze|Patients who undergo dialyze
62175136|NCT06347029|ACTIVE_COMPARATOR|Control|Healthy volunteer patient, without existing kidney disease
62550915|NCT03404674|EXPERIMENTAL|Group A2: DmLT 100 ng|Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.
62740080|NCT04908384|EXPERIMENTAL|IMPACT Intervention|IMPACT health application and wearable device
62740081|NCT04908384|NO_INTERVENTION|Usual care control|Usual care control.
62740082|NCT04299503|ACTIVE_COMPARATOR|Crisaborole|ointment applied topically in the morning and in the evening
62740083|NCT04299503|PLACEBO_COMPARATOR|Placebo|ointment applied topically in the morning and in the evening
62740084|NCT04004221|EXPERIMENTAL|Tislelizumab|200mg intravenously (IV) every 3 weeks(Q3W)
62740085|NCT05223179|EXPERIMENTAL|CODA-VAX H1N1|Live Attenuated Vaccine administered by Intramuscular Injection
62740086|NCT05223179|ACTIVE_COMPARATOR|Flucelvax Quad|Licensed Injectable Seasonal Influenza Vaccine
62740087|NCT05223179|PLACEBO_COMPARATOR|Saline|Normal Sterile Saline for Intramuscular Injection
62740088|NCT04000607|EXPERIMENTAL|Edwards APTURE transcatheter shunt system|
62550916|NCT03404674|EXPERIMENTAL|Group B: CssBA 5 ug + DmLT 100 ng|Participants received an intramuscular injection of 5 ug CssBA + 100 ng dmLT on days 1, 22, and 43.
62740089|NCT03707990|EXPERIMENTAL|NNC0165-1875|Participants will receive NNC0165-1875 alone in cohorts 1-5 (part 1) and NNC0165-1875 along with semaglutide in cohorts 6-11 (part 2).
62740090|NCT03707990|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo alone in cohorts 1-5 (part 1) and placebo along with semaglutide in cohorts 6-11 (part 2).
62740091|NCT02402205|EXPERIMENTAL|Web Implementation of TF-CBT|"Web implementation (W)provides only web-based (distance learning) training and consultation to mental health therapists providing TF-CBT treatment to adjudicated youth in RTF. Therapists access the initial 10 hour training course(www.musc.edu/tfcbt) and follow-up consultation (www.musc.edu/tfcbtconsult) at their own convenience and as needed during the course of the study, with RTF administrators guaranteeing that therapists have time to do so. This implementation strategy is free and more convenient to therapists and administrators as it can be accessed whenever desired."
62740092|NCT02402205|EXPERIMENTAL|Web + Live Implementation of TF-CBT|"Web + Live (W+L) implementation provides web-based training and consultation as described in W, and also provides 1) face-to-face training and 2) twice monthly phone consultation with an expert TF-CBT trainer. W+L requires greater resource commitment from therapists and administrators and is less convenient, but provides more specific consultation on the therapists' personal TF-CBT treatment cases."
62740093|NCT06166459|EXPERIMENTAL|Yao technique|The following 2 treatment strategies are available. (1) DCB combined with provisional DES implantation 1-2 mm distally to the lesion ostium whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the lesion ostium followed by DCB (DES+DCB strategy).
62740094|NCT06504459|EXPERIMENTAL|Treatment (venetoclax, cladribine, cytarabine, azacitidine)|See Detailed Description
62740095|NCT04183504|EXPERIMENTAL|Early Steps Coaching|Coaching session on positive parenting practices and promoting child development.
62740096|NCT00744380|ACTIVE_COMPARATOR|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4) as other sedatives are down titrated. Daily awakenings are used.
62740097|NCT00744380|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)as other sedatives are down titrated. Daily awakenings are used.
62740098|NCT02360670|PLACEBO_COMPARATOR|Control imaging (NCCT)|Standard imaging
62740099|NCT02360670|EXPERIMENTAL|additional multimodal imaging|CT + CTA + CTP
62740100|NCT02492191|ACTIVE_COMPARATOR|RAPP, e- assessed follow-up|"A mobile application (app) is installed on each patient's own smartphone. The app includes the Swedish web version of the QoR (SwQoR). After a patient is discharged from the day-surgery department, the patients in the intervention group will answer the RAPP daily for 14 days. His or her smartphone will initiate the postoperative recovery measurements daily through a push function. Each question will appear separately on the mobile phone screen and will disappear from the screen immediately after a response is given. The app also contains a question asking if the patient wants to be contacted by a nurse, which they will answer with a YES or NO. If YES, a nurse at the day surgery department will contact the patient and offer further information and assistance. The number of contacts and the reasons for contact requests will be documented."
62740101|NCT02492191|NO_INTERVENTION|Control|The control group will receive standard care; i.e., no follow-up
62740102|NCT02680041|EXPERIMENTAL|18F-fluciclovine PET CT|Single intravenous administration of 18F-fluciclovine PET CT.
62740103|NCT04907305||Feed-forward PRO|Participants in this group will participate in monthly learning collaborative webinars. Feed-forward of patient reported outcomes (PRO) data collected from the main study (NCT04735406) will be used.
62740104|NCT04907305||Control Group (Usual Care)|Participants in the control group will receive usual care practices during the clinical encounters.
62740105|NCT03702569||Patients needing a volume expansion|
62740106|NCT05292924|EXPERIMENTAL|Early SSC|Cesarean delivery and SSC within the first 30 minutes of birth
62740107|NCT05292924|NO_INTERVENTION|Control|Cesarean delivery and SSC one hour after birth
62175137|NCT02151578|NO_INTERVENTION|nothing at home level|No intervention at community level. The study drugs (arthemeter/Lumefantrine and Cotrimoxazole) available at the health facility drug stores level and prescribed exclusively to sick children attending to the health facility for care seeking. No Community Heath Worker /Key Opinion leader (CHWs/KOLs) selected in those clusters
62740108|NCT01794208|EXPERIMENTAL|treatment 1|Follitropin Epsilon 52.5 IU quaque die (QD) s.c.
62740109|NCT01794208|EXPERIMENTAL|treatment 2|Follitropin Epsilon 75 IU QD s.c.
62740110|NCT01794208|EXPERIMENTAL|treatment 3|Follitropin Epsilon 112.5 IU QD s.c.
62740111|NCT01794208|EXPERIMENTAL|treatment 4|Follitropin Epsilon 150 IU QD s.c.
62740112|NCT01794208|EXPERIMENTAL|treatment 5|Follitropin Epsilon 150 IU quaque altera die (QAD) s.c.
62740113|NCT01794208|ACTIVE_COMPARATOR|treatment 6|Follitropin alfa 150 IU QD s.c.
62550917|NCT03404674|EXPERIMENTAL|Group C: CssBA 5 ug + DmLT 500 ng|Participants received an intramuscular injection of 5 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
62550918|NCT03404674|EXPERIMENTAL|Group D: CssBA 15 ug + DmLT 500 ng|Participants received an intramuscular injection of 15 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
62550919|NCT03404674|EXPERIMENTAL|Group E: CssBA 45 ug + DmLT 500 ng|Participants received an intramuscular injection of 45 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
62550920|NCT02825771|EXPERIMENTAL|Usual Care + Caring Contacts messages|Usual care services plus caring contacts messages
62550921|NCT02825771|ACTIVE_COMPARATOR|Usual Care|Usual care services provided in that community following identification of suicidal ideation or behavior.
62550922|NCT01872923|EXPERIMENTAL|Amphinex based PCI of bleomycin|The photosensitiser Amphinex is activated by Laser to enhance the effect of Bleomycin
62550923|NCT04650217|ACTIVE_COMPARATOR|L-DOPA + Exercise|N=20 subjects assigned to L-DOPA + Exercise will receive L-DOPA three times daily for up to 450mg (L-DOPA) and also will receive exercise training 4 times a week (exercise)
62550924|NCT04650217|ACTIVE_COMPARATOR|LDOPA + Control|N=20 subjects assigned to L-DOPA + Control will receive L-DOPA three times daily for up to 450mg (L-DOPA) and also will receive a stretching and toning regime (Control).
62550925|NCT04650217|PLACEBO_COMPARATOR|Placebo + Exercise|N=20 subjects assigned to Placebo + Exercise will receive placebo three times daily and also will receive exercise training 4 times a week (exercise).
62550926|NCT04650217|PLACEBO_COMPARATOR|Placebo + Control|N=20 subjects assigned to Placebo + Control will receive placebo three times daily and also will receive a stretching and toning regime (Control).
62550927|NCT04122040|ACTIVE_COMPARATOR|roxithromycin|roxithromycin 300 mg oral per day
62550928|NCT04122040|PLACEBO_COMPARATOR|placebo|placebo one tablet per day
62550929|NCT00346983|EXPERIMENTAL|A|
62550930|NCT00346983|PLACEBO_COMPARATOR|B|
62550931|NCT01531517|EXPERIMENTAL|Pedyphar|Ointment
62550932|NCT01531517|ACTIVE_COMPARATOR|Panthenol|Ointment
62550933|NCT01163864|EXPERIMENTAL|affect regulation training|
62550934|NCT01163864|ACTIVE_COMPARATOR|health and lifestyle|
62550935|NCT05561725|ACTIVE_COMPARATOR|Standard of Care: Control|"Patients will be screened for participation following indication for surgery by the treating surgeon and/or research assistant. Patients who elect to participate will then be randomized into either the dexamethasone or control groups.~Patients in the control group will receive one 8mg dose of dexamethasone intraoperatively as per standard of care anesthesia protocols. No sham medication will be utilized for control subjects."
62550936|NCT05561725|EXPERIMENTAL|Dexamethasone|"Patients will be screened for participation following indication for surgery by the treating surgeon and/or research assistant. Patients who elect to participate will then be randomized into either the dexamethasone or control groups.~Patients randomized to the dexamethasone cohort will be administered 8 mg of dexamethasone with 3 additional (8mg doses) administered at 8-hour intervals following surgery for a total of 4 doses."
62550937|NCT04994405|NO_INTERVENTION|Standard Pressure|The extremity tourniquet used during hand surgery for these participants will be the standard pressure of 250 mmHg.
62550938|NCT04994405|EXPERIMENTAL|Lower Tiered Pressures|The study intervention is the inflation of the extremity tourniquet to a pressure lower than the standard pressure of 250 mmHg during hand surgery for these participants determined by tiered guidelines based on systolic blood pressure (SBP).
62550939|NCT04500717|ACTIVE_COMPARATOR|Almonertinib 110mg PO once daily|Almonertinib 110mg PO once daily.
62550940|NCT04500717|EXPERIMENTAL|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
62550941|NCT00931645|NO_INTERVENTION|Complete responders|watch and wait policy
62550942|NCT00931645|EXPERIMENTAL|arm 2: complete responders patients|ABMT : TBI, 10 grays d-3-1 \& cyclophosphamide 60 mg/sqm d-5-4
62550943|NCT00931645|EXPERIMENTAL|Non CR patients arm 3|Rescue chemotherapy and ABMT (see arm 2)
62550944|NCT00931645|ACTIVE_COMPARATOR|Non CR patients at random : arm 4|Rescue DHAP, F+C
62740114|NCT06236087||Aim 1 & 2 - Dataset|"For Aims 1 and 2, an existing, de-identified dataset will be used for secondary analysis, including records for a maximum of 500 individuals.~Aim 1 will use machine learning to identify sub-groups for whom OPC use is most and least protective of overdose risk. Identifying key intersectional groups across demographic (e.g., race/ethnicity, gender, and age), PSU factors (e.g., drug types and routes of administration), and socio-behavioral (e.g., mental health history, justice history, and homelessness) characteristics will inform targeted service delivery. Aim 2 will use epidemiological methods to estimate the association of OPC use with mental health services salient to PSU populations (e.g., hospitalization for depression, anxiety, and bipolar disorder). Measuring the association of OPC use with treated mental health outcomes for PSU-involved populations will foster an understanding of the impacts of OPCs on critical but unevaluated outcomes."
62740115|NCT06236087||Aim 3 - Harm Reduction Staff|For Aim 3, individuals employed at harm reduction programs in NYC will be enrolled for a one-time qualitative interview. Qualitative interviews will explore organizational (i.e., readiness, culture, and priorities), individual (i.e., attitudes and norms), and intervention (i.e., complexity and advantage) characteristics related to the integration of mental health and harm reduction services. Findings will inform efforts to scale ancillary mental health services high-risk PSU population.
62740116|NCT06036355|EXPERIMENTAL|Orally take NMN (Vital NAD) combined with DC cell vaccine injection|The arm is a combination of two drugs. The first NMN is a precursor of NAD+, which is used orally. DC vaccine is a kind of immune cells expanded in vitro and used by injection.
62740117|NCT02061072||Population pharmacokinetic estimation|Patients with severe or moderate hemophilia A or B, providing sparse data for population PK estimation
62740118|NCT06621732|EXPERIMENTAL|Mitochondrial disease|
62740119|NCT03122808||Neonatal encephalopathy|"The inclusion criteria will be:~* Moderate or severe neonatal encephalopathy~* Gestational age of 35+0 weeks or greater~* Singleton pregnancy~* Inborn~The exclusion criteria will be:~* Non-hypoxic-ischaemic aetiology or postnatal hypoxic-ischaemia~* Major congenital abnormalities~* Less than 15 minutes of digital CTG recording from labour available"
62740120|NCT03122808||Control|"The inclusion criteria will be:~* Gestational age of 35+0 weeks or greater~* Singleton pregnancy~* Inborn~The exclusion criteria will be:~* APGAR score of less than 5 at 1 minute or less than 7 at 5 or 10 minutes~* Admission to the neonatal unit~* Major congenital abnormalities~* Less than 15 minutes of digital CTG recording from labour available"
62740121|NCT05517980|EXPERIMENTAL|IgAN Cohort Stage 1 Dose 1|Participants will be randomized to receive weekly or biweekly maintenance doses of KP104 at Dose 1. Participants in Stage 1 will also have the opportunity to be switched to the OBD if they are still in the treatment period.
62740122|NCT05517980|EXPERIMENTAL|C3G Cohort Stage 1 Dose 1|Participants will be randomized to receive weekly or biweekly maintenance doses of KP104 at Dose 1. Participants in Stage 1 will also have the opportunity to be switched to the OBD if they are still in the treatment period.
62550945|NCT05864989|EXPERIMENTAL|NIPSA in deep supra-alveolar defects without connective tissue graft|
62550946|NCT05864989|ACTIVE_COMPARATOR|NIPSA in deep supra-alveolar defects with connective tissue graft|
62550947|NCT04063215|EXPERIMENTAL|HB-adMSC|HB-adMSCs will be infused three times over a six week period, spaced 14 days apart
62740123|NCT05517980|EXPERIMENTAL|IgAN Cohort Stage 1 Dose 2|Participants will be randomized to receive weekly or biweekly maintenance doses of KP104 at Dose 2. Participants in Stage 1 will also have the opportunity to be switched to the OBD if they are still in the treatment period.
62740124|NCT05517980|EXPERIMENTAL|C3G Cohort Stage 1 Dose 2|Participants will be randomized to receive weekly or biweekly maintenance doses of KP104 at Dose 2. Participants in Stage 1 will also have the opportunity to be switched to the OBD if they are still in the treatment period.
62740125|NCT05517980|EXPERIMENTAL|IgAN Cohort Stage 2|Participants will receive weekly or biweekly maintenance doses of KP104 at the OBD.
62740126|NCT05517980|EXPERIMENTAL|C3G Cohort Stage 2|Participants will receive weekly or biweekly maintenance doses of KP104 at the OBD.
62740127|NCT05804955||Training Cohort|200 MASLD patients
62740128|NCT05804955||Validation Cohort|60 MASLD patients
62740129|NCT02557776|EXPERIMENTAL|Genetic testing of BRCA1 and BRCA2|"For detailes, please see Study procedure. Women with newely diagnosed breast cancer are offered written genetic counseling and screening of mutations in BRCA1 and BRCA2."
62175138|NCT02151578|EXPERIMENTAL|Home management of malaria|"At the community level, the Community health workers/ keay opinion leader (HWs/KOLs) trained and equipped to provide the antimalarial drug (arthemeter/Lumefantrine ) to any child with fever (hot body) without any other signs of complications like impaired consciousness, convulsions, etc"
62175139|NCT02151578|EXPERIMENTAL|Home management of malaria and pneumonia|"At the community level, the Community health workers/ key opinion leader (HWs/KOLs) trained and equipped to provide the antimalarial drug (arthemeter/Lumefantrine ) or antibiotic (Cotrimoxazole) to any child with fever (hot body) without any other signs of complications like impaired consciousness, convulsions, etc. The treatment decision making for the CHWs/KOLs based on the algorithm"
62175140|NCT00578318|EXPERIMENTAL|Motivational Interviewing Active|Patients received a stepped progression of talk based treatment utilizing Motivational Interviewing as the basis.
62175141|NCT00578318|ACTIVE_COMPARATOR|Delayed Control|Patients received Treatment as usual (TAU) (i.e. no specific intervention and supportive check-ins from the study staff)
62175142|NCT02343978|EXPERIMENTAL|KWA-0711 High dose|
62175143|NCT02343978|EXPERIMENTAL|KWA-0711 Low dose|
62175144|NCT03644706|ACTIVE_COMPARATOR|ADV7103|Patients continue to receive ADV7103 twice a day at their open label dose over 6 days
62175145|NCT03644706|PLACEBO_COMPARATOR|Placebo Comparator|Patients receive matched placebo twice a day until they reach a bicarbonate level of 18mEq/L
62175146|NCT05470881|EXPERIMENTAL|PRO-201|A total of 29 anticipated healthy volunteers will be exposed to the investigation product.
62175147|NCT02201771|ACTIVE_COMPARATOR|Aspirin|aspirin 100mg tablet by mouth daily for 12 months
62175148|NCT02201771|EXPERIMENTAL|Ticagrelor plus Aspirin|ticagrelor 90mg tablet by mouth twice daily and aspirin 100mg tablet by mouth daily for 12 months
62175149|NCT02201771|EXPERIMENTAL|Ticagrelor|ticagrelor 90mg tablet by mouth twice daily for 12 months
62175150|NCT05554042||Instruments Followed By SCID|Participants will complete the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 instruments virtually. Participants will then complete a video recorded virtual Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-5.
62175151|NCT05554042||SCID Followed By Instruments|Participants will complete a video recorded virtual Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-5. Participants will then complete the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 instruments virtually.
62175152|NCT01165164|EXPERIMENTAL|FID 115958D|Lubricant eye drop
62175153|NCT00747045|EXPERIMENTAL|Low tidal volume|Tidal volume of 6 mL/Kg ideal body weight
62175154|NCT00747045|ACTIVE_COMPARATOR|Usual care|Tidal volume of 10 mL/Kg ideal body weight
62550948|NCT05944146|EXPERIMENTAL|cardiac surgery patients with thermodilution technique monitoring|
62175155|NCT01124214|NO_INTERVENTION|High Resolution endoscopy (HRE)|Standard of care, high resolution endoscopy surveillance/ evaluation of BE and or IEN
62175156|NCT01124214|ACTIVE_COMPARATOR|Endomicroscopy (EM)|Standard of care, high resolution endoscopy surveillance/ evaluation of BE and or IEN and endomicroscopy esophageal evaluation
62550949|NCT05954221|EXPERIMENTAL|Red cell lysis buffer (RCLB) group|Patients assigned to this group will receive EUS-FNB as routine. The obtained tissue will be processed with red cell lysis buffer and underwent histological evaluation.
62550950|NCT05954221|ACTIVE_COMPARATOR|conventional group|Patients assigned to this group will receive EUS-FNB as routine. The obtained tissue will be fixed with formalin as usual and underwent histological evaluation.
62550951|NCT05444894|EXPERIMENTAL|EDIT-301|EDIT-301 (autologous gene edited (CD)34+ hematopoietic stem cells) will be administered as a one-time intravenous infusion.
62550952|NCT02358512|EXPERIMENTAL|Intermittent enteral feeding|The intermittent feeding regimen will consist of six bolus feeds (one bolus every four hours).
62550953|NCT02358512|ACTIVE_COMPARATOR|Continuous enteral feeding|The continuous feeding regimen consists of the total volume of feed administered over 24 hours.
62550954|NCT03075020|ACTIVE_COMPARATOR|Active carbon monoxide|Inhalation of carbon monoxide up to a carboxyhemoglobin concentration 22%
62550955|NCT03075020|PLACEBO_COMPARATOR|Air|
62550956|NCT02413229|EXPERIMENTAL|DSXS1411|DSXS applied once a day for a total of 28 days.
62550957|NCT02413229|PLACEBO_COMPARATOR|Placebo|Placebo (vehicle) applied once a day for a total of 28 days.
62550958|NCT04970628||Study group|Patients performed airway obstruction after anterior cervical operation
62550959|NCT04970628||Control group|Patients did not perform airway obstruction after anterior cervical operation
62550960|NCT05314803|EXPERIMENTAL|Yoga|Participants receive online, group-based yoga classes 2 times/week for 60 minutes/class over 12 weeks.
62550961|NCT00165763|EXPERIMENTAL|1|
62550962|NCT02137057||control ( patients without diabetes)|patients without diabetes
62550963|NCT02137057||DM ( patients with diabetes)|patients with diabetes
62550964|NCT02368418||PCP and SRS|participants had received two interventions (PCP and SRS)
62550965|NCT02368418||PCP only|participants had received PCP intervention only
62550966|NCT02368418||SRS only|participants had received SRS intervention only
62550967|NCT02368418||control group|participants had received usual care (neither PCP nor SRS)
62550968|NCT03188744||Group 1|Patients with CC with PFMD.
62550969|NCT03188744||Group 2|Patients with CC without PFMD.
62550970|NCT03188744||Group 3|Patients without CC with PFMD.
62550971|NCT03188744||Group 4|Patients without CC without PFMD.
62550972|NCT01601340|ACTIVE_COMPARATOR|HQK-1001|
62550973|NCT01601340|PLACEBO_COMPARATOR|Placebo|
62550974|NCT03789305||Critically ill patients|Critically ill patients admitted to intensive care for more than 48 hours
62550975|NCT04708223|EXPERIMENTAL|Fast-curing composites|
62550976|NCT04708223|OTHER|Conventionally applied composites|
62550977|NCT01108718|EXPERIMENTAL|Participants: Tempur Pedic first.|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder who receive the Tempur-Pedic mattress first, then the Control Mattress.
62550978|NCT01108718|PLACEBO_COMPARATOR|Participants: Control Mattress first.|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic mattress.
62550979|NCT03196843|EXPERIMENTAL|Raltitrexed plus Radiation|Raltitrexed 2.5mg/m2, iv, every 3 weeks, concurrently with intensity modulated radiotherapy(IMRT)
62550980|NCT03196843|ACTIVE_COMPARATOR|Radiation|Intensity modulated radiotherapy(IMRT) alone radical radiotherapy:70Gy/2Gy/7 weeks preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 weeks
62550981|NCT02074007|ACTIVE_COMPARATOR|AR01 - Topical Otic Solution|"Topical ear drops~The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period"
62550982|NCT02074007|PLACEBO_COMPARATOR|Placebo Comparator|"Topical ear drops~Glycerin ear drops-The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period."
62550983|NCT04905628||Dexcom CGM System|Dexcom CGM System
62550984|NCT02211417|EXPERIMENTAL|Oral DS107 2g|Oral DS1072g, 4 x 500mg capsules administered orally once a day
62550985|NCT02211417|PLACEBO_COMPARATOR|Placebo|Placebo capsules matching Oral DS107 capsules
62550986|NCT01215474||NSCLC Stadium III-IV|
62550987|NCT00237978|ACTIVE_COMPARATOR|1|VIS and wIRA
62550988|NCT00237978|ACTIVE_COMPARATOR|2|VIS, wIRA and Adapalen
62550989|NCT00237978|ACTIVE_COMPARATOR|3|Adapalen
62550990|NCT01774162|ACTIVE_COMPARATOR|FNA for cytology|Fine needle aspiration using conventional FNA for cytology
62550991|NCT01774162|EXPERIMENTAL|FNB core biopsy for histology|Fine needle biopsy using ProCore needle for histology.
62550992|NCT06346925|EXPERIMENTAL|Treatment group A|Take Herombopag Olamine Tablets 7.5mg 30min after high-fat meal in the first cycle. in the second cycle, take Herombopag Olamine Tablets 7.5mg on an empty stomach
62550993|NCT06346925|EXPERIMENTAL|Treatment group B|Take Herombopag Olamine Tablets 7.5mg 30min on an empty stomach in the first cycle. In the second cycle, take Herombopag Olamine Tablets 7.5mg 30min fter high-fat meal
62550994|NCT01456806|NO_INTERVENTION|Patients and provider non educated|In this arm neither the patients nor the providers have attended the groupal education courses
62550995|NCT01456806|ACTIVE_COMPARATOR|Provider educated|Provider attend the interactive group education, while patients do not.
62550996|NCT01456806|ACTIVE_COMPARATOR|Patients Educated|Patients attend the interactive group education, while providers do not.
62550997|NCT01456806|ACTIVE_COMPARATOR|Providers/Patients Educated|Provider and Patients both attend the interactive group education.
62550998|NCT01224197|EXPERIMENTAL|001|TMC435 100 or 200 mg capsule one single dose
62550999|NCT01224197|EXPERIMENTAL|002|TMC435 100 or 200 mg capsule once daily for 5 days
62551000|NCT05134363|ACTIVE_COMPARATOR|Dexmedetomidine 0.5 mic/kg bolus|selective alpha 2 adrenergic receptor agonist
62551001|NCT05134363|ACTIVE_COMPARATOR|dexmedetomidine 0.75 mic/kg bllus|selective alpha 2 adrenergic receptor agonist
62551002|NCT05134363|PLACEBO_COMPARATOR|Placebo group|receving equal volume of normal saline
62551003|NCT01461915|EXPERIMENTAL|Run-in|"During the Run-In Period, patients will receive gemcitabine + nab-paclitaxel + dociparstat to assess the compatibility of the combination.~• Nab-paclitaxel + gemcitabine + dociparstat:~* Nab-paclitaxel 125 mg/m2 will be administered intravenously (IV) over 30 minutes followed by the administration of gemcitabine IV infusion at 1000 mg/m2 over 30 minutes. Nab paclitaxel + gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).~* Dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately following the completion of gemcitabine administration.~* Dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered immediately following the dociparstat IV bolus administration."
62551004|NCT01461915|EXPERIMENTAL|Arm A|"Patients randomized to Arm A will receive gemcitabine + nab-paclitaxel + dociparstat.~• Nab-paclitaxel + gemcitabine + dociparstat:~* Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes followed by the administration of gemcitabine IV infusion at 1000 mg/m2 over 30 minutes. Nab paclitaxel + gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).~* Dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately following the completion of gemcitabine administration.~* Dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered immediately following the dociparstat IV bolus administration."
62551005|NCT01461915|ACTIVE_COMPARATOR|Arm B|"Patients randomized to Arm B will receive gemcitabine + nab-paclitaxel. • Nab-paclitaxel + gemcitabine:~o Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes followed by the administration of gemcitabine IV infusion at 1000 mg/m2 over 30 minutes. Nab paclitaxel + gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle)."
62740130|NCT06251375|EXPERIMENTAL|Dexmedetomidine Intervention|"Patients randomized to the experimental arm will receive dexmedetomidine. The study medication will be reconstituted by mixing 4 vials (8 ml) into a 100 ml bag of normal saline or 5% dextrose, this is the preferred dilution, or 2 vials (4ml) into 50 ml syringe to an equivalent concentration of 8 mcg/ml of dexmedetomidine. The constituted infusion is stable at room temperature for up to 24 hours.~The recommended starting infusion rate is equivalent to 1 µg/kg/h of dexmedetomidine, without loading or bolus. This will be titrated to an equivalent dexmedetomidine dose of 0 to 1.0 µg/kg/h according to study algorithm to maintain target sedation of Richmond Agitation-Sedation Scale (RASS) score of -1 to +1."
62740131|NCT06251375|PLACEBO_COMPARATOR|Control Intervention|Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. The placebo is a matching vial containing 2 mL sterile normal saline.
62740132|NCT06405607|EXPERIMENTAL|Psilocybin Group (Arm 1)|receives individual psychotherapy sessions plus a (30 mg) psilocybin session.
62740133|NCT06405607|ACTIVE_COMPARATOR|Ketamine Group (Arm 2)|receives individual psychotherapy sessions plus a (0.75 mg/kg) ketamine session
62740134|NCT00937742|EXPERIMENTAL|Non-tomato products|Non-tomato products (i.e. teriyaki marinade, sprite, applesauce) to be consumed daily in replace of tomato products
62740135|NCT00097227|ACTIVE_COMPARATOR|Arm A (3-week cycle)|"Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~Paclitaxel 225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks.~Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks."
62740136|NCT00097227|ACTIVE_COMPARATOR|Arm B (4-week cycle)|"Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~Paclitaxel 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.~Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks."
62740137|NCT01937663|EXPERIMENTAL|KWA-0711 Dose1|
62740138|NCT01937663|EXPERIMENTAL|KWA-0711 Dose2|
62740139|NCT01937663|EXPERIMENTAL|KWA-0711 Dose3|
62740140|NCT01937663|EXPERIMENTAL|KWA-0711 Dose4|
62740141|NCT03929952|EXPERIMENTAL|Chronic low back pain|
62740142|NCT02621541|EXPERIMENTAL|Preoperative diagnosis|Preoperative diagnosis
62740143|NCT05285215|EXPERIMENTAL|Integrated psychological program (IPP) group|Patients are assigned to have mindfulness training and music listening before and after delivery. Video counselling will be offered if patient is found to have Edinburgh Postnatal Depression Scale (EPDS) equal to or more than 10. Questionnaires on psychological and pain assessments will be administered before and after delivery, with the final time point being 2 months after delivery.
62740144|NCT05285215|NO_INTERVENTION|Non- Integrated psychological program (IPP) group|Questionnaires on psychological and pain assessments will be administered before and after delivery, with the final time point being 2 months after delivery.
62740145|NCT00750568||Group 1|"* In-patient in the Pediatric Intensive Care Unit~* Diagnosis of Status asthmaticus~* Receiving a continuous infusion of terbutaline as part of their standard of care~* Ages 2 years to 6 years"
62740146|NCT00750568||Group 2|"* In-patient in the Pediatric Intensive Care Unit~* Diagnosis of Status asthmaticus~* Receiving a continuous infusion of terbutaline as part of their standard of care~* Ages greater than 6 years to 12 years"
62740147|NCT00750568||Group 3|"* In-patient in the Pediatric Intensive Care Unit~* Diagnosis of Status asthmaticus~* Receiving a continuous infusion of terbutaline as part of their standard of care~* Ages greater than 12 years to 18 years"
62740148|NCT04481204|ACTIVE_COMPARATOR|Control arm GroupI(mFOLFIRINOX)|Patients receive mFOLFIRINOX for 3 months before and after surgery in the absence of disease progression or unacceptable toxicity.
62740149|NCT04481204|ACTIVE_COMPARATOR|Control arm GroupII(chemotherapy, FOLFIRINOX)|Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for up to 4 months in the absence of disease progression or unacceptable toxicity.
62740150|NCT04481204|ACTIVE_COMPARATOR|Control arm GroupIII(FOLFIRINOX, radiation therapy)|Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
62740151|NCT04481204|ACTIVE_COMPARATOR|Control arm GroupIV(chemotherapy,FOLFIRINOX,radiation therapy)|Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
62740152|NCT04481204|ACTIVE_COMPARATOR|Control arm GroupV(FOLFIRINOX, radiation therapy)|Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors
62740153|NCT04481204|ACTIVE_COMPARATOR|Control arm GroupVI(chemotherapy,FOLFIRINOX,radiation therapy)|Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors
62740154|NCT01231334|ACTIVE_COMPARATOR|Aczone® Gel 5% plus Differin® 0.3% Gel|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
62740155|NCT01231334|ACTIVE_COMPARATOR|Duac® Topical Gel plus Differin® 0.3% Gel|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks.
62551006|NCT02660905|EXPERIMENTAL|Active Treatment|E/C/F/TAF Ledipasvir-Sofosbuvir/TAF
62740156|NCT01435473||Children undergoing heart surgery|The study will follow children undergoing cardiac surgery at The Hospital for Sick Children from pre-consultation, throughout surgery, recovery and post-operative follow-up
62740157|NCT02142400|EXPERIMENTAL|DS-1093|Group 1 will receive 10mg, group 2 will receive 25mg of DS-1093
62740158|NCT02142400|PLACEBO_COMPARATOR|placebo|placebo to match DS-1093 dosage
62740159|NCT05947461|EXPERIMENTAL|diclofenac group|Patients without contraindications in diclofenac group received 100mg rectal diclofenac 30 mins before ERCP procedure.
62740160|NCT05947461|ACTIVE_COMPARATOR|Indomethacin group|Patients without contraindications in indomethacin group received 100mg rectal indomethacin 30 mins before ERCP procedure.
62551007|NCT00391560|EXPERIMENTAL|Group 1 on Perifosine|"Patients with AML, MDS, CML-BP non-lymphoid, CMML, or Agnogenic Myeloid Metaplasia (AMM).~After a one-time loading dose of 600 mg (150 mg x 4 at least 4 hours apart) during the first cycle, perifosine will be given orally at 100 mg once a day continuously. Cycles are 28 days in length.~Intra-patient dose escalation for the maintenance dose to 150 mg daily will be done in the second cycle if no non-hematological toxicities beyond grade 0-1 occurred during the first cycle are observed."
62551008|NCT00391560|EXPERIMENTAL|Group 2 on Perifosine|"Patients with CLL, ALL, or CML-BP lymphoid. After a one-time loading dose of 600 mg (150 mg x 4 at least 4 hours apart) during the first cycle, perifosine will be given orally at 100 mg once a day continuously. Cycles are 28 days in length.~Intra-patient dose escalation for the maintenance dose to 150 mg daily will be done in the second cycle if no non-hematological toxicities beyond grade 0-1 occurred during the first cycle are observed."
62551009|NCT01342601|ACTIVE_COMPARATOR|Ectoin products|
62551010|NCT01342601|PLACEBO_COMPARATOR|Placebo products|
62551011|NCT03869944|EXPERIMENTAL|Intervention|Lamivudine Oral Solution
62551012|NCT04348201|ACTIVE_COMPARATOR|foot reflexology|foot reflexology session which takes about 20 minutes.
62551013|NCT04348201|ACTIVE_COMPARATOR|dietary modification|diet must be rich in vitamins.
62551014|NCT01068548|NO_INTERVENTION|Arm 1|pre-implementation of computer based intervention
62551015|NCT01068548|EXPERIMENTAL|Arm 2|post-implementation of computer based length of stay clinical reminder
62551016|NCT06583018|EXPERIMENTAL|Brief and Blended Mindfulness-based Lifestyle counselling programme (B-Mindful-Life)|"(i) In-Person Mindfulness-based Group Session: A 3-hour group-based session in week 1 focused on experiential mindfulness practices. Participants will enhance their self-awareness of positive, neutral, and negative body sensations, feelings, and thoughts while engaging in healthy behaviors, particularly physical activity.~(ii) Ecological Momentary Interventions (EMI): Personalized mindfulness-based lifestyle counseling delivered through instant messages, with chat-based support throughout the 8-week intervention period.~(iii) Activity Monitoring: All participants will wear an accelerometer-based wristband activity tracker to monitor their physical activity in daily life."
62551017|NCT06583018|ACTIVE_COMPARATOR|Brief lifestyle education|"(i) In-person Group Session: A 3-hour group-based session in week 1 focused on general education on lifestyle modification.~(ii) Activity Monitoring: All participants will wear an accelerometer-based wristband activity tracker to monitor their physical activity in daily life."
62551018|NCT02685735|ACTIVE_COMPARATOR|Gabapentin|Subjects will be randomized, stratifying for norepinephrine serotonin reuptake inhibitor (NSRI) use, to equal number to receive gabapentin or placebo pills. Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
62551019|NCT02685735|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized, stratifying for norepinephrine serotonin reuptake inhibitor (NSRI) use, to equal number to receive gabapentin or placebo pills. Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards.
62551020|NCT02977819|EXPERIMENTAL|Meditation program|Meditation courses and at-home practice
62551021|NCT02977819|ACTIVE_COMPARATOR|English learning courses|English learning courses and at-home practice
62551022|NCT02977819|NO_INTERVENTION|No intervention|Follow-up without Meditation courses or English Learning courses
62551023|NCT02103855|EXPERIMENTAL|belatacept|"Belatacept 5 mg/kg IVPB q 2 wks x 5 doses followed by 5 mg/kg IVPB q month. The belatacept dose will be infused IV over 30 minutes.~Day 14: Reduce tacrolimus dose by 25% Day 30: Reduce tacrolimus dose by additional 25% Day 45: Reduce tacrolimus dose by additional 25% Day 60: Stop tacrolimus."
62551024|NCT03426189||HIV infected individuals on long term ART|"* Leukapheresis~* Lymph node biopsy"
62551025|NCT03771287|EXPERIMENTAL|OpenSound Navigator (OSN) Hearing Aid|Participants will be fit with Oticon OPN™ behind-the-ear hearing aids with the OpenSound Navigator algorithm enabled. Participants are to use the hearing aids at least an average of 8 hours per day over the course of 6-8 months.
62551026|NCT03771287|ACTIVE_COMPARATOR|omni-directional Hearing Aid|Participants will be fit with Oticon OPN™ behind-the-ear hearing aids with the Omni-directional microphone system enabled. Participants are to use the hearing aids at least an average of 8 hours per day over the course of 6-8 months.
62175157|NCT04237623|EXPERIMENTAL|GM-CSF post-transplant|Sargramostim (GM-CSF) will start on Day +5 and continue until ANC \>1000 x3 days or \>1500 x1 day. GM-CSF will be administered not less than 24 hours after the last dose of cyclophosphamide and will be given at a dose of 250mcg/m2/day as an infusion over 2 hours.
62551027|NCT04343131|ACTIVE_COMPARATOR|Mediterranean diet|Mediterranean diet for 7 days
62551028|NCT04343131|ACTIVE_COMPARATOR|Low-carb/high protein diet|Low-carb/high protein diet for 7 days
62551029|NCT04343131|ACTIVE_COMPARATOR|Reference diet|Reference diet for 7 days
62551030|NCT05270408|EXPERIMENTAL|Active stimulation at 1mA|Participants will receive 1 mA active HD-tDCS for 20 minutes.
62551031|NCT05270408|EXPERIMENTAL|Active stimulation at 2mA|Participants will receive 2 mA active HD-tDCS for 20 minutes.
62551032|NCT05270408|SHAM_COMPARATOR|Sham group|Participants will receive sham HD-tDCS for 20 minutes, meaning no stimulation.
62551033|NCT05300750|EXPERIMENTAL|Oral Fluid|The oral fluid intake was in form of peppermint or anise
62551034|NCT05300750|EXPERIMENTAL|Chewing Gum|Free sugar gum
62551035|NCT05300750|NO_INTERVENTION|Standard hospital care|Control group
62551036|NCT00461253||1|Breast Cancer Cases
62551037|NCT00461253||2|Matched Controls for Breast Cancer Cases
62551038|NCT03629184|EXPERIMENTAL|Baloxavir Marboxil|Participants will receive a single oral dose of baloxavir marboxil on Day 1 (based on body weight). Oseltamivir matching placebo will also be administered orally twice daily (BID) for 5 days.
62551039|NCT03629184|ACTIVE_COMPARATOR|Oseltamivir|Participants will receive oseltamivir orally BID for 5 days (based on body weight). Baloxavir marboxil matching placebo will also be administered orally on Day 1
62551040|NCT04671121|ACTIVE_COMPARATOR|Grup LP (n = 31)|CO2 insufflation pressure was kept at 8 mmHg throughout the surgery.
62551041|NCT04671121|ACTIVE_COMPARATOR|Grup SP (n = 31)|CO2 insufflation pressure was kept at 14 mmHg throughout the surgery.
62740161|NCT06660251|ACTIVE_COMPARATOR|Subjects with MetS|"Subjects with a minimum of three criteria according to NCEP-ATP III. Subjects were administered in randomized order after overnight fasting a test food. Test days were on two separate occasions around 2 weeks apart.~Egg intervention: three hard-boiled eggs. Meatball intervention: 170 g meatballs."
62551042|NCT01651793|ACTIVE_COMPARATOR|Caffeinated cocoa|High flavanol, high theobromine, high caffeine, single dose administration in hot water vehicle
62551043|NCT01651793|ACTIVE_COMPARATOR|Cocoa|High flavanol, high theobromine, low caffeine, single dose administration in hot water vehicle
62551044|NCT01651793|ACTIVE_COMPARATOR|Caffeine|Low flavanol, low theobromine, high caffeine, single dose administration in hot water vehicle
62551045|NCT01651793|PLACEBO_COMPARATOR|Placebo|No flavanol, no theobromine, no caffeine, single dose administration in hot water vehicle
62551046|NCT04505566|EXPERIMENTAL|Adult Type II Diabetics - Moderate NPDR - Ketorolac|59 Adult type II diabetic patients with baseline moderate non-proliferative diabetic retinopathy and HbA1c ≥ 8 randomized to Ketorolac treatment.
62551047|NCT04505566|PLACEBO_COMPARATOR|Adult Type II Diabetics - Moderate NPDR - Placebo|59 Adult type II diabetic patients with baseline moderate non-proliferative diabetic retinopathy randomized to placebo treatment.
62551048|NCT04505566|OTHER|Adult Type II Diabetics - No Diabetic Retinopathy (DR)|23 Adult type II diabetic patients with no diabetic retinopathy as a control group.
62740162|NCT06660251|ACTIVE_COMPARATOR|Subjects without MetS|"Subjects, apparently healthy, with normal BMI, blood pressure, waist circumference (see inclusion criteria). Subjects were administered in randomized order after overnight fasting a test food. Test days were on two separate occasions around 2 weeks apart.~Egg intervention: three hard-boiled eggs. Meatball intervention: 170 g meatballs."
62551049|NCT04505566|OTHER|Adult Type 2 Diabetics-Proliferative Diabetic Retinopathy(PDR)|23 Adult type II diabetic patients with proliferative diabetic retinopathy as a control group.
62551050|NCT04505566|OTHER|Age-matched Non-diabetics|We will also enroll 100 age-matched patients without diabetes who are undergoing unilateral vitrectomy surgery for non-inflammatory conditions such as epiretinal membrane or macular hole. Removed aqueous fluid that is typically discarded will instead be collected and stored at -80° C. Aqueous fluid will be tested for inflammatory markers as detailed below to provide a reference level for cross-comparison analysis.
62551051|NCT03723356||MS Patients|Definite diagnosis of RRMS
62551052|NCT03723356||Healthy Controls|gender aged match healthy
62551053|NCT00722904||1|patients undergoing routine post-intervention surveillance of aortic coarctation
62551054|NCT00722904||2|Healthy volunteers
62551055|NCT05095844||Vaccinated|All individuals who have received a vaccine dose.
62551056|NCT03669224|EXPERIMENTAL|Nano Care Gold|Silver and Gold nano particles suspended in 70 % isopropyl alcohol. It will be used for cavity pre-treatment. This arm will be compared with no intervention (negative control).
62551057|NCT03669224|ACTIVE_COMPARATOR|Chlorhexidine|2% chlorhexidine gluconate solution will be applied to prepared cavity followed by adhesive system then resin composite. This arm will be compared with no intervention (negative control).
62551058|NCT04418102|EXPERIMENTAL|Palmitic acid rich interesterified fat|Snacks (muffins) and spread containing palmitic acid rich interesterified fat to replace habitual snacks and spreads, and provide 10% of total daily energy intake with the interesterified fat.
62551059|NCT04418102|ACTIVE_COMPARATOR|Stearic acid rich interesterified fat|Snacks (muffins) and spread containing stearic acid rich interesterified fat to replace habitual snacks and spreads, and provide 10% of total daily energy intake with the interesterified fat.
62551060|NCT06263452|EXPERIMENTAL|Propranolol|Propranolol tablet, 40mg, one-time, orally
62551061|NCT06263452|PLACEBO_COMPARATOR|Placebo|Encapsulated placebo tablet
62551062|NCT03888963|EXPERIMENTAL|PRF|
62551063|NCT03888963|SHAM_COMPARATOR|SHAM|
62551064|NCT06249061|EXPERIMENTAL|Oral Sodium Bicarbonate|Those in the intervention group will be encouraged to sip a solution of sodium bicarbonate (1 imperial teaspoon (\~5g) of sodium bicarbonate dissolved into 250ml of water; if the entire 250mL is consumed, another 1 imperial teaspoon (\~5g) of sodium bicarbonate dissolved in 250mL of water will be provided to the patient) throughout labour with other drinks as desired. All other care will remain the same.
62551065|NCT06249061|NO_INTERVENTION|Usual Care|Those in the usual care group will be encouraged to sip fluids of their choice throughout labour as they would normally be encouraged to do. All other care will remain the same.
62551066|NCT03893084|EXPERIMENTAL|Intervention|Preconception guidance prepared by reference to the guidelines published in the literature, women were given pre-pregnancy training.
62551067|NCT03893084|NO_INTERVENTION|Control|The women in the control group were not given training, and routine practice was performed.
62551068|NCT00373633|EXPERIMENTAL|Continuous extra-pleural intercostal local anesthesia|intra-operatively placed extrapleural intercostal catheter
62551069|NCT00373633|ACTIVE_COMPARATOR|Thoracic Epidural|gold standard
62551070|NCT01801904|EXPERIMENTAL|Panitumumab|
62551071|NCT04841577|EXPERIMENTAL|Co-Ad Group|Participants received 1 dose of RSV_PreF3 Older Adult (OA) investigational vaccine and 1 dose of FLU-QIV at Day 1 and were followed up until the study end.
62551072|NCT04841577|ACTIVE_COMPARATOR|Control Group|Participants received 1 dose of FLU-QIV at Day 1 and 1 dose of RSV_PreF3 OA investigational vaccine at Day 31 and were followed up until the study end.
62551073|NCT03213444|ACTIVE_COMPARATOR|Quimioterapy 1|adjuvant chemotherapy with 5-FU isolated
62551074|NCT03213444|ACTIVE_COMPARATOR|Quimioterapy 2|adjuvant chemotherapy with 5-FU associated with oxaliplatin
62740163|NCT03940638||Patients with septic non-union of the tibia|
62740164|NCT06078371|NO_INTERVENTION|Opioid pain treatment (Block 1)|Standard of care pain treatment regimen that involves the use of opioids. Discretion of the medical care team and surgeon will be used for specific opioid pain treatment prescription (quantity, frequency) based on standard of care procedures. All forms of treatment are allowed for the standard of care group which may include but are not limited to blocks, opioids, patient-controlled analgesia, NSAIDs, acetaminophen, muscle relaxing agents, sedation medications, and neuropathic pain medications.
62740165|NCT06078371|EXPERIMENTAL|Opioid-Free pain treatment (Block 2)|Pain treatment regiment without the use of opioids. All other pain medication may be used under the discretion of the medical care team and surgeon.
62740166|NCT06659978||Infants|Well, infants born between 34 and 42 weeks.
62175158|NCT02617433|EXPERIMENTAL|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours.
62175159|NCT03928678|ACTIVE_COMPARATOR|thefast track (FTS group)|
62551075|NCT05815017|EXPERIMENTAL|Gamified Physical Therapy Exercise Software Intervention + Usual Care|Participants randomized to the intervention group will be asked each day by a volunteer whether they would like to use the gamified physical therapy exercise software while in their beds. Participants willing to exercise will have the device set up for them to participate by a volunteer and the software will begin with a tutorial video for different exercises and then ask patients to perform in sequence with prompting and motion tracking. Exercises include Frontal Bicep Curls, Arm Crosses, Press Ups, Arm Rotations, and Basketball Shots.
62551076|NCT05815017|NO_INTERVENTION|Usual Care|Usual Care
62175160|NCT03928678|PLACEBO_COMPARATOR|Thecontrolgroup|
62175161|NCT00917631|EXPERIMENTAL|Co-bedding|"Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.~Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.~Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes)."
62175162|NCT00917631|NO_INTERVENTION|Standard care|For infants who are randomized to receive standard care, the twin pair will remain in separate incubators as per current NICU policy. The infant will be nested in boundaries consistent with neonatal care practices. The heelstick may occur at any time following randomization (within 10 days) to maintain consistency between groups.
62175163|NCT03271177|EXPERIMENTAL|7F Sheathless Guide Catheter|Patients in this arm will undergo their percutaneous coronary intervention using a 7F Sheathless guide catheter
62175164|NCT03271177|PLACEBO_COMPARATOR|6F Sheath/Guide Catheter Combination|Patients in this arm will undergo their percutaneous coronary intervention using a 6F Sheath/guide combination
62175165|NCT01059526||Patients naive to KALBITOR|HAE patients that have not been treated with KALBITOR (ecallantide) prior to enrollment in the study
62175166|NCT01059526||Patients non- naive to KALBITOR|HAE patients that have been treated with KALBITOR prior to enrollment in the study
62175167|NCT05422339|EXPERIMENTAL|Gamified Intervention|This condition will involve the implementation of an assistive technology software (named the MapHabit system) with added gamification features into the daily care of individuals with mild to moderate stage of dementia. The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The application will be made available to families through compatible tablets.
62175168|NCT05422339|ACTIVE_COMPARATOR|Non-gamified Intervention|This control condition acted as the active comparator to the experimental condition. The same assistive technology, the MapHabit system, will be given to a separate group of participants. The difference here will be that the software will be a version that does not include gamification features.
62175169|NCT05422339|OTHER|Exploratory Intervention|The exploratory condition will be given the same MHS version as the active comparator (control condition). However, for this group, participants will also engage in virtual reality games throughout the duration of the study. These virtual reality games are integrated with the MHS and includes cognitive games revolving around mental acuity, motor skills, etc.
62551077|NCT01790074|EXPERIMENTAL|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
62551078|NCT01790074|PLACEBO_COMPARATOR|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
62551079|NCT06432803||Auto-immune encephalitis patients|Analysis of PET-scan
62551080|NCT06432803||Paraneoplastic Neurological Syndromes patients|Analysis of PET-scan
62551081|NCT02625597|EXPERIMENTAL|Dental Materials|
62740167|NCT06658561|OTHER|cold snare polypectomy group|"1. Rotate the lens body to make the polyp at about 6 o'clock.~2. Place the special cold snare in the normal mucosa 1-2mm away from the polyp edge.~3. Tighten the snare at a constant speed and gently lift it up.~4. Excision.~5. According to the polyp size, use the colonoscope suction channel or directly use the snare to pull out the tissue for further pathological examination.~6. Piecemeal resection will be performed if the en-bloc resection fails."
62740168|NCT06658561|OTHER|hot snare polypectomy group|"1. Rotate the lens body to make the polyp at about 6 o'clock.~2. According to evaluation of the polyps, directly place the snare on the edge of the polyp including a clear margin of normal tissue (1-2 mm) or after submucosal injection.~3. Tighten the snare at a constant speed and gently lift it up.~4. Use the electrocoagulation and electroscission mode, power on for several seconds until the polyp is cut off.~5. According to the polyp size, use the colonoscope suction channel or directly use the snare to pull out the tissue for further pathological examination.~6. Piecemeal resection will be performed if the en-bloc resection fails."
62740169|NCT04270682|EXPERIMENTAL|Adult Cohort|Patients in the adult cohort will participate in a randomized, double-blind, placebo-controlled, 2 period × 2-treatment crossover study with rescue medication and open-label run-in to assess the efficacy and safety of CDCA.
62740170|NCT04270682|EXPERIMENTAL|Pediatric Cohort|Pediatric cohort patients (≥1 month and \<16 years) will participate in a 24-week, open-label cohort with an 8-week titration period and a 16-week treatment period at the tolerated dose.
62740171|NCT02836470|EXPERIMENTAL|LB1148|Active
62740172|NCT02836470|PLACEBO_COMPARATOR|Placebo|Placebo
62740173|NCT06662201||Acute respiratory failure|Adult patients (over 17 years of age) who have been intubated for acute respiratory failure hypoxemia for more than 24 hours, who have overcome a spontaneous breathing trial (SBT) and are fit to be extubated in the intensive care unit of the participating centers, who meet the inclusion criteria, who do not have exclusion criteria and from whom informed consent is obtained (from them or their immediate family member).
62551082|NCT02325076|EXPERIMENTAL|Spirodoc|One time during examination at the outpatient unit
62551083|NCT03347825||Robotic-assisted lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent robotic-assisted lobectomy for lung cancer.
62551084|NCT03347825||VATS (video assisted thoracic surgery) lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent VATS lobectomy for lung cancer.
62551085|NCT03347825||Open lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent open lobectomy for lung cancer.
62551086|NCT02390882|PLACEBO_COMPARATOR|Placebo|Tamsulosin placebo (12 weeks)
62551087|NCT02390882|EXPERIMENTAL|Treatment 1|HGP0412 capsule (12 weeks)
62551088|NCT02390882|EXPERIMENTAL|Treatment2|HIP1402 capsule (12 weeks)
62551089|NCT04320043||Anterior cervical decompression surgery|Adult patients who underwent anterior cervical decompression surgery for radiculopathy and/or myelopathy due to cervical degenerative disc disease. Patients underwent one of the following interventions: ACD, ACDF, ACDF with plating or corpectomy.
62551090|NCT02647801|EXPERIMENTAL|Mindfulness intervention|The experimental group comes to weekly laboratory meetings and practices mindfulness. Participants also fill out self-report questionnaires which assess self-control and mindfulness.
62551091|NCT02647801|NO_INTERVENTION|Control group|The control group comes to weekly laboratory meetings and fills out self-report questionnaires which assess self-control and mindfulness. No mindfulness training is carried out.
62551092|NCT01807312|EXPERIMENTAL|CO2 insufflation|CO2 insufflations was applicated in routine colonoscopy examination with Endoscopic CO2 regulation unit and accessories
62551093|NCT01807312|PLACEBO_COMPARATOR|Air insufflation|Air insufflations is applicated in Routine Colonoscopy Examination
62551094|NCT02068313||Single cohort|
62551095|NCT00115453|EXPERIMENTAL|A|Active treatment arm.
62551096|NCT05186649||Experimental Group|Consecutive patients with severe mitral stenosis and clot in left atrial appendage (LAA) on transesophageal echocardiography fulfilling the inclusion criteria will be recruited for this study. An ACUSON 128-XP echocardiographic system equipped with omniplane and biplane transesophageal probes will be used for this study. TEE followed by CT Angiography will be performed according to the standard procedure after obtaining informed consent.
62551097|NCT02396511|EXPERIMENTAL|TRC105 and Bevacizumab|TRC105 weekly intravenous infusion bevacizumab every 2 weeks intravenous infusion
62551098|NCT05475860||Patients receiving cardiac implantable electronic device|Patients receiving cardiac implantable electronic device for any clinical indication
62551099|NCT04456088|EXPERIMENTAL|Phase 1- Nitric oxide treatment- 80ppm|
62551100|NCT04456088|EXPERIMENTAL|Phase 2- Group 1- Nitric oxide treatment- 150ppm|
62551101|NCT04456088|NO_INTERVENTION|Phase 2- Group 2- control|Standard of Care
62551102|NCT02829203||No-Frailty|Patients without frailty score submitted to a cardiac surgery
62551103|NCT02829203||Pre-Frailty|Patients with pre-frailty score submitted to a cardiac surgery
62551104|NCT04561271|EXPERIMENTAL|foot reflexology|patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. The technique consists in stimulating reflex zones of foot, each zone corresponding to a specific organ. Almond oil will be used. The session is accompanied by relaxing music
62551105|NCT04561271|SHAM_COMPARATOR|toucher massage|patients will receive one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.
62551106|NCT01930201||Standard general anesthesia|Patients receiving standard of care.
62551107|NCT01930201||Caudal Epidural Block|Patients receiving a caudal epidural block in addition to standard of care.
62551108|NCT03835702|NO_INTERVENTION|Usual care with non-sleep provider|Participant will continue the follow up for sleep apnea with the non-sleep provider
62551109|NCT03835702|EXPERIMENTAL|SAM Clinic Intervention|Participants will attend a sleep apnea management group based intervention to improve PAP adherence.
62551110|NCT01391715|ACTIVE_COMPARATOR|Double dose rabeprazole|Rabeprazole 20m bid per day will be given for 2 weeks
62551111|NCT01391715|PLACEBO_COMPARATOR|standard dose rabeprazole|rabeprazole 20mg per day will bi given for 2 weeks
62551112|NCT05330260||Endo-CABG|Group that underwent retrograde arterial cardiopulmonary bypass flow.
62551113|NCT05330260||PCI|Surgical control group
62551114|NCT05330260||Healthy controls|Non-surgical control group
62551115|NCT03740581|ACTIVE_COMPARATOR|Intensive|New anti-diabetic drug regimen with (mandatory) Insulin \>= 3 times per day
62551116|NCT03740581|NO_INTERVENTION|Conventional|Old anti-diabetic drug regimen with or without Insulin (\<3 times per day) to be continued as before
62551117|NCT02666729||AF Ablation Procedure|Patients with AF who are schedule for a first time pulmonary vein isolation (PVI) for AF using the TactiCath catheter. Patients will have four pulmonary veins ablated during procedure. The researcher will perform AF Ablation with contact force information on two veins. The research will perform AF Ablation without contact force information on the other two veins.
62551118|NCT05811416||Cohort 1|Participants that have initiated ozanimod.
62551119|NCT02989909|ACTIVE_COMPARATOR|Goldmann Tonometer|Goldmann Tonometer prism will be used as a based line comparator for tolerance assessment versus the active test comparator CATS tonometer prism
62551120|NCT02989909|EXPERIMENTAL|CATS tonometer|CATS tonometer prism being used as the test product to assess IOP measurement versus active comparator the Goldmann Tonometer prism
62740174|NCT02079116|EXPERIMENTAL|60 grams of fat plus water solution|"In the group with 10 volunteers with obesity, some of them are submitted first to the 60 grams of fat plus water solution (meal challenge) and in another time to only water.~Also, in the group with 10 volunteers without obesity, some of them are submitted first to the 60 grams of fat plus water solution (meal challenge) and in another time to only water."
62551121|NCT02784561|EXPERIMENTAL|Busulfan/FLAG conditioning regimen|"All recipients in this arm received the conditioning regimen consisting of Busulfan/FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor).~The conditioning regimen for peripheral blood stem cell transplantation consisted of busulfan (3.2 mg/kg/ day intravenously \[i.v.\], days -10 to -8), fludarabine (30 mg/m2, day -7 to -3), cytarabine (1.6 g/m2/day, days~-7 to -3), granulocyte colony-stimulating factor (5 ug/ kg, day -8 to -3). ATG (Thymoglobuline, rabbit) for haploidentical and matched unrelated donors transplantation recipients was used on 2.5 mg/kg/d from days -5 to -2)."
62551122|NCT02348112||Altis arm|Subjects will have an Altis sling placed to treat stress urinary incontinence.
62551123|NCT02348112||Comparator arm|Subjects will have a transobturator or retropubic sling placed to treat stress urinary incontinence.
62551124|NCT06297421|EXPERIMENTAL|Fecal Microbiota Transplantation|Oral Fecal Microbiota Transplantation Capsule Take 40 capsules daily, 20 capsules in the morning and 20 capsules in the evening for 3 consecutive days. This is a cycle. Take it for three consecutive cycles.
62551125|NCT06297421|PLACEBO_COMPARATOR|Placebo|Oral Placebo Capsule Take 40 capsules daily, 20 capsules in the morning and 20 capsules in the evening for 3 consecutive days. This is a cycle. Take it for three consecutive cycles.
62551126|NCT02567279|ACTIVE_COMPARATOR|Denosumab subcutaneous injections|The treated group (n = 42) will receive Denosumab (60 mg, two subcutaneous injections at M0 and M6) associated with a daily treatment of vitamin D (800 IU) + calcium (1000 mg).
62551127|NCT02567279|PLACEBO_COMPARATOR|Placebo subcutaneous injections|The control group (n = 42) will received a placebo injection (two subcutaneous injections at M0 and M6) with daily treatment of vitamin D (800 IU) +calcium (1000 mg).
62551128|NCT04253665|NO_INTERVENTION|Usual care|Discharge teaching is usually not delivered in a systematic or consistenly way, nor by relying on a particular intervention model.
62551129|NCT04253665|EXPERIMENTAL|Discharge teaching|Receiving tailored discharge teaching by nurses during hospital stay.
62551130|NCT05323708|EXPERIMENTAL|Bmab 1000, A single 60 mg dose of Bmab 1000 administered by subcutaneous injection.|
62551131|NCT05323708|ACTIVE_COMPARATOR|Prolia®, A single 60 mg dose of Prolia® administered by subcutaneous injection.|
62551132|NCT02208089|EXPERIMENTAL|TransPRKCXL|Simultaneous combined transepithelial photorefractive keratectomy (TransPRK) and corneal collagen cross-linking (CXL)
62551133|NCT02208089|ACTIVE_COMPARATOR|CXL only|Corneal collagen cross-linking (CXL) using the same protocol without transepithelial photorefractive keratectomy
62740175|NCT02079116|PLACEBO_COMPARATOR|Pure water.|"In the same group with 10 volunteers with obesity, some of them are submitted first to only water (control) and in another time to the 60 grams of fat plus water solution (meal challenge).~Also, in the same group with 10 volunteers without obesity, some of them are submitted first to only water (control) and in another time to the 60 grams of fat plus water solution (meal challenge)."
62740176|NCT05787899||Hypothermia Protocol|
62175170|NCT00745121|EXPERIMENTAL|Group-A, Osteoporosis/osteopenia|Patients with osteoporosis/osteopenia.
62175171|NCT00745121|EXPERIMENTAL|Group-B, Control|Control (non-osteoporotic/-osteopenic patients).
62551134|NCT04192461|EXPERIMENTAL|tooth guided immediate implant placement group|
62551135|NCT06578871|ACTIVE_COMPARATOR|Arm1: Standard of Care Treatment|"Radiotherapy to Ipsilateral Neck and to risk Mucosa~There are two possible dose levels:~* 60 Gy in 30 fractions over 6 weeks (CTV60)~  o This applies to the dissected levels of the neck~* 54 Gy in 30 fractions over 6 weeks (CTV54)~  * This applies to the mucosal surfaces. Patients randomized to Arm 2 will not have the mucosal surfaces treated"
62551136|NCT06578871|EXPERIMENTAL|Arm 2: Omission of IMRT to Risk Mucosa but conditional IMRT to Neck|"* If N1 with single node \<= 3cm, no further treatment~* If multiple ipsilateral nodes or single ipsilateral node \>3 cm, radiation to Neck only"
62551137|NCT03189992|EXPERIMENTAL|CC-GSYXZ|Colon cancer with Chinese medicine syndrome Yin deficiency of liver and kidney and spleen deficiency.Intervented by Bushen-Jianpi Dedoction and cinobufotalin injection
62551138|NCT03189992|PLACEBO_COMPARATOR|CC-WZ|Colon cancer with none Chinese medicine syndrome.Intervented by cinobufotalin injection
62551139|NCT03189992|EXPERIMENTAL|HCC-GSYXZ|Hepatoma cancer with Chinese medicine syndrome Yin deficiency of liver and kidney and spleen deficiency.Intervented by Bushen-Jianpi Dedoction and cinobufotalin injection.
62551140|NCT03189992|PLACEBO_COMPARATOR|HCC-WZ|Hepatoma cancer with none Chinese medicine syndrome.Intervented by cinobufotalin injection
62551141|NCT02057887|EXPERIMENTAL|Cohort1|HM10660A SC once weekly
62551142|NCT02057887|EXPERIMENTAL|Cohort2|HM10660A SC once every 2 weeks
62551143|NCT02057887|EXPERIMENTAL|Cohort3|HM10660A SC once every 4 weeks
62551144|NCT02057887|ACTIVE_COMPARATOR|Cohort4|180 mcg Pegasys SC once weekly
62551145|NCT02354404|EXPERIMENTAL|Group 1a: cAd3-EBOZ at 1x10(10) PU|Part 1: cAd3-EBOZ at 1x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
62551146|NCT02354404|EXPERIMENTAL|Group 1b: cAd3-EBOZ at 1x10(11) PU|Part 1: cAd3-EBOZ at 1x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
62551147|NCT02354404|EXPERIMENTAL|Group 1c: cAd3-EBO at 2x10(10) PU|Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
62551148|NCT02354404|EXPERIMENTAL|Group 1d: cAd3-EBO at 2x10(11) PU|Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
62551149|NCT02354404|EXPERIMENTAL|Group 2a:cAd3-EBO at 2x10(10) PU|Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
62740177|NCT03088930|EXPERIMENTAL|Neoadjuvant treatment with Crizotinib|Patients enrolled in this study will be treated with 6 weeks of induction therapy with crizotinib. On the last day of dosing, patients will then undergo surgical resection. 5 years of follow-up will be done via chart review.
62740178|NCT05274971|EXPERIMENTAL|Active management group|Active dietary management and aerobic exercise training. Subjects will receive assessment and education of DASH diet (0, 4, and 8 weeks), with active aerobic exercise training (1 hour everyday exercise, at least 5 times per week for 12 weeks) (aerobic exercise education at baseline, 4, and 8 weeks after randomization). Each set of aerobic exercise consists of 10 minutes warm-up, 40 minutes moderate-intensity treadmill trotting, and 10 minutes cooldown. Telephone counseling at 2, 6, and 10 weeks after randomization.
62551150|NCT02354404|EXPERIMENTAL|Group 2b: cAd3-EBO at 2x10(11) PU|Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
62551151|NCT05697614|EXPERIMENTAL|intervention|valproic acid 15 - 60 mg/kg body weight/day, divided into 2 dosages/day for 12 weeks ; carbamazepine 10 - 30 mg/kg body weight/day, divided into 2 dosages/day for 12 weeks ; phenytoin 5-7 mg/kg body weight/day, divided into 2 dosages/day for 12 weeks
62551152|NCT05697614|ACTIVE_COMPARATOR|control|lamotrigine 0.2 mg/kg body weight/day, divided into 2 dosages/day for 12 weeks ; clobazam 0.1 - 0.8 body weight/day, divided into 2 dosages/day for 12 weeks ; oxcarbazepine10 - 30 mg/kg body weight/day, divided into 2 dosages/day for 12 weeks
62551153|NCT06328049|EXPERIMENTAL|Trilaciclib plus chemotherapy|"Patients with lung adenocarcinoma were treated with Trilaciclib (240mg/m2, d1, within 4 hours before each chemotherapy) combined with pemetrexed and carboplatin (dose according to the guideline recommendation, d1, Q3W). For squamous lung cancer, Trilaciclib (d1, 240mg/m2, 4 hours before each chemotherapy) plus paclitaxel/albumin-bound paclitaxel plus carboplatin (dose according to guideline recommendation, d1), Q3W. In the second cycle, patients were left to their own discretion with or without treaclib combination therapy."
62551154|NCT03352687|EXPERIMENTAL|Anterior SSAX|patients receiving suprascapular and axillary nerve block (SSAX) whose approach to the SS nerve is performed by anterior route
62551155|NCT03352687|EXPERIMENTAL|Posterior SSAX|patients receiving suprascapular and axillary nerve block (SSAX) whose approach to the SS nerve is performed by posterior route
62551156|NCT00527410|EXPERIMENTAL|RTA 744|RTA 744 injection administered intravenously for a maximum of 18 cycles (54 weeks). Dose escalation based on four dose levels and occurance of dose limiting toxicity (DLT).
62551157|NCT00193050|EXPERIMENTAL|Intervention|"In the neoadjuvant setting, patients were administered gemcitabine (800 mg/m2 IV days 1 and 8), epirubicin (75 mg/m2 IV day 1), and docetaxel (30 mg/m2 IV days 1 and 8)repeated every 21 days for 4 cycles~Patients then had either mastectomy or breast conservation surgery and pathologic treatment responses were assessed.~After surgery, 4 cycles of adjuvant gemcitabine (1000 mg/m2 IV days 1 and 8) and docetaxel (35 mg/m2 IV days 1 and 8) were administered at 21 day intervals.~After completion of chemotherapy, local regional radiation therapy and/or anti-estrogen therapy was administered per standard guidelines."
62551158|NCT04189601||Study subjects|Patients with Fabry disease, Gaucher disease, or Niemann-Pick disease, type D
62551159|NCT04189601||Controls|Age- and sex-matched to Study subjects
62551160|NCT04728009|EXPERIMENTAL|longan and lingzhi mushroom syrup|All participants (N = 8) were asked to consume 5 mL of longan and lingzhi mushroom syrup as a sweetener daily for 12 weeks.
62551161|NCT01868347|ACTIVE_COMPARATOR|control|PEEP after pneumoperitoneum and trendelenburg
62740179|NCT05274971|NO_INTERVENTION|Control group|Subjects will not receive education and recommendation of dietary management and aerobic exercise training.
62740180|NCT00073736|EXPERIMENTAL|MB07133 Dose Level 1|7-day continuous infusion in 28-day cycles
62740181|NCT00073736|EXPERIMENTAL|MB07133 Dose Level 2|7-day continuous infusion in 28-day cycles
62551162|NCT01868347|EXPERIMENTAL|Treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
62740182|NCT00073736|EXPERIMENTAL|MB07133 Dose Level 3|7-day continuous infusion in 28-day cycles
62740183|NCT00073736|EXPERIMENTAL|MB07133 Dose Level 4|7-day continuous infusion in 28-day cycles
62740184|NCT00073736|EXPERIMENTAL|MB07133 Dose Level 5|7-day continuous infusion in 28-day cycles
62551163|NCT03345680|NO_INTERVENTION|Control Group|Children will be screened, both parents and children will be informed of any abnormalities in the mouth.
62740185|NCT04435639|EXPERIMENTAL|MLD + Adjustable Compression Sleeve.|Manual lymph drainage + Adjustable Compression Sleeve.
62740186|NCT04435639|ACTIVE_COMPARATOR|MLD + Coban Compression Bandage.|Manual lymphatic drainage + Coban compression bandaging.
62740187|NCT00663806|EXPERIMENTAL|Arm 1|
62740188|NCT00663806|EXPERIMENTAL|Arm 2|
62740189|NCT06416150|EXPERIMENTAL|Stage 1 and 3 SoC|Start with Stage 1 Standard of Care; patient attends baseline colposcopy appointment, no Stage 2 intervention. Continue with Stage 3 Standard of Care; patient attends 12-month follow-up appointment, no Stage 4 intervention.
62740190|NCT06416150|EXPERIMENTAL|Stage 1 and 3 SoC + Stage 4 HERS|Start with Stage 1 Standard of Care; patient attends baseline colposcopy appointment, no Stage 2 intervention. Continue with Stage 3 Standard of Care; patient does not attend 12-month follow-up appointment, continue with Stage 4 HERS intervention.
62740191|NCT06416150|EXPERIMENTAL|Stage 1 SoC + Stage 2 and 3 HERS|Start with Stage 1 Standard of Care; patient does not attend baseline colposcopy appointment, continue with Stage 2 HERS intervention. Continue with Stage 3 HERS intervention; patient attends 12-month follow-up appointment, no Stage 4 intervention.
62740192|NCT06416150|EXPERIMENTAL|Stage 1 SoC + Stage 2, 3, and 4 HERS|Start with Stage 1 Standard of Care; patient does not attend baseline colposcopy appointment, continue with Stage 2 HERS intervention. Continue with Stage 3 HERS intervention; patient does not attend 12-month follow-up appointment, continue with Stage 4 HERS intervention.
62175172|NCT06319547|EXPERIMENTAL|hepatic hydrothorax|patient with hepatic hydrothorax that develop pleural effusion either unilateral or bilateral
62740193|NCT06416150|EXPERIMENTAL|Stage 1 SoC + Stage 2 and 3 HERS + Stage 4 HERS+HC|Start with Stage 1 Standard of Care; patient does not attend baseline colposcopy appointment, continue with Stage 2 HERS intervention. Continue with Stage 3 HERS intervention; patient does not attend 12-month follow-up appointment, continue with Stage 4 HERS+HC intervention.
62740194|NCT06416150|EXPERIMENTAL|Stage 1 and 3 HERS|Start with Stage 1 HERS intervention; patient attends baseline colposcopy appointment, no Stage 2 intervention. Continue with Stage 3 HERS intervention; patient attends 12-month follow-up appointment, no Stage 4 intervention.
62175173|NCT00520403|EXPERIMENTAL|1|
62551164|NCT03345680|EXPERIMENTAL|Interventional Group|Interventional (Dental Screening) Children will be screened for dental caries and referred to a specific hospital for treatment, namely King Saud University Dental College, treatment will be provided free of charge to the referred participants.
62740195|NCT06416150|EXPERIMENTAL|Stage 1, 3, and 4 HERS|Start with Stage 1 HERS intervention; patient attends baseline colposcopy appointment, no Stage 2 intervention. Continue with Stage 3 HERS intervention; patient does not attend 12-month follow-up appointment, continue with Stage 4 HERS intervention.
62740196|NCT06416150|EXPERIMENTAL|Stage 1 and 3 HERS + Stage 4 HERS+HC|Start with Stage 1 HERS intervention; patient attends baseline colposcopy appointment, no Stage 2 intervention. Continue with Stage 3 HERS intervention; patient does not attend 12-month follow-up appointment, continue with Stage 4 HERS+HC intervention.
62740197|NCT06416150|EXPERIMENTAL|Stage 1, 2, and 3 HERS|Start with Stage 1 HERS intervention; patient does not attend baseline colposcopy appointment, continue with Stage 2 HERS intervention. Continue with Stage 3 HERS intervention; patient attends 12-month follow-up appointment, no Stage 4 intervention.
62740198|NCT06416150|EXPERIMENTAL|Stage 1, 2, 3, and 4 HERS|Start with Stage 1 HERS intervention; patient does not attend baseline colposcopy appointment, continue with Stage 2 HERS intervention. Continue with Stage 3 HERS intervention; patient does not attend 12-month follow-up appointment, continue with Stage 4 HERS intervention.
62740199|NCT06416150|EXPERIMENTAL|Stage, 2, and 3 HERS + Stage 4 HERS+HC|Start with Stage 1 HERS intervention; patient does not attend baseline colposcopy appointment, continue with Stage 2 HERS intervention. Continue with Stage 3 HERS intervention; patient does not attend 12-month follow-up appointment, continue with Stage 4 HERS+HC intervention.
62551165|NCT02567240|EXPERIMENTAL|Carbon monoxide-bubbled mediums|Islets will be harvested with Carbon monoxide-saturated mediums
62740200|NCT06416150|EXPERIMENTAL|Stage 1 HERS + Stage 2 and 3 HERS+HC|Start with Stage 1 HERS intervention, patient does not attend baseline colposcopy appointment, continue with Stage 2 HERS+HC intervention. Continue with Stage 3 HERS+HC intervention; patient attends 12-month follow-up appointment, no Stage 4 intervention.
62740201|NCT06416150|EXPERIMENTAL|Stage 1 HERS + Stage 2, 3, and 4 HERS+HC|Start with Stage 1 HERS intervention, patient does not attend baseline colposcopy appointment, continue with Stage 2 HERS+HC intervention. Continue with Stage 3 HERS+HC intervention; patient does not attend 12-month follow-up appointment, continue with Stage 4 HERS+HC intervention.
62740202|NCT01143363|PLACEBO_COMPARATOR|Resting - control|No exercise
62740203|NCT01143363|EXPERIMENTAL|Moderate intensity exercise|Moderate intensity exercise (continuous) 1h after breakfast
62740204|NCT01143363|EXPERIMENTAL|High intensity intermittent training|High intensity intermittent training 1h after breakfast
62740205|NCT01143363|EXPERIMENTAL|Short sprint|Short sprint 1h after breakfast
62740206|NCT02638467|EXPERIMENTAL|Bosutinib and Bone Marrow Transplant|Subjects will receive 400mg of bosutinib from day at least -45 to day -15 to assess the sensitivity of patient Chronic Myeloid Leukemia (CML) to this TKI. Patients will be transplanted with the aim to transplant \> 3 x 106 CD34+ cells/kg Body Weight (BW) recipient from bone marrow or \> 3 x 108 nucleated cells/kg BW recipient from bone marrow. Then, subjects will receive 400mg of bosutinib once daily from day +30 after transplant.
62740207|NCT06169943|OTHER|Control|Participants in the control group will receive the same mobile app as the intervention group but with limited function.
62740208|NCT06169943|EXPERIMENTAL|Intervention|Participants in the intervention group will receive the mHealth social support program.
62740209|NCT02459431|ACTIVE_COMPARATOR|21G needle group|21 gauge endobronchial ultrasound guided transbronchial aspiration needle ( Vizishot, Olympus ) would be used to perform endobronchial ultrasound guided Transbronchial needle aspiration
62175174|NCT00439361|EXPERIMENTAL|Bortezomib + ICE|"Bortezomib + ICE (Ifosfamide, Carboplatin, Etoposide):~Bortezomib 1.0 mg/m\^2 intravenous (IV) over 5 Seconds on Days 1 and 4; + ICE (Ifosfamide 5 Gm/m\^2 IV continuous infusion on Day 1, Carboplatin 5 AUC IV over 1 Hour Day 1, Etoposide 100 mg/m\^2 IV over 2 Hours Days 1-3) + Mesna 5 mg/m\^2 IV continuous infusion Day 1; 2 Gm/m\^2 IV continuous infusion over 12 Hours."
62175175|NCT05132088|EXPERIMENTAL|oral semaglutide 50 mg once daily|All participants will get semaglutide or placebo tablets, 1 tablet every morning.
62175176|NCT05132088|PLACEBO_COMPARATOR|oral semaglutide placebo once daily|All participants will get semaglutide or placebo tablets, 1 tablet every morning.
62175177|NCT05439525|EXPERIMENTAL|Group A|the patient will receive Shoulder complex mobilization with movement three time a week for two weeks
62175178|NCT05439525|ACTIVE_COMPARATOR|Group B|will receive Conventional therapy three times a week for two weeks.
62551166|NCT02567240|NO_INTERVENTION|Normal mediums|Islets will be harvested with regular mediums
62551167|NCT04077944||Preterm prelabor rupture of membranes|"The diagnosis of Preterm prelabor rupture of membranes was made in the case of apparent spontaneous leakage of AF from the cervical canal during sterile speculum inspection before the onset of active labor at 37 weeks of pregnancy. The study population consisted of 55 women with a singleton pregnancy who were diagnosed with pP-ROM between 24+0 and 36+6 weeks of gestation.~The Amnisure test (AmniSure International LLC, Boston, MA) was used when there was inconclusive results to confirm the final diagnosis. The gestational age was determined by calculation from the last menstrual period and supported by the ultrasonography measurements at the first trimester of gestation."
62740210|NCT02459431|ACTIVE_COMPARATOR|22G needle group|22 gauge endobronchial ultrasound guided transbronchial aspiration needle ( Vizishot, Olympus ) would be used to perform endobronchial ultrasound guided Transbronchial needle aspiration
62740211|NCT03670654|ACTIVE_COMPARATOR|Pilates Method|The intervention of active comparator will be Pilates Method exercises.
62740212|NCT03670654|SHAM_COMPARATOR|Muscle stretching exercises|The intervention of sham comparator will be muscle stretching exercises.
62740213|NCT00119769|PLACEBO_COMPARATOR|1|
62740214|NCT00119769|ACTIVE_COMPARATOR|2|
62740215|NCT01213459||Cohort A|Women ≥15 years of age attending out-patient departments for routine cervical screening in the Kingdom of Saudi Arabia.
62740216|NCT01536028|ACTIVE_COMPARATOR|BIAsp 30|
62740217|NCT01536028|EXPERIMENTAL|BIAsp 50|
62740218|NCT01536028|EXPERIMENTAL|BIAsp 70|
62740219|NCT01536028|ACTIVE_COMPARATOR|IAsp|
62740220|NCT05671718|EXPERIMENTAL|Nurse-Led Treatment in Primary Care|At a primary care clinic intervention site, a nurse will be available once or twice weekly. The days/times will be dependent on clinic volume (i.e., cluster size), with scheduled rotations between PCCs. This rotation between PCC sites will mimic the physician's responsibilities/availability at a district hospital and creates parity between the trial arms. In this trial, we will have nurses dedicated to the management of RR-TB treatment, yet the volume at each site will not require the presence of a full-time nurse.
62740221|NCT05671718|NO_INTERVENTION|Physician-Led Treatment Hospital Based|Representing standard of care, primary care clinics will refer to hospital-based, physician-led care who will provide outpatient treatment. The typical clinical operations involve initiation of new patients once or twice weekly and PCCs are required to schedule a clinic day/time for the patient prior to referral (generally \< 72 hours from the time of referral). All individuals receiving care at this site will receive care at the district RR-TB treatment program for the catchment area. For HIV co-infected persons, their HIV treatment is also transferred to the RR-TB physician with details about the HIV treatment communicated in the transfer of care letter. Physicians often cover multiple clinics and routinely take on call sessions on the weekend, due to staffing limitations, thus preventing their sole focus on the RR-TB program and limiting the number of days the RR-TB clinic offers new patient visits and, in most cases, days for follow-up visits.
62740222|NCT06110936|EXPERIMENTAL|ts-DCS Group|ts-DCS will be administered using a direct current stimulator (TCT Research Limited, Hong Kong). 2-mA intensity ts-DCS will be applied to the experimental group, with the active electrode being the cathode electrode. The two electrodes (35-cm2) to be used will be immersed in saline solution (0.9% NaCl). The stimulation electrode (cathodal) will be placed slightly above the spinous process of the T10 vertebral process, while the reference electrode (anodal) will be placed horizontally on the left deltoid.
62551168|NCT04077944||Control|The control cases were recruited from the healthy pregnant women with a gestational age-matched cohort who admitted for routine obstetric care to our outpatient clinic. Sixty healthy pregnant women who delivered at term were included in the study as the control group.
62551169|NCT04177446|PLACEBO_COMPARATOR|control group|Patients will be given basic energy intake according to their weight, and will be extra maltodextrin as the placebo
62551170|NCT04177446|EXPERIMENTAL|intervention group|Patients will be given basic energy intake according to their weight, and will be extra protein intake
62551171|NCT03156504|EXPERIMENTAL|Ketamine|Subjects will receive three IV Ketamine Hydrochloride infusions (0.5 mg/kg, infused over 100 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers) and following ketamine treatment (change biomarkers).
62740223|NCT06110936|SHAM_COMPARATOR|Control Group|ts-DCS will be administered using a direct current stimulator (TCT Research Limited, Hong Kong). 2-mA intensity ts-DCS will be applied to the control group, with the active electrode being the cathode electrode. The two electrodes (35-cm2) to be used will be immersed in saline solution (0.9% NaCl). The stimulation electrode (cathodal) will be placed slightly above the spinous process of the T10 vertebral process, while the reference electrode (anodal) will be placed horizontally on the left deltoid. In the application to the control group, the placement of the electrodes will be the same as the active protocol, and unlike the experimental group, the stimulation will be stopped after 30 seconds. This sham procedure has been reported to be a good pseudostimulation method that does not cause significant experimental effects due to the initial itching sensation it provides.
62551172|NCT06498843|EXPERIMENTAL|DM004-Isotonic nasal pump spray group (9g/L)|Isotonic concentration. This solution has a concentration of mineral salts (concentration of halides expressed as NaCl: 9 g/L) similar to the human cells.
62551173|NCT06498843|EXPERIMENTAL|DM020-Hypertonic nasal pump spray group (21g/L)|Hypertonic concentration. This solution has a concentration of mineral salts (concentration of halides expressed as NaCl: 21 g/L) higher than that of human cells.
62551174|NCT06498843|NO_INTERVENTION|common practices|1 control group with common practices people with an upper respiratory tract infection (cold, rhinitis, rhinopharyngitis...), not using nasal sprays nor nasal drops (in single-dose form, for example) but standard practices: hydration, rest, paracetamol if necessary
62551175|NCT03048227|EXPERIMENTAL|Continuous Glucose Measurement (CGM)|Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
62551176|NCT03048227|NO_INTERVENTION|Control|Patients will manage their diabetes as usual as recommended by their care team.
62551177|NCT04441151|EXPERIMENTAL|Experimental group|Pulmonary rehabilitation therapy
62551178|NCT04441151|NO_INTERVENTION|Control group|Routine medical treatment
62551179|NCT04370002||No Intervention|This is an observational study. There is no active treatment that is examined.
62551180|NCT05584111|EXPERIMENTAL|Dose Level 1|30mg capsules, daily administration for 3 week (21 day) cycles
62740224|NCT01912443||Bevacizumab Plus Chemotherapy|
62740225|NCT05407649|EXPERIMENTAL|Radiotherapy Combined with GM-CSF|
62740226|NCT06661070|EXPERIMENTAL|High-intensity percutaneous electrolysis (HIPE)|The HIPE group receives a 660 mA galvanic current for 10 s.
62740227|NCT06661070|EXPERIMENTAL|Low-intensity percutaneous electrolysis (LIPE)|The LIPE group receives a 220 mA × 30 s.
62740228|NCT06661070|ACTIVE_COMPARATOR|Dry Needling (DN)|The DN group received no galvanic current.
62740229|NCT01781806|ACTIVE_COMPARATOR|Cohort H (PrEP)|"Participants in the H cohort will be provided with a CPP, including daily oral emtricitabine/tenofovir-based PrEP.~High Risk Cohort Criteria (one or more of the following has to be met):~1. No condom use during anal intercourse with ≥3 male sex partners who are HIV-positive or of unknown HIV status during the last three months.~2. STD diagnosis during the last 12 months.~3. Previous PEP use during the last 12 months (\* see exclusion criteria)~4. Has at least one HIV infected sexual partner for ≥4 weeks."
62551181|NCT05584111|EXPERIMENTAL|Dose Level 2|30mg capsules, MWF administration for 3 week (21 day) cycles
62551182|NCT05584111|EXPERIMENTAL|Dose Level 3|100mg capsules, MWF administration for 3 week (21 day) cycles
62551183|NCT05584111|EXPERIMENTAL|Dose Level 4|30mg and 100mg capsules, M-MWF administration for 3 week (21 day) cycles
62551184|NCT05584111|EXPERIMENTAL|Dose Level 5|30mg and 100mg capsules, M-MWF administration for 3 week (21 day) cycles
62740230|NCT01781806|ACTIVE_COMPARATOR|Cohort LM (PEP)|Participants who do not meet criteria for High Risk (Cohort H) will be assigned to the LM (low moderate) cohort and will receive a customized prevention package based on baseline assessments (in the same manner as the Cohort H Participants). In addition, they will receive education on the availability and use of post-exposure prophylaxis.
62740231|NCT06659471|SHAM_COMPARATOR|0.76% Sodium Monofluorophosphate|0.76% Sodium Monofluorophosphate
62740232|NCT06659471|ACTIVE_COMPARATOR|0.454% Stannous Fluoride|0.454% Stannous Fluoride
62740233|NCT06659471|EXPERIMENTAL|0.454% Stannous Fluoride, 4.7 pH|0.454% Stannous Fluoride, 4.7 pH
62740234|NCT06659471|EXPERIMENTAL|0.454% Stannous Fluoride, 5.8 pH|0.454% Stannous Fluoride, 5.8 pH
62740235|NCT03869385|EXPERIMENTAL|Albumin group|Patients assigned to the Albumin group will receive a 60 g loading dose of human albumin 20% over 2-3 hours. Serum albumin levels will be maintained at least at 30 g/l in the ICU for a maximum of 28 days following randomization using 40-80 g human albumin 20% infusion.
62551185|NCT06239727|EXPERIMENTAL|Reduced-dose radiotherapy group|All participants will receive induction chemotherapy and immunotherapy (every 3 weeks × 3 cycles of gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1 + camrelizumab 200 mg day 1) followed by reduced-dose intensity-modulated radiation therapy (IMRT; 6360cGy, 30 fractions, 5 fractions/week, 1 fraction/day). During the radiotherapy, all the participants will receive concurrent chemotherapy (every 3 weeks × 2 cycles of cisplatin 100 mg/m2 day 1). After 3 weeks of the completion of concurrent chemoradiotherapy, adjuvant camrelizumab (200 mg per cycle) will be administrated every 3 weeks for 9 cycles.
62551186|NCT06239727|ACTIVE_COMPARATOR|Conventional-dose radiotherapy group|All participants will receive induction chemotherapy and immunotherapy (every 3 weeks × 3 cycles of gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1 + camrelizumab 200 mg day 1) followed by conventional-dose intensity-modulated radiation therapy (IMRT; 6996cGy, 33 fractions, 5 fractions/week, 1 fraction/day). During the radiotherapy, all the participants will receive concurrent chemotherapy (every 3 weeks × 2 cycles of cisplatin 100 mg/m2 day 1). After 3 weeks of the completion of concurrent chemoradiotherapy, adjuvant camrelizumab (200 mg per cycle) will be administrated every 3 weeks for 9 cycles.
62551187|NCT06239727|OTHER|Not-enrolled population|All participants will receive induction chemotherapy and immunotherapy (every 3 weeks × 3 cycles of gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1 + camrelizumab 200 mg day 1) followed by conventional-dose intensity-modulated radiation therapy (IMRT; 6996cGy, 33 fractions, 5 fractions/week, 1 fraction/day). During the radiotherapy, all the participants will receive concurrent chemotherapy (every 3 weeks × 2 cycles of cisplatin 100 mg/m2 day 1). After 3 weeks of the completion of concurrent chemoradiotherapy, adjuvant camrelizumab (200 mg per cycle) will be administrated every 3 weeks for 9 cycles. Besides, all the participants should also receive metronomic adjuvant capecitabine chemotherapy (capecitabine 650 mg/m2 p.o. BID 1 year) immediately after the completion of concurrent chemoradiotherapy.
62551188|NCT04665986|EXPERIMENTAL|NHP|Navelbine, Herceptin, Pertuzumab
62551189|NCT04665986|ACTIVE_COMPARATOR|THP|Docetaxel, Herceptin, Pertuzumab
62551190|NCT03138408|EXPERIMENTAL|SC-004|
62551191|NCT03138408|EXPERIMENTAL|SC-004 and ABBV-181|
62740236|NCT03869385|NO_INTERVENTION|Control group without albumin:|The control group will be treated according to the usual practice with crystalloids as the first choice for the resuscitation and maintenance phase of septic shock.
62551192|NCT03438019|EXPERIMENTAL|TIRE IMT|The TIRE IMT group will receive a tablet with the TIRE software installed and a PrO2® device through which they will train. Training consists of six levels (A-F) with six inspirations at each level for a total of 36 breaths. Recovery times between breaths range from 40 to 5 seconds as the subject advances each level. TIRE data will be stored in the tablet for subsequent interrogation and data retrieval.
62551193|NCT03438019|EXPERIMENTAL|Standard IMT group|The Standard IMT group will receive a Threshold® Inspiratory Muscle Trainer. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject. Subjects will be instructed to perform up to 36 breaths daily. To compare with TIRE training, we will ask participants to perform this within a 30-minute session.
62551194|NCT03438019|SHAM_COMPARATOR|Sham IMT group|The Sham IMT group will also receive a Threshold® device and undergo the exact protocol of group 2 but with minimal resistance applied (7 cm H2O, the lowest in the device).
62551195|NCT02864355|ACTIVE_COMPARATOR|Goal Directed Therapy|In this arm patient will have the FloTrac monitor and a Goal Directed Therapy algorithm will be used to manage blood pressures.
62740237|NCT04379635|EXPERIMENTAL|Neoadjuvant chemotherapy + Neoadjuvant/Adjuvant Tislelizumab|Tislelizumab + cisplatin/carboplatin + paclitaxel or Pemetrexed Disodium
62740238|NCT04379635|PLACEBO_COMPARATOR|Neoadjuvant chemotherapy + Neoadjuvant/Adjuvant Placebo|Placebo + cisplatin/carboplatin + paclitaxel or Pemetrexed Disodium
62740239|NCT05549232||Hematologic Malignancies|Subjects requiring chronic transfusions with red blood cells for treatment of a hematologic malignancy will receive 1 transfusion with 2 units of hypoxic red blood cells manufactured with the Hemanext ONE device. The subjects will be monitored for all adverse events from Informed Consent through Day 28 or the subsequent standard of care transfusion, whichever occurs first.
62740240|NCT05549232||Acute Burn|Subjects requiring transfusion with red blood cells during the excision procedure after an acute burn will receive 2 units of hypoxic red blood cells manufactured with the Hemanext ONE device. As the excision treatments require transfusion of more than 2 units of red blood cells, the first 2 units transfused during the procedure will be hypoxic red blood cells. The subjects will be monitored for all adverse events through Day 28.
62175179|NCT01997437|OTHER|Tissue-engineered airway transplantation|Stem-cell seeded bioartificial tracheal scaffold
62175180|NCT05418868|EXPERIMENTAL|Part A: Participants receiving CAB 200 mg/mL with rHuPH20|Part A of the study (CAB 200 mg/mL with rHuPh20) has been closed to further enrolment based on preliminary results.
62175181|NCT05418868|EXPERIMENTAL|Part C: Participants receiving CAB >=400 mg/mL or CAB Formulation I|
62175182|NCT05418868|EXPERIMENTAL|Part D: Participants receiving CAB >=400 mg/mL with rHuPH20|
62551196|NCT02864355|NO_INTERVENTION|Usual Care|Standard of care will be used to manage blood pressures.
62551197|NCT02068612|EXPERIMENTAL|MICT + IT|Moderate Intensity Continuous Training+Interval Training
62551198|NCT02068612|ACTIVE_COMPARATOR|LICT|Low Intensity Continuous Training
62551199|NCT05708430|EXPERIMENTAL|SVF injection|Intra-articular injection of autologous cells from the stromal vascular fraction derived from adipose tissue
62551200|NCT06142474|NO_INTERVENTION|acute decompensated HF Patients|acute decompensated HF Patients 2：1，have 50 Patients control and 100 Patients randomly assigned empagliflozin or dapagliflozin
62551201|NCT06142474|EXPERIMENTAL|empagliflozin 10mg|acute decompensated HF Patients 2：1,have 50 Patients control and 100 Patients randomly assigned empagliflozin or dapagliflozin ,3 days before ventilator weaning in a ratio of 1:1.empagliflozin 10 mg once daily
62551202|NCT06142474|EXPERIMENTAL|dapagliflozin 10mg|acute decompensated HF Patients 2：1,have 50 Patients control and 100 Patients randomly assigned empagliflozin or dapagliflozin ,3 days before ventilator weaning in a ratio of 2:1. dapagliflozin 10 mg once daily
62551203|NCT06372574|EXPERIMENTAL|RO7617991 Dose Escalation and Expansion|
62551204|NCT01725971||Control group|Group of nonsmokers individuals without respiratory disease.
62551205|NCT01725971||normal exam|subjects with silicosis , but with normal spirometric data
62551206|NCT01725971||mild obstruction|subjects with silicosis with mild obstruction in spirometric data
62551207|NCT01725971||moderate to severe obstruction|subjects with silicosis with moderate to severe obstruction in spirometric data
62551208|NCT00412386||BAV|patients with BAV
62551209|NCT00412386||Normal control|normal patients
62551210|NCT04363567||CKD 1|"Patients with Chronic kidney disease stage 1: Normal kidney function but urine findings or structural abnormalities or genetic trait point to kidney disease. eGFR :90+.~20 patients, maximun 4 patients with diabetes."
62551211|NCT04363567||CKD 2|"Patients with Chronic kidney disease stage 2: Mildly reduced kidney function, and other findings (as for stage 1) point to kidney disease. eGFR: 60-89.~20 patients, maximun 4 patients with diabetes."
62740241|NCT05910957||Non-depressed controls|Subjects without depression will fill out questionnaires about their general health and wellbeing, quality of life, mental health, emotional health, suicide risk, support system, and childhood experiences. Smartwatch data will also be collected to monitor step count, sleep quality, heart rate (resting and active), and activity rates.
62740242|NCT05910957||Antidepressant-treated adults|Subjects diagnosed with depression will fill out questionnaires about their general health and wellbeing, quality of life, mental health, emotional health, suicide risk, support system, and childhood experiences. Smartwatch data will also be collected to monitor step count, sleep quality, heart rate (resting and active), and activity rates.
62740243|NCT06431672|EXPERIMENTAL|intervention group|The intervention was an eight-session P-IPTG, which consisted of four sessions in pregnancy and four in postpartum. All participants replied to the measures at four waves from baseline to one year postpartum. The outcome variables were within-group and between-group changes in depression, social support, dyadic adjustment, interpersonal relationship satisfaction, and mother-infant bonding.
62551212|NCT04363567||CKD 3|"Patients with Chronic kidney disease stage 3: Moderately reduced kidney function. eGFR: 30-59.~20 patients, maximun 4 patients with diabetes."
62551213|NCT04363567||CKD 4|"Patients with Chronic kidney disease stage 4: Severely reduced kidney function. eGFR: 15-29.~20 patients, maximun 4 patients with diabetes."
62551214|NCT04363567||CKD 5|"Patients with Chronic kidney disease stage 5: Very severe kidney function. eGFR: \<15.~20 patients, maximun 4 patients with diabetes."
62551215|NCT04363567||Dialysis|Patients with end stage renal disease in dialysis. 20 patients, maximun 4 patients with diabetes.
62740244|NCT06431672|NO_INTERVENTION|control group|The participants of control group reply questionnaires for four times.
62740245|NCT00485758|OTHER|1|Arm 1: One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study.
62740246|NCT00485758|ACTIVE_COMPARATOR|2|Arm 2: stable lipid-modifying regimen, adding Placebo ER niacin/laropiprant in week 4, for the duration of the study.
62740247|NCT04054479|EXPERIMENTAL|Penehyclidine|Patients in this arm will receive penehyclidine after anesthesia intubation.
62740248|NCT04054479|PLACEBO_COMPARATOR|Normal Saline|Patients in this arm will receive normal saline after anesthesia intubation.
62740249|NCT03392831|EXPERIMENTAL|Peripherally inserted central catheter|The peripherally inserted central catheter (PICC) with 3 to 6 French calibers, with one, two or three lumens Groshong and PowerPICC models. These calibers are dependent on the amount of lumens, which are used for single or concomitant infusions.
62175183|NCT05418868|EXPERIMENTAL|Part E: Participants receiving RPV|
62551216|NCT04363567||Healthy|20 healthy people. Control group
62551217|NCT00836784|EXPERIMENTAL|1|
62740250|NCT03392831|ACTIVE_COMPARATOR|Central venous catheter|The central venous catheter (CVC), with a short stay of 3 to 7 French gauges with one or more lumens.
62740251|NCT02003794|EXPERIMENTAL|IV Fluid|0.9% NaCl solution infusion: 100 ml/hr for three days.
62740252|NCT02003794|NO_INTERVENTION|No IV Fluid|Not receive any intravenous fluid but can consume oral fluid normally for three days.
62740253|NCT02231892|EXPERIMENTAL|Real TMS|rTMS (frequency and intensity)
62740254|NCT02231892|SHAM_COMPARATOR|Sham TMS|Sham setting on coil
62740255|NCT05337982|EXPERIMENTAL|SCI Go|Participants with SCI randomized to the experimental group that have biomarkers that indicate low levels of inflammation will start immediately.
62175184|NCT04807283|EXPERIMENTAL|Treatment|
62551218|NCT00836784|EXPERIMENTAL|2|
62551219|NCT01920529|EXPERIMENTAL|aerobic exercise|The study will consist of two groups: Group Comparison (GC) will be submitted to two evaluations at the beginning of a week and end of 6 weeks, without receiving any kind of physical training intervention. Group Training (GT) will undergo two assessments at the beginning of the end of the 1st and 6th week, however will be submitted to aerobic training for six weeks. Supervised aerobic training will be held three times a week for six weeks,treadmill in four consecutive steps each (05 minutes stretching, 05 minutes heating, 20 training minutes (1 st and 2 nd week) and 30 minutes (3 rd to 6 weeks) and cool down 05 minutes). The exercise intensity will be maintained through a desired percentage of heart rate for training (x%) from 70% to 80%, obtaining then the optimal heart rate training.
62740256|NCT05337982|EXPERIMENTAL|SCI No Go|Participants with SCI randomized to the experimental group that have biomarkers that indicate high levels of inflammation will have a delayed start of 3 months.
62740257|NCT05337982|NO_INTERVENTION|SCI SOC|Participants with SCI randomized to the standard of care (SOC) group will continue with regular therapy.
62740258|NCT05337982|NO_INTERVENTION|Healthy Control|Healthy controls will provide biomarker and/or myelin (MRI) data
62740259|NCT04552041|EXPERIMENTAL|Prospekta|Two tablets per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablets should be held in mouth until completely dissolved. The overall duration of treatment is 24 weeks.
62740260|NCT04552041|PLACEBO_COMPARATOR|Placebo|Two tablets per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablets should be held in mouth until completely dissolved. The overall duration of treatment is 24 weeks.
62740261|NCT01679600|EXPERIMENTAL|FC-RATE|Feedback-controlled robotics-assisted treadmill exercise
62740262|NCT01679600|ACTIVE_COMPARATOR|RATE|Robotics-assisted treadmill exercise
62551220|NCT01920529|PLACEBO_COMPARATOR|control|Investigators evaluated the distance walked during the 6-minute walk test and recorded variables such as heart rate, respiratory frequency, pulse oxygen saturation and a scale of perceived exertion (Borg) in the moments before and after the test. There was only evaluation without intervention.
62551221|NCT04304092|EXPERIMENTAL|Low amount, low intensity|
62740263|NCT04252313|NO_INTERVENTION|Group A|This arm represents the control group. They will be undergoing the circumcision without any music, with the established standard for analgesia \[EMLA+Sucrose+Ring Block\]
62740264|NCT04252313|EXPERIMENTAL|Group B: Music|"In addition to the standard analgesia as explained for group A, Music will be played from the Baby Go to Sleep playlist which includes nursery rhymes and lullabies metonymized to an actual human heartbeat (Houser, 1994). Music will start after the baby settles on the board and before the surgeon starts the procedure."
62740265|NCT06516146|EXPERIMENTAL|Exercise, Diet, Mindfulness|The intervention group will start the intervention immediately following their baseline assessment. They will undergo another assessment after the 6 month intervention period.
62740266|NCT06516146|NO_INTERVENTION|Waitlist Group|Participants randomized into the waitlist group will undergo a baseline assessment, and will then be encouraged to continue their daily activities as usual for 6 months. Physical activity and sleep will be monitored during this time using wearable devices. Links to questionnaires will be emailed monthly. After the 6-month waitlist period, participants will undergo a second assessment prior to starting the intervention. The multimodal intervention will be 6-months in length, using the same measures of adherence, and will be followed by a final assessment.
62740267|NCT02963168|EXPERIMENTAL|Oradoxel|To determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered once every 3 weeks, then to determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered for two days every three weeks.
62740268|NCT03718806|EXPERIMENTAL|Regimen A|3 g zoliflodacin oral suspension; oral administration after an overnight fast
62740269|NCT03718806|EXPERIMENTAL|Regimen B|3 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast
62740270|NCT03718806|EXPERIMENTAL|Regimen C|4 g zoliflodacin oral suspension; oral administration after an overnight fast
62740271|NCT03718806|EXPERIMENTAL|Regimen D|4 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast
62740272|NCT01166893||Burn wound|Modulated Imaging and Laser Speckle Imaging
62740273|NCT06180616|NO_INTERVENTION|Insulin Treatment|Participants will remain on their typical insulin therapy regime for 32 weeks
62740274|NCT06180616|EXPERIMENTAL|Tirzepatide Treatment|Participants will remain on their typical insulin therapy regime and will also receive tirzepatide (dose incremented to 15mg QW) for 32 weeks.
62740275|NCT00883818|EXPERIMENTAL|Antibiotics therapy|
62740276|NCT06210594|EXPERIMENTAL|Education + Household supplies + Nasal antibiotic + Antiseptic regimen|Participants in this arm will receive education about SA and household supplies (e.g., cleaning products, pump lotion, laundry detergent, towels) plus use of a nasal antibiotic (mupirocin) twice daily for 5 days then maintenance with an antiseptic regimen (Nozin twice daily plus chlorhexidine gluconate wash 3 times per week)
62740277|NCT06210594|ACTIVE_COMPARATOR|Education + Household supplies|Participants in this arm will receive education about SA and household supplies (e.g., cleaning products, pump lotion, laundry detergent, towels).
61986213|NCT02206425|EXPERIMENTAL|carfilzomib + pomalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
62175185|NCT01768741|ACTIVE_COMPARATOR|Laparoscopic liver resection group|
62175186|NCT01768741|ACTIVE_COMPARATOR|Open liver resection|
62740278|NCT06658548|EXPERIMENTAL|Group A|
62551222|NCT04304092|EXPERIMENTAL|Low amount, high intensity|
62551223|NCT04304092|EXPERIMENTAL|High Amount, low intensity|
62551224|NCT04304092|EXPERIMENTAL|High Amount, high intensity|
62551225|NCT04304092|NO_INTERVENTION|Control|
62551226|NCT02683421|OTHER|Cohort 1|Healthy Volunteers: 50 mcg tilmanocept with 2 millicuries (mCi) Tc 99m
62551227|NCT02683421|OTHER|Cohort 2|Healthy Volunteers: 200 mcg tilmanocept with 2 mCi Tc 99m
62551228|NCT02683421|EXPERIMENTAL|Cohort 3|RA Group: 50 mcg tilmanocept with 2 mCi Tc 99m
62551229|NCT02683421|EXPERIMENTAL|Cohort 4|RA group:200 mcg tilmanocept with 2 mCi Tc 99m
62740279|NCT06658548|ACTIVE_COMPARATOR|Group B|
62740280|NCT06314659|EXPERIMENTAL|Basic immunization|Perform basic immunization with a program of 0, 1, and 2 months, booster vaccination with 1 dose at 18 months of age.
62740281|NCT06314659|ACTIVE_COMPARATOR|Booster immunization|Perform booster vaccination with 1 dose at 18 months of age.
62740282|NCT03090659|EXPERIMENTAL|LCAR-B38M treatment group|r/r multiple myeloma patients be treated with a split doses of LCAR-B38M cells. Total dose of 0.5-5 millions /kg cells will be administered at day 0, day 2 and day 6 by split dose (20%, 30% and 50% respectively).
62551230|NCT05884944|EXPERIMENTAL|Interventional Group- OMM- Muscle energy|For the OMM treatment group, an osteopathic manipulative treatment protocol will be applied to the lower extremities, specifically muscle energy technique (MET) to the hip, knee, and ankle bilaterally based on the protocol from Atlas of Osteopathic Techniques. The adductor, extensor, and flexor muscles of the hip joint will be treated, the extensors and flexors of the knee joint will be treated, and the plantar and dorsiflexion muscles of the ankle will be treated
62740283|NCT00999635|EXPERIMENTAL|Custom made insole|Custom made functional moulded insole
62551231|NCT05884944|SHAM_COMPARATOR|Control Group- Sham- Light touch, not reaching restrictive barrier|Joint articulation without engaging joint barriers The sham group will serve as the control group and will receive a sham-control procedure as outlined in the paper by Wells, et al in which they will undergo voluntary ROM and then passive movement with the same joint movements without reaching their barrier and no isometric contraction (Wells et al. 1999) The proposed sham procedure will occupy the same amount of time as MET treatment.
62551232|NCT00626561|EXPERIMENTAL|Bevacizumab + Paclitaxel|Bevacizumab 10 mg/kg intravenous (IV) twice weekly and Paclitaxel 60 mg/m\^2 IV weekly.
62551233|NCT00492440|EXPERIMENTAL|CYT107 (r-hIL-7)|
62551234|NCT05741229|ACTIVE_COMPARATOR|Group I (nebulized nitroglycerine)|Patients with persistent pulmonary hypertension (PPHN) and will receive nebulized nitroglycerine as an adjuvant therapy for PPHN
62551235|NCT05741229|PLACEBO_COMPARATOR|Group II (conentional treatment group)|Patients with PPHN and will be treated with conventional regimen for PPHN
62551236|NCT01514461|EXPERIMENTAL|LCQ908 20 mg|"In period II (0-12 weeks) double-blind treatment: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40mg tablet, once daily. No dose titration allowed.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 10 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
62551237|NCT01514461|EXPERIMENTAL|LCQ908 40 mg|"In period II (0-12 weeks) double-blind treatment: one LCQ908 40 mg active tablet + one LCQ908 placebo matching to 20mg tablet, once daily. No dose titration allowed.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
62551238|NCT01514461|PLACEBO_COMPARATOR|Placebo|"In period II (0-12 weeks) double-blind treatment: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet, once daily.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
62551239|NCT02543944|ACTIVE_COMPARATOR|Gabapentin|"Gabapentin started on day 3 of week 1, increased up to a maximum dose of 800 mg BID by day 3 of week 2 and maintained for 2 weeks followed by 5-day taper.~Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.~During week 4, detoxed subjects get 0.1 mg of clonidine followed by oral naltrexone (NTX) at 6.25 mg and another 6.25 mg (day 1), 25 mg (day 2) and 50 mg (day 3) then depot NTX injection (later on day 3 or day 4)."
62551240|NCT02543944|PLACEBO_COMPARATOR|Placebo|"Participants in this arm begin receiving placebo (microcrystalline cellulose) in twice daily capsules on day 3 of week 1 and continue to do so through the beginning of week 5.~Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.~During week 4, detoxed subjects get 0.1 mg of clonidine followed by oral naltrexone (NTX) at 6.25 mg and another 6.25 mg (day 1), 25 mg (day 2) and 50 mg (day 3) then depot NTX injection (later on day 3 or day 4)."
62551241|NCT05856851|EXPERIMENTAL|Intra-arterial alteplase|Participants in the experimental group will receive a 15-minute continuous infusion of intra-arterial alteplase at a drug concentration of 1.0 mg/ml. 15 minutes after the start of intra-arterial thrombolysis, the infusion will be stopped and an angiogram will be performed to assess the eTICI score. If the angiographic eTICI score improves from the baseline score, the procedure will be terminated, otherwise, a new angiogram will be repeated 5-10 minutes after the end of drug administration.
62551242|NCT05856851|NO_INTERVENTION|Standard medical treatment|Participants allocated to the control group will receive standard medical treatment without intra-arterial alteplase after mechanical thrombectomy.
62740284|NCT00999635|ACTIVE_COMPARATOR|Prefabricated Insole|Prefabricated accommodative moulded insole
62551243|NCT01749423||All participants|Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective review of medical records.
62551244|NCT04333485|ACTIVE_COMPARATOR|Home-based Active Case Finding (HACF)|
62551245|NCT04333485|ACTIVE_COMPARATOR|Telephonic Active Case Finding (TACF)|
61986214|NCT05319795|EXPERIMENTAL|Effortful Swallow Maneuver|Adults with a confirmed diagnosis of Parkinson Disease who have radiographically confirmed difficulties with timely airway protection and/or bolus clearance during swallowing. Individuals will complete a 4-week intervention program with two 30-minute sessions of Effortful Swallow (ES) practice daily, 5 days per week.
62551246|NCT01277211|EXPERIMENTAL|ENG-EE (NuvaRing)|Participants were to complete 13 cycles of etonogestrel (ENG) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day ring-free period. Participants used one ring per cycle. Each ring contained 11.7 mg ENG and 2.7 mg EE, and released on average 120 mcg/day of ENG and 15 mcg/day of EE.
62740285|NCT06406582|EXPERIMENTAL|Zirconia laminate veneer|"Intervention: Single-tooth restoration using zirconia ceramic laminate veneers.~Procedure:~Tooth preparation following standard protocols for laminate veneer placement. Fabrication of zirconia laminate veneers. Cementation of zirconia laminate veneers with appropriate bonding protocol. Follow-Up: after 2 weeks, 6 months, and 12 months"
61986215|NCT03240679|ACTIVE_COMPARATOR|Endoscopic submucosal resection with Extracelluar Matrix|Subjects with lesions that lift and are amenable to cap-assisted endoscopic submucosal resection (EMR) will receive extracellular matrix (ECM) to the defect site.
62551247|NCT01277211|ACTIVE_COMPARATOR|DRSP-EE|Participants were to complete 13 cycles of drospirenone (DRSP) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received a total of 21 tablets of DRSP-EE per cycle. Each tablet contained 3 mg DRSP and 30 μg EE.
62551248|NCT05298826||Junior staff has started the management and called for the senior staff.|
62551249|NCT05298826||senior staff. managed the case from the start|
62551250|NCT02995863|EXPERIMENTAL|Experimental Group|Rigid rocker sole footwear
62551251|NCT02995863|ACTIVE_COMPARATOR|Control Group|Therapeutic footwear
62551252|NCT05729490|EXPERIMENTAL|Participants|
62551253|NCT03516656|ACTIVE_COMPARATOR|Standard heparin dose|The investigators will identify surgical patients placed on fixed dose heparin infusions at their attending surgeon's discretion-the proposed research will not dictate the initiation of the heparin drip intraoperatively. However, the investigators will identify patients already on heparin, evaluate steady state heparin anti-Xa levels and adjust patient's dose if necessary based on steady state anti-Xa levels. Eligible patients will be started on heparin fixed-dose intraoperatively and transitioned to a weight-based dose by their surgeons. Steady state anti-Xa levels will be drawn at least 6 hours after initiation of heparin infusion. Goal anti-Xa levels will be 0.1-0.35 IU/mL.
62551254|NCT03516656|ACTIVE_COMPARATOR|Real time heparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time heparin dose adjustment and will receive follow-up steady state anti-Xa levels. Anti-Xa level monitoring will be discontinued when in range peak levels are obtained, when heparin infusions are discontinued at surgeon discretion, or when the patient is discharged
62551255|NCT05466045|EXPERIMENTAL|experimental group|Experimental group received olive oil application
62551256|NCT05466045|PLACEBO_COMPARATOR|control group|Control group received normal saline application
62551257|NCT01470092|ACTIVE_COMPARATOR|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed anti-depressant medication.
62551258|NCT01470092|NO_INTERVENTION|Placebo|Subjects will take oral placebo tablets packaged daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
62551259|NCT02633787|EXPERIMENTAL|Study Group|Participants received a booster dose of Menactra vaccine approximately four years earlier
62551260|NCT02688660||ADAPT Study Population|This cohort will be subjects from the ADAPT study who had an acute MRI scan which has been uploaded into the ADAPT database from all participating sites.
62551261|NCT02688660||Follow-Up MRI|This cohort will include patients from ADAPT sites who choose to participate in this option and obtain a follow-up MRI approximately 1 year after the TBI.
62551262|NCT02688660||Healthy Controls|This cohort will have one MRI to be used in comparison of the above cohorts.
62551263|NCT01513278|PLACEBO_COMPARATOR|Control arm|All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201, the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.
62551264|NCT01513278|ACTIVE_COMPARATOR|APN201|APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel)
62551265|NCT06340607||Recipients with neohepatic ALBI ≥ -1.615|The ALBI score was calculated using the formula: (log10bilirubin × 0.66) + (albumin × -0.085), where bilirubin is measured in μmol/L and albumin in g/L. Recipients with neohepatic (post-reperfusion) ALBI ≥ -1.615
62551266|NCT06340607||Recipients with neohepatic ALBI < -1.615|Recipients with neohepatic (post-reperfusion) ALBI \< -1.615
62740286|NCT06406582|ACTIVE_COMPARATOR|Lithium Disilicate laminate veneer|"Intervention: Single-tooth restoration using lithium disilicate ceramic laminate veneers.~Procedure:~Tooth preparation following standard protocols for laminate veneer placement. Fabrication of lithium disilicate laminate veneers. Cementation of lithium disilicate laminate veneers with appropriate bonding protocol.~Follow-Up: after 2 weeks, 6 months, and 12 months"
62551267|NCT05082974|EXPERIMENTAL|OC-01 (varenicline 0.6mg/ml) nasal spray|
62551268|NCT05082974|PLACEBO_COMPARATOR|Placebo (vehicle) nasal spray|
62175187|NCT03439345|EXPERIMENTAL|Fenofibrate 145 mg|Name: fenofibrate; Form: tablet; Dosage: 145 mg; Frequency: one tablet daily with normal renal function, one tablet every 2nd day with chronic kidney disease
62175188|NCT03439345|PLACEBO_COMPARATOR|Placebo Oral Tablet|Name: placebo; Form: tablet; Dosage: not applicable; Frequency: one tablet daily with normal renal function, one tablet every 2nd day with chronic kidney disease
62740287|NCT05932654|EXPERIMENTAL|300 mg|BSI-045B 300 mg SC QW × 4 weeks, then BSI-045B 300 mg SC Q2W through Week 24
62175189|NCT03471390|EXPERIMENTAL|ProQuaS 2- Intervention|
62175190|NCT02450617|EXPERIMENTAL|Stabilizing group treatment for PTSD|Group treatment, 20 sessions psychoeducation and skills-training. In combination with conventional individual treatment.
62551269|NCT01815476|OTHER|RT Positioning Intervention: Supine|Patient will be treated in a supine position as per standard of care/control.
62551270|NCT01815476|EXPERIMENTAL|RT Positioning Intervention: Prone|Patient will be treated in the prone position.
62551271|NCT06576648|EXPERIMENTAL|Standard PrEP counseling, mHC, and FRESH content|Participants in this arm will receive standard PrEP counseling, followed by four mHC sessions and six FRESH sessions to reduce stigma and increase utilization of HIV prevention services.
62551272|NCT06576648|EXPERIMENTAL|Standard PrEP counseling and mHC|Participants in this arm will receive standard PrEP counseling, followed by four mHC sessions to reduce stigma and increase utilization of HIV prevention services.
62551273|NCT06576648|EXPERIMENTAL|Standard PrEP counseling and FRESH content|Participants in this arm will receive standard PrEP counseling, followed by six FRESH sessions to reduce stigma and increase utilization of HIV prevention services.
62551274|NCT06576648|EXPERIMENTAL|Standard PrEP counseling|Participants in this arm will receive the standard PrEP counseling.
62551275|NCT02715011|EXPERIMENTAL|Part 1: Dose Escalation|Participants will receive JNJ-63709178 in Part 1 (in different cohorts). Each subsequent cohort will receive JNJ-63709178 at an increased dose level. Ascending doses may be given initially to minimize or prevent cytokine release syndrome. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered.
62551276|NCT02715011|EXPERIMENTAL|Part 2: Dose Expansion|Participants will receive JNJ-63709178 at the recommended Phase 2 dose(s) (RP2D) determined in dose expansion phase.
62551277|NCT01949220||Von Willebrand factor deficient patient|Inherited von Willebrand disease
62551278|NCT01380548|PLACEBO_COMPARATOR|Placebo|
62551279|NCT01380548|PLACEBO_COMPARATOR|Iron alone|
62551280|NCT01380548|EXPERIMENTAL|Low-dose 5-aminolevulinic acid|
62551281|NCT01380548|EXPERIMENTAL|Medium-dose 5-aminolevulinic acid|
62551282|NCT01380548|EXPERIMENTAL|High-dose 5-aminolevulinic acid|
62740288|NCT04470050|EXPERIMENTAL|Cohort 1- Dexmedetomidine (30 Micrograms) vs. Placebo|Sublingual film containing 30 Micrograms Dexmedetomidine or Placebo Sublingual film
62740289|NCT04470050|EXPERIMENTAL|Cohort 2- Dexmedetomidine (60 Micrograms) vs. Placebo|Sublingual film containing 60 Micrograms Dexmedetomidine or Placebo Sublingual film
62551283|NCT00971373|EXPERIMENTAL|Exp Scrubs|antimicrobial impregnated scrubs
62551284|NCT00971373|NO_INTERVENTION|Non-antimicrobial scrubs|Non-antimicrobial scrubs
62551285|NCT03409237||Group 1|Mannitol 0.2-0.3 g/kg 4 times/day.
62551286|NCT03409237||Group 2|Hypertonic saline solution 3%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
62551287|NCT03409237||Group 3|Hypertonic solution saline 4%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
62551288|NCT03409237||Group 4|Hypertonic saline solution 7%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
62740290|NCT04470050|EXPERIMENTAL|Cohort 3- Dexmedetomidine (90 Micrograms) vs. Placebo|Sublingual film containing 90 Micrograms Dexmedetomidine or Placebo Sublingual film
62740291|NCT04470050|EXPERIMENTAL|Cohort 4- Dexmedetomidine (120 Micrograms) vs. Placebo|Sublingual film containing 120 Micrograms Dexmedetomidine or Placebo Sublingual film
62740292|NCT04470050|EXPERIMENTAL|Cohort 5- Dexmedetomidine (180 Micrograms) vs. Placebo|Sublingual film containing 180 Micrograms Dexmedetomidine or Placebo Sublingual film
62740293|NCT04470050|EXPERIMENTAL|Cohort 6- Dexmedetomidine (240 Micrograms) vs. Placebo|Sublingual film containing 240 Micrograms Dexmedetomidine or Placebo Sublingual film
62740294|NCT02748421|OTHER|Lumera Microscope with OCT RESCAN|in the group microscope coupled to OCT, patients will undergo retinal surgery using the Lumera microscope with Rescan OCT Zeiss
62740295|NCT02748421|OTHER|Conventional Microscope|control group without OCT RESCAN
62740296|NCT03625778|PLACEBO_COMPARATOR|Placebo Cohort 1|Participants will receive subcutaneous (SC) placebo matched to MEDI0382 Cohort 1 once daily for 9 weeks.
62175191|NCT02450617|ACTIVE_COMPARATOR|Conventional Individual treatment - PTSD|Conventional individual treatment.
62740297|NCT03625778|EXPERIMENTAL|MEDI0382 Cohort 1|Participants will receive SC MEDI0382 titrated doses of Dose 1 to 7 once daily (7-step titration/ 1 week per dose) from Weeks 1 to 7 followed by additional treatment of SC MEDI0382 Dose 7 once daily from Weeks 7 to 9.
62740298|NCT03625778|PLACEBO_COMPARATOR|Placebo Cohort 2|Participants will receive SC placebo matched to MEDI0382 Cohort 2 once daily for 14 weeks.
62740299|NCT03625778|EXPERIMENTAL|MEDI0382 Cohort 2|Participants will receive SC MEDI0382 titrated doses of Doses 1, 2, 3, 5, and 7 once daily (5-step titration/ 2 week per dose) from Weeks 1 to 10 followed by additional treatment of SC MEDI0382 Dose 7 once daily from Weeks 11 to 14.
62740300|NCT03625778|PLACEBO_COMPARATOR|Placebo Cohort 3|Participants will receive SC placebo matched to MEDI0382 Cohort 3 once daily for 18 weeks.
61986216|NCT03240679|NO_INTERVENTION|Endoscopic submucosal resection standard of care|Subjects with lesions that lift and are amenable to cap-assisted endoscopic submucosal resection (EMR) will receive standard of care.
61986217|NCT03394287|EXPERIMENTAL|SHR-1210 +Apatinib daily dosing|SHR-1210 200mg(3mg/kg for patient whose weight is below 50kg) iv Q2W combination With Apatinib 250mg, po, daily dosing (d1-d14)
62175192|NCT02450617|EXPERIMENTAL|Stabilizing group treatment for Dissociative disorders|Group treatment, 20 sessions psychoeducation and skills-training. In combination with conventional individual treatment.
62175193|NCT02450617|ACTIVE_COMPARATOR|Conventional Individual treatment - Dissociative disorders|Conventional individual treatment.
62551289|NCT00564512|EXPERIMENTAL|FCCAM|Fludarabine-Cyclophosphamide-Campath (FCCam) Oral Fludarabine: 40 mg/m2 per os, D1 to D3 Oral Cyclophosphamide: 250 mg/m2/day as one dose at noon, D1 to D3 Campath®: 30 mg sc, D1 to D3 without dose escalation
62551290|NCT00564512|ACTIVE_COMPARATOR|FCR|"Fludarabine-Cyclophosphamide-Rituximab (FCR)~First course:~Rituximab 375 mg/m2 on D1.~D2 to D4:~oral Fludarabine: 40 mg/m2/day as a single morning dose oral Cyclophosphamide: 250 mg/m2/day as a single dose at noon~Subsequent courses (2 to 6)~Rituximab 500 mg/m2 on D1~D1 to D3:~oral Fludarabine: 40 mg/m2/day as a single morning dose oral Cyclophosphamide: 250 mg/m2/day as a single dose at noon"
62551291|NCT04622241|EXPERIMENTAL|Eave Tubes - Traditional House|Installation of eave tubes in traditional homes.
62740301|NCT03625778|EXPERIMENTAL|MEDI0382 Cohort 3|Participants will receive SC MEDI0382 titrated doses of Doses 1, 8, 4, and 7 once daily (4-step titration/ 4 week per dose) from Weeks 1 to 16 followed by additional treatment of SC MEDI0382 Dose 7 once daily from Weeks 17 to 18.
62740302|NCT04994028|ACTIVE_COMPARATOR|Conventional treatment|Conventional treatment that include behavioral and life style modification and dyspnea prevention education
62551292|NCT04622241|EXPERIMENTAL|Eave Tubes - Modern House|Installation of eave tubes in modern homes.
62551293|NCT04622241|EXPERIMENTAL|Eave Ribbons - Traditional House|Installation of eave ribbons in traditional homes.
62551294|NCT04622241|EXPERIMENTAL|Eave Ribbons - Modern House|Installation of eave ribbons in modern homes.
62551295|NCT04622241|EXPERIMENTAL|Full House Screening - Traditional House|Installation of full house screening, includes screening eaves and windows, in traditional homes.
62551296|NCT04622241|EXPERIMENTAL|Full House Screening - Modern House|Installation of full house screening, includes screening eaves and windows, in modern homes.
62551297|NCT04622241|EXPERIMENTAL|Partial House Screening - Traditional House|Installation of partial screening, includee either screening of the eaves or installing a screened ceiling, in traditional homes.
62551298|NCT04622241|EXPERIMENTAL|Partial House Screening - Modern House|Installation of partial screening, includee either screening of the eaves or installing a screened ceiling, in modern homes.
62551299|NCT04622241|NO_INTERVENTION|Control - Traditional House|Control group with no intervention in traditional homes
62740303|NCT04994028|EXPERIMENTAL|conventional treatment with volume Spirometry and deep breathing|Conventional treatment along with volume Spirometry and deep breathing exercise
62740304|NCT04027283|ACTIVE_COMPARATOR|Erythritol|18 volunteers receive 50g erythritol dissolved in 300mL tap water via a nasogastric tube
62740305|NCT04027283|ACTIVE_COMPARATOR|Erythritol + lactisole|18 volunteers receive 50g erythritol with lactisol (450ppm) dissolved in 300mL tap water via a nasogastric tube
62740306|NCT04027283|ACTIVE_COMPARATOR|D-allulose|18 volunteers receive 25g D-allulose dissolved in 300mL tap water via a nasogastric tube
62740307|NCT04027283|ACTIVE_COMPARATOR|D-allulose + lactisole|18 volunteers receive 25g D-allulose with lactisole (450ppm) dissolved in 300mL tap water via a nasogastric tube
62740308|NCT04027283|PLACEBO_COMPARATOR|Tap water|18 volunteers receive 300mL tap water via a nasogastric tube
62740309|NCT04027283|PLACEBO_COMPARATOR|Tap water + lactisole|18 volunteers receive 300mL tap water + lactisole (450ppm) via a nasogastric tube
62740310|NCT05636046||transseptal catheterization performed without auxiliary tools|patients in whom transseptal catheterization have been performed without auxiliary tools
62740311|NCT05636046||transseptal catheterization performed with auxiliary tools|patients in who transseptal catheterization have been performed with the use of auxiliary tools
62740312|NCT05815810|EXPERIMENTAL|Transgender and gender diverse (TGGD) individuals using the pilot app|The investigators will develop Attuned, an open access voice and communication modification training (VCMT) app based on standard of care. Participants will undergo VCMT via the mobile application, Attuned. Participants will include healthy transgender and gender diverse (TGGD) individuals seeking voice modification to better reflect their identity.
62740313|NCT05815810|ACTIVE_COMPARATOR|Transgender and gender diverse (TGGD) individuals receiving standard voice modification|VCMT via speech pathology will be compared to the efficacy of an app-based VCMT program. Participants will undergo VCMT in-person. Participants will include healthy transgender and gender diverse (TGGD) individuals seeking voice modification to better reflect their identity.
62740314|NCT01509976|OTHER|Red|This arm will either start with personal care products that contain triclosan and then and cross over to personal care products that do not contain triclosan or vice-versa. Since the investigators are blinded, it is not clear which arm is which.
62740315|NCT01509976|OTHER|Blue|This arm will either start with personal care products that contain triclosan and then and cross over to personal care products that do not contain triclosan or vice-versa. Since the investigators are blinded, it is not clear which arm is which.
62740316|NCT00582543|EXPERIMENTAL|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position.
62551300|NCT04622241|NO_INTERVENTION|Control - Modern House|Control group with no intervention in modern homes.
62551301|NCT02881697||Obese insulin-resistant subjects|Adipose tissue sampling in obese volunteers (BMI \> 35kg/m2) aged 18- max. 60 years, males and females; insulin-resistant, scheduled for elective bariatric surgery
62740317|NCT03783442|EXPERIMENTAL|Tislelizumab + Chemotherapy|"Tislelizumab 200 milligrams (mg) administered intravenously (IV) on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days~* Chemotherapy Doublet A: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m\^2 on Days 1 to 5 of each cycle Q3W;~* Chemotherapy Doublet B: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m\^2 on Days 1 to 14 of each cycle, twice a day; or~* Chemotherapy Doublet C: cisplatin 60-80 mg/m\^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m\^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines"
62740318|NCT03783442|ACTIVE_COMPARATOR|Placebo + Chemotherapy|"Matched placebo administered IV on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days~* Chemotherapy Doublet A: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m\^2 on Days 1 to 5 of each cycle Q3W;~* Chemotherapy Doublet B: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m\^2 on Days 1 to 14 of each cycle, twice a day; or~Chemotherapy Doublet C: cisplatin 60-80 mg/m\^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m\^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines"
62740319|NCT04322435|OTHER|Adrenal insufficiency|Patients followed in the paediatric endocrinology department of the Necker Hospital, with primary and secondary adrenal insufficiency, aged from 6 months to 6 years.
62740320|NCT02778542|ACTIVE_COMPARATOR|Electronic Pill Bottle|Participants will be mailed an electronic pill bottle for their blood pressure medication.These pill bottles will track how often the participant opens the bottle to take their medication and will transmit that information to study team via cellular data. Participants will also receive a daily text message reminder to take your blood pressure medication.
62740321|NCT02778542|ACTIVE_COMPARATOR|Bidirectional Text Messaging|Participants assigned to bi-directional texting, will receive a daily text message reminder to take their blood pressure medication. Patients in this arm are expected to send a response to the reminder message, indicating if they took their medication that day.
62740322|NCT02778542|NO_INTERVENTION|Usual Care|Participants in this arm do not receive a medication reminder system.
61986218|NCT03394287|EXPERIMENTAL|SHR-1210+Apatinib intermittent dosing|SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) iv Q2W combination With Apatinib 250mg, po, intermittent dosing(Continuous administration for 7 days every 14 days, d1-d7)
62551302|NCT02881697||Lean insulin-sensitive controls|Adipose tissue sampling in normal weight patients (BMI \< 27kg/m2) aged 18- max. 60 years, males and females; insulin-sensitive, scheduled for elective surgery
62551303|NCT02881697||Obese diabetic subjects|Adipose tissue sampling in obese volunteers (BMI \> 35kg/m2) aged 18- max. 60 years, males and females; diabetic, scheduled for elective bariatric surgery
62551304|NCT03872687|EXPERIMENTAL|single tufted brush with IDB|Subjects in this group will receive a single tufted brush and interdental brushes of an appropriate size for 6 months.
62740323|NCT00309985|EXPERIMENTAL|Androgen-Deprivation Therapy and Docetaxel|Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone \[LHRH\] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62740324|NCT00309985|ACTIVE_COMPARATOR|Androgen-Deprivation Therapy alone|Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone \[LHRH\] agonist therapy, LHRH antagonist therapy, or surgical castration) alone.
62740325|NCT03601039|EXPERIMENTAL|Absnow Absorbable ASD Closure System|All subjects are implanted with Absnow Absorbable ASD Occluder
62740326|NCT03459534|EXPERIMENTAL|Radotinib HCl|"Enrolled subjects will continue to administer Radotinib 400mg twice daily (800mg/day) orally every 12 hours at regular dosing hours for 12 months.~Dose modification is allowed if the subject cannot comply with the protocol-defined dosing schedule due to hematologic or non-hematologic toxicities and toxicities resolve within 28 days (within 42 days for hematologic toxicities). For radotinib, maximum 2 dose reductions will be allowed by stage to 600mg and to 400mg."
62740327|NCT02378233|EXPERIMENTAL|iodine|"iodine containing multivitamin~150 ug, 1 tablet daily"
62740328|NCT02378233|PLACEBO_COMPARATOR|placebo|placebo, 1 tablet Daily of a non-iodine containing multivitamin
62740329|NCT00127452|EXPERIMENTAL|EPA + DHA|Margarine spread that yields 400 mg of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) per day for average margarine use of 20 grams per day
62740330|NCT00127452|EXPERIMENTAL|ALA|Margarine spread that yields 2 grams of alpha-linolenic acid (ALA) per day for average margarine use of 20 grams per day
62740331|NCT00127452|EXPERIMENTAL|EPA + DHA plus ALA|Margarine spread that yields 400 mg of EPA + DHA per day plus 2 grams of ALA per day, for average margarine use of 20 grams per day
62740332|NCT00127452|PLACEBO_COMPARATOR|Placebo|Margarine spread that contains no EPA, DHA or ALA (exchanged for oleic acid)
62740333|NCT01530178|ACTIVE_COMPARATOR|Part A|Sitagliptin 25mg
62740334|NCT01530178|ACTIVE_COMPARATOR|Part B|Sitagliptin 50mg
62740335|NCT01530178|ACTIVE_COMPARATOR|Part C|Sitagliptin 100mg
62740336|NCT01530178|PLACEBO_COMPARATOR|Part D|Placebo oral tablet
62740337|NCT01814397||Women starting AI therapy|There is only a single cohort. Postmenopausal women with ER positive breast cancer who are starting treatment with anastrozole 1 mg daily, letrozole 2.5 mg daily, or exemestane 25 mg daily. Choice of therapy is at the discretion of the treating physician.
62740338|NCT00152828|EXPERIMENTAL|Celecoxib|Celecoxib
62740339|NCT02289053||Positive Family History|"Eligible participants with a family history of colorectal cancer or polyps will be grouped into the subjects group."
61986219|NCT03904238|EXPERIMENTAL|CBT-H (Individual format)|Individual CBT-H consists of 6 weekly sessions that are conducted one-on-one with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes.
62175194|NCT04199676||Intervention|75g glucose tolerance test to be administered during postpartum hospitalization
62551305|NCT03872687|ACTIVE_COMPARATOR|interdental brushes|Subjects in this group will only receive interdental brushes 6 months.
62551306|NCT02430480|EXPERIMENTAL|1/Arm 1- Enzalutamide and Goserelin|Patients will have an multi-parametric magnetic resonance imaging (mpMRI) guided biopsy, then receive enzalutamide and goserelin subcutaneous (SC) treatment for 6 months followed by a second mpMRI examination.
62551307|NCT00365703|EXPERIMENTAL|1|Orogastric feeding tube.
62551308|NCT00365703|EXPERIMENTAL|2|Nasogastric feeding tube.
62175195|NCT05599646|EXPERIMENTAL|traditional pedometer group|
62175196|NCT05599646|EXPERIMENTAL|gamified smartphone pedometer group|
62175197|NCT05599646|NO_INTERVENTION|control group|
62551309|NCT03478722||Maintenance Hemodialysis Patients|Protein meal, stable isotope amino acid infusion
62740340|NCT02289053||Average Risk Patients|"Eligible participants without a family history of colorectal cancer or polyps will be grouped into the control group."
62740341|NCT04110756|EXPERIMENTAL|ChangeGradients|100 adolescents will be enrolled in the CHANGEGRADIENTS intervention.
62740342|NCT04110756|NO_INTERVENTION|Comparison, non-intervention condition|100 participants will not participate in the ChangeGradients intervention, and will continue to have treatment as usual at the clinic.
62740343|NCT06132724||Healthy Volunteers|"Subjects who will agree to participate to the study will be healthy subject with no particular antecedents.~Subjects will be enroled for two sessions with a 20 min monitoring phase in each session, to coect physiological data with non invasive sensors."
62740344|NCT04699838|EXPERIMENTAL|Cisplatin or Carboplatin + Etoposide + Durvalumab + Ceralasertib|"Initial Phase: Cycles 1-4 Cisplatin or Carboplatin: Day 1 Etoposide: Days 1-3 Durvalumab, 1500 mg: Day 1 q 3 weeks~Maintenance Phase, Cycles 5+ Durvalumab, 1500 mg: Day 8 q 4 wks. Ceralasertib at 240mg po BID twice a day: Days 1-7"
62740345|NCT02461446||PTEN ASD|PTEN participants with Autism Spectrum Disorder group
62740346|NCT02461446||PTEN no ASD|PTEN participants without Autism Spectrum Disorder group
62740347|NCT02461446||Controls|Healthy control group
62740348|NCT03629223|EXPERIMENTAL|Part A: First Tepotinib TF2 then TF3|Participants received a single oral dose of 500 milligrams (mg) Tepotinib tablet formulation 2 (TF2, reference treatment) on Day 1 of treatment period 1 followed by a single oral dose of 500 mg (2 x 250 mg) Tepotinib tablet formulation 3 (TF3, test treatment) on Day 1 of treatment period 2 under fasting conditions. The washout period was 21 days between Day 1 of each period.
62740349|NCT03629223|EXPERIMENTAL|Part A: First Tepotinib TF3 then TF2|Participants received a single oral dose of 500 mg (2 x 250 mg) Tepotinib TF3 (test treatment) on Day 1 of treatment period 1 followed by a single oral dose of 500 mg Tepotinib TF2 (reference treatment) on Day 1 of treatment period 2 under fasting conditions. The washout period was 21 days between Day 1 of each period.
62740350|NCT03629223|EXPERIMENTAL|Part B: First Tepotinib TF2 Fasted then TF2 Fed|Participants received a single oral dose of 500 mg Tepotinib TF2 (reference treatment) on Day 1 of treatment period 1 under fasting conditions followed by a single oral dose of 500 mg Tepotinib TF2 (reference treatment) on Day 1 of treatment period 2 under fed conditions. The washout period was 21 days between Day 1 of each period.
62551310|NCT03478722||Control Subjects|Protein meal, stable isotope amino acid infusion
62551311|NCT03026998|OTHER|MRI|
62551312|NCT02719275||Suicidal Behaviour|
62740351|NCT03629223|EXPERIMENTAL|Part B: First Tepotinib TF2 Fed then TF2 Fasted|Participants received a single oral dose of 500 mg Tepotinib TF2 (reference treatment) on Day 1 of treatment period 1 under fed conditions followed by a single oral dose of 500 mg Tepotinib TF2 (reference treatment) on Day 1 of treatment period 2 under fasting conditions. The washout period was 21 days between Day 1 of each period.
62551313|NCT02719275||Suicidal Ideation|
62551314|NCT02719275||Other Mental Health|
62551315|NCT02719275||Other Health|
62551316|NCT03892018|ACTIVE_COMPARATOR|Fed/ Fasted Treatment Sequence|"Subjects will be assigned a fed/fasted sequence.~Fed sequence- subjects will fast overnight and continue fasting until they consume a standardized test meal at a predetermined time after paclitaxel administration.~Fasted Sequence- subjects will fast overnight and continue fasting until 4 hours post paclitaxel dose."
62551317|NCT03892018|ACTIVE_COMPARATOR|Fasted/ Fed Treatment Sequence|"Subjects will be assigned a fasted/fed sequence.~Fasted Sequence- subjects will fast overnight and continue fasting until 4 hours post paclitaxel dose.~Fed sequence- subjects will fast overnight and continue fasting until they consume a standardized test meal at a predetermined time after paclitaxel administration."
62551318|NCT02166710|EXPERIMENTAL|Adductor canal femoral nerve blockade|Patients will receive continuous adductor canal femoral nerve blockade for 48 hours with a catheter connected to a pump infusing bupivacaine 0.125% and multi-modal analgesia for pain management following total knee arthroplasty. Knee extensor muscle strength will be measured at different time-points prior and after surgery.
62740352|NCT03629223|EXPERIMENTAL|Part C: First Tepotinib TF3 Fasted then TF3 Fed|Participants received a single oral dose of 500 mg (2 x 250 mg) Tepotinib TF3 (test treatment) on Day 1 of treatment period 1 under fasting conditions followed by a single oral dose of 500 mg (2 x 250 mg) Tepotinib TF3 (test treatment) on Day 1 of treatment period 2 under fed conditions. The washout period was 21 days between Day 1 of each period.
61986220|NCT03904238|EXPERIMENTAL|CBT-H (Group format)|Group-based CBT-H consists of 6 weekly sessions that are conducted in groups with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes. The treatment package consists of the same cognitive and behavioral modules as the individual CBT-H. However, participants are also provided the opportunity to share their experiences and provide peer support in the group format.
62551319|NCT02166710|PLACEBO_COMPARATOR|Simulated nerve blockade|Patients will receive a simulated continuous femoral nerve block at the level of the adductor canal for 48 hours with a catheter connected to a pump infusing bupivacaine 0.125% and multi-modal analgesia for pain management following total knee arthroplasty. Knee extensor muscle strength will be measured at different time-points prior and after surgery.
62551320|NCT03892603|EXPERIMENTAL|Strengthening exercises program|
62551321|NCT03892603|EXPERIMENTAL|Motor control exercises program|
62551322|NCT03892603|ACTIVE_COMPARATOR|Education and advice|
62551323|NCT06277089|OTHER|Correction of EOS by serial cast|
62551324|NCT03923647||Laparoscopy and CT scan|Usage of laparoscopy after inflation of co2 infra umbilical
62551325|NCT04050215|EXPERIMENTAL|Diagnostic (68Ga-PSMA-11 PET/CT)|Patients receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 3 hours. Patients may be reenrolled in the study, if 68Ga-PSMA-11 PET/CT is performed for subsequent management decision.
62551326|NCT05694689|ACTIVE_COMPARATOR|Usual care plus placebo|Infants will receive placebo (normal saline) in the first 28 days after birth. Co-interventions will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices.
62551327|NCT05694689|EXPERIMENTAL|Usual care plus vitamin D supplementation|Infants will receive cholecalciferol 800 IU/day in the first 28 days after birth, given enterally four times per day (0.5mL per dose = 200 IU) until the infant is provided 400 IU/day. At that point the study cholecalciferol will be reduced to 400 IU/day for a total supplementation of 800 IU/day.
62551328|NCT05257681|EXPERIMENTAL|Fissure completion and adhesiolysis arm|Patients will undergo a VATS or robotic interlobar lung fissure completion with pleural adhesiolysis. After a 3 month follow-up period, patients will fill additional quality of life questionnaires including the St.George Respiratory Questionnaire, COPD Assessment tool, and the modified medical research council dyspnea scale. Pulmonary function testing and a high-resolution CT scan will be performed at the end of the 3-month postoperative follow-up.
62551329|NCT03123068|ACTIVE_COMPARATOR|Active treatment group - Group A|Participants will receive a daily oral dose of 1,000 mg cocoa flavanol (CocoaVia®) for 5 days before surgery. The daily dose will consist of 8 capsules in divided doses throughout the day.
62551330|NCT03123068|PLACEBO_COMPARATOR|Placebo treatment group - Group B|Participants will receive a daily oral dose of a placebo for 5 days before surgery. The daily dose will consist of 8 capsules in divided doses throughout the day.
62551331|NCT01922505||PPI triple therapy|7-day PPI triple therapy regimen: PPI (esomeprazole 40 mg or omeprazole 20 mg or lansoprazole 30 mg or pantoprazole 40 mg or rabeprazole 20 mg) plus amoxicillin (1000mg) and clarithromycin (500mg) twice daily for 7 days.
62551332|NCT04604340|ACTIVE_COMPARATOR|transfemoral access|control
62551333|NCT04604340|ACTIVE_COMPARATOR|transradial access|case
62551334|NCT02737774|EXPERIMENTAL|Icotinib and Pemetrexed/Carboplatin|"Icotinib: Icotinib for 18 weeks, 125mg Tid，PO. Chemotherapy: pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.~Then continue with Icotinib, 125mg Tid，PO. until disease progression."
62551335|NCT05190939|ACTIVE_COMPARATOR|no-dye/saline|Subjects assigned to the no-dye/saline group will have cystoscopy performed using saline as the bladder distending media and will not utilize any intravenous dye
62551336|NCT05190939|EXPERIMENTAL|dye/saline|Subjects assigned to the dye/saline group will have cystoscopy performed using saline as the bladder distending media and will utilize intravenous dye (methylene blue or fluorescein) as a ureteral jet visualization aid
62551337|NCT05190939|EXPERIMENTAL|no-dye/water|Subjects assigned to the no-dye/water group will have cystoscopy performed using water as the bladder distending media and will not utilize any intravenous dye
62551338|NCT05190939|EXPERIMENTAL|dye/water|Subjects assigned to the dye/water group will have cystoscopy performed using water as the bladder distending media and will utilize intravenous dye (methylene blue or fluorescein) as a ureteral jet visualization aid
62551339|NCT00871208|EXPERIMENTAL|1|Altabax (R) and Locoid Lipocream (R):Patients will apply both drugs sequentially to active lesions of atopic dermatitis. Physical examination, skin cultures, photos and quality of life scores will be performed at baseline, week 1, week 2 and week 4.
62551340|NCT00871208|ACTIVE_COMPARATOR|2|Vehicle and Locoid Lipocream (R):Patients will apply both drugs sequentially to active lesions of atopic dermatitis. Physical examination, skin cultures, photos and quality of life scores will be performed at baseline, week 1, week 2 and week 4.
62551341|NCT05667025|ACTIVE_COMPARATOR|Conservative Rehabilitation|Conservative Rehabilitation
62551342|NCT05667025|ACTIVE_COMPARATOR|Cycling Functional Electrical Stimulation in addition to Conservative Rehabilitation|Cycling Functional Electrical Stimulation in addition to Conservative Rehabilitation
62551343|NCT05085262||Mild Disease|Those assessed as an outpatient or discharged from the emergency department and never admitted elsewhere based on patient history
62551344|NCT05085262||Moderate Disease|Those admitted but never requiring transfer to ICU or similar advanced care setting
62551345|NCT05085262||Severe Disease|Those requiring admission to ICU or other advanced care settings (i.e. other Level 2 beds)
62551346|NCT05085262||Control Group|Those with a negative COVID-19 and no history of COVID-19
62551347|NCT05225779|ACTIVE_COMPARATOR|sevoflurane|General Anesthesia procedure with sevoflurane
62551348|NCT05225779|ACTIVE_COMPARATOR|desflurane|General Anesthesia procedure with desflurane
62551349|NCT01133457|EXPERIMENTAL|Finasteride|Finasteride tablets 1 mg of Dr. Reddy's
62551350|NCT01133457|ACTIVE_COMPARATOR|Propecia|Propecia 1 mgTablets of Merck \& Co.,
62551351|NCT01957397|EXPERIMENTAL|Coloplast Test 1|"The subjects are randomised to two arms~In both arms the subjects start measuring the performance of own product to collect baseline data.~In this arm the subjects are randomised to test Coloplast Test1 first and thereafter Coloplast Test 2~Finally the all subject test Coloplast Test 3"
62740353|NCT03629223|EXPERIMENTAL|Part C: First Tepotinib TF3 Fed then TF3 Fasted|Participants received a single oral dose of 500 mg (2 x 250 mg) Tepotinib TF3 (test treatment) on Day 1 of treatment period 1 under fed conditions followed by a single oral dose of 500 mg (2 x 250 mg) Tepotinib TF3 (test treatment) on Day 1 of treatment period 2 under fasting conditions. The washout period was 21 days between Day 1 of each period.
62551352|NCT01957397|EXPERIMENTAL|Coloplast Test 2|"The subjects are randomised to two arms~In both arms the subjects start measuring the performance of own product to collect baseline data.~In this arm the subjects are randomised to test Coloplast Test 2 first and thereafter Coloplast Test 1~Finally the all subject test Coloplast Test 3"
62740354|NCT05070819|EXPERIMENTAL|Cardiac surgery patients|"1. After admission to OR and arterial catheter is placed the pro-ANP probe is obtained.~2. After anesthesia induction, trachea intubation before Teboul' test pro-ANP is obtained~3. At the end of Teboul' test when lower limbs are lifted~4. 30 minutes of CPB~5. End of CPB~6. End of volume transition from CPB circuit to patient~7. Before Teboul' test at the end of surgery~8. End of Teboul' test when lower limbs are lifted"
62740355|NCT06659835||CRRT group|intensive care patients with continuous renal replacement therapy
62740356|NCT06659835||non-CRRT group|intensive care patients without renal replacement therapy
62740357|NCT06401694|EXPERIMENTAL|Enhanced|Home-delivered meals plus Community Health Worker Calls and supplemental grocery bags
62182401|NCT01776008|EXPERIMENTAL|Treatment (MK2206, anastrozole, goserelin acetate)|Patients receive Akt inhibitor MK-2206 PO on days 2, 9, 16, and 23; anastrozole PO daily on days 1-28; and goserelin acetate SC on day 1 (premenopausal patients only). Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62551353|NCT02153983|EXPERIMENTAL|Obese Adults with Metabolic Syndrome Randomized to Placebo|Experimental treatment with placebo capsules identical in appearance to the experimental colchicine preparation
62551354|NCT02153983|EXPERIMENTAL|Obese Adults with Metabolic Syndrome Randomized to Colchicine|Experimental treatment with colchicine capsules identical in appearance to the experimental placebo preparation
62551355|NCT02153983|EXPERIMENTAL|Diet-controlled Type 2 Diabetes Adults Assigned to Colchicine|Participants with Diet-controlled Type 2 Diabetes who were assigned to Open-label treatment with colchicine. These participants were not randomized and were not part of the randomized controlled trial.
62551356|NCT02153983|NO_INTERVENTION|Evaluation Only Non-obese Adults|Participants without obesity seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort.
62551357|NCT02153983|NO_INTERVENTION|Evaluation Only Obese Adults Not Randomized|Participants with obesity seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort. These participants were found not eligible for randomization.
62551358|NCT02153983|NO_INTERVENTION|Evaluation Only Adults with Type 2 Diabetes|Participants with Diet-controlled Type 2 Diabetes seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort.
62551359|NCT00556868|EXPERIMENTAL|A|Breakfast on the first day of intervention, fasting (no breakfast) on the second day of intervention
62551360|NCT00556868|EXPERIMENTAL|B|Fasting (no breakfast) on the first day of intervention, breakfast on the second day of intervention
62740358|NCT06401694|ACTIVE_COMPARATOR|Usual care|Home-delivered meals
62740359|NCT06650748|EXPERIMENTAL|Arm 1|gene high-risk according to Epclin who are insensitive to single-agent AI treatment for two weeks
62740360|NCT06650748|EXPERIMENTAL|Arm 2|gene high-risk according to Epclin who are sensitive to single-agent AI treatment for two weeks and gene low-risk according to Epclin who are insensitive to single-agent AI treatment for two weeks, randomly assigned to letrozole treatment arm
62740361|NCT06650748|EXPERIMENTAL|Arm 3|gene high-risk according to Epclin who are sensitive to single-agent AI treatment for two weeks and gene low-risk according to Epclin who are insensitive to single-agent AI treatment for two weeks, randomly assigned to Dalpiciclib and letrozole treatment arm
62740362|NCT06650748|EXPERIMENTAL|Arm 4|gene low-risk according to Epclin who are sensitive to single-agent AI treatment for two weeks
62740363|NCT06478316|EXPERIMENTAL|Study|a 10 ml syringe will be filled with 7 ml of lidocaine and 1 ml of bicarbonate (total 70 mg of lidocaine).
62740364|NCT06478316|SHAM_COMPARATOR|Control|a 10 ml syringe will be filled with 8 ml of 0.9% NaCl saline
62740365|NCT05898620|EXPERIMENTAL|Low Dose|Dose Level 1
62551361|NCT05915260||Patients with type 2 diabetes|This group will be split up into different groups. DM2 with vs. without complications to diabetes DM2 with vs. without albuminuria/nephropathy or autonomic neuropathy or retinopathy or peripheral neuropathy or macrovascular angiopathy
62551362|NCT05915260||sex and age matched control subjects|
62551363|NCT01074944|EXPERIMENTAL|Twice Daily (BID) Dose Regimen|Patients will receive either 50 mg BID or 100 mg BID
62551364|NCT01074944|EXPERIMENTAL|Once Daily (QD) Dose Regimen|Patients will receive either 100 mg QD or 200 mg QD
62551365|NCT04138381|OTHER|selinexor as a single agent and in combination with imatinib|"This is a single-arm, two-cohort, open label phase Ib/II trial studying the combination of oral imatinib 400 mg, once daily, and oral selinexor given once weekly (Cohort A); and single-agent oral selinexor 60 mg BIW (Cohort B). The study will consist of:~* Cohort A: an initial escalation phase (Ib) evaluating increasing doses of selinexor in combination with fixed doses of imatinib administered in repeated 28-day cycles in advanced/metastatic, imatinib-resistant GIST patients, followed by en expansion phase (II) testing for safety and preliminary evidence of antitumor activity~* Cohort B: single-agent, fixed selinexor dose in the same target population"
62551366|NCT04428814|EXPERIMENTAL|CT-P43 (Part 1)|45mg single dose administration
62551367|NCT04428814|ACTIVE_COMPARATOR|EU-approved Stelara (Part 1)|45mg single dose administration
62740366|NCT05898620|EXPERIMENTAL|High Dose|Dose Level 2
62740367|NCT02516995|EXPERIMENTAL|Patients with prostate cancer|
62175198|NCT05091554|NO_INTERVENTION|Single visit control|"The root canals were obturated in the same session using cold lateral compaction technique with AH Plus sealer (Dentsply DeTrey, Konstanz, Germany), Protaper Universal gutta-percha (ProTaper Universal gutta-percha, Dentsply) and .02 tapered auxiliary gutta-percha (Diadent, Chongju, Korea) cones. Residual gutta-perchas in the access cavity were removed with the aid of heated hand tools. The quality of root canal filling was checked with periapical radiographs.~The pulp chamber was filled with flowable composite resin (Filtek Ultimate Flowable, 3M-ESPE, St. Paul, MN, USA) and nanohybrid composite resin (3M-ESPE) using an incremental technique.~Intraoral cryotherapy was not applied."
62551368|NCT04428814|EXPERIMENTAL|CT-P43 (Part 2)|45mg single dose administration
62551369|NCT04428814|ACTIVE_COMPARATOR|EU-approved Stelara (Part 2)|45mg single dose administration
62551370|NCT04428814|ACTIVE_COMPARATOR|US-licensed Stelara (Part 2)|45mg single dose administration
62551371|NCT04970303||Case group|investigator will recruit 60 patients with ADHD (aged between 6 and 16). Blood (10 ml) and urine (10 ml) will be obtained from each participant to analyze the levels of EDCs (Phthalates, Phenols and Parabens), growth hormone and thyroid function (TSH, T3, Free T4, T4, growth hormone, IGF-1and IGF-BP3). Behavior symptoms (ADHD-RS and SNAP-IV) and neuropsychological function (WISC, CPT and CATA) of each participant will be assessed. Patients with ADHD will receive treatment in a clinical practice and then will be followed up for 12 months. At the 12th month, the same procedures as those performed at the baseline will be replicated for patients with ADHD.
62551372|NCT04970303||Control group|investigator will recruit 60 age- and gender-matched control subjects. Blood (10 ml) and urine (10 ml) will be obtained from each participant to analyze the levels of EDCs (Phthalates, Phenols and Parabens), growth hormone and thyroid function (TSH, T3, Free T4, T4, growth hormone, IGF-1and IGF-BP3). Behavior symptoms (ADHD-RS and SNAP-IV) and neuropsychological function (WISC, CPT and CATA) of each participant will be assessed.
62551373|NCT02542956|ACTIVE_COMPARATOR|Exparel|Injection of Exparel
62551374|NCT02542956|ACTIVE_COMPARATOR|Marcaine|Receive Marcaine in a pain pump or by injection
62551375|NCT00954343|EXPERIMENTAL|Group I|
62551376|NCT00954343|EXPERIMENTAL|Group II|
62551377|NCT00954343|EXPERIMENTAL|Group III|
62551378|NCT00954343|EXPERIMENTAL|Group IV|
62740368|NCT01736072|ACTIVE_COMPARATOR|Laparoscopic Resection of Rectal Cancer|Research Subjects will be randomized to Surgical Resection of Rectal Cancer by Standard Laparoscopic Surgery.
62740369|NCT01736072|ACTIVE_COMPARATOR|Robotic Resection of Rectal Cancer|Research Subjects will be randomized to Surgical Resection of Rectal Cancer by Robotic Assisted Laparoscopic Surgery.
62740370|NCT06658145|EXPERIMENTAL|Full visibility vnotes group|A suitable size of multi-channel vaginal sealing instrument was inserted from the vagina, pneumoperitoneum formed air pressure, and the vaginal dome was dilated and fully exposed. The dome was opened under laparoscopy, and an approach platform was established to complete the total hysterectomy.
62740371|NCT06658145|EXPERIMENTAL|Traditional vnotes group|The vaginal fornix and part of cervical ligaments were incised by vaginal operation, and an approach platform was established to complete hysterectomy.
62740372|NCT06615661||C-Rex surgery - combination|C-Rex surgery combined with cataract extraction/intraocular lens (IOL) implantation
62740373|NCT06615661||C-Rex surgery - standalone|C-Rex surgery as a standalone intervention
62740374|NCT06222346|EXPERIMENTAL|CommonGround Platform|Online Peer Support and Psychoeducational Platform
62551379|NCT00954343|NO_INTERVENTION|Group V|
62551380|NCT01764399|EXPERIMENTAL|Care4U intervention|Care4U intervention with 6 weekly sessions focusing on physical activity, healthy eating, self-management, emotional responses.
62551381|NCT01764399|NO_INTERVENTION|Information group|The information group receives 6 weekly socialization sessions.
62740375|NCT06222346|ACTIVE_COMPARATOR|Control|"National Health Service (NHS) Mental Health webpage(s)"
62740376|NCT05719350|EXPERIMENTAL|Experimental Group|Tele-rehabilitation exercises for the knee joint to reduce pain
62740377|NCT05719350|ACTIVE_COMPARATOR|Control Group|Exercises in presence for the knee joint to decrease pain
62740378|NCT05810571|PLACEBO_COMPARATOR|patient controlled analgesia|this group of patients received no block, received only postoperative patient-controlled analgesia with morphine
62740379|NCT05810571|ACTIVE_COMPARATOR|erector spina plane block|this group of patients received erector spina plane block preoperatively, received only postoperative patient-controlled analgesia with morphine
62740380|NCT05810571|ACTIVE_COMPARATOR|quadratus lumborum block|this group of patients received erector spina plane block preoperatively, received only postoperative patient-controlled analgesia with morphine
62740381|NCT05032677|EXPERIMENTAL|Conventional Epidural Technique|
62740382|NCT05032677|ACTIVE_COMPARATOR|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|
62551382|NCT02245412|EXPERIMENTAL|ALXN1007 10 mg/kg once weekly|Cohort 1, the first dosing cohort, received 10 mg/kg ALXN1007 IV once weekly for 8 weeks.
62551383|NCT02245412|EXPERIMENTAL|ALXN1007 20 mg/kg once weekly|Cohort 2 received 20 mg/kg ALXN1007 IV once weekly for 8 weeks. For the first 2 participants enrolled, the first ALXN1007 dose was not to be administered on the same day and a safety and tolerability review was to take place after the second (and prior to the third) ALXN1007 dose for each participant. If the ALXN1007 dose was determined to be sufficiently tolerated by the participant, dosing was to continue for that participant. For any other participants enrolled in the dosing cohort, participants were not to proceed to the third ALXN1007 dose prior to the completion of the safety and tolerability review (of the first 2 doses) for the first 2 participants.
62551384|NCT02245412|EXPERIMENTAL|ALXN1007 20 mg/kg twice weekly|Cohort 3 received 20 mg/kg ALXN1007 IV twice weekly for 8 weeks. For the first 2 participants enrolled, the first ALXN1007 dose was not to be administered on the same day and a safety and tolerability review was to take place after the second (and prior to the third) ALXN1007 dose for each participant. If the ALXN1007 dose was determined to be sufficiently tolerated by the participant, dosing was to continue for that participant. For any other participants enrolled in the dosing cohort, participants were not to proceed to the third ALXN1007 dose prior to the completion of the safety and tolerability review (of the first 2 doses) for the first 2 participants.
62551385|NCT03352739|EXPERIMENTAL|DBS of the fornix, power on|
62551386|NCT03352739|EXPERIMENTAL|DBS of the NbM, power on|
62551387|NCT03352739|SHAM_COMPARATOR|DBS of the fornix, power off|
62551388|NCT03352739|SHAM_COMPARATOR|DBS of the NbM, power off|
62551389|NCT03352739|NO_INTERVENTION|Control group|The patients are going to prescribe stable dosage of donepezil during observation period without surgical interference.
62551390|NCT01509274|EXPERIMENTAL|Plasma|
62551391|NCT01509274|SHAM_COMPARATOR|Saline|
62551392|NCT01509274|ACTIVE_COMPARATOR|Physiotherapy + heel cap|
62551393|NCT02139137|EXPERIMENTAL|High Interference Control Condition|Computerized training program requiring participants to repeatedly practice controlling interference on a cognitive task
62551394|NCT02139137|ACTIVE_COMPARATOR|Low Interference Control Condition|Computerized training program requiring participants to minimally practice controlling interference on a cognitive task
62551395|NCT02841982|EXPERIMENTAL|single-injection QLB(quadratus lumborum block)|Single-injection of QLB is given preoperatively + postoperative IPCA(intravenous patient controlled analgesia)
62551396|NCT02841982|ACTIVE_COMPARATOR|IPCA|postoperative IPCA is given alone
62551397|NCT06241625|EXPERIMENTAL|VR-Visual Function Test|Assessment of virtual reality based vision function in Patients with AMD
62551398|NCT02392949|EXPERIMENTAL|Experimental group|Passive mobilization on cervical spine
62551399|NCT02392949|PLACEBO_COMPARATOR|Control|Placebo exercise on arms
62740383|NCT02083341|EXPERIMENTAL|Muscle tension dysphonia - treatment|external vibration device. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP.
62364826|NCT03030014|EXPERIMENTAL|educational programm|"Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.~Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children."
62551400|NCT03956940|EXPERIMENTAL|Intplex test|In vitro diagnostic device
62551401|NCT00958893|EXPERIMENTAL|25 mg Proellex|25 mg Proellex daily
62551402|NCT02888730|EXPERIMENTAL|Tobramycin nebulized nasally|Nebulized Tobramycin, one bulb (tobramycin 300 mg and sodium chloride 11.25 mg) nasally twice a day for 15 days
62551403|NCT02888730|PLACEBO_COMPARATOR|Physiologic serum nebulized nasally|Nebulized sodium chloride 0.9%, one bulb twice a day nasally for 15 days
62551404|NCT04138498|EXPERIMENTAL|Sequence 1 (ADBC)|Subjects in sequence ADBC will receive study treatments in the following order: Focalin XR 5 mg capsule, CTx-1301 50 mg tablet, CTx-1301 6.25 mg tablet, Focalin XR 40 mg capsule.
62551405|NCT04138498|EXPERIMENTAL|Sequence 2 (BACD)|Subjects in sequence BACD will receive study treatments in the following order: CTx-1301 6.25 mg tablet, Focalin XR 5 mg capsule, Focalin XR 40 mg capsule, CTx-1301 50 mg tablet.
62551406|NCT04138498|EXPERIMENTAL|Sequence 3 (CBDA)|Subjects in sequence CBDA will receive study treatments in the following order: Focalin XR 40 mg capsule, CTx-1301 6.25 mg tablet, CTx-1301 50 mg tablet, Focalin XR 5 mg capsule.
62551407|NCT04138498|EXPERIMENTAL|Sequence 4 (DCAB)|Subjects in sequence DCAB will receive study treatments in the following order: CTx-1301 50 mg tablet, Focalin XR 40 mg capsule, Focalin XR 5 mg capsule, CTx-1301 6.25 mg tablet.
62551408|NCT02051556|EXPERIMENTAL|Best Side Improvement|Physical Therapy BSI (Best Side Improvement), aimed to potentiate the less affected body side.
62551409|NCT02051556|EXPERIMENTAL|Worse side improvement|Physical Therapy WSI (Worst Side Improvement), aimed to potentiate the most affected body side.
62551410|NCT02051556|ACTIVE_COMPARATOR|Standard treatment|Physical Therapy ST (Standard Treatment), aimed to potentiate both sides equally.
62551411|NCT01748201|EXPERIMENTAL|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
62551412|NCT00978874|EXPERIMENTAL|All subjects|
62551413|NCT01644617|PLACEBO_COMPARATOR|Placebo|Placebo rapidly dissolving tablet administered sublingually once daily (q.d.), at approximately the same time each day, for 24 weeks
62551414|NCT01644617|EXPERIMENTAL|MK-8237 6 Developmental Units (DU)|MK-8237 6 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks
62551415|NCT01644617|EXPERIMENTAL|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks
62551416|NCT04407273||with statins|Covid-19 infected patients with statins
62551417|NCT04407273||without statins|Covid-19 infected patients without statins
62551418|NCT05892744|OTHER|Sertraline hydrochloride, up to 200mg/day or maximum tolerable dose|Established FDA-approved treatment for major depressive disorder
62551419|NCT00451178|EXPERIMENTAL|R-CHOP and Enzastaurin|R-CHOP includes rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment therapies.
62740384|NCT02083341|SHAM_COMPARATOR|Muscle tension dysphonia - Sham|external vibration device - sham. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP. Lelo® Siri vibrator with vibration component removed.
62740385|NCT02083341|EXPERIMENTAL|Classically trained singers|external vibration device. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP.
62740386|NCT02083341|SHAM_COMPARATOR|Classically trained singers - Sham|external vibration device - sham. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP. Lelo® Siri vibrator with vibration component removed.
62551420|NCT00451178|ACTIVE_COMPARATOR|R-CHOP|R-CHOP includes rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment therapies.
62551421|NCT05543798|EXPERIMENTAL|Non-Randomized|All subjects with ventricular tachycardia associated with ischemic cardiomyopathy will undergo catheter ablation using the Vision-MR Ablation Catheter 2.0
62175199|NCT05091554|EXPERIMENTAL|Single visit 15 minutes cryotherapy|"The root canals were obturated in the same session using cold lateral compaction technique with AH Plus sealer (Dentsply DeTrey, Konstanz, Germany), Protaper Universal gutta-percha (ProTaper Universal gutta-percha, Dentsply) and .02 tapered auxiliary gutta-percha (Diadent, Chongju, Korea) cones. Residual gutta-perchas in the access cavity were removed with the aid of heated hand tools. The quality of root canal filling was checked with periapical radiographs.~The pulp chamber was filled with flowable composite resin (Filtek Ultimate Flowable, 3M-ESPE, St. Paul, MN, USA) and nanohybrid composite resin (3M-ESPE) using an incremental technique.~15 minutes intraoral cryotherapy was applied."
62551422|NCT00670969||A|People who will have the portable measurement taken first and handheld measurement taken second
62551423|NCT00670969||B|People who will have the handheld measurement taken first and portable measurement taken second
62740387|NCT06482099||RSVpreF vaccine|Pregnant women who have been vaccinated with Abrysvo for the first time.
62740388|NCT05019508||High Risk for Gestational Diabetes Mellitus (GDM)|"High risk women screened with HbA1c at initiation of prenatal care who were not diagnosed with Type 2 Diabetes Mellitus or Early GDM.~These women will have Fetal Cardiac Function Parameters at their 20 week anatomy scan (E/A ratio, IVS, MPI). At their 24-28 week routine GDM screening, we will repeat the HbA1c and will repeat the E/A ratio, IVS, MPI. If women have a growth scan for any reason between 32 and 36 weeks, E/A ratio, IVS, and MPI will be repeated at those times."
62740389|NCT00351793||Combined Deformity <30 degrees|
62740390|NCT00351793||Combined Deformity >30 degrees|
62551424|NCT06581029||control healthy group|is 1) no history of psychiatric and medical disease 2) Intelligence quotation more than 70.
62551425|NCT06581029||SLE group|"I. Age from 11 to 18 years II. Both sex III. diagnosed with SLE for at least 6 months to allow for an adjustment period following diagnosis.~use of The multidimensional peer victimization scale (PVS), a self-report scale for children and adolescents, was used to assess the victimization"
62551426|NCT03561649|EXPERIMENTAL|Adalimumab|"Adalimumab is not the experimental study drug. This treatment justifies the inclusion of patients and is used in accordance with its marketing authorization.~The patients will be seen as part of their follow-up consultation in Rheumatology.~Modality of administration: The baseline visit should take place no more than 4 weeks before the start of adalimumab treatment, 40mg every 2 weeks, subcutaneously, in accordance with Summary of Product Characteristics.~At baseline and 6 months follow-up visits, a single blood draw for the biomarker dosage will be added to the standard patient health care follow-up. The clinical examination will also be performed at these two visits, and the clinical response will be assessed after 6 months of adalimumab treatment at M6 follow-up visit."
62551427|NCT06025240||cf-DNA arm|Participants will be recruited on the basis of having received a renal transplant within the last 6-12 months which has been deemed high risk. They will be identified from a database currently held within the renal transplant unit by members of the direct care team. They will be approached at a routine outpatient appointment for inclusion into the study and testing can be performed at their time of routine post-transplant testing where they will undergo blood (dd-cf DNA NGS assay), standard of care tests: blood count, renal profile, donor specific antibodies (DSA) sample, BK virus PCR, CMV PCR, urine testing and an ultrasound of the graft.
62551428|NCT06025240||Immunological Events following renal transplant in older age|The renal transplant population will be divided on the basis of age into two cohort: ≥60 and \<60. All renal transplant patients are regularly followed up in the outpatient clinic where blood and urine tests are collected, and clinical evaluations are performed. It is not foreseen that this study will necessitate any additional hospital visits or testing above and beyond the usual standard of care. Serum samples are taken at the time intervals indicated for routine storage and we will simply use those samples for HLA testing (either screening alone or screening and single antigen bead testing if screening yields a positive result).
62740391|NCT05522582|EXPERIMENTAL|methotrexate+anti-PD-1 antibody+radiotherapy|Tablets with 5mg methotrexate are taken orally twice a week during radiotherapy. With anti-PD-1 monoclonal antibody, 200mg, Q3W.
62740392|NCT05906472|EXPERIMENTAL|Feeds continued|Enteral feeds are continued up until time of tracheostomy.
62740393|NCT05906472|OTHER|Feeds withheld|Enteral feeds are withheld at least 6 hours prior to time of tracheostomy.
62740394|NCT02994082|EXPERIMENTAL|Tailored Intervention|The tailored behavioral intervention includes both behavioral and pharmacological components. The behavioral component will consist of six sessions of cognitive behavioral therapy and coping skills training delivered over the telephone. In addition, participants will be screened for conditions commonly associated with tobacco use (depressive symptoms, risky alcohol use, weight concerns) and offered supplementary behavioral treatment modules to address these issues. Participants will also be offered pharmacotherapy for tobacco cessation, with decisions regarding specific medication(s) based on patients' medical history, contraindications, prior experiences, and preferences.
62740395|NCT02994082|ACTIVE_COMPARATOR|Facilitated tobacco quit line referral|Participants assigned to this condition will receive information about the VA telephone tobacco quit line and educational materials and encouraged to enroll in treatment. In addition, they will be given information regarding available medications for smoking cessation and encouraged to contact their primary care provider to discuss their options.
62740396|NCT06419556|EXPERIMENTAL|Group H|"The patient's head was rested on a pillow and turned to the opposite side. A linear probe with higher frequencies was placed transversely over the midpoint of the SCM muscle. The carotid artery was identified and traced upwards to its bifurcation. Probe was then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle was advanced underneath the investing fascia of SCM muscle and above the interscalene groove until the pop on piercing the investing fascia was felt. Group H received 20 ml 0.25 % bupivacaine"
62740397|NCT06419556|ACTIVE_COMPARATOR|Group L received 20 ml 0.125% bupivacaine|"The patient's head was rested on a pillow and turned to the opposite side. A linear probe with higher frequencies was placed transversely over the midpoint of the SCM muscle. The carotid artery was identified and traced upwards to its bifurcation. Probe was then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle was advanced underneath the investing fascia of SCM muscle and above the interscalene groove until the pop on piercing the investing fascia was felt. Group L received 20 ml 0.125% bupivacaine."
62551429|NCT06025240||Determining Predictive Models for Post-transplant HLA-specific Antibody Formation|A subset of the cohort of recruits to the immunological factors in older age study will be used to determine machine learning algorithms of predictive factors for the development of de novo donor specific antibody. Only patients who were unsensitised prior to the kidney transplant will be included into the study because prior sensitisation makes determining de novo specificities much harder. The follow up period will be set at 1 year to synchronise with the older age study.
62551430|NCT05708716|EXPERIMENTAL|Diet and Cognitive Training|The arm will follow a modified ketogenic diet using an exogenous ketogenic formula (KetoCal) and use the online cognitive training program Lumosity at time of enrollment on the study.
62551431|NCT05708716|ACTIVE_COMPARATOR|WaitList Control|The arm will only use the online cognitive training program Lumosity 3 months after enrollment in the study.
62551432|NCT05124119||Focus Group One|Participants in Focus Group 1 will be assigned a unique study name or pseudonym and requested to answer a set of three different questionnaires that are described in the study's protocol. This study does not involve any type of intervention. The participants will not be administered any type of medications but only questionnaires. This is an observational (cross-section) type of study and not an experimental or randomized clinical trial.
62551433|NCT05124119||Focus Group Two|Participants in Focus Group 2 will be assigned a unique study name or pseudonym and requested to answer a set of three different questionnaires that are described in the study's protocol. This study does not involve any type of intervention. The participants will not be administered any type of medications but only questionnaires. This is an observational (cross-section) type of study and not an experimental or randomized clinical trial.
62551434|NCT06124729||Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy|
62551435|NCT02928055|EXPERIMENTAL|PNS (3 hr/day)|The PNS (3 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (3 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
62551436|NCT02928055|EXPERIMENTAL|PNS (6 hr/day)|The PNS (6 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
62551437|NCT02928055|EXPERIMENTAL|PNS (9 hr/day)|The PNS (9 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (9 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
62551438|NCT06116630||Stroke|Patients who have a history of stroke will be in the first group.
62551439|NCT06116630||Control|Patients who do not have a history of stroke, but have a history of cardiovascular risk factors will be in the second group.
62551440|NCT05269095|EXPERIMENTAL|spinal anesthesia only|Patients will receive spinal anesthesia only
62551441|NCT05269095|EXPERIMENTAL|spinal anesthesia and ultrasound-guided Genicular nerves block|Patients will receive spinal anesthesia and ultrasound-guided Genicular nerves block
62551442|NCT05269095|EXPERIMENTAL|Spinal anesthesia and US guided Adductor canal nerve block plus infiltration of the interspace|Patients will receive spinal anesthesia and ultrasound-guided Adductor canal nerve block plus infiltration of the interspace between the popliteal artery and the capsule of the posterior knee (PACK) block.
62551443|NCT01790087|EXPERIMENTAL|ANX-188 Therapeutic dose level|IV administration. 100 mg/kg for one hour followed by 30 mg/kg/hour for five hours
62551444|NCT01790087|EXPERIMENTAL|ANX-188 Supratherapeutic dose|IV administration. 300 mg/kg for one hour followed by 200 mg/kg/hr for five hours
62740398|NCT03193970||Bladder Cancer Patients Undergoing Radical Cystectomy|Prospective registry of bladder cancer patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating centers.
62740399|NCT03273452|EXPERIMENTAL|treatment group|In this group, patients will be given prednisone 100mg,qd,d1-5; etoposide 100mg,qd,d1-5; thalidomide 100mg,qn,d1-14; Chidamide 30mg,biw;
62364827|NCT03030014|PLACEBO_COMPARATOR|no educational programm|without educational program Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
62551445|NCT01790087|PLACEBO_COMPARATOR|Saline|IV administration. Six hour infusion.
62551446|NCT01790087|ACTIVE_COMPARATOR|Moxifloxacin|Oral tablet. 400 mg.
62740400|NCT05492227||Fresh left-over specimens of SARS-CoV-2 positive subject swabs|All fresh swab specimens that were sent to the biobank Hospital Puerta del Hierro between March 2020 and December 2021 under the standard requirements for SARS-CoV-2 specimens (ISO 201916) were kept frozen (-80ºC) after analysis by RT-PCR (left-over samples).
62740401|NCT05492227||Fresh left-over specimens of SARS-CoV-2 negative subject swabs|All fresh swab specimens that were sent to the biobank Hospital Puerta del Hierro between March 2020 and December 2021 under the standard requirements for SARS-CoV-2 specimens (ISO 201916) were kept frozen (-80ºC) after analysis by RT-PCR (left-over samples).
62740402|NCT00499330|OTHER|Arm A|Patients undergo a standard operation for lung cancer called a lobectomy.
62740403|NCT00499330|EXPERIMENTAL|Arm B|Patents undergo a limited resection (segentectomy or wedge resection), which a smaller portion of the lung is removed.
62551447|NCT05719935||KinematX patients|Patients undergoing total wrist replacement with the KinematX implant.
62740404|NCT03273647|EXPERIMENTAL|surgery plus radiation|adjuvant radiotherapy is developed in this arm
62740405|NCT03273647|NO_INTERVENTION|surgery alone|No adjuvant radiotherapy,that is surgery alone is developed in this arm
62740406|NCT03267433|EXPERIMENTAL|Group I (auto-HCT, rituximab)|Patients receive standard of care preparative chemotherapy and undergo auto-HCT. Beginning 100-140 days after transplant, patients receive rituximab IV or rituximab and hyaluronidase human SC or any approved rituximab biosimilar at the approved dose once every 8 weeks for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET, CT or PET/CT throughout the study. Patients may undergo blood sample collection during screening and on study. Patients also may undergo bone marrow biopsy and aspirate during screening.
62740407|NCT03267433|EXPERIMENTAL|Group II (rituximab)|Patients receive standard of care induction chemotherapy. Beginning 40-180 days after completion of chemotherapy, patients receive rituximab or rituximab and hyaluronidase human or any approved rituximab biosimilar at the approved dose, as in Group I. Patients undergo PET, CT or PET/CT throughout the study. Patients may undergo blood sample collection during screening and on study. Patients also may undergo bone marrow biopsy and aspirate during screening.
62740408|NCT06310642|EXPERIMENTAL|Prochlorperazine 10 mg|Subjects received 10 mg Prochlorperazine one time.
62740409|NCT06310642|PLACEBO_COMPARATOR|Placebo|Subjects received Placebo one time.
62740410|NCT04270149|EXPERIMENTAL|ESR1 peptide vaccine|200 mcg ESR1 peptides plus 1ml Montanide and 100 mcg GM-CSF administered subcutaneously weeks 0, 1, 2, 4, 5, 6 for a total of 6 injections.
62551448|NCT01275729|EXPERIMENTAL|Lasix|Pt to get dose of furosemide after meeting entry criteria - dose dependent on previous exposure to diuretics
62551449|NCT02191293||Viramune®|
62551450|NCT03335137||ICU Patients with Severe Burns|Patients suffering from severe burns treated on a burn unit - Drug Level Monitoring Piperacillin/Tazobactam
62551451|NCT03335137||ICU Patients without Burns - Drug Level Monitoring|Patient suffering from disease treated on an ICU - Drug Level Monitoring Piperacillin/Tazobactam
62551452|NCT03203200|EXPERIMENTAL|health literacy and technology skill building|ZETRA cognitive behavioral and structural
62551453|NCT03203200|NO_INTERVENTION|Standard Counselling|Standard of care prevention counselling
62551454|NCT01776632|EXPERIMENTAL|Physical activity|Latinas exposed to multi-level Faith in Action intervention promoting physical activity.
62551455|NCT01776632|ACTIVE_COMPARATOR|Cancer screening|Latinas exposed to Faith in Action intervention on cancer screening and prevention.
62740411|NCT04788004||Cohort 1|Participants in this group started their recovery process \< 1 year ago
62740412|NCT04788004||Cohort 2|Participants in this group started their recovery process 1 to \<2 years ago
62740413|NCT04788004||Cohort 3|Participants in this group started their recovery process 2 to \<3 years ago
62740414|NCT04788004||Cohort 4|Participants in this group started their recovery process 3 to \<4 years ago
62740415|NCT04788004||Cohort 5|Participants in this group started their recovery process 4 to \<5 years ago
62740416|NCT04788004||Cohort 6|Participants in this group started their recovery process 5 to \<6 years ago
62740417|NCT04788004||Cohort 7|Participants in this group started their recovery process 6 to \<7 years ago
62740418|NCT04788004||Cohort 8|Participants in this group started their recovery process 7 to \<8 years ago
62740419|NCT04788004||Cohort 9|Participants in this group started their recovery process 8 to \<9 years ago
62551456|NCT00984724|EXPERIMENTAL|Standard Treatment|Standard Treatment (ST): Mailed Packet with standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months). Referral to Quitline.
62551457|NCT00984724|EXPERIMENTAL|MAPS-6|Standard Treatment (ST) plus 6 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 6 MAPS proactive telephone counseling sessions over 2-year period.
62551458|NCT00984724|EXPERIMENTAL|MAPS-12|Standard Treatment (ST) plus 12 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 12 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline.
62551459|NCT00984724|EXPERIMENTAL|Standard Treatment + NRT|Standard Treatment (ST): Mailed Packet with standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months). Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
62551460|NCT00984724|EXPERIMENTAL|MAPS-6 + NRT|Standard Treatment (ST) plus 6 proactive telephone counseling sessions; delivered 4 times (at Baseline, 6, 12, and 18 months). 6 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline. Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
62740420|NCT04788004||Cohort 10|Participants in this group started their recovery process 9 to \<10 years ago
62740421|NCT03966209|EXPERIMENTAL|treatment|JS001（PD-1 inhibitor）, 240mg I.V. Q3W,
62740422|NCT02145052|ACTIVE_COMPARATOR|Continuous suture|0 non-looped PDS using a tapered needle starting at the superior and the inferior portions of the wound. Fascia is then approximated with at least 1cm distance from the edge of the fascia and 1cm advancement. The two sutures are then knotted in the center with 8 square knots.
62740423|NCT02145052|ACTIVE_COMPARATOR|Interrupted Suture|Using a tapered needle, 0 non-looped PDS interrupted figure of eight suture 1cm from the edge and advancing 1cm between each suture.
62740424|NCT05052255|EXPERIMENTAL|Part 1: Dose Escalation / Part 2: Cohort Expansion|"Part 1-Dose Escalation: Escalating doses of RVU120, in patients who have progressed from previous therapy.~Part 2-Cohort Expansion and Alternative Schedule Investigation: Recommended dose in patients with tumor types selected from part 1 and escalation for alternative schedule."
62740425|NCT03865433|EXPERIMENTAL|Exercise Group|Intervention: aerobic exercise Subjects in the exercise group will be prescribed exercise at a target heart rate (THR) of approximately 80% of the achieved heart rate during the Buffalo Concussion Treadmill Test (BCTT). They will be given this prescription in writing to provide to their athletic trainer. Subjects will complete 30 minutes of daily exercise (including 5 minutes of warm up and 5 minutes of cool down) on an exercise bike or walking and supervised by an athletic trainer. This program may be modified by increasing heart rate threshold 5-10 beats per minute per week by the athletic trainer as the heart rate for symptom exacerbation increases.
62740426|NCT03865433|PLACEBO_COMPARATOR|Placebo/Stretching|Intrvention: stretching program Subjects assigned to the Stretching/Placebo group will be given a stretching protocol and instructions to report to their athletic trainer on a daily basis as soon as possible. . Subjects will then complete a 15-25 minute stretching program under supervision by the athletic trainer or other designated research personnel. The stretching protocol will be progressive and will change weekly as subjects continue their recovery.
62740427|NCT06651268|EXPERIMENTAL|while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T|
62740428|NCT06651268|OTHER|: Group A (control, n=12) received standard closure techniques without vancomycin powder|Group A (control, n=12) received standard closure techniques without vancomycin powder
62740429|NCT00339651||Cases|Women in one large U.S. health care plan. Cases will consist of women who developed endometrial carcinoma or censored complex atypical hyperplasia at least 1 year after receiving a diagnosis of endometrial hyperplasia.
62740430|NCT00339651||Controls|Women in one large U.S. health care plan. Controls will consist of individually matched women who received a diagnosis of endometrial hyperplasia at the same age and date as the cases and were cancer-free and hysterectomy-free until the date at which the index cases were diagnosed with endometrial carcinoma or censored complex atypical hyperplasia.
62551461|NCT00984724|EXPERIMENTAL|MAPS-12 + NRT|Standard Treatment (ST) plus 12 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 12 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline. Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
62551462|NCT03851029|EXPERIMENTAL|Tai chi|(Yang 24 postures) Moderate intensity HRR (40%-60%)
62740431|NCT06251466|EXPERIMENTAL|Telemonitoring group|Participants randomized in the telemonitoring group receive a glucose meter to monitor their blood glucose levels at home. They need to perform the same measurements as the control group. The only difference lies in how they transmit their blood glucose measurement to the hospital. After each measurement, they need to register these levels once a week in the iHealth Gluco-Smart application. This data is send, via Bluetooth and Wi-Fi, to an online dashboard, called Dharma, for review by the researchers of the Mobile Health Unit of Hospital Oost-Limburg (ZOL) in Genk. Participants measuring abnormal blood glucose levels at one of the four time points are requested to measure their blood glucose levels again on the following day. The researcher contacts the endocrinology department if any abnormal blood glucose values are detected. Interventions including, starting insulin treatment, will be performed by the endocrinologist when necessary.
62740432|NCT06251466|NO_INTERVENTION|Control group|Pregnant women randomized in the control group receive a glucose meter to monitor their blood glucose levels at home. They need to measure their blood glucose levels four times a week, including: before breakfast, two hours after breakfast, two hours after lunch, two hours after dinner. These values are then called by the pregnant women to the endocrinology department. Interventions including, starting insulin treatment, will be performed by the endocrinologist when necessary.
62740433|NCT01610219|ACTIVE_COMPARATOR|Lifestyle Modification for Diabetes Prevention|Family based intervention utilizing Traffic Light Diet, self monitoring, parent behavioral skill training and tool kit of items promoting physical activity.
62740434|NCT01610219|OTHER|Nutrition and Physical Activity|Family based intervention providing education on healthy eating and physical activity but no behavioral skills training, goal setting, self monitoring or physical activity toolkit.
62740435|NCT04216563|EXPERIMENTAL|Treatment (asciminib)|Patients receive asciminib PO BID for up to 36 months while receiving standard of care dasatinib or nilotinib in the absence of disease progression or unacceptable toxicity. Patients may continue to receive asciminib after 36 months at the discretion of investigator.
62740436|NCT02844244|EXPERIMENTAL|training group|Two two-hour training sessions for the participants. It aimed to train lay resident leaders to be peer health promoters. The peer health promoters were taught either to independently implement or to assist social workers to conduct a series of community-based family well-being activities.
62740437|NCT06661200|EXPERIMENTAL|Healthy subjects N = 70 no cardiac and no pulmonary disease|Healthy subjects who should undergo SMC recording after echocardiography and resporatory exploration.
62551463|NCT03851029|ACTIVE_COMPARATOR|Aerobic Training|Elliptical Moderate intensity HRR (40%-60%)
62551464|NCT06165887||Moderate-to-severe Psoriasis patients|Participants will fill out questionnaires to assess sleep status and the severity of psoriasis.
62551465|NCT06165887||Healthy people|Participants will fill out questionnaires to assess sleep status
62551466|NCT04960592||SCS Responders|Patients who receive Spinal Cord Stimulation treatment and experience greater than 50% reduction in pain score following treatment.
62551467|NCT04960592||SCS Non Responders|Patients who receive Spinal Cord Stimulation treatment and do not experience greater than 50% reduction in pain score following treatment.
62551468|NCT05333055||Group 1|Eyes with treatment naive DR with or without DME
62551469|NCT05333055||Group 2|Eyes with DME that are incompletely responsive to anti-VEGF therapy
62551470|NCT05333055||Group 3|Eyes with various retinal conditions including eyes with DR and DME that is anti-VEGF responsive as well as non-exudative retinal pathologies such as epiretinal membrane and macular hole
62551471|NCT03905577|EXPERIMENTAL|Action Observation|This group receives an action observation training through the visualization of a video of cervical movements.
62740438|NCT06661200|EXPERIMENTAL|Cardiac disease group|Patients in this group had heart disease (n = 150): (i) aortic stenosis (ii) aortic leakage (iii) mitral leakage (iv) dilated cardimyopathy (v) or restrictive cardiomyopathy.
62740439|NCT06661200|EXPERIMENTAL|Respiratory failure|
62740440|NCT01849575|ACTIVE_COMPARATOR|Intervention|The intervention: Giving communication about risk of cardiovascular disease in the form of written and graphical information about silent atheroscslerosis measured by carotid ultrasound examination as carotid intima-media thickness, highlighted as vascular age, and plaque formation, visualized as a traffic light (green - no plaque, red - plaque).The ultrasound results are given to the study person and his/her physician, in addition to information about conventional risk factors for cardiovascular disease
62740441|NCT01849575|NO_INTERVENTION|Control|The comaparator is that the study person and his/her physician do not get any information about carotid ultrasound results on silent atherosclerosis. They are only informed about results of measured conventional CVD risk factors
62740442|NCT01794663|EXPERIMENTAL|OPN-305|
62740443|NCT01794663|PLACEBO_COMPARATOR|Matching placebo|
62740444|NCT06018311|EXPERIMENTAL|Exercising Together|Dyads perform partnered exercise over 1 hour, 3 days per week in a supervised, group setting remotely for 3 months.
62740445|NCT03779867|EXPERIMENTAL|Arm I (acute exercise)|Participants undergo a moderate-intensity acute exercise bout over 45 minutes.
62551472|NCT03905577|EXPERIMENTAL|Motor Imagery|This group receives an motor imagery through the imagery process of cervical movements.
62740446|NCT03779867|ACTIVE_COMPARATOR|Arm II (rest)|Participants rest by sitting for 45 minutes.
62740447|NCT01469143|EXPERIMENTAL|NN1218|
62740448|NCT01469143|ACTIVE_COMPARATOR|insulin aspart|
62740449|NCT04938310|ACTIVE_COMPARATOR|Control Group|Sleeve gastrectomy
62740450|NCT04938310|EXPERIMENTAL|Support garment group|Sleeve gastrectomy followed by a period of 12-month with a support garment
62551473|NCT03905577|PLACEBO_COMPARATOR|Placebo Group|This group receives a placebo action observation training through the visualization of a video of a documentary video
62551474|NCT04663971||Crohn's disease|Patients with Crohn's disease.
62551475|NCT04663971||Ulcerative colitis|Patients with Ulcerative colitis
62740451|NCT04058561|EXPERIMENTAL|6 weeks|6-week lengthening interval
62740452|NCT04058561|ACTIVE_COMPARATOR|16 weeks|16-week lengthening interval
62740453|NCT06344104|EXPERIMENTAL|2 mg baxdrostat|2 mg baxdrostat administered orally, once daily (QD)
62740454|NCT06344104|EXPERIMENTAL|1 mg baxdrostat|1 mg baxdrostat administered orally, once daily (QD).
62175200|NCT05091554|EXPERIMENTAL|Single visit 30 minutes cryotherapy|"The root canals were obturated in the same session using cold lateral compaction technique with AH Plus sealer (Dentsply DeTrey, Konstanz, Germany), Protaper Universal gutta-percha (ProTaper Universal gutta-percha, Dentsply) and .02 tapered auxiliary gutta-percha (Diadent, Chongju, Korea) cones. Residual gutta-perchas in the access cavity were removed with the aid of heated hand tools. The quality of root canal filling was checked with periapical radiographs.~The pulp chamber was filled with flowable composite resin (Filtek Ultimate Flowable, 3M-ESPE, St. Paul, MN, USA) and nanohybrid composite resin (3M-ESPE) using an incremental technique.~30 minutes intraoral cryotherapy was applied."
62182402|NCT02785276|EXPERIMENTAL|Ropivacaine infusion|Following the insertion of the 2mm fenestrated catheter, the wound catheter will be connected to the 270mL AutoFuser Pain Pump. The intraperitoneal infusion with ropivacaine (0.2%) at 4 mL/hour will start immediately and continue for 68 hours post-operatively uninterrupted.
62740455|NCT06344104|PLACEBO_COMPARATOR|placebo|Placebo administered orally, once daily (QD)
62740456|NCT01749124|EXPERIMENTAL|My Coach Connect|"To evaluate the feasibility and effectiveness of this telephone tool while engaging clients and providers in discussion groups and surveys to better understand how this tool impacts the care provided and their overall experience in healthcare. Clients will use this tool to leave voice messages and survey answers which their providers will have access to by logging in to a secure website. Providers will have access to audio recordings of the voice responses, transcribed text of the responses, as well as word clouds generated from the text. Word clouds are a method of displaying the content of text such that words that are used more frequently are displayed in a larger size than words used less frequently."
62740457|NCT04098419|EXPERIMENTAL|Williams Implementation|
62551476|NCT02554162|ACTIVE_COMPARATOR|Extruded wholegrain rye flakes|Rye products with varying structures
62551477|NCT02554162|ACTIVE_COMPARATOR|Extruded wholegrain rye puffs|Rye products with varying structures
62551478|NCT02554162|ACTIVE_COMPARATOR|Fresh wholegrain rye bread|Rye products with varying structures
62551479|NCT02554162|ACTIVE_COMPARATOR|Wholegrain rye beverage|Rye products with varying structures
62551480|NCT02554162|ACTIVE_COMPARATOR|Fresh wheat bread|Rye products with varying structures
62551481|NCT01555216|ACTIVE_COMPARATOR|Posterior tibial nerve catheter|5 ml bolus of 0.5% ropivacaine. The catheter will then be connected to a portable pump delivering 3 ml/h of 0.2% ropivacaine with a 2ml bolus every two hours.
62551482|NCT01555216|ACTIVE_COMPARATOR|Single injection PTNB|Single injection posterior tibial nerve block (PTNB) of 0.5% ropivacaine
62551483|NCT01364376|ACTIVE_COMPARATOR|FOLFOX|
62551484|NCT01364376|EXPERIMENTAL|SOX|
62551485|NCT01457937|ACTIVE_COMPARATOR|PEG IFN/Ribavirin|Standard of care for HCV-positive CAH
62551486|NCT01457937|EXPERIMENTAL|PEG IFN/Ribavirin/Boceprevir|Combination to be tested for possible higher efficacy
62551487|NCT05723939|EXPERIMENTAL|Carnosine|Intake of carnosine supplement in form of capsules or functionally enriched chicken meet for three weeks
62551488|NCT05723939|PLACEBO_COMPARATOR|Control|Intake of placebo capsules or regular chicken meet for three weeks
62551489|NCT03340090|EXPERIMENTAL|Intervention|First group of patients will undergo standard CABG procedure in CPB. In addition, two pieces of Hemopatch will be applied in one patient. One piece to improve hemostasis in the bed of left internal mammary artery (LIMA) harvesting and second piece of Hemopatch will be placed beneath the sternum.
62551490|NCT03340090|NO_INTERVENTION|Control|Second group of patients will undergo standard CABG procedure in CPB only.
62740458|NCT04098419|EXPERIMENTAL|Pittsburg Implementation|
62740459|NCT03853382|EXPERIMENTAL|Cognitive Analytic Informed Brief Therapy|
62740460|NCT03853382|NO_INTERVENTION|Treatment As Usual|
62740461|NCT00738569|EXPERIMENTAL|Raltegravir|
62551491|NCT04205058|EXPERIMENTAL|standard coffee|Hot standard coffee with caffeine (one 30 mL espresso cup twice a day, from postoperative day one to first bowel movement or postoperative day three).
62551492|NCT04205058|PLACEBO_COMPARATOR|caffeine-free coffee|Hot caffeine-free coffee (one 30 mL espresso cup twice a day, from postoperative day one to first bowel movement or postoperative day three).
62551493|NCT04205058|SHAM_COMPARATOR|water|Hot water (one 30 mL espresso cup twice a day, from postoperative day one to first bowel movement or postoperative day three).
62551494|NCT02044913|EXPERIMENTAL|Phone-based Aftercare-Coordination|After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention aims at supporting the patients in coordinating their aftercare treatment which can help to maintain or even improve longterm treatment outcome.
62740462|NCT06655298|EXPERIMENTAL|group Q|Group Q; (28 patients) Quadratus lumborum block group; patients will receive general anesthesia initially then bilateral QLB type III (anterior subcoastal approach) with a volume of 30 mL of bupivacaine 0.25% for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg)
62740463|NCT06655298|EXPERIMENTAL|group E|Group E; (28 patients) Erector spinae plane block; patients will receive general anesthesia initially then bilateral ESPB with a volume of 30 mL of bupivacaine 0.25 % for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg)
62551495|NCT02044913|NO_INTERVENTION|Treatment as usual|After inpatient treatment patients receive treatment as usual within routine care.
62740464|NCT03316118|ACTIVE_COMPARATOR|Group 1|Patient will receive genicular nerve block with bupivacaine
62740465|NCT03316118|PLACEBO_COMPARATOR|Group 2|Patient will receive normal saline as the nerve block
62740466|NCT02546258|OTHER|A Funagl Nail Treatment|Marketed treatment of Fungal Nail Follow instructions on pack
62551496|NCT06056141|ACTIVE_COMPARATOR|Group A|Drug: Misoprostol 25mcg (200 mcg dissolved with 200 ml water and divided to 8 doses) every 2 hours
62551497|NCT06056141|ACTIVE_COMPARATOR|Group B|Device: Foley Catheter Transcervical Foley catheter (silicone, size 20F with 30ml balloon)
62551498|NCT02539966|EXPERIMENTAL|Cohort A|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group A (6-month angiographic follow-up)
62740467|NCT04619238||no urinary incontinence|patients without UI
62740468|NCT04619238||stress urinary incontinence|patients with SUI
62182403|NCT02785276|PLACEBO_COMPARATOR|Placebo infusion|In the same manner as described for the ropivacaine infusion arm, 0.9% Normal Saline will be administered over 68 hours.
62182404|NCT01010997||Dry AMD|Intermediate AMD subjects
62364828|NCT01851525|ACTIVE_COMPARATOR|Contact Force Sensing (CFS) Blinded|Contact Force Sensing (CFS) Blinded: Operator will be blinded to data provided by the integrated force sensor in the ablation catheter (ThermoCoolSmartTouch ablation catheter)
62551499|NCT02539966|EXPERIMENTAL|Cohort B|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group B (9-month angiographic follow-up)
62551500|NCT02539966|EXPERIMENTAL|Cohort C|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group C (6-month angiographic follow-up), Long Lesion/Multi-Vessel
62551501|NCT00442962|EXPERIMENTAL|EFV + FTC/TDF|Participants will efavirenz (600mg in pill form, taken orally, once daily) and emtricitabine/tenofovir disoproxil fumarate (200/300mg in pill form, taken orally, once daily), for 48 weeks
62551502|NCT04678050|ACTIVE_COMPARATOR|group I received ketamine/propofol (ketofol) solution|ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
62551503|NCT04678050|ACTIVE_COMPARATOR|group II received the Dex solution (4 µg/mL|A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h.
62551504|NCT03907371|EXPERIMENTAL|Donepezil|Patients receive donepezil with a dosage of 5 milligram at 8 am for one week (Week 1), then 10 milligram at 8 am for 23 weeks (Week 2-24), in the absence of unacceptable toxicity or severe deterioration.
62551505|NCT03907371|PLACEBO_COMPARATOR|Control|Patients receive placebo with a dosage of one half pill at 8 am for one week (Week 1), then one pill at 8 am for 23 weeks (Week 2-24), in the absence of unacceptable toxicity or severe deterioration.
62551506|NCT06550622||Group A|CHB patients with HBsAg level\<0.005 IU/mL
62551507|NCT06550622||Group B|CHB patients with 0.005 IU/mL\< HBsAg level \< 0.05 IU/mL
62551508|NCT05115695|ACTIVE_COMPARATOR|PNF/Interventional|Upper extremity and scapular patern of PNF exercise approach will be applied to the first group for 6 weeks, 3 days a week, 30 minutes a day.
62551509|NCT05115695|EXPERIMENTAL|NDT/Experimental|Upper extremity strengthening exercises consisting of Neurodevelopmental Therapy (NGT-Bobath) approaches will be applied to the second group for 45 minutes, 3 days a week for 6 weeks.
62551510|NCT06221826|EXPERIMENTAL|Main (Mexidol and standard treatment)|Mexidol IV 500 mg for 10 days, then Mexidol FORTE 250 orally 250 mg 1 tablet 3 times a day for 8 weeks; and standard treatment
62551511|NCT06221826|NO_INTERVENTION|Control|Standard treatment: basic practices of kinesitherapy, occupational therapy, speech therapy, clinical psychology, supplemented by adjuvant procedures of electrotherapy and rehabilitation environment therapy. The patient's rehabilitation load was at least 3 hours a day for 12 days
62740469|NCT04619238||overactive bladder|patients with OAB
62740470|NCT04619238||mix urinary incontinence|patients with MUI
62740471|NCT04619238||Urge|patients with urge incontinence
62740472|NCT04583215|ACTIVE_COMPARATOR|Active PAS|After completing the N-back and PAS-EEG at Visit 4, MCI participants randomized to the active condition will receive a 10-session course of PAS (Visits 5-14), followed by the three follow-up assessments at 0 days, 7 days, and 28 days post intervention.
62740473|NCT04583215|SHAM_COMPARATOR|PAS-Control (PAS-C)|After completing the N-back and PAS-EEG at Visit 4, MCI participants randomized to the sham condition will receive a 10-session course of PAS-C (Visits 5-14), followed by the three follow-up assessments at 0 days, 7 days, and 28 days post intervention.
62182405|NCT01010997||Wet - treated AMD|AMD subjects under treatments
62182406|NCT05768737||Patients wiht Hepatitis B Virus Infection|Patients with hepatitis b virus infection.
62182407|NCT03599622|EXPERIMENTAL|BMS-986165 Dose 1|
62182408|NCT03599622|EXPERIMENTAL|BMS-986165 Dose 2|
62551512|NCT05758857|EXPERIMENTAL|Guidelines-based physical activity|150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening
62551513|NCT05758857|EXPERIMENTAL|Guidelines-based physical activity and healthy eating|150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening + counselling to follow Canada's Food Guide
62740474|NCT04583215|NO_INTERVENTION|Healthy Control|Healthy Controls will complete screening and baseline N-Back and PAS-EEG. 10 HC participants will also complete the optional pilot eye tracking VPC assessment following N-Back at the Baseline visit. HC participants will not complete the 10-session course of PAS or follow-up assessments.
62740475|NCT02468531|OTHER|Oxygen group|50% oxygen inhalation one hour before and after CPB,and Pulmonary Static Inflation with 50% oxygen during CPB.
62740476|NCT02468531|EXPERIMENTAL|Xenon group|50% oxygen inhalation one hour before and after CPB,and Pulmonary Static Inflation with 50%,75% and 100% Xenon during CPB respectively.
62740477|NCT00771706|EXPERIMENTAL|Proton Pump Inhibitor|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
62740478|NCT00771706|PLACEBO_COMPARATOR|Sugar Pill|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough
62740479|NCT06610838||ENDS users|Long-term stable users of electronic nicotine delivery systems, 21-40 years of age, who do not use combustible (conventional) cigarettes
62740480|NCT06610838||Non-users|Gender-matched control participants who do not use ENDS or combustible cigarettes
62740481|NCT05921266|EXPERIMENTAL|Intervention|
62740482|NCT05921266|PLACEBO_COMPARATOR|Control|
62175201|NCT05091554|NO_INTERVENTION|Multiple visit control|"Root canals were filled with calcium hydroxide paste (Kalsin, Turkey), prepared according to the rate recommended by the manufacturer using a lentulo spiral (Dentsply Sirona, Switzerland) 2 mm from the working length. Sterile dry cotton pellets were placed in the pulp chamber, then the access cavity was sealed with a temporary filling material and occlusion was checked.~Intraoral cryotherapy was not applied. Patients were given an appointment 7 days later for second visit. In this appointment, patients were anesthetized, the tooth was isolated with rubber dam, the temporary filling material was removed. Then calcium hydroxide paste was removed by using the last instrument used to prepare the root canals at the working length during the first appointment using sufficient irrigation.~The final irrigation protocol was repeated. Root canal fillings and permanent restorations were completed by applying the same techniques as in single session groups."
62175202|NCT05091554|EXPERIMENTAL|Multiple visit 15 minutes cryotherapy|"Root canals were filled with calcium hydroxide paste (Kalsin, Turkey), prepared according to the rate recommended by the manufacturer using a lentulo spiral (Dentsply Sirona, Switzerland) 2 mm from the working length. Sterile dry cotton pellets were placed in the pulp chamber, then the access cavity was sealed with a temporary filling material and occlusion was checked.~15 minutes intraoral cryotherapy was applied. Patients were given an appointment 7 days later for second visit. In this appointment, patients were anesthetized, the tooth was isolated with rubber dam, the temporary filling material was removed. Then calcium hydroxide paste was removed by using the last instrument used to prepare the root canals at the working length during the first appointment using sufficient irrigation.~The final irrigation protocol was repeated. Root canal fillings and permanent restorations were completed by applying the same techniques as in single session groups."
62551514|NCT05758857|PLACEBO_COMPARATOR|Stretching exercise|Whole-body stretching
62551515|NCT05237492|EXPERIMENTAL|procoagulant effect on platelet function|LTA platelet function measurement on whole blood with addition of tramadol, demonstration of a dose-response relationship and determination of the effect of combination with other drugs.
62551516|NCT02755649|EXPERIMENTAL|Placebo QW + TCS|Participants received one subcutaneous (SC) injection of dupilumab matching placebo once per week (QW) (following two SC injections on day 1) from Week 1 to Week 15. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety (\[Week 28, end of study (EOS) period\]).
62740483|NCT04057924||CIN 2 women|Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
62740484|NCT06247345|ACTIVE_COMPARATOR|SAD Cohort 1: ADEL Y-01 antibody at a dose of 2.5mg/Kg|This arm represents the group receiving ADEL Y-01 antibody at a dose of 2.5mg/Kg in SAD cohort 1.
62740485|NCT06247345|PLACEBO_COMPARATOR|SAD Cohort 1: Placebo at a dose of 2.5mg/Kg|This arm represents the group receiving placebo at a dose of 2.5mg/Kg in SAD cohort 1.
62740486|NCT06247345|ACTIVE_COMPARATOR|SAD Cohort 2: ADEL Y-01 antibody at a dose of 7.5mg/Kg|This arm represents the group receiving ADEL Y-01 antibody at a dose of 7.5 mg/Kg in SAD cohort 2.
62740487|NCT06247345|PLACEBO_COMPARATOR|SAD Cohort 2: Placebo at a dose of 7.5mg/Kg|This arm represents the group receiving placebo at a dose of 7.5mg/Kg in SAD cohort 2.
62740488|NCT06247345|ACTIVE_COMPARATOR|SAD Cohort 3: ADEL Y-01 antibody at a dose of 20mg/Kg|This arm represents the group receiving ADEL Y-01 antibody at a dose of 20mg/Kg in SAD cohort 3.
62740489|NCT06247345|PLACEBO_COMPARATOR|SAD Cohort 3: Placebo at a dose of 20mg/Kg|This arm represents the group receiving placebo at a dose of 20mg/Kg in SAD cohort 3.
62740490|NCT06247345|ACTIVE_COMPARATOR|SAD Cohort 4: ADEL Y-01 antibody at a dose of 50mg/Kg|This arm represents the group receiving ADEL Y-01 antibody at a dose of 50mg/Kg in SAD cohort 4.
62740491|NCT06247345|PLACEBO_COMPARATOR|SAD Cohort 4: Placebo at a dose of 50mg/Kg|This arm represents the group receiving placebo at a dose of 50mg/Kg in SAD cohort 4.
62740492|NCT06247345|ACTIVE_COMPARATOR|SAD Cohort 5: ADEL Y-01 antibody at a dose of 100mg/Kg|This arm represents the group receiving ADEL Y-01 antibody at a dose of 100mg/Kg in SAD cohort 5.
62740493|NCT06247345|PLACEBO_COMPARATOR|SAD Cohort 5: Placebo at a dose of 100mg/Kg|This arm represents the group receiving placebo at a dose of 100mg/Kg in SAD cohort 5.
62740494|NCT06247345|ACTIVE_COMPARATOR|MAD Cohort 1: ADEL Y-01 antibody at a dose of 7.5mg/Kg|This arm represents the group receiving ADEL Y-01 antibody at a dose of 7.5 mg/Kg in MAD cohort 1.
62740495|NCT06247345|PLACEBO_COMPARATOR|MAD Cohort 1: Placebo at a dose of 7.5mg/Kg|This arm represents the group receiving placebo at a dose of 7.5mg/Kg in MAD cohort 1.
62551517|NCT02755649|EXPERIMENTAL|Dupilumab 300 mg Q2W + TCS|Participants received one subcutaneous (SC) injection of dupilumab 300 mg every 2 weeks (Q2W) from Week 1 to Week 15 (following a SC loading dose of 600 mg on day 1). During weeks in which dupilumab was not administered, participants received matching placebo. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety (\[Week 28, end of study (EOS) period\]).
62551518|NCT02755649|EXPERIMENTAL|Dupilumab 300 mg QW + TCS|Participants received one subcutaneous (SC) injection of dupilumab 300 mg once per week (QW) (following an SC loading dose of 600 mg on day 1) from Week 1 to Week 15. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety (\[Week 28, end of study (EOS) period\]).
62551519|NCT05286866|EXPERIMENTAL|Low speed drilling without irrigation|The dental implants will be placed using a low-speed drilling technique without irrigation for the experimental group.
62551520|NCT05286866|ACTIVE_COMPARATOR|High speed drilling with irrigation|The dental implants will be placed using a high-speed drilling technique with irrigation for the control group.
62740496|NCT06247345|ACTIVE_COMPARATOR|MAD Cohort 2: ADEL Y-01 antibody at a dose of 20mg/Kg|This arm represents the group receiving ADEL Y-01 antibody at a dose of 20mg/Kg in MAD cohort 2.
62740497|NCT06247345|PLACEBO_COMPARATOR|MAD Cohort 2: Placebo at a dose of 20mg/Kg|This arm represents the group receiving placebo at a dose of 20mg/Kg in MAD cohort 2.
62740498|NCT06247345|ACTIVE_COMPARATOR|MAD Cohort 3: ADEL Y-01 antibody at a dose of 50mg/Kg|This arm represents the group receiving ADEL Y-01 antibody at a dose of 50mg/Kg in MAD cohort 3.
62175203|NCT05091554|EXPERIMENTAL|Multiple visit 30 minutes cryotherapy|"Root canals were filled with calcium hydroxide paste (Kalsin, Turkey), prepared according to the rate recommended by the manufacturer using a lentulo spiral (Dentsply Sirona, Switzerland) 2 mm from the working length. Sterile dry cotton pellets were placed in the pulp chamber, then the access cavity was sealed with a temporary filling material and occlusion was checked.~30 minutes intraoral cryotherapy was applied. Patients were given an appointment 7 days later for second visit. In this appointment, patients were anesthetized, the tooth was isolated with rubber dam, the temporary filling material was removed. Then calcium hydroxide paste was removed by using the last instrument used to prepare the root canals at the working length during the first appointment using sufficient irrigation.~The final irrigation protocol was repeated. Root canal fillings and permanent restorations were completed by applying the same techniques as in single session groups."
62175204|NCT00335374|EXPERIMENTAL|1|
62175205|NCT05592769|EXPERIMENTAL|HealthBeacon Injection Care Management System (ICMS) Arm|All participants enrolled will be recruited to this study arm and provided with access to the HealthBeacon ICMS.
62175206|NCT05362760|EXPERIMENTAL|Abemaciclib + Aromatase-Inhibitor|The patients will receive Abemaciclib in combination with an Aromatase-Inhibitor (either Anastrozole, Letrozole or exemestane)
62175207|NCT05362760|EXPERIMENTAL|Abemaciclib + Fulvestrant|The patients will receive Abemaciclib in combination Fulvestrant
62175208|NCT00245440|ACTIVE_COMPARATOR|1|Subjects assigned Azithromycin
62740499|NCT06247345|PLACEBO_COMPARATOR|MAD Cohort 3: Placebo at a dose of 50mg/Kg|This arm represents the group receiving placebo at a dose of 50mg/Kg in MAD cohort 3.
62175209|NCT00245440|ACTIVE_COMPARATOR|2|Subjects assigned Telithromycin
62175210|NCT04115371|NO_INTERVENTION|Control|Standard emergency department care
62175211|NCT04115371|OTHER|Intervention|Standard emergency department are plus GEDI consult
62175212|NCT05808062|ACTIVE_COMPARATOR|Total dryness|matching paper points are used till they come out completely dry
62175213|NCT05808062|ACTIVE_COMPARATOR|Partial dryness|a single matching cone is inserted in the canal for 3 seconds only.
62175214|NCT02606383|EXPERIMENTAL|Dapaconazole|Dapaconazole 2% Cream Topical
62175215|NCT02606383|ACTIVE_COMPARATOR|Ketoconazole|Ketoconazole 2% Cream Topical
62175216|NCT00873561|ACTIVE_COMPARATOR|1 Experimental|NBI-6024 0.1 mg
62175217|NCT00873561|ACTIVE_COMPARATOR|2 Experimental|NBI-6024 0.5 mg
62175218|NCT00873561|ACTIVE_COMPARATOR|3 Experimental|NBI-6024 1 mg
62175219|NCT00873561|NO_INTERVENTION|4 placebo|Placebo injection
62175220|NCT05615480|NO_INTERVENTION|Control group|The control group maintain the target blood pressure only according to the controlled hypotension guideline.
62175221|NCT05615480|EXPERIMENTAL|Experimental group|The experimental group adjust the controlled hypotension level under the guidance of cerebral oxygen saturation monitoring.
62175222|NCT04530877|EXPERIMENTAL|Exclusive enteral nutrition|the administration of a liquid formula diet with the exclusion of all other regular food for 8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (\>110%-120% of the average requirement).
62175223|NCT04530877|ACTIVE_COMPARATOR|Infliximab|the participants with active CD accept anti-TNF therapy (Infliximab) at 0week, 2week, 6week, 14week. Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD
62175224|NCT05261230|EXPERIMENTAL|Vedic Counselling Group|Vedic Counselling was given by trained and experienced therapists
62175225|NCT05261230|ACTIVE_COMPARATOR|Usual Care Group|Standard psychosocial care delivered by psychologists.
62364829|NCT01851525|ACTIVE_COMPARATOR|Contact Force Sensing (CFS) Guided|Contact Force Sensing (CFS) Guided: Operator will be guided by integrated force sensor in the ablation catheter (ThermoCoolSmartTouch ablation catheter)
62740500|NCT03018197|EXPERIMENTAL|Medication Education|Patients will receive training on the use of the personal health record and health education via the personal health record.
62175226|NCT06219681|EXPERIMENTAL|Active neurofeedback|Receiving feedback signals from the repetitive negative thinking (RNT)-related brain functional connectivity
62175227|NCT06219681|SHAM_COMPARATOR|Sham neurofeedback|Receiving artificially generated feedback signals.
62182409|NCT03599622|PLACEBO_COMPARATOR|Placebo|
62175228|NCT03703141|EXPERIMENTAL|Sucralose 48 mg|Sucralose 48 mg in 60 ml of water O.D. for ten weeks
62175229|NCT03703141|EXPERIMENTAL|Sucralose 96 mg|sucralose 96 mg in 60 ml of water O.D. for ten weeks
62175230|NCT03703141|PLACEBO_COMPARATOR|Placebo|60 ml of water as placebo O.D. for ten weeks
62740501|NCT03018197|NO_INTERVENTION|No Medication Education|Patients will receive the current standard of care for the personal health record. Patients will not receive training on the use of the personal health record or health education via the personal health record.
62175231|NCT02295852|EXPERIMENTAL|Group A: LOW-SODIUM LOW LIPID CALCIUM RICH DIET|Experimental Group A: patients will change their diet in a diet similar for total daily calories, sodium and macronutrients but enriched in calcium (1200 mg/daily) and will be followed up to 1 year with an intermediate control after the first 3 months;
62175232|NCT02295852|ACTIVE_COMPARATOR|Group B: LOW-SODIUM LOW LIPID DIET|Experimental Group B: patients will continue the low-lipid, low-sodium diet up to 1 year with an intermediate control after the first 3 months.
62175233|NCT06090019|EXPERIMENTAL|Control group|Nursing interns students learned the routine nursing care of children on mechanically ventilation to prevent VAP by PICU nurses staff.
62175234|NCT06090019|EXPERIMENTAL|Study group|Nursing interns students received comprehensive education about VAP care bundle prevention by self-instructional module through the researchers.
62740502|NCT05646784|EXPERIMENTAL|Cerebiome for Depressive patient|Patients in a current episode of MDD, as determined by the Mini International Neuropsychiatric Interview (MINI) per DSM-V criteria recruited from Hôtel-Dieu de France hospital as well as from clinics in North Lebanon.
62175235|NCT02867241|EXPERIMENTAL|Intervention|"1. Motivational interviews (3 visits) + supportive phone calls~2. Feedback of child hair nicotine levels~3. Feedback of home air quality (PM2.5)~4. New Media (Website and/or Facebook with information and parental forum)"
62175236|NCT02867241|OTHER|Control Regular|This group will get no intervention during the study period. Following the close of the study, participants in this group will receive a shortened version of the intervention (1 motivational interview, with feedback on child hair nicotine levels and feedback on home air quality (PM2.5))
62175237|NCT02867241|OTHER|Control Expanded|This group will get no intervention during the study period. However, participants will fill out a detailed questionnaire on parental perceptions of exposure and risk, as well as questions on social norms, self-efficacy, and knowledge Following the close of the study, participants in this group will receive a shortened version of the intervention (1 motivational interview, with feedback on child hair nicotine levels and feedback on home air quality (PM2.5))
62364830|NCT01783470|EXPERIMENTAL|beta3-adrenergic receptor agonist|single dose. Each subject was randomized to receive placebo at one visit and then the beta3-adrenergic receptor agonist on another study day.
62364831|NCT04565236|EXPERIMENTAL|Part A: PTPs <12 years of age|Previously treated severe hemophilia A patients (PTPs) \<12 years of age
62364832|NCT04565236|EXPERIMENTAL|Part A: PTPs ≥12 to 65 years of age|Previously treated severe hemophilia A patients (PTPs) ≥12 to 65 years of age
62740503|NCT05646784|PLACEBO_COMPARATOR|Placebo for Control group|Second group of patients in a current episode of MDD, as determined by the Mini International Neuropsychiatric Interview (MINI) per DSM-V criteria recruited from Hôtel-Dieu de France hospital as well as from clinics in North Lebanon.
62740504|NCT05646784|NO_INTERVENTION|Healthy control|"Healthy control not suffering from any mental condition according to the Mini International Neuropsychiatric Interview (MINI) per DSM-V criteria.~Healthy volunteers will be recruited from students at the Saint-Joseph and the Lebanese universities."
62740505|NCT03773237|ACTIVE_COMPARATOR|SMOFLipid|SMOFlipid is a lipid emulsion that contains a combination of soybean oil, medium chain triglycerides, olive oil, and fish oil.
62740506|NCT03773237|ACTIVE_COMPARATOR|IntraLipid|Intralipid is a lipid emulsion that contains soybean oil
62740507|NCT05898581|EXPERIMENTAL|PENG Block|Participants will receive ultrasound-guided PENG block (PENG group) with local anesthetics (20 ml of 0.5% ropivacaine) before administration of spinal anesthesia.
62740508|NCT05898581|SHAM_COMPARATOR|Control Group|Participants will receive a sham PENG block performed with 20ml of normal saline solution before spinal anesthesia. After, patients will receive ILAI (performed by the operating surgeon) with a plain solution of ropivacaine 0.25% 60ml.
62740509|NCT01223651|ACTIVE_COMPARATOR|CGMS at sea level.|To assess reliability of continuous glucose monitoring system at sea level whilst subject undergo's a hyperinsulinaemic glucose clamp study.
62740510|NCT01223651|ACTIVE_COMPARATOR|CGMS reliability at simulated 8000 feet.|To assess reliability of continuous glucose monitoring system at a simulated altitude of 8,000 feet whilst the participant undergo's a hyperinsulinaemic glucose clamp study.
62740511|NCT04333524||Group A|Staging
62740512|NCT04333524||Group B|Criteria for response assessment
62740513|NCT01712997|EXPERIMENTAL|Combination therapy|combine inhaled iloprost, 10μg, 4-6times/day with bosentan,125mg,po,bid.
62740514|NCT01712997|ACTIVE_COMPARATOR|monotherapy|Bosentan,125mg,po,bid.
62740515|NCT05068791|EXPERIMENTAL|Psilocybin|Participants in the Psilocybin condition will receive .36 mg/kg of psilocybin.
62740516|NCT05068791|ACTIVE_COMPARATOR|Active Placebo|Participants in the Active Placebo condition will receive 2.6 mg/kg of dextromethorphan (DXM).
62740517|NCT05931471|EXPERIMENTAL|Yogurt Consumption|Participants will complete a 2-week baseline with no yogurt intake, followed by a three-week yogurt intervention, and then a 2-week follow-up period with no yogurt intake.
62740518|NCT05663177||Study arm|Almonertinib plus metronomic oral vinorelbine
62740519|NCT01158820|PLACEBO_COMPARATOR|Placebo|midazolam load fentanyl load midazolam demand fentanyl demand benadryl demand
62740520|NCT01158820|ACTIVE_COMPARATOR|dexmedetomidine and ketamine|dexmedetomidine load ketamine load dexmedetomidine maintenance ketamine maintenance midazolam demand fentanyl demand benadryl demand
62740521|NCT02713984|EXPERIMENTAL|HER2 positive cancers|Patients with relapsed and refractory cancer of HER2 expression will be treated with anti-HER2 CAR-T cells
62740522|NCT01248988||Synflorix Group|Infants and children who received at least one dose of Synflorix™ as a part of routine practice at a private clinic or hospital
62740523|NCT01698619||Climbers on Mount Aconcagua|The Cohort consists of volunteers climbing Mount Aconcagua.
62740524|NCT01157338|ACTIVE_COMPARATOR|diagnostic cardiac catheterization|patients with diagnostic cardiac catheterization
62740525|NCT01157338|ACTIVE_COMPARATOR|therapeutic cardiac catheterization|patient with angioplasty
62740526|NCT00107432|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62740527|NCT04707118|EXPERIMENTAL|Thermal perfusion cisplatin+Nab-paclitaxel+GEM|Laparoscopic exploration + thermal perfusion cisplatin 40 mg/m2, Postoperative exploration D1, 8 Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 after the second thermal perfusion 4 weeks plan, 6 cycles
62175238|NCT02547298||All participants|All participants will be filling out questionnaires and undergoing cystoscopy with hydrodistension for evaluative reasons
62551521|NCT01225185||Patients undergoing shoulder surgery|"This observational study will compare cerebral blood flow autoregulation in patients undergoing surgery in either the supine lateral position or the semi-recumbent or beach chair position. The choice of patient positioning is not randomized but based on usual surgical considerations."
62551522|NCT02655497|EXPERIMENTAL|Cognitive Training|Cognitive training intervention. The intervention includes seven 2-hour group sessions interspersed with four individual 45-minute sessions for a total of 17 hours of intervention over an 8-week period. The experimental group will receive real-world strategy training, a cognitive strategy based approach that trains people to improve their level of independence on meaningful activities of daily life with which they are having difficulty.
62551523|NCT02655497|ACTIVE_COMPARATOR|Psychosocial education|The intervention includes seven 2-hour group sessions interspersed with four individual 45-minute sessions for a total of 17 hours of intervention over an 8-week period. The control group will receive brain-health education.
62551524|NCT00108004|EXPERIMENTAL|Pramlintide|"Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection.~It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43-mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative"
62551525|NCT03730844||Critically ill children|Children admitted to the PICU.
62551526|NCT03730844||Healthy controls|Healthy controls, not admitted to the PICU, without pre-existing medical conditions.
62551527|NCT01004809||Dutasteride|Patients administrated dutasteride with male hair loss
62551528|NCT05736861|EXPERIMENTAL|Arm A - Ivermectin 400|"Ivermectin - 7-mg tablets~Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight for a daily dose of approximately 300-400 µg/kg."
62551529|NCT05736861|PLACEBO_COMPARATOR|Arm A - Placebo|"Placebo - appearance and size matched to active study drug.~Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight, matched to active study drug dosing."
62551530|NCT04298632|EXPERIMENTAL|Youth-only|Only the youth receives the education program
62175239|NCT01294410|EXPERIMENTAL|Cohort 1: Induction|Placebo or Anti-IP-10 Antibody
62175240|NCT01294410|EXPERIMENTAL|Cohort 2: Induction|Placebo or Anti-IP-10 Antibody
62175241|NCT01294410|EXPERIMENTAL|Cohort 3: Induction|Placebo or Anti-IP-10 Antibody
62551531|NCT04298632|EXPERIMENTAL|Family enhanced|A parent and the youth both receive the education program
62551532|NCT04298632|NO_INTERVENTION|Control|neither parent, nor youth receives the education program
62551533|NCT00348829|ACTIVE_COMPARATOR|1|Surgical mitral valve reconstruction
62551534|NCT00348829|NO_INTERVENTION|2|conservative treatment
62551535|NCT03536884|EXPERIMENTAL|Bimekizumab dosage regimen 1|"Subjects randomized to this arm will receive bimekizumab dosage regimen 1 (BKZ 1).~At Week 16 subjects will be re-randomized and continue to receive BKZ 1 or to switch to bimekizumab regimen 2 (BKZ 2).~Placebo will be administered at pre-specified time-points to maintain the blinding over the double-blind Treatment Period.~Subjects allowed to enroll in the open-label extension (OLE) Period will receive BKZ 1 or BKZ 2. Subjects will switch from BKZ 1 to BKZ 2 at Week 64 or at the next scheduled Visit.~Eligible subjects who completed OLE, have entered Safety Follow Up (SFU) or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks or start OLE2 on BKZ 2."
62551536|NCT03536884|EXPERIMENTAL|Bimekizumab dosage regimen 2|"Subjects randomized to this arm will receive bimekizumab dosage regimen 2 (BKZ 2) starting at Week 16 after initial treatment on bimekizumab regimen 1 (BKZ 1) for 16 weeks.~Placebo will be administered at pre-specified time-points to maintain the blinding over the double-blind Treatment Period.~Subjects allowed to enroll in the open-label extension (OLE) Period will receive BKZ 1 or BKZ 2. Subjects will switch from BKZ 1 to BKZ 2 at Week 64 or at the next scheduled Visit.~Eligible subjects who completed OLE, have entered SFU or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks or start OLE2 on BKZ 2."
62740528|NCT04707118|ACTIVE_COMPARATOR|Nab-paclitaxel+GEM|Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 4 weeks plan, 6 cycles
62740529|NCT00990431|ACTIVE_COMPARATOR|Carbon dioxide laser treatment|
62740530|NCT00990431|ACTIVE_COMPARATOR|Erbium:YAG laser treatment|
62175242|NCT01294410|EXPERIMENTAL|Maintenance|Placebo or Anti-IP-10 Antibody
62175243|NCT01294410|OTHER|Open Label|
62175244|NCT01856010||ECT Treatment|Those who were referred for ECT treatment for behavior refractory to standard care and who opted to undergo ECT treatment
62175245|NCT01856010||Standard Care (Non-ECT Group)|Those who were referred for ECT treatment for behavior refractory to standard care, but who opted to not undergo ECT treatment and continue with standard care.
62175246|NCT06478732|EXPERIMENTAL|the experimental group|receive comprehensive heart failure management
62175247|NCT06478732|NO_INTERVENTION|the controlled group|receive the current outpatient follow-up management
62175248|NCT03704649|NO_INTERVENTION|Standard nutrition education|The comparison group for the participatory video intervention.
62175249|NCT03704649|EXPERIMENTAL|Participatory nutrition education|Intervention arm integrates participatory video model to standard girls' club sessions to promote nutrition education.
62175250|NCT03891498|EXPERIMENTAL|MgSO4|The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
62175251|NCT02306213|EXPERIMENTAL|Hydroxyethylstarch 6% 130/0.4|These patients have received Hydroxyethylstarch 6% 130/0.4 intraoperatively or postoperatively in addition to standard volume therapy.
62175252|NCT02306213|ACTIVE_COMPARATOR|No Hydroxyethylstarch 6% 130/0.4|These patients have not received Hydroxyethylstarch 6% 130/0.4 at any time point. Only standard volume therapy has been used.
62175253|NCT03703843|EXPERIMENTAL|Active|ARTUS MONO
62551537|NCT03536884|ACTIVE_COMPARATOR|Secukinumab|"Subjects will receive secukinumab. Subjects allowed to enroll in the open-label extension (OLE) Period will be re-randomized to receive bimekizumab dosage regimen 1 (BKZ 1) or bimekizumab dosage regimen 2 (BKZ 2).~Eligible subjects who completed OLE, have entered SFU or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks or start OLE2 on BKZ 2."
62740531|NCT02406924|EXPERIMENTAL|Sausage graft|Bone graft performed with a mixture of particulated autogenous and lyophilized bovine bone, stabilized with collagen membrane and pins.
62551538|NCT05625074||CHUP Angiology and Vascular Surgery Service|"A transversal study, recruiting consecutive patients undergoing great saphenous vein saphenectomy by stripping technique.~Evaluation and Qol Questionnaires performed at the 30th day of the postoperative period (acceptable scope - 25 to 45 days)"
62740532|NCT02406924|ACTIVE_COMPARATOR|Bone block graft|Bone graft performed with a block of autogenous bone stabilized by a screw associated with lyophilized bovine bone and collagen membrane.
62740533|NCT00768846|ACTIVE_COMPARATOR|1|Endeavor Resolute Stent
62740534|NCT00768846|ACTIVE_COMPARATOR|2|Xience V Stent
62740535|NCT02819843|EXPERIMENTAL|Intralesional TALIMOGENE LAHERPAREPVEC with radiotherapy|Patients will receive 3 radiotherapy treatments (one treatment every 3-5 days) during weeks 3 and 4. The first treatment will occur 6 (+/- 2) hours after the Talimogene Laherparepvec administration at week 3.Talimogene Laherparepvec will be administered at weeks 0, 3, 5, 7, 9, 11, 13 and 15. The first dose of Talimogene Laherparepvec will be 10\^6 plaque forming units (PFU)/mL, followed three weeks later by a dose of 10\^8 pfu/mL.
62740536|NCT02819843|EXPERIMENTAL|Intralesional TALIMOGENE LAHERPAREPVEC without radiotherapy|Patients will receive Talimogene Laherparepvec alone, as described above, without radiotherapy.
62740537|NCT03703804||Women postpartum|Women -over 18 years, ability to understand Swedish in spoken and written terms, gave birth to a child approximately 3 months ago via vaginal delivery or cesarean section will be included. Exclusion criteria will be chronic pain in the pelvis or back (defined as pain in pelvic or back in more than 3 months before pregnancy), major rupture of the pelvic floor at delivery e.g. sphincter rupture grade III/IV or other diseases or surgery that prevents examination of the pelvic floor or abdominal muscles.
62740538|NCT00564733|EXPERIMENTAL|Chemotherapy|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients undergo FDG PET/CT (fludeoxyglucose F 18 positron emission tomography/computed tomography) scan between days 18-21. The FDG PET/CT is an imaging biomarker analysis. Patients that are responding to treatment receive paclitaxel IV and carboplatin IV on day 1. Treatment repeats every 3 weeks for up to 3 additional courses in the absence of disease progression or unacceptable toxicity.Patients that are not responding to chemotherapy per FDG PET then receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 3 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Non-responding patients undergo an additional FDG PET/CT scan between days 18-21 of course 2.
62740539|NCT03530995|EXPERIMENTAL|Part 1, Period 1|Drug: Belumosudil. Subjects will receive belumosudil 200 mg single dose on Day 1
62740540|NCT03530995|EXPERIMENTAL|Part 1, Period 2|"Drug: Itraconazole. Subjects will receive itraconazole 200 mg QD on Day 1 through Day 7.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg + itraconazole 200 mg QD on Day 8 Subjects will receive itraconazole 200 mg QD on Day 9"
62740541|NCT03530995|EXPERIMENTAL|Part 1, Period 3|"Drug: Rabeprazole. Subjects will receive rabeprazole 20 mg BID on Day 1 through Day 3.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg + rabeprazole 20 mg QD on Day 4."
62740542|NCT03530995|EXPERIMENTAL|Part 1, Period 4|"Drug: Rifampicin. Subjects will receive rifampicin 600 mg QD on Day 1 through Day 9.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg on Day 10."
62740543|NCT03530995|EXPERIMENTAL|Part 2, Period 1|Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID on Day 1.
62740544|NCT03530995|EXPERIMENTAL|Part 2, Period 2|"Drug: Omeprazole. Subjects will receive omeprazole 20 mg QD on Day 1 through Day 3.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID + omeprazole 20 mg QD on Day 4."
62740545|NCT06556875|ACTIVE_COMPARATOR|HIIT group|
62740546|NCT06556875|ACTIVE_COMPARATOR|HIIT combined IET group|
62740547|NCT06556875|NO_INTERVENTION|Control group|
62740548|NCT00331994|EXPERIMENTAL|1|
62740549|NCT00331994|ACTIVE_COMPARATOR|2|
62740550|NCT05547399|EXPERIMENTAL|Low Dose Cohort|Zanubrutinib will be administered as a single low dose of treatment (tablet) or reference (capsule) on separate occasions across several treatment sequences
62175254|NCT04389918|EXPERIMENTAL|Tality|Participants will receive TalityTM as their sole intake for nutritional purposes for a 4 week period.
62175255|NCT02253147|EXPERIMENTAL|Left side TEOSYAL® RHA Ultra Deep, Right side Perlane-L®|Split-face injection of TEOSYAL® RHA Ultra Deep into the left Naso Labial Folds (NLFs) and Perlane-L® into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
62364833|NCT04565236|EXPERIMENTAL|Part B: PUPs/MTPs <6 years of age|Previously untreated/minimally treated severe hemophilia A patients (PUPs/MTPs) \<6 years of age
62551539|NCT05625074||CHUSJ Angiology and Vascular Surgery Service CHUSJ|"A transversal study, recruiting consecutive patients undergoing great saphenous vein saphenectomy by stripping technique.~Evaluation and Qol Questionnaires performed at the 30th day of the postoperative period (acceptable scope - 25 to 45 days)"
62740551|NCT05547399|EXPERIMENTAL|High Dose Cohort|Zanubrutinib will be administered as a single high dose of treatment (tablet) or reference (capsule) on separate occasions across several treatment sequences
62740552|NCT02027311|EXPERIMENTAL|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
62740553|NCT02027311|EXPERIMENTAL|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
62740554|NCT06660511|EXPERIMENTAL|Experimental|The dose of Disitamab Vedotin(RC48) is 2.0 mg/kg iv q2w d1; The dose of Anlotinib Hydrochloride Capsules is 10mg po qd (recommended to be taken before meals and at the same time every day), taken orally continuously for 2 weeks and stopped for 1 week, with a treatment cycle of 21 days.
62740555|NCT05483712|EXPERIMENTAL|Post-Mastectomy Radiation Therapy Patients|Any patient who is going through radiation to their chest wall following mastectomy using a rotational delivery technique and 6 MV, and uses Superflab bolus for some but not all fractions of radiotherapy
62740556|NCT06106581|EXPERIMENTAL|VLA1553 full dose|
62740557|NCT06106581|EXPERIMENTAL|VLA1553 half dose|
62740558|NCT06106581|ACTIVE_COMPARATOR|Control|Single intramuscular vaccination on Day 1 with Nimenrix (Men ACWY vaccine), a conjugate vaccine indicated for the active immunization
62740559|NCT06659653|EXPERIMENTAL|CAR-T treatment|Plan to design three dose levels (0.5x10\^6 CAR-T/kg ，1.0x10\^6 CAR-T/kg and 2.0x10\^6 CAR-T/kg ), with 3-6 R/R B-ALL subjects included in each dose group, totaling 9-18 subjects. Within each dose group, the next subject can be administered after the previous subject has completed at least 14 days of safety observation.
62551540|NCT05625074||CHUC Angiology and Vascular Surgery Service CHUSJ|"A transversal study, recruiting consecutive patients undergoing great saphenous vein saphenectomy by stripping technique.~Evaluation and Qol Questionnaires performed at the 30th day of the postoperative period (acceptable scope - 25 to 45 days)"
62551541|NCT04642365|EXPERIMENTAL|Part I|Dose-Escalation: Mixed solid tumors participants will receive ascending doses of RO7296682 with a fixed dose of Atezolizumab, every three weeks (Q3W) until either the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) is defined.
62551542|NCT04642365|EXPERIMENTAL|Part II|Dose-Expansion: Will start once MTD/RP2D dose of RO7296682 in combination with Atezolizumab is defined in Part I. Participants with selected tumor types will receive a fixed dose of RO7296682 in combination with Atezolizumab.
62740560|NCT01234454|EXPERIMENTAL|Risperidone Treatment Group|A two-week cross-titration phase followed randomization when patients started treatment with Risperidone in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose was 6mg/day or highest dose tolerated.
62740561|NCT01234454|EXPERIMENTAL|Olanzapine Treatment Group|A two-week cross-titration phase followed randomization when patients started treatment with Olanzapine in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose 20mg/day (or the highest dose tolerated) for 8 weeks, following 4 weeks of baseline Thiothixene.
62740562|NCT01234454|NO_INTERVENTION|Thiothixene|Subjects were first stabilized on open-label Thiothixene for four weeks, target dose 25 mg per day. Patients were then randomized to either Risperidone or Olanzapine treatment for 8 weeks.
62740563|NCT01228136|ACTIVE_COMPARATOR|Tranexamic acid|
62740564|NCT01228136|PLACEBO_COMPARATOR|Placebo|
62740565|NCT01304992|EXPERIMENTAL|Lupin Protein|Lupin protein (cultivar: Lupinus angustifolius Boregine; incorporated in a drink)
62740566|NCT01304992|ACTIVE_COMPARATOR|Reference protein|Reference Protein (75% sodium caseinate (EM7; DMV international) and 25% milk protein (Megglosat HP; Meggle), incorporated in a drink)
62740567|NCT01304992|NO_INTERVENTION|Wash out|Wash out (four weeks without any intervention between interventional periods)
62740568|NCT05656469|EXPERIMENTAL|PSY-PGx Group|This is the intervention group. All patients will be treated according to a personalised medication recommendation based on the results of pharmacogenetic testing, following the prespecified dosing guideline. Prescribing physicians will prescribe one of the predefined drugs and will be unblinded for genotype and the resulting metabolisation phenotype.
62740569|NCT05656469|NO_INTERVENTION|Dosing as usual (DAU) group|This is the control group. In this group, prescribing physicians will also prescribe one of the predefined drugs, but will remain blinded to their patients' genotype and resulting metabolism phenotype for the duration of their participation in the study. After the study, patients in the control group will also be given their pharmacogenetic profile, which will make it possible to personalise their medication if necessary.
62740570|NCT01930422|EXPERIMENTAL|Real tDCS|Direct transcranial electrical stimulation (tDCS procedure)
62740571|NCT01930422|SHAM_COMPARATOR|Placebo tDCS|Sham procedure
62740572|NCT01591837|EXPERIMENTAL|Adults|Healthy volunteers aged 18 to 59 years received a single 0.5 mL dose of CSL Influenza Vaccine by intramuscular or subcutaneous injection.
62740573|NCT01591837|EXPERIMENTAL|Older Adults|Healthy volunteers aged 60 years or older received a single 0.5 mL dose of CSL Influenza Vaccine by intramuscular or subcutaneous injection.
62740574|NCT01538355|EXPERIMENTAL|Prolonged fasting|Patients undergo an initial 7-day fasting episode.
62740575|NCT01538355|EXPERIMENTAL|Ketogenic low glycemic load treatment|Patients receive a ketogenic low glycemic load treatment from the outset of the study.
62175256|NCT02253147|EXPERIMENTAL|Left side Perlane-L®, Right side TEOSYAL® RHA Ultra Deep|Split-face injection of Perlane-L® into the left Naso Labial Folds (NLFs) and TEOSYAL® RHA Ultra Deep into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
62740576|NCT01538355|EXPERIMENTAL|Control diet|Patients stay on their regular diet.
62740577|NCT03296748|ACTIVE_COMPARATOR|TOT only group|60 patients with stress incontinence and asymptomatic grade 2 cystocele.
62740578|NCT03296748|ACTIVE_COMPARATOR|concomitant repair group|63 patients with stress incontinence and asymptomatic grade 2 cystocele.
62740579|NCT03007199||AGNES Controls|AGNES controls are individuals with a first acute ST-elevation myocardial infarction but without ventricular fibrillation.
62740580|NCT03007199||AGNES cases|AGNES cases have ECG- registered ventricular fibrillation occurring before reperfusion therapy for an acute and first ST-elevation myocardial infarction.
62740581|NCT02551380|EXPERIMENTAL|Treated|treatment with Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
62740582|NCT02551380|PLACEBO_COMPARATOR|control|treatment with one capsule of placebo twice a day during 12 weeks
62740583|NCT04493424|EXPERIMENTAL|Treatment group|Up to 260 weeks
62740584|NCT00604149||1|case of out-of-hospital cardiac arrest
62740585|NCT00604149||2|cases of MI
62740586|NCT00604149||3|controls without coronary disease
62740587|NCT00757510||Congenital heart disease|All subjects will have known or suspected congenital heart disease
62175257|NCT02459236|EXPERIMENTAL|CERC-301 12mg|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
62740588|NCT05126810||Observational (questionnaire)|Patients complete a questionnaire over 15-20 minutes. Patients positive for a TP53 mutation complete an additional questionnaire over 15-20 minutes within 1 month after test results.
62740589|NCT06090305|EXPERIMENTAL|Intervention group|"Participants allocated to the intervention group will receive access to levidex in addition to treatment as usual (TAU). levidex is a digital health application designed for individuals with Multiple Sclerosis (MS), accessible through a web browser. The application comprises 16 modules, with the majority focusing on treatment methods derived from cognitive behavioral therapy (CBT) and health behavior change. The program operates through interactive dialogues, which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 365 days."
62740590|NCT06090305|ACTIVE_COMPARATOR|Control group|Participants allocated to the control group will receive an overview of relevant brochures from the Deutsche Multiple Sklerose Gesellschaft (German Multiple Sclerosis Society) on the topic of lifestyle in Multiple Sclerosis (MS) in addition to treatment as usual (TAU). After 6 months, they will be offered access to levidex.
62551543|NCT04642365|EXPERIMENTAL|Part III (Exploratory)|Dose-Expansion: Will start once MTD/RP2D dose of RO7296682 in combination with Atezolizumab is defined in Part I and if clinical activity is seen in this trial or in the single agent study (WP41188). Participants with selected tumor types will receive a fixed dose of RO7296682 in combination with Atezolizumab at the dosing regimen established in Part I.
62551544|NCT00321191|EXPERIMENTAL|N2O|
62551545|NCT00321191|PLACEBO_COMPARATOR|No N2O|
62551546|NCT04778475|EXPERIMENTAL|Group A|The treatment group will receive increased frequency of PT services within the first 3-5 days of admission, followed by daily PT services for the duration of their inpatient stay.
62551547|NCT04778475|ACTIVE_COMPARATOR|Group B|The control group will receive standard care of PT services 3-5 times per week during their hospitalization.
62551548|NCT00047112|EXPERIMENTAL|CHIMIORADIOTHERAPIE SUIVIE DE CHIRURGIE|CHIMIORADIOTHERAPIE SUIVIE DE CHIRURGIE
62551549|NCT00047112|ACTIVE_COMPARATOR|CHIRURGIE SEULE|CHIRURGIE SEULE
62551550|NCT05611554|EXPERIMENTAL|Treatment|Psychological intervention will consist in an 3-session group ACT-based treatment.
62551551|NCT05611554|NO_INTERVENTION|Waiting List|Participants assigned to Waiting List arm waited for 5 months before receiving treatment (i.e., after completing the measures they continued in the study and received Psychological intervention five months later)
62551552|NCT05666076|ACTIVE_COMPARATOR|Group PENG|The investigators performed a pericapsular nerve block on that patient group for postoperative analgesia.
62551553|NCT05666076|ACTIVE_COMPARATOR|Group SSNB|The investigators performed a suprascapular nerve block on that patient group for postoperative analgesia.
62551554|NCT05985629|EXPERIMENTAL|IPACK|After the adductor canal block, the anesthesiologist will reposition, visualize the anatomy of the IPACK block with ultrasound, and place 1% lidocaine for skin infiltration. Once adequate needle visualization is achieved within the correct anatomic position and plane, 20mL of 0.5% bupivacaine will be injected.
62551555|NCT05985629|PLACEBO_COMPARATOR|Placebo|After the adductor canal block, the anesthesiologist will reposition, visualize the anatomy of the IPACK block with ultrasound, and place 1% lidocaine for skin infiltration. Once adequate needle visualization is achieved within the correct anatomic position and plane, 20mL of normal saline will be injected.
62551556|NCT02449980|ACTIVE_COMPARATOR|Primary Surgery Group|Patients randomized to the primary surgical intervention group will undergo VATS (video-assisted thoracoscopic surgery), apical blebectomy and mechanical pleurodesis during the initial hospital admission by the admitting staff surgeon. The general principles of the surgical technique consist of a 3-port thoracoscopic approach, stapled blebectomy, apical mechanical pleurodesis, and placement of chest tube . Variations of this technique will be at the discretion of the surgeon.
62551557|NCT02449980|ACTIVE_COMPARATOR|Initial Non-operative management|Those randomized to the control group will be admitted and their chest tube or percutaneous drainage catheter managed according to standard protocol. This consists of a minimum of 48 hours of Pleur-Evac suction and daily chest radiographs. The drainage tube is then placed to water seal when resolution of the pneumothorax is documented by x-ray, as well as absence of an air leak. If there are no clinical or radiographic changes after a water seal period, the chest tube is then removed. A post-removal chest radiograph is obtained and the patient is discharged if clinical and radiographic criteria are met.
62740591|NCT01173107|EXPERIMENTAL|MDRD eGFR 10~50 ml/min/1.73m2|
62740592|NCT02048137|ACTIVE_COMPARATOR|Active transcranial direct current stimulation|
62740593|NCT02048137|SHAM_COMPARATOR|Sham transcranial direct current stimulation|
62740594|NCT02236234|EXPERIMENTAL|Vaccine|one group with HPV vaccine
62551558|NCT03541161||Early rehabilitation group|Breast cancer patients who underwent reconstructive surgery in samsung medical center from Jan 2017 to August 2017. Following early rehabilitation protocol, patients were educated to undergo a self-exercise program after short-term immobilization of 2 weeks.
62551559|NCT03541161||Conventional protocol group|Breast cancer patients who underwent reconstructive surgery in samsung medical center from May 2016 to Dec 2016. Following conventional protocol, patients were asked to immobilize their shoulder for more than 4 weeks and then undergo self-exercise program.
62551560|NCT03560128|EXPERIMENTAL|Endocuff Vision Arm|Colonoscopy with Endocuff Vision device attached to the distal end of the scope.
62551561|NCT03560128|EXPERIMENTAL|AmplifEYE Arm|Colonoscopy with AmplifEYE device attached to the distal end of the scope.
62740595|NCT01006655|PLACEBO_COMPARATOR|placebo, adenosine challenge test|Controlled or partially controlled multiple trigger wheezing children received 4 weeks of placebo, preceded and succeeded by AMP challenge test,
62740596|NCT01006655|ACTIVE_COMPARATOR|Qvar, adenosine challenge test|Patients will receive 4 weeks of inhale QVAR (HFA beclomethasone) 100µg through a spacer device, twice a day
62740597|NCT01039324|EXPERIMENTAL|Intermediate Intervention (arm #1)|Care transition reports sent to primary care clinics, care transition letters sent to patients, release of information requests about care transitions sent on behalf of primary care clinics.
62740598|NCT01039324|EXPERIMENTAL|Full Intervention (arm #2)|E-mail notices sent to care managers about care transitions plus care transition reports sent to primary care clinics, care transition reports sent to patients, release of information requests about care transitions sent on behalf of primary care clinics.
62740599|NCT01039324|EXPERIMENTAL|Control (arm #3)|"Subjects assigned to the control group will receive usual care which is the standard of care coordination currently existent between patients, providers and care managers."
62551562|NCT06581887||Cohort|"* Social Responsiveness Scale (SRS - II)~* ADHD Rating scale (5th edition) (ADHD - RS V)~* Child Behaviour Checklist (CBCL)~* Revised Children's Anxiety and Depression Scale (RCADS-P)~* Behaviour Rating Inventory of Executive Function (BRIEF - P)~* Wechsler Intelligence test for children version V (WISC-V)~* Autism Diagnostic Observation Schedule (ADOS)~* Behavioural Assessment of the Dysexecutive Syndrome for Children (BADS-C)~* Psychophysiological task: A task previously used to measure the emotional response of patients through the usage of visual and auditory aversive stimuli. The emotional response will be measured through skin conductance, heartrate, pupil responses.~* Purdue Pegboard~* A subset of patients will be also asked to undergo an MRI brain scan"
62740600|NCT05607173|EXPERIMENTAL|Participants with mild HI|Mild HI is defined as a total score ranging from 5 to 6, inclusive (Child-Pugh score A)
62740601|NCT05607173|EXPERIMENTAL|Participants with moderate HI|Moderate HI is defined as a total score ranging from 7 to 9, inclusive (Child-Pugh score B)
62740602|NCT05607173|EXPERIMENTAL|Participants with normal hepatic function|Participants with normal hepatic function matched to participants
62740603|NCT04791215||Prospective Sample Collection|Prospective sample collection from participants treated with pembrolizumab monotherapy at Columbia University Irving Medical Center under standard of care treatment. Prospective cohort subjects must consent to provide available archived tumor and blood for whole exome sequencing (WES) (matched tumor and normal) for creation of plasma ctDNA panels. The tumor sample must be from a site that was not previously irradiated or has progressed after radiation.
62740604|NCT04791215||Retrospective Sample Collection|Retrospective sample collection from participants that consent to provide genetic data from previous whole exome sequencing (WES) in the form of files for creation of plasma ctDNA panels.
62740605|NCT06658925|EXPERIMENTAL|Olverembatinib as maintenance therapy or preemptive therapy post-HSCT|Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.
62740606|NCT01719458||Alcohol|Subjects diagnosed with alcohol dependence
62740607|NCT01719458||Obese|Subjects diagnosed with obesity
62740608|NCT01719458||Healthy|Subjects deemed to be medically healthy
62740609|NCT04624919|ACTIVE_COMPARATOR|Hot/Dry|
62740610|NCT04624919|EXPERIMENTAL|Warm/Humid|
62740611|NCT02130349||Crohns Disease|IBD patients diagnosed with Crohn's disease
62740612|NCT02130349||Ulcerative colitis|IBD patients diagnosed with ulcerative colitis
62740613|NCT02130349||IBD-Undefined|IBD patients with undefined IBD
62740614|NCT04774588|OTHER|Using VSI Streamer and Telemedicine Study|Using the real time streaming of input from video capture devices to a head mounted display during interventional radiology procedures
62740615|NCT04774588|PLACEBO_COMPARATOR|Not using VSI Streamer and Telemedicine Study|Not using real time streaming of input from video capture devices to a head mounted display and just using current standard imaging in the Interventional Suite.
62740616|NCT05694871|ACTIVE_COMPARATOR|Arm I (palbociclib)|Patients receive palbociclib PO on study. Patients will be allowed to cross over to Arm II following documentation of disease progression. Patients undergo MRI or CT scans throughout the trial. Patients may also undergo blood sample collection on study.
62740617|NCT05694871|EXPERIMENTAL|Arm II (palbociclib, cemiplimab)|Patients receive palbociclib PO and cemiplimab IV on study. Patients undergo MRI or a CT scan throughout the trial. Patients may also undergo blood sample collection on study.
62740618|NCT01884506|EXPERIMENTAL|labeled iron meal|Test meal (bread with honey) with a labeled iron solution
62740619|NCT01884506|EXPERIMENTAL|labeled iron and ascorbic acid meal|Test meal (bread with honey) with a labeled iron solution and ascorbic acid
62740620|NCT05139329||Patients with symptoms of typical/atypical chest pain|Patients will be retrospectively included based on their presenting ICD codes or symptoms of typical/atypical chest pain, and those patients with positive ischemic workup will be excluded. The patients with negative ischemic workup will be included, and through chart review these patients will be followed to further assess their continued diagnostic workup.
62740621|NCT05862974|EXPERIMENTAL|LPM3480392 X1mg|8 subjects will receive LPM3480392 X1mg and 2 receive placebo
62740622|NCT05862974|EXPERIMENTAL|LPM3480392 X2mg|8 subjects will receive LPM3480392 X2 mg and 2 receive placebo
62740623|NCT05862974|EXPERIMENTAL|LPM3480392 X3mg|8 subjects will receive LPM3480392 X3mg and 2 receive placebo
62740624|NCT05862974|EXPERIMENTAL|LPM3480392 X4mg|8 subjects will receive LPM3480392 X4mg and 2 receive placebo
62740625|NCT05862974|EXPERIMENTAL|LPM3480392 X5mg|8 subjects will receive LPM3480392 X5mg and 2 receive placebo
62740626|NCT05862974|EXPERIMENTAL|LPM3480392 X6mg|8 subjects will receive LPM3480392 X6mg and 2 receive placebo
62740627|NCT05862974|EXPERIMENTAL|LPM3480392 X7mg|8 subjects will receive LPM3480392 X7mg and 2 receive placebo
62740628|NCT05862974|EXPERIMENTAL|LPM3480392 X8mg|8 subjects will receive LPM3480392 X8mg and 2 receive placebo
62740629|NCT05871424|EXPERIMENTAL|buprenorphine patch group|
62740630|NCT05871424|SHAM_COMPARATOR|placebo group|
62740631|NCT02250794|ACTIVE_COMPARATOR|insulin glargine and insulin lispro|insulin glargine 0.3 units per kg and insulin lispro 0.1 units per kg with each meal
62740632|NCT02250794|EXPERIMENTAL|metformin and sitagliptin|metformin 750 mg PO twice daily and sitagliptin 100 mg PO once daily
62740633|NCT03185598||non-MACE|no MACE occurred
62740634|NCT03185598||MACE|MACE occurred
62740635|NCT06101342|EXPERIMENTAL|Randomized Phase: Lenacapavir (LEN) Group|Participants will receive subcutaneous (SC) LEN 927 mg on Day 1 and Week 26 and oral LEN 600 mg on Days 1 and 2.
62740636|NCT06101342|EXPERIMENTAL|Randomized Phase: Emtricitabine/ Tenofovir Disoproxil Fumarate (F/TDF) Group|Participants will receive daily F/TDF (200/300 mg) fixed dose combination (FDC) tablets for up to 52 weeks.
62551563|NCT06456242|EXPERIMENTAL|MedCM plus CounsCM|Mobile Contingency Management for counseling attendance and medication intake
62551564|NCT06551337|ACTIVE_COMPARATOR|Vitamin D replacement|Those with vitamin D deficiency will be replaced with vitamin D3 at 1000 IU at the first visit. Vitamin D3 1000 IU is expected to increase blood 25-hydroxyvitamin-D level by 25 nmol/L. Blood 25-hydroxyvitamin-D level will be rechecked 3 months after replacement. If the blood 25-hydroxyvitamin-D level is still below 50 nmol/L, the vitamin D3 replacement dosage will be increased to 2000 IU.
62551565|NCT06551337|NO_INTERVENTION|Vitamin D non-deficiency|No drug will be given to patients with Vitamin D non-deficiency.
62551566|NCT03786887|EXPERIMENTAL|Nalbuphine|
62551567|NCT05273346|EXPERIMENTAL|Comprehensive Conservative TCM Treatment Group|"1. Traditional Chinese medicinal ointment;~2. Acupotomy;~3. Cupping therapy with bamboo cup;~4. Oral Chinese medicine granules."
62551568|NCT05273346|ACTIVE_COMPARATOR|Modern Medicine Conservative Treatment Program Group|"1. Epidural Steroid Injections (ESIs);~2. Interferential current therapy;~3. Thermal therapy;~4. Oral painkillers."
62740637|NCT06101342|EXPERIMENTAL|Open-label Extension Phase: LEN|Participants randomized to LEN in the Randomized Phase who choose to participate in the LEN Open-Label Extension (OLE) Phase will receive SC LEN every 26 weeks (± 7 days) and have study visits every 13 weeks (± 7 days). Participants randomized to F/TDF in the Randomized Phase who choose to participate in LEN OLE Phase will switch to SC LEN and have study visits at LEN OLE Day 1, Week 4 (± 2 days), Week 13 (± 7 days), and every 13 weeks (± 7 days) thereafter. SC LEN will be administered at the LEN OLE Day 1 visit and every 26 weeks thereafter. These participants will also receive loading doses of oral LEN on OLE Days 1 and 2. Upon completion of the LEN OLE Phase, participants will transition to local HIV prevention services and return for a 30-day follow-up visit. At that time, participation in the study will end.
62551569|NCT00620685|PLACEBO_COMPARATOR|1|
62551570|NCT00620685|EXPERIMENTAL|2|
62551571|NCT00620685|EXPERIMENTAL|3|
62551572|NCT04587726|EXPERIMENTAL|Intervention Group|
62551573|NCT04587726|ACTIVE_COMPARATOR|Control Group|
62551574|NCT02925403|ACTIVE_COMPARATOR|Group 1|10μg R21/Matrix-M1 on days 0, 28, and 56.
62551575|NCT02925403|ACTIVE_COMPARATOR|Group 2|50μg R21/Matrix-M1 on days 0, 28, and 56.
62551576|NCT02925403|PLACEBO_COMPARATOR|Group 3|Saline injection on days 0, 28, and 56.
62551577|NCT04960293|EXPERIMENTAL|Spherical gelfoam|Patients who receive uterine artery embolization for symptomatic fibroids
62551578|NCT04960293|ACTIVE_COMPARATOR|Microsphere|Patients who receive uterine artery embolization for symptomatic fibroids
62551579|NCT03382587||Aflibercept|Treatment-naive wet age-related macular degeneration patients under routine intravitreal aflibercept treatment in a treat-and-extend scheme
62551580|NCT03481010|EXPERIMENTAL|PAO with hip arthroscopy|"Patient's in the Scope PAO group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the Scope-PAO group have been randomized to receive a periacetabular osteotomy with a hip arthroscopy."
62551581|NCT03481010|ACTIVE_COMPARATOR|PAO without hip arthroscopy|"Patient's in the PAO-only group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the PAO-only group have been randomized to receive a periacetabular osteotomy only."
62551582|NCT01207310|EXPERIMENTAL|Pager Arm|Participants in the Pager Arm will be provided with alphanumeric pagers and will receive therapeutic messages on these pagers for 3 months in addition to individual smoking cessation counseling and nicotine patches.
62551583|NCT01207310|ACTIVE_COMPARATOR|Control Arm|Participants in the Control Arm will receive individual smoking cessation counseling and nicotine patches.
62551584|NCT03785119||Standard strategy|According to embryo quality (morphologic criteria)
62551585|NCT03785119||Experimental strategy|Association of embryo quality and sCD146 rate
62551586|NCT01101113|EXPERIMENTAL|Cinacalcet|stepwise dose of cinacalcet + regular medical medication including vit D
62551587|NCT01101113|ACTIVE_COMPARATOR|Control|conventional treatment for secondary HPT including vit D and phosphate binder
62551588|NCT00372814|EXPERIMENTAL|Multisystemic Therapy (MST)|Adolescents receiving MST will receive Intensive Home-Based Family Therapy which will consist of home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their daily diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
62551589|NCT00372814|ACTIVE_COMPARATOR|Telephone Support Calls|Adolescents receiving Supportive Telephone Calls (TS) will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
62551590|NCT02893085||patients with malignant biliary stricture|
62551591|NCT02893085||patients with benign biliary diseases|
62551592|NCT04742374|EXPERIMENTAL|Group A|Patients alternating single plasma exchange followed by double filtration plasmapheresis etc.
62551593|NCT04742374|EXPERIMENTAL|Group B|Patients alternating double filtration plasmapheresis followed by single plasma exchange etc.
62551594|NCT03295630|OTHER|Actigraph GT3X accelerometer|Ward based patients recovering from critical illness will wear two accelerometers placed on the thigh and ankle of the non-dominant leg
62551595|NCT01823367|EXPERIMENTAL|Lifestyle counseling mom only|This intervention, delivered to groups of mothers only, builds upon the evidence-based curriculum used in the Diabetes Prevention Program (DPP) and incorporates into the curriculum detailed education regarding ways to help their children adopt healthier lifestyle behaviors.
62551596|NCT01823367|EXPERIMENTAL|Lifestyle counseling mom and child|The second intervention is delivered to both mothers and children in separate groups using the same parent Diabetes Prevention Program (DPP) curriculum, but adds a group program for children that directly teach these children strategies for eating better and increasing physical activity.
62740638|NCT06101342|EXPERIMENTAL|Pharmacokinetic (PK) Tail Phase: F/TDF|Participants eligible for the PK Tail Phase will receive open-label oral F/TDF once daily for up to 78 weeks and complete study visits every 13 weeks (± 7 days). PK Tail Day 1 visit will occur 26 weeks (± 7 days) after the last SC LEN injection.
62551597|NCT05622487|ACTIVE_COMPARATOR|Neural Therapy|Segmental neural therapy will be administered with intradermal 0.5% lidocaine from cervical 1st to sacral 1st vertebra and upper trapezius region with quaddel injections.. Sham kinesio taping will be applied to the bilateral arms of the patients. Home exercise program; trapezius stretching, cervical, thoracic and lumbar paravertebral muscle stretching exercises will be required to be performed 10 times and every day.
62551598|NCT05622487|ACTIVE_COMPARATOR|Kinesio Taping|Kinesio taping will be applied with muscle inhibition technique by stretching from the origin to the insertion of the upper trapezius, cervical thoracic and lumbar paravertebral muscles. Sham neural therapy will be applied to the bilateral arms of the patients. Home exercise program; trapezius stretching, cervical, thoracic and lumbar paravertebral muscle stretching exercises will be required to be performed 10 times and every day.
62551599|NCT04442464|EXPERIMENTAL|Study Eye|One eye will be randomly selected to wear the scleral lenses to be worn during study measurements
62551600|NCT04442464|NO_INTERVENTION|Control Eye|Non-lens wearing eye
62551601|NCT04743726||Endoscopy|Chinese volunteers who are scheduling for gastro-colonoscopy
62551602|NCT06498882|EXPERIMENTAL|press needle acupoint stimulation combined with breast massage group|On the basis of the routine care, press needle acupoint stimulation and breast massage were administered to the intervention group
62740639|NCT03645096|EXPERIMENTAL|Pregnenolone 500 > Pregnenolone 800 > Placebo|"3 exposures in order:~1. Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.~2. Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.~3. Matching placebo capsule by mouth, daily for 7 days."
62740640|NCT03645096|EXPERIMENTAL|Pregnenolone 500 > Placebo > Pregnenolone 800|"3 exposures in order:~1. Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.~2. Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.~3. Pregnenolone 800 mg capsule by mouth, daily for 7 days."
62740641|NCT03645096|EXPERIMENTAL|Pregnenolone 800 > Pregnenolone 500 > Placebo|"3 exposures in order:~1. Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.~2. Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.~3. Matching placebo capsule by mouth, daily for 7 days."
62740642|NCT03645096|EXPERIMENTAL|Pregnenolone 800 > Placebo > Pregnenolone 500|"3 exposures in order:~1. Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.~2. Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.~3. Pregnenolone 500 mg capsule by mouth, daily for 7 days."
62740643|NCT03645096|EXPERIMENTAL|Placebo > Pregnenolone 500 > Pregnenolone 800|"3 exposures in order:~1. Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.~2. Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.~3. Pregnenolone 800 mg capsule by mouth, daily for 7 days."
62551603|NCT06498882|OTHER|control group|Control group received routine care
62551604|NCT06208137|EXPERIMENTAL|Intervention group|Remind patients to test their immune status among 120-180 days post-transplantation. Physicians assessed the risk level of patients in the intervention group based on their immune status on days 91-180 using the CIRS.
62551605|NCT06208137|NO_INTERVENTION|Control group|Only remind patients to test their immune status among 120-180 days post-transplantation.
62551606|NCT01325402|EXPERIMENTAL|Part 1 Cohort 1|Patients with mild to moderate Alzheimer's Disease
62551607|NCT01325402|EXPERIMENTAL|Part 1 Cohort 2|Patients with mild to moderate Alzheimer's Disease. To run if Maximum Detective Mass is detected in cohort 1.
62551608|NCT01325402|EXPERIMENTAL|Part 2|Healthy Volunteers
62551609|NCT01942421|EXPERIMENTAL|Cultivated mucosal epithelial transplant|Cultivated mucosal epithelial transplantaion to limbal deficiency patients
62551610|NCT04623892|EXPERIMENTAL|TQB2618|TQB2618 administered intravenously (IV) on Day 1 of each 21-day.
62551611|NCT03409588|EXPERIMENTAL|Study Drug|Riociguat (Adempas) 0.5mg to 2.5 mg three time daily - oral medication
62551612|NCT02742883|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for up to 104 days. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dosage is reached, but not exceeding 12.0 g/kg/d Atengenal or 0.4 mg/kg/d Astugenal.
62551613|NCT03672591||HFpEF patients|Patients suffering from heart failure with preserved ejection fraction
62551614|NCT03672591||Control group|Subjects without HFpEF who participated in different studies during which renal clearance examination has been performed with the constant infusion input clearance technique in our Clinical Research Center (clin. gov. numbers: NCT00627952, NCT01835678, NCT00136188, NCT00905528, NCT00160745)
62551615|NCT01818115|EXPERIMENTAL|IOL placement with Hydrus Implant|Cataract extraction with intraocular lens (IOL) placement and Hydrus Implant
62551616|NCT01818115|ACTIVE_COMPARATOR|IOL placement only.|Cataract Extraction with IOL placement only.
62551617|NCT02083068|EXPERIMENTAL|Experimental|10 individuals per sub- group to be immunized with the Vaccine PvCS N+C at month 0 and the Vaccine PvCS N+C+R at months 2 and 6
62551618|NCT02083068|PLACEBO_COMPARATOR|Control|six individuals for each sub- group to be immunized with placebo SSN Montanide ISA-51
62551619|NCT06306261||patients in remission of the disease|UC patients will be subjected to a questionnaire every month about their habits.
62551620|NCT06306261||patients in reactivation of the disease|UC patients will be subjected to a questionnaire every month about their habits.
62551621|NCT05886712|EXPERIMENTAL|SAIA-Naloxone|SAIA-Naloxone is an intervention that facilitates an organizational SSP level analysis of naloxone delivery by assigning a trained SAIA-Naloxone coach to apply tools and techniques and engage staff to define barriers, identify solutions, and evaluate their success in cycles until achieving desired change regarding naloxone distribution. Coaches will meet with SSPs twice per month for the first 3 months and once per month for the remaining 9 months during the 12-month intervention period.
62740644|NCT03645096|EXPERIMENTAL|Placebo > Pregnenolone 800 > Pregnenolone 500|"3 exposures in order:~1. Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.~2. Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.~3. Pregnenolone 500 mg capsule by mouth, daily for 7 days."
62740645|NCT01179828|ACTIVE_COMPARATOR|1|Oxycodone 15mg
62740646|NCT01179828|ACTIVE_COMPARATOR|2|Clobazam 20mg
62740647|NCT01179828|ACTIVE_COMPARATOR|3|Imipramine 75mg
62740648|NCT01179828|PLACEBO_COMPARATOR|4|Tolterodine 1mg
62740649|NCT00869791|OTHER|Sequence 1|"Treatment Period 1:~IPX066 - 7 days; Washout Period - 7 days;~Treatment Period 2:~IR CD-LD- 7 days"
62740650|NCT00869791|OTHER|Sequence 2|"Treatment Period 1:~IR CD-LD - 7 days; Washout period - 7 days;~Treatment Period 2:~IPX066- 7 days"
62740651|NCT06660108|OTHER|DLD patient and relative|
62740652|NCT05751993|EXPERIMENTAL|ADAPT intervention|Participants will receive a smart scale and a physical activity tracker and will have three daily goals: weigh daily, a daily personalized active minutes goal, and a daily calorie goal. For 12 weeks, participants will receive 0-3 text messages per day about their behaviors and progress towards their goals which they will be able to rate (like/dislike), along with weekly personalized feedback, progress graphs, and lessons and resources available on the website.
62740653|NCT04935190||Group 1|Subjects that have a diagnosis of a cardiac, pulmonary, or cardio-pulmonary condition (e.g., Congestive Heart Failure, COPD, Asthma) will be assigned to Group 1.
62740654|NCT04935190||Group 2|Subjects who are not known to have a cardiac, pulmonary, or cardio-pulmonary condition will be assigned to Group 2.
62740655|NCT06091943|EXPERIMENTAL|Part 1: Dose/Injection Site Exploration|Different injection sites will be evaluated; participants will receive tislelizumab in predefined administration sequences plus histology-based chemotherapy consisting of either cisplatin/carboplatin and pemetrexed or carboplatin and paclitaxel/nab-paclitaxel depending on the cancer subtype.
62740656|NCT06091943|EXPERIMENTAL|Part 2: Dose Expansion|The recommended dose of tislelizumab SC determined from Part 1 plus histology-based chemotherapy consisting of either cisplatin/carboplatin and pemetrexed or carboplatin and paclitaxel/nab-paclitaxel depending on the cancer subtype will be evaluated.
62740657|NCT04930120||Transferred group|The transferred group includes all severe COVID patients admitted in a French ICU ward and then transferred between the 03/13/2020 and 04/10/2020 to another ICU located outside the region of the initial ICU stay.
62551622|NCT05886712|OTHER|Implementation as Usual|SSPs randomized to the IAU arm will not receive support to improve naloxone distribution. SSPs in California have already adopted naloxone distribution. The investigators are therefore testing the ability of SAIA-Naloxone to optimize naloxone distribution within SSPs. Accordingly, IAU is characterized by the absence of SAIA-Naloxone with the goal of comparing whether SAIA-Naloxone improves SSPs' Naloxone distribution.
62551623|NCT01938495|EXPERIMENTAL|NeuRx® Diaphragm Pacing System™ (DPS)|Patients randomized to the experimental arm will receive The NeuRx® Diaphragm Pacing System™ (DPS) device. Under general anesthesia, the intramuscular electrodes are surgically implanted in the diaphragm.
62740658|NCT04930120||Control group|The control group includes patients selected out of those whose entire ICU care has taken place in one of the hospitals which transferred patients. Up to 4 control patients will be selected for each transferred patient.
62740659|NCT01532076|EXPERIMENTAL|cellularized composite graft augmentation|lipoaspiration by experienced plastic surgeon, isolation of SVF cells using a Cellution/CR800® cell isolation device and single use kits (Cytori Therapeutics Inc., San Diego) during open reduction and internal fixation, augmentation of bone with cell-seeded bone graft substitute;
62740660|NCT01532076|ACTIVE_COMPARATOR|Control acellular composite graft augmentation|open reduction internal fixation (ORIF) of the fracture, augmentation with acellular bone graft substitute.
62740661|NCT04746118|NO_INTERVENTION|CONTROL|During routine clinical visits the patients will receive a written standard general guidelines for diet and physical activity.
62740662|NCT04746118|EXPERIMENTAL|DIET CHANGE|In scheduled nutritional care the patients will receive an individual program with social media supervision. Those patients will also receive a written general guidelines for exercising without supervision.
62740663|NCT04746118|EXPERIMENTAL|DIET CHANGE + PHYSICAL ACTIVITY|In scheduled nutritional care the patients will receive an individual program with social media supervision. Those patients will also receive an exercise physical program prescription with fitness evaluation and close supervision.
62740664|NCT04746118|EXPERIMENTAL|DIET CHANGE + PHYSICAL ACTIVITY + INTEGRATIVE PRACTICES|"In scheduled nutritional care the patients will receive an individual program with social media supervision. Those patients will also receive an exercise physical program prescription with fitness evaluation and close supervision and submitted to orientated mind-fullness, auriculotherapy and laying on of hands approaches that belong to health integrative practices."
62740665|NCT02237001|EXPERIMENTAL|Treatment|Suture-based meniscal repair
62740666|NCT04075006|EXPERIMENTAL|Ketamine Group|adjunct low dose continuous infusion ketamine in addition to the standard of care. Ketamine will be given at a fixed infusion rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
62740667|NCT04075006|NO_INTERVENTION|Control Group|Standard of care in the ICU including propofol and / or fentanyl and/or midazolam according to KFSHRC sedation and analgesia protocol.
62175258|NCT02459236|EXPERIMENTAL|CERC-301 20mg|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
62175259|NCT02459236|PLACEBO_COMPARATOR|Placebo|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
62551624|NCT01938495|NO_INTERVENTION|Standard of Care|patients randomized to the standard of care arm will not have the Diaphragm Pacing System surgically implanted but will receive standard medical care.
62740668|NCT00911976|EXPERIMENTAL|Xience V|Implantation of the Xience V stent in saphenous vein graft lesions
62740669|NCT04418492|EXPERIMENTAL|SAFE intervention|The single group received the SAFE intervention for 10 weeks.
62740670|NCT06136689||Severe Aortic Stenosis - High Flow, High Gradient|patients undergoing surgical aortic valve replacement for severe AS
62740671|NCT06136689||Severe Aortic Stenosis - classical Low Flow, Low Gradient|patients undergoing surgical aortic valve replacement for severe AS
62740672|NCT06136689||Severe Aortic Stenosis - paradoxical Low Flow, Low Gradient|patients undergoing surgical aortic valve replacement for severe AS
62740673|NCT06136689||Moderate Aortic Stenosis|patients undergoing aortic root replacement (Bentall procedure)
62740674|NCT06136689||Heart Transplant|patients undergoing orthotopic heart transplant for any reason
62740675|NCT01827436|ACTIVE_COMPARATOR|Conventional physical therapy|Includes traditional physical treatment, such as gait and balance training and muscle strengthening.
62740676|NCT01827436|ACTIVE_COMPARATOR|Asymmetrical gait training|Includes walking on a split-belt treadmill with the belts moving at different speeds under each leg, alternated with overground walking training.
62740677|NCT00784888||Aromatase inhibitors|Early stage postmenopausal breast cancer patients under tamoxifen treatment who are switching to aromatase inhibitor treatment
62551625|NCT05327153|EXPERIMENTAL|intervention group|Breast cancer patients from the IPPT Breast Clinic who meet the inclusion criteria will be contacted and informed about the study and procedure. Informed consent will be obtained once the respondent agrees to participate. In the case of group psychological intervention, 8 breast cancer patients form one group, and group psychological intervention is given once a week for four weeks as part of the treatment process. The batteries of assessment were carried out at 3-time points; pre-intervention, post-intervention, and 3 months after the intervention.
62551626|NCT05327153|OTHER|waitlist group|After the intervention of the intervention group, the waitlist group was interfered again. The batteries of assessment was same as the intervention group.
62551627|NCT03567928|ACTIVE_COMPARATOR|Standard Treatment|Standard Treatment Sedation with propofol target controlled infusion (TCI) and no airway devices (mandatory spontaneous breathe)
62551628|NCT03567928|EXPERIMENTAL|Interventional Treatment|Interventional Treatment Sedation with propofol target controlled infusion (TCI) and Gastro Cuff Pilot Laryngeal Mask (possibility to use a pressure-support ventilation)
62551629|NCT00751192|EXPERIMENTAL|A|
62740678|NCT04305509||LDH patients|Patients with lumbar disc herniation which was treated with manual therapy
62740679|NCT03694340|OTHER|Re-programming of cochlear implant|The cochlear implant is programmed with a new MAP based on behavioral measurements of T- and C-levels and used by the participant for 4 months before follow up.
62175260|NCT03704571|EXPERIMENTAL|Tailored Group|In the tailored group, high-risk patients are instructed to drink the first 2 L of Polyethylene Glycol (PEG) at 19:00-21:00 hours on the day before colonoscopy at a rate of 250 ml every 15 min. On the day of the procedure, they take another 2 L PEG 4-6 h before colonoscopy. The low-risk patients were given a standard dose of 2 L PEG 4-6 h before colonoscopy.
62175261|NCT03704571|ACTIVE_COMPARATOR|Control Group|In the control group, all the patients drink single dose of 2 l Polyethylene Glycol (PEG) 4-6 h before colonoscopy at a rate of 250 ml every 15 min.
62175262|NCT04205214|EXPERIMENTAL|Integrative Cognitive Behavioural Therapy Intervention Group|The group receive 12 weekly individual Integrative Cognitive Behavioural Therapy sessions from the principal investigator and Trainee counselling Psychologist. The sessions last up to 60 minutes on a weekly basis. The participants in this group are required to complete self-reported questionnaires assessing: anxiety, depression, stress and quality of life. They are also required to attend a scalp assessment and undergo a blood test and medical photography. These assessments occur at the initial assessment prior to beginning the intervention and after the 12-week intervention.
62175263|NCT04205214|NO_INTERVENTION|Wait List Control Group|The group do not receive the intervention and are told that they can start the intervention after 12 weeks. The participants in this group are required to complete self-reported questionnaires assessing: anxiety, depression, stress and quality of life. They are also required to attend a scalp assessment and undergo a blood test and medical photography. These assessments occur at the initial assessment prior to beginning the intervention and after the 12-week waiting period. After this 12-week waiting period, they are offered the individual therapy and their data is added to the experimental group data.
62175264|NCT01355471|EXPERIMENTAL|CD07805/47 gel|
62551630|NCT00751192|ACTIVE_COMPARATOR|B|
62551631|NCT06113835||successful group|CTO PCI Technical success ,deployment of a balloon or stent with final antegrade TIMI flow grade 2 or 3, residual stenosis \<30% , and no significant side branch occlusion.
62175265|NCT01355471|PLACEBO_COMPARATOR|Placebo|
62175266|NCT06059209|NO_INTERVENTION|Breast Milk|
62175267|NCT06059209|OTHER|Enfamil Infant|
62175268|NCT06059209|ACTIVE_COMPARATOR|Enfamil NeuroPro|
62551632|NCT06113835||unsuccessful group|CTO PCI Technical unsuccess
62551633|NCT06488144|NO_INTERVENTION|No Intervention|Neither Intervention
62551634|NCT06488144|EXPERIMENTAL|Health Coaching, No Incentives|Receives a Health Coach but no Incentive Program
62551635|NCT06488144|EXPERIMENTAL|No Health Coach, Receives Incentives|Does not receive a health coach but does receive the incentive program.
62551636|NCT06488144|EXPERIMENTAL|Health Coaching, Receives Incentives|Receives both a health coach and the incentive program
62551637|NCT06325605|EXPERIMENTAL|Observation group|"Patients in the observation group were treated with oral Bifidobacterium (0.07g/capsule, approval number: Guo Yao Zhun Zi S10950032, Shanghai Sine Pharmaceutical Co., Ltd.) 3 capsules, 3 times a day, for 8 consecutive weeks, and high-frequency rTMS. In the rTMS treatment, the transcranial magnetic stimulation device with an 8-shaped coil with a diameter of 70mm was placed on the dorsolateral area of the left prefrontal lobe of the patient. The motor threshold was set to 90%. A 10-Hz pulse sequence was applied for 4 secs followed by a 20 secs interval. 10 pulses per train were used, and the total stimulation time was 30mins per day, 4 times a week, for 8 consecutive weeks."
62740680|NCT05614609|ACTIVE_COMPARATOR|Lidocaine spray on the glottis|Lidocaine 20 mgl/ml- 4,4 ml will be sprayed on the glottis. Ventilation for 90 sek, intubation
62740681|NCT05614609|ACTIVE_COMPARATOR|Muscle relaxing medication|Rocuronium 0,6 mg/kg administered intravenous. Ventilation for 2.5 minutes (150seconds), intubation
62740682|NCT06660134|EXPERIMENTAL|Strict Weight Reduction Intervention Group|In addition to the routine use of Antiarrhythmic Drugs (AADs) and anticoagulants, the strict weight reduction intervention group also uses GLP-1 receptor agonists for glycemic control and weight loss according to guidelines. This group receives a structured weight loss program, regular nutritional advice in accordance with current guidelines, and physical training assistance over a 12 month period. The intervention plan aims for a total weight loss of 10 kilograms while using GLP-1 receptor agonists.
62740683|NCT06660134|ACTIVE_COMPARATOR|Standard Care Group|Receives standard glycemic control treatment for diabetes and follows the recommended anticoagulant and antiarrhythmic drug regimens post ablation.
62740684|NCT04405778|EXPERIMENTAL|TAK-102 Cohort 1|TAK-102, 1 × 10\^7 Chimeric antigen receptor (CAR) (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min and completed within 60 minutes.
62740685|NCT04405778|EXPERIMENTAL|TAK-102 Cohort 2|TAK-102, 1 × 10\^8 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min and completed within 60 minutes.
62740686|NCT04405778|EXPERIMENTAL|TAK-102 Cohort 3|TAK-102, 1 × 10\^9 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min and completed within 60 minutes.
62740687|NCT02340858|EXPERIMENTAL|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
62740688|NCT02340858|NO_INTERVENTION|Control|The patients without treatment
62740689|NCT02902302|EXPERIMENTAL|Ibuprofen 400 mg/10 mL oral suspension|Single dose of 1 ibuprofen 400 mg/10 mL stick administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
62740690|NCT02902302|ACTIVE_COMPARATOR|MOMENT 400 mg coated tablet|Single dose of 1 MOMENT 400 mg coated tablet administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
62740691|NCT04003051|EXPERIMENTAL|Supportive Care (Project Prepare website)|Patients use the password-protected Project Prepare website on a computer, tablet, or phone over 10 weeks to view: videos of the swallowing and trismus exercises, tips and stories from former patients, what to expect each week of treatment, recipes and cooking demonstrations, how to take care of their teeth during treatment, strategies for stress relief, and strategies for dry mouth and nausea. This website is designed to reach underserved populations who do not have ready access to specialized preventive care.
62740692|NCT04949516|EXPERIMENTAL|Mono Antiplatelet and Colchicine Therapy|Aspirin-free, single P2Y12 inhibitor (prasugrel or ticagrelor) and colchicine treatment
62740693|NCT02907216|EXPERIMENTAL|Co-administration Group|Subjects aged 6 to 12 weeks who receive the Squarekids vaccine (diphtheria, tetanus, pertussis and inactivated poliovirus \[DPT-IPV\] vaccine) according to a 3, 4, 6 month schedule and the liquid Rotarix vaccine (oral live attenuated human rotavirus \[HRV\] vaccine) according to a 2, 3 month schedule. The HRV vaccine is administered orally while the DTP-IPV vaccine is administered subcutaneously in the upper arm or upper thigh.
62740694|NCT02907216|ACTIVE_COMPARATOR|Staggered Group|Subjects aged 6 to 12 weeks who receive the Squarekids vaccine (diphtheria, tetanus, pertussis and inactivated poliovirus \[DPT-IPV\] vaccine) according to a 3, 4.5, 6 month schedule and the liquid Rotarix vaccine (oral live attenuated human rotavirus \[HRV\] vaccine) according to a 2, 3.5 month schedule. The HRV vaccine is administered orally while the DTP-IPV vaccine is administered subcutaneously in the upper arm or upper thigh.
62740695|NCT06604858|EXPERIMENTAL|Pembrolizumab and Carboplatin plus Paclitaxel|"Patients will receive treatment with Pembrolizumab and Carboplatin plus Paclitaxel up to surgery.~The treatment is composed by 4 cycles of 21 days each (patients will be treated for a total of 84 days) and treatment will last until surgery."
62740696|NCT02502292|EXPERIMENTAL|Intervention: Fotonovela|The Photo Novel Intervention is presented to users of four different facilities (sports clubs, senior homes) who are older than 50 years. The researchers welcome scheduled eligible participants, introduce the study and ask them for their consent. Afterwards, the participants are asked to fill in the questionnaire. Then, participants are randomized to one of the four groups and are presented with the photo novel or traditional brochure either as a hard copy brochure or as pdf on a tablet computer (2x2 group design). They are instructed to read the material in their own pace and answer the accompanying questions after each story / tip.and the accompanying questionnaire.
62740697|NCT03680196|EXPERIMENTAL|cerebral palsy patients|cerebral palsy patients who have GMFCS level3,4,5 and 2 years old and under 10 years old apply an A injection of medication Botulinum A injection
62740698|NCT03981757|EXPERIMENTAL|NeurOS Group|Apply the single use NeurOS cerebral oximetry sensor adhesive onto patients' head who are going to have CEA surgery in the operating room before anesthesia induction.
62740699|NCT04985500|EXPERIMENTAL|ESP group|Patient will receive ESP block with ultrasound guidance the transverse process of the vertebra at T7 is visualized and 20 mL of 0.25% bupivacaine will be injected between the transverse process and the erector spinae muscle on each side using a 21-gauge block needle.
62740700|NCT04985500|EXPERIMENTAL|PIF group|Patient will receive PIF block after intubation with ultrasound placed 1-2 cm lateral to the sternal border and the pectoralis major and external intercostal muscles are visualized at the level of ribs 3-4 where 10 mL of 0.25% bupivacaine will be injected on each side using a 21-gauge block needle.
62740701|NCT04985500|NO_INTERVENTION|No Block group|Patient will not receive block.
62740702|NCT04208386|EXPERIMENTAL|Part A: Group 1|Participants with liver cirrhosis with moderate hepatic impairment will receive single subcutaneous (SC) injection of JNJ-73763989 on Day 1 under fasted condition.
62740703|NCT04208386|EXPERIMENTAL|Part A: Group 2|Participants with normal liver function with no liver cirrhosis will receive single SC injection of JNJ-73763989 on Day 1 under fasted condition.
62740704|NCT04208386|EXPERIMENTAL|Part B: Group 3 (optional)|Participants with liver cirrhosis with mild hepatic impairment will receive single SC injection of JNJ-73763989 on Day 1 under fasted condition.
62740705|NCT04208386|EXPERIMENTAL|Part B: Group 4 (optional)|Participants with liver cirrhosis with severe hepatic impairment will receive SC injection of JNJ-73763989 on Day 1 under fasted condition.
62740706|NCT03928418|EXPERIMENTAL|Live Phone Call Booster Arm|The live phone call arm will include in-person counseling during 2 quarterly clinic visits plus live booster phone calls every three weeks in the interim.
62740707|NCT03928418|EXPERIMENTAL|Technology Booster Arm|The technology booster arm will include in-person counseling during 2 quarterly clinic visits plus tech (choice of SMS or IVR) boosters once to twice weekly in the interim.
62740708|NCT03928418|NO_INTERVENTION|Standard of Care (SOC) Arm|The standard of care (SOC) control (brief unstructured advice, with a wait-listed intervention).
62740709|NCT01754038||Integrative Medicine Clinic Attendees|All patients attending a participating Integrative Medicine clinic for clinical services will be invited to participate in the PRIMIER Registry
62740710|NCT04042909|EXPERIMENTAL|Counter Attitudinal Advocacy|Participants in this arm will articulate ways to avoid alcohol-related consequences using self-generated protective strategies and publicly state those strategies.
62740711|NCT04042909|ACTIVE_COMPARATOR|Personalized Normative Feedback|Participants in this arm will view personalized normative feedback regarding their 1) own drinking quantity and frequency of drinking, 2) perceptions of typical drinking by same-sex students' on campus (i.e., perceived descriptive norms), and 3) actual drinking rates by same-sex students' on campus (i.e., actual descriptive norms).
62740712|NCT04042909|NO_INTERVENTION|Assessment-only Control|Participants in this arm will not receive any intervention.
62740713|NCT06661135|EXPERIMENTAL|TLPD|This is the group that will receive laparoscopic pancreaicoduodenectomy trocars were inserted (between 5 and 6 trocars were required) and pneumoperitoneum induction was done. The surgeries were performed as previously described . Single loop reconstruction was adopted which involved the formation of all three anastomoses (pancreatico-jejeunostomy, hepatico-jejeunostomy, and gastro-jejeunostomy) on a single jejunal loop. The distance between the hepatico-jejeunostomy, and gastro-jejeunostomy was adjusted at 60 cm for all patients.
62551638|NCT06325605|ACTIVE_COMPARATOR|Control group|Patients in the control group were treated with oral escitalopram oxalate (manufacturer: Sichuan Kelun Pharmaceutical Co., Ltd.; approval No.: Guo Yao Zhun Zi H20080788). The initial dose was 5mg/d, for 7 consecutive days. The dose was increased to 10 mg/d according to the tolerance of the patients for another 7 consecutive days, and then to 20 mg/d according to the patient's condition and tolerance for 8 weeks.
62551639|NCT04290455|EXPERIMENTAL|treatment arm|using the microblepharoexfoliative procedure
62740714|NCT06661135|ACTIVE_COMPARATOR|OPD|this group will receive open PD In the OPD group, a bilateral abdominal subcost incision was performed for open surgery
62740715|NCT00809835|NO_INTERVENTION|Standard Treatment As Usual (TAU)|Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals. This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment. The counseling program's theoretical orientation is described as client-centered.
62740716|NCT00809835|EXPERIMENTAL|TAU Plus Galantamine|Standard treatment plus Galantamine. In this study, we will use 8 mg galantamine extended release (ER). Galantamine ER is used once daily. The recommended initial dose is 8 mg/day and the maintenance dose is 16-24 mg/day.
62740717|NCT00809835|EXPERIMENTAL|TAU plus Computer Assisted Cognitive Behavioral Therapy (CBT)|TAU plus computer assisted CBT plus placebo. All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project. Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.
62740718|NCT00809835|EXPERIMENTAL|TAU plus CBT plus galantamine|Standard treatment, plus computer assisted cognitive behavioral therapy, plus galantamine.
62740719|NCT06131983|EXPERIMENTAL|ARO-DUX4|ARO-DUX4 for Injection
62740720|NCT06131983|PLACEBO_COMPARATOR|Placebo|(0.9%NaCl)
62740721|NCT03709069|NO_INTERVENTION|Traditional Group|"Traditional group receives diet from hospital kitchen quantity of which calculated depending on calorie requirement per kg body weight. This diet is same for all burn patients fulfilling the inclusion criteria of the study and it will be labelled as routine diet.~Wounds of patients will be managed by closed dressing to be changed on every third day."
62740722|NCT03709069|EXPERIMENTAL|Albumin Group|Interventional group receiving enteral supplemental albumin 2mg per kg body weight along with routine hospital kitchen diet same as group A and same wound management with closed dressing to be changed on every third day similar to group A.
62740723|NCT04601259|EXPERIMENTAL|Orkla corn plaster with Salicylic acid|
62551640|NCT04290455|ACTIVE_COMPARATOR|control arm|using eyelid wipe (Optase)
62551641|NCT03399513|EXPERIMENTAL|Ibrutinib and R-CHOEP chemotherapy|"All patients will receive 8 cycles of R-CHOEP immunochemotherapy every two weeks with the following doses per cycle: rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m² (dose capped at 2 mg), etoposide 300 mg/m², prednisolone 500 mg.~In addition, ibrutinib capsules will be administered orally once daily at a dose of 560 mg (4 x 140 mg hard capsules) for 112 days."
62551642|NCT04912232|EXPERIMENTAL|Trauma Patients|"Patients suffering blunt and/or penetrating trauma but without physiologic criteria suggestive of ongoing hemorrhage:~1. Awake and alert GCS \>14~2. Admission systolic blood pressure greater than 90 and heart rate less than 120~3. Without signs of clinically significant ongoing external hemorrhage with no active bleeding documented on radiology/ultrasound and stable vital signs (no signs of hemodynamic deterioration) during initial evaluation (approximately 15 minutes post admission)"
62551643|NCT03397225|EXPERIMENTAL|Intervention group|The lifestyle intervention, including educational sessions were given to the intervention group of diabetes patients. The educational sessions were scheduled every two weeks and a total of four sessions was provided to the intervention group, the session held in the lecture room at the polyclinic. Also, they were received two individual sessions including dietary and physical activity advice during the consultation session in the diabetic clinic at the beginning and at the end of the study.
62551644|NCT03397225|ACTIVE_COMPARATOR|Control group|Lifestyle intervention, including individual lifestyle consultation, including dietary and physical activity consultation at the beginning and the end of the study, two sessions. This is done after the screening of the participants in the diabetic clinic at the beginning and at the end of the study.
62551645|NCT03397225|NO_INTERVENTION|Anonymous data|The patients, n = 60, were recruited randomly and anonymously from the same diabetes clinic, and the HbA1c data was taken from the anonymous patients at two points over the 12-month study duration.
62551646|NCT05017246|ACTIVE_COMPARATOR|Epidural bupivacaine with hydromorphone patient-controlled anesthesia (EPCA)|"* Standard of care at Washington University School of Medicine/Barnes-Jewish Hospital~* Day of surgery: preoperative tylenol, gabapentin, celebrex, and epidural dosing per standard protocol.~* Intraoperative: dexamethasone and epidural bupivacaine~* Day of surgery postoperative: hydromorphone PCA, toradol, ibuprofen, tylenol, epidural bupivacaine~* Postoperative: hydromorphone PCA, ibuprofen, oxycodone"
62740724|NCT04601259|ACTIVE_COMPARATOR|Orkla corn protector without salicylic acid|
62740725|NCT04941183|EXPERIMENTAL|NTR-441|Single Ascending Dose; Multiple Ascending Dose.
62740726|NCT04941183|PLACEBO_COMPARATOR|Placebo|Single Ascending Dose; Multiple Ascending Dose.
62740727|NCT04963244||AECOPD|
62740728|NCT04963244||Stable COPD|
62740729|NCT04963244||Control|
62740730|NCT01887730|ACTIVE_COMPARATOR|arm 2|Hand washing with soap and water according to instructions. The effect of intervention is assessed by following occurrence of infections.
62740731|NCT01887730|PLACEBO_COMPARATOR|arm 0|No specific advice on hand hygiene. The effect of intervention is assessed by following occurrence of infections.
62740732|NCT01887730|ACTIVE_COMPARATOR|Arm 3|Hand cleaning with alcohol-containing hand rub
62740733|NCT06516991|EXPERIMENTAL|Temporal Interference Stimulation|Temporal Interference Stimulation
62740734|NCT04678037|ACTIVE_COMPARATOR|Group A (PROs assessment every 2 weeks)|
62551647|NCT05017246|EXPERIMENTAL|Intrathecal morphine with intraoperative lidocaine infusion|"* Day or surgery: tylenol, gabapentin, celebrex, and preoperative intrathecal morphine one time injection (150mcg)~* Intraoperative: dexamethasone and lidocaine infusion 1 mg/kg ideal body weight~* Day of surgery postoperative: toradol, ibuprofen, tylenol~* Postoperative: ibuprofen, oxycodone, and hydromorphone prn"
62551648|NCT01194167|EXPERIMENTAL|Eltrombopag|Eltrombopag 75 mg per day. Possible escalation to 150 mg per day after day 15 lab results. Possible escalation to 300 mg per day after day 29 lab results.
62551649|NCT03959111|EXPERIMENTAL|Ear stimulation (Location 1)|
62551650|NCT03959111|EXPERIMENTAL|Ear stimulation (Location 2)|
62551651|NCT03100123|ACTIVE_COMPARATOR|Standard of Care Arm|Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.
62551652|NCT03100123|EXPERIMENTAL|Experimental Arm|Open-label low-dose Aspirin 81 mg daily from randomization until delivery.
62551653|NCT00790725|OTHER|PAV|Proportional Assist Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
62551654|NCT00790725|OTHER|PS|Pressure Support Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
62551655|NCT00743717|EXPERIMENTAL|1|
62551656|NCT00743717|ACTIVE_COMPARATOR|2|
62551657|NCT03637010|OTHER|Breakfast in the Classroom|Baseline data will be collected to include anthropometric measures, participant characteristics, and past eating habits. For the first 8 weeks, the students will be provided with breakfast meals containing the USDA nutrition requirements. These meals are typically higher in carbohydrates and lower in protein. For the second 8 weeks, the students will be provided with higher-protein breakfast meals. These meals also contain the USDA nutrition requirements but include high-quality protein-rich foods. For the remaining 8 weeks, the students will be provided both types of meals and will be permitted to choose which they prefer to consume each day. At the end of each 8-week period, eating habits, appetite, mood, cognitive performance, and anthropometrics will be completed along with measurements of breakfast waste.
62551658|NCT01651078||Main cohort|Patients with radiographic evidence of lesion regrowth following prior treatment with stereotactic radiosurgery (regardless of the process being suspected recurrent or progressive brain metastasis versus radiation necrosis) and who already scheduled for NeuroBlate procedure.
62551659|NCT06550817|EXPERIMENTAL|growth mindset + e-health|Participants received an e-health program intervention plus a growth mindset intervention over 12 weeks, with weekly sessions for the first 6 weeks and biweekly follow-up phone calls for the next six weeks.
62740735|NCT04678037|ACTIVE_COMPARATOR|Group A (PROs assessment every 4 weeks)|
62740736|NCT04329728|EXPERIMENTAL|DLBCL and high-grade B-cell lymphoma|Diffuse Large Cell B-Lymphoma High-grade B-cell Lymphoma
62740737|NCT04329728|EXPERIMENTAL|MCL (Chronic Lymphoid Leukemia)|Chronic Lymphoid Leukemia
62740738|NCT04329728|EXPERIMENTAL|Primary Mediastinal Large B-cell lymphoma|Primary mediastinal large B-cell lymphoma
62740739|NCT04329728|EXPERIMENTAL|Burkitt or Burkitt-like lymphoma/leukemia|Burkitt or Burkitt-like lymphoma/leukemia
62740740|NCT04329728|EXPERIMENTAL|CLL/SLL|Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
62740741|NCT04329728|EXPERIMENTAL|B- or T-ALL|B-lymphoblastic leukemia/lymphoma, T-lymphoblastic leukemia/lymphoma, acute leukemia/lymphoma, acute leukemias of ambiguous lineage, or natural killer (NK) cell lymphoblastic leukemia/lymphoma
62740742|NCT04053855||Renal mass patients|"Patients with renal mass requiring surgery (partial or total nephrectomy) will be included.~They will have an urinary sample."
62740743|NCT04053855||Control patients|Control patients (without renal mass) will be included. They will have an urinary sample.
62740744|NCT06662396|EXPERIMENTAL|MK-6552 + Diltiazem|Participants receive a single dose of MK-6552 on Period 1 Day 1. Participants receive a Diltiazem every day (QD) for 6 days (Period 2 Days 1-6). On Period 2 Day 2 participants receive a single dose of MK-6552.
62740745|NCT01434901|EXPERIMENTAL|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
62740746|NCT01434901|EXPERIMENTAL|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
62740747|NCT01434901|EXPERIMENTAL|Type 2 Diabetes Mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
62740748|NCT06548087|EXPERIMENTAL|Use of Gigstride Ambulatory Device|"The participant will be use the Gigstride ambulatory device to perform the following tasks:~* Walk a different distances to assess speed and fatigue~* Perform functional mobility tasks (sit-to-stand, stand-to sit, stand-pivots, etc.)~The participants will then be asked to fill out a questionnaire, Gigstride Clinical Trial Questionnaire that will be used for qualitative data, such as ease of use and comfortability with using the device.~The overall amount of time for the evaluation and questionnaire will take approximately 30 minutes to 1 hour."
62740749|NCT06658782||non contrast MRI AND standard of care USS|Participants undergo ultrasound every 6 months as per routine clinical care. In addition they undergo research non-contrast enhanced MRI at the same 6 monthly intervals
62740750|NCT01978054|EXPERIMENTAL|Dissemination|Dissemination of public health knowledge: Participating states will help develop and choose 3-5 dissemination strategies they prefer for their state health department chronic disease units to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, and information on ways to enhance organizational climates favorable to evidence-based chronic disease prevention.
62740751|NCT01978054|NO_INTERVENTION|Comparison|Comparison state health department chronic disease units will be provided links to preexisting sources of public health evidence-based information such as the Community Guide, Cancer Control P.L.A.N.E.T. (Plan, Link, Act, Network, with Evidence-based Tools), and NCI Research to Reality.
62740752|NCT00428571|PLACEBO_COMPARATOR|Intensive Medical Management|Medical management of obesity including medication optimization and lifestyle and dietary advice.
62740753|NCT00428571|ACTIVE_COMPARATOR|Laparoscopic Gastric Bypass|
62740754|NCT00428571|ACTIVE_COMPARATOR|Laparoscopic Adjustable Gastric Band|
62740755|NCT00553436|EXPERIMENTAL|Enrolled Subjects treated with TAS device|All enrolled subjects treated with the Tissue Apposition System (TAS) device
62740756|NCT05546697|ACTIVE_COMPARATOR|Yoga-based Intervention|Yoga classes will be gentle and physically accessible for people who are naïve to yoga. Teachers will frequently guide participants to focus on their breathing and coordinate movements with breath. Teachers will offer variations on the postures and encourage participants to choose variations that provide some challenge but do not cause strain or pain. Classes will be 1 hour long and include a brief sitting meditation, warm-ups, standing postures, and a final resting meditation. All participants will be invited to attend a synchronous yoga class via a HIPAA-compliant videoconference option once per week during the first 3 months of the study. Classes will be offered at multiple times throughout the week.
62551660|NCT06550817|ACTIVE_COMPARATOR|e-health only|Participants received an e-health program intervention over 12 weeks, with weekly sessions for the first 6 weeks and biweekly follow-up phone calls for the next six weeks.
62551661|NCT06191029||Healthy adults|
62551662|NCT00307086|OTHER|Autologous PBSCT|bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous peripheral blood stem cell transplant (PBSCT)
62551663|NCT01221207|ACTIVE_COMPARATOR|Device - Total Contact Cast (TCC)|A total contact cast (TCC) is a special cast technique that is used to take the pressure and shear stress off the ulcer to assist in the healing.
62551664|NCT01221207|ACTIVE_COMPARATOR|Removable Cast Walker (RCW)|The removable cast walker (RCW) is a commercial product that is similar to a cast. It is secured with Velcro straps around the foot and leg and it is also effective at removing the pressure and shear stress on the foot.
62551665|NCT01221207|ACTIVE_COMPARATOR|Instant Total Contact Cast (ITCC)|The instant total contact cast (ITCC) is a technique that uses the removable cast walker, but secures it so it cannot be removed between clinic visits and evaluation by the subject or the physician.
62551666|NCT06322784|EXPERIMENTAL|Experimental group|12 week Mediterranean diet+dietary fiber intervention
62551667|NCT06322784|NO_INTERVENTION|Control group|12 week Mediterranean diet
62551668|NCT05516355|EXPERIMENTAL|Group 1 (MBSR + CCT)|Group 1 will begin the retreat with a 3-day MBSR intervention. On day 4 of the retreat, they will crossover and begin a 3-day CCT intervention.
62551669|NCT05516355|EXPERIMENTAL|Group 2 (CCT + MBSR)|Group 2 will begin the retreat with a 3-day CCT intervention. On day 4 of the retreat, they will crossover and begin a 3-day MBSR intervention.
62551670|NCT06581718|EXPERIMENTAL|Eye Gaze|
62551671|NCT02501928|EXPERIMENTAL|Fesoterodine PR 4 mg|Fesoterodine PR 4 mg for 28 or 40 weeks in open-label treatment period
62551672|NCT02501928|EXPERIMENTAL|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg for 28 or 40 weeks in open-label treatment period
62551673|NCT02501928|EXPERIMENTAL|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg for 28 weeks in open-label treatment period
62551674|NCT02501928|EXPERIMENTAL|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg for 28 weeks in open-label treatment period
62551675|NCT00390637|EXPERIMENTAL|1|Low Protein, Low GI Diet
62551676|NCT00390637|EXPERIMENTAL|2|Low Protein, High Glycemic Index Diet
62551677|NCT00390637|EXPERIMENTAL|3|High Protein, Low Glycemic Index diet
62175269|NCT00333502|EXPERIMENTAL|CRLX101 (formerly known as IT-101)|CRLX101 dosing per protocol dose escalation cohorts to MTD, then expansion cohort treated at MTD of CRLX101 15mg/m2
62175270|NCT04263389||control group|control group is a normal matched group.
62551678|NCT00390637|EXPERIMENTAL|4|High Protein, High glycemic index diet
62551679|NCT00390637|EXPERIMENTAL|5|Control diet (current recommendations)
62551680|NCT00659243|EXPERIMENTAL|rhBSSL|
62551681|NCT00659243|PLACEBO_COMPARATOR|Placebo|
62551682|NCT06575543||2 portal group|The conventional 2-portal technique uses the anterolateral portal as the viewing portal and the anteromedial portal as the working portal
62551683|NCT06575543||3 portal group|the 3-portal technique allows interchangeable use of the portals as a viewing and working portals depending on the specific task that is being performed
62551684|NCT00934024|OTHER|Abstinent|"All participants received varenicline. A priori determined analysis was between participants who quit smoking and those who continued to smoke.~This arm was abstinent after 5 weeks of varenicline treatment.."
62551685|NCT00934024|OTHER|Non-abstinent|"All participants received varenicline. A priori determined analysis was between participants who quit smoking and those who continued to smoke.~This arm was participants who continued to smoke after 5 weeks of varenicline treatment."
62551686|NCT03790371|ACTIVE_COMPARATOR|misoprostol group|misoprostol (misotac® sigma pharmaceutical industries) 200 mcg vaginally applied ten and four hours prior to the second attempt of IUD insertion
62551687|NCT03790371|PLACEBO_COMPARATOR|placebo|while the control group received a placebo tablet in the same regimen as the study group.
62551688|NCT02134990|EXPERIMENTAL|Oshadi D and Oshadi R with Docetaxel|Oshadi D and Oshadi R anti cancer agents with Docetaxol chemotherapy
62551689|NCT03296527|EXPERIMENTAL|Follitropin delta|Recombinant follicle-stimulating hormone (rFSH). Follitropin delta for subcutaneous injection
62551690|NCT03296527|ACTIVE_COMPARATOR|Gonal-F|rFSH. Follitropin alfa for subcutaneous injection
62551691|NCT06581679|ACTIVE_COMPARATOR|The levonorgestrel-releasing intrauterine system Group|
62551692|NCT06581679|ACTIVE_COMPARATOR|GnRHa Group|
62551693|NCT01705379||MenACWY-CRM|2 years of age and older
62551694|NCT00329082|EXPERIMENTAL|1|
62551695|NCT00329082|EXPERIMENTAL|2|
62551696|NCT00329082|EXPERIMENTAL|3|
62551697|NCT00329082|EXPERIMENTAL|4|
62551698|NCT00329082|PLACEBO_COMPARATOR|5|
62551699|NCT03971474|ACTIVE_COMPARATOR|Arm A (docetaxel, gemcitabine, ramucirumab, pemetrexed)|Patients receive docetaxel IV over 10-30 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 or ramucirumab IV over 60 minutes and docetaxel IV over 10-30 minutes on day 1. Patients with non-squamous NSCLC receiving docetaxel and gemcitabine hydrochloride, also receive pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62740757|NCT05546697|ACTIVE_COMPARATOR|Behavioral Activation|The goal of Behavioral Activation Psychotherapy is to help people identify and (re)engage in meaningful and positive activities through psychoeducation, identification of values and associated activities, goal setting, problem-solving, and monitoring of goal completion. There will be a BA manual for therapists and training provided by study staff on the manual (e.g., asynchronous and synchronous training sessions). BA therapists will be community clinicians. BA will be provided individually via telehealth and will be billed to participant insurance. At the start of BA treatment, participants will be oriented to the time-limited nature of BA, with the expectation that they will attend 8 sessions over the course of 3 months.
62740758|NCT06614101|EXPERIMENTAL|Patient with type 2 diabetes or non-diabetic patient treated in the Diabetology departments|
62740759|NCT02775591|EXPERIMENTAL|Motilitone arm|DA-9701 (Motilitone) 30mg 1T three times per day for 4+8 weeks
62740760|NCT02775591|PLACEBO_COMPARATOR|Placebo arm|DA-9701 placebo 30mg 1T three times per day for 4 weeks, DA-9701 (Motilitone) 30mg 1T three times per day for 8 weeks
62551700|NCT03971474|EXPERIMENTAL|Arm B (ramucirumab, pembrolizumab)|Patients receive ramucirumab IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
62551701|NCT03595046|EXPERIMENTAL|erector spinae plane block group (group E)|ultrasound-guided erector spinae plane block
62740761|NCT03465644|EXPERIMENTAL|Tailored arm|early (\<6-month post-PCI) intensified (low-dose ticagrelor \[120 mg loading, then 60 mg bid maintenance\] and aspirin) and late (\>6-month post-PCI) deescalated (clopidogrel alone) strategy
62740762|NCT03465644|ACTIVE_COMPARATOR|Conventional arm|clopidogrel + aspirin for 12months
62740763|NCT05313269|EXPERIMENTAL|ISAFE technique|Adductor canal block catheter tip located in the fascial plane between sartorious muscle and femoral artery.
62740764|NCT05313269|ACTIVE_COMPARATOR|Conventional technique|Adductor canal block catheter tip located in lateral to the femoral artery.
62740765|NCT02919202|EXPERIMENTAL|Fluoride Varnish|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.
62740766|NCT02919202|ACTIVE_COMPARATOR|SEDBA|Self-etching Dentine Bonding Agent. Scotchbond Universal by 3M ESPE. Topical application followed by light curing for 20 seconds.
62740767|NCT01636336|ACTIVE_COMPARATOR|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
62740768|NCT01636336|ACTIVE_COMPARATOR|Female Smokers (Early Follicular Phase; cycle days 4-8)|
62740769|NCT04249492|EXPERIMENTAL|IOL implantation experimental|Experimental arm: Enhanced depth of focus (EDOF) intraocular lens.
62740770|NCT04249492|ACTIVE_COMPARATOR|IOL implantation active comparator|Comparator arm: Monofocal intraocular lens.
62740771|NCT01596140|EXPERIMENTAL|Vemurafenib + Oral Everolimus|Vemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Oral Everolimus starting dose 5 mg daily.
62740772|NCT01596140|EXPERIMENTAL|Vemurafenib + Intravenous Temsirolimus|Vemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Intravenous Temsirolimus starting dose 15 mg daily on Days 1, 8, 15, and 22 of each cycle.
62740773|NCT03245554|EXPERIMENTAL|placebo and propranolol|We used propranolol and placebo as an control drug to treat with patients.
62740774|NCT00372619|EXPERIMENTAL|Clofarabine 40 mg/m² to assess feasibility in ALL patients.|Clofarabine 40 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
62551702|NCT03595046|ACTIVE_COMPARATOR|thoracic paravertebral block group (group P)|ultrasound-guided thoracic paravertebral block
62740775|NCT00372619|EXPERIMENTAL|Clofarabine 40 mg/m² to assess feasibility in AML patients.|Clofarabine 40 mg/m² to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
62551703|NCT00549432|EXPERIMENTAL|1|
62551704|NCT05469295|EXPERIMENTAL|CGM_MB_1701 treatment|Subjects will be treated with the study device for about 36 minutes.
62551705|NCT05469295|SHAM_COMPARATOR|Sham (CGM MB1701C) treament|Subjects will be treated with the Sham device for about 36 minutes.
62551706|NCT04722250|EXPERIMENTAL|Medtronic Self-Expanding TAV|Subjects will be randomized on a 1:1 basis to receive TAVR with either a Medtronic SE TAV or an Edwards BE THV.
62551707|NCT04722250|EXPERIMENTAL|Edwards Balloon-Expandable THV|Subjects will be randomized on a 1:1 basis to receive TAVR with either a Medtronic SE TAV or an Edwards BE THV.
62551708|NCT04320823|EXPERIMENTAL|Experimental Group|Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.
62551709|NCT04320823|ACTIVE_COMPARATOR|Control Group|Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.
62551710|NCT05451628|ACTIVE_COMPARATOR|Default CI fitting|Programming of cochlear implant speech processor according to standard clinical care
62175271|NCT04263389||study group|study group is a group of chronic mechanical cervical pain
62551711|NCT05451628|ACTIVE_COMPARATOR|Anatomy-based CI fitting|Programming of cochlear implant speech processor with anatomy-based fitting
62551712|NCT00038025|EXPERIMENTAL|Deoxycoformycin (DCF)/Pentostatin|
62551713|NCT02836925|EXPERIMENTAL|Ledipasvir+Sofosbuvir,Sofosbuvir+Velpatasvir|The study includes an antiviral treatment with interferon-free regimen followed by lymphoma restaging; following the end of antiviral treatment patients will be evaluated for sustained virological response and safety parameters every 3 months for 1 year and then every 6 months for 2 years. ORR and vital status will be also evaluated
62551714|NCT05869864|EXPERIMENTAL|Intervention|Half of the participants in the pilot will receive the experimental behavioral intervention.
62551715|NCT05869864|NO_INTERVENTION|Control|Half of the participants in the pilot will receive nothing, and serve as the control.
62551716|NCT00248872|NO_INTERVENTION|control group|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to adhere to their medication goal.
62551717|NCT00248872|EXPERIMENTAL|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to engage adhere to their medication goal. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level.
62551718|NCT01917214||Non-Interventional Study|
62551719|NCT02734407|EXPERIMENTAL|Open-Label Arm|"2mg Aflibercept, as needed, intravitreal administration.~All subjects will be treated with intravitreal (IVT) aflibercept injections as needed in the presence of clinically relevant diabetic macular edema (CR-DME). If CR-DME is not present the subject will not receive an IVT aflibercept injection and will be observed.~If a subject has recurrent CR-DME they will receive an IVT aflibercept 2.0 mg injection and interval between visits will be reduced to 4 weeks.~At week 12 through end of study, all subjects will be evaluated for focal laser treatment."
62551720|NCT01937871|PLACEBO_COMPARATOR|Placebo|Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.
62551721|NCT01937871|EXPERIMENTAL|5 mg Tadalafil|"Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.~Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period"
62551722|NCT01937871|OTHER|0.2 mg Tamsulosin|"Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.~Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period"
62551723|NCT06438718||Validation group|"This Cross-sectional study consists of five phases. PHASE 1 \[T1\] Consist on the linguistic validation and it will be carried out the transcultural adaptation of Frail'BESTest in a population sample (named group A), which will be made up of 30 individuals over 60 years of age, community living independently in their houses, cognition preserved, who have a preserved physical functional status, and able to stand up still, without assistive devices for 10s or over (Group A).~PHASE 2 \[T2\] consist on reliability. One subgroup (GROUP B and GROUP C) of institutionalized frail aged participants, n=30 with mild cognitive impairment (named group B) and 30 without mild cognitive impairment (named group C) will be tested. We will examine between raters reliability and test-retest reliability.~PHASE 3 \[T3\] consisting on construct validity. PHASE 4 \[T4\] consisting on predictive falls/concurrent validity. PHASE 5 \[T4\] consisting on predictive decease/concurrent validity."
62551724|NCT04578405|ACTIVE_COMPARATOR|Extracorporeal anastomosis|
62551725|NCT04578405|EXPERIMENTAL|Intracorporeal anastomosis|
62551726|NCT06581107|EXPERIMENTAL|Singel arm|CT-fluoroscopy guided robot-assisted percutaneous lung Cryoablation group
62551727|NCT00839397|OTHER|Paroxetine|A 52-week, non-comparative, uncontrolled study (However, the baseline phase is single blind)
62551728|NCT05382403|EXPERIMENTAL|Jada® System|Patients in this group will have the Jada® System applied when the initial medical treatment fails, and estimated blood loss reaches 1000 mL. It is a U.S. FDA-cleared device intended for treatment of PPH when conservative management is warranted.
62551729|NCT05382403|ACTIVE_COMPARATOR|Standard care|Patients in this group will receive care according to the treatment algorithm for PPH from uterine atony at the two teaching hospitals in Ghana. Possible interventions include additional uterotonics, tranexamic acid, and condom catheter balloon uterine tamponade. If bleeding is uncontrolled, patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy
62551730|NCT05565430||Healthy Control|"1. Acute Hyperventilation and effects on vocal cord movement.~2. Chronic Hyperventilation and effects on vocal cord movement.~3. Effects of anticholinergic medication on paradoxical vocal cord movement."
62551731|NCT05565430||Mild Asthmatics|"1. Acute Hyperventilation and effects on vocal cord movement.~2. Chronic Hyperventilation and effects on vocal cord movement.~3. Effects of anticholinergic medication on paradoxical vocal cord movement."
62551732|NCT05565430||Severe Asthmatics|"1. Acute Hyperventilation and effects on vocal cord movement.~2. Chronic Hyperventilation and effects on vocal cord movement.~3. Effects of anticholinergic medication on paradoxical vocal cord movement."
62175272|NCT05424211|EXPERIMENTAL|Music group|the group using the music therapy mobile application
62175273|NCT05424211|NO_INTERVENTION|control group|the group that received routine care and treatment
62175274|NCT05226988|EXPERIMENTAL|Hybrid-RT|hybrid robot-assisted training
62175275|NCT05226988|EXPERIMENTAL|Exo-RT|exoskeleton robot-assisted training
62175276|NCT05226988|EXPERIMENTAL|EE-RT|end-effector robot-assisted training
62175277|NCT05226988|ACTIVE_COMPARATOR|conventional training groups|
62551733|NCT02757755|EXPERIMENTAL|Cohort 10^8|AB-SA01 (10\^8) and Placebo
62740776|NCT00372619|EXPERIMENTAL|Clofarabine 52 mg/m² to assess feasibility in ALL patients.|Clofarabine 52 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
62740777|NCT00372619|EXPERIMENTAL|Clofarabine 52 mg/m² to assess efficacy in ALL patients.|Clofarabine 52 mg/m² to assess efficacy in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
62740778|NCT00372619|EXPERIMENTAL|Clofarabine 52 mg/m² to assess feasibility in AML patients.|Clofarabine 52 mg/m² to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
62551734|NCT02757755|EXPERIMENTAL|Cohort 10^9|AB-SA01 (10\^9) and Placebo
62551735|NCT01845480|EXPERIMENTAL|Healthful eating phys activity coaching|The healthful eating and physical activity skills coaching intervention is designed to help children set goals and self-monitor healthful eating and physical activity; teach kitchen skills for fruit and vegetable snack preparation; teach children enjoyable physical activities to do at home (e.g., dancing); and provide modeling and social support for physical activity and healthful eating.
62551736|NCT01845480|ACTIVE_COMPARATOR|Health education coaching|Health education coaching is designed to help children set goals and self-monitor behavior; educate children on a range of relevant health promotion behaviors (e.g., tooth brushing, not smoking, physical activity, etc.); and provide modeling and social support for practicing healthful behavior.
62551737|NCT03481582|ACTIVE_COMPARATOR|Group without nitroglycerin|They will be subjected to TV ultrasound for folliculometry till maturation of the follicle ≥18mm then Three dimensional power Doppler will be used to assess the uterine and sub-endometrial blood flow.
62551738|NCT03481582|EXPERIMENTAL|Group with nitroglycerin|They will receive (nitrodermal®) 5 mg (patch) from 2nd day of cycle till maturation of the follicles ≥ 18 mm then Three dimensional power Doppler will be used to assess the uterine and sub-endometrial blood flow.
62551739|NCT02574832|EXPERIMENTAL|Spinal Lidocaine Administration|"Spinal anesthesia will be induced with isobaric 2% lidocaine and 15 μg fentanyl.~The study lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). If the lidocaine dose provides an unsatisfactory anesthetic, the case will be categorized as a failure. After a failed case, the next participant will receive a lidocaine dose increased by 4 mg. If the lidocaine dose provides satisfactory anesthesia, the next participant's lidocaine dose will determined by a biased allocation method with a 90% chance of maintaining the dose and a 10% chance of decreasing the dose by 4 mg."
62551740|NCT01436318||Respiratory Function|Children will undergo one session of pulmonary function and strength testing
62551741|NCT03901092|EXPERIMENTAL|Flortaucipir PET Scan|Scans previously acquired from Study A16 (NCT02516046) and A05 (NCT02016560) will be read by independent, blinded readers.
62551742|NCT00247676|EXPERIMENTAL|A|
62551743|NCT03532152|ACTIVE_COMPARATOR|Pure Purr VR technology|"The arm will use the virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen.~The total length of the audio-video sequence is 6 minutes 11 seconds, of which 1 minute 11 seconds is the Pure Purr promotional video, and the duration of the investigational audio-visual sequence itself is 5 minutes."
62551744|NCT03532152|SHAM_COMPARATOR|Sham VR technology|"The arm will use the headset with audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.~The total length of the audio-video sequence is 6 minutes 11 seconds, of which 1 minute 11 seconds is the Pure Purr promotional video, and the duration of the investigational audio-visual sequence itself is 5 minutes."
62551745|NCT03209895|EXPERIMENTAL|Joint Health Product|
62551746|NCT03209895|PLACEBO_COMPARATOR|Placebo|
62551747|NCT03209895|ACTIVE_COMPARATOR|Glucosamine / Chondroitin|
62551748|NCT03860324|NO_INTERVENTION|Control-group|No peripheral nerve block
62551749|NCT03860324|EXPERIMENTAL|Single-shot erector spinae plane block|The patient is positioned in lateral decubitus. The anesthesiologist uses a linear high-frequency probe in a longitudinal direction laterally to the mid-sagittal plane at the level of L4 until the transverse process is identified and, more superficial, the erector spinae muscle. A 22G needle of 80mm is introduced in-plane craniocaudally towards the transverse process of L4 until its tip is in the plane deep to the erector spinae muscle. Single-shot block with 30ml of ropivacaine 0,5% + adrenaline 100mcg
62551750|NCT03860324|ACTIVE_COMPARATOR|Single-shot fascia iliaca block|The patient is positioned in dorsal decubitus. The anesthesiologist uses a linear high-frequency probe in a transversal direction, below the crural arch so as to identify the femoral artery. Afterwards the probe is moved laterally to find the iliac muscle and its fascia. A 22G needle of 80mm is introduced in-plane latero-medially until its tip is below the fascia iliaca (between the muscle and its fascia). Single-shot block with 40ml of ropivacaine 0,2%.
62740779|NCT00372619|EXPERIMENTAL|Clofarabine 52 mg/m² to assess efficacy in AML patients|Clofarabine 52 mg/m² to assess efficacy in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
62740780|NCT00372619|EXPERIMENTAL|Clofarabine 52 mg/m² to assess efficacy - ambiguous lineage pt|Clofarabine 52 mg/m² to assess efficacy in acute leukemia of ambiguous lineage patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
62740781|NCT04136093|EXPERIMENTAL|the MED|The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the MED group
62740782|NCT04136093|EXPERIMENTAL|the DASH|The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the DASH group
62740783|NCT04136093|EXPERIMENTAL|The control group|The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the control group.
62551751|NCT02720848|EXPERIMENTAL|Stiffening wire|A stiffening wire inserted into the instrument channel of the double/single balloon enteroscope will be used.
62551752|NCT02720848|ACTIVE_COMPARATOR|Standard technique|The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
62740784|NCT05812963|ACTIVE_COMPARATOR|Fractional flow reserve-guided PCI|FFR measurement for non-IRA stenosis (\>50% visual estimation) will be performed by continuous infusion of adenosine (140\~180 ug/kg/min) or intracoronary nicorandil (2 mg bolus) injection. The FFR ≤0.80 will be targeted for PCI. In case of non-IRA stenosis \>90%, we will judge FFR value of ≤0.80.
62551753|NCT05416242|ACTIVE_COMPARATOR|Fixed appliance|Patients in this group will be treated using traditional brackets alone.
62740785|NCT05812963|EXPERIMENTAL|Intravascular Ultrasound-guided PCI|"In IVUS-guided PCI group, the current trial evaluates clinical outcome following IVUS-guided treatment decision for revascularization of non-IRA stenosis. According to pre-defined criteria, the decision of revascularization will be made.~Revascularization criteria in the IVUS-guided PCI group is 1) minimal lumen area (MLA) ≤ 3mm2 or 2) 3mm2 \< MLA ≤4mm2 and plaque burden \>70%."
62551754|NCT05416242|EXPERIMENTAL|Self-ligaton appliance|Patients in this group will be treated using self-ligating brackets alone.
62551755|NCT05416242|EXPERIMENTAL|Self-ligaton appliance + piezocision|Patients in this group will be treated using self-ligating brackets associated with piezocision.
62551756|NCT05182021||Case group|The case group represented by 50 primigravida women aged 35 y or more during their pregnancy or at the time of delivery
62740786|NCT05723536|EXPERIMENTAL|PLAI (Partial Left Atrial Isolation)|Partial electrical isolation of the left atrium endo-epicardially (pulmonary veins, posterior wall and left atrial appendage) and left atrial appendage isolation using Atriclip (Atricure, Mason OH, USA) in a single procedure in patients with persistent atrial fibrillation.
62740787|NCT05723536|ACTIVE_COMPARATOR|CA (Catheter Ablation)|Conventional catheter ablation of persistent atrial fibrillation.
62740788|NCT01742442||Older cancer patients|Older cancer patients 70 years or older referred to specialist oncology outpatient clinics
62740789|NCT03208660||Fycompa|Participants diagnosed with epilepsy and treated with Fycompa
62740790|NCT02686632|EXPERIMENTAL|Palate Brushing|"In this group the intervention is palatal brushing, performed by the participants following each meal for a period of 6 months. This will be performed using the provided toothbrush (device). The results will determine if brushing the palate in an efficient intervention for reducing the microbial count and inflammation associated with denture stomatitis."
62740791|NCT02686632|NO_INTERVENTION|Regular Oral Hygiene|The participants in this study arm will not be prescribed or allocated any intervention. The participants will be asked to continue with the regular hygiene and denture maintenance practices for the duration of the trial.
61997462|NCT05645822||People with symptoms attributable to gHAT|The study will include any person that attends any of the participating healthcare facilities with symptoms that could be attributed to gHAT (long-term fever (unless other obvious causes), headache for a long period (more than 14 days), presence of enlarged lymph nodes in the neck, severe weight loss, weakness, pruritus, amenorrhea, abortions or sterility, psychiatric problems (aggressiveness, apathy, mental confusion, anxiety), sleep disturbances, motor weakness, logorrhea, speech impairment, ataxia, abnormal gait, abnormal movements or seizures) and accepts to participate.
62551757|NCT05182021||Control group|The control group represented by 50 primigravida women aged 20 y : 34 y during their pregnancy or at the time of delivery
62551758|NCT03366207|EXPERIMENTAL|Ciprofloxacin|Ciprofloxacin for the treatment of uncomplicated urinary tract infection
62551759|NCT02513862|EXPERIMENTAL|APRP group|APRP group is performed autologous platelet-rich plasma harvest technique before administration of heparin to the patient,the red blood cell(RBC) component is retransfused to the patient when the RBC transfusion protocol is reached,and the autologous platelet-rich plasma is transfused to the patient immediately after heparin is neutralized with protamine.
62551760|NCT02513862|NO_INTERVENTION|control group|APRP group receive no autologous platelet-rich plasma harvest technique.
61997463|NCT00144586|EXPERIMENTAL|1|
62740792|NCT06024239|EXPERIMENTAL|Part A, ABBV-932|Participants will receive ABBV-932 once daily (QD) for 14 days.
62740793|NCT06024239|EXPERIMENTAL|Part A, Placebo for ABBV-932|Participants will receive placebo for ABBV-932 QD for 14 days.
62740794|NCT06024239|EXPERIMENTAL|Part B, ABBV-932|Participants will receive ABBV-932 QD for 28 days.
62740795|NCT06024239|EXPERIMENTAL|Part B, Placebo for ABBV-932|Participants will receive placebo for ABBV-932 QD for 28 days.
62740796|NCT06024239|EXPERIMENTAL|Part C, ABBV-932|Participants will receive ABBV-932 QD for 28 days.
62740797|NCT06024239|EXPERIMENTAL|Part C, Placebo for ABBV-932|Participants will receive placebo for ABBV-932 QD for 28 days.
62740798|NCT06024239|EXPERIMENTAL|Part D, ABBV-932|Participants will receive ABBV-932 QD for 42 days.
62740799|NCT06024239|EXPERIMENTAL|Part D, Placebo for ABBV-932|Participants will receive placebo for ABBV-932 QD for 42 days.
62740800|NCT01116999|EXPERIMENTAL|Tracheal intubation|
62740801|NCT04818216|PLACEBO_COMPARATOR|Placebo Group|Placebo capsules will be administered 2 capsules twice daily for 10 days
62740802|NCT04818216|EXPERIMENTAL|Nicotinamide Riboside Group|Nicotinamide riboside 250mg capsules will be administered 2 capsules twice daily for 10 days
62740803|NCT05096273|EXPERIMENTAL|CPT- Pain relief lotion|During the initial visit participant will do the cold pressor test twice to assess catastrophic symptom expectations. After completing the 1st CPT, participants will be randomized to receive a pain relief lotion or pain sensitivity lotion. Participants will then repeat the CPT with the lotion applied to their hand.
62740804|NCT05096273|EXPERIMENTAL|CPT- Pain sensitivity lotion|During the initial visit participant will do the cold pressor test twice to assess catastrophic symptom expectation. After completing the 1st CPT, participants will be randomized to receive a pain relief lotion or pain sensitivity lotion. Participants will then repeat the CPT with the lotion applied to their hand.
62740805|NCT05096273|ACTIVE_COMPARATOR|ReACT for PNES- Booster therapy sessions|After completing the 12 therapy sessions, half of the participants will be randomized to receive 2 booster therapy sessions, 3 months and 9 months after the 12th ReACT treatment session.
62740806|NCT05096273|EXPERIMENTAL|ReACT for PNES- No Booster therapy sessions|After completing the 12 ReACT treatment sessions, half of the participants will be randomized to not receive the 2 booster therapy sessions.
62740807|NCT05096273|NO_INTERVENTION|Healthy Control|Healthy controls are matched to participants with PNES based on age (+ or - 1 year), gender, race and family income. Healthy controls and their parent come for 1 baseline laboratory visit and a follow up visit 13 weeks after the baseline visit. These visits will be identical to baseline and follow-up visits of children with PNES.
62740808|NCT03803358|EXPERIMENTAL|cycle exercise with additional NIV|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
62740809|NCT03803358|ACTIVE_COMPARATOR|cycle exercise without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
62740810|NCT05420181|OTHER|Short Fast|Participants will fast overnight for a period of 10 hours
62740811|NCT05420181|OTHER|Long fast|Participants will fast overnight for a period of 16 hours
62740812|NCT05405634||Patients with chronic analfissure|1. Consecutive patients referred to the outpatient clinic at the Digestive Disease Centre, Bispebjerg Hospital in Denmark for botox injection for chronic anal fissure. Thus, the included patients will likely all have tried conservative treatment before referral, and are expected to represent a more homogeneous subset with longer standing disease, less spontaneous improvement, and a higher likelihood of being compliant with suggested therapy
62740813|NCT05405634||Patients with an indication for fissurectomy|Consecutive patients with an indication for revision of the fissure and anal injection of botulinum toxin in general anaesthesia
62740814|NCT05405634||Healthy volunteers|Healthy volunteers. These will be recruited among staff at the Digestive Disease Centre, Bispebjerg Hospital, Denmark.
62740815|NCT06662136||Experimental group|Participants in the experimental group will be given motivational interviews at 4 different times.
62740816|NCT06662136||control group|No application will be made to the participants in the control group.
62740817|NCT03839225|OTHER|Children, Adolescents and Adults|children, adolescents and adults who have been victims of the armed conflict in the municipalities of Soacha-Cundimanarca (Colombia)
62740818|NCT06421506|EXPERIMENTAL|Neonates given LISA during HFNC treatment|Infants between 34-38+6 weeks gestation will receive surfactant via less invasive administration whilst on high flow nasal cannula oxygen treatment. They will have respiratory function monitoring before and after LISA.
62740819|NCT06421506|NO_INTERVENTION|Neonates not given LISA|Infants between 34-38+6 will receive routine care and will not receive surfactant unless intubated.
62740820|NCT01193634|EXPERIMENTAL|Paradym RF ICD|Active implantable defibrillators range
62740821|NCT05731817||COVID-19 patients|COVID-19 patients
62740822|NCT03393936|EXPERIMENTAL|CCT301-59|The safety and efficacy of CCT301-59 will be evaluated for subjects with ROR2 positive biopsy in a standard 3+3 dose escalation approach. 3 CAR T dosage will be tested in this study: 1×10\^5/kg, 1×10\^6/kg, 1×10\^7/kg CAR+ T cells.
62740823|NCT03393936|EXPERIMENTAL|CCT301-38|The safety and efficacy of CCT301-38 will be evaluated for subjects with AXL positive but ROR2 negative biopsy in a standard 3+3 dose escalation approach. 3 CAR T dosage will be tested in this study: 1×10\^5/kg, 1×10\^6/kg, 1×10\^7/kg CAR+ T cells.
62740824|NCT02511015||Family Member Control Subjects|Family members, of enrolled EOPD subjects, who themselves do not have Parkinson disease or Parkinsonism can be enrolled as controls on this study.
62740825|NCT02511015||Healthy Control Subjects|Age 18 years to 80 years old with no history or family history of Parkinson disease or Parkinsonism.
62740826|NCT02511015||Parkinson Subjects|Age 18 years to 80 years old with a history of early onset Parkinson disease or Parkinsonism (Presentation within the first five decades of life).
61997464|NCT00688480|PLACEBO_COMPARATOR|I|CKD Stage 3 (estimated GFR 30 - 60 ml/min/1.73m2), Echo LVH
61997465|NCT00688480|ACTIVE_COMPARATOR|2|
61997466|NCT06418386|ACTIVE_COMPARATOR|manual saline|manual k files for pulpectomy and normal saline irrigation
62551761|NCT04053127|EXPERIMENTAL|RAVANS|Electrodes will be placed in the auricle of the left ear. Electrical stimulation to these electrodes will be provided by a current-constant stimulator (Urostim, Schwa-Medico). Stimulation will be gated, with 1-second delay, after peak inhalation (i.e. during exhalation). Respiratory gating for stimulation will require real-time evaluation of the respiratory cycle. The study will use a belt system constructed in-house, and similar to the system used in several previous studies. A pneumatic belt will be placed around the subject's lower thorax. Once electrodes are set up, subjects will be asked to rate stimulation intensity on a NRS of 0 to 10 (0: no sensation, 10: pain detection threshold). Current intensity will be set to achieve moderate to strong (but not painful) sensation, and this current intensity will be used on subsequent stimulation runs.
61997467|NCT06418386|EXPERIMENTAL|manual neem extract|manual k files and 100% neem extract
62740827|NCT00617084|ACTIVE_COMPARATOR|1. Resolute|Medtronic Endeavor Resolute
62740828|NCT00617084|ACTIVE_COMPARATOR|2. XIENCE V|Abbott Xience V
62740829|NCT02783872||Loss of control|30 overweight or obese (BMI≥85th %ile) youth endorsing loss of control eating within the past 3 months
62740830|NCT02783872||Overweight control|30 overweight or obese controls without any history of loss of control eating
62740831|NCT02783872||Normal-weight control|15 normal-weight controls without any history of loss of control eating
62740832|NCT05449340|EXPERIMENTAL|BEAUTIFY application|
62740833|NCT02241733|ACTIVE_COMPARATOR|exercise|Patients will exercise for 12 weeks and then participate in an adherence program
62740834|NCT02241733|EXPERIMENTAL|exercise plus breathing retraining|Patients will exercise plus breathing retraining for 12 weeks and then participate in an adherence program
62740835|NCT00778297|EXPERIMENTAL|Group 1|
62740836|NCT00778297|ACTIVE_COMPARATOR|Group 2|
62740837|NCT00072046|EXPERIMENTAL|Interferon|Treatment with interferon alfa 2b
62740838|NCT00072046|EXPERIMENTAL|Interferon + bevacizumab|Addition of bevacizumab to interferon alfa 2b treatment
62740839|NCT06025695|ACTIVE_COMPARATOR|HRV Group|Participants receive 2 doses of GSK's liquid oral live attenuated HRV study intervention administered at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China.
62740840|NCT06025695|EXPERIMENTAL|HRV PCV-free Group|Participants receive 2 doses of the PCV-free liquid formulation of GSK's oral live attenuated HRV study intervention administered at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China.
62740841|NCT02077829|OTHER|IMR therapists, IMR patients|"30 voluntary therapists from 9 mental health services will be trained and coached in IMR.~40 patients from the 9 mental health services will receive Illness Management and Recovery from the therapists in training."
62740842|NCT04620772|EXPERIMENTAL|Cyclophosphamide arm|Participants randomized to the cyclophosphamide arm will be administered 750 mg/m2 body weight (rounded off to the nearest 50 mg above the calculated value) of cyclophosphamide diluted in normal saline every month (Total 6 months) along with equal dose of mesna 50% administered prior to infusion and 50% after the infusion of cyclophosphamide
62740843|NCT04620772|OTHER|Placebo arm|Participants randomized to the placebo group will be given similar quantity of normal saline and mesna as described above
62740844|NCT03116035|ACTIVE_COMPARATOR|Web-based decision aid|A commercially available web-based breast cancer surgery decision aid
62740845|NCT03116035|ACTIVE_COMPARATOR|Standard websites|selected, high-quality standard web-sites
62740846|NCT00971581|EXPERIMENTAL|FDC KETOPROFEN+OMEPRAZOLE|One capsule of Ketoprofen 200 mg + Omeprazole 20 mg FDC once daily Treatment duration: 4 weeks
62740847|NCT06320106|EXPERIMENTAL|CP group|Participants with cerebral palsy are recruited.
62740848|NCT06320106|EXPERIMENTAL|TD group|Typically developing children are recruited.
62740849|NCT06598787|EXPERIMENTAL|BL-B01D1 for Injection|Participants receive BL-B01D1 in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62740850|NCT02443246|EXPERIMENTAL|Vitamin D deficiency|Group 1
62740851|NCT02443246|EXPERIMENTAL|Vitamin D deficiency (Low)|Group 2
62740852|NCT02817776|EXPERIMENTAL|Treatment group|Pulmonary vein isolation (PVI) by RF ablation treatment with the THERMOCOOL SMARTTOUCH® SF catheter in persistent AF population.
62740853|NCT02402504|PLACEBO_COMPARATOR|Extruded snack control|100% corn flour
62740854|NCT02402504|EXPERIMENTAL|Extruded snack with small particle size pea flour|60% corn flour and 40% small particle size pea flour
62740855|NCT02402504|EXPERIMENTAL|Extruded snack with large particle size pea flour|60% corn flour and 40% large particle size pea flour
62740856|NCT02402504|EXPERIMENTAL|Extruded snack with lentil flour|60% corn flour and 40% lentil flour
62740857|NCT02402504|EXPERIMENTAL|Extruded snack navy bean flour|60% corn flour and 40% navy bean flour
62740858|NCT02402504|EXPERIMENTAL|Extruded snack with pinto bean flour|60% corn flour and 40% pinto bean flour
62740859|NCT03357796|EXPERIMENTAL|Group A: LY03005 cross-over to Pristiq®|Subjects in Group A will receive an 80 mg oral dose of LY03005 and the subjects will stay in the CRU for 4 days (Period 1). After a washout period of up to 4 days, the subjects will be switched and will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) comparator followed by a 4-day stay in the CRU (Period 2).
62740860|NCT03357796|EXPERIMENTAL|Group B: Pristiq® cross-over to LY03005|Subjects in Group B will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) comparator and the subjects will stay in the CRU for 4 days (Period 1). After a washout period of up to 4 days, the subjects will be switched and will receive an 80 mg oral dose of LY03005 followed by a 4-day stay in the CRU (Period 2).
62740861|NCT05046067|EXPERIMENTAL|Diagnostic (CT)|Patients undergo 4 CT scans during standard of care surgery.
62740862|NCT01685242|EXPERIMENTAL|AC-170 0.24%|
62740863|NCT01685242|PLACEBO_COMPARATOR|AC-170 0%|
62740864|NCT00120081|EXPERIMENTAL|Low dose|10 mcg Na-ASP-2/Alhydrogel
62740865|NCT00120081|EXPERIMENTAL|Medium dose|50 mcg Na-ASP-2/Alhydrogel
62740866|NCT00120081|EXPERIMENTAL|High dose|100 mcg Na-ASP-2/Alhydrogel
62740867|NCT00120081|PLACEBO_COMPARATOR|Saline placebo|Saline placebo
62740868|NCT06384313|EXPERIMENTAL|butyrate/hexanoate-enriched triglycerides|Oil containing butyrate and hexanoate-enriched triglycerides
62551762|NCT04053127|SHAM_COMPARATOR|non-RAVANS|For sessions randomized to sham stimulation, the electrodes in the ear will remain as described above, but the leads will be disconnected from the stimulator. Subjects will be instructed that for this session they may or may not feel pulsing in their ear, and that the goal is to ensure that the stimulus was not painful.
62551763|NCT04080466|EXPERIMENTAL|Cam Group|This group will consist of patients that are scheduled for surgery to undergo cam resection by hip arthroscopy.
62551764|NCT04080466|ACTIVE_COMPARATOR|Control Group|This group will consist of a matched cohort of control participants.
62551765|NCT05816109|EXPERIMENTAL|Superficial cervical block|Superficial Cervical Block
62551766|NCT05816109|ACTIVE_COMPARATOR|without superficial cervical block|Without superficial cervical block
62551767|NCT05481671||Questionnaires assessed patients with traumatic fractures|"①Age 18 and above.~②Patients who were diagnosed as fractures due to accidental trauma and were diagnosed by X-rays and clinicians and required surgical treatment.~③Have the normal cognitive ability, expression ability and social participation ability."
62551768|NCT04691427|EXPERIMENTAL|Active Virtual Reality-Based Vision Therapy|Virtual reality vision therapy where participants will be playing a custom-designed video game to act as a therapeutic intervention on a consumer-available virtual reality headset.
62551769|NCT04552795|EXPERIMENTAL|Open-Label 3TC|12 subjects will receive 3TC, 300-mg, daily for 24 weeks.
62551770|NCT01313377|EXPERIMENTAL|ARM A: Gemox 85|Adjuvant chemotherapy for six months with gemcitabine - oxaliplatin 85mg / m² ( GEMOX 85)
62551771|NCT01313377|OTHER|ARM B:|Observation until progression or death
62551772|NCT06316011||Training and testing cohort|
62551773|NCT06316011||External validation cohort|
62740869|NCT06384313|PLACEBO_COMPARATOR|placebo|Oil devoid of butyrate and hexanoate but with similar composition as the intervention oil
62740870|NCT04670068|EXPERIMENTAL|CAR.B7-H3 T cell product|Up to 12 patients will receive three weekly CAR.B7-H3 T cell product infusions at the same dose. To determine the recommended phase 2 dose (RP2D), a modified 3+3 dose escalation design will be used to evaluate two dose levels: Dose Level 1 (7.5x10\^7 cells/infusion), Dose Level 2 (2x10\^8 cells/infusion). If this dose is not tolerated, then a lower dose of 3.75 × 10\^6 cells/infusion will be explored. Up to 3 dose levels of CAR.B7-H3 cells will be tested with at least 3 patients enrolled at each dose cohort before dose escalation is considered based on the incidence of dose limiting toxicity (DLT). An expansion cohort will enroll up to 9 patients at the recommended phase 2 dose. Prior to receiving the infusions, patients will undergo lymphodepletion with fludarabine and cyclophosphamide.
62740871|NCT03668496|EXPERIMENTAL|SHR-1210 +chemotherapy|subject will receive SHR-1210 200mg every 3 weeks, carboplatin AUC 5 on Day 1 of each 21 day, 4-6 cycles Paclitaxel 175mg/m2, Day 1 of each 21 day, 4-6 cycles
62740872|NCT03668496|ACTIVE_COMPARATOR|chemotherapy|carboplatin AUC 5 on Day 1 of each 21 day, 4-6 cycles Paclitaxel 175mg/m2, Day 1 of each 21 day, 4-6 cycles
62740873|NCT06129474|EXPERIMENTAL|DROPIT Intervention|The study intervention is a patient-centred PPI deprescribing intervention aiming to guide GPs and patients through the process of safely deprescribing inappropriate PPIs.
62740874|NCT06129474|NO_INTERVENTION|Usual Care|The reference or control arm will receive usual care. This means that the GPs and patients in this group will conduct their clinical practice as per usual, without receiving the intervention from the study team.
62740875|NCT06302426|EXPERIMENTAL|INI-4001 Monotherapy Dose Escalation - INI-4001 Dose Level 1|For dose-level 1, INI-4001 will be administered intravenously once per week on Days 1, 8 and 15 of a 21-day cycle. A complementary therapy may be introduced in combination with INI-4001.
62740876|NCT06302426|EXPERIMENTAL|INI-4001 Monotherapy Dose Escalation - INI-4001 Dose Level 2|For dose-level 2, INI-4001 will be administered intravenously once per week on Days 1, 8 and 15 of a 21-day cycle. A complementary therapy may be introduced in combination with INI-4001.
62740877|NCT06302426|EXPERIMENTAL|INI-4001 Monotherapy Dose Escalation - INI-4001 Dose Level 3|For dose-level 3, INI-4001 will be administered intravenously once per week on Days 1, 8 and 15 of a 21-day cycle. A complementary therapy may be introduced in combination with INI-4001.
62740878|NCT06302426|EXPERIMENTAL|INI-4001 Monotherapy Dose Escalation - INI-4001 Dose Level 4|For dose-level 4, INI-4001 will be administered intravenously once per week on Days 1, 8 and 15 of a 21-day cycle. A complementary therapy may be introduced in combination with INI-4001.
62740879|NCT06302426|EXPERIMENTAL|INI-4001 Monotherapy Dose Escalation - INI-4001 Dose Level 5|For dose-level 5, INI-4001 will be administered intravenously once per week on Days 1, 8 and 15 of a 21-day cycle. A complementary therapy may be introduced in combination with INI-4001.
62740880|NCT06302426|EXPERIMENTAL|INI-4001 Monotherapy Dose Escalation - INI-4001 Dose Level 6|For dose-level 6, INI-4001 will be administered intravenously once per week on Days 1, 8 and 15 of a 21-day cycle. A complementary therapy may be introduced in combination with INI-4001.
62740881|NCT03628066|EXPERIMENTAL|Arm 1|"Oncotype DX Breast recurrence score on diagnostic tissue~Daily Letrozole for 24 weeks + Palbociclib daily for 24 weeks + Goserelin weekly for 24 weeks"
62740882|NCT06180629|EXPERIMENTAL|Music Consert|During the chemotherapy sessions, the patients in the experimental group listened to music for 20-25 minutes, once a week for a total of 4 weeks, by choosing a music genre decided by the patient himself/herself from 3 music genres selected by the researcher based on scientific content and expert opinion.
62740883|NCT06180629|ACTIVE_COMPARATOR|control group|The control group continued their normal treatment routine. No application was performed. Only pre-test and post-tests were applied.
62740884|NCT05422534|PLACEBO_COMPARATOR|Observational + placebo|Participants will receive placebo with standard of care or regular activity for 12 weeks.
62740885|NCT05422534|ACTIVE_COMPARATOR|Observational+ CoQ10|Participants will receive CoQ10 1800 mg/day with standard of care or regular activity for 12 weeks.
62740886|NCT05422534|PLACEBO_COMPARATOR|HB HIIT +placebo|Participants will receive placebo and home based high intensity interval training for 12 weeks. Exercise will be performed on a non-dialysis day, it will be video-supervised exercise sessions, three days per week for 12 weeks. The three weekly sessions will include: 1 session of 1) body weight high-intensity interval training (bodyweight HIIT), 2) strength training, and 3) walking high-intensity interval training (walking HIIT).
61997468|NCT06418386|EXPERIMENTAL|manual sodium hypochlorite|mannul k files and 1% sodium hypochlorite
62740887|NCT05422534|ACTIVE_COMPARATOR|HB HIIT + CoQ10|Participants will received CoQ10 1800/day with home based high intensity interval training for 12 weeks. Exercise will be performed on a non-dialysis day, it will be video-supervised exercise sessions, three days per week for 12 weeks The three weekly sessions will include: 1 session of 1) body weight high-intensity interval training (bodyweight HIIT), 2) strength training, and 3) walking high-intensity interval training (walking HIIT).
62175278|NCT05256771|ACTIVE_COMPARATOR|Arm A: Full Treatment Arm (Laser + EMS + RF/PEMF)|Arm A: Three (3) diode laser treatments treatments at days 0, 28 and 56 (±2 days). Subjects will also receive bi-weekly electrical muscle stimulation and pulsed electromagnetic fields/vacuum assisted radio frequency treatments at days 0, 14, 28, 42 and 56 (±2 days).
62175279|NCT05256771|ACTIVE_COMPARATOR|Arm B: EMS/RF Arm (EMS + RF/PEMF)|Arm B: Subjects will receive bi-weekly electrical muscle stimulation and pulsed electromagnetic fields/vacuum assisted radio frequency treatments at days 0, 14, 28, 42 and 56 (±2 days).
62175280|NCT05256771|ACTIVE_COMPARATOR|Arm C: EMS Arm (EMS only)|Arm C: Subjects will receive weekly electrical muscle stimulation treatments at days 0, 7, 14, 21, 28 and 35 (±2 days).
62175281|NCT01314898|EXPERIMENTAL|Treatment|
62175282|NCT00583050|EXPERIMENTAL|Endovascular Aneurysm Repair|Endovascular Aneurysm Repair of TAAA/AAA with Fenestrated/Branched Stent Grafts
62175283|NCT06646601|EXPERIMENTAL|Multidisciplinary preventive action and questionnaries|A 6-month multidisciplinary preventive intervention for each patient: gardening, adapted physical activity, nutritional workshops and questionnaries
62175284|NCT06646601|NO_INTERVENTION|No intervention but questionnaries|Refuse the intervention and answers questionnaries about why
62175285|NCT05367752|EXPERIMENTAL|Group 1: Myofascial release with TENS conductive glove|Participants allocated to this group received six sessions of a myofascial release protocol with a TENS conductive glove applying a TENS current of 120Hz frequency through an electrotherapy device.
62175286|NCT05367752|EXPERIMENTAL|Group 2: Myofascial release without TENS conductive glove|Participants allocated to this group received the same myofascial release protocol with group 1 without the TENS conductive glove.
62175287|NCT05367752|EXPERIMENTAL|Group 3: Conventional TENS|Participants allocated to this group received the application of a conventional TENS current.
62175288|NCT05367752|ACTIVE_COMPARATOR|Control: Sham TENS|Participants allocated to this group received the same TENS treatment with group 3, but with the current intensity set to zero to ensure that they received no current.
62175289|NCT00352053|EXPERIMENTAL|OBR + Tenofovir DF|Tenofovir DF administered orally, one tablet daily without regard to meals
62175290|NCT00352053|PLACEBO_COMPARATOR|OBR + Tenofovir DF Placebo|Placebo to match tenofovir DF administered orally, one tablet daily without regard to meals
62175291|NCT04255121|EXPERIMENTAL|alkalinization of adrenaline lidocaine solution arm|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an alkalinization of adrenaline lidocaine solution
62175292|NCT04255121|ACTIVE_COMPARATOR|adrenaline lidocaine solution arm|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using a adrenaline lidocaine solution
62175293|NCT01667042||Without Interstitial lung disease (ILD)|
62175294|NCT01667042||With Interstitial lung disease (ILD)|
62175295|NCT03265847|EXPERIMENTAL|Culturally-tailored Safety Planning|Women in the intervention group receive the SDA intervention with the culturally-specific DA integrated as appropriate to the target group (i.e., immigrant, refugee or indigenous).
62175296|NCT03265847|NO_INTERVENTION|Usual Care|The control group receive non-DA informed usual safety planning resources modeled on national and state domestic violence online resources, but not provided with immediate and visual feedback to their level of danger or a tailored safety planning.
62175297|NCT02777242|EXPERIMENTAL|Testosterone enanthate auto-injector|Testosterone enanthate administered subcutaneously once each week. Auto-injection of QST 50 mg or 75 mg or 100 mg \[Device: QuickShot® Testosterone (QST)\]
62175298|NCT02515656|EXPERIMENTAL|POLYGYNAX®|Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
62175299|NCT02515656|ACTIVE_COMPARATOR|miconazole + placebo|Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
62551774|NCT05224609|EXPERIMENTAL|Cohort 1|Moderate hepatic impairment group
62551775|NCT05224609|EXPERIMENTAL|Cohort 2|Severe hepatic impairment group
62551776|NCT05224609|EXPERIMENTAL|Cohort 3|Normal hepatic function
62740888|NCT05340569|EXPERIMENTAL|DWI-MRI|Patients to undergo DWI-MRI (patients include in the study.
62740889|NCT06400290|EXPERIMENTAL|Patients with stable angina|"Patients who:~1. Are symptomatic with angina~2. Have anatomically severe multi-vessel coronary artery disease~3. Have physiological evidence of myocardial ischaemia"
62740890|NCT01227109||With infection|This group consist of cancer patients with a bacterial infection
62740891|NCT01227109||Without infection|This is a group of cancer patients without infection
62740892|NCT06327373|PLACEBO_COMPARATOR|Room air|Participants will receive no supplemental oxygen.
62740893|NCT06327373|EXPERIMENTAL|Supplemental oxygen (0.5 liters per minute)|Participants will receive supplemental oxygen by oxygen concentrator delivered by nasal cannula at 0.5 liters per minute.
62740894|NCT06327373|EXPERIMENTAL|Supplemental oxygen (3 liters per minute)|Participants will receive supplemental oxygen by oxygen concentrator delivered by nasal cannula at 3 liters per minute.
62740895|NCT05143593|EXPERIMENTAL|the experiment group|antibiotics adjustments are made by two experienced doctors immediately when SSBD results are available, and other treatments are equivalent to those in the control group as routinely
62740896|NCT05143593|NO_INTERVENTION|the control group|As routinely, antibiotics adjustmens are guided on the results of conventional culture tests and other clinical parameters by two experienced doctors.
62740897|NCT03944265|EXPERIMENTAL|Supportive care (treatment decision counseling session)|Patients complete a treatment decision counseling session/interview about genetic testing and supportive/palliative care with a qualified member of the research team in-person or via telephone. Health care providers receive a 1-page summary of session results for use in treatment shared decision making at the next office visit.
62740898|NCT06343818|EXPERIMENTAL|Pilot Ward Site 1|First ward site will pilot the intervention which will then be refined before delivery at second ward site
62740899|NCT06343818|EXPERIMENTAL|Pilot Ward Site 2|Second ward will pilot refined intervention
62740900|NCT05046990||RAC evaluation|Patients older than 18 years without previous history of Hp infection or eradication undergoing a gastroscopy
62740901|NCT06661941||Positive coronary artery disease|Presence of significant coronary artery disease requiring intervention from a coronary angiography result
62740902|NCT06661941||Negative coronary artery disease|Absence of significant coronary artery disease requiring intervention from a coronary angiography result
62740903|NCT05290402||an application-based digital navigator|"JEEVA is a new digital health navigator app. This app can be used on a mobile phone or tablet. JEEVA has all of the surgical teaching information from the traditional paper packet and also has additional resources like brief videos, checklists, and reference photos."
62740904|NCT00584792||1|Controls (No prostate cancer)
62740905|NCT00584792||2|Cases (Prostate Cancer Diagnosed)
62740906|NCT05700786|NO_INTERVENTION|Control Group|"The control group is made up of participants who are eligible but not assigned to the treatment. For ethical reasons they will be able to access the intervention once the experimental group has concluded the study. During the waiting-list phase, participants can access a mental health intervention, but in this case they are excluded from the study. Participants are told that there is only one possible active group and therefore a waiting-list is created. This explanation is given to reduce a worsening symptom bias for feeling excluded from treatment."
62740907|NCT05700786|ACTIVE_COMPARATOR|Experimental Group 1 - Online Format|The experimental intervention is an integrative mindful compassion group therapy as manualized by Cheli, Cavalletti, Flett \& Hewitt (2020). The structure was outlined on the base of standard mindfulness-based interventions, comprising eight 2-hour online group sessions and one day of silence lasting 4 hours. The contents and the phases of the intervention were rooted in two different frameworks. On the one hand, the sequence of and the types of practices were defined in accordance with the mindful compassion protocol (Gilbert \& Choden, 2014). On the other hand, the shared conceptualization of perfectionism and its role in triggering, maintaining, and inducing relapses in personality disoders was proposed through the relational model by Hewitt and colleagues (2017). The hybrid format (online weekly sessions plus an in presence half-day of silence) has been developed in accordance with existing COViD-19 emergency and rules.
62740908|NCT05700786|ACTIVE_COMPARATOR|Experimental Group 2 - Online Format|The experimental intervention is an integrative mindful compassion group therapy as manualized by Cheli, Cavalletti, Flett \& Hewitt (2020). The structure was outlined on the base of standard mindfulness-based interventions, comprising eight 2-hour in presence group sessions and one day of silence lasting 4 hours in presence. The contents and the phases of the intervention were rooted in two different frameworks. On the one hand, the sequence of and the types of practices were defined in accordance with the mindful compassion protocol (Gilbert \& Choden, 2014). On the other hand, the shared conceptualization of perfectionism and its role in triggering, maintaining, and inducing relapses in personality disoders was proposed through the relational model by Hewitt and colleagues (2017).
62740909|NCT03325348|EXPERIMENTAL|Oral Nifedipine|Nifedipine 10mg oral tablet \& 1ml 0.9%N/Saline will be given every 15 minutes up till one hour
62740910|NCT03325348|ACTIVE_COMPARATOR|IV Labetalol|IV labetalol 20 mg and mint tablet will be given every 15 minutes up till one hour
62175300|NCT01329185|PLACEBO_COMPARATOR|Placebo|Eligible consenting kidney transplant donors who are randomized to receive placebo will be given 1 placebo in morning and 1 in evening for 14 days prior to transplant date
62175301|NCT01329185|EXPERIMENTAL|Valganciclovir|Eligible consenting kidney transplant donors who are randomized to the experimental arm of the study will receive 450mg of Valganciclovir twice a day for 14 days prior to the transplant date
62175302|NCT00647998|EXPERIMENTAL|Darbepoetin|Patients received 1mg/kg IV Darbepoetin immediately prior to surgery
62175303|NCT00647998|PLACEBO_COMPARATOR|Standard care|No Darbepoetin
62175304|NCT04010383||normal visual field subjects|"* Cataract yes or no~* Age range 40 - 80 years~* normal visual field (MD: \< +2 dB)~* Refractive error within ±5 dpt. spherical equivalent~* Astigmatism of \< -3 dpt.~* Visual acuity of ≥0.3 logMar (decimal ≥0.5)~* Experience in perimetry (history of at least one perimetry examination)~* False positive or negative errors each less than 20% in each examination"
62175305|NCT04010383||Glaucomatous subjects|"* Primary open-angle/ pseudoexfoliation/ primary angle-closure glaucoma~* Early to moderate visual field loss (MD: +2 to +12 dB)~* Refractive error within ±5 dpt. spherical equivalent~* Astigmatism of \< -3 dpt.~* Visual acuity of ≥0.3 logMar (decimal ≥0.5)~* Experience in perimetry (history of at least one perimetry examination)~* False positive or negative errors each less than 20% in each examination~* Cataract yes or no~* Age range 40 - 80 years"
62175306|NCT05139498|EXPERIMENTAL|Conservative Management for Placenta Accreta Spectrum (PAS)|Subjects who are randomized to to conservative management will undergo a cesarean delivery followed by a period of close observation in the operating room for 30-45 minutes to be sure there is no excessive bleeding or risk to keep the placenta inside
62175307|NCT05139498|ACTIVE_COMPARATOR|Hysterectomy at time of delivery for Placenta Accreta Spectrum (PAS)|Subjects who are randomized to cesarean hysterectomy will undergo a cesarean delivery followed immediately by hysterectomy to remove the placenta and uterus together
62175308|NCT00729053|ACTIVE_COMPARATOR|Previous treatment, 0.16mg/kg|Patients will have clear cell renal carcinoma with previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.16mg/kg
62175309|NCT00729053|ACTIVE_COMPARATOR|Previous treatment, 0.64mg/kg|Patients will have clear cell renal carcinoma with previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.64mg/kg
62175310|NCT00729053|ACTIVE_COMPARATOR|Treatment Naive, 0.16mg/kg|Patients will have clear cell renal carcinoma without previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.16mg/kg
62175311|NCT00729053|ACTIVE_COMPARATOR|Treatment Naive, 0.64mg/kg|Patients will have clear cell renal carcinoma without previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.64mg/kg
62175312|NCT05492123|ACTIVE_COMPARATOR|Standard Chemoradiation|Traditional radiation therapy with a target of 45 Gy in 25 1.8Gy fractions with concurrent weekly cisplatin 40mg/m2/week or carboplatin AUC 2/week
62551777|NCT05392218|EXPERIMENTAL|motivational interviewing|
62551778|NCT05392218|SHAM_COMPARATOR|attention group|
62551779|NCT04727567||Multiple Visit Patient (MVP) Program|"The MVP program aims to manage health and lower hospital utilization among patients with a history of high inpatient hospital stays at Atrium Health. Patients eligible for the program have four or more inpatient visits over the 12-month period prior to enrollment. Once enrolled, each MVP program participant receives on-going support from an assigned MVP care manager and larger care management team, including the following core program components:~customized care plan developed for each patient at the time of enrollment routine, virtual health monitoring and collaborative care management team-based review personalized navigation and coordination across multidisciplinary Atrium Health services, as needed.~Education, health coaching, and support via telephonic and in-person interactions, as needed."
62740911|NCT05302167|EXPERIMENTAL|Feasibility/ acceptability|
61997469|NCT06418386|EXPERIMENTAL|rotary saline|AF baby files for pediatric( fanta ) and normal saline
62175313|NCT05492123|EXPERIMENTAL|Immunotherapy|4 cycles of induction therapy with nivolumab 1mg/kg and ipilimumab 3mg/kg every 3 weeks followed by traditional radiation therapy with a target of 45 Gy in 25 1.8Gy fractions with concurrent weekly cisplatin 40mg/m2/week (or carboplatin AUC 2/week) with concurrent nivolumab 240mg every 2 weeks.
62175314|NCT03421600|ACTIVE_COMPARATOR|Blue laser imaging|Blue laser imaging
62175315|NCT03421600|EXPERIMENTAL|White light imaging|White light imaging
62175316|NCT02625129||Pharmacist-provided travel care|
62175317|NCT04827186|EXPERIMENTAL|highly sensitized patients with either a positive FCXM, or positive CDC cross-match|highly sensitized patients that receive a donor offer and have either a positive FCXM (T or B cell positive) or positive CDC cross-match (B cell positive); a positive CDC cross-match (T cell positive) remains a contraindication at this time.
62175318|NCT04827186|NO_INTERVENTION|historical cohort of highly sensitized patients with a positive FCXM, or positive CDC cross-match|The control group, as comparison, will be an historical cohort of highly sensitized patients with positive flow (B and T) or positive B standard crossmatch, which received kidney transplant alone or simultaneous kidney and pancreas transplant and followed our standard protocol
62175319|NCT01150019||Obese Group|
62175320|NCT01150019||Non Obese Group|
62175321|NCT01335321|ACTIVE_COMPARATOR|Hylan GF-20 alone|This arm will receive a knee infiltration with 6ml of Hylan GF-20 only
62175322|NCT01335321|EXPERIMENTAL|Triamcinolone|This arm will receive a knee infiltration with 6ml of Hylan GF-20 associated with 1ml of triamcinolone
62175323|NCT05903677||Adults undergoing cardiac surgery without preoperative renal affection|Detect the preoperative magnesium levels in adults undergoing cardiac surgery without preoperative renal affection and follow up if they developed postoperative acute kidney injury or not.
62175324|NCT03184142|EXPERIMENTAL|Simulation|During a suturing class at the simulation center, the students enter a classroom. Although the students are not aware of this, among them is an actor playing the role of a student. One of the two professors is also an actor. As the activity progresses, the professor targets the student played by an actor. The intimidation intensifies until the end. At the end of the activity, there is a debriefing explaining to the students that the bullying professor and the victim were actors.
62175325|NCT03184142|EXPERIMENTAL|Video|During a suturing class at the simulation center, after 55 minutes of suturing, the students will be exposed to a 15-minute video on workplace and hospital intimidation and how to manage it.
62175326|NCT03184142|PLACEBO_COMPARATOR|Control|During a suturing class at the simulation center, the students suture for the entire 70-minute duration of the activity. They are not exposed to intimidation (control group).
62175327|NCT05867550|ACTIVE_COMPARATOR|Group A ( Rifaximin + Mebeverine )|"Tab. Rifaximin 550mg thrice daily per orally for 2 weeks~Tab. Mebeverine 135mg twice daily per orally for 2 weeks"
62175328|NCT05867550|ACTIVE_COMPARATOR|Group B ( Rifaximin + Amitriptyline )|"Tab. Rifaximin 550mg thrice daily per orally for 2 weeks~Tab. Amitriptyline 25mg once daily per orally for 2 weeks"
62175329|NCT05867550|ACTIVE_COMPARATOR|Group C ( Rifaximin + Psyllium Husk )|"Tab. Rifaximin 550mg thrice daily per orally for 2 weeks~Psyllium Husk 15-30mg once daily per orally for 2 weeks"
62175330|NCT01932983||TOF test|TOF - train of four test performed on patiens undergoing lumbar spine surgery where introperative neurophysiologic monitoring is applied. Stimulation of peripheral nerve - ulnar nerve resulting with muscle contractions and evaluation of responses by anesthesiologist and neurophysiologists. Stimulation with group of 0.2 millisecond pulses, spaced 500 millisecond apart, at a 2 Hz rate, current 20-60 mA to deliver four muscle contractions. Eligibility criteria included patients for study where subjective visual interpretation and quantitative interpretation of Adductor pollicis muscle responses is followed.
62740912|NCT06372652|EXPERIMENTAL|SAD Cohort|Each participant will receive TE-8214 administered by subcutaneous injection across 5 Cohorts (Cohort 5 optional)
62740913|NCT06372652|EXPERIMENTAL|Placebo|Each participant will receive matching volume doses of Placebo administered by subcutaneous injection
62740914|NCT01109121|ACTIVE_COMPARATOR|Allopurinol|Allopurinol
62740915|NCT01109121|EXPERIMENTAL|Combination 400|Tranilast and Allopurinol
62740916|NCT01109121|EXPERIMENTAL|Combination 600|Tranilast and Allopurinol
62740917|NCT01755962|EXPERIMENTAL|Low Glycemic Load + Resistance Training|12-week intervention diet + resistance training (1 hour, 3 times per week)
62740918|NCT01755962|EXPERIMENTAL|High Glycemic Load + Resistance Training|12-week control diet + resistance training (1 hour, 3 times per week)
62740919|NCT01755962|EXPERIMENTAL|Low Glycemic Load|12-week intervention diet
62740920|NCT01755962|OTHER|High Glycemic Load|12-week control diet
62740921|NCT04653090||Varus group|Radiographic stem axis was assessed on standard anteroposterior hip radiographs performed at the 3-month follow-up visit. Alignment was evaluated as described by Reina et al., by the angular deviation of the anatomic femoral axis and the stem axis. The 3 degrees minimal-value was considered to be the threshold defining a varus stem.
62740922|NCT04653090||Neutral group|Alignment between anatomic femoral axis ans stem axis was less than 3°.
62740923|NCT01283776|EXPERIMENTAL|treatment arm|Cyclophosphamide
62740924|NCT05155761|EXPERIMENTAL|Osteoporotic patients|
62740925|NCT06658639|EXPERIMENTAL|ultrasound lipolysis group|it involves 22 participants and will receive ultrasound lipolysis on abdominal area and low caloric diet treatment. abdominal area was treated for 60-minute session every 2 weeks for 3 months
61997470|NCT06418386|EXPERIMENTAL|rotary neem|AF baby files for pediatric( fanta ) and 100% NEEM EXTRACT
62551780|NCT04727567||Usual Care|Atrium Health standard of care. Patient's post-discharge usual care depends on the inpatient care management assessment at last hospital admission. Patients can be discharged to home and receive no further care, or home with home health, or to a skilled nursing facility (SNF) or another type of Continuing Care facility. Patients can be referred to advanced illness management, hospice, and Community Care Partners by the inpatient care manager. Patient can be referred to Ambulatory Care Management for care management also via telehealth, by a primary care physician or the Transitions Clinic.
62551781|NCT01910818|EXPERIMENTAL|Fractional CO2 laser Treatment|This is the area getting treated with CO2 laser.
62551782|NCT01910818|EXPERIMENTAL|No Treatment|This is the area receiving no treatment.
62551783|NCT03032848|ACTIVE_COMPARATOR|Conjugated Estrogen Group|use of 1 gram per day
62740926|NCT06658639|ACTIVE_COMPARATOR|cryolipolysis group|it involves 22 participants and will receive cryolipolysis on abdominal area and low caloric diet treatment. Each participant underwent a cryolipolysis session on the same abdominal area every 2 weeks for 3 months
62740927|NCT06658639|ACTIVE_COMPARATOR|low caloric diet group|it involves 22 participants and will receive low caloric diet treatment for 3 months.
62740928|NCT04050787|EXPERIMENTAL|D2 Lymphadenectomy including No. 10|lymphadenectomy including spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
62740929|NCT04050787|ACTIVE_COMPARATOR|D2 lymphadenectomy excluding No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy but without No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
62740930|NCT03043690||Ammonium succinate|Patients in main pooled study group received 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
62740931|NCT03043690||Placebo|Patients in placebo study group received 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
62740932|NCT03287934|EXPERIMENTAL|digital light processing stent|according to the allocation, the experimental group will receive a digital light processing stent for immediate implant drilling and placement after atraumatic extraction of the target tooth.
62740933|NCT03287934|ACTIVE_COMPARATOR|selective laser sintering|according to the allocation, the intervention for the control group will be a selective laser sintering stent after atraumatic extraction of the target tooth for immediately implant placement. the selective laser sintering stent will be adapted and drilling will be done through the stent.
62740934|NCT05853705|EXPERIMENTAL|Exercise Group|Participants will participate in a remote, app-enabled exercise program consisting of strength and aerobic exercises for four to twelve weeks. They will perform the exercises 3-5 times a week at home guided by exercise videos in the app. The exercise sessions will increase in frequency throughout the training regimen. The videos will include athletes demonstrating how to perform each exercise safely, and provide tips for optimal form and breathing. Participants will wear wearable fitness trackers and monitor their heart rates during exercise sessions.
62740935|NCT01618435|ACTIVE_COMPARATOR|Fusion, allograft|Allograft used for fusion in the operation site
62740936|NCT01618435|EXPERIMENTAL|Fusion, i-FACTOR|i-FACTOR used for fusion in the operation site
62740937|NCT04952597|EXPERIMENTAL|Arm A: Ociperlimab + Tislelizumab|Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab
62740938|NCT04952597|EXPERIMENTAL|Arm B: Tislelizumab|Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone
62740939|NCT04952597|EXPERIMENTAL|Arm C: Concurrent Chemoradiotherapy (cCRT)|cCRT only for 4 cycles at the investigator's discretion
62740940|NCT06646172|EXPERIMENTAL|Mixture of liposome bupivacaine and bupivacaine hydrochloride|The same anesthesiologist with experience in regional block was used for ultrasound guided bilateral transverse thoracic muscle plane block (T4-5 interstital space, paracentral transverse axis position). According to the literature, in this study, 1.33% bupivacaine liposome 10 mL + 0.5% bupivacaine hydrochloride 10 ml was used.
62740941|NCT06646172|ACTIVE_COMPARATOR|Bupivacaine hydrochloride alone|The same anesthesiologist with experience in regional block was used for ultrasound guided bilateral transverse thoracic muscle plane block (T4-5 interstital space, paracentral transverse axis position). According to the literature, in this study, 0.5% bupivacaine 20ml was used.
62740942|NCT03890926||radioactive Iodine-125 seed implantation|All enrolled patients received the intervention previously as a conventional treatment.
62740943|NCT05626322|EXPERIMENTAL|Phase 1b|Participants will be allocated to sequential dose levels of maplirpacept (PF-07901801), administered in combination with standard doses of tafasitamab and lenalidomide, to select two doses for further evaluation in Phase 2. Approximately 20 participants will be enrolled.
62740944|NCT05626322|EXPERIMENTAL|Phase 2|Participants will be randomized to 1 of 2 different dose levels of maplirpacept (PF-07901801) which will be administered in combination with standard doses of tafasitamab and lenalidomide. Approximately 50 participants will be enrolled (25 per dose).
62740945|NCT02693080|EXPERIMENTAL|Diagnostic (CT perfusion imaging)|Patients undergo CT perfusion imaging of the lungs at baseline, within 48 hours of first SABR, and at 2-4 months after completion of SABR. Isovue-200 is used as contrast agent
62740946|NCT05750056|EXPERIMENTAL|Lidocaine group|Patients received an intravenous bolus injection of lidocaine 1.5 mg/kg over 10 min before induction of anesthesia, followed by a continuous infusion of 2 mg/kg/h until the end of the surgery.
62740947|NCT05750056|PLACEBO_COMPARATOR|Placebo group|Patients received a perioperative 0.9% saline infusion at the same rate as the lidocaine infusion.
62740948|NCT02302248|EXPERIMENTAL|Crowdsourced Reappraisal|Participants received the web-based crowdsourcing reappraisal intervention.
62740949|NCT02302248|ACTIVE_COMPARATOR|Expressive Writing|Participants received the web-based expressive writing intervention.
62740950|NCT03089333|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10mg daily for 12 weeks.
62740951|NCT03089333|ACTIVE_COMPARATOR|Glibenclamide|Glibenclamide 5mg daily for 12 weeks.
62740952|NCT00810277|EXPERIMENTAL|1|
62740953|NCT00368745|ACTIVE_COMPARATOR|Pregabalin|Pregabalin treatment for GAD during 6 week taper/discontinuation from alprazolam treatment; followed by 6 weeks pregabalin treatment 'alprazolam free'.
62740954|NCT00368745|PLACEBO_COMPARATOR|Placebo|Placebo treatment of GAD during 6 week taper/discontinuation of alprazolam treatment followed by 6 weeks continuation of placebo treatment 'alprazolam free'.
62740955|NCT01252160|EXPERIMENTAL|QUTENZA|Cutaneous patch
62740956|NCT00201422|EXPERIMENTAL|Omeprazole, Amoxicillin, Clarithromycin|Anti-H. pylori Therapy (Triple therapy)
62740957|NCT01961297|EXPERIMENTAL|Sodium oxybate|Oral administration of a single dose of sodium oxybate (0.75-2.0 gm)
62740958|NCT02548481||BESTA scale|BESTA scale is administered at T0, T1 (3 months) and T2 (1 year)
62740959|NCT01262638|EXPERIMENTAL|ETC-1002 120 mg (Group 1)|Subjects with hypercholesterolemia and normal triglycerides
62740960|NCT01262638|EXPERIMENTAL|ETC-1002 80 mg (Group 2)|Subjects with hypercholesterolemia and normal triglycerides
62740961|NCT01262638|EXPERIMENTAL|ETC-1002 40 mg (Group 3)|Subjects with hypercholesterolemia and normal triglycerides
62740962|NCT01262638|EXPERIMENTAL|Placebo (Group 4)|Subjects with hypercholesterolemia and normal triglycerides
62740963|NCT01262638|EXPERIMENTAL|ETC-1002 120 mg (Group 5)|Subjects with hypercholesterolemia and elevated triglycerides
62740964|NCT01262638|EXPERIMENTAL|ETC-1002 80 mg (Group 6)|Subjects with hypercholesterolemia and elevated triglycerides
62740965|NCT01262638|EXPERIMENTAL|ETC-1002 40 mg (Group 7)|Subjects with hypercholesterolemia and elevated triglycerides
62740966|NCT01262638|EXPERIMENTAL|Placebo (Group 8)|Subjects with hypercholesterolemia and elevated triglycerides
62740967|NCT02245269|EXPERIMENTAL|TPV/r + Atorvastatin followed by TPV/r + antacid|Day 1: first dose of ATV Day 8: single dose of TPV/r Day 13: single dose of TPV/r, followed by a single dose of Maalox Days 14-21: morning and evening doses of TPV/r on Day 20: second dose of ATV
62740968|NCT04310982||Health Adults|Forty-nine healthy participants (30 females, 19 males) completed the test-retest protocol with 7 days between tests. Participants were; 23,58±2,65 years of age, 62,9±10,08 kg of weight and 168,76±8,31 cm of height. Participants included in the study did not have any musculoskeletal, neurological or other pathology potentially affecting their gait and jump performance.
62740969|NCT04521946|EXPERIMENTAL|Treatment (chemotherapy, HCT)|Patients receive thiotepa IV over 2-4 hours and etoposide IV over 60 minutes on days -8 to -6, melphalan IV over 20 minutes on days -5 and -4, and fludarabine phosphate IV over 1 hour on days -5 to -3. Patients receiving umbilical cord transplant only also receive lapine T-lymphocyte immune globulin IV over 4-12 hours on days -4 and -3. Patients then undergo HCT on day 0. Patients also receive tacrolimus IV or cyclosporine IV beginning on day -2 to and mycophenolate mofetil PO every 8 hours or IV from days 0-40 and tapered to day 90.
62740970|NCT00158249|PLACEBO_COMPARATOR|placebo|matched capsules
62740971|NCT00158249|EXPERIMENTAL|citicoline|2 gm/day
62740972|NCT00423982|ACTIVE_COMPARATOR|Rifampicin-combination therapy|Cloxacillin or vancomycin in combination with Rifampicin. Treatment of early staphylococcal prosthetic joint infections in addition to debridement and retention of the prosthesis.
62740973|NCT00423982|ACTIVE_COMPARATOR|Monotherapy|Cloxacillin or vancomycin in the treatment of early staphylococcal prosthetic joint infections in addition to debridement and retention of the prosthesis.
62740974|NCT03335072|ACTIVE_COMPARATOR|WHO-recommended|Annual mass azithromycin distribution of all residents
62740975|NCT03335072|EXPERIMENTAL|Age-based core group|Annual mass azithromycin treatment of everyone plus quarterly treatment of children
62740976|NCT03335072|EXPERIMENTAL|PCR infection-based core group|Annual mass azithromycin treatment plus quarterly treatment of a PCR-based cohort that would be a subset of the age-based core group.
62740977|NCT03335072|EXPERIMENTAL|TI-based core group|Annual mass azithromycin treatment plus quarterly treatment of a conjunctival photography-based cohort that would be a subset of the age-based core group
62740978|NCT01814046|EXPERIMENTAL|cells + high dose aldesleukin|Patients receiving cells + high dose aldesleukin
62740979|NCT01814046|EXPERIMENTAL|cells and no high dose aldesleukin|Patients receiving cells and no high dose aldesleukin
62740980|NCT01296893|NO_INTERVENTION|Delayed exercise control|Participants asked to maintain usual lifestyle and provided with abbreviated version of intervention upon completion of end of study testing.
62740981|NCT01296893|EXPERIMENTAL|Exercise|Aerobic exercise Intervention as per below
62740982|NCT03206970|EXPERIMENTAL|Zanubrutinib|Zanubrutinib (160 milligrams) administered orally twice daily
62740983|NCT04915118||Patients with HFrEF|Patients with HFrEF (Heart failure with reduced ejection fraction) who had a previous decompensation event.
62740984|NCT02876458|OTHER|Immediate coronary angiogram|An immediate coronary angiogram will be performed
62740985|NCT02876458|OTHER|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 96 hours) will be performed
62740986|NCT04470804|EXPERIMENTAL|Sirolimus on newly diagnosed primary acquired PRCA|A prospective research of the sirolimus efficiency on newly diagnosed primary acquired PRCA patients. Sirolimus dosage: 2mg QD with plasma concentration 4-15ng/mL. Medication time should last at least 6 months
62740987|NCT04470804|ACTIVE_COMPARATOR|Cyclosporine A on newly diagnosed primary acquired PRCA|Cyclosporine A (CsA) efficiency on newly diagnosed primary acquired PRCA patients. CsA dosage: 4mg/kg QD. Medication time should last at least 6 months
62740988|NCT04639466|EXPERIMENTAL|Phase I Arm I (COH04S1)|Participants receive COH04S1 IM in the non-dominant upper arm on day 0 and day 28 in the absence of unacceptable toxicity.
62740989|NCT04639466|ACTIVE_COMPARATOR|Phase I Arm II (COH04S1, placebo)|Participants receive COH04S1 IM in the non-dominant upper arm on day 0 and placebo IM in the non-dominant upper arm on day 28 in the absence of unacceptable toxicity.
62740990|NCT04639466|PLACEBO_COMPARATOR|Phase I Arm III (placebo)|Participants receive placebo IM in the non-dominant upper arm on day 0 and day 28 in the absence of unacceptable toxicity.
62740991|NCT04639466|EXPERIMENTAL|Phase II Arm I (low dose COH04S1 booster)|Participants receive low dose COH04S1 booster IM in non-dominant upper arm on day 1 in the absence of unacceptable toxicity.
62740992|NCT04639466|EXPERIMENTAL|Phase II Arm II (high dose COH04S1 booster)|Participants receive high dose COH04S1 booster IM in non-dominant upper arm on day 1 in the absence of unacceptable toxicity.
62740993|NCT00759876|EXPERIMENTAL|Ataluren|Participants will receive ataluren 3 times per day with meals at doses of 20 milligrams per kilogram (mg/kg) (breakfast), 20 mg/kg (lunch), and 40 mg/kg (dinner) for up to 89 weeks.
62740994|NCT00801073|EXPERIMENTAL|Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
62740995|NCT06232642|ACTIVE_COMPARATOR|Lactoferrin in Whey Protein|Lactoferrin (200 mg), iron (6 mg), and B12 (5.2 ug) in a whey protein isolate drink (20 grams of protein) to be taken 2 times daily; once before the morning meal and once before the evening meal.
62740996|NCT06232642|ACTIVE_COMPARATOR|Lactoferrin in Rice Protein|Lactoferrin (200 mg), iron (6 mg), and B12 (5.2 ug) in a rice protein drink (20 grams of protein) to be taken 2 times daily; once before the morning meal and once before the evening meal.
62740997|NCT06232642|ACTIVE_COMPARATOR|Lactoferrin Control|Lactoferrin (200 mg), iron (6 mg), and B12 (5.2 ug) in a maltodextrin drink (0 grams of protein) to be taken 2 times daily; once before the morning meal and once before the evening meal.
62740998|NCT01932372||Tofacitinib (Xeljanz)|Tablets 5 mg BID
62740999|NCT01932372||Standard of Care|Standard of Care for Rheumatoid Arthritis
62741000|NCT04382586|EXPERIMENTAL|Zanubrutinib + Supportive Care|Participants received zanubrutinib plus supportive care
62741001|NCT04382586|ACTIVE_COMPARATOR|Placebo + Supportive Care|Participants received placebo plus supportive care alone
62551784|NCT03032848|ACTIVE_COMPARATOR|Promestriene Group|use of 1 gram per day
62741002|NCT06409936|EXPERIMENTAL|Asciminib single agent|"Core phase (2 years): asciminib 80 mg QD will be given as single-agent.~Consolidation phase (2 years): If patients will have achieved a DMR (MR4), or if it will be in their interest, the treatment will be continued with asciminib 80 mg QD.~Treatment free remission phase (1 year): patients maintaining a stable MR4 up to the end of the fourth year will discontinue the treatment"
62741003|NCT06409936|EXPERIMENTAL|Asciminib plus nilotinib|"Core phase (2 years): asciminib 80 mg QD will be started, then after 90 days asciminib will be given 40 mg BID and nilotinib 300 mg BID, or 300 mg OAD according to the presence/absence of asciminib adverse events, will be added-on.~Consolidation phase (2 years): If patients will have achieved a DMR (MR4), or if it will be in their interest, the treatment will be continued with asciminib 40 mg BID and nilotinib reduced to 300 mg daily.~Treatment free remission phase (1 year): patients maintaining a stable MR4 up to the end of the fourth year will discontinue the treatment"
62741004|NCT06623994|NO_INTERVENTION|Usual care Group|The current standard of care will be delivered. Care will be provided to the individual at the health facility by a clinician (clinical officer in levels 3, 4 \& 5, medical officer in level 5), including regular consultation, vital signs, clinical history, physical examination, and prescriptions as required to control seizures.
62175331|NCT01729091|EXPERIMENTAL|Treatment (chemotherapy, UCB-derived NK cells, transplant)|Patients receive elotuzumab IV over 2-5 hours on day -15 and -8, lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.
62551785|NCT03032848|ACTIVE_COMPARATOR|Estriol Group|use of 1 gram per day
62551786|NCT03032848|PLACEBO_COMPARATOR|Vaginal Moisturizer Cream|use of 1 gram per day
62551787|NCT06166524|ACTIVE_COMPARATOR|Early invasive strategy|Patients will undergo early catheter ablation for atrial fibrillation using pulsed-field ablation energy
62175332|NCT02016664|EXPERIMENTAL|Chronic pain patients on oral ketamine|"Days 1-7:~Subjects will be given a 7 day supply of 10 mg ketamine tablets three times per day for seven days and to return to clinic on Day 7. They will be instructed not to take their morning dose of ketamine and to eat a light breakfast on Day 7. Upon arrival, the patient will have a 20 gauge (saline locked) IV started in the antecubital fossa to allow for five blood samples: Time Zero,30, 60,90 and 120 minutes. The first blood sample at Time 0 will be obtained just before the patient takes his/her oral dose of ketamine.~Days 8-14:~The subjects will be given a supply of 20 mg ketamine capsules and instructed to take them three times per day, at specified times, and to return to clinic on Day 14. The instructions and procedures at the second clinic visit will be the same as on Day 7."
62175333|NCT03723915|EXPERIMENTAL|Treatment (pembrolizumab, wild-type reovirus)|See Detailed Description
62551788|NCT06166524|PLACEBO_COMPARATOR|Conservative arm|Patients will undergo cardioversion with antiarrhythmic drug treatment. In patients with atrial fibrillation reoccurrence, an optimalization of bradycardia medication will be done using smart watches heart rate monitoring
62551789|NCT06369441||Oncology|Adults (aged 18 or older) who have an active cancer diagnosis with confirmatory pathology results indicating solid tumor and/or hematologic malignancy.
62741005|NCT06623994|EXPERIMENTAL|BEACON Group|Those randomized to the BEACON group will receive care from clinicians who received training in epilepsy management and care. Epilepsy management tasks will be shared among the trained clinicians (e.g., nurses will offer care at all levels). ASMs used will be the same as usual care. Details about the patient will be entered in the medical records system to help with return appointment patient tracking and follow-up. Two days before the follow-up appointment date, participants will be contacted via phone or text messaging to remind them about the follow-up appointments. If participants cannot be contacted via phone a day before the appointment, the local CHW will make attempts to contact them at home. Participants who miss the appointment will be contacted again, and another appointment date will be given.
62741006|NCT03536780|EXPERIMENTAL|Avelumab and Gemcitabine|
62741007|NCT04985201|EXPERIMENTAL|Simvastatin + Irinotecan|received intravenous infusions of Irinotecan 60 milligrams per square meter (mg/m\^2) on Day 1,8 of every 21-day cycle (4 cycles) in combination with oral simvastatin (20mg daily) (10 months)
62741008|NCT04985201|ACTIVE_COMPARATOR|Irinotecan|received intravenous infusions of Irinotecan 60 milligrams per square meter (mg/m\^2) on Day 1,8 of every 21-day cycle (4 cycles)
62182410|NCT02505477|EXPERIMENTAL|N-acetylcysteine|Patients in this group will receive N-acetylcysteine (NAC) 1200mg orally twice daily (total daily dose 2400mg), for eight weeks. Each individual tablet contains 300mg NAC, therefore patients will take two tablets by mouth each morning and two tablets by mouth each evening. Manufacturer: Jarrow Industries, Inc.; Brand name: N-A-C Sustain
62551790|NCT01824381|EXPERIMENTAL|Amniotic membrane in large wounds|
62551791|NCT05593744||Thyroid dysfunction|Patients had thyroid dysfunction during anti-PD-1 therapy.
61997471|NCT06418386|EXPERIMENTAL|rotary sodium hypochloride|AF baby files for pediatric( fanta ) and 1% sodium hypochloride
62551792|NCT05593744||No thyroid dysfunction|Patients didn't have thyroid dysfunction during anti-PD-1 therapy.
62551793|NCT04966689|EXPERIMENTAL|combined speech and music therapy|the telerehabilitation intervention that include both speech therapy and music therapy at the same time
62741009|NCT00036855|EXPERIMENTAL|Group A (no planned PBSC support)|"Patients receive rituximab IV over 4-6 hours followed by IDEC-In2B8 IV over 10 minutes on day 0 and undergo whole body imaging. Patients may then receive rituximab IV over 4-6 hours followed by IDEC-Y2B8 IV over 10 minutes on day 7.~Some patients receive autologous PBSC IV over 30-60 minutes on day 35."
62741010|NCT00036855|EXPERIMENTAL|Group B (planned PBSC support)|Patients receive rituximab, IDEC-In2B8, and IDEC-Y2B8 as in group A. Patients also receive autologous PBSC IV over 30-60 minutes on day 21 and G-CSF subcutaneously beginning on day 22 and continuing until blood counts recover or day 35.
62741011|NCT01463696|EXPERIMENTAL|MK-8242 60 mg BID|In Cycle 1, participants received MK-8242 60 mg administered orally (PO) twice a day (BID) on Days 1-6 and PO once daily (QD) in the morning on Day 7 of the 21-day cycle to accommodate pharmacokinetic (PK) sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 60 mg PO BID on Days 1-7 of each 21-day cycle.
62741012|NCT01463696|EXPERIMENTAL|MK-8242 120 mg BID|In Cycle 1, participants received MK-8242 120 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 120 mg PO BID on Days 1-7 of each 21-day cycle.
62741013|NCT01463696|EXPERIMENTAL|MK-8242 170 mg BID|In Cycle 1, participants received MK-8242 170 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 170 mg PO BID on Days 1-7 of each 21-day cycle.
62741014|NCT01463696|EXPERIMENTAL|MK-8242 250 mg BID|In Cycle 1, participants received MK-8242 250 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 250 mg PO BID on Days 1-7 of each 21-day cycle.
62741015|NCT01463696|EXPERIMENTAL|MK-8242 300 mg BID|In Cycle 1, participants received MK-8242 300 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 300 mg PO BID on Days 1-7 of each 21-day cycle.
62741016|NCT01463696|EXPERIMENTAL|MK-8242 350 mg BID|In Cycle 1, participants received MK-8242 350 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 350 mg PO BID on Days 1-7 of each 21-day cycle.
62741017|NCT01463696|EXPERIMENTAL|MK-8242 400 mg BID|In Cycle 1, participants received MK-8242 400 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 400 mg PO BID on Days 1-7 of each 21-day cycle.
62741018|NCT01463696|EXPERIMENTAL|MK-8242 500 mg BID|In Cycle 1, participants received MK-8242 500 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 500 mg PO BID on Days 1-7 of each 21-day cycle.
62741019|NCT03683316||all infants|"There will be one arm for this study. All infants will receive a similar intervention during their routine kangaroo mother care (KMC). KMC is a national and international standard of care. This is an observational study of how infants breath while participating in KMC compared to how they breath while in a crib or incubator. Work of breathing will be measured at baseline and then during KMC. Mothers will participate in KMC regardless of participation in the study. Work of breathing will be measured by using Respiratory Inductance Plethysmography (RIP). This scientifically measures work of breathing (specifically phase angles) by placing soft bands around the abdomen and chest. The actual intervention is a standard of care and something that the mother infant dyad will do regardless of the study. Each mother / infants pair is expected to be actively enrolled for approximately 2 hours."
62741020|NCT06096090|ACTIVE_COMPARATOR|Aldesleukin every 4 weeks|
62741021|NCT06096090|ACTIVE_COMPARATOR|Aldesleukin every 2 weeks|
62741022|NCT06096090|PLACEBO_COMPARATOR|Placebo|
62741023|NCT05484973|EXPERIMENTAL|All patients will use AMMA|Device: AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
62551794|NCT04966689|ACTIVE_COMPARATOR|speech therapy|A behavioural speech therapy program including breathing exercises, loudness, pitch, and intelligibility which are adapted from Lee Silverman Voice Treatment (LSVT) and voice exercises Which is delivered through telerehabilitation
62551795|NCT04966689|ACTIVE_COMPARATOR|music therapy|music exercises Will be designed based on the music therapy protocols of previous studies Which is delivered through telerehabilitation
62551796|NCT04563507|ACTIVE_COMPARATOR|ARM 1 - Letrozole and Palbociclib|Patients randomized to arm 1 will start standard Letrozole followed by Palbociclib at day 21.
62551797|NCT04563507|ACTIVE_COMPARATOR|ARM 2 - Letrozole and Palbociclib + I-SBRT|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions.
62551798|NCT03888846|OTHER|Colchicine|Colchicine therapy as part of supportive care routinely offered in Behcet's Clinic-Istanbul
62551799|NCT03888846|EXPERIMENTAL|Topical Pentoxifylline Gel and Colchicine|Topical Pentoxifylline Gel administration in addition to the colchicine therapy as part of supportive care routinely offered in Behcet's Clinic-Istanbul
62551800|NCT04768660|OTHER|normal|people will not use chewing gums after whipple operation
62551801|NCT01833663|EXPERIMENTAL|Solifenacin Succinate Tablets and Estrogen capsules|Solifenacin Succinate Tablets (5mg/d) + local estrogen for 12 weeks
62551802|NCT01833663|ACTIVE_COMPARATOR|Solifenacin Succinate Tablets|Solifenacin Succinate Tablets (5mg/d) for 12 weeks
62551803|NCT02614105|EXPERIMENTAL|Pelvic floor muscle training|Participants in the pelvic floor muscle training group will receive group exercise sessions (1 hour) at the physiotherapy out-patient department of the hospital once a week for 16 weeks with guidance from an experienced pelvic floor physiotherapist. The group exercise sessions will focus on pelvic floor muscle training, relaxation and breathing techniques. Participants in the pelvic floor muscle training group will also receive an individually adapted pelvic floor muscle training program for daily home use.
62741024|NCT02995161|EXPERIMENTAL|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62741025|NCT03066700||Hemospray application|The patients with GI bleeding from tumor and received Hemospray as a hemostasis method.
62741026|NCT04932434|EXPERIMENTAL|Psilocybin therapy|Participants will receive one or two doses of psilocybin in a monitored setting approximately two weeks apart, with preparation sessions before and integration sessions after.
62741027|NCT04147429|NO_INTERVENTION|Usual care|Newborns randomized to the usual care group will receive standard education about safe sleep practices, measuring temperatures and newborn feeding needs. This information will be accompanied by printed instructions that will be added to the family's discharge instructions. This reflects current practice in the Duke Hospital Newborn Nursery.
62741028|NCT04147429|EXPERIMENTAL|Intervention|In addition to usual care, families randomized to the intervention group will receive an early literacy intervention, delivered by a trained research assistant. To ensure intervention and delivery fidelity, the PI will meet with research assistants at bi-weekly intervals to review procedures and perform structured observations of intervention delivery.
62741029|NCT04823286|EXPERIMENTAL|Virtual reality health platform during hemodialysis|During 12 weeks subjects will use a VR platform during hemodialysis. The intervention will be virtual reality exercise, nutritional advice and psychological wellbeing support plus cognitive training.
62741030|NCT04823286|NO_INTERVENTION|Control group-usual care|During 12 weeks subjects will carry on with the usual care in the hemodialysis unit
62551804|NCT02614105|EXPERIMENTAL|Cough-suppression|Participants in the cough-suppression group will receive a group education session with general information about cough-suppression therapy and advice about how to distinguish between unproductive and productive cough to enable them to perform airway clearance techniques when required. In addition, participants will receive one to two individual sessions (30-60 minutes) of cough-suppression therapy tailored to the individual needs based on symptoms and underlying disease activity
62551805|NCT02614105|EXPERIMENTAL|Control group|Participants in the group will receive guidance and instruction in terms of correct contraction of the pelvic floor muscles at clinical assessment. Control group participants will receive brief written information about pelvic floor muscle training and cough-suppression therapy, but no other form of regular follow-up or intervention throughout the intervention period.
62741031|NCT02675751|EXPERIMENTAL|wavefront-guided PRK with iDesign|wavefront-guided PRK for treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser
62741032|NCT03055715||Locally advanced NSCLC-patients|Inoperable stage III (A and B) non-small-cell lung cancer (NSCLC) with indication for radical radiotherapy.
62741033|NCT01691105|NO_INTERVENTION|Academic Detailing (AD)|Standard of care for patients who are smokers and admitted to the hospital.
62551806|NCT00491868|EXPERIMENTAL|1|
62551807|NCT00491868|EXPERIMENTAL|2|
62741034|NCT01691105|EXPERIMENTAL|AD + Integrated Tobacco Order Set|Access to the Integrated Tobacco Order Set (ITOS) Nicotine Replacement Therapy with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center
62741035|NCT00949923|ACTIVE_COMPARATOR|tea capsules|3 tea capsules daily for 3 weeks
62741036|NCT00949923|NO_INTERVENTION|Control|No tea capsules
62175334|NCT03982875|EXPERIMENTAL|SmartBag arm|"The Alfred SmartBag System will be placed on the ostomy site during surgery. The system will be used to wirelessly monitor ostomy function in the hospital setting and the patient will otherwise receive the standard of care. At discharge the patient will continue to use the Alfred SmartBag System and ostomy function will be monitored by the research and clinical teams remotely.~If participant's output is (i) less than 50mL or greater than 1500mL per day or (ii) greater than 1200mL in two days; the mobile app will alert not only the participant but also the clinical staff (nurse).~Participants will also receive support from a 'Patient Coach', a trained health coach who is also an ostomy patient to provide quality of life support."
62175335|NCT03936075|EXPERIMENTAL|intervention|treatment with the provision of 6 individual sessions of the Guided Imagery and Music method as a psychological supportive intervention, and psychometric questionnaires collection
62175336|NCT03936075|PLACEBO_COMPARATOR|control|standard care treatment with psychometric questionnaires collection and two individual counselling sessions, at baseline (week 1) and at the end (week 6)
62175337|NCT01128777|EXPERIMENTAL|Cognitive behavioral group therapy|Cognitive behavioral group therapy for adolescents and a parallel group for parents
62175338|NCT01128777|ACTIVE_COMPARATOR|Nondirective supportive group therapy|Nondirective supportive group therapy for adolescents and a parallel group for parents
62175339|NCT03966534|NO_INTERVENTION|Control Group|Blood culture obtained as first test after venipuncture and prior to biochemistry test
62175340|NCT03966534|EXPERIMENTAL|Diversion Group|Biochemistry test obtained as first test after venepuncture and prior to blood culture
62175341|NCT02036606||mood disorders|Questionary and neuropsychological tasks will be administered
62175342|NCT02036606||control|Questionary and neuropsychological tasks will be administered
62175343|NCT00841477|NO_INTERVENTION|A1|standard behavioral intervention, standard HB vaccine schedule (0,1,6month)
62175344|NCT00841477|ACTIVE_COMPARATOR|A2|standard behavioral intervention, accelerated HB vaccine schedule (0,1,2month)
62175345|NCT00841477|ACTIVE_COMPARATOR|B1|enhanced behavioral intervention, standard vaccine schedule
62551808|NCT00491868|ACTIVE_COMPARATOR|3|
62175346|NCT00841477|ACTIVE_COMPARATOR|B2|enhanced behavioral intervention, accelerated vaccine schedule (0,1,2MONTH)
62175347|NCT02906995|EXPERIMENTAL|Sublingual tablet 4 mg|The 24 study participants will be administered the sublingual 4 mg nicotine tablet on one occasion. Blood samples will be obtained for 4 hours for analysis of nicotine plasma levels.
62551809|NCT00491868|ACTIVE_COMPARATOR|4|
62551810|NCT03883035|EXPERIMENTAL|EAS-aided group|esophagogastroduodenoscopy examination with the assistance of automatic quality-control system
62551811|NCT03883035|NO_INTERVENTION|control group|conventional standard esophagogastroduodenoscopy examination without the assistance of automatic quality-control system
62551812|NCT05175040|EXPERIMENTAL|Prophylactic manual rotation|Prophylactic manual rotation involves a vaginal examination performed with an obstetric provider's hands to turn the baby from a position in which the baby's face is looking up in the direction of the ceiling (occiput posterior) or to the side (occiput transverse) to a position in which the baby's face is looking down in the direction of the mother's spine (occiput anterior). Prophylactic manual rotation will occur at the initiation of pushing once the individual achieves complete cervical dilation.
62741037|NCT03166462|NO_INTERVENTION|Control|"Patients in this arm will proceed through the current standard of care for pre-operative screening performed by either the patient's primary care physician or the pre-operative anesthesia clinic which screens patients prior to total knee or total hip arthroplasty."
62741038|NCT03166462|EXPERIMENTAL|Intervention|Patients in this arm will be referred to the Sleep Medicine clinic at the University of Miami Hospital for additional testing and evaluation for obstructive sleep apnea. If they are successfully diagnosed, they will receive appropriate treatment and any interventions for the peri-operative period as recommended by the pulmonary medicine team.
62741039|NCT04266730|EXPERIMENTAL|PANDA-VAC combined with pembrolizumab|The final primary therapeutic neoantigen vaccine product will comprise 6 peptides at a dose of 300 μg per peptide and Poly-ICLC at a dose of 500 μg formulated in an aqueous solution containing \<5% DMSO in isotonic dextrose for a total volume of 750 μL. The vaccine will be administered subcutaneously via 3 equal volume (250 μL) injections, one in an arm and one in each leg. The product will be administered on the following schedule: Days 1 and 4 of Week 1, Day 1 of Week 2, Day 1 of Week 3, Day 1 of Week 4, Day 1 of Week 11, and Day 1 of Week 21.
62741040|NCT01232504|EXPERIMENTAL|rhGM-CSF group|subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) once daily
62741041|NCT01232504|ACTIVE_COMPARATOR|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) and 2-3μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) each
62741042|NCT01232504|ACTIVE_COMPARATOR|rhG-CSF group|subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) once daily
62551813|NCT05175040|SHAM_COMPARATOR|Sham rotation|Sham rotation involves a vaginal exam that obstetric providers commonly do with their hands to assess cervical dilation and fetal position during routine labor, and will occur at the initiation of pushing once the individual achieves complete cervical dilation.
62551814|NCT00367302|EXPERIMENTAL|1|Buprenorphine maintenance
62741043|NCT06660186|EXPERIMENTAL|Rigid Sternal Fixation|The surgeon will close the sternum (breastbone) using the SternalPlate system. The SternalPlate System consists of implants and instruments used to hold the two halves of the sternum together.
62741044|NCT06660186|ACTIVE_COMPARATOR|Wire Cerclage|The surgeon will close the sternum (breastbone) using Wire Cerclage. Wire Cerclage consists of stainless steel wires used to hold the two halves of the sternum together.
62741045|NCT01854216|EXPERIMENTAL|Rotigotine in Japanese subjects|Repeated-Dose application of 1,2, and 4 mg / 24 hours Rotigotine in healthy Japanese subjects; Transdermal patch over 24 hours
62175348|NCT02906995|ACTIVE_COMPARATOR|Nicorette lozenge 4 mg|The 24 study participants will be administered the Nicorette lozenge containing 4 mg of nicotine on one occasion. Blood samples will be obtained for 4 hours for analysis of nicotine plasma levels.
62175349|NCT03824145|EXPERIMENTAL|Immediate Intervention|"The experimental arm will receive a 16-week lifestyle intervention that promotes nutritional and physical activity changes concordant with those contained in the ACS nutrition and physical activity guidelines for cancer survivors. The 16-week intervention includes:~1) a curriculum binder covering weekly topics and including self-monitoring tools to support adherence; 2) lifestyle coaching for 16-weeks, with in-person or virtual supervised exercise sessions and telephone-based sessions; 3) exercise supplies (Fitbit, resistance bands), 4) twice weekly text messaging targeting self-efficacy and social support; and 5) attendance to cooking classes emphasizing plant-based eating."
62175350|NCT03824145|OTHER|Attention Control|"The attention control participants will receive a home/work organization intervention:~* Participants will receive a book with overview of home/work organization program with 16 weekly topics with an overview of each chapter.~* Virtual or weekly phone calls- with a home organization coach with standard prompts.~* Text messages supporting home/work organization."
62175351|NCT00669266||Tumor|Tumor material and corresponding biosamples from patients with adrenal tumors
62175352|NCT00669266||control group|Biomaterial from patients without adrenal tumor
62175353|NCT04897685|EXPERIMENTAL|Nature-based treatment group|The participants in the treatment group were offered 12 nature-based group therapy sessions in addition to standard care.
62175354|NCT04897685|NO_INTERVENTION|Control group|The participants in the control group continued treatment as usual in the health care services.
62175355|NCT05216029|EXPERIMENTAL|Group I (oncology dashboard)|Radiologist records information from patient's recent scan into oncology dashboard. Patients view images of how disease may have changed over time on oncology dashboard.
62175356|NCT05216029|EXPERIMENTAL|Group II (standard of care)|Patients receive standard of care.
62175357|NCT06293014|EXPERIMENTAL|second-line maintenance treatment group|TAS-102 combined with bevacizumab
62175358|NCT06293014|ACTIVE_COMPARATOR|second-line continuous treatment group|Standard chemotherapy (FOLFOX，FOLFIRI or CAPEOX) combined with bevacizumab
62175359|NCT04184856||Binge eating disorder (BED) patients|Individuals with BED diagnosis.
62175360|NCT04184856||non-BED controls|Individuals that do not experience binges
62175361|NCT04184856||subsyndromal BED controls|individuals that experience binges but do not fulfill the requirements for BED diagnosis.
62175362|NCT01191697|EXPERIMENTAL|Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine|"Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine for patients with HER2-positive metastatic esophagogastric cancer. Each cycle is 21 days.~Cycle 1, Day 1 Trastuzumab (loading dose) 4mg/kg IV~Cycle 2, Day 1 and all Subsequent Cycles Bevacizumab (7.5mg/kg) IV Trastuzumab (6mg/kg) IV Oxaliplatin (130mg/m2) IV Capecitabine (1200mg/m2) PO (taken Days 1-14 of each cycle)~Patients remained on treatment until disease progression, intercurrent illness that prevented further administration of treatment, unacceptable adverse events, participant decision to withdraw consent or general or specific changes in the participant's condition that rendered the participant unacceptable for further treatment."
62175363|NCT05529225||Boulder Care|People seeking buprenorphine for opioid use disorder via telehealth.
62175364|NCT05529225||OHSU|People seeking buprenorphine for opioid use disorder via treatment as usual.
62551815|NCT00367302|ACTIVE_COMPARATOR|2|Methadone maintenance
62741046|NCT01854216|EXPERIMENTAL|Rotigotine in Caucasian subjects|Multiple-Dose application of 1, 2, and 4 mg / 24 hours Rotigotine in healthy Caucasian subjects; Transdermal patch over 24 hours
62551816|NCT01140789||Crohn's disease patients|Diagnosis of Crohn's disease by endoscopy, radiology and histology
62551817|NCT01140789||Ulcerative colitis patients|Diagnosis of ulcerative colitis defined by endoscopy, radiology and histology
62551818|NCT01140789||Non-IBD patients|Ethically, sex and aged-matched controls attending clinics or endoscopy for functional upper gastrointestinal diseases or screening colonoscopy.
62551819|NCT02521649|EXPERIMENTAL|10µg, Stage I-III|10µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
62551820|NCT02521649|EXPERIMENTAL|100µg, Stage I-III|100µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
62551821|NCT02521649|EXPERIMENTAL|250µg, Stage I-III|250µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
62741047|NCT01833728|EXPERIMENTAL|nefopam-propacetamol combination group|
62551822|NCT02521649|EXPERIMENTAL|100µg, Stage IV|100µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
62551823|NCT02521649|EXPERIMENTAL|250µg, Stage IV|250µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
62551824|NCT05467631|ACTIVE_COMPARATOR|Plain Tea Tree Oil Control|Topical application of 1ml 20% tea tree oil in almond oil base as a carrier twice daily for 2 weeks.
62551825|NCT05467631|EXPERIMENTAL|Verum|Topical application twice daily of 1ml mixture for 2 weeks of essential oils containing tea tree oil, rosemary, clove, pepper, in a formulation with skin permeation enhancers including limonene.
62551826|NCT05478616||Natural cycles|Endometrium will be sampled at the day of LH surge + 7 days.
62551827|NCT05478616||Artificial cycles|Endometrium will be sampled at the day of P4 + 5 days.
62551828|NCT06408129||Patients clinically suspected of active tuberculosis or in contact with index cases|patients had either a clinical suspicion of active tuberculosis or underwent screening due to a close contact with another patient which had a bacteriologically confirmed active tuberculosis.
62551829|NCT02368483|EXPERIMENTAL|Neuromuscular training|
62741048|NCT01833728|ACTIVE_COMPARATOR|propacetamol alone group|
62741049|NCT06014229|EXPERIMENTAL|Cryoablation|Device: Cryoablation Single session with an argon-based device; a V-probe 17-G applicator will be used for the treatments; gas release 100%; local anesthesia or moderate sedation or general anesthesia at discretion of the anesthesiology / interventional radiology team; benign thyroid nodules (two benign cytological examinations) measuring between 5 and 65 mL of volume and less than 40% of cystic component;
62175365|NCT04335370||Patients with CF lung disease receiving Polymyxin B (PMB)|Participants receiving polymyxcin B as part of standard of care treatment for CF exacerbation will have blood drawn measure blood concentrations of PMB
62741050|NCT05357339|EXPERIMENTAL|Interventional 20% Albumin|Septic patients requiring a fluid bolus randomised to receive 100ml 20% albumin as boluses until they are stable or no longer require fluid resuscitation.
62741051|NCT05357339|ACTIVE_COMPARATOR|Control Crystalloid|Septic patients requiring a fluid bolus randomised to receive 250ml boluses of crystalloid fluid until they no longer require fluid resuscitation.
62175366|NCT04131010|EXPERIMENTAL|SpyGlass Pancreatoscopy|ERP with direct pancreatoscopy
62175367|NCT05900401|EXPERIMENTAL|Kidney and Stem Cell Recipients|Months-Years after standard transplant, patients will undergo bone marrow transplant (either from prospective collection of stem cells from their living donor, or from bone marrow collected at the time of deceased donation)
62175368|NCT05900401|EXPERIMENTAL|Kidney and Stem Cell Donors|PBSC will be collected from the LD via leukapheresis 1-4 weeks before the scheduled HSCT. The donor will first undergo standard GCSF mobilization: GCSF (can be TBO-GCSF) dosed at 10 mcg/kg/d (rounded to nearest pre-filled syringe) administered subcutaneously daily for 5 consecutive days. On the 5th day, the donor will undergo standard large volume leukapheresis. The target yield will be 2-3 x 106 CD34+ cells / kg of actual recipient body weight. A maximum of 3 days of pheresis will be allowed. A minimum of 2 x 106 CD34+ cells / kg of actual recipient body weight will be required to proceed
62175369|NCT03389451|EXPERIMENTAL|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET
62175370|NCT05524415||Patients|Patients who are hospitalized in Soroka University Medical Center (SUMC) Neurology department with a diagnosis of acute stroke
62175371|NCT02766010|EXPERIMENTAL|group A TensorTip|Male or female, age \> 18
61997472|NCT01138280|EXPERIMENTAL|Heat disinfection|Experimental arm: Heat disinfection link to RO water treatment system and piping system to dialysis machine
62175372|NCT02021305||Patients|60 children with a recorded episode of acute Urinary Track infection who attended 4th Department of Pediatrics of Medical School of Aristotle University of Thessaloniki.
62175373|NCT02021305||Controls|100 children with no history of Urinary Track Infection who attended 4th Department of Pediatrics of Medical School of Aristotle University of Thessaloniki.
62175374|NCT06645938|EXPERIMENTAL|Sequence 1: Treatment A followed by Treatment B|Participants will receive a single 200 mg dose of vepdegestrant registrational tablet on Day 1 of Period 1 followed by a single 200 mg dose of vepdegestrant variant tablet on Day 1 of Period 2.
62175375|NCT06645938|EXPERIMENTAL|Sequence 2: Treatment B followed by Treatment A|Participants will receive a single 200 mg dose of vepdegestrant variant tablet on Day 1 of Period 1 followed by a single 200 mg dose of vepdegestrant registrational tablet on Day 1 of Period 2.
62551830|NCT00902694|EXPERIMENTAL|ACHIEVE Intervention|Group and individual weight counseling and group physical activity classes for 18 months.
62551831|NCT00902694|OTHER|Control|Control arm receives group health classes quarterly with topics not related to weight
62551832|NCT04795895|EXPERIMENTAL|ultrasonography (US)|
62551833|NCT04795895|ACTIVE_COMPARATOR|Standard routine (SR)|
62741052|NCT00761384|EXPERIMENTAL|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
62551834|NCT02496182|PLACEBO_COMPARATOR|Placebo|Conventional treatment (Prednisone 0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Placebo tablet 2 times at day.
62551835|NCT02496182|EXPERIMENTAL|Pirfenidone 1800 mg|Conventional treatment (0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Pirfenidone long release tablet 900 mg 2 times at day, starting with 600 mg at day
62551836|NCT02496182|EXPERIMENTAL|Pirfenidone 1200 mg|Conventional treatment (0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Pirfenidone long release tablet 600 mg 2 times at day starting with 600 mg at day
62175376|NCT05927714|ACTIVE_COMPARATOR|Use Amnio Chorion Membrane (ACM) with hemostatic agent|ACM or amnion-only membranes have been used in oral surgical procedures primarily because they contain a host of growth factors that play a role in normal wound healing.
62551837|NCT04760717|EXPERIMENTAL|Spironolactone|Participants randomized to the Spironolactone arm will be receiving Spironolactone in addition to their normal routine blood pressure treatment.
62551838|NCT04760717|NO_INTERVENTION|Standard Care|Participants randomized to the Standard care arm will be receiving their normal routine blood pressure treatment.
62551839|NCT00580502|EXPERIMENTAL|LAGB for low BMI patients|the LAP-BAND® Adjustable Gastric Band (LAGB®) for patients with BMI between 30-40 kg/m2 with co-morbidities
62551840|NCT04533035||Single cohort|30 patients undergoing hallux valgus surgery
62551841|NCT02550301||Mean Platelet Volume|4 blood samples (1 pre procedure before clopidogrel loading) and 3 after Percutaneous Coronary Intervention will be drawn to assess the MPV
62551842|NCT04077554||Study group|women and men with excess body mass
62551843|NCT04077554||Control group|women and men with proper body mass
62551844|NCT02666443|PLACEBO_COMPARATOR|Control (C)|Control intervention (no dexamethasone)
62551845|NCT02666443|EXPERIMENTAL|Peri-neural (N)|Peri-neural Dexamethasone 1 mg
62551846|NCT02666443|EXPERIMENTAL|Intravenous|Intravenous Dexamethasone 1 mg
62551847|NCT06582823|EXPERIMENTAL|Intervention|The intervention integrate behavioral modeling to promote knowledge and skill retention and uptake. The content of the education sessions is consistent with the clinical management guidelines published by the E
62551848|NCT06582823|ACTIVE_COMPARATOR|Control|The control group
62175377|NCT05927714|PLACEBO_COMPARATOR|Use of ActCel Cellulose Gauze (Commercial Hemostatic Agent)|Palatal wound dressing with hemostatic agent
62551849|NCT05886205|EXPERIMENTAL|iPSC-exosome treatment|group1-low-dose group, 8 papatients are treated with 2 μg iPSC-Exos in 200 μL. group2-mid-dose group, 8 papatients are treated with 6 μg iPSC-Exos in 200 μL. group3-mid-dose group, 8 papatients are treated with 18 μg iPSC-Exos in 200 μL. group4-Dose expansion, 10 papatients are treated with iPSC-Exos in 200 μL. iPSC-Exos were administrated for nasal drip, bid for 12 weeks.
62551850|NCT01916044|EXPERIMENTAL|Lower Uterine Segment Ultrasound|Measure of Uterine Segment by Ultrasound
62551851|NCT01916044|NO_INTERVENTION|control|no measure of Uterine Segment Ultrasound
62551852|NCT03464721||Surgery Outpatients|
62551853|NCT02749500|ACTIVE_COMPARATOR|Conventional Occupational Therapy (OT)|Standard of care occupational therapy for stroke recovery
62551854|NCT02749500|EXPERIMENTAL|OT + Device-assisted therapy|Conventional OT plus 1 hour additional bimanual-to-unimanual device-assisted therapy. The m2 BAT will enable repeated movement of the affected body part without the help of a therapist, providing the opportunity to maintain range-of motion in the affected limb to limit spasticity, contracture and the ensuing deformity, a major goal of rehabilitation therapy and produces movement in the affected limb from activating the patient's own brain, rather than from being acted on by an external powered source such as a robot.
62551855|NCT05148091|EXPERIMENTAL|18~59 yrs. low dosage (20 μg) - SCTV01C VACCINE|20 participants in Phase I and 120 participants in Phase II at the age of 18\~59 years old will receive two doses of low dosage (20 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28
62551856|NCT05148091|PLACEBO_COMPARATOR|18~59 yrs. low dosage (20 μg) - Adjuvant (SCT-VA02B )|4 participants in Phase I and 20 participants in Phase II at the age of 18\~59 years old will receive two doses of study adjuvant (SCT-VA02B ,0.5mL) on Day 0 and Day 28
61997473|NCT01138280|NO_INTERVENTION|Conventional RO water treatment|Placebo arm: conventional chemical disinfection link to RO water treatment system.
62551857|NCT05148091|PLACEBO_COMPARATOR|18~59 yrs. low dosage (20 μg) - Saline|4 participants in Phase I and 20 participants in Phase II at the age of 18\~59 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28
62551858|NCT05148091|EXPERIMENTAL|≥60 yrs. low dosage (20 μg) - SCTV01C VACCINE|20 participants in Phase I and 120 participants in Phase II at the age of ≥60 years old will receive two doses of low dosage (20 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28
62551859|NCT05148091|PLACEBO_COMPARATOR|≥60 yrs. low dosage (20 μg) - Adjuvant (SCT-VA02B )|4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of study adjuvant (SCT-VA02B, 0.5mL) on Day 0 and Day 28
62551860|NCT05148091|PLACEBO_COMPARATOR|≥60 yrs. low dosage (20 μg) - Saline|4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28
62551861|NCT05148091|EXPERIMENTAL|18~59 yrs. high dosage (40 μg) - SCTV01C VACCINE|20 participants in Phase I and 120 participants in Phase II at the age of 18\~59 years old will receive two doses of high dosage (40 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28
62551862|NCT05148091|PLACEBO_COMPARATOR|18~59 yrs. high dosage (40 μg) - Adjuvant (SCT-VA02B )|4 participants in Phase I and 20 participants in Phase II at the age of 18\~59 years old will receive two doses of study adjuvant (SCT-VA02B, 0.5mL) on Day 0 and Day 28
61997474|NCT04004728|OTHER|laser, leg veins, sclerotherapy|to compare laser and sclerotherapy on treating leg veins
62175378|NCT01874665|EXPERIMENTAL|Cohort A|Participants with KIT exon 11-mutant GIST.
62741053|NCT06426875|EXPERIMENTAL|Effects Of Isometric Muscle Training On Shoulder Pain, Function And Performance In Bowlers|The Isometric Exercise Program which comprises targeted exercises for declining pain, improving function and performance, exercises were focused only on shoulder flexion, extension, abduction, adduction, internal rotation and external rotation. Exercises were performed via Thera Bands, free weights and resistance. Each repetition was of 10 to 15 seconds and 10 to 15 number of repetition total of three sets according to FITT formula. Under the supervision of a therapist, these exercises were performed three times each week. Every training session lasts 35 to 40 minutes, with a 5-minute warm-up and a 5-minute cool-down in between. Instruction in the correct form and technique was provided to participants throughout the intervention, and their development was closely evaluated to guarantee safety and effectiveness. Total duration of 35 to 40-minute session three sessions per week total four weeks of intervention, reading will be taken on baseline and after 2nd week and 4th week.
62741054|NCT06426875|NO_INTERVENTION|Control Group|(control group) in this group participants will receive Traditional Physical therapy
62741055|NCT05542095|EXPERIMENTAL|topical nasal simvastatin - 0.1 mg dose|"topical nasal simvastatin - 0.1 mg dose~Subjects are entered into the study in groups of 3. This first cohort will receive the lowest dose of simvastatin (0.1mg) via nasal irrigation for 4 weeks. If none of the 3 subjects report toxicity, the next group of 3 subjects enrolled will receive the consecutive higher dose of simvastatin for 1 month. If \>2 of the 3 subjects enrolled in the first group report toxicity then the dose is considered toxic or MTD is exceeded. If 1 of the first 3 reports toxicity, then the next group of 3 enrolled subjects will receive the same dose as group 1. When 6 subjects receive the same dose, and \<1 of them report toxicity, the consecutive group of 3 subjects will receive the successive higher dose. If \>2 of the 6 subjects on the same dose report toxicities, then MTD is exceeded. Intra-patient dose escalation will not be performed."
62741056|NCT05542095|EXPERIMENTAL|topical nasal simvastatin - 0.25 mg dose|"topical nasal simvastatin - 0.25 mg dose~Subjects are entered into the study in groups of 3. This 2nd cohort will receive the 0.25mg simvastatin via nasal irrigation for 4 weeks. If none of the 3 subjects report toxicity, the next group of 3 subjects enrolled will receive the consecutive higher dose of simvastatin for 1 month. If \>2 of the 3 subjects enrolled in the first group report toxicity then the dose is considered toxic or MTD is exceeded. If 1 of the first 3 reports toxicity, then the next group of 3 enrolled subjects will receive the same dose as group 1. When 6 subjects receive the same dose, and \<1 of them report toxicity, the consecutive group of 3 subjects will receive the successive higher dose. If \>2 of the 6 subjects on the same dose report toxicities, then MTD is exceeded. Intra-patient dose escalation will not be performed."
62741057|NCT05542095|EXPERIMENTAL|topical nasal simvastatin - 0.5 mg dose|"topical nasal simvastatin - 0.5 mg dose~Subjects are entered into the study in groups of 3. This 3rd cohort will receive the 0.5mg simvastatin via nasal irrigation for 4 weeks. If none of the 3 subjects report toxicity, the next group of 3 subjects enrolled will receive the consecutive higher dose of simvastatin for 1 month. If \>2 of the 3 subjects enrolled in the first group report toxicity then the dose is considered toxic or MTD is exceeded. If 1 of the first 3 reports toxicity, then the next group of 3 enrolled subjects will receive the same dose as group 1. When 6 subjects receive the same dose, and \<1 of them report toxicity, the consecutive group of 3 subjects will receive the successive higher dose. If \>2 of the 6 subjects on the same dose report toxicities, then MTD is exceeded. Intra-patient dose escalation will not be performed."
62741058|NCT05542095|EXPERIMENTAL|topical nasal simvastatin - 1 mg dose|"topical nasal simvastatin - 1 mg dose~Subjects are entered into the study in groups of 3. This 4th cohort will receive the 1mg simvastatin via nasal irrigation for 4 weeks. If none of the 3 subjects report toxicity, then the drug will be considered tolerated at the maximum tested dose. If \>2 of the 3 subjects enrolled in the first group report toxicity then the dose is considered toxic or MTD is exceeded. If 1 of the first 3 reports toxicity, then the next group of 3 enrolled subjects will receive the same dose as group 1. When 6 subjects receive the same dose, and \<1 of them report toxicity, then this maximum dose is considered tolerable. If \>2 of the 6 subjects on the same dose report toxicities, then MTD is exceeded. Intra-patient dose escalation will not be performed."
62741059|NCT04217811||Late neutropenia|Neutrophil count \< 1500
62741060|NCT04217811||No late neutropenia|Neutrophil count \> 1500
62741061|NCT03941379||Subjects previously participated in an Aura Biosciences bel-sar study|Subjects with Choroidal Melanoma or Indeterminate Lesions.
62741062|NCT03333252|EXPERIMENTAL|Intervention Condition|Exposing caregivers to caregiving-related information and care recipients to cognitive training tasks
62741063|NCT03333252|PLACEBO_COMPARATOR|Control Condition|Exposing caregivers to Nutrition and Health promotional material. The care recipients are exposed to plain words games from computer.
62741064|NCT05145322|EXPERIMENTAL|Group 1|Group 1: Lesion-specific cavity design with 90 degree cavosurface angle throughout the cavity margins
62741065|NCT05145322|EXPERIMENTAL|Group 2|Lesion-specific cavity design with wide bevel throughout the cavity margins
62741066|NCT05636969|EXPERIMENTAL|Prehabilitation|Patients in this group will attend a supervised multimodal prehabilitation programme
62551863|NCT05148091|PLACEBO_COMPARATOR|18~59 yrs. high dosage (40 μg) - Saline|4 participants in Phase I and 20 participants in Phase II at the age of 18\~59 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28
62551864|NCT05148091|EXPERIMENTAL|≥60 yrs. high dosage (40 μg) - SCTV01C VACCINE|20 participants in Phase I and 120 participants in Phase II at the age of ≥60 years old will receive two doses of high dosage (40 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28
62551865|NCT05148091|PLACEBO_COMPARATOR|≥60 yrs. high dosage (40 μg) - Adjuvant (SCT-VA02B )|4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of study adjuvant (SCT-VA02B, 0.5mL) on Day 0 and Day 28
62551866|NCT05148091|PLACEBO_COMPARATOR|≥60 yrs. high dosage (40 μg) - Saline|4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28
62741067|NCT05636969|NO_INTERVENTION|Control|Patients in the control group will follow standard of care of their hospitals and will be given general recommendations on physical activity, nutrition and stress/anxiety management.
62741068|NCT05523609|EXPERIMENTAL|Control Group|20 patients will receive Letrozole only for 12 weeks.
62741069|NCT05523609|EXPERIMENTAL|VitD/Ca group|20 patients will receive Letrozole in addition to 2000 IU vitamin D3 and 1000 mg of calcium per day for 12 weeks.
62741070|NCT06662214|EXPERIMENTAL|Refined maize flour|This arm will be given a meal of corn bread made from refined maize flour and a portion of the mung bean stew meat together with 250mL of water
62741071|NCT06662214|EXPERIMENTAL|Whole grain flour|This arm will be given a meal of corn bread made from whole grain maize flour and a portion of the mung bean stew meat together with 250mL of water
62741072|NCT00559455|EXPERIMENTAL|1|
62175379|NCT01874665|EXPERIMENTAL|Cohort B|Participants with GIST that lack KIT exon 11 mutations (Cohort B).
62175380|NCT00825734|EXPERIMENTAL|Dose Level 1|Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (40mg/m\^2)
62175381|NCT00825734|EXPERIMENTAL|Dose Level -1|Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (32mg/m\^2)
62175382|NCT00825734|EXPERIMENTAL|Dose Level 1a|Sorafenib PO BID (400mg), Ixabepilone IV every 21 days (32mg/m\^2)
62175383|NCT01463514|EXPERIMENTAL|AIR|"Randomization sequences according to modified catheter protocol.~1. AIR 2. Target Oxygen(88-90%) 3. 100% Oxygen 4. Nitric Oxygen"
62551867|NCT05978752|ACTIVE_COMPARATOR|A|The patients will undergo endoscopic gel embolization of gastric fundus varices and esophageal varices ligation.
62551868|NCT05978752|ACTIVE_COMPARATOR|B|The patients will undergo endoscopic gel embolization of gastric fundus varices and sclerotherapy of esophageal varices.
62551869|NCT05978752|EXPERIMENTAL|C|The patients will undergo endoscopic gelatinization of gastric varices (esophageal varices were not treated).
62551870|NCT00261443|PLACEBO_COMPARATOR|A1|/Active Comparator
62551871|NCT00261443|EXPERIMENTAL|A2|
62551872|NCT05184452|EXPERIMENTAL|PGDM1400LS 5 mg/kg IV|Participants will receive PGDM1400LS 5 mg/kg by intravenous (IV) infusion at Month 0
62741073|NCT03957421|EXPERIMENTAL|Aquatic exercise is more beneficial than land based exercise|use of aquatic exercise will be evaluated for individuals with stroke
62175384|NCT01463514|EXPERIMENTAL|NO|"Randomization sequences according to modified catheter protocol.~1.Nitric Oxygen 2. AIR 3. Target Oxygen(88-90%) 4. 100% Oxygen"
62175385|NCT01463514|EXPERIMENTAL|Oxygen|"Randomization sequences according to modified catheter protocol.~1. 100% Oxygen 2. NO 3. AIR 4. Target Oxygen (88-90%)"
61997475|NCT05008991||Study group|The study group will consist of (20) obese menopausal women whom are recently recovered from mild-moderate COVID-19 after one month.
61997476|NCT05008991||Control group|The control group will consist of (20) obese menopausal women; whom are not be affected by COVID-19.
62175386|NCT01463514|EXPERIMENTAL|Target Oxygen|"Randomization sequences according to modified catheter protocol.~1. Target Oxygen (88-90%) 2. 100% Oxygen 3. NO 4. AIR"
62175387|NCT03140449|EXPERIMENTAL|Rapamycin|Rapamycin(0.1%)
62175388|NCT03140449|EXPERIMENTAL|Calcitriol|Calcitriol(3mcg/g)
62175389|NCT03140449|EXPERIMENTAL|Rapamycin-calcitriol combination|Rapamycin(0.1%) with Calcitriol(3mcg/g)
62551873|NCT05184452|EXPERIMENTAL|PGDM1400LS 20 mg/kg IV|Participants will receive PGDM1400LS 20 mg/kg by IV infusion at Month 0
62551874|NCT05184452|EXPERIMENTAL|PGDM1400LS 20 mg/kg SC|Participants will receive PGDM1400LS 20 mg/kg by subcutaneous (SC) infusion at Month 0
62741074|NCT06173544|ACTIVE_COMPARATOR|Standard of Care (SOC)|35 adolescents living with HIV seeking HIV care at participating clinics in Lilongwe, Malawi will be enrolled in this study arm during study recruitment. Enhanced usual care will include general training of the HIV providers and clinics about common mental disorder (CMD) identification and management, and feedback to the HIV provider of the status of their enrolled patient to allow follow-up per the clinic's standard care. Enhanced usual care will included a mental health evaluation provided by a rained study nurse; brief supportive counseling; information, education, and support on depression; and (if indicated) facilitation of referral to the clinic's psychiatric nurse or mental health clinic or to the tertiary care hospital.
62741075|NCT06173544|EXPERIMENTAL|Adapted Friendship Bench (AFB)|35 adolescents living with HIV seeking HIV care at participating clinics in Lilongwe, Malawi will be enrolled in this study arm during study recruitment. Individuals enrolled in this arm will receive 6 weekly counseling sessions per the AFB protocol.
62551875|NCT05184452|EXPERIMENTAL|PGDM1400LS 40 mg/kg IV|Participants will receive PGDM1400LS 40 mg/kg by IV infusion at Month 0
62551876|NCT05184452|EXPERIMENTAL|PGDM1400LS 40 mg/kg SC|Participants will receive PGDM1400LS 40 mg/kg by SC infusion at Month 0
62741076|NCT06173544|EXPERIMENTAL|Enhanced Friendship Bench (EFB)|35 adolescents living with HIV seeking HIV care at participating clinics in Lilongwe, Malawi will be enrolled in this study arm during study recruitment. Individuals enrolled in this arm will receive 6 weekly counseling sessions and peer support per the EFB protocol.
62741077|NCT01374347||One dose, Repeat doses|First group recives one dose Second group receives several doses
62741078|NCT01374347||One dose, several doses|15 patients will take one dose of 20 mg cialis, and will have a second brain SPECT 24 hours after cialis administration. 15 other patients (age and risk factor matched) will be prescribed 5 mg of cialis once daily for 7 days, and a second SPECT study will be performed 24 hours after the last dose.
62741079|NCT05103384||PD Virtual Reality Cohort|
62741080|NCT05999630|EXPERIMENTAL|Experimental Arm (Artificial Tears)|"Participants in this arm will receive artificial tears to be administered in the 4 days immediately following radioactive iodine therapy. The schedule of administration will be as follows:~Day 1 (day of radioactive iodine therapy): Every 15 minutes for 2 hours, then every 30 minutes for at least 4 hours or until bedtime at night Day 2: Once every 1 hour for 12 hours Day 3: Four times (approximately morning, lunch, dinner, and evening) Day 4: Two times (morning and evening)"
62741081|NCT05999630|NO_INTERVENTION|No Intervention (No Artificial Tears)|Participants in this arm will not administer artificial tears in the 4 days immediately following radioactive iodine therapy.
62551877|NCT05184452|EXPERIMENTAL|PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg IV|Participants will receive PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg by IV infusion sequentially in this order at Month 0 and Month 4
62551878|NCT05184452|EXPERIMENTAL|PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg SC|Participants will receive PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg by SC infusion sequentially in this order at Month 0 and Month 4
62741082|NCT03300024|ACTIVE_COMPARATOR|Expanded polytetrafluoroethylene (ePTFE)|The ePTFE grafts used are the Flixene (Maquet-Atrium Medical, Hudson, NH), Advanta VXT (Maquet-Atrium), GORE-TEXStretch Vascular Graft For Vascular Access (W. L. Gore and Associates, Flagstaff, Ariz), or Venaflo (Bard Peripheral Vascular, Tempe, Ariz). The choice of graft used is at the surgeons' discretion. The graft it is offered in both large and small diameters, as well as thin-wall and rapidly-tapering designs for cases where arterial steal syndrome is a potential complication. A 6 mm graft featuring external supporting rings in 5 cm centered or 7 cm offset sections enables tight loop configurations and crossing the cubitus. A 4-7 mm tapered graft with 10 or 15 cm of removable rings allows for tailoring or exact placement of the ringed section.
62741083|NCT03300024|EXPERIMENTAL|Bovine carotid Artery Graft|The bovine carotid artery biological grafts (Artegraft®; Artegraft, Inc., North Brunswick, NJ) consist of a biological fibrous matrix processed to enhance long-term patency and provide a tightly woven, cross-linked conduit that is flexible and compliant.
62741084|NCT03361657||One sample|Laparoscopic surgeries will be performed according to the standard surgical and anesthesia protocols. Pneumo-peritoneum will be achieved using non-heated non-humidified CO2 with the intra-abdominal pressure (IAP) maintained at 10-12mmHg
62741085|NCT02293252|EXPERIMENTAL|Interventional group|Remote patient monitoring system (Motiva)
62741086|NCT02293252|NO_INTERVENTION|Control group|Best medical treatment according to the guidelines of the European Society of Cardiology (ESC)
62741087|NCT05809544|EXPERIMENTAL|WELT-IP|Eligible subjects were able to access WELT-IP (an investigational digital therapeutic) on a mobile device (iOS and Android) as scheduled to receive CBT-I.
62741088|NCT05809544|SHAM_COMPARATOR|Sham|Eligible subjects were able to access a sham app downloaded on a mobile device (iOS and Android) which included sleep diary and general content regarding sleep.
61997477|NCT03119415|EXPERIMENTAL|Cooperative Learning|Teachers in intervention schools are training in cooperative learning (CL).
62551879|NCT05184452|EXPERIMENTAL|PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram IV|Participants will receive PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram by IV infusion sequentially in this order at Month 0 and Month 4
62551880|NCT05184452|EXPERIMENTAL|PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram SC|Participants will receive PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram by SC infusion sequentially in this order at Month 0 and Month 4
62551881|NCT05184452|EXPERIMENTAL|PGDM1400LS 40mg/kg + VRC07-523LS 40mg/kg + PGT121.414.LS 40 mg/kg IV|Participants will receive PGDM1400LS 40mg/kg + VRC07-523LS 40mg/kg + PGT121.414.LS 40 mg/kg by IV infusion sequentially in this order at Month 0 and Month 4
62551882|NCT01396512|EXPERIMENTAL|IMOJEV™ Vaccine Group|Participants will receive a single dose of the Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV™) on Day 0.
62551883|NCT01396512|ACTIVE_COMPARATOR|CD.JEVAX ™ Vaccine Group|Participants will receive a single dose of the Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine), CD.JEVAX™ on Day 0
62551884|NCT03029728||Participants with Hereditary Angioedema|Participants diagnosed with Hereditary Angioedema disease aged between 2 months and 60 years
62741089|NCT03397745|OTHER|BIS group|Patients who received the esophageal surgery
62741090|NCT05025397|EXPERIMENTAL|Cohort A1: Danavorexton Low Dose|Danavorexton low dose or danavorexton placebo-matching infusion, once, intravenously on Day 1 in healthy adult participants with intravenous propofol as induction anesthetic and inhaled sevoflurane as the primary maintenance anesthetic.
62551885|NCT06371625|ACTIVE_COMPARATOR|Transeversus Thoracic Plane Block (TTPB) [Group A]:|block performed in a supine position before general anesthesia. Linear probe of the ultrasound system will be attached at sagittal plane to the sternum and counted from T2 near the clavicle to T5. Then the linear probe will be rotated by 90° and attached between the forth and the fifth costal cartilages connecting at the sternum near nipple. Then, the transversus thoracic muscle and the internal intercostal muscle will be identified.
62551886|NCT06371625|ACTIVE_COMPARATOR|Pectoral Nerves (PECS) Block [Both Groups] :|Positioned supine with the ipsilateral arm abducted and externally rotated. The infra-clavicular and axillary regions will be cleaned with chlorhexidine. The probe will be positioned under the lateral third of the clavicle. After locating the subclavian artery, the axillary artery and the axillary vein we will move the probe distally towards the axilla, until the pectorals major muscle is identified. We will start counting the ribs, from 1st rib under the axillary artery and maintaining the pectorals major as a reference, we will move distally and laterally until the lateral border of pectorals major is reached. Serratus anterior muscle cover 2nd, 3rd, 4th rib, this point being the entrance into the anterior axillary line we will use atraumatic needle with extension line and electrode for nerve stimulator (Stimuplex D).
62551887|NCT05467787|EXPERIMENTAL|Message-based psychotherapy (MBP)|
62741091|NCT05025397|EXPERIMENTAL|Cohort A2: Danavorexton Middle Dose|Danavorexton middle dose or danavorexton placebo-matching infusion, once, intravenously on Day 1 in healthy adult participants with intravenous propofol as induction anesthetic and inhaled sevoflurane as the primary maintenance anesthetic.
62741092|NCT05025397|EXPERIMENTAL|Cohort A3: Danavorexton High Dose|Danavorexton high dose or danavorexton placebo-matching infusion, single, intravenously on Day 1 in healthy adult participants with intravenous propofol as induction anesthetic and inhaled sevoflurane as the primary maintenance anesthetic.
62741093|NCT05025397|EXPERIMENTAL|Cohort P: Danavorexton TBD|"Danavorexton dose to be decided (TBD) or danavorexton placebo-matching infusion, once, intravenously on Day 1 in healthy adult participants with intravenous propofol as induction and primary maintenance anesthetic.~Dose of danavorexton will be based on the review of observed safety and tolerability data and pharmacokinetic (PK) data of previous cohorts."
62741094|NCT00868088|ACTIVE_COMPARATOR|ALA + PDT|Topical ALA will be applied to the entire lip surface and allowed to incubate for 60 minutes plus or minus 30 minutes. Blue light at a wavelength of 405-420 nm will be used for treatment at a dose of 1000 seconds.
62741095|NCT00868088|PLACEBO_COMPARATOR|placebo + PDT|Topical placebo will be applied to the entire lip surface and allowed to incubate for 60 minutes plus or minus 30 minutes. Blue light at a wavelength of 405-420 nm will be used for treatment at a dose of 1000 seconds.
62741096|NCT03203824|EXPERIMENTAL|dark chocolate|Three EEG measurements will be recorded: 1) at baseline, 2) during visualization of rest for one minute, and 3) during visualization of usual vigorous exercise for one minute. Measurements 2 and 3 will be recorded savoring dark chocolate and after fully ingesting the dark chocolate respectively.
62741097|NCT03203824|ACTIVE_COMPARATOR|non dark chocolate|three EEG measurements will be recorded: 1) at baseline, 2) during visualization of rest for one minute, and 3) during visualization of usual vigorous exercise for one minute.
62741098|NCT02780583|PLACEBO_COMPARATOR|placebo|methylprednisolone intravenously, placebo shots every 6 hours
62741099|NCT02780583|EXPERIMENTAL|anakinra (Kineret)|methylprednisolone intravenously, anakinra shots every 6 hours
62741100|NCT03987139|OTHER|All patients|Patients included in the study.
62551888|NCT05467787|EXPERIMENTAL|Video-chat psychotherapy (VCP)|
62551889|NCT00561119|NO_INTERVENTION|Arm 1|Observation after 6 cycles of gemcitabine plus paclitaxel till progression
62741101|NCT03935789|EXPERIMENTAL|BLAST|All participants in this study will be assigned to this group to participate in the BLAST intervention. The intervention will be a self-guided web-based platform using a self-management model to help support better engagement in everyday life activity
62741102|NCT04142424|EXPERIMENTAL|Cohort 1 healthy subjects: AZD2693 Dose 1|Subjects will receive a subcutaneous (SC) injection of single dose 1 of AZD2693 or placebo matched to AZD2693 on Day 1.
62741103|NCT04142424|EXPERIMENTAL|Cohort 2 healthy subjects: AZD2693 Dose 2|Subjects will receive a SC injection of single dose 2 of AZD2693 or placebo matched to AZD2693 on Day 1.
62741104|NCT04142424|EXPERIMENTAL|Cohort 3 healthy subjects: AZD2693 Dose 3|Subjects will receive a SC injection of single dose 3 of AZD2693 or placebo matched to AZD2693 on Day 1.
62741105|NCT04142424|EXPERIMENTAL|Cohort 4 healthy subjects: AZD2693 Dose 4|Subjects will receive a SC injection of single dose 4 of AZD2693 or placebo matched to AZD2693 on Day 1.
62741106|NCT04142424|EXPERIMENTAL|Cohort 5 healthy subjects: AZD2693 Dose 5|Subjects will receive a SC injection of single dose 5 of AZD2693 or placebo matched to AZD2693 on Day 1.
62741107|NCT04142424|EXPERIMENTAL|Cohort 6 healthy subjects: AZD2693 Dose 6|Subjects will receive a SC injection of single dose 6 of AZD2693 or placebo matched to AZD2693 on Day 1.
62741108|NCT04142424|EXPERIMENTAL|Cohort 7 healthy Japanese subjects: AZD2693 Dose 7|Subjects will receive a SC injection of single dose 7 of AZD2693 or placebo matched to AZD2693 on Day 1.
62741109|NCT04142424|EXPERIMENTAL|Cohort 8 healthy Japanese subjects: AZD2693 Dose 8|Subjects will receive a SC injection of single dose 8 of AZD2693 or placebo matched to AZD2693 on Day 1.
62741110|NCT04142424|EXPERIMENTAL|Cohort 9 healthy Chinese subjects: AZD2693 Dose 9|Subjects will receive a SC injection of single dose 9 of AZD2693 or placebo matched to AZD2693 on Day 1.
62551890|NCT00561119|EXPERIMENTAL|Arm 2|Maintenance chemotherapy with gemcitabine plus paclitaxel after 6 cycles of gemcitabine plus paclitaxel till progression
62551891|NCT03181412||Patients with suspected ischemic stroke|The cohort will be constituted of patients treated for a stroke suspicion after calling emergency medical services of the Rhone and presenting a symptom-onset (the last time the patient was seen without deficit) less than 6 hours.
62551892|NCT01187056|EXPERIMENTAL|Training, decision making|General practitioners receive training in shared decision-making and risk communication, and use their newly acquired skills in real-life consultations with 7 patients with high cholesterol.
62741111|NCT06661447|ACTIVE_COMPARATOR|Autogenous Onlay bone graft|All patients will be submitted under a Onlay bone graft Technique with autogenous block bones is perform in one of the two Bilateral Mandibular Posterior Edentulous areas. The inner space is filled with a mixture of autogenous and xenogeneic particulated bone
62741112|NCT06661447|EXPERIMENTAL|Xenogeneic Onlay bone graft|In 20 patients, A xenogeneic onlay bone graft is positioned in the remaining mandibular posterior edentulous area. The inner space is filled with a mixture of autogenous and xenogeneic particulated bone
62741113|NCT06661447|EXPERIMENTAL|Allogenic Onlay bone graft|In 20 patients, A allogenic onlay bone graft is positioned in the remaining mandibular posterior edentulous area. The inner space is filled with a mixture of autogenous and xenogeneic particulated bone
62741114|NCT03834610|ACTIVE_COMPARATOR|Group A|receive L-arginine 5 g oral caps daily for 8 weeks serum testosterone level measurement penile doppler
62741115|NCT03834610|ACTIVE_COMPARATOR|Group B|receive tadalafil 10 mg oral tablets daily for 8 weeks serum testosterone level measurement penile doppler
62741116|NCT03834610|ACTIVE_COMPARATOR|Group C|receive L-arginine 5 g oral caps plus tadalafil 10 mg oral tablets daily for 8 weeks serum testosterone level measurement penile doppler
62741117|NCT03834610|PLACEBO_COMPARATOR|Group D|receive oral methyl cellulose daily for 8 weeks serum testosterone level measurement penile doppler
62741118|NCT03010774|EXPERIMENTAL|Intervention - Risk Stratification|Study participants will be risk stratified according to the eCART scoring algorithm each night. If they are stratified as low risk, they will not receive routine nighttime spot-check vital signs unless indicated by a change in patient status or monitor alarm.
62741119|NCT03010774|ACTIVE_COMPARATOR|Control - Usual Care|Study participants will be woken at night for routine nighttime spot-check vital signs regardless of patient disease severity or risk.
62741120|NCT05878678|ACTIVE_COMPARATOR|Fixed positions of arm up|Patients will receive particle radiotherapy in arm up position. Radiation: adjuvant hypofractionated intensity-modulated proton radiotherapy; For patients received modified radical mastectomy, Clinical Target Volume (CTV) 1: chest wall ± regional lymph drainage area, 40.05Gy (RBE) in 15 fractions with proton radiotherapy; For patients received lumpectomy, CTV1: whole breast ± regional lymph drainage area, 40.05 Gy (RBE) in 15 fractions with proton radiotherapy; CTVtb: tumor bed SIB（simultaneous integrated boost） to 48 Gy (RBE) in 15 fractions with proton radiotherapy.
62741121|NCT05878678|EXPERIMENTAL|Fixed positions of arm down|Patients will receive particle radiotherapy in arm down position. Radiation: adjuvant hypofractionated intensity-modulated proton radiotherapy; For patients received modified radical mastectomy, CTV1: chest wall ± regional lymph drainage area, 40.05Gy (RBE) in 15 fractions with proton radiotherapy; For patients received lumpectomy, CTV1: whole breast ± regional lymph drainage area, 40.05 Gy (RBE) in 15 fractions with proton radiotherapy; CTVtb: tumor bed SIB to 48 Gy (RBE) in 15 fractions with proton radiotherapy.
62741122|NCT00582270||1|Follicular Lymphoma
62741123|NCT00582270||2|Non-follicular Lymphoma
62741124|NCT06661239|EXPERIMENTAL|The benson group|Patients who received the intervention
62741125|NCT06661239|PLACEBO_COMPARATOR|Control group|Patients who receive routine care in units
62741126|NCT03263910|EXPERIMENTAL|NPO-11|
62741127|NCT03263910|PLACEBO_COMPARATOR|Placebo|
62741128|NCT00912834||1|tract and field athletes
62741129|NCT00912834||2|swimming athletes
62741130|NCT00912834||3|tennis athletes
62551893|NCT01187056|ACTIVE_COMPARATOR|Training, usual practice|The control group GPs will receive 2 hours of training in the primary care guideline for prevention of cardiovascular disease
62551894|NCT02644915|EXPERIMENTAL|study group|"Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion, ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)\> 6 mmHg."
62741131|NCT00912834||4|football athletes
62551895|NCT02644915|PLACEBO_COMPARATOR|control group|"100ml 0.9%%NaCl solution,but without edaravone, will be treated at 10 minutes before kidney reperfusion, ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)\> 6 mmHg."
62741132|NCT00912834||5|basketball athletes
62741133|NCT00912834||6|Badminton athletes
62741134|NCT00912834||7|control group
62741135|NCT02519478|EXPERIMENTAL|Helmetless Tackling Training (HuTT)|The HuTT program is modeled after a tackling drill progression common to the sports of rugby and American football, but participants do not wear helmets or should pads as they normally would in football. Drills will be executed at 50%-75% effort. The goal of the contact is to execute proper technique. Drills will be supervised at all times and feedback will be provided to confirm proper technique and correct improper technique. The HuTT drill will be completed in two phases and takes approximately 6-10 minutes per session. A research assistant will ensure adherence and standardization of the treatment throughout the season. Subjects in the intervention group will participate in HuTT 4 times per week throughout the 2 weeks of pre-season and 2 times a week during in-season.
62741136|NCT02519478|NO_INTERVENTION|Control|Control group subjects participate in normal football activities as they would normally have during a football season
62741137|NCT01825512|EXPERIMENTAL|Deferiprone|75-100 mg/kg/day seven days per week
61997478|NCT03119415|NO_INTERVENTION|Business as Usual|Schools continue with business as usual.
62551896|NCT00004883|EXPERIMENTAL|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Treatment continues once a week in the absence of disease progression or unacceptable toxicity.
62551897|NCT01804179|ACTIVE_COMPARATOR|Standard Intervention (SI)|"At Baseline Visit, Participants in the standard intervention (SI) condition will get: I-FOBT kit and Screen for Life brochure, a mailed reminder card at two weeks post-intervention to remind them about FOBT testing and follow up assessments at 12 months."
62741138|NCT01825512|ACTIVE_COMPARATOR|Deferasirox|20 to 40 mg/kg/day seven days per week
62741139|NCT01926899|EXPERIMENTAL|Bortezomib administration|0.7 milligrams per meter squared given on Day 0 and Day +3
62741140|NCT05097560|EXPERIMENTAL|HFNC group|"* Set FiO2 28%~* Titrate the flow of HFNC at the highest tolerated value up to 60 L/min"
62741141|NCT05097560|ACTIVE_COMPARATOR|VM group|- Keep FiO2 constant with VM and HFNC during the two trial
62551898|NCT01804179|EXPERIMENTAL|CARES Intervention|Colorectal Cancer Awareness, Research, Education and Screening (CARES). At Baseline Visit, Participants in the CARES intervention will receive: I-FOBT kit, a newly developed DVD and booklet, and a mailed reminder card at two weeks post-intervention to remind them about FOBT testing, and follow-up assessments at 12 months.
62551899|NCT05924321|EXPERIMENTAL|Carbetocin|Single IV infusion of carbetocin
62551900|NCT05924321|PLACEBO_COMPARATOR|Placebo|Single IV Infusion of matching placebo
62551901|NCT05924321|ACTIVE_COMPARATOR|Placebo and Moxifloxacin|Single IV infusion of matching placebo with a single oral dose of moxifloxacin
62551902|NCT01819870|EXPERIMENTAL|Dilatrend SR capsule 32mg|
62551903|NCT01819870|ACTIVE_COMPARATOR|Dilatrend IR tablet 25mg|
62551904|NCT01699958|EXPERIMENTAL|Problem-solving intervention|2 individual sessions teaching problem-solving skills with the use of videos, handouts, and worksheets.
62551905|NCT01699958|NO_INTERVENTION|Control: Standard Care|Control arm participants will receive standard of care from their primary care provider.
62551906|NCT04469777|EXPERIMENTAL|Systemic erythropoietin injections|20 patients diagnosed as late onset optic neuropathy that were attending Alexandria main university hospital.Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
62551907|NCT06128486|EXPERIMENTAL|Yung Sheng 55% Color Contact Lens|
62551908|NCT03021330|ACTIVE_COMPARATOR|DA Regimen|Patients receive standard DA induction regimen including daunomycin and cytarabine.
62551909|NCT03021330|EXPERIMENTAL|Intermediate Dose of DA Regimen|Patients receive DA induction regimen including daunomycin and intermediate dose of cytarabine.
62551910|NCT02556957|EXPERIMENTAL|HealthScouts Intervention|HealthScouts (CHWs) regularly visit residents and counsel them using a motivational interviewing approach, supported by a smartphone application.
62551911|NCT02556957|ACTIVE_COMPARATOR|Standard of Care|Referral by RCCS to HIV services. Free HIV clinic available in the community.
62551912|NCT00580892||Airway and Pleural Disorders|Optical Coherence Tomography imaging
62551913|NCT06361199|PLACEBO_COMPARATOR|Placebo|Placebo, qd, oral administration for 28 days
62551914|NCT06361199|EXPERIMENTAL|Proximod|Proximod Tablets, 5mg, qd, oral administration for 28 days
62551915|NCT03420911|ACTIVE_COMPARATOR|dexketoprofen trometamol group|Received the study drugs in 100 mL of normal saline within 5 minutes. The dexketoprofen trometamol dose was 50 mg
62551916|NCT03420911|ACTIVE_COMPARATOR|dexketoprofen trometamol plus midazolam group|Received the study drugs in 100 mL of normal saline within 5 minutes. The dexketoprofen trometamol dose was 50 mg and the midazolam dose was 1 mg.
62551917|NCT01648530||Participants with Migraines|Participants who returned completed internet survey with positive screening for migraines. No intervention was administered in this study.
62551918|NCT04177082|EXPERIMENTAL|Pulsed 6mW/cm2|6mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 30 minute total treatment time
62551919|NCT04177082|EXPERIMENTAL|Pulsed 4mW/cm2|4mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 45 minute total treatment time
62551920|NCT03062709|EXPERIMENTAL|All Participants|Breathe Easy Coalition written materials provided to parent/guardian, plus Maine Tobacco Helpline referral provided to smoking adult in the home, plus testing of the child's urine cotinine and results reported to parent/guardian
62551921|NCT02354729|EXPERIMENTAL|Intervention|Participants received text messages and financial incentives after successfully documenting that they were carrying their epinephrine auto-injectors, based on principles of behavioral economics.
62551922|NCT02354729|NO_INTERVENTION|Control|Participants received text messages.
62551923|NCT01649063||the shape and frequency of uterine contractions in delivery|Uterine contractions were recorded by using fetal monitoring system (Model FC1400) at the beginning of the active phase (cervical dilatation 3-4 cm) for 30 min in two groups.
62741142|NCT03756155|EXPERIMENTAL|Group 1|Group 1 will complete a protocol with 10 sets of 10 second isometric holds followed by 10 second rest intervals between sets. Each repetition will be performed as closely to the targeted 30%-40% value.
62741143|NCT03756155|EXPERIMENTAL|Group 2|Group 2 will complete a protocol with 5 sets of 20 second isometric holds followed by 20 second rest intervals between sets. Each repetition will be performed as closely to the targeted 30% value.
62741144|NCT03110978|EXPERIMENTAL|Arm I (stereotactic body radiation therapy)|Patients undergo stereotactic body radiation therapy over 1-2 weeks.
62741145|NCT03110978|EXPERIMENTAL|Arm II (stereotactic body radiation therapy, nivolumab)|Patients undergo stereotactic body radiation therapy over 1-2 weeks. Beginning within 36 hours before or after the first fraction of stereotactic body radiation therapy, patients also receive nivolumab IV over 30 minutes on day 1. Cycles with nivolumab repeat every 4 weeks for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
62741146|NCT02013557|EXPERIMENTAL|Intervention Group|Women in the intervention group will receive a test text-message reminder at the time of enrollment. They will then receive a text-reminder to schedule their oral glucose tolerance test at 6 weeks postpartum, with further reminders at 3 months and 6 months if they have not completed their testing.
62741147|NCT02013557|NO_INTERVENTION|Control group|This arm will only receive the test text-message reminder at the time of enrollment. Otherwise they will receive usual postpartum care.
62741148|NCT05849272|EXPERIMENTAL|Toludesvenlafaxine hydrochloride sustained-release tablets 80-160 mg group|orally once a day
62741149|NCT00752934|EXPERIMENTAL|group a|Baclofen followed by Placebo
62741150|NCT00752934|EXPERIMENTAL|group b|Placebo followed by Baclofen
62741151|NCT03624478|EXPERIMENTAL|Treatment (hypofractionated radiation therapy)|Participants undergo hypofractionated radiation therapy daily for 5 days, then undergo standard of care surgery 4-16 weeks after radiation therapy.
62741152|NCT05386862|NO_INTERVENTION|Naturalistic Group|This group will followed as they follow their naturalistic cannabis use.
62741153|NCT05386862|EXPERIMENTAL|THC Reduction Group|This group will be asked to reduce the THC content and increase CBD content of their cannabis products to study the effect of PTSD symptom severity.
62741154|NCT06658691|NO_INTERVENTION|Control group|Patients did not receive multidisciplinary approach
62741155|NCT06658691|EXPERIMENTAL|Intervention group|Patients received multidisciplinary approach
62741156|NCT06491823|EXPERIMENTAL|MEPs (M1) / altered auditory feedback / MEPs + retention tests at 24h|Evoked potentials will be recorded from brain area M1 (motor cortex) in combination with a speech motor learning procedure known as adaptation to altered auditory feedback. Retention of learning will be tested 24h later along with additional evoked potential recordings.
62741157|NCT06491823|EXPERIMENTAL|AEPs (A1) / altered auditory feedback / AEPs + retention tests at 24h|Evoked potentials will be recorded from brain area A1 (auditory cortex) in combination with a speech motor learning procedure known as adaptation to altered auditory feedback. Retention of learning will be tested 24h later along with additional evoked potential recordings.
62741158|NCT06491823|EXPERIMENTAL|SEPs (S1) / altered auditory feedback / SEPs + retention tests at 24h|Evoked potentials will be recorded from brain area S1 (somatosensory cortex) in combination with a speech motor learning procedure known as adaptation to altered auditory feedback. Retention of learning will be tested 24h later along with additional evoked potential recordings.
62741159|NCT06491823|EXPERIMENTAL|MEPs (M1) / unaltered auditory feedback / MEPs + retention tests at 24h|Evoked potentials will be recorded from brain area M1 (motor cortex) in combination with unaltered auditory feedback. Retention of learning will be tested 24h later along with additional evoked potential recordings.
62741160|NCT06491823|EXPERIMENTAL|AEPs (A1) / unaltered auditory feedback / AEPs + retention tests at 24h|Evoked potentials will be recorded from brain area A1 (auditory cortex) in combination with unaltered auditory feedback. Retention of learning will be tested 24h later along with additional evoked potential recordings.
62741161|NCT06491823|EXPERIMENTAL|SEPs (S1) / unaltered auditory feedback / SEPs + retention tests at 24h|Evoked potentials will be recorded from brain area S1 (somatosensory cortex) in combination with unaltered auditory feedback. Retention of learning will be tested 24h later along with additional evoked potential recordings.
62741162|NCT05561595|EXPERIMENTAL|Healing HEARTS Intervention|The Healing Health-Related Stigma (Healing HEARTS) intervention will provide group telehealth sessions adapted from prior disease-specific interventions for internalized stigma and from standard techniques and structures used in evidence-based cognitive-behavioral therapies. Fifty-minute sessions will be delivered weekly for 12 weeks, followed by 2 every-other-week and 2 monthly sessions. Groups will consist of 8-10 participants and will be led by a doctoral- or masters-level clinician in clinical or counseling psychology or social work. Handouts and homework assignments will be used as part of the group meetings. All group sessions will be conducted remotely using telehealth technology.
62741163|NCT05561595|ACTIVE_COMPARATOR|Peer Support|The peer support condition will provide group telehealth sessions without any tailored stigma content. Group sessions will be 50 minutes and will meet weekly for 12 weeks, followed by 2 every-other-week and 2 monthly sessions. Groups will consist of 8-10 participants and will be led by a doctoral- or masters-level clinician in clinical or counseling psychology or social work. All group sessions will be conducted remotely using telehealth technology.
62741164|NCT05561595|NO_INTERVENTION|Waitlist Control|The waitlist control group will not receive any active intervention until after completing week 12 and week 26 assessments. Participants will receive periodical updates and reminders from study staff to enhance retention. After assessments are completed, participants will be provided with 12 weeks of the Healing HEARTS intervention.
62741165|NCT01935323|EXPERIMENTAL|High Intensity Interval Training|Participants will perform the HIIT protocol on an electronically-braked cycle ergometer (Quinton Excalibur, Quinton Instrument Company, Bothell, WA). Participants will perform a 20-minute protocol, consisting of four minutes of cycling at 15% of maximum anaerobic power (Max-AP) followed by 30 seconds at 85% of Max-AP. These workloads will be based upon pre-trial Wingate tests. This cycle was repeated four times within each protocol, ending with two minutes at 15% of Max-AP. This will be performed 3d/wk for 6wks, with at least 24 hrs between each session.
62551924|NCT01649063||the shape and frequency of uterine contractions in cesarean|Uterine contractions were recorded by using fetal monitoring system (Model FC1400) at the beginning of the active phase (cervical dilatation 3-4 cm) for 30 min in two groups.
62551925|NCT01749202|PLACEBO_COMPARATOR|Negative Control|
62741166|NCT01935323|ACTIVE_COMPARATOR|Moderate Intensity Training|Participants will perform 45-60 min (graduated over time to 60) of continuous cycling at 65% of VO¬2peak on a Monark cycle ergometer. Workload will be based upon pre-trial VO¬2peak testing. MIT exercise will be performed 5d/wk for 6wks.
62175390|NCT01580007|ACTIVE_COMPARATOR|Active Sodium Phenylbutyrate and active cholecalciferol|500 mg sodium phenylbutyrate (4-phenylbutyric acid, sodium salt) in tablet form twice daily and 5000 IU of cholecalciferol once daily will be given orally for 2 months
62175391|NCT01580007|ACTIVE_COMPARATOR|Placebo Sodium Phenylbutyrate plus active cholecalciferol|Drug: Cholecalciferol Placebo: Sodium Phenylbutyrate
62175392|NCT01580007|ACTIVE_COMPARATOR|Active Sodium Phenylbutyrate and placebo cholecalciferol|Drug: Sodium Phenylbutyrate Placebo: cholecalciferol
62175393|NCT01580007|PLACEBO_COMPARATOR|Placebo Sodium Phenylbutyrate plus placebo cholecalciferol|Placebo Sodium Phenylbutyrate Placebo cholecalciferol
62741167|NCT05577000|EXPERIMENTAL|Dose Escalation (150 x 10^6 CAR + T cells/ infusion)|Participants will undergo apheresis with collection of autologous peripheral blood mononuclear cells that will be used to generate CAR-T cells. After successful generation of the anti-BCMA CAR-T cells, participants will undergo lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by 2-5 days of rest. A single infusion of anti-BCMA CAR-T cells at the starting dose of 150 x 10\^6 flat dose will then be given on Day 1.
62551926|NCT01749202|ACTIVE_COMPARATOR|Positive Control|
62551927|NCT01749202|EXPERIMENTAL|Active|
62551928|NCT06583161||Moderate drinkers|Participants who report drinking up to 16 grams of alcohol daily or almost daily on a repeated assessment center visit, or who report drinking 8-16 grams of alcohol 4 or more times per week on the web-based mental health questionnaire.
62175394|NCT05207631|NO_INTERVENTION|Control cohort|Participants in the control cohort received standard care.
62551929|NCT06583161||Quitters|Participants who report not drinking alcohol on a repeated assessment center visit or in the web-based mental health questionnaire.
62551930|NCT06583161||Social drinkers|Participants who report drinking up to 16 grams of alcohol 1-2 days per week or drinking 1-3 times per month or only on special occasions on a repeated assessment center visit, or who report drinking 8-16 grams of alcohol 2-3 times per week or drinking 4 times per month or less in the web-based mental health questionnaire.
62551931|NCT06583161||Heavy/binge drinkers|Participants who report drinking more than 16 grams of alcohol daily or almost daily or drinking more than 40 grams of alcohol 1-2 days per week on a repeated assessment center visit, or who report drinking 24 grams of alcohol or more 4 or more times per week or 40 grams of alcohol or more 2-3 times per week on the web-based mental health questionnaire.
62741168|NCT05577000|EXPERIMENTAL|Dose Escalation (450 x 10^6 CAR + T cells/ infusion)|Participants will undergo apheresis with collection of autologous peripheral blood mononuclear cells that will be used to generate CAR-T cells. After successful generation of the anti-BCMA CAR-T cells, and no dose limiting toxicities were reported for the previous dose level, participants will undergo lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by 2-5 days of rest. A single infusion of anti-BCMA CAR-T cells at the next highest dose of 450 x 10\^6 flat dose will then be given on Day 1.
62741169|NCT05577000|EXPERIMENTAL|Dose Escalation (600 x 10^6 CAR + T cells/ infusion)|Participants will undergo apheresis with collection of autologous peripheral blood mononuclear cells that will be used to generate CAR-T cells. After successful generation of the anti-BCMA CAR-T cells, and no dose limiting toxicities were reported for the previous dose level, participants will undergo lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by 2-5 days of rest. A single infusion of anti-BCMA CAR-T cells at the next highest dose of 600 x 10\^6 flat dose will then be given on Day 1.
62175395|NCT05207631|ACTIVE_COMPARATOR|Cohort with intervention|Participants included in the intervention cohort receive a systematic and standardised assessment of their inhaler on admission to our department. Their inhalers are adapted in accordance with a prescribing guide.
62741170|NCT05577000|EXPERIMENTAL|Dose Expansion: Maximum Tolerated Dose (MTD)|Participants will undergo apheresis with collection of autologous peripheral blood mononuclear cells that will be used to generate CAR-T cells. After successful generation of the anti-BCMA CAR-T cells, and no dose limiting toxicities were reported for the previous dose level, participants will undergo lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by 2-5 days of rest. A single infusion of anti-BCMA CAR-T cells at the MTD will then be given on Day 1.
62741171|NCT03669757|EXPERIMENTAL|LEO 134310 Dose A|Once daily application
62741172|NCT03669757|EXPERIMENTAL|LEO 134310 Dose B|Once daily application
62551932|NCT05584189|EXPERIMENTAL|At least 30 persons 14-65+ years of age who test themselves|Participants between the ages of 14-65+ years will perform candidate Ag self-test kit anterior nasal specimen collection and testing under the supervision of qualified site personnel in person.
62551933|NCT05584189|EXPERIMENTAL|At least 30 persons 18-65+ years of age who test another participant|Participants between the ages of 18-65+ years will perform candidate Ag self-test kit anterior nasal specimen collection on another participant aged 2-65+ years and testing of the candidate Ag self-test kit under the supervision of qualified site personnel in person.
62741173|NCT03669757|EXPERIMENTAL|LEO 134310 Dose C|Once daily application
62741174|NCT03669757|EXPERIMENTAL|LEO 134310 Dose D|Once daily application
62175396|NCT03795402||Group A|Three microneedle device samples will be collected from a psoriasis lesion and from nonlesional (healthy) skin on Day 1. Two skin biopsies of 4 millimeter (mm) will be performed on Day 1. No investigational drug product will be administered during this study.
62551934|NCT00635310|ACTIVE_COMPARATOR|HD patients with CHC or CHB|Chronic hepatitis C (CHC) or chronic hepatitis B (CHB) patients with hemodialysis (HD), pretreated with DDAVP 0.3 ug/kg body weight infusion 30-60 minutes before percutaneous liver biopsies (PLBs)
62741175|NCT03669757|PLACEBO_COMPARATOR|LEO 134310 vehicle|Once daily application
62175397|NCT03795402||Group B|One microneedle device sample will be collected from a psoriasis lesion and from nonlesional (healthy) skin on Day 1 and at Weeks 2 and 4. Two skin biopsies of 4 mm will be performed on Day 1. No investigational drug product will be administered during this study.
62175398|NCT04048798|ACTIVE_COMPARATOR|Oxygen therapy via HFNC|Patients who will be applied high frequency nasal cannula before and after surgery
62175399|NCT04048798|ACTIVE_COMPARATOR|Oxygen therapy via face mask|Patients who will be applied O2 via face mask before and after surgery
62175400|NCT00853021|EXPERIMENTAL|Bevacizumab and Aldesleukin|
62551935|NCT00635310|ACTIVE_COMPARATOR|Ordinary patients with CHC or CHB|Chronic hepatitis C (CHC) or chronic hepatitis B (CHB) patients with normal renal function (NRF) receiving percutaneous liver biopsies (PLBs)
62551936|NCT01395446||prolonged neutropenic patients|patients that will undergo treatment for a hematological malignancy expected to result in grade 4 neutropenia of prolonged duration
62551937|NCT00676260|EXPERIMENTAL|Pioglitazone QD|
62551938|NCT00676260|PLACEBO_COMPARATOR|Placebo QD|
62551939|NCT04319354|EXPERIMENTAL|pCR|
62551940|NCT04319354|EXPERIMENTAL|Partial responders|
62551941|NCT04319354|ACTIVE_COMPARATOR|Non-responders|
62551942|NCT06009276||Heart Failure|Patients diagnosed with Heart Failure (HFrEF and HFpEF). Oral microbiome will be analyzed through tongue swabs, saliva samples, and a saliva rinse. Patients will undergo a maximal exercise test, blood draws, and vascular testing. Patients will have the option to participate in a supplementation assessment with concentrated beetroot juice.
62551943|NCT06009276||Peripheral Artery Disease|Patients diagnosed with Peripheral Artery Disease (PAD). Oral microbiome will be analyzed through tongue swabs, saliva samples, and a saliva rinse. Patients will undergo a maximal exercise test, blood draws, and vascular testing. Patients will have the option to participate in a supplementation assessment with concentrated beetroot juice.
62551944|NCT06009276||Healthy Controls|Individuals that are not diagnosed with cardiovascular disease. Oral microbiome will be analyzed through tongue swabs, saliva samples, and a saliva rinse. Patients will undergo a maximal exercise test, blood draws, and vascular testing. Patients will have the option to participate in a supplementation assessment with concentrated beetroot juice.
62551945|NCT00814476|ACTIVE_COMPARATOR|2|Regular treated group in the first segment and CareLink treated group in the second segment
62741176|NCT03669757|ACTIVE_COMPARATOR|0.1% betamethasone valerate ointment (class III steroid)|Once daily application
62741177|NCT05295121|EXPERIMENTAL|XC221, fasted|Administration of XC221 in fasted state in Dosing Periods 1 and 2 followed by administration of XC221 in fasted state in Dosing Period 3
62741178|NCT05295121|EXPERIMENTAL|XC221, fed|Administration of XC221 in fed state in Dosing Periods 1 and 2 followed by administration of XC221 in fasted state in Dosing Period 3
62551946|NCT00814476|EXPERIMENTAL|1. CareLink team supported group|CareLink team supported group
62175401|NCT05965960|ACTIVE_COMPARATOR|Active Low Intensity Transcranial Focused Ultrasound|NeuroFUS device stimulation with 4 channel transducer Stimulation target = M1/GPi Stimulation parameters = Theta burst protocol and 30 Watts
62175402|NCT05965960|SHAM_COMPARATOR|Sham Low Intensity Transcranial Focused Ultrasound|NeuroFUS device stimulation with 4 channel transducer Stimulation target = M1/GPi Stimulation parameters = Theta burst protocol and 0 Watts
62175403|NCT05336136|EXPERIMENTAL|Custom mask|Custom mask based on 3D facial photograph for administration of non-invasive ventilation
62175404|NCT05336136|ACTIVE_COMPARATOR|Current commercial mask|Current commercial mask used by the participant for administration of non-invasive ventilation
62175405|NCT03974451|EXPERIMENTAL|IOL implantation experimental|Implantation of the PhysIOL FineVision POD F® IOL
62175406|NCT03974451|ACTIVE_COMPARATOR|IOL implantation active comparator|Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL.
62175407|NCT02763150|EXPERIMENTAL|Lifestyle Intervention|Intervention group will receive a comprehensive, multicomponent weight loss intervention targeting diet, physical activity, and behavioral strategies.
62175408|NCT02763150|ACTIVE_COMPARATOR|Health Promotion|Health promotion group will receive education on healthy eating and activity before pregnancy.
62175409|NCT02969629|EXPERIMENTAL|apomorphine|1.5 mg apomorphine, administered subcutaneously
62175410|NCT02969629|PLACEBO_COMPARATOR|Normal saline|saline, administered subcutaneously
62175411|NCT04702399|EXPERIMENTAL|GEL GROUP|Intracavitary application of an anti-adhesion hyaluronic acid gel (HYALOBARRIER® GEL ENDO)
62175412|NCT04702399|NO_INTERVENTION|CONTROL GROUP|No Intervention
62175413|NCT06392919|NO_INTERVENTION|Sham repetitive transcranial magnetic stimulation (rTMS group)|After the surgical anesthesia, the patient is transferred to the Post-Anesthesia Care Unit (PACU). The Sham rTMS intervention occurs after the tracheal tube is removed in the PACU.In the sham rTMS group, the setup, including the stimulation site and parameters, is identical to that of the rTMS group. However, although the rTMS device is connected to the patient, no actual stimulation is delivered.
62175414|NCT06392919|EXPERIMENTAL|repetitive transcranial magnetic stimulation (rTMS group)|After the surgical anesthesia, the patient is transferred to the Post-Anesthesia Care Unit (PACU). The rTMS intervention occurs after the tracheal tube is removed in the PACU. The stimulation site is the DLPFC (left dorsolateral prefrontal cortex); the stimulation intensity is 100% of the Resting Motor Threshold (RMT); the frequency is 10 Hz; and the total number of pulses is 2000. The pulse characteristics include a duration of 5 seconds per session with a 25-second interval between sessions.
62175415|NCT01001130||fluticasone furoate group|Korean patients administered fluticasone furoate according to the Prescription information
62741179|NCT06661512||Patients with Acquired Brain Injury|Any patient who begins neurorehabilitation treatment at the Institut Guttmann Neurorehabilitation Hospital (Badalona) during the recruitment period will be considered a candidate for the study. The inclusion and exclusion criteria will then be checked, and those who meet the criteria will be offered participation in the study.
62741180|NCT01887561|NO_INTERVENTION|treatment|
62741181|NCT02540187||haemophilia A|"1. Blood specimen for measuring :~   * Free TFPI and TFPI activity levels~  * Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)~  * Thrombin generation assay (TGA) in fresh PRP and frozen PPP~2. Hemorrhage score for each patient"
62551947|NCT02324582|EXPERIMENTAL|Intravenous MK-3475/ Intravesical BCG|3 subjects will be treated at a dose of 100 mg MK-3475 at 100 mg every 3 weeks (Q3W) intravenously (IV) for 6 doses and 1 vial intravesicular BCG suspended in 50 ml preservative-free saline once per week of 6 weekly doses 12 subjects will be treated at a dose of 200 mg MK-3475 at 100 mg every 3 weeks (Q3W) intravenously (IV) for 6 doses and 1 vial intravesicular BCG suspended in 50 ml preservative-free saline once per week of 6 weekly doses
62551948|NCT02562573|EXPERIMENTAL|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once a day.
62175416|NCT02007759|EXPERIMENTAL|VitalStim|This group will be assigned to the active VitalStim unit.
62175417|NCT02007759|SHAM_COMPARATOR|Sham VitalStim|This group will be assigned to the sham VitalStim unit.
62175418|NCT06047613|EXPERIMENTAL|Suicide attempters|Currently depressed patients with a suicide attempt within the 8 last days (with a maximal lifetime number of 3 previous suicide attempt including the most recent );
62175419|NCT06047613|ACTIVE_COMPARATOR|Affective controls|Currently depressed patients without any lifetime history of suicide attempt
62175420|NCT06047613|ACTIVE_COMPARATOR|Healthy controls|Participants with no lifetime history of psychiatric disorders
62175421|NCT01209286|EXPERIMENTAL|Blinatumomab 15 μg|Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.
62551949|NCT03792022||Group 1|Adherence to timely vaccine uptake
62551950|NCT05494073|EXPERIMENTAL|Hybrid Remnant Repair|Patients in this arm will have an ACL reconstruction with preservation and incorporation of the the ACL remnant.
62551951|NCT05494073|ACTIVE_COMPARATOR|Control|Patients in this arm will have a ACL reconstruction where the ACL remnant is not incorporated into the graft.
62551952|NCT03938909||Patients with Multiple Sclerosis|200 patients and 200 control
62551953|NCT03938909||Patients with dementia|100 patients and 100 control
61997479|NCT00006095|EXPERIMENTAL|Vincristine Sulfate 1.5 mg/m2/wk and Irinotecan|
62175422|NCT01209286|EXPERIMENTAL|Blinatumomab 5/15 μg|Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, followed by 15 μg/m²/day starting from Week 2 of treatment.
62175423|NCT01209286|EXPERIMENTAL|Blinatumomab 5/15/30 μg|Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, a dose of 15 μg/m²/day in the subsequent 7 days, followed by 30 μg/m²/day starting from Week 3 of treatment.
62175424|NCT01090700|EXPERIMENTAL|001|TMC435 TMC435 150 mg daily for 7 days
62741182|NCT02540187||Haemophilia B|"1. Blood specimen for measuring :~   * Free TFPI and TFPI activity levels~  * Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)~  * Thrombin generation assay (TGA) in fresh PRP and frozen PPP~2. Hemorrhage score for each patient"
62551954|NCT03938909||Patients with Parkinson's disease|50 patients and 50 control
62551955|NCT04641104|EXPERIMENTAL|Thiamine|Patients in this arm will receive a solution of 500 mg of Thiamine Hydrocloride in a solution of 100 ml of NaCl 0.9%.
62551956|NCT04641104|PLACEBO_COMPARATOR|Placebo|Patients in this arm will receive a solution of 100 ml of NaCl 0.9% alone.
62551957|NCT06581484|EXPERIMENTAL|Intervention|This is a digital (web and mobile-based) multicomponent patient engagement behavioral intervention. The intervention components include digital medical passport, health-specific updated information, credible resources, connections with the community, peer- and expert support and guidance, among others
62175425|NCT01090700|OTHER|002|Escitalopram Escitalopram 10 mg daily for 7 days
62175426|NCT01090700|EXPERIMENTAL|003|TMC435 + Escitalopram TMC435 150 mg + escitalopram 10 mg daily for 7 days
62175427|NCT03579433|EXPERIMENTAL|ORA with VerifEye+|First surgical eye randomly assigned to Acrysof® IQ Toric IOL and ORA with VerifEye+ or Acrysof® IQ Toric IOL and Barrett Toric Calculator, with the second surgical eye (fellow eye) assigned to the alternative group.
62175428|NCT03579433|ACTIVE_COMPARATOR|Barrett Toric Calculator|First surgical eye randomly assigned to Acrysof® IQ Toric IOL and ORA with VerifEye+ or Acrysof® IQ Toric IOL and Barrett Toric Calculator, with the second surgical eye (fellow eye) assigned to the alternative group.
62175429|NCT00877747||PET2 negative|Patients with negative early interim PET after 2 courses of ABVD who continued therapy with ABVD
62175430|NCT00877747||PET2 positive|Patients with positive early interim PET after 2 courses of ABVD who changed their therapy to BEACOPP
62175431|NCT05169814|PLACEBO_COMPARATOR|Acute Wounds - Control|This arm will include patients with acute wounds and will receive standard of care: irrigation with normal saline.
62175432|NCT05169814|EXPERIMENTAL|Acute Wounds - Experimental|This arm will include patients with acute wounds and will receive experimental treatment: irrigation with micro/nanobubbles (MNB's) in normal saline.
62175433|NCT05169814|PLACEBO_COMPARATOR|Chronic Wounds - Control|This arm will include patients with chronic wounds and will receive standard of care: negative pressure wound therapy with instillation (NPWTi) using normal saline.
62175434|NCT05169814|EXPERIMENTAL|Chronic Wounds - Experimental|This arm will include patients with chronic wounds and will receive experimental treatment: negative pressure wound therapy with instillation (NPWTi) using micro/nanobubbles (MNB's) in normal saline.
62175435|NCT01747629|PLACEBO_COMPARATOR|Placebo MDPI|Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
62175436|NCT01747629|EXPERIMENTAL|Albuterol MDPI|Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.
62175437|NCT05188872|EXPERIMENTAL|68Ga-Pentixafor|Each subject receive a single intravenous injection of 68Ga-Pentixafor, and undergo PET/CT imaging within the specificed time
62175438|NCT03330717|PLACEBO_COMPARATOR|General anesthesia|Patients will undergo oncologic breast surgery on general anesthesia.
62175439|NCT03330717|EXPERIMENTAL|Hypnosis sedation|Patients will undergo oncologic breast surgery on hypnosis sedation.
62175440|NCT03330717|EXPERIMENTAL|General anesthesia with preoperative session of hypnosis|Patients interested in hypnosis but too anxious to have surgery while on hypnosis sedation will undergo surgery on general anesthesia but will have a preoperative session of hypnosis relaxation using technology of virtual reality
62551958|NCT04450758||resection|Patients who present with obstruction due to colon cancer with a need for urgent intervention who are treated with acute resection.
62551959|NCT04450758||bridge to sugery|Patients who present with obstruction due to colon cancer with a need for urgent intervention who are treated with bridge to surgery i.e. either stent or stoma and resection later on.
62175441|NCT00468065|EXPERIMENTAL|A|TO use Veinviewer to improve the effectiveness of IV starts in children
62175442|NCT00468065|NO_INTERVENTION|B|Standard approach to placing IV s in children
62551960|NCT04522726|EXPERIMENTAL|Treatment group A|"Treatment group A received Weiyang Yupingfang Granules orally for 1 month on the Sanfu days and on theSanjiudays each year for a total of 2 months a year."
62551961|NCT04522726|EXPERIMENTAL|Treatment group B|Treatment group A received Weiyang Yupingfang Granules orally for 1 month in the first month of each quarter in the four quarters of the year, for a total of 4 months a year.
62551962|NCT01618565|EXPERIMENTAL|Hands-On Training|30 minutes hands-on training of maneuvers to manage shoulder dystocia
62175443|NCT06276634|EXPERIMENTAL|AIH First|Participants in the AIH First arm will undergo 5 days of Acute Intermittent Hypoxia Interventions. Following the 5 Days of AIH, after a 2-week washout period, this group will then undergo 5 days of Sham AIH Interventions. The procedures are identical to AIH but with 21% oxygen for both breath cycles
62175444|NCT06276634|EXPERIMENTAL|Sham First|Participants in the Sham First arm will undergo 5 days of Sham-Acute Intermittent Hypoxia Interventions. Following the 5 Days of Sham-AIH, after a 2-week washout period, this group will then undergo 5 days of AIH Interventions. The procedures are identical to Sham-AIH but with 9-10% oxygen for the first breath cycle
62175445|NCT01032356|EXPERIMENTAL|Dynasplint|Patients will be treated with the current standard of care and the Wrist Extension Dynasplint.
62175446|NCT06479447|EXPERIMENTAL|PORTAL-PTSD Intervention|Chicago Family Health Center clinics are randomly assigned to any of the 5 steps. The PORTAL-PTSD intervention is implemented after clinic staff and clinicians have been trained.
62175447|NCT06479447|NO_INTERVENTION|No PORTAL-PTSD Intervention|Standard of care offered to all patients
62175448|NCT03433209|ACTIVE_COMPARATOR|Ligasure device|This group of women undergoing hysterectomy were randomized to the Ligasure energy device
62551963|NCT01618565|ACTIVE_COMPARATOR|Demonstration|30 minutes passive training by watching an expert instructor explain and perform maneuvers to manage shoulder dystocia
62551964|NCT03657225|ACTIVE_COMPARATOR|Mini CPB (ECCO, Sorin, Italy)|Utilization of the mini CPB circuit (Extra Corporeal Circuit Optimized; Phisio, Sorin Group, Italy)
62741183|NCT06433154||Arthroscopic surgery to the temporomandibular joint|Arthroscopic lysis and lavage in patients with internal derangement of the temporomandibular joint. Retrospective observational follow-up cohort trial.
62175449|NCT03433209|ACTIVE_COMPARATOR|Articulating Enseal|This group of women undergoing hysterectomy were randomized to the articulating Enseal energy device
62741184|NCT04973683|EXPERIMENTAL|Treatment (AL101)|Patients receive AL101 IV over 60 minutes QW for 6-8 weeks in the absence of disease progression or unacceptable toxicity. Within 24-72 hours after the last infusion of AL101, patients undergo surgery per standard of care. Patients may continue AL101 after surgery at the discretion of the study doctor.
62551965|NCT03657225|PLACEBO_COMPARATOR|Conventional|Use of conventional CPB circuit
62551966|NCT00633997|EXPERIMENTAL|1|Healthy volunteers
62741185|NCT01255176|NO_INTERVENTION|placebo group|not receive physical therapy intervention, there will only support the achievement of a handbook on the abdomen of the baby.
62175450|NCT00397137|EXPERIMENTAL|Stapled Anopexy|Circular stapled anopexy
62175451|NCT00397137|ACTIVE_COMPARATOR|Conventional Haemorrhoidectomy|Closed diathermy haemorrhoidectomy
62175452|NCT00931008|EXPERIMENTAL|SID530|Study participants who meet eligibility criteria will be randomized to one of two treatment sequences, SID530 or Taxotere (i.e., SID530 on Day 1 followed by Taxotere on Day 21 or Taxotere on Day 1 followed by SID530 on Day 21)
62175453|NCT00931008|ACTIVE_COMPARATOR|Taxotere|Study participants who meet eligibility criteria will be randomized to one of two treatment sequences, SID530 or Taxotere (i.e., SID530 on Day 1 followed by Taxotere on Day 21 or Taxotere on Day 1 followed by SID530 on Day 21)
62175454|NCT01093170|EXPERIMENTAL|RNA-144101|
62175455|NCT01162564||NG-TSM|Patients receiving NG-TSM to repair an abdominal incisional/ventral hernia
62175456|NCT05291806|PLACEBO_COMPARATOR|Reference|
62175457|NCT05291806|ACTIVE_COMPARATOR|Whole cereal kernels Dose A|
62175458|NCT05291806|ACTIVE_COMPARATOR|Whole cereal kernels Dose B|
62175459|NCT05291806|ACTIVE_COMPARATOR|Cut cereal kernels Dose A|
62741186|NCT01255176|NO_INTERVENTION|control group|not receive any type of intervention, and infants remain at rest
62175460|NCT05428241|EXPERIMENTAL|Experimental|Study group intervention consists 6-session Motivational Interviews and 3-month follow-up.
62175461|NCT05428241|NO_INTERVENTION|No Intervention|Control group receives general care and the training booklet at the end of the study. Also includes 3-month follow-up.
62175462|NCT02274519|EXPERIMENTAL|Tai Chi|Group randomized to participate in Tai Chi intervention
62175463|NCT02274519|ACTIVE_COMPARATOR|Educational|Group randomized to participate in educational intervention
62175464|NCT06215625|EXPERIMENTAL|Stroke: TIGER group|Participants in the TIGER (tenodesis-induced-grip exoskeleton robot) group will operate the TIGER system. They will undergo a 30-minute home-based training program twice a day, 5 days a week for 4 weeks.
62551967|NCT00633997|EXPERIMENTAL|2|Type II diabetics
62551968|NCT03369769|EXPERIMENTAL|Canine & Adult Handler Activity|Unstructured 10-minute small group interaction with canine \& handler
62551969|NCT03369769|ACTIVE_COMPARATOR|Toy and Adult Handler Activity|Unstructured 10-minute small group interaction with toy \& handler
62551970|NCT01948115|PLACEBO_COMPARATOR|Medical air|
62741187|NCT01255176|EXPERIMENTAL|Thoracoabdominal rebalancing|infants who receive physical therapy through the application of the handlings of the RTA.
62741188|NCT05706623|EXPERIMENTAL|Moderate hepatic impairment|Child-Pugh B
62741189|NCT05706623|EXPERIMENTAL|Normal hepatic function|
62741190|NCT05706623|EXPERIMENTAL|Mild hepatic impairment|Child-Pugh A
62741191|NCT06658587||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the exploration cohort.
62741192|NCT01183520|ACTIVE_COMPARATOR|90 grams of Salmon|Subjects will consume 90 grams of salmon twice a week for 4 weeks
62175465|NCT06215625|ACTIVE_COMPARATOR|Stroke: TOT group|Participants in the TOT (task-oriented training) group will receive task-oriented training as home program. They will undergo a 30-minute home-based training program twice a day, 5 days a week for 4 weeks.
62175466|NCT06215625|EXPERIMENTAL|Spinal cord injury: TIGER group|Participants in the TIGER (tenodesis-induced-grip exoskeleton robot) group will operate the TIGER system. They will undergo a 40-minute home-based training program once a day, 5 days a week for 4 weeks.
62175467|NCT06215625|ACTIVE_COMPARATOR|Spinal cord injury: TOT group|Participants in the TOT (task-oriented training) group will receive task-oriented training as home program. They will undergo a 40-minute home-based training program once a day, 5 days a week for 4 weeks.
62175468|NCT01527903|ACTIVE_COMPARATOR|Propofol|
62175469|NCT01527903|ACTIVE_COMPARATOR|Midazolam|
62175470|NCT03545178||Diabetic patients using CGM/FGM|Evaluation of glucose control and application of hypoglycemia prediction models in diabetic patients wearing CGM and/or FGM devices for at least 50% of the time during the last 4 weeks prior to the medical consultation.
62175471|NCT05722613||(Group A) periodontally healthy as a control|BOP \<10%, PPD ≤ 3mm, intact periodontium (no probing attachment loss).
62175472|NCT05722613||(Group B) periodontitis currently unstable|Generalized periodontitis, currently unstable (PPD ≥ 5mm or PPD at ≥ 4mm with BOP).
62175473|NCT05722613||(Group C)periodontitis currently stable .|Generalized periodontitis, currently stable (BOP \< 10 % PPD ≤4 mm and no BOP at 4mm sites)
62175474|NCT02893358|ACTIVE_COMPARATOR|Active treatment|Treatment will be started with allisartan isoproxil 80mg once daily taken in the morning during 8:00-9:00. After 2 months, to achieve the target BP (24h BP\<130/80 mmHg, and daytime BP \<135/85 mmHg, and nighttime BP \<120/70 mmHg), allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan Isoproxil.
62551971|NCT01948115|EXPERIMENTAL|equimolar mixture of oxygen and nitrous oxide|
62741193|NCT01183520|ACTIVE_COMPARATOR|180 grams of salmon|Subjects will consume 180 grams of salmon twice a week for 4 weeks
62741194|NCT01183520|ACTIVE_COMPARATOR|270 Grams of Salmon|Subjects will consume 270 grams of salmon twice a week for 4 weeks
62741195|NCT06391008|EXPERIMENTAL|SBRT+Evoximab +pemetrexed/albumin paclitaxel+carboplatin|"Radiotherapy induction sensitization stage: For the primary lung lesion and irradiable mediastinal lymph nodes, stereotactic large segment radiotherapy is performed to complete the prescribed dose, PTV (planned target area): 5Gy x 3f.~Drug combination therapy stage: Within 7 days after radiotherapy.Evoximab (20mg/kg, Q3W)+pemetrexed (500mg/m2, Q3W)/albumin paclitaxel 260 mg/m2, Q3W+carboplatin (AUC5, Q3W)"
62175475|NCT02893358|PLACEBO_COMPARATOR|Placebo|Placebo tablets are identical to the active study drugs, with a similar schedule of administration.
62551972|NCT02617797|EXPERIMENTAL|Radiofrequency|Experimental group: women with urinary incontinence are subjected to standard treatment kinesiotherapy perineal ( pelvic muscle exercises ) every day in home and one session per week in the clinic in beyond the RF application in the genital area once a week to total 5 sessions.
62551973|NCT02617797|SHAM_COMPARATOR|Radiofrequency Off|Control group: women with stress urinary incontinence will be submitted to the treatment of kinesiotherapy standard perineal ( pelvic muscle exercises ) every day in home and one session per week in the clinic beyond the application of radiofrequency off in genital area once a week with the total of 5 sessions.
62551974|NCT03817827|EXPERIMENTAL|Acupuncture|this group will receive Acupuncture therapy for 30 minutes three times per week
62551975|NCT03817827|EXPERIMENTAL|diet modification|this group will receive diet using soy products a
62551976|NCT03817827|EXPERIMENTAL|combined group|will receive both acupuncture therapy and soy products
62551977|NCT05960058||Cases (Autologous Haematopoietic Stem Cell Transplantation (AHSCT))|Systemic Sclerosis (SSc) patients treated by AHSCT and actively followed at Saint Louis on January 1st, 2021
62551978|NCT05960058||Controls (without Autologous Haematopoietic Stem Cell Transplantation)|Systemic Sclerosis (SSc) patients treated by AHSCT and actively followed at Saint Louis on January 1st, 2021
62551979|NCT04555434|EXPERIMENTAL|Probiotics group|The selected test subjects were randomly assigned to test group 1, test group 2, test group 3, or control group according to the order registered at visit 2 (week 0) after a 2-week run-in period, and for 8 weeks, the study drug or study After taking the treaty, analyze the results of the observations.
62551980|NCT04555434|PLACEBO_COMPARATOR|Placebo group|The selected test subjects were randomly assigned to test group 1, test group 2, test group 3, or control group according to the order registered at visit 2 (week 0) after a 2-week run-in period, and for 8 weeks, the study drug or study After taking the treaty, analyze the results of the observations.
62551981|NCT01835041|EXPERIMENTAL|Treatment (6,8-bis[benzylthio]octanoic acid, mFOLFIRINOX)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 3. Patients also receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously over 46 hours on day 1. Treatment repeats every 2 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
62551982|NCT01320501|EXPERIMENTAL|Erlotinib|150 mg PO daily
62175476|NCT00702546||Corifollitropin alfa 100 μg|In follow-up study, no medication or investigational product was administered. But in base study P05690 (NCT00702845), participants received single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of the menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants in base study P05690 also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
62175477|NCT00702546||recFSH 150 IU|In this follow-up study, no medication or investigational product was administered. However, in base study P05690 (NCT00702845), participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including the day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
62551983|NCT02016183||Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil/Hydrochlorothiazide 4 mg/6.25 mg or 8 mg/6.25 mg combination tablets, orally, once daily for up to 12 months. This drug should not be used as a first-line drug for hypertension treatment. Participants received interventions as part of routine medical care.
62175478|NCT06050083|EXPERIMENTAL|Treatment|8 weeks of access to online hypnosis recordings
62175479|NCT06050083|ACTIVE_COMPARATOR|Waitlist Control|4 weeks of waitlist (no access to recordings) and then 4 weeks of access to hypnosis recordings
62175480|NCT02634398||Treated subjects|All subjects recruited and treated wiht the Axium neurostimulator
62175481|NCT01742234||Kidney Donors|People who will donate a kidney at the University of Minnesota, Mayo Clinic, or University of Alabama
62175482|NCT01742234||Lung Donors|People who will donate a lung at the Washington University School of Medicine or the University of Southern California
62175483|NCT01630837|OTHER|12h|Frequency of oral hygiene was 12 to 12 hours.
62175484|NCT01630837|OTHER|24h|Frequency of oral hygiene was 24 to 24 hours.
62175485|NCT01630837|OTHER|48h|Frequency of oral hygiene was 48 to 48 hours.
62175486|NCT01630837|OTHER|72h|Frequency of oral hygiene was 72 to 72 hours.
62175487|NCT00833183|ACTIVE_COMPARATOR|25 J/cm2, with occlusion on right side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to either 25 J/cm2 of red light starting with the occluded side first.
62551984|NCT06454097|OTHER|Evaluate the response of patients with glioma to radiochemotherapy|The response of patients with glioma to radiochemotherapy will be assessed by the RANO criteria and the established radiogenomics-based artificial intellegent model.
62551985|NCT02633592|ACTIVE_COMPARATOR|HRARM|Patients and healthy volunteers are subjected to position change ( LLP to SP) during pressure measurements with HR-ARM.
62551986|NCT02633592|ACTIVE_COMPARATOR|MRI Defecography|Patients and healthy volunteers are subjected to position change during MRI Defecography
62551987|NCT05309018||Patients|
62551988|NCT05309018||medical staff|
62551989|NCT02130908|EXPERIMENTAL|Lean fish|
62551990|NCT02130908|EXPERIMENTAL|Fatty fish|
62551991|NCT02130908|EXPERIMENTAL|Lean meat|
62175488|NCT00833183|ACTIVE_COMPARATOR|37 J/cm2, with occlusion on right side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to 37 J/cm2 of red light starting with the occluded side first.
62551992|NCT03035578|EXPERIMENTAL|Morphine Blood and Saliva sampling|"The infants will receive a 50 mcg/kg loading dose of morphine followed by a constant infusion.Morphine Injection: 10mg/mL, 1mL ampoules.Two strengths of stock syringes:~a)patients \<1.5kg, morphine 0.5mg/25mL; b)patients 1.5kg to \<5kg, morphine 1mg/25mL.~Time blood samples will be collected for measurement of whole blood concentration of morphine in 24h. Total morphine, morphine-3-glucuronide and morphine-6-glucuronide concentrations; volume of blood required is 0.25 ml. Sparse sampling strategy will be used for those neonates \< 1250; total volume of blood required is 0.50 ml. Frequent sampling strategy will be used for those neonates ≥ 1250 gm; total volume of blood required is 0.50 ml.Saliva samples will be collected at 10 and 30 minutes and at 6, 12 and 24h after morphine infusion started.100 uL of saliva, captured using a collection swab."
62175489|NCT00833183|ACTIVE_COMPARATOR|25 J/cm2 , with occlusion on left side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to either 25 J/cm2 of red light starting with the occluded side first.
62741196|NCT04012502|ACTIVE_COMPARATOR|conventional treatment arm|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
62741197|NCT04012502|EXPERIMENTAL|Toxicities reduced treatment arm|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
62741198|NCT05687773|EXPERIMENTAL|Leap Motion Controller on Flat display - Non-Immersive Group|
62175490|NCT00833183|ACTIVE_COMPARATOR|37 J/cm2 , with occlusion on left side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to 37 J/cm2 of red light starting with the occluded side first.
62175491|NCT03334695|EXPERIMENTAL|Group 1: Ad26.RSV.preF|Participants will receive single intramuscular injection of 1\*10\^11 virus particles (vp) of Ad26.RSV.preF during Day -90 to Day -28. On Day 0, intranasal challenge with respiratory syncytial virus (RSV)-A Memphis 37b virus will occur for all participants.
62175492|NCT03334695|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will receive single intramuscular injection of placebo as sterile 0.9 percent (%) saline for injection during Day -90 to Day -28. On Day 0, intranasal challenge with RSV-A Memphis 37b virus will occur for all participants.
62175493|NCT04620031|EXPERIMENTAL|HSK3486|HSK3486 for Sedation
62175494|NCT04620031|ACTIVE_COMPARATOR|Propofol|Propofol for Sedation
62175495|NCT03331432|PLACEBO_COMPARATOR|Placebo|Taking daily placebo capsules for 4 weeks
62175496|NCT03331432|EXPERIMENTAL|Tauroursodeoxycholic acid|Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks
62741199|NCT05687773|EXPERIMENTAL|Leap Motion Controller on Head-Mounted Display - Immersive Group|
62175497|NCT03087994|EXPERIMENTAL|girls with obesity attending a dietary intervention|Participants in this group will attend 12 meetings of dietary interventions that will be guided by a dietician.
62741200|NCT05816343|ACTIVE_COMPARATOR|Orlistat Drug|Drug will be given orally.
62741201|NCT05816343|PLACEBO_COMPARATOR|Placebo|Placebo will be given orally.
62175498|NCT03087994|ACTIVE_COMPARATOR|girls with obesity|participants in this group will only receive nutrition guidance once during the study
62175499|NCT03087994|ACTIVE_COMPARATOR|girls with normal weight|participants in this group will only receive nutrition guidance once during the study
62741202|NCT05435807|EXPERIMENTAL|intervention group|Clinical Pilates Exercises+TNE
62741203|NCT05435807|EXPERIMENTAL|control group|Clinical Pilates Exercises
62741204|NCT04813835||suicidal depressed patients|psychiatric history suicidal scale mental state examination screening for sleep disturbance electroencephalography
62175500|NCT02737202|EXPERIMENTAL|Saracatinib|Saracatinib will be given orally at a dose of 125 milligrams once daily for 9 months. Saracatinib is provided as a pink tablet.
62175501|NCT05736445||Students at the University of Michigan|Students enrolled in the Winter 2023 academic semester at the University of Michigan
62741205|NCT04813835||depressed patients|psychiatric history suicidal scale mental state examination screening for sleep disturbance electroencephalography
62741206|NCT04813835||control|psychiatric history suicidal scale mental state examination screening for sleep disturbance electroencephalography
62741207|NCT01885884|EXPERIMENTAL|Supportive Care Intervention|Monthly (minimum) patient \& caregiver visits with a Supportive Care physician, embedded within their standard oncological care (through collaboration with oncology providers).
62175502|NCT02880124|EXPERIMENTAL|Maple syrup|A maple syrup solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
62741208|NCT01885884|NO_INTERVENTION|Usual Care|Participants will receive standard oncology care from their oncology providers.
62741209|NCT01688245|NO_INTERVENTION|Control|No SMS dialog
62741210|NCT01688245|ACTIVE_COMPARATOR|SMS Assessments|Weekly post-weekend drinking outcome assessments
62741211|NCT01688245|EXPERIMENTAL|SMS Assessments & Feedback|Weekly pre-weekend drinking intention \& post-weekend drinking outcome assessments with personalized feedback and harm-reduction support
62551993|NCT06042244|OTHER|Control Group|Participants randomized to the control group will be put on a waitlist (passive control group) for 6 weeks. Upon completion of post-training assessment, participants in the control group will be able to receive the intervention, if they wish so.
62551994|NCT06042244|EXPERIMENTAL|Multimodal Exercise Group|Participants will complete 15 minutes of virtual reality treadmill training (VRTT), followed by 30 minutes of progressive evidence-based resistance training (RT), followed by other 15 minutes of VRTT.
62551995|NCT03487289|EXPERIMENTAL|natural orifice|Patients who underwent laparoscopic surgery and removed the specimen from the natural orifice will be gathered. demographic data and perioperative results will be compiled
62551996|NCT03487289|NO_INTERVENTION|conventional|patients who underwent laparoscopic surgery and removed specimen with conventional will be gathered. demographic data and perioperative results will be compiled. (conventional extraction is suprapubic or median incision)
62551997|NCT01085071|ACTIVE_COMPARATOR|Normal-high potassium (NHP)|A potassium target of 4.5 mmol/L.
62551998|NCT01085071|ACTIVE_COMPARATOR|Normal-low potassium (NLP)|A potassium target of 4.0 mmol/L.
62551999|NCT00795327|EXPERIMENTAL|1|single arm study
62552000|NCT05463640|EXPERIMENTAL|ADGRE2 CAR-T|"Dose Escalation:After enrollment ,Participants complete the PBMC apheresis,then complete the Lymphocyte clearance,and then receive the dose climning test: 3×10e6/kg，6 ×10e6/kg，9×10e6/kg.~Dose Expansion:Participants receive a single dose (at the MTD determined)."
62552001|NCT02309307|EXPERIMENTAL|Arm 1 Tissue Repair Device|Tissue Repair Device
62552002|NCT01153425|ACTIVE_COMPARATOR|Teriparatide (Forteo)|20 µg of Teriparatide will be self-injected subcutaneously once a day for 12 months and an MRI at 3T ('Virtual Bone Biopsy') will be performed at 0 and 12 months.
62552003|NCT01153425|ACTIVE_COMPARATOR|Zoledronic Acid (Reclast)|5 mg of zoledronic Acid will be administered intravenously at baseline and 12 months and an MRI at 3T ('Virtual Bone Biopsy) will be performed at 0 and 12 months.
62552004|NCT05919719||study of diagnostic accuracy|Patients included in this study would have received fluid expansion in all cases, as the prescription of 10 to 20ml/kg crystalloid fluid expansion by the physician in charge is the main inclusion criterion.
62552005|NCT02289872|EXPERIMENTAL|Scenario A|The control scenario, where neither chest compression nor cervical stabilization was applied during intubation.
62552006|NCT02289872|EXPERIMENTAL|Scenario B|The chest compression scenario, where continuous chest compression was applied using chest compression system LUCAS-2 (Physio-Control, Redmond, WA, USA). Chest compression was provided at a rate of 100 min-1 to a depth of 5-6 cm during all intubation procedures.
62552007|NCT02289872|EXPERIMENTAL|Scenario C|The chest compression with cervical stabilization scenario, where both chest compression using Lucas-2 and cervical stabilization were applied. A correctly fitting standard cervical immobilization collar (StifNeck Select, Laerdal, Stavanger, Norway) was applied to the manikin's neck to prevent movement of the cervical spine.
62552008|NCT02966977|ACTIVE_COMPARATOR|Conventional microbiological diagnostics|Conventional microbiological identification by culture plate (overnight cultures with subsequent bacterial/fungal identification).
62552009|NCT02966977|EXPERIMENTAL|Conventional plus mass spectrometry|Conventional microbiological identification by culture plate plus Direct mass spectrometry identification from urine sample. This additional diagnostic procedure is supplied additionally to conventional diagnostics.
62552010|NCT05547217|EXPERIMENTAL|Neurorehabilitation of the Hand|Participants will undergo a 2-hour training session, 2-3 days per week, over 12 weeks, for a total of 30 sessions. Hand function therapy will be administered in a specific and gamified manner to enhance rehabilitation of the hand and provide participants with greater opportunity to regain hand function over the course of the study.
62552011|NCT04508738|EXPERIMENTAL|ERP Intervention|Combination of different methods to improve recovery.
62741212|NCT01202188|EXPERIMENTAL|indacaterol and glycopyrronium (QVA149)|QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
62552012|NCT04508738|NO_INTERVENTION|Control|Passive recovery by sitting on a chair
62552013|NCT04508738|PLACEBO_COMPARATOR|Placebo|A combination of methods similar to the ERP intervention but at an intensity / mixture supposed to be ineffective at improving recovery.
62552014|NCT04812522|OTHER|Clean Cut intervention - Cluster 1|"Cluster 1 will receive the Clean Cut infection prevention intervention at random time point A"
62552015|NCT04812522|OTHER|Clean Cut intervention - Cluster 2|"Cluster 2 will receive the Clean Cut infection prevention intervention at random time point B"
62552016|NCT04812522|OTHER|Clean Cut intervention - Cluster 3|"Cluster 3 will receive the Clean Cut infection prevention intervention at random time point C"
62552017|NCT04812522|OTHER|Clean Cut intervention - Cluster 4|"Cluster 4 will receive the Clean Cut infection prevention intervention at random time point D"
62552018|NCT04812522|OTHER|Clean Cut intervention - Cluster 5|"Cluster 5 will receive the Clean Cut infection prevention intervention at random time point E"
62552019|NCT03748446|ACTIVE_COMPARATOR|X-TAU (xenon)|"Xenon is a potent antiglutaminergic agent that has been used as an anesthetic with minimal side effects, has neuroprotective effects consistent with antidepressants and has the potential to be a novel antidepressant drug.~- xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group)"
62552020|NCT03748446|PLACEBO_COMPARATOR|N-TAU (nitrogen-placebo)|Nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group)
62552021|NCT01205360|ACTIVE_COMPARATOR|Bupivacaine-Fentanyl (3-15)|Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.
62552022|NCT01205360|EXPERIMENTAL|Bupivacaine-Fentanyl (4-20)|Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
62741213|NCT01202188|ACTIVE_COMPARATOR|glycopyrronium (NVA237)|NVA237 50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
61997480|NCT00006095|EXPERIMENTAL|Vincristine sulfate 2.0 mg/m2/wk and Irinotecan|
62552023|NCT01205360|EXPERIMENTAL|Bupivacaine-Fentanyl (6-30)|Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
62175503|NCT02880124|EXPERIMENTAL|Maple sap|A maple sap solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
62175504|NCT02880124|ACTIVE_COMPARATOR|Glucose|A glucose solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
62175505|NCT02880124|ACTIVE_COMPARATOR|Sport drink|A Gatorade (TM) solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
62175506|NCT02880124|PLACEBO_COMPARATOR|Trace|A solution containing stevia (sugar substitute) and trace amounts of glucose (3g) labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
62175507|NCT03175198||Patients with nonvalvular atrial fibrillation (NVAF)|Patients with nonvalvular atrial fibrillation (NVAF) taking daily oral dose of Prazaxa® Capsules (Dabigatran etexilate). Dosage of Dabigatran etexilate approved in Japan: 300 milligram (mg) daily (150 mg \[as 2 capsules of 75 mg\] twice a day (b.i.d)) or 220 mg (110 mg \[as 1 capsule of 110 mg\] b.i.d) for a treatment duration of 52 weeks.
62552024|NCT01049178|EXPERIMENTAL|Oral silymarin dose|Dose escalation study
62552025|NCT01049178|PLACEBO_COMPARATOR|placebo|A randomized, double-masked, placebo-controlled cross-over clinical pilot investigation of an inducer of endogenous antioxidant enzymes, silymarin, in humans with atopic asthma.
62552026|NCT02723344|EXPERIMENTAL|L. reuteri|Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.
62552027|NCT02723344|PLACEBO_COMPARATOR|Sunflower and medium chain triglyceride oils|Sunflower and medium chain triglyceride oils
62175508|NCT03386214|EXPERIMENTAL|Arm 1: Starting Dose - 5 mg/m^2 pevonedistat + ruxolitinib|"* Pevonedistat will be given as an IV infusion at the assigned dose over the course of 60 minutes on Days 1, 3, and 5 of each 28-day cycle.~* Ruxolitinib will be continued at the same dose as prior to enrollment and will be administered as standard of care outside the study protocol."
62175509|NCT03386214|EXPERIMENTAL|Arm 2: Dose Level 2 - 10 mg/m^2 pevonedistat + ruxolitinib|"* Pevonedistat will be given as an IV infusion at the assigned dose over the course of 60 minutes on Days 1, 3, and 5 of each 28-day cycle.~* Ruxolitinib will be continued at the same dose as prior to enrollment and will be administered as standard of care outside the study protocol."
62175510|NCT03386214|EXPERIMENTAL|Arm 3: Dose Level 3 - 20 mg/m^2 pevonedistat + ruxolitinib|"* Pevonedistat will be given as an IV infusion at the assigned dose over the course of 60 minutes on Days 1, 3, and 5 of each 28-day cycle.~* Ruxolitinib will be continued at the same dose as prior to enrollment and will be administered as standard of care outside the study protocol."
62175511|NCT05420623||Amputees patients|
62175512|NCT05420623||control group: non-amputees|
62175513|NCT03041701|EXPERIMENTAL|Phase 1 Dose Level 1: Ganitumab and Dasatinib|Phase I Dose Level 1: Combination of ganitumab and dasatinib with limited dose escalation of dasatinib
62175514|NCT03041701|EXPERIMENTAL|Phase 1 Dose Level 2: Ganitumab and Dasatinib|Phase I Dose Level 2: Combination of ganitumab and dasatinib with limited dose escalation of dasatinib
62175515|NCT03041701|EXPERIMENTAL|Phase 2 Dose Level 1: Ganitumab and Dasatinib|Phase 2 Dose Level 1: Combination of ganitumab and dasatinib at the maximum tolerated dose (MTD) (or highest safe dose)
62552028|NCT01848600|EXPERIMENTAL|abstract without limitation section|the experimental arm is abstract without the limitation section
62552029|NCT01848600|OTHER|abstract with limitation section|the control arm is abstract with the original limitation section
62552030|NCT03355612|EXPERIMENTAL|experimental group|Drug:Apatinib with XELOX(Capecitabine and Oxaliplatin)
62552031|NCT03355612|ACTIVE_COMPARATOR|active comparator|Drug:XELOX(Capecitabine and Oxaliplatin)
62552032|NCT04493671|ACTIVE_COMPARATOR|SAD (Part 1): Cohort 1, TBAJ-876 10mg|In cohort 1 with 8 subjects, n= 6 will receive TBAJ-876 10mg under fasting conditions.
62175516|NCT05300997||Haemorrhagic Stroke [N=100]|Haemorrhagic stroke subjects presenting within 24 hours from symptom onset will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital within 24 hours of the onset of symptoms; b) 18 hours +/- 6 hours from symptom onset (if available); and c) 30 hours+/- 6 hours from symptom onset (if available).
62175517|NCT05300997||Acute Ischaemic Stroke [N=300]|Acute Ischaemic stroke subjects presenting within 24 hours from symptom onset will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital within 24 hours of the onset of symptoms; b) 18 hours +/- 6 hours from symptom onset (if available); and c) 30 hours+/- 6 hours from symptom onset (if available).
62175518|NCT05300997||Stroke of uncertain origin [N=45]|Stroke of uncertain origin subjects presenting within 24 hours from symptom onset will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital within 24 hours of the onset of symptoms; b) 18 hours +/- 6 hours from symptom onset (if available); and c) 30 hours+/- 6 hours from symptom onset (if available).
62175519|NCT05300997||Transient Ischemic Attack (TIA) [N=75]|TIA subjects presenting within 24 hours from symptom onset will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital within 24 hours of the onset of symptoms; b) 18 hours +/- 6 hours from symptom onset (if available); and c) 30 hours+/- 6 hours from symptom onset (if available).
62175520|NCT05300997||Stroke Mimics [N=30]|Stroke Mimics subjects presenting within 24 hours from symptom onset will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital within 24 hours of the onset of symptoms; b) 18 hours +/- 6 hours from symptom onset (if available); and c) 30 hours+/- 6 hours from symptom onset (if available).
62175521|NCT05300997||Control Subjects [N=100]|Control group subjects, if they agree, will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital on day 1; b) 18 hours +/- 6 hours after sample 1 (if available); and c) 30 hours+/- 6 hours after sample 1 (if available).
62175522|NCT05171361||Pancreaticojejunostomy|With Dunking Technique after Pancreaticodudenectomy
62175523|NCT05171361||Pancreaticogastrostomy|With Dunking Technique after Pancreaticodudenectomy
62175524|NCT04959825|ACTIVE_COMPARATOR|melatonin group|Melatonin group (group M )will receive melatonin as a premedication 1 hour before surgery in a dose of 5 mg
62175525|NCT04959825|PLACEBO_COMPARATOR|control group|15 patients will be enrolled for open nephrectomy will receive sugar-coated tablets. Control group(group C)
62175526|NCT03605368|ACTIVE_COMPARATOR|Phase IIA - in-person|Participants will be assigned to either a) a virtual reality-based intervention or b) an video modeling intervention both aimed at improving police interaction skills. Assessments of police skills will occur before intervention and after intervention (three sessions of each).
62175527|NCT03605368|ACTIVE_COMPARATOR|Phase IIB - remote|Participants will be assigned to either a) three sessions of virtual reality-based intervention aimed at improving police interaction skills or b) no intervention. Assessments of police skills will occur before intervention, after intervention, and 3-4 weeks follow up in the intervention group and at comparable timepoints in the no intervention group.
62175528|NCT02690415||Antibiotics Given|Patients who's treating physician prescribed antibiotics following incision and drainage of their abscess.
62175529|NCT02690415||Antibiotics Not Given|Patients who's treating physician did not prescribed antibiotics following incision and drainage of their abscess.
62175530|NCT00629551|EXPERIMENTAL|Saredutant 100mg and Paroxetine 20 mg|combined saredutant 100mg and paroxetine 20mg once daily for a maximum of 8 weeks
62175531|NCT00629551|EXPERIMENTAL|Saredutant 30mg and Paroxetine 20mg|combined saredutant 30mg and paroxetine 20mg once daily for a maximum of 8 weeks
62175532|NCT00629551|ACTIVE_COMPARATOR|Paroxetine 20 mg and saredutant placebo|paroxetine 20mg and saredutant placebo once daily for a maximum of 8 weeks
62741214|NCT01202188|ACTIVE_COMPARATOR|indacaterol (QAB149)|QAB149 150 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
62741215|NCT01202188|ACTIVE_COMPARATOR|tiotropium|Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
62175533|NCT00629551|PLACEBO_COMPARATOR|Placebo|Saredutant placebo and paroxetine placebo once daily for one week during screening period and maximum of 8 weeks for the active phase
62175534|NCT04157959|EXPERIMENTAL|SHR4640|SHR4640 dose1 Oral Tablet Day1\~Day14 qd,Febuxostat dose2 Oral Tablet Day8 and Day14 qd.
62175535|NCT04157959|EXPERIMENTAL|Febuxostat|Febuxostat dose2 Oral Tablet Day1 and Day14 qd, SHR4640 dose1 Oral Tablet Day8\~Day14 qd.
62552033|NCT04493671|PLACEBO_COMPARATOR|SAD (Part 1): Cohort 1, placebo for TBAJ-876 10mg|In cohort 1 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 10mg under fasting conditions.
62552034|NCT04493671|ACTIVE_COMPARATOR|SAD (Part 1): Cohort 2, TBAJ-876 25mg|In cohort 2 with 8 subjects, n= 6 will receive TBAJ-876 25mg under fasting conditions.
62552035|NCT04493671|PLACEBO_COMPARATOR|SAD (Part 1): Cohort 2, Placebo for TBAJ-876 25mg|In cohort 2 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 25mg under fasting conditions.
62552036|NCT04493671|ACTIVE_COMPARATOR|SAD (Part 1): Cohort 3, TBAJ-876 50mg|In cohort 3 with 8 subjects, n= 6 will receive TBAJ-876 50mg under fasting conditions.
62552037|NCT04493671|PLACEBO_COMPARATOR|SAD (Part 1): Cohort 3, Placebo for TBAJ-876 50mg|In cohort 3 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 50mg under fasting conditions.
62552038|NCT04493671|ACTIVE_COMPARATOR|SAD (Part 1): Cohort 4, TBAJ-876 100mg|In cohort 4 with 8 subjects, n= 6 will receive TBAJ-876 100mg under fasting conditions.
62741216|NCT01202188|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
62552039|NCT04493671|PLACEBO_COMPARATOR|SAD (Part 1): Cohort 4, Placebo for TBAJ-876 100mg|In cohort 4 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 100mg under fasting conditions.
62552040|NCT04493671|ACTIVE_COMPARATOR|SAD (Part 1): Cohort 5, TBAJ-876 200mg|In cohort 5 with 8 subjects, n= 6 will receive TBAJ-876 200mg under fasting conditions.
62552041|NCT04493671|PLACEBO_COMPARATOR|SAD (Part 1): Cohort 5, Placebo for TBAJ-876 200mg|In cohort 5 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 200mg under fasting conditions.
62552042|NCT04493671|ACTIVE_COMPARATOR|SAD (Part 1): Cohort 6, TBAJ-876 400mg|In cohort 6 with 8 subjects, n= 6 will receive TBAJ-876 400mg under fasting conditions.
62552043|NCT04493671|PLACEBO_COMPARATOR|SAD (Part 1): Cohort 6, Placebo TBAJ-876 400mg|In cohort 6 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 400mg under fasting conditions.
62552044|NCT04493671|ACTIVE_COMPARATOR|SAD (Part 1): Food effect Cohort, TBAJ-876|In food-effect cohort with 10 subjects, n=8 will return after plasma concentrations are expected to be below LLQ, for at least 7 days to receive the chosen dose of TBAJ-876 under fed conditions.
62552045|NCT04493671|PLACEBO_COMPARATOR|SAD (Part 1): Food effect Cohort, Placebo|In food-effect cohort with 10 subjects, n=2 will return after plasma concentrations are expected to be below LLQ, for at least 7 days to receive matching placebo for the chosen dose of TBAJ-876 under fed conditions.
62552046|NCT04493671|ACTIVE_COMPARATOR|MAD (Part 2): Cohort 1, TBAJ-876 Dose 1|In cohort 1 with 12 subjects, n=9 is expected to receive TBAJ-876 for 28 days with corresponding PK and safety measurements.
62552047|NCT04493671|PLACEBO_COMPARATOR|MAD (Part 2): Cohort 1, Placebo|In cohort 1 with 12 subjects, n=3 is expected to receive the matching placebo for TBAJ-876 for 28 days with corresponding PK and safety measurements.
62741217|NCT05252013|PLACEBO_COMPARATOR|Plain Bread|Participants will be attending the Human Nutrition Unit in the morning (day 1), following an overnight fast. Fasted blood samples will be taken and one portion of plain bread (122g) served with 25g of jam will be consumed by the volunteers. The meal will be consumed within 15 minutes and postprandial blood samples will be collected. Participants will be provided with the meals for the rest of the day to take away and for days 2 and 3. In total, they will consume 6 plain bread rolls on days 1, 2 and 3 (2 bread rolls/day).
62175536|NCT00690859||1|Ambulatory bipolar I and II patients, clinically stabilized for at least the two months prior to recruitment and who had at least one acute episode (depressive, manic, hypomanic or mixed) within the year prior to recruitment.
62175537|NCT01490359|EXPERIMENTAL|HIV/STD risk-reduction|Men Making a Difference HIV/STD Risk Reduction Intervention was designed to reduce sexual risk behaviors that increase risk of HIV and other sexually transmitted diseases.
62175538|NCT01490359|ACTIVE_COMPARATOR|Health Promotion Control|Health Promotion Intervention was designed to increase physical activity, healthful diet, and other behaviors to reduce risk of noncommunicable diseases, including diabetes, hypertension, and cancers.
62175539|NCT04915079|EXPERIMENTAL|PRISM|Patients in this arm will be recipients of the PRISM intervention
62175540|NCT04915079|NO_INTERVENTION|Usual Care|Patients in this arm will not receive the PRISM intervention, but will continue to receive usual care the discretion of their treating clinicians.
62175541|NCT05534464|EXPERIMENTAL|Skimmed milk powder|One rumen-fistulated Holstein-Friesian dairy cow in high lactation status will be given 0.6 L deuteriated water 3 times per day for 3 days long. Milk collection will take place twice a day on the fourth and fifth day. Milk will be processed into skimmed milk powder.
62175542|NCT05534464|EXPERIMENTAL|Sorghum whole grain|Sorghum plants are grown in the greenhouse. Those receive deuteriated water for five days with one day in between. On the first day the water has a 25% dilution and the other four days the water has a 5% dilution.
62175543|NCT05534464|EXPERIMENTAL|Black beans|Black bean plants are grown in the greenhouse. Those receive deuteriated water for five days with one day in between. On the first day the water has a 25% dilution and the other four days the water has a 5% dilution.
62175544|NCT05060237|EXPERIMENTAL|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~One single photodynamic therapy (PDT)."
62175545|NCT01849913|EXPERIMENTAL|Group B & Group C|Group B equal to low-level laser therapy dosis 5,9 j per point Group C equal to Placebo group
62175546|NCT01849913|NO_INTERVENTION|Group A & Group C|Group A equal to Control (no intervention) Group C equal to Placebo group
62175547|NCT00001077||1|Participants will receive peptamen drinks and multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
62175548|NCT00001077||2|Participants will receive NuBasics drinks or equivalent amounts of NuBasics soups or bars and daily multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
62175549|NCT00001077||3|Participants will receive multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
62175550|NCT04466397||3D printed implants reconstruction group|The patients with large bone defects who treated by 3D printed individualized porous implants
62175551|NCT04564859|EXPERIMENTAL|Noninvasive Ventilation group|Noninvasive Ventilation group initial setting： Insp. Pressure：12 \~ 16 centimeter of water Exp. Pressure ： 4 \~ 6 centimeter of water FiO2：Keep oxygen saturation measured by pulse oximeter：\> 92% By condition, gradually tap 2\~3 centimeter of water inspiratory positive airway pressure Keep Tidal volume：6\~10 ml/kg
62391452|NCT05183932||Stereotactic body radiotherapy (SBRT)|"* Participants will have standard of care 1-10 fractions of radiation therapy. Decision for treatment will be made at the discretion of the treating physician.~* PROMIS instruments include 8 domains and will be completed prior to treatment, 1 month post-treatment, 6 months post-treatment, 12 months post-treatment, 24 months post-treatment, and 36 months post-treatment~  * Bank v2.0 - Physical Function~ * Bank v1.1 - Pain Interference~ * Bank v1.0 - Fatigue~ * Bank v1.0 - Depression~ * Bank v1.0 - Anxiety~ * Bank v1.0 - Dyspnea Severity~ * Bank v2.0 - Ability to Participate in Social Roles and Activities~ * Bank v2.0 - Cognitive Function"
62175552|NCT04564859|ACTIVE_COMPARATOR|Heated Humidified High-Flow Nasal Cannula group|Heated Humidified High-Flow Nasal Cannula group initial setting： Flow setting: 50 L/m FiO2：Keep oxygen saturation measured by pulse oximeter \> 92% temperature:37 ℃ By condition, gradually tap Flow 5 L/m
62175553|NCT04193709|NO_INTERVENTION|Measure symptomatic indices of autonomic dysreflexia|The purpose of this arm is to systematically measure symptomatic indices of autonomic nervous system activation and corresponding cardiovascular changes in persons with spinal cord injuries during bladder filling and bowel stimulation.
62552048|NCT04493671|ACTIVE_COMPARATOR|MAD (Part 2): Cohort 2, TBAJ-876 Dose 2|In cohort 2 with 12 subjects, n=9 is expected to receive TBAJ-876 for 28 days with corresponding PK and safety measurements.
62552049|NCT04493671|PLACEBO_COMPARATOR|MAD (Part 2): Cohort 2, Placebo|In cohort 2 with 12 subjects, n=3 is expected to receive matching placebo for TBAJ-876 for 28 days with corresponding PK and safety measurements.
62552050|NCT04493671|ACTIVE_COMPARATOR|MAD (Part 2): Cohort 3, TBAJ-876 Dose 3|In cohort 3 with 12 subjects, n=9 is expected to receive TBAJ-876 for 28 days with corresponding PK and safety measurements
62552051|NCT04493671|PLACEBO_COMPARATOR|MAD (Part 2): Cohort 3, Placebo|In cohort 3 with 12 subjects, n=3 is expected to receive matching placebo for TBAJ-876 for 28 days with corresponding PK and safety measurements.
62552052|NCT00946920|EXPERIMENTAL|Degarelix 240 mg/480 mg|
62552053|NCT00946920|ACTIVE_COMPARATOR|Goserelin acetate|
62552054|NCT02540083|EXPERIMENTAL|Experimental: DBT and FFDM|Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT).
62552055|NCT06138691|EXPERIMENTAL|Ketamine Infusion|
62552056|NCT06138691|EXPERIMENTAL|Radically Open Dialectical Behavior Therapy (RO DBT)|
62552057|NCT03126435|EXPERIMENTAL|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m² twice weekly plus Gemcitabine 1000mg/m² once weekly for 1 cycle (8 weeks) consisting of 3 weeks of treatment and 1 week rest followed by 3 weeks of treatment and 1 week rest until any one of the following occurs: progressive disease or unacceptable toxicity or withdrawal of consent.
62552058|NCT03126435|ACTIVE_COMPARATOR|Gemcitabine Monotherapy|Gemcitabine 1000mg/m² once weekly, for 1 cycle (8 weeks) consisting of 3 weeks of treatment and 1 week rest followed by 3 weeks of treatment and 1 week rest until any one of the following occurs: progressive disease or unacceptable toxicity or withdrawal of consent.
62552059|NCT02006732|EXPERIMENTAL|tiotropium + olodaterol low dose|Once daily 2 puffs solution for inhalation Respimat
62552060|NCT02006732|EXPERIMENTAL|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
62552061|NCT02006732|ACTIVE_COMPARATOR|tiotropium|Once daily 2 puffs solution for inhalation Respimat
62552062|NCT02006732|PLACEBO_COMPARATOR|placebo|Once daily 2 puffs solution for inhalation Respimat
62552063|NCT03223584||Pharmacists-Leuven|Individual interviews with approximately 5 pharmacists
62552064|NCT03223584||Pharmacists-Bruges|Individual interviews with approximately 5 pharmacists
62552065|NCT03223584||Pharmacists-Mortsel|A focus group with pharmacists and general practitioners
62552066|NCT03223584||General Practitioners-Leuven|Individual interviews with approximately 5 general practitioners
62552067|NCT03223584||General Practitioners-Bruges|Individual interviews with approximately 5 general practitioners
62552068|NCT03223584||General Practitioners-Mortsel|A focus group with pharmacists and general practitioners
62552069|NCT00960219|EXPERIMENTAL|DAAOI-1|
62552070|NCT00960219|PLACEBO_COMPARATOR|placebo|
62552071|NCT04105010|EXPERIMENTAL|AZD4205 Group A|Group A: Open label AZD4205 at dose A, once daily (Phase 1)
62552072|NCT04105010|EXPERIMENTAL|AZD4205 Group B|Group B: Open label AZD4205 at dose B, once daily (Phase 1)
62552073|NCT04105010|EXPERIMENTAL|AZD4205 Group C|Group C: Open label AZD4205 at a selected dose, once daily (Phase 1)
62552074|NCT04105010|EXPERIMENTAL|AZD4205 Group D|Group D: Open label AZD4205 at the RP2D, once daily (Phase 2)
62552075|NCT06340997|OTHER|Patients with mitral stenosis|
62552076|NCT05434169|EXPERIMENTAL|Positive Therapeutic communication|
62552077|NCT05434169|ACTIVE_COMPARATOR|Nocebo communication|
62741218|NCT05252013|EXPERIMENTAL|Broad bean hull bread|Participants will be attending the Human Nutrition Unit in the morning, following an overnight fast. Fasted blood samples will be taken and one portion of the bean hull bread (155g) served with 25g of jam will be consumed by the volunteers. The meal will be consumed within 15 minutes and postprandial blood samples will be collected. Participants will be provided with the meals for the rest of the day to take away and for days 2 and 3. In total, they will consume 6 bean hull bread rolls on days 1, 2 and 3 (2 bread rolls/day).
62741219|NCT01426893||1|The inhaler device usage in patients with asthma or COPD
62741220|NCT06517277||Patients|Hospitalized patients for a Haemophilus influenzae pneumonia in 13 AP-HP hospitals between 09/01/2022 to 08/31/2023.
62552078|NCT05434169|ACTIVE_COMPARATOR|Neutral communication|
62552079|NCT00986050|ACTIVE_COMPARATOR|Bare metal stent (BMS)|
62552080|NCT00986050|ACTIVE_COMPARATOR|Drug eluting stent (DES)|
62552081|NCT00986050|ACTIVE_COMPARATOR|Abciximab|
62552082|NCT00986050|NO_INTERVENTION|No abciximab|
62552083|NCT02499796|EXPERIMENTAL|Single Arm|"Every patient receives 20 minutes of invasive mechanical ventilation with each of the three humidification systems in random sequence:~* Heated and moisture exchanger (HME)~* Heated humidifier (HH)~* Hygrovent Gold"
62552084|NCT05506670|EXPERIMENTAL|proved RSV infection (RSV positive patients|
62552085|NCT05506670|EXPERIMENTAL|suspected but not proved RSV infection (RSV negative patients)|
62552086|NCT04599478|EXPERIMENTAL|Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication|Participants randomly assigned to this arm will receive 16 weeks of BWL counseling and NB medication. The naltrexone and bupropion will be taken daily in pill form.
62552087|NCT04599478|EXPERIMENTAL|BWL + Placebo|Participants randomly assigned to this arm will receive 16 weeks of BWL counseling and placebo. Placebo will be inactive and taken daily in pill form.
62552088|NCT04599478|EXPERIMENTAL|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication taken daily in pill form.
62552089|NCT04599478|PLACEBO_COMPARATOR|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
62552090|NCT05714462|EXPERIMENTAL|postmenopausal with normal/overweight BMI that eats primarily beef as their protein source|
62552091|NCT05714462|EXPERIMENTAL|postmenopausal with normal/overweight BMI that eats vegetables as their protein source|
62552092|NCT05714462|EXPERIMENTAL|postmenopausal with obese BMI that eats primarily beef as their protein source in study meals|
62552093|NCT05714462|EXPERIMENTAL|postmenopausal with obese BMI that eats vegetables as their protein source in study meals|
62552094|NCT05714462|ACTIVE_COMPARATOR|premenopausal with normal/overweight BMI that eats primarily beef as their protein source|
62552095|NCT02899962|ACTIVE_COMPARATOR|LEO 90100 aerosol foam|Topical application twice weekly for 52 weeks
62552096|NCT02899962|PLACEBO_COMPARATOR|LEO 90100 aerosol foam vehicle|Topical application twice weekly for 52 weeks
62175554|NCT04193709|EXPERIMENTAL|Cardiovascular spinal cord epidural stimulation|The purpose of this arm is to use spinal cord epidural stimulation for maintenance of blood pressure and heart rate in the lab during cystometry (bladder filling) and anorectal filling (bowel distension) and in the at-home setting for maintenance of normative blood pressure and heart rate that can be triggered from bladder filling and during bowel evacuation.
62175555|NCT03379779||Pneumonia patient with respiratory failure|Sputum and stool sampling day 1, 3 and 7 after enrolling into study
62175556|NCT04359264|EXPERIMENTAL|Cash transfer|
62175557|NCT04359264|NO_INTERVENTION|Control|
62175558|NCT03618719||Obstructive sleep apnea|Patients with treatment-naive obstructive sleep apnea (OSA) who need continuous positive airway pressure (CPAP) therapy on clinical basis
62175559|NCT03618719||Control|Healthy controls without OSA
62175560|NCT05644535||Group A|Patients were aged 60-69 years
62175561|NCT05644535||Group B|Patients were aged 70-79 years
62175562|NCT05644535||Group C|Patients were aged 80-89 years
62552097|NCT06345807|EXPERIMENTAL|Individualized physical activity program|
62552098|NCT06345807|ACTIVE_COMPARATOR|Physical Activity program defined without optimisation|
62552099|NCT06345807|OTHER|no Physical Activity program|
62552100|NCT01096797|EXPERIMENTAL|Children undergoing adenotonsillectomy|Children between 2-6 years old undergoing elective adenoidectomy with or without tonsillectomy from the ENT Service of the San Gerardo Hospital.
62552101|NCT01654315|EXPERIMENTAL|Experimental: Myomo Only Group|"Experimental: Myomo Only Group Patients are administered rehabilitative therapy known as repetitive task specific practice (RTP) using only the Myomo robotic device targeting their affected arms on 3 days/week, in 1/2 hour increments, during an 8-week period."
62175563|NCT05644535||Group D|Patient age \> 90 years
62175564|NCT04063345|EXPERIMENTAL|IVUS-guided PCI|Percutaneous intervention under IVUS-guidance
62175565|NCT04063345|ACTIVE_COMPARATOR|Angiography-guided PCI|Percutaneous intervention under angiograhy-guidance only
62175566|NCT02090998|ACTIVE_COMPARATOR|SPG Nerve Block with Lidocaine 5% gel|Sphenopalatine Ganglion Nerve Block (SPG Nerve Block) will be administed weekly for 4 weeks using 5% Lidocaine gel This intervention (a nerve block) will treat the headache for the time period investigated
62552102|NCT01654315|EXPERIMENTAL|Experimental: Myomo + RTP Group|Experimental: Myomo + RTP Group Patients are administered rehabilitative therapy using both the Myomo robotic device and RTP targeting their affected arms on 3 days/week in 1/2 hour increments, during an 8 week period. These patients engage in activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the device during the activities is reduced.
62175567|NCT02090998|ACTIVE_COMPARATOR|Amitriptyline / Elavil|Amitriptyline / Elavil 10 mg once a day for one week then Amitriotyline 20 mg once a day for three weeks This intervention will treat the headache for the time period investigated
62175568|NCT03354897|OTHER|Treatment|16 weeks treatment 5mg/day
62175569|NCT00621946|PLACEBO_COMPARATOR|Placebo|Placebo Matching Escitalopram given orally daily (for a 12-week duration).
62175570|NCT00621946|ACTIVE_COMPARATOR|Escitalopram|Once daily oral administration (for a 12-week duration) of 10 mg escitalopram tablets with an increase to 20 mg in those with a less than 30% decrease in HAM-D scores at week 4.
62175571|NCT04561583|OTHER|LED light source system for endoscope|This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).Test grop use LED light source system for endoscope
62175572|NCT04561583|OTHER|Pinpoint Endoscopic Fluorescence Imaging System|This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).control group use Pinpoint Endoscopic Fluorescence Imaging System (Model: PC9000)
62182411|NCT02505477|PLACEBO_COMPARATOR|Placebo|Patients in this group will receive placebo tablets indistinguishable from NAC tablets, with the same protocol as NAC: two placebo tablets by mouth each morning, and two placebo tablets by mouth each evening. Manufacturer: Jarrow Industries, Inc.; Brand name: N-A-C Sustain
62552103|NCT01654315|ACTIVE_COMPARATOR|Active Comparator: RTP Group|Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.
62552104|NCT01079728||ischemic stroke patients|patients with an ischemic stroke in the anterior (ACA, MCA) and posterior flow area (PCA, BA) of any severity in the last 36h
62552105|NCT05955183|ACTIVE_COMPARATOR|AZD5055|Participants will orally receive AZD5055.
62552106|NCT05955183|PLACEBO_COMPARATOR|Placebo|Participants will orally receive placebo.
62552107|NCT06451341||Patients|Patients receiving care at the University of Nebraska Medical Center (UNMC) Specialty Care Center who live outside of the Omaha metropolitan area and who choose to start CAB+RPV LA as part of clinical care.
62552108|NCT06451341||Staff|Staff at the University of Nebraska Medical Center (UNMC) Specialty Care Center or the Nebraska Medicine Grand Island clinic who provide HIV-related care and are involved in this study.
62552109|NCT06582810||Lidocaine infusion|Patients will receive a 100 mg intravenous lidocaine bolus followed by an initial infusion at a rate of 2 mg∙kg -1∙h-1 based on ideal body weight. Lidocaine infusions will continue for a minimum of 1 h post-bolus. If headache numeric pain score decreases at all after initiation of infusion, then the rate will drop to 1 mg∙kg -1∙h-1. If headache numeric pain score starts increasing again, then the rate will return to 2 mg∙kg -1∙h-1, otherwise it will remain at 1 mg∙kg -1∙h-1 for up to 48 h.
62552110|NCT00317694|EXPERIMENTAL|1|
62552111|NCT00317694|PLACEBO_COMPARATOR|2|
62552112|NCT02952586|EXPERIMENTAL|Avelumab + SOC Chemoradiation Therapy|"* Avelumab 10 mg/kg IV: Day 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; and Q2W for 12 months during the Maintenance Phase~* Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase~* Intensity Modulated Radiation Therapy (IMRT) 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase"
62552113|NCT02952586|PLACEBO_COMPARATOR|Placebo + SOC CRT|"* Placebo IV matching avelumab: Days 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; Q2W for 12 months during the Maintenance Phase~* Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase~* IMRT 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase"
62552114|NCT05258201|EXPERIMENTAL|Muscle Energy Technique|Muscle energy Technique will be applied on the subjects, when they will be lying supine and on the effect side therapist will stabilize shoulder by one hand, while the ear / mastoid area of the affected side will be hold by opposite hand. The head and neck will be bend to contralateral side, then bends on the same side. Subject will raise his shoulder with the shoulder fixed to the ear with less effort than the maximum. Isometric contraction will be maintain for 7-10 seconds. This position will be held for 30 seconds and repeat three to five times per on treatment session
62552115|NCT05258201|EXPERIMENTAL|Strain-counterstrain|Strain And Counter Strain will be applied on subject in normal position and will be produced by placing the muscle in a short / relaxed position, the point where the pain will reduce of at least 70% will be produce will easily define. The patient will be in a supine position while the doctor will place the labial arm in flexion, abduction and external rotation to reduce the reported Trp pain. Once the position is easy to find, the pressure will be apply to the Trp and will be hold for 20-30 seconds and repeat this process for up to five times
62175573|NCT06389929|EXPERIMENTAL|Skill Group|"Students in the skill group will take one of the applications in the Skill Checklists (Breastfeeding Education Skill Check Form, Breast Care and Caregiving to Mothers with Breast Engorgement Skill Check Form, Breast Self-Examination (KKMM) Training Skill Check Form) within the scope of the Women's Health and Diseases Nursing Course. Health education material was prepared in line with the skills they determined. The duration of training material preparation is determined as 1 week for each student. The health education material developed was prepared and presented by evaluating the reason, importance, awareness aspect and innovative perspective of the determined skill."
62175574|NCT06389929|NO_INTERVENTION|Control Group|The post-test will be applied to the control group 1 day after the pre-test, and the questionnaires and scales applied in the pre-test to the skill group were re-evaluated after the presentation of the health education material.
62175575|NCT02275845|EXPERIMENTAL|intervention|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg. All the subjects are receiving a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
62175576|NCT02275845|ACTIVE_COMPARATOR|control diet|a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
62175577|NCT03503487|NO_INTERVENTION|Control|Patients receiving standard informed consent procedure before intervention
62175578|NCT03503487|EXPERIMENTAL|Planner 1|Patients receiving 3D informed consent procedure before intervention with Surgical Theater
62175579|NCT03503487|EXPERIMENTAL|Planner 2|Patients receiving 3D informed consent procedure before intervention with Vesalius
62175580|NCT03220776|EXPERIMENTAL|Gabapentin, then N-Acetylcysteine, then Placebo Oral Capsule|"Three, 1-week conditions.~Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Gabapentin: 5 day trial of gabapentin with titration to 1,200mg~Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg~Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Placebo Oral Tablet: 5 day trial of matched placebo"
62552116|NCT06285292|EXPERIMENTAL|EMY (connected biofeedback medical device)|2 rehabilitation between M0 and M2 and pelvic-perineal exercises with the EMY device on 3 different days a week, for 15 minutes, over a period of 3 months.
62552117|NCT06285292|NO_INTERVENTION|standard|15 sessions of pelvic floor rehabilitation (gold standard)
62552118|NCT03688633|EXPERIMENTAL|Candesartan|
62552119|NCT03688633|ACTIVE_COMPARATOR|Usual care|
62552120|NCT06384833|EXPERIMENTAL|Ascorbic Acid and N-acetylcysteine|Vitamin C 500 mg IV q4h for 4 doses PO d0 N-acetylcysteine 600mg 1 tab PO OD for 45 days Vitamin C 100mg 5 tab PO BID for 45 days
62552121|NCT06384833|PLACEBO_COMPARATOR|Placebo|Placebo of vitamin C (0.9%NaCl) 100 ml IV q4h for 4 doses PO day0 Placebo of N-acetylcysteine 1 tab PO OD for 45 days Placebo of Vitamin C 5 tab PO BID for 45 days
62182412|NCT01792843||Parkinson's disease|Patients with Parkinson's disease according to international criteria
62182413|NCT05336981|EXPERIMENTAL|Low-Level Light Therapy ACTIVE|Patients will receive applications of photobiomodulation directly in the region extraoral of the salivary glands ( parotid and submaxilar) will be given once a week for another 6 weeks.
62552122|NCT00734058|EXPERIMENTAL|Persistent AF|Treatment arm to be compared with historical control.
62552123|NCT03867747|EXPERIMENTAL|Cardiac Radiosurgery|25 Gy in a single fraction
62552124|NCT00159224|EXPERIMENTAL|Lopinavir/ritonavir monotherapy|Patients with undetectable viral load while on 1st line ARV therapy will be randomized to the expermental arm: Lopinavir/ritonavir monotherapy
62552125|NCT00159224|ACTIVE_COMPARATOR|Lopinavir/Ritonavir plus 2 NRTIs|Patients randomized to this arm will continue with standard of care triple therapy, based on Lopinavir/Ritonavir plus 2 NRTIs
62552126|NCT00814268|EXPERIMENTAL|Combination therapy|Administration of Aspirin + Clopidogrel for 30 days
62175581|NCT03220776|EXPERIMENTAL|N-Acetylcysteine, then Placebo Oral Capsule, then Gabapentin|"3, 1 week conditions.~Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg~Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Placebo Oral Tablet: 5 day trial of matched placebo~Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Gabapentin: 5 day trial of gabapentin with titration to 1,200mg"
62175582|NCT03220776|PLACEBO_COMPARATOR|Placebo Oral Tablet, then Gabapentin, then N-Acetylcysteine|"Three, 1-week conditions. Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Placebo Oral Tablet: 5 day trial of matched placebo~Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Gabapentin: 5 day trial of gabapentin with titration to 1,200mg~Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg"
62175583|NCT03220776|EXPERIMENTAL|Placebo Oral Capsule, then N-Acetylcysteine, then Gabapentin|"Three, 1-week conditions.~Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Placebo Oral Tablet: 5 day trial of matched placebo~Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Gabapentin: 5 day trial of gabapentin with titration to 1,200mg"
62552127|NCT00814268|ACTIVE_COMPARATOR|Monotherapy|Administration of Aspirin + Clopidogrel placebo for 30 days
62552128|NCT06376058|ACTIVE_COMPARATOR|chloroprocaine group|intrathecal fixed dose of chloroprocaine 1%
62552129|NCT06376058|ACTIVE_COMPARATOR|ropivacaine group|intrathecal fixed dose of ropivacaine 0.75%
62552130|NCT03541317|EXPERIMENTAL|Stage 1: Optimal First Line Implementation Strategy|"All schools enrolled will first be randomized to an optimal first line treatment in order to compare REP vs. REP + Coaching. Schools assigned to Stage 1 treatment REP will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; and ongoing technical assistance in CBT implementation. Schools assigned to Stage 1 treatment REP + Coaching will receive the REP components plus weekly visits from a CBT expert or Coach, for a minimum of 12 weeks."
62552131|NCT03541317|EXPERIMENTAL|Stage 2: Added Value of Providing Facilitation|"After 2 months, schools will be assessed to determine whether they could benefit from augmenting their current strategy with a step-up strategy called Facilitation. Schools identified as potentially benefiting will be re-randomized to compare the added value of augmenting their current strategy with Facilitation, compared to continuing with their same strategy. Stage 2 treatment strategy: step-up will include provision of an additional implementation strategy called Facilitation. A full-time Facilitator who is a member of the study team and has expertise in CBT, implementation methods, and use of EBPs in schools will support school professionals in strategic thinking and leadership skills to address organizational barriers. Sites receiving Facilitation will receive regular calls for up to a minimum of 10 weeks from the Facilitator. All schools will also continue to receive their first line treatment (i.e. REP or REP + Coaching)."
62552132|NCT05309395|EXPERIMENTAL|Food Rx- meal plans and groceries|These households will receive grocery delivery weekly for 6 months
62552133|NCT05309395|ACTIVE_COMPARATOR|Wait-listed control|These households will not receive grocery delivery for the first 6 months, but will get them the second six months after recruitment.
62552134|NCT03337399|EXPERIMENTAL|Stepped PC|"* Patients will receive Stepped PC~* During step 1, patients will be scheduled to meet with the outpatient PC clinician within four weeks of study enrollment and after they are admitted to the hospital or have a change in their cancer treatment~* Patients will complete the Functional Assessment of Cancer Therapy-Lung (FACT-L) to monitor their quality of life every six weeks and if their quality of life deteriorates substantially, they will step up to step 2 of the protocol~* Patients who transition to step 2 will then meet with the PC clinician at least every four weeks for the remainder of their illness"
62552135|NCT03337399|EXPERIMENTAL|Early Integrated PC|"* Patients will receive Early Integrated PC~* Patients will meet with the PC clinician within four weeks of enrollment and at least every four weeks throughout their course of illness"
62552136|NCT05146830||Participants with Cystinosis Disease|This is a long-term follow-up study of participants who previously received CTNS-RD-04 (single dose administration). No investigational product will be administered in this study.
62552137|NCT01707056|ACTIVE_COMPARATOR|Black coffee|Synthroid will be administered with 12 ounces of black coffee for a period of 6 weeks.
62552138|NCT01707056|ACTIVE_COMPARATOR|Coffee with Milk|Synthroid will be administered with 12 ounces of coffee and 2 ounces of 2% milk for a period of 6 weeks.
62552139|NCT01707056|ACTIVE_COMPARATOR|Black Tea|Synthroid will be administered with 12 ounces of black Lipton tea for a period of 6 weeks.
62552140|NCT01707056|PLACEBO_COMPARATOR|Water|Synthroid will be administered with 12 ounces of water for a period of 6 weeks.
62175584|NCT03220776|EXPERIMENTAL|Gabapentin, then Placebo Oral Capsule, then N-Acetylcysteine|"Three, 1-week conditions.~Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Gabapentin: 5 day trial of gabapentin with titration to 1,200mg~Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Placebo Oral Tablet: 5 day trial of matched placebo~Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg"
62175585|NCT03220776|EXPERIMENTAL|N-Acetylcysteine, then Gabapentin, then Placebo Oral Capsule|"Three, 1-week conditions.~Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg~Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Gabapentin: 5 day trial of gabapentin with titration to 1,200mg~Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Placebo Oral Tablet: 5 day trial of matched placebo"
62552141|NCT06551194||UC patients|Adult patients (age ≥18) diagnosed with UC
62175586|NCT02671864|OTHER|1: incretin-based therapy|Patients with incretin-based therapy
62552142|NCT06551194||CD patients|Adult patients (age ≥18) diagnosed with UC
62175587|NCT02671864|OTHER|2: other antidiabetic|Patients with other antidiabetic
62175588|NCT01098799||Control|Healthy controls
62552143|NCT03655730|EXPERIMENTAL|intervention arm|follow weekly psychotherapeutic individual sessions following the IPT method during one year.
62741221|NCT03690401||Moving On Group|Participants' body composition will be estimated using a SOZO device at 5 different time points over 12 weeks. Participant will also complete questionnaires and physical assessments during each study visit. These include waist \& hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, 6 minute walk test, cancer distress assessment, ECOG performance status, hand grip strength test, and 3-day food diary. DEXA scans will be performed before treatment and after completion of treatment. Moving On assessments will be performed at first and last study visits.
62552144|NCT03655730|EXPERIMENTAL|usual care arm|continue with the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
62552145|NCT03038386|OTHER|Dual Energy CT|In this study all patients undergo DECT scan to assess the value of DECT scan in diagnosing acute arthritis caused by gout. If the DECT scan demonstrates MSU depositions and the diagnosis of gout was not ascertained prior to DECT scanning by MSU crystals in the synovial fluid, then additional ultrasound guided aspiration will take place, with knowledge of DECT results, followed by repeat microscopy
62552146|NCT06007235|OTHER|A: CACIPLIQ20 before placebo|Arm A will receive at first CACIPLIQ20 (experimental product) for 1 month, followed by 1-month washout, then 1 month of saline (placebo comparator).
62552147|NCT06007235|OTHER|B: placebo before CACIPLIQ20|Arm B will receive at first saline (placebo comparator) for 1 month, followed by 1-month washout, then 1 month of CACIPLIQ20 (experimental product).
62552148|NCT02372279|NO_INTERVENTION|No embryo observation (NEO)|Study group. No embryonic observation from day one to day five of embryo development.
62552149|NCT02372279|EXPERIMENTAL|Embryo observation (EO)|Control group. Conventional embryonic observations performed in day two, three and five of embryo development.
62552150|NCT06124898|EXPERIMENTAL|"Moderate drinking technologies with lower tech facilitation"|"Brief motivational-interviewing-based counseling followed by use of three moderate drinking technologies (breath alcohol device and app, blood alcohol content estimator app and self-texting procedure) with lower tech facilitation."
62552151|NCT06124898|EXPERIMENTAL|"Moderate drinking technologies with higher tech facilitation"|"Brief motivational-interviewing-based counseling followed by use of three moderate drinking technologies (breath alcohol device and app, blood alcohol content estimator app and self-texting procedure) with higher tech facilitation"
62552152|NCT06124898|ACTIVE_COMPARATOR|Attention control condition|To be determined attention control condition, which will involve either non-personalized information about alcohol or feedback regarding another health behavior with minimal relationship to alcohol use, followed by related technology use.
62552153|NCT03591510|EXPERIMENTAL|Chemotherapy followed by Midostaurin|"In Part 1, midostaurin with standard induction (Block 1 induction according to local practice, Block 2 induction containing fludarabine, cytarabine, daunorubicin/idarubicin) and consolidation (Block 3: cytarabine + mitoxantrone, Block 4: cytarabine + etoposide, Block 5: cytarabine) followed by single agent midostaurin post-consolidation therapy.~In Part 2, midostaurin with standard induction (Block 1 induction according to local practice, Block 2 induction containing cytarabine + mitoxantrone) and consolidation (Block 3: cytarabine + etoposide, Block 4: cytarabine + mitoxantrone, Block 5: cytarabine) followed by single agent midostaurin post-consolidation therapy."
62552154|NCT03790657|EXPERIMENTAL|tDCS Dosage A|"mild electrical stimulation (Dosage level A) delivered to the frontal region of the brain during practice of a complex walking task"
62175589|NCT01098799||Chronic kidney disease-1|Chronic kidney disease not taking dialysis treatment
62175590|NCT01098799||Kidney Transplant|Kidney transplants
62175591|NCT01218295|EXPERIMENTAL|Respiratory muscle training|Patients assigned to this arm train the respiratory muscles by means of normocapnic hyperpnea.
62175592|NCT00260676|OTHER|conventional ventilation, protective ventilation|
62175593|NCT06435741|EXPERIMENTAL|Experimental arm|there is only one arm the included patients in which receive 99mTc-3PRGD2 Spect-CT scan.
62175594|NCT05394389|ACTIVE_COMPARATOR|sensory-stimulating therapy|
62175595|NCT05394389|ACTIVE_COMPARATOR|social interaction|
62552155|NCT03790657|EXPERIMENTAL|tDCS Dosage B|"mild electrical stimulation (Dosage level B) delivered to the frontal region of the brain during practice of a complex walking task"
62175596|NCT05394389|EXPERIMENTAL|combined sensory-stimulating therapy and social interaction.|
62552156|NCT06383455||Smoking individuals with periodontitis|The participants were divided into two groups according to self-reported smoking habits. The smoker group consisted of individuals with stage 3/4 periodontitis who smoked at least ten cigarettes per day for at least five years.
62175597|NCT02750553|EXPERIMENTAL|Pre-test|Three healthy male subjects were randomized in 2:1 ratio to receive single and then multiple (14 days) oral dose of 5 mg SHR0534 or matching placebo.
62175598|NCT02750553|EXPERIMENTAL|Cohort 1|Eight healthy subjects were randomized in 3:1 ratio to receive single and then multiple (14 days) oral dose of 5 mg SHR0534 or matching placebo.
62552157|NCT06383455||Non-smoking individuals with periodontitis|The non-smoker group consisted of individuals with Stage 3/4 periodontitis who had never smoked in a lifetime or had quit smoking at least two years ago.
62552158|NCT04133987|EXPERIMENTAL|Tetravalent live attenuated dengue vaccine admixture TV005|Tetravalent live attenuated dengue vaccine admixture TV005
62175599|NCT02750553|EXPERIMENTAL|Cohort 2|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 10 mg SHR0534 or matching placebo.
62175600|NCT02750553|EXPERIMENTAL|Cohort 3|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 25 mg SHR0534 or matching placebo.
62552159|NCT04133987|PLACEBO_COMPARATOR|placebo|Plasma-Lyte A
62552160|NCT02475928|PLACEBO_COMPARATOR|100 mg placebo|100 mg Placebo plus nutritional education
62552161|NCT02475928|EXPERIMENTAL|100 mg zinc supplement|Nutritional education plus 100 mg of zinc gluconate
62552162|NCT03092219|EXPERIMENTAL|TEOSYAL RHA Redensity|Injection of TEOSYAL RHA Redensity into the perioral lines (n=150). Up to 6.0 mL (max 3 mL for upper and max 3 mL for lower) injected into the dermis, including the superficial dermis. Touch-up treatment provided at 2 weeks.
62552163|NCT03092219|NO_INTERVENTION|No Treatment|No treatment control group (n=52).
62175601|NCT02750553|EXPERIMENTAL|Cohort 4|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 50 mg SHR0534 or matching placebo.
62175602|NCT02750553|EXPERIMENTAL|Cohort 5|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 100 mg SHR0534 or matching placebo.
62552164|NCT05796076|OTHER|Control group|Participants in the control group will be received standard care
62552165|NCT04944706|EXPERIMENTAL|Low dose group|The standard basic treatment is given according to the guidelines related to the underlying disease
62552166|NCT04944706|EXPERIMENTAL|High dose group|The standard basic treatment is given according to the guidelines related to the underlying disease
62552167|NCT04944706|EXPERIMENTAL|Placebo group|The standard basic treatment is given according to the guidelines related to the underlying disease
62552168|NCT04170556|EXPERIMENTAL|Regorafenib plus Nivolumab|Regorafenib will be initiated at full dose (160 mg/day; 3 weeks on and 1 week off) in monotherapy for the first 8 weeks. After week 8, regorafenib will be continued in combination with nivolumab, until symptomatic tumor progression, unacceptable adverse events, patient decision or death
62552169|NCT02680236||Breast Cancer Patients|"This pilot study proposes to explore the effect of art therapy on breast cancer patients' perception of pain, and its impact on daily functioning by offering four sessions of individual art therapy, spaced between one to three weeks apart.~The study will be open to breast cancer patients over the age of 18, who have been assessed by the Royal Marsden (RM) Pain Team, and who report having persistent post treatment pain of at least moderate intensity for the preceding two weeks despite having been optimally treated for their pain already, and who fulfil the inclusion criteria."
62552170|NCT05545189||colonoscopy group1|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients.
62175603|NCT03238456|EXPERIMENTAL|Intervention|The intervention entitled Motivating Pacifika Against Cigarettes and Tobacco (MPACT) was implemented for eight weeks starting on the quit date that the participant chose with their assigned coach during the baseline assessment. At the baseline assessment, each participant watched an introductory video that described the online smoking cessation program. The online program was accessed through the participant's Facebook account. The program included eight education modules and a forum. Participants also received automated daily text messages to provide support and encouragement during the quitting process.
62175604|NCT03238456|NO_INTERVENTION|Control|Participants in the control group set a quit date within two weeks of their baseline assessment and watched an introductory video that described the smoking cessation program. They received one text message every other week over a period of eight weeks following the quit date. The messages were delivered by a web-based system not connected to the online intervention program. Participants were also given a handout listing local tobacco cessation and education resources, a link to a generic online smoking cessation program, a fact sheet on smoking and tobacco use among PI young adults, and a quit kit containing chewing gum and a stress ball.
62552171|NCT05545189||colonoscopy group 2|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients
62552172|NCT05545189||colonoscopy group 3|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients
62552173|NCT05545189||colonoscopy group 4|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients
62552174|NCT05545189||colonoscopy group 5|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients
62552175|NCT05545189||colonoscopy group 6|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients
62552176|NCT05725551|EXPERIMENTAL|ShotBlocker group|Pain in intramuscular injection It is a noninvasive, plastic tool used to reduce.
62552177|NCT05725551|EXPERIMENTAL|Finger Puppet group|Finger puppetry is an alternative method of interacting with the child through play while performing an intramuscular injection.
62552178|NCT05725551|EXPERIMENTAL|Balloon group|Balloon inflation method, the child inflating the balloon while performing an intramuscular injection.
62552179|NCT05725551|NO_INTERVENTION|Control Group|Intramuscular injection without any intervention.
62741222|NCT03690401||Non-Moving On Group|Participants' body composition will be estimated using a SOZO device at 5 different time points over 12 weeks. Participant will also complete questionnaires and physical assessments during each study visit. These include waist \& hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, 6 minute walk test, cancer distress assessment, ECOG performance status, hand grip strength test, and 3-day food diary. DEXA scans will be performed at first and last study visits.
62741223|NCT03539744|EXPERIMENTAL|Arm 1 VenDex|Venetoclax administered orally once daily (QD) plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
62175605|NCT00570921|EXPERIMENTAL|Fulvestrant + Everolimus|"Fulvestrant + Everolimus~Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14, and then 250 mg on day 28 and every 4 weeks ± 3 days thereafter. Everolimus was administered initially at a dose of 5 mg daily in the first 5-patient cohort for the first month of treatment and then increased to 10 mg PO daily after that."
62175606|NCT01315197|EXPERIMENTAL|massage|The massage Anma has Japanese origin and a protocol was used with smoothing, kneading and pressure points on the bladder meridian.
62175607|NCT04279756|ACTIVE_COMPARATOR|Mildly Impaired Group|This group is with participants with mildly impaired hip internal range of motion, from 25-30 degrees.
62175608|NCT04279756|ACTIVE_COMPARATOR|Moderately Impaired Group|This group is with participants with moderately impaired hip internal range of motion, from 20-24 degrees.
62175609|NCT04279756|ACTIVE_COMPARATOR|Severely Impaired Group|This group is with participants with severely impaired hip internal range of motion, less than 20 degrees.
62175610|NCT05157568|ACTIVE_COMPARATOR|Control (C)|Participants will receive a exercise prescription and a home exercise plan. It will specify how many days per week they should exercise and will indicate how hard they should be working using their heart rate and rating of perceived exertion (RPE) as a guide. They will attend 8 onsite rehabilitation classes at the University of Ottawa Heart Institute (1 class per week for 8 weeks). These classes will be led by a specially trained instructor who will teach and encourage self-monitoring of heart rate and RPE. The class will include a warm-up, 30 minutes of aerobic exercise and a 15 min cool-down, including strength exercises and stretches. Following each class there will be a short mini-education session highlighting a variety of topics on how to manage risk factors. Patients will have access to onsite classes for nutrition and stress management. Participants will receive access to 8 additional educational videos that highlight topics such as exercise safety, goal setting and nutrition.
62175611|NCT05157568|ACTIVE_COMPARATOR|Exercise Streaming (ES)|"Participants will complete 1 live virtual class per week for 8-weeks. Classes will be led by a specially trained instructor and will include a warm-up, 30 minutes of aerobic exercise, 10 minutes of strength exercises, and a cooldown and stretching segment. During each live class, the instructor will play the corresponding video and supervise the participants through the Zoom for Healthcare platform. Heart rates and RPE data will be collected from each participant. Participants will have access to other pre-recorded exercise videos that they can stream on demand at any time. They will be encouraged to access them on demand throughout the week. In addition participants will have access to the same 8 pre-recorded educational videos that the control group will receive. Topics include; exercise safety, goal setting, nutrition, stress management, medication information, risk factor awareness and transition planning."
62175612|NCT05157568|ACTIVE_COMPARATOR|Exercise Streaming + Equipment (ES+E)|"Participants will receive an indoor bicycle and an exercise band (delivered and set up in their home). Participants will complete 1 live class per week for 8 weeks. Their exercise prescription will be based on a stress test. Classes will be led by a specially trained instructor and will include a warm-up, 30 minutes of aerobic exercise, 10 minutes of strength exercises, and a cooldown and stretching segment. During each live class, the exercise supervisor will play the corresponding video and supervise the participants through the Zoom for Healthcare platform. Heart rate and RPE data will be collected from each participant. Participants will have access to other pre-recorded exercise videos that they can stream on demand at any time. Participants will be encouraged to access them throughout the week. Participants will have access to the same 8 pre-recorded educational videos that the control and exercise streaming groups will receive."
62552180|NCT03222856|EXPERIMENTAL|Pembrolizumab + eribulin|All eligible patients will be treated with MK3475 (pembrolizumab) 200 mg on day 1 of each 21-day cycle and eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) on days 1 and 8 of every 21-day cycle. Treatment with MK3475 (pembrolizumab) and eribulin will continue based on physician criteria. No maximum duration of treatment is specified. Study follow-up will be performed 12 months after last study dose.
62175613|NCT01862185|EXPERIMENTAL|semi-quantitative procalcitonin|patients whom checked semi-quantitative procalcitonin examination
62175614|NCT01862185|NO_INTERVENTION|control|patients whom do not checked semi-quantitative procalcitonin examination
62175615|NCT05221983||Patients with COVID-19 + with vitamin D levels|Patients with COVID-19 + and vitamin D levels were included in the study retrospectively. Vitamin D level was categorized into 3 groups as inadequacy, deficiency and normal from medical records. No intervention was made.
62175616|NCT02269917|EXPERIMENTAL|Experimental Treatment Regimen|Participants will receive a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily, up to Week 48. After Week 48, all participants will continue to receive the D/C/F/TAF tablet in a 48 week extension phase (up to Week 96).
62175617|NCT02269917|ACTIVE_COMPARATOR|Current Treatment Regimen|Participants will receive a boosted protease inhibitor (bPI) (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) up to Week 52. After Week 52, all participants will receive the D/C/F/TAF tablet in a 44 week extension phase (up to Week 96).
62741224|NCT03539744|ACTIVE_COMPARATOR|Arm 2 PomDex|Pomalidomide administered orally once daily (QD) on Days 1 - 21 for each 28-day cycle plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
62741225|NCT04003207|EXPERIMENTAL|Phelan-McDermid syndrome|Patients with Phelan-McDermid syndrome receive 12 weeks of growth hormone therapy
62741226|NCT03322046||Therapeutic Lifestyle Change (TLC) Intervention Group|TLC group received CVD risk lecture, enrolled in lifestyle program, received follow-up visits from team practitioner after each blood draw, access to food journaling portal for 12 month period, telephonic coaching
62552181|NCT04012567|EXPERIMENTAL|The Biosure Regenesorb Interference Screw|The Biosure Regenesorb Interference Screw, an absorbable screw designed with an open structure and made of biocomposite material, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery.
62552182|NCT04012567|ACTIVE_COMPARATOR|The BIOSURE HA Interference Screw|The Biosure HA Interference Screw, an absorbable screw made of biocomposite material, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery.
62552183|NCT05697523||Patient group|people with mild RRMS
62175618|NCT01801462|EXPERIMENTAL|Simulation-based ultrasound training|The initial training is provided on a high-fidelity Virtual-Reality (VR) simulator (Scantrainer, Medaphor). The VR simulator provides images obtained from real patients and haptic feedback from the ultrasound probe. The basic gynecologic and advanced gynecologic modules are selected for training purposes. When all modules are passed on the VR simulator, the participants receive 30 minutes of training on the low-fidelity simulator (BluePhantom) to allow participants to review the functions, they just trained, using real ultrasound equipment.
62175619|NCT01801462|NO_INTERVENTION|Control|Participants randomized to the control group receive traditional clinical introduction locally in the departments. This may include observation and supervised practice and the different types of clinical training provided by each department are gathered through the department's head of education and registered.
62175620|NCT00057044|OTHER|Arm 1|
62175621|NCT02216149|EXPERIMENTAL|S-1 plus oxaliplatin (SOX)|Oxaliplatin 130 mg/m2 d. 1 followed by oral S-1 25 mg/m2/day BID d1-14.
62175622|NCT02216149|ACTIVE_COMPARATOR|Oxaliplatin plus capecitabine (XELOX)|Intravenous oxaliplatin 130 mg/m2 d.1 followed by oral capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14.
62552184|NCT05697523||Healthy group|healthy people
62552185|NCT01088230|EXPERIMENTAL|Botox®|this group will receive an injection of botox in the wrist flexors and forearm pronators
62175623|NCT00931918|ACTIVE_COMPARATOR|RCHOP|RCHOP \[rituximab, cyclophosphamide, doxorubicin, prednisone\] administered as follows: rituximab 375 mg/m\^2 intravenous (IV) infusion, cyclophosphamide 750 mg/m\^2 IV infusion, doxorubicin 50 mg/m\^2 IV injection and vincristine 1.4 mg/m\^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
62175624|NCT00931918|EXPERIMENTAL|Vc-RCHOP|Vc-RCHOP \[bortezomib (VELCADE®), rituximab, cyclophosphamide, doxorubicin, prednisone\] administered as follows: bortezomib (VELCADE ®) 1.3 mg/m\^2 administered intravenous (IV) push on Days 1 and 4 of each cycle with RCHOP administered as follows: rituximab 375 mg/m\^2 intravenous (IV) infusion, cyclophosphamide 750 mg/m\^2 IV infusion, doxorubicin 50 mg/m\^2 IV injection and vincristine 1.4 mg/m\^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
62552186|NCT01088230|PLACEBO_COMPARATOR|Saline|This group will receive an injection of saline solution in the same muscle groups as the treatment group (wrist flexors and pronators).
62552187|NCT03063411|EXPERIMENTAL|Executive function intervention|The intervention comprises four weekly sessions lasting 15-20 minutes. In these sessions, children complete computerised tasks requiring working memory and inhibitory control. These tasks are child friendly and are based on established measures of executive function. The working memory tasks involve maintaining information in mind and processing information (for example, finding items hiding in different locations that move around) and suppressing a dominant but incorrect response (for example, a game where children try to catch fish but not sharks). Children receive feedback on their responses. If children score 75% or more correct in a session the difficulty level increases in the following session.
62175625|NCT06479122|ACTIVE_COMPARATOR|Acetaminophen|
62175626|NCT06479122|EXPERIMENTAL|Acetaminophen/Ibuprofen|
62552188|NCT03063411|ACTIVE_COMPARATOR|Visual search and simple decision making|The control task program, like the intervention, comprises four weekly sessions lasting 15-20 minutes. In these sessions, children complete computerised tasks not requiring executive function skills. Instead, they require simple attention and decision making skills and visual search skills. For example, finding an item among distractors (e.g., a spaceship), or deciding which of two animals can fly (out of a bird and a fish). Children receive feedback on their responses.
62175627|NCT00555646|EXPERIMENTAL|1|Each subject's study plaque areas will be assigned by the investigator to two PH-10 treatment plaque areas and one control plaque area.
62175628|NCT02536547||patients with suspected VAP|"All patients with suspected VAP will be included in the study (new or extension of a radiological image in a patient in mechanical ventilation for at least 48 hours associated with at least two of the following:criteria :~fever ≥38.5 ° C or \<36, 5 ° C leukocytosis\> 10 \* 103 / ml or leukopenia \<4 \* 103 / ml secretions purulent tracheal reduction in PaO2 / FiO2 \<300 or PaO 2 \<60 mmHg"
62552189|NCT02046603|EXPERIMENTAL|Tocilizumab Monotherapy|Participants will receive a weekly SC injection of tocilizumab 162 mg as monotherapy for 52 weeks.
62175629|NCT02795715|EXPERIMENTAL|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
62552190|NCT02046603|EXPERIMENTAL|Tocilizumab in Combination With Methotrexate or Other DMARDs|Participants will receive a weekly SC injection of tocilizumab 162 mg in combination with methotrexate or other non-biologic DMARDs for 52 weeks.
62552191|NCT06124417|EXPERIMENTAL|Treatment group|The Hamilton Rating Scale for Depression (HAMD) will be applied to assess the depressive status of all enrolled patients. This scale consists of 24 survey items, each with a score of 0-4. Patients will be assigned to the treatment group if their score was ≥8. Patients were given sertraline for antidepressant treatment in the treatment group. The initial dose ranged from 25 to 50 mg, taken orally once daily, and the dosage was adjusted based on the patient's response to the medication.
62552192|NCT06124417|NO_INTERVENTION|Control group|Patients will be assigned to the control group if their HAMD score was \<8.
62552193|NCT04031625||Metastatic Colorectal Cancer|
62741227|NCT03322046||Control Group|Control group received CVD risk lecture, then baseline, 3, 6, 12 month blood draws and 3 day food journals prior to each blood draw.
62741228|NCT06658964|EXPERIMENTAL|Cohort 1：JMKX003142 and itraconazole|Interaction between JMKX003142 and itraconazole
62741229|NCT06658964|EXPERIMENTAL|Cohort 2：JMKX003142 and rifampicin|Interaction between JMKX003142 and rifampicin
62175630|NCT02795715|SHAM_COMPARATOR|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
62741230|NCT06660927|EXPERIMENTAL|Endovascular Treatment of Patients with Common Iliac Artery Aneurysms|Endovascular Treatment of Patients with Common Iliac Artery Aneurysms Using the Iliac Bifurcation Stent Graft System
62741231|NCT06235359|OTHER|intercostal tube|"A chest tube is a hollow, flexible tube placed into the chest. It acts as a drain.~Chest tubes drain blood, fluid, or air from around your lungs, heart, or esophagus.~The tube around your lung is placed between your ribs and into the space between the inner lining and the outer lining of your chest cavity. This is called the pleural space. It allows your lungs to fully expand."
62552194|NCT04097340|ACTIVE_COMPARATOR|Attentional Training Group|Each condition involves use of a smartphone app. One smartphone app includes a task that targets attention directed to substance-related cues while the other app includes a similar task that does not target attention in this way. Neither participant nor the staff members working on the study will know which condition the participant has been randomly assigned to.
62175631|NCT02878460|EXPERIMENTAL|monitoring with ORI + SpO2|"Patients receive the regular monitoring with SpO2, but in this group, the ORI parameters is shown on the scope.~Lower and upper SpO2 limits are prescribed for each patient."
62552195|NCT04097340|PLACEBO_COMPARATOR|Control Training Group|Each condition involves use of a smartphone app. One smartphone app includes a task that targets attention directed to substance-related cues while the other app includes a similar task that does not target attention in this way. Neither participant nor the staff members working on the study will know which condition the participant has been randomly assigned to.
62552196|NCT02905188|EXPERIMENTAL|GLYCAR T cells + Fludarabine and Cytoxan|GPC3-CAR (GLYCAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with hepatocellular carcinoma.
62552197|NCT04258176||Intervention group|Patients seen in the multidisciplinary pathway
62552198|NCT04258176||Comparison group|Multimorbid patients seen several outpatient clinics who did not undergo the trajectory
62175632|NCT02878460|OTHER|monitoring with SpO2|"Patients receive the regular monitoring; the ORI parameters is not shown (but it is recorded each time a blood gas is drown).~Lower and upper SpO2 limits are prescribed for each patient."
62552199|NCT06281444|ACTIVE_COMPARATOR|ESWT group|The participants in this group will be applied with ESWT plus a home-based exercise program.
62552200|NCT06281444|SHAM_COMPARATOR|Sham-ESWT group|The participants in this group will be applied with sham-ESWT plus a home-based exercise program.
62175633|NCT04930185|EXPERIMENTAL|Pamphlet|Participants will received pamphlet about COVID-19 vaccination
62175634|NCT04930185|EXPERIMENTAL|Webinar|Participants will received webinar about COVID-19 vaccination
62175635|NCT04930185|EXPERIMENTAL|SMS|Participants will received SMS about COVID-19 vaccination
62175636|NCT06374342||CERAFORM Granules Orthopedics|Bone grafting
62391453|NCT00182793|EXPERIMENTAL|Arm I|Patients undergo stem cell collection. Patients receive high-dose melphalan IV with or without trastuzumab (Herceptin®). One day later, patients undergo autologous peripheral blood stem cell (PBSC) transplantation. No more than 7 weeks later, patients proceed to course 2. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.
62552201|NCT00712790|EXPERIMENTAL|Sequential Radioembolization-Sorafenib|Sorafenib (400 mg twice-daily) was initiated 14 days post-radioembolization with yttrium-90 (Y) resin microspheres given as a single procedure.
62552202|NCT02256423|ACTIVE_COMPARATOR|REFERENCE 1: Nurofen® 200 mg tablet|Single group 3-way crossover study
62552203|NCT02256423|ACTIVE_COMPARATOR|REFERENCE 2: Ibuprofen 200 mg soft gel capsule|Single group 3-way crossover study
62552204|NCT02256423|EXPERIMENTAL|ibuprofen 200 mg soft gel capsule|single group, 3-way cross
62552205|NCT05051514||No-Mild Severity OSAS|Mild sleep apnea: An Apnea-Hypopnea Index (AHI) of five to 14 events per hour.
62741232|NCT05243524|EXPERIMENTAL|MVP-S + CPA|All subjects will receive two doses of maveropepimut-S (q3w) followed by up to six doses (q8w) plus low-dose cyclophosphamide on a repeating cycle of one week on/one week off.
62741233|NCT05157971|EXPERIMENTAL|Treatment (venetoclax, C10403 regimen)|See Detailed Description
62741234|NCT05677490|EXPERIMENTAL|Arm I (mFOLFIRINOX, nivolumab)|Patients receive fluorouracil IV, leucovorin calcium IV, oxaliplatin IV, and irinotecan IV on study and nivolumab IV as clinically indicated. Patients undergo MRI and a CT scan throughout the trial. Patients may also undergo blood sample collection on study.
62741235|NCT05677490|ACTIVE_COMPARATOR|Arm II (mFOLFOX, nivolumab)|Patients receive fluorouracil IV, leucovorin calcium IV, and oxaliplatin IV on study and nivolumab IV as clinically indicated. Patients undergo MRI and a CT scan throughout the trial. Patients may also undergo blood sample collection on study.
62741236|NCT03941873|EXPERIMENTAL|Sitravatinib Monotherapy: 80 mg|Sitravatinib 80 mg orally once daily in 21-day cycles in participants with unresectable locally advanced or metastatic HCC or G/GEJ cancer
62552206|NCT05051514||Moderate to Severe OSAS|Moderate sleep apnea: An Apnea-Hypopnea Index (AHI) of 15 to 29 events per hour.Severe sleep apnea: An Apnea-Hypopnea Index (AHI) of 30 or more events per hour.
62552207|NCT02872428|EXPERIMENTAL|Valproic acid (Depacon)|Valproic acid by IV infusion over one hour
62552208|NCT02872428|PLACEBO_COMPARATOR|Isotonic saline solution|The placebo administered by IV infusion over 1 hour
62741237|NCT03941873|EXPERIMENTAL|Sitravatinib Monotherapy: 120 mg|Sitravatinib 120 mg orally once daily in 21-day cycles in participants with unresectable locally advanced or metastatic HCC or G/GEJ cancer
62741238|NCT03941873|EXPERIMENTAL|Sitravatinib 80 mg + Tislelizumab|Sitravatinib 80 mg orally once daily in 21-day cycles with tislelizumab 200 mg intravenously (IV) once every 3 weeks in participants with unresectable locally advanced or metastatic HCC or G/GEJ cancer
62175637|NCT06374342||CERAFORM Granules Spine|Spinal fusion
62175638|NCT06374342||CERAFORM Sticks Orthopedics|Bone grafting
62552209|NCT06176729|EXPERIMENTAL|Experimental arm|Pola-R2 regimen Drug: Polatuzumab Vedotin, Rituximab, Lenalidomide polatuzumab vedotin 1.8 mg/kg ivgtt D1, rituximab375 mg/m2 ivgtt D1, lenalidomide 25mg po D1-14, one cycle every 21 days
62175639|NCT06374342||CERAFORM Wedge Orthopedics|Bone grafting
62552210|NCT01867892|EXPERIMENTAL|ICT of oxaliplatin,irinotecan,5-FU and leucovorinon and CCRT|Arm1:oxaliplatin,irinotecan,5-FU and leucovorinon D1,15 every 28days for 3 cycles,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
62175640|NCT06374342||TRIHA+ Spine|Spinal fusion
62175641|NCT06374342||TRIHA+ Orthopedics|Bone grafting
62175642|NCT06374342||NANOGEL Spine|Cage filling
62175643|NCT06374342||NANOGEL Orthopedics|Bone grafting
62175644|NCT01079377||Adolescent Surgical Candidates|Adolescents at the Center for Adolescent Bariatric Surgery, Columbia University Medical Center
62552211|NCT01867892|ACTIVE_COMPARATOR|ICT of gemcitabine,oxaliplatin,5-FU,leucovorin and CCRT|Arm 2:gemcitabine,oxaliplatin,5-FU,leucovorin on D1,15 every 28 days for 3 cycles,Evaluation of Tumor Response,CR/PR/SD or localized disease RT 5,040cGy in 28 fractions/ 5.5 wks Arm 2: Gem 400mg/m2 iv 40min weekly
62552212|NCT04324021|ACTIVE_COMPARATOR|Emapalumab|Emapalumab i.v. infusion every 3rd day for a total 5 infusions. Day 1: 6mg/kg. Days 4, 7, 10 and 13: 3 mg/kg
62552213|NCT04324021|ACTIVE_COMPARATOR|Anakinra|Anakinra i.v. infusion four times daily for 15 days. 400 mg/day in total, divided into 4 doses given every 6 hours
62552214|NCT04324021|NO_INTERVENTION|Standard of care|Standard of care according to local practice
62552215|NCT00743418|OTHER|1|Healthy controls Mini Mental State evaluation score \>28/30
62552216|NCT00743418|OTHER|2|Mild Cognitive Impairment: Mini Mental State Evaluation Score (MMSE)=26-28/30
62552217|NCT00743418|OTHER|3|Mild Dementia: Mini Mental State Evaluation Score (MMSE)=21-25/30
62175645|NCT01079377||Obese Treatment-Seeking Adolescents|Obese Treatment-Seeking Adolescents, Maxcor Program for Overweight Education and Reduction (POWER) Program
62175646|NCT01079377||Normal-Weight Adolescents|Normal-Weight Adolescents
62175647|NCT02469077|EXPERIMENTAL|6 week aerobic exercise intervention|Participants randomly assigned to the exercise condition will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks). Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.
62552218|NCT05808322|EXPERIMENTAL|Study Group|Treated with P1101 (Ropeginterferon alfa-2b) plus standard of care (SOC)
62552219|NCT05808322|ACTIVE_COMPARATOR|Control Group|Treated with SOC alone
62175648|NCT02469077|ACTIVE_COMPARATOR|Normal exercise (control)|Participants assigned to the control condition will not undergo any exercise manipulation during this 6 week period, and will be asked to continue their current activity levels and not engage in any additional exercise activity during the study period. Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.
62741239|NCT03941873|EXPERIMENTAL|Sitravatinib 120 mg + Tislelizumab|Sitravatinib 120 mg orally once daily in 21-day cycles with tislelizumab 200 mg IV once every 3 weeks in participants with unresectable locally advanced or metastatic HCC or G/GEJ cancer
62175649|NCT05324813|EXPERIMENTAL|Domain-Specific Episodic Future Thinking|
62175650|NCT05324813|ACTIVE_COMPARATOR|Episodic Recent Thinking Control Condition|
62175651|NCT04106583||Single Arm|Single Arm - Patients with intracranial aneurysms treated with WAVE, as part of the Penumbra SMART COIL System
62552220|NCT02712723|ACTIVE_COMPARATOR|Placebo + Letrozole|Placebo randomized to 3 capsules/day 3 weeks on/1week off or 2 capsules/day continuous dosing + Letrozole 2.5 mg PO daily
62552221|NCT02712723|EXPERIMENTAL|Ribociclib 600 mg + Letrozole|Ribociclib 600 mg PO daily 21 days on/7 days off + Letrozole 2.5 mg PO daily
62552222|NCT02712723|EXPERIMENTAL|Ribociclib 400 mg + Letrozole|Ribociclib 400 mg continuous daily dosing + Letrozole 2.5 mg PO daily
62552223|NCT00669305||Cohort 1|Human participants affected with sickle cell disease or thalassemia will donate bone marrow for use in experimental models
62552224|NCT03399045|EXPERIMENTAL|9-minute withdrawal group|Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw. A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included in the 9 minutes.
62552225|NCT03399045|ACTIVE_COMPARATOR|6-minute withdrawal group|Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw. A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy willwill not be included in the 9 minutes.
62741240|NCT01377155|OTHER|Insulin determir|
62175652|NCT05688098|OTHER|Irbesartan/Amlodipine High Fixed dose combination|participants will receive one tablet of Irbesartan/Amlodipine High FDC in a crossover design
62552226|NCT05615727|EXPERIMENTAL|Dexmedetomidine|
62552227|NCT05615727|ACTIVE_COMPARATOR|Zolpidem|
62552228|NCT05615727|PLACEBO_COMPARATOR|Placebo|
62552229|NCT01439581|EXPERIMENTAL|Patients on mapping systems|
62175653|NCT05688098|OTHER|Co-administration of Irbesartan and Amlodipine High|participants will receive one table each of Irbesartan and Amlodipine High in a crossover design
62175654|NCT01974934|EXPERIMENTAL|Desvenlafaxine Succinate|
62175655|NCT01011049|EXPERIMENTAL|Group 1: Fluzone ID After Fluzone ID|Participants will receive Fluzone intradermal (ID) following Fluzone ID in Study FID31
62175656|NCT01011049|EXPERIMENTAL|Group 2: Fluzone IM After Fluzone ID|Participants will receive Fluzone intramuscular (IM) following Fluzone ID in Study FID31
62552230|NCT01439581|ACTIVE_COMPARATOR|Patients not on mapping systems|
62552231|NCT00668317|OTHER|omeprazole and ranitidine|20 mg oralomeprazole oral tablet twice daily and ranitidine 300 mg oral tablet once daily nocte
62741241|NCT04178525|EXPERIMENTAL|Arm A (Experimental group|ChitoCare gel administered topically 2-3 times a week or more (accordingly with the frequency of dressing change)
62741242|NCT04178525|PLACEBO_COMPARATOR|Arm B (Control group)|Placebo gel administered topically 2-3 times a week or more (accordingly with the frequency of dressing change)
62175657|NCT01011049|EXPERIMENTAL|Group 3: Fluzone IM After Fluzone IM|Participants will receive Fluzone intramuscular (IM) following Fluzone IM in Study FID31
62175658|NCT01011049|EXPERIMENTAL|Group 4: Fluzone ID After Fluzone IM|Participants will receive Fluzone intradermal (ID) following Fluzone intramuscular (IM) in Study FID31
62552232|NCT05424679|EXPERIMENTAL|Intervention group|Individuals randomized to the intervention group will receive an evidence-based tool (coping plan + two additional check-in calls or visits), up to three COVID-19 safety messages, information on and facilitated referrals to community support services (e.g., tribal behavioral health), and up to seven culturally responsive caring messages (i.e. Caring Contacts) from the research team over a period of three months.
62552233|NCT05424679|ACTIVE_COMPARATOR|Control group|Individuals randomized to the control group will receive an evidence-based tool (coping plan + two additional check-in calls or visits), up to three COVID-19 safety messages, and information on and facilitated referrals to community support services (e.g., tribal behavioral health) from the research team over a period of three months.
62552234|NCT03529201|EXPERIMENTAL|QLB|At the end of surgery, QLB with ropivacaine will be done on the side of the operation.
62552235|NCT03529201|EXPERIMENTAL|Control|Standard care. No regional blocks.
62552236|NCT05332821||Study group: TACE+PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|TACE was performed up to 3 months after the first PD-1/PD-L1 inhibitor/anti-angiogenic drug treatment or within 1 month before treatment. The interval between first use PD-1/PD-L1 inhibitors and anti-angiogenesis drugs ≤1 week；
62552237|NCT05332821||Control group: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|The interval between first use PD-1/PD-L1 inhibitors and anti-angiogenesis drugs ≤1 week；
62552238|NCT01190631|EXPERIMENTAL|Acrysof IQ (SN60WF) IOL|AcrySof IQ SN60WF intraocular lens (IOL) implanted in one eye only during cataract surgery.
62552239|NCT01765335|EXPERIMENTAL|NICaS system efficacy in HF patients|NICaS system efficacy in HF patients
62552240|NCT00687830|ACTIVE_COMPARATOR|Polythylene Glycol (PEG) in the evening|"Bowel preparation with Polyethylene Glycol given in the evening prior to the day of the afternoon colonoscopy.~'Polyethylene Glycol afternoon'"
62552241|NCT00687830|EXPERIMENTAL|Polythylene Glycol (PEG) in the Morning|"Bowel preparation with Polyethylene Glycol given on the morning of the day of the afternoon colonoscopy.~'Polyethylene Glycol morning'"
62552242|NCT04284072|EXPERIMENTAL|All subjects|Single arm study with a device intervention for epileptic seizure monitoring in subjects with refractory focal impaired awareness, tonic-clonic, and/or typical absence seizures.
62175659|NCT06192017||Post-menopausal women with AUB|"The patients will be divided into different study groups: Control and cases or EC, the latter could be subdivided and analyzed in separate groups related to their prognosis. The Control patients are those patients with symptoms compatible with endometrial cancer but who are diagnosed with benign and / or healthy pathology; while EC patients present associated symptoms and are diagnosed with endometrial cancer."
62175660|NCT02186314|ACTIVE_COMPARATOR|Apical stimulation|Pacemaker Biotronik: apical stimulation
62552243|NCT03376334|EXPERIMENTAL|Motor Imagery (MI)|Those meeting the inclusion criteria were selected (n=22). Each participant was necessary to complete the Movement Imagery Questionnaire in a quiet room. Finally, each participant assigned a score by using a 7-point scale regarding the ease/difficulty associated with representing each movement mentally. Next their baseline balance measurement was performed using the SEBT. Later this group had 9 motor imagery sessions, each session for 15 minutes, 3 sessions (alternate days) per week for a total of 3 weeks. Reassessment of balance was done after every 3 sessions.
62552244|NCT03376334|NO_INTERVENTION|Control (C)|Those meeting the inclusion criteria were selected (n=10). Baseline measurement of SEBT was done on day 1, end of week 1, end of week 2 and end of week 3.
62552245|NCT03032627|OTHER|Cardiac surgery|Subjects will be recruited by a coordinator through electronic medical record (EMR) searches to identify those undergoing left ventricle assist device (LVAD) implantation and explantation, heart transplant, valve replacement or repair, endomyocardial biopsy during catheterization, and arterial bypass surgery. Prior to the procedure, potential subjects will be informed about the clinical study and if interested, they will be consented.
62552246|NCT00603707||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
62552247|NCT00603707||Constipated|Adult subjects with functional constipation as define by Rome II criteria
62552248|NCT05999214|EXPERIMENTAL|Experimental group|99mTc-H7ND SPECT/CT imaging was performed
62552249|NCT05999214|NO_INTERVENTION|Control group|99mTc-H7ND SPECT/CT imaging was not performed
62552250|NCT01395927|EXPERIMENTAL|001|Canagliflozin Type=1 unit=mg number=300 form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10,Rifampin Type=2 unit=mg number=300 Form=capsule route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
62552251|NCT02071030|OTHER|CBCT|Cone Beam CT
62552252|NCT02071030|OTHER|Panoramic radiograph|
62552253|NCT03042091|ACTIVE_COMPARATOR|Arm I (mechanical bowel prep, oral antibiotics)|Patients receive polyethylene glycol orally (PO), neomycin PO, and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.
62552254|NCT03042091|EXPERIMENTAL|Arm II (oral antibiotics)|Patients receive neomycin PO and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.
62552255|NCT03849157|ACTIVE_COMPARATOR|self-cut mesh procedure|This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10\*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.
62552256|NCT03849157|ACTIVE_COMPARATOR|mesh-kit procedure|This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.
62175661|NCT02186314|ACTIVE_COMPARATOR|Bifocal stimulation|Pacemaker Biotronik: bifocal stimulation
62175662|NCT01474421|EXPERIMENTAL|AQW051 High Dose|AQW051 high dose daily given orally for 28 days.
62175663|NCT01474421|EXPERIMENTAL|AQW051 Low Dose|AQW051 low dose daily given orally for 28 days.
62552257|NCT06046898|EXPERIMENTAL|SV - R / SV + R / PSV|Spontaneous ventilation without resistance (SV - R) / Spontaneous ventilation with resistance (SV + R) / Pressure support ventilation (PSV)
62552258|NCT06046898|EXPERIMENTAL|SV - R / PSV / SV + R|Spontaneous ventilation without resistance / Pressure support ventilation / Spontaneous ventilation with resistance
62175664|NCT01474421|PLACEBO_COMPARATOR|Placebo|Placebo daily given orally for 28 days.
62175665|NCT01802892|EXPERIMENTAL|Ronacaleret 100 mg|Subjects will receive ronacaleret (100 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
62552259|NCT06046898|EXPERIMENTAL|SV + R / PSV / SV - R|Spontaneous ventilation with resistance / Pressure support ventilation / Spontaneous ventilation without resistance
62175666|NCT01802892|EXPERIMENTAL|Ronacaleret 400 mg|Subjects will receive ronacaleret (400 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
62175667|NCT06073444|NO_INTERVENTION|Standard care|Participants assigned to this group will be screened for neonatal jaundice with the current used method consisting in visual assessment
62552260|NCT06046898|EXPERIMENTAL|SV + R / SV - R / PSV|Spontaneous ventilation with resistance / Spontaneous ventilation without resistance / Pressure support ventilation
62552261|NCT06046898|EXPERIMENTAL|PSV / SV + R / SV - R|Pressure support ventilation / Spontaneous ventilation with resistance / Spontaneous ventilation without resistance
62552262|NCT06046898|EXPERIMENTAL|PSV / SV - R / SV + R|Pressure support ventilation / Spontaneous ventilation without resistance / Spontaneous ventilation with resistance
62552263|NCT06250218|EXPERIMENTAL|Intervention Group|The group will receive the intervention Video Interaction Guidance.
62552264|NCT06582030|EXPERIMENTAL|Group A (chronically relapsing brain disease vignette, SAS)|Participants view the chronically relapsing brain disease vignette and attend a SAS workshop on study.
62552265|NCT06582030|EXPERIMENTAL|Group B (brain disease vignette, SAS)|Participants view the brain disease vignette and attend a SAS workshop on study.
62175668|NCT06073444|EXPERIMENTAL|Standard care + Picterus JP|Participants assigned to this group will be screened for neonatal jaundice with the current used method consisting in visual assessment and the smartphone app Picterus JP
62741243|NCT00964002|EXPERIMENTAL|Efavirenz|"Patients will receive efavirenz 600 mg daily as oral tablets at bedtime and in fast condition (1-2 hours far from dinner) until objective biological, radiological or clinical disease progression or study discontinuation (withdrawal of consent or when the patient meets one criterion for treatment discontinuation).~Individual dose escalation will be possible: if biological progression occurs at month 3, dose could be increased to 1200 mg/day in asymptomatic and non radiological progression patients (by step of 200 mg every 15 days)."
62175669|NCT06010550||Dizziness/vertigo|Patients aged 20 or above, presenting to the emergency department with dizziness or vertigo.
62175670|NCT01448382|EXPERIMENTAL|Healthy volunteers|healthy volunteers
62552266|NCT06582030|EXPERIMENTAL|Group C (disease vignette, SAS)|Participants view the disease vignette and attend a SAS workshop on study.
62552267|NCT06582030|EXPERIMENTAL|Group D (illness vignette, SAS)|Participants view the illness vignette and attend a SAS workshop on study.
62552268|NCT06582030|EXPERIMENTAL|Group E (disorder vignette, SAS)|Participants view the disorder vignette and attend a SAS workshop on study.
62552269|NCT06582030|EXPERIMENTAL|Group F (problem vignette, SAS)|Participants view the problem vignette and attend a SAS workshop on study.
62552270|NCT01497769|EXPERIMENTAL|Group 1|Aerosol inhaled MVA85A and intradermal saline placebo
62175671|NCT01448382|EXPERIMENTAL|GI bleeding subjcets|Symptomatic patients referred to undergo standard Gastroscopy (EGD) as part of their standard medical care
62552271|NCT01497769|EXPERIMENTAL|Group 2|Intradermal MVA85A and inhaled aerosol saline placebo
62552272|NCT06299787|ACTIVE_COMPARATOR|Active Bilateral|Bilteral TBS, applied as cTBS over the right DLPFC followed by iTBS over the left DLPFC
62175672|NCT02703402|EXPERIMENTAL|Exercise protocol|Will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA
62182414|NCT05336981|SHAM_COMPARATOR|Low-Level Light Therapy sham|Patients will receive applications of photobiomodulation sham directly in the region extraoral of the salivary glands ( parotid and submaxilar) will be given once a week for another 6 weeks
62552273|NCT06299787|SHAM_COMPARATOR|Sham|Sham TBS
62552274|NCT01312558|EXPERIMENTAL|Prudent diet group|Participants follow CPAP therapy, a prudent diet while receiving counselling to increase their physical activity.
62552275|NCT01312558|EXPERIMENTAL|Mediterranean diet group|Participants follow CPAP therapy, Mediterranean diet, while receiving counselling to increase their physical activity.
62552276|NCT06405594|EXPERIMENTAL|Language condition|All participants will receive this arm. In this arm, the intervention involves asking participants to speak and understand words and sentences with different linguistic manipulations such as morphological, semantic, phonological priming, predictability of the subject and object nouns associated with verbs, naming of verbs and nouns, production of sentences with past, future or present tense. Accuracy, response times and brain activity are the outcome measures.
62552277|NCT01128907||1|Hematological neutropenic patients at high risk of Invasive Aspergillosis with persistent fever and an opportunist infection suspicion.
62552278|NCT01128907||2|Patients without hematological illness and without Invasive Aspergillosis suspicion.
62552279|NCT01883466|EXPERIMENTAL|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise
62552280|NCT01883466|EXPERIMENTAL|Biodiesel exhaust exposure|1 hour exposure to dilute biodiesel exhaust (generated at same running conditions as diesel exhaust) during intermittent exercise
62552281|NCT04152967|EXPERIMENTAL|new-designed PTFE valved conduit|In this group, new-designed PTFE valved conduits will be applied for patients.
62552282|NCT04152967|ACTIVE_COMPARATOR|Bovine jugular valved conduit|In this group, bovine jugular vein valved conduits will be applied for patients.
62552283|NCT03724435||Pancreatic Cancer Participants|No intervention will be administered. Assessments are performed as standard of care.
62552284|NCT05211635|EXPERIMENTAL|Vitamin D|Vitamin D3 capsule 50 µg
62552285|NCT05211635|PLACEBO_COMPARATOR|Placebo|Placebo capsule with identical appearance to the experimental drug
62552286|NCT01526057|EXPERIMENTAL|A - PF-05280586|
62552287|NCT01526057|ACTIVE_COMPARATOR|B - Rituximab EU|
62552288|NCT01526057|ACTIVE_COMPARATOR|C- Rituximab-US|
62552289|NCT03632213|ACTIVE_COMPARATOR|Losartan|Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
62552290|NCT03632213|PLACEBO_COMPARATOR|Placebo|Placebo group:15 patients, both sexes, will receive oral placebo for 12 months.
62552291|NCT02459743||Patients with hematological malignancies|Patients with a conclusive diagnosis of haematological malignancies according to WHO criteria referred to the Rete Ematologica Lombarda (REL) clinical network will be enrolled. The investigators will analyse genomic DNA extracted from hematopoietic cells at different time points of patient disease. The study contemplates the use of two optimized molecular platforms aimed at the identification of recurrent mutations in myeloid and lymphoid neoplasms, respectively. Screening of gene mutations by NGS will be prospectively implemented in the context of REL clinical network. Patient samples will be analyzed at diagnosis and sequentially during the course of the disease at specific timepoints.
62552292|NCT00271401|EXPERIMENTAL|Angioplasty With Abciximab Plus Low-Dose Heparin|Participants will receive conventional angioplasty/atherectomy along with bolus abciximab 0.25 milligram per kilogram (mg/kg) of body weight followed by a 0.125 microgram per kilogram per minute (mcg/kg/minute) infusion for 12 hours plus 7 unit per kilogram per hour (U/kg/hr) continuous infusion of heparin.
62552293|NCT00271401|EXPERIMENTAL|Intracoronary Stent With Reo Pro Plus Low Dose Heparin|Participants will receive intracoronary stent along with receive bolus abciximab 0.25 mg/kg of body weight followed by a 0.125 mcg/kg/minute infusion for 12 hours plus 7 U/kg/hr continuous infusion of heparin (low dose).
62552294|NCT00271401|PLACEBO_COMPARATOR|Intracoronary Stent With Placebo Plus Standard Dose Heparin|Participants will receive intracoronary stent along with bolus placebo followed by placebo infusion for 12 hours plus 10 U/kg/hr continuous infusion of heparin (standard dose).
62552295|NCT06008184||Healthy controls|
62552296|NCT01370031|EXPERIMENTAL|Clenil® Modulite® via AeroChamber Plus™|Clenil® Modulite® administered via AeroChamber Plus™ spacer
62552297|NCT01370031|ACTIVE_COMPARATOR|Clenil® Modulite® via Volumatic™|Clenil® Modulite® administered via Volumatic™ spacer
62552298|NCT01370031|EXPERIMENTAL|Clenil® Modulite® via AeroChamber Plus™ plus charcoal block|Clenil® Modulite® administered via AeroChamber Plus™ spacer plus charcoal block
62552299|NCT01370031|ACTIVE_COMPARATOR|Clenil® Modulite® via Volumatic™ plus charcoal block|Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block
62552300|NCT00425204|EXPERIMENTAL|Open Label|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
62552301|NCT02741414|EXPERIMENTAL|H pylori culture negative group|The patients who have the negative result of H pylori culture were classified into H pylori culture negative group.
62175673|NCT02703402|EXPERIMENTAL|Manual of exercises|Treatment Group: will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises.
62175674|NCT01431950|EXPERIMENTAL|FF 100mcg once daily|Inhaled corticosteroid (ICS)
62175675|NCT01431950|EXPERIMENTAL|FF 200mcg once daily|Inhaled corticosteroid
62552302|NCT02741414|EXPERIMENTAL|The first successful eradication group|The patients with first eradication therapy of H. pylori infection have the first successful treatment based on the standardized treatment including antibiotics selection from antibiotic susceptibility testing and proton pump inhibitors （PPIs) dose selection from CYP2C19 gene sequencing.
62552303|NCT02741414|EXPERIMENTAL|The refractory infection of H. pylori group|The patients with first eradication therapy of H. pylori infection have the two failure treatment based on the standardized treatment including antibiotics selection from antibiotic susceptibility testing and PPIs dose selection from CYP2C19 gene sequencing.
62552304|NCT01570478|EXPERIMENTAL|Foster® NEXThaler®|Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
62552305|NCT01570478|ACTIVE_COMPARATOR|Seretide® Accuhaler®|Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
62552306|NCT05713565|EXPERIMENTAL|Digital Care Solution group|"Participants will be instructed to download the SKH mobile app to which the participants will have access for 12 months, and the participants will receive an access code to activate the SKH CAD program. The aim of the program is to empower self-assessment of CAD symptoms as well as positive lifestyle change by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.~Beyond this, all patients in the interventional arm will also receive standard of care as defined below for the control arm."
62175676|NCT01532583||Patients operated on with the TOT|
62182415|NCT05423106|EXPERIMENTAL|Part 1: JNJ-64457744 or Placebo (Single Ascending Dose [SAD] Cohorts A-F)|Non-Asian healthy participants will receive a SAD of either JNJ-64457744 or matching placebo as an oral formulation under fasted conditions on Day 1. Cohort F will be optional.
62552307|NCT05713565|ACTIVE_COMPARATOR|Standard of Care - control group|The participants in the Standard of Care - control group will receive an information leaflet about relevant lifestyle modifications for CAD. After baseline measurements and data collection, follow-up and continuous care will be as usual in outpatient care (i.e., Standard of Care).
62552308|NCT02289703|EXPERIMENTAL|Group A|Participants with end-stage renal disease (ESRD), will receive a single 15-milligram (mg) oral dose of rivaroxaban in Treatment Period 1 on Day 1, administered 2 hours before the start of a 4-hour hemodialysis session followed 7 to 14 days later by Treatment Period 2 wherein a single 15-mg oral dose of rivaroxaban will be given 3 hours after the completion of a 4-hour hemodialysis session on Day 1.
62552309|NCT02289703|EXPERIMENTAL|Group B|Healthy control participants matching to 'Group A' participants, will receive a single 15-mg oral dose of rivaroxaban on Day 1.
62175677|NCT03521206|EXPERIMENTAL|Intervention group|"The ACP+ programme aims to improve or establish advance care planning (ACP) in the day-to-day routine of staff working in nursing homes.~The intervention implementation period has a total duration of 8 months and is divided into:~* a four-month preparation and training phase. During this phase the ACP reference persons will attend a two-day training given by the ACP trainers. Other staff will receive training by the reference persons on conducting ACP conversation or recognizing triggers for an ACP conversation in nursing home residents.~* A four-month follow-up phase in which ACP conversations are held with residents. Additional training sessions will be organized to give more in-depth knowledge to the ACP reference persons."
62552310|NCT01772875|ACTIVE_COMPARATOR|lavage Isobetadine Dermicum solution|Patient will receive 1 bladder lavage daily with a solution of 5ml Isobetadine Dermicum in 100cc saline
62552311|NCT01772875|ACTIVE_COMPARATOR|lavage Acetic Acid solution|Patients will receive a daily bladder lavage during 5 consecutive days with a solution of 0.5% acetic acid in 100cc of saline
62552312|NCT01772875|SHAM_COMPARATOR|lavage with saline|patients will receive during 5 consecutive days a bladder lavage with 100cc saline
62552313|NCT01772875|ACTIVE_COMPARATOR|lavage Urotainer Suby G|patients will receive during 5 consecutive days a bladder lavage with 100cc of Urotainer Suby G
62552314|NCT03427515|EXPERIMENTAL|Lactobacillus|Lactobacillus rhamnosus GG (ATCC 53103) - encapsulated
62552315|NCT03427515|PLACEBO_COMPARATOR|Placebo|Placebo - encapsulated mixture of maltodextrins
62552316|NCT03427515|EXPERIMENTAL|Saccharomyces|Saccharomyces boulardii (CNCM I-1079) - encapsulated
62552317|NCT06551285|ACTIVE_COMPARATOR|Dietary supplement in PCOS|Subjects will recieve nutritional intervention by a registered dietitian and a supplement containing inositol, vitamin D, zinc, and curcumin for 3 months. The dietary intervention consists of healthy dietary recommendations and hipocaloric diet if needed (overweight, obesity).
62552318|NCT06551285|PLACEBO_COMPARATOR|Placebo in PCOS|Subjects will recieve nutritional intervention by a registered dietitian and a supplement containing yellow colorant for 3 months. The dietary intervention consists of healthy dietary recommendations and hipocaloric diet if needed (overweight, obesity).
62552319|NCT06551285|NO_INTERVENTION|No intervention in healthy subjects|Healthy subjects will not recieve supplement/placebo nor dietary intervention.
62552320|NCT02585778|EXPERIMENTAL|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to stable, maximally tolerated dose of statin therapy with or without other lipid-modifying therapy (LMT), insulin alone or with other antihyperglycemic drugs for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
62175678|NCT03521206|NO_INTERVENTION|Control group|The staff of nursing homes in the control group will receive no additional training next to any standard education or continuous training. After the intervention and follow-up measures are finished, all nursing homes in the control group will be offered a shortened version of the ACP+ training programme as well as all ACP+ training materials.
62175679|NCT02111720|EXPERIMENTAL|Maybe, Maybe Not|The intervention is an individual-level 4-session + 3 month booster series designed to assist persons with HIV in making decisions regarding the disclosure of their HIV serostatus to family members.
62175680|NCT02111720|ACTIVE_COMPARATOR|Comprehensive Risk Counseling and Services|Comprehensive Risk Counseling and Services (CRCS) will be used to provide the attention-placebo control (CDC, 2006). CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.
62175681|NCT03781947|EXPERIMENTAL|90 mg s.c.|A single s.c. injection of 90 mg teverelix TFA administered on Day 1
62552321|NCT02585778|PLACEBO_COMPARATOR|Placebo Q2W|Placebo (for alirocumab) SC injection Q2W added to stable, maximally tolerated dose of statin therapy with or without other LMT, insulin alone or with other antihyperglycemic drugs for 24 weeks.
61986221|NCT06091280|EXPERIMENTAL|Respiratory Muscle Strength Training|"Pursed Lip Breathing: Participants will perform two sets of 10 repetitions twice per day.~Inspiratory Muscle Strength Training (IMST): The participant will use an IMST trainer provided by the study (Threshold Inspiratory Muscle Strength Trainer). This exercise is repeated for a 3-minute duration, followed by a rest period of 2 minutes. This cycle is repeated for 6 cycles over a 30-minute timespan. This exercise will be performed 3 times/week on alternating days.~Expiratory Muscle Strength Training (EMST): The participant will use an EMST trainer (EMST 150) provided by the study. This exercise is repeated for a 3-minute duration, followed by a rest period of 2 minutes. The cycle is repeated for 6 cycles over a 30-minute timespan. This exercise will be performed 3 x/week on opposite days of the inspiratory muscle strength training."
62175682|NCT03781947|EXPERIMENTAL|60 mg s.c.|A single s.c. injection of 60 mg teverelix TFA administered on Day 1
62175683|NCT03781947|EXPERIMENTAL|90 mg i.m.|A single i.m. injection of 90 mg teverelix TFA administered on Day 1
62175684|NCT03781947|EXPERIMENTAL|120 mg s.c.|A single s.c. injection of 120 mg teverelix TFA administered on Day 1
62175685|NCT04372537|EXPERIMENTAL|Hypnosis|"Patients will benefit from formal hypnosis (trance induction, hypno analgesia, comfort suggestions) and/or conversational hypnosis (confusion, distraction, use of chosen words, goodwill using verbal and non verbal languages).~They will also get to be informed of the proceedings of the performed examination as the standard procedure group."
62552322|NCT03022916|ACTIVE_COMPARATOR|Nail Polish + Efinaconazole Solution|One big toe will receive application of Efinaconazole Solution on top of nail polish (without the presence of a top coat or base coat)
62552323|NCT03022916|PLACEBO_COMPARATOR|Nail Polish Only|Both big toes will use nail polish only
62552324|NCT03022916|ACTIVE_COMPARATOR|Base Coat + Nail Polish + Top Coat + Efinaconazole Solution|One big toe will receive application of Efinaconazole solution on top of nail polish with base coat and top coat.
62552325|NCT03022916|ACTIVE_COMPARATOR|Nail Polish + Top Coat + Efinaconazole Solution|One big toe will receive application of Efinaconazole solution on top of nail polish with top coat.
62175686|NCT04372537|ACTIVE_COMPARATOR|Standard procedure group.|"Patients will be informed of the proceedings of the performed examination, without using any hypnosis technique.~This corresponds to the standard clinical procedures used while performing an electroneuromyogram."
62175687|NCT03683914|EXPERIMENTAL|dinoprostone arm|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
62175688|NCT03683914|PLACEBO_COMPARATOR|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
62175689|NCT02387281||"PD with FOG on"|"Subjects diagnosed with Parkinson disease (PD) and sub-categorized as on freezing of gait (FOG) based on evaluation using motion capture"
62175690|NCT02387281||"PD with FOG off"|"Subjects diagnosed with Parkinson disease (PD) and sub-categorized as off freezing of gait (FOG) based on evaluation using motion capture"
62175691|NCT02387281||PD without FOG|Subjects with Parkinson disease (PD) and an absence of freezing of gait (FOG)
62175692|NCT02387281||Non-PD with FOG|Subjects with freezing of gait (FOG) and an absence of Parkinson disease (PD) (exception granted for those with FOG and atypical parkinsonism: PSP or MSA)
62175693|NCT02369588|EXPERIMENTAL|100% Portion Sizes|Food portion size Test meal consists of baseline (100%) portion size of all foods
62175694|NCT02369588|EXPERIMENTAL|133% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 133% the size of baseline portions
62552326|NCT00866021|EXPERIMENTAL|1|Lopinavir/ritonavir (LPV/r) as single antiretroviral administered concomitantly with peg-interferon and ribavirin
62175695|NCT02369588|EXPERIMENTAL|167% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 167% the size of baseline portions
62175696|NCT02369588|EXPERIMENTAL|200% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 200% the size of baseline portions
62175697|NCT01708005|ACTIVE_COMPARATOR|Intervention|80 participants start the oral intake of Lecitone®Se-Vitamin D3 the day after inclusion and during 24 weeks
62175698|NCT01708005|PLACEBO_COMPARATOR|Placebo|"80 participants in this arm start the oral intake of placebo the day after inclusion and during 12 weeks.~Then, they start the oral intake of Lecitone®Se-Vitamin D3 12 weeks after inclusion until the 24th week."
62175699|NCT02169778|EXPERIMENTAL|Intermittent energy restricted diet|The intermittent energy restricted group will undergo 3 nonconsecutive days of partial fasting per week. During the 3 days of partial fasting, participants will be asked to consume a very-low calorie diet (VLCD) providing 550kcal/day for women and 650kcal/day for men. The VLCD products provide 110kcal/pack and include a variety of shakes, smoothies and soups. For the feeding days a diet matching energy needs will be prescribed, using meal replacements (such as smoothies, soups and cereal bars) and conventional food. Drinking at least 2.5 liters of non-caloric liquids will be recommended.
62175700|NCT02169778|EXPERIMENTAL|Continuous energy restricted diet|The continuous energy restricted group will be prescribed a low calorie diet (LCD) with 33% energy restriction, using meal replacements (such as smoothies, soups and cereal bars) and conventional food. The diets' macronutrient composition of the two groups will be matched (50% carbohydrates, 20% protein and 30% fat).
62175701|NCT01229527|EXPERIMENTAL|Remifentanil RS1|
62175702|NCT01229527|EXPERIMENTAL|Remifentanil RS2|
62175703|NCT01229527|ACTIVE_COMPARATOR|Meperidine|
62175704|NCT01318538|EXPERIMENTAL|Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
62182416|NCT05423106|EXPERIMENTAL|Part 1: JNJ-64457744 (Cohorts G-H)|Non-Asian healthy participants will receive 3 single doses of JNJ-64457744 as an oral formulation in 3 intervention periods (to assess inter-subject PK-PD) matching the doses evaluated in Cohorts A, C and E for Cohort G and Cohorts B, D and F for Cohort H, under fasted conditions on Day 1. Cohort H will be optional for Intervention period 3.
62552327|NCT00866021|ACTIVE_COMPARATOR|2|Lopinavir/ritonavir (LPV/r) with 2 NRTIs, administered concomitantly with peg-interferon and ribavirin
62552328|NCT00055731|EXPERIMENTAL|Chemotherapy|
62552329|NCT00055731|ACTIVE_COMPARATOR|Without Chemotherapy|
62552330|NCT04784611|EXPERIMENTAL|Group 1 - OP-ENS Intervention|Participants will be matched with a peer health navigator. As part of this complex behavioral intervention, participants and peer health navigators will engage in a systematic process of barrier and strength identification, goal setting and action planning related to issues of healthcare access and quality. Participants and peers will meet at least monthly over the course of the 12-month study period (but frequency is determined by participant need). Given the nature of the disability and healthcare experience, we anticipate the needs and therefore frequency will fluctuate over the duration of the study period. Beginning in month 10, participants and peers will engage in a period of transition planning to ensure that participants have the strategies and supports in place to assume the role of their own health navigator.
62552331|NCT04784611|NO_INTERVENTION|Group 2 - Usual Care|Participants randomized to the usual care group will continue with their usual health and healthcare routines. Participants in the usual care group will receive a monthly newsletter with general interest information relevant to the disability community.
62175705|NCT01318538|ACTIVE_COMPARATOR|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
62175706|NCT05380388|EXPERIMENTAL|Malaria Vaccine|PvRII/Matrix-M month 0, month 1, month 6
62175707|NCT05380388|OTHER|control|HBV vaccine month 0, month 1, month 6
62552332|NCT05636267|EXPERIMENTAL|AK119 + AK112|Subjects will receive AK119 plus AK112 via intravenously (IV) Q3W, up to 2 years.
62175708|NCT05621213|EXPERIMENTAL|Intervention|Patients who will be followed up by teleconsultation assisted by a physiotherapist or a nurse at home.
62175709|NCT05621213|NO_INTERVENTION|Control group|Patients not wishing to be followed up by teleconsultation but agreeing to participate in the study and the collection of questionnaires. They will follow up as usual in person (no teleconsultation).
62552333|NCT05636267|EXPERIMENTAL|AK119 + AK112 + Pemetrexed + Carboplatin|Subjects will receive AK119 and AK112 plus pemetrexed and carboplatin via intravenously (IV) Q3W, up to 4 cycles. Afterward, AK119 and AK112 plus pemetrexed will continue to be treated up to 2 years.
62552334|NCT05636267|EXPERIMENTAL|AK112|Subjects will receive AK112 monotherapy via intravenously (IV) Q3W, up to 2 years.
62552335|NCT01152372|OTHER|Arm 1|Beta cell function by frequently sampled intravenous glucose tolerance test
62552336|NCT01152372|OTHER|Arm 2|Modified glucose disposal test assessment of insulin sensitivity, endogenous glucose production and insulin secretion
62175710|NCT02795819|EXPERIMENTAL|Cohort minus 1 (-1)|Participants take 10 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
62552337|NCT01152372|OTHER|Arm 3|Endogenous glucose production and insulin sensitivity by isotope dilution and isoglycemic, heperinsulinemic clamp
62175711|NCT02795819|EXPERIMENTAL|Cohort 1|Participants take 20 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
62175712|NCT02795819|EXPERIMENTAL|Cohort 2|Participants take 20 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
62552338|NCT04904133|ACTIVE_COMPARATOR|Saccharine Group|140 mg saccharin (Hermesetas) dissolved in 330 mL water for 4 weeks.
62175713|NCT02795819|EXPERIMENTAL|Cohort 3A|Participants take 30 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
62175714|NCT02795819|EXPERIMENTAL|Cohort 3B|Participants take 30 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
62175715|NCT02795819|EXPERIMENTAL|Cohort 4A|Participants take 40 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
62175716|NCT02795819|EXPERIMENTAL|Cohort 4B|Participants take 40 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
62552339|NCT04904133|ACTIVE_COMPARATOR|Sucralose Group|66 mg sucralose (Splenda) dissolved in 330 mL water for 4 weeks.
62552340|NCT04904133|ACTIVE_COMPARATOR|Aspartame+Acesulfame-K Group|88 mg aspartame+88 mg acesulfame-K (Takita) dissolved in 330 mL water for 4 weeks.
62552341|NCT04904133|PLACEBO_COMPARATOR|Control Group|330 mL water for 4 weeks.
62552342|NCT02377297|ACTIVE_COMPARATOR|Restoration with Fuji IX|The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
62552343|NCT02377297|EXPERIMENTAL|Restoration with Vitro Molar|The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
62552344|NCT02377297|EXPERIMENTAL|Restoration with Maxxion R|The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
62552345|NCT00271193|NO_INTERVENTION|1|Control group, receives physician advice for weight loss and materials
62741244|NCT02431780|NO_INTERVENTION|non ANSeR Software System|Routine clinical EEG monitoring
62552346|NCT00271193|ACTIVE_COMPARATOR|2|Active treatment group, receives physician advice, materials, and brief weight loss counseling
62552347|NCT02255968|EXPERIMENTAL|EDP-788|Multiple doses with dose escalation to continue in successive cohorts
62552348|NCT02255968|PLACEBO_COMPARATOR|Placebo|Multiple doses with dose escalation to continue in successive cohorts
62552349|NCT00688532||1|Prostate cancer patients treated with bicalutamide or not
62175717|NCT02094547|EXPERIMENTAL|New infant formula|New infant formula with key ingredients.
62175718|NCT02094547|ACTIVE_COMPARATOR|Standard infant formula|Standard infant formula
62175719|NCT02094547|OTHER|Breastfeeding|Control
62175720|NCT03280108|EXPERIMENTAL|Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
62552350|NCT00688532||2|General population cohort
62552351|NCT06551480|EXPERIMENTAL|Pilot Study|Pilot study in healthy participants and cataract patients
62552352|NCT00599248|EXPERIMENTAL|1|TissueGene-C single intraarticular injection of 3x10e6 cells/joint
62552353|NCT00599248|EXPERIMENTAL|2|TissueGene-C single intraarticular injection of 1x10e7 cells/joint
62552354|NCT00599248|EXPERIMENTAL|3|TissueGene-C single intraarticular injection of 3x10e7 cells/joint
62552355|NCT00599248|PLACEBO_COMPARATOR|4|Placebo control single intraarticular injection
62552356|NCT01918566|PLACEBO_COMPARATOR|300ml tap water|Single intragastric instillation of 300ml tap water via nasogastric tube
62552357|NCT01918566|ACTIVE_COMPARATOR|Glucose|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
62552358|NCT01918566|ACTIVE_COMPARATOR|Glucose plus Lactisole|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole
62552359|NCT01918566|ACTIVE_COMPARATOR|Fructose|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
62552360|NCT01918566|ACTIVE_COMPARATOR|Glucose and Exendin|Single intragastric instillation of 75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39
62552361|NCT01918566|SHAM_COMPARATOR|tap water, lactisole|Single intragastric instillation of 300ml tap water with 450ppm lactisole
62552362|NCT03065192|EXPERIMENTAL|VY-AADC01 Single Dose|9.4 x 10\^12 vector genomes of VY-AADC01
62552363|NCT01847404|EXPERIMENTAL|Overall Study Arm|All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order after an overnight fasting of at least 10 hours fast in each period. Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet
62552364|NCT04422600||Mothers who report use of THC with or without CBD|Mothers who report THC and CBD usage during the trimester month of pregnancy, at a frequency of at least three time per week. Information will be collected from mothers receiving their obstetrical care at UAMS and will include data on the exact products used and the frequency of use.
62552365|NCT04422600||Mothers who report use of CBD only|Mothers who report CBD usage during the trimester month of pregnancy, at a frequency of at least three time per week. Information will be collected from mothers receiving their obstetrical care at UAMS and will include data on the exact products used and the frequency of use.
62552366|NCT04422600||Control Mothers|Recruitment of pregnant women who do not use THC or CBD will be conducted using the Epic MyChart research participant recruitment tool
62552367|NCT03926351|PLACEBO_COMPARATOR|Arm 1a; Placebo|Valid for the first 24 weeks of the study. Arm 1a: placebo, soft gelatine capsule containing 1000 mg olive oil, refined.
62552368|NCT03926351|EXPERIMENTAL|Arm 2a; Omega-3 capsules|Valid for the first 24 weeks of the study. Arm 2a; Omega-3, (1000 mg fill weight per capsule) containing omega-3 ethyl ester concentrate with a high proportion of DHA.
62552369|NCT01286753|EXPERIMENTAL|Tyrosine Kinase Inhibitor (TKI) Naive|Vemurafenib in participants naive to any prior systemic TKI therapy.
62552370|NCT01286753|EXPERIMENTAL|TKI Experienced|Vemurafenib in participants previously treated with TKI therapy active against vascular endothelial growth factor receptor 2 (VEGFR).
62552371|NCT03552380|EXPERIMENTAL|Entinostat, Nivolumab and Ipilimumab|"Entinostat: 5mg, 3mg, or 2mg orally (PO) on D1, 8, 15 plus Nivolumab: 3 mg/kg IV D1 and Ipilimumab 1 mg/kg IV D1~Each cycle is 21 days"
62552372|NCT05153993|EXPERIMENTAL|Stretch fascia plantaris|
62552373|NCT05153993|NO_INTERVENTION|Control group|
62552374|NCT01469728|EXPERIMENTAL|Awake VATS|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
62552375|NCT01469728|ACTIVE_COMPARATOR|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
62175721|NCT03280108|ACTIVE_COMPARATOR|Monofocal IOL|AcrySof Monofocal IOL Model SN60AT implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
62175722|NCT01495234|EXPERIMENTAL|Cohort 1|Each patient will receive 15mg of rhBMP-2 in rhBMP-2/BCP device and implant unilaterally during a posterolateral spinal fusion procedure. The contralateral side was fused using standard fusion techniques with autograft bone.
62175723|NCT01495234|EXPERIMENTAL|Cohort 2|Each patient will receive 20mg of rhBMP-2 in rhBMP-2/BCP device and implant bilaterally.
61986222|NCT01227941|EXPERIMENTAL|Part A: MK-4827 + pegylated liposomal doxorubicin|MK-4827 and pegylated liposomal doxorubicin combination. Dose escalation/confirmation in participants with advanced solid tumors
62175724|NCT04003961||Moderate/high risk for OSA with EDS|All clinical data of the patients who has moderate/high risk for OSA with excessive daytime sleepiness (EDS) will be assessed with statistical methods.
62391454|NCT00182793|EXPERIMENTAL|Arm II|Patients undergo stem cell collection. Patients receive high-dose carboplatin, thiotepa, and cyclophosphamide IV continuously over 4 days followed by autologous PBSC transplantation. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.
62552376|NCT01782014|EXPERIMENTAL|Water Insufflation|Colonoscopy using water insufflation
62552377|NCT01782014|ACTIVE_COMPARATOR|Carbon dioxide insufflation|Colonoscopy using carbon dioxide insufflation
62552378|NCT01782014|ACTIVE_COMPARATOR|Air insufflation|Colonoscopy using air insufflation
62552379|NCT05662527|EXPERIMENTAL|Neoadjuvant pembrolizumab|Pembrolizumab
62175725|NCT04003961||Moderate/high risk for OSA without EDS|All clinical data of the patients who has moderate/high risk for OSA without excessive daytime sleepiness(EDS) will be assessed with statistical methods.
62175726|NCT04003961||Low risk for OSA|All clinical data of the patients who has low risk for OSA will be assessed with statistical methods.
62175727|NCT02811393||Bariatric surgery|Women who have been submitted to a Roux-en-Y Gastric Bypass Surgery for at least 2 years
62175728|NCT02811393||Unoperated|Women with similar characteristics to control group (age, body mass index, physical activity level), but they have not been submitted to bariatric surgery
62552380|NCT01982955|EXPERIMENTAL|Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg|Participants received Tepotinib 300 milligram (mg) along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
62552381|NCT01982955|EXPERIMENTAL|Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg|Participants received Tepotinib 500 milligram (mg) along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
62552382|NCT01982955|EXPERIMENTAL|Phase 2: Tepotinib 500 mg + Gefitinib 250 mg (MET + T790 negative)|Participants randomized to receive Tepotinib recommended Phase 2 dose 500 mg once daily along with 250 mg Gefitinib tablets orally once daily over a 21-day cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
62552383|NCT01982955|EXPERIMENTAL|Phase 2: Pemetrexed and Cisplatin/Carboplatin (MET + T790 negative)|Participants randomized to receive 500 milligram per square meter (mg/m\^2) of Pemetrexed as intravenous infusion over 10 minutes in combination with Cisplatin (75 mg/m2 as an intravenous infusion over 2 hours) or Carboplatin (intravenously at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator) on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity or withdrawal from treatment or up to 6 cycles if or 4 cycles followed by Pemetrexed maintenance monotherapy.
62552384|NCT01982955|EXPERIMENTAL|Phase 2: Single-arm Cohort (MET+ T790M positive)|Participants with MET+ T790M positive Non-small Cell Lung Cancer (NSCLC) received a Tepotinib recommended Phase 2 dose 500 mg once daily along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
62552385|NCT06452134|EXPERIMENTAL|Intervention group|This arm of the study includes 35 of participants who will be given Coenzyme Q10 100 MG Oral Tablet for 30 days.
62552386|NCT06452134|PLACEBO_COMPARATOR|Control group|This arm of the study includes 35 of participants who will be given Placebo ( a look-alike substance ) with same tablet form given daily for a period of 30 days after surgery.
62175729|NCT01755247|PLACEBO_COMPARATOR|Topical Gel Vehicle|Once daily application of topical gel vehicle to forehead for 3 days
62552387|NCT02748148|EXPERIMENTAL|Medication therapy management|Medication therapy management service that is enhanced by the incorporation of pharmacogenomics and medication risk mitigation factor technology
62552388|NCT03147430||Invasive Cancer|Invasive cancer confirmed by biopsy
62552389|NCT03147430||Benign or pre-invasive lesion|Benign or pre-invasive lesion confirmed by biopsy
62552390|NCT03905694|EXPERIMENTAL|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
62552391|NCT05808608|EXPERIMENTAL|Combination treatment group|Subjects in this group will receive AK104 (RP2D, administered intravenously) plus Axitinib 5 mg bid, administered orally.
62552392|NCT01289145|EXPERIMENTAL|Intervention|"Participants will be allocated to a motivational intervention, a volitional intervention or the active control group.~The motivational intervention promotes positive outcome expectancies on physical activity. The volitional intervention promotes the formulation of action plans for physical activity. Participants in the active control group, receive a quiz on physical activity and sports."
62552393|NCT00652561|EXPERIMENTAL|1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks.
62552394|NCT03886298|EXPERIMENTAL|radiofrequency splanchnic denervation|
62552395|NCT03886298|ACTIVE_COMPARATOR|retrocrural celiac denervation|
62552396|NCT05991791|OTHER|Children with autism spectrum disorders|
62552397|NCT06581458|EXPERIMENTAL|tDCS immediate intervention group|Participants in the tDCS Immediate Intervention Group will receive an initial two-week period of transcranial Direct Current Stimulation (tDCS) treatment. This will be followed by three months of continued tDCS intervention.
62552398|NCT06581458|SHAM_COMPARATOR|Late intervention group (tDCS+ sham)|Participants in the Late Intervention Group will first receive a placebo (sham) treatment for three months. This will be followed by a two-week period of active transcranial Direct Current Stimulation (tDCS) treatment, then three months of continued tDCS intervention.
62175730|NCT01755247|ACTIVE_COMPARATOR|8% NVN1000 Topical Gel|Once daily application of 8% NVN1000 Topical Gel to the forehead for 3 days
62552399|NCT06583005|EXPERIMENTAL|Stimulation|Participants will stimulate with the device, called the Stanford CR glove, on a daily or weekly basis depending on their progress through the study procedures. The device itself is a glove that is designed to deliver vibrations to the fingertips of each hand.
62552400|NCT02431364|PLACEBO_COMPARATOR|Placebo|Participants received matched placebo tablets to verdinexor tablets orally once daily on Days 1 and 3.
62552401|NCT02431364|EXPERIMENTAL|Verdinexor 5 mg|Participants received verdinexor 5 milligrams (mg) (2 tablets of 2.5 mg each) orally once daily on Days 1 and 3.
62552402|NCT02431364|EXPERIMENTAL|Verdinexor 10 mg|Participants received verdinexor 10 mg tablet orally once daily on Days 1 and 3.
62552403|NCT02431364|EXPERIMENTAL|Verdinexor 20 mg|Participants received verdinexor 20 mg tablet (2 tablets of 10 mg each) orally once daily on Days 1 and 3.
62552404|NCT02431364|EXPERIMENTAL|Verdinexor 40 mg|Participants received verdinexor 40 mg tablet (4 tablets of 10 mg each) orally once daily on Days 1 and 3.
62552405|NCT03014843|ACTIVE_COMPARATOR|Naloxone|Administration of a centrally acting µ-opioid receptor antagonist Naloxone (20µg/kg/h intravenous infusion after 0.4mg bolus) to investigate the effect of esophageal sensitivity assessed by multimodal esophageal stimulation.
62175731|NCT01755247|ACTIVE_COMPARATOR|8% NVN1000 Topical Gel and moisturizer|Once daily application of 8% NVN1000 Topical Gel to the forehead, followed 15 minutes later by application of a commercially available moisturizer
62741245|NCT02431780|EXPERIMENTAL|ANSeR Software System|The intended use of the ANSeR Software System is to provide a real time decision support tool to assist in the diagnosis of seizures in neonates (between 36 weeks and 44 weeks corrected age) and to provide a review tool for EEG and seizure analysis. ANSeR is intended to provide a reliable, effective, objective and intuitive means of identifying seizures
62741246|NCT03211611||Patients with BRCA ½ mutation|Women with BRCA 1 / 2 mutation with or without cancer Age over 18
62175732|NCT05203224|EXPERIMENTAL|Intravenous Dornase alfa (DNase)|Patients will receive a single intravenous dose of dornase alfa (at either 0.125mg/kg, 0.25mg/kg, 0.5mg/kg or 1mg/kg in escalating tiers), administered as a bolus over \~30 seconds.
62552406|NCT03014843|ACTIVE_COMPARATOR|Methylnaltrexone bromide|Administration of a peripherally acting µ-opioid receptor antagonist Methylnaltrexone (12mg/0.6mL subcutaneous injection) to investigate the effect of esophageal sensitivity assessed by multimodal esophageal stimulation.
62175733|NCT01263990|NO_INTERVENTION|Nexfin|Nexfin is used in all patients
62175734|NCT04897789||children/pregnant women|children/pregnant women (2,310)
62175735|NCT04897789||parents|parents (2,310)
62175736|NCT04897789||classrooms/teachers|classrooms/teachers (840)
62552407|NCT03014843|PLACEBO_COMPARATOR|Placebo|Administration of placebo injection (1mL 0.9% saline IV or 0.6 IM) as a control condition to compare to the administration of naloxone or methylnaltrexone bromide in the multimodal esophageal stimulation protocol.
62741247|NCT03211611||GP|GP of the patients with BRCA 1 / 2 mutation
62552408|NCT04983134|NO_INTERVENTION|Standard Intervention(SI)|the HealthStreet Standard Intervention to include a CHW referral to an accessible and acceptable lung cancer screening site to include a financial counselor (if needed), tobacco cessation and quit resources (if still smoking) and, additionally, will watch the Genentech lung cancer screening video with the CHW;
62552409|NCT04983134|EXPERIMENTAL|Enhanced CHW Intervention|After 1:1 randomization, 30 women will additionally receive a 6-hour four week Enhanced CHW Intervention (E-CHW-I) modelled on successful peer-partnered interventions and informed by Stages of Change theory, which will add to the SI, calls and texts (if appropriate) to help problem solve and encourage screening receipt and transportation to the screening (if needed);
62741248|NCT03293849|EXPERIMENTAL|Patient Navigation Arm|After an assessment of supportive care needs, a patient navigator will present assessment results and develop and implement a personalized supportive care intervention plan based on the findings in collaboration with a multidisciplinary supportive care team, formed by oncologists and pain and palliative care specialists. The developed plan will be sent to the treating oncologist and oncology team.
61986223|NCT01227941|EXPERIMENTAL|Part B: MK-4827 + pegylated liposomal doxorubicin|MK-4827 and pegylated liposomal doxorubicin combination at 1 or 2 dose levels of MK-4827 to be determined from the results of Part A. Ovarian Cancer Cohort
62552410|NCT00372840|EXPERIMENTAL|Arm I|Patients receive a specific print intervention manual entitled Facing Forward Series: Life After Cancer Treatment and a general print intervention fact sheet entitled The Cancer Information Service, Questions and Answers.
61986224|NCT04696939|EXPERIMENTAL|Atezolizumab + Carboplatin +Etoposide +surgery|"Neoadjuvant therapy: Atezolizumab, 1200 milligrams(mg) on Day 1 of every 21-day cycle, 2 cycles; Carboplatin, 75 mg per square meter(mg/m\^2) on Day 1 of every 21-day cycle, 2 cycles; Etoposide, 100 mg/m\^2 on Day 1 of every 3-day cycle, 2 cycles.~Surgery: patients will receive surgery."
61986225|NCT04696939|ACTIVE_COMPARATOR|Carboplatin +Etoposide +surgery|"Neoadjuvant therapy: Carboplatin, 75 mg/m\^2 on Day 1 of every 21-day cycle, 2 cycles; Etoposide, 100 mg/m\^2 on Day 1 of every 3-day cycle, 2 cycles.~Surgery: patients will receive surgery."
62364834|NCT04266249|EXPERIMENTAL|Arm A (pCR after surgery)|"PRE-OPERATIVE/NEOADJUVANT THERAPY: Patients receive either paclitaxel or nab-paclitaxel IV on days 1, 8 and 15, or docetaxel IV on day 1 at the discretion of the treating oncologist. Patients also receive trastuzumab IV on day 1 or days 1, 8, and 15, and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Within 42 days after last dose of neoadjuvant therapy, patients undergo standard of care lumpectomy and/or mastectomy.~POST-OPERATIVE.ADJUVANT THERAPY: Patients with pCR after surgery receive trastuzumab and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo standard of care radiation therapy and receive hormone therapy if appropriate."
62364835|NCT04266249|EXPERIMENTAL|Arm B (residual invasive disease after surgery)|"PRE-OPERATIVE/NEOADJUVANT THERAPY: Patients receive either paclitaxel or nab-paclitaxel IV on days 1, 8 and 15, or docetaxel IV on day 1 at the discretion of the treating oncologist. Patients also receive trastuzumab IV on day 1 or days 1, 8, and 15, and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Within 42 days after last dose of neoadjuvant therapy, patients undergo standard of care lumpectomy and/or mastectomy.~POST-OPERATIVE/ADJUVANT THERAPY: Patients with remaining tumor after surgery receive standard of care trastuzumab emtansine for 14 doses in the absence of disease progression or unacceptable toxicity. Patients may also receive additional standard of care chemotherapy, as well as hormone therapy if appropriate."
62364836|NCT01151176|ACTIVE_COMPARATOR|Insulin|Intensive Insulin Therapy
62364837|NCT01151176|OTHER|Regular Insulin|Sub Cutaneous Regular Insulin
62364838|NCT00882336||1|Patients 50+ years old, with at least one additional CV risk factor (with no previous CV event or hospitalization for a CV event)
62364839|NCT03254888||Low Grade group|"• 50 tumor tissue samples from patients with Low Grade Bladder Cancer undergoing either trans urethral resection of bladder tumor or Radical Cystectomy ,~The followings markers must be estimated :~1. Autophagy markers:~   * ( Atg7) level using (quantitative real time polymerase chain reaction).~  * (LC3A)level using immunohistochemistry .~2. ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~3. Oxidative stress Marker:(MDA)using chemical method~4. Apoptotic marker:(caspase 3) using(quantitative real time polymerase chain reaction) ."
62364840|NCT03254888||High Grade group|"• 50 tumor tissue samples from patients with High Grade Bladder Cancer undergoing either trans urethral resection of bladder tumor or Radical Cystectomy,~The followings markers must be estimated :~1. Autophagy markers:~   * ( Atg7) level using (quantitative real time polymerase chain reaction).~  * (LC3A)level using immunohistochemistry .~2. ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~3. Oxidative stress Marker:(MDA)using chemical method~4. Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction) ."
62391455|NCT01013805|EXPERIMENTAL|Arm 1|Integrated Preoperative Radiotherapy (external beam radiotherapy) and Chemotherapy (Oxaliplatin, Fluorouracil and Leucovorin), then surgical resection.
62552411|NCT00372840|ACTIVE_COMPARATOR|Arm II|Patients receive the general print intervention fact sheet entitled The Cancer Information Service, Questions and Answers.
62552412|NCT05646459|PLACEBO_COMPARATOR|Control - Floss|Subjects will use only floss at study site
62552413|NCT05646459|SHAM_COMPARATOR|Proxabrush - Control|Subjects will use only proxabrush at study site.
62552414|NCT05646459|EXPERIMENTAL|Proxabrush - CBD|Subject will use CBD + proxabrush on study site.
62552415|NCT04257539|EXPERIMENTAL|Intervention Group|These subjects will participate in a behavioral intervention that will focus on reducing sedentary behavior. This will include an initial, in-person behavioral intervention with a health coach trained and a 4 week phone call. Participants will receive a wrist-worn activity prompter to aid in sedentary behavior reduction.
62552416|NCT04257539|NO_INTERVENTION|Wait-list Control Group|Chronic low back pain participants in this group will not receive the intervention until completion of the study. Over the 8 week intervention period, participants will be asked to maintain currently levels of physical activity, sedentary behaviors, and treatment for low back pain.
62552417|NCT04257539|NO_INTERVENTION|Pain-free Control Group|These subjects will be healthy, pain-free adults and receive no intervention. Over the 8 week intervention period, participants in this group will be asked to maintain currently levels of physical activity, sedentary behaviors, and medication regimen.
62552418|NCT01358747|ACTIVE_COMPARATOR|Standard arm|Induction treatment: Patients will be treated by a BEACOPPesc regimen every 3 weeks for 4 cycles. A PET will be performed after 2 cycles of chemotherapy (PET2) with no decisional value, and after 4 cycles with decisional value. Consolidation treatment: depends on the reviewed PET4 result. In case of PET4 negative result, patient will received 2 additional cycles of BEACOPPesc, whatever the result of the PET2. In case of PET4 positive, the patient will be considered in treatment failure and proposed to a salvage therapy after pathologic confirmation of failure by biopsy of the hypermetabolic residual mass when possible.
62175737|NCT04897789||home visitors|home visitors (630)
62552419|NCT01358747|EXPERIMENTAL|Experimental arm|"Induction treatment: Patients will be treated by a BEACOPPesc regimen every 3 weeks for 2 cycles followed by a PET scan (PET2).~After PET2 central review:~* In case of positive PET2, the induction treatment will be completed by 2 additional cycles of BEACOPPesc~* In case of negative PET2, the induction treatment will be completed by 2 cycles of ABVD delivered every 4 weeks. The first cycle of ABVD will start at day 21 of the second cycle of BEACOPPesc.~Consolidation treatment: depends on the reviewed PET4 result In case of PET4 negative result, consolidation treatment will depends on PET2 results:~* If PET2 was positive, patient will received 2 additional cycles of BEACOPPesc delivered every 3 weeks~* If PET2 was negative, patient will received 2 additional cycles of ABVD delivered every 4 weeks In case of PET4 positive, the patient will be considered as treatment failure."
62552420|NCT02939794|ACTIVE_COMPARATOR|ferinject|-Patients will receive 1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
62552421|NCT02939794|PLACEBO_COMPARATOR|placebo|Patients will receive a placebo drug intravenous approximately 24 hours before surgery
62552422|NCT04756115||CASES|Adults (age\<18 years) diagnosed with a first episode of critical limb ischemia revascularized at our center from January 2016 to July 2019.
62552423|NCT06332014|EXPERIMENTAL|Prolia|Participants will receive Prolia every six months (Q6M)
62552424|NCT03878212|EXPERIMENTAL|mHealth+I|This group of participants will receive a proactive mHealth with interactivity program which includes two main elements: 1) mHealth application designed by the research team with the information technological support by Smartone and 2) nurse case management supported by a social service team
62552425|NCT03878212|ACTIVE_COMPARATOR|mHealth|The mHealth group will have access to the health content on the mHealth platform. This group 2018 HMRF Open Call Proposal Section 13: Proposed Research Project 5 will enjoy the same content and client-initiated help if needed. Same as the above group, the client is invited to use the mHealth application. A reminder message will pop up on the screen of smartphone when participants have not used it for more than one week. The participants are encouraged to read the self-care information that is featured in the app. There is a button for the client-imitated call if they would like to consult a nurse.
62552426|NCT03878212|NO_INTERVENTION|Control|All groups will receive usual community services. The study district provides community-based health talks and basic health checks such as measuring blood pressure and blood glucose that are accessible to all residents, and their participation is voluntary. Both health and social services are available in the community for those who need help, including referral for further help if appropriate. These services are however episodic with design for continuity of care. No mHealth application will be provided to the participants in this group but the individuals are free to do their own surfing for e-health information.
62552427|NCT03610152|NO_INTERVENTION|Control|Hospitals made aware of Choosing Wisely Canada recommendations and Health Quality Ontario data.
62552428|NCT03610152|EXPERIMENTAL|Hospital wide policy|A hospital-wide policy will be implemented whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologists based on their clinical assessment of the patient.
62552429|NCT03885687|EXPERIMENTAL|Exercise with Music Intervention|The Exercise with Music intervention is a recorded exercise playlist, which is tailored to a patient's individual physical abilities and music choices.
62552430|NCT03885687|ACTIVE_COMPARATOR|Active Control Group|The active control group will receive exercise brochure and will be advised to exercise at least twice daily.
62552431|NCT02970487|EXPERIMENTAL|investigational device|Subjects implanted with the Precisight intraocular lens.
62552432|NCT01073085|EXPERIMENTAL|Web-based coaching|"Those in the coaching arm will benefit from e-mails with advice, information, support for smoking cessation. These mails will be adapted to their personal profile."
62552433|NCT01073085|ACTIVE_COMPARATOR|Self-help guide|"Those in the active comparator arm will be allowed to download a self-help guide with step-by-step advice for smoking cessation."
62552434|NCT02538822|EXPERIMENTAL|thoracic ascending aorta (ATA)|the risk of rupture of thoracic ascending aorta (ATA) is assessed fom the dynamic imaging and mechanical testing
62552435|NCT06054035|EXPERIMENTAL|Dapagliflozin (Forxiga®) and lifestyle counselling|
62552436|NCT06054035|PLACEBO_COMPARATOR|Placebo matching Dapaglifolzin and lifestyle lifestyle counselling|
62552437|NCT02681510|EXPERIMENTAL|Three drug intervention|varenicline, nicotine patch and nicotine lozenge for 12 weeks
62552438|NCT06020144|EXPERIMENTAL|sequence A|TLL018 tablets, 2piece,BID
62552439|NCT06020144|ACTIVE_COMPARATOR|sequence B|Tofacitinib tablets, 1piece,BID
62552440|NCT06581302|EXPERIMENTAL|Magnetic seizure therapy plus antipsychotics|"The patients will receive antipsychotic drugs plus MST during the first 2 weeks.~A TwinCoil of MagPro XP will be positioned centrally over the frontal cortex in the midline position. The output power of MagPro XP is set to 100%, and stimulation frequency is 100 Hz. For MST titration, the first step is given at a 5-second train duration; if there is no seizure, the duration is increased to 10 seconds with a maximum limit of 10 seconds. The subsequent MST treatment will be maintained at 10 seconds. This procedure will be carried out under anesthesia.~A total of up to 10 treatments will be administered to participants, usually five times a week, for 2 weeks."
62552441|NCT06581302|ACTIVE_COMPARATOR|antipsychotic drugs|The patients will receive second-generation antipsychotic drugs without MST or ECT during the first 2 weeks.
62175738|NCT04897789||center directors|center directors (493)
62175739|NCT04897789||program directors|program directors (140)
62182417|NCT05423106|EXPERIMENTAL|Part 1: JNJ-64457744 or Placebo (Cohort I)|Non-Asian healthy participants who previously received study intervention under fasted conditions will receive either JNJ-64457744 or matching placebo as an oral formulation (depending upon what was administered previously in Cohorts A to F) under fed conditions on Day 1.
62741249|NCT03293849|NO_INTERVENTION|Control Arm|Assessment results will be provided in printed and electronic form to the treating oncologist for their review. Referrals or interventions for patients allocated to the control arm will be coordinated by the treating oncologist without involvement from the patient navigator or the study team.
62741250|NCT03922594||Cameroon|Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
62175740|NCT05085808|ACTIVE_COMPARATOR|Quetiapine|"Start study medication at 25 mg daily PO ; may increase to BID or TID if RASS\>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS\>=2 and/or \>1 dose of rescue medication is given within 24 hours \[max dose 200 mg/day\]~* dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~* dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
62175741|NCT05085808|EXPERIMENTAL|Trazodone|"Start study medication at 25 mg daily PO ; may increase to BID or TID if RASS\>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS\>=2 and/or \>1 dose of rescue medication is given within 24 hours \[max dose 200 mg/day\]~* dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~* dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
62175742|NCT05085808|PLACEBO_COMPARATOR|Placebo|"Start study medication at 25 mg daily PO ; may increase to BID or TID if RASS\>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS\>=2 and/or \>1 dose of rescue medication is given within 24 hours \[max dose 200 mg/day\]~* dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~* dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
62741251|NCT03922594||China|Fetuses or newborns (still-born, medical abortions or alive) with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
62741252|NCT03922594||Ivory Coast|Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex and severely disproportionate length or weight according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
62741253|NCT03922594||Sri Lanka|Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
62741254|NCT03922594||Vietnam|Fetuses or newborns (still-born, medical abortions or alive) with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
62741255|NCT05724953|EXPERIMENTAL|Affective Awareness|Intervention involving psychoeducation and daily emotion awareness practices
62741256|NCT01379248|EXPERIMENTAL|thrombus aspiration|Manual thrombus aspiration with dedicated catheter (Export, Medtronic Inc. Minneapolis, Minnesota, USA)
62741257|NCT01379248|NO_INTERVENTION|no thrombus aspiration|
62741258|NCT03029182|EXPERIMENTAL|Walking+simulated-altitude|8-week exercise training program that involves 3 supervised, treadmill walking sessions each week with 16% oxygen, which will be administered through an exercise mask.
62741259|NCT03029182|ACTIVE_COMPARATOR|Walking (control)|8-week exercise training program that involves 3 supervised, treadmill walking session each week.
62741260|NCT05181618|EXPERIMENTAL|Cohort 1, Hemophilia A and Without Arthropathy: Emicizumab|Cohort 1 comprises participants with severe or moderate hemophilia A and with no synovitis and no osteochondral damage (Haemophilia Early Arthropathy Detection with Ultrasound \[HEAD-US\] score of 0) in all index joints.
62741261|NCT05181618|EXPERIMENTAL|Cohort 2, Hemophilia A and with Synovitis Only: Emicizumab|Cohort 2 comprises participants with severe or moderate hemophilia A and with synovitis (HEAD-US synovitis score of ≥1) in at least one index joint and no osteochondral damage (HEAD-US bone and cartilage score of 0).
62741262|NCT05181618|EXPERIMENTAL|Cohort 3, Hemophilia A and with Osteochondral Damage: Emicizumab|Cohort 3 comprises participants with severe or moderate hemophilia A and with osteochondral damage (HEAD-US bone and cartilage score of ≥1) in at least one index joint and with any synovitis score.
62741263|NCT01650649|ACTIVE_COMPARATOR|Lofexidine Titration in Methadone Maintained Subjects|Methadone maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID (4 tablets QID) or to the highest level tolerated. Following this initial titration attempt, all subjects will have their methadone dose reduced by 50% and lofexidine titration efforts will resume.
61986226|NCT03689998|EXPERIMENTAL|implant placement with melatonine|immediate implant placement with melatonine
62552442|NCT01925963||Normal cohort|Normal, healthy adults without history of brain injury
62552443|NCT01551030|EXPERIMENTAL|Buparlisib|This is an open-label phase II study of the pan-class I selective phosphoinositide 3-kinase (PI3K) inhibitor Buparlisib in patients with metastatic urothelial carcinoma which has progressed despite treatment with prior cytotoxic chemotherapy.
62552444|NCT04154631|EXPERIMENTAL|Standard TranS-C|Standard TranS-C is modularized and delivered across eight 50-minute, weekly, individual sessions. It is comprised of 4 cross-cutting interventions featured in every session; 4 core modules that apply to the vast majority of patients; and 7 optional modules used less commonly, depending on the presentation.
62552445|NCT04154631|EXPERIMENTAL|Adapted TranS-C|The process for developing Adapted TranS-C has been iterative and grounded in theory, data and stakeholder feedback. The core elements of the evidence-based theory of change underpinning TranS-C have been retained. Adapted TranS-C is delivered in four 20-minute, weekly, individual sessions.
62552446|NCT04154631|ACTIVE_COMPARATOR|UC-DT|Usual Care Delayed Treatment. Usual care in the partner CMHCs starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
62552447|NCT00937716||Diagnosis of Schizophrenia|Patients with a diagnosis of schizophrenia that have been off antipsychotic medicine and would like to resume treatment will be enrolled in the study.
62552448|NCT00937716||Healthy Volunteers|Healthy Volunteers without a psychiatric diagnosis, central nervous system condition, serious head injury, or current drug use will be matched on an individual basis to schizophrenic participants and used as a control population.
62741264|NCT01650649|PLACEBO_COMPARATOR|Placebo titration in methadone maintained subjects|Methadone maintained subjects will be titrated on placebo tablets in ascending doses of 1 tablet starting with 2 tablets (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc) to mimic titration for subjects randomized to lofexidine.
62741265|NCT05714449|EXPERIMENTAL|Patching group|part-time patching following PEDIG guidelines.
62741266|NCT05714449|EXPERIMENTAL|foveation therapy|After-image foveation therapy training is 10 mins; MIT training is 5 minutes.
62741267|NCT03938766|OTHER|PSMA PET/CT|Repeat PSMA PET/CT after ADT
62741268|NCT02072876||Asymptomatic ICAD on MRI Absent|Those who test negative on QVSFS, Questionnaire to Verify Stroke Free Status, and do not have ICAD on MRI. They are clinically and biologically free of disease.
62741269|NCT02072876||Asymptomatic ICAD Present on MRI|Those who are negative for Stroke Symptoms on QVSFS, Questionnaire to Verify Stroke Free Status, yet have evidence of ICAD on MRI
62741270|NCT06661382|EXPERIMENTAL|Infiltrative treatment with CB-PRP Group|
62741271|NCT06661382|PLACEBO_COMPARATOR|Placebo infiltrative treatment Group|
62741272|NCT04646304|OTHER|Objective Feedback (Motion Capture)|Participants in the objective feedback group will receive a report that compares their performance in Set 1 to that of the staff surgeons' using the target interval as a reference. Participants receiving objective feedback will then complete Sets 2 and 3 knowing what factors to improve upon.
62741273|NCT04646304|NO_INTERVENTION|No Feedback|Participants receiving no feedback will complete all sets with no intervention.
62741274|NCT04597216|OTHER|unique arm|there is only 1 arm in this study (all the participants will undergo the same diagnosis procedure)
62741275|NCT04145921|EXPERIMENTAL|ERAS for MIS-THA|enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
62741276|NCT04145921|ACTIVE_COMPARATOR|conventional MIS-THA|conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
61986227|NCT03689998|ACTIVE_COMPARATOR|immediate implant placement alone|immediate implant placement alone
62175743|NCT00930735||Myocardial fibrosis, outcomes|Groups with none and variable amounts of myocardial fibrosis
62552449|NCT04296591||study group|The study group consisted of late preterm cases(34-37 weeks of gestation) and
62552450|NCT04296591||control group|the control group consisted of term cases (\<37 weeks of gestation).
62552451|NCT03877679|EXPERIMENTAL|turmeric paste|Topical curcumin gel (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University traumeric extracted from Curcuma plant, it has anti-inflammatory, antioxidative and antineoplastic properties ((Nosratzehi et al., 2018), The curcumin is safe even in high doses, Since oxidative stress may play a role in pathophysiology of OLP, and by noting that OLP is a chronic inflammatory disease, the herbs which have both anti-inflammatory and antioxidant properties may efficiently control OLP (Kia et al., 2015).
62552452|NCT03877679|ACTIVE_COMPARATOR|Triamcenolone in orabase|Triamcenolone + na ploycarboxylate
62552453|NCT05180448|EXPERIMENTAL|Coach Share On + Group Share On + Friend/Family Share On|
62552454|NCT05180448|EXPERIMENTAL|Coach Share On + Group Share On + Friend/Family Share Off|
62552455|NCT05180448|EXPERIMENTAL|Coach Share On + Group Share Off + Friend/Family Share On|
62552456|NCT05180448|EXPERIMENTAL|Coach Share On + Group Share Off + Group Share Off|
62552457|NCT05180448|EXPERIMENTAL|Coach Share Off + Group Share On + Friend/Family Share On|
62552458|NCT05180448|EXPERIMENTAL|Coach Share Off + Group Share On + Friend/Family Share Off|
62552459|NCT05180448|EXPERIMENTAL|Coach Share Off + Group Share Off + Friend/Family Share On|
62552460|NCT05180448|EXPERIMENTAL|Coach Share Off + Group Share Off + Friend/Family Share Off|
62741277|NCT02876237|EXPERIMENTAL|geriatric assessment and quality of life|"Included patient must have a geriatric assessment before radiotherapy and 6 months later.~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later."
62741278|NCT01437579|ACTIVE_COMPARATOR|Botulinum toxin|Bladder intratrigonal injection of botulinum toxin (100 units) in 10 injection sites during cystoscopy under general anesthesia
62741279|NCT01437579|SHAM_COMPARATOR|cystoscopy with hydrodistension|cystoscopy with hydrodistension under general anesthesia
62741280|NCT02499900|EXPERIMENTAL|Copaxone® 40 mg/mL|Subcutaneous Injections 40 mg/mL Three Times a Week for the core period which last 6 months. In the extension period patient are administered Copaxone® 40 mg/mL for months 7 - 12.
62741281|NCT02499900|ACTIVE_COMPARATOR|Copaxone® 20 mg/mL|Subcutaneous Injections 20 mg/mL Daily for the core period which last 6 months. In the extension period patient are administered Copaxone® 40 mg/mL for months 7 - 12.
62741282|NCT03661307|EXPERIMENTAL|Treatment (decitabine, quizartinib, venetoclax)|Patients receive decitabine IV over 1 hour on days 1-10, quizartinib PO every day beginning on day 1 of cycle 1, and venetoclax PO on days 1-14 (days 1-21 if persistent leukemia). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62552461|NCT04481555|NO_INTERVENTION|"Eosinophil_Control/Azithro_Control"|"1. Azithromycin: patients are given placebo~2. ICS: The patients are given the usual LAMA/LABA/ICS product in the usual dose."
62552462|NCT04481555|EXPERIMENTAL|"Eosinophil_Active/Azithro_Control:"|"a. Azithromycin: placebo b. ICS: All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months): i. If blood eosinophil ≥ 300 cells/μL, ICS in usual dose next 3 months. Blood eosinophils are measured every 3 months.~ii. If blood eosinophil \<300 cells/μL, ICS is discontinued."
62552463|NCT04481555|EXPERIMENTAL|"Eosinophil_Control/Azithro_Active group"|Azithromycin: 250 mg azithromycin three times weekly. b. ICS: The patients are given the usual LAMA/LABA/ICS product in the usual dose, where the medical treatment for severe COPD is unchanged throughout the entire project period
62552464|NCT04481555|EXPERIMENTAL|"Eosinophil_Active/Azithro_Active:"|"1. Azithromycin: 250 mg azithromycin three times weekly.~2. ICS: All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months):"
62552465|NCT04504994|EXPERIMENTAL|exclusion BPD|cyberball exclusion condition - BPD patients
62552466|NCT04504994|EXPERIMENTAL|over-inclusion BPD|cyberball over-inclusion condition - BPD patients
62552467|NCT04504994|EXPERIMENTAL|exclusion healthy controls|cyberball exclusion condition - healthy controls
62552468|NCT04504994|EXPERIMENTAL|over-inclusion healthy controls|cyberball over-inclusion condition - healthy controls
62741283|NCT05373784|EXPERIMENTAL|FMT cohort|This will be a single-arm pilot study of patients with uncomplicated diverticulitis. All subjects enrolled as recipients will undergo FMT via colonoscopy.
62741284|NCT05366621||Used osteoporosis medication|Patients who had used osteoporosis medication after osteoporotic fractures.
62741285|NCT05366621||Did not use osteoporosis medication|Patients who didn't use osteoporosis medication after osteoporotic fractures.
62741286|NCT03866408|ACTIVE_COMPARATOR|Immediate weight loss - placebo|Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to placebo during this period.
62552469|NCT06388005|NO_INTERVENTION|control group|
62552470|NCT06388005|EXPERIMENTAL|experimental group|
62552471|NCT00599053|EXPERIMENTAL|1|Early treatment with azithromycin
62552472|NCT00599053|NO_INTERVENTION|2|Expectant (usual) management
62552473|NCT03535012||Reconstruction using an implant|Immediate 2 stage implant based breast reconstruction after mastectomy. All expanders are placed in the subpectoralis muscle using ADM as a sling. After expansion of the tissue expander change to the permanent implant is performed.
62364841|NCT03254888||Safety margin group|"• 50 normal bladder urothelial tissue samples from the safety margin around the tumor(0.5cm to the tumor),~The followings markers must be estimated :~1. Autophagy markers:~   * ( Atg7) level using (quantitative real time polymerase chain reaction).~  * (LC3A)level using immunohistochemistry .~2. ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~3. Oxidative stress Marker:(MDA)using chemical method~4. Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction)."
62552474|NCT03535012||Reconstruction using abdominal tissue|immediate free DIEP flap breast reconstruction after mastectomy. DIEP(deep inferior epigastric perforator) free flap was prepared and transferred to the breast pocket. Microanastomosis was done under the microscopic magnification. On sitting position, free flap was inset into breast pocket with confirming of satisfactory inflammatory fold.
62552475|NCT02988414||Staphylococcus aureus Infection|Patients with blood culture confirmed S. aureus bloodstream infections.
62552476|NCT02988414||Gram Negative Infection|Patients with blood culture confirmed Gram Negative bloodstream infecrions
62552477|NCT02988414||Endocarditis|Patients admitted for evaluation of acute endocarditis classified using the Duke Criteria.
62552478|NCT01960439||Endoscopic evaluation|The study population contained a broad spectrum of endoscopic disease and clinical activity. At entry to the trial patients had active disease defined by the presence of a modified UCDAI score between 4 and 10.1 Only patients who had a MMCS endoscopy subscale score according to a single central reader (n= 194 of 281 participants) were eligible for assessment in the current study.
62552479|NCT02656069|OTHER|G-Pen first, then Lilly Glucagon|A single 1 mg subcutaneous (SC) injection of G-Pen (glucagon injection) with a 7-28 day wash-out, followed by a single 1 mg SC injection of Lilly Glucagon (glucagon injection \[rDNA origin\])
62552480|NCT02656069|OTHER|Lilly Glucagon first, then G-Pen|A single 1 mg SC injection of Lilly Glucagon (glucagon injection \[rDNA origin\]) with a 7-28 day wash-out, followed by a single 1 mg SC injection of G-Pen (glucagon injection)
62552481|NCT06530797||First-line treatment for advanced stage|Any first-line regiment including Adebrelimab for advanced stage ES-SCLC
62552482|NCT06530797||Second-line and beyond for advanced stage|Any Second- or later-line and regiment including Adebrelimab for advanced stage ES-SCLC
62552483|NCT03519789||Post-Traumatic Stress Disorders (PTSD)|30 patients with PTSD (diagnosis based on the standard DSM criteria)
62552484|NCT03519789||Controls|30 healthy controls without any psychiatric or neurological diagnosis
62741287|NCT03866408|PLACEBO_COMPARATOR|Deferred control group - placebo|After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are also randomized to placebo. At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without placebo.
62741288|NCT03866408|ACTIVE_COMPARATOR|Immediate weight loss - pioglitazone|Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to pioglitazone during this period.
62741289|NCT03866408|ACTIVE_COMPARATOR|Deferred group - pioglitazone|"After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are randomized to pioglitazone. They will be monitored to prevent the usual but modest weight gain associated with pioglitazone. They will be on pioglitazone during the 'wait' period.~At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without pioglitazone."
62175744|NCT05762471|EXPERIMENTAL|Cohort 1|Patients will receive once daily doses of study drug (GSBR-1290 or Placebo) for a total of 4 weeks
62552485|NCT02237586|EXPERIMENTAL|Group IA|"Adults with naturally acquired immunity and HbAA (Group IA, n=10)~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge will be administered once intravenously. If 50% or less of volunteers become parasitemic in Groups IA or IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
62552486|NCT02237586|EXPERIMENTAL|Group IS|"Adults with naturally acquired immunity and HbAS (Group IS, n=10)~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge will be administered once intravenously. If 50% or less of volunteers become parasitemic in Groups IA or IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
62741290|NCT06279949|NO_INTERVENTION|No provider training or clinic protocols|This clinic will not receive training on state-specific laws regulating minors' access to confidential HIV testing or implementation of new protocols to support confidential care provision.
62741291|NCT06279949|ACTIVE_COMPARATOR|Clinic protocols|This clinic will receive training on navigating new protocols to support confidential care provision.
62741292|NCT06279949|ACTIVE_COMPARATOR|Provider training|This clinic will receive training on state-specific laws regulating minors' access to confidential HIV testing.
62741293|NCT06279949|ACTIVE_COMPARATOR|Provider training and clinic protocols|This clinic will receive training on state-specific laws regulating minors' access to confidential HIV testing and navigating new protocols to support confidential care provision.
62741294|NCT01071252|EXPERIMENTAL|AIN457 1x25mg|
62741295|NCT01071252|EXPERIMENTAL|AIN457 3x25mg|
62741296|NCT01071252|EXPERIMENTAL|AIN457 3x75mg|
62741297|NCT01071252|EXPERIMENTAL|AIN457 3x150mg|
62741298|NCT01071252|PLACEBO_COMPARATOR|Placebo|
62741299|NCT04008303||Patients with migraines|"Patients seen in clinic and assessed with Migraine Headache Diagnostic Criteria to ensure diagnosis.~Patients track the characteristics of migraine headaches for one month before surgery.~After this month, patients receive surgery in the operating room for migraine.~After surgery, patients track the characteristics of migraine headaches for 3 months.~Patients will then be asked to track the characteristics migraine headaches again at 1 year and 2 years and 5 years after surgery. For these time periods, patients only have to keep track of the characteristics for 1 month intervals."
62741300|NCT02353819|EXPERIMENTAL|Stereotactic Ablative Radiotherapy|Stereotactic Ablative Radiotherapy (SABR)
62741301|NCT03737448|EXPERIMENTAL|Group 1|"* AD with serum creatinine ≥ 1 and \< 2 mg/dL, OR~* ACLF 1 with~  * liver failure and serum creatinine ≥ 1.5 and \< 2 mg/dl, or~ * liver failure and West Haven grade 1-2 hepatic encephalopathy, or~ * coagulation failure and serum creatinine ≥ 1.5 and \< 2 mg/dl, or~ * coagulation failure and West Haven grade 1-2 hepatic encephalopathy, OR~* ACLF 2 with~  * liver failure and coagulation failure, or~ * liver failure and West Haven grade 3-4 hepatic encephalopathy."
62741302|NCT03737448|EXPERIMENTAL|Group 2|"* ACLF 1 with renal failure (serum creatinine ≥ 2.0 and \< 3.5 mg/dL), OR~* ACLF 2 with~  * liver failure and renal failure (serum creatinine ≥ 2.0 and \< 3.5 mg/dL), or~ * coagulation failure and renal failure (serum creatinine ≥ 2.0 and \< 3.5 mg/dL)."
62175745|NCT05762471|EXPERIMENTAL|Cohort 2|Patients will receive once daily doses of study drug (GSBR-1290 or Placebo) for a total of 4 weeks
62175746|NCT05762471|EXPERIMENTAL|Cohort 3|Patients will receive once daily doses of study drug (GSBR-1290 or Placebo) for a total of 4 weeks
62552487|NCT02237586|EXPERIMENTAL|Group NI|"Adults without previous exposure to malaria and HbAA (Group NI, n=5)~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge administered once intravenously should lead to consistent infection in naïve adults (15/15 in prior studies) and thus should infect all volunteers in Group NI. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
62552488|NCT02864992|OTHER|Part 1: Cohort A: METex14 Skipping Alterations|Participants received 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
62741303|NCT03280849|EXPERIMENTAL|Patient with bilaminar chitosan implant|A 65 year old woman, right handed, started with progressive bilateral visual loss in her temporal field, over 10 months, she underwent an MRI and it was found a sellar lesion that compressed the optic chiasm, an endoscopic endonasal transsphenoidal surgery was done for the resection of the lesion, using a novel bilaminar chitosan scaffold to assist the closure of the sellar floor.
62741304|NCT01974206|EXPERIMENTAL|ASP0113|Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).
62741305|NCT01974206|PLACEBO_COMPARATOR|Placebo|Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).
62741306|NCT01132651|EXPERIMENTAL|Chillow cooling pillow|This group of subjects will follow their current eczema regimen with the addition of using the cooling pillow at night to sleep on.
62741307|NCT01132651|PLACEBO_COMPARATOR|Standard of care (regular pillow at night)|This group of subjects will serve as the control group following a their current eczema care regimen, including sleeping on their normal pillow.
62741308|NCT05195437||Growth hormone treatment|Adolescents and young adults followed or having been followed by the endocrinology, gynecology and pediatric diabetology department of the Necker Enfants Malades hospital, who reached their final height and who have been treated with growth hormone due to short stature.
62741309|NCT04551898|EXPERIMENTAL|BGB-DXP593 Low Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
62741310|NCT04551898|EXPERIMENTAL|BGB-DXP593 Medium Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
62741311|NCT04551898|EXPERIMENTAL|BGB-DXP593 High Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
62741312|NCT04551898|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo on Day 1, and followed up for safety for up to 85 days
62741313|NCT03931382|EXPERIMENTAL|Virtual Reality|In this arm, participants will receive 45 minutes of preparation using a simulated virtual reality experience designed in collaboration with Medical Imaging and Child Life Specialists.
62741314|NCT03931382|ACTIVE_COMPARATOR|Mock MRI|In this arm, participants will receive 45 minutes of preparation using the standard of care simulator, conducted by a Child Life Specialist
62741315|NCT03931382|ACTIVE_COMPARATOR|Manual|In this arm, participants will receive 45 minutes of preparation using the standard of care MRI Preparation Booklet for non-sedated MRIs.
62741316|NCT01877850||case|patients with BPAW-M more than 15 or between 10 and 15, but with Tobin \<100 will be weaned with the weaning protocol by nurses
62175747|NCT05762471|EXPERIMENTAL|Cohort 4|HOV participants (Cohort 4) will receive multiple-ascending doses of GSBR-1290 or placebo for a total of 12 weeks
62741317|NCT01877850||control|patients with any BWAP-M will be weaned by clinical judgment of physicians
62741318|NCT05809050||control group|represents the control group ( ITP cases
62741319|NCT05809050||AL group|cases of AcuteLeukemia.
62175748|NCT05762471|EXPERIMENTAL|Cohort 5|Participants with T2DM(Cohort 5) will be randomized to placebo, low-dose, or high-dose arms. Participants in the low-dose, high-dose or placebo arms will receive multiple-ascending doses for 12 weeks
62552489|NCT02864992|OTHER|Part 1: Cohort B: MET Amplification|Participants received 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
62552490|NCT02864992|OTHER|Part 2: Cohort C: Confirmatory Part for METex14 Skipping Alterations|Participants received 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
62552491|NCT05697016|EXPERIMENTAL|the Sivelestat group|The patients in this group will receive sivelestat sodium via continuous intravenous infusion (0.2mg/kg/h) over a 24-hour period for 7 days
62741320|NCT03815058|EXPERIMENTAL|Safety Run-in Period: Autogene Cevumeran + Pembrolizumab|Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by intravenous (IV) infusion followed by 200 mg pembrolizumab IV infusion every 3 weeks (Q3W) plus a recommended dose of autogene cevumeran.
62741321|NCT03815058|ACTIVE_COMPARATOR|Randomized Period: Arm A: Pembrolizumab|Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W. Participants in Arm A have the option to cross over to combination treatment with autogene cevumeran plus pembrolizumab (Arm B) after confirmed disease progression.
62741322|NCT03815058|EXPERIMENTAL|Randomized Period: Arm B: Autogene Cevumeran + Pembrolizumab|Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by IV infusion followed by 200 mg pembrolizumab IV infusion Q3W plus a recommended dose of autogene cevumeran.
62741323|NCT00677846||3|Patients with symptoms of deep venous thrombosis less than for 2 weeks, with thrombus occluding without any reperfusion in color mode in the common femoral vein (CFV), the femoral vein (FV) or the popliteal vein (PV)
62175749|NCT05297253||telescopic overdenture group|patients receiving implant retained telescopic overdentures
62175750|NCT05297253||fixed group|patients receiving fixed implant prostheses
62175751|NCT02143063|ACTIVE_COMPARATOR|standard care|standard care
62741324|NCT05687032|EXPERIMENTAL|inotuzumab ozogamicin|Dose: inotuzumab ozogamicin 0.8-0.5 mg/m\^2 IV, weekly, 3 times per cycle Cycle length: 21-28 days Total number of cycles: 6
62741325|NCT06657638||Cancer breast|malignant pleural effusion in breast cancer
62552492|NCT05697016|PLACEBO_COMPARATOR|The Placebo group|The patients in this group will receive the placebo via continuous intravenous infusion (0.2mg/kg/h) over a 24-hour period for 7 days
62552493|NCT03746392|EXPERIMENTAL|Jumpstart Intervention|
62552494|NCT03746392|NO_INTERVENTION|Usual Care|
62552495|NCT04279210|EXPERIMENTAL|PRP Treatment|Women with SUI received PRP injection into anterior vaginal wall (near external urethral sphincter) once per month for three times.
62552496|NCT01313052|EXPERIMENTAL|Forensic Assertive Community Treatment (FACT)|Individuals in this arm will receive the services of an Assertive Community Treatment team and close supervision of a judge trained in the FACT model.
62552497|NCT01313052|ACTIVE_COMPARATOR|Enhanced Treatment as Usual|Individuals in this arm of the study will receive an expedited appointment at a clinic specializing in the treatment of psychotic disorders. These individuals will receive the services of a therapist, psychiatrist, and case manager.
62552498|NCT00929851|EXPERIMENTAL|BDP/FF|Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose inhaler
62552499|NCT00929851|ACTIVE_COMPARATOR|Formoterol fumarate|Formoterol fumarate 12 µg per metered dose
62552500|NCT02717455|EXPERIMENTAL|Treatment (STRATUM 1)|Patients with recurrent/progressive DIPG will be enrolled at the time of progression. All patients will take the study drug panobinostat (LBH589).
62552501|NCT02717455|EXPERIMENTAL|Treatment (STRATUM 2)|Patients with non-progressed DIPG or H3K27M+ Thalamic DMG will be enrolled. All patients will take the study drug panobinostat (LBH589).
62552502|NCT05821335|EXPERIMENTAL|Leap motion assisted rehabilitation|Individuals who will participate in the study will be treated 2 days a week for 5 weeks with Leap Motion sensor-supported games aimed at increasing patient-specific wrist flexion, wrist extension, ulnar and radial deviation of the wrist, flexion, extension and abduction of the fingers. Each training period will last 30 minutes.
62741326|NCT05684445|EXPERIMENTAL|Distant reiki group|According to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced every day for 10 days by researchers who have completed the Phase 1 training. The time of remote reiki application will be planned by talking with the patient.
62741327|NCT01059487|OTHER|Traditional Chinese Medicine|Assessing efficacy of treating subjects/patients with Traditional Chinese Medicine (TCM) by administering SF-36v2 and PIQ-6 surveys to subjects/patients to create a baseline and then re-assessing quality of life achieved through TCM treatments by administering follow-up SF-12v2 and PIQ-6 surveys every four weeks
62741328|NCT06252870|EXPERIMENTAL|(CLO)-BALTIMORE|BALTIMORE conditioning regime for LYMPHOID HEMOPATHY CLO-BALTIMORE conditioning regime for MYELOID HEMOPATHY
62741329|NCT06252870|ACTIVE_COMPARATOR|TBF|Conditioning regimen for LYMPHOID AND MYELOID HEMOPATHY
62741330|NCT01577264||Cimzia treatment|
62552503|NCT05821335|EXPERIMENTAL|Traditional program|They will be included in traditional rehabilitation training consisting of stretching exercises, strengthening exercises and functional exercises including activities of daily living for 2 days a week for 5 weeks.
62552504|NCT01594255|EXPERIMENTAL|AEB071 300 mg|
62552505|NCT01594255|EXPERIMENTAL|AEB071 900 mg|
62741331|NCT04715828||"control arm fresh"|Fresh semen treated without irradiation before cryopreservation
62741332|NCT04715828||"control arm cryopreserved"|cryopreserved semen without irradiation (n=60)
62741333|NCT04715828||acute irradiation at low dose|Pelvis scanning : acute irradiation (1 or 2 second) using low dose (n=30),
62552506|NCT01594255|PLACEBO_COMPARATOR|Placebo to AEB071|
62552507|NCT01594255|ACTIVE_COMPARATOR|Moxifloxacin|
62552508|NCT03688048|EXPERIMENTAL|Bright light treatment|Single-dose bright light treatment (1 hour, 10 000 lux)
62552509|NCT03688048|PLACEBO_COMPARATOR|Sham placebo|Deactivated negative ion generator in conjunction with a plausible cover story
62552510|NCT00490841|EXPERIMENTAL|RX Herculink Elite|To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.
62552511|NCT05716126|EXPERIMENTAL|[14]Iruplinalkib(WX-0593) 120 mg(orla solution)|Volunteer will receive a single oral dose of 120 mg \[14C\]Iruplinalkib (WX-0593) administered by mouth, as a solution.
62552512|NCT05642715|EXPERIMENTAL|EX+/HR|The harm reduction arm (described in detail elsewhere)
62552513|NCT05642715|ACTIVE_COMPARATOR|EX+/TAU|The treatment as usual arm
62552514|NCT04757597|EXPERIMENTAL|RIC group|RIC treatment and regular treatment.
62741334|NCT04715828||long irradiation at low dose|Bone scintigraphy : long irradiation (3h) using low dose (n=30),
62741335|NCT04715828||long irradiation at medium dose|Radioactive Iodine 131 therapy (RAT) applied for thyroid cancer : long irradiation (3h) using medium dose (n=60),
62741336|NCT03985943|PLACEBO_COMPARATOR|Placebo|Placebo
62741337|NCT03985943|EXPERIMENTAL|Nemolizumab|Nemolizumab Active
61986228|NCT01489293||atopic subjects|Patients with one atopic disease or more (atopic dermatitis,rhinitis, asthma, food allergy)
61986229|NCT01489293||non-atopic subjects|Control group without atopic diseases.
61986230|NCT03616899|ACTIVE_COMPARATOR|KPI-121 0.25% Ophthalmic Suspension|
62552515|NCT04757597|NO_INTERVENTION|Regular treatment|Regular treatment alone.
62552516|NCT06178627|ACTIVE_COMPARATOR|Normal dose amphotericin B (0.7 mg/kg/d)|Study regimen 1: amphotericin B 0.7 mg/kg/day i.v. plus flucytosine for 4 weeks
62741338|NCT02378077|EXPERIMENTAL|Lean or Obese, Non-Diabetic|To determine whether eosinophil content of adipose tissue is related to insulin sensitivity. We will use euglycemic clamps, fat biopsy (obtained during a scheduled abdominal surgery) and fat aspiration for analysis of subcutaneous (Sc) and omental (OM) adipose tissue from obese, insulin resistant and lean, insulin sensitive volunteers to test the hypothesis that, as in mice, eosinophil content in human subcutaneous and omental white adipose tissue, inversely correlates with body weight, with skeletal muscle and hepatic insulin sensitivity.
62741339|NCT02378077|EXPERIMENTAL|Fish oil supplementation|Determine whether, in adipose tissue, levels of, anti-inflammatory molecules correlate with insulin sensitivity and whether these levels are altered by a treatment designed to promote resolution of inflammation. Volunteers will take a fish oil supplement for three months.
62741340|NCT00985608|ACTIVE_COMPARATOR|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
62741341|NCT00985608|ACTIVE_COMPARATOR|Group A: NCA 600mg +antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
62741342|NCT04715854|ACTIVE_COMPARATOR|Nasal canula (flexicare)|Patients will receive oxygen by classical nasal cannula
62741343|NCT04715854|ACTIVE_COMPARATOR|Intersurgical aerosol mask with one hole closed by tape|Patients will receive oxygen by classical nasal cannula associated with an aerosol mask partially closed (one lateral hole of the face mask closed by tape)
62741344|NCT04715854|ACTIVE_COMPARATOR|Intersurgical aerosol mask|Patients will receive oxygen by classical nasal cannula associated with an aerosol mask
62741345|NCT05530863|ACTIVE_COMPARATOR|Sleep Hygiene|This arm will receive behavioral education, such as sleep hygiene and other advice. Additional details cannot be provided since that will compromise the participant blinding
62741346|NCT05530863|EXPERIMENTAL|ART and Sleep Hygiene|This arm will receive behavioral education, such as sleep hygiene and other training. Additional details cannot be provided since that will compromise the participant blinding
62741347|NCT04833686|ACTIVE_COMPARATOR|Sonata for 2 pianos in D major, K.488 by Mozart|An Mp3 player, upload with music by Mozart. Music was played using headphones suitable and approved for use in children.
62741348|NCT04833686|ACTIVE_COMPARATOR|"Instrumental music (To the Point, by Dean Evenson & Tom Barabas)"|An Mp3 player, upload with instrumental music. Music was played using headphones suitable and approved for use in children.
62741349|NCT04833686|ACTIVE_COMPARATOR|Silence|An Mp3 player, upload with silence. Silence was played using headphones suitable and approved for use in children.
62741350|NCT00884962|EXPERIMENTAL|PLVR|
62741351|NCT03379948||Group 1 with central venous line|lab investigation Complete blood count blood culture
62741352|NCT03379948||Group 2 with only peripheral line|lab investigation Complete blood count blood culture
62741353|NCT01803100||Hospitalized inpatients|Inpatients newly admitted into freshly-cleaned rooms.
62741354|NCT06020391|EXPERIMENTAL|Intervention group|Collaborative drug review.
62741355|NCT06020391|NO_INTERVENTION|Control group|Usual care.
62552517|NCT06178627|EXPERIMENTAL|Low dose amphotericin B (0.5 mg/kg/d)|Amphotericin B 0.5 mg/kg/day i.v. plus flucytosine for 4 weeks
62552518|NCT01579747|PLACEBO_COMPARATOR|Nerve stimulation sciatic nerve block|Time taken to complete a sciatic nerve block via the lateral popliteal approach using nerve stimulation
62552519|NCT01579747|ACTIVE_COMPARATOR|Ultrasound guided sciatic nerve block|Time taken to complete a sciatic nerve block via the lateral popliteal approach when using an ultrasound
62552520|NCT00198055|EXPERIMENTAL|Aripiprazole|Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
62741356|NCT01108731|ACTIVE_COMPARATOR|Patients taking the drug Milnacipran|Randomize patients signing informed consent and give 50% of them Milnacipran -- blinded to the investigators.
62741357|NCT01108731|PLACEBO_COMPARATOR|Patients taking the placebo|Randomize patients signing informed consent and give 50% of them the placebo -- blinded to the investigators.
62391456|NCT03396406|EXPERIMENTAL|PCRF group|received Pulsed radiofrequency (PRF) at 42°C for 8 minutes followed by CRF at 60°C for 270s
62552521|NCT04190758||Patients with rheumatoid arthritis (RA)|Patients with RA meeting the classification criteria of American College of Rheumatology (ACR) and/or European League Against Rheumatism (EULAR) från 2010.
62552522|NCT04190758||Patients with psoriatic arthritis (PsA)|Patients with PsA meeting the classification criteria of Classification for Psoriatic Arthritis (CASPAR).
62552523|NCT04190758||Patients with undifferentiated arthritis|Defined as a patients with a clear arthritis, but not meeting with established classifications criteria of any now known rheumatic disease.
62552524|NCT04190758||Patients with psoriasis|Patients with psoriasis diagnosed at a dermatology department. The patients should not have any history of joint complaints with a duration of more than 6 weeks.
62552525|NCT04190758||General population controls|General population controls retrieved from the Population Register, matched for age, sex and residence of living to the included patients.
62741358|NCT01684696|EXPERIMENTAL|mHealth TLC|"The mhealth TLC group will meet with a nurse before each of 4 clinician visits and use the mHealth TLC on an iPad with an interactive 3-dimensional intervention that allows individuals to experience virtual visits with their clinicians. Key aspects of mHealthTLC include informational videos about lung cancer and LCS. Blame and self-blame will be addressed, information about the role of addiction, social/cultural factors, and tobacco industry influence on smoking behaviors will be highlighted. Patients will experience practiced interaction in ever increasing complex situations with avatars (i.e., receptionist, medical assistant, and clinician). A virtual coach will accompany the patient through the virtual visit and will provide information and coaching (as needed)."
62741359|NCT01684696|ACTIVE_COMPARATOR|Attention Control|Attention control group (ACG) - Patients assigned to the ACG will meet with a nurse and receive only the informational videos on an iPad before 4 clinician visits with assessments after each clinician visit. An effort will be made to match the intervention condition on salience, credibility, and contact time.
62741360|NCT03415594|EXPERIMENTAL|FE203799 5 mg|FE203799 GLP-2 analogue, once weekly, subcutaneous administration
62741361|NCT03415594|PLACEBO_COMPARATOR|Placebo|Placebo FE203799 GLP-2 analogue, once weekly, subcutaneous administration
62741362|NCT03415594|OTHER|FE203799 10 mg|FE203799 GLP-2 analogue, once weekly, subcutaneous administration
62741363|NCT04428788|EXPERIMENTAL|Administration of CC-94676, CC1083611, and CC1083610|
62741364|NCT05655650||Normal cognition|75 subject without any of the following: subjective memory complaint and cognitive impairment base on cognitive assessments
62741365|NCT05655650||Subjective Cognitive Disorder|75 subjects without cognitive impairment based on cognitive cognitive assessments but with subject memory complaint
62741366|NCT05655650||Mild Cognitive Impairment|75 subjects with both subjective memory complaints and mild cognitive impairment base on cognitive assessments
62741367|NCT05655650||Dementia|75 subjects with both subjective memory complaints and moderate to severe cognitive impairment base on cognitive assessments
62741368|NCT05507567|EXPERIMENTAL|Neumifil multiple dose prophylactic treatment|Neumifil intranasal spray administered as 3 single daily doses prior to viral challenge
62741369|NCT05507567|EXPERIMENTAL|Neumifil single dose prophylactic treatment|Neumifil intranasal spray administered as a single dose and blinded by placebo administered as two single daily doses. All administrations completed prior to viral challenge
62741370|NCT05507567|PLACEBO_COMPARATOR|Placebo|Intranasal spray administered as 3 single daily doses prior to viral challenge
62741371|NCT01478269||Cases of aggressive B-cell lymphoma|Cases of aggressive B-cell lymphoma diagnosed between 2001 to 2007 in Italy
62175752|NCT02143063|ACTIVE_COMPARATOR|standard care plus traditional contingency managment|prize contingency management on a traditional twice weekly schedule for cocaine abstinence
62552526|NCT03197441|EXPERIMENTAL|PRP group|Arthroscopic knee surgery plus intraoperative platelet-rich plasma
62552527|NCT04730583|ACTIVE_COMPARATOR|Kybella Injection|
62552528|NCT04730583|ACTIVE_COMPARATOR|1064nm laser|
62552529|NCT04730583|ACTIVE_COMPARATOR|755nm laser|
62552530|NCT04005001|EXPERIMENTAL|Experimental|The experimental arm will involve patients monitored by HindSight.
62552531|NCT04005001|ACTIVE_COMPARATOR|Control|The control arm will involve patients monitored by InSight.
62741372|NCT00494650|EXPERIMENTAL|1|Participants will receive cognitive behavioral therapy.
62741373|NCT00494650|ACTIVE_COMPARATOR|2|Participants will receive brief PTSD treatment.
62741374|NCT02463084|EXPERIMENTAL|Low Diet|Diet intervention consisting of foods with low saturated fats, low glycemic index and low salt
62741375|NCT02463084|EXPERIMENTAL|High Diet|Diet intervention consisting of foods with high saturated fats, high glycemic index and high salt
62741376|NCT06284590|EXPERIMENTAL|Systemic pembrolizumab in combination with intralesional L19IL2 (Arm 1)|Two-weeks screening period and a 4-weeks open-label intralesional treatment period with L19IL2. Pembrolizumab will be administered by i.v. infusion on the first day of intralesional treatment with L19IL2, and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first.
62741377|NCT06284590|EXPERIMENTAL|Systemic pembrolizumab in combination with intralesional L19TNF (Arm 2)|Two-weeks screening period and a 4-weeks open-label intralesional treatment period with L19TNF. Pembrolizumab will be administered by i.v. infusion on the first day of intralesional treatment with L19TNF, and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first.
62175753|NCT02143063|EXPERIMENTAL|standard care plus variable interval contingency management|prize contingency management on a variable interval schedule for cocaine abstinence
62175754|NCT04210804|EXPERIMENTAL|Omega-3|1gEPA and 1gDHA in 200mls smoothie
62552532|NCT02190370|EXPERIMENTAL|Resources activation|At first patients get informed about Tics in general. Through different exercises existing resources and skills are activated and strengthened. Feeling of self-esteem and self-respect are strengthened. Also the emotional awareness is strengthened. Relaxation methods are also introduced.
62175755|NCT04210804|PLACEBO_COMPARATOR|Placebo|200mls smoothie without EPA or DHA. Looks and tastes identical to omega-3 arm
62175756|NCT02303847|ACTIVE_COMPARATOR|Active Drug|ketamine 16 mg in flavored syrup by mouth twice daily for 1 week, then ketaming 32 mg in flavored syrup by mouth twice daily for 1 week
62175757|NCT02303847|PLACEBO_COMPARATOR|Placebo|Flavored syrup (without ketamine) by mouth twice daily for 2 weeks
62552533|NCT02219412|EXPERIMENTAL|ticagrelor mono-therapy|Take ticagrelor 90 mg Bid for 2 weeks.
62552534|NCT02219412|ACTIVE_COMPARATOR|aspirin/ticagrelor dual-therapy|Take ticagrelor 90mg Bid plus Aspirin 100mg Qd and treated for 2 weeks.
62552535|NCT02480517|EXPERIMENTAL|Investigational Therapy (Surround Sound)|Investigational Therapy using external focused ultrasound
62552536|NCT02480517|SHAM_COMPARATOR|Sham Control|Blinded Sham Control Arm
62741378|NCT06284590|EXPERIMENTAL|Systemic pembrolizumab in combination with intralesional L19IL2/L19TNF (Arm 3)|Two-weeks screening period and a 4-weeks open-label intralesional treatment period with L19IL2/L19TNF. Pembrolizumab will be administered by i.v. infusion on the first day of intralesional treatment with L19IL2/L19TNF, and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first.
62741379|NCT02485249|EXPERIMENTAL|Dexamethasone Phosphate|Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 14.0 mA-min at 3.5 mA on Day 0, Day 4, and Day 14
62741380|NCT06426563|ACTIVE_COMPARATOR|Radiofrequency ablation treatment (RFA) to thyroid nodule|Participants who are undergo thyroid nodule treatment by RFA
62741381|NCT06426563|ACTIVE_COMPARATOR|Microwave ablation treatment (MWA) to thyroid nodule|Participants who are undergo thyroid nodule treatment by MWA
61986231|NCT03616899|PLACEBO_COMPARATOR|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
62364842|NCT03254888||Control group|"• 50 (age and sex matched )control~The followings markers must be estimated :~1. Autophagy markers:~   * ( Atg7) level using (quantitative real time polymerase chain reaction).~  * (LC3A)level using immunohistochemistry .~2. ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~3. Oxidative stress Marker:(MDA)using chemical method~4. Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction).."
62364843|NCT05031104|ACTIVE_COMPARATOR|Control group|Patients in this group undergone a standard exercise program.
62552537|NCT02940496|EXPERIMENTAL|Arm A (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62552538|NCT02940496|EXPERIMENTAL|Arm B (pembrolizumab, elbasvir/grazoprevir, ribavirin)|Patients receive pembrolizumab as in arm A. Patients also receive elbasvir/grazoprevir orally PO QD and ribavirin PO QD on days 1-28. Treatment continues for 12-16 weeks in the absence of disease progression or unacceptable toxicity.
62364844|NCT05031104|EXPERIMENTAL|LLT group|Patients in this group undergone a standard exercise program as the control group in addition to the LLT.
62364845|NCT03193450|EXPERIMENTAL|Re-education group|Patients in this arm will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
62364846|NCT03193450|ACTIVE_COMPARATOR|Non re-education group|Patients in this arm only received an instruction card about the drug administration at the clinic by doctors but no re-education by telephone during treatment
62552539|NCT04635917|EXPERIMENTAL|Personalized diet - Black adults|Young Black adults in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting their dietary goals, participants will be provided with nuts, fruits, and vegetables.
62552540|NCT04635917|EXPERIMENTAL|Personalized diet - White adults|Young White adults in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting their dietary goals, participants will be provided with nuts, fruits, and vegetables.
62552541|NCT04635917|OTHER|Conventional dietary advice- Black adults|Young Black adults will receive non-personalized, conventional dietary advice based on the MyPlate guidelines.
62552542|NCT04635917|OTHER|Conventional dietary advice- White adults|Young White adults will receive non-personalized, conventional dietary advice based on the MyPlate guidelines.
62364847|NCT03383068|OTHER|control|metformin(1000-1500mg/d) treated for 6 months, reverse to normal glucose tolerance
62364848|NCT03383068|EXPERIMENTAL|acarbose|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with acarbose (100mg tid ) for 3 months
62364849|NCT03383068|EXPERIMENTAL|Exenatide|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with Exenatide 10μg/bid ) for 3 months
62364850|NCT03383068|EXPERIMENTAL|Orlistat|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with Orlistat(0.12mg/tid ) for 3 months
62364851|NCT01025297|EXPERIMENTAL|CYT107|
62364852|NCT05786534|EXPERIMENTAL|Metabolic Syndrome patients|Green seaweed Ulva Lactuca is used for preventing symptoms in Metabolic Syndrome patients
62364853|NCT01016808|EXPERIMENTAL|Q8003 12 mg/8 mg|Combination
62364854|NCT01016808|ACTIVE_COMPARATOR|Morphine sulfate 12 mg|Single component
62364855|NCT01016808|ACTIVE_COMPARATOR|Oxycodone HCl 8 mg|Single component
62364856|NCT04963634||Patients with bradykinin angioedema|
62364857|NCT04963634||Patients with histamine-mediated angioedema|
62364858|NCT01453933|ACTIVE_COMPARATOR|Raltegravir|At baseline, lopinavir-ritonavir will be switched to raltegravir (cross-over after 8 weeks).
62364859|NCT01453933|NO_INTERVENTION|Lopinavir/ritonavir|Subjects will continue lopinavir/ritonavir (cross-over after 8 weeks)
62552543|NCT01913886|EXPERIMENTAL|MSCs injection|Injection of autologous bone marrow-derived mesenchymal cells
62552544|NCT00172029|EXPERIMENTAL|ZOL446 Standard radiotherapy dosage|
62552545|NCT00172029|EXPERIMENTAL|ZOL446 Low radiotherapy dosage|
62741382|NCT00422630|ACTIVE_COMPARATOR|Average American Diet|
62741383|NCT00422630|ACTIVE_COMPARATOR|The DASH diet|
62741384|NCT00422630|ACTIVE_COMPARATOR|The Low Glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
62741385|NCT03122678|EXPERIMENTAL|Thiamine Supplementation Group|Patients will receive 200mg thiamine in 50mL of 5% dextrose once daily for 7 days or until discharge from the intensive care unit.
62741386|NCT03122678|PLACEBO_COMPARATOR|Placebo Group|Patients will receive placebo (50mL 5% dextrose) once daily for 7 days or until discharge from the intensive care unit.
62741387|NCT04332536|EXPERIMENTAL|Chronic Heart Failure|
62741388|NCT04332536|ACTIVE_COMPARATOR|Age-matched healthy controls|
62741389|NCT05963282||Sacubitril/valsartan|Prescribed sacubitril/valsartan
62741390|NCT05963282||ACEi/ARB|Prescribed ACEi or ARB
62552546|NCT03709511|NO_INTERVENTION|Conventional Treatment Group|Participants in the control group will receive the usual care protocol. On the day of admission, a registered nurse in cardiac ward will provide operating skills of deep breathing, cough exercises, and incentive spirometry, then patients will be instructed to perform the respiratory exercise as much as they can during the hospitalization without supervision. These participants will not receive additional rehabilitation interventions, unless individual indications are present.
62552547|NCT03709511|ACTIVE_COMPARATOR|Cardiac Rehabilitation Group|"The intervention group will receive the PORT protocol, contains education, IMT, ACBT, EM. Participants will be provided information about the cardiac surgery and adverse effect on postoperative recovery, and the importance of PORT program.~An inspiratory threshold-loading device is used for IMT. Participants will be instructed to breathe in as forcefully as possible before slowly breathing out five times and then rest for one minute, followed by another set of five breaths. Patients will complete three sessions of ACBT consisting of breathing control, thoracic expansion exercises and forced expiratory techniques. The mobilization protocol will be performed via a progressive approach, consisting of 6 steps. EM will be personalized to each patient."
62552548|NCT06550414|PLACEBO_COMPARATOR|bupivacaine group|group given 0.1% bupivacaine 10ml as loading dose in labor epidural.
62552549|NCT06550414|ACTIVE_COMPARATOR|dexmedetomidine group|group given 50 micrograms of dexmedetomidine along with 0.1% bupivacaine in labor analgesia dose.
62552550|NCT06200506|EXPERIMENTAL|Transabdominal radiofrequency application|"Tecartherapy equipment (Capenergy CM500) specially designed for Uro-Gynecological Physiotherapy will be used.~A transabdominal radiofrequency application will be performed, with a suprapubic active plate and a passive plate at the sacral level.~Patient position: Supine position. Sessions:9 Duration: 20 minutes Total intervention: 3 weeks Frequency: 3 times a week sessions will be held three times a week for three weeks"
62741391|NCT01954459|ACTIVE_COMPARATOR|Sensor alone|Glucose sensor site will not have Insupatch
62741392|NCT01954459|EXPERIMENTAL|Sensor with Insupatch|Glucose sensor site with Insupatch
62741393|NCT06255002||Patients|Patients giving birth in the Cochin Port Royal and Necker Enfants Malades (APHP) maternity units and cared for severe postpartum haemorrhage defined as bleeding greater than 1000 ml within 24 hours of postpartum, regardless of the route of delivery (vaginal delivery and cesarean section).
62552551|NCT06200506|EXPERIMENTAL|Intracavitary radiofrequency application|"Tecartherapy equipment (Capenergy CM500) specially designed for Uro-Gynecological Physiotherapy will be used.~An intracavitary vaginal radiofrequency application will be performed, with an active intracavitary head and with a fixed plate at the sacral level.~Patient position: Supine position. Sessions:9 Duration: 20 minutes Total intervention: 3 weeks Frequency: 3 times a week sessions will be held three times a week for three weeks"
62741394|NCT04516070|EXPERIMENTAL|Treatment (SRS)|Patients undergo SRS in the absence of disease progression or unacceptable toxicity. Patients whose disease progresses may be treated with additional courses of SRS per physician discretion.
62741395|NCT06660849||group 1 ,group 2|The patients' median age was 70 years. Patients with New York Heart Association class 1, 2, or 3 heart failure (HF) were included, regardless of the cause of HF. Both groups comprised patients with a similar number and duration of comorbidities that contributed to their CHA2DS2-VASc scores.
62741396|NCT04860557||problematic video game player|
62741397|NCT04860557||control subjects|
62741398|NCT05129280|EXPERIMENTAL|Part I: Single Participant Cohort (SPC) Dose Escalation|In Part I, RO7444973 is administered intravenously (IV) every 3 weeks (Q3W) at a fixed dose in a single participant per dose level.
62175758|NCT01878136|ACTIVE_COMPARATOR|Intraventricular tPA|"Tissue Plasminogen Activator (tPA)~Dose: 1 mg Q8 hr x 12 doses, or until blood is cleared from the ventricles and cisterns Adminstration: Intraventricular; via previously placed external ventricular drain"
62175759|NCT01878136|PLACEBO_COMPARATOR|Placebo|"Placebo~Dose 1 mL sterile saline"
62552552|NCT06200506|NO_INTERVENTION|Control Group|Not treatment received
62552553|NCT01134302|ACTIVE_COMPARATOR|Arm 1|Hybrid Management
62552554|NCT01134302|ACTIVE_COMPARATOR|Arm 2|Norwood Management
62552555|NCT03169088|EXPERIMENTAL|Coaching procedure|Volunteers will received Updated National Dietary Guidelines about food and physical activity with a one-year follow-up, plus connected coaching.
62741399|NCT05129280|EXPERIMENTAL|Part II: Multiple Participant Cohort (MPC) Dose Escalation|In Part II, RO7444973 is administered IV Q3W at a fixed dose in multiple participants per dose level. Step-up dosing may also be explored.
62741400|NCT05129280|EXPERIMENTAL|Part III: Recommended Phase 2 Dose (RP2D) Expansion|Based on emerging data from Part II, an RP2D and dosing regimen will be further investigated in Part III.
62741401|NCT04234646|ACTIVE_COMPARATOR|Group 1: One-on-One Patient Navigation|One-on-one Patient Navigation will be based on a Case Management Model where patients navigators perform appointment scheduling and reminders; facilitate communication between patients and care teams; and identify and reduce patient barriers through education, outreach, and referrals to community, local, and state resources.
62741402|NCT04234646|EXPERIMENTAL|Group 2: Patient Navigation 2.0 Checklist|The PN 2.0 Checklist intervention is centered on a learning health system checklist that enumerates a patient's Social Determinants of Health (SDoH) related barriers and tracks completion of services to address SDoH (at community oncology and community social service settings) as well as completion of USPSTF recommended cancer-related screenings, behavioral counseling, and immunizations.
62175760|NCT02456675|EXPERIMENTAL|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
62175761|NCT02456675|EXPERIMENTAL|INCB040093 and itacitinib (INCB039110) Combination Therapy|Subjects allocated to Group B will be given INCB040093 BID in combination with itacitinib SR tablets. The dose of itacitinib will be orally given once daily (QD). Doses should be taken in the morning on an empty stomach if possible.
62175762|NCT05253911||Cohort 1|150 patients receiving tucatinib/trastuzumab/capecitabine (=study treatment) in 1st or 2nd palliative therapy line.
62175763|NCT05253911||Cohort 2|150 patients receiving tucatinib/trastuzumab/capecitabine (=study treatment) in 3rd or 4th palliative therapy line.
62391457|NCT03396406|EXPERIMENTAL|CRF group|received sole thermocoagulation at 70°C for 270 s
62552556|NCT03354260|EXPERIMENTAL|intervention|Optimized personalized oral nutrition in ICU and nutritional follow up with therapeutic educational after exit of ICU
62175764|NCT01319227|EXPERIMENTAL|Hip Arthroplasty, ultra-short stem, conventional cup|Hip replacement with a hydroxy-apatite covered ultra-short uncemented femoral stem and a conventional uncemented acetabular cup with hydroxy-apatite covered porous coating and a moderately cross-linked polyethylene cup liner
62175765|NCT01319227|EXPERIMENTAL|Hip Arthroplasty, conventional stem, trabecular-titanium cup|Hip replacement with an uncemented tapered femoral stem and an uncemented acetabular cup with trabecular-Titanium backside and E-vitamin-treated polyethylene cup liner
62741403|NCT06028152|EXPERIMENTAL|Game participants|"All participants will engage in playing the end-of-life conversation game called Hello, which involves answering open-ended questions about medical decision making and end-of-life issues."
62741404|NCT00053677|PLACEBO_COMPARATOR|Naltrexone|17 weeks of double-blind Naltrexone. Subjects were randomized into one of these three conditions (if they weren't randomized to placebo): naltrexone 50mg/day, 100mg/day, 150mg/day. To minimize nausea, treatment for all subjects was initiated at 25mg/day naltrexone for two days, then the dose was increased to 50mg/day. At week 3, subjects were randomly assigned to 50mg/day continued at that dose, while subjects who were randomized to naltrexone 100mg/day or 150mg/day were raised to the higher doses.
62741405|NCT00053677|PLACEBO_COMPARATOR|Placebo|Subjects who were assigned to placebo in the 17 week double-blind phase.
62552557|NCT03354260|NO_INTERVENTION|Control|
62552558|NCT01624025|EXPERIMENTAL|HER2 positive|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.(Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks)
62741406|NCT06477952|EXPERIMENTAL|Single group|Open label Dronabinol treatment for two weeks.
62175766|NCT06230133|EXPERIMENTAL|mindfulness based stress reduction (MBSR) intervention|MBSR intervention include 8 sessions. Each session took place once a week, 2 h per session, and lasted 8 consecutive weeks. Each session covered specific exercises and topics within the context of mindfulness practice and training. Participants were required to attend at least seven out of eight lessons, and to practice MBSR at least once per day as the homework. We provided participants with a series of audio recordings of MBSR exercises to help them do better. Participants were required to hand in the records of homework assignments before each intervention session, and they shared and discussed their homework assignments with other partners at the beginning of the intervention session. Additionally, the authors encouraged practitioners to develop an ability to bring mindfulness into the varied circumstances of daily living (e.g. Mindful running, mindful eating, mindful walking, and even mindful talking), especially stressful situations.
62175767|NCT06230133|NO_INTERVENTION|Control condition|Participants in the control condition received university medical courses and physical training as usual.
62175768|NCT00563745|EXPERIMENTAL|Telemedicine|Patients were submitted to a Telemedicine program for 1 year
62175769|NCT00563745|NO_INTERVENTION|Control group|Patients were submitted to usual care (i.e: educational plan and outpatient visits every 3 months)
62175770|NCT02801409|ACTIVE_COMPARATOR|General anesthesia alone|General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.
62175771|NCT02801409|EXPERIMENTAL|Combined epidural-general anesthesia|Combined epidural-general anesthesia is performed during surgery; patient-controlled epidural analgesia is provided after surgery.
62175772|NCT01268696||control group|healthy volunteers
62175773|NCT01268696||Metabolic group|Patients with metabolic syndrome
62175774|NCT04935762|EXPERIMENTAL|CST-103/CST-107 to Placebo|Subjects will receive daily doses of CST-103 co-administered with CST-107 for 14 days, followed by a washout period of no drug for 14 days, followed by matching placebo for CST-103 and matching placebo for CST-107 for 14 days.
62175775|NCT04935762|EXPERIMENTAL|Placebo to CST-103/CST-107|Subjects will receive daily doses of matching placebo for CST-103 and matching placebo for CST-107 for 14 days, followed by a washout period of no drug for 14 days, followed by daily doses of CST-103 co-administered with CST-107 for 14 days.
62175776|NCT02934893|EXPERIMENTAL|Intervention Group|Patient in standard diabetes management in the Medication Management Clinic plus the use of Diabetes+Me plus connected glucometer
62175777|NCT02934893|ACTIVE_COMPARATOR|Standard Diabetes Management|Patient in standard diabetes management in the Medication Management Clinic
62364860|NCT03718273|ACTIVE_COMPARATOR|Digoxin|Digoxin 0,25 mg. The initial dose will be based on whether there are factors such as age over 80 years, weight under 60 kg and creatinine clearance \<60ml / min,
62552559|NCT01624025|ACTIVE_COMPARATOR|HER2 negative|"Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.~(Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks)"
62552560|NCT01027598|EXPERIMENTAL|Erlotinib + Pazopanib|"Erlotinib: 150 mg orally daily~Pazopanib: 600 mg orally daily"
62552561|NCT01027598|PLACEBO_COMPARATOR|Erlotinib + Placebo|"Erlotinib: 150 mg orally daily~Placebo: orally daily"
62552562|NCT04858932||Fried Frailty Phenotype 0|Those who are considered Robust under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
62741407|NCT04400019|NO_INTERVENTION|Tracking control|"According to the randomization process described, those nursing homes assigned to the control arm of the trial will receive the same treatment as those assigned to the intervention group, except for the medication, which will be a masked placebo.~The study is triple blind, so neither the professionals who carry out the follow-up, nor the patients, nor the person in charge of analyzing the data, know to which group each nursing home belongs."
62741408|NCT04400019|EXPERIMENTAL|Intervention|The dose to be used as chemoprophylaxis will be 800mg of Hydroxychloroquine (HCQ) on the first day and 400mg during the subsequent four days. Participating subjects will be followed up at 6, 14 and 28 days.
62552563|NCT04858932||Fried Frailty Phenotype 1-2|Those who are considered Intermediate/Pre-frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
62552564|NCT04858932||Fried Frailty Phenotype 3+|Those who are considered Frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
62552565|NCT03617783|ACTIVE_COMPARATOR|Prebiotin|
62552566|NCT03617783|PLACEBO_COMPARATOR|Placebo|
62175778|NCT02934893|NO_INTERVENTION|Primary Care|Matched cohort managed through their primary care physician (PCP) and standard of care.
62741409|NCT02119429|PLACEBO_COMPARATOR|Wheat Germ Oil|Participants will be instructed to consume 2 wheat germ oil capsules ,2g, per day for 12 weeks.
62741410|NCT02119429|EXPERIMENTAL|Pumpkin Seed Oil|Participants will be instructed to consume 2 pumpkin seed oil capsules ,2g, per day for 12 weeks
62741411|NCT06659237||Pancreatic cancer|Patients pathologically diagnosed with cancer or high-grade mucinous tumors based on surgical specimens or puncture samples
62741412|NCT06659237||Benign or low-grade malignant pancreatic tumor|Patients with pathological diagnoses such as low-grade intraductal papillary mucinous neoplasm (IPMN), mucinous cystadenoma, serous cystadenoma, chronic pancreatitis, neuroendocrine tumors, or solid pseudopapillary tumors
62741413|NCT05959577|EXPERIMENTAL|Ferguson hemorrhoidectomy|The patients who meet the inclusion and exclusion criteria in this group will undergo Ferguson hemorrhoidectomy
62741414|NCT05959577|ACTIVE_COMPARATOR|Stapled hemorrhoidopexy with anoplasty|The patients who meet the inclusion and exclusion criteria in this group will undergo Stapled hemorrhoidopexy with anoplasty
62175779|NCT05770908|EXPERIMENTAL|Multimedia animation videos plus paper-based therapeutic exercise program|
62364861|NCT03718273|EXPERIMENTAL|Ivabradine|Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.
62364862|NCT01316380|EXPERIMENTAL|tiotropium 5 mcg|once daily delivered via Respimat inhaler
62364863|NCT01316380|EXPERIMENTAL|tiotropium 2.5 mcg|once daily delivered via Respimat inhaler
62364864|NCT01316380|PLACEBO_COMPARATOR|placebo|once daily delivered via Respimat inhaler
62364865|NCT03771001|OTHER|Convenience sample participants|In this feasibility study all participants will receive the intervention.
62364866|NCT03024710|EXPERIMENTAL|Intervention cluster|"The study participants (the infant who has completed his/her 6 month of age from the date of birth along with their mother) will be enrolled from MNCH database according to criteria for the intervention group.All the mothers of the selected infants along with family member/s will receive training on standard complementary feeding practices . Refresher training will be arranged 3 months after the first training.~The CHRW will visit each infant house till the infant reaches at 12 month of age at every two month interval. During the visit CHRWs will measure weight through standard SECA digital weighing scale in nearest 100 gm (precision 20 gram) and length in nearest 0.1 cm by local made standard length board with movable foot board."
62364867|NCT03024710|NO_INTERVENTION|Controlled cluster|The participants for control clusters will be (the infant who has completed his/her 6 month of age from the date of birth along with their mother) will be enrolled from MNCH database according to criteria. The mother-infant pairs from control cluster will receive the usual care.
62364868|NCT03788824||pCLE group|pCLE is used to distinguish the inflammation activity of UC, and compared with histology
62364869|NCT04279652|EXPERIMENTAL|Supervised exercise group|The treatment program was determined as 3 sessions per week for 8 weeks and 60 minutes per session. The treatment program consists of 5 min warm-up exercises, 20 min aerobic exercise, 20 min balance-coordination exercises, 10 min strengthening exercises and 5 min cooling exercises.
62364870|NCT04279652|ACTIVE_COMPARATOR|Home exercise group|The exercise program, which is prepared for the individual, will be applied to the home exercise group with 60 minutes of 3 times a week.
62364871|NCT04279652|NO_INTERVENTION|Control group|Children will not be included in any treatment program. The assessments will be done again 8 weeks later.
62552567|NCT05443815||HaemoCer-PLUS|Patients who had receive HaemoCer-PLUS
62552568|NCT04498026|EXPERIMENTAL|Adherus Dural Sealant System|Device: Adherus Dural Sealant, In situ polymerizing sealant
62552569|NCT04498026|ACTIVE_COMPARATOR|DuraSeal Exact Dural Sealant System|Device: DuraSeal Exact (P080013b)
62552570|NCT06147427|EXPERIMENTAL|ACL reconstruction with hamstrings combined with ALL plasty|Patient treated by ACL reconstruction with hamstrings combined anterolateral plasty using the ALL reconstruction technique (Gracilis throught the femur tunnel of the ACL graft and fixed to the tibia by an anchor on its point of isometry on the tibia).
62552571|NCT06147427|EXPERIMENTAL|ACL reconstruction with hamstrings combined with modified Lemaire's LET|Patient treated by ACL reconstruction with hamstrings combined with modified Lemaire's lateral extra-articular tenodesis technique (Fascia lata strip pedicled to the Gerdy and fixed to the femur throught the tunnel of the ACL graft).
62741415|NCT00560651||1|Cross linked eyes
62741416|NCT04743336||Normal weight (<25 kg/m2)|
62741417|NCT04743336||overweight (25-29.9 kg/m2)|
62175780|NCT05770908|ACTIVE_COMPARATOR|Paper-based therapeutic exercise program|
62175781|NCT01620307|ACTIVE_COMPARATOR|with Rapamune treatment|"All patients were treated with Oseltamivir (Tamiflu, Roche) 50 mg twice a day for 10 days and oral prednisolone 20 mg/day for 14 days. At ICU admission, patients started on empiric antimicrobial therapy with moxifloxacin 500 mg per day until results of microbiological studies were available.~Each patient received best support treatment including mechanical ventilator, fluid resuscitation, gastrointestinal and thromboembolic prophylaxis, and enteral nutrition for most aspects of care. After radomization, patients were received Sirolimus (Rapamune 2mg/day, Pfizer)for a course of 14 days."
61986232|NCT05492175|EXPERIMENTAL|proximal-prioritized robotic practice plus kinetic exergaming group|60 minutes per day, 3 days per week for 6 weeks
62175782|NCT01620307|PLACEBO_COMPARATOR|Without Rapamune treatment.|"All patients were treated with Oseltamivir (Tamiflu, Roche) 50 mg twice a day for 10 days and oral prednisolone 20 mg/day for 14 days. At ICU admission, patients started on empiric antimicrobial therapy with moxifloxacin 500 mg per day until results of microbiological studies were available.~Each patient received best support treatment including mechanical ventilator, fluid resuscitation, gastrointestinal and thromboembolic prophylaxis, and enteral nutrition for most aspects of care. After radomization, patients were not to receive Sirolimus (Rapamune 2mg/day, Pfizer)for a course of 14 days."
62741418|NCT04743336||obese (≥30 kg/m2)|
62175783|NCT01613807|EXPERIMENTAL|Mix 50/50|Insulin LISPRO: 3 doses of Humalog® Mix50/50™ at mealtime.
62175784|NCT01613807|ACTIVE_COMPARATOR|Usual insulin regimen|Usual insulin regimen of insulin, Long-Acting and Insulin: 3 injections of Humalog(r) daily with meals; 3 injections of Humulin N (r) daily on rising, mid-afternoon, and at bedtime
62175785|NCT01388478|EXPERIMENTAL|R(+)pramipexole|Each study participant will be given the active study drug, R-pramipexole. There is no placebo arm.
62175786|NCT04809168||AS patients|AS patients diagnosed according to the modified New York criteria
62175787|NCT04809168||Control|Age- and sex-matched control subjects with nociceptive/mechanical pain complaint lasting more than three months
62175788|NCT01797133|ACTIVE_COMPARATOR|Fellow arm|Patients in this arm will receive the ID fellow-based antibiotic pre-authorization intervention.
62175789|NCT01797133|ACTIVE_COMPARATOR|Pharmacist arm|Patients in this arm will receive the pharmacist-based antibiotic pre-authorization intervention.
62741419|NCT05171400|SHAM_COMPARATOR|Control Group (CG)|The palatal wound area will not receive any treatment
62741420|NCT05171400|EXPERIMENTAL|Blank Film Group (BF)|The palatal wound area will receive silk fibroin film as a dressing
62741421|NCT05171400|EXPERIMENTAL|Insulin-loaded film (IF)|The palatal wound area will receive an insulin-loaded silk fibroin film as a drug delivery system
62741422|NCT05425394|EXPERIMENTAL|delayed first bath time|Delay first bath to 8 hours after birth
62741423|NCT05425394|NO_INTERVENTION|regular bath|Birth temperature 36.5°C, regular bath
62741424|NCT01319253||Cayston Only Cohort|This cohort will be on a previously established medication regiment of Cayston inhaled antibiotic alternating regimen every other month.
62741425|NCT01319253||Tobi Only Cohort|This Cohort will be on a previously established medication regiment that includes Tobi inhaled antibiotic regimen alternating every other month.
62741426|NCT01319253||Cayston and Tobi Cohort|This Cohort will be on a previously established medication regiment that includes Cayston and Tobi inhaled antibiotic alternating every other month
62741427|NCT04549571|EXPERIMENTAL|Arm I: (iCanDecide - ESE)|Patients utilize the iCanDecide - ESE website, then undergo surgery within 5 weeks of registration. Patients may also participate in an audio-recorded phone interview over 20 minutes at 9-12 months post registration.
62741428|NCT04549571|ACTIVE_COMPARATOR|Arm II: (iCanDecide - S)|Patients utilize the iCanDecide - S website, then undergo surgery within 5 weeks of registration. Patients may also participate in an audio-recorded phone interview over 20 minutes at 9-12 months post registration.
62741429|NCT04549571|EXPERIMENTAL|Clinics 1-5: (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 1-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
62741430|NCT04549571|EXPERIMENTAL|Clinics 6-8 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 10-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
62741431|NCT04549571|EXPERIMENTAL|Clinics 9-11 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 20-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
62741432|NCT04549571|EXPERIMENTAL|Clinics 12-14 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 30-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
62741433|NCT04549571|EXPERIMENTAL|Clinics 15-17 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 40-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
62741434|NCT04549571|EXPERIMENTAL|Clinics 18-20 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 50-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
62741435|NCT04549571|ACTIVE_COMPARATOR|Clinics 21-25 (usual care)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and continue to provide breast cancer surgical care per their usual care. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
62741436|NCT05416372|NO_INTERVENTION|Control communities|Communities randomized to the control arm will receive a strengthening of the capacity to manage blood pressure at their local health center. Healthcare workers at the local health center will receive standard supplies, reference materials, and training in blood pressure measurement and management on-site. In the event of any stock-outs due to higher demand for antihypertensives during the trial implementation, the trial will temporarily provide these medications to primary health facilities until the Ministry of Health supply chain is restored. Of note, control communities will receive Religious Engagement in Health Intervention after the trial is complete.
62741437|NCT05416372|EXPERIMENTAL|Religious Engagement in Health Intervention communities|Communities randomized to the intervention arm will receive a strengthening of the capacity to manage blood pressure at their local health center plus Religious Engagement in Health Intervention for blood pressure (BP), which includes three evidence-based components; 1) educational sessions for Christian and Muslim leaders on religious teachings and medical aspects of BP, 2) equipping religious leaders to provide BP teaching in their communities using knowledge learned from educational sessions and through longitudinal mentorship meetings, and 3) community BP screening organized by religious leaders in partnership with local health care workers, and referrals for clinical care as needed.
62741438|NCT02214888|EXPERIMENTAL|BIRB 796 BS, low dose|
62741439|NCT02214888|EXPERIMENTAL|BIRB 796 BS, high dose|
62741440|NCT02214888|PLACEBO_COMPARATOR|Placebo|
62741441|NCT03091517|OTHER|GlycoLeap|Since this is a single arm study, all participants will receive the GlycoLeap intervention.
62741442|NCT03851406|ACTIVE_COMPARATOR|5% Hypertonic Saline, then No Inhaled Treatment|Participants will receive 5% Hypertonic Saline following WSP exposure. After a 2-week washout period, participants will receive no treatment following WSP exposure.
62175790|NCT03028012|EXPERIMENTAL|Ketorolac|Participants may be randomized to receive Ketorolac for their TPI.
62741443|NCT03851406|ACTIVE_COMPARATOR|No Inhaled Treatment, then 5% Hypertonic Saline|Participants will receive no inhaled treatment following WSP exposure. After a 2-week washout period, participants will receive 5% Hypertonic Saline following WSP exposure.
62741444|NCT06570512|EXPERIMENTAL|transcutaneous posterior tibial nerve stimulation (TPTNS)|TPTNS group underwent ten sessions of electrical stimulation along the course of the posterior tibial nerve behind the medial malleoli using cup electrodes, with a width pulse of 250 microseconds, and a frequency of 20 Hz
62741445|NCT06570512|ACTIVE_COMPARATOR|sham transcutaneous electrical nerve stimulation (TENS).|TENS group used a sham device with the same parameters, but the electrodes were placed behind the lateral malleoli with underpowered amplitudes.
62741446|NCT01639339|PLACEBO_COMPARATOR|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
62741447|NCT01639339|EXPERIMENTAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
62741448|NCT06659120||Women with menstrually-related migraine attacks|"* Premenopausal women of 18 years of age or older.~* Women with a regular cycle 21-32 days.~* The patient has a diagnosis of chronic or episodic migraine.~* Women suffering from migraine with or without aura according to International Headache Society (IHS) Classification (ICHD-3 code A1.1.2 or A1.2.0.2) for at least one year.~* Women suffering of at least 2 days of menstrually-related migraine per period on average in the last three periods (baseline measurements and inclusion criteria)."
62741449|NCT01651819|EXPERIMENTAL|Urological physical therapy|Urologic physical therapy is going to be apply in 20 patients with HTLV-1 infection and overactive bladder symptoms like urgency, incontinence and nocturia. There will be 20 sessions with one hour duration and a interval of 3 or 4 days between the sections.
62741450|NCT00425698|ACTIVE_COMPARATOR|intravenous erythropoietin|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
62741451|NCT00425698|PLACEBO_COMPARATOR|intravenous placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
62741452|NCT05537064|NO_INTERVENTION|Control|Control arm exposed only to usual care, which consists of the passive decision support functionality Health Maintenance flag that is the current decision-support tool in the EMR.
62175791|NCT03028012|EXPERIMENTAL|Lidocaine|Participants may be randomized to receive Lidocaine for their TPI.
62552572|NCT03815825|EXPERIMENTAL|IONIS-FB-LRx|Stage 1 participants will receive IONIS-FB-LRx randomized to 1 of 3 dose levels, administered subcutaneously every 4 weeks, completing the treatment period at Week 45. Stage 2 will expand 2 of the dosing cohorts in a new randomized group of participants based on the Stage 1 interim analysis. Participants will be randomized to 1 of 2 of the expanded cohorts, administered subcutaneously every 4 weeks, completing the treatment period at Week 45.
62552573|NCT03815825|EXPERIMENTAL|Placebo|Stage 1 participants will receive a placebo matching solution, administered subcutaneously every 4 weeks, completing the treatment period at Week 45. Stage 2 participants will receive a placebo matching solution, administered subcutaneously every 4 weeks, completing the treatment period at Week 45.
62741453|NCT05537064|EXPERIMENTAL|Non-visit Based Intervention|In this arm the investigators will evaluate a non-visit-based nudge to refer patients eligible for but not prescribed high-intensity statins to centralized pharmacy services for initiation and/or titration of a statin. Practices will be randomized to usual care versus the non-visit-based nudge. The non-visit-based nudge will consist of an EPIC In-basket message sent to each provider that identifies their patients eligible for but not prescribed high- or moderate-intensity statins and notifies them that pended orders for a referral to centralized pharmacy services for statin management will be entered for these patients unless the provider opts out. At the time the in-basket message is sent out, PCPs will also have the opportunity to opt out of participating in the trial entirely.
62175792|NCT03028012|EXPERIMENTAL|Dexamethasone|Participants may be randomized to receive Dexamethasone for their TPI.
62175793|NCT00891189||1 Control|Healthy participants without asthma
62175794|NCT00891189||2 Non-nocturnal asthma|Participants with non-nocturnal asthma
62175795|NCT00891189||3 Nocturnal asthma|Participants with nocturnal asthma
62175796|NCT04751461|EXPERIMENTAL|Product usage order ABECD|Subjects will use each of the 5 products (ABECD) during an evaluation period, followed by a 4 hour Test Session
62175797|NCT04751461|EXPERIMENTAL|Product usage order BCADE|Subjects will use each of the 5 products (BCADE) during an evaluation period, followed by a 4 hour Test Session
62552574|NCT02122029|EXPERIMENTAL|Bariatric Surgery|
62552575|NCT02122029|EXPERIMENTAL|Lifestyle counselling|
62175798|NCT04751461|EXPERIMENTAL|Product usage order CDBEA|Subjects will use each of the 5 products (CDBEA) during an evaluation period, followed by a 4 hour Test Session
62175799|NCT04751461|EXPERIMENTAL|Product usage order DECAB|Subjects will use each of the 5 products (DECAB) during an evaluation period, followed by a 4 hour Test Session
62175800|NCT04751461|EXPERIMENTAL|Product usage order EADBC|Subjects will use each of the 5 products (EADBC) during an evaluation period, followed by a 4 hour Test Session
62175801|NCT04751461|EXPERIMENTAL|Product usage order DCEBA|Subjects will use each of the 5 products (DCEBA) during an evaluation period, followed by a 4 hour Test Session
62175802|NCT04751461|EXPERIMENTAL|Product usage order EDACB|Subjects will use each of the 5 products (EDACB) during an evaluation period, followed by a 4 hour Test Session
62175803|NCT04751461|EXPERIMENTAL|Product usage order AEBDC|Subjects will use each of the 5 products (AEBDC) during an evaluation period, followed by a 4 hour Test Session
62175804|NCT04751461|EXPERIMENTAL|Product usage order BACED|Subjects will use each of the 5 products (BACED) during an evaluation period, followed by a 4 hour Test Session
62175805|NCT04751461|EXPERIMENTAL|Product usage order CBDAE|Subjects will use each of the 5 products (CBDAE) during an evaluation period, followed by a 4 hour Test Session
62552576|NCT06370741|EXPERIMENTAL|Achilles tendon stretching|Participants in this group will use a stretching device designed to stretch the dominant side Achilles tendon. With the help of this tool, the fingers will be positioned in extension and the other leg will be placed in front with the dominant side leg at the back. The knee of the other leg will be bent forward while the back knee is kept straight with the heel firmly on the ground. The toes of the evaluated foot will point to the heel of the front foot. For the non-dominant side, the same stretching exercise will be performed without equipment.
62552577|NCT06370741|ACTIVE_COMPARATOR|Plantar fascia specific stretching|A special stretching protocol known as PFSS (Plantar Fascia-Specific Stretching) will be applied. The method will be performed by placing the non-dominant leg over the opposite leg in a seated position. Following this, participants will apply force distal to the metatarsophalangeal joints in the assessed foot and pull the toes upwards towards the proximal side until a visible stretch is felt in the plantar fascia. Participants in this group will use the stretching device designed for their dominant side. The method will be performed by placing the toes on the bar of the device in the extension position and moving the knee forward so that the foot is in the dorsiflexion position without lifting the heel off the ground.
62175806|NCT02054598|NO_INTERVENTION|Control group|Usual care.
62175807|NCT02054598|EXPERIMENTAL|Intervention group|Decision aid and navigation
62175808|NCT05925114|EXPERIMENTAL|Dose Level 1: S-309309|Participants will receive S-309309 (low dose) once daily for 24 weeks
62175809|NCT05925114|EXPERIMENTAL|Dose Level 2: S-309309|Participants will receive S-309309 (middle dose) once daily for 24 weeks
62175810|NCT05925114|EXPERIMENTAL|Dose Level 3: S-309309|Participants will receive S-309309 (high dose) once daily for 24 weeks
62175811|NCT05925114|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo once daily for 24 weeks
62175812|NCT06304597|EXPERIMENTAL|Durvalumab-680LT and nivolumab-800CW|"Study procedure 1: Combined intravenous tracer administration with 15mg IMFINZI and 15mg OPDIVO followed by fluorescence molecular endoscopy~Study procedure 2: Combined intravenous tracer administration with 15mg IMFINZI and 15mg OPDIVO followed by fluorescence molecular endoscopy"
62175813|NCT02945007|EXPERIMENTAL|JNJ-53718678: PART 1|Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and B (novel concept formulation 1), and under fed condition for treatment C (novel concept formulation 1).
62175814|NCT02945007|EXPERIMENTAL|JNJ-53718678: PART 2|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and D (novel concept formulation 2), and under fed condition for treatment E (novel concept formulation 2).~Part 2 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
62175815|NCT02945007|EXPERIMENTAL|JNJ-53718678: PART 3|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and F (novel concept formulation 3), and under fed condition for treatment G (novel concept formulation 3).~Part 3 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
62175816|NCT02945007|EXPERIMENTAL|JNJ-53718678: PART 4|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and H (novel concept formulation 4), and under fed condition for treatment I (novel concept formulation 4).~Part 4 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
62175817|NCT02945007|EXPERIMENTAL|JNJ-53718678: PART 5|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and J (novel concept formulation 5), and under fed condition for treatment K (novel concept formulation 5).~Part 5 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
62175818|NCT02945007|EXPERIMENTAL|JNJ-53718678: PART 6|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and L (novel concept formulation 6), and under fed condition for treatment M (novel concept formulation 6).~Part 6 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
62175819|NCT02945007|EXPERIMENTAL|JNJ-53718678: PART 7|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and N (novel concept formulation 7), and under fed condition for treatment O (novel concept formulation 7).~Part 7 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
62182418|NCT05423106|EXPERIMENTAL|Part 1: JNJ-64457744 or Placebo (Cohort J)|Asian healthy participants will receive a single dose at one single dose level of either JNJ-64457744 or matching placebo, as an oral formulation, under fasted conditions on Day 1.
62391458|NCT04370041|EXPERIMENTAL|Dokimos Plus aortic valve implantation|Dokimos Plus aortic valve implantation in all included patients.
62175820|NCT02945007|EXPERIMENTAL|JNJ-53718678: PART 8|"Participants will receive a single dose of JNJ-53718678, 500 mg oral solution under fasted or fed conditions on day 1 for treatment A and P (oral concept formulation 1, 2, 3, 4, 5, 6 or 7) and under fed conditions for treatment Q (oral concept formulation 1, 2, 3, 4, 5, 6 or 7).~Part 8 of the study is optional, might be performed, depending on the interim results of prior parts. One of the concept formulations might be re-evaluated under different feeding conditions."
62175821|NCT06043453||with AP|
62175822|NCT06043453||without AP|
62175823|NCT05233761|EXPERIMENTAL|Defined CBD|Defined CBD will be administered as two small capsules that will be taken orally with a glass of water one hour before bedtime that contain a total of 300 mg CBD and 8 mg terpenes. Participants will take the treatment on a minimum of four nights per week, over a total of four-weeks.
62175824|NCT05233761|PLACEBO_COMPARATOR|Placebo|The placebo control will be administered as two small capsules that will be taken orally with a glass of water one hour before bedtime that do not contain any CBD or terpenes. Participants will take the treatment on a minimum of four nights per week, over a total of four-weeks. The Placebo capsules will look and smell identical to the Defined CBD capsules.
62552578|NCT01934985||Group 1|Patients scheduled to have clinically indicated stress MPI with low pre-test likelihood (0-15%) of coronary disease based on criteria of Diamond and Forrester. And those who have already had a clinical indicated stress MPI in the last three years with a low likelihood of having active coronary disease with no significantly narrowed coronary arteries.
62552579|NCT01934985||Group II|Patients in Group II who will have the dynamic imaging protocol studies after SCA, patients will be selected for protocol enlistment only if the decision is made by the patient's physician, based totally on clinical and social factors, that any considered revascularization intervention would not be performed on the day of diagnostic selective coronary angiography (SCA) and will be performed electively, at least 4 to 7 days later. Viability will be assessed in these patients only in the presence of WM abnormalities, and with serial analysis of WM, as described above. Patients will be followed for death or infarction or other events more than 3 months after study, for up to 3 years following participation in the protocol.
62552580|NCT01934985||Group III|"Patients found at SCA to have lesions of borderline clinical significance, preferably in the absence of other associated lesions."
62175825|NCT00799747|EXPERIMENTAL|1|AZD4017 in ascending doses (start dose 2mg)
62552581|NCT01934985||Group IV|Patients who were diagnosed with advanced heart failure including patients who had or will have cardiac resynchonization therapy (CRT) or a heart transplant.
62552582|NCT04997863|EXPERIMENTAL|Sericin hydrogel sheet impregnated with EBN extract|Apply sericin hydrogel sheet impregnated with EBN extract on one-half of the donor site once daily for 8-12 hours per day for 6 months.
62552583|NCT04997863|PLACEBO_COMPARATOR|Placebo hydrogel sheet|Apply placebo hydrogel sheet on another half of the donor site once daily for 8-12 hours per day for 6 months.
62175826|NCT00799747|PLACEBO_COMPARATOR|2|Placebo
62175827|NCT02003378|ACTIVE_COMPARATOR|Minute Ventilation (MV)|Pacemaker sensor set to MV (Cross over study)
62175828|NCT02003378|ACTIVE_COMPARATOR|Accelerometer (XL)|Pacemaker sensor set to XL (Cross over study)
62175829|NCT03391583|EXPERIMENTAL|Standard of Care plus Education|Educational material will be provided at three time points along with the current standard of care provided in tertiary health care setting
62175830|NCT03391583|NO_INTERVENTION|Standard of Care|Current standard of care provided in tertiary health care setting
62175831|NCT03670199|EXPERIMENTAL|Experimental group|nutritional and functional management coordinated by dieticians and physiotherapists, with adapted nutritional and physical advice and support, realized with the use of Nutrimus booklet in order to facilitate coordination and delivration of cares proposed to the patients
62175832|NCT03670199|ACTIVE_COMPARATOR|Control group|usual preoperative advice for patients who undergoing surgical procedure concerning nutritional cares and physical activity
62175833|NCT05240547|EXPERIMENTAL|Spinal manipulation|Spinal manipulative therapy will be delivered to the cervical spine (segments including occiput-atlas to C7-D1) according to the chiropractors' evaluation during each visit. During each session, one or two segments will be manipulated using a high-velocity low-amplitude thrust manipulation (a joint cavitation will be expected, if not, the thrust can repeated once) applied to the segments with the highest motion restriction, as determined by the chiropractor by static and motion palpation of the cervical spine.
62175834|NCT05240547|PLACEBO_COMPARATOR|Placebo|Sham manipulation will be delivered to the cervical spine (segments including occiput-atlas to C7-D1) according to the chiropractors' evaluation during each visit. During each session, one or two segments will receive a sham manipulation applied to the segments with the highest motion restriction, as determined by the chiropractor by static and motion palpation of the cervical spine. The sham manipulation will consist in a identical contact to the real manipulation, except the thrust will be delivered towards the table, away from the target segment and with the intention to lower the cervical drop piece of the table, which will substitute the joint cavitation noise.
62364872|NCT04216706||Tailored treatment advise in suboptimal adaptation|High-risk women admitted to a non-pregnant cardiovascular and cardiometabolic risk factor assessment are invited to participate in a follow-up program at four time-points during a subsequent pregnancy (i.e. at 12, 16, 20 and 30 weeks of gestational age). This program is additive to regular pregnancy check-ups, and all women are otherwise managed by their referring physicians. The aim of this program is to evaluate adaptation of maternal hemodynamic parameters in response to pregnancy, and to adjust deviant adaptation with tailored antihypertensive medication. Participation in this program is on voluntary basis, and not restricted to severity of complications in the first pregnancy.
62364873|NCT04216706||Care as usual during pregnancy|High-risk women admitted to a non-pregnant cardiovascular and cardiometabolic risk factor assessment who do not participate in the additional follow-up program.
62364874|NCT00662389|EXPERIMENTAL|A|
62364875|NCT03528590|ACTIVE_COMPARATOR|size 3 i-gel®|size 3 i-gel supraglottic airway device in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
62364876|NCT03528590|EXPERIMENTAL|size 4 i-gel®|size 4 i-gel supraglottic airway device in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
62364877|NCT03035136||Patients with colorectal lesions|Patients with a full colonoscopy that showed either a cancer or a polyp.
62364878|NCT03035136||Patients without colorectal lesions|Patients with a full colonoscopy that showed no polyps.
62552584|NCT02289443||Simplified|Complete denture fabricated by simple way than the textbook traditional method.
62175835|NCT06112522|EXPERIMENTAL|Experimental : 5 Day treatment course 1 with Tirbanibulin Ointment 1%|Subjects will be given one study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days. Subjects with unresolved lesion at d28 or d56 or d72 or d84 will be given an additional study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days.
62175836|NCT04171921|ACTIVE_COMPARATOR|Robotic ventral hernia repair|
62175837|NCT04171921|ACTIVE_COMPARATOR|Open ventral hernia repair|
62175838|NCT01370018|EXPERIMENTAL|alpha-1 proteinase inhibitor in HIV|HIV-1 infected individuals treated with Alpha-1 proteinase inhibitor
62175839|NCT03163836||double valve replacement group|Patients received aortic+mitral valve replacement at Guangzhou General Hospital of Guangzhou Military Command with persistent or long-standing atrial fibrillation(AF) but did not received concomitant AF ablation. Persistent AF was defined as AF lasting more than 7 days and long-standing persistent AF as continuous AF for more than 12 months. Exclusion criteria for consideration for concomitant AF ablation includes \>70 years old, left atrium (LA) diameter \>7 cm, or preoperative left ventricle (LV) ejection fraction \< 40% and patients falls in these criteria were excluded from this group.
62175840|NCT03163836||surgical ablation group|Patients received aortic+mitral valve replacement at Guangzhou General Hospital of Guangzhou Military Command with persistent or long-standing atrial fibrillation(AF) and received concomitant surgical ablation. Persistent AF was defined as AF lasting more than 7 days and long-standing persistent AF as continuous AF for more than 12 months.
62175841|NCT01349036|EXPERIMENTAL|PLX3397-Cohort 1|10 patients with recurrent glioblastoma who require reoperation will be treated with PLX3397 for 7 days prior to surgery and their tumor tissue will be evaluated for pharmacokinetic levels and pharmacodynamic effects.
62175842|NCT01349036|EXPERIMENTAL|PLX3397-Cohort 2|30 patients will be orally dosed with PLX3397 continuously on 28 day cycles.
62175843|NCT00387907|EXPERIMENTAL|Larotaxel + Trastuzumab|
62175844|NCT06117202|EXPERIMENTAL|music therapy|The patients involved in the study will be randomly divided into two groups. One group will be provided with a set of headphones that completely cover the ears and will be played their selected music from a predetermined album for 20 minutes before the procedure. The music will continue to be played through the headphones during the procedure.
62175845|NCT06117202|NO_INTERVENTION|control group|The control group will be taken to the operating room with standard anesthesia care protocol.
62175846|NCT02081118|EXPERIMENTAL|HM11260C (8 mg)|Monthly administration of 8 mg of HMC11260C by subcutaneous injection for 16 weeks
62175847|NCT02081118|EXPERIMENTAL|HM11260C (12 mg)|Monthly administration of 12 mg of HMC11260C by subcutaneous injection for 16 weeks
62175848|NCT02081118|EXPERIMENTAL|HM11260C (16 mg)|Monthly administration of 16 mg of HMC11260C by subcutaneous injection for 16 weeks
62175849|NCT02081118|PLACEBO_COMPARATOR|Placebo|Monthly administration of placebo by subcutaneous injection for 16 weeks
62175850|NCT06045325||Myopic -1.00D|Myopic patients with a diopter of at least -1.00
62552585|NCT02289443||Traditional|Complete denture fabricated by textbook discribed traditional method.
62552586|NCT05593094|EXPERIMENTAL|ZN-A-1041 50mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 50mg Bid, for 21days as one cycle"
62552587|NCT05593094|EXPERIMENTAL|ZN-A-1041 100mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 100mg Bid, for 21days as one cycle"
62552588|NCT05593094|EXPERIMENTAL|ZN-A-1041 200mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 200mg Bid, for 21days as one cycle"
62175851|NCT02251197|EXPERIMENTAL|BIII 890 CL|escalating doses
62175852|NCT02251197|PLACEBO_COMPARATOR|Placebo|
62175853|NCT05324007|EXPERIMENTAL|White-White|"Infants will first view 4 familiarization trials, in which the two adults each take turns waving and saying a short sentence. Each trial will last 10.5s. Which adult speaks first and which side she appears on will be counterbalanced. These familiarization trials will ensure infants encode each person separately. Then infants will watch 6 test trials (3 affiliation and 3 disengagement). The test trials will alternate, and the order will be counterbalanced across infants. In affiliation trials, the two adults will say hello and wave, whereas in the disengagement trials, the two adults will say hmph, and turn away from each other. Both affiliation and disengagement will have the same length (3s), with actors maintaining the same distance from each other throughout the video. The procedure will be identical for all arms except in White-White arm, the two adults infants see will be two White adults."
62175854|NCT05324007|EXPERIMENTAL|Black-Black|"The procedure is identical to the White-White arm except the two adults infants see will be two Black adults."
62552589|NCT05593094|EXPERIMENTAL|ZN-A-1041 400mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 400mg Bid, for 21days as one cycle"
62552590|NCT05593094|EXPERIMENTAL|ZN-A-1041 600mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 600mg Bid, for 21days as one cycle"
62175855|NCT05324007|EXPERIMENTAL|Black-White|"The procedure is identical to the White-White arm except the two adults infants see will be one White and one Black adult."
62552591|NCT05593094|EXPERIMENTAL|ZN-A-1041 800mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 800mg Bid, for 21days as one cycle"
61986233|NCT05492175|ACTIVE_COMPARATOR|distal-prioritized robotic practice plus kinetic exergaming group|60 minutes per day, 3 days per week for 6 weeks
62552592|NCT05593094|EXPERIMENTAL|ZN-A-1041 1000mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 1000mg Bid, for 21days as one cycle"
62552593|NCT05593094|EXPERIMENTAL|1b: ZN-A-1041 + T-DM1 3.6 mg/kg iv.|"Phase 1b Arm1:~1. If the MTD of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2)~2. If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study."
62552594|NCT05593094|EXPERIMENTAL|1b: ZN-A-1041 + T-Dxd 5.4 mg/kg iv.|"Phase 1b Arm2:~1. If the MTD of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2)~2. If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study."
62552595|NCT05593094|EXPERIMENTAL|1b: ZN-A-1041 + PHESGO / Herceptin plus Perjeta|"Phase 1b Arm3:~1. If the MTD of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2)~2. If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study."
62552596|NCT05593094|EXPERIMENTAL|1c: ZN-A-1041 + T-DM1 3.6 mg/kg iv.|"Phase 1c Arm1:~The dose levels of ZN-A-1041 in the Phase 1c study will be the recommended doses determined in the Phase 1b study."
62552597|NCT05593094|EXPERIMENTAL|1c: ZN-A-1041 + T-Dxd 5.4 mg/kg iv.|"Phase 1c Arm2:~The dose levels of ZN-A-1041 in the Phase 1c study will be the recommended doses determined in the Phase 1b study."
62552598|NCT05593094|EXPERIMENTAL|1c: ZN-A-1041 + Herceptin plus Perjeta/PHESGO|"Phase 1c Arm3:~The dose levels of ZN-A-1041 in the Phase 1c study will be the recommended doses determined in the Phase 1b study."
62552599|NCT00242424|PLACEBO_COMPARATOR|1|0.25 ml normal saline placebo given as injection to infants at 2 and 3 months of age
62552600|NCT00242424|EXPERIMENTAL|2|2005-6 Fluzone, pediatric formulation of trivalent inactivated influenza vaccine (sanofi pasteur) administered to infants at 2 and 3 months of age
62175856|NCT00631397||Premature Infants|Premature Infants weighing less than 1500 gms
62175857|NCT06184555||colorectal cancer|colectomy
62175858|NCT01520844|OTHER|Cohort study|Blood sampling
62175859|NCT05943210|OTHER|Single cohort|Eligible patients will receive short course radiation therapy (scRT) of 25Gy over 5 days (fractions) for their localized rectal cancer. Research bloods stool and tissue will be collected at three time points: Baseline, end of radiation therapy and at surgery.
62175860|NCT02025361|EXPERIMENTAL|intrarectal lidocaine gel|transrectal ultrasound guided prostate biopsy was performed with intrarectal lidocaine gel anesthesia: 10 minutes before the procedure % 2 lidocaine hydrochloride gel instilated into the rectum for local anesthesia
62364879|NCT01188460|PLACEBO_COMPARATOR|Control Group|Receive one weekly telephone follow-up call per week to monitor sleep progress, complete 7 weeks of sleep diaries only (sleep diary measures Total Sleep Time in hours, Time to Fall Asleep in minutes, Number of Nocturnal Awakenings, Sleep Efficiency as a percentage, and Sleep Quality as units on a scale), complete questionnaires at three study timepoints
62552601|NCT05629819|EXPERIMENTAL|PNS group|"In addition to conventional respiratory therapy and pulmonary rehabilitation, neuromuscular electrical stimulator was used for PNS~* Device Settings Strength: Maximum current tolerated by the patient (0-100mA, commonly used below 13mA) ； Stimulation time: 1.0s; Frequency: 40Hz;~* Location: The stimulation electrodes were attached to the left and right sides of the neck under the outer margin of the sternocleidomastoid muscle 1/3; The reference electrodes were attached to the surface of both pectoralis major muscles.~* Treatment frequency: 30 at a time, Bid, until withdrawal/death/for 4 weeks."
62552602|NCT05629819|NO_INTERVENTION|conventional group|"* conventional respiratory therapy and pulmonary rehabilitation, including airway management, early activity, and respiratory muscle training.~* No intervention"
62552603|NCT01905995||Patients with advanced Parkinson's disease|no intervention - observational study
62552604|NCT00587860|PLACEBO_COMPARATOR|Placebo|
62552605|NCT00587860|ACTIVE_COMPARATOR|St. John's Wort|
62364880|NCT01188460|EXPERIMENTAL|Experimental Group|Receive one weekly telephone call to monitor sleep progress, complete 7 weeks of sleep diaries (sleep diary measures Total Sleep Time in hours, Time to Fall Asleep in minutes, Number of Nocturnal Awakenings, Sleep Efficiency as a percentage, and Sleep Quality as units on a scale), implement one chapter per week of self-help manual for insomnia over 7 weeks at home, complete questionnaires at three study timepoints
62364881|NCT05410977||Observational (biospecimen collection, record review)|Patients undergo collection of blood and stool samples no more than 90 days prior to or between 7-90 days after standard of care colonoscopy or flexible sigmoidoscopy. Patients' medical records are also reviewed.
62364882|NCT01216904|PLACEBO_COMPARATOR|Placebo patch|
62364883|NCT01216904|ACTIVE_COMPARATOR|Nicotine patch|
62552606|NCT02477410|EXPERIMENTAL|Hydrolysed porcine protein from blood|Dietary intervention with hydrolysed porcine protein from blood
61986234|NCT05492175|ACTIVE_COMPARATOR|robotic practice plus conventional therapy group|60 minutes per day, 3 days per week for 6 weeks
62175861|NCT02025361|EXPERIMENTAL|periprostatic nerve blockade|transrectal ultrasound guided prostate biopsy was performed with intrarectal lidocaine gel anesthesia: 10 minutes before the procedure transrectal ultrasound guided 10 ml prilocaine and serum physiologic blend (5ml %2 prilocaine and 5 ml serum physiologic) injected separetly 5ml right and 5ml left junction between the prostate base and seminal vesicle.
62182419|NCT05423106|EXPERIMENTAL|Part 1: JNJ-64457744 (Cohort K)|Optional Cohort K: Non-Asian healthy participants will receive an oral formulation of JNJ-64457744 in the first intervention period and will cross over to receive the other formulation during the second intervention period, under fasted conditions on Day 1.
62364884|NCT02939313|EXPERIMENTAL|medial prefrontal|Individuals will receive medial prefrontal cortex stimulation
62364885|NCT02939313|EXPERIMENTAL|dorsolateral prefrontal|Individuals will receive dorsolateral prefrontal cortex stimulation
62364886|NCT02939313|SHAM_COMPARATOR|sham|Individuals will receive sham stimulation to the medial prefrontal and dorsolateral prefrontal cortex
62364887|NCT04748913|NO_INTERVENTION|No intervention|
62364888|NCT04748913|OTHER|Remineralization|
62364889|NCT02556411|ACTIVE_COMPARATOR|LNG-IUS|LNG-IUS 13,5 mg di Levonorgestrel
62552607|NCT02477410|EXPERIMENTAL|Hydrolysed porcine protein from muscle|Dietary intervention with hydrolysed porcine protein from muscle
62552608|NCT02477410|EXPERIMENTAL|Hydrolysed whey protein|Dietary intervention with hydrolysed whey protein
62552609|NCT05522127|ACTIVE_COMPARATOR|Group R (Restrictive)|Group R (Restrictive, 2ml/kg 0.9% NaCl during colonoscopy)
62552610|NCT05522127|ACTIVE_COMPARATOR|Group L (Liberal )|Group L (Liberal 15ml/kg 0.9% NaCl during colonoscopy)
62552611|NCT03519087|EXPERIMENTAL|Interdisciplinary Evaluation|Participants will receive an Interdisciplinary Evaluation for Nonarthritic Hip Disease from a hip arthroscopist, followed by an examination from a physical therapist, and then will participate in a shared decision-making process with both providers to determine a plan of care.
62552612|NCT03519087|NO_INTERVENTION|Standard Evaluation|Participants will receive a standard-of-care evaluation from a hip arthroscopist who will then determine the plan of care with the participant.
62552613|NCT03519087|EXPERIMENTAL|Posture and Movement Training|Participants will receive six training sessions with a physical therapist over a 3-week period.
62552614|NCT03519087|NO_INTERVENTION|3-week Wait Period|Participants will undergo a 3-week wait period. They will be instructed to not receive any treatment (e.g. chiropractic services, physical therapy, medication, surgery, injections) for their hip symptoms during this time.
62175862|NCT06477250|EXPERIMENTAL|Empathy- and compassion-based socio-emotional mental training|"Core practice: In the EmCo Dyad, participants perform a 13-minute partner-based exercise that involves contemplating over one difficult situation and one situation that incurred gratitude in the past 24 hours. Both partners take turns speaking about the two situations while the other partner listens in a non-judgmental manner. While the participants elaborate on the situations, they are asked to focus on the bodily experience of the emotions generated during the situation.~The focus is on empathic listening in the first 5 weeks, and on compassionate listening in the remaining 5 weeks.~The coaching sessions help deepen the Dyad practice and educate teachers about body language, coping better with difficult emotions/stress, the benefits of empathy versus compassion and the act of listening from a mindset of empathy versus compassion."
62175863|NCT06477250|NO_INTERVENTION|Control Group (Waitlist control)|The control group will not undergo an intervention. This group will complete the self-report questionnaires but not the EMA and the pre-post dyad practice ratings. In a second step, the waitlist control group will also undergo a 5-week period of empathy-based socio-emotional intervention, followed by another 5-week period of compassion-based socio-emotional intervention, using the same protocol and testing as above (sequential intervention approach).
62552615|NCT03519087|OTHER|Observational Arm|Participants who refuse randomization to receive posture and movement training may continue participation in an observational group. These participants complete the same baseline and follow-up testing but proceed with their treatment-of-choice during the 3-week intervention period.
62175864|NCT02671578|EXPERIMENTAL|Nitrous oxide|Nitrous oxide sedation
62175865|NCT02650934||Adverse remodelling|EF below 40% following MI and remain below 40% after reperfusion
62175866|NCT02650934||not adverse remodelling|EF below 40% following MI and remodelling after reperfusion or EF above 40 % following MI
62552616|NCT04566055||Prospective observational cohort|
62175867|NCT02856061|OTHER|PRT|Children with ASD who are currently receiving PRT treatment.
62175868|NCT02856061|NO_INTERVENTION|Wait List / Non-Treatment Control|Children with ASD who are not currently receiving PRT treatment.
62175869|NCT02856061|NO_INTERVENTION|Typically Developing|Children without ASD or developmental delay.
62175870|NCT05362513|ACTIVE_COMPARATOR|Group A(permethrin topical)|Group A received Permethrin 5% twice with a one-week interval, whereas Group B received a single dose of oral ivermectin 200 mcg per kg.
62175871|NCT05362513|ACTIVE_COMPARATOR|Group B oral ivermectin|Group A received Permethrin 5% twice with a one-week interval, whereas Group B received a single dose of oral ivermectin 200 mcg per kg
62175872|NCT01068223|EXPERIMENTAL|001|A:JNJ-39758979/Placebo #1 Single oral dose of JNJ-39758979 600 mg and Placebo
62175873|NCT01068223|PLACEBO_COMPARATOR|002|B: JNJ-39758979 Matching Placebo /Placebo #2 A single dose of 2 different Placebos JNJ-39758979 Matching Placebo and Placebo #2
62175874|NCT01068223|ACTIVE_COMPARATOR|003|C:Cetirizine/JNJ-39758979 Matching Placebo Single oral dose of 10mg cetirizine and JNJ-39758979 Matching Placebo
62175875|NCT00819013|EXPERIMENTAL|Study Group 1|ACAM-FLU-A low dose + Adjuvant 1
62175876|NCT00819013|EXPERIMENTAL|Study Group 2|ACAM-FLU-A low dose + Adjuvant 2
62175877|NCT00819013|EXPERIMENTAL|Study Group 3|ACAM-FLU-A low dose
62175878|NCT00819013|PLACEBO_COMPARATOR|Study Group 4|Saline placebo
62552617|NCT05579457||elderly people living in rural areas|
62552618|NCT05579457||elderly people living in urban areas|
62552619|NCT03906110||C-Cares|Participants will be given Community Colorectal Cancer Awareness, Research, Education and Screening (C-CARES) Materials and FIT kits.
62552620|NCT03906110||C-Cares Plus|Participants will be given Community Colorectal Cancer Awareness, Research, Education and Screening (C-CARES) materials, FIT kits, and personalized one-on-one education and coaching.
62552621|NCT04273191|EXPERIMENTAL|Brexanolone|Participants will receive a single dose of commercial brexanolone as part of standard of care.
62552622|NCT05726786|EXPERIMENTAL|Immunonutrition|Seven days of preoperative oral supplementation with an immune-enhanced oral nutrition
62552623|NCT05726786|NO_INTERVENTION|No immunonutrition (control)|Standard of care
62552624|NCT00003610|EXPERIMENTAL|capsaicin + radiation therapy|Patients receive one lozenge orally of capsaicin four times daily. Treatment begins within the first 3 days of radiation therapy and continues during and for two weeks after radiation therapy is completed.
62175879|NCT02660112|EXPERIMENTAL|(+)-Epicatechin|Total daily dose 75mg (+)-Epicatechin; 25mg cap three times per day by mouth for 24 weeks
62175880|NCT01176435|ACTIVE_COMPARATOR|0.76 mg/kg L-DOPA|Solution taken orally three times a day.
62175881|NCT01176435|ACTIVE_COMPARATOR|0.51 mg/kg L-DOPA|Solution taken orally three times a day.
62175882|NCT01176435|PLACEBO_COMPARATOR|Placebo|Solution taken orally three times a day.
62175883|NCT05217290|EXPERIMENTAL|experiment group|
62175884|NCT05217290|NO_INTERVENTION|control group|
62175885|NCT02122549|EXPERIMENTAL|HWD1000|Subjects using HWD1000
62175886|NCT01746108|EXPERIMENTAL|At-risk-Unprimed Group|Subjects who have not been previously vaccinated with any pneumococcal vaccine and are at an increased risk of pneumococcal infection.
62175887|NCT01746108|EXPERIMENTAL|At-risk-Primed Group|"Subjects who have been previously vaccinated~* with at least one dose of a pneumococcal conjugate vaccine i.e. either Synflorix (10Pn-PD-DiT), Prevenar or Prevenar13.~* with plain polysaccharide pneumococcal vaccine more than 2 years and less than 5 years before enrollment.~and are at an increased risk of pneumococcal infection."
62175888|NCT01746108|ACTIVE_COMPARATOR|Healthy-Unprimed Group|Subjects who have not been previously vaccinated with any pneumococcal vaccine and are healthy.
62175889|NCT01746108|ACTIVE_COMPARATOR|Healthy-Primed Group|Subjects who have been previously vaccinated with at least one dose of a pneumococcal vaccine and are healthy.
62552625|NCT00003610|PLACEBO_COMPARATOR|placebo + radiation therapy|Patients receive one lozenge orally of placebo four times daily. Treatment begins within the first 3 days of radiation therapy and continues during and for two weeks after radiation therapy is completed.
62552626|NCT06489210|ACTIVE_COMPARATOR|popliteal block posterior approach group|through posterior approach ultrasound guided sciatic nerve block at popliteal fossa 20ml of the selected local anesthetic mixture (10ml of 0.5% bupivacaine mixed with 10ml of 2% lidocaine, each with 1:200,000 epinephrine) was injected incrementally
62552627|NCT06489210|ACTIVE_COMPARATOR|popliteal block lateral approach group|ultrasound guided sciatic nerve block at popliteal fossa through lateral approach 20ml of the selected local anesthetic mixture (10ml of 0.5% bupivacaine mixed with 10ml of 2% lidocaine, each with 1:200,000 epinephrine) was injected incrementally
62175890|NCT03853642||Single-arm trial|Patient receiving blood sampling, spirometry and Feno
62175891|NCT03819842|NO_INTERVENTION|Aphakic Measure only|Eye measured in aphakic state only
62175892|NCT03819842|ACTIVE_COMPARATOR|Pseudophakic measure|Eye measured in aphakic state then again in pseudophakic state with toric IOL using the ORA System. Pseudophakic measurement obtained will provide data about placement of toric iol and the surgeon will use that data to rotate the iol if necessary.
62175893|NCT01319578|ACTIVE_COMPARATOR|Chewing Arm 1|
62175894|NCT01319578|PLACEBO_COMPARATOR|Chewing Arm 2|
62175895|NCT01319578|ACTIVE_COMPARATOR|Chewing Arm 3|
62175896|NCT01319578|ACTIVE_COMPARATOR|Chewing Arm 4|
62552628|NCT06489210|ACTIVE_COMPARATOR|poplitea block medial approach group|ultrasound guided sciatic nerve block at popliteal fossa through medial approach 20ml of the selected local anesthetic mixture (10ml of 0.5% bupivacaine mixed with 10ml of 2% lidocaine, each with 1:200,000 epinephrine) was injected incrementally
62552629|NCT03817645|EXPERIMENTAL|Panaceo MED|Zeolite, Medicinal product, class IIa for oral intake, daily intake of 2 sachets (3 g), for 3 months.
62552630|NCT03817645|PLACEBO_COMPARATOR|Control|Micro crystalline cellulose daily intake of 2 sachets (3 g), for 3 months.
62175897|NCT02262065||Patients|Patients with suspected arthroplasty intolerance
62175898|NCT02262065||Controls|Patients with well tolerated arthroplasties
62175899|NCT01820637|EXPERIMENTAL|Test device arm (DES SFA)|Patients in this arm will receive the study device: the Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)
62175900|NCT00691847||1|Bilateral post refractive procedure
62175901|NCT02945371|EXPERIMENTAL|IC Training|"The experimental arm (ARM1) is a person-centered inhibitory control training intervention, or PeCIC.~Between the baseline and endpoint sessions, participants come to our lab 12 times to participate in the training sessions. Each participant is randomly assigned to either the PeCIC training or an active control training. The training sessions will take place approx. every other day for 24 days.~Beginning 2-3 days after the baseline session, the experimental group (will come to our behavioral testing lab to receive the PeCIC training. At 11 sessions spaced one every other day, participants will complete one 8-min run of a modified stop-signal task. The cue on each trial (preceding the go signal arrow) will be an image of a personalized risk-cue (PRC) or a neural image."
62175902|NCT02945371|ACTIVE_COMPARATOR|Control Training|Participants in the active control group (ARM2) of the PeCIC intervention will come to the behavioral testing laboratory to complete an 8-min control task every other day for 12 sessions. This control task is identical to the PeCIC except the auditory stop cues are omitted. All other procedures, settings, and schedules are identical to those in the experimental group. The only difference between the groups is that the active control does not practice IC.
62552631|NCT05970224|EXPERIMENTAL|Ir-CPI|Ir-CPI will be administered on top of standard of care
62552632|NCT05970224|NO_INTERVENTION|Standard care|Only standard of care
62175903|NCT06413017|EXPERIMENTAL|Nimtuzumab combined ICIs|Patients will be treated with nimotuzumab combined immune checkpoint inhibitors treatment
62175904|NCT04714788|EXPERIMENTAL|Intervention group RECAP_MyLife mobile app|Participants in the intervention group will be instructed to use the mobile app daily for four weeks.
62175905|NCT04714788|ACTIVE_COMPARATOR|Control group|Comparator will be the usual data collection method applied by the cohorts.
62175906|NCT02199249|ACTIVE_COMPARATOR|Open Reduction Tightrope fixation (OT)|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
62175907|NCT02199249|ACTIVE_COMPARATOR|Open Reduction screw fixation (OS)|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
62175908|NCT05230095||Parkinson's disease patients|30 parkinsonian patients scheduled for deep brain stimulation implantation surgery will be recruited
62175909|NCT05230095||Controls|15 healthy volunteers matched in age and sex will be recruited
62175910|NCT03630523|OTHER|Vaccination|Arm contains all subjects; vaccination with Influvac Tetra will be administered at start of study, response will be measured in 7 and 21 days.
62175911|NCT01579110|EXPERIMENTAL|prednisolone + levamisole|
62175912|NCT01579110|ACTIVE_COMPARATOR|Prednisone|
62175913|NCT02852811|OTHER|group education|To measure improvement of menopause symptoms and depression all participating women answered a baseline questionnaire and a follow-up questionnaire four month later. The questionnaires who were used: The Menopause Rating Scale (MRS) and The Montgomery-Asberg Depression Rating Scale (MADRS). MRS were used for reflecting menopause symptom and MADRS for depression symptoms.
62175914|NCT02852811|NO_INTERVENTION|control group|The control group did not obtain any group education or any other intervention. Women answered at baseline questionnaire and four month later. The questionnaires who were used: The Menopause Rating Scale (MRS) and The Montgomery-Asberg Depression Rating Scale (MADRS). MRS were used for reflecting menopause symptom and MADRS for depression symptoms.
62175915|NCT02105727|EXPERIMENTAL|Salt reduction|Community-based salt reduction
62175916|NCT03413540|EXPERIMENTAL|Group 1|10-cm step, 10 reps
62175917|NCT03413540|EXPERIMENTAL|Group 2|10-cm step, 50 reps
62175918|NCT03413540|EXPERIMENTAL|Group 3|10-cm step, 100 reps
62175919|NCT03413540|EXPERIMENTAL|Group 4|20-cm step, 10 reps
62175920|NCT03413540|EXPERIMENTAL|Group 5|20-cm step, 50 reps
62175921|NCT03413540|EXPERIMENTAL|Group 6|20-cm step, 100 reps
62175922|NCT03413540|EXPERIMENTAL|Group 7|30-cm step, 10 reps
62175923|NCT03413540|EXPERIMENTAL|Group 8|30-cm step, 50 reps
62175924|NCT03413540|EXPERIMENTAL|Group 9|30-cm step, 100 reps
62175925|NCT03413540|NO_INTERVENTION|Group 10|Control
62175926|NCT00649142|ACTIVE_COMPARATOR|A|Open sutured mesh repair
62175927|NCT00649142|ACTIVE_COMPARATOR|B|Laparoscopic mesh glue fixation
62175928|NCT01680302|EXPERIMENTAL|High intensity exercise|High intensity exercise(Borg 16) in intervals.
62175929|NCT01680302|EXPERIMENTAL|Moderate intensity exercise|Moderate intensity exercise 3 times a week.
62175930|NCT01680302|EXPERIMENTAL|Control group|Exercise on their own. Follow current guidelines.
62175931|NCT02315079||Eye inflammation|This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
62175932|NCT02315079||Without eye inflammation|This group will have a regular eye exam with the collection of tears.
62175933|NCT04301700|EXPERIMENTAL|relaxation|The progressive muscle relaxation intervention, designed by Jacobson (1987), will be consist of sessions involving straining and relaxing all muscle groups from head to foot with deep breathing and last for 20 min. The patients will be asked to tense a very muscle group for 5 s and relax after counting up to 10 s while breathing out. In this way, facial, head, neck, shoulders, arms, chest, abdomen, legs, hips, feet and fingers muscles are stretched and relaxed on purpose for relaxing in patients with COPD.
62175934|NCT04301700|EXPERIMENTAL|mindfulness meditation|The research team closely will be following the mindfulness meditation intervention, developed by Kabat-Zinn, Lipworth, and Burney (1985), which is a part of the mindfulness-based stress reduction program. Mindfulness meditation is including interventions such as yoga, body scan, walking meditation, and sitting meditations. In the present study, the researchers will prefer sitting meditation. In this context, the second co-author will want patients to sit up in the chair in an upright and comfortable position. The patients will focus on deep breathing and felled the breath flowing throughout their body during the interventions that will last for 20 min in each session.
62175935|NCT04301700|NO_INTERVENTION|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
62175936|NCT04145323|EXPERIMENTAL|ICG microangiography for necrotic tissue determination|During flap procedure, the study area of the patient will be imaged with a white light digital camera prior to a 5 mg dose of ICG as per FDA approved protocol for use of SPY device in microangiography. Following ICG injection, the study area will undergo fluorescence imaging using the SPY system to obtain microangiography perfusion data (baseline imaging - Standard of Care). During the standard postoperative evaluation (approximately 4 hours after baseline) and 24 hours after baseline, the study area will undergo repeat digital photography and fluorescence imaging using SPY for necrosis avid detection of ICG (Research only session). This evaluation with digital photography and fluorescence imaging will continue every 24 hours for the first 3 days after surgery or one day prior to discharge(Research only session).
62175937|NCT01625949|ACTIVE_COMPARATOR|Control Arm (Standard Therapy)|Control Arm Receiving The Standard Therapy including successful coronary intervention and stenting
62175938|NCT01625949|EXPERIMENTAL|Intracoronary stem cells|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting
62175939|NCT00221702|EXPERIMENTAL|A|Peg Intron 100 mcg SC/week for 36 months
62175940|NCT00221702|ACTIVE_COMPARATOR|B|Intron A 3 X 3 MIU, weekly, sc, for 18 months
62175941|NCT02928809|NO_INTERVENTION|TMD control|Patients with diagnosis of temporomandibular disorder and that are not submitted to pre-fatigue low-level laser therapy
62175942|NCT02928809|EXPERIMENTAL|TMD LLL|Patients with diagnosis of temporomandibular disorder and that are submitted to pre-fatigue low-level laser therapy
62175943|NCT02928809|NO_INTERVENTION|Without TMD control|Patients without diagnosis of temporomandibular disorder and that are not submitted to pre-fatigue low-level laser therapy
62175944|NCT02928809|EXPERIMENTAL|Without TMD LLL|Patients without diagnosis of temporomandibular disorder and that are submitted to pre-fatigue low-level laser therapy
62175945|NCT02928809|PLACEBO_COMPARATOR|TMD placebo|Patients with diagnosis of temporomandibular disorder and that are submitted to placebo low-level laser treatment
62175946|NCT02928809|PLACEBO_COMPARATOR|Without TMD placebo|Patients without diagnosis of temporomandibular disorder and that are submitted to placebo low-level laser treatment
62175947|NCT03932422||Controlled Hypertensive Patients (CHP)|Hypertensive patients that have blood pressure less than 140 x 90 mmHg. This parameter must be evaluated by ambulatory blood pressure monitoring
62175948|NCT03932422||Resistant Hypertensive Patients (RHP)|Hypertensive patients that have blood pressure more than 140 x 90 mmHg and they use three antihypertensive medicines; or hypertensive patients that have blood pressure less than 140 x 90 mmHg, but they use four or more antihypertensive medicines. This parameter must be evaluated by ambulatory blood pressure monitoring.
62175949|NCT02189577|EXPERIMENTAL|CHF 5259|CHF 5259
62175950|NCT02189577|PLACEBO_COMPARATOR|Placebo|Placebo
62175951|NCT00496834|EXPERIMENTAL|1|Losartan or Losartan/HCTZ
62175952|NCT00496834|ACTIVE_COMPARATOR|2|Carvedilol or Carvedilol/HCTZ
62175953|NCT04772313|EXPERIMENTAL|Pegloticase plus Methotrexate (MTX)|Pegloticase (8 mg) intravenous (IV) every two weeks. Methotrexate (15 or 25 mg weekly) SC.
62175954|NCT04529811|EXPERIMENTAL|Formulation 1 - Low Dose|Rifaximin Formulation 1 Capsules
62175955|NCT04529811|EXPERIMENTAL|Formulation 1 Capsules - Mid Dose|Rifaximin Formulation 1 Capsules
62175956|NCT04529811|EXPERIMENTAL|Formulation 1 Capsules - High Dose|Rifaximin Formulation 1 Capsules
62175957|NCT04529811|EXPERIMENTAL|Formulation 1 Capsules - Max Dose|Rifaximin Formulation 1 Capsules
62175958|NCT04529811|PLACEBO_COMPARATOR|Formulation 1 Capsules - Placebo|Placebo Formulation 1 Capsules
62175959|NCT04529811|EXPERIMENTAL|Formulation 2 - Low Dose|Rifaximin Formulation 2 Capsules
62175960|NCT04529811|EXPERIMENTAL|Formulation 2- Mid Dose|Rifaximin Formulation 2 Capsules
62175961|NCT04529811|EXPERIMENTAL|Formulation 2 - High Dose|Rifaximin Formulation 2 Capsules
62175962|NCT04529811|EXPERIMENTAL|Formulation 2 - Max Dose|Rifaximin Formulation 2 Capsules
62175963|NCT04529811|PLACEBO_COMPARATOR|Formulation 2 - Placebo|Placebo Formulation 2 Capsules
62552633|NCT05825443|EXPERIMENTAL|Treatment group|Patients who meet the protocol and sign the informed consent form received 4 cycles of chemotherapy combined with camrelizumab, followed by maintenance with camrelizumab until one year or the disease progressed or unacceptable toxicity. The chemotherapy regimen is decided by the researcher.
62552634|NCT04175288|EXPERIMENTAL|Ultrasound, manual therapy and exercise|This group will receive Ultrasound, manual therapy and exercise
62552635|NCT04175288|ACTIVE_COMPARATOR|manual therapy and exercise|This group will receive manual therapy and exercise
62552636|NCT02998086|EXPERIMENTAL|Individual (1:1)|Individual, 1:1 version of the Promoting Resilience in Stress Management for Parents (PRISM-P) intervention
62552637|NCT02998086|EXPERIMENTAL|Group|Group-based version of the Promoting Resilience in Stress Management for Parents (PRISM-P) intervention
62552638|NCT02998086|NO_INTERVENTION|Usual Care|Usual non-directed psychosocial supportive care
62552639|NCT02995408|EXPERIMENTAL|Experimental: 3RP treatment|"An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.~Experimental arm participated in the 8-week 3RP program starting immediately after enrollment."
62552640|NCT02995408|ACTIVE_COMPARATOR|Waitlist control|"An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.~The waitlist arm participated in the 8-week 3RP program starting 3 months after enrollment."
62741454|NCT05537064|EXPERIMENTAL|Visit-Based Intervention|In this arm the investigators will evaluate a visit-based nudge to refer to centralized pharmacy services to refer patients eligible for but not prescribed high-intensity statins to centralized pharmacy services for initiation and/or titration of a statin. Physicians in a single practice will be randomized to usual care versus visit-based nudge. The visit-based nudge will consist of an interruptive Best Practice Advisory (BPA) in the EMR that will trigger during non-acute patient visits and will prompt the provider to refer the patient to a centralized pharmacy service for statin initiation and management.
62552641|NCT00830973||Active Study Group|The active study group consists of 50 year or older postmenopausal women taking tamoxifen for the prevention of reoccurrence of breast cancer, do not meet exclusion criteria, meet all inclusion criteria, and are enrolled members for Medco clients agreeing to participate.
62552642|NCT05820126|EXPERIMENTAL|Cold-stored platelet concentrate|Cold-stored, pathogen-reduced platelet transfusion
62552643|NCT05820126|OTHER|Room temperature-stored platelet concentrate|Room temperature-stored, pathogen reduced platelet transfusion
62552644|NCT00876330|EXPERIMENTAL|1|Receives Hypertension and Hyperlipidemia Intervention using Clinical Decision Support.
62552645|NCT00876330|EXPERIMENTAL|2|Receives Hypertension and Hyperlipidemia Intervention with automated telephone outreach.
62552646|NCT03348163|EXPERIMENTAL|Switch ART|Switch from current antiretroviral therapy (ART) to bictegravir + tenofovir alafenamide + emtricitabine (B/FTC/TAF) for 48 weeks
62552647|NCT03348163|ACTIVE_COMPARATOR|Continue Current ART|Continue current antiretroviral therapy (ART) therapy (which is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent) for 48 weeks.
62552648|NCT06331169|EXPERIMENTAL|Anlotinib dose escalation + trastuzumab deruxtecan|"Various doses of anlotinib (8 mg QD, 10 mg QD, and 12 mg QD) administered during dose escalation to determine the recommended phase 2 Dose (RP2D) + trastuzumab deruxtecan 5.4 mg/kg.~Anlotinib at the RP2D + trastuzumab deruxtecan 5.4 mg/kg combination therapy"
62552649|NCT06550856|ACTIVE_COMPARATOR|SUTURE-CLOSURE OMENTOPEXY IN REPAIR OF PERFORATED PEPTIC ULCER|Group (A ) includes modification of the Graham's patch will be used in this group, where suitable sutures are passed between the edges of perforation and tied to close the perforation. A pedicle of omentum based on right omental artery is brought between these sutures, and these sutures are tied again with pedicle of omentum between knots over the perforation (thus the omentum remains sandwiched between the two levels of secured knots).
62552650|NCT06550856|ACTIVE_COMPARATOR|OMENTOPEXY ALONE IN REPAIR OF PERFORATED PEPTIC ULCER|Group (B) includes Grahm's technique of omentopexy will be performed by closing the perforation by placing interrupted full thickness suitable sutures along the margins of the ulcer with a patch of pedicled omentum laid over these sutures, which are then tied (without any attempt for primary closure of the perforation before placing the omentum as a plug).
62552651|NCT01892124|EXPERIMENTAL|Motivational Interviewing/Cognitive Behavioral-based Therapy|Receives an immediate weekly 10 session intervention based on a culturally-adapted, motivational interviewing and Cognitive Behavioral Therapy grounded protocol.
62552652|NCT01892124|EXPERIMENTAL|Wait-List Control|Receives a weekly 10 session intervention based on a culturally-adapted, motivational interviewing and Cognitive Behavioral Therapy grounded protocol after a three month, no-intervention waiting period.
62552653|NCT01699815|ACTIVE_COMPARATOR|Preemptive group|The preemptive group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered within 60 minutes prior to incision. Each infusion will be administered over 15 minutes as recommended by manufacturer package insert.
62175964|NCT04529811|EXPERIMENTAL|Formulation 3 - Low dose|Rifaximin Formulation 3 Capsules
62175965|NCT04529811|EXPERIMENTAL|Formulation 3 - Mid dose|Rifaximin Formulation 3 Capsules
62175966|NCT04529811|EXPERIMENTAL|Formulation 3 - High dose|Rifaximin Formulation 3 Capsules
62175967|NCT04529811|EXPERIMENTAL|Formulation 3 - Max dose|Rifaximin Formulation 3 Capsules
62175968|NCT04529811|PLACEBO_COMPARATOR|Formulation 3 - Placebo|Placebo Formulation 3 Capsules
62175969|NCT02287883||Patients at high PAE clinic|"Patients with diabetes or cardiovascular disease receiving care within two Accountable Care Organizations (ACOs) at clinics with high implementation of patient activation and engagement activities.~Observational: Patient Activation and Engagement (PAE)"
62364890|NCT02556411|EXPERIMENTAL|combined oral contraceptive plus LNG-IUS|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg+ LNG-IUS 13,5 mg di Levonorgestrel
62175970|NCT02287883||Patients at low PAE clinic|"Patients with diabetes or cardiovascular disease receiving care within two Accountable Care Organizations (ACOs) at clinics with low implementation of patient activation and engagement activities.~Observational: Patient Activation and Engagement (PAE)"
62175971|NCT03134261|OTHER|SPECT-CT|The participants will undergo two project scans: WB-MRI and SPECT-CT
62552654|NCT01699815|ACTIVE_COMPARATOR|Closure group|The closure group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered upon onset of skin closure.
62552655|NCT05248347|ACTIVE_COMPARATOR|Bronchoscopy training simulator|Bronchoscopy training simulator LM-092 (Koken Co., Ltd, Tokyo, Japan) was used to train the participants.
62552656|NCT05248347|EXPERIMENTAL|The BRONCH Mentor|Group B: The BRONCH Mentor (Simbionix, GI-Bronch Mentor, USA) was used.
62741455|NCT02832557||MCHAT-R Positive|Children identified at risk for the development of autism spectrum disorder (ASD) by scoring a 3 or higher on the MCHAT-R. Participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy.
62741456|NCT02102685|ACTIVE_COMPARATOR|VAC Therapy|active comparator: 14 patients within the first three days the VAC therapy was placed , proceeding as follows : organize the material , bandage removal , cleaning of the wound with irrigation solution , cut the sponge and placement on the wound , use of polyvinyl alcohol and / or silver foam, insertion of the tube seal and connection to the containing recipient.
62175972|NCT03134261|OTHER|Cholin-PET-CT|The participants will undergo two project scans: WB-MRI and Cholin-PET-CT
62175973|NCT03134261|OTHER|PSMA-PET-CT|The participants will undergo two project scans: WB-MRI and PSMA-PET-CT
62175974|NCT06647199|EXPERIMENTAL|CAD/CAM Milled PEEK|In the first group (CAD/CAM PEEK MODs), the mandibular master cast, mandibular trial denture, and maxillary denture were scanned using an intraoral digital scanner both separately while biting. The scanned data were saved in standard tessellation language (STL) file format and entered into the design software . The mandibular denture base and set-up were virtually designed. Based on the virtually created mandibular denture bases, the STL file of the designed denture base was imported into the milling machine to mill the prepolymerised PEEK discs to construct the CAD/CAM PEEK MOD base .
62175975|NCT06647199|EXPERIMENTAL|CAD/CAM milled PMMA|In the second group (CAD/CAM PMMA MODs), the STL file of the designed denture base was imported into the milling machine to mill the PMMA MOD base. The mandibular denture base and set-up were virtually designed. Based on the virtually created mandibular denture bases, the CAD/CAM PMMA MOD base was milled .Based on the scanned denture teeth, denture teeth were milled from tooth-coloured prepolymerized PMMA blocks, finished and polished, and then bonded with a methacrylate-based bonding agent into the PMMA milled base.
62175976|NCT06647199|EXPERIMENTAL|conventional PMMA MOD|the traditional heat-cured PMMA MOD was constructed. The waxed-up overdenture was processed in heat-cured PMMA resin using the compression mould technique.
62175977|NCT06647056|EXPERIMENTAL|Patients with PNES|
62175978|NCT04851171|ACTIVE_COMPARATOR|Semi-rigid Ureteroscopy|Patient with upper ureteric stone who are randomized in this arm will undergo semi-rigid ureteroscopy for treatment of the stone.
62175979|NCT04851171|ACTIVE_COMPARATOR|Flexible Ureteroscopy|Patient with upper ureteric stone who are randomized in this arm will undergo flexible ureteroscopy for treatment of the stone.
62175980|NCT02072278|EXPERIMENTAL|Vortioxetine 10 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
62175981|NCT02072278|EXPERIMENTAL|Vortioxetine 20 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
62175982|NCT02072278|ACTIVE_COMPARATOR|Escitalopram 15 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
62175983|NCT02072278|PLACEBO_COMPARATOR|Placebo|capsules; 3 daily doses in each treatment period; orally
62175984|NCT01172899|EXPERIMENTAL|Laparoscopic adjustable gastric band|
62175985|NCT01172899|ACTIVE_COMPARATOR|Control group|
62175986|NCT06353802|OTHER|group 1|Participants will be measured using iPhone® Inclinometer Application. The measurement app level, a measuring tool, was utilised with the iPhone® 10 (Apple Inc., California, USA). A free application that is built into the iPhone®, The measurement app level shows the numerical size in a manner similar to a digital inclinometer. The programme shows the angle measured using a digital display and the accelerometer included into the iPhone®. Degrees (°) were used as the measurement unit.
62175987|NCT03140878|EXPERIMENTAL|LGG|Lactobacillus rhamnosous (LGG) 450 billion CFU dissolved in water
62175988|NCT03140878|PLACEBO_COMPARATOR|Placebo|The placebo product is the same vegetable capsule as the experimental product, identical in composition, taste and appearance but without probiotics
62175989|NCT01187147|EXPERIMENTAL|Green Tea|Recruited subjects will be asked to take green tea capsules for 3 months and then stopped for another 3 months.
62175990|NCT01123642||Group 1|Operation Enduring Freedom and Operation Iraqi Freedom Veterans
62175991|NCT03291873|ACTIVE_COMPARATOR|topography guided PRK in one eye|Topography-guided (placido disk- based) using T-CAT Contoura treatment.
62175992|NCT03291873|ACTIVE_COMPARATOR|Q-value adjusted ( custom Q) PRK in the other eye|The target Q will be estimated according to a nomogram considering the patient's age
62175993|NCT03065478||Colon carcinoma|"Dietary supplementation with OnLife to improve signs and symptoms of CIPN in adult colon cancer patients who experienced a CIPN after adjuvant oxaliplatin-containing chemotherapy."
62175994|NCT03065478||Mamma carcinoma|"Dietary supplementation with OnLife to improve signs and symptoms of CIPN in adult breast cancer patients who experienced a CIPN after adjuvant paclitaxel regimen."
62175995|NCT02475018|EXPERIMENTAL|Milk fortified with plant sterol esters|250mL of Shuhua Milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
62175996|NCT02475018|PLACEBO_COMPARATOR|Plain milk|250mL of placebo milk(plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
62175997|NCT02475018|NO_INTERVENTION|No dairy product consumption|Participants have not consumed any dairy product during the 60-days of study period.
62175998|NCT06406998||Pregnant women with pre-existing atherosclerotic cardiovascular disease|Among the total cohort, pregnant women with pre-existing atherosclerotic cardiovascular disease were selected (N=145,315).
62552657|NCT02770482|EXPERIMENTAL|AD Patients|
62175999|NCT06406998||Matched cohort|Among the total cohort, 1:4 matched offspring born to women without pre-existent atherosclerotic cardiovascular disease using a propensity score were generated (N=581,260).
62176000|NCT06437054|ACTIVE_COMPARATOR|Dexamethasone+Saline+ICG|The experimental group received a single injection of Dexamethasone (5mg/ml) and Saline (D+Saline) mixed in a 1:1 ratio (with a possibility of a second injection if necessary). Additionally, two drops of Indocyanine Green (ICG: 25mg) were added, approximately 100μl (2.5mg/ml).
62176001|NCT06437054|EXPERIMENTAL|Dexamethasone+Hyaluronic Acid+ICG|The experimental group received a single injection of Dexamethasone (5mg/ml) and Hyaluronic acid (D+HA) mixed in a 1:1 ratio (with a possibility of a second injection if necessary). Additionally, two drops of Indocyanine Green (ICG: 25mg) were added, approximately 100μl (2.5mg/ml).
62176002|NCT01623414||Healthy schoolchildren|
62176003|NCT03120299|EXPERIMENTAL|Group A Drug|"Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks~Other Names:~Omega-3 Fatty Acid fish oil Omega 3 Treasure"
62176004|NCT03120299|PLACEBO_COMPARATOR|Group B Drug|Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
62176005|NCT05470361||People who suffer from PTSD|The sample will be composed of 30 patients from Stella's Chicago practice: 712 N Dearborn St, Chicago, Illinois 60654
62176006|NCT06442293|PLACEBO_COMPARATOR|Placebo|a placebo (microcrystalline cellulose) identical in size, shape and color to the treatment
62176007|NCT06442293|EXPERIMENTAL|Circulatory Beverage - low dose|A beverage containing natural ingredients at a low dose
62176008|NCT06442293|EXPERIMENTAL|Circulatory Beverage - medium dose|A beverage containing natural ingredients at a medium dose
62176009|NCT06442293|EXPERIMENTAL|Circulatory Beverage - high dose|A beverage containing natural ingredients at a high dose
62176010|NCT06442293|EXPERIMENTAL|TCM Beverage - low dose|A traditional Chinese medicine-based beverage containing natural ingredients at a low dose
62176011|NCT06442293|EXPERIMENTAL|TCM Beverage - high dose|A traditional Chinese medicine-based beverage containing natural ingredients at a high dose
62176012|NCT02041221|EXPERIMENTAL|SPARC1316 Dose 1|Subjects will be administered with SPARC1316 dose 1
62176013|NCT02041221|PLACEBO_COMPARATOR|Placebo|The subjects will receive placebo.
62176014|NCT02041221|EXPERIMENTAL|SPARC1316 Dose 2|Subjects will be administered with SPARC1316 dose 2
62176015|NCT02041221|EXPERIMENTAL|SPARC1316 Dose 3|Subjects will be administered with SPARC1316 dose 3
62567155|NCT05430750|ACTIVE_COMPARATOR|'Streamed -in' N2O carrier gas group|Ventilation will be initiated with 2% Sevoflurane in O2 -Air (60 % FiO2) @3.0L/min to achieve a MAC of 0.5. Then, the FGF will be decreased to 1.0 L (low flow) and N2O will be 'streamed-in' @ 40 %. When MAC 1.0 is reached incision will be allowed. At 20-minutes time point post induction if MAC 1.0 is not achieved at 2% sevoflurane then the sevoflurane vaporizer concentration will be adjusted to achieve MAC 1.0, before incision is allowed. Anaesthesia will be maintained at MAC 1.0 throughout. After surgery is over, the N2O - Sevoflurane will be stopped and FGF increased to 3.0L with 100% O2.
62176016|NCT02041221|EXPERIMENTAL|SPARC1316 Dose 4|Subjects will be administered with SPARC1316 dose 4
62176017|NCT02041221|EXPERIMENTAL|SPARC1316 Dose 5|Subjects will be administered with SPARC1316 dose 5
62176018|NCT04766047|ACTIVE_COMPARATOR|DEXMEDETOMIDINE AND AKI|The patients of the group undergoing EVAR under general anesthesia will receive dexmedetomidine intraoperatively.
62176019|NCT04766047|NO_INTERVENTION|CONTROL AND AKI|The patients of the group undergoing EVAR under general anesthesia will not receive dexmedetomidine intraoperatively.
62176020|NCT06094335|EXPERIMENTAL|Study|Virtual reality plus traditional physical therapy
62176021|NCT06094335|ACTIVE_COMPARATOR|Control|Traditional physical therapy
62176022|NCT05255198||Anterolateral approach|
62176023|NCT05255198||Direct anterior approach|
62176024|NCT02723383|EXPERIMENTAL|BACLOFEN|patient will receive baclofen caps
62176025|NCT02723383|PLACEBO_COMPARATOR|PLACEBO|patient will receive placebo caps (lactose)
62176026|NCT02555488|EXPERIMENTAL|2|in the second group diode laser (810 nm, 1.2 W, 30 s) was irradiated. Then second samples were taken from all canals.
62176027|NCT02555488|EXPERIMENTAL|1|In the first group Photodynamic therapy (PDT) with Methylene blue and diode laser (810 nm, 0.2 W, 40 second) was done
62176028|NCT00064428|EXPERIMENTAL|Fondaparinux - UFH not indicated|Subjects with no indication for UFH therapy: 2.5mg od, sc, (1st dose IV) x 8 days or discharge
62176029|NCT00064428|PLACEBO_COMPARATOR|Control - UFH not indicated|Subjects with no indication for UFH therapy: Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
62176030|NCT00064428|EXPERIMENTAL|Fondaparinux - UFH indicated|Subjects indicated for UFH: 2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus + 24-48 hr infusion
62176031|NCT00064428|ACTIVE_COMPARATOR|Control - unfractionated heparin|Subjects indicated for UFH: UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
62176032|NCT02187926||Roflumilast|Roflumilast will be administered according to the prescribing information of the approved label in Greece.
62176033|NCT04116242||cirrhosis of the liver, stadium Child A|sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months
62176034|NCT04116242||cirrhosis of the liver, stadium Child B|sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months
62176035|NCT04116242||cirrhosis of the liver, stadium Child C|sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months
62176036|NCT04116242||cirrhosis of the liver, acutely decompensated|sampling of biological material and health related data collection on days 1 (Baseline), 3, 7, and 14. If acutely decompensated patients re-compensate they will be followed 6-monthly for up to 36 months
62176037|NCT04116242||acute liver failure|sampling of biological material and health related data collection on days 1 (Baseline), 3, 7, and 14. If acutely decompensated patients re-compensate they will be followed 6-monthly for up to 36 months
62176038|NCT04116242||healthy controls|sampling of biological material and health related data collection on day 1 (Baseline)
62176039|NCT03503162|EXPERIMENTAL|Colonoscopy with Pure-Vu System|Standard colonoscopy procedure with Pure-Vu System
62176040|NCT01069887||adult with hematological malignancies|
62176041|NCT01069887||pediatrics with hematological malignancies|
62176042|NCT01069887||pediatrics receiving stem cell transplant|
62176043|NCT01069887||adult receiving stem cell transplant|
62176044|NCT02413099|EXPERIMENTAL|KBMSI-2 6gm|Patients were instructed to take investigational products (KBMSI-2 6g) twice a day for 8weeks at least 1 hour after food intake
62176045|NCT02413099|PLACEBO_COMPARATOR|Placebo|Patients were instructed to take placebo twice a day for 8weeks at least 1 hour after food intake
62176046|NCT04630470|PLACEBO_COMPARATOR|The placebo control group|Each patient received the massage therapy with baby oil on both lower leg areas for 10 minutes on each leg, for 4 weeks, three times a week, in the first half of the HD session (first 2 hours).
62552658|NCT04815577||CHD group|The CHD group is made up of the children included in the first study. From these 496 children with CHD, children with a second CPET more than one year from the first referral CPET were included. If several CPETs were performed in the follow-up, we retain the most distant CPET from the first, excluding the CPETs that were performed after a cardiopulmonary rehabilitation program implemented in the region in 2018. The group corresponding to the first CPET was called. Among the initial 496 children, if patients had not had a second CPET, the cause was indicated. As a reminder, the patients included in the initial study were aged 5-18 years old and they were referred by their paediatric cardiologists to one of the two CPET laboratories after their annual medical check-up. The anatomical and clinical classification of congenital heart diseases was used to define the type of malformation. The demographic, clinical, echocardiographic data were collected during the first CPET.
62176047|NCT04630470|EXPERIMENTAL|The study group|Each patient received the massage therapy with lavender oil on both lower legs for 10 minutes on each leg, for 4 weeks, three times a week, in the first half of the HD session (first 2 hours).
62176048|NCT02943642|EXPERIMENTAL|A-dmDT390-bisFv(UCHT1)|A-dmDT390-bisFv(UCHT1) will be administered as Total Dose µg/kg given as 1/8 Total Dose µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes.
62176049|NCT02943642|ACTIVE_COMPARATOR|Vorinostat|Subjects in the control arm will receive oral vorinostat capsules at a dose of 400 mg daily up to 12 months in duration until disease progression or uncontrolled side effects take place. Subjects in the vorinostat arm who experience progressive disease may cross over into the experimental arm after 6 months of treatment after a 2-week vorinostat washout period.
62741457|NCT02102685|PLACEBO_COMPARATOR|Traditional Therapy|14 patients: after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
62741458|NCT04907825|EXPERIMENTAL|Pharmacist Intervention Arm|Pharmacist to prescribe/monitor/manage oral anticoagulation therapy for atrial fibrillation stroke prophylaxis (under collaborative practice agreement with participants primary care provider) in accordance with ACC/AHA/HRS Guidelines.
62176050|NCT02943642|EXPERIMENTAL|Lead-in Dosing single arm|"Dose Group 1: A-dmDT390-bisFv(UCHT1) will be administered as 5 µg/kg given as 0.625 µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes.~Dose Group 2: A-dmDT390-bisFv(UCHT1) will be administered as 10 µg/kg given as 1.25 µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes."
62176051|NCT00816621|EXPERIMENTAL|ABC for Children Adopted Internationally|ABC for Children Adopted Internationally: 10 session in home intervention that targets parent nurturance, synchrony, pseudo-autistic behaviors, and indiscriminate sociability
62552659|NCT04815577||Controle|The controle Group consisted of children referred for nonsevere functional symptom linked to exercise (murmur, palpitations or dyspnea) or for a medical sports certificate. We included controlled children from 2015 to 2020 period who will be added to the controlled patients of the initial study. These patients only had one CPET.
62552660|NCT04881786|NO_INTERVENTION|Untreated teeth control group|Premolars without orthodontic forces
62552661|NCT04881786|EXPERIMENTAL|Moderate force group|Premolars were submitted to tipping and extrusion orthodontic movements, the activation angle was 45º with a force of 56 g. Forces were measured with an orthodontic dynamometer. For 7 days
62552662|NCT04881786|EXPERIMENTAL|Severe force group|Premolars were submitted to tipping and extrusion orthodontic movements, the activation angle was 90º with a force of 224 g. Forces were measured with an orthodontic dynamometer. For 24 hours
62741459|NCT04907825|ACTIVE_COMPARATOR|Enhanced Usual Care Control Arm|Pharmacist to notify primary care provider that patient has 'actionable' atrial fibrillation and provide current medication list.
62741460|NCT03877315|ACTIVE_COMPARATOR|Stemmed|Subjects operated with stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.
62176052|NCT00816621|ACTIVE_COMPARATOR|DEF for Children Adopted Internationally|DEF for Children Adopted Internationally: 10 session in home intervention that targets cognitive and motor delays
62176053|NCT00922441|EXPERIMENTAL|Fimasartan 1|Fimasartan 60 mg group
62176054|NCT00922441|EXPERIMENTAL|Fimasartan 2|Fimasartan 120 mg group
62176055|NCT00922441|ACTIVE_COMPARATOR|Valsartan|Reference (Valsartan 80 mg) group
62552663|NCT01810302|EXPERIMENTAL|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
62176056|NCT01705145|EXPERIMENTAL|Ivacaftor|"Part A: Ivacaftor 50 milligram (mg) (for participants weighing less than \[\<\] 14 kilograms \[kg\]) or 75 mg (for participants weighing greater than or equal to \[\>=\] 14 kg) every 12 hours (q12h) from Day 1 through Day 3 and 1 morning dose on Day 4 during Part A of the study..~Part B: Ivacaftor 50 mg (for participants weighing \<14 kg) or 75 mg (for participants weighing \>=14 kg) q12h for 24 weeks during Part B of the study."
62176057|NCT01643564||Group 1|Heart Transplant Recipients with Unexplained Graft Dysfunction
62176058|NCT01643564||Group 2|Normal Control
62176059|NCT01643564||Group 3|Class III-IV Heart Failure
62176060|NCT01643564||Group 4|Heart Transplant Recipients with Normal Graft Function
62364891|NCT06242093|EXPERIMENTAL|GROUP A WBVT and Conservative treatment|"WBVT and Conservative treatment~* Group A will receive WBVT with conservative treatment. The treatment will be given with the frequency of 34 times/week for 25-30 minutes with the help of Galileo vibration platform.~* Time: 3-4 Times/WEEK for 8 weeks"
62176061|NCT03092245|ACTIVE_COMPARATOR|OctaplasLG|OctaplasLG® is an industrial donor plasma product pooled from 630 -1520 single donor units. It possesses unique features when compared to standard FFP, such as having a standardized concentration of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen-free.12 Most importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration. The manufacturing process also inactivates viral, bacterial and prion pathogen by immune neutralization, solvent-detergent treatment and a prion specific ligand affinity chromatography step.
62176062|NCT03092245|PLACEBO_COMPARATOR|Ringer-Acetate|standard of care resuscitation fluid Ringer-acetate is a mixture of electrolytes in water to a slightly hypotonic solution.
62176063|NCT00110955|EXPERIMENTAL|Darbepoetin alfa - Group A|
62176064|NCT00110955|PLACEBO_COMPARATOR|Placebo- Group B|
62176065|NCT03645005|EXPERIMENTAL|My Guide (psychoeducation & self-management program)|
62176066|NCT03645005|ACTIVE_COMPARATOR|My Health (health education program)|
62176067|NCT02546778|EXPERIMENTAL|Dermosux RF|The group received the radio frequency for 20 minutes with the frequency of 1 MHz with 40 W.
62176068|NCT05764642|EXPERIMENTAL|Chronic Kidney Disease Group|Subjects with Chronic Kidney Disease (CKD) with clinically indicated renal biopsy will have microvessel images obtained by Super-Resolution Ultrasound Imaging (SRUI) using Definity ultrasound contrast agent.
62176069|NCT05764642|ACTIVE_COMPARATOR|Healthy Control Group|Healthy volunteers with normal eGFR will have microvessel images obtained by Super-Resolution Ultrasound Imaging (SRUI) using Definity ultrasound contrast agent.
62176070|NCT05431725|EXPERIMENTAL|Sinovac-QIV group|800 subjects aged 3 years and older will receive one dose of Sinovac-QIV for vaccine-primed subjects or two doses of Sinovac-QIV for vaccine-unprimed subjects.
62176071|NCT05431725|ACTIVE_COMPARATOR|Vaxigrip Tetra-QIV group|800 subjects aged 3 years and older will receive one dose of Vaxigrip Tetra-QIV for vaccine-primed subjects or two doses of Vaxigrip Tetra-QIV for vaccine-unprimed subjects.
62176072|NCT02591797|EXPERIMENTAL|"hand-eye-mouth technique"|"hand-eye-mouth (MOB) seeks to focus the patient in performing a sequence of movements in a fun way so that your attention is diverted from the puncture dental needle, also it seeks to the patient does not see the needle. The operator prior to infiltrate local anesthetic teaches the child a game to put the sleepy little water.After explain a first time, the sequence once or twice is repeated until the patient has mastered. We call this test. When we apply the anesthetic, the entire sequence must be repeated as in trials with the same tranquility and in the same tone of the game. The operator will use this technique during the inferior alveolar and lingual nerve block procedure"
62176073|NCT02591797|ACTIVE_COMPARATOR|Conventional technique|the operator will explain how he/she will do the inferior alveolar and lingual nerve block procedure in phrases appropriates to the child. Then quietly cover the child´s field of view by hand during the inferior alveolar and lingual nerve block
62176074|NCT03067610|EXPERIMENTAL|Radiation Therapy|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
62176075|NCT06232317|EXPERIMENTAL|Virtual Reality Software|Participants in this arm will receive cognitive exercises using ReCognitionVR virtual reality software
62176076|NCT06232317|ACTIVE_COMPARATOR|Traditional Orientation Methods|Participants in this arm will receive cognitive exercises using traditional (standard-of-care) orientation methods,
62176077|NCT01115283|EXPERIMENTAL|Perceptual learning|Patients will be asked to practice a range of visual discrimination tasks for a period of time (each therapy session:1-2 hrs, 4-5 sessions/wk for \~1-6 months).
62176078|NCT01115283|EXPERIMENTAL|Occlusion therapy|The fellow sound will be covered with a standard eye patch for a period of time (1-2 hrs/day, 4-5 days/wk for \~1-3 months). The idea is to push the brain to use the weaker amblyopic eye.
62176079|NCT01115283|EXPERIMENTAL|Video game|Patients will be asked to play videogames for a period of time (each therapy session:1-2 hrs, 4-5 sessions/wk for \~1-6 months).
62176080|NCT05964556||Functional Movement Screen and Isokinetic Muscle Evulation of Knee Muscles|Functional movement screen was evaluated with 7 basic parameters determined by Gray Cook Isokinetic muscle measurements were performed with an ISOMED 2000
62552664|NCT01810302|PLACEBO_COMPARATOR|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
62552665|NCT06575465|EXPERIMENTAL|Full Intervention|"* Will receive a tailored healthy lifestyle intervention program focusing on nutrition, physical activity, and behavioral changes.~* Ten sessions will be conducted separately for men and women.~* Each session will last for approximately 2 hours.~* The program will include educational workshops, cooking demonstrations, physical activity sessions, and group discussions."
62176081|NCT02335398|EXPERIMENTAL|methadone|single group
62176082|NCT00751205|EXPERIMENTAL|Arm 1|
62176083|NCT00751205|PLACEBO_COMPARATOR|Arm 2|
62176084|NCT01472471||acute asthmatic children|Children hospitalized with a diagnosis of acute asthma exacerbation
62552666|NCT06575465|ACTIVE_COMPARATOR|Control group|Participants will continue to receive standard care from their healthcare providers without additional intervention.
62176085|NCT01472471||stable asthmatic children|Children with a history of asthma currently asymptomatic
62176086|NCT00742898|EXPERIMENTAL|1|Non-targeted opt-out rapid HIV screening fully integrated into an urban, inner-city ED.
62176087|NCT00742898|ACTIVE_COMPARATOR|2|Diagnostic rapid HIV testing fully integrated into an urban, inner-city ED.
62552667|NCT04132687|OTHER|autologous blood patch|autologoust blood patch therapy
62176088|NCT04316221|ACTIVE_COMPARATOR|Control|The standard of nutrition care in Guatemala includes the following clinical care, as determined to be necessary by the MHA medical and nutrition teams: frequent growth monitoring, general nutrition education, parasite treatment, and multiple micronutrient supplementation.
62176089|NCT04316221|EXPERIMENTAL|Intervention|The intervention group will receive an intervention to promote daily egg consumption for a six month period, in addition to the local standard of nutrition care. Specifically, intervention group participants will be provided with enough eggs for the infant to consume one egg, daily, for six months, and also with education on preparation and consumption of eggs.
62176090|NCT05127590|EXPERIMENTAL|RBN-2397 in combination with pembrolizumab|RBN-2397 orally in combination with the fixed approved dose of IV pembrolizumab
62552668|NCT00801502|OTHER|Control|No change in diet
62552669|NCT00801502|ACTIVE_COMPARATOR|Oily fish|Two portions of salmon per week from week 20 of pregnancy until giving birth
62176091|NCT01521689|EXPERIMENTAL|Rituximab|Consolidation treatment with sub cutaneaous low doses of Rituximab
62176092|NCT05662683|EXPERIMENTAL|Working Group 1|"From the preparation stage of the PAP-SMEAR removal procedure to the completion of the PAP-SMEAR removal procedure until the completion of the PAP-SMEAR removal procedure, after providing an internet connection with a smartphone for the image, clicking the youtube.com link and watching Relaxation (https://www.youtube.com/watch?v=H1iboKia3AQ) nature video virtual reality Goggles will be provided.~Virtual reality glasses to be used in the research are not a medical device."
62552670|NCT00676832|PLACEBO_COMPARATOR|Group 1|
62552671|NCT00676832|EXPERIMENTAL|Group 2|
62552672|NCT00676832|EXPERIMENTAL|Group 3|
62552673|NCT00676832|EXPERIMENTAL|Group 4|
62552674|NCT00676832|EXPERIMENTAL|Group 5|
62552675|NCT04019171|EXPERIMENTAL|interval exercise training|
62552676|NCT04019171|NO_INTERVENTION|waiting list|
62552677|NCT04433754||patients with pancreatic injury|patients with higher amylase and lipase levels (higher than the laboratory upper limits) in the course of SARS-CoV-2 infection
62741461|NCT03877315|ACTIVE_COMPARATOR|Non-Stemmed|Subjects operated with stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.
62741462|NCT02855866|EXPERIMENTAL|cryotherapy|
62741463|NCT02855866|ACTIVE_COMPARATOR|Cortisone aerosol|
62741464|NCT02855866|PLACEBO_COMPARATOR|Management|
61986235|NCT04278547|EXPERIMENTAL|Experimental group|Preventive strategy based on the ELISPOT IFN-γ result: If patients are stratified as high risk they will receive prophylaxis with valgancyclovir for 3 months and if they are stratified as low risk they will be treated with preemptive therapy guided by CMV polymerase chain reaction analysis;
62176093|NCT05662683|EXPERIMENTAL|Working Group 2|Distraction cards containing five optical illusion figures will be shown to the women by the researcher
62176094|NCT05662683|EXPERIMENTAL|Working Group 3|From the preparation stage of the PAP-SMEAR ALDIRAN procedure to the completion of the application process that takes PAP-SMEAR, the virtual reality glasses for breathing exercise by clicking the youtube.com link (https://www.youtube.com/watch?v=Pddb09FAs68) after providing an internet connection with a smartphone for the image. will be provided.
61986236|NCT04278547|NO_INTERVENTION|Control group|Standard of care, universal prophylaxis with valgancyclovir for 3 months).
62176095|NCT05662683|NO_INTERVENTION|Control Group|The maintenance and applications in the routine PAP-SMEAR application will be done exactly.
62176096|NCT04006236|EXPERIMENTAL|Experimental Infant Formula|extensively hydrolyzed casein protein
62176097|NCT04006236|ACTIVE_COMPARATOR|Control Infant Formula|extensively hydrolyzed casein protein
62552678|NCT04433754||patients without pancreatic injury|patients with normal amylase and lipase levels in the course of SARS-CoV-2 infection
62552679|NCT05296005|EXPERIMENTAL|Treatment (chemotherapy, chemoradiation, surgery)|"NEOADJUVANT CHEMOTHERAPY: Patients receive FLOT chemotherapy consisting of docetaxel intravenously (IV) , oxaliplatin IV, leucovorin IV, and fluorouracil IV over 24 hours on day 1 or FOLFOX chemotherapy consisting of oxaliplatin IV and leucovorin IV, and fluorouracil IV continuously over 24 hours on days 1 and 2. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.~NEOADJUVANT CHEMORADIATION: Within 4 weeks after completing neoadjuvant chemotherapy, patients undergo radiation therapy in 25 fractions over 5 weeks. Patients also receive either fluorouracil IV continuously for 24 hours on days 1-5 or capecitabine orally (PO) twice daily (BID) on days 1-5. Cycles repeat weekly for 5 weeks in the absence of disease progression or unacceptable toxicity.~SURGERY: Within 4-8 weeks after neoadjuvant chemoradiation, patients undergo surgical resection according to tumor location and per surgeon expertise."
62552680|NCT04128189|ACTIVE_COMPARATOR|Transplanted subject|In addition to receiving standard dose (2) of Shingrix prior to transplantation, participant may receive a 3rd dose several months after transplantation if they meet criteria related to no rejection.
62552681|NCT04128189|SHAM_COMPARATOR|Non-Transplanted subject|Receives standard Shingrix dose (2), but not transplanted within 16 month time frame post-dose, so does not receive additional Shingrix dose.
62552682|NCT00641888||1|10 patients starting on non-nucleoside reverse transcriptase inhibitor based regimen. 5 women and 5 men.
62552683|NCT00641888||2|10 patients starting a protease inhibitor based regimen. 5 women and 5 men.
62552684|NCT00771498|OTHER|lopinavir|Patients with HIV/TB co-infection will receive treatment for both infection, and PK of lopinavir 800mg + ritonavir 200mg (PO BID) during 5 months will be performed
62552685|NCT04519073|PLACEBO_COMPARATOR|Placebo|0.5 mL of diluent (phosphate buffer)
62552686|NCT04519073|EXPERIMENTAL|V-306 low dose|V-306 at 15 µg
62552687|NCT04519073|EXPERIMENTAL|V-306 intermediate dose|V-306 at 50 µg
62552688|NCT04519073|EXPERIMENTAL|V-306 high dose|V-306 at 150 µg
62552689|NCT03188224|EXPERIMENTAL|Intervention|MyTransition app
62552690|NCT03188224|NO_INTERVENTION|Control|Usual care
62741465|NCT00479505|EXPERIMENTAL|Active|
62741466|NCT00479505|PLACEBO_COMPARATOR|Placebo|
62741467|NCT06316934|PLACEBO_COMPARATOR|Placebo|Prior to starting the procedure, the clinic nurse will prepare the distilled water on a paper towel by applying two drops of each solution on a paper towel. The patients will hold the paper towel over their nose and then they will be asked to take two deep breaths. Before the physician comes in, the nurse will ask the participant to take a deep breath while holding the towel 3 inches from her face and will instruct the participant to continue to take normal breaths subsequently
62741468|NCT06316934|EXPERIMENTAL|Experimental|Prior to starting the procedure, the clinic nurse will prepare the aromatherapy Lavender essential oil on a paper towel by applying two drops of each solution on a paper towel. The patients will hold the paper towel over their nose and then they will be asked to take two deep breaths. Before the physician comes in, the nurse will ask the participant to take a deep breath while holding the towel 3 inches from her face and will instruct the participant to continue to take normal breaths subsequently
62741469|NCT05368259|EXPERIMENTAL|AGBS + Moderate Intensity Lifestyle Therapy Group|Patients randomized to treatment will receive the AGBS device
62741470|NCT05368259|NO_INTERVENTION|Moderate Intensity Lifestyle Therapy (CONTROL) Group|Patients randomized to the control arm will receive moderate-intensity lifestyle therapy.
62176098|NCT04208542|ACTIVE_COMPARATOR|Interventional|Under general anaesthesia, ultrasound guided ESP block will perform at the T5 level with 0.375% ropivacaine 20ml. Fentanyl 1 ug/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with fentanyl (10 ug/kg) and palonosetron 0.075mg will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 48 hours. Pain assessment will record 3 months after surgery.
62176099|NCT04208542|NO_INTERVENTION|Control|Fentanyl 1 ug/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with fentanyl (10 ug/kg) and palonosetron 0.075mg will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 48 hours. Pain assessment will record 3 months after surgery.
62176100|NCT01228305|EXPERIMENTAL|Acetaminophen|Subjects will be randomly assigned to treatment using a permuted-block randomization algorithm. Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children \>=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to \<2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
62176101|NCT01228305|PLACEBO_COMPARATOR|Placebo|Subjects will be randomly assigned to treatment using a permuted-block randomization algorithm. Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children \>=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to \<2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
62176102|NCT04512898|EXPERIMENTAL|Patient with IBS|Patients with IBS and positive H. pylori.
62176103|NCT01978236|EXPERIMENTAL|Cohort A|The first cohort of 15 subjects will receive oral dabrafenib 150 mg twice daily orally for 7 to 14 days prior to surgery in Cohort A; Subjects will be treated for at least 7 days prior to craniotomy, but not more than 14 days. Subjects in either cohort with intracranial and/or extracranial metastases remaining after surgery may resume treatment with the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily no earlier than 72 hours after surgery
62176104|NCT01978236|EXPERIMENTAL|Cohort B|The second cohort of 15 subjects will receive dabrafenib 150 mg twice daily combined with trametinib 2 mg once daily (Cohort B) orally for 7 to 14 days prior to surgery; Subjects will be treated for at least 7 days prior to craniotomy, but not more than 14 days. Subjects in either cohort with intracranial and/or extracranial metastases remaining after surgery may resume treatment with the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily no earlier than 72 hours after surgery
62176105|NCT04770142|EXPERIMENTAL|TIRA|treated with transcatheter RF ablation system (TIRA catheter with its supplemental devices)
62176106|NCT01251887|EXPERIMENTAL|Diet A: Low omega-3 (n-3) + High linoleic acid (LA)|Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks
62176107|NCT01251887|EXPERIMENTAL|Diet B: Low omega-3 (n-3) + Low linoleic acid (LA)|Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks
62176108|NCT01251887|EXPERIMENTAL|Diet C: High omega-3 (n-3) + Low linoleic acid (LA)|Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks
62176109|NCT01806532||18F-FDG PET-CT|A total of 10 patients with acute respiratory distress syndrome (ARDS) will be imaged with 2-18F-fluoro-2-deoxy-D-glucose (18F-FDG) and PET-CT scan.
62176110|NCT02383927|EXPERIMENTAL|Cohort 1|Thyroid Cancer
62176111|NCT02383927|EXPERIMENTAL|Cohort 2|Squamous Head and Neck Cancer
62176112|NCT02657759|EXPERIMENTAL|CARDICHOL|Food supplement formula in shape of pill called CARDICHOL. 2 pills daily during 12 weeks (from visit V1 to visit V4). One pill immediately before, after or during breakfast and lunch.
62176113|NCT02657759|PLACEBO_COMPARATOR|Placebo|"placebo with the same characteristics, appearance, packaging, and composition as the active formula, except for active ingredients replaced by dicalcium phosphate and flavouring substances.~2 pills daily during 12 weeks (from visit V1 to visit V4). One pill immediately before, after or during breakfast and lunch."
62176114|NCT04441996|EXPERIMENTAL|Therapeutic plasma exchange (TPE)|Participants with COVID-19-associated hyperviscosity randomized to receive therapeutic plasma exchange (TPE).
62176115|NCT04441996|ACTIVE_COMPARATOR|Standard of care|Participants with COVID-19-associated hyperviscosity randomized to receive standard of care treatment.
62176116|NCT05712655||Study group|Post-pubertal females with forward head posture and temporomandibular disorders
62176117|NCT05712655||Control group|Post-pubertal females with neutral head posture and with no temporomandibular disorders
62176118|NCT00866918|EXPERIMENTAL|Arm I (standard risk, combination chemotherapy)|See Detailed Description
62741471|NCT03990623|EXPERIMENTAL|Diagnostic (CT perfusion scans, liver biopsy)|Prior to PVE, patients undergo CT perfusion scan of the liver and liver biopsy over 15 minutes. Patients undergo a second CT perfusion scan immediately after PVE and a third CT perfusion scan 3-6 weeks post PVE.
62176119|NCT00866918|EXPERIMENTAL|Arm II (high risk, combination chemotherapy)|See Detailed Description.
62741472|NCT05055011||Observational (survey, medical record review)|Parents complete survey over 20 minutes. Patients' medical records are reviewed.
62741473|NCT03641716|EXPERIMENTAL|Mealtime PREP Intervention|Parents of young children will receive 6 weekly sessions, each lasting approximately one-hour, in the home environment. An occupational therapy clinician will deliver the Mealtime PREP intervention to the family.
61986237|NCT02420691|EXPERIMENTAL|Treatment (ribociclib)|Patients receive ribociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62176120|NCT01431105|EXPERIMENTAL|Atorvasatin|Atorvastatin dose titration to maximum tolerated dose
62176121|NCT04041661|EXPERIMENTAL|Active tDCS plus gait training group|Participants in Active tDCS plus gait training group will execute Active tDCS on left dorsolateral prefrontal cortex which combined with treadmill, 12 times per week, least 4 weeks.
62552691|NCT02045901|ACTIVE_COMPARATOR|Diclegis|Participants will be randomized to receive Diclegis or placebo. On Day 1, all participants will take 2 tablets of study drug at bedtime. On Days 2 to 14, participants will take 2 tablets of study drug at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
62176122|NCT04041661|SHAM_COMPARATOR|Sham tDCS plus gait training group|Participants in Sham tDCS plus gait training group will executeSham tDCS on left dorsolateral prefrontal cortex which combined with treadmill, 12 times per week, least 4 weeks.
62176123|NCT06089486|OTHER|Invasive Coronary Angiography|Patients in this arm will undergo annual CAV surveillance with ICA
62176124|NCT06089486|OTHER|Positron Emission Tomography|Patients in this arm will undergo annual CAV surveillance with PET
62741474|NCT00606034|EXPERIMENTAL|All subjects active|All subjects will receive the experimental treatment (U-500 insulin via Omnipod) since they have already failed all other previous insulin treatment regimens.
62176125|NCT03821064|EXPERIMENTAL|Patient Navigation|45 patients (15 African American, 30 white) will interact with a patient navigator three times over three months to identify and address barriers before they cause breakdowns in care delivery, employing resources, education, and care coordination from the day of surgery until post-operative radiation treatment begins.
62176126|NCT00812123|EXPERIMENTAL|Calcineurin free|Immunosuppression with Sirolimus, Mycophenolate and Steroids
62176127|NCT00812123|ACTIVE_COMPARATOR|Calcineurin|Immunosuppressive therapy with Cyclosporin A, Mycophenolate and Steroids
62176128|NCT02540343||acute neck pain patients|Participant recently received the diagnosis of neck pain (\< 30 days) \>18 years old able to speak, read and write German, questionnaires
62176129|NCT02540343||chronic neck apin patients|Participant has neck pain for a longer period of time (\> 90 days) \> 18 years old able to speak, read and write German, questionnaires
62176130|NCT02540343||test persons|no neck pain \> 18 years old able to speak, read and write German, questionnaires
62176131|NCT02681445||Group 1 Healthy Non Smokers|No TB Symptoms No TB History Negative Mantoux test Normal Chest X-ray Non-Smoker
62176132|NCT02681445||Group-2 Smokers|No TB History No TB Symptoms No TB History Negative Mantoux test Smoker 10 + Cigarettes/day
62176133|NCT02681445||HIV Positive|"No TB Symptoms No TB History Negative Mantoux test Normal Chest X-ray HIV Positive~CD4 count \>200"
62176134|NCT02681445||TB Suspect Group|WHO Screening Recommendation Protocls Unexplained Cough Sputum production Fever Weight Loss or loss of appetite Night Sweats
62176135|NCT02681445||Lower Respiratory Track Infection|TB Lab test Negative Ab Normal Chest X-ray HIV Negative
62741475|NCT02903225|NO_INTERVENTION|Usual Care|usual care and no changes in their previous physical activity
62741476|NCT02903225|ACTIVE_COMPARATOR|Cardiac Rehabilitation|Exercise Training program on a 3-days/week basis during 24 weeks (68-74 sessions). Each session started with a 10-min warm-up walking period followed by 20-min of breathing exercises and free non-resistance movements of limbs. This stage was followed by pedaling during 20-minutes at a circuit resistance training protocol using a stationary cycle-ergometer. Each session ended with a cool down period (5-minutes) including diverse stretching maneuvers of engaged muscle groups. The initial bicycle-ergometer workload (WL) was defined as 50% of the maximum achieved in the previous stress testing
62741477|NCT04246775|OTHER|Treatment|Peristeen given
62741478|NCT06592833|ACTIVE_COMPARATOR|Psilocybin + Pimavanserin|single dose Psilocybin and single dose Pimavanserin
62741479|NCT06592833|PLACEBO_COMPARATOR|Psilocybin + Placebo|single dose Psilocybin and single dose Placebo
62741480|NCT02851797|ACTIVE_COMPARATOR|givinostat|Givinostat oral suspension (10 mg/mL) twice daily
62176136|NCT04927338|EXPERIMENTAL|BacoMind® 300mg/day|Participants randomized to the experimental arm will receive 12 weeks of 300 mg/day BacoMind® Bacopa monnieri standardized extract.
62176137|NCT04927338|PLACEBO_COMPARATOR|Placebo|Participants randomized to the placebo arm will receive 12 weeks of daily placebo identical to the experimental treatment in size, color, and shape.
62176138|NCT02024477|PLACEBO_COMPARATOR|Placebo|Matching placebo 1 pill daily for 12 weeks
62176139|NCT02024477|ACTIVE_COMPARATOR|saxagliptin|Saxagliptin 5mg once daily for 12 weeks
62176140|NCT01309113|PLACEBO_COMPARATOR|Placebo of VAC BNO 1095|1 tablet of placebo in the morning, 1 tablet of placebo in the evening
62741481|NCT02851797|PLACEBO_COMPARATOR|placebo|Placebo oral suspension (10 mg/mL) twice daily
61986238|NCT04145999|EXPERIMENTAL|PRP + PBM group|This group will receive both PRP application and photobiomodulation.
62176141|NCT01309113|ACTIVE_COMPARATOR|10 mg VAC BNO 1095|1 tablet of VAC BNO 1095 10 mg in the morning, 1 tablet of placebo in the evening
62176142|NCT01309113|ACTIVE_COMPARATOR|20 mg VAC BNO 1095|1 tablet of VAC BNO 1095 10 mg in the morning, 1 tablet of VAC BNO 1095 10 mg in the evening
62176143|NCT00596258|EXPERIMENTAL|A-007|Single arm open label
62176144|NCT04072666|EXPERIMENTAL|ASSIP plus SPP|Participants in the ASSIP group will receive a combination of the comprehensive clinical SPP (i.e. standardised assessment, risk evaluation and formulation, safety planning and follow-up), and the ASSIP psychological intervention where they will receive three therapy sessions followed by regular ongoing contact through individually focused letters sent over 24 months.
62176145|NCT04072666|EXPERIMENTAL|CBT plus SPP|Participants in the CBT group will receive a combination of the comprehensive clinical SPP (i.e. standardised assessment, risk evaluation and formulation, safety planning and follow-up), and the CBT psychological intervention where they will receive five CBT 60-minute individual sessions.
62176146|NCT04072666|ACTIVE_COMPARATOR|SPP alone|"The Suicide Prevention Pathway (SPP) comprises seven steps:~i) Initial screening - persons experiencing suicide ideation and who may also have a history of, or recent, suicide attempt, are placed on the pathway; ii) Assessment of suicide risk iii) Formulation of suicide risk (based on a prevention oriented approach) iv) Safety planning (collaboratively developed with the client) and Counselling on access to lethal means v) Structured follow-up (within 24-48 hrs); vi) Transition of care plan; and vii) Caring contacts - ongoing contact/support for the person for the next 2 years (through personalised letters or phone texts)."
62176147|NCT05087667|EXPERIMENTAL|Polymer Cerclage System OrthoLoop|Patients receives Ortholoop Cerclage System
62176148|NCT05087667|ACTIVE_COMPARATOR|cerclages used in standard care|"Patients receives cerclages used in standard care"
62176149|NCT02230423|EXPERIMENTAL|Patients receiving nose surgery|"Patients in need of nose surgery, before and after surgery; or only after successful surgery, then with or without Empty Nose Syndrome."
62176150|NCT04270747|EXPERIMENTAL|ABP 938-Treatment Group A|Subjects will receive 2 mg (0.05 mL) of ABP 938 by intravitreal (IVT) injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8) and every 8 weeks from week 16 until week 48.
62741482|NCT02029755|EXPERIMENTAL|TAP block|postoperative analgesia with sono-guided transversus abdominis plane block and intravenous patient controlled analgesia (IV-PCA). Bilateral sono-guided TAP block will be performed after the induction of general anesthesia. 20 ml of 0.25% ropivacaine will be injected to the transversus abdominis plane under ultrasound guidance at each side (total 40 ml). IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
62176151|NCT04270747|ACTIVE_COMPARATOR|Aflibercept-Treatment Group B1|Subjects will receive 2 mg (0.05 mL) of aflibercept (Treatment Group B) by IVT injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8). Subjects will be re-randomized to receive aflibercept by IVT injection every 8 weeks from week 16 until week 48.
62176152|NCT04270747|ACTIVE_COMPARATOR|ABP 938-Treatment group B2|Subjects will receive 2 mg (0.05 mL) of aflibercept (Treatment Group B) by IVT injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8). Subjects will be re-randomized to receive ABP 938 by IVT injection every 8 weeks from week 16 until week 48
62176153|NCT04595097|EXPERIMENTAL|Intervention Group|The training volume will be 24 sessions. Training frequency will be 3 sessions per week. Duration of training sessions will be around 60min. Patients will perform endurance training or interval training at moderate to high intensities. IMT in both groups will be performed using the PowerBreathe KHP2 device (POWERbreatheKHP2, HaB, International, Southam, UK). Training intensity in the intervention group will be set initially at a load of 50% of patients' maximal inspiratory mouth pressure (MIP). This initial load will be continuously and gradually increased to the highest tolerable intensity during each of the supervised sessions.
62176154|NCT04595097|ACTIVE_COMPARATOR|Control group|The training volume will be 24 sessions. Training frequency will be 3 sessions per week. Duration of training sessions will be around 60min. Patients will perform endurance training or interval training at moderate to high intensities. Sham IMT will be performed using the PowerBreathe KHP2 device (POWERbreatheKHP2, HaB, International, Southam, UK). Training intensity in the control group will be set at 10% baseline PImax and will be not modified throughout the intervention period.
62176155|NCT02685007||Inpatients|Inpatients planned for laparoscopic surgery, in the field of gynecology, urology and visceral surgery will be documented from of surgery until date of discharge from hospital
62176156|NCT04125771|OTHER|Diclofenac + HBB|Women who will receive Diclofenac + HBB
62176157|NCT04125771|OTHER|Diclofenav + placebo|Women who will receive Diclofenav + placebo
62741483|NCT02029755|ACTIVE_COMPARATOR|Local infiltration|postoperative analgesia with local anesthetics infiltration at surgical wound and intravenous patient controlled analgesia (IV-PCA). 20 ml of 0.5% ropivacaine will be injected at the surgical wound by the surgeon before the closure of wound. IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
62176158|NCT03730311|EXPERIMENTAL|Elpida 120 mg once weekly|elsulfavirine 120mg or placebo orally once weekly for 4 weeks
62176159|NCT03730311|EXPERIMENTAL|Elpida 200 mg once weekly|elsulfavirine 200mg or placebo orally once weekly for 4 weeks
62741484|NCT02029755|ACTIVE_COMPARATOR|PCA only|postoperative analgesia with intravenous patient controlled analgesia. IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
62176160|NCT03730311|EXPERIMENTAL|Elpida 280 mg once weekly|elsulfavirine 280mg or placebo orally once weekly for 4 weeks
62176161|NCT05493228|EXPERIMENTAL|patient is receiving dexmedetomidine|dexmedetomidine infusion at the rate of 0.5 μg kg-1 hr-1, started after the induction of general anesthesia without a loading dose
62741485|NCT00101920|EXPERIMENTAL|ABX-EGF|Open-label, single arm panitumamab monotherapy
62741486|NCT03332017|EXPERIMENTAL|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) intravenously on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2 to 6; and then every 8 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; each cycle is 28 days
62741487|NCT03332017|EXPERIMENTAL|Zanubrutinib + Obinutuzumab|Zanubrutinib 160 mg twice a day orally with or without food; Obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2 to 6; and then every 8 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; each cycle is 28 days
62741488|NCT00711048|EXPERIMENTAL|1|30 mg, oral, single dose
62741489|NCT00711048|EXPERIMENTAL|2|95 mg, oral, single dose
62741490|NCT00711048|PLACEBO_COMPARATOR|3|Oral solution, single dose
62741491|NCT02143453|EXPERIMENTAL|High intensity interval training|
62741492|NCT02143453|EXPERIMENTAL|Endurance training|
61986239|NCT04145999|EXPERIMENTAL|PRP + placebo PBM|This group will receive PRP application and placebo photobiomodulation.
61986240|NCT04145999|EXPERIMENTAL|PBM + placebo PRP|This group will receive placebo PRP application with a saline solution and active photobiomodulation.
62176162|NCT05493228|PLACEBO_COMPARATOR|standard treatment (saline)|saline injection only after the induction of general anesthesia
62176163|NCT02601105|PLACEBO_COMPARATOR|Placebo Vehicle Cream|Lipoderm® base served as the placebo vehicle control to be applied every night to demarcated 10 x 10 cm area containing stretch marks on randomly assigned side of abdomen for 12 weeks.
62176164|NCT02601105|EXPERIMENTAL|Centella Asiatica Cream|An alcoholic extract of CA (verified by HPLC) mixed into a Lipoderm® base served as the treatment cream to be applied every night to demarcated 10 x 10 cm area containing stretch marks on the opposite side of the abdomen for 12 weeks.
62552692|NCT02045901|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive Diclegis or placebo. On Day 1, all participants will take 2 tablets of study drug at bedtime. On Days 2 to 14, participants will take 2 tablets of study drug at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
62552693|NCT06582472||cohort 1 (longitudinal study)|This group will include patients affected by type 2 diabetes for less than 10 years and without signs of diabetic retinopathy, nephropathy, and neuropathy.
62176165|NCT04734847|ACTIVE_COMPARATOR|High-frequency rTMS|"Intensity: rTMS treatment intensity determined using resting motor threshold (RMT). Treatment will be delivered at 80% of the RMT.~Site of Stimulation: Region of supplementary motor area (SMA) that regulates pelvic floor muscle activity. This target is defined in Montreal Neurological Institute (MNI) Coordinates of X=-2, Y=-16, and Z=68 mm.~Frequency: 10 Hz.~Duration: 20 Trains, 10 second duration, 50 second inter-train interval.~Total number of pulses per session: 2000.~Total number of session: 5 (one session per day for 5 consecutive days)."
62176166|NCT04734847|SHAM_COMPARATOR|Sham rTMS|"Identical to the High-frequency rTMS arm except delivered with an inert sham stimulation coil."
62176167|NCT02973477|EXPERIMENTAL|Group A: Dapagliflozin/Glimepiride|Participants will take open-label dapagliflozin 5 mg daily for 4 weeks and escalate the dose gradually up to dapagliflozin 10 mg daily as needed based on their glucose monitoring for a total of 12 weeks on dapagliflozin. Patients will then begin a 2 week washout period where they are not taking any study drugs. After the washout period, participants will receive open-label glimepiride 2 mg daily for 4 weeks and escalate the dose gradually up to glimepiride 4 mg daily (no more than 4 mg daily) as needed based on their glucose monitoring for a total of 12 weeks on glimepiride.
62176168|NCT02973477|EXPERIMENTAL|Group B: Glimepiride/Dapagliflozin|Participants will take open-label glimepiride 2 mg daily for 4 weeks and escalate the dose gradually up to glimepiride 4 mg daily (no more than 4 mg daily) as needed based on their glucose monitoring for a total of 12 weeks on glimepiride. Patients will then begin a 2 week washout period where they are not taking any study drugs. After the washout period, participants will receive open-label dapagliflozin 5 mg daily for 4 weeks and escalate the dose gradually up to dapagliflozin 10 mg daily as needed based on their glucose monitoring for a total of 12 weeks on dapagliflozin.
62176169|NCT03788954|ACTIVE_COMPARATOR|Kinesiotaping on FCU|Muscle fasilitation and Fascia Correction techniques of Kinesiotaping on m. flexor carpi ulnaris.
62176170|NCT03788954|ACTIVE_COMPARATOR|Kinesiotaping on ECR|Muscle fasilitation and Fascia Correction techniques of Kinesiotaping on m. extensor carpi radialis.
62176171|NCT03788954|PLACEBO_COMPARATOR|Plasebo Kinesiotaping on FCU|Same kinesiotape used on m. flexor carpi ulnaris without any taping techniques.
62176172|NCT03788954|PLACEBO_COMPARATOR|Plasebo Kinesiotaping on ECR|Same kinesiotape used on m. extensor carpi radialis without any taping techniques.
62176173|NCT01536613||BIAsp 30 users|
62176174|NCT01929577|EXPERIMENTAL|ASP015K Test Tablet - Fasting Conditions|ASP015K administered as a single tablet under fasting conditions.
62176175|NCT01929577|EXPERIMENTAL|ASP015K Reference Tablet - Fasting Conditions|ASP015K administered via multiple tablets under fasting conditions
62176176|NCT01929577|EXPERIMENTAL|ASP015K Test Tablet -Fed Conditions|ASP015K administered as a single tablet under fed conditions
62176177|NCT03159325|NO_INTERVENTION|Usual Care|The usual care group will receive all standard treatment, instructions and information for patients with cardiovascular disease, but no Healing Circles program.
62176178|NCT03159325|EXPERIMENTAL|Healing Circles|Healing Circles is an evidence-based and patient-informed novel self-management platform designed to support patients with CVD. It uses a private, secure social network that helps connect patients to one another, to personalized, disease management information , and provides functions to assist patients in self-management via evidence-based principles of behaviour change.
62176179|NCT01626729|EXPERIMENTAL|Traffic Light|
62176180|NCT01626729|EXPERIMENTAL|Traffic Light+|
62176181|NCT01626729|EXPERIMENTAL|Facts Up Front|
62176182|NCT01626729|EXPERIMENTAL|Facts Up Front+|
62176183|NCT01626729|PLACEBO_COMPARATOR|No front of package label|
62176184|NCT02960126|ACTIVE_COMPARATOR|Intervention: Clopidogrel|Case management with clopidogrel 75mg once daily is provided for stroke prevention in AF patient.
62176185|NCT02960126|EXPERIMENTAL|Control: Aspirin|Usual care with aspirin 100mg once daily is provided for stroke prevention in AF patient.
62176186|NCT01297699|EXPERIMENTAL|Tocilizumab|
62176187|NCT01297699|PLACEBO_COMPARATOR|Sterile 0.9% Sodium Chloride|
62176188|NCT05896137|EXPERIMENTAL|2mg CS0159|QD for 12 weeks
62176189|NCT05896137|EXPERIMENTAL|4mg CS0159|QD for 12 weeks
62176190|NCT05896137|EXPERIMENTAL|Placebo|QD for 12 weeks
62176191|NCT01828385|EXPERIMENTAL|Group Mg|Magnesium sulfate 40 mg.kg-1 + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1
62176192|NCT01828385|ACTIVE_COMPARATOR|Group C|Saline 100 ml + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1
62176193|NCT02493881|ACTIVE_COMPARATOR|Group 1|The RLNs having motor function on the anterior branch assessed by intraoperative neuromonitoring.
62176194|NCT02493881|ACTIVE_COMPARATOR|Group 2|RLNs having motor function on anterior and posterior branch assessed by intraoperative neuromonitoring.
62176195|NCT01916642|PLACEBO_COMPARATOR|Control|0.9% Normal Saline is given instead of Lidocaine in the same volume and duration. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
62176196|NCT01916642|ACTIVE_COMPARATOR|Lidocaine 1mg/kg|Lidocaine 1mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
62176197|NCT01916642|ACTIVE_COMPARATOR|Lidocaine 1.5mg/kg|Lidocaine 1.5mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
62176198|NCT01916642|ACTIVE_COMPARATOR|Lidocaine 2mg/kg|Lidocaine 2mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
62176199|NCT01916642|ACTIVE_COMPARATOR|Lidocaine 2.5mg/kg|Lidocaine 2.5mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
62182420|NCT05423106|EXPERIMENTAL|Part 2 JNJ-64457744 or Placebo|Chronic hepatitis B participants who are virologically suppressed on nucleos(t)ide analog (NA) treatment (tenofovir disoproxil fumarate \[TDF\], tenofovir alafenamide \[TAF\] and entecavir \[ETV\]) will receive a single dose at one single dose level of either JNJ-64457744 or matching placebo as an oral formulation, under fasted condition on Day 1.
62552694|NCT06582472||cohort 2 (longitudinal study)|healthy controls: subjects in good general health as evidenced by medical history without diagnosis of type 2 diabetes
62176200|NCT01529021||humanoid robot distration|The robot NAO, academic edition (Aldebaran Robotics) was used in this study. Some of its features include an on-board fully programmable computer CPU: x86 AMD Geode with 500 MHz, 256 MB SDRAM and 1 GB flash memory, WiFi (802.11g) and Ethernet, two cameras with up to 30 frames per second, two hands with self adaptive gripping abilities, force sensitive sensors on its arms and feet to perceive contact with objects, Light Emission Diodes in its eyes and body, four microphones to identify the source of sounds, and two loud speakers for communication where tone and voice pitch can be modified in real-time. It runs on a native Linux Operating system platform and can be programmed using a proprietary SDK called NaoQi, or in C, C++, Ruby and Urbi, which makes it compatible with other robot simulators such as Microsoft Robotics Developer Studio.
62176201|NCT01529021||control|standard care procedures were used during the vaccination
62176202|NCT01620398|EXPERIMENTAL|BALANCE group|BALANCE Program is composed by 3 concepts: a) a diet composed of 50-60% of energy from carbohydrate, 10-15% of energy from protein; 25-35% of energy from fat (\<7% saturated fatty acid; \<10% polyunsaturated fatty acid; \<20% monounsaturated fatty acid, \<1% trans fatty acid), \<200 mg/day of cholesterol, 20-30 g/day of fiber and \<2400 mg/day of sodium; b) Nutrition education program based on ludic strategies and indication of affordable foods; c) An intense follow up by individual and group visits and phone calls.
62176203|NCT01620398|ACTIVE_COMPARATOR|Control Diet group|generalized advices to follow a low fat, low energy, low sodium and low cholesterol diet are given.
62741493|NCT04189965|OTHER|Pilot group|"Subjects are volunteers of 18 to 50 years of age that have given consent and that are affiliated to a social security. Overall, subjects must be in good health (no chronic pain, neuropathy or cardiac/respiratory issues etc.) and (for women) non-pregnant.~The subject will be seated in an armchair. He will be asked to explore the virtual environment using virtual reality glasses to validate it.~The subject will also have headphones and different shouts or noises will be broadcast and he will have to rate the level of dislike of each sound stimulation."
62176204|NCT03431480|EXPERIMENTAL|hCBMNC|Autologous human placental cord blood mononuclear cells (buffy coat fraction)
62176205|NCT05813535|OTHER|Baseline|Patient on heparin locks when off venous nutrition
62176206|NCT01997749|EXPERIMENTAL|Ketogenic diet|Acute stroke patients will receive a ketogenic diet (Ketocal 4:1 and ketogenic meals) for the first week after inclusion
62176207|NCT01997749|ACTIVE_COMPARATOR|Control diet|Acute stroke patients will receive a control diet (the regular diet, enteral or oral, offered at the hospitals) for the first week after inclusion.
62176208|NCT00857233|EXPERIMENTAL|Memantine|
62176209|NCT06276114||Consecutive patients with stent underexpantsion treated with IVL|
62176210|NCT06276114||Consecutive patients with stent underexpantsion treated ELCA|
62176211|NCT00676897|EXPERIMENTAL|1|Simvastatin 40 mg PO or NGT
62176212|NCT00676897|PLACEBO_COMPARATOR|2|Placebo
62176213|NCT05290857|EXPERIMENTAL|High thrombotic risk|For patients at high thrombotic risk, DOACs will be resumed within 7 days of clinical hemostasis after GI bleeding.
62176214|NCT05290857|EXPERIMENTAL|Moderate thrombotic risk|For patients at moderate thrombotic risk, DOACs will be resumed between 7 and 14 days of clinical hemostasis after GI bleeding.
62176215|NCT05404698|EXPERIMENTAL|Aerobic intradialytic exercise|10 patients will perform Aerobic exercise with the cycle ergometer prototype (EXALT) during hemodialysis
62176216|NCT05404698|EXPERIMENTAL|Standard care|10 patients will receive hemodialysis treatment (usual care)
62176217|NCT00815022|ACTIVE_COMPARATOR|1|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 20 degree celsius
62176218|NCT00815022|EXPERIMENTAL|2|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 10 degree celsius
62176219|NCT00815022|EXPERIMENTAL|3|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 15 degree celsius
62176220|NCT00815022|EXPERIMENTAL|4|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 25 degree celsius
62176221|NCT00815022|EXPERIMENTAL|5|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 30 degree celsius
62176222|NCT00815022|EXPERIMENTAL|6|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 35 degree celsius
62176223|NCT03646695|EXPERIMENTAL|ILM flap|vitrectomy with ILM flap transposition and gas-tamponade will be performed
62176224|NCT03646695|ACTIVE_COMPARATOR|ILM peeling|vitrectomy with ILM peeling and gas-tamponade will be performed
62176225|NCT06404073|EXPERIMENTAL|Structured Pacing (PEM)|Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.
62176226|NCT06404073|OTHER|Usual Care|Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.
62176227|NCT03494985|EXPERIMENTAL|OralBalance moisturizing gel|All the participants in this arm used an experimental Oralbalance gel as instructed under the supervision of trained site staff on their visits.
62176228|NCT03494985|EXPERIMENTAL|Oral rinse|All the participants in this arm used an Oral rinse as instructed under the supervision of trained site staff on their visits.
62176229|NCT03494985|EXPERIMENTAL|Moisturizing mouth spray|All the participants in this arm used a moisturising mouth spray as instructed under the supervision of trained site staff on their visits.
62176230|NCT03494985|SHAM_COMPARATOR|Water only use|All the participants in this arm used water as instructed under the supervision of trained site staff on their visits.
62176231|NCT06042023|EXPERIMENTAL|Remote monitoring|Participants that consent to the study will undergo additional remote monitoring with the applied wearable sensor.
62741494|NCT04189965|OTHER|Experimental group|"Subjects are volunteers of 18 to 50 years of age that have given consent and that are affiliated to a social security. Overall, subjects must be in good health (no chronic pain, neuropathy or cardiac/respiratory issues etc.) and (for women) non-pregnant.~The subject will be seated in an armchair. He will be asked to explore the virtual environment using virtual reality glasses. He will also have headphones and different shouts or noises will be broadcast and an electric stimulation glove to study in humans the mechanisms of long-term memory of pain by exploring the parallel between memory of pain and memory of a traumatic event.~3 sessions of stimulation will be done (D0, D2 and D30)"
62741495|NCT04189965|OTHER|Experimental subgroup|"Subjects are volunteers of 18 to 50 years of age that have given consent and that are affiliated to a social security. Overall, subjects must be in good health (no chronic pain, neuropathy or cardiac/respiratory issues etc.) and (for women) non-pregnant.~The subject will be seated in an armchair. He will be asked to explore the virtual environment using virtual reality glasses. He will also have headphones and different shouts or noises will be broadcast and an electric stimulation glove to study in humans the mechanisms of long-term memory of pain by exploring the parallel between memory of pain and memory of a traumatic event.~3 sessions of stimulation will be done (D0, D2 and D30)"
62176232|NCT01281917|EXPERIMENTAL|Velcade plus Temsirolimus|"Velcade 1.6 mg/m2 weekly (days 1, 8, 15, and 22) Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)~Treat for up to 6 cycles, cycles are 35 days long."
62741496|NCT03468751|EXPERIMENTAL|HLX10, Dose Finding Cohort|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX10 once every two weeks. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 0.3, 1.0, 3.0, and 10 mg/kg, starting from 0.3 mg/kg.
62176233|NCT00583115|EXPERIMENTAL|Gleevec|Drug taken orally 260mg/M2/day once per day
62176234|NCT01246232|EXPERIMENTAL|Amisulpride|400mg, 2 x 200mg amisulpride capsules for the first 4 weeks, then the option of titrating up to 800mg, 4 x 200mg amisulpride capsules for the remaining 8 weeks.
62741497|NCT03468751|EXPERIMENTAL|HLX10, Dose Expansion Cohort (200 mg )|Each cycle of treatment consists of 4 weeks. Patients who enroll into this expansion cohort will receive an infusion of assigned dose of HLX10 at 200 mg once every two weeks.
62741498|NCT00633568|ACTIVE_COMPARATOR|A|One course of chemotherapy with cisplatin and docetaxel followed by induction chemoradiotherapy followed by two courses of consolidation chemotherapy
62741499|NCT00633568|EXPERIMENTAL|B|Three courses of induction chemotherapy followed by consolidation chemoradiotherapy
62741500|NCT02494518|ACTIVE_COMPARATOR|Forced Exercise & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~1. 45 minutes of cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed~2. 45 minutes of upper extremity repetitive arm exercises"
62176235|NCT01246232|PLACEBO_COMPARATOR|Placebo|400mg, 2 x 200mg amisulpride capsules, or 2 matching placebo capsules for the first 4 weeks, then the option of titrating up to 800mg, 4 x 200mg amisulpride capsules, or 4 matching placebo capsules for the remaining 8 weeks.
62176236|NCT04801784|EXPERIMENTAL|Fluid balance neutralization|Fluid balance neutralization using increased net ultrafiltration, aiming to neutralize the cumulative fluid input received over the first 72 hours of study participation.
62176237|NCT04801784|ACTIVE_COMPARATOR|Standard care|Active control group of positive fluid balance during the first 72 hours of study participation with zero or near-zero net ultrafiltration.
62176238|NCT02383238|ACTIVE_COMPARATOR|Dapagliflozin|Dapagliflozin, 10 mg/day, oral administration, 6 weeks
62176239|NCT02383238|PLACEBO_COMPARATOR|Placebo|Placebo, oral administration, 6 weeks
62176240|NCT05896540|EXPERIMENTAL|STUDY GROUP ENFOCATE|The selected students will be randomly divided into the study and control groups; the intervention will take place in the same schools that the students attend. The assignment to groups will use simple random sampling, performed in two stages. In the first stage the available schools will be randomly assigned to the study and control groups, while the second stage will select randomly the groups in each school that will participate in the study. The study groups will receive a 10-session intervention in sexual education, covering topics related to preventive sexual conduct, gender equity and mental health.
62741501|NCT02494518|ACTIVE_COMPARATOR|Voluntary Exercise & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~1. 45 minutes of cycling on a recumbent stationary bike at your self-selected speed~2. 45 minutes of upper extremity repetitive arm exercises"
62741502|NCT02494518|ACTIVE_COMPARATOR|Stroke Education & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~1. 45 minutes of stroke education~2. 45 minutes of upper extremity repetitive arm exercises"
62741503|NCT06659952|EXPERIMENTAL|HIV D+/R+ Arm|If HIV+ donor heart is available prior to HIV-negative donor heart, HIV-positive participant who agreed to receive HIV+ donor heart as part of this study receives the organ (heart) from an HIV- positive donor.
62176241|NCT05896540|NO_INTERVENTION|CONTROL GROUP|The control groups will not receive intervention; they will continue with the sexual orientation that each school provides to its students.
62176242|NCT05657132|EXPERIMENTAL|Costus paste|Costus paste used as an intracanal medication for decreasing the number of enterococcus faecalis present in the necrotic root of the primary molar
62176243|NCT05657132|ACTIVE_COMPARATOR|metapaste|metapaste used as an intracanal medication for decreasing the number of enterococcus faecalis present in the necrotic root of the primary molar
62741504|NCT06659952|NO_INTERVENTION|HIV D-/R+ Arm (Control Arm)|If HIV- donor heart is available first, the HIV-positive participant receives the organ (heart) from an HIV- negative donor as part of standard organ waitlist/ clinical care.
62741505|NCT06058429||2-3 months infants group|Subjects in this group had recieved three dose of sIPV as primay immunization, and about half of them recieved DTaP simultaneously.
62176244|NCT02136342|EXPERIMENTAL|chlorogenic acid|
62176245|NCT02870751|EXPERIMENTAL|ST-only ETEC strain TW11681 or TW10722|Oral inoculum of several doses of bacteria to establish range to achieve diarrhea attack rate in around 70% of volunteers.
62176246|NCT03917537||HNSCC patients have used Nivolumab|Retrospectively analyze WGS information from cancer tissues from HNSCC patients have used Nivolumab
62176247|NCT06079203|NO_INTERVENTION|No intervention|No intervention, serving as a usual care control group
62741506|NCT06058429||18 months children group|Subjects in this group had recieved one dose of sIPV as booster immunization, and about half of them recieved MMR or hepatitis A vacine(live-attenuated or inactivated) simultaneously.
62176248|NCT06079203|EXPERIMENTAL|Single intervention: Emergency Care Redesign (ECR)|
62176249|NCT06079203|EXPERIMENTAL|Single intervention: Nurse-led Telephonic Care (NLTC)|
62176250|NCT06079203|EXPERIMENTAL|Single intervention: Community Paramedic-led Transitions Intervention (CPTI)|
62176251|NCT06079203|EXPERIMENTAL|Two intervention: ECR and NLTC|
62176252|NCT06079203|EXPERIMENTAL|Two interventions: ECR and CPTI|
62176253|NCT06079203|EXPERIMENTAL|Two interventions: NLTC and CPTI|
62176254|NCT06079203|EXPERIMENTAL|All interventions: ECR, NLTC, and CPTI|
62176255|NCT03756922|EXPERIMENTAL|Part 1|To receive a single dose of FDL176 on Day 1, followed by FDL169 TID for 28 days starting on Day 29; and another single dose of FDL176 on Day 42.
62176256|NCT03756922|EXPERIMENTAL|Part 2|To receive FDL169 TID for 3 days from Day 1, followed by FDL176 QD for 19 days starting on Day 8; and FDL169 TID for 3 days from Day 24.
62176257|NCT03756922|EXPERIMENTAL|Part 3|FDL169 and FDL176 for 28 days and 4 weeks of follow-up
62176258|NCT03756922|EXPERIMENTAL|Part 4|FDL169 and FDL176 for 28 days and 4 weeks of follow-up
62176259|NCT02228135||Non post-tonsillectomy hemorrhage|Children who do not have post-tonsillectomy hemorrhage.
62176260|NCT02228135||Post-tonsillectomy hemorrhage|Children return to the hospital after surgery with post-tonsillectomy hemorrhage.
62176261|NCT03262155||ECMO / ECLS|Patients hospitalized for ARDS or Cardiogenic shock with ECMO / ECLS
62176262|NCT03262155||No ECMO / ECLS|Patients hospitalized for ARDS or Cardiogenic shock without ECMO / ECLS
62176263|NCT04758546|EXPERIMENTAL|Aggressive screening criteria + high minimal ventilatory settings|
62176264|NCT04758546|EXPERIMENTAL|Aggressive screening criteria + low minimal ventilatory settings|
62176265|NCT04758546|EXPERIMENTAL|Conservative screening criteria + high minimal ventilatory settings|
62176266|NCT04758546|ACTIVE_COMPARATOR|Conservative screening criteria + low minimal ventilatory settings|
62176267|NCT02552810|ACTIVE_COMPARATOR|Plasma of Argon|Abutment cleaning by plasma of Argon protocol .
62741507|NCT00395486|EXPERIMENTAL|Rosuvastatin|
62741508|NCT00395486|ACTIVE_COMPARATOR|Atorvastatin|
62176268|NCT02552810|ACTIVE_COMPARATOR|Steam clean|Abutment cleaning by steam clean device.
62176269|NCT03101033|EXPERIMENTAL|Epidural neuroplasty group|This group will be given epidural neuroplasty once enrolled.
62176270|NCT03101033|ACTIVE_COMPARATOR|Transforaminal steroid injection group|This group will be given transforaminal betamethasone injection once enrolled, if no obvious pain relief was reported, another epidural injection will be given one week later.
62176271|NCT02357719|EXPERIMENTAL|VistaO2 FLUX device|This device combines the transcutaneous oxyhemoglobin saturation (allowing to compute the oxyhemoglobin desaturation index), the slow variations in heart rate, the nasal flow and an index of nocturnal respiratory events calculated by analyzing the movements of the chest performed by chest impedance variations.
62176272|NCT01088178|EXPERIMENTAL|Immediate Postplacental|Within 10 minutes from delivery of placenta
62176273|NCT01088178|EXPERIMENTAL|Early Postpartum|After 10 minutes from delivery of placenta but within 48hrs from delivery
62176274|NCT01088178|EXPERIMENTAL|Interval|After 6 weeks postpartum
62176275|NCT03456635|NO_INTERVENTION|usual antimicrobial prophylaxys|standard of care: perioperative antimicrobial prophylaxis without computerized decision support system
62176276|NCT03456635|EXPERIMENTAL|guided antimicrobial prophylaxis|perioperative antimicrobial prophylaxis guided by a computerized decision support system
62176277|NCT04340466||Suspected or proven COVID-19 critically ill patients|
62176278|NCT04340466||Control|
62176279|NCT01020942|EXPERIMENTAL|Pretreatment|
62176280|NCT01020942|NO_INTERVENTION|Control|
62176281|NCT02979613|EXPERIMENTAL|TAF 25 mg|Double-blind (DB) phase: TAF 25 mg + TDF placebo for up to 53 weeks. Open-label extension (OLE) phase: TAF 25 mg for up to 52 weeks.
62176282|NCT02979613|ACTIVE_COMPARATOR|TDF 300 mg|DB phase: TDF 300 mg + TAF placebo for up to 50 weeks. OLE phase: TAF 25 mg for up to 52 weeks.
62176283|NCT03277417||Isolated Oligohydramnios|Fetuses with amniotic fluid index (AFI) equal or less than 5 cm
62176284|NCT03277417||Isolated Polyhydramnios|Fetuses with amniotic fluid index (AFI) more than 25 cm
62176285|NCT03277417||Control Group|Fetuses with normal amount of amniotic fluid
62176286|NCT00468858|EXPERIMENTAL|T-DEN-Post-Transfection F17|Post-Transfection F17, full dose
62176287|NCT00468858|EXPERIMENTAL|T-DEN-Post-Transfection F19|Post-Transfection F19, full dose
62176288|NCT00468858|PLACEBO_COMPARATOR|Placebo|Control
62176289|NCT03383809|EXPERIMENTAL|Strawberry juice with inulin|One dose of 300 g of strawberry with 10 g of inulin will be given to subjects in the form of juice
62176290|NCT03383809|EXPERIMENTAL|Strawberry juice|One dose of 300 g of strawberry juice will be given to subjects in the form of juice
62176291|NCT03383809|EXPERIMENTAL|Inulin|One dose of 10 g of inulin will be given to subjects in the form of a drink
62176292|NCT01593865||BIMA Grafting Group|Group consists of patients who received bilateral internal mammary artery grafting for treatment of severe coronary disease since June 2012.
62176293|NCT01593865||Control Group|This Group consists of historical control patients who received conventional coronary artery bypass grafting (left mammary artery graft only plus great saphenous vein grafts) in the 2010-2012 period, and who are propensity-matched to the BIMA Group patients.
62176294|NCT03122483||OSA|Blood biomarker results in subjects with obstructive sleep apnea.
62176295|NCT03122483||Non-OSA|Blood biomarker results in subjects without obstructive sleep apnea
62176296|NCT00141713|EXPERIMENTAL|1|etanercept treatment for GVHD
62741509|NCT03441035||Adults, uncomplicated|Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.
62741510|NCT03441035||Adults, complicated|Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until hospital discharge or postoperative day 21. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points. A infusion of deuterium labeled phenylalanine will be given in the ICU at 1-3 occasions to determine the synthesis rate of albumin.
62741511|NCT03441035||Children|Children undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. P-albumin and B-Hb is only taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.
62741512|NCT03924219||Pediatric Solid Organ Transplant (SOT) Recipients|Pediatric patients (\<18 years of age) undergoing or anticipated to undergo solid organ transplantation (heart, kidney, or liver) will be prospectively enrolled with serial blood collection for CMV T cell Immunity Assay performance.
62741513|NCT04192136|EXPERIMENTAL|Nicotinamide Riboside (NR)|"Investigators will use Good Manufacturing Process (GMP)-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA). Investigators dose based on body weight, and monitor for adverse effects (AEs).~For individuals with weight \> 72 kg: 900 mg po qd x 12 wks.~For individuals with weight \> 48 kg and ≤ 72 kg: 600 mg po qd x 12 wks.~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 12 wks."
62741514|NCT04192136|PLACEBO_COMPARATOR|Placebo|"Matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule). Doses of placebo will match the body weight schema for dosing of NR. Investigators dose based on body weight, and monitor for adverse effects (AEs).~For individuals with weight \> 72 kg: 900 mg po qd x 12 wks.~For individuals with weight \> 48 kg and ≤ 72 kg: 600 mg po qd x 12 wks.~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 12 wks."
62176297|NCT03214250|EXPERIMENTAL|Gem/NP/nivolumab|Gemcitabine+Nab-Paclitaxel+nivolumab
62176298|NCT03214250|EXPERIMENTAL|Gem/NP/APX005M|Gemcitabine+Nab-Paclitaxel+APX005M
62741515|NCT04192136|EXPERIMENTAL|Exercise Intervention and NR|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands. All sessions will begin with stretching and brief aerobic warm-up exercise on the in-home bike trainer. On resistance training days, subjects will be given instructions to complete circuits of resistance exercises.~Participants in this arm will receive both the Exercise Intervention and the NR."
62741516|NCT04192136|EXPERIMENTAL|Exercise Intervention and Placebo|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands. All sessions will begin with stretching and brief aerobic warm-up exercise on the in-home bike trainer. On resistance training days, subjects will be given instructions to complete circuits of resistance exercises.~Participants in this arm will receive both the Exercise Intervention and the Placebo."
62741517|NCT03021655|EXPERIMENTAL|Adventure-based intervention group|Adventure-based intervention group included 1 day-camp and will be divided into 2 parts: (1) physical activity such as wall climbing, ropes course etc, (2) health education delivering about the relationship of self-efficacy, self-esteem, emotion and smoking abstinence. The training will be held before the 6-month follow-up. Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
62741518|NCT03021655|EXPERIMENTAL|WhatsApp intervention group|For WhatsApp intervention group, not more than 8 subjects with same gender will be assigned into a group. Messages about mood and stress management will be sent to the group per week and the group will last for 6 months. It aims to relieve their pressure and emotion by sharing their unhappy things with other subjects. Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
62741519|NCT03021655|OTHER|Control group|For the control group, the subjects will receive telephone counseling on quitting smoking at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
62741520|NCT04798352|EXPERIMENTAL|LUTONIX(R)035 drug-coated balloon catheter|
62741521|NCT04798352|EXPERIMENTAL|RANGER TM drug-coated balloon catheter|
62741522|NCT04164095|EXPERIMENTAL|lappg|
62741523|NCT04164095|ACTIVE_COMPARATOR|ladgbi|
62741524|NCT04748328||ACL Reconstruction Group|This group received reconstruction treatment in Cipto Mangunkusumo Hospital, Gatot Subroto Hospital, Hasan Sadikin Hospital
62176299|NCT03214250|EXPERIMENTAL|Gem/NP/nivolumab/APX005M|Gemcitabine+Nab-Paclitaxel+nivolumab+APX005M
62741525|NCT04748328||Rehabilitation Group|This group received rehabilitation treatment with optional delayed reconstruction if needed in Arifin Achmad Hospital, Pekanbaru
62741526|NCT02507466|EXPERIMENTAL|Variable high-intensity Training|high intensity variable stepping exercise on a treadmill and overground
62741527|NCT02507466|ACTIVE_COMPARATOR|Variable low-intensity training|low intensity variable stepping exercise on a treadmill and overground
62741528|NCT02507466|ACTIVE_COMPARATOR|Constant High Intensity Training|high intensity constant (forward) stepping exercise on a treadmill and overground
62741529|NCT04926610|EXPERIMENTAL|proactive clinical ethics consultation group|
62176300|NCT06263530||Standard first line treatment, stages I or II without risk factors|Standard first-line treatment that includes 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and involved site radiotherapy of 20 Gy in early clinical stages I or II without risk factors.
62741530|NCT04926610|NO_INTERVENTION|routine care group|
62176301|NCT06263530||Patients < 60 years, stages I or II and 1 risk factor|Patients below 60 years in intermediate clinical stages I or II with at least one risk factor are treated with 2 cycles of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) escalated and 2 cycles of ABVD in PET-4 negative cases. Involved site radiotherapy of 30 Gy is indicated in PET-4 positive patients with intermediate stages after chemotherapy.
62176302|NCT06263530||Patients < 60 years, stages III or IV with MMT and/or EN disease|Patients in advanced stages III or IV and patients in stage IIB with massive mediastinal tumor and/or extranodal disease are treated with 4 or 6 cycles of BEACOPP escalated based on PET-2 negativity or positivity.
62176303|NCT06263530||Elderly patients ≥ 60 years and 1 risk factor|Elderly patients in intermediate stages are treated with 2 cycles of ABVD and 2 cycles of AVD without bleomycin and involved site radiotherapy of 30 Gy.
62741531|NCT05497531|EXPERIMENTAL|ctDNA collection from draining and peripheral veins|Patient with suspected primary hepatobiliary or pancreatic cancer undergoing a diagnostic work-up with a percutaneous or trans-jugular biopsy (standard of care) and will undergo a sampling of the cancer draining vein during their biopsy procedure with a collection of an additional 10mL of blood.
62741532|NCT03315793|EXPERIMENTAL|Duloxetine Hydrochloride|Duloxetine hydrochloride given orally.
62741533|NCT03315793|PLACEBO_COMPARATOR|Placebo|Placebo given orally.
62741534|NCT00249808|EXPERIMENTAL|Efalizumab|
62741535|NCT04075890|ACTIVE_COMPARATOR|Healthy subjects|
62176304|NCT06263530||Elderly patients ≥ 60 years, stages III or IV|Elderly patients in advanced stages are treated with 2 cycles of ABVD and 4 cycles of AVD without bleomycin
62176305|NCT06263530||Relapsed patients up to 65 years|The treatment for patients in relapse up to the age of 65 years is two cycles of platinum based salvage chemotherapy: cisplatin, cytarabine and dexamethasone (DHAP) or ifosfamide, carboplatin, etoposide (ICE) followed by high- dose chemotherapy and autologous stem cell transplantation (ASCT).
62176306|NCT05185492||Cardiogenic shock cohort|Primary diagnosis of Cardiogenic Shock at the time of index evaluation. The clinical and hemodynamic criteria used to diagnose Cardiogenic Shock will be those as defined in the Society for Cardiovascular Angiography and Interventions clinical expert consensus statement on the classification of cardiogenic shock.
62176307|NCT02570256|EXPERIMENTAL|Deficit-fields to reduce error|We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
62176308|NCT02570256|EXPERIMENTAL|Deficit-fields to expand range of motion|Amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
62176309|NCT02570256|EXPERIMENTAL|Deficit-fields to improve function|Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
62176310|NCT01351883|NO_INTERVENTION|Standard enteral nutrition supplement|regular standard enteral nutrition(SEN) was made by hospital for patient
62741536|NCT04075890|ACTIVE_COMPARATOR|OCD subjects|
62741537|NCT02835313|EXPERIMENTAL|FAST+SAM|Subjects participate in fast walking training in combination with a step activity monitoring program
62741538|NCT02835313|ACTIVE_COMPARATOR|FAST alone|Subjects participate in fast walking training
62741539|NCT02835313|ACTIVE_COMPARATOR|SAM alone|Subjects participate in a step activity monitoring program
62741540|NCT05923827|ACTIVE_COMPARATOR|Intervention Group|Omnipod 5 System with FreeStyle Libre 2 continuous glucose monitor
62741541|NCT05923827|NO_INTERVENTION|Control Group|Multiple daily injections of insulin with FreeStyle Libre 2 continuous glucose monitor
62741542|NCT02426567|EXPERIMENTAL|Healthy Adult Participants A|Participants who will get two interventional diets, for 7 days each, but allocated to start with Exclusive Enteral Nutrition (EEN)
62741543|NCT02426567|EXPERIMENTAL|Healthy Adult Participants B|Participants who will get two interventional diets, for 7 days each, but allocated to start with Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)
62741544|NCT00616018|EXPERIMENTAL|A|all subjects receive 4 g/day of acetaminophen for 10 consecutive days in this open-label study
62741545|NCT06287840||Children with Type-1 Diabetes|"* Females: 10-11 years old~* Males: 11-12 years old~* Diagnosed with type-1 diabetes for at least 6 months"
62741546|NCT06287840||Control|"* Females: 10-11 years old~* Males: 11-12 years old"
62741547|NCT02461459||Tuberous Sclerosis Complex|Tuberous Sclerosis Complex
62741548|NCT06230419||The cerebral trauma group|
62741549|NCT02920528|PLACEBO_COMPARATOR|Placebo|placebo controlled arm
62741550|NCT02920528|EXPERIMENTAL|very low dose ketamine|0.25 mg/kg of sub-dissociative ketamine as an experimental arm
62741551|NCT02920528|EXPERIMENTAL|low dose ketamine|0.50 mg/kg of sub-dissociative ketamine as an experimental arm
62741552|NCT06326008|EXPERIMENTAL|Arm-1|Participants receive donor-derived CD19 CAR therapy bridged Allo-HSCT and sequential donor-derived CD22 CAR therapy
62741553|NCT06096688||FAP without treatment with NSAIDs|Patients with the Hereditary Cancer Syndrome known as Familial Adenomatous Polyposis (FAP) undergoing upper or lower endoscopy/surgery without treatment with NSAIDs
62741554|NCT06096688||FAP on treatment with NSAIDs|Patients with the Hereditary Cancer Syndrome known as Familial Adenomatous Polyposis (FAP) undergoing upper or lower endoscopy/surgery on treatment with NSAIDs
62741555|NCT06096688||HNPCC without treatment with NSAIDs|Patients with the Hereditary Cancer Syndrome known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC) undergoing lower endoscopy/surgery without treatment with NSAIDs
62741556|NCT06096688||HNPCC on treatment with NSAIDs|Patients with the Hereditary Cancer Syndrome known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC) undergoing lower endoscopy/surgery on treatment with NSAIDs
62741557|NCT06096688||Other Hereditary Colorectal Cancer Syndromes|Other Hereditary Colorectal Cancer Syndromes undergoing lower endoscopy/surgery
62741558|NCT06096688||Average-risk population|Average-risk population undergoing lower endoscopy/surgery in the lower gastrointestinal tract.
62741559|NCT03658343|EXPERIMENTAL|T2* Imaging|Participants undergo T2\* MRI imaging before beginning their course of radiation therapy and then after completing radiation therapy, about 2 weeks before their surgery.
62741560|NCT05607511|EXPERIMENTAL|Active probiotics arm|The SIM03 (supplied by GenieBiome Limited and produced under Good Manufacturing Practice, GMP) contains a blend of naturally occurring food-grade Bifidobacterium strains (1 billion CFU in 1 sachet). Recruited subjects will receive one sachet of baby immunity formula SIM03 twice daily for 3 months.
62741561|NCT02553551|EXPERIMENTAL|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given."
62741562|NCT02553551|PLACEBO_COMPARATOR|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given."
62741563|NCT04167059|EXPERIMENTAL|Waitlist-Control Group|The 'waitlist control' group will receive the 12-week non-intervention period first, followed by 12 week intervention period.
62741564|NCT04167059|EXPERIMENTAL|Immediate Treatment|The 'immediate treatment' group will receive the 12-week intervention period first, followed by 12 week non-intervention period.
62741565|NCT00748618|OTHER|Standard vitamin treatment|10,000 I.U. of vitamin D3 weekly
62741566|NCT00748618|ACTIVE_COMPARATOR|50,000 I.U. of vitamin D3|50,000 I.U. of vitamin D3 weekly
62741567|NCT03940846||Maastro (Lung1)|Open source dataset available at TCIA.org. The cohort includes CT scans of 422 patients diagnosed with NSCLC.
62176311|NCT03535077||Suspicious Nevi undergoing biopsy|Subject with suspicious Nevi undergoing biopsy per SOC
62741568|NCT03940846||UCSF|A cohort of patients diagnosed with NSCLC at UCSF medical center. It includes CT scans of 165 patients.
62741569|NCT03940846||Radboud|A cohort of patients diagnosed with NSCLC at Radboud medical center. It includes CT scans of 255 patients.
62741570|NCT03940846||Stanford|Open source dataset available at TCIA.org. The cohort includes CT scans of 211 patients diagnosed with NSCLC.
62741571|NCT05398159|EXPERIMENTAL|treatment|3 bi-weekly treatments
62741572|NCT05612061|EXPERIMENTAL|Treatment Group|Receives Indigenous Recovery Planning (IRP) intervention, which includes 6 weekly group intervention sessions lasting about 2 hours each.
62741573|NCT05612061|NO_INTERVENTION|Waitlist Control Group|Participants in the waitlist control group do not receive the intervention until after treatment group completes the intervention. Outcomes will be compared between the 2 study arms at baseline and at follow-up, at which point the treatment group will have completed the intervention and the waitlist control group will have not yet been exposed to the intervention, thereby serving as the control group.
62741574|NCT05312749|EXPERIMENTAL|Experimental:|Experimental: will do progressive relaxation exercises
62741575|NCT05312749|NO_INTERVENTION|Control|won't do progressive relaxation exercises
62741576|NCT04551963|EXPERIMENTAL|Arm A: Zanubrutinib with or without Moderate CYP3A|"Cycle 1 (30 days): Participants were administered zanubrutinib at a dose of 320 mg once a day from Day 1 to Day 3; From Day 4 to Day 10, fluconazole was administered once a day at a dose of 400 mg with zanubrutinib at a reduced dose of 80 mg twice a day; On Day 11 and Day 12, zanubrutinib monotherapy was administered at 80 mg twice a day, followed by 320 mg once a day from Day 13 to Day 21; From Day 22 to Day 28, diltiazem was administered once a day at a dose of 180 mg with 80 mg zanubrutinib twice a day; On Day 29 and Day 30, zanubrutinib monotherapy was administered 80 mg twice a day.~Cycles 2 to 6 (28 days each cycle): Zanubrutinib 160 mg twice a day or 320 mg once a day."
62741577|NCT04551963|EXPERIMENTAL|Arm B: Zanubrutinib with or without Strong CYP3A|"Cycle 1 (30 days): Participants were administered zanubrutinib at a dose of 320 mg once a day from Day 1 to Day 3; From Day 4 to Day 10, voriconazole was administered twice a day at a dose of 200 mg (total daily dose of 400 mg) with zanubrutinib at a reduced dose of 80 mg once a day; On Day 11 and Day 12, zanubrutinib monotherapy was administered at 80 mg once a day, followed by 320 mg once a day from Day 13 to Day 21; From Day 22 to Day 28, clarithromycin was administered twice a day at a dose of 250 mg (total daily dose of 500 mg) with 80 mg zanubrutinib once a day; On Day 29 and Day 30, zanubrutinib monotherapy was administered 80 mg once a day.~Cycles 2 to 6 (28 days each cycle): Zanubrutinib 160 mg twice a day or 320 mg once a day."
62176312|NCT02456298|ACTIVE_COMPARATOR|Standard FA+FCT|Parents are coached via weekly telehealth visits to use Functional Analysis (FA) to assess problem behavior and Functional Communication Training (FCT) to treat the problem behavior identified.
62552695|NCT06582472||cohort 1 (cross sectional study)|Patients with a diagnosis of type 2 diabetes for longer than 20 years without clinical signs of retinopathy and other diabetic complications
62176313|NCT02456298|EXPERIMENTAL|Pragmatic FA+FCT|Parents are coached via weekly telehealth visits to use a brief, streamlined version of Functional Analysis (FA) to assess problem behavior and to follow that assessment with Functional Communication Training (FCT) to treat the problem behavior identified. The version of FCT used in the Pragmatic arm involves significantly less data scoring and graphing than the version used in the Standard arm.
62176314|NCT02146092|ACTIVE_COMPARATOR|Standard physiotherapy|Standard physiotherapy includes routine physiotherapy care as per current institutional standards. This consists of two daily visits by the physiotherapist. During the visits, the patient will be taught deep breathing and will be instructed to practice it 10 times every hour. They are also shown shoulder movements and lung expansion exercises. They will receive a sheet summarizing the exercises for future reference. The patient is discharged from physiotherapy when they are ambulatory, on room air, and able to clear their respiratory secretions independently, although they will be asked to continue the exercises on their own until 30 days from surgery.
62182421|NCT05423106|EXPERIMENTAL|Part 3: JNJ-64457744 or Placebo (Multiple Ascending Doses [MADs])|Participants will receive MADs of either JNJ-64457744 or matching placebo once weekly under fasted conditions as an oral formulation.
62182422|NCT01796223|EXPERIMENTAL|Feedback|Feedback system included in psychotherapy
62552696|NCT06582472||cohort 2 (cross sectional study)|Patients with a diagnosis of type 2 diabetes for longer than 20 years with clinical signs of retinopathy and other diabetic complications
62741578|NCT04934839|EXPERIMENTAL|Patients with osseointegrated prostheses|Patients with an osseointegrated prosthesis following a lower limb amputation
62741579|NCT04934839|EXPERIMENTAL|Patients with socket prostheses|Patients with a socket-mounted prosthesis following a lower limb amputation
62741580|NCT04874883|ACTIVE_COMPARATOR|Intervention Group|You will receive 6 grams of the symbiotic (association of fructooligosaccharides, prebiotics, and four probiotic strains: Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus Acidophilus, and Bifidobacterium bifidum) either enterally or twice a day.
62182423|NCT01796223|ACTIVE_COMPARATOR|control|Psychotherapy as usual
62552697|NCT04662814|EXPERIMENTAL|shock wave|shock wave for primary dysmenorrhea for study group along side to dietary modification
62552698|NCT04662814|ACTIVE_COMPARATOR|dietary modification|dietary modification for primary dysmenorrhea for control group
62552699|NCT01833650|NO_INTERVENTION|Standard care|This arm represents the current standard care in patients with thyroid cancer undergoing radioiodine.
62741581|NCT04874883|PLACEBO_COMPARATOR|Control Group|Will receive 6 grams of the maltodextrin placebo (carbohydrate easily absorbed and digested, not fermented by colonic bacteria and which does not interfere in the microbial ecology of the gastrointestinal tract or in the metabolism and function of the intestine), either enterally or orally in two sachets times a day
62741582|NCT06660875|ACTIVE_COMPARATOR|Serratus posterior superior intercostal plane block|With the patient in the prone position the skin is disinfected .Linear USG probe is placed on the spine of the scapula using an in-plane technique and moved medially. The 3rd rib is identified just on the medial scapular border. After visualizing the trapezius, rhomboid major, and serratus posterior superior muscles (from top to bottom) under USG guidance, a 22-G X 80-mm block needle is directed caudally and advanced until it contacted the rib. To confirm and obtain a plane between the serratus posterior superior and intercostal muscles, hydrodissection is performed using 2 ml of isotonic solution. After the needle site is confirmed, 30 ml of 0.25% bupivacaine is injected ; the local anesthetic spread is confirmed by USG.
62741583|NCT06660875|ACTIVE_COMPARATOR|Interscalene brachial plexus block and superficial cervical plexus block|"İBPB:While the patient is in the supine position, the ultrasound probe is placed on the cricoid cartilage and moved laterally to visualize the trachea, thyroid, carotid artery, internal jugular vein, and sternocleidomastoid muscle. The brachial plexus is identified by directing it posteriorly and laterally between the anterior and middle scalene muscles. After entering between the roots using the in-plane technique and confirming the location with a 2 ml isotonic sodium injection, 20 ml of 0.25% bupivacaine is injected.~SCPB:While the patient is in the supine position, the ultrasound probe is placed at the midpoint of the sternocleidomastoid (SCM) muscle. The cervical plexus is visualized deep to the posterior border of the SCM muscle. The needle is inserted deep to the SCM, directed towards the levator scapula. After confirming the location with a 2 ml isotonic sodium injection, 10 ml of 0.25% bupivacaine is injected."
62741584|NCT05103553|EXPERIMENTAL|Annual screening at outpatient clinic|After signing informed consent, patients with low risk for disease progression (in the low or intermediate risk group) wil be randomized into the intervention group (annual assessment at the outpatient clinic). Due to the nature of the intervention, the randomization will not be blinded, as this is not possible.
62741585|NCT05103553|NO_INTERVENTION|Annual screening at Care Pathway Systemic Sclerosis|After signing informed consent, patients with low risk for disease progression (in the low or intermediate risk group) will be randomized into the control group (annual assessment at the care pathway). Due to the nature of the intervention, the randomization will not be blinded, as this is not possible.
62741586|NCT04472650|EXPERIMENTAL|Dosing Sequence 1: Sitravatinib Free Base then Malate Salt|Sitravatinib free base capsule 120 mg on Day 1 in Period 1 then sitravatinib malate salt capsule 100 mg on Day 1 in Period 2, with a minimum washout period between dose administrations of 14 days
62741587|NCT04472650|EXPERIMENTAL|Dosing Sequence 2: Sitravatinib Malate Salt then Free Base|Sitravatinib malate salt capsule 100 mg on Day 1 in Period 1 then sitravatinib free base capsule 120 mg on Day 1 in Period 2, with a minimum washout period between dose administrations of 14 days
62741588|NCT03077438|EXPERIMENTAL|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve participants aged 2 to 9 years received a single dose of MenACYW Conjugate vaccine on Day 0.
62741589|NCT03077438|ACTIVE_COMPARATOR|Group 2: MENVEO® Vaccine|Healthy, meningococcal-vaccine naïve participants aged 2 to 9 years received a single dose of MENVEO® Conjugate vaccine on Day 0.
62741590|NCT04692649|EXPERIMENTAL|PPCS|Novel intervention
62741591|NCT04692649|ACTIVE_COMPARATOR|CBS|Cross arm stretch gave to individuals
62741592|NCT03397433|EXPERIMENTAL|Intervention|"In this arm, an Information Technology physician assist tool will be used to predict best available therapy for patients coming to the hospital with either pneumonia, cellulitis, intraabdominal infection, or complicated urinary tract infection.~Intervention: After review of the information technology recommendation by a board certified Infectious Disease physician, the recommendation will be discussed with the primary care physician and treatment implemented."
62741593|NCT03397433|NO_INTERVENTION|Control|In the two control hospitals there will be no use of the information technology tool for implementation of initial treatment (No intervention). No notes will be placed in the electronic health record and no contact as a result of this research will be made with the medical care team.
62741594|NCT02701283|EXPERIMENTAL|Medtronic Transcatheter Aortic Valve Replacement Systems|Treatment of Aortic Stenosis with the Medtronic CoreValve System Transcatheter Aortic Valve Implantation (TAVI) device or the Medtronic Corevalve Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
62741595|NCT02701283|ACTIVE_COMPARATOR|Surgical Aortic Valve Replacement (SAVR)|Treatment of Aortic Stenosis with commercial Surgical Aortic Valve Replacement (SAVR)
62741596|NCT00583752|EXPERIMENTAL|Androgen deprivation therapy (ADT) + Adenovirus/PSA Vaccine|On Arm B, subjects will be started on androgen deprivation therapy (ADT) 14 days prior to beginning the vaccinations.
62741597|NCT00583752|EXPERIMENTAL|Adenovirus/PSA Vaccine|On Arm A, subjects can begin the three vaccinations immediately.
62741598|NCT06659211|EXPERIMENTAL|Mentalisation-Based Therapy|MBT is conducted according to the treatment manual developed by Bateman \& Fonagy. Patients are offered weekly individual sessions with an MBT therapist for 12 months.
62741599|NCT06659211|ACTIVE_COMPARATOR|Treatment as usual|The TAU group will receive treatment as usual, which in mental health services might include medication, supportive counseling, short therapy, and other limited psychotherapeutic treatments such as DKT. There is no requirement for a frequency of visits for the usual psychiatric care of the TAU group, as this would not be realistic in the current service system.
62741600|NCT03350035|EXPERIMENTAL|IV Ganaxolone active|Ganaxolone IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.
62741601|NCT03350035|PLACEBO_COMPARATOR|IV Placebo, non-active|Placebo IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.
62741602|NCT02364427||Arterial stiffness|Arterial stiffness - Vicorder to measure pulse wave velocity
62741603|NCT05904496|EXPERIMENTAL|Phase 1a: Dose Escalation Part A: BGB-30813 Monotherapy|
62741604|NCT05904496|EXPERIMENTAL|Phase 1a: Dose Escalation Part B: BGB-30813 + Tislelizumab|
62741605|NCT05904496|EXPERIMENTAL|Phase 1b: Dose Expansion BGB-30813 in Combination with Tislelizumab|
62741606|NCT06312410|EXPERIMENTAL|VIA Family 2.0|"In the intervention all child-involving elements are adapted to the specific age groups of the children, but everything is built on the same basic multidisciplinary, holistic and cross-sectional team model.~Every family will be affiliated to a case manager, who will coordinate all activities and appointments and be available throughout the intervention period of two years. A range of intervention elements will be offered to the family, depending on age of the child(ren), the family's needs and will always rely on their motivation:~* Case-management supporting to reach good family functioning~* Family-based psychoeducation~* Parents' and children's groups with integrated peer-support~* Parenting support and training~* Mapping and nurturing of resources in the social network and social counseling~* Early assessment of children's possible mental health problems~* All elements will be adapted to the age of the children (details available upon request)"
62176315|NCT02146092|EXPERIMENTAL|Incentive Spirometry|"Patients in the Incentive Spirometry arm will receive standard physiotherapy care in addition to training and use of an incentive spirometer. The physiotherapy care includes routine care as per current institutional standards.~They will also receive an incentive spirometer on the first postoperative day and will be taught how to use it with an accompanying instructional sheet for later reference. Teaching will emphasize slow deep breathing, sustained vacuum pressure, and gradual increase in difficulty. Patients will be instructed to use the spirometer 10 times every hour until 30 days after surgery."
62176316|NCT02778334|NO_INTERVENTION|patients who return home|
62176317|NCT02778334|EXPERIMENTAL|patients who continued hospitalization in rehabilitation|
62176318|NCT04612699|EXPERIMENTAL|Jaktinib 50mg Bid|Jaktinib 50mg Bid+ Placebo 50mg Bid+ Placebo 75mg Bid
62741607|NCT06312410|ACTIVE_COMPARATOR|Treatment as usual (TAU)|"TAU varies to some extent in the two regions, but common is that it consists of 2-3 family consultations (family sessions) with the presence of parents and all children above the age of six years.~These consultations will be managed by the Center for Relatives in the North Denmark Region and by the clinical 'child key persons' , who are staff with a special training in children and family impact in all departments of mental health services in the Capital Region.~The child is also referred to participate in a psychoeducational group for same aged children. Children can participate in a group with peers, who have a parent with a mental illness as well. These groups are run by two therapists with many years of experience working with groups like this for different age groups. Participation in groups like this is voluntary, and not all children continue in a group after the family consultations."
62741608|NCT05142917|EXPERIMENTAL|fNIRS based hand motor area real stimulation|Real stimulation is applied to functional brain image-based hand function area (20 minutes) and then hand motor task (20 minutes).
62741609|NCT05142917|ACTIVE_COMPARATOR|Traditional hand motor area real stimulation|Real stimulation is applied to the traditional hand function area (20 minutes) and then hand motor task (20 minutes).
62741610|NCT05142917|SHAM_COMPARATOR|Traditional hand motor area sham stimulation|Sham stimulation is applied to the traditional hand function area (20 minutes) and then hand motor task (20 minutes).
62741611|NCT02912494|EXPERIMENTAL|JR-131|
62176319|NCT04612699|EXPERIMENTAL|Jaktinib 75mg Bid|Jaktinib 75mg Bid+ Placebo 50mg\*2 Bid
62176320|NCT04612699|EXPERIMENTAL|Jaktinib 100mg Bid|Jaktinib 50mg\*2 Bid+ Placebo 75mg Bid
62176321|NCT04612699|PLACEBO_COMPARATOR|Placebo|Placebo 50mg\*2 Bid+ Placebo 75mg Bid
62364892|NCT06242093|ACTIVE_COMPARATOR|GROUP B Pelvic floor muscle training (PFMT) and conservative treatment.|"Pelvic floor muscle training (PFMT) and conservative treatment.~* Group B will receive (PFMT) with conservative treatment. The PMFT group will be educated to do each exercise in 3-4 set with 15-20 repetitions and a 60-second relax between each set.~* Time: 3-4 Times/WEEK for 8 weeks"
62364893|NCT06338033||VFA/BMI<5.49|
62176322|NCT00700518|PLACEBO_COMPARATOR|1.|placebo cream applied to 2 adjacent fingers on non-dominant hand one time
62176323|NCT00700518|ACTIVE_COMPARATOR|2|0.6mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand
62741612|NCT02912494|ACTIVE_COMPARATOR|Darbepoetin alfa|
62741613|NCT02446678|ACTIVE_COMPARATOR|Capsule group: PillCam ESO2|Perform capsule endoscopy and esophagogastroduodenoscopy will be preformed within 24 hours after capsule ingestion
62741614|NCT02446678|NO_INTERVENTION|Standard group|Perform standard esophagogastroduodenoscopy
62176324|NCT00700518|ACTIVE_COMPARATOR|3|1.2mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
62176325|NCT00700518|ACTIVE_COMPARATOR|4|1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers on non-dominant hand one time
62176326|NCT00700518|ACTIVE_COMPARATOR|5|2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
62176327|NCT03116672|EXPERIMENTAL|ketorolac 10 mg|Administration of one dose Ketorolac 10 mg 15 minutes before treatment
62176328|NCT03116672|EXPERIMENTAL|Diclofenac|Administration of one dose Diclofenac 15 minutes before treatment
62176329|NCT03116672|EXPERIMENTAL|Placebo oral capsule|Administration of Placebo capsule 15 minutes before treatment
62176330|NCT02445183||Lung Cancer|Confirmed diagnosis of lung cancer
62176331|NCT02445183||No Lung Cancer Controls|Unconfirmed lung cancer diagnosis, false positive
62176332|NCT04231747|EXPERIMENTAL|CC-97540 monotherapy|Subjects will be assigned to receive CC-97540 followed by 3 consecutive doses of lymphodepleting chemotherapy (fludarabine IV (30 mg/m2/day) and cyclophosphamide IV (300 mg/m2/day).
62176333|NCT02846597|NO_INTERVENTION|Control|Infants in this group will not receive sustained lung inflation in the delivery room and will be put immediately on CPAP at a pressure of 5 cm H2O.
62176334|NCT02846597|ACTIVE_COMPARATOR|High pressure for long duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 20 cm H2O for a duration of 20 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
62364894|NCT06338033||VFA/BMI≥5.49|
62364895|NCT03250624|EXPERIMENTAL|CD5024 0.3% cream|
62364896|NCT03250624|PLACEBO_COMPARATOR|Placebo|
62176335|NCT02846597|ACTIVE_COMPARATOR|High pressure for short duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 20 cm H2O for a duration of 10 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
62176336|NCT02846597|ACTIVE_COMPARATOR|Low pressure for long duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 15 cm H2O for a duration of 20 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
62176337|NCT02846597|ACTIVE_COMPARATOR|Low pressure for short duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 15 cm H2O for a duration of 10 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
62176338|NCT02897999|EXPERIMENTAL|SAD Cohort 1|Single dose of 0.05 mL QBKPN or Placebo
62176339|NCT02897999|EXPERIMENTAL|SAD Cohort 2|Single dose of 0.10 mL QBKPN or Placebo
62176340|NCT02897999|EXPERIMENTAL|SAD Cohort 3|Single dose of 0.20 mL QBKPN or Placebo
62176341|NCT02897999|EXPERIMENTAL|SAD Cohort 4|Single dose of 0.40 mL QBKPN or Placebo
62176342|NCT02897999|EXPERIMENTAL|SAD Cohort 5|Single dose of 0.80 mL QBKPN or Placebo
62176343|NCT02897999|EXPERIMENTAL|SAD Cohort 6|Single dose of 1.2 mL QBKPN or Placebo
62176344|NCT02897999|EXPERIMENTAL|MAD Cohort 1|5 doses of QBKPN or Placebo administered every other day (using one of the dose from the SAD Cohort)
62176345|NCT02897999|EXPERIMENTAL|MAD Cohort 2|5 doses of QBKPN or Placebo administered every other day (using one of the dose from the SAD Cohort)
62176346|NCT02897999|EXPERIMENTAL|MAD Cohort 3|5 doses of QBKPN or Placebo administered every day (using one of the dose from the SAD Cohort)
62176347|NCT02897999|EXPERIMENTAL|MAD Cohort 4|5 doses of QBKPN or Placebo administered every day (using one of the dose from the SAD Cohort)
62176348|NCT02881021|EXPERIMENTAL|Rehabilitation program and kinesiotaping.|"Each patient will attend 10 physiotherapy sessions over six. Patients from the Experimental group (KT group) will receive the same standardized rehabilitation program as control group (No-KT group) including manual therapy, movement training, stretching, muscular strengthening, and patient education.~Only KT-group (experimental) will receive therapeutic KT added to the rehabilitation program.~Kinesio® Tex Classic will be applied using a combination of techniques designed for RCTe and underlying symptoms following the instructions and principles described by Kase et al (2003).~Kinesiotaping strips will be weaned gradually, according to the individual improvements of deficits evaluated weekly by the physiotherapist treating."
62176349|NCT02881021|ACTIVE_COMPARATOR|Rehabilitation program.|"Each patient will attend 10 physiotherapy sessions over six. Patients allocated at the control group (No-KT group) will receive only the rehabilitation program, including manual therapy, movement training, stretching, muscular strengthening, and patient education.~The rehabilitation program will be exactly the same applied to the experimental group (KT group)."
62176350|NCT03416621|ACTIVE_COMPARATOR|Experimental: Cognitive behavioral cessation counseling|Standard smoking cessation plus support text messages
62176351|NCT03416621|PLACEBO_COMPARATOR|Placebo Comparator: Counseling and placebo drug intervention|enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo
62176352|NCT03416621|EXPERIMENTAL|Active Comparator: Counseling and active drug intervention|enhanced cue exposure treatment (lab-based + interactive SMS texting) + active DCS. In addition to an in-person screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
62176353|NCT02132078||Lung transplant recipients with uncomplicated diverticulitis|Retrospective data analysis of treatment, outcome and recurrency-rate
62176354|NCT02132078||Lung transplant recipients with complicated diverticulitis|Retrospective data analysis of treatment, outcome and recurrency-rate
62176355|NCT01130714|EXPERIMENTAL|Resistance training|Group assigned to complete resistance training during duration of chemotherapy.
62176356|NCT01130714|NO_INTERVENTION|Control|Usual care.
62176357|NCT04015596|EXPERIMENTAL|Intervention|Participants receive Naproxen Sodium.
62176358|NCT04015596|PLACEBO_COMPARATOR|Placebo|Participants receive placebo.
62176359|NCT01989923|ACTIVE_COMPARATOR|Nicotine replacement therapy|"Women in this arm of the study will receive 24-hour Nicotine Patches - either 21 mg patches (for 1 pack per day smokers), or 14 mg patches (for 1/2 pack per day smokers) smokers). Patients will use one patch per day for 6 weeks for a total of 42 patches. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.~Women will also receive nicotine gum or lozenges (subject choice)- these will be 2 mg pieces of nicotine gum or lozenge (approximately 210 pieces). This will account for using 8-10 per day at the beginning of the study and tapering to 2-3 pieces per day by the end of the study."
62182424|NCT03217461|EXPERIMENTAL|Corneal epithelial autograft|Corneal dermoid tumor resection combined with femtosecond laser assisted corneal epithelial autograft
62391459|NCT00876902|EXPERIMENTAL|1|Active Group: (18 subjects) YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient PRIOR to arterial reperfusion of the liver. One extra IV dose of 1 mg/kg will be given at the end of the procedure only to patients that have experienced an intraoperative blood loss of greater than 10 units.
62552700|NCT01833650|EXPERIMENTAL|Candy plus thymus honey mouthwash 12|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 12 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
62741615|NCT06555016|EXPERIMENTAL|High intensity reactive balance training|Training sessions will be overseen by a physiotherapist and will last for 1 hour over 4 consecutive days.Participants assigned to the RBT groups will experience 36 multi-directional (left-, right-, and forward-fall) perturbations in each training session, presented in an unpredictable sequence. Balance perturbations will be provided using a custom moving platform. Participants assigned to high-intensity RBT will experience perturbations at 150% of the multi-step threshold; for example, for a multi-step threshold of 2 m/s\^2 the high intensity will be 3 m/s\^2.
62176360|NCT01989923|ACTIVE_COMPARATOR|Electronic Cigarettes|"Women in this arm of the study will receive one Blu Cig Electronic Nicotine Delivery Device (E-cigarette) along with 2 electronic cigarette batteries, 1 wall charger and 1 USB charger, cartridges/refills in menthol or regular (patient choice). The number of cartridges is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation."
62176361|NCT02118038||HELPMOM1|corresponds to the cohort of patients in whom psychological state will be studied in the immediate waning PPH then during a 6 months through appropriate questionnaires
62741616|NCT06555016|ACTIVE_COMPARATOR|Moderate intensity reactive balance training|Training sessions will be overseen by a physiotherapist and will last for 1 hour over 4 consecutive days.Participants assigned to the RBT groups will experience 36 multi-directional (left-, right-, and forward-fall) perturbations in each training session, presented in an unpredictable sequence. Balance perturbations will be provided using a custom moving platform. Participants assigned to the moderate-intensity RBT group will experience perturbations at the multi-step threshold.
62741617|NCT06555016|SHAM_COMPARATOR|Walking control group|Training sessions will be overseen by a physiotherapist and will last for 1 hour over 4 consecutive days. Participants in the walking control group will complete 36 unperturbed walking trials on the moving platform in each training session.
62176362|NCT02118038||HELPMOM2|corresponds to the cohort of patients enrolled in group HELPMOM1 who experienced a cardiac abnormality in the initial management and will therefore be included in a cardiac monitoring
62176363|NCT04961983|EXPERIMENTAL|Intervention group|Tour guides who will receive a comprehensive travel health education model.
62176364|NCT04961983|NO_INTERVENTION|Control group|Tour guides who will receive no intervention.
62176365|NCT02840071|EXPERIMENTAL|Intervention|Psychological therapy.
62176366|NCT05459025|EXPERIMENTAL|Aromatherapy yoga|Each intervention session lasted 90 min, between 6 p.m. and 7:30 p.m. The course was held in a yoga classroom once a week, in an area of 30 m × 35 m. Furthermore, the total intervention period lasted for 12 weeks.
62741618|NCT05913050|EXPERIMENTAL|Therapeutic exercise plus education|The treatment will consist of a progressive resistance exercise program along with education.
62176367|NCT05459025|ACTIVE_COMPARATOR|Yoga|Each intervention session lasted 90 min, between 6 p.m. and 7:30 p.m. The course was held in a yoga classroom once a week, in an area of 30 m × 35 m. Furthermore, the total intervention period lasted for 12 weeks.
62176368|NCT02582034|ACTIVE_COMPARATOR|Standard dosimetry|Standard Internal Radiation Therapy : Dose of radiation delivered to the tumoral volume is fixed : 120 Gray (GY)
62176369|NCT02582034|EXPERIMENTAL|Optimized dosimetry|Optimized Internal Radiation Therapy : Dose of radiation absorbed by the tumor is \> 205 GY, if possible 250 or 300 Gy.
62176370|NCT00591604|EXPERIMENTAL|1|Vitamin D administration
62176371|NCT03223714|EXPERIMENTAL|Conbercept|Conbercept
62741619|NCT04728360|EXPERIMENTAL|BAT2206|"Patients who weigh ≤ 100 kg: BAT2206 45 mg (1 injection of 45 mg/0.5 mL) by SC injection via PFS.~Patients who weigh \> 100 kg: EU-sourced Stelara 90 mg (2 injections of 45 mg/0.5 mL each) by SC injection via PFS."
62741620|NCT04728360|ACTIVE_COMPARATOR|Stelara (EU-sourced)|"Patients who weigh ≤ 100 kg: EU-sourced Stelara 45 mg (1 injection of 45 mg/0.5 mL) by SC injection via PFS.~Patients who weigh \> 100 kg: EU-sourced Stelara 90 mg (2 injections of 45 mg/0.5 mL each) by SC injection via PFS."
62741621|NCT04969094|EXPERIMENTAL|NMES + MMBI|Neuromuscular electrical stimulation applied to hip abductors along with participation in a multi-modality balance intervention
62741622|NCT04969094|ACTIVE_COMPARATOR|MMBI|Participation in a multi-modality balance intervention
62741623|NCT01659996|EXPERIMENTAL|Menactra Vaccine Group|Participants will receive Meningococcal polysaccharide diphtheria toxoid conjugate (Menactra®) at 9 months of age and Menactra® at 15 to 18 months of age.
62741624|NCT01659996|EXPERIMENTAL|Menactra and Pentacel Vaccine Group|Participants will receive Meningococcal polysaccharide diphtheria toxoid conjugate (Menactra®) at 9 months of age and Menactra® + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed (Pentacel®) concomitantly at 15 to 18 months of age.
62741625|NCT01659996|ACTIVE_COMPARATOR|Pentacel Vaccine Group|Participants will receive only Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Pentacel®) at 15 to 18 months of age.
62741626|NCT06660940|EXPERIMENTAL|Keluoxin Capsules|Patients will take Keluoxin Capsules and renin-angiotensin-aldosterone system inhibitors (RAASIs).
62741627|NCT06660940|PLACEBO_COMPARATOR|Placebo|Patients will take placebo and RAASIs.
62176372|NCT03223714|SHAM_COMPARATOR|Conbercept or sham|Conbercept or sham
62176373|NCT03806413||Open heart surgery|The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
62741628|NCT03755674|EXPERIMENTAL|CHRONOTYPE-ADJUSTED DIET|Patients that undergo a chronotype adjusted diet
62741629|NCT03755674|NO_INTERVENTION|CONTROL|Patients following a traditional or conventional hypocaloric diet
62176374|NCT00437619|EXPERIMENTAL|1|
62176375|NCT03074045|EXPERIMENTAL|Test|LCS16 (Low-dose LNG IUS)
62176376|NCT03074045|ACTIVE_COMPARATOR|Reference|COC (Yarina)
62176377|NCT00726388|EXPERIMENTAL|A|IV administration of multiple doses of DIC075V (intravenous diclofenac sodium) over multiple days
62176378|NCT02760472|ACTIVE_COMPARATOR|Clinoleic|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
62176379|NCT02760472|EXPERIMENTAL|SMOFlipid|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
62182425|NCT03217461|ACTIVE_COMPARATOR|Limbal autograft|Corneal dermoid tumor resection combined with femtosecond laser assisted limbal autograft
62182426|NCT04189510|EXPERIMENTAL|Artificial Pancreas (AP) Insulin Group|
62176380|NCT05568199||Group 1|"Patients will make one visit to the M Health Clinical Research Unit (CRU) after overnight withdrawal of PD medications (still on-DBS) and undergo motor and cognitive assessments in the following three conditions:~1. clinically-optimized stimulation~2. model-based stimulation directed towards motor subregions of STN and GPi~3. model-based stimulation directed towards associative/limbic subregions of STN/GPi~Randomized to start with condition1 assessment"
62176381|NCT05568199||Group 2|"Patients will make one visit to the M Health Clinical Research Unit (CRU) after overnight withdrawal of PD medications (still on-DBS) and undergo motor and cognitive assessments in the following three conditions:~1. clinically-optimized stimulation~2. model-based stimulation directed towards motor subregions of STN and GPi~3. model-based stimulation directed towards associative/limbic subregions of STN/GPi~Randomized to start with condition 2 assessment"
62176382|NCT05568199||Group 3|"Patients will make one visit to the M Health Clinical Research Unit (CRU) after overnight withdrawal of PD medications (still on-DBS) and undergo motor and cognitive assessments in the following three conditions:~1. clinically-optimized stimulation~2. model-based stimulation directed towards motor subregions of STN and GPi~3. model-based stimulation directed towards associative/limbic subregions of STN/GPi~Randomized to start with condition 3 assessment"
62741630|NCT04475523|EXPERIMENTAL|CI-8993 dose escalation|Patients will be administered CI-8993 intravenously at a planned infusion rate over 2 hours at planned step-doses and subsequent full doses. The planned schedule of administration is every 2 weeks. The MTD of full doses of CI-8993 will be determined based on the occurrence of DLTs 28 days from the first full dose. Eligible patients may receive CI-8993 at the dose and schedule, according to their assigned cohorts, until disease progression or unacceptable toxicity.
62741631|NCT00504361||1: Lung Disease|Individuals with at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) patients with diseases of organs with known association with lung disease; and (7) individuals suspected of history of lung diseased based on history and/or physical examination
62176383|NCT02517125|EXPERIMENTAL|Patients with head and neck cancer|
62176384|NCT04189341|ACTIVE_COMPARATOR|Group E = ESPB group|In group E, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).
62176385|NCT04189341|ACTIVE_COMPARATOR|Group T = mTLIP group|In group T, mTLIP block will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).
62176386|NCT04189341|NO_INTERVENTION|Group C = Control group|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
62176387|NCT01503437|EXPERIMENTAL|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
62176388|NCT01503437|ACTIVE_COMPARATOR|Zyprexa Zydis 5 mg Tablets|Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK
62741632|NCT00504361||2: Normal Control|Individuals without a history of lung disease.
62741633|NCT06659757|EXPERIMENTAL|Part A: Single Ascending Dose (SAD)|Healthy volunteers - Up to 6 dose levels of KIT2014 will be evaluated in Part A. Dose levels will be investigated in sequential cohorts (A1 to A6) of 8 healthy participants per cohort (ratio 3:1 active:placebo).
62741634|NCT06659757|EXPERIMENTAL|Part B: Multiple Ascending Dose (MAD)|Healthy volunteers - Up to 3 dose levels of KIT2014 will be evaluated in Part B. Dose levels will be investigated in sequential cohorts (B1 to B3) of 8 healthy participants per cohort (ratio 3:1 active:placebo).
62176389|NCT05996497|OTHER|Auditory Rhythmic at 30 Hz then GraphoGame|Training 1 with Auditory Rhythmic at 30 Hz (6 weeks) then Training 2 with GraphoGame (6 weeks)
62176390|NCT05996497|OTHER|GraphoGame then Rhythmic Auditory at 30 Hz|Training 1 with GraphoGame (6 weeks) then Training 2 with Auditory Rhythmic at 30 Hz (6 weeks)
62176391|NCT05996497|OTHER|Auditory Rhythmic at low frequencies then GraphoGame|Training 1 with Auditory Rhythmic at low frequencies (6 weeks) then Training 2 with GraphoGame (6 weeks)
62176392|NCT05996497|OTHER|GraphoGame then Auditory Low Frequency Rhythmic|Training 1 with GraphoGame (6 weeks) then Training 2 with Auditory Rhythmic at Low Frequency Rhythmic (6 weeks)
62741635|NCT01092780|EXPERIMENTAL|MK-7288 10mg/Pbo/MK-7288 20mg/Modafinil|Participants received single doses of study drug in the following order: MK-7288 10 mg in Treatment Period 1, Placebo (Pbo) in Treatment Period 2, MK-7288 20 mg in Treatment Period 3 and Modafinil 200 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
62741636|NCT01092780|EXPERIMENTAL|MK-7288 20mg/MK-7288 10mg/Modafinil/Pbo|Participants received single doses of study drug in the following order: MK-7288 20 mg in Treatment Period 1, MK-7288 10 mg in Treatment Period 2, Modafinil 200 mg in Treatment Period 3 and Placebo in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
62741637|NCT01092780|EXPERIMENTAL|Modafinil/MK-7288 20mg/Pbo/MK-7288 10mg|Participants received single doses of study drug in the following order: Modafinil 200 mg in Treatment Period 1, MK-7288 20 mg in Treatment Period 2, Placebo in Treatment Period 3 and MK-7288 10 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
62741638|NCT01092780|EXPERIMENTAL|Pbo/Modafinil/MK-7288 10 mg/MK-7288 20mg|Participants received single doses of study drug in the following order: Placebo in Treatment Period 1, Modafinil 200 mg in Treatment Period 2, MK-7288 10 mg in Treatment Period 3 and MK-7288 20 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
62741639|NCT03269916|EXPERIMENTAL|IBD patients|IBD patients, 17-40 years old, female
62741640|NCT03269916|OTHER|healthy control|17-40 years old , female, without any gynecological disease
62176393|NCT02134613|EXPERIMENTAL|anti-TNF-alpha scintigraphy|99mTc-anti-TNF-alpha Scintigraphy will be compared with MRI results, analysed and discussed by physicians who are in charge of the patients.
62176394|NCT01363336||Group 1|
62176395|NCT01827852||Cohort|
62176396|NCT00413075|EXPERIMENTAL|oral belinostat|
62176397|NCT05823805|EXPERIMENTAL|Community Health Worker + Quality Improvement reports|Family physicians with ten or more patients living with schizophrenia and/or bipolar disorder will work with a community health worker who will assist them in reviewing their individualized reports, which presents data on patient's preventive health care status and engagement in care.
62176398|NCT05823805|NO_INTERVENTION|Quality Improvement dashboard|Family physicians with ten or more patients living with schizophrenia and/or bipolar disorder will have access to an individualized reports, which presents data on patient's preventive health care status and engagement in care.
62176399|NCT05764577||Surgical intervention|Participants who underwent secondary DIEP flap breast reconstruction
62176400|NCT05417464|OTHER|Management of conductive disorders after TAVR|Evaluation of efficacy and safety of a flowchart for screening, monitoring and management of conductive disorders after TAVR
62176401|NCT01179906|EXPERIMENTAL|Lifestyle intervention-exercise & diet|Subjects trained for 48 weeks with a personal trainer
62176402|NCT04528290|EXPERIMENTAL|Group A (reference): Current ozanimod capsule formulation|Single oral dose of ozanimod 0.92 mg
62176403|NCT04528290|EXPERIMENTAL|Group B (test): Ozanimod granule formulation|Single oral dose of ozanimod 0.92 mg using Sprinkle capsule. Ozanimod Sprinkle Capsule will be opened, and the entire contents sprinkled onto a teaspoon (5 mL) of applesauce.
62176404|NCT05848453|EXPERIMENTAL|Cohort 1|1 mg/mL (0.1%) BAC6027 formulation; placebo
62176405|NCT05848453|EXPERIMENTAL|Cohort 2|5 mg/mL (0.5%) BAC6027 formulation; placebo
62176406|NCT05848453|EXPERIMENTAL|Cohort 3|10 mg/mL (1.0%) BAC6027 formulation; placebo
62176407|NCT05205252|ACTIVE_COMPARATOR|Arm 1-Tazemetostat plus tafasitamab-cxix (CD19 Ab)/lenalidomide|"Participants with R/R, diffuse large B-cell lymphoma (DLBCL) will receive tazemetostat, tafasitamab, and lenalidomide for approximately 1 year.~After approximately 1 year, participants will receive tazemetostat and tafasitamab."
62176408|NCT05205252|ACTIVE_COMPARATOR|Arm 2-Tazemetostat plus lenalidomide|Participants with R/R DLBCL will receive tazemetostat and lenalidomide for approximately 1 year. After approximately 1 year, participants will receive tazemetostat alone.
62176409|NCT05205252|ACTIVE_COMPARATOR|Arm 3- Tazemetostat plus BTKi (acalabrutinib)|Participants with R/R mantle cell lymphomawill (MCL) will receive tazemetostat and acalabrutinib for the entire study.
62176410|NCT05205252|ACTIVE_COMPARATOR|Arm 4-Tazemetostat plus CD38 mAbPD (daratumumab/pomalidomide/dexamethasone)|"Participants with R/R multiple myelomawill (MM) will receive tazemetostat, daratumumab, pomalidomide, and dexamethasone for the entire study.~Daratumumab may be given intravenously or subcutaneously during this study."
62176411|NCT05205252|ACTIVE_COMPARATOR|Arm 5- Tazemetostat plus CD20/CD3 BsAb (mosunetuzumab)|Participants with R/R follicular lymphoma will receive tazemetostat and mosunetuzumab for approximately 1 year. After approximately 1 year, participants will receive tazemetostat alone.
62176412|NCT02845375|PLACEBO_COMPARATOR|PLACEBO|Placebo (normal saline) will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
62176413|NCT02845375|OTHER|NEOSTIGMINE|intravenous neostigmine will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
62176414|NCT02845375|EXPERIMENTAL|SUGAMMADEX|intravenous sugammade will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
62176415|NCT01136798|PLACEBO_COMPARATOR|Usual T2 DM med regimen|Subjects will continue on Type 2 DM therapy but will add placebo injected subcutaneously twice daily to their regimen for a total of 6 weeks.
62176416|NCT01136798|EXPERIMENTAL|Usual T2 DM med regimen plus Exenatide|Subjects will continue on Type 2 DM therapy but will add injectable exenatide to their regimen There will be twice daily treatment with subcutaneous injections of 5 µg of Exenatide for 2 weeks followed by 4 weeks of treatment with twice daily subcutaneous injections of 10 µg of Exenatide.
62176417|NCT01307917|EXPERIMENTAL|healthy controls high flavonoid|20 healthy adolescents (12-21 years old) receiving the flavonoid-rich capsule/supplement
62176418|NCT01307917|ACTIVE_COMPARATOR|healthy controls low flavonoid|20 healthy adolescents (12-21 years old) receiving the placebo
62176419|NCT01307917|EXPERIMENTAL|T1DM or T2DM high flavonoid|20 adolescents (12-21 years old) with Type 1 diabetes mellitus or Type 2 diabetes mellitus receiving the capsule/supplement
62176420|NCT01307917|ACTIVE_COMPARATOR|T1DM or T2DM low flavonoid|20 adolescents (12-21 years old) with Type 1 diabetes mellitus or Type 2 diabetes mellitus receiving the placebo
62176421|NCT03618212||Myeloma patients|
62176422|NCT03962478|EXPERIMENTAL|Stent with high-intensity focused ultrasound ablation|Patients undergo stent insertion with high-intensity focused ultrasound ablation on day 1.
62176423|NCT03962478|ACTIVE_COMPARATOR|Stent without high-intensity focused ultrasound ablation|Patients undergo stent insertion on day 1.
62176424|NCT03614221|EXPERIMENTAL|Lindioil|Lindioil ointment is applied twice daily for 6 weeks, followed by a washout period of 4 days to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA. If relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA is achieved, the patient is using Protopic ointment 0.1% twice daily for another 6 weeks. If the criteria for entering the 2nd treatment are not achievable after 8-week of ceasing 1st treatment, the subject will be followed up for another 6 weeks to the end of the study
62741641|NCT03145064|EXPERIMENTAL|Zanubrutinib|Participants received zanubrutinib BID.
62741642|NCT03892057|EXPERIMENTAL|Internet-based Positive Psychological Intervention|The investigator's culturally-tailored internet-based Positive Psychology (PP) Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
62182427|NCT04189510|ACTIVE_COMPARATOR|Multiple Daily Injections (MDI) Insulin Group|
62182428|NCT01749163|EXPERIMENTAL|Control|Saline will be coninfused during the pancreatic clamp
62176425|NCT03614221|ACTIVE_COMPARATOR|Protopic|Protopic ointment 0.1% is applied twice daily for 6 weeks, followed by a washout period of 4 days to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA. If relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA is achieved, the patient is using Lindioil ointment twice daily for another 6 weeks. If the criteria for entering the 2nd treatment are not achievable after 8-week of ceasing 1st treatment, the subject will be followed up for another 6 weeks to the end of the study
62176426|NCT05798247||Patients with cutaneous diphteria|The study group consists of all the patients suffering from cutaneous diphtheria in metropolitan France and for which microbiological data were registered by the National Reference Center fo corynebacteria of the diphteriae complex between 2018 and 2022.
62176427|NCT04885634|ACTIVE_COMPARATOR|Intervention group|Semaglutide 2.4 mg subcutaneously once weekly in addition to standard AF care with lifestyle and risk factor management focusing on cardiovascular risk reduction
62176428|NCT04885634|PLACEBO_COMPARATOR|Control group|Placebo treatment with volume-matched placebo s.c. once weekly in addition to standard AF care with lifestyle and risk factor management focusing on cardiovascular risk reduction
62176429|NCT03904277||No PFO|Research subjects who present no evidence of PFO - IE no appearance of saline contrast microbubbles within 3 cardiac cycles
62176430|NCT03904277||Small PFO|Research subjects who present evidence of having a small PFO or ASD - IE appearance of 1-11 saline contrast microbubbles within 3 cardiac cycles
62176431|NCT03904277||Large PFO|Research subjects who present evidence of having a large PFO - IE appearance of 12+ saline contrast microbubbles within 3 cardiac cycles.
62176432|NCT01742650|ACTIVE_COMPARATOR|Screw fixation|3,5mm fully threaded cortical screw transfixation of syndesmosis
62176433|NCT01742650|ACTIVE_COMPARATOR|TightRope|TightRope transfixation of syndesmosis
62176434|NCT05414201|EXPERIMENTAL|Adalimumab|Participants will receive a loading dose of Adalimumab 80mg SC at Baseline followed a week later by a dose of Adalimumab 40mg SC every other week.
62176435|NCT03653377||Patients with self-administered questionnaire|
62176436|NCT04785586|EXPERIMENTAL|Individual|"HWC protocol + three individual face-to-face sessions via video"
62176437|NCT04785586|EXPERIMENTAL|Group|"HWC protocol + three face-to-face group sessions via video"
62176438|NCT04785586|ACTIVE_COMPARATOR|Control|Standard HWC protocol
62176439|NCT02078947|EXPERIMENTAL|High Intensity Exercise|Patients perform interval- type endurance exercise at high intensity
62176440|NCT02078947|ACTIVE_COMPARATOR|Moderate Continuous Exercise|Patients perform endurance exercise at moderate intensity
62741643|NCT03892057|NO_INTERVENTION|Attention Control Group|Participants will complete computerized surveys to document the frequency of positive and negative emotions experienced in daily life. The attention control group will be given the option to access our positive psychological intervention and associated content via the web at the conclusion of the 12-week data collection phase.
62176441|NCT02078947|SHAM_COMPARATOR|Usual Care|Patients receive advice on being physically active as well as usual care
62176442|NCT03535480|EXPERIMENTAL|G-CSF|Only receives G-CSF subcutaneously five days for stem cell mobilization
62176443|NCT03535480|EXPERIMENTAL|ASCOT|Receives G-CSF subcutaneously five days and then plasmapheresis for hematopoietic stem cell collection and catheterism for infusion in ovarian artery
62176444|NCT03135613|EXPERIMENTAL|Normal|Participants of this group are as controls.
62176445|NCT03135613|EXPERIMENTAL|MF|Participants of this group are patients with tumor around knee after microwave ablation with plate internal fixation.
62176446|NCT02691637||H. pylori eradication group|Patients who have had H. pylori infection. After diagnosis of H. pylori infection, the patients who subsequently received successful H. pylori eradication treatment according to appropriate indication.
62176447|NCT02691637||Control Group|Patients who still have H. pylori infection. The patients of control group do not have successful H. pylori eradication result or do not received eradication treatment for any reason.
62741644|NCT04517695||COVID-19 ICU Patients|Patients who are admitted to the ICU with a confirmed SARS-CoV-2 infection
62176448|NCT03975296|EXPERIMENTAL|TMQLB group|
62176449|NCT03975296|ACTIVE_COMPARATOR|TPVB group|
62176450|NCT03545321|EXPERIMENTAL|MOON+|MOON+ includes pharmacist online training on opioid safety and naloxone provision, academic detailing of the pharmacy, materials for use at the pharmacy, standardized overdose response safety protocols, and reminder tools for training reinforcement
62176451|NCT05542225|EXPERIMENTAL|conventional physical therapy with strength training|TENS with a frequency of 2-125Hz for about 30mins in prone position. FITT guidelines for strength training: frequency: 2-3 times perweek, time: 3o mins for the whole session, intensity: 8-15 repetitions and type : major muscles( shoulder flexors and extensors, hip and knee flexors, hip abductors and adductors, foot plantar flexors and dorsiflexors using resistance bands)
62176452|NCT05542225|ACTIVE_COMPARATOR|conventional physical therapy with flexibility training|TENS with a frequency of 2-125 Hz for 30 minutes. FITT guidelines for flexibility; frequency: 5 times per week, intensity: stop before it becomes painful, time: 10-15 minutes,hold for 15 secs and type: major muscle groups( latissmus dorsi, trapezius, gluteus maximus, gluteus medius, gatrocnemius, soleus, hamstringsand paraspinals( errector spinae and multifidus through static stretching technique.
62176453|NCT05147649|ACTIVE_COMPARATOR|non-OSAS patients|Patients without OSAS (Apnea-Hypopnea Index (AHI) \< 15/h and absence of excessive daytime sleepiness with Epworth score \<11)
62176454|NCT05147649|EXPERIMENTAL|OSAS patients|Patients with severe OSAS with an Apnea-Hypopnea Index (AHI) \> 30/h
62176455|NCT00610818||A|Patients receiving palifermin to prevent mucositis from bone marrow transplant.
62176456|NCT00858247|EXPERIMENTAL|Vitamin D3-low dose|Vitamin D3 400 IU capsule, one capsule daily for 12 weeks.
62176457|NCT00858247|EXPERIMENTAL|Vitamin D3-high dose|Vitamin D3 2000 IU capsule, one capsule daily for 12 weeks.
62182429|NCT01749163|EXPERIMENTAL|GIP|GIP will be infused intravenously during the pancreatic clamp at 1.5 pmol/kg/min
62176458|NCT06170502|EXPERIMENTAL|mobile application development and implementation|"The aim of the project is to develop and evaluate the effectiveness of a mobile application (AkilMobil) that prevents parents who continue to use drugs for their children at home after their child is discharged from the hospital. The research is a randomized controlled experimental study. In the study, The Form for Determining the Educational Needs of Parents Administering Medicines at Home, Introductory Information Form, Parental Drug Preparation Information Evaluation Form, Parent Evaluation Form in Suspension Drug Administration, Capsule Drug Application Parent Evaluation Form, developed by the researchers in line with the literature, Tablet Pharmaceutical Application Parent Evaluation Form, Mobile Application Usability Questionnaire, AkilMobil Expert Opinion Evaluation Form and STAI State Anxiety Inventory developed by Spielberger et al. will be used."
62176459|NCT03484078|EXPERIMENTAL|Vibration Platform|The vibration group will stand on a platform that emits a mild vibration 10 minutes per day for 6 months. There will also be a 6 month no-treatment period.
62176460|NCT03484078|PLACEBO_COMPARATOR|Placebo Platform|The placebo group will stand on a placebo platform 10 minutes per day for 6 months. There will also be a 6 month no-treatment period.
62176461|NCT04311385||Diverticulitis|"Patients admitted as an emergency with acute diverticulitis diagnosed by CT scan.~Inclusion criteria~* Patients over 18 years old~* Informed consent form signed~* Diagnosed of acute diverticulitis~* CT scan reported as 1-2 pericolic bubbles with or without free fluid~Exclusion criteria~o CT scan showing free distant bubbles in the abdomen"
62176462|NCT05111678||Indoor air pollutant groups|50 patients that have been exposed to indoor air pollutants
62176463|NCT05111678||Neurological symptoms groups|50 patients with neurological symptoms possibly due to adverse external exposure without any exposure to indoor air pollutants
62176464|NCT05111678||Healthy controls|25 healthy age- and gender-matched controls
62176465|NCT02618564|ACTIVE_COMPARATOR|2 TABS QHS|Sennosides 2 tabs, taken two nights before the colonoscopy
62176466|NCT02618564|ACTIVE_COMPARATOR|3 TABS QHS|Sennosides 3 tabs, taken two nights before the colonoscopy
62176467|NCT02618564|ACTIVE_COMPARATOR|2 TABS AM|Sennosides 2 tabs, taken the morning before the colonoscopy
62176468|NCT02618564|ACTIVE_COMPARATOR|3 TABS AM|Sennosides 3 tabs, taken the morning before the colonoscopy
62176469|NCT02618564|ACTIVE_COMPARATOR|2 TABS AM & QHS|Sennosides 2 tabs taken the morning before and 2 tabs taken the evening before the colonoscopy.
62176470|NCT00422305||1-Healthy Infants|"Group 1: The investigators will recruit 80 healthy infants born at \> 37 weeks gestation, and between 2 and 36 months of age. Infants will be excluded for any of the following reasons:~1. Congenital cardio-respiratory disease~2. Hospitalization for respiratory illness~3. Treatment with asthma medications~4. Small for gestational age at birth"
62176471|NCT00422305||2-Healthy Infants computerized Tomography|"Group 2: The investigators recruited 4 infants born at \> 37 weeks gestation and they were evaluated between 2 and 36 months of age when scheduled for high resolution computed tomography (HRCT) imaging for non-respiratory medical problems. Subjects were enrolled and HRCT of the chest were obtained. Infants were excluded for the following reasons:~1. Congenital cardio-respiratory disease~2. Hospitalization for respiratory illness~3. Treatment with asthma medications"
62176472|NCT00422305||3-Premature Infants|"Group 3: The investigators have recruited 45 infants born prematurely at 23-35 weeks gestation. Subjects were evaluated at corrected age at between 2 and 24 months. The subjects had no oxygen requirements, and were clinically stable outpatients when evaluated. Infants were excluded for any of the following reasons:~1. Congenital cardio-respiratory disease~2. Severe developmental delay"
62176473|NCT01133925|ACTIVE_COMPARATOR|ODESSA|ODESSA trial (NCT 00693030)Patients were randomized (2:2:2:1) to receive multiple TAXUS Libertè™ vs Cypher Select™ vs Endeavor™ vs Libertè BM stents, in overlap. At 6-months follow-up coronary angiography (QCA), IVUS and Optical Coherence Tomography assessments were made. Data reported in J. Am. Coll. Cardiol. Intv. 2010;3;531-539. DOI 10.1016/j.jcin.2010.02.008.
62176474|NCT01133925|EXPERIMENTAL|Resolute Sprint arm|Zotarolimus Eluting stents (Resolute Sprint) implanted in overlap to treat long coronary lesions
62176475|NCT03442140|EXPERIMENTAL|Experimental|Patients who completed the Baylor Martha Foster Lung Center Pulmonary Rehabilitation Program at least six months ago will participate in the 12-week harmonica program
62741645|NCT04517695||ICU Patients with bacterial infection|"Patients who are admitted to the ICU with a confirmed bacterial infection.~Bacterial infection is defined as the clinical suspicion of a bacterial infection with the presence of two or more clinical markers of infection:~* abnormal body temperature (\>38C or \<36C)~* increased heart rate (\>90 b/min),~* increased respiratory rate \> 20/min or a decreased arterial CO2: PaCO2 \< 32 mmHg~* Abnormal white blood cell count: \< 4000 mm3 or \> 12,000 /mm3 or \> 10% immature cells~OR~* The presence of a positive (blood) culture with bacterial growth."
62741646|NCT04714827|EXPERIMENTAL|Low Dose Group|KQ-2003 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 1.0×10\^6 CAR+T cells/kg.
62176476|NCT01006447|ACTIVE_COMPARATOR|Instructor contact 1 class|
62176477|NCT01006447|ACTIVE_COMPARATOR|Instructor contact 4 classes|
62176478|NCT05306522|EXPERIMENTAL|Telerehabitation Group|Patients will undergo telerehabilitation based spinal stabilization exercise 3 days per week for 6 weeks.
62176479|NCT05306522|EXPERIMENTAL|Face to face Group|Patients will undergo spinal stabilization exercise 3 days per week for 6 weeks.
62176480|NCT06238297|EXPERIMENTAL|Intervention|Patients included into the intervention arm will undergo a nasal swab for MRSA and empirical anti-MRSA therapy will be discontinued f the nasal swab result is negative.
62176481|NCT06238297|NO_INTERVENTION|Control|Patients randomized into the control arm will continue pneumonia treatment as per standard of care
62176482|NCT01240239||telephone group|The telephone group must be healthy adults scheduled for an ENT surgery.
62176483|NCT01240239||telemedicine group|This group if qualified will randomly be chosen to be in the telemedicine group.
62176484|NCT01240239||pre-anesthesia consultation|This will be the group that will be randomized to the pre-anesthesia clinic.
62176485|NCT02344056|EXPERIMENTAL|having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
62741647|NCT04714827|EXPERIMENTAL|Middle Dose Group|KQ-2003 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 2.5×10\^6 CAR+T cells/kg.
62741648|NCT04714827|EXPERIMENTAL|High Dose Group|KQ-2003 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 5.0×10\^6 CAR+T cells/kg.
62176486|NCT02344056|EXPERIMENTAL|skipping lunch/having lunch|no lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
62176487|NCT03590717|OTHER|BCC-Only|Intervention: Households in the 'BCC-only' arm receive SBCC but do not receive vouchers.
62176488|NCT03590717|EXPERIMENTAL|Small-voucher|Intervention: Households in the 'Small-voucher' arm receive a voucher (\~$12-17) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
62176489|NCT03590717|EXPERIMENTAL|Large-voucher|Intervention: Households in the 'Large-voucher' arm receive a larger voucher (\~$21-23) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
62741649|NCT04714827|EXPERIMENTAL|Amplification Dose Group|KQ-2003 CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 1.0-5.0×10\^6 CAR+Tcells/kg.
62176490|NCT03248713|ACTIVE_COMPARATOR|Mifepristone|Mifepristone 600 mg/day in 2 tablets
62176491|NCT03248713|PLACEBO_COMPARATOR|Placebo|matching placebo in 2 tablets
62741650|NCT04291196|EXPERIMENTAL|Immersive Virtual Reality|Patients will be immersed in the ECT experience using VR-ECT 360o video (VR-ECT).
62176492|NCT01330992|EXPERIMENTAL|Ocular Light or Dark Exposure|Ocular Light or Dark Exposure
62176493|NCT06309485|EXPERIMENTAL|Arm A|WGI-0301 at MTD / RP2D dose with standard dose Sorafenib
62176494|NCT06309485|EXPERIMENTAL|Arm B|WGI-0301 at MTD / RP2D -1 dose with standard dose Sorafenib
62176495|NCT06309485|ACTIVE_COMPARATOR|Arm C|Standard dose Sorafenib alone
62176496|NCT00569036|EXPERIMENTAL|BMS-754807|Single arm, multiple-ascending dose escalation study
62176497|NCT00329017||1|Post-menopausal women who are at increased risk for development of breast cancer on the basis of family or personal history.
62176498|NCT02631616|EXPERIMENTAL|Treatment arm|Monthly injections of Somatostatin (Sandoatatin LAR - 30mg)
62176499|NCT05550597|EXPERIMENTAL|Group F|The intrathecal additive Fentanyl with hyperbaric bupivacaine
62176500|NCT05550597|EXPERIMENTAL|Group FT|The intrathecal additive of fentanyl with hyperbaric bupivacaine along with Ultrasound-guided TAP block
62176501|NCT05550597|EXPERIMENTAL|Group T|Hyperbaric bupivacaine along with Ultrasound-guided TAP block without the intrathecal addition of fentanyl
62176502|NCT05469906||interventional group|kidney graft preserved with M101
62176503|NCT05469906||control group|kidney graft preserved in standard condition (without M101)
62741651|NCT04291196|OTHER|Standard Treatment|Patients will receive standard preparation for their ECT session.
62176504|NCT00961896|ACTIVE_COMPARATOR|LDE225 (applied in parallel with vehicle) [Part I]|Participants were exposed to both topically applied 0.75% LDE225 cream and LDE225 vehicle cream twice daily for 28 days where each treatment was randomized to two different test areas on each participant.
62176505|NCT00961896|PLACEBO_COMPARATOR|Vehicle cream (applied in parallel with LDE225 [Part I]|Participants were exposed to both topically applied 0.75% LDE225 cream and LDE225 vehicle cream twice daily for 28 days where each treatment was randomized to two different test areas on each participant.
62176506|NCT00961896|ACTIVE_COMPARATOR|LDE225 0.25% [Part II]|Participants were exposed to topically applied 0.25% LDE225 cream twice daily for 6 weeks.
62176507|NCT00961896|ACTIVE_COMPARATOR|LDE225 0.75% [Part II]|Participants were exposed to topically applied 0.75% LDE225 cream twice daily where some basal cell carcinomas (BCCs) were teated for 6 weeks and some BCCs were treated for 9 weeks.
62176508|NCT04986670|EXPERIMENTAL|NutriCare|The oncology care team will provide participants with nutrition toolkit involving printed educational materials, a nutrition prescription, referral to registered dietitians (RDs) for remotely-delivered medical nutrition therapy counseling, and home-delivery of medically tailored meals.
62176509|NCT04986670|ACTIVE_COMPARATOR|NutriTool|The oncology care team will provide participants with a nutrition toolkit involving printed educational materials.
62176510|NCT05598606|EXPERIMENTAL|Denosumab|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months
62176511|NCT05598606|ACTIVE_COMPARATOR|zoledronate|Intravenous zoledronic acid 5 mg plus subcutaneous placebo every 12 months.
62176512|NCT00593970||1|All women presenting to our prenatal clinic and postpartum floor during the study period.
62176513|NCT03679468|SHAM_COMPARATOR|Cognitive Rehab & Sham Exercise|Cognitive Rehabilitation by computer based brain tasks, and Sham exercises focusing primary on balance and stretching. Sessions will take place twice a week for 12 weeks.
62176514|NCT03679468|SHAM_COMPARATOR|Sham Cognitive Rehab & Sham Exercise|Sham cognitive Rehabilitation will consist of basic internet searches and learning to use a computer, and sham exercises focusing primary on balance and stretching. Sessions will take place twice a week for 12 weeks.
62176515|NCT03679468|SHAM_COMPARATOR|Sham Cognitive rehab & Aerobic Exercise|Sham cognitive rehabilitation will consist of basic internet searches and learning to use a computer, and aerobic exercises will focus primarily on improving cardio-respiratory fitness using a recumbent bike. Sessions will take place twice a week for 12 weeks.
62182430|NCT01749163|EXPERIMENTAL|GLP-1|GLP-1 will be infused intravenously during the pancreatic clamp at 0.5 pmol/kg/min
62741652|NCT06300151|EXPERIMENTAL|Ultrasound Real-time Guidance combined with Dural Puncture Epidural Group|Ultrasound real-time guidance combined with dural puncture epidural Can improve the clinical effect of labor analgesia.
62741653|NCT06300151|ACTIVE_COMPARATOR|Dural Puncture Epidural Group|Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
62741654|NCT03673085|EXPERIMENTAL|Group 1-1|The dose of CN128 is 2.5 mg/kg bw.
62741655|NCT03673085|PLACEBO_COMPARATOR|Group 1-2|The dose of placebo is 2.5 mg/kg bw.
62741656|NCT03673085|EXPERIMENTAL|Group 2-1|The dose of CN128 is 5 mg/kg bw.
62176516|NCT03679468|ACTIVE_COMPARATOR|Cognitive Rehab & Aerobic Exercise|Cognitive Rehabilitation by computer based brain tasks and aerobic exercises will focus primarily on improving cardio-respiratory fitness using a recumbent bike. Sessions will take place twice a week for 12 weeks.
62176517|NCT01891656|EXPERIMENTAL|Motivational Interviewing|"Participants randomized to the MI group will receive a single 60-minute MI session focused on motivation to initiate and engage in treatment. The MI session will be organized around the Check-Up format, with additional planning components as desired by the client."
62176518|NCT01891656|NO_INTERVENTION|Supervision As Usual|Participants randomized to the SAU group will receive the standard agency intake process as well as baseline and follow-up research interviews, but will not receive any additional intervention as part of the study. They will be referred to a treatment program as per the normal routine.
62176519|NCT01891656|EXPERIMENTAL|Motivational Computer|Participants randomized to the MC group will complete a 60 minute computer intervention focused on motivation to initiate and engage in treatment. The program will be self-guided, interactive, and to the extent possible, will mirror the features of MI session. The MC program will have two main components: a motivation component and a planning component.
62176520|NCT05515913||ASD ( autistic spectrum disorder)|Children already diagnosed with autistic spectrum disorder
62176521|NCT05515913||TDC (typically developing children)|Children within the typically development
62176522|NCT05424094|EXPERIMENTAL|'kinderleicht' programme|Children receive coaching in the areas of behaviour, exercise, nutrition and medicine from qualified professionals.
62176523|NCT05394883|EXPERIMENTAL|Supervised Exercise|Women randomized to Supervised Exercise group will attend two to three exercise classes/week.
62176524|NCT05394883|EXPERIMENTAL|Home Exercise|Women assigned to Home Exercise group will receive instructions for their home walking and exercise program.
62176525|NCT05394883|NO_INTERVENTION|Usual Care|The Usual Care group will receive an exercise log to record any weekly activity in addition to a weekly phone call/text/email to remind the individual to complete the weekly exercise log.
62176526|NCT06161818|EXPERIMENTAL|TNT FLOT-CROSS|Patients allocated to the TNT FLOT-CROSS arm will be treated with 4 cycles of FLOT chemotherapy followed by a response evaluation consisting of a CT-scan and upper endoscopy with bite-on-bite biopsies of the primary tumor site and of any other suspected lesions in the esophagus. Patients with distant metastases will go off-study. All other patients will proceed to CROSS chemoradiotherapy.
62176527|NCT06161818|EXPERIMENTAL|TNT CROSS-FLOT|Patients allocated to the TNT CROSS-FLOT arm will be treated with CROSS chemoradiotherapy followed by a response evaluation consisting of a CT-scan and upper endoscopy with bite-on-bite biopsies of the primary tumor site and of any other suspected lesions in the esophagus. Patients with distant metastases will go off-study. All other patients will proceed to FLOT chemotherapy.
62176528|NCT02066493||conservative management|neither surgical nor endovascular management
62176529|NCT02066493||endovascular management|endovascular management
62176530|NCT02066493||surgical management|surgical management
62176531|NCT02017132|ACTIVE_COMPARATOR|Pomegranate extract|1.1g pomegranate extract capsule administered daily to each participant for 8 weeks
62176532|NCT02017132|PLACEBO_COMPARATOR|Placebo capsule|1.1g placebo capsule taken daily by each participant for 8 weeks
62176533|NCT04148521|EXPERIMENTAL|Behavioral Health - Virtual Patient Navigation|All patients who meet eligibility criteria at sites where the virtual patient navigation behavioral health program is offered will be considered exposed to the intervention.
62176534|NCT04148521|NO_INTERVENTION|Usual care Behavioral Health|All patients who meet eligibility criteria at sites where the virtual patient navigator behavioral health program is not offered will be considered exposed to usual care.
62176535|NCT04356638|ACTIVE_COMPARATOR|The sedative pre-medication oral Midazolam|
62176536|NCT04356638|ACTIVE_COMPARATOR|The sedative pre-medication intranasal Dexmedetomidine|
62176537|NCT04356638|PLACEBO_COMPARATOR|Placebo|
62176538|NCT04356638|NO_INTERVENTION|No Sedative Pre-medication|
62176539|NCT03716947|ACTIVE_COMPARATOR|ORBIT Mechanical disc prosthesis|"Surgical procedure with total disc replacement using mechanical disc prosthesis device, ORBIT, Globus Medical"
62176540|NCT03716947|EXPERIMENTAL|ZACK viscoelastic disc prosthesis|"Surgical procedure with total disc replacement using viscoelastic disc prosthesis device, ZACK, FH Orthopaedics"
62176541|NCT03716947|ACTIVE_COMPARATOR|ORBIT SASCA|Surgical procedure with total disc replacement (TDR) using ORBIT disc prostheses device combined with adjacent level anterior intracorporal fusion (ALIF) with intracorporal device SASCA.
62176542|NCT03716947|EXPERIMENTAL|ZACK SASCA|Surgical procedure with total disc replacement (TDR) using ZACK disc prostheses device combined with adjacent level anterior intracorporal fusion (ALIF) with intracorporal device SASCA.
62176543|NCT00668512|EXPERIMENTAL|Antimelanoma injection-GSL alpha-Gal|Intervention consists of injection of a single melanoma metastasis with two injections of GSL alpha-Gal separated by four weeks. Both injections done with the same dose of GSL alpha-GAL each time. Phase 1 dose escalating scheme: 0.1mg, 1 mg, 10mg
62176544|NCT01801423|EXPERIMENTAL|Hydroxyurea|Study investigators propose to enroll 60 children with SCA and an elevated TCD measurement between 5 and 12 years of age in this one arm feasibility study of hydroxyurea therapy, with follow-up of at least 12 months per subject. The study intervention will include HU to begin at \~ 20 mg/kg/day(range 17.5 - 26 mg/kg/day). No dose escalation will occur. Given the success of the first year of enrollment and the favorable response of TCD measurement after 3 months on HU therapy, the study investigators have participants as an internal pilot. The definitive phase III trial will now compare low dose HU therapy to the result of no treatment arm from the STOP Trial.
62176545|NCT02024750|EXPERIMENTAL|Tailored Resources|Use of PRISM screening tool to identify self-management needs and to provide tailored group session resources over 1 year
62176546|NCT02024750|NO_INTERVENTION|Usual Care|Patients and families obtain routine multidisciplinary diabetes care
62182431|NCT01284309|EXPERIMENTAL|Mirabegron|
62552701|NCT01833650|EXPERIMENTAL|Candy plus thymus honey mouthwash 24|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 24 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
62741657|NCT03673085|PLACEBO_COMPARATOR|Group 2-2|The dose of placebo is 5 mg/kg bw.
62176547|NCT05590962|NO_INTERVENTION|Control|"Clinicians of patients in both arms will receive education on the availability of early palliative care and performance reports.~Clinicians will receive no further interventions beyond usual practice."
62176548|NCT05590962|EXPERIMENTAL|Intervention|"Clinicians of patients in both arms will receive education on the availability of early palliative care and performance reports.~Clinicians in the intervention arm will receive an EHR nudge with option to opt-out for palliative care referral for any eligible high-risk patient."
62176549|NCT05338112||Patients with active pemphigus lesions|
62741658|NCT03673085|EXPERIMENTAL|Group 3-1|The dose of CN128 is 10 mg/kg bw.
62741659|NCT03673085|PLACEBO_COMPARATOR|Group 3-2|The dose of placebo is 10 mg/kg bw.
62741660|NCT03673085|EXPERIMENTAL|Group 4-1|The dose of CN128 is 15 mg/kg bw.
62741661|NCT03673085|PLACEBO_COMPARATOR|Group 4-2|The dose of placebo is 15 mg/kg bw.
62741662|NCT03673085|EXPERIMENTAL|Group 5-1|The dose of CN128 is 20 mg/kg bw.
62741663|NCT03673085|PLACEBO_COMPARATOR|Group 5-2|The dose of placebo is 20 mg/kg bw.
62741664|NCT03673085|EXPERIMENTAL|Group 6-1|The dose of CN128 is 30 mg/kg bw.
62741665|NCT03673085|PLACEBO_COMPARATOR|Group 6-2|The dose of placebo is 30 mg/kg bw.
62741666|NCT03673085|EXPERIMENTAL|Group 7-1|The dose of CN128 is 45 mg/kg bw.
62741667|NCT03673085|PLACEBO_COMPARATOR|Group 7-2|The dose of placebo is 45 mg/kg bw.
62741668|NCT03673085|EXPERIMENTAL|Group 8-1|The dose of CN128 is 60 mg/kg bw.
62741669|NCT03673085|PLACEBO_COMPARATOR|Group 8-2|The dose of placebo is 60 mg/kg bw.
62741670|NCT04559022|OTHER|Fat Grafting for Acne Scar Treatment|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
62741671|NCT05977816|EXPERIMENTAL|Negative Pressure Wound Therapy|The wound is dressed using negative pressure wound therapy.
62741672|NCT05977816|ACTIVE_COMPARATOR|Standard Wound dressing|After the skin is closed, the wound is covered using sterile standard gauze dressing.
62741673|NCT02712983|EXPERIMENTAL|Cohort A (3 capsules o.d.): TIP|Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)
62741674|NCT02712983|EXPERIMENTAL|Cohort A (3 capsules o.d.): TIP/PBO|Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
62741675|NCT02712983|PLACEBO_COMPARATOR|Cohort A (3 capsules o.d.): PBO|Cohort A (3 capsules o.d.): Inhaled placebo (PBO)
62741676|NCT02712983|EXPERIMENTAL|Cohort B (5 capsules o.d.): TIP|Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)
62741677|NCT02712983|EXPERIMENTAL|Cohort B (5 capsules o.d.): TIP/PBO|Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
62741678|NCT02712983|PLACEBO_COMPARATOR|Cohort B (5 capsules o.d.): PBO|Cohort B (5 capsules o.d.): inhaled placebo (PBO)
62741679|NCT02712983|EXPERIMENTAL|Cohort C (4 capsules b.i.d.): TIP|Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)
62741680|NCT02712983|EXPERIMENTAL|Cohort C (4 capsules b.i.d.): TIP/PBO|Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
62741681|NCT02712983|PLACEBO_COMPARATOR|Cohort C (4 capsules b.i.d.): PBO|Cohort C (4 capsules b.i.d.): inhaled placebo (PBO)
62176550|NCT06329271|EXPERIMENTAL|Early-Weight bearing|Early Weight bearing was defined as starting Weight bearing within 48 h postoperatively, and WBAT referred to the adjustment of fracture site weight-bearing by pain tolerance.
62176551|NCT06329271|NO_INTERVENTION|Weight-bearing restriction|Weight bearing as toleration started after 48 h postoperatively.
62176552|NCT00001941|EXPERIMENTAL|Phase I - 2 mg/kg cohort|2 mg/kg daclizumab over 60 minutes intravenously on days 1 and 2
62176553|NCT00001941|EXPERIMENTAL|Phase I - 4 mg/kg cohort|4 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
62176554|NCT00001941|EXPERIMENTAL|Phase I - 6 mg/kg cohort|6 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
62176555|NCT00001941|EXPERIMENTAL|Phase I - 8 mg/kg cohort|8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
62176556|NCT00001941|EXPERIMENTAL|Phase II - 8 mg/kg cohort|8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
62176557|NCT01100918|ACTIVE_COMPARATOR|1: Dyssynchrony positive|
62176558|NCT01100918|ACTIVE_COMPARATOR|2a: Dyssynchrony negative|
62176559|NCT01100918|ACTIVE_COMPARATOR|2b: Dyssynchrony negative|
62741682|NCT05140304|OTHER|A|
62741683|NCT02745704|EXPERIMENTAL|PEG-IFN group|Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg \<1500 IU/ mL and Hepatitis B virus DNA not detectable, are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for 48 weeks.
62741684|NCT02745704|NO_INTERVENTION|NAs group|Patients do not need to change their NAs treatment.
62741685|NCT04091581|EXPERIMENTAL|Non-Dry Eye|Instill eye drop and perform followup assessments on people with a Ocular Surface Disease Index score \<13 and a non-invasive Keratograph break-up time of \>/= 10 seconds in the worst eye
62741686|NCT04091581|EXPERIMENTAL|Dry Eye|Instill eye drop and perform followup assessments on people with an Ocular Surface Disease Index score \>/= 13 and a non-invasive Keratograph break-up time \</= 5 seconds in the worst eye
62741687|NCT03595020||MDD group|The major depression group (MDD group) received antidepressant treatment but did not interfere with drug selection.
62741688|NCT03595020||HC group|The healthy control group (HC group) don't accept intervention and treatment.
62741689|NCT05460533|EXPERIMENTAL|Tisagenlecleucel|Patients will receive reinfusion of tisagenlecleucel on day +30-60 after their initial infusion if meeting eligibility criteria. Tisagenlecleucel is an autologous cellular immunotherapy product that is comprised of CD3+T cells that have undergone ex vivo T cell activation, gene modification, expansion, and formulation in infusible cryomedia.
62741690|NCT06661083|EXPERIMENTAL|Patients with HPV infection|
62741691|NCT02920736||sepsis with acute renal injury group|Based on definition of sepsis with Sepsis 3.0 and AKI was defined using KDIGO（Kidney Disease: Improving Global Outcomes） consensus definition of AKI.The group was the secondary AKI in sepsis patients
62741692|NCT02920736||sepsis non-acute renal injury group|The group was the non-AKI in sepsis patients
62741693|NCT02920736||control group|Approximately 110 persons(18-80years) with healthy physical examination and without liver and kidney dysfunction
62741694|NCT06657963|EXPERIMENTAL|Interventional Arm|
62741695|NCT01777464|EXPERIMENTAL|patients|patients allergic to house dust mite receive sham solution for 5 minutes on first visit and histamine (16mg/ml) for 5 minutes on second visit
62741696|NCT01777464|SHAM_COMPARATOR|healthy controls|healthy controls receive sham solution for 5 minutes on first visit and histamine (16mg/ml) for 5 minutes on second visit
62741697|NCT03501992|OTHER|Practice A|Practice A will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice A will be assigned to receive the current care intervention. in the second step, Practice A will be assigned to receive the current care intervention. In the third step, Practice A will receive the reminder-recall intervention. In the fourth step, Practice A will receive the combined reminder-recall and audit-and-feedback intervention.
62176560|NCT04287634|EXPERIMENTAL|Segmental Mobilization|Hot Fermentation Soft tissue mobilization + Targeted Segmental Mobilization Home plan exercise= cervical muscles stretching, postural care
62741698|NCT03501992|OTHER|Practice B|Practice B will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice B will be assigned to receive the current care intervention. In the second step, Practice B will be assigned to receive the reminder-recall intervention. In the third step, Practice B will receive the combined reminder-recall and audit-and-feedback intervention. In the fourth step, Practice A will receive the combined reminder-recall and audit-and-feedback intervention.
62741699|NCT03501992|OTHER|Practice C|Practice C will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice C will be assigned to receive the current care intervention. In the second step, Practice C will be assigned to receive the audit-and-feedback intervention. In the third step, Practice C will receive the audit-and-feedback intervention. In the fourth step, Practice C will receive the combined reminder-recall and audit-and-feedback intervention.
62741700|NCT03501992|OTHER|Practice D|Practice D will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice D will be assigned to receive the current care intervention. In the second step, Practice D will be assigned to receive the current care intervention. In the third step, Practice D will receive the audit-and-feedback intervention. In the fourth step, Practice D will receive the combined reminder-recall and audit-and-feedback intervention.
62741701|NCT03501992|OTHER|Practice E|Practice E will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice E will be assigned to receive the current care intervention. In the second step, Practice E will be assigned to receive the reminder-recall intervention. In the third step, Practice E will receive the reminder-recall intervention. In the fourth step, Practice E will receive the combined reminder-recall and audit-and-feedback intervention.
62741702|NCT03501992|OTHER|Practice F|Practice F will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice F will be assigned to receive the current care intervention. In the second step, Practice F will be assigned to receive the audit-and-feedback intervention. In the third step, Practice F will receive the combined reminder-recall and audit-and-feedback intervention. In the fourth step, Practice F will receive the combined reminder-recall and audit-and-feedback intervention.
62741703|NCT02464995|EXPERIMENTAL|Thermoplasty group|Procedure: Bronchial thermoplasty with the Alair System and conventional therapy
62741704|NCT02464995|NO_INTERVENTION|Control group|Conventional therapy
62741705|NCT05739006|EXPERIMENTAL|Group 1|BCD-201 200 mg by intravenous infusions once every 3 weeks
62741706|NCT05739006|ACTIVE_COMPARATOR|Group 2|Keytruda 200 mg by intravenous infusions once every 3 weeks
62741707|NCT04060069||Before pneumoperitoneum|Fluid administration
62741708|NCT04590430|EXPERIMENTAL|HFB30132A|Participants will receive HFB30132A administered across 3 fixed-dose cohorts via intravenous infusions (to be administered sequentially)
62741709|NCT04590430|PLACEBO_COMPARATOR|Placebo|Placebo will be administered to participants across three fixed-dose cohorts similar to the active treatment.
62741710|NCT06625099||Group L|"After the study group patients were informed preoperatively and accepted to participate in the study, different mechanical ventilation strategies will be applied to the randomly grouped patients after standard propofol, fentanyl, rocuronium midazolam induction anesthesia according to the groups they are in. Group L patients will be applied standard 5 cmH2O PEEP after anesthesia induction.~The ventilation parameters and vital signs obtained will be recorded, and the mechanical power applied to the patients will be calculated according to Gattinoni's mechanical power calculation formula in volume controlled patients. The groups will be compared for power hemodynamic values and blood gas for oxygenation."
62741711|NCT06625099||Group O|"After the study group patients are informed preoperatively and accepted to participate in the study, different mechanical ventilation strategies will be applied to the patients randomly grouped after standard propofol, fentanyl, rocuronium midazolam induction anesthesia according to their groups. Optimum PEEP will be applied to Group O patients after anesthesia induction, with the highest compliance values.~The ventilation parameters and vital signs obtained will be recorded and the mechanical power applied to the patients will be calculated according to Gattinoni's mechanical power calculation formula in volume-controlled patients. The groups will be compared in terms of power hemodynamic values and blood gas for oxygenation."
62741712|NCT04149470|EXPERIMENTAL|Omeprazole|Participants will receive high dose PPI therapy (Omeprazole 20mg twice daily) and will be evaluated for histological improvement.
62741713|NCT01391169|ACTIVE_COMPARATOR|1sup group|enforcement of the anastomoses with seromuscular flap
62741714|NCT01391169|PLACEBO_COMPARATOR|2nd group|primary anastomosis without enforcement
62176561|NCT04287634|EXPERIMENTAL|Entire Spine Mobilization|Hot fermentation Soft tissue mobilization + Entire spine mobilization Home plan exercises=cervical muscles stretches, postural care
62176562|NCT03988478|EXPERIMENTAL|Behavioral, detoxificaiton & psychotherapy|Providing treatment as usual (detoxificaion) \& psychotherapy
62176563|NCT03342170||CIRRAL|alcoholic cirrhosis
62176564|NCT03342170||CIRVIR|Viral cirrhosis
62176565|NCT03226106|EXPERIMENTAL|Physical Activity Behavior Intervention|A 12-week behavior change intervention that supplements conventional rehabilitation including: 10 telerehabilitation sessions, daily activity sensor use, education, self-monitoring, tailored feedback, barrier/facilitator identification, promotion of problem solving, action planning, and encouragement.
62176566|NCT03226106|ACTIVE_COMPARATOR|Attention Control|Conventional rehabilitation with 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
62741715|NCT04541043|EXPERIMENTAL|Active Nefecon treatment|Nefecon 16 mg once daily by mouth for 9 months
62741716|NCT03186508|ACTIVE_COMPARATOR|Optimize Sleep (OS)|Optimize Sleep will focus exclusively on enhancing sleep by using effective behavioral strategies. Specific strategies to be used include: goal setting and self-monitoring, positive bedtime routines, stimulus control/sleep hygiene strategies, problem-solving regarding challenges, and review of effective strategies for relapse prevention.
62741717|NCT03186508|ACTIVE_COMPARATOR|Optimize Sleep-Plus (OS-Plus)|OS-Plus will focus on enhancing sleep and targeted eating (decreasing sugar-sweetened beverages and sweet and salty snack foods) and activity (increasing physical activity and decreasing TV viewing) behaviors. Specific strategies to be used include: goal setting and self-monitoring, positive bedtime routines, stimulus control/sleep hygiene strategies, problem-solving regarding challenges, and review of effective strategies for relapse prevention.
62741718|NCT06658860|EXPERIMENTAL|Modified Socket Shield Technique|Participants in this group underwent partial tooth extraction using the modified socket shield technique to preserve the alveolar ridge for delayed implant placement. CBCT scans were used to evaluate ridge preservation over time.
62741719|NCT06658860|ACTIVE_COMPARATOR|Conventional Tooth Extraction|Participants in this group underwent conventional tooth extraction without the socket shield technique. The alveolar ridge was evaluated using CBCT over the same period as the experimental group for comparison.
62741720|NCT06659380|EXPERIMENTAL|Intervention|This group consist of postmenopausal women diagnosed with bacterial vaginosis. All subjects will receive metronidazole oral 400-500 mg twice daily or 0,75% metronidazole gel 5 grams intravaginally once daily for 5 days, then blind-randomly including to the treatment group and will receive Floragyn® probiotic tablets (Lapi, Indonesia) orally once daily for two weeks.
62741721|NCT06659380|PLACEBO_COMPARATOR|Placebo|This group consist of postmenopausal women diagnosed with bacterial vaginosis. All subjects will receive metronidazole oral 400-500 mg twice daily or 0,75% metronidazole gel 5 grams intravaginally once daily for 5 days, then blind-randomly including to the placebo group and will receive Cal95® probiotic tablets (Lapi, Indonesia) orally once daily for two weeks.
62741722|NCT06659380|ACTIVE_COMPARATOR|Control|This group consist of postmenopausal women with no bacterial vaginosis. All subjects will receive Floragyn® probiotic tablets (Lapi, Indonesia) orally once daily for two weeks.
62741723|NCT04223765|EXPERIMENTAL|CAR.k.28/CAR.k.4-1BB|Up to 12 patients will receive a single infusion of CAR.k.28. The starting dose will be 2.5x10\^5 cells/kg of each product. Up to 3 dose levels of CAR.k.28 cells will be tested with at least 3 patients enrolled at each dose cohort before dose escalation is considered based on the incidence of dose limiting toxicity (DLT). An expansion cohort will enroll up to 8 patients at the recommended phase 2 dose. Prior to receiving the infusions, patients will undergo lymphodepletion with fludarabine and bendamustine. Patients with a known history of intolerance to bendamustine may be considered for lymphodepletion with fludarabine and cyclophosphamide.
62741724|NCT04607174|OTHER|Pathologic group|At least 20 participants with various neurologic or orthopaedic conditions (for example, hemiparesis post-stroke, multiple sclerosis, traumatic knee injuries, knee osteoarthritis) will be enrolled.
62391460|NCT00876902|PLACEBO_COMPARATOR|2|Placebo Control: (18 subjects) Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient PRIOR to arterial reperfusion of the liver. One additional infusion of 0.1 mL/kg placebo control (saline) will be given at the end of the procedure to patients that have experienced an intraoperative blood loss of greater than 10 units.
62741725|NCT04450706|EXPERIMENTAL|Treatment: all patients|"Blood will be collected, and a biopsy will be performed prior to starting the first systemic therapy (triple-negative) or first chemotherapy (hormone receptor-positive). If enough tumor is collected, the patient is eligible for the trial. Malignant tissue collected from this biopsy will be used for genomic sequencing and for the development of organoid models for drug screening. Drugs selected for sensitivity testing will be guided by the results of the genome analysis and NCCN guidelines. Following tissue acquisition, the patient will begin therapy as selected by the treating physician. This first-line of on study therapy, either standard-of-care or investigational in the context of another existing active clinical trial, will be defined as the first uninformed line of therapy.~Patient response is tracked for up to two uninformed lines of therapy. The first line of the therapy started after the biopsy will count as the first uniformed line."
62741726|NCT04450706|EXPERIMENTAL|Physician Questionnaire|"The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy. Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the informed line of therapy."
62741727|NCT03763656|EXPERIMENTAL|Open Label|Novel oral solution formulation of hydroxyurea
62741728|NCT03186443|ACTIVE_COMPARATOR|pregabalin|experiment group: pregabalin 300mg,q12h for 6 months
62741729|NCT03186443|EXPERIMENTAL|gabapentin|compared to pregabalin effect on herpetic neuralgia
62741730|NCT02336685|PLACEBO_COMPARATOR|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase in addition to opioids as standard of care.
62176567|NCT02553876||Observational|All patients referred with pain in the hand and/or upper limb will be evaluated. Patients will first be assessed for suitability for neurostimulation implantation and then included in the study. Patients wiil fill in questionnaires (pain scores, Quality of Life and satisfaction) at baseline and post-operatively at regular intervals (as per standard of care in the Netherlands.)
62176568|NCT04314570|EXPERIMENTAL|Ropivacaine Treatment|After the patient has been consented for a post-operative nerve block, physicians will provide a loading dose of Ropivacaine through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
62182432|NCT01284309|PLACEBO_COMPARATOR|Placebo|
62176569|NCT04314570|PLACEBO_COMPARATOR|Saline Control|After the patient has been consented for a post-operative nerve block, physicians will provide a loading dose of Normal Saline through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
62741731|NCT02336685|EXPERIMENTAL|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase in addition to opioids as standard of care.
62741732|NCT02336685|EXPERIMENTAL|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase in addition to opioids as standard of care.
62741733|NCT06662071||positive control group|BCG vaccine for bladder instillation
62741734|NCT06662071||test group|Organoid-sensitive drug infusion
62741735|NCT06662071||control group|Organoid non-sensitive drug infusion group
62741736|NCT06586918||Healthy Volunteers|
62741737|NCT05192616||iCover covered stent|Percutaneous transluminal angioplasty (PTA)
62741738|NCT06002906|EXPERIMENTAL|Interventional group (with drug)|The interventional group will receive indocyanine green during bariatric surgery inside the operating room before and after making the gastrojejunostomy.
62741739|NCT06029283|PLACEBO_COMPARATOR|Placebo arm of non-dietary nitrate gum|Placebo gum with no dietary nitrate
62741740|NCT06029283|EXPERIMENTAL|Test arm of dietary nitrate containing gum|Functional gum with dietary nitrate
62741741|NCT05957393|EXPERIMENTAL|Quantity (present) x Quality (present)|Participants will receive a social norm-based message (for quantity) and will learn the AIMS method, a trust-building method using presumptive language (for quality).
62741742|NCT05957393|EXPERIMENTAL|Quantity (present) x Quality (absent)|Participants will receive a social norm-based message (for quantity).
62741743|NCT05957393|EXPERIMENTAL|Quantity (absent) x Quality (present)|Participants will learn the AIMS method, a trust-building method using presumptive language (for quality).
62741744|NCT05957393|EXPERIMENTAL|Quantity (absent) x Quality (absent)|Control: Participants in this condition will receive general information about vaccines, including vaccine principles, uptake barriers, and guidelines. This information will come directly from the CDC's Advisory Committee on Immunization Practices (ACIP) website.
62741745|NCT05241860|EXPERIMENTAL|Treatment (discontinue hormonal medication, follow up)|Patients stop both hormonal medications (medication to decrease testosterone levels in the body and potent oral hormonal medication to block growth signals from male hormones in the cancer cells). Patients are then followed every 12 months for symptoms. Patients with an increase in PSA level to greater than or equal to 5 ng/ml, changes on imaging studies suggesting that their cancer is growing back, or symptoms that the doctor thinks is related to their cancer growing back, resume both hormonal treatments.
62741746|NCT05199233|EXPERIMENTAL|Muse S™ Headband system for post-Covid Syndrome|Subjects will utilize the Muse S™ Headband system at least 4 times per week for a minimum of 10 minutes each time over a period of 3 months (12 weeks).
62741747|NCT00123162|EXPERIMENTAL|Sildenafil Citrate|A single vaginal dose of Viagra 100 mg.
62176570|NCT03044002||4French Intervention|Patient with infrainguinal Peripheral Artery Disease (PAD), requiring endovascular treatment
62176571|NCT03044002||6French Intervention|Patient with infrainguinal Peripheral Artery Disease (PAD), requiring endovascular treatment
62176572|NCT00125853|EXPERIMENTAL|atenolol 25mg daily|atenolol 25mg daily
62176573|NCT00125853|ACTIVE_COMPARATOR|nebivolol 2.5mg daily|nebivolol 2.5mg daily
62176574|NCT00806299|EXPERIMENTAL|1|Drug (including placebo)
62741748|NCT00123162|PLACEBO_COMPARATOR|Placebo|A single vaginal dose of placebo.
62741749|NCT06519513|EXPERIMENTAL|Laughter yoga group|Laughter yoga will be performed in 8 sessions, 2 days a week for 4 weeks. The duration of each session will be 40 minutes. Laughter yoga sessions will be held on a day suitable for all participants and with the participation of at least 8 people. The session will start with warm-up exercises and continue with laughter exercises. People in the group will do these exercises with the guidance of the researcher.
62741750|NCT06519513|NO_INTERVENTION|Control group|Participants in this group will consist of people who do not routinely do any practice on their own to reduce stress and burnout levels. The researcher will ask the participants via phone 4 times a week for 1 month whether they have taken any action to reduce their stress and burnout symptoms. Participants who use any of the pharmacological or non-pharmacological practices to reduce stress and burnout symptoms will be excluded from the study.
62741751|NCT00218634|EXPERIMENTAL|CBT-AD|Cognitive behavioral therapy for adherence and depression
62741752|NCT00218634|ACTIVE_COMPARATOR|ETAU|Enhanced treatment as usual
62741753|NCT06659926|OTHER|mCRPC patients with bone-only disease according to 68Ga-PSMA-PET/CT|a prospective clinical study in which patients with mCRPC and bone-only disease according to ceCT and bone scan will receive standard-of-care treatment with Radium-223. In addition to standard-of-care systemic treatment, each patient will undergo an additional 68Ga-PSMA-PET/CT scan at baseline and will be followed throughout the treatment with online patient reported outcome measure (PROM) questionnaires (Kaiku application) and blood sampling for circulating tumor DNA (ctDNA) analysis.
62741754|NCT03955250|EXPERIMENTAL|Mobile After-Care Support (MACS) app|All participants download the app to their mobile phone. The app runs through a third-party software platform. It is designed to provide ecological momentary assessment and intervention.
62176575|NCT00806299|EXPERIMENTAL|2|Drug (including placebo)
62176576|NCT00806299|EXPERIMENTAL|3|Drug (including placebo)
62176577|NCT02730676||Electronic Cigarette #1|VUSE® Original Digital Vapor Cigarettes (29 mg nicotine)
62176578|NCT02730676||Electronic Cigarette #2|VUSE® Menthol Digital Vapor Cigarettes (29 mg nicotine)
62176579|NCT04165525|ACTIVE_COMPARATOR|HelixAR Electrosurgical Generator (HEG)|Argon gas and high frequency electrical current ablation device
62176580|NCT04165525|ACTIVE_COMPARATOR|Conventional Electrosurgical Coagulation (CEC) Systems|Standard Bovie electrosugical device without argon gas
62176581|NCT00131547|NO_INTERVENTION|1|Usual Clinical Care
62176582|NCT00131547|EXPERIMENTAL|2|Behavioral (e.g., Counseling)
62182433|NCT02168231||Complex abdominal wall repair Strattice|Complex abdominal wall repair Strattice
62182434|NCT05333575|EXPERIMENTAL|Experimental Group: Lullaby|The mothers in this group sang lullabies to their babies next to the incubator during feeding.
62741755|NCT03955250|ACTIVE_COMPARATOR|Mobile app attention control|All participants download the app to their mobile phone. The app runs through a third-party software platform. It is designed to provide ecological momentary assessment and psychoeducation about illness.
62741756|NCT02965794||Usual care|quality of care will be measured in the participating hospitals, using a retrospective patient record analysis
62176583|NCT03994341||NEC Group|Infrared images of the abdomen, timed at handling. A FLIR Thermovision a320M thermal IR camera bound with an Microsoft Kinect RGB-D sensor system connected to a laptop will be used. Both imaging technologies are non-invasive and represent no risk to the subject. The thermal images record the temperature distribution, the Kinect sensor will acquire color image and depth image that will be used to segment the subject from the background bedding surface. All three sets of images will be collected in synchronization. Thermography requires period of slight cooling of the skin surface to stabilize the body surface temperature. The room temperature will be maintained slightly below thermoneutrality. Thermographic camera will be positioned about 60-70 cm above the baby.
62176584|NCT03994341||Normal Group|Same procedure for both experimental and active comparator.
62176585|NCT02290197|EXPERIMENTAL|Hinged External Fixator|Hinged external fixator allows early and aggressive joint mobility in the sagittal plane only. Flexion and extension are permitted, but rotational movements, translations in the anterior-posterior plane, lateral (varus) and medial (valgus) openings are not allowed. Thus protective stability is ensured for ligament reconstruction procedures. Simultaneously we allow immediate joint mobilization, reducing the risk of arthrofibrosis, joint stiffness and postoperative ligament laxity.
62176586|NCT02290197|ACTIVE_COMPARATOR|Cast Immobilization|In these patients we used cast postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
62176587|NCT00020709|EXPERIMENTAL|Arm I (gefitinib, combination chemotherapy, radiation)|"Patients receive induction therapy comprising cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning within 24 hours after starting chemotherapy, patients receive concurrent induction radiotherapy 5 days a week for 5 weeks and then boost radiotherapy 5 days a week for 1.5 weeks.~Beginning approximately 4-8 weeks after completion of chemoradiotherapy, patients with stable or responding disease receive consolidation therapy comprising docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 3 courses.~Patients with stable or responding disease are randomized to one of two treatment arms for maintenance therapy. Patients begin maintenance therapy approximately 4-7 weeks after completion of consolidation therapy.~Patients receive oral gefitinib daily."
62176588|NCT00020709|EXPERIMENTAL|Arm II (placebo, combination chemotherapy, radiation)|"Patients receive induction therapy comprising cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning within 24 hours after starting chemotherapy, patients receive concurrent induction radiotherapy 5 days a week for 5 weeks and then boost radiotherapy 5 days a week for 1.5 weeks.~Beginning approximately 4-8 weeks after completion of chemoradiotherapy, patients with stable or responding disease receive consolidation therapy comprising docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 3 courses.~Patients with stable or responding disease are randomized to one of two treatment arms for maintenance therapy. Patients begin maintenance therapy approximately 4-7 weeks after completion of consolidation therapy.~Patients receive oral placebo daily. In both arms, maintenance therapy continues for a maximum of 5 years in the absence of disease progression or unacceptable toxicity."
62176589|NCT05490147|EXPERIMENTAL|conventional tidal volume (tidal volume [ml]= ideal body weight [kg]* 10~12) group|In the conventional tidal volume group, patients are ventilated with a tidal volume \[ml\]= ideal body weight \[kg\]\* 10\~12 throughout the surgery.
62176590|NCT05490147|EXPERIMENTAL|low tidal (tidal volume [ml]= ideal body weight [kg] * 6~8) volume|In the low tidal volume group, patients are ventilated with a tidal volume \[ml\]= ideal body weight \[kg\]\* 6\~8 throughout the surgery.
62176591|NCT06309849|EXPERIMENTAL|Efficacy of Physical Therapy Intervention in Cervical Angina Patients|Randomized Control Trail (RCT) will be used in the study. Participants will be dived into experimental group and control group. Each group will includes 30 participants.The physiotherapy program intervention will includes cervical traction, cervical mobilization, Sub occipital release, Muscle energy technique. and ultra sound with parameters 5 min × 3 times × 4 weeks, 1 MHz, continuous: 1.5 W/cm2; pulsed: 2.5 W/cm2, for study group.
62391461|NCT06342440||Non-disease controls (Discovery cohort)|Individuals who underwent colonoscopy and were found not to have any adenomas or cancer.
62176592|NCT06309849|PLACEBO_COMPARATOR|know the effect of Physical Therapy Intervention in Cervical Angina Patients|30 participants in control.The physiotherapy program intervention will include ultrasound with parameters 5 min × 3 times × 4 weeks, 1 MHz, continuous: 1.5 W/cm2; pulsed: 2.5 W/cm2
62176593|NCT00160979|EXPERIMENTAL|hypoxia and RT in prostate cancer|
62176594|NCT02815137|OTHER|XPO1 E571K mutation detection|Determination of mutation of XPO1571K in patient with classical hodgkin Lymphoma by digital PCR on blood samples and biopsy
62176595|NCT05306340|EXPERIMENTAL|Giredestrant plus Everolimus|
62176596|NCT05306340|ACTIVE_COMPARATOR|Physician's Choice of Endocrine Therapy plus Everolimus|The physician's choice of endocrine therapy is defined as either exemestane, fulvestrant, or tamoxifen.
62741757|NCT02965794||Care Pathway|Care pathways for colorectal cancer
62176597|NCT00196378|EXPERIMENTAL|1|
62176598|NCT00196378|PLACEBO_COMPARATOR|2|
62741758|NCT06574126|EXPERIMENTAL|Dara_VRD plus cilta-cel|Study participants will be assigned to either Group 1 (n=10) or Group 2 (n=10), depending on cilta-cel manufacturing availability. Participants in Group 1 will receive a maximum of 2 cycles of Dara-VRD induction therapy followed by apheresis and infusion of cilta-cel. Participants in Group 2 will undergo apheresis followed by 2 cycles of Dara-VRD induction therapy and cilta-cel infusion with the objective of evaluating changes in the quantity and quality of T cells collected.
62741759|NCT06661928|EXPERIMENTAL|Papilla preservation flap|Access flap for open flap debridement using intrasulcular incisions and papilla preservation approaches to preserve the entire interdental tissues
62741760|NCT06661928|ACTIVE_COMPARATOR|Conventional surgery|Access flap for open flap debridement using a conventional modified Widman flap procedure
62741761|NCT06661876|EXPERIMENTAL|5Gy whole heart radiotherapy|
62741762|NCT04887610|SHAM_COMPARATOR|Ischemic preconditioning control|
62741763|NCT04887610|ACTIVE_COMPARATOR|Ischemic preconditioning|
62741764|NCT04887610|ACTIVE_COMPARATOR|High fat meal|
62741765|NCT04887610|PLACEBO_COMPARATOR|Low fat meal|
62741766|NCT06532500|EXPERIMENTAL|CBT-MyOWL|A novel talk therapy model where we incorporate the standard CBT model with experiential learning while reading the third novel in the Harry Potter series to teach coping skills and emotional resiliency. The 12 sessions of CBT-MyOWL will follow a modestly adapted version of the intervention offered on www.myowl.org. The therapist will cover topics such as risk and protective factors for distress and mental health problems, cognitive distortions, cognitive reframing, fear hierarchies, behavioural activation and core beliefs while reading Harry Potter and the Prisoner of Azkaban.
62741767|NCT06532500|ACTIVE_COMPARATOR|CBT-as-usual|A talk therapy where participants will be encouraged to recognize distortions in thinking and then to reevaluate them in light of the evidence, gain a better understanding of how their behaviour contributes to wellbeing, learn to use problem-solving skills to cope with difficult situations, and learn to develop a greater sense of confidence in one's own abilities. This is the control group, and they will be utilizing the 'Mind over Mood' and/or the 'Anxiety and Phobia Workbook' according to the primary diagnosis.
62741768|NCT03503097||Ancillary-Correlative (questionnaires, Color kit, counseling)|Participants receive web-based or hard-copy questionnaires and saliva collection kits via mail or in person. Participants also provide saliva samples to be mailed back to Color Genomics for genetic testing once complete. Participants then receive phone-based genetic counseling if they are identified to have an inherited mutation in a DNA repair gene. All participants have access to phone-based genetic counseling whether or not they are not found to have a mutation.
62741769|NCT00614718||1|Total number of patients receiving an ICD between 1993 and 2004 and not having re interventions due to malfunctioning leads.
62741770|NCT00614718||2|Patients with ICD lead failure receiving a new ICD lead
62741771|NCT00614718||3|Patients with ICD lead failure but intact shock-coil of the ICD lead receiving only an additional pace/sense lead.
62741772|NCT05844943|EXPERIMENTAL|Soft tissue hand injury|
62741773|NCT05210582|EXPERIMENTAL|Afamelanotide|
62741774|NCT03922672|EXPERIMENTAL|Piano group|This group will consist of the adult with Parkinson's disease and their caregiver for a total of 14 pairs.
62176599|NCT01689467|EXPERIMENTAL|Fermented Velvet Antler extract|
62176600|NCT01689467|PLACEBO_COMPARATOR|Placebo|
62741775|NCT04046016|EXPERIMENTAL|Subjects|A total of two subjects were enrolled. Those are breast cancer patients.
62741776|NCT00340002||Pregnant women|Pregnant women aged 18 years and older
62741777|NCT00974441|EXPERIMENTAL|Divalproex Sodium|500 mg Extended Release Tablet
62741778|NCT00974441|ACTIVE_COMPARATOR|Depakote®|500 mg Extended Release Tablet
62741779|NCT06652412|EXPERIMENTAL|CGA cohort|"in cohort 1, all patients will receive Ultrafractionated RT, PD-1 antibody, and Comprehensive Geriatric Assessment (CGA) Guided systemic treatment.~Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive single agent chemotherapy and BSC; Fit patients will receive doublet chemotherapy and BSC."
62741780|NCT06652412|OTHER|external control cohort|external control from real word, data of patients with the same baseline characteristics from the same period and the same institute will be prospectively collected.
62741781|NCT02603601|ACTIVE_COMPARATOR|Standard lifestyle intervention|The standard lifestyle intervention is a 1-hour individual nutritional counseling session with a registered dietician at BIDMC.
62741782|NCT02603601|EXPERIMENTAL|Mind-body lifestyle intervention|The mind-body lifestyle intervention is a 10-week mindfulness-based intervention that integrates mindfulness with traditional behavioral strategies to improve long-term weight maintenance.
62741783|NCT01147887|EXPERIMENTAL|001|Drug combination/ 26489112 On Day 1 and on Day 19 a single oral dose of a drug combination consisting of midazolam (2 mg/mL liquid) tolbutamide (a 500 mg tablet) and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21 a single oral dose of two 26489112 tablets will be taken.
62741784|NCT02676947|EXPERIMENTAL|Open Label|Intravenous Tocilizumab 8mg/kg monthly (up to a maximum dose 800mg) for 6 months
62741785|NCT01185314|OTHER|1|EGFR mutation testing
62741786|NCT06224140|ACTIVE_COMPARATOR|Heparin Anticoagulation|
62741787|NCT06224140|EXPERIMENTAL|Regional Anticoagulation Procedure (RAP)|
62741788|NCT05707442|EXPERIMENTAL|Stent Implantation|The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to \> 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure.
62741789|NCT05707442|ACTIVE_COMPARATOR|Medical Therapy|The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade \<1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily. In addition, the weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
62176601|NCT06620432|ACTIVE_COMPARATOR|Low Segment Hysterotomy + Crossed hysterorrhaphy|The participant will undergo a cesarean section in which the surgical technique of Low Segment Hysterotomy and Crossed hysterorrhaphy for uterine closure will be employed. The initial incision and skin closure will be performed at the discretion of the gynecologist.
62176602|NCT06620432|EXPERIMENTAL|High Segment Hysterotomy + Crossed hysterorrhaphy|The participant will undergo a cesarean section in which the surgical technique of High Segment Hysterotomy and Crossed hysterorrhaphy for uterine closure will be employed. The initial incision and skin closure will be performed at the discretion of the gynecologist.
62182435|NCT05333575|EXPERIMENTAL|Experimental Group: Classic Music|Babies in this group were listened to classical music during feeding.
62741790|NCT04444986|EXPERIMENTAL|FAVIR then AVIGAN|Participants first received Favir 200 mg FT manufactured by Kocak in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
62741791|NCT04444986|EXPERIMENTAL|AVIGAN then FAVIR|Participants first received Favir 200 mg FT manufactured by Kocak in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
62741792|NCT06660615|EXPERIMENTAL|Receiving midwife-led care|The birth process will be followed by the same midwife from the beginning of the intrapartum period until the birth of the baby and placenta. In this process, positive respectful maternal care will be included in line with the recommendations of WHO (İsbir \& Sercekuş, 2017).
62741793|NCT06660615|NO_INTERVENTION|Midwife-Led Non-Care Receiving Care|Participants in the group will receive routine care normally provided only in the hospital. Within this care, from the beginning of the intrapartum period until the birth of the baby and placenta, the birth process will be followed under the supervision of a midwife or physician who is randomly available within the working conditions of the birth unit.
62741794|NCT06659510|EXPERIMENTAL|experimental group|"Experimental:~Before intervention, both Control and Face-to-face interviews were held with the intervention groups and a survey was conducted.~and 'Descriptive questionnaire' and 'Transtheoretical Model Scale' and Young Internet Addiction Test-Short Form (YİBT-SF) Scale' were used to collect data.~This training, conducted by the researcher, It was supported with presentations, slide shows, questions and answers, brochures and posters.~After the training, the Intervention group After the 10-week training, they were subjected to 3-month monitoring and the follow-up process was asked at least twice a month via a social media application or by calling."
62741795|NCT06659510|NO_INTERVENTION|Control Group|"As for the control group, a survey was administered via face-to-face interview method in the pre-test and post-test, but no training was given.~In the survey application, the Diagnostic Form, Transtheoretical Model Scale and Young Internet Addiction Test Short Form Scale consist of the same questions as the survey application in the experimental group. The study continued with 38 students in the control group, as in the experimental group."
62741796|NCT04022226|ACTIVE_COMPARATOR|Methohexital|Standard of care anesthesia that does not affect slow wave characteristics
62741797|NCT04022226|EXPERIMENTAL|Ketamine|Standard of care anesthesia that suppresses slow wave characteristics
62741798|NCT04387357||Control|Neurologically healthy older adults above the age of 50
62741799|NCT04387357||Experimental|Older adults above the age of 50 with Mild Cognitive Impairment or Dementia
62176603|NCT06620432|EXPERIMENTAL|Low Segment Hysterotomy + Non-Crossed hysterorrhaphy|The participant will undergo a cesarean section in which the surgical technique of Low Segment Hysterotomy and Non-Crossed hysterorrhaphy for uterine closure will be employed. The initial incision and skin closure will be performed at the discretion of the gynecologist.
62741800|NCT02014506|EXPERIMENTAL|HAPLO|
62176604|NCT06620432|EXPERIMENTAL|High Segment Hysterotomy + Non-Crossed hysterorrhaphy|The participant will undergo a cesarean section in which the surgical technique of High Segment Hysterotomy and Non-Crossed hysterorrhaphy for uterine closure will be employed. The initial incision and skin closure will be performed at the discretion of the gynecologist.
62176605|NCT05940714|EXPERIMENTAL|Video participants|Patients treated at the Hospital Odontològic Universitat de Barcelona (HOUB) who go for a routine visit in the period of the study and wish to participate. Parameters are measured and an oral hygiene teaching intervention is carried out.
62741801|NCT04265157||Early occlusion of hepatoduodenal ligament|Early occlusion of hepatoduodenal ligament during mobilization of the liver of the recipient by using portal vein clamp or occlusive temporary bands.
62741802|NCT04265157||classical occlusion of hepatoduodenal ligament|classical occlusion of hepatoduodenal ligament after mobilization of the liver of the recipient immediately before explantation by suing of portal vein clamp
62741803|NCT01360749|EXPERIMENTAL|Lambdalina and placebo|Eligible patients will receive lambdaline (lidocaine cream 40 mg/g) in Left Lower Extremity and placebo in Right Lower Extremity.
62741804|NCT01360749|EXPERIMENTAL|Placebo and lambdalina|Eligible patients will receive placebo in Left Lower Extremity and lambdaline (lidocaine cream 40 mg/g) in Right Lower Extremity.
62741805|NCT03383913|EXPERIMENTAL|Intervention|The intervention arm baseline visit will include: Institutional Review Board (IRB) consent, PROMIS measure baseline and outcome assessments, instructions on placement of Firstbeat device and use of Firsbeat journal, resting HRV recording using Firsbeat software for 15 minutes, saliva collection, and distribution of actigraph watch to quantify sleep quality. Participants placed in the intervention arm will receive 4-6 weeks of Heart Rate Variability Biofeedback training. All measures will be repeated at the end of the six week period.
62176606|NCT05940714|NO_INTERVENTION|Non video participants|Patients treated at the Hospital Odontològic Universitat de Barcelona (HOUB) who go for a routine visit in the period of the study and wish to participate. Parameters are measured and and no initial intervention is performed.
62176607|NCT05193500|ACTIVE_COMPARATOR|Addressed|Children participate in an interaction with an experimenter who uses the word to be learned.
62176608|NCT05193500|EXPERIMENTAL|Overheard|Children are present in the room while an experimenter uses the word to be learned in an interaction with another experimenter.
62176609|NCT01848262|ACTIVE_COMPARATOR|ECALMIST|ECALMIST will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant
62552702|NCT01833650|EXPERIMENTAL|Candy plus thymus honey mouthwash 1|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting immediate after the ingestion of 131I therapy (about 1 hour) and for a duration of no more than 4 days
62741806|NCT03383913|NO_INTERVENTION|Control|The control arm baseline visit will include: Institutional Review Board (IRB) consent, PROMIS measure assessments, instructions on placement of Firstbeat device and use of Firsbeat journal, resting HRV recording using Firstbeat software for 15 minutes, saliva collection, and distribution of actigraph watch to quantify sleep quality. The control group will receive their usual care for SCD and complete baseline and post-baseline outcome assessments without any HRV-B training. All measures will be repeated at the end of the six week period.
62741807|NCT05781945|EXPERIMENTAL|probiotic +|
62741808|NCT05781945|ACTIVE_COMPARATOR|standard therapy|
62741809|NCT05592626|EXPERIMENTAL|Phase 1: Advanced Solid Tumors|Dose Escalation; Intervention: Drug: STAR0602
62741810|NCT05592626|EXPERIMENTAL|Phase 2: Advanced Solid Tumors|Dose Expansion; Recommended Phase 2 Dose (RP2D) identified from Phase 1 will be used in Phase 2; Intervention: Drug: STAR0602
62741811|NCT05085093||Study Group|HPV vaccine group
62741812|NCT05085093||Control group|non HPV vaccine group
62741813|NCT06646965|EXPERIMENTAL|individual dietetic follw-up|the patient receives individual counseling (as usual clinical practice if the pregnant woman is followed by a dietetician during her pregancy).
62741814|NCT06646965|ACTIVE_COMPARATOR|family-based dietary counseling follw-up|the woman and the person who shares meals with her receive family-based counseling by a dietetician during her pregancy.
62741815|NCT03866317|EXPERIMENTAL|Secukinumab|Secukinumab 300 mg injection at week 0, 1, 2, 3, 4, then every 4 weeks until week 12
62176610|NCT01848262|EXPERIMENTAL|InSurE|InSurE will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant
62176611|NCT01730547|ACTIVE_COMPARATOR|Early treatment with mesenchymal stem cells|Patients receive a single intravenous dose of autologous bone marrow-derived MSCs followed by placebo at week 24. Fommow up at week 48
62741816|NCT06430463||patients undergoing shoulder surgery with interscalene block|Ultrasound-guided Interscalene block will be applied to all patientsand also every patients will be treated with the same multimodal analgesia for postoperative pain control. The patient will be examined by ENT physician on the morning of the operation, after a detailed anamnesis. otoscopic examination will be performed, pure tone audiometry, speech audiometry and tympanometric examination will be performed and recorded.The same tests will be performed at the next day after the surgery but before the discharge and also when he/she applies for the first week check-up.
62741817|NCT05675722|EXPERIMENTAL|autologous vaginal construct for patients with vaginal aplasia|Biologic vaginal construct, surgically implanted into native vaginal site
62741818|NCT06659081|EXPERIMENTAL|socket shield technique|
62741819|NCT06659081|EXPERIMENTAL|immediate implant placement|
62741820|NCT06658821|EXPERIMENTAL|LDL557-HK capsule|Subjects will take one capsule of the experimental group(LDL557-HK capsule) within 30 minutes before lunch during the experimental period.
62176612|NCT01730547|ACTIVE_COMPARATOR|Delayed treatment with mesenchymal stem cells|Patients receive placebo for 24 weeks followed by autologous MSCs at week 24, with a follow-up visit at week 48.
62176613|NCT05501847|NO_INTERVENTION|Patient with ventricular hypertrophy|Screening for cardiac amyloidosis in a patient with heart failure and ventricular hypertrophy is performed as part of routine care according to a standardised care protocol that follows the Gullimor algorithm.
62176614|NCT05501847|EXPERIMENTAL|Patient with no ventricular hypertrophy|"In the context of TEAM-HF research, the heart failure patient without ventricular hypertrophy will undergo a bone scan.~If the diagnosis of amyloidosis is most often suspected on the electrocardiogram and cardiac echography, only cardiac MRI or bone scan with diphosphonates (for transthyretin amyloidosis) can make the diagnosis."
62176615|NCT04816708|ACTIVE_COMPARATOR|Arm 1: Intervention group (access to LIFT mindfulness app)|Participants randomized to the intervention arm will be provided access to LIFT app's daily mobile mindfulness therapy for 30 days.
62176616|NCT04816708|NO_INTERVENTION|Arm 2: Control waitlist group (delayed access to LIFT mindfulness app)|Control participants will not receive access to the LIFT app daily mobile mindfulness therapy during study period. They may have access to LIFT app daily mobile mindfulness therapy after completion of the study period.
62176617|NCT03505918|NO_INTERVENTION|Standard municipal rehabilitation|Standard care with postoperative rehabilitation at the municipal facility.
62176618|NCT03505918|EXPERIMENTAL|No referral for rehabilitation|No referral for supervised postoperative rehabilitation. Only standard information booklet and advice during hospitalization.
62176619|NCT03133078|EXPERIMENTAL|Exercise: step-down test (2 min)|The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.
62176620|NCT03133078|EXPERIMENTAL|Exercise: side hop test (30 s)|The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
62182436|NCT05333575|NO_INTERVENTION|Control Group|Premature newborns in the control group were fed according to the routine of the clinic and no intervention was performed other than routine practice.
62741821|NCT06658821|PLACEBO_COMPARATOR|Placebo capsule|Subjects will take one placebo capsule within 30 minutes before lunch during the experimental period.
62741822|NCT01353443|NO_INTERVENTION|Group A|Monofilament absorbable MonoPlus® suture material will be used for closing of the midline incision.
62182437|NCT01041768|ACTIVE_COMPARATOR|antidiabetic medical therapy|
62741823|NCT01353443|OTHER|Group B|Abdominal wall closure with monofilament absorbable MonoPlus® suture material and onlay placement of Optilene® Mesh Elastic fixed by sutures.
62741824|NCT01353443|NO_INTERVENTION|Group C|Monofilament, absorbable MonoMax suture material will be used for the closure of the abdominal cavity.
62741825|NCT03895580|NO_INTERVENTION|Group 1|Medical nutrition therapy session with no further dietary counseling throughout the study.
62741826|NCT03895580|EXPERIMENTAL|Group 2|Medical nutrition therapy session plus in-store point-of-purchase (POP) education.
62741827|NCT03895580|EXPERIMENTAL|Group 3|Medical nutrition therapy session plus combined in-store/online point-of-purchase (POP) education.
62741828|NCT06660329|EXPERIMENTAL|Janus kinase inhibitors|Tofacitinib is used according to weight: 5\~\<7kg，2mg；7\~\<10kg，2.5mg；10\~\<15kg，3mg；15\~\<25kg，3.5mg；25\~\<40kg，4mg；≥40kg，5mg. All is twice a day.
62741829|NCT04168203|EXPERIMENTAL|Extended Duration Thromboprophylaxis|apixaban 2.5 mg orally twice daily for a duration of 12 months
62741830|NCT04168203|PLACEBO_COMPARATOR|Control|oral placebo for a duration of 12 months
62741831|NCT04974905|OTHER|patients with infrainguinal arterial occlusive disease after failed antegrade approach|
62741832|NCT05130905|EXPERIMENTAL|Supplementation with RiteStart|Once enrolled into the study, participants were instructed to take RiteStart Supplement daily for 12 weeks.
62741833|NCT04771299|ACTIVE_COMPARATOR|Cariprazine|1.5mg of Cariprazine added to their current treatment for 6 week period
62741834|NCT04771299|PLACEBO_COMPARATOR|Placebo|Matching placebo added to their current treatment for 6 week period.
62176621|NCT04832581|EXPERIMENTAL|Experimental Group|The experimental group was informed that they participated in a study. After the data collection forms were introduced, written and verbal consents were obtained. Information has been received. The experimental group was included in the program based on the Orem Self Care Model. The program includes anatomical, physiological and hormonal changes during pregnancy, urinary system infections and preventive measures. A phone call was scheduled 2 weeks later. Second evaluation forms were applied. Both groups were informed that the study was concluded.
62741835|NCT02993822|EXPERIMENTAL|Orvepitant 10mg|Orvepitant 10mg tablet, once daily for 12 weeks
62741836|NCT02993822|EXPERIMENTAL|Orvepitant 20mg|Orvepitant 20mg tablet, once daily for 12 weeks
62741837|NCT02993822|EXPERIMENTAL|Orvepitant 30mg|Orvepitant 30mg tablet, once daily for 12 weeks
62741838|NCT02993822|PLACEBO_COMPARATOR|Placebo|Placebo to match tablet, once daily for 12 weeks
62741839|NCT05010200|EXPERIMENTAL|Cohort 1 - Primary treatment cohort|Patients receive the personalized genomic vaccine (PGV) and Poly-ICLC.
62741840|NCT05010200|EXPERIMENTAL|Cohort 2 - Secondary treatment cohort|Patients receive the personalized genomic vaccine (PGV) and Poly-ICLC, and CDX-301
62741841|NCT05010200|EXPERIMENTAL|Cohort 3 - Expansion treatment cohort|An expansion cohort if the treatment of all 3 together has not triggered a safety stopping event.
62741842|NCT01454128|ACTIVE_COMPARATOR|Non-EPB|with exercise
62741843|NCT01454128|EXPERIMENTAL|EPB with exercise|with exercise
62741844|NCT06486493|ACTIVE_COMPARATOR|Overweight conventional treatment group|Children between 9 to 12 years old, from the Family Medicine Unit No. 1 and 3 (IMSS, Morelos) with a BMI Z-score 1 to 2 standard deviations above the median of the established growth patterns by age and sex, and a BMI above the 85th percentile, according to the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). Who will be treated with conventional medical treatment by their physicians, following the Clinical Practice Guideline for the Prevention and Diagnosis of Overweight and Obesity in Children and Adolescents (SS-025-08) and the Guideline for the Diagnosis, Treatment, and Prevention of Overweight and Obesity in Adults (IMSS 46-08), over six months, with a follow-up of 18 months post-intervention.
62741845|NCT06486493|EXPERIMENTAL|Overweight workshop group|"Children between 9 to 12 years old, from the Family Medicine Unit No. 23 (IMSS, Mexico City) with a BMI Z-score 1 to 2 standard deviations above the median of the established growth patterns by age and sex, and a BMI above the 85th percentile according to WHO and CDC. Treated with a workshop based on national and international guidelines for the management of overweight and obesity, and best practices for the control and reduction of overweight and obesity in school-aged children, by the Food and Agriculture Organization (FAO). The workshop will consist of a monthly session over six months for parents and children, with a follow-up of 18 months post-intervention.~In addition to the conventional medical treatment by their physicians, according to the Clinical Practice Guidelines."
62741846|NCT06486493|ACTIVE_COMPARATOR|Obesity conventional treatment group|Children between 9 to 12 years old, from the Family Medicine Unit No. 1 and 3 (IMSS, Morelos) with a BMI Z-score 3 standard deviations above the median of the established growth patterns by age and sex, and a BMI above the 97th percentile according to WHO and CDC. Treated with conventional medical treatment by their physicians, according to the Clinical Practice Guideline for the Prevention and Diagnosis of Overweight and Obesity in Children and Adolescents (SS-025-08) and the Guideline for the Diagnosis, Treatment, and Prevention of Overweight and Obesity in Adults (IMSS 46-08), over six months, with a follow-up of 18 months post-intervention.
62741847|NCT06486493|EXPERIMENTAL|Obesity reinforcement group|"Children between 9 to 12 years old, from the Family Medicine Unit No. 23 (IMSS, Mexico City) with a BMI Z-score 3 standard deviations above the median of the established growth patterns by age and sex, and a BMI above the 97th percentile according to WHO and CDC. Treated with conventional medical treatment by their physicians, according to the Clinical Practice Guideline for the Prevention and Diagnosis of Overweight and Obesity in Children and Adolescents (SS-025-08) and the Guideline for the Diagnosis, Treatment, and Prevention of Overweight and Obesity in Adults (IMSS 46-08).~Furthermore, in addition to the previously mentioned workshop with monthly sessions over six months for parents and children, there will be reinforcement through biweekly technological algorithms. This will be followed by an 18-month post-intervention follow-up."
62176622|NCT04832581|NO_INTERVENTION|Control Group|The control group was informed that they participated in a study. After the data collection forms were introduced, written and verbal consents were obtained. Information has been received. A phone call was scheduled 2 weeks later. Second evaluation forms were applied. After the research was completed, information was given in order to avoid bias and the brochure was delivered. Both groups were informed that the study was concluded.
62176623|NCT03372577|EXPERIMENTAL|patient and partner|
62176624|NCT03372577|EXPERIMENTAL|patient ,partner and cardiac rehabilitation team|
62741848|NCT03697005|EXPERIMENTAL|BioHPP PEEK single posterior crowns|BioHPP PEEK copings veneered with composite resin
62741849|NCT03697005|ACTIVE_COMPARATOR|zirconia-based single posterior crowns|yttria stabilized tetragonal zirconia used as copings to be veneered with porcelain
62176625|NCT03372577|ACTIVE_COMPARATOR|Treatment as usual|
62176626|NCT00547183|ACTIVE_COMPARATOR|2|2.5 mg tadalafil
62176627|NCT00547183|ACTIVE_COMPARATOR|3|5 mg tadalafil
62176628|NCT00547183|PLACEBO_COMPARATOR|1|
62176629|NCT04226651|ACTIVE_COMPARATOR|First dental visit|Virtual Reality Exposure Therapy
62176630|NCT04226651|PLACEBO_COMPARATOR|Second Dental Visit|Protective Glasses
62176631|NCT03800485|EXPERIMENTAL|IMT-GE|the participants will perform a training protocol of the inspiratory muscles during 8 weeks with a load that will increase from the 15% of the maximal inspiratory preassure until the 60% of the maximal inspiratory preassure.
62176632|NCT03800485|PLACEBO_COMPARATOR|IMT-GP|The participants will perform a training protocol of the inspiratory muscles during 8 weeks with a load that will be the 10% of the maximal inspiratory preassure during all the 8 weeks
62741850|NCT05041907|ACTIVE_COMPARATOR|Positive control: Nirmatrelvir/ritonavir (e.g. PAXLOVID™)|
62176633|NCT03412578|NO_INTERVENTION|Control|Infants in this group will receive ordinary supportive care and will not receive Massage Therapy
62176634|NCT03412578|ACTIVE_COMPARATOR|Massage group|"Infants in this group will receive Massage Therapy Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).~During massage therapy, infant's behavioural reaction was observed for signs of distress (e.g., yawning, finger splaying, crying)."
62741851|NCT05041907|EXPERIMENTAL|Nitazoxanide|
62741852|NCT05041907|EXPERIMENTAL|Molnupiravir and Nirmatrelvir/ritonavir (e.g. PAXLOVID™) [This arm is now closed to recruitment]|
62741853|NCT05041907|EXPERIMENTAL|Hydroxychloroquine|
62741854|NCT05041907|OTHER|Negative control group|
62741855|NCT05041907|EXPERIMENTAL|AZD7442 (EVUSHELD™) [This arm is now closed to recruitment]|
62741856|NCT05041907|EXPERIMENTAL|Fluoxetine [This arm is now closed to recruitment]|
62741857|NCT05041907|EXPERIMENTAL|Molnupiravir [This arm is now closed to recruitment]|
62176635|NCT03691142||Women with Hereditary Haemorrhagic Telangiectasia|Women with Hereditary Haemorrhagic Telangiectasia with at least one full term pregnancy
62176636|NCT03134274|EXPERIMENTAL|Pregnant women|Pregnant women above the age of 18 years, undergoing routine pre-natal care, who own and are familiar with use of a smartphone receive a Dip HBDA kit for home use.
62176637|NCT05458154|EXPERIMENTAL|Experimental group|"Seven of the 22 pain measures demonstrated satisfactory psychometric properties and clinical utility and are thereby recommended for clinical and research use in adults with a diagnosis of cancer.~Participants received Physical therapy program is critical to preserve flexibility, strength, range of motion, and normal neuromuscular recruitment. Patients' efforts to cut back their pain through avoidance behaviors can severely undermine function if mobility, activity of daily living, performance, or vocational capacity are affected. Physical therapy may involve trials of analgesic modalities like desensitization techniques, transcutaneous electrical nerve stimulation (TENS), and topical cold. Modality trials are rapid, relatively harmless, and inexpensive with the additional benefit that patients can self-administer effective treatments The pain management protocol of physiotherapy of PMPS depends mainly on education regarding the subsequent points that are paramount."
62176638|NCT03465085|EXPERIMENTAL|Group I: Heparin nebulized group|Group (I): 20 patients received inhaled Unfractionated Heparin at a dose of 10000 IU/4h by nebulizer, with the total daily dose of nebulized Unfractionated Heparin 60,000 IU
62176639|NCT03465085|EXPERIMENTAL|Group II: Streptokinase group|Group (II): 20 patients received inhaled Streptokinase at a dose of 250,000 IU/4h by nebulizer, with the total daily dose of nebulized Streptokinase 1,500,000 IU.
62176640|NCT03465085|NO_INTERVENTION|Group III: Control group|Twenty patients whom guardian declined to participate actively in the study but accepted to participate passively by consenting for using their data were assigned as Group III or the control group and received conservative management
62176641|NCT02650726|PLACEBO_COMPARATOR|control group|The participants in this group are instructed to consume placebo capsules every day during the trial period.
62552703|NCT05294250|EXPERIMENTAL|XC8, fasted|Administration of XC8 20 mg in fasted state in Dosing Periods 1 and 2 followed by administration of XC8 20 mg in fasted state in Dosing Period 3
62176642|NCT02650726|EXPERIMENTAL|treatment group|The participants in this group are instructed to consume anthocyanin capsules every day during the trial period.
62176643|NCT04255654|EXPERIMENTAL|Brief Intervention|There is only 1 intervention for this study. They will have the brief intervention completed on them. There is no control group.
62552704|NCT05294250|EXPERIMENTAL|XC8, fed|Administration of XC8 20 mg in fed state in Dosing Periods 1 and 2 followed by administration of XC8 20 mg in fasted state in Dosing Period 3
62552705|NCT00719875|EXPERIMENTAL|1|
62552706|NCT03342885|EXPERIMENTAL|Intervention group|Participants enrolled into the intervention group receive specific sleep ergonomics guidance
62741858|NCT05041907|EXPERIMENTAL|Sotrovimab [Pending addition]|
62741859|NCT05041907|EXPERIMENTAL|Ensitrelvir [This arm is now closed to recruitment]|
62741860|NCT05041907|ACTIVE_COMPARATOR|Positive control (REGN-COV2) [This arm is now closed to recruitment]|
62741861|NCT05041907|EXPERIMENTAL|Favipiravir [This arm is now closed to recruitment]|
62741862|NCT05041907|EXPERIMENTAL|Ivermectin [This arm is now closed to recruitment]|
62741863|NCT05041907|EXPERIMENTAL|Remdesivir [This arm is now closed to recruitment]|
62741864|NCT05041907|EXPERIMENTAL|Atilotrelvir/ritonavir [Pending addition]|
62741865|NCT05041907|EXPERIMENTAL|Metformin (modified release) [Pending addition]|
62741866|NCT05041907|EXPERIMENTAL|Nirmatrelvir/ritonavir - 300/50 - dose finding [Pending addition]|
62741867|NCT05041907|EXPERIMENTAL|Nirmatrelvir/ritonavir - 150/50 - dose finding [Pending addition]|
62741868|NCT05041907|EXPERIMENTAL|Nirmatrelvir - dose finding [Pending addition]|
62741869|NCT03844672|EXPERIMENTAL|Low Concentration / Low Power|Participant will receive an e-liquid with a low nicotine concentration and an e-cigarette with a low power for three weeks.
62741870|NCT03844672|EXPERIMENTAL|Low Concentration / High Power|Participant will receive an e-liquid with a low nicotine concentration and an e-cigarette with a high power for three weeks.
62741871|NCT03844672|EXPERIMENTAL|High Concentration / Low Power|Participant will receive an e-liquid with a high nicotine concentration and an e-cigarette with a low power for three weeks.
62741872|NCT03844672|EXPERIMENTAL|High Concentration / High Power|Participant will receive an e-liquid with a high nicotine concentration and an e-cigarette with a high power for three weeks.
62741873|NCT03462017|EXPERIMENTAL|SAR247799|SAR247799 repeated doses once daily in the morning under fasted condition for 28 days according to a sequential dose design
62741874|NCT03462017|PLACEBO_COMPARATOR|Placebo|Identical matching placebo for SAR247799 and for sildenafil once daily in the morning under fasted condition for 28 days
62741875|NCT03462017|ACTIVE_COMPARATOR|Sildenafil|Sildenafil once daily in the morning under fasted condition for 28 days
62741876|NCT06529003|PLACEBO_COMPARATOR|Placebo|
62741877|NCT06529003|ACTIVE_COMPARATOR|TENS unit|
62741878|NCT00987441|ACTIVE_COMPARATOR|Local anesthetic plus opioid 1|Local anesthetic (ropivacaine 0.125%) plus first opioid dose (sufentanil 0.3 microgram/ml) delivered peridural space
62741879|NCT00987441|ACTIVE_COMPARATOR|Local anesthetic plus opioid 2|Local anesthetic (ropivacaine 0.125%) plus second opioid dose (sufentanil 0.4 microgram/ml) delivered peridural space
62741880|NCT00987441|ACTIVE_COMPARATOR|Local anesthetic plus opioid 3|Local anesthetic (ropivacaine 0.125%) plus third opioid dose (sufentanil 0.5 microgram/ml) delivered peridural space
62176644|NCT04964778|EXPERIMENTAL|Arm1: SKED© only first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 1 will be in the following order: SKED© only; SKED©+OSS-II©; SKED©+Vacuum mattress; SKED©+foam padding
62176645|NCT04964778|EXPERIMENTAL|Arm 2: SKED©+Vacuum mattress first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 2 will be in the following order: SKED©+Vacuum mattress; SKED©+OSS-II©; SKED©+foam padding, SKED© only
62176646|NCT04964778|EXPERIMENTAL|Arm 3: SKED©+OSS-II© first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 3 will be in the following order: SKED©+OSS-II©;SKED©+Vacuum mattress; SKED© only; SKED©+foam padding
62176647|NCT04964778|EXPERIMENTAL|Arm 4: SKED©+foam padding first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 4 will be in the following order: SKED©+foam padding, SKED©+Vacuum mattress; SKED© only; SKED©+OSS-II
62176648|NCT05790187|EXPERIMENTAL|visual test|Presentation of differents face pictures
62176649|NCT05654558|EXPERIMENTAL|Auxiliary intrusion cantilevers|"Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription. Lower first molars received double tubed bands while 2nd molars received single bondable tubes. Leveling and alignment phase then started with 0.014 inch NiTi wires engaging all teeth and synched behind 2nd molars. Two 0.017 x 0.025 TMA (Ormco) sectional wires were attached to auxiliary tubes on 1st molars with tip back bends mesial to the molars and attached with hooks distal to lateral incisors on top of basal leveling arch wire. Amount of intrusive force was measured to range between 20 and 40 grams per side. Basal leveling arches were upgraded whenever needed. All patients were assessed after 6 months of treatment."
62176650|NCT05654558|ACTIVE_COMPARATOR|Routine leveling and alignment|Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription, 1st and 2nd molars received tubes or bands according to each patient's further needs Lower arch was leveled and aligned with sequential wires starting with 14 NiTi and upgraded when needed. All patients were assessed after 6 months of treatment.
62176651|NCT05680285|EXPERIMENTAL|diode laser pulpotomy|"* Diode laser (Solase-976 Dental Diode Laser)~* With a wavelength of 980 nm and a frequency of 110 Hz~* In pulse mode, working for 1 ms and stopping for 8 ms~* With a power output of 1 W during each laser pulse from the 400 µm fiber optic tip~* By touching the fiber optic tip to the remaining pulp tissue~* for 3 seconds~* With 3 J energy to each root pulp during the process"
62182438|NCT01041768|EXPERIMENTAL|Bariatric Surgery|
62391462|NCT06342440||Low-risk Adenoma (Discovery cohort)|"Individuals who underwent colonoscopy and were found to only have low-risk adenomas, defined as all of the following:~* 1 to 4 adenomas at most.~* All adenomas have low-grade dysplasia at most.~* All adenomas are \<10 mm in diameter"
62552707|NCT03342885|ACTIVE_COMPARATOR|Control group|Participants enrolled into the control group will receive general sleep ergonomics guidance
62552708|NCT04350411|EXPERIMENTAL|Conventional diathermy|DIEP/ MS-TRAM breast reconstruction free flap raise performed with conventional diathermy
62552709|NCT04350411|EXPERIMENTAL|PEAK PlasmaBlade™|DIEP/ MS-TRAM breast reconstruction free flap raise performed with PEAK PlasmaBlade™
62552710|NCT03261505|EXPERIMENTAL|VGAIT|
62741881|NCT00987441|ACTIVE_COMPARATOR|Local anesthetic 1 plus opioid|First local anesthetic dose (ropivacaine 0.0625%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
62741882|NCT00987441|ACTIVE_COMPARATOR|Local anesthetic 2 plus opioid|Second local anesthetic dose (ropivacaine 0.1875%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
62741883|NCT00987441|ACTIVE_COMPARATOR|Local anesthetic 3 plus opioid|Third local anesthetic dose (ropivacaine 0.25%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
62741884|NCT02340208|EXPERIMENTAL|L-DOS47|Patient will be recruited into cohorts of L-DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort. The starting dose of L-DOS47 will be 0.12 μg/kg; further possible dose levels include 0.21, 0.33, 0.46, 0.59, 0.78, 1.04, 1.38, 1.84, 2.45, 3.26 and 4.33 μg/kg.
62741885|NCT04641728|EXPERIMENTAL|pembrolizumab plus olaparib|Until RECIST-based confirmation of progressive disease (PD), death, manifestation of intolerable toxicity, or participant withdrawal from the study, study participants will continue intravenous infusion of pembrolizumab 200 mg every three weeks (Q3W) in combination with oral olaparib 300 mg twice daily (BID) (combination therapy)
62741886|NCT06657118|ACTIVE_COMPARATOR|Conventional arthrocentesis|"* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side.~* External auditory meatus will be blocked with a cotton plug.~* A line will be drawn from tragus of the ear to the outer canthus of the eye with ink.~* Double needled canula is inserted into superior compartment of the joint space 2mm below and 10 mm ahead of mid-tragal end of Holmund Hellsing's line.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours"
62741887|NCT06657118|ACTIVE_COMPARATOR|Ultrasound guided arthrocentesis|"Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side.~* External auditory meatus will be blocked with a cotton plug.~* Transducer is placed over TMJ, parallel to the long axis of mandibular ramus. • Transducer is tilted until the optimal visualization is obtained.~* Disc is visualized as a thin homogenous, hypo-to-iso-echoic band lying adjacent to the inferior relation. The bony landmarks of the mandibular condyle and the articular eminence are visualized as hyperdense lines.~* Superior joint space located between the disc and articular eminence is the targeted point of the needle.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours"
62741888|NCT00596557|EXPERIMENTAL|Everolimus, Immunosupression|everolimus and reduced dose CNI: reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
62741889|NCT04654624|EXPERIMENTAL|Silver Diamine Fluoride|
62741890|NCT04654624|ACTIVE_COMPARATOR|Atraumatic Restorative Treatment|
62741891|NCT01299337||placebo|Subjects will be randomized either receiving T3 or placebo.
62741892|NCT06410352|ACTIVE_COMPARATOR|Pharmacologic weight loss (Combination Product)|The 1st group (n=50) receives subcutaneous Semaglutide (GLP-1RA) 1 mg once a 7 day with oral Empagliflozin (SGLT-2i) 25 mg once a day that is a novel combination additionally to standard medical treatment including anti-diabetes, antihypertensive, lipid-lowering, symptomatic therapy.
62176652|NCT05680285|EXPERIMENTAL|low level diode laser pulpotomy|"* Diode laser (Solase-976 Dental Diode Laser)~* It has a wavelength of 980 nm and a frequency of 165 Hz.~* In pulse mode by setting it to run for 2 ms and stop for 4 ms~* At a power of 0.2 W during each laser pulse from a 400 µm fiber optic tip~* Without the fiber optic tip touching the remaining pulp tissue~* for 10 seconds~* With 2 J Energy to each root pulp"
62176653|NCT04237675||regional anesthesia|
62176654|NCT04237675||general anesthesia|
62741893|NCT06410352|ACTIVE_COMPARATOR|Surgical weight loss|The 2nd group (n=50) receives surgical method (laparoscopic MGB). These patients pass through additional pre-operation examination (blood tests and electrocardiography, esophagogastroscopy, ultrasound, and other necessary standard methods).
62741894|NCT06410352|EXPERIMENTAL|Very-low-calorie-restriction diet|The 3rd group (n=50) receives very-low-calorie-restriction diet ('Analimentary-detoxication') including \<100 kcal/day with fat-free vegetables (tomato/cucumber) and salt intake (5-6 g/day), optimum physical activity, and sexual self-restraint. The program goals the next outputs: a) use of own fatty store; b) control endogen intoxication; c) reuse of interim metabolic substrates.
62741895|NCT06410352|EXPERIMENTAL|Ramadan fast's weight loss|"The 4th group (n=30) adheres to fasting on Ramadan fast (RF) season. They strictly adhered to two principles of nutrition during RF: 1) no blood, no smell of fat which means don't eat meat and don't eat fatty foods; 2) the 'Sehri time' (a meal eaten before dawn) included just 1.5-2.0 glass of water and fruits of 80-100 gr (apple, dates, and persimmon). Indeed, the patients followed a diet in which they ate one meal a day - participants have a meal during 'Iftar time' (a meal eaten after sunset)."
62741896|NCT01656005|EXPERIMENTAL|Carvedilol|Beclometasone/Formoterol Beclometasone Tiotropium
62741897|NCT01656005|ACTIVE_COMPARATOR|Bisoprolol|Beclometasone/Formoterol Beclometasone Tiotropium
62741898|NCT00239993|EXPERIMENTAL|1|skin reactions with the use of warm compress prior to performing a Copaxone® injection
62741899|NCT00239993|EXPERIMENTAL|2|skin reactions without the use of warm compress prior to performing a Copaxone® injection
62741900|NCT04464655||Healthy Volunteers|Age: \>18 y, No known current or pre-existing medical conditions that would affect the cardiovascular or respiratory system.
62741901|NCT04464655||Patients|Age: \> 18y, Clinically indicated CMR exam
62741902|NCT04699695||Biologic Treatment|Subjects prescribed a biologic agent per standard of care
62741903|NCT04699695||Other Treatments|Subjects prescribed other treatment modalities exclusive of biologic therapy per standard of care
62741904|NCT06661824|NO_INTERVENTION|Control group (routine care)|Patients in the control group will be given routine care by clinic nurses. There are aggression management interventions that the clinic has adopted so far. In the face of an aggressive event, 1. contact the patient, 2. notify the physician and perform chemical restraint according to the order, 3. perform mechanical restraint and seclusion according to the patient's condition. The researcher will not be involved and will not intervene at this stage. The same scales will be applied to the patients as the experimental group.
62741905|NCT06661824|EXPERIMENTAL|experimental group (aggression management care bundle)|The elements of the aggression management care bundle (risk assessment, cognitive remediation training, social skills training, tension reduction techniques, environmental therapy, improving sleep) developed for the experimental group will be applied by the clinical nurses and the researcher. Data will be collected by applying the same scales to the patients as the control group.
62741906|NCT06353295|OTHER|P4P intervention|Peer-led PrEP/PEP intervention
62176655|NCT01239537||Baxter H1N1 vaccine|Previously received 2 dose schedule of Baxter H1N1 vaccine
62176656|NCT01239537||GSK H1N1 vaccine|Previously received 2 dose schedule of GSK H1N1 vaccine
62176657|NCT02068378|EXPERIMENTAL|CMPE Optical Sensor Device|Single arm study
62176658|NCT04089839||CP-CML participants initiating dasatinib|
62176659|NCT04565210|EXPERIMENTAL|Oriental music|Infants assigned to this group will be exposed to oriental music.
62176660|NCT04565210|ACTIVE_COMPARATOR|Western music|Infants assigned to this group will be exposed to western music.
62176661|NCT04565210|PLACEBO_COMPARATOR|Silence / control|Infants assigned to this group will be exposed to the same protocol but using a track of silence.
62176662|NCT06646133||Standard care weight estimation|Simulated patients in whom standard methods of weight estimation will be used.
62176663|NCT06646133||3D camera weight estimation|Simulated patients in whom 3D camera estimates of weight will be used.
62176664|NCT03838419|ACTIVE_COMPARATOR|BCS + WBI|breast conserving surgery followed by whole breast irradiation
62176665|NCT03838419|EXPERIMENTAL|BCS + IORT|Breast conserving surgery incl intraoperative radiotherapy
62552711|NCT03261505|SHAM_COMPARATOR|VGAIT Control|
62552712|NCT03261505|ACTIVE_COMPARATOR|Real Acupuncture|
62552713|NCT03261505|PLACEBO_COMPARATOR|Sham Acupuncture|
62741907|NCT05422495|EXPERIMENTAL|Activity|cognitive-motor training : Cycléo device (COTTOS ®),
62741908|NCT05422495|PLACEBO_COMPARATOR|No activity|no training
62176666|NCT01553227|EXPERIMENTAL|ventilator|The overall purpose of this study is to determine the effects of auto-Trilevel ventilation on patients with OSAHS and OHS by comparison with BiPAP ventilation. The following parameters are compared such as apnea hypopnea index, lowest SPO2, arousal index, sleep efficiency, PaCO2, daytime sleepiness and so on.
62176667|NCT04974086|EXPERIMENTAL|CDS Tool Evaluation|All participants will receive intervention and feasibility, acceptability, and usability of intervention will be assessed from each participant cohort group.
62176668|NCT04857047|EXPERIMENTAL|Group A|"\[Period1\] administration of BR9003A 1mg twice a day for six days~- Wash out for 9days -~\[Period2\] administration of BR9003 2mg once a day for six days"
62741909|NCT04643873|EXPERIMENTAL|Experimental group 1|physical activity counseiling +pilates exercise group
62741910|NCT04643873|EXPERIMENTAL|Experimental group 2|only physical activity counseiling group
62176669|NCT04857047|EXPERIMENTAL|Group B|"\[Period1\] administration of BR9003 2mg once a day for six days~- Wash out for 9days -~\[Period2\] administration of BR9003A 1mg twice a day for six days"
62176670|NCT01274559|EXPERIMENTAL|Extended-release niacin/laropiprant|ERN/LRPT 1 g (1 tablet for 4 wks) followed by ERN/LRPT 2 g (2 tablets for 8 wks); Each 1-g tablet contains 1 g of ER niacin and 20 mg of laropiprant.
62176671|NCT01274559|PLACEBO_COMPARATOR|Placebo|Matching 1 g Placebo (1 tablet for 4 wks) followed by 2 g placebo (2 tablets for 8 weeks)
62741911|NCT04643873|NO_INTERVENTION|Control Group|only followed by family physician
62741912|NCT06657924|EXPERIMENTAL|Tranexamic Acid|TXA administered as a 1 gram IV bolus in 100ml of normal saline administered over 10 minutes at the start and end of the surgery for a total of 2 grams TXA
62741913|NCT06657924|NO_INTERVENTION|Control (no tranexamic acid)|Standard of care
62741914|NCT05667584|EXPERIMENTAL|HPI|"Standard intraoperative monitor and non-invasive continuous arterial pressure waveforms (ClearSight) are set up in this group. ClearSight data and hypotension prediction index (HPI) derived from ClearSight are used for recording and monitoring. Blood pressure is monitored with ClearSight and HPI. Attending anesthesiologists controlled the blood pressure according to HPI values.~1. Maintain HPI below 85~2. HPI \> 85 and heart rate \> 60/min, IV bolus norepinephrine 5-10 mcg~3. HPI \> 85 and heart rate \< 60/min, IV bolus norepinephrine 5-10 mcg with atropine 0.01 mg/kg"
62741915|NCT05667584|ACTIVE_COMPARATOR|ClearSight|"Standard intraoperative monitor and non-invasive continuous arterial pressure waveforms (ClearSight) are set up in this group. ClearSight data and HPI derived from ClearSight are used for recording, and HPI are masked for attending anesthesiologists. Blood pressure is monitored with ClearSight. Attending anesthesiologists controlled the blood pressure according to continuous arterial pressure values.~1. Maintain mean arterial pressure (MAP) above 65 mmHg~2. MAP \< 65mmHg and heart rate \> 60/min, IV bolus norepinephrine 5-10 mcg~3. MAP \< 65mmHg and heart rate \< 60/min, IV bolus norepinephrine 5-10 mcg with atropine 0.01 mg/kg"
61986241|NCT02067299|EXPERIMENTAL|Cohort A|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of placebo (Period 1), JNJ-42847922 10 mg (Period 2), JNJ-42847922 20 mg (Period 3), and JNJ-42847922 40 mg (Period 4). Each treatment period and each subsequent treatment period will be separated by 1 week.
61986242|NCT02067299|EXPERIMENTAL|Cohort B|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 10 mg (Period 1), JNJ-42847922 40 mg (Period 2), placebo (Period 3), and JNJ-42847922 20 mg (Period 4). Each subsequent treatment period will be separated by 1 week.
61986243|NCT02067299|EXPERIMENTAL|Cohort C|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 20 mg (Period 1), placebo (Period 2), JNJ-42847922 40 mg (Period 3), and JNJ-42847922 10 mg (Period 4). Each subsequent treatment period will be separated by 1 week.
61986244|NCT02067299|EXPERIMENTAL|Cohort D|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 40 mg (Period 1), JNJ-42847922 20 mg (Period 2), JNJ-42847922 10 mg (Period 3), and placebo (Period 4). Each subsequent treatment period will be separated by 1 week.
62176672|NCT05985083|EXPERIMENTAL|Dose escalation|"It's a dose escalation to identify the Maximum Tolerated dose (MTD) , recommended Phase II dose (RP2D) of IMM47, an accelerated titration method and the traditional 3+3 design method will be adopted. IMM47 will be sequentially escalated at the dose of 5 μg/kg，50 μg/kg, 250 μg/kg，1.0 mg/kg，3.0 mg/kg and 5.0 mg/kg or higher dose levels, administered via intravenous infusion every 2 weeks in 28-day treatment cycles.~The duration of the infusion is 120 min (± 10 min) for the 1st infusion and 60 min (± 5 min) for subsequent infusions."
62552714|NCT05085444|EXPERIMENTAL|Treatment of Scleroderma|Experimental：Administration of CD19/BCMA CAR T-cells A dose levels of 1-4\*10E6/kg are administrated for each subject.
62552715|NCT03162874|PLACEBO_COMPARATOR|PLACEBO|
62552716|NCT03162874|EXPERIMENTAL|PXT002331 - 10mg|
62552717|NCT03162874|EXPERIMENTAL|PXT002331 - 30mg|
62552718|NCT01696747||Diabetic|participants with a primary etiology of diabetic gastroparesis
62552719|NCT01696747||Idiopathic|participants with a primary etiology of idiopathic gastroparesis
62552720|NCT01696747||Post-Nissen|participants with a primary etiology of post-Nissen fundoplication gastroparesis
62552721|NCT03267212|ACTIVE_COMPARATOR|Non-invasive Ventilation(NIV)|Subjects will perform FES-row testing while receiving bi-level positive airway pressure ventilation applied through a full face-mask.
62552722|NCT03267212|SHAM_COMPARATOR|Sham Non-invasive ventilation(NIV)|Subjects will perform FES-row testing while receiving sham ventilation applied through a full face-mask.
62552723|NCT03649997|EXPERIMENTAL|Part 1 (Single Ascending Dose [SAD]): Cohort 1|Participants will receive single oral dose of JNJ-61393215 145 milligram (mg) suspension or matching placebo on day 1, under fasted conditions.
62552724|NCT03649997|EXPERIMENTAL|Part 1 SAD: Cohort 2|Participants will receive single oral dose of JNJ-61393215 225 mg suspension or matching placebo on day 1 under fasted conditions. Dose in this cohort will be determined based on safety and PK data of cohort 1.
62176673|NCT02380638|EXPERIMENTAL|DS-WBV|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform squat on a vibratory platform (3 times per week; 10 repetitions 30 to 60 seconds; Frequency: 25-30 Hz; Amplitude: 2 mm).
62741916|NCT05667584|NO_INTERVENTION|NIBP|"Standard intraoperative monitor and non-invasive continuous arterial pressure waveforms (ClearSight) are set up in this group. ClearSight data and HPI derived from ClearSight are used for recording, and are masked for attending anesthesiologists. Blood pressure is monitored with conventional non-invasive blood pressure (NIBP). Attending anesthesiologists controlled the blood pressure according to continuous arterial pressure values.~1. Maintain mean arterial pressure (MAP) above 65 mmHg~2. MAP \< 65mmHg and heart rate \> 60/min, IV bolus norepinephrine 5-10 mcg~3. MAP \< 65mmHg and heart rate \< 60/min, IV bolus norepinephrine 5-10 mcg with atropine 0.01 mg/kg"
62176674|NCT02380638|NO_INTERVENTION|DS-NONWBV|This group will continue with their day-to-day lifestyle during the course of the project.
62176675|NCT02380638|EXPERIMENTAL|NONDS-WBV|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform squat on a vibratory platform (3 times per week; 10 repetitions 30 to 60 seconds; Frequency: 25-30 Hz; Amplitude: 2 mm).
62176676|NCT02380638|NO_INTERVENTION|NONDS-NONWBV|This group will continue with their day-to-day lifestyle during the course of the project.
62176677|NCT03549988||Control|"The group will receive current standard of care as the usual practice of the attending physician. Basic research data will be collected and participants in this group will be asked to complete the on-line questionnaires (SIBDQ and EQ-5D 5L) on the baseline visit and month 6, 12 and month 18.~When endoscopy is performed biopsies should be taken and the endoscopic and histologic assessment will be recorded. If a fecal calprotectin is measured, every effort should be made to use the IBDoc with the result being sent to the central primary investigator via the IBDoc Web Portal. However, should a different fecal calprotectin measure be used, this will be recorded as part of the study documentation and will be included in the study data."
62176678|NCT03549988||Intervention: FC measurements with IBDoc|"Fecal Calprotectin (FC) measurements with IBDocTM home kits will be performed by participants in the intervention group every 2 months until final visit.~Basic research data will be collected and participants in this group will be asked to complete the on-line questionnaires (SIBDQ and EQ-5D 5L) on baseline visit and month 6, 12 and month 18."
62176679|NCT02907450|EXPERIMENTAL|Clinical evaluation of the tolerance of the orthosis|
62176680|NCT02470611|EXPERIMENTAL|Sodium Alendronate|Adjunctive use of 1% sodium alendronate gel as part of periodontitis treatment
62741917|NCT02888691|EXPERIMENTAL|Low Carbohydrate Diet|\< 100 grams of carbohydrate per day
62176681|NCT02470611|PLACEBO_COMPARATOR|Placebo|Adjunctive use of placebo gel as part of periodontitis treatment
62741918|NCT02888691|EXPERIMENTAL|High Carbohydrate Diet|\> 250 grams of carbohydrate per day
62176682|NCT02001389|EXPERIMENTAL|EVP-6308; Arm 1|low dose, Capsule, Twice Daily, Day 1 through Day 3
62176683|NCT02001389|EXPERIMENTAL|EVP-6308; Arm 2|low intermediate dose, Capsule, Twice Daily, Day 1 through Day 3
62176684|NCT02001389|EXPERIMENTAL|EVP-6308; Arm 3|high intermediate dose, Capsule, Once Daily, Day 1 through Day 3
62176685|NCT02001389|EXPERIMENTAL|EVP-6308; Arm 4|high dose, Capsule, Once Daily, Day 1 through Day 3
62552725|NCT03649997|EXPERIMENTAL|Part 2 Cohort 3: Treatment Sequence CDEF|Participants will receive single oral dose of JNJ-61393215 30 mg suspension under fasted condition (Treatment C) in Period 1, then participants will receive single oral dose of JNJ-61393215 30 mg capsule under fasted condition (Treatment D) in Period 2, single oral dose of JNJ-61393215 30 mg capsule with high fat/high-calorie breakfast (Treatment E) in Period 3 followed by single oral dose of JNJ-61393215 30 mg capsule with standardized breakfast (Treatment F) in Period 4, on day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods.
62741919|NCT06658197|EXPERIMENTAL|tenecteplase|Subjects assigned to this arm will receive an intravenous bolus of 0.25mg/kg tenecteplase before the mechanical thrombectomy.
61986245|NCT03779464|EXPERIMENTAL|S/nab|Nab-paclitaxel 125 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area \< 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area \>1.5 m²; D1-14, q3w)
61986246|NCT03779464|ACTIVE_COMPARATOR|Gem/nab|Nab-paclitaxel 125 mg/m² (D1, D8, q3w) and Gemcitabine 1000 mg/m² (D1, D8, q3w)
61986247|NCT05771142||Smart t-shirt, ECG Holter and smartwatch patients|24h ECG Monitoring - All participants will wear the smart t-shirt, the ECG Holter and the smartwatch at the same time
61986248|NCT03636347|PLACEBO_COMPARATOR|Placebo oral tablet|
62741920|NCT06658197|ACTIVE_COMPARATOR|alteplase|Subjects assigned to this arm will receive an intravenous 0.9 mg/kg alteplase(10% bolus +90% infusion/1 hour) before the mechanical thrombectomy.
62741921|NCT02461290||Combination Therapy|Rituximab 375mg/m2, on day 1 of each cycle of chemotherapy, total of 8 infusions. Chemotherapy according to standard regimens.
61986249|NCT03636347|ACTIVE_COMPARATOR|Alvelestat oral tablet - dose 1|MPH966
61986250|NCT03636347|ACTIVE_COMPARATOR|Alvelestat oral tablet - dose 2|MPH966
62176686|NCT00635570|ACTIVE_COMPARATOR|Contraceptive vaginal ring|Contraceptive vaginal ring (NuvaRing)
62176687|NCT00635570|ACTIVE_COMPARATOR|Oral contraceptive pill|Oral contraceptive pill (Ortho Tri-cyclen Lo)
62176688|NCT01187810|EXPERIMENTAL|Combination of Fenretinide, Cytarabine, and Methotrexate|IV for 7 days for each 21 day cycle
62176689|NCT04183244|ACTIVE_COMPARATOR|Erector spinae block|"Ultrasound guidance will be used to visualize the transverse processes of T2 and the overlying muscles.~Under sterile conditions, a 5-cm, 21-gauge needle will be inserted using the out-of-plane technique parallel to the sagittal plane directly over the transverse process,then 30mL of the local anesthetic solution will be injected and observed for the linear spread of LA the under direct ultrasound visualization"
62176690|NCT04183244|ACTIVE_COMPARATOR|infraclavicular subomohyoid block|Performing posterior approach infraclavicular BP block followed by subomohioid block via the same puncture site under ultrasound guidance.
62176691|NCT04560777|EXPERIMENTAL|experimental arm|CO-OP intervention
62176692|NCT06076798||Wear AFGen1|Wear AFGen1 for 7 days. ECG co-measurement with 12 lead device at start and end of wear period
62176693|NCT03385798|ACTIVE_COMPARATOR|Endo-GIA|
62176694|NCT03385798|EXPERIMENTAL|Endo-wrist|
62741922|NCT02195999||Individuals with DMD|"Magnetic Resonance Imaging is a non-invasive method to determine ventricular size, volumes, mass, and ejection fraction.~Pulmonary Function testing (PFT) are a series of non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.~Metabolic exercise testing using stationary bicycle (exercise capacity and MVO2) evaluates global cardiopulmonary functional status.~Echocardiogram with multiple-echo Dixon method helps to assess cross-sectional and longitudinal variations in myocardial structure."
62741923|NCT04739553|EXPERIMENTAL|His Pacing|Implant of a supplementary His pacing lead in addition to a traditional RV pacing lead.
62741924|NCT04653922|EXPERIMENTAL|Bioengineered corneal substitute|A cell-free, sterilized bioengineered corneal substitute made from medical grade collagen
62741925|NCT06334159|EXPERIMENTAL|Control Group|Horizontal Guided Bone Regeneration with a mixture of xenograft (Cerabone 0.5-1mm particles) and allograft (Maxgarft \<2mm particles) bone substitute (50/50) with non-fixed resorbable collagen membranes (Jason Membrane 20x30mm)
62741926|NCT06334159|EXPERIMENTAL|Test Group|Horizontal Guided Bone Regeneration with a mixture of xenograft (Cerabone 0.5-1mm particles) and allograft (Maxgarft \<2mm particles) bone substitute (50/50) with fixed resorbable collagen membranes(Jason Membrane 20x30mm) with the use of pins (Titan Pins)
62741927|NCT05929391|EXPERIMENTAL|sandblasted group (T1)|the side of mouth patient that receives fixed orthodontic appliance that renewed by sandblast
62741928|NCT05929391|PLACEBO_COMPARATOR|control group (T3)|the side of mouth patient that receives new fixed orthodontic appliance.
62741929|NCT05929391|EXPERIMENTAL|tungsten bur group (T0)|the side of mouth patient that receives fixed orthodontic appliance that renewed by tungsten bur.
62741930|NCT05929391|PLACEBO_COMPARATOR|control group (T2)|the side of mouth patient that receives new fixed orthodontic appliance.
62741931|NCT06661343|EXPERIMENTAL|C4 Intervention|Participants in this arm will receive care coordination and support through the C4 intervention. This program focuses on addressing structural barriers, such as healthcare access and mental health, to improve PrEP adherence. Participants will also attend regular counseling sessions and have their PrEP use monitored through dried blood spot (DBS) tests.
62741932|NCT06661343|EXPERIMENTAL|C4 + 3MV Intervention|Participants in this arm will receive the C4 intervention, along with the 3MV (Many Men, Many Voices) behavioral intervention. The 3MV program aims to reduce stigma, promote safer behaviors, and increase self-efficacy. This arm integrates both structural and behavioral approaches to enhance PrEP adherence. Participants will complete counseling sessions, group activities, and DBS testing for monitoring adherence.
62741933|NCT04776720|EXPERIMENTAL|Yoga Program|The 3-month yoga intervention provides instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population.
62741934|NCT04776720|ACTIVE_COMPARATOR|Physical Conditioning Program|The 3-month physical conditioning program provides instruction and practice in a variety of exercises and stretches that have been designed by the study physical therapist.
62741935|NCT03172754|EXPERIMENTAL|Phase I patients|Phase I patients must have received at least 1 prior tyrosine kinase inhibitor for RCC.
62176695|NCT02035098|EXPERIMENTAL|The Pac-IFicO programme|The Pac-IFicO programme is a complex interventions aimed at improving the quality of pain managementi in hospitalized patients.
62176696|NCT06024135|EXPERIMENTAL|NeoKidney therapy|"Every patient will receive NeoKidney therapy which will be referenced to SDHD sessions with the usual device as their own baseline.~The study is designed in a way that allows an incremental increase of the ratio of NeoKidney versus SDHD sessions with the usual device. In order to minimize the study burden to the patient, most SDHD sessions with the usual device will be done in the patient's home. The NeoKidney therapy sessions, and 2 SDHD sessions with the usual device will be performed in the study center, thus ensuring the necessary patient care and observation as well as sample collection."
62176697|NCT04662736||patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy|
62741936|NCT03172754|EXPERIMENTAL|Phase II patients: cohort 1|Phase II cohort 1 patients must have received at least 1 prior tyrosine kinase inhibitor for RCC.
62741937|NCT03172754|EXPERIMENTAL|Phase II patients: cohort 2|Phase II cohort 2 patients must not have received prior systemic therapy for advanced RCC.
62741938|NCT06657950|EXPERIMENTAL|Experimental: Integrative hatha yoga and mindful self-compassion|12 weeks of adapted, integrative yoga and mindful self-compassion specifically designed to be administered to women survivors of interpersonal violence.
62741939|NCT06459999||Cohort A|Patients with heart failure (HF) undergoing clinically indicated right heart catheterisation (RHC) +/- clinically- indicated repeat RHC in the Scottish Advanced Heart Failure Service (SNAHFS)
62741940|NCT06459999||Cohort B|Patients with HF undergoing RHC during implantation of a cardiac resynchronisation therapy (CRT) device.
62741941|NCT06459999||Cohort C|Patients hospitalised with HF receiving intravenous (IV) diuretic therapy.
62741942|NCT06659965||IV methocarbamol|Patients who received intravenous methocarbamol
62741943|NCT06659965||Usual Care|Patients who received usual postoperative pain management after surgery without any intravenous methocarbamol administration
62741944|NCT03235895|EXPERIMENTAL|Internet based|"* Six days of Instructional online CME educational material using Test-Enhanced E-Learning strategy.~* Followed by one day face to face CME activity"
62741945|NCT03235895|ACTIVE_COMPARATOR|Face to Face|Three days face to face Conventional CME educational materials
61986251|NCT06372015||Control group - Nutritional Approach|Patients who, after a multidisciplinary visit, are found to be ineligible for bariatric surgery.
61986252|NCT06372015||Case group - Surgery Approach|Patients who, after a multidisciplinary visit, are referred for bariatric surgery.
61986253|NCT05481515||Critically ill adults|Adult patients admitted to an intensive care unit who require mechanical ventilation and supplemental oxygen
62176698|NCT00555997|ACTIVE_COMPARATOR|1|Patients in group 1 will receive Ziprasidone for the full 12 weeks of the study.
62176699|NCT00555997|ACTIVE_COMPARATOR|2|Patients in Group 2 will receive placebo for the first 6 weeks of the study, then will receive Ziprasidone for the last 6 weeks.
62176700|NCT00555997|PLACEBO_COMPARATOR|3|Patients in Group 3 will receive placebo for the full 12 weeks of the study.
62741946|NCT03235895|NO_INTERVENTION|Wait listed|No CME activity will be given
62741947|NCT05143528|PLACEBO_COMPARATOR|Arm A: Placebo|425 subjects will be randomized to the placebo group.
62741948|NCT05143528|ACTIVE_COMPARATOR|Arm B: Experimental Low Dose|425 subjects to each of the Nilotinib BE, 84mg.
62741949|NCT05143528|ACTIVE_COMPARATOR|Arm C: Experimental High Dose|425 subjects to each of the Nilotinib BE, 112mg.
62741950|NCT03419897|EXPERIMENTAL|Tislelizumab|200 milligrams once every 3 weeks
62176701|NCT03851614|EXPERIMENTAL|Cohort A|Olaparib (given orally at a dose of 300 mg twice a day) in combination with Durvalumab (given intravenously at a dose of 1500 mg every 4 weeks)
62176702|NCT03851614|EXPERIMENTAL|Cohort B|Cediranib (given orally at a dose of 20 mg daily, 5 days on 2 days off) in combination with Durvalumab (given intravenously at a dose of 1500 mg every 4 weeks)
62741951|NCT04406818|ACTIVE_COMPARATOR|Healthy Control|
62741952|NCT04406818|ACTIVE_COMPARATOR|Sickle Cell Anemia|
62176703|NCT05056675|EXPERIMENTAL|PENG block for anterior total hip arthroplasty or surgical hip dislocation|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating theatre, routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance, 20 mL of 0.5% ropivacaine iv is injected.
62741953|NCT03734926|EXPERIMENTAL|Part 1|Participants with advanced solid tumors including hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumors.
62741954|NCT03734926|EXPERIMENTAL|Part 2 Cohort A|Participants with hepatocellular carcinoma.
62741955|NCT03734926|EXPERIMENTAL|Part 2 Cohort B|Participants with gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumor.
62741956|NCT02326168|EXPERIMENTAL|non-muscle invasive bladder cancer|"Every patient meeting eligibility criteria will receive a standard WHO adult potency Bacillus Calmette-Guerin (BCG) immunization (1cc/50mg live mycobacilli) in the right or left deltoid. Following a 19 - 31day wait period after BCG vaccination patients will then receive standard strength BCG intravesical therapy returning once a week for 6 consecutive weeks. Cystoscopy will be performed at 3 and 6 months.~Interventions: BCG immunization in deltoid and BCG intravesical therapy once a week for 6 weeks."
62176704|NCT05056675|PLACEBO_COMPARATOR|Placebo for anterior total hip arthroplasty or surgical hip dislocation|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating theatre, routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance, 20 mL of NaCL 0.9% is injected.
62176705|NCT06414759|EXPERIMENTAL|Group 1|First group (IV loop Diuretics + oral acetazolamide): patients will receive IV loop diuretic 2 times the outpatient oral (PO) daily dose, and oral loop diuretics will be stopped. In cases where the patient was not previously on oral diuretics, a starting dose of 40 mg of IV furosemide, IV bumetanide 1 mg or a bolus of 20 mg of IV torsemide can be utilized, together with acetazolamide: 500 mg PO once daily.
62741957|NCT03907176|EXPERIMENTAL|Cohort 1|HTX-011; Ibuprofen and Acetaminophen (regimen 1)
62741958|NCT03907176|EXPERIMENTAL|Cohort 2|HTX-011; Ibuprofen and Acetaminophen (regimen 2)
62741959|NCT01771692|ACTIVE_COMPARATOR|Conventional ligation|Modules ligated in a conventional manner (figure of 0)
62741960|NCT01771692|ACTIVE_COMPARATOR|Figure of 8 ligation|Modules ligated in a figure of 8 configuration
62176706|NCT06414759|EXPERIMENTAL|Group 2|Second group (IV loop diuretics + oral metolazone): patients will receive IV loop diuretic approximately 2 times the outpatient oral daily dose, and oral loop diuretics will be stopped. In cases where the patient was not previously on oral diuretics, a starting dose of 40 mg of IV furosemide, IV bumetanide 1 mg or a bolus of 20 mg of IV torsemide can be utilized, together with metolazone: 5 mg PO once daily.
62176707|NCT04033770|ACTIVE_COMPARATOR|Air-charged measurement system|"UDI (same session repeat filling cystometry and pressure flow study) according to Good Urodynamic Practice recommended by the ICS but using an air-charged instead of a water-filled measurement system."
62176708|NCT04033770|ACTIVE_COMPARATOR|Water-perfused measurement system|"UDI (same session repeat filling cystometry and pressure flow study) according to Good Urodynamic Practice recommended by the ICS."
62176709|NCT04377412||Albania|
62741961|NCT06512675|EXPERIMENTAL|Resistance combined with cardiovascular training group|Participants in this group will receive the resistance combined with cardiovascular training intervention for up to 6 weeks
62741962|NCT03709277|EXPERIMENTAL|Pharmacist-Driven Intervention|The study group will receive a patient-tailored, pharmacist-driven intervention(s) to overcome patient-specific barriers to adherence. Each patient in the study group will be intervened upon using a protocol that is based on their reason for non-adherence.
62741963|NCT03709277|NO_INTERVENTION|Standard of Care|The usual care group will receive the standard of care provided to all patients that utilize Vanderbilt Specialty Pharmacy.
62741964|NCT04868682|EXPERIMENTAL|Behavioral Education Intervention I|Manual-based education program provided in individual sessions
62741965|NCT04868682|ACTIVE_COMPARATOR|Behavioral Education Intervention II|Manual-based education program provided in individual sessions
62741966|NCT06365216|EXPERIMENTAL|NX210c 5 mg/kg|Dose: 5 mg/kg
62741967|NCT06365216|EXPERIMENTAL|NX210c 10 mg/kg|Dose: 10 mg/kg
62741968|NCT06365216|PLACEBO_COMPARATOR|Placebo|
62741969|NCT06660901||Patients with cannabinoid hyperemesis syndrome|
62741970|NCT06145035|PLACEBO_COMPARATOR|control group|Four doses of vehicle (Plasma-Lyte A supplemented with 1% HSA) will be given 2 months apart. Each dose will be infused IV at a rate of 2 ml/min for a total of 60 ml over 30 minutes.
62741971|NCT06145035|EXPERIMENTAL|single-dose group|One dose of UC-MSCs (100 x 106 cells) will be infused IV at a rate of 2 ml/min for a total of 60 ml over 30 minutes (3.3 million cells/ml/min). This will be followed by three IV infusions of placebo (same volume and rate) 2, 4, and 6 months later.
61986254|NCT03885141|PLACEBO_COMPARATOR|Men - Placebo|Men - Placebo, 1 tablet if a wake up occurs
62176710|NCT04377412||Australia|
62176711|NCT04377412||Czech Republic|
62176712|NCT04377412||France|
62176713|NCT04377412||Germany|
62176714|NCT04377412||Hong Kong|
62176715|NCT04377412||Israel|
62176716|NCT04377412||Italy|
62176717|NCT04377412||Lebanon|
62176718|NCT04377412||Norway|
62176719|NCT04377412||Poland|
62176720|NCT04377412||Russia|
62741972|NCT06145035|EXPERIMENTAL|repeated-dose group|Four doses of UC-MSCs (100 x 106 cells each) will be given 2 months apart. Each dose will be infused IV at a rate of 2 ml/min for a total of 60 ml over 30 minutes (3.3 million cells/ml/min).
62176721|NCT04377412||Spain|
62364897|NCT04738604|ACTIVE_COMPARATOR|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) is the ideal choice for single-tooth restorations, both in the anterior and the posterior region. It has an ultrafine, radiopaque porcelain filler for use in adhesive filling treatment. It can be polished to a high lustrer due to the ultra- fine particle filler, extremely homogeneous restorations can be placed which are easily polished to a high luster. The mechanical properties of a light-cured dental composite material are particularly dependent on its filler content, the type of incorporated fillers and the efficiency of the filler-resin coupling, so high Vickers hardness, compressive strength and flexural strength are recorded refereed to Zenit filler content 83% by weight (70% by volume) and size 0.7 microns
62741973|NCT06062667|EXPERIMENTAL|experimental group|Fathers will accompany their husbands during the birth process
62741974|NCT06062667|NO_INTERVENTION|Control group|routine maintenance
62741975|NCT04720755|EXPERIMENTAL|Treatment|Participants will receive twice-weekly Li-ESWT treatments of 0.2mJ/mm² over 3 treatment sites along the dorsal penile shaft (distal, mid-shaft, proximal), 1500 shocks per treatment (500 shocks per treatment site) for a total of 3000 shocks per week, for 6 weeks (total of 18,000 shocks)
62741976|NCT06331546|EXPERIMENTAL|Idiopathic Calcium Oxalate Kidney Stone Patients|Low and High oxalate fixed diets. Soluble oxalate absorption test.
62741977|NCT06331546|ACTIVE_COMPARATOR|Healthy non-kidney stone forming individuals|Low and High oxalate fixed diets. Soluble oxalate absorption test.
62741978|NCT06402955||Parkinson's Disease|This group will consist of people who have been diagnosed with Parkinson's Disease, but not Major Depressive Disorder.
62176722|NCT04377412||Sweden|
62176723|NCT04377412||Taiwan|
62176724|NCT04377412||Ukraine|
62176725|NCT04377412||United States|
62176726|NCT01202669||Epilepsy patients, EMU stay|
62176727|NCT01751165|EXPERIMENTAL|HZ/su-0,2 Group|Subjects will receive HZ/su vaccine on a 0,2-month schedule.
62552726|NCT03649997|EXPERIMENTAL|Part 2 Cohort 3: Treatment Sequence DFCE|Participants will receive Treatment D in Period 1, then Treatment F in Period 2, then Treatment C in Period 3 followed by Treatment E in Period 4 on Day 1.
62552727|NCT03649997|EXPERIMENTAL|Part 2 Cohort 3: Treatment Sequence ECFD|Participants will receive Treatment E in Period 1, then Treatment C in Period 2, then Treatment F in Period 3 followed by Treatment D in Period 4 on Day 1.
62552728|NCT03649997|EXPERIMENTAL|Part 2 Cohort 3: Treatment Sequence FEDC|Participants will receive Treatment F in Period 1, then Treatment E in Period 2, then Treatment D in Period 3 followed by Treatment C in Period 4 on Day 1.
62741979|NCT06402955||Parkinson's Disease with Major Depressive Disorder|This is the main group that the other three groups will be compared to. This study aims to identify mechanisms unique to patients with both Parkinson's Disease and Major Depressive Disorder.
62741980|NCT06402955||Major Depressive Disorder|This group will consist of people who have been diagnosed with Major Depressive Disorder, but not Parkinson's Disease.
62741981|NCT06402955||Healthy Controls|This group will consist of people that do not have Parkinson's Disease or Major Depressive Disorder.
62741982|NCT03651765|EXPERIMENTAL|Setmelanotide|Once daily subcutaneous injection
62741983|NCT06660953|ACTIVE_COMPARATOR|Group E|Group that Erector spinae plane block was applied.
62741984|NCT06660953|ACTIVE_COMPARATOR|Grup Q|Group that Quadratus lumborum type II block was applied
62741985|NCT06660953|NO_INTERVENTION|Group K|no block was applied
62741986|NCT06167291|EXPERIMENTAL|Arm 1- Ipsilateral|Participants with ipsilateral-only drainage (Arm 1- Ipsilateral) will be randomized to assign definitive ipsilateral RT (without concurrent chemotherapy) -vs- ipsilateral surgery (TORS/ND).
61986255|NCT03885141|EXPERIMENTAL|Men - Zolpidem 1.75 mg|Men - Zolpidem 1.75 mg, 1 tablet if a wake up occurs
61986256|NCT03885141|EXPERIMENTAL|Men - Zolpidem 3.5 mg|Men - Zolpidem 3.5 mg, 1 tablet if a wake up occurs
62176728|NCT01751165|EXPERIMENTAL|HZ/su-0,6 Group|Subjects will receive HZ/su vaccine on a 0,6-month schedule.
62176729|NCT01751165|EXPERIMENTAL|HZ/su-0,12 Group|Subjects will receive HZ/su vaccine on a 0,12-month schedule.
62364898|NCT04738604|EXPERIMENTAL|Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany)|contains organically modified ceramic nanoparticles (2 to 3 nm) and nano-fillers (10 nm) that are combined with conventional glass fillers (mean particle size: 1.1 to 1.5 μm). Nanoparticles and nano-fillers comprise a polysiloxane backbone and have methacrylate groups available for polymerization. According to the manufacturer's data, filler concentration is 76% by weight and 57% by volume. Furthermore, most of the conventional resin matrix is replaced by a matrix full of highly dispersed methacrylate modified polysiloxane particles (2- 3 nm).These nano-ceramic particles are inorganic-organic hybrid particles. Both, nano-ceramic particles and nano- fillers have methacrylate groups available for polymerization. CeramX does not contain triethylene glycol dimethacrylate (TEGDMA) as it was found mutagenic and cytotoxic in vitro
62741987|NCT05475743|EXPERIMENTAL|Pain Informed Movement program|
62741988|NCT05475743|ACTIVE_COMPARATOR|Standard medical care and leaflet education|
61986257|NCT03885141|PLACEBO_COMPARATOR|Women - Placebo|Women - Placebo, 1 tablet if a wake up occurs
62176730|NCT04306913|ACTIVE_COMPARATOR|Control|
62176731|NCT04306913|EXPERIMENTAL|Esmolol|
62176732|NCT03494621|NO_INTERVENTION|Control group|Participants randomly assigned to the control group will have three prenatal contacts at the same gestational ages as the intervention participants. These contacts will include collection of covariate data, review of locally available educational materials on pregnancy/infant care led by trained study staff, and assessment of the overall session quality and acceptability. The educational materials provided during these sessions are drawn from materials currently available at local health care facilities
62741989|NCT03275506|EXPERIMENTAL|Pembrolizumab + Chemotherapy|"Arm B (n=60): 4 neo-adjuvant cycles of standard 3 weekly Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²)~Arm B: Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)~The total number of cycles of chemotherapy will be 6 cycles from the start of the neo-adjuvant chemotherapy. Three additional cycles are allowed if required (maximum 9 cycles in total).~The planning of administration or not of bevacizumab will be defined before the randomization and could not be modified (stratification factor).~After chemotherapy:~* In the Arm A \& B, for patients receiving bevacizumab (as standard therapy) (15 mg/kg Q3W), this will be continue until a maximum of 15 months in total from the beginning of the adjuvant therapy.~* In the arm B, patient will receive Pembrolizumab 200 mg until a maximum of 15 months in total from the beginning of the adjuvant therapy."
62364899|NCT03816397|ACTIVE_COMPARATOR|Continue adalimumab|Patients randomized to this arm will continue adalimumab at their current dose (either 20mg/0.2mL or 40mg/0.4mL) administered subcutaneously every other week.
62741990|NCT03275506|ACTIVE_COMPARATOR|Chemotherapy alone|"Arm A (n=30): 4 neo-adjuvant cycles of standard 3 weekly carboplatin (AUC5 or 6) and paclitaxel (175mg/m²)~Arm A: carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), q3 weeks +/- bevacizumab (15 mg/kg Q3W)~The total number of cycles of chemotherapy will be 6 cycles from the start of the neo-adjuvant chemotherapy. Three additional cycles are allowed if required (maximum 9 cycles in total).~The planning of administration or not of bevacizumab will be defined before the randomization and could not be modified (stratification factor).~After chemotherapy:~- In the Arm A \& B, for patients receiving bevacizumab (as standard therapy) (15 mg/kg Q3W), this will be continue until a maximum of 15 months in total from the beginning of the adjuvant therapy."
62741991|NCT02304887||Bisphosphonate|
62182439|NCT04001738|ACTIVE_COMPARATOR|Direct Transfer to Angio Suite|After a fast neurological evaluation, patient will be direct transferred to angiography suite where endovascular treatment (EVT) team will be waiting for it. It will be done a cone beam-CT and if the image don't contraindicate endovascular treatment it will be performed and the large vessel occlusion will be confirmed by arteriography. If intravenous treatment have not been previously administered, it will be able to start in parallel.
62552729|NCT03649997|EXPERIMENTAL|Part 2 Cohort 4: Treatment Sequence GHIJ|Participants will receive single oral dose of JNJ-61393215 suspension under fasted condition (Treatment G) in Period 1, then participants will receive single oral dose of JNJ-61393215 capsule under fasted condition (Treatment H) in Period 2, single oral dose of JNJ-61393215 capsule with high fat/high-calorie breakfast (Treatment I) in Period 3 followed by single oral dose of JNJ-61393215 capsule with standardized breakfast (Treatment J) in Period 4, on day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods. Dose in this cohort will be based on the results obtained in Part 1.
62741992|NCT02304887||Selective estrogen receptor modulator|
62741993|NCT02304887||Teriparatide|
62741994|NCT02304887||Senosumab|
62741995|NCT06660706|EXPERIMENTAL|Multidomain intervention group|The multidomain intervention program is designed as structural training sessions of 2-hour training sessions two times per week.
62741996|NCT06660706|NO_INTERVENTION|Usual care group|Provide conventional health educations in every three-month interval
62741997|NCT02672059||Peripheral Neuropathy|Patients with peripheral neuropathy (observational study, no interventions)
62741998|NCT05997914|EXPERIMENTAL|Intervention - Patient Videos|Videos of African Americans currently taking anticoagulation talking about their experiences with using anticoagulation or blood thinners and successfully navigating setbacks occurring with use including bleeding, falls, strokes, and affording the medications.
62741999|NCT05997914|NO_INTERVENTION|Control - Informational Videos (not patients)|Informational videos about anticoagulation and blood thinners presented by experts or actors.
62742000|NCT01263418|EXPERIMENTAL|Ofatumumab|
62742001|NCT02777203|OTHER|EcoSac 46 400 ECO-T morcellation bag cohort|Prospective study of one cohort of subjects undergoing power morcellation within the EcoSac 46 400 ECO-T morcellation bag after a laparoscopic or robotic-assisted hysterectomy or myomectomy.
62742002|NCT06473077||ACDF Patients|Single Group of patients planned for anterior cervical decompression and fusion
62742003|NCT05034627|EXPERIMENTAL|Treatment (calaspargase pegol-mknl, cobimetinib)|Patients receive calaspargase pegol-mknl IV over 1 hour on day 1 and cobimetinib PO QD on days 1-14. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62364900|NCT03816397|PLACEBO_COMPARATOR|Stop adalimumab|Patients randomized to this arm will receive a volume-matched placebo (0.8mL) administered subcutaneously every other week.
62742004|NCT06662253|ACTIVE_COMPARATOR|Standard of Care|Participants will receive Enoxaparin dosed at the discretion of the most responsible physician (MRP). In cases of severe renal insufficiency (CrCl \< 30mL/min\^:), the LMWH may dose reduced or changed to Heparin at the discretion of the MRP.
62742005|NCT06662253|EXPERIMENTAL|Intervention (Anti-Xa Guided)|Participants will receive Enoxaparin 0.5 mg/kg twice daily (rounded up or down to the nearest 10 mg) the initial starting dose. Dose adjustments will be made based on trough levels drawn between the 3rd and 4th dose. The target anti-Xa level range is between 0.1 and 0.2 IU/mL. If the patient is below the target range, then the next Enoxaparin dose will be increased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. If the patient is above the target range, then the next Enoxaparin dose will be decreased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. This dose will be maintained until hospital discharge.
62742006|NCT05733949|EXPERIMENTAL|Treatment (ST-SBRT)|Patients undergo ST-SBRT on study. Patients also undergo collection of blood samples at screening and on study and undergo CT at screening, on study, and during follow up.
62742007|NCT05393531|OTHER|Mandibular advancement device|Active therapy
62742008|NCT05393531|OTHER|Continuous positive airway pressure|Active therapy
62742009|NCT03738631||Under 35 years|
62742010|NCT03738631||Over 44 years|
62742011|NCT01152593|EXPERIMENTAL|Intranasal Mupirocin|
62742012|NCT02160665|PLACEBO_COMPARATOR|Vehicle|Vehicle of Test product (G \& W Laboratories, Inc.)
62742013|NCT02160665|OTHER|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
62742014|NCT02160665|ACTIVE_COMPARATOR|Test:Tazarotene Cream, 0.05%|Test: Tazarotene Cream, 0.05% (G \& W Laboratories, Inc.)
62742015|NCT05767398|EXPERIMENTAL|Sequence 1|Zanubrutinib will be administered as a single dose of treatment (tablet) or reference (capsule) on separate occasions.
62742016|NCT05767398|EXPERIMENTAL|Sequence 2|Zanubrutinib will be administered as a single dose of treatment (tablet) or reference (capsule) on separate occasions.
62742017|NCT05118165|NO_INTERVENTION|control group|
62742018|NCT05118165|EXPERIMENTAL|intervention group|
62742019|NCT03178825|EXPERIMENTAL|Hybrid Fractional Laser|Hybrid fractional 2940 nm and 1470 nm laser treatment
62742020|NCT01709110|EXPERIMENTAL|Teriparatide|"Teriparatide 20 microgram (µg) administered by subcutaneous (SC) injection once daily for 24 months.~Placebo given orally once weekly for 24 months.~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment."
62182440|NCT04001738|NO_INTERVENTION|Direct Transfer to CT Scan|After a fast neurological evaluation, patient will be transferred to CT suite where usual image protocol will be performed (CT and CT-angio). Within 6 hours from onset CT perfusion could be required to take detections. Once interpreted image results, it will be decided intravenous and/or endovascular treatment.
62742021|NCT01709110|ACTIVE_COMPARATOR|Risedronate|"Risedronate 35 milligram (mg) administered orally once weekly for 24 months.~Placebo given by SC injection once daily for 24 months.~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment."
62742022|NCT03385915||TAVI cohort|Patients who underwent transcatheter aortic valve implantation for aortic valve stenosis
62742023|NCT03385915||SAVR cohort|Patients who underwentsurgical aortic valve replacement for aortic valve stenosis
62364901|NCT05894772|EXPERIMENTAL|Intervention arm|Power over Pain Portal
62364902|NCT02866929|ACTIVE_COMPARATOR|Conventional orthodontic treatment|Patients that will receive conventional orthodontics
62364903|NCT02866929|EXPERIMENTAL|Orthodontics with decortication|Patients that will receive orthodontic treatment with selective alveolar decortication
62742024|NCT01140100|ACTIVE_COMPARATOR|propofol-propofol|
62742025|NCT01140100|EXPERIMENTAL|thiopental-propofol|
62742026|NCT02677207|EXPERIMENTAL|JNJ-39393406|2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.
62742027|NCT02677207|PLACEBO_COMPARATOR|Placebo|2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.
62742028|NCT02331589|ACTIVE_COMPARATOR|Korea Red Ginseng (KRG)|KRG capsule (3,000 mg/day) for 3 weeks
62364904|NCT02866929|EXPERIMENTAL|Orthodontics decortication and Mucograft|Orthodontic treatment, selective alveolar decortication and Mucograft® on the mandibular anterior segment
62742029|NCT02331589|PLACEBO_COMPARATOR|Placebo (for KRG)|placebo (for KRG) for 3 weeks
62742030|NCT02379988|EXPERIMENTAL|Verify radiation dose to heart and lung|Subjects will undergo the standard of care CT simulation, which includes an additional breath hold CT. Inspiratory gated breath-hold will be used. Two radiation plans will be generated: one for the CT scan performed free breathing, and one for the CT scan performed with inspiratory gated breath hold. The cardiac and lung doses will be determined. At the discretion of the treating physician, the plan with the lower cardiac and lung dose may be used to treat the patient.
62742031|NCT02910752|EXPERIMENTAL|"CLAM|PBSC"|CLAM chemotherapy with mobilized PBSC infusion: Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
62364905|NCT02866929|EXPERIMENTAL|Orthodontics and Mucograft®|Patients that will receive orthodontic treatment and Mucograft® on the mandibular anterior segment
62552730|NCT03649997|EXPERIMENTAL|Part 2 Cohort 4: Treatment Sequence HJGI|Participants will receive Treatment H in Period 1, then Treatment J in Period 2, then Treatment D in Period G followed by Treatment I in Period 4 on Day 1.
62742032|NCT01292889||Seasonal Affective Disorder|Consists of Individuals with Seasonal Affective Disorder
62742033|NCT01292889||Subsyndromal Seasonal Affective Disorder|Consists of individuals who do not meet SAD criteria,but present more symptoms for the disorder than do controls.
62742034|NCT01292889||Major Depressive Disorder|Consists of individuals who have MDD.
62742035|NCT01292889||Controls|Consists of individuals who do not present symptoms of SAD or MDD.
62742036|NCT01986231|EXPERIMENTAL|Open-Label Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg.
62742037|NCT06388746|EXPERIMENTAL|Caries removal group|Cavitated lesion will be isolated with cotton rolls and air-dried. Gel will be placed in the cavity and kept there for 60 seconds to allow for the decayed tissue to become softer. The softened tissue will be removed with a hand instrument. The gel will be reapplied, until complete removal of the carious tissue is achieved. Teeth will be restored using a high viscosity glass ionomer cement.
61986258|NCT03885141|EXPERIMENTAL|Women - Zolpidem 1.0 mg|Women - Zolpidem 1.0 mg, 1 tablet if a wake up occurs
62742038|NCT06388746|ACTIVE_COMPARATOR|Caries arrest group|Cavitated lesion will be isolated with cotton rolls and air-dried. One drop of component 1 (38% Silver Fluoride (AgF) in water) will be applied for 60 seconds using a microbrush, followed by two drops of component 2 (potassium iodide) for 90 seconds. Teeth will be restored using a high viscosity glass ionomer cement.
62742039|NCT00603096|EXPERIMENTAL|1|patients will benefit from a complete polysomnography under NIV
62742040|NCT00603096|ACTIVE_COMPARATOR|2|settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas
61986259|NCT03885141|EXPERIMENTAL|Women - Zolpidem 1.75 mg|Women - Zolpidem 1.75 mg, 1 tablet if a wake up occurs
62182441|NCT02958059|EXPERIMENTAL|Treatment|The intervention group
62182442|NCT02958059|PLACEBO_COMPARATOR|Comparator|The comparator group
61986260|NCT00622479|EXPERIMENTAL|Arm 1|
62364906|NCT01480232|EXPERIMENTAL|EVP-6124 + NicoDerm (Active)|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
62364907|NCT01480232|ACTIVE_COMPARATOR|Placebo + NicoDerm (Active)|One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
62176733|NCT03494621|EXPERIMENTAL|Protecting Babies While They Sleep|The intervention curriculum derives from information gathered at previously conducted focus groups and interviews, which aimed to ascertain the role of caregiver knowledge, beliefs, and access to resources in implementation of infant safe sleep practices. The protocol for the focus groups and interviews has been reviewed by the Tribal Institutional Review Board. The focus groups were conducted in Rapid City and a western Tribal reservation with pregnant adult women and pregnant, parenting, or other interested adolescent women; fathers (adult men); and elder women. Two focus groups were held for each category of individuals. Additional qualitative data was collected via key informant interviews with individuals vested and experienced in maternal and child health.
62176734|NCT02046447||Primary Cervical Dystonia (Trihexyphenidyl)|"These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.~After the above baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional fMRI scan. The subjects will be done with the study after the second MRI scan has been completed."
62742041|NCT02330653|EXPERIMENTAL|Fecal Microbiota Transplant (FMT)|Induction retention enema for the first week of treatment followed by once weekly administration of 15 capsules of study treatment (the equivalent of 7.5 grams of human stool) will be (administered within 60 minutes of thawing once weekly) for 7 weeks. After completing 8 weeks of blinded study treatment, study subjects on FMT who have shown improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks of once weekly FMT capsule administration.
62742042|NCT02330653|PLACEBO_COMPARATOR|Placebo|Induction placebo enema for the first week of treatment followed by once weekly administration of 15 capsules of study placebo (administered within 60 minutes of thawing once weekly) for 7 weeks. After completing 8 weeks of blinded study placebo, study subjects on placebo who DO NOT demonstrate improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks, beginning with a FMT induction enema followed by 7 weeks of weekly FMT capsule administration.
62742043|NCT04452331|EXPERIMENTAL|OAA Intervention|Visit recorded, both patient and provider aware, both patient and provider have access to audio post-visit
62742044|NCT04452331|SHAM_COMPARATOR|OAA Physician Aware Control|Visit recorded, both patient and provider aware, neither patient nor provider have access to audio post-visit
62176735|NCT02046447||DYT 1 Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
62176736|NCT02046447||Primary Cervical Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
62742045|NCT04452331|PLACEBO_COMPARATOR|OAA Physician Unaware Control|Visit recorded, patient aware but provider unaware, neither patient nor provider have access to audio post-visit
62176737|NCT02046447||DYT 1 Dystonia|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed; and 6) Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) to assess dystonia severity.
62176738|NCT02709447|EXPERIMENTAL|Date SMART|Group based prevention
62176739|NCT02709447|ACTIVE_COMPARATOR|Health Promotion|Group based prevention
62742046|NCT03037476|EXPERIMENTAL|Web-Based PFI|Participants randomized to the web-based PFI in Study 2 receive a 5 component Personalized Feedback Tool. The first component is presented immediately after the baseline survey and a link to each of the remaining 4 components is sent to participants spaced 1 to 2 weeks apart. The PFI components cover: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol. Each component is comprised of personalized feedback presented in text and graphic format, and each component includes links to tips for making changes if and when the participant is contemplating or ready to commit to change. These tips include general relapse prevention strategies, as well as information about the importance of regular class attendance, study habits, and sleep habits for academic success. General educational tips/strategies for time management, as well as tips for initiating behavior change are also included. Each component takes approximately 5-10 minutes to review.
62176740|NCT03879083|EXPERIMENTAL|With reproduction of palatal rugae|Participants will receive maxillary complete dentures with a reproduction of the patients's own palatal rugae to the palatal surface.
62176741|NCT03879083|ACTIVE_COMPARATOR|Without reproduction of palatal rugae (smooth surface)|Participants will receive maxillary complete dentures with smooth palatal surfaces without a reproduction of the patients's own palatal rugae to the palatal surface.
62742047|NCT03037476|OTHER|Assessment Only|The Assessment Only group receives assessment on substance use, health behaviors, and academic behaviors at baseline, 6-month follow-up, and 12-month follow-up in Study 2.
62742048|NCT02625480|EXPERIMENTAL|Single Arm|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR+ T cells/kg or 1 x 10\^6 anti-CD19 CAR+ T cells/kg
62742049|NCT00564902|PLACEBO_COMPARATOR|Lutein|9 mg of Lutein for 12 months
62742050|NCT00564902|ACTIVE_COMPARATOR|Zeaxanthin and Lutein|3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
62742051|NCT00564902|ACTIVE_COMPARATOR|Zeaxanthin|3R 3'R Zeaxanthin 8 mg per day during 12 months
62176742|NCT02440646||CCTA group|All stable chest pain comers admitted to the chest-pain outpatient or inpatient cardiac center with the chronic coronary syndrome who underwent functional tests (CMR and/ or SPECT, and Echo are mandatory) and coronary computed tomography angiography (CCTA) without further immediate quantitative coronary angiography (QCA), applicable intravascular imaging (FFR, QFR, OCT, IVUS, VH-IVUS) and/ or percutaneous intervention (PCI).
62176743|NCT02440646||CCTA + Invasive group|All stable chest pain comers admitted to the chest-pain outpatient or inpatient cardiac center with the chronic coronary syndrome who underwent functional tests (CMR, and/ or SPECT, and Echo are mandatory) and coronary computed tomography angiography (CCTA) with further quantitative coronary angiography (QCA), applicable intravascular imaging (FFR, QFR, OCT, IVUS, VH-IVUS) with or without implantation of a stent.
62176744|NCT00668785|EXPERIMENTAL|Ranibizumab|Ranibizumab is being used off-label to test the safety and efficacy of its use in Diabetic Macular Edema post panretinal photocoagulation. Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
62176745|NCT00888407|EXPERIMENTAL|HBV Screening|Small group educational session with HBV screening resources provided.
62176746|NCT00888407|SHAM_COMPARATOR|Nutrition|Small group educational discussion, diet \& nutrition resources provided.
62742052|NCT05980416|EXPERIMENTAL|Part A: Escalation|Adult patients with select advanced unresectable or metastatic solid tumors likely to express CLDN18.2 will receive EO-3021 IV infusion at various doses every 3 weeks to determine MTD/RP2D(s).
62176747|NCT05452421|EXPERIMENTAL|Group A|Isotonic carbohydrate beetroot juice drink
62176748|NCT05452421|EXPERIMENTAL|Group B|Beetroot juice drink
62176749|NCT06310226|EXPERIMENTAL|Responders to spinal cord stimulation|Patients with chronic low back pain, with \>50% pain reduction in response to spinal cord stimulation
62176750|NCT06310226|EXPERIMENTAL|Non-responders to spinal cord stimulation|Patients with chronic low back pain, with minimal to no pain reduction in response to spinal cord stimulation
62176751|NCT05463926|EXPERIMENTAL|Standard hospital care with follow-up + PDA mobile application|Receive standard hospital care and follow-up, and access to the Parentbot - a Digital healthcare Assistant (PDA) mobile application from pregnancy until one-month postpartum
62176752|NCT05463926|NO_INTERVENTION|Standard hospital care with follow-up|Receive standard hospital care with follow-up
62176753|NCT05233098||Clinical Cohort|Patients enrolled in the study will have 3 imaging scans taken after Tc-99m MAA injection. The final scan will occur between 18 and 24 hours after Tc-99m MAA injection.
62176754|NCT00702650|EXPERIMENTAL|Testosterone MD-Lotion|"Participants received Testosterone Metered Dose (MD)-Lotion for 120 days. Participants started by receiving 3.0 mL (60 mg) of 2% Testosterone MD-Lotion, and based upon restoration to eugonadal levels, may have had their dose of testosterone adjusted upwards or downwards on Days 45 and 90.~Doses could be titrated to one of the following:~1.5 mL (30 mg) of 2% Testosterone MD-Lotion applied daily by 1 dose to the axilla (1.5 mL to one axilla).~3.0 mL (60 mg) of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to each axilla).~4.5 mL (90 mg) of 2% Testosterone MD-Lotion applied daily by 3 doses to the axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla).~6.0 mL (120 mg) of 2% Testosterone MD-Lotion applied daily by 4 doses to the axilla (2 x 1.5 mL to each axilla)."
62176755|NCT00056329|EXPERIMENTAL|1|vitamin E plus multivitamin
62176756|NCT00056329|PLACEBO_COMPARATOR|2|placebo with multivitamin
62176757|NCT00002597|EXPERIMENTAL|Neoadjuvant TAS + RT|Neoadjuvant total androgen suppression (TAS) - Flutamide and Zoladex or Lupron - two months before and during radiation therapy.
62176758|NCT00002597|OTHER|Radiation therapy alone|Radiation therapy alone
62176759|NCT03743129|EXPERIMENTAL|Anlotinib|Anlotinib p.o, qd. Treatment from Day 1 of randomization(after concurrent chemoradiation 4-6 weeks) to disease progress or untolerated toxicity or consent withdrawal. The 2:1 ratio (Anlotinib to blank).
62176760|NCT03743129|NO_INTERVENTION|Blank|No intervention from Day 1 of randomization(after concurrent chemoradiation 4-6 weeks) .The 2:1 ratio (Anlotinib to blank).
62176761|NCT01692132||Prucalopride|
62176762|NCT05268822|ACTIVE_COMPARATOR|Movement control exercise with specific breathing techniques|Movement control exercise with specific breathing techniques (experimental group)
62176763|NCT05268822|ACTIVE_COMPARATOR|Movement control exercise without specific breathing techniques|Movement control exercise without specific breathing techniques (control group)
62176764|NCT05341063|EXPERIMENTAL|Intervention Group|Following the first meeting after the pre-tests, a weekly training was created via Zoom. Diabetes education presentations prepared beforehand were explained in two parts in each training. Training interventions were carried out weekly over Zoom for 4 weeks, lasting approximately 40 minutes. Patients' questions were answered.
62176765|NCT05341063|EXPERIMENTAL|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
62176766|NCT05175300|EXPERIMENTAL|Group 1|Prosthesis with a second-generation ceramic-on-highly cross-linked polyethylene (CoPXE) couple.
62176767|NCT05175300|ACTIVE_COMPARATOR|Group 2|Prosthesis with ceramic-on-ceramic (CoC) torque.
62176768|NCT02010983|EXPERIMENTAL|longstanding achalasia|
62176769|NCT01919177|ACTIVE_COMPARATOR|Nitrate rich beetroot juice|Subjects with heart failure with preserved ejection fraction will receive 140 mL of Nitrate-rich concentrated beetroot juice (containing 12 mmol of NO-3). This will be a cross-over study. Therefore all subjects will receive both interventions, but the order of the interventions will be randomized.
62742053|NCT05980416|EXPERIMENTAL|Part B Expansion|Patients with select advanced unresectable or metastatic solid tumors will receive EO-3021 IV infusion every 3 weeks to confirm the RP2D.
62742054|NCT05208606|EXPERIMENTAL|Wawokiya Health Advocate|Patients and caregivers allocated to the Wawokiya Health Advocate arm will receive a palliative intervention consisting of regular needs assessments and home visits. After the first 2 visits, visits will occur bi-weekly, though a WHA may increase or decrease frequency of visits pending patient and caregiver needs and cancer status. The first two study visits will follow the same broad structure-structure of follow up visits will be flexible based on patient and caregiver needs. The location of study visits will vary and may include the local IHS site, cancer centers, and the patient's home depending on health status. Patients will be randomized to either receive home visits upon enrollment or be placed on a waitlist.
62742055|NCT05208606|NO_INTERVENTION|Waitlist Arm|Patients enrolled into the waitlist group will not receive any additional services beyond what is available to them in their standard course of care. Patients randomized to the waitlist group will be asked to identify a primary caregiver upon enrollment. Data collection procedures will occur as described below. While on the waitlist, any services available for patients and their families will be according to the standards of their local providers and primary cancer providers.
62176770|NCT01919177|PLACEBO_COMPARATOR|Nitrate depleted beetroot juice|Subjects with heart failure with preserved ejection fraction will receive 140 mL of nitrate-depleted beetroot juice (containing \<0.01 mmol of NO-3).This will be a cross-over study. Therefore all subjects will receive both interventions, but the order of the interventions will be randomized.
62176771|NCT00700947|EXPERIMENTAL|1|Patients who are asymptomatic with normal left ventricular systolic function and who agree to be treated medically for severe primary mitral regurgitation with Beta-blocker therapy. Patients may entered into the Arm 2 (surgical treatment) later on when they develop symptoms or enlarged left ventricle or left ventricular dysfunction or wishes to have surgical treatment of severe primary mitral regurgitation.
62742056|NCT04510987|EXPERIMENTAL|Experimental: Treatment 1|Participants in Groups 1-4 and Group 6 will receive a single dose of BAY2433334 on one occasion. Participants in Group 5 will receive a single dose of BAY2433334 on a dialysis-free day.
62742057|NCT04510987|EXPERIMENTAL|Experimental: Treatment 2|Participants in Group 5 will receive a single dose of BAY2433334 on a day with dialysis treatment.
62176772|NCT00700947|NO_INTERVENTION|2|Patients will be surgically treated for severe primary mitral regurgitation as a routine clinical care if they want to be treated surgically or develop symptoms or significant adverse left ventricular remodeling or left ventricular dysfunction.
62176773|NCT00700947|NO_INTERVENTION|3|Health Control includes the subjects with no remarkable past medical history and not currently taking any medications. Normal subjects will be used for comparison with patients with severe primary mitral regurgitation in term of clinical, echocardiographic and neuro-hormonal findings.
62176774|NCT06266468|EXPERIMENTAL|Intervention|12 weeks of mobile intervention (website and text messaging)
62176775|NCT06266468|PLACEBO_COMPARATOR|Waitlist|No intervention for 12 weeks, or until completion of 2nd study visit
62742058|NCT01496326|EXPERIMENTAL|Ibuprofen|
62364908|NCT01480232|EXPERIMENTAL|EVP-6124 + NRT Patch (Placebo)|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
62176776|NCT02316392||Post transplant subjects|Hyperpolarized Helium-3 MRI. Subjects who have had or are scheduled to have a lung transplant
62742059|NCT01496326|PLACEBO_COMPARATOR|Placebo|
62742060|NCT02108327|EXPERIMENTAL|surgical blade|
62742061|NCT02108327|ACTIVE_COMPARATOR|Unipolar electrocautery|
62742062|NCT06325657|EXPERIMENTAL|RSVpreF vaccine|RSV vaccine (RSVpreF)
62742063|NCT06325657|PLACEBO_COMPARATOR|Placebo|Placebo
62742064|NCT04310436|EXPERIMENTAL|Looking down to naval.|Modifying Saccade origin by looking down to naval.
62742065|NCT04310436|PLACEBO_COMPARATOR|Looking up in the air.|Modifying Saccade origin by looking up in the air.
62742066|NCT06320678|EXPERIMENTAL|Blended Learning|
62742067|NCT06320678|NO_INTERVENTION|Education|
62742068|NCT01943058|EXPERIMENTAL|Arm A (megestrol acetate)|Patients receive megestrol acetate PO BID for up to 18 months in the absence of disease progression or unacceptable toxicity.
62742069|NCT01943058|EXPERIMENTAL|Arm B (levonorgestrel-releasing IUS)|Patients receive levonorgestrel-releasing IUS with continuous release for up to 18 months in the absence of disease progression or unacceptable toxicity.
62742070|NCT03983382||HER2-Positive Breast Cancer|
62742071|NCT04165382|OTHER|Pre-implementation study group|Preterm infants receiving NIV before the implementation of the guideline
62176777|NCT06240546|EXPERIMENTAL|2 mg/m2|LPM6690176 capsules administered 2 mg/m2 on day 1-5 (qd) every two weeks.
62176778|NCT06240546|EXPERIMENTAL|4 mg/m2|LPM6690176 capsules administered 4 mg/m2 on day 1-5 (qd) every two weeks.
62176779|NCT06240546|EXPERIMENTAL|8 mg/m2|LPM6690176 capsules administered 8 mg/m2 on day 1-5 (qd) every two weeks.
62176780|NCT06240546|EXPERIMENTAL|16 mg/m2|LPM6690176 capsules administered 16 mg/m2 on day 1-5 (qd) every two weeks.
62176781|NCT06240546|EXPERIMENTAL|24 mg/m2|LPM6690176 capsules administered 24 mg/m2 on day 1-5 (qd) every two weeks.
62176782|NCT06240546|EXPERIMENTAL|36 mg/m2|LPM6690176 capsules administered 36 mg/m2 on day 1-5 (qd) every two weeks.
62176783|NCT06240546|EXPERIMENTAL|48 mg/m2|LPM6690176 capsules administered 48 mg/m2 on day 1-5 (qd) every two weeks.
62176784|NCT02154477|ACTIVE_COMPARATOR|diabetes|All patient will receive insulin at one visit and saline at another visit
62176785|NCT02154477|ACTIVE_COMPARATOR|control|All patient will receive insulin at one visit and saline at another visit
62176786|NCT03979547|EXPERIMENTAL|Exercise intervention|The exercise program will be similar to the Exercise in All ChemoTherapy (ENACT) study which combines in-person and home-based strength training and aerobic exercise five days a week.
62176787|NCT03979547|NO_INTERVENTION|Standard of Care|Subjects are instructed to maintain their current activity level.
62364909|NCT01480232|PLACEBO_COMPARATOR|Placebo + NRT Patch (Placebo)|One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
62742072|NCT04165382|OTHER|Post-implementation study group|Preterm infants receiving NIV after the implementation of the guideline
62742073|NCT03007329|ACTIVE_COMPARATOR|Dapagliflozin & Exenatide|Dapagliflozin 10mg orally once daily \& Exenatide 2mg subcutaneous once weekly
62742074|NCT03007329|PLACEBO_COMPARATOR|Dapagliflozin & Placebo|Dapagliflozin 10mg orally once daily \& Exenatide matching Placebo 2mg subcutaneous once weekly
62742075|NCT06657872|ACTIVE_COMPARATOR|general anesthesia|REZUM procedure under general anesthesia
62742076|NCT06657872|ACTIVE_COMPARATOR|Local anesthesia|REZUM procedure under local anesthesia
62742077|NCT04017819|ACTIVE_COMPARATOR|Healthy volunteers (Group 1)|Group 1(n = 5) healthy volunteers. Each participant in this part of the study will receive a single dose of \[18F\]-C-SNAT4 and then undergo three times of whole body (WB) PET/CT scans (Scan 1: 60 minutes dynamic scan; Scan 2: WB skull base-thigh at 90 minutes +/- 10 minutes post injection; Scan 3: WB skull base-thigh at 120 minutes +/- 10 minutes post-injection of \[18F\]-C-SNAT4).
62742078|NCT04017819|EXPERIMENTAL|Patients with newly diagnosed lung cancer (Group 2)|Group2 (n = 5) newly diagnosed lung cancer. Each participant in this part of the study will receive a single dose of \[18F\]-C-SNAT4 and then undergo three times of whole body (WB) PET/CT scans (Scan 1: 60 minutes dynamic scan; Scan 2: WB skull base-thigh at 90 minutes +/- 10 minutes post injection; Scan 3: WB skull base-thigh at 120 minutes +/- 10 minutes post-injection of \[18F\]-C-SNAT4).
62176788|NCT06009263|SHAM_COMPARATOR|Control|The participants will receive conventional treatment in the form of TENS and Ultrasound.
62176789|NCT06009263|EXPERIMENTAL|Intervention 1|"The participants will receive open chain segmental control exercises plus conventional treatment in the form of TENS and Ultrasound."
62742079|NCT04017819|EXPERIMENTAL|Patients with lung cancer undergoing non-surgical tx (Group 3)|Group 3 (n = 10) lung cancer after non-surgical therapy. Each participant in this part of the study will receive a total of 2 doses of \[18F\]-C-SNAT4 (on 2 separate occasions spaced at least 1 week apart, each of which will be followed by undergoing a \[18F\]-C-SNAT4 PET/CT scan)
62176790|NCT06009263|EXPERIMENTAL|Intervention 2|"The participants will receive closed chain segmental control exercises plus conventional treatment in the form of TENS and Ultrasound."
62176791|NCT00949598|EXPERIMENTAL|Arm I|Patients receive oral letrozole once daily for 16 weeks.
62176792|NCT00949598|EXPERIMENTAL|Arm II|Patients receive oral tamoxifen citrate once daily for 16 weeks.
62176793|NCT02428218|EXPERIMENTAL|BG00012|Participants will receive 120 mg capsule(s) BG00012 taken orally.
62176794|NCT02428218|EXPERIMENTAL|Placebo|Participants will receive matching placebo capsule(s) taken orally.
62176795|NCT05188898|EXPERIMENTAL|Hyaluronic acid Group|Hyaluronic acid gel will be applied in intraosseous periodontal defects, after Minimally Invasive Non Surgical Debridement (MINSD)
62176796|NCT05188898|ACTIVE_COMPARATOR|No-hyaluronic acid Group|Only Minimally Invasive Non Surgical Debridement (MINSD) will be performed
62176797|NCT03209050|OTHER|Central Venous Access Placement|Central venous access placement
62176798|NCT05449847||Complicated HCV|
62176799|NCT05449847||Non Complicated HCV|
62742080|NCT01804426||Trauma Exposed participants|18-50 years old men and women who have been brought to the ER after being involved or witnessing a life threatening event (or an event which was perceived as such).
62742081|NCT06341114|EXPERIMENTAL|Co-administration of BAT8008 and BAT1308.|BAT1308 injection: 25 mg/mL concentrate for solution for infusion.200 mg on Day 1 of each 14-day cycle BAT8008 injection: 20 mg/mL concentrate for solution for infusion.Climbing group A: 2.1mg/kg on Day 1 of each 14-day cycle,and Climbing group B: 2.4mg/kg on Day 1 of each 14-day cycle
62742082|NCT06460493|EXPERIMENTAL|Ensifentrine|Inhaled ensifentrine twice daily for 12 weeks via standard jet nebulizer.
62176800|NCT02694796|EXPERIMENTAL|Intervention|The 'Physical activity program after a balneotherapy' intervention involves providing a workshop during a balneotherapy about physical activity and use of automated physical activity program including website, mobile app and connected devices, and after the balneotherapy, the access to the automated program during 12 months.
62742083|NCT05634694||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the exploration cohort.
62552731|NCT03649997|EXPERIMENTAL|Part 2 Cohort 4: Treatment Sequence IGJH|Participants will receive Treatment I in Period 1, then Treatment G in Period 2, then Treatment J in Period 3 followed by Treatment H in Period 4 on Day 1.
62176801|NCT02694796|NO_INTERVENTION|Control|Patients included in the control arm will receive a booklet including informations about physical activity recommendations and practice.
62176802|NCT05262218|EXPERIMENTAL|PBF-680|PBF-680 is an Adenosine A1 receptor antagonist formulated in oral gelatine capsules
62176803|NCT05262218|PLACEBO_COMPARATOR|Placebo|Placebo formulated in oral gelatine capsules
62176804|NCT06479200|EXPERIMENTAL|VR-guided mindfulness intervention|Participants will receive a 6-week home-based VR-guided mindfulness intervention using the Oculus Quest 3 (or equivalent) headset and a mindfulness application. They will be instructed to practice 10-15 minutes of VR-guided mindfulness daily. The intervention will consist of guided meditation practices, such as body scans, breath awareness, and loving-kindness meditation, delivered in immersive virtual environments designed to promote relaxation and focus.
62176805|NCT06479200|SHAM_COMPARATOR|Sham VR control|Participants will receive a 6-week home-based sham VR intervention. They will view relaxing nature videos without mindfulness content for 10-15 minutes daily, matched for duration and VR experience with the experimental group. The sham VR control condition will use the same VR headset as the intervention group but will not include any guided mindfulness practices or instructions.
62176806|NCT06379555|EXPERIMENTAL|Walanpoigne|This arm will combine WALANT anesthesia WALANT with arthroscopy to reduce a joint fracture of the wrist
62182443|NCT02956122|EXPERIMENTAL|Study Part 1 - All Participants - GLASSIA|Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
62391463|NCT06342440||Advanced Adenoma (Discovery cohort)|"Individuals who underwent colonoscopy and were found to have high-risk adenomas, defined as one or more of the following:~* 5 or more adenomas.~* One or more adenomas have high-grade dysplasia.~* One or more adenomas are \>10 mm in diameter"
62391464|NCT06342440||Colorectal Cancer (Discovery cohort)|Individuals who underwent colonoscopy and were found to have colorectal cancer.
62391465|NCT06342440||Non-disease controls (Training cohort)|Individuals who underwent colonoscopy and were found not to have any adenomas or cancer.
62552732|NCT03649997|EXPERIMENTAL|Part 2 Cohort 4: Treatment Sequence JIHG|Participants will receive Treatment J in Period 1, then Treatment I in Period 2, then Treatment H in Period 3 followed by Treatment G in Period 4 on Day 1.
62552733|NCT03649997|EXPERIMENTAL|Part 3 Cohort 5: Multiple Ascending Dose|Participants will receive oral JNJ-61393215 145 mg suspension or matching placebo once daily for 7 days under fasted conditions.
62742084|NCT04989309|EXPERIMENTAL|Experiment 2. Phonetic precision disrupted by TMS|"Experiment 2 tests the influence of temporary disruption of activity within the left or right temporal cortex on the speed and precision of phonetic decisions compared to vertex stimulation. Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). Immediately following stimulation pulses, participants will perform a visual analog scale (VAS) phonetic rating task on tokens from the four continua, embedded in speech-shaped noise. To control for the possibility that TMS leads to a generalized deficit in categorization, a control task will involve categorization of visual objects on a morphed dog to cat object continuum. (We expect this task to be unaffected by TMS). The variables of interest are the steepness of the categorization curve, mean reaction time to all items on the continuum, and the difference in reaction time for boundary vs. endpoint tokens."
62742085|NCT04989309|EXPERIMENTAL|Experiment 3. Phonetic ambiguity in continuous speech|"Experiment 3 is designed to test whether left vs. right temporal lobe stimulation selectively disrupts processing of naturally-occurring phonetic ambiguity as compared to vertex stimulation (control). Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). Stimuli will be nonsense sentences produced clearly or in a casual register. By-sentence phonetic ambiguity is estimated by the proximity of each token to other vowels belonging to different categories. Sentences will be embedded in speech-shaped noise to increase difficulty. Participants will listen to each sentence, then respond whether a visually-presented probe word appeared in the sentence (BRASS?). Dependent variables are accuracy and reaction time on this probe verification task."
62742086|NCT04989309|EXPERIMENTAL|Experiment 6: Disruption of talker-specific phonetic learning using TMS.|"Experiment 6 is designed to test whether disruption of activity in left or right temporal regions (vs. vertex control) using TMS interferes with talker-specific learning. Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). The study uses a training paradigm where one talker's speech is manipulated to always have relatively short voice onset times (VOTs) for voiceless stops (e.g., /k/ in coal) and another to have relatively long VOTs. Immediately after stimulation, listeners will undergo a training trial where they identify sounds as mapping to Talker 1 or Talker 2's voice, and to the word (e.g. gain vs. cane). At test, listeners hear two VOT variants and are asked which is more typical of that talker's speech. The dependent variable is the accuracy of reporting which variant is typical of the talker."
62742087|NCT01246765||Atypical Antipsychotic Cohort|"Pregnant women who have taken at least one type of atypical antipsychotic at some point during pregnancy.~Medications of Special Interest:~* Abilify (aripiprazole)~* Aristada (aripiprazole lauroxil)~* Aristada Initio (aripiprazole lauroxil)~* Clozaril (clozapine)~* Lybalvi (olanzapine and samidorphan)~* Rexulti (brexpiprazole)~* Risperdal (risperidone)~* Seroquel (quetiapine)~* Symbax (olanzapine-fluoxetine HCL)~* Zyprexa (olanzapine)"
62742088|NCT01246765||Antidepressant Medications|"Pregnant women who have taken at least one type of antidepressant medication at some point during pregnancy.~Medications of Special Interest:~* Spravato (esketamine)~* Zulresso (brexanolone)"
62742089|NCT01246765||ADHD Medications|"Pregnant women who have taken at least one type of ADHD medication at some point during pregnancy.~Medications of Special Interest:~• Qelbree (viloxazine)"
62742090|NCT01246765||Sedative Hypnotic Medications|"Pregnant women who have taken at least one type of sedative hypnotic medication at some point during pregnancy.~Medications of Special Interest:~• Dayvigo (lemborexant)"
62742091|NCT01246765||Other Psychiatric Medications|Pregnant women who have taken other psychiatric medications (other than atypical antipsychotics, ADHD medications, antidepressants, or sedative hypnotics) at some point during pregnancy.
62742092|NCT01575639|EXPERIMENTAL|High dose|Oral Prednisolone will be given at dose of 4 mg/kg/day for 14 days
62742093|NCT01575639|ACTIVE_COMPARATOR|Usual dose|Oral prednisolone will be given at dose of 2 mg/kg/day for 14 days
62176807|NCT02901483|EXPERIMENTAL|PEP503+Cisplatin+Radiotheraphy|"Phase 1b: There are 6 levels (L1- 5% + 40mg/m2 weekly cisplatin, L2- 10% + 40mg/m2 weekly cisplatin, L3- 15% + 40mg/m2 weekly cisplatin, L4-22% + 100mg/m2 tri-weekly cisplatin, L3a- 15% + 100mg/m2 tri-weekly cisplatin, and L5- 33% + 100mg/m2 tri-weekly cisplatin) in this phase 1b study. Only primary tumor will receive PEP503 implementation via intratumor injection. A 3 + 3 dose escalation study design will be adopted in this phase to identify the recommended intratumor injection volumes of PEP503.~Phase 2: The recommended volume identified from phase 1b will be applied in phase 2 for both primary tumor and ≥ 3 cm lymph node lesions."
62176808|NCT02645773|EXPERIMENTAL|Pre-laser|non-ablative laser Laser Pre-wounding low dose laser Pre-wounding medium dose laser Pre-wounding high dose
62176809|NCT02645773|EXPERIMENTAL|Immediate-laser|non-ablative laser Laser low dose - immediate after wounding Laser medium dose - immediate after wounding Laser high dose - immediate after wounding
62742094|NCT03723330|EXPERIMENTAL|Plant sterol with a healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet. Subjects will also be provided with specific instructions to consume plant sterols-enriched food (contains 2 g plant sterols).
62176810|NCT02645773|EXPERIMENTAL|Post-laser|non-ablative laser Laser low dose - post wounding Laser medium dose - post wounding Laser medium dose - post wounding
62176811|NCT02645773|NO_INTERVENTION|Control|Untreated control wound
62176812|NCT03128541||Ultrasound Spine in sitting position|Participants will be assigned to a sitting decubitus position to identify the Tuffier's Line
62176813|NCT03128541||Ultrasound Spine in lateral position|Participants will be assigned to a lateral decubitus position to identify the Tuffier's Line
62391466|NCT06342440||Low-risk Adenoma (Training cohort)|"Individuals who underwent colonoscopy and were found to only have low-risk adenomas, defined as:~* 1 to 4 adenomas at most.~* All adenomas have low-grade dysplasia at most.~* All adenomas are \<10 mm in diameter."
62391467|NCT06342440||Advanced Adenoma (Training cohort)|"Individuals who underwent colonoscopy and were found to have high-risk adenomas, defined as one or more of the following:~* 5 or more adenomas.~* One or more adenomas have high-grade dysplasia.~* One or more adenomas are \>10 mm in diameter."
62391468|NCT06342440||Colorectal Cancer (Training cohort)|Individuals who underwent colonoscopy and were found to have colorectal cancer.
62742095|NCT03723330|ACTIVE_COMPARATOR|Healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet.
62742096|NCT04751604|EXPERIMENTAL|Nicotinamide|Daily oral administration of 1,000 mg nicotinamide \[1x 500-mg conventional nicotinamide tablet and 1x 500-mg tablet with controlled-ileocolonic-release nicotinamide (CICR-NAM)\] for 4 weeks
62176814|NCT04739488|EXPERIMENTAL|Breathing exercise and inhaler training|This group were given pursed lip breathing exercise and inhaler training.
62176815|NCT04739488|EXPERIMENTAL|inhaler training|This group were given only inhaler training
62742097|NCT04751604|PLACEBO_COMPARATOR|Placebo|Daily oral administration of 2 matching placebo tablets for 4 weeks
62742098|NCT02791932|EXPERIMENTAL|Exercise|The intervention will last 8-10 months depending on when during pregnancy the participant is randomized. The intervention will consist of three components (i.e., telephone, print materials, and exercise log/goal setting) designed to increase exercise. Social Cognitive Theory (SCT) and Self-Determination Theory will guide the exercise intervention. The counseling sessions will be a collaboration between the counselor and participants on how to best integrate exercise into the participant's daily routine. Participants will receive 15 intervention phone calls lasting approximately 15-20 minutes each. There will be a one-month intensive phase (weekly contacts), followed by bi-weekly contacts for two months, and then monthly until delivery. Beginning at 6 weeks postpartum, bi-weekly contacts will resume through 3 months postpartum.
62742099|NCT02791932|NO_INTERVENTION|Usual Care|Participants in the usual care condition will follow their usual standard of care as suggested by their healthcare provider. Participants will complete the same assessments and incentives as the active interventions but will not receive the exercise counseling sessions. Following completion of the nine-month follow-up, the usual care arm can choose to receive a six-month version of the exercise intervention.
62176816|NCT05767814||PsO patients at risk of PsA development|
62176817|NCT05767814||naive to treatment PsA|
62364910|NCT04600453|EXPERIMENTAL|Training group|"Multicomponent exercise group (intervention): The intervention will consist of a multicomponent exercise training programme24, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. During the training period, patients will be trained in 20 min sessions twice a day (morning and evening).~The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RMcombined with balance and gait retraining exercises that progressed in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital."
62364911|NCT04600453|NO_INTERVENTION|Usual care group|Usual care
62364912|NCT05778357||Evaluation of neuromotor development of healthy infants|75 healthy infants were included. Neuromotor development was evaluated with the Denver II Developmental Screening Test and Alberta Infant motor scale.
62742100|NCT01971944||Patients achieving steady state concentrations of carvedilol|Patients achieving steady state concentrations of carvedilol who receive a trial of dobutamine followed by milrinone.
62176818|NCT05767814||TNF-inhibitor resistant PsA|
62176819|NCT05767814||IL-17-inhibitor resistant PsA|
62176820|NCT05767814||TNF-inhibitor induced remission PsA|
62176821|NCT05767814||IL-17-inhibitor induced remission PsA|
61986261|NCT02736045|NO_INTERVENTION|Control|Sham control. Subjects will be asked to write a journal (per week).
62176822|NCT05767814||c-DMARDs resistant PsA|
62742101|NCT01971944||Patients achieving steady state concentrations of metoprolol|Patients achieving steady state concentrations of metoprolol who receive a trial of dobutamine followed by milrinone.
62742102|NCT01971944||Patients not receiving beta blocker|Patients not receiving beta blocker who receive a trial of dobutamine followed by milrinone.
62176823|NCT05767814||c-DMARDs resistant RA|
62176824|NCT04531878|EXPERIMENTAL|BSEP trafficking abnormal group|Patients with ABCB11 missense mutations that were speculated to affect the BSEP trafficking
62176825|NCT04854902|EXPERIMENTAL|Cyanoacrylate|The graft is stabilized and the donor site is coated with cyanoacrylate.
62176826|NCT04854902|ACTIVE_COMPARATOR|Suture|6/0 polyvinylidene fluoride sutures are used for stabilization, while the donor site is left untreated.
62176827|NCT02859558|EXPERIMENTAL|Arm 1: Fiebig I/II|Participants enrolled during Fiebig stages I or II (non-reactive HIV-1 antibody).
62176828|NCT02859558|EXPERIMENTAL|Arm 2: Fiebig III/IV|Participants enrolled during Fiebig stages III or IV (reactive HIV-1 antibody and negative or indeterminate results on the Western blot or Geenius HIV-1/HIV-2).
62176829|NCT02859558|EXPERIMENTAL|Arm 3: Fiebig V|Participants enrolled during Fiebig stage V (reactive HIV-1 antibody and positive Western blot or Geenius HIV-1/HIV-2 without p31 band).
62176830|NCT00439647|EXPERIMENTAL|Zoledronic Acid|5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.
62176831|NCT00439647|PLACEBO_COMPARATOR|Placebo|100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The i.v. infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.
62176832|NCT01397188|EXPERIMENTAL|PiCCO group|Intervention: Device: Picco- thermodilution catheter
62176833|NCT01397188|SHAM_COMPARATOR|sham group|No PiCCO Intervention
62176834|NCT03357471|EXPERIMENTAL|Certolizumab Pegol Q2W injection by e-Device|Subjects will self-inject Certolizumab Pegol 200 mg (1 x 200 mg injection) using the e-Device every 2 weeks.
62176835|NCT03357471|EXPERIMENTAL|Certolizumab Pegol Q4W injection by e-Device|Subjects will self-inject Certolizumab Pegol 400 mg (2 x 200 mg injection) using the e-Device every 4 weeks.
62176836|NCT05162196|EXPERIMENTAL|SBRT combined with Niraparib and Toripalimab|"Induction therapy (cyc1: D1-D28): Niraparib 200mg QD + SBRT 8Gy✖️3 QD, D4-D6 + Toripalimab 240mg iv drip D7~Maintenance (cyc2+): Niraparib 200mg QD, D1-D21 + Toripalimab 240mg iv drip D1, until disease progression or intolerable toxicity"
62176837|NCT03179059|EXPERIMENTAL|Pregnancy tests at baseline & follow-up|We offer free pregnancy test service at baseline and at follow-up survey.
62742103|NCT05016817|EXPERIMENTAL|Treatment Group|Single intravenous infusion of 100 million cells
62176838|NCT03179059|EXPERIMENTAL|Pregnancy tests only at baseline|We offer free pregnancy test service at baseline
62176839|NCT03179059|NO_INTERVENTION|Do Not Offer Pregnancy Test|Control group. No intervention is implemented.
62364913|NCT05505149|ACTIVE_COMPARATOR|0 to 6 years old spastic cerebral palsy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
62176840|NCT02176356|OTHER|All Participants|JUVÉDERM® ULTRA XC and/or JUVÉDERM® ULTRA PLUS XC and/or JUVÉDERM® VOLUMA® XC injection into facial areas, volume as determined by the investigator on Day 1 with additional treatment at Day 14 if applicable. LATISSE® 1 drop applied to upper eyelid at the base of the eyelashes once daily in the evening for 17 weeks beginning on Day 1. BOTOX® Cosmetic 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas at Month 3.
62364914|NCT05505149|ACTIVE_COMPARATOR|7 to 12 years old spastic cerebral palsy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
62364915|NCT05505149|ACTIVE_COMPARATOR|13 to 18 years old spastic cerebral palsy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
62742104|NCT05128786|EXPERIMENTAL|CCT301-38|To determine the safety, tolerability, DLT and MTD of CCT301-38 cell therapy in patients with AXL-positive relapsed or refractory sarcomas.
62742105|NCT02193737|EXPERIMENTAL|Early oral fluid recovery.|
62176841|NCT05896696|EXPERIMENTAL|BeShape One Device Treatment|
62176842|NCT05436600|NO_INTERVENTION|Control|The control group will undergo standard-of-care vascular risk factor modification. Control participants will be contacted via telephone on a weekly basis to discuss the importance of vascular risk factor management and adherence to prescribed medical management.
62176843|NCT05436600|EXPERIMENTAL|Exercise Intervention|The exercise intervention group will undergo 12 weeks of AeroBal exercise training (approximately 3 times/week). Each exercise session will consist of a 5-minute warm-up walk, approximately 30 minutes of aerobic exercise at a goal of 60-75% HRmax, 15 minutes of balance exercises, and a 5-minute cool-down walk.
62742106|NCT02193737|ACTIVE_COMPARATOR|Delayed oral fluid recovery.|
62742107|NCT05070845|EXPERIMENTAL|Open Label PF-06835375 dose 1 Treatment|subcutaneous injection once monthly for 3 months
62176844|NCT04597099|EXPERIMENTAL|Flutamide|Prior to the first or second admission (randomly determined), subjects will be pretreated for 4 weeks with Flutamide (250 mg twice daily)
62742108|NCT05070845|EXPERIMENTAL|Open Label PF-06835375 dose 2 Treatment|subcutaneous injection once monthly for 4 months
62742109|NCT05070845|EXPERIMENTAL|Open Label PF-06835375 dose 3 Treatment|subcutaneous injection once monthly for 4 months
62176845|NCT04597099|PLACEBO_COMPARATOR|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
62176846|NCT04958941|EXPERIMENTAL|Intervention group|The group will receive the ecological momentary intervention (CUIDA-TE APP). This intervention will allow the individual to learn and practice adaptive ways to regulate their emotions. The protocol contains the following components: Distraction, acceptation skills, re-appraisal and problem-solving skills.
62176847|NCT04958941|NO_INTERVENTION|Control group|This condition is a waiting list control group with no intervention. The participants will wait for a period of 3 months. They will be offered the possibility of receiving the intervention APP (CUIDA-TE) after the waiting list period.
62176848|NCT01956955|ACTIVE_COMPARATOR|enoxaparin and alteplase|After alteplase therapy , 4-6 hour later, activated partial thromboplastin time (APTT) was checked. According to initial SC LMWH use time, fixed dose SC LMWH, enoxaparin, was administered subcutaneous every 12 hours.
62176849|NCT01956955|ACTIVE_COMPARATOR|Unfractionated heparin and alteplase|After thrombolytic treatment, a bolus of 10 mg of alteplase followed by 90 mg over 2-h infusion, patients either administered a constant heparin infusion (18 U/Kg per hour) adjusted to maintain an activated partial thromboplastin time of 46-70 s.
62176850|NCT03891641|EXPERIMENTAL|Treadling Group|Treadling subjects will do so 3x per week (15 min sessions) for 6 weeks.
62176851|NCT03891641|NO_INTERVENTION|Control Group|Control Subjects continue their normal daily activities.
62176852|NCT05142072|EXPERIMENTAL|vitamin D film|Prepared intranasal films containing vitamin D3 by the investigators and administered to the right nostril with the aid of an ENT surgeon
62176853|NCT05142072|OTHER|control group|No devices will be added
62176854|NCT05694533|EXPERIMENTAL|INDV-2000 BID + Midazolam|Participants will receive a single oral dose of 5 mg midazolam on Day 1. Participants will receive a dose of INDV-2000 twice a day (BID) from Days 2 to 15. On Day 15 participants will also receive a single oral dose of 5 mg midazolam co-administered with the INDV-2000 morning dose.
62742110|NCT03260374||children with cochlear implant|"30 subjects whose age ranges from 2-6 years old who are implanted with Medel multichannel cochlear implant male and female will be included and will undergo:-~* Electric compound action potential~* Electric stapedial reflex threshold~* Electric auditory brain stem response"
62742111|NCT05895331||Dexmedetomidine used group in Coronary Bypass Surgery|
62742112|NCT05895331||Dexmedetomidine non-used group in Coronary Bypass Surgery|
62742113|NCT00726791|EXPERIMENTAL|1|high frequency rTMS applied to the motor cortex
62176855|NCT02935777|EXPERIMENTAL|Pomegranate Extract|"POMANOX® pomegranate extract capsules with water by mouth, once. Dosage: 2 capsules~Capsules weigh1.083g and contain: 210mg punicalagin, 328mg other pomegranate polyphenols (e.g. flavonoids and ellagic acid), 0.37mg anthocyanins and maltodextrin."
62176856|NCT02935777|PLACEBO_COMPARATOR|Placebo|Identical placebo capsules by mouth, administered once. Dosage 2 capsules. Each capsule contains maltodextrin to provide PE capsule energy equivalent i.e.6.52 kcal or 27.28kJ.
62742114|NCT06290076||Severe Complications Group|Patients with severe complications (including symptomatic intracranial hemorrhage and malignant cerebral edema) occurred within 72 hours after endovascular thrombectomy are classified into severe complications group.
62742115|NCT06290076||Non-Severe Complications Group|Patients without severe complications (including symptomatic intracranial hemorrhage and malignant cerebral edema) occurred within 72 hours after endovascular thrombectomy are classified into non-severe complications group.
62176857|NCT04218552|EXPERIMENTAL|Experimental 1|AD-209 High
62552734|NCT03649997|EXPERIMENTAL|Part 3 Cohort 6: Multiple Ascending Dose|Participants will receive oral JNJ-61393215 225 mg suspension or matching placebo once daily for 7 days under fasted conditions. Dose may be lowered or increased based on the evaluation of safety and PK of Cohort 5. This dose may be the same as the dose chosen for Cohort 2 (Part 1), or it could be different.
62742116|NCT03776669|ACTIVE_COMPARATOR|LSG alone|"Intervention: laparoscopic sleeve gastrectomy alone.~LSG will be performed laparoscopically via a 5-port technique. The greater omentum is dissected by using the 5-mm laparoscopic LigaSure or Harmonic from 4 cm proximal to the pyloric ring to the angle of His. Sleeve calibration is done by a 36-French bougie inserted along the lesser curvature. Then the stomach is transected with sequential firings of linear green, gold, and blue 60 mm staplers starting about 4 cm proximal to the pylorus and ending approximately 2 cm distal to the left of the esophagus. The staple-line of the remnant gastric tube is oversewn with 3-0 V-Loc to prevent leakage and hemorrhage."
62742117|NCT03776669|EXPERIMENTAL|LSG + HHR|"Intervention: concomitant laparoscopic sleeve gastrectomy + hiatal hernia repair.~The surgical detail of LSG is the same as described in LSG alone arm, and the surgical detail of HHR is described as below.~The hiatus is approached from the right side of the EGJ, through the lesser omentum. The hiatal defect is repaired by 1-0 Surgilon interruptedly, and then a commercialized U-shaped Biodesign Hiatal Hernia Graft is placed to the EGJ to cover the posterior side but spare the anterior side of the hiatus. Care must be taken to avoid direct contact of mesh to the esophagus to avoid any unnecessary complication. After the mesh is appropriately placed and oriented, 2 ml of TISSEEL solution for sealant is applied all over the mesh for fixation."
62742118|NCT06484179|ACTIVE_COMPARATOR|Usual Care|
62742119|NCT06484179|EXPERIMENTAL|Usual Care + Targeted Self-Help Intervention|
62742120|NCT04047706|EXPERIMENTAL|Methylated Cohort (radiation, temozolomide, BMS-986205 25mg QD, nivolumab)|"RADIATION THERAPY: Patients with MGMT methylated promoter undergo radiation therapy 5 days per week (Monday-Friday) for up to 6 weeks. Patients also receive temozolomide PO QD, IDO1 inhibitor BMS-986205 PO QD, and nivolumab IV over 30 minutes every 2 weeks for up to 6 weeks in the absence of disease progression, unacceptable toxicity, withdrawal of consent, the study ends, or until Q4W dosing begins.~MAINTENANCE THERAPY: Patients receive IDO1 inhibitor BMS-986205 PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-5 and on day 1 of subsequent cycles. Within 4 weeks of radiation therapy completion, patients also receive temozolomide PO QD on days 1-5 of cycles 2-6. Cycles repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
62742121|NCT04047706|EXPERIMENTAL|Unmethylated Cohort (radiation, BMS-986205 50mg QD, nivolumab)|"RADIATION THERAPY: Patients with MGMT unmethylated promoter undergo radiation therapy 5 days per week (Monday-Friday) for up to 6 weeks. Patients also receive IDO1 inhibitor BMS-986205 PO QD and nivolumab IV over 30 minutes every 2 weeks for up to 6 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive IDO1 inhibitor BMS-986205 PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-5 and on day 1 of subsequent cycles. Cycles repeats every 28 days for up to 2 years in the absence of disease progression, unacceptable toxicity, withdrawal of consent, the study ends, or until Q4W dosing begins."
62742122|NCT04047706|EXPERIMENTAL|Unmethylated Cohort (radiation, BMS-986205 100mg QD, nivolumab)|"RADIATION THERAPY: Patients with MGMT unmethylated promoter undergo radiation therapy 5 days per week (Monday-Friday) for up to 6 weeks. Patients also receive IDO1 inhibitor BMS-986205 PO QD and nivolumab IV over 30 minutes every 2 weeks for up to 6 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive IDO1 inhibitor BMS-986205 PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-5 and on day 1 of subsequent cycles. Cycles repeats every 28 days for up to 2 years in the absence of disease progression, unacceptable toxicity, withdrawal of consent, the study ends, or until Q4W dosing begins."
62742123|NCT01786213||Colonoscopist A|
62742124|NCT01786213||Colonoscopist B|
62742125|NCT01786213||Colonoscopist C|
62742126|NCT01786213||Colonoscopist D|
62742127|NCT01786213||Colonoscopist E|
62742128|NCT01786213||Colonoscopist F|
62742129|NCT01786213||Colonoscopist G|
62552735|NCT02704169|EXPERIMENTAL|Spatially registered endoscopy for H&N cancer|
62742130|NCT01786213||Colonoscopist H|
62742131|NCT01786213||Colonoscopist I|
62742132|NCT01786213||Colonoscopist J|
62742133|NCT06658106|EXPERIMENTAL|Thera-Band Elastic Band-Assisted Progressive Resistance Training Group|In the Thera-Band Elastic Band-Assisted Progressive Resistance Training Group, participants will engage in a structured exercise program utilizing Thera-Band elastic bands for resistance training. The intervention will occur three times a week for 12 weeks, with each session lasting approximately 50 minutes. Exercises will target major muscle groups, including upper and lower limbs, and will be designed to improve strength, balance, and overall physical function. Participants will be instructed to exercise at 60%-80% of their maximum heart rate to ensure an effective training intensity. The program aims to enhance physical health, reduce frailty, and improve quality of life for older adults with diabetes mellitus and frailty syndrome. Participants will receive guidance from trained exercise instructors and will be monitored for any adverse reactions during the training sessions.
62176858|NCT04218552|EXPERIMENTAL|Experimental 2|AD-209 Middle
62176859|NCT04218552|EXPERIMENTAL|Experimental 3|AD-209 Low
62176860|NCT04218552|ACTIVE_COMPARATOR|Active Comparator 1|Amlodipine Low
62176861|NCT04218552|ACTIVE_COMPARATOR|Active Comparator 2|Amlodipine High
62176862|NCT04218552|ACTIVE_COMPARATOR|Active Comparator 3|Telmisartan
62364916|NCT02976545|OTHER|PNES|Psychogenic Non-epileptic Seizures subjects
62176863|NCT04218552|PLACEBO_COMPARATOR|Placebo comparator|Placebo
62364917|NCT02976545|OTHER|PTSD|Post Traumatic Stress Disorder
62364918|NCT02976545|OTHER|Healthy controls|Healthy controls
62364919|NCT01769599||Grid Treatment|30 patients that were treated with laser grid treatment
62364920|NCT01769599||Avastin Treatment|patients that were treated with Avastin injections
62364921|NCT00044655|ACTIVE_COMPARATOR|Stay on baseline medication prescribed|Participants will continue taking medication prescribed at study entry: 1) either long-acting injectable haloperidol or fluphenazine, OR 2) two antipsychotic medications which might include a combination of any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.
62364922|NCT00044655|ACTIVE_COMPARATOR|Switch per study protocol|Participants will change medications from medication prescribed at study entry, either: 1) long-acting injectable risperidone, OR 2) one of the two antipsychotic medications prescribed at baseline which may include any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.
62176864|NCT01716091||saline irrigation|irrigation group:saline irrigation after uterine wall closed control group:no irrigation after uterine wall closed
62176865|NCT06173232||Group 1|Subjects with ETDRS ≥ 35 with or without DME
62176866|NCT06173232||Group 2|Subjects with ETDRS 20 or less and no DME
62176867|NCT02899819|EXPERIMENTAL|meconium|The meconium will be sampled in the first 2 days of life
62176868|NCT04532983|ACTIVE_COMPARATOR|fixation group|; group A; patients underwent laparoscopic TAPP repair of inguinal hernia and the mesh prosthesis was fixed in position using absorbable Vicryl tacks (abstack30 medtronic),
62176869|NCT04532983|ACTIVE_COMPARATOR|non fixation group|group B patient underwent laparoscopic TAPP repair of inguinal hernia and the mesh prosthesis was placed in position without fixation.
62364923|NCT04586075||Undiagnosed Disease Group|Blood or other relevant biological samples obtained from consenting research subjects will be banked and extracted for DNA and RNA.
62364924|NCT02848313|EXPERIMENTAL|Intermediate AMD - HRD without GA|"Participants had one 1 eye with intermediate age-related macular degeneration with high-risk drusen without geographic atrophy \[GA\]), i.e. the presence of either at least 1 large (≥125 μm) druse or multiple medium-size (63-124 μm) drusen.~Participants received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection."
62364925|NCT02848313|EXPERIMENTAL|Intermediate AMD with NCGA|"Participants had 1 eye with intermediate AMD with noncentral geographic atrophy \[NCGA\]; i.e. evidence of GA with cumulative area ≥1.27 mm2 (approximately 0.5 disc area\[DA\]) by fundus autofluorescence (FAF) that spared the fovea (defined as retinal pigment epithelium (RPE) and outer retina intact by spectral-domain optical coherence tomography \[SD-OCT\]).~Participants in this arm also received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection."
62176870|NCT02579278||mrEMVI positive rectal tumours|Patients will be registered whose rectal tumours are mrEMVI positive (i.e. EMVI is present in baseline and post-chemoradiotherapy MRI scans).
62176871|NCT02579278||mrEMVI negative rectal tumours|Patients registered who were mrEMVI positive at baseline MRI but have become mrEMVI negative post-chemoradiotherapy.
62176872|NCT02846935|EXPERIMENTAL|Decitabine + Tetrahydrouridine|"oral THU dosed by weight, followed by oral decitabine dosed by weight for 60 minutes (± 10 minutes) after the THU, twice weekly on consecutive days.~Treatment on protocol monitoring continues for 52 weeks."
62176873|NCT00548002||1 and 2|Patients were randomly assigned to receive either 1) standard treatment or 2) standard treatment combined with a fluoroquinolone (trovafloxacin or levofloxacin).
62176874|NCT04612478|OTHER|Clinic-Based Physical Therapy|Patients will be referred to PT by the orthopaedic surgeon for enrollment into a clinic-based PT program per usual referral patterns at the surgeon's center. Patients will receive services based on their health care benefits defined by his or her insurance plan.
62176875|NCT04612478|OTHER|Self-Directed Exercise Program|The full SDEP program, which will be developed by physical therapists, orthopaedic trauma surgeons, and investigators with experience in health behavior change, will be designed to maximize adherence/compliance with the program. The SDEP manual will provide detailed instructions on exercises, such as repetitions, frequency, and required equipment, which can be implemented in the home environment. The basis for the exercise regimen is derived from the American Academy of Orthopaedic Surgeons (AAOS) sample home based exercise program available in handout form. The program provides instructions on exercises, repetitions or duration, frequency, and required equipment which can be implemented in the home environment.
62176876|NCT04612478|NO_INTERVENTION|Observational|Patients who are unwilling to be randomized will be enrolled in an observational arm of the study. They will be asked to complete all baseline and follow-up assessments, and participation in formal PT or SDEP will be documented.
62176877|NCT01508832|ACTIVE_COMPARATOR|Lidocaine|Lidocaine 1% Digital Nerve Block (2 cc)
62176878|NCT01508832|ACTIVE_COMPARATOR|Bupivacaine|Bupivacaine 0.25% Digital Block (2 cc)
62364926|NCT03395067|ACTIVE_COMPARATOR|Lifestyle counseling|
62364927|NCT03395067|NO_INTERVENTION|Control group|
62364928|NCT01468038|ACTIVE_COMPARATOR|Active trazodone and placebo|trazodone 50mg with Sentra PM-like placebo
62364929|NCT01468038|ACTIVE_COMPARATOR|placebo and active Sentra PM|Trazodone-like placebo and Sentra PM
62364930|NCT01468038|ACTIVE_COMPARATOR|Sentra PM and trazodone|Active Sentra PM and active trazodone
62364931|NCT01468038|PLACEBO_COMPARATOR|placebo trazodone and placebo Sentra PM|trazadone-like placebo and Sentra PM-like placebo
62364932|NCT05355181|EXPERIMENTAL|Group A: scar mobilization and core stabilization exercises group|Group A will perform exercises for 3 weeks. Participants will perform core stabilization exercises as well as scar mobility exercises. All exercises will be performed in 3 sessions per week for a period of 3 weeks.
62391469|NCT06342440||Non-disease controls (Validation cohort)|Individuals who underwent colonoscopy and were found not to have any adenomas or cancer.
62176879|NCT02396758|EXPERIMENTAL|APT/2 Hours-r-tPA/2 mg/hr/Catheter|A total of 4 or 8 mg r-tPA (as 2 mg/hour \[hr\]/catheter) will be delivered through Ekosonic® Endovascular Device (EKOS) ultrasonic infusion catheter for 2 hrs.
62176880|NCT02396758|EXPERIMENTAL|APT/4 Hours-r-tPA/1 mg/hr/Catheter|A total of 4 or 8 mg r-tPA (as 1 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 4 hrs.
62742134|NCT06658106|ACTIVE_COMPARATOR|Conventional Diabetes Management Group|In the Conventional Diabetes Management Group, participants will receive standard care for diabetes management, which includes basic health education and guidance on diet, exercise, medication adherence, and daily care practices. This group will not engage in the Thera-Band exercise program but will continue their usual activities and follow-up care as prescribed by their healthcare providers. The aim of this arm is to provide a comparison to the experimental group regarding the effectiveness of the elastic band-assisted progressive resistance training on physical health and frailty outcomes. Participants will be monitored for their blood glucose levels and overall health status throughout the study period, and any changes in their condition will be documented.
62742135|NCT04116983||All patients|Recruited participants will be attending a dermatology clinic with at least one skin lesion where there is a suspicion of skin cancer. All suspicious lesions suitable for photographing will be photographed six times in a single visit. A macro and dermoscopic image of each lesion will be captured by three different mobile phones: an iPhone, a Samsung and a Nokia smart phone, without (macro image) or with (dermoscopic image) a Dermlite DL1 lens attached. Dermoscopic images of healthy skin will also be captured by each camera. Images of the lesions will be analysed by DERM. The DERM results for lesions biopsied will be compared to the biopsy result; the DERM results for lesions not biopsied will be compared to the clinical assessment.
62742136|NCT05400057||group 1|Oral Lichen Planus patients. Patients will be diagnosed clinically and histologically.
62176881|NCT02396758|EXPERIMENTAL|APT/6 Hours-r-tPA/1 mg/hr/Catheter|A total of 6 or 12 mg r-tPA (as 1 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 6 hrs.
62742137|NCT05400057||Group 2|Healthy patients. Patients without any systemic or oral lesions, not taking drugs for at least the the last 6 months
62176882|NCT02396758|EXPERIMENTAL|APT/6 Hours-r-tPA/2 mg/hr/Catheter|A total of 12 or 24 mg r-tPA (as 2 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 6 hrs.
62176883|NCT01929564|ACTIVE_COMPARATOR|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet.
62176884|NCT01929564|PLACEBO_COMPARATOR|Parthenon broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet.
62176885|NCT04349657|EXPERIMENTAL|Supera Peripheral Stent System treatment group|These patients will be treated endovascularly with the Supera Peripheral Stent System (Abbott).
62364933|NCT05355181|ACTIVE_COMPARATOR|Group B: scar mobilization techniques group|"Group B will perform scar mobilization exercises for 3 weeks along with baseline treatment.~All exercises will be performed in 3 sessions per week for a period of 3 weeks."
62742138|NCT05400057||Group 3|Oral Squamous Cell Carcinoma
62364934|NCT02578992|EXPERIMENTAL|Head-lift Position|The patients' head was placed in the head-lift position(A 7 cm high pillow was set beneath the patients' head with head in neutral position) and then the patient was intubated with Trachway by single-handed chin lift technique
62742139|NCT02250508|EXPERIMENTAL|Optivate®|
62742140|NCT02250508|ACTIVE_COMPARATOR|Haemate P®|
62364935|NCT02578992|NO_INTERVENTION|Neutral Position|The patients' head was placed in the neutral position and then the patient was intubated with Trachway by single-handed chin lift technique
62742141|NCT05346744|EXPERIMENTAL|Zirconia|10 crowns made of zirconia from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
62742142|NCT05346744|EXPERIMENTAL|Celtra Duo|10 crowns made of Celtra Duo from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
62742143|NCT05346744|EXPERIMENTAL|e.max CAD|10 crowns made of e.max CAD from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
62742144|NCT05346744|EXPERIMENTAL|Lici UPCERA|10 crowns made of Lici from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
62742145|NCT05346744|EXPERIMENTAL|Enamic|10 crowns made of Enamic from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
62742146|NCT05346744|EXPERIMENTAL|Runci UPCERA|10 crowns made of Runci from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
62742147|NCT01214408|EXPERIMENTAL|GRP-A|
62742148|NCT01214408|EXPERIMENTAL|GRP-B|
62364936|NCT06118762|EXPERIMENTAL|Fruquintinib combined with Raltitrexed group|Fruquintinib combined with Raltitrexed therapy
62176886|NCT04349657|ACTIVE_COMPARATOR|Endarterectomy treatment group|These patients will be treated surgically with endarterectomy
62176887|NCT00507975|PLACEBO_COMPARATOR|A|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
62742149|NCT01606176|EXPERIMENTAL|GW-1000-02|Each 100 μl actuation contains 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose was 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
62364937|NCT01909219|ACTIVE_COMPARATOR|Group A: standard regimen|Patients in the group A (standard regimen) will be instructed to take the two sachets of sodium picosulphate/magnesium citrate diluted in a glass of water 2-4 hours apart, starting at 5 pm the day before colonoscopy.
62364938|NCT01909219|ACTIVE_COMPARATOR|Group B|Patients in the group B (split regimen) will be instructed to take the first sachet of sodium picosulphate/magnesium citrate at 7 pm the day before colonoscopy and the second one at 6 am in the morning on the day of colonoscopy.
62364939|NCT01609738||Sinus node dysfunction|Patients with sinus node dysfunction and structurally normal hearts
62364940|NCT01609738||CRT indication|Patients with an indication for CRT (heart failure with an LVEF \<35% and LBBB)
62364941|NCT00611767|ACTIVE_COMPARATOR|Family History Negative for Alcoholism|Family History Negative for Alcoholism subjects will receive 2 interventions
62742150|NCT01606176|PLACEBO_COMPARATOR|Placebo|Each 100 μl actuation contains the excipients only. The maximum permitted dose was 48 actuations in any 24 hour period
62552736|NCT02033538|EXPERIMENTAL|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
62552737|NCT05009017||Biosimilar group|
62176888|NCT00507975|EXPERIMENTAL|B|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
62176889|NCT00925288|ACTIVE_COMPARATOR|Regular schedule|Duration: Gardasil HPV vaccine administered intramuscularly at 0,2,6 months
62742151|NCT05994924|ACTIVE_COMPARATOR|Handout Only|Parents in this group receive an educational handout at the baseline visit.
62742152|NCT05994924|ACTIVE_COMPARATOR|Online-Only Video Series|Parents will be given (QR) quick-response codes to watch the videos on their own time with no discussion afterward.
62742153|NCT05994924|ACTIVE_COMPARATOR|Group Sessions|Parents will participate in 2 weekly group sessions with video viewing and group discussion.
62742154|NCT02321917|ACTIVE_COMPARATOR|Rheoparin coating|MECC system with rheoparin coating
62742155|NCT02321917|NO_INTERVENTION|No rheoparin coating|MECC system without rheoparin coating
62742156|NCT02119195|NO_INTERVENTION|No treatment|The composite resin restorations had marginal defects, but were clinically acceptable, did not receive treatment
62742157|NCT02119195|NO_INTERVENTION|Positive control|Composite resins with alpha value in marginal adaptation criteria
62742158|NCT02119195|EXPERIMENTAL|Intervention|For this group, defective areas were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3M ESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure
62742159|NCT06169319|EXPERIMENTAL|Group 1: EN3835|Participants will receive EN3835 Dose 1.
62176890|NCT00925288|EXPERIMENTAL|Modified Schedule|Duration: Gardasil HPV vaccine administered intramuscularly at 0,3,6 months
62176891|NCT02836054|OTHER|Patients with cognitive disorders|lumbar punction + brain MRI
62742160|NCT06169319|EXPERIMENTAL|Group 2: EN3835|Participants will receive EN3835 Dose 2.
62742161|NCT06169319|PLACEBO_COMPARATOR|Group 3: Placebo|Participants will receive matching placebo.
62742162|NCT06403982|EXPERIMENTAL|Oxytocin Group|Oxytocin Group will comprise 100 women in labor either stimulated or induced by oxytocin requesting epidural analgesia (ELA). The use of oxytocin will be continued after the administration of ELA.
62742163|NCT06403982|PLACEBO_COMPARATOR|Control Group|Control Group will comprise 100 women in labor either stimulated or induced by oxytocin requesting epidural analgesia (ELA). The oxytocin pump will be changed to 0.9% sodium chloride solution pump after the administration of ELA.
62742164|NCT00298623|PLACEBO_COMPARATOR|Placebo|
62742165|NCT00298623|EXPERIMENTAL|XP13512 (GSK1838262)|
62742166|NCT01018329|EXPERIMENTAL|I|Patients undergo multimodality MRI imaging at baseline, weeks 1, 2, 3, 5, and 6 and then 4-6 weeks after completion of radiation therapy.Patients undergo MRI imaging at baseline, weeks 1, 2, 3, 5, 6 and then 6 weeks after radiation therapy.
62176892|NCT02836054|OTHER|Patients without cognitive disorders|lumbar punction + brain MRI
62176893|NCT01820221|ACTIVE_COMPARATOR|Arm 1: Skin closure with suture|Subjects in this group will be randomized to suture for skin closure with computer generated random card draw.
62176894|NCT01820221|ACTIVE_COMPARATOR|Arm 2: Skin closure with staples|Subjects randomized to skin closure with staples with computer generated random card draw.
62176895|NCT00372177|ACTIVE_COMPARATOR|EP1645|Single-Dose
62176896|NCT01951378|ACTIVE_COMPARATOR|Hudson RCI® nebulizer|"Patients randomized to the standard arm will receive treatments as dictated by our standard ED asthma pathway (Fig. 1). All treatments will be administered with our standard ED nebulizer, the Hudson RCI® Up-Draft® Neb-U-Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ), and a simple mask (Hudson RCI®, Teleflex Medical®, Research Triangle Park, NJ)."
62182444|NCT02956122|EXPERIMENTAL|Study Part 2 - GLASSIA|Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
62182445|NCT02956122|PLACEBO_COMPARATOR|Study Part 2 - Albumin (Control)|Participants to receive control (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
62182446|NCT02869815||ICG+Methylene Blue|"ICG+Methylene Blue:~Sentinel Lymph Node (SLN) identification and resection using dual tracer technique with the sub-areolar injection of ICG+Blue dye, before surgery."
62552738|NCT05009017||Originator group|
62742167|NCT00648388|EXPERIMENTAL|1|Cilostazol Tablets 100 mg
62742168|NCT00648388|ACTIVE_COMPARATOR|2|Pletal® Tablets 100 mg
62742169|NCT06615817|NO_INTERVENTION|Control group - Mediterranean diet with low glycemic index|Control group in which patients will follow a Mediterranean diet with a low glycemic index
62742170|NCT06615817|EXPERIMENTAL|Case group - Intermittent Fasting|Intermittent fasting 14/10 with 14 hours of nocturnal fasting and 10 hours of feeding with a low glycemic index Mediterranean diet.
62742171|NCT06054113|EXPERIMENTAL|Blinatumomab|Participants will receive up to 5 cycles of blinatumomab (cycle is 42 days), including a 28-day continuous intravenous infusion (CIVI) of blinatumomab and a 14-day treatment free interval.
62742172|NCT04597645|EXPERIMENTAL|Elastic band (EB)|EB group participants who are attending sheltered employment will received Elastic Thera band training program two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainer) over 16 weeks for a total of 32 sessions.
62742173|NCT04597645|NO_INTERVENTION|Control group (CG)|Control group participants will receive usual care.
62742174|NCT05007899|ACTIVE_COMPARATOR|Daily|Patients receive standard regimen of ferrous sulfate 325 mg (65 mg elemental iron) once every morning.
62742175|NCT05007899|EXPERIMENTAL|Alternate Day|Patients receive ferrous sulfate 325 mg (65 mg elemental iron) once every other morning.
62742176|NCT06553118||Central Sensitization Group|Patients with central sensitization
62742177|NCT06553118||Non-sensitized Group|Patients without central sensitization
62742178|NCT00772915|EXPERIMENTAL|Lenalidomide with On-Demand Dexamethasone|"Lenalidmoide: 25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.~Dexamethasone: 10-40 mg once weekly (days 1, 8, 15, \& 22) orally with food until progression."
62176897|NCT01951378|ACTIVE_COMPARATOR|NebuTech® HDN® nebulizer|"Patients randomized to the NebuTech® arm will receive treatments as dictated by our trial pathway, referred to as the rapid Albuterol/Proventil delivery pathway (Fig. 2). All nebulizations in this arm will be administered via the Breath-Enhanced High Density Jet Nebulizer, NebuTech® HighDensityNebulizer®,(Salter Labs®, Arvin, CA). Respiratory Therapists (RT) will attempt to deliver all treatments with a mouthpiece, as that has been shown to be the most efficient and reliable mode of aerosol delivery for most children 31, 32. If the Respiratory Therapist feels that the child will not or cannot effectively use a mouthpiece, a mask will be used."
62176898|NCT02747719|EXPERIMENTAL|Light and exercise|Exposure to light with exercise
62176899|NCT03681353|EXPERIMENTAL|Reduced Use Condition|This arm includes six weeks of mobile contingency management treatment administered via a smart-phone based application (mobile CM), in which participants are provided monetary reinforcement for reducing cannabis use.
62176900|NCT02304562|EXPERIMENTAL|UCB Mesenchymal Stem Cells|UCB Mesenchymal Stem Cells treatment of patients with skin injury
62176901|NCT01780545|EXPERIMENTAL|Experimental Arm: Arm A|Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle.
62176902|NCT01780545|ACTIVE_COMPARATOR|Control Arm: Arm B|Docetaxel (75 mg/M2) will be administered IV on day 1 of each 21 day cycle for a maximum of 10 cycles.
62742179|NCT03905148|EXPERIMENTAL|Part A: Dose Escalation/Dose finding Dose Level Cohorts ranging in dose levels and dose regimens.|Combination doses of, Mirdametinib at once a day and lifirafenib at once a day And Mirdametinib at twice a day and lifirafenib at once a day
62742180|NCT03905148|EXPERIMENTAL|Part B: Expansion|Approximately 20 participants with NRAS mutated solid tumors will be enrolled
62742181|NCT02148887||SCI patients with upper limb impairment - Upper limb training|
62176903|NCT06171282|EXPERIMENTAL|Experimental: R130 Treatment Group|Every 7-14 days,1-2 ml R130 （concentration of 1x10\^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral in patients with relapsed/refractory bone and soft tissue tumors.
62176904|NCT04597905||CD Participants|Participants diagnosed with CD from the 7 participating countries will take part in survey to collect data regarding their preferences towards the attributes of treatments based on DCE survey with advanced therapies for IBD, including safety and efficacy profiles, frequency and RoA in a real-world setting and data collection will be conducted in a real-world setting via an online self-reported questionnaire hosted on the Carenity platform, an international patient community.
62552739|NCT06042582||Ulcerative Colitis (UC)|"* subjects undergoing endoscopy and biopsies collection per standard of care~* adult patients ≥18 and \<60 years~* clinical and endoscopic evaluation (Mayo score≥2)"
62742182|NCT02148887||SCI patients with lower limb impairment - Lower limb training|
62742183|NCT02148887||Healthy controls - Upper limb training|
62552740|NCT06042582||Crohn's Disease (CD)|"* subjects undergoing endoscopy and biopsies collection per standard of care~* adult patients ≥18 and \<60 years~* clinical and endoscopic evaluation (Harvey-Bradshaw score ≥5 and overall simplified endoscopic score (SES-CD) \>2)"
62552741|NCT06042582||NO UC/CD|"* subjects undergoing endoscopy and biopsies collection (≥18 and \<60 years) according to the normal clinical practice (as patients undergoing cancer surveillance, irritable bowel syndrome (IBS), diarrhea)~* subjects not affected by UC or CD according to the previously reported clinical and endoscopic evaluation criteria"
62552742|NCT04366323|EXPERIMENTAL|Experimental|
62552743|NCT04366323|NO_INTERVENTION|Control|
62552744|NCT00993356|OTHER|Group 2|After a baseline evaluation, patients underwent transsphenoidal surgery (direct surgery group).
62552745|NCT00993356|EXPERIMENTAL|Group 1|Patients received lanreotide for 16 weeks before the surgical resection \[starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH \> 5 mU/L on GH day curve (GHDC)\] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
62552746|NCT03904290|OTHER|Pre-PFO closure|Subjects evaluated at 'baseline' prior to percutaneous closure of PFO, and re-evaluated at 3 months post percutaneous closure of PFO
62552747|NCT05442801|ACTIVE_COMPARATOR|Cyclopentolate arm|"To study the effect of cyclopentolate 1% for cycloplegic refractions in pediatric populations:~Firstly, we instilled an anesthetic drop into patients' eyes. Secondly, 2 drops of cyclopentolate 1% (cyclogel) 5 minutes apart were instilled.~Autorefraction was taken at 60 minutes after first drop instillation. Primary outcome: spherical equivalent (SE) of cycloplegic refraction at 60 minutes."
62552748|NCT05442801|ACTIVE_COMPARATOR|Tropicamide arm|"To study the effect of tropicamide 1% for cycloplegic refractions in pediatric populations:~Firstly, we instilled an anesthetic drop into patients' eyes. Secondly, 2 drops of tropicamide 1% (mydriacil) 5 minutes apart were instilled. Autorefraction was taken at 30 minutes after first drop instillation. Primary outcome: spherical equivalent (SE) of cycloplegic refraction at 30 minutes."
62552749|NCT03616457||All Study Participants|All study participants will undergo the same study procedures, including Automated Breast Ultrasound (ABUS).
62552750|NCT01254773|EXPERIMENTAL|Bapineuzumab SC Dose 1; 2 mg|
62552751|NCT01254773|EXPERIMENTAL|Bapineuzumab SC Dose 2; 7 mg|
62552752|NCT01254773|EXPERIMENTAL|Bapineuzumab SC Dose 3; 20 mg|
62552753|NCT01254773|PLACEBO_COMPARATOR|Placebo|
62552754|NCT02371434|EXPERIMENTAL|Treatment arm|"Patients in ONEnTreg13 will be treated with four immunosuppressive agents, all of which are classified as an Investigational Medicinal Products (IMPs):~* nTregs~* Prednisolone~* MMF~* Tacrolimus"
62552755|NCT01627678|EXPERIMENTAL|Arm 1= Arm A: Vacc-C5 /GM-CSF.|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
62552756|NCT01627678|EXPERIMENTAL|Arm 2=Arm B: Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
62552757|NCT02308124|EXPERIMENTAL|Midodrine|Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.
62742184|NCT02148887||Healthy controls - Lower limb training|
62742185|NCT02148887||Healthy controls - No intervention|
62742186|NCT03722420|EXPERIMENTAL|Radotinib 300mg|Oral adminstration of Radotinib 300mg BID (600mg/day) for 12months
62742187|NCT03722420|ACTIVE_COMPARATOR|Imatinib 400mg|Oral administration of Imatinib 400mg QD (400mg/day) for 12months
62176905|NCT04597905||UC Participants|Participants diagnosed with UC from the 7 participating countries will take part in survey to collect data regarding theirpreferences towards the attributes of treatments based on DCE survey with advanced therapies for IBD, including safety and efficacy profiles, frequency and RoA in a real-world setting and data collection will be conducted in a real-world setting via an online self-reported questionnaire hosted on the Carenity platform, an international patient community.
62176906|NCT03460093||case (SHPB+)|Superior hypogastric plexus block present
62176907|NCT03460093||control (SHPB-)|Superior hypogastric plexus block not present
62742188|NCT02269553|ACTIVE_COMPARATOR|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. They are constructed from methacrylate polymers - the same material as has been used in hearing aids. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the individuals' ear canals when the jaw is in the open position and permit full passage of sound into each ear. The device is FDA cleared under a 510(k) with an indication of reducing TMD pain.
62176908|NCT01012596||Creighton Model|New and return users of the Creighton Model FertilityCare System, a method of Natural Family Planning.
62176909|NCT02740621||Patients with coronary heart disease|coronary angiography with finding coronary heart disease currently no cancer 40 years or older
62176910|NCT02740621||control patients|coronary angiography with exclusion coronary heart disease or other patients with non-cardiac diseases currently no cancer 40 years or older
62176911|NCT03847922|PLACEBO_COMPARATOR|Control group|lidocaine gel injected in the urethra 10 minutes prior to calcium hydroxylapatite injection plus self-administered room air
62742189|NCT02269553|ACTIVE_COMPARATOR|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch. Each patient assigned to the occlusal splint treatment group may wear either maxillary or mandibular splints or both, as prescribed by the subject's dentist, during the study. All occlusal splints used in the study will be custom fit to each patient using standard dental processes. All occlusal splints used in the study will be manufactured by Paul O'Neill Dental Lab, Yucaipa , CA, USA using clear ADA approved orthodontic acrylic
62742190|NCT01677598||Patients with plaque psoriasis|Patients with plaque psoriasis using ustekinumab in Asia-Pacific countries.
62176912|NCT03847922|EXPERIMENTAL|Study group|lidocaine gel injected in the urethra 10 minutes prior to calcium hydroxylapatite injection + self-administered Pro-Nox 50% nitrous oxide/50% oxygen.
62176913|NCT04151823|EXPERIMENTAL|Postbiotic &vitamin D3, lifestyle intervention.|Postbiotics will be given at the dose of 80 mg/day (2 ml per day SMART D3 MATRIX Smartfarma S.r.l. Via San Vittore 40 - 20123 MILAN; immunofos from Lactobacillus paracasei CNCM I-5220). 2 mL of product will give 1600 UI/die of VIT D3. Healthy living habits will be encouraged at t0, t1 and t2 visit.
62176914|NCT02692287|OTHER|Use of the PPH Butterfly|The PPH Butterfly will be inserted into the vagina of a healthy postnatal woman
62176915|NCT02370199|EXPERIMENTAL|670 nm light|Subjects will have baseline blood flow measured in the gastrocnemius using octafluoropropane infusion and ultrasound.After baseline flow measurements are obtained, a 670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2. Contrast images will be obtained up to 5 minutes after the commencement of light.
62176916|NCT05927506||Adolescents with ADHD|Observational study of behavior cognitive and motor control
62176917|NCT05927506||Adolescents without ADHD|Observational study of behavior cognitive and motor control
62176918|NCT01497340|ACTIVE_COMPARATOR|Position at introitus level|The newborn will be held by the neonatologist at the level of the introitus, the cord will be clamped at 2 minutes after birth with a plastic clamp placed at 1 cm from its cutaneous insertion.
62176919|NCT01497340|EXPERIMENTAL|position at Maternal Abdomen|The newborn will be placed on the abdomen and of the mother immediately after the first weight measurement. The cord will be clamped at 2 minutes after birth .
62176920|NCT04488978|EXPERIMENTAL|Irbesartan low/Amlodipine low|Irbesartan low \& Amlodipine low, once daily for 8 weeks
62176921|NCT04488978|EXPERIMENTAL|Irbesartan low/Amlodipine high|Irbesartan low \& Amlodipine high, once daily for 8 weeks
62176922|NCT04488978|EXPERIMENTAL|Irbesartan high/Amlodipine low|Irbesartan high \& Amlodipine low, once daily for 8 weeks
62742191|NCT05242068|OTHER|Standard care of group|Patients in standard care of group received traditional peripheral intravenous catheterization
62742192|NCT05242068|EXPERIMENTAL|Veinlite group|Patients in veinlite group received peripheral intravenous catheterization with Veinlite
62742193|NCT00093197|EXPERIMENTAL|A1: KAI-9803|
62742194|NCT00093197|EXPERIMENTAL|A2: KAI-9803|
62176923|NCT04488978|EXPERIMENTAL|Irbesartan high/Amlodipine high|Irbesartan high \& Amlodipine high, once daily for 8 weeks
62742195|NCT00093197|EXPERIMENTAL|A3: KAI-9803|
62742196|NCT00093197|EXPERIMENTAL|A4: KAI-9803|
62742197|NCT00093197|PLACEBO_COMPARATOR|A5: Placebo|
62742198|NCT06662110||neoadjuvant chemotherapy cohort|Resectable gastric cancer patients who received neoadjuvant chemotherapy, with the SOX regimen as the representative treatment plan, in accordance with standard clinical practice.
62742199|NCT06662110||neoadjuvant chemotherapy plus immunotherapy cohort|Resectable gastric cancer patients who received neoadjuvant chemotherapy plus immunotherapy in accordance with standard clinical practice.
62176924|NCT04488978|ACTIVE_COMPARATOR|Amlodipine low|Amlodipine low, once daily for 8 weeks
62176925|NCT04488978|ACTIVE_COMPARATOR|Amlodipine high|Amlodipine high, once daily for 8 weeks
62176926|NCT04488978|ACTIVE_COMPARATOR|Irbesartan low|Irbesartan low, once daily for 8 weeks
62176927|NCT04488978|ACTIVE_COMPARATOR|Irbesartan high|Irbesartan high, once daily for 8 weeks
62176928|NCT02596399|EXPERIMENTAL|DSTA4637S|
62176929|NCT02596399|PLACEBO_COMPARATOR|Placebo|
62176930|NCT00996359|EXPERIMENTAL|Irradiated allogeneic lymphocytes after Total Body Irradiation|
62176931|NCT01797978|EXPERIMENTAL|Intravenous methylene blue administration|2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion for 6hrs
62742200|NCT04573153|EXPERIMENTAL|Treatment Arm|Subjects in ambulatory-at home-treatment will receive hydroxychloroquine (standard therapy) + dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside.
62176932|NCT01797978|PLACEBO_COMPARATOR|Placebo|Normal saline administration instead of methylene blue
62176933|NCT04502043|EXPERIMENTAL|Exercise therapy|Exercise therapy consists of improving dynamic hip joint stability by means of hip-specific and functional lower limb strengthening, core stability and postural balance exercises.
62176934|NCT04835233|EXPERIMENTAL|methyldopa|maintaining postpartum the use of methyldopa 250 mg 01 tablet every 8 hours, being able to double the dose depending on pressure levels, up to 15 days postpartum
62176935|NCT04835233|ACTIVE_COMPARATOR|captopril|postpartum exchange methyldopa for captopril 25 mg 01 tablet every 8 hours, doubling the dose depending on pressure levels, up to 15 days postpartum
62176936|NCT04083937|ACTIVE_COMPARATOR|70.0/ 2.0 Gray (RBE)|Normofractionated radiotherapy with photons (70.0/ 2.0 Gray)
62176937|NCT04083937|EXPERIMENTAL|57.0/ 3.0 Gray (RBE)|Hypofractionated radiotherapy with photons (57.0/ 3.0 Gray)
62176938|NCT04083937|EXPERIMENTAL|57.0/ 3.0 (RBE)|Hypofractionated radiotherapy with protons (57.0/ 3.0 Gray relative biological effectiveness \[RBE\]).
62552758|NCT02308124|EXPERIMENTAL|Pyridostigmine|Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.
62552759|NCT02308124|EXPERIMENTAL|Midodrine + Pyridostigmine|Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.
62552760|NCT01284452|PLACEBO_COMPARATOR|Placebo|Normal saline 50 ml intravenous every 6 hours for 7 days
62552761|NCT01284452|ACTIVE_COMPARATOR|Hydrocortisone|Hydrocortisone 50 mg intravenous every 6 hours for 7 days
62552762|NCT01005147|EXPERIMENTAL|Tranexamic acid arm|
62742201|NCT04573153|PLACEBO_COMPARATOR|Placebo Arm|Subjects will take hydroxychloroquine (standard therapy) + dietary supplement placebo.
62742202|NCT02497365|EXPERIMENTAL|Group A: Besifloxacin|Patients presenting with bacterial keratitis. These patients will be treated with besifloxacin ophthalmic suspesnion 0.6%, initially 6x a day and tapered down as the patient's condition improves based on the clinical judgement of the treating physician.
62552763|NCT01005147|PLACEBO_COMPARATOR|Control arm|Will receive a placebo in place of tranexamic acid treatment
62742203|NCT02497365|ACTIVE_COMPARATOR|Group B: Fortified Antibiotics|Patients presenting with bacterial keratitis. These patients will be treated initially with fortified cefazolin and vancomycin drops every 1 hour around the clock (24hours) for a minimum of 48 hours, and will subsequently have their dosages tapered gradually by the treating physician as is the standard of care for bacterial keratitis.
62742204|NCT01390974||Patients treated for ACS|ACS patients who recently underwent stent PCI, who are stable and eligible for prasugrel or clopidogrel therapy.
62742205|NCT04115878|ACTIVE_COMPARATOR|High dose ato-oxy|
62742206|NCT04115878|ACTIVE_COMPARATOR|Low dose ato-oxy|
62742207|NCT04771520|EXPERIMENTAL|Treatment (avapritinib)|Patients receive avapritinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62742208|NCT02619591|ACTIVE_COMPARATOR|Ultrasound Imaging - Single View|Ultrasound performed on patient. A single view of each hemithorax with ultrasound was performed on patient
62742209|NCT02619591|EXPERIMENTAL|Ultrasound Imaging - Multiple Views|Ultrasound performed on patient. Multiple view of each hemithorax with ultrasound was performed on patient
62742210|NCT06355414|EXPERIMENTAL|Psilocybin|This arm will receive a single, absolute dose (25 mg) of psilocybin.
62742211|NCT06355414|ACTIVE_COMPARATOR|Methylphenidate|This arm will receive a single, absolute dose (40 mg) of methylphenidate.
62742212|NCT05042323|EXPERIMENTAL|TF-CBT-Skills|Step 1: 4-5 sessions with stabilization/skill building Step 2: 4-5 sessions with narrative and cognitive processing
62742213|NCT05042323|ACTIVE_COMPARATOR|TF-CBT-Narr|Step 1: 4-5 sessions with narrative and cognitive processing Step 2: 4-5 sessions with stabilization/skill building
62176939|NCT03313583||Blood product recipients|All patients who received at least one blood product on the day of the study
62176940|NCT06153498|EXPERIMENTAL|Normal renal function group|
62176941|NCT06153498|EXPERIMENTAL|Renal injury group|
62552764|NCT06115525||Survivors|Patients admitted to the intensive care unit due to respiratory failure with no mortality in the 3-month follow-up period
62552765|NCT06115525||Nonsurvivors|Patients who were admitted to the intensive care unit due to respiratory failure and mortality was observed in the 3-month follow-up period
62552766|NCT05411341||Study Group|100 patients with diagnosed cataract or presbyopia who will undergo implantation of intraocular lenses surgery
62552767|NCT05083065||Women who underwent Covid-19 vaccination|This group includes women who underwent both the first or complete cycle of Covid-19 vaccination, regardless of the vaccine used.
62552768|NCT01659957|EXPERIMENTAL|Group Couples Couseling|Patients randomized to this arm will receive group couples counseling plus 12-step oriented alcoholism counseling.
62552769|NCT01659957|EXPERIMENTAL|One-on-One Couples Couseling|Patients randomized to this arm will receive one-on-one couples counseling plus 12-step oriented alcoholism counseling.
62176942|NCT01280383|EXPERIMENTAL|non-invasive NAVA|application of non-invasive NAVA in critically ill patients
62176943|NCT04767802|EXPERIMENTAL|PTG-300|Evaluate PTG-300's efficacy and safety in subjects with PV and baseline elevated hematocrit.
62176944|NCT00332488|EXPERIMENTAL|1|Technosphere Insulin
62176945|NCT00332488|ACTIVE_COMPARATOR|2|Metformin \& Secretagogues
62176946|NCT00332488|EXPERIMENTAL|3|Technosphere \& Metformin
62176947|NCT03284489||ICU patients|Patients with pancreatitis
62176948|NCT05784649|OTHER|control group|The interventions of the control group will receive the routine health education proposed by relevant experts in China which are chosen by the Chinese Medical Association.
62742214|NCT03871010||Neutropenia patients, Dept. of Haematooncology|Patients with neutropenia from the Department of Haematooncology were included in this group.
62742215|NCT03871010||No neutropenia patients, Dept. of Haematooncology|Patients without neutropenia from the Department of Haematooncology were included in this group.
62742216|NCT03871010||No neutropenia patients, other clinical depts.|Patients with neutropenia from the other clinical departments of the University Hospital Ostrava were included in this group.
62742217|NCT04044053|EXPERIMENTAL|Relative Bioavailability|Each participant will receive 400 mg IR, 400 mg MR, and 50 mg MR in the fed state, and 400 mg MR in the fasted state
62742218|NCT04044053|EXPERIMENTAL|Fasted State|Comparison of 400 mg MR in fed and fasted states
62742219|NCT03420508|EXPERIMENTAL|ensartinib|The screening portion of the trial will test archival tumor material for the presence of ALKATI using a Nanostring-based RNA assay for any patients deemed to be current or future candidates for this trial. This will require approximately 5 formalin-fixed paraffin- embedded (FFPE) slides of 5-8 micron thickness. For the treatment portion of the study, all patients will receive ensartinib orally at a dose of 225mg daily.
62742220|NCT06227676|PLACEBO_COMPARATOR|Granola Bites|This snack contains no known spices or nutrients that have been shown to help with spasmodic or congestive dysmenorrhea. It is the same shape and size as the active comparator.
62742221|NCT06227676|ACTIVE_COMPARATOR|Cramp Bites|This snack contains spices and ingredients that have been shown to help with both spasmodic and congestive dysmenorrhea. It is the same shape and size as the placebo comparator.
62742222|NCT04588220||preterm premature rupture of membranes|Preterm premature rupture of membranes is the rupture of membranes during pregnancy before 37 weeks' gestation.
62176949|NCT05784649|EXPERIMENTAL|intervention group|The interventions of the intervention group will include routine health education. And then the participants will have individual counsel about health-promoting behaviors with a midwife and a doctor. The counseling will be based on the procedure of the health promotion model.
62176950|NCT01750086|ACTIVE_COMPARATOR|Denosumab 60mg subcutaneous injection|Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
62176951|NCT01750086|ACTIVE_COMPARATOR|Alendronate 70mg weekly x 8 weeks|Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
62176952|NCT00977795|EXPERIMENTAL|Tumor fluorescence|A single arm in this open-label study where all patients are treated with the study drug. Areas of the brain that are fluorescent and areas that are not fluorescent are evaluated for presence of tumor cells
62176953|NCT02917798||Genetic Testing in Ovarian ,Prostate or Pancreas Cancer|This study is a prospective single-arm study to examine how an alternative clinical genetics cancer care delivery model affects ovarian, prostate or pancreas cancer patients' cognitions, emotions, and behaviors. Participants will be contacted 1 week (+/- 1 week) (Assessment #2; and 3 months (+/- 2 weeks) (Assessment #3;) following the telephone post-test counseling session to complete the follow-up assessments. These assessments will measure psychological and behavioral study constructs.
62742223|NCT04588220||Control group|Healthy subjects who had a normal pregnancy and outcomes without any fetal-neonatal complications will be accepted into the control group. Forty-four gestational age-matched healthy pregnant women who will be delivered at term will be included in the study as the control group.
62742224|NCT03946774|ACTIVE_COMPARATOR|High protein|Subjects getting high protein shake
62742225|NCT03946774|ACTIVE_COMPARATOR|Low protein|Subjects getting low protein shake
62742226|NCT04877288|EXPERIMENTAL|Arm 1: Conversion from a CNI- to belatacept-based regimen after a period of overlap|Conversion followed by tapering and discontinuation of the calcineurin inhibitor (CNI)
62742227|NCT04877288|ACTIVE_COMPARATOR|Arm 2: Continue calcineurin inhibitor-based regimen|
62742228|NCT04629391|ACTIVE_COMPARATOR|Anatomic TSA|The control group will receive through a deltopectoral approach an anatomic total shoulder arthroplasty (TSA) for a primary glenohumeral arthritis
62742229|NCT04629391|EXPERIMENTAL|RTSA|The experimental group will receive through a deltopectoral approach a reverse total shoulder arthroplasty RTSA for a primary glenohumeral arthritis
62742230|NCT05563805|EXPERIMENTAL|Intervention|intervention participants will engage in a 30-minutes VR adventure games on a non-mobilized treadmill (5-min warm-up, 20-minutes treadmill, and 5-min cool-down) for a total of 6 sessions over 6-8 weeks. Participants in the V-RATE group will be instructed to self-pace walking/running on the treadmill while they are fully immersed in the VR games for two 10-minute bouts with a complete rest interval (heart rate reduces to normal range). Participants will complete measures at baseline, post-training, and one-month follow-up.
62742231|NCT05563805|NO_INTERVENTION|Control|Control participants will not receive the intervention. Participants will complete measures at baseline, post-training, and one-month follow-up.
62742232|NCT06661018|EXPERIMENTAL|Group A (Oral Coenzyme Q10)|"Experimental: Group A (Oral Coenzyme Q10) Participants who received standard treatment plus Coenzyme Q10 100 mg / 12 hours orally for up to 8 weeks.~Intervention/Treatment Drug: Oral Coenzyme Q10~\* Participants will be randomized into group receiving either oral Coenzyme Q10 or placebo for up to 8 weeks"
62742233|NCT06661018|PLACEBO_COMPARATOR|Group B (Placebo)|"Placebo Comparator: Group B (Placebo) Participants who received standard treatment plus Placebo / 12 hours orally for up to 8 weeks.~Intervention/Treatment Drug: Placebo~\* Participants will be randomized into group receiving either oral Coenzyme Q10 or placebo for up to 8 weeks."
62176954|NCT04782700|NO_INTERVENTION|Watchful Waiting|The patients randomized to the watchful waiting group will not be prescribed any steroids at the time of randomization.
62176955|NCT04782700|EXPERIMENTAL|Prednisone (Steroid) Taper|The patients randomized to the steroid group will be prescribed prednisone PO or an equivalent corticosteroid at a dose of 0.5 mg/kg/day for 4 weeks ((plus BACTRIM-DS (1PO qd. 160/800mg) as prophylaxis against infection - If patient have a sulfa allergy, their physician will prescribe atovaquone 1500mg qd instead of Bactrim) and followed by a gradual taper of 0.25 mg/kg/day for 4 weeks, followed by 0.125 mg/kg qd for 4 weeks.
62742234|NCT06568731|EXPERIMENTAL|Single Arm|Participants will receive multiple doses of danuglipron
62182447|NCT02319863|ACTIVE_COMPARATOR|conventional resection|Perform hepatectomy with conventional method for HCC patients.
62742235|NCT04435600|EXPERIMENTAL|Part 1: Risankizumab Dose A|Participants age 12 to less than 18 receive fixed dose of risankizumab Dose A for 40 weeks.
62742236|NCT04435600|EXPERIMENTAL|Part 2: Ustekinumab Dose A/B/C then Risankizumab Dose A/B|"Participants age 12 to less than 18 will receive:~Period A: Ustekinumab Dose A, Dose B, or Dose C based on body weight for 16 weeks (at Week 0 and Week 4).~Period B: Risankizumab Dose A or B based on body weight for 24 weeks."
61997481|NCT04217486|EXPERIMENTAL|A - will be shown their photograph at 2 weeks post-operative.|40-50 arms: patients undergoing a unilateral, cementless primary TKA, secondary to osteoarthritis will be shown a photograph of their knee, photographed in maximum flexion and extension, at 2 weeks postoperatively.
62176956|NCT05363605|EXPERIMENTAL|Phase 1|Depending on assigned cohort, \[In111\]-FPI-1967/\[225Ac\]-FPI-1966 will be administered with or without pre-dosing with vofatamab.
62176957|NCT05363605|EXPERIMENTAL|Phase 2|Depending on assigned cohort, \[In111\]-FPI-1967/\[225Ac\]-FPI-1966 will be administered either with or without pre-administration of vofatamab, depending on the RP2D/regimen as determined in the phase 1 portion of the study.
62176958|NCT00672672|EXPERIMENTAL|Platelet Gel|Participants receive platlet gel.
62176959|NCT00672672|PLACEBO_COMPARATOR|Control (No platelet gel)|Participants do not receive platlet gel.
62176960|NCT04933838|PLACEBO_COMPARATOR|Control Group|1% licocaine 3 mL + Normal saline 3 mL mixture
62176961|NCT04933838|EXPERIMENTAL|Atelocollagen group|1% lidocaine 3 mL + atelocollagen 3 mL mixture
62176962|NCT01319864|EXPERIMENTAL|Plerixafor, Dose Escalation|Dose escalation of plerixafor administered intravenously in combination with IV cytarabine and IV etoposide in pediatric patients wtih relapsed/refractory AML/ALL.
62176963|NCT01885936|EXPERIMENTAL|Albuterol|Initially 4 mg daily for one week, then 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
62176964|NCT01885936|PLACEBO_COMPARATOR|Placebo Comparator|Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
62742237|NCT04435600|EXPERIMENTAL|Part 2: Risankizumab Dose A/B|"Participants age 12 to less than 18 will receive:~Period A: Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4).~Period B: Participants who respond to Risankizumab in Period A are re-randomized to continue Risankizumab Dose A or B based on body weight for up to 24 weeks or withdraw from treatment until flare.~Period C: Participants withdrawn from treatment in Period B and experience a flare in symptoms at Week 28 or beyond are eligible for re-treatment with Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4)."
62742238|NCT04435600|EXPERIMENTAL|Part 3: Risankizumab Dose A/B|Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks.
62742239|NCT04435600|EXPERIMENTAL|Part 4: Risankizumab Dose A/B|Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks (Japan only: participants age 12 to less than 18 years will be included).
62176965|NCT00039117|EXPERIMENTAL|Arm I|"INDUCTION THERAPY: Patients receive oblimersen (G3139) IV continuously on days 1-10 and cytarabine IV continuously on days 4-10. Patients also receive daunorubicin IV daily on days 4-6.~Patients with bone marrow cellularity of at least 20% and at least 5% leukemic blasts at day 17 or evidence of refractory disease receive a second induction comprising G3139 IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.~CONSOLIDATION THERAPY: Beginning no sooner than 14 days after hematologic recovery from induction therapy, patients receive G3139 IV continuously on days 1-8 and cytarabine IV over 4 hours on days 4-8. Patients receive a second course of consolidation therapy no sooner than 14 days after hematologic recovery from the first course."
62176966|NCT02654899|EXPERIMENTAL|Part 1_Cohort 1_Active;|Single ascending dose of PF-06815345
62176967|NCT02654899|PLACEBO_COMPARATOR|Part 1_Cohort 1_Placebo;|Single dose of placebo
62176968|NCT02654899|EXPERIMENTAL|Part 1_Cohort 2_Active|Single ascending dose of PF-06815345
62742240|NCT06659588||Humoral primary immunodeficiencies (PIDs)|Patients with no age limit followed in one of the skills centers of the Reference Center for Hereditary Immune Deficits (CEREDIH) within the APHP (Necker-Enfants Malades Hospital, Saint-Louis Hospital and Cochin Hospital) for humoral primary immunodeficiencies.
62742241|NCT06659588||Secondary form of humoral immunodeficiencies|Patients with no age limit, followed in one of the skills centers of the Reference Center for Hereditary Immune Deficits (CEREDIH) within the APHP (Necker-Enfants Malades Hospital, Saint-Louis Hospital and Cochin Hospital) for a secondary form of humoral immunodeficiencies post anti-CD20 monoclonal antibody or post CAR-T cells therapy with alymphocytosis B and/or hypo IgA or IgM or IgG).
62742242|NCT06659588||Combined immunodeficiency (CID)|Patients with no age limit followed in one of the skills centers of the Reference Center for Hereditary Immune Deficits (CEREDIH) within the APHP (Necker-Enfants Malades Hospital, Saint-Louis Hospital and Cochin Hospital) for a combined immunodeficiency.
61986262|NCT02736045|EXPERIMENTAL|emWave|Our approach will be to test the impact of a behavioral intervention through a smartphone application, emWave software, which will be provided to all our subjects. The intervention (emWave) is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention.
62176969|NCT02654899|PLACEBO_COMPARATOR|Part 1_Cohort 2_Placebo|Single dose of placebo
62176970|NCT02654899|EXPERIMENTAL|Part 2|Single dose of solid dosage formulation (test) versus liquid dosage formulation (reference) of PF-06815345
62176971|NCT02450097|OTHER|Lifestyle counseling|"Intermittent Caloric restriction in 3 Groups:~I- 40 patients with diabetes type 2 BMI 25.1-37 II- 40 non diabetic over weight subjects with BMI 25.1-37 III- 20 non diabetic subject with BMI 23.1 - 25 and visceral fat"
62176972|NCT02845713|ACTIVE_COMPARATOR|Single IDA dose W. bancrofti positive|Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) W. bancrofti infections positive
62176973|NCT02845713|ACTIVE_COMPARATOR|Single IDA dose W. bancrofti negative|Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) in 40 individuals who are free of W. bancrofti infection.
62176974|NCT06347770|NO_INTERVENTION|control group|pregnancies in control group need no intervention
62176975|NCT06347770|EXPERIMENTAL|probiotics group|pregnancies in probiotics group need probiotics management
62176976|NCT05537519|EXPERIMENTAL|Open Label Arm|
62176977|NCT01219777|EXPERIMENTAL|Carboplatin|AUC 5.0 or 6.0
62176978|NCT01219777|EXPERIMENTAL|Bevacizumab|15 mg/kg
62176979|NCT01219777|EXPERIMENTAL|Paclitaxel|60-80 mg/m2
62182448|NCT02319863|EXPERIMENTAL|new method|The new technique of rapid ligating the corresponding inflow and outflow vessels without hills dissection before parenchyma transection during hepatectomy.
62176980|NCT05279534|EXPERIMENTAL|Probiotic|Active test product contains four lactic acid bacteria strains with Qualified Presumption of Safety (QPS) status by European Food Safety Authority (EFSA): Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483, with maltodextrin (E1400, qs) as excipient, formulated in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0. Active test product is a food supplement and not an investigational medicinal product
62176981|NCT05279534|PLACEBO_COMPARATOR|Control|The control study product is identical in packaging and formulation except that none of strains Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485 and Pediococcus acidilactici CECT7483 (probiotic bacteria) are present. The Control product contains maltodextrin (E1400, qs) only, in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0.
62742243|NCT06659588||Severe combined immunodeficiency (SCID)|Patients with no age limit followed in one of the skills centers of the Reference Center for Hereditary Immune Deficits (CEREDIH) within the APHP (Necker-Enfants Malades Hospital, Saint-Louis Hospital and Cochin Hospital) for a severe combined immunodeficiency beyond 2 years post cell therapy (allogeneic haematopoietic stem cell transplantation (aHSCT) or gene therapy).
62176982|NCT02673554|EXPERIMENTAL|Oral glucose tolerance test|An oral glucose challenge (75 g)
62176983|NCT02673554|ACTIVE_COMPARATOR|GIP Bolus|Hyperglycemic clamp (capillary venous glucose concentration \~ 8.5 mmol/l) with two repeated intravenous bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
62176984|NCT02673554|ACTIVE_COMPARATOR|GIP Infusion|Hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
62176985|NCT03447977|EXPERIMENTAL|cervical group|cervical spinal mobilizations, exercises, 2 session for 6 weeks
62176986|NCT03447977|EXPERIMENTAL|thoracic group|cervical and thoracic spinal mobilizations, exercises, 2 session for 6 weeks
62176987|NCT03447977|EXPERIMENTAL|exercise group|exercises, 2 session for 6 weeks
62176988|NCT05550714|EXPERIMENTAL|General anesthesia|
62176989|NCT05550714|ACTIVE_COMPARATOR|Conscious sedation|
62176990|NCT04523298|EXPERIMENTAL|Laser|
62176991|NCT04523298|ACTIVE_COMPARATOR|PFE|
62176992|NCT01180790|EXPERIMENTAL|Segment 1: 200 milligrams (mg) ACH-0141625|200 mg ACH-0141625 for 28 days plus pegylated interferon (Peg-IFN) alpha-2a and ribavirin (RBV) for 48 weeks
62742244|NCT03300141|ACTIVE_COMPARATOR|Healthy|Healthy participants will participate in reaching activity using the Looking Glass and Leap motion tracking system
62742245|NCT03300141|EXPERIMENTAL|Chronic Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
62176993|NCT01180790|EXPERIMENTAL|Segment 1: 400 mg ACH-0141625|400 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a plus RBV for 48 weeks
62176994|NCT01180790|EXPERIMENTAL|Segment 1: 800 mg ACH-0141625|800 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a plus RBV for 48 weeks
62176995|NCT01180790|PLACEBO_COMPARATOR|Segment 1: Placebo|Placebo for 28 days plus Peg-IFN alpha-2a plus RBV for 48 weeks
62176996|NCT01180790|EXPERIMENTAL|Segment 2: 200 mg ACH-0141625|200 mg ACH-0141625 for 12 weeks plus Peg-IFN and RBV for up to a total of 24 or 48 weeks
62176997|NCT01180790|EXPERIMENTAL|Segment 2 : 400 mg ACH-0141625|400 mg ACH-0141625 for 12 weeks plus Peg-IFN and RBV for up to a total of 24 or 48 weeks
62176998|NCT01180790|EXPERIMENTAL|Segment 2 : 800 mg ACH-0141625|800 mg ACH-0141625 for 12 weeks plus Peg-IFN and RBV for up to a total of 24 or 48 weeks
62176999|NCT02509988|EXPERIMENTAL|Intervention (study nutritional drink)|"Study nutritional drink comes in the form of a sachet to mix with water \& take twice a day (once in the morning and once in the evening).~The drink will be taken before the participant becomes pregnant (for up to 1 year) and throughout pregnancy."
62742246|NCT03300141|EXPERIMENTAL|Chronic Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
62177000|NCT02509988|ACTIVE_COMPARATOR|Control (standard nutritional drink)|"Standard nutritional drink comes in the form of a sachet to mix with water \& take twice a day (once in the morning and once in the evening).~The drink will be taken before the participant becomes pregnant (for up to 1 year) and throughout pregnancy."
62742247|NCT03300141|EXPERIMENTAL|Acute Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
62742248|NCT03300141|EXPERIMENTAL|Acute Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
62742249|NCT03714217|EXPERIMENTAL|Intervention|Telenutrition counseling
62742250|NCT04637724|EXPERIMENTAL|active tDCS|active prefrotal tDCS: 20 mins pes tDCS session, twice a day for 5 days. Total of 10 ative tDCS sessions.
62742251|NCT04637724|SHAM_COMPARATOR|Sham tDCS|Sham prefrontal tDCS: sham stimulation 20 mins per session, twice a day for 5 days. Total of 10 sham stimulation sessions
62742252|NCT03102827|ACTIVE_COMPARATOR|Oxygen - ambient air|high-flow oxygen therapy administered during first night, ambient air without high-flow therapy (placebo) administered during second night
62177001|NCT06144788|EXPERIMENTAL|JP-2266 Low-dose|Subjects take the investigational products once a day for 12 weeks.
62177002|NCT06144788|EXPERIMENTAL|JP-2266 High-dose|Subjects take the investigational products once a day for 12 weeks.
62177003|NCT06144788|EXPERIMENTAL|placebo|Subjects take the investigational products once a day for 12 weeks.
62177004|NCT04993807|EXPERIMENTAL|Shared decision-making tool|Participants in this arm will view a shared decision-making tool while they are undergoing consultation to have an atrial fibrillation ablation.
62177005|NCT01193023|ACTIVE_COMPARATOR|Pressure support|"in this arm, pressure support will be recorded under 3 conditions:~* with the initial Expiratory Trigger Setting (ETS)~* with ETS +10%~* with ETS -10%"
62182449|NCT02509312|EXPERIMENTAL|Experimental|Patients in this arm will be given ketorolac at cord clamp with standard dose of 30 mg, then 3 additional 30 mg doses every 6 hours
62742253|NCT03102827|PLACEBO_COMPARATOR|Ambient air - oxygen|Ambient air without high-flow therapy (placebo) administered during first night , high-flow oxygen therapy administered during second night
62177006|NCT01193023|EXPERIMENTAL|NAVA|Neurally Adjusted ventilatory Assist is a ventilation mode where the ventilator is piloted by the electrical activity of the diaphragm Ventilation is triggered and cycled off by the electrical activity of the diaphragm, the pressure delivered being proportional to this activity.
62177007|NCT00096109|EXPERIMENTAL|Treatment (tanespimycin)|Patients receive tanespimycin IV over 1-6 hours on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62177008|NCT06175221|EXPERIMENTAL|Treatment - Investigational Product|"Product Name: Tumor lysate, particle only (TLPO) vaccine~Dosage Form: Intradermal Injection~Unit Dose: 1x10\^8 autologous tumor lysate-loaded, yeast cell wall particles~Route of Administration: Intradermal; primary vaccine series at 0, 1, 2 months followed by boosters at 6, 9, and 12 months~Physical Description: 250 uL clear liquid vials~Manufacturer: Elios Therapeutics, LLC"
62177009|NCT04848103|EXPERIMENTAL|Radial extracorporeal shockwave therapy|
62177010|NCT01729923|EXPERIMENTAL|Treatment (capecitabine, celecoxib, radiation therapy)|"Patients proceed to surgery, radiation therapy with ADAPT therapy followed by maintenance ADAPT therapy, or ADAPT therapy. Eligible patients undergo surgical resection at baseline or upon achievement of resectable disease after radiation therapy.~RADIATION + ADAPT: Patients undergo radiation therapy 5 days per week and receive capecitabine PO BID and celecoxib PO BID 5 days per week during radiation.~ADAPT: Patients receive capecitabine PO BID on days 1-14 and celecoxib PO BID on days 1-21. Courses repeat every 21 days for up to 3 years in the absence of disease progression or unacceptable toxicity."
62177011|NCT01580111|EXPERIMENTAL|Short storage|Short storage arm: Will receive blood (Packed red blood cells) of 1 (one) to 10 (ten) days in storage.
62177012|NCT01580111|ACTIVE_COMPARATOR|Long storage arm|Will be transfused with blood ( packed red cells) of storage age 21- 35 days.
62177013|NCT03377725|EXPERIMENTAL|Experimental group|MDS patients of the experimental group will be treated with decitabine and arsenic trioxide.
62177014|NCT03377725|ACTIVE_COMPARATOR|Controlled group|MDS patients of the controlled group will be treated with decitabine alone.
62177015|NCT06162065|ACTIVE_COMPARATOR|Group 1|women with overactive bladder will be treated using oral antimuscarinics for 4 weeks under strict medical indication, with a treatment scheme consisting of 10 mg tablet of oxybutynin once a day.
62177016|NCT06162065|EXPERIMENTAL|Group 2|5 women will receive combined oral treatment. 1 tablet of 10 mg once a day of oral of oxybutynin and they will also be supplemented with powder boldo capsules for 4 weeks under strict medical indication. This group will be supplemented with 1 capsules of 340 mg every 8 hours of boldo (take suggested by the manufacturer), for 5 days in a row and 5 days off.
62177017|NCT04655183|EXPERIMENTAL|Part 1A (Dose escalation): Niraparib plus M4344 once daily|Participants with baseline body weight \< 77 kilograms (kg) or baseline platelet count \< 150, 000 per cubic millimeter will be included in this Part. Dose escalation of M4344 administered along with niraparib.
62177018|NCT04655183|EXPERIMENTAL|Part 1B (Dose escalation): Niraparib plus M4344 once daily|Participants with baseline body weight \> =77 kilograms (kg) and baseline platelet count \>=150, 000 per cubic millimeter will be included in this Part. M4344 will be administered at a dose and schedule that was determined as the recommended dose for expansion (RDE) in Part 1A. Dose of niraparib will be escalated to the next higher dose level.
62177019|NCT04655183|EXPERIMENTAL|Part 2 (Dose expansion): PARPi resistant, Niraparib plus M4344|Participants with Poly(ADP-ribose) polymerase inhibitor (PARPi) resistant, germline breast cancer 1/2 mutated (gBRCA1/2m) human epidermal growth factor receptor 2 (HER2) negative advanced Breast Cancer (aBC) will receive the combination of niraparib and M4344 at the RDE which was determined in Part 1.
62177020|NCT04655183|EXPERIMENTAL|Part 3 (Dose expansion): PARPi-naive, Niraparib|Participants with PARPi-naive germline BRCA1/2 wild type (gBRCAwt) homologous recombination repair gene mutated (HRRm) advanced breast cancer (aBC) will be randomized to receive niraparib as a single agent.
62177021|NCT04655183|EXPERIMENTAL|Part 3 (Dose expansion): PARPi-naive, Niraparib plus M4344|Participants with PARPi-naive germline BRCA1/2 wild type (gBRCAwt) homologous recombination repair gene mutated (HRRm) advanced breast cancer (aBC) will be randomized to receive the combination of niraparib and M4344 at the RDE as determined in Part 1 of this study.
62177022|NCT06399341||Adult women with ASCUS or LSIL result in routine Pap-test.|Adult HPV-positive women with Atypical Squamous Cells of Undetermined Significance (ASCUS) or Low-grade Squamous Intraepithelial Lesions (LSIL) cervical cytology with concordant colposcopy were treated with Papilocare for 6 months (1 cannula/day for 21 days during first month + 1 cannula/alternate days for subsequent 5 months), extending to a total of 12 months if needed.
62742254|NCT01905046|EXPERIMENTAL|Arm I: metformin hydrochloride|Patients receive metformin hydrochloride PO QD or BID for 24 months. Patients will continue metformin 850 mg PO BID for months 13-24. Patients will undergo RPFNA at 24 months. Follow up visits will be performed at 36 and 48 months after the start of treatment.
62177023|NCT05908305|ACTIVE_COMPARATOR|Tramadol Addicted Patients|It represents the group of tramadol addicted patients seeking dental care that require dental anesthesia.
62177024|NCT05908305|ACTIVE_COMPARATOR|Non addicted patients|The group of patients requiring dental care with local anesthesia and who are not addicted to tramadol.
62177025|NCT01939405|NO_INTERVENTION|standard physical activity counseling|
62177026|NCT01939405|EXPERIMENTAL|built environment use counseling|personalized counseling on active use of the built environment
62177027|NCT02482935|EXPERIMENTAL|Abemaciclib High Fat Meal|Abemaciclib capsules administered once orally in the fed state.
62177028|NCT02482935|EXPERIMENTAL|Abemaciclib Fasted|Abemaciclib capsules administered once orally in the fasted state.
62177029|NCT06400797||ECMO patients|Patients recieving Venoarterial or Venovenous extracorporeal membrane oxygenation (VA-ECMO, VV-ECMO)
62182450|NCT02509312|PLACEBO_COMPARATOR|Control|Patients in this arm will be given a placebo medication at cord clamp, and then 3 additional doses of placebo every 6 hours.
62182451|NCT00505414|PLACEBO_COMPARATOR|Matching Placebo|Oral Tapentadol 100 mg to 250 mg twice daily. Followed by matching placebo in the maintenance (i.e. randomized withdrawal phase).
62182452|NCT00505414|ACTIVE_COMPARATOR|Morphine Controlled Release|Oral Morphine 45 mg to 90 mg twice daily.
62182453|NCT00505414|EXPERIMENTAL|Tapentadol Extended Release|Oral Tapentadol 100 mg to 250 mg twice daily.
62742255|NCT01905046|PLACEBO_COMPARATOR|Arm II: placebo|Patients receive placebo PO QD or BID for 12 months. Patients may crossover to Arm I for months 13-24.
62742256|NCT03702959||Betamethasone group 1|Betamethasone Group 1 (5am-11am)
62177030|NCT02604706|EXPERIMENTAL|NADA Acupuncture|NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
62177031|NCT02604706|EXPERIMENTAL|LP Acupuncture|The LP-acupuncture was delivered in two phases: (1) three treatments each week during the two first weeks; (2) two treatments each week for two weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. BC-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
62177032|NCT02604706|ACTIVE_COMPARATOR|Relaxation|Relaxation consisted of listening to soft music in a quiet room with dampened light and was delivered to match the amount and phases of the LP-acupuncture. Relaxation were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
62177033|NCT01194271|EXPERIMENTAL|Neoadjuvant Ipilimumab|Leuprolide Acetate 22.5 mg administered as a single intramuscular 3 month depot + Ipilimumab 10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy + Radical Prostatectomy Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
62177034|NCT01182181|EXPERIMENTAL|Investigational Test Product|Anastrozole Tablets, 1 mg
62177035|NCT01182181|ACTIVE_COMPARATOR|Reference Listed Drug|Arimidex® Tablets, 1 mg
62177036|NCT04563247||Asymptomatic frontline HCWs for COVID 19|All healthcare workers who worked in high exposure areas of hospital dealing with COVID 19.
62177037|NCT00097669|ACTIVE_COMPARATOR|Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug)|Active Treatment Arm: VITATOPS study tablet (folate 2 mg, B6 25 mg, B12 500 ug). Taken daily for the duration of the study.
62177038|NCT00097669|PLACEBO_COMPARATOR|Placebo Tablet|Placebo Treatment Arm: The placebo tablet will have the same appearance, taste and texture as the vitamin preparation and contains excipients, coating and coating aids.
62177039|NCT04410315||Tumorcraniotomy patients|
62177040|NCT03065205|EXPERIMENTAL|Single Arm|Patients will have adherence monitoring devices placed on their asthma inhalers (both daily and rescue medication). Adherence information will be sent to their PCP, specialist and school nurse monthly. Additionally, the navigator will speak with families every 2 months to discuss adherence data and address barriers.
62177041|NCT05600036|EXPERIMENTAL|ESK-001 Dose Level 1|ESK-001 administered as an oral tablet
62177042|NCT05600036|EXPERIMENTAL|ESK-001 Dose Level 2|ESK-001 administered as an oral tablet
62177043|NCT05600036|EXPERIMENTAL|ESK-001 Dose Level 3|ESK-001 administered as an oral tablet
62177044|NCT05600036|EXPERIMENTAL|ESK-001 Dose Level 4|ESK-001 administered as an oral tablet
62177045|NCT05600036|EXPERIMENTAL|ESK-001 Dose Level 5|ESK-001 administered as an oral tablet
62177046|NCT05600036|PLACEBO_COMPARATOR|Placebo|Placebo administered as an oral tablet
62177047|NCT06355128||the pandemic period (Phase A)|the pandemic period (Phase A)
62177048|NCT06355128||the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 ).|the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 and Phase C: December 7, 2021 to January 6, 2022).
62177049|NCT06355128||the prevention and control periods (Phase C: December 7, 2021 to January 6, 2022).|the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 and Phase C: December 7, 2021 to January 6, 2022).
62177050|NCT03226353|EXPERIMENTAL|somofilcon A 1-day soft contact lenses|Habitual and refitted wearers of omafilcon A were refit into somofilcon A for a week
62177051|NCT05950776|EXPERIMENTAL|1x10E7 IU (low dose)|1x10E7 IU MVA-SARS-2-S Intervention: Biological: MVA-SARS-2-S vaccinations (days 0 \& 28)
62177052|NCT05950776|EXPERIMENTAL|1x10E8 IU (high dose)|1x10E8 MVA-SARS-2-S Intervention: Biological: MVA-SARS-2-S vaccinations (days 0 \& 28)
62177053|NCT05950776|PLACEBO_COMPARATOR|Placebo|Days 0 \& 28
62177054|NCT04609410|EXPERIMENTAL|Deep neuromuscular blockade|"During surgery, deep neuromuscular blockade will be achieved with the use of train of four (TOF) monitoring, aiming for a Post-Tetanic Count (PTC) = 0 or PTC = 1 and Train of Four Count (TOFC) = 0. TOF and PTC measurements will be performed every 15 minutes. Boluses of 0,1 mg/kg Rocuronium will be administered if monitored PTC is \> 1.~Complete neuromuscular blockade reversal at the end of surgery will be achieved with an i.v. bolus of Sugammadex (variable dose according to depth of residual blockade) if TOF ratio is ≤ 0.9. If TOF ratio is \> 0.9, pharmacological neuromuscular blockade reversal can be avoided."
62742257|NCT03702959||Betamethasone Group 2|Betamethasone Group 2 (11am-5pm)
62742258|NCT03702959||Betamethasone Group 3|Betamethasone Group 3 (5pm-11pm)
62177055|NCT04609410|ACTIVE_COMPARATOR|Moderate neuromuscular blockade|"During surgery, a moderate neuromuscular blockade will be achieved with the use of train of four (TOF) monitoring. TOF and Post-Tetanic Count (PTC) measurements will be performed every 15 minutes. Boluses of 0,1 mg/kg Rocuronium will be administered if monitored TOF count is ≥ 1 and/or PTC \> 5.~Complete neuromuscular blockade reversal at the end of surgery will be achieved with an i.v. bolus of Sugammadex (variable dose according to depth of residual blockade) if TOF ratio is ≤ 0.9. If TOF ratio is \> 0.9, pharmacological neuromuscular blockade reversal can be avoided."
62177056|NCT03364478|EXPERIMENTAL|DML group|The group underwent laparoscopic right hemicolectomy with dorsal and medial hybrid approach. In DML group, the dissecting based on CME is performed with dorsal approach and medial approach hybridized.
62177057|NCT03364478|ACTIVE_COMPARATOR|MLA group|The group underwent laparoscopic right hemicolectomy with traditional medial-to-lateral approach. In MLA group,the dissecting based on CME is performed with meidial-to-lateral approach.
62742259|NCT03702959||Betamethasone Group 4|Betamethasone Group 4 (11pm-5am).
62742260|NCT03916536|ACTIVE_COMPARATOR|Holmium Laser|holmium laser enucleation of the prosteate
62742261|NCT03916536|ACTIVE_COMPARATOR|Thulium Laser|Thulium laser enucleation of the prosteate
62177058|NCT04704388||patients hospitalized in intensive care units for SARS-CoV-2|patients hospitalized in intensive care units for SARS-CoV-2
62177059|NCT04704388||patients hospitalized outside intensive care units|patients hospitalized outside intensive care units
62177060|NCT00246610|EXPERIMENTAL|Open-label|Non-randomized, open-label, single-arm
62177061|NCT03635840|NO_INTERVENTION|Control|Group of patients not receiving IABP
62177062|NCT03635840|EXPERIMENTAL|Intra Aortic Balloon Pump|Group of patients receiving Intra Aortic Balloon Pump prior to revascularization
62177063|NCT02936492|EXPERIMENTAL|BAY1003803|Topical treatment: dose escalating in 9 steps from 0.13 mg to 61.7 mg per subject
62177064|NCT02936492|PLACEBO_COMPARATOR|Placebo|Topical treatment using matching amount of placebo
62364942|NCT00611767|PLACEBO_COMPARATOR|Family History Positive for Alcoholism|Family History Positive for Alcoholism subjects will receive 2 interventions
62364943|NCT06436820||Suspected IIH patient group|Patients with suspected Idiopathic intracranial hypertension, who require a lumbar puncture as part of their standard care.
62177065|NCT02936492|ACTIVE_COMPARATOR|Clobetasol propionate|Topical treatment using 16.5 mg of clobetasol propionate per subject
62177066|NCT04912700||Unvaccinated|Unvaccinated individuals are defined as having positive laboratory COVID-19 testing with no record of immunization against COVID-19 or first-dose vaccination after symptom onset.
62177067|NCT04912700||Partially vaccinated|Partially vaccinated individuals are defined as having positive laboratory COVID-19 testing and symptom onset after a single dose of either mRNA (Pfizer, Moderna) vaccine, or \< 14 days after the second dose of either mRNA vaccine (Pfizer, Moderna) or \< 14 days after the administration of the single dose of viral vector vaccine (Johnson \& Johnson).
62177068|NCT04912700||Fully vaccinated|Fully vaccinated individuals are defined as having positive laboratory testing for COVID-19 and symptom onset \>14 days since administration of second dose of either mRNA vaccine, or \>14 days since administration of viral vector vaccine (Johnson \& Johnson).
62177069|NCT01233414|EXPERIMENTAL|Parent Training|
62177070|NCT01233414|ACTIVE_COMPARATOR|Psychoeducation|
62177071|NCT01859221|EXPERIMENTAL|Castration Resistant|There are two different prognostic categories, hormones receptive and castration resistant, that have differing historical disease progression rates. We have therefore stratified the trial so that we can independently monitor the hypothesized improvement provided by radiation therapy in these two groups. Both groups will receive the same radiation modality which is interventional stereotactic radiation with two possible schedules of SBRT and SHRT.
62177072|NCT01859221|EXPERIMENTAL|Hormone Receptive|There are two different prognostic categories, hormones receptive and castration resistant, that have differing historical disease progression rates. We have therefore stratified the trial so that we can independently monitor the hypothesized improvement provided by radiation therapy in these two groups. Both groups will receive the same radiation modality which is interventional stereotactic radiation with two possible schedules of SBRT and SHRT.
62177073|NCT02906696|EXPERIMENTAL|Treatment (bosutinib)|Patients receive bosutinib PO daily on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62177074|NCT06136507|EXPERIMENTAL|The main test period and the extension period|Group 1:≥6 years old and \<12 years old; Group 2: \<6 years old pediatric patients Preventive treatment: 25\~50 is recommendedlU/kg, Q3D, can adjust the dose to 65 IU/kg based on the patient's response, and if necessary, the investigator can adjust the frequency of administration based on the clinical outcome of the subject (the occurrence of bleeding and its clinical manifestations) and the FVIII valley concentration.PK intensive blood collection will be performed for the PK subgroup at V1 (DO) and appropriate PK blood collection will be performed at other specified visit time points. After completion of ∠50EDs and 26 months of treatment, the original prophylactic regimen can be continued until 100EDs
62742262|NCT03916536|ACTIVE_COMPARATOR|Bipolar Enucleation|Bipolar enucleation of the prosteate
62742263|NCT05265234|EXPERIMENTAL|Dupixent|"Patients will receive initial dose of 600 mg (two 300 mg injections in different injection sites), followed by 300 mg given every other week for 16 weeks.~Patients will self-administer by subcutaneous injection at home, instructions will be provided at first visit."
62742264|NCT03008668|EXPERIMENTAL|experimental group: Acupuncture|acupuncture on 5 most sensitized points/ acupoints
61986263|NCT06496776|EXPERIMENTAL|Choukroun's method|Patients in this group will have a specific suturing technique (called Choukroun's method) after dental implant insertion.
62177075|NCT05375617||Acute lymphoblastic leukemia cohort|
62177076|NCT05375617||Brain tumor cohort|
62177077|NCT04440930|EXPERIMENTAL|White tea|
62177078|NCT04440930|ACTIVE_COMPARATOR|Salt water with soda|
62177079|NCT03722797||Unilateral Transtibial Amputation|Individuals with a unilateral, transtibial amputation.
62177080|NCT03722797||Controls|Healthy adults without a lower-limb amputation who have been matched to participants in the Unilateral Transtibial Amputation group based on age, sex, and body mass index.
62177081|NCT04615910|EXPERIMENTAL|Verapamil|Patients treated with Verapamil within the Ver-A-T1D trial
62177082|NCT04615910|PLACEBO_COMPARATOR|Placebo|Patients treated with placebo within the Ver-A-T1D trial
62364944|NCT06436820||Control group|Patients who require lumbar puncture for reasons not pertaining to raised intracranial pressure as part of their standard care.
62364945|NCT02032186|EXPERIMENTAL|Mg++|Magnesium Citrate oral supplementation from early pregnancy; 160 mg twice per day.
62364946|NCT02032186|PLACEBO_COMPARATOR|Placebo|Placebo pills twice per day.
62364947|NCT02321072|ACTIVE_COMPARATOR|High-normal PaO2|In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a PaO2 of 120 mmHg (16 kPa), range 105-135 mmHg (14-18 kPa).
62364948|NCT02321072|ACTIVE_COMPARATOR|Low-normal PaO2|In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a target PaO2 of 75 mmHg (10 kPa), range 60-90 mmHg (8-18 kPa).
62364949|NCT03385525|EXPERIMENTAL|BIIB074 150 mg and Valproic Acid 500 mg|Participants will receive BIIB074 in tablet form in 150 mg doses. BIIB074 will be taken once daily (QD) on Days 1-16 after an 8-hour fast. Valproic Acid will be given in capsule form in 500 mg doses on prescription (TID) every 8 hours on Days 8-22. The morning dose on Day 16 will be coadministered with BIIB074 following an 8-hour fast.
62742265|NCT03008668|ACTIVE_COMPARATOR|Control group: Acupuncture|acupuncture on 5 least low/non-sensitized points
62177083|NCT03858647||Sensorineural hearing loss patients post cochlear implant|Patients who have documented sensorineural hearing loss and have received cochlear implantation (per standard of care).
62177084|NCT02730000|ACTIVE_COMPARATOR|ART with Equia|Occlusal-proximal restoration in primary molars using Equia (Easy/Quick/Unique/Intelligent/Aesthetic) from GC Corp, encapsulated, pre-dosed and mechanized handling.
62177085|NCT02730000|EXPERIMENTAL|ART with Riva Self Cure|Occlusal-proximal restoration in primary molars using Riva Self Cure from SDI, encapsulated, pre-dosed and mechanized handling.
62364950|NCT00788918|EXPERIMENTAL|Chronic hepatitis C treatment|30 Chronic HCV patients with pending antiviral treatment. A majority will have pending treatment with interferon and ribavirin, and the treated patients will be assessed 8-12 weeks after starting treatment for interferon-induced depression.
62364951|NCT00788918|NO_INTERVENTION|Healthy Controls|50 age, sex and education matched controls (matched 1:1 to participants in the HCV patient groups (+/- treatment)
62364952|NCT00788918|NO_INTERVENTION|Former HCV infected|20 Subjects with prior HCV infection identified through positive HCV antibodies, but negative HCV RNA.
62177086|NCT03675412|ACTIVE_COMPARATOR|Glaucoma Patients|Eligible participants include patients with mild, moderate or advanced primary open angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.
62177087|NCT03675412|ACTIVE_COMPARATOR|Healthy controls|Eligible participants include healthy subjects with no eye diseases. Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.
62177088|NCT05955755|EXPERIMENTAL|experimental group|A butterfly vacuum blood collection set will be used in the blood collection process from the children in the experimental group.
62177089|NCT05955755|NO_INTERVENTION|control group|A standard vacutanier needle will be used for blood collection from the children in the control group. Vacutanier needle is used routinely in the blood collection unit where the study will be performed.
62177090|NCT00706914|EXPERIMENTAL|Once-daily aclidinium/formoterol|Aclidinium bromide 200 µg/ formoterol fumarate 12 µg fixed-dose combination (FDC) once-daily in the morning, plus placebo once-daily in the evening
62364953|NCT00788918|NO_INTERVENTION|Chronic HCV patient - no treatment|20 chronic HCV patients without pending antiviral treatment.
62177091|NCT00706914|EXPERIMENTAL|Morning aclidinium/formoterol plus evening formoterol|Aclidinium bromide 200 µg/formoterol fumarate 12 µg FDC once-daily in the morning, plus formoterol fumarate 12µg once-daily in the evening
62177092|NCT00706914|ACTIVE_COMPARATOR|Formoterol BID|Formoterol fumarate 12 µg twice-daily (BID)
62177093|NCT04052932|PLACEBO_COMPARATOR|Placebo|Placebo once a day, orally, for 12 weeks, followed by SHR4640 treatment to 36 weeks
62364954|NCT03838380|NO_INTERVENTION|conventional management group|The conventional management group received standard GDM management and could freely use the smartphone healthcare application.
62742266|NCT00668382|EXPERIMENTAL|Alpha-Gal Glycosphingolipid injection|Intervention: Intratumoral injection of a single dose of Alpha-Gal Glycosphingolipid (0.1 mg,1mg, 10mg)
62742267|NCT00542373|EXPERIMENTAL|Diagnostic (fluorescent/reflectance imaging, spectroscopy)|Participants' oral cavities are inspected by a clinician using a standard white light headlamp. Participants then undergo oral mucosa examination using wide-field reflectance and fluorescence imaging, and/or fluorescence spectroscopy imaging. Standard oral brush biopsies are also performed and examined microscopically. Participants may undergo repeated imaging procedures and biopsy during subsequent follow up visits.
62742268|NCT00722722|ACTIVE_COMPARATOR|4 dose group|4 doses of bortezomib (1.3mg/m\^2 of body surface area)
62742269|NCT00722722|ACTIVE_COMPARATOR|16 dose group|16 doses of bortezomib (1.3mg/m\^2 of body surface area)
62742270|NCT00722722|ACTIVE_COMPARATOR|32 dose group|32 doses of bortezomib (1.3mg/m\^2 of body surface area)
62742271|NCT01664611|EXPERIMENTAL|Treatment arm|Participants in this arm will receive remote ischaemic conditioning on a daily basis for 4 weeks post MI
62177094|NCT04052932|EXPERIMENTAL|SHR4640 dose1|SHR4640 dose1 once a day, orally, for 36 weeks
62177095|NCT04052932|EXPERIMENTAL|SHR4640 dose2|SHR4640 dose2 once a day, orally, for 36 weeks
62177096|NCT04052932|ACTIVE_COMPARATOR|Allopurinol|Allopurinol 300mg (milligram) once a day, Orally, for 36 week
62177097|NCT04509414|EXPERIMENTAL|dexmedetomidine|2ug/kg intranasal atomized dexmedetomidine
62177098|NCT04509414|ACTIVE_COMPARATOR|midazolam|0.2mg/kg intranasal atomized midazolam
62177099|NCT01967719|ACTIVE_COMPARATOR|mTHS 2.2 then mCC|"Each subject will follow the below study design:~* Day 0 = Wash-out (1 day)~* Day 1 = 1st intervention (single product use of mTHS 2.2)~* Day 2 = wash-out~* Day 3 = 2nd intervention (single product use of mCC)."
62177100|NCT01967719|ACTIVE_COMPARATOR|mCC then mTHS 2.2|"Each subject will follow the below study design:~* Day 0 = Wash-out (1 day)~* Day 1 = 1st intervention (single product use of mCC)~* Day 2 = wash-out~* Day 3 = 2nd intervention (single product use of mTHS 2.2)."
62177101|NCT01967719|ACTIVE_COMPARATOR|mTHS 2.2 then NNS|"Each subject will follow the below study design:~* Day 0 = Wash-out (1 day)~* Day 1 = 1st intervention (single product use of mTHS 2.2)~* Day 2 = wash-out~* Day 3 = 2nd intervention (single administration of NNS)"
62177102|NCT01967719|ACTIVE_COMPARATOR|NNS then mTHS 2.2|"Each subject will follow the below study design:~* Day 0 = Wash-out (1 day)~* Day 1 = 1st intervention (single administration of NNS)~* Day 2 = wash-out~* Day 3 = 2nd intervention (single product use of mTHS 2.2)."
62742272|NCT01664611|SHAM_COMPARATOR|Sham arm|Participants in this arm will receive sham ischaemic conditioning on a daily basis for 4 weeks post MI
62742273|NCT01117298|EXPERIMENTAL|Tadalafil|
62742274|NCT01117298|PLACEBO_COMPARATOR|Placebo|
61986264|NCT06333769|EXPERIMENTAL|Short-course Radiotherapy Combined with CAPOX and Tislelizumab|
62177103|NCT00917423||Inpatients with anorexia nervosa|Hospital inpatients with anorexia nervosa
62177104|NCT00917423||Normal weight controls|Healthy, normal-weight volunteers
62177105|NCT01533558||caspofungin|caspofungin dosing
62182454|NCT06372106||Neonates|Even distribution of sex per skin pigmentation category (Light, Medium, Dark)
62182455|NCT06372106||Infants|Even distribution of sex per skin pigmentation category (Light, Medium, Dark)
62177106|NCT06478810|EXPERIMENTAL|Ambulatory follow-up (Domomedicine and dedicated nursing care) after a minor Hepatectomy|"Actions added by the research :~* Ambulatory minor Hepatectomy :~* Return home on the day of the operation (no overnight stay in hospital instead of 4-5 nights in standard hospitalization including hospitalization the day before surgery)~* Recording and transmission to the paramedical and medical team of clinical-biological data by connected tools (domomedecine)~* Early care at home via the PRADO health insurance program by a nurse chosen by the patient or one designated by the program.~* Satisfaction Questionnaires and MDASI~* Pain, transit and diet questionnaire~* Paramedical and technological visit on Day -3 Telephone call from the dedicated nurse on Day -1 Telephone interview of the nurse dedicated to Day 1"
62177107|NCT01520077|OTHER|Vytorin|"Subjects will receive Vytorin for 24 weeks. At 24 weeks if regrowth greater or equal than 20%, subjects will be randomized 1/1 to either stop or continue vytorin. Subjects will be follow for additional 24 weeks.~Subjects that at 24 weeks don't meet the 20% regrowth will be dropped out of the study."
62177108|NCT01457833|ACTIVE_COMPARATOR|Endobronchial valves (EBV)|Complete occlusion of one emphysematous destroyed lobe by implantation of endobronchial valves
62177109|NCT01457833|ACTIVE_COMPARATOR|Intrabronchial valves (IBV)|Complete occlusion of one emphysematous destroyed lobe by implantation of intrabronchial valves
62177110|NCT01039259||subjects with lip piercing|
62177111|NCT01039259||subjects with tongue piercing|
62364955|NCT03838380|EXPERIMENTAL|mobile management group|The mobile management group received mobile healthcare services through smartphone application specifically developed for this trial including tailored mobile coaching.
62364956|NCT05376956|EXPERIMENTAL|Muscle Energy Technique|Using Muscle Energy Technique in Individuals With Hamstring Shortness
62177112|NCT04384718||Medea Group|Group of children with Developmental Dyslexia treated with Tachidino protocol at IRCCS Medea
62177113|NCT04384718||Asur Group|Group of children with Developmental Dyslexia treated with Tachidino protocol at Asur Marche
62177114|NCT04384718||Waiting list Group|Group of children with Developmental Dyslexia on a waiting list for treatment with Tachidino protocol at IRCCS Medea or Asur Marche
62177115|NCT02347969|EXPERIMENTAL|X34|Arm supplemented with X34
62364957|NCT05376956|EXPERIMENTAL|Proprioception neuromuscular facilitation (PNF)|Using proprioception neuromuscular facilitation (PNF) in Individuals With Hamstring Shortness
62177116|NCT00688077|EXPERIMENTAL|1|
62177117|NCT00688077|PLACEBO_COMPARATOR|2|NaCl 0,9% 2 ml, single subcutaneous injection
62177118|NCT01701271|EXPERIMENTAL|Volunteers|20 volunteers both men and women with an age between 18 and 70 years suffering from Androgenetic Allopecia in several types apply on the scalp drops of the hair loss prevention lotion
62177119|NCT04826926|EXPERIMENTAL|Non-surgical periodontal treatment NSPT|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
62177120|NCT05033899|EXPERIMENTAL|group E: ERAS group|36 non-insulin dependent diabetic patients will undergo lumbar decompression surgery following ERAS protocol.
62742275|NCT00711230|EXPERIMENTAL|1: Low dose DermaVir|"* Dosage: 0.2 mg DNA~* Dosage form: 1.6 mL DNA/PEIm nanomedicine~* Administration with 2 DermaPrep patches~* Frequency: every six weeks~* Duration: 18 weeks (4 DermaVir treatments)"
62177121|NCT05033899|NO_INTERVENTION|group C: conventional group|conventional perioperative care.
62177122|NCT03688997|EXPERIMENTAL|Experts|"For the novice group, the investigators recruited 30 residents within their first year of surgical residency (Post-Graduate Year \[PGY\]-1) in general surgery, vascular surgery, plastic surgery, orthopedic surgery, cardio-thoracic surgery, gynecology and urology.~The intervention administered was the use of a simulator by the participants."
62177123|NCT03688997|EXPERIMENTAL|Novice|"The expert's group included 15 attending surgical faculty members in the general surgery, vascular surgery, cardio-thoracic surgery and gynecology services.~The intervention administered was the use of a simulator by the participants."
61986265|NCT02133950|EXPERIMENTAL|freeze all embryos following PGD|no fresh embryo transfer; elective cryopreservation of all embryos after PGD
62177124|NCT01999543|OTHER|Reference food format|reference food format with and without plant-based ingredient added
62177125|NCT01999543|EXPERIMENTAL|Food format one|Food format one with and without plant-based ingredient added
62177126|NCT01999543|EXPERIMENTAL|Food format two|Food format two with and without plant-based ingredient added
62177127|NCT01999543|EXPERIMENTAL|Food format three|Food format three with and without plant-based ingredient added
62177128|NCT05286008|PLACEBO_COMPARATOR|Normal Saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side.
62177129|NCT05286008|EXPERIMENTAL|Ropivacaine at high concentration|Before the induction of anesthesia, 0.375% Ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
62177130|NCT05286008|EXPERIMENTAL|Ropivacaine and dexamethasone|Before the induction of anesthesia, 0.375% Ropivacaine and 5.0mg dexamethasone are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
62364958|NCT05240612|EXPERIMENTAL|MT-3921|Intravenous (IV)
62364959|NCT05240612|PLACEBO_COMPARATOR|Placebo|Intravenous (IV)
62364960|NCT04488757|OTHER|Study Arm|All participants enrolled in the study will undergo baseline fMRI and baseline and follow-up (4-month post-baseline) assessment of stress physiology (i.e., allostatic load). Treatment as usual information will be gathered for all participants to assess observational intervention response.
62177131|NCT02181998|ACTIVE_COMPARATOR|tenecteplase + unfractioned heparin|
62177132|NCT02181998|EXPERIMENTAL|tenecteplase + enoxaparin|
62177133|NCT01547247|EXPERIMENTAL|cap-assisted water immersion colonoscopy|Cap-fitted colonoscopy using purely water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
62177134|NCT01547247|ACTIVE_COMPARATOR|water immersion colonoscopy|Standard colonoscopy without attached cap using purely water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
62364961|NCT02929368|ACTIVE_COMPARATOR|Fluoroscopy|PICC Implantation under x-ray
62364962|NCT02929368|ACTIVE_COMPARATOR|Sherlock System (BARD)|PICC Implantation with Integrated Magnetic Tracking and ECG-guided Tip Location System
62742276|NCT00711230|EXPERIMENTAL|2: Low dose Placebo|"* Dosage form: 1.6 mL Placebo~* Administration with 2 DermaPrep patches~* Frequency: every six weeks~* Duration: 18 weeks (4 Placebo treatments)"
62177135|NCT01717547|EXPERIMENTAL|Yoga|Yoga-based treatment - manualized group treatment - classes will be held twice per week for approximately 85 minutes for a period of eight weeks.
62177136|NCT03905421||usual care|The patient will be seen in the PH clinic and will be approached to consent and participate in the SYMPACT trial. They will not be randomized to palliative care.
62177137|NCT03905421||palliative care|The patient will be seen in the PH clinic and will be approached to consent and participate in the SYMPACT trial. Based on the patients in Group 1 and 3 PH and a high SYMPACT score\> 1.0 in any domain they will be randomized to receive standard care or a palliative care initial consult.
62177138|NCT01935596|ACTIVE_COMPARATOR|ropivacaïne 0,5%,|intrathecal administration of 15mg of ropivacaine 0.5%.
62177139|NCT01935596|ACTIVE_COMPARATOR|lévobupivacaïne 0,5%|intrathecal administration of 15mg of levobupivacaine 0.5%
62177140|NCT06302413|EXPERIMENTAL|Virtual Reality|"Participants in this arm will receive the following interventions:~Virtual Reality Park Virtual Reality Avatar"
62177141|NCT06302413|PLACEBO_COMPARATOR|Treatment As Usual|"Participants in this arm will receive the following interventions:~Virtual Reality Park"
62177142|NCT02459808||GBS Patients|Patients with Guillain-Barré syndrome
62177143|NCT01376050|ACTIVE_COMPARATOR|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 milliWatts (mW) 635 nanometer (nm) light emitting diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center, and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
62177144|NCT01376050|PLACEBO_COMPARATOR|Placebo Laser|Placebo Laser has the same appearance and application as the Erchonia MLS but does not emit an therapeutic output.
62177145|NCT02205723|EXPERIMENTAL|Smartphone Asthma Control|Smartphone Asthma Control
62177146|NCT02205723|ACTIVE_COMPARATOR|Control|Control group
62177147|NCT00361842|EXPERIMENTAL|Irinotecan|
62177148|NCT02251340|EXPERIMENTAL|Intervention|Families in the intervention group will receive an Eczema Care Plan
62177149|NCT02251340|NO_INTERVENTION|Control|Families in the control group will not receive an Eczema Care Plan
62177150|NCT03220165|EXPERIMENTAL|Treatment|MGL-3196
62177151|NCT02867111|OTHER|ICSI Control|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with no intervention of the Sperm Selection Assay
62177152|NCT02867111|PLACEBO_COMPARATOR|ICSI + SSA placebo|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with intervention of the Sperm Selection Assay with control solution (culture medium)
62177153|NCT02867111|EXPERIMENTAL|ICSI + SSA Attractant substance|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with intervention of the Sperm Selection Assay with attractant solution (attractant diluted in culture medium at 10 pM)
62177154|NCT06104579||Patients operated on rectal cancer, included in the Catalan Cancer Registry|Patients operated on rectal cancer, included in two compulsory audits of the Catalan Cancer registry, and who suffered an organ-space surgical infection.
62177155|NCT06104579||Patients operated on rectal surgery, included in the Catalan Infection Surveillance Program|Patients included in the voluntary Catalan Infection Surveillance Program, and followed for 30 days postoperatively, and who suffered an organ-space surgical infection.
62177156|NCT02234635|OTHER|monofocal IOLs group|monofocal IOLs group were implantation with Tecnis® ZCB00
62177157|NCT02234635|ACTIVE_COMPARATOR|Diffractive multifocal IOLs group|Diffractive multifocal IOLs group were implantation with Tecnis® ZMB00
62177158|NCT03557450|EXPERIMENTAL|PET/CT scanning with sodium fluoride|Subjects will received PET/CT scanning with sodium fluoride
62177159|NCT02987322|EXPERIMENTAL|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months for the patients in the honey group.
62177160|NCT00275145|EXPERIMENTAL|Resistance Training|8 months of Resistance Exercise Training
62177161|NCT00275145|EXPERIMENTAL|Aerobic Exercise|8 months of Aerobic Exercise Training
61986266|NCT02133950|ACTIVE_COMPARATOR|elective fresh embryo transfer|
62177162|NCT00275145|EXPERIMENTAL|Combination RT & AT|8 months of Combined Aerobic and Resistance Exercise Training
62177163|NCT00275145|EXPERIMENTAL|Control|Control/sedentary intervention
62177164|NCT04854278||Pilot study|Pilot study with 22 cases, no intervention
62177165|NCT04854278||Baseline measurement|Baseline measurement of +/- 100 cases, no intervention
62177166|NCT04854278||Post measurement|Post measurement of +/- 100 cases after implementation of a Massive Open Online Course
62177167|NCT04435405||Video microanalisys|Video footage analysis of group and individual behavioral processes.
62177168|NCT00053352|EXPERIMENTAL|Arm I|"Patients enrolled with gonadal tumors of stage II or greater or extragonadal tumors of any stage receive cisplatin IV over 90 minutes \& etoposide IV over 90 minutes days 1-3 and bleomycin sulfate IV over ≥ 10 minutes day 1. Treatment repeats every 3 weeks, 3 courses (weeks 0,3 \& 6).~After completion of compressed induction chemotherapy, patients with no change in disease status or disease progression are removed from study. Patients with no evidence of disease receive no further therapy. Patients with a partial response or abnormal tumor markers proceed to conventional surgery (second-look) and/or 3 more courses of compressed consolidation chemotherapy.~After surgery, patients with pathologic complete response and have normal tumor markers receive no further therapy. Patients who remain with a partial response after surgery receive compressed consolidation chemotherapy.~Patients receive cisplatin, etoposide, and bleomycin as induction chemotherapy in weeks 10,13, \& 16."
62177169|NCT00053352|NO_INTERVENTION|Arm 2|"Patients who are enrolled with stage I gonadal tumors receive no further anticancer therapy until evidence of tumor recurrence or the diagnosis of a second malignant neoplasm.~Observation only for recurrence or development of an SMN"
62177170|NCT01182207|EXPERIMENTAL|Investigational Test Product|Drospirenone/Ethinyl Estradiol Tablets, 3 mg/0.02 mg
62177171|NCT01182207|ACTIVE_COMPARATOR|Reference Listed Drug|YAZ® Tablets, 3 mg/0.02 mg
62177172|NCT02276209|EXPERIMENTAL|Dasotraline 4 mg|Dasotraline 4 mg once daily
62177173|NCT02276209|EXPERIMENTAL|Dasotraline 6 mg|Dasotraline 6 mg once daily
62177174|NCT02276209|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62177175|NCT03439098|EXPERIMENTAL|Fermented Codonopsis lanceolata 525mg|Fermented Codonopsis lanceolata 525mg/day
62177176|NCT03439098|EXPERIMENTAL|Fermented Codonopsis lanceolata 1050mg|Fermented Codonopsis lanceolata 1050mg/day
62177177|NCT03439098|PLACEBO_COMPARATOR|Placebo|Placebo
62177178|NCT01174485|EXPERIMENTAL|exercise|exercise plus liposuction
62177179|NCT01174485|NO_INTERVENTION|sedentary|physical inactivity plus liposuction
62177180|NCT03935932|EXPERIMENTAL|baseline followed by intervention|Subjects randomized to perform baseline measurement of clearance on study day 2 and measurement of clearance with nasal delivery of heated and humidified air on day 3
62177181|NCT03935932|EXPERIMENTAL|intervention followed by baseline|Subjects randomized to perform measurement of clearance with nasal delivery of heated and humidified air on day 2 and baseline measurement of clearance on study day 3
62177182|NCT06196073|EXPERIMENTAL|Visceral osteopathy and conservative treatment|Osteoaptic manual treatment techniques
62177183|NCT06196073|EXPERIMENTAL|conservative treatment|Nutritional supplements
62177184|NCT06480370|EXPERIMENTAL|Study Arm|Application of TES at different stimulation circuits, with different stimulation parameters and recording montages.
62177185|NCT01293799|EXPERIMENTAL|The follow-up group|The intervention in the follow-up group consists of regular tests of the patients´ theoretical and practical skills regarding peritoneal dialysis. The test goals should be passed. If not, retraining will be given if needed til the goals are reached. The peritonitis rate in this group will be compared with that of the control group.
62177186|NCT01293799|NO_INTERVENTION|Control group|Patients randomised to the control group will be treated according to the routines of the clinic.
62177187|NCT01831726|EXPERIMENTAL|TKI258|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
62177188|NCT03453424|ACTIVE_COMPARATOR|TEA+DEX group|"Intra operative thoracic epidural injection of (bupivacaine 0.125% +fentanyl 2 mic/ ml) , initial bolus dose of 8 ml before skin incision followed by fixed rate infusion of 6 ml/h till end of abdominal layer closure.~Postoperative, thoracic epidural injection of (bupivacaine 0.0625%+fentanyl 2 mic /ml + dexmedetomidine 0.5 mic/ ml) at infusion rate 6 ml /h and bolus dose of 3 ml with lockout time 10 min"
62177189|NCT03453424|ACTIVE_COMPARATOR|TEA group|"Intraoperative,thoracic epidural injection of bupivacaine (0.125%+fentanyl 5 mic/ml ) ,initial bolus dose of 8 ml before skin incision followed by fixed rate infusion of 6 ml/h till start of abdominal layer closure.~Postoperative, thoracic epidural injection of (bupivacaine 0.0625%+fentanyl 2 mic /ml) at infusion rate 6 ml /h and bolus dose of 3 ml with lockout time 10 min"
62177190|NCT05323188||Subjects|Control pediatric population: no excess of chronic inflammatory or allergic disease compared to the general French population.
62177191|NCT04054453|NO_INTERVENTION|Pre-intervention|Baseline data on neonatal encephalopathy and epilepsy before the introduction of the care bundle
62177192|NCT04054453|EXPERIMENTAL|Post-intervention|Baseline data on neonatal encephalopathy and epilepsy after the introduction of the care bundle
62177193|NCT02299856||Myocarditis|Patients with strong clinical evidence for acute myocarditis (recent infection, elevated troponin and white blood cell count).
62177194|NCT02299856||Healthy Controls|Healthy volunteers without any signs of cardiac disease.
62177195|NCT00002621|EXPERIMENTAL|Alpha interferon (aIFN) treatment|See detailed description.
62177196|NCT01053897|EXPERIMENTAL|GBT009|
62177197|NCT01053897|PLACEBO_COMPARATOR|Placebo|
62177198|NCT01960348|ACTIVE_COMPARATOR|patisiran (ALN-TTR02)|
62177199|NCT01960348|PLACEBO_COMPARATOR|Sterile Normal Saline (0.9% NaCl)|
62177200|NCT00349388|EXPERIMENTAL|Asacol once a day dosing|Asacol total dose in mg/kg given once a day
62177201|NCT00349388|ACTIVE_COMPARATOR|Asacol BID/TID dosing|Asacol total dose split BID or TID
62177202|NCT03672071|OTHER|Group E|If a 20% decrease in any parameter compared to their baseline levels is sustained, necessary interventions 5 mg Ephedrine i.v. will be administered to patient will be performed. In the case of hypotension,
62177203|NCT03672071|OTHER|Group NE|.If a 20% decrease in any parameter compared to their baseline levels is sustained, necessary interventions 5 mg Noradrenaline, i.v. will be administered to patient will be performed. In the case of hypotension,
62177204|NCT03672071|OTHER|Group N|. If a 20% decrease in parameter compared to their baseline levels is sustained, necessary interventions mg Ephedrine + 2.5 mg Noradrenaline i.v. will be administered to patient will be performed. In the case of hypotension,
62177205|NCT03126214|EXPERIMENTAL|Active Pharmacist Arm|OAC therapy will be initiated/adjusted by the community pharmacist in accordance to the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation.
62177206|NCT03126214|ACTIVE_COMPARATOR|Enhanced Usual Care Arm|Pharmacist will be refer participants to their physician in regards to OAC therapy for atrial fibrillation. The pharmacist will provide a current medication list to the physician as well as notification of a new diagnosis of atrial fibrillation
62177207|NCT03185585||Adults 60 yrs and older|Participants will be asked to take the full MNA and COAST tools, separately .They will take a hand grip strength test to evaluate their functional status and five times Sit to Stand test as part of the COAST screening tool. Moreover, their weight, height, mid-arm circumference and calf circumference, will be measured as part of the MNA screening tool.
62177208|NCT01009762|PLACEBO_COMPARATOR|Saline|Sterile saline for injection is used as placebo arm. It is administered i.m. in the same way as for the active vaccine, week 0, 2, 4, 8.
62177209|NCT01009762|ACTIVE_COMPARATOR|AFO-18 vaccine|the intervention is injection of the experimental therapeutic peptide vaccine (AFO-18) consisting of 18 peptides in CAF01 adjuvant intra muscularly (i.m.) week 0, 2, 4, 8
62177210|NCT04584216|EXPERIMENTAL|Steam Eye Mask With Acupoints Stimulation|"The Steam Eye Mask with acupoints stimulation (SEM with acupoints stimulation), is an eye mask which contains iron (Fe) and generates the heat with the steam (the moist heat) by the oxidative reaction of the iron with oxygen in air.~Also, on the eyebrow have the acupoints made by nonwoven fabric can use hands to massage.~The temperature of the moist heat is approximately 40 degree C and the moist heat lasts for around 20 minutes and use hands to massage the acupoints on the eyebrows for the first 3 minutes."
62182456|NCT06372106||Pediatrics|Even distribution of sex per skin pigmentation category (Light, Medium, Dark)
62177211|NCT04584216|ACTIVE_COMPARATOR|Steam Eye Mask|"The Steam Eye Mask (SEM), is an eye mask which contains iron (Fe) and generates the heat with the steam (the moist heat) by the oxidative reaction of the iron with oxygen in air.~The temperature of the moist heat is approximately 40 degree C and the moist heat lasts for around 20 minutes."
62177212|NCT03256370||Infants with allergic diseases|allergic disease : atopic dermatitis or food allergy
62177213|NCT03256370||Healthy infants with atopic mothers|atopic mothers : mothers with asthma or allergic rhinitis or allergic dermatitis (diagnosed by doctors)
62364963|NCT04938271|EXPERIMENTAL|Healables Wearable Microcurrent Electroceutical HEAL-122 with e-Textile Sports Sleeve|Subjects activate electroceutical at home for 60 minutes (+/- 20 minutes) daily, 5 times per week, for 4 weeks
62364964|NCT01392768|EXPERIMENTAL|Levetiracetam|
62364965|NCT01392768|PLACEBO_COMPARATOR|Placebo|
62177214|NCT03256370||Healthy infants with non-atopic mothers.|non-atopic mothers : mothers without history of asthma or allergic rhinitis or allergic dermatitis
62177215|NCT02618863|ACTIVE_COMPARATOR|1 , cricoid pressure|30 male
62177216|NCT02618863|ACTIVE_COMPARATOR|2,cricoid pressure|30 female
62364966|NCT04936204|EXPERIMENTAL|Group 1 ConnettivinaBio Plus cream|ConnettivinaBio Plus cream is a topical preparation constituted by Principal component: Hyaluronic acid sodium salt 0.2% Other components: Silver Sulfadiazine 1%, The medication should be applied once a day as a thin layer to cover the entire surface of the wound previously cleansed
62177217|NCT01086332|EXPERIMENTAL|phase 1/2|An escalating study of gemcitabine when combined with 1250 mg of nelfinavir twice daily. Dose of gemcitabine is increased for new subjects based on the experiences and tolerance of prior subjects. When the maximum tolerated dose is identified, a recommended phase 2 dose will be assigned and further subjects will receive that dose.
62177218|NCT01726517|EXPERIMENTAL|LDV/SOF 8 Weeks (TN)|Treatment-naive (TN) participants will be randomized to receive LDV/SOF for 8 weeks.
62177219|NCT01726517|EXPERIMENTAL|LDV/SOF+RBV 8 Weeks (TN)|Treatment-naive participants will be randomized to receive LDV/SOF plus RBV for 8 weeks.
62177220|NCT01726517|EXPERIMENTAL|LDV/SOF 12 Weeks (TN)|Treatment-naive participants will be randomized to receive LDV/SOF for 12 weeks.
62177221|NCT01726517|EXPERIMENTAL|LDV/SOF 12 Weeks (TE)|Treatment-experienced (TE) participants (had virologic failure following prior therapy with a protease-inhibitor \[PI\]+pegylated interferon \[PEG\]+RBV regimen) will be randomized to receive LDV/SOF for 12 weeks.
62177222|NCT01726517|EXPERIMENTAL|LDV/SOF+RBV 12 Weeks (TE)|Treatment-experienced participants (had virologic failure following prior therapy with a PI+PEG+RBV regimen) will be randomized to receive LDV/SOF plus RBV for 12 weeks.
62177223|NCT06074445||People with Cancer|No intervention
62177224|NCT06074445||Partners of People with Cancer|No intervention
62177225|NCT03047902|ACTIVE_COMPARATOR|Parent Present|"The adolescents in group 1 (Parent Present) will be aware that their parents will be able to share the information on the questionnaire, but they will be assured of the confidentiality of the CO test. This will also be explained to the parent.~Intervention: Parents will be present for the questionnaire but not for the CO test."
62177226|NCT03047902|ACTIVE_COMPARATOR|Parent Absent|"The adolescents in group 2 (parents not present) will be assured of the confidentiality of the questionnaire and CO test. The confidentiality of the test will also be explained to the parent.~Intervention: Parents will not be present for the questionnaire or the CO test"
62364967|NCT04936204|ACTIVE_COMPARATOR|Group 2 ConnettivinaBio cream|ConnettivinaBio Cream is a topical preparation constituted by Principal component: Hyaluronic acid sodium salt 0.2% The medication should be applied once a day as a thin layer to cover the entire surface of the wound previously cleansed
62364968|NCT01431469|PLACEBO_COMPARATOR|Cow's Milk|Powdered Whole Cow's Milk
62364969|NCT01431469|EXPERIMENTAL|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
62364970|NCT06089655|NO_INTERVENTION|Negative control|no continuous glucose monitoring system nor AI diet application
62177227|NCT02414555|ACTIVE_COMPARATOR|NaCl 0.9% BBraun (normale saline)|154mmol/l sodium, 154mmol/l chloride
62177228|NCT02414555|ACTIVE_COMPARATOR|Elo-Mel Isoton (balanced acetat-based infusate)|sodium 140mmol/l, potassium 5.0mmol/l, calcium 2.5mmol/l, magnesium 1.5mmol/l, chlorid 108mmol/l, acetate 45mmol/l
62177229|NCT06123364|ACTIVE_COMPARATOR|Active treatment arm|Patients in this study arm will receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB according to current treatment guidelines. Additionally they will twice a week receive an actual extracorporeal electromagnetic stimulation in the duration of 20 minutes, for 8 weeks.
62177230|NCT06123364|SHAM_COMPARATOR|Sham treatment arm|Patients in this study arm will receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB according to current treatment guidelines. Additionally they will twice a week receive a sham extracorporeal electromagnetic stimulation in the duration of 20 minutes, for 8 weeks.
62177231|NCT04322916||RM Pressfit vitamys|Participants treated with a RM Pressfit vitamys hip cup in combination with a Mathys hip stem
62364971|NCT06089655|ACTIVE_COMPARATOR|Positive control|Continuous glucose monitoring system only
62364972|NCT06089655|EXPERIMENTAL|Intervention|Continuous glucose monitoring system +AI diet application
62364973|NCT03820908|EXPERIMENTAL|Bisantrene|patients will receive bisantrene 250mg/m2/d for 7 days
62364974|NCT00656760|EXPERIMENTAL|A|All patients have PET/CT and biopsies with the surgeon blinded to the result of PET/CT. Additional biopsies are performed (or not) after the surgeon has the PET/CT results revealed.
62364975|NCT06330324||Keratinisation disorders|Keratinisation disorders comprise a heterogeneous group characterised by abnormal epidermal differentiation, such as variants of ichthyosis and palmoplantar keratoderma.
62364976|NCT06330324||Skin fragility disorders|Skin fragility disorders comprise a group of inherited blistering diseases, such as variants of epidermolysis bullosa.
62364977|NCT06330324||Ectodermal dysplasias|Ectodermal dysplasias consists of multiple inherited disorders that are characterised by abnormalities of the embryonic ectoderm, such as hair, nails, sweat glands or teeth.
62742277|NCT00711230|EXPERIMENTAL|3: Medium dose DermaVir|"* Dosage: 0.4 mg DNA~* Dosage form: 3.2 mL DNA/PEIm nanomedicine~* Administration with 4 DermaPrep patches~* Frequency: every six weeks~* Duration: 18 weeks (4 DermaVir treatments)"
62177232|NCT03618927|EXPERIMENTAL|Daily physical activity intervention|The intervention consisted of a DPA program designed by a national organization with expertise in school-based physical activity programming and delivered in school by teachers. The program was offered to students in grades 4 through 8 and consisted of 20 minutes of structured DPA in school for 20 consecutive weeks. The DPA activities included jumping jacks, squats, running and other body weight exercises.
62177233|NCT03618927|NO_INTERVENTION|Control - treatment as usual|Participants in control classes completed regular school activities as per the Ontario curriculum.
62177234|NCT03834207|EXPERIMENTAL|Intervention Group|Use of the C3-Cloud IT system
62177235|NCT03844178|ACTIVE_COMPARATOR|The right eyes with compensation for Pupil centroid shift|
62177236|NCT03844178|ACTIVE_COMPARATOR|The left eyes without compensation for Pupil centroid shift|
62177237|NCT03592823|NO_INTERVENTION|control|receiving radiofrequency ablation and anticoagulant therapy
62177238|NCT03592823|EXPERIMENTAL|hydrochloroquine|receiving radiofrequency ablation, anticoagulant therapy and hydrochloroquine treatment (200 mg,bidpo)
62177239|NCT06308549|EXPERIMENTAL|Intervention|2/3 of participants will be randomised into this arm. They will receive access to MyDiaMate in the language of their participation country for 6 months.
62177240|NCT06308549|NO_INTERVENTION|Care As Usual|1/3 of participants will be randomised into this arm. They will receive Care As Usual, so no intervention, for 3 months. After 3 months, they receive access to MyDiaMate, if so wished.
62177241|NCT06104384||Adult chronic pain patients|Adult chronic pain patients who received pain management
62177242|NCT02168478|EXPERIMENTAL|Patch Test Group|"All subjects are patched with the following: 1.Neo-Synalar Cream 2.Sodium Lauryl Sulfate and 3. Saline.~Test material is applied to the absorbent pad and allowed to remain in direct skin contact for a period of 48 hours."
62177243|NCT01738464||Pelvic Pain|Interstitial Cystitis or Chronic Prostatitis/Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, and Overactive Bladder patients will be compared to Healthy and Depressed patients.
62177244|NCT01738464||Controls|Healthy patients will be used as controls to compare to patients diagnosed with Interstitial Cystitis, Chronic Prostatitis, Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, Overactive Bladder, and Depressed patients.
62177245|NCT01738464||Major Depression|Major Depression patients will be compared to Controls and Pelvic Pain cohorts.
62177246|NCT01077622|EXPERIMENTAL|2000 mg dose|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
62177247|NCT02014415||Liver Biopsy|Participants will provide liver tissue specimens collected at the time of liver biopsy, to determine the rate of progression of liver injury in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
62177248|NCT02014415||Known Severe Liver Disease|Participants will provide samples of serum, plasma, and DNA at defined time points to determine what genetic and environmental modifiers and biomarkers are associated with severe clinical liver disease, such cirrhosis, portal hypertension and liver failure in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
62177249|NCT02014415||Post Liver Transplant|Participants will provide a DNA sample to determine what genetic and environmental modifiers are associated with the need for liver transplantation in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
62177250|NCT04143906|EXPERIMENTAL|Vinorelbine/Carboplatin|Vinorelbine 25 mg/m2 d1,8; Carboplatin AUC=6 d1; q 3 weeks
62177251|NCT04143906|EXPERIMENTAL|Gemcitabine/Carboplatin|Gemcitabine 1000 mg/m2 d1,8; Carboplatin AUC=6 d1; q 3 weeks
62177252|NCT02018471|EXPERIMENTAL|Pilot group|Forty-three patients who had to undergo one or more diagnostic tests (PET, TAC, fMRI, Mammography, Endoscopy, Colonoscopy) took part in the study. Most of the 43 patients had to undergo only one diagnostic test, and only 6 patients had more than one. They have attended a psychoeducative training.
62177253|NCT00528710|PLACEBO_COMPARATOR|P|Placebo Control Group
62177254|NCT02778906|ACTIVE_COMPARATOR|Abatacept|Abatacept 125 mg s.c. weekly
62177255|NCT02778906|PLACEBO_COMPARATOR|Placebo|Placebo (NaCl 0,9%) s.c. weekly
62177256|NCT01414556|EXPERIMENTAL|hyperglycemia|
62177257|NCT01414556|EXPERIMENTAL|fasting glycemia|
62177258|NCT01414556|EXPERIMENTAL|hypoglycemia|
62177259|NCT05934656||People with cystic fibrosis|People with confirmed diagnosis aged over six year old
62177260|NCT03336073|EXPERIMENTAL|carfilzomib, dexamethasone and cyclophosphamide|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose of 20 mg (10 mg for patients \>75 years) days 1, 2, 8, 9, 15 and 16 and cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15, in 28 days cycles
62177261|NCT03336073|ACTIVE_COMPARATOR|carfilzomib and dexamethasone|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose of 20 mg (10 mg for patients \>75 years) days 1, 2, 8, 9, 15 and 16 , in 28 days cycles
61997482|NCT04217486|ACTIVE_COMPARATOR|B - will not be shown their photograph|40-50 arms: patients undergoing a unilateral, cementless primary TKA, secondary to osteoarthritis will not be shown a photograph of their knee, photographed in maximum flexion and extension, at 2 weeks postoperatively.
62177262|NCT02212483|EXPERIMENTAL|Intervention group|"After randomisation and agreement of the patient and the family, the  intervention group  will benefit from a first home intervention of a MIEC during the 4 weeks following inclusion, then a final visit at the end of the study after 12 months."
62177263|NCT02212483|ACTIVE_COMPARATOR|Control group|"The  control group  is one of the two comparative groups who will benefit from a first home intervention of a MIEC but without advices (only audit + sampling), then a final and a complete visit at the end of the study.~This group has been suppressed with the last amendment. But data of the subjects included in this group will be analyzed."
62177264|NCT02212483|OTHER|Non intervention group|"The  non intervention  group is the second comparative group with no initial visit, but will benefit from a complete home intervention of a MIEC at the end of the study."
62177265|NCT00978783|ACTIVE_COMPARATOR|speaking valve|
62177266|NCT00978783|ACTIVE_COMPARATOR|Positive end expiratory pressure|
62177267|NCT01887990|ACTIVE_COMPARATOR|Suicidal, Depression with Ketamine|suicidal ideation and depression (no substance use disorder) 0.2 mg/kg IV ketamine administered as a one time dose
62177268|NCT01887990|PLACEBO_COMPARATOR|Suicidal, Depression with Saline|Suicidal ideation and depression (no substance use disorder) comparable amount of placebo (saline)
62177269|NCT01887990|ACTIVE_COMPARATOR|Suicidal, opioid use with ketamine|suicidal ideation,depression, opioid use disorder 0.2 mg/kg IV ketamine one time dose
62177270|NCT01887990|PLACEBO_COMPARATOR|Suicidal, opioid use with Saline|Patients with suicidal ideation and depression with opioid use disorder who are given comparable amount of placebo (saline) as would have been used with the Ketamine arm
62177271|NCT03936764|OTHER|Group 1|5 Preoperative Pulmonary Rehabilitation sessions / week during 3 weeks.
62177272|NCT03936764|OTHER|Group 2|3 Preoperative Pulmonary Rehabilitation sessions / week during 5 weeks.
62177273|NCT03166397|EXPERIMENTAL|ACT TIL|"1. Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..~2. Preparation and administration of TIL~3. Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
62177274|NCT03166397|EXPERIMENTAL|ACT TIL + Anti PD-1|"1. Single dose of Nivolumab 480 mg fixed dose~2. Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..~3. Preparation and administration of TIL~4. Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.~5. Second dose of Nivolumab 480 mg fixed dose (at least 4 weeks from the first dose)"
62177275|NCT03166397|EXPERIMENTAL|ACT TIL FMT + Anti CTLA4|"1. FMT loading dose given via colonoscopy~2. FMT 12 oral capsules as maintenance - given 2 times~3. Single dose of Ipilimumab 1mg/kg up to 100 mg~4. Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..~5. Preparation and administration of TIL~6. Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
62177276|NCT04739189|EXPERIMENTAL|Obese adolescent|
62177277|NCT05051124|EXPERIMENTAL|Patients Enrolled in the AMPATH CDM Program|
62177278|NCT04584333|EXPERIMENTAL|INTERVENTION|Group 1 (intervention group): depending on the willingness to change evaluated with the RCQ at each visit, the characteristics of the intervention to be performed will be established.
62177279|NCT04584333|NO_INTERVENTION|NO INTERVENTION|Group 2 (non-intervention group): you will receive the usual information regarding the characteristics of your injuries and the role of tobacco and alcohol in their evolution and the importance of abandoning these habits.
62177280|NCT04310176|ACTIVE_COMPARATOR|Standard|"Chemotherapy (mFOLFOX-6/mOXELL) + Bevacizumab for 12 cycles (24 weeks)~Maintenance treatment (Standard): Fluoropyrimidines (5-Fluorouracil/Capecitabine) + Bevacizumab until disease progression or unacceptable toxicity"
62177281|NCT04310176|EXPERIMENTAL|Experimental|"Chemotherapy (mFOLFOX-6/mOXELL) + Bevacizumab + Valproic Acid administered oral daily from day -14 increasing doses and an intra-patient titration for a target serum level of 50-100µg/ml for 12 cycles (24 weeks)~Maintenance treatment (Experimental): Fluoropyrimidines (5-Fluorouracil/Capecitabine) + Bevacizumab + Valproic Acid until disease progression or unacceptable toxicity"
62177282|NCT05510739|EXPERIMENTAL|Motor-cognitive exercise using eHealth|10-week eHealth based motor-cognitive home training using digital tablets. Cognitive behavioural strategies to promote increase in physical activity levels (walking). Participants will be encouraged to perform 150 minutes of home exercise per week, occurring on three non-consecutive days.
62177283|NCT05510739|ACTIVE_COMPARATOR|Individualised home training program|Participants will receive an individualized home exercise program on paper and one instructional session. They will receive written instructions on performing the program 2-3 times weekly and instructions on exercise progression. They will receive no support during the 10-week period.
62177284|NCT05861778|EXPERIMENTAL|89Zr-girentuximab|A single administration of 37 MBq (+/-10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab
62177285|NCT03128788|ACTIVE_COMPARATOR|Active Comparator: supine position|Active Comparator: supine position thoracic epidural catheterization with supine position
62177286|NCT03128788|ACTIVE_COMPARATOR|Active Comparator: flexed lateral position|Active Comparator: flexed lateral position thoracic epidural catheterization with flexed lateral position
62177287|NCT06345378||Elegible population|All adult patients presenting to the emergency department with non-specific cardiopulmonary or abdominal manifestations, represented by one or more of the following symptoms: chest pain, abdominal pain, dyspnoea, transient loss of consciousness.
62177288|NCT01029678|EXPERIMENTAL|experimental|
62177289|NCT02713607|EXPERIMENTAL|doxycycline|Given doxycycline and assessment of gut, blood and skin
62177290|NCT02713607|NO_INTERVENTION|Control|Control subjects to assess if there is baseline difference in these micro-evironments.
62177291|NCT05402618||minimally invasive surgery|
62177292|NCT05402618||open surgery|
62177293|NCT04760197||patient under cancer immunotherapy with inflammatory ophthalmological manifestations|patient(\>18 years old) under cancer immunotherapy with inflammatory ophthalmological manifestations
62177294|NCT02224352|EXPERIMENTAL|Single-Arm Study|Functional neuromuscular electrical stimulation of abdominal-wall muscles triggered by an airway pressure signal
62177295|NCT03206476|EXPERIMENTAL|Intervention group|Nutritional intervention based on the SCT and the TM
62177296|NCT03206476|ACTIVE_COMPARATOR|Control group|Nutritional information
62177297|NCT04684771|ACTIVE_COMPARATOR|MYOSTIM®|MYOSTIM® 2 bars/day during 12 weeks MYOSTIM® as a food bar. Active ingredient: Pomegranate extract, L-leucine, Creatine, D3 Vitamin, Proteins IP Status: Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment.
62177298|NCT04684771|PLACEBO_COMPARATOR|PLACEBO|PLACEBO 2 bars/day during 12 weeks
62177299|NCT05431621||Digestive system cancer group|A total of about 1035 cases are expected to be enrolled, including 432 cases in stage I and 603 cases in II-IV.
62742278|NCT00711230|EXPERIMENTAL|4: Medium dose Placebo|"* Dosage form: 1.6 mL Placebo~* Administration with 4 DermaPrep patches~* Frequency: every six weeks~* Duration: 18 weeks (4 Placebo treatments)"
62742279|NCT00711230|EXPERIMENTAL|5: High dose DermaVir|"* Dosage: 0.8 mg DNA~* Dosage form: 6.4 mL DNA/PEIm nanomedicine~* Administration with 8 DermaPrep patches~* Frequency: every six weeks~* Duration: 18 weeks (4 DermaVir treatments)"
62177300|NCT05431621||Negative group|985 healthy individuals.
62177301|NCT05431621||High risk group|410 cases with precancerous diseases.
62177302|NCT03168698|ACTIVE_COMPARATOR|Carbetocin 20mcg|Carbetocin 20mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
62177303|NCT03168698|ACTIVE_COMPARATOR|Carbetocin 100mcg|Carbetocin 100mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
62177304|NCT03168698|ACTIVE_COMPARATOR|Oxytocin 0.5IU|Oxytocin 0.5IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
62177305|NCT03168698|ACTIVE_COMPARATOR|Oxytocin 5IU|Oxytocin 5IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
62177306|NCT05213325||Cases|Children with acute diarrhea
62177307|NCT05213325||Control|Healthy control children
62177308|NCT00989313||1|
62177309|NCT06041178|EXPERIMENTAL|scaling and root planing + 2.5% flurbiprofen on one site and placebo on contralateral site|Following scaling and root planing, the prepared 2.5% flurbiprofen was injected subgingivally in the selected deep pocket and the same was done with a placebo on the contralateral site
62177310|NCT06041178|EXPERIMENTAL|scaling and root planing + 98% aloe vera on one site and placebo on contralateral site|Following scaling and root planing, the prepared aloe vera was injected subgingivally in the selected deep pocket and the same was done with a placebo on the contralateral site
62177311|NCT06041178|EXPERIMENTAL|scaling and root planing + 2.5% flurbiprofen on one site and 98% aloe vera on contralateral site|Following scaling and root planing, the prepared 2.5% flurbiprofen was injected subgingivally in the selected deep pocket while the same was done with 98% aloe vera on the contralateral site
62177312|NCT02127489|ACTIVE_COMPARATOR|Midazolam|1 mL/kg bupivacaine 0.25%.
62177313|NCT02127489|PLACEBO_COMPARATOR|saline|5mL rectal saline
62177314|NCT04130581|EXPERIMENTAL|TMS|Six 30-pulse trains of 20 Hz repetitive Transcranial Magnetic Stimulation to left primary motor cortex hand area, separated by 60 seconds, repeated at 0, 24, 48, and 72 hours post-immobilisation.
62177315|NCT04130581|SHAM_COMPARATOR|Sham|Six 30-pulse trains of 20 Hz repetitive sham Transcranial Magnetic Stimulation above, but not in contact with, the head, separated by 60 seconds, repeated at 0, 24, 48, and 72 hours post-immobilisation.
62177316|NCT04146285|EXPERIMENTAL|BAT4406F|
62177317|NCT00920699|EXPERIMENTAL|600 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day of CoQ10 in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
62177318|NCT00920699|EXPERIMENTAL|1200 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
62177319|NCT00920699|EXPERIMENTAL|2400 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
62177320|NCT01225159|EXPERIMENTAL|Tight glycaemic control (TGC)|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
62742280|NCT00711230|EXPERIMENTAL|6: High dose Placebo|"* Dosage form: 6.4 mL Placebo~* Administration with 8 DermaPrep patches~* Frequency: every six weeks~* Duration: 18 weeks (4 Placebo treatments)"
62177321|NCT01225159|PLACEBO_COMPARATOR|Conventional glycaemic control (Control)|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
62177322|NCT02183350|EXPERIMENTAL|BI 1356 BS - single rising dose|
62742281|NCT03558269|EXPERIMENTAL|Study group|This group will receive UCB after the first palliative surgery
61997483|NCT05935579|EXPERIMENTAL|Durvalumab and Lenvatinib|
61997484|NCT05935579|ACTIVE_COMPARATOR|Durvalumab and Lenvatinib plus chemotherapy|
62177323|NCT02183350|PLACEBO_COMPARATOR|Placebo|
62177324|NCT05694936|EXPERIMENTAL|Experimental arm (n=60)|Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks, with sodium valproate oral continuously in a twice daily dose (target daily dose of 20 mg/kg/d at Cycle 1 Day 13, then dose adjusted to maintain serum VPA levels within the target range of 50-100 μg/mL)
62177325|NCT05694936|ACTIVE_COMPARATOR|Control arm (n=30)|Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks
62177326|NCT04357964||obese and lean individuals|obese and lean individuals
62177327|NCT02044341|ACTIVE_COMPARATOR|AR01 - Topical Otic Solution|"Topical ear drops~The dosing regimen is every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period~Children 2 Months to 12 Years: dispense five drops of study drug into the affected ear canal(s) each hour, as needed for ear pain, or Children 12 years to \<19 years: dispense 10 drops of study drug into the affected ear canal(s) each hour, as needed for ear pain."
62177328|NCT02044341|PLACEBO_COMPARATOR|Glycerin ear drops|"Topical ear drops~The dosing regimen is every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period~Children 2 Months to 12 Years: dispense five drops of study drug into the affected ear canal(s) each hour, as needed for ear pain, or Children 12 years to \<19 years: dispense 10 drops of study drug into the affected ear canal(s) each hour, as needed for ear pain."
62742282|NCT03558269|NO_INTERVENTION|Control group|This group will not receive any treatment
62742283|NCT05584163|NO_INTERVENTION|Control group|Group not using drugs used for the prevention of cardiomyopathy caused by doxorubicin, including extracorporeal shock wave
62742284|NCT05584163|EXPERIMENTAL|ESWT treatment group|Group receiving extracorporeal shock wave therapy
62742285|NCT05273255|EXPERIMENTAL|FMT-Recipients|"FMT-Recipients are patients with stage IV cancer, who have not sufficiently responded (stable disease or non-response) after at least 1 full cycle of CI. These patients will undergo the FMT procedure after the colon cleansing performed per routine treatment protocols at the Departement of Gastroenterology at the University Hospital of Zürich.~The stool is donated by FMT-Donors, which are patients with any solid cancer stage III or IV cancers, who received any ICI-Therapy and have experienced a durable partial or complete response.~FMT infusate will be administered via colonoscopy."
62742286|NCT01055938|EXPERIMENTAL|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
62742287|NCT01055938|ACTIVE_COMPARATOR|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
62742288|NCT01164891|EXPERIMENTAL|Single Arm|
62742289|NCT05028348|EXPERIMENTAL|Selinexor, pomalidomide and dexamethasone (SPd)|"Selinexor will be given as an oral dose:~40 mg (2 20 mg tablets) once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle.~* Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.~* Patients ≤75 years:~  o Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Dose may be divided over 2 days at the Investigator's discretion.~* Patients \> 75 years:~  * Dexamethasone will be given as an oral 20 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Dose may be divided over 2 days at the Investigator's discretion."
62177329|NCT01123512|EXPERIMENTAL|Kiva VCF Treatment System|
62177330|NCT01123512|ACTIVE_COMPARATOR|Balloon Kyphoplasty|
62177331|NCT02476708|EXPERIMENTAL|Curcumin 1800mg|curcumin capsule 600mg taken 3 times per day for 8 weeks
62177332|NCT02476708|PLACEBO_COMPARATOR|Placebo|placebo capsule taken 3 times per day for 8 weeks
62177333|NCT02018705||POEM|group of Achalasia patients treated with POEM (peroral endoscopic myotomy)
62177334|NCT02018705||LHM|group of Achalasia patients treated with LHM (laparoscopic Heller myotomy)(+ fundoplication)
62177335|NCT02222961|EXPERIMENTAL|BIIR 561 CL|
62177336|NCT02222961|PLACEBO_COMPARATOR|Placebo|
62177337|NCT06061224|NO_INTERVENTION|non-PT group|with no physical treatment intervention (group 1)
62177338|NCT06061224|EXPERIMENTAL|Early-PT group|with physical treatment intervention started in ICU admission day 3 (group 2)
62177339|NCT06061224|EXPERIMENTAL|Delayed-PT|with physical treatment intervention started after ICU admission day 3 (group 3)
62177340|NCT02253745|EXPERIMENTAL|Placebo:V81444|Placebo followed by a 7 day washout then V81444
62177341|NCT02253745|EXPERIMENTAL|V81444:placebo|V81444 followed by a 7 day washout then Placebo
62177342|NCT02714699|EXPERIMENTAL|diclofenac potassium|oral diclofenac potassium
62177343|NCT02714699|ACTIVE_COMPARATOR|hyoscine butyl bromide|oral hyoscine butyl bromide
62177344|NCT02714699|PLACEBO_COMPARATOR|placebo|oral placebo
62177345|NCT02923817|EXPERIMENTAL|Treatment|
62177346|NCT00997932|OTHER|Complete Cohort|The complete cohort of all women enrolled and stated they wanted an LNG-IUS between 48 and 72 hours of vaginal delivery.
62177347|NCT00296023|EXPERIMENTAL|stem cell transplant|
62177348|NCT01865578|EXPERIMENTAL|tDCS|Transcranial direct current stimulation
62177349|NCT01865578|SHAM_COMPARATOR|sham stimulation|sham stimulation
62177350|NCT02863913|EXPERIMENTAL|Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10\^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
62177351|NCT02863913|PLACEBO_COMPARATOR|Comparable group|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10\^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
62177352|NCT01174498|ACTIVE_COMPARATOR|t-VNS sytem Vagus stimulation|Subjects experience a transcutaneous vagal stimulation by the t-VNS device
62177353|NCT01174498|SHAM_COMPARATOR|Sham transcutaneous stimulation|Sham stimulation with an attached t-VNS device
62177354|NCT04591964|ACTIVE_COMPARATOR|baseline|standard medical therapy + using of mobile application + improving therapy
62177355|NCT04591964|NO_INTERVENTION|Control|standard medical therapy
62177356|NCT06234813|EXPERIMENTAL|Glanzmann Thrombasthenia Group|Patient with a clear diagnosis of Glanzmann Thrombasthenia, whatever the subtype of disease
62177357|NCT06234813|ACTIVE_COMPARATOR|Healthy donors|Healthy donor without haemorrhagic ant thrombotic medical history
62177358|NCT02654613|ACTIVE_COMPARATOR|Quality Improvement Intervention|In intervention clinics, staff will follow QI methodology to undertake a detailed assessment of their HIV-TB care and to prioritize the steps to improve treatment outcomes. A senior nurse will be identified to be the QI champion and will be trained by the study team to fulfil this role. The QI champion in the clinic then provides peer-leadership, mentorship and support for the implementation of the prioritized changes until the checklist is complete and all integrated HIV-TB service components meet the required standard.
62177359|NCT02654613|NO_INTERVENTION|Control Standard of Care|The control arm will continue with the usual support that is received for HIV-TB service integration
62177360|NCT06118177||Test group|"20-ml blood samples were taken from the antecubital vein of the patient's right or left arm in one attempt. The blood was gently transferred to glass-coated plastic tubes free from anticoagulant agents without wasting time. The tubes were immediately centrifuged at 2800 rpm for 12 min with a centrifuge device.~After the subepithelial connective tissue graft harvesting from in the palate, obtained L-PRF was placed into donor site at the palate then incision line was suturedwith 5/0 synthetic, non-absorbable, sterile monofilament suture."
62177361|NCT06118177||Control group|After the subepithelial connective tissue graft harvesting from in the palate, the incision line was sutured with 5/0 synthetic, nonabsorbable, sterile monofilament suture. No additional material was performed into the donör area.
62177362|NCT01916798|ACTIVE_COMPARATOR|Intralipid infusion|100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.
62177363|NCT01916798|NO_INTERVENTION|Control group|100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.
62364978|NCT06330324||Dermato-oncogenetic syndromes|This group are genodermatoses associated with the development of malignancies ((non-)cutaneous), such as basal cell nevus syndrome (BCNS), Birt-Hoog-Dubé syndrome, tuberous sclerosis, etc.
62364979|NCT06330324||Other genodermatoses|In this group genodermatoses are listed that do not fit the other groups as mentioned above, for example albinism and cutis laxa.
62364980|NCT01680939|EXPERIMENTAL|Morphine|Receives morphine for post-surgical pain
62364981|NCT01680939|EXPERIMENTAL|Ibuprofen|Receives ibuprofen for post-surgical pain
62177364|NCT03424525|EXPERIMENTAL|Biodistribution|The Biodistribution cohort referred from orthopedics who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution \[11C\]trimethoprim PET/CT scans over a period of approximately 2 ½ hours.
62364982|NCT01061645|EXPERIMENTAL|MOC31-PE|
62364983|NCT01230918|EXPERIMENTAL|Diagnostic Imaging|A single dose of 800 to 1100 mBq of 99mTc-NC100692 radiopharmaceutical will be injected. Serial cardiac nuclear imaging will be done over a 3 hour period.
62364984|NCT03997981||Breast cancer patients with weekly/biweekly paclitaxel regimen|
62364985|NCT03997981||Breast cancer patients receiving docetaxel regimen|
62364986|NCT03997981||Lymphoma patients receiving vincristine regimen|
62364987|NCT03997981||Multiple myeloma patients receiving bortezomib regimen|
62364988|NCT03997981||Colorectal cancer patients receiving oxaliplatin-based regimens|
62364989|NCT06257940||intra-operative glove changing group|in which, the surgeon will replace his/her outer surgical gloves with a new pair of sterile gloves just prior to abdominal closure
62364990|NCT06257940||usual care group|in which, surgeon won't change his/her gloves before abdominal closure
62364991|NCT04111146||1|Liver transplant patients with severe vitamin D deficiency (\<10ng/ml)
62364992|NCT04111146||2|Liver transplant patients with vitamin D insufficiency (10-20ng/ml)
62364993|NCT04111146||3|Liver transplant patients with normal vitamin D status (\>20ng/ml)
62364994|NCT04308954|EXPERIMENTAL|Fragile X Syndrome|Adult males aged 18-30 years diagnosed with FXS will undergo a non-invasive F18 FMZ PET/MRI scan to determine GABA(A) receptor density; developmental dynamics of GABA(A) receptor distribution, and structural neuroanatomy and connectional anatomy.
62364995|NCT04308954|EXPERIMENTAL|Idiopathic Intellectual Developmental Disorder|Adult males aged 18-30 years diagnosed with idiopathic intellectual developmental disorder will undergo a non-invasive F18 FMZ PET/MRI scan to determine GABA(A) receptor density; developmental dynamics of GABA(A) receptor distribution, and structural neuroanatomy and connectional anatomy.
62364996|NCT03274245|EXPERIMENTAL|Latrine Use|Men and women in villages randomized to the latrine use arm will receive the intervention package that includes activities at the community and household levels, with additional activities and hardware for mothers of children under five.
62364997|NCT03274245|NO_INTERVENTION|Control Group|Men and women in villages randomized to the control group will not receive an intervention.
62364998|NCT03274245|EXPERIMENTAL|Qualitative Research Group|Six villages unassociated with the randomized villages will engage in qualitative research. Three villages will receive the intervention. Three villages will not receive the intervention.
62364999|NCT03607071|EXPERIMENTAL|Prednisolone|The patient who has detected myocardial inflammation from cardiac MRI from baseline is given prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
62365000|NCT02635685|EXPERIMENTAL|Intervention group|Intervention with Clinical Decision Support tool installed on units.
62365001|NCT02635685|NO_INTERVENTION|Control group|Control group without intervention with Clinical Decision Support tool installed on units.
62365002|NCT02690389|NO_INTERVENTION|Control|standard procedure is used
62365003|NCT02690389|SHAM_COMPARATOR|Flumazenil only group|flumazenil is given
62365004|NCT02690389|ACTIVE_COMPARATOR|control with acupuncture|control with acupuncture
62365005|NCT02690389|ACTIVE_COMPARATOR|control with acupuncture and flumazenil|control with acupuncture and flumazenil
62365006|NCT05078671|ACTIVE_COMPARATOR|Standard olaparib|Olaparib 300mg twice daily
62365007|NCT05078671|EXPERIMENTAL|Boosted olaparib|Olaparib 100mg twice daily + cobicistat 150mg twice daily
62365008|NCT06075498|ACTIVE_COMPARATOR|transversus abdominis plane block|The group that underwent bilateral transversus abdominis plane block with 0.375 mg 20 ml bupivacaine on each side after open retropubic prostatectomy operations
62365009|NCT06075498|ACTIVE_COMPARATOR|quadratus lumborum plane block|The group that underwent bilateral quadratus lumborum plane block with 0.375 mg 20 ml bupivacaine on each side after open retropubic prostatectomy operations
62365010|NCT04326881|EXPERIMENTAL|SHR-1314 A|single dosing SHR-1314 A
62365011|NCT04326881|EXPERIMENTAL|SHR-1314 B|single dosing SHR-1314 B
62365012|NCT04326881|EXPERIMENTAL|SHR-1314 C|single dosing SHR-1314 C
62365013|NCT03662555|EXPERIMENTAL|NMES and BFR (80%)|Group 1, participants will undergo NMES and BFR (80% pressure) applied to the quadriceps for 25 min.
62365014|NCT03662555|EXPERIMENTAL|NMES and BFR (40%)|Group 2, participants will undergo NMES and BFR (40% pressure) applied to the quadriceps for 25 min.
62177365|NCT03424525|EXPERIMENTAL|Dynamic|The Dynamic cohort will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans imaging post injection of \[11C\]trimethoprim. Some subjects who may be selected clinically to undergo surgical or antibiotic treatment may undergo a second therapy may also undergo an optional second \[11C\]trimethoprim PET/CT after the initiation of therapy to collect pilot data on the changes in \[11C\]trimethoprim biodistribution and uptake with therapy, the timing of this scan may vary depending on the type of treatment the patient is receiving.
62177366|NCT02929316|EXPERIMENTAL|Vedolizumab|Vedolizumab (Entyvio) 300mg IV at week 0, 2 and 6
62365015|NCT03662555|ACTIVE_COMPARATOR|NMES alone|Group 3, participants will undergo NMES applied to the quadriceps for 25 min.
62365016|NCT02485613||bortezominb and dexamethasone group|
62365017|NCT06454162|EXPERIMENTAL|Modified Ketogenic Diet|thirty-two patients will receive modified ketogenic diet and exercise program for three months
62365018|NCT06454162|ACTIVE_COMPARATOR|exercise program|thirty-two patients will receive an exercise program three times per week for three months
62365019|NCT02667028||patients receiving PCI|patients receiving percutaneous coronary intervention(PCI)
62177367|NCT01133197||controls|No hand arthritis
62177368|NCT01133197||CMC Arthritis|Patients with arthritis
62177369|NCT05388097|NO_INTERVENTION|Standard Of Care - No Managed Services|Subjects receive standard medical care and follow-up after hospital discharge
62177370|NCT05388097|EXPERIMENTAL|Managed Services After Discharge|Subjects receive in-home assessment and care coordination/connection with community resources after hospital discharge
62177371|NCT03168399|EXPERIMENTAL|Consumption of PKU Explore|Daily feed, substituting the participant's normal phe-free protein substitute for PKU Explore.
62177372|NCT01287871||Social media intervention|Women between the ages of 18-70 who have not been diagnosed with any type of cancer and are of African descent or Latina
62177373|NCT03577925||HSIL|the patients with HSIL
62177374|NCT03577925||stage IA1 cervical squamous cancer|the patients with stage IA1 cervical squamous cancer
62177375|NCT04983225|EXPERIMENTAL|1×10^6 cells/site group|Human Dental Pulp Stem Cells Injection: 1×10\^6 cells/periodontal defect site.
62177376|NCT04983225|EXPERIMENTAL|5×10^6 cells/site group|Human Dental Pulp Stem Cells Injection: 5×10\^6 cells/periodontal defect site.
62177377|NCT04983225|EXPERIMENTAL|1×10^7 cells/site group|Human Dental Pulp Stem Cells Injection: 1×10\^7 cells/periodontal defect site.
62177378|NCT04983225|EXPERIMENTAL|2×10^7 cells/two sites group|Human Dental Pulp Stem Cells Injection: 1×10\^7 cells/periodontal defect site, two locations in total, and the total cell injection volume is 2 × 10\^7 cells/2 periodontal defect sites.
62365020|NCT02361489|ACTIVE_COMPARATOR|Titration Algorithm A|All patients that are initiated on a V-Go 20 will have a starting bolus dose of 6 clicks (12 units) during the day and all patients who are initiated on a V-Go 30 will have a starting bolus dose of 9 clicks (18 units) during the day. All patients randomized to Algorithm A will use a fixed starting dose of either 2 clicks per meal (if on the V-Go 20) or 3 clicks per meal (if on the V-Go 30).
62365021|NCT02361489|ACTIVE_COMPARATOR|Titration Algorithm B|All patients that are initiated on a V-Go 20 will have a starting bolus dose of 6 clicks (12 units) during the day and all patients who are initiated on a V-Go 30 will have a starting bolus dose of 9 clicks (18 units) during the day. All patients randomized to Algorithm B will have 50% of their initial bolus dose given at the largest meal with less bolus insulin at the other meals as noted below:
62365022|NCT04128605|EXPERIMENTAL|Intervention: Suprascapular nerve block (SSNB)|SSNB performed by skilled interventionist who is not blinded for safety reason. 5 mls of Bupivacaine, 5 mls Lidocaine and 10 mls of saline.
62177379|NCT04983225|EXPERIMENTAL|3~4×10^7 cells/three or four sites group|Human Dental Pulp Stem Cells Injection: 1×10\^7 cells/periodontal defect site, three or four locations in total, and the total cell injection volume is 3 × 10\^7 to 4 × 10\^7 cells/3 to 4 periodontal defect sites.
62177380|NCT04983225|PLACEBO_COMPARATOR|Saline solution group|Saline solution: 0.6mL/periodontal defect site.
62177381|NCT04071093|OTHER|Telemonitoring|
62177382|NCT04071093|NO_INTERVENTION|Usual Care|
62177383|NCT04933162|EXPERIMENTAL|High Protein and Low Fiber Group|Subjects will consume a high protein and low fiber diet for 8 weeks
62177384|NCT04933162|EXPERIMENTAL|Low Protein and High Fiber Group|Subjects will consume a low protein and high fiber diet for 8 weeks
62177385|NCT00912054|EXPERIMENTAL|1|DuoTrav APS
62177386|NCT00912054|ACTIVE_COMPARATOR|2|Xalacom
62177387|NCT02991703|ACTIVE_COMPARATOR|SphygmoCor®|
62177388|NCT02991703|EXPERIMENTAL|pOpmètre®|
62177389|NCT01919346|EXPERIMENTAL|Eculizumab|Eculizumab 1200 mg (diluted in Sodium Chloride (NaCl) to 5mg/mL, volume = 240 mL) will be given intraoperatively at the time of transplantation prior to reperfusion of the renal allograft and again at 900 mg (diluted in NaCl to 5mg/mL, volume = 180 mL) 12-24 hours post-transplantation
62177390|NCT01919346|PLACEBO_COMPARATOR|Normal Saline|Administered at same volume and time as Experimental arm
62177391|NCT01281215|EXPERIMENTAL|Pharmaceutical Education|The patients will receive pharmaceutical education.
62177392|NCT01281215|NO_INTERVENTION|Control|
62177393|NCT02435797|ACTIVE_COMPARATOR|Nicorandil|Nicorandil for injection
62177394|NCT02435797|PLACEBO_COMPARATOR|normal saline|normal saline
62177395|NCT05194228|EXPERIMENTAL|Group 1|$1 Payment per EMA 2 EMAs per day 15 questions per EMA Fixed schedule Slider first
62365023|NCT04128605|ACTIVE_COMPARATOR|Control: Intraarticular shoulder steroid injection (IAS)|"IAS performed by skilled interventionist who is blinded on patient's initial measurement.~40 mg of Triamcenolone Acetate + 2 ml of Lidocaine 1%"
62365024|NCT01980225|EXPERIMENTAL|Collapse|This arm includes the patients where laser-induced collapse (=artificial shrinkage) of all blastocysts is performed before vitrification
62365025|NCT01980225|NO_INTERVENTION|control|This control arm includes the patients of which the blastocysts are vitrified without performing collapse
62365026|NCT05344612|EXPERIMENTAL|CTCA|
62365027|NCT05344612|NO_INTERVENTION|Standard care|
62177396|NCT05194228|EXPERIMENTAL|Group 2|$1 Payment per EMA 2 EMAs per day 15 questions per EMA Fixed schedule Likert first
62177397|NCT05194228|EXPERIMENTAL|Group 3|$1 Payment per EMA 2 EMAs per day 15 questions per EMA Random schedule Slider first
62177398|NCT05194228|EXPERIMENTAL|Group 4|$1 Payment per EMA 2 EMAs per day 15 questions per EMA Random schedule Likert first
62365028|NCT00971542|EXPERIMENTAL|low dose of antigen + low dose of adjuvant|
62365029|NCT00971542|EXPERIMENTAL|high dose of antigen + high dose of adjuvant|
62177399|NCT05194228|EXPERIMENTAL|Group 5|$1 Payment per EMA 2 EMAs per day 25 questions per EMA Fixed schedule Slider first
62177400|NCT05194228|EXPERIMENTAL|Group 6|$1 Payment per EMA 2 EMAs per day 25 questions per EMA Fixed schedule Likert first
62177401|NCT05194228|EXPERIMENTAL|Group 7|$1 Payment per EMA 2 EMAs per day 25 questions per EMA Random schedule Slider first
62177402|NCT05194228|EXPERIMENTAL|Group 8|$1 Payment per EMA 2 EMAs per day 25 questions per EMA Random schedule Likert first
62177403|NCT05194228|EXPERIMENTAL|Group 9|$1 Payment per EMA 4 EMAs per day 15 questions per EMA Fixed schedule Slider first
62742290|NCT05028348|ACTIVE_COMPARATOR|Elotuzumab, Pomalidomide and Dexamethasone (EloPd)|"Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles ≥3 of each 28-day cycle.~* Pomalidomide will be given as an oral 4 mg dose once a day (QD) on Days 1 to 21 of each 28-day cycle.~* Patients ≤75 years:~  * Dexamethasone 28 mg PO + 8 mg IV on days of elotuzumab dosing~ * Dexamethasone 40 mg PO on non-elotuzumab days (e.g., days 8, 15, and 22 of cycle 3 and beyond). Dose may be divided over 2 days at the Investigator's discretion.~* Patients \>75 years:~  * Dexamethasone 8 mg PO + 8 mg IV on days of elotuzumab dosing~ * Dexamethasone 20 mg PO on non-elotuzumab dosing weeks (e.g., days 8, 15, and 22 of cycle 3 and beyond). Dose may be divided over 2 days at the Investigator's discretion."
62742291|NCT00526656|EXPERIMENTAL|sunitinib malate|Drug
62742292|NCT03305588|EXPERIMENTAL|130 Gy Radiation & Unframed Virtual Cone|130 Gy Virtual Cone Radiosurgery Unframed (Face Mask)
62742293|NCT02381717|EXPERIMENTAL|ultra-sound guided femoral nerve block|Patients in this arm will receive a bed-side ultrasound guided femoral nerve block with analgesia 0.5% bupivacaine (2mg/kg)
62742294|NCT02381717|ACTIVE_COMPARATOR|standard of care- IV morphine|Patients in this arm will have the femoral nerve block block with no ultrasound for guidance with analgesia (IV morphine)
62742295|NCT04207593|ACTIVE_COMPARATOR|Oxygen Therapy provided|Patients will be divided in a supplemental-oxygen group (primary intervention group) throughout the study
62742296|NCT04207593|SHAM_COMPARATOR|no-supplemental-oxygen group (control group)|Patients of the control group will beginn the study without Oxygen Therapie and will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group).
62742297|NCT01252186|EXPERIMENTAL|91-day Levonorgestrel Oral Contraceptive|Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10 µg EE monotherapy in each 91-day cycle for a total of two 91-day cycles.
62177404|NCT05194228|EXPERIMENTAL|Group 10|$1 Payment per EMA 4 EMAs per day 15 questions per EMA Fixed schedule Likert first
62177405|NCT05194228|EXPERIMENTAL|Group 11|$1 Payment per EMA 4 EMAs per day 15 questions per EMA Random schedule Slider first
62177406|NCT05194228|EXPERIMENTAL|Group 12|$1 Payment per EMA 4 EMAs per day 15 questions per EMA Random schedule Likert first
62365030|NCT00971542|EXPERIMENTAL|high dose of antigen|
62391470|NCT06342440||Low-risk Adenoma (Validation cohort)|"Individuals who underwent colonoscopy and were found to only have low-risk adenomas, defined as:~* 1 to 4 adenomas at most.~* All adenomas have low-grade dysplasia at most.~* All adenomas are \<10 mm in diameter."
62177407|NCT05194228|EXPERIMENTAL|Group 13|$1 Payment per EMA 4 EMAs per day 25 questions per EMA Fixed schedule Slider first
61997485|NCT02273219|EXPERIMENTAL|Dose 1: AEB071 and BYL719|AEB071, oral, 100 mg twice daily BYL719, oral, 200 mg daily
61997486|NCT02273219|EXPERIMENTAL|Dose 2: AEB071 and BYL719|AEB071, oral, 200 mg twice daily BYL719, oral, 250 mg daily
61997487|NCT02273219|EXPERIMENTAL|Dose 3: AEB071 and BYL719|AEB071, oral, 200 mg twice daily BYL719, oral, 300 mg daily
62177408|NCT05194228|EXPERIMENTAL|Group 14|$1 Payment per EMA 4 EMAs per day 25 questions per EMA Fixed schedule Likert first
62177409|NCT05194228|EXPERIMENTAL|Group 15|$1 Payment per EMA 4 EMAs per day 25 questions per EMA Random schedule Slider first
62177410|NCT05194228|EXPERIMENTAL|Group 16|$1 Payment per EMA 4 EMAs per day 25 questions per EMA Random schedule Likert first
62177411|NCT05194228|EXPERIMENTAL|Group 17|Payment by % EMAs 2 EMAs per day 15 questions per EMA Fixed schedule Slider first
62177412|NCT05194228|EXPERIMENTAL|Group 18|Payment by % EMAs 2 EMAs per day 15 questions per EMA Fixed schedule Likert first
62177413|NCT05194228|EXPERIMENTAL|Group 19|Payment by % EMAs 2 EMAs per day 15 questions per EMA Random schedule Slider first
62177414|NCT05194228|EXPERIMENTAL|Group 20|Payment by % EMAs 2 EMAs per day 15 questions per EMA Random schedule Likert first
62177415|NCT05194228|EXPERIMENTAL|Group 21|Payment by % EMAs 2 EMAs per day 25 questions per EMA Fixed schedule Slider first
62177416|NCT05194228|EXPERIMENTAL|Group 22|Payment by % EMAs 2 EMAs per day 25 questions per EMA Fixed schedule Likert first
62177417|NCT05194228|EXPERIMENTAL|Group 23|Payment by % EMAs 2 EMAs per day 25 questions per EMA Random schedule Slider first
62177418|NCT05194228|EXPERIMENTAL|Group 24|Payment by % EMAs 2 EMAs per day 25 questions per EMA Random schedule Likert first
62391471|NCT06342440||Advanced Adenoma (Validation cohort)|"Individuals who underwent colonoscopy and were found to have high-risk adenomas, defined as one or more of the following:~* 5 or more adenomas.~* One or more adenomas have high-grade dysplasia.~* One or more adenomas are \>10 mm in diameter."
62742298|NCT01252186|ACTIVE_COMPARATOR|28-day Levonorgestrel Oral Contraceptive|Participants received 21 days of active combination tablets containing 150 µg LNG/30 µg EE, followed by no treatment for 7 days in each 28-day cycle for a total of six 28-day cycles.
62177419|NCT05194228|EXPERIMENTAL|Group 25|Payment by % EMAs 4 EMAs per day 15 questions per EMA Fixed schedule Slider first
62177420|NCT05194228|EXPERIMENTAL|Group 26|Payment by % EMAs 4 EMAs per day 15 questions per EMA Fixed schedule Likert first
62177421|NCT05194228|EXPERIMENTAL|Group 27|Payment by % EMAs 4 EMAs per day 15 questions per EMA Random schedule Slider first
62177422|NCT05194228|EXPERIMENTAL|Group 28|Payment by % EMAs 4 EMAs per day 15 questions per EMA Random schedule Likert first
62177423|NCT05194228|EXPERIMENTAL|Group 29|Payment by % EMAs 4 EMAs per day 25 questions per EMA Fixed schedule Slider first
62177424|NCT05194228|EXPERIMENTAL|Group 30|Payment by % EMAs 4 EMAs per day 25 questions per EMA Fixed schedule Likert first
62742299|NCT01252186|ACTIVE_COMPARATOR|28-day Desogestrel Oral Contraceptive|Participants received 21 days of active combination tablets (containing 150 µg desogestrel (DSG)/30 µg EE, followed by no treatment for 7 days in each 28-day cycle for a total of six 28-day cycles.
62177425|NCT05194228|EXPERIMENTAL|Group 31|Payment by % EMAs 4 EMAs per day 25 questions per EMA Random schedule Slider first
62177426|NCT05194228|EXPERIMENTAL|Group 32|Payment by % EMAs 4 EMAs per day 25 questions per EMA Random schedule Likert first
62177427|NCT02358083|NO_INTERVENTION|Arm 1. HPV + Control + Control|HPV is target vaccine. No message regarding relative safety of vaccine; Provider provides brief routine recommendation for vaccination.
62177428|NCT02358083|EXPERIMENTAL|Arm 2. HPV + Control + Strong|HPV is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination.
62742300|NCT02182024|EXPERIMENTAL|Dabigatran high dose in healthy subjects|healthy subjects with a creatinine clearance of \>80 mL/m
62742301|NCT02182024|EXPERIMENTAL|Dabigatran high dose in mild renal impairment|patients with a creatinine clearance of \>50 up to 80 mL/min
62177429|NCT02358083|EXPERIMENTAL|Arm 3. HPV + Control + Disclosure|HPV is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
62177430|NCT02358083|EXPERIMENTAL|Arm 4. HPV + Safety + Control|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides brief routine recommendation for vaccination.
62742302|NCT02182024|EXPERIMENTAL|Dabigatran high dose in moderate renal impairment|patients with a creatinine clearance of \>30 up to 50 mL/min
62742303|NCT02182024|EXPERIMENTAL|Dabigatran high dose in severe renal impairment|patients with a creatinine clearance of up to 30 mL/min
62177431|NCT02358083|EXPERIMENTAL|Arm 5. HPV + Safety + Strong|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination.
62177432|NCT02358083|EXPERIMENTAL|Arm 6. HPV + Safety + Disclosure|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
62177433|NCT02358083|NO_INTERVENTION|Arm 7. Flu + Control + Control|Flu is target vaccine. No message regarding relative safety of vaccine; Provider provides brief routine recommendation for vaccination.
62177434|NCT02358083|EXPERIMENTAL|Arm 8. Flu + Control + Strong|Flu is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination.
62177435|NCT02358083|EXPERIMENTAL|Arm 9. Flu + Control + Disclosure|Flu is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
62177436|NCT02358083|EXPERIMENTAL|Arm 10. Flu + Safety + Control|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides brief routine recommendation for vaccination.
62177437|NCT02358083|EXPERIMENTAL|Arm 11. Flu + Safety + Strong|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination.
62177438|NCT02358083|EXPERIMENTAL|Arm 12. Flu + Safety + Disclosure|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
62182457|NCT06315114|EXPERIMENTAL|Lighthouse MBT Parenting Program (LPP)|The experimental group is a manualized transdiagnostic mentalization-based parenting intervention (Lighthouse MBT Parenting Program). This is a 12-week parenting group intervention (weekly session of 2 hours) with one preperatory initial individual session (1 hour) before the group commence.
62742304|NCT02182024|EXPERIMENTAL|Dabigatran low dose in haemodialysis patients|patients requiring haemodialysis
62742305|NCT05230446|OTHER|Percutaneous Coronary Intervention|Interventional comparitor, compared to an optimal performance goal of 7% MACCE resulted from past CABG results
62177439|NCT06208800|EXPERIMENTAL|Experimental group to which the essential oil mixture will be applied|Thirty elderly individuals will be included in the experimental group. The elderly individuals in the intervention group were given essential oil mixtures in 5 ml bottles prepared by the expert aromatherapist and the researcher, and it was decided to inhale these essential oils by dropping 5 drops on cotton wool for 10 minutes each for 4 weeks.
62177440|NCT06208800|NO_INTERVENTION|Experimental group without essential oil mixture.Control group|Thirty elderly individuals will be included in the control group. This group will not be intervened, only questionnaires will be administered.
62365031|NCT04142710|EXPERIMENTAL|Follow-up using telehealth solutions|Participants in this arm are followed up using a telehealth solution, as specified by the National Directorate of Health at the local centre. The actual follow-up is personalized to the individual user. All users receive a tablet, which can be used to answer questions about own health and/or transmit clinical measurements.
62365032|NCT04142710|NO_INTERVENTION|Standard clinical care|Participants in this arm receive standard clinical care in accordance with their medinal needs.
62365033|NCT04142710|EXPERIMENTAL|Non-randomized follow-up using telehealth solutions|Participants in this arm are followed up using a telehealth solution, as specified by the National Directorate of Health at the local centre. The actual follow-up is personalized to the individual user. All users receive a tablet, which can be used to answer questions about own health and/or transmit clinical measurements. This arm is not randomized, but otherwise identical to the randomized experimental arm.
62177441|NCT02411695|EXPERIMENTAL|Cohort 1|0.5 mg, Brexpipraxzole (OPC-34712)
62365034|NCT04771481|EXPERIMENTAL|metoclopramide|Metoclopramide 10mg with normal saline up to 10 ml IV slowly push in 5minutes.
62365035|NCT04771481|PLACEBO_COMPARATOR|placebo|Normal saline 10 ml IV slowly push in 5 minutes.
62365036|NCT01119963|ACTIVE_COMPARATOR|17-alpha hydroxyprogesterone caproate, Makena®|250 mg of 17P, Makena® intramuscular (IM) weekly.
62177442|NCT02411695|EXPERIMENTAL|Cohort 2|1mg, Brexpipraxzole (OPC-34712)
62177443|NCT02411695|EXPERIMENTAL|Cohort 3|2mg, Brexpipraxzole (OPC-34712)
62177444|NCT02411695|EXPERIMENTAL|Cohort 4|3 mg, Brexpipraxzole (OPC-34712)
62177445|NCT02411695|EXPERIMENTAL|Cohort 5|4mg, Brexpipraxzole (OPC-34712)
62177446|NCT04120662|ACTIVE_COMPARATOR|Group A: Surgery group|Surgical procedure according to the injury type
62365037|NCT01119963|PLACEBO_COMPARATOR|Placebo|Castor Oil (Placebo)intramuscular (IM) weekly
62365038|NCT04907890||Cases|All survivor patients hospitalised for COVID-19 and previously recruited in the CORIST study
62177447|NCT04120662|ACTIVE_COMPARATOR|Goup B: Shockwave group|3 weekly sessions of Focused Shock Wave Treatment (F-ESWT), using an electrohydraulic device set to an energy flux density (EFD) of 0.21 mJ/mm2 and 2000 impulses
62177448|NCT02183077|EXPERIMENTAL|Meloxicam gel|
62365039|NCT04907890||Controls 1|Individuals who had a positive diagnosis for SARS-Cov-2 infection in the past (at least 6 months) and that was never hospitalised for COVID-19 as he/she had not severe symptoms.
62365040|NCT04907890||Controls 2|Individuals who was never diagnosed for SARS-Cov-2 infection
62177449|NCT02183077|ACTIVE_COMPARATOR|Meloxicam tablet|
62365041|NCT02657837||Cystic Fibrosis|Children 2.5 to 18 years old with confirmed diagnosis of cystic fibrosis
62177450|NCT02844348|NO_INTERVENTION|Standard pain control|Classical pain assessment and drug treatment at each dialysis session.
62365042|NCT02657837||Children with other respiratory disease|Children 2.5 to 18 years old with confirmed diagnosis of respiratory disease including but not limited to asthma, transplant, and sickle cell anemia.
62177451|NCT02844348|EXPERIMENTAL|Hypnosis|Besides the classical pain assessment and drug treatment, hypnosis sessions during 2 periods of one week of dialysis sessions.
62177452|NCT01145417|EXPERIMENTAL|Pregabalin (Lyrica)|
62177453|NCT03025555|ACTIVE_COMPARATOR|group 1|patients will receive partial denture constructed from breflex material.
62365043|NCT02657837||Healthy Children|Children and adults 2.5 to 30 years old with no history of chronic disease
62365044|NCT01333462|PLACEBO_COMPARATOR|Phosphate Buffered Saline (PBS) IN|
62365045|NCT01333462|ACTIVE_COMPARATOR|Fluzone 4 mcg HA IN|
62365046|NCT01333462|ACTIVE_COMPARATOR|Fluzone 15 mcg HA IM|
62365047|NCT01333462|EXPERIMENTAL|NB-1008 4 mcg HA 5% W805EC|
62365048|NCT01333462|EXPERIMENTAL|NB-1008 4 mcg HA 10% W805EC|
62365049|NCT01333462|EXPERIMENTAL|NB-1008 4 mcg HA 15% W805EC|
62742306|NCT06659731||ASD Group|Patients with ASD diagnosis according to DSM-V, between 5 and 17 years old
62742307|NCT06659731||Control Group|Healthy participants, between 5 and 17 years old, without ASD diagnosis and withour neurological and psychiatric deseases
62742308|NCT04801459|EXPERIMENTAL|Antiperistaltic direction of gastrointestinal anastomosis in Roux-en-Y reconstruction group|The isoperistaltic anastomosis represents the peristalsis direction of remnant stomach and jejunal efferent loop was consistent.
62742309|NCT04801459|ACTIVE_COMPARATOR|Isoperistaltic direction of gastrointestinal anastomosis in Roux-en-Y reconstruction group|The antiperistaltic anastomosis represents the peristalsis direction of remnant stomach and jejunal efferent loop was opposite.
62365050|NCT01333462|EXPERIMENTAL|NB-1008 4 mcg HA 20% W805EC|
62365051|NCT01333462|ACTIVE_COMPARATOR|Fluzone 10 mcg HA IN|
62365052|NCT01333462|EXPERIMENTAL|NB-1008 10 mcg HA 5% W805EC|
62365053|NCT01333462|EXPERIMENTAL|NB-1008 10 mcg HA 10% W805EC|
62365054|NCT01333462|EXPERIMENTAL|NB-1008 10 mcg HA 15% W805EC|
62177454|NCT03025555|EXPERIMENTAL|group 2|patients will receive partial denture constructed from PEEK material.
62365055|NCT01333462|EXPERIMENTAL|NB-1008 10 mcg HA 20% W805EC|
62365056|NCT03682055|EXPERIMENTAL|Phase 1 Dose Escalation (Accelerated Titration)|VK-2019 QD in Accelerated Titration dose escalation cohorts enrolling EBV+ NPC
62177455|NCT04061863|EXPERIMENTAL|ER+/HER2- breast cancer|will be treated with a combination of eribulin and nivolumab
62177456|NCT04061863|EXPERIMENTAL|ER-/HER2- breast cancer|will be treated with a combination of eribulin and nivolumab
62177457|NCT01650727|EXPERIMENTAL|Dinaciclib + Rituximab|"Rituximab will be administered in Cycles 1 and 3-13.~Dinaciclib will be administered in Cycles 2-13."
62177458|NCT00899379|EXPERIMENTAL|Treatment Sequence 1|Placebo-Rizatriptan-Rizatriptan-Rizatriptan
62365057|NCT03682055|EXPERIMENTAL|Phase 1 Dose Escalation (Rolling Six)|VK-2019 QD in Rolling Six dose escalation cohorts enrolling EBV+ NPC.
62365058|NCT03682055|EXPERIMENTAL|Phase 1 Dose Expansion(s)|VK-2019 QD in expansion cohorts that may be opened at doses that meet pre-specified criteria for clinical and/or biological activity.
62365059|NCT03682055|EXPERIMENTAL|Phase 2a Dose Expansion(s)|VK-2019 QD in expansion cohorts that may be opened at doses that meet pre-specified efficacy criteria in Phase 1 Dose Escalation cohorts.
62177459|NCT00899379|EXPERIMENTAL|Treatment Sequence 2|Rizatriptan-Placebo-Rizatriptan-Rizatriptan
62177460|NCT00899379|EXPERIMENTAL|Treatment Sequence 3|Rizatriptan-Rizatriptan-Placebo-Rizatriptan
62177461|NCT00899379|EXPERIMENTAL|Treatment Sequence 4|Rizatriptan-Rizatriptan-Rizatriptan-Placebo
62177462|NCT00899379|EXPERIMENTAL|Treatment Sequence 5|Rizatriptan-Rizatriptan-Rizatriptan-Rizatriptan
62365060|NCT02637804|ACTIVE_COMPARATOR|stenfilcon A vs narafilcon A (Group 1)|Participants are randomized to wear either stenfilcon A lens pair or narafilcon A lens pair, bilaterally, for 1 week during the cross over study.
62365061|NCT02637804|ACTIVE_COMPARATOR|stenfilcon A vs delefilcon A (Group 2)|Participants are randomized to wear either stenfilcon A lens pair or delefilcon A lens pair, bilaterally, for 1 week during the cross over study.
62177463|NCT02606097|EXPERIMENTAL|regorafenib|regorafenib 160 mg daily, 3 weeks on/1 week off
62177464|NCT02599090|EXPERIMENTAL|Dose Level 1|"Temozolomide + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle~Temozolomide 75mg/m\^2 daily during radiation therapy, and 150mg/m\^2 in the first cycle of adjuvant therapy. Dose Level 1 will receive sorafenib in the adjuvant phase (following radiation therapy) at the dose of 400mg BID in combination with standard dose temozolomide 150-200 mg/m\^2 two days out of 28 day cycle. Radiotherapy 2.0 Grey (Gy)/day given daily 5 days per week for total of 60.0 Gy over 6 weeks."
62177465|NCT02599090|EXPERIMENTAL|2|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle + Higher Dose Sorafenib
62742310|NCT06509997|EXPERIMENTAL|MRG003+Dalpicicilip|Patients meeting the inclusion criteria were given MRG003 (D1, IVGTT, Q3W) in combination with Darcilil (D1-21, PO, Q4W) after completing the relevant pre-treatment examination until progression or intolerable toxicity occurred.
61997488|NCT02273219|EXPERIMENTAL|Dose 4: AEB071 and BYL719|AEB071, oral, 200 mg twice daily BYL719, oral, 350 mg daily
62177466|NCT02599090|EXPERIMENTAL|3|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Lower Dose Sorafenib
62365062|NCT04058158|EXPERIMENTAL|Treatment Sequence I|Subjects who are randomised to initially receive SB12 will be switched to receive Soliris® at Week 26
62365063|NCT04058158|EXPERIMENTAL|Treatment Sequence II|Subjects who are randomised to initially receive Soliris® will be switched to receive SB12 at Week 26
62365064|NCT03158090||Surgical treatment|The subject was received transnasal butterfly surgery.
62365065|NCT03158090||Drug therapy|The subject was received drug treatment including somatostatin analogues such as sandostatin and lanreotide, dopamine receptor agonists and GH receptor antagonists.
62177467|NCT02599090|EXPERIMENTAL|4|Temozolomide + Higher Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Higher Dose Sorafenib
62177468|NCT04310683|OTHER|natural cycle for endometrium preparation|patients will have ovulation before embryo transfer
62365066|NCT03158090||Radiotherapeutics|he subject was received radiotherapy methods including radiotherapy, linear accelerator X knife, gamma knife and so on.
62365067|NCT05543824||Epidural and arterial catheter|Patients who require placement of an epidural catheter to control postoperative pain and invasive blood pressure will be identified, allowing advanced monitoring using the MostCare Up® device. After identification, the objective of the study will be explained and their consent will be requested to collect the data after the intervention, recording the hemodynamic data before and after the initial bolus of local anesthetic administered: 0.25% levobupivacaine, the dose of which is calculated with the Takasaki formula: 0.05ml x weight (kg) x number of dermatomes to anesthetize.
62177469|NCT04310683|EXPERIMENTAL|hormone replaced cycle for endometrium preparation|patients will do not have ovulation before embryo transfer
62177470|NCT01327027|EXPERIMENTAL|Vasopressin, Arginine, ADH|We will test how vasopressin affects emotional responses to facial stimuli in healthy men and women.
62177471|NCT01327027|PLACEBO_COMPARATOR|Sterile Salilne|Sterile saline will be administered intranasally and emotional responses to facial stimuli measured.
62177472|NCT04299113|EXPERIMENTAL|Treatment (vinorelbine, mocetinostat)|Participants receive mocetinostat in combination with vinorelbine
62365068|NCT03423563|EXPERIMENTAL|Flexible fiberoptic bronchoscopy|Fiberoptic intubation has been considered for a long time the gold standard technique for intubation when there is anticipated or known difficult airway or as a rescue device in can't intubate but can ventilate scenarios
62391472|NCT06342440||Colorectal Cancer (Validation cohort)|Individuals who underwent colonoscopy and were found to have colorectal cancer.
62742311|NCT02626429|EXPERIMENTAL|Active, Young Adult Famale|Participants will complete a bout of exercise and then consume a randomly assigned amino acid intake prior to measuring whole body 13CO2 excretion and phenylalanine oxidation.
62742312|NCT06661213|EXPERIMENTAL|Tapinarof Treatment|CLE participants treated with tapinarof
62742313|NCT04377321||group 1 on cochicine|The first group patients received colchicine 0.5 twice daily for 6 months
62177473|NCT02790112|OTHER|GnRHas - Not GnRHas patients|Compared long term outcome of treated and untreated patients with idiopathic central precocious puberty : hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
62177474|NCT02790112|OTHER|GnRHas - controls patients|Compared long term outcome of treated patients with idiopathic central precocious puberty and control patients for: hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
62177475|NCT02790112|OTHER|Not GnRHas - Controls patients|Compared long term outcome of untreated patients with idiopathic central precocious puberty and control patients for: hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
62177476|NCT03294421|ACTIVE_COMPARATOR|standard closed tympanomastoidectomy|In this group it will be performed the standard technique for closed tympanomastoidectomy, in which a surgical microscope is used.
62177477|NCT03294421|EXPERIMENTAL|combined access tympanomastoidectomy|In this group a closed tympanomastoidectomy with combined access will be performed. This technique combines the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation.
62177478|NCT03556540|PLACEBO_COMPARATOR|Control|The volunteers without performing exercise during hemodialysis. Autonomic heart rate modulation, quality of life, physical fitness and safety level of exercise will be evaluated.
62177479|NCT03556540|EXPERIMENTAL|Experimental|The volunteers will perform physical exercise during hemodialysis. Autonomic heart rate modulation, quality of life, physical fitness and safety level of exercise will be evaluated.
62177480|NCT05436106|EXPERIMENTAL|intervention educational content|The base intervention design will contain educational content informed by the Transgender Resilience Intervention Model (TRIM) and adapted from Seeking Safety specific to a) identifying symptoms of psychological distress, b) managing symptoms via coping (individual resilience), and c) developing a social network and using social support/community connection (group resilience).
62177481|NCT02269683|EXPERIMENTAL|Robot-assisted|Distal pancreatectomy via robot-assisted minimally-invasive approach
62177482|NCT02269683|ACTIVE_COMPARATOR|Laparoscopic|Distal pancreatectomy via a conventional laparoscopic approach
62177483|NCT03184597|EXPERIMENTAL|Group with two strong risk factors|When HLA screening before commencing aromatic AEDs shows positive for both HLA-A\*24:02 and HLA-B\*15:02 in a patient, aromatic AEDs were not administrated for this patient.
62177484|NCT03184597|EXPERIMENTAL|Group with one strong risk factors|"When HLA screening before commencing aromatic AEDs shows positive for HLA-B\*15:02, carbamazepine (CBZ) was not administrated, and other aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead.~When HLA screening before commencing aromatic AEDs shows positive for HLA-B\*15:01 or HLA-A\*24:02, aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead."
62177485|NCT03184597|EXPERIMENTAL|Group with one potential risk factors|When HLA screening before commencing aromatic AEDs shows positive for any potential risk allele such as HLA-B\*15:11, HLA-A\*02:01and HLA-DRB1\*01:01, aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead.
62177486|NCT03184597|EXPERIMENTAL|Group without known risk factors|When HLA screening before commencing aromatic AEDs shows negative for any known HLA risk allele , aromatic AEDs was administrated to these patients.
62177487|NCT00506922|EXPERIMENTAL|No Pentostatin|Group 1: No Pentostatin
62177488|NCT00506922|EXPERIMENTAL|Pentostatin 0.5|Group 2: Pentostatin 0.5 mg/m\^2
62177489|NCT00506922|EXPERIMENTAL|Pentostatin 1|Group 3: Pentostatin 1 mg/m\^2
62177490|NCT00506922|EXPERIMENTAL|Pentostatin 1.5|Group 4: Pentostatin 1.5 mg/m\^2
62177491|NCT00506922|EXPERIMENTAL|Pentostatin 2|Group 5: Pentostatin 2 mg/m\^2
62177492|NCT04737005|OTHER|Nano-ceramic hybrid (Grandio Blocs) Endo-crown.|Nano-ceramic hybrid ( intervention)
62177493|NCT04737005|ACTIVE_COMPARATOR|Lithium di-silicate Ceramic (E.max CAD blocks) Endo-crown|Lithium di-silicate Ceramic ( Control)
62177494|NCT00443677|ACTIVE_COMPARATOR|abvd|
62177495|NCT00443677|EXPERIMENTAL|beacopp|
62177496|NCT00443677|EXPERIMENTAL|coppebvcad|
62177497|NCT05498454|ACTIVE_COMPARATOR|Breathworks Mindfulness for Health|an 8-week, online, protocol based mindfulness course designed to manage chronic pain and chronic health conditions
62177498|NCT05498454|ACTIVE_COMPARATOR|Breathworks Mindfulness for Stress|an 8-week, online, protocol based mindfulness course designed to manage stress
62177499|NCT05498454|NO_INTERVENTION|Waiting list|The Waiting list will be for the whole sample of participants (acting as a waiting list control). From this, participants will be randomly allocated to one of the Arms above
62177500|NCT04049240|ACTIVE_COMPARATOR|Active Comparator: 18<BMI<30 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
62177501|NCT04049240|ACTIVE_COMPARATOR|Active Comparator: 30≤BMI<35 kg/m2 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
62177502|NCT04049240|ACTIVE_COMPARATOR|Active Comparator: BMI≥35 kg/m2 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
62177503|NCT04049240|ACTIVE_COMPARATOR|Experimental: 18<BMI<30 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
62177504|NCT04049240|ACTIVE_COMPARATOR|Experimental: 30≤BMI<35 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
62177505|NCT04049240|ACTIVE_COMPARATOR|Experimental: BMI≥35 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
62177506|NCT06640491|EXPERIMENTAL|Intraosseous Administration of Vancomycin and Cefazolin|Intraosseous vancomycin plus cefazolin is administered via an intraosseous cannulation device (Arrow EZ-IO; Teleflex, Morrisville, NC) in the OR after sterile prep of the leg and draping has occurred prior to skin incision and after the tourniquet has been inflated. The injection will take place into the tibial tubercle, which is a known safe IO injection site. The IO injection will include 500mg of vancomycin and a 1g dose of cefazolin, previously used in prior IO studies of cefazolin.
62177507|NCT06640491|ACTIVE_COMPARATOR|Standard IV Administration of Vancomycin and Cefazolin|Patients will receive the Houston Methodist Hospital orthopedic surgery standard of care pre-operative antibiotic regimen for primary total knee arthroplasty patients. This includes IV antibiotics cefazolin will be started in the pre-operative period approximately 1 hour prior to incision. The cefazolin dose is generally 2g if patient is under 120kg, and 3g is the patient is above 120kg in line with guidelines. Vancomycin IV administration will be dosing will be weight-based at approximately 15mg/kg generally 1000-1750mg in 500mL NS.
62177508|NCT05729945|EXPERIMENTAL|Home Visiting Group|The home visiting group receives the program interventions which comprises home visits.
62177509|NCT05729945|NO_INTERVENTION|Business as Usual Group|The control group is business as usual and does not receive the program intervention.
62177510|NCT02603861|PLACEBO_COMPARATOR|Placebo|Placebo matching LY3154207 administered once orally in one of four periods.
62177511|NCT02603861|EXPERIMENTAL|LY3154207 - Dose 1|LY3154207 administered orally in no more than one of the four periods.
62177512|NCT02603861|EXPERIMENTAL|LY3154207 - Dose 2|LY3154207 administered orally in no more than one of the four periods.
62177513|NCT02603861|EXPERIMENTAL|LY3154207 - Dose 3|LY3154207 administered orally in no more than one of the four periods.
62177514|NCT02603861|ACTIVE_COMPARATOR|Modafinil|200 mg modafinil administered orally in no more than one of the four periods.
62177515|NCT00857298|ACTIVE_COMPARATOR|HIV-MS|HIV-positive obese women with metabolic syndrome will be studied before and after losing 6-8% of body weight
62177516|NCT00857298|ACTIVE_COMPARATOR|MS only|HIV-negative obese women with metabolic syndrome will be studied before and after losing 6-8% of body weight
62177517|NCT04316520|EXPERIMENTAL|Ketogenic diet|Ketogenic diet + standard of care
62177518|NCT04318314||Healthy and asymptomatic healthcare workers|Healthy and asymptomatic healthcare workers
62177519|NCT03426553|EXPERIMENTAL|Riboflavin+UV RBC|35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology
62177520|NCT03426553|ACTIVE_COMPARATOR|irradiated RBC|35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension
62177521|NCT05959161||improvement and no improvement|We observed whether the symptoms of patients improved after DBS surgery and divided them into groups.
62177522|NCT05959161||imp+ and imp-|
62177523|NCT04938934|EXPERIMENTAL|Aversive conditioning|
62177524|NCT04938934|SHAM_COMPARATOR|Sham conditioning|
62742314|NCT04377321||group 2 on glucophage 1 gm twice daily|second group received glucophage 1gm twice daily for 6 months
62177525|NCT02151071|OTHER|Breast conserving surgery|Females ≥ 30 years of age with a diagnosis of invasive breast cancer or ductal carcinoma in situ (DCIS), scheduled for BCS +/- SLNB or ALND
62177526|NCT02787759|ACTIVE_COMPARATOR|Hands-Free Walking|Body-weight supported treadmill training
62177527|NCT02787759|EXPERIMENTAL|Challenge Based plus Hands-Free|9 different balance and locomotor challenges applied during walking while not holding onto anything
62177528|NCT02158247||Conventional group, Touch and Read group|
62177529|NCT03803553|EXPERIMENTAL|ctDNA-POSITIVE: FOLFIRI Protocol|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance~- ctDNA-POSITIVE: FOLFIRI Protocol~* FOLFIRI chemotherapy via intravenous infusion on days 1-3 of each cycle. Cycle is 14 days long. This will occur for up to 12 cycles (24 weeks).~* infusions will consist of the drugs~* 5-Fluorouracil~* Irinotecan~* Leucovorin"
62177530|NCT03803553|ACTIVE_COMPARATOR|ctDNA-POSITIVE: ACTIVE SURVEILLANCE|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance~-- Active surveillance.~* Observation and monitoring with imaging (every 3 months), tumor markers, and ctDNA draws every 1 month for the initial 6 months.~* After 6 months, followed with ctDNA, tumor markers, and scans every 3 months for the first 3 years and every 6 months thereafter.~Additional scans and tumor markers will be at the discretion of the clinician. ."
62177531|NCT03803553|ACTIVE_COMPARATOR|ctDNA-NEGATIVE: ACTIVE SURVEILLANCE|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance~- Observation and monitoring with imaging, tumor markers, and ctDNA collections every 3 months for the first 3 years and every 6 months thereafter.~Additional scans and tumor markers will be at the discretion of the clinician"
62742315|NCT04377321||group 3 control|the third group patients were on diet only for 6 months
62742316|NCT06660680|EXPERIMENTAL|Study Group|received MBI treatment to their surgical incisions upon completion of surgery
62742317|NCT06660680|NO_INTERVENTION|Control group|administered lornoxicam on an as-needed basis for analgesia.
62742318|NCT00623233|EXPERIMENTAL|Gemcitabine + Bevacizumab|"Gemcitabine 2500 milligrams per square meter (mg/m\^2) intravenous (IV) over 30 minutes given on Day 1 every 14 days (q 14 days) until disease progression (PD) or unacceptable toxicity.~Bevacizumab 10 milligrams per kilogram (mg/kg) initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity."
62177532|NCT03803553|EXPERIMENTAL|ctDNA-POSITIVE MSI-H: NIVOLUMAB|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests.~If these tests show that the participant is eligible to participate in the research study and is ctDNA positive and MSI-H, the participant will not be randomized and will be placed into the group: ctDNA positive, MSI-H: Nivolumab~-ctDNA-Positive, MSI-H: Nivolumab Protocol~* Nivolumab treatment via intravenous infusion on day 1 of each cycle. Cycle is 28 days long. This will occur for up to 12 cycles (48 weeks).~* infusions will consist of the drug Nivolumab"
62177533|NCT03803553|EXPERIMENTAL|ctDNA-POSITIVE BRAF Mutant: ENCORAFENIB/BINIMETINIB/CETUXIMAB|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests.~If these tests show that the participant is eligible to participate in the research study and is ctDNA positive and has a BRAF mutation, the participant will not be randomized and will be placed into the group: ctDNA positive, BRAF mutant: Encorafenib/Binimetinib/Cetuximab~-ctDNA-Positive, MSI-H: Encorafenib/Binimetinib/Cetuximab Protocol~* Encorafenib/Binimetinib treatment is received orally every day and Cetuximab via intravenous infusion on day 1 of each cycle. Cycle is 14 days long. This will occur for up to 12 cycles (24 weeks).~* infusions will consist of the drug Cetuximab"
62177534|NCT03803553|EXPERIMENTAL|6 Months Additional Trastuzumab and Pertuzumab|Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. Participants that are eligible to receive Trastuzumab and Pertuzumab will be placed in this HER2 cohort: ctDNA-positive \& HER2 amplification and MSS Trastuzumab and Pertuzumab. Trastuzumab is received via intravenous administration, and Pertuzumab treatment is received intravenously by infusion. Cycle is 21 days. This will occur for up to 8 cycles.
62177535|NCT02639078|EXPERIMENTAL|TD-0714|One time dosing in capsule formulation
62177536|NCT02639078|PLACEBO_COMPARATOR|Placebo|Placebo comparator one time dosing in capsule formulation
62177537|NCT02648113|EXPERIMENTAL|Restrictive transfusion strategy|Transfusions are withheld unless Hb is \<= 8 g/dL, with a target Hb of 8 to 10 g /dL
62177538|NCT02648113|EXPERIMENTAL|Liberal transfusion strategy|Transfusions are allowed as soon as Hb \<= 10 g/dL with a target of 11 g /dL.
62177539|NCT03228953|EXPERIMENTAL|Pharmacogenomic-guided therapy group|In this group, results of pharmacogenomic testing will be provided to the treating physician within 2-5 working days. Thus, the patient's treatment provider will be able begin antidepressant adjustments based on pharmacogenomic testing report within a week of the baseline visit.
62177540|NCT03228953|NO_INTERVENTION|Treatment as usual (TAU) group|For patients randomized to this group, medication treatment decisions by the treating clinicians will be made without the availability of the pharmacogenomic report; however, the test results will be provided after the study completion to the patient treating physician.
62177541|NCT05077241|EXPERIMENTAL|Experimental group - inspiratory muscle training group with load|Experimental group: Inspiratory muscle training with POWERbreathe® (POWERbreathe®, HaB Ltd, Southam, UK) with 30% of Pimax. with weekly load increment of 10% of the Pimax value. initial. The sessions will consist of 30 repetitions, twice a day, one in the morning and one in the afternoon, 7 consecutive days a week, for 6 weeks. Individuals will be instructed to perform a rapid contraction of the inspiratory muscles and sustain it for 2 seconds in each maneuver, and will have the possibility to rest every 3 repetitions of the TMI, for 30 seconds, to avoid muscle fatigue or any other complication.
62177542|NCT05077241|PLACEBO_COMPARATOR|Control group - inspiratory muscle training group without load|Subjects will use a IMT POWERbreathe® (POWERbreathe®, HaB Ltd, Southam, UK) device without any load and will receive the same guidelines as experimental group (The sessions will consist of 30 repetitions, twice a day, one in the morning and one in the afternoon, 7 consecutive days a week, for 6 weeks. Individuals will be instructed to perform a rapid contraction of the inspiratory muscles and sustain it for 2 seconds in each maneuver, and will have the possibility to rest every 3 repetitions of the TMI, for 30 seconds, to avoid muscle fatigue or any other complication). At the end of the research, the control group will have the right to experimental treatment with the IMT protocol, if this is effective.
62177543|NCT02036255|EXPERIMENTAL|Taurolidine Urokinase|Taurolock Urokinase is used weekly in this arm substituting the classic Taurolock HEP500
62177544|NCT02036255|ACTIVE_COMPARATOR|Taurolidine Heparin|Taurolock HEP 500 is used as locking solution after each dialysis session
62177545|NCT02046941|EXPERIMENTAL|Speech Production Treatment|This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction. The investigators chose this treatment for the following reasons: 1) rigor of development demonstrated across multiple studies, 2) large and predictable effects with published, quantified effect sizes, 3) a demonstrated pattern of generalization to untrained items, illustrating experimental control, 4) an established multi-modal stimulation protocol, and 5) use of repeated practice, which is associated with neural plasticity.
62177546|NCT03084198|ACTIVE_COMPARATOR|Control group|Standard care for ALF
62177547|NCT03084198|EXPERIMENTAL|Experimental group|Continuous treatment with the hiHep bioartificial liver support system.
62177548|NCT00887380|ACTIVE_COMPARATOR|Arm A: Concurrent|Investigational treatment: Anastrozole commenced before (Pre-radiotherapy commencement of anastrozole) and continued during radiotherapy.
62742319|NCT06071663|ACTIVE_COMPARATOR|single visit|Necrotic primary molar treated in single visit
62742320|NCT06071663|ACTIVE_COMPARATOR|Two visits|Necrotic primary molar treated in two visits
62742321|NCT06493786|OTHER|Malignant melanoma (MM)|"For each group of patients (MM, CBC\*, CE), the chromatographic profiles of cutaneous VOCs (nature of molecules and content) will be described and compared as follows:~healthy areas (excluding contralateral areas) versus healthy areas of matched healthy subjects, by area and overall.~\* For the BCC group, the same analyses will be performed for the 3 BCC categories: superficial BCC, nodular BCC, infiltrating BCC."
62742322|NCT06493786|OTHER|Basocellular carcinoma (BCC)|"For each group of patients (MM, CBC\*, CE), the chromatographic profiles of cutaneous VOCs (nature of molecules and content) will be described and compared as follows:~healthy areas (excluding contralateral areas) versus healthy areas of matched healthy subjects, by area and overall.~\* For the BCC group, the same analyses will be performed for the 3 BCC categories: superficial BCC, nodular BCC, infiltrating BCC."
62177549|NCT00887380|ACTIVE_COMPARATOR|Arm B: Sequential|Standard Treatment: Anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy (Post radiotherapy commencement of anastrozole)
62177550|NCT00192322|EXPERIMENTAL|CAIV-T 10^5|a single intranasal 0.2 mL dose of liquid CAIV-T 10\^5 (approximately 0.1 mL into each nostril)
62177551|NCT00192322|EXPERIMENTAL|CAIVT 10^7|A single intranasal 0.2 mL dose of liquid CAIV-T 10\^7 (approximately 0.1 mL into each nostril)
62177552|NCT00192322|PLACEBO_COMPARATOR|Placebo|A single intranasal 0.2 mL dose of placebo
62177553|NCT00192322|ACTIVE_COMPARATOR|Trivalent inactivated vaccine (TIV)|A single intramuscular injection of commercially available vaccine
62177554|NCT00088452|ACTIVE_COMPARATOR|Ethosuximide|"Ethosuximide~Frequency and Duration: twice a day, every day for the duration of the study treatment~Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight and ability to swallow): 250mg Zarontin capsules OR 250 mg/5 mL Zarontin syrup~Dosing: Ethosuximide was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 2000 mg/day (whichever was lower)"
62177555|NCT00088452|ACTIVE_COMPARATOR|Lamotrigine|"Lamotrigine~Frequency and Duration: twice a day, every day for the duration of the study treatment~Formulation: Three formulations were used (actual formulation used was dependent on the patient's weight): 5mg Lamictal chewable tablets OR 25 mg Lamictal chewable tablets OR 25 mg (Lamictal tablets~Dosing: Lamotrigine was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 12 mg/kg/day or 600 mg/day (whichever was lower)."
62177556|NCT00088452|ACTIVE_COMPARATOR|Valproic acid|"Valproic acid~Frequency and Duration: twice a day, every day for the duration of the study treatment~Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight): 250mg Depakote capsules OR 125mg Depakote sprinkles.~Dosing: Depakote was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 3000 mg/day (whichever was lower)"
62742323|NCT06493786|OTHER|Epidermoid carcinoma (EC)|"For each group of patients (MM, CBC\*, CE), the chromatographic profiles of cutaneous VOCs (nature of molecules and content) will be described and compared as follows:~healthy areas (excluding contralateral areas) versus healthy areas of matched healthy subjects, by area and overall.~\* For the BCC group, the same analyses will be performed for the 3 BCC categories: superficial BCC, nodular BCC, infiltrating BCC."
62742324|NCT06493786|OTHER|Healthy volunteers|"For each group of patients (MM, CBC\*, CE), the chromatographic profiles of cutaneous VOCs (nature of molecules and content) will be described and compared as follows:~healthy areas (excluding contralateral areas) versus healthy areas of matched healthy subjects, by area and overall.~\* For the BCC group, the same analyses will be performed for the 3 BCC categories: superficial BCC, nodular BCC, infiltrating BCC."
62177557|NCT02396953|EXPERIMENTAL|lanreotide PRF|One single dose of lanreotide PRF (via subcutaneous injection) either 180mg or 270mg or 360mg.
62177558|NCT00695136|EXPERIMENTAL|Open label single arm|Single group study of Donepezil
62177559|NCT04219917|EXPERIMENTAL|Hip|Gluteus medius facilitation tape
62177560|NCT04219917|EXPERIMENTAL|Knee|Patellar sling tape
62177561|NCT04219917|EXPERIMENTAL|Hip and Knee|Gluteus medius facilitation and patellar sling tape
62177562|NCT05511558|EXPERIMENTAL|Dosing Group|All 8 subjects will receive a single dose of study drug
62177563|NCT00347737|EXPERIMENTAL|1|Teriparatide
62177564|NCT03807700|EXPERIMENTAL|Experimental denture adhesive|In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
62177565|NCT03807700|NO_INTERVENTION|No adhesive|In this arm, participants will not use any denture adhesive.
62177566|NCT00887185|ACTIVE_COMPARATOR|1 - Traditional training|Temporal bone dissection training in cadaveric laboratory. Subjects are provided 2 cadaveric temporal bones and asked to spend 2 weeks practicing the surgical technique of complete mastoidectomy with facial recess approach.
62177567|NCT00887185|EXPERIMENTAL|2 Simulator training|Subjects perform temporal bone surgical dissection training on a simulator.
62177568|NCT00913783|EXPERIMENTAL|1|Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)
62177569|NCT00913783|ACTIVE_COMPARATOR|2|Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)
62177570|NCT01027663|NO_INTERVENTION|Iron Deficiency Anemia|
62177571|NCT01027663|NO_INTERVENTION|Hereditary Hemochromatosis|
62177572|NCT01027663|ACTIVE_COMPARATOR|Iron Supplements|
62177573|NCT01486511||Liver resection patients|All patients that underwent elective liver resection for both malignant and benign diseases.
62177574|NCT00498433|EXPERIMENTAL|Aliskiren|"Part 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase (period 1) consisting of treatment with one tablet of placebo to aliskiren once daily (o.d.). This was followed by a 4 week treatment phase (period 2) consisting of treatment with 300 mg aliskiren o.d..~Part 2: Eligible randomized patients in this arm received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks."
62391473|NCT02249858||Control Group: Cranial Vault Protocol Group|Cranial vault protocol group will receive cranial vault hold.
62177575|NCT00498433|ACTIVE_COMPARATOR|Amlodipine|"Part 1: After aliskiren treatment (period 2), each patient was entered into a second washout period (4 weeks) during which blood pressure was required to be ≤ 140/90 mmHg. If blood pressure exceeded 140/90 mmHg on two consecutive days (home monitoring) and was confirmed at the study center, the patient was entered into the amlodipine treatment period (period 3). In period 3, all patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks.~Part 2: Eligible patients randomized to part 2 received amlodipine 5 mg o.d. and aliskiren placebo for 12 weeks"
62177576|NCT02868619|OTHER|Healthy controls|Non obese adolescents without Binge Eating Disorder (BED)
62177577|NCT02868619|OTHER|Patients with BED|Obese adolescents with BED with Binge Eating Disorder (BED)
62177578|NCT01202409|EXPERIMENTAL|Panitumumab|Starting Dose of Panitumumab: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
62177579|NCT03290222||TRACK|Children will be followed for four weeks (3 to 5 weeks) after the inclusion in the study. Parents will complete the TRACK questionnaire in both visit and will answer additional questions about respiratory symptoms and use of medication.
62177580|NCT04826497|EXPERIMENTAL|Nicorandil|Patients who received intracoronary and intravenous nicorandil before and after reperfusion with primary percutaneous coronary intervention
62177581|NCT04826497|PLACEBO_COMPARATOR|Placebo （normal saline）|Patients who received intracoronary and intravenous placebo before and after reperfusion with primary percutaneous coronary intervention
62177582|NCT05643443|NO_INTERVENTION|Control Group|Control Group
62177583|NCT05643443|EXPERIMENTAL|Active Group|Active Group
62177584|NCT03497780||ACL Tear|Patients with ACL tears
62177585|NCT03497780||Healthy Subjects|Healthy subjects
62177586|NCT03927222|EXPERIMENTAL|DC vaccination with Td preconditioning and GM CSF|This single-arm phase II study will assess the impact of tetanus pre-conditioning and adjuvant GM-CSF on overall survival of newly diagnosed glioblastoma (GBM) patients who have undergone definitive resection, are unmethylated, and completed standard temozolomide and radiation treatment. All enrolled patients will undergo a leukapheresis for the generation of DCs. Patients will then receive approximately 6 weeks of standard of care radiation therapy (RT) and concurrent TMZ. A single post-RT cycle of dose intensified TMZ (100 mg/m2/day for 21 days) will then be given. On day 23 (± 2 days) of the cycle, patients will receive the first of 3 pp65 DC vaccines every 2 weeks. All patients will receive up to a total of 10 DC vaccines
62177587|NCT00735462|EXPERIMENTAL|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks
62177588|NCT00735462|EXPERIMENTAL|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
62177589|NCT00735462|PLACEBO_COMPARATOR|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks.
62177590|NCT04228900|EXPERIMENTAL|Intervention group|Drug review and tailored nutritional supply.
62177591|NCT04228900|NO_INTERVENTION|Control group|"Follow-up by home nurse service and family physician as usual."
62742325|NCT06232980|ACTIVE_COMPARATOR|Anesthesia induction group guided by BIS in geriatric patients.|The BIS index will be evaluated every 30 seconds. The initial dose and infusion rate will be applied as 1.5 mg/kg and 100 mg/min, respectively. In the BIS group, the target index is set between 40-60, and additional doses of 20 mg will be planned every 30 seconds until reaching this target index.
62742326|NCT06232980|ACTIVE_COMPARATOR|Observer's Alertness/Sedation Score-guided induction group in geriatric patients.|The initial dose will be applied as 1.5 mg/kg, and the infusion rate will be 100 mg/min. An additional 20 mg of propofol will be administered every 30 seconds until the Observer's Assessment of Alertness/Sedation (OAA/S) score reaches 1.
61997489|NCT02273219|EXPERIMENTAL|Dose 5: AEB071 and BYL719|AEB071, oral, 300 mg twice daily BYL719, oral, 350 mg daily
62177592|NCT05243537||QTc time interval in former preterm neonates, or term born healthy controls|former preterms and healthy term controls are defined as described in the cohort as previously published (Salaets et al, Pediatr Res 2021; Gervais et al, Pediatr Res 2020; Bassareo et al, J Matern Fetal Neonatal Med 2011). This includes both the perinatal characteristics as well as the characteristics collected at assessment (pediatric age or young adulthood) In all cases, an ECG was collected at rest, and these individual values (preterm or healthy term controls will be pooled.
62177593|NCT04342988|OTHER|Cequa Treatment In Cataract Patients with Dry Eye Disease|Duration of Study Treatment - 4 weeks All patients will receive cyclosporine ophthalmic solution (0.09%) BID in both eyes for 28 days, 1 drop per dose. Dosing will be BID, both eyes, assuming both eyes will eventually undergo cataract surgery. Otherwise, single eye treatment in the operative eye will be permitted.
62177594|NCT05475496||Elderly cardiac patients with multimorbidity and their caregivers|"elderly patients (60 years and over) \[2\] with multimorbid conditions and a cardiovascular disease is one of them .~caregivers of elderly patients included in the study"
62177595|NCT06591767|EXPERIMENTAL|Quercetin group|In this group hyperuricemic patients (uric acid \> 8 mg/dL) received oral supplemental Quercetin, twice a day for 90 days.
62177596|NCT06591767|ACTIVE_COMPARATOR|Control group 1|In this group hyperuricemic patients (uric acid \> 8 mg/dL) received oral supplemental Berberine and monacolins based supplement, twice a day for 90 days.
62177597|NCT06591767|ACTIVE_COMPARATOR|Control group 2|In this group normouricemic patients (uric acid \< 7 mg/dL) received oral supplemental Berberine and monacolins based supplement, twice a day for 90 days.
62177598|NCT01355822|PLACEBO_COMPARATOR|Placebo|
62177599|NCT01355822|EXPERIMENTAL|PETN|Pentalong, Actavis Germay: 80 mg twice a day
62177600|NCT02949076|EXPERIMENTAL|Exercise|Lung cancer patients will undergo unilateral resistance exercise 3 times per week for 8 weeks during cancer treatment, while the other leg remains unexercised and will serve as a within-subject control.
62391474|NCT02249858||Experimental Group: HVLA Protocol Group|HVLA protocol group will receive cervical HVLA to the key somatic dysfunction C2-C7 segment.
62177601|NCT06210399|EXPERIMENTAL|Extracorporeal Shockwave Therapy|The parameters for shock wave therapy will be: frequency 4-6 Hz, intensity 0.075-0.11 mJ/mm2 (millijoules per millimeter), number of pulses 350+10xcm2 (square centimetre) of wound surface (the number of pulsations is dependent of the surface), with sterile field (sterile gel on the wound and sterile transparent film to cover it). They will be applied by sweeping the surface of the wound and 1 centimetre around it. In each session, the session-specific data notebook and the appearance of side effects (pain, bleeding, others) will be recorded. Subsequently, the conventional healing procedure will be applied, according to the procedures for healing chronic wounds of the Guadarrama Hospital.
62177602|NCT03010345|EXPERIMENTAL|Osmed self inflating tissue expanders|All patients will undergo a two-stage procedure ,second stage under General endotracheal anesthesia. The first stage will be placement of the expanders. The second stage will be 21 days later, with removal of the expanders, palatal revision, and closure of the oronasal fistula
62177603|NCT03010345|EXPERIMENTAL|Iliac bone graft|Placement of bone graft without the use of self inflating expanders
62177604|NCT02001077|ACTIVE_COMPARATOR|CBT-I|Participants will complete 8 weekly therapy sessions focused on improving sleep. A multicomponent CBT-I (Cognitive Behavioral Therapy for Insomnia) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, and cognitive restructuring.
62177605|NCT02001077|ACTIVE_COMPARATOR|CBT-P|Participants will complete 8 weekly therapy sessions focused on improving pain. A multicomponent CBT-P (Cognitive Behavioral Therapy for Pain) protocol will involve: pain education, relaxation, activity pacing, and cognitive restructuring.
62177606|NCT02001077|NO_INTERVENTION|Waitlist Control (WLC)|Participants in the WLC group will not receive any treatment between the baseline and post-treatment assessments. After the final follow-up assessment, they will be offered the opportunity to receive therapy which combines aspects of both CBT-I and CBT-P.
62177607|NCT04550286|EXPERIMENTAL|Intervention Group|"Intervention points in time include:~1. Baseline measure~2. Installation of the study app~3. Advice on general enhancements regarding study environment and behavior (BCT 4.1)~4. Students are to develop up to three action plans (BCT 1.4) and coping plans (BCT 1.2) to reduce smartphone interference during exam preparation periods by putting the smartphone away~5. Students receive weekly questionnaire (t1-t3) and one questionnaire after their first exam (t4). All these questionnaires concern their academic performance and well-being. A short questionnaire (t5) asks for the participants' exam grades approx. 2 months after their exam. A time period of 2 months has been chosen to ensure that universities have enough time to announce the grades.~6. During the whole period of the study, the mobile application tracks the students' smartphone behavior (i.e., daily smartphone use, daily screen activations, and specific app usage)."
62177608|NCT04550286|ACTIVE_COMPARATOR|Control Group|Control points in time include all parts except for number 4. Here students in the control group will receive questionnaires on general health behavior in order to achieve an equal questionnaire completion time compared to the intervention group.
62177609|NCT04825834||Individuals eligible for Lung Cancer screening with Lung Cancer diagnosis|
62177610|NCT04825834||Individuals eligible for Lung Cancer screening with no cancer diagnosis|
62177611|NCT04825834||Individuals eligible for Lung Cancer screening with Non-Lung Cancer diagnosis|
62177612|NCT02554552|EXPERIMENTAL|YY1201 2ml|YY1201 2ml
62177613|NCT02554552|EXPERIMENTAL|YY1201 3ml|YY1201 3ml
62177614|NCT02554552|PLACEBO_COMPARATOR|Placebo 2ml|Phosphate buffered saline 2ml
62177615|NCT02554552|PLACEBO_COMPARATOR|Placebo 3ml|Phosphate buffered saline 3ml
62177616|NCT00797511|EXPERIMENTAL|Study Group|Participants will receive one dose of Tetanus, diphtheria (reduced antigen content), pertussis (acellular components) vaccine (TdcP-IPV, ADACEL Polio) on Day 0
62177617|NCT04817033|ACTIVE_COMPARATOR|High risk OSA Dexmedetomidine|High risk OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
62177618|NCT04817033|ACTIVE_COMPARATOR|High risk OSA Midazolam|High risk OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
62742327|NCT00042952|EXPERIMENTAL|Treatment (imatinib mesylate and surgical resection)|Patients receive oral imatinib mesylate once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients who achieve a partial response or stable disease with normalization of human chorionic gonadotropin may undergo surgical resection of residual lesions at each tumor status assessment. If residual viable germ cell tumor is present in the resected specimen, patients may resume imatinib mesylate. If no viable germ cell tumor is present in the resected specimen, then no further therapy is administered.
62742328|NCT01813058|PLACEBO_COMPARATOR|Placebo|Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery.
62177619|NCT04817033|ACTIVE_COMPARATOR|Low&Medium OSA Dexmedetomidine|Low\&Medium OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
62177620|NCT04817033|ACTIVE_COMPARATOR|Low&Medium OSA Midazolam|Low\&Medium OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
62177621|NCT02222337|ACTIVE_COMPARATOR|Nueva Vida Intervention|Nueva Vida Intervention consists of 8 sessions of a skills-building group held twice a month for 4 months. Latina survivors and their caregivers arrive at the group together, separate into different rooms to learn the coping and communication skills, and then join together for discussion of the topic.
62177622|NCT02222337|NO_INTERVENTION|Usual Care|Usual care as provided by each of our 4 community-based organization partners. Usual care can include but is not limited to support groups, patient navigation, individual, couple or family therapy.
62177623|NCT06276101|EXPERIMENTAL|NWRD08 administered by electroporation|Patients will be assigned to three dose groups:1mg, 4mg, and 8mg. Each patient will be administered NWRD08 by electroporation in entire study period. The Maximum Tolerated Dose of NWRD08 will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
62177624|NCT04150341|EXPERIMENTAL|TD-8236 Dose A (low dose)|TD-8236 Dose A (QD x 14 days)
62177625|NCT04150341|EXPERIMENTAL|TD-8236 Dose B (high dose)|TD-8236 Dose B (QD x 14 days)
62177626|NCT04150341|PLACEBO_COMPARATOR|Placebo|Placebo (QD x 14 days)
62177627|NCT02913170|EXPERIMENTAL|Nattokinase group|A nattokinase group composed of 50 individuals who consumed a 300mg nattokinase capsule (100mg of nattokinase and 200mg of maltodextrin) daily after meal.
62177628|NCT02913170|PLACEBO_COMPARATOR|Placebo group|A placebo group composed of 50 individuals who consumed a 300mg placebo capsule (300mg of maltodextrin) daily after meal.
62177629|NCT01673100|EXPERIMENTAL|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. These messages will be tips to help them engage in physical activity and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
62177630|NCT01673100|NO_INTERVENTION|Atttention Control|Subjects in the attention control group will receive only general health messages on their study cell phone (not physical activity promoting messages). They also will receive any usual post-PCI procedure care that all get.
62177631|NCT06298968|EXPERIMENTAL|Combined therapy using GC, Lenvatinib and Adebrelimab|GC chemotherapy every 3 weeks,with a total of 6 cycles. Lenvatinib 8 mg once daily (QD) oral dosing. Adebrelimab 1200mg intravenously every 3 weeks.
62177632|NCT01559532||ATK patients|Patients from our institution that underwent cemented TKA for degenerative knee disorders.
62177633|NCT05687318|EXPERIMENTAL|Trial Ⅰ|Subjects underwent colonoscopy with the investigator's combined instrument, and then underwent traditional colonoscopy with the same investigator
62177634|NCT05687318|EXPERIMENTAL|Trial Ⅱ|Subjects underwent a traditional colonoscopy, followed by a colonoscopy with the same investigator's instrument
62177635|NCT01489098||Breast Fed reference group|3 and 5 year olds from the above group
62177636|NCT01489098||Infant formula - protein level 1|3 ad 5 year olds from the above group
62177637|NCT01489098||Infant formula - protein level 2|3 and 5 year olds from the above group
62177638|NCT03772613|ACTIVE_COMPARATOR|Low ACT Target|ACT target range of 225 to 275 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
62177639|NCT03772613|ACTIVE_COMPARATOR|Medium ACT Target|ACT target range of 275 to 325 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
62177640|NCT03772613|ACTIVE_COMPARATOR|High ACT Target|ACT target range of 325 to 375 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
62177641|NCT01473641||New users of Nexplanon|
62177642|NCT06114134|EXPERIMENTAL|Fenugreek extract|Participants in this group will receive fenugreek extract capsules (500 mg/day, three times a day, 30 minutes before each main meal) along with common treatments
62177643|NCT06114134|PLACEBO_COMPARATOR|Placebo|Participants in this group will receive starch with added color (similar to the color of fenugreek extract) capsules (with the same size and color of fenugreek) (500 mg/day, three times a day, 30 minutes before each main meal) along with common treatments
62177644|NCT01193062|EXPERIMENTAL|Cohort 1|Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
62177645|NCT01193062|EXPERIMENTAL|Cohort 2|Subjects will be receive single oral doses of PF-04995274 not exceeding 15mg or a placebo
62177646|NCT05867914|EXPERIMENTAL|Inhaled Nitric Oxide (iNO)|"eNOfit an Electric Nitric Oxide (NO) Ambulatory Production and Delivery System, Delivering Nitric Oxide for Inhalation~The treatment period with inhaled Nitric Oxide (iNO) will include start of iNO at a device setting of 2 mg/hr iNO for 2 hours (+15 minutes), device setting escalation to 6 mg/hr iNO for 2 hours (+15 minutes) and then weaning of iNO treatment"
62177647|NCT04252170|EXPERIMENTAL|Feasibility study, Stroke Survivors|BAC feasibility study at PowerBack, Piscataway NJ, with stroke patients.
62742329|NCT01813058|ACTIVE_COMPARATOR|Tranexamic acid|Tranexamic acid 100 mg/ml; 50 mg/kg loading dose = 0.5 ml/kg LD given over 15 minutes and 10 mg/kg/hr = 0.1 ml/kg/hr infusion for the duration of the surgery.
62177648|NCT04578899|ACTIVE_COMPARATOR|Transvertebral magnetic stimulation (Experimental group)|Experimental intervention will receive non-invasive transvertebral magnetic stimulation of the sacral spine roots (level S2-S3).
62742330|NCT00705250|EXPERIMENTAL|1|bendamustine hcl 120mg/m\^2
62177649|NCT04578899|PLACEBO_COMPARATOR|Transvertebral magnetic stimulation (Control group)|"Control group will receive an equivalent number of stimulation sessions using the placebo option."
62177650|NCT03188536||Multiple Myeloma (MM) Participants|Adult participants with a diagnosis of MM who received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
62177651|NCT02845310|EXPERIMENTAL|Restricted fluid therapy group|Patients will receive restricted fluid management guided by concomitant SVV monitoring. GDT protocol
62177652|NCT02845310|PLACEBO_COMPARATOR|Control group|Patients will receive standard fluid management.
62177653|NCT00402636|EXPERIMENTAL|1|rapamycin plus 17beta estradiolvalerat-eluting stent
62177654|NCT00402636|EXPERIMENTAL|2|rapamycin-eluting stent
62177655|NCT06348745|EXPERIMENTAL|chronic obstructive pulmonary disease (COPD)|ultrasound to COPD patients to asses' diaphragmatic function.
62177656|NCT06348745|EXPERIMENTAL|bronchial asthma|ultrasound to bronchial asthma patients to asses' diaphragmatic function.
62177657|NCT02589418|EXPERIMENTAL|Healthy subjects|All subjects participate at 3 experimental conditions (Acupuncture, Sham-Acupuncture and No Acupuncture) at 3 different days in a randomized order.
62177658|NCT03165578|EXPERIMENTAL|Neurofeedback|Neurofeedback training.
62177659|NCT03165578|SHAM_COMPARATOR|Sham Feedback|Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
62177660|NCT00035802|EXPERIMENTAL|001|"Topiramate Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.~OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months."
62742331|NCT03294044|EXPERIMENTAL|ICT programs|ICT programs that include health information learning by disease, and self-management based on Smart Management Strategy for Health (SMASH) are provided. After that, subjects will conduct self-management health care for 12 weeks. After 3 months, they finish self-management ICT programs, and then they fill out the questionnaire.
62177661|NCT00035802|PLACEBO_COMPARATOR|002|Placebo Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
62177662|NCT00814632|EXPERIMENTAL|Study Drug CC 10004|Study drug CC-10004 20mg taken orally twice a day.
62177663|NCT01512914|PLACEBO_COMPARATOR|CONTROL group|
62177664|NCT01512914|EXPERIMENTAL|PREOPERATIVE nebulization|
62177665|NCT01512914|EXPERIMENTAL|POSTOPERATIVE nebulization|
62177666|NCT01512914|ACTIVE_COMPARATOR|INSTILLATION group|
62177667|NCT04358614|ACTIVE_COMPARATOR|Case patients|Consecutive patients with COVID moderate pneumonia treated with baricitinib tablets 4 mg/day
62177668|NCT04358614|OTHER|Controls|Consecutive patients with COVID moderate pneumonia treated with standard therapy before the date of the first baricitinib-treated patient.
62177669|NCT06170229|ACTIVE_COMPARATOR|Education and High Intensity Interval Training (eHIIT)|1 educational session lasting 1 hour. 12 weeks of supervised High Intensity Interval Training (HIIT) 3 times/week.
62177670|NCT06170229|ACTIVE_COMPARATOR|Neuromuscular exercise and education program (NEMEX-e)|2 educational sessions lasting 1 hour each. 8 weeks of supervised Neuromuscular Exercise 2 times/week.
62177671|NCT06223841|EXPERIMENTAL|Phase Ib - Dose escalation|
62177672|NCT06223841|EXPERIMENTAL|Phase II - Clinical Exploratory Stage|
62177673|NCT01830764|OTHER|Red light dose (PDT) 75 J/cm2|Subjects in Cohort 1 will receive active and vehicle solution followed by a red light dose of 75 J/cm2 at 25 mW/cm2
62177674|NCT01830764|OTHER|Red Light (PDT) 150 J/cm2|Subjects in Cohort 2 will receive active and vehicle solution followed by a red light dose of 150 J/cm2 at 40 mW/cm2
62177675|NCT02038088||A|intravenous inhalational anesthesia
62177676|NCT02038088||B|intravenous anesthesia
62177677|NCT05266625|EXPERIMENTAL|Intervention BT-001 + Standard of Care|Patients in this arm will receive the BT-001 treatment for up to 720 days.
62742332|NCT03294044|ACTIVE_COMPARATOR|A book about chronic disease|Subjects in the group get a book about chronic disease for patients. After 3 months, they finish reading the materials, they fill out the questionnaire.
62742333|NCT06661148|EXPERIMENTAL|EPI-003 group|Part A：Single Ascending Dose； Part B：Dose Expansion
62742334|NCT01038479|ACTIVE_COMPARATOR|Childsmile programme with xylitol|Childsmile program with maternal xylitol consumption;
62177678|NCT05266625|OTHER|Standard of Care|Patients will have access to a control mobile application for 180 days and then will have the option to use the treatment for the remainder of the 720 day study
62177679|NCT05513950|EXPERIMENTAL|Test Treatment|A single intravenous (IV) dose of CHF10067
62177680|NCT05513950|PLACEBO_COMPARATOR|Reference treatment|A single dose of placebo (commercial source of 0.9% sodium chloride aqueous solution)
62742335|NCT01038479|PLACEBO_COMPARATOR|Childsmile programme only|Childsmile programme
62742336|NCT06657651|EXPERIMENTAL|immediate implant with dentin-derived membrane|
62742337|NCT06657651|EXPERIMENTAL|immediate implant with extended platelet rich fibrin membrane|
62742338|NCT00967694|EXPERIMENTAL|Nitrous oxide administration|All 20 healthy volunteers had their intraocular pressure (IOP) measured at baseline and then after 3, 6, 9, and 12 minutes of nitrous oxide administration, and then after 5, 10, and 15 minutes of breathing room air. There was therefore only one study arm, with each individual serving as their control for baseline and then intervention values of IOP measurement.
62742339|NCT05540340|EXPERIMENTAL|Cohort 1: Pharmacokinetic directed melphalan|This is a feasibility study of pharmacokinetic (PK)-directed Captisol Enabled (CE) melphalan dosing to target an AUC of 8.5 (+/- 1.5) using a population PK model in lymphoma patients receiving BEAM \[carmustine (BCNU) (B), etoposide (E), cytarabine (Ara-C) (A), and melphalan (M)\], followed by autologous hematopoietic cell transplantation (AHCT). This study will enroll patients with lymphoma planned for BEAM-AHCT. Carmustine IV will be given on day -6, followed by etoposide IV and cytarabine IV from day -5 to -2 as per the MSK inpatient or outpatient standard of care. The calculated melphalan dose based on population PK model to achieve the proposed melphalan target exposure \[8.5 (+/- 1.5) mg\*h/L\], will be administered on day -1, and six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan, for PK testing to determine if the goal AUC was achieved.
62177681|NCT05643313|EXPERIMENTAL|Treatment|Participants will then undergo a training programme with the ABLE Exoskeleton three to five times a week for up to 8 weeks for a total of 18 training sessions and 4 assessment sessions.
62177682|NCT02602795|EXPERIMENTAL|Distress Tolerance (DT)|Acceptance and Commitment Therapy based Distress Tolerance (DT) intervention to facilitate opioid detoxification delivered in six 50-minute individual telehealth sessions.
62177683|NCT02602795|ACTIVE_COMPARATOR|HIV/STI Intervention|Information Motivation Behavioral model based HIV/STI risk reduction intervention delivered in six 50-minute individual telehealth sessions.
62177684|NCT02602795|NO_INTERVENTION|Treatment As Usual (TAU)|Traditional treatment given to patients who elect to transition to XR-NTX at the treatment sites.
62177685|NCT05493098|EXPERIMENTAL|Experimental group|The experimental group will include 18 participants with episodic tension-type headache. The treatment will include dry needling of the suboccipital, levator scapula, upper trapezius, masseter, sternocleidomastoid, splenius capitis, and cervicis, frontalis, and temporalis muscles and routine physical therapy. The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes. In each session, three muscles from one side will be needled. Routine physical therapy will include information on nature, management, course of episodic tension-type headaches, and Multimodal care that includes craniocervical exercises and postural correction. The treatment will last two weeks, six sessions, three times a week.
62177686|NCT05493098|PLACEBO_COMPARATOR|Control group|"The control group will include 18 participants with episodic tension-type headache. The treatment will include sham dry needling of the suboccipital, levator scapula, upper trapezius, masseter, sternocleidomastoid, splenius capitis, and cervicis, frontalis and temporalis muscles and routine physical therapy. The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes. In each session, three muscles from one side will be needled. Routine physical therapy will include information on nature, management, course of episodic tension-type headaches, and Multimodal care that includes craniocervical exercises and postural correction. The treatment will last two weeks, six sessions, three times a week."
62177687|NCT00519714|PLACEBO_COMPARATOR|1|three placebo capsules PO three times daily.
62177688|NCT00519714|ACTIVE_COMPARATOR|2|1-MNA 90 mg daily: one active treatment capsule and two placebo capsules PO three times daily
62177689|NCT00519714|ACTIVE_COMPARATOR|3|1-MNA 270 mg daily: three active treatment capsules PO three times daily.
62177690|NCT04304313|EXPERIMENTAL|Sildenafil citrate tablets|
62177691|NCT05705336|ACTIVE_COMPARATOR|1. Tranexamic Acid Oral Product (n=30 cases)|Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision. The dose was administered by the nurse on duty who provided 100ml of water to swallow the pills.
62177692|NCT05705336|PLACEBO_COMPARATOR|2. Placebo (30 cases)|Nursery team would provide 100ml of water, and 3 tablets of placebo pills administered 2 hours prior to surgery.
62177693|NCT06088810|ACTIVE_COMPARATOR|Sleep Education Group|Participants in this group will receive sleep education.
62177694|NCT06088810|EXPERIMENTAL|CoMPoSER Intervention Group|Participants in this group will use a mobile application that plays calming music personalized for sleep enhancement.
62177695|NCT02028468|ACTIVE_COMPARATOR|Anterolateral Approach|Patient Operated with Watson Jones Approach
62177696|NCT02028468|ACTIVE_COMPARATOR|Trans-gluteal Approach|Patient operated with Trans-gluteal Hardinge Approach
62177697|NCT02456259||Neck cannula group|Patients in this group are indicated for neck cannula insertion due to tzpu of cardiac surgery (MICS)
62177698|NCT02456259||Central venous catheter only group|Patients in this group are indicated for central venous catheter insertion only.
62177699|NCT03694119|ACTIVE_COMPARATOR|Phenelzine|Following tyramine challenging in Period 1, eligible subjects randomly assigned to Phenelzine arm are receiving Phenelzine placebo BID plus ozanimod placebo QD from Days 11 to 31, then receiving Phenelzine 15mg BID plus ozanimod placebo QD from Days 32 to 38. Subjects receive second tyramine challenge from Day 39 to up to Day 49
62177700|NCT03694119|PLACEBO_COMPARATOR|Placebo|Following tyramine challenging in Period 1, eligible subjects randomly assigned to Placebo arm are receiving Phenelzine placebo BID plus ozanimod placebo QD from Days 11 to 38. Subjects receive second tyramine challenge from Day 39 to up to Day 49
62177701|NCT03694119|EXPERIMENTAL|ozanimod|Following tyramine challenging in Period 1, eligible subjects randomly assigned to ozanimod arm are receiving Phenelzine placebo BID plus ozanimod 1.84mg QD from Days 11 to 38, including dose escalation days. Subjects receive second tyramine challenge from Day 39 to up to Day 49
62742340|NCT05540340|EXPERIMENTAL|Cohort 2: Pharmacokinetic directed melphalan|In cohort 2, carmustine will be on Day -7, cytrabine and etoposide on Day -6 to Day -3, and melphalan (70mg/m2 /day IV) will be administered on day -2 followed by PK samples to determine the melphalan dose on day -1 using the population PK model. PK samples will be collected again after the dose on day -1 to confirm the total melphalan AUC of 8.5 (+/- 1.5) mg\*h/L. Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan, for PK testing. The first four time points are +/- 2 min and the last two time points are +/- 5 minutes.
62177702|NCT01121913|EXPERIMENTAL|Trazodone Contramid® OAD (test product 1)|Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)
62177703|NCT01121913|EXPERIMENTAL|Trazodone Contramid® OAD(test product 2)|Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)
62177704|NCT01121913|ACTIVE_COMPARATOR|Triticco®|
62177705|NCT01121913|ACTIVE_COMPARATOR|Desyrel®|
62177706|NCT00338988|EXPERIMENTAL|Capecitabine + Oxaliplatin|Combination of intravenous (IV) oxaliplatin 100 mg/m\^2 Day 1 and oral (PO) capecitabine 750 mg/m\^2 twice daily (total daily dose 1500 mg/m2) on Days 1-14.
62177707|NCT05321381|ACTIVE_COMPARATOR|RISE Early|RISE peer support program available early, launched study year 1
61997490|NCT06358456|ACTIVE_COMPARATOR|IOL Master 700|Patients in this arm are measured twice with the IOL master 700 without intervention. After this artificial tears are applied and followed by 4 more measurements
62177708|NCT05321381|ACTIVE_COMPARATOR|RISE Late|RISE peer support program available later, launched study year 2
62177709|NCT05866341|ACTIVE_COMPARATOR|Nitrate-rich Diet|Daily consumption of 200 mg nitrate via the consumption of 300 mL of a nitrate-rich lettuce juice beverage.
62177710|NCT05866341|PLACEBO_COMPARATOR|Nitrate-depleted Diet|Daily consumption of 300 mL of a nitrate-depleted lettuce juice beverage.
62177711|NCT05288777|OTHER|Her2/neu positive and lymph node positive|T-DM1/ trastuzumab emtansine infusion along with radiation to the breast or chest wall and lymph nodes
62177712|NCT05288777|OTHER|Her2/neu positive and lymph node negative|T-DM1/trastuzumab emtansine infusion along with radiation to the whole breast or chest wall
62177713|NCT05288777|OTHER|Her2/neu negative and lymph node positive|oral capecitabine twice per day along with radiation to the breast or chest wall and lymph nodes
62177714|NCT05288777|OTHER|Her2/neu negative and lymph node negative|oral capecitabine twice per day along with radiation to the whole breast or chest wall
62177715|NCT05006417|EXPERIMENTAL|Participants with R-CECS|Botox to be injected under standard palpatory technique into the affected lower leg compartment.
62177716|NCT02625753|ACTIVE_COMPARATOR|Codeine plus paracetamol|Codeine plus paracetamol every 6 hours for 72 hours after photorefractive keratectomy.
62177717|NCT02625753|PLACEBO_COMPARATOR|placebo|Placebo every 6 hours for 72 hours after photorefractive keratectomy.
62177718|NCT05245305|EXPERIMENTAL|MBSR Intervention|The intervention group will take part in mindfulness-based stress reduction (MBSR) program led by a certified MBSR instructor via Zoom. The MBSR program was structured as 11 weeks, taking into account the characteristics of the participants.
62177719|NCT05245305|NO_INTERVENTION|Control|No intervention was applied to the control group. Data will be collected from the control group simultaneously with the study group.
62177720|NCT02762539|NO_INTERVENTION|Control group|Control group in which patients will follow our local protocol for TBI management without SMOF-lipid infusion
62177721|NCT02762539|EXPERIMENTAL|SMOF group|SMOF-lipid group in which patients will receive 0.5 g/Kg SMOF lipid 10% emulsion (Lipid emulsion for intravenous nutrition containing; 6% soybean oil / 6% medium chain triglycerides / 5% olive oil / 3%fish oil) daily over 12 hours starting once admitted to ICU for 7 days.
62177722|NCT05296252|EXPERIMENTAL|Mind Wandering Intervention|75% of participants will receive proactive and reactive mind-wandering information and redirection.
62177723|NCT05296252|ACTIVE_COMPARATOR|Mind Wandering Comparison|25% of participants will receive only mind-wandering redirection, but only at random times.
62177724|NCT00815347|OTHER|1 Crossover|
62177725|NCT01807936|EXPERIMENTAL|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field lymphadenectomy
62177726|NCT01807936|NO_INTERVENTION|Two -field lymphadenectomy|Thoracic-upper abdominal two -field lymphadenectomy
62177727|NCT01922622||Bipolar hemiarthroplasty.|Group of patients who will stay in lateral position during whole surgery.
62177728|NCT01922622||Dynamic hip screw.|Group of patients who will be supine during surgery.
62177729|NCT00607256|EXPERIMENTAL|Open Label|
62742341|NCT05051293||male cirrhotic with hypotension|Patients with cirrhosis have decreased spontaneous vascular resistance leading to hypotension.
62177730|NCT05188313|ACTIVE_COMPARATOR|Chemoradiation according to the CROSS regimen|"Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given by intravenous infusion on days 1, 8, 15, 22 and 29.~A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy."
62177731|NCT05188313|EXPERIMENTAL|Chemoradiation according to the CROSS regimen combined with trastuzumab and pertuzumab|"Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given by intravenous infusion on days 1, 8, 15, 22 and 29.~A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.~Pertuzumab will be administered intravenously first, on Day 1, 22, 43, 64, and 85 using a fixed dose of 840 mg.~Trastuzumab will be administered intravenously on Day 1 of each treatment cycle, using an initial dose of 4 mg/kg on day 1, followed by doses of 2 mg/kg weekly up to week 6. From week 7 onwards trastuzumab will be administered at a dose of 6 mg/kg, every three weeks."
62177732|NCT01488838|EXPERIMENTAL|Arm 1:|Radiation: 60-66 Gy in 2 Gy daily fractions Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
62177733|NCT01488838|ACTIVE_COMPARATOR|Arm 2:|Radiation: 60-66 Gy in 2 Gy daily fractions
62177734|NCT03106935|ACTIVE_COMPARATOR|Obstet Gynecol,SecondSoochowU|Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
62177735|NCT03106935|NO_INTERVENTION|reproductive center,SecondSoochowU|For the control group ,women with subclinical hypothyroidism are not given any drugs .
62177736|NCT03333083|EXPERIMENTAL|Raltegravir + Lamivudine|
62177737|NCT06037239|EXPERIMENTAL|Linperlisib + Chidamide|Linperlisib combined with chidamide
62177738|NCT00646711|EXPERIMENTAL|Sequence Group I|Depakote Delayed Release/Depakote Sprinkle
62177739|NCT00646711|EXPERIMENTAL|Sequence Group II|Depakote ER
62177740|NCT05131711|EXPERIMENTAL|rGBM Group with combined stereotactic radiosurgery and enhanced immunotherapy|Patients with rGBMs will receive combined stereotactic radiosurgery and enhanced immunal adjuvants (GM-CSF, Sapylin, MnCl2). The safety and efficacy will be analyzed.
62177741|NCT05131711|NO_INTERVENTION|rGBM Group with|After biopsy or tumor resection, this rGBM group was treated with FDA-approved strategies proposed by the MDT group.
62177742|NCT02314585|OTHER|Education|In the second phase, participants will partake in an instructional class relating to gait, balance, and falls.
62177743|NCT02314585|OTHER|Exercise|In the second phase,participants will partake in an exercise course relating to gait, balance, and falls.
62177744|NCT04996537|EXPERIMENTAL|Micro-video with pressure injury(PI) education|"The experimental group's flipped education and training courses adopt a digital learning method and provide a digital learning platform. Log in according to personal account and password, and learn the curriculum units planned by the researcher in order: Prevention and management of stressful injury care as the main axis, enter the digital platform The provided video audio-visual digital teaching materials, combined with clinical situational learning, are equipped with basic knowledge learning, in-class test questions, and unit review, and can open courses for self-study anytime and anywhere, regardless of time and space constraints."
62177745|NCT04996537|ACTIVE_COMPARATOR|NIS with PI education|At the login interface of the Nursing Information System (NIS) used by the nursing staff daily, a link to the lecture notes (PDF file) of the course on prevention of stress injury is attached, and the nursing staff can view or download them according to their needs. Learn. At the same time, it provides a digital learning platform to download the self-study course handouts (PDF files) and complete the basic demography, pre-test, and post-test data on the platform.
62177746|NCT01723007|EXPERIMENTAL|Other: Apple|Women were supplemented with apples. Sixteen women were asked to ingest three apple daily between meals ( approximately 120g kcal) between meals (breakfast, lunch and dinner).
62177747|NCT01723007|ACTIVE_COMPARATOR|Other: oatmeal cookies|A another group with nineteen women were asked to ingest three oatmeal cookies a day, approximately 60g and similar caloric content to experimental group (approximately 120 kcal) between meals (breakfast, lunch and dinner).
62177748|NCT01723007|ACTIVE_COMPARATOR|Other: Pear|Women were supplemented with pear. Sixteen women were asked to ingest daily three pears (approximately 120 kcal) between meals daily (breakfast, lunch and dinner).
62177749|NCT01410526||VAC group|Patients with intra-abdominal sepsis treated with Vacuum Assisted Closure (VAC) system plus the dynamic sutures
62177750|NCT01410526||Control group|Patients suffering major abdominal surgery
62177751|NCT06034028|EXPERIMENTAL|J-Valve TF System|
62177752|NCT03882996|EXPERIMENTAL|Ezetimibe 10 mg + Atorvastatin|Ezetimibe 10 mg plus atorvastatin 10 to 80 mg daily for up to 12 months
62177753|NCT02652377|EXPERIMENTAL|EDP-494 SAD Cohorts|EDP-494, oral 50 mg, 100mg, 200mg, 400mg and 800 mg, capsules, once daily in one single administration
62177754|NCT02652377|EXPERIMENTAL|EDP-494 MAD/POC Cohorts|EDP-494, oral 200mg, 400mg and 800 mg, capsules, once daily for 14 days
62177755|NCT02652377|PLACEBO_COMPARATOR|EDP-494 SAD Placebo Cohort|
62177756|NCT02652377|PLACEBO_COMPARATOR|EDP-494 MAD/POC Placebo Cohort|
62177757|NCT05912569|EXPERIMENTAL|Delay sentinel node biopsy|sinlge arm
62391475|NCT01967134|EXPERIMENTAL|H56:IC31 (50 ug H56) LTBI Neg|LTBI Negative 3 Doses
62742342|NCT05051293||male cirrhotic without hypotension|The concentration of estrogen in cirrhotic patients is thought to increase by fourfold compared to individuals without cirrhosis.
62177758|NCT04924088|EXPERIMENTAL|Medical-legal partnership|Treatment group will receive the MLP intervention through the Connecticut Veterans Legal Center in partnership with the VA Connecticut Healthcare System. The MLP intervention can be categorized into seven activity components: initial in-person and subsequent in-person interviews; discussions with clients by phone; research and review of relevant documents; consultations with clinicians or other attorneys; interactions with opposing parties; time appearing at formal hearings; and travel time.
62177759|NCT04924088|ACTIVE_COMPARATOR|Referral to pro-bono lawyer|Control group will receive outside legal aid, i.e., control participants will be referred to pro-bono lawyers in the state.
62177760|NCT00334971|OTHER|1|Healthy Caucasian women 18-35 years old
62177761|NCT00334971|OTHER|2|Healthy African-American women 18-35 years old
62177762|NCT00334971|OTHER|3|Healthy Caucasian women 36-45 years old
62177763|NCT00334971|OTHER|4|Female fragile X premutation carriers 18-45 years old
62742343|NCT02319616|EXPERIMENTAL|Clobetasol 0.05% ointment|All patients will have one arm assigned to receive the experimental treatment (topical clobetasol 0.05% ointment) applied daily for a period of fourteen days.
62742344|NCT02319616|PLACEBO_COMPARATOR|Placebo|All patients will have one arm assigned to receive the placebo treatment (topical petrolatum ointment) applied daily for a period of fourteen days.
62742345|NCT03430843|EXPERIMENTAL|Tislelizumab|Tislelizumab on Day 1, given every 21 days
62742346|NCT03430843|ACTIVE_COMPARATOR|Investigator chosen chemotherapy (ICC)|Paclitaxel on Day 1, given every 21 days or on a weekly schedule; OR Docetaxel on Day 1, given every 21 days; OR Irinotecan on Days 1 and 8, given every 21 days
62742347|NCT06655792|NO_INTERVENTION|Control group|"Standard Care (No Educational Program) Participants in this group will not receive the educational program designed to reduce stigma toward mental illness. Instead, they will continue with their usual professional development and work routines without any specific interventions related to mental health stigma reduction.~No intervention: This group serves as a comparison group to evaluate the effectiveness of the educational program provided to Arm 1.~Follow-up: Similar assessments of knowledge, beliefs, and attitudes towards mental illness will be conducted before and after the study period to measure any changes that may occur in the absence of the educational intervention."
62742348|NCT06655792|EXPERIMENTAL|Study Group|"Educational Program on Mental Illness Stigma Reduction~Participants in this group will receive the educational program designed to reduce stigma toward mental illness. The educational program will be delivered through a series of structured sessions that aim to improve healthcare providers' knowledge, beliefs, and attitudes towards mental illness. These sessions will focus on the following key elements:~Increasing knowledge about mental illness: This will include education on common mental health disorders, their symptoms, and treatments.~Addressing misconceptions: Participants will learn about myths and misconceptions surrounding mental illness, with discussions on the importance of recognizing mental health as part of overall health.~Promoting positive attitudes: Activities and discussions will aim to foster empathy and understanding, encouraging participants to develop supportive and non-judgmental attitudes towards individuals with mental illness."
62177764|NCT01612221|EXPERIMENTAL|Patients receiving N-acetylcysteine|Patients receiving NAC (N-acetylcysteine)
62177765|NCT01612221|PLACEBO_COMPARATOR|Placebo Group|Participants not receiving NAC (N-acetylcysteine)
62177766|NCT05436652|EXPERIMENTAL|SPI-62|Active drug / placebo by mouth each morning for up to 4 weeks + standard of care 10mg prednisolone. Each participant will receive both placebo and active drug but will be blinded to the sequence of active drug and placebo.
62177767|NCT05436652|EXPERIMENTAL|SPI-62 + additional prednisolone|Active drug / placebo by mouth each morning for up to 4 weeks + standard of care 10mg prednisolone + additional prednisolone or placebo. Each participant will receive both placebo and active drug but will be blinded to the sequence of active drug and placebo.
62177768|NCT05854121|OTHER|Functional Electrical Stimulation|
62177769|NCT05854121|EXPERIMENTAL|Constrained Induced Movement Therapy|
62177770|NCT05727488|EXPERIMENTAL|Exercise|The SARAH exercise program will be delivered by sending messages and video instructions via a freeware and cross-platform messaging service (WhatsApp Messenger) on a weekly basis.
62177771|NCT05727488|NO_INTERVENTION|Control|Patients in the control group will not receive any exercise intervention. They will only maintain their routine medical treatment.
62177772|NCT03948399||STROKE GROUP|150 patients admitted to Stroke Unit with a diagnosis of acute ischemic stroke (IS) or transient ischemic attack (TIA)
62177773|NCT03948399||CONTROL GROUP|50 individuals admitted to hospital without diagnosis of acute cerebrovascular disease; with diagnosis of dizziness, epilepsy, sclerosis multiplex.
62177774|NCT01208870|EXPERIMENTAL|Variety Group|Traditional family based weight control treatment program with components to reduce variety of high energy dense foods incorporated into the treatment. Families meet weekly for 12 weeks, then by-weekly for 1 month and 1 monthly session for a total of 15 behavioral intervention sessions.
62177775|NCT01208870|EXPERIMENTAL|Nutrition Education Control|Traditional family based weight control treatment program, without components from habituation theory incorporated into the treatment. Families meet weekly for 12 weeks, then by-weekly for 1 month and 1 monthly session for a total of 15 behavioral intervention sessions.
62177776|NCT01040923||Cardiac CT|All patients in the study will be those presenting themselves for cardiac CT angiography who meet the proper inclusion / exclusion criteria
62177777|NCT04498988||Substance use disorder (SUD) group|In the substance use disorder (SUD) group, participants had a diagnosis of alcohol and/or tobacco use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) but no lifetime non-substance-related addictive disorder (ND).
62177778|NCT04498988||Non-substance-related addictive disorder (ND) group|In the non-substance-related addictive disorder (ND) group, participants were included who fulfilled two or more criteria for a DSM-5 gambling disorder or for an addictive behavior related to Internet use (not for gambling, gaming, or shopping), gaming, or shopping assessed with adapted criteria from DSM-5 substance use disorder (SUD). Participants in the ND group had no lifetime SUD.
62177779|NCT04498988||Control group|The control participants had no current or lifetime substance use disorder (SUD) or non-substance-related addictive disorder (ND).
62177780|NCT04677933|EXPERIMENTAL|Arm A|Patients will receive 5 µg OLP-1002 BIW for 15 days (Day 1, 4, 8, 11 and 15). Mode of Administration: Subcutaneous injection
62177781|NCT04677933|EXPERIMENTAL|Arm B|Patients will receive 10 µg OLP-1002 BIW for 15 days (Day 1, 4, 8, 11 and 15). Mode of Administration: Subcutaneous injection
62177782|NCT04677933|EXPERIMENTAL|Arm C|Patients will receive Diluent placebo BIW for 15 days (Day 1, 4, 8, 11 and 15) Mode of Administration: Subcutaneous injection
62742349|NCT04724694|EXPERIMENTAL|Brief CBT for Chronic Pain and treatment as usual|Participants will receive Brief CBT-CP in addition to usual primary care treatment. Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6-12 weeks. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
62742350|NCT04724694|OTHER|Treatment as usual only|Participants assigned to treatment as usual will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
62742351|NCT04802512||patients|patients who were used telehealth
62742352|NCT04802512||health professional|health professional who were used telehealth.
62742353|NCT01063608|EXPERIMENTAL|Anti-H1N1v Vaccine|
62742354|NCT02377752|EXPERIMENTAL|Part A cohort 1: Olaratumab+Doxorubicin|"15 milligram per kilogram (mg/kg) of olaratumab administered intravenously (IV) on Day 1 and Day 8, and 25 milligram per square meter (mg/m2) of doxorubicin administered IV on Day 1, Day 2, and Day 3 every 21-day cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met~."
62177783|NCT00815919|EXPERIMENTAL|Velcade (bortezomib)|
62742355|NCT02377752|EXPERIMENTAL|Part A cohort 2: Olaratumab+Doxorubicin|15 mg/kg of olaratumab administered IV on Day 1 and Day 8, and 75 mg/m2 of doxorubicin administered IV on Day 1 every 21 day-cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met.
62742356|NCT02377752|EXPERIMENTAL|Part A cohort 3 Olaratumab + Doxorubicin|20 mg/kg loading dose of olaratumab administered IV on Day 1 and Day 8 in Cycle 1, followed by 15 mg/kg IV on Day 1 and Day 8 in subsequent cycles, and 75 mg/m2 of doxorubicin administered IV on Day 1 of every 21 day-cycle up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met.
62177784|NCT02223013|ACTIVE_COMPARATOR|BIBV 308 SE solution|
62177785|NCT02223013|EXPERIMENTAL|BIBV 308 SE capsule L|
62177786|NCT02223013|EXPERIMENTAL|BIBV 308 SE capsule S|
62177787|NCT05957445|ACTIVE_COMPARATOR|active cTBS group|active cTBS combined with speech language therapy
62177788|NCT05957445|SHAM_COMPARATOR|sham cTBS group|sham cTBS combined with speech language therapy
62177789|NCT04717713|EXPERIMENTAL|steroid group|patients receiving steroid injection for preventing postoperative dysphagia
62177790|NCT04717713|PLACEBO_COMPARATOR|placebo group|patients receiving saline injection for comparator
62177791|NCT01470664|EXPERIMENTAL|FST-100|
62177792|NCT01470664|EXPERIMENTAL|FST-100 (Component #1)|
62177793|NCT01470664|PLACEBO_COMPARATOR|FST-100 Vehicle|
62177794|NCT00982540|NO_INTERVENTION|preemptive|Patients with persistent fever and neutropenia despite appropriate antibacterial therapy
62177795|NCT05257252|EXPERIMENTAL|"Persons With Disability Friendly Nursing Education Program"|Intervention group after determining the students according to the research criteria, they were randomized into intervention and control groups. Firstly, pre-tests were applied to the students in the experimental group.
62177796|NCT05257252|NO_INTERVENTION|"non-Persons With Disability Friendly Nursing Education Program"|Firstly, Pre-tests were applied to the students in the control group. No intervention was applied to this group. Posttests were made 3 months after pre-test.
62177797|NCT02251756|EXPERIMENTAL|Actinica, 0.8 mg/cm2, 1application|Actinica, 0.8 mg/cm2, 1application over one day of sun exposure
62391476|NCT01967134|EXPERIMENTAL|H56:IC31 (15 ug H56) LTBI Pos|LTBI Positive 3 Doses
62177798|NCT02251756|EXPERIMENTAL|Actinica, 0.8 mg/cm2, 2 applications|Actinica, 0.8 mg/cm2, 2 applications over one day of sun exposure
62177799|NCT02251756|EXPERIMENTAL|Actinica, 2 mg/cm2, 1 application|Actinica, 2 mg/cm2, 1 application over one day of sun exposure
62177800|NCT02251756|EXPERIMENTAL|Actinica, 2 mg/cm2, 2 applications|Actinica, 2 mg/cm2, 1 application over one day of sun exposure
62177801|NCT03157492|EXPERIMENTAL|Aural Rehabilitation Group|The AR Group will receive six 90-minute sessions including auditory training, informational counseling, and communication strategies.
62177802|NCT03157492|SHAM_COMPARATOR|Cognitive Training Group|The Cognitive Training Group will receive six 90-minute sessions including training exercises (Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Difference) to improve speed and accuracy.
62177803|NCT03841006||patient group|symptomatic patient and suspicious to have ODS by history and clinical examination those patient will have MRI defecography
62177804|NCT03841006||asymptomatic group|Asymptomatic group not suspicious to have ODS by history or clinical examination they will undergone MRI defecography
62177805|NCT03053115|EXPERIMENTAL|CASES|treatment with levothyroxine and liothyronine
62177806|NCT03053115|ACTIVE_COMPARATOR|CONTROLS|treatment with levothyroxine and placebo
62177807|NCT05193747||Paediatric patients scheduled for general anesthesia|Paediatric patients (between 1 year -19 years) undergoing elective general anaesthesia with presumed duration over 1 hour will be eligible for inclusion
62177808|NCT03143296|EXPERIMENTAL|Current recipient of a Med-El cochlear implant|Participants who have received a MED-EL cochlear implant as a standard of care for treatment of hearing loss. Participants are tested at one time point with a simulated reverberant environment.
62177809|NCT03143296|ACTIVE_COMPARATOR|Future Med-El Recipient|Cochlear implant candidates not yet implanted and chose Med-El device as standard of care for treatment of hearing loss. Participants are tested at 3 time points over 6 months in a simulated reverberant environment.
62177810|NCT02403284|EXPERIMENTAL|Liraglutide|Liraglutide titration up to 1.8 mg/d over approximately 3 weeks
62177811|NCT02403284|PLACEBO_COMPARATOR|Sugar pill|matching placebo and titration
62177812|NCT05820321|ACTIVE_COMPARATOR|Experimental (Beetroot juice NO3)|8-day supplementation with beetroot juice rich in NO3 (400mg) during 8 days.
62177813|NCT05820321|PLACEBO_COMPARATOR|Placebo (Beetroot juice without NO3)|8-day supplementation with beetroot juice NO3 depleted during 8 days.
62177814|NCT01359878|EXPERIMENTAL|Fibrinogen Concentrate|
62177815|NCT01359878|PLACEBO_COMPARATOR|Placebo|Isotonic Saline
62177816|NCT01212484|EXPERIMENTAL|Placebo (first), Carbidopa (second)|Crossover design Placebo first followed by carbidopa
62177817|NCT01212484|EXPERIMENTAL|Carbidopa (first), Placebo (second)|Crossover design carbidopa first followed by placebo
62177818|NCT03328845|OTHER|Tresiba & NovoRapid|Patients treated with Tresiba insulin and NovoRapid insulin
62177819|NCT03328845|OTHER|Toujeo SoloStar & NovoRapid|Patients treated with Toujeo SoloStar insulin and NovoRapid insulin
62177820|NCT03328845|OTHER|Tresiba & Humalog Kwikpen|Patients treated with Tresiba insulin and Humalog kwikpen insulin
62177821|NCT03328845|OTHER|Toujeo SoloStar & Humalog Kwikpen|Patients treated with Toujeo SoloStar insulin and Humalog kwikpen insulin
62177822|NCT03328845|OTHER|Tresiba & Apidra|Patients treated with Tresiba insulin and Apidra insulin
62177823|NCT03328845|OTHER|Toujeo SoloStar & Apidra|Patients treated with Toujeo SoloStar insulin and Apidra insulin
62177824|NCT06120114|EXPERIMENTAL|Modified percutaneous internal ring suturing|Patients with indirect inguinal hernia operated with modified percutaneous internal ring suturing
62742357|NCT02377752|EXPERIMENTAL|Part B: Olaratumab|15 mg/kg olaratumab administered IV on Day 1 and Day 8 of every 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62177825|NCT04265911|EXPERIMENTAL|ASP3772 (subcutaneous) in Adults|Participants will receive a single dose of ASP3772 administered as an subcutaneous injection on Day 1 at one of three dose levels.
62177826|NCT04265911|EXPERIMENTAL|ASP3772 ((intramuscular) in Adults|Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels.
62177827|NCT04265911|EXPERIMENTAL|ASP3772 (subcutaneous) in Elderly|Participants will receive a single dose of ASP3772 administered as an subcutaneous injection on Day 1 at one of three dose levels.
62177828|NCT04265911|EXPERIMENTAL|ASP3772 (intramuscular) in Elderly|Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels
62177829|NCT04265911|ACTIVE_COMPARATOR|PPSV23 (subcutaneous) in Elderly|Participants will receive a single subcutaneous injection of the standard dose of PPSV23 on Day 1.
62177830|NCT04265911|ACTIVE_COMPARATOR|PPSV23 (intramuscular) in Elderly|Participants will receive a single intramuscular injection of the standard dose of PPSV23 on Day 1.
62177831|NCT00742014|EXPERIMENTAL|1|
62177832|NCT00655083|EXPERIMENTAL|1|Nepadutant 0.1 mg/kg
62177833|NCT00655083|EXPERIMENTAL|2|Nepadutant 0.5 mg/kg
62177834|NCT04598945|EXPERIMENTAL|Adults|The subject will be subjected to 2 functional MRI sessions spaced 3 days apart Each session will be composed of the same MRI sequences without injection, namely an anatomical exploration sequence followed by sequences of functional exploration of rest and activation (while the subject performs the task motor). The resting functional exploration sequences will frame (1 before, 1 after) the functional activation sequence.
62177835|NCT04598945|EXPERIMENTAL|Children|The subject will be subjected to 2 functional MRI sessions spaced 3 days apart Each session will be composed of the same MRI sequences without injection, namely an anatomical exploration sequence followed by sequences of functional exploration of rest and activation (while the subject performs the task motor). The resting functional exploration sequences will frame (1 before, 1 after) the functional activation sequence.
62391477|NCT01967134|EXPERIMENTAL|H56:IC31 (50 ug H56) LTBI Pos|LTBI Positive 3 Doses
62742358|NCT00606541|EXPERIMENTAL|1|Quetiapine XR 50mg-400mg per day
62742359|NCT00606541|PLACEBO_COMPARATOR|2|Placebo
62742360|NCT06659614||Carriers|Eligible subjects will have confirmed pathogenic or likely pathogenic variants in a prostate cancer risk gene, and will also be undergoing prostate needle biopsy, prostatectomy or metastatic biopsy. Study participation will request access to medical information, blood and tissue samples.
62177836|NCT06180902|EXPERIMENTAL|Fluid responsiveness testing|In our clinical study to evaluate infusion therapy responsiveness, we'll start by measuring the inferior vena cava diameter. Two minutes later, we'll assess central venous pressure. After another two-minute pause, the passive leg raise test begins, followed by a 15-minute wait. Then, we conduct the fluid challenge. Post-evaluation, we administer balanced crystalloid solutions at 1000 ml, infused at 15 ml/kg/h, adjusting for any previous infusions during the fluid challenge.
62177837|NCT01437813|EXPERIMENTAL|Group A: Glimepiride / Extended Release Metformin|Pharmaceutical Form: Tablets Dosage: 4 mg / 850 mg Administration way: Oral
62177838|NCT06096818|EXPERIMENTAL|Experimental Group: Kegel exercises and abdominal exercises|Kegel exercises and abdominal exercises training has given to this group
62177839|NCT06096818|NO_INTERVENTION|Control Group: Kegel exercises|Kegel exercises exercises training has given to this group
62177840|NCT00988117|EXPERIMENTAL|Rivastigmine Patch 9.5 cm2|
62177841|NCT03500263|ACTIVE_COMPARATOR|Cohorts 1 and 2: PTI-808 Active Co-admin with PTI-801 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
62177842|NCT03500263|PLACEBO_COMPARATOR|Cohorts 1 and 2: PTI-808 Placebo Co-admin with PTI-801 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
62177843|NCT03500263|ACTIVE_COMPARATOR|Cohort 3 PTI-808 Active + PTI-801 Active + PTI-428 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
62177844|NCT03500263|PLACEBO_COMPARATOR|Cohort 3 PTI-808 placebo + PTI-801 Placebo + PTI-428 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
62177845|NCT03500263|ACTIVE_COMPARATOR|Cohort 4 PTI-808 Active + PTI-801 Active + PTI-428 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for 7 days immediately followed by PTI-808 co-administered with PTI-801 or placebos once-a-day for 7 days. A follow-up visit will occur on Day 21.
62177846|NCT03500263|PLACEBO_COMPARATOR|Cohort 4 PTI-808 Placebo + PTI-801 Placebo + PTI-428 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for 7 days immediately followed by PTI-808 co-administered with PTI-801 or placebos once-a-day for 7 days. A follow-up visit will occur on Day 21.
62177847|NCT03124550|EXPERIMENTAL|Exergame Experience|Participants will use the exergame for 6 weeks, during which time game telemetry data (all interactions with the software) will be automatically logged by the system. The participants will be asked to use the game at least every other day. Caregivers will be sent an email or text message to remind them to use the system if they have not done so within three days. Utilizing two-way text messaging, an experience sampling protocol will be employed: once per week, participants will be sent brief questions probing their level of satisfaction with the exergame and their level of perceived connectedness to the community of other caregivers using the exergame.
62177848|NCT06546514|EXPERIMENTAL|Grup 1|the group that performed breathing exercises
62177849|NCT06546514|NO_INTERVENTION|Grup 2|the group that did not perform breathing exercises
62177850|NCT00676195|EXPERIMENTAL|N-Acetyl Cysteine|"Dosage of orally administered N-Acetyl Cysteine is as follows:~Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day"
62177851|NCT02748902|EXPERIMENTAL|ingenol mebutate 0.05% gel|Single group, open label. All subjects will receive active product.
62177852|NCT01347177|EXPERIMENTAL|Zirconia-based adhesive bridges|Patients in this group will be treated with the employment of zirconia-based adhesive bridges to replace the missing tooth/teeth.
62177853|NCT01347177|EXPERIMENTAL|Metal-based adhesive bridges|Patients in this group will be treated with the employment of metal-based adhesive bridges.
62177854|NCT00937456|EXPERIMENTAL|Laparoscopically-assisted esophagectomy|Laparoscopically-assisted esophagectomy: standard abdominal procedure of gastric mobilisation but through laparoscopic route. Right thoracotomy as usual.
62177855|NCT00937456|ACTIVE_COMPARATOR|Open esophagectomy|Conventional open esophagectomy: Esophagectomy with extended 2-field lymphadenectomy through laparotomy and right thoracotomy (Ivor-Lewis standard procedure)
62177856|NCT06439147|ACTIVE_COMPARATOR|U-shaped group|Participants on which U shaped capsular incision will be used during capsulorrhaphy
62177857|NCT06439147|ACTIVE_COMPARATOR|T-shaped group|Participants on which T shaped incision will be used during capsulorrhaphy
62742361|NCT06659614||Controls|Eligible subjects will be undergoing prostate needle biopsy, prostatectomy or metastatic biopsy. Study participation will request access to medical information, blood and tissue samples.
62177858|NCT01211223|EXPERIMENTAL|Scaling and root planning + placebo + antibiotics|"* Scaling and root planning + placebo~* Scaling and root planning + metronidazole plus amoxicillin~* Metronidazole plus amoxicillin + scaling and root planning"
62177859|NCT00193596|EXPERIMENTAL|Regimen A|"Paclitaxel 200 mg/m2 by 1-hour IV infusion, day 1~Carboplatin area under the curve (AUC) 6.0 IV, day 1~Etoposide 50 mg alternating with 100 mg by mouth, days 1 and 10~Regimen A was repeated at a 21-day interval"
62177860|NCT00193596|EXPERIMENTAL|Regimen B|"Irinotecan 100 mg/m2 IV, days 1 and 8~Gemcitabine 1000 mg/m2 IV, days 1 and 8~Regimen B was repeated at a 21-day interval"
62177861|NCT00900406||Recipients of stem cells with graft versus host disease|
62177862|NCT00900406||Recipients of stem cells at risk of graft versus host disease|
62177863|NCT00900406||Donator of stem cells|
62177864|NCT00297778|EXPERIMENTAL|pramipexole|A daily dose of pramipexole 0.125 mg t.i.d.; titration-to-response up to 1.0 mg t.i.d.
62177865|NCT00297778|PLACEBO_COMPARATOR|placebo|Placebo (matching) tablets
62177866|NCT04470570|NO_INTERVENTION|Control Group|This group will undergo a standardized rehabilitation protocol of the involved shoulder only.
62177867|NCT04470570|EXPERIMENTAL|Cross-Education Group|This group will undergo a standardized rehabilitation protocol of the involved shoulder with the addition of upper extremity strengthening exercises to the uninvolved side.
62742362|NCT06249698|EXPERIMENTAL|Active Nutrition program|Subjects in this arm will follow the Active Nutrition program for 60 days with study visits at 0 days, 30 days, and 60 days.
62177868|NCT04470570|EXPERIMENTAL|Cross-Education + Blood-Flow Restriction Group|This group will undergo a standardized rehabilitation protocol of the involved shoulder with the addition of upper extremity strengthening exercises to the uninvolved side with blood-flow restriction simultaneously.
62177869|NCT06039943|EXPERIMENTAL|All participants|Participants will undergo wheeze monitoring during tidal breathing prior to spirometry and during a spirometry test.
62742363|NCT06249698|NO_INTERVENTION|Regular Diet|Subjects in this arm will follow their regular diet for 60 days with study visits at 0 days, 30 days, and 60 days.
62177870|NCT01562587|EXPERIMENTAL|Adults|
62177871|NCT01562587|EXPERIMENTAL|Paediatric|
62177872|NCT05404217|ACTIVE_COMPARATOR|LN-OS-22|2 capsules orally once a day for 56 days
62177873|NCT05404217|PLACEBO_COMPARATOR|Maltodextrin|2 capsules orally once a day for 56 days
62177874|NCT03228277|EXPERIMENTAL|Olmutinib|Single arm of Olmutinib, staring dose of 800 mg
62177875|NCT00979745|EXPERIMENTAL|Afamelanotide|
62177876|NCT00979745|PLACEBO_COMPARATOR|Placebo|
62177877|NCT01907022|EXPERIMENTAL|Left dorsolateral prefrontal cortex (DLPFC) Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.
62177878|NCT06465992|ACTIVE_COMPARATOR|Study Group 1: Foot/Ankle Surgery with Exparel Nerve Block|Prior to participants surgical procedure, the anesthesiologist will administer a popliteal and saphenous nerve block consisting of 20 mL Liposomal bupivacaine (Exparel) + 10 mL of 0.75% bupivacaine
62177879|NCT06465992|ACTIVE_COMPARATOR|Study Group 2: Foot/Ankle Surgery with Exparel + Dexamethasone Nerve Block|Prior to participants surgical procedure, the anesthesiologist will administer a popliteal and saphenous nerve block consisting of 20 mL Liposomal bupivacaine (Exparel) + 1 mL of 10 mg preservative free Dexamethasone + 10 cc's of 0.75% bupivacaine
62177880|NCT04020198||Parkinson's Disease|Subjects who have a PD diagnosis
62177881|NCT04020198||Multiple System Atrophy|Subjects who have an MSA diagnosis
62177882|NCT04020198||Age-matched controls|Subjects who do not have a diagnosed parkinsonian disorder
62177883|NCT04020198||Rapid Eye Movement Sleep Behavior Disorder (RBD)|Subjects who have a diagnosis of RBD
62177884|NCT04020198||Normal Pressure Hydrocephalus|Subjects who are prescribed a lumbar puncture to treat normal pressure hydrocephalus
62177885|NCT01639014|EXPERIMENTAL|F2695|
62177886|NCT01639014|PLACEBO_COMPARATOR|placebo|
62177887|NCT06123832||Experimental Group|Liposomal Amphotericin B for Injection (Ampicillin®)
62177888|NCT06123832||Control Group|Liposome of Amphotericin B for Injection (Fungoxone®), Cholesteryl Sulfate Complex of Amphotericin B for Injection (Amphotericin®), Amphotericin B for Injection
62177889|NCT05573347||Bone marrow harvest from side-lying patient|This group will have bone marrow harvested from the PSIS extraction site while lying in the lateral decubitus position.
62177890|NCT05573347||Bone marrow harvest from patient lying prone|This group will have bone marrow harvested from the PSIS extraction site while lying in the prone position.
62177891|NCT01091519||Toviaz(fesoterodine) plus educational materials|
62177892|NCT01091519||Toviaz(fesoterodine) alone|Toviaz(fesoterodine) without additional educational materials
62177893|NCT02970786|EXPERIMENTAL|68Ga-NODAGA-E(c[RGDyK])2 PET|One injection of 68Ga-NODAGA-E(c\[RGDyK\])2 PET (app. 200 MBq) followed by 3 PET/CT scans 10 minutes, 1 hour and 2 hours post injection
62177894|NCT01871168|SHAM_COMPARATOR|Sham TAP block|Patients receive TAP catheters but saline infusion instead of local anesthetic
62177895|NCT01871168|EXPERIMENTAL|TAP block|Patients receive a continuous TAP block
62177896|NCT03511378|EXPERIMENTAL|Lupin's Pegfilgrastim|6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
62177897|NCT03511378|EXPERIMENTAL|Neulasta®|6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
62177898|NCT03246399|EXPERIMENTAL|0.03mg SM04690|0.03mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
62177899|NCT03246399|EXPERIMENTAL|0.07mg SM04690|0.07mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
62177900|NCT03246399|EXPERIMENTAL|0.15mg SM04690|0.15mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
62177901|NCT01664897|EXPERIMENTAL|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62177902|NCT00334139|EXPERIMENTAL|zoledronic acid|
62177903|NCT01577433||Control Group|Historical control HeartMate II BTT and DT data
62177904|NCT01577433||Prospective and Retrospectively identified SSI|Prospectively and Retrospectively identified HeartMate II patients where the full length of the velour coated portion of the driveline is tunneled under the skin
62177905|NCT04107077|EXPERIMENTAL|Drug Administration Period|
62177906|NCT03752489|EXPERIMENTAL|Fluid treatment-specific algorithm|The experimental arm will involve patients monitored by the fluid treatment-customized version of InSight.
62177907|NCT03752489|ACTIVE_COMPARATOR|Standard InSight|The control arm will involve patients monitored with the standard, non-treatment specific version of InSight.
62177908|NCT04233502|EXPERIMENTAL|Melatonin|Slenyto® 1 mg / 5 mg prolonged release Melatonin tablets (pink and yellow) film coated 3 mm in diameter,
62177909|NCT04233502|PLACEBO_COMPARATOR|Placebo melatonin|Placebo melatonin will be identical in appearance (pink and yellow) and formulation to active Slenyto® tablets, but will contain no active melatonin.
62177910|NCT06235853||Patients after TURBT with NMIBC|Patients who underwent successful TURBT with histopathological proof of non-muscle invasive bladder cancer. Blood and urine specimen have been gathered prior to hospital admission during visit in out-patient clinic.
62391478|NCT02108158|EXPERIMENTAL|Azzalure 10 Speywood units/injection|Azzalure (botulinum toxin type A), powder for solution for injection, Total dose 50 s.U (5 x 10s.U)
62742364|NCT03249909|OTHER|Exufiber Ag +|Gelling fibre dressing with silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
62177911|NCT02176837|EXPERIMENTAL|Sodium Nitrite|One dose cohort is planned, 64 nmol/min/kg sodium nitrite (0.1325 mg/hour/kg; 0.0442 ml/hour/kg at a concentration of 3mg/ml).
62177912|NCT02679313|EXPERIMENTAL|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit).
62177913|NCT00212797|EXPERIMENTAL|Org 34517_1|low dose Org 34517
62177914|NCT00212797|EXPERIMENTAL|Org 34517_2|high dose Org 34517
62177915|NCT00212797|PLACEBO_COMPARATOR|Placebo|
62177916|NCT01860495||perforated membrane group|perforated membrane group (G1- 15 sites)
62177917|NCT01860495||occlusive membrane group|occlusive collagen membrane that are tradetionally used in guided tissue regeneration , control occlusive group (G2-15 sites)
62177918|NCT01649297|EXPERIMENTAL|empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
62177919|NCT01649297|EXPERIMENTAL|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
62177920|NCT01649297|EXPERIMENTAL|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
62177921|NCT01649297|EXPERIMENTAL|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
62177922|NCT01649297|PLACEBO_COMPARATOR|Placebo|Patients receive placebo matching Empagliflozin
62177923|NCT01774019|ACTIVE_COMPARATOR|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|Patients in this group will receive a fully covered or uncovered study SEMS (self-expanding metal stent)
62177924|NCT01774019|NO_INTERVENTION|None (No Pre-Operative Biliary Drainage)|Patients in this group will not receive pre-operative biliary drainage with a study SEMS
62177925|NCT02650206|EXPERIMENTAL|Liraglutide group|"Drug with diet control intervention: Subjects assigned to this group receive blinded pens containing liraglutide (commonly known as Victoza), manufactured by Novo Nordisk. Subjects will inject 0.6 mg daily into abdomen during the first week of the study, and if tolerated, will increase dose to 1.2 mg the second week of the study, and then up to 1.8 mg daily from the third week until the end of the 12-week study. Any adverse symptoms as well as fasting blood glucose will be monitored weekly for safety.~Subjects, with the guidance of the study's dietitian, will remain weight-stable for the first four weeks of the study, and then will be allowed to lose weight for the remaining eight weeks of the study."
62177926|NCT02650206|PLACEBO_COMPARATOR|Placebo group|"Diet control-only intervention: Subjects assigned to this group receive blinded pens containing placebo (normal saline) instead of liraglutide (commonly known as Victoza). Subjects will inject 0.6 mg of placebo daily during the first week of the study, will increase to 1.2 mg the second week of the study, and then up to 1.8 mg daily from the third week until the end of the 12-week study. Any adverse symptoms as well as fasting blood glucose will be monitored weekly for safety.~Subjects, with the guidance of the study's dietitian, will remain weight-stable for the first four weeks of the study, and then will be allowed to lose weight for the remaining eight weeks of the study."
62177927|NCT06088797||healthy subjects|First time :WISC V 40 minutes Second time :Completion of the 4 experimental tasks 105 minutes
62177928|NCT06088797||blind|First time :WISC V 40 minutes Second time :Completion of the 4 experimental tasks 105 minutes
62177929|NCT06088797||low visual acuity|First time :WISC V 40 minutes Second time :Completion of the 4 experimental tasks 105 minutes
62177930|NCT06088797||reduced visual field|First time :WISC V 40 minutes Second time :Completion of the 4 experimental tasks 105 minutes
62177931|NCT06086522|OTHER|Cohort 1|Starting dose in Phase 1a dose escalation
62177932|NCT06086522|OTHER|Cohort 2|2nd cohort in Phase 1a dose escalation
62177933|NCT01530477|EXPERIMENTAL|Skeletal|"Recruitment for each cohort will include approximately equal male/female split (no gender bias). Depending on the weight category, for each cohort, a minimum of 30 adult subjects will be measured on two of three systems \[Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)\], and 60 will be measured on all three systems \[Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)\],(total of evaluable 90 subjects).~\*\* Subjects can enroll in both Skeletal and Body Composition cohorts. Analysis will be performed within each cohort.\*\*"
62177934|NCT01530477|EXPERIMENTAL|Body Composition|"Recruitment for each cohort will include approximately equal male/female split (no gender bias). Depending on the weight category, for each cohort, a minimum of 30 adult subjects will be measured on two of the three systems \[Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)\], and 60 will be measured on all three systems \[Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)\], (total of evaluable 90 subjects).~\*\* Subjects can enroll in both Skeletal and Body Composition cohorts. Analysis will be performed within each cohort.\*\*"
62177935|NCT01530477|EXPERIMENTAL|Skeletal & Body Composition|"Skeletal and Body Composition was not a cohort that was actively recruited to, it is a cohort for reporting purposes. Subjects will be measured on two of three systems \[Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)\]Subjects were able to consent and enroll to both Skeletal and Body Composition cohorts and these subjects will be counted for under this joint cohort."
62177936|NCT06531811|EXPERIMENTAL|Sequence 1 (Treatment A- Treatment B)|Participants will receive Treatment A (AZD8630 Monodose inhalation powder) crossover to Treatment B (AZD8630 test inhalation powder)
62177937|NCT06531811|EXPERIMENTAL|Sequence 2 (Treatment B- Treatment A)|Participants will receive Treatment B (AZD8630 test inhalation powder) crossover to Treatment A (AZD8630 Monodose inhalation powder)
62177938|NCT00814645|ACTIVE_COMPARATOR|Dose level 1|a single dose (5 mg sodium nitrite)of AIR001 Inhalation Solution administered by inhalation following nebulization
62177939|NCT00814645|ACTIVE_COMPARATOR|Dose level 2|a single dose(15 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
62177940|NCT00814645|ACTIVE_COMPARATOR|Dose level 3|a single dose(45 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
62177941|NCT00814645|ACTIVE_COMPARATOR|Dose level 4|a single dose(113 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
62177942|NCT00814645|PLACEBO_COMPARATOR|Expansion arm|On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
62177943|NCT05641714||multiple sclerosis|Patients with Multiple Sclerosis
62177944|NCT05641714||healthy controls|healthy controls
62177945|NCT06369883||Subjects under 18 years of age who underwent spinal radiography|Angle measurement with Cobb method in posterior-anterior and lateral radiographs of patients who underwent spinal radiographs
62177946|NCT00463580|EXPERIMENTAL|Infliximab|Participants in this arm will receive an infusion of infliximab.
62177947|NCT00463580|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive an infusion of normal saline.
62177948|NCT03147508||Neck pain patients|
62177949|NCT02016690||Immunocompromised children|Children with immunocompromised conditions or Down syndrome at high-risk of serious RSV disease who received palivizumab during the RSV season
62177950|NCT04811118|EXPERIMENTAL|Albumin-bound docetaxel|Subjects will receive albumin-bound docetaxel via intravenous infusion (IV) once every three weeks (a cycle), at the dose of 75mg/m2
62177951|NCT04811118|EXPERIMENTAL|Taxotere|Subjects will receive Taxotere via intravenous infusion once every three weeks (a cycle), at the dose of 75mg/m2.
62177952|NCT00135785|ACTIVE_COMPARATOR|1|Bupropion
62742365|NCT03249909|OTHER|Exufiber|Gelling fibre dressing without silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
62177953|NCT00135785|PLACEBO_COMPARATOR|2|Placebo
62177954|NCT03371485|EXPERIMENTAL|Participants with advanced NSCLC, to receive AST-VAC2|Participants will receive up to a maximum of six vaccinations over six weeks. Each weekly AST-VAC2 vaccination will be administered as a split dose via two intradermal injections at a target dose defined as 1 x 10\^7 viable cells. There is no dose escalation planned during the study; only one dose level will be explored.
62177955|NCT02107729|EXPERIMENTAL|Needle gauge small|injection needle 23 G
62177956|NCT02107729|EXPERIMENTAL|Needle gauge normal|injection needle 25 G
62177957|NCT02107729|EXPERIMENTAL|Needle gauge large|injection needle 27 G
62177958|NCT05458830|EXPERIMENTAL|Intervention|After selecting a barrier in the barrier survey, participants receive tailored information with the purpose of addressing common concerns and misconceptions about the helpline.
62177959|NCT05458830|OTHER|Care as usual|Plain advisory text
62177960|NCT02172950|EXPERIMENTAL|Previously treated patients (PTPs)|The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII-SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule for the subject based upon the subject's pharmacokinetic (PK) profile, rVIII-SingleChain PK data, previous FVIII treatment regimen, and bleeding phenotype, if available.
62177961|NCT02172950|EXPERIMENTAL|Previously untreated patients (PUPs)|The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII-SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule at their discretion, taking into consideration the World Federation of Hemophilia (WFH) guidelines, the type of bleeding episode, location of the bleeding, subject's age, and other disease characteristics.
62177962|NCT01265121|EXPERIMENTAL|CPAP treatment|This acromegalic patients is going to have sleep apnea treated for 3 months with a with a continuous positive air pressure device (CPAP)
62177963|NCT01265121|PLACEBO_COMPARATOR|Nasal adhesive|This acromegalic patients will be treated will an external nasal dilator adhesive intended to serve as a placebo treatment
62742366|NCT03249909|OTHER|Aquacel® Ag Extra|Gelling fibre dressing with silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
62177964|NCT00225277|EXPERIMENTAL|Pioglitazone QD|
61997491|NCT06358456|ACTIVE_COMPARATOR|Pentacam AXL|Patients in this arm are measured twice with the Pentacam AXL without intervention. After this artificial tears are applied and followed by 4 more measurements
62177965|NCT00225277|ACTIVE_COMPARATOR|Glimepiride QD|
62177966|NCT05146661|EXPERIMENTAL|Treatment|The NEURESCUE device will be used as an adjunct to ALS.
62177967|NCT04360434|EXPERIMENTAL|NI006|Dose escalation in up to 6 dose cohorts. Subjects will be administered a single dose of NI006 in the SAD, multiple doses of NI006 in the MAD and OLE phases.
62177968|NCT04360434|PLACEBO_COMPARATOR|Placebo|"Subjects will be administered a single dose of placebo in the SAD phase and multiple doses of placebo in the MAD phase.~In the OLE phase, all subjects will be administered multiple doses of NI006."
62177969|NCT00935714|ACTIVE_COMPARATOR|Muscle Group|Exercise
62177970|NCT00935714|ACTIVE_COMPARATOR|Sequence|Exercise
62177971|NCT03453203|PLACEBO_COMPARATOR|Control|"Both arms with be diagnosed using tenderpoints In the control arm the tenderpoint will Be palpated for 90 secs with no counterstrain treatment applied.~Both treatment and control groups will remain on their current migraine medication regiment."
62182458|NCT06315114|ACTIVE_COMPARATOR|Care as usual (CAU)|1-2 next of kin sessions (called 'Familiesamtale') is considered the care as usual offered to parents in adult mental health service in the Capital Region of Denmark.
62182459|NCT05087836||Patient undergoing cardiac surgery|Each patient will has 2 sets of sensors attached at forehead and temporal area.
62182460|NCT04666376|OTHER|Vitrified ovarian tissue|Ovarian tissue will be vitrified and warmed by Ova kit type M protocol.
62182461|NCT00715637|EXPERIMENTAL|Arm A|Amonafide in Combination with Cytarabine
62182462|NCT00715637|ACTIVE_COMPARATOR|Arm B|Daunorubicin in Combination with Cytarabine
62177972|NCT03453203|OTHER|Treatment (conterstrain)|Both arms with be diagnosed using tenderpoints. Treatment arm will be treated with counterstrain technique. Counterstrain is a passive manipulative technique which the tissue being treated is positioned at a point of balance, or ease, AWAY from the restrictive barrier (The most thought of form of manipulative technique is high velocity low amplitude which is typically performed by chiropractors in spinal manipulation which goes TOWARD the restrictive barrier and actually pass through the restrictive barrier). Once a tenderpoint is found in the muscles the area of treatment is placed in a (three dimensional) position that will eliminate the sensation (tenderness).The treatment position is held for 90 seconds or until a release is felt (a decrease in muscle tension). Both treatment and control groups will remain on their current migraine medication regiment.
62177973|NCT04527783|EXPERIMENTAL|experimental group|"Each subject will perform a variety of VR exercises to reduce impairments in their finger range of motion, speed and strength.~It includes a glove-shaped sensor device and a software application."
62177974|NCT04527783|ACTIVE_COMPARATOR|control group|Each subject will perform usual care rehabilitation aimed at improving manual dexterity
62177975|NCT01282749|EXPERIMENTAL|SisterTalk Hartford First|12-week group support and film-based healthy lifestyle education program, including information on healthy nutrition and food preparation, increasing activity and exercise, healthy lifestyle behavior modification, and supportive spiritual materials.
62177976|NCT01282749|OTHER|SisterTalk Hartford Second|Participants received general film series on healthy lifestyles while waiting to participate in the experimental arm.
62177977|NCT02831998|EXPERIMENTAL|ZP (70% IPA)|Isopropyl alcohol (IPA) 70%
62177978|NCT02831998|ACTIVE_COMPARATOR|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
62177979|NCT02831998|PLACEBO_COMPARATOR|ZP Vehicle|ZP without IPA
62177980|NCT01013064|EXPERIMENTAL|Cohort1|
62742367|NCT04129268|OTHER|No exercise control|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
62742368|NCT04129268|EXPERIMENTAL|175kcal Cycle ergometry exercise at 60% VO2max|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
62742369|NCT04129268|EXPERIMENTAL|350kcal Cycle ergometry exercise at 60% VO2max|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
62177981|NCT01013064|EXPERIMENTAL|Cohort2|
62177982|NCT01013064|EXPERIMENTAL|Cohort3|
62177983|NCT01013064|EXPERIMENTAL|Cohort4|
62177984|NCT01013064|EXPERIMENTAL|Cohort5|
62177985|NCT01013064|EXPERIMENTAL|Cohort6|
62177986|NCT00014222|ACTIVE_COMPARATOR|Arm 1: CEF|6 cycles - q 28 days (6 months) - Cyclophosphamide 75 mg/m2 - po - Days 1-14 - Epirubicin 60 mg/m2 - IV - Days 1 and 8 - 5 Fluorouracil: 500mg/m2 - IV - Days 1 and 8 + Continuous Antibiotic Prophylaxis with Cotrimoxazole 960 mg (i.e.2x480 mg tablets) po-bid or Ciprofloxacin 500 mg - po-bid
62177987|NCT00014222|ACTIVE_COMPARATOR|Arm 2: EC/T|6 cycles - q 14 days (3 months) - Epirubicin 120 mg/m2 - IV - Day 1 - Cyclophosphamide 830 mg/m2 - IV - Day 1 - Filgrastim 5μg/kg/d - SC - Days 2 - 13 + Epoetin Alfa 40,000 IU - SC - once weekly (to begin within 1 week after start of protocol therapy as needed) 21 days from last administration of EC (EC/T) 4 cycles - q 21 days (3 months) - Adriamycin 60 mg/m2 - IV - Day 1 - Cyclophosphamide 600 mg/m2 - IV - Day 1 - 21 days from last administration of AC 4 cycles - q 21 days (3 months) - Paclitaxel 175 mg/m2 IV 3 hour infusion
62177988|NCT00014222|ACTIVE_COMPARATOR|Arm 3: AC/T|4 cycles - q 21 days (3 months) - Adriamycin 60 mg/m2 - IV - Day 1 - Cyclophosphamide 600 mg/m2 - IV - Day 1 21 days from last administration of AC 4 cycles - q 21 days (3 months) - Paclitaxel 175 mg/m2 IV 3 hour infusion
62177989|NCT05212311|ACTIVE_COMPARATOR|Group A (Control group)|Group A (n=27) will receive a conventional physical therapy program only for 5 weeks in the form of Splinting, Ultrasound and Exercises.
62177990|NCT05212311|EXPERIMENTAL|Group B (Chitosan phonophoresis group)|Patients in group B (n=27) will receive phonophoresis with chitosan nanoparticles. Patients will also receive the conventional physical therapy program: in the form of Splinting, Ultrasound and Exercises. Session will be applied 3 times per week for a total of 5 weeks.
62177991|NCT00679549|EXPERIMENTAL|DEVICE|Provided CPAP as an inpatient
62177992|NCT00679549|NO_INTERVENTION|Control|No device provided
62177993|NCT01793298|EXPERIMENTAL|Healthy Subjects - ASM-024 Single Administration|Single administration of ascending doses of ASM-024
62177994|NCT01793298|PLACEBO_COMPARATOR|Healthy Subjects - Placebo|Single administration of placebo
62177995|NCT01793298|EXPERIMENTAL|Healthy Subjects - ASM-024 Repeat Administration|Repeat administration of ascending doses of ASM-024
62177996|NCT01793298|PLACEBO_COMPARATOR|Healthy Subjects - Placebo Repeat Administration|Repeat administration of ascending doses of placebo
62177997|NCT01793298|EXPERIMENTAL|Subjects with Asthma|Repeat administration of ascending doses of ASM-024 or placebo in a crossover fashion
62177998|NCT04435470||Critical ill children|Critial ill children admited in pediatric intensive care units 1-16 years old
62177999|NCT04435470||Control|Healthy children 1-16 years old
62178000|NCT01245335|ACTIVE_COMPARATOR|BMAC Treatment|Intervention- Injection of 40 ml of autologous bone marrow concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
62178001|NCT01245335|PLACEBO_COMPARATOR|Placebo Injection|Injection of placebo (diluted peripheral blood) into ischemic tissue of the lower extremity
62178002|NCT05566353|EXPERIMENTAL|Patients followed at the implantation reference centers|Patients eligible for implant processor renewal in 2 years and corresponding to inclusion criteria will be enrolled during their routine check-up appointment at the implantation reference centers of the University Hospitals of Montpellier and Toulouse. Patients will be their own controls through the use of their medical history data.
62178003|NCT01997489|EXPERIMENTAL|Fabry patients during treatment|39 patients with Fabry disease having had baseline examinations of the eyes were assessed also at follow-up 10 years after enzyme replacement therapy
62178004|NCT03935061|EXPERIMENTAL|Mulberry juice|Two bottles (600 ml/bottle) of sanitized mulberry juice are delivered to the patients of the experimental group 20 days before the next clinic visit, with instruction to consume 50 ml of juice diluted with drinking water at room temperature. A reminder of the next clinic visit for continuous treatment is attached.
62178005|NCT03935061|NO_INTERVENTION|Controlled|Patients of the controlled group are informed of their allocation results along with a reminder of the next clinic visit. On the second visit at the 1st month, measurements of clinical symptoms and inflammation status are conducted. No mulberry juice is given to patients further on. All patients are evaluated again with the same assessment tools, as well as the immunology markers in their sera during the third visit.
62178006|NCT05087953||FAC group|Patients with familial amyloidotic cardiomyopathy.
62178007|NCT05087953||Non-FAC group|Patients with transthyretin gene mutations who do not have FAC.
62178008|NCT05087953||Control group|Healthy subjects.
62178009|NCT04840498||Magic Camp Session #1|Children ages 9-18
62178010|NCT04840498||Magic Camp Session #2|Children ages 9-18
62178011|NCT05858801|EXPERIMENTAL|PRIMUS|PRIMUS system
62178012|NCT02324309|EXPERIMENTAL|BIOD-531 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
62178013|NCT02324309|ACTIVE_COMPARATOR|Humalog Mix 75/25 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
62178014|NCT02324309|ACTIVE_COMPARATOR|Humulin R U-500 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
62178015|NCT02324309|EXPERIMENTAL|BIOD-531 post-meal|Subcutaneous injections of 1.2 U/kg 20 minutes after the start of a standardized breakfast and 0.8 U/kg 20 minutes after the start of a standardized dinner.
62178016|NCT04479514|EXPERIMENTAL|Preventative Skin Care Routine|"Participants will perform a preventative skin care routine that includes daily sun protection, daily gentle skin care and every-other-day dilute bleach baths for the duration of the study.~Participants will receive skin examinations and complete a survey about their skin condition at the initial visit when anti-cancer treatment is started, at six weeks after the start of treatment, and at twelve weeks after the start of treatment."
62178017|NCT03402321|ACTIVE_COMPARATOR|control group|Gelatin Sponge Sheet is a heamostatic agent act as a mechanical barrier to protect the palatal donor site
62178018|NCT03402321|EXPERIMENTAL|intervention group|alvogyl in a paste form with analgesic action to protect the palatal donor site and help to relief pain
62178019|NCT02187445|EXPERIMENTAL|Budesonide inhalation suspension|To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
62178020|NCT04237714|EXPERIMENTAL|IBI-based automated support|Internet-based intervention with automated support by the system. It consistes in phone text messages twice a week for users. The content of the messages focuses on motivating and reminding users to complete the activities proposed in the program and reviewing the treatment contents. Additionally an automatic email is send if participants have not access the program for a week. The program also provides continuous feedback to users through transversal tools.
62178021|NCT04237714|EXPERIMENTAL|IBI-plus human support|In this condition, the participants receive automated support explained above and additionally human support for a maximum of 5 minutes that consist in a weekly phone call provided by a psychologist. The content of phone calls is related with resolve questions or doubts about the use and clinical content of the IBI and also motivating and reminding the importance to complete activities in the program.
62178022|NCT04237714|NO_INTERVENTION|Control group|Waiting list control group.
62178023|NCT01674452|EXPERIMENTAL|home-based group|
62178024|NCT01674452|ACTIVE_COMPARATOR|supervised exercise group|
62178025|NCT01674452|NO_INTERVENTION|control|Control group:no intervention
62178026|NCT03144778|EXPERIMENTAL|Cohort I (durvalumab)|Participants receive durvalumab IV over 1 hour on days 1 and 29 in the absence of disease progression or unaccepted toxicity. Between days 52 and 72, participants undergo standard of care surgery.
62178027|NCT03144778|EXPERIMENTAL|Cohort II (durvalumab, tremelimumab)|Participants receive durvalumab IV over 1 hour and tremelimumab IV over 1 hour on days 1 and 29 in the absence of disease progression or unaccepted toxicity. Between days 52 and 72, participants undergo standard of care surgery.
62178028|NCT06186726|EXPERIMENTAL|Study arm|The patients received 72GyE/18 fractions of carbon ion radiotherapy. Combined with platinum-containing schemes (including etoposide combined with cisplatin or carboplatin or loplatin or nedaplatin, paclitaxel combined with cisplatin or carboplatin or loplatin or nedaplatin, etc.); Docetaxel combined with cisplatin or carboplatin or loplatin or nedaplatin) for at least 4 cycles
62178029|NCT02564718|EXPERIMENTAL|Arm 1|Rivaroxaban oral suspension from granules will be dosed according to body weight as oral 0.1% suspension (1 mg/mL)
62178030|NCT06538519|ACTIVE_COMPARATOR|direct anterior approach group|
62178031|NCT06538519|ACTIVE_COMPARATOR|lateral approach group|
62178032|NCT05414006|EXPERIMENTAL|Group E1|S-ketamine was administered intravenously after delivery，patient controlled epidural analgesia（PCEA）was administered postoperatively PCEA formula：（10μg/ml hydromorphone+0.11% ropivacaine) 200ml
62178033|NCT05414006|EXPERIMENTAL|Group E2|S-ketamine was administered intravenously after delivery，patient controlled intravenous analgesia（PCIA) was administered postoperatively PCIA formula：（100μg/ml hydromorphone) 100ml
62178034|NCT05414006|PLACEBO_COMPARATOR|Group C1|placebo was administered intravenously after delivery，patient controlled epidural analgesia（PCEA) was administered postoperatively PCEA formula：（10μg/ml hydromorphone+0.11% ropivacaine) 200ml
62178035|NCT05414006|PLACEBO_COMPARATOR|Group C2|placebo was administered intravenously after delivery，patient controlled intravenous analgesia（PCIA） was administered postoperatively PCIA formula：（100μg/ml hydromorphone) 100ml
62178036|NCT00932555||Group 1|
62178037|NCT04799418|EXPERIMENTAL|Experimental Treatment 1|Study participants will self-administer \~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
62178038|NCT00506272|EXPERIMENTAL|Standard care|Patients admitted for elective surgery will receive standard diabetes care, including but not limited to finger stick blood glucose determinations, and insulin injections delivered by the nursing staff.
62742370|NCT04129268|EXPERIMENTAL|700kcal Cycle ergometry exercise at 60% VO2max|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
62742371|NCT01651065|EXPERIMENTAL|Microclinic Social Network Program|Subjects will be receiving a 10/9-month Microclinic Diabetes Education Program (Team Up 4 Health) and 6 months of follow up. In the intervention these subjects will engage in the Microclinic Program support groups. The intervention program consists of 25 event sessions. Sessions are offered weekly the first month, and biweekly thereafter.
62178039|NCT00506272|EXPERIMENTAL|Patient administered care|Patients will self-monitor and record finger-stick blood glucose measurements, and self administer insulin at doses agreed upon with the consulting endocrinology in-patient service.
62178040|NCT03292497|EXPERIMENTAL|Treatment algorithm|"Mitral valve will be replaced if posterior leaflet tethering angle \>=25 degrees.~Mitral valve will be repaired if posterior leaflet tethering angle \<25 degrees"
62178041|NCT03292497|ACTIVE_COMPARATOR|No treatment algorithm|Mitral valve will be repaired or replaced at surgeon's discretion.
62178042|NCT02157129|EXPERIMENTAL|LipoAerosol©|LipoAerosol© inhalation, 5x/d for 30min
62178043|NCT02157129|OTHER|Physiologic saline inhalation|Physiologic saline inhalation, 5x/d for 30min
62178044|NCT04518761||Prospective group|
62742372|NCT01651065|ACTIVE_COMPARATOR|Active Controls|Individuals will receive screening by clinical staff. Control group subjects are offered standard of care from local health department, but will not participate in program activities, other than offered option to join open-community health events.
62742373|NCT05757440|EXPERIMENTAL|Icon resin|Low-viscosity Icon resin infiltration
62178045|NCT04518761||Retrospective group|
62178046|NCT02097849|ACTIVE_COMPARATOR|Non-Pegylated IFN Treated Plus Vaccinations|"Participants on a stable approved dose of a non pegylated IFN for ≥3 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL"
62178047|NCT02097849|EXPERIMENTAL|Tecfidera Treated Plus Vaccinations|"Participants on a stable approved dose of Tecfidera (240 mg BID) for ≥6 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL"
62178048|NCT06165536|OTHER|Voice therapy|Resonant voice therapy is a standard of care procedure for treating phonotraumatic vocal hyperfunction. The full standardized voice therapy program will have a duration of four weeks, each week with one 60-minute therapy session.
62178049|NCT03767400||Group A - Young skin (18 - 30 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
62178050|NCT03767400||Group B - Aged skin (55 - 75 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
62178051|NCT03767400||Group C - Atrophic acne scars (18 - 75 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
62178052|NCT01920178|ACTIVE_COMPARATOR|PinPointe Foot Laser|Active laser
62178053|NCT01920178|SHAM_COMPARATOR|Sham laser group|Treatment with only localizing (aiming) beam of Pinpointe Foot Laser
62178054|NCT05384236|EXPERIMENTAL|kinesiology taping|Application of a neuromuscular bandage on the plantar fascia
62178055|NCT05384236|ACTIVE_COMPARATOR|taping or Low-dye taping|Application of a taping on the plantar fascia
62178056|NCT03945097||Letters|Education program focuses on learning letters.
62178057|NCT03945097||Language|Education program focuses on language comprehension.
62178058|NCT01406808|OTHER|standard of care plus genetic information|
62178059|NCT01406808|NO_INTERVENTION|usual standard of care without genetic information|
62178060|NCT00570557|NO_INTERVENTION|Group A Nurses|Participants receive neither web-based refresher courses nor periodic feedback by SLP
62178061|NCT00570557|EXPERIMENTAL|Group B Nurses|Participants receive web-based skill refresher courses but no periodic feedback by SLP
62178062|NCT00049335|EXPERIMENTAL|Capecitabine|Capecitabine 1,000 mg/m\^2/dose (2,000 mg/m\^2/day) BID, PO, Days 1-14 of 21 day cycle.
62742374|NCT05111002|EXPERIMENTAL|Lefamulin alone|Lefamulin 600mg tablet orally twice daily for 7 days
62742375|NCT05111002|EXPERIMENTAL|Doxycycline followed by lefamulin|Doxycycline 100mg tablet orally twice daily for 7 days followed by lefamulin 600mg tablet orally twice daily for 7 days
62742376|NCT04840485|EXPERIMENTAL|Treatment group A|
62742377|NCT04840485|EXPERIMENTAL|Treatment group B|
62742378|NCT04840485|PLACEBO_COMPARATOR|Treatment group C|
62742379|NCT05394597|EXPERIMENTAL|Treatment group|Receives a dose of repellent on the lower portion of the leg that is exposed
62742380|NCT05394597|NO_INTERVENTION|Control group|Does not receive a dose of repellent, but subject to similar exposure period
62742381|NCT06002555|EXPERIMENTAL|Single SC dose of 5 mg from DCS|
62742382|NCT06002555|EXPERIMENTAL|Two concomitant single SC doses of 2.5 mg from DCS|
62178063|NCT06365125|NO_INTERVENTION|Assessment Only|Assessment only condition, no intervention material delivered to this group
62178064|NCT06365125|ACTIVE_COMPARATOR|Intervention (BAI) Only|Only the brief alcohol intervention, eCHECKUP TO GO, is administered to this group
62742383|NCT06002555|ACTIVE_COMPARATOR|Single SC dose of 5 mg from vial|
62742384|NCT01851265|OTHER|Fasted|Olaparib capsules following no breakfast
62742385|NCT01851265|OTHER|Standard meal|Olaparib capsules after standard breakfast
62742386|NCT01851265|OTHER|High Fat|Olaparib capsules after high fat breakfast
62742387|NCT06104878||ABVD: Doxorubicin 25 mg/m^2 + Bleomycin 15 mg + Vinblastine 6 mg/m^2 + Dacarbazine 375 mg/m^2|Participants treated with doxorubicin 25 mg/m\^2, bleomycin 15 mg, vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2 as first line therapy in each 28-day cycle for up to 6 cycles from July 1st, 2017, to December 31st, 2020, will be observed retrospectively.
62178065|NCT06365125|EXPERIMENTAL|Enhanced Intervention|Brief alcohol intervention, eCHECKUP TO GO, + 4 weeks of text messaging boosters (Monday, Thursday-Sunday)
62178066|NCT06308497|EXPERIMENTAL|Trial Group|Patients within this group will undergo probiotic supplementation in addition to standard treatment
62178067|NCT06308497|ACTIVE_COMPARATOR|Control Group|Patients within this group will undergo standard treatment
62178068|NCT01237652||ISH and normotensive|This is a prospective cohort study to compare the incidence of perioperative myocardial ischemia between ISH and normotensive patients admitted for elective non-cardiac surgery. To reduce the number of confounding factors for perioperative myocardial ischemia, RCRI Class I or II patients will be recruited.
62178069|NCT01237652||ISH, Normotensive|This is a prospective cohort study to compare the incidence of perioperative myocardial ischemia between ISH and normotensive patients admitted for elective non-cardiac surgery. To reduce the number of confounding factors for perioperative myocardial ischemia, RCRI Class I or II patients will be recruited.
62178070|NCT05226247|OTHER|high-risk of weaning-induced pulmonary edema|Critically-ill patients under mechanical ventilation for more than 48h, who are at high-risk of weaning-induced pulmonary edema and in whom the attending physician decided to perform a spontaneous breathing trial.
62178071|NCT02864199|EXPERIMENTAL|Group A: Moderate Renal Impairment|Participants with CrCl 30 to 50 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 micrograms (mcg) via subcutaneous (SC) injection once weekly, in combination with ribavirin, 600 milligrams (mg) orally (PO) daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
62178072|NCT02864199|EXPERIMENTAL|Group B: Severe Renal Impairment|Participants with CrCl \<30 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 mcg via SC injection once weekly, in combination with ribavirin, 400 mg PO daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
62178073|NCT02864199|EXPERIMENTAL|Group C: Hemodialysis/ESRD|Participants requiring hemodialysis will receive 12 weeks of peginterferon alfa-2a, 135 mcg via SC injection once weekly, in combination with ribavirin, 200 mg PO every morning. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
62182463|NCT05436015|EXPERIMENTAL|Intervention Group|In addition to usual standard care during childbirth in hospital, the intervention group will receive a virtual nature-based intervention
62742388|NCT06104878||A+AVD: Brentuximab Vedotin 1.2mg/kg+Doxorubicin 25mg/m^2 +Vinblastine 6mg/m^2 +Dacarbazine 375mg/m^2|Participants treated with brentuximab vedotin 1.2 mg/kg, doxorubicin 25 mg/m\^2, vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2 as first line therapy in each 28-day cycle for up to 6 cycles from July 1st, 2017, to December 31st, 2020, will be observed retrospectively.
62742389|NCT01882556|EXPERIMENTAL|Botulinum Toxin - Type A (onabotulinumtoxinA)|Botulinum Toxin - Type A. One set of injections of up to 200 Units of Botox (Allergan). Injected to Biceps, Brachialis, Flexor Dig Superficialis, Flexor Dig Profundus, Flexor Carpi Radialis and Flexor Carpi Ulnaris.
62178074|NCT02864199|EXPERIMENTAL|Group D: Normal Renal Function|Participants with CrCl \>80 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 mcg via SC injection once weekly, in combination with ribavirin, 800 to 1200 mg PO daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
62178075|NCT04877249|EXPERIMENTAL|Gait training for stroke|
62178076|NCT04877249|ACTIVE_COMPARATOR|Gait training for healthy|
62178077|NCT01435798|PLACEBO_COMPARATOR|0% MTD Dex|0% MTD Dextromethorphan
62178078|NCT01435798|EXPERIMENTAL|25% MTD Dex|25% MTD Dextromethorphan
62178079|NCT01435798|EXPERIMENTAL|50% MTD Dex|50% MTD Dextromethorphan
62178080|NCT01435798|EXPERIMENTAL|100% MTD Dex|100% MTD Dextromethorphan
62178081|NCT04082377|EXPERIMENTAL|Recruitment maneuver with tidal volume (RM TV)|RMs were conducted under volume controlled ventilation with initial settings of a limit of peak inspiratory pressure at 40cmH2O, TV at 6 mL/kg PBW ,RR at 7 breaths/min, PEEP at 5 cmH2O, and I:E ratio at1:1. The TV was then increased by steps of 4 mL/kg PBW until plateau airway pressure (Pplt) was 40 cmH2O, after which 3 breaths were allowed. Finally, the limit of peak inspiratory pressure, TV, RR, and I:E ratio were reset at values equal to those preceding the RM. The ventilation protocol could be changed at any time when concerned about patient safety.
62178082|NCT04082377|ACTIVE_COMPARATOR|Recruitment maneuver by PEEP (RM PEEP)|"The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, inspiratory-to-expiratory (I:E) ratio at 1:2, and respiratory rate (RR) set to normocapnia 5 cmH2O PEEP.~RMs was conducted under pressure controlled ventilation so ventilation technique will be changed, pressure-control mode will be started and inspiratory time is increased to 50% (inspiratory: expiratory ratio will be set to 1:1). Peak airway inspiratory pressure (Ppeak) will be initially set to 20 cmH2O for three breaths, and then PEEP will be increased in steps from 5 to10 cmH2O for five breaths, from 10 to 15 cmH2O for seven breaths, from 15 to 20 cmH2O for ten breaths while Ppeak increased to 40 cmH2O and will be maintained for three more breaths. Following ARM, volume control will be re-established using Vt 6 mL/kg and step-wise reductions in PEEP from 20 to 15 cmH2O for three breaths,and then to 5 cmH2O until the end of recruitment maneuver."
62178083|NCT03671798||REM sleep behavior disorder (RBD)|Diagnosis of RBD according to ICSD-3: 1) Sleep talking or complex movement during sleep. 2) Such movement was recorded by video PSG (AV-PSG) during REM sleep or according to history the movements were occurred during REM. 3) REM sleep without atonia (RWA) during PSG monitoring. 4) This abnormal phenomenon cannot be explained by other sleep disorder, psychiatric disease, drug or substance abuse.
62178084|NCT03671798||Controls|Subjects with 1) No RBD symptoms and PSG characteristics. 2) No neurological symptoms or diseases, MRI scan will be employed to exclude brain pathology. 3) No narcolepsy or hypersomnia, ruled out by multiple sleep latency test. 4) No history of mental illnesses or use of antidepressants
62178085|NCT03552237|EXPERIMENTAL|dietary fiber intervention group|
62178086|NCT01154465|ACTIVE_COMPARATOR|Anatomical guidance puncture|"The patient is placed supine (with a slight neck extension for jugular punctures).~The preparation of the CVC installation will follow the procedures for disinfection, for skin preparation of the operator, for installation of sterile fields and for local anaesthesia.~The veins will be tracked by simple palpation of the carotid pulse.~The puncture will be made following:~* The anterior Boulanger's incision for the internal jugular vein;~* When venous aspiration is obtained, the catheter is assembled according to the Seldinger method."
62178087|NCT01154465|EXPERIMENTAL|US-guided puncture|"The patient is placed supine (with a slight neck extension for jugular punctures).~The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed. A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:~- The anterior Boulanger's incision for the internal jugular vein pathway;"
62178088|NCT03553849|EXPERIMENTAL|Very Low Calorie Diet|If they are randomized into the treatment arm, they will be prescribed with a 2-week VLCD that will begin 2 weeks prior to the scheduled elective surgery. Patients will be required to pay for the meal replacements.
62178089|NCT03553849|NO_INTERVENTION|Standard Preop Diet|The control group will continue a regular diet until the day before surgery.
62742390|NCT01882556|PLACEBO_COMPARATOR|0.9% NaCl Saline Injection|Saline - Injected to Biceps, Brachialis, Flexor Dig Superficialis, Flexor Dig Profundus, Flexor Carpi Radialis and Flexor Carpi Ulnaris.
62742391|NCT06660043|EXPERIMENTAL|physical activity|
62742392|NCT06660043|ACTIVE_COMPARATOR|analgesic physical therapy|
62178090|NCT05993520||Interstitial Lung Disease|Between June 2020 and June 2023, a total of 36 voluntary participants, aged 18 and above, who were receiving treatment at the Department of Chest Diseases, Istanbul Faculty of Medicine, Istanbul University, and met the inclusion criteria, were included in the study.
62178091|NCT03987659|ACTIVE_COMPARATOR|Root Canal Treatment without dECMs release|Two visit non-surgical root canal therapy with conventional irrigation protocols
62178092|NCT03987659|EXPERIMENTAL|Root Canal Treatment with dECMs release|Two visit non-surgical root canal treatment with irrigation protocols that optimise release of soluble dentine extracellular matrix components (dEMCs)
62178093|NCT00488228|EXPERIMENTAL|1|Participants in the behavioral self-regulation intervention will receive a modified standard treatment that incorporates daily weighing and training in self-regulation methods for weight loss. All treatment modules are adapted for a young adult age group.
62178094|NCT00488228|EXPERIMENTAL|2|Participants in the Standard group will receive a brief version of standard behavioral weight loss treatment with treatment modules tailored to better meet the needs of young adults.
62742393|NCT06660043|EXPERIMENTAL|analgesic physical therapy AND physical activity|
62742394|NCT03934580|EXPERIMENTAL|hallucinated meal|A breakfast meal (white bread plus ham and cheese with 250 ml still water) is hallucinated under hypnosis by participants for 15 minutes
62742395|NCT03934580|ACTIVE_COMPARATOR|real meal|A real meal (white bread plus ham and cheese with 250 ml still water) is consumed by participants in 15 minutes
62742396|NCT02417662|ACTIVE_COMPARATOR|Systemic Anti-Cancer Therapy (SACT) alone|The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
62178095|NCT00363649|EXPERIMENTAL|Arm A|Patients will receive injections of interferon alfa and sargramostim once a day for 6 months. Some patients may receive treatment for up to 1 year. After 1 year, some patients may receive treatment as in arm II.
62178096|NCT00363649|EXPERIMENTAL|Arm B|Patients will receive an injection of GM-K562 cell vaccine every 3 weeks for at least 6 months. Some patients may receive treatment for up to 1 year. After 1 year, some patients may receive treatment as in arm I. NOTE: Study Arm B is not available to newly accrued and enrolled subjects based on the interim analysis directing all new subjects to the combination of Interferon + sargramostim (Arm A).
62178097|NCT03667599|EXPERIMENTAL|Home care|This is the arm for patients who receive their transplant care in their homes.
62178098|NCT03667599|NO_INTERVENTION|Hospital Care|Standard of care for stem cell transplant recipients where the aftercare is done in hospital.
62742397|NCT02417662|EXPERIMENTAL|SACT + Radical Radiotherapy (Conventional RT and SABR)|"SACT followed by radical RT (conventional or SABR) to the primary and SABR to the metastatic sites.~The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines."
62178099|NCT03667599|NO_INTERVENTION|Clinic Care|Standard of care for stem cell transplant recipients who live at home but receive aftercare in the daily outpatient clinic.
62178100|NCT00392886|EXPERIMENTAL|Regimen C|Patients receive induction therapy of vincristine IV on days 1, 8, and 15 of courses 1-3, oral temozolomide once daily on days 1-5, and carboplatin IV over 4 hours on days 1 and 2. Patients also receive G-CSF SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients receive consolidation therapy of carboplatin IV over 4 hours on days -8 to -6 and thiotepa IV over 3 hours on days -5 to -3, undergo reinfusion of bone marrow or peripheral blood stem cells on day 0, and receive G-CSF SC beginning on day 1 and continuing until blood counts recover. Beginning within 6 weeks after transplantation, some patients undergo radiotherapy once daily 5 days a week for 4-6 weeks in the absence of disease progression or unacceptable toxicity and some patients undergo radiotherapy if there is evidence of tumor remaining after completion of induction chemotherapy.
62742398|NCT04926636|NO_INTERVENTION|Standard Mobile App|This group will be supplied with Novidan DTC hearing aids and documentation following standard of care as a control. They will be provided with the mobile application allowing for the monitoring of data for study analysis and personal control of their hearing aids, but not Health and Wellness Coaching features.
62742399|NCT04926636|EXPERIMENTAL|Enhanced Mobile App with Health Coaching|This group will also be supplied with the Novidan DTC hearings aids and documentation, same as the control group, but will be supplied the enhanced mobile application that allows for participation in health coaching features. They will be assigned to a health coach and will have coaching sessions scheduled.
62742400|NCT05255991|PLACEBO_COMPARATOR|Placebo|Matching placebo inhaled using an ultrasonic nebulizer QID
62178101|NCT00392886|EXPERIMENTAL|Regimen D2|In courses 1, 3, and 5, patients receive cisplatin IV over 6 hours on day 1, cyclophosphamide IV over 1 hour and etoposide IV over 2 hours on days 2 and 3, high-dose methotrexate IV over 4 hours on day 4, vincristine IV on days 1, 8, and 15 (in courses1 and 3), and filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until blood counts recover. In courses 2 and 4, patients receive oral temozolomide once daily on days 1-5, oral etoposide once daily on days 1-10, cyclophosphamide IV over 1 hour on days 11 and 12, vincristine IV on days 1, 8, and 15 (in course 2), and G-CSF SC beginning on day 13 and continuing until blood counts recover. Patients receive consolidation therapy as in regimen C in combination with etoposide IV over 3 hours on days -5 to -3 and undergo autologous bone marrow or peripheral blood stem cell transplantation, receive G-CSF, and undergo radiotherapy as in regimen C.
62178102|NCT06134583|ACTIVE_COMPARATOR|Superior cervical ganglion block group (CSB)|standardized protocol + CSB
62178103|NCT06134583|ACTIVE_COMPARATOR|Stellate ganglion block group (SGB)|standardized protocol + SGB
62178104|NCT02986750|EXPERIMENTAL|Experimental: Patients with dry eye syndrome 1|40 Patients with dry eye syndrome
62178105|NCT02986750|ACTIVE_COMPARATOR|Experimental: Patients with dry eye syndrome 2|40 Patients with dry eye syndrome
62742401|NCT05255991|EXPERIMENTAL|Inhaled Treprostinil|Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.
62742402|NCT06090864|EXPERIMENTAL|ATLCAR.CD30|Subjects will be enrolled on 1 of 3 dose levels as determined by a 3+3 design. Up to 25 evaluable subjects may then be enrolled in the phase II portion of the study. Subjects may have cells procured to manufacture the ATLCAR.CD30.CCR4 cells if they meet eligibility for procurement. During the time period necessary to manufacture the ATLCAR.CD30.CCR4 cells, Subjects will be allowed to receive standard-of-care bridging therapy at the discretion of their local oncologist. Prior to cell infusion, subjects will undergo additional eligibility evaluations, and then if eligible, will undergo lymphodepletion followed by cell infusion 2-14 days later. Subjects will then be followed for 15 years as is required for studies involving gene transfer experiments
62742403|NCT05629065|EXPERIMENTAL|Both patient and clinician receive a nudge|"* Patient nudge consists of a letter and SHARE questionnaire~* Clinician nudge email encouraging discussion to initiate discussion on SIC"
62742404|NCT05629065|NO_INTERVENTION|Neither the patient nor clinician receive a nudge|Standard Care
62742405|NCT05629065|EXPERIMENTAL|Patient receives a nudge but not the clinician|-Patient nudge consists of a letter and SHARE questionnaire
62742406|NCT05629065|EXPERIMENTAL|Clinician receives a nudge but not the patient|"-Clinician nudge email encouraging discussion to initiate discussion on SIC"
62742407|NCT06660394|EXPERIMENTAL|LP352|Participants will be titrated up to highest tolerated dose of LP352 during the Titration period (Visit 2 - Visit 5), followed by maintenance period (Visit 5 - Visit 8) and then taper/down titration period.
62742408|NCT06660394|PLACEBO_COMPARATOR|Placebo|Placebo for LP352
62178106|NCT02986750|ACTIVE_COMPARATOR|Experimental: Patients with dry eye syndrome 3|40 Patients with dry eye syndrome
62178107|NCT02950688|EXPERIMENTAL|Group 1: Seasonal LAIV|Participants will receive 1 dose of seasonal LAIV on Day 0. They will receive 1 dose of the wild-type A/California/2009-like influenza challenge virus on Day 56.
62178108|NCT02950688|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will receive 1 dose of placebo on Day 0. They will receive 1 dose of the wild-type A/California/2009-like influenza challenge virus on Day 56.
62178109|NCT03822195||asymptomatic|asymptomatic patients undergoing carotid endoarterectomy for stenosis \>70% (velocimetric criteria at echodoppler)
62178110|NCT03822195||symptomatic|symptomatic (TIA, crescendo TIA, minor stroke) patients undergoing carotid endoarterectomy, independently from stenosis evaluated by echodoppler
62178111|NCT06416319|EXPERIMENTAL|Daily Activity Goal and Feedback|The participants in the Daily Activity Goal and Feedback arm receive a defined daily activity goal in the form of a defined number of steps, feedback on the achievement of this goal, and push-up notifications sent directly to the wristband to encourage them to remain active.
62178112|NCT06416319|NO_INTERVENTION|No Daily Activity Goal or Feedback|The display of the fitness wristbands of the No Daily Activity Goal or Feedback arm is covered up. The participants in this arm neither receive a daily activity goal nor get feedback on the achievement of the activity goal/push-up notifications.
62178113|NCT04423536||tested group|
62178114|NCT04423536||controlled group|
62178115|NCT06240377|ACTIVE_COMPARATOR|Epte Bipolar System 2.0 - Ultrasound-guided percutaneous neuromodulation (NMP)|EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system. Ultrasound-guided percutaneous neuromodulation (NMP)
62178116|NCT06240377|ACTIVE_COMPARATOR|Epte Bipolar System 2.0 - Transcranial direct current stimulation (tDCS)|EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system. Transcranial direct current stimulation (tDCS)
62178117|NCT02299427|EXPERIMENTAL|dog safety|2 weeks of regular use of website on child dog safety developed for this research
62178118|NCT02299427|ACTIVE_COMPARATOR|transportation safety|2 weeks of regular use of publicly-available website on child transportation safety
62178119|NCT06178575||Manual microscopic observation|Control Group: Manual analysis of urine crystal images, distinguishing crystal types, recording accuracy, and analyzing the time consumed.
62178120|NCT06178575||Machine interpretation|The urine crystal images undergo analysis for crystal types, followed by image preprocessing and category labeling for machine software learning and inference. Subsequently, the interpreted results will be subjected to statistical analysis software to assess accuracy.
62178121|NCT02651883|ACTIVE_COMPARATOR|Screening invitation (with education)|Participants will receive a phone call providing (i) education on cervical cancer, and (ii) assistance scheduling an appointment for free cervical cancer screening at a study-affiliated clinic.
62178122|NCT02651883|EXPERIMENTAL|Self-collection for HPV testing|Participants in the intervention arm will receive a kit to self-collect a sample and return it for HPV testing. Participants will then receive a phone call providing their HPV results plus (i) education on cervical cancer, and (ii) assistance scheduling an appointment for free cervical cancer screening at a study-affiliated clinic, if desired.
62178123|NCT03553485|EXPERIMENTAL|taVNS|Treatment will be carried out twice a day (once before the RT session and 8h later) during 7 weeks. Each treatment takes 30 minutes.
62178124|NCT03553485|SHAM_COMPARATOR|Control|Treatment will be carried out twice a day (once before the RT session and 8h later) during 7 weeks. Each treatment takes 30 minutes.
62178125|NCT03497221|OTHER|Education intervention|The educational intervention is based on a hospital institutional protocol for patient using enteral tubes. A clinical simulation will be performed using a low fidelity manikin, where nursing technicians will identify and correct erros, such as: inconsistency between the patient's identification and the diet label, the administration of the diet with a low headboard, fixation of tube not detached and dirty, delay of the diet and others. The simulation will be described through a guide.
62178126|NCT03497221|OTHER|Visual identity campaign|"The visual identity will be given by a set of actions, called campaign. The campaign consists in the creation and implantation of different materials to be used at the bedside of the patients in use of diet by SNE, such as: (a) poster summarizing care, (b) colored adhesive label to identify devices (c) badge with safety care reminders."
62178127|NCT06479226|NO_INTERVENTION|Control|Toothbrushing alone
62178128|NCT06479226|EXPERIMENTAL|cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwash|Toothbrushing + mouthrinse
62178129|NCT02053064|EXPERIMENTAL|SAF-301|
62178130|NCT04152395||Metabolic group|Patients with metabolic syndrome undergoing EVAR
62178131|NCT04152395||Control group|Patients without metabolic syndrome undergoing EVAR
62178132|NCT00594178|EXPERIMENTAL|A|Exercise group
62178133|NCT05155709|EXPERIMENTAL|Arm 1: Unfit adult participants with AML who responded sub-optimally to standard of care|Unfit adult participants with AML who responded sub-optimally to at least 2 and not more than 4 cycles ( 1 cycle=28 days) of first-line venetoclax plus azacitidine therapy
62178134|NCT05155709|EXPERIMENTAL|Arm 2: Newly diagnosed unfit adult participants with high-risk AML|Unfit adult participants with newly diagnosed AML and with adverse genetic risk stratification (according to ELN 2022)(Except TP53 mutation positive participants).
62178135|NCT01584271|ACTIVE_COMPARATOR|2 Dex-Otic ear drops|Dex-Otic(R) ear drops are used for pain relief and treating ears of AOE patients. It contains: Dexamethasone Sodium Phosphate 1 mg; Neomycin sulfate 5 mg; Polymyxin B sulfate 10,000 units. It
62178136|NCT01584271|EXPERIMENTAL|3 Ear Comfort(TM) ear drops|Natural Ear comfort(TM) ear drops contains Chamomile extract and Thyme oil in anhydrous glycerin for pain relief and ear healing.
62182464|NCT05436015|NO_INTERVENTION|Control Group|The control group receives the usual standard care during childbirth in hospital
62178137|NCT01584271|ACTIVE_COMPARATOR|1 Otidin(R) ear drops|Otidin(R): Ear drops containing Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin for pain relief in AOE patients.
62178138|NCT00510263|EXPERIMENTAL|1|
62178139|NCT00510263|EXPERIMENTAL|2|
62178140|NCT00510263|EXPERIMENTAL|3|
62178141|NCT00510263|PLACEBO_COMPARATOR|4|
62178142|NCT02358213|OTHER|Procedure|5 ultrasounds were done on 20 patients by 5 different sonographers
62178143|NCT03987464|EXPERIMENTAL|Patients with MCI|Participants diagnosed with mild cognitive impairment (MCI) and their study partners
62178144|NCT06105047|EXPERIMENTAL|Patients with Alzheimer disease|Patients will perform experimental task in four conditions : control, mime, emotion, dual
62178145|NCT01721174|ACTIVE_COMPARATOR|SEMS only|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. An uncovered self expanding metallic stent (SEMS) would be inserted to bypass the site of narrowing (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea)
62178146|NCT01721174|ACTIVE_COMPARATOR|EBRFA and SEMS|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. The radiofrequency ablation (EBRFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter with energy delivered by an RFA generator would be used to apply RFA to the entire length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. Patients would undergo 2 sessions of EBRFA 2 weeks apart. A plastic stent would be inserted in between the 2 sessions. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after the second EBRFA.
62178147|NCT02316847|EXPERIMENTAL|diazepam nasal spray (Adults)|One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
62178148|NCT02316847|EXPERIMENTAL|Diazepam Nasal Spray (Adolescents)|One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
62178149|NCT04520841|ACTIVE_COMPARATOR|Standard dry dressing in total hip or knee arthroplasty|Standard dressing in total hip or knee arthroplasty surgery revision: a dry sterile dressing is applied on the surgical wound at the end of surgery
62178150|NCT04520841|EXPERIMENTAL|Prevena in total hip or knee arthroplasty|"Prevena incision management system in total hip or knee arthroplastsy surgery revision:~The Prevena incision management system is applied on the surgical wound at the end of surgery"
62178151|NCT04520841|ACTIVE_COMPARATOR|Standard dry dressing in lower limb amputation|Standard dressing in lower limb amputation: a dry sterile dressing is applied on the surgical wound at the end of surgery
62178152|NCT04520841|EXPERIMENTAL|Prevena in lower limb amputation|"Prevena incision management system in lower limb amputation:~The Prevena incision management system is applied on the surgical wound at the end of surgery"
62178153|NCT01102387|EXPERIMENTAL|LAS41003|
62178154|NCT01102387|ACTIVE_COMPARATOR|LAS189962|
62178155|NCT01102387|ACTIVE_COMPARATOR|LAS189961|
62178156|NCT00474383|EXPERIMENTAL|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) tablet or capsule will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study, along with prednisone/prednisolone 5 mg tablet orally twice daily or dexamethasone 0.5 mg tablet orally once daily.
62178157|NCT05772481||Adult population with rectal cancer|
62178158|NCT04185987|EXPERIMENTAL|Microbial colonisation|microbial sample collection was done at the end of the time periods T1 (6 weeks after bonding ), 10 weeks after bonding (T2), 14 weeks after bonding (T3), 18 weeks after bonding (T4)
62178159|NCT04185987|EXPERIMENTAL|Plaque index|Plaque index was measured prior to bonding (T0), 6 weeks after bonding (T1),10 weeks after bonding (T2), 14 weeks after bonding (T3), 18 weeks after bonding (T4)
62178160|NCT04185987|EXPERIMENTAL|Gingival index|Gingival index was measured prior to bonding (T0), 6 weeks after bonding (T1), 10 weeks after bonding (T2), 14 weeks after bonding (T3), 18 weeks after bonding (T4)
62178161|NCT04185987|EXPERIMENTAL|surface roughness|surface roughness was measured before usage and after 4-weeks usage
62178162|NCT04915547|EXPERIMENTAL|Group-Based Exercise|The group-based exercise (GBE) programme will be delivered by a physiotherapist. The GBE comprises three sessions per week of group-based exercise in a local community centre, for 8 weeks.
62178163|NCT04915547|NO_INTERVENTION|Control Group|Participants randomly allocated to the control group will remain on a waiting list. In addition, weekly contact will be made to ensure that they do not start treatment during the study protocol. After the end of the study, participants randomly allocated to the control group will receive the same intervention as the Group-Based Exercise.
62178164|NCT05127330|EXPERIMENTAL|LifePlans|LifePlans is a video series using real patients telling their stories of overcoming suicidal thoughts and behaviors to help others who are struggling with these issues.
62178165|NCT05127330|ACTIVE_COMPARATOR|Treatment as Usual|Individuals will receive unrestricted routine care only.
62178166|NCT01648985||Acute stroke and TIA patients|Cohort of acute stroke patients, admitted to the Stroke Unit Danderyd hospital 2010 - 2012
62178167|NCT02774564|EXPERIMENTAL|Nebicapone 50 mg|1 tablet of 50 mg plus 3 tablets of placebo concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
62178168|NCT02774564|EXPERIMENTAL|Nebicapone 100 mg|2 tablets of 50 mg plus 2 tablets of placebo concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
62178169|NCT02774564|EXPERIMENTAL|Nebicapone 200 mg|4 tablets of 50 mg concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
62178170|NCT02774564|PLACEBO_COMPARATOR|Placebo|4 tablets concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
62178171|NCT02664025|ACTIVE_COMPARATOR|simulation group|Interns will carry out 10 VE on a simulator
62178172|NCT02664025|NO_INTERVENTION|Control group|Interns who will not perform any simulated VE
62178173|NCT01099683|EXPERIMENTAL|NRL001|All subjects will receive 10 mg NRL001 in a 2 g rectal suppository
62178174|NCT01099683|PLACEBO_COMPARATOR|Placebo|All subjects will receive placebo
62178175|NCT03471897||RCC|Patients with pathologically confirmed diagnosis of RCC
62178176|NCT03471897||Controls|Subjects self-reported as healthy
62178177|NCT06233474|OTHER|Safety run-in phase - Allocetra increasing dose|An open-label dose escalation phase to characterize the safety and tolerability of Allocetra injections to the knee in different doses and select the Allocetra dose and regimen for the randomized phase.
62178178|NCT06233474|PLACEBO_COMPARATOR|Randomization phase - Placebo.|Three intra-articular injections of placebo into the index knee.
62178179|NCT06233474|EXPERIMENTAL|Randomization phase - Allocetra|Three intra-articular injections of Allocetra at a selected dose, into the index knee.
62178180|NCT04145609|EXPERIMENTAL|Intensified care|Experimental: Multidisciplinary team (MDT) care + Acute kidney disease (AKD) clinic Participants randomized to this arm will receive multidisciplinary team (MDT) care by a specialized medical team which is composed of nephrologist, pharmacist and dietitian. Besides intensified care, participants of this arm receive evaluation of biochemical and physiological renal function more frequently. In order to provide seamless care of this group, post-discharge acute kidney disease (AKD) clinic will also be arranged for them. Clinic visits consist of evaluation of renal function, reconciliation of medication and steering necessity of renal replacement therapy.
62178181|NCT04145609|NO_INTERVENTION|Usual care|No intervention: Usual care Participants randomized to this arm will receive usual care according to the medical decisions of principal care physician. Nephrologist consultation and nephrology outpatient clinic follow-up will be allowed. However, this group of patient will not have access to MDT care and AKD clinic.
62178182|NCT03023852|EXPERIMENTAL|Panel 1: Group 1|Participants will receive Treatment A (JNJ-63623872 600 milligram (mg) (2\*300 mg) oral tablets \[reference\]) followed by Treatment B (JNJ- 63623872 600 mg (2\*300 mg) concept oral tablet formulation 1 (test 1) and then Treatment C (JNJ-63623872 600 mg (2\*300 mg) concept oral tablet formulation 2 (test 2). Each treatment period will be separated 7 days washout period.
62178183|NCT03023852|EXPERIMENTAL|Panel 1: Group 2|Participants in Group 2 will receive Treatment A followed by Treatment C and then Treatment B with a washout period of minimum 7 days.
62178184|NCT03023852|EXPERIMENTAL|Panel 1: Group 3|Participants in Group 3 will receive Treatment B followed by Treatment A and then Treatment C with a washout period of minimum 7 days.
62178185|NCT03023852|EXPERIMENTAL|Panel 1: Group 4|Participants in Group 4 will receive Treatment B followed by Treatment C and then Treatment A with a washout period of minimum 7 days.
62178186|NCT03023852|EXPERIMENTAL|Panel 1: Group 5|Participants in Group 5 will receive Treatment C followed by Treatment A and then Treatment B with a washout period of minimum 7 days.
62178187|NCT03023852|EXPERIMENTAL|Panel 1: Group 6|Participants in Group 6 will receive Treatment C followed by Treatment B and then Treatment A with a washout period of minimum 7 days.
62178188|NCT03023852|EXPERIMENTAL|Panel 2: Group 7|Participants in Group 7 will receive Treatment D \[JNJ-63623872/37.5 mg Oseltamivir oral fixed dose combination (FDC) tablet concept formulation (test 3)\] followed by Treatment E (JNJ-63623872 600 mg, administered as 2\*300 mg and Oseltamivir 75 mg, administered as 1\*75 mg). Both treatment periods will be separated with a minimum of 7 days washout period.
62178189|NCT03023852|EXPERIMENTAL|Panel 2: Group 8|Participants in Group 8 will receive Treatment E followed by Treatment D with a washout period of minimum 7 days.
62178190|NCT02025647||Innerview MHCDS|Innerview, Mental Health Clinical Decision Support tool
62178191|NCT05910697|NO_INTERVENTION|Control arm - Baseline comparison|The Control group treats their simulated patients using standard practice and has no introduction to the new MyProststate 2.0 test.
62178192|NCT05910697|EXPERIMENTAL|MyProstateScore 2.0|The intervention will receive information regarding the MyProstateScore 2.0 test and will be given the test results in their round of CPV information and for each sample that they submit.
62178193|NCT05708313|EXPERIMENTAL|Cardiac Rehabilitation|people recruited for the trial will participate in the Intensive cardiac rehabilitation arm.
62178194|NCT04938765|EXPERIMENTAL|Magnesium sulfate arm|MgSo4 diluted to 20% will be administered at 40 mg/kg dosed to ideal body weight over 10min to the study arm followed by 10mg/kg/hr infusion.
62178195|NCT04938765|PLACEBO_COMPARATOR|Normal Saline|20 ml of normal saline bolus will be administered to the control group over 10 mins.
62178196|NCT02413593|EXPERIMENTAL|LDV/SOF+RBV|LDV/SOF FDC plus RBV for 12 weeks
62178197|NCT04947826|EXPERIMENTAL|HAIC + HLX10 + HLX04|HAIC: FOLFOX, q3w, up to 8 times; HLX10: 4.5mg/kg, iv, q3w, up to 2 years; HLX04: 15.0mg/kg, iv, q3w, up to 2 years.
62178198|NCT04947826|PLACEBO_COMPARATOR|HAIC + Placebo|HAIC: FOLFOX, q3w, up to 8 times; Placebo1: saline, iv, q3w, up to 2 years; Placebo2: saline, iv, q3w, up to 2 years.
62178199|NCT01572298|ACTIVE_COMPARATOR|allograft alone|guided bone regeneration with allograft alone (includes tenting screws and overlying allograft membrane material)
62178200|NCT01572298|EXPERIMENTAL|allograft with autograft|guided bone regeneration with allograft and autograft combined (includes tenting screws and overlying allograft membrane material)
62182465|NCT03308747|EXPERIMENTAL|High systemic inflammation|Individuals assigned in the high systemic inflammation group will be characterized by IL6: ≥ 1.7 pg/ml and hs-CRP: \> 2.0 mg/L.
62365069|NCT03423563|EXPERIMENTAL|Fexible intubation video endoscopy|Video-assisted techniques allow to indirectly visualize the laryngeal structures with fiber optical or camera chip technique and to show the video picture on an external or built-in monitor
62365070|NCT02062476|EXPERIMENTAL|Treatment with Lactobacillus GG|extensively hydrolyzed casein formula containing LGG
62365071|NCT02062476|NO_INTERVENTION|Children at diagnosis|
62365072|NCT05401604|EXPERIMENTAL|Moderate probiotic beer consumption|1 can of 330ml (3.5-5% alcohol) probiotic beer. Ingredients: water, grains, raspberry puree, yeast, and lactic acid bacteria (Lactobacillus paracasei Lpc-37®, or Lactobacillus paracasei LAFTI®L26).
62365073|NCT05401604|PLACEBO_COMPARATOR|Moderate normal beer consumption|1 can of 330ml (3.5-5% alcohol) normal beer. Ingredients: water, grains, raspberry puree, and yeast.
62365074|NCT06056401|EXPERIMENTAL|VCV group|For patients assigned in this group, after standard anesthesia, in which the following drugs were used (midazolam 0.05 mg / kg;propofol 1.5-2.5 mg / kg; sufentanil 0.3-0.5 μg / kg; and cisatracurium0.2-0.3 mg / kg), their mechanical ventilation mode was adjusted to the VCV mode.
62742409|NCT03848130|ACTIVE_COMPARATOR|Knee Taping with Home Exercises (Group 1)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into knee taping group.Each subject in first group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
62742410|NCT03848130|ACTIVE_COMPARATOR|Lateral wedge insoles with Home Exercises (Group 2)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into lateral wedge insole group.Each subject in second group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
62742411|NCT03848130|ACTIVE_COMPARATOR|Traditional Physiotherapy with Home Exercises (Group 3)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into traditional physiotherapy group.Each subject in third group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
62742412|NCT04668833|EXPERIMENTAL|Treatment (Autologous Lymphocyte Infusions)|The purpose of this study is to determine the safety and preliminary efficacy of un-manipulated autologous lymphocyte infusion (ALI) using the patient's own lymphocytes collected using apheresis, and infused after the completion of radiation/chemoradiation.
62742413|NCT01524224|EXPERIMENTAL|LY2495655|"Administered intravenously (IV) every 2 weeks (14 days) for four (4) 14 day cycles. Participants receiving clinical benefit may continue to receive treatment until one or more of the discontinuation criteria are met.~Starting dose in Part 1 (dose escalation) will be 2 mg. The dose will be subsequently increased to 7 mg, 21 mg, 70 mg, 210 mg, and 700 mg. The dose administered in Part 2 (dose confirmation) will be determined from Part 1."
62742414|NCT06658379||fracture cohort|Humerus fracture, forearm fracture, femoral fracture. tibia fracture
62742415|NCT06553300|EXPERIMENTAL|Autotransplantation with PRF|
62742416|NCT06553300|ACTIVE_COMPARATOR|Autotrasplantation only|
62742417|NCT06209138|EXPERIMENTAL|CO2 laser assisted dermabrasion and 5FU film|
62742418|NCT06209138|ACTIVE_COMPARATOR|CO2 laser assisted dermabrasion and saline|
62742419|NCT04801849|ACTIVE_COMPARATOR|Vitamin E, 200 IU|200 IU of d-alpha tocopherol (vitamin E) taken once daily with breakfast
62742420|NCT04801849|ACTIVE_COMPARATOR|Vitamin E, 400 IU|400 IU of d-alpha tocopherol (vitamin E) taken once daily with breakfast
62742421|NCT04801849|ACTIVE_COMPARATOR|Vitamin E, 800 IU|800 IU of d-alpha tocopherol (vitamin E) taken once daily with breakfast
62742422|NCT04801849|PLACEBO_COMPARATOR|Placebo|matching placebo taken once daily with breakfast
62742423|NCT01562314|EXPERIMENTAL|GWP42003|GWP42003 was administered orally at a dose of 50 mg up to 250 mg, BID, in the fasted state in the morning and evening, for 10 weeks. Following randomization, participants entered a 2-week dose escalation period to achieve their maximum tolerated dose, up to 500 mg, and maintained this dose for the rest of the treatment period. Participants were then followed for 1 week.
62742424|NCT01562314|PLACEBO_COMPARATOR|Placebo|Placebo capsules matching the study drug were administered orally, BID, in the fasted state in the morning and evening, for 10 weeks. Participants were then followed for 1 week.
62742425|NCT01716039|ACTIVE_COMPARATOR|MTX 12.5|Receive once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX and/or placebo in addition to doses of adalimumab
62742426|NCT01716039|ACTIVE_COMPARATOR|MTX 25 mg|Once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX in addition to doses of adalimumab
62742427|NCT01716039|PLACEBO_COMPARATOR|Placebo|Once weekly oral dosing with placebo (n=20) two weeks prior to the initiation of adalimumab. Subjects will receive 18 weekly doses of placebo in addition to doses of adalimumab
62742428|NCT05457153|EXPERIMENTAL|Technology-Based Well-Being Process Program|"WEBEPROP will be conducted for 8 weeks. The program for the intervention group is included the modüls. In the program, the modules of Self-Knowledge, Inner Communication and Awareness of Perceptions, Emotion and Thought Management will be completed in 8 weeks (each model two weeks) . The other module will not be accessible and cannot be switched before the prevous module is completed."
62742429|NCT05457153|ACTIVE_COMPARATOR|Control Group|After the first follow-ups have been made to the control group, they will continue to receive standard care. After the monitoring of the initiative group within the scope of the program is completed, the website of the well-being process program will be made available to the control group. Children and adolescents will benefit from the modules by promoting the website.
62742430|NCT06435416||PNI trajectory group 1|
62742431|NCT06435416||PNI trajectory group 2|
62742432|NCT01247025||Veterans|Veterans receiving mental health services at the Eastern Colorado Healthcare System (ECHCS)/Denver Veterans Affairs Medical Center (VAMC)
62742433|NCT06661187|EXPERIMENTAL|Cryoanalgesia|Patients who received cryoanalgesia: patients subjects underwent arterial puncture. patients in the intervention group had a small plastic bag filled with 12 oz of crushed ice applied to the radial artery puncture site for 3 min (timed with a stopwatch) without external compression or massage.
62178201|NCT00574600|EXPERIMENTAL|Vaccine|SAAVI DNA-C2 administered as 1 ml intramuscularly in either deltoid at study entry and Months 1 and 2; SAAVI MVA-C administered as 0.5 ml intramuscularly in either deltoid at Months 4 and 5
62178202|NCT00574600|PLACEBO_COMPARATOR|Placebo|Placebo administered at Months 0, 1, 2, 4 and 5
62178203|NCT03427008|NO_INTERVENTION|Standard of Care|Participants in the control arm will be instructed to take their immunosuppressive medications as prescribed and attend required follow-up as is standard of care, and will not receive the mHealth app.
62178204|NCT03427008|EXPERIMENTAL|mHealth Intervention|Participants in the intervention arm will receive the mHealth app either while they are an inpatient post-transplant, or at their first post-transplant clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the mHealth app and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
62178205|NCT02981537|EXPERIMENTAL|two-staged|positioning endobronchial blockers to appropriate bronchus with two-staged methods
62178206|NCT02981537|ACTIVE_COMPARATOR|single-staged|positioning endobronchial blockers with traditional single-staged methods
62178207|NCT02999932|EXPERIMENTAL|Low SpO2 group|SpO2 90-95%, with FiO2 as low as possible.
62178208|NCT02999932|ACTIVE_COMPARATOR|High SpO2 group|SpO2 96-100%, with FiO2 no lower than 30%.
62178209|NCT01575483||Patients with T2DM|Patients with diagnosis of type 2 diabetes mellitus (T2DM) initiating Onglyza® treatment within the approved indications will be enrolled
62178210|NCT00575367|ACTIVE_COMPARATOR|AzaSite|
62178211|NCT00575367|ACTIVE_COMPARATOR|Vigamox|
62178212|NCT05052749|EXPERIMENTAL|High Intensity Resistance Training (HIRT)|In this HIRT group, participants will perform warm-up activity for 15 minutes then high intensity resistance exercises with 120 seconds of rest interval between each set of exercise and between exercises respectively. After that, generalized stretching exercises as a cool down activity will be performed by the participants. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks under supervision.
62178213|NCT05052749|ACTIVE_COMPARATOR|Low-moderate Resistance Exercise Training|In this low-moderate resistance training group, participants will perform warm-up activity for 15 minutes then low-moderate intensity resistance exercises with 120 seconds of rest interval between each set of exercise and between exercises respectively. After that, generalized stretching exercises as a cool down activity will be performed by the participants. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks under supervision.
62178214|NCT02182583|EXPERIMENTAL|Ba253BINEB|
62178215|NCT02182583|ACTIVE_COMPARATOR|Ba253MDI|
62178216|NCT02010398|ACTIVE_COMPARATOR|Cross-Training healthy subjects|A cohort of healthy subjects (N=15) will undergo a phase of intervention consisting of cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
62178217|NCT02010398|ACTIVE_COMPARATOR|Standard-Training multiple sclerosis|A cohort of patients with multiple sclerosis (N=15), presenting with a marked asymmetry in limb strength, will undergo a standard-training of the more-impaired limb employing an isokinetic contraction regimen at maximal intensity.
62178218|NCT02010398|EXPERIMENTAL|Cross-Training multiple sclerosis|A cohort of patients with multiple sclerosis (N=15), presenting with a marked asymmetry in limb strength, will undergo a cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
62178219|NCT02010398|NO_INTERVENTION|Healthy Control|A cohort of healthy subjects (N=15) will undergo baseline assessment and a second evaluation after one month of no-intervention
62365075|NCT06056401|EXPERIMENTAL|PCV group|For patients assigned in this group, after standard anesthesia, in which the following drugs were used (midazolam 0.05 mg / kg;propofol 1.5-2.5 mg / kg; sufentanil 0.3-0.5 μg / kg; and cisatracurium0.2-0.3 mg / kg), their mechanical ventilation mode was adjusted to the PCV mode.
62365076|NCT04960462||the treatment of sacral cysts in patients with sacral cysts by using nerve root sleeve reinforcement|The clinical data of patients with sacral cysts treated with nerve root sleeve reinforcement and reconstruction of the sacral canal cyst were summarized and followed up from 3 to 6 months after the operation to form a case summary and report.
62178220|NCT06183619||Pulmonary vein isolation plus superior vena cava isolation|
62178221|NCT06183619||Pulmonary vein isolation|
62365077|NCT05911737||Patients diagnosed with Obstructive Sleep Apnea|Patients diagnosed with Obstructive Sleep Apnea
62365078|NCT05911737||Patients not diagnosed with Obstructive Sleep Apnea|Patients not diagnosed with Obstructive Sleep Apnea
62178222|NCT02210013||Caucasian women|200 Caucasian infertile women undergoing their first or second IVF cycle
62178223|NCT02210013||Indian women|200 Indian women undergoing their first or second IVF cycle.
62178224|NCT01836016|EXPERIMENTAL|conventional medicine|According to the individualized assessment of symptoms and exacerbation risk recommended by revised 2011 GOLD, patients in this group will be given conventional medicine treatment including three drugs, which are Salbutamol (Ventolin®), Formoterol (Oxis Turbuhaler®), Salmeterol / fluticasone (Seretide®).
62178225|NCT01836016|EXPERIMENTAL|traditional Chinese medicine|Patients in this group will receive four types of TCM treatment according to traditional Chinese syndrome differentiation and treatment, which are Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule.
62178226|NCT01836016|EXPERIMENTAL|conventional medicine + TCM|Patients in this group will receive conventional medicine and traditional Chinese medicine.
62178227|NCT00664456|ACTIVE_COMPARATOR|AHT group|Randomized patients undergo 3-month neoadjuvant therapy (NHT)within 14 days and receive 9-month adjuvant therapy (AHT) following after Iodine I-125 implantation (TPPB).
62178228|NCT00664456|ACTIVE_COMPARATOR|Non-AHT group|Rondomized patients undergo 3-month neoadjuvant therapy (NHT) within 14 days and receive Iodine I-125 implantation therapy (TPPB). 40 weeks observation is followed under no further treatment.
62742434|NCT06661187|EXPERIMENTAL|Psychological instructions|Psychological interventions using verbal signals of the impending procedure, music distraction, visual distraction, and breathing interventions be used during arterial puncture injections in adults
62178229|NCT00337285|EXPERIMENTAL|1|
62178230|NCT02604797|EXPERIMENTAL|Nalbuphine|Nalbuphine group: nalbuphine 100 mg, ramosetron 0.3mg, background dose 1ml/h,patient-controlled analgesia(PCA) 1ml/time, lockout time 10 min, flurbiprofen axetil 50mg 6h after operation.
62742435|NCT06661187|PLACEBO_COMPARATOR|control group|Patients received routine care
62365079|NCT02177214||ventral hernia|Adult patients scheduled for elective laparoscopic repair of ventral hernia, with inclusion of primary and incisional hernias. Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
62365080|NCT01229280|EXPERIMENTAL|Darisec(R) 7.5 mg|
62365081|NCT01229280|ACTIVE_COMPARATOR|Enablex(R) 7.5 mg|
62365082|NCT02853149|EXPERIMENTAL|Spinal Cord Injury (SCI)|Experimental: Lifestyle Intervention This arm will examine whether a twelve month treatment program (one year) for Spinal Cord injury individuals enrolled with their caregivers, can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life using a 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
62365083|NCT02853149|ACTIVE_COMPARATOR|Caregiver Intervention(CCC)|Lifestyle Intervention This arm will examine whether a twelve month treatment program (one year) enrolled with their Care-receivers( SCI individuals) can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life using a 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
62178231|NCT02604797|EXPERIMENTAL|Sufentanil|Sufentanil group: sufentanil 100ug, ramosetron 0.3mg, background dose 1ml/h, PCA 1ml/time, lockout time 10 min, flurbiprofen axetil 50mg 6h after operation.
62178232|NCT00718198||Pre-protocol group|Group admitted 1 (one) month before CPOE protocol changes were made
62365084|NCT02853149|PLACEBO_COMPARATOR|Caregiver Control (CC)|Placebo: This arm will examine whether a twelve month treatment program (one year) enrolled with their Care-receivers( SCI individuals) can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life. The control group intervention will test benefits of exercise alone while controlling for investigator contact.
62365085|NCT02168712|ACTIVE_COMPARATOR|Moderate continuous exercise training|Moderate intensity continuous exercise training
62365086|NCT02168712|EXPERIMENTAL|Interval exercise training|High intensity interval exercise training
62742436|NCT05148650|EXPERIMENTAL|Crystalloid infusion|Intravenous (IV) transfusions were performed of a 20ml/kg of a balanced crystalloid solution (Optilyte®, Fresenius Kabi). The infusions were performed through an intravenous cannula (18G) inserted into a vein in the antecubital fossa on the non-dominant limb at 1000 ml/h
62391479|NCT02108158|ACTIVE_COMPARATOR|Azzalure, 10 Speywood units/injection|Azzalure (botulinum toxin type A), powder for solution for injection, Total dose 50 s.U (5 x 10s.U)
62391480|NCT03283813|ACTIVE_COMPARATOR|Active group - Zinc and Myo-inositol|This arm will receive a supplementation with Zinc and Myo-inositol once a day.
62742437|NCT05148650|EXPERIMENTAL|Colloid infusion|Intravenous (IV) transfusions were performed of a 20ml/kg of gelatin 26,500 Da (Geloplasma®, Fresenius Kabi). The infusions were performed through an intravenous cannula (18G) inserted into a vein in the antecubital fossa on the non-dominant limb at 1000 ml/h
62178233|NCT00718198||Post-protocol group|Group admitted 1 (one) year after CPOE protocol changes were made
62178234|NCT03282578|ACTIVE_COMPARATOR|Sternalock 360 sternal plating system|use of the SternaLock 360 system to close the sternum: 3 plates with 3 bands and measured screw length to engage but not penetrate the posterior sternal cortex, used to close the sternum
62178235|NCT03282578|ACTIVE_COMPARATOR|Sternal wires|"Stainless steel sternal wires applied in a figure of 8 configuration to close the sternum"
62742438|NCT00682903|EXPERIMENTAL|1|This arm will benefit from the nonstop measure of the subcutaneous glucose during the hospitalization and the week on returning to the place of residence,
62742439|NCT03583268|ACTIVE_COMPARATOR|Moderate Intensity Exercise Alone|45 minutes of moderate intensity exercise at 45-55% of maximum aerobic capacity (active participants) or heart rate reserve (sedentary participants) used as a control condition. Participants will consume a glucerna bar at 10pm following this session.
62742440|NCT03583268|EXPERIMENTAL|70% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 70% heart rate reserve every 4 minutes. Note: this session is not included for the active participants. Participants will consume a glucerna bar at 10pm following this session.
62742441|NCT03583268|EXPERIMENTAL|80% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 80% of heart rate reserve every 4 minutes. Note: this session is not included for the active participants. Participants will consume a glucerna bar at 10pm following this session.
62178236|NCT03903562|EXPERIMENTAL|V503|V503 administered as a 0.5 mL intramuscular injection at Day 1, Month 2 and Month 6.
62178237|NCT04068909||acute coronary syndrome|All patients should receive standard therapy for acute coronary syndrome and concomitant diseases. All drugs are prescribed according current guidelines and approved indications.
62178238|NCT04458987|EXPERIMENTAL|Expert patient in addictology|before/ after comparison, each patients being its own control
62178239|NCT02189369|EXPERIMENTAL|Day 3 embryo-Own-above cutoff|Day 3 embryo transfer for IVF with own oocytes, and prostaglandine levels with higher receptivty rates
62178240|NCT02189369|EXPERIMENTAL|Day 5 embryo-Own-above cutoff|Day 5 embryo transfer for IVF with own oocytes, and prostaglandine levels with higher receptivty rates
62178241|NCT02189369|EXPERIMENTAL|Day 3 embryo-Donor-above cutoff|Day 3 embryo transfer for IVF with donor oocytes, and prostaglandine levels with higher receptivty rates
62178242|NCT02189369|EXPERIMENTAL|Day 5 embryo-Donor- above cutoff|Day 5 embryo transfer for IVF with donor oocytes, and prostaglandine levels with higher receptivty rates
62178243|NCT02189369|EXPERIMENTAL|Day 3 embryo-Donor-lower cutoff|Day 3 embryo transfer for IVF with donor oocytes, and prostaglandine levels with lower receptivty rates
62178244|NCT02189369|EXPERIMENTAL|Day 5 embryo-Donor-lower cutoff|Day 5 embryo transfer for IVF with donor oocytes, and prostaglandine levels with lower receptivty rates
62178245|NCT02189369|EXPERIMENTAL|Day 3 embryo-own-lower cutoff|Day 3 embryo transfer for IVF with own oocytes, and prostaglandine levels with lower receptivty rates
62178246|NCT02189369|EXPERIMENTAL|Day 5 embryo-own-lower cutoff|Day 5 embryo transfer for IVF with own oocytes, and prostaglandine levels with lower receptivty rates
62742442|NCT03583268|EXPERIMENTAL|90% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 90% of maximum aerobic capacity (active participants every two minutes) or heart rate reserve (sedentary participants every 4 minutes). Participants will consume a glucerna bar at 10pm following this session.
62391481|NCT03283813|PLACEBO_COMPARATOR|Placebo group|This arm will receive a supplementation with a same product equal to the active product but without Zinc and Myo-inositol inside.
62742443|NCT01630252|ACTIVE_COMPARATOR|Part A2 - Active Treatment arm|PGL5001 for 8 weeks + one DMPA injection
62742444|NCT01630252|PLACEBO_COMPARATOR|Part A2 - Placebo Treatment arm|PGL5001 matching placebo for 8 weeks + one DMPA injection
62742445|NCT01630252|ACTIVE_COMPARATOR|Part B - Active treatment arm|PGL5001 for 20 weeks + two DMPA injections
62178247|NCT05923502||All enrolled patients.|All patient who signed the consent form for participation to the study.
62178248|NCT03394183|EXPERIMENTAL|Peripheral Artery Disease Participants|Patients diagnosed with peripheral artery disease will undergo a 6 month cardiac rehabilitation program that is standard of care at the Toronto Rehabilitation Institute Rumsey Centre.
62178249|NCT03394183|ACTIVE_COMPARATOR|Coronary Artery Disease Participants|Patients diagnosed with coronary artery disease will undergo a 6 month cardiac rehabilitation program that is standard of care at the Toronto Rehabilitation Institute Rumsey Centre. The responses to cardiac rehabilitation for participants with coronary artery disease will be compared to participants with peripheral artery disease.
62178250|NCT02872818|ACTIVE_COMPARATOR|Control group|Medicated with only 4mg/kg 17β estradiol hemihydrate for 20 days to develop endometrial hyperplasia
62178251|NCT02872818|ACTIVE_COMPARATOR|Metformin group|Having been obtained hyperplasia, the investigators continued medication with 50 mg/kg metformin in addition to 17β estradiol hemihydrate for 10 days
62178252|NCT02872818|ACTIVE_COMPARATOR|Medroxyprogesterone acetate group|Having been obtained hyperplasia, the investigators continued medication with 1mg/day medroxyprogesterone acetate in addition to 17β estradiol hemihydrate for 10 days
62742446|NCT01630252|PLACEBO_COMPARATOR|Part B - Placebo Treatment arm|PGL5001 matching placebo for 20 weeks + two DMPA 150mg injections
62742447|NCT01630252|EXPERIMENTAL|Part A1 - Active Treatment arm|PGL5001 for 8 weeks + one unique DMPA 150 mg injection
62178253|NCT03294941|OTHER|HepQuant SHUNT Liver Diagnostic Kit|All subjects receive HepQuant SHUNT test and DSI measurement. HepQuant SHUNT is a combination product where 13C Cholate 20mg is administered intravenously once for each test and d4 Cholate 40mg is administered once orally for each test
62178254|NCT02142998|ACTIVE_COMPARATOR|GERD Symptoms|
62178255|NCT02142998|ACTIVE_COMPARATOR|No GERD Symptoms|
62178256|NCT05259397|EXPERIMENTAL|Part 1A PF-07225570 monotherapy|Intravesical (IVe) Single Agent Dose Escalation
62742448|NCT04751994|EXPERIMENTAL|Iron supplement/ ferrous sulphate syrup|administration of daily iron drops, 7.5mg/day iron as ferrous sulphate
62178257|NCT05259397|EXPERIMENTAL|Part 1B PF-07225570 and sasanlimab|PF-07225570 IVe and sasanlimab Subcutaneous (SQ) Combination Dose Escalation
62178258|NCT05259397|EXPERIMENTAL|Part 2A PF-07225570 monotherapy|IVe Single Agent Dose Expansion
62178259|NCT05259397|EXPERIMENTAL|Part 2B PF-07225570 and sasanlimab|PF-07225570 IVe and sasanlimab SQ Combination Dose Expansion
62178260|NCT05082233|EXPERIMENTAL|SHR7280 tablets|Treatment group A: oral SHR7280 tablets; 300mg bid p.o.; Treatment group B: oral SHR7280 tablets; 200mg bid p.o.; Treatment group C: oral SHR7280 tablets; 200mg qd p.o.; Treatment group D: oral SHR7280 tablets; 400mg bid p.o.; as an alternative.
62178261|NCT03315234||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
62178262|NCT03315234||0 < SYNTAX score < 23|Low SYNTAX group
62178263|NCT03315234||SYNTAX score ≥ 23|Intermediate-High SYNTAX group
62178264|NCT04306549|EXPERIMENTAL|Bulk-fill resin composite-sonic activated|5 mm bulk-filling without capping lightcured 40s
62178265|NCT04306549|EXPERIMENTAL|Bulk-fill resin composite|4 mm bulk-filling without capping lightcured 10s
62178266|NCT04306549|EXPERIMENTAL|Microhybrid resin composite|2 mm layers, lightcured 20s
62178267|NCT02615548|EXPERIMENTAL|Community exercise class|Regular community exercise class is the intervention. It is an exercise class that incorporate PWR moves( UP,ROCK,STEP,TWIST) and cardiovascular training.
62178268|NCT02615548|ACTIVE_COMPARATOR|self-directed exercise activity|Self-directed exercise.
62178269|NCT03111797||video-assisted lobectomy group|patients operated of lung lobectomy for an early stage cancer using a video-assisted surgical procedure
62178270|NCT03111797||robot-assisted lobectomy group|patients operated of lung lobectomy for an early stage cancer using a robot-assisted surgical procedure
62742449|NCT04751994|PLACEBO_COMPARATOR|supplement with placebo|administration of daily placebo drops
62742450|NCT03724058|EXPERIMENTAL|Trident® II Clusterhole HA Acetabular Shell|Hip arthroplasty using Trident II Clusterhole HA Acetabular Shells
62742451|NCT03724058|ACTIVE_COMPARATOR|Trident® Hemispherical Acetabular Shell|Hip arthroplasty using Trident Hemispherical Acetabular Shell
62178271|NCT06479330|PLACEBO_COMPARATOR|Control chocolate with sugar|Milk chocolate made with sugar at a dose of 45 g (2 servings)
62178272|NCT06479330|ACTIVE_COMPARATOR|Maltitol chocolate|Milk chocolate with maltitol replacing all sugar at a dose of 45 g (2 servings)
62178273|NCT06479330|ACTIVE_COMPARATOR|Kestose chocolate|Milk chocolate with kestose oligofructose replacing all sugar at a dose of 45 g (2 servings)
62178274|NCT06479330|ACTIVE_COMPARATOR|Kestose + cocoa and polydextrose premix dose 1 chocolate|Millk chocolate with kestose oligofructose + cocoa and polydextrose premix dose 1 replacing all sugar at a dose of 45 g (2 servings)
62742452|NCT01697423|EXPERIMENTAL|platelet-rich plasma|
62742453|NCT01697423|ACTIVE_COMPARATOR|durolane|
62742454|NCT02512874|OTHER|Pulmonary Rehabilitation|One arm study - all participants will go to pulmonary rehabilitation, received questionnaires, Dual-energy X-ray absorptiometry (DEXA) scans, Dynamometer and gait speed tests and activity measured through an activity monitor.
62742455|NCT06029868|EXPERIMENTAL|Black seed|Black seed oil capsule taken orally
62742456|NCT06029868|PLACEBO_COMPARATOR|Placebo|Placebo capsule taken orally
62182466|NCT03308747|ACTIVE_COMPARATOR|Low systemic inflammation|Individuals assigned in the high systemic inflammation group will be characterized by IL6: \< 1.7 pg/ml and hs-CRP: \< 1.0 mg/L.
62365087|NCT02829775|EXPERIMENTAL|Interferon Alfa-2A in Cancer Participants|Participants who responded to interferon alfa-2A (either pegylated interferon alfa-2A or recombinant interferon alfa 2A) treatment during the parent study will continue to receive the same treatment in this study. Pegylated interferon alfa-2A will be administered subcutaneously once weekly and recombinant interferon alfa 2A will be administered subcutaneously once daily, until disease progression, withdrawal, or death whichever occurs first (up to approximately 3 years).
62178275|NCT06479330|ACTIVE_COMPARATOR|Kestose + cocoa and polydextrose premix dose 2 chocolate|Millk chocolate with kestose oligofructose + cocoa and polydextrose premix dose 2 replacing all sugar at a dose of 45 g (2 servings)
62178276|NCT01344499|EXPERIMENTAL|Adept|1000ml Adept will be left in the abdomen and measured over time
62178277|NCT01344499|ACTIVE_COMPARATOR|Ringer-lactate|1000 ml of Ringer lactate left in the abdomen and measured over time
62178278|NCT02880332|ACTIVE_COMPARATOR|Usual care + Extra care|This group will receive usual care and one additional session; extra care.
62365088|NCT02457299|ACTIVE_COMPARATOR|Two Stage Esophagectomy|Ischemic gastric preconditioning performed 7-10 prior to esophagectomy
62178279|NCT02880332|EXPERIMENTAL|Usual care + PNE|Next to usual care, this group will also receive pain neuroscience education.
62178280|NCT02032108|EXPERIMENTAL|lifestyle counselling|"A 45-min lifestyle educational session will be delivered to the subjects randomized to the intervention group every month for one year.~Lifestyle intervention will consist in group counselling on dietary habits, effects of regular physical activity, importance of adherence to medications, diabetes complications, actions to control blood sugar and ways of coping with stress."
62178281|NCT05593510|EXPERIMENTAL|No prep ready-to-eat meals|
62178282|NCT05593510|ACTIVE_COMPARATOR|Ingredient bundles (e.g. meal kits)|
62178283|NCT01085812|EXPERIMENTAL|2|40, 80 or 120 mg/day Levomilnacipran ER capsules, oral administration, once daily dosing.
62178284|NCT01085812|PLACEBO_COMPARATOR|1|Matching placebo capsules, oral administration, once daily dosing.
62178285|NCT03628690|EXPERIMENTAL|BandGrip|Topical skin closure device
62178286|NCT03628690|ACTIVE_COMPARATOR|Standard Suture|Standard sutures will be used for wound closure
62178287|NCT02779283|EXPERIMENTAL|Arm I (AML)|Patients receive cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 30 minutes on days 1-3.Patients receive cyclophosphamide IV over 3 hours twice daily (BID) on days 1-3, vincristine sulfate IV on days 4 and 11, doxorubicin hydrochloride IV on day 4, dexamethasone PO on days 1-4 and 11-14, and rituximab IV on day 1 and 11 (day 11 only of course 1). Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Based on the results of the kinase inhibitor assay (In Vitro Kinase Inhibitor Assay), patients receive either sorafenib tosylate PO BID, sunitinib malate PO daily, dasatinib PO daily, ponatinib hydrochloride PO daily, ruxolitinib phosphate or idelalisib PO BID on days 8-28 in the absence of disease progression or unacceptable toxicity.
62178288|NCT02779283|EXPERIMENTAL|Arm II (ALL)|Patients receive cytarabine IV over 2 hours BID on days 2-3, methotrexate IV over 2-22 hours on day 1, methylprednisolone sodium succinate IV BID on days 1-3, leucovorin calcium IV every 6 hours until methotrexate level is \< 0.05 uM and rituximab IV on days 1 and 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Based on the results of the kinase inhibitor assay (In Vitro Kinase Inhibitor Assay), patients receive either sorafenib tosylate PO BID, sunitinib malate PO daily, dasatinib PO daily, ponatinib hydrochloride PO daily, ruxolitinib phosphate or idelalisib PO BID on days 8-28 in the absence of disease progression or unacceptable toxicity.
62178289|NCT04459221|EXPERIMENTAL|Facilitating access to HPV vaccination|
62178290|NCT04459221|NO_INTERVENTION|promotion of HPV vaccination|
62178291|NCT03106298||Iron Sucrose Treatment|All patients with iron deficiency anemia (those without CKD or HF, those with CKD only, those with HF only, and those with CKD/HF) will be given 5 weekly doses of 200 mg of intravenous iron sucrose.
62178292|NCT03411928|EXPERIMENTAL|Tracheolator|Tracheal dilatation using the study device as per the protocol.
62178293|NCT01649037|EXPERIMENTAL|nor adrenaline and terlipressin|
62178294|NCT01649037|ACTIVE_COMPARATOR|step up terlipressin|
62178295|NCT00723918|ACTIVE_COMPARATOR|1|methadone plus SAB placebo
62178296|NCT00723918|EXPERIMENTAL|2|methadone plus active SAB
62178297|NCT00723918|PLACEBO_COMPARATOR|3|methadone placebo plus SAB placebo
62178298|NCT02684799|EXPERIMENTAL|Part 1 Group 1 (Cenicriviroc)|Part 1 Group 1 (12 subjects) will receive CVC 150 mg on Days 1, 7 and 13.
62178299|NCT02684799|ACTIVE_COMPARATOR|Part 1 Group 1 (Omeprazole)|Part 1 Group 1 (12 subjects) will receive Omeprazole 20 mg from Days 2-7, and Omeprazole 40 mg from Days 8-13.
62365089|NCT02457299|ACTIVE_COMPARATOR|One Stage Esophagectomy|Esophagectomy alone
62365090|NCT06097325||Residents in Anaesthesiology|"The residents in Anaesthesiology (French-speaking part of Switzerland) will be enrolled to both:~* Fill a cross-sectional online survey~* Enter a qualitative study from the beginning of their residency at Geneva's university hospital"
62178300|NCT02684799|EXPERIMENTAL|Part 1 Group 2 (Cenicriviroc)|Part 1 Group 2 (12 subjects) will receive CVC 150 mg on Days 1, 5, 9 and 13.
62178301|NCT02684799|ACTIVE_COMPARATOR|Part 1 Group 2 (Famotidine)|Part 1 Group 2 (12 subjects) will receive Famotidine 40 mg on Days 5, 9 and 13.
62365091|NCT06097325||Chief-Residents in Anaesthesiology|Chief-Residents (Board-certified anaesthesiologists after post-graduate training) in French-speaking part of Switzerland will be enrolled to fill a cross-sectional online survey
62365092|NCT05545878|EXPERIMENTAL|Intervention: Super enhanced single vision lens 01 for spectacles|Participants in the intervention group will wear the newly designed SESL01 lens with anti-reflection coating. Participants will be asked to wear their spectacles for all daily tasks as normal including when looking at digital screens and near tasks.
62178302|NCT02684799|EXPERIMENTAL|Part 2 (Cenicriviroc)|Part 2 (24 subjects) will receive Cenicriviroc from Days 1-10 and Days 11-20.
62178303|NCT02684799|ACTIVE_COMPARATOR|Part 2 (Omeprazole)|Part 2 (24 subjects) will receive Omeprazole from Days 11-20.
62182467|NCT02788526|EXPERIMENTAL|Adjuvant TACE|Adjuvant TACE were performed 4-6 weeks after surgery
62182468|NCT02788526|OTHER|Follow-up|Routine follow-up were performed instead of adjuvant TACE
62365093|NCT05545878|NO_INTERVENTION|Control: Standard single vision lenses with an anti-reflection coating|Participants in the control group will be corrected with standard single vision lenses with an anti-reflection coating. Participants will be asked to wear their spectacles for all daily tasks as normal including when looking at digital screens and near tasks.
62365094|NCT01614340|OTHER|Usual Care|Usual Physical Therapy Plan of Care
62365095|NCT01614340|OTHER|Usual Care Plus Pain Management Program|Behavioral: Cognitive-Behavioral Pain Self-management Program.
62365096|NCT01878227|EXPERIMENTAL|Coenzyme A 400mg|Coenzyme A 400mg per day
62365097|NCT01878227|ACTIVE_COMPARATOR|Fenofibrate 200mg|Fenofibrate 200mg per day
62365098|NCT01963936|EXPERIMENTAL|Supreme LMA|
62365099|NCT01963936|ACTIVE_COMPARATOR|Facial mask|
62365100|NCT04916756|EXPERIMENTAL|baricitinib 2mg per day|
62365101|NCT04977024|EXPERIMENTAL|Arm I (GEO-CM04S1)|Patients receive one dose of GEO-CM04S1 IM in the upper arm on days 0 and 28.
62365102|NCT04977024|EXPERIMENTAL|Arm II (SOC mRNA SARS-CoV-2 vaccine)|Patients receive one dose of SOC mRNA SARS-CoV-2 vaccine IM in the upper arm on days 0 and 28.
62365103|NCT05337150|EXPERIMENTAL|Lifestyle Modification with a Balanced Calorie Deficit Diet|Lifestyle modification intervention with a balanced calorie deficit diet (i.e., participants will be prescribed a calorie goal and will track their dietary intake in order to meet this goal).
62365104|NCT05337150|EXPERIMENTAL|Lifestyle Modification with an Ad Libitum Whole Food Plant-Based Eating Plan|Lifestyle modification intervention with an ad libitum whole food plant-based diet (i.e., participants will eat, ad libitum, fruits, vegetables, starches, legumes, and whole grains, and will avoid eating processed foods, refined oils, and animal products)
62365105|NCT02680119|EXPERIMENTAL|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
62365106|NCT02680119|ACTIVE_COMPARATOR|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
62365107|NCT00621010|EXPERIMENTAL|Cohort|
62365108|NCT02021071||XperGuide|Image-guided needle procedures with XperGuide performed prior to this study within institution (retrospective data).
62365109|NCT02021071||XperGuide with virtual path planning|Image-guided needle procedures with XperGuide with virtual path planning
62365110|NCT05197309|ACTIVE_COMPARATOR|Women with anorexia nervosa|adult women with anorexia nervosa who have been recently restored to normal weight
62742457|NCT02482597|EXPERIMENTAL|WBPA (Whole Body Accleration)|"Whole-body periodic acceleration (WBPA) is a new, non-invasive, and promising therapy for a diverse and growing list of disorders including cardiovascular disease 6. During WBPA, patients lie in the supine position on a bed that is capable of translating back and forth parallel to the ground, along the head-to-foot axis of the patient. Thus, this treatment is best described as a form of passive exercise. The frequency of the translation (up to 180 cycles/minute; cpm) as well as the distance traveled (2-24mm) by the bed can be adjusted by the patient or health care professional."
62365111|NCT05197309|ACTIVE_COMPARATOR|Women with no history of eating disorders|adult women with no history of eating disorders
62365112|NCT05407493||Buccal flap|The buccal flap is slid over the fistula and sutured to the undermined palatal mucosa using horizontal mattress sutures.
62365113|NCT05407493||Double-layer|A combination between a buccal trapezoidal flap and a palatal connective pedicle flap.
62365114|NCT05407493||Buccal flap with L-PRF|A L-PRF plug is interposed between the fistula and the buccal sliding flap.
62365115|NCT00871936|EXPERIMENTAL|1|SLx-4090 in combination with Metformin
62365116|NCT00871936|OTHER|2|Placebo
62365117|NCT02899260|NO_INTERVENTION|Control|Subjects who are randomized to to the control group will labor without the use of the peanut ball in labor.
62365118|NCT02899260|EXPERIMENTAL|Experimental/Peanut Ball|Subjects randomized to the intervention (peanut ball) arm will have the peanut ball planed between their upper legs for at least 30minutes during their labor. Time on the peanut ball will be quantified by the bedside nursing staff.
62365119|NCT02945228||Chronic infection of hepatitis C virus (HCV) genotype 2|Participants with confirmed chronic HCV genotype 2, receiving paritaprevir/ritonavir/ombitasvir and ribavirin according to standard of care and in line with the current local label
62365120|NCT00866398||1 DES|Patients receiving drug-eluting stent
62365121|NCT00866398||2 BMS|Patients receiving bare metal stent
62365122|NCT01402388|EXPERIMENTAL|Lifestyle intervention group.|
62365123|NCT02017457|EXPERIMENTAL|Azacytidine + Donor lymphocyte infusion|"Azacytidine will be administered subcutaneously for 5 days. During the first cycle, a dose of 100mg/m2/day will be used and for the following cycles a dose of 35mg/m2/day will be administered. Each cycle will consist in 28 days. All patients will receive at least 6 cycles of Azacytidine and the total number of cycles will depend on the response to treatment.~Donor lymphocyte infusion will be performed on day 1 of cycle 2, 4 and 6 of Azacytidine. The amount of cells infused will depend on donor origin."
62365124|NCT00668252||1|Non menopausal women
62365125|NCT00668252||2|age matched men
62365126|NCT00668252||3|Menopausal women
62365127|NCT00668252||4|age matched men
62365128|NCT04329325|EXPERIMENTAL|Blinatumomab & Concurrent Oral Tyrosine Kinase Inhibitor (TKI)|Patients may receive steroids and hydroxyurea pre-study entry and receive a 7-day steroid prephase before starting TKI therapy. Planned initial TKI is dasatinib 140 mg daily; dasatinib dose may be reduced or TKI may be changed to a different agent under certain conditions. Induction consists of continuous TKI + 24 days of dexamethasone, followed by taper of dexamethasone, with bone marrow aspirate/biopsy (BMA) and CNS prophylaxis at days 22 and 43. Patients achieving morphologic complete response post-induction proceed to consolidation with up to 3 cycles of blinatumomab (28-day cycles, 14 days between cycles) + TKI, with BMA and CNS prophylaxis between cycles. Patients achieving complete molecular response may proceed to maintenance with up to 4 more cycles of blinatumomab (28-day cycles with 28 days between cycles) + TKI, with CNS prophylaxis between cycles and BMA after cycles 5 and 7. Patients can come off study to undergo allogeneic hematopoietic cell transplantation at any time.
62365129|NCT03163173|EXPERIMENTAL|Single Arm - Treatment Group|30 mg (\~100 μCi) dose of \[14C\]GC4419 administered as an IV infusion over 15 minutes on Day 1 following an overnight fast
62365130|NCT02558283|EXPERIMENTAL|JUVÉDERM® VOLIFT® with Lidocaine - Right Side|JUVÉDERM® VOLIFT® with lidocaine injected into the right nasolabial fold on Day 1, with optional touch-up injections into the right nasolabial fold on Month 1.
62365131|NCT02558283|ACTIVE_COMPARATOR|Restylane® - Right Side|Restylane® injected into the right nasolabial fold on Day 1, with optional touch-up injections into the right nasolabial fold on Month 1.
62365132|NCT02558283|EXPERIMENTAL|JUVÉDERM® VOLIFT® with Lidocaine - Left Side|JUVÉDERM® VOLIFT® with lidocaine injected into the left nasolabial fold on Day 1, with optional touch-up injections into the left nasolabial fold on Month 1.
62365133|NCT02558283|ACTIVE_COMPARATOR|Restylane® - Left Side|Restylane® injected into the left nasolabial fold on Day 1, with optional touch-up injections into the left nasolabial fold on Month 1.
62365134|NCT00987636|EXPERIMENTAL|R1|Standard Risk R1: in a randomised trial, to examine whether add-on treatment with zoledronic acid in addition to induction and maintenance chemotherapy improves event-free survival in patients with localised Ewing sarcoma and good histological response or with initial tumour volume \<200 mL compared to no add-on treatment.
62365135|NCT00987636|EXPERIMENTAL|R2|High Risk R2: in a randomised trial, to examine whether high-dose chemotherapy using busulfan-melphalan with autologous stem cell reinfusion, compared with standard chemotherapy, improves event-free survival in patients with localised Ewing sarcoma and poor histological response or tumour volume ≥200 mL (R2loc). In patients with pulmonary metastases high dose busulfan-melphalan chemotherapy with autologous stem cell reinfusion is randomised versus standard chemotherapy plus whole lung irradiation (R2pulm).
62365136|NCT00987636|EXPERIMENTAL|R3|Very High Risk R3: in a randomised trial, to examine whether the addition of high dose chemotherapy using treosulfan-melphalan followed by autologous stem cell reinfusion to eight cycles of standard adjuvant chemotherapy, compared to eight cycles of standard adjuvant chemotherapy alone, improves event-free survival in patients with primary disseminated disease.
62742458|NCT02482597|ACTIVE_COMPARATOR|Active Recovery|Active recovery methods (e.g.walking, biking) have been shown to decrease blood lactate levels more than passive recovery 1,2. This arm requires subjects to walk at a low intensity as recovery.
62365137|NCT06298760|EXPERIMENTAL|Knee Massage With Black Cumin Oil Group|Necessary explanations were made to the patients in this group. Before application, 5 drops of black cumin oil were applied to the patient's knee for 20 minutes. waited. After making sure that there was no allergy, both knees were massaged with oil for a total of 30 minutes.
62365138|NCT06298760|PLACEBO_COMPARATOR|Placebo Knee Massage Application Group|Patients in this group received a 30-minute knee massage with pure petroleum jelly.
62365139|NCT06298760|EXPERIMENTAL|Foot Reflexology Group With Black Cumin Oil|Patients in this group underwent foot reflexology with pure black cumin oil for 40 minutes on both feet.
62365140|NCT06298760|PLACEBO_COMPARATOR|Placebo Foot Reflexology Group|Patients in this group underwent foot reflexology with vaseline for 40 minutes on both feet.
62365141|NCT06298760|NO_INTERVENTION|Control Group|No intervention was performed on patients in this group. Followed for 6 weeks. Face-to-face meetings were held once a week.
62365142|NCT04115345|EXPERIMENTAL|Renal Autologous Cell Therapy (REACT)|The volume of REACT to be administered will be determined by pre-procedure MRI volumetric 3D evaluation or ellipsoid formula. The participant will receive a second injection 6 months after the first injection into the same kidney.
62365143|NCT00849199||High risk of breast or ovarian cancer|
62365144|NCT01597440|EXPERIMENTAL|N-Carbamylglutamate|Active NCG \& Standard of Care
62365145|NCT01597440|PLACEBO_COMPARATOR|Placebo|Standard of Care therapy
62365146|NCT00638586||1|Femoral access
62365147|NCT00638586||2|Radial access
62365148|NCT00899600|PLACEBO_COMPARATOR|Normal saline|
62365149|NCT00899600|EXPERIMENTAL|Ketamine|
62365150|NCT03732521|EXPERIMENTAL|Intervention group|educational therapy
62365151|NCT03732521|NO_INTERVENTION|Control group|usual clinical practice
62365152|NCT01316939|PLACEBO_COMPARATOR|Placebo|Placebo
62365153|NCT01316939|EXPERIMENTAL|GSK1605786A once daily|500 milligrams once daily
62365154|NCT01316939|EXPERIMENTAL|GSK1605786A twice daily|500 milligrams twice daily
62365155|NCT02882165|EXPERIMENTAL|Intervention arm|Participants receive a comprehensive medical review by a Respiratory Clinical Fellow.
62365156|NCT02882165|NO_INTERVENTION|Control arm|Participants receive usual care as required via their primary care practice.
62742459|NCT06660823|ACTIVE_COMPARATOR|Group A (Study group)|group A will receive levothyroxine via Ryle, dose of 25 to 50 ug/ day according to BMI,
62742460|NCT06660823|PLACEBO_COMPARATOR|• Group B (Control)|group B will receive placebo in form of inert starch tablet
62365157|NCT04024241||high dose of cytarabine|high dose of cytarabine
62365158|NCT04024241||HAM|medium dose of cytarabine and mitoxantrone
62365159|NCT03786406||T2DM patients seen in routine practice|All anti-diabetic and cardiovascular (CV) medication will be prescribed at the physician's discretion under routine clinical practice conditions.
62365160|NCT04801641|PLACEBO_COMPARATOR|Placebo|Placebo
62365161|NCT04801641|EXPERIMENTAL|Low-Dose Nabilone|pms-nabilone titrated to 2 mg daily
62365162|NCT04801641|EXPERIMENTAL|High-Dose Nabilone|pms-nabilone titrated to 6 mg daily
62365163|NCT00956462|EXPERIMENTAL|NSAID|
62365164|NCT00956462|ACTIVE_COMPARATOR|Steroids|
62365165|NCT03628495|EXPERIMENTAL|SSCP + SPMS|
62365166|NCT03628495|ACTIVE_COMPARATOR|PG|
62365167|NCT03146403|EXPERIMENTAL|GEN-003|60μg of each GEN-003 antigen with 50μg Matrix-M2 adjuvant, administered as a 0.5mL intramuscular (IM) injection
62365168|NCT03146403|PLACEBO_COMPARATOR|Placebo|0.9% normal saline administered as a 0.5mL intramuscular (IM) injection
62742461|NCT06661889||Healthy Volunteers|
62742462|NCT00916201|EXPERIMENTAL|Intranasal Insulin|Intranasal administered insulin
62742463|NCT00916201|EXPERIMENTAL|Cannabidiol CR|Cannabidiol is the main non psychoactive compound of the Cannabis sativa plant.
62742464|NCT00916201|EXPERIMENTAL|URB597|URB597 is a selective inhibitor of the Fatty acid amide hydrolase enzyme.
62365169|NCT01899651||Infants of 30-34 weeks gestation.|Inclusion criteria will be infants 30-34 weeks gestation. Exclusion criteria will be any infants with evidence of pre-existing skin condition, breakdown, rashes, or problems with skin integrity. Infants with a known neurological condition (hydrocephalus, Dandy Walker malformation, craniosynostosis, arteriovenous malformation) will be excluded as well. Also, secondary to the nature of the device and the surface area it takes up, infants on continuous positive airway pressure will be excluded as well.
62365170|NCT02448797|EXPERIMENTAL|icotinib|125 mg three times daily (375 mg per day) orally for two years.
62365171|NCT02448797|ACTIVE_COMPARATOR|standard chemotherapy|"Vinorelbine 25 mg/m\^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles.~cisplatin 75 mg/m\^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles.~For adenocarcinoma: pemetrexed (500 mg/m\^2, day 1)/cisplatin (75 mg/m\^2, day 1) for 4 cycles."
62365172|NCT03148795|EXPERIMENTAL|Talazoparib|Talazoparib 1 mg daily
62365173|NCT04063644|EXPERIMENTAL|Vis Glyc Neo|"Vis glyc eye drops is administered.~Eye drops based on N-Acetylcoarnosine, Vaccinium myrtillus and Chondroitin sulfate"
62365174|NCT04063644|ACTIVE_COMPARATOR|physiological saline solution|Physiological saline solution ALVITA is administered.
62365175|NCT02279979|EXPERIMENTAL|Treatment Arm|All enrolled patients will be treated with the HeartMate PHP device
62365176|NCT02311790|EXPERIMENTAL|Trans-C16:1 supplement|Volunteers will take trans-C16:1 supplement for 3 weeks
62365177|NCT02311790|EXPERIMENTAL|Cis-C16:1 supplement|Volunteers will take cis-C16:1 supplement for 3 weeks
62365178|NCT05057325|EXPERIMENTAL|Wave One Gold|Receporcating single file used for preparation of root canals in primary molars
62365179|NCT05057325|EXPERIMENTAL|One shape|Rotation single file used for preparation of root canals in primary molars
62365180|NCT02264015|EXPERIMENTAL|Cilobradine low|
62365181|NCT02264015|PLACEBO_COMPARATOR|Placebo|
62365182|NCT02264015|ACTIVE_COMPARATOR|Moxifloxacin|
62365183|NCT02264015|EXPERIMENTAL|Cilobradine high|
62365184|NCT03507881||Ennovate|Implantation of an Ennovate® internal fixation
62365185|NCT05193851|EXPERIMENTAL|healthy subjects|12 healthy Chinese adult subjects, both male and female, are treated with ricolinostat
62365186|NCT04445688|EXPERIMENTAL|AD036|AD036 oral capsule administered before sleep
62365187|NCT04445688|ACTIVE_COMPARATOR|Atomoxetine|Atomoxetine oral capsule administered before sleep
62365188|NCT04445688|PLACEBO_COMPARATOR|Placebo|Placebo oral capsule administered before sleep
62365189|NCT01160263|OTHER|patients without stiffness|
62365190|NCT01160263|OTHER|patients with pyramidal stiffness|
62365191|NCT01160263|OTHER|patients with mixed stiffness|
62365192|NCT06436560|EXPERIMENTAL|STRIVE Peer Support Intervention|A virtual group-based peer support intervention led by trans peers who have had genital gender-affirming surgery.
62365193|NCT06436560|NO_INTERVENTION|Enhanced Usual Care|Usual care enhanced with written and web-based education materials.
62365194|NCT03140124|OTHER|Group 1|First session: worry stone, second session: exercise peddler
62365195|NCT03140124|OTHER|Group 2|First session: exercise peddler, second session: worry stone
62365196|NCT02881671||Patients with congenital atrioventricular block|Patient with congenital atrioventricular block
62365197|NCT02881671||relatives with congenital atrioventricular block|Normal relatives of patients with congenital atrioventricular block
62365198|NCT02881671||Patients with progressive Cardiac Conduction Disease|Patients with progressive Cardiac Conduction Disease,
62365199|NCT02881671||relatives with progressive Cardiac Conduction disesae|Normal relatives of patients with progressive Cardiac Conduction Disease
62365200|NCT03828500|EXPERIMENTAL|Experimental Arm|encouraged by Research Assistant to drink clear fluids up to 2 hour limit. Arm 2 - standard of care
62365201|NCT03828500|NO_INTERVENTION|Control Arm|
62365202|NCT05302102|EXPERIMENTAL|Paretic-limb-only plyometric training group|Participants in this group performed plyometric movements/exercises unilaterally using the paretic leg.
62365203|NCT05302102|EXPERIMENTAL|Doule-limb plyometric training|Participants in this group performed plyometric movements/exercises bilaterally through the paretic and non-paretic legs.
62365204|NCT05302102|ACTIVE_COMPARATOR|Control group|Participants in this group received the standard physical rehabilitation program.
62365205|NCT02435394|EXPERIMENTAL|Remote Coach plus Asthma Module|The intervention is for practices to have remote coach support for patients with asthma in addition to doctors using CHADIS-Asthma module. Practices will start sequentially for a time series analysis.
62365206|NCT02435394|EXPERIMENTAL|Asthma Module- No Coach|The intervention is for practices to use CHADIS-Asthma module to improve patient care without a remote coach assisting patient adherence.
62365207|NCT02435394|ACTIVE_COMPARATOR|CHADIS- no Asthma module|Practices using CHADIS but no Asthma module as a control condition.
62365208|NCT00768768|ACTIVE_COMPARATOR|1|Iontophoretic Dose Level 1
62365209|NCT00768768|ACTIVE_COMPARATOR|2|Iontophoretic Dose Level 2
62365210|NCT00768768|ACTIVE_COMPARATOR|3|Iontophoretic Dose Level 3
62365211|NCT00768768|ACTIVE_COMPARATOR|4|Iontophoretic Dose Level 4
62365212|NCT00768768|ACTIVE_COMPARATOR|5|Iontophoretic Dose Level 5
62365213|NCT00632996|EXPERIMENTAL|1|
62365214|NCT02217683|NO_INTERVENTION|Young blood transfusion|The first group of patients (n=30) will be randomized to receive leukoreduced blood transfusion stored for less than 10 days
62365215|NCT02217683|NO_INTERVENTION|Old blood transfusion|This randomized group of patients (n=30) will receive leukoreduced blood transfusion stored for more than 30 days
62365216|NCT02217683|ACTIVE_COMPARATOR|Old blood transfusion and Nitric Oxide|This randomized group of patients (n=30) will receive leukoreduced blood transfusion stored for more than 30 days while breathing nitric oxide (80 part per million) and oxygen
62365217|NCT04541732|EXPERIMENTAL|Thoracic epidural block|Patients will receive thoracic epidural block following induction of general anaesthesia
62365218|NCT04541732|ACTIVE_COMPARATOR|Bilateral quadratus lumborum block|Patients will receive Ultrasound-guided bilateral quadratus lumborum block following induction of general anaesthesia
62365219|NCT03476967||Pretreatment x Posttreatment|The group was evaluated through non-invasive complementary examinations before laser therapy and at the 1-year follow-up visit to analyze possible optical disc alterations that may occur after retinal panretinal photocoagulation in patients with proliferative diabetic retinopathy.
62365220|NCT05490498|EXPERIMENTAL|Breastfeeding mother|Breastfeeding mother with infants between 1 and 89 days of age who presented with suspected neonatal bacterial sepsis due to the presence of a fever.
62365221|NCT06239285|PLACEBO_COMPARATOR|Treatment as Usual (TAU) Group|The treatment-as-usual (TAU) group will receive a community resource brochure (the same one that is provided at the end of BVI-VR). This brochure provides contact detail for services in the local area.
62365222|NCT06239285|EXPERIMENTAL|Intervention Group|Patients randomized into the BVI-VR group will answer questions about the session content and the rationale for the content. Their responses will provide an estimate of engagement providing a better understanding of treatment fidelity.
62365223|NCT02901080|EXPERIMENTAL|Cranial electrotherapy stimulation|Alpha Stim AID cranial electrotherapy stimulation, Pregnancy test, Anxiety questionnaire, Quality of life questionnaire, Work and social questionnaire, Sleep questionnaire, Depression questionnaire, Quality of life and financial questionnaire
62365224|NCT03882853|ACTIVE_COMPARATOR|Conservative exercise group (CEG)|Conservative exercise group
62365225|NCT03882853|EXPERIMENTAL|Tree pose added exercise group (TPAEG)|Tree pose added exercise group
62365226|NCT03039049|EXPERIMENTAL|GnRH agonist|"Drug: Triptorelin 0.1mg Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg.~Other Names:~• Decapeptyl 0.1 mg"
62365227|NCT03039049|NO_INTERVENTION|Control|No intervention
62365228|NCT06229210|EXPERIMENTAL|Lumateperone|
62365229|NCT03650036|EXPERIMENTAL|Group 1|In group 1, Pulp Therapy will be done with the CTZ paste (composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline, 125 mg of zinc oxide) will be manipulate with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use and will be taken at the tip of a number 5 exploratory probe and dispensed at the entrances of the root canals where it will be accommodated with light pressure of sterile cotton balls. The CTZ paste will be protected with a thin layer of gutta-percha, previously heated in an alcohol lamp and placed in a thin layer on the CTZ pulp. The gutta-percha blade will be condensed with medium size amalgam presser and has the objective of physically isolating the CTZ paste from the restorative material.
62365230|NCT03650036|EXPERIMENTAL|Group 2|In Group 2, Pulp Therapy will be done with ZOE paste. The mechanical preparation of the root canals with 2% chlorhexidine solution and first-series K files will be performed. The instrumentation limit shall be 1 mm short of the radiographic apex. After finishing the chemical-mechanical preparation, drying of the root canals with sterile absorbent paper cones and ZOE paste insertion with K files will be performed. The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use. The protection of the ZOE paste will follow the same sequence as the CTZ paste.
62365231|NCT01619813|ACTIVE_COMPARATOR|Docetaxel, Reolysin and Prednisone|
62365232|NCT01619813|ACTIVE_COMPARATOR|Docetaxel and Prednisone|
62365233|NCT05231421||Low-income smokers|Interested participants will first complete a screening survey asking about their demographic information and checking whether are eligible for this study. If eligible, participants will read a consent statement. Only those who give consent would be allowed to proceed. If participants agree to be in this study, they will continue to participate in the study and schedule a time for focus group discussion.
62365234|NCT01674816|ACTIVE_COMPARATOR|Repeated Measurements of Knee Alignment and Kinematics|Patients in the Repeated Measurements Arm will have the kinematic measurement protocol repeated twice before and twice after the surgical procedure; the procedure itself will be performed with the traditional technique, i.e without guidance by the system.
62365235|NCT01674816|ACTIVE_COMPARATOR|Computer Guidance of Surgical Actions|Patients in the Computer Guidance of Surgical Actions Arm will have the kinematic measurement protocol performed only once before and once after the surgical procedure; the procedure itself will be performed with guidance by the system.
62365236|NCT03880006|NO_INTERVENTION|Standard of care|Participants assigned to the Senegalese standard of care treatment for people living with HIV.
62365237|NCT03880006|EXPERIMENTAL|Case management|Individuals in the intervention arm will receive Senegalese standard of care treatment for people living with HIV, and the case management intervention.
62365238|NCT01386229|ACTIVE_COMPARATOR|Ketamine|
62365239|NCT01386229|ACTIVE_COMPARATOR|Etomidate|
62365240|NCT02396693|EXPERIMENTAL|NIPPV|NIPPV - Newborns randomized to this group underwent NIPPV, in noninvasive ventilation support intermittent, in TIME mode of the respirator.
62365241|NCT02396693|PLACEBO_COMPARATOR|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, in noninvasive ventilation continuous, in bubble NCPAP.
62365242|NCT02396693|PLACEBO_COMPARATOR|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, in noninvasive ventilation continuous, in NCPAP mode of the respirator.
62365243|NCT04306666||Walant group|Walant group
62365244|NCT04306666||Axillary Brachial Plexus Block|Axillary Brachial Plexus Block
62365245|NCT02949713|EXPERIMENTAL|Text messaging-motivational interviewing|Every Monday morning, a text message (SMS) will be sent to participants in the intervention group encouraging participants to continue breastfeeding, and inquire if participants have any problems breastfeeding their infants. Participants will be asked to respond within 48 hours, indicating that they either do not have a problem or they have a problem and require help. In addition to text messaging, participants will have motivational interviews post-delivery at weeks 2, 6, and 10. Motivational interviews will explore and support the participant's commitment to continue breastfeeding.
62365246|NCT02949713|NO_INTERVENTION|Usual standard of care|Usual standard of care
62365247|NCT04283357|ACTIVE_COMPARATOR|Exercise Group|One group only treated with short foot exercises.
62365248|NCT04283357|ACTIVE_COMPARATOR|Virtual Reality Group|The second group treated with virtual reality
62365249|NCT01158638|NO_INTERVENTION|Usual Care|Usual Care
62365250|NCT01158638|ACTIVE_COMPARATOR|10,000 Steps Group|Each participant randomized to this study arm will receive a pedometer and a generic recommendation to accumulate 10,000 Steps per Day.
62365251|NCT01158638|EXPERIMENTAL|Web Mediated Step Group|Participants randomized to this study arm receive an introduction to the study website. Each person utilizes the website to track their daily physical activity steps. Goals are given on a weekly basis to increase steps by 10% per day per week over baseline values. The website channels each participant through a series of motivational messages designed to increase compliance with recommended physical activity targets
62365252|NCT03860623||Overweight|Otherwise healthy overweight and obese men (BMI 30-40kg/m2) aged 18 to 60 years Group will consume a standard meal (Feeding) and measurements will be made before (baseline) and for 300 minutes after eating
62365253|NCT03860623||Normal Weight|Healthy normal weight men (BMI 18-25kg/m2, but including those with BMI up to 28kg/m2 if waist circumference \<96cm) aged 18 to 60 years Group will consume a standard meal (Feeding) and measurements will be made before (baseline) and for 300 minutes after eating
62365254|NCT02072746|ACTIVE_COMPARATOR|Zinc|zinc sulfate 220 mg daily
62365255|NCT02072746|PLACEBO_COMPARATOR|Placebo|Placebo study for comparison
62365256|NCT05152368|EXPERIMENTAL|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
62365257|NCT04756349|ACTIVE_COMPARATOR|Clearfil SE|Group containing 10-MDP and HEMA monomers
62365258|NCT04756349|ACTIVE_COMPARATOR|Optibond All-in-One|Group containing HEMA monomer
62365259|NCT04756349|ACTIVE_COMPARATOR|Prime & Bond Universal|Control Group containing other monomers
62365260|NCT00901862|ACTIVE_COMPARATOR|1 Active PEFs|The pulsed electromagnetic fields were directed to the wrist. The model used has the form of a bracelet called Quantum MH-2MR which uses, as a source of power, an alkaline battery of 1.5 volts connected to an electronic circuit formed by two hybrid circuits of magnetic oscillation and a control system of all the generating frequency system.
62365261|NCT00901862|SHAM_COMPARATOR|2 Sham|The sham machines were identical to the machines in actual operation in both phases of the study. The only difference was that the hybrid circuits crucial for the generation of the electromagnetic field had been removed.
62365262|NCT00728663|EXPERIMENTAL|Arm: Cetuximab and Docetaxel|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8 and Docetaxel: 75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
62365263|NCT01714713|EXPERIMENTAL|EVP-6124 low dose|low dose Tablet, Once Daily, Day 1 through Day 182
62365264|NCT01714713|EXPERIMENTAL|EVP-6124, high dose|high dose Tablet, Once Daily, Day 1 through Day 182
62365265|NCT01946113||Retrospektive Cohort|Patients requiring renal replacement therapy from 2011 to 2012 on intensive care unit
62365266|NCT01946113||Prospektive Cohort|Patients requiring renal replacement on intensive care unit in 2013 and 2014
62365267|NCT02636738|EXPERIMENTAL|experiment|Vela XL thulium laser, laser fiber and accessories
62365268|NCT04853277|EXPERIMENTAL|Education Group|Participants will receive an educational intervention focusing on psychosocial stressors and timeline of symptoms associated with the transplant/CAR-T experience.
62365269|NCT04526704|EXPERIMENTAL|Treatment Continuation Cohort|Previously-treated participants with TGCT continuing their current dose of pexidartinib treatment.
62365270|NCT04526704|EXPERIMENTAL|Treatment-Free/Re-Treatment Cohort|Previously-treated participants with TGCT who discontinue pexidartinib treatment (Treatment-Free Period) and resume pexidartinib treatment at dose at completion of prior study (Re-Treatment Period).
62365271|NCT01514604||Little or no experience.|All participants will be asked to declare their degree of experience in the technique being studied. Those declaring themselves as 'New to in-plane ultrasound guided needling. Little or no experience in technique' belong to this cohort and will form the study group.
62365272|NCT01514604||Regular practitioner. Teaching|Participants declaring themselves as 'Regularly incorporate in-plane ultrasound guided needling in clinical practice. Teaching technique to others' fall within this cohort and form the 'control' group allowing application of a realistic acceptable failure rate to Cusum analysis of the study group.
62365273|NCT01514604||Some exposure. Infrequent clinical use.|Participants declaring themselves as belonging to this group will not form part of the analysis. They will be welcome to complete training and receive feedback on their performance according to the study protocol.
62365274|NCT02437968|EXPERIMENTAL|Wave 1|South New Jersey school service providers.
62365275|NCT02437968|EXPERIMENTAL|Wave 2|Philadelphia suburbs and surrounding community service providers
62365276|NCT02437968|EXPERIMENTAL|Wave 3|Mississauga, ON (Canada) school district service providers.
62365277|NCT03232229||Tennis players|
62365278|NCT02837809|EXPERIMENTAL|Intervention|Low Dose CT, annual or biennial, associated with primary prevention and pulmonary function test evaluation.
62365279|NCT02837809|NO_INTERVENTION|Control|Program of primary prevention with pulmonary function test evaluation
62742465|NCT06658392|EXPERIMENTAL|arithmetic|exploring neurocognitive mechanisms underlying development of arithmetic competencies in healthy children.
62365280|NCT02542670||Cancer colon with no distant metastasis|Genetic: Whole genome Sequencing
62365281|NCT02542670||Cancer colon with distant metastases|Genetic: Whole genome Sequencing
62365282|NCT02542670||control group|Genetic: Whole genome Sequencing
62365283|NCT06280053|EXPERIMENTAL|HealiAid group|The patients' wound conditions were divided into three types: venous ulcers, bedsores and burn wounds.
62365284|NCT05911113|EXPERIMENTAL|sensory re-education training|the patients will receive sensory re-education training three times a week for six weeks
62365285|NCT05911113|ACTIVE_COMPARATOR|traditional treatment|the patients will receive traditional treatment three times a week for six weeks
62365286|NCT04269941||prognostic factors of gastrointestinal stromal tumors|for the patient diagnosed with gastic GIST , they underwent subtotal or total gastrectomy.
62365287|NCT05610241|EXPERIMENTAL|Compression Therapy System Prototype|Identifies legs randomized to receive the experimental intervention
62365288|NCT05610241|ACTIVE_COMPARATOR|Coban 2 (2 Layer Compression Wrap)|Identifies the legs randomized to receive the control intervention
62365289|NCT04901104||thymosin α1 group|The patient was treated with thymosin α1 in sepsis
62365290|NCT04901104||placebo group|The patient was treated without thymosin α1 in sepsis
62742466|NCT01267110|EXPERIMENTAL|Intervention|
62365291|NCT06067724|ACTIVE_COMPARATOR|Pelvic and trunk control exercises|Twenty Egyptian male stroke patients will receive 40 minutes of pelvic and trunk control exercises for six weeks after a 30 minutes of traditional physical therapy program.
62365292|NCT06067724|SHAM_COMPARATOR|Traditional physical therapy|Twenty Egyptian male stroke patients will receive 30 minutes of sham traditional physical therapy program for six weeks.
62365293|NCT01496144|EXPERIMENTAL|Manual therapy and active exercises|Spinal manipulation /mobilisation
62365294|NCT01496144|PLACEBO_COMPARATOR|Detuned ultrasound and active exercises|
62365295|NCT02769013||S. haematobium positives in Gabon|Asymptomatic volunteers infected with S. haematobium and living in Gabon
62365296|NCT02769013||S. haematobium negatives in Gabon|Volunteers not infected with S. haematobium and living in Gabon
62365297|NCT02769013||S. haematobium positives in Ghana|Asymptomatic volunteers infected with S. haematobium and living in Ghana
62365298|NCT02769013||S. haematobium negatives in Ghana|Volunteers not infected with S. haematobium and living in Ghana
62365299|NCT01711658|PLACEBO_COMPARATOR|IMRT + cisplatin + placebo|Intensity Modulated Radiation Therapy (IMRT) with cisplatin and placebo
62365300|NCT01711658|ACTIVE_COMPARATOR|IMRT + cisplatin + lapatinib|IMRT with cisplatin and lapatinib
62365301|NCT06391476||Extremely preterm infants, born between 22 and 25 weeks gestational age|Infant born between 22 and 25 weeks gestational age and hospitalized at the Croix-Rousse Hospital
62365302|NCT03137056|ACTIVE_COMPARATOR|Hemodialysis with Theranova|This arm is represented by the period during which the patients will undergo dialysis with the Theranova membrane.
62365303|NCT03137056|ACTIVE_COMPARATOR|Hemodialysis with FX1000|This arm is represented by the period during which the patients will undergo dialysis with the FX1000 membrane.
62365304|NCT03137056|ACTIVE_COMPARATOR|Hemodiafiltration with FX1000|This arm is represented by the period during which the patients will undergo dialysis with the FX1000 membrane.
62365305|NCT02905110|EXPERIMENTAL|Methotrexate / Etoposide Infusion|12 infusions of intraventricular Methotrexate and 15 infusions of intraventricular Etoposide into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle. Methotrexate will be infused twice weekly for 6 weeks and etoposide will be infused 5 times a week on weeks 1, 3 , and 5.
62742467|NCT01267110|ACTIVE_COMPARATOR|Control|
62365306|NCT04731922|EXPERIMENTAL|TAK-510: Part 1|TAK-510 at starting dose of 5 microgram (mcg) or placebo-matching solution, subcutaneously, once on Day 1. Staggered dosing will be done in the first cohort of Part A (Cohort 1). Staggered dosing in subsequent Cohorts (Cohorts 2-12 and 21-25) will be used based on emerging safety, tolerability, and PK data from Cohort 1 as determined in the dose escalation meeting.
62365307|NCT04731922|EXPERIMENTAL|TAK-510: Part 2|TAK-510 to be decided (TBD) or placebo-matching solution, subcutaneously, once daily from Day 1 through Day 5. Dose of MRD Cohorts (Cohorts 13-17 and 26-28) of Part 2 will be determined based on emerging safety, tolerability, and available PK data from Part 1 (SRD) and any available PK data from Part 2 as determined in the dose escalation meeting.
62742468|NCT04181008|EXPERIMENTAL|0.2 mg|
62365308|NCT04731922|EXPERIMENTAL|TAK-510: Part 3|TAK-510 TBD or placebo-matching solution, subcutaneously, once daily from Days 1 to 7. Dose of dose titration and redosing Cohorts (Cohorts 18-20) of Part 3 will be based on emerging safety, tolerability, and available PK data from Part 1 (SRD) and Part 2 (MRD) as determined in the dose escalation meeting. Single redosing will be performed on Day 14 after 7 days of washout period following the 7 days treatment period.
62365309|NCT04379323|EXPERIMENTAL|YuWell YE900 and mercury sphygmomanometer|Blood Pressure Measurement with the YuWell YE900 Electronic Sphygmomanometer (YuWell YE900) and with Desk Mercury Sphygmomanometer.
62365310|NCT02637648|EXPERIMENTAL|Sodium oxbate|oral administration of sodium oxybate, 6-18ml per night, starting with 6ml in two nightly dosages of 1.5g each, increased by steps of 1.5g every second or third night until treatment response
62552770|NCT02145715|EXPERIMENTAL|Velcade, Thalidomide, Dexamethasone (VTD) + Panobinostat|"Up to 16 cycles of VTD+Panobinostat followed by panobinostat maintenance for 1 year or until disease progression.~* Induction - Cycles 1-16 (21-day cycle)~  * Velcade: 1.3mg/m2 (subcutaneous) on days 1 and 8~ * Thalidomide: 100mg (PO)on days 1 -21~ * Dexamethasone: 20 mg (PO) on days 1, 2, 8 and 9~ * Panobinostat: 10mg, 15mg or 20mg days 1, 3, 5, 8, 10 and 12 Dose depends on cohort entry at registration during the dose escalation phase. The recommended dose will be used during the expansion phase.~* Panobinostat monotherapy maintenance for 1 year. Panobinostat will be given at the same dose as the recommended dose during expansion phase"
62742469|NCT04181008|EXPERIMENTAL|0.4 mg|
62742470|NCT04181008|EXPERIMENTAL|0.6 mg|
62742471|NCT04917952|EXPERIMENTAL|BFR group|The intervention group will receive resisted knee extension 30% of 1RM with blood flow restriction.
62742472|NCT04917952|PLACEBO_COMPARATOR|Sham BFR group|The control group will receive resisted knee extension 30% of 1RM with sham blood flow restriction.
62742473|NCT03691337|ACTIVE_COMPARATOR|Low dosis bupivacaine|Preoperative fascia iliaca block with Marcaine 0.25% (0.11 mL x subject height)
62365311|NCT02637648|PLACEBO_COMPARATOR|Placebo|oral administration of placebo, 6-18ml per night, starting with 6ml in two nightly dosages
62365312|NCT02305550|EXPERIMENTAL|electrical synthesis nitric oxide|Participants will breath 20 minutes of electrical pulsed plasma discharge synthesis of nitric oxide at 25 parts per million
62365313|NCT02061904|OTHER|Bone Mineral Density|"Bone mineral density measurement with intervention DEXA at the bone impaction graft site:~DEXA: dual energy X-ray absorptiometry"
62365314|NCT02061904|OTHER|Hip function|"Hip Function/mobility development:~Harris Hip Score"
62365315|NCT02061904|OTHER|pain experience|Pain experiences after surgery in the hip joint VAS-pain
62365316|NCT02061904|OTHER|General Patients Health condition|"Patients health condition monitoring: intervention SF12:~Short Form Health Survey 12"
62365317|NCT02061904|OTHER|Intervention Satisfaction|Patients satisfaction development after the intervention VAS-satisfaction
62742474|NCT03691337|ACTIVE_COMPARATOR|High dosis bupivacaine|Preoperative fascia iliaca block with Marcaine 0.25% (0.22 mL x subject height)
62742475|NCT03691337|PLACEBO_COMPARATOR|Placebo|Preoperative fascia iliaca block with Sodium Chloride 0.9% (0.11 mL x subject height)
62742476|NCT01263431|ACTIVE_COMPARATOR|Hemorrhoidectomy|Excision of hemorrhoid cushions
62742477|NCT01263431|EXPERIMENTAL|Hemorrhoidal dearterialization|Ligation of therminbal branches oh hemorrhoid arteries
62365318|NCT02114489|EXPERIMENTAL|Ibandronate|Unique perfusion of ibandronate 3 mg IV
62365319|NCT02114489|PLACEBO_COMPARATOR|Placebo|Unique perfusion of NaCl 3mg IV
62365320|NCT00607919|EXPERIMENTAL|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 milligram/kilogram/day (mg/kg/day) given orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine
62365321|NCT00607919|PLACEBO_COMPARATOR|Placebo|Placebo will be packaged in the same way as experimental drug to enforce double-blind study design. Placebo will be administered orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine.
62365322|NCT04498468|EXPERIMENTAL|Treatment Arm|Commercially available Sustained Release Dexamethasone, 0.4 mg intracannalicular insert (DEXTENZA® - Ocular Therapeutix, Bedford, MA)
62365323|NCT04498468|SHAM_COMPARATOR|Control Arm|Commercially available EXTENDED WEAR SYNTHETIC ABSORBABLE PUNCTAL PLUG made of E-Caprolactone-L-Lactide copolymer (PCL) (Vera90™ - Elkridge, MD)
62365324|NCT01855841|ACTIVE_COMPARATOR|Hemin|A peripheral perfusion of 4mg/kg of hemin (Normosang) diluted in 100mL NaCL (sodium chloride) 0.9% will be administered in 30-60minutes as soon as possible after the end of the ERCP, followed by 100mL of NacL 0.9% to flush the vein
62365325|NCT01855841|PLACEBO_COMPARATOR|Placebo|The same amount of NaCl 0.9% (100 ML followed by a flushing perfusion of 100mL) will be perfused to the patient as soon as possible after the end of the ERCP
62365326|NCT06311253|EXPERIMENTAL|Trial group|
62365327|NCT06311253|ACTIVE_COMPARATOR|Control group|
62365328|NCT01871415|EXPERIMENTAL|Aleglitazar + metformin|
62365329|NCT01871415|ACTIVE_COMPARATOR|Placebo + metformin|
62365330|NCT04836546|EXPERIMENTAL|Self monitoring of blood glucose, then CGM System|All participants will first manage their diabetes with SMBG for 6 months followed by managing their diabetes with Eversense CGM system for the next 6 months
62365331|NCT01122888|EXPERIMENTAL|Arm I (course 1)|Patients receive cilengitide IV over 1 hour twice weekly for 2 weeks.
62365332|NCT01122888|OTHER|Arm II (course 1)|Patients do not receive treatment and undergo a 2-week rest period.
62365333|NCT01553045||atrial fibrillation, catheter ablation|Patients referred for ablation of atrial fibrillation
62365334|NCT03289052|EXPERIMENTAL|Restylane Volyme|Single injection and optional touch up injection with Restylane Volyme in Midface
62365335|NCT03289052|NO_INTERVENTION|No intervention arm|No treatment
62365336|NCT01005199|EXPERIMENTAL|Arm A: Sorafenib standard|• Arm A (standard treatment): Sorafenib 2 x 400 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (46 patients).
62365337|NCT01005199|EXPERIMENTAL|Arm B: Sorafenib + everolimus|• Arm B (investigational treatment): Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (60 patients)
61986267|NCT04192877||Experimental|30 healthy subjects from both genders, aged between 18 and 60 years will be screened for neurological deficits. If neurological examination will be negative markers for motion capture, analysis will be placed on the chest and shoulders and a rubber band, with 3 markers, will be placed on the forehead. The subjects will be invited to lay on a medical table and heart rate (HR) will be assessed at rest. The vagus nerve neurodynamic test (VN-NDT) will be performed by an expert and a novice, in a random order, and under ultrasound imaging (USI). Assessors will be blinded to their results. Heart rate (HR) of the subjects will be monitored and a pain drawaing tools will be used to describe and locate the symptoms induced during the test administration.
61997492|NCT06358456|ACTIVE_COMPARATOR|Galilei G6|Patients in this arm are measured twice with the Galilei G6 without intervention. After this artificial tears are applied and followed by 4 more measurements
62365338|NCT06147778|EXPERIMENTAL|MuCopilot comparison to clinical standards|Performance of digital tests and questionnaire at Day 0, D1, D3, D5, D7, M1, M2, M3-1 and M3, against clinical standards performed at Day 0 and 3 months.
62365339|NCT04509401|ACTIVE_COMPARATOR|Interventional|High dose of Vitamin B6 with Magnesium. Vitamin B6 will be given orally 150 mg for ages 2-3 years, 200 mg for ages 4-6 years,300 mg for ages 7-8 years and Magnesium will be given orally 50 mg for 2-3 years, 100 mg for ages 7-8 years for three months.
62365340|NCT04509401|PLACEBO_COMPARATOR|Control|Control group will receive oral placebo in the same manner, schedule and time frame.
62365341|NCT01502670|EXPERIMENTAL|Lung Nodule|
62552771|NCT03982147||Stroke patients|Patients with recent ischaemic stroke
61997493|NCT04685564|EXPERIMENTAL|RBD1016 experiment group|Subjects in experiment groups will receive a single subcutaneous injection of RBD1016.
61997494|NCT04685564|PLACEBO_COMPARATOR|placebo gruop|Subjects in placebo groups will receive a single subcutaneous injection of placebo.
62365342|NCT01611922||Symptomatic Lens Wearers|Contact lens wearers reporting a habitual wear time of less than eight hours and a noticeable reduction in comfort over a wearing day
62365343|NCT01611922||Non-Symptomatic Contact Lens Wearers|Contact lens wearers reporting a comfortable wear time of more than 10 hours and minimal reduction in comfort over a wearing day
62365344|NCT01611922||Asymptomatic Non-Contact Lens Wearers|Non-contact lens wearers reporting a minimal reduction in ocular comfort over the course of a day
62365345|NCT03268642||Life-support Based Comprehensive Treatment Regimen group|"meet all the following conditions:~1. intravenous immune globulin;~2. large dose of glucocorticoids;~3. mechanical ventilation;~4. hemodynamic support: intra-aortic balloon pump (IABP) or/and extracorporeal membrane oxygenation (ECMO);~5. continuous renal replacement therapy."
62365346|NCT03268642||conventional therapy group|"meet one of the following conditions:~1. without/insufficient intravenous immune globulin;~2. without/with various doses of glucocorticoid ;~3. vasoactive drug;~4. without/delayed mechanical ventilation;~5. without/delayed hemodynamic support;~6. without/delayed continuous renal replacement therapy."
62365347|NCT05884268|ACTIVE_COMPARATOR|Laparoscopic Cholecystectomy|
62365348|NCT05884268|PLACEBO_COMPARATOR|Control|
62552772|NCT05506293||paravalvular leak|patients referred for percutaneous paravalvular leak closure
62552773|NCT02129322|ACTIVE_COMPARATOR|Sorafenib|Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential : Sorafenib maintenance
62365349|NCT01983449|EXPERIMENTAL|Adventitial Dexamethasone|In patients receiving either angioplasty or atherectomy-based revascularization (pre-stratified to each by 50% of the total study), dexamethasone will be delivered to the adventitia following revascularization.
62365350|NCT03086590||Group 1|COPD mild. The individuals allocated to this group have FEV1 ≥ 80% predicted.
62365351|NCT03086590||Group 2|COPD Moderate. The individuals allocated to this group have 50% ≤ FEV1 \< 80% predicted.
62365352|NCT03086590||Group 3|COPD Severe. The individuals allocated to this group have 30% ≤ FEV1 \< 50% predicted.
62365353|NCT03086590||Group 4|COPD Very severe. The individuals allocated to this group have FEV1 \< 30% predicted.
62365354|NCT05374291|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10 mg/day (oral)
62365355|NCT05374291|PLACEBO_COMPARATOR|Placebo|Placebo 10 mg/day (oral)
62365356|NCT04611061||ARVI and influenza prophylaxis with Kagocel|"Prophylaxis according to routine practice and instructions for medical use of Kagocel.~Group of patients receiving Kagocel for prevention of ARVI and influenza"
62365357|NCT04611061||ARVI and influenza prophylaxis without any antiviral medicines|Group of patients receiving no any antiviral medicines for prevention of ARVI and influenza
62365358|NCT05480800|EXPERIMENTAL|iNTS-TCV low dose Group|Participants 18 to 50 years of age in Stage 1 (Europe) randomized to receive 3 doses of iNTS-TCV low dose vaccine and 3 doses of saline solution, administered in different arms, at Days 1, 57, and 169.
62365359|NCT05480800|ACTIVE_COMPARATOR|iNTS-GMMA and TCV low doses Group|Participants 18 to 50 years of age in Stage 1 (Europe) randomized to receive 3 doses of iNTS-GMMA low dose vaccine and 3 doses of TCV low dose vaccine, administered in different arms, at Days 1, 57, and 169.
62365360|NCT05480800|PLACEBO_COMPARATOR|Placebo _Step 1 Group|Participants 18 to 50 years of age in Stage 1 (Europe) randomized to receive 3 doses of placebo and 3 doses of saline solution, administered in different arms, at Days 1, 57, and 169.
62365361|NCT05480800|EXPERIMENTAL|iNTS-TCV full dose_1 Group|Participants 18 to 50 years of age in Stage 1 (Europe) randomized to receive 3 doses of iNTS-TCV full dose vaccine and 3 doses of saline solution, administered in different arms, at Days 1, 57, and 169.
62365362|NCT05480800|ACTIVE_COMPARATOR|iNTS-GMMA and TCV full doses_1 Group|Participants 18 to 50 years of age in Stage 1 (Europe) randomized to receive 3 doses of iNTS-GMMA full dose vaccine and 3 doses of TCV full dose vaccine, administered in different arms, at Days 1, 57, and 169.
62365363|NCT05480800|PLACEBO_COMPARATOR|Placebo_Step 2 Group|Participants 18 to 50 years of age in Stage 1 (Europe) randomized to receive 3 doses of placebo and 3 doses of saline solution, administered in different arms, at Days 1, 57, and 169.
62365364|NCT05480800|EXPERIMENTAL|iNTS-TCV full dose_2 Group|Participants 18 to 50 years of age in Stage 2 (Africa) randomized to receive 3 doses of iNTS-TCV full dose vaccine and 3 doses of saline solution, administered in different arms, at Days 1, 57, and 169.
62365365|NCT05480800|ACTIVE_COMPARATOR|iNTS-GMMA and TCV full doses_2 Group|Participants 18 to 50 years of age in Stage 2 (Africa) randomized to receive 3 doses of iNTS-GMMA full dose vaccine and 3 doses of TCV full dose vaccine, administered in different arms, at Days 1, 57, and 169.
62365366|NCT05480800|ACTIVE_COMPARATOR|Control_Stage 2 Group|Participants 18 to 50 years of age in Stage 2 (Africa) randomized to receive one dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered at Day 1, one dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered at Day 57, one dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered at Day 169, and 3 doses of saline solution administered at Days 1, 57 and 169.
62742478|NCT04082845|EXPERIMENTAL|Experimental Group|The experimental group will be educated via a website that was created by the researchers.
62365367|NCT05226143|EXPERIMENTAL|Gel Cream|Participants will be provided with the Gel Cream to apply on clean, dry face (facial skin) once per day and on the target lesion on the face or body at least 2 times per day or more as needed, in the morning and at night for 14 days.
62365368|NCT03641794|EXPERIMENTAL|DN1406131|25 mg,50 mg,100 mg,200 mg,400 mg,600 mg,800 mg
62365369|NCT03641794|PLACEBO_COMPARATOR|Placebo|25 mg,50 mg,100 mg,200 mg,400 mg,600 mg,800 mg
62365370|NCT04836923|EXPERIMENTAL|LIFT subgroup|PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members.
62365371|NCT04836923|EXPERIMENTAL|LIFT + REAP subgroup|"PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members. We will also employ Realistic Effort Action Planning (REAP), a form of personality-informed motivational interviewing in a subset of patients to potentially enhance patient engagement and adherence to the home-exercise prescription."
62365372|NCT00408291||1|Winsta PH osteosynthesis device (Fischer Medical)for treatment of humeral fracture
62365373|NCT02726048|EXPERIMENTAL|Full face/Nasal masks|Simplus/Eson
62365374|NCT02725268|EXPERIMENTAL|Paclitaxel 80 mg/m^2|Paclitaxel 80 milligrams per square meter (mg/m\^2), IV, weekly on Days 1, 8, and 15 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 13 weeks).
62365375|NCT02725268|EXPERIMENTAL|Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg|Paclitaxel 80 mg/m\^2, IV, weekly on Days 1, 8, and 15 of a 28-day cycle along with sapanisertib 4 milligrams (mg), capsule, orally on Days 2-4, 9-11, 16-18, and 23-25 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 20 weeks).
62365376|NCT02725268|EXPERIMENTAL|Sapanisertib 30 mg|Sapanisertib 30 mg, capsule, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 6 weeks).
62365377|NCT02725268|EXPERIMENTAL|Sapanisertib 4 mg + MLN1117 200 mg|Sapanisertib 4 mg, capsule, orally and MLN1117 200 mg, capsule, orally on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 8 weeks).
62365378|NCT04078074|EXPERIMENTAL|Maxillary OSS|
62365379|NCT04078074|EXPERIMENTAL|Mandibular OSS|
62365380|NCT04078074|EXPERIMENTAL|Modified farrar splint|
62365381|NCT00136357|EXPERIMENTAL|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
62742479|NCT04082845|NO_INTERVENTION|Control Group|The control group will take rutin patient care.
62365382|NCT00136357|NO_INTERVENTION|Delayed Intervention|Comparison group not receiving intervention until after the initial intervention was completed.
62365383|NCT01722903||Stage IV colorectal cancer|CTCs will be drawn during liver and/or lung metastasectomy for colorectal cancer
62742480|NCT06552793|EXPERIMENTAL|Autogenous partially demineralized dentin graft|Following atraumatic tooth extraction, curettes will be used to remove granulation tissues, and the socket will be irrigated with sterile normal saline.Then the socket will be filled with Autogenous partially demineralized dentin graft (that will be prepared using tooth transformer device) followed by placement of a collagen membrane to cover the socket(The membrane will be shaped to extend 2-3 mm beyond the margins of the extraction socket and positioned just beneath the marginal mucosa) . Suturing technique will be a criss cross horizontal mattress to ensure that most of the grafting material is covered.
62365384|NCT05458362|EXPERIMENTAL|EMI group|"For two weeks after the intervention session, participants will report on their anxiety level four times per day. When participants endorse elevated anxiety, they will receive a message relevant to their most stressful symptom at the moment reminding them of the topics covered in the intervention session.~As the efficacy of the EMI component is being tested, only the EMI group will receive EMI."
62365385|NCT05458362|ACTIVE_COMPARATOR|Control group|The control group will not receive EMI prompts and will be offered to complete EMI after the follow-up assessment.
62742481|NCT06552793|ACTIVE_COMPARATOR|Xenograft|Following atraumatic tooth extraction, curettes will be used to remove granulation tissues, and the socket will be irrigated with sterile normal saline.Then the socket will be filled with xenograft graft followed by placement of a collagen membrane to cover the socket.( The membrane will be shaped to extend 2-3 mm beyond the margins of the extraction socket and positioned just beneath the marginal mucosa) Suturing technique will be a criss cross horizontal mattress to ensure that most of the grafting material is covered.
62742482|NCT05558358|EXPERIMENTAL|1|Randomized sham-controlled crossover design - participants have baseline assessments/evaluation, 1 week detoxification, surgery, 30 days residential care, then begin DBS stimulation, 12 weeks IOP/CM and are followed for 52 weeks.
62742483|NCT05558358|EXPERIMENTAL|2|Randomized sham-controlled crossover design - participants have baseline assessments/evaluation, 1 week detoxification, surgery, 30 days residential care, then begin DBS stimulation, 12 weeks IOP/CM and are followed for 52 weeks.
62742484|NCT06661473|OTHER|Avance Solo ciNPT|
62742485|NCT01066104|PLACEBO_COMPARATOR|Xolair placebo|Xolair placebo 150-375 mg is administered subcutaneously (SC) every 2 or 4 weeks depending on the patient's baseline serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg) ). Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site.
62742486|NCT01066104|ACTIVE_COMPARATOR|Xolair (omalizumab)|Xolair (omalizumab) 150-375 mg is administered subcutaneously (SC) every 2 or 4 weeks depending on the patient's baseline serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site.
62742487|NCT01222117|EXPERIMENTAL|Plasmin Open-label Treatment Group A|Open-label 150 mg Plasmin administered without initial proximal pulse; 5-hour infusion using 10 mL/hour infusion rate.
62742488|NCT01222117|EXPERIMENTAL|Plasmin Open-label Treatment Group B|Open-label 150 mg Plasmin administered with initial proximal pulse; 5-hour infusion using 15 mL/hour infusion rate
62742489|NCT01222117|EXPERIMENTAL|Plasmin Open-label Treatment Group C|Open-label 150 mg Plasmin administered with proximal pulse; 5 hour infusion using 30 mL/hour infusion rate.
62742490|NCT01222117|EXPERIMENTAL|Plasmin Open-label Treatment Group D|Open-label 150 mg Plasmin administered with proximal pulse; 2-hour infusion using 35 mL/hour infusion rate
62742491|NCT01222117|ACTIVE_COMPARATOR|Plasminogen Activator Blinded Group E|PA administered for five hours at a dose and volume according to the Investigator's clinical judgement/standard practice
62742492|NCT01222117|PLACEBO_COMPARATOR|PA Placebo Blinded Treatment Arm F|PA placebo (normal saline for injection) administered for five hours at a dose and volume according to the Investigator's clinical judgement/standard practice for PA administration
62742493|NCT01222117|EXPERIMENTAL|Plasmin Open-label Treatment Group G|Open-label 150 mg Plasmin administered without pulsing; 5-hour infusion using 60 mL/hour infusion rate
62742494|NCT01222117|EXPERIMENTAL|Plasmin Open-label Treatment Group H|Open-label 150 mg Plasmin administered without pulsing; 2-hour infusion using 75 mL/hour infusion rate
62742495|NCT01222117|EXPERIMENTAL|Plasmin Open-label Treatment Group I|Open-label 150 mg Plasmin administered without pulsing; 5-hour infusion using 30 mL/hour infusion rate with balloon occlusion catheter
61997495|NCT01919658|ACTIVE_COMPARATOR|proximal nerve block|The anesthesiologist will administer a proximal nerve block if specified in the randomization envelope.
62365386|NCT05859906||Group 12 mmHg|All patients in this group will be operated with an insufflation pressure of 12 mmHg during laparoscopic cholecystectomy surgery.
62365387|NCT05859906||Group 14 mmHg|All patients in this group will be operated with an insufflation pressure of 14 mmHg during laparoscopic cholecystectomy surgery.
62365388|NCT03654560|ACTIVE_COMPARATOR|HemoStyp|Subjects with an appropriate target bleeding site will have Hemostyp applied in accordance to instructions for use.
62365389|NCT03654560|ACTIVE_COMPARATOR|Surgicel|Subjects with an appropriate target bleeding site will have Surgicel applied in accordance to instructions for use.
62365390|NCT00776490|EXPERIMENTAL|1|Glimepiride 1 MG Tablets of ranbaxy
62365391|NCT00776490|ACTIVE_COMPARATOR|2|AMARYL® 1 mg tablets
62365392|NCT06398951|ACTIVE_COMPARATOR|Two Nare (Duet) high flow nasal cannula|Recently a new mode of high flow oxygen therapy has presented on the market where the cannula of high flow have different diameters. Left cannula larger in diameter than the right. These two-nare size high flow nasal cannula are capable of delivering gases at a flow rate of 15-60 L/min, similar to the conventional HFNP but the difference in the diameters provide different levels of positive pressure as compared to conventional HFNP. The two nare nasal cannula will be used for 30 minutes to assess the gas exchange, hemodynamic parameters, the tolerance and comfort of the device to the patient.
62365393|NCT06398951|PLACEBO_COMPARATOR|Conventional High flow nasal cannula|Conventional high flow nasal cannula that has been used for many years will be compared with two-nare high flow nasal cannula. The two nare nasal cannula will be used for 30 minutes to assess the gas exchange, hemodynamic parameters, the tolerance and comfort of the device to the patient.
62365394|NCT00053222|EXPERIMENTAL|Arm A|Arsenic trioxide (0.3 mg/kg/day iv for 5 days every 28 days)
62365395|NCT05527106|EXPERIMENTAL|Citicoline|Cebrolux 800 is a food supplement based on citicoline (163 mg) that also contains vitamin A, E, C and B6.
62365396|NCT05527106|EXPERIMENTAL|Docosahexaenoic Acid (DHA)|Brudypio 1.5g is a food supplement based on Omega-3 fatty acid in the form of triglycerides (DHA 70% \[350 mg\], EPA 8.5%, DPA 6%) that also contains vitamins (A, B1, B2, B3, B6, B9, B12, C, E), carotenoids ( lutein, zeaxanthin, lycopene), glutathione, coenzyme Q10 and minerals (Zn, Se, Cu, Mn).
62365397|NCT05527106|EXPERIMENTAL|Citicoline and Docosahexaenoic Acid (DHA)|Cebrolux 800 and Brudypio 1.5g (see above).
62365398|NCT05527106|EXPERIMENTAL|Vitamin C|Vitamin C.
62365399|NCT01131845|EXPERIMENTAL|Treprostinil diethanolamine|
62365400|NCT04263415|PLACEBO_COMPARATOR|group P|once-weekly injection with placebo pen.
62365401|NCT04263415|EXPERIMENTAL|group S|Once-weekly application of semaglutide
62365402|NCT00425945|PLACEBO_COMPARATOR|Placebo|Placebo delivered as four tablets matching the active product once daily orally.
62365403|NCT00425945|ACTIVE_COMPARATOR|Pine Bark Extract|Flavangenol 200 mg Flavangenol is a brand of Pine Bark Extract manufactured by Toyo Shinyaku of Saga, Japan. Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day.
62365404|NCT05367167||Case group|Patients who meet the 2010 American College of Rheumatology diagnostic criteria and were diagnosed with OSAS in the sleep laboratory will be considered as the case group.
62365405|NCT05367167||Control group|Patients who did not meet the 2010 American College of Rheumatology diagnostic criteria and were diagnosed with OSAS in the sleep laboratory will be considered as the control group.
62365406|NCT03624439|EXPERIMENTAL|Normal airway|normal airway. the language has not been inflated. the instructor assessed the difficulty of intubation based on the Cormack - Lehane scale to the first degree
62365407|NCT03624439|EXPERIMENTAL|Difficult airway|dofficult airway. Difficult airways were obtained by means of language inflation using a simulator control panel, so as to obtain the degree of intubation difficulty assessed by an independent anesthesiologist to the third degree according to the Cormack-Lehane scale
62365408|NCT01159821|EXPERIMENTAL|001|31001074/paroxetine 1 tablet of 31001074 will be administered on Day 1 and Day 13. One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
62365409|NCT04165304|NO_INTERVENTION|control|the range of products offered by the vending machines remains unchanged
62365410|NCT04165304|OTHER|Intervention group 1|vending machines will be re-equipped to contain 60% drinks containing a maximum of 6.7g sugar/100ml, 20% drinks containing more than 6.7g sugar/100ml and 20% water
62365411|NCT04165304|OTHER|Intervention group 2|In the second intervention group, the vending machines offer 80% water and 20% products with a maximum of 6.7g sugar/100ml.
62365412|NCT04961827|EXPERIMENTAL|Intervention: Self-efficacy based images|Intervention group with self-efficacy based images sent through instant messaging biweekly for 6 times.
62365413|NCT04961827|ACTIVE_COMPARATOR|Active control: knowledge based images|Active control group with knowledge based images sent through instant messaging biweekly for 6 times.
62365414|NCT05068388|PLACEBO_COMPARATOR|Placebo|oral capsule
62365415|NCT05068388|EXPERIMENTAL|1 mg (Z)-endoxifen|oral capsule
62365416|NCT05068388|EXPERIMENTAL|2 mg (Z)-endoxifen|oral capsule
62365417|NCT04757376|EXPERIMENTAL|CT-P41|60 mg/mL single dose administration, Solution for injection in prefilled syringe(PFS)
62365418|NCT04757376|ACTIVE_COMPARATOR|US-licensed Prolia|60 mg/mL single dose administration, Solution for injection in PFS
62365419|NCT02733471|EXPERIMENTAL|Lidocaine|Five lidocaine solution puffs (10mg lidocaine/puff) on the four posterior quadrants of the pharynx and on the base of the tongue, 3 minutes before the oesophago-gastro-duodenoscopy.
62365420|NCT02733471|PLACEBO_COMPARATOR|Control|Five placebo solution puffs on the four posterior quadrants of the pharynx and on the base of the tongue, 3 minutes before the oesophago-gastro-duodenoscopy
62365421|NCT06427148|EXPERIMENTAL|Intervention|To evaluate the feasibility and safety of the GoldenBreath before and after the procedure, the researchers asked the children to report their fears about the procedure. In addition, the children were asked to indicate the pain level they experienced, especially during the needle procedure. Possible missing data, withdrawal from the trial, and intervention fidelity were monitored during this process. Also, the children were monitored for fifteen minutes to see if they experienced any side effects related to the intervention.
62365422|NCT01394367|EXPERIMENTAL|Respiratory and exercise therapy|Randomized, prospective, controlled, blinded study of three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional rehabilitation without a specific training program. After 15 weeks training is also offered to patients in the control group.
62365423|NCT01394367|NO_INTERVENTION|respiratory and exercise therapy|
61997496|NCT01919658|ACTIVE_COMPARATOR|distal nerve block|The anesthesiologist will administer a distal nerve block if specified in the randomization envelope.
62365424|NCT01285752|EXPERIMENTAL|1|
62365425|NCT01285752|EXPERIMENTAL|2|
62365426|NCT01285752|ACTIVE_COMPARATOR|3|
62365427|NCT03871465|EXPERIMENTAL|Triamcinolone SASD injection|2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
62365428|NCT03871465|EXPERIMENTAL|Physiotherapy|The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
62365429|NCT03871465|EXPERIMENTAL|Triamcinolone injections & Physiotherapy|"2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.~The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles."
62365430|NCT01240304|EXPERIMENTAL|Gemcitabine, radiation therapy, surgery|
62365431|NCT03615989|PLACEBO_COMPARATOR|Exercise and Carbohydrate (CHO)|Participants had a fasted, baseline blood sample (10ml) taken upon arrival to the lab. They then completed a supervised resistance and plyometric exercise bout. Immediately following exercise, 50g of carbohydrate (maltodextrin) + water was consumed. Two more blood samples followed the exercise bout at 5 minutes post (10ml) and 1 hour post (10ml). An additional 50g of carbohydrate was consumed with water 1 hour post exercise. Two more fasting blood samples (10ml) were taken 24 and 48 hours later.
62365432|NCT03615989|EXPERIMENTAL|Exercise and Milk (Milk)|Participants had a fasted, baseline blood sample (10ml) taken upon arrival to the lab. They then completed a supervised resistance and plyometric exercise bout. Immediately following exercise, \~500 ml of skim milk was consumed. Two more blood samples followed the exercise bout at 5 minutes post (10ml) and 1 hour post (10ml). An additional 500 ml of skim milk was consumed 1 hour post exercise. Two more fasting blood samples (10ml) were taken 24 and 48 hours later.
62365433|NCT05392166|ACTIVE_COMPARATOR|case|
62365434|NCT05392166|ACTIVE_COMPARATOR|control|
62365435|NCT05417659|PLACEBO_COMPARATOR|Control|A placebo drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise and placebo tablets to be consumed 30 minutes prior to exercise, at the onset of exercise and 30 minutes into exercise.
62365436|NCT05417659|ACTIVE_COMPARATOR|Exercise plus carbohydrate|A high carbohydrate drink (1.6g/kg) to be consumed 1 hour prior to exercise and further drinks (0.2g/kg) every 15 minutes during exercise.
62365437|NCT05417659|EXPERIMENTAL|Exercise plus niacin|A dose of niacin (10mg/kg) to be consumed 30 minutes prior to exercise and two further doses (5mg/kg) at the onset of exercise and 30 minutes into exercise.
62365438|NCT04038385|EXPERIMENTAL|Intervention|This group will receive routine services provided by WIC and an intervention that will combine behaviorally-focused nutrition education with 1) the establishment of a WIC-based farmers' market (implemented in 2019 during the WIC Farmers' Market Nutrition Program voucher issuance period \[June 19 to August 19\]), and 2) monthly trips to an area farmers' market (between September 1, 2019 and November 30, 2019 \[the end of the local growing season\]).
62365439|NCT04038385|NO_INTERVENTION|Control|This group will receive routine services provided by WIC only.
62365440|NCT00910013|EXPERIMENTAL|Ropivacaine + femoral block|After the surgery is proceeded and after the closure of the joint capsule, 20 cc of ropivacaine 0.5% is inserted intra-articular through a catheter.
62365441|NCT02746770|EXPERIMENTAL|Cawthorne and Cooksey exercises group|Intervention: Participants allocated in both control and experimental groups were receiving treatment for their specific vestibular disorders. Patients assigned to the experimental group also performed the Cawthorne and Cooksey exercises for vestibular rehabilitation during a six week of treatment period.
62365442|NCT02746770|NO_INTERVENTION|control group|intervention: The control group will not perform the active exercise that will be applied to intervention group.
62365443|NCT00774969|EXPERIMENTAL|All|6 patients with Perianal Crohn's Disease and 10 healthy Volunteers
62742496|NCT01222117|EXPERIMENTAL|Plasmin Open-label Treatment Group J|Open-label 150 mg Plasmin administered without pulsing; 2-hour infusion using 35 mL/hour infusion rate with balloon occlusion catheter
62742497|NCT01222117|EXPERIMENTAL|Plasmin Open-label Treatment Group M|Open-label 250 mg Plasmin administered without pulsing; 5-hour infusion using 30 mL/hour infusion rate with balloon occlusion catheter
62742498|NCT04015817|EXPERIMENTAL|Etude longitudinale|Work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, support from the mobile palliative care team
62365444|NCT03519841|EXPERIMENTAL|RSP-13-01|Experimental: IMD data collection Subjects will intensively collect spectral Raman data on P0.1 in a home-based setting for 5 days. Data will be paired with reference measurements.
62365445|NCT03519841|EXPERIMENTAL|RSP-13-02|Experimental: IMD data collection Subjects will collect spectral Raman data on P0.1 during four measuring sessions a day for 30 days distributed over a time period of 60 days. Each timepoint is conducted in duplicate. Spectral data will be compared to standard BG measurements.
62365446|NCT02393222||Patients with ESRD on HD|Adult patients with ESRD on HD. Observing the effect of a single HD session on cerebral blood flow (assessed by transcranial doppler) and cognitive function (assessed by neurocognitive questionnaires). Subgroup to undergo brain MRI.
62365447|NCT00905268|EXPERIMENTAL|Group A: Idebenone|Patients under/equal 45 kg: idebenone 180 mg/day Patients over 45 kg: idebenone 360 mg/day
62365448|NCT00905268|EXPERIMENTAL|Group B: Idebenone|Patients under/equal 45 kg: idebenone 450 mg/day Patients over 45 kg: idebenone 900 mg/day
62365449|NCT00905268|EXPERIMENTAL|C: Idebenone|Patients under/equal 45 kg: idebenone 1350 mg/day Patients over 45 kg: idebenone 2250 mg/day
62365450|NCT00905268|PLACEBO_COMPARATOR|D: Placebo|placebo
62365451|NCT04646226|EXPERIMENTAL|fistula surgically placed|Randomized group to have surgically placed fistula for permanent hemodialysis access
62365452|NCT04646226|ACTIVE_COMPARATOR|graft surgically placed|Randomized group to have surgically placed graft for permanent hemodialysis access
62365453|NCT04258293||Patients|Patients on prolonged corticosteroid therapy (more than three months)
62365454|NCT01257672|EXPERIMENTAL|ondansetron|ondansetron, syrup, 0,15 mg/Kg of body weight, 1 dose
62365455|NCT01257672|ACTIVE_COMPARATOR|domperidon|domperidone, syrup, 0,5 mg/Kg of body weight, one dose
62365456|NCT01257672|PLACEBO_COMPARATOR|placebo|placebo, syrup, one dose
62365457|NCT04107636|EXPERIMENTAL|Assigned Interventions|First, the tumor will be removed under local anesthesia using the VAB system with US guidance, through a small skin incision (\<0.5 cm). A localization marker will be placed in the biopsy cavity, to help determine the cavity location. After 3 weeks, the breast conserving surgery is performed, excising the VAB excision cavity and a ≥1 cm of surrounding tissue, as deemed appropriate by the attending breast surgeon. A sentinel node biopsy will be performed in the same procedure.
62365458|NCT01376388|EXPERIMENTAL|GSK573719/GW642444|125/25mcg
62742499|NCT05638412|EXPERIMENTAL|JASPER Intervention Group|"Caregivers receiving the JASPER intervention will undergo weekly virtual 60-minute sessions for 10 weeks conducted via Zoom.~The content of the intervention includes teaching and implementation of contingent responding and specific strategies to provide a high-quality response to children's communication, and play behaviors. Caregiver training is completed through review of pre-recorded videos of the caregiver-child dyad each week. The first half of each session will be dedicated to reviewing previous content and feedback on the play recording. The following half will consist of new material. The coaching support includes contingent responding, the parent is also taught to use specific strategies to provide a rich, high-quality response to children's communication, and play behaviors."
62742500|NCT05638412|EXPERIMENTAL|Psychoeducational Curriculum Group|"Caregivers receiving the 10 weekly psychoeducational curriculum modules will be provided with the resources via secure email and encouraged to engage with the material a self-directed manner.~The psychoeducational modules will include written information about child development, communication and social interaction skills, behavioral principles for managing challenging behavior and strategies for teaching new skills. No direct caregiver-child mediated coaching will be provided. The content of the modules will include information about developmental milestones in this age group for children with DS, behavior management strategy recommendations, positive parenting materials, and materials on increasing engagement through play."
62365459|NCT04753723|EXPERIMENTAL|Platform wound device with antibiotic|Antibiotic cream will be applied to study wounds and then dressed with the platform wound device.
62365460|NCT04753723|NO_INTERVENTION|Standard of Care|Study wounds will be treated per the standard of care.
62365461|NCT06009198|EXPERIMENTAL|Advance Education with Iron Folate Supplement|"1. Nutrition education~2. WASH education~3. Micronutrient supplementation"
62365462|NCT06009198|NO_INTERVENTION|Routine Education|Routine school education
62365463|NCT04307953|EXPERIMENTAL|AZD0530|
62742501|NCT05927428|ACTIVE_COMPARATOR|BRM424 Ophthalmic Solution - Dose1|
62742502|NCT05927428|ACTIVE_COMPARATOR|BRM424 Ophthalmic Solution - Dose2|
62742503|NCT00613327|EXPERIMENTAL|Oxybutynin Chloride OROS|
62742504|NCT01485731|EXPERIMENTAL|Nelfinavir + Cisplatin + Pelvic Radiation Therapy|Nelfinavir in combination with Cisplatin and Pelvic Radiation Therapy
62365464|NCT04307953|EXPERIMENTAL|Placebo/AZD0530|
62365465|NCT01448707|EXPERIMENTAL|Darunavir monotherapy|Darunavir (DRV) + ritonavir (rtv): 2 tablets DRV 400 mg should be taken together with 1 tablet rtv 100 mg within 30 minutes after a meal. Following the primary efficacy analysis after Week 48, patients who entered the study with a nadir CD4+ count of \<200 cells/μL will also receive 2 N\[t\]RTIs (ie, triple therapy) as soon as possible
62365466|NCT01448707|ACTIVE_COMPARATOR|Triple therapy containing darunavir|Darunavir (DRV) + ritonavir (rtv) + 2 N\[t\]RTIs: 2 tablets DRV 400 mg should be taken together with 1 tablet rtv 100 mg within 30 minutes after a meal in combination with 2 N\[t\]RTIs (an investigator-selected dual combination of either abacavir (ABC), lamivudine (3TC), zidovudine (AZT), tenofovir disoproxil fumarate (TDF) or emtricitabine (FTC)
62365467|NCT05934136|EXPERIMENTAL|My Healthy Brain 1|My Healthy Brain 1 is an 8-week group program delivered via 90-minute Zoom meetings led by a clinical psychologist. It provides education on the link between dementia and lifestyle factors, including poor exercise, sleep, diet/nutrition, mental and social stimulation, alcohol, and smoking. My Healthy Brain 1 participants learn evidence-based mindfulness and behavior change skills to address common barriers to healthy habits, such as stress and setting achievable goals. My Healthy Brain 1 participants wear an activity watch to monitor lifestyle changes during the program.
62742505|NCT02047422|EXPERIMENTAL|Add furosemide/no spironolactone|
62742506|NCT02047422|EXPERIMENTAL|Add metolazone/no spironolactone|
62742507|NCT02047422|EXPERIMENTAL|Add furosemid/spironolactone|
62742508|NCT02047422|EXPERIMENTAL|Add metolazone/spironolactone|
62742509|NCT04651686|EXPERIMENTAL|Bronchial artery protection|All patients underwent chest enhanced CT examination with 64 slice spiral CT before operation. The bronchial artery was reconstructed by Mimics software. The bronchial artery was protected according to the preoperative three-dimensional reconstruction image during the lymph node dissection
62742510|NCT05203211||Men who have undergone icsi from ejaculated semen|
62365468|NCT05934136|ACTIVE_COMPARATOR|My Healthy Brain 2|My Healthy Brain 2 condition controls for the effect of time spent and support/feedback from the group and interventionist. Participants in My Healthy Brain 2 will receive education on lifestyle, brain health, and cognitive decline symptoms in addition to usual care as determined by their medical team. Each weekly session will focus on a different topic: 1) lifestyle and brain health, 2) physical activity, 3) sleep, 4) nutrition, 5) medical adherence, 6) cognitive health, 7) social support, and 8) a program overview. My Healthy Brain 2 is conducted in the same format as My Healthy Brain 1 (8 weekly Zoom sessions, 90 minutes each), but does not include behavior change strategies. My Healthy Brain 2 participants wear an activity watch to monitor lifestyle changes during the program.
62365469|NCT06350006|EXPERIMENTAL|SHR-A1904 combined with Adebrelimab|SHR-A1904+ Adebrelimab
62742511|NCT05203211||Men who have undergone icsi from testicular sperm|
62742512|NCT06053541||Patients diagnosed with COPD, admitted to the hospital with acute exacerbations|Patients over 40 years of age, diagnosed with Chronic Obstructive Pulmonary Disease (COPD), admitted to the hospital with acute exacerbations as recorded in the DATASUS (Unified Health Brazilian System Informatics Department (in Portuguese) between August 2017 and July 2019. Patients were treated with either Tiotropium bromide in soft mist inhaler (SPIRIVA® RESPIMAT®) or with Glycopyrronium bromide in dry powder inhaler (Seebri® Breezhaler®) as part of the treatment plan for Chronic Obstructive Pulmonary Disease (COPD) defined by the Health State Secretariat of Distrito Federal (DF) in Brazil.
62742513|NCT06164652|EXPERIMENTAL|Healthy adults (M/V/X, 18-80)|
62365470|NCT06350006|EXPERIMENTAL|SHR-A1904 combined with CAPOX and Adebrelimab|SHR-A1904+ CAPOX+ Adebrelimab
62365471|NCT02527902|EXPERIMENTAL|IgAN with glomerular filtration rate (GFR) >90 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with glomerular filtration rate (GFR) \>90 ml/min/1.73 m2
62365472|NCT02527902|EXPERIMENTAL|IgAN with GFR 60-89 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 60-89 ml/min/1.73 m2
62365473|NCT02527902|EXPERIMENTAL|IgAN with GFR 30-59 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 30-59 ml/min/1.73 m2
62365474|NCT02527902|EXPERIMENTAL|IgAN with GFR 15-29 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 15-29 ml/min/1.73 m2
62365475|NCT02527902|EXPERIMENTAL|IgAN with GFR < 15ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR \< 15ml/min/1.73 m2.
62365476|NCT02989480||Sarcoidosis|Patients with cardiac sarcoidosis diagnosed according to the Japanese Ministry of Health and Welfare criteria will be included. All patients will have histologically proven sarcoidosis (cardiac biopsy not mandatory) and no other potential cardiac disease. They will have no family history of cardiomyopathy.
62365477|NCT02989480||Arrhythmogenic RV cardiomyopathy|Patients with ARVC diagnosed according to the Task Force criteria with in addition either a positive family history for the condition or harbour a known pathological mutation associated with it.
62365478|NCT02947490|SHAM_COMPARATOR|Standard BP management|Participants will continue to receive routine measurement of BP and management of treatment from their General Practitioner (GP).
62365479|NCT02947490|PLACEBO_COMPARATOR|Self BP measurement and standard care|Participants in this group (Se-Mo) will be taught to use a validated British Hypertension Society (BHS) approved home BP monitor (with built in memory/printer) by the study nurse along with written information on the procedure and a copy of the BHS Home BP Monitoring DVD. Participants will be contacted before each recording week \& arrangements will be made to deliver and demonstrate the use of self BP monitor by the study nurse. Home BP monitoring will be performed over a 7 day period 3 times during the 6 month follow-up and on each occasion the patient will be given a copy of the BP results and asked to inform the GP of the results and the GP will decide if any alteration in therapy is needed.
62365480|NCT02947490|ACTIVE_COMPARATOR|Self BP measurement and treatment|Participants in this group will undergo exactly the same self BP monitoring training process as the Se-MO group and will undertake monitoring at the same time intervals. However they will be equipped with a validated BP monitor with a Bluetooth interface phone, BP values recorded by the patient will be transmitted automatically via mobile telephone to the trial coordinating centre. The data will be password protected and saved on a secure server and be available only to the trial team (study nurse \& supervising physicians). The patient would then be contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels. This will be recorded on the CRF and the GP notified of any treatment changes.
62365481|NCT00442949|ACTIVE_COMPARATOR|2|Catheterization immediate PCI
62365482|NCT00442949|EXPERIMENTAL|1|delayed PCI
62365483|NCT05702736|EXPERIMENTAL|Intervention group|Beck Depression Inventory, Psychache Scale, Meaning of Life Questionnaire was applied to intervention group as a pre-test. Inaddition to the Standard treatment, the intervention group received a logotherapy-based intervention. Beck Depression Inventory, Psychache Scale, Meaning of Life Questionnaire was applied to intervention group as a post test and follow up test.
62365484|NCT05702736|NO_INTERVENTION|Control group|Beck Depression Inventory, Psychache Scale, Meaning of Life Questionnaire was applied to control group as a pre-test. The control group received only standard treatment. Beck Depression Inventory, Psychache Scale, Meaning of Life Questionnaire was applied to control group as a post test and follow up test.
62365485|NCT01784614|EXPERIMENTAL|0.1 milligrams (mg) LY2624803|Single dose of 0.1 mg LY2624803 administered orally in up to 2 of 4 treatment periods
62365486|NCT01784614|EXPERIMENTAL|1.0 mg LY2624803|Single dose of 1.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
62365487|NCT01784614|EXPERIMENTAL|3.0 mg LY2624803|Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
62365488|NCT01784614|EXPERIMENTAL|6.0 mg LY2624803|Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
62742514|NCT04579536|EXPERIMENTAL|Study group|This is the study group; it will consist of 84 first permanent molars. These molars will be sealed using light curing resin-modified glass ionomer varnish (ClinproTM XT Vanish, 3M ESPE, Dental Products, St. Paul, MN, USA). reapplication will be done after 3,6, 12, and 18 months.
62365489|NCT01784614|PLACEBO_COMPARATOR|Placebo|Single dose of placebo administered orally in up to 1 of 4 treatment periods
62365490|NCT01985386|EXPERIMENTAL|GDS (gastric delivery system), meal|GDS capsule with meal
62365491|NCT01985386|ACTIVE_COMPARATOR|Ferrous sulfate, meal|Ferrous sulfate with meal
62365492|NCT05038787|EXPERIMENTAL|LY3473329|LY3473329 administered orally.
62365493|NCT05038787|PLACEBO_COMPARATOR|Placebo|Placebo administered orally.
62365494|NCT02795455|EXPERIMENTAL|Interoceptive Exposure (IE)|IE is an exposure-based intervention that involves consuming a food in session and tolerating uncomfortable feelings around eating.
62365495|NCT02795455|ACTIVE_COMPARATOR|Family Based Therapy-Weight Gain Control (FBT-WG)|Family-based therapy uses parent(s) to help modify disordered eating and develop contingencies to motivate eating.
62365496|NCT02795455|NO_INTERVENTION|Healthy Controls (HC)|HC participants will only participate in the pre and post-intervention visits and not in the intervention sessions.
62365497|NCT05270083|ACTIVE_COMPARATOR|Athletes with mild to moderate traumatic brain injury (mTBI) and good outcome|Young athletes who have sustained one or more concussions without persistent cognitive complaints at least one year post-injury
62365498|NCT05270083|ACTIVE_COMPARATOR|Athletes with persistent cognitive deficits due to mild to moderate traumatic brain injury (mTBI)|Young athletes who have sustained one or more concussions with persistent cognitive complaints at least one year post-injury in spite of medical and cognitive treatment intervention.
62365499|NCT02820688|ACTIVE_COMPARATOR|Concentrated|Infraclavicular nerve block under guidance of ultrasonography will be performed using an undiluted solution of 45mg bupivacaine and 180mg prilocaine (bupivacaine 0.25% and prilocaine 1%, 18mL in total) to patients in this group
62365500|NCT02820688|ACTIVE_COMPARATOR|Diluted by 33%|Infraclavicular nerve block under guidance of ultrasonography will be performed using a solution of 45mg bupivacaine and 180mg prilocaine diluted by 33% (bupivacaine 0.167% and prilocaine 0.66%, 27mL in total) to patients in this group
62742515|NCT04579536|OTHER|Control group|This group will consist of 84 first permanent molars. These molars will receive 5% Sodium Fluoride (NaF) with Tri-Calcium Phosphate topical varnish (Vanish White Varnish, 3M ESPE, Dental Products, St. Paul, MN, USA). These molars will serve as a control group. reapplication will be done after 3,6, 12, and 18 months.
62742516|NCT06412978|ACTIVE_COMPARATOR|subcuticular absorbable polyglycolic acid (INSORB) staples|Insorb absorbable staples are used for skin closure
62365501|NCT02820688|ACTIVE_COMPARATOR|Diluted by 50%|Infraclavicular nerve block under guidance of ultrasonography will be performed using a solution of 45mg bupivacaine and 180mg prilocaine diluted by 50% (bupivacaine 0.125% and prilocaine 0.5%, 36mL in total) to patients in this group
62365502|NCT01364857|OTHER|PWS cohort|search for polymorphisms of RASA1 gene
62365503|NCT05537493|EXPERIMENTAL|Telerehabilitation|Videos of the exercises they will do via whatsapp will be sent to the telerehabilitation group. Again, in telerehabilitation, whatapp application will be made in the form of videoconference. Rehabilitation program will be applied to the patients 4 times a week for 6 weeks.
62365504|NCT05537493|ACTIVE_COMPARATOR|Face to face|A rehabilitation program will be applied to the Face to Face rehabilitation group by a physiotherapist in the hospital for a total of 30 sessions per week for 6 weeks.
62365505|NCT05795257||None-mild ARDS|
62365506|NCT05795257||Moderate-severe ARDS|
62365507|NCT03189407|OTHER|Moringa oleifera tea in T2DM patients|The study was a pre/post design for type 2 diabetes mellitus patients on metformin in which each patient acted as his/her control. Intervention of twice daily pre-packed 400g dried Moringa oleifera leaves to be prepared as tea by the patients was done. Evaluation of the effect of the tea on metformin steady state concentrations and blood glucose measurements were done.
62365508|NCT05166551|EXPERIMENTAL|Experimental Group|"Acupressure will be applied to the infants in this group by the researcher in accordance with the technique for 1 minute on the GB31 acupuncture point on the leg where the vaccine will be administered.The considerations before, during and after acupressure application are as follows:~* The hands will be washed to warm them up to body temperature.~* The acupressure will be applied using the thumb to the GB31 acupuncture point for 1 minute before the vaccine is administered to the infants in the experimental group.~* Pain scoring will be performed using the FLACC scale by the parents, the observing nurse, and the researcher after the vaccination procedure. In addition, the HR and SPO2 level of the infants before, during and after the procedure will be evaluated and recorded by the researcher.The crying time of infants will also be recorded."
62365509|NCT05166551|PLACEBO_COMPARATOR|Placebo Group|"Pressure will be applied by the researcher on a placebo point at least 2 cun above the GB31 acupuncture point, on the leg to be vaccinated, for 1 minute. The considerations before, during and after pressure are as follows:~* The hands will be washed to warm them up to body temperature.~* For the infants in the placebo group, pressure will be applied using the thumb for 1 minute to a placebo point that does not coincide with any acupuncture point at least 2 cun above the acupuncture point before the vaccine is administered.~* Pain scoring will be performed using the FLACC scale by the parents, the observing nurse, and the researcher after the vaccination procedure. In addition, the HR and SPO2 level of the infants before, during and after the procedure will be evaluated and recorded by the researcher.The crying time of infants will also be recorded."
62365510|NCT05166551|NO_INTERVENTION|Control Group|"The considerations before, during and after are as follows:~Without any intervention, the infants in this group pain scoring will be performed using the FLACC scale by the parents, the observing nurse, and the researcher after the vaccination procedure. In addition, the HR and SPO2 level of the infants before, during and after the procedure will be evaluated and recorded by the researcher.The crying time of infants will also be recorded."
62365511|NCT01703104|ACTIVE_COMPARATOR|Paludrine + Folic Acid|This arm uses routine drugs, Paludrine + Folic Acid
62365512|NCT01703104|ACTIVE_COMPARATOR|Paludrine + Folic Acid + Jobelyn|This group uses Paludrine + Folic Acid + Jobelyn
62365513|NCT04800094|EXPERIMENTAL|Investigational Ultrasound Imaging for Liver Fat Quantification|
62365514|NCT05810298|EXPERIMENTAL|Smokers Group|"Education about smoking~Asana practice (Only standing yoga poses with rhytmic breathing)~Pranayam (Rhytmic regulated breathing)"
62365515|NCT05810298|ACTIVE_COMPARATOR|Control Group|"Asana practice (Only standing yoga poses with rhytmic breathing)~Pranayam (Rhytmic regulated breathing)"
62742517|NCT06412978|ACTIVE_COMPARATOR|subcuticular absorbable polyglecaprone suture (Monocryl)|Monocryl absorbable staples are used for skin closure
62742518|NCT01028768|EXPERIMENTAL|Teduglutide|
62742519|NCT06662149|EXPERIMENTAL|Pleasant First|Participants will experience the pleasant smell in the participant's first visit and the unpleasant smell in the participant's second visit.
62365516|NCT01227720|EXPERIMENTAL|A NSL2L|Experimental Nicotine Replacement Therapy (NRT)(L) 2 mg
62365517|NCT01227720|ACTIVE_COMPARATOR|B Lozenge|Marketed Nicotine Lozenge 2 mg
62365518|NCT01227720|EXPERIMENTAL|C NSL4M|Experimental NRT (M) 4 mg
62365519|NCT01227720|ACTIVE_COMPARATOR|D Lozenge|Marketed Nicotine Lozenge 4 mg
62365520|NCT01227720|EXPERIMENTAL|E NSL4L|Experimental NRT (L) 4 mg
62365521|NCT01227720|EXPERIMENTAL|F NSL4H|Experimental NRT (H) 4 mg
62742520|NCT06662149|EXPERIMENTAL|Unpleasant First|Participants will experience the unpleasant smell in the participant's first visit and the pleasant smell in the participant's second visit.
62742521|NCT02021383|EXPERIMENTAL|Contest Plus|The Contest Plus group were eligible to receive the financial incentives for weight loss maintenance at three monthly follow ups; weeks 16, 20 and 24. Eligible participants completed online surveys and in person weigh ins verifying weight maintenance. In addition to the financial incentives, participants in this group had bi-weekly in person meetings with a Registered Dietician during phase 2 (week 16-24) of the trial. They also received an in home scale to monitor weight daily.
62742522|NCT02021383|NO_INTERVENTION|Control|The Control condition did not receive any intervention and were not eligible to win the lottery based incentive. Participants completed follow surveys (weeks 16, 20 and 24) and received remuneration for completing surveys and in person weigh in.
62365522|NCT06512831|EXPERIMENTAL|TB Risk factors with INH group (R-INH)|
62365523|NCT06512831|NO_INTERVENTION|TB Risk factors without INH group (R-NINH)|
62365524|NCT06512831|NO_INTERVENTION|Non-Risk group (NR)|
62365525|NCT04828850|EXPERIMENTAL|EBUS-TBNA procedure|Single arm protocol. Invasive mediastinal staging with EBUS-TBNA in clinical N0 NSCLC patients candidate to surgical resection with systematic lymphadenectomy.
62365526|NCT01300949|ACTIVE_COMPARATOR|Glaucoma|154 glaucoma, ocular hypertension and glaucoma suspect patients will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart.
62365527|NCT01300949|ACTIVE_COMPARATOR|Controls|125 patients with no eye diseases will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart. This included patients with refractive errors (needing glasses) and nuclear sclerosis (cataract).
62365528|NCT01300949|ACTIVE_COMPARATOR|Age-Related Macular Degeneration (ARMD)|35 retina patients with age-related macular degeneration (ARMD) will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart.
62365529|NCT05316519|EXPERIMENTAL|Transcutaneous Vagus Nerve Stimulation|Transcutaneous vagus nerve stimulation paired with visuomotor task training
62365530|NCT05316519|PLACEBO_COMPARATOR|Transcutaneous Stimulation (Sham)|Transcutaneous stimulation paired with visuomotor task training
62365531|NCT00049140|EXPERIMENTAL|EF5|This is a non randomised single arm pilot study.
62365532|NCT02069704|EXPERIMENTAL|Bevacizumab biosimilar (BEVZ92)|Bevacizumab 25 mg/mL (strength: 100 mg/4 mL).
62365533|NCT02069704|ACTIVE_COMPARATOR|Avastin® (bevacizumab, ref. product)|Bevacizumab 25mg/ml (strength: 100mg/4ml)
62365534|NCT01181752||Group A|Baseline/control subjects who are only tested on postoperative day 30
62365535|NCT01181752||Group B|Subjects who will be tested on postoperative day 1 and day 30
62365536|NCT01181752||Group C|"Subjects who cannot proficiently administer the medication on postoperative day 1 will be re-classified as Group C subjects"
62365537|NCT01781624|EXPERIMENTAL|Study Oral Nutritional Supplement|2 containers a day of a high calorie, complete, balanced, ready-to-drink oral nutritional supplement with a new protein blend.
62365538|NCT01770145|EXPERIMENTAL|APOKYN|"APOKYN (apomorphine hydrochloride injection) is used as needed to treat off-episode motor symptoms, such as muscle stiffness, slow movements, and difficulty starting movements, in people with advanced Parkinson's disease (PD).~In the study, subjects will complete an L-Dopa Baseline Period in which they record daily time to on following their regularly scheduled L-Dopa morning dose for 7 days. At the end of the baseline period, patients will start trimethobenzamide therapy during a minimum 3-Day Anti-Emetic Pretreatment Period. Patients determined to remain eligible at the end of the required Anti-Emetic Pretreatment Period will be initiated on APOKYN therapy by an investigator. Once the appropriate dose is identified by a study investigator, patients will inject APOKYN at their regularly scheduled levodopa morning dose time (levodopa will be delayed by 40 minutes) daily during a 7-day APOKYN Treatment Period and record time to on following the APOKYN injection."
62365539|NCT04125875||Patients with cirrhosis of esophageal varices|
62365540|NCT04125875||Patients with gastric polyps|
62365541|NCT00531908|EXPERIMENTAL|A|To compare natriuretic effect of a single dose administration of amiloride (20 mg) in patients with acromegaly
62365542|NCT03431792|EXPERIMENTAL|Long-Tail-FETO|"Fetus with severe CDH and o/e TFLV Ratio of \< 25% or \< 35% with liver herniation. The Long tail FETO will performed between 26 and 30 weeks of gestation.~The MRI control will be perfirmed ar 32-34 weeks of gestation. Long Tail FETO: fetal i.m. application of 0.1 mg/kg Pancuronium, 1 µg/kg Fentanyl® and 0.01 mg/kg atropine. (Long-Tail Goldbal 5, 2,5 ml, BALT Extrusion, Montmorency, France). The fetoscope (Karl Storz, Tuttlingen, Germany) with a diameter of 1.3 mm, will be percutaneously inserted through a sheath into the uterus and then into the fetal trachea. The fetoscope will be removed and the balloon will be inserted under 4-D ultrasound guidance into the fetal trachea. The position of the balloon and suture will be visualized using the fetoscopy.~The Long tail ballon will be removed by a second FETO after 34 weeks' gestation or bei the fetus itself with or without of the long tail balloon puncture with 22 gauge needle. The EXIT procedure is also possible."
62365543|NCT05373082||Patients with hereditary spastic Paraplegia|Patients with hereditary spastic Paraplegia
62365544|NCT02330445|EXPERIMENTAL|Part A|Up to 12 Part A recipients will have rheumatoid arthritis since this was an entry criterion for Study 104. All subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses followed by 5 monthly doses of PRTX-100. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 8 months. Subjects will be evaluated for adverse events, rheumatoid arthritis activity and the development of anti-PRTX-100 antibodies. The feasibility of different assessment methods of disease activity may be explored. Novel methods of joint evaluation will be explored. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
62365545|NCT02330445|EXPERIMENTAL|Part B|Five healthy subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses. All subjects will have a serum collection requiring approximately 600 mL of blood. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 3 months. Subjects will be evaluated for adverse events and the development of anti-PRTX-100 antibodies. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
62365546|NCT01319513|EXPERIMENTAL|protein feeding|Participants will complete 2 trials in a cross-over fashion in which they will consume whey protein either as a single bolus or as 10 small divided doses
62365547|NCT00297128|ACTIVE_COMPARATOR|1|
62365548|NCT05664555|ACTIVE_COMPARATOR|Na Fluorescein 3mL Arm|Participants in this arm will receive Na Fluorescein 10% Inj 3mL (300mg) before taking fluorescein angiography.
62365549|NCT05664555|EXPERIMENTAL|Na Fluorescein 1mL Arm|Participants in this arm will receive Na Fluorescein 10% Inj 1mL (100mg) before taking fluorescein angiography.
62391482|NCT01376765|EXPERIMENTAL|Cohort 1|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine received with aluminum hydroxide adjuvant (Alhydrogel®), without adjuvant, or placebo in 2 intramuscular doses, 28 days apart, at 5 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine {(SARS vaccine with aluminum hydroxide adjuvant (Alhydrogel®)}; 4 subjects receive placebo.
62365550|NCT05824767|EXPERIMENTAL|Angiotensin II|For patients randomized to the intervention group, once the dose of background norepinephrine reaches ≥0.10 mcg/kg/min for ≥30 minutes, angiotensin II will be started at a dose of 20 ng/kg/min (recommended starting dose in package insert).Thereafter, angiotensin II and norepinephrine will both be titrated to mean arterial pressure (MAP) goal of \>/= 65 mmHg according to the protocol titration scheme and in accordance with the University of New Mexico Hospital (UNMH) Nursing Department Titration Guideline. Angiotensin II treatment will be capped at 72 hours, at which point (if a second vasopressor is still needed) the patient will be started on an alternative agent.
62365551|NCT05824767|NO_INTERVENTION|Standard of Care (SOC)|Vasopressor therapy be titrated by the clinical team per usual SOC and UNMH Nursing Department Titration Guideline. using other available vasopressor agents (e.g., higher-dose norepinephrine, vasopressin, epinephrine, phenylephrine, and/or dopamine). To provide a comparator arm, patients in the SOC will have renin and DPP3 levels obtained at equivalent timepoints.
62365552|NCT01993667|ACTIVE_COMPARATOR|Acetazolamide normal dose|Experimental : Acetazolamide 125 mg twice daily
62365553|NCT01993667|EXPERIMENTAL|Acetazolamide low dose|Experimental: Acetazolamide 62.5 mg twice daily
62365554|NCT01451866|ACTIVE_COMPARATOR|classic leg-press training|Classic resistance training on the dynamic leg press. 6 x 8 repetitions at 60% 1 RM
62365555|NCT01451866|EXPERIMENTAL|Complex leg-press training|Complex leg-press training with visual feed-back on a dynamic leg-press.
62365556|NCT04176536|EXPERIMENTAL|All participants|
62365557|NCT04066010|NO_INTERVENTION|Control|
62365558|NCT04066010|OTHER|Intervention|Mobile application intervention
62365559|NCT03126240||sleeve Gastrectomy|This is a five-trocar technique. The abdominal cavity is accessed through a 1cm supraumbilical incision using an optical trocar. The operating ports are inserted under direct vision. The gastroesophageal (GE) junction is exposed. A point on the greater curvature approximately 3-6cm to the pylorus is identified as the distal extent of the resection. Ultrasonic shears are used to divide the vessels long the greater curve up to the angle of His. Linear cutting staplers are used to vertically transect the stomach, creating a narrow gastric tube with. A 19Fr drain is placed in the subhepatic space near the staple line. The resected portion of the stomach is extracted through one of the working ports.
62365560|NCT04456595|EXPERIMENTAL|Adult - Vaccine|Participants aging 18-59 years receiving two doses with 14-days interval of Adsorbed COVID-19 (inactivated) Vaccine
62365561|NCT04456595|EXPERIMENTAL|Elderly - Vaccine|Participants aging 60 years or above receiving two doses with 14-days interval of Adsorbed COVID-19 (inactivated) Vaccine
62365562|NCT04456595|PLACEBO_COMPARATOR|Adult - Placebo|Participants aging 18-59 years receiving two doses with 14-days interval of placebo
62365563|NCT04456595|PLACEBO_COMPARATOR|Elderly - Placebo|Participants aging 60 years or above receiving two doses with 14-days interval of placebo
62365564|NCT00558233|EXPERIMENTAL|Intervention group|
62365565|NCT00558233|PLACEBO_COMPARATOR|Placebo group|
62365566|NCT00135525|EXPERIMENTAL|Paroxetine|"Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.~Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan."
62365567|NCT00135525|PLACEBO_COMPARATOR|Placebo|
62365568|NCT05475444|EXPERIMENTAL|Paste and solution of ciprofloxacin as Conventional Treatment|Paste and solution of ciprofloxacin as conventional dosage forms and drugs used to treat endodontics infections. For ciprofloxacin solution is used once daily while the paste form used weekly.
62365569|NCT05475444|EXPERIMENTAL|Chitosan coated PLGA nanoparticles entrapping ciprofloxacin and incorporated in smart poloxamer gel|Chitosan coated PLGA nanoparticles entrapping ciprofloxacin and incorporated in smart poloxamer gel dosage forms treat endodontics infections
62365570|NCT03013959||Resting control group|The rest group is to study the effect of the inhibition of recurrence . Patients with redness, pain, decreased visual acuity and other reaction activity in the past 30 days are observed as control group
62365571|NCT03013959||Resting test group|The rest group is to study the effect of the inhibition of recurrence . Patients with redness, pain, decreased visual acuity and other reaction activity in the past 30 days are treated with pranoprofen and observed as test group
62365572|NCT03013959||Active control group|The active control group is to study the effect of anti--inflammatory. Patients with a new redness, pain, decreased visual acuity and other reaction activity recently are observed as control group
62365573|NCT03013959||Active test group|The active test group is to study the effect of anti--inflammatory. Patients with a new redness, pain, decreased visual acuity and other reaction activity recently are treated with pranoprofen and observed as test group
62365574|NCT00444418|EXPERIMENTAL|1|Active medication (Naltrexone) combined with Modified Behavioral Self-Control Psychotherapy
62365575|NCT00444418|EXPERIMENTAL|2|Placebo combined with Modified Behavioral Self-Control Psychotherapy
62365576|NCT00444418|EXPERIMENTAL|3|Active medication (Naltrexone) combined with Brief Behavioral Compliance Enhancement Therapy
62365577|NCT00444418|PLACEBO_COMPARATOR|4|Placebo + Brief Behavioral Compliance Enhancement Therapy
62365578|NCT06506851|EXPERIMENTAL|AR-based Training Group|Practical nurses in this arm receive AR-based training using Microsoft HoloLens 2®. This training method incorporates augmented reality technology to provide immersive and interactive learning experiences, enhancing their proficiency in device utilization.
62365579|NCT06506851|SHAM_COMPARATOR|Traditional Self-Learning Group|Practical nurses in this arm follow traditional guideline-based self-learning methods without augmented reality technology. They rely on conventional educational materials and guidelines for learning device utilization skills.
62365580|NCT06257134|OTHER|Control group|Patients in the control group will complete three HRQoL questionnaires every six months via a digital tablet during their dialysis session.
62365581|NCT06257134|EXPERIMENTAL|Experimental group|Every three months, patients in the experimental group will have their symptoms systematically recorded using the IPOS-Renal questionnaire via a digital tablet during their dialysis session.
62365582|NCT06066606|EXPERIMENTAL|Vilanterol + fluticasone furoate|Participants are administered Vilanterol + fluticasone furoate from an inhaler device testing
62365583|NCT06066606|PLACEBO_COMPARATOR|Placebo|Participants are administered placebo from an inhaler device testing
62365584|NCT06039150|EXPERIMENTAL|M-TAPA group|The group to be administered 0.025% Bupivacaine by the anesthesiologist bilaterally in M-TAPA block with a maximum dose of 2 mg/kg before extubation.
62365585|NCT06039150|ACTIVE_COMPARATOR|LAİ group|The group to be divided and administered 0.025% Bupivacaine with a maximum dose of 2 mg/kg by the surgeon to 3 port entry sites before extubation
62365586|NCT02283333|EXPERIMENTAL|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy are delivered in 7 weekly sessions to the participant.
62365587|NCT02283333|ACTIVE_COMPARATOR|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling are delivered in 7 weekly sessions to the participant.
62365588|NCT03595449|ACTIVE_COMPARATOR|Lidocaine jelly|This is the group that will have lidocaine jelly applied during Mohs surgery
62365589|NCT03595449|SHAM_COMPARATOR|Surgilube|This is the group that will have surgilube (placebo) applied during Mohs surgery
62365590|NCT04176718|EXPERIMENTAL|Daratumumab,Carfilzomib, Pomalidomide and Dexamethasone|"Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment.~Participants will receive daratumumab, carfilzomib, pomalidomide, and dexamethasone on a 28 day schedule.~* Daratumumab will be given according to cycle and dosage determined by protocol.~* Carfilzomib will be given at 56 mg/m2 on days 1, 8, 15 (except for C1D1 where it is 20 mg/m2)~* Pomalidomide will be given daily on days 1-21.~* Dexamethasone will be given weekly, split over two days."
62365591|NCT02456454|EXPERIMENTAL|Risperidone|Risperidone, PO 0.25-2 mg/day
62365592|NCT02456454|EXPERIMENTAL|Valproic|Valproic Acid PO to achieve plasma levels of 85-100
62365593|NCT02456454|PLACEBO_COMPARATOR|Placebo|Liquid placebo PO matched for color and taste.
62365594|NCT04775394|EXPERIMENTAL|Pilot Part: Healthy subjects|3-5 healthy ex-smokers with normal lung function to establish methods
62365595|NCT04775394|EXPERIMENTAL|Main Part: COPD patients and Healthy Controls|8 subjects with COPD stage II and III who are ex-smokers and have a history of chronic cough and sputum production and 5-8 healthy, age-matched controls
62365596|NCT02200068|ACTIVE_COMPARATOR|PHR Group|This group will have access to a personal health record website SANOIA in addition to all resources they use or find online
62365597|NCT02200068|NO_INTERVENTION|Non-PHR Group|This group will not be informed of the Personal Health Record Website and will use Internet as they usually do.
62365598|NCT05475704||Case group|Test-positive cases are study participants that meet the SARI case definition AND test positive for at least one SARS-CoV-2 diagnostic test, with specimens collected up to 14 days prior to ER visit or hospitalization or up to 24 hours thereafter
62365599|NCT05475704||Control group|Test-negative controls are study participants that meet the SARI case definition AND test negative for all SARS-CoV-2 diagnostic test with specimens collected up to 14 days prior to ER visit or hospitalization or up to 24 hours thereafter
62365600|NCT01883219|EXPERIMENTAL|TKI therapy|Treatment with TKI will be initiated if the level of BCR-ABL transcript in the bone marrow is detectable and transcript levels increased for two consecutive tests. TKIs will be given for patients without BCR/ABL mutations and sensitive TKIs will be given for those with mutations.
62365601|NCT05359445|EXPERIMENTAL|Dose-Finding Escalation/De-escalation (Phase Ia) and Extension Part (Phase Ib)|"Dose-Finding Escalation/De-escalation of IMA401 (Phase Ia)~IMA401 monotherapy extension cohort following the determination of the recommended dose for extension (RDE) (Phase Ib)"
62365602|NCT01451983||ASD with PTEN|Individuals with autism spectrum disorder who are also found to have a PTEN mutation.
62365603|NCT01451983||ASD no PTEN macrocephaly|Individuals with autism spectrum disorder who do not have a PTEN mutation with a large head circumference.
62365604|NCT01451983||ASD no PTEN no macrocephaly|Individuals with autism spectrum disorder who do not have a PTEN mutation without a large head circumference.
62365605|NCT01451983||Siblings|Siblings of individuals with autism spectrum disorders.
62365606|NCT01868594|EXPERIMENTAL|Subetta group|Patients with poor glycemic control (HbA1c=7.0-10.0%) in basal-bolus insulin regimen with a stable basal insulin dose (permissible fluctuations are ±10%) during the previous 3 months are included
62365607|NCT01868594|PLACEBO_COMPARATOR|Placebo group|Patients with poor glycemic control (HbA1c=7.0-10.0%) in basal-bolus insulin regimen with a stable basal insulin dose (permissible fluctuations are ±10%) during the previous 3 months are included.
62365608|NCT02580591|EXPERIMENTAL|Empagliflozin low dose|
62365609|NCT02580591|EXPERIMENTAL|Empagliflozin high dose|
62365610|NCT02580591|EXPERIMENTAL|Empagliflozin medium dose|
62365611|NCT02580591|PLACEBO_COMPARATOR|Placebo|
62365612|NCT03561168||Developmental Delay|Children under age 3 who underwent MRI brain with anesthesia for the indication of Developmental Delay (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
62365613|NCT03561168||Seizure|Children under age 3 who underwent MRI brain with anesthesia for the indication of Seizure (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
62365614|NCT03561168||Developmental Delay and Seizure|Children under age 3 who underwent MRI brain with anesthesia for the indication of Developmental Delay and Seizure (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
62365615|NCT02031757|EXPERIMENTAL|perturbation training|Standard physiotherapy augmented with perturbation training (BaMPer system).
62365616|NCT02031757|ACTIVE_COMPARATOR|balance exercise|standard physiotherapy augmented with balance exercises.
62365617|NCT05145673|PLACEBO_COMPARATOR|Placebo (OGTT)|The control group was given an glucose solution to oral glucose tolerance test (OGTT) .
62365618|NCT05145673|EXPERIMENTAL|Cinnamon (OGTT plus aqueous cinnamon extract)|The Experimental group was given an glucose solution to oral glucose tolerance test (OGTT) followed by aqueous cinnamon extract.
62365619|NCT00693693|ACTIVE_COMPARATOR|Cream-|topical hydrocortisone 17-butyrate 0.1% Cream preparation applied twice daily to all lesions of atopic dermatitis
62365620|NCT00693693|ACTIVE_COMPARATOR|Ointment|topical hydrocortisone 17-butyrate 0.1% Ointment preparation applied twice daily to all lesions of atopic dermatitis
62365621|NCT00693693|ACTIVE_COMPARATOR|Lipocream|topical hydrocortisone 17-butyrate 0.1% Lipocream preparation applied twice daily to all lesions of atopic dermatitis
62365622|NCT02443155|EXPERIMENTAL|NNC0114-0006 + Liraglutide|
62365623|NCT02443155|EXPERIMENTAL|NNC0114-0006 + Placebo|
62365624|NCT02443155|ACTIVE_COMPARATOR|Liraglutide + Placebo|
62365625|NCT02443155|PLACEBO_COMPARATOR|Placebo|
62365626|NCT01203124|PLACEBO_COMPARATOR|1|Placebo given once daily on 7 days
62365627|NCT01203124|EXPERIMENTAL|2|Active treatment at Day 1 and Day 7. Placebo on Day 2, 3, 4, 5 and 6
62365628|NCT01203124|EXPERIMENTAL|3|Active treatment at Day 1, 4 and 7. Placebo on Day 2, 3, 5 and 6.
62365629|NCT01203124|EXPERIMENTAL|4|Active treatment at Day 1, 3, 5 and 7. Placebo on Day 2, 4 and 6.
62365630|NCT01203124|EXPERIMENTAL|5|Active treatment once daily on 7 days
62365631|NCT00251017|ACTIVE_COMPARATOR|Vancomycin|Effects of OCT2 genetic variation in renal elimination of Vancomycin
62365632|NCT04254445|EXPERIMENTAL|Training video arm|Patients will watch a personalized custom training video, in addition to the standard explanation provided by the medical staff
62365633|NCT04254445|NO_INTERVENTION|Verbal explanation arm|Patients will standard explanation about the procedure, provided by the medical staff
62365634|NCT01989871|NO_INTERVENTION|protocol feeding|Feeding of preterm infants according to current unit protocol: every 3 hours a prescribed amount
62365635|NCT01989871|EXPERIMENTAL|Adjusted individual feeding|Feeding every 2-4 hours, starting with que of hunger and finished upon infant signs.
62365636|NCT06248242|NO_INTERVENTION|The control group|The control group received basic treatment following intravenous drip of rt-PA (specification: 50 mg), including statins and drugs that improve circulation.
62365637|NCT06248242|EXPERIMENTAL|The edaravone dexborneol group|The edaravone dexborneol group received an injection of concentrated edaravone dexborneol solution (specifications: edaravone, 10 mg and dexborneol, 2.5 mg in a 5 mL solution) and 0.9% sodium chloride injection \[(100 mL), intravenous infusion twice per day, completed within 30 minutes\]. The time between the two doses was no less than 6 hours, and each cycle lasted 12 days.
62365638|NCT04713111|OTHER|Lifestyle Intervention Group (Exercisers)|"All Interested and enrolled participants in the main Stress and Recovery were invited to participate in a lifestyle intervention arm. Participants were instructed to self-select into either a physical activity arm, or a meditation arm.~Participants were excluded if they were already partaking in both regular physical exercise, and meditation.~Those in the meditation arm (exercisers) were instructed to complete meditation sessions from the smartphone app, Headspace, 2 or more times a week for a duration of 4 weeks."
62365639|NCT04713111|OTHER|Lifestyle Intervention Group (Meditators)|"All Interested and enrolled participants in the main Stress and Recovery were invited to participate in a lifestyle intervention arm. Participants were instructed to self-select into either a physical activity arm, or a meditation arm.~Participants were excluded if they were already partaking in both regular physical exercise, and meditation.~Those in the physical activity arm (meditators) were instructed to complete 30 minutes to 1 hour of physical activity for 2 or more sessions per week for 4 weeks."
62365640|NCT04713111|NO_INTERVENTION|Garmin wearable arm|Existing stress and recovery participants were invited to participate in a Garmin wearable arm where they were provided a Garmin Vivoactive 4 smartwatch to wear continuously, and in particular, while they were on shift at work for a total of 4 consecutive weeks.
62365641|NCT04713111|NO_INTERVENTION|Hair cortisol arm|Interested existing stress and recovery participants were invited to participate in a one time hair sample collection for cortisol analysis.
62365642|NCT03933124|EXPERIMENTAL|Virtual Reality Intervention group|"The intervention group includes 60 patients who will use Virtual Reality for postoperative pain. Participants will use Virtual Reality minimal 10 minutes, minimal 3 times a day on the second, third and fourth day after surgery, on the general ward.~* 20 participants will receive an Oculus Go immersive 3D nature videos, games, meditation videos, google earth experiences and sports games.~* 20 participants will receive a Relaxmaker with 2D nature videos~* 20 participants will receive CareVRx with 3D nature videos and meditation videos."
62365643|NCT03933124|NO_INTERVENTION|Control group|The control group receives standard postoperative care.
62365644|NCT04342416|EXPERIMENTAL|Trauma exposed women|"No Intervention: Baseline phase ('A'):~Measurements collected in a daily diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.~Experimental: Intervention phase ('B'):~A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game-play with mental rotation) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a daily diary four times a day following the intervention for the primary outcome (occurrence of intrusive memories of trauma).~Intervention: Behavioral: Brief cognitive intervention"
62365645|NCT01646567|EXPERIMENTAL|SHP-141C & Placebo & Calcipotriol & Betamethasone Valerate|A 100 mg dose of SHP-141C cream at three concentrations (0.5%, 1.0% and 2.0%), a matched placebo cream and two reference treatments: Calcipotriol 0.005% cream and Betamethasone Valerate 0.02% cream, applied topically to a selected plaque on each subject, six times per week over 28 days for a total of 24 doses.
62365646|NCT05430204|ACTIVE_COMPARATOR|one-hour Glucose tolerance test (GCT)|
62365647|NCT05430204|EXPERIMENTAL|CGM screening|
62365648|NCT02617329|OTHER|cervical flexion|Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
62365649|NCT02617329|OTHER|Extracorporeal shock wave therapy (ESWT)|The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group.
62365650|NCT05818072|EXPERIMENTAL|One biopsy|Obtain one biopsy specimen at the proximal part of the the longest columnar-lined esophagus for patients with suspected Barrett's Esophagus
62365651|NCT05818072|ACTIVE_COMPARATOR|Three biopsy|Obtain three biopsy specimens at the proximal, middle and distal part of the longest columnar-lined esophagus for patients with suspected Barrett's Esophagus
62552774|NCT02129322|EXPERIMENTAL|S-1 and Sorafenib|Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential : 4 cycles of S-1 + Sorafenib maintenance
62365652|NCT05818072|SHAM_COMPARATOR|Seattle protocol|Obtain 4-quadrant biopsy specimens at intervals of every 1 to 2 cm throughout the the columnar-lined esophagus for patients with suspected Barrett's Esophagus
62365653|NCT00852423|EXPERIMENTAL|DHAPQ|Three-day treatment with dihydroartemisinin-piperaquine
62365654|NCT00852423|EXPERIMENTAL|MQAS|Three-day treatment with mefloquine artesunate
62365655|NCT00852423|ACTIVE_COMPARATOR|AQAS|Three-day treatment with artesunate-amodiaquine
62365656|NCT00852423|ACTIVE_COMPARATOR|AL|Three day treatment with artemether-lumefantrine (Coartem(R)
62365657|NCT03672669|ACTIVE_COMPARATOR|Advanced Platelet Rich Fibrin (A-PRF)|A-PRF was applied into the tooth socket after mandibular third molar surgery.
62365658|NCT03672669|ACTIVE_COMPARATOR|Leukocyte- and platelet-rich fibrin (L-PRF)|L-PRF was applied into the tooth socket after mandibular third molar surgery.
62365659|NCT03938012||Lung and head and neck tumours|"1. Age 18 years or older~2. Histologic or cytologic confirmation of metastatic squamous cell carcinoma of the lung or head and neck region~3. No other active malignancy within the past 24 months~4. Refractory disease"
62365660|NCT00757640|NO_INTERVENTION|B|no cholecystectomy
62365661|NCT00757640|EXPERIMENTAL|A|cholecystectomy
62365662|NCT03968081|EXPERIMENTAL|Social exclusion|Participating at the cyberball game in exclusion condition in wich they will receive 2 time the ball in the 10 first throw then none of them in the last 20 throw.
62365663|NCT03968081|ACTIVE_COMPARATOR|Social inclusion|Participating at the cyberball game in inclusion condition in wich they will receive 33% of the throw : 10 in a total of 30
62365664|NCT03080051|EXPERIMENTAL|[18F]MNI-952|To evaluate \[18F\]MNI-952 (also known as \[18F\]UCB-K), a tau targeted PET radioligand.
62365665|NCT00639496|EXPERIMENTAL|1|patients taking NAC 600 mg t.i.d.
62365666|NCT00639496|PLACEBO_COMPARATOR|2|
62365667|NCT04115527|ACTIVE_COMPARATOR|Standard lymphadenectomy|Standard lymphadenectomy includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes harvested during the pancreaticoduodenectomy with CHILD's digestive reconstruction
62365668|NCT04115527|EXPERIMENTAL|Extended lymphadenectomy|In addition to the standard lymphadenectomy, para-aortic lymph nodes (No16) is included, in particular No 16b1 lymph nodes (Lymph nodes along the psterior side of the pancreas between the aorta and inferior vena cava).
62365669|NCT02565277|ACTIVE_COMPARATOR|Influenza Vaccine|Fluzone injection once IM
62365670|NCT02565277|PLACEBO_COMPARATOR|Placebo|Saline Injection once IM
62365671|NCT01954810|NO_INTERVENTION|Japanese encephaltis chimerix vaccine|This is a single-arm study. Japanese encephalitis chimeric vaccine (JECV) will be administered to all subjects and check for antibody response 4 weeks after vaccination.
62365672|NCT05495191||Grouped as the favorable outcome|\<3 mRS of discharge or 7th day in the patients with the lenticulostriate artery infarction
62365673|NCT05495191||Grouped as the unfavorable outcome|≥3 mRS of discharge or 7th day in the patients with the lenticulostriate artery infarction
62365674|NCT03101449|EXPERIMENTAL|Group 1|"20 individuals of Coral UFCSPA without voice problems carry out the exercise with Finnish tube before choir practice once a week for a period of 14 weeks. The exercise will be carried out with blowing set to sound at regular frequency, with frequency variation and with the melody of Happy Birthday; each sequence will be held for 2 minutes with 1 minute interval between them."
62365675|NCT03101449|EXPERIMENTAL|Group 2|"20 individuals of Coral UFCSPA without voice problems carry out the exercise straw phonation before choir practice once a week for a period of 14 weeks. The exercise will be carried out with blowing set to sound at regular frequency, with frequency variation and with the melody of Happy Birthday; each sequence will be held for 2 minutes with 1 minute interval between them."
62365676|NCT03101449|NO_INTERVENTION|Group 3|10 individuals of Coral UFCSPA without voice problems. Untreated group.
62365677|NCT01481506|EXPERIMENTAL|Telemonitoring|
62365678|NCT01481506|NO_INTERVENTION|Usual care|
62365679|NCT02685111|ACTIVE_COMPARATOR|A. Pegfilgrastim|D2 once a cycle pegfilgrastim arm
62365680|NCT02685111|EXPERIMENTAL|B. Filgrastim|Intermittent Every Other Days of 5 Shot (D3-11) filgrastim arm
62365681|NCT03503812|NO_INTERVENTION|No intervention to DDS exposure - Asthma in Children|
62365682|NCT03503812|EXPERIMENTAL|Intervention 1 - Asthma in Children|
62365683|NCT03503812|EXPERIMENTAL|Intervention 2 - Asthma in Children|
62365684|NCT03503812|NO_INTERVENTION|No intervention to DDS exposure - Atrial Fibrillation|
62365685|NCT03503812|EXPERIMENTAL|Intervention 1 - Atrial Fibrillation|
62552775|NCT01932333|EXPERIMENTAL|Cohort 1|
62365686|NCT03503812|EXPERIMENTAL|Intervention 2 - Atrial Fibrillation|
62365687|NCT05041062|EXPERIMENTAL|All Participants in Study Who Have Mesothelioma|Individuals in this group will receive a combination of two immunotherapy drugs (nivolumab and ipilimumab) before and after surgery to remove their cancer. There will also be a follow up period to determine how well the drugs and surgery worked to get rid of your cancer. Your overall participation in this study (including drug treatment, surgery and follow up visits) will last for roughly one and a half years. All eligible participant who enroll in the study will participate in this group.
62365688|NCT06221956|EXPERIMENTAL|relevis + TAU|"Participants allocated to the intervention group will receive access to relevis in addition to treatment as usual (TAU).~relevis is a digital health application designed for individuals with subacute or chronic back pain, accessible through a web browser. The application consists of six physical exercise modules that cover four exercises with thiree different levels of difficulty, each, and ten interactive conversations on different topics (changes in the body, pain development and processing, chronic pain, pain and mood, relaxation and mindfulness, becoming active against pain, stress and pain, nutrition and pain, sleep and pain, work and pain). Conversations are accompanied by illsutrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days."
62365689|NCT06221956|NO_INTERVENTION|TAU|Participants allocated to the control group will receive access to treatment as usual (TAU).
62365690|NCT00762580||Prospective|Patients with full thickness rotator cuff tears being treated with physical therapy
62552776|NCT01932333|EXPERIMENTAL|Cohort 2|
62552777|NCT06577922|NO_INTERVENTION|Pre-intervention group|This is the group before the intervention
62552778|NCT06577922|EXPERIMENTAL|Post-intervention group|This is the group after intervention.
62365691|NCT06153199|ACTIVE_COMPARATOR|Self-management videos|Participants will review short video modules on pain self-management without medication and ergonomic work adjustment and select 1 self-management option and 1 ergonomic option to use for 10 weeks
62365692|NCT06153199|EXPERIMENTAL|Self-management videos + Multimodal personalized support|"Participants will review short video modules on pain self-management without medication and ergonomic work adjustment and select 1 self-management option and 1 ergonomic option to use for 10 weeks.~Participants will use 1) checklists to guided choices for strategies based on their self-identified most difficult work activities due to pain and options that they are not using regularly, 2) review video recordings of their own work movements to assist with ergonomic problem-solving and 3) receive text message reminders"
62365693|NCT01858597|OTHER|gestational diabetes mellitus|Those women (subjects) with gestational diabetes mellitus
62365694|NCT01858597|OTHER|control|Those healthy pregnant women
62365695|NCT05227768|EXPERIMENTAL|VV116|Subjects will receive VV116 orally for single dose.
62365696|NCT05227768|EXPERIMENTAL|Placebo|Subjects will receive placebo orally for single dose.
62365697|NCT00949806|EXPERIMENTAL|Administrated|All patients included will receive an intradermal administration of BNT
62365698|NCT02877316|EXPERIMENTAL|MYPLAN app|MYPLAN app (safety plan) as part of treatment
62365699|NCT02877316|ACTIVE_COMPARATOR|Safety plan on paper|Safety plan on paper as part of treatment
62365700|NCT04737967|EXPERIMENTAL|Venlafaxine Treated Arm|
62365701|NCT04737967|EXPERIMENTAL|Memantine Treated Arm|
62365702|NCT01192100|EXPERIMENTAL|Breakfast Skipping|Breakfast skipping serves as the baseline/control arm since the participants habitually skip breakfast (i.e., skip breakfast at least 5 times/week). Thus, during the week prior to and including the testing day, the participants will continue to skip breakfast each morning.
62365703|NCT01192100|EXPERIMENTAL|Normal Protein Breakfast Meals|For 7 days, the participants will consume normal protein breakfast meals each morning. These meals will consist of cereal-based foods and will be 350 kcal, which is approximately 18% of daily energy intake for overweight and obese adolescents ages 9-18 y. The macronutrient composition of these meals will contain 15% protein (13 g of dietary protein), 65% CHO, and 20% fat.
62365704|NCT01192100|EXPERIMENTAL|Protein-rich Breakfast Meals|For 7 days, the participants will consume protein-rich breakfast meals each morning. These meals will consist of home-cooked foods and will be 350 kcal, which is approximately 18% of daily energy intake for overweight and obese adolescents ages 9-18 y. The macronutrient composition of these meals will contain 40% protein (35 g of protein), 40% CHO, and 20% fat.
62365705|NCT02163772|EXPERIMENTAL|Intracordal hyaluronate injection (HI)|The intervention of Intracordal hyaluronate (Restylane) injection is given in this group No other therapies are given
62365706|NCT02163772|NO_INTERVENTION|Conservative management (CM)|In this arm, only observation is arranged. No therapy is given.
62365707|NCT00656578|EXPERIMENTAL|1|4975
62365708|NCT00656578|PLACEBO_COMPARATOR|2|Drug, Single dose, solution
62365709|NCT01113788||imaging|imaging with usual catheter/fluoroscopy, no cartosound
62365710|NCT02116361|PLACEBO_COMPARATOR|Placebo for onabotulinumtoxinA 50 U|Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
62365711|NCT02116361|EXPERIMENTAL|onabotulinumtoxinA 50 U|OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
62365712|NCT02116361|PLACEBO_COMPARATOR|Placebo for onabotulinumtoxinA 30 U|Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
62365713|NCT02116361|EXPERIMENTAL|onabotulinumtoxinA 30 U|OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
62365714|NCT05915117|EXPERIMENTAL|Polyphenols of pomegranate fruit peel extract (PoPex)|All subjects will treated only with PoPex in total daily dosis of 500 mg/orally over 8 weeks.
62365715|NCT05915117|PLACEBO_COMPARATOR|Placebo|All subjects will treated only with PoPex placebo capsules/orally over 8 weeks
62365716|NCT05013697|EXPERIMENTAL|Experimental group 1|"Initial treatment: Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib (4-6 cycles).~Maintenance treatment: TQB2450 injection+Anlotinib."
62365717|NCT05013697|EXPERIMENTAL|Experimental group 2|Initial treatment: Paclitaxel + Cisplatin + TQB2450 injection (4-6 cycles). Maintenance treatment: TQB2450 injection.
62365718|NCT04450342|EXPERIMENTAL|ARCR augmented with REGENETEN™ Bioinductive Implant|During the ARCR procedure, the REGENETEN™ Bioinductive Implant is covering the tendon and attached to the bone and the tendon with small anchors.
62365719|NCT04450342|SHAM_COMPARATOR|ARCR alone|The rotator cuff is repaired during arthroscopic standard procedure. No product is added for healing
62365720|NCT04450342|OTHER|ARCR revision group|ARCR revision group allows treatment of subjects having recurrent tears, ARCR supplemented with REGENETEN
62365721|NCT02997462||Heart Failure|"Heart Failure patients admitted to the ICU or Heart Failure Service.~No changes in service-directed plan of care for patients."
62365722|NCT02997462||Healthy Control|Healthy, age-matched controls.
62365723|NCT00329784|EXPERIMENTAL|Peanut Consumption Group|Participants on this arm will consume peanut protein.
62365724|NCT00329784|NO_INTERVENTION|Peanut Avoidance Group|Participants on this arm will avoid peanut as per United Kingdom (UK) public health recommendations.
62365725|NCT02813863|EXPERIMENTAL|SP2086 and Metformin|In the first day,the subject takes metformin 1000mg once,and from Day 4 to Day 7 they need to take SP2086 100mg everyday. In Day 8,they will be given SP2086 100mg and metformin 1000mg.
62365726|NCT02491216|EXPERIMENTAL|Acupressure Group|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
62365727|NCT02491216|NO_INTERVENTION|Control Group|No acupressure therapy will be provided during the study.
62365728|NCT00272480|PLACEBO_COMPARATOR|Placebo|Placebo in HAM/TSP 24
62365729|NCT00272480|ACTIVE_COMPARATOR|Zidvoudine plus lamivudine|Zidvoudine plus lamivudine in HAM/TSP 24
62365730|NCT00398138|EXPERIMENTAL|vaccine|Six vaccinations of the WT-1 peptide (1.0 ml of emulsion) will be administered on weeks 0, 4, 6, 8, 10 \& 12. Vaccinations will be administered subcutaneously with sites rotated among extremities. Injection sites will be pre-stimulated with Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 \& -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) if they have been appropriately instructed on SQ injection administration. Patients will keep a logbook noting the time \& placement of the injection. Note: during each vaccination, the Sargramostim (GM-CSF) \& the vaccine emulsion will be administered to the same anatomical site. This site will be marked by the patient or treating healthcare professional by a permanent marker pen. For patients who have a clinical, molecular, or immunologic response \& have not had disease progression, they may receive up to 6 more vaccinations administered approximately every month.
62365731|NCT03661255|EXPERIMENTAL|PC CARES Intervention|Experimental: PC CARES Intervention Participants will attend 1-7 sessions of the PC CARES curriculum, either virtually or in-person. Investigators will collect data from this group at baseline, after each session they attend, and at follow-up.
62365732|NCT03661255|NO_INTERVENTION|No intervention|This group will not attend the PC CARES sessions. Investigators will collect data from this group at baseline and follow-up
62365733|NCT02198560||Normal (Eyes without pathology)|
62365734|NCT00937326|PLACEBO_COMPARATOR|Placebo|"The Placebo treatment group will be administered eight placebo capsules per day.~Placebo will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
62365735|NCT00937326|ACTIVE_COMPARATOR|Arm1 - 0.25g|"The 0.25g SRT2104 treatment group will be administered one SRT2104 capsules with 7 placebo capsules, for a total of 8 capsules per day.~0.25g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
62365736|NCT00937326|ACTIVE_COMPARATOR|Arm2 - 0.5g|"The 0.5g SRT2104 treatment group will be administered two SRT2104 capsules with 6 placebo capsules, for a total of 8 capsules per day.~0.5g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
62365737|NCT00937326|ACTIVE_COMPARATOR|Arm3 - 1g|"The 1g SRT2104 treatment group will be administered four SRT2104 capsules with four placebo capsules, for a total of 8 capsules per day.~1g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
62365738|NCT00937326|ACTIVE_COMPARATOR|Arm4 - 2g|"The 2g SRT2104 treatment group will be administered eight SRT2104 capsules per day.~2g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
62365739|NCT00845507|EXPERIMENTAL|Exenatide Group|Exenatide dstarted at 5 mcg subcutaneously twice daily within one hour before the morning and evening meals, and increased (as tolerated) to 10 mcg.
62365740|NCT00845507|PLACEBO_COMPARATOR|Placebo Group|Placebo: Sterile solution in equivalent doses as Exenatide
62365741|NCT00288041|EXPERIMENTAL|Treatment (bortezomib, paclitaxel, carboplatin)|Patients will receive an infusion of bortezomib twice in week 1 and once in week 2. They will also receive a 3-hour infusion of paclitaxel and an infusion of carboplatin once in week 1. Treatment may repeat every 3 weeks for as long as benefit is shown.
62365742|NCT01002495|EXPERIMENTAL|Cohort 1|Eight endocardial injection for a total dose of 1mg VM202
62365743|NCT01002495|EXPERIMENTAL|Cohort 2|Eight endocardial injections for a total dose of 2mg VM202
62365744|NCT01002495|EXPERIMENTAL|Cohort 3|Twelve endocardial injections for a total dose of 3mg VM202
62365745|NCT02797769||Non-TNFi Biologics|Real world patients with RA with a dispensing history for non-TNFi biologics (such as abatacept or tofacitinib) will be included.
62365746|NCT02797769||TNFi Biologics|Real world patients with RA with a dispensing history for TNFi biologics will be included.
62365747|NCT02797769||Tocilizumab|Real world patients with RA with a dispensing history for tocilizumab will be included.
62365748|NCT01007513||At risk patient for preterm delivery|Patient referred to the MFM clinic for a risk evaluation for preterm delivery.
62365749|NCT04838041|EXPERIMENTAL|Asciminib 40 mg PO daily plus imatinib (maximum dose of 400 mg PO once daily)|All eligible patients will begin a combination of asciminib in combination with a TKI cycle 1 day 1 in the combination treatment phase. They will continue combination therapy for a total of 12 cycles (minimum of 12 months). At the end of 12 cycles asciminib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase. Once in the TFR phase, patients will discontinue their TKI and be monitored off treatment.
62365750|NCT04838041|EXPERIMENTAL|Asciminib 40 mg twice daily plus nilotinib (maximum dose of 300 mg twice daily)|All eligible patients will begin a combination of asciminib in combination with a TKI cycle 1 day 1 in the combination treatment phase. They will continue combination therapy for a total of 12 cycles (minimum of 12 months). At the end of 12 cycles asciminib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase. Once in the TFR phase, patients will discontinue their TKI and be monitored off treatment.
62365751|NCT04838041|EXPERIMENTAL|Asciminib 80 mg daily plus dasatinib (maximum dose of 100 mg PO once daily)|All eligible patients will begin a combination of asciminib in combination with a TKI cycle 1 day 1 in the combination treatment phase. They will continue combination therapy for a total of 12 cycles (minimum of 12 months). At the end of 12 cycles asciminib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase. Once in the TFR phase, patients will discontinue their TKI and be monitored off treatment.
62365752|NCT03751969|EXPERIMENTAL|HSK3486|"0.4 mg/kg of HSK3486 emulsion injection (containing \[14C\] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg)~."
62365753|NCT02734199||Enrollment Period 1 Cohort|Cohort 1 includes approximately 650 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Contraceptive access will be the same as it was prior to the study beginning, meaning participants either have to use insurance or self-pay for their method of choice.
62365754|NCT02734199||Enrollment Period 2 Cohort|Cohort 2 includes approximately 1000 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Financial barriers are removed for Period 2 participants and they can initiate which ever contraceptive method they want at no cost to them for three years.
62365755|NCT02734199||Enrollment Period 3 Cohort|Cohort 3 includes approximately 1350 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Financial barriers are removed for Period 3 participants and they can initiate which ever contraceptive method they want at no cost to them for three years. During enrollment period 3, a community-wide, media driven intervention will be implemented and population level changes in HER-C initiation will be examined.
62365756|NCT02868164|EXPERIMENTAL|Fecal Microbiota Transplantation (FMT)|
62365757|NCT02868164|ACTIVE_COMPARATOR|Weight Reduction|
62365758|NCT03288441||antiplatelet only|"Patients receiving antiplatelet medication, but not anticoagulation. Antiplatelet drugs include any class, dose or duration of any platelet aggregation inhibitor.~This refers to the antithrombotic regimen when the current thrombocytopenia, or risk thereof (i.e. predicted), was first identified (even if the treatment is subsequently stopped)"
62365759|NCT03288441||anticoagulant-based|"Patients receiving only anticoagulants or both anticoagulant and antiplatelet medication combined. This includes any class, dose or duration of any antiplatelet or anticoagulant drug.~This refers to the antithrombotic regimen when the current thrombocytopenia, or risk thereof (i.e. predicted), was first identified (even if the treatment is subsequently stopped)"
62365760|NCT05983016||Patients|All ten patients had their abdominal aortic aneurysm measured by experts and novices using both two-dimensional and three-dimensional ultrasound
62365761|NCT01407406|EXPERIMENTAL|Chinese Subjects - low dose BIIB023 IV|
62365762|NCT01407406|EXPERIMENTAL|Chinese Subjects - high dose BIIB023 IV|
62742523|NCT02021383|EXPERIMENTAL|Contest Only|The Contest only group were eligible to receive the financial incentives for weight loss maintenance for maintaining weight lost at three monthly follow ups; weeks 16, 20 and 24. Eligible participants completed online surveys and in person weigh ins verifying weight maintenance.
62742524|NCT06368505|EXPERIMENTAL|Platelet rich plasma|3 ml PRP injection
62742525|NCT06368505|EXPERIMENTAL|hydrodissection|5ml injectate
62365763|NCT01407406|EXPERIMENTAL|Japanese Subjects - low dose BIIB023 IV|
62365764|NCT01407406|EXPERIMENTAL|Japanese Subjects - high dose BIIB023 IV|
62365765|NCT01407406|EXPERIMENTAL|Causasian Subjects - low dose BIIB023 IV|
62365766|NCT01407406|EXPERIMENTAL|Caucasian Subjects - high dose BIIB023 IV|
62365767|NCT00809055|EXPERIMENTAL|High dose caffeine|Loading dose 40mg/kg IV caffeine citrate, followed 12 hours later by 20mg/kg IV caffeine citrate, followed 12 hours later by 10mg/kg IV caffeine citrate, followed 12 hours later by 10mg/kg IV caffeine citrate.
62365768|NCT00809055|ACTIVE_COMPARATOR|Standard dose caffeine|Loading dose 20mg/kg IV caffeine citrate, followed 12 hours later with D5W placebo, followed 12 hours later with 10mg/kg IV caffeine citrate, followed 12 hours later with D5W placebo.
62365769|NCT00047853|EXPERIMENTAL|Healthy Volunteer|Healthy volunteer will undergo Functional magnetic resonance imaging (fMRI) and/or magneto-encephalography (MEG) and will be scanned during runs of either shock or no shock.
62365770|NCT00047853|EXPERIMENTAL|Patient|Participant with a current diagnosis of generalized anxiety disorder (GAD), panic disorder, social anxiety disorder (SAD), specific phobia, posttraumatic stress disorder (PTSD), or major depression will undergo Functional magnetic resonance imaging (fMRI) and will be scanned during runs of either shock or no shock.
62365771|NCT01369446||Women undergoing IVF treatment|
62365772|NCT00744640|EXPERIMENTAL|single|single arm study with triple combination chemotherapy
62742526|NCT04711369|ACTIVE_COMPARATOR|Intervention group (laser therapy)|Participants allocated to the laser-therapy group will receive 2 laser treatments over a period of 3 months. Laser therapy will be performed according to a standardized protocol.
62742527|NCT04711369|SHAM_COMPARATOR|Control group (sham laser therapy)|Participants allocated to the control group will receive 2 sham laser treatments over a period of 3 months. Laser therapy will be performed according to a standardized protocol.
62365773|NCT00420342|EXPERIMENTAL|0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)|0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
62365774|NCT00420342|EXPERIMENTAL|2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)|2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
62365775|NCT00420342|ACTIVE_COMPARATOR|1.5 mg MPA / 0.3 mg CEE (Prempro)|1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
62365776|NCT03955497|EXPERIMENTAL|Autologous Adipose-derived Mesenchymal Stem Cell Gel|The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.
62365777|NCT03955497|PLACEBO_COMPARATOR|sodium hyaluronate|The control group received intra-articular injection of sodium hyaluronate one month after operation.
62365778|NCT04119401|ACTIVE_COMPARATOR|doppler-guided|ligation of hemorrhoidal arteries with doppler guidance
62365779|NCT04119401|EXPERIMENTAL|finger-guided group|ligation of hemorrhoidal arteries without doppler guidance but with finger detection
62365780|NCT01632176|NO_INTERVENTION|Standard of care|Patients in the control group will not receive any intervention, but will receive standard care for dating abuse issues.
62365781|NCT01632176|EXPERIMENTAL|Intervention|Patients in the intervention group will participate in brief, motivational interview and one booster session to prevent adolescent dating abuse.
62365782|NCT05948319|ACTIVE_COMPARATOR|myocardial performance and epicard thickness in obese pregnant women|obese pregnant versus normal-weight pregnant women were evaluated for MPI and fetal epicardial thickness
62365783|NCT05948319|ACTIVE_COMPARATOR|obese pregnant|obese pregnant versus normal-weight pregnant women were evaluated for MPI and fetal epicardial thickness
62365784|NCT01569997|OTHER|Intervention group|Intervention group: nursing homes whose residents benefit from MDTM to identify the cases of dementia and to propose an adequate care project
62365785|NCT01569997|NO_INTERVENTION|control group|Control group: nursing homes whose residents continue to benefit from usual care
62365786|NCT04557618|EXPERIMENTAL|Auricular VNS Stimulation|Participants receive twice daily auricular vagal nerve stimulation
62365787|NCT04557618|SHAM_COMPARATOR|Sham Auricular VNS Stimulation|Participants will have an auricular vagal nerve stimulator applied twice daily, without the stimulation applied
62365788|NCT06506292|EXPERIMENTAL|Study arm|"Neoadjuvant therapy:~Adebrelimab: 1200 mg, iv, d1, q3w, 3 cycles of treatment; XELOX regimen: oxaliplatin: 130 mg/m2,iv,d1; capecitabine: 1000 mg/m2,po,pid,d1-d14; q3w, 3 cycles;~Surgery within 3-6 weeks of the end of neoadjuvant therapy, with adjuvant therapy starting 4-6 weeks after surgery.~Postoperative adjuvant therapy： Adebrelimab: 1200 mg, iv, d1; q3w, 5 cycles of treatment; XELOX regimen: oxaliplatin: 130 mg/m2,iv,d1; capecitabine: 1000 mg/m2,po,pid,d1-d14; q3w, treatment for 5 cycles;~Perioperative adebelizumab combined with XELOX chemotherapy for a total of no more than 8 cycles of treatment.~Maintenance therapy:~Adebrelimab maintenance therapy up to 1 year."
62365789|NCT01503619||Basic science (biomarker analysis)|DNA isolated from archived tumor tissue and blood samples are analyzed for genetic mutations and gene expression profiling using Illumina exome sequencing. Results are compared with transcriptome of tumors (or cell lines) with and without the specific mutation. Cell culture studies overexpressing or inhibiting the genes of interest are also performed in a mouse model to identified potential drivers of small cell lung cancer.
62365790|NCT01318525|EXPERIMENTAL|ALF-5755|
62365791|NCT01318525|PLACEBO_COMPARATOR|Saline solution (0.9% NaCl)|
62742528|NCT03268954|EXPERIMENTAL|Azacitidine 75 mg/m^2|Azacitidine 75 milligram per square meter (mg/m\^2) intravenous (IV) or subcutaneous (SC) injection on Days 1 to 5, Days 8 and 9, in 28-day treatment cycles until disease progression or unacceptable toxicity or up to approximately 42 months.
62742529|NCT03268954|EXPERIMENTAL|Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2|Azacitidine 75 mg/m\^2 IV or SC injection on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m\^2 IV infusion, on Days 1, 3, and 5 in 28-day treatment cycles until disease progression or unacceptable toxicity or up to approximately 42 months.
62365792|NCT03125161|EXPERIMENTAL|Arm A|HAI plus chemotherapy ± target therapy
62365793|NCT03125161|ACTIVE_COMPARATOR|Arm B|chemotherapy ± target therapy
62365794|NCT03600870|EXPERIMENTAL|Open Label|All subjects enrolled will be assigned to receive midodrine. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
62365795|NCT00259519|NO_INTERVENTION|1|Expectant management
62365796|NCT00259519|ACTIVE_COMPARATOR|2|Induction of delivery
62365797|NCT03438760|PLACEBO_COMPARATOR|Science + Phonological Awareness|In all conditions, science is taught via the Full Option Science System Next Generation Edition (FOSS, 2015, https://www.fossweb.com/) curriculum that involves 1) Prediction, 2) Experiment, 3) Journal/Reflection, and 4) dialogic reading centered around a given theme such as plant life. In the control condition, a minimum of six phoneme identifications and five rhymes will be incorporated into each lesson of this curriculum. While these activities are likely to improve the children's awareness of the sounds of the language (a foundational skill for learning to read), they are not likely to improve their access to the science being taught. Therefore, this intervention constitutes a placebo.
62365798|NCT03438760|EXPERIMENTAL|Science + Grammar Intervention|In the science + grammar condition, focused stimulation, an intervention commonly used to target expressive language, will be used to treat complement clauses during the FOSS activities. The approach is incidental, rather than explicit. The active ingredients are models and recasts of the target structure. Recasts occur when an examiner responds to a child's naturally occurring utterance by expanding or extending the child's utterance to include a target grammatical structure. Recasts and/or models will be provided at an average rate of one per minute, an accepted therapeutic dose.
62365799|NCT03438760|EXPERIMENTAL|Science + Vocabulary Intervention|This arm involves Robust Vocabulary Instruction, an explicit approach that emphasizes multiple and rich encounters in authentic contexts to promote depth of semantic knowledge of 20 words that pertain to scientific practices applicable to the FOSS lessons. The children receive a cumulative exposure of at least 20 times per word (a minimum of 5 times per each of four lessons) and at least 4 chances to produce the word (a minimum of 1 chance per each of four lessons).
62365800|NCT02154334|EXPERIMENTAL|Cohort 1|One Intranasal spray of 14 milligram (mg) esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 (Treatment A). Two intranasal sprays of 50 microgram (mcg) mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg at time -1 hour prior to 1 intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg on Day 16 in Period 2 (Treatment B).
62365801|NCT02154334|EXPERIMENTAL|Cohort 2: Sequence 1|One Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 (Treatment A) and pretreatment with 2 sprays of oxymetazoline 0.05 percent (%) weight by volume (w/v) solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 2 (Treatment C).
62552779|NCT05236192|EXPERIMENTAL|Take Root Home Visitation (TRHV)|TRHV is an evidence-informed, manualized home-visiting curriculum.
62552780|NCT05236192|ACTIVE_COMPARATOR|Services as Usual (SAU)|SAU involves the current standard of care implemented at the participating Navy and Marine Corps installations.
62742530|NCT05704257|EXPERIMENTAL|fetoscopic surgical repair|Single arm study. All patients will receive the fetoscopic repair.
62742531|NCT01919580||Normal team|"Subjects who have problem at third molar of impacted tooth need to receive a surgery with general anesthesia.~Subjects must:~Should have a blood exam (20ml) before the surgery.~Site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample around third molar during the surgery."
62365802|NCT02154334|EXPERIMENTAL|Cohort 2: Sequence 2|Pretreatment with 2 sprays of oxymetazoline 0.05 percent (%) weight by volume (w/v) solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1 (Treatment C) and 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 2 (Treatment A).
62365803|NCT05362461||Bitewing first, CariVu second|Bitewing images will be taken first. CariVu images will be taken second.
62365804|NCT05362461||CariVu first, Bitewing second|CariVu images will be taken first. CariVu images will be taken second.
62365805|NCT01301417||ColonRing™|Adult Patients who underwent a laparoscopic or open colorectal resection with the creation of an anastomosis using the ColonRing™ in routine clinical practice
62742532|NCT01919580||Oral dysplasia|"Subjects who are diagnosed with dysplasia of oral cavity.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
62365806|NCT01778036||Neck pain patients following physiotherapy treatment|Neck pain patients will follow physiotherapy treatment in primary health care.
62365807|NCT03049072||Ion beam therapy|All patients treated with ion beam therapy at MedAustron who consent to the participation in the registry.
62365808|NCT01006694|ACTIVE_COMPARATOR|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
62365809|NCT01006694|EXPERIMENTAL|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
62365810|NCT02836080|EXPERIMENTAL|Integrated Collaborative Care Team|Integrated Collaborative Care Team (ICCTs) are housed in the local community to improve youth access, in three neighborhoods across Toronto (East Metro Youth Services \[EMYS\]-Scarborough, EMYS-Southeast Toronto, and Delisle Youth Services-Central Toronto). Each ICCT will include a variety of service providers and coordinated patient care delivering evidence-informed interventions in a stepped-care model.
62365811|NCT02836080|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|"The comparator arm consists of out-patient TAU in a hospital setting and will occur at one of four outpatient hospital sites across Toronto.~Partners include the following four hospitals: Hospital for Sick Children (SickKids), the Centre for Addiction and Mental Health (CAMH), Michael Garron Hospital (formerly the Toronto East General Hospital), and Sunnybrook Hospital."
62365812|NCT02323308||vaccination|Anti-HBV vaccine injection
62365813|NCT03599544|ACTIVE_COMPARATOR|Robot-Assisted Therapy (RT)|Armeo \& Amadeo robot-assisted intensive upper limb therapy 1 hour sessions 3x week for 6 weeks.
62365814|NCT03599544|EXPERIMENTAL|Robot + Active Learning Program(RT-ALPS)|Armeo \& Amadeo robot-assisted intensive upper limb therapy 1 hour sessions 3x week for 6 weeks plus training in active problem solving, analysis of performance, and goal-setting focused on the transfer of acquired motor skills to daily activities in the home and community.
62365815|NCT02001688|EXPERIMENTAL|Kamada-AAT for Inhalation, 80mg|Daily inhalation of Kamada-AAT for Inhalation, 80mg
62365816|NCT02001688|PLACEBO_COMPARATOR|Placebo|Placebo administered by inhalation daily
62365817|NCT02001688|EXPERIMENTAL|Kamada-AAT for Inhalation, 160mg|Daily inhalation of Kamada-AAT for Inhalation, 160mg
62365818|NCT01930656||Group A, B, C|Group A- American cut-point Group B- Translational approach cut-point Group C- Cost-effectiveness cut-point
62365819|NCT05572541||Patients with traumatic brain injury|Temporomandibular joint range of motion, Fonseca questionnaire, facial asymmetry, and massater and temporal pain threshold will be evaluated by measuring both TBI patients and healthy individuals. In addition, post-injury dietary intake and dominant chewing side will be questioned in TBI patients. Temporomandibular movements will be measured with a disposable cardboard ruler.
62365820|NCT05572541||healthy volunteers|Temporomandibular joint range of motion, Fonseca questionnaire, facial asymmetry, and massater and temporal pain threshold will be evaluated by measuring both TBI patients and healthy individuals. Temporomandibular movements will be measured with a disposable cardboard ruler.
62365821|NCT00397553|EXPERIMENTAL|Insulin Glulisine|
62365822|NCT02353338|EXPERIMENTAL|Group A: Surgical|Individuals in Group A will receive surgery to correct their radial fracture
62365823|NCT02353338|ACTIVE_COMPARATOR|Group B: Conservative Treatment|Individuals in Group B will be immobilized in a cast, as per usual standard of conservative treatment.
62365824|NCT00810043|ACTIVE_COMPARATOR|Curette-First|All of patients in the study were treated with Balloon Kyphoplasty. During Balloon Kyphoplasty, two inflatable bone tamps (IBTs) are placed into the vertebral body bilaterally via a transpedicular or extrapedicular approach under fluoroscopic guidance. In this arm, curettage was performed prior to use of inflatable bone tamps.
62365825|NCT00810043|ACTIVE_COMPARATOR|IBT-First|All of patients in the study were treated with Balloon Kyphoplasty. During Balloon Kyphoplasty, two inflatable bone tamps (IBTs) are placed into the vertebral body bilaterally via a transpedicular or extrapedicular approach under fluoroscopic guidance. In this arm, inflatable bone tamps were used prior to curettage, then followed by a second inflation of the bone tamps.
62365826|NCT04076618|EXPERIMENTAL|Weight Loss plus Vest|
62365827|NCT04076618|ACTIVE_COMPARATOR|Weight Loss Plus Resistance Exercise Training|
62365828|NCT04076618|ACTIVE_COMPARATOR|Weight Loss|
62365829|NCT01063946|EXPERIMENTAL|[14C]-AVE8062|Single, 30 minute, intravenous infusion of 25 mg/m² of \[14C\]-AVE8062 containing 1.85 MBq (50µCi) at the first cycle, followed by subsequent administrations with non-radiolabelled AVE8062 in combination with cisplatin every 3 weeks, according to the investigator's judgment.
62552781|NCT05044117|NO_INTERVENTION|Clinical observation|The standard treatment followed by clinical observation.
62552782|NCT05044117|EXPERIMENTAL|Metronomic capecitabine|The standard treatment followed by a maintenance therapy with capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year.
62552783|NCT01228799|ACTIVE_COMPARATOR|Trabeculectomy|Trabeculectomy with Mitomycin C
62365830|NCT01578590|EXPERIMENTAL|Subjects will consume lean minced meat|Subjects will perform resistance exercise and consume a piece of meat (135 grams, 35 g of protein)
62365831|NCT01578590|ACTIVE_COMPARATOR|Subjects will consume a milk beverage|Subjects will perform resistance exercise and consume a milk protein beverage
62365832|NCT04541095|EXPERIMENTAL|EX_IMF group|Infants will receive infants formula with large amounts of beta-palmitate (EX_IMF).
62365833|NCT04541095|ACTIVE_COMPARATOR|ST_IMF group|Infants will receive infants formula with low amounts of beta-palmitate (ST_IMF).
62742533|NCT01919580||Oral cancer|"Subjects who suffer from oral cancer.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
62742534|NCT05213637|EXPERIMENTAL|EAL Treatment Group|The patients with primary HCC will receive 12\~20 doses of EAL infusion (1×10\^9\~2×10\^10 cells per dose) in combination of a single transarterial chemoembolization (TACE) after radical resection.
62742535|NCT05213637|ACTIVE_COMPARATOR|Control Group|The patients with primary HCC will receive a single TACE after radical resection.
62742536|NCT05829447|EXPERIMENTAL|GI-EYE endoscope with inflated ballon (Interventional arm)|all individuals receive colonoscopy examination with G-EYE 760R colonoscopes; once the cecum is reached the balloon is inflated, and the endoscope is withdrawn with the inflated balloon; the colonoscopy is performed with the support of the CADEYE system for polyp detection in both insertion and withdrawal phase; all polyps identified are removed and sent for histopathology examination.
62742537|NCT05829447|NO_INTERVENTION|G-EYE endoscope with deflated balloon (Control arm)|all subjects receive colonoscopy with G-EYE 760R colonoscope but the balloon remains deflated for the entire procedure; the colonoscopy is performed with the support of the CADEYE system for polyp detection in both insertion and withdrawal phase; all polyps identified are removed and sent for histopathology examination
62742538|NCT00464061|EXPERIMENTAL|Volinanserin|
62742539|NCT00464061|PLACEBO_COMPARATOR|Placebo|
62742540|NCT06659666||Usual care COPD consultation with the COPD Optimiser|Primary care patients with a current COPD diagnosis who visit the GP team for their COPD are eligible to participate in the study. Patients with COPD will be recruited from 10-15 primary care practices in the Netherlands. The population includes men and women ≥35 years of age with clinically diagnosed COPD. The diagnosis of COPD is allowed to be a clinical diagnosis rendered by a member of the GP team, without the requirement to conduct additional confirm- atory testing. Furthermore, a limited number of in- and exclusion criteria will be adopted, to make sure the research population closely resembles the real world.
62742541|NCT02110680|ACTIVE_COMPARATOR|TENS 1|TENS at posterior tibial nerve area
62742542|NCT02110680|SHAM_COMPARATOR|TENS 2|TENS at shoulder area
62742543|NCT04251897|ACTIVE_COMPARATOR|Standard care mattress|Patient will have 2 days to familiarize with the novel support surface. Patient will be on standard care mattress. They will be turned over every 2 hours for 3 days.
62742544|NCT04251897|EXPERIMENTAL|Novel support surface|"After the standard care mattress, the same patient will be placed on novel support surface. They will be turned over every 2 hours for 3 days.~Patient will then continue with the novel support surface and turned every 3 hours for 3 days.~They will then continue with the novel support surface and turned every 4 hours for 3 days."
62742545|NCT03347526|EXPERIMENTAL|Cosyntropin Injectable Suspension, 1mg/mL + vigabatrin|
62742546|NCT03347526|EXPERIMENTAL|Cosyntropin Injectable Suspension, 1 mg/mL|
62742547|NCT03347526|ACTIVE_COMPARATOR|Vigabatrin|
62742548|NCT01965769|EXPERIMENTAL|no gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding
62365834|NCT04541095|NO_INTERVENTION|HM group|Infants will receive human milk (HM).
62365835|NCT02101671||trendelemburg positioning|Patients undergone laparoscopic surgery in trendelemburg position
62365836|NCT02101671||Not trendelemburg positioning|Patients undergone laparoscopic surgery not in trendelemburg position
62365837|NCT03796195|EXPERIMENTAL|.5% Bupivacaine|Guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
62365838|NCT06349343|EXPERIMENTAL|CD19/BCMA Hi-TCR-T intervention|The first 3 participants will be enrolled to receive Hi-TCR-T cell infusion without pretreatment chemotherapy. Then participants' peripheral blood samples would be collected for Hi-TCR-T cell testing. If test results showed the presence of Hi-TCR-T cells on certain time points, TCR-T cell therapy without pretreatment chemotherapy is considered feasible, and the subsequent 17 participants will receive the consistent regimen; Otherwise, the 3 participants will be re-treated with pretreatment chemotherapy and Hi-TCR-T cell infusion, and the subsequent 17 participants will receive pretreatment chemotherapy-containing regimen.
62365839|NCT02164604|EXPERIMENTAL|Ranibizumab|All eyes receive one intravitreal injection with 0.03ml ranibizumab
62365840|NCT03895918|EXPERIMENTAL|Delayed Group (delayed parental skills)|Participants continue medication adherence monitoring over 2 weeks and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
62552784|NCT01228799|ACTIVE_COMPARATOR|Canaloplasty|Canaloplasty with implant of suture
62552785|NCT05748587||Control|24 healthy age and sex-matched controls
62742549|NCT01965769|NO_INTERVENTION|gastric residual evaluation|Infants will receive routine gastric residual evaluation
62742550|NCT00113672|EXPERIMENTAL|A|Increase healthy eating and increase healthy activity
62742551|NCT00113672|EXPERIMENTAL|B|Increase healthy eating and decrease unhealthy activity
62742552|NCT00113672|EXPERIMENTAL|C|Decrease unhealthy eating and increase healthy activity
62742553|NCT00113672|EXPERIMENTAL|D|Decrease unhealthy activity and decrease unhealthy eating
62365841|NCT03895918|EXPERIMENTAL|Early Group (early parental skills)|Participants continue medication adherence monitoring over 1 week and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
62365842|NCT03895918|EXPERIMENTAL|Late Group (late parental skills)|Participants continue medication adherence monitoring over 3 weeks and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
62365843|NCT00853190|EXPERIMENTAL|A|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule
62365844|NCT00853190|ACTIVE_COMPARATOR|B|Tussionex® Pennkinetic® Extended Release Oral Suspension
62365845|NCT05601050||PSD (Psychosis spectrum disorder) group|Current DSM-V-defined diagnosis of schizophrenia, schizophreniform, schizoaffective disorder, unspecified psychotic disorder, or brief psychotic disorder, or bipolar 1 disorder with psychotic features or major depressive disorder with psychotic features using the Structured Clinical Interview for Axis I DSM-V Disorders (SCID-I/P).
62365846|NCT01698177|ACTIVE_COMPARATOR|Group A|This group will receive the influenza vaccine preoperatively.
62365847|NCT01698177|ACTIVE_COMPARATOR|Group B|Group B will receive the influenza vaccine postoperatively, prior to hospital discharge.
62365848|NCT01698177|NO_INTERVENTION|Group C|Group C subjects have already received the seasonal flu vaccine.
62365849|NCT01698177|PLACEBO_COMPARATOR|Group D|Group D subjects have refused the vaccine, but agree to have serum titers drawn.
62365850|NCT01673490|EXPERIMENTAL|Combodart/Duodart|Single arm testing the efficacy/safety of the combinnation of Dutasteride/Tamsulosin
62365851|NCT06321276|ACTIVE_COMPARATOR|two thousand pulse ESWT Group|ESWT will be applied to the patient's wrist and conventional treatment consisting of hand-wrist rest splint and nerve gliding exercises will be applied. The point of the ESWT site was located by ultrasonography interfaced with a 5-12 MHz linear array transducer, and the median nerve was visualized at the line of the proximal carpal tunnel (scaphoid pisiform level). (0,06 mj/mm2, 2000 impulses, 4 bar) (Modus ESWT Radial Shockwave Therapy)
62365852|NCT06321276|ACTIVE_COMPARATOR|one thousand pulse ESWT Group|ESWT will be applied to the patient's wrist and conventional treatment consisting of hand-wrist rest splint and nerve gliding exercises will be applied. The point of the ESWT site was located by ultrasonography interfaced with a 5-12 MHz linear array transducer, and the median nerve was visualized at the line of the proximal carpal tunnel (scaphoid pisiform level). (0,06 mj/mm2, 1000 impulses, 4 bar) (Modus ESWT Radial Shockwave Therapy)
62365853|NCT06321276|NO_INTERVENTION|Conventional Control Group|The patient will receive conventional treatment consisting of hand-wrist rest splint and nerve gliding exercises as directed by the physiotherapist
62365854|NCT04732572|EXPERIMENTAL|Adenotonsillectomy|Within 1 to 4 weeks (30 days) of randomization, participants randomized to the adenotonsillectomy arm will undergo surgery under general anesthesia, as occurs as part of routine standard of care.
62365855|NCT04732572|ACTIVE_COMPARATOR|Watchful waiting with supportive care|Within 1 to 4 weeks after the 7-month visit, participants in the Arm 2 group will be referred for re-evaluation of surgical candidacy. Symptoms and polysomnographic findings (baseline and month 7) will be reviewed by the ENT and a decision whether to proceed with adenotonsillectomy as part of routine clinical care will be made.
62365856|NCT05646719|EXPERIMENTAL|Nyxol + low dose pilocarpine|
62365857|NCT05646719|EXPERIMENTAL|Nyxol + low dose pilocarpine vehicle|
62365858|NCT05646719|EXPERIMENTAL|Placebo + low dose pilocarpine|
62365859|NCT05646719|EXPERIMENTAL|Placebo + low dose pilocarpine vehicle|
62365860|NCT01520688|EXPERIMENTAL|1 Treatment Sequence, FPQ|Period 2 Flovent Diskus Period 4 Pulmicort Flexhaler Period 6 QVAR
62365861|NCT01520688|EXPERIMENTAL|2 Treatment Sequence, FQP|Period 2 Flovent Diskus Period 4 QVAR Period 6 Pulmicort
62742554|NCT06407869|EXPERIMENTAL|Functional Progressive Strength Training|group of 20 children with spastic cerebral palsy on which FPST techniques including 3 or 4 PRT sessions per week for 12 weekswill be applied.
62365862|NCT01520688|EXPERIMENTAL|3 Treatment Sequence, PFQ|Period 2 Pulmicort Period 4 Flovent Period 6 QVAR
62365863|NCT01520688|EXPERIMENTAL|4-Treatment Sequence, PQF|Period 2 Pulmicort Period 4 QVAR Period 6 Flovent
62365864|NCT01520688|EXPERIMENTAL|5 Treatment Sequence, QFP|Period 2 QVAR Period 4 Flovent Period 6 Pulmicort
62365865|NCT01520688|EXPERIMENTAL|6 Treatment Sequence, QPF|Period 2 QVAR Period 4 Pulmicort Period 6 Flovent
62365866|NCT01570062|ACTIVE_COMPARATOR|Indoor Air HEPA Filtration|HEPA filters will be placed in participant's main living area and bedroom. Actual filtration will occur during only one of the two 7-day sampling periods.
62365867|NCT01570062|PLACEBO_COMPARATOR|HEPA Filtration Placebo|For one of two 7-day sampling sessions, HEPA filters placed in participants' homes will be run without an actual filter in the housing unit.
62365868|NCT04006067|EXPERIMENTAL|Group A|
62365869|NCT04006067|NO_INTERVENTION|Group B|
62365870|NCT05094804|EXPERIMENTAL|OR2805 monotherapy and combination therapy dose-escalation phase (Part A)|"Escalating repeated doses of OR2805 by IV administration as monotherapy or in combination with cemiplimab or docetaxel in subjects with advanced solid tumors. OR2805 will be administered once every 3 weeks (Q3W) or once-weekly (QW) for 3 weeks as an IV infusion over 30 minutes.~Cemiplimab will be administered as an IV infusion at a dose of 350 mg.~Docetaxel will be administered as an IV infusion at a dose of 75 mg/m2."
62742555|NCT06407869|OTHER|Control|group of 20 children with spastic cerebral palsy on which conventional physical therapy techniques will be applied
62742556|NCT06446375|EXPERIMENTAL|The experimental Group|FIFA 11+ KIDS Training Protocol will be conducted by the experimental group twice a week for 8 weeks with 15-20-minute interventions. Volleyball players continued their standard volleyball training after the training protocol.
62742557|NCT06446375|ACTIVE_COMPARATOR|Control Group|The control group will continue their regular volleyball training interventions. All tests were conducted at the same time of day (13:30-16:30) to minimize the impact of circadian rhythms on the results.
62742558|NCT03716778|OTHER|Classical exercise training modality in concentric mode (CON)|Description: Control group, usual medical care according to the rehabilitation recommendations
62365871|NCT05094804|EXPERIMENTAL|OR2805 monotherapy and combination therapy dose-expansion phase (Part B)|"OR2805 administered IV at the RP2D and dosing regimen identified in Part A as monotherapy or in combination with cemiplimab or docetaxel in subjects with NSCLC and melanoma.~Cemiplimab will be administered as an IV infusion at a dose of 350 mg.~Docetaxel will be administered as an IV infusion at a dose of 75 mg/m2."
62365872|NCT05094804|EXPERIMENTAL|OR2805 biological effects phase (Part C)|OR2805 administered IV at the RP2D and dosing regimen identified in Part A as monotherapy to determine the mechanism of action and potential predictors of response and pharmacodynamic markers in subjects with liposarcoma, leiomyosarcoma, or SCCHN or are not otherwise eligible for Cohort B.
62365873|NCT02455362|PLACEBO_COMPARATOR|Placebo|Double-blind placebo capsule, looking identical to capsules with active treatment, during all three treatment weeks.
62365874|NCT02455362|EXPERIMENTAL|Morphine sulfate (0, 0, 8 mg)|Placebo during treatment week one and two and morphine 8 mg per day week three.
62365875|NCT02455362|EXPERIMENTAL|Morphine sulfate (0, 8, 8 mg)|Placebo during treatment week one and morphine 8 mg per day week two and three.
62365876|NCT02455362|EXPERIMENTAL|Morphine sulfate (0, 8, 16 mg)|Placebo week one, morphine 8 mg per day week two, and morphine 16 mg per day week three.
62365877|NCT02455362|EXPERIMENTAL|Morphine sulfate (8, 8, 8 mg)|Morphine 8 mg per day during all three treatment weeks.
62365878|NCT02455362|EXPERIMENTAL|Morphine sulfate (8, 8, 16 mg)|Morphine 8 mg per day week one and two and morphine 16 mg per day week three.
62365879|NCT02455362|EXPERIMENTAL|Morphine sulfate (8, 16, 16 mg)|Morphine 8 mg per day week one and morphine 16 mg per day week two and three.
62365880|NCT02455362|EXPERIMENTAL|Morphine sulfate (8, 16, 24 mg)|Morphine 8 mg per day week one, morphine 16 mg per day week two, and morphine 24 mg per day week three.
62365881|NCT02455362|EXPERIMENTAL|Morphine sulfate (16, 16, 16 mg)|Morphine 16 mg per day during all three treatment weeks.
62365882|NCT02455362|EXPERIMENTAL|Morphine sulfate (16, 16, 24 mg)|Morphine 16 mg per day week one and two, and morphine 24 mg per day week three.
62365883|NCT02455362|EXPERIMENTAL|Morphine sulfate (16, 24, 24 mg)|Morphine 16 mg per day week one and morphine 24 mg per day during week two and three.
62365884|NCT02455362|EXPERIMENTAL|Morphine sulfate (16, 24, 32 mg)|Morphine 16 mg per day week one, morphine 24 mg per day week two, and morphine 32 mg per day week three.
62365885|NCT02955368|EXPERIMENTAL|DP-R212 group|DP-R212 + C1-R212 placebo + C2-R212 placebo
62365886|NCT02955368|ACTIVE_COMPARATOR|C1-R212 group|DP-R212 placebo + C1-R212 + C2-R212 placebo
62365887|NCT02955368|ACTIVE_COMPARATOR|C2-R212 group|DP-R212 placebo + C1-R212 placebo + C2-R212
62365888|NCT00618904|EXPERIMENTAL|1|Probiotic containing Lactobacillus and Bifidobacterium
62365889|NCT00618904|PLACEBO_COMPARATOR|2|Placebo
62365890|NCT05212376|EXPERIMENTAL|Foot massage|Foot massage (reflexology) is an application that allows the individual to relax, reduce stress, and thus restore the balance of the body by stimulating the nerve cells in the legs.It is stated that reflexology is an effective complementary treatment method that can help the body relax, reduce the symptoms of menopause by affecting the nervous and endocrine system, and thus create a smooth transition to the menopausal period.
62365891|NCT05212376|NO_INTERVENTION|Control group|No intervention will be applied to the control group.
62365892|NCT00429572|EXPERIMENTAL|Allogeneic Transplantation|Intravenous Fludarabine 30 mg/m\^2 daily on days 1-5, and Melphalan 70 mg/m\^2 on days 4 and 5 followed by blood stem cell transplant on day 7.
62365893|NCT00800930|ACTIVE_COMPARATOR|1|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
62365894|NCT00800930|PLACEBO_COMPARATOR|2|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
62365895|NCT02033655|EXPERIMENTAL|Weight loss high protein|Protein supplementation. Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of protein, including substantial amounts of supplemental protein provided as lean beef. Intakes of \> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60% of animal protein from pork.
62365896|NCT02033655|ACTIVE_COMPARATOR|Weight loss control|Diet counseling and group education lessons. Subjects follow a calorie-reduction diet for a weight loss of ≥10%.
62365897|NCT05833568|ACTIVE_COMPARATOR|10-Hz tACS Stimulation Group|tACS stimulation will be delivered over to parieto-occipital sites using only 2-minute ramp up and down and a continuous 20-minute 10 Hz sinusoidal current administered. The stimulation electrode montage will be identical for both conditions.
62365898|NCT05833568|SHAM_COMPARATOR|Sham Stimulation Group|Sham stimulation will be delivered over to parieto-occipital sites using only 2-minute ramp up and down, without any sinusoidal current administered for 20 minutes. The stimulation electrode montage will be identical for both conditions.
62365899|NCT02200250||Post Barretts Excision|Patients who have undergone an EMR for Barretts Oesophagus
62365900|NCT05573568|EXPERIMENTAL|Group A - single ascending dose|Administration of up to 2 inhaled doses of DMT within a single day (5 mg, followed by 20 mg) with a 2-hour dose interval (5 subjects).
62365901|NCT05573568|EXPERIMENTAL|Group B - single ascending dose|Administration of up to 2 inhaled doses of DMT within a single day (7.5 mg, followed by 30 mg) with a 2-hour dose interval (5 subjects).
62365902|NCT05573568|EXPERIMENTAL|Group C - single ascending dose|Administration of up to 2 inhaled doses of DMT within a single day (10 mg, followed by 40 mg) with a 2-hour dose interval (5 subjects).
62365903|NCT05573568|EXPERIMENTAL|Group D - single ascending dose|Administration of up to 2 inhaled doses of DMT within a single day (12.5 mg, followed by 50 mg) with a 2-hour dose interval (5 subjects).
62742559|NCT03716778|EXPERIMENTAL|experimental, active group (ECC)|Patients perform a mixed program combining eccentric pedalling session with the usual sessions
62365904|NCT05573568|EXPERIMENTAL|Group E - single ascending dose|Administration of up to 2 inhaled doses of DMT within a single day (15 mg, followed by 60 mg) with a 2-hour dose interval (5 subjects).
62365905|NCT04500067|EXPERIMENTAL|Study Group (IVIG)|Patients receive IVIG (trade name - Bioven) with base therapy
62365906|NCT04500067|NO_INTERVENTION|Control group|Patients receive base therapy only
62365907|NCT01142544||Pediatric ALIEN|All children from 1 month to 18 years old meeting the American-European Consensus Conference definition of acute lung injury
62365908|NCT05126134||adolescents followed for gender dysphoria|The data collection by the examiner takes place during a single interview centered around the child's completion of a semi-structured questionnaire: the Kiddie Schedule for Affective Disorders and Schizophrenia. The child is interviewed alone and then with an accompanying parent.
62365909|NCT01841489|EXPERIMENTAL|Sequence 1|
62365910|NCT01841489|EXPERIMENTAL|Sequence 2|
62365911|NCT01841489|EXPERIMENTAL|Sequence 3|
62365912|NCT01841489|EXPERIMENTAL|Sequence 4|
62365913|NCT01894867|EXPERIMENTAL|magnesium|will get magnesium for 6 weeks
62742560|NCT00204594|EXPERIMENTAL|Antibody|
62365914|NCT01894867|PLACEBO_COMPARATOR|placebo|will get placebo for 6 weeks
62365915|NCT02473224|EXPERIMENTAL|Cohort 1|9 secretor-positive subjects will receive 1.2x10\^4 Genome Equivalent Copies (GEC) oral dose on Day 1; and 2 secretor-positive subjects will receive the placebo, n=11
62365916|NCT02473224|EXPERIMENTAL|Cohort 2|9 secretor-positive subjects will receive either 1.2 x 10\^2GEC, or 1.2 x10\^6 GEC oral dose on Day 1, depending on the percentage of subjects with illness from Cohort 1; 2 secretor-positive subjects will receive the placebo, n=11
62365917|NCT02473224|EXPERIMENTAL|Cohort 3|9 secretor-positive subjects will receive either 1GEC, 1.2 x 10\^1 GEC, 1.2 x 10\^2 GEC, 1.2 x 10\^3 GEC, 1.2 x 10\^5 GEC, 1.2 x 10\^6 GEC, or 1.2 x 10\^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2; 2 secretor-positive subjects will receive the placebo, n=11
62365918|NCT02473224|EXPERIMENTAL|Cohort 4|8 secretor-negative and 3 secretor-positive subjects will receive 1.2 x 10\^7 GEC oral dose on Day 1, n=11
62365919|NCT02398721|OTHER|FNAC|patients will then be randomized routine FNAC strategy
62365920|NCT02398721|NO_INTERVENTION|No FNAC|patients will be randomized to watchful observation strategy (no FNAC)
62365921|NCT02348840|EXPERIMENTAL|mHealth midwives|Midwives will receive access to mHealth technology immediately and use it for 12 months
62742561|NCT06156657|ACTIVE_COMPARATOR|TAP group|patients candidate for laparoscopic sleeve gastrectomy to receive GA and subcostal TAP block to control postoperative pain and minimize opioid consumption
62742562|NCT06156657|NO_INTERVENTION|Control group|healthy controls candidate for laparoscopic sleeve gastrectomy to receive GA only opioids were used
62742563|NCT06014606|PLACEBO_COMPARATOR|HV/Placebo|Oral placebo (tablet)
62742564|NCT06014606|ACTIVE_COMPARATOR|HV/Haloperidol|2mg (oral)
62365922|NCT02348840|ACTIVE_COMPARATOR|mHealth midwives - control|Midwives will not have access to mHealth technology for the first six months, and then will receive the technology for the remaining six months.
62365923|NCT02348840|ACTIVE_COMPARATOR|Pregnant Women|Pregnant women may or may not receive mHealth technology, based on the collaborating midwife they are assigned.
62365924|NCT00966680||1|Observational study comparing the speed of general versus spinal anesthesia during emergency cesarean
62365925|NCT03639987|EXPERIMENTAL|Group 1|Aducanumab, intravenous infusion, every 4 weeks for up to Week 52 during the randomized treatment period. The dose will be titrated to a desirable dose. Participants will be managed for drug continuation and suspension. Following a 4-week follow-up period, eligible participants will continue to receive aducanumab, intravenous infusion, every 4 weeks for an additional 104 weeks in the long-term extension period.
62365926|NCT03639987|EXPERIMENTAL|Group 2|Aducanumab, intravenous infusion, every 4 weeks for up to Week 52 during the randomized treatment period. The dose will be titrated to a desirable dose. Participants will be managed for drug continuation and suspension. Following a 4-week follow-up period, eligible participants will continue to receive aducanumab, intravenous infusion, every 4 weeks for an additional 104 weeks in the long-term extension period.
62365927|NCT01295190||Propofol|Patients receiving Propofol during cardiopulmonary bypass.
62365928|NCT01295190||Sevoflurane|Patients receiving sevoflurane during cardiopulmonary bypass
62365929|NCT02114060|EXPERIMENTAL|GEN-003 Vaccine 30μg / Matrix-M 25μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
62365930|NCT02114060|EXPERIMENTAL|GEN-003 Vaccine 30μg / Matrix-M2 50μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
62365931|NCT02114060|EXPERIMENTAL|GEN-003 Vaccine 30μg / Matrix-M2 75μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
62365932|NCT02114060|EXPERIMENTAL|GEN-003 Vaccine 60μg / Matrix-M2 25μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
62365933|NCT02114060|EXPERIMENTAL|GEN-003 Vaccine 60μg / Matrix-M2 50μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
62365934|NCT02114060|EXPERIMENTAL|GEN-003 Vaccine 60μg / Matrix-M2 75μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
62365935|NCT02114060|PLACEBO_COMPARATOR|Placebo|0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection.
62365936|NCT00641706|EXPERIMENTAL|Stratum 1 (not undergoing surgery)|Patients receive oral vorinostat (SAHA) once daily on days 1-14 and bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62742565|NCT06014606|ACTIVE_COMPARATOR|HV/Propranolol|40mg (oral)
62742566|NCT05704023|EXPERIMENTAL|Mobile app (WIapp) group|"Standard physical therapy program: 2x10 sessions, 5 times a week, 3-week break in between;~Mobile app with instructions on exercise at home and daily reminder to exercixse"
62742567|NCT05704023|NO_INTERVENTION|Control group|Standard physical therapy program: 2x10 sessions, 5 times a week, 3-week break in between, written instructions on exercises at home
62365937|NCT00641706|EXPERIMENTAL|Stratum 2 (undergoing surgery)|Patients receive oral SAHA once daily for 2 days prior to surgery and then on the day of surgery. Patients also receive bortezomib IV on the day of surgery. After receiving the 3rd dose of SAHA, patients undergo surgery to remove the tumor. Beginning at least 7 days after surgery, patients receive SAHA and bortezomib as in stratum 1.
62365938|NCT04695236|EXPERIMENTAL|Study group|Study Group: Intravascular hypothermia therapy group ZOLL Intravascular Temperature Management system, Quattro catheter will be used in study group
62742568|NCT06204900|EXPERIMENTAL|Undergoing a single-level or two-level TLIF between L2-S1|During the surgery, the standard monitoring devices and the EARP monitoring study devices and techniques will be used.
62365939|NCT04695236|PLACEBO_COMPARATOR|Control group|"Control group: Without intravascular hypothermia therapy group~ZOLL Intravascular Temperature Management system, Quattro catheter will not be used in control group"
62365940|NCT04021576|EXPERIMENTAL|intervention|preventative training program
62365941|NCT04021576|NO_INTERVENTION|control|no such training
62365942|NCT04449991|EXPERIMENTAL|Intervention arm: Repeat kidney biopsy at M12|Patients will undergo repeat kidney biopsy at month 12 from baseline.
62365943|NCT04449991|NO_INTERVENTION|Control arm: No repeat kidney biopsy|Patients will not undergo repeat kidney biopsy at month 12 from baseline.
62365944|NCT01463124|EXPERIMENTAL|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
62365945|NCT01463124|ACTIVE_COMPARATOR|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
62365946|NCT02341404|EXPERIMENTAL|Liproca Depot|A parenteral controlled release depot formulation of 2-hydroxyflutamide (2-HOF) is given as a single dose injection into the prostate gland within the lobe area where the tumour tissue is localized.
62365947|NCT03185312||patients with acne vulgaris|Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin .immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.
62365948|NCT03185312||patients with vitiligo|Clinical evaluation including full history taking and dermatological examination will be done . Assessment of disease severity will be performed using VASI score Skin biopsies will be taken from lesional and non-lesional skin .immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3..
62365949|NCT03185312||control|"Skin biopsies will be taken from skin of controls.~. Five micron thick sections will be cut from paraffin blocks for immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3."
62365950|NCT02103595|OTHER|Accu-Chek FlexLink Plus cross over to Accu-Chek FlexLink|
62365951|NCT02103595|OTHER|Accu-Chek FlexLink cross over to Accu-Chek FlexLink Plus|
62365952|NCT05406440|EXPERIMENTAL|MK-8189 Panel A|Participants will receive MK-8189 starting at 48 mg on Day 1 and 60 mg on Day 2.
62365953|NCT05406440|EXPERIMENTAL|MK-8189 Panel A-1|Participants will receive MK-8189 48 mg on Day 1 and 80 mg on Day 2.
62365954|NCT05406440|EXPERIMENTAL|MK-8189 Panel C|Participants will receive MK-8189 48 mg on Days 1-2 and 80 mg on Day 3 based on safety and tolerability.
62365955|NCT05406440|PLACEBO_COMPARATOR|Placebo|Participants will receive MK-8189-matching placebo.
62365956|NCT03472040|EXPERIMENTAL|BCX7353 150 mg once daily|
62365957|NCT05317260||Chronic hepatitis B patients without hepatic steatosis|Patients with chronic hepatitis B will be defined as the non-steatosis group if they had histological evidence of visible lipid droplets in hepatocytes less than 5%.
62365958|NCT05317260||Chronic hepatitis B with steatosis but no steatohepatitis|Patients with chronic hepatitis B will be categorized as the steatosis but not steatohepatitis group if they had histological evidence of visible lipid droplets in hepatocytes more than 5% in the absence of steatohepatitis feature.
62365959|NCT05317260||Chronic hepatitis B patients with steatohepatitis|Patients with chronic hepatitis B will be classified as the steatohepatitis group if they had histological evidence of steatosis, hepatocyte ballooning, mixed lobular acute and chronic inflammation, and intra-acinar perisinusoidal fibrosis according to Brunt's classification.
62365960|NCT03999385|EXPERIMENTAL|Immediate Training Group|8 weeks of training in Mindful Self-Compassion.
62365961|NCT03999385|OTHER|Waitlist Control Group|No intervention for approximately 12 weeks. After this waiting period, participants will complete 8 weeks of training in Mindful Self-Compassion.
62742569|NCT04022629|ACTIVE_COMPARATOR|Treatment Group 1|Patients aged between 18-35 years who have sustained a first-time traumatic anterior dislocation of the shoulder.
62742570|NCT04022629|ACTIVE_COMPARATOR|Treatment Group 2|Patients aged between 18-35 years who have sustained a first-time traumatic anterior dislocation of the shoulder.
62552786|NCT05748587||Patients with acute Ischemic stroke|"24 patients between 50-70 years having neurological symptoms of acute ischemic stroke will be included.~Patients with acute hemorrhagic stroke, Parkinson's disease, dementia, Alzheimer's disease, malignancy, and central nervous system infection will be excluded."
62365962|NCT02257125|EXPERIMENTAL|high incentive|game version including visual effects and monetary rewards
62365963|NCT02257125|ACTIVE_COMPARATOR|low incentive|game version without visual effects or monetary rewards
62365964|NCT04623255|NO_INTERVENTION|STANDARD OF CARE|Standard patient care for severe COVID-19
62365965|NCT04623255|ACTIVE_COMPARATOR|Plasma exchange|Standard patient care for severe COVID-19 with. plasma exchange daily for 5 days x 3 courses as required
62365966|NCT03062267|NO_INTERVENTION|Treatment as Usual|Treatment as usual for 3 months.
62552787|NCT05748587||Control rats|8 rats will be subjected to a Sham operation and will be injected intramuscularly immediately after the operation with an equivalent 0.9% saline solution. After 24 hours they will be sacrificed.
62365967|NCT03062267|EXPERIMENTAL|Mobile Interventionist|Participants will exchange text messages with a mobile interventionist throughout the day for 3 months.
62365968|NCT04447911|EXPERIMENTAL|Empagliflozin|Empagliflozin (Jardiance)® 25mg per os once daily for 30 days
62365969|NCT04447911|PLACEBO_COMPARATOR|Placebo|Placebo (Lactose tablet) per os once daily for 30 days
62365970|NCT03529890|EXPERIMENTAL|Radio-Immunotherapy before cystectomy|Single arm treatment with Nivolumab during a neoadjuvant radiation therapy of the pelvis before radical cystectomy with standardized pelvic lymphadenectomy
62365971|NCT04207008|EXPERIMENTAL|iBDecide App Decision-support Arm|Participants will download the iBDecide app on their smartphone approximately two weeks prior to the scheduled clinic visit. Approximately one week after the clinic visit, survey data, along with demographic data will be collected from all participants via a brief telephone call. We will collect data on app use between installation and the clinic visit as well as in the 3 months following the clinic visit.
62365972|NCT04207008|NO_INTERVENTION|Control Arm|Control participants will not use the iBDecide app prior to their clinic visit. They will complete a brief telephone survey approximately one week from clinic visit.
62365973|NCT02324868|EXPERIMENTAL|Shower patch IV catheter protection|Newly developed waterproof catheter dressing may be used for bathing activities
62365974|NCT02324868|OTHER|Conventional IV catheter protection|No specific dressing will be provided to the patient to protect the catheter entry site during bathing activities.
62365975|NCT01126684|ACTIVE_COMPARATOR|Atorvastatin|
62365976|NCT01126684|PLACEBO_COMPARATOR|Placebo|
62365977|NCT05823610||study group|The ultrasound parameters to be collected included the angle of progression, head-perineum distance and head-symphysis distance at rest and while pushing during contraction and the data between measurements taken at rest and while pushing. Also anatomical scanning for the episiotomy, perineal tears and obstetric anal sphincter injuries (OASI), also trauma to the levator ani muscle. All demographic, clinical and ultrasound variables were compared between women who had a spontaneous vaginal delivery (SVD) and those who eventually had an operative delivery (OD), vacuum -assisted or cesarean section (CS).
62365978|NCT00864344|EXPERIMENTAL|A|Sertraline HCl 100 mg tablets, single dose
62365979|NCT00864344|ACTIVE_COMPARATOR|B|Zoloft® 100 mg tablets, single dose
62742571|NCT06125925|EXPERIMENTAL|Radiofrequency catheter ablation (RFCA)|Radiofrequency ablation is adopted in the study, instead of cryo ablation, surgical ablation or pulsed field ablation. 3-dimensional model is constructed after transseptal puncture. Circumferential pulmonary vein isolation (CPVI) is performed with irrigated contact force catheter. Previously published STABLE-SR approach is recommended as the ablation strategy beyond CPVI.
62742572|NCT06125925|ACTIVE_COMPARATOR|Medical therapy|AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.
62742573|NCT02881931||Pre-Manifest HDGEC Participant|
62742574|NCT02881931||Early-Manifest HDGEC Participant|
62742575|NCT02881931||Corresponding HDGEC participant Companion|
62742576|NCT01781793|PLACEBO_COMPARATOR|Fibrotic ILD Patients, Room Air|Fibrotic ILD patients will breathe room air (21% oxygen) during a constant work rate exercise test
62742577|NCT01781793|ACTIVE_COMPARATOR|Fibrotic ILD Patients, Hyperoxia|Fibrotic ILD patients will breathe hyperoxia (60% oxygen) during a constant work rate exercise test
62742578|NCT02806336|EXPERIMENTAL|Multi Modal Balance Training & Weight Loss|Supervised exercise 3 times per week for about 1 hour. The classes will consist of a group balance class (about 30 minutes), a supervised obstacle course (about 10 minutes), and lower body and core body strength exercises (about 20 minutes). Weekly nutrition sessions for individual dietary recommendations designed to produce about a 10% weight loss over the first six months of the study.
62365980|NCT03156413|EXPERIMENTAL|F&P Nasal Mask|Trial nasal pillows CPAP mask
62365981|NCT02401113|EXPERIMENTAL|UA group|UA group who takes Ursolic acid of Loquat Extract , 500 mg/ day during 12 weeks for treatment of muscle function improvement with relatively health adults
62365982|NCT02401113|PLACEBO_COMPARATOR|placebo group|placebo group who takes a placebo, 500 mg/day for 12 weeks
62365983|NCT00858676|ACTIVE_COMPARATOR|Acarbose|
62365984|NCT06321640||Cohort A: primarily operable disease, candidate to adjuvant|"This cohort includes any patient with nonmetastatic disease, candidate to surgery as primary treatment, for whom adjuvant therapy with targeted or immune therapy is recommended based on prior information obtained on the diagnostic biopsy. This cohort represents a control group, for whom high-throughput DNA/RNA sequencing is considered feasible in the vast majority of cases, and will not be considered in the computation of the primary endpoint. Small groups representative of relevant diseases will be collected, as follows:~* Breast~* Lung~* Melanoma~* Head and Neck~* Urothelial~* Colorectal cancer~* Metastasectomy from lung or liver, from any cancer"
62365985|NCT06321640||Cohort B: locally advanced disease|Patients in this cohort are eligible if diagnosed with or highly suspected of locally advanced (nonmetastatic) neoplasm and candidate to a diagnostic/confirmatory biopsy and subsequent treatment with targeted therapy, immune therapy or radiotherapy, where the treatment is administered with potentially curative intent. Patients in this cohort may be considered for enrolment prior to a formal diagnosis, so the study should be offered on the basis of a high suspicion of invasive cancer upon radiological evidence.Cohort B1: patients who, at the moment of biopsy, are expected to be subsequently treated with targeted therapy. Cohort B2: patients who, at the moment of biopsy, are expected to be subsequently treated with immune therapy. Cohort B3: patients who, at the moment of biopsy, are expected to be treated with combined chemo-immuno-radiotherapy
62365986|NCT06321640||Cohort C: metastatic disease|"In this cohort, patients are eligible if diagnosed with invasive cancer with radiologically proven metastatic localization and candidate to treatment with targeted or immune therapy.~Cohort C1: patients candidate to targeted therapy Cohort C2: patients candidate to immune therapy"
62552788|NCT05748587||Rats with ischemic stroke|8 rats will be subjected to bilateral common carotid artery occlusion (CCAO) for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with an equivalent 0.9% saline solution. They will be sacrificed after 24 hours of reperfusion.
62365987|NCT06321640||Cohort D: Progressive disease|"In this cohort, patients are eligible if a tumor biopsy is considered indicated by the referring physician upon disease progression to prior treatment in the metastatic setting or for hematological neoplasms. Definition of progression is based on the investigator's judgement and does not strictly require RECIST 1.1 definition, although all relevant radiological data will be collected whenever possible. Tumor biopsy must be collected no more than 6 months after the documented date of progression.~Subgroups include: Cohort D1: progression disease to targeted. Patients whose last treatment at the moment of enrolment is a targeted agent.~Cohort D2: progression disease to immune. Patients whose last treatment at the moment of enrolment is an immunotherapeutic agent Cohort D3: potential off-label treatment. Any patient that has exhausted standard treatment and that in the judgement of the investigator may benefit from an exome-wide mutational screen to identify actionable alterations"
62365988|NCT06321640||Cohort E: Hematological neoplasms|"Cohort E1: Any patient that is expected to be treated with targeted agents. Special consideration will be given to patients affected by chronic lymphoid leukemia and follicular lymphoma treated with Bruton´s tyrosine kinase (BTK) inhibitor, Phosphoinositide 3-kinase inhibitor, B-cell lymphoma 2 inhibitor +/- monoclonal antibodies.~Cohort E2: Any patient that is expected to be treated with immunotherapy. Special consideration will be given to patients affected by Hodgkin lymphoma and Diffuse Large B-cell lymphoma treated with Immune checkpoint inhibitors, Tafasitamab/Lenalidomide, immunoconjugates."
62365989|NCT06321640||Cohort F: Toxicity|In this cohort, patients are enrolled upon experiencing an adverse event of grade 3/4 as per Common Terminology Criteria for Adverse Events version 5.0 that, in the opinion of the investigator, is unequivocally caused by a targeted or immune therapeutic. The event may occur at any time after the last dose of the drug. Events may be of any nature but particular attention will be given to those events for which pathophysiology is currently poorly understood.Cohort F1: toxicity to Targeted therapy. Patients experiencing Grade 3-Grade 4 adverse events due to targeted therapy Cohort F2: toxicity to Immune therapy. Patients experiencing Grade 3-Grade 4 adverse events due to Immune therapy.
62365990|NCT00853619|EXPERIMENTAL|Services Demo at PHS and RI|Service based CDS intervention at PHS.
62365991|NCT00853619|ACTIVE_COMPARATOR|Normal CDS interventions at PHS and RI|Normal CDS intervention at both PHS and RI hospitals
62365992|NCT05941910|ACTIVE_COMPARATOR|Q10|
62365993|NCT05941910|PLACEBO_COMPARATOR|Placebo|
62365994|NCT01529619|EXPERIMENTAL|Rivastigmine 18 mg|During the 16-week titration period patients received daily rivastigmine 4.5mg patch for the first 4 weeks, rivastigmine 9mg patch for the next 4 weeks, rivastigmine 13.5mg patch for the next 4 weeks and then rivastigmine 18mg patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
62365995|NCT03590093|EXPERIMENTAL|Periodontal Surgery with EMD|A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed. After carefully cleaning root dental surfaces, EMD was placed inside the infrabony periodontal defect. Suture were placed to maintain wound stability.
62365996|NCT03590093|ACTIVE_COMPARATOR|Periodontal Surgery|A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed. Suture were placed to maintain wound stability.
62365997|NCT06153914|EXPERIMENTAL|Surgical group|This study intends to select patients with decompensated hepatitis B cirrhosis who meet the enrollment criteria and perform sequential adult left lateral lobe liver transplantation.
62365998|NCT00674375|EXPERIMENTAL|1|Primary care clinicians (physicians, nurse practitioners, and physician assistants) randomized to the intervention arm will receive electronic alerts within the electronic medical record system during office visits with patients complaining of chest pain.
62365999|NCT00674375|NO_INTERVENTION|2|Primary care clinicians randomized to the 'no intervention' arm will evaluate and treat patients complaining of chest pain without the aid of electronic risk alerts.
62366000|NCT05467072||Discectomy + annular closure|All patients treated with lumbar discectomy and implantation of an annular closure device
62742579|NCT02806336|ACTIVE_COMPARATOR|Multi Modal Balance Training Only|Supervised exercise 3 times per week for about 1 hour. The classes will consist of a group balance class (about 30 minutes), a supervised obstacle course (about 10 minutes), and lower body and core body strength exercises (about 20 minutes).
62742580|NCT05178316|EXPERIMENTAL|JZP150 0.3 mg|Participants who will be randomized to receive JZP150 0.3 mg orally once daily for up to 12 weeks.
62366001|NCT06240793|OTHER|Unilateral transforaminal epidural block|The necessary oblique and cranio-caudal angles will be provided in fluoroscopy for the patients' designated procedure area. Skin and subcutaneous tissue anesthesia will be applied to the injection site with 3 ml of 2% prilocaine. The neural foramen will be entered using a blunt-tipped sympathetic block needle and a guiding needle. After needle localization is confirmed with antero-posterior and lateral fluoroscopic images, 1-2 ml of contrast material will be injected following negative aspiration. After confirming the contrast material spread in the anterior epidural area and periradicular area, 8 mg dexamethasone will be injected. If the application will be performed bilaterally, the specified techniques will be applied in half the same way on the bilateral side. Patients will be observed for one hour after the procedure for possible complications.
62391483|NCT01376765|EXPERIMENTAL|Cohort 3|SARS vaccine with adjuvant, without adjuvant, or placebo; l in 2 intramuscular doses, 28 days apart, at 45 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine (SARS vaccine with adjuvant); 4 subjects receive placebo.
62391484|NCT01376765|EXPERIMENTAL|Cohort 2|SARS vaccine with adjuvant, without adjuvant, or placebo in 2 intramuscular doses, 28 days apart, at 15 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine (SARS vaccine with adjuvant) 4 subjects receive placebo.
62391485|NCT05489146|ACTIVE_COMPARATOR|tRNS and FES facilitated task practice|In this arm, participants received real transcranial random noise stimulation with FES facilitated task practice
62742581|NCT05178316|EXPERIMENTAL|JZP150 4.0 mg|Participants who will be randomized to receive JZP150 4.0 mg orally once daily for up to 12 weeks.
62742582|NCT05178316|PLACEBO_COMPARATOR|Placebo|Participants who will be randomized to receive placebo orally once daily for up to 12 weeks.
62742583|NCT03062280|EXPERIMENTAL|Chronocort®|Chronocort® modified release hydrocortisone
62742584|NCT06651385|EXPERIMENTAL|Remote digital therapeutic exercise program|
62366002|NCT06240793|ACTIVE_COMPARATOR|bilateral transforaminal epidural block|The necessary oblique and cranio-caudal angles will be provided in fluoroscopy for the patients' designated procedure area. Skin and subcutaneous tissue anesthesia will be applied to the injection site with 3 ml of 2% prilocaine. The neural foramen will be entered using a blunt-tipped sympathetic block needle and a guiding needle. After needle localization is confirmed with antero-posterior and lateral fluoroscopic images, 1-2 ml of contrast material will be injected following negative aspiration. After confirming the contrast material spread in the anterior epidural area and periradicular area, 8 mg dexamethasone will be injected. If the application will be performed bilaterally, the specified techniques will be applied in half the same way on the bilateral side. Patients will be observed for one hour after the procedure for possible complications.
62366003|NCT01824862||eyes without diabetic retinopathy|eyes of patients with diabetes mellitus type 2 that does not have retinopathy
62366004|NCT01824862||CSME without centre involvement|eyes with CSME without thickening in the 500 µm adjacent to the centre of the macula
62366005|NCT01824862||CSME with centre involvement|eyes with CSME with thickening in the 500 µm adjacent to the centre of the macula
62366006|NCT00663338|EXPERIMENTAL|A|All patients receive placebo or rotigotine at some stage in the trial but the exact point is randomized.
62366007|NCT04460365|ACTIVE_COMPARATOR|Active|Softgel capsules: 10 mg Lutein, 2 mg zeaxanthin, 10 mg meso-zeaxanthin once a day with a meal for 18 months
62366008|NCT04460365|PLACEBO_COMPARATOR|Placebo|Identical capsule containing no active ingredients
62366009|NCT02157584|EXPERIMENTAL|Treatment A|Subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) on Day 1 in a fed condition. Days 2 to 5 will be Washout Days. On Day 6, subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) 1 in a fasted condition.
62366010|NCT02157584|EXPERIMENTAL|Treatment B|Subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) on Day 1 in a fasted condition. Days 2 to 5 will be Washout Days. On Day 6, subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) 1 in a fed condition.
62366011|NCT02635529|ACTIVE_COMPARATOR|OFD + DFDBA|Intrabony defects treatment was carried out with OFD + DFDBA
62366012|NCT02635529|ACTIVE_COMPARATOR|OFD+DFDBA+AM|Intrabony defects treatment was carried out with OFD + DFDBA+ AM
62366013|NCT05240963|EXPERIMENTAL|PEEK implant|Temporal PEEK implant to prevent temporal hollowing after temporalis muscle transfer
62366014|NCT02446860|EXPERIMENTAL|Nivolumab|Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit
62366015|NCT05932394|EXPERIMENTAL|Control group|In the control group, after the surgical intervention and 30 minutes after the patient's extubation the CAM-ICU scale is administered, recording its value as R0. The following day, at 9:00 a.m., another nurse uses the CAM-ICU scale, noting its value as R1. If postoperative delirium was detected during the day and night, the unit's usual treatment was followed: administration of haloperidol and/or dexmedetomidine.
62366016|NCT05932394|ACTIVE_COMPARATOR|Intervention group|In the intervention group, patients and/or companions are asked to provide visual material, which could consist of photographs of loved ones and/or places known to the patient. 30 minutes after the extubation of the patients, the CAM-ICU scale is administered, recording its value as R0. At night, the projection of images provided by the patient are replaced by a nocturnal visual projection (night sky with stars and moon), ensuring that the patient is able to identify that it was nighttime. Finally, at 9:00 a.m., a nurse who had not worked at night and therefore did not know which patients had received the intervention, administers the CAM-ICU scale again, recording its value as R1.
62366017|NCT06300892||Patients undergoing open GI surgery|Patients with SSI
62366018|NCT06300892||Control group|age-, sex-, diagnosis-, and wound class-matched control patients without SSI
62366019|NCT03975530|EXPERIMENTAL|Precision Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive a customized version of Family Spirit that is unique to your circumstances. The two sites randomized to provide the Precision approach will receive additional training on how to provide it. At 6 months postpartum, and upon completion of the intervention, participants in the treatment group will be asked to participate in brief semi-structured phone interviews.
62366020|NCT03975530|ACTIVE_COMPARATOR|Standard Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive Family Spirit lessons based on a standard program schedule.
62366021|NCT02204410|EXPERIMENTAL|Omega-3 Fatty Acids and Stimulant Treatment|Participants will receive open-label treatment with Omega-3 Fatty Acids. All participants must also be treated with a stable dose of a traditional ADHD medication at the time of enrollment.
62366022|NCT01685203|EXPERIMENTAL|Group 1|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants
62366023|NCT01685203|EXPERIMENTAL|Group 2|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve HCV GT1b-infected participants
62742585|NCT03684603|ACTIVE_COMPARATOR|Acoustic cueing|The melody will be played during training and during slow wave sleep.
62742586|NCT03684603|SHAM_COMPARATOR|Control|The melody will be played during training.
62742587|NCT02565264|EXPERIMENTAL|plasma-derived exosomes|plasma-derived exosomes
62742588|NCT00570011|EXPERIMENTAL|1|
62742589|NCT00570011|EXPERIMENTAL|2|
62742590|NCT05200611||Fecal Immunochemical Test|People in this group with positive fecal immunochemical test results were further examined by colonoscopy.
62742591|NCT03841513|NO_INTERVENTION|Control|Patients in this arm will undergo standard laparoscopic or robotic sacrocolpopexy, without the addition of a laparoscopic/robotic Burch colposuspension
62366024|NCT01685203|EXPERIMENTAL|Group 3|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, HCV GT1b-infected, pegylated-interferon/ribavirin (pegIFN/RBV) treatment null responder participants
62366025|NCT01685203|EXPERIMENTAL|Group 4|ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if \< 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants
62366026|NCT01685203|EXPERIMENTAL|Group 5|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-experienced, HCV GT4-infected participants
62366027|NCT01685203|EXPERIMENTAL|Group 6|ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if \< 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, HCV GT4-infected, pegylated-interferon/RBV (pegIFN/RBV) treatment-experienced participants
62366028|NCT01685203|EXPERIMENTAL|Group 7|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, treatment-naïve participants with compensated cirrhosis
62366029|NCT01685203|EXPERIMENTAL|Group 8|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, pegylated-interferon/RBV(pegIFN/RBV) treatment-experienced participants with compensated cirrhosis
62366030|NCT00879047|EXPERIMENTAL|HIV+, Ritonavir-regimen|10 subjects will be HIV+ and will begin receiving Ritonavir-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
62366031|NCT00879047|EXPERIMENTAL|HIV+/HCV+ Co-infected, Ritonavir-regimen|10 subjects will be HIV+/HCV+ co-infected and will begin receiving Ritonavir-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
62366032|NCT00879047|EXPERIMENTAL|HIV+, Efavirenz-regimen|10 subjects will be HIV+ and will begin receiving Efavirenz-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
62366033|NCT00879047|EXPERIMENTAL|HIV+/HCV+ Co-infected, Efavirenz-regimen|10 subjects will be HIV+/HCV+ co-infected and will begin receiving Efavirenz-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
62366034|NCT00879047|EXPERIMENTAL|Maraviroc in Healthy Subjects|10 healthy subjects will begin receiving maraviroc, and their PK interactions with alcohol/placebo will be evaluated.
62366035|NCT03736551|EXPERIMENTAL|Intervention|The intervention arm will involve standard care plus an intermittent modified fasting regimen consisting of a very low energy diet (600 kcal/day) on 2 consecutive days of the week, and 5 days each week on an energy restricted diet to maintain a similar overall energy deficit of 600 kcal/day across the week (5:2 diet). All dietary intake on modified fasting days will be from LighterLife foodpacks, (4 x 150 kcal portions/day presented as milkshakes, cereal bars, soups and modified meals such as spaghetti bolognese, or macaroni cheese) providing \~600 kcal/day and 100% of the RNI for vitamins and minerals.
62366036|NCT03736551|ACTIVE_COMPARATOR|Standard Care|Renal Weight management Programme - Patients will attend individual appointments with the specialist dietitian and physiotherapist once a month, for 6 months. Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure (9). In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
62366037|NCT03265925||Epilepsy patients Right Temporal Lobe|Epilepsy patients with seizures originating from the right temporal lobe
62366038|NCT03265925||Epilepsy patients Left Temporal Lobe|Epilepsy patients with seizures originating from the left temporal lobe
62366039|NCT03265925||Healthy|Healthy controls
62366040|NCT01094808|EXPERIMENTAL|Pregabalin 75 mg|Subjects randomized to this arm received a single dose of pregabalin 75 mg orally
62366041|NCT01094808|EXPERIMENTAL|Pregabalin 200 mg|Subjects randomized to this arm received a single dose of pregabalin 200 mg orally
62366042|NCT01094808|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm received a single dose of placebo medication orally
62366043|NCT03630016|ACTIVE_COMPARATOR|Reference CO-Oximetry|Reference Co-Oximetry
62366044|NCT03630016|EXPERIMENTAL|Owlet BabySat v1.0|Owlet BabySat v1.0
62366045|NCT03630016|EXPERIMENTAL|Owlet Smart Sock V2 v1.1|Owlet Smart SockTM 2 , OSS v1.1 Sensor and Custom Adult Thumb Sock
62366046|NCT03771781|OTHER|Empagliflozin Tablets|The test formulation is manufactured by Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd.During the study session,subjects will be administered a single does of Empagliflozin Tablets 25mg after fasting and fed conditions.
62366047|NCT03771781|OTHER|Empagliflozin Tab 25 MG|The reference formulation is manufactured by Boehringer Ingelheim International GmbH.During the study session,subjects will be administered a single does of Empagliflozin Tab 25 MG after fasting and fed conditions.
62366048|NCT03825497|EXPERIMENTAL|Intervention|1) On admission, patients will receive a welcome folder focusing on physical activity; 2) daily during hospitalization, patients will be encouraged to walk along a walk path in the hallway; 3) during hospitalization, patients will be encouraged to consult and use posters with exercises (sit to stand, heel raise, balance); 4) on admission, patients will receive a prescribed walk plan with 3 daily walking sessions to perform during hospitalization (3 times 1 minute, 5 minutes or 10 minutes); 5) during hospitalization patients will be motivated to pick up of clothes and beverages themselves; 6) patients will be discharged with a walk plan to use at home; 7) after discharge the municipality will follow up on patients receiving home care and patients with a rehabilitation plan
62366049|NCT03825497|NO_INTERVENTION|Usual care|All patients admitted to the control wards will receive usual care during and after hospitalization.
62366050|NCT05243004|EXPERIMENTAL|Phone Nurse Consultation|Patients will benefit, in addition to the usual care, including a reminder by the secretary of the PORU the day before the operation, a phone call from nurse no later than 72 hours before surgery to explain and remind them of the instructions for preoperative preparation and answer any questions they may have.
62366051|NCT05243004|NO_INTERVENTION|Standard care|Patients in this group will follow the usual preparation schedule including a reminder by the secretary of the PORU the day before the operation.
62391486|NCT05489146|SHAM_COMPARATOR|sham tRNS and FES facilitated task practice|In this arm, participants received sham transcranial random noise stimulation with FES facilitated task practice
62366052|NCT05849636|EXPERIMENTAL|ALERTA CANNABIS|The Experimental Group receives the ALERTA CANNABIS intervention, which consists of four sessions at school (baseline questionnaire, two sessions in three scenarios: at home, celebrations, and public places, and a final evaluation). The adolescents are provided with answers related to their views of each scenario; this information is used to provide highly specific feedback regarding their knowledge, risk perception, self-esteem, attitude, social influence (modelling, norms and social pressure), self-efficacy and action plans. The post-tests will be carried out at six and twelve months from the baseline.
62366053|NCT05849636|NO_INTERVENTION|CONTROL|Control Group: The Control Group just completes the baseline and the evaluation questionnaires. Evaluation takes place after six and twelve months from baseline
62366054|NCT02685124|EXPERIMENTAL|Bahia orange juice|250 ml twice daily for 7 days
62366055|NCT02685124|EXPERIMENTAL|Cara Cara orange juice|250 ml twice daily for 7 days
62366056|NCT02685124|PLACEBO_COMPARATOR|Isocaloric control drink|250 ml twice daily for 7 days
62366057|NCT05634876|EXPERIMENTAL|Treatment First - MSA|"Includes participants with MSA only.~Patients in the treatment-first arm will receive active treatment at weeks 1, 5, 13, 25, 37, 49, 73, and 97; and placebo doses at weeks 17, 61, 85, and 109. Participants will be followed up for 24 weeks after their last dose.~All participants will receive three priming doses of UB-312 300 µg, followed by 5 booster doses of UB-312 300 µg. To keep the blind, both treatment arms will receive active treatment and placebo injections for a total of 12 injections (8 active treatment injections + 4 placebo injections)."
62366058|NCT05634876|EXPERIMENTAL|Delayed Start - MSA|"Includes participants with MSA only~Patients in the delayed-start arm will receive placebo injections at weeks 1, 5, 73, and 97; and active treatment at weeks 13, 17, 25, 37, 49, 61, 85, and 109. Participants will be followed up for 24 weeks after their last dose.~All participants will receive three priming doses of UB-312 300 µg, followed by 5 booster doses of UB-312 300 µg. To keep the blind, both treatment arms will receive active treatment and placebo injections for a total of 12 injections (8 active treatment injections + 4 placebo injections)."
62366059|NCT05634876|EXPERIMENTAL|Treatment First - PD|"Includes participants with PD only.~Patients in the treatment-first arm will receive active treatment at weeks 1, 5, 13, 25, 37, 49, 73, and 97; and placebo doses at weeks 17, 61, 85, and 109. Participants will be followed up for 24 weeks after their last dose.~All participants will receive three priming doses of UB-312 300 µg, followed by 5 booster doses of UB-312 300 µg. To keep the blind, both treatment arms will receive active treatment and placebo injections for a total of 12 injections (8 active treatment injections + 4 placebo injections)."
62366060|NCT05634876|EXPERIMENTAL|Delayed Start - PD|"Includes participants with PD only.~Patients in the delayed-start arm will receive placebo injections at weeks 1, 5, 73, and 97; and active treatment at weeks 13, 17, 25, 37, 49, 61, 85, and 109. Participants will be followed up for 24 weeks after their last dose.~All participants will receive three priming doses of UB-312 300 µg, followed by 5 booster doses of UB-312 300 µg. To keep the blind, both treatment arms will receive active treatment and placebo injections for a total of 12 injections (8 active treatment injections + 4 placebo injections)."
62366061|NCT01328678||Alopecia Areata|Individuals with Alopecia Areata (AA)
62366062|NCT03882723|EXPERIMENTAL|Randomized Crossover Trial with 4 NIV Masks|Order of the masks (BiTrac MaxShield™ with standard elbow, BiTrac™ Full Face with standard elbow, Respironics PerforMax with standard elbow, and Respironics AF531 with standard elbow) were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out between masks. EPAP levels will be 0, 2, 4, \& 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
62366063|NCT01763112|PLACEBO_COMPARATOR|Placebo group|This group will not do any specific training baseline and week 4 investigation will be done only
62366064|NCT01763112|ACTIVE_COMPARATOR|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
62366065|NCT03237429||cancer patients|The first study population will represent patients scheduled for surgery for a new diagnosed cancer pathology
62366066|NCT03237429||non-cancer patients|The second study population will represent patients scheduled for surgery not for cancer disease
62366067|NCT05070325|EXPERIMENTAL|Cold application group (Group 1)|In the children in this group, the injection site was cleaned before the injection using antiseptic cotton and then the gel pad was placed on the injection site. In line with the literature, the cold gel pad was applied to the intramuscular injection site for 30-45 seconds before the injection and then the injection was delivered. The children were told to breathe deeply and not to tense up during the injection.
62742592|NCT03841513|ACTIVE_COMPARATOR|Laparoscopic Burch Colposuspension|Patients in this arm will undergo standard laparoscopic or robotic sacrocolpopexy, with the addition of a laparoscopic/robotic Burch colposuspension
62391487|NCT00888992|NO_INTERVENTION|Group A|Receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls.
62391488|NCT00888992|EXPERIMENTAL|Group B|
62552789|NCT05748587||Rats with ischemic stroke + deferoxamine|8 rats will be subjected to bilateral CCAO for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with deferoxamine (200 mg/kg), They will be sacrificed after 24 hours of reperfusion.
62552790|NCT02012270||Conventional Group|Group of patients in whom after open AAA repair abdominal wall will be closed by conventional technique by the operating surgeons. There will be a great variation in sutures and techniques used
62552791|NCT02012270||PRINCIPLES Group|Group of patients in whom after open AAA repair abdominal wall will be closed by PRINCIPLES technique by the operating surgeons.
62742593|NCT00917683||1|Autistic patients.
62742594|NCT00917683||2|Matched controls
62742595|NCT00825942|EXPERIMENTAL|C-KAD Ophthalmic Solution|
62742596|NCT06447779|EXPERIMENTAL|Vaccine Group|Subjects will receive Recombinant Zoster Vaccine (CHO cell) according to a 0, 2-month schedule
62742597|NCT06447779|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
62366068|NCT05070325|EXPERIMENTAL|Shotblocker group (Group 2)|The injection site was cleaned using antiseptic cotton. The surface of the Shotblocker with the contact points was placed on the site just before the injection in a way not to contaminate the injection point. Injection was carried out through the opening in the middle of ShotBlocker. The children were told to breathe deeply and not to tense up during the injection. After the injection was completed, ShotBlocker was removed from the skin.
62366069|NCT05070325|EXPERIMENTAL|Control Group (Group 3)|The routine IM injection was applied to the children in this group. The injection site was cleaned using antiseptic cotton. The children were told to breathe deeply and not to tense up during the injection.
62366070|NCT04585672|OTHER|Healthy and Cirrhosis|Ammonia infusion with and without ammonia targeting
62366071|NCT05154578|EXPERIMENTAL|Group 1: 4 week dose interval; 2 doses|Participants will receive one injection of placebo at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA and one injection of GBS- NN/NN2 at 30 (±1) weeks GA
62366072|NCT05154578|EXPERIMENTAL|Group 2: early intervention; 4 week dose interval; 2 doses|Participants will receive one injection of GBS-NN/NN2 at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA and one injection of placebo at 30 (±1) weeks GA
62366073|NCT05154578|EXPERIMENTAL|Group 3: early intervention; 8 week dose interval; 2 doses|Participants will receive one injection of GBS-NN/NN2 at 22 (±1) weeks GA, one injection of placebo at 26 (±1) weeks GA and one injection of GBS- NN/NN2 at 30 (±1) weeks GA
62366074|NCT05154578|EXPERIMENTAL|Group 4: single dose|Participants will receive one injection of placebo at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA, and one injection of placebo at 30 (±1) weeks GA.
62366075|NCT05154578|PLACEBO_COMPARATOR|Group 5: placebo|Participants will receive one injection of placebo at 22, 26 and 30 weeks (±1) GA
62366076|NCT04319770|ACTIVE_COMPARATOR|periodontal regenerative surgery + EMD (control)|periodontal regenerative surgery with enamel matrix derivative
62366077|NCT04319770|EXPERIMENTAL|periodontal regenerative surgery + HA (test)|periodontal regenerative surgery with hyaluronic acid
62366078|NCT00561340|EXPERIMENTAL|1 Can of Pediasure Supplement Plus Nutritional Counseling|Pediasure and nutritional counseling
62366079|NCT00561340|ACTIVE_COMPARATOR|Counseling by the Provider on Ways to Encourage Caloric Intake|Behavioral intervention - Nutritional Counseling
62366080|NCT01412151|OTHER|Creatine monohydrate|single arm long-term open label follow-up
62366081|NCT04755283|EXPERIMENTAL|Abelacimab (MAA868)|"Treatment group 1: Abelacimab middle dose subcutaneous (s.c.) monthly~Treatment group 2: Abelacimab high dose subcutaneous (s.c.) monthly~Extension Treatment Group: Abelacimab high dose subcutaneous (s.c.) monthly"
62366082|NCT04755283|ACTIVE_COMPARATOR|Rivaroxaban|"Treatment group 3: Rivaroxaban 20 mg by mouth; orally (p.o.) once per day with the evening meal~Patients with a Creatinine Clearance (CrCl) ≤50 ml/min by the Cockcroft-Gault equation will have a dose adaptation to rivaroxaban 15 mg p.o. daily."
62366083|NCT01048047|EXPERIMENTAL|aliskiren/amlodipine|aliskiren, 300 mg/amlodipine 10 mg
62366084|NCT01048047|ACTIVE_COMPARATOR|amlodipine|amlodipine 10 mg
62366085|NCT02215616|PLACEBO_COMPARATOR|Placebo|Participants will receive 3 capsules of matching laquinimod placebo, orally once daily for 52 weeks.
62366086|NCT02215616|EXPERIMENTAL|Laquinimod 0.5 mg|Participants will receive 1 capsule of laquinimod 0.5 milligrams (mg) and 2 capsules of matching placebo, orally once daily for 52 weeks.
62366087|NCT02215616|EXPERIMENTAL|Laquinimod 1.0 mg|Participants will receive 2 capsule of laquinimod 0.5 mg (total 1.0 mg laquinimod) and 1 capsule of matching placebo, orally once daily for 52 weeks.
62366088|NCT02215616|EXPERIMENTAL|Laquinimod 1.5 mg|"Participants will receive 3 capsules of laquinimod 0.5 mg (total 1.5 mg laquinimod), orally once daily.~Note: The treatment of this high dose arm was discontinued as of 10 January 2016."
62366089|NCT02122055|EXPERIMENTAL|Propofol/Dexmedetomidine|"1. Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.~2. After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning."
62366090|NCT02122055|EXPERIMENTAL|Midazolam/Dexmedetomidine|"1. Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.~2. After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning."
62366091|NCT03039790|EXPERIMENTAL|NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose|Eligible participants who received Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MLP) and 500 µg aluminium hydroxide, IM on Day 28 in previous study NOR-107 were enrolled at 3rd year post-primary vaccination in this study.
62366092|NCT03039790|EXPERIMENTAL|NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
62366093|NCT03039790|EXPERIMENTAL|NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
62391489|NCT00888992|EXPERIMENTAL|Group C|
62391490|NCT02698020|NO_INTERVENTION|Control|High level of supplemental inspired oxygen
62391491|NCT02698020|EXPERIMENTAL|Room-air|Supplemental oxygen only provided if oxygen saturation below target
62366094|NCT03039790|EXPERIMENTAL|NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
62366095|NCT03039790|EXPERIMENTAL|NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose|Eligible NOR-107 participants who had received IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
62366096|NCT03039790|EXPERIMENTAL|NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
62366097|NCT03039790|EXPERIMENTAL|NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
62366098|NCT03039790|EXPERIMENTAL|NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
62366099|NCT03039790|EXPERIMENTAL|NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
62366100|NCT03039790|EXPERIMENTAL|NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
62366101|NCT03039790|EXPERIMENTAL|NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
62366102|NCT03039790|EXPERIMENTAL|NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose|Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
62366103|NCT03039790|EXPERIMENTAL|NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose|Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
62366104|NCT03039790|EXPERIMENTAL|NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose|Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
62366105|NCT03039790|EXPERIMENTAL|NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose|Eligible NOR-210 participants who had received Norovirus GI.1/GII.4 bivalent VLP vaccine NoV Vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminium hydroxide), IM injection, once on Day 1 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
62366106|NCT03039790|EXPERIMENTAL|NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose|Eligible NOR-204 participants who had received Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) \[15 μg of GI.1 and 50 μg of GII.4 bivalent virus-like particle (VLP)\] adjuvanted with 500 µg aluminium hydroxide and 15 μg of monophosphoryl lipid A (MPL) (Composition B), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
62366107|NCT03039790|EXPERIMENTAL|NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 yrs)|Eligible NOR-204 participants of age 60-94 years who had received Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus (NoV) \[15 μg of GI.1 and 50 μg of GII.4 bivalent virus-like particle (VLP)\] adjuvanted with 500 µg aluminium hydroxide (Composition A), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
62366108|NCT03039790|EXPERIMENTAL|NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 yrs)|Eligible NOR-204 participants of age 18-49 years who had received Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus (NoV) \[15 μg of GI.1 and 50 μg of GII.4 bivalent virus-like particle (VLP)\] adjuvanted with 500 µg aluminium hydroxide (Composition A), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
62366109|NCT03039790|EXPERIMENTAL|NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose|Eligible NOR-204 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide and 15 μg of MPL (Composition B), IM, on Day 1 and Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
62742598|NCT06492707|EXPERIMENTAL|Treatment (DR-18)|"INDUCTION: Patients receive DR-18 SC once weekly on approximately days 0, 7, 14, and 21.~MAINTENANCE: Two weeks after induction treatment, patients without grade 3-4 acute GVHD, grade 2 acute GVHD requiring ongoing systemic immunosuppression, or moderate/severe chronic GVHD may receive DR-18 SC once weekly on approximately days 35, 42, 49 and 56.~Additionally, patients undergo blood and bone marrow sample collection throughout the study."
62742599|NCT03938103|EXPERIMENTAL|Enhanced Go NAPSACC|Enhanced delivery model
62742600|NCT03938103|ACTIVE_COMPARATOR|Basic Go NAPSACC|Basic delivery model
62742601|NCT02684058|EXPERIMENTAL|LGG cohort: dabrafenib and trametinib|Participants in the LGG cohort randomized to receive dabrafenib (orally, twice daily and dosed based on weight and age) in combination with trametinib (orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on weight)
62366110|NCT03039790|EXPERIMENTAL|NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose|Eligible NOR-204 participants who had received Norovirus bivalent placebo-matching vaccine (15 μg of GI.1 50 μg of GII.4 bivalent VLP) adjuvanted with 500 µg aluminium hydroxide (Composition A) IM, on Day 1 and Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
62742602|NCT02684058|ACTIVE_COMPARATOR|LGG cohort: carboplatin and vincristine|Participants in the LGG cohort randomized to receive active comparator chemotherapy (carboplatin and vincristine). Participants received one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy.
62742603|NCT02684058|EXPERIMENTAL|HGG cohort: dabrafenib and trametinib|Participants in the HGG cohort received dabrafenib (orally, twice daily and dosed based on weight and age) and trametinib (orally, once daily in combination with the first daily dose of dabrafenib and dosed based on weight)
62742604|NCT06491641|EXPERIMENTAL|Experimental Group|During the application process, the babies in the experimental group will receive care based on Kolcaba's comfort theory during their stay in intensive care.
62742605|NCT06491641|NO_INTERVENTION|Control Group|In this study, the control group will receive standard care.
62742606|NCT02818023|EXPERIMENTAL|Pembrolizumab plus vemurafenib and Cobimetinib|"* Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ), and vemurafenib/cobimetinib will be given at 480 mg twice daily/20 mg daily, 720 mg twice daily/40 mg daily, or 960 mg twice daily/60 mg daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.~* One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
62742607|NCT05556421||case group|dislocated intrauterine device
62742608|NCT05556421||control group|normal intrauterine device position
62742609|NCT01555853|EXPERIMENTAL|Phase I-Dose Level 0|Abraxane 100 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
62742610|NCT01555853|EXPERIMENTAL|Phase I-Dose Level 1|Abraxane 125 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
62742611|NCT01555853|EXPERIMENTAL|Phase I-Dose Level 2|Abraxane 150 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
62742612|NCT01555853|EXPERIMENTAL|Phase II|Abraxane (dose to be determined in Phase I) IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
62742613|NCT06303375|EXPERIMENTAL|Kinesio taping along with conventional physical therapy|treatment with moist hot pack along with stretching of tight erector spinae, hip flexors and strengthening of weak abdominals and gluteal muscles along with Kinesiotaping using inhibition and facilitation technique for LCS.
62742614|NCT06303375|ACTIVE_COMPARATOR|conventional physical therapy|Treatment with moist hot pack along with stretching of tight erector spinae, hip flexors and strengthening of weak abdominals and gluteal muscles.
62366111|NCT02137304|EXPERIMENTAL|neuromuscular patients|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)
62366112|NCT06405685|EXPERIMENTAL|Nimotuzumab+AG|Patients will receive Nimotuzumab plus AG as conversion therapy, and imaging assessments (according to RECIST V.1.1 criteria) will be performed every two cycles (every two months) of conversion therapy.
62742615|NCT03773536|EXPERIMENTAL|ASAQ + SLD Primaquine|Artesunate + amodiaquine (WHO prequalified Artesunate/Amodiaquine Winthrop®) was administered orally as a fixed dose combination, at a dose of approximately artesunate 4 mg/kg + amodiaquine 10mg/kg once daily for 3 consecutive days. Primaquine was administered orally, as a single dose (0.25 mg/kg) together with the first artesunate + amodiaquine dose. All doses of medicine were administered under direct supervision. Any patient who vomited within a 30 minute observation period was re-treated with the same dose of medicine and observed for an additional 30 minutes. If the patient vomited again after the second study drug administration, he/she was withdrawn and offered rescue therapy (Artesunate IV).
62742616|NCT03070639|NO_INTERVENTION|Standard Care Study Condition|The Standard of Care control group will not receive any additional services at the newborn visit.
62742617|NCT03070639|ACTIVE_COMPARATOR|Attention-Matched Control Condition|The Attention-Matched Control Condition will include the Scald Prevention Intervention.
62742618|NCT03070639|EXPERIMENTAL|Safe Sleep Intervention Condition|The Intervention Condition will include the Safe Sleep Intervention.
62742619|NCT05872542|EXPERIMENTAL|Silver Diamine Fluoride (SDF)|SDF will be applied once to affected carious teeth surfaces at the end of the first visit. Under proper isolation, only gross debris will be removed and SDF will be applied directly to the carious lesion using micro brush according to the manufacturer's instructions.
62742620|NCT05872542|ACTIVE_COMPARATOR|Glass ionomer restoration (GI)|GI will be applied to carious lesions following the manufacturer's instructions.
62742621|NCT05872542|ACTIVE_COMPARATOR|Sodium Fluoride varnish with silver nano-particles (NaF-AgNP)|NaF-AgNP will be applied once to affected carious teeth surfaces at the end of the first visit. Under proper isolation, only gross debris will be removed and NaF-AgNP will be applied directly to the carious lesion using micro brush according to the manufacturer's instructions.
62742622|NCT03771638|EXPERIMENTAL|DOT Diary Intervention|DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet (once daily)
62742623|NCT03771638|OTHER|DOT Diary Control|Standard of care for Emtricitabine / Tenofovir Disoproxil Oral Tablet (once daily)
62742624|NCT06625138|EXPERIMENTAL|Non-latex band|Non-latex bands will be placed on hemorrhoids during banding
62366113|NCT01674946|PLACEBO_COMPARATOR|ID saline|ID saline by feeding tube
62366114|NCT01674946|ACTIVE_COMPARATOR|ID saline + CDCA (5 mmol/L)|CDCA = chenodeoxycholic acid (primary bile acid)
62366115|NCT01674946|ACTIVE_COMPARATOR|ID + CDCA (15 mmol/L)|CDCA = chenodeoxycholic acid (primary bile acid)
62366116|NCT01674946|ACTIVE_COMPARATOR|ID saline + oleanolic acid (1 mmol/L)|
62366117|NCT01674946|ACTIVE_COMPARATOR|ID saline + CDCA (5 mmol/L) + oleic acid|
62366118|NCT01674946|PLACEBO_COMPARATOR|ID saline + oleic acid (20 mmol/L)|
62366119|NCT04212936|NO_INTERVENTION|Control group|8 mmHg pressure group
62366120|NCT04212936|EXPERIMENTAL|Study group|10 mmHg group
62366121|NCT04595409|EXPERIMENTAL|FYB202 (Proposed ustekinumab biosimilar)|Patients will receive subcutaneous injections of FYB202 as detailed in the protocol.
62742625|NCT06625138|ACTIVE_COMPARATOR|Latex band|latex bands will be placed on hemorrhoids during banding
62742626|NCT02185573|NO_INTERVENTION|Conventional Technique|Multi-layer filling technique
62742627|NCT02185573|ACTIVE_COMPARATOR|Bulk fill technique|Bulk fill technique
62366122|NCT04595409|ACTIVE_COMPARATOR|Stelara® (Ustekinumab)|Patients will receive subcutaneous injections of Stelara® as detailed in the protocol.
62366123|NCT06126406|EXPERIMENTAL|Intravenous of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 3-10x10\^6 cells/kg
62366124|NCT06126406|EXPERIMENTAL|intraperitoneal injection of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg
62366125|NCT04882358|EXPERIMENTAL|GROUP 1 DIRECT SODIUM REMOVAL + SGLT-2 INHIBITOR|SUBJECTS TREATED WITH DSR + STANDARD DOSE OF APPROVED SGLT-2 INHIBITOR
62742628|NCT02185573|EXPERIMENTAL|SonicFill technique|SonicFill technique
62742629|NCT06524635|EXPERIMENTAL|SS 1: Lutikizumab Hidradenitis Suppurativa (HS) Bio-Naïve|HS Bio-naïve participants will receive Lutikizumab Dose A followed by Dose B as part of the 16 week treatment duration.
62366126|NCT04882358|EXPERIMENTAL|GROUP 2 DIRECT SODIUM REMOVAL|SUBJECTS TREATED WITH DSR
62366127|NCT03638713|EXPERIMENTAL|colonoscopy first group|Patients received water-exchange colonoscopy first and followed by esophagogastroduodenoscopy
62366128|NCT03638713|ACTIVE_COMPARATOR|EGD first group|Patients received esophagogastroduodenoscopy first and followed by water-exchange colonoscopy
62366129|NCT00005675|EXPERIMENTAL|1|Participants will receive oral bovine type I collagen (CI) daily for 15 months
62366130|NCT00005675|PLACEBO_COMPARATOR|2|Participants will receive placebo daily for 15 months.
62366131|NCT06347965|NO_INTERVENTION|Routine care group (Control group, CON)|During hospitalization, patients will be given routine exercise and dietary guidance.
62366132|NCT06347965|EXPERIMENTAL|Low load blood flow restriction training group (LL-BFRT)|"On the basis of routine care, participants who meet the inclusion and exclusion criteria will be guided to undergo low-load blood flow restriction training. Based on the constructed Low load Blood Flow Restriction Training Program for Chemotherapy Stage Lung Cancer Patients with Sarcopenia, participants will be guided to undergo low-load blood flow restriction training."
62366133|NCT06347965|ACTIVE_COMPARATOR|Progressive resistance training group (PRE)|"On the basis of routine care, progressive resistance training will be conducted on subjects who meet the inclusion and exclusion criteria, guided by the progressive resistance training program for malignant tumor patients in the ACSM Exercise Testing and Exercise Prescription Guidelines: 10th Edition published by the People's Health Press."
62366134|NCT03499340|EXPERIMENTAL|Text-only PWL, absolute risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
62366135|NCT03499340|EXPERIMENTAL|Text-only PWL, relative risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
62366136|NCT03499340|EXPERIMENTAL|Low arousal graphic PWL, absolute risk|Exposure to FDA-mandated warning labels, paired with a low arousal graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
62366137|NCT03499340|EXPERIMENTAL|Low arousal graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a low arousal graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
62366138|NCT03499340|EXPERIMENTAL|High arousal graphic PWL, absolute risk|Exposure to FDA-mandated warning labels, paired with a high arousal graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
62366139|NCT03499340|EXPERIMENTAL|High arousal graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a high arousal graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
62366140|NCT04673812|ACTIVE_COMPARATOR|Bupivacaine-Fentanyl Spinal Anaesthesia|
62366141|NCT04673812|ACTIVE_COMPARATOR|Bupivacaine-Fentanyl-Naloxone Spinal Anaesthesia|
62366142|NCT04734626||Mitochondrial Disease|Individuals with suspected (based on clinical presentation) or definite genetic mitochondrial disease
62366143|NCT04734626||Healthy Controls/Volunteers|Individuals with no history of suspected (based on clinical presentation) or definite genetic mitochondrial disease
62366144|NCT02372110|EXPERIMENTAL|HPA, ANS stimulation|Oral administration of 400mg caffeine and 20mg hydrocortisone will stimulate HPA axis and ANS activity, respectively
62366145|NCT02372110|PLACEBO_COMPARATOR|Two cellulose placebo capsules|two cellulose capsule filled with acidophilus powder will be administered orally
62366146|NCT01496989|EXPERIMENTAL|Group 1: HIV-MAG followed by Ad35-GRIN/ENV|HIV-MAG (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo = 12/3)
62366147|NCT01496989|EXPERIMENTAL|Group 2: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo=12/3)
62366148|NCT01496989|EXPERIMENTAL|Group 3: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo= 12/3)
62366149|NCT01496989|EXPERIMENTAL|Group 4: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Month 0 followed by Ad35-GRIN/ENV (IM) at Month 4. (Vaccine:Placebo=12/3)
62366150|NCT01496989|EXPERIMENTAL|Group 5: Ad35-GRIN/ENV followed by HIV-MAG+GENEVAX® IL-12|Ad35-GRIN/ENV (IM) at Month 0 followed by HIV-MAG + GENEVAX® IL-12 (IM/EP) at Month 4. (Vaccine:Placebo=12/3)
62366151|NCT01193049|EXPERIMENTAL|Prednisone, then Placebo|Prednisone in the first crossover treatment period and placebo in the second crossover treatment period
62366152|NCT01193049|EXPERIMENTAL|Placebo, then Prednisone|Placebo in the first crossover treatment period and prednisone in the second crossover treatment period
62391492|NCT04794491|EXPERIMENTAL|Open-Label Conversion and Treatment Optimization|Conversion from Xyrem to XYWAV, maintaining the dose and regimen of any concomitant anticataplectics or stimulants unchanged throughout study.
62391493|NCT02027324|EXPERIMENTAL|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
62742630|NCT06524635|EXPERIMENTAL|SS 1: Lutikizumab HS Tumor Necrosis Factor-Inadequate Response|Tumor Necrosis Factor-Inadequate Response (TNF-IR) participants will receive Lutikizumab Dose A followed by Dose B as part of the 16 week treatment duration.
62742631|NCT06524635|EXPERIMENTAL|SS 2: Lutikizumab Atopic Dermatitis (AD) Bio-naïve|AD Bio-naïve participants will receive Lutikizumab Dose C followed by Dose D as part of the 16 week treatment duration.
62366153|NCT04062370|EXPERIMENTAL|1+PRN|"Intravitreal injection of Ranibizumab 0.5 mg (IVR): initial injection for 1 time ( month 1), and then IVR is required if central macular thickness (CMT) greater than 300 μm during the follow-up observation (Pro re nata, PRN, means if necessary).~After 6 months follow-up, patients in this arm will be randomly divided to receive IVR PRN only or laser photocoagulation combined with IVR PRN.~IVR PRN only: patient will receive IVR PRN if CMT greater than 300 μm during the follow-up observation (PRN) after month 6.~Laser photocoagulation with IVR PRN: patient will receive laser photocoagulation for non-perfusion area according to FFA results after month 6, and then received IVR PRN if CMT greater than 300 μm."
62366154|NCT04062370|ACTIVE_COMPARATOR|3+PRN|"Intravitreal injection of Ranibizumab 0.5 mg (IVR): initial injection for 3 consecutive times ( months 1, 2 and 3 ),and then IVR is required if CMT greater than 300 μm during the follow-up observation (PRN).~After 6 months follow-up, patients in this arm will be randomly divided to receive IVR PRN only or laser photocoagulation combined with IVR PRN.~IVR PRN only: patient will receive IVR PRN if CMT greater than 300 μm during the follow-up observation (PRN) after month 6.~Laser photocoagulation with IVR PRN: patient will receive laser photocoagulation for non-perfusion area according to FFA results after month 6, and then received IVR PRN if CMT greater than 300 μm."
62742632|NCT06524635|EXPERIMENTAL|SS 2: Lutikizumab AD Dupilumab-Inadequate Response (IR)|AD Dupilumab-IR participants will receive Lutikizumab Dose C followed by Dose D as part of the 16 week treatment duration.
62366155|NCT05058404|EXPERIMENTAL|Standard arm (A)|"Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).~Patients randomized to Arm A will receive an induction immunochemotherapy at full doses (standard schedule).~After cycle 4, patients will be assessed for response and will complete their planned therapy if at least a stable disease is confirmed.~At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction."
62366156|NCT05058404|EXPERIMENTAL|Experimental arm (B)|"Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).~Patients randomized to Arm B will start their induction treatment with 4 cycles of the immunochemotherapy standard dose chosen by the physician: after cycle 4, patients will be assessed for response and will proceed with subsequent treatment based on the quality of their response. Specifically:~* Patients achieving a CR will receive a shortened treatment: in detail, they won't receive any further chemotherapy but will complete induction with 4 additional cycles of only the Monoclonal Antibody (MoAb) given during the first four cycles;~* In case if response less than CR, (PR,SD), patients will complete treatment as planned for patients in Arm A.~At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction."
62366157|NCT01749800|EXPERIMENTAL|Cognitive test with/without GVS|Subjects with attention span deficits and no significant motor impairments undergo solely a cognitive test. The test is carried out in multiple trials. For some of the trials (randomly selected), subjects receive galvanic vestibular stimulation (GVS). For other trials, subjects received sham GVS. GVS is delivered using a device by A-M Systems.
62366158|NCT01749800|ACTIVE_COMPARATOR|Armeo Spring +GVS|Subjects with both attention span deficits and significant motor impairments undergo robot-assisted upper-limb rehabilitation in combination with galvanic vestibular stimulation (GVS). Robot-assisted training is carried out using the Armeo Spring system by Hocoma AG. GVS is delivered using a device by A-M Systems.
62366159|NCT01749800|SHAM_COMPARATOR|Armeo Spring + sham GVS|Subjects with both attention span deficits and significant motor impairments undergo robot-assisted upper-limb rehabilitation in combination with sham GVS. Robot-assisted training is carried out using the Armeo Spring system by Hocoma AG. Sham stimulation is delivered by connecting the subject to a device by A-M Systems, but the device is not active.
62366160|NCT01934868|EXPERIMENTAL|Prolotherapy Injections|"Each patient will be evaluated clinically and the spinal levels to be injected will be decided upon during each visit. The levels to be injected will largely depend on the pain referral patterns. All prolotherapy injections will be performed under ultrasound guidance.~A prolotherapy solution of 20% dextrose combined with 1% lidocaine will be injected to facet capsular ligaments and interspinous ligaments of the lumbar spine and the posterior sacroiliac ligaments. Six points will be injected in each treatment session. These sessions will be 4 weeks apart."
62366161|NCT01934868|ACTIVE_COMPARATOR|Epidural Steroid Injections (ESI)|Those patients assigned to the ESI group will receive epidural steroid injections with 80mg methylprednisolone and 10mg buvicaine to the interlaminar space. These will be performed 4 weeks apart and under fluoroscopy. The level that will be injected will depend both on the clinical presentation as well as the size of the interlaminar space seen under fluoroscopy.
62366162|NCT00324740|EXPERIMENTAL|Treatment (vorinostat and isotretinoin)|Patients receive oral vorinostat (SAHA) twice daily and oral isotretinoin twice daily on days 3-5, 10-12, 17-19, and 24-26. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62366163|NCT04773847|EXPERIMENTAL|MimetikOss 3D|
62366164|NCT00156013|EXPERIMENTAL|1|Clofarabine 4 mg/m\^2 days 1-5 of every cycle for a maximum of 6 cycles.
62366165|NCT03105661|ACTIVE_COMPARATOR|Treatment Arm|"Patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.~Labetalol Hydrochloride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily"
62366166|NCT03105661|NO_INTERVENTION|Non-treatment Arm|Patients who are randomized to the non-treatment arm will not receive antihypertensive medications.
62366167|NCT04432571|ACTIVE_COMPARATOR|SOC-REC/SOC-OIC|Standard of care - routine education and counseling (SOC-REC)/SOC-Outreach and Intensified Counseling (OIC)
62366168|NCT04432571|EXPERIMENTAL|SOC-REC/CCT|SOC-REC/Conditional Cash Transfer (CCT)
62366169|NCT04432571|EXPERIMENTAL|SOC-REC/IP-NAV|SOC-REC/In-Person Peer Navigation (IP-NAV)
62366170|NCT04432571|EXPERIMENTAL|E-NAV/SOC-OIC|Electronic Navigation/SOC-OIC
62742633|NCT03325868|EXPERIMENTAL|Ulipristal|Ulipristal acetate 5mg daily for 12 weeks
62742634|NCT05866029|ACTIVE_COMPARATOR|60mg of Denosumab treatment|Monotherapy with denosumab injection ( 60mg, subcutaneous injection, semi-annually) for 24 months.
62366171|NCT04432571|EXPERIMENTAL|E-NAV/CCT|E-Nav/Conditional cash transfer
62366172|NCT04432571|EXPERIMENTAL|E-NAV/IP-NAV|E-Nav/In-Person Peer Navigation
62366173|NCT01813968|EXPERIMENTAL|Ischemic postconditioning|"Ischemic postconditioning via the cardioplegia line starting with 2 min of reperfusion followed by 2 min of ischemia x 3"
62366174|NCT01813968|NO_INTERVENTION|Control|Standard operating technique
62366175|NCT02957344||Text without context|
62366176|NCT02957344||Text with context|
62366177|NCT02957344||Map without context|
62366178|NCT02957344||Map with context|
62366179|NCT01038089|EXPERIMENTAL|resveratrol|Resveratrol
62366180|NCT03518034|ACTIVE_COMPARATOR|AndroGel 1.62%|Participants receive topical testosterone starting with a 40.5 mg dose (2 pump actuations) of the study drug once daily (OD). Participants may receive a dose in the range of 20.25 mg (1 actuation) to 101.25 mg (5 actuations) in 20.25 mg increments during the course of the study if titrations are necessary.
62366181|NCT03518034|PLACEBO_COMPARATOR|Placebo|Participants receive matching placebo OD.
62366182|NCT03121456|EXPERIMENTAL|18F-FDG PET SCAN|"REALIZATION OF INITIAL 18F-FDG PET SCAN (PRE THERAPEUTIC), THEN BETWEEN CYCLE 2 DAY 10 AND CYCLE 3 DAY 1~MRI DIFFUSION REALIZATION OF INITIAL MRI DIFFUSION WITHIN 7 DAYS AFTER INITIAL 18F-FDG PET SCAN, THEN WITHIN 7 DAYS AFTER 18F-FDG PET SCAN 1."
62366183|NCT03039569|EXPERIMENTAL|Text messaging|Participants will receive 3 messages weekly consisting of nutrition education and diabetes self-management information and skills for 3 months (12 weeks).
62366184|NCT03039569|NO_INTERVENTION|Control|Participants will not receive text message intervention. This is the measurement-only group
62366185|NCT06451276|ACTIVE_COMPARATOR|Adhesive nasoalveolar molding (GS-NAM)|3D (3 dimensional ) printed conventional NAM in thickness of 2 mm. The cleft area will be blocked in software, and NAM will be fabricated using a 3D (3 dimensional ) printer. Soft acrylic resin will be added to make pressure area and reduction in opposing for relief. The appliance will be evaluated and adjusted monthly. A nasal stent will be fabricated when the cleft is 5mm
62366186|NCT06451276|EXPERIMENTAL|Conventional nasoalveolar molding|(positive control group) comprises 10 cases of unilateral cleft lip and palate that will be scheduled for construction of 3D (3 dimensional ) printed conventional NAM in thickness of 2 mm. The cleft area will be blocked in software, and NAM will be fabricated using a 3D printer. Soft acrylic resin will be added to make pressure area and reduction in opposing for relief. The appliance will be evaluated and adjusted monthly. A nasal stent will be fabricated when the cleft is 5mm
62366187|NCT06451276|NO_INTERVENTION|normal children|normal children which will be compared with groups 1 and 2 for results evaluation
62366188|NCT04248686|NO_INTERVENTION|Control|Referral to standard care - student health center on campus.
62366189|NCT04248686|ACTIVE_COMPARATOR|Intervention|Online, guided self-help ED intervention that offers cognitive behavioral therapy (CBT) based tools to improve ED symptoms, while also teaching the healthy methods of behavioral WL, for individuals with clinical/sub-clinical binge-type EDs with comorbid overweight/obesity.
62366190|NCT05118711||COVID-19 (18 months post-infection)|Individuals with a positive Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) antigen-/polymerase chain reaction (PCR) test within the last 18 months that required hospitalisation. Symptoms typically worsened within a period of 5 to 10 days leading to e.g., prolonged fever, feeling of sickness and/or shortness of breath. This also includes individuals hospitalised in an intensive care ward. Individuals need to be hospitalised due to COVID-19 and not only with COVID-19.
62366191|NCT05118711||Control group|Age-, sex-, and comorbidity-matched (frequency matching), fully vaccinated individuals with no history of symptomatic SARS-CoV-2 infection.
62366192|NCT03869216|EXPERIMENTAL|Intervention|Patients in the intervention will receive the educational intervention
62366193|NCT03869216|NO_INTERVENTION|Usual Care|Patients in the control arm will receive usual care
62366194|NCT02253472|EXPERIMENTAL|Deep Brain Stimulation|Stimulation is on.
62366195|NCT02253472|SHAM_COMPARATOR|Placebo|Stimulation is off.
62366196|NCT05402722|EXPERIMENTAL|Eribulin in combination with anti-PD-1 antibody|Participants receive eribulin1.4mg/m2 and anti-PD-1 antibody intravenously (IV) every 3 weeks (Q3W) .
62366197|NCT02167412||Syncope without POTS|Patients meeting syncope criteria without POTS. There will be no intervention for this study arm.
62366198|NCT02262338|EXPERIMENTAL|Treated subjects|AGT-182 solution for infusion will be administered intravenously at doses of 1.0 mg/kg or 3.0 mg/kg weekly for 8-13 weeks.
62366199|NCT01027572|EXPERIMENTAL|Thalamic stimulation|Patients in Vegetative or Minimally Conscious State
62366200|NCT05610969|ACTIVE_COMPARATOR|Music group|self-selected music
62366201|NCT05610969|ACTIVE_COMPARATOR|Midazolam group|IV midazolam (1mg to 2mg max)
62366202|NCT01770756|EXPERIMENTAL|Enhancing willpower using active skills|This group will use active tasks such as learning skills using hands to enhance willpower.
62366203|NCT01770756|EXPERIMENTAL|Enhancing willpower using passive tasks|This group will use passive tasks such as taking still postures to enhance willpower.
62366204|NCT02027974|ACTIVE_COMPARATOR|Iconacy Hip System|Iconacy hip system prosthesis components
62366205|NCT02027974|ACTIVE_COMPARATOR|Stryker Accolade Hip System|Stryker Accolade hip system prosthesis components
62366206|NCT02323399|EXPERIMENTAL|Phenylephrine|Phenylephrine Hydrochloride Injection, USP (United States Pharmacopeia) 10 mg/mL label claim
62366207|NCT02004925||Pneumoperitoneum|Patients with a diagnosis of pneumoperitoneum by CT or surgery
62366208|NCT02004925||no pneumoperitoneum|patients with acute abdominal pain with a diagnosis other than pneumoperitoneum in whom pneumoperitoneum was excluded by CT or surgery
62366209|NCT01379560|EXPERIMENTAL|unoprostone isopropyl (2 drop)|
62366210|NCT01379560|EXPERIMENTAL|unoprostone isopropyl (3 drop)|
62366211|NCT01228981||Type-2 Diabetic Retinopathy|
62366212|NCT03049943|ACTIVE_COMPARATOR|Laser wavelength of 830 nm|This group comprised 15 female patients with hyposalivation whose major salivary glands were treated for 10 consecutive days with low level laser therapy of 830 nm.The whole unstimulated and stimulated saliva was measured each day during 10 days, before and after laser treatment and 10th day after treatment was ended.
62391494|NCT02027324|EXPERIMENTAL|Povidone-Iodine group|10% Povidone-iodine applied topically according to manufacturer's instructions
62366213|NCT03049943|EXPERIMENTAL|Laser wavelength of 685 nm|This group comprised 15 female patients with hyposalivation whose major salivary glands were treated for 10 consecutive days with low level laser therapy of 685 nm.The whole unstimulated and stimulated saliva was measured each day during 10 days, before and after laser treatment and 10th day after treatment was ended.
62366214|NCT01209806|ACTIVE_COMPARATOR|simethicone|
62366215|NCT01209806|NO_INTERVENTION|no simethicone|
62366216|NCT01766245|EXPERIMENTAL|Formulation A followed by Formulation B|
62366217|NCT01766245|ACTIVE_COMPARATOR|Formulation B followed by Formulation A|
62366218|NCT05022641|EXPERIMENTAL|PTeye|The surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
62366219|NCT05022641|NO_INTERVENTION|Standard of Care|The surgeon will rely solely on her/his surgical experience in identifying the parathyroid glands during the operations.
62366220|NCT05136040|ACTIVE_COMPARATOR|Group İzobarik bupivakain (5 mg) + fentanil|Patients were given a solution containing 5 mg isobaric bupivacaine + 15 µg fentanyl (1.3 ml)
62366221|NCT05136040|ACTIVE_COMPARATOR|Group İzobarik bupivakain (7 mg) + fentanil|Patients were givena solution containing 7 mg isobaric bupivacaine + 15 µg fentanyl (1.7 ml)
62366222|NCT02062372|EXPERIMENTAL|Biopsy|Subjects will receive a 7 T MRI and one additional biopsy to their standard diagnostic biopsies
62366223|NCT06025084|ACTIVE_COMPARATOR|first group (A1)|About 24 patients hypersensitive teeth. So the hypersensitive teeth will be treated with egg shell nanoparticles
62366224|NCT06025084|ACTIVE_COMPARATOR|second group (A2)|About 24 patients hypersensitive teeth. treated with the combination therapy of eggshell and TiO2.
62366225|NCT02542813|EXPERIMENTAL|IM oxytocin - IH placebo/IH oxytocin (50, 200, 400, 600)|Subjects will receive IM oxytocin, IH placebo/IH oxytocin at doses of 50, 200, 400, 600 mcg.
62366226|NCT02542813|EXPERIMENTAL|IM oxytocin - IH placebo/IH oxytocin (50)|Subjects will receive IM oxytocin and IH placebo and/or IH oxytocin at 50 mcg.
62366227|NCT02294669|EXPERIMENTAL|Turris Facet Fuser|
62366228|NCT05702372|EXPERIMENTAL|Glucose as reference food|Eleven healthy, normal body weight adults (male: 4, female: 7) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g of available carbohydrates from crackers made by wheat, rye and sunflower flours, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62366229|NCT05702372|EXPERIMENTAL|Cracker made by wheat flour|Eleven healthy, normal body weight adults (male: 4, female: 7) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g of available carbohydrates from crackers made by wheat, rye and sunflower flours, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62366230|NCT05702372|EXPERIMENTAL|Cracker made by rye flour|Eleven healthy, normal body weight adults (male: 4, female: 7) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g of available carbohydrates from crackers made by wheat, rye and sunflower flours, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62366231|NCT05702372|EXPERIMENTAL|Cracker made by sunflower flour|Eleven healthy, normal body weight adults (male: 4, female: 7) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g of available carbohydrates from crackers made by wheat, rye and sunflower flours, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62366232|NCT05750485||Pupilometric evaluation under procedural sedation with propofol|
62366233|NCT01068613|EXPERIMENTAL|QAX028 high dose|
62366234|NCT01068613|EXPERIMENTAL|QAX028 low dose|
62366235|NCT01068613|ACTIVE_COMPARATOR|Tiotropium|
62366236|NCT01068613|PLACEBO_COMPARATOR|Placebo|
62366237|NCT00322387|EXPERIMENTAL|Plerixafor PM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. After the first apheresis, plerixafor (240 µg/kg) was administered each evening (approximately 10pm) followed by apheresis 10 to 11 hours later for up to 4 consecutive days.~Called 'Cohort A' in protocol, study report and publications."
62366238|NCT00322387|EXPERIMENTAL|Plerixafor AM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. The morning of the second day after the first apheresis, plerixafor (240 µg/kg) was administered followed by apheresis 6 hours later. Plerixafor (240 µg/kg) was administered in the morning followed by apheresis 6 hours later for up to 4 consecutive days.~Called 'Cohort B' in protocol, study report and publications."
62366239|NCT00322387|EXPERIMENTAL|Low CD34+ Count/ Plerixafor PM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. If participants had a CD34+ count of \>=10 cells/µL but \<20 cells/µL on 2 consecutive days, plerixafor (240 µg/kg) was given in the evening. G-CSF was administered and apheresis performed in the morning. Plerixafor (240 µg/kg) administered in the evening followed by G-CSF and apheresis 10 to 11 hours later was repeated for up to 4 consecutive days.~Called 'Cohort C' in protocol, study report and publications."
62552792|NCT02185079|ACTIVE_COMPARATOR|Group C|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm. Access to epidural simulator for 2 days will be given.
62366240|NCT00322387|EXPERIMENTAL|Plerixafor After Chemo|"This investigational cohort evaluated the effect of administering plerixafor before white blood cell recovery.~Participants received mobilizing chemotherapy, followed by 5 consecutive days of G-CSF (10 µg/kg). Starting on the sixth day, participants received G-CSF (10 µg/kg) plus plerixafor (240 µg/kg) daily for up to 3 consecutive days. If CD34+ counts reached \>= 20 cells/µL 6 hours after any of the 3 plerixafor doses, apheresis began. If not, G-CSF administration continued until the participant qualified for one of the other treatment arms.~Called 'Investigational Cohort' in protocol, study report and publications."
62366241|NCT06350357|EXPERIMENTAL|punching closure|punching closure for defect closure after ESD
62366242|NCT06350357|ACTIVE_COMPARATOR|Conventional clipping|Conventional clipping for defect closure after ESD
62366243|NCT02394223||Full Field Optical Coherence Tomography (FFOCT) procedure|
62366244|NCT03510910|EXPERIMENTAL|Acetaminophen along with a reduced quantity of Percocet|
62366245|NCT03510910|EXPERIMENTAL|Percocet only|
62366246|NCT03379441|EXPERIMENTAL|Experimental|"Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3 week cycle until:~* PD,~* unacceptable toxicity,~* investigator choice,~* patients IC withdrawal,~* up to a maximum of 24 months (35 administrations) Experimental"
62366247|NCT03379441|NO_INTERVENTION|Observation|
62366248|NCT00470678|EXPERIMENTAL|1|Ranibizumab
62366249|NCT02975349|EXPERIMENTAL|Placebo then Evobrutinib 25 mg QD|Participants who received placebo matched to Evobrutinib tablet orally for 24 weeks in active treatment period 1 received Evobrutinib 25 milligram (mg) orally, once daily (QD) in blinded extension (BE) period from week 25 to week 48.
62366250|NCT02975349|EXPERIMENTAL|Evobrutinib 25 mg QD|Participants received Evobrutinib 25 mg orally, QD up to Week 48 in active treatment period 1 and BE period.
62366251|NCT02975349|EXPERIMENTAL|Evobrutinib 75 mg QD|Participants received Evobrutinib 75 mg orally, QD up to Week 48 in active treatment period 1 and BE period.
62366252|NCT02975349|EXPERIMENTAL|Evobrutinib 75 mg BID|Participants received Evobrutinib 75 mg orally, twice daily (BID) up to Week 48 in active treatment period 1 and BE period.
62366253|NCT02975349|ACTIVE_COMPARATOR|Tecfidera|Participants received Tecfidera 120 mg twice daily (BID) for first 7 days followed by 240 mg orally, BID up to Week 48 in active treatment period 1 and BE period.
62366254|NCT02975349|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to Evobrutinib tablet orally for 24 weeks in active treatment period 1.
62366255|NCT00445341|EXPERIMENTAL|Flavopiridol in lymphoma patients|Flavopiridol 30 mg/m\^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
62366256|NCT05318040|EXPERIMENTAL|Single ascending dose - CMS121|Subjects will receive a single oral dose of CMS121 under fed conditions.
62366257|NCT05318040|PLACEBO_COMPARATOR|Single ascending dose - placebo|Subjects will receive a single oral dose of placebo under fed conditions.
62366258|NCT05318040|EXPERIMENTAL|Multiple ascending dose - CMS121|Subjects will receive multiple oral doses of CMS121 once daily (QD) for 7 days under fed conditions.
62366259|NCT05318040|PLACEBO_COMPARATOR|Multiple ascending dose - placebo|Subjects will receive multiple oral doses of placebo once daily (QD) for 7 days under fed conditions.
62366260|NCT05318040|EXPERIMENTAL|Multiple ascending dose - Elderly cohort - CMS121|Subjects will receive multiple oral doses of CMS121 once daily (QD) for 7 days under fed conditions.
62366261|NCT05318040|PLACEBO_COMPARATOR|Multiple ascending dose - Elderly cohort - placebo|Subjects will receive multiple oral doses of placebo once daily (QD) for 7 days under fed conditions.
62366262|NCT05318040|EXPERIMENTAL|Food Effect - CMS121|On Day 1 of each of 2 treatment periods, a single oral dose of CMS121 will be administered following either a standard high fat/high calorie meal (Treatment A) or an overnight fast (Treatment B), as per each subject's assigned randomization sequence (AB or BA). There will be a washout of at least 7 days between doses.
62366263|NCT04841850||Hazelnut allergic children under oral immunotherapy|"* Children Under eighteen years of age~* Convincing clinical history of hazelnut allergy~* Positive hazelnut prick test or specific IgE~* Under IOT hazelnut protocol in pneumology and allergology-paediatric departement of the Mother and Child Hospital in Bron"
62366264|NCT05248646|ACTIVE_COMPARATOR|Sibeprenlimab 400 mg s.c. q 4weeks|
62742635|NCT05866029|EXPERIMENTAL|Teriparatide was sequentially treated with Denosumab|"1. Treatment with teriparatide injection ( 20ug, subcutaneous injection, once daily) for 6 months, followed by discontinuation of teriparatide and change to denosumab injection ( 60mg, subcutaneous injection, once every six months) and continued until the 24th month.~2. Treatment with teriparatide injection ( 20ug, subcutaneous injection, once daily) for 12 months, followed by discontinuation of teriparatide and change to denosumab injection ( 60mg, subcutaneous injection, semi-annually) treatment continued until the 24th month."
62742636|NCT05841888||Group 1|standard perioperative care (SC)
62366265|NCT05248646|PLACEBO_COMPARATOR|Placebo|
62366266|NCT06244719|EXPERIMENTAL|Vibrotactile Stimulation|Participants wear vibrotactile stimulation shirts and gloves for 5 hours per day, 7 days per week, during their stay at the rehabilitation unit, which is expected to be between 2-3 weeks. Participants wear the devices after conventional therapy is done for the day.
62366267|NCT06244719|NO_INTERVENTION|Control|Participants undergo conventional therapy only.
62366268|NCT02953067|ACTIVE_COMPARATOR|Open reduction and internal fixation|After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
62366269|NCT02953067|ACTIVE_COMPARATOR|Primary Arthrodesis|After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
62552793|NCT02185079|EXPERIMENTAL|Group M|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm as well.Trainees in this arm in addition will be subjected to training to proficiency based on the metrics developed for labor epidural catheter placement in a epidural simulator.
62552794|NCT01822717|EXPERIMENTAL|Nonvisual foot inspection|Instruction for nonvisual foot inspection included in comprehensive diabetes self-management education
62742637|NCT05841888||Group 2|Enhanced Recovery after Surgery (ERAS)
62366270|NCT02953067|ACTIVE_COMPARATOR|Conservative treatment|Non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
62366271|NCT00739960|OTHER|Abatacept|
62366272|NCT05793684|EXPERIMENTAL|Order: Period A, Period B, Period C|The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
62366273|NCT05793684|EXPERIMENTAL|Order: Period B, Period C, Period A|The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
62366274|NCT05793684|EXPERIMENTAL|Order: Period C, Period A, Period B|The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
62366275|NCT05793684|EXPERIMENTAL|Order: Period A, Period C, Period B|The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
62366276|NCT05793684|EXPERIMENTAL|Order: Period B, Period A, Period C|The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
62366277|NCT05793684|EXPERIMENTAL|Order: Period C, Period B, Period A|The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
62366278|NCT04645004|OTHER|Aspirin|81mg aspirin daily
62366279|NCT01039311||Optical Coherence Tomography|Examine OCT images and compare them to conventional biopsies in same subject.
62366280|NCT00110591|PLACEBO_COMPARATOR|Placebo|Intravenous placebo for PRO 140
62366281|NCT00110591|EXPERIMENTAL|PRO 140 dose 1|0.1 mg/kg PRO 140 by intravenous infusion
62366282|NCT00110591|EXPERIMENTAL|PRO 140 dose 2|0.5 mg/kg PRO 140 by intravenous infusion
62366283|NCT00110591|EXPERIMENTAL|PRO 140 dose 3|2.0 mg/kg PRO 140 by intravenous infusion
62366284|NCT00110591|EXPERIMENTAL|PRO 140 dose 4|5.0 mg/kg PRO 140 by intravenous infusion
62366285|NCT00798473|EXPERIMENTAL|1|Zoledronic acid, 0.06 mg/kg IV in a single infusion, maximum of 4 mg
62366286|NCT00798473|PLACEBO_COMPARATOR|2|IV saline infusion
62366287|NCT00572728|EXPERIMENTAL|Diagnostic (18F-FLT)|Patients undergo 18F-FLT PET /CT at baseline (prior to chemotherapy, FLT-1), early therapy (5-10 days after the initiation of the first course of chemotherapy, FLT-2), and post therapy (within 3 weeks prior to surgery, FLT-3). Patients undergo standard surgical resection of residual tumor following completion of neoadjuvant chemotherapy.
62366288|NCT05843591||Aerobic Exercise group|Participants in the aerobic exercise (AE) group were asked to perform moderate to high intensity regular aerobic exercise. Exercise was required 3 times per week for at least 1 hour each time. At the beginning of the exercise, they were required to sign in at the research personnel, and at the end of the exercise, they were also required to sign out at the research personnel. However, there was no restriction on the type of exercise, which could be running, basketball, badminton, table tennis, tennis, rope skipping, dancing, etc.; there was no restriction on the form of exercise, which could be individual or group exercise; there was no restriction on the period of exercise start, which could be any time of the day to start exercise.
62366289|NCT05843591||Tai Chi Chuan group|Participants in the Tai Chi Chuan (TCC) group attended an 8-week Tai Chi training program, which consists of 24-form Tai Chi and Bafa Wubu of Tai Chi. Certified instructors administer and guide Tai Chi Chuan activities. We set up 6 Tai Chi Chuan classes each week, and participants in the Tai Chi Chuan group can participate in any 3 of the 6 classes each week to be considered as completing the task. Each 1-hour training session consists of a brief warm-up stretching session followed by standard Tai Chi routine activities.
62366290|NCT05843591||Wait-List Control group|Participants in the wait-list control (WLC) group received no intervention in addition to their usual physical education classes.
62366291|NCT02740712|OTHER|single arm probe drugs and rucaparib|Caffeine Warfarin Vitamin K Omeprazole Midazolam Digoxin rucaparib
62366292|NCT05693103||Urinary Incontinence|Stress Urinary Incontinence Urge incontinence
62366293|NCT01496404|EXPERIMENTAL|Electrocautery|Epidermis and dermis incised with cutting setting of electrocautery.
62366294|NCT01496404|ACTIVE_COMPARATOR|Scalpel|Control, incision of epidermis and dermis with scalpel.
62366295|NCT00524667|EXPERIMENTAL|1|
62366296|NCT00571519|EXPERIMENTAL|1|rivoglitazone HCl 0.5mg
62366297|NCT00571519|EXPERIMENTAL|2|rivoglitazone HCl 1.0 mg
62366298|NCT00571519|EXPERIMENTAL|3|rivoglitazone HCl 1.5 mg
62366299|NCT00571519|PLACEBO_COMPARATOR|4|placebo matching rivoglitazone HCl tablets
62366300|NCT00571519|ACTIVE_COMPARATOR|5|pioglitazone HCl 15 mg
62366301|NCT00571519|ACTIVE_COMPARATOR|6|pioglitazone HCl 30 mg
62366302|NCT00571519|ACTIVE_COMPARATOR|7|pioglitazone HCl 45 mg
62366303|NCT00571519|PLACEBO_COMPARATOR|8|matching placebo for pioglitazone
62366304|NCT00969488|EXPERIMENTAL|high protein diet group|"Women in high protein diet will be stimulate to consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group. The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats). The experimental groups will also receive six cans of sardine to increase the women's commitment to the study.~Both women group will receive a nutritional plan based on an 1800 kcal diet."
62366305|NCT00969488|ACTIVE_COMPARATOR|normal protein diet group|The control group will receive a diet to lose weight with norma protein intake and will receive 2kg of pasta to increase the women's commitment to the study. The nutritional plan based on an 1800 kcal diet.
62366306|NCT05244941||Cross site-case study|Qualitative methods: semi-structured interviews for patients, front line clinical practitioners, and health system stakeholders, case study building across sites
62366307|NCT06180733|EXPERIMENTAL|Primary MMRd endometrial cancer patients|
62366308|NCT04742036|EXPERIMENTAL|capivasertib|single-dose and multiple-dose capivasertib as monotherapy (Part A) and then in combination with paclitaxel (Part B)
62366309|NCT05076097|EXPERIMENTAL|Orelabtutinib in combination of rituximab and lenalidomide(OLR) Arm|Induction phase of mantle cell L lymphoma: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1
62366310|NCT00247273|ACTIVE_COMPARATOR|1|5 mg risedronate, once daily for 2 years
62366311|NCT00247273|EXPERIMENTAL|2|150 mg risedronate taken once a month for 2 years
62366312|NCT03486561|OTHER|Ranolazine|Ranolazine was approved by the U.S. Food and Drug Administration in 2006 in 500 mg and 1000 mg extended-release doses, advising 500 mg BID as a starting dose and 1000 mg BID as maximum dose
62366313|NCT00530491|ACTIVE_COMPARATOR|1|conventional perioperative management for lung surgery
62366314|NCT00530491|EXPERIMENTAL|2|fast track management for lung surgery
62366315|NCT04909294|EXPERIMENTAL|stereotaxic external radiation therapy|
62366316|NCT01807091|EXPERIMENTAL|Treatment (chemotherapy)|Participants received intensive initial or salvage induction chemotherapy regimens. These regimens would usually be administered in the inpatient setting, however participants received them outpatient. This study did not dictate the choice of induction chemotherapy regimen. The regimen was decided upon by patient and their treating oncologist and clinical care team. The induction chemotherapy regimens administrations spanned 4-7 days.
62366317|NCT02970539|EXPERIMENTAL|Oraxol +Ramucirumab|"Oraxol (oral HM30181 + oral paclitaxel)~* HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets~* Paclitaxel - supplied as 30-mg capsules Ramucirumab - supplied as a solution at a concentration of 10 mg/mL"
62366318|NCT02106104|EXPERIMENTAL|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
62366319|NCT02106104|ACTIVE_COMPARATOR|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
62366320|NCT02136550|EXPERIMENTAL|Smoking cessation|36 smokers will participate in the study and will be evaluated at baseline, 6 months e 12 months of the smoking cessation program. If they quit the program, they will be asked to continue the study.
62366321|NCT01870791|EXPERIMENTAL|Omegaven|Omegaven in combination with EOX chemotherapy
62366322|NCT03787095|EXPERIMENTAL|Cohort 1: Cemiplimab|"Participants received 0.3 mg/kg of cemiplimab, administered at Day 0 and Week 6 for a total of two infusions.~Participants continued their current non-study provided ART regimen."
62366323|NCT03787095|PLACEBO_COMPARATOR|Cohort 1: Placebo|"Participants received placebo, administered at Day 0 and Week 6 for a total of two infusions.~Participants continued their current non-study provided ART regimen."
62366324|NCT01574417|EXPERIMENTAL|Plant stanol-enriched margarine|
62366325|NCT01574417|PLACEBO_COMPARATOR|control margarine|
62366326|NCT02668952|ACTIVE_COMPARATOR|Normal Saline group|0.9% Normal Saline (0.9% Sodium Chloride) injection intravenously as needed. The amount administered (dosage, frequency, and duration) will be left to the clinical judgment of the attending physicians, and will follow usual patterns of use in cardiac surgery patients.
62742638|NCT02692768|ACTIVE_COMPARATOR|Live Music Therapy|Live sedative guitar playing within a limited chord progression will be utilized. Added to this music will be vocal and verbal therapeutic suggestion for active listening, focused breathing, muscle relaxation, and guided imagery. Patients will choose from one of three nature scene options for the guided imagery in order to include patient preference of content. This treatment group will experience this music intervention live, including patient-centered interaction with the music therapist and education for repeated use of the routine on recording.
62742639|NCT02692768|ACTIVE_COMPARATOR|Recorded Music Therapy|Recorded sedative guitar playing within a limited chord progression will be utilized. Added to this music will be vocal and verbal therapeutic suggestion for active listening, focused breathing, muscle relaxation, and guided imagery. Patients will choose from one of three nature scene options for the guided imagery in order to include patient preference of content. This treatment group will be given a recording of their chosen music relaxation routine for use throughout the study process.
62742640|NCT02692768|ACTIVE_COMPARATOR|Control|This group will receive standard of care with no music therapy intervention
62742641|NCT02621151|EXPERIMENTAL|Pembrolizumab, Gemcitabine, and RT|"* Lead-in single dose Pembrolizumab 200 mg, intravenously (IV)~* Transurethral Resection of Bladder Tumor (TURBT) at pre-RT (maximal) and completion of therapy (diagnostic)~* External Beam Radiation Therapy (EBRT) - 52 Gy in 20 fractions over 4 weeks (1 fraction = 2.6 Gy)~* Gemcitabine 27 mg/m\^2 IV twice weekly for 4 weeks concurrent with EBRT~* Pembrolizumab 200 mg IV every 3 weeks for total 3 doses starting day 1 of EBRT"
62742642|NCT05420311|EXPERIMENTAL|A balanced hypocaloric diet in macronutrients (MedDiet).|Mediterranean diet based on olive oil as main fat and regular consumption of vegetables (2 daily rations), fruits (3 daily rations), legumes (3 weekly rations), fish (3 weekly rations), with low consumption of red meat and meat products (less than twice a week), dairy foods (less than once a week) and no sweets, pastries or sugary drinks. Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein distributed in at least 4 meals (breakfast, lunch, afternoon snack and dinner).
62366327|NCT02668952|EXPERIMENTAL|Isolyte group|Isolyte S (B Braun, Irvine CA) injection intravenously as needed. The amount administered (dosage, frequency, and duration) will be left to the clinical judgment of the attending physicians, and will follow usual patterns of use in cardiac surgery patients. Isolyte S is a prepackaged solution containing sodium chloride 0.53%, sodium gluconate 0.5%, sodium acetate trihydrate 0.37%, potassium chloride 0.037%, and magnesium chloride hexahydrate 0.03% w/v.
62366328|NCT03375970|EXPERIMENTAL|Collaborative Care of TCM and Western Medicine|
62366329|NCT03375970|ACTIVE_COMPARATOR|Western Medicine|
62366330|NCT05936346|EXPERIMENTAL|Lower dose (175mg)|The study intervention consists of a single daily oral intake 175 mg of Salvia haenkei as soft capsule over a period of 3 months.
62366331|NCT05936346|EXPERIMENTAL|Higher dose (350mg)|The study intervention consists of a single daily oral intake 350 mg of Salvia haenkei as soft capsule over a period of 3 months.
62366332|NCT04314609|EXPERIMENTAL|Ultrasound , fluroscope|After injection of corticosteroids with 1 ml contrast in sacroiliac joint using ultrasound and withdrawal of the needle, an antero-posterior fluoroscopy image will be obtained and recorded for the injected joint to detect the spread pattern of the contrast and whether its pre-dominantly intra or periarticular.
62366333|NCT00381589|EXPERIMENTAL|A|Random assignment to investigational spray
62366334|NCT01769482|EXPERIMENTAL|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg or placebo po q d for 3 months.
62366335|NCT01769482|PLACEBO_COMPARATOR|Placebo|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg or placebo po q d for 3 months.
62366336|NCT02447640|EXPERIMENTAL|Part 1|A receptor occupancy dose curve will be obtained by using an adaptive design in this arm.
62366337|NCT02447640|EXPERIMENTAL|Part 2|In this arm, the time course of the receptor occupancy will be studied for the dose which gives 70% receptor occupancy as determined in Part 1.
62366338|NCT04880681|EXPERIMENTAL|Novel needle|Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator.
62366339|NCT04880681|ACTIVE_COMPARATOR|Standard Tru Cut needle|Standard tru cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000).
62366340|NCT02167724|EXPERIMENTAL|Patients with schizophrenia|
62366341|NCT01376895|EXPERIMENTAL|POWER|Power is a 3 session intervention delivered through the internet in real time by a trained health educator. It focuses on reducing HIV risk. Each session last from 1 to 2 hours.
62366342|NCT01376895|ACTIVE_COMPARATOR|Power Health|Power Health is a 1 session general health promotion program designed to be delivered via the internet in real time by a trained health educator. The sessions focus on healthy life styles, cardiovascular health, and prostate health. Participants also receive information regarding safe sex.
62366343|NCT05460390|EXPERIMENTAL|TDM based adalimumab dose optimization group|Therapeutic drug monitoring (TDM) provides an opportunity for a proactive and individualized therapy optimization based on serum drug concentration and anti-drug antibodies development.
62366344|NCT05460390|NO_INTERVENTION|Standard of care|Standard of care practice for RA management is based on disease activity guided therapy adjustments.
62366345|NCT01425645|ACTIVE_COMPARATOR|Lifestyle and behavioural change support|Interventional arm will be offered a 12 month lifestyle program translating DM prevention issues to the family milieu
62366346|NCT01425645|NO_INTERVENTION|control|Control arm will receive standard diabetes prevention care as outlined in the current Canadian diabetes association Clinical Practice Guidelines.
62366347|NCT05618327|EXPERIMENTAL|JS203|
62366348|NCT03953885|EXPERIMENTAL|Fire needle group|Participants in experimental group will receive Fire needle therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
62366349|NCT03953885|PLACEBO_COMPARATOR|Fire needle placebo group|Participants in experimental group will receive Fire needle placebo therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
62366350|NCT02562027|EXPERIMENTAL|High-risk NSCLC participants|"* Baseline assessment of demographics and comorbidities~* Comorbidity scoring by interview and chart review: the Adult Comorbidity Evaluation 27, Charlson Comorbidity Index, Global Initiative for Chronic Obstructive Lung Disease, Cumulative Illness Rating Scale, and COMorbidities in Chronic Obstructive Lung Disease.~* Katz Activities of Daily Living: assessment of grip strength, walk speed, and activities of daily living~* HRQOL questionnaires will also be administered prior to treatment and then repeated throughout follow-up: the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30, EORTC QLQ-LC13, Modified Medical Research Council, EQ-5D, CES-D, and Medical Outcomes Study Social Support Survey.~* All questionnaire responses will be obtained with the use of a computer assisted interview system which can be used to collect data in person or through telephone interviews"
62366351|NCT06360536|EXPERIMENTAL|Intervention/Treatment|A home-based resistance training condition that is delivered through a web-based platform.
62366352|NCT05793112|EXPERIMENTAL|INF108F|INF108F
62366353|NCT05793112|PLACEBO_COMPARATOR|Placebo|Placebo
62366354|NCT01975675|EXPERIMENTAL|LDV/SOF (treatment naive)|Treatment-naive participants will receive LDV/SOF for 12 weeks.
62366355|NCT01975675|EXPERIMENTAL|LDV/SOF+RBV (treatment naive)|Treatment-naive participants will receive LDV/SOF plus RBV for 12 weeks.
62366356|NCT01975675|EXPERIMENTAL|LDV/SOF (treatment experienced)|Treatment-experienced participants will receive LDV/SOF for 12 weeks.
62366357|NCT01975675|EXPERIMENTAL|LDV/SOF+RBV (treatment experienced)|Treatment-experienced participants will receive LDV/SOF plus RBV for 12 weeks.
62366358|NCT03676205|EXPERIMENTAL|Platelet-Rich Plasma|"24-72 hours after having a muscular lesion, the doctor injects an intramuscular ecoguided infiltration of 6-7 ml of PRP .~After 4-5 days from the injury the patient starts physiotherapy adapted by stages, according to the muscular group affected.~After 7 days from the first infiltration, the patient will recived the second infiltration of 6-7 ml of PRP."
62366359|NCT03676205|OTHER|Traumel ®|"24-72 hours after having a muscular lesion, the doctor injects an intramuscular ecoguided infiltration of 4 ml of a homeopathic product (Traumeel ®) After 4-5 days from the date of injury, the patient starts physiotherapy adapted by stages, according to the muscular group affected.~After 7 days from the first infiltration, the patient will receive the second infiltration of 4 ml of a homeopathic product."
62366360|NCT02482649|EXPERIMENTAL|EAA/T|EAA/TEquine-Assisted Activities and Therapy) bi-weekly for 12eeks
62366361|NCT02482649|ACTIVE_COMPARATOR|Drugs|Methylphenidate or Atomoxetine
62366362|NCT06021847|ACTIVE_COMPARATOR|Group I patients treated with ozonated water|The patients were used ozonated water as mouth wash for treatment of denture associated oral stomatitis.
62366363|NCT06021847|ACTIVE_COMPARATOR|Group II patients treated with chlorhexidine mouthwash|The patients were used chlorhexidine mouth wash for treatment of denture associated oral stomatitis
62366364|NCT00723853|EXPERIMENTAL|Group 1|Reach-Out Program, Nutritional and Exercise Intervention
62366365|NCT00723853|ACTIVE_COMPARATOR|Group 2|Reach-In Program, Standard of Care
62366366|NCT01291706||Mild TBI with mild lesions on CT scan|Negative predictive value of transcranial doppler for patients with mild to moderate traumatic brain injury and mild brain lesions on initial CT scan (TCDB II)
62366367|NCT02551913|ACTIVE_COMPARATOR|control|The adolescents will not receive any specific information
62366368|NCT02551913|EXPERIMENTAL|Intervention|The adolescents will receive relevant information on the importance of adequate sleep, the consequences of sleep deprivation, Provide information about others' approval,Provide normative information about others' behaviour,Goal setting ,action planning, coping planning, Set graded tasks,Prompt self-monitoring of sleep behaviour
62366369|NCT03554304|EXPERIMENTAL|WCK 5222|WCK 5222 IV solution administered as either a 30- or 60-minute IV infusion)
62366370|NCT03554304|PLACEBO_COMPARATOR|Placebo (IV placebo matched toWCK 5222IV solution)|placebo capsule matched to moxifloxacin overencapsulated tablet IV placebo matched to WCK 5222 IV solution
62366371|NCT03554304|ACTIVE_COMPARATOR|Moxifloxacin 400-mg|positive control
62366372|NCT02342613|EXPERIMENTAL|MILs treatment|Patients treated with the activated PTCy-MILs
62366373|NCT00714337|EXPERIMENTAL|1|fasting state
62366374|NCT00714337|EXPERIMENTAL|2|fasting state
62366375|NCT00714337|EXPERIMENTAL|3|non-fasting state
62366376|NCT00714337|EXPERIMENTAL|4|fasting state
62366377|NCT00714337|EXPERIMENTAL|5|non-fasting state
62366378|NCT05932381|EXPERIMENTAL|Complete decongestive therapy|the patients will receive complete decongestive therapy twice a week for ten weeks
62366379|NCT05932381|ACTIVE_COMPARATOR|medical treatment|the patients will receive routine medical treatment for ten weeks
62366380|NCT06400693|OTHER|Template|Template is provided to prepare necessary equipment for emergency airway management
62366381|NCT06400693|OTHER|No template|No template is provided to prepare necessary equipment for emergency airway management
62366382|NCT06382961|EXPERIMENTAL|Experiment|
62366383|NCT06382961|ACTIVE_COMPARATOR|Control|
62742643|NCT05420311|EXPERIMENTAL|A very low carbohydrate diet (KetoDiet).|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein
62742644|NCT05420311|EXPERIMENTAL|An intermittent fasting (IF) approach.|In this diet subjects alternate norm caloric diet during 24 h (according to Harris-Benedict equation) and a diet including only 25% of caloric requirements the following 24 h (this day diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein).
62366384|NCT05185219|EXPERIMENTAL|Valerian|generic name: XIE CAO CONC dosage form: capsule dosage: 500 mg/capsule, 6 capsules a day frequency: 3 times a day after each meal, 2 capsules each time duration: 30 days
62366385|NCT05185219|PLACEBO_COMPARATOR|Control|generic name: placebo (Caramel Colors dyed starch) dosage form: capsule dosage: 500 mg/capsule, 6 capsules a day frequency: 3 times a day after each meal, 2 capsules each time duration: 30 days
62366386|NCT02939651|EXPERIMENTAL|Pembrolizumab|Monotherapy with PD-1 antibody pembrolizumab
62366387|NCT03486249|EXPERIMENTAL|Patient difficult to wean|Repetition of medical examinations performed as part of the care. All patients will have a cardiac echo examination and diaphragm function assessment before the spontaneous breathing trial.
62366388|NCT00838383|EXPERIMENTAL|sitaxsentan (1.0 mg/kg)|
62366389|NCT00838383|EXPERIMENTAL|sitaxsentan (2.0 mg/kg)|
62742645|NCT05023291|OTHER|test group|All patients who give their consent for this study will participate in the test group and will therefore receive the injection with 18F-FDG and images (PET / CT) will be made of the resection piece.
62366390|NCT00838383|PLACEBO_COMPARATOR|Placebo|
62366391|NCT04889612|EXPERIMENTAL|motor coordination and grip strength in dominant/non-dominant hand|Dominant and non-dominant hand motor coordination and grip strength were tested in the stable position of the trunk and the upper arm, in post-stroke patients (study group) and in healthy subjects (control group).
62366392|NCT05480501|EXPERIMENTAL|IM19 CAR-T cells|
62366393|NCT00756093|EXPERIMENTAL|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each one time
62366394|NCT00756093|ACTIVE_COMPARATOR|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
62366395|NCT00756093|ACTIVE_COMPARATOR|Blink Tears|Blink Tears 1 drop each eye one time
62366396|NCT00756093|ACTIVE_COMPARATOR|GenTeal Moderate Lubricant Eye Drops|GenTeal Moderate Lubricant Eye Drops 1 drop each eye one time
62366397|NCT03625492|EXPERIMENTAL|Reduce Potentially Irritating Beverages|This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.
62366398|NCT03625492|ACTIVE_COMPARATOR|Adopt Healthy Eating Habits|This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
62366399|NCT04073641||Survey population|Adults with type 1 and type 2 diabetes and caregivers of people with diabetes including parents of children and young people with diabetes.
62366400|NCT00369746||Alcohol and major depression, citalopram|Patients with alcohol use disorder and major depression, treated with citalopram tablets, 20-60 mg, once daily, for 12 weeks
62366401|NCT00369746||Major Depression, citalopram|Patients with major depression, treated with citalopram tablets 20-60 mg daily, for 12 weeks
62366402|NCT02417675|ACTIVE_COMPARATOR|Standard of Care (SOC)|"Women who choose the SOC will receive postpartum antiretroviral therapy (ART) services at their nearest primary care clinic, following the Standard of Care for Mothers. Details are provided in the intervention description.~Infants receive the same care in each arm, according to the Standard of Care for Infants."
62366403|NCT02417675|EXPERIMENTAL|Intervention (AC)|"Women who choose the Community-based Adherence Clubs (AC) will receive postpartum antiretroviral therapy (ART) services at an AC, rather than at their nearest primary care clinic as in the SOC arm. Details are provided in the intervention section.~Infants receive the same care in each arm, according to the Standard of Care for Infants."
62366404|NCT01690819|ACTIVE_COMPARATOR|Conventional Ventilatory Strategy|Conventional Ventilatory Strategy
62366405|NCT01690819|EXPERIMENTAL|Protective Ventilatory Strategy|Protective ventilatory strategy
62366406|NCT03456180||Haemoadsorption with Cytosorb cartridge|patients with septic shock and acute renal failure requiring renal replacement therapy with the haemoadsorption cartridge Cytosorb
62366407|NCT06268509|EXPERIMENTAL|Intervention group|"Participants in the intervention group will receive:~* Fetomaternal ultrasound examination each trimester by fetomaternal consultants~* Complete laboratory examination for nutritional panel (complete blood count with reticulocyte profile and iron profile, vitamin D level, zinc level, fatty acid profile, electrophoresis for Thalassemia) as an addition to standard maternal routine laboratory examination~* Supplements: multivitamin, minerals, vitamin D, fatty acid~* Intervention regarding any abnormal results of nutritional panel~* All standard maternal health services according to Indonesian Ministry of Health protocol"
62366408|NCT06268509|NO_INTERVENTION|Control group|"Participants in the control group will receive:~- All standard maternal health services according to Indonesian Ministry of Health protocol"
62366409|NCT04544124|EXPERIMENTAL|Contingency management for treatment attendance|Participants who receive contingency management in addition to their usual care (treatment-as-usual). These participants are in the 12-week contingency management program which provides incentives for their treatment attendance.
62366410|NCT04544124|NO_INTERVENTION|Treatment-as-usual|Participants who solely receive their usual care (treatment-as-usual) and do not receive contingency management.
62742646|NCT06660524|EXPERIMENTAL|Sevelamer Treatment|Sevelamer is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
62742647|NCT06660524|ACTIVE_COMPARATOR|Calcium Carbonate Treatment|Calcium carbonate is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
62366411|NCT01269177||Patients with acute cardiogenic pulmonary edema|
62366412|NCT02959970|EXPERIMENTAL|PK Cohort: ACZONE 7.5%|Participants applied ACZONE 7.5 % gel topically, once-daily to the entire face, neck, upper chest, upper back and shoulders starting from Day 1 under maximal use conditions (2 grams per day) for Day 8 consecutive days, followed by a thin layer to their face and acne-affected areas on the upper chest, upper back, and shoulders for next 11 weeks.
62366413|NCT02959970|EXPERIMENTAL|Non-PK Cohort: ACZONE 7.5%|Participants applied ACZONE 7.5% gel topically, once-daily in a thin layer to their face and acne-affected areas on upper chest, upper back, and shoulders for 12 weeks.
62366414|NCT05999812|EXPERIMENTAL|Treatment Arm|"* ATRA orally 45 mg/m2 daily in 2 divided doses days 1-7, repeat every 14 days~* Atezolizumab IV D1, 840 mg every 14 days~* Bevacizumab IV D1, 10 mg/kg every 14 days"
62366415|NCT03338036|EXPERIMENTAL|Heart Rate Variability/Neurofeedback|Participants in this arm of the study will receive HRV biofeedback and neurofeedback. HRV biofeedback will occur twice daily, using an android device and application. Additionally, three times per week they will have one-hour long neurofeedback sessions.
62366416|NCT03338036|NO_INTERVENTION|Post-Concussed Control Group|Age-matched, previously concussed individuals that have completed the same concussion rehabilitation program (Brain Ex 90) will be recruited for this arm.
62366417|NCT03338036|NO_INTERVENTION|Non-Concussed Control Group|Age-matched individuals who have not been diagnosed with a concussion in the previous two years
62366418|NCT00881699|EXPERIMENTAL|1|Participants will complete HIV risk reduction group meetings.
62366419|NCT00881699|ACTIVE_COMPARATOR|2|Participants will complete health promotion group meetings.
62366420|NCT04682249|EXPERIMENTAL|Systemic Chemotheray, Apatinib plus Sintilimab|
62366421|NCT02253628|EXPERIMENTAL|Trial 1|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
62366422|NCT02253628|EXPERIMENTAL|Trial 2|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
62366423|NCT02253628|EXPERIMENTAL|Trial 3|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
62366424|NCT02253628|EXPERIMENTAL|Trial 4|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
62366425|NCT03020212|ACTIVE_COMPARATOR|Oxygen|Long-term oxygen therapy in patients with chronic obstructive pulmonary disease (COPD)
62366426|NCT03020212|NO_INTERVENTION|Not oxygen|No intervention ( no therapy with oxygen)
62366427|NCT02189304|EXPERIMENTAL|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
62366428|NCT02189304|EXPERIMENTAL|PT009|PT009; Budesonide and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
62366429|NCT02189304|ACTIVE_COMPARATOR|Symbicort Turbohaler|Symbicort Turbohaler; Budesonide and Formoterol Fumarate Inhalation Powder taken as 2 inhalations
62366430|NCT01304472|EXPERIMENTAL|Prasugrel|Prasugrel 10mg per day
62366431|NCT01304472|ACTIVE_COMPARATOR|Clopidogrel|
62366432|NCT06260072|ACTIVE_COMPARATOR|Active study product|400 mg of Magnesium Oxide and 400 mg Riboflavin in capsule formation
62366433|NCT06260072|PLACEBO_COMPARATOR|Placebo study product|Inert placebo in capsule formation
62366434|NCT01689324|EXPERIMENTAL|Study Group|Participants will receive a single booster dose of Tdap vaccine (ADACEL®) on Day 0.
62366435|NCT00340171||Pregnant women and infants|pregnant women with singleton pregnancy and their newborns
62366436|NCT02855645|EXPERIMENTAL|Trichosanthes root|Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
62366437|NCT02855645|PLACEBO_COMPARATOR|Placebo|Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
62742648|NCT06657092|ACTIVE_COMPARATOR|erector spinae plane block group|Single-shot ultrasound (US)-guided ESP block with 20 ml 0.25% bupivacaine at the T4 vertebral level
62742649|NCT06657092|ACTIVE_COMPARATOR|control group|morphine pca to patient
62366438|NCT04445051|ACTIVE_COMPARATOR|Intermittent catheter; SpeediCath® Standard male or female|Participants underwent catheterization with standard of care intermittent catheter. The catheterization was performed by a trained nurse.
62366439|NCT04445051|EXPERIMENTAL|New intermittent catheter Variant 1 for male or female|Participants underwent catheterization with the new intermittent catheter Variant 1 for males or females. The catheterization was performed by a trained nurse.
62366440|NCT04445051|EXPERIMENTAL|New intermittent catheter Variant 2 for male or female|Participants underwent catheterization with the new intermittent catheter Variant 2 for males or females. The catheterization was performed by a trained nurse.
62366441|NCT01352845|EXPERIMENTAL|rLP2086|
62366442|NCT01352845|PLACEBO_COMPARATOR|Control|Steril normal saline solution
62366443|NCT02025530||Cases|A structured questionnaire will be administered to women who have experienced a late ≥ 28 weeks gestation stillbirth, who have a singleton pregnancy with no congenital abnormality.
62366444|NCT02025530||Controls|A structured questionnaire will be administered to controls. These are women matched to the case group by gestation and unit of birth, who have a normal ongoing singleton pregnancy with no congenital abnormality.
62366445|NCT02315105|EXPERIMENTAL|Morbid Obese patients|This purpose of this study is to find out more about the safety and effectiveness of the Laparoscopic Greater Curvature Plication (LGCP) for Morbid Obese Patients with related problems such as diabetes, hypertension, high cholesterol, mild obstructive sleep apnea and joint problems.
62366446|NCT05264636|ACTIVE_COMPARATOR|Sucrose|sucrose sweetened beverage 16 oz (473 ml) given daily for 28 days
62366447|NCT05264636|EXPERIMENTAL|Steviol glycosides|steviol glycosides sweetened beverage 16 oz (473 ml) given daily for 28 days
62366448|NCT04097080|EXPERIMENTAL|NBTX-001|30% medical grade xenon/70% Oxygen
62366449|NCT04097080|PLACEBO_COMPARATOR|Standard of Care|Reconstituted air
62742650|NCT00316225|EXPERIMENTAL|Pemetrexed|Pemetrexed 500 mg/m\^2 intravenous (IV) every 21 days for 6 cycles
62742651|NCT03668470|EXPERIMENTAL|Dulaglutide|Experimental group receiving 1.5 mg Dulaglutide subcutaneously weekly in addition to their usual insulin regimen during 24 weeks
62366450|NCT04446767|EXPERIMENTAL|Bioptron light therapy and medical care|bioptron light therapy sessions, about 12 minutes on the foot ulcer 3 sessions per week for about 8 weeks plus medical care in the form of Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
62366451|NCT04446767|ACTIVE_COMPARATOR|medical care|Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
62366452|NCT01712490|EXPERIMENTAL|A + AVD|A+AVD consists of brentuximab vedotin (ADCETRIS®) 1.2 milligram per kilogram (mg/kg) plus doxorubicin 25 milligram per square meter (mg/m\^2), vinblastine 6 mg/m\^2, and dacarbazine (DTIC) 375 mg/m\^2.
62366453|NCT01712490|ACTIVE_COMPARATOR|ABVD|ABVD consists of doxorubicin 25 mg/m\^2, bleomycin 10 units per square meter (units/m\^2), vinblastine 6 mg/m\^2, and dacarbazine (DTIC) 375 mg/m\^2.
62366454|NCT01024660|ACTIVE_COMPARATOR|1|5 mg Donepezil (first 14 days), 10 mg Donepezil (next 70 days)
62366455|NCT01024660|PLACEBO_COMPARATOR|2|
62366456|NCT00653068|EXPERIMENTAL|Arm I (chemotherapy, autologous PBSC, 3D-CRT)|"Patients receive vincristine IV on days 1, 8, and 15; high-dose methotrexate IV on day 1; leucovorin calcium orally or IV; etoposide IV on days 4, 5, and 6; cyclophosphamide IV on days 4 and 5; cisplatin IV on day 6, and G-CSF IV or SC on day 7 until ANC recovers.~Within 2-6 weeks after induction therapy or radiation therapy, patients receive high-dose carboplatin IV and high-dose thiotepa IV on days 1 and 2 and undergo autologous PBSC rescue on approximately day 4. Patients also receive G-CSF IV or SC once daily until ANC recovers. Treatment with consolidation therapy followed by stem cell rescue repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. After consolidation therapy, patients undergo 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks."
62366457|NCT00653068|EXPERIMENTAL|Arm II (chemotherapy, 3D-CRT, autologous PBSC)|"Patients receive vincristine IV on days 1, 8, and 15; high-dose methotrexate IV on day 1; leucovorin calcium orally or IV; etoposide IV on days 4, 5, and 6; cyclophosphamide IV on days 4 and 5; cisplatin IV on day 6, and G-CSF IV or SC on day 7 until ANC recovers.~Patients undergo 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks. Within 2-6 weeks after completion of radiation therapy, patients receive high-dose carboplatin IV and high-dose thiotepa IV on days 1 and 2 and undergo autologous PBSC rescue on approximately day 4. Patients also receive G-CSF IV or SC once daily until ANC recovers. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
62366458|NCT03491904|EXPERIMENTAL|Auto-injector (AI)|
62366459|NCT03491904|EXPERIMENTAL|Prefilled syringe (PFS)|
62366460|NCT00481221||1|Screened pregnant women
62366461|NCT03683043|ACTIVE_COMPARATOR|Transabdominal guided transfer|In the trans-abdominal guided embryo transfer group, the patients' bladder were filled by 500-700 ml saline; in order to enhance the visualization. The trans-abdominal probe is applied on pelvis by an assistant nurse or the attending gynecologist intern
62552795|NCT01822717|ACTIVE_COMPARATOR|Usual Care for foot inspection|Usual instruction for foot care included in comprehensive diabetes self-management education
62742652|NCT03668470|PLACEBO_COMPARATOR|placebo|Control group receiving placebo subcutaneously weekly in addition to their usual insulin regimen during 24 weeks
62742653|NCT01096368|EXPERIMENTAL|Arm I (chemotherapy, observation)|Patients with classic histology(WHO Grade II) supratentorial ependymoma who have undergone microscopic gross total resection (GTR1) or achieved CR either after first or second resection or after post-operative induction chemotherapy are assigned to observation. For patients without GTR1, induction chemotherapy is comprised of vincristine intravenously (IV) over 1 minute on days 1 and 8 of cycles 1 and 2, carboplatin IV over 15-60 minutes on day 1 of cycles 1 and 2, and cyclophosphamide IV over 30-60 minutes on days 1-2 of cycle 1 only. Patients also receive etoposide IV over 60-120 minutes on days 1-3 of cycle 2 only. Cycle 1 continues for 3 weeks and cycle 2 continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
62366462|NCT03683043|ACTIVE_COMPARATOR|Transvaginal guided transfer|the trans-vaginal guided embryo transfer group had their bladder emptied by the gynecologist via catheter prior to transfer or else the patient was asked to void. The speculum is applied followed by insertion of the outer sheath of the transfer catheter. The speculum is removed with caution; to maintain the outer sheath in place. The TVUS probe is applied vaginally and endometrium is visualized before transfer. The transfer is done through an inner catheter applied to the already inserted outer sheath
62366463|NCT03015623|EXPERIMENTAL|Low dose cohort|SBI-101 device containing 250 million MSCs
62366464|NCT03015623|EXPERIMENTAL|High dose cohort|SBI-101 device containing 750 million MSCs
62366465|NCT03015623|SHAM_COMPARATOR|Control|Sham device containing no MSCs
62366466|NCT06291545|EXPERIMENTAL|Coronary artery scoring balloon dilation catheter（JW Medical Systems Ltd）|Patients with Coronary Artery Disease will be treated with Coronary artery scoring balloon dilation catheter（JW Medical Systems Ltd）
62366467|NCT06291545|ACTIVE_COMPARATOR|ScoreFlex NC Coronary Dilatation Catheter|Patients with Coronary Artery Disease will be treated with ScoreFlex NC Coronary Dilatation Catheter（OrbusNeich Medical \[Netherlands\] Ltd）
62366468|NCT03778580|EXPERIMENTAL|pyridoxamine|pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid for one year
62366469|NCT03778580|PLACEBO_COMPARATOR|identical placebo|identical placebo po bid for one year
62366470|NCT02866461||Fibromyalgia|No treatment
62366471|NCT00779363|EXPERIMENTAL|Implanted Device|
62366472|NCT01502761|EXPERIMENTAL|Regional Intra-arterial Magnesium 0.75g|Regional Intra-arterial magnesium only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients
62366473|NCT01502761|EXPERIMENTAL|Regional Intra-arterial magnesium 1.5g|Regional Intra-arterial magnesium Sulfate Only 1.5g (100% TD): 5 patients
62366474|NCT01502761|EXPERIMENTAL|Regional/ Distal (75/25%) Magnesium 1.5g|Regional/ Distal intra-arterial magnesium (75% TD regional- 1.125g / 25% distal-0.375g): 5 patients
62366475|NCT01502761|EXPERIMENTAL|Regional/ Distal (50/50%) Magnesium 1.5g|Regional/ Distal intra-arterial magnesium (50% TD regional- 0.75g/ 50% distal-0.75g): 5 patients
62366476|NCT00077922|EXPERIMENTAL|LMB-2 in chronic lymphocytic leukemia|40 micrograms/kg every other day (QOD) x 3 every 4 weeks in patients with chronic lymphocytic leukemia, the most prevalent form of adult leukemia.
62366477|NCT05423704|EXPERIMENTAL|Proton radiotherapy|Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W,with cisplatin 40 mg/m2/W and nimorazole to suitable patients
62366478|NCT01346020||CLL|
62366479|NCT04012333|EXPERIMENTAL|Intervention|Patients will receive standard care plus OLIMEL 7,6%E or if no central venous access available PeriOLIMEL 2,5%E to reach protein targets: \>2.2g/kg/day
62366480|NCT04012333|NO_INTERVENTION|Standard Care|Patients will receive standard care (enteral nutrition only) to stay below the protein level: \<1.2g/kg/day
62366481|NCT05768893|EXPERIMENTAL|Group 1: Combined Er:YAG laser and long-pulsed Nd:YAG laser group|This group included 120 wart lesions, treated with Er:YAG laser followed by LP Nd:YAG laser after 1-2 minutes. Cryo 6 (Zimmer Medizin Systems) was used to cool the lesions before, during and after applying the Nd:YAG laser.
62366482|NCT05768893|ACTIVE_COMPARATOR|Group 2: Er:YAG laser group.|This group included 120 wart lesions, treated with Er:YAG laser only.
62366483|NCT06022224|EXPERIMENTAL|hAd5-S-Fusion+N-ETSD|Prime (SC, Day 1) + Boost (SC, Day 22) @ 1x10\^11 VP/dose
62366484|NCT06022224|PLACEBO_COMPARATOR|Placebo|Prime (SC, Day 1) + Boost (SC, Day 22)
62366485|NCT05117268|EXPERIMENTAL|Silver Diamine Fluoride|In the experimental group, 44 children will be provided with SDF application, after gross debris removal to allow better contact of SDF. The entire dentition will be treated with sodium chloride fluoride varnish to prevent caries.
62366486|NCT05117268|PLACEBO_COMPARATOR|Glass Ionomer Restoration|In placebo control group n= 44 participants will be enrolled. High viscosity glass ionomer restoration will be placed after complete caries excavation using high-speed handpiece and air/water coolant. Patient will be dispensed with clear postoperative instructions.
62366487|NCT05117268|ACTIVE_COMPARATOR|Hall Technique|In active comparator group, n= 44 study participants will be enrolled. Pre-formed metal crowns will be selected according to the tooth size and filled with low viscosity glass ionomer cement and seated using digital/ finger pressure.
62366488|NCT06337994|ACTIVE_COMPARATOR|Drug treatment (interventional)|"- number of participant: \>/= 60. This open-label clinical trial consisted of 24 weeks of memantine intake period, followed by 4-week (or more) post-trial observation period to monitor the drug adverse effects (e.g. sleep problems, sleepiness, sedation, anxiety, weight change and hypotension). Clinic visits will be scheduled at baseline and follow-ups after 6, 12, 18, 24 weeks of treatment initiation. Concomitant medications were essentially kept unchanged during the trial, i.e. the intake of antidepressant or antianxiologic psychotropic medications, psychotherapy to treat depressive or anxiety symptoms does not exclude participation in the study.~Memantine was added to each patient's current medication, with the initial dosage of 5 mg/day (once daily). The dosage was then increased to 10 mg/day after a week and maintained till the end of the study. In the case of intolerance to this increase, the dosage was flexibly adjusted according to the condition of the patient."
62366489|NCT06337994|NO_INTERVENTION|No intervention|number of participants: \>/= 40
62366490|NCT03147573|EXPERIMENTAL|Blood pressure monitoring|
62366491|NCT06294093||treadmill group|healthy subjects who run regularly at least twice a week for half an hour, over 80% of the training on treadmill.
62366492|NCT06294093||road group|healthy subjects who run regularly at least twice a week for half an hour, over 80% of the training on road.
62366493|NCT03401476|ACTIVE_COMPARATOR|Morphine sulfate - Visit 1|Patients who are randomized to this group will be administered a fixed 5mg dose of oral morphine sulfate prior to performing their 6MWT at Visit 1.
62366494|NCT03401476|ACTIVE_COMPARATOR|Morphine sulfate - Visit 2|Patients who are randomized to this group will be administered a fixed 5mg dose of oral morphine sulfate prior to performing their 6MWT at Visit 2.
62366495|NCT03441555|EXPERIMENTAL|Venetoclax + Alvocidib|Venetoclax administered orally once daily (QD) and Alvocidib administered as an intravenous infusion on Days 1, 2, and 3 for all 28-day treatment cycles. Different combinations of dose levels for venetoclax and alvocidib may be explored.
62366496|NCT02347462|EXPERIMENTAL|BiPAP plus standard care|Bilevel Positive Airway Pressure (BiPAP) plus standard care according to the hospital's severe asthma protocol
62366497|NCT02347462|ACTIVE_COMPARATOR|Standard care alone|Standard care according to the hospital's severe asthma protocol
62366498|NCT00741806|EXPERIMENTAL|GHB04L1|Single dose, dose escalation
62366499|NCT00741806|PLACEBO_COMPARATOR|SPGN buffer|
62366500|NCT02480998|EXPERIMENTAL|IL-YANG Flu Vaccine QIV 0.5mL|A single 0.5mL dose administrated as an intramuscular injection.
62366501|NCT02480998|ACTIVE_COMPARATOR|IL-YANG Flu Vaccine TIV 0.5mL|A single 0.5mL dose administrated as an intramuscular injection.
62366502|NCT03258944|EXPERIMENTAL|Breath-Stacking|Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session
62366503|NCT04555408|ACTIVE_COMPARATOR|blue light group|The blue light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
62366504|NCT04555408|ACTIVE_COMPARATOR|bright light group|The bright light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
62366505|NCT04555408|PLACEBO_COMPARATOR|dim light group|The dim light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
62366506|NCT03799627|EXPERIMENTAL|Vadadustat|The initial dose of Vadadustat (300, 450, or 600 milligrams \[mg\]) will be based upon the dose of Epoetin Alfa dose participants had received prior to Vadadustat treatment
62366507|NCT03799627|EXPERIMENTAL|Vadadustat TIW|Participants randomized to Vadadustat (Main and erythropoiesis-stimulating agent \[ESA\] hyporesponder parallel studies) who complete a once-daily dosing regimen treatment period and meet eligibility criteria for transition to three times weekly (TIW) dosing will switch to TIW dosing
62366508|NCT03799627|ACTIVE_COMPARATOR|Epoetin Alfa|Epoetin Alfa
62366509|NCT02509611|EXPERIMENTAL|Immediate treatment|Participants who are randomly assigned to the immediate treatment group will receive 60-minute biweekly Hatha yoga for 12 weeks.
62366510|NCT02509611|ACTIVE_COMPARATOR|Waitlist control|Participants who are randomly assigned to the wait-list group will receive no intervention during the first 12 weeks. Not only will they serve as the comparative group, they will also serve as their own control and receive the same yoga intervention at the end of 12 weeks when the immediate treatment group completed their program.
62366511|NCT04645576|OTHER|Midface zone|Injection in the mid-facial areas (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
62366512|NCT04645576|OTHER|Temple|Injection in the temples (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
62366513|NCT04645576|OTHER|Jaw-line|Injection in the jaw-line areas (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
62366514|NCT04645576|EXPERIMENTAL|Chin|The chin will only receive one injection of Art Filler Volume.
62366515|NCT00766064|EXPERIMENTAL|Paliperidone Dosing|Paliperidone Dosing up to 6 weeks, with a maximum dosage of 6mg
62366516|NCT02353689|EXPERIMENTAL|low FODMAP group|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
62366517|NCT02353689|EXPERIMENTAL|moderate FODMAP group|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
62366518|NCT02353689|EXPERIMENTAL|high FODMAP group|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
62366519|NCT03352128|EXPERIMENTAL|Creatine supplementation|7-day creatine supplementation
62366520|NCT03352128|PLACEBO_COMPARATOR|Placebo supplementation|7-day calcium lactate supplementation
62366521|NCT00735527|EXPERIMENTAL|1|Intra-nasal lorazepam 0.1 mg/kg (max 4 mg)
62366522|NCT00735527|ACTIVE_COMPARATOR|2|Intra-venous lorazepam 0.1 mg/kg (max 4 mg)
62366523|NCT04236219|EXPERIMENTAL|ALLN-346|ALLN-346
62366524|NCT04236219|PLACEBO_COMPARATOR|Placebo|Placebo
62366525|NCT04841213|ACTIVE_COMPARATOR|Group after vitamin D3 level stabilization|Patients with loss of teeth and mineral metabolism disorders due to vitamin D3 imbalance (n=192) who will undergo dental implant placement after stabilization of vitamin D3 levels
62366526|NCT04841213|ACTIVE_COMPARATOR|Group before vitamin D3 level stabilization|Patients with the loss of teeth and mineral metabolism disorders due to vitamin D3 imbalance (n=192) who undergo the dental implantation during treatment by an endocrinologist
62366527|NCT01039428|EXPERIMENTAL|HS219|
62366528|NCT01039428|PLACEBO_COMPARATOR|Placebo|
62366529|NCT03534791|EXPERIMENTAL|Reminders|Reminders customized for each PLS, containing a name of the PLS indicated in the message. If the participants do not translate PLS within 2 months from PLS assignment, we will stop sending them reminders and we will consider them as dropouts.
62366530|NCT03534791|NO_INTERVENTION|Control group|Control group will receive no intervention, i.e. standard procedure. Participants in the control group will receive PLSs for translation, in the frequency they indicated, and they will not receive any reminders. They will be assigned new PLSs once they translate the ones that were previously assigned.
62366531|NCT05651984|ACTIVE_COMPARATOR|Communication board|The communication board consists of a printed paper interface with a size of 42 x 30 cm.
62366532|NCT05651984|EXPERIMENTAL|Eye tracking|The eye tracking device combines a laptop computer with a screen size of 29 x 16 cm, an eye tracker (PCEye Mini, Tobii dynavox, Danderyd, Sweden), an interface generated by a communication software (Communicator 5, Tobii dynavox) and a telescopic support.
62366533|NCT04061941||Stimulant Users|Stimulant users that fulfill SCID-5 clinician version definition for assessment on stimulant use disorder under DSM-5
62366534|NCT05298228|EXPERIMENTAL|Remimazolam|A bolus dose of remimazolam is administered to facilitate LMA insertion
62366535|NCT02212080|EXPERIMENTAL|BAY1214784|Dose 1 to 7 of BAY1214784
62366536|NCT02212080|PLACEBO_COMPARATOR|Placebo|Placebo Dose 1 to 7 of BAY1214784
62366537|NCT01882192|EXPERIMENTAL|Family physical activity planning|The intervention condition will receive the same guidelines as the comparison condition but will also be provided with family physical activity planning material.
62366538|NCT01882192|NO_INTERVENTION|Control|The standard (comparison group) package will consist of Canada's family guide to physical activity guidelines recommending 60 minutes of activity a day in bouts as short as five to ten minutes for children and a breakdown of ways for the family to achieve this physical activity (structured, unstructured, endurance, strength, activities, less than 60 minutes of sustained sedentary activity, reduce screen viewing by 30 min per day) commensurate with this guide. This will include the new insert by CSEP. The guide also contains arguments and information about the benefits of physical activity.
62366539|NCT05333640||AVFs treated with Sirolimus Drug Coated Balloon|Dysfunctional matured AVF that have underwent thrombolysis or balloon angioplasty with SDCB within 6 months witll be considered for the registry.
62366540|NCT05333640||AVFs treated with Paclitaxel Drug Coated Balloon|Dysfunctional matured AVF that have underwent thrombolysis or balloon angioplasty with PDCB within 6 months witll be considered for the registry.
62366541|NCT03362203||Patients with chronic neck pain|Patients,aged 21-80 years, must have experienced neck pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
62366542|NCT03362203||Subjects without chronic neck pain|Subjects,aged 21-80 years, must not have presented episodes of chronic neck pain for more than 7 days in the last 12 months.
62366543|NCT02478918|EXPERIMENTAL|Receiving reminder phone call|Will receive phone call to remind colonoscopy date and bowel prep
62366544|NCT02478918|NO_INTERVENTION|Not receiving reminder phone call|Will not receive phone call to remind colonoscopy date and bowel prep
62366545|NCT00736593|EXPERIMENTAL|1|
62366546|NCT04536493|ACTIVE_COMPARATOR|1 application|Patients receive single dose LET
62366547|NCT04536493|ACTIVE_COMPARATOR|3 applications|Patients receive 3 doses of LET
62366548|NCT02708472|EXPERIMENTAL|Open-label|"Subjects who qualify will receive daily active synchronized Transcranial Magnetic Stimulation (sTMS) treatments. Treatment will be initiated on Day 1 of the study. Subjects will come to the clinic for 5 daily treatment sessions for a total of 4 treatment weeks (20 treatment sessions). Treatment will be discontinued at the end of Week 4. Subjects will be clinically evaluated for safety and efficacy at the end of each of the four weekly treatment courses.~At the end of Week 4, subjects who have not met the endpoint of 50% reduction in Hamilton Anxiety Rating Scale (HAM-A) score will be eligible to be considered for 2 additional weeks of daily treatment in an extended phase (for a total of 30 treatment sessions)."
62366549|NCT00106249|ACTIVE_COMPARATOR|Active rTMS|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
62366550|NCT00106249|SHAM_COMPARATOR|Sham rTMS|Placebo Repetitive Transcranial Magnetic Stimulation (rTMS)
62366551|NCT05668325|EXPERIMENTAL|Mini trampoline exercise group|"Structured Patient Information Form and Foot care behavior scale, 5.07/10 g Semmes-Weinstein Monofilament, 128 Hz Manual Electronic Tunnel and Goniometer were applied to the patients as a pre-test and recorded in the patient registry. related forms. Afterwards, diabetic foot care information was given to the patients and Diabetic Foot Care Information Brochure was given. Afterwards, the patients were visited for a total of 24 times a week, three days a week for eight weeks. At the first visit, the patients were informed about the exercise program and then the Home-based Mini Trampoline Exercise Information Brochure was given to the patients. The patients were given an exercise program three times a week, a total of 24 times for eight weeks. In addition, the Foot Monitoring Form was applied to the patients once a week. Apart from the Structured Patient Information Form, other data collection tools were applied to this patient group as a post-test."
62366552|NCT05668325|EXPERIMENTAL|Control group|"Data collection tools were applied to this group of patients before the study. Diabetic foot care information was given and Diabetic Foot Care Information Brochure was given. A total of eight home visits were made for eight weeks, once a week, and the Foot Monitoring Form was applied. At the end of eight weeks, all data collection tools except the Structured Patient Information Form were applied again."
62366553|NCT00918346|EXPERIMENTAL|Tafluprost 0.0015% preserved formulation|
62366554|NCT00918346|EXPERIMENTAL|Tafluprost 0.0015% unpreserved formulation|
62366555|NCT03900663||Breast fed infants|
62366556|NCT03900663||Formula fed infants|
62366557|NCT03900663||vaginally delivered infants|
62366558|NCT03900663||Infants delivered by caesarean section|
62366559|NCT02958085|EXPERIMENTAL|NNC0174-0833|
62366560|NCT02958085|PLACEBO_COMPARATOR|Placebo|
62366561|NCT02463318|EXPERIMENTAL|Multiple slerosis|Melatonin,,one millimolar,one micromolar,one nanomolar, 12 hr treatment.
62366562|NCT02463318|EXPERIMENTAL|Healthy subjects|Melatonin,one millimolar,one micromolar,one nanomolar, 12 hr treatment. hydrogen peroxide, 250 micromollar,2 hr treatment
62366563|NCT01855945|EXPERIMENTAL|Group A|3.75 µg H3N2c HA + 0.125 mL MF59
62366564|NCT01855945|EXPERIMENTAL|Group B|7.5 µg H3N2c HÁ + 0.250 mL MF59
62366565|NCT01855945|EXPERIMENTAL|Group C|15 µg H3N2c unadjuvanted
62366566|NCT01506219|EXPERIMENTAL|Geriatrician-performed CGC|Geriatrician-performed CGC in addition to the usual care at Community Rehabilitation Unit.
62366567|NCT01506219|NO_INTERVENTION|Usual care|Usual services at Community Rehabilitation Unit.
62366568|NCT05164263|EXPERIMENTAL|Empagliflozin naive uncontrolled T2DM on oral anti-diabetics & lifestyle modifications for 3 months|"Type 2 diabetic males \& females between 18-65 years.~* HbA1c: 7.0% - 10%~* eGFR ˃60 mL/min/1.73m2.~* Patient who will give informed consent"
62366569|NCT02732184|EXPERIMENTAL|AEB1102 (Co-ArgI-PEG) administered via IV weekly.|Co-ArgI-PEG modified human arginase I
62552796|NCT02537691|OTHER|Inhaled Corticosteroids (ICS) + Controller Medications|Participants with severe asthma Global Initiative for Asthma (GINA) step 4/5 as indicated by current treatment with daily ICS consisting of \>/=500 mcg FP administered by DPI (or equivalent), and at least one of the following controller medications: LABAs, LTRAs, LAMAs, theophylline or oral corticosteroids.
62366570|NCT06231030||Multiple Sclerosis Group|Method Description Study data will be collected multicenter. It will be obtained from individuals diagnosed with MS who applied to Niğde Ömer Halisdemir University Training and Research Hospital Neurology Polyclinic and Hacettepe University, Faculty of Medicine, Department of Neurology and referred to Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation.
62366571|NCT05083949|EXPERIMENTAL|(A): empagliflozin 10mg (R1)+Glifage® 850mg (R2),then (B): FDC 12.5mg empagliflozin/850mg metformin|"On Day 1 of Period 1 subjects received treatment A: Single dose tablet of 10 milligram(mg) empagliflozin film-coated and a 850mg of metformin hydrochloride (HCl) (Glifage®) tablet, orally with 200 milliliter(mL) of water.~On Day 1 of Period 2 subjects received treatment B: Fixed dose combination (FDC) tablet of 12.5mg empagliflozin/850 mg metformin HCl, orally with 200mL of water.~A high-fat, high-calorie meal was served 30 minutes(min) before drug administration. The treatments were separated by a wash-out phase of at least 7 days."
62366572|NCT05083949|EXPERIMENTAL|(B): FDC 12.5mg empagliflozin/850mg metformin,then (A): empagliflozin 10mg(R1) + Glifage® 850mg(R2)|"On Day 1 of Period 1 subjects received treatment B: Fixed dose combination (FDC) tablet containing 12.5 milligram (mg) empagliflozin/850 mg metformin HCl, orally with 200 milliliter (mL) of water.~On Day 1 of Period 2 subjects received treatment A: Single dose tablet of 10mg empagliflozin and 850 mg of metformin hydrochloride (HCl) (Glifage®) tablet, orally with 200mL of water.~A high-fat, high-calorie meal was served 30 minutes (min) before drug administration. The treatments were separated by a wash-out phase of at least 7 days."
62366573|NCT02428933|OTHER|Before and after bromocriptine|Subjects will be investigated before and after the use of bromocriptine. They will use bromocriptine for two weeks in the evening (1.25mg/day during the first week and 2.5mg/day during the second week).
62366574|NCT03702855|EXPERIMENTAL|Tetrabenazine Tablets|Tetrabenazine Tablets 25 mg of Dr. Reddy's Laboratories Limited
62366575|NCT03702855|ACTIVE_COMPARATOR|Xenazine|Xenazine Tablets 25 mg of Lundbeck Inc.
62366576|NCT00971230|EXPERIMENTAL|FTC/TDF- Daily|FTC/TDF dosed daily
62366577|NCT00971230|EXPERIMENTAL|FTC/TDF-Intermittent|FTC/TDF dosed intermittently
62366578|NCT00971230|PLACEBO_COMPARATOR|Placebo-Daily|Placebo dosed daily
62366579|NCT00971230|PLACEBO_COMPARATOR|Placebo-Intermittent|Placebo dosed intermittently
62366580|NCT03582436||Prospective cohort|Kidney transplantation
62366581|NCT04695418|PLACEBO_COMPARATOR|Placebo|an isocaloric wheat germ-based supplement
62366582|NCT04695418|ACTIVE_COMPARATOR|Rice Germ|
62366583|NCT04123171||The Three Villages Cohort|Individuals aged 60 years or more identified by means of door-to-door surveys, living in Atahualpa, El Tambo, and Prosperidad. Individuals will be interviewed with validated field instruments, and there will be invited for the practice of complementary exams to recognize markers of aterosclerosis and cerebral small vessel disease.
62366584|NCT02985489|EXPERIMENTAL|Experimental Group|Participants assigned to the experimental group will commence Olimel Parenteral Nutrition therapy delivered through central venous catheter (CVC) access within 24-48 hours of admission.
62366585|NCT02985489|NO_INTERVENTION|Control Group|Participants assigned to the control group will receive standard of care (SOC) nutritional therapy. Control group patients will be assessed by the RD assigned to the medical unit to which the patient has been admitted (independent RD assessment). The unit RD will follow standard nutrition screening processes to determine nutrition risk, followed by a complete nutrition assessment in the presence of nutrition risk.
62366586|NCT03981185|EXPERIMENTAL|Accelerated theta burst treatment|All participants will receive theta-burst TMS.
62366587|NCT04618406|EXPERIMENTAL|PICO VAC|PICO14 device from Smith and Nephew. It is a Single-Use Negative Pressure Wound Therapy Device that provides an effective negative pressure of -80 mmHg for 14 days. It is an easily applied all-in-one system that ensures uniform application each time it is applied. The dressing consists of 4 distinct layers that reduce the risk of skin trauma, applies equal negative pressure to the skin and manages fluid transport away from the wound through a combination of absorption and evaporation through an airlock layer. The device is approved for the treatment of open wounds, closed surgical incisions and skin grafts. Both PICO-VAC and soft dressing are applied immediately postoperatively and removed after 12 days.
62366588|NCT04618406|ACTIVE_COMPARATOR|Standard care|Standard care (sterile surgical silicone foam dressing and soft dressing)
62742654|NCT01096368|EXPERIMENTAL|Arm II (radiotherapy, chemotherapy)|Patients with supratentorial ependymoma (Grade II without GTR1 or Grade III) or any infratentorial ependymoma who have undergone gross or near total resection (GTR or NTR) or achieved CR either after first or second resection or after post-operative induction chemotherapy are randomized to undergo conformal radiotherapy over 6-7 weeks followed by maintenance chemotherapy. Maintenance chemotherapy comprised of vincristine IV on days 1, 8, and 15 of cycles 1-3 only, etoposide IV over 60-120 minutes on days 1-3, cisplatin IV over 1-8 hours on day 1, and cyclophosphamide IV over 30-60 minutes on days 2-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without GTR or NTR at enrollment require induction chemotherapy (see Arm I) and possibly second surgery before randomization.
62366589|NCT05141357|EXPERIMENTAL|HBI-8000 in combination with pembrolizumab|
62366590|NCT06068647|EXPERIMENTAL|Thoracic ultrasonographic, tomographic and patch-based cardio-respiratory evaluations|"Ultrasonographic findings will be obtained with clinical machines. Additionally, ultrasonographic scans as acquired with research platform will also be gathered. Metal cutaneous landmarks will be positioned and left during computed tomography scans, indicating the areas of ultrasonographic assessment. This method will support a more accurate comparison between ultrasonographic patterns and CT scans peripheral lung findings.~Finally, on the same day of enrolment, a wearable system for measuring physiological signals, will be applied. The sensors will be applied to the upper chest. The following information will be collected by each sensor: ECG, respiratory effort, respiratory flow, activity, position, and sound pressure level."
62366591|NCT05021172|EXPERIMENTAL|Arm I (Passport to Health booklet, ePrognosis)|Participants receive Passport to Health booklet and complete ePrognosis before scheduled primary care visit.
62366592|NCT05021172|ACTIVE_COMPARATOR|Arm II (usual care)|Participants receive usual care before scheduled primary care visit.
62366593|NCT03512119||Patient|Patient with cystic fibrosis homozygous for Phe 508 del CFTR having a glucose intolerance or newly diagnosis diabetes
62366594|NCT00010803|PLACEBO_COMPARATOR|Placebo|Placebo 1 pill twice a day
62366595|NCT00010803|ACTIVE_COMPARATOR|Ginkgo biloba|Ginkgo biloba EGb761 120 mg twice daily
62366596|NCT05778929||patients diagnosed as recurrent acute pancreatitis in 12 month|Recurrent acute pancreatitis: relapse occurs more than three months after the previous episode ended, with the exclusion of re-hospitalization due to local or systemic complications of the initial episode and chronic pancreatitis.
62366597|NCT05778929||patients not diagnosed as recurrent acute pancreatitis in 12 months|No relapse occurs more than three months after the previous episode ended, with the exclusion of re-hospitalization due to local or systemic complications of the initial episode and chronic pancreatitis.
62366598|NCT02757404|EXPERIMENTAL|Ultrasonography guidance|Ultrasonography guidance injection of Meditoxin®.
62366599|NCT02757404|EXPERIMENTAL|Electrical stimulation guidance|Electrical stimulation guidance injection of Meditoxin®.
62366600|NCT02757404|EXPERIMENTAL|Manual needle placement|Manual needle placement injection of Meditoxin®.
62366601|NCT04263493|ACTIVE_COMPARATOR|Early mobilization (loading)|"This constitutes the currently accepted regime and is therefore considered the control group.~Cast/orthopedic boot for 6 weeks No weight bearing: week 0-2 Partiel weightbearing from week 3 Full weightbearing from week 7 ROM exercises 5 times a day from week 3"
62366602|NCT04263493|EXPERIMENTAL|Delayed mobilization (loading)|Loading of the Achilles tendon is delayed for 6 weeks. Cast/orthopedic boot for 12 weeks No weight bearing: week 0-6 Partiel weightbearing from week 7 Full weightbearing from week 13 ROM exercises 5 times a day from week 3
62366603|NCT03571113||Development|The study population was divided into two parts by random: development dataset (5,775) and validation dataset (1,457)
62742655|NCT01096368|ACTIVE_COMPARATOR|Arm III (radiotherapy, observation)|Patients with supratentorial ependymoma (Grade II without GTR1 or ST Grade III) or any infratentorial ependymoma (Grade II or III) who have undergone gross or near total resection or achieved CR either after first or second resection or after post-operative induction chemotherapy are randomized to undergo conformal radiotherapy over 6-7 weeks and then undergo observation. Patients without GTR or NTR at enrollment require induction chemotherapy (see Arm I) and possibly second surgery before randomization.
62742656|NCT01096368|ACTIVE_COMPARATOR|ARM IV (radiotherapy, chemotherapy)|Patients with subtotal resection after induction chemotherapy (see Arm I) and second surgery are nonrandomly assigned to Arm II treatment.
62366604|NCT03571113||Validation|The study population was divided into two parts by random: development dataset (5,775) and validation dataset (1,457)
62366605|NCT04994522|EXPERIMENTAL|Belzutifan in Participants with ESRD|Participants with ESRD will receive a single dose of belzutifan 120 mg orally on Day 1 of a 4-day treatment period (Period 1), followed by a ≥7 day washout period. Participants receive another single dose of belzutifan 120 mg orally on Day 1 of a 4-day treatment period (Period 2).
62366606|NCT04994522|EXPERIMENTAL|Belzutifan in Healthy Participants|Participants in the healthy matched control group will receive a single dose of belzutifan 120 mg orally on Day 1 of a 4-day treatment period (Period 1).
62366607|NCT03880617||Chronic Myeloid Leukemia (CML)|For CML, the first-line targeted drug is imatinib, and then second line as nilotinib and dasatinib. In the past, the median survival of CML is around 4 to 6 years (NCI, 2008). Fortunately, the launch of the targeted therapy, the median survival is expected to approach normal life expectancy for most patients. However, limited to the less than 20 years of advent of TKI, the exact effects on survival time is not yet determined.
62366608|NCT03880617||Gastrointestinal Stromal Tumor (GIST)|For patients with GIST, the imatinib mesylate (Glivec, Novartis Pharma, Basel, Switzerland) (Heinrich et al, 2003) is the first line drug and sunitinib as the second line drug. Sunitinib is an anti-angiogenesis agent by virtue of targeting multiple tyrosine kinases, including the vascular endothelial growth factor receptors (VEGFR). With these target drugs, the survival of advanced GIST patients is prominently prolonged (Lamba, Ambrale, Lee, Gupta, Rafiyath, \& Liu D, 2012). The median overall survival (OS) of advanced GIST patients increased from 18 to 57 months with imatinib therapy (Blanke et al, 2008).
62366609|NCT06269588|EXPERIMENTAL|Endoscopic hemostasis using Nexpowder|Subjects with non variceal upper GI bleeding will undergo nndoscopic hemostasis using Nexpowder as primary treatment
62366610|NCT05460689|EXPERIMENTAL|Smartphone Application|mHealth App provided to caregivers of children undergoing tonsillectomy and/or adenoidectomy
62366611|NCT05460689|SHAM_COMPARATOR|standard support|Information provided by nurses and physician orally or through printed booklets.
62366612|NCT00351806|EXPERIMENTAL|Chinese herbal medicine|
62366613|NCT00351806|PLACEBO_COMPARATOR|placebo|
62366614|NCT05757024|EXPERIMENTAL|experimental group|study group receive high power laser therapy in combination with conventional tempromandibular joint exercises.
62366615|NCT05757024|ACTIVE_COMPARATOR|control group|control group receive traditional tempromadibular joint exercises.
62366616|NCT03793634|EXPERIMENTAL|topical chamomile|herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect.
62366617|NCT03793634|ACTIVE_COMPARATOR|Topical Triamcinolone Acetonide|topical triamcinolone acetonide is the gold standard treatment of oral lichen planus.
62366618|NCT02518542|ACTIVE_COMPARATOR|Per oral endoscopic therapy A|Per oral endoscopic myotomy
62366619|NCT02518542|ACTIVE_COMPARATOR|Per oral endoscopic therapy B|Prolonged dilatation by implantation of large diameter stents.
62366620|NCT02518542|ACTIVE_COMPARATOR|Per oral endoscopic therapy C|Dilatation
62366621|NCT02518542|ACTIVE_COMPARATOR|Laparoscopic surgery|Laparoscopic Heller myotomy
62366622|NCT00774956|EXPERIMENTAL|1|Subject with shoulder impingement
62366623|NCT00774956|ACTIVE_COMPARATOR|2|Healthy persons
62366624|NCT06156449|NO_INTERVENTION|Control Group|No intervention will be applied to the control group and the measurements will be recorded simultaneously.
62391495|NCT03939858||Cognitive Function Analysis|Cognitive function will be evaluated using a customized cognitive battery designed for brain tumor patients. Tests have been selected to represent a range of cognitive functions affected by cancer and radiotherapy including basic attention, recent memory, executive functions (spanning verbal fluency, cognitive set-shifting, and abstract reasoning), and visual perceptual/spatial skills.
62366625|NCT06156449|EXPERIMENTAL|experimental group|After filling out the forms, thyme oil aromatherapy will be applied to the patients assigned to the experimental group .The oregano oil to be prepared must have a high carvacrol ratio. Thyme oil with a carvacrol ratio of at least 74% will be specific to each patient and will be given to the patient in the form of an inhaler stick. According to expert opinion; The patient's own room should be visited every 8 hours and the patient-specific inhaler stick should be sniffed into 8 breathing lungs. Each patient will use an inhaler stick for 5 days. Hemodynamic parameters (ph, CO 2, O 2 ) and COPD symptom will be measured before the intervention with the patient (pretest) and at the end of the 5th day (posttest). Vital signs will be measured and recorded three times a day in the patient's room at 08:00, 16:00 and 24:00.
62366626|NCT03904576|EXPERIMENTAL|Treatment (T)|
62366627|NCT03904576|PLACEBO_COMPARATOR|Reference Treatment (R)|
62366628|NCT02919917|EXPERIMENTAL|Usual Care Group|"Individuals randomized to the usual care group will receive BP management according to the usual care in current practice in the SCI Rehabilitation Unit.~Will receive treatment only if they experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.).~Treatment to lessen or eliminate these symptoms of low blood pressure will be guided by the attending physician and can include physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.) and/or midodrine ."
62366629|NCT02919917|EXPERIMENTAL|BP Threshold Treatment Group|"Individuals assigned to the BP threshold treatment group will receive BP management, regardless of symptoms, to maintain systolic BP between 111-135 mmHg for males and 101-135 mmHg for females for the duration of their in-patient hospital stay.~This treatment will be started based on your low BP, regardless of if you experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.). Before you start on any medication you will receive physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.).~If your blood pressure remains low after using these countermeasures you will begin to take midodrine 3 times a day as described in the intervention section. The dosage will increase and be stopped once until your seated SBP is between 111-135 mmHg."
62366630|NCT03898388|EXPERIMENTAL|Knee Synovial Fluid collection before Regenexx-SD|Measure components of knee synovial fluid 2-4 days before the Regenexx-SD treatment.
62366631|NCT06086457|ACTIVE_COMPARATOR|PD-1 inhibitor plus chemotherapy arm|"Drugs: TP or PF regimen depended on investigator's choice. A maximum of six cycles was recommended for chemotherapy.~Biological: PD-1 inhibitor (Camrelizumab)."
62366632|NCT06086457|EXPERIMENTAL|Radiotherapy arm|"Radiation: Intensity-modulated Radiation Therapy/Volumetric Modulated Arc Therapy (IMRT/VMAT) technique. Patients will receive radiotherapy between the first and third cycle of chemotherapy.~Drugs: TP or PF regimen depended on investigator's choice. Biological: PD-1 inhibitor (Camrelizumab)."
62366633|NCT01755325|EXPERIMENTAL|Compound realgar natural indigo Tablet|"Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd"
62366634|NCT01755325|PLACEBO_COMPARATOR|placebo|"placebo tablet,65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib 0.4g qd"
62366635|NCT06048380|EXPERIMENTAL|Treatment|Participants in this group will be asked to instill Glanatec Ophthalmic Solution (containing Ripasadil 0.4%) 4 times a day for 3 months following cataract removal surgery.
62366636|NCT06048380|PLACEBO_COMPARATOR|Placebo|Participants in this group will be asked to instill saline solution 4 times a day for 3 months following cataract removal surgery.
62366637|NCT03168841|EXPERIMENTAL|Intervention Group, receiving medication|Enrolled subjects with confirmed onychomycosis will be dispensed topical medication for treatment.
62366638|NCT03346291|EXPERIMENTAL|Persistence Targeted Smoking Cessation|8 weekly counseling sessions + 10 weeks of over-the-counter nicotine patch
62366639|NCT03696004|ACTIVE_COMPARATOR|Retros FEC-100 +BRS|Contains record of already treated patients with six cycles of FEC-100 Fluorouracil ,Epirubicin and Cyclophosphamide and later had Breast conservative Surgery(BRS)
62366640|NCT03696004|ACTIVE_COMPARATOR|PROS 30 FEC-100 +BRS|These are new patients who will be treated with six cycles of FEC-100 (Flourouracil,Epirubicin and Cyclophosphamide) and will undergo Breast Conservative Surgery (BRS)after 6 weeks
62366641|NCT04904341|EXPERIMENTAL|active|The first Cerebrolysin infusion (30 ml mixed with 250 mL of saline) is intended to be initiated as soon as possible after successful recanalization is achieved and within 8h of AIS stroke onset. Cerebrolysin treatment will be continued (30 ml/d) once daily until day 21 (first cycle). The patients will receive a second cycle of treatment (30 ml/d for 21 days given in the Outpatient Department or Neurorehabilitation Clinic) from day 69 to 90 (± 3 days).
62366642|NCT04904341|NO_INTERVENTION|historical control|Historical data will be obtained by retrospective clinical chart reviews of patients hospitalized in the study center between 2017 and Dec.2020 and fulfilling the same clinical and radiological inclusion criteria in whom 12-month follow-up (including mRS, NIHSS, BI, EQ-5D-5L) could be obtained.
62366643|NCT03554785|NO_INTERVENTION|Control/Usual Care|"* Readiness Assessment (web survey for CHC leadership and providers)~* Patient web surveys (10 total per site; 5 SGM and 5 cisgendered)~* Option to view 60 minute online webinar Do Ask, Do Tell: Collecting Data on Sexual Orientation and Gender Identity at Health Centers"
62366644|NCT03554785|ACTIVE_COMPARATOR|Intervention|"* Readiness Assessment (web survey for CHC leadership and providers)~* Patient web surveys (10 total per site; 5 SGM and 5 cisgendered)~* CHC staff leadership key informant interviews (up to 5 at each site)~* Tailored Educational Clinician and Non-clinician staff training intervention and technical assistance follow-up"
62366645|NCT04979962|EXPERIMENTAL|CAC Group|Inspection with computer assisted colonoscopy.
62366646|NCT04979962|NO_INTERVENTION|CC Group|Inspection with conventional colonoscopy
62366647|NCT02151799|EXPERIMENTAL|Body contouring surgery|
62366648|NCT02663180|EXPERIMENTAL|Intervention group|they will be enrolled in an educational program and video contact.
62366649|NCT02663180|NO_INTERVENTION|Control group|No intervention
62366650|NCT03225560|EXPERIMENTAL|Smart Phone Application|A novel smart phone application available for both Apple iOS and Google Android platforms with capabilities to populate the phone calendar with automated reminders/notifications at the appropriate times prior to the colonoscopy.
62366651|NCT03225560|ACTIVE_COMPARATOR|Traditional Paper Instructions|Traditional paper instructions for bowel preparation
62552797|NCT05851027|EXPERIMENTAL|QL0911 Group 1|Starting dose 1μg/kg；PLT 100\~200×10\^9/L
62366652|NCT02498327|PLACEBO_COMPARATOR|Gelatine Capsules|Gelatine capsules containing only inactive ingredients (starch amyral white, di-calcium phosphate DC and magnesium stearate fine), will be taken once per day, in the morning after breakfast, for 30 days. These capsules will be of identical appearance to the experimental comparator.
62742657|NCT03540589|EXPERIMENTAL|Video distraction|A video will be available as soon as the child is randomized to this group, thus enabling the child to become more involved with distraction. A tablet will be delivered to the parents in the reception room to be viewed by the child before entering the vaccine room. After entering the room, the parents will keep the child entertained with the videos. There will be several videos, and it may be optional for the parents to choose according to their preferences.
62366653|NCT02498327|EXPERIMENTAL|Venavine Intensive®|Gelatine capsules containing the active ingredients of: 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butcher's Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate, will be taken once per day, in the morning after breakfast, for 30 days.
62366654|NCT00995605|EXPERIMENTAL|Groups SAD|AMAP102 or Placebo as single ascending doses in five groups
62366655|NCT00995605|EXPERIMENTAL|Groups MAD|AMAP102 or Placebo as multiple ascending doses twice daily for seven days in two groups
62366656|NCT02152150|EXPERIMENTAL|Iron bio-fortified pearl millet|Pearl millet variety ICTP8203-Fe (82 mg/kg iron content)
62366657|NCT02152150|ACTIVE_COMPARATOR|Control pearl millet|Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content)
62366658|NCT00481988|ACTIVE_COMPARATOR|transcranial direct current stimulation|The active group of patients will receive active Iomed II Phoresor transcranial direct current stimulation for the first two weeks followed by another two weeks of active transcranial direct current stimulation.
62366659|NCT00481988|SHAM_COMPARATOR|sham tDCS|The patients in the sham arm receive active Iomed II Phoresor transcranial direct current stimulation for the second two weeks of the clinical trial only. For the first two weeks the Iomed II Phoresor constant current generator is turned on for 10 seconds to produce the tingling sensation on the scalp experienced by the patients in the active arm but the generator is then turned off and the patients receive no stimulation for the remainder of the 20 minute session.
62366660|NCT03224260|EXPERIMENTAL|Treatment A|Receive 50 mg BMS-986177 once daily or placebo
62366661|NCT03224260|EXPERIMENTAL|Treatment B|Receive 200 mg BMS-986177 once daily or placebo
62366662|NCT03224260|EXPERIMENTAL|Treatment C|Receive 500 mg BMS-986177 once daily or placebo
62366663|NCT01885949|EXPERIMENTAL|Experimental Treatment Arm|Tivozanib, taken daily for 21 days followed by a 7 day break Enzalutamide taken daily for 28 days
62366664|NCT02259946|EXPERIMENTAL|BI 1744 CL - single rising dose + Tiotropium|Single rising dose of BI 1744 CL (conjointly with Tiotropium bromide)
62366665|NCT02259946|PLACEBO_COMPARATOR|Placebo|
62366666|NCT02556970|EXPERIMENTAL|Single-port surgery|"After induction of anaesthesia and lung isolation, a single intercostal incision will be placed laterally. This will usually be anterior to the border of the latissimus dorsi muscle, and in the 4th-7th space as appropriate to the planned surgery.~A soft tissue wound protector can be used to protect the wound edges, but rigid intercostal retraction is not permitted. All instruments will be placed via this incision."
62366667|NCT02556970|ACTIVE_COMPARATOR|Multiple port surgery|Patients in this arm will have 3 separate incisions placed to site the camera and other instruments. This will involve three separate incisions.
62366668|NCT03077243|EXPERIMENTAL|Radiotherapy and/or chemotherapy.|Subjects with Oropharyngeal Squamous Cell Carcinoma receiving radiotherapy and/or chemotherapy.
62366669|NCT04313504|EXPERIMENTAL|Niraparib & Dostarlimab|"Niraparib starting on Day 0. Niraparib will be administered as continuous daily dose, orally 200 or 300 mg.~Dostarlimab IV administered via a 30-minute infusion on Day 1 of every 21 day cycle. 500mg for first 4 doses followed by 1000 mg every 6 weeks."
62366670|NCT04967911|EXPERIMENTAL|Rhythmic stabilization exercises|baseline physical therapy conventional treatment along Rhythmic stabilization exercises
62366671|NCT04967911|OTHER|Conventional treatment|Baseline physical therapy conventional treatment
62366672|NCT01802515|ACTIVE_COMPARATOR|Atomoxetine, low dose|1 capsule containing 40mg of atomoxetine by mouth everyday for 8 weeks followed by 1 week of daily placebo capsules.
62366673|NCT01802515|ACTIVE_COMPARATOR|Atomoxetine, high dose|One capsule containing 80mg of atomoxetine by mouth everyday for 8 weeks, followed by 1 week of daily 40mg atomoxetine capsules
62366674|NCT01802515|PLACEBO_COMPARATOR|Placebo (sugar pill)|1 placebo capsule by mouth everyday for 8 weeks of treatment invention followed by one week of placebo capsule during study medication taper.
62366675|NCT00550290|ACTIVE_COMPARATOR|Cefazolin Preoperatively|Participants received Cefazolin 2 grams intravenously within 30 minutes prior to incision
62366676|NCT00550290|EXPERIMENTAL|Cefazolin Postoperatively|Participants received Cefazolin 2 gram intravenous within 30 minutes prior to incision and 1 gram Cefazolin every 8 hours for the first 24 hours post-op
62366677|NCT02273414|EXPERIMENTAL|BIIL 284 BS - rising dose|
62366678|NCT02273414|PLACEBO_COMPARATOR|Placebo|
62366679|NCT01678313|EXPERIMENTAL|Study group|Doxazosin 4 mg daily plus celecoxib 200 mg every day (QD)
62366680|NCT01678313|EXPERIMENTAL|Control group|Doxazosin 4 mg every day (QD)
62366681|NCT04331925|OTHER|Anxiety and depression screening|Hospital Anxiety and Depression Scale (HADS) questionnaire administered at the start of the study. After two weeks or at the time of discharge, participants will complete the HADS questionnaire again
62366682|NCT04331925|EXPERIMENTAL|Anxiety and depression screening with journaling|Parents randomized into the intervention group be given verbal instructions to use a journal how/when they choose for the duration of the intervention period. They will also complete the HADS questionnaire before and after the intervention period of two weeks. At the end of the intervention period, these parents will also complete a survey regarding their experience with journaling
62366683|NCT03425851|EXPERIMENTAL|Intervention Group|Receive 600 diapers.
62366684|NCT03425851|ACTIVE_COMPARATOR|Control Group|Receive resources of diaper banks as requested.
62552798|NCT05851027|EXPERIMENTAL|QL0911 Group 2|Starting dose 2μg/kg；PLT 100\~200×10\^9/L
62552799|NCT05851027|EXPERIMENTAL|QL0911 Group 3|Starting dose 2μg/kg；PLT \<100×10\^9/L
62552800|NCT01223378|EXPERIMENTAL|BOL-303259-X|ophthalmic solution
62366685|NCT04424004||MURDOCK Study Participants with valid email address|"Randomized for testing: 1.A randomly selected subset of individuals who consent to participate (N\~300-500), will be invited to participate in COVID-19 polymerase chain reaction (PCR) viral testing by at-home collection and return of self-administered nasal swabs. Saliva specimens may replace the nasal swab specimen.~2. The same randomly selected subset of individuals who collect at-home samples for COVID-19 PCR testing (N\~300-500), will also provide a blood sample for serologic testing for SARS-CoV-2 IgG antibodies."
62366686|NCT03051269|EXPERIMENTAL|calcium chloride|Only one arm. All 6 enrolled patients are treated with calcium electroporation.
62366687|NCT06508788||CO2 laser cohort|Patients with a history of oncology and for whom a diagnosis of genitourinary syndrome is established and who are not eligible for treatment with hormonal therapy
62366688|NCT00608881|ACTIVE_COMPARATOR|A - coenzyme Q10 2400 mg/day|Randomized to active treatment (coenzyme Q10 2400 mg/day)
62366689|NCT00608881|PLACEBO_COMPARATOR|B - Placebo|Randomized to placebo
62366690|NCT04992299|EXPERIMENTAL|Mindfulness-Based Intervention|6-week group intervention, Learning to BREATHE, an adolescent mindfulness-based intervention derived from mindfulness-based stress reduction
62366691|NCT04992299|ACTIVE_COMPARATOR|Cognitive-Behavioral Therapy|6-week group intervention, the Blues Program, a cognitive-behavioral intervention for adolescents with elevated symptoms of depression
62366692|NCT04992299|OTHER|Health Education|6-week group program providing didactic information on adolescent health topics
62366693|NCT05730127|EXPERIMENTAL|Mechanical pressure stimulation|"Mechanical compression is applied with the thumb to the upper trapezius muscle on the non-dominant side at the midpoint between the acromion and C7. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 5/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. The stimulation will be carried out for 2 minutes."
62366694|NCT05730127|ACTIVE_COMPARATOR|Electrical stimulation|To perform this procedure a TENS will be used applying a biphasic current, since it is the most used and studied type of electrotherapy. A frequency of 100hz and a bandwidth of 150 will be used. The intensity will be increased and decreased with the patient's feeback in order to provoke a pain of approximately 5/10 in the NPRS. The stimulation will be performed for 2 minutes on the upper trapezius of the non-dominant side at the midpoint between acromion and C7.
62366695|NCT05730127|ACTIVE_COMPARATOR|Cold pressor task|The non-dominant hand shall be placed in a bucket of cold water at 10.5° for 2 minutes.
62366696|NCT02907281||Multiple sclerosis patients|Multiple sclerosis patients
62366697|NCT02907281||Healthy volunteers|Healthy volunteers
62366698|NCT01191970||Epidural recipients|Subjects who received epidural analgesia during labor
62366699|NCT01191970||Non-epidural recipients|Subjects who did not receive epidural analgesia during labor
62366700|NCT01830244|EXPERIMENTAL|Nab-Paclitaxel 125mg/m2|"Epirubicin 90 mg/m2 and cyclophosphamide 600mg/m2 IV every 3 weeks for 4 cycles.~Nab paclitaxel 125mg/m2 IV days 1, 8 and 15 for 12 weeks In case of HER2 positive tumour patients will receive trastuzumab in combination with nab-Paclitaxel"
62366701|NCT03021044|OTHER|STANDARD OF CARE|The standard of care group will be recommended about medications and a correct life style (physical activity, low salt and low fat diet, no smoking) in order to prevent cardiovascular events. In this 15-minutes talk study doctor will explain to patients and relatives the importance of aerobic physical activity (30-60 minutes daily, moderate intensity, for example speedy walking, for at least 5 days/weekly) with the aim of reducing cardiovascular risk. Patients will also receive a brochure with clear explanations. Study doctor and study coordinator will be helpful for any question and they will ensure that patients and relatives understand the importance of physical activity for cardiovascular health.
62366702|NCT03021044|EXPERIMENTAL|PHYSICAL ACTIVITY INTERVENTION|Besides standard of care, the experimental group will participate to a program of physical activity intervention. Following hospital discharge, participants in stable clinical conditions will be referred by their cardiologist to the exercise-based secondary prevention program. All exercise testing and training sessions will be performed without discontinuing the prescribed medications. On admission to the program, and quarterly during follow-up, each patient will perform a 1-km treadmill walk test as previously described (1k-TWT).
62366703|NCT02758925|EXPERIMENTAL|DLBCL patients|they will receive a combination of: Rituximab 375mg/m2 IV at Day 1 Bendamustine 90mg/m2 IV at Day 1 and 2 Cytarabine 1000mg/m2 IV at day 2 every 21 days for 6 cycles
62366704|NCT00688623|EXPERIMENTAL|Everolimus|Everolimus
62366705|NCT04888728|EXPERIMENTAL|DWN12088 and Nebivolol|Period 1 - Nebivolol A mg, Tablet, oral, once daily, Period 2 - DWN12088 X mg, Tablet, oral, twice daily, Period 3 - 1) Nebivolol A mg, Tablet, oral, once daily \& DWN12088 X mg, Tablet, oral, twice daily, 2) DWN12088 X mg, Tablet, oral, once daily
62366706|NCT04888728|EXPERIMENTAL|DWN12088 and Paroxetine|Period 1 - DWN12088 X mg, Tablet, oral, once daily , Period 2 - Paroxetine B mg, Tablet, oral, once daily, Period 3 - 1) DWN12088 X mg, Tablet, oral, once daily \& Paroxetine B mg, Tablet, oral, once daily, 2) Paroxetine B mg, Tablet, oral, once daily
62366707|NCT01090674||1|Patients with amyotrophic lateral sclerosis.
62366708|NCT02508519|EXPERIMENTAL|Zonal|The zonal acupuncture group will receive a treatment according to a zonal method and a pain level will be estimated by the investigator according to a visual analog pain scale (VAS) before and 10 minutes and 15 minutes after the beginning of the treatment and the change of the pain level will be recorded. If possible the pain level will be measured again approximately 24 hours after the treatment and the change of the pain level will be again recorded.
62366709|NCT02508519|EXPERIMENTAL|Balance|The balance acupuncture group will receive a treatment according to a balance method, and a pain level will be estimated according to a visual analog pain scale (VAS) before and 10 minutes and 15 minutes after the beginning of the treatment and the change of the pain level will be recorded. If possible the pain level will be measured again approximately 24 hours after the treatment and the change of the pain level will be again recorded.
62366710|NCT02508519|NO_INTERVENTION|Control|The control group will provide only the estimation of the the pain level according to a visual analog pain scale (VAS) but receive no acupuncture treatment. Then if possible the pain level will be measured again approximately 24 hours after the first measurement and the change of the pain level will be recorded.
62552801|NCT01223378|ACTIVE_COMPARATOR|Latanoprost|ophthalmic solution
62552802|NCT01673230|OTHER|Ventricular dysfunction|cardiac surgery for ventricular dysfunction
62366711|NCT06127511|EXPERIMENTAL|Peanuty group|Families allocated in the intervention group will receive the whole skin roasted peanuts packed in daily doses (25 g per day, 750 g per month), starting the day that we will visit the participants for the first time. They will consume 25 g of whole skin roasted peanuts as a daily snack to be incorporated into their diet for six months.
62366712|NCT06127511|NO_INTERVENTION|Control group|Usual care
62366713|NCT05166603|EXPERIMENTAL|TeleGRACE|Patients receive a virtual home visit and care from the GRACE team
62366714|NCT05166603|NO_INTERVENTION|Usual Care|Patients receive usual care
62366715|NCT02050451|EXPERIMENTAL|Nutrition Intervention|Ensure Plus®, consumed orally twice daily for 2 weeks before and 4 weeks after surgery
62366716|NCT02050451|ACTIVE_COMPARATOR|Control|Over the counter daily multivitamin for 2 weeks before and 4 weeks after surgery
62366717|NCT04843943|EXPERIMENTAL|Sintilimab+Bevacizumab|
62366718|NCT04430790|EXPERIMENTAL|Doxapram|Blinded doxapram (2mg/ml, in glucose 5%) loading dose of 2.0 to 2.5 mg/kg administered in 5 to 10 minutes, followed by a continuous infusion of 0.5 - 1.0 mg/kg/hr ('www.kinderformularium.nl') as long as needed. Therapy is down titrated or stopped based on the patients' respiratory condition. If endotracheal intubation is needed study drug is stopped. After extubation study drug may be restarted. Switch to gastro-enteral administration is allowed if no iv-access is needed for other reasons.
62366719|NCT04430790|PLACEBO_COMPARATOR|Placebo|Placebo (glucose 5%) will also be administered with a loading dose and continuous infusion (in equal amounts of fluid as in experimental arm) by intravenous or gastro-intestinal infusion. The treatment protocol will be equal to the protocol in the doxapram arm.
62366720|NCT00646581|PLACEBO_COMPARATOR|Placebo (1)|Subjects are given a one-time, single dose of placebo intranasal spray
62366721|NCT00646581|EXPERIMENTAL|Single-Dose Intranasal Insulin|Subjects are given a one-time, single dose of intranasal insulin
62366722|NCT05801172|ACTIVE_COMPARATOR|A (NSAID)|ketoprofen 100 mg intravenously 30 min. pre-office hysteroscopy
62366723|NCT05801172|ACTIVE_COMPARATOR|B (A+infiltration anesthesia)|ketoprofen 100 mg intravenously 30 min. pre-office hysteroscopy plus 20 ml 1% lidocaine in intracervical administration at the start of the procedure
62742658|NCT03540589|EXPERIMENTAL|Vibration device|Buzzy® specific vibration device will be placed by the professional or caregiver at the application site, 15 to 45 seconds before the procedure.
62742659|NCT03540589|EXPERIMENTAL|Distraction plus vibration|Combination of the two interventions described above
62366724|NCT05801172|ACTIVE_COMPARATOR|C (A+paracervical block)|ketoprofen 100 mg intravenously 30 min. pre-office hysteroscopy 20 ml 1% lidocaine in pericervical administration at the start of the procedure
62366725|NCT05549414|EXPERIMENTAL|Patients with locally recurrent, previously irradiated thoracic cancer|Prospective study shall evaluate treatment efficacy, toxicity, QOL and plan parity in patients with recurrent thoracic cancer previously irradiated, undergoing proton radiation therapy
62366726|NCT05549414|EXPERIMENTAL|Patients with recurrent Head and Neck, Brain and Spinal Cord tumors, indicated for re- irradiation|The prospective study shall evaluate treatment Efficacy, Toxicity, Quality of Life (QOL), and plan parity in adult patients with recurrent Head and Neck and Brain cancer undergoing proton radiation therapy
62366727|NCT05549414|EXPERIMENTAL|Patients with unresectable pancreatic cancer|This prospective study shall evaluate treatment feasibility utilizing the CBGS for unresectable pancreatic cancer with concurrent chemotherapy
62366728|NCT00663104|ACTIVE_COMPARATOR|1|exercise (3 sessions/week)
62366729|NCT00663104|ACTIVE_COMPARATOR|2|"exercise and phytoestrogen (cimicifuga racemosa)"
62366730|NCT00663104|PLACEBO_COMPARATOR|3|wellness control, placebo
62552803|NCT06582992||Young healthy subjects|This cohort is characterized by 50 healthy subjects aged \< 40 years (blood donor volonteers)
62552804|NCT06582992||Aged healthy subjects|This cohort is characterized by 50 healthy subjects aged \> 60-65 years (blood donor volonteers) without signs and symptoms of heart failure
62742660|NCT03540589|NO_INTERVENTION|Usual care|The vaccine will be carried out according to the routine of the Vaccine Center. Lidocaine plus prilocaine, non-nutritive sucking or breastfeeding may be used.
62366731|NCT01665976|EXPERIMENTAL|A: film coated tablets, fasted condition|
62366732|NCT01665976|EXPERIMENTAL|B: film coated tablets, fed condition|
62366733|NCT01665976|EXPERIMENTAL|C: hard gelatin capsules|
62366734|NCT01665976|EXPERIMENTAL|D: oral suspension|
62366735|NCT01399840|EXPERIMENTAL|Arm 1: BMN 673|Arm 1 will enroll patients with either AML or MDS
62366736|NCT01399840|EXPERIMENTAL|Arm 2: BMN 673|Arm 2 will enroll patients with either CLL or MCL
62366737|NCT02816476|EXPERIMENTAL|Daratumumab|Patient will receive Daratumumab every week for the first 2 cycles then every 2 weeks from cycle 3 through cycle 6.
62366738|NCT03383614|EXPERIMENTAL|cohort 1 (8 subjects)|6 subjects with LSF emodepside 5mg, OD 2 subjects with matching placebo
62366739|NCT03383614|EXPERIMENTAL|cohort 2 (8 subjects)|6 subjects with LSF emodepside 10mg, OD 2 subjects with matching placebo
62366740|NCT03383614|EXPERIMENTAL|cohort 3 (8 subjects)|6 subjects with LSF emodepside 10mg, BID 2 subjects with matching placebo
62366741|NCT01519349|EXPERIMENTAL|Cohort 1|Low Dose: 2E11 vg/kg of rAAV1.CMV.huFollistatin344 administered via intramuscular injection unilaterally to single quadriceps muscle (n=3, sIBM only)
62366742|NCT01519349|EXPERIMENTAL|Cohort 2|Mid Dose: 3E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)
62366743|NCT01519349|EXPERIMENTAL|Cohort 3|Low Dose: 6E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)
62366744|NCT06507332|ACTIVE_COMPARATOR|Group 1 (Letrozole group)|About 32 patients will receive letrozole 2.5 mg tablets only , once daily from the third date of the menses for 5 days for 3 successive periods
62366745|NCT06507332|ACTIVE_COMPARATOR|Group 2 (Letrozole and Clomiphene Citrate)|About 32 patients will receive combined letrozole 2.5 mg tablets once daily and clomiphene citrate 50 mg tablets once daily from the third date of the menses for 5 days for 3 successive periods
62552805|NCT06582992||Patients with heart failure|This cohort is characterized by 50 subjects aged \> 60-65 years with signs and symptoms of heart failure with preserved ejection fraction
62366746|NCT04099836|EXPERIMENTAL|atezolizumab and bevacizumab|Atezolizumab 1200 mg IV every 3 weeks and bevacizumab 15 mg/kg IV every 3 weeks (1 cycle=3 weeks)
62366747|NCT06322017|EXPERIMENTAL|Rhythm control by Pulmonary Vein Isolation (PVI) procedure|
62366748|NCT06322017|ACTIVE_COMPARATOR|Conventional care by antiarrhythmic drugs or bradycardic drugs|
62366749|NCT03285204||ALS patients|
62366750|NCT03285204||Friedreich Ataxia patients|
62366751|NCT03285204||Healthy control|
62366752|NCT02891252|ACTIVE_COMPARATOR|outpatient|outpatient
62366753|NCT02891252|NO_INTERVENTION|inpatient|inpatient
62366754|NCT00962468|EXPERIMENTAL|Pathway|A care pathway will be implemented in this experimental group.
62366755|NCT00962468|NO_INTERVENTION|Usual care|Usual care will be provided.
62366756|NCT03238352|EXPERIMENTAL|Test Product|Participants will rinse twice daily (morning and evening) with 10 milliliters (mL) of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
62366757|NCT03238352|OTHER|Negative Control|Participants will rinse twice daily (morning and evening) with 10 mL of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
62366758|NCT03238352|PLACEBO_COMPARATOR|Placebo|Participants will rinse twice daily (morning and evening) with 10 mL of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
62366759|NCT04494477|EXPERIMENTAL|The IN•clued program|The IN•clued program for youth consists of a three-hour in-person workshop for youth which includes lessons about safe sex practices and self-efficacy at healthcare centers, exam room roleplays, and a discussion on patient rights. Youth receive a Zine, or a magazine-style booklet, that they may take home. They also receive a list of local healthcare providers that highlights those that have participated in the IN•clued healthcare provider workshop or have had training on working with the LGBTQ population. Program youth can also receive text messages with health tips and reminders to visit a healthcare center.
62366760|NCT04494477|NO_INTERVENTION|Control|"The youth control group receives a 10-minute presentation and a list of local sexual healthcare providers, with no indication of which providers have been trained to be more LGBTQ friendly and accepting. This 10-minute presentation is a part of a longer three-hour activity unrelated to sexual health or accessing sexual healthcare. During the three-hour session, the list of approved activities includes but is not limited to:~* Films by, and for, LGBTQ youth about sexual orientation and gender identity;~* Community scavenger hunts;~* Poetry slams;~* Discussions about relationships; and~* Activities related to the appreciation of individuals' unique strengths."
62366761|NCT02868255||Ascites|"30 inflammatory ascites of HCC patients (Collection of human samples ) Ascites will be selected only from HCC patients with an elevated protein level (ie inflammatory ascites) Puncture of ascites will be collected by paracentesis on HCC or ovarian cancer patients during their routine care These biological samples are affiliated with the biobank hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
62366762|NCT02868255||Resections|"30 HCC resections (Collection of human samples ) Fragment of resected HCC will be obtained after surgery and histological analysis will be performed by the anatomo-pathology service These biological samples are affiliated with the biobank hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
62366763|NCT02868255||blood samples|"blood samples (Collection of human samples )will be collected prospectively for complementary functional analysis of peripheral These biological samples are affiliated with the biocollection hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
62366764|NCT02758041|EXPERIMENTAL|Sebacia Microparticles|
62366765|NCT04443036|EXPERIMENTAL|Albumin-bound Paclitaxel Combined With Toripalimab|"* Albumin-bound Paclitaxel：125mg/m2 IV d1、8，Q3W~* Toripalimab：240 mg，IV d1，Q3W~* until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration of Toripalimab is 24 months"
62366766|NCT04517110|EXPERIMENTAL|Pregabalin + Usual Care|300 mg pregabalin taken orally within 2 hours before surgery and 75 mg pregabalin taken orally twice daily after surgery beginning after successful extubation (day after surgery or later) until discharge or 5 days, whichever comes first. Participants will also receive standard pain management.
62366767|NCT04517110|PLACEBO_COMPARATOR|Placebo + Usual Care|Placebo taken orally within 2 hours before surgery and placebo taken orally twice daily after surgery beginning after successful extubation (day after surgery or later) until discharge or 5 days, whichever comes first. Participants will also receive standard pain management.
62366768|NCT06181227|EXPERIMENTAL|Low dose AVD-104|Three intravitreal injections at 1.0 milligram per eye each 28 days apart will be administered to the study eye. Participants will be followed for 84 days total.
62366769|NCT06181227|EXPERIMENTAL|High dose AVD-104|Two intravitreal injections at 2.0 milligrams per eye 56 days apart will be administered to the study eye. Participants will be followed for 84 days total.
62366770|NCT04072536|EXPERIMENTAL|Electric wheelchair with activated assistance module|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance, in a random order established upstream.
62366771|NCT04072536|OTHER|Electric wheelchair with assistance module not activated|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 without activated assistance, in a random order established upstream.
62366772|NCT02353676|EXPERIMENTAL|BUPIVACAINE GROUP|1.5 ml of 0.5% Bupivacaine solution to be injected into the operative site postoperatively.
62366773|NCT02353676|PLACEBO_COMPARATOR|PLACEBO GROUP|1.5 ml of saline solution to be injected into the opposite site postoperatively.
62366774|NCT03716687|EXPERIMENTAL|ciNPWT|"Prophylactic negative pressure wound dress (Hartmann) is set up for 5 days right after operation.~Continous -90 Hgmm negative pressure mode selected. No change of wound dress until 5 days completed."
62366775|NCT03716687|NO_INTERVENTION|Traditional wound dressing|Control group with traditional, dry laparotomy wound dressing.
62366776|NCT04538261|SHAM_COMPARATOR|Control|Non-inflation of the balloon device
62366777|NCT04538261|EXPERIMENTAL|Intervention|Inflation of the balloon device
62366778|NCT03879460|EXPERIMENTAL|Open Label|Open label
62366779|NCT03365336|EXPERIMENTAL|Intervention Group|Each Flu Care capsule consists of combination of seven polyherbal formulation (350 mg). Participant will be instructed to take one capsule thrice daily at a fixed time in the day for the study duration of 7 days along with 75 mg of Oseltamivir.
62366780|NCT03365336|ACTIVE_COMPARATOR|Standard Care Group|Standard of care consist of 75 mg of Oseltamivir for five days and any other required provision of care. These will be determined on case by case basis by research clinician.
62366781|NCT04480346|EXPERIMENTAL|CHP treatment|Participants assigned to this arm received the treatment described in another section.
62366782|NCT04480346|NO_INTERVENTION|Community Care|Participants randomly assigned to this condition received information about service providers in the community, but no services from the investigators.
62366783|NCT04869111|EXPERIMENTAL|Online SMART Intervention & Stress Solutions|Strategic Memory Advanced Reasoning Training (SMART) teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance
62366784|NCT04974268|EXPERIMENTAL|Exercise and nutritional program|Intervention group that receives supervised exercise and weight loss program based on individual and group intervention with Mediterranean diet and substitute for a daily meal (non-mandatory), manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
62366785|NCT04974268|NO_INTERVENTION|Control Group|Control group will receive recommendations for aerobic unsupervised exercise 150 min per week, standard dietary recommendations (Mediterranean diet pattern and 1800 Kcal diet), manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
62366786|NCT01186094|ACTIVE_COMPARATOR|Cypher|Sirolimus-eluting stent
62366787|NCT01186094|ACTIVE_COMPARATOR|Endeavor Resolute|Zotarolimus-eluting Stent
62366788|NCT05228197||Calibration Stage|"Patients referred to hospital urology departments by their GP due to a clinical suspicion of prostate cancer (elevated serum prostate specific antigen \[PSA\], abnormal feeling prostate on rectal examination). These patients are normally recommended to undergo a prostate MRI as part of standard care.~Patients will need to meet the Inclusion/Exclusion criteria but in addition, purposive identification of cases with a variety and representative sample of different pathology features are needed for this stage (e.g. normal glands, cancer glands, high-grade PIN, inflammation)."
62366789|NCT05228197||Validation Stage|"Patients referred to hospital urology departments by their GP due to a clinical suspicion of prostate cancer (elevated serum prostate specific antigen \[PSA\], abnormal feeling prostate on rectal examination). These patients are normally recommended to undergo a prostate MRI as part of standard care.~Patients will need to meet the Inclusion/Exclusion."
62366790|NCT04250740|EXPERIMENTAL|Coffee A|
62366791|NCT04250740|EXPERIMENTAL|Coffee B|
62366792|NCT04250740|EXPERIMENTAL|Coffee C|
62366793|NCT04300881|EXPERIMENTAL|Treatment|Eplerenone
62366794|NCT04300881|NO_INTERVENTION|Control|
62366795|NCT03538990|EXPERIMENTAL|DASH Eating Pattern|The DASH eating pattern meals prepared for study participants will strictly follow DASH meal planning guidelines published by National Heart, Lung, and Blood Institute of the National Institutes of Health. During the intervention phase of the study, all participants will exclusively consume prepared meals and provided beverages which will be delivered to participants' homes. Meals will be planned and prepared based on individual participant energy needs and dietary restrictions by a Registered Dietitian at the Georgia Clinical and Translational Science Alliance (CTSA) Bionutrition Unit located at Emory University.
62366796|NCT01442441||chronic pancreatitis|
62366797|NCT05981378||Native Amazonian group|Amazonian people that belongs to a indigenous community located in the Peruvian Amazon
62366798|NCT05981378||Urban Amazonian mestizos group|Amazonian mestizo people that lives on a urban district in the Peruvian Amazon
62366799|NCT00291187|PLACEBO_COMPARATOR|Placebo|Take orally 30 minutes prior to bedtime.
62366800|NCT00291187|EXPERIMENTAL|20 mg VEC-162|20 mg taken orally 30 minutes prior to bedtime.
62366801|NCT00291187|EXPERIMENTAL|50 mg VEC-162|50 mg taken orally 30 minutes prior to bedtime.
62366802|NCT00291187|EXPERIMENTAL|100 mg VEC-162|100 mg taken orally 30 minutes prior to bedtime.
62366803|NCT03797690|EXPERIMENTAL|Percutaneous needle aponeurotomy|It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia. The procedure can be repeated as required during the same session. One to three sessions with at least one-week interval are usually sufficient and will be allowed. It will be performed in outpatient setting by a senior physician experienced in the procedure. End of treatment will be considered as the last session of needle aponeurotomy.
62366804|NCT03797690|ACTIVE_COMPARATOR|Open surgery with limited aponeurectomy|It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay). Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy). End of surgical treatment will be considered as the removal of the stitches (two weeks after the surgical treatment).
62366805|NCT00920946|PLACEBO_COMPARATOR|Placebo|
62366806|NCT00920946|EXPERIMENTAL|Dimebon|
62366807|NCT05326568|EXPERIMENTAL|Experimental|Sesame oil was applied by the researcher to the patients assigned to the intervention group. Sesame oil was applied to the 10 cm circumference of the cannula, in the form of 10 drops and 10 minutes.
62366808|NCT05326568|NO_INTERVENTION|Control|No treatment was applied to the patients assigned to the control group and only standard care was applied.
62366809|NCT02732223|EXPERIMENTAL|Functional treatment|Daily functional treatment consisted of seven fish oil softgels (1.7g EPA+DHA), two dark chocolate truffles containing plant sterol esters and two green tea sachets.
62366810|NCT02732223|PLACEBO_COMPARATOR|Control treatment|Control treatment consisted of seven soy bean oil softgels, two regular dark chocolate truffles and two anise tea sachets
62366811|NCT05341284||Exposed group|The subject who is receiving first or second dose of the AS04 adjuvanted HPV 16/18 vaccine at the enrollment.
62366812|NCT05341284||Non-exposed group|The subject who does not have any HPV vaccination history at the enrollment or during the study period.
62366813|NCT01055457|EXPERIMENTAL|Experimental Multi-Purpose Solution|contact lens care solution
62366814|NCT01055457|ACTIVE_COMPARATOR|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
62366815|NCT06117904|EXPERIMENTAL|MEBO ointment + symptomatic therapy|This group included twenty-five patients given Mebo ointment in combination with the symptomatic therapy 3 times daily for 7 weeks.
62366816|NCT06117904|ACTIVE_COMPARATOR|symptomatic therapy|"This group included twenty-five patients given symptomatic therapy 3 times daily for 7 weeks.~These therapies included anti-fungal agents (Miconaz oral gel), topical anesthetics and anti-inflammatory drugs (BBC oral spray), topical analgesic gel (Oracure gel), sodium bicarbonate mouthwash (Alkamisr sachets)."
62366817|NCT01722357|EXPERIMENTAL|Pedometer + Exercise Counseling|
62366818|NCT01722357|EXPERIMENTAL|Pedometer|
62366819|NCT01722357|NO_INTERVENTION|Usual Care|"Self-help information provided on physical activity (WIN:Weight Control Network Active At Any Size provided by National Institute of Diabetes and Digestive and Kidney Diseases, 2006)."
62366820|NCT05944029|EXPERIMENTAL|Metabolic syndrome Patients|Pomegranate seed powder is administered for alleviating symptoms of metabolic syndrome
62366821|NCT03803449|ACTIVE_COMPARATOR|Control group|Participants are given standard regimen: 50-200mg propofol and 1 mg midazolam
62366822|NCT03803449|EXPERIMENTAL|Fentanyl group|Participants are given intervention regimen: 50ug fentanyl, plus 50-200mg propofol and 1 mg midazolam.
62366823|NCT06119555|EXPERIMENTAL|Cinnamon Group|In the cinnamon group, participants will consume four cinnamon capsules daily for 60 days (each 1.5 grams, totaling 3 grams), two with breakfast and two with dinner.
62366824|NCT06119555|NO_INTERVENTION|Control Group|The control group will not receive intervention.
62366825|NCT00223652|EXPERIMENTAL|Arm 1 - Telephone CBT|Telephone cognitive behavioral therapy
62366826|NCT00223652|NO_INTERVENTION|Arm 2 - Treatment as Usual|Treatment as usual control.
62366827|NCT01379729|ACTIVE_COMPARATOR|Group A|Patients with loss of long-term function after intraportal implantation
62366828|NCT01379729|ACTIVE_COMPARATOR|Group B|Patients that are candidates for islet cell transplantation
62366829|NCT04483297|EXPERIMENTAL|AK1320 MS|AK1320 MS + Local Autologous Bone + Posterior Fixation
62366830|NCT04483297|OTHER|Control|Local Autologous Bone + Posterior Fixation
62366831|NCT02557334|EXPERIMENTAL|Low Dose Strawberry Powder|40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
62366832|NCT02557334|EXPERIMENTAL|High Dose Strawberry Powder|40 g freeze dried strawberry powder
62366833|NCT02557334|PLACEBO_COMPARATOR|Placebo Powder|40 g color and taste matched placebo powder
62366834|NCT03127852|EXPERIMENTAL|Telemonitoring (Medly)|The telemonitoring technology will enable patients with complex chronic illnesses, to take clinically relevant physiological measurements with wireless home medical devices and to answer symptom questions on the mobile phone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
62366835|NCT03127852|NO_INTERVENTION|Control|Standard of care: Patients are followed in a specialty care clinic treating their primary conditions. Patients typically have scheduled appointments every six months.
62366836|NCT01761994|ACTIVE_COMPARATOR|M100|heparin free CRRT group
62366837|NCT01761994|EXPERIMENTAL|HF1000|CRRT with nafamostat mesilate anticoagulation group
62366838|NCT03372447|EXPERIMENTAL|Megadose multivitamin complex|Intramuscular injection of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg
62366839|NCT04377789|NO_INTERVENTION|non-quercetin group|Participants, who accept to enroll the study without having quercetin prophylaxis and who do not have a history of COVID-19, will be in this group.
62366840|NCT04377789|ACTIVE_COMPARATOR|quercetin prophylaxis group|Participants, who takes a daily dose of 500mg quercetin and who not have a history of COVID-19, will be in this group.
62366841|NCT04377789|ACTIVE_COMPARATOR|quercetin treatment group|Participants, who takes a daily dose of 1000mg quercetin and who are proven cases for COVID-19, will be in this group.
62366842|NCT04831268|EXPERIMENTAL|Glucose as reference food|"Twelve healthy, normal weight subjects (male: 7, female:~7) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from lentils and lupins, trahanas with tomato sauce and halva with currants, tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink."
62366843|NCT04831268|EXPERIMENTAL|Lentils and lupins mixed meal|"Twelve healthy, normal weight subjects (male: 7, female:~7) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from lentils and lupins, trahanas with tomato sauce and halva with currants, tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink."
62366844|NCT04831268|EXPERIMENTAL|Trahanas with tomato sauce mixed meal|"Twelve healthy, normal weight subjects (male: 7, female:~7) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from lentils and lupins, trahanas with tomato sauce and halva with currants, tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink."
62552806|NCT04146012|ACTIVE_COMPARATOR|Early Access|Artegraft® Collagen Vascular Graft™ (Artegraft) will be accessed in less than 72 hours after implantation.
62366845|NCT04831268|EXPERIMENTAL|Halva with currants mixed meal|"Twelve healthy, normal weight subjects (male: 7, female:~7) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from lentils and lupins, trahanas with tomato sauce and halva with currants, tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink."
62366846|NCT03154294|EXPERIMENTAL|Cohort 1|Paclitaxel 60mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 100mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
62366847|NCT03154294|EXPERIMENTAL|Cohort 2|Paclitaxel 60mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
62366848|NCT03154294|EXPERIMENTAL|Cohort 3|Paclitaxel 80mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
62366849|NCT03154294|EXPERIMENTAL|Cohort 4|Paclitaxel 80mg/m Day 1, Day 8, Day 15 TAK-228 3mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
62366850|NCT03154294|EXPERIMENTAL|Cohort 5|Paclitaxel 80mg/m2 Day 1, Day 8, Day 15 TAK-228 4mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
62366851|NCT03967847|NO_INTERVENTION|Control|
62366852|NCT03967847|EXPERIMENTAL|Ketorolac|
61986268|NCT04811170|EXPERIMENTAL|Counselling group|Counselling sessions will be conducted at the designated centers operated by the Zubin foundation. According to the level of the DASS score, 6 to 10 sessions (based on the algorithm) of counselling service will be provided to the participants by three registered counsellors. A lead counsellor will oversee all cases and services. The counselling program consists of 6-10 60-minute sessions, and the sessions can be flexibly delivered over 1 to 2 weeks, ranging from one 60-minute session biweekly or weekly.
62366853|NCT02683707|EXPERIMENTAL|PCI without IV opiate|IV midazolam and Local Anesthetic, with removal of IV fentanyl from peri-procedural analgesia (which is otherwise routinely given)
62366854|NCT02683707|ACTIVE_COMPARATOR|PCI with IV opiate|IV midazolam and Local Anesthetic and IV fentanyl for peri-procedural analgesia
62366855|NCT00367341|OTHER|Escitalopram|
62366856|NCT00367341|OTHER|Cognitive Behavioral Therapy|
62366857|NCT04831593||Group Elective|In our clinic, pediatric patients who will undergo elective surgery, are performed gastric ultrasound before the operation. We aimed to see how often we met with empty and full stomach and to determine relationship between fasting time and qualitative assessment of gastric content in elective pediatric patients before general anesthesia.
62366858|NCT04831593||Group Emergency|In our clinic, pediatric patients who will undergo emergency surgery, are performed gastric ultrasound before the operation. We aimed to see how often we met with empty and full stomach and to determine relationship between fasting time and qualitative assessment of gastric content in emergency pediatric patients before general anesthesia.
62366859|NCT01033604|EXPERIMENTAL|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
62366860|NCT01033604|ACTIVE_COMPARATOR|Split skin graft alone|Full thickness defects treated with split skin graft alone.
62366861|NCT03561246|ACTIVE_COMPARATOR|Personalized training effect on SSWS and Pp - Incline|"Determine the efficacy of motor control deficit guided personalized training on SSWS and Paretic Propulsion (Pp).~Incline treadmill walking: Those with a Pp \<0.47 or \>0.53 will undergo INCLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs."
62366862|NCT03561246|ACTIVE_COMPARATOR|Personalized training effect on SSWS and Pp - Decline|"Determine the efficacy of motor control deficit guided personalized training on SSWS and Paretic Propulsion (Pp).~Decline treadmill walking: Those with a Pp \<0.47 or \>0.53 will undergo DECLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs."
62366863|NCT03561246|ACTIVE_COMPARATOR|Personalized training effect on SSWS and Pp - Level treadmill (Control)|"Determine the efficacy of motor control deficit guided personalized training on SSWS and Paretic Propulsion (Pp).~Level treadmill walking: Those with a Pp \<0.47 or \>0.53 will undergo LEVEL training during which individuals will walk for 15 minutes at a 0-degree treadmill tilt, stopping each five minutes for monitoring of vital signs."
62366864|NCT01856855|EXPERIMENTAL|Stereotactic Body Radiation Therapy with Integrated Boost|
62366865|NCT03613818|EXPERIMENTAL|eCHECKUP TO GO|Brief, web-based alcohol intervention
62552807|NCT04146012|ACTIVE_COMPARATOR|Normal Access|Artegraft® Collagen Vascular Graft™ (Artegraft) will be accessed after 10 days as per current IFU.
61986269|NCT04811170|OTHER|Waiting group|For participants in the waiting list control group, they will receive monitoring service over phone calls during the 8-12 weeks wait period. Counselling service will be offered after the post-treatment assessment.
61986270|NCT01382017|PLACEBO_COMPARATOR|Placebo|Placebo arm
62366866|NCT03613818|NO_INTERVENTION|Control|Assessment only
62366867|NCT01600417||clinical suspicion of lumbar instability|
62366868|NCT05255705||Patients undergoing Revascularisation at Barts Heart Centre|This study aims to assess, in a real-world setting, the safety, efficacy and feasibility of further investigations in patients with coronary artery disease undergoing revascularisation.
62366869|NCT06278155|EXPERIMENTAL|Experimental social relations group|In the experimental group, a social robot is expected to mediate the relationship among peers. Its task is to prompt, reinforce and support the participants' responses. In this case, it is the therapist who mediates the relationship by prompting, reinforcing and supporting the participants' responses.
62366870|NCT06278155|OTHER|Control social relations group|In the control group, the therapist is expected to act as a mediator of the relationship, prompting, reinforcing and supporting the participants' responses.
62366871|NCT02714608|EXPERIMENTAL|Ginsenoside H dripping pills|Drug: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
62742661|NCT06656078|EXPERIMENTAL|Group 1 male|"All members of group number 1 who fall in the eligibility criteria will undergo three different types of cognitive loading.~Three types of cognitive loading will be applied randomly to eliminate any bias.~Each Method will be applied three times with pre and post-recordings to ensure reliability."
62366872|NCT02714608|EXPERIMENTAL|Ginsenoside H dripping pills+Placebo|Drug: Ginsenoside H dripping pills ,Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
62366873|NCT02714608|PLACEBO_COMPARATOR|Placebo|Drug: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
62366874|NCT02944734|EXPERIMENTAL|Candesartan Cilexetil (CC) 8mg|Candesartan Cilexetil 8mg, once a day for 8 weeks
62366875|NCT02944734|EXPERIMENTAL|CC 16mg|Candesartan Cilexetil 16mg, once a day for 8 weeks
62366876|NCT02944734|EXPERIMENTAL|Amlodipine(AML) 5mg|Amlodipine 5mg, once a day for 8 weeks
62366877|NCT02944734|EXPERIMENTAL|AML 10mg|Amlodipine 10mg, once a day for 8 weeks
62366878|NCT02944734|EXPERIMENTAL|CC 8mg / AML 5mg|Candesartan 8mg and Amlodipine 5mg, once a day for 8 weeks
62366879|NCT02944734|EXPERIMENTAL|CC 8mg / AML 10mg|Candesartan 8mg and Amlodipine 10mg, once a day for 8 weeks
62366880|NCT02944734|EXPERIMENTAL|CC 16mg / AML 5mg|Candesartan 16mg and Amlodipine 5mg, once a day for 8 weeks
62366881|NCT02944734|EXPERIMENTAL|CC 16mg / AML 10mg|Candesartan 16mg and Amlodipine 10mg, once a day for 8 weeks
62366882|NCT05798819|EXPERIMENTAL|GLS-010+chemotherapy± bevacizumab|GLS-010 in combination with cisplatin or carboplatin and paclitaxel± bevacizumab
62366883|NCT05798819|PLACEBO_COMPARATOR|Placebo+chemotherapy± bevacizumab|Placebo in combination with cisplatin or carboplatin and paclitaxel± bevacizumab
62366884|NCT00868361|EXPERIMENTAL|Slow and rapid N-acetyl transferase genotypes|
62366885|NCT02287662|EXPERIMENTAL|Vancouver 3M Clinical Pathway|The Vancouver 3M Clinical Pathway utilizes objective anatomical and functional screening criteria as well as strict peri-procedural guidelines to determine if next day discharge home is appropriate.
62366886|NCT05905770||Sickle cell disease patients aged 16 years and older with an available matched sibling donor.|Alemtuzumab 1mg/kg/TBI 3Gy conditioning
62366887|NCT04119388|EXPERIMENTAL|Adapted sports practice|patients with osteogenesis imperfect will practice adapted sport twice a week during 12 months in order to improve their aerobic capacity, cardiovascular and bone benefits, and gain of quality of life.
62366888|NCT01063504|ACTIVE_COMPARATOR|Teriparatide 20 microgram daily for 2 months|
62366889|NCT01063504|PLACEBO_COMPARATOR|Placebo|
62366890|NCT04253470||cleavage stage embryo|embryo which is on day 2 or 3
62366891|NCT04253470||blastocyst embryo|embryo which is on day 5
62366892|NCT01024062|EXPERIMENTAL|Paclitaxel|
62366893|NCT03296280||Early Intervention|This cohort of 10 facilities will undergo early training by participating in the first 6 POCUS course sessions during FY17
62366894|NCT03296280||Late Intervention|This cohort of 10 facilities will undergo late training by participating in the last 6 POCUS courses during FY17.
62366895|NCT00772746||exercise|Respiratory and cognitive exercises in panic disorder patients.
62366896|NCT02603406|EXPERIMENTAL|Group A|mechanical barrier disruption procedure + hrEPO manufactured by Dong-A pharmaceutics Multiple burrholes with local anesthesia after medication Drug: Erythropoietin 33,000u daily for 3 day via intravenous
62366897|NCT02603406|NO_INTERVENTION|Group B|mechanical barrier disruption procedure Drug: no-specific intervention
62366898|NCT00250497|EXPERIMENTAL|New Moves Intervention Group|The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
62366899|NCT00250497|NO_INTERVENTION|control group|Girls in the control group participated in an all-girls physical education class but did not receive additional components offered in the intervention such as individual coaching.
62366900|NCT05106439|EXPERIMENTAL|Competition arm|"Programs with at least five interns were grouped into program-based teams. Interns within the same residency institution in programs that did not meet this criterion were grouped into institution-based teams, with a minimum of five participants per team.~For each week, an eligible team is randomized to either competition or non-competition group with 50/50 chance. For those randomized to competition arm, teams were assigned an opponent team according to a weekly equally randomly selected rule from three options: 1. total randomization, by which the opponent team was assigned regardless of institution and specialty; 2. within-institution randomization, by which two competing teams were from the same institution; 3. within-specialty randomization, by which two paired teams were from the same specialty. For each pair of competing teams, there was a 50/50 chance that they would compete on average daily step counts or average daily sleep minutes."
62366901|NCT05106439|EXPERIMENTAL|Non-competition group|For each week, an eligible team is randomized to either competition or non-competition group with 50/50 chance.
62366902|NCT06269575|EXPERIMENTAL|experimental|safe nutrition arm
61986271|NCT01382017|EXPERIMENTAL|Lasosamide 200|Lacosamide 200 mg
61986272|NCT01382017|EXPERIMENTAL|Lacosamide 400|Lacosamide 400 mg
61986273|NCT01382017|ACTIVE_COMPARATOR|Carbamazepine 600|Carbamazepine 600 mg
62366903|NCT06269575|NO_INTERVENTION|control arm|control arm
62366904|NCT04629586||Individuals diagnosed with type 1 diabetes|"T1D Exchange Registry is currently looking for participants:~* Of all ages, genders, races, and ethnic groups~* Living in the United States~* Diagnosed with type 1 diabetes~* Currently taking insulin or have had a pancreatic or islet cell transplant"
62366905|NCT00473291||Patients with pleural effusion|Patients diagnosed with pleural effusion and presenting for treatment
62366906|NCT02590640|ACTIVE_COMPARATOR|Inhibitory insular rTMS|Inhibitory (1 Hz) repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
62366907|NCT02590640|SHAM_COMPARATOR|Sham insular rTMS|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
62366908|NCT00784706|EXPERIMENTAL|CIT with eye-patching|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log. Participants were also asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
62366909|NCT00784706|EXPERIMENTAL|constraint-induced therapy|The intervention in this group resembled the intervention of the CIT+EP group, except participants did not wear the EP glasses.
62366910|NCT00784706|ACTIVE_COMPARATOR|conventional therapy|traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
62366911|NCT04518020|ACTIVE_COMPARATOR|Short implant|Short implant 6 mm installed
62366912|NCT04518020|OTHER|Conventional implant + bone augmentation|Standard length implant 13 mm in conjunction with maxillary sinus floor augmentation serves as a control group
62366913|NCT03961295|ACTIVE_COMPARATOR|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
62366914|NCT03961295|EXPERIMENTAL|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
62366915|NCT06007755||Delirium is determined by 3D-CAM score|
62366916|NCT06007755||No delirium is determined by 3D-CAM score|
62366917|NCT04520178|ACTIVE_COMPARATOR|Low-dose 5HTP|50mg 5-HTP in combination with 50mg carbidopa
62366918|NCT04520178|ACTIVE_COMPARATOR|High-dose 5HTP|100mg 5-HTP in combination with 50mg carbidopa
62366919|NCT04520178|SHAM_COMPARATOR|Carbidopa|50mg carbidopa only
62366920|NCT04520178|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62366921|NCT03472768||ECMO-supported group|Thirty critically-ill children (age newborn to 18 years) who are intubated and supported by ECMO. Normal adult-level haptoglobin concentrations are achieved by 6-12 months of age. We will target enrollment of 15 subjects less than 12 months of age and 15 subjects over 12 months of age
62366922|NCT03472768||Age-matched group with respiratory failure|Sixty critically-ill children (age newborn to 18 years) who are intubated with acute respiratory failure due to any cause and not supported by ECMO. Two control subjects will be enrolled for every 1 experimental ECMO subject.
62366923|NCT00374036|EXPERIMENTAL|1|ECC
62366924|NCT00374036|EXPERIMENTAL|2|FOLFIRI
62366925|NCT05160662|NO_INTERVENTION|Women with BMI>=35 (2019-2020)|Pregnant women with BMI\>=35 delivered at the hospital 2019-2020
62366926|NCT05160662|EXPERIMENTAL|Women with BMI>=35 (2021-2023)|Pregnant women with BMI\>=35 delivered at the hospital 2021-2023
62366927|NCT01735097|EXPERIMENTAL|Arsenical keratosis (Study)|Vitamin E (200 mg, soft capsule) plus Nigella sativa (500 mg, soft capsule) twice daily, orally for 12 weeks
62366928|NCT01735097|ACTIVE_COMPARATOR|Arsenical keratosis (Control)|Vitamin E (200 mg, soft capsule) plus Placebo (refined oil in soft capsule with same size and color as that contains N sativa) twice daily, orally for 12 weeks
62366929|NCT05980676|NO_INTERVENTION|Control|The control group will be told that they can work a WOW routine on their own, with the opportunity to complete the intervention after completing the 4-week follow-up assessment.
62366930|NCT05980676|EXPERIMENTAL|No-Coach|This is a fully automated intervention. The No-Coach group will complete an online activity that will guide the creation of a habitual instigation implementation intention (e.g., When I finish eating lunch at work, then I will put on my walking shoes and go outside) and receive a 2-week long personalized email campaign. They will not be able to reply to the emails for support.
62366931|NCT05980676|EXPERIMENTAL|Coached|This is a semi-automated intervention. The Coached group will complete an online activity that will guide the creation of a habitual instigation implementation intention (e.g., When I finish eating lunch at work, then I will put on my walking shoes and go outside) and receive a 2-week long personalized email campaign. Prompts will be added to the end of each email such that these participants can respond to give feedback, ask questions, and receive additional support from a (human) coach.
62366932|NCT03723785|EXPERIMENTAL|Participants with normal renal function|Participants with normal renal function (glomerular filtration rate \[GFR\] of greater than or equal to 90 ml/min) will receive single dose of insulin 287 on Day 1.
62366933|NCT03723785|EXPERIMENTAL|Participants with mildly decreased renal function|Participants with mildly decreased renal function (GFR of 60 to less than 90 ml/min) will receive single dose of insulin 287 on Day 1.
62366934|NCT03723785|EXPERIMENTAL|Participants with moderately decreased renal function|Participants with moderately decreased renal function (GFR of 30 to less than 60 ml/min) will receive single dose of insulin 287 on Day 1.
62366935|NCT03723785|EXPERIMENTAL|Participants with severely decreased renal function|Participants with severely decreased renal function (GFR of less than 30 not requiring dialysis) will receive single dose of insulin 287 on Day 1.
62366936|NCT03723785|EXPERIMENTAL|Participants with end-stage renal disease|Participants with end-stage renal disease requiring haemodialysis will receive single dose of insulin 287 on Day 1.
62366937|NCT05578313||• Group 1 (study group)|IBD patients prescribed cannabis as treatment of their bowel disease.
62366938|NCT05578313||• Group 2 (Control group)|One hundred healthy patients who do not use cannabis and are not eligible or not interested to commence this intervention.
62366939|NCT05578313||• Group 3 (control group)|Up to 100 IBD patient who experience pain and do not use cannabis
62366940|NCT05578313||• Group 4 (control group)|Up to 100 IBD patient who do not experience pain and do not use cannabis
62366941|NCT05578313||• Group 5 (Cannabis responders group)|up to 100 IBD patients previously prescribed cannabis and were identified to have positive effect on their disease
62366942|NCT04055025|OTHER|Sleeve gastrectomy operated patients|Six test days in a randomized, patient-blinded, cross-over design
62366943|NCT05728762|NO_INTERVENTION|Regular LEDs|Students will accept regular LEDs with a spectrum of 430-630 nm for lighting in the classroom.
62366944|NCT05728762|EXPERIMENTAL|Novel LEDs|Students will accept novel LEDs with a spectrum of 430-780 nm for lighting in the classroom.
62366945|NCT06361420|EXPERIMENTAL|Driving pressure-guided lung protective ventilation during the surgery|A 10-cycle experimental ventilation will be carried out at each level of positive end expiratory pressure after intubation, and the driving pressure of the last cycle will be recorded. The positive end expiratory pressure value corresponding to the lowest driving pressure is recognised as the optimal ventilation parameter.
62366946|NCT06361420|OTHER|Conventional lung protective ventilation|Positive end expiratory pressure will be maintained at the level facilitating optimal oxygenation during the off-pump period.
62366947|NCT03781388|EXPERIMENTAL|Starting dose of Bupivacaine (9 mg)|The starting dose of hyperbaric bupivacaine for the first patient in this study will be 9mg; the dose for the subsequent subject will be based on the response of the preceding subject as per the Narayana Rule, a modification of the biased-coin design (BCD) up-down sequential method (UDM).
62366948|NCT03781388|EXPERIMENTAL|Subsequent dose|
62366949|NCT05637957|EXPERIMENTAL|Physiotherapy + Active tDCS|20 minutes of active anodal tDCS immediately prior to physiotherapy intervention, twice a week for total of 10 sessions.
62366950|NCT05637957|ACTIVE_COMPARATOR|Physiotherapy + Sham tDCS|20 minutes of sham anodal tDCS immediately prior to physiotherapy intervention, twice a week for total of 10 sessions.
62366951|NCT00474006|ACTIVE_COMPARATOR|arm I|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 45 mg/m2/d civ x 3 days
62366952|NCT01690988|EXPERIMENTAL|Ketamine (0.5 mg/kg)|Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
62366953|NCT01690988|PLACEBO_COMPARATOR|Normal saline (placebo)|Intravenous normal saline
62366954|NCT01690988|EXPERIMENTAL|Ketamine (1 mg/kg)|Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
62366955|NCT00544466|EXPERIMENTAL|Treatment (enzyme inhibitor, radiation therapy, transplant)|PREPARATIVE REGIMEN\*: Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. Patients also undergo helical tomotherapy twice daily on days -7 to -4. TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0. NOTE: \*Treatment begins 2 days earlier in patients receive tacrolimus and/or sirolimus for GVHD prophylaxis.
62366956|NCT04749160||Rheumatoid arthritis (RA) with connected device|"RA with DAS28 ≥ 3.2 despite methotrexate therapy and initiating for the first time a bDMARD or a tsDMARD.~the physical activity and sleep quality measured with connected device"
62366957|NCT01581996|EXPERIMENTAL|Lanthanum carbonate treatment|One Treatment arm. All patients will receive the following doses of lanthanum carbonate(Fosrenol)for 10-12 days each: 0 mg, 500 mg tid, 1000 mg tid and 1500 mg tid.
62366958|NCT02607462|EXPERIMENTAL|PRP|Platelet-rich plasma taken made from centrifuged venous blood.
62366959|NCT02607462|PLACEBO_COMPARATOR|Saline|Sodium chloride 0.9% used as placebo.
62366960|NCT05753202|ACTIVE_COMPARATOR|Left dorsolateral prefrontal cortex|15 sessiones of anodal tDCS over the left dorsolateral prefrontal cortex (2 mA, 20 minutes) associated with cognitive training.
62366961|NCT05753202|ACTIVE_COMPARATOR|Left M1|15 sessiones of anodal tDCS over the left M1 (2 mA, 20 minutes) associated with cognitive training.
62366962|NCT00806650||Blood draw for diagnosis testing|
62366963|NCT01048255|EXPERIMENTAL|VX-765|
62366964|NCT00776334|EXPERIMENTAL|1|fosinopril sodium 40 mg tablets of Ranbaxy
62366965|NCT00776334|ACTIVE_COMPARATOR|2|Monopril® 40mg tablets
62366966|NCT03417505|EXPERIMENTAL|Treated followed by untreated|Patients wear the Hydra-PEG treated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the untreated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered prior to the control treatment (untreated scleral lenses).
62366967|NCT03417505|EXPERIMENTAL|Untreated followed by treated|Patients wear the untreated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the Hydra-PEG treated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered after the control treatment (untreated scleral lenses).
62366968|NCT03058302|EXPERIMENTAL|Full CETA|Full CETA participants will complete 12 CETA sessions. this is the same version of CETA that has been tested in other sites. They will be monitored weekly for clinical purposes (symptoms and safety) during treatment. they will also receive monthly research assessments (research outcomes) for 6 months after baseline assessment and commencement of treatment.
62366969|NCT03058302|EXPERIMENTAL|Brief CETA|Brief CETA participants is a new shorter version of CETA that has the same content as Full CETA but provided in fewer sessions. Each participant will complete 5 CETA sessions and will be monitored weekly for clinical purposes (symptoms and safety) during treatment and thereafter monthly for research purposes (research outcomes) for 6 months after baseline assessment and commencement of treatment.
62366970|NCT03058302|NO_INTERVENTION|Wait-Control|Wait-control participants will undergo monthly monitoring after enrollment in the study for research purposes (research outcomes) for 6 months after baseline assessment.
62366971|NCT00813267|EXPERIMENTAL|stem cell|mesenchymal stem cell infusion and bone marrow mononuclear cell infusion
62366972|NCT04969627|ACTIVE_COMPARATOR|Metformin (BMI<24)|Subjects: PCOS patients whoseBMI\<24 Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
62366973|NCT04969627|EXPERIMENTAL|Metformin (BMI≥24)|Subjects: PCOS patients whoseBMI≥24 Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
62366974|NCT04969627|EXPERIMENTAL|Combination (BMI<24)|Subjects: PCOS patients whoseBMI\<24 Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months
62366975|NCT04969627|EXPERIMENTAL|Combination (BMI≥24)|Subjects: PCOS patients whoseBMI≥24 Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months
62366976|NCT01100294|EXPERIMENTAL|Vaccination with Fluval P|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant. Dose: 0.25 ml (total 3 μg HA), single dose.
62366977|NCT04884906|EXPERIMENTAL|Camrelizumab combined with radiotherapy and chemotherapy|
62366978|NCT05347771|EXPERIMENTAL|Dupilumab|"Participants between 12-17 years of age, will receive an initial dose of 600 mg (two 300 mg injections) followed by 300 mg given every other week (Q2W).~Participants between 6-11 years of age will not complete a loading dose and will receive injections based on their body weight:~Participants with a body weight of 15 kg to less than 30 kg, will receive 100mg Q2W.~Participants with a body weight of 30 kg or more, will receive 200 mg Q2W."
62366979|NCT05347771|PLACEBO_COMPARATOR|Placebo|"Participants between 12-17 years of age, will receive an initial dose of placebo (two injections) followed by a placebo injection given every other week (Q2W).~Participants between 6-11 years of age will not receive an initial loading dose of placebo and will receive injections Q2W based on their body weight."
62366980|NCT02044315|SHAM_COMPARATOR|Conventional|Conventional ICD programming
62366981|NCT02044315|EXPERIMENTAL|High-zone|High-zone ICD programming
62366982|NCT04421612|EXPERIMENTAL|Intensive|This group recieve access to a new module every 3rd day.
62366983|NCT04421612|EXPERIMENTAL|Ordinary|This group recieve access to a new module every 5th day.
62366984|NCT00850928||Subjects|65 years and older scheduled for spine surgery will be undergoing serial assessments preoperatively and postoperatively over 6 time-points.
62366985|NCT00271791|EXPERIMENTAL|1|Prednisone
62366986|NCT00271791|PLACEBO_COMPARATOR|2|Placebo
62366987|NCT02869685|OTHER|a prospective, open,phase I clinical study|The investigators have designed five kinds of radiation-division with bioequivalent doses, and detected the expression levels of PD-L1 in pExo after 24h, 48h of each stage of radiotherapy.
62366988|NCT04319445|EXPERIMENTAL|Migraine Patients/Providers/Faculty/Staff/Other|
62366989|NCT02020928|EXPERIMENTAL|Low level laser therapy|The Low level laser therapy application is performed from the first day of conditioning of the patient until the second day after bone marrow transplantation (D + 2). The patients are divided into two groups. The first will contain the patients who will receive the red laser light, whereas the second will cover patients who receive sham or placebo controlled - the device is triggered, but not deliver the laser light.
62366990|NCT02020928|SHAM_COMPARATOR|sham|patients will receive sham Low level laser therapy - the device is triggered, but not deliver the laser light
62366991|NCT00784082||Homozygous SS sickle cell children|"Hydroxycarbamide, Hydroxyurea (drug):~1. Homozygous SS sickle cell children, aged \> 3 years, of sub-Saharian Africa extraction, in a steady-state of disease , taken no drug except penicillin-V, folate or iron supplementation, hydroxyurea, divided into three groups :~   * children treated with hydroxyurea 20-25 mg/kg/day since at least 3 months with clinical efficacy on vaso-occlusive events~  * untreated children with major vaso-occlusive events~  * children \> 5 year-old without a history of vaso-occlusive events~2. Controls : heterozygous AS parents or siblings of the patients, and AA siblings or healthy African unrelated subjects, aged \> 3 years, taken no drug on the day of blood sampling."
62366992|NCT00784082||Homozygous SS children|"Hydroxycarbamide, Hydroxyurea (drug):~1. Homozygous SS children, aged \> 3 years, of sub-Saharian Africa extraction, in a steady-state of disease, taken no drug except penicillin-V, folate or iron supplementation, hydroxyurea, divided into three groups :~   * children treated with hydroxyurea 20-25 mg/kg/day since at least 3 months with clinical efficacy on vaso-occlusive events~  * untreated children with major vaso-occlusive events~  * children \> 5 year-old without a history of vaso-occlusive events~2. Controls : heterozygous AS parents or siblings of the patients, and AA siblings or healthy African unrelated subjects, aged \> 3 years, taken no drug on the day of blood sampling."
62366993|NCT00502619|EXPERIMENTAL|Acupuncture plus Treadmill Exercise|Acupuncture plus Treadmill Exercise
62366994|NCT02142855|NO_INTERVENTION|Old Control|Older individuals (65-75 y) with no exercise intervention
62366995|NCT02142855|EXPERIMENTAL|Old Concentric|Older individuals (65-75 y) studied before and after 8 weeks concentric exercise training
62366996|NCT02142855|EXPERIMENTAL|Old Eccentric|Older individuals (65-75 y) studied before and after 8 weeks eccentric exercise training
62366997|NCT02142855|NO_INTERVENTION|Young Control|Young individuals (18-30 y) with no exercise intervention
62366998|NCT02142855|EXPERIMENTAL|Young Concentric|Young individuals (18-30 y) studied before and after 8 weeks concentric exercise training
62366999|NCT02142855|EXPERIMENTAL|Young Eccentric|Young individuals (18-30 y) studied before and after 8 weeks eccentric exercise training
62367000|NCT00952601|EXPERIMENTAL|Modified Atkins Diet|Patients are started on the modified Atkins diet at 15 grams per day.
62367001|NCT02027272|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone 12 mg, 2 doses, 12 hours apart.
61986274|NCT03836547|EXPERIMENTAL|Multicomponent Intervention for weight loss|12-week intervention that consists of Weight Watcher on-line program, Garmin Fitness Tracker, blue-tooth scale, and telephonic health coaching.
62367002|NCT02027272|PLACEBO_COMPARATOR|Placebo|Placebo, 2 doses, 12 hours apart
62367003|NCT01492166||Novolet®|
62367004|NCT02880735|EXPERIMENTAL|Non Invasive Ventilation.|"It will provide noninvasive mechanical ventilation with the following specifications:~Bilevel devices: Pressurized bilevel mode Spontaneous/Time. Interface: Facial mask Usage: During sleep Frequency: Daily Duration: Three months."
62367005|NCT04363944|EXPERIMENTAL|mRehab|Use of mRehab in a home program completing unilateral and bilateral activities. Participants are able to complete unilateral activities with their paretic arm/hand
62367006|NCT04363944|EXPERIMENTAL|mRehab completing all activities bilaterally|Use of mRehab in a home program completing unilateral and bilateral activities. Participantsare can only complete intended unilateral activities using both hands
62367007|NCT01298895||PEX group|The first group consisted of 47 eyes with cataract complicated with pseudoexfoliation syndrome (PEX).
62367008|NCT01298895||control group|The control group included 177 eyes with uncomplicated cataract in eyes without other ocular pathology
62367009|NCT01729676||Group A|Degarelix or gonadotrophin releasing hormone (GnRH) agonist for treatment of prostate cancer according to physicians current practice
62367010|NCT02007252|EXPERIMENTAL|ACZ885|Participants received ACZ885 150 mg subcutaneously (s.c.) once per month for 12 months.
62367011|NCT02007252|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo to ACZ885 s.c. once per month for 12 months.
62367012|NCT03366597|EXPERIMENTAL|Sevoflurane|Sevoflurane will be used as a narcotic drug in one group during cardiac surgery.
62367013|NCT01779583||Advanced gastric cancer patients|Treatment näive advanced gastric cancer patients candidates to first-line chemotherapy
62367014|NCT01779583||Control group|Healthy adult volunteers without a cancer diagnosis
62367015|NCT00653094|OTHER|A|
62367016|NCT04894227|EXPERIMENTAL|Inactivated SARS-CoV-2 vaccine Lot 1|Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 1 according to 0,28-day immunization schedule.
62367017|NCT04894227|EXPERIMENTAL|Inactivated SARS-CoV-2 vaccine Lot 2|Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 2 according to 0,28-day immunization schedule.
62367018|NCT04894227|EXPERIMENTAL|Inactivated SARS-CoV-2 vaccine Lot 3|Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 3 according to 0,28-day immunization schedule.
62367019|NCT06445569|ACTIVE_COMPARATOR|KH-1|Three capsules containing spermidine and amino acids. One stick packet containing probiotics.
62367020|NCT06445569|PLACEBO_COMPARATOR|Placebo|"Three capsules containing hypromellose, hypromellose acetate succinate, purified water, pigments and gellen gum.~One stick packet containing microcrystalline cellulose."
62367021|NCT05339204|EXPERIMENTAL|allo-HSCT|Patients with AML in CR1, MRD-negative after first course recieve allo-HSCT
62367022|NCT05339204|ACTIVE_COMPARATOR|Chemo|Patients with AML in CR1, MRD-negative after first course continue chemotherapy
62367023|NCT04884945|ACTIVE_COMPARATOR|Robotic Surgery|Robotic-Assisted Laparoscopic Pyeloplasty (RALP), standard of care treatment option for UPJ obstruction
62367024|NCT04884945|ACTIVE_COMPARATOR|Open Surgery|Open Pyeloplasty (OP), standard of care treatment option for UPJ obstruction
62367025|NCT01470365|EXPERIMENTAL|Treatment (radiation therapy)|Patients undergo 3-dimensional CRT or IMRT QD, 5 days a week for 10-30 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
62367026|NCT05704842|OTHER|Exercise|Intervention: Subject will be assessed by a Physical Therapist. Based on the assessment, the Physical Therapist will provide the patient with a home-based exercise program including core exercises as follows: Core Stabilization, core extension, leg extensions, squats with and without weights, shoulder and arm exercises. Patients will be asked to complete a symptom survey weekly via a web-based platform for tracking cancer and treatment-related symptoms and fatigue.
62367027|NCT05704842|NO_INTERVENTION|Control|Subject will not be provided an exercise program but will be asked to complete the symptom survey weekly via a web-based platform for tracking cancer and treatment-related symptoms and fatigue.
62367028|NCT02768103|EXPERIMENTAL|SCI transfer + training|Individuals with tetraplegia and brachioradialis to flexor pollicis longus transfer will participate in 10 week home training program to improve surgical outcome (pinch strength)
62367029|NCT04427228|EXPERIMENTAL|Arm A|
62367030|NCT04427228|ACTIVE_COMPARATOR|ARM B|
62367031|NCT06039969||Cardiac MRI will be performed in patients with heart failure caused by cardiomyopathy.|Cardiac MRI will be performed in patients with heart failure caused by cardiomyopathy. At the same time Collect patient feces.this is a obvertional study ,ther is no intervetion
62367032|NCT00333424|PLACEBO_COMPARATOR|Placebo|placebo containing diluent alone
62367033|NCT03689972|EXPERIMENTAL|Part 1: IV Q4W|Participants received natalizumab 300 mg intravenous (IV) infusion once Q4W up to Week 72.
62367034|NCT03689972|EXPERIMENTAL|Part 1: IV Q6W|Participants received natalizumab 300 mg IV infusion once Q6W up to Week 72.
62367035|NCT03689972|EXPERIMENTAL|Part 2: Run-in Period: IV Q6W|Participants who completed Part 1 or were newly enrolled in Part 2 received natalizumab 300 mg IV infusion Q6W from Week 72 through Week 102.
62367036|NCT03689972|EXPERIMENTAL|Part 2: Crossover Period: IV Q6W, then SC Q6W|Participants who completed run-in period of Part 2 were randomized to receive natalizumab 300 mg IV infusion Q6W from Week 108 through Week 126 followed by natalizumab 300 mg subcutaneous (SC) injection Q6W from Week 132 through Week 150 along with a single dose of natalizumab 300 mg SC injection or IV infusion as per participant's choice at Week 156.
62367037|NCT03689972|EXPERIMENTAL|Part 2: Crossover Period: SC Q6W, then IV Q6W|Participants who completed run-in period of Part 2 were randomized to receive natalizumab 300 mg SC injection Q6W from Week 108 through Week 126 followed by natalizumab 300 mg IV infusion Q6W from Week 132 through Week 150 along with a single dose of natalizumab 300 mg SC injection or IV infusion as per participant's choice at Week 156.
62367038|NCT05622513||cases|obesity / overweight children
62367039|NCT05622513||controls|normal weight children
62367040|NCT05406245||Group C|Patients drank carbohydrate fluid 2 hours prior to surgery.
62367041|NCT03859804|EXPERIMENTAL|Group 1|In Group 1, Patients detected with a PI-RADS (Prostate Imaging Reporting and Data System) ≥3 lesion on MpMRI underwent MpMRI-guided MRI- US fusion prostate biopsy. In this fusion biopsy, 12 core standard biopsy and 2-4 cores of biopsies from lesions defined on multiparametric prostate MRI
62367042|NCT03859804|ACTIVE_COMPARATOR|Group 2|In Group 2, patients who had no suspected lesions or had a PI-RADS \<3 lesion on MpMRI underwent Transrectal ultrasound guided 12 core prostate biopsy (SPB).
62367043|NCT05076331||Health and Aging Brain Study Cohort|Health and Aging Brain Study participants age 50 and older.
62367044|NCT00675662|EXPERIMENTAL|1|Stratification by angiotensin converting enzyme (ACE) genotype
62367045|NCT00675662|PLACEBO_COMPARATOR|2|Waiting list controls
62367046|NCT02120560|ACTIVE_COMPARATOR|Interrupted Anticoagulation|Patients randomized to undergo atrial fibrillation ablation with interrupted anticoagulation with apixaban (5mg twice daily; 2.5mg twice daily \>80 years old, Cr \> 1.5, wt \< 60kg), rivaroxaban (20mg daily; 15mg daily CrCl \< 50 mL/minute), dabigatran (150mg twice daily; 75mg twice daily CrCl \< 30mL/minute), or warfarin (dosed case-by-case).
62367047|NCT02120560|ACTIVE_COMPARATOR|Uninterrupted anticoagulation with warfarin|Patients randomized to undergo atrial fibrillation ablation with uninterrupted anticoagulation with warfarin (dosed case-by-case).
62367048|NCT00107172|ACTIVE_COMPARATOR|Arm I|Patients undergo open or thoracoscopic sublobar resection comprising either a wedge resection or anatomical segmentectomy.
62367049|NCT00107172|EXPERIMENTAL|Arm II|Patients undergo surgery as in arm I. Patients also undergo intraoperative brachytherapy comprising an iodine I 125 implant at the resection margin.
62367050|NCT05912348|EXPERIMENTAL|Low Physical Activity and Added Carbohydrate Group|10-days of low physical activity (\~5,000 steps/day) while consuming added sugar-sweetened beverages (\~180 g/day).
62367051|NCT05912348|PLACEBO_COMPARATOR|Low Physical Activity Control|10-days of sedentary activity (\~5,000 steps/day).
62367052|NCT05912348|NO_INTERVENTION|Normal Activity Control|Maintains normal physical activity levels and exercise training
62367053|NCT05912348|EXPERIMENTAL|High Physical Activity and Added Carbohydrate Group|10-days of high physical activity (\~11,000 steps/day) while consuming added sugar-sweetened beverages (\~180 g/day).
62367054|NCT04083794|OTHER|Laboratory based assessments|The current study has no arms; it is a cross-sectional assessment where all participants will undergo the same procedures.
62367055|NCT02134041||traumatic brain injury|mild traumatic brain injury
62367056|NCT02134041||without TBI|without TBI
62367057|NCT03885609|EXPERIMENTAL|Treatment - toothwave brush|Subjects using the Silk'n ToothWave RF utilizing toothbrush
62367058|NCT03885609|SHAM_COMPARATOR|Control - powered toothbrush|Subject using a regular powered toothbrush with no RF.
62367059|NCT04745390|ACTIVE_COMPARATOR|Standard Dose Radiation|Patients in the standard arm will receive a standard dose of 2000cGy in 5 fractions using simple CT planning. IMRT is allowed. Treatment will be every second day excluding weekends and holidays.
62367060|NCT04745390|EXPERIMENTAL|Personalized Dose Selection Radiation|Patients in the experimental arm will receive individually selected prescription dose guided by radiobiological parameters described below, preferably delivered in 5 fractions every other day, excluding weekends and holidays. Volumetric-modulated arc therapy (VMAT) is the preferred planning technique. Typical planning uses 2 arcs, \<=10MV and FFF mode where possible as almost all liver treatments are gated). In the event of multiple lesions, multiple isocentres are allowed. Often lateral isocentre shifts are significant and therefore arc ranges should be chosen to minimize collision risk. Treatment will be every second day excluding weekends and holidays.
62367061|NCT04568876|ACTIVE_COMPARATOR|PEA Group|Normast® MPS (mPEA and umPEA 300mg + 600mg) oral suspension: 2700mg/die in 3 doses for 28 days, in add-on to standard therapy
62367062|NCT04568876|OTHER|Control Group|Standard therapy only
62367063|NCT01801657||Bronchiectasis,stable|A patient was defined as stable if there was no exacerbation for the previous 4 wk
62367064|NCT01801657||Bronchiectasis,exacerbations|Bronchiectasis exacerbations were defined by subjective and persistent(\>24 h) deterioration in at least three respiratory symptoms, including cough, dyspnea, hemoptysis, increased sputum purulence or volume, chest pain (with or without fever), radiographic deterioration, systemic disturbances, or changes in chest auscultation
62367065|NCT04885127|EXPERIMENTAL|All patients|All patients enrolled in this trial will be referred to palliative care for planned monthly virtual visits, be instructed on the use of a digital application Noona that can be downloaded on their personal electronic device, and will be prompted to fill out symptom questionnaires using Noona prior to palliative care visits (required) as well as weekly (optional).
62367066|NCT05267145|EXPERIMENTAL|the blood storage bag contains blood preservation solution III|a blood storage bag containing blood preservation solution III preserves the washed RBC
62367067|NCT05267145|NO_INTERVENTION|empty blood bag to store washed RBC|an empty blood storage bag preserves the washed RBC
62367068|NCT01863901|EXPERIMENTAL|Treatment with the Cryo-Touch III Device|
62367069|NCT05015322|ACTIVE_COMPARATOR|subacromial injection|ultrasound (US)-guided subacromial injection
62367070|NCT05015322|ACTIVE_COMPARATOR|acromioclavicular joint and subacromial injection|ultrasound (US)-guided acromioclavicular joint and subacromial injection
62367071|NCT05015322|ACTIVE_COMPARATOR|suprascapular nerve block|ultrasound (US)-guided suprascapular nerve block
62367072|NCT02349204|EXPERIMENTAL|Exposure to music|The participants in this groups will have to complete the tasks on the intraocular surgery simulator while listening to Mozart's sonata for 2 pianos in D-440
62367073|NCT02349204|NO_INTERVENTION|No exposure|The participants in this groups will have to complete the tasks on the intraocular surgery simulator in silence
62367074|NCT03254940|EXPERIMENTAL|Arm 1: WT-SM-OR-SS-CS|Charge: weekly tracking, self-generated motivational messages, one reminder, summary score, compare to self
61986275|NCT03836547|ACTIVE_COMPARATOR|Wait-list Control|The participant will receive usual care for 12 weeks and then will compassionately be offered the active intervention.
62367075|NCT03254940|EXPERIMENTAL|Arm 2: WT-SM-OR-SS-CG|Charge: weekly tracking, self-generated motivational messages, one reminder, summary score, compare to group
62367076|NCT03254940|EXPERIMENTAL|Arm 3: WT-SM-OR-SF-CS|Charge: weekly tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to self
62367077|NCT03254940|EXPERIMENTAL|Arm 4: WT-SM-OR-SF-CG|Charge: weekly tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to group
62367078|NCT03254940|EXPERIMENTAL|Arm 5: WT-SM-MR-SS-CS|Charge: weekly tracking, self-generated motivational messages, multiple reminders, summary score, compare to self.
62367079|NCT03254940|EXPERIMENTAL|Arm 6: WT-SM-MR-SS-CG|Charge: weekly tracking, self-generated motivational messages, multiple reminders, summary score, compare to group.
62367080|NCT03254940|EXPERIMENTAL|Arm 7: WT-SM-MR-SF-CS|Charge: weekly tracking, self-generated motivational messages, multiple reminders, specific feedback, compare to self
62742662|NCT06656078|EXPERIMENTAL|Group 2 female|"All members of group number 2 who fall in the eligibility criteria will undergo three different types of cognitive loading.~Three types of cognitive loading will be applied randomly to eliminate any bias.~Each Method will be applied three times along with pre and post-recordings to ensure reliability."
62367081|NCT03254940|EXPERIMENTAL|Arm 8: WT-SM-MR-SF-CG|Charge: weekly tracking, self-generated motivational messages, multiple reminders, specific feedback, compare to group
62367082|NCT03254940|EXPERIMENTAL|Arm 9: WT-EM-OR-SS-CS|Charge: weekly tracking, expert-generated motivational messages, one reminder, summary score, compare to self
62367083|NCT03254940|EXPERIMENTAL|Arm 10: WT-EM-OR-SS-CG|Charge: weekly tracking, expert-generated motivational messages, one reminder, summary score, compare to group
62367084|NCT03254940|EXPERIMENTAL|Arm 11: WT-EM-OR-SF-CS|Charge: weekly tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to self
62367085|NCT03254940|EXPERIMENTAL|Arm 12: WT-EM-OR-SF-CG|Charge: weekly tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to group.
62367086|NCT03254940|EXPERIMENTAL|Arm 13: WT-EM-MR-SS-CS|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, summary score, compare to self
62367087|NCT03254940|EXPERIMENTAL|Arm 14: WT-EM-MR-SS-CG|Charge: weekly tracking, expert-generated motivational messages, multiple reminders,summary score, compare to group
62367088|NCT03254940|EXPERIMENTAL|Arm 15: WT-EM-MR-SF-CS|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to self
62367089|NCT03254940|EXPERIMENTAL|Arm 16: WT-EM-MR-SF-CG|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to group
62367090|NCT03254940|EXPERIMENTAL|Arm 17: DT-SM-OR-SS-CS|Charge: daily tracking, self-generated motivational messages, one reminder, summary score, compare to self.
62367091|NCT03254940|EXPERIMENTAL|Arm 18: DT-SM-OR-SS-CG|Charge: daily tracking, self-generated motivational messages, one reminder, summary score, compare to group
62367092|NCT03254940|EXPERIMENTAL|Arm 19: DT-SM-OR-SF-CS|Charge: daily tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to self.
62367093|NCT03254940|EXPERIMENTAL|Arm 20: DT-SM-OR-SF-CG|Charge: daily tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to group
62742663|NCT06053138|EXPERIMENTAL|Ketosis|Ketosis (the condition being investigated) is obtained by ingestion of a ketone monoester
62367094|NCT03254940|EXPERIMENTAL|Arm 21: DT-SM-MR-SS-CS|Charge: daily tracking, self-generated motivational messages, multiple reminders, summary score, compare to self
62367095|NCT03254940|EXPERIMENTAL|Arm 22: DT-SM-MR-SS-CG|Charge: daily tracking, self-generated motivational messages, multiple reminders, summary score, compare to group.
62367096|NCT03254940|EXPERIMENTAL|Arm 23: DT-SM-MR-SF-CS|Charge: daily tracking, self-generated motivational messages, multiple reminders, specific goal feedback, compare to self.
62367097|NCT03254940|EXPERIMENTAL|Arm 24: DT-SM-MR-SF-CG|Charge: daily tracking, self-generated motivational messages, multiple reminders, specific goal feedback, compare to group
62367098|NCT03254940|EXPERIMENTAL|Arm 25: DT-EM-OR-SS-CS|Charge: daily tracking, expert-generated motivational messages, one reminder, summary score, compare to self
62367099|NCT03254940|EXPERIMENTAL|Arm 26: DT-EM-OR-SS-CG|Charge: daily tracking, expert-generated motivational messages, one reminder, summary score, compare to group
62367100|NCT03254940|EXPERIMENTAL|Arm 27: DT-EM-OR-SF-CS|Charge: daily tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to self
62367101|NCT03254940|EXPERIMENTAL|Arm 28: DT-EM-OR-SF-CG|Charge: daily tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to group
62367102|NCT03254940|EXPERIMENTAL|Arm 29: DT-EM-MR-SS-CS|Charge: daily tracking, expert-generated motivational messages, multiple reminders, summary score, compare to self
62367103|NCT03254940|EXPERIMENTAL|Arm 30: DT-EM-MR-SS-CG|Charge: daily tracking, expert-generated motivational messages, multiple reminders, summary score, compare to group
62367104|NCT03254940|EXPERIMENTAL|Arm 31: DT-EM-MR-GF-CS|Charge: daily tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to self
62367105|NCT03254940|EXPERIMENTAL|Arm 32: DT-EM-MR-GF-CG|Charge: daily tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to group.
62367106|NCT02071641|EXPERIMENTAL|Sunitinib|Patients will be treated in repeated 6-week cycles with 50 mg sunitinib orally daily for 4 weeks followed by 2 weeks off.
62367107|NCT02808013|EXPERIMENTAL|NDS-446|NDS-446
62367108|NCT02808013|PLACEBO_COMPARATOR|Placebo|Placebo
62367109|NCT04573192|EXPERIMENTAL|Phase 1 part: Dose Finding|"Phase I part:~Dose Finding Patients will be treated in cohorts according to a traditional 3+3 design with lomustine on Day 1 and L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26, of a 42-days cycle at different dose levels.~The RD will be confirmed following a traditional 3+3 design.~Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine~The dose of 13 ug/kg L19TNF will be declared the RD in case none of three or not more than one out of 6 patients experienced a DLT. Dose limiting toxicity will be assessed during the dose-escalation from Day 1 through Day 42 after the first administration of lomustine and study drug (Cycle 1). Not more than 2 patients might be treated simultaneously in Cycle 1."
62367110|NCT04573192|EXPERIMENTAL|Phase II part: Signal Seeking|"118 Patients will be randomized 1:1 and treated with either lomustine on day 1 and L19TNF on Days 1, 3 and 5, and on Days 22, 24, and 26 of a 42-days cycle at the RD established in the phase I part of the study or with lomustine on day 1 of a 42-days cycle.~* Treatment Arm 1: L19TNF plus Lomustine~* Treatment Arm 2: Lomustine"
62367111|NCT00539318||GI Cancer|
62367112|NCT00111436|EXPERIMENTAL|50 mg|50 mg once weekly
62367113|NCT00111436|EXPERIMENTAL|100 mg|50 mg twice weekly
62367114|NCT00557323||1|Patients being treated for hyperphosphatemia with any marketed product
62367115|NCT00646750|EXPERIMENTAL|1|BEAM preceded by Ybritumomab Tiuxetan (Zevalin)
62367116|NCT01570452||healthy volunteers|healthy subjects not affected by benign or malignant colonic disease
62367117|NCT01570452||benign colonic tumor patients|patients affected by benign colonic tumor such as adenoma
62367118|NCT01570452||cancer patient I-II stage|Patients affected by colonic cancer in I-II stage
62367119|NCT01570452||cancer patients III-IV stage|Patients affected by colonic cancer in III-IV stage
62742664|NCT06053138|PLACEBO_COMPARATOR|Control|The control arm is a drink matched in taste, volume, appearence, and viscosity to that of the active/experimental arm
62742665|NCT05780801|EXPERIMENTAL|Live microbiome therapeutic|Live microbiome therapeutic prepared as Allogeneic Microbiota in Glycerol (10%) (AMG)
62742666|NCT03440151|EXPERIMENTAL|contralateral submental flap for tongue cancer defect|
62742667|NCT03440151|ACTIVE_COMPARATOR|primary closure for tongue cancer defect|
62367120|NCT02296294|ACTIVE_COMPARATOR|Fluid Therapy|"Intravenous isotonic fluid therapy of Elo-mel® (Fresenius Kabi Austria) at a rate of 0,50ml/kg/min for one hour.~Body Composition Monitoring every 10 minutes for 6hours."
62367121|NCT02296294|PLACEBO_COMPARATOR|Zero Therapy|Body Composition Monitoring every 10 minutes for 6hours. No intravenous fluid therapy
62367122|NCT00565357|EXPERIMENTAL|E|
62367123|NCT00565357|NO_INTERVENTION|C|
62367124|NCT02109978||Responders|Patients with Type 2 diabetes that have been taking a second- or third-line glucose-lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R agonists, SGLT2 inhibitors, Glitazone or insulin) for at least 4 months.
62367125|NCT02109978||Progressors|Patients with Type 2 diabetes that progressed to requiring insulin treatment ≤10 years from diagnosis or have had no requirement for insulin treatment \>10 years from diagnosis.
62367126|NCT00223912|OTHER|1|Lower-extremity functional electrical stimulation
62367127|NCT02058641|EXPERIMENTAL|Part A|Part A will consist of 2 sessions. In Session 1, 3 blisters will be induced by a challenging agent (cantharidin solution 0.2 %, with 5 microliter administered topically) in T2DM subjects on Day 1. Blisters will be harvested 48 (+/-2) hour (hr) post induction. In Session 2, the same subjects will be administered darapladib EC tablet 160 mg orally, once daily for 11 days. On Day 10, 3 blisters will be induced by cantharidin. Blisters will be harvested 48 (+/-2) hr post induction.
62367128|NCT02058641|EXPERIMENTAL|Part B|In Part B, healthy subjects will be enrolled and will follow the same dosing procedure as in Part A. The decision to initiate Part B will be made by the GSK study team based on an evaluation of data from Part A.
62367129|NCT02031627|EXPERIMENTAL|pneumatic compression - 1 hour per day|Pneumatic compression device - 12 consecutive days undergoing a 1 hour treatment regimen.
62367130|NCT02031627|EXPERIMENTAL|pneumatic compression - 2 hours per day|Pneumatic compression device - 5 consecutive days undergoing 1 hour treatment in the am and 1 hour of treatment in the pm.
62367131|NCT02031627|EXPERIMENTAL|pneumatic compression - 4 hours per day|Pneumatic compression device - 5 consecutive days undergoing treatment twice per day consisting of 2 consecutive 1 hour treatments in the am and the pm (4 hours total)
62367132|NCT06318260|EXPERIMENTAL|ATTRwt|Dobutamine (Dobutrex®) infusion.
62367133|NCT03136913|ACTIVE_COMPARATOR|Closed Flap Technique|Healing by primary intention: Extraction and ridge preservation, utilizing non-resorbable membrane (Cytoplast® TXT-200 ) and freeze dried bone allograft (MinerOss® Cortical and Cancellous Chips (FDBA)), with flaps in primary coverage.
62367134|NCT03136913|ACTIVE_COMPARATOR|Open Flap Technique|Healing by secondary intention: Extraction and ridge preservation, utilizing non-resorbable membrane (Cytoplast® TXT-200) and freeze dried bone allograft (MinerOss® Cortical and Cancellous Chips (FDBA)), with flaps in position for healing by secondary intention.
62367135|NCT05137275|EXPERIMENTAL|Anti-5T4 CAR-raNK Cells|
62367136|NCT02811172||Healthy pregnant women|Healthy pregnant women
62367137|NCT02811172||Risk pregnant women|Hypertensive, obese and diabetic women
62367138|NCT03224104|EXPERIMENTAL|Group A - TG02 + RT|Elderly patients with IDH1R132H-non mutant and MGMT promoter-unmethylated anaplastic astrocytoma or glioblastoma who will receive TG02 and radiation therapy.
62367139|NCT03224104|EXPERIMENTAL|Group B - TG02 + TMZ|Elderly patients with IDH1R132H-non mutant and MGMT promoter-methylated anaplastic astrocytoma or glioblastoma who will receive TG02 and temozolomide.
62367140|NCT03224104|EXPERIMENTAL|Group C - TG02|Patients initially diagnosed with anaplastic astrocytoma or glioblastoma at first relapse post TMZ/RT --\> TMZ therapy who will receive TG02.
62742668|NCT02904629|EXPERIMENTAL|RCL Intervention|"Respecting the Circle of Life (RCL) includes peer-group \& youth-parent components. The peer-group component has 8 educational lessons, each lasting 90-120 minutes, delivered to self-selected same-sex peer groups of 8-10 AI teens. RCL lessons are delivered once/day during an 8-day summer basketball camp. The youth-parent component is one educational lesson lasting 90-120 minutes delivered within 3 months after camp to a teen and parent together at home. Total RCL duration is 810-1,080 minutes over 3 months. All 8 days of the camp are study days, in which RCL youth will receive one lesson each day. The investigators will evaluate RCL's impact on key sexual and reproductive health risk factors at 3-, 9-, 12-, 24-, and 36-month post-intervention follow-up time points."
62367141|NCT00668772|EXPERIMENTAL|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
62367142|NCT00668772|ACTIVE_COMPARATOR|Tiotropium QD|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
62367143|NCT00668772|ACTIVE_COMPARATOR|Salmeterol BID|Salmeterol Inhalation Powder, hard PE capsule
62367144|NCT00668772|ACTIVE_COMPARATOR|Tiotropium/Salmeterol QD + Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
62367145|NCT00668772|PLACEBO_COMPARATOR|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
62367146|NCT02817750|EXPERIMENTAL|zolpidem hemitartarate (fasting + post-prandial)|zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
62367147|NCT02817750|EXPERIMENTAL|zolpidem hemitartarate (post-prandial + fasting)|zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
62367148|NCT04964557|EXPERIMENTAL|AZD8233|AZD8233 for subcutaneous use
62367149|NCT04964557|PLACEBO_COMPARATOR|Placebo|Placebo solution for subcutaneous injection
62367150|NCT01041001|EXPERIMENTAL|Cartistem|A single dose of 500㎕/㎠ of cartilage defect
62367151|NCT01041001|ACTIVE_COMPARATOR|Microfracture treatment|
62367152|NCT05018468|EXPERIMENTAL|ventilation with an anatomical facial mask|Intervention group 1: Patients in this group undergo ventilation with an anatomical facial mask and 100% oxygen for three minutes. Intervention group 2: Patients in this group undergo ventilation with a nasal mask and 100% oxygen for three minutes. In both groups, ventilation will be performed with the controlled mode of the anesthesia machine with a volume of 8 cc/kg and a speed of 12-20/min.
62367153|NCT05018468|EXPERIMENTAL|ventilation with a nasal mask|Intervention group 2: Patients in this group undergo ventilation with a nasal mask and 100% oxygen for three minutes. Ventilation will be performed with the controlled mode of the anesthesia machine with a volume of 8 cc/kg and a speed of 12-20/min.
62367154|NCT03944304|EXPERIMENTAL|Paclitaxel|Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
62367155|NCT03157336|EXPERIMENTAL|Peer-led Intervention|Peers (community women in leading roles) training other women in the wetting method for safe processing of cassava in a non-inferiority intervention trial.
62367156|NCT03157336|EXPERIMENTAL|Specialist-led Intervention|Specialists (nutritionists) training other women in the wetting method for safe processing of cassava in a non-inferiority intervention trial..
62367157|NCT00829062|NO_INTERVENTION|Glucose sensor|Children who have assented to wear a 72 hour physician ordered continuous glucose monitor.
62367158|NCT03382262|EXPERIMENTAL|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
62367159|NCT03382262|ACTIVE_COMPARATOR|TAcs 40 mg|Single intra-articular (IA) injection of TAcs 40 mg
62367160|NCT02705222|ACTIVE_COMPARATOR|D&C group|Women will undergo D\&C
62367161|NCT02705222|ACTIVE_COMPARATOR|Hysteroscopy group|Women will undergo hysteroscopy
62367162|NCT03869164|EXPERIMENTAL|ValmpClamp Arm|
62367163|NCT00439725|EXPERIMENTAL|Rivaroxaban (Xarelto, BAY59-7939)|Participants were to receive rivaroxaban 20 mg oral tablet once daily
62367164|NCT00439725|PLACEBO_COMPARATOR|Placebo|Participants were to receive matching placebo oral tablet once daily
62367165|NCT00929136|EXPERIMENTAL|Endotoxin|
62367166|NCT01455506|EXPERIMENTAL|Decitabine with fludarabine and busulfan|decitabine with fludarabine and busulfan in the setting of allogeneic stem cell transplantation
62367167|NCT05616845|EXPERIMENTAL|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|There is only one arm in this study which is to enable high qualitative estimation of bilirubin levels in the blood of new-borns with darker skin and with high melanin content such as Filipino neonates.
62367168|NCT01313039|EXPERIMENTAL|AZD6244|
62367169|NCT05455307|EXPERIMENTAL|single arm|single arm without placebo control
62367170|NCT02596828|EXPERIMENTAL|RIST|
62367171|NCT00647907|EXPERIMENTAL|A|
62367172|NCT00914238|EXPERIMENTAL|5 year|5 years OPUS treatment
62367173|NCT00914238|ACTIVE_COMPARATOR|2 years of OPUS treatment|2 years OPUS treatment and 3 years of treatment as usual
62367174|NCT02219737|EXPERIMENTAL|Treatment (ibrutinib, R-ICE)|Patients receive ibrutinib PO QD on days 1-21, rituximab IV on day 1, ifosfamide IV on day 3, carboplatin IVPB on day 3, and etoposide IVPB on days 2-4. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62367175|NCT02915289|ACTIVE_COMPARATOR|Povidone Iodine|10% povidone iodine solution will be used for vaginal cleansing prior to non-emergent cesarean section. The preparation will be applied according to the manufacture guidelines with a minimum of four completed minutes of drying time before placement of surgical drapes. The group will receive standard obstetrical care, continuous fetal monitoring, and pre-operative prophylactic antibiotics at least one hour prior to skin incision.
62367176|NCT02915289|ACTIVE_COMPARATOR|Chlorhexidine gluconate|4% chlorhexidine gluconate solution will be used for vaginal cleansing prior to non-emergent cesarean section. The preparation will be applied according to manufacture guidelines. The group will receive standard obstetrical care, continuous fetal monitoring, and pre-operative prophylactic antibiotics at least one hour prior to skin incision.
62367177|NCT02748525|EXPERIMENTAL|CCK then Milk|CCK administered and HIDA scan performed. Results analyzed, if ejection fraction is low, patient is given milk to drink, and HIDA scan performed again. Results are analyzed to determine if ejection fraction is still low.
62367178|NCT05171855|EXPERIMENTAL|Lonapegsomatropin|Lonapegsomatropin administered once-weekly by subcutaneous injection
62367179|NCT01620593|PLACEBO_COMPARATOR|Placebo|Metabolic consequences including development of hyperinsulinemia and insulin resistance using metformin compared to placebo in men on castration therapy.
62367180|NCT01620593|ACTIVE_COMPARATOR|Metformin|Metabolic consequences including development of hyperinsulinemia and insulin resistance using metformin compared to placebo in men on castration therapy. In the rare case where a patient may not tolerate 500 mg three times a day, he may remain on the study taking only 500 mg twice a day.
62367181|NCT01332695|EXPERIMENTAL|ST101|ST101 oval tablets
62367182|NCT01332695|PLACEBO_COMPARATOR|Placebo|oval tablets to match ST101 tablet
62367183|NCT01176890|EXPERIMENTAL|Vago|Truncally vagotomized subjects (due to duodenal ulcer operation)
62367184|NCT01176890|EXPERIMENTAL|Cardia|truncally vagotomized subjects (due to esophagus resection)
62367185|NCT01176890|EXPERIMENTAL|Healthy controls|Healthy control subjects
62367186|NCT04602819|EXPERIMENTAL|Experimental|
62367187|NCT03362489|OTHER|IVF / IVF-ICSI|In Vitro Fertilization / In Vitro Fertilization - Intracytoplasmic Sperm Injection (ICSI)
62367188|NCT03362489|OTHER|IUI|Intrauterine insemination
62367189|NCT04822441||Patients who contracted dengue fever before 34 weeks of amenorrhea|Patients who contracted biologically proven dengue fever during pregnancy before 34 weeks outside the peri-partum period (more than 12 days before childbirth)
62367190|NCT04822441||Patients who contracted dengue fever after 34 weeks of amenorrhea|Patients who contracted biologically proven dengue fever during pregnancy after 34 weeks outside the peri-partum period (more than 12 days before childbirth)
62367191|NCT04822441||Patients who have contracted dengue during the peripartum period|Patients who have contracted dengue during the peripartum period or who have a suspicion of dengue (in the 12 days preceding childbirth)
62367192|NCT02883426|EXPERIMENTAL|Group 1: H3N2v Seronegative Adults: H3N2v LAIV|Participants will receive one dose of H3N2v LAIV on Day 0 (study entry). They will then receive one dose of H3N2v IIV on Day 84.
62367193|NCT02883426|EXPERIMENTAL|Group 2: H3N2v Seropositive Adolescents: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
62367194|NCT02883426|PLACEBO_COMPARATOR|Group 2: H3N2v Seropositive Adolescents: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
62367195|NCT02883426|EXPERIMENTAL|Group 3: H3N2v Seronegative Adolescents: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
62367196|NCT02883426|PLACEBO_COMPARATOR|Group 3: H3N2v Seronegative Adolescents: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
62367197|NCT02883426|EXPERIMENTAL|Group 4: Children: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
62367198|NCT02883426|PLACEBO_COMPARATOR|Group 4: Children: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
62367199|NCT01603706|ACTIVE_COMPARATOR|Echo guided implantation group|Echo guided implantation group Patients undergoing speckle tracking based LV lead implantation.
62367200|NCT01603706|NO_INTERVENTION|Conventional implantation group|Patients undergoing conventional LV lead implantation
62367201|NCT02918539||RAmP Registry Patients|Patients who have a) objectively verified cognitive impairment and etiology diagnosed or suspected to be Alzheimer's disease and b) a positive amyloid scan from either an existing amyloid scan that has been interpreted as positive or a florbetapir F 18 PET scan via protocol addendum
62367202|NCT00493610|OTHER|1|
62367203|NCT03809247||Pancreatic cancer|such as Pancreatic ductal adenocarcinoma, Pancreatic acinar adenocarcinoma, and so on.
62367204|NCT03809247||Other pancreatic diseases|such as chronic pancreatitis, Intraductal papillary mucinous neoplasm (IPMN); Solid pseudopapillary tumors (SPT); Serous cystic neoplasm (SCN); Pancreatic neuroendocrine neoplasm (P-NN); Mucinous cystic neoplasm (MCN) and so on.
62367205|NCT02392468|EXPERIMENTAL|BI 409306 25 milligram (mg) - Alzheimer patients|Alzheimer patients received once daily (QD) orally one tablet of 25 mg of BI 409306 and two 50 mg matching placebo tablets for 14 days.
62367206|NCT02392468|EXPERIMENTAL|BI 409306 100 mg - Alzheimer patients|Alzheimer patients received once daily (QD) orally 100 mg of BI 409306 (two 50 mg active tablets) and one 25 mg matching placebo tablet for 14 days.
62367207|NCT02392468|EXPERIMENTAL|BI 409306 25 mg - Schizophrenia patients|Schizophrenia patients (cognitive impairment associated with schizophrenia) received once daily (QD) orally one tablet of 25 mg of BI 409306 and two 50 mg matching placebo tablets for 14 days.
62367208|NCT02392468|EXPERIMENTAL|BI 409306 100 mg - Schizophrenia patients|Schizophrenia patients (cognitive impairment associated with schizophrenia) received once daily (QD) orally 100 mg of BI 409306 (two 50 mg active tablets) and one 25 mg matching placebo tablet for 14 days.
62367209|NCT02392468|ACTIVE_COMPARATOR|BI 409306 25 mg - Healthy volunteers|Age-comparable healthy volunteers received once daily (QD) orally one tablet of 25 mg of BI 409306 and two 50 mg matching placebo tablets for 14 days.
62367210|NCT02392468|ACTIVE_COMPARATOR|BI 409306 100 mg - Healthy volunteers|Age-comparable healthy volunteers received once daily (QD) 100 mg of BI 409306 (two 50 mg active tablets) and one 25 mg matching placebo tablet orally for 14 days.
62367211|NCT00961558|NO_INTERVENTION|Observation arm|Patient will not to undergo any form of Assisted Reproductive Technologies for a period of 6 months
62367212|NCT00961558|OTHER|Surgery Arm|Patients will have varicocelectomy within 1 month of assessment and will not undergo any form of Assisted Reproductive Technologies for a period of 6 months after surgery
62367213|NCT03713827|ACTIVE_COMPARATOR|"composite resin, Ceram-x One Universal"|"tooth restoration with nano-ceramic composite resin Ceram-x one Universal"
62367214|NCT03713827|ACTIVE_COMPARATOR|"glass ionomer cement, Equia Forte"|"Tooth restoration with glass ionomer cement (Glass hybrid restorative system) Equia Forte"
62367215|NCT00610207|EXPERIMENTAL|AFP|Anal fistula plug placement performed during surgical procedure
62367216|NCT04148768|ACTIVE_COMPARATOR|Inferential therapy|Interferential therapy will be given using 4 electrode methods. The 'medium frequency' currents (medium frequency in electromedical terms is usually considered to be 1KHz-100KHz). These medium frequency currents, passed through the tissues simultaneously, where they are set up so that their paths cross \& they literally interfere with each other. This interaction gives rise to an interference current (or beat frequency) which has the characteristics of low-frequency stimulation. Pre-Post Y balance test will be used after 4 sessions to measure the improvement in balance in the population
62367217|NCT04148768|ACTIVE_COMPARATOR|Shortwave diathermy|4 sessions of treatment will be given to the participants with SWD. Pre-post Y balance test will be used to measure balance in the population
62367218|NCT04833790|EXPERIMENTAL|Free distribution of ORS + standardized patient with ORS preference|Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates a preference for ORS.
62367219|NCT04833790|EXPERIMENTAL|Free distribution of ORS + standardized patient with Antibiotic preference|Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates a preference for Antibiotics.
62367220|NCT04833790|EXPERIMENTAL|Free distribution of ORS + standardized patient with no preference|Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment.
62367221|NCT04833790|EXPERIMENTAL|Free distribution of ORS + standardized patient with no preference + no financial incentive|Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment and indicates that they will purchase whatever the provider recommends from a relative's drug shop.
62367222|NCT04833790|EXPERIMENTAL|Status quo ORS supply + standardized patient with ORS preference|Providers assigned to this arm will have status who ORS supply. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates a preference for ORS.
62367223|NCT04833790|EXPERIMENTAL|Status quo ORS supply + standardized patient with Antibiotic preference|Providers assigned to this arm will have status who ORS supply. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates a preference for Antibiotics.
62367224|NCT04833790|EXPERIMENTAL|Status quo ORS supply + standardized patient with no preference|Providers assigned to this arm will have status who ORS supply. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment.
62367225|NCT04833790|EXPERIMENTAL|Status quo ORS supply + standardized patient with no preference + no financial incentive|Providers assigned to this arm will have status who ORS supply. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment and indicates that they will purchase whatever the provider recommends from a relative's drug shop.
62367226|NCT00678236|ACTIVE_COMPARATOR|1|Refobacin Bone Cement R
62367227|NCT00678236|ACTIVE_COMPARATOR|2|Refobacin Plus Bone Cement
62367228|NCT00703430|EXPERIMENTAL|1|Memantine
62367229|NCT01608529|EXPERIMENTAL|Cyclist group|
62367230|NCT03892434|ACTIVE_COMPARATOR|Bevacizumab|
62367231|NCT03892434|ACTIVE_COMPARATOR|Dexamethasone|
62367232|NCT05703113|EXPERIMENTAL|Group trained with Web 2.0 tools|Group trained with Web 2.0 tools: Web 2.0 tools were used both while making presentations to the students and at the time of evaluation. Wordaart, google form, padlet, canva, bubbl.us were used in the presentation as Web 2.0 tools. For reviews kahoot, Socrative, Bamboozle, Mentimeter and Who Wants To Be A Millionaire? application is used.
62367233|NCT05703113|NO_INTERVENTION|Control Group|Lessons were taught with traditional learning method.
62367234|NCT04713670|EXPERIMENTAL|(A) T-V14|
62367235|NCT04713670|EXPERIMENTAL|(B) T-V7|
62367236|NCT04713670|EXPERIMENTAL|(C) D-V14|
62367237|NCT04713670|EXPERIMENTAL|(D) HD-V14|
62367238|NCT04713670|EXPERIMENTAL|(E) BQ-V14|
62367239|NCT04713670|EXPERIMENTAL|(F) RH-V14|
62742669|NCT02904629|OTHER|Control|"The control program includes peer-group \& youth-parent components. The peer-group component has 8 educational lessons, each lasting 90-120 minutes, delivered to self-selected same-sex peer groups of 8-10 AI teens. Control lessons are delivered once/day during an 8-day summer basketball camp. The youth-parent component is one educational lesson lasting 90-120 minutes delivered within 3 months after camp to a teen and parent together at home. Total control duration is 810-1,080 minutes over 3 months. All 8 days of the camp are study days, in which control youth will receive one lesson each day. The investigators will evaluate the control program's impact on key sexual and reproductive health risk factors at 3-, 9-, 12-, 24-, and 36-month post-intervention follow-up time points."
62367240|NCT04713670|EXPERIMENTAL|(G) BQ-L14|
62367241|NCT04713670|EXPERIMENTAL|(H) T-L14|
62567156|NCT05430750|ACTIVE_COMPARATOR|Non-N2O group|Ventilation will be initiated with 2% Sevoflurane in O2-Air (60 % FiO2 @ 3.0L/min) till the time it reaches MAC 0.5. Once MAC 0.5 reached, the FGF is decreased to 1.0L (Low-flow). The incision is allowed when MAC 1.0 is achieved .At 20-minutes time point post induction if MAC 1.0 is not achieved at 2% sevoflurane then the sevoflurane vaporizer concentration will be adjusted to achieve MAC 1.0, before incision is allowed. Anaesthesia will be maintained at MAC 1.0 throughout. After surgery is over, the O2 - Sevoflurane will be stopped and FGF increased to 3.0L with 100% O2.
62567157|NCT06377813|EXPERIMENTAL|Group A|This group will include 24 participants, the interventions will be given for 35-45 mins. All the participants will follow the same standardized exercise protocol 5 days a week, for 12 weeks.
62742670|NCT04324541||Mexican American Adults|No intervention
61986276|NCT02280772|EXPERIMENTAL|Glucomannan|Glucomannan orally, 3g/day (in three divided doses), for 12 weeks
62367242|NCT02774044|EXPERIMENTAL|Cadisurf (goat lung surfactant extract)|Neonates in the intervention group will be intratracheally administered 100 mg/kg of GLSE (CADISURF®).
62367243|NCT02774044|ACTIVE_COMPARATOR|Survanta (Beractant)|
62367244|NCT00493155|EXPERIMENTAL|1|
62367245|NCT04829461|EXPERIMENTAL|Ambu® aScope™ 4 Cysto|Ureteral stent removal procedure performed with Ambu® aScope™ 4 Cysto (single-use cystoscope).
62367246|NCT04829461|ACTIVE_COMPARATOR|Standard of Care (SOC)|Ureteral stent removal procedure performed with standard of care (reusable cystoscope).
62367247|NCT06396988|EXPERIMENTAL|Novamin|
62367248|NCT06396988|ACTIVE_COMPARATOR|Parodontax|
62367249|NCT02756546|NO_INTERVENTION|Control|Healthy volunteers
62367250|NCT02756546|ACTIVE_COMPARATOR|Patients|SLE patients further divided into mild and severe patients
62367251|NCT00003838|OTHER|Donor|The HLA matched donor will receive granulocyte colony-stimulating factor (G-CSF) with apheresis collections of PBPC on day 5 and day 6 if required. G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.
62367252|NCT00003838|EXPERIMENTAL|Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality|Participants at high risk for transplant related complications and mortality will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m\^2 intravenously daily x 5 days followed by a peripheral blood hematopoietic progenitor cell graft targeted to deliver \>5x10\^6 CD34+ cells/kg.
62367253|NCT00003838|EXPERIMENTAL|Group B: Stem Cell Transplant in Debilitating Hematologic Diseases|Participants with hematologic diseases associated with reasonable longevity, shown to be curable by allogeneic Bone Marrow Transplant (BMT) but where concern for a high procedural mortality with conventional BMT will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m\^2 intravenously daily x 5 days followed by a peripheral blood hematopoietic progenitor cell graft targeted to deliver \>5x10\^6 CD34+ cells/kg.
62367254|NCT05029336|EXPERIMENTAL|CD3/CD19 depleted ASCT|The test article is autologous stem cell transplant with a CD3/CD19-depleted stem cell product.
62742671|NCT04190381|EXPERIMENTAL|FR-Mask application|
62742672|NCT04313400|EXPERIMENTAL|Part 1 Dose Escalation: 3% to 70% of the BSA|Open-label, five (5) cohorts were sequentially enrolled. AMTX-100 CF 1.1% w/w, topically applied twice a day for 7 consecutive days to all treatable AD affected areas from 3% to 70% of the Body Surface Area (BSA) (3% BSA ≤ AD Affected Area ≤ 70% BSA)
62742673|NCT04313400|EXPERIMENTAL|Part 2 Group A: 1.1% w/w|AMTX-100 CF3 (1.1% w/w), topically applied twice a day for 28 consecutive days to all treatable AD affected areas
62742674|NCT04313400|PLACEBO_COMPARATOR|Part 2 Group B: Placebo|Placebo (Vehicle) (0% w/w), topically applied twice a day for 28 consecutive days to all treatable AD affected areas
62742675|NCT02353702|EXPERIMENTAL|Infusion of Ropivacaine during 48 hours|"Evaluation of diaphragmatic function with Sniff test after 48h continuous parietal infiltration of Ropivacaine using parietal catheter at the following dose :~20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml)"
62742676|NCT02353702|PLACEBO_COMPARATOR|Infusion of placebo during 48 hours|"Evaluation of diaphragmatic function with Sniff test after 48h continuous parietal infiltration of placebo using parietal catheter at the following dose :~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour (NaCl 0.9 %)"
62742677|NCT06444867|EXPERIMENTAL|LEO 158968|Participants with gout flares will receive a single SC dose of LEO 158968 on Day 1.
62742678|NCT06329752|EXPERIMENTAL|Sciatic Nerve block Arm (Single Arm)|
62742679|NCT01925118|EXPERIMENTAL|High-dose IL-2|
62742680|NCT03430024||Cases|"We will enrol 100 women who have been newly diagnosed with T2 (\>2cm) palpable invasive breast cancer having primary surgical treatment at Maidstone Hospital. We will exclude all patients with a metabolic disorder, significant co-morbidities and locally advanced or metastatic disease as well as those with a previous history of cancer treatment. We will collect data on tumour size, grade and phenotype as well as ER, progesterone receptor (PR) and Her-2 expression status and patient demographic information.~We will investigate the Association of Myosin VI with oestrogen receptor."
62742681|NCT03430024||Controls|A cohort of control breast tissue will be obtained from 20 patients undergoing benign surgical breast procedures. For those control patients having reduction mammoplasties the excised tissue will be core biopsied but patients having other types of benign surgery will have an extra core biopsy taken from breast tissue surrounding the lesion being excised.
62742682|NCT06659549|EXPERIMENTAL|GAL-101 ophthalmic solution|Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval
62742683|NCT06659549|PLACEBO_COMPARATOR|Placebo|Patient will apply daily 2 eye drops ofPlacebo at 5 minutes interval
62367255|NCT00023205|EXPERIMENTAL|Individualized education|Individualized education with materials written in plain language. Follow-up sessions/ phone contact as requested by the subject.
62367256|NCT00023205|ACTIVE_COMPARATOR|Standard care|1 session of education with provision of standard Arthritis Foundation materials.
62367257|NCT01494025|EXPERIMENTAL|Diet and Exercise|
62367258|NCT04739241|EXPERIMENTAL|Group A (experimental arm)|Premixed insulin therapy
62367259|NCT04739241|ACTIVE_COMPARATOR|Group B (active comparator)|Basal bolus insulin therapy
62367260|NCT03437993|EXPERIMENTAL|Recollect|Recollect is a video game which incorporates scientifically supported renditions of N-Back, Item Span, and Multiple-Identity tracking tasks. These tasks are independently shown to improve working memory in a manner that transfers to untrained tasks.
62367261|NCT03437993|SHAM_COMPARATOR|Tetris|Tetris is a video game which has not been shown to have any benefits in the improvement of executive functioning.
62367262|NCT03795636|EXPERIMENTAL|Garlic extracts root canal irrigation group|"Experimental group treated with garlic extract~A 100 gram of garlic cloves has been cleaned, peeled and dried. Ethanol of 70% concentration was added for 60 seconds. The cloves were placed in a laminar airflow chamber for evaporation of residual ethanol. Using a sterile mortar and pestle, cloves were homogenized aseptically and filtered through a double layer paper. The fully concentrated extracted was diluted to the concentration of 25% with distilled water"
62367263|NCT03795636|ACTIVE_COMPARATOR|Sodium hypochlorite root canal irrigation group|Control group which treated conventionally using .5 ml of 5.25% NaOCl (COLTENE®ENDO, Switzerland)
62367264|NCT00644124|EXPERIMENTAL|Aflibercept RCHOP 14|Aflibercept (25 mg/ml by IV over an hour) in combination with fixed dose of rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) administered every 2 weeks. A dose of 2.0 mg/kg administered as Dose Level 1, 4.0 mg/kg as Dose Level 2, and 6.0 mg/kg dose as Dose level 3.
62367265|NCT00644124|EXPERIMENTAL|Aflibercept RCHOP 21|Aflibercept (25 mg/ml by IV over an hour) in combination with fixed dose of rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) administered every 3 weeks. A dose of 3.0 mg/kg administered as Dose Level 1, 6.0 mg/kg as Dose Level 2, and 8.0 mg/kg dose as Dose level 3.
62552808|NCT05228678||Dyspnea group|"Patients with prior diagnosis of COVID-19 and present with persistent dyspnea after 12 weeks of occurrence of symptoms every patient in this group will undergo Cardiopulmonary exercise test (CPET) protocol: -~1. As regard CPET protocol we prepared incremental treadmill exercise protocol in which the work rate increased at one-minute intervals.~2. The following parameters observed:~   1. Metabolic response~      * Oxygen consumption VO2 (ml/ min):~     * P ETO2: Is the end-tidal O2 tension as measured from the exhaled air.~     * P ETCO2: Is the end-tidal CO2 tension as measured from the exhaled air. Normally decreased during exercise.~     * Anaerobic Threshold (AT): Is defined as the VO2 (in L/min) at which there is substantial transition to anaerobic metabolism to produce extra energy~  2. Ventilatory response~      * Minute ventilation :~     * Breathing reserve(BR): Breathing reserve = measured/predicted minute ventilation maximum~     * Tidal volume (VT):~     * Respiratory frequency (RF)"
62742684|NCT01374165||Low dose SANGUINATE™|"160 mg/kg of SANGUINATE™.~SANGUINATE™ (PEG-bHb-CO) an OTA is composed of three moieties, polyethylene glycol, bHb and carbon monoxide that act in a specific manner to promote the delivery of oxygen to tissue. SANGUINATE™ was not developed to be used as a blood substitute. It is instead an oxygen transfer agent intended to functionally deliver and release oxygen to hypoxic tissues."
61986277|NCT02280772|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin orally, 3g/day (in three divided doses), for 12 weeks
62742685|NCT01374165||High dose of SANGUINATE™|"320 mg/kg of SANGUINATE™.~SANGUINATE™ (PEG-bHb-CO) an OTA is composed of three moieties, polyethylene glycol, bHb and carbon monoxide that act in a specific manner to promote the delivery of oxygen to tissue. SANGUINATE™ was not developed to be used as a blood substitute. It is instead an oxygen transfer agent intended to functionally deliver and release oxygen to hypoxic tissues."
62367266|NCT02005510|EXPERIMENTAL|In-home HPV Screening|"Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). Usual care consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women."
62367267|NCT02005510|PLACEBO_COMPARATOR|Usual Care|"Usual care. Usual care consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women."
62367268|NCT01353183|EXPERIMENTAL|Colonic biopsies|Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy
62367269|NCT01285336|EXPERIMENTAL|The genetic and the functional study|
62367270|NCT03945201|ACTIVE_COMPARATOR|Standard of care|"Participants receive normal cardiac rehabilitation according to approved standard of care. They use multiple pieces of exercise equipment at each session for increasing amounts of time and at incrementally increasing levels of difficulty. After establishing a baseline, participants are allowed to use the treadmill for up to 15 minutes at each session."
62367271|NCT03945201|EXPERIMENTAL|Virtual walking trails|"Participants use multiple pieces of exercise equipment at each session for increasing amounts of time and at incrementally increasing levels of difficulty. After establishing a baseline, participants are allowed to use the treadmill for up to 15 minutes at each session. The treadmill is positioned in front of a vertically oriented high definition television screen showing Bionautica Trails, virtual walking trails created by Plas.md."
62367272|NCT01762527|EXPERIMENTAL|ART|Online adaptive radiotherapy
62367273|NCT01235338|EXPERIMENTAL|LDX (SPD489) + Venlafaxine XR (Effexor XR)|
62367274|NCT01235338|EXPERIMENTAL|Venlafaxine XR + LDX|
62367275|NCT00427791|EXPERIMENTAL|Etoposide + Total Body Irradiation + Rituximab|Etoposide 60 mg/kg intravenous (IV) Daily Over 4 Hours for 1 Day + Total Body Irradiation (TBI) 3 Gy Daily for 4 Days + Rituximab 375 mg/m\^2 IV Weekly Over 4-8 Hours for 4 Weeks
62367276|NCT00427791|EXPERIMENTAL|Etoposide + Total Body Irradiation|Etoposide 60 mg/kg IV Daily Over 4 Hours for 1 Day + TBI 3 Gy Daily for 4 Days
62367277|NCT02795611|EXPERIMENTAL|Treatment group|Patients who receive 'family-centered occupational therapy' in our hospital
62367278|NCT02795611|ACTIVE_COMPARATOR|Control group 1|Patients who receive regular occupational therapy in our hospital
62742686|NCT03023579|EXPERIMENTAL|The star excursion balance test|The star excursion balance test: simple test for dynamic balance
62367279|NCT02795611|OTHER|Control group 2|Patients who don't receive intervention in our hospital
62367280|NCT03657589||patients with 1 missing tooth|Patients with 1 missing anterior or premolar tooth and planned for implant surgery were recruited. Gingiva and alveolar bone were ultrasound scanned and compared to CT scans and direct measures during implant surgery.
62567158|NCT06377813|ACTIVE_COMPARATOR|Group B|This group will also include 24 participants, the interventions will be given for 20-30 mins. All the participants will follow the same standardized exercise protocol 5 days a week, for 12 weeks.
62742687|NCT02159339||gene-methylation|"gene-low-level of methylation: patients with early stage gastric carcinoma containing low-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.~gene-middle-level of methylation: patients with early stage gastric carcinoma containing middle-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.~gene-high-level of methylation: patients with early stage gastric carcinoma containing high-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.~gene-without of methylation: patients with early stage gastric carcinoma NOT containing methylated E-cadherin,GFRA1,p16,SRF or ZNF382 CpG island."
62742688|NCT05289141||Patients treated by high flow nasal oxygen therapy (Optiflow™)|
62742689|NCT05289141||Patients treated by other non-invasive ventilation or high concentration oxygen masks|
62742690|NCT03927547|EXPERIMENTAL|Inclined Sleep|Inclined mattress at 15 degrees
62742691|NCT03927547|NO_INTERVENTION|Flat Sleep|Plane mattress
62742692|NCT03791281|EXPERIMENTAL|BASIS|Received a 3-hour BASIS implementation strategy.
62742693|NCT03791281|ACTIVE_COMPARATOR|Attention Control|Received a 3-hour session designed to control for dose, information provided, and presenter effects.
62367281|NCT00863941|EXPERIMENTAL|A|Abrika Bupropion 150 mg XL Tablet, single dose
62367282|NCT00863941|ACTIVE_COMPARATOR|B|Wellbutrin XL® 150 mg Tablet, single dose
62367283|NCT05299138|EXPERIMENTAL|Marriage and Relationship Enhancement Skills (MRES) Intervention|The Intervention group will be assigned a Case Manager and begin Marriage and Relationship Enhancement Skills (MRES) class weekly and meet with their Case Manager as needed.
62367284|NCT05299138|NO_INTERVENTION|Wait list control|The Control group will be placed on a wait-list and offered services as soon as they complete the study's final 22-week follow-up measures. Control participants will not be assigned a Case Manager and will not receive any comparable services from our agency until they complete their 22-week measures.
62367285|NCT01747824||Agitation Group|Patients that are evaluated to have an altered mental status score greater than 1 will be enrolled in the Agitation Group.
62367286|NCT01747824||Pain Group|Patients that report severe pain secondary to a long bone fracture or dislocation and report a visual analog scale pain score greater than 7 will be enrolled in the Pain Group.
62367287|NCT02377271|EXPERIMENTAL|Bosentan|Bosentan at a dose of 125 mg two times daily, will be administered orally, twice a day, during eight weeks
62367288|NCT02377271|PLACEBO_COMPARATOR|Placebo|placebo drug , twice a day, during eight weeks
62367289|NCT04399824|EXPERIMENTAL|Arm I (SBRT)|Patients undergo SBRT in 5 fractions over 14 days in the absence of disease progression or unacceptable toxicity.
62742694|NCT06268873|EXPERIMENTAL|Baxdrostat/dapagliflozin|Participants randomised to the baxdrostat/dapagliflozin arm will initially receive a dose of baxdrostat lower dose and dapagliflozin. For participants that meet the up-titration criteria, baxdrostat may be up-titrated to higher dose.
62367290|NCT04399824|EXPERIMENTAL|Arm II (HDR brachytherapy)|Patients undergo HDR brachytherapy on day 1 and a second fraction within 14 days in the absence of disease progression or unacceptable toxicity.
62367291|NCT04057040|EXPERIMENTAL|Dose finding PTG-300 (Part 1); PTG-300 (Part 2); Open label extension PTG-300 (Part 3)|
62367292|NCT04057040|EXPERIMENTAL|Dose finding PTG-300 (Part 1); Placebo (Part 2); Open label extension PTG-300 (Part 3)|
62367293|NCT01886755|EXPERIMENTAL|ORS with probiotic and zinc|ORS with probiotic and zinc Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate
62367294|NCT01886755|PLACEBO_COMPARATOR|Placebo Comparator|Standard oral rehydration solution
62367295|NCT04597515|EXPERIMENTAL|Robot Reduction|The project consists in removing a breast disc at the base, causing a circular sagging skin cut of 2 to 3 cm .
62367296|NCT03478462|EXPERIMENTAL|CLR 131|CLR 131 intravenous administration
62367297|NCT05899894|ACTIVE_COMPARATOR|A - Low dose morphine|Low dose morphine 5mcg/kg/hr
62367298|NCT05899894|ACTIVE_COMPARATOR|B- standard dose morphine|Standard dose morphine 20mcg/kg/hr
62367299|NCT01352013|PLACEBO_COMPARATOR|Colored olive oil|
62367300|NCT01352013|ACTIVE_COMPARATOR|Omega-3 (oil)|
62367301|NCT05581355|EXPERIMENTAL|The effectiveness of receiving abdominal breathing training|Training for 8 weeks (1 time a week, 15 minutes each time). Performed one-on-one by a trainer in a sleep center. At home, you can use the abdominal breathing training video to train yourself (10 minutes a day, can be divided into 10 minutes), and you need to fill in the abdominal breathing training log.
62367302|NCT05581355|NO_INTERVENTION|The effectiveness of not receiving abdominal breathing training|The trainer does not provide abdominal breathing training, does not perform abdominal breathing exercises at home, and does not need to fill in abdominal breathing training logs.
62367303|NCT00044213|ACTIVE_COMPARATOR|EDTA + high dose vitamin|Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.
62367304|NCT00044213|PLACEBO_COMPARATOR|EDTA + high dose vitamin placebo|Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.
62367305|NCT00044213|PLACEBO_COMPARATOR|EDTA placebo + high dose vitamin|Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.
62367306|NCT00044213|PLACEBO_COMPARATOR|EDTA placebo + high dose vitamin placebo|Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.
62367307|NCT05263726|EXPERIMENTAL|DSMP through a mobile applications|This interventional divided the disease self-management program manual for patients with hypertension into 4 units, including: Unit 1: hypertension brief introduction and complications. Unit 2: dietary precautions for patients with hypertension. Unit 3: medication treatments for patients with hypertension. Unit 4: the content included stress management (emotional control, spiritual support) of patients with hypertension. The experimental group received the mobile apps educational program for at least 30 minutes each session and at least once every two days. After two weeks and six weeks, a follow-up telephone interview helped to strengthen the health self-management self-confidence. The researcher used the back office administration at the computer end to observe how the experimental group operated and used the mobile devices. The effect of interventions was then evaluated after three months when the patients returned.
62367308|NCT05263726|NO_INTERVENTION|Usual Care|Routine care
62367309|NCT04752917|EXPERIMENTAL|Intervention|Headphones
62367310|NCT04752917|NO_INTERVENTION|Control|Standard of care
62367311|NCT02480803|ACTIVE_COMPARATOR|continuous levodopa infusion|continuous intrajejunal infusion of levodopa-carbidopa
62367312|NCT02480803|ACTIVE_COMPARATOR|deep brain stimulation|Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
62367313|NCT04912661|ACTIVE_COMPARATOR|Immediate iron treatment|intravenous iron carboxymaltose before vaccination
62367314|NCT04912661|NO_INTERVENTION|No iron treatment|no intravenous iron carboxymaltose before vaccination
62367315|NCT03596970|EXPERIMENTAL|Everolimus with MMF (TAC-withdrawal)|Everolimus (RAD001) with MMF and Steroids
62367316|NCT03596970|ACTIVE_COMPARATOR|Everolimus with reduced TAC|Everolimus (RAD001) with reduced TAC and Steroids
62367317|NCT01067313|EXPERIMENTAL|Dialyzer Ultraflux EMiC2|Dialyzer Ultraflux EMiC2 used in Continuous Hemodialysis
62367318|NCT01067313|ACTIVE_COMPARATOR|Dialyzer Ultraflux AV1000S|Dialyzer Ultraflux AV1000S used in continuous Hemofiltration
62367319|NCT02422394|EXPERIMENTAL|Eltrombopag|"Phase 1: Eltrombopag 50 mg/day for 3 weeks. At the end of these 3 weeks of treatment: platelet count higher than 100 x10e9/L and no spontaneous bleeding, end therapy. In the other cases, treatment with eltrombopag 75 mg/day for 3 additional weeks.~Phase 2: Eltrombopag will be administered for 16 weeks. Eltrombopag will be initially given at 25 mg/day for 4 weeks. Every 4 weeks, the dosage will be modified as follows. (1) Bleeding score (WHO bleeding scale) 0-1 and platelet count between 30 and 100 x10e9/L: continue at the current dose; (2) Bleeding score 0-1 and platelet count higher than 100 x10e9/L: switch to the next lower dose; (3) Bleeding score 2-4 or platelet count lower than 30 x 10e9/L: switch to the next higher dose. The following dosages of eltrombopag are considered: 12.5 mg/day; 25 mg/day; 50 mg/day; 75 mg/day."
62367320|NCT04955301|NO_INTERVENTION|Control message group|Participants will not receive the priming manipulation.
62367321|NCT04955301|EXPERIMENTAL|Health benefits priming group|"Participants will be cueing with health benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have health benefits, such as..."
62367322|NCT04955301|EXPERIMENTAL|Environmental benefits priming group|"Participants will be cueing with environmental benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have environmental benefits, such as..."
62367323|NCT04955301|EXPERIMENTAL|Environmental and health co-benefits priming group|"Participants will be cueing with environmental and health co-benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have both benefits for health and the environment, such as..."
62367324|NCT04282460|EXPERIMENTAL|Baduanjin practice|Baduanjin practice group will be asked to use the Baduanjin training system to practice the whole set of Baduanjin at least once a day and at least 5 days each week for 3 months.
62367325|NCT04282460|ACTIVE_COMPARATOR|Regular physical exercise|The regular physical exercise group will be asked to take physical exercise for at least half an hour every day in addition to regular physical activities at school.
62367326|NCT00331084|EXPERIMENTAL|antibiotic steroid drops/single vial|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having cataract surgery
62367327|NCT00331084|ACTIVE_COMPARATOR|antibiotic steroids drops|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having cataract surgery
62367328|NCT03565991|EXPERIMENTAL|Combination of avelumab and talazoparib|Single arm open label
62742695|NCT06268873|ACTIVE_COMPARATOR|Dapagliflozin|Patients will receive one dose of dapagliflozin (active comparator) in combination with matching placebo daily
62742696|NCT06365775||Bilateral SSNHL|150 participants will be enrolled with SSNHL involving bilateral ears.
62742697|NCT06365775||Unilateral SSNHL|150 participants will be enrolled with SSNHL involving unilateral ear.
62367329|NCT01651312|EXPERIMENTAL|14C-labeled YM178|Single oral administration of 14C-labeled YM178
62742698|NCT06365775||Healthy Controls|100 age-matched healthy controls will be enrolled.
62367330|NCT05109611|ACTIVE_COMPARATOR|Nitric Oxide Releasing Solution|"Nasal spray with nitric oxide releasing solution (NORS) delivered up to 3 times daily morning, mid-day, and evening.~Maximum volume delivered: 0.56 mL NORS @ 0.11ppm\*hrs"
62367331|NCT05109611|PLACEBO_COMPARATOR|Placebo|"Nasal spray with isotonic saline delivered up to 3 times daily morning, mid-day, and evening.~Maximum volume delivered: 0.56 mL Saline @ 0.9%"
62367332|NCT03945448|EXPERIMENTAL|Single dose liposomal Amphotericin and fluconazole|"Experimental:~Single dose Ambisome 10mg/kg and Fluconazole 800mg for two weeks ,400mg for 8 weeks and 200mg upto 6 months. (standard of care therapy)"
62367333|NCT03945448|ACTIVE_COMPARATOR|fluconazole (standard of care)|Standard of care pre-emptive treatment fluconazole 800mg for two weeks ,400mg for 8 weeks and 200mg upto 6 months
62367334|NCT06265467|EXPERIMENTAL|Test Group- Closed Sinus elevation|Maxillary sinus floor elevation using osteotomes through a crestal approach. Followed by bone grafting using allogenic bone graft and simultaneous dental implant placement.
62367335|NCT06265467|ACTIVE_COMPARATOR|Control Group- Open sinus elevation|Maxillary sinus floor elevation using sinus elevation tools through a lateral window approach. Followed by bone grafting using allogenic bone graft and simultaneous dental implant placement.
62367336|NCT04439812||R=0|Patients without positive margins after gastrectomy for gastric cancer
62367337|NCT04439812||R=1|Patients with positive margins after gastrectomy for gastric cancer
62367338|NCT03557736|EXPERIMENTAL|Home-HIT|Home-based high-intensity interval training: participants performed 12 weeks of simple body weight exercises in a place of their own choosing 3x/week
62367339|NCT03557736|EXPERIMENTAL|Home-MICT|Home-based moderate-intensity interval training: participants performed 12 weeks of continuous exercise (running, swimming or cycling) in a place of their own choosing 3x/week
62367340|NCT03557736|EXPERIMENTAL|Lab-HIT|Laboratory-based high-intensity interval training: participants performed supervised cycle exercise under laboratory conditions 3x/week for 12 weeks
62367341|NCT03460470|ACTIVE_COMPARATOR|Sildenafil 40mgx3 daily|Sildenafil 40mgx3 daily for 6 months
62367342|NCT03460470|PLACEBO_COMPARATOR|Placebo tablet x3 daily|Placebo for Sildenafil 40mgx3 daily for 6 months
62367343|NCT02667392|EXPERIMENTAL|Biofeedback Group|Participants will wear a pressure-sensitive insole inside the shoe of their paretic limb. An auditory tone will sound when participants have provided sufficient load to active the pressure-sensitive in-sole.
62367344|NCT02667392|ACTIVE_COMPARATOR|Verbal Feedback Group|Participants will receive verbal feedback from a physical therapist regarding the amount of loading they are exerting on their paretic limb.
62367345|NCT06212388|EXPERIMENTAL|group A: IFN-α1B+ γδ T cells|"Stage 1: Neoadjuvant stage (Week 1-9, 3 cycles)~Stage 2: Surgical period (2 weeks, ±7 days after the last dose of neoadjuvant therapy) After multidisciplinary MDT team evaluation, the primary lesion and metastasis were resected in the corresponding departments.~Stage 3: Postoperative adjuvant period (3 weeks ±7 days -45 weeks, 15 cycles) γδ T cells administered intravenously every three weeks. Recombinant human interferon α1b administered 300μg every other day."
62367346|NCT06212388|ACTIVE_COMPARATOR|group B: Palizizumab+ γδ T cells|"Stage 1: Neoadjuvant stage (Week 1-9, 3 cycles)~Stage 2: Surgical period (2 weeks, ±7 days after the last dose of neoadjuvant therapy) After multidisciplinary MDT team evaluation, the primary lesion and metastasis were resected in the corresponding departments.~Stage 3: Postoperative adjuvant period (3 weeks ±7 days -45 weeks, 15 cycles) γδ T cells administered intravenously every three weeks.Pembrolizumab administered 200mg intravenously every three weeks."
62742699|NCT04343170|PLACEBO_COMPARATOR|control group|Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo.
62742700|NCT04343170|EXPERIMENTAL|ultra-short-term treatment|Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
62367347|NCT04059874|EXPERIMENTAL|donafenib tablets 1|This is the dose group was given once a day. donafenib tablets 1 100mg qd dose group
62367348|NCT04059874|EXPERIMENTAL|donafenib tablets 2|This is the dose group was given twice a day. donafenib tablets 2 100mg bid dose group
62367349|NCT06032572|EXPERIMENTAL|VRS100 robotic-assisted PCI|VRS100 robotic-assisted PCI
62367350|NCT06032572|ACTIVE_COMPARATOR|Manual PCI|Manual PCI
62367351|NCT05211245|EXPERIMENTAL|Pulse mode|Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central \& peripheral sensitization. The non-thermal effect of US can be explain by frequency resonance theory which states that the proteins in these structures absorbs mechanical energy thus altering the structure \& function, finally resulting in stimulation of phagocytosis, increase number of free radicals, increase cell membrane permeability, cellular proliferation \&acceleration of fibrinolysis
62742701|NCT06651151|EXPERIMENTAL|Experimental|"LTX-315 will be injected directly into the selected tumor once weekly for a maximum of 5 dosing days.~Pembrolizumab will be given as 200 mg IV infusion over 30 minutes every 3 weeks for a maximum of 18 doses of which three doses will be given prior to the planned surgery."
62742702|NCT04458441|ACTIVE_COMPARATOR|warm skin desenfection group|Povidion iodine will be used as a skin cleanser. povidion iodine will be heated sterile to 38 degrees with a ben-mari method and its temperature will be controlled by degrees. When it reaches the appropriate degree, the skin cleaning of the baby will be done sterile.
62367352|NCT05211245|ACTIVE_COMPARATOR|Continous mode|Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons \& joint capsules, thus leading to decrease in the pain \& muscle spasm, stiffness of the joint \& temporary increase in the blood flow.
62367353|NCT02619006||Immediate Cord Clamping|Healthy term infants who were previously randomized or assigned at birth to the control group known as immediate cord clamping. The cord was clamped and cut within10 seconds after birth.
62367354|NCT02619006||Delayed Cord Clamping or Cord Milking|Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
62367355|NCT04599972|EXPERIMENTAL|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
62367356|NCT04599972|PLACEBO_COMPARATOR|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
62367357|NCT01603979|EXPERIMENTAL|Dose-escalation AV-203 Monotherapy|dose-escalation of monotherapy AV-203 (an ERBB3 inhibitory antibody) by IV every two weeks
62367358|NCT01794546|EXPERIMENTAL|Immediate Telehealth|"The immediate intervention group will receive the telehealth intervention during the first 6 months of the study timeline."
62367359|NCT01794546|ACTIVE_COMPARATOR|Wait List Control|"The wait list control group will receive the telehealth intervention during months 6 through 12 of the study timeline."
62367360|NCT04761952|EXPERIMENTAL|n-3PUFA treatment group|On the basis of routine treatment, oral supplement of n-3PUFA was given to CD patients since 2-week-postoperative till 1-year-postoperative.
62742703|NCT04458441|NO_INTERVENTION|cold skin desenfection group|Povidion iodine will be used as a skin cleanser. povidion iodine will be used in the skin cleaning of the baby without any heating procedure.
62742704|NCT03094091|ACTIVE_COMPARATOR|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
62742705|NCT03094091|EXPERIMENTAL|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
62742706|NCT06495060||Clinical Nurse (Registered Nurse)|
62742707|NCT06495060||Nursing Practitioners|
62742708|NCT06439654|OTHER|LDL-C|Most recent LDL-C result
62742709|NCT04122911|EXPERIMENTAL|Temozolomide|Temozolomide 75mg/m2 metronomic schedule: one week on/one week off in a cycle of 28 days
62742710|NCT02419222|EXPERIMENTAL|Prism Adaptation|Prism Adaptation Treatment is 20 minutes long, administered 10 consecutive days
62742711|NCT06012318||Monoimmunotherapy group|
62367361|NCT04761952|PLACEBO_COMPARATOR|Conventional treatment group|Treatment of azathioprine (daily orally) or infliximab (intravenously, at 0, 2,6 weeks with every 8-week-interval later) was given since 2-week-postoperative till 1-year-postoperative.
62367362|NCT03746314||Supportive Care Leader|A staff member who is knowledgeable about supportive care services for adult oncology patients.
62367363|NCT03746314||Oncology Providers|Physicians, nurses, physicians assistants, nurse practitioners who routinely provide cancer care to adult oncology patients.
62367364|NCT05685394|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10mg P.O. daily for 6 months add-on to standard treatment
62367365|NCT05685394|NO_INTERVENTION|Control|No intervention. Patients will be followed for 6 months on their standard treatment.
62367366|NCT03647748|NO_INTERVENTION|Cellulize 532nm|Cellulize device using 532nm Green Light.
62367367|NCT03647748|SHAM_COMPARATOR|Cellulize Placebo (Sham Comparator)|"Cellulize modified to appear as if it is running, but does not use the 532nm light.~Sham Device, or Placebo."
62367368|NCT03121482|ACTIVE_COMPARATOR|HFNC alone|Control group
62367369|NCT03121482|EXPERIMENTAL|HFNC and NIV|
62367370|NCT05326074|EXPERIMENTAL|Animal assisted therapy cohort|This arm will be the group that is randomized to receiving animal assisted therapy during outpatient office visits.
62367371|NCT05326074|NO_INTERVENTION|Control therapy cohort|This arm will be the group that will receive the standard outpatient psychiatric treatment without animal therapy.
62367372|NCT02123394|PLACEBO_COMPARATOR|Placebo|The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
62367373|NCT02123394|EXPERIMENTAL|McKenzie method|The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
62742712|NCT06012318||Chemoimmunotherapy group|
62742713|NCT03654404|EXPERIMENTAL|Positive Psychology|"Participants will receive check-in/psychosocial support phone calls at weeks four, eight and twelve following enrollment.~At approximately 100-days post-HSCT, participants will begin an 8-week positive-psychology program involving weekly calls with an interventionist, in this case the principal investigator, and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).~Participants will complete self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
62742714|NCT06658444|EXPERIMENTAL|phonophoresis group|Twenty women will receive onion extract phonophoresis (3 sessions/week) for 12 weeks in addition to deep friction massage.
62742715|NCT06658444|SHAM_COMPARATOR|control group|Twenty women will receive sham ultrasound (3 sessions/week) for 12 weeks in addition to deep friction massage.
62742716|NCT01983488||Uveitis|Patient with a clinical diagnosis of Uveitis.
62367374|NCT01148576|OTHER|control group|patients only with chronic hepatitis B
62367375|NCT01148576|ACTIVE_COMPARATOR|model group|patients with chronic hepatitis B and hepatic steatosis
62367376|NCT01148576|EXPERIMENTAL|Essentiale group|patients with chronic hepatitis B and hepatic steatosis
62367377|NCT01148576|EXPERIMENTAL|treatment group 2|patients with chronic hepatitis B and hepatic steatosis
62367378|NCT03512275|EXPERIMENTAL|400mg cohort, no prior treatment with anti-TNF agent(s)|N=10 patients that have had no prior treatment with biological agents that block TNF will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.
62367379|NCT03512275|EXPERIMENTAL|400 mg cohort, prior treatment with anti-TNF agent(s)|N=10 patients that have failed anti-TNF therapy will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.
62367380|NCT01436357|EXPERIMENTAL|Arm A (Stage I and II)|Receive AdCh3NSmut1 at 2.5 x 10\^10 total virus particles (vp)/dose at day 0 followed by 1 dose of MVA-NSmut intramuscularly 56 days later at the dosage 1.8 x10\^8 plaque forming units (pfu): 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.
62367381|NCT01436357|PLACEBO_COMPARATOR|Arm B (Stage I and II)|Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56: 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.
62367382|NCT00654420|EXPERIMENTAL|Ph I: Dalotuzumab 5 mg/kg + Erlotinib|During the Phase I part of the study, participants receive dalotuzumab intravenously (IV) at 5 mg/kg weekly plus open-label erlotinib at 150 mg daily for 4 weeks. After 4 weeks of therapy, participants in Phase I who do not have disease progression and are satisfactorily tolerating study drug can continue to receive study drug.
62367383|NCT00654420|EXPERIMENTAL|Ph I: Dalotuzumab 10 mg/kg + Erlotinib|During the Phase I part of the study, participants receive dalotuzumab intravenously (IV) at 10 mg/kg weekly plus open-label erlotinib at 150 mg daily for 4 weeks. After 4 weeks of therapy, participants in Phase I who do not have disease progression and are satisfactorily tolerating study drug can continue to receive study drug.
62367384|NCT00654420|EXPERIMENTAL|Ph II: Dalotuzumab 10 mg/kg + Erlotinib|During the Phase II part of the study, participants are randomized to receive dalotuzumab intravenously (IV) at 10 mg/kg weekly plus open-label erlotinib at 150 mg daily until disease progression or occurrence of unacceptable toxic effects.
62367385|NCT00654420|ACTIVE_COMPARATOR|Ph II: Erlotinib|During the Phase II part of the study, participants are randomized to receive open-label erlotinib at 150 mg daily until disease progression or occurrence of unacceptable toxic effects.
62367386|NCT04296604|EXPERIMENTAL|Traumatic Brain Injury|This group consists of individuals diagnosed with traumatic brain injury. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
62367387|NCT04296604|EXPERIMENTAL|Major Depressive Disorder|This group consists of individuals diagnosed with major depressive disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
62367388|NCT04296604|EXPERIMENTAL|Bipolar Disorder|This group consists of individuals diagnosed with bipolar disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
62367389|NCT04296604|EXPERIMENTAL|Schizophrenia|This group consists of individuals diagnosed with schizophrenia. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
62367390|NCT04296604|EXPERIMENTAL|Attention Deficit Hyperactivity Disorder|This group consists of individuals diagnosed with attention deficit hyperactivity disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
62742717|NCT04109807|EXPERIMENTAL|6 hour Filtered Air (FA) followed by O3 exposure|For the first exposure session, participants are exposed to filtered air (FA) for 6 hours. For the second exposure session, the same participant will be exposed to ozone at a concentration of 0.07ppm for 6 hours.
62742718|NCT04109807|EXPERIMENTAL|6 hour O3 exposure followed by FA exposure|For the first exposure session, a participant will be exposed to ozone at a concentration of 0.07ppm for 6 hours. For the second exposure session, the same participant will be exposed to FA for 6 hours.
62367391|NCT04296604|EXPERIMENTAL|Borderline Personality Disorder|This group consists of individuals diagnosed with borderline personality disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
62742719|NCT00969644|ACTIVE_COMPARATOR|GH|
62367392|NCT04296604|EXPERIMENTAL|Substance Use Disorder|This group consists of individuals diagnosed with substance use disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
62367393|NCT04296604|ACTIVE_COMPARATOR|Healthy Controls|This group consists of individuals diagnosed with healthy controls. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
62367394|NCT04857736||Trial group: 62 healthy female college students during menstruation|"The pulse sound waves of three parts and five layers of each of the two hands of 62 healthy female college students during menstruation will be collected by thePulse Detection System of Sound Waves."
62742720|NCT00969644|ACTIVE_COMPARATOR|Pegvisomant|
62367395|NCT04857736||Control group :62 healthy female college students during non-menstrual period|"The pulse sound waves of three parts and five layers of each of the two hands of 62 healthy female college students during non-menstrual period will be collected by the Pulse Detection System of Sound Waves."
62367396|NCT03633513||Patients|Clinical diagnosed Parkinson's disease patients
62367397|NCT03633513||Caregivers|Environmentally matched healthy control subjects
62367398|NCT03945656|EXPERIMENTAL|Insulin 287 followed by insulin glargine|"Run-in period (3 to 28 days): Once daily insulin glargine treatment with or without any usual metformin treatment.~After run-in, participants will receive insulin 287 once a week (OW) for 6 weeks.~After insulin 287 treatment, participants will receive insulin glargine U100 OD for 12 days."
62742721|NCT04030546|ACTIVE_COMPARATOR|Ivabradine|Patients will receive ivabradine just before anthracycline chemotherapy, 5 mg per oral twice daily, until the last chemotherapy session
62742722|NCT04030546|NO_INTERVENTION|Usual care|Patient will receive usual care
62742723|NCT06658626|EXPERIMENTAL|[¹⁴C]Enlicitide chloride|Participants will receive a single dose of \[¹⁴C\]enlicitide chloride on Day 1.
62367399|NCT03945656|ACTIVE_COMPARATOR|Insulin glargine followed by insulin 287|"Run-in period (3 to 28 days): Once daily insulin glargine treatment with or without any usual metformin treatment.~After run-in, participants will receive insulin glargine U100 OD for 12 days.~After insulin glargine treatment, participants will receive insulin 287 OW for 6 weeks."
62367400|NCT00862394|EXPERIMENTAL|1|CHF 1535 Next DPI : BDP/Formoterol : 200/12 µg
62367401|NCT00862394|ACTIVE_COMPARATOR|2|CHF 1535 HFA pMDI : BDP/Formoterol : 200/12 µg
62367402|NCT00862394|EXPERIMENTAL|3|CHF 1535 Next DPI : BDP/Formoterol : 400/24 µg
62367403|NCT00862394|ACTIVE_COMPARATOR|4|CHF 1535 HFA pMDI : BDP/Formoterol : 400/24 µg
62367404|NCT03454724|EXPERIMENTAL|MeRes100 BRS|MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
62367405|NCT03454724|ACTIVE_COMPARATOR|Xience EES|Xience EES is a Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
62367406|NCT06445010|EXPERIMENTAL|Creating Musical Playlist|Participants created a musical playlist over 1 week based on themes and emotions from their grief journey.
62367407|NCT03903913|EXPERIMENTAL|Dose Escalation Study|"Subjects will receive up to three inhaled doses of S- 1226. Each dose will be administered over a 2-minute treatment period (with a minimum 2-minute break between treatments) with a nebulizer as follows.~Three S-1226 formulations will be tested sequentially:~* S-1226(4%) is composed of 3 mL PFOB and 4% CO2~* S-1226(8%) is composed of 3 mL PFOB and 8% CO2~* S-1226(12%) is composed of 3 mL PFOB and 12% CO2~Each formulation will be administered by inhalation for a period of 2 minutes.The nebulizer will be filled with 3 mL of PFOB. The nebulizer is connected to a compressed medical gas mixture consisting of either 4%, 8% or 12%, CO2. A driving pressure of 20 psi will be used, producing a gas flow rate of 9 L/min."
62367408|NCT03903913|EXPERIMENTAL|Daily Dosing Study|"Eligible subjects will receive S-1226 twice daily for 5 consecutive days. Subjects will receive up to three doses of S-1226 in the morning and afternoon, administered over three 2-minute periods with a Circulaire nebulizer, filled with one of the dosages outlined below, depending on the safety and tolerability data gathered from the dose escalation study for that particular subject.~* S-1226(4%) is composed of 3 mL PFOB and 4% CO2~* S-1226(8%) is composed of 3 mL PFOB and 8% CO2~* S-1226(12%) is composed of 3 mL PFOB and 12% CO2"
62367409|NCT03169114|ACTIVE_COMPARATOR|Amikacin injection|Antibiotic Non-Operative Management Strategy
62367410|NCT03169114|ACTIVE_COMPARATOR|Appendicectomy|Surgery Management Strategy
62367411|NCT04827719|EXPERIMENTAL|BST-236|Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)
62367412|NCT03382327|EXPERIMENTAL|Surgical planning|Two surgical plans will be established preoperatively. The first plan will be based on standard preoperative images (CT-scan, MRI) review. The second plan will be based on the 3D model review.
62367413|NCT03389269||Obese patients treated with AspireAssist|Healthy, obese with BMI \> 27, treated with AspireAssist for weight management, the postprandial glucose metabolism will be tested with a meal test
62367414|NCT03389269||Matched controls|Healthy, obese with BMI \> 27, the postprandial glucose metabolism will be tested with a meal test
62367415|NCT02814136|ACTIVE_COMPARATOR|WACA|wide area circular ablation
62367416|NCT02814136|ACTIVE_COMPARATOR|EWACA|extra-wide area circular ablation
62367417|NCT03230357|EXPERIMENTAL|PICC guided by EDUG|PICC(Peripherally Inserted Central Catheter)guided by ECG Doppler ultrasonic Guidance（EDUG),EDUG is a combination device which can be used for selecting the right vein and precise positioning for the catheter tip during the PICC cathetering.
62367418|NCT02428075|EXPERIMENTAL|FCHV visit-normotensive|
62367419|NCT02428075|NO_INTERVENTION|FCHV no visit-normotensive|
62367420|NCT02428075|EXPERIMENTAL|FCHV visit-prehypertensive|
62367421|NCT02428075|NO_INTERVENTION|FCHV no visit-prehypertensive|
62367422|NCT02428075|EXPERIMENTAL|FCHV visit-hypertensive|
62367423|NCT02428075|NO_INTERVENTION|FCHV no visit-hypertensive|
62367424|NCT05479006|ACTIVE_COMPARATOR|Anodal stimulation|Anodal stimulation targets the primary motor cortex (arm area) in the lesioned hemisphere, sham on the contralesional hemisphere.
62742724|NCT05434871|EXPERIMENTAL|Yoga Group|There will be a 45-minute yoga session 2 days a week for 8 weeks. Warm up with yoga-specific moves for 10 minutes (light stretching), yoga postures for 25 minutes and rest and meditate for the last ten minutes.
62742725|NCT05434871|ACTIVE_COMPARATOR|Control Group|The routine physiotherapy and rehabilitation program consists of strength, flexibility, balance, gait and coordination exercises 2 days a week for 8 weeks.
62367425|NCT05479006|ACTIVE_COMPARATOR|Cathodal stimulation|Cathodal stimulation targets the dorsal premotor cortex (arm area) in the contralesional hemisphere, sham on the lesioned hemisphere.
62367426|NCT05479006|ACTIVE_COMPARATOR|Bilateral Stimulation|Anodal stimulation targets the primary motor cortex (arm area) in the lesioned hemisphere and cathodal stimulation targets the dorsal premotor cortex (arm area) in the contralesional hemisphere at the same time.
62367427|NCT05479006|SHAM_COMPARATOR|Sham stimulation|Sham stimulation to both hemisphere of the brain
62367428|NCT00588757|ACTIVE_COMPARATOR|1|Optease filter
62367429|NCT00588757|ACTIVE_COMPARATOR|2|Tulip filter
62367430|NCT03964493|EXPERIMENTAL|TNP-2092|TNP-2092 300 mg intravenous every 12 hours
62367431|NCT03964493|ACTIVE_COMPARATOR|Vancomycin|vancomycin 1 g intravenous every 12 hours
62367432|NCT04716049|EXPERIMENTAL|Protocol I|Powerade© Carbohydrates+Protein Cherry Juice Foam Roller Cold Water Immersion
62367433|NCT04716049|EXPERIMENTAL|Protocol II|Powerade@ Carbohydrates+Protein Stretching Intermittent Cold-Water Immersion
62742726|NCT02894723|ACTIVE_COMPARATOR|l-arginine|Patients will receive L-arginine 30 ml twice a day for 8 weeks.
62367434|NCT03135639|EXPERIMENTAL|Sham Stim followed by Alpha Stim|"20 minutes of sham stimulation (sham stim) is followed by a washout period of 20 minutes. 20 minutes of alpha stimulation (alpha stim) is applied next.~Sham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham.~Participants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS."
62367435|NCT03135639|EXPERIMENTAL|Alpha Stim followed by Sham Stim|"20 minutes of alpha stimulation (alpha stim) is followed by a washout period of 20 minutes. 20 minutes of sham stimulation (sham stim) is applied next.~Participants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS.~Sham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham."
62367436|NCT02945839|ACTIVE_COMPARATOR|Acute Treatment+ED-initiated preventive medication +PMR|All subjects will be discharged on acute migraine therapy (naproxen, triptan) unless there is a contraindication and will also be started on topiramate (25mg/night) with a plan to increase the dose every week by 25 mg up to 100 mg/night. Subjects will receive medicine along with progressive muscle relaxation therapy
62367437|NCT02945839|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|Subjects will be given a general education session consisting of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently. Any migraine treatment decisions on discharge will be left up to the ED attending. The RC will load the APP onto the subjects' smart phones but the PMR component will be blocked on the version of the APP that they receive. All subjects will be asked to track headache frequency, intensity, and acute medication use on the APP.
62367438|NCT02128204|EXPERIMENTAL|HYADERMIS LA Facial Dermal Implant|Subjects will be randomly assigned to receive experiment treatment, lidocaine contained hyaluronate facial dermal filler, in one side of the face.
62367439|NCT02128204|ACTIVE_COMPARATOR|Hya-Dermis Facial Dermal Implant|Subjects will be randomly assigned to receive control treatment, hyaluronate facial dermal filler, in one side of the face.
62367440|NCT03102463|SHAM_COMPARATOR|Water Control|
62367441|NCT03102463|ACTIVE_COMPARATOR|Milk derived hydrolysate|
62367442|NCT03102463|ACTIVE_COMPARATOR|Parent Protein|
62367443|NCT01529450|ACTIVE_COMPARATOR|Refractory Group|Patients previously treated with non-LDE225 Smo inhibitor who were refractory.
62367444|NCT01529450|ACTIVE_COMPARATOR|Resistance Developed Group|Patients previously treated with non-LDE225 Smo inhibitor who were initially responsive but became resistant with progressive disease.
62367445|NCT06087731|EXPERIMENTAL|tocilizumab|administrated with tocilizumab (8mg/kg) every four weeks
62367446|NCT02187224|EXPERIMENTAL|Progesterone|For the three days prior to each test day every participant in this arm will receive one progesterone capsule (200 mg. bid) on the first day and 2 progesterone capsules per day for days 2 and 3. On the test day the participant will receive the last progesterone capsule (200 mg.bid). On the test day two scripts will be read one trauma related script (most traumatic experience) and one neutral script (relaxed scene given by participant)
62367447|NCT02187224|PLACEBO_COMPARATOR|Placebo|For the three days prior to each test day every participant in this arm will receive one placebo capsule on the first day and 2 placebo capsules per day for days 2 and 3. On the test day the participant will receive the last placebo capsule. On the test day two scripts will be read one trauma related script (most traumatic experience) and one neutral script (relaxed scene given by participant)
62367448|NCT03032250|EXPERIMENTAL|Group I Supportive Care (Prepare to Care kit)|Caregivers watch introduction video on a DVD over 10 minutes at baseline. Caregivers receive Prepare to Care kit including 8 workbook modules and complete at least 1 module over 30-45 minutes each week. Caregivers also attend interventionist session over 10-30 minutes weekly.
62367449|NCT03032250|EXPERIMENTAL|Group II Control Group|Caregivers received standard of care throughout course of intervention, with option to receive study intervention at end of study
62367450|NCT00422240|EXPERIMENTAL|Adapalene/Benzoyl Peroxide Gel|Participants were treated with adapalene 0.1 % \[weight by weight (W/W)\]/benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening for 12 Weeks.
62367451|NCT00422240|EXPERIMENTAL|Adapalene Gel, 0.1%|Participants were treated with 0.1% of adapalene gel topically daily in the evening for 12 Weeks.
62367452|NCT00422240|EXPERIMENTAL|Benzoyl Peroxide Gel 2.5%|Participants were treated with 2.5% of benzoyl peroxide gel topically daily in the evening for 12 Weeks.
62367453|NCT00422240|PLACEBO_COMPARATOR|Gel Vehicle|Participants were treated with gel vehicle topically daily in the evening for 12 Weeks.
62367454|NCT04154397|NO_INTERVENTION|error-enhancing feedback|The project of the first arm was to investigate how visualized error size affects postural training effect of the elderly, with a particular focus on error amplification strategy to optimize training benefits for postural training that favors the use of feedback mechanism on postural control and error correction. All participants were randomly assigned into the control and error amplification groups. The control group was trained to remain static stance on the stabilometer with visual guidance that displayed the target signal and tilting angle of the stabilometer. For the error amplification group, they were trained with the same postural paradigm, except that the visual guidance was virtually manipulated so that the participants visually perceived twice of the execution errors during stabilometer stance. We contrasted training benefits between the two groups after completion of eight training trails of 1 minute.
62391496|NCT03812614|EXPERIMENTAL|FAM-ACT|"Patient and Support Person (dyad) will be included together as much as possible. The dyad will:~1. Take part in a one-hour introductory session and review of the patient's Diabetes Complications Risk Assessment profile.~2. Be invited to 4-6 Support Person-focused, group diabetes self-management education (DSME) sessions lasting 1-2 ½ hours each.~3. Receive case management contacts with a Community Health Worker (CHW) once every 2-4 weeks, subject to participant availability. Successful contacts will last approximately 20 minutes."
62742727|NCT02894723|PLACEBO_COMPARATOR|syrup|Patients will receive placebo, 30 ml twice a day for 8 weeks.
62367455|NCT04154397|EXPERIMENTAL|positive cerebellar transcranial stimulation|The project of the second arm was to investigate the training benefits of using combined cerebellar transcranial direct current stimulation and visual error amplification on postural training during static stabilometer stance, in reference to sole visual error amplification. A particular focus was training-related alterations in error correction strategy and underlying cortical plasticity for postural balance.They were randomly assigned into the control (traditional error amplification)and cerebellar transcranial direct current stimulation groups. Both groups were trained to remain static stance on the stabilometer with visual guidance that displayed the target signal and tilting angle of the stabilometer. Under the condition of visual feedback without error amplification, we again contrasted training benefits between the two groups after completion of eight training trails of 1 minute.
62367456|NCT04154397|EXPERIMENTAL|sham cerebellar transcranial stimulation|The project of the third arm was to investigate the training benefits of using combined cerebellar transcranial random current stimulation and visual error amplification on postural training during static stabilometer stance, in reference to sole visual error amplification. A particular focus was training-related alterations in error correction strategy and underlying cortical plasticity for postural balance. All participants were randomly assigned into the control (sham stimulation) and cerebellar transcranial random current stimulation and visual error amplification (ES) groups. Both groups were trained to remain static stance on the stabilometer with visual guidance that displayed the target signal and tilting angle of the stabilometer. Under the condition of visual feedback without error amplification, we again contrasted training benefits between the two groups after completion of eight training trails of 1 minute.
62367457|NCT02451865|EXPERIMENTAL|Treatment (binimetinib and docetaxel)|Patients receive binimetinib PO BID on days 1-21 and docetaxel IV on day 21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have stable disease or better after completing 6 courses of binimetinib and docetaxel may continue receiving binimetinib PO BID in the absence of disease progression or unacceptable toxicity.
62367458|NCT02948504||Observation|Aneurysms are left untreated based on patients and family's wishes. These patients will be included in the observation group.
62367459|NCT02948504||Coiling or Clipping|Patients are included in the coiling group if they undergo endovascular coiling, such as single coiling, stent-assisted coiling and balloon-assisted coiling. Or Patients are included in the clipping group if they undergo surgical coiling, such as aneurysm neck clipping, aneurysm isolation or trapping.
62367460|NCT03813199|EXPERIMENTAL|ABX464 50mg + methotrexate|"Participants will receive one capsule of 50mg ABX464 plus one capsule of matching placebo once daily for 12 weeks~+ methotrexate"
62367461|NCT03813199|EXPERIMENTAL|ABX464 100mg + methotrexate|"Participants will receive two capsules of 50mg ABX464 once daily for 12 weeks~+ methotrexate"
62367462|NCT03813199|PLACEBO_COMPARATOR|Placebo + methotrexate|"Participants will receive two capsules of matching placebo once daily for 12 weeks~+ methotrexate"
62367463|NCT03418220|OTHER|AMD early / intermediate|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD early / intermediate
62367464|NCT03418220|OTHER|AMD exudative|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD exudative
62367465|NCT03418220|OTHER|AMD atrophic|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD atrophic
62367466|NCT03418220|OTHER|control group|A blood and aqueous humor sample will be taken during cataract surgery in patients with cataract (control group)
62367467|NCT04745689|EXPERIMENTAL|AZD2811 + Durvalumab|"Induction:~Durvalumab + Platinum Chemotherapy (Carboplatin or cisplatin \& Etoposide)~Maintenance:~AZD2811 + Durvalumab"
62367468|NCT06357962|EXPERIMENTAL|Acupuncture|This group will receive sessions the study intervention (semi-permanent acupuncture)
62367469|NCT06357962|SHAM_COMPARATOR|Control|This group will receive a sham treatment of semi-permanent acupuncture
62367470|NCT02802956|EXPERIMENTAL|intervention group|Daily Life Promotion Program
62367471|NCT02802956|EXPERIMENTAL|control group|general rehabilitation treatment
62367472|NCT02963766|EXPERIMENTAL|Placebo/0.75 milligram (mg) Dulaglutide|Participants received placebo administered subcutaneously (SC) for 26 weeks during the double-blind period and open-label 0.75 mg/week dulaglutide for 26 weeks during the Open Label Extension (OLE).
62742728|NCT06194604|EXPERIMENTAL|experimental group|In addition to the routine physical therapy program, Instrument-assisted soft tissue mobilization will be applied 3 days a week, for a total of 18 sessions. Each session will last 5 minutes.
62367473|NCT02963766|EXPERIMENTAL|0.75 mg Dulaglutide|Participants received 0.75 mg/week dulaglutide administered SC for 26 weeks during the double-blind period and open-label 0.75 mg/week for 26 weeks during the OLE.
62367474|NCT02963766|EXPERIMENTAL|1.5 mg Dulaglutide|Participants received 1.5 mg/week dulaglutide administered SC for 26 weeks during the double-blind period and open-label 1.5 mg/week for 26 weeks during the OLE.
62367475|NCT00255008|ACTIVE_COMPARATOR|Genotype 1 SEA PEG-IFN/RIB 48 w|Genotype 1 hepatitis C virus (HCV)-infected Southeastern Asian (SEA) subjects treated for up to 48 weeks with PEG-Intron (peginterferon alfa-2b; PEG-IFN) REDIPEN and REBETOL (ribavirin; RIB) combination therapy
62367476|NCT00255008|ACTIVE_COMPARATOR|Genotype 1 Caucasian PEG-IFN/RIB 48 w|Genotype 1 HCV-infected Caucasian subjects treated for up to 48 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
62367477|NCT00255008|EXPERIMENTAL|Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 24 w|Genotype 6, 7, 8, 9 HCV-infected SEA subjects randomized to treatment for 24 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
62367478|NCT00255008|ACTIVE_COMPARATOR|Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 48 w|Genotype 6, 7, 8, 9 HCV-infected SEA subjects randomized to treatment for 48 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
62367479|NCT01444183|ACTIVE_COMPARATOR|Progressive muscle relaxation|Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM
62367480|NCT01444183|SHAM_COMPARATOR|Sham exercise|Subjects practice a sham exercise consisting of focused attention activities
62367481|NCT05825586|EXPERIMENTAL|Eyedrops treatment arm|
62367482|NCT04055844|EXPERIMENTAL|Decitabine + Ruxolitinib + DLI|Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.
62367483|NCT02043509|EXPERIMENTAL|MiQuit|12 weeks of MiQuit text support plus a standard NHS leaflet giving information and advice on stopping smoking in addition to usual care
62367484|NCT02043509|NO_INTERVENTION|Control|Usual care plus the same standard NHS leaflet giving information and advice on stopping smoking
62367485|NCT00638690|EXPERIMENTAL|Abiraterone acetate plus prednisone/prednisolone|
62367486|NCT00638690|PLACEBO_COMPARATOR|Placebo plus prednisone/prednisolone|
62367487|NCT03185468|EXPERIMENTAL|4SCAR-PSMA|4SCAR PSMA-modified T cells can recognize and kill tumor cells through the recognize of PSMA .This study will evaluate the side effects and effective doses of 4SCAR-PSMA T cells in treating refractory and recurrent solid tumors.
62367488|NCT03185468|EXPERIMENTAL|4SCAR-FRa|4SCAR FRa-modified T cells can recognize and kill tumor cells through the recognize of FRa .This study will evaluate the side effects and effective doses of 4SCAR-FRa T cells in treating refractory and recurrent solid tumors.
62367489|NCT02606344|EXPERIMENTAL|Intervention Group (IG)|Loans were provided to poor women who enrolled in the intervention group. A participatory learning and action curriculum was integrated into loan meetings, which took place every 2 weeks.
62367490|NCT02606344|NO_INTERVENTION|Control Group (CG)|
62367491|NCT03480646|EXPERIMENTAL|CPI-1205 Combination with Enzalutamide|
62367492|NCT03480646|EXPERIMENTAL|CPI-1205 Combination with Abiraterone/Prednisone|
62367493|NCT03423615|EXPERIMENTAL|CHHIP Arm|"All enrolled students in schools in the CHHIP Arm were eligible to receive the CHHIP intervention. The CHHIP intervention was delivered by lay fieldworkers (SHAs). Intervention activities included:~1. Health Education: activity-based curriculum with lessons delivered once per week. Units include hygiene, nutrition, safety, disease prevention\& management, and social, emotional, and behavior development.~2. Basic Primary Health Services: school-based treatment including deworming and iron supplementation; screening and referral programs including growth monitoring, well-child exam, vision screening, epilepsy screening, and oral health; psychosocial and counseling support for students with atypical behaviors.~3. Health School Environment: improvements to physical infrastructure including latrines and water systems; modeling of positive behavior reinforcement, inclusive learning environment, and avoidance of corporal punishment."
62367494|NCT03423615|NO_INTERVENTION|Comparison Arm|All enrolled students in schools in the Comparison Arm received school health activities as were routinely available in their school, through their curriculum, or through special events.
62367495|NCT03531606|EXPERIMENTAL|Experimental|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
62367496|NCT03531606|PLACEBO_COMPARATOR|Placebo comparator|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into placebo comparator group will take one pack of 'Placebo' which is composed of lactose and simulates a 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
62367497|NCT02621645|EXPERIMENTAL|Early intervention|Intervention between 12.0 and 14.0 weeks. Early selective reduction of TRAP mass.
62367498|NCT02621645|ACTIVE_COMPARATOR|Late intervention|Intervention between 16.0 and 19.0 weeks. Late selective reduction of TRAP mass. This is the standard timing of the intervention. One of two possible techniques for late reduction is chosen by the treating physician.
62367499|NCT05182541|EXPERIMENTAL|Guided self help|Introduce the knowledge about twins pregnancy, and reduce the pregnant stress, and relief the anxiety and depressor.
62367500|NCT05182541|EXPERIMENTAL|Face to face PST course|Problem cognition and emotional response guidance
62567159|NCT06010953|EXPERIMENTAL|PK period: Cohort 1 (90 μg/kg) and Cohort 2 (270 μg/kg)|In the PK study period, subjects are divided into 2 cohorts (90 μg/kg and 270 μg/kg), which are sequentially conducted. Cohort 1 (90 μg/kg) enrollment is performed firstly, and Cohort 2 (270 μg/kg) enrollment is performed after Cohort 1 enrollment is completed. Subjects enter the PK study period as non-randomized. All screened eligible subjects will receive a single dose of comparator NovoSeven® in the absence of significant active hemorrhage, followed by PK/PD sample collection; then receive a single dose of the same dose of investigational drug SS109, followed by PK/PD sample collection.
62742729|NCT06194604|OTHER|Control group|Only the routine physical therapy program will be applied.
62742730|NCT00779428|EXPERIMENTAL|A1|
62742731|NCT03589989|EXPERIMENTAL|Intervention group|
62742732|NCT03589989|ACTIVE_COMPARATOR|Control group|
62367501|NCT05182541|EXPERIMENTAL|Professional psychological intervention|Give the pregnancy woman the professional psychological intervention
62367502|NCT04904536|EXPERIMENTAL|Study Medication Arm|6-monthly supplies of atorvastatin 40mg on top of standard care for a period of 12 months.
62367503|NCT04904536|ACTIVE_COMPARATOR|Standard Care Arm|Standard care for a period of 12 months.
62742733|NCT06212115||donor-mNGS-testing group|Organ donors are treated with mNGS testing before organ donation
62742734|NCT06212115||donor-non-mNGS-testing group|Organ donors are not treated with mNGS testing before organ donation
62742735|NCT05031091||Case: patients with confirmed leprosy|diagnosed or followed up in French Guiana between the beginning of 2006 and the end of 2022
62742736|NCT05031091||Control: patient with a dermatological condition not clinically suspicious of leprosy|Any patient, of any age, consulting for a dermatological pathology not clinically suspicious of leprosy during a dermatological consultation by a practitioner of the Cayenne Hospital
62367504|NCT02959190|EXPERIMENTAL|120mg/120mg Galcanezumab - Episodic Migraine (EM)|240 milligram (loading dose) of Galcanezumab at first dosing visit followed by 120 milligram (mg) once a month for a year by subcutaneous (SC) injection. EM participants (pts) rolled over from CGAN (NCT02959177) 120 mg Galcanezumab.
62367505|NCT02959190|EXPERIMENTAL|240mg/240mg Galcanezumab - EM|240 mg Galcanezumab given SC once a month for a year. EM participants rolled over from CGAN (NCT02959177) 240 mg Galcanezumab.
62367506|NCT02959190|EXPERIMENTAL|Placebo/ 120mg Galcanezumab - EM|240 mg (loading dose) of Galcanezumab at first dosing visit followed by 120 mg once a month for a year by SC injection. EM participants rolled over from CGAN (NCT02959177) placebo.
62367507|NCT02959190|EXPERIMENTAL|Placebo/ 240mg Galcanezumab - EM|240 mg Galcanezumab given SC once a month for a year. EM participants rolled over from CGAN (NCT02959177) Placebo.
62367508|NCT02959190|EXPERIMENTAL|120mg Galcanezumab - CM|240 mg (loading dose) of Galcanezumab at first dosing visit followed by 120 mg once a month for a year by SC injection. Participants with CM were enrolled.
62367509|NCT02959190|EXPERIMENTAL|240mg Galcanezumab - CM|240 mg Galcanezumab given SC once a month for a year. Participants with CM were enrolled.
62367510|NCT02746445||ASD Subjects|No interventions. This is an observation of subjects who received MeRT utilizing assessment documentation.
62367511|NCT03889990|OTHER|healthy smokers|"Healthy smokers males, aged \>18years, with \>10 pack/years,receiving no medications~Intervention: the use of an IQOS"
62367512|NCT02826876|PLACEBO_COMPARATOR|Ropivacaine|Topical use of Ropivacaine
62367513|NCT02826876|PLACEBO_COMPARATOR|Placebo|Topical use of placebo
62367514|NCT06233838|EXPERIMENTAL|KHA80 hemoperfusion treatment|The experimental group (197 cases) were randomly assigned to receive Jianfan KHA80 hemoperfusion treatment on the basis of hemodialysis or hemodiafiltration treatment, and the frequency of hemoperfusion treatment was ≥2 times/month.
62367515|NCT06233838|NO_INTERVENTION|Routine hemodialysis|Randomly assign the control group (197 cases) to receive hemodialysis or hemodialysis filtration treatment, and the frequency of treatment is ≥2 times/week.
62367516|NCT01966653|ACTIVE_COMPARATOR|nitrofurantoin|Nitrofurantoin will be given orally at a dose of 100 mg three times daily for 5 days.
62367517|NCT01966653|ACTIVE_COMPARATOR|fosfomycin|A single 3g dose of oral fosfomycin will be given.
62367518|NCT02353403|PLACEBO_COMPARATOR|Sugar|Control group consuming a dairy dessert containing 35g of dextrose.
62367519|NCT02353403|EXPERIMENTAL|FOS|Group consuming a dairy dessert in which 30% of the dextrose was replaced by FOS.
62367520|NCT00252317|ACTIVE_COMPARATOR|1|Captopril test dose and Trandolapril
62367521|NCT00252317|PLACEBO_COMPARATOR|2|
62742737|NCT01139203|ACTIVE_COMPARATOR|lamivudine|
62742738|NCT01139203|ACTIVE_COMPARATOR|lamivudine and adefovir|
62742739|NCT01139203|ACTIVE_COMPARATOR|entecavir|
62742740|NCT06538051|OTHER|lying positions|
62742741|NCT01663116|EXPERIMENTAL|Treatment|"1. first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~2. second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~3. third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
62742742|NCT01663116|PLACEBO_COMPARATOR|Placebo|Lactate Ringer´s solution
62742743|NCT04176991|EXPERIMENTAL|CTI-1601|
62367522|NCT01098032|ACTIVE_COMPARATOR|Systemic alone therapy group|Systemic alone therapy group will be treated by intravenous sodium bicarbonate plus NAC administration. Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. (9) The initial i.v. bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days. Additional NAC dose (1.2 g) will be administered i.v. during the procedure.
62367523|NCT01098032|EXPERIMENTAL|RenalGuard System group|Prophylactic controlled hydration with saline (0.9%) plus N-acetylcystein (NAC; 6 g in total). In the RenalGuard group, an initial bolus (priming) of 250 ml will be administered. In case of left ventricular dysfunction (ejection fraction ≤30%) and/or unstable hemodynamic conditions the bolus will be reduced to 150 ml. Following the initial bolus, furosemide (0.25 mg/kg) will be administered in order to achieve the optimal urine flow (≥300 ml/h). The hydration will be continued throughout the duration of the procedure and will last 4 hours following the procedure. Additional doses of furosemide are allowed in case of decrease of urine flow \<300 ml/h.
62367524|NCT04553978|EXPERIMENTAL|Treatment A|"After an overnight fasting of at least 10 hours, a single oral dose of WD-1603 Extended-Release Carbidopa/Levodopa Tablets will be administered to the subjects at ambient temperature by the trained study personnel.~Subjects will be in sitting posture or ambulatory posture for the first 04 hours post-dose unless medically necessary."
62367525|NCT04553978|EXPERIMENTAL|Treatment B|"At least 03 hours after taking dinner, a single oral dose of WD-1603 Extended-Release Carbidopa/Levodopa Tablets will be administered to the subjects at ambient temperature by the trained study personnel.~Subjects will be in supine/lateral recumbent positions post-dose till morning when they will wake up unless medically necessary."
62367526|NCT03850171|EXPERIMENTAL|ExEarly|Patients completing the exercise training concurrent to anthracycline chemotherapy treatment during months 1 to 3
62367527|NCT03850171|NO_INTERVENTION|ExStandard|Patients will be encouraged to continue with their regular physical activity routine and will be medically managed as per standard of care by their Cardiologist and Oncologists.
62367528|NCT02108223|ACTIVE_COMPARATOR|fix dose r-FSH (Gonal-f)|The patients who had normal ovarian response were included as the control group (Group 1). The dose of r-FSH (Gonal-f) was continued for the fix dose until the day of hCG in Group 1
62742744|NCT04176991|PLACEBO_COMPARATOR|Placebo|
62742745|NCT03539211|EXPERIMENTAL|Rotation Exercises|8 minute program of rotation based exercises
62742746|NCT03539211|ACTIVE_COMPARATOR|Control Exercises|8 minute program of traditional exercises
62742747|NCT05609370|EXPERIMENTAL|Phase 1b: Cohort-1: LBL-007 + tislelizumab + bevacizumab + capecitabine|LBL-007 + tislelizumab + bevacizumab + capecitabine
62742748|NCT05609370|EXPERIMENTAL|Phase 1b: Cohort 1a: LBL-007 + tislelizumab + bevacizumab + capecitabine|LBL-007 + tislelizumab + bevacizumab + capecitabine
62367529|NCT02108223|ACTIVE_COMPARATOR|r-LH supplementation to r-FSH|On day 7 of the stimulation, if at least six follicles between 6-10mm were present but there was no follicle over 10 mm on transvaginal ultrasound, E2 level was under 180 pg/ml, it has been considered that the patients had suboptimal response to the stimulation and were divided into Group 2. Group 2 received supplemental r-LH ( Lutropin alpha; Luveris, Merck Serono, France), 75IU/day to r-FSH (Gonal-f) treatment.
62367530|NCT02108223|ACTIVE_COMPARATOR|r-FSH (Gonal-f)|Group 3: Daily 75 IU/L r-FSH was added to r-FSH treatment until the end of ovarian stimulation.
62367531|NCT05248529|EXPERIMENTAL|Intervention group|Within 12-24 hours before the surgery, the demonstrative education was given based on 'Hip Replacement Adaptation Booklet' and 'Knee Replacement Adaptation Booklet' to the patients in the intervention group.
62367532|NCT05248529|NO_INTERVENTION|Control gorup|Routine preoperative preparation training was performed to the patients in the control group.
62367533|NCT04605185|EXPERIMENTAL|Donafenib/JS001/TACE|Donafenib and JS001 Combined With TACE
62367534|NCT01297023|EXPERIMENTAL|calcium phosphate|
62367535|NCT01297023|EXPERIMENTAL|vitamin d|
62742749|NCT05609370|EXPERIMENTAL|Phase 1b: Cohort 2: LBL-007 + tislelizumab + bevacizumab + fluoropyrimidine|LBL-007 + tislelizumab (low dose every 3 weeks or high dose every 4 weeks) + bevacizumab (7.5 mg/kg once every 2 weeks or 5 mg/kg once every 3 weeks)+ fluoropyrimidine (5-FU or capecitabine)
62742750|NCT05609370|EXPERIMENTAL|Phase 2: Arm A and Arm D: LBL-007 + tislelizumab + bevacizumab + fluoropyrimidine|LBL-007 + tislelizumab (low dose every 3 weeks or high dose every 4 weeks) + bevacizumab (7.5 mg/kg once every 2 weeks or 5 mg/kg once every 3 weeks) + fluoropyrimidine (5-FU or capecitabine)
62367536|NCT01297023|EXPERIMENTAL|calcium phosphate and vitamin d|
62367537|NCT01297023|PLACEBO_COMPARATOR|placebo|
62367538|NCT01459887|EXPERIMENTAL|combination group|
62367539|NCT01459887|EXPERIMENTAL|sequential group|
62367540|NCT01135394|EXPERIMENTAL|Pioglitazone (Actos)|Participants will have metabolism studies to consist of outpatient X-ray and MR measurements of bone density and body composition, metabolic testing (intravenous glucose tolerance test), and muscle and adipose tissue biopsies. Blood will also be drawn for genetic testing and for microarray studies of leukocytes. Upon completion of the above studies, the participant will begin pioglitazone therapy. Every 4 weeks throughout the drug intervention, glycemic control, lipoprotein profile, and weight will be monitored. After 12 weeks of pioglitazone therapy, the X-ray and MR measurements of body composition, the biopsies, microarray studies for leukocytes and the metabolic tests will be repeated.
62367541|NCT05447260|EXPERIMENTAL|Ruxolitinib|
62367542|NCT03807778|EXPERIMENTAL|Mobocertinib, Phase 1 Part|Mobocertinib 40 milligrams (mg) (as the starting dose), capsules, orally, once daily on Days 1-28 of each 28-day treatment cycle for up to disease progression or intolerable toxicity, or another discontinuation criterion, and increasing until 160 mg, once daily (for up to approximately 10-12 cycles).
62367543|NCT03807778|EXPERIMENTAL|Mobocertinib, Phase 2 Part|Mobocertinib 160 mg, once daily, for up to approximately 10-12 cycles.
62367544|NCT03243955|ACTIVE_COMPARATOR|TEAS|True acupoint locations for placement of TENS unit pads
62367545|NCT03243955|SHAM_COMPARATOR|Placebo|non-acupoint locations for placement of TENS unit pads
62367546|NCT05445336||Internal Champion & LTC Leadership Team #1 from Site #1|The internal champion and LTC leadership team of each LTC home will attend two virtual focus group sessions to help co-design the PREVENT Program educational material. The internal champion will receive training on how to deliver the PREVENT program to the leadership team. The internal champion/pharmacist/data analyst will receive training on how to develop an audit and feedback report on fall and fracture management. All participants will attend an educational meeting facilitated by the internal champion who will use a combination of didactic and interactive activities. After the educational meeting, the leadership team will complete an action and care planning report for each LTC resident at high risk of fracture. Lastly, all participants will attend two virtual focus group sessions to discuss the successes and challenges of implementing the PREVENT program in practice.
62367547|NCT05445336||Internal Champion & LTC Leadership Team #2 from Site #2|The internal champion and LTC leadership team of each LTC home will attend two virtual focus group sessions to help co-design the PREVENT Program educational material. The internal champion will receive training on how to deliver the PREVENT program to the leadership team. The internal champion/pharmacist/data analyst will receive training on how to develop an audit and feedback report on fall and fracture management. All participants will attend an educational meeting facilitated by the internal champion who will use a combination of didactic and interactive activities. After the educational meeting, the leadership team will complete an action and care planning report for each LTC resident at high risk of fracture. Lastly, all participants will attend two virtual focus group sessions to discuss the successes and challenges of implementing the PREVENT program in practice.
62367548|NCT05445336||Internal Champion & LTC Leadership Team #3 from Site #3|The internal champion and LTC leadership team of each LTC home will attend two virtual focus group sessions to help co-design the PREVENT Program educational material. The internal champion will receive training on how to deliver the PREVENT program to the leadership team. The internal champion/pharmacist/data analyst will receive training on how to develop an audit and feedback report on fall and fracture management. All participants will attend an educational meeting facilitated by the internal champion who will use a combination of didactic and interactive activities. After the educational meeting, the leadership team will complete an action and care planning report for each LTC resident at high risk of fracture. Lastly, all participants will attend two virtual focus group sessions to discuss the successes and challenges of implementing the PREVENT program in practice.
62367549|NCT02803814|EXPERIMENTAL|Superior mesenteric artery approach|Initial approach of the superior mesenteric artery to perform a pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area
62367550|NCT02803814|ACTIVE_COMPARATOR|Classic approach|Classic approach to perform a pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area
62367551|NCT00493441|EXPERIMENTAL|Treatment|
62367552|NCT05784870|EXPERIMENTAL|Shengxuening Tablets|Oral treatment with Shengxuening Tablets 1 week before chemotherapy, usage: 0.5gtid, for 28 consecutive days
62742751|NCT05609370|EXPERIMENTAL|Phase 2: Arm B: LBL-007 + bevacizumab + fluoropyrimidine|LBL-007 + bevacizumab (7.5 mg/kgonce every 2 weeks or 5 mg/kg once every 3 weeks) + fluoropyrimidine (5-FU or capecitabine)
62367553|NCT05784870|ACTIVE_COMPARATOR|ferrous succinate|Oral treatment with ferrous succinate 1 week before chemotherapy, usage: 200mgqd, for 28 consecutive days
62367554|NCT02327078|EXPERIMENTAL|Phase 1 Part 1 Epacadostat 25mg BID +Nivolumab|Epacadostat 25mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab administered intravenously (IV) at 3mg/kg Q2W
62367555|NCT02327078|EXPERIMENTAL|Phase 1 Part 1 Epacadostat 50mg BID +Nivolumab|Epacadostat 50mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab administered intravenously (IV) at 3mg/kg Q2W
62367556|NCT02327078|EXPERIMENTAL|Phase 1 Part 1 Epacadostat 100mg BID +Nivolumab|Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab administered intravenously (IV) at 3mg/kg Q2W.
62367557|NCT02327078|EXPERIMENTAL|Phase 1 Part 1 Epacadostat 300mg BID +Nivolumab|Epacadostat 300mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab administered intravenously (IV) at 3mg/kg Q2W.
62367558|NCT02327078|EXPERIMENTAL|Phase 1 Part 2 Epacadostat 100mg BID +Nivolumab +5-FU/Platinum|Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 360mg Q3W and 5-FU/Platinum( Carboplatin or Cisplatin+5-Fluorouracil) administered intravenously (IV).
62367559|NCT02327078|EXPERIMENTAL|Phase 1 Part 2 Epacadostat 100mg BID +Pemetrexed/Platinum|Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 360 mg Q3W and Pemetrexed/Platinum (Carboplatin orCisplatin+Pemetrexed) administered intravenously (IV).
62367560|NCT02327078|EXPERIMENTAL|Phase 1 Part 2 Epacadostat 100mg BID +Paclitaxel/Platinum|Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 360 mg Q3W and Paclitaxel/Platinum(Carboplatin+Cisplatin+Paclitaxel)administered intravenously (IV).
62367561|NCT02327078|EXPERIMENTAL|Phase 2 Epacadostat 100mg BID + Nivolumab|Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 240mg Q2W or 480 mg Q4W based on tumor type administered intravenously (IV).
62367562|NCT02327078|EXPERIMENTAL|Phase 2 Epacadostat 300mg BID + Nivolumab|Epacadostat 300mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 240mg Q2W administered intravenously (IV).
62367563|NCT01651234|EXPERIMENTAL|Active|
62367564|NCT01651234|PLACEBO_COMPARATOR|Placebo|
62367565|NCT03753386|EXPERIMENTAL|Healthy subjects|Subjects not presenting any pulmonary pathology that will follow the intervention Oxygen therapy simulation.
62367566|NCT04212546|PLACEBO_COMPARATOR|Control drink|200 mL milk + 16 g maltodextrin
62367567|NCT04212546|ACTIVE_COMPARATOR|Test drink|200 mL milk + 16 g inulin + Lactobacillus casei \[\>106 cfu/mL\]
62742752|NCT05609370|OTHER|Phase 2: Arm C and Arm E: bevacizumab + fluoropyrimidine|bevacizumab (7.5 mg/kg once every 2 weeks or 5 mg/kg once every 3 weeks) + fluoropyrimidine (5-FU or capecitabine)
62742753|NCT05609370|EXPERIMENTAL|Phase 1b: Cohort 1b: LBL-007 + Tislelizumab + Bevacizumab + 5- Flurouracil (5-FU)|LBL-007 + Tislelizumab + Bevacizumab + 5- Flurouracil
62742754|NCT02825706|EXPERIMENTAL|Experimental group|The patients in experimental group received 60-minute educational sessions every two weeks about the pathophysiology of hemophilia, clinical manifestations, postural advice and prevention advice to avoid recurrent bleeding. Likewise, doubts on the clinical progress of hemophilic arthropathy, functional limitations and management of joint pain were resolved. In parallel with the educational sessions, patients followed a 15-week home exercise program performed once a day, 6 days a week. The program included muscle stretching exercises; isometric exercises; proprioceptive exercises on one leg with visual support; and a 20-minute walk. Low-intensity exercises with 20-25 repetitions were included.
62742755|NCT02825706|NO_INTERVENTION|Control group|The patients in the control group did not receive any educational sessions and did no exercise at all at home.
62367568|NCT04552626|EXPERIMENTAL|Prolonged sitting (social breaks)|
62367569|NCT04552626|EXPERIMENTAL|Prolonged sitting with step-up exercise break|
62367570|NCT04552626|EXPERIMENTAL|Prolonged sitting with simple resistance activity breaks|
62367571|NCT05656118||Paclitaxel Coated Balloon|Patients treated with Genoss® DCB in patients with coronary artery in-stent restenosis (ISR)
62367572|NCT03510728|NO_INTERVENTION|No single-session intervention-EMA|Participants will be assessed both using a computer and using their phone. However, they will not receive an intervention at the start of the study and will only be using their phone for ecological assessment only data collection.
62367573|NCT03510728|ACTIVE_COMPARATOR|Standard single-session intervention-EMA|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will be followed up. Participants in this condition will interact with their phone only for assessment purposes.
62367574|NCT03510728|EXPERIMENTAL|Augment single-session intervention-EMA|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will also take a computerized intervention developed to increase the use of protective behavioral strategies during drinking (Protective Behavioral Strategies Intervention). Participants in this condition will interact with their phone only for assessment purposes.
62367575|NCT03510728|EXPERIMENTAL|No single-session intervention-EMI|Participants in this group will not take a single-session intervention at baseline, but will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
62367576|NCT03510728|EXPERIMENTAL|Standard single-session intervention-EMI|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will be followed up. Participants in this condition will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
62367577|NCT03510728|EXPERIMENTAL|Augment single-session intervention-EMI|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will also take a computerized intervention developed to increase the use of protective behavioral strategies during drinking (Protective Behavioral Strategies Intervention). Participants in this condition will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
62367578|NCT03383055|EXPERIMENTAL|CMV positive cohort|CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT
62367579|NCT03383055|EXPERIMENTAL|CMV negative cohort|CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT
62367580|NCT05148689|EXPERIMENTAL|test product|Oxymetazoline Cream, 1%
62367581|NCT05148689|ACTIVE_COMPARATOR|reference|Rhofade™ (oxymetazoline) cream, 1%
62367582|NCT05148689|PLACEBO_COMPARATOR|placebo|Vehicle of Test product
62367583|NCT04509557|EXPERIMENTAL|50mCi|Using a drug product for which dose is determined (50±5 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
62367584|NCT04509557|EXPERIMENTAL|75mCi|Using a drug product for which dose is determined (75±8 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
62367585|NCT04509557|EXPERIMENTAL|100mCi|Using a drug product for which dose is determined (100±10 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
62367586|NCT04509557|EXPERIMENTAL|125mCi|Using a drug product for which dose is determined (125±13 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
62367587|NCT04509557|EXPERIMENTAL|150mCi|Using a drug product for which dose is determined (150±15 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
62367588|NCT02724280|ACTIVE_COMPARATOR|Group A|Patients with indications for gastroduodenoscopy will be evaluated with WLE and then LCI.
62367589|NCT02724280|PLACEBO_COMPARATOR|Group B|Patients with indications for gastroduodenoscopy will be evaluated with LCI and then WLE.
62367590|NCT01237301|EXPERIMENTAL|CGM Group|Wear an unblinded CGM for 16 weeks. Subjects continued previously started medication regiments for their diabetes. Subjects in this arm were randomized to use real time continuous glucose monitoring (rt CGM).
62367591|NCT01237301|ACTIVE_COMPARATOR|SMBG Group|Use SMBG 4 to 7 times a day for 16 weeks. Subjects continued previously started medication regiments for their diabetes. Subjects in this arm were randomized to use structured self monitoring blood glucose (stSMBG) and periodic, blinded continuous glucose monitoring (CGM).
62367592|NCT05537961|EXPERIMENTAL|Mindfulness|Weekly mindfulness instruction embedded in classroom setting
62367593|NCT05537961|NO_INTERVENTION|No Intervention|Classroom setting completed as usual
62367594|NCT01144091|EXPERIMENTAL|pentoxyphylline cardio|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo coronary angiography
62367595|NCT01144091|PLACEBO_COMPARATOR|placebo cardio|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo coronary angiography
62367596|NCT01144091|EXPERIMENTAL|radiology pentoxyphylline|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo computed tomography with contrast
62367597|NCT01144091|PLACEBO_COMPARATOR|radiology placebo|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo computed tomography with contrast
62367598|NCT00755391|PLACEBO_COMPARATOR|supportive psychotherapy|supportive psychotherapy: 14 sessions
62367599|NCT00755391|ACTIVE_COMPARATOR|cognitive behavior therapy|cognitive behavior therapy: 14 sessions
62367600|NCT05264740|EXPERIMENTAL|Motivational interviewing|
62367601|NCT05264740|ACTIVE_COMPARATOR|no motivational interviewing|
62367602|NCT01553760|EXPERIMENTAL|Tri-MICS|
62367603|NCT01553760|ACTIVE_COMPARATOR|Conventional Phaco|
62367604|NCT01231828|EXPERIMENTAL|Carnitine|Versus placebo.
62367605|NCT01231828|EXPERIMENTAL|Lactulose|Versus placebo
62367606|NCT01577004|EXPERIMENTAL|Omega-3 fatty acid supplement|Data obtained after the intervention was compared to baseline data
62367607|NCT03197350|ACTIVE_COMPARATOR|HFpEF|"We intend to recruit consecutive patients admitted for HFPEF in our institution during the next years. Eligible patients include those with age ≥50 years, LVEF ≥50%, symptomatic HF, and either a hospitalization for HF within the prior year or an elevated natriuretic peptide level (BNP ≥100 pg/mL or NT-proBNP ≥350 pg/mL) within the 60 days before inclusion.~Intervention: cMR"
62367608|NCT03197350|ACTIVE_COMPARATOR|Controls|"We plan to recruit 10 per decade of age. These subjects will allow us to evaluate the effects of age on the parameters of our study. They will have no risk factors, a normal ECG at rest and normal heart ultrasound and no abnormalities on a stress test.~Intervention: cMR"
62367609|NCT03197350|ACTIVE_COMPARATOR|HFrEF|"We intend to recruit consecutive patients admitted for HFrEF in our institution during the next years. Eligible patients include those with age ≥50 years, LVEF ≤40%, symptomatic HF, and either a hospitalization for HF within the prior year or an elevated natriuretic peptide level (BNP ≥100 pg/mL or NT-proBNP ≥350 pg/mL) within the 60 days before inclusion.~Intervention: cMR"
62367610|NCT00373880|EXPERIMENTAL|Aripiprazole (15mg) + Cocaine|Aripiprazole (15 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg).
62367611|NCT00373880|PLACEBO_COMPARATOR|Placebo + Cocaine|Placebo (0 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg)
62367612|NCT04941157|EXPERIMENTAL|Prophylactic cerebrospinal fluid drain placement|Patients randomized to receive the experimental treatment will have a prophylactic cerebrospinal fluid drain placed prior to their endovascular aortic repair. All components of the endovascular aortic repair are standard of care treatments.
62367613|NCT04941157|NO_INTERVENTION|Selective cerebrospinal fluid drain placement|Patients randomized to the control arm of the study will not receive a prophylactic cerebrospinal fluid drain prior to their endovascular aortic repair. Patients will receive a CSF drain post-operative as needed to treat any symptoms of spinal cord ischemia. This arm of the study is current standard of care.
62367614|NCT01248585|ACTIVE_COMPARATOR|Dexamethasone|2 x 4 mg dexamethasone tablets taken once daily for 5 days
62367615|NCT01248585|PLACEBO_COMPARATOR|Placebo|2 placebo tablets taken once daily for 5 days
62367616|NCT03914651|ACTIVE_COMPARATOR|300IU rFSH stimulation group|300IU rFSH stimulation group is defined as patients using gonadotropin-releasing hormone（GnRH）antagonist protocol with a 300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation.
62367617|NCT03914651|EXPERIMENTAL|150IU rFSH stimulation group|150IU rFSH Gonal-F® stimulation group is defined as patients using GnRH antagonist protocol with a 150IU rFSH starting dose during controlled ovarian stimulation.
62367618|NCT02470429|EXPERIMENTAL|SYSTANE HYDRATION|SYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
62367619|NCT02470429|ACTIVE_COMPARATOR|Hyabak 0.15%|Hyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
62367620|NCT04631367|EXPERIMENTAL|Kukaa Salama: mHealth intervention|This is a pre-test/post-test trial, therefore all participants will receive the Kukaa Salama mHealth intervention and will be offered a COVID-19 prevention parcel.
62367621|NCT04923321||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
62367622|NCT04923321||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
62367623|NCT04923321||Non exposure|Non-pharmacological treatment (psychotherapy)
62367624|NCT02778373|PLACEBO_COMPARATOR|Placebo|Flavored Water
62367625|NCT02778373|ACTIVE_COMPARATOR|Low Molecular Weight Carbohydrate|low molecular weight carbohydrate delivered post-endurance exercise in a 10% solution providing 1.2 grams/kg body weight carbohydrate
62367626|NCT02778373|EXPERIMENTAL|High molecular weight carbohydrate|high molecular weight carbohydrate delivered post-endurance exercise in a 10% solution providing 1.2 grams/kg body weight carbohydrate
62367627|NCT02911051|EXPERIMENTAL|Actreen Hydrolite Cath|a new hydrophilic coated catheter for Urinary Intermittent Catheterisation
62367628|NCT00877760|EXPERIMENTAL|ETV + pegIFN|Patients receive Entecavir in a dosage of 0.5 mg once daily per os from day 0, up to week 48. From week 24 to week 48, they also receive pegylated-interferon a-2a in a dose of 180 μg per week s.c. At week 48, response will be assessed. Responders will continue to take Entecavir until week 72, and quit subsequently. Non-responders at week 48 will continue on Entecavir up to week 96.
62367629|NCT00877760|ACTIVE_COMPARATOR|ETV|Patients receive Entecavir in a dosage of 0.5 mg once daily per os from day 0, up to week 48. At week 48, response will be assessed. Responders will continue to take Entecavir until week 72, and quit subsequently. Non-responders at week 48 will continue on Entecavir up to week 96.
62367630|NCT04803890|EXPERIMENTAL|No touch radiofrequency ablation|A total of 150 patients who have decided to participate in the study will be included, and prospective study will be performed to these patients for radio-frequency ablation using octopus electrodes, combined high-frequency transmission mode, and the 'No touch' technique.
62367631|NCT01340404|EXPERIMENTAL|Stem Cell Transplantation|
62367632|NCT01340404|ACTIVE_COMPARATOR|Transfusion program|
62367633|NCT00725829|EXPERIMENTAL|1|simvastatin 40g + ezetimibe 10g once a day
62367634|NCT00725829|PLACEBO_COMPARATOR|2|simvastatin 40g + placebo once a day
62367635|NCT04481945|ACTIVE_COMPARATOR|bioceramic sealer|pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
62367636|NCT04481945|EXPERIMENTAL|bioceramic sealer and silver nanoparticles|silver nanoparticles are antibacterial ions that can interact with multiple targets in the bacterial cell
62367637|NCT04481945|EXPERIMENTAL|bioceramic sealer and chitosan|chitosan has an excellent antibacterial, antiviral and antifungal properties, as an antibacterial, it works better on gram negative than gram positive
62367638|NCT00964249|EXPERIMENTAL|LABA|After randomization subject will inhale either 12.5 microgram or 25 microgram GW642444M once daily for 7 days.
62367639|NCT00964249|PLACEBO_COMPARATOR|Placebo|After randomization subjects will inhale placebo once daily for 7 days.
62367640|NCT01150604|EXPERIMENTAL|Self-help course|
62367641|NCT02280525|EXPERIMENTAL|Lymphodepleting Chemotherapy Option #1|"Preferred regimen for CLL and low grade lymphoma~Lenalidomide 2.5 mg by mouth once a day on Days -2 through Day +14. Fludarabine 25 mg/m2 by vein over 1 hour on Days -5 to -3. Cyclophosphamide 200 mg/m2 by vein over 3 hours on Days -5 to -3. Rituximab 375 mg/m2 by vein over 3-6 hours on Day -5 for participants with B-cell cancer.~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10\^7 NK cells/kg given by vein on Day 0.~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
62367642|NCT02280525|EXPERIMENTAL|Lymphodepleting Chemotherapy Option #2|"For all malignancies if able to tolerate higher dose cyclophosphamide per the discretion of the treating physician~Lenalidomide 2.5 mg by mouth once a day on Days -2 through Day +14. Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2. Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4.~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10\^7 NK cells/kg given by vein on Day 0.~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
62367643|NCT02280525|EXPERIMENTAL|Lymphodepleting Chemotherapy Option #3|"For myeloid malignancies~Lenalidomide 2.5 mg by mouth once a day on Days -2 to Day +14. Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2. Cytarabine 2 mg/m2 by vein on Days -6 to -2.~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10\^7 NK cells/kg given by vein on Day 0.~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
62567160|NCT06010953|EXPERIMENTAL|On-demand treatment period: Group 1：90 μg/kg Group 2：180 μg/kg Group 3：270 μg/kg|After completion of the PK study period, subjects will enter a 90-day on-demand treatment period and will be randomized into 3 groups (Group 1: 90 µg/kg, Group 2: 180 µg/kg, and Group 3: 270 µg/kg) at a ratio of 1:1:1. During on-demand treatment, subjects are treated on-demand with SS109 at the time of a new hemorrhage event and their efficacy is observed.
62567161|NCT05183542|EXPERIMENTAL|Patients|Patients with bone scan
62367644|NCT02774668|ACTIVE_COMPARATOR|"Grab-and-Go meal plan"|"The intervention of this arm is to use a Grab-and-Go meal plan. This meal plan provides Atkins shakes and bars for breakfast, lunch, and snacks for 2 weeks. For dinner the subject is given a freshly-prepared meal. Upon finishing the 2-week provided food phase, the subject will consume a self-prepared meal of similar nutrient composition at home for another 2 weeks. For the next four weeks while he/she is still enrolled in the study, he/she will have his/her options for food choices which are not controlled for the study."
62367645|NCT02774668|ACTIVE_COMPARATOR|"Jump-Start meal plan"|"The intervention of this arm is to use a Jump Start meal plan. This meal plan provides Atkins frozen meals at breakfast, lunch and dinner for 2 weeks and these meals are supplemented with fresh salads and vegetables. Upon finishing the 2-week provided food phase, the subject will consume a self-prepared meal of similar nutrient composition at home for another 2 weeks. For the next four weeks while he/she is still enrolled in the study, he/she will have his/her options for food choices which are not controlled for the study."
62367646|NCT02126527|EXPERIMENTAL|Treatment (auranofin and sirolimus)|Patients receive auranofin PO QD and sirolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62367647|NCT02623491|EXPERIMENTAL|Part 1: Single Ascending Dose (SAD)|Participants will receive 0.75 milligrams (mg) of JNJ-55375515 (starting dose) or Placebo on Day 1. Dose of the study medication will be escalated sequentially up to a maximum of 200 mg.
62367648|NCT02623491|EXPERIMENTAL|Part 2: Multiple Ascending Dose (MAD)|Participants will receive JNJ-55375515 (at doses determined based on the data from the SAD part) or Placebo from Day 1 to 10.
62367649|NCT05255536|ACTIVE_COMPARATOR|Serratus Anterior Plan Block with 20 ml %0.25 Bupivacaine|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
62367650|NCT05255536|ACTIVE_COMPARATOR|Serratus Anterior Plan Block with 30 ml %0.25 Bupivacaine|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 30 ml 0.25% bupivacaine will be injected into the area.
62367651|NCT04321278|EXPERIMENTAL|Hydroxychloroquine + azithromycin|Hydroxychloroquine \[400mg 2x/day, 12/12h\] + azithromycin \[500mg 1x/day\]
62367652|NCT04321278|ACTIVE_COMPARATOR|Hydroxychloroquine|Hydroxychloroquine \[400mg 2x/day, 12/12h\]
62367653|NCT02623699|PLACEBO_COMPARATOR|Part A-SAD: Combined Placebo|Participants will be administered tofersen-matching placebo once by intrathecal bolus injection on Day 1 of Cohorts 1, 2, 3, and 4 respectively.
62367654|NCT02623699|EXPERIMENTAL|Part A-SAD: Cohort 1: Tofersen 10 mg|Participants will be administered tofersen 10 mg once by intrathecal bolus injection on Day 1.
62367655|NCT02623699|EXPERIMENTAL|Part A-SAD: Cohort 2: Tofersen 20 mg|Participants will be administered tofersen 20 mg once by intrathecal bolus injection on Day 1 of Cohort 2 after the safety review of Cohort 1.
62367656|NCT02623699|EXPERIMENTAL|Part A-SAD: Cohort 3: Tofersen 40 mg|Participants will be administered tofersen 40 mg once by intrathecal bolus injection on Day 1 of Cohort 3 after the safety review of Cohort 2.
62367657|NCT02623699|EXPERIMENTAL|Part A-SAD: Cohort 4: Tofersen 60 mg|Participants will be administered tofersen 60 mg once by intrathecal bolus injection on Day 1 of Cohort 4 after the safety review of Cohort 3.
62367658|NCT02623699|PLACEBO_COMPARATOR|Part B-MAD: Combined Placebo|Participants will be administered tofersen-matching placebo, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection.
62367659|NCT02623699|EXPERIMENTAL|Part B-MAD: Cohort 5: Tofersen 20 mg|Participants will be administered tofersen 20 mg, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection.
62367660|NCT02623699|EXPERIMENTAL|Part B-MAD: Cohort 6: Tofersen 40 mg|Participants will be administered tofersen 40 mg, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection after the safety and PK review of Cohort 5.
62367661|NCT02623699|EXPERIMENTAL|Part B-MAD: Cohort 7: Tofersen 60 mg|Participants will be administered tofersen 60 mg, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection after the safety, PK review and SOD1 PD review of Cohort 6.
62367662|NCT02623699|EXPERIMENTAL|Part B-MAD: Cohort 8: Tofersen 100 mg|Participants will be administered tofersen 100 mg, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection after the safety, PK review and SOD1 PD review of Cohort 7.
62367663|NCT02623699|PLACEBO_COMPARATOR|Part C-Pivotal: Placebo|Participants will be administered tofersen-matching placebo, 3 loading doses administered once every 2 weeks on Days 1, 15, 29 followed by 5 maintenance doses administered once every 4 weeks on Days 57, 85, 113, 141, 169 up to 24 weeks by intrathecal bolus injection.
62367664|NCT02623699|EXPERIMENTAL|Part C-Pivotal: Tofersen 100 mg|Participants will be administered tofersen 100 mg, 3 loading doses administered once every 2 weeks on Days 1, 15, 29 followed by 5 maintenance doses administered once every 4 weeks on Days 57, 85, 113, 141, 169 up to 24 weeks by intrathecal bolus injection.
62367665|NCT03749213|EXPERIMENTAL|Icotinib|Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib as neoadjuvant therapy before surgery and adjuvant therapy or till progressive disease or unaccepted toxicity.
62367666|NCT03757260|EXPERIMENTAL|Treatment Group|Antimicrobial photodynamic therapy with methylene blue applied to test site after mechanical debridement.
62367667|NCT03757260|PLACEBO_COMPARATOR|Placebo Group|Photodynamic therapy laser is not activated with saline water in the test site after mechanical debridement.
62367668|NCT04701749||with atrial closure|
62367669|NCT04701749||without atrial occlusion|
62367670|NCT00804986|EXPERIMENTAL|0.5 mg LY2428757|Once weekly, subcutaneous injection of 0.5 milligram (mg) LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
62367671|NCT00804986|EXPERIMENTAL|2.0 mg LY2428757|Once weekly, subcutaneous injection of 2.0 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
62367672|NCT00804986|EXPERIMENTAL|6.2 mg LY2428757|Once weekly, subcutaneous injection of 6.2 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
62367673|NCT00804986|EXPERIMENTAL|12.0 mg LY2428757|Once weekly, subcutaneous injection of 12.0 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
62367674|NCT00804986|EXPERIMENTAL|17.6 mg LY2428757|Once weekly, subcutaneous injection of 17.6 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
62367675|NCT00804986|PLACEBO_COMPARATOR|Placebo|Once weekly, subcutaneous injection of placebo for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
62367676|NCT05514925|ACTIVE_COMPARATOR|Preoperative Anti-VEGF Intravitreal Injection|Three to five days before vitrectomy, each participant received one intravitreal Bevacizumab injection (1.25 mg,0.05 ml).
62367677|NCT05514925|EXPERIMENTAL|Peripheral Retinal Cryoapplication|Four to six weeks before vitrectomy, each participant underwent peripheral retinal cryoapplication.
62367678|NCT05990166|EXPERIMENTAL|Active intervention|Mineral-enriched powder
62367679|NCT05990166|PLACEBO_COMPARATOR|Placebo|Placebo powder
62367680|NCT01351389|ACTIVE_COMPARATOR|Brief Motivational Intervention (BMI)|
62367681|NCT01351389|ACTIVE_COMPARATOR|Brief Advice|
62367682|NCT04776889|ACTIVE_COMPARATOR|Control/statin non-users|newly diagnosed metastatic prostate cancer patients who underwent surgical castration in the form of bilateral subcapsular orchiectomy.
62367683|NCT04776889|EXPERIMENTAL|Interventional/statin users|newly diagnosed metastatic prostate cancer patients who underwent surgical castration in the form of bilateral subcapsular orchiectomy and administered rosuvastatin 20 mg/day for 6 months
62367684|NCT06234072|EXPERIMENTAL|Astragalus + Gemcitabine|"Participants will receive Astragalus in combination with Gemcitabine by intravenous infusion (IV).~Participants will receive IV infusion of 20ml of Astragalus injection (the content of Astragalus crude drug is 2g/ml plus 250ml of normal saline 1 day before chemotherapy, once a day for 21 consecutive days constitute a course of treatment a total of 4 courses of treatment.~Gemcitabine is one of the main chemotherapy drugs used to treat pancreatic cancer."
62367685|NCT06234072|ACTIVE_COMPARATOR|Gemcitabine alone|Participants will receive Neoadjuvant Chemotherapy of Gemcitabine 1000 mg/m2 as a 30- to 40-minute infusion (maximum 40 minutes) administered weekly for 7 weeks followed by a week of rest (8-week cycle; cycle 1 only), followed by cycles of weekly administration for 3 weeks (on days 1, 8, and 15) followed by one week of rest (4-week cycle).
62367686|NCT04746781|ACTIVE_COMPARATOR|Risk notification/education arm|We will send all participants a short message service (SMS) message with a link to a website that educates the public about their risk for developing T2DM and about the availability and efficacy of the DPP to address their risk
62367687|NCT04746781|EXPERIMENTAL|Mobile 360° Video intervention arm|After risk notification and education, participants will receive links to two 3-minute immersive Mobile 360° Videos (in which the viewer moves their phone to 'look around' the world of the video) on their smart phones. These videos are intended to influence affective and experiential perceptions of risk. The first video tells an emotional story of the negative effects on an individual's health and family life as they progress from prediabetes to T2DM and develop cardiovascular complications. The second video provides the viewer with a vicarious experience of the changes in vision that occur as diabetic retinopathy develops and worsens.
62367688|NCT04746781|EXPERIMENTAL|Motivation and Problem Solving (MAPS) arm|After risk notification and education, participants will be called by a health coach trained in counseling/coaching. The coach will guide them in setting goals related to their health, and addressing any practical barriers to enrolling/engaging in the DPP if that is consistent with their health goals. Per their preference, participants will receive up to 5 phone calls from the health coach over a 4 week period.
62367689|NCT04434261||Patients tested for SARS-CoV-2|Patients who underwent the preoperative screening program for SARS-CoV-2
62367690|NCT02725736|EXPERIMENTAL|Atosiban|Women with twin pregnancy with preterm labor between 24 weeks 0 days and 32 weeks 6 days of gestation will be included and randomly assigned to the Atosiban group.
62367691|NCT02725736|EXPERIMENTAL|Nifedipine|Women with twin pregnancy with preterm labor between 24 weeks 0 days and 32 weeks 6 days of gestation will be included and randomly assigned to the Nifedipine group.
62367692|NCT02027064|EXPERIMENTAL|interferon|
62742756|NCT02407080|EXPERIMENTAL|RG7388|"Part A: RG7388 as a single agent; given at a starting dose of 100 mg each day for five days for the first cycle which will be 56 days.~Part B: combination of RG7388 and Pegasys if subject does not achieve at least a PR by the end of 3 cycles of single agent RG7388"
62742757|NCT04414592|EXPERIMENTAL|Human Umbilical Cord Mesenchymal Stem Cells|Injection of twenty million human umbilical cord mesenchymal stem cells into the degenerative disc
62367693|NCT02825940|EXPERIMENTAL|Atezolizumab Monotherapy: PK and Extension Phases|Participants during the PK and extension phases of the study will receive atezolizumab alone at a dose of 1200 milligrams (mg) IV every 3 weeks (q3w) (in 21-day cycles) continuously until loss of clinical benefit, disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death. Study treatment may continue beyond disease progression based on the investigator's discretion.
62367694|NCT02825940|EXPERIMENTAL|Atezolizumab and Chemotherapy: Extension Phase|Participants during the extension phase of the study will receive atezolizumab at a dose of 1200 mg IV on Day 1 in combination with gemcitabine at a dose of 1250 milligrams per square meter (mg/m\^2) on Days 1 and 8 and cisplatin at a dose of 75 mg/m\^2 on Day 1 (four or six 21-day cycles at the discretion of the investigator), followed by atezolizumab as a single agent at a dose of 1200 mg IV q3w on Day 1 of a 21-day cycle) as maintenance treatment continuously until loss of clinical benefit, disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death. Study treatment may continue beyond disease progression based on the investigator's discretion.
62742758|NCT02991495|ACTIVE_COMPARATOR|Stamaril, Sanofi Pasteur: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
62742759|NCT02991495|EXPERIMENTAL|Stamaril, Sanofi Pasteur: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
62367695|NCT04921657||Patients treated with statin.|Patients with hypercholesterolemia treated with rosuvastatin 10 mg daily or simvastatin 40 mg daily.
62367696|NCT02781415|EXPERIMENTAL|Acupuncture|Traditional Acupuncture Session:Patients in this group will benefit from a 30 minutes acupuncture session made by an experimented physician.
62367697|NCT02781415|ACTIVE_COMPARATOR|Titrated Morphine|Morphine Titration:Patients will receive an intravenous titration of morphine by a qualified nurse.
62367698|NCT06508970|EXPERIMENTAL|experimental group|RAM-based virtual reality glasses were applied to the experimental group for 4 weeks.
62367699|NCT06508970|OTHER|Control group|Nursing students will receive their regular semester courses; no additional intervention will be implemented.
62367700|NCT00882167||1|Patients with laparotomy in history
62367701|NCT06252740||control group|Baseball players without a history of low back pain
62367702|NCT06252740||experimental group|Baseball players with a history of low back pain
62367703|NCT04409730|EXPERIMENTAL|Children with Cerebral Palsy|"Aged 5-12 years, diagnosed as spastic diplegia or hemiplegia , having a level of I, II, III according to GMFCS"
62367704|NCT04144179|EXPERIMENTAL|Quadrivalent RIV with H3 strain 1|1 injection of Quadrivalent RIV containing H3 strain 1
62367705|NCT04144179|EXPERIMENTAL|Quadrivalent RIV with H3 strain 2|1 injection of Quadrivalent RIV containing H3 strain 2
62367706|NCT04144179|EXPERIMENTAL|Quadrivalent RIV with H3 strain 3|1 injection of Quadrivalent RIV containing H3 strain 3
62367707|NCT04144179|EXPERIMENTAL|Quadrivalent RIV with H3 strain 4|1 injection of Quadrivalent RIV containing H3 strain 4
62367708|NCT04144179|ACTIVE_COMPARATOR|Quadrivalent RIV Control|1 injection of Quadrivalent RIV containing 2018-19 NH recommended H3 strain
62367709|NCT06187285|EXPERIMENTAL|Empagliflozin 25 mg|
62367710|NCT06187285|ACTIVE_COMPARATOR|Sitagliptin 100 mg|
62367711|NCT00115544|EXPERIMENTAL|1|stannsoporfin 0.75mg/kg
62367712|NCT00115544|EXPERIMENTAL|2|stannsoporfin 1.5mg/kg
62367713|NCT00115544|PLACEBO_COMPARATOR|3|saline injection
62367714|NCT01505244|EXPERIMENTAL|Physical Activity|Before-school moderate to vigorous physical activity 3 days/week
62367715|NCT03299452|EXPERIMENTAL|Alphacait-guided therapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines until the patient progresses, intolerant, the patient withdrawn or the investigator determines that the medication must be discontinued.
62367716|NCT05154071||ECMO VV dedicated unit|Patient having benefited from an ECMO within the structured care unit
62367717|NCT05154071||ECMO VV without dedicated unit|Patient having benefited from an ECMO without the structured care unit
62367718|NCT04479449|EXPERIMENTAL|SP-8203|SP-8203 80 mg (40 mg/dose twice a day for three days)
62367719|NCT04479449|PLACEBO_COMPARATOR|Placebo|Placebo group: twice a day for three days
62367720|NCT02380482|OTHER|Traumatic brain injury|"Two dimensional and speckle tracking transthoracic echocardiography in traumatic brain injured patients~* Glasgow score \< or = 9 or~* Glasgow score between 9 and 13 (included) and Following Traumatic Coma Data Bank Tomographic Damages:~diffuse injuries type III or IV or mass lesion over 25ml and/or neurosurgical injuries"
62367721|NCT02380482|OTHER|Controls|"Two dimensional and speckle tracking transthoracic echocardiography in control patients paired with traumatic brain injured patient on age, BMI and sex with the following criteria:~* Intubated and mechanically ventilated~* Undergoing urgent non severe surgery"
62367722|NCT00068484|EXPERIMENTAL|Treatment (topotecan hydrochloride, bortezomib)|Patients receive topotecan IV over 30 minutes on days 1-5. Beginning with course 2, patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62367723|NCT02224274|ACTIVE_COMPARATOR|Clopidogrel|These patients will be treated with clopidogrel 600 mg loading and than 75 mg/24 h.
62367724|NCT02224274|EXPERIMENTAL|Ticagrelor|These patients will be treated with ticagrelor 180 mg loading and than 90 mg/12 h.
62367725|NCT01707095|EXPERIMENTAL|Bundling of cords|The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
62367726|NCT01707095|EXPERIMENTAL|Unbundling of cords|The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
62367727|NCT00605358|ACTIVE_COMPARATOR|Open Door Intervention|Subjects who receive the Open Door Intervention will work with the study counselor to identify barriers to participation in mental health treatment, set goals, and problem-solve, in addition to receiving a referral.
62367728|NCT00605358|NO_INTERVENTION|Services Referral|"Subjects who do not receive the Open Door intervention will receive:~1. an evaluation~2. referral to a local mental health provider~3. booklet information on depression and mental health care, and will complete an application for HEAP, a Westchester County service that provides reduced rates from oil companies on heating to seniors."
62367729|NCT01505660|NO_INTERVENTION|Usual Care|Patients not randomized to the intervention will receive usual care which includes a patient reported outcomes assessment every 6 months as part of routine clinical procedures and patient-initiated interactions with case managers.
62367730|NCT01505660|EXPERIMENTAL|Care management|The intervention will include frequent healthcare delivery team notification of PROs including medication adherence and adherence barriers such as depression symptoms along with tailored intervention recommendations and targeted care management using a stepped care approach.
62367731|NCT03234270|EXPERIMENTAL|F35 pilots|
62367732|NCT03234270|ACTIVE_COMPARATOR|F15 pilots|
62367733|NCT03300427|EXPERIMENTAL|sacubitril/valsartan|subjects received sacubitril/valsartan 100 mg orally twice daily (BID). The dose was then up-titrated to 200 mg BID (or maintained at the starting dose level, if up-titration was not possible).
62367734|NCT03300427|ACTIVE_COMPARATOR|valsartan|subjects received 80 mg orally twice daily (BID). The dose was then up-titrated to 160 mg BID (or maintained at the starting level, if up-titration was not possible)
62367735|NCT03209011|EXPERIMENTAL|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
62367736|NCT03209011|NO_INTERVENTION|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
62367737|NCT03790072|EXPERIMENTAL|Treatment Arm|"After inclusion, patients will receive conditioning chemotherapy consisting of non-investigational medicinal products (non-IMPs): fludarabine 25 mg/m2 from day -6 until day -2 (inclusive) and cyclophosphamide 500 mg/m2 on days -6 and -5.~Subsequently, patients in will be dosed with investigational medicinal product (IMP) OmnImmune® on day 0."
62367738|NCT03986567|ACTIVE_COMPARATOR|control|Providing with a paper notification card to the STI diagnosed young person
62742760|NCT02991495|ACTIVE_COMPARATOR|Yellow fever vaccine, Bio-Manguinhos: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
62367739|NCT03986567|EXPERIMENTAL|intervention web app|providing to the STI diagnosed young person, with a code number to enter into the app to notify sexual partners
62367740|NCT03986567|EXPERIMENTAL|intervention game|providing to the STI diagnosed young person, with a code number to enter into the app and play a game to get motivated to notify sexual partners
62367741|NCT05376189|ACTIVE_COMPARATOR|Control Group|This group will be given standardized tuberculosis drug with 400 IU of oral Vitamin D3
62367742|NCT05376189|EXPERIMENTAL|Moderate Dose|This group will be given standardized tuberculosis drug with 5000 IU of oral Vitamin D3
62367743|NCT05376189|EXPERIMENTAL|High Dose|This group will be given standardized tuberculosis drug with 10000 IU of oral Vitamin D3
62367744|NCT02242760|EXPERIMENTAL|SB204 2% Twice daily|Twice daily SB204 2%
62367745|NCT02242760|EXPERIMENTAL|SB204 4% daily|Once daily SB204 4%
62367746|NCT02242760|PLACEBO_COMPARATOR|Vehicle Gel Daily|Vehicle Gel Daily
62367747|NCT02242760|PLACEBO_COMPARATOR|Vehicle Gel Twice Daily|Twice daily Vehicle Gel
62367748|NCT02242760|EXPERIMENTAL|SB204 4% Twice Daily|Twice daily SB204 4%
62367749|NCT01604395||growth hormone|
62367750|NCT01769612||CL Detect Rapid Test and Microsopy Samples|Samples taken to be evaluated in the CL Detect and Microscopy assays
62367751|NCT04449497||Bereaved caregivers|Caregivers who, in the past two years,have lost a family member or close friend after a brief or extended period of illness or injury
62367752|NCT04449497||Country experts|Qualified individuals (providers, palliative care experts, policy makers) from countries across the globe with knowledge of the phenomenon of interest-end-of-life care.
62367753|NCT00666380|EXPERIMENTAL|10 ug of FMP010 antigen in 0.5 mL AS01B adjuvant|
62367754|NCT00666380|EXPERIMENTAL|50 ug of FMP010 antigen in 0.5 mL AS01B adjuvant|
62367755|NCT05882123||Comparison of clinical data between AIS patients in CMB and non-CMB groups|
62367756|NCT05882123||without CMBs; with CMBs|
62367757|NCT05882123||male; female|
62367758|NCT05887089||no intervention|
62367759|NCT05887089||drone transportation|
62367760|NCT02707601|EXPERIMENTAL|E/C/F/TAF + LDV/SOF|"Part 1: Participants will switch from 2 nucleoside reverse transcriptase inhibitors (NRTI) plus a third agent to E/C/F/TAF.~Part 2: After 8 weeks of E/C/F/TAF treatment, the participants maintaining HIV-1 RNA \< 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study."
62367761|NCT02707601|EXPERIMENTAL|F/R/TAF + LDV/SOF|"Part 1: Participants will switch from 2 NRTI plus a third agent to F/R/TAF.~Part 2: After 8 weeks of F/R/TAF treatment, the participants maintaining HIV-1 RNA \< 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study."
62367762|NCT00626769||1|Postmenopausal women with established osteopenia receiving aglycone genistein 54 mg/day for 3 years
62367763|NCT00626769||2|Postmenopausal women with established osteopenia receiving placebo (Calcium and vitD) for 3 years
62367764|NCT00560794|EXPERIMENTAL|Blinatumomab|Participants received blinatumomab as continuous intravenous infusion at constant flow rate over 4 weeks followed by a 2 week treatment-free period (defined as one treatment cycle), for up to a maximum of 10 cycles. The initial dose was 15 μg/m\^2/day. A dose increase to 30 μg/m\^2/day was permitted with evidence for insufficient response to blinatumomab treatment.
62367765|NCT06455384|EXPERIMENTAL|Genetics Navigator|Participants in the intervention arm will use the Genetics Navigator to support the delivery of genetic services, including intake, education, pre- and post-test counselling, return of results, and physician-generated management recommendations. Participants in the experimental arm will also receive standard of care genetics care.
62367766|NCT06455384|ACTIVE_COMPARATOR|Standard Care with Genetics Professionals|Participants in the control arm will receive their genetic counselling and test results through usual care, which consists of in-person/phone/video-conference consults with genetic counsellors and medical geneticists.
62367767|NCT00533169|EXPERIMENTAL|ZD6474 + Retinoic Acid|Part A = ZD6474 Alone, Starting dose 50 mg/m\^2 by mouth daily for 28 days; Part B, C = ZD6474 + Retinoic Acid 80 mg/m\^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
62367768|NCT02049229|EXPERIMENTAL|OPTIMAX stent|Patients randomised to receive titanium-nitride-oxide coated OPTIMAX-stent
62367769|NCT02049229|ACTIVE_COMPARATOR|SYNERGY stent|Patients randomised to receive everolimus-eluting, biabsorabble polymer coated stent
62367770|NCT01450969||Interventional Radiologists|All operators are Interventional Radiologists and co-investigators. Prior to start of the study, all operators are asked to provide written informed consent to participate in the study.
62367771|NCT05369780|EXPERIMENTAL|Hydrolized Collagen Peptide|This arm will be allocated randomly and receive 10 g hydrolized collagen peptide (Investigational Product) daily throughout the study.
62367772|NCT05369780|PLACEBO_COMPARATOR|Placebo|This arm will be allocated randomly and receive placebo daily throughout the study.
62367773|NCT00655304|ACTIVE_COMPARATOR|1|Treatment with 6-8 hours of Prometheus (R) liver support dialysis
62367774|NCT00655304|ACTIVE_COMPARATOR|2|Treatment with 6-8 hours of CVVHDF
62742761|NCT02991495|EXPERIMENTAL|Yellow fever vaccine, Bio-Manguinhos: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
62742762|NCT02991495|ACTIVE_COMPARATOR|Yellow fever vaccine, Institut Pasteur: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
62367775|NCT02111629|EXPERIMENTAL|Fluconazole and Secnidazole|
62367776|NCT02135549|EXPERIMENTAL|SugarDown 4 grams|SugarDown 4 gram dose in tablet form, before meals, daily for one week
62367777|NCT02135549|EXPERIMENTAL|SugarDown 8 grams|SugarDown 8 gram dose in tablet form, before meals, daily for one week
62367778|NCT02135549|PLACEBO_COMPARATOR|Placebo|Placebo dose in tablet form, before meals, daily for one week
62367779|NCT04463238|EXPERIMENTAL|Cartilage membrane surgery|"The test group applied the guidance provided by Shaanxi Baiao Regenerative Medicine Co., Ltd.~Cartilage regeneration membrane combined with microfracture surgery."
62367780|NCT04463238|OTHER|Microfracture|The control group was treated with microfractures widely recognized at home and abroad.
62367781|NCT04125381||Exposed to high Arsenic concentration|All the inhabitants, residing in one of the municipalities of Viterbo Province with high Arsenic concentration in drinking water, were enrolled
62367782|NCT04125381||Exposed to low Arsenic concentration|All the inhabitants, residing in one of the municipalities of Viterbo Province with low Arsenic concentration in drinking water, were enrolled
62367783|NCT00246376|PLACEBO_COMPARATOR|1|Subjects receive lifestyle advice and placebos for Niaspan and Tricor
62367784|NCT00246376|EXPERIMENTAL|2|Diet, exercise, and two placebos
62367785|NCT00246376|EXPERIMENTAL|3|Diet, exercise, Niaspan, and placebo
62367786|NCT00246376|EXPERIMENTAL|4|Diet, exercise, placebo, and Tricor
62367787|NCT00246376|EXPERIMENTAL|5|Diet, exercise, Niaspan, and Tricor
62367788|NCT02792283|EXPERIMENTAL|patients undergoing hemodialysis|
62367789|NCT05021380||Group|50 generally healthy children diagnosed with dental pain as symptomatic irreversible pulpitis (SIP) or symptomatic apical periodontitis (SAP) aged from 6 to 12 years old will be included to the GROUP.
62367790|NCT06244524|NO_INTERVENTION|Well-ventilated bedroom|The participants will stay and sleep for eight hours in a well-ventilated bedroom.
62367791|NCT06244524|EXPERIMENTAL|Non-ventilated bedroom|The participants will stay and sleep for eight hours in a closed bedroom.
62367792|NCT03199144|EXPERIMENTAL|Stereotactic radiotherapy|Stereotactic radiotherapy delivering 30 Gy in 5 fractions over 9 days
62367793|NCT03587922|EXPERIMENTAL|Treatment Arm|Single arm study with treatment of Fantom scaffold
62367794|NCT04523467|EXPERIMENTAL|Combined group|Anti-angiogenic targeted drug + Rg3 + TACE
62367795|NCT04523467|ACTIVE_COMPARATOR|Single group|TACE alone
62367796|NCT02697058|EXPERIMENTAL|Part 1: Safety and PK|BAX2398 in combination with 5-FU/calcium levofolinate
62367797|NCT02697058|EXPERIMENTAL|Part 2: Safety, PK, Efficacy|BAX2398 in combination with 5-FU/calcium levofolinate
62367798|NCT02697058|ACTIVE_COMPARATOR|Part 2: 5-FU/calcium levofolinate alone|5-FU/calcium levofolinate
62367799|NCT04171063|OTHER|Bracing arm|Patients that will be using the thoracic compressor
62367800|NCT05378048|EXPERIMENTAL|PDO-guided treatment|"A biopsy of the tumour will be performed for PDO culture and Genome-guided drug screening.~An Multidisciplanary Tumour Board will review the drug screen results and recommend the use of a drug with a response in a PDO."
62367801|NCT05378048|EXPERIMENTAL|standard of care|the standard of care will include all treatments that have been reported to improve survival or quality of life in randomized trials.
62367802|NCT04703062|EXPERIMENTAL|Experimental group 1|physical activity counseling group + exercise group
62367803|NCT04703062|EXPERIMENTAL|Experimental group 2|physical activity counseling group
62367804|NCT01199497|EXPERIMENTAL|Group 1|Fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
62367805|NCT01199497|PLACEBO_COMPARATOR|Group 2|Placebo
62367806|NCT04289194|EXPERIMENTAL|HCR040 (Phase 1)|Participants with moderate to severe acute respiratory distress syndrome (6 patients)
62367807|NCT04289194|PLACEBO_COMPARATOR|Control group (Phase 2)|Participants with moderate to severe acute respiratory distress syndrome (10 patients)
62367808|NCT04289194|EXPERIMENTAL|HCR040 (Phase 2)|Participants with moderate to severe acute respiratory distress syndrome (10 patients)
62367809|NCT00625014|EXPERIMENTAL|1|Healthy men
62367810|NCT03275805|ACTIVE_COMPARATOR|12 weeks Pavlik Treatment Arm|This arm will receive 12 weeks of full-time Pavlik Harness treatment. Patients will most likely begin the 12-week regiment at their first visit to our hip clinic.
62367811|NCT03275805|EXPERIMENTAL|6 weeks Pavlik Treatment Arm|This arm will receive treatment to normalization, but for no less than 6 weeks. Patients will begin their treatment around the time of their first visit to our designated hip clinic.
62367812|NCT00698776|EXPERIMENTAL|Active|10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
62367813|NCT00666536|ACTIVE_COMPARATOR|Aggressive treatment regimen (5/320 mg to 10/320 mg)|Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)
62367814|NCT00666536|ACTIVE_COMPARATOR|Moderate treatment regimen (5/160 mg)|Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)
62367815|NCT01900223||Shoulder prosthesis bearer|
62367816|NCT02260388|EXPERIMENTAL|Nortriptyline|Nortriptyline - 25 mg daily for 1 week at bedtime, then 50 mg daily at bedtime for 1 week, then 75 mg daily at bedtime for the remainder of the study.
62367817|NCT02260388|EXPERIMENTAL|Duloxetine|Duloxetine - 20 mg daily for 1 week, then 40 mg daily for 1 week, then 60 mg daily for the remainder of the study.
62367818|NCT02260388|EXPERIMENTAL|Pregabalin|Pregabalin - 100 mg at bedtime for 1 week, then 100 mg 2 times per day for 1 week, then 100 mg 3 times per day for the remainder of the study.
62367819|NCT02260388|EXPERIMENTAL|Mexiletine|Mexiletine - 200 mg at bedtime for 1 week, then 200 mg 2 times per day for 1 week, then 200 mg 3 times per day for the remainder of the study.
62367820|NCT02650440|EXPERIMENTAL|Novel Protocol|Progressive decrease of speed and guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.0 km/h.
62367821|NCT02650440|EXPERIMENTAL|Standard Protocol|Progressive increase of speed and decrease of guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.9 km/h.
62367822|NCT06305091||OBP exposed|Veterans exposed to Open Burn Pits (N=220)
62367823|NCT06305091||OBP not exposed|Veterans not exposed to Open Burn Pits (N=110)
62367824|NCT04399057||andrological patients|shear wave elastosonography of the corpora cavernosa was performed to all patients who went to our clinic for andrological problems. in addition, the International Index of Erectile Function short form (IIEF5) questionnaire and the Erectile Hardness Score (EHS) questionnaire were administered.
62367825|NCT05143918||Hypothyroid patients as a cases|"1. Inclusion criteria:~   1. age ranges will be 18 - 60 years~  2. both genders~  3. previously confirmed diagnosed~2. Exclusion criteria:~   1. pregnancy~  2. other comorbidities (hypertension, diabetes, malignancy,,,etc)"
62367826|NCT05143918||Control group|Healthy people without chronic disease
62367827|NCT01546090|EXPERIMENTAL|alprazolam|Alprazolam is a short-acting anxiolytic of the benzodiazepine class of psychoactive drugs
62367828|NCT01546090|PLACEBO_COMPARATOR|placebo|placebo capsules were filled with starch
62367829|NCT01736709|EXPERIMENTAL|trivalent seasonal influenza vaccine|2012-2013 trivalent seasonal influenza vaccine in 60 infants with two-dose regimen, 21 days interval trivalent seasonal influenza vaccine in 60 adults and 60 old people with single-dose regimen
62367830|NCT02979561|EXPERIMENTAL|group of dabigatran|
62367831|NCT02979561|ACTIVE_COMPARATOR|group of warfarin|
62367832|NCT03699904|EXPERIMENTAL|Active arm|Valaciclovir 1 gram orally three times daily for 8 weeks.
62367833|NCT03699904|PLACEBO_COMPARATOR|Placebo arm|Matching placebo capsules (containing Avicel blend). Two capsules three times daily for 8 weeks.
62367834|NCT05409118|EXPERIMENTAL|Alto Abdominal Stent Graft System|Subjects randomized to receive the Endologix Alto Abdominal Stent Graft System for implantation to repair Abdominal Aortic Aneurysm.
62367835|NCT05409118|ACTIVE_COMPARATOR|Comparators|Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm.
62367836|NCT00333970|EXPERIMENTAL|cognitive remediation|cognitive remediation
62367837|NCT00333970|NO_INTERVENTION|treatment as usual|treatment as usual
62367838|NCT05058118|EXPERIMENTAL|FL058|a single ascending dose (SAD) of intravenous (IV) FL058(50mg\~2000mg)
62367839|NCT05058118|PLACEBO_COMPARATOR|Placebo|FL058 Placebo
62367840|NCT04823741||PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA|All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).
62367841|NCT03523949|EXPERIMENTAL|PNE.|Procedure: This educational intervention is based in the latest evidence of pain neuroscience education, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptive thoughts and behaviors.
62367842|NCT03007628|EXPERIMENTAL|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
62367843|NCT03007628|ACTIVE_COMPARATOR|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
62367844|NCT01339208|EXPERIMENTAL|Telemedicine Diabetes Intervention|
62367845|NCT05258526|EXPERIMENTAL|Home-based exercise program|This is a single study arm consisting of a home-based exercise program for individuals with breast or prostate cancer during active treatment.
62367846|NCT00083304|EXPERIMENTAL|Efaproxiral + WBRT + Supplemental Oxygen|
62367847|NCT00083304|ACTIVE_COMPARATOR|WBRT + Supplemental Oxygen|
62367848|NCT04039763|EXPERIMENTAL|Real Time Continuous Glucose Monitoring|"Participants wear Real time continous glucose monitoring (Dexcom G6), with alarms for when their glucose is too low or too high. They will be able to view their data on the Dexcom app on their smartphones or a Dexcom receiver and share this with a nominated caregiver. Participants can chose to share data between study visits via Dexcom clarity with the research/clinical team, who will support them making changes to their insulin regime in light of the data."
62367849|NCT04039763|PLACEBO_COMPARATOR|Standard care|Standard care - finger prick self monitoring of blood glucose.
62367850|NCT04644055||Chronic liver disease with liver cirrhosis|Evaluation of the right and left hepatic lobe with EUS-guided share wave evaluation. All patients with chronic liver disease will have a transient elastography evaluation, EUS- elastography of the liver and an EUS-guided liver biopsy.
62367851|NCT04644055||Control patients|Patients without history of chronic liver disease after clinical and transient elastography evaluation will be submitted for EUS-guided share wave evaluation of the liver. Patients were originally undergoing EUS evaluation for evaluation of suspected subepithelial lesions.
62367852|NCT02552667|EXPERIMENTAL|HCP1102+HGP0711Placebo|HCP1102Placebo+HGP0711Placebo(1week) -\> HCP1102+HGP0711Placebo(4weeks) Each 1 capsule, once daily
62367853|NCT02552667|ACTIVE_COMPARATOR|HCP1102Placebo+HGP0711|HCP1102Placebo+HGP0711Placebo(1week) -\> HCP1102Placebo+HGP0711(4weeks) Each 1 capsule, once daily
62367854|NCT00345514|NO_INTERVENTION|1|
62367855|NCT00345514|ACTIVE_COMPARATOR|2|
62367856|NCT00345514|ACTIVE_COMPARATOR|3|
62367857|NCT05628129|EXPERIMENTAL|reminder intervention|On the basis of standard appointment, parents in intervention group will receive phone reminders at 4 days and 1 day before their scheduled appointments, and relevant scientific and educational knowledge will be relayed to them from the smartphone application at 1 week before appointments.
62367858|NCT05628129|NO_INTERVENTION|standard appointment|Patients will be required to attend follow-up appointments at 1 week, 1 month, 3 months after surgery.
62567162|NCT05224128|EXPERIMENTAL|Imatinib Drug|Standard medication of liver fibrosis + Imatinib 200 mg 1 time a day.
62567163|NCT05224128|PLACEBO_COMPARATOR|Placebo|Standard medication of liver fibrosis + placebo as a control group.
62567164|NCT05289336|EXPERIMENTAL|Transoral Laser Microsurgery|Transoral Laser Microsurgery
62367859|NCT06395740|EXPERIMENTAL|enteral nutrition group|patients will be scheduled for enteral nutrition via nasogastric tube.The amount of nasogastric feed given each day will be calculated according to the patient's calorie requirement and administered as 100 ml nasogastric tube feeding every four hours escalating to 200 ml every four hours according to patients' toleration and caloric needs. Patients will be positioned at ≥ 45° head-end elevation during feeds. They will be observed regularly during feeds, and the position of the nasogastric tube will be confirmed before each feed by auscultation by stethoscope.
62367860|NCT06395740|EXPERIMENTAL|total parentral nutrition group|patients will be scheduled for continuation of NPO strategy except for medications to be given via nasogastric tube till 14 days from day of stroke with fulfilment of nutrition requirement by parenteral route
62367861|NCT02373306|ACTIVE_COMPARATOR|NIPS-sensitive group|Patients who had sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation.
62367862|NCT02373306|NO_INTERVENTION|Control group|Patients who had no sustained or hemodynamically unstable arrhythmias induction during non-invasive programmed stimulation.
62367863|NCT03385434|EXPERIMENTAL|Endorings-assisted screening colonoscopy|146 patients with an indication for screening endoscopy will receive an Endorings-2-assisted colonoscopy.
62367864|NCT03385434|NO_INTERVENTION|Standard screening colonoscopy|146 patients with an indication for screening endoscopy will receive a standard colonoscopy.
62367865|NCT01782404|EXPERIMENTAL|Chlorhexidine|
62367866|NCT02572804|ACTIVE_COMPARATOR|Rectus Sheath Catheter Group|Patients will have rectus sheath catheters surgically inserted with infusion of 0.125% Bupivicaine at 5mls an hour.
62367867|NCT02572804|ACTIVE_COMPARATOR|Epidural Group|Patients will have a standard epidural placement with infusion of 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response
62367868|NCT04090697|EXPERIMENTAL|Oxandrolone Cohort 1|Participants randomized to Oxandrolone Cohort 1 will receive 0.1mg/kg of oxandrolone suspended in a multi-chain triglyceride (MCT) oil buccally twice per day.
62367869|NCT04090697|NO_INTERVENTION|Standard of Care|Participants randomized to standard of care will receive the standard therapies provided at the institution at which they are being treated. Control subjects will receive standard therapy with no placebo and no oxandrolone.
62367870|NCT00815776|EXPERIMENTAL|1|Treatment group receiving the CID
62367871|NCT00815776|ACTIVE_COMPARATOR|2|Group assigned a mouth splint
62367872|NCT00815776|ACTIVE_COMPARATOR|Exercise Control Group|Group who received no device but were instead assigned a study-specified jaw exercise program
62742763|NCT02991495|EXPERIMENTAL|Yellow fever vaccine, Institut Pasteur: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
62367873|NCT00466024|EXPERIMENTAL|1|Health coach and 2 HEPA air cleaners
62367874|NCT00466024|ACTIVE_COMPARATOR|2|Standard asthma education and 2 HEPA air cleaners
62367875|NCT00466024|ACTIVE_COMPARATOR|3|Standard asthma education and delayed receipt of 2 HEPA air cleaners
62367876|NCT02977533|EXPERIMENTAL|GZ402668|Dose 1 (up to a maximum optional Dose 2) will be given as a single subcutaneous administration under fed conditions. Acyclovir will be given twice daily starting on Day 1 and continuing for 28 days after investigational medicinal product administration.
62367877|NCT02977533|PLACEBO_COMPARATOR|Placebo|A dose of matching placebo will be given as a single subcutaneous administration under fed conditions. Acyclovir will be given twice daily starting on Day 1 and continuing for 28 days after investigational medicinal product administration.
62367878|NCT05658419|ACTIVE_COMPARATOR|control group|immediate implant placement
62367879|NCT05658419|ACTIVE_COMPARATOR|study group|socket shield immediate implant placement
62367880|NCT04347616|EXPERIMENTAL|NK cells without IL-2|On day 0, patients will receive a fixed dose of 1.0-3.0 x 10\^9 allogeneic UCB-NK cells. Prior to NK cell infusion, patients will receive cyclophosphamide and fludarabine (Cy/Flu) based lymphodepleting chemotherapy. NK cells administration will not be followed by sc IL-2. N=3.
62367881|NCT04347616|ACTIVE_COMPARATOR|NK cells with low dose IL-2|On day 0, patients will receive a fixed dose of 1.0-3.0 x 10\^9 allogeneic UCB-NK cells. Prior to NK cell infusion, patients will receive cyclophosphamide and fludarabine (Cy/Flu) based lymphodepleting chemotherapy. IL-2 will be administered in a fixed dose of 3.0 x 10\^6 units starting 4 hours after NK cell infusion and given every other day for 6 doses in total. N=3
62367882|NCT04347616|ACTIVE_COMPARATOR|NK cells with higher dose IL-2|On day 0, patients will receive a fixed dose of 1.0-3.0 x 10\^9 allogeneic UCB-NK cells. Prior to NK cell infusion, patients will receive cyclophosphamide and fludarabine (Cy/Flu) based lymphodepleting chemotherapy. IL-2 will be administered in a fixed dose of 6.0 x 10\^6 units starting 4 hours after NK cell infusion and given every other day for 6 doses in total. N=6
62367883|NCT03137875||Patient with sputum smear positive 2+|patient who will have a positive diagnostic of tuberculosis using microscopy with a 2+ grade
62367884|NCT03137875||patient smear positive scanty or 1+|patient who will have a positive diagnostic of tuberculosis using microscopy with a scanty or 1+ grade
62367885|NCT03137875||patient smear negative|patient with a negative TB microscopy result
62367886|NCT02225925|EXPERIMENTAL|Dynamic dosimetry brachytherapy|Cohort treated with dynamic dosimetry brachytherapy
62367887|NCT04486612||hypotension|
62367888|NCT04486612||non-hypotension|
62367889|NCT02597985|ACTIVE_COMPARATOR|Prehabilitation|Will receive 4 weeks of supervised exercised prescription before they undergo TAVR and will monitor and record, improvement if any, in the short-term physical performance battery score
62367890|NCT02597985|PLACEBO_COMPARATOR|Usual care|Will receive usual care
62367891|NCT01706991||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
62567165|NCT04796532|NO_INTERVENTION|Control|No intervention. The control group will maintain their normal physical and dietary activity.
62742764|NCT02991495|ACTIVE_COMPARATOR|Yellow fever vaccine, Chumakov Institute: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
62742765|NCT02991495|EXPERIMENTAL|Yellow fever vaccine, Chumakov Institute: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
62742766|NCT02991495|ACTIVE_COMPARATOR|YF, Chumakov Institute: Standard dose in Children|Subcutaneous administration of 1 dose of the yellow fever vaccine
62742767|NCT02991495|EXPERIMENTAL|YF, Chumakov Institute: Fractional dose in Children|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
62742768|NCT02991495|ACTIVE_COMPARATOR|YF, Chumakov Institute: Standard dose in HIV+ adults|Subcutaneous administration of 1 dose of the yellow fever vaccine
62742769|NCT02991495|EXPERIMENTAL|YF, Chumakov Institute: Fractional dose in HIV+ adults|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
62742770|NCT03219034|EXPERIMENTAL|Oral appliance - A|"Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.~Trade Name: TAP1 Oral Appliance, Airway Management Inc. Dallas, TX"
62742771|NCT03219034|EXPERIMENTAL|Oral appliance - B|"Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.~Trade name: SomnoDent Flex Oral Appliance, SomnoMed Inc., Plano TX"
62742772|NCT01601106|ACTIVE_COMPARATOR|Liposomal prednisolone|
62742773|NCT01601106|PLACEBO_COMPARATOR|Placebo control|
62742774|NCT06094361|EXPERIMENTAL|IONTOPHORESIS|The group that received 75 mg diclofenac sodium with Chattanooga Physio device.
62742775|NCT06094361|EXPERIMENTAL|PHONOPHORESIS|It is a treatment performed by applying 75 mg of 1% diclofenac sodium gel to the intervention area with the Chattanooga ultrasound device.
62742776|NCT02175719||E2014|
62742777|NCT04569864|EXPERIMENTAL|Mild hypothermia (30-32°C)|During aortic hemiarch replacement, mild hypothermia (30-32°C) will be used during circulatory arrest.
62742778|NCT04569864|ACTIVE_COMPARATOR|Moderate hypothermia (26-28°C)|During aortic hemiarch replacement, moderate hypothermia (26-28°C) will be used during circulatory arrest.
62742779|NCT03878381|EXPERIMENTAL|Compounded Skin Care Cream|One side of the face will be randomly chosen as the treatment side
62742780|NCT03878381|PLACEBO_COMPARATOR|Placebo|The other side of the face will be randomly chosen as the control
62742781|NCT00992199|NO_INTERVENTION|control arm|adjuvant intravenous system chemotherapy
62742782|NCT00992199|EXPERIMENTAL|IP Chemo arm|adjuvant system intravenous chemotherapy combined with adjuvant intraperitoneal chemotherapy
62742783|NCT04884217|ACTIVE_COMPARATOR|Pro-ocular™|Pro-ocular™ Topical Gel
62742784|NCT04884217|PLACEBO_COMPARATOR|Placebo|Placebo Topical Gel
62742785|NCT02139878|EXPERIMENTAL|Wild blueberry juice|240 ml wild blueberry juice
62742786|NCT02139878|PLACEBO_COMPARATOR|Placebo wild blueberry juice|240 ml placebo wild blueberry juice
62742787|NCT06412705|EXPERIMENTAL|Tooth extraction and bone regeneration|The present arm received tooth extraction and guided bone regeneration (performed with xenograft porcine material and collagen barrier membrane). After 4 months, a dental implant was inserted.
62742788|NCT03379259|EXPERIMENTAL|Phase 1A: BGB-A333 monotherapy dose escalation|
62742789|NCT03379259|EXPERIMENTAL|Phase 2A: BGB-A333 monotherapy dose expansion|
62742790|NCT03379259|EXPERIMENTAL|Phase 1B: BGB-A333 and BGB-A317 dose confirmation|
62742791|NCT03379259|EXPERIMENTAL|Phase 2B: BGB-A333 and BGB-A317 dose expansion|
62742792|NCT00699387|EXPERIMENTAL|Benznidazole|Treatment of pediatric Chagas disease with benznidazole
62742793|NCT02137018|ACTIVE_COMPARATOR|laparotomy with PPL mesh implantation|control group: laparotomy with PPL mesh implantation (traditional method)
62742794|NCT02137018|EXPERIMENTAL|laparotomy with PPL fixation by BP|laparotomic surgery with PPL mesh fixation by BP (new fixing method)
62742795|NCT02137018|ACTIVE_COMPARATOR|laparoscopy with PPL mesh implantation|control group: laparoscopy with PPL mesh implantation (traditional method)
62742796|NCT02137018|EXPERIMENTAL|laparoscopy with PPL fixation by BP|laparoscopic surgery with PPL mesh fixation by BP (new fixing method)
62742797|NCT05998850|EXPERIMENTAL|CHW Dialysis Implementation|A single-arm 6-month pilot study testing the feasibility of tailored implementation, by using IMPaCT model with a Community Health Worker to help low-income dialysis patient to navigate the health system and community resources to eliminate or minimize health-related social needs among dialysis patients so that they adhere to the treatment, improve their health and may be candidates for transplantation.
62742798|NCT04195399|EXPERIMENTAL|Treatment (nirogacestat)|Patients receive nirogacestat PO BID on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO and CT or MRI on study. Patients may also undergo x-ray imaging and blood sample collection on study.
62742799|NCT04661371|EXPERIMENTAL|The experimental group in acute cholecystitis|"inclusion criteria~1. among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~2. cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~3. Gallbladder with surrounding organs due to gallbladder inflammation~4. Patients over 19 years of age~normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) was used before surgery."
62742800|NCT04661371|EXPERIMENTAL|The controled group in acute cholecystitis|"1. among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~2. cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~3. Gallbladder with surrounding organs due to gallbladder inflammation~4. Patients over 19 years of age~First-generation cephalosporin (Cefazolin inj., 1g, Cefazolin sodium, Chong-geun-dang pharm.co.) was used before surgery."
62742801|NCT03939962|EXPERIMENTAL|treatment group|"Neoadjuvant therapy:SHR1210 combined with FOLFOX repeat every 14 days for a total of 4 cycles.~Adjuvant therapy:SHR1210 combined with chemotherapy (the specific regimen will be chosen at the discretion of the investigator), every 14 days for a total of 4 cycles. After that, the patients will receive camrelizumab monotherapy for up to 1 year (from the first SHR1210 treatment)."
62742802|NCT05572606|EXPERIMENTAL|Hypnotherapy for bloating symptoms|Subjects experiencing bloating symptoms will receive hypnotherapy delivered electronically
62742803|NCT01773005|SHAM_COMPARATOR|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
62742804|NCT01773005|ACTIVE_COMPARATOR|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
62367892|NCT01706991||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~* VA \<20/40 and 2 logMAR lines difference in normal eye~* Mild amblyopia (\>20/40)~* Moderate amblyopia (20/40 and \<20/100)~* Severe amblyopia (≥20/100 or worse)~* Bilateral amblyopia: \>4 years age VA\<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~* Constant: \>2 PD at near and or distance.~* Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~* 'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~* 'hypermetropia' (≥3.5 D),~* 'myopia' (≥-4.0 D),~* 'astigmatism' (≥1.5 D).~* 'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
62367893|NCT01706991||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
62367894|NCT03896906|EXPERIMENTAL|Group N|pre-oxygenation with High-flow nasal cannula
62367895|NCT03896906|ACTIVE_COMPARATOR|Group M|pre-oxygenation with simple mask
62367896|NCT02767206||portal hypertension|Patients with cirrhosis or non-cirrhotic portal hypertension.
62367897|NCT03111589|EXPERIMENTAL|SCD patients under regular chronic exchange transfusion|Sickle cell disease patients (SCD) under regular chronic exchange transfusions. Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
62367898|NCT03111589|EXPERIMENTAL|SCD patients under HU treatment alone|Sickle cell disease patients (SCD) under hydroxyurea (HU) alone. Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
62367899|NCT03111589|EXPERIMENTAL|SCD patients under HU treatment+sporadic transfusion|Sickle cell disease patients (SCD) under hydroxyurea (HU) and receiving sporadic transfusions.Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
62367900|NCT03111589|ACTIVE_COMPARATOR|Control group|Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
62367901|NCT04556201|EXPERIMENTAL|Thulium Fiber Laser lithotripsy|Subjects who have a medical indication for ureteroscopy, percutaneous nephrolithotomy (PCNL) or mini PCNL
62367902|NCT05783492|EXPERIMENTAL|Intranasal ketamine|Intranasal ketamine 10 mg/kg
62367903|NCT01000519|ACTIVE_COMPARATOR|Aerobic Training|50 minutes of aerobic training, 18 sessions within 2 months period
62742805|NCT00295009|ACTIVE_COMPARATOR|1-Level Fusion|Spinal fusion at a single lumbar level.
62367904|NCT01000519|EXPERIMENTAL|Progressive Resistance Training|50 minutes of progressive resistance training consisting of nine resistance exercises, each conducted 3 sets of 10 repetitions. 18 sessions over 2 months period.
62367905|NCT06087094|EXPERIMENTAL|Cohor 1: HRS-7450 dose 1 or Placebo;|
62367906|NCT06087094|EXPERIMENTAL|Cohor 1: HRS-7450 dose 2 or Placebo;|
62367907|NCT06087094|EXPERIMENTAL|Cohor 1: HRS-7450 dose 3 or Placebo;|
62367908|NCT06087094|EXPERIMENTAL|Cohor 1: HRS-7450 dose 4 or Placebo;|
62367909|NCT06087094|EXPERIMENTAL|Cohor 1: HRS-7450 dose 5 or Placebo;|
62367910|NCT04459104|EXPERIMENTAL|chronic low back patients|Participants will be given two beverages, (isomaltulose or sucrose) in a random order (one of each on each of the two test dates).
62367911|NCT04459104|EXPERIMENTAL|breast cancer survivors having chronic pain|Participants will be given two beverages, (isomaltulose or sucrose) in a random order (one of each on each of the two test dates).
62367912|NCT04459104|ACTIVE_COMPARATOR|healthy pain-free controls|Participants will be given two beverages, (isomaltulose or sucrose) in a random order (one of each on each of the two test dates).
62367913|NCT04679714|EXPERIMENTAL|Single-arm study of PLAR Implant and Delivery System|All enrolled patients will receive the study device
62367914|NCT04907812|EXPERIMENTAL|Tranexamic Acid (TXA)|Patients in the TXA arm will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before their surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after the first dose on the day of their surgery
62367915|NCT04907812|PLACEBO_COMPARATOR|Standard of Care (SOC)|Patients in the (SOC) arm will receive 50cc of IV Placebo (standard intravenous normal saline fluid - 0.9% sodium chloride) before their surgery and 50cc of IV Placebo (standard intravenous normal saline fluid - 0.9% sodium chloride) 3-6 hours after the first dose on the day of their surgery
62367916|NCT04693806|EXPERIMENTAL|Continuous CO2 Level|embryos will remain in a single incubator set at a continuousCO2 level
62367917|NCT04693806|NO_INTERVENTION|Sequential CO2 Level|Current standard of care
62367918|NCT03868670|EXPERIMENTAL|Responsive Neurostimulation|Surgical arm. Patients expected to receive treatment.
62367919|NCT04922710|EXPERIMENTAL|Home-based aerobic exercise|Un-supervised exercise will be held 3 times a week for 60 minutes in the participant's home. Those who are unable to do a 60-minute session would instead complete it in two 30-minute sessions to reach the goal of exercising 150 minutes per week.
62367920|NCT02429349|EXPERIMENTAL|Diagnostic Procedure|Surgery - Unilateral surgical removal of ovary, freezing of tissue, post cancer cure autotransplant
62367921|NCT02318069|ACTIVE_COMPARATOR|TBE vaccine at 0+30 days|This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later
62367922|NCT02318069|ACTIVE_COMPARATOR|TBE vaccine at 0+7+21 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later
62742806|NCT00295009|EXPERIMENTAL|1-Level ProDisc|Total disc replacement with the ProDisc device at one spinal lumbar level.
62367923|NCT02318069|ACTIVE_COMPARATOR|TBE vaccine at 0+30+90 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later
62742807|NCT00295009|ACTIVE_COMPARATOR|2-Level Fusion|Spinal fusion at two adjacent lumbar levels.
62742808|NCT00295009|EXPERIMENTAL|2-Level ProDisc|Total disc replacement with the ProDisc device at two adjacent lumbar levels.
62742809|NCT00295009|EXPERIMENTAL|1-level ProDisc (non-randomized)|Total disc replacement with the ProDisc device for non-randomized subjects at one spinal lumbar level.
62367924|NCT02318069|ACTIVE_COMPARATOR|younger participants|This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later
62367925|NCT02318069|ACTIVE_COMPARATOR|double dose of vaccine|This group of 50 participants will be given two doses of TBE vaccine 0.5 ml FSME immune at the first day of the study and an additional dose at day 30 as well as one year later
62742810|NCT00295009|ACTIVE_COMPARATOR|2-Level ProDisc (Continued Access)|Total disc replacement with the ProDisc device for non-randomized subjects at two spinal lumbar levels (only followed out to 24 months)
62367926|NCT05735236|NO_INTERVENTION|Control|Participants undergo standard post-operative physical therapy as prescribed by their surgeon.
62367927|NCT05735236|ACTIVE_COMPARATOR|BFR Cuff|Patients undergo standard post-operative physical therapy as prescribed by their surgeon with the addition of a Blood Flow Restriction (BFR) cuff that is used during their exercises.
62367928|NCT05483283|OTHER|Arm 1|Empowerment and Navigation
62367929|NCT05483283|OTHER|Arm 2|Standard of Care (SOC)
62367930|NCT04682106|EXPERIMENTAL|LY3493269|Multiple doses of LY3493269 administered orally.
62367931|NCT04682106|PLACEBO_COMPARATOR|Placebo|Placebo administered orally.
62367932|NCT05795400|EXPERIMENTAL|Dapagliflozine group|20 patients diagnosed with heart failure and amyloid cardiomyopathy, regardless of HF phenotype, are planned to be enrolled in the study. Patients with the edematous syndrome are allowed to participate in the study, but the condition of stable hemodynamics must be observed. Regardless of the group, patients will receive standard therapy for ADHF (diuretics and MRA). Patients will not receive beta-blockers/ACE-I/ARNI. In the treatment group the therapy will include the SGLT-2 inhibitor dapagliflozin, which will be prescribed during the first 24 hours after the hospitalization.
62367933|NCT05795400|PLACEBO_COMPARATOR|Control group|In the control group, patients will be treated with standard diuretic therapy without SGLT-2 inhibitors.
62367934|NCT01300767|EXPERIMENTAL|Lotrafilcon B|Lotrafilcon B commercially marketed contact lens randomly assigned to one eye, with balafilcon A commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW) modality.
62367935|NCT01300767|ACTIVE_COMPARATOR|Balafilcon A|Balafilcon A commercially marketed contact lens randomly assigned to one eye, with lotrafilcon B commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW) modality.
62367936|NCT02394262|EXPERIMENTAL|Serial CCTA and atherothrombosis markers|Sequential coronary CT-angiography and assesment of biomarkers involved in atherothrombosis after 1 year follow-up.
62367937|NCT00054756|EXPERIMENTAL|Thyrotropin Releasing Hormone|Subjects receiving TRH (Thyrotropin Releasing Hormone)
62367938|NCT05157776|ACTIVE_COMPARATOR|Control group|Neoadjuvant therapy of Sintilimab and chemotherapy in 2 cycles before surgery and optional adjuvant therapy of Sintilimab and chemotherapy in 2 cycles after surgery
62367939|NCT05157776|EXPERIMENTAL|Experimental group|Neoadjuvant therapy of Sintilimab and chemotherapy in 4 cycles before surgery
62367940|NCT02885272|EXPERIMENTAL|Diagnostic (PET/CT)|Patients receive fluorodeoxyglucose F-18 IV over 1 minute and then undergo PET/CT scans over 30 minutes at 1 hour, 4-5 hours, and 7-8 hours after injection. Patients also undergo a standard of care MRI scan over 45 minutes if not already completed as part of standard of care.
62367941|NCT02708966|EXPERIMENTAL|Gymnema Sylvestre|Patients with IGT
62367942|NCT02708966|PLACEBO_COMPARATOR|Placebo|Patients with IGT
62367943|NCT05337345|EXPERIMENTAL|Part 1|
62552809|NCT05228678||Control group|"Patients with prior diagnosis of COVID-19, fully recovered, without persistent dyspnea every patient in this group will undergo Cardiopulmonary exercise test (CPET) protocol: -~1. As regard CPET protocol we prepared incremental treadmill exercise protocol in which the work rate increased at one-minute intervals.~2. The following parameters observed:~   1. Metabolic response~      * Oxygen consumption VO2 (ml/ min):~     * P ETO2: Is the end-tidal O2 tension as measured from the exhaled air.~     * P ETCO2: Is the end-tidal CO2 tension as measured from the exhaled air. Normally decreased during exercise.~     * Anaerobic Threshold (AT): Is defined as the VO2 (in L/min) at which there is substantial transition to anaerobic metabolism to produce extra energy~  2. Ventilatory response~      * Minute ventilation :~     * Breathing reserve(BR): Breathing reserve = measured/predicted minute ventilation maximum~     * Tidal volume (VT):~     * Respiratory frequency (RF)"
62367944|NCT05337345|EXPERIMENTAL|Part 2|
62552810|NCT00309855|PLACEBO_COMPARATOR|Double Placebo|(i.m. vehicle 0.5 mL weekly x three injections and oral placebo once daily x 21 days)
62552811|NCT00309855|OTHER|Testosterone IM and oral placebo|IM injections weekly x three injections and oral placebo once daily x 21 days
62552812|NCT00309855|OTHER|Testosterone and Oral Anastrozole|IM injections weekly x 3 injections and oral daily x 21 days
62552813|NCT00309855|OTHER|Testosterone and Dutasteride|IM injections weekly x 3 injections and oral once daily x 21 days
62742811|NCT05875727|EXPERIMENTAL|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine (20vPnC)
62742812|NCT06660836|OTHER|Yo-Yo performance test|Participants will undergo the Yo-Yo performance test both while using and not using mouthguards prepared with a digital workflow.
62742813|NCT03807791|EXPERIMENTAL|Patient living in the Unit of Long Term Care|Patient living in the Unit of Long Term Care without any limit time
62742814|NCT04309890||Study group|
62742815|NCT04645654|EXPERIMENTAL|Hypnosis|3 sessions of script-based hypnosis (analgesic suggestions) + recordings provided for self-hypnosis
62742816|NCT04645654|NO_INTERVENTION|Standard of care|Standard of care ERAS based optimized multimodal analgesia, without any complementary medicine
62367945|NCT04100291|ACTIVE_COMPARATOR|FMT|Faecal microbiota transplantation
62367946|NCT04100291|PLACEBO_COMPARATOR|Placebo|Placebo mixture
62367947|NCT02049788|ACTIVE_COMPARATOR|low calorie/fat diet|The low calorie/fat diet group, obese children aged 9-16, received conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
62552814|NCT03700502||patients with painful diabetic neuropathy|
62367948|NCT02049788|EXPERIMENTAL|Low glycaemic index diet|Low glycaemic index diet group, obese children of both sexes aged 9-16, received experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
62367949|NCT04046276|PLACEBO_COMPARATOR|Conventional Physical Therapy|Three sessions a week of hospital-based conventional physical therapy, all in presence and with the guidance of a registered physical therapist, for nine months
62367950|NCT04046276|SHAM_COMPARATOR|Medium Intensity Aerobic exercise (50% VO2 max)|Three sessions a week of hospital-based Medium Intensity Aerobic exercise (50% VO2 max); on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
62367951|NCT04046276|EXPERIMENTAL|High Intensity Aerobic exercise|Three sessions a week of hospital-based High Intensity Aerobic exercise (70% VO2 max) on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
62367952|NCT05770739|OTHER|ERAS group|To apply accelerated rehabilitation surgery to children with biliary dilatation during perioperative period
62367953|NCT05770739|OTHER|placebo group|In this gruop,Children with cholangiectasia were given traditional perioperative treatment
62367954|NCT01898962|EXPERIMENTAL|Definitive locoregional treatment|All sites of active disease should be treated definitively (with one of the interventions listed below). Definitive treatment does not have to be the same for all sites of disease.
62367955|NCT06350149|EXPERIMENTAL|SSB+ HI- GI|All standardized mixed meal challenges will be similar in calories (kcal) and percent of calories from carbohydrates (45%), protein (15%), and fat (40%). Each meal will provide 1/3rd of the subject's estimated kcal needs per current CF nutrition guidelines
62367956|NCT06350149|EXPERIMENTAL|SSB + LO- GI|All standardized mixed meal challenges will be similar in calories (kcal) and percent of calories from carbohydrates (45%), protein (15%), and fat (40%). Each meal will provide 1/3rd of the subject's estimated kcal needs per current CF nutrition guidelines
62367957|NCT06350149|EXPERIMENTAL|NSSB+ HI- GI|All standardized mixed meal challenges will be similar in calories (kcal) and percent of calories from carbohydrates (45%), protein (15%), and fat (40%). Each meal will provide 1/3rd of the subject's estimated kcal needs per current CF nutrition guidelines
62367958|NCT06350149|EXPERIMENTAL|NSSB+ LO- GI|All standardized mixed meal challenges will be similar in calories (kcal) and percent of calories from carbohydrates (45%), protein (15%), and fat (40%). Each meal will provide 1/3rd of the subject's estimated kcal needs per current CF nutrition guidelines
62367959|NCT02947334|EXPERIMENTAL|Bococizumab|Bococizumab Q2wks
62367960|NCT02947334|PLACEBO_COMPARATOR|Placebo|Bococizumab placebo Q2wks
62367961|NCT04820036|OTHER|Patients with Obesity and NASH scheduled/recommended for P-ESG Procedure|We will perform a 12-month prospective, single-center, pilot observational study on patients with obesity and NASH with advanced fibrosis who are undergoing P-ESG. A total of 15 patients will undergo EUS-LB with EUS-PPG measurement in a single session prior to and at 12 months following P-ESG
62367962|NCT03387930||Low back pain group|Participants will be followed up over 2 years to monitor the course of low back pain
62367963|NCT03387930||Asymptomatic group|Participants will be followed up over 2 years to monitor the incidence and course of low back pain
62367964|NCT05843617|EXPERIMENTAL|Liposomal Vitamin C|Single oral dose of liposomal vitamin C formulation
62367965|NCT05843617|ACTIVE_COMPARATOR|Traditional Vitamin C|Single oral dose of traditional vitamin C formulation
62367966|NCT06237673|EXPERIMENTAL|CT|CT-directed clinical management strategy
62367967|NCT06237673|ACTIVE_COMPARATOR|Invasive coronary angiography (ICA)|Standard clinical management directed by conventional invasive coronary angiography (ICA).
62367968|NCT00946023|EXPERIMENTAL|Transplant|Non-myeloablative allogeneic bone marrow transplant (BMT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD (graft vs host disease) prophylaxis. Rituximab will be given as post-transplant maintenance.
62367969|NCT01249157|EXPERIMENTAL|MRI and PEM scans|All consenting patients who are to have staging breast MRI, will be offered 18FDG PEM (Positron Emission Mammography) within 30 days. If the patient had a previous breast MRI that was done within 30 days at an outside institution, this MRI can be used if a radiologist determines that it is an adequate study. The surgery date will not be affected by the additional PEM evaluation. All imaging will be done and reviewed by MSKCC breast imagers. MRI and PEM findings suggestive of malignancy will be prospectively recorded in both the ipsilateral and contralateral breast.
62367970|NCT04143425||Received bevacizumab treatment|Recurrent glioblastoma patients with received anti-angiogenic treatment
62367971|NCT02352649|EXPERIMENTAL|Neovasculgen 1|Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 0,6 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.
62367972|NCT02352649|EXPERIMENTAL|Neovasculgen 2|Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 1,2 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.
62367973|NCT02352649|PLACEBO_COMPARATOR|water for injections|Instead of the gene therapy drug, 1 ml of aqueous vehicle (water for injections) will be administered by several intraneural injections.
62742817|NCT05066152|EXPERIMENTAL|Probiotic|For 8 weeks of interventional period, the patient received 10 probiotic drops (1x1010 Cfu LGG) once daily at breakfast.
62367974|NCT02525952|EXPERIMENTAL|Hepatectomy with NDR 0-2|Surgical removal of all lesions for patients with a NDR score 0-2 according to the NDR scoring system
62367975|NCT02525952|ACTIVE_COMPARATOR|TACE with NDR 0-2|Transarterial chemoembolization for patients with a NDR score 0-2 according to the NDR scoring system
62367976|NCT02525952|EXPERIMENTAL|Hepatectomy with NDR >2|Surgical removal of all lesions for patients with a NDR score more than 2 according to the NDR scoring system
62552815|NCT03700502||diabetics with non-pain neuropathy|
62552816|NCT03700502||gender and age matched healthy controls|
62552817|NCT05709379|EXPERIMENTAL|Control trial|Sitting from 8 am until 3pm.
62367977|NCT02525952|ACTIVE_COMPARATOR|TACE with NDR >2|Transarterial chemoembolization for patients with a NDR score more than 2 according to the NDR scoring system
62367978|NCT04323891||Higher Trainee/Service Doctor|
62367979|NCT04485468||Parkinson's disease patients|Parkinson's disease patients and over 18 years old
62367980|NCT04929847|EXPERIMENTAL|Group 1|All patients will receive the experimental emollient during 3 weeks.
62367981|NCT00440141|EXPERIMENTAL|1|
62367982|NCT00440141|ACTIVE_COMPARATOR|2|
62367983|NCT05369793|ACTIVE_COMPARATOR|Alpha-lipoic acid arm|Administration of alpha-lipoic acid 600 mg orally once daily for 3 months.
62367984|NCT05369793|EXPERIMENTAL|Roflumilast arm|Administration of roflumilast 500 mcg orally once daily for 3 months.
62367985|NCT01209572|EXPERIMENTAL|calorimetric chamber|
62367986|NCT01209572|EXPERIMENTAL|Free living conditions|
62367987|NCT03099798||Non-Operative Management (NOM)/Observational|"Patients treated observationally for (traumatic) spleen injury."
62367988|NCT03099798||Splenic Artery Embolization|Patients treated with splenic artery embolization for (traumatic) spleen injury.
62367989|NCT03099798||Surgery|Patients treated surgically for (traumatic) spleen injury.
62367990|NCT05476380|EXPERIMENTAL|CCNT-ESCC|"This study is a single-arm, open-label, exploratory clinical study, the main purpose of which is to evaluate the efficacy and safety of neoadjuvant treatment of camrelizumab combined with chemotherapy for resectable locally advanced esophageal squamous cell carcinoma.~After screening, subjects who meet the requirements for entry and exclusion signed the informed consent, received neoadjuvant treatment of carrelizumab combined with combined with chemotherapy.The patient will receive three cycles of treatment of camrelizumab(200 mg, IV., d1, q3w), paclitaxel(175 mg/m2,continuous IV., d1, 24h q3w), cisplatin(75 mg/m2, iv., d1,q3w).Patients who are assessed as being able to undergo surgical resection receive elective resection surgery,and the maintenance treatment of postoperative patients implements individualized treatment."
62367991|NCT01427660|ACTIVE_COMPARATOR|Traditional CERSG Arm|CHWs will provide and review with patients language-appropriate versions of the AHRQ consumer guides. CHWs will highlight key points on each page, review information on each medication and elicit and address questions. They will use the autonomy enhancing, motivational-interviewing based skills. As with the first arm, CHWs will schedule follow-up clinic appointments for participants who note a specific treatment change they would consider and will call participants two times after the session at three and six weeks to address additional questions and to follow up on any goals the participant set.
62367992|NCT01427660|EXPERIMENTAL|Web-Based Materials Arm|Participants randomized to this arm will be scheduled within 3 weeks of enrollment to have a one-hour face-to-face session with a CHW who will deliver the ipad platform personally tailored diabetes medication decision aid. Participants will receive a printed tailored preference summary at the completion of this visit. If participants note a specific treatment change they would like to discuss with their providers, the CHW will facilitate scheduling a clinic visit within the next month. Finally, CHWs will call participants two times after the session at 3 and 6 weeks to assess if the participant has additional questions and to follow up on any treatment or other goals the participant set during their session.
62367993|NCT05560919|EXPERIMENTAL|Group 1|Six participants were bonded with 0.022 × 0.028 inch slot brackets (Ortho Smile) using pre-adjusted edgewise appliance with 0.022 MBT prescriptions. Local periodontal injection of 1,25 DHC at weekly interval (3 times). The gingival fluid volume will measured befor and after 1-1.5 hours after first injection. the same is done visit at the second and third visits. Pain during injection and treatment will be assessed using the FLACC scale and face scale
62367994|NCT05560919|EXPERIMENTAL|Group 2|Six participants were bonded with 0.022 × 0.028 inch slot brackets (Ortho Smile) using pre-adjusted edgewise appliance with 0.022 MBT prescriptions. Local periodontal injection of dimethylsulfoxide at weekly interval (3 times). The gingival fluid volume will measured befor and after 1-1.5 hours after first injection. the same is done visit at the second and third visits. Pain during injection and treatment will be assessed using the FLACC scale and face scale.
62742818|NCT05066152|PLACEBO_COMPARATOR|Placebo|For 8 weeks of interventional period, the patient received 10 probiotic drops (placebo) once daily at breakfast.
62367995|NCT05560919|EXPERIMENTAL|Group 3|Six participants were bonded with 0.022 × 0.028 inch slot brackets (Ortho Smile) using pre-adjusted edgewise appliance with 0.022 MBT prescriptions. ocal periodontal injection of serum at weekly interval (3 times). The gingival fluid volume will measured once. Pain during treatment will be assessed using the FLACC scale and face scale.
62367996|NCT01894425||Study population|"The study population consists of couples under care for infertility in the participating centers. Gamete donations are not included. Please see inclusion and exclusion criteria.~Intervention: HPV screening for women Intervention: HPV screening for men"
62367997|NCT04359121||Physicians|Questionnaires
62367998|NCT04359121||Medical staff|Questionnaires
62742819|NCT06086704|EXPERIMENTAL|Group 1: Metabolite Analysis|participants will undergo venous blood sampling during the PET/MRI scan
62552818|NCT05709379|EXPERIMENTAL|High intensity sedentary breaks|Physical activity on 80-85% of individual VO2max every hour. Modality: Hill walking/jogging on treadmill.
62552819|NCT05709379|EXPERIMENTAL|Low intensity sedentary breaks|Physical activity on 25-30% of individual VO2max every hour. Modality: Hill walking on treadmill.
62552820|NCT04458285|EXPERIMENTAL|Sacubitril/valsartan|Patients in experimental group will receive sacubitril/valsartan with the recommended starting dose: 50mg twice daily (if previous angiotensin converting enzyme inhibitor(ACEI), ensure 36-hour washout period), after 2-4 weeks, the dose will be doubled to the target maintenance dose of 100mg twice daily(if tolerated) for 12 weeks.
62742820|NCT06086704|EXPERIMENTAL|Group 2: Pre-surgical Treatment|participants will undergo PET/MRI scans before and after 2 weeks treatment with anastrozole
62742821|NCT06086704|EXPERIMENTAL|Group 3: Test-Retest|participants will undergo baseline and repeat PET/MRI scans without intervening treatment to determine repeatability
62742822|NCT03367923|EXPERIMENTAL|Arm I (exercise counseling, Fitbit, phone call)|Participants undergo an exercise counseling session at baseline and wear Fitbit tracker daily for 9 months. Participants receive a short phone call at 2, 4, 6, and 8 weeks, and at 4 and 5 months to discuss the average number of daily steps over the past 2 weeks and to encourage a goal of a 10% increase over the next 2-4 week time period.
62367999|NCT04359121||General public|Questionnaires
62368000|NCT04359121||Patients with psychiatric disorders|Questionnaires
62368001|NCT05538429|EXPERIMENTAL|ESPB&SAPB|erector spinal plane block combined with serratus anterior plane block
62368002|NCT05538429|ACTIVE_COMPARATOR|TPVB|thoracic paravertebral block
62368003|NCT04569760|EXPERIMENTAL|Cannabinoid Oil - Oral Preparation|"50mg CBD: 2mg of THC in each 1ml drop in MCT Oil, flexibly dosed at 200-800 mg per day.~Dosing will start at 2 mls twice a day for one week and be titrated to 4 mls twice/daily for one week. At the end of Week 2, dose may be titrated to 6 mls twice a day ; then at the end of Week 4, dose may be titrated to 8 mls twice daily (the maximum of 800 mg/day total dose of High CBD).~The dose will be titrated in increments of 200 mg (4 mls)/day/week if participants are tolerating their current dose, are experiencing no adverse events and have not fully responded so that they may potentially reach 800 mg/day/week by Week 4."
62368004|NCT04569760|PLACEBO_COMPARATOR|Placebo Oil - Oral Preparation|"MCT Oil~Dosing will start at 2 mls twice a day for one week and be titrated to 4 mls twice/daily for one week. At the end of Week 2, dose may be titrated to 6 mls twice a day ; then at the end of Week 4, dose may be titrated to 8 mls twice daily (a volume equivalent to the maximum of 800 mg/day total dose of High CBD).~The dose will be titrated in incremental volumes equivalent to 200 mg of active product (4 mls)/day/week if participants are tolerating their current dose, are experiencing no adverse events and have not fully responded so that they may potentially reach the volume equivalent to 800 mg/day/week by Week 4."
62368005|NCT03408886|EXPERIMENTAL|Group A|Group A receives treatment in Part 1 and Part 2
62368006|NCT03408886|OTHER|Group B|Group B receives no treatment in Part 1, but does receive treatment in Part 2
62368007|NCT06175754|ACTIVE_COMPARATOR|Laser|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the Canon SX510 HS from a distance of 50 cm.~to measure the maximum diameter of telangiectasia using the Ultrasound Mindray M7 .~to treat the reticular vein by the Nd:YAG laser with a wavelength of 1064 nm, a 7 mm spot, pulse length of 50 msec and fluency 140 J/cm2"
62368008|NCT06175754|ACTIVE_COMPARATOR|Laser with Sclerotherapy|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the Canon SX510 HS from a distance of 50 cm.~to measure the maximum diameter of telangiectasia using the Ultrasound Mindray M7 .~to treat the reticular vein by the Nd:YAG laser with a wavelength of 1064 nm, a 7 mm spot, pulse length of 15 msec and fluency 70 J/cm2 to inject the 0.3% foam polidocanol with a 5 ml luer-lock syringe through 30 G needle into reticular vein until the vessel disappears."
62368009|NCT06175754|ACTIVE_COMPARATOR|Sclerotherapy|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the Canon SX510 HS from a distance of 50 cm.~to measure the maximum diameter of telangiectasia using the Ultrasound Mindray M7 .~to inject the 0.5% foam polidocanol with a 5 ml luer-lock syringe through 30 G needle into reticular vein until the vessel disappears."
62368010|NCT02673528||Directly underwent TLA|Patients with the diagnosis who underwent directly total laparoscopic appendectomy
62368011|NCT02673528||Lap Assisted App|Patients with the diagnosis of acute appendicitis who underwent a successful laparoscopic assisted appendectomy
62368012|NCT02673528||Advanced to TLA|Patients with the diagnosis of acute appendicitis in whom laparoscopic assisted appendectomy attempted; however, because it fail advanced to total laparoscopic appendectomy.
62368013|NCT04723004|ACTIVE_COMPARATOR|Experimental group|Toripalimab combined with Bevacizumab
62368014|NCT04723004|ACTIVE_COMPARATOR|Control group|Sorafenib
62368015|NCT04044313|EXPERIMENTAL|HAIC plus Lenvatinib and Toripalimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 240mg intravenously every 3 weeks.
62368016|NCT06228443|EXPERIMENTAL|Leflunomide 20 mg Tablets (Test Drug)|Leflunomide 20 mg Tablets ,1 x 20 mg, single dose fasting.
62368017|NCT06228443|ACTIVE_COMPARATOR|ARAVA® 20 mg Tablets (Reference Drug)|ARAVA™ 20 mg Tablets,1 x 20 mg, single dose fasting.
62368018|NCT01922739|EXPERIMENTAL|Hydrocodone ER|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain. If enrolled under the original protocol, there was a double-blind titration period of four weeks to adjust the dose taken in study 3103 (NCT01789970). If enrolled under the amended protocol, there was an open-label adjustment period of three weeks to adjust the dose taken in study 3103 (NCT01789970). Both versions of protocol 3104 followed the titration/adjustment period with a open-label treatment period of 22 weeks.
62368019|NCT03935490||e-TREPP|Patients with strangulated inguinal hernia treated with e-TREPP
62368020|NCT01561040|EXPERIMENTAL|Omega 3, Vitamins A, D3 and E|Dry eye patients that have been screened with elevated osmolarity dispensed EZ Tears supplements containing Omega 3, Vitamins A, D3 and E to evaluate the change in dry eye conditions subjectively and objectively.
62368021|NCT03903276|NO_INTERVENTION|Control|assessment of pain scale and functional capacity
62742823|NCT03367923|EXPERIMENTAL|Arm II (exercise counseling, Fitbit, email/text)|Participants undergo an exercise counseling session at baseline and wear Fitbit tracker daily for 9 months. Participants receive an electronic communication (email/text) of their choice at 2, 4, 6, and 8 weeks, and at 4 and 5 months stating the average number of daily steps over the past 2 weeks and encouraging a goal of a 10% increase over the next 2-4 week time period.
62368022|NCT03903276|EXPERIMENTAL|Experimental|assessment of pain scale and functional capacity, TENS 30 minutes 3 sessions
62368023|NCT01379430|EXPERIMENTAL|Group 1|Intramuscular arm
62368024|NCT01379430|EXPERIMENTAL|Group 2|Intradermal arm
62368025|NCT04617106|ACTIVE_COMPARATOR|Conventional Palpation group|In patients undergoing elective surgery who need arterial catheter placement, radial artery cannulation will be done using the conventional palpation method.
62368026|NCT04617106|ACTIVE_COMPARATOR|DNTP group|In patients undergoing elective surgery who need arterial catheter placement, radial artery cannulation will be done using USG-guided dynamic needle tip positioning method.
62552821|NCT04458285|ACTIVE_COMPARATOR|Valsartan|Patients in active comparator group will receive Valsartan with an dose of 80 mg once daily.
62368027|NCT00069017|ACTIVE_COMPARATOR|1|MEDI-522 - 4 mg/kg of MEDI-522 (N=200)
62368028|NCT00069017|PLACEBO_COMPARATOR|2|Placebo (N=100)
62368029|NCT03205189|OTHER|Pre-operative prescription group|This group will have a pre-operative prescription delivered during the preoperative anesthesia clinic.
62368030|NCT03205189|OTHER|Postoperative prescription group|This group will receive the postoperative prescription.
62368031|NCT01802034||Native, Renal Tissue Preservation Group|Subjects who have a renal biopsy and the tissue is possessed and maintained by the RENAL AID repository.
62368032|NCT01802034||Native, Non-tissue Preservation Group|"1. Subjects who have had a renal biopsy but the tissue is not held by RENAL AID repository; and/or~2. Subjects with diabetes and renal disease who have not had a renal biopsy."
62368033|NCT01802034||Transplant Nephropathy Group|"Subjects who have had a renal transplant and require a transplant biopsy for either surveillance or for-cause indications."
62368034|NCT05553262|EXPERIMENTAL|Behavioral support|Usual clinical intervention and in addition: visual pedagogy, instruction of caregivers, a visit every two months for three years, fixed duration of the visit (one hour) regardless of patients' collaboration. General anesthesia if needed.
62368035|NCT05553262|NO_INTERVENTION|Control No behavioral support|Usual clinical treatment (dentist visit and treatments). No visual pedagogy and instruction of caregivers. Twice a year schedule (more if needed), duration of the visits according to compliance. General anesthesia if needed.
62368036|NCT02230839|EXPERIMENTAL|Exercise training protocol|
62368037|NCT02230839|EXPERIMENTAL|Energy restriction-induced weight loss|
62368038|NCT02230839|NO_INTERVENTION|Health Education|
62368039|NCT01929018|EXPERIMENTAL|Exercise, activity, and self-management|Exercise, Walking Program, and Health Self-Management Support. Participants will be visited at home once monthly and contacted by phone once weekly over 12 weeks to deliver the interventions.
62368040|NCT01929018|NO_INTERVENTION|Home and phone visit|No intervention will be applied. Participants will be visited at home once monthly and contacted by phone once weekly over 12 weeks to monitor health status.
62368041|NCT05904314|EXPERIMENTAL|Experimental Group|Investigation of the effectiveness of scenario-based standardized patient simulation training and electronic fetal monitor management of midwifery students
62368042|NCT05904314|NO_INTERVENTION|Control Group|Behavioral: Examining the effectiveness of electronic fetal monitor management of midwifery students with theory training
62368043|NCT02490839|EXPERIMENTAL|High-dose dual therapy|group A-high-dose dual therapy ( rabeprazole 20 mg, tablet, qid + amoxicillin 750 mg, capsule, qid for 14 days)
62368044|NCT02490839|ACTIVE_COMPARATOR|Bismuth-containing quadruple therapy|group B-bismuth-containing quadruple therapy (rabeprazole 20 mg, tablet, bid + tripotassium dicitrate bismuthate 300 mg, tablet, qid + metronidazole 250 mg, tablet, qid + tetracycline 500 mg qid, capsule, for 10 days)
62368045|NCT01895634|EXPERIMENTAL|Treatment|Intervention Device: Rev-01
62368046|NCT03891615|EXPERIMENTAL|Niraparib + Osimertinib|"* Niraparib will be administered orally once daily~* Osimertinib will be administered by mouth once daily"
62742824|NCT03492060||Variant in a hnRNP gene|Individuals with a variant in any hnRNP gene who present with neurodevelopmental abnormalities are eligible for the study.
62368047|NCT01751360|EXPERIMENTAL|SYR-472 100mg|SYR-472 100mg
62368048|NCT01405027|OTHER|Group A - HCEE|Group A - CLDF Hepatology Centers of Educational Expertise (HCEE) are hepatologists experienced in educating health professionals about current developments in the management of chronic liver disease and with clinical trial experience using an HCV protease inhibitor. HCEE investigators provided patient education and management skills training during four (4) educational interventions to Community Site investigators.
62368049|NCT01405027|OTHER|Group B - Community Sites|Group B - community physicians treating HCV but without clinical trial experience with an HCV protease inhibitor received patient education and management skills training from Hepatology Centers of Educational Expertise (HCEEs) during four (4) educational interventions.
62368050|NCT01853852|EXPERIMENTAL|50 mg|GR181413A/AT1001
62368051|NCT01853852|EXPERIMENTAL|150 mg|GR181413A/AT1001
62368052|NCT01853852|EXPERIMENTAL|450 mg|GR181413A/AT1001
62368053|NCT01853852|PLACEBO_COMPARATOR|Placebo|placebo
62368054|NCT01501734|EXPERIMENTAL|all patients with symptomatic CHF|"* Single arm prospective study~* Study population will include all patients referred to our outpatient clinic for congestive heart failure for a two-year period, who will be screened for sleep apnea and found to have sleep disordering breathing (SDB).~* 200 patients will visit the outpatient clinic for congestive heart failure.~* Approximately 30% will be eligible for this study."
62368055|NCT04630210|EXPERIMENTAL|A: Letrozole|Letrozole 2.5 mg/day oral until surgery
62368056|NCT04630210|EXPERIMENTAL|B: Letrozole + atezolizumab|Letrozole 2.5 mg/day oral until surgery and Atezolizumab 840 mg intravenous (IV) single-dose 14 days (+/- 4 days) before surgery
62368057|NCT04630210|EXPERIMENTAL|C: Atezolizumab|Atezolizumab 840 mg IV single-dose 14 days (+/- 4 days) before surgery
62368058|NCT04630210|NO_INTERVENTION|D: Observation|Observation until surgery
62368059|NCT01224106|PLACEBO_COMPARATOR|Placebo (Parts 1 and 2)|Participants with Alzheimer's disease received Placebo by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.
62368060|NCT01224106|EXPERIMENTAL|Gantenerumab 105 mg (Parts 1 and 2)|Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.
62368061|NCT01224106|EXPERIMENTAL|Gantenerumab 225 mg (Parts 1 and 2)|Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.
62368062|NCT01224106|PLACEBO_COMPARATOR|Placebo (Parts 1 and 2) switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])|Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.
62552822|NCT02850731|EXPERIMENTAL|plate-forme Hu360®|the innovative technology (plate-forme Hu360®) will be used in the experimental arm
62742825|NCT03492060||Variant in other gene|Individuals with a confirmed variant in other genes who present with neurodevelopmental abnormalities are eligible for the study.
62742826|NCT06046183|EXPERIMENTAL|Process Group|Medical students enrolled in the small process group, led by psychiatrist.
62368063|NCT01224106|EXPERIMENTAL|Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])|Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.
62368064|NCT03766204||ARDS patients|137 patients were enrolled consecutively over a two-year time period (2017-2018) and identified as ARDS prospectively according to the Berlin definitions of the European Society of Intensive Care Medicine and American Thoracic Society on ARDS. Exclusion criteria were an age of less than 18 years, pregnancy, chronic obstructive pulmonary disease according to medical history and failure to obtain informed consent.
62368065|NCT03766204||Healthy volunteers|Forty healthy volunteers recruited from the general population who had no significant medical history and no medications were categorized as control patients.
62368066|NCT04746313||Patients with systemic sclerosis|The study will be systematically offered to any scleroderma patient seen in scheduled hospitalization
62368067|NCT04746313||Healthy subjects|Healthy subjects who will donate blood to the French Blood Establishment (EFS) and matched to scleroderma patients on age (+/- 5 years) and sex
62368068|NCT01638481||Group #1 - Burns affecting less than 10% BSA|
62368069|NCT01638481||Group #2 - Burns affecting 10%-30% TBSA|
62368070|NCT01638481||Group #3 - Burns affecting 31%-50% TBSA|
62368071|NCT01638481||Group #4 - Burns affecting 51%-70% TBSA|
62368072|NCT01638481||Group #5 - Burns affecting >70% TBSA|
62368073|NCT00805038|PLACEBO_COMPARATOR|Control|Usual care
62368074|NCT00805038|EXPERIMENTAL|Intervention|Navigator will assist patients in completing steps in transplant process
62368075|NCT05394012|EXPERIMENTAL|RQ3013|
62368076|NCT05394012|ACTIVE_COMPARATOR|Comirnaty|
62368077|NCT03272971|EXPERIMENTAL|Radio-frequency Ablation|Single-arm study where subjects receive radio-frequency ablation prior to a scheduled, surgical resection.
62368078|NCT01029327||Healthy subjects|
62368079|NCT02390960|ACTIVE_COMPARATOR|Sildenafil|Sildenafil (SST-6006) is a preserved, white to off-white, topical cream. The active ingredient is 5% sildenafil citrate by weight. During the SST-6006 dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. The plethysmography session will be approximately 75 minutes. This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
62368080|NCT02390960|PLACEBO_COMPARATOR|Placebo|Placebo cream will be the same as SST-6006 without the active ingredient, sildenafil citrate. It will be matched in appearance, smell, consistency, and color to SST-6006 topical sildenafil cream. During the placebo cream dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. The plethysmography session will be approximately 75 minutes. This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
62368081|NCT02120469|EXPERIMENTAL|Treatment (everolimus, eribulin mesylate)|Patients receive everolimus PO QD on days 1-21 and eribulin mesylate IV on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62368082|NCT04614467|EXPERIMENTAL|GCSF-mobilized autologous CD34+ cells|
62368083|NCT04614467|PLACEBO_COMPARATOR|Placebo|
62368084|NCT02360449|NO_INTERVENTION|Wait List|
62368085|NCT02360449|EXPERIMENTAL|Social Initiation Motivation Intervention|
62368086|NCT01308372||1|For this group of patients, the cardiovascular risk will be evaluated by several tools: the SCORE scale, the Framingham 2008 scale d'Agostino and the 1998 scale Wilson ;
62368087|NCT03221660|EXPERIMENTAL|F-Composite 2 system|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the F-Composite 2 system.
62368088|NCT04882904|EXPERIMENTAL|Patient with ALS|Patient with amyotrophic lateral sclerosis
62368089|NCT04251741|ACTIVE_COMPARATOR|Usual care group|Based on a secondary randomization schedule patients are treated with etanercept or a non-TNFi (abatacept, rituximab, tocilizumab, or sarilumab)
62368090|NCT04251741|EXPERIMENTAL|'Drug concentration guided' group|Patients with a concentration \<1.0 mg/L switch to etanercept and patients with a concentration ≥ 1.0 start a non-TNFi (abatacept, rituximab, tocilizumab, or sarilumab)
62368091|NCT04314492|EXPERIMENTAL|Intracapsular tonsillectomy with coblation|(Total) Intracapsular tonsillectomy (ICTE) with coblation
62368092|NCT05838794|ACTIVE_COMPARATOR|Mckenzie exercise for neck|Participants in the McKenzie exercise for neck group will receive a six-week exercise program that includes the McKenzie exercise protocol for neck pain. The program will consist of three 30-45 minute sessions per week, for a total of 18 sessions over six weeks. The exercises will be performed under the supervision of a physiotherapist in the outpatient clinic. The McKenzie exercise protocol for neck pain involves a series of movements that aim to reduce pain and improve range of motion in the cervical spine. The exercises are tailored to each participant's individual needs and may include sustained postures, repeated movements, and mobilization techniques. Participants will be instructed to perform the exercises at home as well, as part of a home exercise program, to ensure that they are performing the exercises correctly and consistently. Participants in this group will not receive any additional stabilization exercises.
62368093|NCT05838794|EXPERIMENTAL|Mckenzie ex for neck + Stabilization exercise for|Participants in the McKenzie exercises for neck with cervical and scapulothoracic stabilization exercises group will receive a six-week exercise program that includes the McKenzie exercise protocol for neck pain and cervical and scapulothoracic stabilization exercises, performed under the supervision of a physiotherapist in the outpatient clinic. The program consists of three 30-45 minute sessions per week for a total of 18 sessions over six weeks. Participants will perform the McKenzie exercise protocol for neck pain first, followed by cervical and scapulothoracic stabilization exercises. Stabilization exercises aim to improve strength, endurance, and neuromuscular control of the cervical and scapulothoracic muscles. Participants will be instructed to perform the exercises at home as part of a home exercise program to ensure proper technique and consistency. This group receives both the McKenzie exercise protocol for neck pain and cervical and scapulothoracic stabilization exercises.
62368094|NCT02533076|OTHER|Cystinosis Patients|Cystinosis patients
62368095|NCT02533076|OTHER|Healthy volunteers|Healthy volunteers
62368096|NCT02684734||Patients on no immunosuppressant|This includes patients on no medication or mesalamine.
62368097|NCT02684734||Patients on immunosuppressants|This includes patients on biologics, azathioprine (AZA), 6-mercaptopurine (6-MP), or corticosteroid. These patients will be sub-analyzed to: a) Patients on one immunosuppressive therapy with AZA, 6-MP, biologic or corticosteroid; b) Patients on combination therapy with AZA or 6-MP and biologic; c) Patients on triple therapy with corticosteroid, AZA or 6-MP, and biologic; d) Patients on corticosteroid and one other immunosuppressive therapy such as AZA, 6-MP, or biologic.
62368098|NCT00856817|EXPERIMENTAL|1|L-arginine treatment first, heme arginate treatment second
62368099|NCT00856817|EXPERIMENTAL|2|Heme arginate treatment first, L-arginine treatment second
62368100|NCT04969185||Group 1: Children eligible to receive SMC diagnosed with uncomplicated Plasmodium falciparum malaria|Children eligible to receive SMC (6-59 months of age) who were diagnosed with uncomplicated P. falciparum malaria at the health facility.
62368101|NCT04969185||Group 2: Children eligible to receive SMC presenting at health facility without malaria parasitemia|Group 2 will be defined as children eligible to receive SMC (6-59 months of age) who presented at the health facility and tested negative for malaria parasitemia.This group will serve as the control group to Group 1 Cases to compare the SP-AQ drug levels between children who did and did not get malaria.
62368102|NCT04969185||Group 3: Children 5-10 years of age diagnosed with uncomplicated Plasmodium falciparum malaria|Group 3 will be defined as children ineligible to receive SMC (5-10 years of age) who were diagnosed with uncomplicated P. falciparum malaria at the health facility. This group will serve as the control group to Group 1 Cases to compare the prevalence of SP and AQ resistance markers.
62368103|NCT01503892|PLACEBO_COMPARATOR|Placebo|The control group will receive placebo pill twice daily for twelve months.
62368104|NCT01503892|ACTIVE_COMPARATOR|Metanx|Metanx group will receive one pill twice daily for twelve months.
62368105|NCT03256136|EXPERIMENTAL|Nivolumab Plus Ipilimumab EGFR|Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
62368106|NCT03256136|EXPERIMENTAL|Nivolumab Plus Ipilimumab ALK|Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
62368107|NCT03256136|EXPERIMENTAL|Nivolumab + Carboplatin + Pemetrexed with EGFR Chemo naive|Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
62368108|NCT03256136|EXPERIMENTAL|Nivolumab + Carboplatin + Pemetrexed ALK Chemo naive|Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
62368109|NCT01556789|EXPERIMENTAL|ONT-10 Vaccine|ONT-10 investigational agent
62368110|NCT01894555|EXPERIMENTAL|Aspirin|Participants treated with aspirin - there is no control group. Participant's baseline will act as their control.
62368111|NCT02282930|EXPERIMENTAL|ACTH Gel|Injected does of 80 units subcutaneously twice weekly for 6 months.
62368112|NCT04898868|EXPERIMENTAL|vaginal delivery with cord blood spontaneous drainage|In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recorded.
62368113|NCT04898868|EXPERIMENTAL|vaginal delivery with cord milking|In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The newborns will be taken care by the nurse. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
62368114|NCT04898868|EXPERIMENTAL|CS with cord blood spontaneous drainage|In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recorded.
62368115|NCT04898868|EXPERIMENTAL|CS with cord milking|In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The newborns will be taken care by the nurse. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
62742827|NCT06046183|NO_INTERVENTION|Control Group|Medical students from the same cohorts, not enrolled in the small process group.
62742828|NCT03576196|EXPERIMENTAL|Pain Neuroscience Education|"Single session of pain neuroscience education a week prior to surgery, of an individual character, lasting approximately 30 minutes, performed by a physiotherapist trained. The main contents addressed in the educational session were: neurophysiological aspects of pain, biopsychosocial aspects of pain, concept of peripheral and central sensitization, using audio-visual support, examples and metaphors for a better understanding by the patient, as reported in previous studies.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
62368116|NCT02505802|EXPERIMENTAL|BoNT-A treatment group|In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu). Both groups received comprehensive rehabilitation for 8 weeks.
62742829|NCT03576196|OTHER|Usual Care|"Patients in the control group received usual care, which consists of an educational session prior to surgery, based on medical, anatomical and pathological aspects of the syndrome.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
62742830|NCT03303170|EXPERIMENTAL|Sebacia Microparticles|
62742831|NCT03303170|ACTIVE_COMPARATOR|Nd:Yag Laser|
62368117|NCT02505802|NO_INTERVENTION|Control group|No special treatment was performed in the control group. Both groups received comprehensive rehabilitation for 8 weeks.
62552823|NCT02850731|NO_INTERVENTION|supervision by a therapist|an adapted physical activity program under supervision of a therapist
62368118|NCT04720313|EXPERIMENTAL|CART BCMA|The dose escalation phase (Part A) will include the following doses of CAR-positive (CAR+) T cells: 150×10\^6, 450×10\^6, 800×10\^6 or 1200 ×10\^6 The expansion phase (Part B) will include a dose between 450×10\^6 to 800×10\^6 CAR-positive (CAR+) T cells
62368119|NCT05469100|EXPERIMENTAL|Cohort 1: Selpercatinib (Healthy participants)|Single oral dose of Selpercatinib administered in a fasted state to participants with normal renal function.
62368120|NCT05469100|EXPERIMENTAL|Cohort 2: Selpercatinib (Participants with mild renal impairment)|Single oral dose of Selpercatinib administered in a fasted state to participants with mild renal impairment.
62368121|NCT05469100|EXPERIMENTAL|Cohort 3: Selpercatinib (Participants with moderate renal impairment)|Single oral dose of Selpercatinib administered in a fasted state to participants with moderate renal impairment.
62368122|NCT05469100|EXPERIMENTAL|Cohort 4: Selpercatinib (Participants with severe renal impairment)|Single oral dose of Selpercatinib administered in a fasted state to participants with severe renal impairment and not on dialysis.
62368123|NCT05788029|EXPERIMENTAL|laparoscopic pancreaticoduodenectomy|laparoscopic pancreaticoduodenectomy
62368124|NCT05788029|ACTIVE_COMPARATOR|open pancreaticoduodenectomy|open pancreaticoduodenectomy
62368125|NCT04085692|EXPERIMENTAL|Intervention|"The intervention group begins LDHF dispatcher training with one introduction week followed by twelve weeks of LDHF training.~During the study period, all regular quality improvement (QI) activities, such as self-audits, case reviews, mentor groups, and status meetings will continue for all EMDs."
62368126|NCT04085692|NO_INTERVENTION|Comparison|During the study period, all regular quality improvement (QI) activities, such as self-audits, case reviews, mentor groups, and status meetings will continue for all EMDs.
62368127|NCT04971993||Heart Failure NYHA Class II|Participants are diagnosed with NYHA Class II heart failure.
62368128|NCT04971993||Heart Failure NYHA Class III|Participants are diagnosed with NYHA Class III heart failure.
62368129|NCT04971993||At risk for arrythmias|Participants are indicated for an insertable cardiac monitor with no history of heart failure.
62368130|NCT02094729|EXPERIMENTAL|BAN2401 2.5 mg/kg|Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401
62368131|NCT02094729|EXPERIMENTAL|BAN2401 5 mg/kg|Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401
62368132|NCT02094729|EXPERIMENTAL|BAN2401 10 mg/kg|Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401
62368133|NCT02094729|PLACEBO_COMPARATOR|Placebo|Intravenous infusions of placebo for 60 +/- 10 minutes.
62368134|NCT01283178|EXPERIMENTAL|Arm I|Patients undergo intensity-modulated image-guided adaptive radiotherapy once daily 5 days a week for 6 weeks. Patients also receive cisplatin IV on days 1 and 22. Treatment continues in the absence of disease progression or unacceptable toxicity.
62368135|NCT01452191|ACTIVE_COMPARATOR|Injury Prevention Briefing and facilitation|Children's Centres will be given an Injury Prevention Briefing which offers guidance on best evidence on reducing fire related injuries in the home, and facilitation by the research team to support implementation of the IPB
62368136|NCT01452191|ACTIVE_COMPARATOR|Injury Prevention Briefing only|Children's Centres will be given an Injury Prevention Briefing (IPB) , which offers guidance on best evidence on reducing fire related injuries in the home.
62368137|NCT01452191|NO_INTERVENTION|Usual Care|
62368138|NCT01313468|EXPERIMENTAL|4 x 4 Interval|4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
62368139|NCT01313468|EXPERIMENTAL|1 4 minutes interval|1 x 4 minutes intervals at 90-95% of HR max
62368140|NCT01313468|EXPERIMENTAL|Moderate continuous Training|47 minutes of Moderate continuous Training
62368141|NCT01086449|EXPERIMENTAL|Group A|
62368142|NCT00132522|EXPERIMENTAL|Arm 1|
62368143|NCT01791465|EXPERIMENTAL|Bydureon treatment|Treatment for 16 weeks with extended-release Exenatide (Bydureon)
62368144|NCT06438744|EXPERIMENTAL|Experimental|TEA combined with standard therapy
62368145|NCT00439894||blood draw|One time blood draw
62368146|NCT01141699||female|Women who live in the Shuang Ho Region of Taipei City. Women can read and write chinese language.
62368147|NCT00948428|ACTIVE_COMPARATOR|Generic Imiquimod|imiquimod cream, 5%
62368148|NCT00948428|ACTIVE_COMPARATOR|Aldara™|Aldara™ (imiquimod) cream, 5%
62368149|NCT00948428|PLACEBO_COMPARATOR|Vehicle cream|Vehicle cream (Actavis)
62368150|NCT00552344|EXPERIMENTAL|Certolizumab Pegol|Certolizumab Pegol 200 mg/vial; 400 mg subcutaneously at Week 0, 2 and 4, thereafter 400 mg subcutaneously at every 4 weeks.
62368151|NCT01861613|EXPERIMENTAL|HBV vaccine|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)
62368152|NCT04587895|EXPERIMENTAL|MI Intervention|The VITAAL exergame intervention for MI includes 36 training sessions with three sessions per week, each lasting around 45 minutes (30 minutes real training time) resulting in 12 weeks of training (two weeks of break/holiday allowed). A training session includes an individually calculated amount of strength, cognitive-motor and balance training, which remains the same over the 12 week intervention period.
62368153|NCT04587895|ACTIVE_COMPARATOR|MI Control|"Participants of the MI control group are instructed to do a non-individualized conventional training including 15 minutes walking exercise (in nature or on treadmill) and additional 15 minutes of strength, balance, and cognitive-motor exercises (at the therapy centre or at home). The exercises are based on recommendations from the Beratungsstelle für Unfallverhütung (bfu). The participants will receive a training booklet with the exercises. In total there are three different training programs which are divided according to their level of difficulty. Participants are instructed to start with the first level for four weeks and then go on to the next level for another 4 weeks. The control group training in this study includes 36 training session with three sessions per week, each lasting around 45 minutes resulting in 12 weeks of training (two weeks of break/holiday allowed)."
62552824|NCT04574570|OTHER|interventional patient|Personalised High Tibial Osteotomy (HTO) using a patient-specific fixation plate (TOKA®)
62552825|NCT02255799|ACTIVE_COMPARATOR|Donepezil|Donepezil 5 mg capsules daily for 14 days. Donepezil 10 mg capsules daily for 56 days.
62368154|NCT04587895|EXPERIMENTAL|UI Intervention|For the incontinent women in this study, the VITAAL exergame intervention will last over 12 weeks and consists of three parts 1) VITAAL exergame (2 sessions/week) lasting 45 minutes each (30 minutes real training time) at the physio centre, 2) PFM exercises according to a training booklet (3 sessions/week) lasting 10 minutes each at home and 3) education related to UI at home.
62368155|NCT04587895|ACTIVE_COMPARATOR|UI Control|The control group training will last over 12 weeks. The training sessions will be divided in three parts 1) 30 minutes of brisk walking (2 sessions/week, 2) PFM exercises according to a training booklet (3 sessions/week) lasting 10 minutes each at home and 3) education related to UI at home. The PFM training booklet will be based on two studies that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises. The PFMT program will consist of 4 PFM exercises and will be divided into three phases allowing for the gradual progression in treatment (from first to third month), with gradual increase in difficult exercises in terms of duration, repetition and position. Each phase will last four weeks.
62368156|NCT05194605||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
62368157|NCT05194605||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is an external validation cohort.
62368158|NCT02755012||Longitudinal|155 women enrolled in 2nd or 3rd trimester of pregnancy, and seen again, with their infant, at 0-6 wk postpartum, and 4-6 mo postpartum
62368159|NCT02755012||Early Postpartum|60 women enrolled at 0-6 wk postpartum and seen once with their infant (cross-sectional)
62368160|NCT02755012||Later Postpartum|56 women enrolled at 0-6 wk postpartum and seen once with their infant (cross-sectional)
62368161|NCT00241449|ACTIVE_COMPARATOR|1|Tamoxifen
62368162|NCT00241449|EXPERIMENTAL|2|Fulvestrant
62368163|NCT01997138|EXPERIMENTAL|Anakinra|Anakinra 100 mg in 2 ml saline IA
62368164|NCT01997138|PLACEBO_COMPARATOR|Placebo|Saline 2 ml IA
62368165|NCT01201967|EXPERIMENTAL|Collaborative care|Study care manager provides education and coordinates treatment between study psychiatrist, patient, and primary medical physician. This occurs in the hospital and by phone after discharge. Care manager may also provide phone-based therapy.
62368166|NCT01201967|PLACEBO_COMPARATOR|Usual care|Patient's physicians are informed of diagnosis of depression/anxiety disorder
62368167|NCT02547519|EXPERIMENTAL|oral insulin capsule (dose escalation using 3 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 22.5 mg rH-insulin crystals; dose 3 is 67.5 mg rH-insulin crystals. The insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) and contained in hard gelatine capsules. The study treatment will be given orally.
62368168|NCT02547519|PLACEBO_COMPARATOR|Placebo capsule|Daily treatment with placebo capsules containing filling substance (microcrystalline cellulose).
62368169|NCT01844570||Levamlodipine Maleate (Xuanning)|Primary hypertensive patients who take Levamlodipine Maleate (Xuanning) as the only anti-hypertensive medication or one of their medications
62368170|NCT01844570||Amlodipine Besylate (Norvasc)|Primary hypertensive patients who take Amlodipine Besylate (Norvasc) as the only anti-hypertensive medication or one of their medications
62368171|NCT01525745|ACTIVE_COMPARATOR|Radiosurgery/SBRT|Radiosurgery/SBRT
62368172|NCT01525745|ACTIVE_COMPARATOR|External Beam Radiation Therapy|External Beam Radiation Therapy
62368173|NCT04348188|EXPERIMENTAL|Supervised exercise group|Supervised intervention group: 3 weekly sessions of 1 hour during 6 weeks of therapeutic exercise in which aerobic physical activity will be combined with exercise strength of different muscle groups plus stretches on a supervised basis and strengthening of self-care.
62368174|NCT04348188|ACTIVE_COMPARATOR|Not supervised exercise group|Unsupervised intervention group: The same therapeutic exercise protocol will be scheduled which will be carried out autonomously without supervision with telephone tracking.
62368175|NCT00310063|EXPERIMENTAL|Arm I|Sea Band elastic acupressure wristband
62368176|NCT00310063|SHAM_COMPARATOR|Arm II|Sham wristband
62368177|NCT02868099|PLACEBO_COMPARATOR|Placebo|Subjects received placebo for injection treatment will be administered subcutaneously once a week
62368178|NCT02868099|EXPERIMENTAL|Drug|Subjects received Romiplostim for injection treatment will be administered subcutaneously once a week
62368179|NCT03555968|PLACEBO_COMPARATOR|THC 0 + BAC 0|Participants will receive 0mg of THC in combination with blood alcohol concentrations of .000%.
62368180|NCT03555968|EXPERIMENTAL|THC 5 + BAC 0|Participants will receive 5mg of THC in combination with blood alcohol concentrations of .000%.
62368181|NCT03555968|EXPERIMENTAL|THC 10 + BAC 0|Participants will receive 10mg of THC in combination with blood alcohol concentrations of .000%.
62368182|NCT03555968|EXPERIMENTAL|THC 5 + BAC .025|Participants will receive 5mg of THC in combination with blood alcohol concentrations of .025%.
62368183|NCT03555968|EXPERIMENTAL|THC 10 + BAC .025|Participants will receive 125 µg/kg of THC in combination with blood alcohol concentrations of .025%.
62368184|NCT03555968|EXPERIMENTAL|THC 0 + BAC .049|Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .049%.
62368185|NCT03555968|EXPERIMENTAL|THC 5 + BAC .049|Participants will receive 5mg of THC in combination with blood alcohol concentrations of .049%.
62368186|NCT03555968|EXPERIMENTAL|THC 10 + BAC .049|Participants will receive 10mg of THC in combination with blood alcohol concentrations of .049%.
62368187|NCT03555968|EXPERIMENTAL|THC 0 + BAC .025|Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .025%.
62368188|NCT02001506|ACTIVE_COMPARATOR|FEC3-D3|"3 cycles of FEC followed by 3 cycles of Docetaxel~Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
62368189|NCT02001506|NO_INTERVENTION|AC4-D4|"4 cycles of Adriamycin plus Cyclophosphamide (AC) followed by 4 cycles of Docetaxel~Adriamycin 60 mg/m2, every 3 weeks Cyclophosphamide 600 mg/m2, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
62552826|NCT02255799|PLACEBO_COMPARATOR|Placebo|Placebo capsules once daily for 70 days.
62742832|NCT00585442|EXPERIMENTAL|Calcitriol|
62368190|NCT01637090|EXPERIMENTAL|all patients on study|"This will be a prospective, phase II non-randomized, open label study of single agent everolimus for the treatment of CTCL recurrent or refractory to at least one previous treatment other than topical medication. The purpose will be evaluation of safety and anti-tumor response as evaluated by serial skin examinations and assessment of tumor burden in tissue and blood.~This study will be conducted in 2 stages. During stage 1 we will enroll a maximum of 11 subjects to evaluate response rate and will only continue to stage 2, if we observe two or more responses. During stage 2, we will expand the study to an overall N of 28 patients."
62368191|NCT05448508|EXPERIMENTAL|Automatic Lancet|Manual lancet, needle tips and automatic lancets are used in the heel blood collection process. It has been reported that there may be complications arising from health professionals in the use of manual lancet or needle tip. In this study, an automatic lancet penetrating 2.4 mm-3 mm depth was used for safe puncture in term newborns.
62368192|NCT05448508|NO_INTERVENTION|Control|No intervention, routine maintenance performed
62368193|NCT01442519|ACTIVE_COMPARATOR|Intravesical BCG alone|
62368194|NCT01442519|EXPERIMENTAL|Intravesical sequential BCG and EMDA MMC|
62368195|NCT00618865|EXPERIMENTAL|1|omega-3 fatty acid with 2.2 g of eicosapentanoic acid (EPA) and 1.2 g of docosahexanoic acid (DHA)
62368196|NCT00618865|PLACEBO_COMPARATOR|2|Placebo (olive oil ethyl esters)
62368197|NCT05620173|EXPERIMENTAL|Vedea Amblyopia Therapy (VAT) then Vedea Amblyopia Therapy|"Children in this intervention arm will use the VAT for 16 weeks.~After the initial 16 weeks of treatment these children will be allowed to use the VAT for another 16 weeks."
62368198|NCT05620173|ACTIVE_COMPARATOR|Occlusion therapy then Vedea Amblyopia Therapy (VAT)|"Children in this intervention arm will adhere to a 'care as usual' regimen consisting of occlusion therapy as prescribed by their health care provider. They will do so for 16 weeks.~After the initial 16 weeks of treatment these children will crossover into the experimental arm to examine if they are still responsive to the VAT after already completing 16 weeks of traditional treatment."
62742833|NCT00585442|PLACEBO_COMPARATOR|Placebo|
62742834|NCT06659029||Exposed cohort|Pregnant individuals with a diagnosis of SLE who are exposed to anifrolumab at any time during pregnancy
62742835|NCT06659029||Unexposed cohort|Pregnant individuals with a diagnosis of moderate/severe SLE who are not exposed to anifrolumab at any time during pregnancy but who are exposed to other products for the treatment of SLE
62742836|NCT04645316|ACTIVE_COMPARATOR|Sevoflurane|Sevoflurane will use for anesthesia maintenance for liver donor hepatectomy surgery
62742837|NCT04645316|ACTIVE_COMPARATOR|Desflurane|Desflurane will use for anesthesia maintenance for liver donor hepatectomy surgery
62368199|NCT04691557|EXPERIMENTAL|Intervention Group|The intervention group receives the YoungAsthma developing for the smartphone or tablet additionally usual nursing care.
62368200|NCT04691557|ACTIVE_COMPARATOR|Control Group|The control group receives the usual nursing care.
62368201|NCT00724646||1|Habilitation assistants
62368202|NCT00724646||2|Parents/ legal guardians
62368203|NCT05391620|EXPERIMENTAL|CAD group|Coronary artery diseases
62368204|NCT05391620|EXPERIMENTAL|HFrEF group|Heart Failure with reduced Ejection Fraction
62368205|NCT05728749||Asthma patients|Trimbow pMDI prescribed for maintenance treatment of adult asthma as per the licensed indication.
62368206|NCT06063525||childhood onset schizophrenia (COS)|diagnosis of schizophrenia under the age of 13 years.
62368207|NCT06063525||schizophrenia (SZ)|patients with schizophrenia with and age of onset later than 13 years
62368208|NCT06063525||autism spectrum disorder (ASD)|dual diagnosis of schizophrenia and ASD, including SZ with ASD, COS with ASD
62368209|NCT03405974|EXPERIMENTAL|Aspirin|"Aspirin 100 mg~1 tablet/ day for 2 years"
62368210|NCT03405974|PLACEBO_COMPARATOR|Placebo|"Placebo~1 tablet/ day for 2 years"
62368211|NCT05254587||Retrospective|
62368212|NCT05254587||Prospective|
62368213|NCT01636453|EXPERIMENTAL|Liberty Stent arm|Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
62391497|NCT03812614|ACTIVE_COMPARATOR|I-DSMES|"This arm will focus on the patient only. The Support Person assigned to this arm will not be invited to the introduction sessions, care management contacts, or diabetes self-management education sessions. Patients assigned to this arm will:~1. Take part in a one-hour introductory session and review of patient's diabetes management risk assessment.~2. Be invited to 4-6 group diabetes self-management education (DSME) sessions lasting 45 min to 2 hours each.~3. Receive case management contacts with a Community Health Worker (CHW) once every 2-4 weeks, subject to participant availability. Successful contacts will last approximately 20 minutes."
62552827|NCT05664269|EXPERIMENTAL|Canola protein|20g of canola protein
62742838|NCT04645316|PLACEBO_COMPARATOR|Total intravenous anesthesia|Total intravenous anesthesia (propofol/remifentanyl) will use for anesthesia maintenance for liver donor hepatectomy surgery
62742839|NCT04062214|EXPERIMENTAL|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM) was developed to promote engagement in multi-modal non-pharmacological pain management among compensation-seeking Veterans with chronic pain. In SBIRT-PM, a clinician meets with the Veteran after the compensation examination to address the presenting MSD complaint. The clinician addresses Veterans' motivation for multi-modal pain care, and explains how pain can be managed using a variety of non-pharmacological pain management services. The clinician spells out how those services can be accessed at VA. Using permissive language about how pain is commonly self-medicated with substances, the clinician transitions to inquiries about use of prescription and non-prescription substances. The clinician then attempts to motivate Veterans to change their behavior if they are misusing substances. Thus, SBIRT-PM addresses the Veteran's presenting pain complaint first and nascent substance use subsequently.
62742840|NCT04062214|NO_INTERVENTION|Usual Care|A Veteran who completes a Compensation examination ordinarily has no further treatment, referral or debriefing as part of the Compensation examination. Veterans will be advised that they should continue to pursue whatever counseling they need outside the study.
62742841|NCT06537310|EXPERIMENTAL|Part I: RO7567132 Dose Escalation With or Without Atezolizumab|
62742842|NCT06537310|EXPERIMENTAL|Part II: RO7567132 Backfill With Atezolizumab|
62368214|NCT02293590|EXPERIMENTAL|intensive, adapted treatment strategy|"Experimental: intensive, adapted treatment strategy Certolizumab pegol (CZP, Cimzia (R)): 200mg every 2 weeks after loading d 400mg at Weeks 0, 2 and 4~DMARD:~Patients without sufficient treatment response will be taken to the next step according to the therapeutic algorithm or next drug, for example: 15=\>25mg Metoject (R)/week =\> Leflunomide Gebro (R)20mg/d =\> Salazopyrine EN(R) 2000mg/d~Glucocorticoids:~At Week, 0 patients will be initiated on Spiricort (R) 20mg/d and tapered every 5 days~Joint injections:~Starting at Week 0 up to 5 joint injections may be conducted into synovitic joints at every visit of the study.~The maximum cumulative Lederlon (R) dose is 100mg/visit. Joints are to be infiltrated with the following doses of triamcinolone and lidocaine"
62368215|NCT02293590|ACTIVE_COMPARATOR|fixed-dosed program|"Intervention:~Certolizumab pegol (Cimzia (R), CZP) CZP of 400mg at Weeks 0, 2 and 4, followed by 200mg injections from Week 6, every 2 weeks until Week 24.~DMARD:~Patients are to continue to receive their stable weekly dose of DMARD as noted at study entry for the duration of the study (24 weeks)~Glucocorticoids:~Prednisolone (Spiricort (R)) daily dose of ≤ 10 mg~Joint injections:~None"
62368216|NCT02549521|ACTIVE_COMPARATOR|Oral magnesium substitution|Daily 240 mg Magnesium Nycomed Pharma. Intervention day 0 - day 28.
62368217|NCT02549521|PLACEBO_COMPARATOR|Magnesium + or Magnesium -|Placebo tablets without magnesium.
62742843|NCT04530487|EXPERIMENTAL|Treatment (conditioning regimen, HSCT)|"CONDITIONING REGIMEN: Patients receive thiotepa IV over 2-4 hours, etoposide IV over 60 minutes on days -8 to -6, melphalan IV over 20 minutes on days -5 and -4, and fludarabine phosphate IV over 1 hour on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients receiving umbilical cord transplant also receive rabbit anti-thymocyte globulin IV on days -3 and -4.~TRANSPLANT: Patients undergo HSCT on day 0.~GVHD PROPHYLAXIS: Beginning day -2, patients receive tacrolimus or cyclosporine IV continuously until able to receive PO. Patients continue tacrolimus or cyclosporine PO to day 60 and tapered to day 100. Patients also receive mycophenolate mofetil PO or IV every 8 hours until day 40 and tapered to day 90."
62368218|NCT02482792|EXPERIMENTAL|Norwegian Psychomotor Physiotherapy|NPMP is a body-mind awareness approach, often given in a combination of massage, exercises and conversations. The NPMP is individualized, with duration of 45-60 minutes in each session. As the NPMP is a longitudinal and normally slow process to obtain change, treatment can last up till one year, in the beginning once a week, and after some time once a month.
62368219|NCT02482792|ACTIVE_COMPARATOR|Cognitive Patient Education and PT|The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.They will receive one session weekly with COPE, given by a physiotherapist, maximum 4 times, followed by active individual Physiotherapy (PT).
62368220|NCT04159701|EXPERIMENTAL|LY3454738|500 milligram (mg) LY3454738 administered intravenously (IV).
62368221|NCT04159701|PLACEBO_COMPARATOR|Placebo|Placebo administered IV.
62368222|NCT04803019|ACTIVE_COMPARATOR|DEB-TACE or chemoembolization with microspheres|The chemotherapy used in this arm is the Doxorubicin that will be carried into the tumor by Embozene TANDEM® (Boston Scientific) microspheres. TANDEM® embozene microspheres are made of non-resorbable, biocompatible, hydrogel microspheres, subjected to precision calibration and coated with an inorganic perfluorate polymer (Polyzene®-F)
62368223|NCT04803019|ACTIVE_COMPARATOR|TAE or embolization with microspheres|The TAE will be performed with Embozene microspheres (Boston Scientific). Embozene microspheres are spherical particles of hydrogel, precisely calibrated, biocompatible, non-absorbable and coated with a perfluorinated inorganic polymer (Polyzene®-F)
62368224|NCT01650441|EXPERIMENTAL|beclomethasone dipropionate + formoterol fumarate|All patients will be treated with the active product. No placebo arm will be used. The active product is a fixed combination containing extra-fine beclometasone dipropionate and formoterol fumarate in a new dry powder inhaler device, NEXThaler® (Chiesi Farmaceutici, Parma, Italy).
62368225|NCT00780104|EXPERIMENTAL|Rapamycin + MEC|
62368226|NCT00287846|EXPERIMENTAL|Imatinib|400 to 800 mg/day for a maximal 12 months study duration.
62368227|NCT02494271||Total intravenous anesthesia|Total intravenous anesthesia using propofol and remifentanil
62742844|NCT06659900|EXPERIMENTAL|CORE (Arm A)|CORE arm will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials and a voucher for a medication starter kit
62368228|NCT02494271||Inhalation|Balanced inhalation anesthesia using volatile anesthetics and remifentanil
62368229|NCT04430699|EXPERIMENTAL|Pembrolizumab, Cisplatin and Radiation Therapy|"Treatment period is 36 weeks with 21 day study cycles.~Participants will receive cisplatin at a predetermined dose 1x weekly, pembrolizumab at a predetermined dose every 3 weeks, concurrently with daily radiation therapy from week 1 up to week 8.~First 3 participants on the study, may skip 1 or 2 pembrolizumab dosages while receiving radiation therapy.~Following completion of daily radiation therapy with 1x weekly cisplatin and 1x every 3 weeks pembrolizumab, participants will continue at a pre-determined maintenance dose of pembrolizumab 1x every 3 weeks for a total of 12 cycles or 36 weeks."
62368230|NCT02211950|EXPERIMENTAL|Treatment A|single dose BI 44847 administered to white subjects
62368231|NCT02211950|EXPERIMENTAL|Treatment B|100 mg acarbose for 2 days, on the second day a single dose BI 44847 administered to white subjects
62368232|NCT02211950|EXPERIMENTAL|Treatment C|single dose BI 44847 after a Japanese diet of 6 days administered to white subjects
62368233|NCT02211950|EXPERIMENTAL|Treatment D|single dose BI 44847 administered to asian subjects
62368234|NCT02211950|EXPERIMENTAL|Treatment E|single dose BI 44847 administered to african subjects
62368235|NCT01804842|ACTIVE_COMPARATOR|500 mg Met DR BID|Two doses of 500 mg metformin delayed-release
62368236|NCT01804842|EXPERIMENTAL|1000 mg Met DR qAM|One dose of 1000 mg metformin delayed-release in the morning
62368237|NCT01804842|EXPERIMENTAL|1000 mg Met DR qPM|One dose of 1000 mg metformin delayed-release in the evening
62368238|NCT05241288|EXPERIMENTAL|Albuterol eMDPI DS (ProAir® Digihaler®)|This arm will receive the intervention of the Albuterol eMDPI DS for three months.
62368239|NCT03325010|PLACEBO_COMPARATOR|Placebo|Participants received placebo (matching valbenazine) once daily for 12 weeks.
62552828|NCT05664269|ACTIVE_COMPARATOR|Whey protein|20g of whey protein
62552829|NCT05664269|SHAM_COMPARATOR|Placebo|Water, matched for taste and volume
62368240|NCT03325010|EXPERIMENTAL|Valbenazine|Participants received valbenazine once daily for 12 weeks. The starting dose was 20 mg for participants \<50 kg at baseline and 40 mg for participants ≥50 kg at baseline, and could be escalated in increments of 20 mg every 2 weeks to a maximum of 60 mg for subjects \<50 kg and 80 mg for subjects ≥50 kg to achieve an optimal dose of valbenazine for each participant.
62368241|NCT01554189|EXPERIMENTAL|Panel A (GT1 10 mg)|
62368242|NCT01554189|EXPERIMENTAL|Panel B (GT1 50 mg)|
62368243|NCT01554189|EXPERIMENTAL|Panel C (GT1 100 mg)|
62368244|NCT01554189|EXPERIMENTAL|Panel D (GT1 200 mg)|
62368245|NCT01554189|EXPERIMENTAL|Panel E (GT3 10 mg)|
62368246|NCT01554189|EXPERIMENTAL|Panel F (GT3 50 mg)|
62368247|NCT01554189|EXPERIMENTAL|Panel G (GT3 100 mg)|
62368248|NCT01554189|EXPERIMENTAL|Panel H (GT3 200 mg)|
62368249|NCT01554189|EXPERIMENTAL|Panel I (GT1a 10 mg)|
62368250|NCT01554189|EXPERIMENTAL|Panel J (GT1a 50 mg)|
62368251|NCT01554189|PLACEBO_COMPARATOR|Placebo Panel|
62368252|NCT03812783|EXPERIMENTAL|HAIC of FOLFIRINOX plus sorafenib|
62368253|NCT03812783|ACTIVE_COMPARATOR|HAIC of FOLFOX plus sorafenib|
62368254|NCT02128958|EXPERIMENTAL|CF102|orally q12h
62742845|NCT06659900|EXPERIMENTAL|CORE PLUS (Arm B)|CORE PLUS arm will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials, a voucher for a medication starter kit PLUS support from a Community Health Advisor who will serve as a connector to primary care for HTN management and send reminder text messages.
62368255|NCT02128958|PLACEBO_COMPARATOR|Placebo tablets of CF102|orally q12h
62368256|NCT04459078|EXPERIMENTAL|Camrelizumab combined with Albumin Paclitacxel and Apatinib.|Participants are given intravenous administration of Camrelizumab (200mg/3w) in addition with intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles) and Apatinib (250mg Qd po for 5 days,, take rest for 2 days every week). Treatment terminates when disease progression, death or unacceptable toxicity.
62368257|NCT02903368|EXPERIMENTAL|Arm 1A: AAPL Neoadjuvant Therapy [Part 1]|"Eligible Participants will be randomized to receive:~AAPL: Abiraterone acetate (240 mg/day orally), Apalutamide (1000 mg/day orally), Leuprolide (22.5 mg every 12 weeks intramuscularly), Prednisone (5 mg/twice daily orally) for 6 months~Pts x weeks to RP"
62368258|NCT02903368|EXPERIMENTAL|Arm 1B: APL Neoadjuvant Therapy [Part 1]|"Eligible Participants will be randomized to receive:~APL: Abiraterone acetate (1000 mg/day orally), Leuprolide (22.5 mg every 12 weeks intramuscularly), Prednisone (5 mg/day orally) for 6 months"
62368259|NCT02903368|EXPERIMENTAL|Arm 2A: AAPL Adjuvant Therapy [Part 2]|"Eligible Participants will be randomized to receive:~AAPL: Abiraterone acetate (240 mg/day orally), Apalutamide (1000 mg/day orally), Leuprolide (22.5 mg every 12 weeks intramuscularly), Prednisone (5 mg/twice daily orally) for 12 months"
62368260|NCT02903368|NO_INTERVENTION|Arm 2B: Observation [Part 2]|
62368261|NCT03527186|EXPERIMENTAL|Risperidone ISM® 100 mg|A single intramuscular (IM) dose of 100 mg risperidone ISM® will be administered deeply into the gluteal muscle. A total of 4 IM doses will be given; each dose will be separated by 4 weeks
62368262|NCT01287767|NO_INTERVENTION|Control group, ordinary support|Home care as usual.
62368263|NCT01287767|EXPERIMENTAL|A multidimensjonalt support program|•Behavioral (e.g., Psychotherapy, Lifestyle Counseling) The family will receive individual consulting, teaching and problem solving in support groups.
62368264|NCT00878813||1|All consecutive stroke patients undergoing acute intra-arterial revascularisation therapy
62368265|NCT00878813||2|All consecutive stroke patients undergoing acute intra-venous revascularisation therapy
62368266|NCT00878813||3|All consecutive stroke patients treated conservatively
62368267|NCT00878813||4|All consecutive TIA patients
62368268|NCT00802724|EXPERIMENTAL|1 Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
62368269|NCT00802724|ACTIVE_COMPARATOR|2 Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
62368270|NCT00269295|EXPERIMENTAL|Cohort 1: Arm 1|12 subjects to receive vaccine dose 1: 5 X 10\^7 cfu.
62368271|NCT00269295|PLACEBO_COMPARATOR|Cohort 1: Arm 2|6 subjects to receive placebo.
62368272|NCT00269295|EXPERIMENTAL|Cohort 2: Arm 1|12 subjects to receive vaccine dose 2: 5 X 10\^8 cfu.
62368273|NCT00269295|EXPERIMENTAL|Cohort 3: Arm 1|12 subjects to receive vaccine dose 3: 5 X 10\^9 cfu.
62368274|NCT00269295|PLACEBO_COMPARATOR|Cohort 3: Arm 2|6 subjects to receive placebo.
62368275|NCT00269295|PLACEBO_COMPARATOR|Cohort 2: Arm 2|6 subjects to receive placebo.
62368276|NCT00988377|EXPERIMENTAL|10 g whey protein|
62368277|NCT00988377|EXPERIMENTAL|20 g whey protein|
62368278|NCT00988377|EXPERIMENTAL|30 g whey protein|
62368279|NCT00988377|EXPERIMENTAL|40 g whey protein|
62742846|NCT03625947||Hemoptysis patients|Hemoptysis patients caused by endobronchial malignancies
62368280|NCT00988377|EXPERIMENTAL|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
62368281|NCT01784497||Recipients of Living Donor Liver Transplantation|Patients who will undergo Living Donor Liver Transplantation (LDLT) In Ain Shams Center For Organ Transplantation (ASCOT) .
62368282|NCT06153394|EXPERIMENTAL|Redesca|Patients in the extended thromboprophylaxis group will receive Redesca (enoxaparin sodium for injection) (40mg) once a day, starting on the day of surgery, for 90 days postoperatively.
62368283|NCT06153394|ACTIVE_COMPARATOR|Fragmin|Patients in the standard of care group will receive Fragmin (daletparin) (5,000 I.U) once a day, starting on the day or surgery, for 30 days postoperatively.
62368284|NCT03739736||Combination of TB/HIV prevention activities (A)|Communities in the intervention group (A) were exposed to a combination of TB/HIV prevention activities, including active case finding (ACF) for TB and Universal Testing and Treatment for HIV delivered in the community. In this arm, ART was initiated regardless of CD4 count
62368285|NCT03739736||Standard of care (C)|"The standard of care arm (C) communities have access to TB/HIV testing, care and treatment services (usually at the health facility) and according to national guidelines. TB case finding is passive i.e. relies on individuals to present with symptoms to the health facility."
62368286|NCT03739736||Combination of TB/HIV prevention activities (B)|The intervention in arm B was the same as in arm A, consisting in a package of combination of TB/HIV prevention activities, including active case finding (ACF) for TB and Universal Testing and Treatment for HIV delivered in the community. Differently to arm A, in arm B national guidelines on CD4 count were used for ART initiation. During the trial the thresholds for commencement of ART changed from 500 CD count to 350 CD count and then, in 2016, to universal ART regardless of CD4 count.
62368287|NCT00432185|ACTIVE_COMPARATOR|1|One day treatment
62368288|NCT00432185|ACTIVE_COMPARATOR|2|Two day treatment
62368289|NCT02845999|EXPERIMENTAL|Allogenic NK cells transfer|Patients will be treated with a conditioning chemotherapy including 60 mg/kg intravenous cyclophosphamide, 25 mg/m2 intravenous fludarabine for 5 consecutive days and cetuximab. A lymphapheresis from an haploidentical related donor will be performed and T cells will be depleted . Allogenic NK cells will then be adoptively transferred by hepatic intraarterial infusion according to a dose escalation protocol (three doses with at least three patients per cohort)to define the dose-limiting toxicity (DLT). T
62368290|NCT02451254|EXPERIMENTAL|Atrial Fibrillation|Atrial Fibrillation patients electively admitted for circumferential ablation of the pulmonary veins.
62368291|NCT02451254|ACTIVE_COMPARATOR|control|patients electively admitted for SVT ablation
62368292|NCT04069624|ACTIVE_COMPARATOR|Services as Usual (SAU)|Substance abuse program (SAP) managed by the Kentucky Department of Corrections, with the option to initiate MOUD prior to jail release.
62368293|NCT04069624|EXPERIMENTAL|MOUD Pre-Treatment Telehealth|Telehealth connection to a community MOUD provider.
62368294|NCT04069624|EXPERIMENTAL|MOUD Pre-Treatment Telehealth and Peer Navigator|Telehealth connection to a community MOUD provider, in addition to a peer navigator
62368295|NCT01507623|EXPERIMENTAL|With Capnograpy|Intervention group with the addition of capnography to standard monitoring (non-invasive blood pressure, pulse, pulse oximetry, clinical observation of respiration, electrocardiography (ECG) and respiratory frequency measured by the ECG)
62368296|NCT01507623|NO_INTERVENTION|No Capnography|Control group without the addition of capnography to standard monitoring (non-invasive blood pressure, pulse, pulse oximetry, clinical observation of respiration, electrocardiography (ECG) and respiratory frequency measured by the ECG)
62368297|NCT04921410|EXPERIMENTAL|Biofeedback Sleeve Effects on Preventive Biomechanics|Biofeedback wearable sleeve will be utilized in at least 2 groups of athletes. This randomized group will receive an 'active' wearable device. The device will be worn during regular sport practice sessions for 8-16 weeks. The device will provide haptic feedback directly associated with potentially injurious events as determined by previously established cut-off values and artificially-intelligent algorithms.
62368298|NCT04921410|SHAM_COMPARATOR|Sham Biofeedback|Biofeedback wearable sleeve will be utilized in at least 2 groups of athletes. This randomized group will receive a 'sham' wearable device. The device will be worn during regular sport practice sessions for 8-16 weeks. The device will provide random feedback at random intervals not directly associated with potentially injurious events.
62368299|NCT02837861|EXPERIMENTAL|Experimental Group|Routine Nutritional Support plus supplemental IV amino acids, to begin within 24h of injury. (Target approximately 1.5-2g protein/kg/day)
62368300|NCT02837861|ACTIVE_COMPARATOR|Control Group|Routine Nutritional Support (i.e. enteral nutrition as tolerated, to begin as early as medically feasible)
62368301|NCT04301011|EXPERIMENTAL|Arm A: TBio-6517 alone|Dose escalation of TBio-6517 alone administered by direct injection into tumor(s) x 4. Booster injections of TBio-6517 are permitted for up to 24 months.
62368302|NCT04301011|EXPERIMENTAL|Arm B: TBio-6517 and Pembrolizumab|Dose escalation of TBio-6517 administered in combination with pembrolizumab. TBio-6517 will be directly injected into tumor(s) x 4. Booster injections of TBio-6517 are permitted for up to 24 months. Pembrolizumab will be administered beginning at Day 9 via intravenous (IV) infusion every 3 weeks for up to 24 months.
62368303|NCT04301011|EXPERIMENTAL|TBio-6517 and Pembrolizumab in MSS-CRC|Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 9 given every 3 weeks for up to 24 months in patients with microsatellite stable colorectal carcinoma (MSS-CRC). Booster injections of TBio-6517 are permitted for up to 24 months.
62368304|NCT04301011|EXPERIMENTAL|TBio-6517 and Pembrolizumab in cutaneous melanoma|Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 9 given every 3 weeks for up to 24 months in patients with malignant melanoma of the skin. Booster injections of TBio-6517 are permitted for up to 24 months.
62552830|NCT05703087|NO_INTERVENTION|Standard information video before primary total knee arthroplasty|Information video (about procedure, complications, rehabilitation) shown to the participants before TKA in the OLVG.
62368305|NCT04301011|EXPERIMENTAL|TBio-6517 and Pembrolizumab in cutaneous squamous cell carcinoma of the skin|Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 8 given every 3 weeks for up to 24 months in patients with cSCC. Booster injections of TBio-6517 are permitted for up to 24 months.
62368306|NCT04301011|EXPERIMENTAL|TBio-6517 and Pembrolizumab in HPV positive head and neck cancer|Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 9 given every 3 weeks for up to 24 months in patients with HPV associated oropharyngeal cancer. Booster injections of TBio-6517 are permitted for up to 24 months.
62368307|NCT04301011|EXPERIMENTAL|Arm C: TBio-6517 intravenous|Dose escalation of TBio-6517 alone administered by intravenous infusion x 4. Booster infusions of TBio-6517 are permitted for up to 24 months.
62368308|NCT04301011|EXPERIMENTAL|Arm D: TBio-6517 intravenous and Pembrolizumab|Dose escalation of TBio-6517 administered in combination with pembrolizumab. Dose escalation of TBio-6517 alone administered by intravenous infusion x 4. Booster infusions of TBio-6517 are permitted for up to 24 months. Pembrolizumab will be administered beginning at Day 9 via intravenous (IV) infusion every 3 weeks for up to 24 months.
62368309|NCT02245880|ACTIVE_COMPARATOR|Glidescope videolaryngoscope|cervical collar was applied to 47 patients then facemask ventilations were recoded intubated with Glidescope and insertion time: handling of the device till the good glottic visualisation intubation time: handling of the device till the capnography appears mucosal damage: bloodstain on the device after removal heart rate preinduction heart rate postinduction heart rate postinsertion heart rate postintubation mean arterial pressure preinduction mean arterial pressure postinduction mean arterial pressure postinsertion mean arterial pressure postintubation wrere recorded. postoperative minor complications were recorded.
62368310|NCT02245880|ACTIVE_COMPARATOR|Intubating laryngeal mask airway|cervical collar was applied to 47 patients then facemask ventilations through the collar were recorded and intubated with ILMA insertion time: handling of the device till the good glottic visualisation appears intubation time: handling of the device till the capnography appears mucosal damage: bloodstain on the device heart rate preinduction heart rate postinduction heart rate posinsertion heart rate postintubation mean arterial pressure preinduction mean arterial pressure postinduction mean arterial pressure postinsertion mean arterial pressure postintubation
62368311|NCT05905861|PLACEBO_COMPARATOR|Group_A: skin incision with scalpel.|In the scalpel group, the skin incision will be made using the traditional method, with a scalpel (No. 22).
62368312|NCT05905861|ACTIVE_COMPARATOR|Group_B: skin incision with diathermy.|In the diathermy group, the incision will be made using a small flat blade pen electrode without applying pressure. The electrode will be set to cutting mode, delivering a sinusoidal current of maximum 120 watts.
62368313|NCT01666990|EXPERIMENTAL|TwHF, lifestyle counseling|Participants will receive TwHF (20mg each time, 3 times per day, for 48 weeks) from Day 0 through the Week 48 study visit.
62368314|NCT01666990|PLACEBO_COMPARATOR|placebo, Lifestyle|Participants will receive placebo treatment (20mg each time, three times per day for 48 weeks) from Day 0 through the Week 48 study visit.
62368315|NCT04483752|OTHER|Patients hospitalised for SARS CoV-2 infection.|
62368316|NCT04268303|EXPERIMENTAL|120 Micrograms|Sublingual film containing 120 Micrograms dexmedetomidine
62368317|NCT04268303|EXPERIMENTAL|180 Micrograms|Sublingual film containing 180 Micrograms dexmedetomidine
62368318|NCT04268303|PLACEBO_COMPARATOR|Placebo|Sublingual placebo film
62368319|NCT02615262|EXPERIMENTAL|Experimental|Dexamethasone 1 mg per 1 kg of body weight intravenously immediately after induction of anesthesia
62368320|NCT02615262|PLACEBO_COMPARATOR|Control|0.9% Sodium Chloride 0.25 ml per 1 kg of body weight intravenously immediately after induction of anesthesia
62368321|NCT01337518|EXPERIMENTAL|EZN-4176|
62368322|NCT05421091||Asciminib|Patients prescribed with Asciminib
62368323|NCT05556915|EXPERIMENTAL|Ultrasound-guided AVF cannulation method|The AVF cannulation is carried out using ultrasoud guidance
62368324|NCT05556915|OTHER|Conventional AVF cannulation method|The AVF cannulation is carried out by palpation
62742847|NCT02222194||VAM|"Patients with operable and resectable cT1-2-selected T3 cN1cM0 NSCLC undergo VAM for mediastinal lymph node staging. After VAM, patients without tissue proof of N2/3 disease at surgical staging undergo a VATS or thoracotomy with systematic lymph node dissection during the same anaesthesia or at a later stage.~Sensitivity, NPV and accuracy of staging with VAM will be calculated. Provided N2 lymph node metastases are proven by VAM the patient goes off study protocol and can further be assessed/treated according to local clinical practice."
62368325|NCT00595868|EXPERIMENTAL|Varenicline|
62368326|NCT00595868|PLACEBO_COMPARATOR|Placebo|
62368327|NCT04011644|ACTIVE_COMPARATOR|Self monitored|"Patients of this group will continue receiving regular care from their physician with no interference from the two experimental groups. Patient subjects will download the app on their Android or Apple smart phone that will direct them to external information hosted on the internet that may help reduce their drinking (e.g., NIAAA resources). For the first 12 weeks, once a week patients can set a weekly goal related to their alcohol use or other health related behaviors (e.g., I will only drink on Friday this week.). At the end of the week subjects will be prompted to take a weekly survey, which will include questions such as a variation of the brief alcohol monitor (BAM) and timeline followback. Patients will then receive feedback on the amount of drinks they had compared to their goal. Then the patient will set a new goal for the following week. Patients will complete quarterly surveys on the A-CHESS app to assess study outcomes."
62368328|NCT04011644|EXPERIMENTAL|Peer supported|Patients will be asked to take the same surveys and have the access to the same information as the self-monitoring group. Patient subjects in this group will have access to discussion boards where they can talk to one another and have the ability to share and see stories of other patients. The only involvement of someone other than patients themselves in the peer-supported group will be by a sponsor (i.e., a dedicated user from the area with a sustained history of successful alcohol reduction). The sponsor will participate in discussion groups and encourage use of the system. Patient-reported feedback will be presented directly to the patient.
62742848|NCT02269813||ET/GOOD|Endocrine therapy only.
62368329|NCT04011644|EXPERIMENTAL|Clinically integrated|Patients in the clinically integrated group will receive the same intervention as the peer-supported group aside from three differences: 1) patients have the option to share selected elements of their app data with the University of Wisconsin (UW) Health health coach, 2) the health coach will replace the role of the sponsor in the peer-support group, and 3) patients will have the option to attend an initial 60- to 90-minute and two 30-minute follow-up consultations with the health coach in-person, via phone, or via video chat.
62368330|NCT01916187|EXPERIMENTAL|Imetelstat|285 mg/m2/dose, IV, for 2 hours. Days 1 and 8 every three weeks.
62368331|NCT01041404|EXPERIMENTAL|Trastuzumab, Fluoropyrimidine, Cisplatin|Participants received an initial loading dose of 8 milligrams per kilogram (mg/kg) trastuzumab i.v. on Day 1 of cycle, followed by 6 mg/kg i.v. every 3 weeks until disease progression; 800 mg/m2 fluorouracil i.v. on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.
62368332|NCT01041404|ACTIVE_COMPARATOR|Fluoropyrimidine, Cisplatin|Participants received 800 milligrams per square meter (mg/m2) fluorouracil intravenous (i.v.) on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine orally (p.o.) twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.
62368333|NCT05258513|PLACEBO_COMPARATOR|Placebo|From weeks 1-4, participants will consume 150mg daily of a visually identical placebo. For weeks 5-8, the dose will be escalated as participants will consume 300mg daily of placebo supplementation.
62368334|NCT05258513|EXPERIMENTAL|Geranylgeraniol Treatment|From weeks 1-4, participants will consume 150mg daily of a Geranylgeraniol (GG). For weeks 5-8, the dose will be escalated as participants will consume 300mg daily of GG.
62742849|NCT02269813||CT/POOR|Chemoendocrine therapy according to national guidelines.
62368335|NCT02524535|OTHER|Therapetic alliance|
62368336|NCT01973972|EXPERIMENTAL|Weight management/shared medical appointment (WM/SMA)|Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
62368337|NCT01973972|ACTIVE_COMPARATOR|Shared medical appointments (SMA)|Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.
62368338|NCT01526317|EXPERIMENTAL|1|This arm is consist of 6 subject. Crestor 10mg and Glucodown 750mg for 5 day during period 1. Crestor 10mg alone for 5 day during period 2. Glucodown 750mg alone for 5 day during period 3.
62368339|NCT01526317|EXPERIMENTAL|2|This arm is consist of 6 subject. Glucodown 750mg alone for 5 day during period 1. Crestor 10mg and Glucodown 750mg for 5 day during period 2. Crestor 10mg alone for 5 day during period 3.
62368340|NCT01526317|EXPERIMENTAL|3|This arm is consist of 6 subject. Crestor 10mg alone for 5 day during period 1. Glucodown 750mg alone for 5 day during period 2. Crestor 10mg and Glucodown 750mg for 5 day during period 3.
62368341|NCT01526317|EXPERIMENTAL|4|This arm is consist of 6 subject. Glucodown 750mg alone for 5 day during period 1. Crestor 10mg alone for 5 day during period 2. Crestor 10mg and Glucodown 750mg for 5 day during period 3.
62368342|NCT01526317|EXPERIMENTAL|5|This arm is consist of 6 subject. Crestor 10mg alone for 5 day during period 1. Crestor 10mg and Glucodown 750mg for 5 day during period 2. Glucodown 750mg alone for 5 day during period 3.
62368343|NCT01526317|EXPERIMENTAL|6|This arm is consist of 6 subject. Crestor 10mg and Glucodown 750mg for 5 day during period 1. Glucodown 750mg alone for 5 day during period 2. Crestor 10mg alone for 5 day during period 3.
62368344|NCT06074718|EXPERIMENTAL|pricking therapy and wheat grain moxibustion combined with chemotherapy|pricking therapy and wheat grain moxibustion on the back shu points or positive reaction points combined with chemotherapy
62368345|NCT06074718|ACTIVE_COMPARATOR|chemotherapy|Conventional chemotherapy regimen
62368346|NCT00671970|EXPERIMENTAL|Bevacizumab + Erlotinib|Bevacizumab + Erlotinib
62368347|NCT05956262|EXPERIMENTAL|AR group|Student in AR group received a two-time repeated AR-based training for 30 minutes at two-week intervals.
62368348|NCT05956262|EXPERIMENTAL|traditional group|Students in the traditional group received a two-time repeated 10-minute lesson regarding proper toothbrushing skills in the classroom at two-week intervals.
62368349|NCT02283541|EXPERIMENTAL|ASTM|Participants in Automatic self-transcending meditation (ASTM) arm will complete a 12 week meditation training program in addition to their existing treatment plan. This involves participating in 120-minute sessions on each of four consecutive days of the first week. Participants will individually be given a mantra on day one, and then be instructed in use of the mantra according to specific criteria over the four session program. This will be followed by weekly 60-minute follow up sessions for the 11 subsequent weeks. In addition, participants will be asked to practice ASTM at home for 20 minutes twice daily over the study period. Assessments of depression severity will be completed at specific times over the 12 week training period: at Weeks 0, 4, 8 and 12.
62368350|NCT02283541|NO_INTERVENTION|TAU|Participants in TAU arm will continue with their existing treatment schedule as usual. Assessments of depression severity will be completed at specific times over the 12 week training period: at Weeks 0, 4, 8 and 12. However, no assessments will be done or information collected on the TAU arm from week 12 onwards. After week 12, TAU arm participants will be offered the opportunity to learn ASTM and attend follow up meditation.
62368351|NCT00063388|EXPERIMENTAL|1|Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
62368352|NCT01638169||20 children with DMD|
62368353|NCT02971007|EXPERIMENTAL|CAMB 200 mg|200 mg CAMB (MAT2203) Oral Amphotericin B
62368354|NCT02971007|EXPERIMENTAL|CAMB 400 mg|400 mg CAMB (MAT2203) Oral Amphotericin B
62368355|NCT02971007|ACTIVE_COMPARATOR|Fluconazole 150 mg|Fluconazole Diflucan
62742850|NCT06636318||General Surgery Residents|General Surgery residents on during 24-hour rotation shifts
62742851|NCT01278121|OTHER|Diet A: High-fat diet|"Diet given for 3 days to reset all of the participants"
62742852|NCT01278121|ACTIVE_COMPARATOR|Diet B: A carbohydrate-restricted diet|The diet will be given for 10 days, 6 meals a day
62742853|NCT00302172|EXPERIMENTAL|ARQ 197|
62742854|NCT06098911|EXPERIMENTAL|MI varnish (CPP ACP) under glass ionomer in ART group|Application of a thin layer of casein phosphopeptide amorphous calcium phosphate ( CPP ACP ) varnish as indirect pulp capping material under glass-ionomer (Riva Light cure GC company ) in Atraumatic restorative technique.
62368356|NCT05977803|OTHER|Radiation therapy|Patient treated for metastatic cerebral lung cancer who has been treated with external beam radiotherapy such as in toto brain irradiation or stereotactic radiosurgery followed in the thoracic oncology department of Bichat Hospital.
62368357|NCT01498497||PR-021 Eosinophilic Esophagitis (EoE) Subjects|Subjects who received study drug and completed PR-021 study
62368358|NCT00741260|EXPERIMENTAL|Neratinib and Capecitabine (Dose Level 1)|Neratinib 160 mg and Capecitabine 1500 mg/m\^2
62368359|NCT00741260|EXPERIMENTAL|Neratinib and Capecitabine (Dose Group 2)|Neratinib 240 mg and Capecitabine 1500 mg/m\^2
62368360|NCT00741260|EXPERIMENTAL|Neratinib and Capecitabine (Dose Group 3)|Neratinib 240 mg and Capecitabine 2000 mg/m\^2
62368361|NCT00741260|EXPERIMENTAL|Neratinib and Capecitabine (Dose Group 4)|Neratinib 200 mg and Capecitabine 2000 mg/m\^2
62368362|NCT00741260|EXPERIMENTAL|Neratinib and Capecitabine (Dose Group 5)|Neratinib 160 mg and Capecitabine 2000 mg/m\^2
62368363|NCT00741260|EXPERIMENTAL|Neratinib and Capecitabine MTD (Dose Group 6)|Neratinib and Capecitabine Maximum Tolerated Dose without prior lapatinib
62368364|NCT00741260|EXPERIMENTAL|Neratinib and Capecitabine MTD (Dose Group 7)|Neratinib and Capecitabine Maximum Tolerated Dose with prior lapatinib
62742855|NCT06098911|NO_INTERVENTION|Conventional ART|Placement of glass-ionomer restoration ( Riva Light Cure ) only in Atraumatic restorative technique.
62742856|NCT02094378|EXPERIMENTAL|Esketamine-Placebo|Participants assigned to treatment sequence 1 will receive 84 mg esketamine intranasally on Day 1 of Period 1 and then receive placebo intranasally on Day 1 in Period 2. Periods 1 and 2 will be separated by 7 days.
62742857|NCT02094378|PLACEBO_COMPARATOR|Placebo-Esketamine|Participants assigned to treatment sequence 2 will receive placebo intranasally on Day 1 of Period 1 and then receive 84 mg esketamine intranasally on Day 1 in Period 2. Periods 1 and 2 will be separated by 7 days.
62742858|NCT01322113||Na+, K+-ATPase/DLC system in BD|Bipolar patients in the various phases of the disease.
62742859|NCT01766063||Group 1|
62742860|NCT03070223|EXPERIMENTAL|Pitavastatin|Participants who were randomized to pitavastatin in the main study REPRIEVE.
62742861|NCT03070223|PLACEBO_COMPARATOR|Placebo|Participants who were randomized to placebo for pitavastatin in the main study REPRIEVE.
62368365|NCT02804373|PLACEBO_COMPARATOR|placebo daily|daily administration of placebo during 28 days : placebo continuous
62368366|NCT02804373|ACTIVE_COMPARATOR|24 IU of oxytocin daily|24 IU of daily oxytocin administration during 28 days : oxytocin continuous
62368367|NCT02804373|ACTIVE_COMPARATOR|24 IU of oxytocin every 3 days|24 IU of daily oxytocin every 3 days and placebo the following 2 days after each oxytocin administration during 28 days
62368368|NCT00882830|EXPERIMENTAL|EMS group|
62368369|NCT00882830|NO_INTERVENTION|control group|
62368370|NCT00723268|ACTIVE_COMPARATOR|Prednisolone|
62368371|NCT00723268|ACTIVE_COMPARATOR|Colchicine|
62742862|NCT04204694||Patient in septic shock|
62742863|NCT04204694||blood donor tests|
62742864|NCT05203757|EXPERIMENTAL|Conventional CT-arthrogram + CBCT arthrogram|"Conventional CT-arthrogram + CBCT arthrogram (CBCT in the minutes following the conventional CT arthrogram).~Routine care (arthroCT) and CBCT of ankle."
62742865|NCT04362488|EXPERIMENTAL|Patients with chronic post-traumatic lateral ankle instability|"The study population consists in patients affected by chronic post-traumatic lateral ankle instability who must undergo surgical intervention of ankle external ligament reconstruction.~The patients will be analyzed pre and postoperatively using differents tests, questionnaires, instrument and clinical evaluation:~* Delos system (computerized oscillating platform)~* Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~* modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
62742866|NCT01828606|EXPERIMENTAL|Coban 2 system|The two layer system is more stiff and the material is different designed
62742867|NCT01828606|EXPERIMENTAL|coban lite systems|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
62742868|NCT05005403|EXPERIMENTAL|Part 1 Dose Escalation: ABBV-514|Participants will receive ABBV-514.
62742869|NCT05005403|EXPERIMENTAL|Part 1 Dose Escalation: ABBV-514 + Budigalimab|Participants will receive ABBV-514 in combination with budigalimab.
62368372|NCT03954704|EXPERIMENTAL|Phase 1a, Part A - Dose Escalation|Part A will consist of dose escalation by an accelerated dosing design and a 3+3 dose escalation scheme. Participants will receive escalating dose levels dalutrafusp alfa of up to 45 mg/kg on Day 1 of each 2-week cycle (Q2W) until the participant meets study treatment discontinuation criteria or for up to 1 year.
62742870|NCT05005403|EXPERIMENTAL|Part 2 Dose Expansion: ABBV-514|Participants will receive ABBV-514 at recommended dose determined in Dose Escalation portion.
62742871|NCT05005403|EXPERIMENTAL|Part 2 Dose Expansion: ABBV-514 + Budigalimab|Participants will receive ABBV-514 at recommended dose determined in Dose Escalation portion in combination with budigalimab.
62742872|NCT00210353|ACTIVE_COMPARATOR|ARM A|chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment; two weeks rest; chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)
62742873|NCT00210353|EXPERIMENTAL|ARM B|rituximab 375 mg/m2 iv, d1, d8, d15, d22 chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment two weeks rest chlorambucil 6 mg/m2 os daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle
62742874|NCT00210353|EXPERIMENTAL|ARM C (Since April 2006)|rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140
62742875|NCT00157196|EXPERIMENTAL|Tecemotide(L-BLP25)+Cyclophosphomide+best standard of care|
62742876|NCT03017872|ACTIVE_COMPARATOR|Standard of Care (SoC) arm|2 x NRTIs + darunavir/ritonavir 800mg/100mg po od
62742877|NCT03017872|EXPERIMENTAL|Dolutegravir arm|Dolutegravir 50mg + darunavir/ritonavir 800mg/100mg po od
62742878|NCT03017872|EXPERIMENTAL|Dolutegravir 2NRTI arm (D2N)|Dolutegravir 50mg + 2 x NRTIs (tenofovir plus emtricitabine or lamivudine)
62742879|NCT00980512|EXPERIMENTAL|Parent Training|Parent Training of foster parents
62742880|NCT00980512|NO_INTERVENTION|Control|Control group
62742881|NCT05315115|EXPERIMENTAL|Experimental group|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
62742882|NCT05315115|SHAM_COMPARATOR|Control group|The participant's head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor.No spinal adjustment will be performed during any control intervention.
62742883|NCT06273722||D-OCT scanned patients|This diagnostic cohort study will include patients (18+ years) who underwent a biopsy and D-OCT scan for lesions suspect for BCC skin cancer. Patient data was retrieved from a pre-existing registry (METC: 2022-3555). All D-OCT scans were obtained at the outpatient dermatology clinic of Maastricht University Medical Center+ (MUMC+) using a Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner (Michelson Diagnostics Maidstone, Kent, UK; resolution \<7.5 µm lateral, \<5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm). All scanned lesions were histopathologically examined by a dermatopathologist blinded to D-OCT scans and D-OCT assessment.
62742884|NCT02970630|EXPERIMENTAL|Envarsus once a day, everolimus b.i.d.|"Tacrolimus tablets at starting dose of 0.07 mg/kg/day will be administered once daily in the morning.~Everolimus tablets at starting dose of 2 mg/day (1 mg b.i.d.) will be administered twice daily, every 12 hours."
62742885|NCT01054053||1|children born between 06/04/2004 and 17/04/2008 and called to menBvac vaccination and living around Neufchatel en Bray.
62368373|NCT03954704|EXPERIMENTAL|Phase 1a, Part B - Flat Dose Regimen|Part B will consist of 3 adaptive cohorts. Based on PK, pharmacodynamics, and safety results from the Part A study, participants will be administered a flat dose of dalutrafusp alfa on Day 1 of each cycle QW, Q2W and/or every 3 weeks (Q3W) until the participant meets study treatment discontinuation criteria or for up to 1 year.
62368374|NCT03954704|EXPERIMENTAL|Phase 1b, Cohort 1 (Gastric Cancer)|"Safety run-in: A standard 3+3 dose escalation design will be used to determine the DLT and MTD or RP2D of dalutrafusp alfa in combination with mFOLFOX6. The planned starting dose of dalutrafusp alfa will be targeted to achieve the exposure at -1 dose of RP2D monotherapy (Q2W) determined from Phase 1a. Dalutrafusp alfa will be administered in combination with mFOLFOX6.~Post safety run-in: Approximately 70 participants will be enrolled to receive dalutrafusp alfa at the dose level determined from the safety run-in period, in combination with mFOLFOX6 regimen.~Participants will receive dalutrafusp alfa on Day 1 of each 14-day cycle up to 2 years until PD, or unacceptable toxicity, substantial noncompliance with study procedures or study drug, study discontinuation or withdrawal from study. Participants will also receive mFOLFOX6 regimen Q2W for up to 12 cycles."
62368375|NCT03954704|EXPERIMENTAL|Phase 1b, Cohort 2 (Paired Biopsy)|Participants will receive dalutrafusp alfa at the dose level determined from Phase 1a Q2W until the participants meets study treatment discontinuation criteria or for up to 1 year.
62368376|NCT01095939|PLACEBO_COMPARATOR|Control Arm|
62368377|NCT01095939|EXPERIMENTAL|Benazepril|
62368378|NCT02082665|EXPERIMENTAL|Arm 1|On Day 1 subjects will simultaneously receive single dose of Rosuvastatin 10 mg tablet and Midazolam 3 mg syrup administered orally in the morning.
62368379|NCT05642065|EXPERIMENTAL|Arm 1|Participants will undergo lower extremity movement assessment on the Forward Step Down Test before and after a home exercise program (HEP) consisting of five hip activation exercises. These exercises will be performed 2x/week for 8 weeks. Surface EMG of the gluteus maximus and medius, in addition to tracking of participant compliance on the HEP program will also be assessed pre- and post-intervention.
62368380|NCT01071369|ACTIVE_COMPARATOR|Xylocaine|0.5% Xylocaine
62368381|NCT01071369|ACTIVE_COMPARATOR|Xylocaine and Celestone|0.5% Xylocaine with 6 mg of non-particulate Celestone.
62368382|NCT04146038|EXPERIMENTAL|Treatment (salsalate, decitabine, azacitidine, venetoclax)|"CYCLE 1: Patients receive salsalate PO BID until completion of cycle 1. 24-48 hours later or concurrent with salsalate, patients begin to receive decitabine IV for 10 days or azacitidine IV for 7 days. Starting 24 hour after salsalate, patients also receive venetoclax PO continuously until completion of cycle 1.~CYCLE 2: Patients receive decitabine IV for 5 days or azacitidine IV for 7 days, salsalate PO BID, and venetoclax PO continuously.~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62368383|NCT02237898|EXPERIMENTAL|MoMba Contingency Management|Study will provide access to the web-based MoMba Live Long application \& Sensodrone™ carbon-monoxide sensor for purposes of researching the acceptability of the smartphone application, operating and functioning of it, and providing remote contingency management for smoking cessation to postpartum women.
62368384|NCT02237898|ACTIVE_COMPARATOR|Office contingency management|Traditional contingency management with financial incentives delivered in-person in the office for smoking cessation to postpartum women
62368385|NCT01934608|EXPERIMENTAL|Refill synch|Participants in this group will have their medication refill schedule synchronized.
62368386|NCT01934608|NO_INTERVENTION|Control|Participants in this arm will receive usual care
62368387|NCT05549089|EXPERIMENTAL|CAD/CAM Insignia™ brackets|The result from this group (10 patients) considered as a gold standard for other two groups through assessing the treatment outcomes using American Board of Orthodontics (ABO) scoring.
62368388|NCT05549089|EXPERIMENTAL|Software-driven indirect bonding tray|The first comparison group (10 patients): digital setup, virtual bracket placement and creation of 3D printing indirect bounding tray by using Maestro® 3D Ortho Studio software.
62368389|NCT05549089|EXPERIMENTAL|Manual-driven indirect bonding tray|the second comparison group (10 patients): digital setup by using Maestro® 3D Ortho Studio software, but the bracket positioning done manually by using Ray Set® device. in this group using double-layer vacuum-formed thermoplastic indirect bonding tray.
62368390|NCT00925067|EXPERIMENTAL|lightweight TiMesh|
62368391|NCT00925067|EXPERIMENTAL|lightweight VyproII|
62368392|NCT00925067|EXPERIMENTAL|Heavyweight Marlex|
62368393|NCT04046601|EXPERIMENTAL|Impedance|every resected tissue will measured by an impedance probe
62368394|NCT01091142|EXPERIMENTAL|NP001|
62368395|NCT01091142|PLACEBO_COMPARATOR|Placebo|
62368396|NCT02030093||High-frequency telephone-based continuing care|High-frequency telephone-based continuing care
62368397|NCT02030093||Low-frequency telephone-based continuing care|Low-frequency telephone-based continuing care
62368398|NCT02030093||SMS group|SMS group
62368399|NCT02030093||Control group|Control group
62368400|NCT05592158|EXPERIMENTAL|Test|Amnion-chorion membrane with collagen plug
62368401|NCT05592158|ACTIVE_COMPARATOR|Control|Collagen plug
62368402|NCT04783376|ACTIVE_COMPARATOR|Arm 1 (usual treatment)|intervention A
62368403|NCT04783376|ACTIVE_COMPARATOR|Arm 2(splitted bolus dose, fast-acting insulin only)|intervention B
62368404|NCT04783376|ACTIVE_COMPARATOR|Arm 3 (splitted bolus dose, fast acting insulin before the meal and regular insulin after the meal)|intervention C
62368405|NCT05412836|EXPERIMENTAL|One Treatment Arm|Subjects will receive a single intra-articular injection of AqueousJoint.
62368406|NCT01070706|EXPERIMENTAL|Paclitaxel, Gemcitabine, Sunitinib|Paclitaxel, Gemcitabine, Sunitinib
62368407|NCT03103776|OTHER|Patients who have Graves disease|
62368408|NCT03103776|OTHER|Patients having a goiter|
62368409|NCT02680561|EXPERIMENTAL|Treatment A: Fp MDPI|Single inhalation dose of Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
62368410|NCT02680561|EXPERIMENTAL|Treatment B: FS MDPI|Single inhalation dose of Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler (FS MDPI) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
62368411|NCT02680561|ACTIVE_COMPARATOR|Treatment C: Comparator|Single inhalation dose of fluticasone propionate/salmeterol (ADVAIR DISKUS) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
62368412|NCT02000219|EXPERIMENTAL|Oxabact OC5 capsule|"This is an open-label study so all patients will receive the active drug product, Oxalobacter formigenes, OC5. This will be administered as an enteric-coated capsules twice daily for 6 weeks of treatment.~In Germany, the protocol has been amended such that patients can receive OC5 for a further 3 year of continued treatment after the initial part of the study."
62368413|NCT05885568|ACTIVE_COMPARATOR|car transportation|blood sample tube will be transported by courier (reference treatment)
62368414|NCT05885568|EXPERIMENTAL|drone transportation|blood sample tube will be prepared for transport by drone (departure from CHAM, 1 hour flight, arrival at CHUAP)
62368415|NCT04905810|EXPERIMENTAL|Treatment (azacitidine, decitabine, venetoclax)|Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7 (for patients with prior decitabine use), or decitabine IV on days 1-5 (for patients with prior azacitidine), and venetoclax PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62368416|NCT04846972||Control group|After inclusion, patients will receive standard care. Women allocated in this group will have the standard care.
62368417|NCT04846972||FASTRACS intervention group|Women allocated in the FASTRACS intervention group will follow a structured care pathway comprising three successive steps (end of chemotherapy interview with a nurse, transitional visit with their GP, pre-RTW visit with their OP), plus one optional step (late visit with an OP- RTW to work coordinator). Four tools will be used during the intervention (RTW guide or checklist for the patient, the GP, the OP and the employer).
62368418|NCT02584023|PLACEBO_COMPARATOR|Control|No intervention during the perioperative period. Perform lung ultrasound twice only for the diagnostic purpose after the endotracheal intubation and and at the end of surgery.
62368419|NCT02584023|ACTIVE_COMPARATOR|Alveolar recruitment|Perform lung ultrasound twice during the perioperative period after the endotracheal intubation and and at the end of surgery. Conduct alveolar recruitment maneuver after first lung ultrasound assessment.
62368420|NCT01553591|EXPERIMENTAL|Eluxadoline 75 mg|Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.
62368421|NCT01553591|EXPERIMENTAL|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.
62368422|NCT01553591|PLACEBO_COMPARATOR|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.
62368423|NCT03815760|EXPERIMENTAL|Exercise with Blood Flow Restriction|"Subjects will perform the sidelying external rotation exercise 2x a week for 8 weeks.~The BFR cuff will be applied to the upper arm. Arterial occlusion will be set to 50%.~Subjects will perform 4 sets (30, 15, 15, 15 reps) with a 30 sec rest period between reps. The occlusion will be maintained for the 8 min treatment period."
62368424|NCT03815760|ACTIVE_COMPARATOR|Exercise without Blood Flow Restriction|"Subjects will perform the sidelying external rotation exercise 2x a week for 8 weeks.~This group will not have BFR applied. Subjects will perform 4 sets (30, 15, 15, 15 reps) with a 30 sec rest period between reps."
62742886|NCT06225518|EXPERIMENTAL|Individualized physical activity management system|The mobile application will be downloaded to the smartphones of the participants in the experimental group and the application will be introduced by the nurse at the family health center. Participants will receive daily and weekly goals with personalized physical activity recommendations, using the exercise recommendations determined by the decision system by public health nursing and physiotherapy and rehabilitation experts in the mobile application. With the initial data collected, a personalized physical activity program will be created according to each participant's lifestyle, physical activity level and physical activity barriers. The physical activity program will include a daily step count goals, exercises and stretching movements for each participant, and this program will be offered to the participants via the mobile application. The exercises that the participants are expected to complete will be shown in the application as videos with animated characters.
62368425|NCT04737759|EXPERIMENTAL|Taking Care of Us|Taking Care of Us involves seven sessions delivered via Zoom to couples over approximately two months. Sessions last approximately 45-60 minutes and are delivered by a trained interventionist. The program is a communication-based, relationship-focused intervention that is strengths-based and fosters new skills to support couples managing heart failure. The goals of the program are to 1) target the couple with heart failure as a team; 2) increase shared appraisal within the couple; 3) improve communication skills within the couple; 4) improve collaboration within the couple and dyadic management of heart failure; 5) improve confidence within the couple; and 6) improve both individual and dyadic health and well-being.
62368426|NCT04737759|ACTIVE_COMPARATOR|SUPPORT|The SUPPORT program involves three sessions delivered via Zoom to couples over approximately two months. Sessions last approximately 45-60 minutes and are delivered by a trained interventionist. This arm is an educational intervention to support management of heart failure.
62368427|NCT04389268||HCV patients|Patients with uncomplicated newly diagnosed hepatitis C virus
62368428|NCT04389268||Control group|Age and sex matched with patients
62368429|NCT04842877|EXPERIMENTAL|Experimental arm|Experimental arm: Valemetostat tosylate (DS-3201b) is given continuously at 200 mg QD.
62368430|NCT02844140|EXPERIMENTAL|Scans|Patients included in the trial will receive DE-CT in stead of SE-CT's.
62368431|NCT06004440||Subjects with biopsy, with or without localization, of pulmonary lesion using Ion Endoluminal System|Subjects in which a pulmonary lesion biopsy, with or without localization, was attempted or performed with the Ion Endoluminal System.
62368432|NCT05666206|ACTIVE_COMPARATOR|Fibrin group|Fibrin sealant covered with 2ry dartos flap.
62368433|NCT05666206|ACTIVE_COMPARATOR|Standard TIP technique|standard TIP technique with second dartos flap and no use of fibrin sealant
62368434|NCT01438359|EXPERIMENTAL|PA21 and Furosemide with food|
62368435|NCT01438359|EXPERIMENTAL|No PA21; Furosemide with food|
62368436|NCT01438359|EXPERIMENTAL|PA21 with food and Furosemide 2hrs later|
62567166|NCT04796532|EXPERIMENTAL|Homebased HIIT|16-week exercise program with HIIT with a frequency of 3 days/week. The Homebased HIIT group participants will attend HIIT workout sessions supervised by a specialised instructor via a videoconference application. This group will have 16 week follow-up.
62368437|NCT05187572|EXPERIMENTAL|Reminiscence Therapy (RT)|The RT program is composed of activities that follow older adults' lifespan (e.g., school, professional life, travelling, holidays and celebrations, historical dates/moments). Such activities allow older adults to revive and share life-changing/significant moments and integrate them into their autobiographical narrative. The program was developed and validated by Gil and colleagues for Portuguese older adults with cognitive decline.
62368438|NCT05187572|EXPERIMENTAL|Cognitive Stimulation (CST)|"The CST intervention was based on the Making a Difference program, specifically developed for older adults with cognitive decline and previously adapted and validated to the European Portuguese language and culture. This program offers a sequence of activities that covers different cognitive domains and promotes older adults' socialization and self-esteem."
62368439|NCT04290260|EXPERIMENTAL|Use of breast bra|Patients allocated on this group wear a breast bra from admission to hospital discharge.
62368440|NCT04290260|ACTIVE_COMPARATOR|Usual care|Usual care: participants will not wear a breast bra until discharge from the hospital
62368441|NCT00195624|EXPERIMENTAL|Relapsed severe aplastic anemia|Subjects diagnosed with relapsed severe aplastic anemia
62368442|NCT00195624|EXPERIMENTAL|Refractory severe asplastic anemia|Subjects diagnosed with refractory severe aplastic anemia
62368443|NCT00195624|EXPERIMENTAL|Relapse after Alemtuzumab|Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit.
62368444|NCT03562624|EXPERIMENTAL|BAY98-7443 (low IND dose)|Combi IUS Treatment, LNG (Levonorgestrel) with lowest dose of IND (indomethacin)
62368445|NCT03562624|EXPERIMENTAL|BAY98-7443 (middle IND dose)|Combi IUS Treatment, LNG with medium dose of IND
62368446|NCT03562624|EXPERIMENTAL|BAY98-7443 (high IND dose)|Combi IUS Treatment, LNG with highest dose of IND
62368447|NCT03562624|ACTIVE_COMPARATOR|Marketed comparator|Marketed comparator IUS
62368448|NCT06224868|ACTIVE_COMPARATOR|PEEP 0|After the patient is intubated, PEEP 0 will be set on the mechanical ventilator.
62368449|NCT06224868|ACTIVE_COMPARATOR|PEEP 5|After the patient is intubated, PEEP 5 will be set on the mechanical ventilator.
62368450|NCT06224868|ACTIVE_COMPARATOR|PEEP 10|After the patient is intubated, PEEP 10 will be set on the mechanical ventilator.
62368451|NCT01121952|PLACEBO_COMPARATOR|Placebo|Single high-velocity, low-amplitude (HVLA) thrust manipulation towards Tibia, not affecting the dysfunctional talo-crural joint
62368452|NCT01121952|EXPERIMENTAL|Treatment|Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation on dysfunctional talo-crural joint
62368453|NCT06353789||Dysmenorrhoea|Reports period pain ≥4/10 and no other chronic pain
62368454|NCT06353789||Controls|Reports period pain ≤3/10 and no other chronic pain
62368455|NCT00148525|EXPERIMENTAL|social cognitive theory|This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory and delivered by an automated telephone system.
62368456|NCT00148525|EXPERIMENTAL|Goal Systems Theory|This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory.
62368457|NCT00148525|NO_INTERVENTION|Comparison group|comparison group
62368458|NCT03395041||ATD - SG 01|"Patients with acute coronary syndrome in whom dental examination performed in the first 7 days after the index event revealed the presence of periodontal disease.~They will undergo complex cardiac imaging tests to assess plaque vulnerability and severity of coronary artery disease."
62368459|NCT03395041||ATD - SG 02|"Patients with acute coronary syndrome in whom dental examination performed in the first 7 days after the index event did not reveal the presence of periodontal disease.~They will undergo complex cardiac imaging tests to assess plaque vulnerability and severity of coronary artery disease."
62368460|NCT03783013|OTHER|No Soy and Low Lycopene Juice|Participants will consume two cans daily of a low lycopene tomato juice in addition to a diet low in lycopene and isoflavones.
62368461|NCT03783013|OTHER|Soy and Lycopene Juice|Participants will consume two cans daily of a high lycopene tomato juice with added soy germ extract in addition to a diet low in lycopene and isoflavones.
62368462|NCT06109129|EXPERIMENTAL|Intervention Group|First group will participate in the Mollii Suit application for 60 minutes 3 days a week. Mollii Suit consists of a pair of trousers and a jacket. It is a neuromodulation garment consisting of a non-invasive removable control unit that sends electrical signals to the user through electrodes inside. The child will wear the Molli Suit when he/she comes to each session, and the child will be asked to sit or lie down throughout the application in order to avoid any interference with the effectiveness of the suit.
62368463|NCT06109129|NO_INTERVENTION|Control Group|The control group will continue the routine pediatric physiotherapy program 3 days a week. This program, which includes exercises appropriate to the child's motor function level, includes stair climbing, walking exercises, balance, strengthening and flexibility exercises.
62368464|NCT05016440|ACTIVE_COMPARATOR|Lisinopril|10mg Lisinopril tablets
62368465|NCT05016440|PLACEBO_COMPARATOR|Sugar pill|sugar pill
62368466|NCT00092391|ACTIVE_COMPARATOR|Control Group|M-M-R(TM) II at current release potency
62368467|NCT00092391|EXPERIMENTAL|Mumps Expiry Group 1|M-M-R(TM) II at intermediate expiry potency
62368468|NCT00092391|EXPERIMENTAL|Mumps Expiry Group 2|M-M-R(TM) II at expiry potency
62368469|NCT05263401|EXPERIMENTAL|Ketone salt|Na-D/L-3-hydroxybutyrate dissolved in tap water.
62368470|NCT05263401|EXPERIMENTAL|Ketone ester|(R)-3-Hydroxybutyl (R)-3-hydroxybutyrate
62368471|NCT05263401|PLACEBO_COMPARATOR|Placebo|Tap water
62368472|NCT02599857|EXPERIMENTAL|CONCOR smartphone application|Use of CONCOR smartphone application
62368473|NCT02599857|NO_INTERVENTION|Standard care (no CONCOR smartphone application)|No CONCOR smartphone application
62368474|NCT01896414|EXPERIMENTAL|EPA (marine fatty acids)|Subjects will receive EPA , four 1 gram capsules daily.
62368475|NCT01896414|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to receive placebo, four 1 gram capsules daily.
62742887|NCT06225518|NO_INTERVENTION|Control|The mobile application will be downloaded to the smartphones of the participants in the experimental and control groups and the application will be introduced by the nurse at the family health center to which the participants are affiliated. Participants in the control group will use the mobile application only to enter and track daily step counts and other data.
62567167|NCT04796532|EXPERIMENTAL|Traditional HIIT|16-week exercise program with HIIT with a frequency of 3 days/week. The Traditional-HIIT group participants will attend presential HIIT workout sessions supervised. This group will have 16 week follow-up.
62567168|NCT02702830||Diagnostic (MRI and CPET)|Patients undergo CPET using a one-way breathing mask in 2 separate days 1-2 weeks apart. Patients also undergo MRI before and within 60 seconds after exercising.
62742888|NCT02989584|EXPERIMENTAL|Atezolizumab, Gemcitabine, Cisplatin|"This is a two phase study with a single study arm for each phase.~For Phase 1: Following enrollment participants will be treated with combination therapy on a 21 day cycle x 6 cycles. Gemcitabine (1000 mg/m2 on Day 1 and Day 8), cisplatin (70 mg/m2 on Day 1), and atezolizumab (1200 mg on Day 8) will be administered intravenously.~Phase 2: Following enrollment participants will be treated with a single dose of atezolizumab alone followed by combination therapy on a 21-day cycle x 4 cycles, followed by a single dose of atezolizumab alone. Gemcitabine 1000mg/m2, cisplatin (70 mg/m2 on Day 1), and atezolizumab (1200 mg on Day 8) will be administered intravenously."
61986278|NCT02331147|SHAM_COMPARATOR|Standard of Care|Surgical debridement of DFU, The wound will be debrided and cleaned. Patient ulcers will be assessed and measured weekly in cm length by width. Application of collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice off loading
62368476|NCT05226767|ACTIVE_COMPARATOR|Active Arm|Patients who receive treatment with the NLC-V research product depending on the weight of the patients, as follows - Patients weighing less than 70 kg will receive 2 capsules, 4 times a day (80 mg in total per day) Patients weighing between 70 kg and 100 Kg will receive 3 capsules, 4 times a day (a total of 120 mg per day). Patients weighing over 100 kg will receive 4 capsules, 4 times a day (a total of 160 mg per day). NLC-V capsules Will be taken during days 1-10 for the patient's hospitalization NLC-V capsules will be taken during days 1-10 for the patient's hospitalization
62368477|NCT05226767|PLACEBO_COMPARATOR|Placebo|Patients who receive placebo in addition to the usual treatment for COVID-19. The placebo consists of the same solvent, but without the active ingredients of NLC-V. Placebo will be given to patients in the same manner and with the same frequency as NLC-V
62368478|NCT03444467|EXPERIMENTAL|NNC9204-1513|Participants will receive increasing doses of NNC9204-1513.
62368479|NCT03444467|ACTIVE_COMPARATOR|Glucagon|Participants will receive a single fixed dose of glucagon.
62368480|NCT00796224|ACTIVE_COMPARATOR|1.|60 mg/kg azithromycin ER (Extended Release)arm
62368481|NCT00796224|ACTIVE_COMPARATOR|2.|30 mg/kg azithromycin IR (Immediate Release) arm
62368482|NCT01604434|SHAM_COMPARATOR|Incubator-no plastic bag|Placement into an incubator without a plastic bag
62368483|NCT01604434|ACTIVE_COMPARATOR|Incubator-torso bag|Placement into a plastic bag inside incubator
62368484|NCT06097741|OTHER|MRI sequence|patients receive an MRI
62368485|NCT05243147|EXPERIMENTAL|nasal stents|using nasal stents after septoplasty
62368486|NCT05243147|OTHER|merocel|using merocel as nasal packing after septoplasty
62368487|NCT02774291|EXPERIMENTAL|Treatment (mTCR, aldesleukin)|Patients receive standard cyclophosphamide IV over 1 hour on days -7 to -6 and fludarabine phosphate via IVPB over 30 minutes on days -5 to -1 followed by anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes IV over 20-30 minutes on day 0 and aldesleukin IV over 15 minutes approximately every 8 hours on days 0-4. Patients also receive filgrastim SC on days 1-4.
62368488|NCT02515188|EXPERIMENTAL|propacetamol group|
62368489|NCT02515188|PLACEBO_COMPARATOR|placebo group|
62368490|NCT02038725||TIA in last 2 weeks|
62368491|NCT01548209|EXPERIMENTAL|Group D|A single dose dexmedetomidine 0.5 mcg/kg iv. 30 min before end of the surgery
62742889|NCT03631771|EXPERIMENTAL|Iodixanol, iohexol, iopromide, or ioversol|Investigational medicinal product administered intravascularly per usual clinical practice at each participating institution. Doses will be per usual practice. The dose of ICM, timing of ICM administration in relation to the diagnostic procedure, rate of ICM administration, and route of ICM administration will be determined by the physician performing the enhanced radiologic procedure per medical need and local clinical practice.
62368492|NCT01548209|PLACEBO_COMPARATOR|Group P|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
62368493|NCT04787263|EXPERIMENTAL|CD19-CAR_Lenti|Following lymphodepletion with chemotherapy (fludarabine + cyclophosphamide), patients will be treated with 1.0 to 3.0 x 10\^6/kg CD19-Chimeric Antigen Receptor (CAR)_Lenti positive cells as a single dose. The product will be infused fresh, at the end of manufacturing.
62368494|NCT00651768|EXPERIMENTAL|1|
62368495|NCT00651768|SHAM_COMPARATOR|2|
62368496|NCT04308928||Children with suspected meningitis|Patients must have a clinical diagnosis of meningitis including one or more of the following symptoms: headache, irritability, vomiting, fever and neck stiffness (Table 1). The diagnosis of probable or possible TBM is based on 1) clinical findings 2) CSF results 3) neuroimaging findings 4) evidence for TB outside the central nervous system and 5) additional laboratory criteria. A scoring system then determines whether a patient falls in the probable or possible TBM category. Points are allocated for a positive finding in each of the categories, with a maximum score for each category. A total score of at least 10 is compatible with probable TBM, while a total score of at least 6 equates with a possible TBM diagnosis.
62368497|NCT04308928||Children with definite tuberculous meningitis|Definite TBM requires demonstration of acid- fast bacilli in the CSF, Mycobacterium tuberculosis culture from CSF, a positive nucleic acid amplification test (PCR) of CSF or histopathological evidence of Mycobacterium tuberculosis from a central nervous system site.
62368498|NCT04556929|EXPERIMENTAL|Intraoperative imaging of 5-ALA during tumour resection|Participants will undergo 5-ALA guided tumour resection via craniotomy with the aim of achieving maximal safe tumour resection without significant neurological deficit. On completion of tumour resection, digital images will be taken of the resection cavity under blue light using (i) an in-built camera in the operative microscope and (ii) an ultra-high sensitivity camera attached to the side arm of the operative microscope. Biopsies approximately 5x5x5mm in size will then be taken from the anterior, posterior, lateral and inferior areas of the resection cavity which were imaged. These biopsies will be analysed by histopathology to determine the presence of glioma cells.
62368499|NCT04362189|EXPERIMENTAL|HB-adMSCs|Subjects assigned to this arm will receive 4 intravenous infusions of HB-adMSCs at 100 million cells/dose. HB-adMSC infusions will occur at day 0, 3, 7, and 10.
62742890|NCT05512065|EXPERIMENTAL|Ultrasound|Ultrasound will be used to measure velocimetric indices of both right and left uterine arteries and umbilical artery.
62368500|NCT04362189|PLACEBO_COMPARATOR|Placebo|Subjects assigned to this arm will receive 4 intravenous infusions of placebo (saline solution). Infusions will occur at day 0, 3, 7, and 10.
62368501|NCT01072240||Cohort|
62368502|NCT05682768||Patients|Patients with cancer pancreas with soft pancreas and non-dilated pancreatic duct
62368503|NCT02155504|EXPERIMENTAL|ASP3700 single ascending dose cohort|Part 1
62368504|NCT02155504|PLACEBO_COMPARATOR|Placebo single ascending dose cohort|Part 1
62368505|NCT02155504|EXPERIMENTAL|ASP3700 alone|Part 2
62368506|NCT02155504|ACTIVE_COMPARATOR|ASP3700 and itraconazole|Part 2
62742891|NCT00962533|EXPERIMENTAL|ROADMAP Group (Group I)|"Patients were to take telbivudine 600 mg orally daily from Baseline.At Week 24, patients in Group I were split into Group I-A or Group I-B based on their virologic load:~* Group I-A: This group of patients was those with HBV DNA ≥300 copies/mL at Week 24 and adefovir was to be added at Week 28;~* Group I-B: This group of patients was those with HBV DNA \<300 copies/mL at Week 24. Telbivudine monotherapy was to be continued until there was a viral breakthrough (confirmed by two examinations with at least 1 month interval with compliance factor excluded) and then adefovir was to be added;~The total treatment duration was 104 weeks."
62742892|NCT00962533|ACTIVE_COMPARATOR|SOC (Standard of Care) Group (Group II)|patients were to take telbivudine 600 mg monotherapy from Baseline until Week 104. If viral breakthrough (defined as HBV DNA 1 log10 above nadir) was confirmed (by two examinations with at least a 1 month interval with compliance factor excluded), adefovir 10 mg daily was to be added.
62742893|NCT04424823|EXPERIMENTAL|LED|LED photobiomodulation therapy for the non-specific LBP working nurse
62742894|NCT04424823|SHAM_COMPARATOR|Sham|Shame group. The all procedure was same as the LED group but the LED ped was upside down without direct treatment.
62742895|NCT02684877||Intensive care survivors|Observational study
62742896|NCT03296137|EXPERIMENTAL|Tumor-infiltrating Lymphocyte (TIL) Therapy with checkpoint inhibitors|
62742897|NCT01647243|EXPERIMENTAL|Preoperative strength training|Progressive strength training on group basis four weeks before the operation and progressive strength training on group basis four weeks after the operation
62742898|NCT01647243|NO_INTERVENTION|Living as usual|The patients are living as usual the last 4 weeks before operation
62742899|NCT06658795|EXPERIMENTAL|Left DLPFC stimulation group|The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. Based on the EEG 10-20 international system, the positive electrode was placed at position F3, and the negative electrode was placed in the right supraorbital area/FP2 (e.g., Dubreuil-Vall et al., 2021, Biol Psychiatry: CNNI)
62742900|NCT06658795|EXPERIMENTAL|Right VLPFC stimulation group|The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. Based on the EEG 10-20 international system, the positive electrode for stimulating the right VLPFC was placed at position F6, while the negative electrode was placed in the left supraorbital area/FP1 (e.g., He et al., 2020, Psychol Med).
62742901|NCT06658795|SHAM_COMPARATOR|Sham stimulation group|In the sham stimulation group, the electrode positions were randomized to match those of the rVLPFC or lDLPFC groups, but the stimulation only lasted for the first 30 seconds.
62742902|NCT02899455|EXPERIMENTAL|Experimental|HGP0904 + HGP0608 + HGP0816, once daily
62742903|NCT02899455|ACTIVE_COMPARATOR|Active Comparator1|HGP0904 placebo + HGP0608 + HGP0816, once daily
62742904|NCT02899455|ACTIVE_COMPARATOR|Active Comparator2|HGP0904 + HGP0608 + HGP0816 placebo, once daily
62742905|NCT01033006|ACTIVE_COMPARATOR|Arm 1: catheter injection|40 ml of LA through the catheter
62742906|NCT01033006|ACTIVE_COMPARATOR|Arm 2: transarterial injection|30 ml deep and 10 ml superficial to the artery
62368507|NCT06168474|EXPERIMENTAL|Simplified layered consent process|For participants randomized to the SIMPLY-SNAP experimental group, a simplified layered consent process will be used to explain information for the SNAP trial. The research staff member obtaining consent will provide a standardized explanation, providing summarized information in simple English or French contained in a 4-page concise participant information sheet. Throughout the consent process, the research staff member will answer any questions that the participant has, to reflect routine consent discussion practice.
62368508|NCT06168474|ACTIVE_COMPARATOR|Full-length consent form|For participants randomized to the control group, the existing consent process will be used including going through the currently approved full-length informed consent form. The research staff member will provide an explanation using the full-length informed consent form as per standard clinical trial procedures. Similarly, throughout the consent process, the research staff member will answer any participant questions as per normal procedures.
62368509|NCT03104959|PLACEBO_COMPARATOR|Placebo|Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take placebo capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
62368510|NCT03104959|EXPERIMENTAL|N-acetyl cysteine|Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take N-Acetyl Cysteine capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
62368511|NCT02108444||group with HBV reactivation|group with hepatitis B virus reactivation
62368512|NCT02108444||group without HBV reactivation|group without hepatitis B virus reactivation
62368513|NCT05068427|EXPERIMENTAL|Chidamide + Envafolimab|Patients receive Chidamide 20mg or 30mg orally twice per week and Envafolimab 400mg subcutaneous infusions every 4 weeks untile disease progression or unacceptable toxicity.
62368514|NCT05837507|EXPERIMENTAL|Experimental|"A group of 29 patients with ALS will be formed to the multimodal digital platform associated with Non Invasive Ventilation (NIV) and usual management~Patients will be treated with NIV equipment from the manufacturer LOWENSTEIN and will benefit from the usual follow-up carried out at the reference center of Montpellier University Hospital."
62368515|NCT05837507|ACTIVE_COMPARATOR|Control Comparator|"A group of 29 patients with ALS will be formed : control group following usual management including NIV.~Patients will be treated with NIV equipment from the manufacturer LOWENSTEIN and will benefit from the usual follow-up carried out at the reference center of Montpellier University Hospital."
62368516|NCT04386473||Left Bundle Branch Pacing|
62368517|NCT04386473||Right Ventricular Outflow Tract Septal Pacing|
62368518|NCT04974957|EXPERIMENTAL|SHR-1701+BP102|
62368519|NCT04625088|EXPERIMENTAL|Standardized liquid test meal|
62368520|NCT04625088|EXPERIMENTAL|Atropine + Standardized liquid Test meal|
62368521|NCT05428540|EXPERIMENTAL|Intervention group|Polyphenol-rich dietary supplement (3 capsules/day) + hypocaloric diet (1,200 kcal/day)
62368522|NCT05428540|PLACEBO_COMPARATOR|Control group|Placebo (3 capsules/day) + hypocaloric diet (1,200 kcal/day)
62368523|NCT04469257|EXPERIMENTAL|Sunbathing|During the activities for the intervention group, the individuals were exposed directly to sun in the nursing home garden on open and sunny days without sunscreen for five days a week for a month with an average of 21.0 ± 5.0 min (min 15 min - max 30 min). About 30-35% of their bodies (hand, face, neck, forearm open up to elbows and legs open up to the knee caps) were open. Sunbathing sessions were held between 10:30 and 11:30 to prevent elderly individuals from being affected by extreme temperatures, and UV index values were monitored during the time and duration of the event at WHO website (http://www.who.int/uv/resources/link/indexlinks/en/, Access date: July 1, 2018). During the hours of the day when UV index was \> 6-7, elderly individuals were not taken out. After each sunbathing session, elderly individuals in the intervention group were evaluated for sensitivity and erythema that may occur in the exposed body areas
62368524|NCT04469257|NO_INTERVENTION|Control|Elderly individuals in the control group were not invited to the activities held in the nursing home garden. There were no restrictions on them for not going out in the sun or spending time inside the nursing home
62368525|NCT02451189|EXPERIMENTAL|Inulin acetate ester|Inulin acetate ester, 10g/day for 30 days
62368526|NCT02451189|EXPERIMENTAL|Inulin propionate ester|Inulin propionate ester, 10g/day for 30 days
62368527|NCT02451189|EXPERIMENTAL|Inulin butyrate ester|Inulin butyrate ester, 10g/day for 30 days
62368528|NCT03788967|EXPERIMENTAL|TBPM-PI-HBr 600 mg|TBPM-PI-HBr 600 mg (300 mg×2 ) film-coated tablets, administered orally three times per day (every 8 hours \[q8h\] ± 0.5 h) plus a single dummy IV infusion over 30 minutes (min) once daily (every 24 hours \[q24h\] ± 0.5 h) up to Day 15; participants with moderate renal insufficiency (creatinine clearance \[CrCl\] \>30 to ≤50 mL/min) required TBPM-PI-HBr dosage adjustment to 300 mg (one tablet) q8h ± 0.5 h.
62368529|NCT03788967|ACTIVE_COMPARATOR|Ertapenem 1 g|Ertapenem for IV injection, administered as a 1-gram IV infusion over 30 min once daily (q24h ± 0.5 h) plus dummy placebo tablets administered orally q8h (±0.5 h) up to Day 14; no dose adjustment of ertapenem was required for participants with renal insufficiency.
62742907|NCT01033006|ACTIVE_COMPARATOR|Arm 3: catheter and transarterial injection|20 + 10 ml transarterial block and 10 ml through the catheter
62742908|NCT01258933|EXPERIMENTAL|Ofatumumab|Ofatumumab 300 mg dose 1, then 1,000 mg weekly \* 7, (treatment) then 1,000 mg every 2 months beginning on week 12 for a total of 2 years of treatment or until progression (maintenance) of disease. The follow-up period will be the period after completion of maintenance.
62742909|NCT01545791||Insulin detemir users|
62742910|NCT03044119|ACTIVE_COMPARATOR|Dental Implant with PRFM|Intervention in the form of Dental Implants placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix a biological material procured from patient's peripheral blood
62742911|NCT03044119|EXPERIMENTAL|Dental Implant with PRFM and PBMSCs|Intervention in the form of Dental Implant placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix and peripheral blood mesenchymal stem cells which are the biological materials procured from patient's peripheral blood
62742912|NCT06114914||ISLAND cohort|About 1,000 participants completed hand motor and speech tests online and 150 will attend the research centre for usablity assessments
62742913|NCT06114914||Clinical|The new app will be tested in about 100 patients at each of the ISLAND Cognitive Clinic or the Royal Hobart Hospital
62742914|NCT02814240|EXPERIMENTAL|Pituitary gland failure|
62742915|NCT06035172|EXPERIMENTAL|guided imagery group|
62368530|NCT05434936|OTHER|Collection|There is only one arm of the study, all patients enrolled will have surgery in which the attempt will be made to collect ovarian tissue.
62368531|NCT05154643||patients with liver fibrosis|
62368532|NCT05154643||healthy controls|
62742916|NCT06035172|EXPERIMENTAL|music group|
62368533|NCT05324956||Postmenopausal Women|Postmenopausal women be between 40-79 years and being diagnosed with osteoporosis or osteopenia
62368534|NCT04333992|ACTIVE_COMPARATOR|propofol-remifentanil group|"Anesthetic induction was achieved with an initial target concentration of propofol 4 ㎍/mL and remifentanil 3-4 ng/mL.~Anesthesia was maintained with a fixed target concentration of propofol 2-4 ㎍/mL and remifentanil 2-3 ng/mL"
62368535|NCT04333992|ACTIVE_COMPARATOR|sevoflurane-remifentanil group|"Anesthetic induction was achieved with thiopental 5 mg/kg and initial target concentration of remifentanil 3-4 ng/mL.~Anesthesia was maintained with 1.5-2.5% end-tidal concentration sevoflurane in 50% oxygen with air and remifentanil 2-3 ng/mL"
62368536|NCT01948349|NO_INTERVENTION|Non-tongue scraping and twin brackets|Patients in this subgroup will be instructed to follow standard at-home oral hygiene protocols. They will be instructed by the study coordinators to utilize the traditional Bass brushing technique \[31\], brushing twice daily (morning and night) for 2 minutes each time. Patients will all be given the same toothbrush and toothpaste to use during the study. They will also be instructed on the method of flossing and be shown how to use interdental brushes to clean around the orthodontic appliances.
62368537|NCT01948349|EXPERIMENTAL|Tongue scraping with standard twin brackets|Patients allocated to this group will receive the same oral hygiene protocol as the non-tongue scraping subjects. However, they will also be in instructed and asked to use the tongue-scraping method of cleaning the tongue as part of their oral hygiene regimen. Patients will be instructed to scrape the tongue once during their nighttime oral hygiene session of brushing and flossing. All patients in this subgroup will be given the same tongue scraper.
62368538|NCT01948349|EXPERIMENTAL|No tongue scraping with self-ligating brackets|Patients in this group are treated with passive self-ligating Carrier brackets (Ortho Organizer). They will be instructed to use the traditional Bass brushing technique, brushing twice daily (morning and night) for 2 minutes each time. Patients will all be given the same toothbrush and toothpaste to use during the study. They will also be instructed on the method of flossing and be shown how to use interdental brushes to clean around the orthodontic appliances.
62368539|NCT01948349|EXPERIMENTAL|Tongue scraping with SLB|Patients in this group are treated with passive self-ligating Carrier brackets (Ortho Organizer). Patients allocated to this group will receive the same oral hygiene protocol as non-tongue scraping subjects. However, they will also be in instructed and asked to use the tongue-scraping method of cleaning the tongue as part of their oral hygiene regimen. Patients will be instructed to scrape the tongue once during their nighttime oral hygiene session of brushing and flossing. All patients in this subgroup will be given the same tongue scraper.
62368540|NCT01826448|EXPERIMENTAL|Dose extension cohort|Patients will take PLX3397 and vemurafenib at the recommended phase 2 dose. This will be determined by the tolerability and safety of these drugs in the previous 3 cohorts.
62368541|NCT01826448|EXPERIMENTAL|Cohort 3|Patients will take 1000mg/day of PLX3397 and 960mg BID of vemurafenib
62368542|NCT01826448|EXPERIMENTAL|Cohort 2|Patients will take 800mg/day of PLX3397 and 960mg BID of vemurafenib
62368543|NCT01826448|EXPERIMENTAL|Cohort 1|Patients will take 800mg/day of PLX3397 and 720mg BID of vemurafenib
62368544|NCT05743257||Experimental group|Volunteers living in a deprived neighborhood with urban transformations in Paris (France)
62368545|NCT05743257||Control group|Volunteers living in a deprived neighborhood without urban transformations in Paris (France).
62368546|NCT00033449|EXPERIMENTAL|Treatment (gefitinib, radiation therapy, cisplatin)|See detailed description.
62368547|NCT01791790|EXPERIMENTAL|0,75 Hz stimulation|slow transcranial oscillating stimulation (\~0,75Hz) during periods of Slow Wave Sleep
62368548|NCT01791790|SHAM_COMPARATOR|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
62742917|NCT06035172|NO_INTERVENTION|Control group|
62368549|NCT03530761||Acute kidney injury|Increase in serum creatinine more than 0.3 mg/dl within 48 hours or a percentage increase serum creatinine more than 50% from baseline.
62368550|NCT03530761||Hepatorenal syndrome|"1. Diagnosis of cirrhosis and ascites,~2. Diagnosis of AKI according to ICA-AKI criteria~3. No response after 2 consecutive days of diuretic withdrawal and plasma volume expansion with albumin 1 g per kg of body weight~4. Absence of shock~5. No current or recent use of nephrotoxic drugs (non-steroidal anti-inflammatory drugs, aminoglycosides, iodinated contrast media, etc.)~6. No macroscopic signs of structural kidney injury, defined as: absence of proteinuria (\> 500 mg/day), absence of microhaematuria (\> 50 RBCs per high power field), normal findings on renal ultrasonography."
62742918|NCT06203457|EXPERIMENTAL|efgartigimod|Participants will receive efgartigimod IV infusions
62742919|NCT02815696|EXPERIMENTAL|lumbar spine segmental instability|Patients with a segmental instability of the lumbar spine having undergone surgery. Lumbar spine instability diagnosis is based on imaging (Magnetic resonance imaging, standard radiography, and EOS imaging). Surgical treatment is indicated if the pain is relieved by wearing a brace during at least three months.
62742920|NCT00678938|EXPERIMENTAL|1|
62742921|NCT00678938|EXPERIMENTAL|2|
62742922|NCT00678938|NO_INTERVENTION|3|
62742923|NCT06659016|ACTIVE_COMPARATOR|Group A|
62742924|NCT06659016|EXPERIMENTAL|Group B|Dietary supplement of D-mannose, collagen, hyaluronic acid, chondroitin sulphate, propolis plus quercetin (Proqutin ®) and Bacillus Coagulans (Uroxin 4G, Pharmasuisse laboratories, Milan, Italy) administered twice daily for seven days in the first month, then once daily for 14 days a month for two months, repeated every three months for a total treatment duration of 12 months.
62742925|NCT06659016|EXPERIMENTAL|Group C|Combination of treatment A and B
62742926|NCT03515135|EXPERIMENTAL|Intervention group|"Subjects in this group will receive the Metacognitive Executive Function Training (MEFP) program in aiming to reduce ADHD symptoms and improve the executive function."
62742927|NCT03515135|NO_INTERVENTION|Waiting group|Subjects in this group will not receive the MEFP program during the study period.
62742928|NCT04451226|EXPERIMENTAL|Fezolinetant|Participants will receive fezolinetant 30 milligrams (mg) orally once daily for 52 weeks.
62742929|NCT04918290|EXPERIMENTAL|Tegaderm Left|After general anesthesia is administered, Tegaderm will be placed on the left eye and Transpore will be placed on the right eye
62368551|NCT05148117||suspected sepsis group|We will perform a prospective observational study of patients admitted to the intensive care units (ICU) with suspected sepsis or septic shock.
62368552|NCT05148117||control group|This group will be compared to suspected sepsis or sepsis shock patients. The control group will be age matched, gender-matched, and cardiovascular risk-factor matched controls.
62368553|NCT04228445|EXPERIMENTAL|HIGH DOSE|48 subjects randomly treated with 5 mL of drug
62368554|NCT04228445|EXPERIMENTAL|LOW DOSE|48 subjects randomly treated with 2.5 mL of drug
62368555|NCT04228445|PLACEBO_COMPARATOR|Saline|96 subjects treated with 5 ml of saline than crossover to treatment arm
62368556|NCT00767793|PLACEBO_COMPARATOR|Arm 1|One drop in each eye every 12 hours for seven days
62368557|NCT00767793|EXPERIMENTAL|Arm 2|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
62368558|NCT00767793|EXPERIMENTAL|Arm 3|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
62368559|NCT00767793|EXPERIMENTAL|Arm 4|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
62368560|NCT05001568|EXPERIMENTAL|Optimized Providence brace|The braces will be designed using optimization and finite element analysis.
62368561|NCT05001568|ACTIVE_COMPARATOR|Conventional Providence brace|The braces will be designed by an orthotist using the conventional design method.
62368562|NCT05810389|EXPERIMENTAL|FFA toothbrush|
62368563|NCT05810389|ACTIVE_COMPARATOR|Varnish|
62368564|NCT05810389|ACTIVE_COMPARATOR|FFA gel|
62368565|NCT03081572||Abacavir Group|HIV positive individuals currently taking an abacavir based regimen
62368566|NCT03081572||Tenofovir Group|HIV positive individuals currently taking a tenofovir based regime
62368567|NCT00493714||Arm 1 (Patient)|Cancer patient who recently experienced confusion or restlessness.
62368568|NCT00493714||Arm 2 (Caregiver)|Caregivers of cancer patients who recently experienced confusion or restlessness.
62368569|NCT06450808|EXPERIMENTAL|Pesto with 3% Phaeodactylum|Dried Microalgae integrated in the Pesto
62368570|NCT06450808|EXPERIMENTAL|Pesto with 4% Phaeodactylum|Dried Microalgae integrated in the Pesto
62368571|NCT06450808|EXPERIMENTAL|Pesto with 5% Phaeodactylum|Dried Microalgae integrated in the Pesto
62368572|NCT01505114|EXPERIMENTAL|Arm 1|MVC 300 mg plus FTC placebo and TDF placebo orally once daily
62742930|NCT04918290|EXPERIMENTAL|Transpore Right|After general anesthesia is administered, Transpore will be placed on the right eye and Tegaderm will be placed on the left eye.
62368573|NCT01505114|EXPERIMENTAL|Arm 2|MVC 300 mg plus FTC 200 mg and TDF placebo orally once daily
62368574|NCT01505114|EXPERIMENTAL|Arm 3|MVC 300 mg plus FTC placebo and TDF 300 mg orally once daily
62368575|NCT01505114|EXPERIMENTAL|Arm 4|MVC placebo plus FTC 200 mg and TDF 300 mg orally once daily
62368576|NCT03932890|ACTIVE_COMPARATOR|Lower Volume fluid bolus arm|The 'lower volume' (LV) fluid bolus arm will receive a continuous background infusion of 4% dextrose in 0.18% NaCl at 50ml/hr for the entire 4 hour rehydration period. Subjects will be given a hand-held trigger, which when pressed will deliver an additional volume of fluid from the infusion pump; this will be administered over a 10-minute period (thus allowing a maximum of 6 boluses per hour). In the LV arm, the trigger will deliver 50mls over 10 mins at a rate of 300ml h-1. A green LED will signal to the patient that no additional infusion is running, and that pressing the trigger will activate delivery of another bolus. The volume and lockout periods for the boluses may vary but will remain within the maximum fluid administration of 1200mls per hour.
62368577|NCT03932890|EXPERIMENTAL|Higher Volume fluid bolus arm|The 'higher volume' (HV) fluid bolus arm will receive a continuous background infusion of 4% dextrose in 0.18% NaCl at 50ml/hr for the entire 4 hour rehydration period. Subjects will be given a hand-held trigger, which when pressed will deliver an additional volume of fluid from the infusion pump; this will be administered over a 10-minute period (thus allowing a maximum of 6 boluses per hour). In the HV arm, the trigger will deliver 200mls over 10 mins at a rate of 1200ml h-1. A green LED will signal to the patient that no additional infusion is running, and that pressing the trigger will activate delivery of another bolus. The volume and lockout periods for the boluses may vary but will remain within the maximum fluid administration of 1200mls per hour.
62368578|NCT05228704|EXPERIMENTAL|activities in the Botanical Garden or Urban|experiment group is activities in the Botanical Garden, and the control group is activities in urban
62368579|NCT05228704|OTHER|Cross-over design|The participants are randomized divided into in two groups following by the experiment which is designed by two consecutive times at one week intervals, and the experimental activities and the control activities are staggered.
62368580|NCT06262204|OTHER|conventional group|standard surgery with metal screw
62368581|NCT06262204|EXPERIMENTAL|Shark Screw® group|new surgical procedure with human allogeneic cortical bone screw
62368582|NCT01226472|EXPERIMENTAL|KW-0761|
62368583|NCT04276779|EXPERIMENTAL|Alcohol and Negative Mood|
62368584|NCT04276779|PLACEBO_COMPARATOR|Placebo and Negative Mood|
62368585|NCT04276779|ACTIVE_COMPARATOR|Alcohol and Positive Mood|
62368586|NCT04276779|PLACEBO_COMPARATOR|Placebo and Positive Mood|
62742931|NCT04739670|EXPERIMENTAL|Atezolizumab, Bevacizumab, Gemcitabine and Carboplatin|Atezolizumab 1200 mg Day 1 of each 21 day cycle IV, Bevacizumab 15 mg/kg Day 1 of each 21 day cycle IV, Gemcitabine 1000 mg/m2 Day 1 and 8 of each 21 day cycle IV, Carboplatin AUC 5 Day 1 of each 21 day cycle IV
62742932|NCT00654745|EXPERIMENTAL|aml + olm + hctz|amlodipine; and olmesartan medoxomil, if required; and hydrochlorothiazide, if required.
62742933|NCT00413894|EXPERIMENTAL|1|
62742934|NCT04270578||Women with GDM|
62742935|NCT04270578||Women without GDM|
62742936|NCT04650568|EXPERIMENTAL|Mesenchymal Stem Cell Recipient|Patients in this group will receive between 1-4 ml of bone marrow aspirate concentrate (BMAC) containing mesenchymal stem cells (MSCs) obtained from their iliac crest. A small incision will be made on the anterior superior iliac spine in order to withdraw the aspirate. The aspirate will be ran through a centrifuge in order to isolate the BMAC containing MSCs. The BMAC will be injected into the ACL allograft prior to implanting into the patient.
62368587|NCT04580888|EXPERIMENTAL|Intervention arm|Assessment using an early transthoracic echocardiography (after 500 mL of fluids) to identify the hemodynamic profile responsible for the acute circulatory failure associated with sepsis / septic shock and to guide ongoing treatment (therapeutic algorithm) and monitor its efficacy and tolerance.
62368588|NCT04580888|OTHER|Control arm|Conventional management according to current standards of care based on SSC recommendations, including a standardized fluid resuscitation of 30 mL/kg.
62368589|NCT04053218|ACTIVE_COMPARATOR|Exercise and supplement|Supervised aerobic exercise three times weekly and daily omega-3 supplements
62368590|NCT04053218|PLACEBO_COMPARATOR|Placebo|Olive oil capsules. No supervised exercise but written recommendations for daily physical activity from the American Heart Association
62368591|NCT01055470|ACTIVE_COMPARATOR|Diclofenac|Tab.Diclofenac 50 mg ,Orally, 12 hrly in morning and in evening after taking food for 3 months.
62368592|NCT01055470|EXPERIMENTAL|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
62368593|NCT04336111|NO_INTERVENTION|control group|will receive sham bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position.
62368594|NCT04336111|EXPERIMENTAL|retrolaminar block|will receive real bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position. The total desired volume used in the whole injection will be 40 ml containing 3mg / kg bupivacaine with adrenaline 2.5 2 µg/ml. The total 40 ml volume will be divided into 10 ml for each injection.
62368595|NCT05287724|EXPERIMENTAL|N-acetyl Cysteine then Placebo|Subjects will be treated with N-acetyl cysteine twice daily for seven days. Subject will complete a minimum of 30-day washout period before crossing over to take the placebo.
62368596|NCT05287724|EXPERIMENTAL|Placebo then N-acetyl Cysteine|Subjects will be treated with placebo twice daily for seven days. Subject will complete a minimum of 30-day washout period before crossing over to take N-acetyl cysteine.
62368597|NCT05720962|EXPERIMENTAL|experimental group|The experimental group will be provided with routine midwife support and uninterrupted accompanying support.
62368598|NCT05720962|NO_INTERVENTION|control group|Only routine midwife support will be provided to the control group.
62368599|NCT01105949|OTHER|Marketed nasal strip|Marketed nasal strip
62368600|NCT01105949|EXPERIMENTAL|NexGen JB Organic PET/PE|NexGen JB Organic PET/PE, prototype nasal dilator strip
62368601|NCT01105949|EXPERIMENTAL|NexGen AB 2R11|NexGen AB 2R11
62368602|NCT02002065||Inactivated HAV vaccine|Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
62368603|NCT02002065||Attenuated alive HAV vaccine|Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
62742937|NCT04650568|PLACEBO_COMPARATOR|Control Sham Incision|Patients will receive a sham incision on the anterior superior iliac spine where the bone marrow aspirate is obtained in the the experimental group. This ensures proper blinding. The patient will receive the normal standard of care.
62742938|NCT05955820|EXPERIMENTAL|Conventional exercises for impingement syndrome|Four exercises (prone extension, side-lying external rotation, side-lying forward flexion, prone horizontal abduction with external rotation) will be performed for three sets of 10 repetitions
62742939|NCT05955820|EXPERIMENTAL|Suspension system exercises for impingement syndrome|Four exercises (Kneeling shoulder extension, Supine/ standing / kneeling row, sitting press up, kneeling push up) will be performed for 3-6 sets of 10 repetitions
62368604|NCT06362395|EXPERIMENTAL|MRL adaptive high dose|Magnetic resonance (MR)-guided stereotactic ablative single-fraction with high dose radiation (27Gy)
62368605|NCT06362395|OTHER|MRL adaptive ultra-high dose|Magnetic resonance (MR)-guided stereotactic ablative single-fraction with ultra-high dose radiation (38Gy)
62368606|NCT05597904||Coeliac disease patients|Adult (18 years or over) patients with previous coeliac disease or dermatitis herpetiformis diagnosis
62368607|NCT05597904||Healthy controls|500 adult (18 years or over) friends or non-related family members of coeliac disease or dermatitis herpetiformis patients participating in the study, no previous coeliac disease or dermatitis herpetiformis diagnosis. In addition 1000 controls will be included from Biobank
62368608|NCT04412772|EXPERIMENTAL|Tocilizumab (TCZ) Arm|Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen.
62368609|NCT04412772|PLACEBO_COMPARATOR|Placebo Arm|Participants will receive 1 IV infusion of placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
62368610|NCT01378845|PLACEBO_COMPARATOR|Prostavasin|
62368611|NCT01378845|ACTIVE_COMPARATOR|Prostavasin + Bosentan|
62368612|NCT04273841|ACTIVE_COMPARATOR|Caffeine Group|This group will receive caffeine gum.
62368613|NCT04273841|PLACEBO_COMPARATOR|Placebo|This group will receive gum without caffeine.
62368614|NCT00797810|EXPERIMENTAL|therapy|
62368615|NCT03304262|ACTIVE_COMPARATOR|Cathodal tDCS + rTMS then Anodal tDCS + rTMS then Sham tDCS + rTMS|Participant will receive 10 minutes of cathodal tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2. After 1 week washout, participant will receive 10 minutes of anodal tDCS and rTMS for 900 1Hz pulses at 0.85 RMT. After 1 week washout, participant will receive 10 minutes of sham tDCS and rTMS for 900 1 Hz pulses at 0.85 RMT.
62742940|NCT00911196||Group A|
62742941|NCT06306729||Standard Implantation|
62742942|NCT06306729||Rapid Deployment|
62742943|NCT01179750|NO_INTERVENTION|No Ultrasonic Coagulating Shears group|the one arm: operated group without using Ultrasonic coagulation shears during gastrectomy;
62742944|NCT01179750|EXPERIMENTAL|ultrasonic coagulation shears group|the other arm: operated group using ultrasonic coagulation shears during gastrectomy
62742945|NCT00565149|EXPERIMENTAL|1|Normal Protein (15%) diet
62742946|NCT00565149|EXPERIMENTAL|2|Low Protein (5%) diet
62742947|NCT00565149|EXPERIMENTAL|3|High Protein (25%) diet
62742948|NCT05733234|EXPERIMENTAL|Test|Laser-assisted surgical treatment of peri-implantitis
62742949|NCT05733234|ACTIVE_COMPARATOR|Control|Surgical treatment of peri-implantitis - No laser
62742950|NCT01726400||Interferon and ribavirin|Treatment with standard of care pegylated interferon alpha and ribavirin.
62742951|NCT05793255|EXPERIMENTAL|Treatment group|
62742952|NCT00104416|PLACEBO_COMPARATOR|Placebo|
62368616|NCT03304262|ACTIVE_COMPARATOR|Anodal tDCS + rTMS then Sham tDCS + rTMS then Cathodal tDCS + rTMS|Participant will receive 10 minutes of anodal tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2. After 1 week washout, participant will receive 10 minutes of sham tDCS and rTMS for 900 1 Hz pulses at 0.85 RMT. After 1 week washout, participant will receive 10 minutes of cathodal tDCS and rTMS for 900 1 Hz pulses at 0.85 RMT.
62368617|NCT03304262|SHAM_COMPARATOR|Sham tDCS + rTMS then Cathodal tDCS + rTMS then Anodal tDCS + rTMS|Participant will receive 10 minutes of sham tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2. After 1 week washout, participant will receive 10 minutes of cathodal tDCS and rTMS for 900 1 Hz pulses at 0.85 RMT. After 1 week washout, participant will receive 10 minutes of anodal tDCS and rTMS for 900 1 Hz pulses at 0.85 RMT.
62368618|NCT00174928|EXPERIMENTAL|Lansoprazole 0.5 mg/kg QD|
62368619|NCT00174928|EXPERIMENTAL|Lansoprazole 1.0 mg/kg QD|
62368620|NCT00904111|EXPERIMENTAL|Lidocaine 5% Patch|Lidocaine 5% patch (Lidoderm®,Endo Pharmaceuticals Inc.), 2 patches applied directly to the most painful area of the low back once daily (q24h)
62368621|NCT00904111|PLACEBO_COMPARATOR|Placebo Topical Patch|Matching placebo patch, 2 patches applied directly to the most painful area of the low back once daily (q24h)
62368622|NCT02382965||ultrasound|
62368623|NCT06082349|EXPERIMENTAL|Lymphaticovenous anastomosis (LVA)|Patients in this group will undergo lymphaticovenous anastomosis at one or more locations on the affected limb, and the procedure will be performed under local anesthesia. During the operation, patients will be blinded using a noise-canceling headphone and blindfolds. Incisions will be made at the sites where lymphatic vessels are obstructed, ensuring no harm to the viable part of the lympahtic system. The locations will be determined prior to the surgery using ICG lymphography. The LVA(s) will be made in the subdermal plane with the aid of a surgical microscope. Generally, 1 to 4 LVAs are made. The LVA(s) is made using a surgical microscope and the operation will take approximately 60 to 90 minutes.
62368624|NCT06082349|SHAM_COMPARATOR|Sham surgery|Patients in this group will undergo sham surgery at one location on the affected limb, and the procedure will be performed under local anesthesia. During the operation, patients will be blinded using a noise-canceling headphone and blindfolds. The locations for LVA surgery will be determined prior to the surgery using ICG lymphography. However, the incision for the sham procedure will be made 2 centimeters medial or lateral to the predetermined site. This is done in order to avoid damage to the lymph vessels as to allow for future LVA surgery. After the incision, no LVA is made. Rather than performing the actual operation, the plastic surgeon will simulate the procedure by applying pressure in the surgical area. To mimic the approximate duration of a regular LVA procedure, the sham operation will take approximately 60 to 90 minutes.
62368625|NCT05255627|EXPERIMENTAL|Control Group|"Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using written educational material prepared in line with the literature."
62368626|NCT05255627|EXPERIMENTAL|Mobile application group (Experimental Group)|"A mobile application program was installed on their phones for the experimental group students to benefit from. Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using a mobile application program prepared in line with the literature."
62368627|NCT02192619||observational|
62368628|NCT01820494|EXPERIMENTAL|Experimental Infant Formula|Complete amino acid-based infant formula
62742953|NCT00104416|EXPERIMENTAL|lamotrigine (LAMICTAL) extended-relesase|
62742954|NCT02966145||PSP & CBD|Observational study of participants with a diagnosis of Progressive Supranuclear Palsy or Corticobasal Degeneration (also called Corticobasal Syndrome or Cortical-basal Ganglionic Degeneration).
62368629|NCT02193854|EXPERIMENTAL|Mobile phone|"General practitioners (GPs) received TD consultation through Sana system.~Mobile phones with Sana system installed were provided to 10 rural GPs from three different districts of Mongolia."
62368630|NCT05328414|PLACEBO_COMPARATOR|Placebo group|
62742955|NCT02966145||o/vPSP|Observational study of participants with a diagnosis of an oligosymptomatic or variant Progressive Supranuclear Palsy syndrome.
62368631|NCT05328414|EXPERIMENTAL|steroid based intranasal film|
62368632|NCT01770886|ACTIVE_COMPARATOR|UE2343|Oral capsule
62368633|NCT01770886|PLACEBO_COMPARATOR|Placebo|Oral capsule
62368634|NCT03029767|EXPERIMENTAL|Aerobic exercise|Aerobic exercise training will be carried out as an intervention activity
62368635|NCT03029767|EXPERIMENTAL|Resistance exercise|Resistance exercise training will be conducted as an intervention activity
62368636|NCT03029767|EXPERIMENTAL|Aerobic and resistance exercise|Aerobic and resistance training will be implemented
62368637|NCT03029767|NO_INTERVENTION|Control group|standard or usual activity carried out.Additional intervention will not be given.
62368638|NCT04127240|EXPERIMENTAL|Meat assignment in DASH intervention|Participants consumed 3 ounces of red meat per day as a part of the DASH diet.
62368639|NCT04127240|EXPERIMENTAL|Meat allocation in DASH intervention|Participants consumed 6 ounces of red meat per day as a part of the DASH diet.
62368640|NCT04078191|EXPERIMENTAL|RA Subjects on Stable Therapy|RA subjects who are on stable treatment will receive a single dose of 150 mcg tilmanocept radiolabeled with 10 mCi Tc 99m.
62368641|NCT05288855|EXPERIMENTAL|Voclosporin treatment group 1|2 capsules (15.8 mg) BID of voclosporin
62368642|NCT05288855|PLACEBO_COMPARATOR|Placebo treatment group|2 capsules BID of placebo
62368643|NCT05288855|EXPERIMENTAL|Voclosporin treatment group 3|3 capsules (23.7 mg) BID of voclosporin
62368644|NCT05288855|EXPERIMENTAL|Voclosporin treatment group 4|Maximum dose of 4 capsules (31.6 mg) BID of voclosporin.
62742956|NCT02966145||Normal Volunteers|Observational study of participants with no known diagnosis of a neurological or neurodegenerative condition, and no known history of memory complaints.
62742957|NCT06314373|EXPERIMENTAL|Dose Escalation|Dose Escalation:Participants will receive escalating doses of HSK39775
62742958|NCT06314373|EXPERIMENTAL|Cohort Expansion|Cohort Expansion:Participants will receive HSK39775 at the identified RP2D
62742959|NCT01830283|ACTIVE_COMPARATOR|1 dose varicella vaccine|The providers would get the 2nd dose since they had one dose varicella vaccine
62742960|NCT01830283|EXPERIMENTAL|2 dose varicella vaccine|The provider never get the varicella vaccine
62742961|NCT02890953|PLACEBO_COMPARATOR|Control|Control group receives placebo medication (normal saline)
62368645|NCT03430336|EXPERIMENTAL|Computer-assisted medication management|"Family physician adds, modifies and optimizes medication in patient's with polypharmacy assisted by an user-initiated computerized decision support system (CDSS) which provides drug-therapy relevant information about patients (e.g. diagnoses and treatments) and alerts in case of drug-drug, drug-disease, drug-age interactions to systematically assess the appropriateness of medication:~* CDSS provides drug-therapy relevant information~* modification of medication~* assessment of medication appropriateness~* medication plan~* Guidance in medication process"
62368646|NCT03430336|NO_INTERVENTION|Control arm|Patients will receive the usual clinical care based on current clinical practice guidelines during intervention period. After completion of trial, the patients in the control group will be invited to participate after written informed consent to receive the intervention.
62368647|NCT01083225|EXPERIMENTAL|Client feedback|
62368648|NCT01083225|ACTIVE_COMPARATOR|Treatment as usual|
62368649|NCT00650897|EXPERIMENTAL|A|Patients with Diabetes Mellitus and Major Depression
62368650|NCT02782247||Short term Hepatitis C patients|60 patients with chronic hepatitis C infection and cirrhosis who are planning to start antiviral therapy will be enrolled. Patients will be tested within 3 months prior to starting treatment. This will be repeated at 16 weeks (+/- 1 week) and again 1 calendar year after treatment initiation. Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
62368651|NCT02782247||Medium term Hepatitis C patients|60 patients with chronic hepatitis C infection and cirrhosis who have been successfully treated in the past 3 or 5 years (+/- 3 months). Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
62368652|NCT02782247||Hepatitis B Patients|60 patients with chronic hepatitis B and cirrhosis will be tested within 3 months prior to starting treatment. This will be repeated at 16 weeks (+/- 1 week) and again 1 calendar year after treatment initiation. Patients who have started treatment past 3 or 5 years (+/- 3 months) will also be tested. Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
62368653|NCT02404584||The study population|"Patients with kidney cancer and will be starting treatment via sunitinib at the study start will be included.~Intervention: Blood drawn for genotyping Intervention: Blood drawn for pharmacokinetic measures"
62368654|NCT00054418|EXPERIMENTAL|calcium carbonate, vitamin D and risedronate|Patients receive calcium carbonate 600 mg daily, vitamin D 400 U daily and risedronate 35 mg weekly.
62368655|NCT00054418|PLACEBO_COMPARATOR|calcium carbonate, vitamin D and placebo|Patients receive calcium carbonate 600 mg daily, vitamin D 400 U daily and placebo weekly.
62368656|NCT04350424||Propofol Arm|Outpatients receiving anesthesiologist-administered propofol for elective outpatient endoscopic procedures
62368657|NCT04350424||Opioid / Benzodiazepine Arm|Outpatients receiving endoscopist-administered opioid / benzodiazepine for elective outpatient endoscopic procedures
62368658|NCT04104204|SHAM_COMPARATOR|Intrathecal morphine|Intrathecal morphine 0.1 mg, A sham subcutaneous injection of 0.5 ml normal saline at inguinal area
62368659|NCT04104204|EXPERIMENTAL|Ultrasound guided supra-inguinal fascia iliaca block|0.25% bupivacaine 40 ml
62368660|NCT02653352|NO_INTERVENTION|Control|The control group received two one-hour general sessions on health issues and printed general advices regarding healthy diets.
62368661|NCT02653352|EXPERIMENTAL|Lifestyle modification|Intervention was focused on the reduction in consumption of sugar-sweetened carbonated beverages by students. During seven months of one school year, a healthy lifestyle education programme was implemented using simple messages encouraging water consumption instead of sugar-sweetened carbonated beverages. Education was delivered via classroom activities; banners were hung promoting water consumption, and water bottles with the logo of the campaign were given to children and schoolteachers.
62742962|NCT02890953|EXPERIMENTAL|MSC group|MSC group receives mesenchymal stem cells transplantation (Pneumostem)
62368662|NCT03991936|PLACEBO_COMPARATOR|Placebo|Participants receive an intralesional injection of 0.1-0.2 mL of normal saline in one psoriatic fingernail once per 6 weeks until 24 weeks.
62368663|NCT03991936|EXPERIMENTAL|Triamcinolone Acetonide 2.5 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 2.5 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
62368664|NCT03991936|EXPERIMENTAL|Triamcinolone Acetonide 5.0 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 5.0 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
62368665|NCT03991936|EXPERIMENTAL|Triamcinolone Acetonide 7.5 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 7.5 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
62368666|NCT03991936|EXPERIMENTAL|Triamcinolone Acetonide 10 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 10 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
62368667|NCT04746157|EXPERIMENTAL|Intervention group|Patients will have a directly contact with the lead nurse by telephone during the study. The referent nurse will provide support and will promote engagement of patient to adequate secondary prevention measures. In addition, she will provide education based on stroke risk and identified vascular risk factors by Stroke Riskometer.
62742963|NCT00307281||Registry|10 pack year tobacco smoking history required, current or former smokers accepted.
62742964|NCT05647772|EXPERIMENTAL|Group 1: Standalone App|Standalone parenting app called UseIt!
62742965|NCT05647772|EXPERIMENTAL|Group 2: App plus Coach|Standalone parenting app called UseIt! plus a coach.
62742966|NCT05647772|ACTIVE_COMPARATOR|Group 3: Control App|Control condition: mindfulness app called SmilingMind.
62742967|NCT04339998||Patients with Suspected or Confirmed COVID-19|Patients 18 years of age and older under investigation for COVID-19 and those patients that are positive for COVID-19 at University of Minnesota Medical Center and Bethesda Hospital. Informed consent will be obtained from the patient or decision maker prior to study inclusion
62368668|NCT04746157|NO_INTERVENTION|Usual care|Usual care
62742968|NCT00060541||Patients|Patients age 4 or older seeking care from, or being referred to the Surgical Neurology Branch for evaluation and management of neurosurgical conditions
62742969|NCT03142841|NO_INTERVENTION|Standard Care|Study participants will receive the usual standard care they would receive had they not been enrolled in this study
62368669|NCT06136455|EXPERIMENTAL|Arm 1: Brush / Listerine Clinical Solutions Teeth Strength|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Clinical Solutions Teeth Strength mouthwash.
62368670|NCT06136455|EXPERIMENTAL|Arm 2: Brush / Listerine Total Care Zero|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash.
62368671|NCT06136455|EXPERIMENTAL|Arm 3: Brush / Listerine Cool Mint Zero|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash.
62368672|NCT06136455|OTHER|Arm 4: Brush / Water (Negative Control)|After brushing for 1 timed minute, participants will rinse with for 1 minute with tap water.
62368673|NCT03821480|EXPERIMENTAL|Fluconazole 50 mg, Manufacturer: Amboise|Test drug
62742970|NCT03142841|EXPERIMENTAL|Problem Solving Intervention|The intervention consists of a problem-solving intervention and information/tools on the previously developed, evidenced-based Spanish-version of the RESCUE stroke caregiver website to improve stroke caregiver outcomes. The intervention will be conducted via telephone by a trained rehabilitation counselor. The intervention consists of four components: 1. Introduction to the RESCUE website and the problem-solving method; 2. Illustrative example on how to use the problem-solving approach and the RESCUE website to address caregiving problems; 3. Individualized practice exercise to develop a personalized problem-solving plan; and 4. Summary of the problem-solving method.
62368674|NCT03821480|ACTIVE_COMPARATOR|Fluconazole 50mg, Manufacturer:West Ryde|Reference drug
62368675|NCT02221960|EXPERIMENTAL|Monotherapy Arm|MEDI6383
62368676|NCT02221960|EXPERIMENTAL|Combination Arm|MEDI6383 and MEDI4736
62368677|NCT05888532|EXPERIMENTAL|Cohort A: 64Cu-GRIP B, Metastatic GU malignancies|Participants with metastatic GU malignancy (renal, urothelial, or prostate) (3 males, 3 females), dosimetry calculation will be performed by obtaining whole body (vertex to thighs) PET images up to five time points from 0.5 to 24 hours post 64Cu-GRIP B injections. An additional intravenous line will be placed in the contra-lateral arm to collect blood for this group.
62368678|NCT05888532|EXPERIMENTAL|Cohort B: 64Cu-GRIP B, RCC and UC participants|Participants with renal cell and urothelial carcinoma will have longitudinal imaging performed prior to treatment outside of this study with anti-programmed death-1 (PD-1)/anti-PD-1 ligand 1 (PD-L1) blockade (with or without concomitant anti-CTLA4 treatment), after 8 weeks of checkpoint blockade, and again at the time of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
62368679|NCT05888532|EXPERIMENTAL|Cohort C: 64Cu-GRIP B, mCRPC participants|Participants with metastatic castration resistant prostate cancer (mCRPC)) will have longitudinal imaging performed prior to treatment outside of this study, 8 weeks following initiation of treatment outside of this study, and at the time of disease progression by Prostate Cancer Working Group 3 (PCWG3) criteria.
62368680|NCT05888532|EXPERIMENTAL|Cohort D: 64Cu-GRIP B, Advanced malignancies|participants with solid tumor malignancies will have longitudinal imaging performed prior to treatment outside of this study, 8 weeks following initiation of treatment, and the opportunity to have an optional scan at the time of progression.
62368681|NCT01865838|ACTIVE_COMPARATOR|Seprafilm (Sanofi, USA)|Patients in this arm received Seprafilm during surgery.
62368682|NCT01865838|NO_INTERVENTION|Control|Patients in this arm does NOT receive Seprafilm during surgery.
62368683|NCT05522855|EXPERIMENTAL|Intervention Version- EEG Sensorband and mobile application|EEG headband to record brain signals. The Sensorband uses Bluetooth to link to the mobile application on a user's device. This raw EEG data is processed on a HIPPA compliant cloud based server and displays mental workload and brain energy data on the application. This can help the user with cognitive pacing to avoid overexertion.
62368684|NCT05522855|ACTIVE_COMPARATOR|Control Version- EEG Sensorband and mobile application|EEG headband to record brain signals. The Sensorband uses Bluetooth to link to the mobile application on a user's device. This raw EEG data is processed on a HIPPA compliant cloud based server like the Intervention version, but no mental workload or brain energy data will be displayed.
62368685|NCT05305976|EXPERIMENTAL|Ambulant Group|Individuals unable to walk according to the Brooke Function Classification System
62368686|NCT05305976|EXPERIMENTAL|Non-ambulant Group|Individuals who can walk according to the Brooke Function Classification System
62368687|NCT06166290|EXPERIMENTAL|CO2 LASER Vaporization Group|
62742971|NCT01129765||Parents of congested children|Parents of children less than six years of age with nasal congestion for which nasal suctioning and salt water irrigation is traditionally recommended.
62742972|NCT06658353|EXPERIMENTAL|VC004 Capsules|
62368688|NCT06166290|ACTIVE_COMPARATOR|Electrosurgical Fulguration Group|
62368689|NCT06071780|ACTIVE_COMPARATOR|VCO contact lens|contact lens soaked in VCO
62368690|NCT06071780|PLACEBO_COMPARATOR|control contact lens|contact lens soaked in saline
62368691|NCT05181241|EXPERIMENTAL|Group No. 1 (n=6) Dimolegin - 20 mg|Group No. 1 (n=6) consisted of 2 cohorts with 3 volunteers per each. Volunteers of Cohorts 1 and 2 received Dimolegin (DD217) once at a dose of 20 mg
62368692|NCT05181241|EXPERIMENTAL|Group No. 2 (n=6) Dimolegin - 40 mg|Group No. 2 (n=6) consisted of 2 cohorts with 3 volunteers per each. Volunteers of Cohorts 3 and 4 received Dimolegin (DD217) once at a dose of 40 mg
62368693|NCT05181241|EXPERIMENTAL|Group No. 3 (n=12) Dimolegin - 60 mg|Group No. 3 (n=12) consisted of 3 cohorts. Cohorts 5 and 6 included 3 volunteers per each, and Cohort 7 included 6 volunteers. All Group 3 volunteers received Dimolegin (DD217) once at a dose of 60 mg
62368694|NCT04728815|EXPERIMENTAL|CAMS to Maintenance|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Responder, thus placed into ongoing Maintenance/Monitoring.
62368695|NCT04728815|EXPERIMENTAL|CAMS to CAMS|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 CAMS.
62368696|NCT04728815|EXPERIMENTAL|CAMS to DBT|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 DBT.
62368697|NCT04728815|EXPERIMENTAL|TAU to Maintenance|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Responder, thus placed into ongoing Maintenance/Monitoring.
62368698|NCT04728815|EXPERIMENTAL|TAU to CAMS|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 CAMS.
62742973|NCT02446249|EXPERIMENTAL|single arm dose escalation|single arm dose escalation
62368699|NCT04728815|EXPERIMENTAL|TAU to DBT|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 DBT.
62368700|NCT04728815|EXPERIMENTAL|DBT Only|Subject Assigned to DBT for Phase 1, continuing up to 16 weeks.
62368701|NCT04728815|NO_INTERVENTION|Study Counselors|Consented Study Counselors from each of the 4 sites. Data collected regarding the Counselors is minimal and is maintained completely separately from the other 7 Student Participant Arms/Groups.
62368702|NCT01624467|EXPERIMENTAL|Necitumumab|800 mg necitumumab, administered once per week as an intravenous infusion (IV)
62368703|NCT01764022|EXPERIMENTAL|BCD-022|BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BCD-022 at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).
62368704|NCT01764022|ACTIVE_COMPARATOR|Herceptin®|In this arm patients will receive 6 courses of treatment with Herceptin® (F. Hoffmann-La Roche Ltd., Switzerland) in combination with paclitaxel. Patients will receive Herceptin® at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).
62368705|NCT05488925|PLACEBO_COMPARATOR|Vitamin E|
62368706|NCT05488925|EXPERIMENTAL|Diclofenac sodium|
62368707|NCT05488925|EXPERIMENTAL|Piroxicam|
62368708|NCT05488925|EXPERIMENTAL|Tramadol|
62368709|NCT01406158|EXPERIMENTAL|Treatment A|
62368710|NCT01406158|EXPERIMENTAL|Treatment B|
62368711|NCT01406158|EXPERIMENTAL|Treatment T|
62368712|NCT02762045|EXPERIMENTAL|Low dose Ad5-gag or Placebo|1ml low dose Ad5-gag(2x10\^9VP) or Preservation solution at weeks 0 and weeks 4.
62742974|NCT06661330||Mediterranean Diet Intervention Group|This group consists of 200 adults who participated in a 6-month Mediterranean diet intervention combined with regular physical activity. The intervention focused on reducing energy intake by approximately 600 kcal/day while emphasizing plant-based foods, fish, and poultry. Participants' metabolic parameters, including body composition, fasting glucose, lipid profiles, and liver enzymes, were assessed at baseline and after 6 months.
62742975|NCT03576404|EXPERIMENTAL|Eligible participants|The intervention of patient-centered pharmacist care included a comprehensive interview patients conducted at month 3 and 5 ,which included and reviewing all their medications using concepts of MTM and MI All study participants were assessed at baseline and on monthly basis for the changes in the study outcomes.
62742976|NCT06611345|EXPERIMENTAL|Tumor Treating Fields combined with durvalumab and GemCis|
62742977|NCT00657293|SHAM_COMPARATOR|C|In an attempt to make the groups comparable in terms of attention, the control group will receive a sham.
62742978|NCT00657293|ACTIVE_COMPARATOR|ATP|Patients will undergo a specific arm training program (ATP).
62368713|NCT02762045|EXPERIMENTAL|Medium dose Ad5-gag or Placebo|1ml medium dose Ad5-gag(2x10\^10VP) or Preservation solution at weeks 0 and weeks 4.
62368714|NCT02762045|EXPERIMENTAL|High dose Ad5-gag or Placebo|1ml high dose Ad5-gag(2x10\^11VP) or Preservation solution at weeks 0 and weeks 4.
62368715|NCT05799547|NO_INTERVENTION|control group|
62368716|NCT05799547|EXPERIMENTAL|experimental group|
62368717|NCT04642378|EXPERIMENTAL|iNCDSS group|Artificial intelligence assisted insulin titration system group
62368718|NCT04642378|ACTIVE_COMPARATOR|Routine treatment group|Physician decided insulin titration group
62368719|NCT03598660||Breast cancer patients|"The present study will be carried on 50 breast cancer patients before surgery.~The followings markers must be estimated:~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using enzyme linked immuno sorbent assay (ELISA)."
62368720|NCT03598660||Healthy controls|"The present study will be carried on 15 age and sex matched controls.~The followings markers must be estimated:~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA."
62368721|NCT03598660||Benign breast diseases|"The present study will be carried on 15 patients with benign breast diseases.~The followings markers must be estimated:~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA."
62368722|NCT01755338|ACTIVE_COMPARATOR|Methylprednisolone|Methylprednisolone i.v. 15mg/kg x 1 intraoperative Aortic Valve Replacement
62368723|NCT01755338|PLACEBO_COMPARATOR|Placebo (NaCl)|Placebo i.v., x1, intraoperative Aortic Valve Replacement
62368724|NCT06266871|EXPERIMENTAL|SOX+Tislelizumab+LDRT|"Laparoscopic exploration is required in all patients to detect occult peritoneal metastases.~All patients will start with one cycle of neoadjuvant therapy of SOX plus tislelizumab regimen: S-1: 40-60 mg Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; tislelizumab: 200 mg, iv drip, d1, q3w.~Then, LDRT will be performed in the target area (including the primary gastric lesion and positive/suspected positive lymph nodes).~After radiotherapy, patients will receive another two cycles of SOX plus tislelizumab regimen.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of SOX plus tislelizumab regimen.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with SOX regimen for up to 5 cycles."
62742979|NCT03493451|EXPERIMENTAL|Cohort 1: ENKTL|Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
62742980|NCT03493451|EXPERIMENTAL|Cohort 2: PTCL-NOS, AITL, and ALCL|Participants with other R/R mature T-cell neoplasms \[limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
62742981|NCT03493451|EXPERIMENTAL|Cohort 3: MF and SS|Participants with R/R cutaneous T-cell lymphoma \[limited to mycosis fungoides (MF) and Sèzary syndrome (SS)\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
62742982|NCT03788642|ACTIVE_COMPARATOR|Control LED Shoe arm|Patients with DFU will wear LED shoe 30 minutes per day
62368725|NCT02218762|EXPERIMENTAL|Sequence 1|Subjects will receive FSC 100/50 mcg delivered via the Ddpi (Treatment A) and FSC 100/50 mcg delivered via the Rdpi (Treatment B) in the sequence of A-B-B-A in four treatment periods of 10 days each. Subjects will receive both active treatment and matching placebo at the same time from two separate devices twice daily. There will be no wash-out between treatment periods
62368726|NCT02218762|EXPERIMENTAL|Sequence 2|Subjects will receive FSC 100/50 mcg delivered via the Ddpi (Treatment A) and FSC 100/50 mcg delivered via the Rdpi (Treatment B) in the sequence of B-A-A-B in four treatment periods of 10 days each. Subjects will receive both active treatment and matching placebo at the same time from two separate devices twice daily. There will be no wash-out between treatment periods
62368727|NCT00923962|ACTIVE_COMPARATOR|Type 2 Diabetes patients|
62368728|NCT00923962|ACTIVE_COMPARATOR|Healthy|
62368729|NCT00923962|ACTIVE_COMPARATOR|Artherosclerosis|
62368730|NCT02611518|EXPERIMENTAL|Panel 1|Participant will be administered a single oral dose of rosuvastatin 10 milligram (mg) on Day 1 and Day 14 and JNJ-54861911 at a dose of 25 mg once daily from Day 8 until Day 17.
62368731|NCT02611518|EXPERIMENTAL|Panel 2|Participant will be administered a single oral dose of metformin 500-mg on Day 1 and Day 14 and JNJ-54861911 at a dose of 25 mg once daily from Day 8 until Day 16.
62368732|NCT05292573|EXPERIMENTAL|metformin group|"1. During the intervention period, metformin is given 500 mg tablet b.i.d.~2. We will deliver education for exercise and weight control to all eligible participants"
62368733|NCT05292573|NO_INTERVENTION|Observation group|only exercise and weight control to all eligible participants
62368734|NCT02995473|EXPERIMENTAL|NP000888|Pharmaceutical form: Ointment
62368735|NCT02995473|PLACEBO_COMPARATOR|Vehicle|Pharmaceutical form: Ointment
62368736|NCT01785498|NO_INTERVENTION|Control Group|Receive standard clinical care and supports.
62368737|NCT01785498|EXPERIMENTAL|Supplementary resources|Receive standard care and supports plus supplementary resources developed for the intervention.
62368738|NCT00533351|EXPERIMENTAL|AGN201781|AGN201781 50 mg capsules three-time daily for 2 weeks
62368739|NCT00533351|PLACEBO_COMPARATOR|Placebo|placebo 50 mg capsules three-times daily for 2 weeks
62368740|NCT05421546|ACTIVE_COMPARATOR|Spermidine arm|This arm will enrol 20 volunteers aged 65 years of age or older (65-90) who have received two doses of the Coronavirus vaccine, with the vaccination course completed more than 8 weeks before recruitment. Following a baseline venous blood sample, participants will receive Spermidine supplements 6mg/day and oral administration once daily. A research appointment and venous blood sample will be requested at the point of recruitment, 5 weeks, 13 weeks and 37 weeks after recruitment of the participant.
62368741|NCT05421546|PLACEBO_COMPARATOR|Placebo arm|This arm will enrol 20 volunteers aged 65 years of age or older (65-90) who have received two doses of the Coronavirus vaccine, with the vaccination course completed more than 8 weeks before recruitment. Following a baseline venous blood sample, participants will receive placebo oral administration once daily. A research appointment and venous blood sample will be requested at the point of recruitment, 5 weeks, 13 weeks and 37 weeks after recruitment of the participant.
62368742|NCT06508398||ICU Patients with Healthcare-Associated Infections|This group consists of patients admitted to the Intensive Care Units (ICUs) in Lviv hospitals who are diagnosed with healthcare-associated infections (HAIs). The study involves collecting clinical samples, including blood, urine, sputum, bronchoalveolar lavage, wound swabs, and oropharyngeal/nasopharyngeal swabs, to identify bacterial and fungal pathogens and analyze their antimicrobial resistance profiles. The data collected will be used to evaluate the effectiveness of new 4-thiazolidinone derivatives against these pathogens.
62368743|NCT00432640|EXPERIMENTAL|1|Endoscopic ultrasound staging
61986279|NCT02331147|ACTIVE_COMPARATOR|Human Dermis|"Application of Human Allogenic Dermis with Dressing Application, to be changed weekly. Patient would will be measured in cm length by width weekly Patient will practice Offloading.~If the ulcer has not closed completely, an additional piece of Human Dermis will be applied weekly at weeks 2-11 in a similar fashion"
62368744|NCT00432640|ACTIVE_COMPARATOR|2|Surgical staging
62368745|NCT05903378|EXPERIMENTAL|Relational touch group|Touch in care aims to improve the patient's perception of potentially painful or anxiety-provoking acts of care. It is based on techniques of skin contact, developing and deepening.
62368746|NCT05903378|NO_INTERVENTION|Standard care group|Routine care without relational touch practice.
62368747|NCT03307018|EXPERIMENTAL|Bronch|Postoperative systematic bronchial aspiration.
62368748|NCT03307018|NO_INTERVENTION|Control|In this arm bronchial aspiration with bronchoscope will not be done.
62368749|NCT02579902|ACTIVE_COMPARATOR|Vitamin D3|50000 IU vitamin D3 capsule, one capsule every 2 weeks for 6 months.
62368750|NCT02579902|PLACEBO_COMPARATOR|placebo|Placebo capsule, one capsule every 2 weeks for 6 months.
62368751|NCT03286881|EXPERIMENTAL|Group 1|
62368752|NCT03286881|EXPERIMENTAL|Group 2|
62368753|NCT03286881|EXPERIMENTAL|Group 3|
62742983|NCT03788642|ACTIVE_COMPARATOR|Laser Shoe arm|Patients with DFU will wear Laser shoe 30 minutes per day
61986280|NCT02344030|EXPERIMENTAL|standard blade|Standard Blade: tracheal intubation with standard blade
61986281|NCT02344030|EXPERIMENTAL|channeled blade|Channeled Blade: tracheal intubation with channeled blade
62368754|NCT03286881|EXPERIMENTAL|Group 4|
62368755|NCT03286881|ACTIVE_COMPARATOR|Group 5|
62368756|NCT03403855|EXPERIMENTAL|Rocket® IPC- Long External Length|"Intervention Rocket® IPC- Long External Length: a regular full length (long catheter) Rocket catheter inserted at baseline, with an external length of 16cm. Catheter length will be modified at 2 weeks in clinic, shortened to an external length of 5cm (short catheter). Patient satisfaction will be collected at 2 weeks prior to the modification, and at 4 weeks when the patient has a shorter catheter.~The modification is easily done without any use of anesthesia as it is external to the patient using the tool kit that comes along with the catheter.~Patients will be referred to palliative home care services for assistance with drainage. The drainage catheters to be used in this study will be samples supplied by Rocket Medical Inc., for Dr. Amjadi to evaluate their product."
62742984|NCT00113399|OTHER|Radiotherapy and chemotherapy|Radiotherapy/paclitaxel/cisplatin/filgrastim
62742985|NCT00113399|OTHER|Chemotherapy|Cisplatin/fluorouracil/paclitaxel/docetaxel
62742986|NCT06170463|ACTIVE_COMPARATOR|Met Group|
62742987|NCT06170463|ACTIVE_COMPARATOR|MI Group|
62742988|NCT06170463|ACTIVE_COMPARATOR|MM Group|
62368757|NCT03403855|EXPERIMENTAL|Rocket® IPC- Short External Length|"Intervention Rocket® IPC- Short External Length : a regular full length (long catheter) Rocket catheter inserted at baseline, with an external length of 16cm. Catheter length will be modified at 2 weeks in clinic, shortened to an external length of 5cm (short catheter). Patient satisfaction will be collected at 2 weeks prior to the modification, and at 4 weeks when the patient has a shorter catheter.~The modification is easily done without any use of anesthesia as it is external to the patient using the tool kit that comes along with the catheter.~Patients will be referred to palliative home care services for assistance with drainage. The drainage catheters to be used in this study will be samples supplied by Rocket Medical Inc., for Dr. Amjadi to evaluate Rocket's product."
62368758|NCT00415623|ACTIVE_COMPARATOR|Amlodipine 5mg|
62368759|NCT00415623|EXPERIMENTAL|Amlodipine 10mg|
62368760|NCT00628342|EXPERIMENTAL|1|
62368761|NCT00628342|EXPERIMENTAL|2|
62368762|NCT00628342|PLACEBO_COMPARATOR|3|
62368763|NCT02977507|EXPERIMENTAL|Lytera 2.0|Lytera 2.0 applied to the affected areas (dark patches) on one side of the face twice a day, in the morning and evening, every day for 12 weeks. SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen were also applied to the face as directed.
62368764|NCT02977507|ACTIVE_COMPARATOR|4% Hydroquinone Topical Cream|4% hydroquinone topical prescription cream applied to the affected areas (dark patches) on the other side of the face twice a day, in the morning and evening, every day for 12 weeks. SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen were also applied to the face as directed.
62368765|NCT03342404|EXPERIMENTAL|Luspatercept (ACE-536) plus Best Supportive Care (BSC)|Arm Description: Luspatercept, subcutaneous(ly) (SC) once every 21 days
62368766|NCT03342404|PLACEBO_COMPARATOR|Placebo plus Best Supportive Care (BSC)|normal saline solution subcutaneous(ly) (SC) once every 21 days
62368767|NCT00668850|EXPERIMENTAL|1|Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
62368768|NCT00668850|ACTIVE_COMPARATOR|2|Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
62368769|NCT05907772||Recipients with preoperative PIVKA-II≤240mAU/mL|
62368770|NCT05907772||Recipients with preoperative PIVKA-II>240mAU/mL|
62368771|NCT04762264|ACTIVE_COMPARATOR|Short term post inguinal hernia repair with ProFlor|MRI of the pelvic area in patients who underwent inguinal hernia repair with ProFlor from 1 to 3 months before to assess tissue incorporation into the 3D scaffold
62368772|NCT04762264|ACTIVE_COMPARATOR|Mid term post inguinal hernia repair with ProFlor|MRI of the pelvic area in patients who underwent inguinal hernia repair with ProFlor from 4 to 7 months before to assess tissue incorporation into the 3D scaffold
62368773|NCT04762264|ACTIVE_COMPARATOR|Long term post inguinal hernia repair with ProFlor|MRI of the pelvic area in patients who underwent inguinal hernia repair with ProFlor after 8 months and beyond to assess tissue incorporation into the 3D scaffold
62368774|NCT04934293|EXPERIMENTAL|Arm A_ first with RV then without|Use of the virtual reality headset from the first week of proton therapy
62368775|NCT04934293|EXPERIMENTAL|Arm B- first without RV than with|Use of the virtual reality headset from the second week of proton therapy
62368776|NCT05119972|EXPERIMENTAL|part1:ZSP1603 dose1|
62368777|NCT05119972|EXPERIMENTAL|part1:ZSP1603 dose2|
62368778|NCT05119972|EXPERIMENTAL|part1:ZSP1603 dose3|
62368779|NCT05119972|EXPERIMENTAL|Part2: ZSP1603 dose|
62368780|NCT05119972|PLACEBO_COMPARATOR|Part2: placebo|
62368781|NCT01500863|ACTIVE_COMPARATOR|hCG|
62368782|NCT01500863|EXPERIMENTAL|Triptorelin 0.2mg s.c.|
62368783|NCT01500863|EXPERIMENTAL|0.2mg triptorelin plus estradiol/progesterone|
62567169|NCT05184205|EXPERIMENTAL|Active Intervention|The procedure is initiated by swabbing the Formulation Applicator, pre-saturated with photosensitizer formulation, inside the patient's nares. The operator then connects the Nasal Light Illuminator (NLI) to the Light Source and inserts the NLIs into the patient's nostrils. The Light Source is turned on, and a 4-minute illumination cycle provides two channels of diffused red light (one for each nostril) to activate the applied formulation. Illumination stops automatically upon completion of the 4-minute cycle. The process is then repeated using two new Formulation Applicators to ensure full disinfection coverage.
62368784|NCT01500863|EXPERIMENTAL|0.2mg tripoterlin plus single bolus hCG 1500 IU|
62368785|NCT01500863|EXPERIMENTAL|0.2mg tripoterlin plus multiple boluses hCG 500 IU|
62368786|NCT01500863|EXPERIMENTAL|0.2mg tripoterlin plus multiple doses recLH|
62368787|NCT00132158|OTHER|1|
62368788|NCT02734095|EXPERIMENTAL|Intravascular Ultrasound data|Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
62368789|NCT05193604|EXPERIMENTAL|TQB2858 injection|"Cohort 1: TQB2858 injection administered intravenously on day 1 of each 21-day cycle.~Cohort 2: TQB2858 injection administered intravenously on day 1 of each 21-day cycle, gemcitabine and albumin paclitaxel administered intravenously on day 1 and day 7 of each 21-day cycle.~Cohort 3: TQB2858 injection administered intravenously on day 1 of each 21-day cycle，gemcitabine and albumin paclitaxel administered intravenously on day 1 and day 7 of each 21-day cycle，Anlotinib capsules 8 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)."
62368790|NCT05579223|EXPERIMENTAL|Intrathecal Hydromorphone Group (ITHM)|Dosage Form: Hydromorphone Hydrochloride Injection 2mg:2ml. Dosage: 75 μg+ 5% glucose injection diluted to 1.5ml. Frequency and Duration: i.t., st
62368791|NCT05579223|PLACEBO_COMPARATOR|Intrathecal Placebo Group (ITPO)|Dosage Form: 5% glucose injection, 100ml/Package. Dosage: 1.5ml. Frequency and Duration: i.t., st
62368792|NCT03766542|ACTIVE_COMPARATOR|CPAP|Oronasal CPAP therapy applied as per current international guidelines
62368793|NCT03766542|EXPERIMENTAL|Bi-level|Oronasal Bi-level therapy + supplemental oxygen (if necessary) applied as per current international guidelines
62368794|NCT06450223|EXPERIMENTAL|Perampanel Tablets|Perampanel Tablets 12mg
62368795|NCT06450223|ACTIVE_COMPARATOR|Fycompa film-coated tablets|Fycompa 12mg film-coated tablets (Perampanel12 mg)
62567170|NCT05184205|SHAM_COMPARATOR|Sham Comparator: Control|Sham comparator
62368796|NCT02403960|ACTIVE_COMPARATOR|probiotic|The participants of the probiotic group were asked to let a probiotic tablet dissolve on their tongue 2 times a day for 3 months.
62742989|NCT02723916|EXPERIMENTAL|Intervention: ezParent Program|
62742990|NCT02723916|ACTIVE_COMPARATOR|Control: Health-e Kids App|
62742991|NCT04756999|EXPERIMENTAL|Intervention|informed consent forms, nine sessions of foot reflexology massage will be given to reflex points including the solar plexus, brain, pituitary, thyroid, diaphragm, upper lymphs, lung, spinal cord and adrenal glands for 3 weeks. Then data collection tools were applied.
62368797|NCT02403960|PLACEBO_COMPARATOR|placebo|The participants of the control group were asked to let a placebo tablet dissolve on their tongue 2 times a day for 3 months.
62368798|NCT01695213|ACTIVE_COMPARATOR|HA-Omnifit|Patients who receive a HA-Omnifit uncemented hip stem
62368799|NCT01695213|ACTIVE_COMPARATOR|Symax hip stem|Patients with the Symax uncemented hip stem
62368800|NCT02972281|OTHER|Patients with bacterial infections|Patients with recurrent and/or severe bacterial infections
62368801|NCT04974190|ACTIVE_COMPARATOR|Patients treated with actual device with actual solution|
62368802|NCT04974190|PLACEBO_COMPARATOR|Patients treated with actual device with placebo solution|
62368803|NCT02792036|EXPERIMENTAL|Treatment|"Participants with retinoblastoma that is refractory or has relapsed inside the eye.~Interventions: Carboplatin, Maxitrol® , focal therapy, plaque radiotherapy."
62368804|NCT05154357|EXPERIMENTAL|Group 1|Half an hour before the first feeding hour, the infant's heart rate and oxygen saturation will be recorded. Then, he/she will be placed in the elastic sac, positioned and will be allowed to take a rest until the feeding hour for 30 minutes. His/her physiological parameters will be recorded ten minutes before the feeding time, during feeding and ten minutes after feeding. When the feeding time begins, the chronometer will be started and it will be stopped when feeding is completed. At the second feeding time, the infant's heart rate and oxygen saturation will be recorded half an hour before the feeding hour. Then, he/she will be positioned without performing any different application and will be allowed to take a rest until the feeding time. His/her physiological parameters will be recorded ten minutes before the feeding time, during feeding and ten minutes after feeding. When feeding begins, the chronometer will be started and when it is over, the chronometer will be stopped.
62368805|NCT05154357|EXPERIMENTAL|Group 2|Half an hour before the first feeding time of the infant, his/her heart rate and oxygen saturation will be recorded. Then, he/she will be positioned without performing any different application and will be allowed to take a rest until the feeding time. His/her physiological parameters will be recorded ten minutes before the feeding hour, during feeding and ten minutes after feeding. When feeding begins, the chronometer will be started and when it is over, the chronometer will be stopped. At the second feeding hour, the infant's heart rate and oxygen saturation will be recorded half an hour before the feeding hour. Then, he/she will be placed in the elastic sac, positioned, and allowed to take a rest until the feeding hour. His/her physiological parameters will be recorded ten minutes before the feeding hour, during feeding and ten minutes after feeding. When feeding begins, the chronometer will be started and when it is over, the chronometer will be stopped.
62368806|NCT02002624|ACTIVE_COMPARATOR|Conventional|Conventional instrumentation
62368807|NCT02002624|EXPERIMENTAL|PSI|Patient specific instrumentation
62368808|NCT04567420|EXPERIMENTAL|Arm A|Palbociclib/Fulvestrant Combination
62368809|NCT04567420|ACTIVE_COMPARATOR|Arm B|Adjuvant Therapy
62368810|NCT05024890|EXPERIMENTAL|WASH in Schools programme|Schools in the intervention group will receive the Splash WASH in Schools programme (Project WISE) during the study period (2021/2022 academic year), including sanitation, water storage and filtration, drinking water and handwashing stations, and hygiene and menstrual health education.
62368811|NCT05024890|NO_INTERVENTION|Control|Schools in the control group will receive no intervention during the study period (2021/2022 academic year), but will be on a waitlist to receive the Project WISE intervention after the end of the study period (2022/2023 academic year or later).
62368812|NCT01283893||Laparoscopy group|Laparoscopy group: patients who underwent laparoscopic distal gastrectomy with D2 lymphadenectomy
62368813|NCT01283893||Open group|Open group: patients who underwent open distal gastrectomy with D2 lymphadenectomy
62368814|NCT00598806|EXPERIMENTAL|Apaziquone|TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
62368815|NCT00598806|PLACEBO_COMPARATOR|Placebo|TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT
62742992|NCT04756999|PLACEBO_COMPARATOR|Control|informed consent forms, foot massage were performed. Then data collection tools were applied.
62742993|NCT05056805|ACTIVE_COMPARATOR|Arm A (aerobic exercise, nutritional recommendation)|Patients are encouraged to complete at least 30 minutes of moderate intensity aerobic exercise, at least 3 times per week. Patients receive nutrition consultation with a registered dietitian and monitor dietary intake. Aerobic exercises and nutrition are tracked in the Pt Pal app
62368816|NCT03702140|ACTIVE_COMPARATOR|TPTD 6M|
62368817|NCT03702140|ACTIVE_COMPARATOR|TPTD 6-12M|
62368818|NCT03702140|ACTIVE_COMPARATOR|TPTD 12-24M|
62368819|NCT02801006|EXPERIMENTAL|stenfilcon A|Participants will be randomized to wear stenfilcon A lens pair for two weeks during the cross over study.
62368820|NCT02801006|ACTIVE_COMPARATOR|etafilcon A|Participants will be randomized to wear etafilcon A lens pair for two weeks during the cross over study.
62368821|NCT00584779|EXPERIMENTAL|1|
62368822|NCT00584779|EXPERIMENTAL|2|
62368823|NCT00584779|EXPERIMENTAL|3|
62368824|NCT00584779|EXPERIMENTAL|4|
62368825|NCT03858569|ACTIVE_COMPARATOR|Oxytocin|10 units of oxytocin will be given intramuscularly immediately after delivery of the fetus
62742994|NCT05056805|EXPERIMENTAL|Arm B (aerobic, strength exercise, nutritional recommendation)|Patients complete at least 30 minutes of moderate intensity aerobic exercise (such as brisk walking or stationary bike cycling) at least 3 times per week. Patients also complete strength exercises with resistance tubes/bands at least 2 times per week, with at least 2 sets of 8-15 repetitions of the exercises taught. Patients receive nutrition consultation with a registered dietitian and monitor dietary intake. Patients also consume a high protein snack/meal/shake (15-25 grams) within 1 hour after any strengthening exercises. Exercise activities and nutrition are tracked in the Pt Pal app.
62368826|NCT03858569|ACTIVE_COMPARATOR|Oxytocin plus uterine massage|10 units of oxytocin will be given intramuscularly immediately after delivery of the fetus and transabdominal uterine massage will be performed.
62368827|NCT02849184|EXPERIMENTAL|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
62368828|NCT02849184|PLACEBO_COMPARATOR|placebo|Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
62368829|NCT00944580|EXPERIMENTAL|Vaccine Intervention|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine: A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
62368830|NCT06204289|EXPERIMENTAL|Nurse-led Supportive Care Group|Nurse-led supportive care was given to family caregivers of patients with lung cancer.
62368831|NCT06204289|NO_INTERVENTION|Control Group|The control group received only usual care. They did not receive any intervention during the study period.
62742995|NCT05786937|PLACEBO_COMPARATOR|Placebo|The participants will receive a placebo, which is the excipient solution of aDC1 cell suspension consisting of a commercial ringer´s lactate solution.
62368832|NCT02619058|EXPERIMENTAL|Arm 1（NKT cells single low dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 1×10\^9 on d1, 2×10\^9 on d3, 4×10\^9 on d29, 8×10\^9 on d31.
62368833|NCT02619058|EXPERIMENTAL|Arm 2（NKT cells single high dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 5×10\^9 on d1, 5×10\^9 on d3, 5×10\^9 on d29, 5×10\^9 on d31.
62368834|NCT02619058|EXPERIMENTAL|Arm 3（NKT cells multiple dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 5×10\^9 on d1, 5×10\^9 on d3 of each 28 days-cycle, the dosing will be ended after 8 cycles.
62368835|NCT05840523|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation (PNF) Exercise Group|The PNF group performed flexion-abduction-internal rotation and extension-abduction-internal rotation patterns as 15 repetitions, 2 sets. The metronome was used to fix the construction speed of the exercises (50bpm). PNF exercises were performed with EB at a metronome speed of 50bpm at a ratio of 1:2 sec. In other words, while transition from the antagonist to agonist pattern in 3 clicks, there was return from agonist to antagonist in 6 clicks.
62368836|NCT05840523|EXPERIMENTAL|Range Of Motion (ROM) Exercise Group|The ROM group performed hip flexion abduction, neutral abduction and extension abduction exercises with an EB at 50bpm metronome speed in 3 sets of 10 repetitions. In both groups, 30 seconds of rest was given between exercises.
62368837|NCT05840523|NO_INTERVENTION|Control Group|No exercise practice was done
62368838|NCT02329145|EXPERIMENTAL|Active treatment|Renal denervation
62368839|NCT02329145|NO_INTERVENTION|Observational|
62368840|NCT04247789||Total sample|This group consists of older adults living in a rest home, who are proper for inclusion criteria
62368841|NCT02321397|EXPERIMENTAL|OXN PR HST|Prolonged release oxycodone/naloxone higher strength tablets
62368842|NCT02321397|ACTIVE_COMPARATOR|OXN PR LST|Prolonged release oxycodone/naloxone lower strength tablets
62742996|NCT05786937|ACTIVE_COMPARATOR|aDC1immunization|The participants will be immunized with aDC1 unpulsed with HIV peptides.
62742997|NCT05786937|EXPERIMENTAL|aDC1 immunization with analytical treatment interruption of ART|The participants will be immunized with aDC1 pulsed with HIV peptides.
62368843|NCT06444594|PLACEBO_COMPARATOR|Vehicle Gel|Non-active topical gel
62368844|NCT06444594|EXPERIMENTAL|Transient Receptor Potential (M8) Agonist|Topical menthol gel applied once at 10%
62368845|NCT06444594|EXPERIMENTAL|Transient Receptor Potential (V4) Agonist|Topical capsaicin gel applied once at 0.05%
62368846|NCT06444594|EXPERIMENTAL|Transient Receptor Potential (V1) Agonist|Topical camphor gel applied once at 0.6%
62368847|NCT06444594|EXPERIMENTAL|Transient Receptor Potential M8 V4 V1 Agonist|Topical menthol 10%, capsaicin 0.05%, camphor 0.6% applied once
62368848|NCT06444594|NO_INTERVENTION|no gel|no gel comparison
62368849|NCT00625040||A|Obese patients without diabetes with a Body Mass Index \> 37 kg/m2
62368850|NCT05299645|EXPERIMENTAL|Arm 1 - Transvestites and young transsexual women|Qualitative interviews
62368851|NCT04033380|ACTIVE_COMPARATOR|Resin bloc endocrown|composite-based blocs (Grandio Blocs, VOCO)
62368852|NCT04033380|ACTIVE_COMPARATOR|Ceramic endocrown|glass ceramic zirconia enhanced lithium silicate glass ceramics (Suprinity, VITA)
62368853|NCT02388672|EXPERIMENTAL|Drink high-CGA|Participants will drink once 250ml of decaffeinated coffee enriched with chlorogenic acid (CGA) (6g decaffeinated coffee (5 mg caffeine) with high total CGA (560 mg)).
62368854|NCT02388672|PLACEBO_COMPARATOR|Drink low-CGA|6g decaffeinated coffee (250 ml) with normal total CGA (224 mg)
62368855|NCT02388672|EXPERIMENTAL|Capsules high-CGA|6g decaffeinated coffee (250 ml) with normal total CGA and 800mg green coffee bean extract supplement with total CGA (560mg)
62368856|NCT02388672|PLACEBO_COMPARATOR|Capsules low-CGA|6g decaffeinated coffee (250 ml) with normal total CGA and placebo
62368857|NCT02388672|NO_INTERVENTION|Control|No treatment control group
62368858|NCT05856279|EXPERIMENTAL|mulligan SNAG|Patients in this group will receive mulligan SNAG from sitting position and McGill stabilization exercises.The glide will be performed six repetitions for three sets for one session and McGill stabilization exercises as a home program: 7 days a week and 10 repetitions of each exercise for 2times per day and a rest interval of 2 minutes between exercises
62742998|NCT04838054|EXPERIMENTAL|Test - stabilized chlorine dioxide rinse|Subjects will receive CloSYS Ultra Sensitive Rinse
62742999|NCT04838054|PLACEBO_COMPARATOR|Placebo - oral rinse, no active ingredients|Subjects will receive oral rinse - no active ingredients
62743000|NCT06274034|EXPERIMENTAL|Supportive Care (MUSE S headband, meditation)|Patients wear the MUSE S headband to bed every night for 8 weeks and meditate using the MUSE phone app during day hours for at least 5 minutes over 8 weeks.
62743001|NCT05097651|EXPERIMENTAL|CBD|Participants will receive oral liquid cannabidiol
62743002|NCT05097651|PLACEBO_COMPARATOR|Placebo|Participants will receive an inert oral liquid
62368859|NCT05856279|EXPERIMENTAL|mulligan lion position|Patients in this group will receive mulligan modified lumbar SNAG lion position and McGill stabilization exercises.Modified lumbar SNAGs (lion position) will be applied in a quadruped position (lion position)six repetitions for three sets for one session . McGill stabilization exercises as a home program: 7 days a week and 10 repetitions of each exercise for 2times per day and a rest interval of 2 minutes between exercises The therapist stands to one side of the patient and applies (SNAG) centrally to the spinous process of the involved segment. The medial border of the hand is hooked under the chosen segment while the other arm encircles the trunk to stabilize the upper body. The therapist maintains the glide while the patient sits back towards their heels (for flexion) .
62368860|NCT01756638|EXPERIMENTAL|Abiraterone plus Prednisolone|Abiraterone 1000 milligram (mg) oral tablets will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
62368861|NCT04601844|EXPERIMENTAL|Cohort 1|Cemdisiran at dose 1 SC single dose on day 1 followed by pozelimab at dose 1 SC single dose on day 29
62368862|NCT04601844|EXPERIMENTAL|Cohort 2|Cemdisiran at dose 2 SC single dose on day 1 followed by pozelimab at dose 1 SC single dose on day 29
62368863|NCT04601844|EXPERIMENTAL|Cohort 3|Cemdisiran at dose 2 SC single dose and pozelimab at dose 2 SC single dose, both administered on day 1
62368864|NCT04718402|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection|Subjects with advanced gastric carcinoma will receive 20mg/m2Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles.
62368865|NCT01562197|EXPERIMENTAL|Axitinib|axitinib treatment arm
62368866|NCT01562197|EXPERIMENTAL|Axitinib plus Lomustine|Axitinib plus Lomustine
62368867|NCT02412527||Primary insomnia|Primary insomnia patients, without combined any other sleep disorders
62368868|NCT02412527||Periodic limb movement in sleep|Patients have periodic limb movement in sleep, without combined any other sleep disorders
62368869|NCT02412527||Simple snores|Simple snore patients, without combined any other sleep disorders
62368870|NCT02412527||Obstructive sleep apnea|Obstructive sleep apnea patients, including mild, moderate and severe types, without combined any other sleep disorders or CPAP treatment during PSG study
62368871|NCT00087386|EXPERIMENTAL|Treatment (tanespimycin)|Patients receive tanespimycin IV over 1-6 hours once weekly for 6 weeks. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
62368872|NCT05093569||Iteration|35 patients will be included in 7 iterations.
62368873|NCT04809025||the pathology of endoscopic biopsy|The histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status of gastric cancer testing on endoscopic biopsies
62368874|NCT04809025||the pathology of surgical resection specimen|The histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status of gastric cancer testing on surgical resection specimens
62368875|NCT02497053|EXPERIMENTAL|Arm A|Four cycles of pemetrexed/platinum
62368876|NCT02497053|ACTIVE_COMPARATOR|Arm B|Six cycles of pemetrexed/platinum
62368877|NCT05911945|ACTIVE_COMPARATOR|Flexible Ureterorenoscopy|Underwent a JJ stent insertion and underwent f-URS 4-6 weeks later (Group 1).
62368878|NCT05911945|ACTIVE_COMPARATOR|Mini Percutaneous Nephrolithotomy|Underwent mPNL operation in the same session after prone positioning (Group 2).
62368879|NCT06005272||Cases|Recently pregnant women/people who have experienced baby loss during pregnancy, labour or shortly after birth between 20-28 weeks of pregnancy
62368880|NCT06005272||Controls|Individuals still pregnant at same gestational age
62368881|NCT02685618|EXPERIMENTAL|Iloprost + M1006B offset by -10 mmHg|"Administration of 1 ng/kg/min Ilomedin® as a 48h continuous i.v infusion. Administration of blood pressure modules M1006B: offset by -10 mmHg~Intervention: Drug: Iloprost + M1006B offset -10mmHg"
62368882|NCT02685618|EXPERIMENTAL|Iloprost + M1006B, No offset|"Administration of 1 ng/kg/min Ilomedin® as a 48h continuous i.v infusion Administration of blood pressure modules M1006B: No offset~Intervention: Drug: Iloprost + M1006B, No offset"
62368883|NCT02685618|PLACEBO_COMPARATOR|Placebo + M1006B offset by -10 mmHg|"Double dummy 0.9% saline as a 48h continuous i.v infusion. Administration of blood pressure modules M1006B: offset by -10 mmHg~Intervention: Drug: Placebo + M1006B offset -10mmHg"
62368884|NCT02685618|PLACEBO_COMPARATOR|Placebo + M1006B, No offset|"Double dummy 0.9% saline as a 48h continuous i.v infusion Administration of blood pressure modules M1006B: No offset~Intervention: Drug: Placebo + M1006B, No offset"
62368885|NCT05874336|EXPERIMENTAL|Single dose administration of Aramchol in Part 1 and Part 2|6 subjects received Aramchol in Part 1 and Part 2 of the study
62368886|NCT05635279||HCC patients who received ICIs combined with TKIs|HCC patients who received ICIs combined with TKIs regularly and periodically.
62368887|NCT05635279||HCC patients treated with TACE|HCC patients who underwent TACE as initial treatment.
62368888|NCT00610077|EXPERIMENTAL|1|Letrozole
62368889|NCT00610077|ACTIVE_COMPARATOR|2|Clomiphene citrate
62368890|NCT03049930|EXPERIMENTAL|Ketamine|Participants randomized to this arm will receive ketamine (1 mg/ml solution) infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
62368891|NCT03049930|PLACEBO_COMPARATOR|Placebo|Participants randomized to this arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
62368892|NCT03026205|EXPERIMENTAL|Single Arm|ARMS-I dosage of 0.75 mg will be sprayed orally in the mouth once as a single dose of four sprays on Day 1, and then three times a day starting on Day 3 for 4 Days.
62368893|NCT02668172|EXPERIMENTAL|Pasireotide LAR 60 mg monotherapy week 12|"After enrollment, acromegaly patients on combination treatment will half their regular weekly dose of pegvisomant (PEGV) for 12 weeks (run-in period).~When insuline-like growth factor 1 (IGF-I) remains within the age adjusted normal limits after 12 weeks, PEGV and the LA-SSA (Octreotide Long Acting Release (LAR) or Lanreotide Autogel) with Pegvisomant (PEGV) are discontinued and patients are switched to pasireotide LAR 60 mg for 12 weeks."
62368894|NCT02668172|EXPERIMENTAL|Pasireotide LAR 60 mg and Pegvisomant week 12|When IGF-I rises above the adjusted normal limits after 12 weeks (run-in period), these subjects will switch their LA-SSA to Pasireotide LAR 60 mg every 4 weeks and continue with the reduced PEGV dose of the run-in period, for the remaining 12 weeks.
62743003|NCT05851534|NO_INTERVENTION|Standard care|Receiving standard preoperative care
62743004|NCT05851534|EXPERIMENTAL|Best practice program|Implementation of best practice preoperative optimisation program
62368895|NCT02668172|EXPERIMENTAL|Pasireotide LAR 60 mg and Pegvisomant week 24|"Between week 12 and 24 dose adaptations of PEGV are not permitted unless IGF-I drops below the age adjusted normal limits, then the dose of PEGV will be decreased stepwise with 20 mg weekly until IGF-I is within the age adjusted normal limits.~At week 24, efficacy will be assessed, as the number of patients with a normal IGF-I in the two different groups; the combination Pasireotide LAR 60 mg / PEG V dose and monotherapy Pasireotide LAR 60 mg.~From week 24 patients will continue with Pasireotide LAR 60 mg monotherapy, or Pasireotide LAR will be combined with 50% of the original dose of PEGV, or with an increasing dose of PEGV every 8 weeks depending on the treatment arm."
62368896|NCT00926991||traumatic rib fractures|
62368897|NCT05478057|EXPERIMENTAL|PD patients with speech disturbance treated with 10 Hz rTMS|
62368898|NCT05478057|SHAM_COMPARATOR|PD patients with speech disturbance treated with sham rTMS|
62368899|NCT05478057|EXPERIMENTAL|PD patients without speech disturbance treated with 10 Hz rTMS|
62368900|NCT05478057|SHAM_COMPARATOR|PD patients without speech disturbance with sham rTMS|
62368901|NCT02495090|OTHER|Hypospadias|Familial hypospadias trios (patients + parents)
62368902|NCT05381389|ACTIVE_COMPARATOR|Group In-plane approach:|An in-plane approach was used for the interscalene block. The needle was brought in the same plane as the probe at a shallow angle to the skin, some distance away from the edge of the probe in a lateral to medial direction so that the whole length of the needle can be visualized. After negative aspiration and assurance that high resistance to injection was absent, the LA was injected in a 5 ml increment below the lower root, between the 3 roots and above the upper root.
62368903|NCT05381389|ACTIVE_COMPARATOR|Group Out-of-plane approach|An out-of-plane approach was used for the interscalene block. The needle was inserted cranial to the probe and after negative aspiration and assurance that high resistance to injection was absent, the LA was injected in a 10 ml increment; lateral and medial to the nerve roots. The needle appeared as a bright dot on the screen and by tilting the probe, the tip was identified as the point where further tilting leads to no longer visualization of the bright dot on the screen.
62368904|NCT01025232|ACTIVE_COMPARATOR|4 Week Re-treatment|Subjects can receive re-treatment every 4 weeks if there is persistent or recurrent intraretinal, subretinal, or sub-RPE fluid on any OCT modality, or any evidence of hemorrhage on clinical evaluation. Subjects will go no longer than 12 weeks without treatment.
62368905|NCT01025232|ACTIVE_COMPARATOR|6 Week Re-treatment|Subjects can receive re-treatment every 6 weeks if there is persistent or recurrent intraretinal, subretinal, or sub-RPE fluid on any OCT modality, or any evidence of hemorrhage on clinical evaluation. Every 6 weeks regimen will test potential longer duration of action of 2.0 mg ranibizumab. Subjects will go no longer than 12 weeks without treatment.
62368906|NCT05698004|ACTIVE_COMPARATOR|Group-1: prone positioning + standard treatment|Patients randomized to the intervention group will be subjected to awake prone positioning. The target duration of prone positioning is 8 h/d to 10 h/d with 2 to 3 breaks (1-2 hours each), if needed. Daily prone positioning sessions will be protocolized to continue until 1 of the following stopping criteria is met: a relative improvement in the FIO2 requirement by 40% from the baseline value that sustained for 24 hours; endotracheal intubation; or discharge from the ICU. The treating team will supervise patients who could move themselves during the prone positioning process and assist the patients with positioning as required.
62368907|NCT05698004|NO_INTERVENTION|Group-2: Standard treatment only|Patients randomized to the control group, and their treating team, will be informed of their group assignment. Nurses instruct patients not to position themselves in the prone position.
62368908|NCT04583345||Hypertensive|Diagnosis of hypertension
62368909|NCT04583345||Healthy|Healthy blood pressure level and absence of any chronic disease
62368910|NCT00591175||1|Standard Care
62368911|NCT00591175||2|Standard Care with Hygienist Counseling
62368912|NCT00591175||3|Standard Care with Hygienist Counseling \& Personalized Risk Communication
62743005|NCT00705913|ACTIVE_COMPARATOR|1|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)
62743006|NCT00705913|ACTIVE_COMPARATOR|2|
62743007|NCT02744495|EXPERIMENTAL|postoperative nausea and vomiting risk factors|Preoperative collection of postoperative nausea and vomiting risk factors available for practicians.
62743008|NCT02744495|NO_INTERVENTION|control|No prophylaxis whatever risk score is. Postoperative nausea and vomiting risk factors not available for practicians.
62743009|NCT06355596|ACTIVE_COMPARATOR|Face-to-face teaching|Face-to-face teaching of laparoscopic skills
62368913|NCT05425524|EXPERIMENTAL|Care Bundle Group|Treatment step by step we have 5 steps STEP 1: Leptospirosis suspected case STEP 2: Investigations STEP 3: Antibiotics within 1 hour after Hemocultures were taken STEP 4: Intravenous Fluid STEP 5: Stage-Base Management of AKI (KDIGO)
62368914|NCT05425524|NO_INTERVENTION|Control Group|
62567171|NCT03870750|EXPERIMENTAL|Arm I (SPC)|Patients undergo SPC on days -15 before to +56 after transplant. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT. Patients may also complete surveys on medical and non-medical (transportation, lodging) costs related to transplant after HCT.
62743010|NCT06355596|EXPERIMENTAL|Virtual teaching|Virtual teaching of laparoscopic skills
62743011|NCT01253694|EXPERIMENTAL|Patients with 3-5 consecutive Avastin injections|These patients will receive 0.5 mg of intravitreal Ranibizumab monthly for 6 months.
62743012|NCT01253694|EXPERIMENTAL|Patients with 6 or more consecutive injections of Bevacizumab|Patients will receive 0.5 mg of intravitreal Ranibizumab during the first 6 months.
62743013|NCT02700035|EXPERIMENTAL|BZDDD Prevention Program Intervention|We employed an experimental randomized block (RB) design; blocked on reservation where 157 were assigned to the intervention condition (Bii-Zin-Da-De-Dah (Listening to One Another) 14 week family based prevention program). The first 4 weeks of the program are oriented towards the Anishinabe cultural traditions and the traditional Anishinabe family. Weeks 5 through 8 focus on identifying feelings and how to manage negative feelings such as anger and sadness in positive ways. The last 6 weeks of the program focus on outside influences and how to build positive support systems. Prior to the intervention, we completed a pre-test with families in the experimental group. Following the program, we completed a post-test and a 6-month youth follow-up.
62368915|NCT03074318|EXPERIMENTAL|Phase 1 (1.5 mg/m^2 trabectedin + avelumab)|Avelumab will be administered every 2 weeks. Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,...) moving forward. After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only. Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first. This will continue until unacceptable toxicity or confirmed disease progression.
62368916|NCT03074318|EXPERIMENTAL|Phase 1 (1.0 mg/m^2 trabectedin + avelumab)|Avelumab will be administered every 2 weeks. Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,...) moving forward. After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only. Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first. This will continue until unacceptable toxicity or confirmed disease progression.
62368917|NCT03074318|EXPERIMENTAL|Phase 1 (1.2 mg/m^2 trabectedin + avelumab)|Avelumab will be administered every 2 weeks. Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,...) moving forward. After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only. Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first. This will continue until unacceptable toxicity or confirmed disease progression.
62368918|NCT03074318|EXPERIMENTAL|Phase 2 (1.0 mg/m^2 trabectedin + avelumab)|Avelumab will be administered every 2 weeks. Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,...) moving forward. After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only. Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first. This will continue until unacceptable toxicity or confirmed disease progression.
62368919|NCT03304093|EXPERIMENTAL|Nivolumab|Nivolumab 3mg/kg every 2 weeks
62368920|NCT03638336|EXPERIMENTAL|flexible ureteroscopy|
62368921|NCT05882604|EXPERIMENTAL|Intra-articular injection with MESNA solution|1 ml of MESNA will be injected intra-articular
62368922|NCT05882604|ACTIVE_COMPARATOR|Arthrocentesis with ringer solution|ringer solution will be used for arthrocentesis
62368923|NCT04214041|EXPERIMENTAL|Autologous fat grafting|
62368924|NCT04214041|ACTIVE_COMPARATOR|Sub-epithelial connective tissue graft|
62368925|NCT02377076|EXPERIMENTAL|DAIRY|Dietary calcium supplementation
62368926|NCT02377076|PLACEBO_COMPARATOR|CONTROL|Control
62368927|NCT01789255|EXPERIMENTAL|Supportive care (vorinostat, tacrolimus, methotrexate)|Patients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180.Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.
62368928|NCT05048225||Low-salt (LS) group|intake of \< 5 g of salt per day
62368929|NCT05048225||Normal-salt (NS) group|intake of 5 - 7.5 g of salt per day
62368930|NCT05048225||High-salt (HS) group|intake of 7.5 - 10 g of salt per day
62368931|NCT05048225||Very high-salt (VHS) group|intake of \> 10 g of salt per day
62368932|NCT06039657|EXPERIMENTAL|SEAS group|The SEAS therapy program comprised a one-year supervised exercise regimen. Supervised sessions were scheduled weekly for the initial month, bi-weekly for the second month, and monthly from the third to the sixth month. Thereafter, sessions were held bimonthly, each lasting one hour. Home exercises were designed to encompass 10-12 distinct exercises, with an approximate duration of 40-45 minutes per session
62368933|NCT06039657|ACTIVE_COMPARATOR|Standard Care Group|Standard care program aimed to provide patients with basic postural education and exercises in a single session, followed by one year of observation to ensure standard care.
62368934|NCT05427175|ACTIVE_COMPARATOR|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
62368935|NCT05427175|ACTIVE_COMPARATOR|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
62368936|NCT05427175|NO_INTERVENTION|healthy individuals as control group|
62368937|NCT04767776|EXPERIMENTAL|Arm A|"* Period  rivaroxaban and 6 milligram of activated charcoal ~* Washout period (6 days)~* Period  rivaroxaban and 12 milligram of activated charcoal ~* Washout period (6 days)~* Period  rivaroxaban and 50 milligram of activated charcoal ~* Washout period (6 days)"
62368938|NCT04767776|EXPERIMENTAL|Arm B|"* Period  rivaroxaban and 12 milligram of activated charcoal ~* Washout period (6 days)~* Period  rivaroxaban and 6 milligram of activated charcoal ~* Washout period (6 days)~* Period  rivaroxaban and 24 milligram of activated charcoal ~* Washout period (6 days)"
62368939|NCT04767776|EXPERIMENTAL|Arm C|"* Period  rivaroxaban and 50 milligram of activated charcoal ~* Washout period (6 days)~* Period  rivaroxaban and 24 milligram of activated charcoal ~* Washout period (6 days)~* Period  rivaroxaban and 6 milligram of activated charcoal ~* Washout period (6 days)"
62368940|NCT04767776|EXPERIMENTAL|Arm D|"* Period  rivaroxaban and 24 milligram of activated charcoal ~* Washout period (6 days)~* Period  rivaroxaban and 50 milligram of activated charcoal ~* Washout period (6 days)~* Period  rivaroxaban and 12 milligram of activated charcoal ~* Washout period (6 days)"
62368941|NCT01591993|EXPERIMENTAL|Test subject|To each subject, the investigators will randomly apply 10% lactic acid on one nasolabial fold, once.
62368942|NCT01591993|PLACEBO_COMPARATOR|Placebo|To each subject, the investigators will apply placebo (0.9% saline solution) on the contralateral nasolabial fold to the lactic acid, simultaneously.
62743014|NCT02700035|NO_INTERVENTION|BZDDD Prevention Program Control|We employed a randomized block (RB) design; blocked on reservation, 147 families were randomly assigned to the control condition. We completed a post-test and a 6-month youth follow-up.
62368943|NCT04462978||Non IgE-mediated food allergy|Children with non IgE-mediated food allergy
62368944|NCT04331028|EXPERIMENTAL|Shockwave therapy|After dental extraction, a shockwave therapy will be applied to the area.
62368945|NCT04331028|NO_INTERVENTION|Control|After dental extraction, no treatment will be applied
62743015|NCT01924273|OTHER|Port Wine Stain Birthmarks|Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
62368946|NCT06384625|OTHER|Air pollution intervention implementation|AIRWISE intervention implementation
62368947|NCT01751204|ACTIVE_COMPARATOR|Calcium tablet|250 mg calcium/tablet
62368948|NCT01751204|EXPERIMENTAL|Calcium ion water (250mg)|250 mg calcium in 200 ml water
62368949|NCT01751204|EXPERIMENTAL|Calcium ion water (125mg)|125 mg calcium in 200 ml water
62368950|NCT00305734|EXPERIMENTAL|Treatment (bortezomib, gemcitabine hydrochloride)|"Patients receive bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses of treatment with bortezomib.~Patients who experience disease progression on single-agent bortezomib and did not receive prior gemcitabine hydrochloride may begin combination therapy within 10-28 days of the last dose of bortezomib. Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and bortezomib IV on days 1, 4, 8, 11. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond the confirmed CR."
62368951|NCT00278551|EXPERIMENTAL|heatopoietic stem cell transplant|
62368952|NCT05218538||Learning e-cohort|Includes the entire population within Clalit Healthcare's electronic records database which spans from the year 2000 to 2021.
62368953|NCT05218538||FIB-4 score group|One of the two validation population invited to the clinic. The FIB-4 score group are individuals invited by their score.
62368954|NCT05218538||Model based group|"One of the two validation population invited to the clinic:~The Model based group are individuals invited by their predicted time-to-event to liver cirrhosis diagnosis."
62368955|NCT01619488|EXPERIMENTAL|Gastric Banding|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
62368956|NCT04173403|EXPERIMENTAL|AK102|450mg AK102, Q4W, subcutaneous injection; OR 300mg AK102, Q4W, subcutaneous injection;OR 150mg AK102, Q4W, subcutaneous injection;
62368957|NCT04432181||Group 1, astigmatic patients with amblyopia|astigmatic children with amblyopia
62368958|NCT04432181||Group 2, astigmatic patients without amblyopia|astigmatic children without amblyopia
62743016|NCT03706742|NO_INTERVENTION|Usual Care|Patients randomized to Group 1 will receive visit-based HCV screening, as offered by clinic providers as part of usual care. Providers must identify at-risk patients who are eligible for HCV screening, understand the benefits of screening in this population, and enter orders for HCV Ab testing. If the HCV antibody is abnormal, providers must order appropriate follow-up tests including HCV viral load to confirm HCV infection. Once HCV is confirmed, providers must refer the patients for fibrosis assessment and treatment evaluation. These efforts are augmented by an established best practice alert and health maintenance reminders.
62743017|NCT03706742|ACTIVE_COMPARATOR|Mailed outreach|Patients randomized to Group 2 will receive low literacy, written materials about HCV screening among baby-boomers in English and Spanish. The invitation will include patient-centered educational materials that discuss the risk of HCV in baby boomers and the benefits and risks of HCV screening. The invitation will include a phone number to schedule the HCV antibody blood test. Written materials will be developed and validated in Spanish using the Spanish Language Translation Resource. Once a potential subject is identified and randomized in Group 2, an outreach invitation will be mailed out. Shortly after the letter, a bilingual patient navigator will place a follow-up call to this potential subject. These follow-up calls will occur in the 2nd - 4th week after mailing invitations; up to three attempts in total will be made to reach the patient to facilitate HCC screening completion.
62368959|NCT01793090|ACTIVE_COMPARATOR|EPI-743|"EPI- 743 in capsule or formulation comprised of USP/NF (United States Pharmacopeia and The National Formulary)Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.~Dose: 100mg or 200 mg tid for 12 months, to be continued if clinically effective"
62368960|NCT01793090|PLACEBO_COMPARATOR|Placebo supplementation|placebo in the same formulation as the active comparator will be administered to patients, assigned to this arm in a randomized design
62368961|NCT00549406|EXPERIMENTAL|1|computer-based visual-training program UFOV
62368962|NCT00549406|EXPERIMENTAL|2|video-game based visual training
62368963|NCT00549406|PLACEBO_COMPARATOR|3|computerized word puzzles
62368964|NCT00746473||1|15 HIV-1 infected individuals, with or without AIDS, who had never received ARV. These patients had not yet been indicated for ARV, or had had HIV-1 infection diagnosed a few days before inclusion in this study.
62368965|NCT00746473||2|"27 HIV-1 infected individuals, sick or not, on ARV treatment, five with two nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) and one nonnucleoside reverse transcriptase inhibitor (NNRTI), and 22 on HAART with two NRTI, or one NRTI and one NNRTI, and one protease inhibitor (PI), and VL equal to or greater than 50 copies of plasma RNA/mL.~Treatment duration in this group varied between three and 145 months (mean 53.62 months; median 42 months)."
62368966|NCT00746473||3|31 HIV-1 infected individuals on ARV treatment, 16 on HAART with two NRTI, or one NRTI and one NNRTI, and one PI, and 15 with two NRTI and one NNRTI. All G3 patients had undetectable VL for at least the past 6 months. Treatment in this group varied between five to 108 months (mean 48.13 months; median 42 months).
62368967|NCT00746473||4|20 blood donors without clinical complaints and negative for anti-HIV-1/2 antibodies. None of them showed any sign of disease.
62368968|NCT02644694|EXPERIMENTAL|Dexamethasone Phosphate Ophthalmic Solution|Experimental: Dexamethasone Phosphate Ophthalmic Solution (40 mg/mL) delivered via the EyeGate II Drug Delivery System
62368969|NCT01766765|EXPERIMENTAL|Early jejunostomy nutrition|
62368970|NCT01766765|ACTIVE_COMPARATOR|Early oral nutrition|
62368971|NCT02756845|EXPERIMENTAL|Talimogene Laherparepvec (TVEC)|The first dose of talimogene laherparepvec will be administered at a dose of up to 4.0 mL of 10ᶺ6 PFU/mL followed by a dose of up to 4.0 mL of 10ᶺ8 PFU/mL 21 days (+3 days) later. Subsequent doses of up to 4.0 mL of 10ᶺ8 PFU/mL will be administered every 14 days (± 3 days) thereafter. Cohorts will be assigned as follows: Cohort A1 (age 12 to ≤ 21 years). Cohort B1 (age 2 to \< 12 years). The DLRT will review the safety data of the first 3 subjects in the older age cohort A1 to decide if the younger age cohort B1 can be opened for enrollment. If dose de-escalation is needed and if permissible based on the incidence of DLTs, additional DLT-evaluable subjects will be enrolled and treated at a lower dose level of talimogene laherparepvec. Dose de-escalation cohorts will be assigned as follows and the same DLT rules will be applied: Cohort A2 (age 12 to ≤ 21 years), Cohort B2 (age 2 to \< 12 years).
62368972|NCT01838655|EXPERIMENTAL|Nitisinone|Oral administration of nitisinone
62368973|NCT03581799|OTHER|Oral dispersible tablet|5 mm calcium carbonate based ODT will be administered by placing it in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
62368974|NCT00185172|PLACEBO_COMPARATOR|1|2 week placebo run-in
62368975|NCT00185172|EXPERIMENTAL|2|Olmesartan medoxomil tablets for 8 weeks
62368976|NCT00185172|EXPERIMENTAL|3|Olmesartan medoxomil tablets, or olmesartan medoxomil tablets + hydrochlorothiazide tablets for 4 weeks
62368977|NCT06059833||cases group|
62368978|NCT06059833||control group|
62368979|NCT06009575|EXPERIMENTAL|intervention group|
62368980|NCT06009575|ACTIVE_COMPARATOR|control group|
62368981|NCT02996500|EXPERIMENTAL|Arm 1: 20 mg QD|PF-06650833 , 20 mg QD
62368982|NCT02996500|EXPERIMENTAL|Arm 2: 60 mg QD|PF-06650833, 60 mg QD
62368983|NCT02996500|EXPERIMENTAL|Arm 3: 200 mg QD|Pf-06650833, 200 mg QD
62368984|NCT02996500|EXPERIMENTAL|Arm 4: 400 mg QD|PF-06650833, 400 mg QD
62368985|NCT02996500|PLACEBO_COMPARATOR|Placebo|Placebo, 0 mg BID
62368986|NCT02996500|ACTIVE_COMPARATOR|Arm 5: Tofacitinib|Tofacitinib 5 mg BID
62368987|NCT04770298|EXPERIMENTAL|Halliwick Assessment Group|8 children with GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM (GMFCS) I, 13 children with GMFCS II, 7 GMFCS III children, 8 GMFCS IV children and 4 children with GMFCS V. Intervention in water environment (Halliwick Concept), 1 times/week- 1 intervention on land/week, 9 months duration.
62368988|NCT04770298|EXPERIMENTAL|Bobath Assessment Group|7 children with GMFCS I, 12 children with GMFCS II, 8 children with GMFCS III, 6 children with GMFCS IV and 2 children with GMFCS V. Intervention on land ( Bobath), 2 times/week, 9 months duration.
62368989|NCT04770298|NO_INTERVENTION|No intervention group|1 children with GMFCS I, 1 child with GMFCS III, 1 child with GMFCS IV and 2 GMFCS V children. No intervention.
62743018|NCT03286829|EXPERIMENTAL|"Tesomet High dose in fasted condition"|"A Tesomet FDC tablet (20 mg immediate release \[IR\] metoprolol, 1 mg tesofensine, 80 mg extended release \[ER\] metoprolol) in fasted condition (High dose)"
62368990|NCT05267938|EXPERIMENTAL|Microneedles|Microneedles is with 750μm of height in order to prepare the palatal mucosa to receive the topical anesthetic
62368991|NCT05267938|SHAM_COMPARATOR|patch flat|The same device as the microneedles but without microneedles
62743019|NCT03286829|EXPERIMENTAL|"Tesomet Low dose in fasted condition"|"Treatment B (Test 2): A Tesomet FDC tablet (5 mg immediate IR metoprolol, 0.2 mg tesofensine, 20 mg ER metoprolol) in fasted condition. (Low dose)"
62743020|NCT03286829|ACTIVE_COMPARATOR|Comperator|1 mg tesofensine (2 tablets of 0.5 mg), 25 mg commercial IR metoprolol (1 tablet of 25 mg), 75 mg commercial ER metoprolol (1 tablet of 25 mg ER metoprolol and 1 tablet of 50 mg ER metoprolol), fasted condition
62368992|NCT02340572|EXPERIMENTAL|PRS-080#022-DP|hepcidin antagonist, single administration, ascending doses
62368993|NCT02340572|PLACEBO_COMPARATOR|PRS-080-Placebo#001|Comparotor treatment, single administration
62368994|NCT06283134|EXPERIMENTAL|Combination therapy with BioTTT001 hepatic artery infusion , Regorafenib and Toripalimab|This study includes a dose escalation phase and a dose expansion phase. The dose escalation phase will adopt a 3+3 design. Subjects were first treated with BioTTT001 monotherapy (hepatic artery infusion, administered every 2 weeks, D1 and D15 for a total of two doses) after enrollment. If the subject does not develop DLT in the monotherapy stage and is judged to be safe and tolerable by the investigator, the subject will enter the treatment phase of BioTTT001 in combination with toripalimab and regorafenib( toripalimab 80mg iv. D1 and D15 , BioTTT001 5×10\^7 VP/5×10\^8 VP/5×10\^9 VP/1×10\^10 VP HAI. D2 and D16 , regorafenib 80 mg Po. D1-D21; 4 weeks per cycle), and the dose of BioTTT001 will be determined according to the safety observation results in the monotherapy phase. In the dose expansion phase, different dose groups can be expanded, and the total number of enrolled subjects is expected to be 30 for further safety, tolerability, pharmacokinetics and preliminary efficacy evaluation.
62368995|NCT02799628|ACTIVE_COMPARATOR|intervention|"1. Give the physical therapy of low back pain educational video + therapist introduction and recommendation video, at the first time of clinic visit.~2. Physical therapy with hot packing + interference current therapy + pelvic traction + therapeutic exercise, 3 times per week for 4 weeks."
62368996|NCT02799628|PLACEBO_COMPARATOR|placebo|"1. Give the physical therapy of low back pain educational video, at the first time of clinic visit.~2. Physical therapy with hot packing + interference current therapy + pelvic traction + therapeutic exercise, 3 times per week for 4 weeks."
62368997|NCT04350372|EXPERIMENTAL|MitraClip|Subject will receive MitraClip procedure with MitraClip NT System
62368998|NCT03577522|ACTIVE_COMPARATOR|Avenir cementless hip stem|Total hip arthroplasty: Avenir vs Corail
62368999|NCT03577522|ACTIVE_COMPARATOR|Corail HA-coated hip stem|Total hip arthroplasty: Corail vs Avenir
62369000|NCT01599572|EXPERIMENTAL|30mg/day zinc supplementation|30mg/day of zinc supplement provided for 3 months to zinc deficient elderly
62369001|NCT01428986||Maraviroc|Those whose take maraviroc as a part of their HIV treatment
62743021|NCT03286829|EXPERIMENTAL|"Tesomet High dose in fed condition"|"A Tesomet FDC tablet (20 mg immediate IR metoprolol, 1 mg tesofensine, 80 mg ER metoprolol in fed condition (High dose)"
62743022|NCT05476497|EXPERIMENTAL|Part A - Group A1|4 parallel cohorts (1-4) of adult healthy subjects. Each cohort will receive 6 ascending subcutaneous administrations of VLP Peanut.
62743023|NCT05476497|EXPERIMENTAL|Part A - Group A2|Adult peanut allergic subjects, will undergo skin prick tests with ascending concentrations of VLP Peanut.
62369002|NCT01428986||No maraviroc|Those who do not take maraviroc
62743024|NCT05476497|EXPERIMENTAL|Part B - Cohorts 1-4|4 parallel cohorts (1-4) of peanut allergic subjects. Each cohort will receive 6 ascending subcutaneous administrations of VLP Peanut.
62369003|NCT03634176||Group M|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received 0.5gr/kg 20% mannitol
62743025|NCT00802997|ACTIVE_COMPARATOR|1|Treatment with Sinergy system
62743026|NCT00802997|PLACEBO_COMPARATOR|2|placebo controlled
62743027|NCT04616183|EXPERIMENTAL|Arm A (ERK1/2 inhibitor LY3214996, cetuximab)|Patients receive ERK1/2 inhibitor LY3214996 PO QD on days 1-28 and cetuximab IV over 1-2 hours on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62743028|NCT04616183|EXPERIMENTAL|Arm B (ERK1/2 inhibitor LY3214996, cetuximab, abemaciclib)|Patients receive ERK1/2 inhibitor LY3214996 and cetuximab as in Arm A. Patients also receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62743029|NCT00725192|ACTIVE_COMPARATOR|1|Cognitive Processing Therapy
62743030|NCT00725192|EXPERIMENTAL|2|Hypnosis plus Cognitive Processing Therapy.
62743031|NCT06445647|ACTIVE_COMPARATOR|Study Group|30 hemodialysis patient
62743032|NCT06445647|ACTIVE_COMPARATOR|Control group|30 hemodialysis patient
62743033|NCT01997606|EXPERIMENTAL|Purotex|use of Purotex treated bedding covers
62743034|NCT01997606|PLACEBO_COMPARATOR|Placebo|no use of Purotex treated bedding covers
62743035|NCT05282030|EXPERIMENTAL|Severe Renal Impairment (RI) group (Part A only)|Single dose of tolebrutinib (SAR442168) will be administered on Day 1 under fed condition
62743036|NCT05282030|EXPERIMENTAL|Normal Renal Function group (Part A and B)|Single dose of tolebrutinib (SAR442168) will be administered on Day 1 under fed condition
62369004|NCT03634176||Group H|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received 1.5 ml/kg 7.5% NaCl solution
62369005|NCT03634176||Group P|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after patients were positioned on reverse Trendelenburg position 30 degrees higher than the feet
62369006|NCT04246541|EXPERIMENTAL|Control|Patients will receive standard of care Percocet for post-operative pain control following meniscus debridement surgery
62369007|NCT04246541|EXPERIMENTAL|Ketorolac|Patients will receive IV ketorolac during surgery. They will then receive 3 days of oral ketorolac every 6 hours for pain control following surgery.
62743037|NCT05282030|EXPERIMENTAL|Moderate RI group (Part B only conditional)|Single dose of tolebrutinib (SAR442168) will be administered on Day 1 under fed condition
62743038|NCT02150551|EXPERIMENTAL|Mesenchymal Stromal Cells (MSCs)|A fixed dose of Mesenchymal Stromal Cells (MSCs) will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.
62369008|NCT04528004|EXPERIMENTAL|Nicotinamide riboside|"Participants randomized to Nicotinamide Riboside (NR) and scheduled to receive an LVAD will receive nicotinamide riboside (NR) capsules according to the following administration schedule:~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg) Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily Washout Day of LVAD Surgery and/or Day 15: None"
62743039|NCT02774200|EXPERIMENTAL|test group|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
62743040|NCT06661629|EXPERIMENTAL|Contralateral nerve stimulation|All participants will be part of this arm - they will have their contralateral nerve stimulated with an external stimulator as well as hypoglossal nerve stimulated with Inspire
62743041|NCT05636124|EXPERIMENTAL|Kaneka i-ED coil|Patients in the experimental arm will be treated according to the standard of care for endovascular aneurysm coiling, with no procedural modifications related to the use of the experimental device.
62743042|NCT05636124|NO_INTERVENTION|Matched patients who underwent intracranial aneurysm embolization|The comparator arm will be comprised of propensity matched patients who underwent intracranial aneurysm embolization as part of the FEAT Trial (NCT01655784).
62743043|NCT02687971|ACTIVE_COMPARATOR|Thermotherapy alone|"Local heat will be applied using a Localized Current Field radio-frequency generating device manufactured by Thermo-Med Technologies, Inc. A wand with 2 electrodes is connected to the main housing by a thin wire. The electrodes are applied to the skin. We will use electrodes 6 mm long, separated by 4 mm. One single session at the site of the lesion(s) at 50°C for 30 applications will be used. Depending on the size of the lesion, more than one application may be administered."
62743044|NCT02687971|EXPERIMENTAL|Thermotherapy plus Miltefosine|"In addition to receiving one single session of thermotherapy as described above, subjects will receive oral miltefosine two or three capsules a day, which is the equivalent of 100 to 150mg respectively for 21 days. Miltefosine capsules will be taken after breakfast, lunch and dinner, in other words, after food.~The daily dose of miltefosine will depend on the weight of each patient. According to dosage instructions if the patient is taking the miltefosine twice a day, it must be taken in the morning and night (dose of 100mg/Kg/day). Whereas if the patient is taking miltefosine three times a day, it must be taken in the morning, noon and night (dose of 150mg/Kg/day)."
62743045|NCT05508984||Single Arm|"Anywhere from 14 to 0 days prior to treatment, enrolled subjects will complete the following questionnaires, and their hair will be photographed by research staff.~Once enrolled, subjects will be provided the Amma device by the clinic on days of chemotherapy treatment, and upon completion of treatment it will be returned to the clinic for safekeeping. Upon completion of chemotherapy, anywhere from 3-6 weeks following treatment, subjects will repeat the questionnaires and their hair will be photographed again.~Subjects will then complete their enrollment in the study."
62743046|NCT06660641|ACTIVE_COMPARATOR|TaurolockTMHep100|
62743047|NCT06660641|PLACEBO_COMPARATOR|0.9% saline|
62743048|NCT01436656|EXPERIMENTAL|LGX818 - Dose escalation|
62743049|NCT01436656|EXPERIMENTAL|LGX818 - Dose Expansion at MTD or RP2D|
62743050|NCT01289275|EXPERIMENTAL|Telephone Counseling|Up to 5 proactive counseling sessions
62743051|NCT01289275|EXPERIMENTAL|Nicotine Patches|8 weeks of nicotine patches
62743052|NCT01289275|EXPERIMENTAL|Telephone Counseling + Patches|5 proactive sessions, 8 weeks patches
62743053|NCT01289275|ACTIVE_COMPARATOR|Brief hospital counseling|brief in hospital counseling, no proactive sessions or patches
62743054|NCT04975412||acne vulgaris group (cases)|Filipino patients, aged 18-25 years old with diagnosis of Acne Vulgaris
62743055|NCT04975412||control group|healthy Filipino patients, aged 18-25 years old
62743056|NCT03408418|EXPERIMENTAL|L-PRF group|The use of autologous leucocyte- and platelet-rich fibrin in alveolar sockets after dental extraction.
62743057|NCT03408418|NO_INTERVENTION|Control|Conventional tooth extraction without any bone substitute.
62743058|NCT00258765|EXPERIMENTAL|Zoledronic Acid|
62743059|NCT00258765|ACTIVE_COMPARATOR|Docetaxel|
62743060|NCT06326359|ACTIVE_COMPARATOR|autologous stromal vascular fraction derived from denovo|autologous stromal vascular fraction derived from denovo in male androgenic alopecia
62743061|NCT06326359|ACTIVE_COMPARATOR|autologous stromal vascular fraction after platelet rich plasma enhanced donner site|autologous stromal vascular fraction after platelet rich plasma enhanced donner site in male androgenic alopecia
62743062|NCT03473730|EXPERIMENTAL|Cohort 1 Renal (daratumumab, biopsy, surgery)|Patients receive daratumumab IV over 8 hours for the first dose and then over 4 hours for all doses thereafter during weeks 1-8. Treatment repeats every week for up to 8 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo biopsy, nephrectomy, or metastasectomy during weeks 10-12. Patients may then restart treatment with daratumumab beginning 2 weeks after biopsy or 4-6 weeks after nephrectomy or metastasectomy. Cycles repeat every 2 weeks for 4 months and then monthly for 1 year in the absence of disease progression or unacceptable toxicity.
62743063|NCT03473730|EXPERIMENTAL|Cohort 2 Bladder (daratumumab)|Patients receive daratumumab IV over 8 hours for the first dose and then over 4 hours for all doses thereafter beginning at week 1. Cycles repeat every week for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
62743064|NCT04116411|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo tablets with similar appearance as the active drug. Patients receive two 450 mg tablets twice daily taken per orally for 6 weeks, thereafter two 450 mg tablet once daily for an additional 22.5 months; a total treatment time of 24 months.
62743065|NCT04116411|ACTIVE_COMPARATOR|Valganciclovir|Patients will receive valganciclovir tablets with similar appearance as the placebo tablets. Patients receive two 450 mg valganciclovir tablets twice daily taken per orally for 6 weeks, thereafter two 450 mg valganciclovir tablets once daily for an additional 22.5 months; a total treatment time of 24 months.
62743066|NCT00443872|OTHER|orally disintegrating selegiline|This is a one arm open label study of patients who are experiencing a dopamine agonist (DA) related adverse effects (AE) of either one or more of the following: excessive daytime sleepiness, hallucinations, pedal edema, impulse control disorder. All subjects received orally disintegrating selegiline.
62743067|NCT01263678|OTHER|Non-Coaching|Usual care for patients with a diagnosis of spinal stenosis after viewing a DA and completing a survey.
62743068|NCT01263678|OTHER|Coaching|Patients randomized to coaching group will receive one week post viewing of Decisional Aid.
62743069|NCT02355652|ACTIVE_COMPARATOR|Cemented TKA|
62369009|NCT04528004|PLACEBO_COMPARATOR|Placebo|"Participants randomized to Placebo and scheduled to receive an LVAD will receive Placebo capsules according to the following administration schedule:~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg) Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily Washout Day of LVAD Surgery and/or Day 15: None"
62743070|NCT02355652|ACTIVE_COMPARATOR|Uncemented TKA|
62743071|NCT02728648|OTHER|Active|Open label IV Oxycodone 0.1 mg/kg Bolus Pharmacokinetic-Pharmacodynamic Study
62743072|NCT06347068|EXPERIMENTAL|iC9-CAR.B7-H3 T cells|Specimen will be collected to prepare the iC9-CAR.B7-H3 T cells. Disease-fighting T cells will be isolated and modified to prepare the iC9-CAR.B7-H3 T cells. In part 2, the iC9-CAR.B7-H3 T cells are given by infusion after completion of lymphodepletion chemotherapy.
62369010|NCT02741310|PLACEBO_COMPARATOR|Placebo|Participants received a placebo intravenous (IV) infusion on day 1 then 12 mg subcutaneous sumatriptan on day 2 (Part 1). After a 2-day washout participants received another placebo IV infusion on day 4 followed by 12 mg subcutaneous sumatriptan on day 5 (Part 2).
62369011|NCT02741310|EXPERIMENTAL|Erenumab|Participants received a placebo intravenous (IV) infusion on day 1 then 12 mg subcutaneous sumatriptan on day 2 (Part 1). After a 2-day washout participants received 140 mg erenumab IV infusion on day 4 followed by 12 mg subcutaneous sumatriptan on day 5 (Part 2).
62369012|NCT00881140|EXPERIMENTAL|antiprogestin|Daily use of 10 mg administrated per vagina
62369013|NCT00917137||Peripheral pulmonary lesions|
62743073|NCT06658184|EXPERIMENTAL|sleep restriction and stimulus control|
62743074|NCT06658184|ACTIVE_COMPARATOR|Sleep hygiene education|
62743075|NCT05536557|ACTIVE_COMPARATOR|Group (EOI) Plane Block|After tracheal intubation, a high-frequency linear probe will be in a cephalad to caudad paramedian direction at the anterior axillary line, and the external oblique muscle identified at the level ribs 6 and 7 in line. A block needle will inserted with in-plane technique and 25 ml 0.25 bupivacaine will be applied to EOI plane. The same procedure will be repeated on the contralateral side. Patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol.
62743076|NCT05536557|SHAM_COMPARATOR|Group N|The patients in Group N will not receive any intervention. In the intervention and control groups, block sites will be covered with dressings, and patients and other health care workers will be blinded to treatment allocation. Patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol.
62743077|NCT01824810|EXPERIMENTAL|Intramuscular Stimulation|Participants in this group will receive up to 12 sessions of Intramuscular Stimulation (IMS). Each session may last from 30 to 60 minutes. Primary and secondary outcome measures will be assessed prior to the first treatment, after completion of the last treatment, and 6 months after treatment is complete.
62743078|NCT01824810|EXPERIMENTAL|myoActivation|Participants in this group will receive up to 12 sessions of myoActivation treatment. Each treatment is approximately 15 minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
62369014|NCT06229808|EXPERIMENTAL|Multifunctional Birthing Ball group|"Massages will be applied to the experimental group in the first stage of labor for 30 minutes each at the end of the latent, active and transition phases (cervical dilatation 3-4 cm, 5-7 cm, 8-10 cm), respectively.~Perineal heating application is planned to be performed at least twice until the delivery occurs as 20 minutes of application and 20 minutes of tissue rest periods when the second stage of labor begins (the duration of this stage may reach 2 hours in primiparous women)."
62369015|NCT06229808|NO_INTERVENTION|Control group|No intervention will be applied
62743079|NCT01824810|EXPERIMENTAL|Neural Prolotherapy|Participants in this group will receive up to 12 sessions of neural prolotherapy. treatment. Each treatment is approximately 30 to 60 minutes minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
62369016|NCT01596192||Patients with acute GVHD|Patients after allogeneic hematopoietic cell transplantation who have developed acute GVHD
62369017|NCT04781049|EXPERIMENTAL|TPLA (Trans-Perineal Laser Ablation of Prostate)|Participants who undergo Trans-Perineal Laser Ablation of Prostate
62369018|NCT04781049|ACTIVE_COMPARATOR|TURP (Trans-Urethral Resection of Prostate)|Participants who undergo the standard treatment, namely Trans-Urethral Resection of Prostate
62369019|NCT02125630||Systemic therapy|Standart chemotherapy
62369020|NCT02125630||Primary surgery|Standart surgery
62369021|NCT02125630||Neoadjuvant chemotherapy|Standart chemotherapy followed by surgery
62369022|NCT03802240|EXPERIMENTAL|Sintilimab +IBI305+Pemetrexed+Cisplatin|"Drug: Sintilimab 200mg IV Q3W Other Name: IBI308~Drug: IBI305 15mg/kg IV Q3W~Drug: Pemetrexed 500mg/m2 IV Q3W~Drug: Cisplatin 75mg/m2 IV Q3W"
62369023|NCT03802240|EXPERIMENTAL|Sintilimab +Placebo2+Pemetrexed+Cisplatin|"Drug: Sintilimab 200mg IV Q3W Other Name: IBI308~Drug: Pemetrexed 500mg/m2 IV Q3W~Drug: Cisplatin 75mg/m2 IV Q3W~Drug: Placebo2 Placebo2 IV Q3W"
62369024|NCT03802240|ACTIVE_COMPARATOR|Placebo1+Placebo2+Pemetrexed+Cisplatin|"Drug: Pemetrexed 500mg/m2 IV Q3W~Drug: Cisplatin 75mg/m2 IV Q3W~Drug: Placebo1 Placebo1 IV Q3W~Drug: Placebo2 Placebo2 IV Q3W"
62743080|NCT01824810|SHAM_COMPARATOR|Sham Needling Control|Participants in this group will receive up to 12 sessions of sham needle treatment. Each treatment is approximately 15 to 60 minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
62743081|NCT04334135|EXPERIMENTAL|MitoQ|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after acute MitoQ supplementation (80 - 160mg).
62369025|NCT04363463|NO_INTERVENTION|Conventional positioning|semi-seated in bed or seated in a chair during the day. The prone position is not allowed during the day (it is allowed at night if it is the natural sleeping position).
62369026|NCT04363463|EXPERIMENTAL|Interventional positioning : prone position|Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.
62369027|NCT03329664|EXPERIMENTAL|CIK Intervention plus routine treatment|Patients who receive their routine treatment (chemotherapy, radiation therapy) + Cytokine-induced killer cell infusion
62743082|NCT04334135|PLACEBO_COMPARATOR|Placebo|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after a placebo matched in appearance to the MitoQ.
62743083|NCT04588415|EXPERIMENTAL|Virtual Support Group Arm|Those with severe symptoms (indicated by an ICG-r score \>25) will be notified that their symptoms are considered to be severe, with a suggestion to attend the virtual support groups. A recent meta-analysis of psychological interventions for grief found higher effect sizes in studies of participants who were \>6 months post-loss, and those with higher baseline symptom levels. However, no participant in our study will be randomized to any treatment assignment, and the decision to attend the VSG will be left to the family members.
62369028|NCT03329664|ACTIVE_COMPARATOR|Control|Patients who receive routine treatments only (chemotherapy, radiation therapy)
62369029|NCT04537572|OTHER|Sample Collection Method|All subjects will provide samples via traditional phlebotomy, finger-stick, and saliva collection.
62369030|NCT06323499||Induced atypical atrial flutter|Sinus rhythm when starting the procedure, so atypical atrial flutter had to be induced.
62369031|NCT06323499||Ongoing atrial flutter|Atypical atrial flutter was already ongoing when starting the procedure.
62743084|NCT04588415|NO_INTERVENTION|Non-Virtual Support Group Arm|Family members that choose not to participate in the Virtual Support Group will be part of this non-intervention arm
62743085|NCT00321074|ACTIVE_COMPARATOR|1|
62743086|NCT00321074|EXPERIMENTAL|2|
62369032|NCT01833806|EXPERIMENTAL|ExAblate Test Arm|Focused Ultrasound Surgery delivered by ExAblate MRgFUS
62369033|NCT01942408|NO_INTERVENTION|Standard care group|Patients will undergo an initial PVI procedure. Further management will be determined by AF recurrences at the responsible Consultant's discretion as per standard care.
62369034|NCT01942408|ACTIVE_COMPARATOR|Repeat study group|Following an initial PVI procedure, all patients (regardless of early AF recurrence) will undergo a repeat electrophysiology (EP) study at 8-10 weeks post-initial PVI, with repeat PVI of any PV reconnection identified
62369035|NCT06152692|EXPERIMENTAL|OSA + CPAP|OSA + CPAP
62369036|NCT06152692|PLACEBO_COMPARATOR|OSA + sham CPAP|OSA + sham CPAP
62369037|NCT06152692|NO_INTERVENTION|Control|Control
62369038|NCT02150460|EXPERIMENTAL|One-site peribulbar injection|Injection of a mixture of lidocaine 2% + adrenaline 0.125mg/ml + hyaluronidase 15 International Units (IU)/ml into the inferior medial orbital compartment
62369039|NCT02150460|ACTIVE_COMPARATOR|Two-site peribulbar injection|Injection of a mixture of lidocaine 2% + adrenaline 0.125mg/ml + hyaluronidase 15IU/ml into the infero-temporal and supero-nasal orbital compartments
62369040|NCT01639300|EXPERIMENTAL|GNbAC1|
62369041|NCT01639300|PLACEBO_COMPARATOR|GNbAC1 placebo|
62369042|NCT02163668|EXPERIMENTAL|Yoga group|8 months of progressive Yoga training
62369043|NCT02163668|NO_INTERVENTION|Control group|No training, just pre and post testing
62369044|NCT02667236|ACTIVE_COMPARATOR|A-101 Solution|A-101 Solution 40% administered once
62369045|NCT02667236|PLACEBO_COMPARATOR|Vehicle Solution|Vehicle Solution administered once
62369046|NCT00626340|ACTIVE_COMPARATOR|MDD diagnosis and Estrogen treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen alone.
62369047|NCT00626340|ACTIVE_COMPARATOR|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
62369048|NCT00626340|ACTIVE_COMPARATOR|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
62369049|NCT00626340|ACTIVE_COMPARATOR|No depression and estrogen treatment|Non-depressed menopausal women between the ages of 40-70 receiving treatment with estrogen alone.
62369050|NCT04880993|EXPERIMENTAL|Test Product|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Drug: Dapagliflozin 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
62369051|NCT04880993|ACTIVE_COMPARATOR|Reference Product|Manufactured by AstraZeneca Pharmaceuticals LP Drug: Farxiga® 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
62369052|NCT05849545|EXPERIMENTAL|Graston Tool|Graston instrument, 20 strokes per minute proximal to distal and 20 strokes per minute distal to proximal for a period of 3 minutes was given over the painful area. GT group protocol included the use application of IASTM along with the application of ice therapy at the end of the session. The assessment of patients was done at the initial and last visit before the completion of the treatment program. Three treatment sessions per week were given to each patient for a total of four weeks.
62369053|NCT05849545|ACTIVE_COMPARATOR|Neuromuscular Re-Education|General stretching and strengthening exercises for the neck muscles. The protocol of treatment for the NMR group included the use of the Neuromuscular re-education soft tissue mobilization technique (NMR) followed by active movements of the patient.
62369054|NCT03655080|EXPERIMENTAL|nab-Paclitaxel and Radiation Therapy|"* 10 fractions of 3Gy radiation therapy will be delivered.~* A total of 4 chemoradiation blocks should be delivered ideally in consecutive days~* On day 1 of the chemoradiation block, nab-paclitaxel is delivered in the morning followed by radiotherapy the latest possible and ideally at least 6 hours later (no earlier than 4 hours after the start of nab-paclitaxel)~* On day 2, radiotherapy is delivered in the morning, ideally within 24 hours from the start of nab-Paclitaxel infusion the previous day~* There will be 2 radiation fractions that won't be part of any chemoradiation block and can be placed anywhere before, after, or between blocks"
62369055|NCT04116190|EXPERIMENTAL|Telerehabilitation (TR)|Shortened inpatient rehabilitation mixed with home-based telerehabilitation.
62369056|NCT04116190|EXPERIMENTAL|Conventional rehabilitation (CR)|Traditional inpatient rehabilitation
62369057|NCT04771104|ACTIVE_COMPARATOR|Allocated to intervention at first experimental day|
62369058|NCT04771104|PLACEBO_COMPARATOR|Allocated to intervention at second experimental day|
62369059|NCT04922580||Hospitalization group|Newborns of ICP mothers require hospitalization after birth
62369060|NCT04922580||without Hospitalization group|Newborns of ICP mothers don't require hospitalization after birth
62369061|NCT00825968||Data collection group|Patients having procedures done at the electrophysiology Laboratories at the Ross Heart Hospital at The Ohio State University Medical Center.
62369062|NCT04123444|EXPERIMENTAL|Iloprost|Patients randomized to active treatment (n=190 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
62369063|NCT04123444|PLACEBO_COMPARATOR|Placebo|Patients randomized to placebo treatment (n=190 patients) will receive continuous infusion of placebo for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
62369064|NCT05645276|EXPERIMENTAL|The dose escalation stage, pharmacodynamic confirmation stage and dose expansion stage of AK129|7 dose groups were set up, which were 0.03mg/kg,0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg and 25 mg/kg in dose escalation stage; 2-3 dose levels that do not exceed maximum tolerated dose(MTD) may be selected for pharmacodynamic confirmation cohort extension in pharmacodynamic confirmation stage;Five cohorts with different indications were included in each group with 10-20 subjects in dose expansion stage.
62369065|NCT05346861|ACTIVE_COMPARATOR|Trastuzumab plus chemotherapy|
62369066|NCT05346861|EXPERIMENTAL|Pyrotinib in combination with Trastuzumab plus chemotherapy|
62743087|NCT05332743|EXPERIMENTAL|Nutraceutical Dietary Supplement|Nutraceutical Dietary Supplement capsules are comprised of primary and secondary ingredients, designed to restore hair health from the inside out. In addition to the necessary vitamins, minerals, proteins to support the nutritional needs of hair.
62743088|NCT03043352|EXPERIMENTAL|Group A (intervention)|'Management of SAM at home' LHWs will identify and treat all cases of severe acute malnutrition (SAM) as per the study eligibility criteria (MUAC \< 11.5 cm) and manage all cases of SAM without complications at home with 'Standard CMAM program'. The LHWs will also identify SAM with complications for further assessment to the BHU Doctor and subsequent referral to the stabilization center . They will also provide one to one health and Infant and Young Child Feeding (IYCF) counselling to care takers of children in their catchment area.
62369067|NCT05001776|ACTIVE_COMPARATOR|Endovenous laser ablation without anticoagulants|Endovenous laser ablation without using of any anticoagulant
62369068|NCT05001776|ACTIVE_COMPARATOR|Endovenous laser ablation with short-term anticoagulant|Endovenous laser ablation and subsequent 7 days of subcutaneous fondaparinux sodium
62369069|NCT05001776|ACTIVE_COMPARATOR|Medical treatment|45 days of subcutaneous fondaparinux sodium
62369070|NCT04011306|EXPERIMENTAL|Lumina24 BLU|Each subject will be randomized to receive standard of care dressing on approximately half of the study burn site, and Lumina24TM BLU treatment on the remaining half of the study burn site.
62369071|NCT02348294|OTHER|Healthy volunteers|Shear- force 19 newton and 3,9 kpa pressure for half an hour
62369072|NCT02348294|OTHER|Diabetes Mellitus type 2 without neuropathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
62369073|NCT02348294|OTHER|Diabetes Mellitus type 2 with neuropathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
62369074|NCT02348294|OTHER|Charcot Osteoarhtopathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
62369075|NCT06189066|EXPERIMENTAL|Ultrasound Group|
62743089|NCT03043352|ACTIVE_COMPARATOR|Group B (Control)|'Management of SAM at facility' LHWs will identify SAM as per 'Standard CMAM program' (MUAC \< 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
62369076|NCT02126241|EXPERIMENTAL|NICaS guided CRT optimization|For each subject, we will determine a set of AV and VV delays values, for which the NICaS measured CO will be maximum. In each patient, the CRT device will then be programmed according to these values.
62369077|NCT01799161|ACTIVE_COMPARATOR|DS-1|6 week course of gp96 Vaccine: \>= 4 x 10\^7 cells twice monthly on Day 1. Up to 3 courses, 9 vaccinations.
62369078|NCT01799161|ACTIVE_COMPARATOR|DS-2|6 week course of gp96 Vaccine: \>= 2 x 10\^7 cells weekly on Day 1. Up to 3 courses, 18 vaccinations.
62369079|NCT01799161|ACTIVE_COMPARATOR|DS-3|6 week course of gp96 Vaccine: \>= 1 x 10\^7 cells twice weekly on Days 1 and 4. Up to 3 courses, 36 vaccinations.
62369080|NCT05154565|EXPERIMENTAL|Immediate intervention (Group A)|Meditation intervention applied during Phase 1 of the study. During Phase 2, the formal meditation intervention is not completed, but participants are followed for outcome measurement. Participants may continue to use meditation in their daily routines or return to their usual routines.
62369081|NCT05154565|OTHER|Delayed intervention (Group B)|No intervention is applied in Phase 1 of the study. This group serves as the control group for Phase 1. The meditation intervention is applied in Phase 2 of the study.
62369082|NCT03167125|ACTIVE_COMPARATOR|Automated Prompts|Patients randomized to this arm will receive automated prompts to complete and return the FIT kit.
62369083|NCT03167125|ACTIVE_COMPARATOR|Automated Plus Live Prompts|Patients randomized to this arm will receive automated prompts plus linguistically and culturally tailored live prompts to complete and return the FIT kit.
62369084|NCT03167125|NO_INTERVENTION|Usual Care|Patients randomized to this arm will receive usual care screening opportunities per recommended colorectal cancer screening guidelines.
62369085|NCT04414488||Patient controlled analgesia|General anaesthesia was induced with midazolam 0.1 mg\*kg-1, propofol 2 mg\*kg-1, cisatracurium 0.15 mg\*kg-1 and fentanyl 1.5 µg\*kg-1. Anaesthesia was maintained with one minimal alveolar concentration sevoflurane. Fractional doses of fentanyl 1-3 µg\*kg-1 were administered if heart rate or mean blood pressure rose more than 20% above the base-line value obtained just before surgery commenced. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). The PCA solution was oxycodone (1mg\*ml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. During the night, basal rate oxycodone was 2-4 mg per hour. Additionally, patients were given 1g intravenous paracetamol every 6h and 100mg of intravenous ketoprofen every 12h, if required.
62369086|NCT04414488||Thoracic paravertebral block and patient controlled analgesia|Before induction of general anesthesia thoracic paravertebral block was performed. General anaesthesia was induced with midazolam 0.1 mg\*kg-1, propofol 2 mg\*kg-1, cisatracurium 0.15 mg\*kg-1 and fentanyl 1.5 µg\*kg-1. Anaesthesia was maintained with one minimal alveolar concentration sevoflurane. Fractional doses of fentanyl 1-3 µg\*kg-1 were administered if heart rate or mean blood pressure rose more than 20% above the base-line value obtained just before surgery commenced. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). The PCA solution was oxycodone (1mg\*ml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. During the night, basal rate oxycodone was 2-4 mg per hour. Additionally, patients were given 1g intravenous paracetamol every 6h and 100mg of intravenous ketoprofen every 12h, if required.
62369087|NCT01978392|EXPERIMENTAL|Self-management group workshops|Self-management group workshops: Participants randomized to the intervention arm will be asked to participate in group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months.
62369088|NCT01978392|NO_INTERVENTION|No treament (wait-list control)|Wait-list control: Participants randomized to the control arm will receive no intervention during the one-year period of data collection, but they will be invited to attend a full-day Saturday workshop after all study data collection is complete). The intent of the full-day workshop will be to provide the same self-management information as in the intervention arm, but on a delayed basis and in a more condensed format.
62369089|NCT00963313||Adalimumab, injection|Adalimumab, one injection every fourteen days during 24 weeks.
62743090|NCT04294901|EXPERIMENTAL|Gabapentin (Gaba)|Patients prescribed gabapentin with a total daily dose \>1800mg without exclusion criteria who have a primary care appointment with a provider in the Gaba cohort
62743091|NCT04294901|EXPERIMENTAL|Diabetes (DM)|Patients prescribed either insulin or a sulfonylurea meeting inclusion/exclusion criteria who have a primary care appointment with a provider in the DM cohort
62743092|NCT04294901|EXPERIMENTAL|Proton Pump Inhibitor (PPI)|Patients prescribed a PPI meeting inclusion/exclusion criteria who have a primary care appointment with a provider in the PPI cohort
62743093|NCT04507828|EXPERIMENTAL|Combined DIBH-Expiration Planning Technique|Patients will undergo a 4D scan as well as a DIBH scan and an expiration breath hold scan. In order to develop a combined DIBH-Expiration treatment plan, the DIBH scan, the expiration phase of the 4D scan or the expiration breath hold scan will be used. If the radiation plan meets the coverage goals and normal tissue constraints, the patient will receive treatment using the new DIBH Planning Technique. If coverage and normal tissue constraints are not met per protocol, the patient will be treated per standard of care and not on protocol. Patients treated on protocol will undergo radiation treatment with SBRT for a total of 3 fractions and will receive each fraction no more frequently then every other day. Patients will then be evaluated at 1 month after SBRT completion and every 3 months for 2 years
62743094|NCT06481878||35 MA TCM (A+ T+)|Group of patients with established Alzheimer's disease at the stage of major cognitive impairment
62743095|NCT06481878||15 MA TCm (A+ T+)|Group of patients with established Alzheimer's disease at the stage of minor cognitive impairment
62743096|NCT06481878||15 TC Non MA LCR negatif (A- T-)|Group of patients with minor or major cognitive impairment but without AD
62743097|NCT06481878||15 TCm LCRdiscordant (A+ T-) ou (A- T+)|Group of patients with minor cognitive impairment and discordant CSF
62743098|NCT06481878||35 VS|Group of healthy volunteers
62743099|NCT02118181|NO_INTERVENTION|Control|
62743100|NCT02118181|EXPERIMENTAL|HMB|Group taking oral supplementation with Beta-hydroxy-beta-methylbutyrate
62369090|NCT02282891|ACTIVE_COMPARATOR|Propofol|Induction of general Anesthesia using propofol 2mg/kg
62369091|NCT02282891|EXPERIMENTAL|Propofol/Ketamine (ketofol)|Induction of general anesthesia using a mixture of 1.5mg/kg:0.75mg/kg Propofol/ketamine
62369092|NCT03764462|EXPERIMENTAL|Raloxifene 60mg to AD-101 45mg|Period 1: Raloxifene 60mg, 1 tab, QD, Per oral / Period 2: AD-101 45mg, 1 tab, QD, Per oral
62369093|NCT03764462|EXPERIMENTAL|AD-101 45mg to Raloxifene 60mg|Period 1: AD-101 45mg, 1 tab, QD, Per oral / Period 2: Raloxifene 60mg, 1 tab, QD, Per oral
62369094|NCT02528838||Patients receiving Revlimid according to clinical practice|
62369095|NCT01964287|EXPERIMENTAL|Gembrax followed by Folfirinox|"Gembrax:~Albumin-bound paclitaxel followed by Gemcitabine Day 1,8,15 followed by 2 weeks of rest~Folfirinox:~Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous"
62369096|NCT03228992|ACTIVE_COMPARATOR|Ibuprofen|Subjects will receive a total of 4 doses of oral ibuprofen 400 mg over a 24 hour period.
62369097|NCT03228992|PLACEBO_COMPARATOR|Placebo|Subjects will receive a total of 4 doses of oral placebo over a 24 hour period.
62369098|NCT02785666|EXPERIMENTAL|Treatment and behavioural intervention:|"Treatment intervention: Patients with a replicating GT 1 and/or 4 HCV infection without or with cirrhosis will be treated with grazoprevir/elbasvir (100mg/50mg) for 12 weeks. GT 1a infected patients with baseline RAV's and GT 4 infected patients with a history of prior HCV treatment failure without or with cirrhosis will be treated with the same regimen for 16 weeks, in combination with weight-adjusted ribavirin.~Behavioural Intervention: Participants with inconsistent condom use with occasional partners will receive the behavioral Intervention and in addition standard of care written and oral information on prevention of HCV reinfection. Study participants with consistent condom use or those reporting inconsistent condom use with occasional partners but not willing to participate in the intervention will receive standard of care written and oral information on prevention of HCV reinfection only"
62369099|NCT01037751||Interview + Questionnaires|1-on-1 interview + Questionnaires, Part 1 of Study
62369100|NCT01037751||Questionnaires|Questionnaires Only, Part 2 of Study
62369101|NCT03297944|EXPERIMENTAL|All Participants|All participants received each intervention with alprazolam, zolpidem and placebo.
62369102|NCT01156363|EXPERIMENTAL|Single Arm|
62369103|NCT01255189|EXPERIMENTAL|Device: near infrared spectroscopy: invos 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements
62369104|NCT00837239|EXPERIMENTAL|Gemcitabine + HuaChanSu|Gemcitabine 1,000 mg/m2 once a week for 3 weeks then 1 week off + HuaChanSu 20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
62369105|NCT00837239|EXPERIMENTAL|Gemcitabine + Placebo|Gemcitabine 1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle) + Placebo 500 ml saline only administered as a 2 hour infusion by central line.
62369106|NCT04873843|EXPERIMENTAL|Functional digital game training group|These functional digital game programs have been developed to improve the intelligence and vitality in the community-dwelling elderly. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
62369107|NCT04873843|EXPERIMENTAL|Individual cognitive training|Individual cognitive training has been used to improve the intelligence and cognitive function in community-dwelling elderly. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
62369108|NCT02506491|EXPERIMENTAL|Pilates exercise program|Incorporate Pilates principles to stimulate core muscles in a dynamic and static way, and exercising arms and legs complementarity with balance as an essential part of standing exercises.
62743101|NCT02591472|ACTIVE_COMPARATOR|Usual Care (UsCare)|This group will receive UsCare for orthopedic trauma involves surgical intervention, acute care therapies, post-acute rehabilitation and follow-up clinic visits after discharge. Additionally, the following test will be performed: Lower Extremity Gain Scale (LEGS), dynamometer isometric handgrip strength, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11), and Patient-Reported Outcomes Measurement Information System (PROMIS).
62369109|NCT02506491|EXPERIMENTAL|Muscular exercise program|To train core muscles in a dynamic and static way, and exercising arms and legs complementarity with balance as an essential part of standing exercises.
62369110|NCT02506491|ACTIVE_COMPARATOR|Control group|Healthy active but nonexercising old women
62369111|NCT00817037|EXPERIMENTAL|Sitaxsentan|"Once daily oral sitaxsentan 100mg given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
62369112|NCT00817037|PLACEBO_COMPARATOR|Placebo|"Once daily oral placebo tablet given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
62369113|NCT00817037|ACTIVE_COMPARATOR|Nifedipine|"Open labeled active comparator~Once daily oral nifedipine 30mg given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
62369114|NCT00028795|EXPERIMENTAL|Chemoradiotherapy|
62369115|NCT05352867|EXPERIMENTAL|50μg group|
62369116|NCT05352867|EXPERIMENTAL|100μg group|
62369117|NCT05352867|PLACEBO_COMPARATOR|Placebo|
62369118|NCT00120510|EXPERIMENTAL|A|Randomly assigned group who will start an ART regimen of 3TC/ZDV and EFV twice daily at study entry
62369119|NCT00120510|ACTIVE_COMPARATOR|B|Randomly assigned group who will delay beginning ART regimen of 3TC/ZDV and EFC twice daily until they develop clinical AIDS or their CD4 count drops below 200 cells/mm3
62369120|NCT05064540|EXPERIMENTAL|Alto Abdominal Stent Graft System|Subjects randomized to receive the Endologix Alto Abdominal Stent Graft System for implantation to repair Abdominal Aortic Aneurysm.
62369121|NCT05064540|ACTIVE_COMPARATOR|Comparators|Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm.
62369122|NCT02779530|EXPERIMENTAL|Diclofenac|
62369123|NCT02779530|PLACEBO_COMPARATOR|Placebo|
62369124|NCT06086236|EXPERIMENTAL|PNS Index<-2 and SNS Index>2|Participants with Parasympathetic Nervous System (PNS) and Sympathetic Nervous System (SNS) Indexes values ''PNS\<-2, SNS\>2'' according to the results of heart rate variability measurements were included in this group. Then bilateral transcutaneous auricular vagus nerve stimulation was performed.
62743102|NCT02591472|EXPERIMENTAL|Integrated Care (ICare)|This group will receive ICare for orthopedic trauma involves surgical intervention, acute care therapies, post-acute rehabilitation and follow-up clinic visits after discharge, plus simultaneous psychosocial support via the Transform-10 Program.. Additionally, the following test will be performed: Lower Extremity Gain Scale (LEGS), dynamometer isometric handgrip strength, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11), and Patient-Reported Outcomes Measurement Information System (PROMIS).
62369125|NCT06086236|EXPERIMENTAL|PNS Index<-2 and SNS Index<2|Participants with Parasympathetic Nervous System (PNS) and Sympathetic Nervous System (SNS) Indexes values ''PNS\<-2, SNS\<2'' according to the results of heart rate variability measurements were included in this group. Then bilateral transcutaneous auricular vagus nerve stimulation was performed.
62369126|NCT06086236|EXPERIMENTAL|PNS Index>-2 and SNS Index>2|Participants with Parasympathetic Nervous System (PNS) and Sympathetic Nervous System (SNS) Indexes values ''PNS\>-2, SNS\>2'' according to the results of heart rate variability measurements were included in this group. Then bilateral transcutaneous auricular vagus nerve stimulation was performed.
62369127|NCT06086236|EXPERIMENTAL|PNS Index>-2 and SNS Index<2|Participants with Parasympathetic Nervous System (PNS) and Sympathetic Nervous System (SNS) Indexes values ''PNS\>-2, SNS\<2'' according to the results of heart rate variability measurements were included in this group. Then bilateral transcutaneous auricular vagus nerve stimulation was performed.
62369128|NCT02408484|EXPERIMENTAL|Octafibrin|Plasma-derived fibrinogen concentrate
62369129|NCT03022513|ACTIVE_COMPARATOR|NCWS patients|Fifty consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients will be recruited between January 2017 and January 2018 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo, Italy.
62369130|NCT03022513|NO_INTERVENTION|CD patients|Fifty sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as first control group. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo, Italy.
62369131|NCT03022513|NO_INTERVENTION|IBS patients|Fifty sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as second control group. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo.
62369132|NCT01600391|ACTIVE_COMPARATOR|Usual Care|A task specific-based intervention that does not include use of visual cues to influence quality or adaptability of gait.
62369133|NCT01600391|EXPERIMENTAL|Overground visual cue training|Overground visual cue training will involve stepping to targets which are positioned to improve gait symmetry and speed. Training will include turning practice and the avoidance of obstacles for adaptability during straight walking.
62369134|NCT01600391|EXPERIMENTAL|Treadmill visual cue training|Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). Walking training will involve stepping to targets which are positioned to improve gait symmetry and speed. Training will include turning practice and the avoidance of obstacles for adaptability during straight walking.
62369135|NCT05187546|EXPERIMENTAL|Imaging characteristics of [18F]PI-2620 for detection of Tau deposition in the brain of PSP patients|All eligible PSP patients will receive two injections of the investigational imaging agent \[18F\]PI-2620: at a baseline PET imaging session and at a follow-up PET imaging session to evaluate the test-retest imaging characteristics. 10 PSP patients will be required to complete the study arm.
62369136|NCT05187546|EXPERIMENTAL|Imaging characteristics of [18F]PI-2620 for detection of Tau deposition in the brain of NDC subjects|All eligible non-demented control (NDC) subjects will receive two injections of the investigational imaging agent \[18F\]PI-2620: at a baseline PET imaging session and at a follow-up PET imaging session to evaluate the test-retest imaging characteristics. 5 NDC subjects will be required to complete the study arm.
62369137|NCT02733146||cardiac arrest patients|Patients who has suffered a cardiac arrest
62369138|NCT04681365||Simulation Suite|Participating staff will use BubblePAPR and evaluate its function in the non-clinical simulation suite, ensuring that simulated tasks appropriate to role can be undertaken safely whilst wearing the Bubble
62369139|NCT04681365||Low-Risk Clinical Environment|Participating staff will use BubblePAPR and evaluate its function in the usual clinical environments (wards, ICUs or Emergency Departments) but with patients who are considered low risk (ie non-COVID-19).
62369140|NCT04681365||High-Risk Clinical Environment|Participating staff will use BubblePAPR and evaluate its function in the usual clinical environments (wards, ICUs or Emergency Departments) but with patients who are considered high risk (ie suspected or confirmed COVID-19).
62369141|NCT00626834|EXPERIMENTAL|Vigabatrin Dose 1|
62369142|NCT00626834|EXPERIMENTAL|Vigabatrin Dose 2|
62369143|NCT00626834|EXPERIMENTAL|Vigabatrin Dose 3|
62369144|NCT00626834|PLACEBO_COMPARATOR|Matching placebo|
62369145|NCT00801710|EXPERIMENTAL|BridgePoint Medial System|
62369146|NCT04516824||Trauma,Spine cases,Arthroplasty,Arthroscopy, Miscellaneous|
62369147|NCT02620046|EXPERIMENTAL|Group A: Vedolizumab SC 108 mg Q2W|"Participants from studies MLN0002SC-3027 and MLN0002SC-3031 who:~* Completed the Maintenance Period (Week 52), or~* Were not randomized into Maintenance Period and achieved response at Week 14 after having received a third vedolizumab IV infusion at Week 6."
62743103|NCT06014541||MECP2 Duplication Syndrome Disease Participants|Participants with a diagnosis of MDS with genetic confirmation of MECP2 duplication (or triplication) will undergo CSF and blood collection, electrophysiological and clinical assessments, up to Week 104 as a part of prospective study. Each participant's medical and family history data will be collected retrospectively from available medical notes and charts, from birth up to the end of the study (up to 110 weeks). Participants will have an option to participate in an optional sub-study that will capture pre-defined list of activities at home video.
62369148|NCT02620046|EXPERIMENTAL|Group B: Vedolizumab SC 108 mg QW|"Participants from studies MLN0002SC-3027 and MLN0002SC-3031 who withdrew early from the Maintenance Period due to treatment failure.~•Participants from current study who experience treatment failure while on study."
62369149|NCT03358004|EXPERIMENTAL|ARM A|Vinorelbine 50 mg, thrice a week
62369150|NCT03358004|EXPERIMENTAL|ARM B|Vinorelbine 40 mg thrice a week + capecitabine 500 mg thrice a day
62369151|NCT01309373||001|Patient assessment 2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
62369152|NCT06401252|EXPERIMENTAL|Nurses receiving Mhealth-based mindfulness-based intervention|The experimental group received five individuals 30-minute sessions of MBI for five weeks in a private and quiet room at the hospital, according to Smith's (2005) recommendation. The study intervention was an audio based MBI sent to them by the WhatsApp application. It is a free, self-paced program developed by an experienced, certified mindfulness practitioner based on the Smith's (2005) protocol to guarantee greater adherence and consistent delivery of MBI. The audio recording of the MBI was evaluated and validated for the clarity of voice and the MBI content by two psychologists who are experts in MBI.
62369153|NCT06401252|NO_INTERVENTION|Control group receiving traditional care|Participants in the control group were not asked to do anything during the study, except their traditional practices. However, the MBI was provided to them after the study.
62369154|NCT04559997|EXPERIMENTAL|Exercise+FU|Parkinson's group takes part in a treadmill treatment that takes place 3 times a week for 6 years.
62369155|NCT04559997|ACTIVE_COMPARATOR|Exercise|After 3 weeks of intensive treatment, no special exercises are performed as a control.
62743104|NCT06659991|EXPERIMENTAL|TMD Group 1|People with an established diagnosis of temporomandibular disorder (TMD) assigned to Ethanol intervention
62743105|NCT06659991|SHAM_COMPARATOR|TMD Group 2|People with an established diagnosis of temporomandibular disorder (TMD) assigned to sparkling water (control)
62369156|NCT04559997|NO_INTERVENTION|Controll|No intervention.
62369157|NCT01801124|EXPERIMENTAL|EXPAREL|undiluted EXPAREL 266 mg
62369158|NCT01481766|EXPERIMENTAL|Iron plus dietary counseling (Non-anemic iron deficiency)|
62369159|NCT01481766|PLACEBO_COMPARATOR|Placebo plus dietary counseling (Non-anemic iron deficiency)|
62369160|NCT01481766|NO_INTERVENTION|Iron sufficient|From the screening cohort of it is anticipated that 25 children will have iron deficiency anemia and an equal number of randomly selected children with iron sufficiency (n=25) will be sampled. These children will be compared to the children with non-anemic iron deficiency.
62369161|NCT01481766|ACTIVE_COMPARATOR|Iron deficiency anemia|From the screening cohort of it is anticipated that 25 children will have iron deficiency anemia and an equal number of randomly selected children with iron sufficiency (n=25) will be sampled. These children will be compared to the children with non-anemic iron deficiency.
62743106|NCT06659991|EXPERIMENTAL|Pain-free Control Group 1|People without an established diagnosis of temporomandibular disorder (TMD) or other chronic pain condition assigned to Ethanol intervention
62743107|NCT06659991|SHAM_COMPARATOR|Pain-free Control Group 2|People without an established diagnosis of temporomandibular disorder (TMD) or other chronic pain condition assigned to sparkling water (control)
62743108|NCT01534299||Renal Denervation Treatment|All patients treated with renal denervation procedure will be enrolled as part of this single arm registry
62369162|NCT01577628|OTHER|Group 1: Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
62369163|NCT01577628|NO_INTERVENTION|Group 2: No intervention control group|Subjects may use a moisturizer if they wish to but no instruction or product is provided
62743109|NCT02177734|EXPERIMENTAL|Formulation 1 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 1 at a 21 day interval
62369164|NCT04935372||Subjective cognitive decline|Male and female, aged 55 to 80 years with subjective cognitive decline, either cognitively unimpaired or with mild cognitive impairment
62369165|NCT02772224|EXPERIMENTAL|Drug eluting balloon angioplasty|Paclitaxel coated balloon angioplasty
62369166|NCT02772224|ACTIVE_COMPARATOR|Conventional balloon angioplasty|Conventional balloon angioplasty
62369167|NCT06507358|EXPERIMENTAL|Parent-Child Interaction group|Inclusion criteria for the experimental group are as follows: (1) Children currently undergoing early intervention; (2) Children experiencing sensory processing issues and caregivers (including grandparents and great-grandparents) seeking to establish parent-child relationships or enhance self-efficacy; (3) Ability to participate on duration of interventive class and to comply with trial procedures and complete home assignments, having attended at least 3/4 of the sessions.
62369168|NCT06507358|NO_INTERVENTION|Control group|Exclusion criteria for study participants are as follows: (1) Children aged under 4 or over 7 years; (2) Caregivers (including grandparents and great-grandparents) unable to communicate or read in Chinese. (3) Inability to participate on duration of interventive class.
62743110|NCT02177734|EXPERIMENTAL|Formulation 2 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 2 at a 21 day interval
62743111|NCT02177734|EXPERIMENTAL|Formulation 3 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 3 at a 21 day interval
62369169|NCT04418739|NO_INTERVENTION|Control Arm|Standard intraoperative fluid regime
62743112|NCT02177734|EXPERIMENTAL|Formulation 4 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 4 at a 21 day interval
62743113|NCT02177734|EXPERIMENTAL|Formulation 5 Group|Subjects in this group will receive two doses of GSK3277509A H7N9 vaccine formulation 5 at a 21 day interval
62743114|NCT02177734|PLACEBO_COMPARATOR|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
62369170|NCT04418739|EXPERIMENTAL|Treatment Arm|Intravenous human albumin 1g/kg at skin incision running at 100ml/hour
62369171|NCT05375825|EXPERIMENTAL|1/ Dose Escalation|LMB-100 at escalating/de-escalating doses + MSLN testing
62369172|NCT05375825|EXPERIMENTAL|2/ Dose Expansion|LMB-100 at the MTD + MSLN testing
62369173|NCT02253992|EXPERIMENTAL|Dose Escalation and Cohort expansion: Urelumab + Nivolumab|"Nivolumab followed by Urelumab~Nivolumab every 2 weeks up to 12 cycles and Urelumab every 4 weeks up to 6 cycles"
62369174|NCT01687049|EXPERIMENTAL|red yeast rice (RYR)|Two RYR capsules three times daily for a minimum of 6 months
62369175|NCT06328855|EXPERIMENTAL|Intermittent Oro-esophageal Tube Feeding+comprehensive rehabilitation therapy|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation therapy. The observation group was provided the support of enteral nutrition by Intermittent Oro-esophageal Tube Feeding.
62743115|NCT02494973|ACTIVE_COMPARATOR|Adjuvant systemic chemotherapy with mFOLFOX6|"started within 8 weeks after surgery for a maximal duration of 6 months and at least 3 months, every 14 days:~* Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,~* Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours."
62743116|NCT02494973|EXPERIMENTAL|Adjuvant HAI oxaliplatin and systemic LV5FU2|"started within 8 weeks after surgery for a maximal duration of 6 months and at least 3 months, and performed every 14 days:~* Oxaliplatin 85 mg/m² in 4-6 hours HAI day (D)1,~* Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours. In both arms, continuation of targeted therapy (if any) used in the preoperative treatment is allowed."
62743117|NCT00665054|EXPERIMENTAL|Arm 1|
62369176|NCT06328855|ACTIVE_COMPARATOR|comprehensive rehabilitation therapy+Nasogastric Tube Feeding|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation. The observation group was provided the support of enteral nutrition by Nasogastric Tube Feeding.
62369177|NCT05280236|ACTIVE_COMPARATOR|Propofol|Patients receiving general anesthesia with propofol-based total intravenous anesthesia
62369178|NCT05280236|EXPERIMENTAL|Remimazolam|Patients receiving general anesthesia with remimazolam-based total intravenous anesthesia
62369179|NCT03879954|OTHER|OOP-IJV|Out of plane inetrnal jugular vein catetherization
62369180|NCT03879954|OTHER|IP-SSV|in plane supraclavicular subclavian vein catetherization
62369181|NCT03422055|EXPERIMENTAL|99mTc-Fucoidan SPECT|
62369182|NCT05604404|EXPERIMENTAL|Positional Changes|The patient will begin in a supine position with the head-of-bed (HOB) at zero (0) degrees. The patient will remain in this position for five (5) minutes while pressure data is collected every fifteen (15) seconds. Next, the HOB will be adjusted to thirty (30) degrees. The patient will remain in this position for five (5) minutes while pressure data is collected every fifteen (15) seconds. Lastly, the HOB will remain at thirty (30) degrees and the foot-of-bed (FOB) will be adjusted to place the patient's leg in a dependent position. The patient will remain in this position for five (5) minutes while pressure data is collected every fifteen (15) seconds.
62369183|NCT03611036|EXPERIMENTAL|Strength|Patients will follow the pulmonary rehabilitation program associated with upper limbs strength training for a duration of 4 weeks
62369184|NCT03611036|ACTIVE_COMPARATOR|Endurance|Patients will follow the pulmonary rehabilitation program associated with upper limbs endurance training for a duration of 4 weeks
62369185|NCT05338944|EXPERIMENTAL|DBT + lifestyle|Participants will receive 90 minutes of dialectical behavioral therapy and 60 minutes of lifestyle sessions each week for 16 weeks.
62369186|NCT05338944|EXPERIMENTAL|Lifestyle alone|Participants will receive 2 lifestyle sessions per week, one 90 minutes in length and the other 60 minutes for 16 weeks.
62369187|NCT05338944|NO_INTERVENTION|Control|Participants will be included in baseline, endpoint and follow up measurements, but will receive no form of intervention.
62743118|NCT00665054|PLACEBO_COMPARATOR|Arm 2|
62743119|NCT03037359||Bivigam|Patients with primary immunodeficiency disease treated with Bivigam™
62743120|NCT03037359||Other IGIV|Patients with primary immunodeficiency disease treated with other IGIVs
62743121|NCT01281254|PLACEBO_COMPARATOR|Placebo plus PLD|Arm B: PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)
62369188|NCT04391153|ACTIVE_COMPARATOR|conventional samplig|"Patients with biliary strictures udergo ERCP or EUS. Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods.~Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology."
62369189|NCT04391153|ACTIVE_COMPARATOR|Fluorescence in situ Hybridization (FISH)|Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods. In addition, FISH inlcuding fluorescence-based polynucleotide probes targeting chromosomes 3, 7, 17 and locus 9p21 was performed. Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology.
62369190|NCT02295436|EXPERIMENTAL|1-mg group|Twelve healthy young subjects were administered a single oral dose of 1 mg minodronic acid tablets at day 1 and then received repeated oral doses of minodronic acid (1 mg) once daily for 7 days (day 3 to day 9).
62369191|NCT02295436|EXPERIMENTAL|2-mg group|Twelve healthy young subjects were administered a single oral dose of 2 mg minodronic acid tablets.
62743122|NCT01281254|EXPERIMENTAL|AMG386 plus PLD|Arm A: PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
62743123|NCT05083403|EXPERIMENTAL|HPI Arm|AcumenTM HPI Software Feature to guide hemodynamic management in cardiac surgery post-CPB
62743124|NCT05083403|PLACEBO_COMPARATOR|Non-HPI Arm|Non-protocolized standard of care management per clinician and provider judgement.
62743125|NCT00640809|EXPERIMENTAL|A|
62743126|NCT00640809|PLACEBO_COMPARATOR|B|
62743127|NCT00640809|ACTIVE_COMPARATOR|C|
62743128|NCT04669262|EXPERIMENTAL|Part 1: BGB-DXP604|Part 1A: Single low dose of BGB-DXP604 or placebo; Part 1B: Single high dose of BGB-DXP604 or placebo
62743129|NCT04669262|EXPERIMENTAL|Part 2 : BGB-DXP604 + BGB-DXP593|Single dose of BGB-DXP593 followed by a single dose of BGB-DXP604 or placebo
62369192|NCT02295436|EXPERIMENTAL|4-mg group|Twelve healthy young subjects were administered a single oral dose of 4 mg minodronic acid tablets under fasting state at period 1.After a washout period of 8 days, they received the same dosage under fed conditions (administrated 30 minutes before high-fat breakfast).
62369193|NCT02295436|EXPERIMENTAL|1-mg elderly group|Twelve healthy elderly subjects were administered a single oral dose of 1 mg minodronic acid tablets.
62369194|NCT01028040|EXPERIMENTAL|AZD3043|
62369195|NCT02400060|EXPERIMENTAL|Supportive (text messages and interactive exchanges)|Patients receive daily text messages reminding them to take AHT and weekly interactive surveys delivered by a smart phone app for 3 months.
62369196|NCT04259346|EXPERIMENTAL|Ixekizumab (Reference)|Approved formulation of 80 milligram (mg) ixekizumab administered as a subcutaneous (SC) injection via autoinjector (AI).
62369197|NCT04259346|EXPERIMENTAL|Ixekizumab (Test)|Test formulation of 80 mg ixekizumab administered as a SC injection via AI.
62369198|NCT02688153|ACTIVE_COMPARATOR|EDWARDS INTUITY|EDWARDS INTUITY Valve System, Model 8300A
62369199|NCT02688153|ACTIVE_COMPARATOR|Stented aortic bioprostheses|Stented aortic bioprostheses
62369200|NCT02809118|PLACEBO_COMPARATOR|Placebo|Placebo gel for intratympanic use
62369201|NCT02809118|EXPERIMENTAL|AM-111 0.4 mg/ml|AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
62369202|NCT02809118|EXPERIMENTAL|AM-111 0.8 mg/ml|AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
62369203|NCT01041391||Surgical treatment for Lumbar disc herniation|Patients who had or will have surgery for Lumbar disc herniation
62369204|NCT01041391||Non-surgical treatment for Lumbar disc herniation|Patients that have chosen conservative treatment for lumbar disc herniation
62369205|NCT00916396|ACTIVE_COMPARATOR|real drug|
62369206|NCT00916396|PLACEBO_COMPARATOR|placebo|
62369207|NCT00659906|EXPERIMENTAL|1|Progressive resistance training program 3 times a week for 12 months
62369208|NCT00659906|ACTIVE_COMPARATOR|2|Flexibility training 3 times a week for 12 months
62369209|NCT01698073|EXPERIMENTAL|mCOL|mCircle of Life is a culturally-based HIV-prevention intervention designed for American Indian and Alaska Native 10-12 year-olds. It includes both online and facilitated material.
62369210|NCT01698073|ACTIVE_COMPARATOR|AS+|After-School Science Plus is a curriculum designed for youth to teach science and literacy using everyday materials. It helps youth see how science is a part of everyday life and provides role models of scientists who come from different backgrounds and ethnicities.
62369211|NCT00419237|ACTIVE_COMPARATOR|Healthy subjects|Subjects with normal liver function test will be administered a single oral inhaled dose of 400 micrograms (mcg) GW685698X in the morning of the study day. Each healthy subject will be matched as closely as possible for age, gender, bodyweight and race to a subject with impaired liver function.
62369212|NCT00419237|EXPERIMENTAL|Subjects with hepatic impairment|Subjects with Child Pugh B hepatic dysfunction will be administered a single oral inhaled dose of 400 mcg GW685698X in the morning of the study day.
62369213|NCT02363855|EXPERIMENTAL|BAY 1841788(ODM-201)|Cohort 1: Safety, tolerability and PK of 300 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 28 days after start of multiple dose (MD) Cohort 2: Safety, tolerability and PK of 600 mg dose given twice daily
62369214|NCT04328441|EXPERIMENTAL|BCG vaccine|Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis.
62369215|NCT04328441|PLACEBO_COMPARATOR|Placebo|Intracutaneously 0.1ml of 0.9% NaCl solution
62369216|NCT04819867|EXPERIMENTAL|propolis|propolis will be applied to the affected teeth
62369217|NCT04819867|ACTIVE_COMPARATOR|gluma desensitizer|Gluma desensitizer will be applied to the affected teeth
62743130|NCT06660914|EXPERIMENTAL|Robotic flexible ureteroscopy with ILY® Robot platform|Robotic ILY® is a flexible ureteroscopy holder with multiple degrees of freedom telemanipulated with a wireless controller. This allows the surgeon to work easily at a distance from the patient and prevents them from exposing to the source of ionizing radiation.
62369218|NCT02891772||Hypotension after anesthetic induction group|Patients with hypotension after anesthetic induction
62369219|NCT04235088|EXPERIMENTAL|Somatosensory intensive intervention|
62369220|NCT04479007||Mechanically ventilated patients|Critically ill patients of 18 years or older who receive invasive mechanical ventilation for acute respiratory failure and have an indication for an intervention in the airways.
62369221|NCT05394207|EXPERIMENTAL|GROUP 1 (Investigational product)|23 patients Investigational product: L. casei DG® (Lactobacillus paracasei CNCM I-1572) containing 8 billion of live cells daily + Vitamin D 4.000 U.I. daily.
62369222|NCT05394207|PLACEBO_COMPARATOR|GROUP 2 (Comparator)|23 patients The comparator product is an identical matching placebo daily + Vitamin D 4.000 U.I. daily.
62369223|NCT02932319|ACTIVE_COMPARATOR|Foley catheter|The patient will have an induction at home after 60 mn of fetal heart rate monitoring.
62369224|NCT02932319|SHAM_COMPARATOR|Expectative|The patient in this arm will have the actual care (expectative until the next day befor starting the induction)
62369225|NCT03632668|EXPERIMENTAL|Sequence 1|Period 1: AD-2071 10/20mg QD Period 2: AD-2072 80/5mg QD and AD-2071 10/20mg + AD-2072 80/5mg QD
62369226|NCT01543646||Liver Biopsy patients|All patients due to have a liver biopsy for the assessment of parenchymal liver disease.
62369227|NCT01555736|ACTIVE_COMPARATOR|preseasonal immunotherapy scheme|
62369228|NCT01555736|ACTIVE_COMPARATOR|perennial immunotherapy scheme|
62369229|NCT03931980|EXPERIMENTAL|Robotic surgery|Patients undergoing robotic surgery for removal of rectal cancer.
62369230|NCT03931980|EXPERIMENTAL|Laparoscopic surgery|Patients undergoing laparoscopic for removal of rectal cancer
62369231|NCT04973085|EXPERIMENTAL|Cold circulated water|Cold water circulated through an adhesive wrap applied to the front of the neck.
62369232|NCT04973085|ACTIVE_COMPARATOR|Body-temperature circulated water|Body-temperature water circulated through an adhesive wrap applied to the front of the neck.
62369233|NCT01840436|PLACEBO_COMPARATOR|Placebo|This arm receives a placebo (saline solution) mouthwash treatment twice a day.
62369234|NCT01840436|EXPERIMENTAL|MUCIPLIQ 0.05 mg/mL|This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.05 mg/mL twice a day.
62369235|NCT01840436|EXPERIMENTAL|MUCIPLIQ 0.015 mg/mL|This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.015 mg/mL twice a day.
62369236|NCT02415504|EXPERIMENTAL|Enhanced care transition|The enhanced care transition will offer: (1) an integrated behavioural care plan, (2) an in- person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
62369237|NCT02415504|OTHER|Standard care transition|The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
62369238|NCT05791006||Patients with Parkinson's Disease/Parkinsonisms|
62369239|NCT05791006||Patients with brain tumors|
62369240|NCT05791006||Patients with ischemic or haemorrhagic stroke|
62369241|NCT05791006||Healthy Controls|
62369242|NCT02719457|OTHER|6 minute walk test (6 MWT)|patients will be perform the six minute walk test (6 mwt) to evaluate their exercise capacity.
62369243|NCT02719457|OTHER|spot marching test (SMT)|patients will be perform the spot marching test (SMT) to evaluate their exercise capacity.
62369244|NCT06507098|EXPERIMENTAL|Video-assisted training|Patients received a QR code and a link for access to a YouTube video recorded where the process of setting up the respiratory polygraph was explained.
62369245|NCT06507098|PLACEBO_COMPARATOR|Nurse training|A trained nurse with long experience in home sleep studies explained the setup of the Respiratory Polygraph.
62369246|NCT04280484|EXPERIMENTAL|Acute Intermittent Hypoxia|1 minute of 9% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 bouts
62369247|NCT04280484|SHAM_COMPARATOR|Sham Acute Intermittent Hypoxia|1 minute of 21% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 bouts.
62369248|NCT03377569||Group #1|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring prior to DBS surgery and in patient polysomnography with neural recording after DBS surgery.
62369249|NCT03377569||Group #2|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring after DBS surgery with DBS stimulation on at night, and in patient polysomnography after DBS surgery.
62369250|NCT03377569||Group #3|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring after DBS surgery with DBS stimulation off at night, and in patient polysomnography after DBS surgery.
62369251|NCT01236768|EXPERIMENTAL|AG200-15|Thin transdermal contraceptive delivery system (TCDS) that gives systemic exposure of levonorgestrel (LNG) and ethinyl estradiol (EE)
62369252|NCT01236768|ACTIVE_COMPARATOR|Levora|oral contraceptive containing 150mcg of LNG and 30mcg of EE
62369253|NCT05309369|EXPERIMENTAL|Preferred Music - Visit 1, Nature Sounds - Visit 2|
62369254|NCT05309369|PLACEBO_COMPARATOR|Nature Sounds - Visit 1, Preferred Music - Visit 2|
62369255|NCT01878240|ACTIVE_COMPARATOR|EVAR|Endovascular repair of an Abdominal Aortic Aneurysm
62369256|NCT01878240|EXPERIMENTAL|Coil embolization during EVAR|coil embolization during Endovascular repair
62369257|NCT06032988|ACTIVE_COMPARATOR|LactoLevure|The probiotic capsule LactoLevure\^R will be given once a day
62369258|NCT06032988|PLACEBO_COMPARATOR|Placebo|Placebo capsules will consist of identical to the LactoLevure\^R capsules of powdered glucose polymer, and will be given once a day
62369259|NCT01816386|ACTIVE_COMPARATOR|Acupuncture Regimen|Standard anaesthetic procedure plus press needle acupuncture
62369260|NCT01816386|NO_INTERVENTION|Standard Treatment Control|"Standard anaesthetic procedure plus No treatment.~All standardized medication according to the perioperative anaesthetic guideline, Department of Anaesthesiology, University of Munich, will be allowed. In special:~According to the guidelines, anxiolysis will be performed intravenously according to the standard guidelines with opioid immediately prior to the induction of anaesthesia.~Intraoperative anaesthesia will be performed according to our in-house guidelines: on general recommendations and guidelines of the German society for anaesthesiology (DGAI). Opioids and propofol will be administered via TCI pumps according to the standard protocol.~It is allowed to treat the subject for pain with metamizol (4\*1.25 g/day) and additional piritramide (PCA; 2 mg each 10 minutes; maximum dosage 30 mg/4 hours) .~Variation of this guideline based regimen are allowed if medically indicated."
62369261|NCT01816386|ACTIVE_COMPARATOR|Acupressure Regimen|Standard anaesthetic procedure plus press plaster acupressure
62369262|NCT00540527|EXPERIMENTAL|1|local intraarterial recombinant tissue plasminogen activator
62369263|NCT00540527|ACTIVE_COMPARATOR|2|intravenous (IV) rt-PA
62369264|NCT02392676|EXPERIMENTAL|1/OLAPARIB|olaparib 300 mg oral tablets; twice daily
62369265|NCT02392676|PLACEBO_COMPARATOR|2/PLACEBO|placebo matching olaparib 300 mg oral tablets; twice daily
62369266|NCT00593775|NO_INTERVENTION|control|control group without intervention
62369267|NCT00593775|ACTIVE_COMPARATOR|AH group|assisted hatching performed on the embryo
62369268|NCT04746989||Probenecid|Exposure group
62369269|NCT04746989||Allopurinol|Reference group
62369270|NCT01873807|EXPERIMENTAL|IDA-Etoposide Intensified Conditioning|
62369271|NCT01873807|ACTIVE_COMPARATOR|Non-IDA Conditioning|
62369272|NCT04064372|EXPERIMENTAL|Mindful Response to Adversity|"The treatment condition will be trained in techniques designed to teach a mindful approach to adversity. These techniques will include: normalizing, attention, equanimity, non-judgment, de-centering, accepting of experiences, and impermanence. Participants will be instructed on the mindset, asked to write about an instance of non-judgment and share with a partner, and then guided through a short training designed to practice each skill."
62369273|NCT04064372|ACTIVE_COMPARATOR|Strength-based approach to adversity|The control condition will be trained in techniques designed to teach a typical narrative self-analysis / strengths-based approach to adversity. These techniques will include: choosing the best approach, minimizing stress, and identifying and enhancing personal strengths. Participants will be instructed on the mindset, asked to write about an instance of personal strength and share with a partner, and then guided through a short training designed to practice each skill.
62369274|NCT01838304|ACTIVE_COMPARATOR|Monitoring|Standard of care sedation by CRNA using proposal with manual recording of drug dosing
62743131|NCT06660914|ACTIVE_COMPARATOR|Standard flexible ureteroscopy|Standard flexible ureterscopy
62369275|NCT01838304|EXPERIMENTAL|Probability ramp control|Propofol titrated to deep sedation using PRC software.
62369276|NCT05933772|EXPERIMENTAL|Lens A, Then Lens B|Participants will wear Lens A for one month and then crossover to Lens B for one month.
62743132|NCT05047939|EXPERIMENTAL|remimazolam group|In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil 0.2mg, is administered at the end of surgery. In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
62743133|NCT05047939|ACTIVE_COMPARATOR|propofol group|In the propofol-based TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using an infusion pump (Orchestra®; Fresenius Vial, France). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
62743134|NCT05358522|NO_INTERVENTION|Standard Feedback|No feedback about opioid prescribing behaviors.
62369277|NCT05933772|EXPERIMENTAL|Lens B, Then Lens A|Participants will wear Lens B for one month and then crossover to Lens A for one month.
62369278|NCT00558740||healthy volunteers|
62369279|NCT04246424|ACTIVE_COMPARATOR|Fitbit + Coaching|Fitbit + coaching will receive both the fitbit and coaching interventions.
62369280|NCT04246424|ACTIVE_COMPARATOR|Coaching|Coaching group will receive weekly remote coaching lessons by phone email or text for 1-6 weeks. They will also receive a weekly email lesson for 1-6 weeks on things such as basics of sleep, enhancing sleep environment and managing stress.
62369281|NCT04246424|ACTIVE_COMPARATOR|Fitbit|Fitbit group will receive a Fitbit and are asked to monitor their sleep over the smartphone application for 1-6 weeks.
62369282|NCT04246424|NO_INTERVENTION|Self-management|Self-management participants will be given some information of improving sleep but asked to keep their same schedule. Once their participation concludes, they will be given the opportunity to receive a fitbit and coaching if they so choose.
62369283|NCT03246711||Totally fasting|Fasting each day from sunrise to sunset the whole month
62369284|NCT03246711||Partially fasting|means fasting from sunrise to sunset part of the month
62369285|NCT03246711||Non fasting|women who did not fast at all
62369286|NCT05838820||Carpal Tunnel Syndrome (CTS) Group|This group will consist of individuals diagnosed with carpal tunnel syndrome (CTS) who are 18 years of age or older and who are able to provide informed consent to participate in the study. The group will be recruited from a single center and will be asked to complete the Jebsen-Taylor Hand Function Test and the Nine-Hole Peg Test twice, with a 1-week interval between the two assessments. The aim is to establish the test-retest reliability of these tests in individuals with CTS. The group will include at least 50 participants and will be diverse in terms of age, gender, and race/ethnicity to ensure that the study findings are generalizable to a broader population.
62369287|NCT00901004||1|Reflux esophageal minimal change in the endoscopic finding
62369288|NCT06289504|EXPERIMENTAL|CagriSema +Atorvastatin + Warfarin|Participants will receive a single dose of atorvastatin and a single dose of warfarin followed by a 16-week CagriSema dose escalation period and a 7-week CagriSema maintenance period. Participants will also receive a single dose of atorvastatin and a single dose of warfarin in the maintenance period.
62369289|NCT01116804|OTHER|inoperable liver cancer patients|
62369290|NCT00260091|ACTIVE_COMPARATOR|I.|Conventional infertility therapy
62369291|NCT00260091|ACTIVE_COMPARATOR|II.|Fast track to in vitro fertilization therapy
62369292|NCT05234190|EXPERIMENTAL|Treatment group|
62369293|NCT02108522|EXPERIMENTAL|Multivirus Specific T cells|"Partially HLA-matched multivirus specific T cells (VSTs) will be thawed and given by intravenous injection. Patients will receive 2 x 10\^7 VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused after discussion with the principal investigator, patient and/or guardian and the treatment team.~If after the first treatment there is persistent infection, there is an option to receive more treatments. These additional treatments might be with cells from the same donor or another donor whose cells are also thought to be a good match for the patient and effective against their virus. This second product will be administered at the same dose level 28 days after the initial infusion, and subsequent infusions should be at least 14 days apart."
62369294|NCT03225651|EXPERIMENTAL|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
62369295|NCT03225651|EXPERIMENTAL|Psychological therapy and rehabilitation|Psychological therapy Rehabilitation in 3 months
62369296|NCT00565240|EXPERIMENTAL|Oral Contraceptive|
62369297|NCT00565240|EXPERIMENTAL|Contraceptive Ring|
62369298|NCT00565240|EXPERIMENTAL|Aromatase Inhibitors|
62369299|NCT00565240|NO_INTERVENTION|Control|
62369300|NCT03320486|EXPERIMENTAL|Group 1 - dapaconazole cream 2%|Topical application of dapaconazole cream 2%, once daily, during 42 days.
62743135|NCT05358522|EXPERIMENTAL|Opioid Prescribing Report Cards|Procedure and prescribing providers will be randomized to when they will begin receiving individual reports on their opioid prescribing.
62743136|NCT01551680|EXPERIMENTAL|Concurrent whole brain radiotherapy and iniparib|
62743137|NCT00170768|EXPERIMENTAL|1|Darifenacin
62743138|NCT00170768|ACTIVE_COMPARATOR|2|Oxybutynin
62743139|NCT00170768|PLACEBO_COMPARATOR|3|Placebo
62369301|NCT03320486|ACTIVE_COMPARATOR|Group 2 - ketoconazole cream 2%|Topical application of ketoconazole cream 2%, once daily, during 42 days.
62369302|NCT02054936|ACTIVE_COMPARATOR|Rivaroxaban (Xarelto)|Rivaroxaban dosing will be 10mg once daily beginning on postoperative day 1 for a duration of 30 days.
62369303|NCT02054936|ACTIVE_COMPARATOR|Warfarin (Coumadin)|Warfarin dosing will be titrated to achieve an INR of 2-3 and dosing will begin on postoperative day 1 for a duration of 30 days.
62369304|NCT01976624||Ganfort®|Patients who received treatment with bimatoprost/timolol (Ganfort®) for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
62369305|NCT04710992|SHAM_COMPARATOR|Needling Group|The needle will be inserted for 90 seconds without galvanic current.
62369306|NCT04710992|EXPERIMENTAL|Low intensity percutaneous electrolysis|A single impact of galvanic current will be applied with an intensity of 0.3 mA for 90 seconds.
62743140|NCT02337998|EXPERIMENTAL|Healthy men|each individual will serve as his own control by comparing baseline values to post intervention values
62743141|NCT06234579||ALK+ NSCLC|The GALILEO project is an Italian observational prospective cohort study on advanced ALK+ NSCLC patient progressing on first-line therapy with alectinib
62743142|NCT02550288|ACTIVE_COMPARATOR|Ezetimibe 10 mg|1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.
62743143|NCT02550288|ACTIVE_COMPARATOR|Atorvastatin 10 mg|1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.
62743144|NCT02550288|ACTIVE_COMPARATOR|Atorvastatin 20 mg|2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.
62743145|NCT02550288|EXPERIMENTAL|Ezetimibe 10 mg + Atorvastatin 10 mg|1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks
62369307|NCT04710992|EXPERIMENTAL|High intensity percutaneous electrolysis|Three impacts of galvanic current will be applied with an intensity of 3 mA and a duration of 3 seconds each.
62369308|NCT02437877||Mouth Breather|Mouth Breathers Children from 7 to 13 years old
62369309|NCT02437877||Nasal Breather|Nasal breathers children from 7 to 13 years old
62743146|NCT02550288|EXPERIMENTAL|Ezetimibe 10 mg + Atorvastatin 20 mg|1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks
62743147|NCT05665101|EXPERIMENTAL|EVAR with SE|Patients in the EVAR-SE arm will receive EVAR with additional coil embolization of the aneurysm sac.
62743148|NCT05665101|NO_INTERVENTION|standard EVAR|Patients in the standard EVAR arm will receive EVAR without additional coil embolization of the aneurysm sac.
62369310|NCT02371018|NO_INTERVENTION|Standard Hemodialysis|Participants will be monitored during their normal hemodialysis treatment with no intervention administered
62369311|NCT02371018|EXPERIMENTAL|Hemodialysis with Nutrition Supplement|Participants will be monitored during a normal hemodialysis treatment in which they consume 1-8oz can of Nepro.
62369312|NCT02371018|EXPERIMENTAL|Nutrition Supplement|Participants will be monitored while drinking 1-8oz can of Nepro with no hemodialysis treatment.
62369313|NCT04261283|EXPERIMENTAL|Circuit Training|Specific exercise are designed in circuit training
62743149|NCT02255448|OTHER|SV1, SV2|SV1 intervention: stroke volume using transthoracic echo SV2 intervention: stroke volume measured using the esCCO device.
62369314|NCT04261283|ACTIVE_COMPARATOR|Control Group|Conventional treatment
62369315|NCT06507137|EXPERIMENTAL|Fractal|
62743150|NCT02454439|EXPERIMENTAL|CRT-D or CRT-P ON|This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
62743151|NCT02454439|OTHER|CRT-D or CRT-P OFF|This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
62743152|NCT06580249|EXPERIMENTAL|Repetitive transcranial magnetic stimulation true stimulation and sertraline treatment|The rTMS was administered once a day, implementing approximately 10-20 minutes of physical therapy, with stimulation parameters of 10 Hz frequency, 120% MT intensity, and 50 treatment sequences of 60 stimulations each, with 30-second intervals between the sequences, for a total of 3000 stimulations. For medication: If the depressive episode is only monophasic, give sertraline hydrochloride tablets 1-2 tablets/day for treatment； if the patient has bipolar disorder-depressive episode, give the emotion stabilizer lithium carbonate tablets 0.5-1.0 g/day (adjust the dose according to the blood concentration) for treatment.
62369316|NCT06507137|EXPERIMENTAL|Isochronous|
62369317|NCT06507137|EXPERIMENTAL|Control|
62369318|NCT03704389|EXPERIMENTAL|Clinical decision support intervention|Participating clinicians will receive any of three clinical decision support nudges within the electronic health record when all eligibility criteria are met within a patient's chart.
62369319|NCT03200795|EXPERIMENTAL|Rebound exercise group|Participants randomized to this group will be instructed on the proper techniques of the desired movements (hopping) on the rebounder.
62369320|NCT03200795|EXPERIMENTAL|Circuit training group|The circuit training for the participants in this group will be designed for each participant. Training will take place 3 times a week for 8 weeks. The participants will undergo 10 minutes warm up before and 10 minutes cool down after the training. Resistance exercises will be performed on weight machines. Throughout the resistance training program, participants will be alternating between the bench press, seated row, lateral pull down, biceps forward, front thigh, back thigh, leg press and rowing.
62369321|NCT02139267|EXPERIMENTAL|1mg of GX-188E per dose|1mg of GX-188E per dose will be administered on 1mg group participants through intramuscular route using EP device. The injection points are at 0 week, 4 week and 12 week.
62369322|NCT02139267|EXPERIMENTAL|4mg of GX-188E per dose|4mg of GX-188E per dose will be administered on 4mg group participants through intramuscular route using EP device. The injection points are at 0 week, 4 week and 12week.
62743153|NCT06580249|SHAM_COMPARATOR|Sham Repetitive transcranial magnetic stimulation stimulation + sertraline treatment group|Pseudo stimulation mimicked the tactile and acoustic sensations of rTMS by flipping the head, at 90 degrees to the scalp, with other intervention parameters remaining consistent with the study group. For medication: If the depressive episode is only monophasic, give sertraline hydrochloride tablets 1-2 tablets/day for treatment； if the patient has bipolar disorder-depressive episode, give the emotion stabilizer lithium carbonate tablets 0.5-1.0 g/day (adjust the dose according to the blood concentration) for treatment.
62743154|NCT00788931|EXPERIMENTAL|IV LBH589 + trastuzumab + paclitaxel|i.v. panobinostat
62743155|NCT00788931|EXPERIMENTAL|Oral LBH589 + trastuzumab + paclitaxel|oral panobinostat
62743156|NCT01749657|ACTIVE_COMPARATOR|Off-the-shelf Device and shoe|subjects will wear an off-the-shelf orthotic device (AirLift PTTD Brace) and standard Edge shoe (Aetrex Co) for 12 weeks
62743157|NCT01749657|EXPERIMENTAL|Custom Device - standard and Shoe|subjects will wear a custom (standard) orthotic device (Arizona Co) and Edge shoes (Aetrex Co.) for 12 weeks.
62743158|NCT01749657|EXPERIMENTAL|Custom Articulated device and Shoe|subjects will wear a custom articulated device (Arizona Co) and Edge shoe (Aetrex Co)for 12 weeks
62369323|NCT01194414|EXPERIMENTAL|Tocilizumab SC|"Participants received tocilizumab 162 mg subcutaneous (SC) injection weekly plus placebo to tocilizumab intravenous (IV) infusion every 4 weeks for a total of 24 weeks in the double-blind period. Participants continued to receive tocilizumab 162 mg SC injection weekly for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
62369324|NCT01194414|EXPERIMENTAL|Tocilizumab IV|"Participants received tocilizumab 8 mg/kg infusion (IV) every 4 weeks plus placebo to tocilizumab SC injection weekly for a total of 24 weeks in the double-blind period. Participants continued to receive tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
62369325|NCT01194414|EXPERIMENTAL|Tocilizumab SC Then Tocilizumab IV|"Participants who received tocilizumab 162 mg subcutaneous (SC) injection weekly plus placebo to tocilizumab IV infusion every 4 weeks for 24 weeks in double blind treatment period switched to tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
62743159|NCT01749657|EXPERIMENTAL|Custom Extended Device and Shoe|subjects will wear a custom extended foot plate orthotic device (Arizona Co) and Edge shoe (Aetrex Co) for 12 weeks.
62369326|NCT01194414|EXPERIMENTAL|Tocilizumab IV Then Tocilizumab SC|"Participants who received tocilizumab 8 mg/kg infusion (IV) every 4 weeks plus placebo to tocilizumab SC injection weekly in double blind treatment period switched to tocilizumab 162 mg SC injection weekly for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose will be continued throughout the study."
62743160|NCT05993429||EUS-FNA/B group; ERCP with or without POCS-TB group|EUS-FNA/B group: Patients with suspected hilar cholangiocarcinoma who were considered suitable for obtaining histopathological diagnosis by EUS-FNA/B by experts
62743161|NCT05993429||ERCP with or without POCS-TB group|ERCP with or without POCS-TB group: Patients with suspected hilar cholangiocarcinoma who were considered suitable for obtaining histopathological diagnosis by ERCP with or without POCS-TB by experts
62369327|NCT00553618|EXPERIMENTAL|Proleukin/DTIC Arm|Adjucant proleukin and DTIC
62369328|NCT01197781|EXPERIMENTAL|Period 1|
62369329|NCT01197781|EXPERIMENTAL|Period 2|
62369330|NCT01465373|ACTIVE_COMPARATOR|Progesterone in Oil|"Donor egg recipients will begin progesterone 50 mg IM injection starting the day after donor egg fertilization, and continue daily until pregnancy results can be determined.~If pregnant, donor egg recipient will continue progesterone 50 mg IM injections daily until approximately 9 weeks of pregnancy."
62369331|NCT01465373|ACTIVE_COMPARATOR|Endometrin|"Donor egg recipients will begin Endometrin 100 mg per vagina three times daily starting the day after donor egg fertilization and continue until pregnancy result can be determined.~If pregnant, donor egg recipients will continue Endometrin 100 mg TID until approximately 9 weeks of pregnancy."
62369332|NCT01823757||Non-pharmaceutical care|Veterans do not receiving pharmaceutical care
62369333|NCT01823757||Pharmaceutical care|Veterans receiving pharmaceutical care
62369334|NCT04861636|EXPERIMENTAL|HealthTRAC|Both the standard behavioral weight control (SBWC) and HealthTRAC interventions include 4 months of intensive treatment, followed by monthly maintenance sessions for a 12-month program. SBWC includes attention to diet and activity coupled with behavioral modification strategies. HealthTRAC integrates these key constructs with an emotion regulation intervention with documented efficacy in teens.
62369335|NCT04861636|ACTIVE_COMPARATOR|Standard Behavioral Weight Control (SBWC)|4 months of intensive treatment focused on attention to diet and activity coupled with behavioral modification strategies, which is then followed by monthly maintenance sessions for a 12-month program.
62743162|NCT02301546|EXPERIMENTAL|experimental cognitive training|Participants will use experimental computerized cognitive training exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks.
62743163|NCT02301546|ACTIVE_COMPARATOR|control cognitive exercises|Participants will use control computerized cognitive activities, 1 hour per day, 3 - 5 days per week, for 13 weeks.
62743164|NCT06662006|EXPERIMENTAL|nal-IRI/5-FU/LV + benmelstobart + anlotinib ± SBRT|liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT
62743165|NCT00487942|ACTIVE_COMPARATOR|50 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 50 mg/day armodafinil treatment arm for the double-blind treatment period of the study took one 50 mg armodafinil tablet plus three placebo tablets each morning.
62743166|NCT00487942|ACTIVE_COMPARATOR|100 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 100 mg/day armodafinil treatment arm for the double-blind treatment period of the study took two 50 mg armodafinil tablets plus two placebo tablets each morning. Subjects began taking 50 mg/day and then titrated to 100 mg/day on Day 2 of the first week of the double-blind treatment period.
62743167|NCT00487942|ACTIVE_COMPARATOR|200 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 200 mg/day armodafinil treatment arm for the double-blind treatment period of the study took four 50 mg armodafinil tablet and no placebo tablets each morning. Subjects were titrated to this dose by starting treatment at 50 mg/day (1 tablet) and increasing by 50 mg increments on days 2, 4, and 6 until they were taking 200 mg/day.
62743168|NCT00487942|PLACEBO_COMPARATOR|Placebo|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the placebo treatment arm for the double-blind treatment period of the study took four placebo tablets and no armodafinil tablets each morning.
62743169|NCT00435227|EXPERIMENTAL|Motavizumab|Participants will receive a single IM dose of 30 mg/kg of motavizumab on Day 0 of the study.
62369336|NCT03396640|EXPERIMENTAL|Unicondylar Knee Arhtroplasty|Operation with insertion of a knee arthroplasty using a unicompartmental device (Oxford phase 3, mobile bearing, uncemented)
62369337|NCT03396640|ACTIVE_COMPARATOR|Total Knee Arthroplasty|Operation with insertion of a knee arthroplasty using a total condylar device (PCR, nexgen with resurfacing, cemented)
62369338|NCT03975049|ACTIVE_COMPARATOR|5-Fu + RT|5Fu + RT for five weeks --- 6-8 weeks of interval --- TME --- mFOLFOX \* 6-8
62369339|NCT03975049|EXPERIMENTAL|mFOLFOXIRI|mFOLFOXIRI \* 4 --- TME --- mFOLFOXIRI \* 4
62743170|NCT00435227|PLACEBO_COMPARATOR|Placebo|Participants will receive a single IM dose of placebo matched to motavizumab on Day 0 of the study.
62743171|NCT04202406|EXPERIMENTAL|Acetaminophen, codeine,and caffeine|Oral single dose of Combination of 1000mg acetaminophen- 16mg codeine- 60mg caffeine.
62369340|NCT03975049|EXPERIMENTAL|mFOLFOX|mFOLFOX \* 9 --- TME --- mFOLFOX \* 3
62369341|NCT00200889|EXPERIMENTAL|Congruent|Participants receive briefings on expectations of stimulation effects on gastric motility consistent with the literature.
62369342|NCT00200889|EXPERIMENTAL|Incongruent|Participants receive briefings on expectations of stimulation effects on gastric motility inconsistent with the literature.
62369343|NCT04677023|OTHER|Admira fusion X--tra® bulk|The special ORMOCER® compound molecules in Admira Fusion x-tra reduce the volume shrinkage to an extremely low level (1.25 % by volume) in conjunction with very low shrinkage stress (3.87 MPa). Admira Fusion x-tra is the bulk fill version of Admira Fusion. This means that this restorative material can be applied in layers of up to 4 mm and then reliably cured. This makes placing posterior restorations particularly quick and economical. The universal shade U further simplifies handling, as it provides aesthetic results by adapting, chameleon-like, to the surrounding dental substance
62369344|NCT04677023|OTHER|GrandioSO x-tra® bulk|a nano-hybrid composite which is in a class of its own. It is distinguished by outstanding handling and excellent physical properties, modelled on the natural tooth.its the packable bulk fill material for the highest standards in durability and aesthetics.GrandioSO x-tra has outstanding surface hardness, at 223 MHV, which is closer to natural tooth enamel, compared with other bulk fill composites. Because of this, GrandioSO x-tra ensures restorations which are abrasionresistant and dimensionally stable over the long term. In addition to the surface hardness, reliable curing is very important when larger increments are used. Here as well, GrandioSO x-tra achieves an outstanding result and, at the 219 MHV measured at a depth of 4 mm, it even significantly exceeds the values measured for other bulk fill composites at the surface.
62369345|NCT03804827||Heart Failure With Sleep Disordered Breathing|AHI3% \>/= 5 events per hour of sleep.
62369346|NCT03804827||Heart Failure without Sleep Disordered Breathing|AHI3% \< 5 events per hour of sleep.
62369347|NCT02776306|EXPERIMENTAL|Mirror box therapy|The participants in the mirror box therapy arm will receive mirror box therapy for 3 weeks for upper limb rehabilitation post stroke.
62369348|NCT02776306|NO_INTERVENTION|Standard treatment group|The participants will receive the standard treatment arm for 3 weeks for upper limb rehabilitation post stroke.
62369349|NCT05516940||Caesarean-section|125 subjects will be selected who have delivered infants by Caesarean-section.
62369350|NCT05516940||Normal delivery|125 subjects will be selected who have delivered infants by vaginal/normal deliveries
62369351|NCT01964729|SHAM_COMPARATOR|Sham rTMS|Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
62369352|NCT01964729|EXPERIMENTAL|Transcranial Magnetic Stimulation|We will deliver high frequency rTMS at 10 Hz rate was over right M1 in sessions consisting of of 4 seconds of stimulation followed by 26 second intervals, with a total of 1600 pulses per session.
62369353|NCT05808660||General population|
62369354|NCT00722098|EXPERIMENTAL|DC Vaccine & Cyclophosphamide|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
62369355|NCT00722098|PLACEBO_COMPARATOR|DC Vaccine & Placebo|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
62369356|NCT01775800|EXPERIMENTAL|Treatment modification|Patients in this arm will be treated to different targets of blood pressure, parathyroid hormone and serum phosphorus.
62369357|NCT01775800|NO_INTERVENTION|Usual care|Patients will receive the usual hemodialysis care with no modifications
62369358|NCT06434025|EXPERIMENTAL|ferric carboxymaltose + SGLT2 inhibitor|Patients will receive 2 vials of ferric carboxymaltose 500 mg (Ferinject® 500 mg, Vifor-Pharma) IV, once; and Dapagliflozin 10 mg PO, once a day, for 30 days.
62369359|NCT06434025|ACTIVE_COMPARATOR|ferric carboxymaltose + placebo of SGLT2 inhibitor|Patients will receive 2 vials of ferric carboxymaltose 500 mg (Ferinject® 500 mg, Vifor-Pharma) IV, once; and placebo PO, once a day, for 30 days.
62743172|NCT04202406|EXPERIMENTAL|Acetaminophen|Oral single dose of 1000mg acetaminophen.
62743173|NCT04202406|PLACEBO_COMPARATOR|Placebo|Maize starch.
62743174|NCT04163861||1|"31 patients diagnosed as heart failure with preserved ejection fraction per ESC guidelines 2016 on the basis of history, clinical examination and investigations presenting to the department of cardiology, BSMMU were selected inclusion criteria~1. Patients with regional wall motion abnormality in 2D echocardiography.~2. Patients with moderate to severe valvular heart diseases.~3. Patients with prosthetic valves and pacemakers.~4. Patients with congenital heart diseases.~5. Patients currently having arrhythmia such as atrial fibrillation on ECG screening during enrollment of patient.~6. Patients with poor echo window.~7. Patients who were not interested to take part in the study."
62743175|NCT04163861||2|31 normal healthy control subjects of similar age and sex of HFpEF subjects were taken. Normal echocardiograms will be defined as normal LV size and geometry, normal LVEF \>55%). patients are free from cardiovascular diseases.
62743176|NCT02834117|OTHER|Natural cycle|Ovulation is not induced by drugs
62743177|NCT02834117|EXPERIMENTAL|Moderate ovarian stimulation|Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
62743178|NCT05834400|EXPERIMENTAL|The Optimal Lymph Flow (TOLF)|Participants in this arm perform lymphatic exercise training AND daily monitoring of fluid overload symptoms for 4 weeks
62743179|NCT05834400|ACTIVE_COMPARATOR|Daily Monitoring|Participants in this arm will only perform daily monitoring of fluid overload symptoms including weight, heart rate, and blood pressure for 4 weeks. Participants will NOT perform TOLF in this arm.
62743180|NCT04842149|ACTIVE_COMPARATOR|Bif195 capsules|The capsule will contain approximately 15\*10\^9 CFU of Bif195 per day. Excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
62743181|NCT04842149|PLACEBO_COMPARATOR|Placebo capsules|The capsule contain only excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
62743182|NCT01009944|EXPERIMENTAL|Lisinopril, Atenolol|
62743183|NCT06601699|EXPERIMENTAL|Stimulation|Participants will undergo TES or TES-TI stimulation in 5-minute blocks up to eight times a day on three separate days each separated by one week.
62743184|NCT06601699|SHAM_COMPARATOR|Sham stimulation|Participants will undergo sham stimulation in 5-minute blocks up to eight times a day on three separate days each separated by one week.
62743185|NCT05311176|EXPERIMENTAL|Arm 1: HER-Vaxx in combination with chemotherapy (ramucirumab plus paclitaxel)|Patients who have received an immune checkpoint inhibitor (ICI) previously will exclusively be enrolled in Arm 1 treated with HER-Vaxx (IM) in combination with chemotherapy (ramucirumab plus paclitaxel)
62743186|NCT05311176|EXPERIMENTAL|Arm 2: HER-Vaxx in combination with pembrolizumab|Arm 2 will investigate the combination of HER-Vaxx plus pembrolizumab in patients who are naïve to ICI treatment including patients who have had chemotherapy only treatment after progression on trastuzumab. As the combination treatment has not been investigated, Arm 2 is planned to initiate with a safety run-in phase.
62743187|NCT03709745|ACTIVE_COMPARATOR|Aflibercept|Aflibercept is given monthly (at least 3 times) until resolution of macular edema after which the patient is observed monthly. If there is recurrence of macula edema, the patient is given aflibercept according to a treat-and-extend regimen.
62743188|NCT03709745|ACTIVE_COMPARATOR|Ranibizumab|Ranibizumab is given monthly (at least 3 times) until resolution of macular edema after which the patient is observed monthly. If there is recurrence of macula edema, the patient is given ranibizumab according to a treat-and-extend regimen.
62743189|NCT01660672|OTHER|LEVETIRACETAM|Open label, dose escalation to optimal dose.
62743190|NCT06661863|ACTIVE_COMPARATOR|autologous bone|"An autologous bone graft is defined as a living tissue capable of promoting bone healing by transferring that tissue from a donor area to a recipient area. It has been defined as the gold standard for having the capacity for osteogenesis, osteoinduction, osteoconduction and providing good structural support, showing high biocompatibility and low immunogenicity, however, autologous bone is limited and has greater morbidity due to the collection of autologous bone from the donor site, increased surgical time, greater infection, inflammation, pain and bleeding."
62743191|NCT06661863|EXPERIMENTAL|Bioactive glass|Bioactive glasses (VB) are a group of synthetic ceramics based on silicates coupled with other minerals. Desirable properties of VB include good biocompatibility, osteoconductivity, antimicrobial activity and a porous structure that promotes vascularization
62743192|NCT04104815|EXPERIMENTAL|Experimental Thickener|Powder thickener
62743193|NCT02824770|ACTIVE_COMPARATOR|Usual Care|After a major abdominal surgery, the control group will receive the usual postoperative care including continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour and infusion of Tramadol HCl (Tramosel®) via PCA (Gemstar®) in the surgical intensive care unit.
62743194|NCT02824770|EXPERIMENTAL|Dimming of lights and decreasing noise|After a major abdominal surgery, the patients in the experimental group will be screened in the side-rooms where normally the patients who either have infections or are at risk of infection, are nursed and will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour and infusion of Tramadol HCl (Tramosel®) via PCA (Gemstar®) as in the control group. The study intervention will include dimming of lights and decreasing noise. The lights will be dimmed to 40 lux. The doors of the side-rooms will be closed decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m.
62743195|NCT02910401|ACTIVE_COMPARATOR|Asthmatic|Asthmatic subjects will be infected with Rhinovirus (GMP RV16 human (H)RV-16)
62743196|NCT02910401|ACTIVE_COMPARATOR|Allergic rhinitis|Allergic rhinitis subjects will be infected with Rhinovirus (GMP RV16 HRV-16)
62743197|NCT02910401|ACTIVE_COMPARATOR|Healthy control|Healthy controls will be infected with Rhinovirus (GMP RV16 HRV-16)
62743198|NCT04115514|EXPERIMENTAL|Treatment Arm|Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation.
62743199|NCT04115514|OTHER|Control arm|Standard of Care
62743200|NCT00703521|PLACEBO_COMPARATOR|1,2,3,4,5|"1. Rabies vaccine 1.0 mL IM on day 0, 7, 28,and 1 year~2. Rabies vaccine 0.5 mL IM on day 0, 7, 28,and 1 year~3. Rabies vaccine 0.1 mL Intradermal on day 0, 7, 28,and 1 year~4. Rabies vaccine 0.1 mL Intradermal on day 0, 28,and 1 year~5. Japanese encephalitis vaccine 0.25 mL subcutaneous"
62743201|NCT00344318|EXPERIMENTAL|Synflorix 1 Group|Subjects aged 6-12 weeks from the Philippines receiving Synflorix™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Polio Sabin™ vaccines at 6, 10, 14 weeks of age.
62743202|NCT00344318|EXPERIMENTAL|Synflorix 2 Group|Subjects aged 6-12 weeks from Poland receiving Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 2, 4, 6 months of age.
62743203|NCT00344318|ACTIVE_COMPARATOR|Prevenar 1 Group|Subjects aged 6-12 weeks from the Philippines receiving the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Polio Sabin™ at 6, 10, 14 weeks of age.
62743204|NCT00344318|ACTIVE_COMPARATOR|Prevenar 2 Group|Subjects aged 6-12 weeks from Poland receiving the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ at 2, 4, 6 months of age.
62743205|NCT06397443|EXPERIMENTAL|Patients with rare skeletal disorders|5-day sailing activity
62743206|NCT04015427|ACTIVE_COMPARATOR|screw-retained|Patients in group A will receive a screw-retained implant crown. Following this first period of 16 weeks, the screw-retained implant crown will be replaced by a new intraorally cemented implant crown. Cement removal will be preformed according to best clinical procedure. These implant crowns will again be left for another period of 16 weeks and followed up for the harvesting of microbiological samples every 8 weeks. After the second 16-week the implant crowns will be removed to evaluate any excess cement. All patients will be fitted with the original screw-retained implant crown. Clinical parameters for inflammation and probing depths will be obtained after each 16 week-period.
62743207|NCT04015427|ACTIVE_COMPARATOR|cement-retained|In group B the implant crowns will be incorporated in a reverse pattern. During the first 16 weeks a cemented implant crown will be inserted and any possible cement residues will be removed according to best clinical procedure, while for the second period of 16 weeks patients will be fitted with a screw-retained single implant crown. Again, microbiological and clinical parameters will be obtained at the same intervals as in Group A.
62743208|NCT02078180|ACTIVE_COMPARATOR|generic bupropion IR75|One oral dose of generic bupropion IR75
62743209|NCT02078180|ACTIVE_COMPARATOR|generic bupropion IR100|One oral dose of generic bupropion IR100
62743210|NCT02078180|ACTIVE_COMPARATOR|generic bupropion SR100|One oral dose of generic bupropion SR100
62743211|NCT02078180|ACTIVE_COMPARATOR|generic bupropion SR150|One oral dose of generic bupropion SR150
62743212|NCT02078180|ACTIVE_COMPARATOR|generic bupropion XL150|One oral dose of generic bupropion XL150
62743213|NCT02078180|ACTIVE_COMPARATOR|generic bupropion XL300|One oral dose of generic bupropion XL300
62743214|NCT02713386|ACTIVE_COMPARATOR|Arm I (paclitaxel and carboplatin)|See Detailed Description.
62743215|NCT02713386|EXPERIMENTAL|Arm II (ruxolitinib, paclitaxel, and carboplatin)|See Detailed Description.
62743216|NCT03968029|EXPERIMENTAL|Suturing meniscal augmented|Non-vascularised area meniscus tear was sutured and bone marrow was injected under a protective collagen membrane (ChondroGide)
62743217|NCT03968029|ACTIVE_COMPARATOR|Suturing meniscal|Non-vascularised area meniscus tear was only sutured
62743218|NCT04815512||exposed group|workers in The Petroleum Pipelines Company who are occupationally exposed to petroleum products will be included in the study.
62743219|NCT04815512||Comparison group (control group)|healthy administrative workers in assiut university
62743220|NCT05643001|EXPERIMENTAL|Electronic Health Record Notification|"For eligible patients presenting with an acute hemorrhagic stroke, a recommendation to measure low-density lipoprotein (LDL) and glycated hemoglobin A1c (HbA1c) together with their last measurement dates will be displayed in the patient's electronic health record through a best practice alert (BPA). The alert will display for the patient's provider when they first open the patient's chart. The provider may accept the automatically generated orders for both measurements displayed in the BPA, may modify one or both of the orders, or choose to dismiss the BPA.~For patients that follow-up with the out-patient stroke clinic and received the in-patient intervention, a second BPA will suggest referrals to sleep study and audiology. The alert will display for the patient's provider when they first open the patient's chart. The provider may accept one or both of the referrals suggested by the BPA, or may choose to dismiss the BPA."
62743221|NCT06659692|EXPERIMENTAL|Gonadotropins 150 IU|150 IU daily for 7 days.
62743222|NCT06659692|EXPERIMENTAL|Gonadotropins 300 IU|300 IU daily for 7 days
62743223|NCT02719691|EXPERIMENTAL|Dose level 1: Alisertib 30mg/MLNO128 1mg|"This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 30 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 1 mg given by mouth (PO) once daily with continuous dosing.~Alisertib: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.~MLN0128: Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study."
62743224|NCT02719691|EXPERIMENTAL|Dose Level 2: Alisertib 30mg/MLNO128 2 mg|"This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 30 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 2 mg given by mouth (PO) once daily with continuous dosing.~Alisertib: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study."
62743225|NCT02719691|EXPERIMENTAL|Dose Level 3: Alisertib 40 mg/MLNO128 2 mg|"This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 40 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 1 mg given by mouth (PO) once daily with continuous dosing.~Alisertib: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study."
62743226|NCT02719691|EXPERIMENTAL|Dose Level 4: Alisertib 40 mg/MLN0128 3 mg|"This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 40 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 3 mg given by mouth (PO) once daily with continuous dosing.~Alisertib: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study."
62743227|NCT02719691|EXPERIMENTAL|Dose-Expansion of Alisertib and Dose-Expansion of MLN0128: Group 1|"This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, single agent Alisertib will be administered at the MTD on days 1-7 and MLN0128 will be administered on days 8-21. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21.~Pancreatic Cancer Cohort:~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. On each cycle, Alisertib will be administered on days 1-7, while MLN0128 will be administered continuously on days 1-21."
62743228|NCT02719691|EXPERIMENTAL|Dose-Expansion of Alisertib and Dose-Expansion of MLN0128: Group 2|This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, MLN0128 will be administered at the MTD days 1-28 and Alisertib will be administered at the MTD on days 8-15. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21.
62743229|NCT02719691|EXPERIMENTAL|Pancreatic Cohort|This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. On each cycle, Alisertib will be administered on days 1-7, while MLN0128 will be administered continuously on days 1-21.
62369360|NCT06434025|PLACEBO_COMPARATOR|Placebo of ferric carboxymaltose and placebo of SGLT2 inhibitor|Patients will receive 2 vials of placebo IV, once; and placebo PO, once a day, for 30 days.
62369361|NCT01170468|EXPERIMENTAL|Vitamin D3|Vitamin D3 5000 IU daily
62369362|NCT01170468|PLACEBO_COMPARATOR|Placebo|Placebo daily
62369363|NCT06356415|ACTIVE_COMPARATOR|Bupivacaine|Patients will undergo an ultrasound-guided infraclavicular brachial plexus block using bupivacaine alone.
62743230|NCT06553651|EXPERIMENTAL|Cryotechnology Necrosectomy Procedure|Enrolled subjects will undergo direct endoscopic necrosectomy using 1.7 mm single use, flexible cryoprobes, aimed at effectively removing necrotic tissue within the pancreatic cavity.
62743231|NCT01402557|ACTIVE_COMPARATOR|Telephone Support Only|These participants receive telephone support only during the weight maintenance phase.
62743232|NCT01402557|EXPERIMENTAL|Telehealth|These participants receive telehealth support (with Internet-enabled digital video recorders) during the weight maintenance phase. These participants also receive telephone support monthly.
62743233|NCT01242839|EXPERIMENTAL|CACICOL20|Arm that receives CACICOL20 treatment each 2 days for 3 months/until closure of the ulcer
62743234|NCT01242839|PLACEBO_COMPARATOR|Placebo|The placebo is applicated each 2 days on patient cornea for 3 months/ until ulcer closure.
62369364|NCT06356415|ACTIVE_COMPARATOR|Bupivacaine+ Dexamethasone+ Dexmedetomidine|Patients will undergo an ultrasound-guided infraclavicular brachial plexus block using bupivacaine combined with dexmedetomidine and dexamethasone.
62369365|NCT02550119|EXPERIMENTAL|Arm I (aprepitant, dolasetron mesylate, dexamethasone)|Patients receive dolasetron mesylate PO or IV, dexamethasone PO or IV, and aprepitant PO 1 day before chemotherapy and dexamethasone PO and aprepitant PO on days 2 and 3 after chemotherapy begins during course 2-3.
62369366|NCT02550119|PLACEBO_COMPARATOR|Arm II (placebo, dolasetron mesylate, dexamethasone)|Patients receive dolasetron mesylate and dexamethasone as in Arm I and placebo PO 1 day before chemotherapy and dexamethasone PO and placebo PO on days 2 and 3 after chemotherapy begins during courses 2-3.
62369367|NCT01159457|ACTIVE_COMPARATOR|1|celiac patients who did not respond to initial hepatitis B vaccine series , will receive Sci-B-Vac vaccination series
62743235|NCT01242839|EXPERIMENTAL|CACICOL20 and Placebo|Patient applies the treatment each 2 days for 3 months or until closure of the ulcer. This treatment is alternatively CACICOL20 or Placebo : so the patient receives CACICOL20 each 4 days. CACICOL20 and placebo strips are strictly similar and cannot be identified.
62743236|NCT00822627|EXPERIMENTAL|Vaccination group|Vaccination group
62743237|NCT00822627|EXPERIMENTAL|Education/referral|Education/referral
62743238|NCT03588806|EXPERIMENTAL|Xtampza ER (oxycodone) Treatment|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study. A standard conversion table will be used to calculate the dose of Xtampza ER that is equivalent to the subject's current opioid medication dosage. Subjects will be converted to 75% of the calculated dose for the first 7-10 days and then to 100% of the calculated dose for the remaining 3 weeks of the study. The Xtampza ER dosage may be modified at the discretion of the PI to ensure the safety of the subject. As per manufacturer recommendations, subjects will be instructed to open the capsules, sprinkle the microspheres onto soft food such as pudding or applesauce, and then consume the food.
62743239|NCT02207049|ACTIVE_COMPARATOR|Three Meals (TM)|Preschoolers will be provided their caloric needs within three meals.
62743240|NCT02207049|ACTIVE_COMPARATOR|Meal plus Snack (M+S)|Preschoolers will be provided three meals and two snacks, with total amount of food provided in the day the same as the Three Meal (TM) arm.
62743241|NCT02207049|ACTIVE_COMPARATOR|Three Meal plus Snack (TM+S)|Preschoolers will be provided three meals and two snacks with total amount provided in the meals equal to the Three Meal (TM) arm and total amount provided in the snacks equal to Meal plus Snacks (M+S) arm.
62743242|NCT06657859|EXPERIMENTAL|10 mg/kg GLM101|GLM101 IV infusions, given weekly
62743243|NCT06657859|EXPERIMENTAL|20 mg/kg GLM101|GLM101 IV infusions, given weekly
62743244|NCT06657859|EXPERIMENTAL|30 mg/kg GLM101|GLM101 IV infusions, given weekly
62369368|NCT01159457|ACTIVE_COMPARATOR|2|celiac patients who did not respond to initial hepatitis B vaccine series , will receive Engerix 3-dose vaccination series
62743245|NCT03635424|EXPERIMENTAL|Medtronic TAVR Systems|Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
62369369|NCT02933372|EXPERIMENTAL|Parkinson's Disease Patients|Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments of severity of Parkinson disease (PD) and cognition are performed.
62369370|NCT02933372|EXPERIMENTAL|Healthy Controls|Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. The PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments for presence of Parkinson disease (PD) and cognition are performed.
62369371|NCT01759628|NO_INTERVENTION|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
62369372|NCT01759628|EXPERIMENTAL|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
62369373|NCT04142944|EXPERIMENTAL|Dexcom G6 with predictive hypo alert|
62369374|NCT04142944|ACTIVE_COMPARATOR|Dexcom G6 without predictive hypo alert|
62369375|NCT02211105||Laparoscopic Nissen Fundoplication|Patients whose GERD is being treated surgically through Laparoscopic Nissen Fundoplication.
62743246|NCT06598670|EXPERIMENTAL|tDCS Group|Active tDCS will be applied to the M1 area of the brain with the conventional therapy
62743247|NCT06598670|ACTIVE_COMPARATOR|Sham tDCS Group|Sham tDCS will be applied to the M1 area of the brain with the conventional therapy
62743248|NCT01877486||Cryoballoon ablation|After pre-treatment with dofetilide and conversion of persistent AF to sinus rhythm, performance of PVI using cryoballoon
62743249|NCT06279598|ACTIVE_COMPARATOR|Prolonged Exposure|Intervention: Prolonged Exposure therapy, 14 sessions of 60 minutes in 8 weeks.
62743250|NCT06279598|ACTIVE_COMPARATOR|Eye Movement Desensitization Reprocessing|Intervention: Eye Movement Desensitization Reprocessing (EMDR), 14 sessions of 60 minutes in 8 weeks.
62743251|NCT06279598|EXPERIMENTAL|Interpersonal Psychotherapy|Intervention: Interpersonal Psychotherapy (IPT), 14 sessions of 60 minutes in 8 weeks. In phase 2 of the study for treatment non-responders, IPT is studied as an alternative switching option compared to the switch of the aforementioned trauma-focused forms of psychotherapy.
62743252|NCT06068478|EXPERIMENTAL|Qingzhu Granules|
62743253|NCT06068478|PLACEBO_COMPARATOR|Qingzhu Granules Placebo|
62743254|NCT02384473|EXPERIMENTAL|Real-time CEUS and SWE|Patients undergo real-time CEUS and SWE at baseline, 6 weeks after initiation of neoadjuvant therapy, and 9 weeks after initiation of neoadjuvant therapy (prior to surgery).
62743255|NCT04785534|EXPERIMENTAL|Screening (survey, biomarker analysis, fibroscan)|Patients complete surveys over 10-15 minutes, and undergo blood testing, clinical evaluation, and fibroscan at baseline.
62743256|NCT00946608|EXPERIMENTAL|1|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)
62743257|NCT00946608|EXPERIMENTAL|2|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)
62743258|NCT00946608|ACTIVE_COMPARATOR|3|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)
62743259|NCT06659172|ACTIVE_COMPARATOR|taVNS|The vagus nerve will be stimulated electrically by using an MRI-safe electrode. The concha of the right ear will be stimulated.
62743260|NCT06659172|PLACEBO_COMPARATOR|Sham stimulation|The vagus nerve will be stimulated electrically by using an MRI-safe electrode. The earlobe of the right ear will be stimulated.
62743261|NCT06659822||People with dementia|People diagnosed with dementia
62743262|NCT06659822||Next of kin|Next of kin to people with dementia
62743263|NCT05236452|EXPERIMENTAL|Integrating of the traditional TB care with modern care through screening, and referral linkage|Integrating traditional care with modern care is a collaboration of two systems through referral linkage. A referral linkage model will be used to detect TB cases in both traditional and modern care services. Health care providers, traditional care providers will participate in the integration process.
62743264|NCT05236452|ACTIVE_COMPARATOR|Patients proceed with the usual care/ control group|The control group will be followed the existing passive case-findings system (self-referral patients to nearby health facilities that use the same national guidelines to treat TB). The usual care will be carried out using nationally standardized guidelines. The findings obtained from the control groups will be compared with the intervention groups. Finally, changes among the two groups will be assessed and concluded.
62743265|NCT06531213|EXPERIMENTAL|Group A|Visual Perception Activities and usual care group
62743266|NCT06531213|EXPERIMENTAL|Group B|Usual Care group (control)
62743267|NCT04666558|NO_INTERVENTION|Standard Care|The standard of care response to COVID. Educational materials will be provided to patients via email. The package will include a combination of personalized exercises, and nutrition information for healthy eating. Participants will also receive a Garmin watch to track their activity over the intervention.
62743268|NCT04666558|EXPERIMENTAL|App-Based, Personnel-Light Care|"An app-based, personnel-light approach to virtual care with a focus on support through group-based interactions with the Trainers, Dietitians and other participants. The patient's personalized 12-week home based exercise program will be enabled in the app after a baseline exercise specialist appointment. The 10-week nutrition program will be enabled at week 3 after a virtual dietitian assessment in week 2 (\~1 hour). The home programs will auto-progress. Participants will also receive a Garmin watch to track their activity over the intervention."
62743269|NCT04666558|EXPERIMENTAL|App-Based, Personnel-Intensive Care|"An app-based, personnel-intensive approach to virtual care with support through a combination of group-based interactions with Trainers, Dietitians and other participants, as well as one-on-one support with Exercise Trainers and Dietitians. In addition to Group 2 features, patient interaction with Trainers will be via live group classes AND 1-to-1 sessions: up to seven 1-to-1 consultations with an exercise specialist and three 1-to-1 consultations with a dietitian to review progress and goals and make any necessary modifications to programming. Participants will also receive a Garmin watch to track their activity over the intervention."
62743270|NCT05456542|EXPERIMENTAL|Intervention - Cuff Leak Test|A respiratory therapist will perform a Cuff Leak Test on all patients prior to extubation. If no air leak is auscultated (a failed CLT), extubation will be delayed. During this time, the patient will receive dexamethasone 4mg intravenous every 6 hours for 12-24 hours and the clinical team will be advised to consider optimizing a patient's fluid status through either diuresis or ultrafiltration if the patient has renal failure. After 12-24 hours, and once the clinical team decides the patient is ready for another extubation attempt, the CLT will be repeated. If the patient fails the CLT again, it will be at the discretion of the clinical team how to proceed (i.e. continue steroid administration, and further delay extubation vs immediately extubating despite a failed CLT) (Figure 3). A passed CLT at any time point will result in immediate extubation.
62743271|NCT05456542|NO_INTERVENTION|Control - No Cuff Leak Test|In the control group, once the patient is deemed ready for extubation by the clinical team, the patient will be extubated without performing a CLT, without administration of corticosteroids, and without delay.
62743272|NCT02973347|ACTIVE_COMPARATOR|Intermittent enteral feeding|Intermittent enteral feeding via the nasogastric tube is applied less than 30 mins.
62369376|NCT02211105||Transoral Incisionless Fundoplication|Patients whose GERD is being treated surgically through Transoral Incisionless Fundoplication.
62369377|NCT02756234||Qualifying CTP patients|A convenience sample of all qualifying patients for CTP procedure
62743273|NCT02973347|ACTIVE_COMPARATOR|Continuous enteral feeding|Continuous enteral feeding via the nasogastric tube using infusion pump is applied for 24 hours.
62743274|NCT06661564|ACTIVE_COMPARATOR|Patients with AD dementia|Patient ≥ 18 years old with AD at a major stage according to the 2018 NIA-AA criteria (dementia)
62743275|NCT06661564|ACTIVE_COMPARATOR|Patients with AD Mild Cognitive Impaiment (MCI)|Patient ≥ 18 years old with AD at a minor stage according to the 2018 NIA-AA criteria (Mild Cognitive Impairment)
62369378|NCT02335034|EXPERIMENTAL|Study group|Intervention: study group will attend two days of classes (two months apart) with the seven professional teams, covering what is the disease arthritis, its causes and treatment options; what is disease, being ill, and the role of the patient in the treatment to obtain behavioral change; the importance of exercise in relieving symptoms, the importance of rest and proper ergonomics at home and at work; proper alimentation; the difference between labor work and regular physical activity as well as the importance of strength resistance and stretching exercises; and the importance of leisure. The second intervention verifies the acquired concepts.
62743276|NCT06661564|SHAM_COMPARATOR|Healthy controls|Participants ≥ 18 years old with no known central neurological pathology, no cognitive decline, and matched by age (± 2 years) and sex with a patient from AD-MCI group
62743277|NCT06212063|EXPERIMENTAL|Aim High Program|Integrated physical and mental optimization training program used as tool for young individuals readying themselves to join the military
62743278|NCT01780337|ACTIVE_COMPARATOR|Oxytocin|Patients will be administered an intranasal dose of the study drug, 20 IU oxytocin. Repeat electrophysiologic measurements will be assessed at 15 minutes and 30 minutes after administration of the study medication/placebo. During the waiting periods in between the electrophysiologic measurements, we will continue with the standard protocol for an AF ablation, including transseptal puncture and left atrial mapping, performed prior to initiation of general anesthesia and actual delivery of ablation lesions. This 'preablation' period normally takes 45 minutes to one hour.
62743279|NCT01780337|PLACEBO_COMPARATOR|Saline|Patients will be administered an intranasal dose of saline. Repeat electrophysiologic measurements will be assessed at 15 minutes and 30 minutes after administration of the study medication/placebo. During the waiting periods in between the electrophysiologic measurements, we will continue with the standard protocol for an AF ablation, including transseptal puncture and left atrial mapping, performed prior to initiation of general anesthesia and actual delivery of ablation lesions. This 'preablation' period normally takes 45 minutes to one hour.
62743280|NCT05570760|EXPERIMENTAL|Adaptos®Ortho Wedge|Bone augmentation after Open Wedge High Tibial Osteotomy (OWHTO), with Adaptos®Ortho Wedge (Biomendex Oy, synthetic bone graft material) in combination with a load bearing TomoFix® Medial High Tibia Plate (DePuy Synthes).
62743281|NCT05570760|SHAM_COMPARATOR|No bone graft|OWHTO with unfilled bony defect of the osteotomy gap with a load bearing TomoFix® Medial High Tibia Plate (DePuy Synthes).
62743282|NCT05570760|ACTIVE_COMPARATOR|chronOS® Wedge|Bone augmentation, after OWHTO, with chronOS® Wedge (DePuy Synthes, synthetic beta-TCP bone graft) in combination with a load bearing TomoFix® Medial High Tibia Plate (DePuy Synthes).
62743283|NCT05214638||Assessed with the paper version of Longshi Scale first and then with electronic version|
62743284|NCT05214638||Assessed with the electronic version of Longshi Scale first and then with the paper version|
62743285|NCT04200755|EXPERIMENTAL|Dupilumab|30 patients; Dupilumab s.c. injection; 2 ready-to-use syringes (600 mg) initial (V1), 1 ready-to-use syringe (300 mg) every 14 days (V2- V13) Dupilumab s.c. injection in healthy skin, 24 weeks
62743286|NCT04200755|PLACEBO_COMPARATOR|Placebo|15 patients; placebo s.c. injection; 2 ready-to-use syringes initial (V1), 1 ready-to-use syringe every 14 days (V2-V13) placebo s.c. injection in healthy skin, 24 weeks
62743287|NCT01511614|ACTIVE_COMPARATOR|active tDCS|(1) anodal left-dlPFC + cathodal right-vmPFC stimulation, with anode over the left dlPFC and cathode over the right-vmPFC; (2) cathodal left-dlPFC + anodal right-vmPFC stimulation, in which polarity is reversed between the two electrodes
62743288|NCT01511614|SHAM_COMPARATOR|sham tDCS|To simulate the experience of tDCS stimulation, current is ramped on and turned off at the beginning and end of the tDCS session. An additional sham option is to have the current ramp up and down only at the beginning of the sham session, and not at the end. This second sham is supported in the literature as an effective blinding technique, which subjects cannot distinguish from active stimulation (Gandiga et al 2006, Brunoni et al 2012) . One of these sham options will be used for data that will be analyzed together, to be determined based on equipment capabilities and preliminary analysis of blinding efficacy in our cross over design. We will assess the efficacy of sham condition by providing participants and the investigator with a questionnaire on the MRI/tDCS session, wherein they will report whether they thought the tDCS session was active or sham. The MRI operator (or other non protocol personnel) will control active/sham conditions.
62743289|NCT01511614|OTHER|Main Study - Treatment|"Healthy male and female adults who smokers are actively seeking treatment for smoking cessation were asked to complete three study phases: pre-treatment study visits, treatment visits and post-treatment follow-up visits.~Pre-treatment (phase 1): 2 MRI sessions: dose-matched nicotine patch or placebo patch during a 36hr smoking abstinence period completed prior to each. Within \~ 2wks of their second scan visit, participants will have 1-3 pre-treatment preparation visits with a therapist.~Treatment (Phase 2): 15-18 visits over \~16-19 weeks. First dose of varenicline (0.5 - 1mg/day), 1 week prior to their quit date followed by 12wks of daily varenicline (2mg/day) as well as weekly and biweekly 30min counseling sessions.~Follow-up Phase 3: visits at 1, 6, and 12 months after their last treatment visit to assess quit status and smoking abstinence since last visit, complete a series of state measures and complete a 15-20 min scan session."
62743290|NCT01511614|OTHER|Main Study - Non-Treatment|Healthy male and female adults who have a history of 1 or more years of consistently smoking cigarettes with a urine cotinine level corresponding to smoker status for the specific test being used, typically corresponding to a urine cotinine above about 200 ng/ml, but who are not currently seeking treatment for smoking cessation. Non-treatment seeking smokers will not set a quit date or make a quit attempt, will not complete a treatment program as part of this study and will not be followed up after they complete the two pre-treatment visits.
62743291|NCT01511614|OTHER|Main Study - Motivational Interviewing|Current smokers who meet criteria for participation but who are not currently ready to enter treatment for smoking cessation. These subjects will receive motivational interviewing to prepare them for a tobacco cigarette quit attempt.
62743292|NCT01037725|EXPERIMENTAL|AZD5847 oral suspension|Active
62743293|NCT01037725|PLACEBO_COMPARATOR|Placebo to AZD5847|Placebo
62743294|NCT06230549|EXPERIMENTAL|Interventional Arm|Adaptive Radiotherapy
62743295|NCT06230549|ACTIVE_COMPARATOR|Standard conventional Treatment Arm, IGRT|Standard conventional Treatment Arm, IGRT
62743296|NCT01051531|EXPERIMENTAL|Paliperidone palmitate|
62743297|NCT03990415|EXPERIMENTAL|Stay Strong, Stay Healthy Group|The Stay Strong, Stay Healthy strength training group will meet two times per week for an hour, for eight consecutive weeks. This class provides participants a structured program to learn and progress through strength training exercises designed to increase overall fitness, flexibility, and balance.
62369379|NCT02335034|EXPERIMENTAL|Control Group|The control group will only make evaluations / consultations with all professional teams without classes for 2 years, then will attend the courses and will be followed by two more years.
62743298|NCT03990415|ACTIVE_COMPARATOR|Walking Group|The walking group will meet two times per week for an hour, for eight consecutive weeks. This class provides participants a structured walking program to help delineate the effects of the strength training program and exercise in general.
62743299|NCT03990415|NO_INTERVENTION|Delayed Start Group|The delayed start group will not make any changes to their sedentary lifestyle and will be encouraged to not begin any exercise programs throughout the duration of the study.
62743300|NCT03674073|EXPERIMENTAL|Microwave Ablation + Neoantigen Vaccines|The HCC patients will be treated firstly by Microwave Ablation, and then treated by courses of Neoantigen Vaccines.
62743301|NCT03674073|ACTIVE_COMPARATOR|Microwave Ablation|The HCC patients will be treated only by Microwave Ablation.No vaccine will be used.
62743302|NCT05403372|EXPERIMENTAL|InterShunt PAS-C|
62743303|NCT01597908|EXPERIMENTAL|Dabrafenib plus Trametinib|BRAF inhibitor plus MEK inhibitor
62743304|NCT01597908|ACTIVE_COMPARATOR|Vemurafenib|BRAF inhibitor
62743305|NCT04731298|EXPERIMENTAL|Emapalumab|"The first cohort of patients will receive a first infusion of 6 mg/kg at TD0, followed by a second infusion at 3 mg/kg after 3 days (treatment day 3 - TD3). Subsequent infusions of 3 mg/kg will be every 3 or 4 days from previous dose until dose 15 or until engraftment.~A maximum of 2 additional cohorts may be added to allow dosing regimen adaptation based on the PK/PD data observed from the previous cohort(s). Efficacy and safety data will also be considered before adding additional cohorts."
62743306|NCT03655054|EXPERIMENTAL|eCoin Tibial Nerve Stimulation|
62743307|NCT03388866|ACTIVE_COMPARATOR|Mite extract sublingual immunotherapy|"Use of mite extract sublingual immunotherapy (SLIT) with increasing weekly doses of extracts of mite Dermatophagoides pteronyssinus, as represented below:~Weekly dose schedule Monday Wednesday Friday~1. st week 1 drop 2 drops 4 drops~2. nd week 6 drops 8 drops 8 drops~Monthly Dilution Schedule Dilution of mite extract~1st and 2nd weeks (1st month) 1: 1000000 v: v 3rd and 4th weeks (1st month) 1: 100000 v: v~1st and 2nd weeks (2nd month)1: 10000 v: v 3rd and 4th weeks (2nd month) 1:1000 v: v~1st and 2nd weeks (3rd month) 1: 100 v:v 3rd and 4th weeks (3rd month) 1:10 v:v 3rd to 18th month 1:10 v: v"
62743308|NCT03388866|PLACEBO_COMPARATOR|SLIT placebo|"Patients in the control group will be submitted to the same administration schedule, but with allergen extract diluent (doubly distilled water solution and glycerin), as described below:~Weekly dose schedule Monday Wednesday Friday~1. st week 1 drop 2 drops 4 drops~2. nd week 6 drops 8 drops 8 drops~Intervention: Placebo - Immunotherapy allergen diluent"
62743309|NCT01357161|EXPERIMENTAL|Part 1: adavosertib 225 mg + paclitaxel +carboplatin|During the open-label run-in, participants receive 225 mg adavosertib twice daily (BID) starting on Day 1 of Cycle 1 (cycle=21 days) for a total of 5 doses. Participants receive adavosertib in combination with paclitaxel (175 mg/m2) and carboplatin (area under the curve \[AUC\] 5).
62743310|NCT01357161|EXPERIMENTAL|Part 2: adavosertib 225 mg + paclitaxel +carboplatin|During Part 2, participants receive 225 mg adavosertib BID starting on Day 1 of each 21 day cycle for a total of 5 doses. Participants receive adavosertib in combination with paclitaxel (175 mg/m2) and carboplatin (AUC 5).
62743311|NCT01357161|PLACEBO_COMPARATOR|Part 2: Placebo + paclitaxel +carboplatin|During Part 2, participants receive matched placebo to adavosertib BID starting on Day 1 of each 21 day cycle for a total of 5 doses. Participants receive placebo in combination with paclitaxel (175 mg/m2) and carboplatin (AUC 5).
62743312|NCT04607512|EXPERIMENTAL|Telaglenastat|800 mg telaglenastat (4 x 200 mg tablets) administered twice daily (BID) on Days 1 3, with a single dose administered on the morning of Day 4
62743313|NCT04607512|PLACEBO_COMPARATOR|Telaglenastat Placebo|800 mg placebo (4 x 200 mg tablets) administered twice daily (BID) on Days 1 3, with a single dose administered on the morning of Day 4
62743314|NCT04607512|ACTIVE_COMPARATOR|Moxifloxacin|Single dose of 400 mg moxifloxacin (1 x 400 mg tablet) administered on the morning of Day 4
62743315|NCT00578877|ACTIVE_COMPARATOR|Arm 1|Gynol II (2% N-9 gel)
62369380|NCT02480062|EXPERIMENTAL|mWELLCARE software arm|The doctor and nurse care coordinators (NCCs) in the mWELLCARE intervention arm will be trained on the use of mWELLCARE software loaded on a tablet computer. Patients diagnosed with hypertension and/or diabetes will be registered by the nurse using mWellcare application. The nurse will record patient parameters, medical history, medication etc and generate a management plan (including drug recommendation, lifestyle advise) using the mWellcare application based on standard treatment guidelines. The doctor will review the recommendation and agree or disagree giving reasons. Patient will be followed up using SMS.
62743316|NCT00578877|EXPERIMENTAL|Arm 2|Buffer Gel
62369381|NCT02480062|ACTIVE_COMPARATOR|Usual care arm|"In the control arm or the usual care arm CHCs, the doctor and Nurse will get refresher training in the detection, management and follow up of hypertension and diabetes patients based on standard guidelines. They will be provided with charts for quick reference to standard treatment guidelines. Patients diagnosed with hypertension and/or diabetes will be managed by the doctor at the CHC. The nurse will assist in recording blood pressure, height, weight etc, providing lifestyle advise and follow up advice to patients."
62369382|NCT03850210|EXPERIMENTAL|Short Splint|
62743317|NCT01440218||Patients with idiopathic diseases|Study population is limited to individuals with a rare severe illness, and/or their family members.
62743318|NCT01490008|EXPERIMENTAL|Veregen|Veregen® (sinecatechins) Ointment, 15%, local application of 250 mg corresponding to 0.5 cm strand of ointment, 3 times daily (total dose of 750 mg/d)
62743319|NCT01490008|ACTIVE_COMPARATOR|Tea|"Lipton® Green Limone, a green tea beverage; oral intake of 500 mL green tea, 3 times daily (total dose on 1500 mL/d)"
62743320|NCT03631004|EXPERIMENTAL|olanzapine tablets|PATIENT WILL TAKE OLANZAPINE 10 MG, 1 hour BEFORE SURGERY
62743321|NCT03631004|PLACEBO_COMPARATOR|Starch tablets|PATIENT WILL TAKE PLACEBO 1 hour BEFORE SURGERY
62743322|NCT01040091|ACTIVE_COMPARATOR|HIV-Infected Participants|HIV-infected participants will receive FTC, TDF, and EFV for 60 days by prescription from their physicians. Participants will receive Truvada (FTC/TDF) and EFV for the first 30 days. After Day 30, participants may switch to the TDF/FTC/EFV co-formulation through Day 60 as directed by their physician.
62743323|NCT01040091|ACTIVE_COMPARATOR|HIV-Uninfected Participants|HIV-uninfected participants will receive Truvada (FTC/TDF) for 30 days.
62743324|NCT03660202|EXPERIMENTAL|Single Arm|Single Arm Safety and Effectiveness Confirmatory Study of Firesorb BVS
62743325|NCT01748708|EXPERIMENTAL|Magnetic seizure therapy|
62369383|NCT03850210|ACTIVE_COMPARATOR|Traditional, Long Splint|
62369384|NCT05418725|EXPERIMENTAL|PEF Arm|PEF is a non-thermal ablation modality using extremely short high voltage pulses to induce cell death, with tissue selectivity, cardiomyocytes being much more sensitive to this energy than Phrenic nerve or Esophageal cells. Energy (2000 V) will be delivered 8 times per vein with 2 different catheter configurations and rotations. Linear lesion will be delivered using 8 deliveries using 2000 V at the posterior left atrium
62369385|NCT05418725|ACTIVE_COMPARATOR|Pulmonary vein isolation and linear lesion using Contact Force RF|The PVI strategy using RF is very standard. The CARTO© platform will be used, with a contact force catheter (SmartTouch), aiming at an ablation index value of 300 to 400 on the posterior wall, and at least 500 on the anterior wall. Power will be limited to 35/45 W, with a distance between consecutive deliveries of 6 mm or less (CLOSE protocol). Linear lesion will be delivered at the posterior left atrium.
62743326|NCT01748708|ACTIVE_COMPARATOR|Electroconvulsive therapy|
62743327|NCT04867512|EXPERIMENTAL|Intervention Group|Participants will be taking one liquid tincture orally per day as well as 2 capsules orally at night. At week 10, non-responders will take another supplement consisting of 2 capsules orally along with the liquid tincture until week 14.
62743328|NCT00296465|EXPERIMENTAL|Lutrepulse® 5mcg IV|5.0 mcg Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
62743329|NCT00296465|EXPERIMENTAL|Lutrepulse® 10 mcg IV|10.0 mcg Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
62743330|NCT00296465|EXPERIMENTAL|Lutrepulse® 20 mcg SC|20.0 mcg Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
62743331|NCT00296465|PLACEBO_COMPARATOR|Placebo IV|Placebo Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
62743332|NCT00296465|PLACEBO_COMPARATOR|Placebo SC|Placebo Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
62743333|NCT00296465|ACTIVE_COMPARATOR|Clomiphene Citrate/Placebo IV|Oral clomiphene citrate (over encapsulated) for 5 days and Placebo Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
62743334|NCT00296465|ACTIVE_COMPARATOR|Clomiphene Citrate / Placebo SC|Oral clomiphene citrate (over encapsulated) for 5 days and Placebo Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
62743335|NCT00842153|EXPERIMENTAL|Clobetasol Propionate Foam|Topical foam formulation that includes clobetasol propionate (Steroid)
62743336|NCT00842153|PLACEBO_COMPARATOR|Vehicle Foam|Vehicle foam is the same as the clobetasol propionate foam except it does not include the active drug.
62743337|NCT02191657|EXPERIMENTAL|Cohort 1|Subjects in this arm were asymptomatic HIV-infected individuals who received a dose of 33 mg/kg deferiprone three times a day for a total daily dosage of 99 mg/kg
62743338|NCT02191657|EXPERIMENTAL|Cohort 2|Subjects in this arm were healthy volunteers who received a dose of 50 mg/kg deferiprone three times a day for a total daily dosage of 150 mg/kg
62743339|NCT02191657|EXPERIMENTAL|Cohort 3|Subjects in this arm were asymptomatic HIV-infected individuals who received a dose of 50 mg/kg deferiprone three times a day for a total daily dosage of 150 mg/kg.
62743340|NCT06658262|EXPERIMENTAL|Experimental Group|Tai Chi Exercises + Cycling exercises. Treatment session of 60 min will be given 3 times a week for 6 weeks.
62743341|NCT06658262|OTHER|Control Group|Tai Chi Exercises Alone. Treatment session of 60 min will be given 3 times a week for 6 weeks.
62743342|NCT04750226|EXPERIMENTAL|ABBV-951|Participants will receive ABBV-951 by continuous subcutaneous infusion (CSCI) for 96 weeks during the Primary Treatment Period and during the optional Extended Treatment Period.
62743343|NCT06660979|EXPERIMENTAL|Reinforcement learning intervention|The intervention is a reinforcement learning program that personalizes EHR-based tools for PCPs to promote deprescribing high-risk medications over follow-up. The reinforcement learning intervention selects a tool for each provider based on an algorithm from an inventory of EHR tools and chooses tools that are predicted to motivate action for the individual provider. The effectiveness of each tool will be assessed on a selected interval based on whether a deprescribing action is taken by PCPs for eligible patients. The algorithm is trained to maximize these actions over time.
62743344|NCT06660979|NO_INTERVENTION|Usual care|No EHR-based tools provided beyond those used in regular clinical practice.
62743345|NCT03465397|EXPERIMENTAL|experimental|Biomarkers driven immunosuppressive therapy: the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
62743346|NCT03465397|NO_INTERVENTION|control|All patients receive the usual triple immunosuppressive treatment, without depending on the results of any biomarker.
62743347|NCT03811392|ACTIVE_COMPARATOR|Hernioraphy/Caudal block|patients will receive a caudal block after induction of general anaesthesia.
62743348|NCT03811392|ACTIVE_COMPARATOR|Hernioraphy/Quadratus Lumborum block|patients will receive ultrasound guided quadrates lumborum block (QL )
62369386|NCT05459506||Subjects with Post Acute Sequale SARS-CoV-2 (PSAC)|Participants with PASC
62743349|NCT00562263|EXPERIMENTAL|Lifestyle Modification|Parents are randomized to attend 12 educational sessions covering strategies to manage children's health behaviors.
62369387|NCT05459506||Subjects with COVID but not PASC|Subjects confirmed COVID-19 positive without Post Acute Sequale SARS-CoV-2 (PASC)
62369388|NCT02019758|ACTIVE_COMPARATOR|Oral Viscous Budesonide (OVB)|Subjects will be treated with OVB at a dose of 1 mg twice daily, and they will also be instructed to use a placebo inhaler identical to the fluticasone MDI, with instructions to swallow 4 puffs twice daily.
62369389|NCT02019758|ACTIVE_COMPARATOR|Active Fluticasone MDI|Subjects will be treated with fluticasone MDI at a dose of 880 mcg twice daily (4 puffs of a 220 mcg inhaler twice daily), and they will also be instructed to take 4 mL twice daily of a placebo slurry of sucralose identical in consistency and taste to the OVB.
62369390|NCT04614376||Control Group|The control group participants have not been diagnosed with mild cognitive impairment or Alzheimer's disease within the past 5 years. There are no interventions to this group.
62369391|NCT04614376||Case Group|The case group participants have been diagnosed with mild cognitive impairment or Alzheimer's disease within the past 5 years. There are no interventions to this group.
62369392|NCT00479934|EXPERIMENTAL|1|6 month treatment with Imtinib 400mg/day
62369393|NCT00479934|PLACEBO_COMPARATOR|2|6 month treatment with Placebo 400mg/day
62369394|NCT00862498|EXPERIMENTAL|Group 1 Treatment in Clinic|Participants will complete the written disclosure treatment in a clinic setting.
62369395|NCT00862498|EXPERIMENTAL|Group 2 Treatment via telephone|Participants will complete the written disclosure treatment in their homes via telephone.
62369396|NCT00862498|NO_INTERVENTION|Group 3 Waitlist|Individuals will be placed on a waitlist for a period of 4 months, during which they will receive a phone call every other week to assess their suicidal ideation and post-traumatic stress disorder symptom severity.
62369397|NCT03959345|EXPERIMENTAL|Combination therapy group|intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment
62369398|NCT03959345|ACTIVE_COMPARATOR|Standard therapy group|intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment
62743350|NCT00562263|NO_INTERVENTION|Control|Teen participates in lifestyle intervention, but parent does not attend parent education sessions
62369399|NCT03828565|ACTIVE_COMPARATOR|ScvO2 group|ScvO2 and Pulse Pressure Variation (PPV) : every 30 min (%) ScvO2 Evolution in case of corrective maneuver (%) PPV evolution in case of filling test (%)
62369400|NCT03828565|NO_INTERVENTION|Control group|End-systolic Volume (ESV) : every 30 min (mL) ESV evolution in case of filling test (%)
62743351|NCT05984758|ACTIVE_COMPARATOR|Standard care|Routine examination for uveitis with assessment of visual function followed by slit lamp examination
62743352|NCT05984758|EXPERIMENTAL|ASOCT imaging|Assessment of visual function followed by image acquisition with the Optovue RTVue OCT and the Heidelberg Spectralis OCT2 machines
62743353|NCT04327362|EXPERIMENTAL|Cluster 1: Sham to active tDCS crossover at PE Session 4.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-3, and 20 min. of active tDCS prior to PE sessions 4-10.
62743354|NCT04327362|ACTIVE_COMPARATOR|Cluster 2: Sham to active tDCS crossover at PE Session 5.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-4, and 20 min. of active tDCS prior to PE sessions 5-10.
62743355|NCT04327362|ACTIVE_COMPARATOR|Cluster 3: Sham to active tDCS crossover at PE Session 6|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-5, and 20 min. of active tDCS prior to PE sessions 6-10.
62743356|NCT04327362|ACTIVE_COMPARATOR|Cluster 4: Sham to active tDCS crossover at PE Session 7.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-6, and 20 min. of active tDCS prior to PE sessions 7-10.
62743357|NCT04327362|ACTIVE_COMPARATOR|Cluster 5: Sham to active tDCS crossover at PE Session 8.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-7, and 20 min. of active tDCS prior to PE sessions 8-10.
62743358|NCT00313313|EXPERIMENTAL|Saxagliptin 2.5 mg + Glyburide 7.5 mg (A)|Metformin 500-2500 mg (as needed)
62743359|NCT00313313|EXPERIMENTAL|Saxagliptin 5 mg + Glyburide 7.5 mg (B)|Metformin 500-2500 mg (as needed)
62743360|NCT00313313|PLACEBO_COMPARATOR|Placebo + Glyburide 7.5 mg (C)|Metformin 500-2500 mg (as needed)
62743361|NCT03828903|EXPERIMENTAL|pleural effusion patients|medical thoracoscopy will e performed to patients with pleural effusion and pleural biopsy by forceps ad cryoprobe will be obtained
62743362|NCT02815657|ACTIVE_COMPARATOR|SP2086 and Valsartan|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12.There were 6 days washout period between the two stages.The whole study needs 31 days.This group patient was given treatment from A stage to B stage.
62743363|NCT02815657|ACTIVE_COMPARATOR|Valsartan and SP2086|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12.There were 6 days washout period between the two stages.The whole study needs 31 days.This group patient was given treatment from B stage to A stage.
62369401|NCT05681897|OTHER|Single Spin Group|Currently, the standard operating procedures for PRP preparation in dr. Cipto Mangunkusumo National General Hospital is by performing a single-spin centrifugation at 3000 rpm for 15 minutes. This first group will received PRP treatment by single-spin centrifugation at 3000 rpm in 15 minutes in addition to topical minoxidil (5%)
62369402|NCT05681897|ACTIVE_COMPARATOR|Double Spin Group|This group will received double-spin centrifugation PRP treatment at 1500 rpm in 6 minutes and continued at 2500 rpm in 15 minutes in addition to topical minoxidil (5%)
62391498|NCT04132817|EXPERIMENTAL|Group A Target class A-1: Nivolumab+nab-paclitaxel|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
62743364|NCT04294615|EXPERIMENTAL|FMT through a naso-jejunal tube|The purified fecal microbiota was delivered into the intestine through a naso-jejunal tube.
62743365|NCT04294615|ACTIVE_COMPARATOR|FMT through TET|The purified fecal microbiota was delivered into the intestine through a transendoscopic enteral tubing (TET) which is fixed to the cecum with clips under endoscopic guidance.
62743366|NCT03549572||Severe Traumatic Brain Injury|We will administer Coma Recovery Scale-Revised (CRS-R) and the Coma Recovery Scale Revised For Accelerated Standardized Testing (CRSR-FAST) to patients in the intensive care unit who have impaired level of consciousness resulting from a severe traumatic brain injury.
62743367|NCT01081704|EXPERIMENTAL|001|ustekinumab Single dose of 45 mg subcutaneous injection
62743368|NCT01081704|EXPERIMENTAL|002|ustekinumab Single dose of 90 mg subcutaneous injection
62369403|NCT05402904|ACTIVE_COMPARATOR|patients with chronic low back pain|50 Patients will be recruited from neuropsychiatric outpatient clinic at Sohag University Hospital complaining of CLBP for more than 12 Weeks. Patients who are suspected of suffering from any autoimmune, rheumatological, or neurological disorders that could explain the pain that they experienced will be excluded from the study. Patients who are suffering from any disease that could affect the results and interpretation of the parameters of the H-reflex, F-wave or SSEP, including polyneuropathy and radiculopathy. Structural Spinal cause of pain will be excluded by relative investigations. Routine nerve conduction studies on both lower limbs as well as H-reflex, F-wave and SSEP will be performed on both patients and controls.Arabic versions of the Beck depression inventory and Taylor's Manifest Anxiety Scale will be used to measure depression and anxiety in both patients and healthy controls.
62369404|NCT05402904|ACTIVE_COMPARATOR|healthy controls|"50 Healthy volunteers will be included in the control group of the study. Routine nerve conduction studies on both lower limbs as well as H-reflex, F-wave and SSEP will be performed on both patients and controls.~Arabic versions of the Beck depression inventory and Taylor's Manifest Anxiety Scale (TMAS) will be used to measure depression and anxiety in both patients and healthy controls."
62369405|NCT05047016|OTHER|Dynamic consent arm|Subjects will receive a virtual investigational product once daily. Subjects also need to measure their body temperature once daily at the scheduled timepoint.
62369406|NCT00476398|NO_INTERVENTION|Diagnostic capsule endoscopy|Patient with non-cardiac chest pain will undergo capsule endoscopy
62369407|NCT04624672|PLACEBO_COMPARATOR|Control Arm|Once weekly injection of placebo 4-6 months at prescribed dose
62369408|NCT04624672|ACTIVE_COMPARATOR|Test Arm|Once weekly injection of 1.0mg Semaglutide 4-6 months at prescribed dose
62369409|NCT02389530||interventional group|All participants will receive the study intervention, intravenous administration of fluorescein dye prior to brain tumor removal.
62369410|NCT00511108|EXPERIMENTAL|1|Arm 1: drug
62369411|NCT00511108|ACTIVE_COMPARATOR|2|Arm 2: active comparator
62369412|NCT00511108|EXPERIMENTAL|3|Arm 3: drug + active comparator
62369413|NCT00511108|PLACEBO_COMPARATOR|4|Arm 4: placebo comparator
62369414|NCT01155791|EXPERIMENTAL|combination sodium selenite and docetaxel|
62369415|NCT04260529|EXPERIMENTAL|Arm A: CyPep-1 monotherapy|"Phase I of the trial, dose escalation, safety and tolerability will be documented and the MTD/RP2D will be determined. Cohorts of 3 subjects (in total 12 subjects) will receive IT injections with CyPep-1 by intratumoral injection at Day 1 of weeks 1, 3 and 5.~In Phase IIa of the trial, dose expansion, the safety and tolerability will be further evaluated in an expanded cohort of 9 subjects at the RP2D of CyPep-1, determined in Phase I. CyPep-1 administration is planned as Q2W injections"
62369416|NCT04260529|EXPERIMENTAL|Arm B: CyPep-1 in combination with pembrolizumab|The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 15 subjects in total, using a staggered approach. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC).
62369417|NCT04260529|EXPERIMENTAL|Arm C: CyPep-1 monotherapy liver lesions|The safety and tolerability of at least two dose levels of CyPep-1, the RP2D and the dose immediately below that, are planned to be evaluated when CyPep-1 is administered intratumorally to a metastatic lesion in the liver. CyPep-1 administration is planned as Q2W injections.
62369418|NCT04260529|EXPERIMENTAL|Arm D: CyPep-1 monotherapy melanoma|The safety and tolerability of CyPep-1 at RP2D will be further evaluated with focus on assessing efficacy signals of CyPep-1 monotherapy in subjects with melanoma. CyPep-1 administration is planned as QW injections until the second iRECIST/itRECIST assessment at week 16, followed by a Q2W dosing scheme.
62369419|NCT02465489|EXPERIMENTAL|ER, fasting conditions|A single 1000 mg dose of deferiprone extended release tablet formulation administered under fasting conditions
62369420|NCT02465489|EXPERIMENTAL|ER, fed conditions|A single 1000 mg dose of deferiprone extended release tablet formulation administered under fed conditions
62369421|NCT02465489|EXPERIMENTAL|ER half-tablets, fed conditions|A single 1000 mg dose of deferiprone extended release tablet formulation (one 1000 mg tablet divided in two) administered under fed conditions
62369422|NCT02465489|ACTIVE_COMPARATOR|IR, fasting conditions|A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fasting conditions
62369423|NCT02465489|ACTIVE_COMPARATOR|IR, fed conditions|A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fed conditions
62743369|NCT01794312|EXPERIMENTAL|T4020|One drop every 2 days
62369424|NCT01301404|NO_INTERVENTION|control|patient receive nothing
62369425|NCT01301404|EXPERIMENTAL|carbohydrate drink|10%carbohydrate drink
62743370|NCT01794312|PLACEBO_COMPARATOR|Vehicle|One drop every 2 days
62369426|NCT05129683|EXPERIMENTAL|Anodal tDCS cerebellar stimulation group:|Anodal tDCS cerebellar stimulation
62369427|NCT05129683|EXPERIMENTAL|Anodal tDCS cerebral (M1) stimulation group:|Anodal tDCS cerebral (M1) stimulation
62369428|NCT05129683|SHAM_COMPARATOR|Sham Group|Sham: Single-session a-tDCS (2 mA, 20 min),
62369429|NCT00887068|EXPERIMENTAL|Azacitidine|Azacitidine 32 mg/m\^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
62369430|NCT00887068|NO_INTERVENTION|No Azacitidine|Standard treatment post allogeneic transplant is supportive care only.
62369431|NCT00245349||FLT|Study group receiving FLT for imaging
62369432|NCT04741295|NO_INTERVENTION|Control Group|Adenomyosis patients in control group have normal luteal progesterone support.
62743371|NCT06388096|EXPERIMENTAL|Glaucoma Suspects|Patients with suspicion of glaucoma based on positive factors of disease.
62369433|NCT04741295|EXPERIMENTAL|Low molecular weight heparin Group|Adenomyosis patients in Low molecular weight heparin group have Low molecular weight heparin in addition to normal luteal progesterone support.
62369434|NCT03516552||Hemoglobin content on blood loss|Hemoglobin content on blood loss, to assess ratio hemoglobin/volume.
62369435|NCT02520713||Genetic testing and GAIN report|All enrolled patients will submit specimens for sequencing and analysis.
62743372|NCT06388096|ACTIVE_COMPARATOR|Controls|Age matched controls to the glaucoma suspect group with no indications of glaucoma.
62369436|NCT02109744|EXPERIMENTAL|Decitabine followed by rapamycin|Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Rapamycin 6mg (loading dose) will be administered on day 6; thereafter 2 mg/day on days 11-22 in cycle 1 and on days 6-22 in subsequent cycles. (Arm A: for patients with non-morphologic M4/M5 subtypes).
62369437|NCT02109744|EXPERIMENTAL|Decitabine followed by ribavirin|Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Ribavirin will be dosed from day 11-day 28 beginning with dose level 1 (1000mg orally twice daily). Number of patients with Dose Limiting Toxicities (DLT) at a given dose level is 0 of out of 3: enter 3 patients at the next dose level (dose Level 2- 1200mg orally twice daily; and then dose Level 3-1400 mg orally twice daily).(Arm B: For patients with morphologic M4/M5 subtypes).
62369438|NCT01493934|ACTIVE_COMPARATOR|Healthy volunteers|First injection in human, on 6 healthy volunteers, sequentially : volunteer number1, then volunteers n°2 to n° 6, before infusion in type 2 diabetic patients.
62369439|NCT01493934|EXPERIMENTAL|type 2 diabetic patients|After completion of the study for the 6 healthy volunteers, infusion in 6 type 2 diabetic patients.
62369440|NCT01518634|EXPERIMENTAL|Imipramine treatment|
62369441|NCT01518634|PLACEBO_COMPARATOR|Placebo|
62369442|NCT01100762|EXPERIMENTAL|Single Group|10 subjects with Parkinson's Disease receiving tPCS during the first session, treadmill walk, 7-10 days later (second session, and combined tPCS and treadmill 7-10 days week later (third session)
62369443|NCT00683501|EXPERIMENTAL|1|dosage X mg BID
62369444|NCT00683501|EXPERIMENTAL|2|dosage Y mg BID
62369445|NCT00683501|EXPERIMENTAL|3|dosage Z mg BID
62369446|NCT00683501|EXPERIMENTAL|4|dosage 2Z mg BID
62369447|NCT00683501|PLACEBO_COMPARATOR|5|Placebo BID
62369448|NCT05784103|OTHER|Multi-Modal Measurement of Oxygen Saturation|During a single study visit, participants will have oxygen saturation measured with a number of oximetry devices including Spatial Frequency Domain Imaging (SFDI), Transcutaneous oxygen monitoring (TCOM), an Apple Watch Oxygen Sensor, and a Pulse Oximeter. Each device will be used to measure oxygen saturation of the thumb and index fingers at rest, during occlusion of blood flow to the arm (using an inflated blood pressure cuff applied to the arm), and during the hyperemic post-occlusion period. Completion of all planned interventions may take up to 2 hours on the study visit day.
62369449|NCT01901367|EXPERIMENTAL|Arm I (intervention)|Patients receive standard of care individualized diet and exercise plan and monthly booster follow-up sessions from the nutritionist and exercise physiologist and weekly phone counseling with a trained health coach to address barriers to improve plan adherence.
62369450|NCT01901367|NO_INTERVENTION|Arm II (control)|Patients receive standard of care individualized diet and exercise plan
62369451|NCT05433974|OTHER|Radiosensitivity|Patient who agree to participate in this research study will have blood sample collected in order to perform the RadioDtect test.
62369452|NCT00554853|OTHER|Pioglitazone then placebo|Oral daily pioglitazone 30 mg tablets daily for 2 weeks, followed by 45 mg daily tablets until end of study for 3 months compared to placebo in tablets of equal presentation for 3 months, then crossover after a 2 month washout.
62369453|NCT00554853|OTHER|placebo then study drug (pioglitazone)|Oral daily placebo for 3 months compared to pioglitazone for 3 months, then crossover after a 2 month washout. Similar doses as mentioned above.
62369454|NCT05478538||Stage IV or metastatic Non Small Cell Lung Cancer (NSCLC)|"Subjects suspected of or diagnosed with Stage IV NSCLC and meet one of the following criteria:~1. Subjects who are undiagnosed, have undergone imaging and are suspected to have Stage IV lung cancer.~2. Subjects with a Stage I, II, or III diagnosis of NSCLC, who are being re-biopsied after imaging-confirmed progression to metastatic disease~3. Subjects who have a confirmed diagnosis of NSCLC, and have undergone a SOC biopsy procedure and will undergo a separate procedure for the purposes of this study.~4. Subjects who have a previous Stage IV/metastatic NSCLC diagnosis and have already received first line treatment."
62369455|NCT04986111|EXPERIMENTAL|Linear skin closure with wound drain|Reduce fluid collection and dead space by inserting drain into the subcutaneous layer using the wound closure method previously used in the experimental center. The linear suture has a relatively quick time to stitch out.
62369456|NCT04986111|ACTIVE_COMPARATOR|Purse-string skin closure with negative pressure wound therapy|Close the wound with a purse-string suture which is better in terms of surgical site infection but known to take a long time for wound healing, and use negative pressure wound therapy to help granulation of tissues and help healing.
62369457|NCT03998891||salt restricted diet|In this group the patients will received after CRTD a restricted (1500 grams/daily) salt intake.
62369458|NCT03998891||normal salt diet|In this group the patients will received after CRTD a normal (2500 grams/daily) salt intake.
62369459|NCT03647462|EXPERIMENTAL|CPAP Intervention Pathway|"Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.~The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying COPD. They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms."
62369460|NCT03647462|NO_INTERVENTION|Usual Care Pathway|Patients will receive contemporary standard of care pharmacotherapy for their underlying COPD condition and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
62369461|NCT02790684|EXPERIMENTAL|DS-8500a|
62369462|NCT06332183||Presence of polymorphisms|Statistical analysis of GWAS data, Genome-wide methylation pattern analysis, Integration of GWAS data and methylation data (meQTL analysis), Pathway enrichment analysis
62369463|NCT01427114|EXPERIMENTAL|R-CVP|6 cycles of R-CVP followed by 2 cycles of rituximab
62369464|NCT05044351|EXPERIMENTAL|(A): NIRAF-assisted surgery|Patients undergoing NIRAF-assisted hemithyroidectomy
62369465|NCT05044351|ACTIVE_COMPARATOR|(B): Conventional surgery|Patients undergoing conventional hemithyroidectomy without NIRAF-assistance
62369466|NCT02052323|EXPERIMENTAL|artesunate/mefloquine (AS/MQ)|The antimalarial drug regimen being evaluated is: artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours; plus mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours; plus primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours
62369467|NCT00675688|EXPERIMENTAL|A|
62369468|NCT00675688|ACTIVE_COMPARATOR|B|
62369469|NCT00675688|PLACEBO_COMPARATOR|C|
62369470|NCT04869189|OTHER|High Sphere|Subjects with a spherical refraction between -1.75 DS and -6.00 DS
62369471|NCT04869189|OTHER|Low Sphere|Subjects with a spherical refraction between -1.50 DS and +1.00 DS
62369472|NCT01140776||OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (\>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (\> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (\> 2 mm).~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required."
62369473|NCT00479167|EXPERIMENTAL|Bortezomib and Tositumomab I-131|
62369474|NCT03190967|EXPERIMENTAL|1/Phase I: Ado-trastuzumab (T-DMI) + Temozolomide (TMZ) Dose Escalation|T-DM1 + TMZ in dose escalation
62369475|NCT03190967|ACTIVE_COMPARATOR|2A /Phase II: Arm A, Ado-trastuzumab (T-DMI) Alone|T-DM1
62369476|NCT03190967|EXPERIMENTAL|2B/Phase II /Arm B, Ado-trastuzumab (T-DMI) + Temozolomide (TMZ)|T-DM1 + TMZ at recommended phase 2 dose (RP2D)
62369477|NCT02116738|EXPERIMENTAL|Flap Transposition Technique|Flap Transposition Technique
62369478|NCT04672070|ACTIVE_COMPARATOR|Selective Caries Removal|The patient will be treated with Selective Caries Removal (SCR)
62369479|NCT04672070|ACTIVE_COMPARATOR|Pulpotomy|The patient will be treated with full coronal Pulpotomy.
62743373|NCT05984654|EXPERIMENTAL|Target ulcer Group 1(Injectable PRP)|Under aseptic conditions, 2 mL of autologous PRP will be injected with 30 G needle at multiple sites in and around target ulcer approximately 1.5 cm apart at 0, 4, 8, and 12 weeks after local anesthesia.
62743374|NCT05984654|EXPERIMENTAL|Target ulcer Group 2(Topical PRP)|Under aseptic conditions, 2 mL of autologous PRP will be applied topically followed by a Platelet poor plasma solution soaked dressing on the second target ulcer at 0, 4, 8, and 12 weeks.
62743375|NCT05984654|NO_INTERVENTION|Target ulcer Group 3(No treatment)|Target ulcer in the control group will receive standard wound care only.
62743376|NCT06538077|EXPERIMENTAL|A1=Experimental:|Drug: Oral BCAA + Rifaximin placebo + Lactulose ( Oral BCAA 15 gm in once daily dose With Lactulose for 24 weeks)
62369480|NCT00369278|EXPERIMENTAL|Intensified Mycophenolate sodium|Enteric-coated mycophenolate sodium was given according to the following dosing regimen: Day 1-14: 2880 mg/day (2 x 1440 mg), then day 15-42: 2160 mg/day (2 x 1080 mg), then day 43-End of study (month 6): 1440 mg/day (2 x 720 mg). Total duration of treatment was 180 days.
62369481|NCT00369278|ACTIVE_COMPARATOR|Standard Mycophenolate sodium|Enteric-coated mycophenolate sodium was given according to the following dosing regimen: Day 1 - End of Study(month 6): 1440 mg/day (2 x 720 mg). Total duration of treatment was 6 months.
62743377|NCT06538077|EXPERIMENTAL|A2= Experimental:|Drug: Rifaximin+ BCAA Placebo + Lactulose ( Oral Rifaximin 550 mg twice daily daily + Lactulose therapy for 24 weeks)
62743378|NCT02428751|ACTIVE_COMPARATOR|R-CHOP|This group received R-CHOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Doxorubicin, 50mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.
62743379|NCT02428751|EXPERIMENTAL|R-CDOP|This group received R-CDOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Pegylated liposomal doxorubicin, 30mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.
62743380|NCT01780246|EXPERIMENTAL|nusinersen|
62743381|NCT04123093|EXPERIMENTAL|Healthy Volunteers|The initial phase of the study is designed to determine the safety of the study device, the Noxsano Bandage, in healthy volunteers without wounds.
62743382|NCT04123093|EXPERIMENTAL|Wound care|The second phase of the study is designed to determine the effectiveness of the study device in wound healing in subjects with active wounds.
62743383|NCT03489655|EXPERIMENTAL|Maintenance Phase Intervention|Participants receive a phone-based Community Health Worker (CHW) intervention in addition to bi-monthly data collection calls with a research assistant.
62743384|NCT03489655|NO_INTERVENTION|Maintenance Phase Control|Participants receive no further interventions, but have bi-monthly data collection calls with a research assistant.
62743385|NCT02249390||Anyone|Any individual may complete this survey
62743386|NCT01093378||Fertile group|fertile group
62369482|NCT05831514|EXPERIMENTAL|Intervention Group|Parents who meet the inclusion criteria will be informed about the study and invited to participate in the study. Verbal and written consent will be obtained from parents who meet the inclusion criteria and agree to participate in the study. In the pretest, the Complications Checklist, Zarit Caregiver Burden Scale, General Self-Efficacy Scale, State/Trait Anxiety Scale are completed by the parents. The mobile application will be introduced to the parents and they will be allowed to download it to their phones. Parents will be ensured to actively use the mobile application for three months. At the first month follow-up, the Complications Checklist, Zarit Caregiver Burden Scale, General Self-Efficacy Scale, State/Trait Anxiety Scale are completed by the parents. In the post-test, the Complications Checklist, Zarit Caregiver Burden Scale, General Self-Efficacy Scale, State/Trait Anxiety Scale are completed by the parents.
62743387|NCT01093378||Infertility group|Fertility troubles
62743388|NCT04331340|EXPERIMENTAL|Pharmacist Intervention|Pharmacist assessment of LUTS, with recommendations and education regarding lifestyle, behaviour, and/or medications related to bladder health. Follow-up at 3 and 6 weeks.
62743389|NCT04331340|ACTIVE_COMPARATOR|Control|Pharmacist questions regarding presence of LUTS, with provision of healthy aging literature. Follow-up at 6 weeks.
62743390|NCT03220464|EXPERIMENTAL|Close contacts of active pulmonary tuberculosis patients|One arm study of conducting ULDCT, chest x-ray, and IGRA
62743391|NCT02050347|EXPERIMENTAL|Subgroup A1|Patients with residual or relapsed B-cell ALL and with an HLA-matched related donor will receive CD19.CAR-CD28Z T Cells - dose escalation 1
62369483|NCT05831514|NO_INTERVENTION|Control Group|Parents who meet the inclusion criteria will be informed about the study and invited to participate in the study. Verbal and written consent will be obtained from parents who meet the inclusion criteria and agree to participate in the study. In the pretest, the Complications Checklist, Zarit Caregiver Burden Scale, General Self-Efficacy Scale, State/Trait Anxiety Scale are completed by the parents. At the first month follow-up, the Complications Checklist, Zarit Caregiver Burden Scale, General Self-Efficacy Scale, State/Trait Anxiety Scale are completed by the parents. In the post-test, the Complications Checklist, Zarit Caregiver Burden Scale, General Self-Efficacy Scale, State/Trait Anxiety Scale are completed by the parents.
62743392|NCT02050347|EXPERIMENTAL|Subgroup B1|Patients with other B-cell malignancies and with an HLA-matched related donor will receive CD19.CAR-CD28Z T Cells - dose escalation 1
62369484|NCT04572685|EXPERIMENTAL|LY03010 Process 1|"Drug Product of Process 1 ( P1): 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study.~LY03010 P1 using a non-sterile Active Pharmaceutical Ingredients (API) with an absolute ethanol recrystallization was manufactured by an optimized production process"
62369485|NCT04572685|EXPERIMENTAL|LY03010 Process 2|"Drug Product of Process 2 (P2): 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study.~LY03010 P2 using a sterile Active Pharmaceutical Ingredients (API) with an isopropanol recrystallization was manufactured by the same optimized production process as that used in P1."
62369486|NCT04572685|EXPERIMENTAL|INVEGA SUSTENNA|INVEGA SUSTENNA 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study
62369487|NCT04539262|EXPERIMENTAL|Remdesivir (RDV), Part A|Participants will receive inhaled RDV 31 mg administered daily for 5 days.
62369488|NCT04539262|EXPERIMENTAL|RDV + Placebo, Part A|Participants will receive inhaled RDV 31 mg administered daily for 3 days followed by placebo to match RDV daily for 2 days.
62369489|NCT04539262|PLACEBO_COMPARATOR|Placebo, Part A|Participants will receive placebo to match inhaled RDV in Part A daily for 5 days.
62369490|NCT04539262|EXPERIMENTAL|RDV, Part B|Participants will receive inhaled RDV 62 mg administered daily for up to 5 days.
62369491|NCT04539262|EXPERIMENTAL|RDV + Placebo, Part B|Participants will receive inhaled RDV 62 mg administered daily for up to 3 days followed by placebo to match RDV daily for 2 days.
62369492|NCT04539262|PLACEBO_COMPARATOR|Placebo, Part B|Participants will receive placebo to match inhaled RDV in Part B daily for 5 days.
62743393|NCT02050347|EXPERIMENTAL|Subgroup A2|Patients with residual or relapsed B-cell ALL and with an unrelated or HLA-mismatched donor will receive CD19.CAR-CD28Z T Cells - dose escalation 2
62743394|NCT02050347|EXPERIMENTAL|Subgroup B2|Patients with other B cell malignancies and with an unrelated or HLA-mismatched donor will receive CD19.CAR-CD28Z T Cells - dose escalation 2
62743395|NCT04676087|EXPERIMENTAL|Treatment (mogamulizumab, ECP)|"INDUCTION (WEEKS 1-7): Patients receive mogamulizumab IV over 60 minutes on days 1, 8, 15, 22, and 36 in the absence of disease progression progression and unacceptable toxicity. Patients also undergo extracorporeal photopheresis on days 1, 8, 15, 22, 29, and 36 in the absence of disease progression and unacceptable toxicity.~TREATMENT (CYCLES 1-12): Patients receive mogamulizumab IV over 60 minutes on days 1 and 15, and undergo extracorporeal photopheresis on days 1 and 15 of cycles 1-6, then day 1 of subsequent cycles. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression and unacceptable toxicity.~MAINTENANCE (CYCLES 13+): Patients with clinical benefit may continue extracorporeal photopheresis on day 1. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity."
62743396|NCT06661720|ACTIVE_COMPARATOR|Arm 1 (Pembrolizumab)|Patients receive pembrolizumab IV on days 1 and 43 of each cycle, or on days 1, 22, 43 and 64 of each cycle. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI or CT throughout the trial and may undergo tissue biopsy on study.
62743397|NCT06661720|EXPERIMENTAL|Arm 2 (pembrolizumab + tivozanib)|Patients receive pembrolizumab IV on days 1 and 43 of each cycle and tivozanib PO QD on days 1-21, days 29-49, and days 57-77 of each cycle for up to 6 months. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI or CT throughout the trial and may undergo tissue biopsy on study.
62743398|NCT00614445|EXPERIMENTAL|Diclectin®|Diclectin® (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) delayed release tablet
62369493|NCT04539262|EXPERIMENTAL|RDV, Part C|Participants will receive inhaled RDV 39 mg administered daily for 5 days.
62369494|NCT04539262|PLACEBO_COMPARATOR|Placebo, Part C|Participants will receive placebo to match inhaled RDV in Part C daily for 5 days.
62369495|NCT01641081|EXPERIMENTAL|Experimental 1|Formoterol Fumarate in the Pressair Pressair Dry Powder Inhaler (DPI), Low Dose
62369496|NCT01641081|EXPERIMENTAL|Experimental 2|Formoterol fumarate in the Pressair Dry Powder Inhaler (DPI), High Dose
62369497|NCT01641081|ACTIVE_COMPARATOR|Active Comparator 1|Foradil Aerolizer, Low Dose
62369498|NCT01641081|ACTIVE_COMPARATOR|Active Comparator 2|Foradil Aerolizer, High Dose
62369499|NCT01641081|PLACEBO_COMPARATOR|Placebo|Dose matched placebo
62369500|NCT00058188|EXPERIMENTAL|Arm I|Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in the absence of toxicity.
62743399|NCT00614445|PLACEBO_COMPARATOR|Placebo|Placebo tablets identical in size, shape, taste, and color to the experimental treatment (Diclectin®)
62743400|NCT06658769|ACTIVE_COMPARATOR|Pre-surgical intervention group (PREG)|Participants in the Pre-surgical intervention group (PREG) will undergo active rTMS 15 days before surgery. The protocol will be intermittent theta-burst (iTBS), with 3 pulses applied at 50Hz and modulated at 5Hz for 2s, repeated every 10s for a total of 120s, totaling 300 pulses, with intensity at 80% of the MRL. The stimulated targets will be the left and right posterior parietal cortex (P3 and P4) and the left and right dorsolateral prefrontal cortex (F3 and F4), totaling 1200 pulses per day
62743401|NCT06658769|SHAM_COMPARATOR|Pre-surgical Control Group (PRECG)|Participants in the Pre-surgical Control Group (PRECG) will undergo simulated rTMS with a 90º coil tilt with the lower part facing the scalp 15 days before surgery. The protocol will be intermittent theta-burst (iTBS), with 3 pulses applied at 50Hz and modulated at 5Hz for 2s, repeated every 10s for a total of 120s, totaling 300 pulses, with intensity at 80% of the MRL. The stimulated targets will be the left and right posterior parietal cortex (P3 and P4) and left and right dorsolateral prefrontal cortex (F3 and F4), totaling 1200 pulses per day.
62743402|NCT06658769|ACTIVE_COMPARATOR|Non-surgical Control Intervention Group (COG)|Participants in the Non-Surgical Control Intervention Group (COG) will undergo active rTMS. The protocol will be intermittent theta-burst (iTBS), with 3 pulses applied at 50Hz and modulated at 5Hz for 2s, repeated every 10s for a total of 120s, totaling 300 pulses, with intensity at 80% of the MRL. The stimulated targets will be the left and right posterior parietal cortex (P3 and P4) and the left and right dorsolateral prefrontal cortex (F3 and F4), totaling 1200 pulses per day
62743403|NCT02414607|EXPERIMENTAL|Elderberry Juice|Participants will drink 5ml of elderberry juice, diluted in 8oz of water, 3 times per day for three months.
62369501|NCT00058188|ACTIVE_COMPARATOR|Arm II|Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.
62369502|NCT05345938|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection|"Stage 1: Subjects with R/R AML will receive one of three dose-escalation (30 mg/m\^2, 36 mg/m\^2, 40 mg/m\^2) Mitoxantrone Hydrochloride Liposome, IV, on day 1 of each 28-day cycle (q4w).~Stage 2: Subjects with R/R AML or unfit AML will receive one dose Mitoxantrone Hydrochloride Liposome every 28 days (a cycle) for a maximum of 6 cycles."
62369503|NCT01184339||Standard of Care|Current practice methods for the determination of bacteremia, specific to site practice.
62369504|NCT01184339||Gold Standard ID/AST|"Identification of S. aureus: coagulase positive, catalase positive, Staphaurex positive, and PYR negative, if performed).~Determination of MRSA:S. aureus gold standard and \</=11mm OXA DD or \</=21mm CFX DD.~Determination of MSSA: S. aureus gold standard and \>/=13mm OXA DD or \>/=22mm CFX DD."
62369505|NCT05384795||General anesthesia|
62369506|NCT05384795||Spinal anesthesia|
62369507|NCT05384795||Peripheral nerve block|
62369508|NCT05210413|EXPERIMENTAL|Pediatric cohort|Multicentre, open-label, non-randomized, phase I clinical study, with dose-finding and expansion phases.
62369509|NCT05210413|EXPERIMENTAL|Adult cohort|Multicenter phase II single-arm open-label clinical trial, with a pre-screening phase to identify patients with mature tertiary lymphoid structure (TLS).
62743404|NCT02414607|PLACEBO_COMPARATOR|Placebo|Participants will drink 5ml of colored water, diluted in 8oz of water, 3 times per day for three months.
62743405|NCT04781855|EXPERIMENTAL|Part A (ipilimumab, ibrutinib)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 1 of cycle 1, patients also receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity. Patients who complete 4 doses of ipilimumab and are deriving benefit from it, without severe toxicities, may continue to receive ipilimumab every 12 weeks for up to a total of 2 years.
62743406|NCT04781855|EXPERIMENTAL|Part B (ipilimumab, nivolumab, ibrutinib)|Patients receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 7 of cycle 1, patients also receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity. Patients who complete 4 doses of ipilimumab and nivolumab, and are deriving benefit from it, without severe toxicities, may continue to receive ipilimumab every 12 weeks and nivolumab every 4 weeks for up to a total of 2 years.
62743407|NCT02390440|EXPERIMENTAL|EXPAREL|single dose, 266mg (20mL) of EXPAREL injected to slowly infiltrate the soft tissue around the site of fracture
62743408|NCT05149651|EXPERIMENTAL|Totalfill|Totalfill® Bioceramic Root Repair Material -Fast Set Putty used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy
62743409|NCT05149651|ACTIVE_COMPARATOR|MTA|ProRoot White MTA® used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy
62743410|NCT04858815|EXPERIMENTAL|Administration of yogic breathing program|This will be a single arm longitudinal trial designed to evaluate the feasibility and estimate the efficacy of implementing a self-administered yogic breathing program for stress reduction among anesthesiology practitioners at one academic medical center.
62743411|NCT01296711|EXPERIMENTAL|CDP6038 (olokizumab)|
62369510|NCT00633360|EXPERIMENTAL|Drospirenone and ethinyl estradiol|
62369511|NCT00633360|PLACEBO_COMPARATOR|Placebo|
62369512|NCT05076994|EXPERIMENTAL|Patient Education Tool|
62369513|NCT05076994|ACTIVE_COMPARATOR|Standard Care|
62369514|NCT03928444|EXPERIMENTAL|stem cells|one side of the face to be treated with intradermal stem cells
62369515|NCT03928444|PLACEBO_COMPARATOR|control|one side of face treated with intradermal saline
62369516|NCT06392178|EXPERIMENTAL|SugarVita|Participants in the intervention group will download and play the app SugarVita on their mobile phone or tablet, or they can borrow a tablet from the research group. All participants are requested to fill in questionnaires concerning diabetes related topics at the start of the study, and after 8 weeks
62369517|NCT06392178|NO_INTERVENTION|Standard care|Participants in the control group will receive standard care, the usual care that is being given at the outpatient clinic. All participants are requested to fill in questionnaires concerning diabetes related topics at the start of the study, and after 8 weeks
62369518|NCT06437548|EXPERIMENTAL|Percutaneous spinal cord stimulation|"All participants will undergo baseline muscle strength and force assessments. Participants will also answer questionnaires on pain and quality of life. An optional nerve health assessment with needle electromyography and neuroimaging may be performed.~Participants will undergo clinically indicated percutaneous (temporal) cervical epidural leads placement.~Weeks 0-4 post-leads placement: during weekly visits upper extremity muscle strength and force will be assessed, pain and quality of life questionnaires will be completed (1 research visit per week)~At approximately 28 days temporary leads will be removed.~At the last visit, muscle strength and force in upper extremity muscle groups will be assessed, participants will complete pain and quality of life questionnaires. Participants may choose to undergo an optional nerve health assessment with needle electromyography and neuroimaging."
62743412|NCT04876066|EXPERIMENTAL|Ketamine dose|The recommended ketamine dose of 0.5 mg/kg will be administered using a transmucosal route of administration wherein the subject will be instructed to place the liquid solution beneath their tongue and hold it in their mouth for 5 minutes. The pharmacy will prepare two 0.5 mg/kg solutions of ketamine in two syringes for each subject based on subject weight. For example, a 70 kg adult subject will receive a 0.35 mL solution of ketamine. The patient will receive a dose every 7 days for two weeks, for a total of two doses.
62743413|NCT02600416|OTHER|AV port reversal|Patients undergoing citrate CVVH.
62743414|NCT02526563||Iliac crest wound catheter group|These patients will receive an iliac crest wound catheter after an iliac crest bone harvest to repair a palatal defect. This catheter is part of standard of care. This study will collect blood to measure unbound ropivicaine levels.
62369519|NCT03174769|ACTIVE_COMPARATOR|Normal Protein with weight loss|"weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age~Meal Pattern USDA Healthy U.S.-Style Eating Pattern with \~5 oz eq of protein foods for 12 wk"
62369520|NCT03174769|EXPERIMENTAL|High protein and weight loss|"weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age~Meal Pattern USDA Healthy U.S.-Style Eating Pattern with \~12.5 oz eq of protein foods for 12 wk"
62369521|NCT01900405||Dexmedetomidine|All children undergoing
62369522|NCT01655940||Cardiac bypass patients|
62369523|NCT03003130|EXPERIMENTAL|Restylane Defyne|Single injection and optional touch up injection with Restylane Defyne in NLF
62369524|NCT03003130|ACTIVE_COMPARATOR|Restylane|Single injection and optional touch up injection with Restylane in NLF
62369525|NCT06037512|EXPERIMENTAL|Subject glucometer measurement|Blood glucose measurement BGM for personal use
62369526|NCT06417008|EXPERIMENTAL|Phase Ib: HS-20117 and Aumolertinib|Participants will receive IV infusion of HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days) at exploratory doses. Aumolertinib will be administered 110 mg orally once daily.
62369527|NCT06417008|EXPERIMENTAL|Phase III: HS-20117 and Aumolertinib|Participants will receive IV infusion of HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days) at exploratory doses. Aumolertinib will be administered 110 mg orally once daily.
62743415|NCT02305017|EXPERIMENTAL|Period 1 OPC + Paracetamol; Period 2 OPC|Period 1 BIA 9-1067 (Opicapone, OPC) + Paracetamol; Period 2 BIA 9-1067 (Opicapone, OPC)
62743416|NCT02305017|EXPERIMENTAL|Period 1 OPC; Period 2 OPC+ Paracetamol|Period 1 BIA 9-1067 (Opicapone, OPC) Period 2 BIA 9-1067 (Opicapone, OPC) + Paracetamol;
62369528|NCT06417008|ACTIVE_COMPARATOR|Phase III: Aumolertinib|Participants will receive Aumolertinib 110 mg orally once daily.
62369529|NCT01126294|EXPERIMENTAL|Melatonin 5 mg|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
62369530|NCT01126294|EXPERIMENTAL|Melatonin 10 mg|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
62369531|NCT01126294|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
62369532|NCT05841641|EXPERIMENTAL|Laser Bandage|Graft site charred with Diode Laser at 5 Watts to created charred layer
62369533|NCT05841641|EXPERIMENTAL|Hemostatic agent with surgical stent|Graft donor site secured with hemostatic agent with surgical stent
62369534|NCT03556982|EXPERIMENTAL|CART-123|The relapsed/refractory AML patients will receive allogenic or autologous CD123-Targeted CAR-T cells infusion after FC chemotherapy.
62369535|NCT02910089|OTHER|Shared Decision Making/Brief Negotiated Interviewing|This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
62369536|NCT02910089|NO_INTERVENTION|Control Arm|Seven hundred patients will also be identified by Horizon Analytics as a control group for analyses purposes only; these patients will not be contacted.
62369537|NCT06092086|EXPERIMENTAL|CROWN Criteria (CC) Cohort、Compassionate use (CU) Cohort|
62369538|NCT02201472|EXPERIMENTAL|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
62369539|NCT02940197|EXPERIMENTAL|restricted diet|Mediterrasian diet according to adjusted ideal body weight with 500 calorie restriction
62369540|NCT02940197|EXPERIMENTAL|Non restricted diet|Mediterrasian diet according to adjusted ideal body weight without 500 calorie restriction
62369541|NCT02665468|OTHER|Arm 1: Supported Adoption Intervention (SAI)|Supported adoption intervention
62369542|NCT02665468|ACTIVE_COMPARATOR|Arm 2: General wellness information|General wellness information
62369543|NCT01222897|EXPERIMENTAL|Test|Valacyclovir hydrochloride tablets 1 gm of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
62369544|NCT01222897|ACTIVE_COMPARATOR|Reference|VALTREX® (valacyclovir HCl) caplets 1 gm of GlaxoSmithKline Research Triangle Park, NC 27709
62369545|NCT01368952|ACTIVE_COMPARATOR|Pure Prone Positioning|Sleeping in prone position by pure prone positioning device, which consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
62369546|NCT01368952|NO_INTERVENTION|Baseline|No intervention for sleep position
62369547|NCT05385926|EXPERIMENTAL|RT group|
62369548|NCT05133206|EXPERIMENTAL|Non-Fasting|Oral fluids and food up to the time of the procedure.
62369549|NCT05133206|NO_INTERVENTION|Fasting|Clear fluids up to the time of the procedure and no food for at least 2 hours before the procedure - current practice.
62743417|NCT05416489|ACTIVE_COMPARATOR|Traditional direct laryngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a traditional direct laryngoscopy technique.
62743418|NCT05416489|ACTIVE_COMPARATOR|C-MAC videolaryngoscope technique|Endotracheal tube will be removed before percutaneous tracheostomy using a C-MAC videolaryngoscope technique.
62743419|NCT00823433|EXPERIMENTAL|Oral Penicillin|2 grams of oral penicillin V given within 4 hours of delivery
62743420|NCT04031664|EXPERIMENTAL|Qianjin Capsule of Gynaecology|"On the basis of the antibiotic levofloxacin + metronidazole for 14 days, Gynecological Qianjin Capsule for 28 days.~One of the levofloxacin quinolones has broadspectrum antimicrobial activity and strong antimicrobial activity. Metronidazole is mainly used to treat or prevent systemic or local infections caused by the abovementioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
62743421|NCT04031664|PLACEBO_COMPARATOR|Antibiotics alone group|"Levofloxacin + metronidazole for 14 days, and gynecological Qianjin capsule simulator for 28 days.~One of the levofloxacin quinolones has broadspectrum antimicrobial activity and strong antimicrobial activity. It has strong antimicrobial activity against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and Haemophilus influenzae, Legionella pneumophila, Neisseria gonorrhoeae and other gramnegative bacteria. Bacterial activity. Metronidazole is mainly used to treat or prevent systemic or local infections caused by the abovementioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
62743422|NCT02930382|EXPERIMENTAL|BAROREFLEX|
62369550|NCT04510155|EXPERIMENTAL|Short overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 11 pm and stay overnight fasted afterwards for (9.5h).
62369551|NCT04510155|EXPERIMENTAL|Long overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 4.30 pm and stay overnight fasted afterwards for (16h).
62369552|NCT05439304||Care staff|
62369553|NCT05439304||Residents|
62369554|NCT05439304||Family members|
62369555|NCT00633893|EXPERIMENTAL|1|2.5 mg
62369556|NCT00633893|EXPERIMENTAL|2|5.0 mg
62369557|NCT00633893|ACTIVE_COMPARATOR|3|0 mg
62743423|NCT03629665|ACTIVE_COMPARATOR|rTMS and naming combined with ILAT|Interventions: Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
62743424|NCT03629665|SHAM_COMPARATOR|sham rTMS and naming combined with ILAT|Interventions: sham Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
62743425|NCT00669825|PLACEBO_COMPARATOR|A|Placebo
62743426|NCT00669825|ACTIVE_COMPARATOR|B|ALV003 (Active Study Drug)
62743427|NCT04150146|OTHER|Sequence A (RT)|"\[Sequence A (RT) \& Sequence B (TR)\] to receive the Investigational Product (IP) by the sequence in each period:~• Rebamipide SR 150 mg: At 9 am on 1d (8d), take with 150 mL of water under the fasting condition for ≥10 hours or after a high-fat meal."
62743428|NCT04150146|OTHER|Sequence B (TR)|"\[Sequence A (RT) \& Sequence B (TR)\] to receive the Investigational Product (IP) by the sequence in each period:~• Rebamipide SR 150 mg: At 9 am on 1d (8d), take with 150 mL of water under the fasting condition for ≥10 hours or after a high-fat meal."
62369558|NCT01695460|ACTIVE_COMPARATOR|Vitamin D|"The active treatment consists of vitamin D and is given in tablets of the brand D3 Vitamin ®, supplied by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.~The tablets contain the vitamin D in the form of vitamin D3, also known as cholecalciferol.~D3 Vitamin ® consists of small white tablets, which are easy to swallow.~D3 Vitamin ® contains 25 micrograms vitamin D3 (colecalciferol) per tablet, equivalent to 1000 IU (International Units).~Tablet Excipients: Cellulose, dicalcium phosphate, magnesium stearate, silicon dioxide and talc. Vitamin D3 ® contains no gluten, soy, gelatin or other animal products."
62369559|NCT01695460|PLACEBO_COMPARATOR|Placebo|Placebo tablets to match D3 Vitamin ®, were produced. They are identical to the D3 Vitamin ® in appearance, ie small white tablets. These tablets do not have a therapeutic effect. Placebo tablets produced and delivered by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.
62369560|NCT00351390|PLACEBO_COMPARATOR|SOC|Standard of care HF therapy without NT-proBNP guidance
62369561|NCT00351390|ACTIVE_COMPARATOR|NT-proBNP arm|NT-proBNP plus standard HF management
62369562|NCT04836091|EXPERIMENTAL|Immediate intervention|From baseline to 2-month post-test, participants in the intervention arm will have access to the OurPlan program app.
62369563|NCT04836091|EXPERIMENTAL|Waitlist-delayed intervention|Participants in this study arm will not have access to the OurPlan program in the app from baseline to day 30 (month 1) of the trial. From day 31 to day 60, participants in this study arm will be given access to the OurPlan program in the app.
62369564|NCT02047968|EXPERIMENTAL|wake therapy, light therapy and sleep time stabilisation|Wake therapy/sleep deprivation: Patients are awake for 36 hours three times in one week with a normal night of sleep between. Light therapy for 30 minutes daily in the entire study period. Sleep time stabilisation which involves psychoeducation regarding sleep hygiene and keeping the day-night cycle constant.
62369565|NCT02047968|NO_INTERVENTION|treatment as usual|
62369566|NCT05153863|EXPERIMENTAL|Single Arm C-Scope Visualization System|The C Scope Visualization System is indicated to be used by a trained physician to provide illumination and visualization in arthroscopic procedures of an interior cavity of the body through a surgical opening.
62369567|NCT05944445||Single arm group|Adult critically ill patients admitted to ICU for different indications
62743429|NCT06323941|EXPERIMENTAL|Motor Imagery plus Isometric Exercise|This group will perform a therapeutic exercise programme (isometric exercises training) to which motor imagery training will be added.
62743430|NCT06323941|ACTIVE_COMPARATOR|Isometric Exercise|This group will perform a therapeutic exercise programme (isometric exercises training) to which sham motor imagery training will be added.
62369568|NCT04381533|EXPERIMENTAL|I-A-CRA|Internet-delivered Adolescent Community Reinforcement Approach: The treatment program consists of 8 extensive treatment modules delivered over 10 weeks with continuous therapist support and guidance. There are two separate treatments for the young adult and the caregiver/significant other.
62369569|NCT04381533|ACTIVE_COMPARATOR|Psychoeducation alcohol use|Psychoeducation focusing on alcohol use: This support program provides 8 brief modules of psychoeducation (alcohol information) over 10 weeks. Participants receive no therapist guidance/support but have the possibility of asking questions to a therapist. There are two separate programs for the young adult and the caregiver/significant other.
62369570|NCT03912324|EXPERIMENTAL|Unipolar voltage subtraction map guided PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury~3. Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture~4. the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes)~5. Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map~6. Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map~7. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~8. Evaluate time to complete isolation after additional ablation~9. Evaluation of Procedure and Ablation time, and perfusion saline dose~10. Rhythm follow-up after the procedure in accordance with the study design."
62743431|NCT02604368|EXPERIMENTAL|SC411|Omega-3 docosahexaenoic acid, soft gelatin capsule, administered once a day on a per weight basis.
62369571|NCT03912324|EXPERIMENTAL|CT myocardial thickness map guided PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. Prepared myocardial thickness map with CT DICOM images conducted prior to procedure.~4. Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map~5. Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map~6. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~7. Evaluate time to complete isolation after additional ablation~8. Evaluation of Procedure time, Ablation time, and perfusion saline dose~9. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
62369572|NCT03912324|ACTIVE_COMPARATOR|Empirical PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner.~4. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~5. Evaluate time to complete isolation after additional ablation~6. Evaluation of Procedure time, Ablation time, and perfusion saline dose~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
62369573|NCT02112461|EXPERIMENTAL|Intervention Group|SCP-Hospice Alert
62369574|NCT02112461|NO_INTERVENTION|Usual Care|Caregiver calls into monitoring system to report the patient's end of life symptoms but does not receive feedback about the symptoms and the hospice nurse does not receive the information.
62369575|NCT03224156||Dilated Cardiomyopathy|
62369576|NCT02628704|EXPERIMENTAL|Selinexor, carfilzomib and dexamethasone|60 mg of selinexor and and 20 mg of dexamethasone will be taken twice weekly. On days coinciding with carfilzomib administration, selinexor will be given between 30 minutes and 4 hours after the end of the carfilzomib infusion.
62369577|NCT02628704|PLACEBO_COMPARATOR|Placebo, carfilzomib and dexamethasone|Placebo (for 60 mg of selinexor) and and 20 mg of dexamethasone will be taken twice weekly. On days coinciding with carfilzomib administration, Placebo (for 60 mg of selinexor) will be given between 30 minutes and 4 hours after the end of the carfilzomib infusion.
62369578|NCT05179057|EXPERIMENTAL|Posoleucel + SoC|Posoleucel + SOC; then placebo + SOC for patients who meet optional protocol-defined crossover criteria
62369579|NCT05179057|PLACEBO_COMPARATOR|Placebo + SoC|Placebo + SOC; then Posoleucel + SOC for patients who meet optional protocol-defined crossover criteria
62369580|NCT02866318||Novice practitioners|Residents in Emergency department who has no experiences of echocardiography prior to the study.
62369581|NCT04951180||Group 1|Femoral acetabular impingement syndrome (FAIS) patients with gluteus medius lesions
62369582|NCT03962634|EXPERIMENTAL|Kovanaze Nasal Spray (Pediatrics)|Children \>20 kg who require pulpotomy, restorative procedures, SS crowns in one maxillary tooth
62369583|NCT03962634|ACTIVE_COMPARATOR|Articaine Injections (Pediatrics)|Children \>20 kg who require pulpotomy, restorative procedures, or stainless steel crowns in one maxillary tooth
62369584|NCT03408288||Nurses|
62369585|NCT03408288||Urologists|
62369586|NCT03966664||Septic patients|Critically ill patients of both sexes admitted to the general ICU of the participating centers with the diagnosis of sepsis will be included.
62369587|NCT03966664||Healthy controls|Age and sex matched healthy volunteers.
62369588|NCT03966664||Non septic patients|Non-septic patients admitted to the general ICU of the participating centers after elective non-cardiac surgery.
62743432|NCT02604368|PLACEBO_COMPARATOR|Placebo|Soybean oil, soft gelatin capsule, administered once a day on a per weight basis.
62369589|NCT03696849|ACTIVE_COMPARATOR|glazed emax Press|
62369590|NCT03696849|EXPERIMENTAL|Polished emax Press|
62369591|NCT04151446|EXPERIMENTAL|Laser Scleral Microporation procedure|Patients suffering from presbyopia will receive bilateral Laser Scleral Microporation procedure.
62743433|NCT02265536|EXPERIMENTAL|LY3022855 1.25 mg/kg Q2W|1.25 milligram per kilogram (mg/kg) LY3022855 administered intravenously (IV), once every two weeks (Q2W). Treatment is 6 week cycle. Participants may receive multiple cycles if they are deriving clinical benefit.
62743434|NCT02265536|EXPERIMENTAL|LY3022855 1.0 mg/kg WK1_2_4_5|1.0 mg/kg LY3022855 administered IV on Weeks 1, 2, 4, and 5 of a 6-week cycle. Participants may receive multiple cycles if they are deriving clinical benefit.
62743435|NCT02265536|EXPERIMENTAL|LY3022855 100 mg Q2W|100 mg of LY3022855 administered IV once every two weeks of a 6-week cycle. Participants may receive multiple cycles if they are deriving clinical benefit.
62743436|NCT02265536|EXPERIMENTAL|LY3022855 100 mg QW|100 mg of LY3022855 administered IV. once a week (QW) of a 6-week cycle. Participants may receive multiple cycles if they are deriving clinical benefit.
62369592|NCT04954391|ACTIVE_COMPARATOR|PRF one nerve|Ultrasound guided PRF neuromodulation of suprascapular nerve and block axillary nerve, and articular branch of the lateral pectoral nerve with ropivacaine and dexamethasone
62743437|NCT05699551|EXPERIMENTAL|Exercise treatment group|This group will serve as both their own controls and study subjects for the experimental intervention. They will take surveys to record bladder symptoms and quality of life before undergoing exercise. They will then take the same surveys after exercise and their scores will be compared.
62369593|NCT04954391|ACTIVE_COMPARATOR|PRF three nerves|Ultrasound guided PRF neuromodulation of suprascapular, axillary nerves, and articular branch of the lateral pectoral nerve
62369594|NCT03011775|EXPERIMENTAL|Pioglitazone + Standard Care|20 patients who received standard medical therapy complex: isosorbide dinitrate 10-20 mg 2 times a day, acetylsalicylic acid 75 mg 1 time a day, bisoprolol 2.5 mg 1 time a day, rosuvastatin 20 mg 1 time a day, ramipril 5 mg 1 time a day. Patients also received recommendations on diet and lifestyle changes. Included pioglitazone 15 mg 1 time per day in the morning for 6 months.
62369595|NCT03011775|OTHER|Standard Care|23 patients who received standard medical therapy complex: isosorbide dinitrate 10-20 mg 2 times a day, acetylsalicylic acid 75 mg 1 time a day, bisoprolol 2.5 mg 1 time a day, rosuvastatin 20 mg 1 time a day, ramipril 5 mg 1 time a day. Patients also received recommendations on diet and lifestyle changes.
62369596|NCT03782844|EXPERIMENTAL|Conventional fixed CPAP and simple CPAP|Participants in this group were manually titrated . They were treated with conventional fixed pressure CPAP and Simple CPAP for two separate nights in random order monitored by full polysomnography.
62743438|NCT02234713|EXPERIMENTAL|Behavioural Intervention/Feedback|The behavioral interventionist will contact the patient and parent by email and telephone to schedule a telephone call to review the downloaded adherence information and discuss barriers experienced by the patient/parent using a standard script. The behavioral feedback will be administered three times: at 1-, 2- and 3-months post-baseline.
62743439|NCT02234713|ACTIVE_COMPARATOR|Video Attention Control|The patients in this arm of the study will be emailed a link to an educational video about Pediatric MS and therapy for MS at three time points: 1-, 2-, and 3-months post-baseline.
62743440|NCT06260631|EXPERIMENTAL|high-intensity laser acupuncture and an exercise therapy program.|The patients will receive high-intensity laser acupuncture and an exercise therapy program.three times a week for four weeks.
62743441|NCT06260631|SHAM_COMPARATOR|sham laser acupuncture and an exercise therapy program.|The patients will receive a sham acupuncture laser and an exercise therapy program three times a week for four weeks.
62743442|NCT05301257|EXPERIMENTAL|Experimental Group SOSteniamoci|Trans-diagnostic, 8 module, 8 week long internet intervention for reducing informal caregiver burden
62743443|NCT05301257|NO_INTERVENTION|Control Group SOSteniamoci|Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention
62743444|NCT05586503|EXPERIMENTAL|ECG-gated CTA|For study's purposes, patients will undergo ECG-gated CTA scans instead of CTA scans at pre-operative planning, prior to discharge, 30 days, 6 months, 12 months in order to assess the stent stability and durability as well as the seal of the stent graft during the cardiac cycle and over time. An additional ECG-gated CTA scan may optionally be performed at 24 months if the device fixation and conformability continue up to the 12 months scan.
62743445|NCT06520462|EXPERIMENTAL|Pharmacopuncture group|"1. Acupoints: The selection of acupoints, depth of insertion, and other procedural details are determined based on the clinical judgment of the physicians according to the participant's symptoms, diagnostic imaging, and degree of improvement. Acupoints may include GB20, GB21, BL11, and EX-B2. However, these acupoints are not restrictive; any acupoints used for the treatment of chronic neck pain will be documented.~2. Pharmacopuncture: The type and dosage of the pharmacopuncture solution used during treatment will be selected based on the clinical judgment of the physicians performing the pharmacopuncture. The types of pharmacopuncture solutions and the total amount administered will be recorded. The choice will be based on the participant's symptoms and the clinical judgment within the range of pharmacopuncture solutions currently used in clinical practice at the trial institution, without adding new solutions specifically for this study."
62743446|NCT06520462|ACTIVE_COMPARATOR|Acupuncture group|The selection of acupoints, depth of insertion, and other procedural details are to be determined based on the clinical judgment of the physicians according to the participant's symptoms, diagnostic imaging, and degree of improvement. Acupoints may include sites such as GB21, SI9, GB20, GV14, and distal points like SI3. The number of needles used can range from 5 to 30. All acupoints treated during the procedure are to be documented.
62743447|NCT04880746|ACTIVE_COMPARATOR|BEAC|Patients in this arm will receive BEAC (Semustine, Etoposide, Cytarabine, Cyclophosphamide) as pretreatment regimen of ASCT
62743448|NCT04880746|EXPERIMENTAL|Cladribine combined with BEAC|Patients in this arm will receive Cladribine combined with BEAC (Semustine, Etoposide, Cytarabine, Cyclophosphamide) as pretreatment regimen of ASCT
62743449|NCT00670618|EXPERIMENTAL|1|CPP-ACP (GC Tooth Mousse)
62369597|NCT03782844|EXPERIMENTAL|Auto CPAP and simple CPAP|Participants in this group after being manually titrated were treated with Auto RemStar CPAP and Simple CPAP for two separate nights in random order monitored by full polysomnography.
62369598|NCT03216980|EXPERIMENTAL|PTSD/GAD Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
62743450|NCT00670618|EXPERIMENTAL|2|GCC-ACP (GC MI Paste Plus)
62743451|NCT00670618|EXPERIMENTAL|3|Fluoride (Elmex Medical Gel)
62743452|NCT00670618|NO_INTERVENTION|4|Control group
62743453|NCT06501547|EXPERIMENTAL|lifestyle counseling|patient will be asked about the mean of sun exposure per week
62743454|NCT06501547|EXPERIMENTAL|Clinical examination|patients's face were assessed by the doctor by using Glogau scale and the doctor will perform dermoscopic tes to assess dermoscopic photoaging scale (DPAS) score to obtain the score of skin aging
62369599|NCT03216980|PLACEBO_COMPARATOR|PTSD/GAD Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
62369600|NCT03216980|EXPERIMENTAL|Healthy Control Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
62369601|NCT03216980|PLACEBO_COMPARATOR|Healthy Control Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
62369602|NCT04616794|EXPERIMENTAL|Cognitive Engagement Group|Participants eligible to enter this group must show low cognitive engagement in cognitively stimulating activities, defined as a score \< 22 on the Cognitive Activity Questionnaire (CAQ)
62369603|NCT04616794|EXPERIMENTAL|Physical Activity Group|Participants eligible to enter this group must have a low level of physical activity defined as less than 600 MET-min/week (\~150 minutes/week) of moderate to vigorous physical activity (MVPA), measured using the International Physical Activity Questionnaire - short form (IPAQ-SF)
62743455|NCT05594498|EXPERIMENTAL|StrataXRT Arm|This is a single-arm trial where all patients will receive the intervention of StrataXRT.
62743456|NCT04897230|ACTIVE_COMPARATOR|Hatha Yoga Condition|An experienced yoga instructor led the 30 minutes yoga condition session which consisted of 5 minutes warm up, 5 minutes breathing exercises, and 20 minutes yoga poses practice. The yoga props were used according to each participant's particular body type and needs to help he/she achieve precise yoga postures safely and comfortably.
62743457|NCT04897230|PLACEBO_COMPARATOR|Control Condition|Participants in the control condition were watching a neutral video on a television.
62743458|NCT04730635|EXPERIMENTAL|Donepezil|Participants receive donepezil in doses up to 10 mg once daily (QD), orally in a scheduled titration for Days 1-56. The total treatment duration is 56 days.
62743459|NCT04730635|PLACEBO_COMPARATOR|Placebo|Participants receive placebo QD, orally for Days 1-56. The total treatment duration is 56 Days.
62743460|NCT05460052||Immediate treatment (IT)|Patients randomized to the IT group will begin the training sessions 14 days after the inclusion.
62743461|NCT05460052||Waiting list (WL)|"Patients randomized to the WL group will receive a weekly phone call for 6 weeks.~Then, they will benefit the same training program as IT group (56 days after the inclusion)."
62743462|NCT03831295|EXPERIMENTAL|Treatment (SD-101, BMS-986178)|"SAFETY COHORT: Patients receive TLR9 agonist SD-101 IT on days 1, 8 and 15. Patients also receive anti-OX40 antibody BMS 986178 IT on days 8 and 15, and IV over 30 minutes on days 8, 29 and 58.~EXPANSION COHORT: Patients receive TLR9 agonist SD-101 IT on days 1, 8 and 15. Patients also receive anti-OX40 antibody BMS 986178 IT on days 1, 8 and 15, and IV over 30 minutes on days 1, 29 and 58."
62743463|NCT06525077|EXPERIMENTAL|FT218|FT218 at stable dose (selected during earlier titration) administered orally once nightly
61986282|NCT01245270|EXPERIMENTAL|Bilberry capsule first, then control cap|"Volunteers will be given a single capsule of 0.47 grams of mirtoselect (a concentrated bilberry extract) followed by a 14 day washout period then a single control placebo capsule.~First Intervention (1 day), Washout (14 days), Second Intervention (1 day)"
62369604|NCT04616794|EXPERIMENTAL|Diet Group|Participants eligible to enter this group must have a low adherence to the Mediterranean-type diet defined as a score of ≤ 8 on the adapted Canadian Mediterranean Diet Scale (MDS).
62369605|NCT04616794|EXPERIMENTAL|Multi-modal Group|Participants eligible to enter this group must be eligible for at least two of the three single-arm conditions.
62369606|NCT03551106||Web based learning module|Laboratory prescriptions made by postgraduate students who were enrolled to follow the web based modules
62369607|NCT01136460||Primary congenital glaucoma|Primary congenital glaucoma patients and their immediate relatives
62369608|NCT03606655|EXPERIMENTAL|Kava|This is a single-arm pre- and post- Phase 0/1 study with one primary goal to explore the feasibility of recruitment of participants, adherence rate, acceptability of treatment and completion rate with 14 day dietary supplement kava treatment in head and neck cancer patients who continue to smoke. The other primary goal is to evaluate distribution of change in nicotine and NNK metabolism after 14 day kava treatment..
62369609|NCT04594304|EXPERIMENTAL|Personalized eToolkit|The intervention arm will receive a personalized eToolkit with community and electronic supports upon survey completion, and their PCP will receive automatic supports in the EMR to assess and treat the patient's alcohol and/or tobacco use. In cases where a patient does not have risky alcohol and tobacco use, a personalized eToolkit based on their physical activity levels will be administered, and their PCP will receive automatic supports in the EMR to facilitate physical activity discussions. Intervention arm patient participants will be asked to complete a baseline e-survey before their scheduled appointment, a process evaluation e-survey 3 days following their appointment, and a 3 months follow-up e-survey following their appointment. Resources will be automatically produced for the patient and PCP following completion of the baseline e-survey.
62743464|NCT06525077|PLACEBO_COMPARATOR|Placebo|Placebo equivalent administered orally once nightly
62743465|NCT01420692|ACTIVE_COMPARATOR|Gliclazide MR|
62743466|NCT01420692|ACTIVE_COMPARATOR|Insulin Detemir|Early initiation of insulin detemir in contrast to Gliclazide MR treatment
62743467|NCT01731158|OTHER|arm A|"sequential therapy with approved drugs~Avastin in combination with Roferon-A (first-line), Afinitor (second-line) and a TKI (Sutent, Nexavar or Votrient) (third-line)"
62743468|NCT01731158|OTHER|arm B|"sequential therapy with approved drugs~Avastin in combination with Roferon-A (first-line), a TKI (Sutent, Nexavar or Votrient) (second-line) and Afinitor (third-line)"
62743469|NCT06435403||Group 1 (N=300)|SARS-CoV-2 anti-nucleocapsid positive, vaccinated
62743470|NCT06435403||Group 2 (N=300)|SARS-CoV-2 anti-nucleocapsid positive, not vaccinated
62743471|NCT06435403||Group 3 (N=300)|SARS-CoV-2 anti-nucleocapsid negative, vaccinated
62743472|NCT06435403||Group 4 (N=100)|SARS-CoV-2 anti-nucleocapsid negative, not vaccinated
62743473|NCT05033886|EXPERIMENTAL|fezolinetant|Participants receive fezolinetant 45 milligrams (mg) (one 30 mg tablet and one 15 mg tablet) orally once daily for 24 weeks of treatment.
62743474|NCT05033886|PLACEBO_COMPARATOR|placebo|Participants receive placebo matched to fezolinetant tablets orally once daily for 24 weeks of treatment.
62743475|NCT00040781|EXPERIMENTAL|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
62743476|NCT05790798|EXPERIMENTAL|intervention group|The universe of this research, which has a randomized controlled design, is all people with disabilities aged 18 and older who are attended at the Etimesgut Family and Life Center in Ankara. The inclusion criteria of this study were to be 18 years of age or older, to have a score of 17 and below according to the Lawton-Brody Instrumental Activity of Daily Living Scale, to have a score of 24 and above in the Modified Mini-Mental test. In addition, there are some exclusion criteria for research. Exclusion criteria from the study were: Having a communication problem that prevented the participant from completing the assessment and the kits; not participating regularly in the intervention program. For this study, people who attended the Family and Life Center and people with disabilities who regularly come to this center for various reasons were contacted. People (n=35) who met the criteria of the study were informed about the study and invited to participate in this study.
62743477|NCT05790798|ACTIVE_COMPARATOR|Control Group|The universe of this research, which has a randomized controlled design, is all people with disabilities aged 18 and older who are attended at the Etimesgut Family and Life Center in Ankara. The inclusion criteria of this study were to be 18 years of age or older, to have a score of 17 and below according to the Lawton-Brody Instrumental Activity of Daily Living Scale, to have a score of 24 and above in the Modified Mini-Mental test. In addition, there are some exclusion criteria for research. Exclusion criteria from the study were: Having a communication problem that prevented the participant from completing the assessment and the kits; not participating regularly in the intervention program. For this study, people who attended the Family and Life Center and people with disabilities who regularly come to this center for various reasons were contacted. People (n=35) who met the criteria of the study were informed about the study and invited to participate in this study.
62743478|NCT00707603||Hepatitis C subjects|Due to start therapy for Hepatitis C
62743479|NCT00707603||Controls|Healthy males
62743480|NCT02895672||Weekly GLP-1 therapy: exenatide|Patients receiving weekly exenatide
62743481|NCT02895672||Daily GLP-1 therapy liraglutide|Patients receiving daily liraglutide
62743482|NCT04826107|EXPERIMENTAL|Part 1: Dose-finding stage|Patients with HER2-positive advanced or metastatic gastric cancer after receiving 1st-line treatment will be treated with DP303c injection at 2.0 mg/kg，2.5 mg/kg or 3.0 mg/kg every 3 weeks to determine the recommended dose.
62743483|NCT04826107|EXPERIMENTAL|Part 2: Cohort A|Patients with HER2-positive advanced or metastatic gastric cancer after receiving 1st-line treatment will be treated with DP303c injection at the recommended dose.
62743484|NCT04826107|EXPERIMENTAL|Part 2: Cohort B|Patients with HER2-positive advanced or metastatic gastric cancer after receiving ≥ 2nd-line treatment will be treated with DP303c injection at the recommended dose.
62743485|NCT04826107|EXPERIMENTAL|Part 2: Cohort C|Patients with advanced or metastatic gastric cancer with HER2 low expression after receiving ≥1st-line treatment will be treated with DP303c injection at the recommended dose.
62743486|NCT04826107|EXPERIMENTAL|Part 2: Cohort D|Patients with advanced or metastatic gastric cancer with HER2 low expression or HER2-positive expression after receiving ≥1st-line treatment will be treated with DP303c injection combined with PD-1/PD-L1 treatment.
62743487|NCT02520869|ACTIVE_COMPARATOR|swim-up|swim-up technique for semen processing
62743488|NCT02520869|ACTIVE_COMPARATOR|zeta test|zeta test technique for semen processing
62743489|NCT03523416|EXPERIMENTAL|Edwards Transcatheter Atrial Shunt System|
62743490|NCT04875377|EXPERIMENTAL|Reformulated pizza|Participants must consume a nutritionally balanced pizza reformulated with seaweed (Ascophyllum nodosum) as an ingredient 3 times a week for 24 weeks
62743491|NCT04875377|PLACEBO_COMPARATOR|Control pizza|Participants must consume a nutritionally balanced pizza without seaweed, 3 times a week for 24 weeks
62743492|NCT04875377|EXPERIMENTAL|Seaweed capsule|Participants must consume a capsule containing powdered Ascophyllum nodosum 3 times a week for 24 weeks
62743493|NCT04875377|PLACEBO_COMPARATOR|Control capsule|Participants must consume an empty capsule 3 times a week for 24 weeks
62743494|NCT03081819|EXPERIMENTAL|SH003|Participant will take SH003 for 3 weeks.
62743495|NCT05126992||AZD1222|at least one dose of AZD1222
62743496|NCT05126992||comparator 1|concurrent unvaccinated
62743497|NCT05126992||comparator 2|historical controls
62743498|NCT05126992||comparator 3|"active comparators\*~\*Feasibility of the active comparator analysis will be assessed prior to conducting the analysis to ensure comparability between groups"
62743499|NCT05045482|EXPERIMENTAL|Saroglitazar Magnesium 1 mg|"The study drug will be administered from Day 1 to Day 28 once daily in the morning before breakfast without food.~Study drug -Saroglitazar Magnesium tablets; Dosage form- Tablets (immediate release); Dose- 1 mg/day; Frequency- One tablet per day (in the morning before breakfast without food); Duration of treatment- 28 consecutive days"
62743500|NCT05045482|EXPERIMENTAL|Saroglitazar Magnesium 2 mg|"The study drug will be administered from Day 1 to Day 28 once daily in the morning before breakfast without food.~Study drug -Saroglitazar Magnesium tablets: Dosage form- Tablets (immediate release); Dose- 2 mg/day; Frequency- One tablet per day (in the morning before breakfast without food); Duration- 28 consecutive days"
62743501|NCT06625606|ACTIVE_COMPARATOR|Single-shot spinal anesthesia (SSSA)|The patient's back was prepared for surgery. They were positioned on their side, with the operative side facing upward. A thin spinal needle was inserted into the L3-4 spinal interspace, after numbing the area. Once cerebrospinal fluid was confirmed, a small dose of isobaric bupivacaine was injected into the spinal canal.
62743502|NCT06625606|ACTIVE_COMPARATOR|Continuous spinal anesthesia (CSA)|A thicker needle was inserted into the L3-4 spinal interspace. After confirming cerebrospinal fluid, a thin catheter was inserted into the spinal canal and secured. An initial dose of isobaric bupivacaine was injected, followed by additional doses as needed to maintain the block height.
62743503|NCT06625606|ACTIVE_COMPARATOR|General anesthesia|General anesthesia was initiated with propofol and rocuronium. Anesthesia was maintained with isoflurane, with additional rocuronium and fentanyl as needed. Breathing was controlled by the ventilator, and muscle relaxation was reversed at the end of surgery.
62743504|NCT04933045||Syndesmotic Fixation Group|Cohort of patients treated with anatomic ATFL reconstruction for syndesmotic ankle injury.
62743505|NCT01669252|EXPERIMENTAL|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
62369610|NCT04594304|NO_INTERVENTION|Usual care|The control arm will not receive intervention materials. Control arm patient participants will be asked to complete a baseline e-survey before their scheduled appointment, a process evaluation e-survey 3 days following their appointment, and 3 months follow-up e-survey following their appointment.
62743506|NCT02808546||Case Group|All the patients who were diagnosed as gallbladder stone disease with definite clinical symptoms and underwent cholecystectomy in Cheju Halla General Hospital, Jeju, Korea during 2009-2013
62369611|NCT04545411|ACTIVE_COMPARATOR|Treatment A|Daily, Oral,10mg dapagliflozin in combination with Weekly, Subcutaneous, 35mg in 1mL solution REMD-477
62369612|NCT04545411|PLACEBO_COMPARATOR|Treatment B|Daily, Oral,10mg dapagliflozin in combination with Weekly, Subcutaneous, 1mL solution Placebo
62369613|NCT02714023|ACTIVE_COMPARATOR|Normal Saline|Patients were randomized to receive normal saline as an irrigation solution during appendectomy.
62369614|NCT02714023|ACTIVE_COMPARATOR|Sterile Water|Patients were randomized to receive sterile water as an irrigation solution during appendectomy.
62369615|NCT02714023|NO_INTERVENTION|No irrigation used|Patients who do not receive any irrigation at time of operation.
62369616|NCT00986804|EXPERIMENTAL|Level 1|Decitabine 5.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
62369617|NCT00986804|EXPERIMENTAL|Level 2|Decitabine 7.5 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
62369618|NCT00986804|EXPERIMENTAL|Level 3|Decitabine 10.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
62369619|NCT00986804|EXPERIMENTAL|Level 4|Decitabine 15.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
62369620|NCT03855761|EXPERIMENTAL|Intervention group|Experimental Occupational Therapy services
62369621|NCT03855761|ACTIVE_COMPARATOR|Comparison group|Treatment as usual
62369622|NCT00681291|ACTIVE_COMPARATOR|1|lightweight polypropylene mesh
62369623|NCT00681291|ACTIVE_COMPARATOR|2|Strattice
62369624|NCT05110404|ACTIVE_COMPARATOR|Group (A): The high-volume HIIT|Exercise group A (n=30): It will include patients that will perform high-volume high-intensity interval training (HIIT), and will receive medical intervention.
62369625|NCT05110404|ACTIVE_COMPARATOR|Group (B): The low-volume HIIT|Exercise group B (n=30): will receive medical intervention. that will perform the low-volume high-intensity interval training, and will receive medical intervention.
62369626|NCT05110404|NO_INTERVENTION|Group C|patients will receive medical intervention only.
62369627|NCT03921606|EXPERIMENTAL|Experimental group|The experimental group will receive a brief MI via WhatsApp/WeChat on a smartphone during the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once every 2 to 3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering the messages via WhatsApp/WeChat will be interactive, depending on the subjects' actions and responses, and may take several sessions of chats within several days or weeks. However, the total time spent by the interventionist will not be more than that for a traditional MI with several long sessions. After 6 months, minimal messages will be provided to the subjects by merely following their progress of behavioural changes and responding to their questions to maintain contact until the 1-year follow-up. The total time spent will be recorded and analysed.
62369628|NCT03921606|OTHER|Control group|The control group will receive individual face-to-face generic health advice (about 5 minutes) on a health-related lifestyle practice such as eating more vegetables and fruits, eating less high salt, fat or sugar foods, consuming less sugary drinks, engaging in more exercise of any kind or intensity, reducing alcohol consumption or reducing weight (if overweight or obese) in SOPCs. A self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs. The subjects in this group will receive the same schedule of follow-ups as in the intervention group, but they will not receive any follow-up booster intervention.
62369629|NCT02244619|ACTIVE_COMPARATOR|Oral acetaminophen|Subjects receive 2 capsules each containing Tylenol 500 mg caplets. The test article administration will be initiated 60 minutes (± 15 minutes) prior to the scheduled surgery start time.
62369630|NCT02244619|ACTIVE_COMPARATOR|IV acetaminophen|Subjects receive Ofirmev 1000 mg in 100 ml Normal Saline IV infusion. The test article will be given perioperatively at the discretion of the attending anesthesiologist.
62369631|NCT02544204|ACTIVE_COMPARATOR|8 mg JVS-100|Biological/Vaccine: JVS-100 Injection Intramuscular Injection
62369632|NCT02544204|PLACEBO_COMPARATOR|8 mg placebo|Biological/Vaccine: Placebo Injection Intramuscular Injection
62369633|NCT02544204|ACTIVE_COMPARATOR|16 mg JVS-100|Biological/Vaccine: JVS-100 Injection Intramuscular Injection
62369634|NCT02544204|PLACEBO_COMPARATOR|16 mg placebo|Biological/Vaccine: Placebo Injection Intramuscular Injection
62369635|NCT05412667|PLACEBO_COMPARATOR|Placebo|Pea protein without TWK10 (20g/day)
62369636|NCT05412667|EXPERIMENTAL|TWK10|Pea protein (20g/day) with TWK10 (10 billion CFU/day)
62369637|NCT05137210|EXPERIMENTAL|Male-specific counseling and facility navigation|
62369638|NCT05137210|EXPERIMENTAL|Home-Based ART Initiation|
62369639|NCT05137210|EXPERIMENTAL|Stepped Intervention|
62369640|NCT02397967|EXPERIMENTAL|Children NF1|Children diagnosed with NF1 according the NIH criteria Neuropsychological assessments
62369641|NCT02397967|PLACEBO_COMPARATOR|Control group|Control group children without NF1 with the same reading level Neuropsychological assessments
62369642|NCT01681290|EXPERIMENTAL|CBX129801 High Dose|Solution for injection, 2.4 mg, weekly for 52 weeks
62369643|NCT01681290|EXPERIMENTAL|CBX129801 Low Dose|Solution for injection, 0.8 mg, weekly for 52 weeks
62369644|NCT01681290|PLACEBO_COMPARATOR|Placebo|Solution for injection, vehicle with no active, weekly for 52 weeks
62369645|NCT02556580|ACTIVE_COMPARATOR|Conscious healthy volunteers|Intervention: intravenious infusion Drug: albumin 20%
62743507|NCT02808546||Control Group|Control group was determined as 1:1 age-sex matched subjects selected from the participants without GBS among Health Promotion Center in the same institute and periods.
62743508|NCT01404403|OTHER|Stroke patients|
62743509|NCT02926027|ACTIVE_COMPARATOR|Active subjects|Vascepa (4 gm/day), oral dose
62743510|NCT02926027|PLACEBO_COMPARATOR|Placebo subject|oral dose of placebo
62743511|NCT01253148|EXPERIMENTAL|Arterial Injection of 90-Y Microspheres|Intrahepatic Arterial Injection of 90-Y Glass Microspheres as First-Line Treatment For Cholangiocarcinoma
62743512|NCT06462365|EXPERIMENTAL|TRX-103|TRX-103 will be infused on time post hematopoietic stem cell transplant (HSCT).
62743513|NCT05712785|EXPERIMENTAL|Shuotong Ureteroscopy group|Shuotong Ureteroscopy: a ureteroscope that can lithotripsy and lithotripsy simultaneously
62743514|NCT05712785|NO_INTERVENTION|Ureteroscopy group|Ureteroscopy group：using conventional ureteroscopy
62743515|NCT05978440|ACTIVE_COMPARATOR|Scanning without rubber dam|After the onlay preparation, standard digital impression will be recorded for the working quadrant using the IOS without applying the rubber dam. Then the opposing quadrant will be scanned in addition to interocclusal bite registration.
62743516|NCT05978440|EXPERIMENTAL|Scanning under rubber dam with cut technique|"In this group a pre-operative scan will be already taken before the preparation for the working arch, opposing arch and the interocclusal bite registration. Then using the Cut feature in the software of the IOS to cut the area of the working tooth. After the preparation, rubber dam will be applied on the working quadrant and then rescan the prepared tooth."
62743517|NCT05978440|EXPERIMENTAL|Scanning under rubber dam with new lock technique|"After the onlay preparation, the rubber dam will be applied to the working quadrant. Digital impression will be taken using the IOS. After that using the lock feature in the software of the scanner, all the preparation area and margins will be locked. Rubber dam will be removed, and scanning will be completed for the whole quadrant and opposing arch in addition to interocclusal bite registration."
62743518|NCT03947281|EXPERIMENTAL|Almond snack|The almond intervention will be roasted almonds 56 grams/day for 28 days. The caloric value is approximately 350 kcals.
62743519|NCT03947281|EXPERIMENTAL|Cereal-based snack|The cereal-based intervention will be a mixture of dry cereal, pretzels, and bread sticks prepared by the Western Human Nutrition Research Center (WHNRC). The caloric value is approximately 350 kcals.
62743520|NCT06416358|EXPERIMENTAL|ALMB-0168|
62743521|NCT06658327|EXPERIMENTAL|Group A|Dynamic stretching
62743522|NCT06658327|EXPERIMENTAL|Group B|Static Stretching
62743523|NCT04104191|EXPERIMENTAL|L-1000AF System|Software device on a wearable device used to detect irregular heart rhythms suggestive of Atrial Fibrillation
62743524|NCT05847660|ACTIVE_COMPARATOR|Progesterone primed ovarian stimulation protocol.|Group (A): Women in progesterone primed (PPOS) will be prescribed a 30 mg oral dose of dydrogesterone (Duphaston, Abbott, Egypt) from the 2nd day of the cycle and continued until the triggering day. Vaginal sonography will be done for all patients since 6th day of the cycle.
62743525|NCT05847660|ACTIVE_COMPARATOR|conventional antagonist protocol.|Group (B): Women in the antagonist group will be monitored by transvaginal ultrasonography till the size of dominant follicles reached to 12-13 mm, 0.25 mg of Cetrotide (Merck-Serono, Germany) will be injected subcutaneously daily and continued until triggering day, follow up for all patients in both groups by transvaginal ultrasound every other day.
62743526|NCT06563466|ACTIVE_COMPARATOR|Treatment as usual (TAU)|"Patients with BPD are offered group-based treatment and individual therapy according to the standardized healthcare delivery models, known as the psychiatric treatment package for borderline personality disorder. The treatment package complies with the description agreed upon in common documents endorsed by all Danish Regions. The content of the treatment package includes psychotherapeutic treatment, according to the evidence based diagnose-specific manuals, and consultations with a psychiatrist. In this study this specifically includes, a treatment program consisting of dialectic behavioral treatment (DBT), delivered according to the manuals by Linehan, 1993 and Linehan, 2015."
62743527|NCT06563466|EXPERIMENTAL|The experimental intervention PEGASUS|"Patients in PEGASUS will, in addition to TAU, be offered to be affiliated with a case manager and to have their families involved in family-based interventions. Duration of the intervention will be nine months.~The case manager will be a trained professional, who will be able to be a guiding figure and when needed, be able to help the patient contacting different authorities. The case manager can support the patient in solving everyday life problems, and will be an occupational therapist, a nurse, or a social worker. The case manager will offer the patients nine extra individual sessions during their treatment course.~The format of the family-based interventions will be two psychoeducational workshops with 6 to 8 families invited and six multifamily group meetings, in which the patient and one or two relatives can participate. Theories behind Psychoeducational Multifamily Groups, Compassion Cultivation Training and Family Connections (FC, Hoffman et al., 2007) will be drawn upon."
62743528|NCT06592014|EXPERIMENTAL|Lithium aspartate|Lithium aspartate with dosage adjusted to achieve a serum lithium level of 0.25-0.50mmol/L
62743529|NCT03424993|EXPERIMENTAL|Dietary Sodium Restriction|Daily habitual dietary sodium intake \< 2000mg
62743530|NCT03424993|SHAM_COMPARATOR|Control|Routine habitual dietary sodium intake \>3400mg
62743531|NCT06285201|EXPERIMENTAL|Group A|T-R
62743532|NCT06285201|EXPERIMENTAL|Group B|R-T
62743533|NCT06576674|EXPERIMENTAL|dietary supplement, then placebo|Participants receive a dietary supplement at the first study session (10g Fibersol®-2 mixed with water and aspartame sweetener + 725mg decaffeinated green tea extract capsule), and then the next study session they receive the placebo supplement (Aspartame sweetener mixed with water + aspartame capsule). Participants will also receive a drink containing alcohol (vodka + cranberry mixer) on both sessions.
62743534|NCT06576674|EXPERIMENTAL|placebo, then dietary supplement|Participants receive a placebo supplement at the first study session (Aspartame sweetener mixed with water + aspartame capsule), then the next session they receive the dietary supplement (10g Fibersol®-2 mixed with water and aspartame sweetener + 725mg decaffeinated green tea extract capsule). Participants will also receive a drink containing alcohol (vodka + cranberry mixer) on both sessions.
62743535|NCT05555641|EXPERIMENTAL|Nafamostat Mesylate|VV-ECMO patients were given continuous anticoagulation with nafamostat mesylate, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
62369646|NCT02556580|EXPERIMENTAL|Surgery under general anesthesia|Intervention: intravenious infusion Drug: albumin 20%
62369647|NCT02556580|EXPERIMENTAL|Post-surgical inflammation|Intervention: intravenious infusion Drug: albumin 20%
62743536|NCT05555641|ACTIVE_COMPARATOR|Unfractionated Heparin|VV-ECMO patients were given continuous anticoagulation with unfractionated heparin, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
62743537|NCT01200407||Filipino Hypertensive patients|Male and Female, 18 to 65 year old Filipino hypertensive patients prescribed by their doctors with Normetec
62743538|NCT01566149|ACTIVE_COMPARATOR|MF/F 200/10 mcg MDI BID|Participants receiving MF/F 200/10 mcg MDI twice daily (BID) for 12 weeks
62743539|NCT01566149|ACTIVE_COMPARATOR|MF/F 400/10 mcg MDI BID|Participants receiving MF/F 400/10 mcg MDI BID for 12 weeks
62743540|NCT03184493|EXPERIMENTAL|Celebrex|Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects.
62743541|NCT03184493|EXPERIMENTAL|Metformin|Patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.
62743542|NCT03184493|ACTIVE_COMPARATOR|Celebrex plus Metformin|Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects. In addition, patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.
62743543|NCT03184493|NO_INTERVENTION|Empty control group|This group patients will not receive any postoperative adjuvant therapy.
62743544|NCT02542033|ACTIVE_COMPARATOR|verum|500mL treated apple juice with low sugar content given on one experimental day
62743545|NCT02542033|PLACEBO_COMPARATOR|control|500mL un-treated apple juice with normal sugar content given on one experimental day
62743546|NCT00024024|EXPERIMENTAL|Arm I|Patients receive oral BMS-275291 1-2 times daily. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 6 patients receive escalating doses of BMS-275291 until the recommended phase II dose (RPTD) is determined. The RPTD is the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity and more than 1 of 6 patients experiences clinical response or at least 5 of 6 patients demonstrate biologic activity. An additional 29 patients are treated at the RPTD.
62743547|NCT05308017|ACTIVE_COMPARATOR|Richard Wolf 24F Laser scope|
62743548|NCT05308017|ACTIVE_COMPARATOR|Karl Storz 28F Laser scope|
62743549|NCT02720380|EXPERIMENTAL|Buteyko|Children in the intervention group will perform 6 sessions (twice a week) of treatment with the Buteyko Method.
62743550|NCT02720380|ACTIVE_COMPARATOR|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
62743551|NCT04901949||BMI Group 1|If BMI is less than 24,9 kg/m2
62743552|NCT04901949||BMI Group 2|If BMI is between 25 - 30 kg/m2
62743553|NCT04901949||BMI group 3|If BMI is more than 30,1 kg/m2
62743554|NCT03016624|ACTIVE_COMPARATOR|OCT guided Magmaris implantation|Percutaneous coronary intervention with Magmaris
62743555|NCT03016624|ACTIVE_COMPARATOR|Angiography guided Magmaris implantation|Percutaneous coronary intervention with Magmaris
62743556|NCT01331837|ACTIVE_COMPARATOR|Etanercept|
62743557|NCT01331837|EXPERIMENTAL|Tocilizumab|
62743558|NCT01355679|EXPERIMENTAL|Guided therapy|A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
62743559|NCT03563742|EXPERIMENTAL|Treatment: Rilpivirine+Combination Therapy (TDF/3TC)|The participants will receive antiretroviral treatment of rilpivirine 25 milligram (mg) tablet orally once daily from Day 1 for 48 weeks with a meal to improve absorption. The participants will also receive background combination therapy of 1 tablet orally once daily containing 300 mg tenofovir disoproxil fumarate (TDF) and 300 mg lamivudine (3TC).
62743560|NCT06661005|EXPERIMENTAL|Nitrous Day|The Nitrous group will receive instructions to arrive at clinic 30 minutes before her procedure in order to sign consent forms. She will not be given instructions to remain NPO and will not be required to have someone bring her to and from the appointment. No IV will be placed. Anesthesia induction will be done by an anesthesiologist with a nitrous oxygen mixture at a 70:30 ratio
62743561|NCT06661005|ACTIVE_COMPARATOR|IV Sedation Day|The IV sedation group will receive instructions to arrive at clinic 1 hour before her procedure in order to sign consent forms and have an IV placed. She will be given instructions to remain NPO status at least 8 hours prior to the procedure and will need someone to bring her to and from the appointment. Anesthesia induction will be done by an anesthesiologist with propofol per standard protocol.
62743562|NCT02978157|ACTIVE_COMPARATOR|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.
62743563|NCT02978157|EXPERIMENTAL|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
62743564|NCT06163950|EXPERIMENTAL|Patients with cerebral palsy|A specially adapted recumbent cycle ergometer with the ability to quickly transform into an isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
62743565|NCT06163950|ACTIVE_COMPARATOR|Healthy people|A specially adapted recumbent cycle ergometer with the ability to quickly transform into an isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
62743566|NCT04187508|EXPERIMENTAL|AZD8154|Subjects will receive AZD8154 QD dosing for 10 days
62743567|NCT04187508|PLACEBO_COMPARATOR|Placebo|Subjects will receive AZD8154 matching placebo QD dosing for 10 days
62743568|NCT02781129|EXPERIMENTAL|RNS® Neurostimulator|Subjects with pharmaceutically intractable seizures who have been implanted with a RNS® Neurostimulator.
62369648|NCT02940860|EXPERIMENTAL|Iron isomaltoside/ferric derisomaltose|Administered IV
62369649|NCT02940860|ACTIVE_COMPARATOR|Iron sucrose|Administered IV
62743569|NCT01205932|EXPERIMENTAL|Arm 1|
62369650|NCT03348813|EXPERIMENTAL|HIV/STI Prevention Intervention|Two-session, small group HIV/STI prevention intervention.
62743570|NCT01205932|EXPERIMENTAL|Arm 2|
62743571|NCT01205932|EXPERIMENTAL|Arm 3|
62743572|NCT01205932|ACTIVE_COMPARATOR|Arm 4|
62743573|NCT00519324|EXPERIMENTAL|RAD001|
62369651|NCT03348813|ACTIVE_COMPARATOR|General Health Control Intervention|Two-session, small group general health promotion intervention.
62743574|NCT02924246|PLACEBO_COMPARATOR|Control group|Regular cholera vaccination
62743575|NCT02924246|ACTIVE_COMPARATOR|Raw milk|Cholera vaccination - raw milk
62743576|NCT02924246|ACTIVE_COMPARATOR|Pasteurized milk|Cholera vaccination - pasteurized milk
62743577|NCT02924246|ACTIVE_COMPARATOR|UHT milk|Cholera vaccination - UHT milk
62369652|NCT02298673||Observation|Patients with Mucolipidosis Disorder type I,II,III or IV or high-grade suspicion for Mucolipidosis Disorder type I,II,III or IV
62369653|NCT02562976||early gastric cancer group|use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia in patients with early gastric cancer or high-grade neoplasia(HGN)
62369654|NCT02562976||non-early gastric cancer group|patients diagnosed as non- gastritis, gastritis or low-grade neoplasia (LGN) by pathology were defined as non-EGC group
62369655|NCT02972593|OTHER|Liberal|Blood and blood products for transfusion. Transfusion will be done to keep Hgb \>7 g/dL.
62369656|NCT02972593|OTHER|Conservative|Blood and blood products for transfusion. Transfusion will be done to keep Hgb \> 5.5 g/dL.
62369657|NCT03625804|EXPERIMENTAL|PNS+AO+Training|"adopted PNS+AO+Training as the intervention"
62369658|NCT03625804|EXPERIMENTAL|PNS+AOsham+Training|"adopted PNS+AOsham+Training as the intervention"
62743578|NCT05015855|PLACEBO_COMPARATOR|OBGYN-PrEP|OBGYN-PrEP has 4 parts: (1) prioritize PrEP; (2) train providers in PrEP and intervention; (3) identify PrEP-appropriate women through a risk screen; and (4) monitor progress and fidelity to protocol.
62743579|NCT05015855|EXPERIMENTAL|NP-PC PrEP|NP-PC PrEP incorporates the standard of care and practices in OBGYN-PrEP but enhances access to additional skilled providers, as the PrEP provider burden is shifted to a Nurse Practitioner (NP) who will use a sex-positive approach to deliver PrEP services via telemedicine
62743580|NCT05098574|EXPERIMENTAL|Combined oral contraceptive (3mg drospirenone/ 0.02mg ethinyl estradiol)|Continuous treatment with 3mg drospirenone/ 0.02mg ethinyl estradiol for 12 weeks
62743581|NCT05098574|PLACEBO_COMPARATOR|Placebo|Continuous treatment with placebo for 12 weeks
62743582|NCT04819893||Women giving birth prematurely|Delivery before 29 WA
62743583|NCT04819893||Women giving birth at term|Childbirth between 39WA and 31WA+6 days
62743584|NCT02161094|EXPERIMENTAL|Group 1: Physicians|Give incentives to physicians based on their patient's HbA1c improvement
62743585|NCT02161094|EXPERIMENTAL|Group 2: Diabetic patients|Give incentives to patients based on their own HbA1c improvement
62743586|NCT02161094|EXPERIMENTAL|Group 3: Both Physicians and Patients|Give incentives to both based on the HbA1c improvements from the physicians' patients
62743587|NCT02161094|NO_INTERVENTION|Group 4: Control group|Receive no incentive but will be provided diabetes education booklet and group education courses for DM control as usual
62743588|NCT06292637|NO_INTERVENTION|Control|
62369659|NCT03625804|PLACEBO_COMPARATOR|PNSsham+AOsham+Training|"adopted PNSsham+AOsham+Training as the intervention"
62369660|NCT05400369|EXPERIMENTAL|Sitafloxacin|Adult participants who will be randomized to receive 100 mg sitafloxacin (2 tablets) orally once a day.
62369661|NCT05400369|ACTIVE_COMPARATOR|Moxifloxacin|Adult participants who will be randomized to receive 400 mg moxifloxacin (1 tablet) orally every 24 hours.
62369662|NCT03411434|EXPERIMENTAL|ADHD patients|90 patients will be enrolled and assessed (i.e., neurocognitive and oculomotor tests) at baseline ; after a single low dose of methylphenidate (10 mg orally); and after 6 months of adequate dose of methylphenidate oral tablet
62369663|NCT01845519|EXPERIMENTAL|Tailored Group|
62369664|NCT01845519|ACTIVE_COMPARATOR|Targeted Group|
62369665|NCT04125303|EXPERIMENTAL|Intervention Group|Based on NANDA diagnosis recommendations, entertainment-sector workers were asked to record their perceptions and the meaning of their substance-use problem in a diary. The intervention was subsequently designed based on brief motivational psychoeducational therapy (BMPT).
62743589|NCT06292637|EXPERIMENTAL|CB-FAITH treatment|
62743590|NCT03172078|ACTIVE_COMPARATOR|Target-control infusion without bispectral index monitoring|Target-control infusion (TCI) with propofol during advanced endoscopic procedure e.g. endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
62743591|NCT03172078|ACTIVE_COMPARATOR|Target-control infusion with bispectral index monitoring|Target-control infusion (TCI) with propofol and BIS monitoring during advanced endoscopic procedure e.g. endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
62743592|NCT04291690|NO_INTERVENTION|Control Group|Usual clinical care as prescribed by their treating clinicians; which may or may not include physiotherapy, geriatric consultation, nutritional consultation and supplementation, and treatment of anemia.
62369666|NCT02896452||Women diagnosed with PCOS without IIH|Women diagnosed with polycystic ovary syndrome without idiopathic intracranial hypertension
62369667|NCT02896452||Women diagnosed with PCOS and IIH|Women diagnosed with polycystic ovary syndrome and idiopathic intracranial hypertension
62369668|NCT02896452||Women diagnosed with IIH without PCOS|Women diagnosed with idiopathic intracranial hypertension without polycystic ovary syndrome
62369669|NCT02896452||Women without PCOS or IIH|Women age and body mass index match controls without polycystic ovary syndrome or intracranial hypertension
62743593|NCT04291690|EXPERIMENTAL|Intervention Group|Multi-component intervention in addition to usual care; which may include - in a targeted fashion - physical training for those with physical weakness, cognitive stimulation for those with cognitive impairment, oral nutritional supplementation for those with malnutrition, and intravenous iron replacement therapy for those with iron deficiency anemia.
62743594|NCT06608524|EXPERIMENTAL|Experimental group|The experimental group used self-regulated learning strategy to improve academic performance of physical education students in China.
62369670|NCT00118404|EXPERIMENTAL|1|Participants received acute phase and continuation phase cognitive therapy
62369671|NCT00118404|PLACEBO_COMPARATOR|2|Participants received acute phase cognitive therapy and continuation phase pill placebo
62369672|NCT00118404|ACTIVE_COMPARATOR|3|Participants received acute phase cognitive therapy and continuation phase fluoxetine
61986283|NCT01245270|EXPERIMENTAL|Control capsule first, then bilberry cap|"Volunteers will be given a single control placebo capsule followed by a 14 day washout period the a single capsule of 0.47 grams of mirtoselect (a concentrated bilberry extract)~First Intervention (1 day), Washout (14 days), Second Intervention (1 day)"
62369673|NCT03139877||HLP|"Intervention Cohorts:The intended target population is the adolescent with a BMI ≥ 95th percentile.~Healthy Lifestyles Program(HLP) will serve as the primary recruitment site for the intervention cohort. A prospective, longitudinal observational case control study will be performed. All participants will receive HLP standard of care (intensive lifestyle modification and access to Bull City Fit.) Groups: (1) HL-only, (2) HL + Low carbohydrate diet, (3) HL + weight loss medication(s) and (4) HL + Bariatric surgery.~Participants will be assigned to groups as per usual HLP clinical care, based on established standards and guidelines, expert medical provider recommendations, and family preference."
62369674|NCT03139877||Healthy Weight Siblings|Healthy weight siblings of HLP participants who meet age and BMI criteria will be offered enrollment at the time their overweight sibling is consented to provide comparative data. This group will be asked to provide a fecal and blood sample at one time point.
62369675|NCT03139877||Healthy Weight age/sex matched controls|"Healthy weight, age and gender matched patients will be recruited from the Duke Children's primary care practice Participants will be recruited at the time of their annual physical to provide comparative data.~This group will be asked to provide a fecal and blood sample at one time point."
62743595|NCT06608524|ACTIVE_COMPARATOR|Control group|The control group used standard learning method to improve physical education academic performance.
62369676|NCT04629976|EXPERIMENTAL|NCO-48 Fumarate 4 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
62369677|NCT04629976|EXPERIMENTAL|NCO-48 Fumarate 20 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
62369678|NCT04629976|ACTIVE_COMPARATOR|Tenofovir alafenamide 25 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
62369679|NCT02324712|ACTIVE_COMPARATOR|Acupuncture|Acupuncture treatment for TMD
62369680|NCT02324712|SHAM_COMPARATOR|Sham Acupuncture|Acupuncture treatment for TMD using the non-penetrating Park Sham Acupuncture Device
62369681|NCT01779895|ACTIVE_COMPARATOR|NCC2461|probiotic blended in maltodextrin powder to be taken daily
62369682|NCT01779895|PLACEBO_COMPARATOR|Placebo|maltodextrin
62369683|NCT01171313|EXPERIMENTAL|Treatment sequence 1|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
62369684|NCT01171313|EXPERIMENTAL|Treatment sequence 2|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
62369685|NCT01171313|EXPERIMENTAL|Treatment sequence 3|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
62369686|NCT01171313|EXPERIMENTAL|Treatment sequence 4|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
62369687|NCT00616772|EXPERIMENTAL|ABT-335 + Atorvastatin|ABT-335 (135 mg) and atorvastatin (up to 40 mg) once daily for 2 years.
62369688|NCT00616772|PLACEBO_COMPARATOR|Placebo + Atorvastatin|Placebo and atorvastatin (up to 40 mg) once daily for 2 years.
62369689|NCT04095793|EXPERIMENTAL|ampreloxetine|Participants will receive a single, oral, daily dose of active drug (TD-9855) for 182 weeks.
62369690|NCT02564068|EXPERIMENTAL|Control|"These 8 subjects will undergo an in the sleep-lab diagnostic polysomnography that would be identical to the one they had for standard of care medical guidelines if they were diagnosed with OSA in the sleep-lab."
62369691|NCT02564068|EXPERIMENTAL|Oxytocin|"These subjects will undergo another in the sleep-lab diagnostic polysomnography that is identical to the one that they had for standard of care to diagnose OSA. Within one hour prior to the research polysomnography the subjects will be given oxytocin (40 IU) intranasally. Outcome measures will be assessed."
62369692|NCT05655728|ACTIVE_COMPARATOR|Metformin intervention treatment group|
62369693|NCT05655728|PLACEBO_COMPARATOR|The placebo treatment group|
62369694|NCT02664389|EXPERIMENTAL|Genetic analysis of patient with early-onset breast cancer|Sequencing of 200 selected genes in patient with early-onset breast cancer without genomic alterations of BRCA1, BRCA2 or TP53
62369695|NCT02664389|EXPERIMENTAL|Genetic analysis of patient with early-onset ovarian cancer|Sequencing of 200 selected genes in patient with early-onset ovarian cancer without genomic alterations of BRCA1, BRCA2
62369696|NCT02664389|EXPERIMENTAL|Genetic analysis of patient with pediatric cancer|Sequencing of 200 selected genes in patient with pediatric cancer without genomic alteration of TP53
62369697|NCT02664389|EXPERIMENTAL|Genetic analysis of patient with early-onset colorectal cancer|Sequencing of 200 selected genes in patient with early-onset colorectal cancer without genomic alteration of APC, MUTYH, SMAD4, BMPR1A, PTEN or STK11 in case of adenomatous polyposis or hamartoma presentation or without genomic alteration of MSH2, MLH1 or MSH6 in case of HNPCC presentation
61986284|NCT02225743||Joint Arthroplasty|Participants undergoing joint replacement
61986285|NCT00937872|EXPERIMENTAL|SRT2104|Single arm with crossover from single dose of oral suspension formulation to single dose intravenous formulation.
62369698|NCT02664389|EXPERIMENTAL|Genetic analysis of patient with multiple primary tumors|Sequencing of 200 selected genes in patient with Multiple primary malignant tumors without syndromic presentation
62369699|NCT04843072|EXPERIMENTAL|Evolut R/Pro bioprosthesis|Study subjects will receive a self-expanding-valve (either the Evolut R or PRO device)
62369700|NCT04843072|ACTIVE_COMPARATOR|Edwards Sapien S3/Ultra bioprosthesis|Study subjects will receive a balloon-expanding-valve (either the Edwards Sapien S3 or Ultra)
62369701|NCT05632913|EXPERIMENTAL|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seed
62369702|NCT05855213|EXPERIMENTAL|High Velocity Nasal Insufflation (HVNI)|"HVNI (Precision Flow; Vapotherm®, Inc, Exeter, NH) will be delivered using a small-bore nasal cannula initiated at a flow rate set to 35 L/min, temperature of 35-37°C and FiO2 at 1.0. Adjustments in flow (up to 40 L/min) and temperature will be titrated to optimize patient's comfort.~The target parameters after initiation will be as follows:~1. RR\< 25 bpm~2. HR\< 120 bpm~3. SpO2 92-94%"
62369703|NCT05855213|ACTIVE_COMPARATOR|Non-invasive positive pressure ventilation (NIPPV)|"NIPPV will be initiated with an oronasal mask, with inspiratory and expiratory positive airway pressures (IPAP, EPAP) set at IPAP 10-20 cm H2O and EPAP 5-7 cm H2O to be titrated according to patient's response and comfort. FiO2 will be initiated at 1.0 for noninvasive positive-pressure ventilation.~The target parameters after initiation will be as follows:~1. RR\< 25 bpm~2. HR\< 120 bpm~3. SpO2 92-94%"
62369704|NCT00899860||patients with renal cell cancer|
62369705|NCT05690906|EXPERIMENTAL|ReSpace™ & gauze packing|All of the subjects will undergo palcement of ReSpace™ hydrogel together with gauze packing in the vagina before brachytherapy
62369706|NCT05690906|ACTIVE_COMPARATOR|gauze packing|All of the subjects will undergo palcement of gauze packing alone in the vagina before brachytherapy
62743596|NCT03139643|EXPERIMENTAL|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
62369707|NCT01365013|EXPERIMENTAL|Lifestyle counseling|
62369708|NCT01365013|ACTIVE_COMPARATOR|control group|
62743597|NCT03139643|EXPERIMENTAL|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
62743598|NCT03139643|PLACEBO_COMPARATOR|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
62743599|NCT01207076|EXPERIMENTAL|receiving AHN-12 and 90Y-AHN-12|Patients receiving nonradiolabeled cold AHN-12 (.20 mg/kg to 1.0 mg/kg) of at least one dose and up to a total of 3 dosimetry infusions (intervals no sooner than 8 days and up to 21 days).
62369709|NCT04379960||Peptides|PBMCs will be incubated with peptides.
62369710|NCT04379960||W/o peptides|PBMCs will be incubated without peptides.
62369711|NCT06086782|EXPERIMENTAL|autogenic inhibition|isometric of muscles and stretching of the same side
62369712|NCT06086782|EXPERIMENTAL|reciprocal inhibition|isometric of muscles and stretching of the opposite side
62369713|NCT04525313||training set|58 unresectable simutaneous CRLM patients with ras mutation accepted Avastin plus chemotherapy treatment after primary tumor resection between 2013.01 and 2017.12.
62369714|NCT04525313||validation set|another 58 unresectable simutaneous CRLM patients with ras mutation accepted Avastin plus chemotherapy treatment after primary tumor resection between 2018.01 and 2022.12.
62369715|NCT03966872|EXPERIMENTAL|Integrated Illness Management and Recovery (I-IMR):|Participants assigned to I-IMR will receive 2 individual sessions to discuss principles of recovery and set personally meaningful goals, with the remainder of the 14 I-IMR sessions delivered in groups of 8-10 (to enable individual tailoring)
62369716|NCT03966872|EXPERIMENTAL|Stanford Chronic Disease Self-Management Program (CDSMP):|Participants randomly assigned get a 6-session group-based educational program co-delivered by two peers (lay people who have successfully managed a chronic illness) or a peer and a professional
62369717|NCT05839236|EXPERIMENTAL|LDL-C Detox|"The participant is continued from the trial NCT05711810. The follow-up study is separately registered for the etiological evidence from vaccine poisoning.~With the prior study's angiotensin-converting enzyme receptor inhibition therapy reaching desired power level and outcome, the participant's blood pressure. has dropped to normal range in a steady state without signs of sudden death risks.~The separate study defines the treatment medicines in NCT05711810 as rescue medicines for discretions, and experiments with Atorvastatin Calcium Tablets with 20 mg per day, and Chinese herb compounded Anti-Viral Granules 12 g (total) in 3 times per day.~The main ingredients for Anti-Viral Granules are the roots of Isatis indigotica L., Forsythia suspensa, Gypsum, Common Anemarrhena, Reed Rhizome, Rehmannia glutinosa, Patchouli, Tatarinow Sweerflag Rhizome, and Curcuma aromatica. They're mixed with dextrin, Sodium cyclamate, patchouli oil, peppermint oil, and angelica dahurica tincture."
62369718|NCT01424319|EXPERIMENTAL|ABT-627, Low dose|
62369719|NCT01424319|EXPERIMENTAL|ABT-627, High dose|
62369720|NCT01424319|PLACEBO_COMPARATOR|ABT-627, Placebo|
62369721|NCT05278936|OTHER|A simplified sclero-cornel tunnel/incision in performing the congenital/pediatric cataract surgery|Participitant
62369722|NCT03435276|EXPERIMENTAL|Cohort 1|Randomized subjects will receive AZD9977 50 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose Day 2 to Day 7
62369723|NCT03435276|EXPERIMENTAL|Cohort 2|Randomized subjects will receive AZD9977 150 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7
62369724|NCT03435276|EXPERIMENTAL|Cohort 3|Randomized subjects will receive AZD9977 300 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7
62369725|NCT05889169||Stroke patients with immunosuppression|Patients with ischemic or hemorrhagic stroke with a neutrophil to lymphocyte ratio \>= 5 at hospital admission
62369726|NCT05889169||Stroke patients without immunosuppression|Patients with ischemic or hemorrhagic stroke with a neutrophil to lymphocyte ratio \< 5 at hospital admission
62369727|NCT05551260|EXPERIMENTAL|People with ASD|30 people with ASD without IDD
62369728|NCT05551260|ACTIVE_COMPARATOR|Neurotypicals|30 neurotypicals
62369729|NCT03278444|EXPERIMENTAL|One-drug Regimes|Basic drugs therapy of HCC
62369730|NCT03278444|EXPERIMENTAL|Two-Drug Regimens|Basic drugs therapy of HCC; Arginine hydrochloride
62369731|NCT03278444|EXPERIMENTAL|Three-Drug Regimens|Basic drugs therapy of HCC; Arginine hydrochloride;Trimetazidine hydrochloride
62369732|NCT05689749||Participants with Sjögren's syndrome|Participants with the diagnose of Sjögren's syndrome; Patients with a confirmed diagnosis who are being followed and treated by a rheumatologist.
62369733|NCT05689749||Volunteers who has not dry eye complaints and Sjögren's syndrome diagnosis.|Voluntary participants without any rheumatic disease diagnosis, without Sjögren's syndrome diagnosis, without dry eye complaints will constitute the other group.
62369734|NCT00760045|EXPERIMENTAL|1|AL-43546 0.15%
62369735|NCT00760045|EXPERIMENTAL|2|AL-43546 0.25%
62369736|NCT00760045|ACTIVE_COMPARATOR|3|AL-43546 0%(Vehicle)
62369737|NCT00760045|ACTIVE_COMPARATOR|4|0.1% sodium hyaluronate ophthalmic solutio
62369738|NCT02738346|EXPERIMENTAL|Arm A : Carboplatin-Etoposide|Intravenous administration of Carboplatin Auc 5 at Day 1 and Intravenous administration of 100 mg / m² / of Etoposide J Day 1 to Day 3 The CT scans evaluations will be conducted during chemotherapy every 6 weeks
62369739|NCT02738346|ACTIVE_COMPARATOR|Arm B : Topotecan|Per os administration of 2.3 mg / m² of Topotecan Day 1 to Day 5 The CT scans evaluations will be conducted during chemotherapy every 6 weeks
62369740|NCT05984628|EXPERIMENTAL|human umbilical cord mesenchymal stem cells|"Injection of human umbilical cord mesenchymal stem cells (hUCMSC) into the donor site.~1. Dosage of stem cell preparation: Calculated based on the area of the donor site, with a cell count of 1X10\^5cells/cm2.~2. Administration method: The cells are prepared as an injectable suspension using a blank solvent for stem cells at a concentration of 1X10\^6 cells/ml (0.1 ml/cm2).~3. Timing of administration: Administered immediately after completion of the donor site harvesting procedure.~4. Treatment duration: The stem cell administration is a single dose, administered at the specified timing as described above"
62369741|NCT05984628|PLACEBO_COMPARATOR|blank solvent|"Injection of an equal volume of blank solvent for suspension of stem cells into the donor site.~1. Dosage of Control group preparation: Calculated based on the area of the donor site.~2. Administration method: Injection of an equal volume of blank solvent for suspension of stem cells into the donor site.~3. Timing of administration: Administered immediately after completion of the donor site harvesting procedure.~4. Treatment duration: The Control group administration is a single dose, administered at the specified timing as described above"
62743600|NCT02719964|EXPERIMENTAL|A: UCR Games→SP-Directed Therapy|Participants in Arm A will first participate in Visual Attention Program (UCR Games) followed by Speech Pathologist-Directed Therapy with assessment sessions prior to and following each treatment intervention.
62743601|NCT02719964|EXPERIMENTAL|B: Lumosity→SP-Directed Therapy|Participants in Arm B will first participate in General Cognitive Rehabilitation Games (Lumosity) followed by Speech Pathologist-Directed Therapy with assessment sessions prior to and following each treatment intervention.
62743602|NCT02719964|EXPERIMENTAL|C: SP-Directed Therapy→UCR Games|Participants in Arm C will first participate in Speech Pathologist-Directed Therapy followed by Visual Attention Program (UCR Games) with assessment sessions prior to and following each treatment intervention.
62743603|NCT02719964|EXPERIMENTAL|D: SP-Directed Therapy→Lumosity|Participants in Arm D will first participate in Speech Pathologist-Directed Therapy followed by General Cognitive Rehabilitation Games (Lumosity) with assessment sessions prior to and following each treatment intervention.
62743604|NCT05787587|EXPERIMENTAL|Module 1 Part 1: Monotherapy Dose Escalation|Participants will be assigned to a dose level.
62369742|NCT04282889||Liver transplantation group|"The study population will include 20 adults (age range of 18 - 75 years) who are undergoing liver transplantation. Inclusion criteria are patients undergoing liver transplantation with English as their native language.~Exclusion criteria include patient's refusal, or on medical anticoagulation therapy. Informed consents will be obtained from the patients who agree to participate in this clinical study."
62369743|NCT04282889||Healthy volunteer|The control population will include 20 adult volunteers (age 18-65 years) who meet the in the American Society of Anesthesiologists (ASA) Physical Status (PS) Classes 1 criteria. Exclusion criteria will be refusal, volunteers on any medication or significant history of bleeding.
62369744|NCT05841953|EXPERIMENTAL|Single arm|All participant will be exposed to the full stimulation protocol 2 different protocols using 2 different electrode arrays will be studied in random order.
62369745|NCT01116310|EXPERIMENTAL|Fitogyn|4 weeks with placebo followed by 16 weeks with Fitogyn, both taking two capsules per day during the breakfast.
62369746|NCT01116310|PLACEBO_COMPARATOR|Placebo|20 weeks with placebo, taking two capsules per day during the breakfast.
62369747|NCT03006926|EXPERIMENTAL|lenvatinib 8 or 12 mg plus pembrolizumab 200 mg|Participants will receive oral lenvatinib at a starting dose of 8 or 12 milligrams (mg) once a day (QD) in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle. The starting dose of lenvatinib will be based on Baseline body weight. Participants weighing greater than or equal to 60 kilograms (kg) will receive 12 mg QD; participants weighing less than 60 kg will receive 8 mg QD.
62369748|NCT01816542|OTHER|patch tests on healthy skin|
62369749|NCT01235507|EXPERIMENTAL|Single Arm|
62369750|NCT00441012|EXPERIMENTAL|1|Modified process Hib/Hep B vaccine
62369751|NCT00441012|ACTIVE_COMPARATOR|2|COMVAX™
62369752|NCT04067011|EXPERIMENTAL|Group 1:Ciprofloxacin + AV7909|"Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.~Group 1 will concomitantly receive ciprofloxacin."
62369753|NCT04067011|EXPERIMENTAL|Group 2: Doxycycline +AV7909|"Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.~Group 2 will concomitantly receive doxycycline."
62369754|NCT04067011|EXPERIMENTAL|Group 3: AV7909|Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.
62743605|NCT05787587|EXPERIMENTAL|Module 1 Part 2: Monotherapy Dose Expansion|After a dose is decided in Part 1, participants entering part 2 will be assigned to a dose level.
62743606|NCT05787587|EXPERIMENTAL|Module 2 Part 1: Combination Dose Escalation with pembrolizumab|Participants will be assigned to a dose level.
62743607|NCT05787587|EXPERIMENTAL|Module 2 Part 2: Combination Dose Expansion with pembrolizumab|After a dose is decided in Part 1, participants entering part 2 will be assigned to a dose level.
62743608|NCT05666999|OTHER|FibDex|IMD
62743609|NCT05666999|ACTIVE_COMPARATOR|Suprathel|Primary Comparator.
62743610|NCT05666999|ACTIVE_COMPARATOR|Aquacel Foam|Secondary Comparator.
62743611|NCT05343689|EXPERIMENTAL|Pneumatic compression group|When inducing general anesthesia, pneumatic compression is performed.
62369755|NCT00300612|EXPERIMENTAL|vaccine group|
62369756|NCT03623022|EXPERIMENTAL|Endotoxin, then Normal Saline|"Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The Clinical Center Reference Endotoxin (CCRE) will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).~Following a washout of 2 weeks to 3 months the participant will undergo a Saline Challenge: Subjects will undergo inhalation of 0.9% sodium chloride. The Normal saline will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes)."
62369757|NCT03623022|EXPERIMENTAL|Normal Saline, then Endotoxin|"Saline Challenge: Subjects will undergo inhalation of 0.9% sodium chloride. The Normal saline will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).~Following a washout of 2 weeks to 3 months the participant will undergo an Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes)."
62369758|NCT04635345|EXPERIMENTAL|Vibrator Therapy + dilator/standard therapy|Patient will receive standard therapy (initial appointment, referral for womens health physiotherapy or psychosexual counselling as standard, together with vadinal dilators and lidocaine gel) plus an external vibrator.
62743612|NCT05343689|NO_INTERVENTION|Control group|When inducing general anesthesia, pneumatic compression is not performed.
62743613|NCT01833910|EXPERIMENTAL|Video-only - DVD|CPR Training with AHA CPR Anytime DVD presented on a TV with DVD player and no psychomotor skill practice.
62743614|NCT01833910|EXPERIMENTAL|Video-only - iPad|CPR Training with AHA CPR Anytime DVD presented on a portable video player and no psychomotor skill practice.
62743615|NCT01833910|EXPERIMENTAL|Video-only with Household Object|CPR Training with AHA CPR Anytime DVD and practice on a household item
62743616|NCT01833910|EXPERIMENTAL|Video Self Instruction Kit|CPR Training with AHA CPR Anytime Video Self-Instruction kit including manikin
62743617|NCT03309319|EXPERIMENTAL|Ros|Rosiglitazone：2 times a day, 4mg each time（4mgBid）
62743618|NCT04218214||LIFE-DM Group|The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and microfinance loans of 2 million VND. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union.
62743619|NCT05625789|EXPERIMENTAL|Postural control (weight shifting) training followed by steady state gait training.|"For postural control training, participants will be provided visual biofeedback to increase weight shift prior to the first step. The feedback program cues participants to reach a target amount of weight shift. Once the target is reached, participants are cued to initiate walking. Participants will complete a total of 30 minutes of training, ensuring at least 45 repetitions.~To create larger amplitude movements during steady state gait, participants will walk on a treadmill set to their comfortable gait speed while attempting to match their steps to a metronome beeping at 85% of their comfortable cadence. Participants will complete a total of 10 minutes of treadmill walking with rest breaks as needed. Next, participants will walk overground to a metronome beeping at 115% of their comfortable cadence with a goal of 10 total minutes of training.~Each training will be three times per week for two weeks. There is a one week break between the two trainings."
62743620|NCT05625789|EXPERIMENTAL|Steady state gait training followed by postural control (weight shifting) training.|"To create larger amplitude movements during steady state gait, participants will walk on a treadmill set to their comfortable gait speed while attempting to match their steps to a metronome beeping at 85% of their comfortable cadence. Participants will complete a total of 10 minutes of treadmill walking with rest breaks as needed. Next, participants will walk overground to a metronome beeping at 115% of their comfortable cadence with a goal of 10 total minutes of training.~For postural control training, participants will be provided visual biofeedback to increase weight shift prior to the first step. The feedback program cues participants to reach a target amount of weight shift. Once the target is reached, participants are cued to initiate walking. Participants will complete a total of 30 minutes of training, ensuring at least 45 repetitions.~Each training will be three times per week for two weeks. There is a one week break between the two trainings."
62743621|NCT05934994|EXPERIMENTAL|Patients with undetermined solitary bone lesions|All patients with indeterminate solitary bone lesions undetermined on conventional imaging for whom a biopsy or excision is scheduled, will be able to participate in the study.
62743622|NCT03223922|EXPERIMENTAL|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy|Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
62743623|NCT02117960|ACTIVE_COMPARATOR|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
62743624|NCT02117960|PLACEBO_COMPARATOR|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
62743625|NCT05769855|EXPERIMENTAL|HR18034|
62743626|NCT05769855|ACTIVE_COMPARATOR|ropivacaine HCl|
62743627|NCT05769855|PLACEBO_COMPARATOR|Sodium Chloride Physiological Solution|
62743628|NCT02095873|EXPERIMENTAL|Glo1-inducer then placebo|Glyoxalase 1 Inducer (8 weeks), then washout (6 weeks), then Placebo (8 weeks).
62743629|NCT02095873|EXPERIMENTAL|Placebo then Glo1-inducer|Placebo (8 weeks), then washout (6 weeks), then Glyoxalase 1 Inducer (8 weeks).
62743630|NCT04651439|EXPERIMENTAL|FILGRASTIM|Standard symptomatic treatment of the SJS/NET (until the reepidermization of the patient) + ZARZIO@ (30 MU/0,5mL and/or 48 MU/0,5mL - solution of 20 ml diluted in GLUCOSE 5%) administrated by IV or subcutaneous route over a period of 5 consecutive days (1 injection per day during 30 minutes)
62369759|NCT04635345|ACTIVE_COMPARATOR|Dilator/standard therapy|Patient will receive standard therapy (initial appointment, referral for womens health physiotherapy or psychosexual counselling as standard, together with vadinal dilators and lidocaine gel).
62369760|NCT05740891|EXPERIMENTAL|Treatment Group|Refractory and relapsed multiple myeloma
62369761|NCT02152540|EXPERIMENTAL|ACTIVE rTMS|Those receiving experimental treatment will receive 20 sessions of rTMS. The treatment will be delivered by trained medical personnel.
62369762|NCT02152540|PLACEBO_COMPARATOR|Sham rTMS|Those receiving the sham rTMS will receive 20 sessions of sham rTMS. The treatment will be delivered by trained medical personnel.
62369763|NCT00410345|EXPERIMENTAL|Pitocin|Treatment with Pitocin after mifegine
62369764|NCT00410345|ACTIVE_COMPARATOR|Cytotec|Treatment with cytotec after mifegine
62369765|NCT03713151|EXPERIMENTAL|Dividat FIT: Computer based exercise|One arm with 10-15 Haemophilia patients and 10-15 Myositis patients.
62369766|NCT05284656|EXPERIMENTAL|folic acid Group|20 patients will receive folic acid 500 µg per day with their standard therapy for 6 months.
62369767|NCT05284656|EXPERIMENTAL|Pentoxifylline Group|20 patients will receive Pentoxifylline ( TRENTAL® Tablets, 400 mg) twice daily with their standard therapy for 6 months.
62369768|NCT05284656|EXPERIMENTAL|folic acid and pentoxifylline Group|20 patients will receive combination therapy of folic acid5 mg per day and pentoxifylline ( TRENTAL® Tablets, 400 mg) twice daily with their standard therapy for 6 months
62369769|NCT05284656|NO_INTERVENTION|control group|20 patients will receive their standard therapy only.
62369770|NCT05208450|NO_INTERVENTION|Usual care (UC) Group|"The study design is a randomized stepped wedge cluster trial whereby all clusters (practice sites) begin as part of the Usual Care (UC) control condition.~Clusters are then randomly assigned to cross over at different times with all clusters eventually receiving PACE. The study will involve each site starting with the UC, followed by a period of 3 months during which practice facilitators will train NCMs and CHWs, and finally followed by the PACE intervention for 12 months with a 6-month follow-up for outcome assessment. During the UC Period, patients at the sites will receive standard HTN care and standard printed HTN treatment guidelines. Immediately following this period, prior to implementation of PACE, we will conduct a practice capacity assessment at each site for 3 months. This period is then followed by the implementation of PACE."
62743631|NCT04651439|PLACEBO_COMPARATOR|PLACEBO|Standard symptomatic treatment of the SJS/NET (until the reepidermization of the patient) + 20 ml GLUCOSE 5% administrated by IV route over a period of 5 consecutive days (1 injection per day during 30 minutes)
62743632|NCT06497062|EXPERIMENTAL|Assigned Interventions|"Experimental: Sonrotoclax combined with intensive chemotherapy. Subjects receive induction therapy consisting of sonrotoclax combined with a 3+7 regimen. According to the ELN risks and MRD status, subjects who achieve composite complete remission (CRc) proceed with consolidation therapy, and allogeneic hematopoietic stem-cell transplant (allo-HSCT) can be included per investigator's decision.~After the consolidation, subjects will receive sonrotoclax combined with azacitidine (AZA) alternating with AZA monotherapy every 2 cycles as maintenance therapy until intolerable toxicity, 12 months, relapse, death, withdrawal of informed consent, or study termination determined by investigators, whichever occurs first."
62369771|NCT05208450|EXPERIMENTAL|Intervention Group|Thus, each cluster will belong successively to the control group and the intervention group. During the control period (UC) patients at the sites will receive standard HTN care delivered by their primary care providers and standard printed HTN treatment guidelines. This period is then followed by the implementation of PACE. Clusters are randomly assigned to cross over at different times with all clusters eventually receiving PACE. During the PACE implementation period, which will last 12 months, practice facilitators will work with each site to implement the components of PACE.
62369772|NCT04348786|EXPERIMENTAL|Doxycyclien|Measure eradication rate of Helicobacter pylori infection with Doxycycline and bismuth subsalicylate
62369773|NCT04348786|ACTIVE_COMPARATOR|Levofloxacine|Measure eradication rate of Helicobacter pylori infection with Livofloxacine and tinadizole
62369774|NCT01481207||neonates with perinatal asphyxia|neonates with suspected perinatal asphyxia (HIE)
62369775|NCT02977039|EXPERIMENTAL|NDPR diet|Subjects randomized to the nutrient dense plant rich (NDPR) diet will eat foods with high micronutrient density, and favorable glycemic index. The diet is low in saturated fat, high in fiber, and rich in phytochemicals. Total caloric intake will range from 1600-2000/day based on individual needs. Foods include vegetables (30-70% of calories), fruits (15-20% of calories), Beans/Legumes (20-30% of calories), raw nuts and seeds (10-20% of calories), fish or fat-free dairy (twice weekly or less), poultry, eggs and oils (once weekly or less) and limited beef, cheese/milk, processed food and beef.
62743633|NCT02806219|ACTIVE_COMPARATOR|Certolizumab Pegol injection by prefilled syringe|
62743634|NCT02806219|EXPERIMENTAL|Certolizumab Pegol injection by e-Device|
62743635|NCT05992844|EXPERIMENTAL|KB Exercises plus Conventional Rehabilitation Group|"While the participants in the study group will continue the conventional rehabilitation program described below for 3 weeks, lasting 45 minutes on average, 5 sessions a week, they will participate in a total of 9 sessions of kinesthetic brain exercises, 3 sessions a week lasting 30 minutes on average.~Kinesthetic Brain Exercises Program; The kinesthetic brain exercises program basically consists of 3 phases: warm-up phase, exercise phase and cool-down phase."
62369776|NCT02977039|EXPERIMENTAL|USDA diet|Subjects randomized to the healthy U.S.-Style pattern diet will eat the types and proportions of foods Americans typically consume, but in nutrient-dense forms and appropriate amounts. It is designed to meet nutrient needs while not exceeding calorie requirements and while staying within limits for overconsumed dietary components. Total caloric intake will range from 1600-2000/day based on individual needs. Foods include fruits, vegetables (dark green, red/orange, beans, and peas, starchy vegetables), grains (whole grains and refined grains), protein foods (meat, poultry, eggs, seafood, nuts, seeds and soy products), dairy, and oils.
62743636|NCT05992844|OTHER|Conventional Rehabilitation Group|Control Group; Conventional Rehabilitation program; strengthening exercises, balance/gait training, Proprioceptive Neuromuscular Facilitation techniques, neuromuscular electrical stimulation.
62743637|NCT06090539|EXPERIMENTAL|Part A1|Single Agent
62743638|NCT06090539|EXPERIMENTAL|Part A2|Combination Treatment
62743639|NCT06090539|EXPERIMENTAL|Part B1|Single Agent
62369777|NCT06213415|ACTIVE_COMPARATOR|Oral steroids|Oral steroids only
62369778|NCT06213415|ACTIVE_COMPARATOR|Oral steroids plus intratympanic injections|Oral steroids plus intratympanic injections
62369779|NCT06246344||LCCRT|"Radiotherapy: The pelvic lymph node drainage area (CTV) is targeted with a dose of 45-50 Gy delivered in 25 fractions.~Concurrent Chemotherapy: During radiotherapy, concurrent administration of capecitabine at a dose of 825 mg/m2, twice daily.~Consolidation Chemotherapy Phase: On Day 1, two cycles of the CAPEOX regimen are administered (capecitabine 1.0 g/m2 po bid d1-14 + oxaliplatin 130 mg/m2, q3w). Initiated 7-10 days after completion of LCCRT.~Surgical Phase: Commencing on Day 1, the patient undergoes Total Mesorectal Excision (TME) following consolidation chemotherapy."
62369780|NCT06246344||MRIg-LCCRT|"Radiotherapy (SIB): Targeting the rectal tumor (GTVp) and regional metastatic lymph nodes (GTVn) with a dose of 60-65 Gy delivered in 25 fractions; the pelvic lymph node drainage area (CTV) receives a dose of 45-50 Gy delivered in 25 fractions.~Concurrent Chemotherapy: During radiotherapy, concurrent administration of capecitabine at a dose of 825 mg/m2, twice daily.~Consolidation Chemotherapy Phase: On Day 1, two cycles of the CAPEOX regimen are administered (capecitabine 1.0 g/m2 po bid d1-14 + oxaliplatin 130 mg/m2, q3w). Initiated 7-10 days after completion of LCCRT.~Surgical Phase: Commencing on Day 1, the patient undergoes Total Mesorectal Excision (TME) following consolidation chemotherapy."
62369781|NCT03562520|EXPERIMENTAL|Adolescents with bipolar disorder|Forty adolescents (aged 13-21) with BD (type I, II, or not otherwise specified/other specified and related disorder) will be enrolled in the behavior change counseling intervention.
62369782|NCT02823613|EXPERIMENTAL|Healthy male test subjects 1-5|High salt diet followed by low salt diet
62369783|NCT02823613|EXPERIMENTAL|Healthy male test subjects 6-10|Low salt diet followed by high salt diet
62369784|NCT03217318|ACTIVE_COMPARATOR|ureteral stenting with standard ureteral stent|Group 1 will receive a standard ureteral stent. Diameter: 6F, length according to surgeons' estimation and patient's height.
62369785|NCT03217318|ACTIVE_COMPARATOR|ureteral stenting with suture-stent|In Group 2, a modification of the standard ureteral stent will be inserted. The stent will be cut through obliquely according to the position of the ureteral calculus. The extend to be removed can be easily measured by the retrograde probing catheter and is replaced by a monofilament, non-absorbable suture as described previously by Vogt et al. (W J Urol, 2015). This suture can be easily attached by puncturing the bevelled stent end.
62369786|NCT01890928||Critically Ill Septic Pediatric Patients|Age 5-12 years; weight ≥ 17kg and Age 13-19 years, males and females
62369787|NCT01890928||Healthy Adolescents|Age 13-19 years, males and females
62369788|NCT05153564|EXPERIMENTAL|One-sequence cross-over arm|
62369789|NCT06000215||Uphold™ Lite Vaginal mesh - Boston Scientific (Anterior)|Patients previousely received the Uphold™ Lite for the surgical management of apical and/or anterior vaginal mesh prolapse.
62369790|NCT06000215||Pinnacle posterior Vaginal mesh - Boston Scientific|Patients previousely received the Pinnacle posterior Vaginal mesh for the surgical management of posterior and/or apical vaginal mesh prolapse.
62369791|NCT06000215||Artisyn® Y-Shaped Mesh (Robotic-assisted Sacral colpopexy)|Patients previousely received the Artisyn® Y-Shaped Mesh via robotic-assisted approach Patients previousely received th Artisyn® Y-Shaped Mesh via robotic-assisted approach for the surgical management of apical prolapse..
62369792|NCT06000215||Native tissue repair|Patients previousely received native tissue repair for the surgical management of prolapse.
62369793|NCT00513370|EXPERIMENTAL|1|
62369794|NCT02708004|EXPERIMENTAL|ACT-132577|3 different dose levels
62369795|NCT02708004|PLACEBO_COMPARATOR|Placebo|Matching active drug
62369796|NCT03933072|EXPERIMENTAL|patients with complete spinal cord injury|the planned interventions have been described in the section below
62369797|NCT00744991|EXPERIMENTAL|Enzastaurin|Open Label
62369798|NCT02277236||Younger Veterans|Male Veterans, 45-64.9 years of age. (Exposures include DXA scanning and CT imaging.)
62369799|NCT02277236||Young-Old Veterans|Male Veterans, 65-84.9 years of age. (Exposures include DXA scanning and CT imaging.)
62369800|NCT00839436|EXPERIMENTAL|3 microgram/kg CYT107|3 microgram/kg CYT107
62369801|NCT00839436|EXPERIMENTAL|10 microgram/kg CYT107|10 microgram/kg CYT107
62369802|NCT00839436|EXPERIMENTAL|20 microgram/kg CYT107|20 microgram/kg CYT107
62369803|NCT04288297||distal minimally invasive distal chevron|The investigators compare the results of a consecutive cohort of patients treated with the above mentioned technique in comparison to the results of patients treated with the minimally invasive Reverdin-Isham technique, presented in literature
62369804|NCT04104841|EXPERIMENTAL|Behaviorally Enhancing Adolescents' Mood in Schools (BEAMS)|8-session modified behavioral activation program
62369805|NCT04104841|ACTIVE_COMPARATOR|Usual Care|Referrals to usual care
62369806|NCT04429074||Group 1 (Registrar)|Group 1 (Registrar): Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology operated on by a registrar (young specialist surgeon)
62369807|NCT04429074||Group 2 (Consultant)|Group 2 (Consultant): Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology operated on by a consultant (expert)
62369808|NCT02724111|EXPERIMENTAL|deep neuromuscular blockade|This arm will be given sufficient dose of rocuronium. In this Arm group, rocuronium will be administered to maintain deep neuromuscular blockade \[NMB\] (train-of-four \[TOF\] count 0, post-tetanic count \[PTC\] of 1-2 twitches) until the end of surgery and the reversal of NMB will be performed by sugammadex 4 mg/kg at the end of surgery'.
62369809|NCT02724111|ACTIVE_COMPARATOR|restricted neuromuscular blockade|This arm will not be given sufficient dose of rocuronium. In this Arm group, sugammadex will be administered according to the prescribing indications (4 mg/kg for deep neuromuscular blockade \[NMB\] state or 2 mg/kg for moderate NMB or less) to reverse the NMB 10 min after position change (sugammadex 10 min after position change \[a prone position\]). Thereafter, muscle relaxants will not be injected any more throughout the surgery except the following situations: If the patients show any body movement during surgery or if surgeons express any complaint about muscle tone (the muscle tone: grade 3), rescue rocuronium 5 mg will be administered and the number of body movements and rescue rocuronium administration (dose) will be recorded.
62369810|NCT03672552|EXPERIMENTAL|FFWP and Improved Oral Care|Receiving dental hygienist cleaning with supervised tooth brushing and FFWP (plain, unmodified water).
62369811|NCT03672552|NO_INTERVENTION|Standard Care|This group has assessments and standard oral care with no dental hygienist cleaning, no FFWP or supervised tooth brushing and continuing with agreed upon diet texture and fluid modification.
62369812|NCT05942170|OTHER|SLN/MRI|
62369813|NCT04118062|OTHER|Metastatic Uveal Melanoma|Questionnaires and semi-structured individual interviews with patients with Metastatic Uveal Melanoma
62743640|NCT06090539|EXPERIMENTAL|Part B2|Combination Treatment
62743641|NCT03886870|EXPERIMENTAL|Lifestyle and work intervention|Lifestyle intervention with work focus.
62743642|NCT03886870|EXPERIMENTAL|Lifestyle intervention|Lifestyle intervention without work focus.
62743643|NCT06659055|OTHER|Healthy Volunteers|Healthy volunteers will undergo EOSedge and DXA imaging
62369814|NCT04118062|OTHER|Triple Negative Breast Cancer|Questionnaires and semi-structured individual interviews with patients with Triple Negative Breast Cancer
62743644|NCT06659055|OTHER|Subjects indicated for EOSedge imaging|Subject receiving EOSedge imaging as SOC will also receive an additional DXA scan.
62743645|NCT04060888|EXPERIMENTAL|Ustekinumab|Participants will receive ustekinumab approximately 6 milligram per kilogram (mg/kg) intravenously (IV) based on body weight-range at Week 0 followed by 90 mg ustekinumab subcutaneously (SC) at Week 8 and every 8 weeks (q8w) thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will continue to receive 90 mg ustekinumab SC q8w through Week 160.
62743646|NCT04060888|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo to ustekinumab IV at Week 0, followed by matching placebo to ustekinumab SC at Week 8 and q8w thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will cross-over to receive 90 mg ustekinumab SC q8w through Week 160.
62743647|NCT05355259|EXPERIMENTAL|GECKO Active Guidewire Use|All patients will be treated using the GECKO guidewire to facilitate endovascular access to the targeted vessel in order to treat the vascular lesion.
62743648|NCT02358161|EXPERIMENTAL|LDE225|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer.
62743649|NCT04005508||OSA (Watch PAT AHI >/= 15 events per hour)|Patients found to have OSA by an overnight sleep study
62369815|NCT04118062|OTHER|Luminal B Breast Cancer|Questionnaires and semi-structured individual interviews with patients with Luminal B Breast Cancer
62369816|NCT04118062|OTHER|Pediatric Cancer|Questionnaires and semi-structured individual interviews with parents of children with cancer.
62743650|NCT04005508||Non-OSA (Watch PAT AHI < 15 events per hour)|Patients found NOT to have OSA by an overnight sleep study
62743651|NCT05662280|EXPERIMENTAL|Active intermittent Theta Burst Stimulation|"In a 2x2 factorial double-blind design, researchers will randomize a sample of adolescents with WM deficits to intermittent theta burst stimulation (iTBS) at the left dorsolateral prefrontal cortex (DLPFC) or inferior parietal lobule (IPL), based on each participant's structural brain MRI.~Participants in both arms will complete an active iTBS session and a sham iTBS session. The primary outcome will be theta-gamma coupling during WM demands, as measured via electroencephalography (EEG) during a Sternberg spatial WM task (SWMT) immediately before and after iTBS."
62743652|NCT05662280|EXPERIMENTAL|Sham intermittent Theta Burst Stimulation|"In a 2x2 factorial double-blind design, researchers will randomize a sample of adolescents with WM deficits to intermittent theta burst stimulation (iTBS) at the left dorsolateral prefrontal cortex (DLPFC) or inferior parietal lobule (IPL), based on each participant's structural brain MRI.~Participants in both arms will complete an active iTBS session and a sham iTBS session. The primary outcome will be theta-gamma coupling during WM demands, as measured via electroencephalography (EEG) during a Sternberg spatial WM task (SWMT) immediately before and after iTBS."
62743653|NCT04029168||Pelvic floor surgery|The group will consist of females with pelvic floor disorders (pelvic organ prolapse, stress urinary incontinence) qualified for pelvic floor surgery
62369817|NCT04118062|OTHER|Expert Patients|Focus groups (or group interviews) and DELPHI consensus method with expert patients
62369818|NCT04118062|OTHER|Researchers and Clinicians|Focus groups (or group interviews) and DELPHI consensus method with Researchers and Clinicians
62369819|NCT03491280||Group 1|Subjects with unclear rare diseases, clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating location, genetic diagnostic (NGS diagnostic) must be performed.
62369820|NCT03491280||Group 2|Subjects with unclear rare diseases, genetic diagnostic (NGS diagnostic) is already performed.
62743654|NCT03526393|EXPERIMENTAL|Support Equipment|Were selected high performance athletes with various kinds of disabilities found in sitting volleyball functional classification. Three equipment was built to aid high-performance athletes. All the volunteers tested the survey training equipment, attack and serve training equipment and pass training equipment The motor sign captured footage of each athlete, lasted 30 minutes and the data collected provided the data for the construction of the equipment, later there was the interaction of the athletes with the equipment ready to test effectiveness.
62743655|NCT04999384|ACTIVE_COMPARATOR|AN4005 dose level 0|One sentinel patient will be orally dosed at 50 mg AN4005 BID. If this dose for one cycle is deemed to be tolerable upon review of safety data and PK data, the dose of AN4005 will be escalated to next level: dose level 1.
62369821|NCT01455155|EXPERIMENTAL|Creative therapy|Conventional physical therapy program (5 times/week) plus creative therapy (Art and Music) 2 times/week for 4 weeks
62369822|NCT01455155|ACTIVE_COMPARATOR|Control|Conventional physical therapy (5 times/week) for 4 weeks
62369823|NCT01473355|EXPERIMENTAL|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) in lengths of 11-15 mm
62369824|NCT05942677||Colorectal lesion diagnostic|Every patient referred to our center for colorectal endoscopy for investigation and/or resection of colorectal lesion can join the cohort of this study and will benefit from diagnosis and treatment by experienced endoscopists.
62369825|NCT03426449|ACTIVE_COMPARATOR|Posterolateral sphincterotomy|Division of internal anal sphincter at 5 o'clock position
62369826|NCT03426449|ACTIVE_COMPARATOR|Lateral sphincterotomy|Division of internal anal sphincter at 3 o'clock position
62369827|NCT02831283|EXPERIMENTAL|Cognitive impairment|Alzheimer's disease, Preclinical Alzheimer's disease or Impairment due to suspected non-Alzheimer's disease pathophysiology
62369828|NCT02831283|ACTIVE_COMPARATOR|No cognitive impairment|Normal aging
62369829|NCT01921283|EXPERIMENTAL|BIS group|The BIS group (n=90) was monitored for sedation depth using BIS during ESD.
62743656|NCT04999384|ACTIVE_COMPARATOR|AN4005 dose level 1|Three patients will be orally dosed at 100 mg AN4005 BID. Based on the number of DLT events during the first cycle, dosing decisions will be made, including add 3 patients at the same dose level (1 DLT), escalation to dose level 3 (\<1/6 DLT), de-escalate to lower dose or stop (\>1/6 DLT).
62743657|NCT04999384|ACTIVE_COMPARATOR|AN4005 dose level 2|Three patients will be orally dosed at 200 mg AN4005 BID. Based on the number of DLT events during the first cycle, dosing decisions will be made, including add 3 patients at the same dose level (1 DLT), escalation to dose level 3 (\<1/6 DLT), de-escalate to lower dose or stop (\>1/6 DLT).
62743658|NCT04999384|ACTIVE_COMPARATOR|AN4005 dose level 3|Three patients will be orally dosed at 400 mg AN4005 BID. Based on the number of DLT events during the first cycle, dosing decisions will be made, including add 3 patients at the same dose level (1 DLT), escalation to dose level 4 (\<1/6 DLT), de-escalate to lower dose or stop (\>1/6 DLT).
62743659|NCT04999384|ACTIVE_COMPARATOR|AN4005 dose level 4|Three patients will be orally dosed at 600 mg AN4005 BID. Based on the number of DLT events during the first cycle, dosing decisions will be made, including add 3 patients at the same dose level (1 DLT), de-escalate to lower dose or stop (\>1/6 DLT).
62743660|NCT04999384|ACTIVE_COMPARATOR|AN4005 food effect|The effect of a high-fat meal on the PK of AN4005 will be evaluated in a separate cohort of approximately 6 patients after a safe and clinically relevant dose is identified during the dose finding part of the study.
62743661|NCT04657705|EXPERIMENTAL|High power ablation|High power ablation parameters (50-55 W)
62743662|NCT04657705|ACTIVE_COMPARATOR|Standard ablation power|Standard ablation power parameters (40-45 W)
62743663|NCT00007696||1|
62743664|NCT01722526|EXPERIMENTAL|Recombinant human acid sphingomyelinase|Participants will receive rhASM of an initial dose of 0.1 mg/kg, followed by several dose escalations, as tolerated, up to 3.0 mg/kg. All doses are given 2 weeks apart.
62743665|NCT02696057|ACTIVE_COMPARATOR|Manual technics|Manual technics was consisted of soft tissue technics, muscle energy technics, joint mobilization.
62743666|NCT02696057|ACTIVE_COMPARATOR|Exercise|Spinal stabilization exercises were applied all the patients in this group accompanied by physiotherapist.
62743667|NCT00271856|EXPERIMENTAL|0|Mindfulness Based Stress Reduction (MBSR)
62743668|NCT00271856|ACTIVE_COMPARATOR|1|HIV education/self-management workshop
62743669|NCT01764477|EXPERIMENTAL|PRI-724 and Gemcitabine|This study will have one arm: all enrolled subjects will be treated with both PRI-724 and Gemcitabine.
62743670|NCT03982719|EXPERIMENTAL|Brief protocol|4 intervention sessions with the occupational therapist of 30 minutes duration.
62743671|NCT03982719|ACTIVE_COMPARATOR|Intense Protocol|6 intervention sessions with the occupational therapist of 60 minutes duration.
62743672|NCT02965742|EXPERIMENTAL|The study population: first 25 patients|"The study population consists of patients referred to the Nuclear Medicine and Medical Biophysics Department of the Montpellier University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body and sub-regions exams using the Stratos Intervention: Whole body and sub-regions exams using the Hologic QDR 4500A Intervention: Whole body and sub-regions exams using the Hologic HORIZON A"
62743673|NCT02965742|EXPERIMENTAL|The study population: last 25 patients|"The study population consists of sportsmen patients referred to the Nuclear Medicine and Medical Biophysics Department of the Montpellier University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body and sub-regions exams using the Stratos Intervention: Whole body and sub-regions exams using the Hologic QDR 4500A Intervention: Whole body and sub-regions exams using the Hologic HORIZON A"
62743674|NCT04585269|EXPERIMENTAL|Bright IDEAS-YA|Intervention consists of six 45-minute one-on-one sessions between a patient and a trainer, who teaches the Bright IDEAS stepwise approach to problem-solving and guides the participant through solving their own problems using the Bright IDEAS approach and worksheets. In addition, participants in this arm will receive a standardized list of resources from the National Comprehensive Cancer Network (NCCN) adolescent and young adult patient guidelines.
62743675|NCT04585269|NO_INTERVENTION|Enhanced Usual Care|Participants in this arm will receive a standardized list of resources from the National Comprehensive Cancer network (NCCN) adolescent and young adult patient guidelines.
62743676|NCT06080464|EXPERIMENTAL|VERABAND information|"Consented patient participants will be given a VERABAND™ activity monitor during an initial clinic visit (baseline) and will then be tracked longitudinally after beginning a new pain treatment regime as part of their normal ongoing care. VERABAND™ activity data reports (including a summary broken down by week) will subsequently be provided to treating clinicians prior to each patient's follow-up clinic visit.~The arm is all of the clinicians of the participants."
62743677|NCT05795569|EXPERIMENTAL|Intervention Group|
62743678|NCT05795569|ACTIVE_COMPARATOR|Control Group|
62743679|NCT02131103|ACTIVE_COMPARATOR|Early ( < 24hr)|Early percutaneous coronary intervention means performed coronary intervention between 3-24 hours after successful fibrinolytic therapy.
62743680|NCT02131103|ACTIVE_COMPARATOR|Delay ( > 24 hours)|Delay percutaneous coronary intervention means received coronary intervention \>24 hours to 2 weeks after successfully fibrinolytic therapy.
62743681|NCT02131103|ACTIVE_COMPARATOR|Early|"We randomized the patients into two groups early (≤ 24 hours) and delay group (\> 24 hours) All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct."
62743682|NCT02688699|EXPERIMENTAL|EndoClot|spraying of Endoclot powder after EMR or ESD
62743683|NCT02688699|NO_INTERVENTION|control|
62743684|NCT00868140|EXPERIMENTAL|1/Pioglitazone|Pioglitazone in pill form at 45mg twice per day for 6 months
62743685|NCT00868140|PLACEBO_COMPARATOR|2/Placebo|Placebo control to arm 1 in pill form identical to treatment form also twice per day for 6 months
62743686|NCT00651430||A|
62369830|NCT01921283|ACTIVE_COMPARATOR|No-BIS group|The no-BIS group (n=90) was monitored by observer's assessment alertness/sedation scale (OAA/S).
62369831|NCT06135454|EXPERIMENTAL|Open Wedge High Tibial Osteotomy|
62369832|NCT06135454|EXPERIMENTAL|Double Level Osteotomy|
62369833|NCT04440462|EXPERIMENTAL|Sugar and water solution|2 ml of a water and sugar solution (3 full-teaspoons of granulated sugar dissolved in half glass of water)
62369834|NCT04440462|ACTIVE_COMPARATOR|Sterile water|2 ml of sterile water
62369835|NCT00902057|ACTIVE_COMPARATOR|desmopressin 1.5|
62369836|NCT00902057|ACTIVE_COMPARATOR|desmopressin 3|
62369837|NCT00902057|ACTIVE_COMPARATOR|desmopressin 15|
62369838|NCT00902057|PLACEBO_COMPARATOR|placebo|
62369839|NCT05846269||2023 Clinical Cohort|Students in the Doctor of Nursing Practice (DNP) nurse practitioner specialties and certificate programs in the clinical year of their programs during 2023.
62369840|NCT04655846|ACTIVE_COMPARATOR|Control group|Usual manage during prenatal control program
62369841|NCT04655846|EXPERIMENTAL|Intervention group|Educational intervention towards the maintenance of exclusive breastfeeding in the first six months in first pregnant adolescents enrolled in the prenatal control program
62369842|NCT02622048|EXPERIMENTAL|Stage 2 Parents experiencing psychosis|Parents all receive the self-directed Triple P Positive Parenting Programme
62369843|NCT00559013|ACTIVE_COMPARATOR|1|PSD Veritas Collagen Matrix Reinforcement Arm
62369844|NCT02131389|OTHER|Iconacy Hip System|Iconacy hip system prosthesis components
62369845|NCT01789749|ACTIVE_COMPARATOR|No Coagulation Arm|Patients do not receive Snare Tip Soft Coagulation to the edge of the endoscopic resection defect
62369846|NCT01789749|EXPERIMENTAL|Coagulation Arm|Patients to receive Snare Tip Soft Coagulation to the edge of the endoscopic resection defect
62369847|NCT03144830|EXPERIMENTAL|Overground walking program|Study participant will be involved in an indoor, overground walking program using an exoskeleton wearable walking device under the supervision of a physiotherapist.
62369848|NCT04530968||Emerged from Minimally Conscious State (EMCS)|Emerged from Minimally Conscious State (EMCS): recovery of functional object uses or communication from chronic
62369849|NCT04530968||Minimally conscious state (MCS)|Minimally conscious state (MCS): have reproducible signs of awareness and exhibit fluctuations in consciousness
62743687|NCT02901587|EXPERIMENTAL|Lu AF35700 (10 mg/day)|Lu AF35700 10 mg/day for 6 weeks
62743688|NCT02901587|EXPERIMENTAL|Lu AF35700 (30 mg/day)|Lu AF35700 30 mg/day for 6 weeks
62743689|NCT02901587|EXPERIMENTAL|Quetiapine (Seroquel XR® 800 mg/day)|Quetiapine (Seroquel XR®) 800 mg/day for 6 weeks
62743690|NCT00876850|EXPERIMENTAL|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
62369850|NCT04530968||Vegetative state (VS)|Vegetative state (VS): can open their eyes and preserve sleep-wake cycles, but unaware of themselves and their surroundings
62369851|NCT04530968||Healthy controls (HCs)|Healthy controls (HCs)
62369852|NCT00741104||RA patients|Patients on maintenance therapy for RA with infliximab for \>= the past 12 months.
62369853|NCT00606294|EXPERIMENTAL|Cohort 1 (closed to accrual)|Cohort 1 (closed to accrual) Cohort 1 (closed to accrual) There will be no change or intervention in a patient's treatment regime using chemoradiation where both the primary and the neck nodes receive 70Gy. This is currently one accepted standard of care. In a subcohort of patients in Cohort 1 with tumors that are positive for HPV who exhibited no evidence of hypoxia on their baseline 18F-FMISO PET/ CT scan or whose tumors have early resolution of hypoxia on their repeat early response 18F-FMISO PET/CT scan will undergo an alternative treatment where the primary tumor site receives 70Gy while the neck nodes receive 60Gy followed by a planned FDG PET/CT scan and observation.
62369854|NCT00606294|EXPERIMENTAL|Cohort 2 (closed to accrual)|Experimental: Cohort 2 (closed to accrual) Cohort 2 HPV+ tumors that demonstrate no evidence of hypoxia on an 18F-FMISO PET scan will receive 30Gy to the surgical bed and neck lymph nodes concurrent with standard chemotherapy followed by a 3-4 month post-treatment neck dissection. In patients who exhibit a complete response with this method of treatment, no further treatment is necessary. For patients within this select group who still have pathologic nodal disease, further standard chemoradiation will be given. All other patients in this cohort (i.e. those who are not in the select HPV+ tumor group outlined above) will receive standard of care treatment following their surgery.
62369855|NCT03809156|EXPERIMENTAL|Combo Riociguat and Ambrisentan Therapy|Riociguat Oral Product and Ambrisentan Oral Product to be given in combination to de novo (untreated) patients.
62369856|NCT05124262|EXPERIMENTAL|Low-FODMAPdiet group|Low-FODMAPdiet intervention as group treatment in three steps during 12 weeks, elimination, re-introduction and personalization of the diet. This group of participants starts immediate.
62369857|NCT05124262|EXPERIMENTAL|Delayed start of treatment low-FODMAPdiet group|Delayed start of treatment. This arm starts after three months
62369858|NCT04634019|NO_INTERVENTION|Control arm|Providers in control facilities will not receive any additional training or knowledge assessments.
62369859|NCT04634019|EXPERIMENTAL|Financial incentive arm|Providers in treatment facilities will be visited once a quarter for a knowledge assessment using vignettes. Facilities performing well in this assessment will receive a quarterly bonus payment, which will be distributed among providers.
62369860|NCT03665207|EXPERIMENTAL|Tight glucose control|Target normal fasting blood glucose concentrations (80-110 mg/dl) with insulin therapy, administered through continuous intravenous infusion.
62369861|NCT03665207|ACTIVE_COMPARATOR|Liberal glucose control|Tolerate hyperglycemia up to 215 mg/dl. In patients requiring insulin therapy, insulin will be titrated to target blood glucose concentrations between 180 and 215 mg/dl.
62369862|NCT05837000|EXPERIMENTAL|Dexmedetomidine|0.5 ml/kg bupivacaine 0.25% + 1μg/kg dexmedetomidine caudally
62369863|NCT05837000|EXPERIMENTAL|Ketamine|0.5 ml/kg bupivacaine 0.25% + 1μg/kg dexmedetomidine caudally
62369864|NCT05837000|EXPERIMENTAL|Magnesium sulphate|0.5ml/kg bupivacaine 0.25% + 1ml volume containing 50mg of magnesium caudally.
62369865|NCT02143141|ACTIVE_COMPARATOR|duramorph|duramorph 150 mcg administered spinally with placebo capsules administered by mouth every 6 hours x 4 doses during first 24 hours
62743691|NCT00876850|ACTIVE_COMPARATOR|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
62743692|NCT01390831|EXPERIMENTAL|Catheter, Renal Denervation, Ablation|Catheter-based renal denervation and maintenance of anti-hypertensive medications
62743693|NCT01390831|NO_INTERVENTION|anti-hypertensive medications|Maintenance of anti-hypertensive medications
62743694|NCT05826613||adults with COPD and asthma|Male or female aged \>18 years with clinical diagnosis of either COPD or asthma.
62743695|NCT03155087||T2DM patients|Metformin dosages ranged from 500 to 2000 mg per day
62743696|NCT03155087||healthy subjects|the healthy subjects was not intervened
62743697|NCT05172245|EXPERIMENTAL|Dose Escalation (ipatasertib, cisplatin, radiation therapy)|Patients receive ipatasertib PO QD or Monday, Wednesday, and Friday depending on dose level on days 1-28 of each cycle. Patients also receive cisplatin IV weekly on day 1 of cycle 1, weeks 1-4 and day 1 of cycle 2, weeks 1-3 for 7 doses. Patients undergo RT daily (Monday-Friday) for 35 fractions during weeks 1-7. Treatment repeats every 28 days for a total of 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT, CT, or MRI during screening, follow-up, and as clinically indicated. Patients undergo blood sample collection on trial.
62743698|NCT05172245|EXPERIMENTAL|Dose Expansion (ipatasertib, cisplatin, radiation therapy)|Patients receive ipatasertib PO MTD on days 2-28 or 3-28 of cycle 1 and 1-28 of subsequent cycles. Patients also receive cisplatin IV weekly on day 1 of cycle 1, weeks 1-4 and day 1 of cycle 2, weeks 1-3 for 7 doses. Patients undergo RT daily (Monday-Friday) for 35 fractions during weeks 1-7. Treatment repeats every 28 days for a total of 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT, CT, or MRI during screening, follow-up, and as clinically indicated. Patients undergo blood sample collection and tumor biopsy on trial.
62743699|NCT02664311|PLACEBO_COMPARATOR|Conventional Ventilation|Patients receiving conventional ventilation for the duration of this study
62743700|NCT02664311|ACTIVE_COMPARATOR|Jet Ventilation|Patients receiving Jet ventilation while under general anesthesia and during mapping and ablation in the left atrium
62743701|NCT05446766|EXPERIMENTAL|Self-guided Exposure-based Digital Intervention for Health Anxiety|Eight weeks of self-guided exposure-based intervention delivered digitally, via the Internet.
62743702|NCT01889264||Critically Ill Pediatric Patients|Critically ill septic pediatric patients, Age 1 month-3 years, Age 4-12 years and Age 13-19 years, males and females
62743703|NCT04621240|EXPERIMENTAL|Online SMART Intervention & Stress Solutions|Strategic Memory Advanced Reasoning Training (SMART) teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance
62743704|NCT01397110|ACTIVE_COMPARATOR|Respiratory and exercise therapy|Randomized, prospective, controlled, blinded study of three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional rehabilitation without a specific training program. After 15 weeks training is also offered to patients in the control group.
62743705|NCT01397110|NO_INTERVENTION|Control group without exercise training|"patients of the control group continue their sedentary lifestyle without given advice for exercise training.~The time before start of rehabilitation (three months) serves as control group. Afterwards patients take part in the training program as well."
62743706|NCT04956276|EXPERIMENTAL|Cohort 1: ALXN1830/Placebo|Participants will be randomized 3:1 to receive ALXN1830 or placebo. Treatment will be received for 8 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period.
62743707|NCT04956276|EXPERIMENTAL|Cohort 2: ALXN1830/Placebo|Participants will be randomized 3:1 to receive ALXN1830 or placebo. Treatment will be received for 8 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period.
62743708|NCT04956276|EXPERIMENTAL|Cohort 3: ALXN1830|If initiated, participants will receive ALXN1830. Treatment will be received for 12 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period.
62743709|NCT06626321|NO_INTERVENTION|Control|Clinics randomized to the control arm will receive standard of care.
62743710|NCT06626321|EXPERIMENTAL|Intervention Arm|Clinics randomized to the intervention arm will receive the toolkit of clinician and patient facing nudges. Patient nudges will be pre-visit text message reminders (standard messaging content). Clinician nudges will be monthly peer comparison feedback and default pended orders.
62743711|NCT06626321|EXPERIMENTAL|High Risk Intensification Arm|Patients in the intervention clinics identified as high risk for noncompletion of the flu vaccine will be randomized 1:1 to receive the high risk intensification arm or remain in the standard intervention arm. Patients in the high risk intensification arm will receive an additional bidirectional texting component.
62369866|NCT02143141|EXPERIMENTAL|no duramorph|no duramorph is administered spinally for surgery; subjects receive acetaminophen 1 G orally x 4 doses during first 24 hours postoperatively
62743712|NCT05805696|EXPERIMENTAL|Treatment for five weeks|The patients will get questionnaires before and 12 weeks and 24 weeks after intervention. The intervention will last for 5 weeks.
62743713|NCT06557057||Observational|Patients undergo blood sample collection, glucose testing, DEXA scan to measure body composition, complete a questionnaire and have their medical records reviewed on study.
62743714|NCT00840268|EXPERIMENTAL|HPGG 0.25%|Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel, 1 drop per eye twice daily (BID) (in the morning upon awakening and in the evening prior to bedtime) for 21 days (Treatment phase).
62743715|NCT00840268|PLACEBO_COMPARATOR|HPGG Vehicle|Hydroxypropyl Guar Galactomannan Vehicle, 1 drop per eye twice daily (BID) (in the morning upon awakening and in the evening prior to bedtime) for 21 days (Treatment phase).
62743716|NCT02986672|ACTIVE_COMPARATOR|Calanus oil|Children receiving omega-3 in form om calanus oil in capsule form
62743717|NCT02986672|PLACEBO_COMPARATOR|Placebo|Children receiving medical paraffin in capsule form (2 ml volume per day)
62369867|NCT04996524|EXPERIMENTAL|epidural analgesia group|
62369868|NCT04996524|NO_INTERVENTION|systemic analgesia group|
62369869|NCT00772811|NO_INTERVENTION|Flu-Mel|Conditioning chemotherapy before infusion of allogeneic stem cells will include fludarabine 30 mg/m2/day for 5 consecutive days (days -6 to -2) and melphalan 100 mg/m2 at day -2.
62743718|NCT05329480|EXPERIMENTAL|Creatine Monohydrate Supplementation|Blinded subjects are instructed to ingest 20g of creatine monohydrate for 7 days divided into 4 dosages of 5g each that should be taken with water or other liquids throughout the day (breakfast, lunch, afternoon and evening).
62369870|NCT01589692|EXPERIMENTAL|Internal Fixation|Open Reduction and Internal Fixation: Internal fixation with a volar locking plating system
62369871|NCT01589692|EXPERIMENTAL|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
62369872|NCT01589692|EXPERIMENTAL|Pinning|Percutaneous pinning with any number of Kirschner wires
62369873|NCT01589692|ACTIVE_COMPARATOR|No Surgery|Closed Reduction and casting: Closed reduction and immobilization with a cast and/or splint
62369874|NCT04903886||All patient colonized with ESBL-E in Brest Intensive Care unit|All patient colonized with ESBL-E in Brest Intensive Care unit, in a 5 years period (2015-2019)
62369875|NCT00649610|ACTIVE_COMPARATOR|Arm 1|
62369876|NCT00649610|ACTIVE_COMPARATOR|Arm 2|
62369877|NCT04420208|EXPERIMENTAL|Modified Pap test|Adding a non-painful event after the most uncomfortable phase of Pap smear.
62369878|NCT04420208|NO_INTERVENTION|Traditional Pap test|Traditional Pap-smear procedure as control.
62369879|NCT01477073|EXPERIMENTAL|FSH-GEX 75 IU|follitropin epsilon 75 IU QD
62369880|NCT01477073|EXPERIMENTAL|FSH-GEX 150 IU|follitropin epsilon 150 IU QD
62369881|NCT01477073|EXPERIMENTAL|FSH-GEX 150 IU QAD|follitropin epsilon 150 IU QAD
62369882|NCT01477073|ACTIVE_COMPARATOR|recombinant FSH|Gonal-f 150 IU QD
62369883|NCT01477073|ACTIVE_COMPARATOR|urinary FSH|Bravelle 150 IU QD
62369884|NCT01477073|PLACEBO_COMPARATOR|Placebo|Placebo QD
62369885|NCT05711719|EXPERIMENTAL|Vericiguat|Initial 2.5 mg/day for two weeks, then 5 mg/day for two weeks, and then 10 mg/day for two weeks. Systolic blood pressure will be measured before and following each titration The participant will receive the final titration dose for a total of six weeks.. The drug is administered as an oral tablet once daily.
62369886|NCT05711719|PLACEBO_COMPARATOR|Placebo|A placebo tablet will be administered orally once daily.
62743719|NCT05329480|PLACEBO_COMPARATOR|Maltodextrin Supplementation|Blinded subjects are instructed to ingest 20g of maltodextrin for 7 days divided into 4 dosages of 5g each that should be taken with water or other liquids throughout the day (breakfast, lunch, afternoon and evening).
62743720|NCT05329480|NO_INTERVENTION|Control|Participants in the control group do not receive a supplement (creatine or placebo) to ingest over the 7 day period.
62743721|NCT03987802||Fiasp®|Adult patients with diabetes mellitus (type 1 and type 2) under routine clinical practice in India.
62743722|NCT02339142|EXPERIMENTAL|Combined radiotherapy and iv corticosteroid|"Therapy: iv MP 500 mg iv weekly for 6 weeks, then 250 mg iv weekly for 6 weeks~+ External beam radiotherapy: 100 Rads to each orbit x 10 doses"
62743723|NCT02339142|ACTIVE_COMPARATOR|iv Corticosteroid|iv MP 500 mg iv weekly for 6 weeks, then 250 mg iv weekly for 6 week No Radiotherapy administered
62369887|NCT04324268|PLACEBO_COMPARATOR|Placebo|Placebo
62369888|NCT04324268|EXPERIMENTAL|SC 0.3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 0.3 mg/kg of lirentelimab (AK002) administered subcutaneously.
62369889|NCT04324268|EXPERIMENTAL|SC 1 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 1 mg/kg of lirentelimab (AK002) administered subcutaneously.
62369890|NCT04324268|EXPERIMENTAL|SC 3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered subcutaneously.
62369891|NCT04324268|EXPERIMENTAL|SC 5 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 5 mg/kg of lirentelimab (AK002) administered subcutaneously.
62369892|NCT04324268|EXPERIMENTAL|IV 1 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 1 mg/kg of lirentelimab (AK002) administered intravenously.
62369893|NCT04324268|EXPERIMENTAL|IV 3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered intravenously.
62369894|NCT04324268|EXPERIMENTAL|IV 3 mg/kg of lirentelimab (AK002) (Priming)|Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered intravenously from an IV bag prepared with extra volume for priming IV set.
62369895|NCT04324268|EXPERIMENTAL|SC 300 mg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 300 mg of lirentelimab (AK002) administered subcutaneously.
62369896|NCT04324268|EXPERIMENTAL|SC 450 mg of lirentelimab (AK002)|Subjects in this arm will receive a total of 450 mg of lirentelimab (AK002), administered as two separate subcutaneous injections.
62369897|NCT02912962|EXPERIMENTAL|Intervention Group|"Cognitive testing 1, 12 intervention sessions, Cognitive testing 2, Approximately a 12 week wait (no intervention), Cognitive testing 3.~The intervention is a 12 week, individualized, one-on-one self-regulation intervention where adolescents will learn to attain, change, or maintain an appropriate level of alertness ."
62369898|NCT02912962|EXPERIMENTAL|Waitlist|Cognitive testing 1, Approximately a 12 week wait (no intervention), Cognitive testing 2, 12 intervention sessions, Cognitive testing 3
62369899|NCT02288442|NO_INTERVENTION|control|
62369900|NCT02288442|EXPERIMENTAL|exercise|exercise intervention during 8 weeks
62369901|NCT01253967||Group A|Subjects who are hospitalised for acute gastroenteritis
62369902|NCT01253967||Group B|Subjects who visit an emergency room for acute gastroenteritis
62369903|NCT01253967||Group C|Subjects who have rotavirus positive laboratory results and developed acute gastroenteritis at least 48 hours after hospitalisation.
62369904|NCT02365805|ACTIVE_COMPARATOR|Standard FEC Regimen|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
62369905|NCT02365805|EXPERIMENTAL|No or Low BRCA1 expression|Epirubicin + Cisplatin + Fluorouracil
62369906|NCT02365805|EXPERIMENTAL|Normal or High BRCA1 expression|Docetaxel + Ciclofosfamide
62743724|NCT06127381|EXPERIMENTAL|1/4 therapeutic dose (TGKP)|"First 5 (five) healthy volunteers will receive (a single intravenous administration) 1/4 therapeutic dose.~Before administration the study drug will be dosed and diluted in 200 ml of isotonic solution of 0.9% sodium chloride, and then will be administered once intravenously via infusion."
62369907|NCT01619527|EXPERIMENTAL|Treatment A|Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fasted condition)
62369908|NCT01619527|EXPERIMENTAL|Treatment B|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fasted condition).
62369909|NCT01619527|EXPERIMENTAL|Treatment C|Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fed condition - standardized breakfast).
62369910|NCT01619527|EXPERIMENTAL|Treatment D|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - standardized breakfast).
62369911|NCT01619527|EXPERIMENTAL|Treatment E|Single-dose co-administration of the fixed dose combination darunavir/cobicistat 800/150-mg (under fasted condition).
62743725|NCT06127381|EXPERIMENTAL|1/2 therapeutic dose (TGKP)|"Next 5 (five) healthy volunteers will receive (a single intravenous administration) 1/2 therapeutic dose.~Before administration the study drug will be dosed and diluted in 200 ml of isotonic solution of 0.9% sodium chloride, and then will be administered once intravenously via infusion."
62369912|NCT01619527|EXPERIMENTAL|Treatment F|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - high-fat breakfast).
62369913|NCT01306604||Observation|Patients from the first day of life with Niemann Pick Type C syndrome NPC1/NPC2 or profound suspicion for Niemann Pick Type C syndrome NPC1/NPC2 disease
62369914|NCT04031924||Liver Transplantation|Sixteen individuals with liver transplantation were included in the study, and their physical and demographic characteristics of the individuals recorded. The Senior Fitness Test (SFT) was used to evaluate to physical fitness. The Tampa Scale for Kinesiophobia (TSK) was used to assess kinesiophobia; the Fatigue Impact Scale (FIS) and Fatigue Severity Scale (FSS) to evaluate fatigue; the Berg Balance Scale (BBS) and the Timed Up and Go test (TUG) to evaluate the balance; the International Physical Activity Questionnaire (IPAQ) to determine the level of physical activity;and the Hospital Anxiety and Depression Scale (HADS) to evaluate psychological status.
62369915|NCT04031924||Healthy Subjects|Sixteen age- and sex-matched healthy subjects were included in the study.
62743726|NCT06127381|EXPERIMENTAL|Full therapeutic dose (TGKP)|"Next 15 (fifteen) healthy volunteers will receive (a single intravenous administration) the full therapeutic dose.~Before administration the study drug will be dosed and diluted in 200 ml of isotonic solution of 0.9% sodium chloride, and then will be administered once intravenously via infusion."
62743727|NCT05175222|EXPERIMENTAL|Laser|Patients receive low-level laser therapy with LightWalker laser from the first day of conditioning chemotherapy till +2 day post hematopoietic stem cell transplantation. Additionally, standard supportive care is introduced.
62743728|NCT05175222|NO_INTERVENTION|Control|Patients are observed and receive standard supportive care.
62743729|NCT04564807|ACTIVE_COMPARATOR|Web-Based Insomnia Education Program|Adult heavy drinkers with insomnia.
62743730|NCT04564807|EXPERIMENTAL|SHUTi Intervention|Adult heavy drinkers with insomnia.
62743731|NCT01608698|EXPERIMENTAL|Belara|The participants who receive OCP in combination of 30 mcg ethinylestradiol/2 mg chlormadinone acetate (Belara®).
62743732|NCT01608698|EXPERIMENTAL|Yasmin|The participants who receive OCP in combination of 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin®).
62743733|NCT01202019|EXPERIMENTAL|Supplement|Participants randomized to the 'supplement' arm will consume a blended drink containing 48g of ionexchange, hydrolyzed vanilla-flavored whey protein (Whey to Go, Solgar Vitamin and Herb, Leonia, NJ; 3g CH2O, \< 3g Total Fat). The drink will be given in split doses immediately before and after each training session, which represents a timing schedule that best stimulates muscle anabolism in persons undergoing exercise training.
62743734|NCT01202019|PLACEBO_COMPARATOR|Placebo|As ingestion of the protein supplement is critically influenced by time of administration, participants assigned to the 'placebo' study arm will consume the identical supplement and dose on days during which training is not performed. This strategy will allow the groups to be isocaloric and equal in protein supplementation.
62743735|NCT04153175|ACTIVE_COMPARATOR|CT-010 Active Therapy|Subjects in the active comparator arm will have been randomized to receive active therapy through the implanted drug delivery system through the 3-month blinded period.
62743736|NCT04153175|PLACEBO_COMPARATOR|Placebo|Subjects in the placebo comparator arm will have been randomized to receive placebo therapy through the implanted drug delivery system for the 3-month blinded period.
62743737|NCT03428477|EXPERIMENTAL|Icosapent Ethyl (EPA-EE)|Soft gelatin capsules containing 1g pure EPA-EE equivalent to 914mg EPA-FFA. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.
62743738|NCT03428477|PLACEBO_COMPARATOR|Placebo|Soft gelatin capsules containing light mineral oil. 4 capsules to be taken per day (2 in the morning and 2 in the evening).
62369916|NCT02945943|EXPERIMENTAL|Mobilization|High Velocity Low Amplitude mobilization group. The three joints manipulated included proximal tibiofibular, the distal tibiofibular, and talocrural joints and were mobilized the first three sessions prior to the participants performing the exercise protocol.
62369917|NCT02945943|ACTIVE_COMPARATOR|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
62369918|NCT01720472||Community, Physical Performance|
62369919|NCT04247321|EXPERIMENTAL|Subjects with acute brain injury|Subjects requiring placement of a Licox Brain Tissue Oxygen device for their clinical care will also have Near-infrared spectroscopy (NIRS) monitoring system placed
62369920|NCT04518592||Severe Major Depressive Disorder|subjects who meet the standards;using conventional antidepressant.
62743739|NCT02650154||Pre-ketamine group|Blood samples are taken prior to the administration of ketamine.
62743740|NCT02650154||Post-ketamine group|Blood samples are taken several hours after the administration of ketamine.
62743741|NCT02865954|EXPERIMENTAL|iball intervention|Use of iball pelvic floor training mhealth application for 16 weeks.
62743742|NCT02865954|NO_INTERVENTION|Standard Care|Standard Care - control group
62743743|NCT02975739|EXPERIMENTAL|Holmium-166 microspheres|Single session of 4 intratumoral injections consisting of 0.1-0.3 ml radioactive Holmium-166 microsphere suspension with a total activity 30 Megabecquerel, 7-12 days prior to surgical resection.
62743744|NCT02582814|EXPERIMENTAL|dapagliflozin 5mg + insulin|dapagliflozin tablet 5mg + adjustable insulin
62743745|NCT02582814|EXPERIMENTAL|dapagliflozin 10mg + insulin|dapagliflozin tablet 10mg + adjustable insulin
62743746|NCT04821102|EXPERIMENTAL|JOINTSTEM|Autologous Adipose Tissue derived MSCs
62743747|NCT04821102|PLACEBO_COMPARATOR|Saline|saline
62369921|NCT04518592||control , healthy|subjects who meet the standards;gender, race, and level of education matched healthy people
62369922|NCT06005038|EXPERIMENTAL|pSOPT|personalized cognitive training with a close-loop parasympathetic nervous system monitored component
62369923|NCT06005038|PLACEBO_COMPARATOR|MLA|computerized mental leisure activities
62369924|NCT04985513|NO_INTERVENTION|Group N|Stopping ventilation during cardiopulmonary bypass
62369925|NCT04985513|ACTIVE_COMPARATOR|Group V|Ventilation was performed using an inhaled oxygen fraction of 20% and a tidal volume of 5ml/kg at the time of cardiopulmonary bypass.
62369926|NCT01611311|PLACEBO_COMPARATOR|Placebo (Young subjects)|Young healthy subjects received placebo matching film-coated tablets of BI 409306 orally after an overnight fast once daily for 14 days
62369927|NCT01611311|EXPERIMENTAL|BI 409306 - 25 milligram (mg) (Young subjects)|Young healthy subjects received 25 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
62369928|NCT01611311|EXPERIMENTAL|BI 409306 - 50 milligram (mg) (Young subjects)|Young healthy subjects received 50 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
62369929|NCT01611311|PLACEBO_COMPARATOR|Placebo (Elderly subjects)|Elderly healthy subjects received placebo matching film-coated tablets of BI 409306 orally after an overnight fast once daily for 14 days
62369930|NCT01611311|EXPERIMENTAL|BI 409306 - 25 milligram (mg) (Elderly subjects)|Elderly healthy subjects received 25 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
62369931|NCT01611311|EXPERIMENTAL|BI 409306 - 50 milligram (mg) (Elderly subjects)|Elderly healthy subjects received 50 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
62369932|NCT01733524|SHAM_COMPARATOR|Picture of a fish|Participants will receive a picture of a betta fish.
62369933|NCT01733524|ACTIVE_COMPARATOR|Pet fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
62369934|NCT01407289|EXPERIMENTAL|Insulin titration protocol|Patients in care at the Division of Endocrinology will be treated by enhanced version of published best paper based practice insulin titration protocol to control glycaemia in hospitalised patients with type 2 diabetes.
62369935|NCT01407289|NO_INTERVENTION|Standard care|Patients in care of the Division of Cardiology will be treated using antihyperglycaemic therapy according to standard care.
62369936|NCT04063865|ACTIVE_COMPARATOR|Control Arm|Tacrolimus as maintenance immunosuppression
62369937|NCT04063865|EXPERIMENTAL|Study Arm|Everolimus monotherapy maintenance immunosuppression
62369938|NCT01210976|EXPERIMENTAL|levosimendan|
62743748|NCT05588960||Term/Near-Term Group|Cohort of term/near-term infants undergoing therapeutic hypothermia for moderate to severe HIE. Data collected from NIRS monitoring and other assessments/investigations that are part of routine clinical care. There are no additional study specific interventions or exposures for this group.
62369939|NCT01210976|PLACEBO_COMPARATOR|placebo|
62369940|NCT01402323|OTHER|early or late tooth extraction|
62369941|NCT01492816|EXPERIMENTAL|Intervention Group|Community members who become engaged in the coalitions and in the broader mobilization effort. A subset of community members.
62369942|NCT03596255||Patients|All public dental clinics in the region of Östergötland, Sweden, were asked to consecutively recruit adult patients returning for their annual examination
62369943|NCT03596255||Dental personnel|All public dental clinics in the region of Östergötland, Sweden were contacted and asked to participate in the study
62369944|NCT02796079|EXPERIMENTAL|Autologous Bone Marrow Stem Cell|Mesenchymal stem cells derived from bone marrow infusion
62369945|NCT02796079|PLACEBO_COMPARATOR|saline|saline injections
62369946|NCT03375762|EXPERIMENTAL|Usual care plus RIPerC|Usual care for stroke code patients, with or without revascularization therapies, with Remote ischemic perconditioning (RIPerC) using an electronic tourniquet.
62369947|NCT03375762|SHAM_COMPARATOR|Usual care plus Sham RIPerC|Usual care for stroke code patients, with or without revascularization therapies, with Sham remote ischemic conditioning (RIPerC)
62369948|NCT04400227|EXPERIMENTAL|Youth-Parent Dyads|Participants will receive the Family Talk intervention and followup.
62369949|NCT02930811|EXPERIMENTAL|Sildenafil|Single Sildenafil oral morning intake (100mg/day) per day for a total duration of 6 months (Sildenafil 100 mg oral morning dose)
62369950|NCT02930811|PLACEBO_COMPARATOR|Placebo|Single Placebo oral morning intake per day for a total duration of 6 months (Placebo oral morning dose)
62369951|NCT02359136|PLACEBO_COMPARATOR|LIA placebo|local infiltration anesthesia using saline i addition to multimodal analgesic regimen
62743749|NCT05588960||Preterm Group (Sub-study 1, First 72 hours after birth)|Cohort of infants born at less than 28 weeks gestational age. Data collected from NIRS monitoring, other physiological monitoring, cranial ultrasound scans and neurodevelopmental follow up assessments that are part of routine clinical care. This data will be analysed to fulfil secondary study objectives. There are no additional study specific interventions or exposures for this group.
62743750|NCT05588960||Preterm Group (Sub-study 2, Skin-to-skin care)|Cohort of infants born at less than 28 weeks gestational age who are considered by clinical team to be suitable to undergo period of skin-to-skin care. Participants will undergo additional research-specific period(s) of NIRS monitoring before, during and after period(s) of skin-to-skin care. Participants with and without severe brain injury on cranial ultrasound will be recruited to allow comparison.
62369952|NCT02359136|EXPERIMENTAL|LIA Ropivacaine|local infiltration anesthesia using Ropivacaine and Epinephrine i addition to multimodal analgesic regimen
62369953|NCT00407641|EXPERIMENTAL|Tinzaparin|Patients will receive Tinzaparin as anticoagulant during the HD session.
62369954|NCT00407641|ACTIVE_COMPARATOR|Heparin|Patients will receive Heparin as an anticoagulant during the HD session
62369955|NCT06419790|EXPERIMENTAL|Healthy volunteers|Data were obtained at two phases at supine semi-sitting position during 15 min sponatenous breathing and 1 min forced breathing. Subjects were breathing through spirometric probe first without electrode belt, and second with electrode belt placed tightly around the thorax as recommened by the manufacturer.
62369956|NCT03216395|EXPERIMENTAL|Over-the-scope Clips|Endoscopic Application of Over-the-scope Clips
62743751|NCT05588960||Preterm Group (Sub-study 3, Bronchopulmonary dysplasia)|Cohort of infants born at less than 28 weeks gestational age who will undergo an additional research-specific period of NIRS monitoring at 36 weeks corrected gestational age. Participants with and without bronchopulmonary dysplasia (BPD) will be recruited to allow comparison.
62743752|NCT02217059||Prehypertension|Using the JNC7 definition
62743753|NCT02217059||Stage I Hypertension|Using the JNC7 definition
62743754|NCT02217059||Stage II Hypertension|Using the JNC7 definition
62743755|NCT04019288|EXPERIMENTAL|Arm I (batiraxcept, durvalumab)|Patients receive batiraxcept IV over 60 minutes on days 1, 15, and 29 of cycle 0, and on days 1 and 15 of subsequent cycles. Beginning cycle 1, patients also receive durvalumab IV over 60 minutes on day 1. Cycle 0 continues for 6 weeks and subsequent cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62743756|NCT04019288|EXPERIMENTAL|Arm II (durvalumab, batiraxcept)|Patients receive durvalumab IV over 60 minutes on days 1 and 22 of cycle 0 and on day 1 of subsequent cycles. Beginning cycle 1, patients also receive batiraxcept IV over 60 minutes on days 1 and 15. Cycle 0 continues for 6 weeks and subsequent cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62743757|NCT05359874|EXPERIMENTAL|treatment arm|
62743758|NCT06100848|ACTIVE_COMPARATOR|Caries treatment|The Koch sedimentation method was used to evaluate the aerobic bacterial content in the dental office air. Thirty plates were opened and then sealed 40 minutes after the initiation of caries treatment.
62743759|NCT06100848|ACTIVE_COMPARATOR|Caries treatment and fumigation|The Koch sedimentation method was employed to evaluate the aerobic bacterial content in the dental office air. Thirty plates were opened and subsequently sealed 60 minutes after the commencement of caries treatment. Fumigation was conducted for 20 minutes.
62743760|NCT01905345|EXPERIMENTAL|Endurance and Resistance Training|Endurance and resistance exercise
62743761|NCT01905345|EXPERIMENTAL|Resistance Training|resistance exercise (12wk)
62369957|NCT03216395|ACTIVE_COMPARATOR|standard treatment|standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine \<=20 clips or pulse
62743762|NCT01905345|EXPERIMENTAL|Resistance and resistance Training|resistance exercise (24 wk)
62743763|NCT00857831|EXPERIMENTAL|Arm 1|Vitamin D \& Calcium supplementation in FES
62743764|NCT06658093|EXPERIMENTAL|Aim 1:Sub-study 2 Daily dosing Cohort Rapamycin|"Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men.~In sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) in milligrams of rapamycin (RAPA) based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design."
62743765|NCT06658093|EXPERIMENTAL|Aim 1: Sub-study 2 Daily dosing Cohort Everolimus|"Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men.~In sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) of everolimus (EVERO) in milligrams based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design."
62743766|NCT06658093|EXPERIMENTAL|Aim 1:Sub-study 2 Intermittent dosing Cohort Rapamycin|"Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men.~In sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) in milligrams and the optimal interval for intermittent delivery of rapamycin (RAPA) based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design."
62743767|NCT06658093|EXPERIMENTAL|Aim 1: Sub-study 2 Intermittent dosing Cohort Everolimus|"Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men.~In sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) in milligrams and the optimal interval for intermittent delivery of everolimus (EVERO) based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design."
62743768|NCT06658093|EXPERIMENTAL|Aim 2: Sub-study 3 Optimized DAILY Dose of an mTOR inhibitor|Based on the findings from Aim 1, the optimal drug (RAPA or EVERO) and dose for DAILY delivery will be tested in a blinded placebo-controlled trial in older human subjects. The drug/dose used in males may differ from the one used in females as the OD will be determined independently for the two sexes. PD parameters 'downstream' from mTOR will be followed.
62743769|NCT06658093|EXPERIMENTAL|Aim 2: Sub-study 3 Optimized INTERMITTENT Dosing of an mTOR inhibitor|Based on the findings from Aim 1, the optimal drug (RAPA or EVERO), interval between doses, and dose for INTERMITTENT delivery will be tested in a blinded placebo-controlled trial in older human subjects. The drug/dose/interval used in males may differ from the one used in females as the OD will be determined independently for the two sexes. PD parameters 'downstream' from mTOR will be followed. Although drug is delivered on an intermittent schedule, subjects will be given a pill each day (either drug or placebo, as scheduled) to maintain blinding.
62743770|NCT06658093|PLACEBO_COMPARATOR|Aim 2: Sub-study 3 Placebo control|Daily administration of a placebo will be given to a cohort of older human subjects. Both males and females will be enrolled as controls.
62743771|NCT02543866|EXPERIMENTAL|Fecal Microbiota Transplantation|Subjects will receive 50mL of prepared stool fecal via nasogastric tube
62743772|NCT04715204|ACTIVE_COMPARATOR|Formula-75/Formula-100|This arm is the control. Formula-75/Formula-100 are the standard formula recommended by WHO to treat severely malnourished children.
62369958|NCT00707486|EXPERIMENTAL|Hemcon Dental Dressing|The HemCon® Bandage is an FDA-cleared chitosan-based flat bandage that controls severe arterial bleeding from traumatic injuries. In comparison to traditional bandages, the HemCon® Bandage provides superior control of bleeding, wound site adhesiveness, multiple injury site usage, biocompatibility and provides a barrier to infective agents.
62369959|NCT00707486|ACTIVE_COMPARATOR|Gauze with pressure and/or Gelfoam|Post operative care for oral surgery subjects consists of the subject biting on sterile cotton gauze to provide pressure to the extraction site. A common alternative practice involves the placement of Gelfoam (with or without antibiotic/steroid medication) into the extraction socket prior to application of the sterile gauze pressure dressing. This treatment was chosen as the study control to compare the HemCon Dental Dressing to the standard of care for oral surgery subjects, including the use of cotton gauze and/or Gelfoam to control post operative bleeding.
62369960|NCT00728728|ACTIVE_COMPARATOR|Arm 1: Pregnenolone|Pregnenolone
62369961|NCT00728728|PLACEBO_COMPARATOR|Arm 2: Placebo|Placebo
62369962|NCT01060124|EXPERIMENTAL|Transdermal Therapeutic System (TTS)-Fentanyl D-trans|
62369963|NCT02157662||No coronary disease and risk factors >=3|
62369964|NCT02157662||Coronary disease and risk factors 0-1|Diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification38 and 0-1 risk factor (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor.
62369965|NCT02157662||No coronary disease and risk factors 0-1|
62369966|NCT02157662||Coronary disease and risk factors >=3|Subjects with diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification38 and 3 or more risk factors (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor
62369967|NCT06139939|EXPERIMENTAL|double layer technique|include 9 patients will receive lateral alveolar ridge augmentation with double bone graft layer technique for GBR (first layer autograft followed by xenograft second layer
62369968|NCT06139939|OTHER|control|include 9 patients will receive lateral alveolar ridge augmentation with stander protocol for GBR technique (mixture of autograft and xenograft
62369969|NCT02620124|NO_INTERVENTION|Natural cycle, control|Treatment cycles with normal luteal support with progesteron
62369970|NCT02620124|EXPERIMENTAL|Natural cycle, intervention|Treatment cycles with normal luteal support with progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days: Intervention is the additional 0.1 mg triptorelin as described in the previous sentence.
62369971|NCT02620124|NO_INTERVENTION|Hormone replacement cycle, control|Standard hormone replacement cycle with estrogen and progesteron
62369972|NCT02620124|EXPERIMENTAL|Hormone replacement cycle, intervention|Standard hormone replacement cycle with estrogen and progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days
62369973|NCT06353867|EXPERIMENTAL|Group Exercise|
62369974|NCT00943410|ACTIVE_COMPARATOR|Surgical Candidate|After 5 consecutive weeks of treatment with Radiation and Herceptin, these subjects will receive mastectomy excision
62369975|NCT00943410|ACTIVE_COMPARATOR|Non-Surgical Candidate|After 5 weeks of consecutive treatment with radiation and herceptin, these subjects will not be eligible for surgery. They will continue with radiation and herceptin for an additional 2 weeks.
62369976|NCT01229410|EXPERIMENTAL|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
62369977|NCT01229410|EXPERIMENTAL|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
62369978|NCT06156462||Adults|\>18 yo
62369979|NCT06156462||Adolescents|\<16 yo
62369980|NCT06263790|EXPERIMENTAL|Intubation via laryngeal mask|Participants will be required to position the endotracheal tube in the manikin via a laryngeal mask
62369981|NCT06263790|ACTIVE_COMPARATOR|Intubation via direct laryngoscope|Participants will be required to position the endotracheal tube in the manikin via direct laryngoscopy
62369982|NCT04738240|EXPERIMENTAL|Intra-operative endoscopy|The intervention arm will have an intra-operative endoscopy performed per rectum once the anastomosis has been performed. The anastomosis will be graded from 1 to 3 in the endoscopic group. Grade 1 is defined as circumferentially normal appearing peri-anastomotic mucosa. Grade 2 is defined as ischemia or congestion involving \<30% of either the colon or rectal mucosa. Grade 3 is defined as ischemia or congestion involving \>30% of the colon or rectal mucosa or ischemia/congestion involving both sides of the staple line. If appearances are grade 2 a suture re-inforcement or re-anastomosis will be performed; if appearances are grade 3 a re-anastomosis will be performed. Images will be obtained via the endoscopy stack during the assessment.
62369983|NCT04738240|NO_INTERVENTION|Standard air leak test|The control arm will receive an intra-operative leak test. This involves insufflation of air per rectum via bladder syringe while the anastomosis is bathed in sterile water. The presence of air bubbles from the anastomosis denotes a positive test.
62369984|NCT05875012|ACTIVE_COMPARATOR|Action observation arm|
62369985|NCT05875012|ACTIVE_COMPARATOR|traditional physical training|
62369986|NCT00534560|EXPERIMENTAL|1|
62369987|NCT00534560|EXPERIMENTAL|2|
62369988|NCT00534560|PLACEBO_COMPARATOR|3|
62369989|NCT01615692||36-mth follow up visit|The cohort will consist of original subjects of the SOX Trial who consent to participate in the extension to follow up sub study.
62369990|NCT00427375|EXPERIMENTAL|1|New surgical option in good responders after neoadjuvant treatment for low rectal cancer
62369991|NCT00427375|ACTIVE_COMPARATOR|2|Standard surgery
62369992|NCT03597789|OTHER|Helping the NonCompliant Child Treatment|"Families will participate in an average of 8 to 12 weeks of Behavioral Parent Training (BPT), by way of the standard-of-care training program Helping the Noncompliant Child (HNC) via weekly sessions and mid-week calls."
62369993|NCT01307410||with CAD|Patients with hypertension and dyslipidemia with prior CAD
62369994|NCT01307410||without CAD|Patients with hypertension and dyslipidemia without prior CAD
62369995|NCT02454452|ACTIVE_COMPARATOR|Saphenous vein stripping|Saphenous venous stripping surgical technique
62369996|NCT02454452|ACTIVE_COMPARATOR|CHIVA|conservative hemodynamic treatment venous insufficiency (CHIVA)
62369997|NCT02454452|EXPERIMENTAL|Radiofrequency|Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
62743773|NCT04715204|EXPERIMENTAL|High Energy Oral Nutrition Supplement|High energy oral nutrition supplement (ONS) has energy density of 1.5 kcal/ml, with protein-energy ratio of 8.9% and complete micronutrients. It is also named as enteral formula and can be used as a sole source of nutrition. It comes as a ready-to-drink bottled package of 200 mL each. The nutrition fact fulfills the requirement of BPOM (Indonesian Food and Drug Authority) for Special Medical Purpose. The ready-to-drink formula is a safe option to treat severely malnourished patient in terms of hygiene assurance of formula. In Indonesia, many severely malnourished children come from areas with poor access to clean water and proper sanitation. The high energy ONS is beneficial for children who cannot tolerate large volume of feeding.
62743774|NCT04715204|EXPERIMENTAL|Standard Energy Oral Nutrition Supplement|Standard energy oral nutrition supplement (ONS) has energy density of 1 kcal/ml, with protein-energy ratio of 9.6% and complete micronutrients. It is also named as enteral formula and can be used as a sole source of nutrition. It comes as a ready-to-drink bottled package of 200 mL each. The nutrition fact fulfills the requirement of BPOM (Indonesian Food and Drug Authority) for Special Medical Purpose. The ready-to-drink formula is a safe option to treat severely malnourished patient in terms of hygiene assurance of formula. In Indonesia, many severely malnourished children come from areas with poor access to clean water and proper sanitation.
62743775|NCT03826654|EXPERIMENTAL|fortified oil|daily intake of fortified sunflower oil (700IU vitamin D/ 35g)
62743776|NCT03826654|PLACEBO_COMPARATOR|control|daily intake of plain oil
62743777|NCT00767663|EXPERIMENTAL|1|dipyridamole
62743778|NCT00767663|PLACEBO_COMPARATOR|2|placebo
62743779|NCT05556057|EXPERIMENTAL|mindfulness meditation(MM)|
62743780|NCT05556057|ACTIVE_COMPARATOR|Health Education|
62743781|NCT01961856|ACTIVE_COMPARATOR|Ticagrelor|Ticagrelor 180mg loading dose
62743782|NCT01961856|EXPERIMENTAL|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by a Ticagrelor 180mg loading dose 2 hours later
62743783|NCT05558592|EXPERIMENTAL|Treatment_group|
62743784|NCT05558592|ACTIVE_COMPARATOR|Control_group|
62743785|NCT06661538||Clinic 1: Type 2 Diabetes Clinic|Families with children who attend the Type 2 Diabetes Clinic and indicate that they are experiencing food insecurity on the 2-item screener will be eligible for participation in this group.
62743786|NCT06661538||Clinic 2: Obesity Clinic|Families with children who attend the Obesity Clinic in Endocrinology and indicate that they are experiencing food insecurity on the 2-item screener will be eligible for participation in this group.
62743787|NCT06661538||Clinic 3: Preventive Cardiology Clinic|Families with children who attend the Preventive Cardiology Clinic for hypertension and/or high cholesterol and indicate that they are experiencing food insecurity on the 2-item screener will be eligible for participation in this group.
62743788|NCT06661538||Clinic 4: Gastroenterology Clinic|Families with children who attend the Gastroenterology Clinic for malnutrition or MASLD and indicate that they are experiencing food insecurity on the 2-item screener will be eligible for participation in this group.
62743789|NCT05910372||Fibromyalgia Patients|Patients with primary fibromyalgia diagnosis. May include other chronic pain comorbidities, but the pain associated with those diseases should be less severe than the pain caused by fibromyalgia.
62743790|NCT05910372||Healthy Controls|Volunteers with no clinical history of chronic pain, musculoskeletal or articular disorders.
62743791|NCT05504291|EXPERIMENTAL|Treatment (CVE, melphalan)|See Detailed Description
62743792|NCT05933356|EXPERIMENTAL|Experimental group|"The experimental group, in addition to scheduled activities, will be provided with the individual brain training exergames (a program for improving cognitive function and eye-hand coordination) three times a week and 30 minutes each time.~Exergame and no intervention are more informative than 1 and 2"
62743793|NCT05933356|OTHER|control group|The control group will be maintained with their scheduled activities in daycare as usual.
62743794|NCT03241680|NO_INTERVENTION|Control Group with conventional citology|Patients who do not have high grade cervical intraepithelial neoplasia and will have anal cytology performed by conventional method
62743795|NCT03241680|NO_INTERVENTION|Control Group with liquid based citology|Patients who do not have cervical intraepithelial neoplasia of high grade and will have anal cytology performed by liquid based method
62743796|NCT03241680|NO_INTERVENTION|CIN 2-3/Conventional Citology|Patients with high grade cervical intraepithelial neoplasia and will have anal citology performed by conventional method
62369998|NCT02823236|ACTIVE_COMPARATOR|Intralesional Triamcinolone|A dosage of 4mg/cm2 of intralesional triamcinolone will be injected in the keloid scar every 4 weeks during 6 months.
62369999|NCT02823236|EXPERIMENTAL|Topical Pirfenidone|Dosage commensurate with scar surface to be treated. After washing and drying the affected area, a thin layer of 8% pirfenidone will be applied on the scar, three times a day, for 6 months.
62370000|NCT02823236|EXPERIMENTAL|Triamcinolone + Pirfenidone|A dosage of 4mg/cm2 of intralesional triamcinolone will be injected in the keloid scar every 4 weeks during 6 months. Simultaneously, a thin layer of 8% pirfenidone will be applied on the scar, three times a day, for 6 months.
62743797|NCT03241680|ACTIVE_COMPARATOR|CIN 2-3/Liquid Based|Patients with high grade cervical intraepithelial neoplasia and will have anal citology performed by liquid based method
62743798|NCT05872386|EXPERIMENTAL|Telehealth|Intervention arm
62743799|NCT05872386|EXPERIMENTAL|Treatment as Usual|Treatment as usual (in-person at clinic)
62743800|NCT02756962|EXPERIMENTAL|Cohort A: HiDAC|"* At the time of diagnostic bone marrow biopsy, samples will be clinically sequenced via ClinSeq~* Patients who have clearance of their leukemia-associated mutations, defined as a LAM VAF \<2.5% will be assigned to the high-dose cytarabine consolidation (HiDAC) arm.~* HiDAC = Standard regimen of cytarabine 1.5 g/m\^2 or 3 g/m\^2 over 2-3 hours twice a day on Days 1, 3, \& 5 of each 28 day cycle for 3-4 cycles. Can be replaced by Onureg with permission from PI.~* For patients with the FLT3-ITD or a FLT3-TKD mutation, therapy with the FDA-approved FLT3 inhibitor midostaurin is permitted at the discretion of the treating physician."
62370001|NCT06031181|EXPERIMENTAL|Sublobar resection|Sublobar resection is performed for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section
62370002|NCT00486512|EXPERIMENTAL|Active Treatment (calcitriol+ASA+CaCO3)|Daily dose of 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol, Rocaltrol; Roche, Basel, Switzerland), 75 mg acetylsalicylic acid (ASA), and 1250 mg calcium carbonate (CaCO3). The daily dose was administered as 1 capsule containing 0.5 mg calcitriol (Rocaltrol; Roche) and 2 tablets containing a 37.5-mg ASA core with a 625-mg calcium carbonate shell (tablet-in-tablet) that was made expressly for this study. Patients should take 1 capsule and 2 tablets daily, together or separately. Timing of the intake is not important; study medication can be taken with or without food. The daily dose should not be exceeded. Before randomization, patients were given the placebo and followed up for a 3-week run-in period. Only patients who showed a placebo medication compliance rate of at least 80% were eligible for randomization. The primary outcome was the proportion of patients with recurrence of any adenomas as detected by colonoscopy after 3 years of treatment.
62370003|NCT00486512|PLACEBO_COMPARATOR|Placebo to calcitriol+ASA+CaCO3|Daily dose of matching placebo to 0.5 mg calcitriol, 75 mg acetylsalicylic acid (ASA), and 1250 mg calcium carbonate (CaCO3). Patients should take 1 capsule and 2 tablets of placebo daily, together or separately. Timing of the intake is not important; study medication can be taken with or without food. The daily dose should not be exceeded. Before randomization, patients were given the placebo and followed up for a 3-week run-in period. Only patients who showed a placebo medication compliance rate of at least 80% were eligible for randomization. The primary outcome was the proportion of patients with recurrence of any adenomas as detected by colonoscopy after 3 years of treatment.
62370004|NCT00664157|OTHER|2|40 patients with an idiopathic Parkinson's disease and 40 healthy paired volunteers (control group)
62370005|NCT05793424||Patients with cerebral small vessel disease ( cSVD)|
62370006|NCT05793424||Control patients|
62370007|NCT02545972|EXPERIMENTAL|Once a day tacrolimus|Tacrolimus extended release will be given at an initial once daily dose equivalent to the total daily dose of the twice a day Tacrolimus formulation.
62370008|NCT03797885||Patients with type 2 diabetes mellitus (T2DM)|Patients with type 2 diabetes, at the hospital setting.
62370009|NCT03797885||Patients with T2DM and established cardiovascular disease|Subgroup of patients with type 2 diabetes and established cardiovascular disease
62370010|NCT05184972||Non-reported patients treated for in-hospital cardiac arrest|
62370011|NCT05184972||Reported patients treated for in-hospital cardiac arrest|
62743801|NCT02756962|EXPERIMENTAL|Cohort B: Investigator's choice (HiDAC, AlloSCT)|"* At the time of diagnostic bone marrow biopsy, samples will be clinically sequenced via ClinSeq~* Patients who have persistent leukemia-associated mutations, defined as a LAM VAF ≥2.5% will be assigned to the investigator's choice arm.~* Patients assigned to this arm may received either HiDAC or AlloSCT.~* HiDAC = Standard regimen of cytarabine 1.5 g/m\^2 or 3 g/m\^2 over 2-3 hours twice a day on Days 1, 3, \& 5 of each 28 day cycle for 3-4 cycles. Can be replaced by Onureg with permission from PI.~* The source of stem cell product, donor selection, conditioning regimen, graft-versus-host-prophylaxis, and supportive care will be at the discretion of the treatment physician~* For patients with the FLT3-ITD or a FLT3-TKD mutation, therapy with the FDA-approved FLT3 inhibitor midostaurin is permitted at the discretion of the treating physician."
62743802|NCT02601235|EXPERIMENTAL|Naridrin|Naridrin: 2 drops in each nostril once daily as prescription
62370012|NCT00591396|EXPERIMENTAL|Single Arm|
62370013|NCT01952613|EXPERIMENTAL|Stroke - FES|Stroke population currently prescribed a FES orthotic device (\< week)
62370014|NCT05468580|ACTIVE_COMPARATOR|endoscopic Coeliac Artery Release (eCAR)|Patients randomized in the Intervention Group.
62743803|NCT02601235|ACTIVE_COMPARATOR|0.05 % Oxymetazoline Hydrochloride|2 pumps in each nostril every 12 hours
62743804|NCT05721352|EXPERIMENTAL|Single Arm Study|"* All participants will receive access to the phone application with a virtual reality headset and heart rate variability Bluetooth ear sensor.~* Participants will be instructed to download a free phone app Elite Heart Rate Variability, login using study provided de-identified research email address, pair the Bluetooth ear sensor and record a five-minute resting heart rate variability reading at baseline and each time point of the study prior to beginning intervention.~* Participants will be asked to use the intervention phone application for 7-10 minute sessions twice daily 5 days a week for 8 weeks.~* For the first 8 weeks, participants will receive brief, daily texts encouraging participation in the smart phone application.~* During weeks 9 through 12, will receive relaxation reminders daily via text to determine if use is sustained past the intervention phase"
62370015|NCT05468580|SHAM_COMPARATOR|Sham Operation|Patients randomized in the Sham group.
62370016|NCT03426761|EXPERIMENTAL|Dalbavancin|Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions
62370017|NCT03426761|ACTIVE_COMPARATOR|Standard of Care|Standard of care intravenous antibiotic based on microbiology susceptibility testing. Infusions may be one to three times daily for three to eight weeks. Examples of standard of care include vancomycin, daptomycin, nafcillin, cefazolin.
62370018|NCT06009861|EXPERIMENTAL|Neoadjuvant Tislelizumab plus chemotherapy and adjuvant RT or Tislelizumab plus CCRT|"Neoadjuvant phase: Patients will receive neoadjuvant Tislelizumab in combination with Albumin-Bound Paclitaxel and Cisplatin Q3W for 2 cycles.~Adjuvant phase:~For High-risk group(non-R0 resection or extranodal extension (ENE) or Lymph node metastasis\>5): Concurrent chemoradiotherapy followed by Tislelizumab Q3W for 14 cycles.~For the other group: intensity-modulated radiation therapy."
62370019|NCT06446895||MICAD|Patients with Myocardial Infarction and Obstructive Coronary Arteries
62370020|NCT06446895||MINOCA|Patients with Myocardial Infarction and Non-obstructive Coronary Arteries
62370021|NCT01977157||bioimpedance measurements while trinking alcohol|Bioimpedance spectroscopy (BIS) measurements on 12 healthy subjects were performed while they were drinking alkohol until reaching a BAC of 0.8 ‰.
62370022|NCT00776191|ACTIVE_COMPARATOR|Physioneal 35 vs. 40|Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks, followed by Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks.
62370023|NCT00776191|ACTIVE_COMPARATOR|Physioneal 40 vs. 35|Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks followed by Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks
62370024|NCT03024229|OTHER|LifePort® perfusion machine|Metabolomic analysis of the preservation fluid of the graft, donor and recipient urine by nuclear magnetic resonance spectroscopy, and if possible by liquid and gas chromatography coupled with mass spectrometry.
62370025|NCT06115824||Cohort A|Cohort A was the cohort of patients who received methotrexate-based chemotherapy alone
62743805|NCT02346643||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
62370026|NCT06115824||Cohort B|cohort B was the cohort of patients who received methotrexate-based chemotherapy + orelabrutinib.
62370027|NCT00486889|EXPERIMENTAL|Alglucosidase Alfa|Participants received alglucosidase alfa 20 milligrams per kilogram (mg/kg) body weight as intravenous infusion every 2 weeks and were followed for 10 years or up to discontinuation from study treatment due to any reason.
62370028|NCT02253394|ACTIVE_COMPARATOR|AMB + Spiro, Cardiopulmonary fitness|Ambrisentan 5 or 10 mg every day (QD) Spironolactone 50 mg QD
62370029|NCT02253394|PLACEBO_COMPARATOR|Placebo Cardiopulmonary fitness|Placebo mimics spironolactone 50 mg and will be taken QD
62370030|NCT01761942|PLACEBO_COMPARATOR|placebo ,anorexia nervosa|2x3 placebo capsules with olive oil
62370031|NCT01761942|EXPERIMENTAL|fatty acids preparation- eye-q|2 x 3 tablets of eye -q preparation daily ( 558 mg of EPA, 175 mg of DHA, 60 mg fo GLA).
62370032|NCT03694067||Androgenetic alopecia patients|Two 1 mm scalp punch skin biopsy will be taken per patient
62370033|NCT05844774|EXPERIMENTAL|HPI-intervention algorithm|In the intervention group the HemoSphere screen is visible and the anesthesiologist and PACU personal are instructed to follow the algorithm (chapter 4) in case of a HPI \>85%. The purpose of the alarm at 85% and the presented algorithm is to prevent hypotension. If hypotension occurs, it should be treated as according to the standard of care.
62370034|NCT05844774|OTHER|Control group|Patients in the control group are connected to the HemoSphere monitor to evaluate the TWA of hypotension in this group. The screen is not visible to the anesthesiologist or PACU personal and the alarm is set silent. It will be explained to the anesthesiologist and PACU personal that the patients are included to this study and that a blood pressure with a MAP of 65 mmHg should be monitored.
62370035|NCT02089867|EXPERIMENTAL|Ezetimibe|The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
62370036|NCT02089867|EXPERIMENTAL|Plant sterols|The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
62370037|NCT02089867|NO_INTERVENTION|Control group|No additional therapy, statin maintenance
62370038|NCT02089867|EXPERIMENTAL|Ezetimibe + plant sterols|The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
62370039|NCT03966092|NO_INTERVENTION|Usual practice|Patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen and morphine. Antimicrobial prophylaxis is performed according to recommendations
62370040|NCT03966092|EXPERIMENTAL|QLB block|"Patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen and morphine. Antimicrobial prophylaxis is performed according to recommendations.~In addition, patients receiving a bilateral QLB at the end of the surgery"
62370041|NCT04692233|EXPERIMENTAL|Qigong|The entire intervention will last 16 weeks, including 1-hour supervised training sessions twice a week during weeks 1 to 8 (training; 16 hours), and 1-hour supervised weekly follow-up sessions during weeks 9 to 16 (follow-up; 8 hours). The sessions will be supervised by an experienced qigong master. Throughout the intervention period, participants will be asked to self-practice BQ for 30 minutes twice a week from weeks 1 to 8, and then three times a week from weeks 9 to 16 (20 hours).
62370042|NCT04692233|ACTIVE_COMPARATOR|Light flexibility exercise|The control group will practice light flexibility exercise without any abdominal breathing and meditation techniques. The duration and frequency of supervised sessions and self-practice will be identical to the qigong sessions. The supervised sessions will be conducted by a certified exercise trainer.
62370043|NCT01908049|EXPERIMENTAL|Probiotic|A probiotic (Saccharomyces boulardii) 2 caps/ 8h for 12 weeks.
62370044|NCT01908049|PLACEBO_COMPARATOR|Placebo|No active substance is given.
62370045|NCT04396327|ACTIVE_COMPARATOR|Active Comparator: 2-Drug Combination|50 mg diphenhydramine and 0.5 mg lorazepam
62370046|NCT04396327|EXPERIMENTAL|Active Treatment: SM-1 3-Drug Combination|3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
62370047|NCT02493335|EXPERIMENTAL|Budesonide 0.5mg orodispersible tablet twice daily|Budesonide 0.5mg orodispersible tablet twice daily
62370048|NCT02493335|EXPERIMENTAL|Budesonide 1mg orodispersible tablet twice daily|Budesonide 1mg orodispersible tablet twice daily
62370049|NCT02493335|PLACEBO_COMPARATOR|Placebo orodispersible tablet twice daily|Placebo orodispersible tablet twice daily
62370050|NCT06482255|EXPERIMENTAL|virtual reality and manual therapy and therapeutic exercise|"* Soft tissue massage~* Mobilization of the glenohumeral joint~* Scapular retraining Therapeutic Exercise"
62370051|NCT06482255|ACTIVE_COMPARATOR|manual therapy and therapeutic exercise|"* Soft tissue massage~* Mobilization of the glenohumeral joint~* Scapular retraining"
62370052|NCT00846352|ACTIVE_COMPARATOR|Early Bronch|This group will receive bronchoscopy within 36 hours of enrollment into the study.
62370053|NCT00846352|ACTIVE_COMPARATOR|Late bronch|This group will receive bronchoscopy within 5 days of enrollment.
62370054|NCT02092168|EXPERIMENTAL|BIA 9-1067 30 mg (once daily) - Elderly Subjects|BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
62370055|NCT02092168|EXPERIMENTAL|BIA 9-1067 30 mg (once daily) - Young Subjects|BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
62370056|NCT02219672|EXPERIMENTAL|Triptolide group|cART for 6 months, and the experimental group will take Triplitode 2 tabs tid po for another 12 months
62370057|NCT02219672|ACTIVE_COMPARATOR|Comparator group|combined antiretroviral therapy (cART): TDF+3TC+LPV/r+RAL for 18 months
62370058|NCT00809510|EXPERIMENTAL|1|
62743806|NCT05105581||Group 1 (Patients)|"Patients: 37 patients with OCD diagnosed according to DSM-5~1. Inclusion criteria:~   1. both sex~  2. age groups : 18 : 60 are included~  3. accept to participate in the study~2. Exclusion criteria~   1. presence of major neurological disease as head trauma and sensory or motor defect as blindness or deafness~  2. Active psychiatric disordes~  3. patients refuse to participate in the study"
62743807|NCT05105581||Group 2 (Controlled)|37 healthy populations matched with PT group in age , sex , socioeconomic state
62743808|NCT01928550||PDR patients|Patients suspected to have Proliferative Diabetic Retinopathy or PDR
62743809|NCT01179217|EXPERIMENTAL|L-glutamine|Patients will be randomized to receive investigational product, L-Glutamine.
62743810|NCT01179217|PLACEBO_COMPARATOR|100% maltodextrin|Patients will be randomized to receive Placebo.
62743811|NCT05970003|ACTIVE_COMPARATOR|Group A: Copenhagen exercise|"Group A will receive the Copenhagen exercise, also known as the adductor strengthening protocol, is a dynamic and high-intensity exercise. It doesn't require any special equipment and can be done in any training center.~There are 3 different levels of exercise were performed by players.~1. Level 1: Side-lying hip adduction exercise.~2. Level 2: Copenhagen adduction exercises while both arms support at the knee.~3. Level 3: Copenhagen adduction exercise - primary support at the ankle and minor support at the knee."
62743812|NCT05970003|ACTIVE_COMPARATOR|Group B : Holmich Exercises|"Group B will receive Holmich continues to provide the strongest evidence for the efficacy of exercise as an ARGP treatment.~The Holmich treatment protocol exercise includes static and dynamic and/or isometric and isotonic strengthening exercises for hip adductors and abductors and also for abdominal muscles.~There are 6 Different types of exercises were performed by players who were a participant with 3 sets of 10 repetitions with 15 sec recovery period."
62743813|NCT01532284|EXPERIMENTAL|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
62743814|NCT01532284|NO_INTERVENTION|No Polar Body Biopsy|
62743815|NCT03492957|EXPERIMENTAL|Physical activity|A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change. There is no control group ion this feasibility study.
62743816|NCT04113733||Crohn's Disease|This group consists of patients with a diagnosis of Crohn's disease undergoing colonoscopy for clinical care. Samples including tissue biopsy, blood and stool will be collected one time. In addition, patient information that may include questionnaires and medical record review will be collected.
62743817|NCT04113733||Control|This group will include patients undergoing screening colonoscopy as part of standard of care. Samples including tissue biopsy, blood and stool will be collected one time. In addition, patient information that may include questionnaires and medical record review will be collected.
62743818|NCT04113733||Cooperative Human Tissue Network|This group will consist of non-IBD patients and Crohn's disease patients participating in the Cooperative Human Tissue Network (CHTN). The CHTN will be utilized to obtain surgical specimens from these patients. The patients will be screened and consented via the CHTN protocol. No additional samples in the form of blood or stool will be collected. Associated clinical data will be collected through medical record review.
62743819|NCT04981639|ACTIVE_COMPARATOR|I (IVPCA)|Intravenous patient controlled analgesia will be performed.
62743820|NCT04981639|ACTIVE_COMPARATOR|II (IVPCA+TAP)|Intravenous patient controlled analgesia and transversus abdominis plane block will be performed.
62743821|NCT04981639|ACTIVE_COMPARATOR|III (IVPCA, IMS, and TAP)|Intravenous patient controlled analgesia, transversus abdominis plane block, and intramuscular muscular stimulation will be performed.
62743822|NCT01323088|OTHER|Control|Standard care control (no-exercise)
62743823|NCT01323088|ACTIVE_COMPARATOR|Aerobic Exercise|
62743824|NCT01323088|ACTIVE_COMPARATOR|Resistance Exercise|
62743825|NCT06658730||Aneurysm/Other Isolated Lesion|
62743826|NCT06658730||Dissection|
62743827|NCT06661902|EXPERIMENTAL|Buffered Lidocaine|1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio
62743828|NCT06661902|ACTIVE_COMPARATOR|1% Lidocaine|
62743829|NCT00235235||A|Doxorubicin 60 mg/m2 + Cyclophosphamide 600 mg/m2 day 2 of every 21-day cycle
62743830|NCT00235235||B|Capecitabine 1000mg/m2 bid days 1-14 of every 21-day cycle
62743831|NCT00235235||C|Vinorelbine 25 mg/m2 days 1, 8, 15 of every 28-day cycle
62743832|NCT00235235||D|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
62743833|NCT05749510||NCRT+TME|Neoadjuvant chemoradiotherapy (NCRT) and total mesorectal excision (TME) Interventions
62743834|NCT00566982|EXPERIMENTAL|Ospemifene 60 mg/day|Ospemifene will be taken orally, once daily, in the morning, with food for 52 weeks.
62743835|NCT00566982|PLACEBO_COMPARATOR|Placebo|Placebo will be taken once daily, in the morning, with food for 52 weeks.
62743836|NCT02136758|EXPERIMENTAL|Lifestyle modification|The intervention group participated in individualized therapeutic lifestyle plans to reduce cardiovascular risk. Participants were introduced to factors contributing to cardiovascular disease and met individually with a registered dietitian, exercise physiologist, stress management instructor, and psychologist to learn effective strategies for integrating healthy changes into their current lifestyle.
62743837|NCT02136758|NO_INTERVENTION|Usual care controls|Control group received standard care from their primary physicians, but did not participate in any component of the lifestyle program or receive any information, advice, or counseling regarding healthy lifestyle behaviors.
62743838|NCT04380194||victims|thirteen patients affected by lightning in collective fulguration
62743839|NCT04380194||healthy witnesses|fourteen healthy witnesses who have never been in contact with lightning, matched on age and sex
62743840|NCT05432596|EXPERIMENTAL|ATI-1777 topical solution 2.0% w/w (BID)|ATI-1777 topical solution 2.0% w/w, twice daily
62743841|NCT05432596|EXPERIMENTAL|ATI-1777 topical solution 1.0% w/w (BID)|ATI-1777 topical solution 1.0% w/w, twice daily
62743842|NCT05432596|EXPERIMENTAL|ATI-1777 topical solution 0.5% w/w (BID)|ATI-1777 topical solution 0.5% w/w, twice daily
62743843|NCT05432596|PLACEBO_COMPARATOR|Vehicle (BID)|Vehicle topical solution, twice daily
62743844|NCT05432596|EXPERIMENTAL|ATI-1777 topical solution 2.0% w/w (QD)|ATI-1777 topical solution 2.0% w/w, once daily
62370059|NCT05923151|EXPERIMENTAL|The cranial-caudal mixed medial approach group|75 patients were diagnosed with right colon cancer and underwent the cranial-caudal mixed medial approach for laparoscopic right hemicolectomy with complete mesocolic excision.
62370060|NCT05923151|OTHER|the medial approach group|73 patients were diagnosed with right colon cancer and underwent the medial approach for laparoscopic right hemicolectomy with complete mesocolic excision.
62370061|NCT00923624|ACTIVE_COMPARATOR|staff emails|Attention control that includes staff sending emails with information about using health information technology system.
62743845|NCT05432596|PLACEBO_COMPARATOR|Vehicle (QD)|Vehicle topical solution, once daily
62370062|NCT00923624|EXPERIMENTAL|study nurse messages|A series of 6 proactive secure messages and 3 proactive booster messages (for a total of 9 secure and personalized messages) sent by the study nurse via the EMR patient web portal.
62370063|NCT01780324|NO_INTERVENTION|No lidocaine|This group will have urinary catheterization without lidocaine (per standard procedure)
62743846|NCT01964157|EXPERIMENTAL|LDK378 arm|
62743847|NCT03441867|EXPERIMENTAL|(CBT-Sz) - PNES|Participants with history of a head injury and confirmed Psychogenic Non-Epileptic Seizures will complete 2 brain fMRI scans along with 12 weeks of one hour CBT-Sz sessions by a trained therapist.
62370064|NCT01780324|EXPERIMENTAL|Lidocaine|The Intervention is the application of intraurethral lidocaine 5 minutes prior to urethral catheterization.
62370065|NCT03021928|EXPERIMENTAL|72 hours (Day 3-4)|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 72 (+/-24) hours correlates to starting treatment on Day 3-4.
62370066|NCT03021928|EXPERIMENTAL|132 hours (Day 6)|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 132 (+/- 12) hours correlates to starting treatment on Day 6.
62370067|NCT03021928|EXPERIMENTAL|228 hours (Day 10)|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 228 (+/- 12) hours correlates to starting treatment on Day 10.
62370068|NCT03021928|EXPERIMENTAL|324 hours Day 14.|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 324 (+/- 12) hours starts Day 14.
62370069|NCT01957085||Hospitalized Patients|Observation only. All patients admitted to Temple University Hospital on the study day. Observational only, no intervention.
62370070|NCT06281314|EXPERIMENTAL|Parkinson'disease group|Rehabilitation takes place with individual one-hour sessions per day. The stimulation intervention is organized on 4 different themes (chosen from orientation, memory, praxis, language, executive functions, attention, problem-solving, and functional activities) for 15' each.
62370071|NCT06281314|EXPERIMENTAL|Multiple Sclerosis group|Rehabilitation takes place with individual one-hour sessions per day. The stimulation intervention is organized on 4 different themes (chosen from orientation, memory, praxis, language, executive functions, attention, problem-solving, and functional activities) for 15' each.
62370072|NCT06281314|EXPERIMENTAL|Alzheimer group|Rehabilitation takes place with individual one-hour sessions per day. The stimulation intervention is organized on 4 different themes (chosen from orientation, memory, praxis, language, executive functions, attention, problem-solving, and functional activities) for 15' each.
62370073|NCT03527303|EXPERIMENTAL|Meditation Group|Participants in the intervention group will assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
62370074|NCT03527303|NO_INTERVENTION|Waitlist Control Group|Waitlist control group participants will continue their normal activities and not add any form of meditation during the study period.
62743848|NCT03441867|EXPERIMENTAL|(CBT-Sz) - PTE|Participants with history of a head injury and confirmed Post-Traumatic Epilepsy (PTE) will complete 2 brain fMRI scans along with 12 weeks of one hour CBT-Sz sessions by a trained therapist.
62370075|NCT02044822|EXPERIMENTAL|Idelalisib + rituximab|Participants will receive rituximab for 8 weeks and Idelalisib continuously throughout the study (up to 10 years).
62743849|NCT03441867|ACTIVE_COMPARATOR|TBI Control|Participants with TBI will complete 2 brain fMRI scans.
62743850|NCT03441867|ACTIVE_COMPARATOR|Healthy Volunteer|Healthy control volunteers will complete 2 brain fMRI scans.
62743851|NCT00675623|EXPERIMENTAL|A|Dimebon, 5 mg orally three times daily
62370076|NCT02737605|EXPERIMENTAL|Sequence 1|Participants will receive Treatment A (intravenous placebo, Intranasal placebo and Oral placebo tablet matched to the moxifloxacin tablet) on Day 1 of period 1, Treatment B (intravenous placebo, 84 milligram (mg) of intranasal esketamine and Oral placebo tablet matched to the moxifloxacin tablet) on Day 1 of period 2, Treatment C (intravenous placebo, Intranasal placebo and 400 mg oral moxifloxacin tablet) on Day 1 of period 3, Treatment D (0.8 milligram per kilogram of intravenous esketamine, Intranasal placebo and Oral placebo tablet matched to the moxifloxacin tablet ) on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
62370077|NCT02737605|EXPERIMENTAL|Sequence 2|Participants will receive Treatment A on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment B on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
62370078|NCT02737605|EXPERIMENTAL|Sequence 3|Participants will receive Treatment B on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
62743852|NCT00675623|EXPERIMENTAL|B|Dimebon 20 mg orally three times daily
62743853|NCT00675623|PLACEBO_COMPARATOR|C|Placebo orally three times daily for six months
62743854|NCT06658743|PLACEBO_COMPARATOR|Standard Care|
62743855|NCT06658743|ACTIVE_COMPARATOR|Shared Medical Appointment|
62743856|NCT05030610|EXPERIMENTAL|Intervention Group|Participants, along with a support person, will complete 12 weekly sessions of the BeatIt-ASD intervention. The support person will complete an initial session before commencement of the 12 weekly sessions.
62743857|NCT04182399|ACTIVE_COMPARATOR|Patients 25 ZNS|30 patients receive oral 25 mg ZNS daily
62743858|NCT04182399|ACTIVE_COMPARATOR|Patients 50 ZNS|30 patients receive oral 50 mg ZNS daily
62743859|NCT04182399|PLACEBO_COMPARATOR|Patients Placebo|30 patients receive placebo
62743860|NCT05414448|NO_INTERVENTION|ENDOAID|CADe system will be used during withdrawal phase of colonoscopy.
62743861|NCT05414448|EXPERIMENTAL|ENDOAID with ENDOCUFF|CADe system and mucosal exposure device (ENDOCUFF) will be used during withdrawal phase of colonoscopy.
62370079|NCT02737605|EXPERIMENTAL|Sequence 4|Participants will receive Treatment B on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment C on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
62370080|NCT02737605|EXPERIMENTAL|Sequence 5|Participants will receive Treatment C on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment B on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
62370081|NCT02737605|EXPERIMENTAL|Sequence 6|Participants will receive Treatment C on Day 1 of period 1, Treatment B on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
62370082|NCT00446797|ACTIVE_COMPARATOR|Non-Selective NSAIDS|nsNSAIDs used in real-life standard practice for treatment of pain due to ankle sprain.
62370083|NCT00446797|EXPERIMENTAL|Celecoxib|
62370084|NCT02331472||Interstitial cystitis|Patients who have been diagnosed with interstitial cystitis/bladder pain syndrome. The group includes both patients with or without Hunner lesion on cystoscopy
62370085|NCT02331472||Control|Adult participants without history of interstitial cystitis/bladder pain syndrome
62743862|NCT01955369||Amyotrophic lateral sclerosis patients|Patients were included into the registry if they had a new diagnosis of ALS, a minimum age of 18 years and lived in Rhineland-Palatinate for at least 6 months before date of diagnosis. Diagnosis was based upon the revised El Escorial criteria.
62370086|NCT03649386|ACTIVE_COMPARATOR|Control|Heated breathing circuit will turned off.
62370087|NCT03649386|EXPERIMENTAL|Heat|Heated breathing circuit will be turned on.
62370088|NCT00005640|EXPERIMENTAL|Mapping and Biopsy|Lymph node mapping and sentinel lymph node biopsy. Patients undergo preoperative endoscopy with injection of technetium Tc 99m sulfur colloid around tumor followed by celiotomy and intraabdominal exploration. At 30 minutes following injection, patients undergo lymphatic mapping with a gamma probe and biopsy of the sentinel lymph node(s). Following biopsy and mapping, patients undergo resection of primary tumor.
62370089|NCT05229588|EXPERIMENTAL|Lurbinectedin|Lurbinectedin will be administered intravenously (IV) as a 1-hour (±10 min) infusion on Day 1 of each cycle (one cycle = 3 weeks ± 48 hours).
62743863|NCT05995678|EXPERIMENTAL|STEP-Home-SP + Usual Care|The core skills of emotional regulation and problem solving are introduced and integrated throughout all Veteran-specific reintegration content modules for practice and repetition for 12 weeks. Attention training augments emotional regulation and problem solving core skills and is interspersed throughout group and individual sessions. Additional 30-minute individual skill building and goal setting sessions occur \~4-6 times based on individual Veteran needs
62370090|NCT06243289||Healthy participants|Volunteers with no kidney disease, autoimmune disease or major cardiovascular comorbidities
62370091|NCT06243289||Participants with kidney disease|Includes patient with chronic kidney disease, dialysis or functioning transplant
62370092|NCT06100107|EXPERIMENTAL|Group A - Mirror Therapy|Group A carried out a ten-minute Mirror Therapy exercise daily, for a total duration of six weeks.
62370093|NCT06100107|EXPERIMENTAL|Group B - control period followed by Mirror Therapy|Group B acted as a control group for six weeks (no Mirror Therapy) followed by six weeks of Mirror Therapy with the same characteristics as Group A.
62370094|NCT05892536|EXPERIMENTAL|blood clot regeneration|the regenerative procedures were performed by over-instrumentation the apices and irritating the apical tissues to induce bleeding into the root canal, then orifices plugged with MTA over blood clot and restored with GI.
62370095|NCT05892536|ACTIVE_COMPARATOR|photo-biomodulation regeneration|photobiomodulation therapy was carried out using diode laser with wavelenght 810 nm and output power 300 mW on the apical root areas of buccal and lingual surfaces at 48 hours intervals for 2 weeks after completion of the regenerative procedures which were performed by over-instrumentation the apices and irritating the apical tissues to induce bleeding into the root canal, then orifices plugged with MTA over blood clot and restored with GI.
62370096|NCT01375439|OTHER|Active search of lower genital tract infections|"Active search of lower genital tract infections~Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome."
62370097|NCT05320536|EXPERIMENTAL|Experimental group|Guilingji capsule Take 2 tablets orally, once before breakfast and dinner, and take them with saline. The total treatment period is 90 days.
62370098|NCT05320536|PLACEBO_COMPARATOR|Control group|Placebo Take 2 tablets orally, once before breakfast and dinner, and take them with saline. The total treatment period is 90 days
62743864|NCT05995678|ACTIVE_COMPARATOR|Usual Care|UC will include the Transition Assistance Program (TAP) as scheduled by DOD prior to military separation, VA Solid Start post-separation, and educational augmentation post-separation.
62370099|NCT06396130|EXPERIMENTAL|Photobiomodulation using diode laser|Irradiation of periapical tissues with low level diode laser therapy buccally and lingually
62370100|NCT06396130|PLACEBO_COMPARATOR|Placebo/ Mock Laser|Application of laser probe without device activation
62743865|NCT02420288|NO_INTERVENTION|Control Group|Pregnant women not participating in supervised physical exercise program. The subjects in this group will be monitored during pregnancy to know if they make any kind of exercise on your own, to know which are really sedentary pregnant women.
62743866|NCT02420288|EXPERIMENTAL|Exercise Group|Pregnant women participating in supervised physical exercise program.
62743867|NCT03201965|ACTIVE_COMPARATOR|CyBorD alone (cyclophosphamide/bortezomib/dexamethasone)|Participants will receive dexamethasone (40 milligrams \[mg\] orally or intravenous \[IV\] dose), followed by cyclophosphamide (300 milligram per meter square \[mg/m\^2\] orally or IV dose), then bortezomib (1.3 mg/m\^2 subcutaneous injection) weekly on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles.
62370101|NCT01863706|EXPERIMENTAL|Misoprostol|400µg oral misoprostol
62370102|NCT01863706|ACTIVE_COMPARATOR|Oxytocin|20 IU oxytocin
62370103|NCT04576416|EXPERIMENTAL|Intervention|During the three months the intervention group will receive access to the AI augmented digital educational platform and its two modules (Training Module and Clinical Feedback Module). They will receive continuous clinical feedback on their registered lesions.
62370104|NCT04576416|NO_INTERVENTION|Control|The control group continues its standard clinical practice without access to the E-app, but does register skin lesions throughout the full 3 month period.
62370105|NCT01600105|EXPERIMENTAL|Perfusion MRI|chronic liver disease who underwent/will undergo liver biopsy or will undergo liver transplant or liver resection as part of standard care during the previous 6 months.
62370106|NCT04827940|EXPERIMENTAL|intervention arm|"Data from the study was collected during the implementation of the Nursing Surgical Diseases class. Students who completed the 4-hour training program on sleep, relaxation exercises and survey practice have been pollsters of the study.~Relaxing music for sleep, prepared by the Turkish Psychological Association, is uploaded to patients' mobile phones. Patients were asked to perform relaxation exercises for a week at bedtime, lasting an average of 30 minutes, and with music every day, taking advantage of nurse observation at the clinic with the patient's declaration in check. Students who took part in the practice served as reminders of patients' compliance with the exercises."
62370107|NCT04827940|OTHER|Control arm|Those who did not do progressive muscle relaxation exercises or did not practice regularly for a week constituted the control group.
62370108|NCT02688725|EXPERIMENTAL|Ultrasound|post mastectomy ultrasound
62370109|NCT03398252|EXPERIMENTAL|Doxazosin XL|Participants will receive increasing doses of doxazosin XL (0, 4, and 8 mg).
62370110|NCT03398252|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive a placebo for doxazosin XL.
62370111|NCT05609136|EXPERIMENTAL|Bobath+ Scapular Stabilization Group|In addition to the Bobath approach, which is one of the neurophysiological treatment methods for the upper extremity, 5 sessions a week for 6 weeks, scapular stabilization exercises will be applied to this group for an additional 6 weeks from the beginning of the treatment. Scapular Stabilization Exercises will be performed with the patient in a sitting position, with the shoulder at 90 degrees and the elbow extended. The patient will be given exercises with isometric contraction while the shoulder is in protraction and retraction by the physiotherapist. Isometric contraction will last for 5 seconds and each exercise will be repeated 2x15 times. There will be a 1-minute rest period between sets. The exercises will be performed in 2 different positions, in the flexion position and in the diagonal position.
62370112|NCT05609136|ACTIVE_COMPARATOR|Bobath Group|The Bobath approach, one of the neurodevelopmental treatment methods for the upper extremities, was applied to all participants included in the study for 6 weeks, 5 sessions per week. Before starting the Bobath exercises, preparation was made with 10 minutes of stretching and upper extremity mobilization. The Bobath approach included functional exercises that patients could perform at home. Bobath program; shoulder flexion, protraction, abduction and extranal rotation; It included extension of the elbow and wrist, extension and opposition of the fingers. After these exercises, task-specific functional upper extremity exercises were performed with or without an object that could help the treatment. These tasks are; required reaching, grasping, or lifting objects such as a cup, pen, cylindrical box, etc., in different body positions. Each session lasted for 1 hour and at the end of each session, patients were given a home exercise program.
62370113|NCT05455840|EXPERIMENTAL|Intervention|Patients with qualified criteria will be enrolled in this study
62370114|NCT04709094|EXPERIMENTAL|Part 1: Danicopan and Warfarin|"Period 1: Participants received a single dose of warfarin.~Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of warfarin.~Scheduled pharmacokinetics (PK) and pharmacodynamics samples were collected, with a washout period of at least 14 days between the dose of warfarin in Period 1 and the first dose of danicopan in Period 2."
62370115|NCT04709094|EXPERIMENTAL|Part 2: Danicopan and Bupropion|"Period 1: Participants received a single dose of bupropion.~Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of bupropion.~Scheduled PK samples were collected, with a washout period of at least 7 days between the dose of bupropion in Period 1 and the first dose of danicopan in Period 2."
62370116|NCT04709094|EXPERIMENTAL|Part 3: Danicopan and EE/NET|"Period 1: Participants received a single dose of EE/NET.~Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of EE/NET.~Scheduled PK samples were collected, with a washout period of at least 7 days between the dose of EE/NET in Period 1 and the first dose of danicopan in Period 2."
62370117|NCT02913833|EXPERIMENTAL|Daily pain evaluation|Patients recruited in a sequential order within the chronic revalidation unit of the CHU Brugmann hospital, Queen Astrid site.
62743868|NCT03201965|EXPERIMENTAL|CyBorD plus Daratumumab|Participants will receive dexamethasone (20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing) followed by 1800 mg of daratumumab subcutaneously followed by cyclophosphamide (300 mg/m\^2 orally or IV dose weekly) and bortezomib (1.3 mg/m\^2 subcutaneous injection weekly) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 2 years.
62743869|NCT05980871|ACTIVE_COMPARATOR|single-dose ceftriaxone plus doxycycline|single-dose ceftriaxone (1g intramuscularly once) plus doxycycline (100 mg orally twice daily for 7 days)
62743870|NCT05980871|ACTIVE_COMPARATOR|single-dose BPG plus doxycycline|single-dose BPG (2.4 MU intramuscularly once) plus doxycycline (100 mg orally twice daily for 7 days)
62370118|NCT02913833|NO_INTERVENTION|Control|Patients recruited in a sequential order within the chronic revalidation unit of the CHU Brugmann hospital, Queen Astrid site.
62370119|NCT02315417|EXPERIMENTAL|gevokizumab|Solution for subcutaneous injection (Part 1, Group B)
62370120|NCT02315417|PLACEBO_COMPARATOR|Placebo|Solution for subcutaneous injection (Part 1, Group A)
62370121|NCT02315417|EXPERIMENTAL|gevokizumab open-label|Solution for subcutaneous injection (Part 2, Open-label)
62743871|NCT02632669|EXPERIMENTAL|Hemigland focal LDR brachytherapy|Hemigland focal LDR brachytherapy using permanent iodine 125 seed implantation
62370122|NCT01737138|ACTIVE_COMPARATOR|RSD+Medicine|The investigators will recruit 50 randomised CKD patients who meet the inclusion criteria. First undergo renal artery angiography procedure to confirm anatomy. If renal artery meet the inclusion criteria, give the renal sympathetic denervation. At the same time, we will use optimal medication to protect renal function. Then we will conduct a clinic follow-up and a telephone follow-up e(Total 36 months).
62370123|NCT01737138|PLACEBO_COMPARATOR|Medicine|The investigators aslo will recruit 50 randomised CKD patients who meet the inclusion criteria. There are no significant differences in age, gender, race, past medical history,personal history and so on between the two groups. In this group we will use optimal medication just like the RSD+Medicine group. Third we will conduct a clinic and a telephone follow-up(Total 36 months).
62370124|NCT02531503||Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of asthma medication during the past 12 months.
62370125|NCT02278224|EXPERIMENTAL|Rumination Focused CBT|11 sessions of manualised group based Rumination Focused CBT for depression. 3 hours sessions are administered once during 11 weeks in groups of approximately 8 patients and two therapist.
62370126|NCT02278224|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|11 sessions of manualised group based CBT for depression. 3 hours sessions are administered once during 11 weeks in groups of approximately 8 patients and two therapist.
62743872|NCT06086158|EXPERIMENTAL|Nordic Reverse Protocol|"The intervention group performed the reverse Nordic exercise or quadriceps drop protocol for four weeks in their training sessions. Participants assigned to the intervention group warm up for approximately 15/20 minutes, consisting of five minutes of continuous running at low speed (approximately 10 km/h), followed by 3 minutes of stretching the lower extremities and three separate progressive sprints.~between them with two minutes of rest to finish, then they will carry out the corresponding series and repetitions of the protocol and continue with their usual training."
62743873|NCT06086158|NO_INTERVENTION|Usual Training Sessions|The control group did not have any intervention, the participants randomly assigned to this group continued with their usual training sessions.
62370127|NCT04005755|EXPERIMENTAL|Maxigesic® IV|Acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion. The study drug will be administered by injection into a dedicated indwelling venous cannula, infused over 15 minutes. The study drug will be administered every 6 hours (q6h) for a minimum of 48 hours up to at least 5 days, with a maximum of 4 doses within a 24 hour period.
62370128|NCT00877734|EXPERIMENTAL|1|Baclofen
62370129|NCT00877734|PLACEBO_COMPARATOR|2|Placebo
62370130|NCT01976585|EXPERIMENTAL|rhuFlt3L/CDX-301|intratumoral injections on days 1-5 and 8-11. and Poly-ICLC intratumoral injection weekly, weeks 2-8
62370131|NCT02807714||No CAD|Patients scheduled for elective cardiac catheterization for evaluation of suspected CAD that are found to not have CAD
62370132|NCT02807714||Obstructive CAD (non-ACS) Group|Patients scheduled for elective cardiac catheterization for evaluation of known or suspected CAD that are found to have obstructive CAD requiring intervention.
62370133|NCT02807714||Stable CAD, no intervention required|Patients scheduled for elective cardiac catheterization for evaluation of known or suspected CAD that are found to have non-obstructive CAD not requiring intervention.
62370134|NCT02807714||Acute Coronary Syndrome (ACS)|Patients who undergo an emergent cardiac catheterization for evaluation of known or suspected STEMI, NSTEMI, Unstable Angina (UA).
62370135|NCT06047860|EXPERIMENTAL|Intervention group|"M-CSF 200 μg administered subcutaneously daily for 7 days on the first day of treatment; IL-2 2 million IU administered subcutaneously daily for 7 days the day after GM-CSF; PD-1/PD-L1 inhibitor within one week of radiotherapy; Recombinant human vascular endothelial inhibitor (Endo) 210 mg CIV72h starting on the first day of treatment, every 21 days for a minimum of ≥ 2 cycles of this combination therapy.~Maintenance treatment phase:~Maintenance with PD-1/PD-L1 inhibitor in combination with recombinant human vascular endothelial inhibitor (Endo) until progression or intolerable side effects."
62370136|NCT03648411||Shwegyin|Shwehyin is a Township in Bago Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.
62370137|NCT03648411||Pinlebu|Pinlebu is a township in Sagaing Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.
62370138|NCT04506385|ACTIVE_COMPARATOR|A - L. delbrueckii LDD01 probiotic bacterial strain administered in sachets of 2 grams|L. delbrueckii LDD01 probiotic bacterial strain
62370139|NCT04506385|ACTIVE_COMPARATOR|B - Bifidobacterium longum DLBL probiotic bacterial strain administered in sachets of 2 grams|Bifidobacterium longum DLBL probiotic bacterial strain
62370140|NCT04506385|ACTIVE_COMPARATOR|C - LP01, LF16, LR06 and B. longum 04 administered in sachets of 2 grams|L. plantarum LP01, L.fermentum LF16, L. rhamnosus LR06 and B. longum 04: low dosage; probiotic bacterial strains blend
62370141|NCT04506385|ACTIVE_COMPARATOR|D - LP01, LF16, LR06 and B. longum 04 administered in sachets of 2 grams|L. plantarum LP01, L.fermentum LF16, L. rhamnosus LR06 and B. longum BL04: high dosage; probiotic bacterial strains blend
62743874|NCT02948556||Chronic fatigue syndrome|Participants with chronic fatigue syndrome
62743875|NCT06153420|EXPERIMENTAL|CIN-103 BID Dose 1|CIN-103 Dose 1, administered as 2 x CIN-103 capsules and 2 x matching placebo per dose. Two doses per day.
62370142|NCT01499212|EXPERIMENTAL|I:E ratio 1:1|
62370143|NCT02180568|EXPERIMENTAL|Lipiodol|Lipiodol-guided lung localization technique
62743876|NCT06153420|EXPERIMENTAL|CIN-103 BID Dose 2|CIN-103 Dose 2, administered as 4 x CIN-103 capsules per dose. Two doses per day.
62743877|NCT06153420|PLACEBO_COMPARATOR|Placebo for CIN-103 BID|Placebo for CIN-103, administered as 4 x matching placebo capsules per dose. Two doses per day.
62370144|NCT02180568|ACTIVE_COMPARATOR|Hookwire|Hookwire-guided lung localization technique
62370145|NCT05935813||1996 birth year|Followed cohort for 6 years (2008-2014) to study time trends in caries experience
62370146|NCT05935813||1997 birth year|Followed cohort for 6 years (2009-2015) to study time trends in caries experience
62370147|NCT05935813||1998 birth year|Followed cohort for 6 years (2010-2016) to study time trends in caries experience
62743878|NCT00733200|NO_INTERVENTION|Control group|
62370148|NCT05935813||1999 birth year|Followed cohort for 6 years (2011-2017) to study time trends in caries experience
62370149|NCT05935813||2000 birth year|Followed cohort for 6 years (2012-2018) to study time trends in caries experience
62370150|NCT05935813||2001 birth year|Followed cohort for 6 years (2013-2019) to study time trends in caries experience
62370151|NCT05935813||2002 birth year|Followed cohort for 6 years (2014-2020) to study time trends in caries experience
62370152|NCT03801798|EXPERIMENTAL|NAs antivirals + GC1102 180,000 IU|"All patients are currently being treated with long-term NA treatment(more than 24 weeks) and will continue using these during the study.~Each vial contains 1mL of study drug or placebo; Single IV bolus injection of 18mL~* V2 to V17 : IV bolus injection twice a week~* V18 to V33 : IV bolus injection once a week"
62370153|NCT03801798|PLACEBO_COMPARATOR|NAs antivirals + GC1102 Placebo|"All patients are currently being treated with long-term NA treatment(more than 24 weeks) and will continue using these during the study.~Each vial contains 1mL of study drug or placebo; Single IV bolus injection of 18mL~* V2 to V17: IV bolus injection twice a week~* V18 to V33: IV bolus injection once a week"
62370154|NCT00510107|ACTIVE_COMPARATOR|1|Docetaxel 35 mg/m2 will be administered on days 1 and 8. Cisplatin 60 mg/m2 will be administered on day 1 every 3 weeks.
62370155|NCT00510107|EXPERIMENTAL|2|Docetaxel 35 mg/m2 will be administered on days 1 and 8. Oxaliplatin 120 mg/m2 will be administered on day 1 every 3 weeks.
62370156|NCT00460525|ACTIVE_COMPARATOR|Rabies Vaccine|Rabies vaccine administered on Days 0, 30, and 60.
62370157|NCT00460525|EXPERIMENTAL|FMP2.1/AS02A|50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.
62370158|NCT05151562|EXPERIMENTAL|Virtual Music Therapy|Participants will attend two 30 minutes long virtual music therapy sessions per week for 8 weeks using Zoom.
62370159|NCT02789072|OTHER|Microgravity|effect of microgravity on central aortic blood pressure.
62370160|NCT03278925|EXPERIMENTAL|Prevention (defined green tea catechin extract)|Participants receive defined green tea catechin extract PO QD or BID for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo ultrasound, CT, or MRI at screening and on study, undergo collection of blood samples on study, and may undergo biopsy at screening and on study.
62370161|NCT05844657||Individuals with Meniere's disease|Voluntary Meniere's patients aged 18-65 years, not in the relapse period, who met the inclusion criteria
62370162|NCT05844657||Healthy individuals without Meniere's disease|Volunteer healthy individuals aged 18-65 years without dizziness who met the inclusion criteria
62370163|NCT02635867|ACTIVE_COMPARATOR|Indirect pulp capping therapy-Resin-modified calcium silicate - TheraCal|Resin modified calcium silicate-TheraCal (light curable)
62370164|NCT02635867|ACTIVE_COMPARATOR|Indirect pulp capping therapy- - Calcium hydroxide - Dycal|Calcium hydroxide - Dycal
62370165|NCT02635867|ACTIVE_COMPARATOR|Indirect pulp capping therapy-- Resin-based dentin bonding agent|Resin-based dentin bonding agent-Self etching adhesive
62370166|NCT02635867|ACTIVE_COMPARATOR|Direct pulp capping therapy-Resin-modified calcium silicate - TheraCal|Resin modified calcium silicate-TheraCal (Light curable)
62370167|NCT02635867|ACTIVE_COMPARATOR|Direct pulp capping therapy-Resin-modified calcium silicate - Calcium hydroxide - Dycal|- Calcium hydroxide - Dycal
62743879|NCT00177294|EXPERIMENTAL|1|Participants who respond partially to 6 weeks of escitalopram 10mg daily then receive 16 weeks of extension therapy with escitalopram 20 mg daily, plus weekly interpersonal psychotherapy (IPT)
62743880|NCT00177294|ACTIVE_COMPARATOR|2|Participants who respond partially to 6 weeks of escitalopram 10mg daily then receive 16 weeks of extension therapy with escitalopram 20 mg daily, plus weekly depression care management(DCM) without interpersonal psychotherapy (IPT)
62370168|NCT01341236|ACTIVE_COMPARATOR|continuous nutrition|
62743881|NCT04418869|EXPERIMENTAL|Exercise|All subject will perform three different exercise bouts and one control session.
62370169|NCT01341236|ACTIVE_COMPARATOR|bolus nutrition|
62370170|NCT01974440|PLACEBO_COMPARATOR|Treatment Arm A|Treatment Arm A = background immune-chemotherapy (bendamustine and rituximab \[BR\] or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-CHOP\]) for 6 cycles + placebo.
62370171|NCT01974440|EXPERIMENTAL|Treatment Arm B|Treatment Arm B = background immune-chemotherapy (BR or R-CHOP) for 6 cycles + PCI-32765 (Ibrutinib).
62370172|NCT01137227||Description|"2137 studies retrieved in 8 databases (Biomed Central, CINAHL, EMBASE, ERIC, PsycInfo, PUBMED, SCOPUS, SPORTDiscus and uploaded in EndNote Web®.~332 studies were excluded as duplicates by EndNote Web®.~1805 titles and abstracts were assessed independently by two researchers (PG/AM): 1541 studies excluded.~264 studies referred for full-text assessment by two independent investigators (PG/AM)~225 studies were excluded according to the eligibility criteria (in case of discrepancies in the assessment of the researchers, studies were reviewed in duplicate)~39 Studies assessed for quality using STROBE~13 Studies were included in the descriptive synthesis"
62370173|NCT04432324|EXPERIMENTAL|Intravenous Immune Globulin + Standard Medical Treatment|Participants will receive the first intravenous (IV) infusion of IVIG on Day 1 up to a net dose of 2 gram per kilogram (g/kg), based upon participant's (body weight) administered in divided doses as infusions of 500 milligram per kilogram (mg/kg), based upon participant's body weight, over 4 days or 400 mg/kg, based upon participant's body weight, over 5 days. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
62370174|NCT04432324|ACTIVE_COMPARATOR|Standard Medical Treatment|Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29
62370175|NCT00275041|EXPERIMENTAL|cetuximab + irinotecan|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and irinotecan hydrochloride IV over 1½ hours on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed periodically for up to 5 years."
62370176|NCT06141499|EXPERIMENTAL|Providers|Dialysis providers will receive educational material about the kidney transplantation and waitlisting process.
62370177|NCT06141499|EXPERIMENTAL|Patients|Dialysis patients will receive letters with information about their status within the kidney transplantation and waitlisting process.
62370178|NCT01715090|EXPERIMENTAL|Web-based insulin titration|An online web-based insulin titration algorithm to guide patients in self-titration
62370179|NCT01715090|NO_INTERVENTION|Standard care|
62370180|NCT02289833|EXPERIMENTAL|Cohort IHC2+|Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.
62370181|NCT02289833|EXPERIMENTAL|Cohort IHC3+|Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.
62370182|NCT04743401|EXPERIMENTAL|Tele-exergame arm|COVID-19 patients or PUI (persons under investigation) or other inpatients admitted to the MEDVAMC (n=60), with an anticipated length of stay of at least 3 days will be recruited. Participants will be randomized (n=1:1) to either intervention (IG) or control (CG) groups. Both groups will receive standard of care. IG will additionally receive Tele-Exergame MP therapy. Tele-Exergame sessions will range from 3-10 minutes based on patient ability and completed twice daily. They will complete assessments at baseline and at one-month post-hospital discharge.
62370183|NCT04743401|NO_INTERVENTION|Convention care or control group|Standard of care only
62370184|NCT00176878|EXPERIMENTAL|Bone Marrow Failure Disorders|Patients with Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome
62370185|NCT06039280|EXPERIMENTAL|NAC+Dexamethasone|"NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure.~Dexamethasone 20 mg in 5 ml NS 1 hour prior to procedure and 8 mg in 5 ml NS at day 2, day 3. Placebo 5 ml NS 1 hr prior to procedure."
62370186|NCT06039280|ACTIVE_COMPARATOR|NAC+Placebo|NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure.
62370187|NCT01167088|EXPERIMENTAL|Mitoquinone mesylate tablets (MitoQ)|
62743882|NCT04343430|OTHER|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:~* Clinical examination centered on congestion~* Cardiopulmonary , peritoneal , jugular and renal venous Doppler ultrasounds~* Blood sample retrieved for biological assessment and biobanking~* Telephone interview"
62743883|NCT01787396|EXPERIMENTAL|Arm1|Gemigliptin 50mg + Metformin Once daily with dinner
62743884|NCT01787396|EXPERIMENTAL|Arm 2|Gemigliptin 50mg + Placebo(Metformin)Once daily with dinner
62743885|NCT01787396|EXPERIMENTAL|Arm3|Metformin+ Placebo(Gemigliptin 50mg)Once daily with dinner
62743886|NCT05051722||Cohort 1 - AUB / PMB|Women ≥45 years of age, presenting with abnormal uterine bleeding (AUB) or post-menopausal bleeding (PMB). These presenting symptoms clinically warrant evaluation such as an endometrial biopsy to assess for underlying endometrial cancer, endometrial hyperplasia or other endometrial pathology.
62743887|NCT05051722||Cohort 2 - Biopsy-proven EC or AEH or EIN|Women ≥18 years of age with biopsy-proven endometrial cancer (EC), atypical endometrial hyperplasia (AEH), or endometrial intraepithelial neoplasia (EIN) presenting for surgical management of their endometrial pathology.
62370188|NCT01167088|PLACEBO_COMPARATOR|Matching placebo tablet|
62370189|NCT05122013|OTHER|intervention group|The comprehensive 3-month remote intervention program by the multidisciplinary study team includes 6-weeks of online meetings with the study registered dietitian, sleep and physical activity consultants, followed by another 6-weeks of online meetings with the study's registered dietitian, overall 12 weeks containing a total of 12 remote consultations (6 dietitian, 3 physical activity consultant, 3 sleep consultant). In addition, the intervention group will receive weekly text messages to their mobile phone, meant to enhance happiness and subjective wellbeing.
62370190|NCT05122013|OTHER|control group|The control group will receive standard nutrition care: A one-time meeting with the study's registered dietitian at the clinic, focusing on nutrition and behavioral recommendations, followed by the standard recommendation to continue follow up, engage in physical activity and general lifestyle recommendations.
62370191|NCT00003282|EXPERIMENTAL|Diagnostic (EF5)|Patients receive etanidazole derivative EF5 IV over 1-2 hours beginning approximately 24 hours prior to surgery. Tumors are then resected or biopsied after Eppendorf needle electrode measurements.
62370192|NCT04019236|OTHER|" interventional "|New other than Routine nursing care will be used.
62370193|NCT04019236|NO_INTERVENTION|" Control group "|Routine care only will be done for this group
62370194|NCT03050307|EXPERIMENTAL|TAK-438 20 mg|Helicobacter Pylori positive (HP+) participants: TAK-438 20 mg tablet, twice daily (BID) along with lansoprazole placebo-matching, capsule BID in addition to bismuth-containing quadruple antibiotic therapy for the first 2 weeks. Following 2 weeks of eradication therapy participants received TAK-438 20 mg QD along with lansoprazole matching placebo 30 mg, capsule QD for up to 6 weeks. HP negative (HP-) participants: TAK-438 20 mg tablet, (QD) along with lansoprazole matching placebo, 30 mg capsule QD for up to 8 weeks.
62370195|NCT03050307|EXPERIMENTAL|Lansoprazole 30 mg|HP+ participants: Lansoprazole 30 mg, capsule, orally, BID and TAK-438 placebo-matching tablet, orally, BID along with bismuth-containing quadruple antibiotic therapy for first 2 weeks. Following 2 weeks participants received Lansoprazole 30 mg, capsule, orally, QD along with TAK-438 placebo-matching tablet, orally, QD for up to 6 weeks. HP- participants: Lansoprazole 30 mg, capsule, orally, QD along with TAK-438 placebo-matching tablet, orally, QD for up to 8 weeks.
62370196|NCT00564265||GIST|GIST from all gastrointestinal origins: esophagus, stomach, duodenum, jejunum, ileum, colon and rectum
62370197|NCT04741087|ACTIVE_COMPARATOR|AMT-101 (Dose A)|Dose A: AMT-101 Tablet
62370198|NCT04741087|ACTIVE_COMPARATOR|AMT-101 (Dose B)|Dose B: AMT-101 Tablet
62370199|NCT02822352|NO_INTERVENTION|High Definition White Light|Surveillance colonoscopy using High Definition White Light alone
62370200|NCT02822352|ACTIVE_COMPARATOR|High Definition Virtualchromoendoscopy|High Definition Virtualchromoendoscopy
62370201|NCT01962389|EXPERIMENTAL|Winsor Laser Catheter|
62370202|NCT01849562|ACTIVE_COMPARATOR|Sovaprevir 200 milligrams (mg), ACH-3102 150/50 mg, RBV 1000-1200 mg|Sovaprevir 200 mg once daily (qd) + ACH-3102 150 mg loading dose on Day 1, followed by 50 mg qd + RBV weight-based 1000-1200 mg qd for 12 weeks.
62370203|NCT01849562|ACTIVE_COMPARATOR|Sovaprevir 400 mg, ACH-3102 150/50 mg, RBV 1000 -1200 mg|Sovaprevir 400 mg qd + ACH-3102 150 mg loading dose on Day 1, followed by 50 mg qd + RBV weight-based 1000-1200 mg qd for 12 weeks.
62370204|NCT01849562|PLACEBO_COMPARATOR|Placebo|Placebo for sovaprevir capsule qd + placebo for ACH-3102 150 mg loading dose on Day 1, followed by placebo for 50 mg qd + placebo for weight-based RBV qd for 12 weeks.
62370205|NCT00957190|EXPERIMENTAL|Cosopt|Cosopt ('Dorzolamide 20 mg and Timolol 5 mg) bid And Xalatan hs Vs Xalatan hs Alone
62370206|NCT03228849|ACTIVE_COMPARATOR|Conservative Treatment|Patients were treated with 6 weeks with splinting and were then started on physical therapy for 2 weeks.
62370207|NCT03228849|ACTIVE_COMPARATOR|Surgical Treatment|Patients were treated with the new suture anchor technique and after 6 weeks were started on physical therapy for 2 weeks.
62370208|NCT01785290|EXPERIMENTAL|Haloperidol 1mg/q8h|Prophylactic haloperidol of 1 mg/q8h i.v.
62743888|NCT05051722||Cohort 3 - Cervix pathology|Women ≥18 years of age presenting for a clinically indicated colposcopy, cervical biopsy, or surgical excision, as follow-up for an abnormal Pap test or cervical mass identified on physical exam. Final clinical diagnoses within this cohort may include mild cervical intraepithelial neoplasia (CIN 1), moderate and/or severe CIN (CIN 2/3), adenocarcinoma in situ (AIS), invasive cervical cancers (adenocarcinoma or squamous cell carcinoma), or possibly benign findings.
62743889|NCT05051722||Cohort 4 - Benign Uterine Pathology|Women with any of four benign gynecologic conditions including: uterine fibroids, benign endometrial polyps, adenomyosis and endometriosis. All women enrolled in this cohort will be undergoing clinically indicated gynecologic surgery (hysterectomy, myomectomy, polypectomy, or laparoscopic tissue excision) for the specific benign gynecologic condition. Verification of the final benign diagnosis will be based on pathology diagnosis of clinically-indicated tissue removed during surgery.
62743890|NCT05051722||Cohort 5 - Healthy Control Women|Healthy women ≥45 years of age presenting for well-woman exams to serve as a control group. These women will have no clinically evident gynecologic precancers, gynecologic cancers, or clinically evident or symptomatic benign gynecologic conditions. These women will not have known or clinically-suspected AUB, PMB, fibroids, endometriosis, benign endometrial polyps, or adenomyosis, nor will they have any active gynecologic or non-gynecologic acute medical conditions.
62743891|NCT05051722||Cohort 6- Isolated Adnexal Mass Cohort (ovarian or fallopian mass)|Women ≥50 years of age and postmenopausal (12 months since LMP or available blood hormone levels confirming postmenopausal status) and an isolated adnexal mass or isolated bilateral adnexal masses being surgically removed. These patients will have a final diagnosis of any of the following: benign ovarian neoplasm, borderline tumor of the ovary, or clinically early-stage OC.
62743892|NCT05051722||Cohort 7 - OC Cohort - Biopsy proven or clinically suspected ovarian cancer (OC)|Women ≥18 years of age with ovarian cancer (OC) (clinically probable based on distribution of pelvic/abdominal masses on imaging, elevated CA-125, ascites, and/or imaging-guided biopsy proven) presenting for neoadjuvant chemotherapy or primary surgical management (debulking or staging) of their OC. The umbrella of OC also includes fallopian tube cancer and primary peritoneal cancer. All histologies are eligible for enrollment.
62743893|NCT03220932|EXPERIMENTAL|Cytoreductive surgery combined with HIPEC|All patients will start with three cycles of CT-BEV 15 mg/kg, and will then be randomly. Then one cycle of monochemotherapy without bevacizumab is administered and followed by an interval CRS and HIPEC with postoperative chemotherapy and bevacizumab (CT-BEV - 15 mg/kg once every 3 weeks) until disease progression
62743894|NCT03220932|ACTIVE_COMPARATOR|Aurelia arm|Chemotherapy and bevacizumab (CT-BEV) once every 3 weeks from enrollment until disease progression
62743895|NCT01649674|ACTIVE_COMPARATOR|PEG|polyethylene glycol solution 2 liters
62743896|NCT01649674|ACTIVE_COMPARATOR|NapP|Sodium picosulphate and magnesium citrate solution 300 ml
62743897|NCT06452641|EXPERIMENTAL|Jones technique|Strain counter strain (Jones technique) will be applied to this group
62743898|NCT06452641|ACTIVE_COMPARATOR|Cross-friction massage|Cross-friction massage will be applied to this group.
61986286|NCT03479476|PLACEBO_COMPARATOR|Placebo Medication|The placebo will be dosed in a weight-dependent manner. Liquid placebo will be provided to any participants unable to swallow the placebo capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
62370209|NCT01785290|EXPERIMENTAL|Haloperidol 2mg/q8h|Prophylactic haloperidol 2mg/q8h i.v.
62370210|NCT01785290|PLACEBO_COMPARATOR|Sodium chloride 0.9%|Placebo (Sodium chloride 0.9%) three times a day
62370211|NCT04998292|EXPERIMENTAL|Low level laser therapy|
62370212|NCT04998292|ACTIVE_COMPARATOR|Control|
62370213|NCT00981292|ACTIVE_COMPARATOR|135mg EGCG|
62370214|NCT00981292|ACTIVE_COMPARATOR|270mg EGCG|
62370215|NCT00981292|PLACEBO_COMPARATOR|0mg EGCG|
62370216|NCT03794011|EXPERIMENTAL|fetoscopic surgical repair|Single arm study. All patients will receive the fetoscopic repair.
62370217|NCT04603274|OTHER|upper extremity diagnosed with carpal tunnel syndrome|8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians
62370218|NCT03904004||Esophageal motility disorders|Individuals with sympmtoms related to esophageal motility disorders who receive a endoscopic or surgical treatment
62370219|NCT01462045|EXPERIMENTAL|Exercise Group|Participants who are screened positive for PTSD and participate in the series of 16 standardized, semiweekly 60-minute mindfulness-based exercise sessions. The intervention consists of stretching and balancing movements combined with breathing and a focus on mindfulness.Over the course of 8 weeks, the intensity of the exercise increases, but the sequence of the movements is the same.
62370220|NCT01462045|NO_INTERVENTION|Control Group|Participants who are screened positive for PTSD but do not participate in the mindfulness-based exercise.
62370221|NCT01462045|NO_INTERVENTION|Base Group|Healthy volunteers who are not screened positive for PTSD and do not participate in the mindfulness-based exercise.
62370222|NCT04816370|EXPERIMENTAL|pSS group|primary Sjögren's syndrome group
62370223|NCT04816370|EXPERIMENTAL|Control Group|Control group
62370224|NCT04816370|EXPERIMENTAL|pSS Premenopausal|primary Sjögren's syndrome premenopausal patients
62370225|NCT04816370|EXPERIMENTAL|pSS Postmenopausal|primary Sjögren's syndrome postmenopausal patients
62370226|NCT04745247|EXPERIMENTAL|RSS|Repetitive somatosensory stimulation (RSS)
62370227|NCT04745247|PLACEBO_COMPARATOR|Sham RSS|Sham Repetitive somatosensory stimulation (RSS)
62370228|NCT06336681|EXPERIMENTAL|Inspiratory Muscle Training (IMT) group|The test protocol requires participants to inhale maximally (maximum inspiratory pressure, MIP) against 2mm diameter leak and sustain inhalation (sustained maximal inspiratory pressure, SMIP) until task failure. Participants will complete 3 SMIP maneuvers with each training session and use the best of the three for that day's training template (corresponding to about 80% SMIP for the IMT group) via the PrO2Fit software. Participants must match or exceed the SMIP template with each increasing level of the work-rest ratio. Work at each level consists of 6 breaths, 36 breaths total. If six breaths are completed, the next level starts. Rest intervals will progressively shorten as training continues from 40-seconds to 5-seconds. The session will be terminated if participants are unable to match at least 90% of the training template for two consecutive breaths or have completed all 36 breaths. Training will be done 3 times a week, and over 8-weeks.
62370229|NCT06336681|SHAM_COMPARATOR|Sham Inspiratory Muscle Training (Sham-IMT) group|Similar to the IMT group protocol, participants will be required to complete 3 SMIP maneuvers with each training session. Participants will use the best of the three for that day's training template (corresponding to about 30% SMIP for the Sham-IMT group) via the PrO2Fit software. Participants must match or exceed the SMIP template with each increasing level of the work-rest ratio. Work at each level consists of 6 breaths, 36 breaths total. If six breaths are completed, the next level starts. Rest intervals will progressively shorten as training continues from 40-seconds to 30-, 20-, 15-, 10-, and 5-seconds. The training session will be terminated if participants are unable to match at least 90% of the training template for two consecutive breaths or have completed all 36 breaths. Training will be done 3 times a week, and over 8-weeks.
62370230|NCT05580185||Weaning failure|Defined as the failure to pass a spontaneous breathing trial or the need for reintubation or death within 48 hours after extubation
62370231|NCT05580185||Weaning success|Defined as a successful spontaneous breathing trial and is not reintubated or dies in the first 48 hours after extubation
62370232|NCT05589012||Human placentas and trophoblasts (biological waste) from uncomplicated pregnancies.|"The placentas will be collected following a birth by caesarean section after oral and written information by delivery of the information note for women who have had a normal singleton pregnancy at term.~Similarly, trophoblasts are collected following endo-uterine aspiration in the context of voluntary termination of pregnancy.~* Cell line and virus~* Infection of human placental culture explants~* Determination of viral load in tissues by qRT-PCR"
62370233|NCT05695404||"The Digital arm"|Surgeons had a virtual 3D reconstruction of the patient's pulmonary anatomy by the Visible Patient Planning (VP) software
62370234|NCT05695404||"The Digital+Object arm"|Surgeons had at their disposal on the operating field, in a transparent sterile bag, the 3D printed model, made from the virtual 3D VP software of the patient's lung anatomy
62370235|NCT01755104|EXPERIMENTAL|Stablor|dietary supplement Stablor
62370236|NCT01755104|PLACEBO_COMPARATOR|Placebo|dietary supplement Placebo
62370237|NCT05963555|EXPERIMENTAL|Whole-Body Photobiomodulation|Light therapy in both the visible and near-infrared range (non-UV) applied to the whole body in a light pod or bed.
62370238|NCT05963555|EXPERIMENTAL|Dry Float|Simulates the effects of traditional Float-REST therapy. Instead of contact with salt water, the dry float system has a very thin membrane that cradles the body and provides a warm sensation, similar to that experienced in a traditional flotation tank.
62370239|NCT05963555|EXPERIMENTAL|Localized Photobiomodulation|Light therapy in both the visible and near-infrared range (non-UV) applied locally to only a specific body region.
62370240|NCT05963555|NO_INTERVENTION|Control|Participants in the control group will be asked to keep their normal daily routine.
62370241|NCT02488356|EXPERIMENTAL|Litramine|Patented fibre complex from Opuntia ficus-indica (Litramine)
62370242|NCT02488356|PLACEBO_COMPARATOR|Placebo|Inert fillers that is manufactured to look and taste the same as verum
62370243|NCT04864327|NO_INTERVENTION|control|Usual care
62370244|NCT04864327|OTHER|intervention|5 minutes brief smoking cessation advise
62370245|NCT03868475|EXPERIMENTAL|Vacuum-assisted percutaneous excision|"Patients will undergo vacuum-assisted percutaneous excision (VAPE). The intervention group will have post-procedure imaging the same day to confirm complete excision.~The intervention group will then have imaging at 6, 12, and 24 months as per the radiology algorithms for following suspicious lesions (BIRADS 3 category). If at any point during the imaging follow up, a suspicious lesion or calcifications are detected, it would be sampled with core needle biopsy and then surgically excised as appropriate.~The intervention group will also be seen in clinic at 1 month with no imaging and then at 6, 12, and 24 months to correspond to the imaging visits."
62743899|NCT00822419|ACTIVE_COMPARATOR|lidocaine|Lidocaine 5% cream 5 gr will be double blindly put on the skin preoperatively
62743900|NCT00822419|EXPERIMENTAL|ketamine|ketamine cream 5% 5gr will be put on the skin preoperatively
62743901|NCT00822419|SHAM_COMPARATOR|placebo|non-drug similar cream will be put on the skin preoperatively
62743902|NCT02789345|EXPERIMENTAL|Arm A: Ramucirumab + Osimertinib|Dose Finding: Participants received Ramucirumab 10 milligrams/kilogram (mg/kg) given intravenously (IV) on day 1 every 2 weeks and osimertinib 80 milligrams (mg) given orally daily during each 14-day cycle.
62743903|NCT02789345|EXPERIMENTAL|Arm B: Necitumumab + Osimertinib|Dose Finding: Participants received Necitumumab 800 mg given IV on days 1 and 8 every 3 weeks and osimertinib 80 mg given orally daily during each 21 day cycle.
62743904|NCT02789345|EXPERIMENTAL|Cohort A: Ramucirumab + Osimertinib|Dose Expansion: Participants received Ramucirumab 10 mg/kg given IV on day 1 every 2 weeks and osimertinib 80 mg given orally daily during each 14-day cycle.
62743905|NCT06277414||ERCP|The postoperative laboratory test results, imaging results and symptoms were collected
62743906|NCT00969592|ACTIVE_COMPARATOR|insulin glulisine, insulin aspart|insulin glulisine administration during first glucose clamp, insulin aspart administration during second glucose clamp
62743907|NCT00969592|ACTIVE_COMPARATOR|insulin aspart, insulin glulisine|insulin aspart administration during first euglycemic clamp, insulin glulisine administration during second clamp
62743908|NCT03667807|EXPERIMENTAL|rTMS condition 1|
62743909|NCT03667807|EXPERIMENTAL|rTMS condition 2|
62743910|NCT03667807|EXPERIMENTAL|rTMS condition 3|
62743911|NCT02487654|ACTIVE_COMPARATOR|Pulmonary vein isolation|Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.
62743912|NCT02487654|EXPERIMENTAL|Ganglionated plexus ablation|Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium
62370246|NCT03868475|ACTIVE_COMPARATOR|Open surgical excision|"Patients will undergo standard open surgical excision.~The control group will then have follow up imaging at 12 and 24 months as per the usual radiology algorithms following excision of a lesion. If at any point during the imaging follow up, a suspicious lesion or calcifications are detected, it would be sampled with core needle biopsy and then surgically excised as appropriate.~The control group will also be seen in clinic at 1 month with no imaging and then at 12 and 24 months to correspond to the imaging visits."
62743913|NCT01584791|EXPERIMENTAL|clopidogrel napadisilate + aspirin|
62743914|NCT01584791|ACTIVE_COMPARATOR|clopidogrel bisulfate + aspirin|
62743915|NCT03789136||Primary colon cancer|
62743916|NCT03789136||Liver metastases|
62743917|NCT03789136||Inguinal hernia (control)|
62743918|NCT03789136||Abdominal hysterectomy (control)|
62370247|NCT04306302|EXPERIMENTAL|Medium-dose ExPEC10V or Placebo: Group 1|Participants will be randomized to receive a single intramuscular (IM) injection of medium dose of ExPEC10V or Placebo on Day 1.
62370248|NCT04306302|EXPERIMENTAL|High-dose ExPEC10V or Placebo: Group 2|Participants will be randomized to receive a single IM injection of high dose (based on safety assessment through Day 15 postvaccination of medium dose) of ExPEC10V or Placebo on Day 1.
62370249|NCT03455634|ACTIVE_COMPARATOR|Twin Block|Twin Block functional appliance
62370250|NCT03455634|ACTIVE_COMPARATOR|Sander|Sander bite jumping appliance
62370251|NCT03455634|NO_INTERVENTION|Control|no intervention
62370252|NCT04001660|EXPERIMENTAL|Subbrow Blepharoplasty Combined with Double Eyelid Surgery|An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
62370253|NCT02692560|EXPERIMENTAL|I-STAND|Participants randomly assigned to the I-STAND intervention group will receive 2 in-person health coaching sessions and 4 biweekly phone-based health coaching sessions. They will receive a wristband that gives a mild vibration after 20 minutes of inactivity and will be encouraged to stand if possible after each inactivity alert. Participants may also choose to receive biweekly email reminders in the weeks between coaching calls. They will also receive a workbook with content around reducing sitting time.
62743919|NCT06088953|EXPERIMENTAL|perception disorder in noise in patients weakened by cognitive disorders.|The CogAudio project aims to detect early and in an ambulatory mode in a memory centre a speech perception disorder in noise thanks to the VRB test in patients weakened by cognitive disorders.
62743920|NCT03118856||HD-WLE|Intervention: Prediction of polyp histology with HD-WLE
62743921|NCT03118856||EC|Intervention: Prediction of polyp histology with EC
62182469|NCT06467214|EXPERIMENTAL|CONNECTED|CONNECTED integrates two evidence-based care models--peer support and patient navigation--and involves the delivery of three services by peers: 1) peer support, which includes person-centered assessment for drivers of social isolation; 2) group-based interventions to address Veterans' social isolation and 3) navigation, which involves connecting Veterans to social resources to facilitate social participation. CONNECTED is delivered through individual and group sessions over 8 weeks. All sessions will be delivered via videoconference. Veterans may choose to receive some peer support sessions in person when feasible, to facilitate engagement and retention.
62743922|NCT02724917|EXPERIMENTAL|APN1125, Low Dose|APN1125, Low Dose
62743923|NCT02724917|EXPERIMENTAL|APN1125, Mid Dose|APN1125, Mid Dose
62743924|NCT02724917|EXPERIMENTAL|APN1125, High Dose|APN1125, High Dose
62743925|NCT02724917|PLACEBO_COMPARATOR|Placebo|Placebo to match
62743926|NCT04008641||Parents after pediatric antenatal consultation|Survey after pediatric antenatal consultation, for both members of couple if possible
62743927|NCT04972682|EXPERIMENTAL|Laparoscopic total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy|This arm includes patients with endometrioid adenocarcinoma of the endometrium of low- and intermediate-risk who will undergo a laparoscopic total hysterectomy and bilateral salpingo-oophorectomy with sentinel lymph node biopsy (SLNB) performed with near-infrared-guided surgery using indocyanine green (ICG).
62743928|NCT00979966|EXPERIMENTAL|A|Temsirolimus
62743929|NCT00979966|EXPERIMENTAL|B|Sunitinib
62743930|NCT05024916|EXPERIMENTAL|Intervention|Participants will receive the dietary intervention. Participants will take 1 serving of blueberries/day.
62743931|NCT05024916|ACTIVE_COMPARATOR|Control|Participants will receive a placebo. Participants will take 1 serving of placebo/day.
62743932|NCT04190407|OTHER|Pediatric patients scheduled for day case surgery|A tourniquet was used to raise the vein for entry into the vein every 15 s after the ciliary reflex disappeared. If the patient showed no response to the tourniquet (movement, coughing, or laryngospasm), an experienced anesthesiologist entered a vein in the dorsum of one hand using a 22-24 gauge cannula.
62743933|NCT00594763||TS|Women with Turner syndrome
62743934|NCT03363087|EXPERIMENTAL|Mapping (Rhythmia) and ablation (IntellaNav MiFi)|Automated high density biatrial scar mapping Pacing confirmation of scar Collection of impedance data during clinical ablation
62743935|NCT03363087|EXPERIMENTAL|Mapping (Rhythmia) and ablation (StablePoint)|Automated high density biatrial scar mapping Pacing confirmation of scar Collection of impedance data during clinical ablation Contact force measurements
62743936|NCT03363087|EXPERIMENTAL|Mapping (Precision)|Automated high density left atrial mapping in AF and SR in different bipole orientations
62743937|NCT00673348||1|Patients suspected of invasive fungal infection (proven or probable cases) with immunocompromised state (for example, during neutropenia, receiving HSCT) in Catholic Hematopoietic Stem Cell Transplantation \[HSCT\] Center in Seoul, Korea.
62743938|NCT04234204|EXPERIMENTAL|Fezolinetant group|Participants will receive fezolinetant once daily for 24 weeks.
62743939|NCT04234204|PLACEBO_COMPARATOR|Placebo group|Participants will receive matching placebo for 12 weeks, and then receive fezolinetant for 12 weeks once daily.
62743940|NCT02189044|OTHER|exercises; muscle strength|Evaluate the effects of Pilates exercises on respiratory muscle strength in elderly women before and after eleven weeks of training
62370254|NCT02692560|ACTIVE_COMPARATOR|Healthy Living|Participants randomly assigned to the Healthy Living enhanced usual care control group will receive 1 in-person health coaching session and 5 biweekly check-in letters by mail. They will receive a workbook with general healthy living topics that are not expected to impact sitting time. All content is taken from Kaiser Permanente Washington's website and is available to all members. Participants will select topics of interest and review them on their own with no further health coaching.
62370255|NCT05469880|ACTIVE_COMPARATOR|moisturizing cream and 5% benzoyl peroxide gel|Participants apply the 5% benzoyl peroxide gel every evening and the moisturizing cream every morning for 3 months. Then they are divided into 2 groups: one applies the anti-acne face cream every morning for 3 months and the other one the moisturizing cream every morning for 3 months.
62370256|NCT05469880|EXPERIMENTAL|anti-acne face cream and 5% benzoyl peroxide gel|Participants apply the 5% benzoyl peroxide gel every other night and the anti-acne face cream every morning for 3 months. Then they are divided into 2 groups: one applies the anti-acne face cream every morning for 3 months and the other one the moisturizing cream every morning for 3 months.
62370257|NCT01364142||thoracic surgery|Patients undergoing thoracic surgery in which one lung ventilation is needed.
62370258|NCT01462591|EXPERIMENTAL|L-citrulline|L-citrulline (100mg/kg of body weight per day for 2 weeks)
62370259|NCT01462591|PLACEBO_COMPARATOR|Maltodextrin|6g/day of placebo (maltodextrin)
62743941|NCT05760131||Patients wiht Hyporthyroidism|Patients diagnosed with hypothyroidism.
62743942|NCT04240041||Pregnant women at 32-36 weeks gestational age|Pregnant women at 32-36 weeks gestational age with sure dates and crown-rump length dating ultrasound
62370260|NCT02768389|EXPERIMENTAL|Modified Atkins Diet and Bevacizumab|Patients and caregivers will be educated by a nutritionist skilled in the MAD. Patients will also be receiving Bevacizumab as standard of care.
62370261|NCT00663689|EXPERIMENTAL|1|non-randomized open-label uncontrolled phase II trial erlotinib 150mg qd until disease progression or unacceptable toxicity
62370262|NCT00954824|EXPERIMENTAL|Endotoxin (LPS)|Single administration low-dose (3 ng/kg) endotoxin (LPS).
62370263|NCT02071329|EXPERIMENTAL|Vaccine FP-01.1|Vaccine FP-01.1
62370264|NCT02071329|PLACEBO_COMPARATOR|Placebo|Placebo
62370265|NCT03580525|EXPERIMENTAL|nicotine saline infusion 0.00mcg/kg/s|0.00 mcg/kg/s The day order will be randomized per day
62370266|NCT03580525|EXPERIMENTAL|nicotine infusion 0.24mcg/kg/s|0.24mcg/kg/s The day order will be randomized per day
62370267|NCT03580525|EXPERIMENTAL|nicotine infusion 0.096mcg/kg/s|0.096mcg/kg/s The day order will be randomized per day
62370268|NCT03580525|EXPERIMENTAL|nicotine infusion 0.048mcg/kg/s|0.048mcg/kg/s The day order will be randomized per day
62370269|NCT03580525|EXPERIMENTAL|nicotine infusion 0.024mcg/kg/s|0.048mcg/kg/s The day order will be randomized per day
62370270|NCT03288727|EXPERIMENTAL|Negative IF result|
62370271|NCT03288727|EXPERIMENTAL|Positive IF result|
62370272|NCT01723176||Patients in Cardiopulmonary Failure|patients in cardiopulmonary failure
62370273|NCT04027036|ACTIVE_COMPARATOR|fIPV Intramuscular|180 children will receive 0,1 ml of inactivated poliovirus vaccine intramuscularly
62370274|NCT04027036|ACTIVE_COMPARATOR|fIPV Intradermal|180 children will receive 0,1ml of inactivated poliovirus vaccine intradermally
62370275|NCT06433024||Individuals with CVD (Treatment Group)|Participants who have been diagnosed with Chronic Venous Disease (CVD).
62370276|NCT06433024||Individuals Without CVD (Control Group)|Participants who have not been diagnosed with CVD.
62370277|NCT01023373|EXPERIMENTAL|B:PTRS|B: the same medical therapy, as previously described in group A, associated with PTRS
62370278|NCT01023373|ACTIVE_COMPARATOR|A:medical therapy|hypotensive drugs, statins and antiplatelet therapy
62370279|NCT00673218|PLACEBO_COMPARATOR|1|Saline injection to match active
62370280|NCT00673218|EXPERIMENTAL|Treatment|Active treatment with Xolair 150 to 375 mg is administered SC every 2 or 4 weeks
62743943|NCT03445377|ACTIVE_COMPARATOR|Real-time continuous glucose monitoring|Subjects will be reviewed and a blood sample will be taken for the measurement of HbA1c. Training on the use of DEXCOM G5 or similar will be provided by the research team. Competency on the use of the system will be evaluated. Participants will be advised to use real-time CGM continuously for the next 8 weeks. At the end of the first intervention, a blood sample for the measurement of HbA1c will be taken. Validated questionnaires evaluating diabetes-related distress, management and user acceptance will be completed.
62743944|NCT03445377|PLACEBO_COMPARATOR|Self-monitoring of blood glucose|Subjects will be reviewed and a blood sample will be taken for the measurement of HbA1c. During the Control Period, masked CGM will be applied for one week, during Week 1, 4 and 8. At the end of this, a blood sample for the measurement of HbA1c will be taken. Validated questionnaires evaluating diabetes-related distress, management and user acceptance will be completed.
62743945|NCT03859440|EXPERIMENTAL|DSiHy (test lens)|
62743946|NCT03859440|ACTIVE_COMPARATOR|Silicone hydrogel soft contact lens CE-marked for daily use|
62743947|NCT04345029|EXPERIMENTAL|Experimental group (Lippia citriodora + sabdariffa)|"Consumption for 60 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.~Two capsules per day will be consumed thirty minutes before breakfast orally for 60 days."
62743948|NCT04345029|PLACEBO_COMPARATOR|control group Placebo (sucrose)|Two capsules per day will be consumed thirty minutes before breakfast orally for 60 days.
62743949|NCT02841683|ACTIVE_COMPARATOR|Lifestyle counseling|A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
62743950|NCT02841683|NO_INTERVENTION|Current practices|Current practices of smoking cessation in France
62743951|NCT05222620|OTHER|Arm A (single fraction SRS)|Patients undergo single fraction SRS.
62370281|NCT03939676||Major Depressive Disorder or Bipolar Disorder|All eligible participants will be included in this single study arm.
62370282|NCT02118636||Aromatase inhibitor therapy|Subjects who are starting treatment with any of the three aromatase inhibitor (AI) medications
62370283|NCT02310360||Healthy volunteers|
62370284|NCT00700349|NO_INTERVENTION|1|Individuals who were rejected from receiving a loan from a micro-lending organization were randomized to continue receiving no loan.
62370285|NCT00700349|EXPERIMENTAL|2|"Individuals who were rejected from receiving a loan from a micro-lending organization were randomized to receive a second look, to be reconsidered for a loan by loan officers."
62370286|NCT06387277||Arms of healthy female from 20 to 45 years old|It is a randomized intra-individual comparative study where two areas of the skin are ablated using an erbium YAG laser at Visit 1, with a surface area of approximately 6cm² (Z1 and Z3). Additionally, two healthy areas (Z2 and Z4), with a similar surface area, are identified on each forearm. The study involves comparing the areas treated with the product RV1551P GB3224 to the untreated areas (randomized arms).
62370287|NCT03949127|EXPERIMENTAL|Exercise Group|The group who will exercise to manage pain.
62743952|NCT05222620|OTHER|Arm B (fractionated SRS)|Patients undergo fractionated SRS.
62743953|NCT02599207|EXPERIMENTAL|Matched related umbilical cord blood|Six subjects will receive an infusion of HLA matched sibling umbilical cord blood cells.
62370288|NCT03949127|NO_INTERVENTION|Control Group|The group who will not take part in any exercises and only have to do assessments.
62370289|NCT04192318|EXPERIMENTAL|Hospital-based violence prevention with community initiative|Youth who are living in communities that receive Communities that Care Prevention System (CTC) will also receive Bridging the Gap (BTG), a hospital-based violence prevention program with 6-months of community case management.
62370290|NCT04192318|EXPERIMENTAL|Hybrid hospital based violence prevention|Youth who do not live in a community that has CTC but will receive BTG.
62743954|NCT02599207|EXPERIMENTAL|Mismatched related umbilical cord blood|Nine subjects will receive an infusion of HLA-mismatched (≥3/6 match) or matched sibling umbilical cord blood cells.
62370291|NCT04192318|ACTIVE_COMPARATOR|Treatment as usual|Youth living in a community without the CTC program and will receive treatment as usual (TAU) in the hospital.
62743955|NCT06662266|OTHER|Diverse group of participants who require hindfoot or ankle arthrodesis|The selection criteria are designed to ensure that the study population represents the typical patients undergoing these procedures.
62743956|NCT03393819|EXPERIMENTAL|Duraprep Surgical Solution|Surgical site (hip) is prepared with Duraprep (iodine-alcohol) prior to surgery according to package instructions.
62370292|NCT04192318|EXPERIMENTAL|Treatment as usual with community initiative|Youth living in a community with the CTC program and will receive treatment as usual (TAU) in the hospital.
62370293|NCT04516941|ACTIVE_COMPARATOR|Edoxaban|Edoxaban 60 mg q.d., or 30 mg q.d. in patients with CrCl = or \<50 ml/min or body weight equal or less than 60 kg from randomization to end of study visit at day 25 (+/-3).
62370294|NCT04516941|ACTIVE_COMPARATOR|Colchicine|Colchicine at 0.5 mg per os (PO) twice daily for the first 3 days and then once daily from randomization to day 14 (+/-3) days. Treatment could be continued to day 25 (+3/-3 days).
62370295|NCT04516941|NO_INTERVENTION|No Edoxaban and No Colchicine|No intervention
62743957|NCT03393819|EXPERIMENTAL|Chloraprep Surgical Solution|Surgical site (hip) is prepared with Chloraprep (chlorhexidine-alcohol) prior to surgery according to package instructions.
62743958|NCT03515733|EXPERIMENTAL|PF-04995274|PF-04995274, three x 5mg tablet (15mg total), once daily for 7-9 days
62370296|NCT04516941|ACTIVE_COMPARATOR|Edoxaban and Colchicine|"Edoxaban 60 mg q.d., or 30 mg q.d. in patients with CrCl = or \<50 ml/min or body weight equal or less than 60 kg from randomization to end of study visit at day 25 (+/-3).~Colchicine at 0.5 mg per os (PO) twice daily for the first 3 days and then once daily from randomization to day 14 (+/-3) days. Treatment could be continued to day 25 (+3/-3 days)."
62370297|NCT01125904|EXPERIMENTAL|crizotinib|
62370298|NCT06417268|ACTIVE_COMPARATOR|Group C|Patients will receive caudal analgesia
62370299|NCT06417268|ACTIVE_COMPARATOR|Group B|patients will receive PENG block and Lateral Femoral Cutaneous Nerve block
62743959|NCT03515733|PLACEBO_COMPARATOR|Placebo|3 placebo tablets, once daily for 7-9 days
62743960|NCT06607666||Low dose to fg-SRLs|Patients responsive to low dose to fg-SRLs
62743961|NCT06607666||High dose to fg-SRLs|Patients responsive to high dose to fg-SRLs
62743962|NCT06607666||Other treatments|Patients not responsive to low/high dose of fg-SRLs
62743963|NCT04308239|EXPERIMENTAL|Reactive balance training|"Four training sessions, conducted twice a week for two weeks in groups of 1-2 participants. Each session was 0.5-1 hours, with an active training time of 30 minutes for each participant.~Reactive balance training involved both slip and trip training.~Slip training involved repeatedly stepping onto a low-friction interface (nylon fabric placed over a 0.9 × 0.9 meter polycarbonate sheet) while practicing controlling/decelerating the slipping foot and properly positioning the non-slipping foot under the pelvis.~Trip training involved repeatedly practicing recovery from simulated trips on a modified treadmill. While standing on a modified treadmill, the treadmill belt was quickly accelerated posteriorly to elicit a forward loss of balance that mimicked a trip while walking. Participants attempted to step to avert a fall, and to establish a stable gait on the treadmill, after which the treadmill speed was slowed to zero to complete the trial."
62743964|NCT04308239|ACTIVE_COMPARATOR|Control balance training|"Four training sessions, conducted twice a week for two weeks in groups of 1-2 participants. Each session was 0.5-1 hours, with an active training time of 30 minutes for each participant.~The control intervention involved general balance exercises adapted from the Otago Exercise program. Briefly, all four sessions involved balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support)."
62370300|NCT05315024|EXPERIMENTAL|Repeat 0.5ml IM Quadrivalent IIV (IIV-IM)|Repeat 0.5ml IM Quadrivalent IIV (IIV-IM) (15micrograms haemagglutinin per vaccine strain)
62370301|NCT05315024|EXPERIMENTAL|0.1ml ID Quadrivalent IIV (IIV-ID)|0.1ml ID Quadrivalent IIV (IIV-ID) (3micrograms haemagglutinin per vaccine strain)
62370302|NCT05315024|EXPERIMENTAL|0.1ml ID Quadrivalent IIV|0.1ml ID Quadrivalent IIV (3micrograms haemagglutinin antigen per vaccine strain) + 5% imiquimod cream (IIV-Q-ID)
62370303|NCT04480749|OTHER|Routine Testing|Among men in the control group, they will receive a list of local clinics that can provide free syphilis testing.
62370304|NCT04480749|EXPERIMENTAL|Self-Testing|In the intervention arm we will provide a treponemal rapid syphilis test kit to all individuals in the intervention arm of the pilot, delivered through MSM community facilitators. This is similar to existing rapid treponemal test kits that are available at many clinical facilities. Kits will be accompanied by simplified pictorial instructions on finger prick blood sample collection.
62370305|NCT03622216|EXPERIMENTAL|Bradanicline QD|Randomized crossover design of 3 different doses of bradanicline (film-coated tablets) to be administered orally QD
62743965|NCT03106441|EXPERIMENTAL|High flow oxygen therapy by nasal cannula|Experimental Device : High flow oxygen therapy by nasal cannula.
62743966|NCT03106441|ACTIVE_COMPARATOR|Facial mask oxygenation in BIPAP ventilation|Active Comparator: Facial mask oxygenation in BIPAP ventilation
62370306|NCT03622216|PLACEBO_COMPARATOR|Placebo|Randomized crossover design of matching placebo tablets to be administered orally QD
62370307|NCT02550093|EXPERIMENTAL|Oxytocin, then Normal Saline|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Oxytocin prior to Thermal Evaluation System Testing on intervention 1 (day 1). Following a wash-out period of 13 days the same subject will then receive a nasal spray(s) into each nostril of 4 Units up to 32 units of Normal Saline prior to Thermal Evaluation System Testing on intervention 2 (day 14).
62370308|NCT02550093|EXPERIMENTAL|Normal Saline, then Oxytocin|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Normal Saline prior to Thermal Evaluation System Testing on intervention 1 (day 1). Following a wash-out period of 14 to 15 days the same subject will then receive nasal spray(s) into each nostril of 4 Units up to 32 units of Oxytocin prior to Thermal Evaluation System Testing on intervention 2 (day 14).
62370309|NCT03878043||Patients without Readmissions|Patients with TSDH who were not readmitted within a 6-month time period following their initial visit.
62370310|NCT03878043||Patients with Readmissions|Patients with TSDH who were readmitted within a 6-month time period following their initial visit.
62370311|NCT04672031|NO_INTERVENTION|Control Arm|Patients in the control arm will be instructed to check blood sugars seven times per day: fasting, pre-prandial, and 1 hour after each meal. The glycemic targets for the control arm will be defined as follows: fasting ≤95 mg/dL, pre-prandial ≤95 mg/dL, and 1-hour postprandial ≤140 mg/dL (i.e. conventional targets). Patients who do not achieve glycemic goals with diet and exercise will be started on medical therapy (metformin or insulin) at the discretion of a maternal-fetal medicine subspecialist and endocrinologist.
62370312|NCT04672031|EXPERIMENTAL|Interventional Arm|Patients in the experimental arm will be instructed to check blood sugars seven times per day: fasting, pre-prandial, and 1 hour after each meal. The glycemic targets for the intervention arm will be defined as follows: fasting ≤80 mg/dL, pre-prandial ≤80 mg/dL, and 1-hour postprandial ≤110 mg/dL. Patients who do not achieve glycemic goals with diet and exercise will be started on medical therapy (metformin or insulin) at the discretion of a maternal-fetal medicine subspecialist and endocrinologist.
62370313|NCT04847141|EXPERIMENTAL|C19-IG 20% 1 g|Participants will receive 1 gram (g) of C19-IG 20% subcutaneous (SC) infusion containing one syringe of 5 milliliters (mL) C19-IG 20% plus one syringe of 5 mL sterile 0.9% sodium chloride (NaCl) on Day 1.
62370314|NCT04847141|EXPERIMENTAL|C19-IG 20% 2 g|Participants will receive 2 g of C19-IG 20% SC infusion containing two syringes 5 mL each of C19-IG 20% on Day 1.
62370315|NCT04847141|PLACEBO_COMPARATOR|Placebo|Participants will receive C19-IG 20% matching placebo as SC infusion containing two syringes of 5 mL each sterile 0.9% NaCl injection on Day 1.
62370316|NCT03669744||Patients with trigeminal neuralgia resistant|a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018
62370317|NCT01013090|ACTIVE_COMPARATOR|Epidural crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-epidural anesthesia in patients undergoing Cesarean section
62370318|NCT01013090|ACTIVE_COMPARATOR|Epidural colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-epidural anesthesia in patients undergoing Cesarean section
62370319|NCT01013090|ACTIVE_COMPARATOR|Spinal crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-spinal anesthesia in patients undergoing Cesarean section
62370320|NCT01013090|ACTIVE_COMPARATOR|Spinal colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-spinal anesthesia in patients undergoing Cesarean section
62743967|NCT05011305|EXPERIMENTAL|Saroglitazar Magnesium 2 mg|Saroglitazar Magnesium 2 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment.
62743968|NCT05011305|EXPERIMENTAL|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium 4 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment.
62743969|NCT05011305|PLACEBO_COMPARATOR|Placebo|Placebo tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment.
62743970|NCT02879643|EXPERIMENTAL|Cohort A: Marqibo and UK ALL R3 backbone|"* Marqibo®: given by intravenous (IV) infusion on days 1, 8, 15 and 22.~* Dexamethasone orally twice daily on days 1-5 and 15-19.~* Mitoxantrone: given by intravenous (IV) infusion on days 1 and 2.~* PEG-asparaginase: given as an injection into the muscle on says 3 and 17.~* Methotrexate IT: given intrathecally (used to treat the brain and spinal cord and is given using a needle inserted into the spinal canal) on days 1 and 8."
62743971|NCT02879643|EXPERIMENTAL|Cohort B: Marqibo and lower intensity UK ALL R3 backbone|"* Marqibo®: given by intravenous (IV) infusion on days 1, 8, 15 and 22.~* Dexamethasone orally twice daily on days 1-5 and 15-19.~* PEG-asparaginase: given as an injection into the muscle on days 3 and 17.~* Methotrexate IT: given intrathecally (used to treat the brain and spinal cord and is given using a needle inserted into the spinal canal) on days 1 and 8."
62370321|NCT01013090|ACTIVE_COMPARATOR|CSEA crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-CSEA anesthesia in patients undergoing Cesarean section
62370322|NCT01013090|ACTIVE_COMPARATOR|CSEA colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-CSEA anesthesia in patients undergoing Cesarean section
62370323|NCT02402881|EXPERIMENTAL|Intervention|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
62743972|NCT02879643|EXPERIMENTAL|Cohort C: Marqibo and maintenance regimen|"* Marqibo®: given by intravenous (IV) infusion on day 1~* Dexamethasone orally twice daily on days 1-5~* Methotrexate: given orally on days 1 and 8~* Mercaptopurine: given orally daily on days 1-13"
62743973|NCT03829462|EXPERIMENTAL|Irinotecan + regorafenib (REGIRI)|irinotecan (180 mg/m2) at day1 of each cycle + regorafenib (160 mg/day) from day 2 to day 8
62370324|NCT02402881|NO_INTERVENTION|Control|Patients will receive only the standard practices of care
62370325|NCT03477669|EXPERIMENTAL|chamomile/probiotic arm|Infant will receive 5 drops of the study product once per day with a feeding at midday.
62370326|NCT03477669|PLACEBO_COMPARATOR|Placebo of chamomile/probiotic arm|Infant will receive 5 drops of a placebo product once a day at midday.
62370327|NCT00783549|EXPERIMENTAL|Cohort 1|6 active 2 placebo
62370328|NCT00783549|EXPERIMENTAL|Cohort 2|9 active 3 placebo
62370329|NCT00783549|EXPERIMENTAL|Cohort 3|Optional cohort
62370330|NCT00783549|EXPERIMENTAL|Cohort 4|12 active
62370331|NCT00783549|EXPERIMENTAL|Cohort 5|12 active
62370332|NCT04534049|EXPERIMENTAL|Intensive strength training (IST)|
62370333|NCT04534049|EXPERIMENTAL|Strength Endurance training (SET)|
62370334|NCT04534049|OTHER|Flexibility training (FT)|
62370335|NCT00757081|EXPERIMENTAL|1|
62370336|NCT04969458||participants|The study included individuals whose native language is Turkish, who are over the age of 18 and under the age 70, diagnosed with chronic low back pain, without Psychiatric disorder, Cognitive impairment, Dementia, or Alzheimer's and who want to participate in the study.
62370337|NCT05193929|EXPERIMENTAL|OptiPulse™|The OptiPulse™ is designed to enhance blood circulation in the venules and arterioles in subjects with diabetic foot ulcers of the lower extremities. OptiPulse™ is supplied as a pair of footwear. One side is fitted with an offloaded and shin pumping unit and the other acts as pressure reducing footwear. Both active and non-active footwear should be worn to give balanced gait.
62370338|NCT05193929|ACTIVE_COMPARATOR|Standard of care offloading device|Diabetic CAM boot
62370339|NCT04202432||Coronary Artery Bypass Surgery patients|Patients undergoing coronary artery bypass surgery (on-pump / off-pump) measured perioperatively and postoperatively.
62370340|NCT01117181|EXPERIMENTAL|Methylphenidate|Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention
62370341|NCT01117181|PLACEBO_COMPARATOR|Placebo|matching placebo and psychosocial intervention
62370342|NCT03573804|EXPERIMENTAL|Prone to Supine MRI|The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
62370343|NCT04769336||Patient|Each patient will undergo simultaneous testing with two different CBC analyzers.
62370344|NCT00880100|EXPERIMENTAL|Ultrase® MT12|
62743974|NCT03829462|ACTIVE_COMPARATOR|regorafenib|Regorafenib (160 mg/day) for 3 weeks followed by 1 week off
62743975|NCT04181593|EXPERIMENTAL|OmegaD|OmegaD Softgels
62743976|NCT04181593|PLACEBO_COMPARATOR|Placebo|Placebo Softgels
62743977|NCT06661317||primary DRMs|patients with the presence of primary DRMs
62743978|NCT06661317||secondary DRMs|patients with the presence of secondary DRMs
62743979|NCT01175265|NO_INTERVENTION|pulmonary rehabilitation, no breathing retraining|Forty COPD patients (23 females) with a mean (SD) age of 66.0 (6.3) years and a FEV1 of 47.1 (18.9) % predicted were randomized to conventional pulmonary rehabilitation (n=20) and conventional pulmonary rehabilitation plus breathing retraining (n=20).
62743980|NCT01175265|NO_INTERVENTION|breathing retraining|Forty COPD patients (23 females) with a mean (SD) age of 66.0 (6.3) years and a FEV1 of 47.1 (18.9) % predicted were randomized to conventional pulmonary rehabilitation (n=20) and conventional pulmonary rehabilitation plus breathing retraining (n=20).
62743981|NCT02243618|ACTIVE_COMPARATOR|Rebamipide group|
62370345|NCT05648123|EXPERIMENTAL|Supportive Psychotherapy|supportive psychotherapy will be given in the form of an online group for 3 times a week with a duration of psychotherapy ranging from 1 - 2 hours per session
62370346|NCT05648123|ACTIVE_COMPARATOR|Education|education about post covid-19 syndrome will be given in the form of an online group for 3 times a week with a duration about 1 - 2 hours per session
62370347|NCT03961893|EXPERIMENTAL|Arm A: Standard colonoscopy then colonoscopy with G-EYE|Arm A: Standard colonoscopy then colonoscopy with G-EYE
62370348|NCT03961893|EXPERIMENTAL|Arm B: G-EYE colonoscopy then standard colonoscopy|Arm B: G-EYE colonoscopy then standard colonoscopy
62370349|NCT01736163||Thyrogen and 131I|Patients were previously treated with Thyrogen in conjunction with a high ablative activity of 131I.
62743982|NCT02243618|ACTIVE_COMPARATOR|Polaprezinc group|
62743983|NCT06087237|EXPERIMENTAL|Pentoxifylline group|oral Pentoxifylline 400 mg three times per day starting the day before the surgery till 2 weeks after surgery
62743984|NCT06087237|PLACEBO_COMPARATOR|Control group|oral placebo tablets three times per day starting the day before the surgery till 2 weeks after surgery
62743985|NCT04199975|OTHER|Orthoses|Only one single arm in this study
62370350|NCT01736163||Thyroid Hormone Withdrawal and 131I|Patients were previously treated with Thyroid hormone withdrawal (THW) in conjunction with a high ablative activity of 131I.
62370351|NCT02147691|EXPERIMENTAL|Azelaic acid 15%, Brimonidine 0.33 % Gel|"Azelaic acid 15% to the face each AM followed 30 minutes later by Brimonidine 0.33%~Azelaic acid 15% to the face each PM"
62370352|NCT02147691|ACTIVE_COMPARATOR|Brimonidine 0.33% Gel|Brimonidine 0.33% Gel
62370353|NCT06234085|EXPERIMENTAL|Intervention|Participants will be provided with access to a feedback report in the VCA app that contains 1) crowdsourced ratings of their error disclosure communication, 2) access to recordings of their responses to the completed VCA cases, 3) a recording of a highly-rated peer response and 4) learning points summarizing what laypeople would like the doctor to say in response to the case.
62370354|NCT06234085|NO_INTERVENTION|Control|Participants will not have access to a feedback report.
62370355|NCT03993301|EXPERIMENTAL|Probiotic A formula|Infant Formula with Lactobacillus salivarius AP-32
62370356|NCT03993301|EXPERIMENTAL|Probiotic B formula|Infant Formula with Bifidobacterium animalis subsp. lactis CP-9
62370357|NCT03993301|PLACEBO_COMPARATOR|Regular formula|The infant formula without any probiotic.
62370358|NCT01161927|EXPERIMENTAL|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited
62370359|NCT01161927|ACTIVE_COMPARATOR|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
62370360|NCT00922038|EXPERIMENTAL|High reward|
62370361|NCT00922038|EXPERIMENTAL|Low reward|
62370362|NCT00922038|NO_INTERVENTION|Control|
62370363|NCT02683460|EXPERIMENTAL|patella resurfacing group|Procedure: Patellar component Resurfacing with onlay technique
62370364|NCT02683460|ACTIVE_COMPARATOR|patella retention|Procedure: patellar retention Trimming of osteophytes when appropriate
62370365|NCT02304640||Early-stage breast cancer patients|
62370366|NCT02304640||Healthy control|
62370367|NCT01291511|EXPERIMENTAL|Iloperidone|After meeting all entry criteria, completing a 1-week open-label iloperidone titation period (up to 12 mg/day), followed by a 14-24 week open-label iloperidone flexible dose-stabilization period (up to 24 mg/day), approximately 260 patients will be randomized to one of two arms in a 1:1 ratio of iloperidone (flexible dosing 8-24 mg/day) to placebo. Post-randomization double-blind study medication will be administered orally twice daily for up to 26 weeks to evaluate relapse prevention. Subsequently, during the extension period, after a 1-week mock double-blind titration, open-label iloperidone (8-24 mg/day) is administered for up to 51 weeks to evaluate long-term safety.
62370368|NCT01291511|PLACEBO_COMPARATOR|Placebo|Post-randomization matching placebo is administered orally bid during the double-blind period.
62370369|NCT06015841|PLACEBO_COMPARATOR|Placebo|Early PD subjects receive placebo at pre-defined time points over 74 weeks.
62370370|NCT06015841|EXPERIMENTAL|ACI-7104.056 at Dose A|Early PD subjects receive dose A of ACI-7104.056 at pre-defined time points over 74 weeks.
62743986|NCT01675297|EXPERIMENTAL|Risendronate/Cholecalciferol combination|Risendronate/Cholecalciferol combination Risenex Plus tablet: one tablet once a week for 12months
62743987|NCT01675297|ACTIVE_COMPARATOR|Risedronate|Sedron tablet: one tablet once a week for 12months
62370371|NCT06015841|EXPERIMENTAL|ACI-7104.056 at Dose B (optional)|Early PD subjects receive dose B of ACI-7104.056 at pre-defined time points over 74 weeks. This arm is optional.
62370372|NCT06015841|EXPERIMENTAL|ACI-7104.056 at Dose C (optional)|Early PD subjects receive dose C of ACI-7104.056 at pre-defined time points over 74 weeks. This arm is optional.
62370373|NCT03000621||Patients with liver injury|
62370374|NCT03000621||Healthy subjects|
62370375|NCT04944927||Patients with Alternating Hemiplegia of Childhood|"Patients that meet the clinical diagnostic criteria (Aicardi et al, 1995) for typical alternating hemiplegia with or without identified mutations in ATP1A3.~At least one prolonged ECG study available is required."
62370376|NCT04438200||Adolescents|Individuals aged 10-19 years
62370377|NCT04438200||Young Adults|Individuals aged 20-39 years
62370378|NCT04438200||Elderly Adults|Individuals aged 40+ years
62370379|NCT03156725|EXPERIMENTAL|Ferrous Sulfate|The ferrous sulfate group was required to consume a test containing ferrous sulfate (10 mg of 57Fe). Participants received a meal containing 17.6 g egg albumin, 45 g corn syrup solids, 17.5 g corn oil, 6 ml vanilla extract, and 100 ml of distilled water.
62370380|NCT03156725|EXPERIMENTAL|Aspiron|The Asprion group was required to follow the same protocol as the 57Fe experimental group, with the exception of taking A. Oryzae containing (8 mg natural abundace Fe and 2 mg 58Fe. Meals composition was similar to ferrous sulafte group.
62370381|NCT06236763||Observation and control|Two accelerometers will be applied on each patient; observation (foot) and control (hand, also the gold standard). Agreement values will be compared between these two monitors.
62370382|NCT03130504|ACTIVE_COMPARATOR|17α hydroxy progesterone caproate group|
62370383|NCT03130504|NO_INTERVENTION|No intervention group|
62370384|NCT00492895|OTHER|A|one arm only. Crossover study
62370385|NCT06066190|EXPERIMENTAL|Experimental: web based training|Web-Based Training will be given to midwives and nurses on ERAS Protocols Applied in Gynecological and Obstetric Surgery. The training will last 6 weeks and they will be asked to watch a training video every week.
62370386|NCT02347254|EXPERIMENTAL|Transcranial ExAblate|Transcranial ExAblate MRgFUS
62370387|NCT03838601|EXPERIMENTAL|MET-4|Subjects diagnosed with Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma (LA-OPSCC) will receive treatment with MET-4 in addition to standard of care CRT. MET-4 is administered orally as an initial daily loading dose over 2 days followed by a daily maintenance dose of MET-4 and will be administered until week 4 of CRT or unacceptable toxicity whichever occurs earlier and in the absence of criteria to discontinue MET-4.
62370388|NCT03531710|EXPERIMENTAL|3 boosters|Subjects will receive 3 doses of UB-311 and 2 doses of placebo.
62370389|NCT03531710|EXPERIMENTAL|3 priming doses followed by 2 boosters|Subjects will receive 5 doses of UB-311.
62370390|NCT02561676|EXPERIMENTAL|Web-Based Education Program Type 1|The education program involves ten weeks of web-based classes (1.5 hours per class) given once per week with daily homework assignments of approximately 30 minutes per day.
62370391|NCT02561676|EXPERIMENTAL|Web-Based Education Program Type 2|The education program involves ten weeks of web-based classes (1.5 hours per class) given once per week with daily homework assignments of approximately 30 minutes per day.
62370392|NCT00938093|ACTIVE_COMPARATOR|Cognitive-behavioral therapy|cognitive-behavioral therapy
62370393|NCT00938093|PLACEBO_COMPARATOR|Enhanced usual care|enhanced usual care
62370394|NCT03529175|ACTIVE_COMPARATOR|Concomitant|Intravenous Abraxane125 mg/m2 30-minute infusion followed immediately by intravenous Gemcitabine 1000 mg/m2 30-minute infusion will be administered on days 1, 8 and 15 of a 4-week cycle.
62370395|NCT03529175|ACTIVE_COMPARATOR|Sequential|Intravenous Abraxane 125 mg/m2 30-minute infusion will be administered on days 1, 8 and 15 of a 4-week cycle. Intravenous Gemcitabine 1000 mg/m2 30-minute infusion will be administered on days 2, 9 and 16 of a 4-week cycle. Gemcitabine must be delivered 24 +/- 2 hours after commencing Abraxane infusion.
62370396|NCT02078089|OTHER|Oxcarbazepine and Morphine|"Patients must be on stable or increasing doses of greater than or equal to 180 mg of morphine sulfate per day. Morphine is taken orally for 42 days.~In addition to Morphine, patients will also receive oral Oxcarbazepine 150 mg, every 12 hours, for 2 weeks, then increase the dose to 300 mg, every 12 hours, for 2 weeks and then increase the dose to 450 mg, every 12 hours, for the final 2 weeks. Patients will take oral tablets of oxcarbazepine for a total of 42 days."
62370397|NCT00657930||A|
62370398|NCT01237223|PLACEBO_COMPARATOR|Placebo|In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In single blind run-in (4 weeks) and double blind treatment period (8 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily.
62370399|NCT01237223|ACTIVE_COMPARATOR|Aliskiren 150 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."
62370400|NCT01237223|ACTIVE_COMPARATOR|Amlodipine 2.5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."
62370401|NCT01237223|ACTIVE_COMPARATOR|Amlodipine 5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."
62370402|NCT01237223|EXPERIMENTAL|Aliskiren/amlodipine 150/2.5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period."
62370403|NCT01237223|EXPERIMENTAL|Aliskiren/amlodipine 150/5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."
62370404|NCT03420157||Focus Group 1 & 2|Each Focus Group of 10 women will be led by a psychologist according to a semi-directive interview pattern. This interview guideline specifies in details the ideal proceedings of Focus Group, as well as the various predetermined topics to be addressed in the form of questions and / or relaunches. The interview guideline is divided into 2 parts: the accompanying letter and the leaflet explaining how to perform the vaginal self-sampling.
62370405|NCT05249803||Patients with COVID-19 pneumonia|These patients were admitted in ICU for management of Covid-19 pneumonia usual care was offered to all patients
62370406|NCT01059890|EXPERIMENTAL|Cefotaxime|
62370407|NCT01059890|EXPERIMENTAL|Metrodinazole|
62370408|NCT01059890|EXPERIMENTAL|Ciprofloxacine|
62370409|NCT01059890|EXPERIMENTAL|Fosfocine|
62370410|NCT03152188|EXPERIMENTAL|FMT|Fecal Microbiota Transplantation (FMT) capsules
62370411|NCT03152188|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62370412|NCT03607149|ACTIVE_COMPARATOR|STANDARD ARM|Calculation of the dose of pemetrexed as a function of body surface area
62370413|NCT03607149|EXPERIMENTAL|EXPERIMENTAL ARM|Calculation of the pemetrexed dose as a function of the Clearance of creatine (CrCLCG)
62370414|NCT03923504|ACTIVE_COMPARATOR|Physical Activity Intervention (PAI)|Tailored multi-level physical activity intervention (PAI) on exercise capacity, cardiovascular and cognitive function, health-related quality of life (QOL), strength and fatigue among lymphoma and breast cancer patients undergoing active treatment with anthracycline based chemotherapy (anthra-bC).
62370415|NCT03923504|ACTIVE_COMPARATOR|Healthy Living Control Group|Healthy living intervention (HLI) on exercise capacity, cardiovascular and cognitive function, health-related quality of life (QOL), strength and fatigue among lymphoma and breast cancer patients undergoing active treatment with anthracycline based chemotherapy (anthra-bC).
62370416|NCT04872504|EXPERIMENTAL|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen
62370417|NCT01442090|ACTIVE_COMPARATOR|Everolimus|Participants will receive everolimus (10 mg) orally daily until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
62370418|NCT01442090|EXPERIMENTAL|GDC-0980|Participants will receive GDC-0980 (40 mg) orally daily until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
62370419|NCT01191957|ACTIVE_COMPARATOR|I. V. Busulphan plus Cyclophosphamide|Conventional conditioning regimen with intravenous (i.v.) Busulphan (Busilvex), 12.8 mg/kg followed by Cyclophosphamide, 120 mg/kg iv.
62182470|NCT06467214|ACTIVE_COMPARATOR|VET BEFRIENDING|VET BEFRIENDING (attention control arm) consists of weekly social interactions with a research assistant (RA). It will match the number of social contacts (12 contacts), frequency (weekly), intervention expectancy (positive treatment expectations), and working alliance (rapport with interventionist) in the intervention arm. The control condition has no overlap with CONNECTED in terms of content and therapeutic elements (e.g., goal setting, navigation).
62370420|NCT01191957|EXPERIMENTAL|I. V. Busulphan plus Fludarabine|Reduced toxicity conditioning regimen with intravenous (i.v.)Busulphan (Busilvex), 12.8 mg/kg plus Fludarabine, 4 x 40 mg/m².
62370421|NCT05490381|EXPERIMENTAL|Treatment (PVA, EOV, tumor vessel embolization)|Patients receive iodixanol via injection and undergo diagnostic cerebral angiogram over 30 minutes. If the tumor blood supply is suitable, patients undergo tumor vessel embolization with PVA suspended in EOV and delivered via a catheter. Patients also undergo head and neck CT scans immediately after completion of tumor vessel embolization, and again between 2-3 months later.
62370422|NCT03058263|EXPERIMENTAL|partial dose of neostigmine|Those who received partial dose of neostigmine as rocuronium reversal
62370423|NCT03058263|EXPERIMENTAL|TOF ratio-based dose of neostigmine|Those who received TOF ratio-based dose of neostigmine as rocuronium reversal
62370424|NCT03651128|EXPERIMENTAL|Arm A - Administration of bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10\^6 CAR+ T cells after receiving lymphodepleting chemotherapy
62370425|NCT03651128|EXPERIMENTAL|Arm B- standard regimens as per Investigator's discretion|"The participants will receive one of following regimens dependent on the subject's most recent anti-myeloma treatment regimen:~* Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose dexamethasone (dex) (DPd) OR~* DARA in combination with bortezomib (BTZ) and low-dose dex (DVd) OR~* Ixazomib (IXA) in combination with lenalidomide (LEN) and low-dose dex (IRd) OR~* Carfilzomib (CFZ) in combination with low-dose dexamethasone (Kd) OR~* Elotuzumab (ELO) in combination with POM and low-dose dexamethasone (EPd)"
62370426|NCT01181297|EXPERIMENTAL|Extensively Hydrolyzed Formula with a Probiotic|Extensively Hydrolyzed Formula with a Probiotic
62370427|NCT01181297|PLACEBO_COMPARATOR|Extensively Hydrolyzed Formula without a Probiotic|
62370428|NCT01670708|EXPERIMENTAL|HOPE|Participation in HOPE program
62370429|NCT01670708|ACTIVE_COMPARATOR|Probation as Usual|Participation in probation as usual
62370430|NCT02389218|EXPERIMENTAL|Cryoablation|Cryoballoon single ablation (as described in the reference) at entry after randomization to this group. Single procedure,not to be repeated.
62370431|NCT02389218|ACTIVE_COMPARATOR|Drug|Conventional, available anti arrhythmic drugs (propafenone, sotalol or flecainide), in a first stage, sequential, with amiodarone in second stage
62370432|NCT03677544||no intraoperative FS examination|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation. procedures were performed between 1980 and 2013
62370433|NCT03677544||intraoperative FS examination|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation procedures were performed between 2001 and 2013
62370434|NCT05764811|ACTIVE_COMPARATOR|Canagliflozin Treatment|Use Canagliflozin 100 mg daily, 1 month
62370435|NCT05764811|NO_INTERVENTION|non-Canagliflozin Treatment|Standard treatment
62370436|NCT06137989|ACTIVE_COMPARATOR|Fill-Up|Bulk-fill resin composite type
62370437|NCT06137989|ACTIVE_COMPARATOR|QuiXfil|Bulk-fill resin composite type
62370438|NCT06137989|ACTIVE_COMPARATOR|Tetric N-Ceram Bulk Fill|Bulk-fill resin composite type
62370439|NCT03822546|EXPERIMENTAL|Conventional cigarette|The subject's preferred brand of commercially available conventional cigarette
62370440|NCT03822546|ACTIVE_COMPARATOR|myblu 25 mg freebase|myblu pod-system containing 25 mg nicotine ('freebase') tobacco flavour
62370441|NCT03822546|ACTIVE_COMPARATOR|myblu 16 mg nicotine salt|myblu pod-system containing 16 mg nicotine salt tobacco flavour
62370442|NCT03822546|ACTIVE_COMPARATOR|myblu 25 mg nicotine salt|myblu pod-system containing 25 mg nicotine salt tobacco flavour
62370443|NCT03822546|ACTIVE_COMPARATOR|myblu 40 mg nicotine salt|myblu pod-system containing 40 mg nicotine salt tobacco flavour
62370444|NCT03822546|ACTIVE_COMPARATOR|blu PRO 48 mg nicotine salt|blu PRO open-system containing 48 mg nicotine salt tobacco flavour
62370445|NCT03253185|EXPERIMENTAL|SC-007|SC-007 intravenous (IV) (various doses and dose regimens)
62370446|NCT06247449|EXPERIMENTAL|Screening MRI|One-time brain magnetic resonance (or computed tomography when magnetic resonance is contraindicated), plus circulating tumor DNA analysis, plus Testing Morbidity Index (TMI)
62370447|NCT05258981|OTHER|Brain MRI|Obtain Brain MRI in adults with congenital heart disease and age/sex matched controls
62370448|NCT01816373|OTHER|Vacuum Bell|Patients with pectus excavatum will be treated with the Vacuum Bell device
62370449|NCT05031806|EXPERIMENTAL|iNexin™ (0.08% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
62370450|NCT05031806|EXPERIMENTAL|iNexin™ (0.4% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
62370451|NCT05031806|EXPERIMENTAL|iNexin™ (2.0% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
62370452|NCT05031806|PLACEBO_COMPARATOR|Vehicle (eye drop formulation without aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
62370453|NCT00691977|EXPERIMENTAL|A|Radiation Therapy followed by prostatectomy
62370454|NCT01609569||coronary complication|"patients with coronary complication and patients without coronary complications.~pro-calcitonin will be measured in both groups to see if any correlation."
62370455|NCT01154907||Girls ages 10-12|"In 18 rural schools in Ugu District, South Africa. Undergoing mass-treatment provided by the Department of Health.~Praziquantel was administered at 40mg/kg in annual mass-treatment"
62370456|NCT01154907||Young adult women|"In rural schools in three districts, South Africa. Undergoing mass-treatment provided by the Departments of Health.~Praziquantel was administered at 40mg/kg in annual mass-treatment"
62370457|NCT05588713|OTHER|Brief assessment protocol|"The brief protocol will contain a minimum according to guidelines for assessing ADHD:~review of medical records, a validated diagnostic interview (MINI-KID), a structured medical history, a pedagogical statement including suspicion of intellectual disability, and rating scales for symptoms such as ADHD, oppositional defiant disorder, autism, anxiety, and depression directed to children (≥ 13 years), parents, and teachers."
62370458|NCT05588713|OTHER|Comprehensive assessment protocol|The comprehensive protocol will extend the brief protocol by adding an approximately three-hour long battery of neuropsychological tests (WISC-V and CPT 3) and biomarkers (heart-rate variability, pupil dilation and the pupillary light reflex) assessed during the CPT 3.
62370459|NCT03905525|EXPERIMENTAL|Cohort 1 /Arm A|CFZ533 dose 1
62370460|NCT03905525|EXPERIMENTAL|Cohort 1/Arm B|CFZ533 dose 2
62370461|NCT03905525|EXPERIMENTAL|Cohort 1/Arm C|CFZ533 dose 3
62370462|NCT03905525|PLACEBO_COMPARATOR|Cohort 1/Arm D|Placebo dose (up to week 24)
62370463|NCT03905525|EXPERIMENTAL|Cohort 1/Arm D1|CFZ533 dose 1 (from week 24)
62370464|NCT03905525|EXPERIMENTAL|Cohort 2/Arm E|CFZ533 dose 1
62370465|NCT03905525|PLACEBO_COMPARATOR|Cohort 2/Arm F|Placebo dose (up to week 24)
62370466|NCT03905525|EXPERIMENTAL|Cohort 2/Arm F1|CFZ533 dose 2 (from week 24)
62743988|NCT01453205|ACTIVE_COMPARATOR|Rituximab+ ICE/DHAP|Participants will receive Rituximab in combination with ifosfamide + carboplatin + etoposide (ICE) or dexamethasone + cisplatin + cytarabine (DHAP) for 3 cycles (21-day cycles) and will followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). Rituximab (375 mg/m\^2) will be administered intravenous (IV) on 2 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of rituximab, IV infusion of ICE as: ifosfamide 5 g/ m\^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m\^2 on Days 1, 2, and 3 in 21-day cycles. After completion of rituximab, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m\^2 continuously for 24 hours on Day 1; cytarabine 2 g/m\^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
62743989|NCT01453205|EXPERIMENTAL|MEDI-551 2 mg/kg + ICE/DHAP|Participants will receive MEDI-551 (2 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (2 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m\^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m\^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m\^2 continuously for 24 hours on Day 1; cytarabine 2 g/m\^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
62370467|NCT01666353|EXPERIMENTAL|Therapeutic response for solid tumors|Adult patients, with documented metastatic melanoma, RCC or NSCLC, about to initiate any line of immune checkpoint blockade therapy will receive a FDG PET scan during mid treatment to check for change in disease.
62370468|NCT05540210|EXPERIMENTAL|PSP sample|
62370469|NCT03458988|OTHER|All patients|Nellcor™ Adult SpO2 Sensor
62370470|NCT04571736|ACTIVE_COMPARATOR|access to the internet information platform|usual preoperative information and access to the internet information platform
62370471|NCT04571736|NO_INTERVENTION|usual preoperative information|medical information delivered to the patient before any surgery
62370472|NCT04106180|EXPERIMENTAL|SBRT + sintilimab + GM-CSF|
62370473|NCT02762760|EXPERIMENTAL|AMPION™|AMPION™, up to 3 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
62370474|NCT02762760|EXPERIMENTAL|Saline|Saline placebo, up to 3 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride
62370475|NCT05265390|EXPERIMENTAL|intervention group|Anxiety level of the group watching the informational video
62370476|NCT05265390|NO_INTERVENTION|control group|Anxiety level of control group adolescents
62370477|NCT00971568||Urine sample|To prepare for SELDI-TOF we will use 15 samples. Each sample (25ul) will be analyzed with the Luminex 100 IS (MiraiBio, South San Francisco, CA) using a LINCOplex cytokine/che-
62370478|NCT01010776|EXPERIMENTAL|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 milligram (mg) will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
62370479|NCT00852761|EXPERIMENTAL|Olux-E Foam|Olux-E (clobetasol propionate 0.05%) foam
62370480|NCT00852761|ACTIVE_COMPARATOR|Clobex lotion|Clobex (clobetasol propionate 0.05%) lotion.
62370481|NCT05298163|EXPERIMENTAL|Intervention Group|Drug: Calcitriol The intervention group will be given calcitriol at a dose of 0.25 mcg/day for six months in the form of capsules that have been marked and numbered. The drugs will be taken through the RSCM pharmacy once a month during visit and the allocation will be given using drug labels that are sealed and packaged identically.
62370482|NCT05298163|ACTIVE_COMPARATOR|Placebo Group|Drug: Placebo oral The placebo drug will be given for six months in the form of capsules that have been marked and numbered. The drugs will be taken through the RSCM pharmacy once a month during visit and the allocation will be given using drug labels that are sealed and packaged identically.
62370483|NCT04312789|EXPERIMENTAL|Treatment (avatrombopag)|Patients receive avatrombopag PO QD for up to 1 year in the absence of disease progression or unacceptable toxicity. Avatrombopag will be titrated weekly until platelet count of greater than or equal to 60,000/uL is achieved and persists for 7 consecutive days, and the patient remains free from platelet transfusion.
62370484|NCT02974660|ACTIVE_COMPARATOR|Protamine sulfate|After obtaining optimal valve deployment patients will receive protamine sulfate (1 mg for each 100 units of UFH i.v.). Measurement of activated clotting time (ACT) will be performed (after heparin administration and after protamine sulfate administration).
62370485|NCT02974660|PLACEBO_COMPARATOR|0.9% NaCl|After obtaining optimal valve deployment patients will receive 0.9% saline (20 ml i.v.). Measurement of activated clotting time (ACT) will be performed (after heparin administration and after placebo administration).
62370486|NCT02603172|EXPERIMENTAL|Part A: Cohort 1|Subjects will receive a single dose of GSK3039294 (Dose level 1) on Day 1 and will remain in-house until Day 4. Wash-out will take place from Day 5 to Day 14. Subjects will receive Dose level 2 on Day 15 (Period 2).
62370487|NCT02603172|EXPERIMENTAL|Part A: Cohort 2|Subjects will receive a single dose of GSK3039294 (Dose level 3) on Day 1 and will remain in-house until Day 4. Wash-out will take place from Day 5 to Day 14. Subjects will receive Dose level 4 on Day 15 (Period 2).
62370488|NCT02603172|EXPERIMENTAL|Part B: Cohort 3a|Subjects will receive repeat dosing of GSK3039294 for a total of 21 days. The dose will be escalated every week throughout the study duration. Subjects will first receive a low dose given once daily. After 7 days, if well tolerated, the total daily dose will be increased and, GSK3039294 will be given, for example, as twice daily dosing for 7 days. At the end of this 7 day period and if previous dosing was well tolerated, the dose will be increased to a maximum daily dose that will not exceed pre-clinical safety exposure limits. On Day 4 and 5 GSK3039294 will be administered under fasted and fed conditions, respectively, to investigate the food effect on the PK.
62370489|NCT02603172|EXPERIMENTAL|Part B: Cohort 3b|Subjects will be enrolled in Cohort 3b only if required for further investigation. Subjects will receive GSK3039294 for 21 consecutive days and more than one dose level or regimen may be investigated, for example on the first 10 days the dose may be administered thrice daily, and on the last 11 days may be administered twice daily.
62370490|NCT02603172|EXPERIMENTAL|Part C: Cohort 4|Subjects will receive repeat dosing of GSK3039294 at the predicted optimal clinical dose determined from Part B for a total of 21 days.
62370491|NCT03260283|EXPERIMENTAL|Group I|0.4 mgkg-1 of pethidine hydrochloride
62370492|NCT03260283|EXPERIMENTAL|Group II|2ml of ropivacaine (0.75%) with 15 mcg of fentanyl
62370493|NCT04126460|EXPERIMENTAL|Toripalimab|Injection; dosage form: 6ml: 240mg; frequency: 240mgQ3W; duration: 17cycles (12 months) or randomization to the date of the first documented progression
62370494|NCT05561634|SHAM_COMPARATOR|SHHI then follow-up|
62370495|NCT05561634|EXPERIMENTAL|SHHI then radiotherapy|
62370496|NCT00832689|EXPERIMENTAL|1|
62370497|NCT03122652|EXPERIMENTAL|Terifunomide|
62370498|NCT03122652|PLACEBO_COMPARATOR|Placebo|
62370499|NCT00959699|PLACEBO_COMPARATOR|PegIFN-2b + RBV|PegIFN-2b (1.5 µg/kg/week subcutaneously) plus RBV (600-1400 mg/day, orally, divided into two daily doses) for 4 weeks followed by placebo to boceprevir plus PegIFN-2b/RBV for 44 weeks with 24 weeks post-treatment follow-up (Control Arm). Participants who do not achieve HCV-RNA \<9.3 IU/mL by Treatment Week 24 (TW24) are eligible to cross-over and receive boceprevir along with the PegIFN-2b and RBV for up to 44 weeks.
62370500|NCT00959699|ACTIVE_COMPARATOR|PegIFN-2b + RBV + Boceprevir|PegIFN-2b (1.5 µg/kg/week subcutaneously) plus RBV (600- 1400 mg/day, orally, divided into two daily doses) for 4 weeks followed by boceprevir (800 mg, orally, 3 times per day) plus PegIFN-2b/RBV for 44 weeks with 24 weeks post-treatment follow-up.
62370501|NCT04712669|EXPERIMENTAL|Rodatristat Ethyl 300 mg BID|Rodatristat ethyl 300 mg tablet BID + standard of care medication(s) taken for 24 weeks
62370502|NCT04712669|EXPERIMENTAL|Rodatristat Ethyl 600 mg BID|Rodatristat ethyl 600 mg tablet BID + standard of care medication(s) taken for 24 weeks
62370503|NCT04712669|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet + standard of care medication(s) taken for 24 weeks
62370504|NCT00903994|OTHER|Single Arm|Single Arm
62370505|NCT00758251||1|Adult schizophrenia patients already on Seroquel XR therapy
62370506|NCT04105322|EXPERIMENTAL|Kinesio Taping on Abdominal Muscles|
62370507|NCT04105322|EXPERIMENTAL|Kinesio Taping on Back Muscles|
62370508|NCT04105322|NO_INTERVENTION|Control|
62370509|NCT06254846|OTHER|Primary screening for UCC|Women aged between 30 and 65 who are candidates for primary screening for UCC will be included.
62370510|NCT03482336|OTHER|Uninstructed Group|"For the first block of participants recruited (39, one of which withdrew from boredom), no overt reference was made regarding the FOP labels that were present on the images that participants viewed during the course of the video game. Participants comprising this block were referred to as uninstructed."
62370511|NCT03482336|OTHER|Minimally trained|"Realizing that subjects might not use the FOP during decision making when not informed that it contained nutrition information, we conducted a second experiment (N= 41) which provided minimal information about the FOP. These subjects (the minimally instructed group) were provided with further instruction. At the beginning of the experiment, in addition to being shown the basic premise of the game and told that Munchy preferred to eat healthy options, the researcher pointed to one of the FOPs and told children this information might be helpful when you decide what's healthy."
62370512|NCT02090673||Group1:Type 2 diabetic patients treated with Exenatide therapy|Korean patients who are at least 18 years old, diagnosed with type 2 diabetes, and are treated with Exenatide in an ambulatory care setting according to the approved label
62370513|NCT02387073||Electrical version|Electrical version patient reported outcome questionnaire was used for patients who had filled-up same questionnaire in a paper version
62370514|NCT02931747|PLACEBO_COMPARATOR|Placebo|Subjects are received the pill of placebo which has same color, shape and smell like the Bacopa Monnieri once daily for 16 weeks.
62370515|NCT02931747|ACTIVE_COMPARATOR|Bacopa Monnieri 300 mg/day|Subjects are received the pill of Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks
62370516|NCT02931747|ACTIVE_COMPARATOR|Bacopa Monnieri 600 mg/day|Subjects are received the pill of Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks
62743990|NCT01453205|EXPERIMENTAL|MEDI-551 4 mg/kg + ICE/DHAP|Participants will receive MEDI-551 (4 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (4 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m\^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m\^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m\^2 continuously for 24 hours on Day 1; cytarabine 2 g/m\^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
62370517|NCT05578560|EXPERIMENTAL|Prehabituation group|Patients with vestibular Schwannoma are indicated for the surgery. The patients in this group undergo chemical labyrinthectomy via intratympanically installed gentamicin before the vestibular Schwannoma resection. After the operation, vestibular training under supervision will be performed.
62370518|NCT05578560|EXPERIMENTAL|Virtual reality group|Patients with vestibular Schwannoma are indicated for the surgery. After the surgery, they will perform vestibular training under supervision and in addition to this, they will be exposed to 3D optokinetic stimulation in virtual reality space.
62370519|NCT05578560|EXPERIMENTAL|Vestibular training group|Patients with vestibular Schwannoma are indicated for the surgery. After the surgery, they will perform vestibular training under supervision.
62370520|NCT04888182|ACTIVE_COMPARATOR|intervention|Individual nutritional guidance of a protein intake of ≥25 E%.
62370521|NCT04888182|NO_INTERVENTION|control|Free diet
62370522|NCT05498025|EXPERIMENTAL|Activated charcoal pouch|The patients in this arm will receive an activated charcoal pouch (Deterra Medium Pouch, UPC #: 850006727001, Verde Environmental Technologies, Minnetonka, MN) for disposal of their opioids after their cesarean delivery pain has resolved.
62370523|NCT02250391|EXPERIMENTAL|NPB-06|1,500 unit, 5 days continuous-infusion
62370524|NCT02250391|PLACEBO_COMPARATOR|Placebo|0 unit, 5 days continuous-infusion
62370525|NCT00937508|PLACEBO_COMPARATOR|Smoking counseling, Placebo|
62370526|NCT00937508|EXPERIMENTAL|Smoking counseling, Varenicline|
62370527|NCT00438490|EXPERIMENTAL|recombinant human prolactin|Recombinant Human Prolactin 60 mcg/kg once daily subcutaneous injection
62370528|NCT00438490|PLACEBO_COMPARATOR|Placebo|Normal saline placebo subcutaneous injection
62370529|NCT04691531|EXPERIMENTAL|group C|After induction of general anesthesia, patients will undergo caudal block by classical Gauge 22 needle under ultrasound guidance using a linear probe 5.5-12 MHz, and Bupivacaine 1 ml/kg of 0.25% will be injected.
62370530|NCT04691531|EXPERIMENTAL|Group S|After induction of general anesthesia, patients will undergo caudal block by Gauge 27 needle under ultrasound guidance using a linear probe 5.5-12 MHz, and Bupivacaine 1 ml/kg of 0.25% will be injected.
62370531|NCT04339725||Fecal DNA|Extraction fecal DNA and compare disease group to normal group
62370532|NCT04094545||Nasopharyngeal carcinoma(NPC)|The patients (1) were diagnosed with NPC; 2)18\< Age \<75.
62370533|NCT04094545||Health adults|(1) 18\< Age \<75, and Han Chinese residents living in Hunan more than 3 years. (2) Health examination population who physical examination, assistant examination and serological examination were normal; None of the patients had rhinitis or used any antibiotics during the three months last 3 months.
62370534|NCT04453605||Patients with neo-diagnosed type 2 diabetes|Patients referring for the first time to the outpatient diabetes clinic in the department of Internal Medicine between January 2008 and December 2015 and matching the inclusion criteria.
62743991|NCT02931513||PBC patients|Patients with primary biliary cholangitis
62370535|NCT02276794|EXPERIMENTAL|Thrust manipulation (TM)|"The patients allocated to the TM group will receive TM aimed at the L4-L5 intervertebral segments. All the patients will be positioned in a standardized position (right side-lying) and will receive a rotational TM technique. The treating therapist will have up to two attempts to perform the TM in each patient.~There is no need for cavitation in order to consider the TM successful; the occurence of cavitation, however, will be recorded.~A single treatment will be provided."
62370536|NCT02276794|EXPERIMENTAL|Non-thrust manipulation (NTM)|"The patients allocated to the NTM group will receive TM aimed at the L4-L5 intervertebral segments. All the patients will be positioned in a standardized position (right side-lying) and will receive 30 oscilations of a grade III rotational NTM.~A single treatment will be provided"
62370537|NCT04705428|EXPERIMENTAL|Group I: intervention group 1|Professional hygiene will be carried out with the application of fluoride varnish (Duraphat) and the use of fluoride paste according to the age will be recommended for oral hygiene at home.
62370538|NCT04705428|EXPERIMENTAL|Group II: intervention group 2|Professional hygiene will be carried out with the application of fluorine varnish (Tiefenfluoride) and the use of fluoride paste according to the age will be recommended for oral hygiene at home.
62370539|NCT04705428|EXPERIMENTAL|Group III: intervention group 3|Professional hygiene will be carried out with the application of fluorine varnish (Fluor Protector S) and the use of fluoride paste according to the age will be recommended for oral hygiene at home.
62370540|NCT04506281|EXPERIMENTAL|Neoadjuvant treatment|"1. Gemox chemotherapy:~   Day1 Oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day 8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 3 courses.~2. Lenvatinib (8mg/d) for 9 weeks of continuous use.~3. Toripalimab (240mg, once every 3 weeks), used 3 times. Evaluate the resectability of the operation within 2-4 weeks after the end of the neoadjuvant treatment course, and implement radical resection. All patients after resection use capecitabine 2500mg/m2 twice a day for 2 weeks, stopping for 1 week as a course of treatment, totaling 8 courses"
62370541|NCT04506281|NO_INTERVENTION|Traditional group|No anti-tumor drug treatment before surgery. All patients undergoing resection use capecitabine 2500mg/m2 twice a day, stopping for 1 week as a course of treatment, totaling 8 courses.
62370542|NCT01449344|EXPERIMENTAL|R-HAD + Bortezomib|
62743992|NCT03762889|EXPERIMENTAL|Eyeprotx™ Group|This group of participants will use the Eyeprotx™ General Anesthesia Protective Goggles when intubated perioperatively under general anesthesia.
62370543|NCT01449344|ACTIVE_COMPARATOR|R-HAD|
62370544|NCT04737161|EXPERIMENTAL|T regulatory cell infusion|Infusion will be administered to the patient within 72 hours of collection from donor.
62370545|NCT01355497|EXPERIMENTAL|GTx-024 3mg once daily|subjects will be randomized to receive GTx-024 3mg sofgel capsule once daily for the duration of the trial
62370546|NCT01355497|PLACEBO_COMPARATOR|placebo|subjects will be randomized to receive matching placebo once daily for the duration of the trial
62743993|NCT03762889|ACTIVE_COMPARATOR|Eyelid Tape Group|This group of participants will be receiving the eyelid tape as the preventative measure when intubated perioperatively under general anesthesia.
62743994|NCT03762889|ACTIVE_COMPARATOR|Eye Ointment Group|This group of participants will be receiving the ointment application when intubated perioperatively under general anesthesia.
62370547|NCT02382289|ACTIVE_COMPARATOR|bipolar RF 6 points|Six RF needles will be put between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. After sensory and motor stimulation, bipolar lesion RF at 80oc for 90 sec will be applied between each successive pairs of needles.
62370548|NCT02382289|ACTIVE_COMPARATOR|monopolar RF 6 points|RF needle is inserted at six levels in the area between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. after sensory and motor stimulation, monopolar lesion RF at 80oc for 90 sec will be applied.
62370549|NCT02382289|ACTIVE_COMPARATOR|monopolar RF 3 points|RF needle is inserted at three levels in the upper , middle and lower part of the area between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. after sensory and motor stimulation, monopolar lesion RF at 80oc for 90 sec will be applied.
62370550|NCT06322108|EXPERIMENTAL|Botensilimab + Balstilimab|botensilimab 75 mg IV every 6 weeks (up to 4 doses) + balstilimab 240 mg IV every 2 weeks
62370551|NCT00285649|EXPERIMENTAL|HVLA-SM|HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
62370552|NCT00285649|EXPERIMENTAL|LVVA-SM|LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation
62370553|NCT00285649|ACTIVE_COMPARATOR|Usual Medical Care|Usual Medical Care, Active Comparator, advice, exercises and medications
62370554|NCT04976478||observation group|All patients will be treated with Nimotuzumab combined with radiotherapy.
62370555|NCT01329068|ACTIVE_COMPARATOR|Individual consult|regular individual consult
62370556|NCT01329068|ACTIVE_COMPARATOR|group medical consult|regular group medical consult
62370557|NCT05848336|EXPERIMENTAL|Gluten Free Casein Free Diet|Foods containing gluten (pasta, bread, etc.), casein (unfermented dairy products), and their disguised sources have been eliminated from the nutrition program. Also, packaged foods (chocolate, crackers, etc.) containing additives such as artificial preservatives, food coloring, and sweeteners that create a tendency to consume in children were avoided from the nutrition program. Goat milk contains type A2 casein, and most of the casein is digested in fermented dairy products. In order to increase calcium intake, the consumption of some foods (dill, kale, spinach, chard, arugula, broccoli, parsley, legumes, nuts, tahini, etc.) has been increased. Elimination was done gradually, considering nervousness, anxiety, etc., due to the effects of opioid mechanisms of action and gastrointestinal system symptoms.
62743995|NCT05972421|EXPERIMENTAL|High Intensity Proactive Outreach|"Patients will receive a mailed letter as well as proactive outreach by phone. The objective of the letter and phone outreach is to describe the Flex Nutrition Program and offer enrollment.~Letters will be written in the primary language spoken by the patient. The letter will contain a call back phone number as well as a primary email contact. Patients will be provided with the phone number of Interpreter Services to utilize if needed.~1 week following the mailing of the letter, patients will receive 3 phone calls within 10 business days, occurring at different times of day. Patients will be provided a call back number. Phone calls will be made to patients in their primary languages, with the use of Interpreters as needed."
62370558|NCT04114045|EXPERIMENTAL|Whey protein|Whey protein isolate
62370559|NCT04114045|ACTIVE_COMPARATOR|Isoenergetic control - Carbohydrate|Carbohydrate or maltodextrin
62370560|NCT04114045|PLACEBO_COMPARATOR|Placebo control - Water|Water - chocolate flavoured
62370561|NCT01804647||33 RRMS patients|No study treatments administered
62370562|NCT01804647||9 PPMS patients|No study treatments administered
62370563|NCT01804647||12 SPMS patients|No study treatments administered
62370564|NCT01804647||4 CIS patients|No study treatments administered
62370565|NCT00728195|PLACEBO_COMPARATOR|Placebo First, Then Olanzapine|Participants will receive 2 matching placebo capsules orally twice daily for 6 consecutive weeks, then 2 matching placebo capsules orally in the morning and olanzapine 10 milligram (mg) capsule along with matching placebo capsule orally in the evening for next 1 week, then 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with olanzapine 5 mg capsule orally in the evening for next 5 weeks.
62370566|NCT00728195|EXPERIMENTAL|JNJ-37822681 10 mg|Participants will receive 1 matching placebo capsule along with JNJ-37822681 10 mg capsule orally twice a day for 12 consecutive weeks.
62370567|NCT00728195|EXPERIMENTAL|JNJ-37822681 20 mg|Participants will receive 1 matching placebo capsule along with JNJ-37822681 20 mg capsule orally twice a day for 12 consecutive weeks.
62743996|NCT05972421|EXPERIMENTAL|Low Intensity Proactive Outreach|"Patients will receive a mailed letter. The objective of the letter is to describe the Flex Nutrition Program and offer enrollment.~Letters will be written in the primary language spoken by the patient. The letter will contain a call back phone number as well as a primary email contact. Patients will be provided with the phone number of Interpreter Services to utilize if needed."
62370568|NCT00728195|EXPERIMENTAL|JNJ-37822681 30 mg|Participants will receive JNJ-37822681 30 mg (one 10 mg capsule along with JNJ-37822681 20 mg capsule) orally twice a day for 12 consecutive weeks.
62370569|NCT00728195|ACTIVE_COMPARATOR|Olanzapine|Participants will receive 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with matching placebo capsule orally in the evening for 1 week, then 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with olanzapine 5 mg capsule orally in the evening for next 11 consecutive weeks.
62370570|NCT00937001|EXPERIMENTAL|Biopsy/Ultrasound|
62370571|NCT01576224|EXPERIMENTAL|Immediate mobilization|Patients start exercises immediately after osteosynthesis.
62370572|NCT01576224|ACTIVE_COMPARATOR|Later mobilization|Patients are allowed exercises after 14 days.
62743997|NCT05972421|NO_INTERVENTION|No Outreach; Usual Care|Patients will not receive any proactive outreach and will serve as a comparison group. These patients may be referred to the Flex Nutrition Program through their Care Managers.
62743998|NCT02086487|EXPERIMENTAL|Nilotinib 300 mg|"Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg but show sub-optimal response on Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg twice daily and will be assessed for timely.~In the absence of safety concerns, nilotinib could be escalated to 400 mg twice daily if patients had not obtained any of the following milestones:~1. BCR-ABL1 transcript level ≤ 10% at 3 months;~2. CCyR at 6 months,~3. BCR/ABL1 ≤ 1% at 6 months~4. MMR at 12 months, or~5. if they showed loss of cytogenetic or molecular response or disease progression at any time. Failure and thus, stopping nilotinib will be considered if any of above milestones happened while on the 400mg twice daily dose."
62743999|NCT03822455|ACTIVE_COMPARATOR|OligoG DPI|Active DPI containing the oligosaccharide OligoG and excipients
62744000|NCT03822455|PLACEBO_COMPARATOR|Placebo DPI|Placebo DPI containing lactose and excipients
62744001|NCT05031338||SX-One MicroKnife with ultrasound guidance|Carpal Tunnel Release using the SX-One MicroKnife with ultrasound guidance
62744002|NCT05031338||Traditional mini-open technique without ultrasound guidance|Carpal Tunnel Release using the traditional mini-open technique without ultrasound guidance
62744003|NCT04548934|ACTIVE_COMPARATOR|No PPE|Cardiopulmonary resuscitation without wearing personal protective equipment (PPE)
62744004|NCT04548934|EXPERIMENTAL|PPE|Cardiopulmonary resuscitation while wearing personal protective equipment (PPE)
62744005|NCT04565444|EXPERIMENTAL|Ketone|Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight) and carbohydrate control.
62744006|NCT04565444|EXPERIMENTAL|Ketone + Protein|Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight) and 10g of whey protein.
62744007|NCT04565444|EXPERIMENTAL|Protein|Carbohydrate control and 10g of whey protein.
62744008|NCT01907308|EXPERIMENTAL|Combination of AMG 386 with Docetaxel|All treated patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
62744009|NCT04723472|ACTIVE_COMPARATOR|Classic bismuth quadruple treatment group|
62370573|NCT02544698|EXPERIMENTAL|One dose of PCV13a vaccine in aged 18 years and older|One dose of PCV13a vaccine will be given in aged 18 years and older
62370574|NCT02544698|EXPERIMENTAL|One dose of PCV13a vaccine in aged 2-5 years old|One dose of PCV13a vaccine will be given in aged 2-5 years old
62370575|NCT02544698|EXPERIMENTAL|One dose of PCV13 vaccine will be given at 2, 4, 6 months|One dose of PCV13 vaccine will be given at 2, 4, 6 months respectively in aged 2 months old
62370576|NCT02544698|EXPERIMENTAL|One dose of PCV13 vaccine will be given at 3、4、5 months|One dose of PCV13 vaccine will be given at 3、4、5 months respectively in aged 3 months old
62370577|NCT05756205|EXPERIMENTAL|Virtual Reality|The intervention will consist of an Immersive Virtual Reality (IVR) application with virtual reality goggles Oculus GO, to reduce anxiety during pregnancy. This application lasts 14 minutes by the use of mindfulness techniques based on breathing, mindfulness and passive muscle relaxation.
62370578|NCT05756205|NO_INTERVENTION|Routine care|The control group will receive the usual follow-up pregnancy monitoring, without the e-health intervention.
62370579|NCT05432895|ACTIVE_COMPARATOR|Control( static splinting)|conventional static splint
62370580|NCT05432895|EXPERIMENTAL|Experiment( dynamic splinting)|Device treats plantar fasciitis and replacing boot immobilization
62370581|NCT05526092|EXPERIMENTAL|Oat-rich and low-gluten diet|Participants will consume oats and oat products and follow low-gluten diet for 6 weeks.
62744010|NCT04723472|EXPERIMENTAL|Cefuroxime containing bismuth quadruple treatment group|
62744011|NCT04283214|ACTIVE_COMPARATOR|Traditional manikin|CPR performed on a traditional manikin
62370582|NCT05526092|PLACEBO_COMPARATOR|Rice-rich and low-gluten diet|Participants will consume rice and rice products and follow low-gluten diet for 6 weeks.
62744012|NCT04283214|EXPERIMENTAL|Traditional manikin with athletic equipment|CPR performed on a traditional manikin wearing athletic equipment
62744013|NCT04283214|EXPERIMENTAL|Bariatric manikin|CPR performed on a bariatric manikin
62744014|NCT04283214|EXPERIMENTAL|Bariatric manikin with athletic equipment|CPR performed on a bariatric manikin wearing athletic equipment
62370583|NCT01704976|EXPERIMENTAL|Intervention|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (5 Hz, noise 4) - T1
62370584|NCT01704976|SHAM_COMPARATOR|Sham group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (1 Hz, noise 1) - T1
62370585|NCT02966236|EXPERIMENTAL|Tranexamic Acid Group|Tranexamic acid 1g IV during anesthesiology induction, single dose
62370586|NCT02966236|PLACEBO_COMPARATOR|Placebo group|normal saline 1g IV during anesthesiology induction, single dose
62370587|NCT02793804|NO_INTERVENTION|Control|All HIV testing and counselling services will be conducted as currently.
62370588|NCT02793804|EXPERIMENTAL|HIV Self-Testing|Community-based distribution agents (CBDA), including Voluntary Male Medical Circumcision (VMMC) mobilisers, will deliver OraQuick® HIV Self-Tests (Orasure Technologies, Thailand). The kits will also be available at the health facility.
62370589|NCT00995189|EXPERIMENTAL|OFR|Opti-Free RepleniSH contact lens care solution used for 30 days
62370590|NCT00995189|ACTIVE_COMPARATOR|RNM|ReNu MultiPlus contact lens care solution used for 30 days
62370591|NCT03398824|EXPERIMENTAL|Treatment arm|Receive metformin HCl
62370592|NCT02490904|EXPERIMENTAL|Eplerenone group|Eplerenone administration within 2 hours prior to patient departure to the operating room and for 4 days after kidney transplantation.
62370593|NCT02490904|PLACEBO_COMPARATOR|Placebo group|Placebo administration within 2 hours prior to patient departure to the operatingroom and for 4 days after kidney transplantation
62370594|NCT05001581|ACTIVE_COMPARATOR|Treatment with biceps augmentation|Complete repair of ISP if possible with partial SSP repair and biceps augmentation after its tenodesis
62370595|NCT05001581|ACTIVE_COMPARATOR|Treatment without biceps augmentation|Complete repair of ISP if possible with partial SSP repair and biceps tenotomy
62370596|NCT04689217|EXPERIMENTAL|Group F|will receive intrathecal injection of 0.5% hyperbaric bupivacaine plus 0.5 ml fentanyl (25 μg)
62370597|NCT04689217|EXPERIMENTAL|Group N|will receive intrathecal injection of 0.5% hyperbaric bupivacaine plus 0.8 mg nalbuphine hydrochloride
62370598|NCT04689217|PLACEBO_COMPARATOR|Group C|will receive intrathecal injection of 0.5% hyperbaric bupivacaine plus 0.5 ml normal saline
62370599|NCT06165016|EXPERIMENTAL|Far red light therapy|Subgroup of participants receiving the 670 nm far red light device
62744015|NCT06077955|ACTIVE_COMPARATOR|Group A (control) - with stapled anastomosis|A variant of the surgery with the stapled formation of a gastrojejunostomy.
62744016|NCT06077955|EXPERIMENTAL|Group B (study) - with hand-sewn anastomosis|A variant with a hand-sewn formation of a gastrojejunostomy.
62744017|NCT01521871|EXPERIMENTAL|Tissue glue wound closure|Skin wound closure by tissue glue
62744018|NCT01521871|ACTIVE_COMPARATOR|Conventional suture + dressing|Skin wound closure by conventional suture + dressing
62370600|NCT06165016|SHAM_COMPARATOR|Sham therapy|Subgroup of participants receiving the sham light device, far red light device covered with blue filter paper to block 670 nm light, resulting in mean power generated of 0.24 mW/cm2, compared to 26.3 mW/cm2 for the intervention, a 100-fold difference.
62370601|NCT00533299|EXPERIMENTAL|1|Topotecan hydralazine valproate
62370602|NCT00533299|PLACEBO_COMPARATOR|2|Placebo, hydralazine, valproate
62370603|NCT00126425|EXPERIMENTAL|123I-mIBG (meta-iodobenzylquanidine|Single dose
62370604|NCT02037204|EXPERIMENTAL|Cartilage repair surgery|Single-stage cartilage repair surgery using autologous chondrons (10-20%) and allogeneic MSCs (80-90%) in a fibrin glue carrier with a dosage of two million cells/ cm2 applied once during a surgical procedure.
62370605|NCT00024206|EXPERIMENTAL|Treatment (orantinib)|"Patients receive oral SU6668 twice daily on days 1-28. Courses repeat every 4 weeks in the absence of unacceptable toxicity or disease progression of 100% or more.~Cohorts of at least 6 patients receive escalating doses of SU6668 until the OBD is determined. Once the OBD is reached, dose escalation continues until the maximum tolerated dose (MTD) is determined (if possible). The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
62370606|NCT04884997|ACTIVE_COMPARATOR|Arm A|toripalimab 3mg/kg, Q2w;
62370607|NCT04884997|EXPERIMENTAL|Arm B|toripalimab 3mg/kg, Q2w; Temozolomide 150mg/m2,d1-5,Q4w
62370608|NCT00320190|ACTIVE_COMPARATOR|Dasatinib|Participants with chronic phase chronic myeloid leukemia (CML) who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.
62370609|NCT00320190|ACTIVE_COMPARATOR|Imatinib|Participants with chronic phase CML who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.
62370610|NCT02195947|EXPERIMENTAL|Antagonist and Growth hormone|HMG IM daily was administrated from day 2 of the cycle. The GnRH antagonist (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
62744019|NCT06659913|EXPERIMENTAL|Intervention group|The participants in the exercise group will be encouraged to follow the Norwegian Health authority's recommendation of being physically active for an average of 60 minutes a day, but they will also be offered a three-part intervention as a supplement to ordinary treatment. Supervised exercise will be offered once a week and they're encouraged to perform two additional exercise sessions per week.
62744020|NCT06659913|ACTIVE_COMPARATOR|Control group|The control group will receive treatment as usual
62744021|NCT00950391|EXPERIMENTAL|Tacrolimus|Treatment with tacrolimus following nerve repair/reconstruction
62370611|NCT02195947|NO_INTERVENTION|Antagonist|HMG IM daily was administrated from day 2 of the cycle. The GnRH antagonist (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
62370612|NCT02625467|EXPERIMENTAL|Penetrating keratoplasty|Conventional penetrating keratoplasty technique
62370613|NCT02625467|EXPERIMENTAL|PALK|Pachymetry and Excimer laser assisted lamellar keratoplasty
62370614|NCT00588380|EXPERIMENTAL|GLP-1|All participants recieved GLP-1 intravenously at 0.75 pmol/kg/min for the first hour and then at 1.5 pmol/kg/min for the next hour
62744022|NCT02897037|EXPERIMENTAL|Bivalirudin|Bivalirudin will be started in the cath lab, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; if ACT\<225s 5min after bolus, an additional dose of 0.3mg/kg bolus should be given. After procedure, a prolonged infusion (1.75mg/kg per h) will be given for at least 30 min (totally no more than 4 h) followed by a reduced dose infusion (0.2mg/kg per h) up to 20 h.
62744023|NCT02897037|ACTIVE_COMPARATOR|Heparin monotherapy|100 IU/kg intravenous bolus. If ACT \<225s 5 min after bolus injection, additional dose of heparin (20U/kg) will be given.
62370615|NCT03051217|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous (sc) injection every two weeks (Q2W)
62370616|NCT03051217|EXPERIMENTAL|CZP 200 mg|Certolizumab Pegol subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by Certolizumab Pegol subcutaneous (sc) injection 200 mg every two weeks (Q2W) with PBO administered to maintain the blind, starting at Week 6
62370617|NCT03051217|EXPERIMENTAL|CZP 400 mg|Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W).
62370618|NCT03710694|EXPERIMENTAL|DAV132 group|Patients randomized to the DAV132 arm will be administered DAV132 concomitantly with fluoroquinolones.
62370619|NCT03710694|NO_INTERVENTION|No DAV132 group|Patients randomized to the No DAV132 arm will receive only fluoroquinolones, according to local standard of care.
62370620|NCT01701856|EXPERIMENTAL|Interferon beta-1b|Interferon beta-1b 250 mcg s.c. every other day
62370621|NCT02001922|EXPERIMENTAL|COPD integrated care|The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
62370622|NCT02001922|NO_INTERVENTION|Usual care|Usual COPD care
62370623|NCT06231004||Experimental group|Take glucocorticosteroid at once in the morning and use the following course of treatment: 6 tablets/day for 7 days-- 5 tablets/day for 2 days-- 4 tablets/day for 2 days-- 3 tablets/day for 2 days-- 2 tablets/day for 2 days-- 1 tablets/day for 2 days--surgery
62370624|NCT00655122|ACTIVE_COMPARATOR|Dalteparin sodium|
62370625|NCT00655122|PLACEBO_COMPARATOR|Placebo|
62370626|NCT05180604|EXPERIMENTAL|experience learning programs of eHealth care|Patients in the experimental group received 6 sections of activities.
62370627|NCT05180604|NO_INTERVENTION|Usual care|Patients in control group received usual care
62370628|NCT01467089||schizophrenia|"Inclusion Criteria: Inpatients and outpatients aged 18-75 years old who have been taking antipsychotics for longer than 6 months in their life time, and that have been compliant for the past week. Patients will be referred by their treating doctors if they have some evidence of movement disorder based on the physician's clinical judgment. We will also include 25% of the sample without any evidence of movement disorder.~Exclusion Criteria: Patients who have medical conditions which make it difficult to perform a physical examination. Patients who are clinically too ill to consent and/or unable to cooperate with the examination procedures."
62370629|NCT04151719|EXPERIMENTAL|MNTX 450 mg QD|Participants will receive methylnaltrexone bromide (MNTX) 450 milligrams (mg) (3 tablets of 150 mg each) once daily (QD) orally. Treatment will continue until participant's death or early withdrawal from the study or study termination by the sponsor.
62370630|NCT01547962|EXPERIMENTAL|Split-mouth design: Treatment|
62370631|NCT01547962|ACTIVE_COMPARATOR|Split-mouth design: Control|
62370632|NCT01938560||Physicians|Retigabine Physicians (e.g. neurologists/epileptologists/neurosurgeons) who have prescribed retigabine at least once in the last 12 months.
62370633|NCT01938560||Pharmacists|Pharmacists who have dispensed an anti-epileptic drug (AED) at least once in the last 3 months.
62370634|NCT02599441||Ankle fracture cases|
62370635|NCT05326204||1 hour|Blood glucose monitoring comprises of 1 hour post meal
62370636|NCT05326204||2 hours|Blood glucose monitoring comprises of 2 hours post meal
62370637|NCT04705350|EXPERIMENTAL|Zampilimab Cohorts|Participants will be randomized to receive predefined single doses of zampilimab.
62370638|NCT04705350|PLACEBO_COMPARATOR|Placebo|Participants randomized to this arm will receive matching Placebo to maintain the blinding.
62370639|NCT00959894|EXPERIMENTAL|Etravirine 400 mg once daily|Etravirine 400 mg once daily with fixed dose tenofovir/emtricitabine (Truvada) one tablet once daily
62370640|NCT01510028|EXPERIMENTAL|Cohort 1 (10 mg)|6 patients treated with HGT-1110 10 mg EOW by IT injection
62370641|NCT01510028|EXPERIMENTAL|Cohort 2 (30 mg)|6 patients treated with HGT-1110 30 mg EOW by IT injection
62370642|NCT01510028|EXPERIMENTAL|Cohort 3 (100 mg)|6 patients treated with HGT-1110 100 mg EOW by IT injection
62744024|NCT04295681|EXPERIMENTAL|MMH-MAP|Oral administration. 2 tablets twice daily (approximately at the same time). The drug is taken outside a meal (between the meals or 15 min prior to meal or fluid intake). Tablets should be held in the mouth until completely dissolved. The overall duration of treatment is 90 days.
62744025|NCT04295681|PLACEBO_COMPARATOR|Placebo|Oral administration. For 90 days according to MMH-MAP dosing regimen.
62370643|NCT01510028|EXPERIMENTAL|Cohort 4 (100 mg)|6 patients treated with HGT-1110 100 mg EOW by IT injection
62370644|NCT06225804|EXPERIMENTAL|ABSK112|"During the escalation part, the administration of oral ABSK112 will be guided by Bayesian optimal interval (BOIN) design based on safety data collected until a maximum tolerated dose (MTD) has been identified. The first dose level will be administered as QD, and different dosing frequencies (e.g., BID) may be explored in subsequent doses depending on emerging safety and pharmacokinetic data.~A separate food effect cohort may be conducted.~In expansion part, patients will be treated at the selected RDE dose level."
62370645|NCT02373566|EXPERIMENTAL|Dermal substitute with STSG|Novomaix dermal substitute in combination with STSG
62370646|NCT02373566|NO_INTERVENTION|STSG alone|STSG alone
62370647|NCT01102140|ACTIVE_COMPARATOR|POMx|15 subjects will received 1000 mg of oral POMx for 12 weeks.
62370648|NCT01102140|PLACEBO_COMPARATOR|Control- sugar Pill|15 subjects will receive a matching sugar pill for 12 weeks.
62370649|NCT05265104|EXPERIMENTAL|SDF with stainless steel crown|mixture of silver , diamine and fluoride applied using a brush to the caries in the primary molar , it is used to arrest the progress of the carious lesion
62370650|NCT05265104|EXPERIMENTAL|Diode laser with stainless steel crown|Diode laser beam is used to sterilize the carious lesions to arrest the progress of the dental caries
62370651|NCT05265104|ACTIVE_COMPARATOR|Control, stainless steel crown only|stainless steel crown is cemented on the carious primary molar to arrest the progress of the caries, by isolating the tooth from the surrounding bacteria, this is the concept of the Hall technique.
62370652|NCT03077789|EXPERIMENTAL|TRABECULOTOMY|
62370653|NCT04520867||Qualifying Subjects|Patients seen in the EGMDC for treatment planning who are recommended to receive neoadjuvant treatment followed by surgery at UCCC Metro
62370654|NCT01909986|EXPERIMENTAL|E1|\[14C\]-ONO-4053
62370655|NCT03749850|EXPERIMENTAL|Study treatment|"LTLD in combination with MR-HIFU induced hyperthermia and cyclophosphamide~Single arm study"
62370656|NCT02805894|EXPERIMENTAL|NBTXR3 activated by IMRT only|"Part I Dose Escalation~NBTXR3 will be administered by intra-prostate injection and then activated 10 days later by:~- EBRT delivered as 45 Gy in 25 fractions of 1.8 Gy each; to the prostate and seminal vesicles, followed by 34.2 Gy in 19 fractions to the prostate and proximal seminal vesicles , over 9-10 weeks, utilizing intensity modulated radiotherapy (IMRT) with daily image guidance aligned to implanted fiducial markers (COHORT A)"
62370657|NCT02805894|EXPERIMENTAL|NBTXR3 activated by Brachytherapy & IMRT|"Part I Dose Escalation~NBTXR3 will be administered by intra-prostate injection and then activated 10 days later by:~- Brachytherapy Boost and EBRT delivered as a single fraction of 15 Gy in one day to the prostate by High Dose Rate Brachytherapy followed by EBRT (initiated within 2-4 weeks after completion of Brachytherapy), delivered as 45 Gy in 25 fractions of 1.8 Gy to the prostate and seminal vesicles utilizing intensity modulated radiotherapy (IMRT) with daily image guidance aligned to implanted fiducial markers (COHORT B)"
62370658|NCT03170908||Phase I Patients|Patients with depression receiving community-based services will receive Interpersonal Psychotherapy
62370659|NCT03170908||Phase II Patients|Patients with depression receiving community-based services will receive Interpersonal Psychotherapy
62370660|NCT01899768|EXPERIMENTAL|Part A|Subjects will receive treatment A (placebo) or treatment B (GSK2339345) in 3 visits of part A (one treatment per visit) in one of the following four sequences: ABA, ABB, BAA, and BAB.
62370661|NCT01899768|EXPERIMENTAL|Part B|Subjects will receive treatment A or treatment B in 2 visits of part B (one treatment per visit) in one of the following two sequences: AB and BA. Subjects will then orally inhale 10 microliter (mcL) of a capsaicin solution of strength ranging from 0.49 micromolar (mcM) to 1000 mcM, which will be administered using a breath activated dosimeter approximately 5 minutes post-dosing with treatment A or B at Visits 4 and 5.
62370662|NCT01899768|EXPERIMENTAL|Part C|Subjects will receive treatment A or treatment B in 2 visits of part C (one treatment per visit) in one of the following two sequences: AB and BA. Subjects will then orally inhale 10 mcL of a citric acid solution of strength ranging from 0.03 to 4.0 M, which will be administered using a breath activated dosimeter approximately 5 minutes post-dosing with treatment A or B at Visits 6 and 7.
62370663|NCT03839056||IC+PIEB+PCEA high flow|Continuous Epidural Infusion to 3ml/h more Programed Intermittent Epidural Boluses of 7ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of high flow as clinical practice routine
62370664|NCT03839056||PIEB+PCEA high flow|Programed Intermittent Epidural Boluses of 10ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of high flow as clinical practice routine
62370665|NCT03839056||PIEB+PCEA standar flow|Programed Intermittent Epidural Boluses of 10ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of standar flow as clinical practice routine
62744026|NCT01631201|EXPERIMENTAL|Rifalazil 25 milligram|
62370666|NCT05078307|ACTIVE_COMPARATOR|OHR System|Use of the OHR system to perform an operative hysteroscopy by resection of the fibroid.
62370667|NCT05078307|EXPERIMENTAL|OHV System|Use of the OHV system to perform an operative hysteroscopy by vaporization of the fibroid.
62370668|NCT06214923|OTHER|High impact TMD|"Other: TMD Phenotype~TMD participants will be clinically phenotyped into two between-subject groups based on their score on the Graded Chronic Pain Scale (GCPS). This group will have a GCPS grade 2b, 3, and 4."
62370669|NCT06214923|OTHER|Low impact TMD|"Other: TMD Phenotype~TMD participants will be clinically phenotyped into two between-subject groups based on their score on the Graded Chronic Pain Scale (GCPS). This group will have a GCPS grade 0, 1, and 2a"
62370670|NCT00392951|EXPERIMENTAL|Sirolimus treatment|Sirolimus treatment
62370671|NCT05528328|ACTIVE_COMPARATOR|CACIPLIQ20®|CACIPLIQ20® is a medical device used for the treatment of chronic skin ulcers, and contains a molecule belonging to the family of ReGeneraTing Agents (RGTA®). CACIPLIQ20® will be administered topically on the vertical and peri-areolar incisions of one breast for 5 minutes, after subcutaneous plans suture and just before final skin suture.
62370672|NCT05528328|PLACEBO_COMPARATOR|placebo|The placebo solution (saline solution) will be administered on the contralateral side.
62370673|NCT03053401|ACTIVE_COMPARATOR|Adductor Canal block|Adductor Canal Block performed at mid-thigh level to block the saphenous nerve under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
62744027|NCT01631201|ACTIVE_COMPARATOR|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
62744028|NCT05686746|EXPERIMENTAL|Baricetinib 4 mg|4 mg oral tablet daily
62744029|NCT05686746|EXPERIMENTAL|Baricetinib 2 mg|2 mg oral tablet daily
62744030|NCT05686746|ACTIVE_COMPARATOR|MMF|MMF 500 mg tablet twice daily
62744031|NCT06532526|ACTIVE_COMPARATOR|First group|Predicat Bioactive desensitizer
62744032|NCT06532526|ACTIVE_COMPARATOR|Second group|Gel with 1.23% sodium fluoride
62744033|NCT06532526|PLACEBO_COMPARATOR|Third group|Placebo gel
62370674|NCT03053401|ACTIVE_COMPARATOR|Femoral Nerve block|Femoral Nerve Block performed under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
62370675|NCT03570190||TAVI patients|elective patients with a diagnosis of sAS and admitted for TAVI attending one of the participating centers for commercially available balloon expandable valve implantation that will be managed by a coordinator
62370676|NCT01279967|NO_INTERVENTION|A|Arm A is control arm with best supportive care.
62370677|NCT01279967|EXPERIMENTAL|B|Arm B is the treatment arm with best supportive care plus ADI-PEG20.
62370678|NCT02789189|EXPERIMENTAL|nedaplatin combined with gemcitabine|
62370679|NCT00948285|EXPERIMENTAL|MRI|Preoperative staging with mammogram, ultrasound, and MRI, followed by surgery (n=200)
62370680|NCT00948285|NO_INTERVENTION|Non-MRI|Preoperative staging with mammogram and ultrasound alone, followed by surgery (n=200)
62370681|NCT03424044|EXPERIMENTAL|Dual Hormone Closed-loop Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in dual hormone mode and XeriSol glucagon to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery and an increase in glucagon delivery upon detection.
62370682|NCT03424044|EXPERIMENTAL|Single Hormone Closed-loop Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in single hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery upon detection.
62370683|NCT03424044|EXPERIMENTAL|Predictive Low Glucose Suspend Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in predictive low glucose suspend mode. The system will run through the closed-loop system but will utilize the patient's optimized basal rates, correction factors and carb ratios as they would normally run on their own insulin pump. But the mode will have the additional safety net of the pump suspending insulin when it predicts a hypoglycemic event.
62370684|NCT01319045|EXPERIMENTAL|Iloprost|Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.
62370685|NCT02253940|EXPERIMENTAL|Dose Group 1 - low dose|Treatment sequences ABC / CAB / BCA
62370686|NCT02253940|EXPERIMENTAL|Dose Group 2 - high dose|Treatment sequences DE / ED
62370687|NCT01948518|EXPERIMENTAL|Oral sildenafil 20 mg|oral sildenafil, single dose at baseline
62370688|NCT02813590||Patients with liver cirrhosis and with SBP|
62370689|NCT02813590||Patients with liver cirrhosis and without SBP|
62370690|NCT03924427|EXPERIMENTAL|BMS-986165|Given daily
62370691|NCT02091193||Placebo to Krill Oil|Group 2 receives supplement B for four weeks, undergoes a two week washout period, and then receives supplement A for another four weeks. Measurements are taken at baseline, after supplement B completion and after supplement A completion. Participants are informed which supplement was krill oil and which was placebo following completion of this phase of the study. Group 2 participants are given an option to also take an additional 17 weeks of Krill Oil and return for a follow up evaluating the long term use of krill oil.
62370692|NCT02091193||Krill Oil to Placebo|Group 1 receives supplement A for four weeks, undergoes a two week washout period, and then receives supplement B for another four weeks. Measurements are taken at baseline, after supplement A completion and after supplement B completion. Participants are informed which supplement was krill oil and which was placebo following completion of this phase of the study. Group 1 participants are given an option to also take an additional 17 weeks of Krill Oil and return for a follow up evaluating the long term use of krill oil.
62370693|NCT01843205|PLACEBO_COMPARATOR|Placebo|Subjects will be maintained on placebo.
62370694|NCT01843205|EXPERIMENTAL|Buspirone|Subjects will be maintained on buspirone.
62370695|NCT02812108||HARET|All patients with intracranial aneurysms, ruptured or unruptured, treated by endovascular treatment
62370696|NCT05896410|ACTIVE_COMPARATOR|Thermoplastic Splint(orthosis)|A static hand-based splint (orthosis) made with a thermoplastic material that immobilizes the CMC and MCP joint will be used.
62370697|NCT05896410|EXPERIMENTAL|3D printed splint (orthosis)|A static hand-based 3D-printed splint (orthosis) made with 3D printing that immobilizes both the CMC and MCP joint will be used.
62370698|NCT05861557|EXPERIMENTAL|Experimental arm|Toripalimab + SBRT radiotherapy
62370699|NCT03587467||health|"1. Alcohol free history or alcohol consumption \<140g per week in male, \<70g per week in female~2. smooth and soft stool like sausage or snake~3. Voluntary participate in this study"
62370700|NCT03587467||chronic hepatitis b carrier|"1. Alcohol free history or alcohol consumption \<140g per week in male, \<70g per week in female~2. Meet diagnostic criteria of chronic HBV infection in EASL 2017 Clinical Practice Guidelines on the management"
62370701|NCT03587467||chronic hepatitis b|"1. Alcohol free history or alcohol consumption \<140g per week in male, \<70g per week in female~2. Meet diagnostic criteria of chronic hepatitis B in EASL 2017 Clinical Practice Guidelines on the management"
62370702|NCT03587467||decompensated cirrhosis|"1. Alcohol free history or alcohol consumption \<140g per week in male, \<70g per week in female~2. Meet diagnostic criteria of chronic hepatitis B in EASL 2017 Clinical Practice Guidelines on the management"
62370703|NCT05821491||non-bedded night|geriatric patients with non-bedded night in the emergency department
62370704|NCT05821491||bedded night|geriatric patients with bedded night in the emergency department
62370705|NCT04249284|EXPERIMENTAL|Treatment A : BMS-986165|
62370706|NCT04249284|EXPERIMENTAL|Treatment B: BMS-986165 prototype 1|
62370707|NCT04249284|EXPERIMENTAL|Treatment C: BMS-986165 prototype 2|
62370708|NCT04249284|EXPERIMENTAL|Treatment D: BMS-986165 prototype 2|
62370709|NCT02858713|EXPERIMENTAL|App as intervention + Enstilar©|Patients prescribed Calcipotriene + Betamethasone Dipropionatecutaneous foam receive the intervention EM with app for smartphone and conventional instruction from a nurse in the consultation.
62370710|NCT02858713|NO_INTERVENTION|Conventional instructions + Enstilar©|Patients receive conventional instructions from a nurse in the consultation in how to use prescribed Enstilar© with EM.
62370711|NCT03552289|ACTIVE_COMPARATOR|Cook Enforcer balloon catheter|The Enforcer balloon will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.
62370712|NCT03552289|ACTIVE_COMPARATOR|Conventional angioplasty balloon catheters|Commercially available angioplasty balloon devices will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.
62370713|NCT05525286|EXPERIMENTAL|SOT102|"SOT102 is administered as intravenous infusion over 45 minutes as monotherapy or in combination with established standard of care therapy, every 14 days until the disease progression or intolerance to SOT102. SoC therapy is administered as per approved local standards. Patients will receive premedication with corticosteroids (4 mg dexamethasone twice daily) the day before, the day of (at least one hour prior), and the day after each SOT102 administration.~Starting dose of SOT102 is 0.032 mg/kg. Dose levels are to be escalated according modified Fibonacci scheme."
62370714|NCT06161688|EXPERIMENTAL|Ensitrelvir (S-217622)|Ensitrelvir fumaric acid (S-217622) given orally 375 mg on day 1 followed by 125 mg daily for 4 additional days
62370715|NCT06161688|PLACEBO_COMPARATOR|Placebo|Placebo administered orally for 5 days
62370716|NCT04551560|OTHER|Mental Stress|Patients will undergo a lab mental stress protocol, and a field protocol using ecological momentary assessment (EMA) to test the effects of psychological stress and negative emotion on PAP in HF patients.
62370717|NCT00831857||Group A|Treatment with sunitinib.
62370718|NCT00831857||Group B|Treatment with bevacizumab and interferon
62370719|NCT04036513|EXPERIMENTAL|MINST|"Usage of magnification loupes, specific thin and delicate tips together with piezoelectric device and specifically designed Hu-Friedy mini five, micro mini five, and after five Gracey curettes under local anaesthesia."
62370720|NCT04036513|ACTIVE_COMPARATOR|Conventional SRP|Conventional non-surgical mechanical treatment using piezoelectric device (PiezoLED, Kavo) and standard Gracey curettes under local anaesthesia.
62744034|NCT04566900|EXPERIMENTAL|Active Treatment|Subjects will be given a choice of videos consisting of still images set to music. Whether the video progresses and music continues to play will depend on the subject's ability to maintain frontal gamma oscillatory activity within a prespecified range. Over successive weeks, the parameters for positive feedback (music and video progression) will become incrementally more difficult.
62744035|NCT04566900|SHAM_COMPARATOR|Placebo|Video and music progression will be random and will not depend on brain activity. Any progression will be by random chance alone.
62744036|NCT03724383|NO_INTERVENTION|Control|Participants in the control arm will receive standard care.
62370721|NCT05557136|EXPERIMENTAL|Multistranded stainless steel fixed retainer|Multistranded stainless steel fixed retainer is used for lower anterior teeth (canine to canine) to maintain the stability of teeth after completion of orthodontic treatment
62370722|NCT05557136|EXPERIMENTAL|Polyether-Ether-Ketone (PEEK) fixed retainer|Polyether-Ether-Ketone (PEEK) fixed retainer is used for lower anterior teeth (canine to canine) to maintain the stability of teeth after completion of orthodontic treatment
62744037|NCT03724383|EXPERIMENTAL|Intervention|Participants in the intervention group will receive risk factor management consultations and take part in 1-hour biweekly diet classes and stress management classes for the first 3 months. This will be followed by 3 months of 1-hour biweekly high intensity interval training exercise classes. At the 6-month time point, participants will be prescribed a home based exercise program and will have the option of participating in weekly group walking sessions. During the final 6 months, participants will use a step/activity tracker to track their steps and heart rate.
62744038|NCT04606706|EXPERIMENTAL|Maternal, lactating mother & young child (Intervention)|mHealth education intervention for 6 months
62744039|NCT04606706|NO_INTERVENTION|Maternal, lactating mother & young child (Control)|Conventional health education
62744040|NCT01477710|ACTIVE_COMPARATOR|Hold Mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
62744041|NCT01477710|ACTIVE_COMPARATOR|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
62744042|NCT01477710|ACTIVE_COMPARATOR|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
62744043|NCT05484934|EXPERIMENTAL|Implant of acellular NAC graft|The implantation of the NAC acellular graft for regenerative nipple areolar complex
62744044|NCT00323960|ACTIVE_COMPARATOR|Methylprednisolone pulse (MPDN)+PDN+CSA|MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A
62370723|NCT04540783|ACTIVE_COMPARATOR|Group 1 - G1|bitemporal anodal stimulation and cathodal stimulation at supraorbital region.
62370724|NCT04540783|ACTIVE_COMPARATOR|Group 2 - G2|dorsolateral prefrontal anodal stimulation and cathodal stimulation at contralateral supraorbital region.
62370725|NCT04540783|SHAM_COMPARATOR|Group 3 - G3|sham anodal stimulation over bitemporal or dorsolateral prefrontal cortex (randomized) and sham cathodal over the orbitofrontal region.
62370726|NCT06455423|ACTIVE_COMPARATOR|MAN group|the standard MAN group will only receive thoracic manipulation and physical therapy
62744045|NCT00323960|ACTIVE_COMPARATOR|MPDN+PDN+MTX|MPDN= methylprednisolone pulse PDN= prednisone or equivalent MTX= methotrexate
62744046|NCT00323960|ACTIVE_COMPARATOR|MPDN+PDN|MPDN= methylprednisolone PDN= prednisone or equivalent
62744047|NCT04186416||Patients less than 6 months old|Patients less than 6 months old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
62744048|NCT04186416||Patients between 6 and 12 months old|Patients between 6 and 12 months old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
62370727|NCT06455423|EXPERIMENTAL|ELDOA-MAN group|The ELDOA-MAN group will receive ELDOA exercises in addition to thoracic manipulation and physical therapy.
62370728|NCT04247529|PLACEBO_COMPARATOR|No exposure to conflict|
62370729|NCT04247529|EXPERIMENTAL|Exposure to conflict|
62370730|NCT01425320|EXPERIMENTAL|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
62370731|NCT01425320|EXPERIMENTAL|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
62370732|NCT01425320|ACTIVE_COMPARATOR|dapsone 5% gel (ACZONE®)|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
62370733|NCT01425320|ACTIVE_COMPARATOR|adapalene 0.3% gel (Differin®)|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
62370734|NCT04889690|EXPERIMENTAL|Cohort 1: 200 mg|All participants under fasted conditions received 200 mg of danicopan or placebo twice daily (BID) over a 14-day period.
62370735|NCT04889690|EXPERIMENTAL|Cohort 2: 500 mg|All participants under fasted conditions received 500 mg of danicopan or placebo BID over a 14-day period.
62370736|NCT04889690|EXPERIMENTAL|Cohort 3: 800 mg|All participants under fasted conditions received 800 mg of danicopan or placebo BID over a 14-day period.
62370737|NCT04889690|EXPERIMENTAL|Cohort 4: 75 mg|All participants under fasted conditions received 75 mg of danicopan or placebo thrice daily (TID) over a 7-day period.
62370738|NCT05116683|EXPERIMENTAL|ATX-101|Patients will be treated with ATX-101 60 mg/m2 IV weekly in continuous 21 day cycles. Patients will receive premedication prior to the ATX-101 infusion to reduce the risk of infusion-related reactions.
62370739|NCT04915872||Participant|Critically Ill Patients with Open Abdomen and Negative Pressure Wound Therapy
62744049|NCT04186416||Patients between 1 and 6 years old|Patients between 1 and 6 years old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
62744050|NCT04186416||Patients between 6 and 10 years old|Patients between 6 and 10 years old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
62744051|NCT01240798||Depression, anxiety|
62744052|NCT06151613|ACTIVE_COMPARATOR|Continuous eCTG monitoring|"For the continuous eCTG monitoring, a wireless abdominal electrode patch (measuring fetal heart rate (FHR) and uterine activity (UA)) is used, developed by Nemo Healthcare: The Nemo Fetal Monitoring System (NFMS).~The advantage of the NFMS is that is a safe method for continuous (24/7) fetal monitoring. Furthermore, the patch does not have to be repetitively repositioned during registration, it can be used under the shower and it is wireless giving women more freedom to move around freely. Another benefit of eCTG monitoring is that it is especially suited for women with obesity, where conventional CTG monitoring often fails"
62744053|NCT06151613|NO_INTERVENTION|Conventional intermittent CTG monitoring|"Conventional intermittent CTG monitoring is performed in Maxima Medical Centre by the use of Philips Avalon FM 30 (Philips Healthcare, Eindhoven, The Netherlands).~This is a combined external measurement method using two transducers placed on the maternal abdomen: one to measure fetal heart rate (FHR) by the use of Doppler ultrasound (DU) and the other at the fundus of the uterus to measure uterine activity (UA) pattern (TOCO), keeping them in place with elastic banding."
62744054|NCT01934712|EXPERIMENTAL|FIAsp|Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits
62744055|NCT01934712|ACTIVE_COMPARATOR|NovoRapid®|Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits
62744056|NCT06430580|EXPERIMENTAL|20mg hydrocortisone + 54mg yohimbine hcl|20mg hydrocortisone, single oral dose 54mg yohimbine hcl, single oral dose
62744057|NCT06430580|EXPERIMENTAL|20mg hydrocortisone + 54mg placebo|20mg hydrocortisone, single oral dose 54mg cornstarch placebo, single oral dose
62744058|NCT06430580|ACTIVE_COMPARATOR|20mg placebo + 54mg yohimbine hcl|20mg cornstarch placebo, single oral dose 54mg yohimbine hcl, single oral dose
62744059|NCT06430580|PLACEBO_COMPARATOR|20mg placebo + 54mg placebo|20mg cornstarch placebo, single oral dose 54mg cornstarch placebo, single oral dose
62744060|NCT03650374|ACTIVE_COMPARATOR|Group 1|standard of care postoperative rehabilitation.
62744061|NCT03650374|EXPERIMENTAL|Group 2|experimental strength training
62370740|NCT01858506|EXPERIMENTAL|I-ACE intervention arm|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
62370741|NCT01858506|ACTIVE_COMPARATOR|Standard lifestyle advice arm|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
62370742|NCT04878289|EXPERIMENTAL|TOTAL Intervention|TOTAL video and participate in three one-on-one, 30-minute motivational sessions via VVC at 1-week, 6-months, and 12-months
62370743|NCT01047436|EXPERIMENTAL|ArTiMist (artemether sublingual spray)|
62370744|NCT01047436|ACTIVE_COMPARATOR|Intravenous Quinine|
62370745|NCT05625815|EXPERIMENTAL|Condition 1: prototypes from (816-v1 001) to (816-v1 050) every day|Application on the brown spots of the face and/or hands for the prototypes (816-v1001) to (816-v1 050) at D0, D1, D2, D3, D4 and D5.
62370746|NCT05625815|EXPERIMENTAL|Condition 2: prototypes from (816-v1 051) to (816-v1 100) every week|Application on the brown spots of the face and/or hands for the prototypes (816-v1 051) to (816-v1 100) at D0, D7, D14, D21, D28 and D35.
62370747|NCT05625815|EXPERIMENTAL|Conditions 3 : prototypes from (816-v1 101) to (816-v1 150) every two weeks|Application on the brown spots of the face and/or hands for the prototypes (816-v1 101) to (816-v1 150) at D0, D14, D28, D42, D56 and D70.
62370748|NCT05625815|EXPERIMENTAL|Condition 4 : prototypes from (816-v1 151) to (816-v1 200) every two weeks|Application on the brown spots of the face and/or hands for the prototypes (816-v1 151) to (816-v1 200) at D0, D14, D28, D42, D56 and D70.
62370749|NCT01117805|ACTIVE_COMPARATOR|Intervention|Subjects will be randomized to the program intervention which is a female-specific, culturally relevant, self-regulation based telephone counseling intervention designed for African American women with asthma.
62370750|NCT01117805|NO_INTERVENTION|usual care|Usual care at the University of Michigan Health System is based on the guidelines as recommended by the National Asthma Education and Prevention Program Expert Panel Report 3 (NAEPP-EPR3): Diagnosis and Treatment of Asthma and is coordinated so that all patients receive the same action plan, educational materials and instructions in use of devices.
62370751|NCT02602704|ACTIVE_COMPARATOR|Bazedoxifene & Calcium/Vit D|"* Enrollment: 57~* Drug: Bazedoxifene 20 mg/day (Viviant)~* Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 \* 2/day)"
62370752|NCT02602704|ACTIVE_COMPARATOR|Calcium/Vit D|"* Enrollment: 57~* Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 \* 2/day)"
62370753|NCT01718119|EXPERIMENTAL|DA-3803|subjects treated with DA-3803(r-hCG)
62370754|NCT01718119|ACTIVE_COMPARATOR|Ovidrel|subjects treated with Ovidrel(r-hCG)
62370755|NCT00836524||1|Pregnant women are included when they attend nuchal transcluency examination and will during their pregnancy be examined 4 times with ultrasound
62370756|NCT03834480|EXPERIMENTAL|• Steroid Group (S)|
62370757|NCT03834480|EXPERIMENTAL|• Platelet rich plasma Group (PRP)|
62370758|NCT05352321|EXPERIMENTAL|Surgery Plus Target-reduction Chemoradiotherapy|"Surgery:~Endoscopic nasopharyngectomy: Radical resection of primary lesion using nasal endoscopy.~Retropharyngeal lymphadenectomy: Radical retropharyngeal LNs resection using nasal endoscopy or da Vinci robotics.~Neck lymph node dissection: Selective neck dissection of the region where the positive lymph nodes are located.~Induction Chemotherapy for stage III-IVa:~Gemcitabine, 1000 mg/m2, Day 1 and Day 8, Q3W, 3 cycles Cisplatin, 80 mg/m2, Day 1, Q3W, 3 cycles~Intensity-modulated Radiotherapy with GTV and CTV1 reduction:~CTV2 : 54.12Gy/33Fr/1.64Gy~Concurrent Chemotherapy:~Cisplatin, 100 mg/m2, intravenously, Day 1, Q3W during radiotherapy"
62370759|NCT05352321|ACTIVE_COMPARATOR|Regular Chemoradiotherapy|"Induction Chemotherapy for stage III-IVa:~Gemcitabine, 1000 mg/m2, intravenously within 30min, Day 1 and Day 8, Q3W, 3 cycles Cisplatin, 80 mg/m2, intravenously, Day 1, Q3W, 3 cycles~Intensity-modulated Radiotherapy:~GTVnx (nasopharyngeal lesions): 69.96Gy/33Fr/2.12Gy GTVrnd (retropharyngeal lymph nodes): 69.96Gy/33Fr/2.12Gy GTVnd: 69.96Gy/33Fr/2.12Gy CTV1: 60.60Gy/33Fr/1.82Gy CTV2: 54.12Gy/33Fr/1.64Gy~Concurrent Chemotherapy:~Cisplatin, 100 mg/m2, intravenously, Day 1, Q3W during radiotherapy"
62370760|NCT00117572|ACTIVE_COMPARATOR|Induction plus chemoradiotherapy|"Induction therapy: Two 21-day cycles of chemotherapy consisting of docetaxel (75 mg/m2, day 1), cisplatin (75 mg/m2, day 1), and 5-fluorouracil (750 mg/m2/day, days 1-5). Total duration of 6 weeks.~Chemoradiotherapy: Five 14-day cycles of docetaxel (25 mg/m2, day 1), 5-fluorouracil (600 mg/m2/day, day 0-4), and hydroxyurea (500 mg PO q 12 hours x 6 days (11 doses)) with twice daily radiation (150 cGy given bid, days 1-5). Total duration of 10 weeks."
62370761|NCT00117572|ACTIVE_COMPARATOR|Chemoradiotherapy|Chemoradiotherapy: Five 14-day cycles of docetaxel (25 mg/m2, day 1), 5-fluorouracil (600 mg/m2/day, day 0-4), and hydroxyurea (500 mg PO q 12 hours x 6 days (11 doses)) with twice daily radiation (150 cGy given bid, days 1-5). Total duration of 10 weeks.
62370762|NCT01347840||All Subjects|This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.
62370763|NCT01560104|EXPERIMENTAL|veliparib and carboplatin and paclitaxel|Veliparib on Days 1-7 and carboplatin and paclitaxel on Day 3 of a 21 day cycle
62370764|NCT01560104|PLACEBO_COMPARATOR|placebo and carboplatin and paclitaxel|Placebo on Days 1-7 and carboplatin and paclitaxel on Day 3 of a 21 day cycle
62370765|NCT00183261|EXPERIMENTAL|1|Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine at study entry and on Weeks 4 and 26
62744062|NCT04200794|EXPERIMENTAL|musical instrumental training|Bi-weekly musical string instrument training in a group setting, over 24 months, provided by professional string instrument teachers
62744063|NCT04200794|ACTIVE_COMPARATOR|sensitization to music|Bi-weekly sensitization to music in a group setting, over 24 months, involving listening, playing small percussive instruments and choir singing, provided by professional school music teachers
62370766|NCT00183261|PLACEBO_COMPARATOR|2|Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine placebo at study entry and on Weeks 4 and 26
62370767|NCT02262013|ACTIVE_COMPARATOR|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
62370768|NCT02262013|EXPERIMENTAL|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program.
62370769|NCT04986891||subjects before first chemotherapy cycle with no neuropathy|at least 75 consecutive subjects sent for an evaluation before 1st chemotherapy cycle (TNSc score equal to 0 which means no neuropathy);
62370770|NCT04986891||subjects with stable CIPN condition after chemotherapy completion|subjects sent for an evaluation due to stable CIPN condition (CIPN defined as TNSc \> or = 1) after chemotherapy completion (at least 2 months off treatment).
62370771|NCT01795261||Lifestyle counseling|Prevention of mother to child transmission of HIV
62370772|NCT01795261||Lifestyle counseling Male|male partners and PMTCT completion rate among HIV-infected pregnant women.
62370773|NCT02903966|EXPERIMENTAL|GSK2982772 in Part A double-blind phase|Subjects will receive GSK2982772 60 mg orally three times daily (approximately 8 hours apart) for 42 days (6 weeks).
62370774|NCT02903966|PLACEBO_COMPARATOR|Placebo in Part A double-blind phase|Subjects will receive placebo orally three times daily (approximately 8 hours apart) for 42 days (6 weeks).
62370775|NCT02903966|EXPERIMENTAL|GSK2982772 in Part B open label extension phase|Subjects from GSK2982772 and placebo arm who complete Part A study will move to Part B open-label extension phase. All subjects will receive GSK2982772 60 mg three times daily (approximately 8 hours apart) for 42 days (6 weeks).
62370776|NCT06144567||Adult patients with PsA according to CASPAR classification criteria|"Adult patients (aged ≥ 18 years old and ≤ 65 years old) with PsA according to CASPAR classification criteria, who have been prescribed upadacitinib over the course of routine practice, in accordance with the applicable approved label and local regulatory and reimbursement policies (In patients with psoriatic arthritis, upadacitinib would be a therapeutic alternative after failure, inadequate response or intolerance to csDMARDs and anti-TNF) and have at least one ultrasound-determined peripheral enthesitis."
62744064|NCT00789594|EXPERIMENTAL|Laboratory Monitoring|Laboratory Monitoring
62744065|NCT00789594|EXPERIMENTAL|Result management|Result management
62744066|NCT00789594|EXPERIMENTAL|Both interventions|Both laboratory monitoring and result management interventions
62744067|NCT00789594|NO_INTERVENTION|Usual care|Usual care
62370777|NCT03138291|EXPERIMENTAL|Somnodent|SomnoDent is a custom-made oral appliance for the treatment of mild to moderate obstructive sleep apnea. SomnoDent is worn during sleep to provide Continuous Open Airway Therapy by moving the lower jaw slightly forward. This movement tightens the soft tissue and muscles of the upper airway, which prevents obstructive apneas while sleeping.
62370778|NCT01786434|EXPERIMENTAL|Routine medication arm|Fentanyl is given routinely to all patients before the procedure
62370779|NCT01786434|ACTIVE_COMPARATOR|Fentanyl on-demand arm|Fentanyl is given during the procedure if the patient experiences pain
62370780|NCT05726643|ACTIVE_COMPARATOR|resistive training group|consists of 20 patients who will receive resistive training for 2times per week for 12 weeks
62744068|NCT05735184|EXPERIMENTAL|Dose Escalation: Ziftomenib/Venetoclax/Azacitidine in R/R NPM1-m (A-1)|Ziftomenib/Venetoclax/Azacitidine in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy
62370781|NCT05726643|EXPERIMENTAL|kinesotaping group|consists of 20 patients who will receive resistive training program augmented by kinesotaping, 2 times /week for 12 weeks.
62370782|NCT00776373|EXPERIMENTAL|Arm 1|Rapamycin in combination with High Dose Etoposide and Cytarabine (HiVAC)
62370783|NCT03119922||SCD french new born|New-borns diagnosed by NBS from 01/01/2006 to 31/12/2010 (AFDPHE data, France)
62370784|NCT00130494|EXPERIMENTAL|Arm A: Zoledronic acid 4 mg|Zoledronate 4 mg every 3 or 4 weeks. This arm will receive study treatment from the time of entry into the trial, until the appearance of the symptoms of bone metastases (or a maximum period of 12 months, whichever occurs first).
62370785|NCT00130494|NO_INTERVENTION|Arm B: Observation|Patients will not receive any treatment with bisphosphonates until the time of onset of symptoms (or a maximum period of 12 months, whichever occurs sooner).
62370786|NCT04179604|EXPERIMENTAL|Levosimemdam|Levosimendan 2.5 mg / ml concentrate for solution for infusion. A 5 ml vial contains 12.5 mg of levosimendan. The concentrate is a clear solution, yellow or orange, for dilution before administration. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.
62370787|NCT04179604|PLACEBO_COMPARATOR|Placebo|Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
62370788|NCT02985684|EXPERIMENTAL|Device|ASD closure with the GORE® CARDIOFORM ASD Occluder
62370789|NCT02795065|ACTIVE_COMPARATOR|Enoxaparin 40 mg subcutaneous once daily|
62370790|NCT02795065|EXPERIMENTAL|Bemiparin 3500 IU subcutaneous once daily|
62370791|NCT02532413|EXPERIMENTAL|HBeAg(+):Poly IC+Entecavir|"45 subjects(HBeAg-positive chronic hepatitis B). Combination therapy will last 24 weeks from 0 week.~Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks. Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week"
62744069|NCT05735184|EXPERIMENTAL|Dose Escalation: Ziftomenib/7+3 in 1L NPM1-m (A-2)|Ziftomenib/7+3 in newly diagnosed NPM1-m AML patients who are candidates for intensive chemotherapy and meet the protocol definition of high-risk disease
62370792|NCT02532413|ACTIVE_COMPARATOR|HBeAg(+):Entecavir|45 subjects(HBeAg-positive chronic hepatitis B). Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks.
62370793|NCT02532413|EXPERIMENTAL|HBeAg(-):Poly IC+Entecavir|"45 subjects(HBeAg-negative chronic hepatitis B). Combination treatment will last 24 weeks from 0 week.~Drug: Enticavir 0.5mg, P.O.,qd, duration:48 weeks. Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week"
62370794|NCT02532413|ACTIVE_COMPARATOR|HBeAg(-):Entecavir|45 subjects(HBeAg-negative chronic hepatitis B). Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks.
62370795|NCT01892241|EXPERIMENTAL|180µg of peginterferon alfa-2a|Cases in group A receive 180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
62370796|NCT01892241|ACTIVE_COMPARATOR|Entecavir|cases in group B received an continual entecavir therapy(0.5 mg orally once daily)
62370797|NCT01892241|NO_INTERVENTION|Control group|Those in group C didn't accept any antiviral regiment .
62370798|NCT03534713|EXPERIMENTAL|Neoadjuvant chemotherapy+standard therapy|neoadjuvant chemotherapy with carboplatin aera Under curve 5 and paclitaxel 175 mg/m² every 21 days during 3 cycles followed by standard therapy with extended field external radiotherapy and concomitant chemotherapy (Cisplatin 40mg/m2 weekly)
62370799|NCT03534713|ACTIVE_COMPARATOR|standard therapy alone|standard therapy with extended field external radiotherapy and concomitant chemotherapy (Cisplatin 40mg/m2 weekly)
62370800|NCT04629365|EXPERIMENTAL|Ketogenic Diet|KD group consumed less than 50g/day of carbohydrates
62370801|NCT04629365|ACTIVE_COMPARATOR|Normal Diet|ND group consumed 55% of the caloric intake from carbohydrates
62370802|NCT02485067|EXPERIMENTAL|THVD-201|"1. Treatment period(12 weeks)~1. Double dummy(A+B) A. THVD-201: capsule B. Placebo(For Detrusitol 2mg tablet)~2. One capsule and One tablet bid on an empty stomach~2. Open-label extension period(An additional 12 weeks)~1. Regardless of the previous type of arm, all patients only take THVD-201 during this period.~2. One capsule bid on an empty stomach"
62370803|NCT02485067|ACTIVE_COMPARATOR|Tolterodine (Detrusitol)|"1. Treatment period(12 weeks)~1. Double dummy(A+B) A. Placebo(For THVD-201): capsule B. Detrusitol 2mg tablet~2. One capsule and One tablet bid on an empty stomach~2. Open-label extension period(An additional 12 weeks)~1. Regardless of the previous type of arm , all patients only take THVD-201 during this period.~2. One capsule bid on an empty stomach"
62370804|NCT04567953|EXPERIMENTAL|Saliva and NP paired specimen collection|
62370805|NCT00702936|ACTIVE_COMPARATOR|R|Twenty-five patients assigned to ramipril 5 mg daily
62370806|NCT00702936|ACTIVE_COMPARATOR|T|Twenty-five patients assigned to Telmisartan 80 mg daily
62744070|NCT05735184|EXPERIMENTAL|Dose Escalation: Ziftomenib/Venetoclax/Azacitidine in R/R KMT2A-r (B-1)|Ziftomenib/Venetoclax/Azacitidine in relapsed/refractory KMT2A-r AML patients who have failed at least one prior line of therapy
62744071|NCT05735184|EXPERIMENTAL|Dose Escalation: Ziftomenib/7+3 in 1L KMT2A-r (B-2)|Ziftomenib/7+3 in newly diagnosed KMT2A-r AML patients who are candidates for intensive chemotherapy and meet the protocol definition of high-risk disease
62370807|NCT05274009|EXPERIMENTAL|Extreme heat event simulation + no cooling (control)|Adults aged 60-85 years with or without type 2 diabetes and/or hypertension
62370808|NCT05274009|EXPERIMENTAL|Extreme heat event simulation + recommended cooling|Adults aged 60-85 years with or without type 2 diabetes and/or hypertension
62370809|NCT05274009|EXPERIMENTAL|Extreme heat event simulation + hybrid cooling|Adults aged 60-85 years with or without type 2 diabetes and/or hypertension
62370810|NCT03073200|EXPERIMENTAL|Ixekizumab|Ixekizumab given subcutaneously (SC) during the double-blind treatment period and the open-label maintenance period.
62370811|NCT03073200|PLACEBO_COMPARATOR|Placebo|Placebo given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period.
62370812|NCT03073200|EXPERIMENTAL|Open-Label Etanercept|Etanercept given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period. Participants will only be randomized to etanercept in countries where it is approved for severe pediatric psoriasis treatment.
62370813|NCT01899001|EXPERIMENTAL|CBT and Nutrition Counseling|8 weeks of Cognitive Behavioral Therapy (CBT) and 16 weeks of Nutrition Counseling
62370814|NCT01899001|OTHER|Nutrition Counseling|16 weeks of Nutrition Counseling alone
62370815|NCT04594668|NO_INTERVENTION|Standard treatment|Standard intensive care
62370816|NCT04594668|ACTIVE_COMPARATOR|Senicapoc|Senicapoc
62370817|NCT01718366|EXPERIMENTAL|ferritin level >300ng/ml and < 1000ng/ml|"Patients will be included in 2 groups according to the ferritin level at time of inclusion.~Patients with the ferritin level \>300ng/ml and \< 1000ng/ml, will be included in Group 1.~Interventions: Deferasirox, Vitamin D (100000/week) and Azacitidine (75 mg/kg/day Day1 today 7)~5 patients in each cohort: Cohort 1: Deferasirox: 5mg/kg/d Cohort 2: Deferasirox: 10mg/kg/d Cohort 3: Deferasirox: 15mg/kg/d"
62744072|NCT05735184|EXPERIMENTAL|Dose Validation/Expansion: Ziftomenib/Venetoclax/Azacitidine in R/R NPM1-m (A-1)|Ziftomenib/Venetoclax/Azacitidine in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy
62744073|NCT05735184|EXPERIMENTAL|Dose Validation/Expansion: Ziftomenib/7+3 in 1L NPM1-m (A-2)|Ziftomenib/7+3 in newly diagnosed NPM1-m AML patients who are candidates for intensive chemotherapy and meet the protocol definition of high-risk disease
62370818|NCT01718366|EXPERIMENTAL|ferritin level > 1000ng/ml|"Patients will be included in 2 groups according to the ferritin level at time of inclusion.~Patients with the ferritin level \> 1000ng/ml, will be included in Group 2. Intervention: Deferasirox, Vitamin D (100000/week) and Azacitidine (75 mg/kg/day Day1 today 7)~5 patients in each cohort: Cohort 1: Deferasirox: 10mg/kg/d Cohort 2: Deferasirox: 15mg/kg/d Cohort 3: Deferasirox: 20mg/kg/d"
62370819|NCT01336595|EXPERIMENTAL|Zirconium Femoral Component|Oxidized zirconium femoral component of Genesis II TKR system is used.
62370820|NCT01336595|ACTIVE_COMPARATOR|Cobalt Chrome|Cobalt-Chromium Femoral component of Genesis II system is used.
62370821|NCT04914195|EXPERIMENTAL|Leuprolide acetate 3.75 mg Depot (Luprodex)|Will be administered subcutaneously once a month for two cycles, on day 0 and on day 28/29
62370822|NCT04914195|ACTIVE_COMPARATOR|Leuprolide acetate 3.75 mg Depot (Lucrin)|Will be administered subcutaneously once a month for two cycles, on day 0 and on day 28/29
62370823|NCT05321589|OTHER|technique 1: conventional splinted open tray impression|"a conventional open tray impression technique splinted with ligature wire and duralay resin was done with polyvinyl siloxane impression .~analogues were screwed to the impression copings and casts were poured."
62370824|NCT05321589|OTHER|technique 2: digital intraoral impression technique|"scan bodies were screwed to implants intraorally and digital scanner was used to record digital impression, scanning protocol started from occlusal ,buccal to palatal surfaces.~The resulting scans were then exported in the standard tessellation format (.STL)"
62370825|NCT06329713|ACTIVE_COMPARATOR|30-Min Interval|"The patients will be given 10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether. Level of sensory block will be tested by testing with ice from S2 dermatome cephally.~Analgesia will be maintained by programmed intermittant epidural (PIE) boluses of 7,5 ml of 0,0625% of bupivacaine and 2 mcg/ml fentanyl every 30 minutes, starting 1 hour after the loading dose. In addition, patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 15 minutes may be administered. Breakthrough pain that requires even further analgesia will be treated with an epidural bolus of 10 ml of 0,1% bupivacain solution."
62370826|NCT06329713|ACTIVE_COMPARATOR|60-Min Interval|"The patients will be given 10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether. Level of sensory block will be tested by testing with ice from S2 dermatome cephally.~Analgesia will be maintained by programmed intermittant epidural boluses of 15 ml of 0,0625% of bupivacaine and 2 mcg/ml fentanyl once in every hour, starting 1 hour after the loading dose. In addition, patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 15 minutes may be administered. Breakthrough pain that requires even further analgesia will be treated with an epidural bolus of 10 ml of 0,1% bupivacain solution."
62370827|NCT03674294|EXPERIMENTAL|Palonosetron/Dexamethasone/Aprepitant|
62370828|NCT03674294|PLACEBO_COMPARATOR|Palonosetron/Dexamethasone/Placebo|
62744074|NCT05735184|EXPERIMENTAL|Dose Validation/Expansion: Ziftomenib/Venetoclax in R/R NPM1-m (A-3)|Ziftomenib/Venetoclax in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy
62370829|NCT02736929|ACTIVE_COMPARATOR|Cognitive Processing Therapy - Cognitive|Cognitive Processing Therapy - Cognitive (CPT-C), is a brief cognitive behavioral treatment for PTSD. CPT-C consists of 2 hours of therapy each week for 6 weeks (i.e., two sessions).
62370830|NCT02736929|NO_INTERVENTION|Waiting Period Control (WP-CON)|WP-CON group will receive minimal attention in the form of weekly telephone calls to assess current emotional state and to provide supportive, nondirective, brief counseling if participants report experiencing a crisis. Any participant assigned to the WP-CON group will be given the opportunity to receive CPT-C after the post-waiting period assessment.
62744075|NCT05735184|EXPERIMENTAL|Dose Validation/Expansion: Ziftomenib/Venetoclax/Azacitidine in 1L NPM1-m (A-4)|Ziftomenib/Venetoclax/Azacitidine in newly diagnosed NPM1-m AML patients
62744076|NCT05735184|EXPERIMENTAL|Dose Validation/Expansion: Ziftomenib/Venetoclax/Azacitidine in R/R KMT2A-r (B-1)|Ziftomenib/Venetoclax/Azacitidine in relapsed/refractory KMT2A-r AML patients who have failed at least one prior line of therapy
62370831|NCT01305941|EXPERIMENTAL|Everolimus +Vinorelbine + trastuzumab|daily everolimus plus weekly (Days 1, 8, and 15) vinorelbine and trastuzumab
62370832|NCT05090098||Breast cancer|Sixty patients with grade I-II-III breast cancer, whose primary treatment (surgery, radiotherapy and/or chemotherapy) is continuing, who applied to the Hospital Breast Unit clinic, will be included in the study. Patients with problems in reading and writing in Turkish, poor cognitive functions and a serious chronic disease, musculoskeletal pain or disease, severe psychiatric illness, current cancer attack or metastasis will be excluded from the study
62370833|NCT05090098||Breast cancer survivors|Sixty patients with grade I-II-III breast cancer, whose primary treatment (surgery, radiotherapy and/or chemotherapy) was completed at least three months ago, who applied to the Hospital Breast Unit clinic, will be included in the study. Patients with problems in reading and writing in Turkish, poor cognitive functions and a serious chronic disease, musculoskeletal pain or disease, severe psychiatric illness, current cancer attack or metastasis will be excluded from the study
62370834|NCT05090098||Healthy people|healthy individuals matched for age and gender will also be included in the study.
62370835|NCT04124224||Unidos Participants|In the Unidos intervention the county/community-based CHWs will: 1) support and connect participants to health promotion resources; 2) provide individual and group-based support guided by a novel framework for understanding Latino's health advantages, the sociocultural resiliency model; and, 3) leverage community resources to help individuals address SDH-related needs.
62370836|NCT04124224||Non-Unidos Participants: Comparison Group|Using propensity score matching, the investigators will use the medical records of Unidos participants and the electronic health record comparison group to compare health outcomes.
62370837|NCT00383266|EXPERIMENTAL|Pemetrexed + Carboplatin|"* Pemetrexed 500 mg/m\^2 IV over 10 minutes~* Carboplatin AUC 5 IV over 30 minutes on day 1 of each cycle~* Each cycle will last 21 days."
62370838|NCT03035422|OTHER|Patients with primary refractory acute myeloid leukemia|Patients with primary refractory acute myeloid leukemia
62370839|NCT01644981||VLBW infants|
62370840|NCT05604066|EXPERIMENTAL|Patients with myofascial-related pain diseases|Subjects diagnosed with myofascial-related pain disease will receive the research MRI imaging including MR elastography and MRI structural imaging.
62370841|NCT05604066|EXPERIMENTAL|Healthy controls without myofascial-related pain diseases|Subjects without myofascial-related pain disease will receive the research MRI imaging including MR elastography and MRI structural imaging.
62370842|NCT02325440|EXPERIMENTAL|Natalizumab - Washout - Fingolimod|One experimental arm: Patients receive one final dose of natalizumab 300mg followed by an 8-week washout Phase and subsequent 32-week treatment Phase with fingolimod 0.5mg o.i.d.
62370843|NCT05242809|NO_INTERVENTION|Control group|The control group receives standard care, which means the participants will receive verbal instruction on PFMT from midwives without any further supervision. For reasons of equipoise, women in the comparator group will be offered the group-based PFMT intervention at the end of the study if they wish.
62370844|NCT05242809|EXPERIMENTAL|Group-based PFMT group|The participants in the intervention group will receive PFMT supervision in groups. The number of women per group and the detail of the intervention will be decided through stakeholder development group meetings.The intervention will be teaching the participants to do PFMT in groups. The intervention will help women to identify their pelvic floor muscles and then guide them how to contract the pelvic floor muscle correctly (the detail of the intervention will be discussed and determined in phase 1 of this project).
62370845|NCT01886352|ACTIVE_COMPARATOR|Infiltration of portal sites with 0,5% levobupivacaine.|The first group of patients will receive the standard treatment (paracetamol, diclofenac and an opioid if necessary) with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine).
62370846|NCT01886352|EXPERIMENTAL|Additional injection of 0.5% levobupivacaine via a trocar|The second group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional injection of the local anesthetic ( 0.5% levobupivacaine, non -diluted) in the peritoneal cavity via a trocar both at the beginning and the end of the surgery.
62370847|NCT01886352|EXPERIMENTAL|Additional intraperitoneal atomization of levobupivacaine.|The third group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional intraperitoneal atomization of the local anesthetic.
62370848|NCT03119441|EXPERIMENTAL|Dental water jet|Dental water jet (Jetpik JP210)
62370849|NCT03119441|ACTIVE_COMPARATOR|Dental floss|Dental floss
62370850|NCT04583670||Patient physical examination with ultrasound|No intervention
62370851|NCT05211973||Fried Frailty Phenotype 0|Those who are considered Robust under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement and body weight composition in healthy adults.
62744077|NCT05735184|EXPERIMENTAL|Dose Validation/Expansion: Ziftomenib/7+3 in 1L KMT2A-r (B-2)|Ziftomenib/7+3 in newly diagnosed KMT2A-r AML patients who are candidates for intensive chemotherapy
62370852|NCT05211973||Fried Frailty Phenotype 1-2|Those who are considered Intermediate/Pre-frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement and body weight composition in healthy adults.
62370853|NCT05211973||Fried Frailty Phenotype 3+|Those who are considered Frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement and body weight composition in healthy adults.
62370854|NCT04350918|EXPERIMENTAL|Muscle Energy Technique (MET)|MET Group received 12 treatment sessions of MET (Nagrale et al, 2010) two times a week in addition to conventional physiotherapy. The procedures employ voluntary muscle contractions by the patient in a precisely controlled direction and intensity against a counterforce applied by the Physiotherapist. The technique requires the therapist to provide stabilization to the segment on which the distal aspect of the muscle attaches. A command for anisometric contraction of the muscle is given that causes accessory movement of the joint. Several specific muscle energy techniques are described for the subcranial region of the cervical spine.
62744078|NCT05735184|EXPERIMENTAL|Dose Validation/Expansion: Ziftomenib/Venetoclax/Azacitidine in 1L KMT2A-r (B-3)|Ziftomenib/Venetoclax/Azacitidine in newly diagnosed KMT2A-r AML patients
62744079|NCT01329276|OTHER|Symbicort® forte Turbohaler®|
62744080|NCT01329276|PLACEBO_COMPARATOR|Placebo (lactose)|
62744081|NCT06128707||Chronic Motion sensitivity group|Participants with a self-reported history of chronic motion sensitivity and who scored greater than or equal to the 30th percentile on the Motion sickness susceptibility questionnaire short form.
62370855|NCT04350918|EXPERIMENTAL|Static stretching (SS)|"Subjects in SS Group received 12 treatment sessions of static stretching (Dutton et al, 2008) two times a week in addition to conventional physiotherapy.~Stretching involves the application of manual or mechanical force to elongate structures that have adaptively shortened and are hypo-mobile (Sullivan, 2007) Static stretching involves stretching a muscle to a point of discomfort and holding the stretch for a length of time, followed by a return to normal resting muscle length (Andrews et al, 2004). Muscles of the neck were stretched in especially in side flexion, extension, flexion and side rotation for 10 seconds and was repeated 10 times for a session."
62370856|NCT02966899|EXPERIMENTAL|Omega-3 fatty acids|30 patients with pulmonary hypertension who are identified as having elevated myocardial triglyceride content by cardiac MRI will receive 4 grams/day of omega-3 fatty acids for six months.
62370857|NCT00906334|EXPERIMENTAL|800 mg/m^2 ON 01910.Na|800 mg/m\^2 ON 01910.Na administered as a continuous intravenous infusion (CIV) over 24 hours for 48 hours (i.e. 2 consecutive 24-hour infusions) every week for the first 3 weeks of 4-week cycle.
62370858|NCT00906334|EXPERIMENTAL|1800 mg ON 01910.Na|1800 mg ON 01910.Na administered as a continuous intravenous infusion (CIV) over 24 hours for 72 hours (i.e., 3 consecutive 24-hour infusions) every 2 weeks for the first four 2-week cycles and every 4 weeks afterwards.
62370859|NCT03447067|EXPERIMENTAL|Conventional surgery|"comprised 9 patient undergoing surgical removal of deeply impacted mandibular third molar by regular manor.~(Based on :Panorama and CBCT ) technique : 1- flap design 2- bone removal 3- tooth division 4- closure flap (suture)"
62370860|NCT03447067|EXPERIMENTAL|computer guided surgery|"comprised 9 patient undergoing surgical removal of deeply impacted mandibular third molar using computer guided surgical cutting stent.~Based on (panorama , CBCT and fabricating computer guided stent technique: 1- flap design 2- accurate setting stent in a predesign site 3- bony window removing according to the stent design 4- surgical separation of the teeth with extraction the remaning part . 5- identify the nerve 6- replace the bony window in to original place with stability 7- closure and depridment"
62370861|NCT04644965||Abdominal Wall Defect|patients born with an abdominal wall defect
62370862|NCT04644965||Control Group|age and sex matched Control Group
62370863|NCT00537771|EXPERIMENTAL|1|Anastrozole (ARIMIDEX)
62370864|NCT00537771|ACTIVE_COMPARATOR|2|Tamoxifen
62370865|NCT05104086|ACTIVE_COMPARATOR|evaluate the value of ultrasound elastography in dignosis of endometriomas|evaluation of endometrioma by ultrasound elastography and will be repeated after 4 weeks
62370866|NCT05104086|ACTIVE_COMPARATOR|evaluate the value of ultrasound elastography in ovarian hemorrhagic cysts|revaluation of ovarian hemorrhagic cyst by ultrasound elastography and noticing the change of values
62370867|NCT02077036|EXPERIMENTAL|Active medical device|
62370868|NCT02077036|PLACEBO_COMPARATOR|Inactive medical device|
62370869|NCT02245230|ACTIVE_COMPARATOR|Intact Study Day|Subjects will receive saline infusion for 60 minutes followed by five ascending doses of Angiotensin (1-7) ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
62370870|NCT02245230|EXPERIMENTAL|Autonomic Blockade Study Day|Autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min. Blood pressure will be restored to pre-trimethaphan levels with intravenous phenylephrine infusion at individually titrated doses, starting with 0.1 ug/kg/min. Angiotensin (1-7) will then be infused in five ascending doses ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
62370871|NCT00085358|EXPERIMENTAL|Treatment (carboplatin, paclitaxel, docetaxel, bevacizumab)|"Patients receive IP carboplatin on day 1, and paclitaxel IV over 3 hour (part A) or docetaxel IV over 1 hour (Part B) on day 1, and IP paclitaxel on day 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients receive IP carboplatin on day 1, paclitaxel IV on day 1, and IP paclitaxel on day 8 in course 1 as in part A dose-escalation phase. Beginning in course 2 and all subsequent courses, patients receive IP carboplatin on day 1, IV paclitaxel on day 1, and IP paclitaxel on day 8 as in the dose-escalation phase, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity."
62370872|NCT02650167|EXPERIMENTAL|Colostrum|
62370873|NCT02650167|EXPERIMENTAL|Witness|
62370874|NCT00940849|EXPERIMENTAL|Dietary Supplement: Plant sterol containing drink|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
62370875|NCT05859867|EXPERIMENTAL|Children resident in the Municipality of Mondovì (Intervention group)|"Recruiting of 1000 children (more or less) with ages between 0 and 5 years resident in the Municipality of Mondovì.~Eligible subjects are children with a date of birth between 1/1/2018 and 31/12/2022 (subjects born in 5 years prior to the start of the project), plus a cohort of newborn between 01/1/2023 and 21/6/2023.~Children of both sex and of any ethnicity could be enrolled in the trial.~Moreover, parents of eligible and enrolled children are also considered in-study subjects."
62370876|NCT05859867|NO_INTERVENTION|Children resident in the Municipality of Savigliano (Control group)|"Recruiting of 1000 children (more or less) with ages between 0 and 5 years resident in the Municipality of Savigliano.~Eligible subjects are children with a date of birth between 1/1/2018 and 31/12/2022 (subjects born in 5 years prior to the start of the project), plus a cohort of newborn between 01/1/2023 and 21/6/2023.~Children of both sex and of any ethnicity could be enrolled in the trial.~Moreover, parents of eligible and enrolled children are also considered in-study subjects."
62370877|NCT01807611|EXPERIMENTAL|Transplant Recipients|"Participants undergo a preparative regimen of total lymphoid irradiation, fludarabine, cyclophosphamide, fludarabine, thiotepa, melphalan, and mycophenolate mofetil, followed by HPC,A infusion and TC-NK infusion. They also receive G-CSF and mesna.~Cells for infusion are prepared using the CliniMACS System."
62370878|NCT03296072|EXPERIMENTAL|Test product|Participants will apply a full ribbon of the test product (1.5 grams \[g\]) containing 0.254% w/w sodium fluoride and 5% KNO3.
62370879|NCT03296072|ACTIVE_COMPARATOR|Comparator Product|Participants will apply a full ribbon of the comparator product (1.5 g orally) containing 0.454% w/w stannous fluoride.
62370880|NCT03296072|PLACEBO_COMPARATOR|Placebo Product|Participants will apply a full ribbon of the placebo (1.5 g orally) containing 5% KNO3.
62370881|NCT03458403|EXPERIMENTAL|Motions during gastroscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for.
62744082|NCT06128707||Non-Chronic Motion sensitivity Group|Participants without a self-reported history of chronic motion sensitivity and who scored less than or equal to the 25th percentile on the Motion sickness susceptibility questionnaire short form.
62370882|NCT01708915|ACTIVE_COMPARATOR|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
62370883|NCT01708915|ACTIVE_COMPARATOR|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
62370884|NCT01708915|ACTIVE_COMPARATOR|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
62370885|NCT01708915|PLACEBO_COMPARATOR|placebo|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
62370886|NCT01476553|EXPERIMENTAL|Intervention arm|Extensive Intraperitoneal Lavage (EIPL)
62370887|NCT03415672|ACTIVE_COMPARATOR|Group 1|Subjects included in Group 1 are adults who are non-responders (did not achieve seroprotection after 3 or more vaccinations with a Hepatitis B vaccine. They will receive three doses of HBVaxPro-10μg at 0, 1, and 2 months. The HBVaxPro-10μg vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
62370888|NCT03415672|EXPERIMENTAL|Group 2|"Subjects included in Group 2 are adults who are non-responders (did not achieve seroprotection after 3 or more vaccinations with a Hepatitis B vaccine). They will receive three doses of HBAI20 at 0, 1, and 2 months.~The HBAI20 vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly."
62370889|NCT02942693|EXPERIMENTAL|Apatinib with Particle Therapy|Participants will receive apatinib (0.5g, daily) for 6 weekly followed by particle radiotherapy (proton: 56 GyE/28 Fx, plus carbon: 15 GyE/5 Fx for boost).
62370890|NCT02942693|EXPERIMENTAL|Particle Therapy|Participants will receive particle radiotherapy alone (proton: 56 GyE/28 Fx, plus carbon: 15 GyE/5 Fx for boost).
62370891|NCT04557995|EXPERIMENTAL|Erythropheresis treatment|Erythropheresis treatment was was added to routine treatment
62370892|NCT04557995|NO_INTERVENTION|Routine treatment|Oxygen delivery and basic care
62370893|NCT01946568|EXPERIMENTAL|Single dose Dalbavancin|
62744083|NCT06661967|ACTIVE_COMPARATOR|Lidocaine spray|Spray lidocaine 10 puffs at oropharynx during preoxygenation if the patient body weight is lower than 60kg, otherwise 15 puffs
62744084|NCT06661967|PLACEBO_COMPARATOR|Placebo|Spray normal saline 10 puffs at oropharynx during preoxygenation if the patient body weight is lower than 60kg, otherwise 15 puffs
62370894|NCT05203328|EXPERIMENTAL|High flow nasal cannula oxygen|High flow nasal cannula oxygen will be provided during the procedure using a Vapotherm device
62370895|NCT05203328|ACTIVE_COMPARATOR|Regular nasal cannula|Regular nasal cannula oxygen will be provided during the procedure
62370896|NCT02728206|EXPERIMENTAL|SOF/VEL|SOF/VEL FDC for 4 weeks starting on the day of or day after the participant's liver transplant
62370897|NCT03535090||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
62370898|NCT04383964|EXPERIMENTAL|Transport distraction osteogenesis|"Locally made and designed submerged monodirectional in the vertical (Y) axis distractor was used.~A transport disc is created at the remaining stump of the RCU with an L shaped osteotomy.~The prepared disc is to be wide enough to fit the upper portion of the distrcator.~The submerged distractor will be placed in a position to guide the transport disc moving up and backwards toward the glenoid fossa.~The length of the distractor is determined according to the amount of distraction planned to reach the glenoid fossa."
62370899|NCT05004389||Acute Stroke|Persons ≥ 18 years of age with acute (≤ 7 days) ischemic or intracerebral hemorrhagic stroke.
62370900|NCT05205928|ACTIVE_COMPARATOR|Placebo + closed-loop insulin system|
62744085|NCT00338286|EXPERIMENTAL|001|epoetin alfa + packed RBC transfusion 40 000 IU SC once a week.
62744086|NCT00338286|OTHER|002|Standard supportive care (packed RBC transfusion) Per doctor prescription
62744087|NCT05664659|ACTIVE_COMPARATOR|Oxytocin+Misoprostol|Patients in this group will receive 600 micrograms misoprostol rectally immediately before sterilization plus 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution immediately after delivery of the fetus.
62370901|NCT05205928|EXPERIMENTAL|Semaglutide, Ozempic® (at maximum tolerated dose) + closed-loop insulin system|Semaglutide is a Glucagon-Like Peptide 1 Receptor Agonist. It stimulates GLP1 in the body, which allows for increased satiety, reduced glucagon levels, delayed gastric emptying, and in some, increased insulin secretion. It is a once per week subcutaneous injection.
62370902|NCT04709250|ACTIVE_COMPARATOR|group A: receive ultrasound-guided interscalene block|The patient will be put in the supine position, with the arm adducted a high-frequency linear ultrasound probe is oriented transversely across the lateral neck. When visualizing the ''stoplight sign,''15 to 30 mL of 0.25% bupivacaine consistent with the overall local anaesthetic dosing of less than 2.5 mg/kg. will be injected with low pressures to avoid intraneural injection.
62370903|NCT04709250|ACTIVE_COMPARATOR|group B: receive ultrasound-guided selective nerve block|The patient will be put in the sitting position, a linear 38-mm high frequency 10-12 MHz transducer will be placed first on the scapula to obtain a view of the suprascapular nerve a 22 G, 8 cm needle will be advanced in-plane and a total of 5-8 mL of 0.25% bupivacaine is injected then the arm adducted the linear probe will be placed at the junction of the pectoralis major muscle and the biceps muscle such that the axillary artery will be visualized in cross-section The probe will be moved towards the biceps muscle (laterally) until the musculocutaneous nerve is visualized and8 ml of 0.25% bupivacaine will be injected
62744088|NCT05664659|EXPERIMENTAL|Carbetocin|Patients in this group will receive 100ug Carbetocin by slow IV infusion (over one minute) intra-operative immediately after delivery of the fetus.
62744089|NCT02042586||Patients|
62370904|NCT05823649|EXPERIMENTAL|Early feeding/intervention group|The postoperative patients will be intervened after one to two hours from the entry of the patients to the postoperative ward.
62744090|NCT02042586||Controls|
62370905|NCT05823649|ACTIVE_COMPARATOR|Delayed feeding/control group|The postoperative patients will be fed delayed as traditionally practiced for long time as per the hospital's protocol that breaks the postoperative fasting only after four to six hours of the surgery according to the patient condition. The guideline of the hospital recommends the patients to drink black tea as first postoperative feeding and then facilitated by the semi-solid diet, especially mushy rice which is generally cooked by mixture of rice, vegetables and pulses with salt and a lot of water.
62370906|NCT01586962|EXPERIMENTAL|Upper Respiratory Infections|
62370907|NCT03649139|ACTIVE_COMPARATOR|artemisia annua (sweet sagewort) allergen extract drops|Drug: sublingual immunotherapy drops
62370908|NCT03649139|PLACEBO_COMPARATOR|Placebo drops|Drug: sublingual placebo drops
62370909|NCT01003340|EXPERIMENTAL|Wee Wheezers asthma education|6 lesson asthma education delivered at home by Community Health Workers
62370910|NCT00470977|EXPERIMENTAL|(Ranibizumab) Lucentis|(Ranibizumab)Lucentis 0.5%
62370911|NCT01046968|EXPERIMENTAL|Lepticore|
62370912|NCT05570357|ACTIVE_COMPARATOR|Intervention|
62370913|NCT05570357|PLACEBO_COMPARATOR|Placebo|
62370914|NCT01456728|EXPERIMENTAL|Progastria|One chewable tablet of the study product is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day together with omeprazole 2x20mg. The study product and omeprazole will be taken daily for 28 consecutive days.
62370915|NCT01456728|PLACEBO_COMPARATOR|Placebo|The placebo will have identical appearance and taste with the study product only lacking the bacteria. All subjects from this group will receive 2 x 20 mg omeprazole per day and Placebo 1 chewable tablet per day for 28 days.
62370916|NCT02565862|ACTIVE_COMPARATOR|Treatment A|"Day 1-2: 500mg twice daily (BID) metformin film-coated tablets~Day 3-8: 1000mg BID metformin film-coated tablets"
62370917|NCT02565862|EXPERIMENTAL|Treatment B|"Day 15-16: 500mg BID metformin film-coated tablets + 60mg once daily (QD) daclatasvir film-coated tablets~Day 17-22: 1000mg BID metformin film-coated tablets~+ 60mg QD daclatasvir film-coated tablets"
62370918|NCT05748236|ACTIVE_COMPARATOR|Lamotrigine|Starting dose 25mg once daily for 2 weeks, then 50 mg once daily for next 2 weeks . Then dose will be increased until seizure control or side effects develop (Maximum 500 mg/day)
62370919|NCT05748236|ACTIVE_COMPARATOR|Carbamazepine|Starting dose 100mg twice daily for 2 weeks, then 200 mg twice daily for next 2 weeks. Then dose will be increased until seizure control or side effects develop (Maximum 1600 mg/day)
62370920|NCT02702167|EXPERIMENTAL|High-frequency rTMS|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
62370921|NCT02702167|EXPERIMENTAL|Low-frequency rTMS|1 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
62370922|NCT02702167|SHAM_COMPARATOR|Sham rTMS|Sham repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
62370923|NCT00872781|EXPERIMENTAL|1|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc (a subsidiary of Ranbaxy pharmaceuticals Inc)
62370924|NCT00872781|ACTIVE_COMPARATOR|2|ACCURETICTM tablets (containing fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg)
62370925|NCT04964804|EXPERIMENTAL|real-time ultrasound-CT fusion imaging|The experimental group of patients underwent selective lumbar nerve root block puncture under real-time ultrasound-CT fusion imaging by sonographers
62370926|NCT04964804|ACTIVE_COMPARATOR|ultrasound alone|The control group underwent puncture under the guidance of ultrasound alone by sonographers
62370927|NCT04008667|EXPERIMENTAL|Intervention arm|"Receiving the acupoint application and optimal supports.~The patients start using the acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.~All patients will receive optimal supports during the observation period, including preoperative gastrointestinal preparation, inserting gastric tube, postoperative fasting, necessary antibiotic use, rational fluid management, detaining drainage tube, etc."
62370928|NCT04008667|PLACEBO_COMPARATOR|Placebo arm|"Receiving the fake acupoint application and optimal supports.~The fake acupoint is~The patients start using the fake acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.~All patients will receive optimal supports during the observation period, including preoperative gastrointestinal preparation, inserting gastric tube, postoperative fasting, necessary antibiotic use, rational fluid management, detaining drainage tube, etc."
62370929|NCT04008667|NO_INTERVENTION|Control arm|"Receiving the optimal supports.~All patients will receive optimal supports during the observation period, including preoperative gastrointestinal preparation, inserting gastric tube, postoperative fasting, necessary antibiotic use, rational fluid management, detaining drainage tube, etc."
62370930|NCT02409264|EXPERIMENTAL|Individualised Homeopathic Remedy|Sucrose pillules will be medicated with the determined individualised homeopathic remedy, in the potency decided by the researcher in accordance with the laws that govern homeopathic prescribing. The dose and repetition of the remedy will be determined by the researcher in accordance with the aforementioned laws. A remedy will be prescribed every 2 weeks, after its determination by the researcher. No remedy will be prescribed after week 8.
62370931|NCT05578326|EXPERIMENTAL|Trilaciclib and Lurbinectedin|Subjects with platinum refractory extensive stage small cell lung cancer receiving laciclib and Lurbinectedin
62370932|NCT00938197|ACTIVE_COMPARATOR|Part A|
62370933|NCT00938197|ACTIVE_COMPARATOR|Part B|
62370934|NCT00384449|EXPERIMENTAL|Lucentis (ranibizumab)|Lucentis (ranibizumab)
62370935|NCT05305625|EXPERIMENTAL|standard therapy|Patients will be treated with Guideline standard
62370936|NCT05305625|EXPERIMENTAL|remote ischemic postcondioning and standard therapy|Patients will be treated with remote ischemic postcondioning and Guideline standard , remote ischemic postcondioning twice a day for a total of 3 days.
62370937|NCT06107790|EXPERIMENTAL|HS022+ Vinorelbine Bitartrate|
62370938|NCT06107790|ACTIVE_COMPARATOR|Trastuzumab®+ Vinorelbine Bitartrate Injection|
62370939|NCT00453323|EXPERIMENTAL|study arm|
62370940|NCT04110444||sildenafile group A|received sildenafil citrate orally 20mg every 8 hours based on previous studies18,21 (Respatio tablet, pharma Egypt group) in addition to low molecular weight heparin daily according to the bodyweight at the booking visit (Clexane 20,40,60 mg, Sanofi eventis company) plus small dose of aspirin 75 mg (Aspocid 75mg tablet, CID pharmaceutical) once daily
62370941|NCT04110444||control group B|received low molecular weight heparin as subcutaneous injection once daily plus low dose aspirin 75mg orally once daily in addition to placebo three times daily prepared by a local pharmacy from a domestic manufacturer
62370942|NCT01456520|EXPERIMENTAL|A: single dose Vycavert (Test)|
62370943|NCT01456520|ACTIVE_COMPARATOR|B: single dose Norco (Reference)|
62370944|NCT02432690|EXPERIMENTAL|Arm A|
62370945|NCT04897594|EXPERIMENTAL|TERN-201 10mg|Orally administered
62370946|NCT04897594|EXPERIMENTAL|TERN-201 20mg|Orally Administered
62370947|NCT04897594|PLACEBO_COMPARATOR|Placebo|Orally administered
62370948|NCT01474889|EXPERIMENTAL|Hypoglycemia Unaware T1 Diabetes RT-CGM|"This arm is the intervention group. It consists of participants with type 1 diabetes complicated by hypoglycemia unawareness. Patients wore an RT-CGM for 18 months. We studied glucose production and symptom generation during insulin-induced hypoglycemia (metabolic testing) by subjecting this intervention group to a pair of metabolic clamps (hypoglycemic and euglycemic) at baseline, at 6 months and at 18 months to determine if hypoglycemia avoidance can reverse unawareness.~Please note: Arms are not assigned to the two control groups (non-diabetics and T1Ds with intact awareness) in ct.gov as they are only used as a baseline for clinical significance. Neither group wore a CGM nor are they analyzed at 6-month and 18-month time-points."
62370949|NCT00926263|EXPERIMENTAL|10 mg/kg cohort|
62370950|NCT00926263|EXPERIMENTAL|20 mg/kg cohort|
62370951|NCT00926263|EXPERIMENTAL|20/20 mg/kg cohort|
62370952|NCT03498989|EXPERIMENTAL|preterm formula milk neoborn|will be given preterm formula milk
62370953|NCT03498989|EXPERIMENTAL|exclusive breast milk|will be given exclusive breast milk
62370954|NCT01730001|ACTIVE_COMPARATOR|Early Intubation|Early intubation is defined as prehospital intubation on the scene of the patient illness/injury, or where the EMS physician first meets the patient (e.g en route to hospital). Intubation includes drug assisted and/or rapid sequence intubation (RSI) with endotracheal tube.
62370955|NCT01730001|ACTIVE_COMPARATOR|Late intubation|Late intubation is defined as on-scene prehospital high-flow (\> 10 L/min) supplemental oxygen by mask, assisted bag-mask-ventilation by EMS physician if required and stable recovery position during transport to hospital. Intubation should be done on arrival in the emergency department.
62370956|NCT00711412|EXPERIMENTAL|Induction, Combination and surgery|"Weeks 1-6:~Capecitabine 1000mg/m2 twice daily Oxaliplatin 70mg/m2 on days 1 and 8~Weeks 7-12:~Capecitabine 825 mg/m2 twice daily Oxaliplatin 50mg/m2 weekly Radiation 1.8 Gy Monday-Friday~Evaluation for response and resection surgery"
62370957|NCT00878306|ACTIVE_COMPARATOR|Disulfiram|Disulfiram
62370958|NCT00878306|EXPERIMENTAL|Disulfiram + Efavirenz|Efavirenz alone, then in addition with Disulfiram
62370959|NCT00878306|EXPERIMENTAL|Disulfiram + Atazanavir|Atazanavir alone, then in addition with Disulfiram
62370960|NCT00878306|EXPERIMENTAL|Disulfiram + Ritonavir|Ritonavir alone, then in addition with Disulfiram
62370961|NCT02306941|EXPERIMENTAL|Internet-delivered CBT|10 sessions of ICBT during 10 weeks for the adolescents. 5 session of parent training during 10 weeks for parents. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
62370962|NCT03645811|EXPERIMENTAL|Implementation of music therapy|"For the music therapy, lecturers specializing in music therapy were consulted and accordingly a mahur maqam, an instrumental piece of traditional Turkish music played on the saz, was chosen. The mahur maqam has a descending scale, which has a relaxing impact as it moves along a 1-2 octave sound spectrum. It elicits feelings of joy and positivity, and immediately draws the attention of the listener, helping keep the mind clear. The mahur maqam belongs to the rast maqam family. Rast maqams are usually evocative of feelings of peacefulness, surrender, tranquility, trust, and mystical sentiments."
62370963|NCT03645811|EXPERIMENTAL|Implementation of EFT|"The EFT application protocol was explained to the students with the help of the image in the picture for 5 minutes. The method was applied through the investigator tapping on their bodies and the students repeating the steps for three sessions. Each of the treatment sessions was approximately three minutes, resulting in a nine-minute treatment for intervention. Each EFT session was performed by following the steps below.~The content of each EFT session was as follows:~1. Preparation~2. Tapping Series~3. The Nine Gamut Sequence and Eye Movements"
62370964|NCT03645811|NO_INTERVENTION|Control|For the control group, 15 minutes of free time was given.
62370965|NCT04434833||Extra nodal diseases|Patients with both lymph node and extra nodal involvement.
62370966|NCT04434833||Target drugs|Patients enrolled in clinical trials of novel target drugs.
62370967|NCT04434833||Relapse|Patients with high risk of relapse.
62370968|NCT04827173|EXPERIMENTAL|Healthy volunteers|
62370969|NCT05165108|EXPERIMENTAL|Non-Invasive VNS|Non-Invasive VNS will decrease inflammation in people with Crohn's disease leading to decrease in inflammatory markers and symptoms of disease.
62370970|NCT00645203|OTHER|1|
62370971|NCT01605890|EXPERIMENTAL|raltegravir / emtricitabine / tenofovir disoproxil fumarate|
62370972|NCT03634293|PLACEBO_COMPARATOR|control group|The group will receive 2 ml' saline subcutaneous injection upon randomization when admitted to the ICU with the diagnosis of sepsis or septic shock
62370973|NCT03634293|ACTIVE_COMPARATOR|treatment group|The group will receive a 2 ml' subcutaneous injection of the study drug Alirocumab 150 mg', upon randomization when admitted to the ICU with the diagnosis of sepsis or septic shock.
62370974|NCT04724213|OTHER|Testing of reliability / validity of new questionnaire|
62370975|NCT03021590|EXPERIMENTAL|Clarithromycin :Concomitant Therapy|Amoxicillin 1000 mg Tablets, Clarithromycin 500 mg Tablets , Tinidazole 500 mg Tablets and Esomeprazole 20 mg Capsule each every 12 hours for 14 days all by mouth
62370976|NCT03021590|ACTIVE_COMPARATOR|Levofloxacin :Concomitant Therapy|Levofloxacin 500 mg Tablets Amoxicillin 1000 mg Tablets,Tinidazole 500 mg Tablets and Esomeprazole 20 mg each every 12 hours for 14 days all by mouth
62370977|NCT01666015|EXPERIMENTAL|Exercise (EX)|This group will perform two phases of an EX program.
62370978|NCT01666015|ACTIVE_COMPARATOR|Standard Care|This group will follow the standard care without any EX prescription.
62370979|NCT02296229|EXPERIMENTAL|Treatment (SBRT)|Patients undergo SBRT daily or every other day for a total of 5 fraction not exceeding 14 consecutive days. Patients may also receive androgen deprivation therapy for up to 9 months at the discretion of the treating physician.
62370980|NCT04514406||APERTO OTW DCB|Dialysis patients treated with APERTO OTW following (re)stenosis of central veins
62370981|NCT03616249|EXPERIMENTAL|Sleep quality|To compare if elderly sartcopics present sleep losses at higher levels than non-sarcopenic elderly
62370982|NCT03616249|EXPERIMENTAL|sleep-wake cycle.|To compare if elderly sarcopenics present sleep-wake cycle. disorders at higher levels than non-sarcopenic elderly
62370983|NCT03616249|ACTIVE_COMPARATOR|Exercise And Sleep quality|Comparing resistance training in the sarcopenician elderly showed improvements in sleep patterns.
62370984|NCT03616249|ACTIVE_COMPARATOR|Exercise And sleep-wake cycle.|Comparing resistance training in the elderly with sarcopenia presents better sleep-wake cycle.
62370985|NCT06430814||Breastcancer patients|A total of 188 patients diagnosed with breast cancer who are scheduled for paclitaxel treatment, either as adjuvant or neo-adjuvant treatment, will be recruited across three trial sites.
62370986|NCT03250130|EXPERIMENTAL|Hypnosis|The patient achieve self-hypnosis sessions in these chemotherapy treatments
62370987|NCT02918721|EXPERIMENTAL|Restylane Lidocaine|Restylane Lidocaine will be injected into one side nasolabial fold on Day 1
62370988|NCT02918721|ACTIVE_COMPARATOR|Restylane|Restylane will be injected into the opposite side nasolabial fold on Day 1
62370989|NCT06104891|PLACEBO_COMPARATOR|Placebo Control 1|Recharge Product Form 1 - control
62370990|NCT06104891|EXPERIMENTAL|Active Product 1|Recharge Product Form 2 - active product 1
62370991|NCT06104891|EXPERIMENTAL|Active Product 2|Recharge Product Form 3 - active product 1
62370992|NCT06104891|EXPERIMENTAL|Active Product 3|Recharge Product Form 4 - active product 1
62370993|NCT04168905|EXPERIMENTAL|Active arm|After receiving standard treatment and AOTI Inc. TWO2 topical oxygen therapy equipment training, patients will apply themselves oxygen therapy at home for 5 days a week, 90 minutes a day, rest for 2 days, and follow-up once a week. A total of 12 weeks of treatment, or recieving treatment till wound healed.
62370994|NCT04168905|PLACEBO_COMPARATOR|Controlled arm|patients receive standard treatment.
62370995|NCT02448095||CML ph+ patients|Chronic myeloid leukemia patients who are philadelphia positive
62370996|NCT03419507|ACTIVE_COMPARATOR|Macintosh group|After separating participants into two groups, doctors that drawed envelop number 1 will be asked to intubate with laryngoscope by using No. 3 Macintosh laryngoscope
62370997|NCT03419507|ACTIVE_COMPARATOR|Endotracheal tube introducer group|After separating participants into two groups, doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by using the adult size endotracheal tube introducer with using No. 3 Macintosh laryngoscope.
62370998|NCT05457400|ACTIVE_COMPARATOR|ENSO 16|The participants receive 30g ENSO 16 dissolved in 200 mL water and blood will be collected at defined time points (0 - 15 - 30 - 45 - 60 - 90 - 120 - 180 minutes; ±3 min at each time point).
62370999|NCT05457400|ACTIVE_COMPARATOR|Glucose Powder|The participants receive Glucose in the same dosage and blood is also taken at the same time points.
62371000|NCT04112953||Upcoming cardiac surgery|Subjects in this group will have an upcoming cardiac surgery with the use of cardiopulmonary bypass and no pre-existing renal insufficiency or failure
62371001|NCT05693649|EXPERIMENTAL|Arm 1A: Usual Care|Patients assigned to the Usual Care arm will receive current usual care and will not receive direct patient outreach or any visit-based interventions from this trial.
62371002|NCT05693649|EXPERIMENTAL|Arm 2A: Colonoscopy Only and No Nudge/Text|Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. Patients randomized to this arm will not receive visit-based interventions.
62371003|NCT05693649|EXPERIMENTAL|Arm 2B: Colonoscopy Only and Visit-Based Nudge/Text|Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. Patients randomized to this arm who attend a visit with their Primary Care Physician (PCP) will additionally receive a visit-based, clinician directed nudge to discuss colorectal cancer screening and a follow-up text 3 days post-visit to encourage screening completion.
62371004|NCT05693649|EXPERIMENTAL|Arm 3A: Sequential Choice and No Nudge/Text|Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. If not completed, patients will receive an order and a mailed fecal immunochemical test (FIT) with a reminder to complete CRC screening. Patients randomized to this arm will not receive visit-based interventions.
62371005|NCT05693649|EXPERIMENTAL|Arm 3B: Sequential Choice and Visit-Based Nudge/Text|Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. If not completed, patients will receive an order and a mailed fecal immunochemical test (FIT) with a reminder to complete CRC screening. Patients randomized to this arm who attend a visit with their Primary Care Physician (PCP) will additionally receive a visit-based, clinician directed nudge to discuss colorectal cancer screening and a follow-up text 3 days post-visit to encourage screening completion.
62371006|NCT00674687|PLACEBO_COMPARATOR|Sequence 1|
62371007|NCT00674687|EXPERIMENTAL|Sequence 2|
62371008|NCT04152668|ACTIVE_COMPARATOR|Titanium curette and ultrasonic.|Control implants will be debrided with titanium curette and ultrasonic device without time limit.
62371009|NCT04152668|EXPERIMENTAL|Titanium curette, ultrasonic and air-polishing.|Test implants will be treated with titanium curette, ultrasonic device and a specially designed nozzle mounted on a hand piece (Perio-Flow) connected to an airflow unit also without time limit.
62371010|NCT03876704|EXPERIMENTAL|High dose of fat-soluble vitamins|Fat-soluble vitamins is administered 0.5 piece/kg (equals to 1150 U/kg vitamin A，200 U/kg vitamin D, 3.2 U/kg vitamin E) intravenously every day until the baby achieve full enteral feeding (120 ml/kg), starting with the first dose within 24 hours after birth.
62371011|NCT03876704|ACTIVE_COMPARATOR|Conventional dose of fat-soluble vitamins|Fat-soluble vitamins is administered 0.1 piece/kg (equals to 230 U/kg vitamin A，40 U/kg vitamin D, 0.64 U/kg vitamin E) intravenously every day until the baby achieve full enteral feeding (120 ml/kg), starting with the first dose within 24 hours after birth.
62371012|NCT01634100|EXPERIMENTAL|A (Reference)|Empagliflozin (BI 10773), Film-coated tablet, single dose
62371013|NCT01634100|EXPERIMENTAL|B (Test 1)|Empagliflozin (BI 10773), Film-coated tablet, single dose, and Rifampicin,Film-coated tablet single dose
62371014|NCT01634100|EXPERIMENTAL|C (Test 2)|Empagliflozin (BI 10773), Film-coated tablet, single dose, and Probenecid Tablet twice daily
62744091|NCT06039176||Mayo Clinic|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
62744092|NCT06039176||University of Florida|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
62371015|NCT03938636|EXPERIMENTAL|Subjects free of inflammatory disease|Arm 1 includes inflammatory-disease-free HCs. Arm 1 was designed to evaluate image/re-image consistency (repeatability and stability) of joint-specific and global TUVs across a variety of image acquisition intervals and to collect normative HC data.
62371016|NCT03938636|EXPERIMENTAL|RA subjects on stable therapy|Arm 2 includes clinically-diagnosed RA subjects on stable treatment. Arm 2 was designed to evaluate image/re-image and test re-test (i.e., repeated dose) consistency of joint-specific and global TUVs across a variety of image acquisition intervals.
62371017|NCT03938636|EXPERIMENTAL|RA subjects who are candidates for initiation of a new anti-TNFα therapy|Arm 3 includes clinically-diagnosed RA subjects on stable treatment who are candidates for initiation of, or change to, new anti-TNFα therapy. Arm 3 was designed to assess the efficacy of global TUVs, obtained before and after initiation of a new anti-TNFα therapy, to predict future clinical responsiveness to the new therapy.
62371018|NCT04461613|EXPERIMENTAL|Group 1|"In the first week, this group will receive a physical activity diary and be required to fill it out for 7 days. After completion of the activity diary, group 1 will receive an original International Physical Activity Questionnaire short form (IPAQ-sf). Group 1 will be asked to fill it out with information about physical activities in the last 7 days.~In the second week, the group will need to fill another physical activity diary for 7 days. After the completion of this, group 1 will be asked to fill a revised version of IPAQ-sf to describe physical activities in the last 7 days."
62371019|NCT04461613|EXPERIMENTAL|Group 2|"In the first week, this group will receive a physical activity diary and be required to fill it out for 7 days. After completion of the activity diary, group 2 will receive a revised version of International Physical Activity Questionnaire short form (IPAQ-sf). Group 2 will be asked to fill it out with information about physical activities in the last 7 days.~In the second week, the group will need to fill another physical activity diary for 7 days. After the completion of this, group 2 will be asked to fill an original IPAQ-sf to describe physical activities in the last 7 days."
62371020|NCT01373125||Radiofrequency Ablation (RFA)|Participants in this group are greater than or equal to 12 months status post radiofrequency ablation (RFA).
62371021|NCT01373125||Radiofrequency Ablation Longitudinal (RFAL)|Participants in this group are part of a longitudinal portion of the study and are enrolled prior to their first radiofrequency ablation procedure and followed at 6 and 12 months after completion of RFA.
62371022|NCT01373125||Gastroesophageal Reflux Disease (GERD)|Participants in this group have been diagnosed with gastroesophageal reflux disease.
62371023|NCT01373125||Asymptomatic Controls (AC)|Participants in this group are asymptomatic controls and enrolled as part of the comparison group.
62371024|NCT02469584|EXPERIMENTAL|1|symptomatic cystocele described as Points Aa or Ba \>= 0 according to the International Continence Society pelvic organ prolapse quantification system (POP-Q). The changes in POPQ score preoperatively and three months after the anterior colporrhaphy with the new small stitch technic will be analyzed.
62371025|NCT02681640|EXPERIMENTAL|uPAR PET|One injection of 68Ga-NOTA-AE105 followed by Positron Emission Tomography (PET/CT scan) to evaluate possible axillary lymph node metastatic lesions
62371026|NCT00706758|ACTIVE_COMPARATOR|1|Structured patients group intervention - IBS school
62371027|NCT00706758|ACTIVE_COMPARATOR|2|Written information - IBS-guidebook
62371028|NCT06020768|EXPERIMENTAL|the different bed-head angles in the supine position|The researcher brought the patient to the supine position with the bed-head at 0 degree, and immediately (minute 0) made haemodynamic measurements: central venous pressure, systolic and diastolic blood pressure, heart rate, breathing rate and peripheral oxygen saturation. It was taken into account that this could change haemodynamic parameters, and immediately after a 10-minute period of rest, the same haemodynamic measurements were repeated. After this, the bed-head was adjusted to an angle of 20 degree, and the same procedure was repeated, with measurements after 0 and 10 minutes. The same procedure was followed with the bed-head raised to 30 degree and then to 45 degree. In positioning the patients' bed-heads to different angles, a spirit level and a protractor were used.
62371029|NCT00790218|EXPERIMENTAL|CF102 1mg|An open-label trial in 28-day cycles.
62371030|NCT00790218|EXPERIMENTAL|CF102 5mg|An open-label trial in 28-day cycles.
62371031|NCT00790218|EXPERIMENTAL|CF102 25mg|An open-label trial in 28-day cycles.
62371032|NCT02159989|EXPERIMENTAL|Treatment (sapanisertib, ziv-aflibercept)|Patients receive sapanisertib PO QD on days 2-4, 9-11, 16-18, and 23-25 and ziv-aflibercept IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62371033|NCT03993119||patients with NVAF|
62371034|NCT00509938|EXPERIMENTAL|1|5mg hLF1-11, single dose iv
62371035|NCT03140657|EXPERIMENTAL|Nanocurcumin Arm|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months.
62371036|NCT03140657|PLACEBO_COMPARATOR|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months.
62371037|NCT05880160|EXPERIMENTAL|Treatment Withdrawal|Participants will undergo phased withdrawal of heart failure/ cardioprotective treatments according to a pre-specified algorithm based on the 'Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy' (TRED-HF) study protocol (Halliday et al 2019). Medications will be down titrated in a phased process every 2 weeks over 16 weeks maximum. Drug doses will be reduced by 50% every 2 weeks, until the patient is taking 25% or less of the maximum recommended dose at which point they will be stopped. Monitoring with fortnightly virtual consultations will confirm dose reduction and provide support. Participants will undergo clinical assessment at 6, 14 and 24 weeks and 6, 9 and 12 months with weight, blood pressure, and biomarker measurement. At baseline, 6- and 12-month visits detailed cardiovascular phenotyping using cardiovascular magnetic resonance scans and symptom and disutility questionnaires will be undertaken.
62371038|NCT05880160|NO_INTERVENTION|Treatment Continuation|Participants will continue their current heart failure/ cardioprotective treatments. Participants will undergo clinical assessment at 6, 14 and 24 weeks and 6, 9 and 12 months with weight, blood pressure, and biomarker measurement. At baseline, 6- and 12-month visits detailed cardiovascular phenotyping using cardiovascular magnetic resonance scans and symptom and disutility questionnaires will be undertaken.
62371039|NCT01432704|PLACEBO_COMPARATOR|placebo capsules|Identically appearing placebo capsules not containing colecalciferol
62371040|NCT01432704|ACTIVE_COMPARATOR|colecalciferol capsules|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
62371041|NCT02756741|ACTIVE_COMPARATOR|STANDARD DOSE|Albumin 1.5gm/kg on day 1 and 1gm/kg on day 3
62371042|NCT02756741|PLACEBO_COMPARATOR|LOW DOSE|Albumin 20g/d for 5 days
62371043|NCT02972736||Interventional Cardiology|All procedures performed by interventional cardiologists
62371044|NCT02972736||Electrophysiology|All procedures performed by electrophysiologists
62371045|NCT02972736||Interventional Radiology|All vascular and non vascular procedures performed by interventional radiologists
62371046|NCT03809195|EXPERIMENTAL|Hypnosis Intervention|The intervention is clinical hypnosis--a single in-person session followed by instructions to listen to audio recordings at home. The sessions consist of the provider's voice guiding the participant into a relaxed and focused state and providing therapeutic suggestions--for example, to replace discomfort with a more pleasant sensation, to ease anxiety, and to increase energy.
62371047|NCT03809195|NO_INTERVENTION|Waitlist Control|This group will serve as a control comparison and be offered the intervention after control data collection is complete.
62371048|NCT04409496|EXPERIMENTAL|Intervention group|Chat-based instant messaging support + Self-help booklet
62371049|NCT04409496|ACTIVE_COMPARATOR|Control group|SMS message support + Self-help booklet
62371050|NCT06302868|ACTIVE_COMPARATOR|Telemedicine-based Virtual Reality Exposure Therapy|This group will receive exposure therapy in a telemedicine-based Virtual Reality Clinic using virtual reality snakes, dogs, or spiders. The VR stimuli range from small to medium to large and have four activity levels: idle, calm, energetic, and aggressive.
62371051|NCT06302868|ACTIVE_COMPARATOR|Standard Telemedicine Exposure Therapy|This group will receive exposure therapy via Doxy.me telemedicine platform using photos and videos of snakes, dogs, or spiders. The photo/video stimuli range from small to medium to large and have four activity levels: idle, calm, energetic, and aggressive.
62371052|NCT00608244|EXPERIMENTAL|LCP-Tacro|"Prograf was administrated BID, doses per product labeling, with an interval of 12±1 hours between the morning and evening doses. Patients continued on the same dose from Day 0 through Day 7. On Day 8, all patients were converted to LCP Tacro QD for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro was administered orally once daily in the morning, with an interval of 24 ± 1 h between doses. Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL.~LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
62371053|NCT03334656|EXPERIMENTAL|Biological Dressing|"It is a cellularized dressing of 100 cm² composed of fetal skin cells associated to a bovine collagen matrix:~* Fetal skin cells were obtained from a single fetal skin sample and consist in two clinical grade banks of keratinocytes (reference BKF07 K CB1) and fibroblasts (reference BKF07 WCB F d P3) produced at the UTCG. These two clinical grade cells banks were fully characterized and secure.~* The matrix is a customized type I calf collagen produced by the company Symatese. Symatese's collagen is in compliance with the European requirements"
62371054|NCT03334656|ACTIVE_COMPARATOR|Paraffin Gauze Dressing|"It is a low-adherent, sterile paraffin Tulle Gras dressing made from open weave gauze. The gauze has interlocking threads which minimize fraying when the dressing is cut to shape. JELONET® dressings are non-medicated and are used as a primary wound contact layer with paraffin present to reduce the adherence of the product to the surface of a granulating wound.~JELONET® is a product of Smith-Nephew, it has the CE-mark (n°0086) and the class of this medical device is IIa.~The features of this dressing are: Soft paraffin base, Sterile leno weave presentation, Comprehensive size range."
62567172|NCT03870750|EXPERIMENTAL|Arm II (CMC)|Patients undergo a CMC program on days -15 to 56. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT. Patients may also complete surveys on medical and non-medical (transportation, lodging) costs related to transplant after HCT.
62371055|NCT03823898|EXPERIMENTAL|Supervised exercise|"Participants in this group received a lifestyle intervention from baseline to 4 months. From 4 to 16 months participants were involved in two supervised exercise sessions per week plus healthy lifestyle interactive sessions.~The experimental intervention consisted of: a) monthly behavioral sessions consisted of lifestyle interactive sessions took place monthly and covered and followed contents that were addressed during the first 4 months of the study; b) The supervised exercise sessions were prescribed using an aerobic mode performed at a moderate-to-vigorous intensity during 45 minutes, twice a week, preferably during the weekends."
62371056|NCT03823898|ACTIVE_COMPARATOR|Control Group|Participants in this group received a lifestyle intervention from baseline to 4 months. From 4 to 16 months participants received no intervention
62371057|NCT03823898|EXPERIMENTAL|Monthly behavioral sessions|"Participants in this group received a lifestyle intervention from baseline to 4 months and then from 4 to 16 months participants were involved in non-supervised exercise group sessions with monthly behavioral sessions.~The experimental intervention consisted of monthly behavioral sessions consisted of lifestyle interactive sessions took place monthly and covered and followed contents that were addressed during the first 4 months of the study"
62371058|NCT03665493|EXPERIMENTAL|PD patients H&Y=1.5-2 Medications ON|Idiopathic Parkinson's patient's with Hoehn and Yahr score of 1.5- 2 i.e. in an early stage of the disease, under stable treatment with the administration of L-dopa and dopamine agonists. Patients will not present severe sensory deficits or any other neurological disease besides PD, as will be assessed by a standard neurological examination, and they will be all right-handed as will be assessed by the Edinburgh handedness inventory. Age range: 40-70
62371059|NCT03665493|EXPERIMENTAL|PD patients H&Y=3 Medications ON|Parkinson's patient's with Hoehn and Yahr score of 3, i.e. in moderate-to-advanced stages of the disease under stable treatment with the administration of L-dopa and dopamine agonists. Patients will not present severe sensory deficits or any other neurological disease besides PD, as will be assessed by a standard neurological examination, and they will be all right-handed as will be assessed by the Edinburgh handedness inventory. Age range: 40-70
62371060|NCT03665493|EXPERIMENTAL|PD patients H&Y=1.5-2 Medications OFF|Same as above described
62371061|NCT03665493|EXPERIMENTAL|PD patients H&Y=3 Medications OFF|Same as above described
62371062|NCT03665493|EXPERIMENTAL|Healthy age-matched controls|Healthy controls. Right-handed healthy subjects (it will be assessed by the Edinburgh handedness inventory) with normal or corrected-to-normal vision, without a history of neurological diseases. Age range: 40-70.
62371063|NCT05726955|NO_INTERVENTION|Control|Control
62371064|NCT05726955|EXPERIMENTAL|Exercise|Group 2 (n=28) were included in an exercise training program applied with conservative treatment and a stretching platform (ETSP)
62371065|NCT02637167|ACTIVE_COMPARATOR|Rifaximin|Rifaximin: one tablet (550 mg) morning and evening for three months
62371066|NCT02637167|ACTIVE_COMPARATOR|Saccharomyces boulardii|S. boulardii: two capsules (500 mg) morning and evening for three months
62371067|NCT02637167|NO_INTERVENTION|Control group|The third group receives no intervention
62371068|NCT06313749|EXPERIMENTAL|MIMS® Device/Procedure Arm|Arm which includes subjects undergoing the MIMS® surgical procedure using the proprietary MIMS® device developed by Sanoculis Ltd.
62371069|NCT06118944|EXPERIMENTAL|ICB00 Group|ICB00 IOL
62371070|NCT06118944|ACTIVE_COMPARATOR|ZCB00 Group|ZCB00 IOL
62371071|NCT06118944|ACTIVE_COMPARATOR|CNA0T0 Group|CNA0T0 IOL
62371072|NCT01998113||Glyburide (Glyburide vs Insulin)|Glyburide vs Insulin trials
62371073|NCT01998113||Insulin (Glyburide vs Insulin)|Glyburide vs Insulin trials
62371074|NCT01998113||Metformin (Metformin vs Insulin)|Metformin vs Insulin trials
62371075|NCT01998113||Insulin (Metformin vs Insulin)|Metformin vs Insulin trials
62371076|NCT01998113||Metformin (Metformin vs Glyburide)|Metformin vs Glyburide trials
62371077|NCT01998113||Glyburide (Metformin vs Glyburide)|Metformin vs Glyburide trials
62371078|NCT02030860|EXPERIMENTAL|Pre-operative Paricalcitol|Subject will receive gemcitabine/abraxane with preoperatively paricalcitol. Patients randomized to receive paricalcitol pre-operatively will begin treatment with intravenous paricalcitol at 25 μg three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days).
62371079|NCT02030860|ACTIVE_COMPARATOR|No Pre-operative Paricalcitol|Subject will receive gemcitabine/abraxane without paricalcitol preoperatively.
62371080|NCT01285414|EXPERIMENTAL|Verubulin & standard of care (RT & TMZ)|Verubulin, at the dose selected in Part A, plus standard of care Radiation Therapy and Temozolomide
62371081|NCT01285414|ACTIVE_COMPARATOR|Standard of care (RT & TMZ)|Standard of care Radiation Therapy and Temozolomide
62371082|NCT00991367|EXPERIMENTAL|A|Cicatrix
62371083|NCT00991367|PLACEBO_COMPARATOR|B|Placebo
62371084|NCT05936372|EXPERIMENTAL|EX-TD|Typical developed children that perform acute exercise prior to the learning task
62371085|NCT05936372|NO_INTERVENTION|CON-TD|Typical developed children that not perform acute exercise prior to the learning task
62371086|NCT05936372|EXPERIMENTAL|EX-DCD|Children with developmental coordination disorder (DCD) that perform acute exercise prior to the learning task
62371087|NCT05936372|NO_INTERVENTION|CON-DCD|Children with developmental coordination disorder (DCD) that not perform acute exercise prior to the learning task
62371088|NCT03144089|ACTIVE_COMPARATOR|Guedel oral airway|Each participant in the study will have both devices (GOA or AOA). The participants reported in this arm were randomized to receive the Guedel oral airway first and measurements were taken during breaths 6 through 10. After its removal the Articulated Oral Airway was inserted and measurements were repeated again during breaths 6 through 10.
62371089|NCT03144089|EXPERIMENTAL|Articulated Oral Airway|Each participant in the study will have both devices (GOA or AOA). The participants reported in this arm were randomized to receive the Articulated oral airway first and measurements were taken during breaths 6 through 10. After its removal the Guedel Oral Airway was inserted and measurements were repeated again during breaths 6 through 10.
62371090|NCT04212403|ACTIVE_COMPARATOR|Control|The control groups receives antimicrobial prophylaxis (AMP) as recommended by the guidelines.
62371091|NCT04212403|NO_INTERVENTION|Treatment group|The treatment group receives no AMP.
62371092|NCT01975376|EXPERIMENTAL|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous
62371093|NCT01975376|PLACEBO_COMPARATOR|Placebo|Placebo comparator, every 2 weeks, subcutaneous.
62371094|NCT02640755|EXPERIMENTAL|[14C]AZD2014 followed by AZD2014 Monotherapy|Arm will be comprised of \[14C\]AZD2014 followed by AZD2014 Monotherapy
62371095|NCT02640755|EXPERIMENTAL|[14C]AZD2014 followed by AZD2014 + Fulvestrant|Arm will be comprised of \[14C\]AZD2014 followed by AZD2014 + Fulvestrant
62371096|NCT02640755|EXPERIMENTAL|[14C]AZD2014 followed by AZD2014 + Paclitaxel|Arm will be comprised of \[14C\]AZD2014 followed by AZD2014 + Paclitaxel
62371097|NCT04028024|OTHER|inhibiting systemic inflammatory response|Ulinastatin 5000U/kg in 20ml NS i.v. before occlusion of aorta
62371098|NCT00844415|EXPERIMENTAL|dabigatran etexilate|open label; patient to receive dabigatran etexilate BID for three days
62371099|NCT04816786||Group 1: Admitted to ICU and died during the hospital stay.|
62371100|NCT04816786||Group 2: Admitted to ICU was were discharged.|
62371101|NCT05982444|OTHER|patient treated by rezum procedure|patients had benign prostatic hyperplasia and treated by rezum procedure from 2 to 4 years included in the study
62371102|NCT04175431|ACTIVE_COMPARATOR|Group I (fluciclovine PET/CT)|Patients for whom initial fluciclovine or PSMA PET/CT does not reveal any abnormalities outside the prostatic fossa undergo PSA rechecks every 3 months, and undergo fluciclovine or PSMA PET/CT once PSA is \> 2 ng/ml. If still no abnormalities are found outside of the prostatic fossa, patients continue to undergo PSA rechecks every 3 months, and undergo fluciclovine or PSMA PET/CT once PSA is \> 5 ng/ml. Patients are off study for treatment plan once PSA reaches 10 ng/ml.
62371103|NCT04175431|EXPERIMENTAL|Group II (surgery, radiotherapy, abiraterone, prednisone)|Patients undergo fluciclovine or PSMA PET/CT and who have =\< 3 regions of metastatic disease outside of the prostatic fossa that are amenable to metastasis-directed therapy undergo lymphadenectomy or radiation therapy. Six to ten weeks after surgery, patients receive abiraterone acetate 1000 mg PO QD and prednisone PO QD. Treatment repeats every 4 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may start radiation therapy after 2 cycles of abiraterone acetate and prednisone.
62371104|NCT04175431|EXPERIMENTAL|Group III (abiraterone, prednisone)|Patients undergo fluciclovine or PSMA PET/CT and who have \> 3 regions of metastatic disease receive abiraterone acetate and prednisone as in Group II.
62371105|NCT03404219|EXPERIMENTAL|Intervention|Mobile intervention (i.e., Ecological momentary intervention \[EMI\]) addressing social motivation and social skills. Twice daily notifications sent to deliver EMI content. Social goal reminders and steps provided to support goal attainment. Social Skills Training content delivered via brief video clips.
62744093|NCT06039176||University of Utah|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
62371106|NCT05467605|ACTIVE_COMPARATOR|CASE, GROUP ONE|Group 1 (group who will receive probiotics): one sachet contains(Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions), dissolved in 10 ml distilled water twice a day for 7days orally or through nasogastric/orogastric tube depending on clinical status of patients.
62371107|NCT05467605|PLACEBO_COMPARATOR|CONTROL, GROUP 2|GROUP 2 will receive only maltose dissolved in 10 ml of distilled water twice a day for 7 days orally or though nasogastric/orogastric tube depending on clinical status of patients.
62371108|NCT01173822|EXPERIMENTAL|Treatment group|Ultra filtration of residual blood.
62371109|NCT01173822|NO_INTERVENTION|Control|The current practice in our institution was to displace all the remaining volume in the CPB circuit into a transfer pack by displacing the remaining blood in the CPB circuit with additional Lactated Ringers solution. This transfer pack is then given to the anesthetist for reinfusion into the patient.
62371110|NCT04457661|EXPERIMENTAL|TCI711 probiotic|Taking one capsule (containing 10\^10 of Bacillus coagulans TCI711) daily for one month
62371111|NCT04609215|EXPERIMENTAL|ALECSAT|"This is an exploratory single arm study. 20 patients will be included with the objective to investigate the safety, tolerability and trends of efficacy of ALECSAT for the treatment of recurrent TNBC.~ALECSAT is a form of adoptive cell therapy medicinal product. ALECSAT is an abbreviation for Autologous Lymphoid Effector Cells Specific Against Tumor. ALECSAT is an autologous product that induces an immune response against a broad repertoire of CTAs expressed on cancer cells (including TNBC) leading to killing of these cells.~Patients will receive standard treatment with carboplatin and gemcitabine along with ALECSAT."
62371112|NCT05915104|EXPERIMENTAL|Budesonide MMX®|Participant received 9 mg delayed and extended-release tablet, once daily, oral administration, for 8 weeks
62371113|NCT05915104|ACTIVE_COMPARATOR|Budesonide controlled ileal release (CR) capsules|Participant received three 3 mg capsules, daily oral administration, for 8 weeks
62371114|NCT03890497|ACTIVE_COMPARATOR|Full dose of IPV|IPV first dose between 9 -13 months with second dose administered 2 months later.
62371115|NCT03890497|ACTIVE_COMPARATOR|Fractional Dose of IPV|fIPV first dose between 9 -13 months with second dose administered 2 months later
62371116|NCT01983046|PLACEBO_COMPARATOR|placebo|placebo
62371117|NCT01983046|ACTIVE_COMPARATOR|high acetate ratio|high acetate ratio
62371118|NCT01983046|ACTIVE_COMPARATOR|high butyrate ratio|high butyrate ratio
62371119|NCT01983046|ACTIVE_COMPARATOR|high propionate ratio|high propionate ratio
62371120|NCT03592394|ACTIVE_COMPARATOR|Somatic IVR (s-IVR)|This group will use an Immersive Virtual Reality (Gear VR) device to focus on encouraging disassociation between pain and visualization and movement of the affected limbs. Subjects in this group will be exposed to an IVR environment that cycles them through a series of stretching and mobility exercises for the affected limbs bilaterally.
62371121|NCT03592394|ACTIVE_COMPARATOR|Distractive IVR (d-IVR)|This group will use an Immersive Virtual Reality (Gear VR) device to focus on distracting the subject from the pain. Subjects in this group will be exposed to a variety of engaging landscape IVR environments, without the ability to visualize their own body.
62371122|NCT00488059|EXPERIMENTAL|Phase I|Phase 1: ENF 90mg SC BID): In the first phase or cohort phase of day I-1 through Week I-12 of the trial all patients received enfuvirtide (ENF) 90 mg subcutaneously (SC) twice daily (BID) + Isentress® \[raltegravir\] (RAL) 400-mg orally (PO) BID + optimized background (OB) with at least 1 fully active antiretroviral (ARV) agent excluding nucleoside reverse transcriptase inhibitor (NRTIs).
62371123|NCT00488059|EXPERIMENTAL|Phase II|"In the randomized comparator Phase II of the trial- (Day II-1 through Week II-16): Virologic responders confirmed HIV-1 RNA ≤50 copies/mL from Phase I were randomized to 1 of 2 treatment arms of~(Phase II Arm A: Phase I then ENF 90mg SC BID): ENF 90 mg SC BID + RAL 400 mg PO BID + OB with at least 1 fully active ARV agent excluding NRTIs or (Phase II Arm B: Phase I then ENF 180mg SC QD): ENF 180 mg SC once daily (QD) + RAL 400 mg PO BID + OB with at least 1 fully active ARV agent excluding NRTIs."
62371124|NCT01995422|EXPERIMENTAL|Physical activity program|A 5-month follow-up including a 3-month period of supervised physical activity
62371125|NCT02308306||Opioid analgesics|Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
62371126|NCT03625960|EXPERIMENTAL|Cantharidine group|Application of cantharidine to perenial warts
62371127|NCT03625960|ACTIVE_COMPARATOR|trichloroacetic acid group|application of trichloroacetic acid to perenial warts
62371128|NCT03139435|EXPERIMENTAL|Diagnostic (ultrasound)|Patients undergo peripheral nerve ultrasound. Patients also undergo skin biopsy.
62371129|NCT01365091|EXPERIMENTAL|Arm 1: Treatments A,B/B,A|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.~Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A)."
62371130|NCT01365091|EXPERIMENTAL|Arm 2: Treatments C,D/D,C|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.~Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C)."
62371131|NCT01365091|EXPERIMENTAL|Arm 3: Treatments E, F/F,E|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.~Period 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E)."
62371132|NCT01365091|EXPERIMENTAL|Arm 4: Treatments G,H/H,G|"Period 1: Participants received a single oral dose of saxagliptin , 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.~Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G)."
62371133|NCT04716712|ACTIVE_COMPARATOR|Biannual mass oral azithromycin + child health days|Bi-annual Mass Azithromycin distribution to all children 1-11 months old in participating communities paired with the Child Health Days Vitamin A distribution platform
62371134|NCT04716712|PLACEBO_COMPARATOR|Biannual mass placebo + child health days|Bi-annual Mass placebo distribution to all children 1-11 months old in participating communities paired with the Child Health Days Vitamin A distribution platform
62371135|NCT04716712|ACTIVE_COMPARATOR|Resistance Sub Study: Azithromycin + Child Health Days|Antimicrobial resistance will be monitored in a parallel study of communities from the target study area. 60 communities will be randomly selected among eligible communities, and randomized in a 1 : 1 fashion
62371136|NCT04716712|PLACEBO_COMPARATOR|Resistance Sub Study: Placebo + Child Health Days|Antimicrobial resistance will be monitored in a parallel study of communities from the target study area. 60 communities will be randomly selected among eligible communities, and randomized in a 1 : 1 fashion
62371137|NCT05408052|ACTIVE_COMPARATOR|Standard Epidural|Standard epidural technic will be applied before the anesthesia induction for perioperative analgesia
62371138|NCT05408052|ACTIVE_COMPARATOR|Dural Puncture Epidural (DPE)|Dural Puncture Epidural technic will be applied before the anesthesia induction for perioperative analgesia
62371139|NCT02691468|ACTIVE_COMPARATOR|PVC DLT|"After the induction of general anesthesia, a left sided PVC DLT was placed by the anesthesiologist using direct laryngoscopy. Tube position was confirmed with fiberotic bronchoscope.~The first set of measurements tracheal distance(from tracheal carina to proximal tip of DLT) and bronchial distance(from bronchial carina to distal tip of DLT) measured by bronchoscope is taken in supine position .~The second set of measurements is taken in lateral position after position change.~The displacement of PVC DLT is calculated from difference in tracheal distance between supine and lateral position."
62371140|NCT02691468|ACTIVE_COMPARATOR|silicon DLT|"After the induction of general anesthesia, a left sided silicon DLT was placed by the anesthesiologist using direct laryngoscopy. Tube position was confirmed with fiberotic bronchoscope.~The first set of measurements tracheal distance(from tracheal carina to proximal tip of DLT) and bronchial distance(from bronchial carina to distal tip of DLT) measured by bronchoscope is taken in supine position .~The second set of measurements is taken in lateral position after position change.~The displacement of silicon DLT is calculated from difference in tracheal distance between supine and lateral position."
62371141|NCT06353425||Reproductive aged women|Reproductive aged women in Asia and Oceania countries
62371142|NCT00360672|EXPERIMENTAL|Revlimid|Revlimid 25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
62371143|NCT02048852|EXPERIMENTAL|Reduced Nicotine Content -Non Menthol|Switch from own brand of cigarette to SPECTRUM research cigarettes (NRC 200-Reduced Nicotine Content cigarette) which contain 0.07mg nicotine yield without menthol.
62371144|NCT02048852|EXPERIMENTAL|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced Nicotine Research Cigarettes which contain 0.07mg nicotine yield with Menthol
62371145|NCT02048852|ACTIVE_COMPARATOR|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette. No research cigarettes used.
62371146|NCT02048852|EXPERIMENTAL|Conventional Nicotine Content- Non Menthol|Switch from own brand of cigarette to SPECTRUM research cigarette (NRC-600 Conventional Nicotine )which contains conventional nicotine yield.
62371147|NCT01848795|EXPERIMENTAL|EndoBarrier Gastrointestinal Liner|The treatment in this arm is the endoscopic positioning of the EndoBarrier Gastrointestinal Liner and follow up.
62371148|NCT01848795|ACTIVE_COMPARATOR|Intragastric Balloon|The treatment in this arm is the endoscopic positioning of the intragastric balloon (Easy life balloon) as a comparator and follow up.
62371149|NCT00744692|EXPERIMENTAL|RIC Cord Blood Transplant|Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
62371150|NCT02270489|EXPERIMENTAL|AFFITOPE® PD01A + Adjuvant|"4 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
62371151|NCT02270489|EXPERIMENTAL|AFFITOPE® PD03A + Adjuvant|"4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
62371152|NCT02270489|PLACEBO_COMPARATOR|Adjuvant without active component|"4 injections of Placebo once every 4 weeks~1 administration 36 weeks after first injection"
62371153|NCT00744731|EXPERIMENTAL|001|placebo placebo for 1 week
62371154|NCT00744731|EXPERIMENTAL|002|carisbamate 400 mg/day to 1,200 mg per day
62744094|NCT06039176||University of California, San Francisco|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
62744095|NCT06039176||Advocate Health|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
62371155|NCT06245824|EXPERIMENTAL|All the subjects enrolled will receive the experimental intervention|Participants will receive 5.4 mg/kg of T-DXd as IV infusion q3w, along with pyrotinib 400mg or 320mg (depend on recommended dose) orally once a day within 30 minutes after breakfast for a 21-day cycle.
62371156|NCT04813289||Anaesthesia type|"1. Inhalational anaesthesia without Remifentanil use~2. Inhalational anaesthesia with Remifentanil use~3. Total intravenous anaesthesia"
62371157|NCT04813289||Blood pressure monitoring|"1. Intraarterial line use~2. Non-invasive blood pressure monitoring"
62371158|NCT00314054|EXPERIMENTAL|1|HCV-796 1000mg single dose
62371159|NCT04649190||TAVI|
62371160|NCT06398093|EXPERIMENTAL|Self-Compassion Toolkit|
62371161|NCT01124513|ACTIVE_COMPARATOR|Digital Camera|Digital camera images will be taken of a a 2cm\^2 area of sun protected skin.
62371162|NCT01124513|ACTIVE_COMPARATOR|Spectrophotometer|The probe of the protable reflectance spectrophotometer is lightly applied to the sufance of the skin and a reading is taken.
62371163|NCT01124513|ACTIVE_COMPARATOR|Videodermoscopy|The instrument is put in contact with sun protected skin and an image is taken of a 2 cm\^2 area.
62371164|NCT06186024|EXPERIMENTAL|Experimental group|Bridge
62371165|NCT06026423||Normal/uncomplicated healing process|100 women with a second-degree tear or episiotomy primarily sutured after labor: identified with a normal/uncomplicated healing process
62371166|NCT06026423||Dehisced wound treated with secondary resuturing|100 women with a second-degree tear or episiotomy: identified with a dehisced wound treated with secondary resuturing
62371167|NCT06026423||Dehisced wound treated with conservative management|100 women with a second-degree tear or episiotomy: identified with a dehisced wound treated with conservative management
62371168|NCT03122249|OTHER|OASIS|Patients that meet the eligibility criteria will be enrolled in the study and will receive the advanced cancer symptom management intervention
62371169|NCT00767299|EXPERIMENTAL|1|
62371170|NCT00767299|PLACEBO_COMPARATOR|2|
62371171|NCT02364661|EXPERIMENTAL|Hepatitis B virus infected patients|HBV patients with detectable viremia will be analyzed for their level of viremia following an over-night starvation (fasting) versus fed state
62371172|NCT03127462|EXPERIMENTAL|Individualized Education|
62371173|NCT03127462|NO_INTERVENTION|Control group|
62371174|NCT01060722|EXPERIMENTAL|MOD-4023, dose level 1|
62371175|NCT01060722|EXPERIMENTAL|MOD-4023, dose level 2|
62371176|NCT01060722|EXPERIMENTAL|MOD-4023, dose level 3|
62371177|NCT02876484|EXPERIMENTAL|Placebo|"Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM.~25 ml water"
62371178|NCT02876484|EXPERIMENTAL|Chenodeoxycholic Acid|Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Chenodeoxycholic acid (1250 mg) mixed in 25 ml yoghurt
62371179|NCT02876484|EXPERIMENTAL|Colesevelam|Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Colesevelam (3,75 g) dissolved in 25 ml water and mixed in 25 ml yoghurt.
62371180|NCT02876484|EXPERIMENTAL|Colesevelam x 2|plus (on another study day) 3,75 g colesevelam administered the evening before the experiment. Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Colesevelam (3,75 g) dissolved in 25 ml water and mixed in 25 ml yoghurt.
62371181|NCT04584944||Healthy adult men|Healthy young men, 20- 44 years old
62371182|NCT04584944||Healthy adult women|Healthy young women, 20- 44 years old
62371183|NCT03436745|ACTIVE_COMPARATOR|Female|Single 5 mg oral dose of zolpidem
62744096|NCT06039176||University of Rochester Medical Center|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
62371184|NCT03436745|EXPERIMENTAL|Zolpidem pre and post castration|5 mg oral dose of zolpidem prior to undergoing ADT followed by 5 mg oral dose of zolpidem after ADT and testosterone reaches castrate levels
62371185|NCT01905514|NO_INTERVENTION|control|using Medication event monitoring system
62371186|NCT01905514|ACTIVE_COMPARATOR|internet mobile application|using both mobile internet application and medication event monitoring system
62371187|NCT02283346|EXPERIMENTAL|HDR Brachytherapy + EBRT|HDR brachytherapy + hypofractionated EBRT
62371188|NCT00108615|EXPERIMENTAL|1|pioglitazone
62371189|NCT00108615|ACTIVE_COMPARATOR|2|metformin
62371190|NCT00874224|ACTIVE_COMPARATOR|1|patients undergoing open left lateral hepatic sectionectomy
62371191|NCT00874224|ACTIVE_COMPARATOR|2|patients undergoing a laparoscopic left lateral hepatic sectionectomy
62371192|NCT00874224|ACTIVE_COMPARATOR|3|Prospective registry of patients that cannot be randomized (both open and laparoscopic left lateral hepatic sectionectomy)
62371193|NCT00873704|ACTIVE_COMPARATOR|1|recieves supplemental oxygen postoperatively
62371194|NCT00873704|NO_INTERVENTION|2|treated as usual without supplemental oxygen
62371195|NCT04662645|EXPERIMENTAL|Supportive care (embedded palliative care)|Participants and caregivers undergo embedded palliative care comprising symptom management (physical and psychological), advanced directives and goals of care discussion, caregiver support, and referral for adjunctive supportive services as needed at each clinic visit.
62371196|NCT01099761|EXPERIMENTAL|ACE-031 0.5 mg/kg q4wk|
62371197|NCT01099761|EXPERIMENTAL|ACE-031 1.0 mg/kg q2wk|
62371198|NCT01099761|PLACEBO_COMPARATOR|Placebo|
62371199|NCT04500223|EXPERIMENTAL|Cervical Cranioflexion exercise plus cardiopulmonary exercise|subjects who received Cervical Cranioflexion exercise plus cardiopulmonary exercise
62371200|NCT04500223|ACTIVE_COMPARATOR|Cervical stretch exercise plus cardiopulmonary rehabilitation|subjects who received Cervical stretch exercise plus cardiopulmonary rehabilitation
62371201|NCT01524926|EXPERIMENTAL|Crizotinib in Anaplastic large cell lymphoma|
62371202|NCT01524926|EXPERIMENTAL|Crizotinib in Inflammatory myofibroblastic tumor|
62371203|NCT01524926|EXPERIMENTAL|Crizotinib in Papillary renal cell carcinoma type 1|
62371204|NCT01524926|EXPERIMENTAL|Crizotinib in Clear cell sarcoma|
62371205|NCT01524926|EXPERIMENTAL|Crizotinib in Alveolar soft part sarcoma|
62371206|NCT01524926|EXPERIMENTAL|Crizotinib in Alveolar rhabdomyosarcoma|
62371207|NCT01866306|EXPERIMENTAL|Healthy 10 TCID50 (Part 1)|Healthy participants were treated with 10 Tissue Culture Infective Dose 50 (TCID50) administered by spraying an atomized viral suspension of RV16UB into a single nostril.
62371208|NCT01866306|EXPERIMENTAL|Healthy 100 TCID50 (Part 1)|Healthy participants were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
62371209|NCT01866306|EXPERIMENTAL|Healthy 1000 TCID50 (Part 1)|Healthy participants were treated with 1000 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
62371210|NCT01866306|EXPERIMENTAL|Asthmatic non-LABA 10 TCID50 (Part 1)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 10 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
62371211|NCT01866306|EXPERIMENTAL|Asthmatic non-LABA 100 TCID50 (Part 1)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
62371212|NCT01866306|EXPERIMENTAL|Asthmatic LABA 100 TCID50 (Part 1)|Participants with mild to moderate asthma, concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
62371213|NCT01866306|EXPERIMENTAL|Asthmatic non-LABA 100 TCID50 (Part 2)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
62371214|NCT01679340|EXPERIMENTAL|S-1+oxaliplatin|S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d oxaliplatin: 65mg/m2, D1,D8, 3weeks/cycle after 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.
62371215|NCT01679340|ACTIVE_COMPARATOR|S-1+cisplatin|S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d) cisplatin: 75mg/m2, D1, every 3 weeks After 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.
62371216|NCT00757367|EXPERIMENTAL|TI Inhalation Powder|TI Inhalation Powder, single dose, 60 units
62371217|NCT02924272|EXPERIMENTAL|Ixazomib|Ixazomib capsule, orally, at same dose and schedule that participants were receiving in the parent study until disease progression, clinical deterioration in the investigator's judgment, experience an unacceptable toxicity, withdraw consent, pursue an alternative therapy, meet other study-specified reasons for discontinuation of study drug, or until the participant is transitioned to ixazomib through commercial channels, including reimbursement for the participant's indication, whichever is sooner. Participants who were receiving a combination therapy with ixazomib and another medication(s) will continue to receive the combination regimen.
62371218|NCT02055729||The study population|"The proposed study is a prospective, single-center pilot study lasting 28 days. Our goal is to study the temporal evolution of the bacterial communities present in the skin and digestive flora (stool) of spinal cord injured persons having one or more sacral bedsores. The study timespan can include treatment initiation, notably of antibiotics. Urinalysis for studying urinary flora will simultaneously occur.~For a description of the study population, see the inclusion/exclusion criteria.~Intervention: Superficial bedsore sample Intervention: 3mm tissue punch biopsy Intervention: Stool sample Intervention: Urine sample"
62371219|NCT02058251|EXPERIMENTAL|Oxytocin|Each participant will self-administer a 40 IU dose of intranasal oxytocin.
62371220|NCT02058251|PLACEBO_COMPARATOR|Control|Each participant will self-administer a 40 IU dose of intranasal saline.
62371221|NCT01386190|EXPERIMENTAL|Exercise Group|Caregivers will be taught progressive exercises to use with their infants from hospital discharge to 1 year of age.
62371222|NCT01386190|ACTIVE_COMPARATOR|Control|Both the control and the intervention groups will be guided in implementing structured social interaction.In the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
62371223|NCT01709604||continuous venovenous hemofiltration|Continuous venovenous hemofiltration(CVVH):blood access was achieved by placing a double lumen catheter in the femoral or internal jugular vein. Continuous diffusive solute transport is achieved by infusing a dialysis fluid that runs counter-current to blood at an ultrafiltration rate of 35 ml/h/Kg.
62371224|NCT01709604||Standardized therapy regimens|The standardized therapy regimens included reduce absorption, accelerate the elimination and prevent the complications in patients with paraquat poisoning.
62371225|NCT02252328|EXPERIMENTAL|Simvastatine|Group of patients receiving simvastatin 80mg once daily in addition to standard care
62371226|NCT02252328|PLACEBO_COMPARATOR|Placebo|Group of patients receiving placebo once daily in addition to standard care
62371227|NCT02897076|ACTIVE_COMPARATOR|12mg betamethasone+12mg betamethasone|"A betamethasone course consists in 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg.~In the BETADOSE trial, the first injection will be unmasked in both groups. In both groups, women will received a first 12 mg injection of betamethasone according to local protocols.~Randomization will be performed after the first injection. Women will then received either a blinded placebo injection (50% reduced dose regimen, 12 mg only from the first injection) or a second blinded 12 mg betamethasone injection (standard full dose regimen, 12 mg from the first injection and 12 mg from the second injection=24 mg)."
62371228|NCT02897076|PLACEBO_COMPARATOR|12 mg betamethasone+ placebo|"A betamethasone course consists in 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg.~In the BETADOSE trial, the first injection will be unmasked in both groups. In both groups, women will received a first 12 mg injection of betamethasone according to local protocols.~Randomization will be performed after the first injection. Women will then received either a blinded placebo injection (50% reduced dose regimen, 12 mg only from the first injection) or a second blinded 12 mg betamethasone injection (standard full dose regimen, 12 mg from the first injection and 12 mg from the second injection=24 mg)."
62371229|NCT03066310||Diagnosed Urinary Bladder Cancers|Patients who are being monitored for bladder cancer will be the experimental group to test the urine-DNA by next generation sequencing for bladder cancer biomarkers
62371230|NCT03066310||Non-Urinary Bladder Cancers|Patients being treated for gross hematuria will provide a negative control to provide data from testing by next generation sequencing for biomarkers in patients being treated for other diseases.
62371231|NCT01711580||Re-irradiation, high grade glioma|EORTC QLQ-C30 EORTC QLQ-BN20 Hopkins Verbal Learning Test-Revised (HVLT-R) Trail Making Test (TMT) Stroop color-word test Controlled oral word association test (COWA) Jamar hand dynamometer EORTC QLQ- FA13 Short Form health survey (SF-36)
62371232|NCT05551910|EXPERIMENTAL|Analgesia and sedation with esmketamine combined with propofol|
62371233|NCT05551910|OTHER|Remifentanil combined with propofol for analgesia and sedation|
62371234|NCT02384785||Spinal Cord Stimulation|"Patients who underwent implantation of electrodes spine for treatment in chronic pain.~'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation (one after another)"
62744097|NCT06039176||University of Kansas Medical System|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
62744098|NCT06039176||Medical University of South Carolina|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
62371235|NCT03928340|ACTIVE_COMPARATOR|combined metformin and insulin|
62371236|NCT03928340|OTHER|Insulin only|
62371237|NCT00858975|EXPERIMENTAL|Cryotherapy|The patients who receive cryotherapy for their renal tumors
62371238|NCT03367611|EXPERIMENTAL|Immunochemical faecal occult blood test|All participants will collect a single faecal sample for haemoglobin measurement (immunochemical faecal occult blood test, iFOBT), and be examined by colonoscopy.
62371239|NCT05355324||anemia|patients with anemia
62371240|NCT05355324||non-anemia|patients without anemia
62371241|NCT06347692|EXPERIMENTAL|control group|The control group received a conventional physical therapy program.
62371242|NCT06347692|EXPERIMENTAL|study group|Conversely, in addition to the conventional physical therapy program provided to the control group, the antigravity treadmill group underwent antigravity treadmill training using the Alter G device.
62371243|NCT03903536||Thrombectomy|Patients with thrombosed external hemorrhoids undergoing thrombectomy
62371244|NCT03903536||Local excision/ Hemorrhoidectomy|Patients with thrombosed external hemorrhoids undergoing local excision/ hemorrhoidectomy
62371245|NCT02021708||Non-smoker|This group will include individuals without any history of lung disease, including asthma, and without recurrent or acute pulmonary disease. Individuals must also have smoked less than 100 cigarettes and/or less than 10 shisha pipes in their lifetime.
62371246|NCT02021708||Shisha smoker|This group will include individuals who have a shisha smoking history of more than 5 pipe-years and must currently smoke more than 5 pipes per week. Individuals must not show any signs of acute lung infection or have medical history of significant illness or other significant medical issues.
62371247|NCT02021708||Cigarette smoker|This group will include individuals who have a cigarette smoking history that will be confirmed by urine testing. Individuals must not show any signs of acute lung infection or have medical history of significant illness or other significant medical issues.
62371248|NCT04528394|EXPERIMENTAL|Photon combined with Carbon ion|The participants received photon: 56 Gy/28 Fx for high-risk area(CTVhigh), 50.4 Gy/28 Fx for lower neck low-risk area(CTVlow), plus carbon ion: 15-17.5 GyE/5 Fx for boost for visible tumors.
62371249|NCT04528394|EXPERIMENTAL|Proton combined with Carbon ion|The participants received proton: 56 GyE/28 Fx for high-risk area(CTVhigh), 50.4 GyE/28 Fx for lower neck low-risk area(CTVlow), plus carbon ion: 15-17.5 GyE/5 Fx for boost for visible tumors.
62371250|NCT00805818|EXPERIMENTAL|NNZ-2566|20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1 mg/kg/h (Cohort 1, n=20), 3 mg/kg/h (Cohort 2, n=20) or 6 mg/kg/h (Cohort 3, n=133) intravenous infusion for a total of 72 consecutive hours.
62371251|NCT00805818|PLACEBO_COMPARATOR|Sodium Chloride (0.9%) for Injection|Intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion (Cohort 1, n=10), (Cohort 2, n=10) or (Cohort 3, n=67) intravenous infusion for a total of 72 consecutive hours.
62371252|NCT04311437|EXPERIMENTAL|Self-acupressure group|The subjects in experimental group will undergo additional self-acupressure therapy in addition to Valsalva and Toynbee maneuvers before the first HBOT. The acupoints used are TE17 (Yifeng, 翳風), TE21 (Ermen, 耳門), SI19 (Tinggong, 聽宮), GB2 (Tinghui, 聽會).
62371253|NCT04311437|PLACEBO_COMPARATOR|Control group|The subjects in control group will receive Valsalva and Toynbee maneuvers alone.
62371254|NCT01819194|EXPERIMENTAL|senofilcon A|Acuvvue Oasys with Hydaclear Plus with 38% water.
62371255|NCT05953272|EXPERIMENTAL|EMG Biofeedback therapy and Bobath therapy|The experimental group will receive EMG Biofeedback therapy for 15 minutes along with Bobath therapy for 45 minutes and home exercise program. The EMG Biofeedback therapy and Bobath therapy will be given for 16 sessions (4 sessions per week for 4 weeks). Patient will perform the home exercise program once a day in home during 4 weeks of treatment period.
62371256|NCT05953272|ACTIVE_COMPARATOR|Bobath therapy only|This group will receive only Bobath therapy for 45 minutes and home exercise program. The Bobath therapy will be given for 16 sessions (4 sessions per week for 4 weeks). Patient will perform the home exercise program once a day in home during 4 weeks of treatment period.
62371257|NCT00835276|EXPERIMENTAL|1|
62371258|NCT00835276|ACTIVE_COMPARATOR|2|
62371259|NCT06127472|OTHER|ASD trained|Periods in the SWTD after receiving training in detection and diagnosis of ASD.
62371260|NCT06127472|OTHER|ASD training - control|Periods in the SWTD before receiving training in detection and diagnosis of ASD.
62371261|NCT06127472|OTHER|PE program|Periods in the SWTD after receiving the PE program.
62371262|NCT06127472|OTHER|PE program - control|Periods in the SWTD before receiving the PE program.
62371263|NCT04264494|EXPERIMENTAL|PRP group|Fifty RA patients were injected intra-articularly with 3 doses of PRP in their joints
62371264|NCT04264494|PLACEBO_COMPARATOR|placebo group|Fifty RA patients were injected intra-articularly with 3 doses of saline in their joints.
62371265|NCT02231489|EXPERIMENTAL|Treatment Sequence AB|Participants will receive treatment A (JNJ-42756493 tablet 10 milligram \[mg\] as single oral dose) along with JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, 2 hours after administration of JNJ-42756493 tablet on Day 1 in Treatment Period 1. Participants will receive treatment B (JNJ-42756493 capsule 10 mg as single oral dose) on Day 1 of Treatment Period 2.
62744099|NCT06039176||PENDING enrollment for 9th cohort-goal is 10 sites|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
62744100|NCT06039176||PENDING enrollment for 10th cohort-goal is 10 sites|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
62371266|NCT02231489|EXPERIMENTAL|Treatment Sequence BA|Participants will receive treatment B (JNJ-42756493 capsule 10 mg as single oral dose) along with 100 microgram (mcg) intravenous infusion over 5 minutes, 2 hours after administration of JNJ-42756493 capsule on Day 1 in Treatment Period 1. Participants will receive treatment A (JNJ-42756493 tablet as single oral dose) on Day 1 of Treatment Period 2.
62371267|NCT02668692|EXPERIMENTAL|LEO 80185 gel|
62371268|NCT02668692|ACTIVE_COMPARATOR|Dovobet ® ointment|
62371269|NCT00209092|ACTIVE_COMPARATOR|Sequential Therapy|Docetaxel will be given at 100mg/m\^2 intravenous Day 1 every 3 weeks for 4 cycles followed by capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) (total 24 weeks).
62371270|NCT00209092|ACTIVE_COMPARATOR|Concurrent Therapy|Docetaxel will be given at 50mg/m\^2 Intravenous Day1 concomitantly with capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
62371271|NCT06189625|EXPERIMENTAL|No-bandaging group|Only general measures will be recommended without the use of external support devices.
62371272|NCT06189625|ACTIVE_COMPARATOR|Bandaging group|functional bandage for 5 days and general measure.
62371273|NCT04601181|EXPERIMENTAL|ThisCART22 cells injection|In this arm，allogeneic anti-CD22 CAR T Cells(ThisCART22 cells) is used to treat patients with refractory or relapsed CD22 positive B cell malignancies.
62371274|NCT00433927|ACTIVE_COMPARATOR|Arm A|FOLFIRI plus Cetuximab
62371275|NCT00433927|ACTIVE_COMPARATOR|Arm B|FOLFIRI plus Bevacizumab
62371276|NCT03684525|EXPERIMENTAL|Extraction of primary canines only|"A total of 43 patients with unilateral mesioangular displaced maxillary canines Interceptive treatment: Extraction of both maxillary primary canines will be held at baseline visit At Baseline (T0): Clinical examinatiion + CBCT scan and then both primary canines will be extracted At 6 month follow-up (T1): Clinical examination only At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~* If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~* If Canine is emerged to oral cavity: No further CBCT scan will be taken~* If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
62371277|NCT03684525|NO_INTERVENTION|Control group- no extraction|"A total of 43 patients with unilateral mesioangular displaced maxillary canines At Baseline (T0): Clinical examinatiion + CBCT scan , no extraction At 6 month follow-up (T1): Clinical examination At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~* If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~* If Canine is emerged to oral cavity: No further CBCT scan will be taken~* If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
62371278|NCT05589766|PLACEBO_COMPARATOR|Placebo|Placebo, no active ingredients. Administered in tablet form twice daily for the duration of the trial (12 weeks).
62371279|NCT05589766|EXPERIMENTAL|Dietary Supplement: NR 1000mg group|Nicotinamide Riboside 1000mg total daily. Administered in capsule form in doses of 500mg twice daily for the duration of the trial (12 weeks).
62371280|NCT05589766|EXPERIMENTAL|Dietary Supplement: NR dose escalation group|Nicotinamide Riboside dose escalation group: 1000mg NR daily in doses of 500mg twice daily (week 1 - week 4), 2000mg NR daily in doses of 1000mg twice daily (week 5 - week 8), 3000mg NR daily in doses of 1500mg twice daily (week 9 - week 12).
62371281|NCT01186315|ACTIVE_COMPARATOR|Prolonged Exposure therapy|These treatments include repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories.
62371282|NCT01186315|EXPERIMENTAL|Exposure therapy + VR/ER|prolonged exposure therapy plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
62371283|NCT00469040|EXPERIMENTAL|GW642444M 25mcg|In Cohort 1 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 25 mcg.
62371284|NCT00469040|EXPERIMENTAL|GW642444M 50mcg|Subjects after randomization will receive two inhalations of 25 mcg GW642444M in Cohort 1.
62371285|NCT00469040|EXPERIMENTAL|GW642444M 100mcg|In Cohort 2 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 100 mcg.
62371286|NCT00469040|EXPERIMENTAL|GW642444M 200mcg|Subjects after randomization will receive two inhalations of 100 mcg GW642444M in Cohort 2.
62371287|NCT00469040|EXPERIMENTAL|GW642444M 400mcg|Subjects after randomization will receive two inhalations of 200 mcg GW642444M in Cohort 3.
62744101|NCT04238481|EXPERIMENTAL|Pudexacianinium chloride - Dose Level A|Participants received single dose of pudexacianinium chloride at dose level A by intravenous (IV) bolus infusion on day 1 once the surgical area of interest is in view.
62744102|NCT04238481|EXPERIMENTAL|Pudexacianinium chloride - Dose Level B|Participants received single dose of pudexacianinium chloride at dose level B by IV bolus infusion on day 1 once the surgical area of interest is in view.
62744103|NCT04238481|EXPERIMENTAL|Pudexacianinium chloride - Dose Level C|Participants received single dose of pudexacianinium chloride at dose level C by IV bolus infusion on day 1 once the surgical area of interest is in view.
62371288|NCT01207804|EXPERIMENTAL|Device|
62371289|NCT01660646|OTHER|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
62371290|NCT01660646|NO_INTERVENTION|control|
62371291|NCT02656524||Cohort1/Regorafenib|All patients with at least 1 treatment with regorafenib
62371292|NCT02314286|PLACEBO_COMPARATOR|control|"After signing an informed consent form and filling a demographic and medical questionnaire, a randomization 1:1 will be carried. 50 women will be in the control arm. the group will be treated according to ACOG guidelines (Appendix). After the delivery, a small placenta sample will be collected.~Control group will be treated with placebo."
62371293|NCT02314286|EXPERIMENTAL|treatment|50 women will be in the treatment arm. the group will be treated according to ACOG guidelines (Appendix). After the delivery, a small placenta sample will be collected. In addition, following randomization experimental group will be treated with Rosuvastatin 40mg that will be administrated orally with or without food. Treatment will be carried within the first hour following delivery. Another dose will be given 24 hours after first administration. Control group will be treated with placebo.
62371294|NCT05006391|EXPERIMENTAL|Tele-Coaching (Online) Community-Based Exercise|This study involves two phases: a six month online Community-Based Exercise Intervention (Phase 1), followed by a six month Follow-Up Monitoring Phase (Phase 2).
62371295|NCT03675594|EXPERIMENTAL|intervention arm|the group of participants will take the CAD/CAM titanium denture bases and assessment during and after the first 3 months after delivery of the first type.
62371296|NCT03675594|EXPERIMENTAL|intervention arm 2|the same group of participants will take the CAD/CAM cobalt/chromium denture bases and assessment during and after the second 3 months after delivery of the second type.
62371297|NCT03394118|EXPERIMENTAL|Group_TAGRISSO|Each subject will continue the study drug(Osimertinib) until disease progression or manifestation of unacceptable toxicity during the study period.
62371298|NCT02264652|EXPERIMENTAL|HD Transcranial Direct Stimulation|Genuine cathodal HD-tDCS approximately 2mA will be delivered through High-Definition electrodes that will be arranged on the skull according to a 4x1-ring configuration with the central cathodal electrode placed over the identified target and surrounding return electrodes forming approximately a 5-cm radius ring.
62371299|NCT01066650|ACTIVE_COMPARATOR|Endeavor Resolute|
62371300|NCT01066650|ACTIVE_COMPARATOR|Xience V|
62371301|NCT00693420|EXPERIMENTAL|1|Bimatoprost 0.03% solution
62371302|NCT00693420|PLACEBO_COMPARATOR|2|Vehicle solution
62371303|NCT02456571||Group A|men with mCRPC starting sipuleucel-T (Provenge) with or without abiraterone acetate or enzalutamide will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, 4-12 weeks after completion of sipuleucel-T, and at progression.
62371304|NCT02456571||Group B|men with mCRPC with visceral or high risk disease pre-abiraterone/enzalutamide will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, and progression.
62371305|NCT02456571||Group C|men with high volume metastatic castration sensitive prostate cancer (mCSPC) starting hormonal therapy and docetaxel chemotherapy or who decline docetaxel chemotherapy will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, and progression.
62371306|NCT02456571||Group D|men with enzalutamide or abiraterone acetate resistant mCRPC will have CTC enumeration and immune checkpoint characterization at baseline (i.e. progression on enzalutamide or abiraterone acetate) and 4-12 weeks after completion of next therapy (ex. radium-223 or chemotherapy)
62371307|NCT03418376|EXPERIMENTAL|MS beta-alanine supplementation|Subjects will perform a 6-month exercise intervention and receive beta-alanine supplements.
62371308|NCT03418376|PLACEBO_COMPARATOR|MS placebo group|Subjects will perform a 6-month exercise intervention and receive placebo tablets.
62371309|NCT03418376|EXPERIMENTAL|HC beta-alanine supplementation|Subjects will perform a 6-month exercise intervention and receive beta-alanine supplements.
62371310|NCT03418376|PLACEBO_COMPARATOR|HC placebo group|Subjects will perform a 6-month exercise intervention and receive placebo tablets.
62744104|NCT04238481|EXPERIMENTAL|Pudexacianinium chloride - Dose Level B - Dose Expansion|Participants who were enrolled in the dose expansion group received single dose of pudexacianinium chloride at dose level B by IV bolus infusion on day 1 once the surgical area of interest is in view.
62744105|NCT01226641|EXPERIMENTAL|Telemedecine|CPAP treatment with telemedicine system
62371311|NCT02384928|EXPERIMENTAL|Shinbaro pharmacopuncture group|The Shinbaro pharmacopuncture group will receive 8 interventional sessions of Shinbaro pharmacopuncture at one Hyeopcheok (Huatuo Jiaji, EX B2) point and acupuncture at 5 acupoints (GB30, BL40, BL25, BL23, GB34) 2 times/week over 4 weeks. All groups will take 4 educational program sessions supervised by physicians once a week.
62371312|NCT02384928|ACTIVE_COMPARATOR|Acupuncture group|The acupuncture group will receive 8 interventional sessions of acupuncture at one Hyeopcheok (Huatuo Jiaji, EX B2) point and 5 other acupoints (GB30, BL40, BL25, BL23, GB34) 2 times/week over 4 weeks. All groups will take 4 educational program sessions supervised by physicians once a week.
62371313|NCT02384928|ACTIVE_COMPARATOR|Usual care group|The usual care group will receive conventional medicine 2 times/day and 2 sessions/week of physical therapy over 4 weeks. Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics, which include aceclofenac, tramadol hydrochloride, talniflumate, diclofenac sodium, and loxoprofen sodium. All groups will take 4 educational program sessions supervised by physicians once a week.
62371314|NCT05379192||Group 1|Sociodemographic and clinical data of the patients who will be operated between 01:01-07:00 AM will be recorded. The total amount of antiemetic, the time of first antiemetic use, and the VAS scores at the postoperative 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours will also be recorded.
62371315|NCT05379192||Group 2|Patients who were operated between 07:01-13:00. Sociodemographic and clinical data of the patients who will be operated between 07:00 AM- 01:00 PM will be recorded. The total amount of antiemetic, the time of first antiemetic use, and the VAS scores at the postoperative 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours will also be recorded.
62371316|NCT05379192||Group 3|Sociodemographic and clinical data of the patients who will be operated between 01:00 - 08:00 PM will be recorded. The total amount of antiemetic, the time of first antiemetic use and the VAS scores at the postoperative 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours will also be recorded.
62371317|NCT05379192||Group 4|Sociodemographic and clinical data of the patients who will be operated between 08:00 PM -01:00 AM will be recorded. The total amount of antiemetic,the time of first antiemetic use, and the VAS scores at the postoperative 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours will also be recorded.
62371318|NCT00475072|EXPERIMENTAL|1|
62371319|NCT00782106|EXPERIMENTAL|1|Tolerability of subcutaneous infusions
62371320|NCT00782106|EXPERIMENTAL|2|Tolerability of subcutaneous infusions and pharmacokinetics
62371321|NCT06331273||"HCC patients fulfill Hangzhou criteria and receive LT with No-touch technique"|
62371322|NCT06331273||"HCC patients exceed Hangzhou criteria and receive LT with No-touch technique"|
62371323|NCT06331273||"HCC patients fulfill Hangzhou criteria and receive LT without No-touch technique"|
62371324|NCT06331273||"HCC patients exceed Hangzhou criteria and receive LT withoutNo-touch technique"|
62371325|NCT05537272|ACTIVE_COMPARATOR|Tadalafil|
62371326|NCT05537272|ACTIVE_COMPARATOR|Tamsulosin|
62371327|NCT05537272|PLACEBO_COMPARATOR|Placebo|
62371328|NCT05295940|EXPERIMENTAL|LY3841136 (Part A)|Single ascending doses of LY3841136 administered subcutaneously (SC).
62371329|NCT05295940|EXPERIMENTAL|LY3841136 (Part B)|Multiple ascending doses of LY3841136 administered SC.
62371330|NCT05295940|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered SC.
62744106|NCT01226641|ACTIVE_COMPARATOR|Standard Care|Standard care, including CPAP
62744107|NCT06661785|EXPERIMENTAL|Interlocking polyetheretherketone patient specific implant for orbital floor reconstruction|This study is conducted on twenty two patients with unilateral large orbital floor fracture reconstructed with interlocking polyetheretherketone patient specific implant
62371331|NCT05295940|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered SC.
62371332|NCT05821374|EXPERIMENTAL|Deucravacitinib|Participants to receive Deucravacitinib 6 mg tablets orally twice daily for 12 weeks.
62371333|NCT00576368|EXPERIMENTAL|1|
62371334|NCT05708560||Non-MAFLD, antiviral therapy|
62371335|NCT05708560||Non-MAFLD, no antiviral therapy|
62371336|NCT05708560||MAFLD, antiviral therapy|
62371337|NCT05708560||MAFLD, no antiviral therapy|
62371338|NCT04454749||Stimulated cycles|Ovarian stimulation will be performed by standard protocols. Stimulation medication dosage will be individualised prior to stimulation start according to the ovarian reserve parameters and during ovarian stimulation according to the ovarian response and the measured levels of E2 and progesterone (P4), in order to avoid progesterone elevation during late follicular phase. Final oocyte maturation will be achieved by administration of either 10.000 IU of hCG, 0.3 mg of GnRH agonist (Triptorelin) or dual trigger (hCG and GnRH-analogue), as soon as ≥ 3 follicles ≥ 17 mm are present. Oocyte retrieval will be carried out 36 hours after administration of the trigger. Embryos will undergo PGT-A at blastocyst stage and be vitrified thereafter.
62567173|NCT03870750|EXPERIMENTAL|Arm III (SPC and CMC)|Patients undergo interventions as outlined in Arm I and Arm II. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT. Patients may also complete surveys on medical and non-medical (transportation, lodging) costs related to transplant after HCT.
62744108|NCT06162078||Subgroup 1, Household longitudinal survey of nulligravida cohort|fieldworkers will visit the households in the study area to identify and enroll women meeting the eligibility criteria. After consenting a fingerprick blood sample will be obtained for pregnancy testing and malaria blood smear, and VAR2CSA antibodies measurement. Enrolled women will be visited every trimester to check for pregnancy and malaria infection. The follow up of each participant will end upon a pregnancy test is positive or at month 9 after the enrolment.
62371339|NCT04454749||Artificial (HRT) Cycles|"Start of estradiol valerate 4mg on day 2 of the cycle for three days. Increase E2 to 6mg on day 4 of E2 treatment. E2 dose may be increased according to clinician discretion based on endometrial thickness. Maximum time of E2 exposure will be 14 days. Transvaginally scan to monitor endometrial development and to exclude the presence of a dominant follicle. Serial measurements of serum LH, estradiol and progesterone levels. Commence the initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 7 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance. Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue estradiol administration 6mg (3 tablets daily).~Blastocyst transfer is scheduled on the 5th full day of progesterone administration, following the initial initiation of progesterone."
62371340|NCT04454749||Spontaneous natural cycles|"Ultrasound scans to monitor follicular growth and serial measurements of serum LH, estradiol and progesterone levels to determine the timing of ovulation. The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter.~Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5ng/ml confirming ovulation (day 0). This is considered as day 0 with initiation of vaginal progesterone 100mg (vaginal suppository) at 2200H. The following day (day 1) increases progesterone administration to 100mg vaginally three times daily (8 hourly) and continues this regime until 7 weeks gestation as per clinic protocol.~Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
62371341|NCT03193944|ACTIVE_COMPARATOR|Intervention group|Intervention group will receive 50,000 U vitamin D3 per week (equivalent to 1,250 μg) for 8 weeks
62371342|NCT03193944|PLACEBO_COMPARATOR|control group|Control group will receive vitamin D as a placebo. placebo will be identical in appearance taste and odourless.
62744109|NCT06162078||Subgroup 2, Single timepoint evaluation for primigravidae 1rst, 2nd and 3 rd trimester|Participants will be enrolled by study staff stationed at the antenatal care clinic. Women attending the ANC visit at any gestational age will be screened and those meeting the eligibility criteria will undergo the study procedures which includes collecting demographic data, medical and pregnancy history. They will then be requested to donate a fingerprick blood sample for malaria infection and hemoglobin measurement.
62371343|NCT05247060||Hypertensive Patients Hospitalized in Internal Medicine|Clinical data will be collected from all consecutive patients diagnosed with arterial hypertension hospitalized in Internal Medicine and able to assume the erect station
62371344|NCT00497159|PLACEBO_COMPARATOR|1|Placebo
62371345|NCT00497159|EXPERIMENTAL|2|Dimebon
62371346|NCT00763607||1|Radically resected Non small cell lung cancer patients in stage I-III
62371347|NCT00665691||1|
62371348|NCT04743869|ACTIVE_COMPARATOR|KYPHON® ActivOs™10 Bone Cement with hydroxyapatite|As a reference device KYPHON® ActivOs™10 Bone Cement with hydroxyapatite (Medtronic) for treatment of vertebral compression fractures will be used. It is a polymethylmethacrylate (PMMA) bone cement containing hydroxyapatite (HA) for use in the treatment of patients with vertebral compression fractures (VCFs) who are undergoing minimally invasive surgery with KYPHON® Balloon Kyphoplasty. This bone substitute has already been approved and is in use in the patients at the age of 50 or older.
62371349|NCT04743869|EXPERIMENTAL|KyphOs FS™|The test device KyphOs FS™ will be used in patients at the age of 50 and older in order to prove its superiority over the currently used PMMA bone cement.
62371350|NCT01387074||botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
62371351|NCT00952770|EXPERIMENTAL|Atorvastatin|Group receiving atorvastatin 20mg/day
62371352|NCT00952770|ACTIVE_COMPARATOR|Simvastatin/Ezetimibe|Group receiving simvastatin/ezetimibe 10/10mg
62371353|NCT04426292|OTHER|General arm|All patients follow this arm. Patients will undergo 3 blood sample testings at 3 different time points and have to fill in a questionnaire at 3 different time points
62371354|NCT03906591|EXPERIMENTAL|allogenic bone ring|
62371355|NCT03906591|ACTIVE_COMPARATOR|autogenous bone ring|
62371356|NCT03873428|OTHER|FES PET|1 ) inclusion; 2 ) FGD PET / FES PET; 3) Hormone therapy
62371357|NCT04925830|EXPERIMENTAL|BF Group|Participants of the BF group are connected with a plethysmograph and a respiration belt in order to assess HRV indices. HRV-BF is principally given by means of a vertical bar graph dynamically varying in height and two graphic curves referring to the heart rate (in beats per minute) and physiological breathing pattern, (inspiration and expiration). Each nirHEG- BF session occurs after a ten-minute pause from the end of the HRV-BF training. nirHEG-BF is principally given by means of a vertical bar graph dynamically varying in height and represented on a computer monitor. The height of the change according to the hemodynamic response measured at each of the three prefrontal points (Fp1, Fpz, Fp2) To maintain motivation, the bar graph is associated with a game-like animation (puzzle) signaling successful regulation, e.g. by forwarding motion of the pieces of a puzzle.
62371358|NCT04925830|NO_INTERVENTION|No BF Group|The no BF group receive the same sensors and is exposed to the same environment of the BF group but real time biofeedback of physiological parameters (HRV and hemodynamic response) is deactivated so that participants can watch documentary videos without interruption.
62371359|NCT03696628|OTHER|Healthy children|Blood test with generated hiPSC-cardiomyocytes Physical Examination. Electrocardiogram. Echocardiography.
62371360|NCT03696628|OTHER|Cardiomyopathic children|Blood test with generated hiPSC-cardiomyocytes Physical Examination. Electrocardiogram. Echocardiography.
62371361|NCT05103995||ABO matched|Donor-recipient ABO matched
62371362|NCT05103995||Minor incompatibility|Donor-recipient minor incompatibility
62371363|NCT05103995||Major incompatibility|Donor-recipient major incompatibility
62371364|NCT05103995||Bidirectional incompatibility|Donor-recipient bidirectional incompatibility
62371365|NCT01976975||Mood disorder patients|Patients with depressive and/or manic or hypomanic symptoms
62371366|NCT01976975||Healthy controls|Participants with no lifetime history of psychiatric illness
62371367|NCT02941406||Healthy subjects|"* Men and Women aged 18 and older~* Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant~* Normal ophthalmological findings unless the investigator considers an abnormality to be clinically irrelevant"
62371368|NCT02941406||Age-related macular degeneration patients|"* Men and Women aged 18 and older~* Presence of a macular disease (such as dry or exudative age-related macular degeneration, diabetic maculopathy, epiretinal membrane)"
62371369|NCT00592176|EXPERIMENTAL|Bevacizumab|Bevacizumab injection: 0.1ml, 6 monthly doses plus baseline and 1 week post baseline
62371370|NCT01154322|EXPERIMENTAL|Pediatric mask|
62371371|NCT05813860|EXPERIMENTAL|Infliximab|Infliximab monotherapy, the first dose of 5 mg/kg of this product is provided, followed by the same dose at weeks 2 and 6 after the first dose and every 8 weeks thereafter.
62371372|NCT05813860|ACTIVE_COMPARATOR|Infliximab+azathioprine|Infliximab was given in combination with azathioprine, and Infliximab dosing was the same as in the experimental group, with azathioprine at 1-2 mg/kg/d.
62371373|NCT02035241|EXPERIMENTAL|Spices 1|220 ml test drink containing spices 1, acute study / one time administration
62371374|NCT02035241|EXPERIMENTAL|Spices 2|220 ml test drink containing spices 2, acute study / one time administration
62371375|NCT02035241|EXPERIMENTAL|Spices 3|220 ml test drink containing spices 3, acute study / one time administration
62371376|NCT02035241|EXPERIMENTAL|Herbs 1|220 ml test drink containing herbs 1, acute study / one time administration
62371377|NCT02035241|EXPERIMENTAL|Herbs 2|220 ml test drink containing herbs 2, acute study / one time administration
62371378|NCT02035241|PLACEBO_COMPARATOR|Placebo|220 ml control drink, acute study / one time administration
62371379|NCT04101370|EXPERIMENTAL|Bosentan|Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
62371380|NCT04101370|ACTIVE_COMPARATOR|Tracleer®|Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition
62371381|NCT01936597|ACTIVE_COMPARATOR|Single set (control Arm)|method of external cardiac massage incentive based on a single set. Intervention : Therapeutic and preventive strategies
62371382|NCT01936597|EXPERIMENTAL|Controller|Audio continuous guidance method by the controller. Intervention : Therapeutic and preventive strategies
62744110|NCT06162078||Subgroup 3, Single timepoint evaluation at primigravidae delivery|"participants will be recruited during any of the ANC visit as consenting process will not be feasible during the labour at delivery. They will be issued a sticker that will be affixed to the health card so that they could easily be recognized when they come for delivery.~At delivery, samples will be collected from fingerprick, cord blood and placenta for detecting malaria infection by microscopy and histopathology. Additional data will be collected on the neonate for secondary outcomes assessment, adverse birth outcomes ."
62744111|NCT03692754|ACTIVE_COMPARATOR|AT with 10 mg/d|The patients will be given receive atorvastatin in 10 mg/d for 1 month plus dexamethasone 40mg/d for 4 days.
62744112|NCT03692754|ACTIVE_COMPARATOR|AT with 20 mg/d|The patients will be given atorvastatin in 20 mg/d for 1 month plus dexamethasone 40mg/d for 4 days.
62744113|NCT03692754|EXPERIMENTAL|Dexamethasone|The patients will be given dexamethasone 40mg/d for 4 days.
62744114|NCT04339933||BC|Patients who were diagnosed with bladder cancer
62371383|NCT01936597|EXPERIMENTAL|Audio|Audio continuous guidance method by the controller relayed by an audio. Intervention : Therapeutic and preventive strategies
62371384|NCT05081089|ACTIVE_COMPARATOR|Artemether-lumefantrine (AL)|Subjects will receive artemether-lumefantrine (AL) twice daily for 3 days.
62371385|NCT05081089|EXPERIMENTAL|AL with 0.25mg/kg primaquine (PQ)|Subjects will receive artemether-lumefantrine (AL) twice daily for 3 days and a single dose of 0.25mg/kg primaquine (PQ) on the first day of AL treatment.
62371386|NCT05081089|ACTIVE_COMPARATOR|Sulphadoxine-pyrimethamine with amodiaquine (SPAQ)|Subjects will receive sulphadoxine-pyrimethamine with amodiaquine (SPAQ) once daily for 3 days.
62371387|NCT05081089|EXPERIMENTAL|SPAQ with 1.66mg/kg tafenoquine (TQ)|Subjects will receive sulphadoxine-pyrimethamine with amodiaquine (SPAQ) once daily for 3 days and a single dose of 1.66mg/kg tafenoquine (TQ) on the first day of SPAQ treatment.
62371388|NCT01147367|NO_INTERVENTION|Control|no physical activity intervention
62371389|NCT01147367|EXPERIMENTAL|Exercise intervention|3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
62371390|NCT02984891||Treatment|Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) will be used in patients with coronary artery disease.
62371391|NCT02224937|EXPERIMENTAL|Melatonin:Melatonincreme 12,5%|Application of melatonincream 12,5% on 80% of the body-surface at start of investigation.
62371392|NCT02224937|PLACEBO_COMPARATOR|Placebo|Application of placebo cream on 80% of the body-surface at start of investigation.
62371393|NCT02766972|EXPERIMENTAL|RVP|
62371394|NCT03865849|ACTIVE_COMPARATOR|Conventional radiofrequent treatment|The patient is placed in a supine position on a fluoroscopy table with the index knee flexed 10-15°. The procedure is performed with a 100 mm long, 18 G straight RF cannula/introducer (Halyard) with a probe/electrode with a 10 mm active tip
62371395|NCT03865849|ACTIVE_COMPARATOR|Cooled radiofrequent treatment|The procedure is performed with a 100 mm long, 18 G straight RF cannula/introducer (Halyard) with a probe/electrode with a 100 mm long, 17 G RF cannula/introducer with an 18 G cooled probe/electrode with a 4 mm active tip (Halyard/Coolief).
62371396|NCT05905679|EXPERIMENTAL|Probiotic Arm|
62371397|NCT05905679|ACTIVE_COMPARATOR|Placebo|
62371398|NCT00255983|EXPERIMENTAL|1|faropenem medoxomil
62371399|NCT00255983|PLACEBO_COMPARATOR|2|
62371400|NCT03820206|ACTIVE_COMPARATOR|Tranexamic acid group|1 g (10 mL) tranexamic acid (Kapron, Amoun, Egypt; stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
62744115|NCT02412891|ACTIVE_COMPARATOR|Patients receive active UroShield device|Patients receive active UroShield device
62744116|NCT02412891|SHAM_COMPARATOR|Patients receive inactive UroShield device|Patients receive inactive UroShield device
62744117|NCT02839720|EXPERIMENTAL|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate PO twice daily (BID) on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience a volume decrease in the target cutaneous neurofibromas may continue treatment for 12 additional cycles.
62744118|NCT04282096|EXPERIMENTAL|Caseine micellar|
62744119|NCT04282096|OTHER|Sodium Casein|
62744120|NCT04282096|OTHER|Calcium casein|
62744121|NCT01045148|OTHER|CyberKnife Radiosurgery|CyberKnife Radiosurgery
62744122|NCT00575276||1|Females with acute cholecystitis
62744123|NCT00575276||2|Females with Chronic Cholecystitis
62744124|NCT00575276||3|Males with acute cholecystitis
62744125|NCT00575276||4|Males with Chronic Cholecystitis
62744126|NCT02581046|EXPERIMENTAL|3 month surgical group|Phacoemulsification pediatric cataract surgery is performed at the age of 3 month of patients without IOL implantation.
62744127|NCT02581046|EXPERIMENTAL|6 month surgical group|Phacoemulsification pediatric cataract surgery is performed at the age of 3 month of patients without IOL implantation..
62744128|NCT03215992|OTHER|Men diagnosed with prostate cancer|This group will include men over the age of 18 suspected of having prostate cancer who will undergo an ultrasound guided transrectal prostate biopsy. Each study participant will undergo a standard prostate biopsy and DOT imaging using the Diffuse Optical Tomography (DOT) System will be performed at the same time.
62371401|NCT03820206|PLACEBO_COMPARATOR|Control group|30 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
62371402|NCT04143490|EXPERIMENTAL|UC Patients|Patient group
62371403|NCT04143490|ACTIVE_COMPARATOR|Healthy controls|Control group
62371404|NCT02853786|EXPERIMENTAL|LENA and advices|With the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development
62371405|NCT02853786|ACTIVE_COMPARATOR|LENA without advices|Regular speech therapy follow blindly the results of LENA
62371406|NCT04341584|EXPERIMENTAL|ANAKINRA|"Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERET® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERET® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERET® 100mg (Total 100 mg) at day 5 (D5).~In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level \> 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter"
62371407|NCT04341584|NO_INTERVENTION|Standard of care|
62744129|NCT03215992|OTHER|Men without prostate cancer|This group will include men who do not have prostate cancer. Each study participant will undergo a standard prostate biopsy and DOT imaging using the Diffuse Optical Tomography (DOT) System will be performed at the same time.
62744130|NCT06438016|EXPERIMENTAL|Stress Management Group|Participants in this group will be provided with a demographic questionnaire, the DASS-21 and the PSS one week prior to and after the stress management training. The treatment group will be sub-divided into 2 groups of 20-25 participants and subjected to a 4-session stress management training program over the course of 4-weeks (one 40 minute session each week). The DASS and the PSS will be administered to this group one week and one month post completion of the final stress management training session.
62744131|NCT06438016|NO_INTERVENTION|Control Group|This control group will fill out the DASS-21 and PSS with the treatment group prior to the treatment group commencing stress management and will also fill out the DASS-21 and PSS upon completion of the treatment group's stress management training. This group will however not obtain stress management training during the study. Training will be provided upon study completion.
62371408|NCT05817422|EXPERIMENTAL|cAd3-Marburg vaccine (1.0 × 10^11 PU)|"Single dose of cAd3-Marburg vaccine (1x10\^11 PU) administered intramuscularly (IM) with needle and syringe in a volume of 0.56 mL.~Placebo (0.9% NaCl solution for injection)administered intramuscularly (IM) with needle and syringe in a volume of 0.56 mL."
62371409|NCT05817422|PLACEBO_COMPARATOR|Placebo|Single dose of Placebo (0.9% NaCl solution for injection) administered intramuscularly (IM) with needle and syringe in a volume of 0.56 mL.
62371410|NCT03446313|EXPERIMENTAL|MVN Group|Participants assigned to the MVN Group will be using the Movn Rehab mobile app after they are discharged from cardiac rehab.
62744132|NCT01832129|ACTIVE_COMPARATOR|i.m. injection of Vitamin B12|Weekly i.m. injections of 1 mg Cyanocobolamin after 1, 2, and 3 weeks.
62744133|NCT01832129|EXPERIMENTAL|Oral administration of vitamin B12|High dose (1 mg/day) oral Cyanocobolamin will be adminstrated with electronic adherence monitoring.
62744134|NCT06658288|EXPERIMENTAL|Group A|12 Participants will be in experimental group A. They will perform rebound training for six weeks. Measure all values before giving them protocol and after protocol.
62744135|NCT06658288|EXPERIMENTAL|Group B|12 Participants will be in experimental group B. They will perform theraband resistance exercise for six weeks. Measure all values before giving them protocol and after protocol.
62744136|NCT03086291|EXPERIMENTAL|simvastatin|One arm Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days Cohort 1: 7.5 mg/kg bid for 7 days 14 days off Cohort 2: 10 mg/kg bid for 7 days 14 days off Cohort 3: ( ) mg/kg bid for 7 days 14 days off (to be determined based on PK data of cohort 1 and 2) Q 3 weeks
62744137|NCT05878886|EXPERIMENTAL|Treatment group|Treatment group received 50 g mangrove sword bean food bar during 15 days.
62744138|NCT05878886|PLACEBO_COMPARATOR|Control group|Control group received 50 g sword bean food bar during 15 days.
62371411|NCT03446313|NO_INTERVENTION|Usual Care|Participants assigned to the Usual Care group will receive standard instructions and educational handouts after they are discharged from cardiac rehab.
62371412|NCT01914939|EXPERIMENTAL|Social Skills Focused CBT|Twelve weekly 60-minute sessions of social skills focused CBT
62744139|NCT00522418|EXPERIMENTAL|VNS Therapy|VNS Therapy + Best Medical Practice
62744140|NCT00522418|ACTIVE_COMPARATOR|Best Medical Practice|Best Medical Practice
62371413|NCT01914939|ACTIVE_COMPARATOR|Stress Management/Relaxation Training|Twelve weekly 60-minute sessions of stress management training
62371414|NCT01914939|EXPERIMENTAL|Oxytocin|Intranasal administration of 24 IU of oxytocin
62371415|NCT01914939|PLACEBO_COMPARATOR|placebo drug|Intranasal placebo drug
62371416|NCT02568852|ACTIVE_COMPARATOR|group 1|Laparoscopic cholecystectomy in general anaesthesia
62371417|NCT02568852|ACTIVE_COMPARATOR|group 2|Laparoscopic cholecystectomy in combined anaesthesia (Spino epidural).
62371418|NCT05928624|SHAM_COMPARATOR|Standard of Care|This arm will receive a home blood pressure monitor and scale; however, these data will not be shared with their treating provider in real-time.
62371419|NCT05928624|EXPERIMENTAL|Home Blood Pressure and Scale Monitoring to Inform Clinical Decisions|This arm will receive a home blood pressure monitor and scale. These data will be reviewed weekly and these data will be shared with the treating provider to inform clinical decisions.
62371420|NCT04487418|EXPERIMENTAL|Surgery group with electro cautery|Surgery will be performed with electro cautery.
62371421|NCT04487418|EXPERIMENTAL|High level diode laser surgery|High power diode laser surgery will be performed.
62371422|NCT04369872|EXPERIMENTAL|Microwave Ablation|Study participants will receive percutaneous microwave ablation of their malignant lung neoplasm.
62371423|NCT02149186|EXPERIMENTAL|Rehabilitation|
62371424|NCT01572636||Laronidase use in Hurler Syndrome|Laronidase receiving prior and post transplant
62371425|NCT01723202|EXPERIMENTAL|Arm A: GSK2118436|Patients receive dabrafenib orally 2 twice a day on days 1-28. Patients with disease progression may cross over to arm II.
62371426|NCT01723202|EXPERIMENTAL|Arm B: GSK2118436 and GSK1120212|Patients receive dabrafenib orally twice a day and trametinib orally once a day on days 1-28.
62371427|NCT01723202|OTHER|Correlative Studies|Tumor pharmacodynamics (PD) evaluation,BRAF mutation quantification in circulating plasma DNA,Tumor mutation screening/Mechanisms of Drug Resistance,Predictive Markers of Response (Archival Tumor Block),Pharmacokinetics(PK,Pharmacogenetics (PGx)
62371428|NCT01528436|EXPERIMENTAL|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation
62371429|NCT01528436|ACTIVE_COMPARATOR|Placebo Umbilical Cord Blood and Rehabilitation|Placebo Umbilical Cord Blood infusion and Active Rehabilitation
62371430|NCT00713284|OTHER|Study|All subjects who enroll in this study will be converted from their calcineurin inhibitor to sirolimus. There is no comparotor arm
62371431|NCT04694157||Treatment group|The treatment group will receive cardiac shock wave therapy. The CSWT entire treatment will period last 3 months with 9 sessions. CSWT will administered in the first week, followed by a 3-week non-treatment interval.
62371432|NCT01547676|EXPERIMENTAL|Arm A (unclamped partial nephrectomy)|Patients undergo unclamped partial nephrectomy. Some patients may undergo unclamped partial nephrectomy with controlled hypotension.
62371433|NCT01547676|ACTIVE_COMPARATOR|Arm B (clamped partial nephrectomy)|Patients undergo clamped partial nephrectomy.
62371434|NCT02374073|EXPERIMENTAL|Intervention group|Treated with protocolized physiotherapy and functional massage
62371435|NCT02374073|EXPERIMENTAL|Control group|Treated with protocolized physiotherapy
62371436|NCT04484038|OTHER|IMRT, any mode|"External radiation therapy with 6-18 MV photons on the 62.5 Gy prostate bed in 25 2.5 Gy fractions (EQD2 71 Gy).~Serving per fraction: 2.5 Gy Total fractions: 25 No. fractions / week: 5 Total treatment time: 5 weeks Total nominal dose: 62.5 Gy EQD3 (TRT): 68.75 Gy EQD1.5 (CaP): 71.43 Gy EQD2 (CaP): 68.75 Gy EQD10 (TRA): 65.10 Gy"
62371437|NCT02864706|EXPERIMENTAL|EVEROLIMUS|patients received everolimus (Certican), low-exposure CsA (Neoral), mycophenolate mofetil (MMF) and corticosteroids with CsA withdrawal after 7-11 weeks
62371438|NCT02864706|ACTIVE_COMPARATOR|Control|patients received standard CsA, MMF and corticosteroids
62744141|NCT01689025|EXPERIMENTAL|NNC0114-0006|
62371439|NCT03327363|EXPERIMENTAL|ICT base monitoring group|In the ICT-based centralized monitoring group, both subjects and medical staff receive feedback regarding decreased lung function and exacerbation in asthma symptoms in the form of text messages
62371440|NCT03327363|PLACEBO_COMPARATOR|control group|Use standard asthma treatment
62371441|NCT02474628|PLACEBO_COMPARATOR|Placebo|0.3 g∙kg-1body mass of calcium carbonate
62371442|NCT02474628|EXPERIMENTAL|Sodium bicarbonate|0.3 g∙kg-1body mass of sodium bicarbonate
62744142|NCT01689025|PLACEBO_COMPARATOR|Placebo|
62744143|NCT01357538|ACTIVE_COMPARATOR|Posiformin 2 %|Eye ointment applied to the eye lid
62371443|NCT02920879|OTHER|0 CPAP/ 0 PEEP, driving pressure 10|Patients will be preoxygenated with a CPAP-level of 0 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
62371444|NCT02920879|OTHER|0 CPAP/ 0 PEEP driving pressure 20|Patients will be pre-oxygenated with a CPAP-level of 0 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 20 cmH2O./PEEP-level, driving pressure
62371445|NCT02920879|OTHER|10 CPAP / 10 PEEP, driving pressure 10|Patients will be pre-oxygenated with a CPAP-level of 10 cmH2O and after anesthesia induction, mask-ventilated with PEEP 10 cmH2O and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
62744144|NCT01357538|PLACEBO_COMPARATOR|Placebo|corresponding vehicle, eye ointment applied to the eye lid
62371446|NCT02920879|OTHER|10 CPAP/ 0 PEEP, driving pressure 10|Patients will be pre-oxygenated with a CPAP-level of 10 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
62371447|NCT00613210||1|women without contraction at 24-34 weeks of gestation
62371448|NCT00613210||2|women without contractions between 24-34 weeks of gestation with a history of preterm labor
62371449|NCT00613210||3|women with preterm contractions 24-34 weeks of gestation
62371450|NCT04225312|EXPERIMENTAL|Personalized extended interval dosing|Patients will be receiving a personalized dosing schedule from 6 weeks, which will be further extended if the trough level exceeds 10 ug/ml.
62371451|NCT04225312|OTHER|Standard interval dosing|Patients who prefer to stay on standard interval dosing.
62371452|NCT04225312|OTHER|Historic cohort|Historic cohort of natalizumab treated patients on standard interval dosing.
62371453|NCT03878160|OTHER|Women and Men, <2 years, Individual Interview|Individual interviews for women and men who have experienced an ACS within the past 2 years and have elevated depression symptoms.
62371454|NCT03878160|OTHER|Women and Men, >2 years, Individual Interview|Individual interviews for women and men who have experienced an ACS greater than 2 years ago and have elevated depression symptoms.
62371455|NCT03878160|OTHER|Women and Men, Lifetime History of ACS, Individual Interview|Individual interviews for women and men who have experienced an ACS at some point in their life and do not have elevated depression symptoms.
62371456|NCT02936362|OTHER|Sourdough bread, white bread|Consumption of sourdough bread for one week, 2 week washout, consumption of white bread for one week
62371457|NCT02936362|OTHER|White bread, sourdough bread|Consumption of white bread for one week, 2 week washout, consumption of sourdough bread for one week
62371458|NCT03624790|EXPERIMENTAL|Cohort 1: rRSV A/Maryland/001/11|Participants will receive a single dose of rRSV A/Maryland/001/11 at study entry (Day 0).
62371459|NCT03624790|EXPERIMENTAL|Cohort 2: rRSV A/Maryland/001/11|Participants will receive a single dose of rRSV A/Maryland/001/11 at study entry (Day 0).
62371460|NCT04737954|EXPERIMENTAL|Suspected VTE patients|Venous blood draw of up to 20ML and up to 6 fingerstick capillary draws
62744145|NCT06162559|EXPERIMENTAL|Tucatinib + trastuzumab + pertuzumab|All patients receive neoadjuvant treatment consisting of trastuzumab, pertuzumab and tucatinib. Patients with hormone receptor positive disease receive concurrent endocrine therapy with an aromatase-inhibitor. Premenopausal women are concurrently treated with a LHRH-agonist. In case of functional tumor volume decrease of at least 65% (responders) after the first three cycles, patients continue treatment for six more cycles of the chemotherapy-free regimen. If tumor response is \<65% (non-responders), patients will switch to receive six cycles paclitaxel, carboplatin, trastuzumab and pertuzumab. This is considered non-investigational treatment.
62371461|NCT04489940|EXPERIMENTAL|Bintrafusp alfa|
62371462|NCT01877031|ACTIVE_COMPARATOR|Ultrasound|Ultrasound only guidance of central line insertion - current standard of care.
62371463|NCT01877031|EXPERIMENTAL|Virtual Reality|Use of ultrasound plus virtual reality guidance to insert central line
62371464|NCT03674307|EXPERIMENTAL|No screening|No further screening for asymptomatic coronary artery disease after wait-list entry
62371465|NCT03674307|ACTIVE_COMPARATOR|Regular screening|Regular (yearly or 2nd yearly) screening for asymptomatic coronary artery disease after wait-list entry
62371466|NCT04237636||Patients with post-operative AKI|"Patients developing acute kidney injury (AKI) following heart valve replacement surgery.~AKI was classified according to the KDIGO definition\[10\]. Stage-1 AKI: increase in serum creatinine of more than or equal to 0.3 mg/dl (≥ 26.5μmol/l) or increase to more than or equal to 150% to 200% (1.5≤x\<2) from baseline within 7 days. Stage-2 AKI: Increase in serum creatinine to more than 200% to 300% (2≤x\<3) from baseline. Stage-3 AKI: Increase in serum creatinine to more than 300% (3≤) from baseline (or serum creatinine of more than or equal to 4.0 mg/dl (≥ 353.6μmol/l) or when the patient commenced RRT."
62371467|NCT04237636||Patients without post-operative AKI|Patients with normal kidney function (without acute kidney injury (AKI)) following heart valve replacement surgery
62371468|NCT03152110|EXPERIMENTAL|HIIT|Exercise sessions will be 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.
62371469|NCT04574869|EXPERIMENTAL|Cohort 1|
62371470|NCT04574869|EXPERIMENTAL|Cohort 2|
62371471|NCT04574869|PLACEBO_COMPARATOR|Placebo Cohorts 1 and 2|Placebo will be administered at the same volume and duration of IV infusion corresponding to the cohort dosing schedule.
62371472|NCT04574869|EXPERIMENTAL|Cohort 3|
62371473|NCT04574869|EXPERIMENTAL|Cohort 4|
62371474|NCT04574869|PLACEBO_COMPARATOR|Placebo Cohorts 3 and 4|Placebo will be administered at the same volume and duration of IV infusion corresponding to the cohort dosing schedule.
62371475|NCT02561104|EXPERIMENTAL|LenSx|Laser-assisted cataract surgery performed using the LenSx femtosecond laser.
62371476|NCT02561104|EXPERIMENTAL|Phaco|Traditional manual phacoemulsification cataract surgery
62371477|NCT04564690|EXPERIMENTAL|QUARTET®|Consumption of three QUARTET® (n-3 PUFA, selenium, vitamin E, lutein enriched) hen eggs per day for three weeks
62371478|NCT04564690|EXPERIMENTAL|Control|Consumption of three regular hen eggs per day for three weeks
62371479|NCT02128919|EXPERIMENTAL|Active tDCS|tDCS 2 ma for 20 minutes with anode at DLPFC once a day for 5 days
62371480|NCT02128919|SHAM_COMPARATOR|Sham tDCS|tDCS 2 ma for 40 seconds with anode at DLPFC for 5 days
62371481|NCT02625389|EXPERIMENTAL|Embolization with Lipiodol Ultra Fluid and glue|
62371482|NCT05688540|EXPERIMENTAL|e book|a multi-media model through e-book for preoperative care of CIED intervention.
62371483|NCT05688540|EXPERIMENTAL|traditional education booklet|traditional education booklet of CIED intervention.
62371484|NCT06315686|EXPERIMENTAL|Experimental group|Eligible patients with advanced non-small cell lung cancer with leptomeningeal metastasis were treated with vormetinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed).
62371485|NCT02433691|ACTIVE_COMPARATOR|Sequential Exercise and Memory Training|Aerobic exercise via stationary bicycling followed by memory training.
62371486|NCT02433691|EXPERIMENTAL|Simultaneous Exercise & Memory Training|Simultaneous aerobic exercise via stationary bicycling while receiving memory training.
62371487|NCT02433691|PLACEBO_COMPARATOR|Stretching and Toning|Anerobic stretching and toning followed by memory training
62744146|NCT04367311|EXPERIMENTAL|NSC: Non-squamous cell tumors|Atezolizumab 1200mg, Pemetrexed 500 mg/m\^2, Cisplatin 60-75 mg/m\^2
62744147|NCT04367311|EXPERIMENTAL|SC: Squamous cell tumors|Atezolizumab 1200mg, Docetaxel 60-75 mg/m\^2, Cisplatin 60-75 mg/m\^2
62371488|NCT06337760||neuroendocrine neoplasm young patient|Patients aged at diagnosis from18 to 39 years of age with neuroendocrine neoplasm NEN from Gastroenteropancreatic (GEP) or lung/thymus origin
62371489|NCT06337760||adenocarcinoma young patient|Patients aged at diagnosis from18 to 39 years of age with carcinoma (without limitations for histologic subtypes) from any primary sites: esophagus, stomach, pancreas, biliary tract, liver, small bowel, colon, rectum, anus and cancer of unknown origin.
62371490|NCT05821192|EXPERIMENTAL|R-GDP plus PD-1 monoclonal antibody|Rituximab, Gemcitabine, Cisplatin, Dexamethasone, PD-1 monoclonal antibody
62371491|NCT01625611|EXPERIMENTAL|Naltrexone|
62371492|NCT06434090|EXPERIMENTAL|Liposomal irinotecan plus bevacizumab|"Patients received Liposomal irinotecan (a '3+3' design was adopted in the experimental arm, with 3 dose levels of 70mg/m2, 80mg/m2, and 90mg/m2 for dose exploration) every 2 weeks (Q2W).~bevacizumab, 5mg/m2, every 2 weeks The two-drug combination therapy was continued every 2 weeks in a cycle until patients developed disease progression or met other criteria for termination of study treatment specified in the protocol."
62371493|NCT03216668|EXPERIMENTAL|TONKA|Administered orally twice a day, 2 tablets each time, for 6 weeks
62371494|NCT03216668|ACTIVE_COMPARATOR|LEGALON|Administered orally three times a day, two tablets each time, for 6 weeks
62371495|NCT04407286|EXPERIMENTAL|Treatment Group|"This group will receive vitamin D.~The dosage for the first two weeks will be 10,000 IU/day b.i.d. (age 18-69 years) or 15,000 IU/day t.i.d. (age 70+)~After two weeks of taking vitamin D, if vitamin D levels are still below 30 ng/ml, continue the dosage for 3 more weeks. If vitamin D levels are 30-49 ng/ml, continue at a dosage of 5000 IU/day. If vitamin D levels are 50+ ng/ml, stop supplementation."
62371496|NCT06317506||Children with ID|The presence of intellectual disability will be evaluated according to DSM-V criteria
62371497|NCT06317506||Children without ID|The presence of intellectual disability will be evaluated according to DSM-V criteria
62371498|NCT01656018|EXPERIMENTAL|Arm 1A|Female participants will receive a single dose of long acting TMC278 1200 mg intramuscularly (IM) at baseline (Day 0) in Arm 1A.
62371499|NCT01656018|EXPERIMENTAL|Arm 1B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline in Arm 1B.
62744148|NCT00957944|EXPERIMENTAL|Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)|Two single applications of rotigotine patches from two different manufacturing sites in the order A-B separated by a washout phase of at least 5 days
62744149|NCT00957944|EXPERIMENTAL|Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)|Two single applications of rotigotine patches from two different manufacturing sites in the order B-A separated by a washout phase of at least 5 days
62744150|NCT03016377|EXPERIMENTAL|iC9-CAR19 cells|The 3+3 design in adult subjects and an independent study using 3+3 design in pediatric subjects. The starting dose of 5 x 10\^5 transduced cells/kg will enroll 3 adult subjects in the initial cohort. If there are no dose limiting toxicities w/in 4 weeks of the cell infusion in these 3 subjects, then the next cohort will evaluate 1 x10\^6 transduced cells/kg in adults. If there is toxicity in 1/3 patients in the initial cohort, the cohort will be expanded to enroll up to 6 adult patients. If the dose level 1 is determined to be above the tolerated cell dose, de-escalation would occur to dose level -1 where subjects would receive 1 x 10\^5 transduced cells/kg. All subjects will receive a lymphodepleting regimen of fludarabine and cyclophosphamide before administration of iC9-CAR19 T cells.
62744151|NCT03016377|EXPERIMENTAL|Expansion Cohort Second Administration of iC9-CAR19 cells|"After the recommended phase 2 dose (RP2D) of iC9-CAR19 T cells has been determined in adults, up to 18 additional adult subjects will be enrolled in an expansion cohort at the RP2D. In the expansion cohort, subjects will be offered a second infusion of iC9-CAR19 T cells based on B-cell recovery and minimal residual disease (MRD) status. All subjects will receive a lymphodepleting regimen of fludarabine and cyclophosphamide before second administration of iC9-CAR19 T cells.~Subjects in the expansion cohort who experience ≥grade 2 CRS or ICANS, did not respond to the initial dose of the standard of care treatment will be enrolled in a sub-study of rimiducid."
62744152|NCT06660628|EXPERIMENTAL|Surface guided radiation therapy (SGRT) combined with Deep Inspiration Breath Hold (DIBH) technique|Patients with left breast cancer treated with Surface guided radiation therapy (SGRT) combined with Deep Inspiration Breath Hold (DIBH) technique
62744153|NCT06660628|ACTIVE_COMPARATOR|laser alignment combined with free breathing treatment|Patients with left breast cancer treated with traditional laser alignment with free breathing treatment
62371500|NCT01656018|EXPERIMENTAL|Arm 2A|Female participants will receive a single dose of long acting TMC278 600 mg IM at baseline in Arm 2A.
62371501|NCT01656018|EXPERIMENTAL|Arm 2B|Male participants will receive a single dose of long acting TMC278 600 mg IM at baseline in Arm 2B.
62371502|NCT01656018|EXPERIMENTAL|Arm 3A|Female participants will receive 3 bi-monthly injections of long acting TMC278 1200 mg IM at baseline, Months 2 and 4 in Arm 3A.
62371503|NCT01656018|EXPERIMENTAL|Arm 3B|Male participants will receive 3 bi-monthly injections of long acting TMC278 1200 mg IM at baseline, Months 2 and 4 in Arm 3B.
62371504|NCT01656018|EXPERIMENTAL|Arm 4A|Female participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 900 mg at Months 2 and 4 in Arm 4A.
62371505|NCT01656018|EXPERIMENTAL|Arm 4B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 900 mg at Months 2 and 4 in Arm 4B.
62371506|NCT01656018|EXPERIMENTAL|Arm 5A|Female participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 600 mg at Months 2 and 4 in Arm 5A.
62371507|NCT01656018|EXPERIMENTAL|Arm 5B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 600 mg at Months 2 and 4 in Arm 5B.
62371508|NCT01066169||Healthy volunteers|Healthy subjects without HIV, vaccinated with Pandemic Influenza A/H1N1
62371509|NCT01066169||HIV-infected patients|HIV-infected patients, vaccinated with Pandemic Influenza A/H1N1
62371510|NCT03327246|EXPERIMENTAL|Intervention group|Implementing the Connecare system to support integrated care for complex patients who are plan to undergo a major elective surgery in Assuta Ashdod and are discharged back to the community with an emphasis on Connecare self managment system for the patient and close follow up and coordination of all of the medical, health and social care in the community for two periods of time: (1) Pre habilitation plan for a month prior to surgery (2) a period of 3 months post discharge.
62371511|NCT03327246|NO_INTERVENTION|No Intervention: Matched control group|The control group will be selected from Maccabi's database and will be patients who are matched 1:1 with the intervention sample and live in another community similar to Ashdod in socioeconomic characteristics who undergo the same elective major surgery in other hospitals
62371512|NCT02210455|EXPERIMENTAL|The Strongest Families FASD intervention|It is a web-based parent training program with a coach. The program is comprised of 11 sessions, each focusing on a different parenting strategy, delivered using easy to read text, instructional videos and audio clips. One Booster Session is conducted 1 month after completion of Session 11.
62371513|NCT02210455|ACTIVE_COMPARATOR|Psychoeducation|It is a static webpage on IRIS providing FASD information and resources, including recommended book titles, websites and organizations that may be helpful.
62371514|NCT00441727|EXPERIMENTAL|Esomeprazole 40 mg|Esomeprazole 40 mg
62371515|NCT00441727|EXPERIMENTAL|Esomeprazole 20 mg|Esomeprazole 20 mg
62371516|NCT00441727|PLACEBO_COMPARATOR|Placebo|Placebo
62371517|NCT05476757|EXPERIMENTAL|Flavivirus naïve|
62371518|NCT02853123|EXPERIMENTAL|Tiotropium + Olodaterol|Patients will receive tiotropium 5mcg + olodaterol 5mcg in a fixed dose combination once daily.
62371519|NCT02853123|ACTIVE_COMPARATOR|Tiotropium|
62371520|NCT05535270||Mood Disorder patients|The participants completed a demographic questionnaire, the self-report Oxford Depression Questionnaire (ODQ-C), the Beck Depression Inventory-II(BDI-II), and the Montgomery-Asberg Depression Rating Scale (MADRS).
62371521|NCT05535270||Healthy Controls|The participants completed a demographic questionnaire, Patient Health Questionnaire - 9(PHQ-9), and the first two sections of Oxford Depression Questionnaire (ODQ-20).
62371522|NCT01977807|EXPERIMENTAL|Myopia|Myopia Lasik treatment of virgin eyes.
62371523|NCT01977807|EXPERIMENTAL|Hyperopia|Hyperopia Lasik treatment of virgin eyes.
62371524|NCT00944957|EXPERIMENTAL|Raltegravir first|Patients treated with Raltegravir for first 2 weeks
62371525|NCT00944957|EXPERIMENTAL|Efavirenz first|Patients treated with Efavirenz for first 2 weeks
62371526|NCT02978170|EXPERIMENTAL|Diagnostic (CBCT)|Patients undergo CBCT during standard of care bronchoscopy.
62371527|NCT02597972|ACTIVE_COMPARATOR|Open Reduction Internal Fixation Proximal Humerus|The patients randomized into the ORIF group will receive standard surgical treatment of their proximal humerus fracture with a proximal humeral locking plate.
62371528|NCT02597972|ACTIVE_COMPARATOR|Reverse Total Shoulder Arthroplasty|The patients randomized into the RTSA group will receive standard surgical treatment of their proximal humeral fracture with a Reverse Total Shoulder Arthroplasty.
62371529|NCT04031157|EXPERIMENTAL|PGT arm|Predictix Antidepressant-guided treatment condition
62371530|NCT04031157|NO_INTERVENTION|soc arm|Standard of Care condition
62371531|NCT03369704|EXPERIMENTAL|Omalizumab|Eligible patients randomized to this arm received omalizumab subcutaneously for 12 weeks
62371532|NCT03369704|PLACEBO_COMPARATOR|Placebo|Eligible patients randomized to this arm received placebo subcutaneously for 12 weeks
62371533|NCT06102928|EXPERIMENTAL|Experimental group|Participants who met the study protocol were treated with anlotinib and aumolertinib.Aumolertinib mesylate tablets are administered 110 mg orally once a day until disease progression or unacceptable toxicity. Anlotinib hydrochloride capsules were given 12 mg once a day, taken for 2 weeks and then discontinued for 1 week, with a treatment cycle every 21 days. If grade 3 or above treatment-related toxicity occurs, anlotinib can be reduced to 10 mg or 8 mg once daily until disease progression or unacceptable toxicity occurs.
62371534|NCT05627791|EXPERIMENTAL|Oxytocin gel|Oxytocin gel 400IU per 1 ml (on HPMC 4,000 cps base gel), applied at vaginal canal 1 ml per day for 8 weeks
62371535|NCT05627791|PLACEBO_COMPARATOR|Placebo gel|Placebo gel (HPMC 4,000 cps base gel) , applied at vaginal canal 1 ml per day for 8 weeks
62371536|NCT04527666||Anticoagulation group|Patients with JAK2 mutation and gastroesophageal varices receive anticoagulation agents.
62371537|NCT04527666||Control group|Patients with JAK2 mutation and gastroesophageal varices who didn't receive anticoagulation agents.
62371538|NCT05135091|EXPERIMENTAL|NRTX-1001 (Stage 1)|Up to 10 subjects.
62371539|NCT05135091|EXPERIMENTAL|NRTX-1001 (Stage 2)|Up to 20 subjects.
62371540|NCT05135091|SHAM_COMPARATOR|Sham Comparator (Stage 2)|Up to 10 subjects.
62371541|NCT02682576|EXPERIMENTAL|Brachial artery ultrasound imaging|Brachial artery ultrasound imaging is a non-invasive procedure for detecting endothelial dysfunction by measuring the flow-mediated dilation of the brachial artery using high resolution continuous electrocardiogram-gated B-mode (2D) ultrasound imaging during reactive hyperemia.
62744154|NCT03116802|EXPERIMENTAL|Statin Group|A total of 35 healthy adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, pre-screened to be receiving long term statin therapy of ≥ 6 months and negative for diabetes (defined as HbA1c \<6.5%) will be enrolled upon written informed consent. They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
62744155|NCT03116802|ACTIVE_COMPARATOR|Control Group|"Another 35 healthy non-diabetic adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, not receiving long-term statins will serve as controls will be enrolled upon written informed consent.~They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)"
62744156|NCT01520701|ACTIVE_COMPARATOR|Ialuset® application|Arm with application to the skin Ialuset ® cervical during radiotherapy
62744157|NCT01520701|EXPERIMENTAL|bandage skin Hydrosorb|Arm bandage skin hydrogel (Hydrotac®) on the skin cervical during radiotherapy
62744158|NCT06495723|EXPERIMENTAL|Dose Escalation part: dose 2 mg/kg|Dose Escalation part: Dose level of LIS1: 2 mg/kg.
62744159|NCT06495723|EXPERIMENTAL|Dose Escalation part: dose 4 mg/kg|Dose Escalation part: Dose level of LIS1: 4 mg/kg.
62744160|NCT06495723|EXPERIMENTAL|Dose Escalation part: dose 6 mg/kg|Dose Escalation part: Dose level of LIS1: 6 mg/kg.
62744161|NCT06495723|EXPERIMENTAL|Expansion part|Expansion part: Participants will receive LIS1 at the RP2D determined in Part 1 of the study.
62744162|NCT05468190|EXPERIMENTAL|Intravenous of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg
62744163|NCT05468190|EXPERIMENTAL|intraperitoneal injection of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg
62744164|NCT06395675|EXPERIMENTAL|Experimental: Female/Male collection|"Each female participant will provide a 20-50 mL first-catch urine sample, and one (1) self-collected vaginal swab sample and three (3) clinician-collected vaginal swabs. Each male participant will provide a 20-50 mL first-catch urine sample.~Each urine sample will be collected in an untreated sterile urine cup. The site staff will test 1.5 ml of urine directly from the specimen cup with ID NOW within two (2) hours of collection. The remaining urine will be aliquoted into applicable transport tubes for each comparator.~One (1) self-collected vaginal swab will be collected by the participant in a clinical setting and tested on the device within 2 hours. Three (3) vaginal swabs will be collected by the clinician according to institutional procedures and manufacturer's instructions, one for each of the three (3) NAATs for comparator testing. For comparator tests, the order of CVS sample collection will be randomized."
62744165|NCT05103670|EXPERIMENTAL|Patients undergoing a Ventilation/Perfusion PET/CT at inclusion and 3 months later|EOLE is an ancillary study which selects patients included in the RAMBO study. The RAMBO study is a 2-arm-parallel study which patients included in one arm will undergo a 3-month pulmonary rehabilitation, and the patients included in the other arm won't. The EOLE study will include specific patients in both arms of the RAMBO study, and all of the participants will undergo a PET/CT scan at the inclusion and 3 months later.
62744166|NCT02241213|ACTIVE_COMPARATOR|Active Transcranial Magnetic Stimulation TMS- r|Application of single stimulation pulses and regularly repeated ones, the frequency may be divided into high frequency EMT (\> 1 Hz), low frequency (\<1 Hz) This classification is based on physiological effects (stimulation or inhibition neuronal respectively). In this particular case, we will use low frequency \<1 Hz with repetitive pulses.
62744167|NCT02241213|PLACEBO_COMPARATOR|Placebo Transcranial Magnetic Stimulation|Placebo coil that will simulate the sound of the pulses.
62744168|NCT00464373|EXPERIMENTAL|1|Botulinum Toxin Type A 200 U in 4ml NaCl 0.9%
62744169|NCT00464373|PLACEBO_COMPARATOR|2|4ml NaCl 0.9%
62744170|NCT04624386||Postmenopausal/Study|Women older than 45 years of age and who have not had any menstruation for the past 12 months are considered as having entered menopause. These women are included in this group.
62744171|NCT04624386||Premenopausal/Control|Healthy women who are still having regular menstruations are included in this group
62744172|NCT00594919||AKI group|Acute kidney injury group after cardiac surgery.
62744173|NCT00594919||NKF group|Normal kidney function group after cardiac surgery
62744174|NCT06239220|EXPERIMENTAL|Dose Level 0: PD-L1 t-haNK + N-803 + Cetuximab|"Dose level modifications of PD-L1 t-haNK and N-803 due to toxicities will follow protocol specifications, starting at Dose Level 0 and de-escalating to Dose Level -1. Participants will complete:~* Baseline visit.~* Imaging scans every 8 weeks while on study.~* Cycle 1 through End of Treatment:~  --Days 1 and 15 of 28 day cycle in the following order: Predetermined dose of PD-L1 t-haNK 1x daily, predetermined dose of N-803 1x daily, and predetermined dose of Cetuximab 1x daily.~* End of Treatment visit with assessments.~* Follow up: follow up every 3-4 months for up to 3 years after end of treatment. Longer-term follow-up every 6-12 months for up to 15 years."
62744175|NCT06239220|EXPERIMENTAL|Dose Level -1: PD-L1 t-haNK + N-803 + Cetuximab|"Dose level modifications of PD-L1 t-haNK and N-803 due to toxicities will follow protocol specifications. Participants will complete:~* Baseline visit.~* Imaging scans every 8 weeks while on study.~* Cycle 1 through End of Treatment:~  --Days 1 and 15 of 28 day cycle in the following order: Predetermined dose of PD-L1 t-haNK 1x daily, predetermined dose of N-803 1x daily, and predetermined dose of Cetuximab 1x daily.~* End of Treatment visit with assessments.~* Follow up: follow up every 3-4 months for up to 3 years after end of treatment. Longer-term follow-up every 6-12 months for up to 15 years."
62744176|NCT02003638|EXPERIMENTAL|Niacin|Niacin titrated up to 6 grams taken orally every day for 12 weeks
62744177|NCT02003638|PLACEBO_COMPARATOR|Placebo|Placebo taken orally every day for 12 weeks
62744178|NCT06658535|EXPERIMENTAL|Cohort 0.025|Loading dose = 0.025 mL/kg followed sustained IV infusion of 0.375 mL/kg over 21 hours.
62744179|NCT06658535|EXPERIMENTAL|Cohort 0.032|Loading dose of 0.032 mL/kg followed sustained IV infusion of 0.48 mL/kg over 21 hours.
62744180|NCT06658535|EXPERIMENTAL|Cohort 0.050|Loading dose of 0.050 mL/kg followed by sustained IV infusion of 0.75 mL/kg over 21 hours.
62744181|NCT03276026|ACTIVE_COMPARATOR|Control Group/Neostigmine|The control group will be the 63 patients who receive Neostigmine in a dose of 5mg, along with the anti-cholinergic glycopyrrolate 0.6mg.
62744182|NCT03276026|ACTIVE_COMPARATOR|Study Group/Sugammadex|63 patients will be given Sugammadex in a dose of 2mg/kg if the train of four twitch count is 2 and 4mg/kg if the twitch response has reached 1-2 post-tetanic counts with no twitch response to train of four.
62371542|NCT03638518|EXPERIMENTAL|Acupuncture|"In the acupuncture experimental group, the technique applied included the use of the following acupuncture points of Traditional Chinesse Medicine: GV20, ST36 and BL60 . One needle insertion was performed in each session and in the case of the last two points the needle insertions were done bilaterally.~Patients laid supine on a treatment table with their legs exposed. The skin on the acupuncture points was prepared with 70% ethyl alcohol. One-time-use disposable sterile stainless steel needles (0,26x50mm) were inserted into acupuncture points.~After insertion, acupuncture needles were manually manipulated to obtain the de qi sensation. The needles remained in place for 20 minutes and there were no further manipulations during the retention time."
62371543|NCT03638518|EXPERIMENTAL|Physiotherapy|The physiotherapy experimental group received core stability based physiotherapy treatment. Before the beginning of the treatment sessions, the basic principles of core stability exercises were explained to the participants. The exercise programme included 7 exercises. The exercises in the crook lying position were core activation with breathing, single leg lift with knees bent, single leg slides, bridging and knee drop sideways. The exercises completed in side lying included hip external rotation with knees bent and hip abduction with knees straight. After each session gentle stretching of the lower limbs and lumbar spine were performed. The sessions were administered twice a week during 30 minutes with groups of no more than 8 people.
62371544|NCT03638518|NO_INTERVENTION|control|The control group did not receive any intervention. The participants continued with their routine medical treatment.
62371545|NCT01681836|EXPERIMENTAL|Oral 15N-labeled sodium nitrate|Oral sodium nitrate 1,000 mg once first, then washout followed by oral sodium nitrite 20 mg once
62371546|NCT01681836|EXPERIMENTAL|Oral 15N-labeled sodium nitrite|Oral sodium nitrite 20 mg once first, then washout followed by oral sodium nitrate 1,000 mg once
62371547|NCT01476020||no clopidogrel 6 months after DES|Patients with a single treatment antiplatelet therapy (aspirin) 6 months after drug-eluting stent implantation (Xience V Abbott company), including a 12-, 24- and 36-month follow-up analysis.
62371548|NCT01476020||2 antiplatelet therapy 2 years after DES|patients with dual antiplatelet therapy with clopidogrel and aspirin 24 months after drug-eluting stent implantation, including a 12-, 24- and 36-month follow-up analysis.
62371549|NCT04063228|ACTIVE_COMPARATOR|Standard of care|
62371550|NCT04063228|ACTIVE_COMPARATOR|Simple Skill Group|
62371551|NCT01381224||Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection.
62371552|NCT03978572|ACTIVE_COMPARATOR|Resistance Training|12 weeks of whole-body progressive resistance training, three days per week, lower-extremity focused (60% of exercises targeting lower extremities)
62371553|NCT03978572|ACTIVE_COMPARATOR|Moderate-intensity continuous cycling|12 weeks of progressive endurance cycling on a stationary bicycle at a target heart rate, three days per week.
62371554|NCT03978572|EXPERIMENTAL|High-intensity interval cycling|12 weeks of progressive high-intensity interval cycling on a stationary bicycle, three days per week.
62744183|NCT01208883|EXPERIMENTAL|repetitive per-treatment [18F]FDG-PET for treatment adaptation|
62744184|NCT03136497|EXPERIMENTAL|400mg ABT-199|Cycle length will be 28 days. 400mg ABT-199 will be administered orally QD (Once Daily), continuously for 24 cycles. Ibrutinib will be administered orally QD, continuously for 24 cycles. Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1), Commercially available rituximab IV will be used.
62744185|NCT03136497|EXPERIMENTAL|800mg ABT-199|Cycle length will be 28 days. 800mg ABT-199 will be administered orally QD (Once Daily), continuously for 24 cycles. Ibrutinib will be administered orally QD, continuously for 24 cycles. Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1), Commercially available rituximab IV will be used.
62371555|NCT01061840|EXPERIMENTAL|1 x 10 ^7 cells/injection|Vigil™
62371556|NCT01061840|EXPERIMENTAL|2.5 x 10 ^7 cells/injection|Vigil™
62371557|NCT01061840|EXPERIMENTAL|1 x 10^6 or 4 x 10^6 cells/injection|Vigil™
62371558|NCT02381067|OTHER|NuCel with Allograft Bone|NuCel will be used with allograft bone for the surgical treatment of one, two or three level degenerative disease of the cervical spine.
62371559|NCT05306262|ACTIVE_COMPARATOR|hypnotic trance|Hypnosis session of comfort for 20 minutes
62371560|NCT05306262|EXPERIMENTAL|hypnotic trance + catalepsy|Catalepsy + Hypnosis session of comfort for 20 minutes
62371561|NCT00508469|EXPERIMENTAL|Travalert with travoprost/timolol fixed combination|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
62371562|NCT00508469|EXPERIMENTAL|Travalert with travoprost and timolol|One drop travoprost in the study eye at 9 p.m. and one drop of timolol in the study eye twice daily (9 a.m. and 9 p.m.) for six months using a separate Travalert device for each medication.
62371563|NCT01084473|EXPERIMENTAL|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
62371564|NCT01084473|ACTIVE_COMPARATOR|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
62371565|NCT01084473|PLACEBO_COMPARATOR|Placebo|The study subjects will be given a saline infusion.
62371566|NCT00911222||antiemetic treatment|epidemiological registry
62371567|NCT03527940||Patients with STEMI|
62371568|NCT03908463||The patients who undergo percutaneous coronary intervention|The patients who undergo percutaneous coronary intervention will be enrolled.
62371569|NCT05260190|EXPERIMENTAL|tSMS|Real tSMS stimulation.
62371570|NCT05260190|SHAM_COMPARATOR|Sham tSMS|Sham tSMS stimulation.
62371571|NCT00850265|EXPERIMENTAL|Spacer|Extrafine formoterol plus beclomethasone with spacer
62371572|NCT00850265|NO_INTERVENTION|No Spacer|Extrafine formoterol plus beclomethasone without spacer
62371573|NCT03484689|OTHER|MBCT arm|8-week MBCT program
62371574|NCT02090218|ACTIVE_COMPARATOR|I-Gel|I-Gel supraglottic airway device
62371575|NCT02090218|ACTIVE_COMPARATOR|LTS, ETI or other airway practice|Laryngeal tube, endotracheal tube or other current airway management practice
62371576|NCT05310760|ACTIVE_COMPARATOR|Vitamin C receiving|Therapeutic doses of Vitamin C are added to rachitic children treatment
62371577|NCT05310760|NO_INTERVENTION|Non Vitamin C receiving|The traditional treatment of nutritional rickets
62371578|NCT02702284|OTHER|Adequate health literacy, control|This group of subjects will be referred to clinic staff for assistance with the advance directives (AD) and will not receive assistance from a research assistant. In addition, the research assistance will ask questions regarding the information received for the AD.
62371579|NCT02702284|EXPERIMENTAL|Adequate health literacy, intervention|The subjects in this group will hear a research assistant review the advance directive and be offered an opportunity to watch a video about advance directives.
62371580|NCT02702284|OTHER|Limited health literacy, control|This group of subjects will be referred to clinic staff for assistance with the advance directives (AD) and will not receive assistance from a research assistant. In addition, the research assistance will ask questions regarding the information received for the AD.
62371581|NCT02702284|EXPERIMENTAL|Limited health literacy, intervention|The subjects in this group will hear a research assistant review the advance directive and be offered an opportunity to watch a video about advance directives.
62371582|NCT03756870|EXPERIMENTAL|CTO PCI|Patients will receive optimal medical therapy, with percutaneous coronary intervention of the chronic total occlusion.
62371583|NCT03756870|NO_INTERVENTION|OMT|Patients will receive optimal medical therapy, without percutaneous coronary intervention of the chronic total occlusion.
62371584|NCT04185740|EXPERIMENTAL|Home-based validation|The home-based validation of the TTT will give insight in the task performance of patients OFF-medication compared to ON-medication and on different time points in the medication cycle during 7 days
62371585|NCT05759481|EXPERIMENTAL|Propofol|Low-dose propofol infusion at 25 mcg/kg/min
62371586|NCT05759481|PLACEBO_COMPARATOR|Placebo|Same volume of 0.9% normal saline as the study group
62371587|NCT01706120|OTHER|First-line chemotherapy with bevacizumab|"* Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks for up to 22 cycles~* Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles~* Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles"
62371588|NCT05299151|EXPERIMENTAL|Vestibular Rehabilitation Group|A vestibular rehabilitation exercise program, which is determined based on the literature and personalized according to the functional disabilities of each patient, will be applied to the participants in the experimental group. An exercise session will be performed for a total of 40 minutes, with each exercise for 1-2 minutes. Exercise training will be applied 2 days a week for 8 weeks and they will be asked to do it at home once a week.
62371589|NCT05299151|ACTIVE_COMPARATOR|Standard Neurorehabilitation Group|A neurorehabilitation program based on stretching, strengthening, posture, mobilization, static and dynamic balance exercises will be applied. Each training session will be 40 minutes in total. Exercise training will be done in the clinical setting 2 days a week for 8 weeks, and they will be asked to do it at home once a week.
62371590|NCT04459442|EXPERIMENTAL|Early cord clamping|Cord clamping at 60 seconds after birth.
62371591|NCT04459442|EXPERIMENTAL|Delayed cord clamping|Cord clamping at 180 seconds after birth.
62371592|NCT00864123|ACTIVE_COMPARATOR|Cognitive-behavioral therapy + placebo|Involves receiving cognitive-behavioral treatment of OCD symptoms for 10 sessions. One hour prior to sessions 4-10, the child will take either 1 or 2 pills containing 25mg of placebo. The number of pills depends on the child's weight (e.g., about 46kgs takes 2 capsules).
62371593|NCT00864123|EXPERIMENTAL|Cognitive-behavioral therapy + D-cycloserine|Involves receiving cognitive-behavioral treatment of OCD symptoms for 10 sessions. One hour prior to sessions 4-10, the child will take either 1 or 2 pills containing 25mg of D-cycloserine. The number of pills depends on the child's weight (e.g., about 46kgs takes 2 capsules).
62371594|NCT06287931|EXPERIMENTAL|Ursodoxycholic acid group|Ursodoxycholic acid, 250mg po tid x 6 months
62371595|NCT06287931|EXPERIMENTAL|Bifidobacterium group|Bifidobacteria, 210 mg po tid x 6 months
62371596|NCT06287931|EXPERIMENTAL|Bifidobacterium and ursodeoxycholic acid group|Ursodoxycholic acid, 250mg po tid x 6 months Bifidobacteria, 210 mg po tid x 6 months
62371597|NCT03906201|EXPERIMENTAL|Control Group|Subjects diagnosed with prediabetes according to the criteria of the American Diabetes Association, version 2019 with placebo treatment
62371598|NCT03906201|EXPERIMENTAL|Ecdysterone Group|Subjects diagnosed with prediabetes according to the criteria of the American Diabetes Association, version 2019 whit ecdysterone treatment
62371599|NCT01431521|EXPERIMENTAL|MK-4074|Participants will receive oral doses of MK-4074 200 mg (2 x 100-mg capsules) twice daily for 4 weeks.
62371600|NCT01431521|PLACEBO_COMPARATOR|Placebo for MK-4074|Participants will receive oral doses of placebo to match MK-4074 twice daily for 4 weeks.
62371601|NCT01431521|EXPERIMENTAL|Pioglitazone|Participants will receive oral doses of pioglitazone hydrochloride 30 mg (1 x 30-mg tablet) once daily for 4 weeks.
62371602|NCT01431521|PLACEBO_COMPARATOR|Placebo for pioglitazone|Participants will receive oral doses of placebo to match pioglitazone hydrochloride once daily for 4 weeks.
62371603|NCT05094570|EXPERIMENTAL|Dupilumab treatment|Treatment with dupilumab to demonstrate decreased staph prevalence and improve microbial diversity
62371604|NCT06141889|EXPERIMENTAL|Single dose, 2-way crossover in Part 1, then daily dosing for 14 days in Part 2|"Study Part 1:~Participants will receive a single Dose A or B on Day 1 and then followed by a crossover to a single Dose B or A on Day 8.~Study Part 2:~Participants in Study Part 2 will receive either a single Dose C or equivalent of Dose C administered twice daily, starting on Day 1 and through Day 14"
62371605|NCT05501457|EXPERIMENTAL|The gastrocnemius group|The patients in the first group (n=15) were given a pulmonary rehabilitation program and additionally 20 minutes of Neuromuscular electrical stimulation (Group 1) to the gastrocnemius muscle,
62371606|NCT05501457|EXPERIMENTAL|The quadriceps femoris group|The second group was given a pulmonary rehabilitation program and an additionally 20 minutes of neuromuscular electrical stimulation to the quadriceps femoris muscle (Group 2),
62371607|NCT05501457|EXPERIMENTAL|The control group|The third group, which was the control group, was given only a pulmonary rehabilitation program (Group 3).
62371608|NCT02094625|EXPERIMENTAL|N-Acetylcysteine Intervention|"This is a dose-finding study using a traditional 3+3 dose escalation scheme. Up to 18 subjects (3 dose levels as per below) will be enrolled to determine the maximum tolerated dose (MTD). The MTD is defined as per traditional 3+3 criteria of less than or equal to one dose-limiting toxicity at the dose level. Once the MTD is determined, subjects will be equally distributed at the safe dose levels (less than or equal to the MTD) to determine the optimum dose to achieve NAC levels in the blood necessary for hearing protection.~As of August 2018: The dose-escalation phase was completed and dose-level three was selected for expansion in 9 subjects."
62371609|NCT02094625|NO_INTERVENTION|Observation only|"Subjects who are ineligible to receive the study drug NAC will have the option to enroll for study assessments only including laboratory testing and hearing assessments identical to the experimental intervention arm. This is a cohort of convenience for which we anticipate up to 36 children will be enrolled over the course of the study."
62371610|NCT02136316|EXPERIMENTAL|ASP7962 low dose|
62371611|NCT02136316|EXPERIMENTAL|ASP7962 medium dose|
62371612|NCT02136316|EXPERIMENTAL|ASP7962 high dose|
62371613|NCT02136316|PLACEBO_COMPARATOR|Placebo|
62371614|NCT00388375|NO_INTERVENTION|CVC Internal Jugular or Subclavian Vein|
62371615|NCT03743298|EXPERIMENTAL|AV-MEL-1|AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
62371616|NCT03942549||MUS Cohort|This cohort will undergo midurethral sling placement.
62371617|NCT04281823||Cardiovascular Magnetic Resonance|All patients who present to the Houston Methodist CMR Laboratory
62371618|NCT00551967|ACTIVE_COMPARATOR|E1 polyethylene|All patients received an E1 polyethylene liner which is the material being monitored in this study.
62371619|NCT01782885|ACTIVE_COMPARATOR|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts.
62371620|NCT01782885|EXPERIMENTAL|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks
62371621|NCT00444834|EXPERIMENTAL|1|Egalet carvedilol
62371622|NCT00444834|ACTIVE_COMPARATOR|2|Coreg
62371623|NCT05148559|EXPERIMENTAL|Enhanced Reminder|
62371624|NCT05148559|OTHER|Standard of Care|
62371625|NCT00789724|EXPERIMENTAL|Anakinra|Anakinra 100 mg given daily by subcutaneous injection for 14 days
62371626|NCT00789724|PLACEBO_COMPARATOR|Placebo|0.67 ml of NaCl 0.9% solution
62371627|NCT04067440||Patients|Subjects to undergo surgery including opening of the jejunum with non-inflammative condition.
62371628|NCT03971292||Validation phase|The project will proceed in two phases: a validation test phase including 5 patients of known genotype and a prospective phase including 10 patients.
62371629|NCT03971292||Prospective phase|The project will proceed in two phases: a validation test phase including 5 patients of known genotype and a prospective phase including 10 patients.
62371630|NCT01948323|OTHER|.HEDUAfrica IT package+ std care info|"The HEDUAfrica IT package website aims to target disadvantaged gravid women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, SA). A healthcare worker will assist women with the touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes. Patients participating in the IT package also receive std car info~Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group."
62567174|NCT03870750|ACTIVE_COMPARATOR|Arm IV (standard of care)|Patients receive standard of care. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT. Patients may also complete surveys on medical and non-medical (transportation, lodging) costs related to transplant after HCT.
62744186|NCT01853579|EXPERIMENTAL|1|Experimental: Drug: Levothyroxine The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
62744187|NCT01853579|PLACEBO_COMPARATOR|2|"Placebo Comparator: Drug: Placebo Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
62744188|NCT03547739|ACTIVE_COMPARATOR|Home visits|Participants randomized to intervention arm receive 5 home visits conducted by one female and one male lay health worker.
62744189|NCT03547739|ACTIVE_COMPARATOR|HIV Self-testing|Women in this study group will receive HIV self-test kits for themselves and their male partner at up to 4 time points.
62744190|NCT03547739|NO_INTERVENTION|Standard Care|Participants will receive current standard clinic-based services including the option for women and partners to return to the clinic for male partner HIV testing or Couples HIV Counseling and Testing (CHCT).
62744191|NCT01396824||Heart failure|Heart failure patients attending a HF clinic with depressed LVEF (\< 45%) or ≥ 1 hospital admission due to HF decompensation.
62371631|NCT01948323|NO_INTERVENTION|Health awareness brochure + std care|Participants in the non-intervention group at another clinic in Soweto, will receive an enhanced form of standard care. This will include, in conjunction with the normal form of care at each clinic,a health awareness brochure that will focus specifically on health information relating to obesity, diabetes, diet, exercise and breastfeeding at each follow-up sessions. These participants will also be asked to fill out the 24 hour dietary recall assessment and short messaging service technology questionnaire (exactly the same as the intervention group) with help from a healthcare worker.
62371632|NCT04847739|EXPERIMENTAL|Standard of Care Treatment + AVB-114|Subjects receive the standard of care treatment (seton placement) prior to Day 0, when it is removed and the AVB-114 study treatment is inserted.
62371633|NCT04847739|ACTIVE_COMPARATOR|Standard of Care Treatment|Subjects receive the standard of care treatment (seton placement) prior to Day 0, when it is removed and then replaced.
62371634|NCT00430027|EXPERIMENTAL|Capecitabine, oxaliplatin, cetuximab, and radiation therapy|Patients enrolled on the trial will receive neoadjuvant combined capecitabine, oxaliplatin, cetuximab, and radiation therapy. This will be followed by surgical resection and adjuvant capecitabine, oxaliplatin, and cetuximab
62744192|NCT00694837|EXPERIMENTAL|B|
62744193|NCT05892770|ACTIVE_COMPARATOR|Botulinum toxin A injection|Botulinum toxin A injection into vocal cords for treatment of spasmodic dysphonia. This is the current standard of care for treatment of this disease process. This will be the control of the study.
62744194|NCT05892770|EXPERIMENTAL|"Botulinum toxin A injection +zinc supplementation"|Botulinum toxin A injection into vocal cords for treatment of spasmodic dysphonia, with subject taking zinc supplementation daily for the 5 days preceding the botox injection. This will be the experimental arm of the study.
62744195|NCT02584530|NO_INTERVENTION|Standard procedure group|PICC line insertion using anatomical landmarks guidance and tip placement confirmation by X-ray
62744196|NCT02584530|EXPERIMENTAL|Interventional group|Ultrasound guidance for PICC line placement and X-ray
62744197|NCT03735199|EXPERIMENTAL|PCL-TCP scaffold|During the surgery, the PCL-TCP scaffold will be shaped by cutting and shaving with a scalpel so as to fit the extraction socket snugly at the crestal half to two-thirds aspect. A Geistlich Bio-Gide collagen membrane will be placed over the scaffold at the crestal aspect of the socket. The periosteum of the buccal flap will then be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
62744198|NCT03735199|ACTIVE_COMPARATOR|Geistlich Bio-Gide collagen membrane|"No space filler will be inserted in the extraction socket but similar to the test group, a Geistlich Bio-Gide collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.~denture overlying the extraction site will be completely relieved."
62744199|NCT02527226|NO_INTERVENTION|No facial exercises|This group will not receive any training in facial exercises.
62371635|NCT02278380|OTHER|Arm 1|"To compare the Glycemic Index value of seven test foods:~Low GI standard Breakfast Medium GI standard Breakfast Nutritional pregnant milk supplement Nutritional product for diabetics Pregnant and lactation women milk powder Nutritional drinks for diabetics Test product"
62371636|NCT01657227|EXPERIMENTAL|Intervention to Patients|Only patients receive intervention
62371637|NCT01657227|EXPERIMENTAL|Intervention to healthcare Professionals|Primary care physicians and nurses practitioners receive the intervention. Their associated patients do not receive direct intervention although indirect intervention through professionals
62744200|NCT02527226|EXPERIMENTAL|Facial exercises|This group will receive instruction to perform a series of self-administered exercises of facial expression and movements.
62744201|NCT00332020|EXPERIMENTAL|Arm 1|
62744202|NCT00332020|ACTIVE_COMPARATOR|Arm 2|
62744203|NCT01126437|EXPERIMENTAL|tiotropium 2.5 mcg and placebo|Patients receive one of the active tiotropium arms daily
62744204|NCT01126437|ACTIVE_COMPARATOR|tiotropium 18 mcg and placebo|Patients receive one of the active tiotropium arms daily
62744205|NCT01126437|EXPERIMENTAL|tiotropium 5 mcg and placebo|Patients receive one of the active tiotropium arms daily
62744206|NCT01848977|EXPERIMENTAL|vascular occlusion test|"The pediatric SomaSensor™ probe of INVOS® and the 15-mm sensor of InSpectra™ are placed on each thenar muscle in the same subject. The side on which the probe will be placed is randomly determined. INVOS® updates data every 5 s and data (SrO2) will be manually recorded. The data of InSpectra™ (StO2) are automatically collected and sampled every 2 s.~Vascular occlusion test (VOT) is done as follows:Adult-size blood pressure cuffs are placed around each upper arm. The both cuffs are simultaneously inflated to 30 mmHg above the initial systolic blood pressure and kept inflated until the SrO2 or StO2 decreased to 40%. When the value reaches 40% or just below it, the cuff on the same side is deflated rapidly. The data will be collected until the SrO2 and StO2 values returned to the baseline."
62744207|NCT03230890|EXPERIMENTAL|HIRREM|This is the intervention, treatment arm that all participants receive in this open label, single arm trial. The intervention is High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM).
62744208|NCT06065657|EXPERIMENTAL|Ketogenic diet|Eat a ketogenic diet for 3 days
62744209|NCT06065657|PLACEBO_COMPARATOR|Control Diet|Eat a control diet for 3 days
62744210|NCT06065657|EXPERIMENTAL|Ketone supplement|Eat a control diet for 3 days with a ketone supplement drink
62744211|NCT06065657|EXPERIMENTAL|Alcohol Intervention|Alcohol lab, participants will receive ethanol drinks that are dose-adjusted for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
62744212|NCT02017392|EXPERIMENTAL|Compound Lidocaine Cream|The cuff of endotracheal tube is covered by 1-2g compound lidocaine cream before the general anesthesia.
62744213|NCT02017392|NO_INTERVENTION|blank control|No intervention.
62744214|NCT04666103|EXPERIMENTAL|Thyroid lobectomy with intraoperative thermal ablation|"Thyroid lobectomy was performed with a standard technique of fine capsular en bloc dissection and resection, from inferior pole to superior pole. Superior parathyroid glands were identified and preserved in situ, inferior parathyroid glands were protected in situ or autotransplanted in the sternocleidomastoid muscle according to three certain types based on their blood supply and location. All the patients underwent lobectomy received ipsilateral therapic central compartment neck dissection. After the thyroid lobectomy, the contralateral benign thyroid nodule was treated with intraoperative thermal ablation. The hydrodissection technique was used during the ablation process to prevent recurrent laryngeal nerve, esophageal and other important structures from being destroyed by heat energy."
62744215|NCT04666103|NO_INTERVENTION|Thyroid lobectomy|Thyroid lobectomy was performed with a standard technique of fine capsular en bloc dissection and resection, from inferior pole to superior pole. Superior parathyroid glands were identified and preserved in situ, inferior parathyroid glands were protected in situ or autotransplanted in the sternocleidomastoid muscle according to three certain types based on their blood supply and location. All the patients underwent lobectomy received ipsilateral therapic central compartment neck dissection.
62744216|NCT06658834|EXPERIMENTAL|romiplostim combined with glucocorticoids|Dexamethasone (HD-DXM) at a dose of 40mg/d for 4 days constitutes one cycle. If there is no response on the 10th day, repeat it once. The administration can be either oral or intravenous. Meanwhile, romiplostim N01 is administered with an initial dose of 3µg/kg by subcutaneous injection once a week for up to 6 months.
62744217|NCT06658834|ACTIVE_COMPARATOR|glucocorticoids|Dexamethasone (HD-DXM) 40mg/d × 4 days, one cycle. If there is no response on the 10th day, repeat once, administered either orally or intravenously.
62744218|NCT05796921|ACTIVE_COMPARATOR|Active|1 daily capsule of the Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain (15 billion of Colony Forming Units/capsule) for 10 days
62744219|NCT05796921|PLACEBO_COMPARATOR|Placebo|1 daily capsule of placebo
62744220|NCT06088394|EXPERIMENTAL|The patients will do pelvic floor exercises and acupuncture|The patients will perform pelvic floor exercises and acupuncture 3 times per week for 12 weeks
62744221|NCT06088394|EXPERIMENTAL|The patient will do pelvic floor exercises|"The patient will perform pelvic floor exercises 3 times per week for 12 weeks. pelvic floor muscles exercises involves repetitive contraction and relaxation of the pelvic floor muscles in an attempt to strengthen the muscles .~Each training session involved three training rounds and each round lasted for five minutes. Women will be instructed to perform PFMC and rest with 10min break between each round. They will be instructed to perform two to three sets of PFE repetitions per day, with 8-10 PFMC lasting for 10 s each set. All women will be asked to document their practice of PFE in PFE diary to assess their compliance."
62744222|NCT01519544|ACTIVE_COMPARATOR|Temazepam|50 subjects are instructed to take 7.5mg temazepam by mouth prior to going to sleep for one night only.
62744223|NCT01519544|ACTIVE_COMPARATOR|Acetazolamide|50 subjects are instructed to take 125mg of acetazolamide by mouth prior to going to sleep one night only.
62744224|NCT01112774|EXPERIMENTAL|tDCS/Spinal cord injury|Subjects will be randomized to receive 10 sessions of either active or sham tDCS. Stimulation will be given on consecutive days (Monday- Friday) at 2 mA over the primary motor cortex area.
62744225|NCT01112774|EXPERIMENTAL|tDCS/Healthy subjects|Subjects will receive 2 sessions of stimulation: one active and one sham tDCS on two separate visits. The order in which they receive the stimulation will be randomized. Stimulation parameters will be at 2 mA for a total of 20 minutes.
62744226|NCT00362271|OTHER|1|
62744227|NCT02414945|EXPERIMENTAL|Tumor Infiltrating lymphocytes (TILs)|"Lymphodepleting preparative regimen: Cyclophosphamide, intravenously, at 60mg/kg/day x 2 days, and Fludarabine, intravenously at 25mg/m2/day x 5 days~Autologous tumor infiltrating lymphocytes (TILs): Intravenously at 1x10\^10 - 1.6x10\^11 cells~Low-dose interleukin-2: Subcutaneously at 125,000 IU/kg per day, for 2 weeks (2 days rest between each week)."
62744228|NCT02321319|EXPERIMENTAL|Hydromorphone HCl ER Tablets|Participants receive Hydromorphone HCl ER Tablets (4-16 mg, based on standard conversion ratios for common opioids)
62744229|NCT06263907|EXPERIMENTAL|Stellate gangalion block group (Group S)|Patients will receive ipsilateral stellate gangalion block (4ml) bupivacaine 0.25 %+( 4ml) normal saline + (8mg) dexamethasone in a total 10 ml
62744230|NCT06263907|NO_INTERVENTION|Control group (Group C)|Patients will not receive stellate gangalion block
62744231|NCT01015495|EXPERIMENTAL|ranibizumab|
62744232|NCT00855933|NO_INTERVENTION|Control - no flossing|Subjects brushed thoroughly for one minute with Crest® Cavity Protection toothpaste and an Oral-B® Indicator soft, manual toothbrush once daily.
62744233|NCT00855933|EXPERIMENTAL|Experimental Floss|Subjects brushed thoroughly for one minute with Crest® Cavity Protection toothpaste and an Oral-B® Indicator soft, manual toothbrush once daily. Subjects flossed once daily with the experimental floss.
62744234|NCT01529515|EXPERIMENTAL|Paliperidone palmitate 3-month (PP3M)|
62744235|NCT01529515|PLACEBO_COMPARATOR|Placebo|
62744236|NCT01258465|ACTIVE_COMPARATOR|Pivotal Response Training|A naturalistic behavioral intervention designed to facilitate verbal communication.
62744237|NCT01258465|ACTIVE_COMPARATOR|Picture Exchange Communication System|Pictorially-based behavioral protocol designed to facilitate communication via picture icons.
62744238|NCT00327015|EXPERIMENTAL|Saxagliptin and Metformin (A)|PLUS open-label pioglitazone (as needed as rescue medication)
62744239|NCT00327015|EXPERIMENTAL|Saxagliptin and Metformin (B)|PLUS open-label pioglitazone (as needed as rescue medication)
62744240|NCT00327015|EXPERIMENTAL|Saxagliptin and Placebo (C)|PLUS open-label pioglitazone (as needed as rescue medication)
62744241|NCT00327015|ACTIVE_COMPARATOR|Metformin and Placebo (D)|PLUS open-label pioglitazone (as needed as rescue medication)
62744242|NCT00580034|EXPERIMENTAL|Campath Purged Non-myeloablative ASCT|Campath Purged Non-myeloablative Allo Stem Cell Transplant (ASCT) in lymphoma, myeloma, or marrow failure: leukemia or myelodysplasia; and solid tumors
62744243|NCT00580034|OTHER|Donor Apheresis|"Donor must be a sibling, half sibling, parent, child or first cousin familial relationship and 3-5/6 Human Leukocyte Antigen matched related to subject. They must not have any medical condition which would make apheresis and G-CSF administration more than a minimal risk, and should have the following:~1. Adequate cardiac function by history and physical examination~2. bilirubin and hepatic transaminases \< 2.5 x upper limit of normal~3. normal hematologic parameters Females should have a negative serum pregnancy test."
62744244|NCT06271265|EXPERIMENTAL|EXPAREL|A total of approximately 24 subjects (8 subjects per Part) will be enrolled. Subjects in this arm will receive EXPAREL
62744245|NCT06271265|ACTIVE_COMPARATOR|bupivacaine|A total of approximately 24 subjects (8 subjects per Part) will be enrolled. Subjects in this arm will receive bupivacaine
62744246|NCT05402163|OTHER|Continuous DBS|
62744247|NCT05402163|ACTIVE_COMPARATOR|Adaptive DBS|
62744248|NCT05764005|EXPERIMENTAL|Intervention website|
62744249|NCT05764005|ACTIVE_COMPARATOR|Control MUSIC website|This is usual care and all urologists are encouraged to refer their patients to the patient educational materials on the MUSIC website (http://www.musicurology.com/patientmaterials/).
62744250|NCT03226379|OTHER|DREAMM|"4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines:~1. Health system strengthening~2. Delivery of a co-designed education program tailored to frontline healthcare workers~3. Implementation of an algorithm for HIV-related meningoencephalitis~4. Infectious diseases/AHD mentorship and laboratory capacity building"
62744251|NCT04663906||Isotretinoin|Test population, prescribed oral isotretinoin between March and October 2020.
62744252|NCT04663906||Control|Background age-matched population, not prescribed oral isotretinoin during March to October 2020
62744253|NCT02125916|EXPERIMENTAL|COLD without long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
62744254|NCT02125916|EXPERIMENTAL|COLD with long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
62744255|NCT02125916|EXPERIMENTAL|ILD without long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
62744256|NCT02125916|NO_INTERVENTION|Controls|Driving in the simulator one time without oxygen therapy
62744257|NCT04955223|EXPERIMENTAL|Yinhu Qingwen Granule|For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day. All treatment should be used for 10 days unless all the symtopms of patient with the viral pneumonia are relieved.
62744258|NCT02503670|OTHER|HealthyDads.ca web-based program|An on-line self-help psychoeducational website tailored to new dads. Psychoeducational learning modules and tools, including a 6 week physical activity challenge..
62744259|NCT02503670|OTHER|Control group|No access to the intervention. Will complete the same questionnaires as the Healthydads.ca group over the study period.
62744260|NCT06341296|EXPERIMENTAL|irinotecan liposome injection combined with 5-FU/LV+ bevacizumab|Patients will be treated with irinotecan liposome injection combined with 5-FU/LV+ bevacizumab. Treatment lasted 8 cycles.
62744261|NCT06026540|EXPERIMENTAL|experimental group|"After the first measurements were made and the groups were determined; Students in the experimental group will be given pilates exercises 2 days a week for 6 months. Pilates mat, pilates circle, tiny pilates ball and pilates band will be used during the pilates exercise. The duration of the Pilates exercise is 30 minutes in total, and the peer-guided application via Zoom includes the following order:~Stretching 5 minutes, superman 1 minute, quodratus stretch 2 minutes, marble 1 minute, half plank kick 4 minutes, side kick 4 minutes, pelvic curl 2 minutes, cat pose 1 minute, spine stretch 2 minutes, one leg circle 3 minutes, side leg lift 3 minutes, single leg kick 2 minutes."
62744262|NCT06026540|NO_INTERVENTION|Control group|No intervention will be applied to the control group
62744263|NCT04683549|OTHER|One-Arm HPV serum level and FDG PET CT|HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy
62744264|NCT04534179|EXPERIMENTAL|Vacuum myofascial therapy and physical activity|The protocol would last 5 weeks, group received fifteen 30-minute sessions of vacuum myofascial therapy and fifteen sessions physical activity program similar to the control group per week.
62744265|NCT04534179|ACTIVE_COMPARATOR|Physical activity Program|The exercise protocol would last 5 weeks, performing 3 exercise sessions per week, with an effective work time of 30 minutes per session. The exercises would be directly focused on activating the core stabilizing muscles.
62744266|NCT04344977||Convalescent survivors of COVID-19|Convalescent survivors of COVID-19: history of COVID-19 like illness or positive test for SARS-CoV-2 and has the protocol-specified minimum anti-SARS-CoV-2 neutralizing antibody titer
62371638|NCT01657227|EXPERIMENTAL|Mixed Intervention|Patients and healthcare professionals (primary care physicians and nurses practitioners) associated with these patients receive intervention
62371639|NCT01657227|OTHER|Control|Patients receive usual care
62371640|NCT01040728|EXPERIMENTAL|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
62371641|NCT01040728|EXPERIMENTAL|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
62371642|NCT01040728|ACTIVE_COMPARATOR|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
62371643|NCT01040728|PLACEBO_COMPARATOR|Placebo|Olodaterol placebo and/or Tiotropium placebo inhaled once daily
62371644|NCT03038516|ACTIVE_COMPARATOR|Vitamin D|Cholecalciferol (Detremin) solved in MIGLYOL® 812
62371645|NCT03038516|PLACEBO_COMPARATOR|Placebo|MIGLYOL® 812
62371646|NCT01700647||smoking controls|patients referred for bronchoscopy who have detailed axamination and do not have any dysplasia proven by bronchoscopy and laryngoscopy Breath test- sampling using ENose
62371647|NCT01700647||In Situ carcinoma larynx|Biopsy proven in situ carcinoma larynx proven by laryngoscopy and bronchoscopy Breath test- sampling using ENose
62371648|NCT01700647||Advanced Larynx Cancer|Biopsy proven stage 3/4 larynx cancer proven by laryngoscopy and bronchoscopy Breath test- sampling using ENose
62371649|NCT01744041|EXPERIMENTAL|Dyadic Interpersonal Psychotherapy|Brief Interpersonal Psychotherapy during pregnancy followed by dyadic mother-infant psychotherapy for one year postpartum
62371650|NCT01744041|ACTIVE_COMPARATOR|Enhanced Treatment as Usual|Personalized referral to community resources for depression treatment
62371651|NCT02267902|EXPERIMENTAL|Part 1|Single oral therapeutic dose of 5mg DA-1229 as a tablet + An IV dose of 20㎍ \[14C\]-DA-1229
62371652|NCT02267902|EXPERIMENTAL|Part 2|Single oral therapeutic dose of 5mg \[14C\]-DA-1229
62371653|NCT01833390|EXPERIMENTAL|HXe MRI lung ventilation|Each subject will inhale a dose of HXe gas (up to one liter HXe) while lying inside an MRI scanner. A high-resolution 3D map of the lung spaces filled with HXe gas will be acquired during a short breath-hold. Additionally, proton MRI of the chest cavity will be recorded during the same breath-hold for registering the lung boundaries. All subjects will undergo Pulmonary Function Tests. Subjects suffering from obstructive lung disease will have Tc-99m DTPA lung scintigraphy performed for comparing with HXe images.
62371654|NCT01413867|EXPERIMENTAL|EEA group|Group of patients with III degree hemorrhoids treated by EEA stapler
62371655|NCT01413867|ACTIVE_COMPARATOR|PPH group|group of patients with III degree hemorrhoids treated by PPH stapler
62371656|NCT04127643||S-ICD patients|patients who have received the EMBLEM S-ICD system
62371657|NCT01955785|ACTIVE_COMPARATOR|PC ventilation|Intervention with pressure controlled ventilator
62371658|NCT01955785|ACTIVE_COMPARATOR|PRVC ventilation|Intervention with Pressure Regulated Volume Controlled Ventilator
62371659|NCT04336007|EXPERIMENTAL|Radio-frequency group|The equipment used, INDIBA® Activ Ct9, (448kHz), with the switch-mode on.
62371660|NCT04336007|PLACEBO_COMPARATOR|Placebo group|The equipment used, INDIBA® Activ Ct9, (448kHz), with the switch-mode off.
62371661|NCT04336007|SHAM_COMPARATOR|Control Group|NO INTERVENTION athlete's usual pre-competition warming-up
62371662|NCT01673425|EXPERIMENTAL|Live Attenuated Influenza Vaccine|Single intervention study- all participants will receive LAIV instead of injectable flu vaccine.
62371663|NCT05589623|EXPERIMENTAL|Copenhagen adduction exercise|The CAE is a body-weight exercise that mainly works the groin and hip adductors. It has a significant eccentric component, meaning the muscles work while lengthening. The CAE is a simple isolated eccentric exercise that does not require special equipment. Due to the heaviness and the high dynamic demands of CAE, a modified progressive Copenhagen adduction (MPCA) program has been created. The MPCA exercise was adapted from the original CAE to lessen the risk of delayed onset muscle soreness (DOMS) and facilitate high participant compliance. An experienced physical therapist will include the MPCA in the usual rehabilitation program for eight weeks, twice weekly. Sessions will last between 30 and 120 minutes.
62371664|NCT05589623|ACTIVE_COMPARATOR|Usual rehabilitation program|The rehabilitation program will be an active exercise based on the available literature and considers the clinical experience in managing groin injuries. An experienced physical therapist will supervise the rehabilitation program for two sessions weekly for eight weeks, with difficulty and volume progressing incrementally. Sessions will last between 30 and 120 minutes.
62371665|NCT02950441|EXPERIMENTAL|Nicotinamide Riboside|1000mg (2x250mg tablets twice daily)
62371666|NCT02950441|PLACEBO_COMPARATOR|Placebo|Two tablets twice daily
62371667|NCT03693352||Patients undergoing surgeries|Patients ASA 1-3, undergoing different types of general anesthesia that need postural changes like Trendelenburg and anti-Trendelenburg positioning.
62371668|NCT02541500|EXPERIMENTAL|Minocycline|Patients in this arm will receive oral minocycline
62371669|NCT00149890|EXPERIMENTAL|With Intraoperative Steroids|Intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was \<35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab was administered as an intravenous bolus injection within 8 hours after reperfusion of the graft.
62371670|NCT00149890|ACTIVE_COMPARATOR|Without Intraoperative Steroids|No intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was \<35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab and the first dose of steroids had to be administered within 8 hours after reperfusion of the graft and basiliximab was given as an intravenous bolus injection.
62371671|NCT02768844|EXPERIMENTAL|SVS vs Control|Prospective, within-subject design. Compare effects of mattress SVS (ON) and Control (SVS OFF) on physiology in opioid-exposed newborns. SVS is alternated in intervals between continuous stimulation (ON) and no stimulation (OFF/Control) throughout inter-feed intervals. The order of the ON-OFF cycles is randomized across subjects and counterbalanced between feeding periods within subjects.
62371672|NCT04774913|EXPERIMENTAL|Invest CTO PCI|A pre-planned two staged procedure in high-risk CTO PCI
62371673|NCT02967640|EXPERIMENTAL|Ketalar|ketalar injection, subacromial
62371674|NCT02967640|PLACEBO_COMPARATOR|Placebo|physiological sodium chloride (NaCl 9%) injection, subacromial
62371675|NCT00985738|EXPERIMENTAL|Dutasteride|The drug, Dutasteride, will be administered at 0.5 mg dose and given everyday (QD), for 3 months.
62371676|NCT00985738|PLACEBO_COMPARATOR|Placebo|The placebo group will receive a placebo drug for 3 months, instead of the intervention drug, Dutasteride.
62371677|NCT00431223|ACTIVE_COMPARATOR|Active Group|7 patients were assigned to Cognitive Remediation Therapy..
62371678|NCT00431223|NO_INTERVENTION|Control Group|4 patients were assigned to Control group or no cognitive remediation therapy.
62371679|NCT01372813|OTHER|Clear Cell Renal Carcinoma|Clear cell renal cancer is a highly vascular tumor characterized by mutations in the von Hippel-Lindau (VHL) gene in the majority of patients, an alteration that leads to overexpression vascular endothelial growth factor (VEGF) as well as other genes such as transforming growth factor-alpha, platelet derived growth factor and glucose transporter 1. Patients received ZD6474 300 mg/day by mouth daily on days 1-28.
62371680|NCT03253029|EXPERIMENTAL|Treatment|(arm 1) consume five scoops total per day of Pure Encapsulations Branched Chain Amino Acid powder on an outpatient basis (take 2 scoops both in the morning and afternoon and 1 scoop in the evening)
62371681|NCT03253029|PLACEBO_COMPARATOR|Control|(arm 2): control group (no BCAAs provided)
62371682|NCT01866813|NO_INTERVENTION|Waiting list control group|Waiting list control group who is offered cognitive training at the end of the data collection period.
62371683|NCT01866813|EXPERIMENTAL|Cognitive training intervention group|"Cognitive training intervention group: 6 weeks of intervention with the online cognitive training scientific brain training pro for 40-60 minutes a day/ 5 days a week. Reminders and motivational phone-calls throughout the intervention period. Phone and Internet-based technical support is available."
62371684|NCT06287658|EXPERIMENTAL|Experimental|Kegel exercises and Ba Duan Jin applications will be applied to women in the experimental group online (via Zoom application) in two sessions per week for a total of 8 weeks. Afterwards, women will be asked to perform these practices three days a week for 12 weeks and will be monitored. The research will last a total of 16 weeks.
62371685|NCT06287658|ACTIVE_COMPARATOR|Control|Women in the control group will be given training on Kegel exercises and Ba Duan Jin applications after the research is completed.
62744267|NCT06019039||Epidural Ultrasound group|After placement of the epidural catheter, parasagittal and transverse views with CFD will be obtained to identify location of the catheter within the epidural space. Two levels above and below the insertion site will be used to locate the epidural catheter.
62744268|NCT01236066||Study Group|Australian children aged \< 5 years who have been vaccinated with RotaTeq or Rotarix from 2007 to 2009 as well as all children aged \< 5 years hospitalised for all-cause gastroenteritis, rotavirus gastroenteritis or bronchiolitis.
62371686|NCT01069809|EXPERIMENTAL|AGS-004|HIV-1 Immune Therapy
62371687|NCT01069809|PLACEBO_COMPARATOR|Inactive Injection|Inactive Placebo Injection
62371688|NCT04140682|EXPERIMENTAL|PAV+ mode|Weaning with PAV+ mode
62371689|NCT04140682|ACTIVE_COMPARATOR|PSV mode|Weaning with PSV mode
62744269|NCT06607497|EXPERIMENTAL|Arm 1|In arm 1, participants will attend the risk communication session utilizing AI module (PERDICT.AI) delivered by the study team integrated with Home-based Diabetes Monitoring (PTEC-DM) providing personalized guidance through teleconsultation in addition to usual care. Screen activity of PERDICT.AI will be recorded using a screen capture software. The entire session will be audio recorded.
62744270|NCT06607497|EXPERIMENTAL|Arm 2|In arm 2, participants will attend the risk communication session utilising AI module (PERDICT.AI) without PTEC-DM. Screen activity of PERDICT.AI will be recorded using a screen capture software. The entire session will be audio recorded.
62744271|NCT06607497|NO_INTERVENTION|Arm 3|Arm 3 will be the active control group, receiving only standard care
62744272|NCT04135560|EXPERIMENTAL|Part A Cohort 1 (1% Body Surface Area)|Each participant in this cohort will receive both PF-07038124 0.06% and vehicle applied to the skin (1% Body Surface Area)
62371690|NCT04548479|ACTIVE_COMPARATOR|PEP group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Positive expiratory pressure (PEP) breathing
62371691|NCT04548479|NO_INTERVENTION|INS group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Inspiratory incentive spirometry breathing
62371692|NCT02415595|EXPERIMENTAL|Arm 1: BMS-955176 60 mg + TDF/FTC|BMS-955176 at 60 mg active dose per day + BMS-955176 placebo matching 120 mg + efavirenz (EFV) placebo matching 600 mg + tenofovir/emtricitabine (TDF/FTC) 300/200 mg per day, orally
62371693|NCT02415595|EXPERIMENTAL|Arm 2: BMS-955176 120 mg + TDF/FTC|BMS-955176 placebo matching 60 mg + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC 300/200mg per day, orally
62371694|NCT02415595|EXPERIMENTAL|Arm 3: BMS-955176 180 mg + TDF/FTC|BMS-955176 at 60mg active dose per day + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC at 300/200mg per day, orally
62371695|NCT02415595|ACTIVE_COMPARATOR|Arm 4: EFV + TDF/FTC|BMS-955176 placebo matching 60mg + BMS-955176 placebo matching 120mg + EFV at 600mg per day + TDF/FTC 300/200mg per day
62371696|NCT00096824||1|Participants will undergo neurological examinations and neuropsychological assessments at entry to both steps of ACTG A5175 and before the administration of the new antiretroviral regimen, then every 24 weeks until they discontinue ACTG A5175. Physicians will make targeted diagnoses at each study visit.
62371697|NCT05312268|OTHER|Group A|Rasburicase treatment at week 1, 4 and 8 with stable dose oral urate-lowering therapy for 24 weeks.
62371698|NCT05312268|OTHER|Group B|Rasburicase treatment at week 12, 16 and 20 with stable dose oral urate-lowering therapy for 24 weeks.
62744273|NCT04135560|EXPERIMENTAL|Part B Cohort 1 (10% Body Surface Area)|
62744274|NCT04135560|EXPERIMENTAL|Part B Cohort 2 (10% Body Surface Area)|
62744275|NCT04135560|EXPERIMENTAL|Part B Cohort 3 (10% Body Surface Area)|
62744276|NCT04135560|EXPERIMENTAL|Part B Cohort 4 (10% Body Surface Area)|
62744277|NCT04135560|EXPERIMENTAL|Part B Cohort 5 (20% Body Surface Area)|
62744278|NCT04135560|EXPERIMENTAL|Part B Cohort 6 (10% Body Surface Area)|Optional cohort of Japanese participants
62371699|NCT02056756|EXPERIMENTAL|CBD|
62371700|NCT00760890|EXPERIMENTAL|A|Medicinal Iron
62371701|NCT00760890|EXPERIMENTAL|B|Iron fortified wet pack cereal
62371702|NCT00760890|NO_INTERVENTION|C|Control
62371703|NCT03751072||Relapse/Refractory|
62371704|NCT03751072||MRD positive|
62371705|NCT03726541|EXPERIMENTAL|Early physiotherapy group|breathing exercise incentive spirometry training ambulation coughing
62371706|NCT03116841|EXPERIMENTAL|Vonoprazan 20 mg|Vonoprazan 20 mg orally administered once daily
62371707|NCT01855490|EXPERIMENTAL|Single-arm treatment with Exenatide|Exenatide 5 mcg sc. injection 15 minutes prior to a MMTT and IVGTT
62371708|NCT01770119|EXPERIMENTAL|MMR vaccination|MMR vaccine to seronegative pediatric SOT recipients
62371709|NCT05307523|EXPERIMENTAL|Enriched Environment Play With Harness Support|Enriched environment play, movement, and exploration for children with Down Syndrome while using a portable partial body weight support harness to facilitate movement and exploration.
62371710|NCT05307523|ACTIVE_COMPARATOR|Enriched Environment Play Without Harness Support|Enriched environment play, movement, and exploration without additional partial body weight support provided.
62371711|NCT02608294|EXPERIMENTAL|Experimental Group|Kinesio Taping Procedure application with 35% strain.
62371712|NCT02608294|SHAM_COMPARATOR|Sham Group|Kinesio Taping Sham procedure application without strain.
62371713|NCT04639505||ELISA|ELISA kit detecting the serum AMH level
62371714|NCT04639505||Chemiluminescence|CLIA method detecting the serum AMH level
62371715|NCT05723874|EXPERIMENTAL|Period 1 (Reference treatment (R)): BI 425809|
62371716|NCT05723874|EXPERIMENTAL|Period 2 (Test treatment (T)): bosentan + BI 425809|
62371717|NCT04430868|EXPERIMENTAL|LRP group|The participants in LRP group receive lifestyle redesign program plus treatment as usual. The LRP intervention consisted of one 90-minute session each week for 10 weeks
62371718|NCT04430868|NO_INTERVENTION|TAU group|The participants in TAU group received usual treatment at the same time as LRP group.
62371719|NCT02745041|EXPERIMENTAL|Fibrinogen Concentrate|Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm \[FIBTEM ≤ A5 10mm\]
62371720|NCT02745041|ACTIVE_COMPARATOR|Cryoprecipitate|Fibrinogen replacement using Cryoprecipitate as per ROTEM guided treatment algorithm \[FIBTEM A5 ≤ 10mm\]
62371721|NCT06000761|ACTIVE_COMPARATOR|Group 1|Standardized oral care performed every 3-4 hours using human milk, donor or breast milk.
62371722|NCT06000761|ACTIVE_COMPARATOR|Group 2|Standardized oral care performed every 3-4 hours using sterile water.
62371723|NCT06000761|ACTIVE_COMPARATOR|Group 3|Standardized oral care performed every 12 hours using sterile water.
62371724|NCT02513394|EXPERIMENTAL|Arm A|Palbociclib at a dose of 125 mg orally once daily, Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle for a total duration of 2 years, in addition to standard adjuvant endocrine therapy for a duration of at least 5 years.
62371725|NCT02513394|OTHER|Arm B|Standard adjuvant endocrine therapy for a duration of at least 5 years.
62744279|NCT04300361||Non-Western patients|Patients of non-Western descent with an indication for treatment with fluoropyrimidine-based chemotherapy. A patient is classified as non-Western if a one (1) of the parents or more than two (\>2) of the grand parents are of non-Western descent.
62371726|NCT01720693|EXPERIMENTAL|hypoperfusion|Hypoperfusion of the renal artery
62371727|NCT01951872|EXPERIMENTAL|Immediate treatment|Immediate manual-based treatment for caffeine dependence: administered within approximately one week following intake.
62371728|NCT01951872|EXPERIMENTAL|Delayed treatment|Delayed manual-based treatment for caffeine dependence: administered within approximately six weeks following intake.
62371729|NCT03134469|EXPERIMENTAL|Probiotics|Intake of a probiotic capsule once daily
62371730|NCT03134469|PLACEBO_COMPARATOR|Placebo|Intake of a placebo capsule once daily
62371731|NCT00628134|EXPERIMENTAL|1|Subjects inhaled calfactant then isotonic saline
62371732|NCT00628134|EXPERIMENTAL|2|Subjects inhaled isotonic saline then calfactant
62371733|NCT01318421|EXPERIMENTAL|ELND002|ELND002 sc injection
62371734|NCT06167772|EXPERIMENTAL|Branched-chain Amino Acid (BCAA) group|"branched-chain amino acid (bcaa) (ratio valine:leucine:isoleucine = 1.2:2:1) 40 g/day (leucine 19 g/day) form: powdered bcaa sealed in 8 g sachet package or bcaa parenteral 250 mL per bag.~frequency: 1 sachet bcaa dissolved in oral nutrition supplement (standard nutrition) 5 times per day, or bcaa parenteral, or combination of bcaa enteral \& parenteral.~duration: 10 days standard nutrition: oral nutrition supplement (high protein) or parenteral with target energy of 20 kcal/kg BW/day standard neuromuscular electrical stimulation 30 minutes per day"
62371735|NCT06167772|PLACEBO_COMPARATOR|Control group|No placebo. Not given intervention product. standard nutrition: oral nutrition supplement (high protein) or parenteral with target energy of 20 kcal/kg BW/day standard neuromuscular electrical stimulation 30 minutes per day
62371736|NCT03929406|EXPERIMENTAL|Brain Tissue Imprint|Evaluation and validation of the samples collected during the brain tissue imprint procedure using a CE marked Medical Device in patients presenting one of the following five disorders: Parkinson's disease (PD), essential tremor (ET), dystonia (DYS), Obsessive compulsive disorder (OCD) and Tourette Syndrome (TS).
62371737|NCT05108961|EXPERIMENTAL|Acupuncture arm|One session of acupuncture with precise acupuncture points
62371738|NCT05108961|SHAM_COMPARATOR|Sham acupuncture arm|One session of sham acupunture (needles inserted 1 mm, outside the acupuncture points)
62371739|NCT05108961|PLACEBO_COMPARATOR|Control arm|One session where no needles are inserted, the subject lies down under the same conditions as group 1 and 2
62371740|NCT06376435||Single drug group|
62371741|NCT06376435||combined rhTPO group|
62371742|NCT06376435||combined IL-11 group|
62371743|NCT03185923|EXPERIMENTAL|TCM plus conventional drug|The experimental group will receive three type of TCM inaddition conventional drug according to china CAP guidline 2016.
62371744|NCT03185923|PLACEBO_COMPARATOR|TCM placebo plus conventional drug|The control group will receive three type of placebo TCM inaddition conventional drug according to china CAP guidline 2016.
62744280|NCT06523218|EXPERIMENTAL|MindMD Supplement|Participants in the experimental group will receive the MindMD supplement, which contains the following ingredients: 600 mg Bacopa monnieri (Bacognize®), 250 mg Cognigrape® Grape Extract, 100 mg Phosphatidylserine, 50 mg Green Tea Leaf Extract, 1.7 mg Vitamin B6, and 200 mcg Folate (120 mcg folic acid).
62371745|NCT06030804|EXPERIMENTAL|Dexmedetomidine group|A loading dose of dexmedetomidine (0.6 μg/kg) will be administered over 10-15 minutes before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/h till 1 hour before the end of surgery. Patient-controlled dexmedetomidine supplemented sufentanil analgesia will be provided after surgery: the formula contains a mixture of sufentanil (1.25 μg/ml) and dexmedetomidine (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
62371746|NCT06030804|PLACEBO_COMPARATOR|Control group|Volume-matched normal saline will be administered in the same rate and volume for the same duration as in the dexmedetomidine group during anesthesia. Patient-controlled sufentanil analgesia will be provided after surgery: the formula contains sufentanil (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
62744281|NCT06523218|PLACEBO_COMPARATOR|Placebo|Participants in the placebo group will receive a placebo, which contains rice flour encapsulated in a vegetable cellulose capsule.
62744282|NCT01940367|ACTIVE_COMPARATOR|PTNS Arm|Subjects randomized to the PTNS arm will undergo PTNS treatment once weekly for 30 minutes for 12 weeks total. If at 12 weeks they are considered to have a positive response to therapy, they will continue maintenance therapy in a tapered fashion: subjects will come in every 2 weeks for the next 8 weeks for 30 minute treatments (4 visits total), then every 3-4 weeks for 30 minute treatments for the remaining 32 weeks of the year (8-10 visits).
62744283|NCT01940367|ACTIVE_COMPARATOR|TENS Arm|Subjects randomized to the TENS arm of the study will begin therapy after their baseline evaluation is complete. They will be issued a home TENS device (EMPI TENS Select) and will administer self-treatment daily for 2 hours per day (1 hour in the morning and 1 hour in the evening) for a total of 12 weeks. If they are considered to have a positive response with TENS treatment, subjects will continue by weaning use over a three-month time period. They will begin with 3 x per week for 1 month, then 2 x per week for 1 month, then 1 x per week for 1 month, all at 2 hours per day.
62744284|NCT05528653|OTHER|Open Label Descovy|Descovy for PrEP
62371747|NCT01074840|ACTIVE_COMPARATOR|Peanut|Peanut flour will be given in increasing amounts.
62744285|NCT02483156|ACTIVE_COMPARATOR|SOF + RBV|Sofosbuvir 400 mg once daily +RBV (1000 mg/day) for 12-24 weeks
62371748|NCT01074840|NO_INTERVENTION|Control|Subjects will be enrolled who meet the inclusion/exclusion criteria and followed as matched controls. These subjects will not receive any treatment.
62744286|NCT02483156|EXPERIMENTAL|sof + RBV + AH|Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg for 12-24 weeks
62744287|NCT05436535|EXPERIMENTAL|Dupilumab-naïve atopic dermatitis participants|"On Day 7, dupilumab-naïve AD participants will begin applying topical corticosteroids twice daily to their specified target area, as well as to active lesions on non-target skin.~Dupilumab-naïve AD participants will return for a Steroid Assessment Visit at Day 35, when response to topical corticosteroids will be evaluated at the target site by TAA and targeted EASI scoring, and overall management of AD body-wide by topical steroid/moisturizer treatment will be evaluated by EASI score.~Participants who are responsive to topical corticosteroids will continue to use them body-wide through Day 140. Participants who are non-responsive to topical corticosteroids at any time before Day 91 will begin use of dupilumab through their penultimate scheduled visit (Day 140-Day 196) and may continue use of topical corticosteroids outside of their specified target area as needed."
62744288|NCT05436535|EXPERIMENTAL|Experienced Dupilumab atopic dermatitis participants|"AD participants already on dupilumab (for \>= 4 months prior to study entry (20 children, 40 adults)) at the start of the study will continue treatment with dupilumab as prescribed by their physician outside of the study. They may also continue treatment with other prescribed topical AD medications outside of the specified target skin area throughout the study; they may continue treatment with other prescribed topical AD medications within the specified target area from Day 7 through Day 140.~Long-term dupilumab participants will apply Vanicream™ beginning at Day 0 through Day 7. Long-term dupilumab participants will return for assessment visits at Day 63 and 140. At Day 140, participants will resume application of Vanicream™ through the End of Study Assessment (Day 168)."
62744289|NCT05436535|ACTIVE_COMPARATOR|Non-atopic dermatitis participants|Approximately 150 will be non-AD controls (including approximately 50 children, 6-17 years of age, and 100 adults, = 18 years of age) Non-AD control participants will apply Vanicream™ beginning at Day 0 through Day 7. Non-AD control participants will return for assessment visits at Day 35, 91, and 140. At Day 140, participants will resume application of Vanicream™ through the End of Study Assessment (Day 168).
62744290|NCT05623787|EXPERIMENTAL|DWI-High Risk|Patients to undergo DWI-MRI (patients included in the study).
62744291|NCT01378702|EXPERIMENTAL|Iscucin populi strength F, G and H|1 ampoule two times/week subcutaneously. Week 1-4: strength F. Week 5-8: strength G. Week 9-12: strength H.
62744292|NCT01378702|EXPERIMENTAL|Viscum Mali e planta tota D3, D2, 2%|1 ampoule two times a week subcutaneously. Week 1-4: D3. Week 4-8: D2. Week 9-12: 2%.
62744293|NCT01378702|PLACEBO_COMPARATOR|Placebo|1 ampoule two times a week subcutaneously
61986287|NCT03479476|ACTIVE_COMPARATOR|Active Metformin Medication|The active metformin medication will be dosed in a weight-dependent manner. Liquid metformin (100mg/cc) will be provided to any participants unable to swallow the metformin capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
62744294|NCT02056886|EXPERIMENTAL|OSNA|"Intra operative sentinel lymph-node sampling. In this experimental arm, the molecular biology technique is only used through the OSNA technique (One Step Nuclear Acid analysis), and no other classical pathology's diagnosis method such as formalin fixation, then parraffin embedding before slices cutting, hematoxylin-eosin-safran staining or any other immunohistochemical stainings.~According to the results of the staging procedure, the treatment in this arm is decided in conformity with local and national guidelines in breast cancer treatments.~SLN detection +/- complementary axillary lymphadenectomy is immediately decided if a tumor invasion is detected within the sentinel LN material."
61986288|NCT00725556|OTHER|1|Speech therapy
62371749|NCT03746145|EXPERIMENTAL|Bifidobacterium longum 1714|Participants consume one 2g sachet containing 10e11 colony-forming units Bifidobacterium longum 1714 strain with maltodextrin and magnesium stearate on a daily basis over 1 year.
62371750|NCT03746145|EXPERIMENTAL|Placebo|Participants consume one 2g placebo sachet containing maltodextrin and magnesium stearate.
62371751|NCT00863317|EXPERIMENTAL|montelukast sodium|4mg granules PO QD for 14 days
62371752|NCT00863317|PLACEBO_COMPARATOR|Placebo|Sucrose granules PO QD for 14 days
62371753|NCT04130100|EXPERIMENTAL|Low Dose of Mesenchymal stem cell|Patients receiving intraarticular injection of low dose of mesenchymal stem cells.
62371754|NCT04130100|EXPERIMENTAL|High Dose of Mesenchymal stem cell|Patients receiving intraarticular injection of high dose of mesenchymal stem cells.
62371755|NCT04130100|ACTIVE_COMPARATOR|Sodium Hyaluronate|Patients receiving intraarticular injection of Sodium Hyaluronate
62371756|NCT01905904|ACTIVE_COMPARATOR|sevorane|Sevorane 4% concentration during anesthesia induction
62371757|NCT01905904|ACTIVE_COMPARATOR|sevorane %7|Sevorane 7% concentration during anesthesia induction
62371758|NCT03080532||european population|
62371759|NCT04930172||Steerable introducers|
62371760|NCT00964639|PLACEBO_COMPARATOR|Saline|
62371761|NCT00964639|ACTIVE_COMPARATOR|Naropin|
62371762|NCT05493436||normoweight|GERD patient with normoweight was evaluating by MII pH-meter
62371763|NCT05493436||obesity|GERD patient with obesity was evaluating by MII pH-meter
62371764|NCT03687476|EXPERIMENTAL|VTS-270 (Part A)|VTS-270 200 milligram per milliliter (mg/mL) will be administered intrathecally by lumbar puncture every 2 weeks followed by dose escalation of 100 mg/mL increments up to a maximum tolerable dose of 900 mg/mL. The highest tolerable dose is considered as clinically relevant dose which will be administered throughout the remaining duration of the 20-week treatment period of Part A.
62371765|NCT03687476|EXPERIMENTAL|VTS-270 (Part B)|VTS-270 200 mg/mL will be administered intrathecally by lumbar puncture every 2 weeks in Part B followed by a re-challenge to dose escalation of 100 mg/mL increments up to a maximum tolerable dose of 900 mg/mL. In case of intolerance, the dose should be returned to previously tolerable dose and should be continued throughout the duration of Part B (end of study).
62371766|NCT02029391|ACTIVE_COMPARATOR|Myofascial pain syndrome patients|Manual pressure release only
61986289|NCT00600938|EXPERIMENTAL|Deferasirox|20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
61986290|NCT00600938|ACTIVE_COMPARATOR|Deferasirox Placebo|50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
61986291|NCT00600938|EXPERIMENTAL|Extension: deferoxamine to deferasirox|"DFO to ICL (patients who switched from DFO to deferasirox in extension)"
62371767|NCT02029391|EXPERIMENTAL|Myofascial pain syndrome|One session of manual pressure release and kinesio tape
62371768|NCT02907411|EXPERIMENTAL|Quadrivas Therapy|Hands on therapy to improve all aspects of fat tissue including the vessels within. Each of 7 subjects receive 12 treatments in one month time.
62371769|NCT01966276|EXPERIMENTAL|Methyl-P plus Nutrient Formula|"Methylphenidate hydrochloride plus a CFS Nutrient Formula, both taken twice daily.~The CFS Nutrient Formula is a broad-spectrum CFS-specific dietary supplement that provides CFS patients with cellular fuel and cofactors (amino acids, antioxidants, and mitochondrial cofactors) while the low-dose CNS stimulant (methylphenidate hydrochloride) provides a metabolic catalyst to enhance cellular metabolism."
62371770|NCT01966276|PLACEBO_COMPARATOR|Methyl-P plus Nutrient matched placebos|Methylphenidate matched placebo + CFS Nutrient Formula matched placebo, both taken twice daily.
62371771|NCT01748006||Blood and urine samples|
61986292|NCT00600938|EXPERIMENTAL|Extension: deferasirox to deferoxamine|"ICL to DFO (patients who switched from deferasirox to DFO in extension)"
62371772|NCT01665898|ACTIVE_COMPARATOR|Cold biopsy forceps|Cold biopsy forceps for removal of colon polyps
62371773|NCT01665898|ACTIVE_COMPARATOR|Cold Snare Biopsy|Cold snare biopsy for removal of colon polyps
62371774|NCT04705168||Participants displaying nevi|"Participants displaying a phenotype that consists of ≥ 100 nevi on the entire cutaneous surface and at least three large acquired nevi (LAN) \> 5 mm in diameter. These patients have atypical mole syndrome, which is a high-risk nevus phenotype and the target patient population in this study."
62371775|NCT03016039|EXPERIMENTAL|Dietary supplementation|This group will receive Dietary supplementation
62371776|NCT03016039|NO_INTERVENTION|conventional treatment|conventional Antibiotic treatment without curcumin supplementation
62371777|NCT04171167|ACTIVE_COMPARATOR|Frequently treated acute rhino sinusitis|Does not meet the European position paper criteria of CRS: asymptomatic periods in between and no objective findings when entering the study.
62371778|NCT04171167|ACTIVE_COMPARATOR|CRSsNP|Meets the European position paper criteria of CRS. Zinreich modification of Lund-Mackey scoringing: Opacification score \< 21 and obstruction score 0-8. No visible nasal polyps in endoscopy
62371779|NCT04171167|ACTIVE_COMPARATOR|Severe CRSsNP and CRSwNP|Meets the European position paper criteria of CRS and not included in the first two groups.
62371780|NCT04171167|NO_INTERVENTION|Healthy volunteers|No nasal symptoms or complaints. No interventions done.
62744295|NCT02056886|OTHER|PATHOLOGICAL ANALYSIS|"No intra operative examination is performed in this arm, but the final pathological examination:~In this arm, the classical pathology's diagnosis method is starting with a formalin fixation of suspected invaded lymph-nodes sampling at least 24Hrs; then parraffin embedding before slices cutting; then hematoxylin-eosin-safran staining or any other immunohistochemical stainings.~According to the results of the staging procedure, the treatment in this arm is decided in conformity with local and national updated guidelines in breast cancer treatments.~SLN detection +/- complementary axillary lymphadenectomy: is decided in a second surgical step when the pathologic analysis has detected a tumor invasion"
62744296|NCT02056886|OTHER|EXTEMPORANEOUS|"Intra-operative pathological frozen sections of sentinel LN samples are coloured and examined immediately by the pathologist, allowing an immediate result at the disposal of the surgeon who can decide to complete by an axillary LN dissection or not.~Then the remaining material will be prepared similarly as in the pathological classical method (Arm B), ie formalin fixation, then parraffin embedding, then slices cutting, then HES staining or ImmunoHistochemistry for a final diagnosis.~SLN detection +/- complementary axillary lymphadenectomy: is decided immediately when the tumor invasion is detected in the sentinel LN material."
62744297|NCT06380322||Active-duty Army Service Members|All measures will be collected one time during the study, except for the dietary recall (measured two times).
62744298|NCT04403152|EXPERIMENTAL|Rehabilitation group|This is the study group in whom post-operative rehabilitation was provided for 5 days.
62744299|NCT04403152|ACTIVE_COMPARATOR|Mobilization group|This is the control group in whom post-operative mobilization was provided for 5 days.
62744300|NCT03471338|EXPERIMENTAL|Experimental Group|Patients benefit cognitive rehabilitation
62744301|NCT03471338|SHAM_COMPARATOR|Standard Psychological care|Patients do not benefit cognitive rehabilitation
62744302|NCT04319029|NO_INTERVENTION|Non-intervention|Patients received a conventional pharmaceutical care plan, the patients offered optimal pharmacological therapy wit statin.
62744303|NCT04319029|ACTIVE_COMPARATOR|Intervention|The Patients offered to predesign pharmaceutical care plans aimed to improved patient's knowledge, adherence, satisfaction, and quality of life. The patients offered optimal pharmacological therapy wit statin.
62744304|NCT03453619|EXPERIMENTAL|APL-2|Open Label, Study Drug, APL-2
62744305|NCT00322452|EXPERIMENTAL|1|gefitinib
62744306|NCT00322452|ACTIVE_COMPARATOR|2|Carboplatin/Paclitaxel
61986293|NCT01317745|PLACEBO_COMPARATOR|Group 5|Two doses of sanofi H5N1 antigen 7.5 mcg plus PBS diluent
62371781|NCT04259034||systemically healthy individuals with oral lichen planus|systemically healthy individuals diagnosed with oral lichen planus on clinical and histopathological basis.
62744307|NCT05598944|EXPERIMENTAL|UGRComp group|This arm will instruct the students on the Más Presente program. This is a socio-emotional competence-based program which has been designed following the European LifeComp framework. This program is a combination of theory and practice aimed at developing the core elements of personal, social and learning to learn key competences for lifelong learning.
62744308|NCT05598944|EXPERIMENTAL|MBSR group|This arm will instruct the students on the Mindfulness-Based Stress Reduction (MBSR) program. The MBSR is a secular, evidence-based practice originally developed for chronic pain, but which has reported positive results among an array of clinical and nonclinical populations. This program aims to cultivate non-judgmental attention to and awareness of present moment experience while promoting stress reduction.
62744309|NCT05598944|ACTIVE_COMPARATOR|Neuro-muscular stimulation group|The students in this arm will receive training on physical wellbeing and neuro-muscular stimulation. Non-specific factors such as number and duration of sessions, or instructor training and qualifications will match the other 2 experimental groups. Active ingredients such as mindfulness or socio-emotional training are not contained in the program.
61986294|NCT01317745|PLACEBO_COMPARATOR|Group 4|Two doses of sanofi H5N1 antigen 3.75 mcg plus Phosphate Buffered Saline (PBS) diluent
61986295|NCT01317745|EXPERIMENTAL|Group 3|Two doses of sanofi H5N1 antigen 15 mcg plus Novartis MF59 adjuvant
61986296|NCT01317745|EXPERIMENTAL|Group 2|Two doses of sanofi H5N1 antigen 7.5 mcg plus Novartis MF59 adjuvant
62744310|NCT00467194|EXPERIMENTAL|Phase I study of rapamycin and bevacizumab|"Rapamycin (available as 1mg per tablet; Wyeth) will be given orally once in the morning before meal. The starting dose of rapamycin will be 1mg administered once daily. All doses of rapamycin will be preceded by an oral loading dose three times the maintenance dose on day 1. The dose of rapamycin will be increased at each dose level.~Bevacizumab (100mg/4ml; Roche) will start concurrently with rapamycin. It will be diluted in a total of 100ml of 0.9% sodium chloride given via intravenous injection. The first dose will be infused over 90 minutes. If the first infusion is tolerated without any adverse infusion-related events (fever and/or chills), the second infusion may be delivered over 60 minutes. If the 60- minute infusion is well tolerated, the subsequent doses may be delivered over 30 minutes."
62371782|NCT04259034||systemically healthy individuals without oral lichen planus|systemically healthy individuals without any clinical feature of oral lichen planus.
62371783|NCT00554528|OTHER|A|patient receiving cervical disc prosthesis with a mobile insert named Mobi-C and product by LDR médical
62371784|NCT00554528|OTHER|B|patient receiving intersomatic cage
62371785|NCT02630485|EXPERIMENTAL|Graceful Lifestyle Changes & MYO|"The 12-week lifestyle intervention will incorporate three lifestyle changes: a low-glycemic diet, increased exercise, and stress reduction through meditation and mindfulness.~In addition, this group will take myo-inositol (6 grams in juice or water every morning)."
62371786|NCT02630485|EXPERIMENTAL|Graceful Lifestyle Changes|"The 12-week lifestyle intervention will incorporate three lifestyle changes: a low-glycemic diet, increased exercise, and stress reduction through meditation and mindfulness.~In addition, this group will take a white powder placebo (6 grams in juice or water every morning)."
62371787|NCT02630485|PLACEBO_COMPARATOR|Letrozole & MYO|"The women assigned to the fertility medication group will be prescribed letrozole. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.~In addition, this group will take myo-inositol (6 grams in juice or water every morning)."
62371788|NCT02630485|PLACEBO_COMPARATOR|Letrozole|"The women assigned to the fertility medication group will be prescribed letrozole. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.~In addition, this group will take a white powder placebo (6 grams in juice or water every morning)."
62371789|NCT00826709|EXPERIMENTAL|Arm 1|2 Nasal swabs
62371790|NCT00826709|EXPERIMENTAL|Arm 2|2 Nasopharyngeal swabs
62371791|NCT00826709|EXPERIMENTAL|Arm 3|Nasal wash or aspirate
62371792|NCT00797706|PLACEBO_COMPARATOR|Vehicle|
62371793|NCT00797706|EXPERIMENTAL|Low dose|
62371794|NCT00797706|EXPERIMENTAL|High dose|
62371795|NCT06004193||Regular Exercisers|The group of regular exercisers includes individuals who engage in at least 150 minutes of exercise per week according to World Health Organization criteria.
62371796|NCT06004193||Non-exercisers|The group of non-exercisers includes individuals who do not have a habit of engaging in regular exercise.
62371797|NCT00357786|EXPERIMENTAL|A|Enzyme replacement for Fabry's Disease
62371798|NCT04708340|ACTIVE_COMPARATOR|Arm A: RJX|"1. RJX 20 mL (10 mL of Vial A plus 10 mL of Vial B) mixed in normal saline, total volume 120 mL, administered by IV infusion over a period of 40 minutes +/- 10 minutes once daily.~2. Standard of care (current antiviral and/or supportive care treatment currently in place at the institution for COVID-19 treatment).~3. Patients in Part 1 are allowed to receive only one 7-day cycle of RJX while patients in Part 2 may be treated daily for up to 14 days."
62371799|NCT04708340|PLACEBO_COMPARATOR|Arm B: Placebo|"1. Placebo (total of 20 mL normal saline) mixed in normal saline IV, total volume 120 mL of normal saline IV, administered by IV infusion over a period of 40 minutes +/- 10 minutes once daily.~2. Standard of care (current antiviral and/or supportive care treatment currently in place at the institution for COVID-19 treatment).~3. Patients in Part 1 will not receive placebo.~4. Patients in Part 2 may be treated daily for up to 14 days."
62371800|NCT05166486|EXPERIMENTAL|Calisthenic exercise|The patients in the calisthenic exercise group will be given one-to-one hands-on calisthenic exercises by the research physiotherapist. They will be asked to do these exercises 3 times a week for 8 weeks. Patients will be followed up by asking whether they do their exercises or not. They will be asked to do the exercises twice a month for 8 weeks under the control of a physiotherapist. In this way, it will be ensured that the exercises are done correctly and that the patients do it completely.
62371801|NCT05166486|NO_INTERVENTION|Control|Control
62371802|NCT02829606|ACTIVE_COMPARATOR|small scotoma using Head Mounted Display No re-mapping|patients with scotoma smaller than 5 degrees NO re-mapping PLUS re-mapping
62371803|NCT02829606|ACTIVE_COMPARATOR|Large scotoma using Head Mounted Display PLUS re-mapping|patients with scotoma larger than 5 degrees NO re-mapping PLUS re-mapping
62371804|NCT01038180||pacemaker group|
61986297|NCT01317745|EXPERIMENTAL|Group 1|Two doses of sanofi H5N1 antigen 3.75 mcg plus Novartis MF59 adjuvant
61986298|NCT01317745|PLACEBO_COMPARATOR|Group 6|Two doses of sanofi H5N1 antigen 15 mcg plus PBS diluent
62371805|NCT04916015||children (0-14 years)|
62371806|NCT04916015||AYAs (15-25 years)|
62371807|NCT03536273|EXPERIMENTAL|Functional Movement Screen|
62371808|NCT03536273|EXPERIMENTAL|Posture Analysis|
62371809|NCT03536273|EXPERIMENTAL|Depression Level|
62371810|NCT03536273|EXPERIMENTAL|Quality of Life|
62371811|NCT05829564|EXPERIMENTAL|virtual reality+Exercise|"An exercise program consisting of stretching exercises, posture exercises and breathing exercises and lasting approximately 20-30 minutes will be applied to the individuals in all 3 groups.~The virtual reality group will performe virtual reality for an additional 20 minutes. (Oculus GO)"
62371812|NCT05829564|EXPERIMENTAL|cervical mobilization+Exercise|"An exercise program consisting of stretching exercises, posture exercises and breathing exercises and lasting approximately 20-30 minutes will be applied to the individuals in all 3 groups.~Mobilization techniques that will mobilize the cervical region will be applied to the cervical mobilization group for 20 minutes."
62371813|NCT05829564|OTHER|Control|Control group will only perform an exercise program.
62371814|NCT03846089||Retrograde reperfusion|After completion of the inferior vena cava anastomosis, the clamps were removed to allow retrograde reperfusion of the graft.
62371815|NCT03846089||Antegrade reperfusion|After completion of the inferior vena cava anastomosis, the portal vein anastomosis is completed and then the clamps were removed to allow antegrade reperfusion of the graft.
62371816|NCT01922986|EXPERIMENTAL|Active rTMS with conventional therapy|20 minutes of active rTMS followed by conventional stroke therapy
62371817|NCT01922986|SHAM_COMPARATOR|sham rTMS with conventional therapy|20 minutes of sham rTMS stimulation followed by conventional stroke therapy
62371818|NCT02929381|EXPERIMENTAL|Innovative colonoscopy|Innovative colonoscopy performed using narrow band imaging and dual focus function (NBI + Dual Focus)
62371819|NCT02929381|ACTIVE_COMPARATOR|Conventional colonoscopy|Conventional colonoscopy performed without innovative techniques assessed in this study.
62744311|NCT02321787|NO_INTERVENTION|Traditional Methods of Assessment|The caudal block will be done using traditional means of assessment, not confirmed by ultrasound.
61986299|NCT00540345|ACTIVE_COMPARATOR|A, RVR LD RBV|Patients who have a RVR will be randomized into two groups with a ratio of 1:1 (Arm A \& B)B, RVR SD RBV A, RVR LD RBV B, RVR SD RBV
62371820|NCT01995786|NO_INTERVENTION|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour
62371821|NCT01995786|EXPERIMENTAL|GDT|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 2,5 ml/kg/h and boluses of crystalloids for values of stroke volume (SV) \< SV TRIGGER. Every additional infusion of colloids, blood derivates, drugs must be recorded
62371822|NCT03521401|EXPERIMENTAL|ACE - Exercise Group|Participants with ACE scores of 4 or higher who will undergo exercise training for the duration of the study (experimental).
62371823|NCT03521401|NO_INTERVENTION|ACE - Non-Exercise Group|Participants with ACE scores of 4 or higher who will not undergo exercise training for the duration of the study (+ control).
62371824|NCT03521401|NO_INTERVENTION|Non-ACE - Non-Exercise Group|Participants with ACE scores of 0 who will not undergo exercise training for the duration of the study (- control).
62371825|NCT06174116|PLACEBO_COMPARATOR|Placebo|
62371826|NCT06174116|EXPERIMENTAL|Lumateperone|
62371827|NCT03642275|EXPERIMENTAL|iCardia4HF|Participants will be using a heart failure mobile app, wearable activity tracking device, Bluetooth-enabled blood pressure monitor and weight scale for self-monitoring, and receive tailored text-messages about self-care.
62371828|NCT03642275|NO_INTERVENTION|Control Group|Participants assigned to the usual care group will receive standard medical care, which includes nurse-led patient education about HF self-care before discharge, and follow-up visits at the UI Health, outpatient Heart Failure program.
62371829|NCT03537183|NO_INTERVENTION|Usual activity level|12 weeks of usual activity level
62371830|NCT03537183|ACTIVE_COMPARATOR|Exercise training|12 weeks of moderate intensity exercise training, 3 hours a week
62371831|NCT03064165|EXPERIMENTAL|Obturator nerve block|Postoperative obturator nerve block with 15 mL bupivacain 5 mg/mL and epinephrine 5 µg/mL.
62371832|NCT03064165|PLACEBO_COMPARATOR|Sham block|Postoperative sham-block with normal saline.
62371833|NCT02422563|EXPERIMENTAL|Arm A: NACT+radical hysterectomy|Arm A includes patients for dose dense chemotherapy using TP (paclitaxel, carboplatin) or TIP (cisplatin, paclitaxel, ifosfamide) weekly for six cycles. Radical hysterectomy is performed after the 6th week + lymphadenectomy
62371834|NCT02422563|OTHER|Arm B: Chemoradiation|Arm B includes patients undergoing primary cisplatin based chemo-radiation
62371835|NCT02014545|ACTIVE_COMPARATOR|WBRT + Lucanthone|Treatment will consist of WBRT given in a dose of 30 Gy in ten fractions with lucanthone given as an adjunct. Lucanthone will be administered as 25 mg and 100 mg tablets to be swallowed. Dosage will be one of the following: 250 mg bid, 250 tid, or 375 mg tid.
62744312|NCT02321787|EXPERIMENTAL|Ultrasound for Confirmation|The caudal block will be performed utilizing ultrasound as an additional method of assessment for successful block (in addition to all traditional means of assessment).
61986300|NCT00540345|ACTIVE_COMPARATOR|B, RVR SD RBV|Patients who have a RVR will be randomized into two groups with a ratio of 1:1 (Arm A \& B)B, RVR SD RBV
62371836|NCT02014545|PLACEBO_COMPARATOR|WBRT + Placebo|Patients will receive prophylactic cranial irradiation at 3 Gy per fraction, 5 days per week, for 2 weeks to a total dose of 30 Gy.
62371837|NCT01836367|EXPERIMENTAL|Ingenol Mebutate 0.015%|two cycles of ingenol mebutate 0.015%
62744313|NCT01534936||Schizophrenic outpatients with affective symptoms.|
62371838|NCT01394211|EXPERIMENTAL|Neoadjuvant enzyme inhibitor therapy|"Patients receive pazopanib hydrochloride\* PO QD and anastrozole PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients then undergo therapeutic conventional surgery.~NOTE: \*Pazopanib hydrochloride is stopped 7-14 days before definitive surgery."
62371839|NCT00521118|EXPERIMENTAL|Treatment (second curettage)|Patients undergo a second curettage rather than standard treatment (immediate chemotherapy) within 14 days of registration.
62371840|NCT02159768|EXPERIMENTAL|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
62371841|NCT03745989|EXPERIMENTAL|MK-8353 and Selumetinib Dose Escalation|Participants will receive a combination MK-8353 and selumetinib for 4 days on and 3 days off until disease progression or discontinuation. MK-8353 will be escalated sequentially from 50 mg to 250 mg based on pharmacokinetic and safety data. Selumetinib will be escalated sequentially from 25 mg to 75 mg based on pharmacokinetic and safety data. Doses may be adjusted downward sequentially based on tolerability
62744314|NCT03394040||1|The study seeks individuals of all ages experiencing diarrhea from the Washington Metropolitan area
62371842|NCT05142176|PLACEBO_COMPARATOR|control group|will receive general anesthesia with bilateral sham erector spinae plane block at the level of T6 transverse process using 0.3 ml/kg normal saline on each side.
62371843|NCT05142176|ACTIVE_COMPARATOR|Erector spinae plane block group|will receive bilateral ultrasound-guided erector spinae plane block at the level of T6 transverse process using 0.3 ml/kg bupivacaine 0.25% (on each side) with a maximum dose of 2 mg/kg.
62371844|NCT06302608|EXPERIMENTAL|Dose level 1|Dose level 1 will be administered
62371845|NCT06302608|EXPERIMENTAL|Dose level 2|Dose level 2 will be administered
62744315|NCT04026009|EXPERIMENTAL|CDIFF Ag 18 - 45 Years Group|Healthy male and female subjects, aged between and including 18 and 45 years old, who receive CDIFF antigen (Ag) vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
62371846|NCT00732706|OTHER|Sartorius Twitch|Femoral Nerve detection using Sartorius Twitch
62371847|NCT00732706|OTHER|Quadriceps Twitch|Femoral Nerve detection using Quadriceps Twitch
62371848|NCT01362972||plerixafor + granulocyte colony stimulating factor (G-CSF)|Patients who receive plerixafor+granulocyte colony stimulating factor (G-CSF) for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
62371849|NCT01362972||plerixafor + G-CSF + chemotherapy|Patients who receive plerixafor+granulocyte colony stimulating factor (G-CSF)+chemotherapy for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
62371850|NCT01362972||granulocyte colony stimulating factor (G-CSF) + chemotherapy|Patients who receive granulocyte colony stimulating factor (G-CSF) + chemotherapy for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
62371851|NCT01362972||granulocyte colony stimulating factor (G-CSF) alone|Patients who receive granulocyte colony stimulating factor (G-CSF) alone for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
62371852|NCT05734014|EXPERIMENTAL|Intervention Group|The feasibility study includes a one-group pre/post intervention that includes 10-hour long sessions with youth to promote healthy relationship knowledge, volition, and communication skills. Elders and near-peer (young adults) will assist during these sessions sharing advice and serving as role models for youth. In addition, to promote the connectedness between youth and their community, there are 3 monthly clan feeds.
62371853|NCT03131011|EXPERIMENTAL|Arm 1 - UV ink|Radiotherapy tattoos will be applied using an invisible UV fluorescent ink that can only be detected while illuminated with a special ultraviolet flashlight.
62371854|NCT03131011|NO_INTERVENTION|Arm 2 - Black ink|Radiotherapy tattoos will be applied using standard black ink.
62371855|NCT05037955||ILIT from trial NCT00470457|Patients who received ILIT in the original trial in 2005
62371856|NCT05037955||SCIT from trial NCT00470457|Patients who received SCIT in the original trial in 2005
62371857|NCT05037955||SCIT outpatient control|Patients who visited the allergy unit at the University Hospital Zurich and completed SCIT in the last 5 years
62371858|NCT01877811|EXPERIMENTAL|RXDX-105|
62371859|NCT03607604||Autoantibody Negative|"Patients who are autoantibody negative (could potentially be either MODY or type 2 diabetes patients)~Suspected MODY patients will be candidates for next generation sequencing (NGS)"
62744316|NCT04026009|PLACEBO_COMPARATOR|Placebo 18 - 45 Years Group|Healthy male and female subjects, aged between and including 18 and 45 years old, who receive Placebo administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
62371860|NCT03607604||Diabetes Mellitus, Type 1|"Patients diagnosed with type 1 diabetes mellitus~Patients with positive UCPCR and negative autoantibodies results will be suspected with MODY and will be candidates for next generation sequencing (NGS)"
62371861|NCT03607604||Non Diabetic|Individuals not diagnosed with any type of diabetes (but could be diagnosed with IFG and/or IGT)
62371862|NCT05386004|EXPERIMENTAL|BSSC group|Participants in the experimental group were allowed to focus with BSSC during uterine contractions in the first stage of labor.
62744317|NCT04026009|EXPERIMENTAL|CDIFF Ag 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive CDIFF antigen (Ag) vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule. A third dose of CDIFF Ag vaccine is to be administered to a subcohort of subjects aged 50-70 years, approximately 15 months after the administration of the second dose.
62371863|NCT05386004|NO_INTERVENTION|control group|The participants in the control group were provided with routine care in the first stage of labor. No intervention was made.
62371864|NCT02466204|ACTIVE_COMPARATOR|corifollitropin alfa (long action FSH)|corifollitropin alfa 150 mcg subcutaneous injection. Seven days after, combines with recombinant FSH 300 IU daily subcutaneous injection
62371865|NCT02466204|ACTIVE_COMPARATOR|Follitropin Beta (recombinant FSH)|300 IU of recombinant FSH, daily subcutaneous injection
62371866|NCT02252588|EXPERIMENTAL|Chlorhexidine|Oral Rinse
62744318|NCT04026009|EXPERIMENTAL|CDIFF Ag + AS01B 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive CDIFF Ag + AS01B adjuvant vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule. A third dose of CDIFF Ag + AS01B adjuvant vaccine is to be administered to a subcohort of subjects aged 50-70 years, approximately 15 months after the administration of the second dose.
62371867|NCT02252588|PLACEBO_COMPARATOR|Placebo|Oral Rinse
62371868|NCT02725749|EXPERIMENTAL|Laser|
62371869|NCT02725749|EXPERIMENTAL|Exercise|
62371870|NCT02725749|EXPERIMENTAL|Laser and Exercise|
61986301|NCT00540345|ACTIVE_COMPARATOR|C, non-RVR 24w|For patients who do not have a RVR will be randomized into two groups with a ratio of 1:1 (Arm C \& D) (C, non-RVR 24w) (D, non-RVR 48w)
62371871|NCT01712191|EXPERIMENTAL|NUsurface Meniscus Implant|
62371872|NCT00471315|NO_INTERVENTION|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
62371873|NCT00641459||001|
62371874|NCT03688893|EXPERIMENTAL|Laser Application|35% Hydrogen Peroxide (Whitening HP, FGM SC Brazil) 40 minutes divided in two phases of 20 minutes each one (5 minutes colocation, 10 minutes Laser Application and 5 minutes moving the product) from premolar to premolar in superior and inferior teeth. Experimental
62744319|NCT04026009|PLACEBO_COMPARATOR|Placebo 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive Placebo administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
62371875|NCT03688893|NO_INTERVENTION|No Laser Application|35% Hydrogen Peroxide (Whitening HP FGM SC Brazil), 40 minutes divided in two phases of 20 minutes each one (5 minutes colocation, 10 minutes waiting and 5 minutes moving the product) from premolar to premolar in superior and inferior teeth. No Laser Application No Intervention
62371876|NCT03644381|NO_INTERVENTION|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
62371877|NCT03644381|EXPERIMENTAL|Treatment|Following randomization, participants in this group will receive escalating doses milk, up to a daily dose of 200 ml. Once they attain that dose, they will maintain it for one month. At the end of this period, they will undergo a open challenge to 300 ml of milk. They will then enter a year-long follow-up period
62371878|NCT04308408|ACTIVE_COMPARATOR|Mexican Guideline Daily Allowance (GDA)|Guideline Daily Amounts (GDA) is a purely numerical and reductive labeling system, indicates the grams and percentages (according to the guideline-based daily intakes) per portion of kilocalories, saturated fats, other fats, sugars, and sodium, with no specific judgement, opinion or recommendation.
62744320|NCT02864888|EXPERIMENTAL|Radiation|Study subjects receive a single daily radiation fraction of 180cGy, 5 days a week, for the 2 weeks of the QT/QTc study and for 6 weeks overall to a total radiation dose of 1600 cGy and 5400cGy, respectively.
62744321|NCT02864888|EXPERIMENTAL|Antineoplaston therapy + Radiation|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 24 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.Study subjects also receive a single daily radiation fraction of 180cGy, 5 days a week, for the 2 weeks of the QT/QTc study and for 6 weeks overall to a total radiation dose of 1600 cGy and 5400cGy, respectively.
62744322|NCT02465723|EXPERIMENTAL|MRI with IVIM DW-MRI|Upon enrollment in the study, each patient will undergo a standard pre-treatment evaluation in the Radiation Oncology Clinic. Imaging will include MRI with IVIM DW-MRI (as a research exam). MR imaging will begin within 30 minutes (+/- 15 mins) of the completion of single-dose radiation or the first dose for patients treated with a multifractioned regime. Patients will have corresponding serum samples collected at approximately 1 hour before and 18-24 hours after the first radiation treatment. If radiation therapy occurs on a Friday, the collection of the serum 18-24 hours post-treatment may still be feasible. Patients will be treated with radiation therapy according to our standard clinical guidelines using one of several Varian megavoltage linear accelerators with on-board kilovoltage image-guidance capabilities, using established immobilization devices that are specific to the anatomical site treated at MD's discretion.
62744323|NCT02529462|EXPERIMENTAL|NEUROPHARMAGEN-Guided Treatment|In the study patient group, the psychiatrist will have the results of the NEUROPHARMAGEN genetic test as supporting information to help him/her select the best treatment for the patient.
62744324|NCT02529462|ACTIVE_COMPARATOR|Treatment As Usual|"In the control patient group, treatment as usual will be selected and prescribed in accordance with routine clinical practice ."
62744325|NCT04313374|ACTIVE_COMPARATOR|Morphine PCA 1 mg|The patient controlled analgesia device give 1mg morphine for each demand of the patient.
62744326|NCT04313374|ACTIVE_COMPARATOR|Morphine PCA 0,5 mg|The patient controlled analgesia device give 0,5 mg morphine for each demand of the patient.
62371879|NCT04308408|EXPERIMENTAL|Ecuador's Multiple Traffic Light (MTL)|Multiple traffic light labels, an interpretive nutrient-specific FOP label, use the typical traffic light colors (green, yellow/amber, red) and text descriptors to indicate the high, medium, or low content of total fat, sugar and salt.
62371880|NCT04308408|EXPERIMENTAL|Chilean Warning Labels in Red|Warning Labels (WL), another nutrient-specific interpretive FOP labelling scheme, include 'high in' symbols for products that exceed limits of energy, sodium, sugar and saturated fat.
62371881|NCT03976193|PLACEBO_COMPARATOR|BfitBwell program|BfitBwell is a 3-month supervised exercise program for cancer survivors delivered at the Anschutz Health and Wellness Center. This program has demonstrated effectiveness for improving physical fitness, fatigue, and depression among participants
62371882|NCT03976193|ACTIVE_COMPARATOR|BfitBwell + 6, bi-weekly PA Behavior Change counseling session|Participants randomized to BfitBwell + PA behavior change counseling sessions will receive six, 1-1.5 hour sessions lead by a Certified Exercise Physiologist, trained on the study protocol. Sessions will be held once per week, every other week at the Anschutz Health and Wellness center. Participants will attend the sessions in groups, as schedules allow. Behavior change discussion topics will target self-efficacy for exercise, barriers to exercise, goal setting, behavior modification strategies, time management, cognitive reframing, and relapse prevention. Participants in this study arm will receive a group education workbook in congruence to discussion session topics to promote notetaking, and self-reflective journaling.
62371883|NCT04685655|NO_INTERVENTION|COVID-19 therapy according to center standard alone|
62371884|NCT04685655|ACTIVE_COMPARATOR|Therapeutic plasma exchange and COVID-19 therapy according to center standard|
62744327|NCT04313374|PLACEBO_COMPARATOR|Placebo|The patient controlled analgesia device give 2 mL serum physiologic for each demand of the patient.The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours. If the VAS skore more than 4 the Group 3 patients will take 1 g paracetamol every 6 hours.
62744328|NCT02374814|ACTIVE_COMPARATOR|Rabies vaccine IM 3 dose|Intramuscular injection: 1mL at 0, 7 and 21 days. An additional 1 mL intramuscular dose at day 365
62744329|NCT02374814|EXPERIMENTAL|Rabies vaccine ID 3 dose|Intradermal injection: 0.1mL at 0, 7 and 21 days. A single intramuscular 1 mL dose at day 365
62744330|NCT02374814|EXPERIMENTAL|Rabies vaccine IM 2 dose|Intramuscular injection: 1mL at 0, 7 days. An additional 1 mL intramuscular dose at day 365
62744331|NCT02374814|EXPERIMENTAL|Rabies vaccine ID 2 dose|Intradermal injection: 0.1mL at 0, 7 days. A single intramuscular 1 mL dose at day 365
62371885|NCT00409396|EXPERIMENTAL|1|Fecal calprotectin and urinary PGEm levels will be tested on all participants.
62744332|NCT02374814|PLACEBO_COMPARATOR|Placebo IM 1 dose|Albumin and saline comparator, Intramuscular injection: 1mL
62744333|NCT02374814|PLACEBO_COMPARATOR|Placebo ID 1 dose|Albumin and saline comparator, Intradermal injection: 0.1mL
62744334|NCT01399151|EXPERIMENTAL|Vitamin D - Treatment 1|400 IU/day Vitamin D
62744335|NCT01399151|EXPERIMENTAL|Vitamin D- Treatment 2|2,000 IU/day Vitamin D
62371886|NCT05305053||high-risk noncardiac surgery patients for preoperative Multidisciplinary Team (MDT) discussion|observation of MDT in 11 hospitals
62371887|NCT01603472||Subjects on Parenteral Nutrition|cases are those on Parenteral Nutrition \>6 weeks for intestinal failure.
62371888|NCT01603472||Subjects not on Parenteral Nutrion|Controls are those who have never been on PN but can be fed via a feeding tube
62744336|NCT01399151|EXPERIMENTAL|Vitamin D- Treatment 3|5,000 IU/day Vitamin D
62371889|NCT05125991|EXPERIMENTAL|Prepectoral reconstruction|Prepectoral breast reconstruction with Braxon dermal matrix
62744337|NCT05091281|ACTIVE_COMPARATOR|Group I|After induction of anesthesia intubation was done by Macintosh laryngoscope
62371890|NCT05125991|ACTIVE_COMPARATOR|Submuscular reconstruction|Submuscolar breast reconstruction
62371891|NCT02331654|EXPERIMENTAL|Experimental Treatment|Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes: the anode will be placed on the thoracic spinal cord (over the spinal process of the tenth thoracic vertebra) and the cathode (reference) above the right shoulder. Stimulating electrodes will be thick (6 mm), rectangular pieces of saline-soaked synthetic sponge. The sDCS polarity (anodal) will refer to the electrode over the spinal cord.
62744338|NCT05091281|ACTIVE_COMPARATOR|Group II|After induction of anesthesia intubation was done by GlideScope®videolaryngoscope
62744339|NCT05091281|ACTIVE_COMPARATOR|Group III|After induction of anesthesia intubation was done byC-MAC®(D) videolaryngoscope
62744340|NCT04461691|OTHER|Heart Failure|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
62371892|NCT02331654|PLACEBO_COMPARATOR|Placebo treatment|For sham sDCS (placebo), electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s.
62371893|NCT04562038|EXPERIMENTAL|YC-PEM e-PRO|Participants are administered an electronic patient-reported outcome measure to obtain information about parent priorities, and they obtain a summary report of their responses to share with their early intervention team for discussion during the annual IFSP meeting.
62371894|NCT04562038|NO_INTERVENTION|Family Assessment|Participants are scheduled to complete a semi-structured family interview to obtain information about parent priorities, for use during the annual IFSP meeting
62371895|NCT03421262|EXPERIMENTAL|One-step:IADPSG Criteria|Gestational diabetes screening with fasting 2 hour 75g. Receive a fasting 2 hour 75 gr oral glucose tolerance test and diagnosed based on the IADPSG which is if one or more values exceed the following diagnostic threshold: Fasting 92, 1-hour 180, or 2-hour 153 mg/dL.
62371896|NCT03421262|ACTIVE_COMPARATOR|Two-step:NDDG Criteria|"Step 1: Perform a 1h 50-g glucose load test (nonfasting. If the plasma glucose level measured 1 h after the load is 140 mg/dL, proceed to a 100-g OGTT.~Step 2: 100-g OGTT. The diagnosis of GDM is made if at least two of the following four plasma glucose levels(measured fasting and 1 h, 2 h, 3 h after the OGTT) are met or exceeded: 105mg/dl, 190mg/dl, 165mg/dl and 145mg/dl respectively"
62371897|NCT00871676|ACTIVE_COMPARATOR|1|Overweight/obese individuals being treated with lifestyle modification to facilitate weight loss.
62371898|NCT00871676|EXPERIMENTAL|2|Lifestyle modification plus use of chewing gum to facilitate weight loss in overweight/obese persons.
62371899|NCT00732654|EXPERIMENTAL|Sublingual Immunotherapy (SLIT)|"These subjects will have a dose escalation of the milk protein extract given sublingually. After dose escalation, they will continue on the sublingual daily maintenance dose for approximately one year.~Milk Protein Extract Immunotherapy : Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years."
62371900|NCT00732654|EXPERIMENTAL|SLIT/ Oral Immunotherpay (OIT) B|"These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 1000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.~Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years."
62744341|NCT04461691|OTHER|Normal cardiac function|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
62744342|NCT01260090|EXPERIMENTAL|Vagus Nerve Stimulation|"Name of the Device:~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).~FDA Facility Registration Number: 1644487"
62744343|NCT01260090|SHAM_COMPARATOR|No Stimulation|
62744344|NCT01076868|EXPERIMENTAL|Primaquine|Primaquine 14 days
62744345|NCT06608550|EXPERIMENTAL|short video film|Children will be trained with a short movie to prepare for the endoscopy procedure. The content of the short movie video training will include; introduction of the outpatient clinic, things to be considered before the procedure, preparation for the procedure, introduction of the endoscopy room, introduction of the service to come after endoscopy, issues to be considered after the procedure. The short movie training is expected to last approximately 5 minutes.
62744346|NCT06608550|NO_INTERVENTION|Control|Routine practice of the clinic (in routine practice; verbal information is given with the information and consent form prepared on the definition of endoscopy, the purpose of the procedure, the risks of the procedure, and what to pay attention to after the procedure).
62744347|NCT03092986|ACTIVE_COMPARATOR|chemotherapy with paclitaxel and carboplatin|Intervention: paclitaxel 200 mg/m2 AUC and carboplatin AUC 6 on day 1 every 3 wks for 2 cycles followed by three dimensional conformal radiotherapy on day 42
61986302|NCT00540345|ACTIVE_COMPARATOR|D, non-RVR 48w|For patients who do not have a RVR will be randomized into two groups with a ratio of 1:1 (Arm C \& D)(C, non-RVR 24w) (D, non-RVR 48w)
62371901|NCT00732654|EXPERIMENTAL|SLIT/ OIT A|"These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 2000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.~Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.~Milk Protein Extract Immunotherapy : Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks."
62371902|NCT05221489|EXPERIMENTAL|lullaby group|For two weeks and 30 minutes every day at home, the lullaby group (LG) only listened to the lullaby record selected by the researcher.
62371903|NCT05221489|EXPERIMENTAL|mix music group|For two weeks and 30 minutes every day at home, the multi-music group (MG) listened to self-selected music from different records presented to them by the researcher.
62371904|NCT05221489|NO_INTERVENTION|control group|The control group (CG) only received routine care.
62371905|NCT03428295|EXPERIMENTAL|Experimental: Single Cohort in CRC|This study is a single-arm, single-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting.
62371906|NCT02040298|ACTIVE_COMPARATOR|3 months Clemastine, 2 months Placebo|4mg clemastine twice daily for first 3 months -- crossover -- equivalent quantity/frequency of placebo for last 2 months
62744348|NCT03092986|EXPERIMENTAL|chemotherapy with cisplatin and vinblastine|Intervention : cisplatin 100 mg/m2 on day 1 and 29 and vinblastine 5mg/m2 on days 1,8,15,22 and 29 followed by three dimensional conformal radiotherapy on day 50
62744349|NCT06302400|EXPERIMENTAL|Radioembolisation with 166Holmium microspheres|
62371907|NCT02040298|ACTIVE_COMPARATOR|3 months Placebo , 2 months Clemastine|Placebo for first 3 months -- crossover -- 4mg clemastine twice daily for last 2 months.
62371908|NCT04358991||invasive bacterial infections|patients who are receiving Ceftazidime-avibactam are asked to provide blood samples around a dosing of the medication for analysis of samples
62371909|NCT05934890|EXPERIMENTAL|Walvax PCV13-TT|"Primary Vaccination: A total of approximately 300 infants 6-8 weeks of age will be enrolled and assigned randomly to receive at 2, 4, and 12-15 months of age 1 dose of PCV13-TT. Standard EPI vaccines will be administered concomitantly.~Booster Vaccination: At 12-15 months of age (8 to 11 months after the 2nd dose of the primary series), infants will receive a booster dose of PCV13-TT."
62371910|NCT05934890|ACTIVE_COMPARATOR|Pfizer PCV13|"Primary Vaccination: A total of approximately 300 infants 6-8 weeks of age will be enrolled and assigned randomly to receive at 2, 4, and 12-15 months of age 1 dose of PCV13. Standard EPI vaccines will be administered concomitantly.~Booster Vaccination: At 12-15 months of age (8 to 11 months after the 2nd dose of the primary series), infants will receive a booster dose of PCV13."
62371911|NCT04935567|EXPERIMENTAL|Predicted responders|Patients indicated VNS therapy as their standard for clinical care and are concerned about the prediction of VNS efficacy based on pre-implantation EEG, (≥50% seizure reduction).
62371912|NCT04935567|ACTIVE_COMPARATOR|Predicted non-responders|Patients indicated VNS therapy as their standard for clinical care and are concerned about the prediction of VNS efficacy based on pre-implantation EEG, (\<50% seizure reduction).
62371913|NCT02034864|EXPERIMENTAL|Osteopathic manipulative treatment|6 sessions of standardized manipulative treatment
62371914|NCT02034864|SHAM_COMPARATOR|Placebo of osteopathic manipulative treatment|6 sessions of standardized placebo of manipulative treatment
62744350|NCT02975479|PLACEBO_COMPARATOR|Intralymphatic placebo injections|ALK Diluent, ATC-code V07AB. 3 injections with 4-7 weeks interval.
62744351|NCT02975479|ACTIVE_COMPARATOR|Intralymphatic active injections|"ATC-code V01AA02. 3 injections with 4-7 weeks interval in an up-dosing protocol; 1000 SQ-U, 3000 SQ-U, 10000 SQ-U.~\*\*\*IMPORTANT INFORMATION! The up-dosing protocol is changed due to an adverse event at the last injection. New regimen: 1000 SQ-U, 3000 SQ-U, 3000 SQ-U. \*\*\*"
62371915|NCT02727504||Patient with aortic valve stenosis|"115 patients will undergo a medical examination in order to analyse their medical history, cardiovascular parameters and check inclusion and non-inclusion criterions.~Then will be performed :~* An electrocardiogram~* 2D and 3D echocardiography~* Dobutamine stress echocardiography~* Blood tests : blood electrolytes, creatinine, hemoglobin, N-terminal pro-brain natriuretic peptide (NT-ProBNP), C reactive protein (CRP), soluble suppression of tumorigenicity-2 (ST-2)~* A cardiac MRI~* A cardiac scanner~* A 6-minutes walking test~* An evolution of the Duke Activity Score"
62371916|NCT00954473||Ancillary-correlative (osteosarcoma genetic risk)|Blood samples undergo polymorphism analysis of common single-nucleotide polymorphisms and haplotypes to examine genetic variation, gene-gene interactions, and the population structure.
62371917|NCT00367705|ACTIVE_COMPARATOR|T|VSL-#3
62371918|NCT00367705|PLACEBO_COMPARATOR|P|
62371919|NCT00169767||A|Comparison study between KTP and HoLAP procedures for BPH
62371920|NCT03667794||PH patients|Patients with known or first diagnosis of PH
62371921|NCT03667794||healthy controls|Healthy controls had normal lung function testing including whole-body plethysmography and transfer factor, no previously diagnosed pulmonary disease as well as no respiratory symptoms.
62371922|NCT03667794||non-healthy controls|Non-healthy controls were allowed to have stable pulmonary comorbidities including chronic obstructive pulmonary disease (COPD), sarcoidosis, asthma, or fibrosis as well as non-pulmonary comorbidities.
62371923|NCT05211492|OTHER|Chronic pain|
62371924|NCT05211492|OTHER|Acute pain|
62371925|NCT05211492|OTHER|Control group|
62371926|NCT05580757||Pharmacists and pharmaceutical technical assistants (FTA)|Dutch-speaking Belgian public pharmacists or pharmaceutical technical assistants (FTA)
62744352|NCT05484505|EXPERIMENTAL|Nicotine replacement therapy (NRT) Preloading|"1. Brief Advice (5 A's \& 5 R's)- 0-day, Month- 1, 3, 6, 9, 12~2. a. Nicotine Replacement Therapy for \> 20 cigarettes per day~Nicotine Patch: Preloading for 4 weeks + 12 weeks post quit date,21 mg: 4 weeks before and after quit date,14 mg: Next 4 weeks,7 mg: Last 4 weeks Nicotine chewing gums 4 mg for 12 weeks post quit date (12/day on week 1(Tapering dose weekly)1/day on week 12~2.b. Nicotine Replacement Therapy for \< 20 cigarettes per day Nicotine Patch: Preloading for 4 weeks + 12 weeks post quit date 21 mg: 4 weeks before and after quit date 14 mg: Next 4 weeks 7 mg: Last 4 weeks~Nicotine chewing gums 2 mg for 12 weeks post quit date (12/day on week~1(Tapering dose)1/day on week 12"
62371927|NCT02038790|EXPERIMENTAL|Suboxone sublingual film 8/2|Participants took a single dose of Suboxone sublingual film 8/2 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study.
62371928|NCT02038790|ACTIVE_COMPARATOR|Zubsolv sublingual tablets 5.7/1.4|Participants took a single dose of Zubsolv sublingual tablets 5.7/1.4 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study.
62371929|NCT02287805||quantitative survey 1|parents of 300 patients with craniosynostosis diagnostic
62744353|NCT05484505|ACTIVE_COMPARATOR|Nicotine replacement therapy (NRT)|"1. Brief Advice (5 A's \& 5 R's)- 0-day, Month- 1, 3, 6, 9, 12~2. a. Nicotine Replacement Therapy for \> 20 cigarettes per day~Nicotine Patch: 12 weeks post quit date 21 mg: 4 weeks after quit date 14 mg: Next 4 weeks 7 mg: Last 4 weeks~Nicotine chewing gums 4 mg for 12 weeks post quit date (12/day on week 1(Tapering dose weekly)1/day on week 12~2.b. Nicotine Replacement Therapy for \< 20 cigarettes per day~Nicotine Patch: 12 weeks post quit date 21 mg: 4 weeks after quit date 14 mg: Next 4 weeks 7 mg: Last 4 weeks~Nicotine chewing gums 2 mg for 12 weeks post quit date (12/day on week 1(Tapering dose)1/day on week 12"
62744354|NCT05608993|EXPERIMENTAL|High Intensity|Community-based clinics and/or urgent care centers that are assigned to the high intensity arm will receive the high intensity intervention.
62744355|NCT05608993|EXPERIMENTAL|Low Intensity|Community-based clinics and/or urgent care centers that are assigned to the low intensity arm will receive the low intensity intervention.
62744356|NCT01986192|EXPERIMENTAL|rivaroxaban|Rivaroxaban 15mg bid for 3 weeks and 20mg qd for 6 months
62744357|NCT01986192|ACTIVE_COMPARATOR|warfarin|Enoxaparin 1mg/kg bid overlapping with warfarin (target PT INR 2.0-3.0) for 6 months
62744358|NCT06440967|EXPERIMENTAL|Fezolinetant|Participants taking tamoxifen or an aromatase inhibitor will receive fezolinetant once daily for 52 weeks.
62744359|NCT06440967|PLACEBO_COMPARATOR|Placebo|Participants taking tamoxifen or an aromatase inhibitor will receive matching placebo once daily for 52 weeks.
61986303|NCT05061979|EXPERIMENTAL|Mild renal impairment|Participants with mild renal impairment will receive a single dose of BAY1747846.
62371930|NCT02287805||qualitative survey|"* parents of 12 newly diagnosed patients, they will be seen 3 times (after the diagnosis, 3 months after surgery, 1 year after surgery~* 12 patients aged over 15 years, operated more than 10 years before"
62371931|NCT02287805||quantitative survey 2|"* 100 parents of patients 1 year after surgery~* 100 parents of patients, 5 years after the operation~* 100 patients aged over 15 years and operated over 10 years ago"
62371932|NCT03685929||Pressure ulcers|Patients with pressure ulcers category II/III at sacrum or trochanter
62371933|NCT03685929||Incontinence-associated dermatitis|Patients with incontinence-associated dermatitis category IIA at sacrum (or trochanter)
62371934|NCT03685929||Combined lesion|Patients with pressure ulcer category II/III and incontinence-associated dermatitis category IIA at sacrum or trochanter
62371935|NCT03743376|NO_INTERVENTION|Standard ART|Subjects will receive standard ART for 48 weeks
62371936|NCT03743376|EXPERIMENTAL|UB-421(25mg/kg) Q2W add-on treatment|UB-421(25 mg/kg) Q2W plus standard ART for 48 weeks
62371937|NCT03743376|EXPERIMENTAL|UB-421(25mg/kg) Q4W add-on treatment|UB-421(25 mg/kg) Q4W plus standard ART for 48 weeks
62371938|NCT00952419|EXPERIMENTAL|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1
62371939|NCT00952419|EXPERIMENTAL|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2
62371940|NCT00952419|PLACEBO_COMPARATOR|Placebo Group|Participants will receive a placebo vaccine
62371941|NCT01547806|EXPERIMENTAL|Hematopoietic Progenitor Cells (HPC)|Subjects will undergo mobilization and collection of HPC, Apheresis for subsequent use in various clinical protocols.
62371942|NCT01044056|ACTIVE_COMPARATOR|Levonorgestrel/ethinylestradiol oral contraceptive pill|Microgynon(R), 1 tablet every day for 21 days; each tablet contains 0.150 mg levonorgestrel (LNG) and 0.030 mg ethinylestradiol (EE).
62371943|NCT01044056|ACTIVE_COMPARATOR|Norelgestrominum and ethinylestradiol contraceptive patch|Evra(TM), One patch applied on lower abdomen for 7 days for 3 consecutive weeks, 3 patches in total. Each patch contains 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
62371944|NCT01044056|ACTIVE_COMPARATOR|Etonogestrel and ethinylestradiol contraceptive vaginal ring|Nuvaring(R), Place the ring in the vagina for 21 days, remove for one week. Repeat with new Ring. Dose: per ring 11.7 mg ENG and 2.7 mg EE releasing a daily average amount of 0.120 mg ENG and 0.015 mg EE.
62371945|NCT02244125|OTHER|Previous IFM/DFCI 2009 arm A|"Patients previously randomized into IFM/DFCI 2009 trial arm A (or if transplantation was not done) will receive:~* The treatment phase:~  * 4 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~* The consolidation phase:~  * Melphalan 200mg/m2 followed by ASCT (Autologous Stem Cell Transplantation)~ * 2 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~* The maintenance phase: Until progression or discontinuation for any other reason~  * Pomalidomide and Dexamethasone"
62371946|NCT02244125|OTHER|Previous transplantation IFM/DFCI 2009 arm B|"Patients previously randomized into IFM/DFCI 2009 trial arm B (RVD plus Transplant) will receive:~* The treatment phase:~  * 4 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~* The consolidation phase:~  * 5 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~* The maintenance phase: Until progression or discontinuation for any oher reason~  * Pomalidomide and Dexamethasone"
62371947|NCT05104788|EXPERIMENTAL|Icotinib with platinum-based chemotherapy|Icotinib 125 mg TID plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
62371948|NCT01339104|EXPERIMENTAL|Regorafenib|
62371949|NCT01537289|EXPERIMENTAL|Pigtail catheter|
62371950|NCT01537289|ACTIVE_COMPARATOR|Traditional chest tube|28-French chest tube
62744360|NCT06398132||Thalidomide Survivors|The group will include Thalidomide Survivors (n=120), who are beneficiaries of the Thalidomide Trust and receive Usual Care for the management of their pain. Usual Care includes among others, over-the-counter or prescribed painkillers, treatment modalities such as physiotherapy and/or psychotherapy, privately accessed or via the National Health Service, exercise, etc.
62744361|NCT01883115||Telescopic group|All eligible patients referred with inguinal/femoral hernias will be enrolled into the study from February 2013
62744362|NCT02184091|EXPERIMENTAL|Nevirapine|Single dose administration
62744363|NCT04948320||Temporomandibular Disorder Group|
62744364|NCT04948320||Control Group|
62744365|NCT00061815|EXPERIMENTAL|Cetuximab+FOLFOX4|"* Day 1 - cetuximab loading dose of 400 mg/m2 IV, infused over 2 hours; oxaliplatin (85 mg/m2) simultaneously with leucovorin (200 mg/m2), followed by 5-FU 400 mg/m2 IV bolus followed by 5-FU 600 mg/m2 as a 22-hour continuous infusion~* Day 2 - leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 IV bolus followed by another dose of 5-FU 600 mg/m2 as a 22-hour continuous infusion~* Day 8 - cetuximab maintenance dose of 250 mg/m2 IV infused over 60 minutes"
62744366|NCT00061815|ACTIVE_COMPARATOR|FOLFOX4.|"* Day 1 - oxaliplatin (85 mg/m2) simultaneously with leucovorin (200 mg/m2), followed by 5-FU 400 mg/m2 IV bolus followed by 5-FU 600 mg/m2 as a 22-hour continuous infusion.~* Day 2 - leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 IV bolus followed by another dose of 5-FU 600 mg/m2 as a 22-hour continuous infusion."
62744367|NCT00664339|ACTIVE_COMPARATOR|Vaccine|Flu Vaccine
62744368|NCT00664339|OTHER|Control|Conventional treatment therapy for heart failure
62744369|NCT03524963|EXPERIMENTAL|Sequence A|Cilostan CR Tab. in phase 1 and Pletaal SR Cap. in phase 2
62744370|NCT03524963|EXPERIMENTAL|Sequence B|Pletaal SR Cap. in phase 1 and Cilostan CR Tab. in phase 2
62744371|NCT01633632|ACTIVE_COMPARATOR|Cognitive behavioral therapy|This group will receive a standardized, 8-session cognitive behavioral therapy course that is offered to the public at our practice.
62744372|NCT01633632|EXPERIMENTAL|Cognitive behavioral therapy + yoga|This group will receive the standardized, 8-session cognitive behavioral therapy course + 8 sessions of Hatha yoga.
62744373|NCT01633632|EXPERIMENTAL|Hatha yoga|This group will receive 8 sessions of Hatha yoga and printed materials to assist with their quit attempt
62744374|NCT00303771|ACTIVE_COMPARATOR|LV5FU2 classique|LV5FU2 classique
62744375|NCT00303771|EXPERIMENTAL|LV5FU2 classique + irinotécan|LV5FU2 classique + irinotécan
62744376|NCT00303771|ACTIVE_COMPARATOR|LV5FU2 simplifié|LV5FU2 simplifié
62744377|NCT00303771|EXPERIMENTAL|LV5FU2 simplifié+ irinotécan|LV5FU2 simplifié + irinotécan
62744378|NCT06661408|NO_INTERVENTION|Control Group|Pregnant women in the control group will be subjected to the routine hospital protocol without any other intervention. Pregnant women in this group are verbally informed about bathing during outpatient clinic follow-ups. After completing the post-test questions, the newborn bath application video will be transmitted to the women in this group on their phones and the disadvantageous situation of this group will be tried to be reduced.
62744379|NCT06661408|EXPERIMENTAL|Intervention group 1|The women assigned to this group will be shown the newborn bath application video prepared by the researchers in groups of 2-4 people in the form of a projection presentation.
62744380|NCT06661408|EXPERIMENTAL|Intervention group 2|In groups of 2, the researcher will first explain the stages of newborn bathing application by the researcher in the form of a projection presentation, and then the pregnant women will be provided to perform the newborn bathing application on the newborn bathing model and tools simultaneously with the researcher.
62744381|NCT02070419|ACTIVE_COMPARATOR|Arm I (TACE)|Patients undergo (transarterial chemoembolization) TACE according to institutional standard with doxorubicin-eluting beads.
62744382|NCT02070419|EXPERIMENTAL|Arm II (TACE+SBRT)|Patients undergo transarterial chemoembolization (TACE) as in Arm I and 3 or 5 fractions of stereotactic radiosurgery (SBRT) given at least 48 hours apart over 14 days.
62744383|NCT06236061|ACTIVE_COMPARATOR|LCZ 200mg|Oral administration, 1 tablet of LCZ 200 mg daily, 4 capsules of Amlodipine placebo daily.
62744384|NCT06236061|EXPERIMENTAL|LCZ 200mg + AML 2.5mg|Oral administration, 1 tablet of LCZ 200 mg daily, 1 capsule of Amlodipine 2.5 mg daily and 3 capsules of Amlodipine placebo daily.
62744385|NCT06236061|EXPERIMENTAL|LCZ 200mg + AML 5mg|Oral administration, 1 tablet of LCZ 200 mg daily, 2 capsules of Amlodipine 2.5 mg daily and 2 capsules of Amlodipine placebo daily.
62744386|NCT06236061|EXPERIMENTAL|LCZ 200mg + AML 10mg|Oral administration, 1 tablet of LCZ 200 mg daily, 4 capsules of Amlodipine 2.5 mg daily.
62744387|NCT00229047||Vein Stripping|Patients undergoing elective varicose vein stripping in our vascular OR. Observe circulation in the exposed soleus/gastrocnemius muscle.
62744388|NCT01216709|EXPERIMENTAL|iron drops|
62371951|NCT01425307|NO_INTERVENTION|Standard Therapy|Standard Therapy of monthly transfusions
62744389|NCT01216709|EXPERIMENTAL|iron-fortified formula (2.3 mg iron/L)|
62744390|NCT01216709|EXPERIMENTAL|iron-fortified formula (12.4 mg iron /L)|
62744391|NCT06279364|EXPERIMENTAL|SKB264|Participants will receive SKB264 on Day 1 and Day 15 of each 4-week cycle
62744392|NCT06279364|ACTIVE_COMPARATOR|Investigator's choice chemotherapy|"If no prior taxane, or prior taxane in the (neo)adjuvant setting and disease-free interval (DFI) \>12 months: paclitaxel or nab-paclitaxel.~If prior taxane and DFI ≤ 12 months: capecitabine, eribulin. If known BRCA1/2 mutation: carboplatin"
62744393|NCT03952468|ACTIVE_COMPARATOR|TMS + Brief Cognitive Behavioral Therapy|Combined transcranial magnetic stimulation and brief cognitive behavioral therapy for suicide
62744394|NCT03952468|SHAM_COMPARATOR|Sham TMS + Brief cognitive behavioral therapy|Sham Transcranial magnetic stimulation and brief cognitive behavioral therapy for suicide
62744395|NCT05155618|EXPERIMENTAL|Intervention group (IG)|Participants randomized to the IG will be offered an individualized counseling during cancer treatments that includes both a dietary and physical activity suggestions to control side effects, to cope with feelings of anxiety or depression and to improve quality of life.
62371952|NCT01425307|EXPERIMENTAL|Treatment Arm|Hydroxyurea will be provided as capsules or liquid
62371953|NCT04437810|EXPERIMENTAL|Albumin+ SMT|Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3) along with standard medical therapy
62371954|NCT04437810|PLACEBO_COMPARATOR|Placebo+SMT|- Patients in placebo arm will receive similar volume of isotonic fluid (saline) over same duration of time along with standard medical therapy
62371955|NCT05333536|EXPERIMENTAL|Experimental group exercises|Experimental performs Strengthening exercises of core.10 reps , 3 sets of each.Prone plank(10 sec hold)(18) ,Side plank (8 sec hold),Bridging (8 sec hold)(19),Bird dog (10 reps ,3 sets),Leg drop (10 reps, 3 sets)(15),Dying bug with their regular swimming practice. First 2 weeks simple strengthening exercises.Next 4 weeks stability ball exercises. Dying bug without stability ball. And strengthening exercises of UL and LL with theraband ,10 reps each.Upper limb: Latissimus dorsi,Serratus anterior, Upper trapezius.Lower Limb: Flexors of hip, Extensors of hip,Plantar flexors.
62371956|NCT05333536|ACTIVE_COMPARATOR|Control group|control only participates in their yearly swimming trainings.
62371957|NCT02240992|EXPERIMENTAL|MSCs&PBSC|PBSC will be intravenously infused at a dose of 2×10\^8/kg. MSCs will be intravenously infused at a dose of 1×10\^6 cells/kg once per week or until complete response(CR) . If the patients do not achieve CR or partial remission (PR) within 4 weeks, they will swithed to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given.
62371958|NCT02240992|EXPERIMENTAL|MSCs|MSCs will be intravenously infused at a dose of 1×10\^6 cells/kg once per week or until CR. If the patients have no response (NR) within 4 weeks, they will switch to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given.
62371959|NCT03973749|EXPERIMENTAL|Group 1|Low salycilate diet on day one and High salycilate diet on day 7
62371960|NCT03973749|EXPERIMENTAL|Group 2|High salycilate diet on day one and Low salycilate diet on day 7
62371961|NCT01471938||Caucasians|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
62744396|NCT05155618|NO_INTERVENTION|Control group (CG)|Participants included in the CG will receive at baseline general advice and materials available for patients undergoing RT. According to the crossover design, the CG will cross to the intervention as proposed for the IG, after the initial 6-month period.
62744397|NCT03006458|EXPERIMENTAL|comfilcon A|"Participants were randomized to wear comfilcon A toric lenses for two weeks during the cross over study.~The final optical design of comfilcon A contact lens was optimized to improve the quality and two further studies (CV-18-10 and CV-18-11) were conducted after completion of this study to evaluate the modified optical design."
62744398|NCT03006458|ACTIVE_COMPARATOR|omafilcon B|Participants were randomized to wear omafilcon B toric lenses for two weeks during the cross over study.
62371962|NCT01471938||Afro Americans|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
62371963|NCT01471938||East and Southeast Asian|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
62371964|NCT01471938||Hispanics|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
62371965|NCT05765214|EXPERIMENTAL|Intervention Group (IG)|Participants randomized to the IG will receive a customized patient-centered, culturally appropriate education program. Patients randomized to the IG will participate in eight (8) education sessions. A booklet with colorectal cancer education and nutrition education will be developed and print materials given to the participants to use as a workbook.
62371966|NCT05765214|NO_INTERVENTION|Usual Care (UC)|Patients randomized to UC group will continue to receive care at the clinic without any intervention from the study team.
62371967|NCT04525560|EXPERIMENTAL|PEG-ELS-S|The dosage of PEG-ELS is given according to body weight: 10-15 kg, PEG-ELS 0.75 L; 15-22.5 kg, PEG-ELS 1.5 L; 22.5-30 kg, PEG-ELS 2.25 L; more than 30 kg, PEG-ELS 3 L.
62371968|NCT04525560|ACTIVE_COMPARATOR|PEG-ELS-L|The dosage of PEG-ELS is given according to body weight: 10-15 kg, PEG-ELS 0.75 L; 15-22.5 kg, PEG-ELS 1.5 L; 22.5-30 kg, PEG-ELS 2.25 L; more than 30 kg, PEG-ELS 3 L.
62371969|NCT00063986|EXPERIMENTAL|Minimally invasive esophagectomy (MIE)|Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
62371970|NCT00005065|EXPERIMENTAL|Arm I|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours every 3 weeks for 3 courses. Three weeks after completion of induction chemotherapy, patients receive Gd-Tex IV over 30 minutes twice weekly for 10 doses during preoperative radiotherapy. Radiotherapy is administered daily 5 days a week for 5 weeks. Approximately 3.5 weeks after completion of preoperative radiotherapy, patients undergo complete surgical resection. Three hours prior to surgery, patients receive an eleventh dose of Gd-Tex if they do not develop grade 3 or 4 toxicity with the tenth dose. Patients also receive a MRI without contrast prior to surgery. If the tumor is found to be unresectable, patients may receive additional radiation and/or chemotherapy.
62371971|NCT00622570|EXPERIMENTAL|1|Pentobarbital
62371972|NCT00622570|ACTIVE_COMPARATOR|2|thiopental
62371973|NCT03930667|ACTIVE_COMPARATOR|clips|Closure of the appendix stump with hem-o-lok clips
62744399|NCT02036333||Concussion Group|
62744400|NCT02036333||Control Group|
62744401|NCT02668770|EXPERIMENTAL|Dose Escalation Group: MGN1703 + Ipilimumab|"Participants receive MGN1703 on Days 1, 8, and 15 of all cycles as an injection under the skin. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.~Each cycle is 21 days long. Participants receive a total of 4 treatment cycles for a total of 12 weeks on treatment."
62744402|NCT02668770|EXPERIMENTAL|MTD Group: MGN1703 (subcutaneously) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy and cutaneous or subcutaneous manifestations.~MGN1703 given subcutaneously at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.~Each cycle is 21 days long."
62371974|NCT03930667|EXPERIMENTAL|knotting|Closure of the appendix stump with intracorporal knotting.
62371975|NCT06099028||HF center|heart failure patients enrolled from heart failure center hospitals
62371976|NCT06099028||non-HF center|heart failure patients enrolled from non-heart failure center hospitals
62371977|NCT02744781|EXPERIMENTAL|Lumbar disc degeneration; LDD|The LDD group included subjects with at least 1 abnormal disc from L1-2 to L5-S1 of grade III, IV, or V. The non-LDD group included subjects with 5 normal discs of grade I or II. For further assessment, the most damaged disc of the 5 constituted the highest grade of LDD.
62371978|NCT04851327|EXPERIMENTAL|High energy|"Child will be given a high energy drink: a flavoured high energy milk or juice-based drink, used clinically to supplement the diet of preschool children (either Pediasure plus or Duocal). This will provide 1.5 kcals per ml in various flavours as preferred. The amount given will supply 10% of the child's daily energy requirements per Kg - for example for a 2-year-old child weighing 15 KG this would be 80 mls of drink supplying 120 Kcal.~They will be given 10 minutes to drink the preload and 30 minutes after this they will eat lunch containing a range of pre-packaged foods of known energy content suitable for their age, chosen in consultation with the parents."
62371979|NCT04851327|EXPERIMENTAL|Low energy|"Child will be given a low energy drink of the same volume selected to be as similar as possible to the high energy drink, made either of skim milk or sugar free fruit juice, with a similar sugar free flavour; for above example this will supply 25 kcal.~They will be given 10 minutes to drink the preload and 30 minutes after this they will eat lunch containing the same range of pre-packaged foods as above."
62371980|NCT02454894|EXPERIMENTAL|Group 1|no anesthesia; postoperative management
62371981|NCT02454894|NO_INTERVENTION|Group 2|no anesthesia; lying without the pillow and fasting water and food for four hours after lumbar puncture
62371982|NCT02454894|EXPERIMENTAL|Group 3|surface anesthesia with lidocaine; postoperative management
62371983|NCT02454894|EXPERIMENTAL|Group 4|surface anesthesia with lidocaine; lying without the pillow and fasting water and food for four hours after lumbar puncture
62371984|NCT06242106|EXPERIMENTAL|Aerobic exercises + self-stretching|• After the baseline assessment, the patient in the experimental group received self-stretching with aerobic exercises. Self-stretching that includes butterfly stretch, wall stretching and cat and cow pose for 5 sec each and 10 repetitions, with aerobic exercises that includes 30 minutes (2 sets each is of 15 minutes) of treadmill, Static cycling for 15 minutes and walking for straight 20 minutes. For 7 weeks
62744403|NCT02668770|EXPERIMENTAL|MTD Group: MGN1703 (intratumoral injection) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy and cutaneous or or subcutaneous manifestations.~MGN1703 given by intratumoral injection at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.~Each cycle is 21 days long."
62744404|NCT02668770|EXPERIMENTAL|MTD Post XRT Group: MGN1703 (subcutaneously) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy treated with radiation (XRT) within the past 2 weeks.~MGN1703 given subcutaneously at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.~Each cycle is 21 days long."
62744405|NCT04890496||inpatients of ZOC|Patients have retrospective hopitalization record of ZOC from 1998 to 2020.
62744406|NCT05524623|SHAM_COMPARATOR|without current emission in the treatment|percutaneous microelectrolysis without current emission in the treatment of cervical pain in myofascial trigger points of the trapezius. Both will take place over 3 weeks, with one session per week.
62744407|NCT05524623|ACTIVE_COMPARATOR|wit current emission in the treatment|percutaneous microelectrolysis with current emission in the treatment of cervical pain in myofascial trigger points of the trapezius. oth will take place over 3 weeks, with one session per week.
62744408|NCT02182063|EXPERIMENTAL|BIBF 1120 low dose|
62744409|NCT02182063|EXPERIMENTAL|BIBF 1120 high dose|
62744410|NCT06259487|EXPERIMENTAL|Coordinated Vaccination against RSV and Influenza|Patients receiving vaccinations against Respiratory Syncytial Virus (RSV) and influenza provided by the research team (i.e. during cardiology visits).
62744411|NCT06259487|ACTIVE_COMPARATOR|Standard of care|Patients following standard recommendations for protective vaccinations (i.e., receiving vaccinations at vaccination points).
62744412|NCT06410742||Patients with primer Sjogren's syndrome|
62371985|NCT06242106|ACTIVE_COMPARATOR|Control Group (Self stretching)|After the baseline assessment, the patient in the control group received self-stretching without aerobic exercises. Self-stretching that includes butterfly stretch, wall stretching and cat and cow pose for 5 sec each and 10 repetitions for 7 weeks
62744413|NCT06410742||Healthy individual|
62371986|NCT05659004||All participants|1 qualitative interview
62371987|NCT01864486|EXPERIMENTAL|Intelligent Retinal Implant System|
62371988|NCT04993755|EXPERIMENTAL|TPN-101, 400 mg/day|
62371989|NCT04993755|PLACEBO_COMPARATOR|Placebo|
62371990|NCT02462122|EXPERIMENTAL|IDP-118 Lotion|Lotion
62371991|NCT02462122|ACTIVE_COMPARATOR|IDP-118 Vehicle Lotion|Vehicle Lotion
62371992|NCT04552067|OTHER|LOVENOX|patients are given a curative dose of Enoxaparin (LOVENOX)
62371993|NCT04552067|ACTIVE_COMPARATOR|Enoxamed|patients are given a curative dose of Enoxaparin (ENOXA)
62371994|NCT05639829|EXPERIMENTAL|Weekday time-restricted eating|The intervention consisted of 8 weeks of ad libitum TRE with a 12-8 pm 8-hour eating window on weekdays. Participants received instructions to only consume water, black coffee, or black tea from 8 pm to 12 pm on weekdays and during the weekend, where there were no restrictions on eating timing. No other dietary or physical activity instructions were given.
62371995|NCT03207724|EXPERIMENTAL|Xilonix plus Onivyde and 5FU|interleukin-1-alpha antagonist (Xilonix) in addition to standard chemotherapy of onivyde and 5-fluorouracil/folinic acid (leucovorin)
62744414|NCT06656650|ACTIVE_COMPARATOR|Treatment group|Participants attend commensality groups
62744415|NCT06656650|NO_INTERVENTION|Waitlist control group|Participants receive no intervention
62744416|NCT03218072|EXPERIMENTAL|HLX01 250 mg/m2|HLX01 250 mg/m2 administrated intravenously
62744417|NCT03218072|EXPERIMENTAL|HLX01 375 mg/m2|HLX01 375 mg/m2 administrated intravenously
62744418|NCT03218072|EXPERIMENTAL|HLX01 500 mg/m2|HLX01 500 mg/m2 administrated intravenously
62744419|NCT04627675|EXPERIMENTAL|1A: Age 18-50; CORVax|Healthy volunteers age 18-50 will receive CORVax
62371996|NCT04304404|EXPERIMENTAL|Intervention group (BrCaRRP)|Individual interventions based on the Health Belief Model and the The Health Promotion Model involving education, guidance, counseling, case management and surveillance for women with high breast cancer risk
62371997|NCT04304404|NO_INTERVENTION|Control Group|An information note will be given to the control group. The post-tests will be collected at the end of 12 weeks
62371998|NCT01500265||Patient naive|Patient with hepatitis B virus naive untreated
62371999|NCT01500265||Patient with TDF|Patient with hepatits B treated with Tenofovir
62372000|NCT01500265||Patient with ETV|Patient with hepatitis B virus treated with Entecavir
62372001|NCT02081911|EXPERIMENTAL|High volume Adductor canal block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine
62372002|NCT02081911|EXPERIMENTAL|Low volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine
62372003|NCT02081911|EXPERIMENTAL|Femoral nerve block|Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
62372004|NCT01936428|OTHER|interview|
62372005|NCT02171039|EXPERIMENTAL|dabigatran plus atorvastatin|
62372006|NCT02171039|ACTIVE_COMPARATOR|dabigatran|
62372007|NCT02171039|ACTIVE_COMPARATOR|atorvastatin|
62372008|NCT03612544|EXPERIMENTAL|Intervention group|
62372009|NCT03612544|ACTIVE_COMPARATOR|Control group|
62372010|NCT03456414|EXPERIMENTAL|Virtual reality during hemodialysis|During 12 weeks subjects will exercise during hemodialysis. The intervention will be virtual reality exercise during hemodialysis.
62372011|NCT03456414|NO_INTERVENTION|Control period - no exercise|During 12 weeks subjects will not exercise during hemodialysis
62372012|NCT01261494|EXPERIMENTAL|GFT505 80mg|
62372013|NCT01261494|PLACEBO_COMPARATOR|Matching placebo|
62372014|NCT03027869|ACTIVE_COMPARATOR|Real Left DLPFC tDCS|Real tDCS on the left dorsolateral prefrontal cortex
62372015|NCT03027869|SHAM_COMPARATOR|Sham tDCS|30sec ramp-up and 30sec ramp-down
62372016|NCT03027869|ACTIVE_COMPARATOR|Real Right DLPFC tDCS|Real tDCS on the right dorsolateral prefrontal cortex
62372017|NCT02431793|NO_INTERVENTION|Usual Care|Employ the standard of care, no intervention
62744420|NCT04627675|EXPERIMENTAL|1B: Age 18-50; CORVax + pIL-12|Healthy volunteers age 18-50 will receive CORVax + pIL-12
61986304|NCT05061979|EXPERIMENTAL|Moderate renal impairment|Participants with moderate renal impairment will receive a single dose of BAY1747846.
62372018|NCT02431793|EXPERIMENTAL|EMC2 strategy|"Patients of providers randomized to EMC2 arm will received educational tool from the ED to support the understanding and safe use of opioids.~1. A single-page medication information sheet with content from a patients perspective and following health literacy best practices.~2. Prescribing instructions will be adapted to the Universal Medication Scheduled Take-Wait-Stop regimen for both the prescribing and dispensing of the medicine. This format uses simplified text and numeric characters to detail dose.~3. Provider counseling prompts: The providers for patients in this arm will be prompted to encourage counseling both in the ED and at follow-up time points. These prompts include: 1) An automated prompt to the ED physician upon signing the order; 2) an automated message to the PCP (if an in-system PCP) notifying them of the ED visit, new prescription, and counseling request; and 3) a request for the pharmacist to counsel patient printed automatically on the prescription."
62372019|NCT02431793|EXPERIMENTAL|EMC2 strategy + SMS Text Reminders|In addition to the EMC2 Strategy Arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
62372020|NCT03547349|ACTIVE_COMPARATOR|Group 1|These study patients will receive a study information/authorization sheet about the study prior to surgery during their pre-operative clinic visit. This subgroup will be provided postoperatively with a digital incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer. Subjects in this group will receive current standard of care with routine surgical and RN encouragement to use the spirometer. The tablet will monitor and record spirometer device utilization.
62372021|NCT03547349|ACTIVE_COMPARATOR|Group 2|These study patients will be consented by members of the research team prior to surgery at their pre-operative clinic visit. The patient will receive RT or RN education preoperatively as to the importance of incentive spirometry in prevention of post-operative respiratory complications. This subgroup will be provided with a digital incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer, and will set a spirometry goal while collecting usage and pulmonary function data. Subjects in this group will also receive daily intensive education from a study team member during the postoperative time up until 72 hours or until discharge.
62372022|NCT03547349|EXPERIMENTAL|Group 3|These study patients will be consented by a member of the research team prior to surgery at their pre-operative clinic visit. The patients will receive RT or RN education preoperatively as to the importance of incentive spirometry in prevention of post-operative respiratory complications. This subgroup will be provided with both intensive education reinforcement and the Jamboxx Respiratory Therapy Device that also includes multiple gaming programs. The games are meant to encourage incentive spirometry and are programmed to progress in accordance with the patient's personal increasing capacity. Subjects in this group will also receive daily intensive education from a study team member during the postoperative time up until 72 hours or until discharge.
62372023|NCT00546936|EXPERIMENTAL|ranibizumab intravitreal injection|0.5 mg intravitreal injection of ranibizumab
62372024|NCT00546936|ACTIVE_COMPARATOR|Photodynamic Therapy|Photodynamic therapy with Visudyne
62372025|NCT02182999|PLACEBO_COMPARATOR|NaCl 0,9%|Continuous wound infiltration NaCl 0,9% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)
62744421|NCT04627675|EXPERIMENTAL|2A: Age > 50; CORVax|Healthy volunteers age \> 50 will receive CORVax
62744422|NCT04627675|EXPERIMENTAL|2B: Age > 50; CORVax + pIL-12|Healthy volunteers age \> 50 will receive CORVax + pIL-12
61986305|NCT05061979|EXPERIMENTAL|Normal renal function|Participants with normal renal function will receive a single dose of BAY1747846.
62372026|NCT02182999|ACTIVE_COMPARATOR|Ropivacaine|Continuous wound infiltration with Ropivacaine 0,2% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)
62744423|NCT01984645|EXPERIMENTAL|Notification|Providers in this arm will receive a secure online notification whenever their patients are visited in the emergency department or admitted as an inpatient.
62744424|NCT01984645|NO_INTERVENTION|No intervention|Providers in this arm will not get a secure online notification about their patient's visit to the emergency department or inpatient admission.
62744425|NCT02141867||Noncardiac surgical patients|Noncardiac surgery patients 16 years or older undergoing inpatient surgery
62372027|NCT02410590|EXPERIMENTAL|Rocuronium + Sugammadex|Participants will receive rocuronium administered at a dosage adequate to make intubation possible and provide deep NMB (defined as no response to train-of-four stimulation but at least one response to five post-tetanic count \[PTC\]) for the duration of surgery, until the end of the procedure. Sugammadex will be administered to participants once at a dosage of 4 mg/kg real body weight (RBW) IV at the end of surgical procedure. Sugammadex will be used as the only reversal drug in all participants who receive rocuronium as a neuromuscular blocker.
62744426|NCT00542490|EXPERIMENTAL|Vaginal Cuff Brachytherapy|
62744427|NCT05548712|EXPERIMENTAL|Treatment group|
62372028|NCT02410590|ACTIVE_COMPARATOR|Succinylcholine + Cisatracurium + Neostigmine/Atropine|After receiving succinylcholine 1.0 mg/kg RBW for intubation, participants will receive cisatracurium administered at dosage adequate to have a moderate NMB (defined as a target of TOF ratio = 10% with a range: 2-3 twitches to TOF ratio of 20%) for the duration of surgery, until the end of the procedure. Neostigmine/Atropine will be administered to participants once at respective dosage of 0.05 mg/kg RBW and 0.01 mg/kg RBW at least after the reappearance of T2 after surgery completion. The maximum allowed dosage for Neostigmine is 5 mg. Neostigmine will be used as only reversal drug in all participants who received Cisatracurium as neuromuscular blocker.
62372029|NCT02174328|EXPERIMENTAL|acetylsalicylic acid|This group will receive 1 tablet of acetylsalicylic acid (100 mg) orally daily from 5-10 weeks gestation until the end of gestation, about week 36
62372030|NCT02174328|PLACEBO_COMPARATOR|Placebo|This group will receive 1 tablet of placebo orally each day from 5-10 weeks gestation until the end of gestation, about week 36
62372031|NCT05431738|ACTIVE_COMPARATOR|STENT WITH ANTI-MIGRATION DEVICE|Placement of a gastroesophageal stent with anti-migration device : Ella®, Leufen, Novatech
62744428|NCT05548712|SHAM_COMPARATOR|Sham group|
62744429|NCT01335724|EXPERIMENTAL|Diclofenac diethylamine 1.16% gel|
62372032|NCT05431738|ACTIVE_COMPARATOR|STENT WITHOUT ANTI-MIGRATION DEVICE|Placement of a gastroesophageal stent without anti-migration device : Hanarostent® ECW, Life Partners Europe
62372033|NCT03832816|PLACEBO_COMPARATOR|Placebo|Distilled Water
62372034|NCT03832816|EXPERIMENTAL|Vaporized THC alone|5mg pure THC
62372035|NCT03832816|EXPERIMENTAL|Vaporized low CBD alone|50mg pure CBD
62372036|NCT03832816|EXPERIMENTAL|Vaporized medium CBD alone|100mg pure CBD
62372037|NCT03832816|EXPERIMENTAL|Vaporized high CBD alone|200mg pure CBD
62744430|NCT01335724|PLACEBO_COMPARATOR|placebo gel|
62372038|NCT03832816|EXPERIMENTAL|Vaporized low CBD with THC|50mg pure CBD paired with 5mg THC
62372039|NCT03832816|EXPERIMENTAL|Vaporized medium CBD with THC|100mg pure CBD paired with 5mg THC
62372040|NCT03832816|EXPERIMENTAL|Vaporized high CBD with THC|200mg pure CBD paired with 5mg THC
62744431|NCT01142778|EXPERIMENTAL|Trastuzumab, Docetaxel, and Bevacizumab|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of \<70% will receive trastuzumab and docetaxel along with bevacizumab in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the bevacizumab infusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
62744432|NCT01142778|ACTIVE_COMPARATOR|Trastuzumab and Docetaxel|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of \<70% will receive trastuzumab and docetaxel in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the study treatment perfusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
62744433|NCT01142778|ACTIVE_COMPARATOR|Trastuzumab and Docetaxel (Standard Regimen)|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of \>/=70% will receive trastuzumab and docetaxel in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the study treatment perfusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
62744434|NCT03760887|SHAM_COMPARATOR|No Home Sensory training|Patients who perform a home exercise program only
62744435|NCT03760887|EXPERIMENTAL|Home sensory training|Patients who perform home exercise and home sensory training
62744436|NCT03011970|ACTIVE_COMPARATOR|Oxytocin; 24IU, 15min|Intranasal administration, 24 international units (IU) oxytocin. Imaging starting 15min after nasal spray administration.
62744437|NCT03011970|ACTIVE_COMPARATOR|Oxytocin; 24IU, 45min|Intranasal administration, 24 IU oxytocin. Imaging starting 45min after nasal spray administration.
62744438|NCT03011970|ACTIVE_COMPARATOR|Oxytocin; 24IU, 75min|Intranasal administration, 24 IU oxytocin. Imaging starting 75min after nasal spray administration.
62744439|NCT03011970|ACTIVE_COMPARATOR|Oxytocin; 12IU, 45min|Intranasal administration, 12 IU oxytocin. Imaging starting 45min after nasal spray administration
62744440|NCT03011970|ACTIVE_COMPARATOR|Oxytocin; 48IU, 45min|Intranasal administration, 48 IU oxytocin. Imaging starting 45min after nasal spray administration
62744441|NCT03011970|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray.
62744442|NCT03401944|ACTIVE_COMPARATOR|Total Parenteral Nutrition (TPN)|Overnight infusion of Parenteral Nutrition supplied in all-in one bag -format. Infusion-rate of 0.16 gram Nitrogen/kg/day.
62372041|NCT04940741|EXPERIMENTAL|VER-01|VER-01 is administered orally (b.i.d.) using a dosing syringe. One unit corresponds to 2.5 mg THC. The optimal dose is titrated on a patient-by-patient basis. The maximum daily dose should not exceed 13 dose units (32.5 mg THC).
62372042|NCT04940741|PLACEBO_COMPARATOR|Placebo|The Placebo is administered orally (b.i.d.) using a dosing syringe. The optimal dose is titrated on a patient-by-patient basis, analogous to VER-01.
62372043|NCT04341311|EXPERIMENTAL|Marizomib|"All patients will initially receive marizomib (MRZ) alone (Course A1) The dose escalation and de-escalation for single agent and combination will be guided using the Bayesian optimal interval (BOIN) design~-Intravenously initially given every other week over a 28 day course but may go to weekly x 3 and weekly x 4 as the dose levels increase. Up to 26 courses."
62372044|NCT04341311|EXPERIMENTAL|Marizomib + Panobinostat|"If tolerated,combination of Marizomib: and panobinostat on subsequent cycles. The dose escalation and de-escalation for single agent and combination will be guided using the Bayesian optimal interval (BOIN) design.~* Intravenously initially given every other week over a 28 day course but may go to weekly x 3 and weekly x 4 as the dose levels increase. Up to 26 courses.~* Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course"
62372045|NCT01986517|EXPERIMENTAL|Feedback|Therapists assigned to this group will receive standardized feedback on their psychotherapeutic competency after every fourth treatment session with a patient for a period of 20 therapy sessions. The feedback will be given by two experienced raters who are licensed as psychological psychotherapists.
62372046|NCT01986517|EXPERIMENTAL|No feedback|Therapists assigned to this group will receive no feedback
62372047|NCT03780985|ACTIVE_COMPARATOR|intrauterine device insertion with a suture fixation|Intruterine device through hysterotomy incision during cesarean section with a suture fixation
62372048|NCT03780985|ACTIVE_COMPARATOR|intrauterine device insertion without a suture fixation|IUD through hysterotomy incision during cesarean section without a suture fixation
62372049|NCT06249880||Normative|40 neurotypical pediatric subjects
62372050|NCT00862524|EXPERIMENTAL|ARRY-334543 + gemcitabine|
62372051|NCT02743975|EXPERIMENTAL|Treatment group|Bevacizumab-800CW
62372052|NCT02705755|EXPERIMENTAL|TD-9855 Part A|Subjects will receive placebo and escalating single doses of TD-9855
62372053|NCT02705755|EXPERIMENTAL|TD-9855 Part B|Subjects will receive a single dose of TD-9855 or placebo.
62372054|NCT02705755|EXPERIMENTAL|TD-9855 Part C|Subjects will receive once daily doses of TD-9855 for up to 5 months as part of an optional outpatient open-label extension arm.
62744443|NCT03401944|PLACEBO_COMPARATOR|Control (saline infusion)|Overnight infusion of physiological saline at the same infusion-rate; ml/kg as intervention (TPN).
62744444|NCT04309877|EXPERIMENTAL|PO theophylline & IV LPS|Oral (PO) theophylline 400 mg/day for 2 weeks followed by a single intravenous (IV) bolus of lipopolysaccharide (LPS) 0.8 ng/kg of body weight
62744445|NCT04309877|EXPERIMENTAL|PO placebo & IV LPS|PO methylcellulose (placebo) daily for 2 weeks followed by a single intravenous (IV) bolus of lipopolysaccharide (LPS) 0.8 ng/kg of body weight
62744446|NCT04309877|EXPERIMENTAL|PO theophylline & IV placebo|PO theophylline 400 mg/day for 2 weeks followed by a single IV bolus of 0.9% saline
62744447|NCT04309877|PLACEBO_COMPARATOR|PO placebo & IV placebo|PO methylcellulose (placebo) daily for 2 weeks followed by a single IV bolus of 0.9% saline
62744448|NCT06324942|EXPERIMENTAL|Surgeon-administered Transversus Abdominis Plane Block (TAP block)|After uterine closure, the anterior abdominal wall on the contralateral side to the surgeon is elevated and retracted laterally by an assistant. The bowel and uterus is retracted using the surgeon's non-dominant hand, with or without a sponge. Under direct visualization, a blunted spinal needle is inserted lateral to the rectus muscle to avoid injury to inferior epigastric blood vessels. The needle is then gently advanced through the transversus abdominis fascia into the TAP plane, identified at loss of resistance, or 'a pop'. After aspiration to confirm no accidental placement of the needle intravascularly, local anaesthetic is infiltrated into the transverse abdominis plane through the parietal peritoneum by the surgeon at a prespecified dose of 0.25% bupivicaine 0.25 mL/kg (approximately 20cc). This is repeated on the contralateral side, after which closure of the fascia, subcutaneous tissue, and skin were performed.
62744449|NCT06324942|NO_INTERVENTION|No TAP block|A sham procedure will not be performed but the patient will be unaware of whether or not an injection was done.
62372055|NCT01814189|ACTIVE_COMPARATOR|sumatriptan+promethazine (SPr)|The SPr group denote patients receiving oral sumatriptan (50 mg) plus oral promethazine (50 mg).
62372056|NCT01814189|PLACEBO_COMPARATOR|Sumatriptan+placebo (SP)|The SP group denote patients receiving oral sumatriptan (50 mg) plus tablet of placebo matched to promethazine.
62372057|NCT03640520|EXPERIMENTAL|Intervention|Family-centered \& Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of Family Centered Care (FCC) practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.
62372058|NCT03640520|ACTIVE_COMPARATOR|Control|An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs, including a brief mention of FCC as one of these standards, with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness.
62372059|NCT00574366|EXPERIMENTAL|Erlotinib/RAD001 Ph I|"Tarceva (OSI-774; erlotinib) Everolimus (RAD001)~Study did not progress to Phase II:~Experimental: Erlotinib/RAD001 Phase II Maximum tolerated dose of erlotinib (Tarceva,OSI-774) and RAD001 (Everolimus)"
62372060|NCT03714789||Meropenem|Patients requiring dialysis and receiving meropenem for infection or suspended infection.
62372061|NCT03714789||Vancomycin|Patients requiring dialysis and receiving vancomycin for infection or suspended infection.
62372062|NCT03714789||Ceftriaxone|Patients requiring dialysis and receiving ceftriaxone for infection or suspended infection.
62372063|NCT03099304|EXPERIMENTAL|Ruxolitinib cream 1.5% twice daily (BID)|Ruxolitinib cream 1.5% BID for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
62372064|NCT03099304|EXPERIMENTAL|Ruxolitinib cream 1.5% once daily (QD)|Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
62372065|NCT03099304|EXPERIMENTAL|Ruxolitinib cream 0.5% QD|Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
62372066|NCT03099304|EXPERIMENTAL|Ruxolitinib cream 0.15% QD|Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (opportunity for re-randomization to a higher dose at Week 24 if \< 25% improvement in F-VASI score), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
62372067|NCT03099304|PLACEBO_COMPARATOR|Vehicle BID|Vehicle cream BID for 24 weeks, followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% QD, or 0.5% QD for Weeks 24 to 52, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
62372068|NCT04818489|EXPERIMENTAL|Colchicine group|Colchicine 0.5 mg (2 tablets: 1 mg) twice per day as a loading dose, followed by one tablet 0.5 twice per day for three weeks in addition to the local standard protocol of COVID19 management
62372069|NCT04818489|PLACEBO_COMPARATOR|Control group|the local standard protocol of COVID19 management
62372070|NCT00493844|EXPERIMENTAL|1|Discharge if clinical risk score \<3 points + Nt-proBNP \<110 ng/L
62372071|NCT00493844|ACTIVE_COMPARATOR|2|Discharge if negative exercise testing
62372072|NCT02023541|OTHER|Resectable disease|Patients with resectable disease will undergo treatment with proton beam therapy.
62372073|NCT02023541|OTHER|Unresectable disease|Patients with unresectable disease will undergo treatment with proton beam therapy.
62372074|NCT06446050|EXPERIMENTAL|MSC-L|Mesenchymal Stem Cells mobilizing Lymphocytes (MSC-L)
62372075|NCT03874104|EXPERIMENTAL|Study product|Extensively Hydrolysed Formula containing Pre- and Probiotics
62372076|NCT00655239|ACTIVE_COMPARATOR|Control|Participants will use commercially available computer games.
62372077|NCT00655239|EXPERIMENTAL|Active|Participants will receive targeted neuroadaptive cognitive training with neuroplasticity-based software created by Posit Science Corporation.
62372078|NCT00655239|ACTIVE_COMPARATOR|Healthy Control|Healthy participants will receive targeted neuroadaptive cognitive training with neuroplasticity-based software created by Posit Science Corporation.
62372079|NCT01942304|ACTIVE_COMPARATOR|Anorganic bovine bone mineral in direct sinus augmentation|Anorganic bovine bone mineral
62372080|NCT01942304|EXPERIMENTAL|Alloplastic bone putty in direct sinus augmentation|Alloplastic bone putty
62372081|NCT02174809|EXPERIMENTAL|5As|Physicians' use of the 5As tool to discuss gestational weight gain with their pregnant patients
62372082|NCT02174809|ACTIVE_COMPARATOR|Usual care|Usual care by physicians in addressing gestational weight gain with their pregnant patients
62372083|NCT01365442||Consenting, eligible participants|All consenting eligible participants in the study area will receive the oral cholera vaccine
62372084|NCT01131078|EXPERIMENTAL|Bevacizumab + Irinotecan + Capecitabine (1000 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle. Irinotecan was administered as a 240 mg/m\^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks. Capecitabine was administered orally at a dose of 1000 mg/m\^2 twice daily (Day 2 to 15). Cycle length was 3 weeks consisting of 2 weeks of capecitabine treatment followed by 1 week without treatment up to 6 cycles. After 6 cycles, participants with objective response or SD were treated with bevacizumab alone until unacceptable toxicity, PD, or participant withdrawal.
62372085|NCT01131078|EXPERIMENTAL|Bevacizumab + Capecitabine (1250 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle in combination with capecitabine administered orally at 1250 mg/m\^2 twice daily (Day 1 to 14). Cycle length was 3 weeks with 2 weeks of capecitabine treatment followed by 1 week without treatment up to 6 cycles. After 6 cycles, participants with objective response or SD were treated with bevacizumab alone until unacceptable toxicity, PD, or participant withdrawal.
62372086|NCT01131078|EXPERIMENTAL|Bevacizumab + Capecitabine (650 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 Week cycle in combination with capecitabine administered orally at 650 mg/m\^2 twice daily (Day 1 to 21). Cycle length was 3 weeks with 3 weeks of capecitabine treatment without interruptions. Participants received the same regimen until unacceptable toxicity, PD, or participant withdrawal.
62372087|NCT00927576||Control subjects|Control subjects = 237. These subjects underwent extensive testing with computerized neuropsychological tests including digit span testing, spatial span testing, simple reaction time testing, choice reaction time testing, finger tapping, verbal fluency, design fluency, verbal list learning, questionnaire completion, and the trail making test.
62372088|NCT00927576||TBI patients|TBI patients N = 28. These patients underwent extensive testing with computerized neuropsychological tests including digit span testing, spatial span testing, simple reaction time testing, choice reaction time testing, finger tapping, verbal fluency, design fluency, verbal list learning, questionnaire completion, and the trail making test.
62372089|NCT02996110|ACTIVE_COMPARATOR|Nivolumab + Ipilimumab|Nivolumab + Ipilimumab
62372090|NCT02996110|EXPERIMENTAL|Nivolumab + Relatlimab|Nivolumab + Relatlimab
62372091|NCT02996110|EXPERIMENTAL|Nivolumab + BMS-986205|Nivolumab + BMS-986205
62372092|NCT02996110|EXPERIMENTAL|Nivolumab + BMS-813160|Nivolumab + BMS-813160 (CCR2/5 dual antagonist)
61986306|NCT02081690|EXPERIMENTAL|Macitentan|Macitentan tablet, dose of 10 mg, once daily
61986307|NCT01214018||Reference|Nearest relatives of brain-dead patients who donated organs
61986308|NCT01214018||Opposition|Nearest relatives of brain-dead patients opposed to organ donation
62372093|NCT01550614|EXPERIMENTAL|Arm A: Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer and standard of care angina medication
62372094|NCT01550614|NO_INTERVENTION|Arm B|Standard of care angina medication
62372095|NCT00712270|NO_INTERVENTION|Standard of Care|Screening and Baseline Procedures followed by Referral to Community Care. Baseline Procedures may be repeated at a later time if appropriate.
62372096|NCT00712270|ACTIVE_COMPARATOR|Drug: Aripiprazole|Screening and Baseline Procedures followed by 16 weeks of treatment with aripiprazole, followed by repeat of baseline procedures and referral to community care.
62372097|NCT00712270|ACTIVE_COMPARATOR|Risperidone|Screening and Baseline Procedures followed by 16 weeks of treatment with Risperidone,followed by repeat of baseline procedures and referral to community care.
62372098|NCT03073369|ACTIVE_COMPARATOR|Oral Ergocalciferol|Oral Ergocalciferol 50000 IU once daily for 6 weeks
62372099|NCT03073369|PLACEBO_COMPARATOR|Placebo|
62372100|NCT02076243|EXPERIMENTAL|nab-paclitaxel|weekly dosed nab-paclitaxel chemotherapy (days 1, 8 , 15 of a 28 day cycle) administered as an I.V. infusion over approximately 30 minutes. Dosage is determined by weight and height of participant.
62372101|NCT01675856|ACTIVE_COMPARATOR|Urgent endoscopy|Oesophagogastroduodenoscopy done within 6hours of first GI specialists consultation
62372102|NCT01675856|PLACEBO_COMPARATOR|Early endoscopy|Oesophagogastroduodenoscopy done within 24hours of first GI specialists consultation
62372103|NCT06398665|EXPERIMENTAL|Accelerated Intermittent Theta-Burst Stimulation|Non-invasive brain stimulation technique, accelerated intermittent theta-burst stimulation (iTBS) repetitive transcranial magnetic stimulation (rTMS), for treating post- concussive syndrome (PCS) in persons with mild traumatic brain injury
62372104|NCT06096389|PLACEBO_COMPARATOR|Maltodextrin (CHO)|This group will be given isocaloric carbohydrate (maltodextrin)
62372105|NCT06096389|ACTIVE_COMPARATOR|Whey Protein Isolate (WIP)|This group will receive whey protein isolate
62372106|NCT06096389|EXPERIMENTAL|House Cricket (HCP)|This group will receive house cricket powder
62372107|NCT01537523|EXPERIMENTAL|community-care program|receive intervention for 12 weeks
62372108|NCT01537523|NO_INTERVENTION|control|
62372109|NCT01501162|PLACEBO_COMPARATOR|alcohol, hepatitis, Placebo|We explored the therapeutic effects of probiotics in patients with alcoholic hepatitis
62372110|NCT01501162|ACTIVE_COMPARATOR|hepatitis, alcohol, probiotics|We explored the therapeutic effects of probiotics in patients with alcoholic hepatitis
62372111|NCT05822960|EXPERIMENTAL|far-infrared radiation on foot acupoints|experimental group far-infrared radiation on foot acupoints during dialysis,during dialysis,, and the irradiation distance was 20 cm for 40 minutes each time for six months.
62372112|NCT05822960|NO_INTERVENTION|The control group received general clinical routine care|no far-infrared radiation on foot acupoints
62372113|NCT01171742|EXPERIMENTAL|IHIO|Intermittent hepatic inflow occlusion (IHIO) by clamping of the portal triad, minimizes blood loss and operation time during liver resection. In addition, ischemic preconditioning with IHIO has been reported to have protective effects in patients undergoing liver resection. IHIO'll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
62372114|NCT01171742|SHAM_COMPARATOR|Control|The donor liver parenchyma'll be transected without IHIO.
62372115|NCT00424840|EXPERIMENTAL|Bortezomib 1.3 mg/m2|Level 1 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
62372116|NCT00424840|EXPERIMENTAL|Bortezomib 1.6 mg/m2|Level 2 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
62372117|NCT00424840|EXPERIMENTAL|Bortezomib 1.8 mg/m2|Level 3 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
62372118|NCT02333136||IVRS studied|subjects will be monitored for changes in hematocrit based on results of in vivo raman spectroscopy scatter
62372119|NCT00102804|EXPERIMENTAL|Pemetrexed and Best Supportive Care|
62372120|NCT00102804|PLACEBO_COMPARATOR|Placebo and Best Supportive Care|
62372121|NCT06367049||Patient group|Sampling their nasopharyngeal swab specimens and peripheral blood specimens.
62372122|NCT06367049||Non-patient group|Sampling their nasopharyngeal swab specimens and peripheral blood specimens.
62372123|NCT01153568|PLACEBO_COMPARATOR|Placebo|placebo
62372124|NCT01153568|EXPERIMENTAL|Vitamin D 3|Vitamin D3 will be available in doses of 60, 90, 120, and 150 µg
62372125|NCT04655690|EXPERIMENTAL|NNC0471-0119|Participants randomised to NNC0471-0119
62372126|NCT04655690|ACTIVE_COMPARATOR|Faster aspart|Participants randomised to faster aspart.
61986309|NCT01214018||Medical/Legal|Nearest relatives of brain-dead patients for whom organ donation was not an option because of medical or legal reasons
62372127|NCT04255368|EXPERIMENTAL|Water-soluble choline|A breakfast meal consisting of 1 cup of tomato soup containing 600 mg choline as choline bitartrate; served with a bagel with margarine-butter spread and one cup of water.
62372128|NCT04255368|EXPERIMENTAL|Fat-soluble choline|A breakfast meal consisting of 1 cup of tomato soup containing 600 mg choline as phosphatidylcholine; served with a bagel with margarine-butter spread and one cup of water.
62372129|NCT04255368|ACTIVE_COMPARATOR|No choline|A breakfast meal consisting of 1 cup of tomato soup containing no choline; served with a bagel with margarine-butter spread and one cup of water.
62372130|NCT01432938|EXPERIMENTAL|Warfarin first, then Dulaglutide + Warfarin|A single, 10-milligram (mg) dose of warfarin administered orally on Day 1 (Treatment 1). There was a washout period of at least 24 days between treatment periods. Then a single, 1.5-mg dose of dulaglutide administered subcutaneously on Day 1, followed by a single, 10-mg dose of warfarin administered orally on Day 3 (Treatment 2).
62372131|NCT01432938|EXPERIMENTAL|Dulaglutide + Warfarin first, then Warfarin|A single, 1.5-mg subcutaneous dose of dulaglutide on Day 1, followed by a single, 10-mg oral dose of warfarin on Day 3 (Treatment 2). There was a washout period of at least 24 days between treatment periods. Then a single, 10-mg oral dose of warfarin on Day 1 (Treatment 1).
62372132|NCT04490265|EXPERIMENTAL|Problem-Solving Treatment|Our PST is 12-weeks and teaches patients strategies to address real-life problems.20 Sessions are once a week for one hour except for the first session, which is two hours. The treatment has four main goals: 1. Safety planning; 2. Problem-orientation-addressing how patients approach problems; 3. Planful problem-solving or a logical approach to address problems; 4. Behavioral activation of daily activities. Patients are provided weekly worksheets on problem-solving and receive weekly assessment of emotional state and suicidal ideation monitoring.
62567175|NCT05897281|EXPERIMENTAL|Exercise Group|In addition to routine training, the experimental group will be done a progressive resistance band exercise program (SHOOT) created for shooters, 3 days a week for 8 weeks, accompanied by a physiotherapist.
62567176|NCT05897281|OTHER|Control Group|The control group will continue their routine training.
62567177|NCT01788631|ACTIVE_COMPARATOR|Regadenoson Arm|1.44 mcg/kg/hour infused over 48 hours
62372133|NCT04490265|PLACEBO_COMPARATOR|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was ... ) in order to help identify experiences for discussion in session. Participants will be informed that the control condition is supportive and non-directive, and that providers will not engage in problem-solving. Providers will be taught to use reflective listening, clarification, empathy, and validation. The control consists of 12 weekly sessions delivered via telephone or video."
62372134|NCT00189436|ACTIVE_COMPARATOR|Treatment with Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
62372135|NCT00189436|ACTIVE_COMPARATOR|Usual care|Subject is treated with usual care as provided by the doctor. Usual care normally consists of treatment with albuterol with or without an oral steroid.
62372136|NCT00928304|EXPERIMENTAL|Florbetaben (BAY94-9172)|
62372137|NCT01921699|OTHER|irrelevant|
62372138|NCT02209168||Infertile Indian Population|200 Infertile Indian population
62372139|NCT02209168||Infertile arabian population|200 Infertile Arabian population
62372140|NCT02209168||Infertile caucasian population|200 Infertile Caucasian population
62372141|NCT00442130|EXPERIMENTAL|GM-K562 Vaccine|"Biological/Vaccine: GM-K562 vaccine The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.~Procedure/Surgery: stem cell transplantation Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation"
62372142|NCT02628899|OTHER|Prospective TAVR Arm|200 patients prospectively undergoing transfemoral TAVR
62372143|NCT02628899|OTHER|Historical SAVR Controls|Historical controls will be selected from among patients at the same site who have undergone isolated bioprosthetic SAVR within the previous 36 months. TAVR patients will then be matched to SAVR patients using STS database variables to perform propensity matching, including (but not limited to) age, gender, race, ethnicity, STS score, and valve prosthesis size.
62372144|NCT02628899|OTHER|Low-Risk TAVR with Bicuspid Aortic Valve|The third arm of the trial will comprise a registry of TAVR in up to 100 low-risk patients with bicuspid aortic valve. The results from the registry arm will be analyzed independently.
62372145|NCT04929691|EXPERIMENTAL|CPAP- Helmet Users|Patients admitted to a study site with suspected or confirmed COVID-19 and who consented to using the CPAP helmet
62372146|NCT04929691|ACTIVE_COMPARATOR|Non-CPAP helmet users|Patients admitted to a study site with suspected or confirmed COVID-19 but who did not use a CPAP helmet
62372147|NCT00732238|EXPERIMENTAL|Arm 1|Removal of Bladder Catheter. Urine Culture Post Catheter Removal. Shorter Duration of Antibiotic Therapy.
62744450|NCT01244594|EXPERIMENTAL|High cadence, low resistance|Subjects in this arm will cycle with functional electrical stimulation at a higher cadence (speed) and a lower resistance.
62744451|NCT01244594|EXPERIMENTAL|Low cadence, high resistance|Subjects in this arm will cycle with functional electrical stimulation at a lower cadence (speed) and a higher resistance.
62744452|NCT01527305|EXPERIMENTAL|Paliperidone palmitate|
62372148|NCT00732238|ACTIVE_COMPARATOR|Arm 2|Urinary Catheter Is Not Exchanged. Antibiotic Therapy Is Based On Culture Obtained From Existing Catheter. Longer Duration of Antibiotic Therapy.
62372149|NCT01505140|NO_INTERVENTION|Usual Western style diet|Participants will consume their usual Western style diet avoiding tree nuts
62372150|NCT01505140|EXPERIMENTAL|Whole walnuts|Participants will consume usual Western style diet adding 75 gm whole walnuts per day
62744453|NCT03155529||radical hysterectomy group|"Using dynamic MRI and 3D reconstruction to assess the effect of RH on pelvic floor muscles and pelvic organs (location and mobility of bladder neck and urethral).~Inclusion Criteria： ①Patients diagnosed as FIGO stage IA2、IB1、IIA1 cervical cancer ; ②Patients diagnosed as FIGO stage IB2、IIA2 cervical cancer, eligible for RH after neoadjuvant chemotherapy; ③Patients diagnosed as FIGO stage IIA endometrial carcinoma; ④Patients didn't have pelvic organ prolapse and urinary incontinence; ⑤Ability to hold Valsalva for dynamic MRI; ⑥Patients aged 20-70 years; ⑦Patients undergone RH surgery; ⑧Informed consent was signed.~Exclusion Criteria：~①With MRI or urodynamic examination contraindication; ②Previously undergone POP or SUI surgery; ③BMI\>30 ④With serious postoperative complications."
62744454|NCT06658652|EXPERIMENTAL|Enlicitide Decanoate Food Effect|Participants will be administered enlicitide decanoate on Day 1 with or without food.
62372151|NCT04889755|OTHER|SibACCESS|This is a single-arm trial of a group-based, posttraumatic stress intervention for adolescent siblings of children with cancer. The intervention includes a parent educational webinar, seven group sibling sessions, one individual parent session, and one individual sibling session.
62372152|NCT03675919|ACTIVE_COMPARATOR|Control group|The control group will be provided a scale, a step counter as well as access to the online portal and will remain in routine care.
62372153|NCT03675919|EXPERIMENTAL|TeLIPro group|The TeLIPro group will be provided a scale, a step counter, a blood glucose meter with test stripes as well as access to the online portal and will get telemedical coaching.
62372154|NCT03766113|OTHER|Healthy volunteer|"* 50 subjects~* A single neurofeedback coupling electroencephalogram and functional MRI in time actual ."
62372155|NCT03766113|OTHER|Patients at the early stage after stroke|"* 30 subjects~* Effectiveness of an electroencephalogram-neurofeedback"
62372156|NCT03766113|OTHER|Patients at the chronic stage after stroke|"* 36 subjects~* Effectiveness of a neurofeedback coupling electroencephalogram and functional MRI in time actual"
62372157|NCT01880203|EXPERIMENTAL|aspiration for Molecular Cytogenetic Analysis.|
62372158|NCT03022604|EXPERIMENTAL|C4/Generation 4|12 grams of C4/Generation 4 Extreme
62372159|NCT03022604|ACTIVE_COMPARATOR|C450X|12 grams of C4X (150% of regular dose)
62372160|NCT03022604|PLACEBO_COMPARATOR|Placebo|12 grams of flavored dextrose
62372161|NCT01387594|EXPERIMENTAL|Cohort 1|Interventions prior to treatment. Control arm
62372162|NCT01387594|EXPERIMENTAL|Cohort 2|Interventions prior to and after 3 monthly injections
62372163|NCT02406339|NO_INTERVENTION|Control|Are not subject to any intervention.
62372164|NCT02406339|EXPERIMENTAL|Electrotherapy|The athletes will be submitted to NMES of bilateral quadriceps. The stimulation will be held in order to induce the move flexion / extension involuntary knee in extension machine, with resistance of 30% of maximum voluntary strength.
62372165|NCT02406339|EXPERIMENTAL|Electrotherapy + Vascular Occlusion|The same as in Electrotherapy group, athletes are subjected to NMES associated total vascular occlusion of the members below the level of the groin.
62372166|NCT00039091|EXPERIMENTAL|Treatment (ipilimumab)|Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody IV over 90 minutes on day 1. Courses repeat every 2 months in the absence of disease progression or unacceptable toxicity.
62372167|NCT01525420|EXPERIMENTAL|ACT|ACT: This is the experimental arm of the study. This included 5 weekly sessions of ACT therapy via telephone.
62372168|NCT01525420|ACTIVE_COMPARATOR|CBT|CBT: This is the control arm of the study. This included 5 weekly sessions of CBT therapy via telephone.
62372169|NCT02365506|EXPERIMENTAL|Eleclazine 24 mg + Eleclazine 48 mg + Placebo|Participants will receive placebo to match eleclazine on Days 1 and 4, eleclazine 24 mg on Day 2 and eleclazine 48 mg on Day 3.
62372170|NCT02365506|EXPERIMENTAL|Eleclazine 48 mg + Placebo|Participants will receive placebo to match eleclazine on Days 1, 2 and 4, and eleclazine 48 mg on Day 3.
62372171|NCT02365506|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo to match eleclazine on Days 1 to 4.
62372172|NCT04223206|EXPERIMENTAL|Hemodialysis with sarcopenia|10 HD patients, affected by sarcopenia will a undergo 3-months supplementation with NATURLENS
62372173|NCT04223206|NO_INTERVENTION|Controls|10 HD patients, affected by sarcopenia will be followed for 3 months without any supplementation
62372174|NCT01801774|PLACEBO_COMPARATOR|Dexamethasone|Dexamethasone 0.1%/Tobramycin 0.3% eye drop 4 times per day for 28 days
62372175|NCT01801774|ACTIVE_COMPARATOR|Triamcinolone|Subtenon 20-mg Triamcinolone injection
62744455|NCT06658652|EXPERIMENTAL|Enlicitide Decanoate Water Effect|Participants will be administered enlicitide decanoate on Day 1 with high, medium, and low volumes of water.
62744456|NCT02350166|EXPERIMENTAL|Laparoscopic group|Laparoscopic group, laparoscopic surgery or laparoscopic-assisted small-incision for resection of laparoscopic colorectal tumor combined with synchronously small-incision open resection of liver metastasis
62744457|NCT02350166|NO_INTERVENTION|Conventional group|Conventional group, conventional laparotomy for simultaneously resection of both primary colorectal tumor and liver metastasis
62372176|NCT02158195||Patients|
62372177|NCT02158195||controls|
62372178|NCT04927351|EXPERIMENTAL|Intervention|New electronic medical record based discharge medication order set.
62372179|NCT04927351|NO_INTERVENTION|Control|Usual Care
62372180|NCT05409092|EXPERIMENTAL|Astaxanthin|The astaxanthin capsules will contain 8 mg of astaxanthin from freshwater algae in starch beadlets. Ingested daily for 4 weeks.
62372181|NCT05409092|PLACEBO_COMPARATOR|Placebo|The placebo capsules will contain just the starch beadlets with natural red coloring from the pitaya fruit. Ingested daily for 4 weeks.
62372182|NCT00005577|EXPERIMENTAL|Arm I|Patients receive gemcitabine IV over 30 minutes weekly for 2 weeks. Patients achieving objective response or stable disease after 3 weeks may receive additional courses of therapy every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity.
62372183|NCT03012360|PLACEBO_COMPARATOR|no antibiotic treatment for VAT|3 days of placebo
62372184|NCT03012360|EXPERIMENTAL|antibiotic treatment for 3 days|"Patients randomized in one of the two experimental groups will receive 3 days of antimicrobials. Antibiotic treatment is standardized, based on the time of onset of VAT, and presence of risk factors for MDR bacteria:~* patients with early-onset VAT (\< 5 days of mechanical ventilation), with no risk factor for MDR will receive ceftriaxone .~* patients with late-onset VAT (≥5 days of mechanical ventilation), or with at least one risk factor for multidrug resistant bacteria will receive imipenem , and ciprofloxacin as empirical treatment.~When methicillin-resistant Staphylococcus aureus (MRSA) is suspected linezolid will be added to empirical treatment.~3 days of imipenem and ciprofloxacin with optional linezolid, followed by 4 d of placebo"
62372185|NCT02616536|ACTIVE_COMPARATOR|Flipped classroom|The flipped classroom is new pedagogical method, which employs asynchronous video lectures and practice problems as homework and active, group-based problem solving activities in the classroom.
62372186|NCT02616536|ACTIVE_COMPARATOR|traditional classroom|The classroom lecture is a special form of communication in which voive, gesture. Movements, facial expression and eye contact can either complement or detract from the content. No matter what your topic, your delivery and manner of speaking immeasurably influence your student's' attentiveness and learning.
62372187|NCT01877005|EXPERIMENTAL|Ruxolitinib|"Induction period: Ruxolitinib will be given twice daily during 6 cycles of 28 days.~Maintenance period: patients who achieve at least a stable disease (according Cheson 2007) at the end of cycle 6 and for whose a clinical benefit is observed according to the Investigator's opinion will be eligible for maintenance treatment by ruxolitinib twice daily every day of 28-day cycles."
62372188|NCT03135262|EXPERIMENTAL|Dose-Escalation Cohort: FL|Induction Treatment: Participants will receive either Regimen A or Regimen B. Regimen A: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Regimen B (in bridging cohort): Participants will receive obinutuzumab alone in Cycle 1 and obinutuzumab with idasanutlin and venetoclax (both at maximum tolerated dose \[MTD\] established from Regimen A) in Cycles 2 to 6. Post-Induction Treatment (Maintenance Treatment): Participants will receive obinutuzumab every 2 months for 24 months; idasanutlin and venetoclax for 6 months.
62567178|NCT01788631|PLACEBO_COMPARATOR|Placebo Arm|Placebo infused over 48 hours
62744458|NCT02793349|EXPERIMENTAL|Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
62372189|NCT03135262|EXPERIMENTAL|Dose-Escalation Cohort: DLBCL|Induction Treatment: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. In bridging cohort, participants will receive rituximab on Day 1 of Cycles 1 to 6 and idasanutlin and venetoclax (both at MTD) in Cycles 1 to 6. Post-Induction Treatment (Consolidation Treatment): Participants will receive obinutuzumab or rituximab (according to study treatment received in the induction) every 2 months for 6 months; idasanutlin and venetoclax for 6 months.
62372190|NCT03135262|EXPERIMENTAL|Expansion Cohort: FL|Induction Treatment: Participants will receive idasanutlin and venetoclax at the RP2D of the selected regimen (Regimen A or B) identified during the dose-escalation phase in combination with obinutuzumab. Regimen A: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Regimen B (in bridging cohort): Participants will receive obinutuzumab alone in Cycle 1 and obinutuzumab with idasanutlin and venetoclax in Cycles 2 to 6. Post-Induction Treatment (Maintenance Treatment): Participants will receive obinutuzumab every 2 months for 24 months; idasanutlin and venetoclax for 6 months.
62744459|NCT06643234|ACTIVE_COMPARATOR|Group (A) modified sublay hernioplasty:|In the classic sublay hernioplasty technique, the hernia sac remains unopened. The procedure involves dissection of the posterior rectus sheath, which is then sutured at the midline. A mesh is placed behind the rectus muscle and in front of the posterior rectus sheath. Subsequently, the rectus muscle and anterior rectus sheath are sutured together at the midline, introducing tension to the repair. Conversely, the modified sublay hernioplasty technique follows a similar approach but with a key difference: the rectus muscle and anterior rectus sheath are left undisturbed without suturing them together. This modification aims to achieve a tension free repair, potentially reducing complications and enhancing overall outcomes.
62372191|NCT03135262|EXPERIMENTAL|Expansion Cohort: DLBCL|Induction Treatment: Participants will receive rituximab on Day 1 of Cycles 1 to 6; idasanutlin and venetoclax (both at RP2D) on Days 1 to 5 of Cycles 1 to 6 or rituximab on Day 1 of Cycles 1 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Post-Induction Treatment (Consolidation Treatment): Participants will receive rituximab every 2 months for 6 months; idasanutlin and venetoclax for 6 months.
62372192|NCT03386006|EXPERIMENTAL|Noom Coach for Bariatric Health|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app.
62372193|NCT03386006|NO_INTERVENTION|Usual Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period."
62372194|NCT00911066|EXPERIMENTAL|MLN4924|
62372195|NCT00911066|EXPERIMENTAL|Azacitidine|
62372196|NCT05935475|ACTIVE_COMPARATOR|group A|75 children and adolescent will insert dialysis catheter using the anatomical landmark technique
62372197|NCT05935475|ACTIVE_COMPARATOR|group B|75 children and adolescent will insert dialysis catheter using the ECG guided technique
62372198|NCT05596474|EXPERIMENTAL|Beet-root juice plus red-light therapy|
62372199|NCT05596474|SHAM_COMPARATOR|Beet-root juice plus sham light therapy|
62372200|NCT05596474|PLACEBO_COMPARATOR|Placebo plus red-light therapy|
62744460|NCT06643234|ACTIVE_COMPARATOR|Group (B) IPOM:|The hernia repair procedure involved several key steps. First, the hernial sac was fully exposed and completely removed. Following this, a synthetic mesh was placed internally, covering the defect with overlapping edges to ensure adequate reinforcement. The mesh was then fixed to the anterior abdominal wall using sutures, which were applied through the supporting layers of the abdominal wall to secure the mesh in place. Preoperatively, all patients underwent comprehensive general and local examinations, routine laboratory blood tests, and abdominal ultrasound to evaluate the size of the hernia defect.
62372201|NCT05596474|ACTIVE_COMPARATOR|Placebo plus sham light therapy|
62372202|NCT02256345|ACTIVE_COMPARATOR|KNO3 active comparator|KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated
62372203|NCT02256345|PLACEBO_COMPARATOR|KCl placebo comparator|KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated
62372204|NCT03399786|EXPERIMENTAL|evinacumab|
62372205|NCT03399786|EXPERIMENTAL|Placebo|
62372206|NCT05789914|EXPERIMENTAL|Small Intestinal Submucosa Membrane|
62372207|NCT05789914|ACTIVE_COMPARATOR|Bio-guide|
62372208|NCT00654368|ACTIVE_COMPARATOR|Etanercept + Methotrexate|After six months of treatment with 50 mg/week subcutaneous etanercept added to existing methotrexate therapy of at least 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses) participants were randomized to continue both etanercept plus methotrexate for an additional 18 months.
62372209|NCT00654368|EXPERIMENTAL|Etanercept Only|After six months of treatment with 50 mg/week subcutaneous etanercept added to existing methotrexate therapy of at least 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses) participants were randomized to discontinue methotrexate (tapered over 6 weeks) and continue etanercept alone for an additional 18 months.
62372210|NCT05810376|EXPERIMENTAL|Experimental Group|Experimental group will receive patient education, exercise, and digital-based physical activity intervention.
62372211|NCT05810376|ACTIVE_COMPARATOR|Control Group|Control group will receive patient education and exercise.
62372212|NCT03238079|EXPERIMENTAL|Open-Label 10% IGIV|"IMP will be administered every 21 or 28 days in accordance with the subject's weekly regimen at screening for a period of 12 months. Subjects on a 21-day regimen will receive approximately 17 infusions, and subjects on a 28-day regimen will receive approximately 13 infusions.~The starting dose will be the previous IGIV dose or a dose calculated from the previous SCIG dose up to a maximum of 900 mg/kg/mo."
62567179|NCT03359993||Preterm infants intubated|All participants were preterm infants intubated in the delivery room for Infantile Respiratory Distress Syndrome (IRDS). The purpose of this research is to determine a premedication of intubation. This consists of describing a simple and effective method for premedication in the delivery room, using the umbilical vein, directly perforated through the Wharton jelly.
62744461|NCT06616740|SHAM_COMPARATOR|Cricoid pressure group|Cricoid pressure will be applied during LMA ProSeal insertion.
62744462|NCT06616740|EXPERIMENTAL|Paratracheal pressure group|Paratracheal pressure will be applied during LMA ProSeal insertion.
62744463|NCT04880083|EXPERIMENTAL|Formula-Fed (FF) Group|Subjects will be fed commercial bovine milk-based, whey-predominant, α-lactalbumin-enriched term formula with high sn-2 palmitate fat blend, supplemented with oligofructose for 6 weeks.
62744464|NCT04880083|NO_INTERVENTION|Breast-Fed (BF) Group|Subjects will continue exclusive/ predominant breastfeeding for 6 weeks. Breastmilk may be consumed directly from the breast or breast milk may be expressed and fed through infant feeding bottle.
62372213|NCT02280096|ACTIVE_COMPARATOR|4-aminopyridine treatment|4-aminopyridine is given as gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as the excipient. Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
62372214|NCT02280096|PLACEBO_COMPARATOR|Placebo|Patients randomized to the placebo sequence will receive placebo for 20 weeks after the run-in period. They will be blinded to the fact that they are taking placebo, and capsules will be identical in appearance to the intervention capsules.
62372215|NCT04570228|ACTIVE_COMPARATOR|Treatment group|Pulmonary artery denervation with the TIVUS™ System will be performed immediately after the right heart catheterization and pulmonary artery angiography.
62744465|NCT06132477|ACTIVE_COMPARATOR|GLP-1 Agonist Group|This cohort will consist of patients undergoing bariatric surgery who are currently receiving a GLP-1 Agonists for weight loss and/or diabetes management, that will be maintained on their preoperative dose of GLP-1 agonist following their bariatric surgery. This includes semaglutide, tirzepitide, among others. The dosage will be variable, but will be the same dose the patient is on prior to the bariatric surgery. Duration will be one of the aims of the study.
62744466|NCT06132477|NO_INTERVENTION|Non-GLP-1 Agonist Group|This cohort will consist of patients undergoing bariatric surgery who are currently receiving a GLP-1 Agonist for weight loss and/or diabetes management that will be required to stop taking their preoperative dose of GLP-1 agonist following their bariatric surgery. Dosage preoperative will be variable based on what the patient is currently taking, as well as the medication being taken.
62744467|NCT04587700||Non-marijuana user|Has never consumed marijuana or has abstained for at least the past 12 months
62744468|NCT04587700||Chronic Marijuana User|Has used marijuana in any form at least once a week for the past 3 months
62744469|NCT05835336|EXPERIMENTAL|Active|VIZO Glasses- personalized
62744470|NCT03459001||Tube Fed Malnourished Outpatients|Outpatients that are malnourished or at risk of malnutrition and have been placed on a nutritional care plan, which includes a complete tube feeding formula as sole source nutrition
62744471|NCT04354077|EXPERIMENTAL|NAc DBS|Subjects will receive bilateral DBS of the NAc
62372216|NCT04570228|SHAM_COMPARATOR|Sham control group|A sham treatment of pulmonary artery denervation with the TIVUS™ System will be performed immediately after the right heart catheterization pulmonary artery angiography. The sham procedure will be identical to the denervation procedure, with the only exception that the procedure will use a sham setting on the control console.
62744472|NCT06394544|EXPERIMENTAL|Brazil nut|"Each patient will receive 30 units of Brazil nuts per month, to consume one nut/day for two months. The time and daily amount of nuts were based on the European Food Safety recommendation Authority (EFSA). The adequate value for selenium intake was determined by EFSA aiming at the maximum serum concentration of Selenoprotein P and glutathione peroxidase activity, reached between four and 10 weeks, with 70 µg/day; we consider that a Brazil nut can contain up to 400 µg of Se.~The use of fresh nuts made it impossible to use a placebo with the same sensory characteristics. Then, in the control stage, volunteers will receive conventional conservative nutritional treatment, without nut supplementation."
62744473|NCT06394544|NO_INTERVENTION|Washout|Time T2 will be a washout period , so that residual effects between stages T1 and T3 are avoided.
62744474|NCT06394544|NO_INTERVENTION|Crossover|the crossover between the groups will allow the same participant to be exposed, at different times, to the intervention stage and the control stage.
62744475|NCT05754944||Cancer patients having surgery|This is a prospective cohort study where patients who are 65 years or older with either a history of diabetes (requiring medication or insulin) or smoking history (current smoker, smoker within the last 15 years, or ≥ 20 year pack history), facing major head and neck, thoracic, abdominal, or pelvic surgery will be screened for PAD with an ABI/TBI to establish prevalence and to compare prevalence among races to meet
62744476|NCT06659107|EXPERIMENTAL|Elderly patients with proximal humeral fractures Neer type 2 and 3|Both sexes, age from 60 to 80
62744477|NCT04426149|EXPERIMENTAL|interventional|supplement: trehalose
62744478|NCT03653156||Mild cognitive impairment (MCI) and its subtypes|MCI cohort consists of mild cognitive impairment subjects with memory loss as predominant symptom, including amnestic mild cognitive impairment and vascular cognitive impairment no dementia, which recruit from community population and hospital population.
62744479|NCT03653156||Sporadic Alzheimer's disease (SAD)|SAD cohort consists of mild to moderate sporadic Alzheimer's disease subjects, which recruit from community population and hospital population.
62744480|NCT03653156||Familial Alzheimer's disease (FAD)|FAD cohort consists of familial Alzheimer disease subjects with known or unknown mutations, which recruit from community population and hospital population.
62372217|NCT00820313|OTHER|Lifestyle Intervention|Comprehensive lifestyle intervention for reversal of heart disease
62372218|NCT05746000|OTHER|Control Group|Participants in the control group will attend three standard diet counselling.
62372219|NCT05746000|OTHER|Intervention Group|Participants in the intervention group will attend three individual diet counselling and will be educated about sugar calculation (sugar exchange).
62372220|NCT03692312|EXPERIMENTAL|Tideglusib|Weight adjusted tideglusib, orally, once daily
62372221|NCT03692312|PLACEBO_COMPARATOR|Placebo|Matching placebo, orally, once daily
62372222|NCT02763267||Pregnant Women|Pregnant women with history of GDM or at risk for diabetes mellitus will enter study during first trimester (4-14 weeks) and receive an oral glucose tolerance test (OGTT) at baseline, mid-pregnancy, and at delivery.
62372223|NCT02763267||Nonpregnant Women|Nonpregnant women with a history of GDM will undergo an OGTT at baseline.
62372224|NCT00935324||Group A: patients following allo-SCT|Patients scheduled for allo-SCT fulfilling all inclusion criteria
62372225|NCT00935324||Group B - healthy controls|healthy voluntary blood donors
62372226|NCT05607160||Cohort 1|Type 2 diabetes patients \>= 75 years
62372227|NCT03810053|EXPERIMENTAL|Mobile App/Online Module|Subjects will watch a short video containing information about cancers and benefits of uptake cancer prevention and early detection measures. Information regarding gender, age, smoking status, BMI and positive cancer history in family will be captured. Subjects will be provided with a list of cancer prevention and early detection measures based on the responses provided.
62372228|NCT05168436||Cohort 1|Participants with renal cell carcinoma (RCC) treated with nivolumab
62372229|NCT05168436||Cohort 2|Oncologists with expertise in renal cancer from Spain and Portugal
62372230|NCT01381809|EXPERIMENTAL|Epoetin alfa|Group 1: Epoetin alfa type = range unit= IU/Kg number= 337.5 to 1050 IU/Kg form= solution for injection route= subcutaneous use weekly injections (max 40 000 IU per week for first 8 weeks of treatment max 80 000 IU per week later) using pre-filled 1mL 40 000 IU syringes for 24 to 48 weeks
62372231|NCT01381809|PLACEBO_COMPARATOR|No treatment|Group 2: Placebo form= solution for injection route= subcutaneous use weekly injections for 24 to 48 weeks
62372232|NCT02289521|ACTIVE_COMPARATOR|Anodal Transcranial Direct Current Stim.|"Transcranial Direct Current Stimulation~Anodal (A-tDCS): Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20 min. To decrease current-induced injuries, at the beginning the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out)."
62744481|NCT03653156||Vascular dementia(VaD）|VaD cohort consists of cognitive impairment subjects caused by cerebral vessel disease, including vascular dementia and mixes dementia, which recruit from community population and hospital population.
62744482|NCT03653156||Normal control|Normal control cohort consists of cognitive normal subjects with ApoE ε4 positive or negative, which recruit from community population and hospital population.
62744483|NCT03653156||Non-Alzheimer degenerative dementia|Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or corticobasal degeneration (CBD); or dementia not otherwise specified.
62744484|NCT01218958|EXPERIMENTAL|Medisorb naltrexone 190 mg|
62372233|NCT02289521|SHAM_COMPARATOR|Sham Transcranial Direct Current Stim.|"Transcranial Direct Current Stimulation~Sham: The parameters mimics the A-tDCS (electrode placement, fade-in and current intensity), except the stimulation duration: the current will reach 1.5mA in 30 sec (fade-in) and lasts only for 30 sec (to give the initial sensation of stimulation).~After the stimulation, language performance and EEG will be recorded. Order of interventions (anodal - sham) will be randomised across subjects."
62744485|NCT01218958|EXPERIMENTAL|Medisorb naltrexone 380 mg|
62372234|NCT00979472|EXPERIMENTAL|with urgency|
62372235|NCT00979472|EXPERIMENTAL|without urgency|
62372236|NCT05458869||Observational (survey, HPV self-collection, interview)|Participants complete a survey, use an HPV self-collection kit, and attend an interview over 30 minutes.
62372237|NCT02773472|EXPERIMENTAL|Electroacupuncture Group|In addition to morphine, patients will receive 4 sessions of electroacupuncture after surgery over four days, with each session lasting 30 minutes.
62372238|NCT02773472|OTHER|Morphine Group|Neither electroacupuncture nor sham acupuncture will be given. Patient use morphine for analgesia.
62372239|NCT05832060|EXPERIMENTAL|tDCS, tRNS, Sham|"1. Active left anodal/right cathodal tDCS over TPC~2. Active tRNS over bilateral TPC~3. Sham tRNS or tDCS over bilateral TPC"
62744486|NCT01218958|PLACEBO_COMPARATOR|Placebo for Medisorb naltrexone 190 mg|
62744487|NCT01218958|PLACEBO_COMPARATOR|Placebo for Medisorb naltrexone 380 mg|
62744488|NCT04825964||Patients|Functional exercise capacity (6 minutes walk test and 6 minutes stepper test), physical activity level (multi-sensor activity monitor), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), quality of life (The Thyroid-Related Quality of Life-ThyPRO), fatigue (Fatigue Severity Scale), depression-anxiety-stress (Depression Anxiety Stress Scale-42), quality of sleep (Pittsburgh Sleep Quality Index) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated at diagnosis and after 1-3 months.
62744489|NCT04825964||Healthy Controls|Functional exercise capacity (6 minutes walk test and 6 minutes stepper test), physical activity level (multi-sensor activity monitor), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), quality of life (The Thyroid-Related Quality of Life-ThyPRO), fatigue (Fatigue Severity Scale), depression-anxiety-stress (Depression Anxiety Stress Scale-42), quality of sleep (Pittsburgh Sleep Quality Index) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated one time.
62372240|NCT05832060|EXPERIMENTAL|tDCS, Sham, tRNS|"1. Active left anodal/right cathodal tDCS over TPC~2. Sham tRNS or tDCS over bilateral TPC~3. Active tRNS over bilateral TPC"
62372241|NCT05832060|EXPERIMENTAL|tRNS, tDCS, Sham|"1. Active tRNS over bilateral TPC~2. Active left anodal/right cathodal tDCS over TPC~3. Sham tRNS or tDCS over bilateral TPC"
62372242|NCT05832060|EXPERIMENTAL|tRNS, Sham, tDCS|"1. Active tRNS over bilateral TPC~2. Sham tRNS or tDCS over bilateral TPC~3. Active left anodal/right cathodal tDCS over TPC"
62372243|NCT05832060|EXPERIMENTAL|Sham, tDCS, tRNS|"1. Sham tRNS or tDCS over bilateral TPC~2. Active left anodal/right cathodal tDCS over TPC~3. Active tRNS over bilateral TPC"
62372244|NCT05832060|EXPERIMENTAL|Sham, tRNS, tDCS|"1. Sham tRNS or tDCS over bilateral TPC~2. Active tRNS over bilateral TPC~3. Active left anodal/right cathodal tDCS over TPC"
62372245|NCT03780088|EXPERIMENTAL|mTranS-C|Access to a mobile and computer accessible adaptation of Transdiagnostic Sleep and Circadian Intervention
62372246|NCT00187044|OTHER|1|
62372247|NCT05265936|ACTIVE_COMPARATOR|Guidewire through DJ stent|Patients who underwent lithotripsy after guidewire insertion through a previously placed double j stent.
62372248|NCT05265936|SHAM_COMPARATOR|DJ stent remove + guidewire|Patients who underwent lithotripsy after double j stent removal and guidewire placement.
62372249|NCT01756833|ACTIVE_COMPARATOR|Doxycycline|100 mg capsules, twice a day, for a period of two years.
62744490|NCT04277663|EXPERIMENTAL|IBI310 + IBI308|Participants will be treated with IBI310 in combination with IBI308
62744491|NCT04277663|EXPERIMENTAL|IBI308|Participants will be treated with IBI308
62744492|NCT04277663|ACTIVE_COMPARATOR|high-dose recombinant interferon a-2B|Participants will be treated with recombinant interferon a-2B
62744493|NCT06238895|EXPERIMENTAL|Intervention Group|Oral iron supplementation with Eisen-II-Sulfat (Tardyferon ®) Every second day 2 x 80 mg Tardyferon® for a duration of 12 weeks.
62744494|NCT06238895|ACTIVE_COMPARATOR|Active Control|Oral iron supplementation with Eisen-II-Sulfat (Tardyferon ®) Every day 1x 80 mg Tardyferon® for a duration of 12 weeks
62744495|NCT00178919|EXPERIMENTAL|Autonomic Failure Patients|To compare the effects of NO inhibition during intact and transient pharmacological blockade of the autonomic nervous system in Patients with Autonomic Failure.
62744496|NCT00178919|EXPERIMENTAL|Controls and hypertensives|To compare the effects of NO inhibition during intact and transient pharmacological blockade of the autonomic nervous system in normal volunteers and hypertensive subjects.
62744497|NCT00624585|EXPERIMENTAL|Dasatinib Dose Escalation|Patients will be started on dasatinib at a continuous oral daily dose of 100 mg per day. At 8 weeks, if the initial dose is well tolerated and patient has not achieved a partial response, the dose may be increased to 150 mg per day. All patients will be followed per protocol for a total core period of 16 weeks from the first dose. Responding patients will continue dasatinib treatment for up to 48 weeks in the absence of treatment failure, disease progression, limiting toxicity or death. Patients continuing after 48 weeks will be enrolled in a separate extension study for future follow up.
62744498|NCT06659562|ACTIVE_COMPARATOR|HER-096 (Part 1)|Older and elderly healthy volunteer subjects
62744499|NCT06659562|ACTIVE_COMPARATOR|HER-096 (Part 2)|Parkinson's Disease patients
62372250|NCT01756833|PLACEBO_COMPARATOR|Placebo|100 mg capsules, twice a day, for a period of two years.
62372251|NCT05565794|EXPERIMENTAL|Pemigatinib|Intake of 13.5 mg pemigatinib once daily per oral
62372252|NCT03180021||Patients with Lupus Nephritis|
62372253|NCT03180021||Patients with IgA Neuropathy|
62372254|NCT02237365|EXPERIMENTAL|81mg aspirin|Aspirin 81mg daily for 60 days
62372255|NCT02237365|EXPERIMENTAL|1000mg aspirin|Aspirin 1000mg daily for 60 days
62372256|NCT02237365|PLACEBO_COMPARATOR|Placebo|Visually matched placebo daily for 60 days
62372257|NCT04533516|EXPERIMENTAL|Manual Therapy additional over Inspiratory muscle training|Participants receive manual therapy protocol session three times a week for 12 weeks. The manual therapy protocol session lasts 30 minutes and included of the following manual therapy techniques: suboccipital decompression, gliding of the cervical vertebral articulations in the anterior/posterior direction, myofascial release of sternocleidomastoid and trapezius muscles, gliding of sternoclavicular joint in the anterior/posterior direction, myofascial release of intercostal muscles and paravertebral muscles, diaphragmatic release, rib raising, mobilization of scapulothoracic joint, and gliding of the thoracic vertebral articulations in the anterior/posterior direction. And all participants receive inspiratory muscle training.
62372258|NCT04533516|ACTIVE_COMPARATOR|Inspiratory Muscle Training|Participants receive only inspiratory muscle training by using Threshold Inspiratory Muscle Training device. Training load is 40% of the measured maximum inspiratory pressure, weekly. Participants receive inspiratory muscle training session for 30 min-per day, 7 days per week, for 12 weeks.
62744500|NCT06659562|PLACEBO_COMPARATOR|Placebo (Part 2)|Parkinson's Disease patients
62744501|NCT06401668|EXPERIMENTAL|PRx with the CHW strategy|Participants in this group will have CHWs to offer participants personalized support by overcoming barriers and leveraging facilitators to PRx uptake.
62372259|NCT05519124|EXPERIMENTAL|BTL-785-7 Treatment|
62744502|NCT06401668|ACTIVE_COMPARATOR|PRx without the CHW strategy|Participants in this group will participate in the PRx without the use of CHWs
62372260|NCT04402385|EXPERIMENTAL|Aspirin|Participants randomized to 81 mg of Aspirin daily
62372261|NCT04402385|PLACEBO_COMPARATOR|Placebo|Participants randomized to placebo daily
62372262|NCT06503133|EXPERIMENTAL|Prenatal Yoga-Supported Birth preparation Training Group|Participants in this group will receive a 6-week prenatal yoga-supported birth preparation training program based on Albert Bandura's self-efficacy theory.
62372263|NCT06503133|ACTIVE_COMPARATOR|Birth Preparation Training Group|"Participants in this group will receive a 6-week birth preparation training program based on Albert Bandura's self-efficacy theory.~After the post-test measurements are taken, participants in this group will also be offered the opportunity to apply prenatal yoga."
62372264|NCT01401101|EXPERIMENTAL|PTSD Care Management (PCM)|PCM has six intervention components: 1) patient education, 2) patient screening and written feedback of screening information to primary care clinicians, 3) clinician education on practice guidelines , 4) structured feedback between primary care and mental health clinicians, 5) continuity of patient care, and 6) a resource guide detailing available community services where the FQHC has established reciprocal referrals. All of the intervention components will be implemented through the CM, except for the clinician education component, which will combine onsite and online continuing medical education (CME)-accredited sessions.
62372265|NCT01401101|PLACEBO_COMPARATOR|Minimally Enhanced Usual Care (MEU)|The MEU condition consists of only the clinician education and patient screening without written feedback.
62372266|NCT04403841|OTHER|Intervention|The intervention of group education on type 2 diabetes, including, in addition to usual diabetes care
62372267|NCT04403841|OTHER|Control|Patients meeting the inclusion criteria assigned to usual diabetes care alone
62372268|NCT06263725|EXPERIMENTAL|Restricted dietary protein|5 week intake of a isocaloric diet restricted in protein
62372269|NCT06263725|EXPERIMENTAL|Habitul diet|5 week intake of habitual, high protein diet
62372270|NCT00748332|ACTIVE_COMPARATOR|1|Standard oral nutritional supplement
62372271|NCT00748332|EXPERIMENTAL|2|Omega-3-enriched oral nutritional supplement
62372272|NCT00982748|ACTIVE_COMPARATOR|Group B|Study participants in this arm attend yoga breathing classes once per week over the span of one chemotherapy cycle.
62744503|NCT01231542|EXPERIMENTAL|Arm 1|Subjects will have a screening visit within 30 days prior to the first dose of study drug, three treatment periods, and a follow-up visit 7-14 days after the last dose of study drug. Subjects enrolled in Arm 1 will receive GSK1349572 50 mg once daily for 7 days, GSK1348572 50 mg twice daily for 7 days, and GSK1349572 50 mg twice daily in combination with rifampin 600 mg once daily for 14 days.
62744504|NCT01231542|EXPERIMENTAL|Arm 2|Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug. Subjects in Arm 2 will receive GSK1349572 50 mg once daily for 7 days and GSK1349572 50 mg once daily in combination with rifabutin 300 mg once daily for 14 days.
62744505|NCT02112474|EXPERIMENTAL|Spinal Cord Stimulation Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
62744506|NCT02112474|EXPERIMENTAL|Spinal Cord Stimulation Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
62744507|NCT02752685|EXPERIMENTAL|HR-Positive Participants|Participants with HR-positive metastatic breast cancer will receive nab-paclitaxel 100 mg/m2 on days 1 and 8 of the first 21-day treatment cycle. On the second 21-day treatment cycle, the participants will receive pembrolizumab 200 mg IV on the first day of the cycle, in addition to nab-paclitaxel 100 mg/m2 on days 1 and 8 of the cycle.
62372273|NCT00982748|EXPERIMENTAL|Group A|Participants in this study arm attend weekly yoga breathing classes during two consecutive cycles of chemotherapy
62744508|NCT02752685|EXPERIMENTAL|cTNBC Participants|Participants with TNBC-positive metastatic breast cancer who in the chemotherapy run-in group (cNTBC) will receive nab-paclitaxel 100 mg/m2 on days 1 and 8 of the first 21-day cycle. On the second 21-day treatment cycle, the participants will receive pembrolizumab 200 mg IV on the first day of the cycle, in addition to nab-paclitaxel 100 mg/m2 on days 1 and 8 of the cycle.
62372274|NCT02868151|NO_INTERVENTION|GROUP A|Standard treatment followed in the regional cancer center for prevention and treatment of oral mucositis during chemo radiotherapy of cancers. 20% Benzocaine 15grms. twice daily for the entire treatment period
62744509|NCT02752685|EXPERIMENTAL|iTNBC Participants|Participants with TNBC-positive metastatic breast cancer in the immunotherapy run-in group (cNTBC) will receive pembrolizumab 200mg IV on day 1 of the first 21-day treatment cycle. nab-paclitaxel 100 mg/m2 on days 1 and 8 of the first 21-day cycle. On the second 21-day cycle, the participants will receive nab-paclitaxel 100 mg/m2 on days 1 and 8 of the cycle, in addition to pembrolizumab 200mg IV on day 1 of the cycle.
62744510|NCT01321944|NO_INTERVENTION|Usual clinical care|Usual clinical care provided by health care system
62744511|NCT01321944|EXPERIMENTAL|DTS intervention|Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP that encourages the smoker to quit, and offers a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC), free nicotine patches, and referral to additional treatment resources including the state's free telephone quitline.
62744512|NCT06340321||Insight study cohort|The proposed study will include the individuals who participated in the baseline assessment of the InSight study at Pennington Biomedical in 2008-2009. These participants were not subjected to any intervention.
62744513|NCT01707654|OTHER|nerve graft|Simultaneous repair of the infected wound and digital nerve defect in the finger using a bipedicled nerve flap including nerve graft from the dorsal branch of the digital nerve.
62372275|NCT02868151|EXPERIMENTAL|GROUP B|"Ascorbic acid oral supplementation 1g four times daily for the entire treatment period of 30 days and after treatment by tapering the dose of the drug to half for another month. The drug has to be started 2 days prior to initiation of treatment of cancer.~Subdivided into 2 groups , 30 patients in each : sub group 1: only radiotherapy patients, subgroup 2 includes concurrent chemo-radiotherapy patients."
62372276|NCT02868151|EXPERIMENTAL|GROUP C|Zinc acetate tablets 50mg orally
62372277|NCT06335160|NO_INTERVENTION|Control Group|control group (Mesalamine group, n =23) who will receive 1 g mesalamine three times daily for 6 months.
62372278|NCT06335160|ACTIVE_COMPARATOR|Treatment Group|Treatment group( mebendazole group, n = 23) which will receive the standard treatment for UC plus mebendazole 500 mg twice daily for 6 months
62744514|NCT05764161|EXPERIMENTAL|Ruxolitinib 1.5% Cream|Participants apply ruxolitinib 1.5% cream topically to the affected areas as a thin film BID for 12 weeks during the DBVC period. Participants who have completed the treatment during DBVC period will enter the open label extension (OLE) period for up to 40 weeks.
62744515|NCT05764161|PLACEBO_COMPARATOR|Vehicle Cream|Participants apply ruxolitinib matching vehicle cream topically to the affected areas as a thin film twice daily (BID) for 12 weeks during the DBVC period. Participants who have completed the treatment during DBVC period will enter the open label extension (OLE) period for up to 40 weeks.
62372279|NCT04135664|ACTIVE_COMPARATOR|Patients undergoing adjuvant esophagectomy|"Patients underwent endoscopic submucosal dissection and diagnosed with pathological-T1b and clinical-N0 squamous cell carcinoma.~Patients randomized into undergoing adjvant esophagectomy."
62372280|NCT04135664|EXPERIMENTAL|Patients undergoing adjuvant chemoradiation|"Patients underwent endoscopic submucosal dissection and diagnosed with pathological-T1b and clinical-N0 squamous cell carcinoma.~Patients randomized into undergoing adjvant chemoradiation."
62372281|NCT04135664|ACTIVE_COMPARATOR|Prospective registry of patients that cannot be randomized|"Patients underwent endoscopic submucosal dissection and diagnosed with pathological-T1b and clinical-N0 squamous cell carcinoma.~Patients cannot be randomized into undergoing adjvant esophagectomy or chemoradiaton.~This arm includes patients undergoing adjuvant esophagectomy; adjuvant chemoradiation and active surveillance."
62372282|NCT01128452|PLACEBO_COMPARATOR|Placebo|Placebo
62372283|NCT01128452|EXPERIMENTAL|EVT 101|EVT 101
62372284|NCT01876472||Children aged 3 - 10 years|Assessment of music perception skills with cochlear implant recipients aged 3 - 10 years
62372285|NCT01876472||Teenagers aged 11 - 15 years|Assessment of music perception skills with cochlear implant recipients aged 11 - 15 years
62372286|NCT01876472||Adults aged 16 - 70 years|Assessment of music perception skills with cochlear implant recipients aged 16 - 70 years
62372287|NCT00179998|ACTIVE_COMPARATOR|Recombinant Human DNase (Pulmozyme) then Placebo|once daily nebulized rhDNAse
62372288|NCT00179998|PLACEBO_COMPARATOR|Placebo (Nebulized Saline) then rhDNase|once daily nebulized vehicle
62372289|NCT05316350|EXPERIMENTAL|Atrial Fibrillation|
62372290|NCT05316350|EXPERIMENTAL|Normal Sinus Rhythm|
62567180|NCT05553990||Acute ischemic stroke with active tumor|Acute ischemic stroke with active tumor
62567181|NCT05553990||Acute ischemic stroke without active tumor|Acute ischemic stroke without active tumor
62567182|NCT04942626|OTHER|Chemoradiotherapy with Anakinra followed by either TME surgery or Watch and Wait|Capecitabine 500 mg/m2 bid or Capecitabine 650 mg/m2 bid or Capecitabine 825 mg/m2 bid combined with Radiotherapy and Kineret
62372291|NCT05049642|EXPERIMENTAL|Group 1|Patients will either be randomized to group 1 (instillation of 1 drop of C-NAC) or group 2 (no instillation of C-NAC) in a 1:1 fashion. Afterwards one drop of C-NAC will be instilled into the study eye of group 1. 1 hour after treatment VAS and the symptom questionnaire will be performed repeatedly in both groups. Both groups will receive antibiotic ointment bandages and antibiotic eye drops for 5 days. Patients assigned to group 1 will receive Lacrimera® for home treatment over the following 5 days. 1 drop of Lacrimera® is supposed to be installed into the eye 20 minutes prior to installation of the respective antibiotic eye drops or ointments.
62372292|NCT05049642|NO_INTERVENTION|Group 2|Both groups will receive antibiotic ointment bandages and antibiotic eye drops for 5 days.
62372293|NCT00636155|EXPERIMENTAL|all patients|EL625 combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide)
62372294|NCT00978133|ACTIVE_COMPARATOR|Skin Staples|Skin closure with skin staples
62372295|NCT00978133|EXPERIMENTAL|Dermabond|Closure of abdominal wound with dermabond (2-octylcyanoacrylate)
62372296|NCT05394181|EXPERIMENTAL|Notification|Notification of the presence of at least moderate coronary artery calcium on a prior non-gated chest CT
62372297|NCT05394181|NO_INTERVENTION|Usual Care|
62372298|NCT02652546|ACTIVE_COMPARATOR|A|CC-11050 200mg (2 capsules) BID with food
62372299|NCT02652546|PLACEBO_COMPARATOR|B|Placebo (2 capsules) BID with food
62372300|NCT04574765||Healthcare Worker|Individuals who work within a food production, healthcare, research or clinical organization of participating institutions.
62372301|NCT03045640|EXPERIMENTAL|FSI ECD|"Vulnerable Households (ubudehe 1 or 2) in the Government of Rwanda's poverty classification system, when categories ranged from 1 to 6; the system has since been restructured to have four categories only. Often a way to identify households for public works opportunities or other government assistance programs. For this arm, families had to be Ubudehe 1 or 2 and have a child aged 0-3 years. Households meeting these criteria in the catchment area(s) received the FSI ECD home-based parenting intervention from bachelor-level interventionists/coaches."
62372302|NCT02283840|EXPERIMENTAL|Cohort A1:BIA 2-093 400 mg|"One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (Clinical Trial Formulation, CTF)"
62372303|NCT02283840|EXPERIMENTAL|Cohort A2:BIA 2-093 400 mg|One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (To-Be-Marketed Formulation, TBM)
62372304|NCT02283840|EXPERIMENTAL|Cohort B1:BIA 2-093 600 mg|"One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (Clinical Trial Formulation, CTF)"
62372305|NCT02283840|EXPERIMENTAL|Cohort B2:BIA 2-093 600 mg|One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (To-Be-Marketed Formulation, TBM)
62372306|NCT02283840|EXPERIMENTAL|Cohort C1:BIA 2-093 800 mg|"One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (Clinical Trial Formulation, CTF)"
62372307|NCT02283840|EXPERIMENTAL|Cohort C2:BIA 2-093 800 mg|One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (To-Be-Marketed Formulation, TBM)
62372308|NCT01149525|EXPERIMENTAL|1|oral solution of L-Carnitine, 4g per day
62372309|NCT01149525|PLACEBO_COMPARATOR|2|Similar oral solution without L-Carnitine
62372310|NCT04245657||Breast Cancer Survivors|Female breast cancer survivors who underwent unilateral breast cancer surgery ( total or conservative) and completed their adjuvant therapies such as chemotherapy and radiotherapy prior to participation in this study.
62372311|NCT02336880|EXPERIMENTAL|Intervention group|4 weeks guided internet-delivered cognitive behavioural therapy program. The program consists of psychoeducation, exposure to physical activity, and a breathing-based relaxation exercise
62744516|NCT05307705|EXPERIMENTAL|Phase 1A: LOXO-783 Monotherapy Dose Escalation|LOXO-783 administered orally
62744517|NCT05307705|EXPERIMENTAL|Phase 1B: Part A|LOXO-783 administered orally in combination with fulvestrant intramuscularly, imlunestrant orally, or an aromatase inhibitor orally
62372312|NCT02336880|NO_INTERVENTION|Control group|Care as usual
62372313|NCT05566327|NO_INTERVENTION|Usual Care|Clinics in this arm will receive the usual information about low value preoperative testing. Staff at these hospitals may be aware of the Choosing Wisely Anaesthesia Guidelines for reducing unnecessary testing, the Ontario Anaesthesiology Toolkit to operationalize the Choosing Wisely guidelines.
62372314|NCT05566327|ACTIVE_COMPARATOR|Intervention Group|The intervention will focus on increasing accountability for preoperative test ordering to reduce the number of inappropriate tests ordered for patients having ambulatory surgeries. A multi-component approach will be used to address the accountability of who should order preoperative tests for patients undergoing ambulatory surgery.
62372315|NCT01716949|EXPERIMENTAL|HyRec|Radiotherapy, Hyperthermia, 5-Fluorouracil (may be replaced by Capecitabine), Capecitabine (may be replaced by 5-Fluorouracil), Oxaliplatin
62372316|NCT01994278|EXPERIMENTAL|Tooth brush|Periclean is a soft rubber gentle toothbrush
62372317|NCT03424616|EXPERIMENTAL|Postoperative immediate Deep brain stimulation|The addicts undergone the deep brain stimulation while the stimulation (Suzhou Sceneray® DBS System) was turned on 1-2 weeks postoperatively.
62372318|NCT03424616|SHAM_COMPARATOR|Postoperative delayed Deep brain stimulation|The addicts undergone the deep brain stimulation while the stimulation (Suzhou Sceneray® DBS System) was off until 25 months postoperatively, during which the following up was kept, then the the stimulation was turned on 25 months postoperatively.
62372319|NCT03395860|EXPERIMENTAL|group A|low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
62372320|NCT03395860|EXPERIMENTAL|group B|low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
62744518|NCT05307705|EXPERIMENTAL|Phase 1B: Part B|LOXO-783 orally in combination with abemaciclib and either physician's choice aromatase inhibitor orally, fulvestrant intramuscularly, or imlunestrant orally
62744519|NCT05307705|EXPERIMENTAL|Phase 1B: Part C|LOXO-783 orally in combination with fulvestrant intramuscularly
62744520|NCT05307705|EXPERIMENTAL|Phase 1B: Part D|LOXO-783 orally in combination with paclitaxel intravenously
62372321|NCT05654662|EXPERIMENTAL|Corsodyl Original Dentifrice|Participants will be instructed to brush their teeth using test product for at least a minute twice a day (morning and evening) for 12 weeks. Participants will dose the toothbrush provided with a ribbon of paste to cover the brush head (a full brush head) on each brushing occasion.
62372322|NCT05654662|ACTIVE_COMPARATOR|Colgate Cavity Protection Dentifrice|Participants will be instructed to brush their teeth using reference product for at least a minute twice a day (morning and evening) for 12 weeks. Participants will dose the toothbrush provided with a ribbon of paste to cover the brush head (a full brush head) on each brushing occasion.
62372323|NCT01644019|EXPERIMENTAL|Device: Teleconsultation|"In cases of suspected acute stroke (including intracranial hemorrhage), if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician who has an audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures (taken with a smartphone), 12-lead-ECGs and video streaming from the inside of the ambulance can also be carried out, if indicated. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, neurological diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
62372324|NCT01776502||Patients with Hyperparathyroidism|The cohort of patients is made of patients with primary mild hyperparathyroidism and who have received a surgery at Nantes, Angers, Limoges or Marseille University Hospitals
62744521|NCT05307705|EXPERIMENTAL|Phase 1B: Part E|LOXO-783 orally
62744522|NCT05307705|EXPERIMENTAL|Phase 1B: Part F|Multiple randomized dose levels of LOXO-783 orally with fulvestrant intramuscularly
62372325|NCT02861118||Cohort 1: Crohn's Disease|Participants with Crohn's disease who received biological treatment between June 2011 and June 2013.
62372326|NCT02861118||Cohort 2: Ulcerative Colitis|Participants with ulcerative colitis who received biological treatment between June 2011 and June 2013.
62372327|NCT03745404|EXPERIMENTAL|Lido-Patch (Open-label Run-in Phase)|All participants applied up to 3 Lido-Patches (lidocaine 5% medicated plaster) per day (depending on the size of PHN area). Patches were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
62372328|NCT03745404|EXPERIMENTAL|Lido-Patch (Double-blind Phase)|Up to 3 patches (lidocaine 5% medicated plaster) per day (depending on the size of PHN area) were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
62372329|NCT03745404|PLACEBO_COMPARATOR|Placebo Patch (Double-blind Phase)|Up to 3 placebo plasters per day (depending on the size of PHN area) were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
62372330|NCT00749528||1|Children vith recurrent wheezing
62372331|NCT00749528||2|Healthy children
62744523|NCT04074694|NO_INTERVENTION|Watchfull waiting|
62744524|NCT04074694|ACTIVE_COMPARATOR|Interventional|
62744525|NCT06486662|EXPERIMENTAL|Part I -Cohort 1|OM-85-IN low Dose
62744526|NCT06486662|PLACEBO_COMPARATOR|Part I -Cohort 1 Placebo|Placebo
62372332|NCT05544006||Active study group|Active study group with self monitoring reminders in 3,7,14,28th days after discharge
62372333|NCT05544006||Usual care group|Usual care group with self monitoring recommendations at discharge
62372334|NCT06404229|EXPERIMENTAL|CardioPulmonary Exercise Testing|All patients included in the study will perform CardioPulmonary Exercise Testing prior to surgery
62372335|NCT00446641|EXPERIMENTAL|1 Cilostazol|100mg of Cilostazol twice a day
62372336|NCT00446641|PLACEBO_COMPARATOR|Placebo|matching placebo to cilostazol
62372337|NCT05068076|EXPERIMENTAL|Patients undergoing ablation for HCC|Pre-procedure CEUS will be performed on patients undergoing ablation followed by targeting of lesions for precise needle placement in the Kupffer phase. 2 hours post procedure USG with contrast will also be done for response assessment
62372338|NCT05590104|EXPERIMENTAL|Hysteroscopic CS scar defect repair|"Patient who is randomized to the hysteroscopic repair of CS scar defect will be prepared to have the surgery postmenstrual.~The surgery will be under general anasthesia. The participants will be placed in the lithotomy position. The cervix will be visualized using a Sims speculum and grasped using a single-toothed tenaculum, and the cervix, fornix, and vagina will be cleaned.~Dilatation of the cervix till 7 mm. Introduce the resctoscope through the cervix. The surgical correction of the isthmocele is done by resection of the inferior and superior edges or just the inferior edge of the defect with a resectoscopic loop, using pure cutting current, until reaching the muscular layer. Coagulation of fragile vessels at the base or even entire niche. At the end of procedure, flow and pressure of distending medium can be reduced to ensure adequate haemostasis. After that the patient will be prepared for another euoploid embryo transfer."
62744527|NCT06486662|EXPERIMENTAL|Part I -Cohort 2|OM-85-IN medium dose
62744528|NCT06486662|PLACEBO_COMPARATOR|Part I -Cohort 2 Placebo|Placebo
62744529|NCT06486662|EXPERIMENTAL|Part I -Cohort 3|OM-85-IN high dose
62744530|NCT06486662|PLACEBO_COMPARATOR|Part I -Cohort 3 Placebo|Placebo
62744531|NCT06486662|EXPERIMENTAL|Part II -Cohort 4|OM-85-IN dose
62744532|NCT06486662|PLACEBO_COMPARATOR|Part II -Cohort 4 Placebo|Placebo
62744533|NCT04336046|SHAM_COMPARATOR|control group|will receive sham bilateral ultrasounded guided erector spinae block using 1 mg /kg normal saline in a total volume of 20 ml for each side after induction of anaesthesia in prone position after induction of anaesthesia in prone position.
62744534|NCT04336046|EXPERIMENTAL|erector spinae block|will receive real bilateral ultrasounded guided erector spinae block by bupivacaine at 1 mg /kg in a total volume of 20 ml for each side after induction of anaesthesia in prone position
62744535|NCT00883545|EXPERIMENTAL|Woman endoscopist|
62744536|NCT00883545|ACTIVE_COMPARATOR|Usual care|
62744537|NCT01541904|EXPERIMENTAL|Arm A. PRO-118/Placebo 0.015%,0.020%|
62744538|NCT01541904|EXPERIMENTAL|Arm B. PRO-118/Placebo 0.015%,0.020%|
62744539|NCT01541904|EXPERIMENTAL|Arm C. PRO-118/Placebo 0.015%,0.020%|
62744540|NCT01541904|EXPERIMENTAL|Arm D. PRO-118/Placebo 0.015%,0.020%|
62744541|NCT01541904|PLACEBO_COMPARATOR|Arm E PRO-118/Placebo 0.015%,0.020%|
62372339|NCT05590104|NO_INTERVENTION|Expectant management|Patient who is randomized to the expectant management will be prepared for another embryo transfer for euoploid embryo.
62372340|NCT05049018|ACTIVE_COMPARATOR|Control Group|"Participants who participated in the control group received a traditional physical therapy program for two hours. It included two parts, each of them was for one hour and 15 minutes rest in between. The first part included: muscle strengthening and facilitation exercises, stretching exercises, and postural reactions exercises. The second part included: functional exercise for facilitation of arm-reaching and arm-hand skills, manipulative tasks (grasping and release activities), and daily living activities for the affected upper limb.~The traditional treatment program was applied for both groups by therapists, experienced in stroke rehabilitation. It was carried out three sessions per week for twelve successive weeks."
62372341|NCT05049018|EXPERIMENTAL|Experimental Group|"Participants in the experimental group received two hours treatment program that included three parts, the first and the second parts (similar to that were applied for participants in the control group). These two parts were applied for one hour followed by 15 minutes rest, then the third part was applied for one hour. The third part of the program was a one-hour virtual reality intervention program by using (ArmeoSpring) virtual reality equipment to simulate a range of upper limb tasks that facilitate arm activities, manipulative skills, and daily living tasks through using different interactive games and soft-wares.~The traditional treatment part of the program was applied by therapists, experienced in stroke rehabilitation. The virtual reality part of the program was applied by other experienced physiotherapists, who were well trained in using the (ArmeoSpring) System. All three parts of the program were carried out three sessions per week for twelve successive weeks."
62744542|NCT04537208|EXPERIMENTAL|Cohort 1: Group 1: SARS-CoV-2 vaccine LD + AF03|Participants received a single intramuscular (IM) injection of SARS-CoV2 vaccine low-dose (LD) formulation along with adjuvant AF03 on Day 1.
62744543|NCT04537208|EXPERIMENTAL|Cohort 1: Group 2: SARS-CoV-2 vaccine LD + AS03|Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1.
62744544|NCT04537208|EXPERIMENTAL|Cohort 1: Group 3: SARS-CoV-2 vaccine HD + AF03|Participants received a single IM injection of SARS-CoV2 vaccine high-dose (HD) formulation along with adjuvant AF03 on Day 1.
62372342|NCT00576147|EXPERIMENTAL|CT scan|The standard head CT done to head trauma patients
62372343|NCT01924195|ACTIVE_COMPARATOR|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62372344|NCT01924195|PLACEBO_COMPARATOR|Placebo Capsule|Placebo capsule QD po and it should be continued until disease progression or patients withdrawal of consent
62372345|NCT05480631|ACTIVE_COMPARATOR|Group A|group A- autograft
62372346|NCT05480631|EXPERIMENTAL|group B|group B- concentrated growth factor with autograft
62744545|NCT04537208|EXPERIMENTAL|Cohort 1: Group 4: SARS-CoV-2 vaccine HD + AS03|Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1.
62744546|NCT04537208|PLACEBO_COMPARATOR|Cohort 1: Group 5: Placebo|Participants received an IM injection of placebo matching to SARS-CoV2 vaccine on Day 1.
62744547|NCT04537208|EXPERIMENTAL|Cohort 2: Group 6: SARS-CoV-2 vaccine LD + AF03|Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively.
62744548|NCT04537208|EXPERIMENTAL|Cohort 2: Group 7: SARS-CoV-2 vaccine LD + AS03|Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively.
62372347|NCT05480631|EXPERIMENTAL|Group C|group C- concentrated growth factor with xenograft
62744549|NCT04537208|EXPERIMENTAL|Cohort 2: Group 8: SARS-CoV-2 vaccine HD + AF03|Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively.
62372348|NCT01352767|EXPERIMENTAL|InsuPad Device|Use of the InsuPad which heats the injection site.
62372349|NCT01352767|NO_INTERVENTION|CONTROL|no treatment
62372350|NCT00090766|EXPERIMENTAL|Valganciclovir Age Group <= 2 Years|Eligible participants aged \<= 2 years received valganciclovir up to maximum of 900 milligrams (mg) once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 \* body surface area (BSA) \* creatinine clearance (CrCLS).
62372351|NCT00090766|EXPERIMENTAL|Valganciclovir Age Group >2 to <12 Years|Eligible participants aged \>2 to \<12 years received valganciclovir up to maximum of 900 mg once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 \* BSA \* CrCLS.
62372352|NCT00090766|EXPERIMENTAL|Valganciclovir Age Group >= 12 Years|Eligible participants aged \>= 12 years received valganciclovir up to maximum of 900 mg once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 \* BSA \* CrCLS.
62372353|NCT06145217|EXPERIMENTAL|SPRYCEL® (dasatinib) 100 mg Film-Coated Tablets|To evaluate the drug-drug interaction between SPRYCEL® 100 mg (US sourced) and Omeprazole under fasted conditions in healthy, adult, human subjects.
62372354|NCT00854061|EXPERIMENTAL|T-Pred|Tobramycin prednisolone acetate combination
62372355|NCT00854061|ACTIVE_COMPARATOR|Pred Forte|Prednisolone acetate
62744550|NCT04537208|EXPERIMENTAL|Cohort 2: Group 9: SARS-CoV-2 vaccine HD + AS03|Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively.
62744551|NCT04537208|EXPERIMENTAL|Cohort 2: Group 10: SARS-CoV-2 vaccine HD|Participants received a single IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively.
62744552|NCT04537208|PLACEBO_COMPARATOR|Cohort 2: Group 11: Placebo|Participants received an IM injection of placebo matching to SARS-CoV2 on Day 1 and Day 22, respectively.
62744553|NCT05362773|EXPERIMENTAL|Dose Escalation|Escalating doses of MGD024 will be assigned based on safety and tolerability of the previous dose level.
62567183|NCT04151186|EXPERIMENTAL|TM4SF1 and EpCAM positive CAR-T cells for solid tumors|The present study is proposed to study advanced malignant solid tumors in adults, and the three escalating doses, namely, 2.0\~2.5. 4.0\~5.0 and 8.0\~10.0 (×10 \^6/kg), will be given.
62744554|NCT04793724|EXPERIMENTAL|Simeox first|Patients who will undergo Simeox intervention first. After three months cross-over to PARI O PEP intervention.
62744555|NCT04793724|ACTIVE_COMPARATOR|PARI O PEP first|Patients who will undergo PARI O PEP intervention first. After three months cross-over to Simeox intervention.
62372356|NCT04944758|OTHER|Light therapy|Daily exposure on weekdays to a standard light device (e.g., fluorescent light box such as the Carex Day-Light Classic, emitting 4000 Kelvin white light rated at 10,000 lux at 14 inches from screen to cornea, with an ultraviolet filter) for 30 minutes as soon as possible after awakening, preferably between 7:00-8:00 am. Participants will also taper and discontinue their antidepressant medication.
62372357|NCT01095328|EXPERIMENTAL|intervention|Screening for Q-fever during pregnancy
62372358|NCT01095328|NO_INTERVENTION|control|No screening for Q-fever during pregnancy
62372359|NCT02209259|EXPERIMENTAL|Intervention Group 1|The first intervention group will be comprised of patients who will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS) after completing the standard PCS.
62372360|NCT02209259|EXPERIMENTAL|Intervention Group 2|The second intervention group will be comprised of patients who will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS) after completing a positively-adjusted version of the PCS.
62744556|NCT00964041|EXPERIMENTAL|D-cycloserine|Participants will receive D-cycloserine weekly, one hour before any assessments, for eight weeks.
62372361|NCT02209259|EXPERIMENTAL|Control|The third group (the control arm) will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS).
62372362|NCT03955120|EXPERIMENTAL|Sleep Apnea- Dayzz|The intervention group is also provided access to the dayzz app, a personalized digital sleep training program. The sleep training begins a sleep assessment questionnaire and ongoing sleep and activity data collection which is used to tailor an individualized sleep training program including behavioral and cognitive techniques to improve the adherence to CPAP. The dayzz sleep program is composed of three main components, (1) a mobile digital program via the dayzz app, (2) guidance of a sleep trainer, and (3) an ambulatory sleep monitoring device. The intervention group meets a CPAP technician at the sleep clinic, as detailed below in the Sleep Apnea TAU group
62372363|NCT03955120|ACTIVE_COMPARATOR|Sleep Apnea- Treatment as Usual|"The treatment as usual \[TAU\] group meets a CPAP technician at the sleep clinic, who provides the participant with a CPAP device and fits the mask. The will also receive a follow-up visit with the same technician for technical support, mask changes or alterations if needed after an initial 7 to 14-day at home CPAP trial."
62372364|NCT03955120|EXPERIMENTAL|Insomnia - Dayzz|The intervention group is provided access to the dayzz app, a personalized digital sleep training program. The sleep training begins a sleep assessment questionnaire and ongoing sleep and activity data collection which is used to tailor an individualized sleep training program including behavioral and cognitive techniques to improve the insomnia concerns, sleep symptoms, and achieve sleep goals. The dayzz sleep program is composed of three main components, (1) a mobile digital program via the dayzz app, (2) guidance of a sleep trainer, and (3) an ambulatory sleep monitoring device.
62372365|NCT03955120|ACTIVE_COMPARATOR|Insomnia - Treatment as Usual|"The treatment as usual \[TAU\] group, will receive standard treatment recommendations for their insomnia, including sleep hygiene suggestions, referral for supportive/non-medical treatments \[e.g. relaxation therapies\], and if needed hypnotics or other medications prescribed by the sleep clinic physician."
62372366|NCT01968304|NO_INTERVENTION|Iron status follow up|
62372367|NCT02481791|EXPERIMENTAL|Remifentanil|"Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.~Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.~Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min."
62372368|NCT01045551|EXPERIMENTAL|Apremilast 20 mg (twice per day)|All subjects will receive Apremilast 20mg taken orally twice per day.
62744557|NCT00964041|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo weekly, one hour before any assessments, for eight weeks.
62744558|NCT06464380|ACTIVE_COMPARATOR|safranal Group|include 20 HCC patients will receive 50 mg safranal regimen in dose of once per day for six months.
62744559|NCT06464380|PLACEBO_COMPARATOR|Control Group|include 20 HCC patients will receive placebo in the form of once per day for six months.
62372369|NCT00914719|ACTIVE_COMPARATOR|Information only|
62372370|NCT00914719|ACTIVE_COMPARATOR|sexual risk reduction intervention|
62372371|NCT00914719|EXPERIMENTAL|SRRI+ETOH|
62372372|NCT00848289||Participants with Bladder Cancer|Patients diagnosed with superficial or muscle-invasive bladder cancer. Specimens, personal and follow-up telephone interviews will be collected and conducted.
62372373|NCT00992914|ACTIVE_COMPARATOR|Lidocaine injection|Stellate Ganglion Injection with Lidocaine
62372374|NCT00992914|PLACEBO_COMPARATOR|saline injection|Superficial subcutaneous injection
62372375|NCT00679380|EXPERIMENTAL|1: budesonide-MMX® 6 mg|One budesonide-MMX® 6 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.
62372376|NCT00679380|EXPERIMENTAL|2: budesonide-MMX® 9 mg|One budesonide-MMX® 9 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.
62372377|NCT00679380|ACTIVE_COMPARATOR|3: Entocort EC® 3 mg|Three Entocort EC® 3 mg overencapsulated capsules plus one placebo budesonide MMX® tablet daily in the morning after breakfast.
62744560|NCT04115748|EXPERIMENTAL|Filgotinib 200 mg (Main Study)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg + PTM adalimumab injection for up to 16 weeks.
62744561|NCT04115748|EXPERIMENTAL|Filgotinib 100 mg (Main Study)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg + PTM adalimumab for up to 16 weeks.
62744562|NCT04115748|ACTIVE_COMPARATOR|Adalimumab (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg + adalimumab 40 mg injection for up to 16 weeks.
62744563|NCT04115748|PLACEBO_COMPARATOR|Placebo (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg + PTM adalimumab injection for up to 16 weeks.
62372378|NCT00679380|PLACEBO_COMPARATOR|4: Placebo|Three placebo Entocort EC® overencapsulated capsules plus one placebo Budesonide MMX® tablet daily in the morning after breakfast.
62372379|NCT01724775||CME surgery for colon cancer|
62372380|NCT01724775||non-CME surgery for colon cancer|
62372381|NCT00896350|EXPERIMENTAL|BOLD MRI|Determine the amount of oxygen supply to tumors.
62372382|NCT04506879|OTHER|Popliteal Sciatic Nerve block|Patients will lie on their chest on the examination couch with both feet rested on the pillow to relax their lower extremity. Ultrasound scan of the nerves in popliteal fossa will be identified and then local anesthetic agents \[1.5% lidocaine with 1:200,000 adrenaline and 0.5ml of 8.4% sodium bicarbonate (total 30ml)\] will be injected close to the nerves (Common peroneal nerve and tibial nerve). The injections below the bifurcation near the two nerves are expected to produce quicker block than the injections above the bifurcation.
62744564|NCT04115748|EXPERIMENTAL|Filgotinib 200 mg (Long Term Extension [LTE])|Participants will receive filgotinib 200 mg + PTM filgotinib 100 mg for up to 34 weeks.
62372383|NCT01126567||High Sampling Rate|Samples will be obtained at a high rate
62372384|NCT01126567||Low Sampling Rate|Samples will be obtained at a low rate
62372385|NCT06113172|OTHER|Control|Patients referred for endovascular procedure (aortic or peripheral), with an indication of CTA comprising the CFA region, without significant lesions of the external iliac and common femoral arteries. In case of difference of calcifications between both CFA, the CFA with less calcifications will be chosen for analysis.
62372386|NCT06113172|OTHER|Stent|Patients referred for endovascular stenting of the common femoral artery with and indication of CTA before the surgery. For these patient a CTA will be performed 1 month before and 1 month after surgery
62372387|NCT03600220|NO_INTERVENTION|drug use|routine drug use, each patient was using 1-3 antihypertensive drug of a heterogeneous pharmacological group ranging from ACE inhibitors, diuretics, and beta blockers
62372388|NCT03600220|EXPERIMENTAL|drug combine acupuncture|routine drug use combine acupuncture twice a week for 3 months
62372389|NCT04185662|PLACEBO_COMPARATOR|placebo|intake 200 ml water daily for 3 months
62372390|NCT04185662|EXPERIMENTAL|low dose sucrolose group|intake 12.3mg sucralose in 200 ml water daily for 3 months
62372391|NCT04185662|EXPERIMENTAL|moderate dose sucrolose group|intake 73.8mg sucralose in 200ml water daily for 3 months
62372392|NCT01966991||Surveyed DNAFirst users|Women who opted for DNAFirst testing and who provided written permission (attested by signature and provision of telephone number)for DNAFirst Study staff to telephone them and conduct a brief telephone survey about their experiences.
62744565|NCT04115748|EXPERIMENTAL|Filgotinib 100 mg (LTE)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 34 weeks.
62744566|NCT00025207|EXPERIMENTAL|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62744567|NCT03134495||PPI exposed children|all children with at least one prescription of PPI
62744568|NCT03134495||non-exposed children|all children with no prescription of PPI
62372393|NCT00764608||No Treatment|
62744569|NCT06649942|EXPERIMENTAL|Treatment T|KP-001 therapeutic dose (KP-001 100 mg + placebo)
62744570|NCT06649942|EXPERIMENTAL|Treatment ST|KP-001 supratherapeutic dose (KP-001 400 mg)
62744571|NCT06649942|ACTIVE_COMPARATOR|Treatment M|moxifloxacin 400 mg
62372394|NCT00731952|EXPERIMENTAL|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
62372395|NCT01228149|ACTIVE_COMPARATOR|Diamox/DexaEDO|Patients receive Diamox (oral acetazolamide) starting 28 days Prior to trabeculectomy. 7 days preoperatively DexaEDO (dexamethasone) eyedrops without preservatives are applied additionally. Patient will undergo trabeculectomy.
62372396|NCT01228149|EXPERIMENTAL|Cosopt S|Patients receive Cosopt S (dorzolamide/timolol) eye drops starting 28 days before trabeculectomy.
62372397|NCT02283372|EXPERIMENTAL|nab-Paclitaxel + Gemcitabine + IMRT|"* Prior to initiation of chemoradiation, patients will undergo 1 full cycle of gemcitabine and nab-paclitaxel on Days 1, 8, and 15 of a 28-day cycle.~* Both gemcitabine and nab-paclitaxel will be given intravenously on an outpatient basis during the one-month lead-in period and during Weeks 1 and 2 (and, if enrolled to Dose Level or 2, Weeks 4 and 5) of radiotherapy. There may be up to 21 days between the last dose of lead-in chemotherapy (given on Day 15) and initiation of chemoradiation (inclusive of the week following Day 15, the fourth week of the lead-in cycle (an off-week), and an additional week following that).~* Intensity modulated radiation (IMRT) - the prescribed dose will range from 40-67.5 Gy over 15 to 25 fractions."
62372398|NCT02206191||Mothers of 6-11 year olds|
62372399|NCT00122070|EXPERIMENTAL|A|Quetiapine at dosage of 50 to 150 mg
62372400|NCT02339376|EXPERIMENTAL|Group 1|Low-frequency repetitive transcranial magnetic stimulation: 30-minute sessions of 1-Hz continuous stimulation at 95% resting motor threshold, with one session each day over 10 consecutive weekdays
62372401|NCT02339376|EXPERIMENTAL|Group 2|High-frequency repetitive transcranial magnetic stimulation: 30-minute sessions of 10-Hz continuous stimulation at 110% resting motor threshold, with one session each day over 10 consecutive weekdays
62372402|NCT02339376|SHAM_COMPARATOR|Group 3|Sham repetitive transcranial magnetic stimulation: use of a specially fabricated coil that provides no magnetic stimulation but has a similar appearance and creates an auditory artifact that mimics TMS
62744572|NCT06649942|PLACEBO_COMPARATOR|Treatment P|placebo
62744573|NCT06400576||Headphone and Smartphone Usage Group|The group where participants listen to music while messaging and also where these activities are evaluated separately. The only group in the study.
62744574|NCT05096247|EXPERIMENTAL|Treatment with RF Device|Subjects in this arm of the study will be treated with the radiofrequency device, and will receive up to 4 treatments on the face.
62744575|NCT05096247|EXPERIMENTAL|Treatment with IPL and RF Device|Subjects treated in this arm of the study will receive 2 treatments with just the radiofrequency device and then 2 treatments with both the radiofrequency and the IPL laser.
62744576|NCT06606327|EXPERIMENTAL|Diazoxide|Subjects will take diazoxide oral suspension at 3 mg/kg per dose for 4 days (total of 8 doses)
62372403|NCT03860844|EXPERIMENTAL|Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia|This arm includes participants from 3 cohorts: AML, T-ALL and B-ALL.; AML: Weekly dosing of isatuximab with induction chemotherapy. The therapy may be repeated one more cycle; ALL: (Includes T-ALL and B-ALL) Weekly dosing of isatuximab with induction chemotherapy, then biweekly dosing of isatuximab with consolidation chemotherapy.
62744577|NCT04186988|EXPERIMENTAL|Diagnostic ([18F]-AraG)|Patients receive \[18F\]-AraG IV and then undergo PET/CT over 2 hours at baseline and within 2 weeks after starting immunotherapy. Patients may also undergo blood sample collection.
62372404|NCT04146402|EXPERIMENTAL|SCT-I10A + Chemotherapy|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Chemotherapy: cisplatin+5-FU
62372405|NCT04146402|ACTIVE_COMPARATOR|Placebo + Chemotherapy|Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Chemotherapy: cisplatin+5-FU
62372406|NCT01384188|EXPERIMENTAL|E1|ONO-5334
62372407|NCT01384188|EXPERIMENTAL|E2|ONO-5334
62372408|NCT03931889|ACTIVE_COMPARATOR|Vitamin D3|Cholecalciferol 80,000 IU (2 capsules of 40,000 IU) per oral per week for consecutive 26 weeks.
62372409|NCT03931889|PLACEBO_COMPARATOR|Vitamin D3 placebo|Placebo (2 capsules) per oral per week for consecutive 26 weeks.
62372410|NCT03285490|EXPERIMENTAL|KX2-391 Ointment 1%|KX2-391 Ointment was applied once daily for 5 consecutive days on the face or scalp.
62372411|NCT03285490|PLACEBO_COMPARATOR|Placebo|The Vehicle Ointment was applied once daily for 5 consecutive days on the face or scalp.
62372412|NCT05616052|ACTIVE_COMPARATOR|standard arm|standard arm will start from 0.25mg per week for four weeks, then increase to 0.5mg per week for four weeks, and 1mg per week maintenance dose for 8 weeks..
62372413|NCT05616052|ACTIVE_COMPARATOR|titration arm|Titration arm dosage regime depends on the tolerance of the semaglutide from patients. The dosage will stabilize on the dose which patients could tolerate
62372414|NCT04333875||TAVR/SAVR|Patients with critical aortic stenosis as defined by an AVA \<0.6 cm2 or a transvalvular mean gradient of \>60 mmHg or a history of cardiac decompensation during the previous 3 months or clinical symptoms on minimal exertion (NYHA III) will be allocated to transcatheter aortic valve replacement or surgical aortic valve replacement.
62372415|NCT04333875||Deferred Intervention|Patients with severe but not critical aortic Stenosis will undergo deferred intervention.
62372416|NCT03502941|EXPERIMENTAL|A single dose of EAAs/whey|Subjects will consume 6.3 g of EAAs/whey in \~12 oz water.
62372417|NCT03502941|EXPERIMENTAL|A double dose of EAAs/whey|Subjects will consume 12.6 g of EAAs/whey in \~12 oz water
62372418|NCT03502941|EXPERIMENTAL|Whey protein alone|Subjects will consume 12.6 g of whey protein isolate which is an equal amount to the double dose of EAAs/whey.
62372419|NCT03037112|ACTIVE_COMPARATOR|Education|All providers will receive identical training on the appropriate prescribing of antibiotics for ARTIs in a 20 minute presentation. Follow up refresher video clips will also be available for all providers to view at their convenience throughout the study. Parents in both arms will receive identical high quality education on the pros and cons of antibiotics and tips for communicating with their provider.
62372420|NCT03037112|ACTIVE_COMPARATOR|Communication Skills|Providers randomized to the communication intervention will receive additional training on communication skills in a 40 minute communication skills training session. This training session will include good and bad communication examples, training on positive and negative behavioral framing, and education regarding key drivers of patient satisfaction.
62372421|NCT01908855|EXPERIMENTAL|ENCERT|ENCERT contains 1) psychoeducation (session1), 2) relaxation techniques for coping with stress (sessions 2-4), 3) non-judgmental awareness of body perceptions, (sessions 5-7), 4) modifying illness behavior and accepting unpleasant body perceptions (sessions 8-13), 5) attention defocusing on positive perceptions plus emotional self-support (sessions 14- 15), 6) analyzing interpretation processes to understand situational cues (sessions 16-17), and 7) change of behavior and interpretations (sessions 18-20). The innovative elements of ENCERT are: improving the awareness for the association of somatic symptoms with emotions, learning non-judgmental awareness and acceptance of unpleasant body perceptions, achieving high-frequent skill exercising with the emotion regulation audio training.
62372422|NCT01908855|ACTIVE_COMPARATOR|CBT|"This arm is based on traditional cognitive-behavioral therapy that can be considered the current treatment of choice, being the only intervention with an evidence grade 1a (Kroenke, 2007). As such, it presents the reference of efficacy and safety for new regimen. The strictly manualized program includes the following components focusing on the special needs of chronic somatoform patients: psychoeducation providing a framework for psychotherapy, attention defocusing, reduction of over-interpretation of symptoms, increase of physical activity, stress reduction."
62372423|NCT04684160|ACTIVE_COMPARATOR|Fixed-bearing group|
62372424|NCT04684160|EXPERIMENTAL|Mobile-bearing group|
62372425|NCT03072368|ACTIVE_COMPARATOR|Blue eyes|50 babies born with blue eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
62372426|NCT03072368|ACTIVE_COMPARATOR|Brown eyes|50 babies born with brown eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
62372427|NCT03072368|ACTIVE_COMPARATOR|Green eyes|50 babies born with green eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
62372428|NCT03072368|ACTIVE_COMPARATOR|Hazel eyes|50 babies born with hazel eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
62372429|NCT00003761|EXPERIMENTAL|rV-DF3/MUC1|"* rV-DF3/MUC1 vaccinations will be administered 4 week intervals for a total of 3 doses.~* Participants will be followed weekly until 28 days after the final dose (day 85) then month for 6 months"
62372430|NCT00583830|ACTIVE_COMPARATOR|A|Paclitaxel and carboplatin
62372431|NCT00583830|EXPERIMENTAL|B|Paclitaxel, carboplatin and Mapatumumab 10 mg/kg
62744578|NCT01468233|PLACEBO_COMPARATOR|Placebo|Placebo for 12 weeks.
62744579|NCT01468233|EXPERIMENTAL|Adalimumab Every Week (EW)|Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
62744580|NCT01468233|PLACEBO_COMPARATOR|Placebo/Placebo|Participants randomized to receive placebo in Period 1 received placebo every week from Week 12 to Week 35 in Period 2 (up to 24 weeks).
62744581|NCT01468233|EXPERIMENTAL|Adalimumab Every Week (EW)/Placebo|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
62744582|NCT01468233|EXPERIMENTAL|Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
62744583|NCT01468233|EXPERIMENTAL|Adalimumab Every Week (EW)/Adalimumab Every Week (EW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
62372432|NCT00583830|EXPERIMENTAL|C|Paclitaxel, carboplatin and Mapatumumab 30 mg/kg
62372433|NCT01611662|EXPERIMENTAL|Treatment (gemcitabine hydrochloride, cisplatin, surgery)|Patients receive gemcitabine hydrochloride IV over 30 minutes on day 1 and cisplatin IV on day 1 or divided over days 1 and 2. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-8 weeks after chemotherapy, patients undergo radical cystectomy.
62372434|NCT00704392|EXPERIMENTAL|1|
62372435|NCT06417398|OTHER|T cell injection targeting CD19 chimeric antigen receptor|This clinical trial was designed as a single-arm, open-label, single-center, investigator-initiated early-stage clinical study to evaluate the safety of UTAA09 injection in patients with relapsed/refractory AID. After signing the informed consent letter, qualified subjects were screened for infusion of UTAA09 injection, and their blood was collected before and after infusion for pharmacokinetics, pharmacodynamics, immunogenicity, safety and other evaluation
62372436|NCT00004056|EXPERIMENTAL|Chemo + STEM cell|See detailed description.
62372437|NCT02332798|EXPERIMENTAL|PF-04958242 0.25 mg|All participants who received PF-04958242 0.25 milligram (mg) twice daily (BID) for 14 consecutive days with the last dose occurring in the morning on Day 14.
62372438|NCT02332798|EXPERIMENTAL|PF-04958242 0.475 mg|All participants who received PF-04958242 0.475 mg BID for 14 consecutive days with the last dose occurring in the morning on Day 14.
62372439|NCT02332798|PLACEBO_COMPARATOR|Matching Placebo|All participants who received placebo BID for 14 consecutive days with the last dose occurring in the morning on Day 14.
62372440|NCT02897258||Without anticoagulant/antiplatelet|
62372441|NCT02897258||Treated with antiplatelet only|
62372442|NCT02897258||Treated with anticoagulant only|
62372443|NCT02897258||With antiplatelet/anticoagulant|
62372444|NCT05546749|ACTIVE_COMPARATOR|RelieVRx|RelieVRx was designed for at-home use and comes with a sequence of daily immersive experiences. Participants in the intervention group will complete 20-30 minute VR sessions twice per week over the course of 6 weeks.
62744584|NCT00735826|EXPERIMENTAL|Vorinostat 400 mg|Vorinostat will be administered orally once daily in an open-labeled unblinded manner to all subjects enrolled in the study. Subjects will received 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection.
62744585|NCT01932229|EXPERIMENTAL|Afatinib treatment|
62744586|NCT00160017||Collaborative group|Participants (i.e. profesionals) participate in a Breakthrough Collaborative intervention to improve diabetes care so that patients are provided more often with diabetes care as described in guidelines
62744587|NCT00160017||usual care group|Participants are offered no intervention and care is provided as usual
62744588|NCT05944081||Arcadius XP L®|all patients who received a Arcadius XP L® interbody fusion device between 2016 until approx. January 2021 (minimum Follow-up is one year) in the study center
62744589|NCT06658990|EXPERIMENTAL|buccal acupuncture|
62372445|NCT05546749|SHAM_COMPARATOR|Sham Virtual Reality|The sham virtual reality (VR) device is also by RelieVRx. However, it lacks the immersive nature of the interventional VR. Control participants will complete 20-30 minute VR sessions twice per week over the course of 6 weeks.
62372446|NCT00741767|OTHER|Salmeterol-fluticasone|Patients randomized to receive salmeterol-fluticasone 250/50 twice daily for 4 weeks. Patients will cross-over and receive placebo medication for 4 weeks later in the study.
62372447|NCT00741767|OTHER|Placebo|Patients randomized to receive placebo medication twice daily for 4 weeks. Patients will cross-over and receive study medication later in the study.
62744590|NCT06658990|ACTIVE_COMPARATOR|control|
62744591|NCT04550832|ACTIVE_COMPARATOR|Arm1(D0)|"Participants receive the following medication for the duration of 16weeks together with food.~* Delpazolid : Will not administered~* Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.~* Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.~* Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
62744592|NCT04550832|EXPERIMENTAL|Arm2(D400)|"Participants receive the following medication for the duration of 16weeks together with food.~* Delpazolid : Will be dosed 400 mg orally once daily~* Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.~* Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.~* Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
62744593|NCT04550832|EXPERIMENTAL|Arm3(D800-OD)|"Participants receive the following medication for the duration of 16weeks together with food.~* Delpazolid : Will be dosed 800 mg orally once daily~* Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.~* Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.~* Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
62372448|NCT03277794|ACTIVE_COMPARATOR|Transitional Case Management Only|Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
62372449|NCT03277794|EXPERIMENTAL|Full HOP-C Service|Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
62372450|NCT03321890|EXPERIMENTAL|Combination therapy regimen|Chidamide + prednisone+cyclophosphamide+etoposide+methotrexate
62372451|NCT00484367|ACTIVE_COMPARATOR|1 AGT|
62372452|NCT00484367|ACTIVE_COMPARATOR|2 TFT|
62372453|NCT02244658|EXPERIMENTAL|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7\~14 consecutive days
62372454|NCT02244658|NO_INTERVENTION|control|no thrombopoietic agents
62372455|NCT03202368|EXPERIMENTAL|Tocilizumab: GCA Flare or Persistent Disease Activity|Participants who were treated with tocilizumab in Study WA28119 and experienced a new GCA flare within 3 years after completion of Study WA28119 or had persistent active GCA at the time of completion of Study WA28119, will receive SC tocilizumab in this study.
62372456|NCT06386536|EXPERIMENTAL|Experimental AB group|In this arm, 5 participants will train on the intelligent bike for 5 sessions followed by 5 sessions on a conventional bike (5 participants).
62372457|NCT06386536|ACTIVE_COMPARATOR|Active comparator BA group|The participants in this arm will start training on a conventional bike for 5 sessions followed by 5 sessions on the intelligent bike (5 participants).
62372458|NCT00834925|NO_INTERVENTION|standard dose diltiazem|
62372459|NCT00834925|EXPERIMENTAL|low dose diltiazem|
62372460|NCT02718625|EXPERIMENTAL|Santyl|Santyl collagenase ointment applied topically once per day for up to six weeks
62372461|NCT02718625|ACTIVE_COMPARATOR|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
62372462|NCT01259921|EXPERIMENTAL|Neurofeedback T4-P4|40 sessions of SMR neurofeedback training using T4-P4 placement administered twice weekly
62372463|NCT01259921|ACTIVE_COMPARATOR|Neurofeedback T3-T4|40 sessions of SMR neurofeedback using T3-T4 placement training administered twice weekly
62372464|NCT05732597||Patients with ACS and no IRA|Patients with acute coronary syndrome (ACS) during a COVID-19 infection, who after undergoing coronary angiography - no infarct-related artery (IRA) is found
62372465|NCT05732597||Patients with ACS and IRA|Patients with acute coronary syndrome (ACS) during a COVID-19 infection, who after undergoing coronary angiography - an infarct-related artery (IRA) is found
62372466|NCT01522118|EXPERIMENTAL|HIFU|(high intensity focused ultrasound)
62372467|NCT04483128|SHAM_COMPARATOR|Sham IFC therapy: Control group|"This group will recieve also instructions for core strengthening exercises and a single session of interferential current (IFC).~IFC parameters:~1. Carrier frequency of 4000 Hz~2. Amplitude modulated frequency of 65 Hz (AMF)~3. Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~4. NO intensity (0 mA)~5. Session duration: 25 minutes"
62372468|NCT04483128|EXPERIMENTAL|IFC therapy: Experimental group|"This group will recieve also instructions for core strengthening exercises and a single session of interferential current (IFC).~IFC parameters:~1. Carrier frequency of 4000 Hz~2. Amplitude modulated frequency of 65 Hz (AMF)~3. Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~4. Intensity will depend on subjet's tolerance but without generating visible muscle twitches.~5. Session duration: 25 minutes"
62372469|NCT01208818|ACTIVE_COMPARATOR|BD|
62372470|NCT01208818|EXPERIMENTAL|C-BD|
62372471|NCT01208818|EXPERIMENTAL|HCO|
62744594|NCT04550832|EXPERIMENTAL|Arm4(D1200)|"Participants receive the following medication for the duration of 16weeks together with food.~* Delpazolid : Will be dosed 1200 mg orally once daily~* Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.~* Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.~* Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
62372472|NCT01208818|ACTIVE_COMPARATOR|Control HD|
62372473|NCT01329172|EXPERIMENTAL|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 (PUFA n-3)
62372474|NCT01329172|PLACEBO_COMPARATOR|placebo|sun flower oil
62372475|NCT04124406||Adults Prescribed Cologuard|Adults prescribed Cologuard for routine colon cancer screening by their healthcare provider.
62372476|NCT01144741||Freeman-Sheldon syndrome Classic Type|"Patients who have all features required by the Stevenson criteria, including: very small mouth (microstomia); whistling-face appearance (pursed lips); H or V shaped chin dimple; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping."
62744595|NCT04550832|EXPERIMENTAL|Arm5(D800-BD)|"Participants receive the following medication for the duration of 16weeks together with food.~* Delpazolid : Will be dosed 800 mg orally twice daily~* Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.~* Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.~* Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
62372477|NCT01144741||Freeman-Sheldon syndrome Craniofacial Type|"Patients who have only the face and skull physical findings required by the Stevenson criteria, including: very small mouth (microstomia), whistling-face appearance (pursed lips), H or V shaped chin dimple, very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases)."
62372478|NCT01144741||Freeman-Sheldon syndrome Mixed Type|Patients who have the face and skull physical findings required by the Stevenson criteria and some but not all required joint problems.
62372479|NCT01144741||Sheldon-Hall syndrome|Patients who have all features required by the Stevenson criteria, including: small mouth (not microstomia); neck webbing (pterygium colli); small but prominent chin; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
62372480|NCT01144741||Distal Arthrogryposis Type 1|Patients with features consistent with this diagnosis, including restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
62372481|NCT01144741||Distal Arthrogryposis Type 3|Patients with features consistent with this diagnosis, including: gap in the roof of the mouth (cleft palate); drooping eyelid (blepharoptosis); and backbones curve problems; and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
62372482|NCT01495260|EXPERIMENTAL|N-acetylcysteine, lipoic acid and vitamin E|Two Dose titration design
62744596|NCT03574610|EXPERIMENTAL|Subjects with Multiple Sclerosis and Voiding Dysfunction|Subjects with Multiple Sclerosis (MS) and voiding dysfunction (VD). In this group 'Transcranial Rotating Permanent Magnet Stimulator (TRPMS)' device will be used.
62744597|NCT06607744||Group1: Selegiline TDS of test formulation (6mg/24 hours)|Group1: 1 x Selegiline TDS 6 mg/24 hours manufactured by Corium Innovations, Inc., worn over 24 hours on cleaned upper left or right arm approximately from 8 AM following the randomisation schedule.
62372483|NCT05934708|EXPERIMENTAL|Low estrogen; low progesterone|Participants will come in while on their period. During this time estrogen and progesterone concentrations are low.
62372484|NCT05934708|EXPERIMENTAL|High estrogen; low progesterone|Participants will come in just before ovulation, when estrogen concentrations are high and progesterone concentrations remain low.
62372485|NCT05934708|EXPERIMENTAL|Medium estrogen; high progesterone|Participants will come in just after ovulation when estrogen concentrations are at a medium level, and progesterone concentrations are high.
62372486|NCT05677854|EXPERIMENTAL|Motivational interview|Motivational interviewing, consisting of 6 sessions with a one-week interval, was applied face to face to this intervention group. Each motivational interview lasted approximately 40 minutes.
62372487|NCT05677854|EXPERIMENTAL|Health education|Health education consisting of 6 sessions, one week apart, was administered face to face to this intervention group. Each training session lasted approximately 40 minutes.
62372488|NCT05677854|NO_INTERVENTION|Control|No intervention has been made.
62372489|NCT01751789|ACTIVE_COMPARATOR|Linkage|Participants will receive Suboxone during their inpatient detoxication and be given outpatient appointments to continue Suboxone treatment after completing inpatient detoxification
62372490|NCT01751789|PLACEBO_COMPARATOR|Detoxification|Participants will receive Suboxone to detoxify from opioids and the standard treatment offered by the inpatient detoxification program
62372491|NCT03304392|EXPERIMENTAL|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
62372492|NCT03304392|ACTIVE_COMPARATOR|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
62372493|NCT04432376|ACTIVE_COMPARATOR|Active treatment arm|Treatment with miconazole 2% oil, 5 drops into each ear twice daily for 14 consecutive days
62372494|NCT04432376|PLACEBO_COMPARATOR|Placebo treatment arm|Treatment with the vehicle oil, placebo, 5 drops into each ear twice daily for 14 consecutive days
62372495|NCT04432376|OTHER|Open-label treatment arm|Application of miconazole 2% oil, 5 drops into each ear twice daily for 14 consecutive days
62372496|NCT02797470|EXPERIMENTAL|Treatment (anti-HIV gene transduced CD34+ cells)|Patients receive BEAM regimen administered as standard of care comprising carmustine on day -6, cytarabine BID on days -5 to -2, etoposide BID on days -5 to -2, and melphalan on day -1. Patients undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells over 1 hour.
62372497|NCT00324272|EXPERIMENTAL|Groin dissection: sealant used.|
62744598|NCT06607744||Group2: EMSAM TDS (6 mg/24 hours)|1 x EMSAM® TDS 6 mg/24 hours manufactured by Somerset Pharmaceuticals, Inc., worn over 24 hours on cleaned upper left or right arm approximately from 8 AM following the randomisation schedule.
62372498|NCT00324272|ACTIVE_COMPARATOR|Groin dissection: no sealant used.|
62372499|NCT00324272|EXPERIMENTAL|Axillary dissection: sealant used.|
62372500|NCT00324272|ACTIVE_COMPARATOR|Axillary dissection: no sealant used.|
62372501|NCT00002981|EXPERIMENTAL|PET Scan|Each patient receives C11-methionine intravenously. PET imaging begins immediately after injection for approximately 60 minutes total using standard imaging procedures. Immediately following the completion of imaging after C11-methionine administration, each patient receives FDG intravenously. PET imaging begins approximately 45 minutes thereafter for approximately 60 minutes using standard imaging procedures.
62372502|NCT00729560|EXPERIMENTAL|1|Flutamide
62372503|NCT00729560|PLACEBO_COMPARATOR|2|control to arm 1
62372504|NCT04819724|OTHER|Group 1: patient group (unilateral rotator cuff tear)|Group 1: 25 patients with unilateral symptomatic rotator cuff tear
62372505|NCT04819724|OTHER|Group 2: control group (asymptomatic volunteers)|Group 2: (asymptomatic volunteers) 25 asymptomatic control subjects (age and sex distribution matching the patient group)
62372506|NCT04819724|OTHER|Group 2: young control group (young asymptomatic volunteers)|Group 3: (young asymptomatic volunteers) 25 asymptomatic control subjects, 20 to 30 years (sex distribution matching the patient group)
62372507|NCT01366534|EXPERIMENTAL|Ad35.CS.01 Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered one dose of Ad35.CS.01 vaccine at Month 0, and 2 doses of GSK257049 at Months 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
62372508|NCT01366534|EXPERIMENTAL|GSK257049 Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered 3 doses of GSK257049 vaccine at Months 0, 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
62372509|NCT01366534|EXPERIMENTAL|Control Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were volunteers who did not receive any immunization but were subjected to the sporozoite challenge. The duration of the study was approximately 8 months for infectivity control subjects.
62372510|NCT00515554|ACTIVE_COMPARATOR|A|8 cycles BEACOPPesc
62372511|NCT00515554|EXPERIMENTAL|B|8 cycles BEACOPPesc plus rituximab
62372512|NCT00515554|ACTIVE_COMPARATOR|C|8 cycles BEACOPPesc
62372513|NCT00515554|EXPERIMENTAL|D|4 cycles BEACOPPesc
62372514|NCT02762136|PLACEBO_COMPARATOR|placebo|Participants will orally take the placebo granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.
62372515|NCT02762136|ACTIVE_COMPARATOR|Xiang-sha-liu-jun granules|Participants will orally take the herbal formula granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.
62744599|NCT05315674||Exacerbators|Patients who experience ≥1 inpatient AECOPD
62744600|NCT05315674||Non-exacerbators|Patients without inpatient AECOPD
62744601|NCT05486325|EXPERIMENTAL|Bariatric Surgery|Up to twenty participants meeting inclusion criteria will undergo laparoscopic or robotic sleeve gastrectomy using the Endolumik Gastric Calibration Tube instead of the standard bougie calibration tube. Up to ten participants meeting inclusion criteria will undergo laparoscopic gastric bypass using the Endolumik Gastric Calibration Tube instead of the standard calibration tube.
62744602|NCT00211757|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive a placebo comparative to the study drug divalproex sodium.
62744603|NCT00211757|EXPERIMENTAL|Divalproex Sodium|Subjects will receive the study drug, divalproex sodium.
62744604|NCT04945278|OTHER|Patients|"Both patients and healthy volunteers arms will undergo the double mirror test within a day.~But the patients arm will additionally respond to the EASE test."
62744605|NCT04945278|OTHER|Healthy volunteers|Both patients and healthy volunteers arms will undergo the double mirror test within a day.
62744606|NCT04147377|EXPERIMENTAL|PD with FOG|Patients with Parkinson's disease who complain of freezing of gait
62744607|NCT03632993|ACTIVE_COMPARATOR|Treatment I: CCH Shallow Injection, 3 Aliquots|"In Treatment I, CCH will be injected subcutaneously while the participant lies in a prone position. Each injection will consist of a single skin injection of study drug administered as three 0.1 milliliters (mL) aliquots (for a total injection volume of 0.3 mL).~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per participant per treatment visit = up to 1.68 milligrams (mg) of CCH (0.84 mg in each treatment area)."
62372516|NCT01614275|EXPERIMENTAL|Technology-enhanced Parent Training|The investigators will demonstrate that web-based instructional technologies provides an efficient and effective mechanism for training military parents of children with autism, regardless of their geographic location, to implement effective behavior management and teaching strategies with high procedural integrity (90% accuracy).
62372517|NCT01614275|EXPERIMENTAL|Technology-enhanced Tutor Training|The investigators will demonstrate that web-based instructional technologies provides an efficient and effective mechanism for training tutors to implement early intervention services that are commonly used with children diagnosed with autism with high procedural integrity (above 80%).
62372518|NCT01614275|EXPERIMENTAL|Technology-enhanced Early Intensive Behavioral Intervention|The investigators will demonstrate that technology-enhanced service delivery will provide remote access to efficient and effective EIBI services to military families affected by autism.
62372519|NCT01614275|PLACEBO_COMPARATOR|Wait-list No-intervention Control Group|Tutors and families will be assigned to treatment and control groups using the process of minimization, which has been recommended for small clinical trials because it minimizes differences between the groups on relevant covariables while guarding against bias in ways comparable to simple randomization. The control group will not receive intervention services.
62744608|NCT03632993|ACTIVE_COMPARATOR|Treatment II: CCH Shallow Injection, 1 Aliquot|"In Treatment II, CCH will be injected subcutaneously while the participant is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single shallow injection of a 0.3 mL aliquot.~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
62744609|NCT03632993|ACTIVE_COMPARATOR|Treatment III: CCH Deep Injection, 1 Aliquot|"In Treatment III, CCH will be injected subcutaneously while the participant is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single deep injection of a 0.3 mL study drug aliquot.~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
62744610|NCT03632993|ACTIVE_COMPARATOR|Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots|"In Treatment IV, CCH will be injected subcutaneously while the participant lies in a prone position. Each injection will consist of a single skin injection of study drug administered as five 0.3 mL (for a total injection volume of 1.5 mL).~During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.5 mL of CCH (5 aliquots of 0.3 mL, for each injection, in each syringe). Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
62744611|NCT03632993|ACTIVE_COMPARATOR|Treatment V: CCH Shallow Injections, 4 Aliquots|"In Treatment V, CCH will be injected subcutaneously while the participant lies in a prone position. Each injection will receive a single skin injection of study drug administered as four 0.3 mL aliquots (for a total injection volume of 1.2 mL).~During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.2 mL of CCH (4 aliquots of 0.3 mL each). Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
62744612|NCT04961528|EXPERIMENTAL|Terlipressin|"Dosage: 1 mg /5 ml Pharmaceutical form: solution for infusion Posology: 1 mg /8 hours Treatment duration: 3 days~Method and route of administration: inhalation using the same jet nebulizers (INT'AIR Medical RN 300) in all Investigating centers"
62744613|NCT04961528|EXPERIMENTAL|Tranexamic Acid|"Dosage : 500 mg /5 ml Pharmaceutical form: solution for infusion Posology (and adjustments based on toxicity) : 500 mg/ 8 hours Treatment duration: 3 days~Method and route of administration: inhalation using the same jet nebulizers (INT'AIR Medical RN 300) in all Investigating centers."
62744614|NCT04961528|PLACEBO_COMPARATOR|Normal Saline Placebo|"Dose : normal saline solution (NaCl 0.9%) Pharmaceutical form : solution for infusion Posology : 5ml / 8 hours Treatment duration: 3 days~Method and route of administration: inhalation using the same jet nebulizers (INT'AIR Medical RN 300) in all Investigating centers."
62372520|NCT01599819|EXPERIMENTAL|Cohort 1|Low dose of ADVATE followed by low dose of BAX 855
62372521|NCT01599819|EXPERIMENTAL|Cohort 2|High dose of ADVATE followed by high dose of BAX 855
62372522|NCT03748420|NO_INTERVENTION|Usual Care|Patients in the usual care arm receive the basic cardiovascular related clinical decision support which is considered standard of care at the organization.
62372523|NCT03748420|EXPERIMENTAL|Adherence Intervention|Patients in the medication adherence enhanced clinical decision support received the enhanced decision support intervention over a 6 month period. Patients were accrued over 6 months and followed for 12 months at which point they were assessed for improved medication adherence and clinical outcomes.
62372524|NCT00479349|ACTIVE_COMPARATOR|1|SAM 531 + placebo
62372525|NCT02866903|EXPERIMENTAL|Patients with peritoneal carcinosis|Patients with peritoneal carcinosis of colorectal origin and uncertain resectability with an indication for systemic chemotherapy compatible with the FOLFIRI + bevacizumab combination.
62744615|NCT06657391|EXPERIMENTAL|intervention group|The intervention group will receive 4 doses of recombinant humanized anti-CD25 monoclonal antibody (Sunshine Guojian Pharmaceutical(Shanghai) Co.,Ltd.) on days +7, +14, +28, and +42 after transplantation, with a recommended dose of 1 mg/kg.
62744616|NCT06657391|NO_INTERVENTION|control group|The control group will receive no treatment at the same time points.
62372526|NCT04007367|EXPERIMENTAL|Open-Label Phase: SAGE-217|Participants self-administered SAGE-217, 30 milligrams (mg), oral capsule, once daily (QD) in the evening from Day 1 to Day 14.
62372527|NCT04007367|PLACEBO_COMPARATOR|Double-Blind Phase: Placebo|Following the OL Phase, participants who exhibited a Hamilton Rating Scale for Depression (HAM-D) response, defined as a greater than or equal to (≥) 50% reduction from baseline in HAM-D total score were to be randomized to receive SAGE-217 matching placebo capsule, orally, QD, in the evening, in a total of five, 14-day treatment periods, each separated by a 6-week follow-up period during the 40-week DB Phase of the study. However, no participants were randomized to receive SAGE-217 matching placebo due to early study termination.
62744617|NCT02777047|EXPERIMENTAL|Intervention|The interdisciplinary multimodal intervention is led by a clinical pharmacologist and includes: a detailed discharge medication reconciliation and management plan focused on oral anticoagulants at hospital discharge; a circle of care handover and coordination with patient, hospital team and community providers; and early post-discharge follow-up virtual medication check-up visits at 24 hours, 1 week, and 1 month.
62372528|NCT04007367|EXPERIMENTAL|Double-Blind Phase: SAGE-217|Following the OL Phase, participants who exhibited a HAM-D response defined as a ≥ 50% reduction from baseline in HAM-D total score to SAGE-217 were randomized to receive SAGE-217, 30 mg, oral capsule, QD, in the evening, up to study termination date (i.e., up to approximately 22 weeks) during the DB Phase of the study.
62372529|NCT01571167|PLACEBO_COMPARATOR|Placebo|
62744618|NCT02777047|NO_INTERVENTION|Control|Patients allocated to the control group will receive usual care, plus the URL to Thrombosis Canada website. Usual care in the participating sites includes OAC management by family doctors except for new thromboembolic events which will be followed short term by thromboembolism or hematology specialists, complicated atrial fibrillation which will have cardiology involved temporarily, and a small proportion of warfarin management which is provided in an anticoagulation clinic. This choice of control group is the most relevant for generalizability to both academic and community practices.
62744619|NCT04799171|ACTIVE_COMPARATOR|Young Adults (Age group 18-39)|31P-Magnetic Resonance Spectroscopy exam on one thigh to measure mitochondrial capacity non-invasively after exercise training.
62372530|NCT01571167|ACTIVE_COMPARATOR|Varenicline 2 mg|
62372531|NCT01571167|ACTIVE_COMPARATOR|Varenicline 1 mg|
62372532|NCT05732493|EXPERIMENTAL|short-course radiotherapy and immunotherapy|A total of 60 patients will receive 5\*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the surgery.
62372533|NCT05732493|ACTIVE_COMPARATOR|chemotherapy|A total of 60 patients will receive 4 cycles of CAPOX chemotherapy ,then receive the surgery.
62372534|NCT03510403|EXPERIMENTAL|Device : nasal airway stent|Patients with OSA or snoring use the nasal airway stent nastent™ each night for sleeping. The device is a tube-shaped medical device that is inserted from the nose and the tip of the tube reaches the soft palate. The inserted tube aids breathing by preventing the obstruction of the airway which causes poor sleep, frequent awakening during sleep and snoring.
62372535|NCT02084875|EXPERIMENTAL|tofacitinib MR 11 mg Fed|tofacitinib modified release (MR) 11 mg tablet administered with food.
62372536|NCT02084875|EXPERIMENTAL|tofacitinib MR 11 mg Fasting|tofacitinib modified release (MR) 11 mg tablet administered without food.
62372537|NCT05580237||Severe aortic valve stenosis|
62372538|NCT04984070|EXPERIMENTAL|PCOS treatment|Lifestyle intervention, oral contraceptive pills and metformin will be given to improve the symptoms of PCOS patients, such as obesity, hyperandrogegism, and insulin resistance, and to compare the different psychological status in PCOS.
62372539|NCT00740428|EXPERIMENTAL|G1|pregnants for the first time who will receive the physical therapy guide
62372540|NCT01327573|EXPERIMENTAL|Eculizumab|"eculizumab will be given in addition to standard immunosuppression regimen (oral tacrolimus or equivalent, MMF \[mycophenolate mofetil~\], prednisone)"
62372541|NCT01327573|NO_INTERVENTION|no additional therapy|patients in this arm will receive standard immunosuppression regimen (oral tacrolimus or equivalent, MMF, prednisone only, no additional therapy
62372542|NCT00380406|PLACEBO_COMPARATOR|Placebo|Placebo
62372543|NCT00380406|ACTIVE_COMPARATOR|depot GnRHa (Leuprolide acetate (LA) 11.25 mg intramuscularly)|
62372544|NCT01788111|EXPERIMENTAL|Low back exercises 1|Specific low back extensor exercises in special training bench
62372545|NCT01788111|ACTIVE_COMPARATOR|Low back exercise 2|Traditional low back exercises.
62372546|NCT00118040|EXPERIMENTAL|Arm I (lower dose genistein)|Patients receive oral genistein twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
62744620|NCT04799171|ACTIVE_COMPARATOR|Middle Aged Adults (Age group 40-59)|31P-Magnetic Resonance Spectroscopy exam on one thigh to measure mitochondrial capacity non-invasively after exercise training.
62744621|NCT04799171|ACTIVE_COMPARATOR|Old Adults (Age group >60)|31P-Magnetic Resonance Spectroscopy exam on one thigh to measure mitochondrial capacity non-invasively after exercise training.
62744622|NCT01292356|EXPERIMENTAL|cetuximab|
62372547|NCT00118040|EXPERIMENTAL|Arm II (higher dose genistein)|Patients receive oral genistein as in arm I but at a higher dose. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
62744623|NCT04171219|EXPERIMENTAL|Treatment (talabostat, pembrolizumab)|Patients receive talabostat PO BID on days 1-14 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62744624|NCT06106061|EXPERIMENTAL|Group one: Decompression + FFX®|
62372548|NCT00118040|PLACEBO_COMPARATOR|Arm III (placebo)|Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
62372549|NCT03167827|EXPERIMENTAL|Group isoflavone and exercise|The isoflavone group received daily 100mg of isoflavones.
62744625|NCT06106061|ACTIVE_COMPARATOR|Group two: Decompression alone|
62744626|NCT01235845|EXPERIMENTAL|DC-DCIK|
62744627|NCT06660992|EXPERIMENTAL|HSK31858 40mg|HSK31858 40mg treat for 52-week
62744628|NCT06660992|PLACEBO_COMPARATOR|Placebo|the placebo comparator of study
62744629|NCT03443479||Patients with type II ARF|All patients with type II respiratory failure that were deemed by the treating physician to require ventilatory support either with non-invasive ventilation (NIV) or High-Flow Nasal Cannula (HFNC).
62372550|NCT03167827|PLACEBO_COMPARATOR|Group placebo and exercise|The placebo group received 100mg containing starch of corn.
62372551|NCT03023319|EXPERIMENTAL|Bosutinib and Pemetrexed|Bosutinib and pemetrexed
62744630|NCT03984474||Single bundle group|Age 13-65 when enrolled. Only include isolated ACL rupture. Excluded revision surgery. Excluded bilateral ACL rupture. Excluded the contralateral ACL tear after surgery.
62744631|NCT03984474||Double bundle group|Age 13-65 when enrolled. Only include isolated ACL rupture. Excluded revision surgery. Excluded bilateral ACL rupture. Excluded the contralateral ACL tear after surgery.
62744632|NCT06659159||GLP-1, New Therapy|Indication, prescription and dosage is determined independently of the study by the endocrinologist/obesity specialist, who is also part of the study team. Since the first gastric ultrasound will take place directly before the initiation of the GLP-1 Agonist therapy, the patients will serve as their own control group/baseline.
62744633|NCT01928589|ACTIVE_COMPARATOR|PBI|270 cGy (centigray) x 15
62744634|NCT01928589|EXPERIMENTAL|PBI with chemotherapy|270 cGy (centigray) x 15 concurrent with chemotherapy of the treating medical oncologist's choice
62744635|NCT01476319|NO_INTERVENTION|control|
62744636|NCT01476319|EXPERIMENTAL|video|
62744637|NCT05720689|EXPERIMENTAL|MEOPA dental care with music|diffusion of relaxing music during dental care under MEOPA
62744638|NCT05720689|ACTIVE_COMPARATOR|MEOPA dental care without music|dental care under MEOPA as usual
62744639|NCT01293344|EXPERIMENTAL|Men and Mediterranean diet|Men who are assigned to a 4 weeks experimental diet formulated to be concordant with characteristics of the traditional Mediterranean diet.
62744640|NCT01293344|EXPERIMENTAL|Women and Mediterranean diet|Women who are assigned to a 4 weeks experimental diet formulated to be concordant with characteristics of the traditional Mediterranean diet.
62744641|NCT00760942|ACTIVE_COMPARATOR|1|Liquid human milk fortifier
62744642|NCT00760942|ACTIVE_COMPARATOR|2|Powdered human milk fortifier
62744643|NCT06660576|OTHER|Gallbladder stones in children|Histochemical analysis of Gallbladder stones in children and correction with aetiological factors
62744644|NCT06429696|EXPERIMENTAL|PD-L1 inhibitor combined with apatinib|Six-month progression-free survival rate (6-month PFS rate) of PD-L1 inhibitor combined with apatinib in first-line maintenance treatment of extensive-stage small cell lung cancer (ES-SCLC)
62744645|NCT02566785|EXPERIMENTAL|Intervention Group|Those allocated to the intervention group will participate in a supervised group session exercise one time per week and be asked to exercise two more times per week at home.
62744646|NCT02566785|OTHER|Wait List Control Group|The wait list control group will not participate in the intervention and will be asked to continue their usual activity level during the first 12 weeks and will receive the multi-component balance intervention during weeks 12-24.
62744647|NCT04607304|EXPERIMENTAL|ABCA2 GIRMS|Leftover breath samples analyzed on ABCA2 GIRMS systems, order of analysis randomized
62744648|NCT04360239|EXPERIMENTAL|Fish Oil|Fish-Oil naïve subjects will be started on fish oil 4 weeks prior to surgery and continued until the 6 week follow up. Subjects already taking fish oil will be switched to the study fish-oil formulation of two capsules twice daily (3000 mg of EPA and DHA).
62744649|NCT04360239|NO_INTERVENTION|Control|No fish oil supplementation
62744650|NCT05935657|EXPERIMENTAL|Remimazolam Group|sedation with remimazolam
62744651|NCT05935657|ACTIVE_COMPARATOR|Dexmedetomidine group|sedation with dexmedetomidine
62744652|NCT02957747|EXPERIMENTAL|Safety and Health Experiences Program|Participants in the SHE arm of the study will receive a web-based intervention utilizing motivational interviewing and education.
62372552|NCT01318928|PLACEBO_COMPARATOR|Periodontal intervention, sugar pill|Group 1: metronidazole + mechanical treatment in one day, Group 2: Placebo + mechanical treatment in one day Group 3: metronidazole + mechanical treatment on day 1 and 21 Group 4: Placebo + mechanical treatment on day 1 and 21
62372553|NCT02826655|ACTIVE_COMPARATOR|Healthy Controls|Study participants will undergo imaging of both eyes with the WF-AO-OCT unit, per standard operating protocol. Imaging is noncontact. Study participants will undergo only a single imaging session on a single day.
62372554|NCT02826655|EXPERIMENTAL|Subjects with diabetic retinopathy|Study participants will undergo imaging of both eyes with the WF-AO-OCT unit, per standard operating protocol. Imaging is noncontact. Study participants will undergo only a single imaging session on a single day.
62744653|NCT02957747|NO_INTERVENTION|Control|Participants randomized to this arm will receive referrals to VA and community resources
62744654|NCT06517225|EXPERIMENTAL|Telepractice delivery|Participants will receive visual-acoustic biofeedback treatment from a clinician in a private, password-protected WebRTC room.
62744655|NCT06517225|ACTIVE_COMPARATOR|In-person delivery|Participants will receive visual-acoustic biofeedback treatment from a clinician in a private room in research space at one of the two clinical research sites.
62744656|NCT04790279|EXPERIMENTAL|Amlodipine|
62744657|NCT04790279|ACTIVE_COMPARATOR|Nifedipine ER|
62372555|NCT02617706|EXPERIMENTAL|Transdermal Continuous Oxygen Therapy|EPIFLO® working study unit, all day, every day for 2 - 4 weeks + standard wound care
62372556|NCT02617706|NO_INTERVENTION|Standard of care|standard wound care for 4 weeks
62372557|NCT01102946|EXPERIMENTAL|PRP plus ranibizumab|Patients will be submitted to panretinal photocoagulation plus intravitreal injections of ranibizumab
62744658|NCT00798460|ACTIVE_COMPARATOR|Lamivudine plus adefovir|
62372558|NCT01102946|ACTIVE_COMPARATOR|PRP|Patients will only be submitted to panretinal photocoagulation
62372559|NCT00824395||1|Individuals with diabetes
62372560|NCT00824395||2|Individuals without diabetes
62372561|NCT05135468|EXPERIMENTAL|CU-40102 Spray|0.25% (2.275mg/mL) Finasteride
62372562|NCT05135468|PLACEBO_COMPARATOR|Placebo for CU-40102 Spray|Placebo Spray
62372563|NCT03252262|ACTIVE_COMPARATOR|Jack Satter House|Residents of Jack Satter House who participated in the Vitalize 360 Program.
62372564|NCT03252262|ACTIVE_COMPARATOR|Center Communities of Brookline|Residents of Center Communities of Brookline who participated in the Vitalize 360 Program.
62372565|NCT03252262|ACTIVE_COMPARATOR|Simon C. Fireman|Residents of Simon C. Fireman who participated in the Vitalize 360 Program
62372566|NCT01581905|ACTIVE_COMPARATOR|LH Group|The LH Group includes individuals undergoing conventional laparoscopic hysterectomy, total or supracervical.
62372567|NCT01581905|ACTIVE_COMPARATOR|RH Group|The RH Group includes individuals undergoing Robot-Assisted laparoscopic hysterectomy, total or supracervical.
62372568|NCT01251315|PLACEBO_COMPARATOR|Placebo low dose|Placebo for low dose group given as a single dose.
62372569|NCT01251315|ACTIVE_COMPARATOR|N Acetyl cysteine, 600mg (low dose)|N-Acetyl Cysteine (NAC)600 mg (low dose) given as a single dose.
62372570|NCT01251315|ACTIVE_COMPARATOR|Proimmune 200(FT061452)|Proimmune 200(FT061452) low dose group 3000 mg given as a single dose.
62372571|NCT01251315|PLACEBO_COMPARATOR|Placebo high dose|Placebo given to high dose group given as a single dose.
62372572|NCT01251315|ACTIVE_COMPARATOR|N Acetyly cysteine, 1200mg (high dose)|N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
62372573|NCT01251315|ACTIVE_COMPARATOR|FT061452, 6000mg high dose|Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
62372574|NCT01725295|EXPERIMENTAL|NST|A form of physical therapy to relieve symptoms of fibromyalgia
62372575|NCT01725295|ACTIVE_COMPARATOR|Hydrotherapy|An alternate form of physical therapy to relieve symptoms of fibromyalgia
62744659|NCT00798460|ACTIVE_COMPARATOR|Clevudine plus adefovir|
62372576|NCT06177015|ACTIVE_COMPARATOR|Continuous treatment group|Darolutamide: 600mg, bid+ADT: Leuprorelin (3.6mg qm or 10.8mg q3m) or goserelin 80mg qm until mCRPC
62372577|NCT06177015|EXPERIMENTAL|Intermittent treatment group|Only ADT as background treatment without Darolutamide. PSA check every three months, when the patient's PSA \> 1ng/ml (or PSA \> 1ng/ml and PSA has risen by more than 20% comparing baseline), restart the darolutamide, until mCRPC.
62372578|NCT05097976|EXPERIMENTAL|Methylprednisolone taper|Methylprednisolone taper - 21 x 4mg tablets beginning on POD 1
62372579|NCT05097976|PLACEBO_COMPARATOR|Placebo taper|2.Placebo taper - 21 sugar tablets beginning on POD 1 with standard management
62372580|NCT06076239|EXPERIMENTAL|ESWT Group|The participants in the ESWT Group (n=16) were given Extracorporeal Shock Wave Therapy to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles for a total of 5 sessions in 3 weeks (2 sessions in the first week, 2 sessions in the second week, 1 session in the third week) in addition to conventional treatment.1000 pulses to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles, 500 pulses to the surrounding area, 2 bars, ESWT (GYMNMA Shockmaster 500) was applied for a total of 5 sessions in 3 weeks at 10 Hz, medium energy level (\<0.28 mJ/mm2).
62372581|NCT06076239|ACTIVE_COMPARATOR|Control Group|Control group (n=16) received only conventional treatment for five days per week for 3 consecutive weeks. Conventional treatment includes Ultrasound therapy(Gymna Pulson200) (1 mHz. treatment dose average 1.5 w/cm², intermittent with a small head (50%), 5 minutes around the glenohumeral joint of the cases in both groups participating in the study; at an intensity that the patient can tolerate, covering the painful area TENS applied (modified biphasic asymmetric pulse, and it was set to a pulse width of 100 μs and a frequency of 100 Hz, 20 min,) (Hometech ht 66b); hotpack and exercises (posterior capsule stretching, wand exercises, mobilization approximately 60 minutes of conventional treatment consisting of exercises and shoulder isometric exercises) was applied once a day, 5 times a week in both groups.
62372582|NCT02545452|EXPERIMENTAL|BAY98-7196|Investigate the pharmacokinetics effect of a vaginally administered antimycotic (miconazole) during the use of an intra-vaginal ring (IVR) releasing anastrozole (ATZ) and levonorgestrel (LNG)
62372583|NCT02545452|EXPERIMENTAL|Administered Antibiotic|Investigate the pharmacokinetics effect of a vaginally administered antibiotic (clindamycin) during the use of an IVR releasing ATZ and LNG
62372584|NCT02545452|EXPERIMENTAL|Administered Spermicide|Investigate the pharmacokinetics effect of a vaginally administered spermicide (nonoxynol-9) during the use of an IVR releasing ATZ and LNG
62372585|NCT02545452|EXPERIMENTAL|Tampons|Investigate the pharmacokinetics effect of the concomitant use of tampons during the use of an IVR releasing ATZ and LNG; investigate the pharmacokinetics over an extended IVR wearing period of 35 days
62372586|NCT06198894|EXPERIMENTAL|Steroid-eluting Sinus Implant|In-office bilateral placement of the sinus stent; Systemic glucocorticoid placebo; saline irrigations (250ml) twice daily
62372587|NCT06198894|SHAM_COMPARATOR|Control|In-office bilateral sham procedure; Systemic glucocorticoid; saline irrigations (250ml) twice daily
62372588|NCT06350877|EXPERIMENTAL|1:1 Physical Activity Intervention Delivery|The physical activity intervention will be delivered using 1:1 coaching.
62744660|NCT06604767|EXPERIMENTAL|PIV3 Dose 1|Participants will receive a single intramuscular (IM) injection at Day 1
62744661|NCT06604767|EXPERIMENTAL|PIV3 Dose 2|Participants will receive a single intramuscular (IM) injection at Day 1
62744662|NCT06604767|EXPERIMENTAL|PIV3 Dose 3|Participants will receive a single intramuscular (IM) injection at Day 1
62744663|NCT06604767|EXPERIMENTAL|PIV3 Dose 4|Participants will receive a single intramuscular (IM) injection at Day 1
62744664|NCT06604767|EXPERIMENTAL|RSV/hMPV /PIV3 Formulation 1|Participants will receive a single intramuscular (IM) injection at Day 1
62744665|NCT06604767|EXPERIMENTAL|RSV/hMPV Formulation 1|Participants will receive a single intramuscular (IM) injection at Day 1
62744666|NCT06604767|EXPERIMENTAL|RSV/hMPV Formulation 2|Participants will receive a single intramuscular (IM) injection at Day 1
62744667|NCT06604767|EXPERIMENTAL|RSV vaccine 1|Participants will receive a single intramuscular (IM) injection at Day 1
62744668|NCT06604767|EXPERIMENTAL|RSV vaccine 2|Participants will receive a single intramuscular (IM) injection at Day 1
62372589|NCT06350877|EXPERIMENTAL|Group Physical Activity Intervention Delivery|The group physical activity intervention will receive the physical activity intervention delivered in small groups of 3-8 students led by a trained sport and recreation coach.
62372590|NCT06350877|NO_INTERVENTION|10-Week Waitlist Control Group|Students who are assigned to the 10-week waitlist control condition will be assessed on primary and secondary outcomes at baseline (T1), at 6-weeks (T2) and at 1-month follow-up (T3). At completion of the 1-month follow-up assessment, students in the wait-list control condition will be offered participation in the physical activity intervention; however, their behaviour will not be monitored or evaluated. Participants will have a choice of engaging in 1:1 physical activity intervention delivery or group-based physical activity intervention delivery.
62372591|NCT04258449||Case|Participants must have suspected or confirmed upper genital tract cancer (uterine, tubal and ovarian) and must be scheduled to undergo surgery for tumor removal.
62372592|NCT05533073|EXPERIMENTAL|Group A: Etoricoxib/Tramadol FDC|Pharmaceutical Form: Sachet with granules to dilute in 100 mL of water Formula: Each sachet contains Etoricoxib 90 mg / Tramadol 50 mg Dosage: 100 mL Administration way: oral
62372593|NCT05533073|ACTIVE_COMPARATOR|Group B: Etoricoxib|Pharmaceutical Form: Tablet Formula: Tablet containing Etoricoxib 90 mg Dosage: 1 tablet of 90 mg Administration way: oral
62372594|NCT05533073|ACTIVE_COMPARATOR|Group C: Tramadol|Pharmaceutical Form: Capsule Formula: Each capsule contains 50mg of Tramadol Dosage:1 capsule of 50 mg Administration way: oral
62372595|NCT06507228|OTHER|NWL PEBBLE STT patients|Real-world clinical care arm investigating novel pathway
62744669|NCT00665795||1Patients with Graves´orbitophathy.|Patients with Graves´orbitophathy.
62372596|NCT01466062|EXPERIMENTAL|Palivizumab|15 mg/kg at 30-day intervals; at least 4 intramuscular injections up to a maximum of 7 intramuscular injections as appropriate for prophylaxis of severe respiratory syncytial virus (RSV) during the RSV season.
62744670|NCT00665795||2 Patients with detected DON|Patients with Graves´orbitophaty and detected dysthyroid optic neuropathy (DON)
62744671|NCT02639169|EXPERIMENTAL|music|Apply live music through techniques music therapy in group experimental and evaluation through the visual analog scale (VAS) and numeric.
62744672|NCT02639169|NO_INTERVENTION|Comparative|Apply the visual analog scale (VAS) and numeric.
62372597|NCT04685369||Active smokers with wet AMD|
62372598|NCT01831011|EXPERIMENTAL|mildronate|infusion of mildronate
62372599|NCT01831011|ACTIVE_COMPARATOR|cinepazide maleate|infusion of cinepazide maleate
62372600|NCT04140474|EXPERIMENTAL|Archimedes procedure|All included patients will receive anesthesia consultation, biological assessment and chest CT scan in thin sections. A surgical treatment will always be planned after presentation of the file in a meeting of multidisciplinary consultation of thoracic oncology. The Archimedes® procedure will be performed during a bronchoscopy under general anesthesia. Immediate monitoring consisted in a chest x-ray 1hour after the procedure.
62372601|NCT05177224|EXPERIMENTAL|Participants with dual mobility cup|
62372602|NCT06274775|EXPERIMENTAL|Educational Video Group|Group A (intervention group), which will be shown an educational video about the nail biopsy procedure in addition to standard of care, which includes verbal information about the procedure and pre-operative and post-operative handouts with instructions provided via quick-response (QR) code.
62372603|NCT06274775|NO_INTERVENTION|Standard of Care Group|Standard of care only, which includes verbal information about the procedure and pre-operative and post-operative handouts with instructions provided via quick-response (QR) code.
62372604|NCT04668547|EXPERIMENTAL|Interventional arm|Single arm, no comparison
62744673|NCT04185337|EXPERIMENTAL|Diagnostic (ultrasound, ultrasound-guided PAI, FNA, biopsy)|Patients undergo standard of care ultrasound of the lymph nodes, then undergo ultrasound-guided PAI over 3-5 minutes. Patients then undergo standard of care ultrasound-guided FNA or biopsy a suspicious lymph node.
62744674|NCT05193201|EXPERIMENTAL|Cohort 1 : 50*10^9/L ≤ Baseline of PLT < 75*10^9/L|The multiple-dose regimen (15000 U subcutaneous injection once a day for 7 days) of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.
62744675|NCT05193201|EXPERIMENTAL|Cohort 2 : 30*10^9/L ≤ Baseline of PLT < 50*10^9/L.|The multiple-dose regimen (15000 U subcutaneous injection once a day for 7 days) of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.
62744676|NCT06232603|ACTIVE_COMPARATOR|Education at baseline|video and ambulatory visit summary (AVS) education will be provided at baseline visit
62744677|NCT06232603|OTHER|Education at the first follow up|video and AVS education will be provided at the first follow up visit
62744678|NCT02900690||recombinant activated factor VII (NovoSeven®)|Group using the Novoseven
62744679|NCT02900690||Standard care|without use of the Novoseven
62744680|NCT05189756|EXPERIMENTAL|Verum|Patients will receive 2 encapsulated capsules containing aprepitant 80mg to be ingested with a sip of water 2 hours before surgery and 24 hours after surgery. Surgery will follow our hospital enhanced recovery after surgery (ERAS) standard (general anaesthesia using volatile anaesthetics, intravenous dexamethasone 8mg and ondansetron 4mg for PONV prophylaxis).
62744681|NCT05189756|PLACEBO_COMPARATOR|Placebo|Patients will receive similar looking encapsulated capsules containing only placebo to be ingested with a sip of water 2 hours before surgery and 24 hours after surgery. Surgical and anaesthetic procedures are identical to the verum arm.
62744682|NCT02710981|ACTIVE_COMPARATOR|Clomiphene citrate only|women with prior 5 ovulatory cycles of Clomiphene citrate induction, but without conception (clomiphene citrate failure), with thin endometrium (\<8mm) in at least 3 cycles.
62744683|NCT02710981|EXPERIMENTAL|Sildenafil vaginal gel and Clomiphene|Women who did not conceive on the Clomiphene citrate only cycle (41 women) were given Clomiphene citrate 100 mg/ day starting from day of the cycle for 5 days, with the addition to sildenafil vaginal gel 5 gm twice daily starting from day 8 of the cycle until day of HCG injection.
62372605|NCT02764086|OTHER|Trial Cohort Description|"Escalated dose of min 65Gy to the iGTV, with 60Gy to PTV delivered to successive cohorts of patients(pts) until the MTD oesophageal dose is determined. Toxicity will be analysed 2 months post 6pts treated in a cohort.~If: ≤2pts have ≥G3 toxicity, next cohort will be enrolled \& receive escalated dose (an additional +5Gy at each escalation upto max 75Gy)/3 of 6pts have ≥G3 toxicity, a further 6pts will be recruited into that dose level/≥4pts have ≥G3 toxicity, the MTD is fixed at dose level of previous cohort~Cohort is extended to 12pts:~If: ≤4pts have ≥G3 toxicity, next cohort will be enrolled \& receive escalated dose/5 of 12pts have ≥G3 toxicity, the MTD is fixed at that dose level \& recruitment continues up to 24pts/≥6pts have ≥G3 toxicity, the MTD is fixed at the dose level of previous cohort.~Once the max dose cohort is established, recruiting will continue at that dose until 24pts. Concurrent \& neo-adjuvant/no chemotherapy arms will be escalated independently of each other"
62372606|NCT03557229|EXPERIMENTAL|Melatonin|
62372607|NCT03557229|EXPERIMENTAL|Vitamin C|
62372608|NCT03557229|EXPERIMENTAL|Vitamin E|
62372609|NCT03557229|EXPERIMENTAL|N-acetylcysteine|
62372610|NCT03557229|NO_INTERVENTION|Control|
62372611|NCT00086385|ACTIVE_COMPARATOR|Brief Treatment|"Pharmacological Treatment - Subjects received 12 weeks of bupropion treatment and 10 weeks of nicotine replacement treatment (NRT)~Brief Counseling - The counseling intervention consisted of five 90-minute group meetings.~There was no further treatment during Weeks 12-52."
62372612|NCT00086385|EXPERIMENTAL|Extended NRT|"Pharmacological Treatment - Following completion of the Brief Treatment, subjects assigned to this condition would continue receiving NRT for up to 52 weeks. Subjects in this condition would be encouraged to continue NRT through Week 24. If a subject terminated NRT and resumed smoking, before Week 50, would be instructed to set a quit date and resume NRT.~Counseling Treatment - This is identical to the Brief Counseling described above."
62372613|NCT00086385|EXPERIMENTAL|Tailored/No Extended NRT|This condition was identical to the Tailored/NRT condition except that no NRT was available after completion of the Brief Treatment.
62372614|NCT00086385|EXPERIMENTAL|Extended Tailored Counseling + NRT|Tailored Counseling Treatment- The primary goal of the extended treatment was to prevent relapse. Secondary goal was to encourage initiation of abstinence for those who have not attained it by Week 12, and re-initiation of abstinence after slips. Subjects would participate in the Brief Treatment followed by individual sessions. The first extended treatment counseling session would occur at Week 10. Additional sessions would be held every two weeks then every four weeks, and finally at Weeks 44 and 52. Each session would be 20-30 minutes long. Between sessions subjects would be contacted by phone for brief check-ins (5-10 minutes).
62372615|NCT03374891|NO_INTERVENTION|Participants will fill out surveys|These participants will fill out surveys in regard to their experiences, opinions, and knowledge of the defibrillator process.
62372616|NCT03374891|ACTIVE_COMPARATOR|Educational video and/or handout|These participants will receive an educational video and/or handout about the defibrillator process. Then they will fill out surveys in regard to their experiences, opinions, and knowledge of the defibrillator process.
62372617|NCT01894776|EXPERIMENTAL|Maraviroc|"Two period pharmacokinetic drug-drug interaction Period one -Maraviroc alone; Period two -Maraviroc and Rifabutin~Substance: Maraviroc (Celsentri, MVC) tablets, 300 mg; dose: oral, 300 mg (1 tablet) twice daily~Substance: Rifabutin (mycobutin, RFB) capsules, 150 mg; dose: oral, 300 mg (2 capsules) once daily"
62372618|NCT00726310||SpineLink® , SpineLink® II Group|Spinal fusion surgery with SpineLink®
62372619|NCT04878276||Dimet 5|"Dimet 5 is a certified medical device for the treatment of head lice infestation. It contains only (liquid) dimeticone oil and, when used correctly, enables physical killing of head lice and their eggs."
62372620|NCT04878276||Hedrin Once Liquid Gel|Hedrin Once Liquid Gel is a certified medical product for the removal of head lice and nits. The liquid gel contains 4% dimethicone and nerolidol (Penetrol®).
62372621|NCT02839044|EXPERIMENTAL|Vitamin K|One group receives tablets of 360 microgram menaquinone-7 daily
62372622|NCT02839044|PLACEBO_COMPARATOR|Placebo|One group receives placebo tablets daily
62372623|NCT05094882||RUL|patients who recieved the resection of right upper lobe (RUL)
62372624|NCT05094882||RML|patients who recieved the resection of right middle lobe ()
62372625|NCT05094882||RLL|patients who recieved the resection of right lower lobe (RML)
62372626|NCT05094882||LUL|patients who recieved the resection of left upper lobe (LUL)
62372627|NCT05094882||LLL|patients who recieved the resection of left lower lobe (LLL)
62372628|NCT03364062||cemented shoulder replacement patients|A total of 350 cases of proximal humeral fracture receiving cemented shoulder replacement in Department of Orthopedics and Trauma
62744684|NCT04812028|EXPERIMENTAL|Prospective Experimental Group|Participants in this group will prospectively receive the intervention.
62372629|NCT03884127||hyperlipidaemia|On the basis of the intervention of therapeutic sexual life style, a case control study was conducted on the intervention of oral ezetimibe tablet and orlistat capsule for 12 weeks and hyperlipidemia patients who persisted in the use of basic treatment.
62372630|NCT04026646|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation stretching exercises|Proprioceptive Neuromuscular Facilitation stretching exercises (contract-relax-antagonist-contract method) will be performed 6 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.
62372631|NCT04026646|EXPERIMENTAL|Static stretching exercises|Passive Static Stretching exercises will be performed 2 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.
62372632|NCT04346004|PLACEBO_COMPARATOR|Control group|Participants in this group are administered N/S.
62372633|NCT04346004|EXPERIMENTAL|Iron isomaltoside group|Participants in this group are administered Iron isomaltoside \& Vitamin B12.
62372634|NCT04835441|EXPERIMENTAL|ALPN-101 (acazicolcept)|
62372635|NCT04835441|PLACEBO_COMPARATOR|Placebo|
62372636|NCT03335306||Healthy subjects in Hong Kong|
62372637|NCT02373891|EXPERIMENTAL|T1|
62372638|NCT02373891|EXPERIMENTAL|T0|
62744685|NCT04812028|NO_INTERVENTION|Retrospective Review Group|Participants in this group will have their medical records retrospectively reviewed.
62372639|NCT03151538|EXPERIMENTAL|Pes Planus Group|This group of patients received children with pes planus. It will be applied exercise training mixed with play
62372640|NCT03151538|OTHER|Controlled Group|This group of patients received healthy children.
62372641|NCT04241120|EXPERIMENTAL|Experimental group - HabitAware condition|This group will receive the device which alerts the participant when performing hair pulling behavior and the app which provides psychoeducation and components of Habit Reversal Training.
62372642|NCT04241120|PLACEBO_COMPARATOR|Control group - reminder bracelet condition|This group will receive only a device that vibrates randomly several times per hour as a reminder not to pull.
62372643|NCT01017692||Lumbar Spinal Stenosis|Subjects who have undergone or will undergo an MRI, with symptoms of LSS
62372644|NCT00785005||1|Females with Type 2 Diabetes
62372645|NCT00785005||2|Females without Type 2 Diabetes
62372646|NCT01992328|EXPERIMENTAL|Immune Globulin|Immunoglobulin G Deficiency Associated with persistent asthma subtypes
62372647|NCT06204510|NO_INTERVENTION|control group|
62372648|NCT06204510|EXPERIMENTAL|study group|
62372649|NCT04154995||Long-term ICU patients|Patients with a ICU length of stay of at least 48 hours.
62372650|NCT01680991|EXPERIMENTAL|CLL: 1000 mg Obinutuzumab|Participants with chronic lymphocytic leukemia (CLL) will receive 1000 milligrams (mg) obinutuzumab as an intravenous (IV) infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. The first infusion on Cycle 1 Day 1 will be given over two days: Day 1 and Day 2. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
62372651|NCT01680991|EXPERIMENTAL|DLBCL: 1000 mg Obinutuzumab|Participants with diffuse large B-cell lymphoma (DLBCL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
62372652|NCT01680991|EXPERIMENTAL|FL: 1000 mg Obinutuzumab|Participants with follicular lymphoma (FL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
62744686|NCT06130254|EXPERIMENTAL|Adagrasib+Olaparib|"Participants will take adagrasib and olaparib by mouth 2 times each day. Each dose should be taken at about 12 hours apart (1 dose in the morning, 1 dose in the evening). The study drugs should be swallowed whole with water. Do not chew, crush, dissolve, or divide the study drugs.~If forget a dose and less than 2 hours have passed since the usual time participants take the study drug, take the dose as soon as participants remember. If more than 2 hours have passed, do not take the dose. Wait and take the next dose as scheduled"
62744687|NCT05538065|NO_INTERVENTION|No Alert (Usual Care)|Providers randomized to usual care will receive no intervention.
62372653|NCT03206983|EXPERIMENTAL|Cana's Ring group|The device Cana's Ring was used during cataract surgery on these patients.
62372654|NCT01326676|EXPERIMENTAL|polypill|Red Heart Pill Version 1 and Red Heart Pill Version 2.
62372655|NCT01326676|ACTIVE_COMPARATOR|usual medication|participants continuing to receive cardiovascular disease medications as separate tablets prescribed by their usual physician
62372656|NCT05743725|ACTIVE_COMPARATOR|A: Dexmedetomidine|Brain tumor excision under general anesthesia. This group will receive dexmedetomidine loading 1 microgram/kg bolus in 10 minutes followed by 0.2-1 microgram/kg/hour till the end of surgery.
62372657|NCT05743725|ACTIVE_COMPARATOR|B: Magnesium sulphate|Brain tumor excision under general anesthesia. This group will receive a 2 gm magnesium infusion for 30 minutes.
62372658|NCT00859573|ACTIVE_COMPARATOR|1. Modafinil|
62372659|NCT00859573|PLACEBO_COMPARATOR|2: Placebo|Placebo
62372660|NCT03634228|EXPERIMENTAL|Phase I (low dose cytarabine, MDM2 inhibitor DS-3032b)|Patients receive low dose cytarabine SC BID on days 1-10 and milademetan tosylate PO QD on days 8-14, 8-21, or 5-7 and 15-17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62372661|NCT03634228|EXPERIMENTAL|Phase II (low dose cytarabine, MDM2 inhibitor DS-3032b)|Patients receive low dose cytarabine SC BID on days 1-10, milademetan tosylate PO QD on days 8-14, 8-21, or 5-7 and 15-17, and venetoclax PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62372662|NCT03275519|ACTIVE_COMPARATOR|Antibiotics prophylaxis cohort|Subjects were prescribed prophylactic antibiotics after the hypospadias surgery.
62372663|NCT03275519|ACTIVE_COMPARATOR|Antibiotic-sparing cohort|Subjects were not prescribed prophylactic antibiotics after the hypospadias surgery.
62372664|NCT06030076||Tildrakizumab|Participants who have been prescribed tildrakizumab to manage moderate-to-severe plaque psoriasis according to summary of product characteristic (SmPC) in routine clinical practice settings will be observed prospectively for up to 28 weeks.
62372665|NCT02740894||targeted therapy|according to national healthy policy, targeted therapy is the optional therapy
62372666|NCT02740894||traditional chemotherapy|according to national healthy policy, chemotherapy is the first line treatment.
62372667|NCT01979042||patients with stones|80 men and women with a normal creatinine for the past year that present in the ER with renal colic and a stone in their ureter according to imaging
62372668|NCT01979042||patients without stones|20 men and women that presented in our department for elective surgery that is not related to stones or bladder outlet obstruction
62372669|NCT02425969|EXPERIMENTAL|Optimal Medical Therapy|Patients will receive secondary prevention and optimal medical therapy to control their anginal symptoms according to international guidelines without PCI of their grey-zone FFR lesion
62372670|NCT02425969|ACTIVE_COMPARATOR|PCI with Optimal Medical Therapy|Patients will undergo PCI of their grey-zone FFR lesion as well as appropriate secondary prevention. Anti-anginal therapy will be administered as per clinical requirements according to international guidelines.
62372671|NCT03922711|EXPERIMENTAL|Pridopidine Dose 1|Dose 1 (oral capsule) for 12 weeks following 2 or 4 week dosage regimen titration period
62372672|NCT03922711|EXPERIMENTAL|Pridopidine Dose 2|Dose 2 for (oral capsule) for 12 weeks following 2 or 4 week dosage regimen titration period
62372673|NCT03922711|PLACEBO_COMPARATOR|Placebo|Matching placebo (oral capsule) for 16 weeks
62372674|NCT01633528|EXPERIMENTAL|Asprin|With the onset of endometrial preparation and estrogen treatment, the study group will receive 100 mg of oral aspirin.
62372675|NCT01633528|PLACEBO_COMPARATOR|placebo|With the onset of endometrial preparation and estrogen treatment, the control group will receive placebo
62744688|NCT05538065|EXPERIMENTAL|Open Encounter + Pre-commitment|There will be an enhanced EHR alert, known as a Best Practice Advisory \[BPA\], which will appear on each provider's EHR screen. We will also test a two-staged pre-commitment BPA in which the providers are prompted to discuss risks of the high-risk medications and share a handout about risks with their patients.
62744689|NCT05538065|EXPERIMENTAL|Open Encounter + Follow-up booster|There will be an enhanced EHR alert, known as a Best Practice Advisory \[BPA\], which will appear on each provider's EHR screen. We will add a boostering option in the enhanced BPA, which is a provider-directed option for a follow-up in-basket message sent 4 weeks after the BPA is triggered.
62372676|NCT06391970|OTHER|DigiCog Intervention|Although DigiCog participants receive two interventions (the new digital device and the gold standard method), they are not randomized to different intervention groups. Instead, each participant serves as their own control, receiving both interventions sequentially. Therefore, the study has one arm.
62744690|NCT05131542||Down Syndrome|Children with down syndrome
62744691|NCT06661096|EXPERIMENTAL|TMJ dysfunction|TMJ arthroscopy
62744692|NCT05582707|EXPERIMENTAL|MIPS + Pioglitazone|20 Subjects will undergo MIPS for evacuation of ICH using the BrainPath access device plus perioperative pioglitazone for 3 weeks
62744693|NCT05582707|NO_INTERVENTION|MIPS Alone|This trial will compare it's subjects to subjects who have previously undergone MIPS for evacuation of ICH using the BrainPath access device as part of the ENRICH trial (NCT02880878). These subjects will be enrolled at an ENRICH trial site independent of our Institution. Deidentified patient information from 20 subjects in this group, who will be matched to those in the ENRICH-PLUS group, will be provided to the principal investigator for comparison of outcomes.
62372677|NCT03987867|EXPERIMENTAL|Arm: CIK+PD-1 inhibitor+chemotherapy|"CIK cell, IBI308, Pemetrexed, Liposome paclitaxel, Carboplatin~IBI308 intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d2 or Liposome paclitaxel intravenous infusion 135mg/m2 d2; Carboplatin intravenous infusion AUC5 d2; CIK cells, 1x10\^10 (10 billion ), intravenous infusion,d14; Q3W."
62744694|NCT05867420|EXPERIMENTAL|ASKG915|Single or multiple ascending dose of ASKG915.
62744695|NCT02604602||PPH|
62372678|NCT04476615|EXPERIMENTAL|FMD|Fasting-Mimicking diet (ProLon®)
62372679|NCT04476615|PLACEBO_COMPARATOR|Placebo|Low-energy bars (L-Nutra®) supplementation
62372680|NCT02505269|EXPERIMENTAL|Brentuximab Vedotin|"The following procedures will take place during study visits beginning after the screening procedures:~- Participants will receive combination therapy:~* Brentuximab Vedotin intravenously on predetermined days per cycle~* Adriamycin intravenously on predetermined days per cycle~* Dacarbazine intravenously on predetermined days per cycle"
62372681|NCT02852291|EXPERIMENTAL|Parents Make the Difference|Parents Make the Difference (Caregivers attend 10 group parent training sessions)
62372682|NCT02852291|EXPERIMENTAL|Parents Make the Difference Plus|Parents Make the Difference Plus (Caregivers attend 10 group parent training sessions and receive 3 home visits)
62372683|NCT02852291|NO_INTERVENTION|Waitlist Control|No parenting intervention until the end of the study period
62372684|NCT02591836|EXPERIMENTAL|Gemcabene 300 mg|Gemcabene 300 mg QD
62372685|NCT02591836|EXPERIMENTAL|Gemcabene 600 mg|Gemcabene 600 mg QD
62372686|NCT02591836|EXPERIMENTAL|Gemcabene 900 mg|Gemcabene 900 mg QD
62372687|NCT02591836|PLACEBO_COMPARATOR|Placebo|
62372688|NCT02591836|ACTIVE_COMPARATOR|Atorvastatin 10 mg|
62372689|NCT02591836|ACTIVE_COMPARATOR|Atorvastatin 40 mg|
62372690|NCT02591836|ACTIVE_COMPARATOR|Atorvastatin 80 mg|
62372691|NCT02591836|EXPERIMENTAL|Gemcabene 300 mg & Atorvastatin 10 mg|
62744696|NCT02604602||non-PPH|
62744697|NCT01350752|NO_INTERVENTION|Control|"In Cameroon: Existing practice (with microscopy widely available)~In Nigeria: Expected practice (RDTs will be provided with basic instructions)"
62744698|NCT01350752|ACTIVE_COMPARATOR|Provider Intervention|"Cameroon: Introduce malaria RDTs with basic provider training and job aids on malaria diagnosis and treatment. This involved 1-day training on: 1) Malaria Diagnosis; 2) Rapid Diagnostic Testing; 3) Malaria Treatment. These modules explain that all febrile patients should be tested for malaria; procedures for using an RDT; that confirmed cases of uncomplicated malaria should be treated with an ACT; and test-negative patients should not be given an antimalarial.~Nigeria: Introduce malaria RDTs with provider training and job aids on malaria diagnosis and treatment. This involved a 2-day training workshop and support visits. The training covered the following topics: causes and symptoms of malaria; demonstration on how to use an RDT; updated malaria guidelines; and communications skills. The training used a combination of seminars and facilitated small-group work, such as a treatment algorithm game, problem-solving exercises, self-developed participatory drama and role-playing."
62372692|NCT02591836|EXPERIMENTAL|Gemcabene 300 mg & Atorvastatin 40 mg|
62372693|NCT02591836|EXPERIMENTAL|Gemcabene 300 mg & Atorvastatin 80 mg|
62372694|NCT02591836|EXPERIMENTAL|Gemcabene 600 mg & Atorvastatin 10 mg|
62372695|NCT02591836|EXPERIMENTAL|Gemcabene 600 mg & Atorvastatin 40 mg|
62372696|NCT02591836|EXPERIMENTAL|Gemcabene 600 mg & Atorvastatin 80 mg|
62372697|NCT02591836|EXPERIMENTAL|Gemcabene 900 mg & Atorvastatin 10 mg|
62372698|NCT02591836|EXPERIMENTAL|Gemcabene 900 mg & Atorvastatin 40 mg|
62372699|NCT02591836|EXPERIMENTAL|Gemcabene 900 mg & Atorvastatin 80 mg|
62372700|NCT02296905|EXPERIMENTAL|Group I|Subjects with mild hepatic impairment
62372701|NCT02296905|EXPERIMENTAL|Group II|Subjects with moderate hepatic impairment
62372702|NCT02296905|EXPERIMENTAL|Group III|Subjects with severe hepatic impairment
62372703|NCT02296905|EXPERIMENTAL|Group IV|Subjects with normal hepatic function
62372704|NCT00005792|EXPERIMENTAL|MTV|Melphalan Topotecan Etoposide VP-16 Phosphate autologous stem cell transplant
62372705|NCT02747329|EXPERIMENTAL|1st month OCT group implanted BuMA Supreme™ stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of BuMA Supreme™ stent. The Primary Endpoint of this group is 1st month QCA and OCT assessment.
62372706|NCT02747329|ACTIVE_COMPARATOR|1st month OCT group implanted Xience V/Prime stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of Xience V/Prime stent. The Primary Endpoint of this group is 1st month QCA and OCT assessment.
62372707|NCT02747329|EXPERIMENTAL|2st month OCT group implanted BuMA Supreme™ stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of BuMA Supreme™ stent. The Primary Endpoint of this group is 2st month QCA and OCT assessment.
62372708|NCT02747329|ACTIVE_COMPARATOR|2st month OCT group implanted Xience V/Prime stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of Xience V/Prime stent. The Primary Endpoint of this group is 2st month QCA and OCT assessment.
62372709|NCT02943668|EXPERIMENTAL|Treatment (deferasirox)|Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
62372710|NCT00614042|EXPERIMENTAL|1|Dose escalation and expansion cohorts
62372711|NCT04162912|EXPERIMENTAL|Experimental group|Participants in the experimental group will receive a MotivationaI Interviewing tailored ACP programme.
62372712|NCT04162912|NO_INTERVENTION|Control group|The participants in the control group will receive usual care offered by the palliative care team under study and its affiliated day care centres, home care team and outpatient clinics.
62372713|NCT04409340||Training cohort|"All patients enrolled will undergo:~* Magnetic Resonance Viscoelastography~* Quantitative ultrasound (QUS)"
62372714|NCT04409340||Validation cohort|"All patients enrolled will undergo:~• Quantitative ultrasound (QUS)"
62372715|NCT00564603|PLACEBO_COMPARATOR|1|Saline with same volume added to tramadol infusion combined with morphine PCA.
62372716|NCT00564603|ACTIVE_COMPARATOR|2|Dexamethasone 10mg in 2mL added to tramadol infusion adjunct to morphine PCA.
62372717|NCT01307228|EXPERIMENTAL|Full-serve evidence service|"The full-serve evidence service consists of:~1. database (Health Systems Evidence) access;~2. monthly e-mail alerts; and~3. full-text article availability."
62372718|NCT01307228|ACTIVE_COMPARATOR|Self-serve evidence service|"Participants allocated to the self-serve evidence service will receive only database access, which is already publicly available at www.healthsystemsevidence.org"
62372719|NCT00644241|EXPERIMENTAL|stem cell|
62372720|NCT03922269||Transgender individual with a diagnosis of HIV|The participant self-identifies as transgender and/or has a current gender identity which differs from gender assigned at birth, is 18 years old or above, has a diagnosis of HIV infection and has been prescribed antiretroviral therapy.
62372721|NCT05533164|EXPERIMENTAL|Rituximab|1000mg rituximab intravenously once
62372722|NCT05533164|PLACEBO_COMPARATOR|Placebo|0mg rituximab (placebo) intravenously once
62372723|NCT00947089|EXPERIMENTAL|group A-the treatment group|Group A-patients have their wound, the site of the previous stoma, wad with ORC
62372724|NCT00947089|ACTIVE_COMPARATOR|group B-the control group|control group-patients have their wound wad with iodoform gauze
62372725|NCT03746990||observational|Total of 2015 Libyan school children aged 7 to 16 years, from urban (Tobruk) and rural (Kufra) areas were included in the main study. The children were of almost equal number of both sexes from each age group (table-I) .The total of 1935 children were examined for enamel fluorosis
62372726|NCT06003452|ACTIVE_COMPARATOR|Giomer Based Sealant Without Pre-Treatment With Bioactive Glass Air Abrasion|giomer based fissure sealnt will be applied without surface treatment
62372727|NCT06003452|EXPERIMENTAL|Giomer Based Sealant With Pre-Treatment With Bioactive Glass Air Abrasion|giomer based fissure sealnt will be applied after surface treatment With Bioactive Glass Air Abrasion
62372728|NCT03649815|EXPERIMENTAL|Use of mHealth Technology|This single arm of the study involves the provision of the mobile health technology entitled App4Independence.
62372729|NCT02220530||Sedation group|Colonoscopies performed with conscious sedation with iv midazolam and fentanyl
62372730|NCT02220530||Control group|Colonoscopies performed without sedation.
62372731|NCT03442595||Cases|patients with uncontrolled type 2 diabetes mellitus that participate in the MedStar Diabetes Pathway
62372732|NCT03442595||Matched controls|patients with uncontrolled type 2 diabetes that match the cases on 5 criteria and received standard of care diabetes management with a MedStar provider
62372733|NCT01314144|EXPERIMENTAL|Bupivacaine|Patients will receive intraoperative wound soakage with 20ml of 0.5% bupivacaine with adrenaline by the surgeon before closure and receive a continuous infusion of 4ml/hr of 0.2% bupivacaine delivered by an elastomeric pump the catheter of which will be placed by the surgeon in the wound before closure. Postoperative anlagesia will be provided with oxycodone, paracetamol and diclofenac.
62372734|NCT01314144|NO_INTERVENTION|Control|Patients will receive morphine up to 0.1mg/kg intraoperatively. Postoperative analgesia will be provided with oxycodone, paracetamol and diclofenac.
62372735|NCT01713257|EXPERIMENTAL|Immunoenhancing diet|Immunoenhancing diet feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
62372736|NCT01713257|ACTIVE_COMPARATOR|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
62372737|NCT02703649|EXPERIMENTAL|Single dose|Single 20 mg dose of Letrozole on day 3 of the menstrual cycle.
62372738|NCT02703649|ACTIVE_COMPARATOR|Daily dose|Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
62372739|NCT05495776||Patients with colorectal cancer|Patients with colon adenocarcinoma who have not previously received antitumor treatment (chemo/radiation therapy) for a currently detected tumor
62372740|NCT00641745|EXPERIMENTAL|1|Lurasidone
62372741|NCT00641745|ACTIVE_COMPARATOR|2|Risperidone
62372742|NCT02777164|EXPERIMENTAL|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
62372743|NCT02749786|OTHER|Control Group|Participants who do not have rosacea (control group)
62372744|NCT04561284|EXPERIMENTAL|Indigestible fiber supplementation|Participants will receive an indigestible fiber supplementation (classified) for a period of 8 weeks. Thrice daily, they will take the fiber powder during their meals.
62372745|NCT04561284|PLACEBO_COMPARATOR|Placebo supplementation|Participants will receive placebo supplementation (Maltodextrin) for a period of 8 weeks. Thrice daily, they will take the fiber powder during their meals. The amount of maltodextrin taken will be isocaloric with the amount of indigestible fiber.
62372746|NCT04970433|EXPERIMENTAL|Electroacupuncture (EA)|Acupoint regimen: Hegu (LI4), Neiguan (PC6), Zusanli (ST36), Sanyinjiao (SP6) and Sishencong (EX-HN1). Electrical stimulation using an EA apparatus, with a pair of electrodes connecting acupoints LI4 with PC6, and another pair of electrodes connecting ST36 with SP6. EA stimulation will last for 15 min with a continuous wave of 2 Hz and a current intensity of 0.1-1 mA.
62372747|NCT04970433|ACTIVE_COMPARATOR|Laser acupuncture (LA)|Participants allocated to the LA group will receive LA therapy at the same acupoints used in EA group. The laser will be applied to each point for 40 seconds, which delivered 3 J of energy at each of the acupoints.
62372748|NCT04970433|SHAM_COMPARATOR|Sham laser acupuncture (SLA)|Participants in the control group will receive sham LA treatment without any laser output. The acupuncture points, application duration, and total number of treatments are the same as those in the LA group.
62372749|NCT00472043|EXPERIMENTAL|Metvix® cream 160 milligram per gram|Methyl aminolevulinate hydrochloride 160 milligram (mg)/gram (g) cream were received by participants with primary nodular basal cell carcinoma. A thick layer of study cream was applied directly on the lesion and on 5 mm of the surrounding tissue. An approximately 1 mm thick layer of cream was applied to cover the lesion completely. The study cream was applied for at least 3 hours followed by illumination using non-coherent red (570-670 nm) light at a fluence of 50- 75 J/cm\^2.
62372750|NCT00472043|PLACEBO_COMPARATOR|Placebo|Participants with primary nodular basal cell carcinoma received Metvix® matching placebo cream. A thick layer of study cream was applied directly on the lesion and on 5 mm of the surrounding tissue. An approximately 1 mm thick layer of cream was applied to cover the lesion completely. The study cream was applied for at least 3 hours followed by illumination using non-coherent red (570-670 nm) light at a fluence of 50- 75 J/cm\^2.
62372751|NCT04539665|EXPERIMENTAL|Intervention Arm|Prospective study arm involving an extended mesenteric ileocolic excision.
62372752|NCT04539665|NO_INTERVENTION|Control Arm|Historical controls from a retrospective chart review of patients who had a limited ileocolic resection.
62372753|NCT01964027|EXPERIMENTAL|Irinotecan plus epirubicin|Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment \* 6 cycles as the second line chemoregime for advanced gastric cancer
62372754|NCT04258904|EXPERIMENTAL|Intervention|Skin Care Program
62372755|NCT04258904|NO_INTERVENTION|Control|Usual Treatment
62372756|NCT02194452|EXPERIMENTAL|Diagnostic (gallium Ga 68-edotreotide PET/CT)|"Patients undergo gallium Ga 68-edotreotide PET/CT at baseline and 1-30 days after surgery.~Interventions: gallium Ga 68-edotreotide, positron emission tomography, computed tomography, laboratory biomarker analysis"
62372757|NCT06198504|EXPERIMENTAL|Protocol using end-tidal oxygen monitoring during preoxygenation before intubation|In 72 consecutive eligible patients tracheal intubation procedure will be performed in accordance with current guidelines except for the duration of the preoxygenation to be individualized by EtO2 monitoring.
62372758|NCT00438776|ACTIVE_COMPARATOR|olanzapine|active zyprexa (olanzapine)
62372759|NCT00438776|PLACEBO_COMPARATOR|sugar pill|Placebo (fake pill)
62372760|NCT00994760||GENISIS|
62372761|NCT04493944|EXPERIMENTAL|Intervention group (with culinary workshop)|This group will be composed of participants that will answer online questionnaires before and after the study, and will participate in a culinary workshop with a chef (3 hours).
62372762|NCT04493944|NO_INTERVENTION|Control group (without culinary workshop)|This group will be composed of participants that will answer online questionnaires before and after the study.
62372763|NCT02382614|EXPERIMENTAL|Spiration Valve System|The treatment group will have valves deployed to achieve leak isolation.
62372764|NCT02382614|NO_INTERVENTION|Medical Management|The control group for this study will receive standard chest tube drainage management and standard-of-care interventions. This group will be evaluated and followed in the same manner as the treatment group, but without having valves placed.
62567184|NCT03076840|ACTIVE_COMPARATOR|Kinesio tape group|treatment by: application of Kinesio tape in the hamstring muscle by using a 1 strip Y shape of (Kinesio Tex® Tape 5cm) insertion to origin technique to relieve the hamstring tightness while the muscle in stretched position for 15 second (hip flexion and knee extension and then application of the tape) with 25% stretch of the tape
62372765|NCT01085773|NO_INTERVENTION|Standard written information on exercise|The Control group got the diabetes outpatients clinics standard written information on exercise as a part of the treatment for Type 2 Diabetes and were, like other Type 2 Diabetes patients in the clinic, advised at inclusion to be physically active.
62372766|NCT01085773|EXPERIMENTAL|Exercise on Prescription|In Denmark, Exercise on Prescription have focused on individual behavioral change and an exercise program for 16 weeks. The physical training consisted of both aerobic and strength training and took place in supervised groups
62372767|NCT01085773|EXPERIMENTAL|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
62372768|NCT05105529|EXPERIMENTAL|Ozone (O3) group|Participants of the experimental group will perform sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling 170ppb ozone delivered continuously during each exercise session.
62372769|NCT05105529|SHAM_COMPARATOR|Filtered Air|Participants of the sham group will also perform sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer similar to intervention. However, only in this group, the ozone generator will not be activated so that just filtered air will be delivered to the participant while performing each exercise session.
62372770|NCT02750501|OTHER|Single Arm: Open label RELiZORB Cartridge & Impact Peptide 1.5|RELiZORB (immobilized lipase) cartridge and Impact Peptide 1.5 with enteral feedings ranging from 500 mL to 1,000 mL per feeding for a period of 90 days.
62372771|NCT00662727|ACTIVE_COMPARATOR|A|A - Treatment group. Patients in this group receive actual shockwave therapy.
62372772|NCT00662727|PLACEBO_COMPARATOR|B|Placebo group. This group of patients undergo the same procedure as the treatment group, however shockwaves are not delivered to the heart.
62744699|NCT01350752|ACTIVE_COMPARATOR|Extended intervention|"Cameroon: Introduce malaria RDTs with basic provider training and job aids on malaria diagnosis and treatment AND enhanced provider training on improving quality of care. Clinicians received 3-days of training: the first day was identical to the basic intervention, while the remainder of the course covered three additional modules targeting improvements in quality of care: 4) Adapting to Change; 5) Professionalism; 6) Communicating Effectively.~Nigeria: Introduce malaria RDTs with provider training and job aids on malaria diagnosis and treatment AND School-based malaria education intervention (with drama, peer-health education and distribution of health education materials). In addition, teachers and Peer Health Educators were offered support to hold malaria events in which parents, guardians, and other community members could participate in the same types of activities."
62372773|NCT04838639|EXPERIMENTAL|NO-13065, oral tablet|
62372774|NCT04838639|PLACEBO_COMPARATOR|Placebo matched to NO-13065, oral tablet|
62372775|NCT00736606|EXPERIMENTAL|Period 1|simvastatin
62372776|NCT00736606|EXPERIMENTAL|Period 2|simvastatin + AZD9056
62552831|NCT05703087|EXPERIMENTAL|Positive cueing in the information video before a primary total knee arthroplasty|"The information video was adapted from the existing standard information video used in OLVG. The concept of positive cueing was applied to the standard video by an expert team including a psychiatrist and clinical psychologist. Illustrations which were incomprehensible or with negative associations were removed.~Four rules were followed to use positive cueing:~1. make patients aware that they are able to influence their own recovery process,~2. be descriptive in explanations; objectively describe the performed procedure, name equivalent, not negatively charged feelings,~3. explain why specific steps and actions during the procedure are performed, so the patients understand what is going to happen,~4. do not use medical langue, but use accessible, understandable language instead."
62552832|NCT04828174|EXPERIMENTAL|anti-TRBC1 CAR-T cell|Administration with anti-TRBC1 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients.
62552833|NCT04847518|EXPERIMENTAL|Kan Jang|70 patients take Kan Jang, two capsules three times a day for the two weeks in the treatment period. Daily dose - 90-120 mg of andrographolides.
62552834|NCT04847518|PLACEBO_COMPARATOR|Placebo|70 patients take Placebo, two capsules three times a day for the two weeks in the treatment period
62552835|NCT03507088|EXPERIMENTAL|fulvestrant|500mg fulvestrant on days 0, 14, 28 and every 28 days thereafter Fluoroestradiol-PET is performed at baseline and after 28 days
62552836|NCT03064555||Participants with end stage renal disease|"Cardiopulmonary exercise test~Cardiopulmonary exercise testing will be conducted on an electronically braked cycle ergometer using a ramped protocol with participants being required to pedal until exhaustion.~Constant load exercise test~Constant load exercise will be performed for 30 min on an electronically braked cycle ergometer whilst seated in a dialysis chair. Blood sampling and echocardiogram will be measured throughout."
62552837|NCT03064555||Healthy participants|"Cardiopulmonary exercise test~Cardiopulmonary exercise testing will be conducted on an electronically braked cycle ergometer using a ramped protocol with participants being required to pedal until exhaustion.~Constant load exercise test~Constant load exercise will be performed for 30 min on an electronically braked cycle ergometer whilst seated in a dialysis chair. Blood sampling and echocardiogram will be measured throughout."
62372777|NCT05953103|EXPERIMENTAL|Part A 1 - Subjects with cerebral hemorrhage (Synbixin 37.5 mg; placebo group )|
62372778|NCT05953103|EXPERIMENTAL|Part A 2 - Subjects with cerebral hemorrhage ( Synbixin 62.5 mg; placebo group )|
62372779|NCT05953103|EXPERIMENTAL|Part B - Subjects with cerebral hemorrhage ( Synbixin TBD mg; placebo group )|
62372780|NCT02031510|ACTIVE_COMPARATOR|bupivacaine-dexmedetomidine|transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
62372781|NCT02031510|ACTIVE_COMPARATOR|bupivacaine|transversus abdominis plane block with bupivacaine 0.25%
62372782|NCT02031510|PLACEBO_COMPARATOR|placebo|Transversus abdominis block with saline 0.9%
61986310|NCT05243225||laparoscopic management of post cholecystectomy bile duct injury.|Under general intubation anaesthesia, trocars are inserted in the abdomen, insufflation by CO2 adhesiolysis is performed to reach the bile duct. Evaluation by intraoperative cholangiogram then according to the site and the size of the injury repair will done. If the injury is small simple repair or repair on T-tube will be done. If the injury is large repair on T-tube or hepaticojejunostomy will be done .If it is a distal injury repair on T-tube or biloenteric shunt will be done .If the injury is proximal biloenteric shunt will be done. Intra-abdominal drains insertion
62372783|NCT03188302|OTHER|Specimen collection|Collection of stool samples
62372784|NCT00216749||Cilostazol|Cilostazol Treatment Patients who were in stable states after the occurrence of cerebral infarction (except cardiogenic cerebral embolism)
62552838|NCT01200225||Cohort|
62552839|NCT01386801||People with Diabetes Mellitus Type II|500 subjects will have T2D
62552840|NCT01386801||Healthy|500 persons who do not have T2D, hypertension or hypercholesterol
62567185|NCT03076840|SHAM_COMPARATOR|sham tape group|treatment by: application of Kinesio tape in the hamstring muscle by using a 1 strip I shape of (Kinesio Tex® Tape 5cm) with no stretch in the hamstring musculature and the tape applied perpendicular over the upper third of the hamstring muscle while the muscle in stretched position
62744700|NCT04217135|ACTIVE_COMPARATOR|conventional treatment|This group will receive conventional evidence-based medications with up-titration to maximal tolerable dose. The evidence-based medications include angiotensin converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, mineralocorticoid receptor antagonist, ivabradine and entresto. Which evidence-based medications will be started first depends on the decision of in-charge doctors without strict regulation. However, all evidence-based medications should be up-titrated to maximal tolerable dose. (Excuse me! Up-titration of evidence-based medications in heart failure isn't multiple intervention. Those medications should be prescribed in each heart failure case if no contraindication was noted.)
62744701|NCT04217135|ACTIVE_COMPARATOR|high-dose hydralazine group|another group will receive low-dose hydralazine initially with rapid up-titration, if no adverse effect including hypotension with worsening low cardiac output sign, skin rash and joint pain occurred. Since the half-life of hydralazine is around 4-6 hours and 3-5 half-life achieves the steady blood concentration, up-titration of hydralazine will be done per 1-2 days. For example, initial dose of hydralazine would be 25 mg tid and the dose would be 50 mg bid next day if no adverse effect occurred. Following this rule, one week is enough to reach high-dose hydralazine with daily dose of 300-400 mg.
62744702|NCT02753907|EXPERIMENTAL|Low LA (linoleic acid)|Individuals who replaced 10 mL soy oil with one apple
62744703|NCT02753907|NO_INTERVENTION|Medium LA|Individuals who maintained their usual food intake
62744704|NCT02753907|EXPERIMENTAL|High LA|Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9 g of soy oil as a supplement
62744705|NCT05497115|EXPERIMENTAL|Trauma Resilience and Recovery Program|TRRP is a stepped model of care that delivers education at the bedside about mental health recovery after traumatic injury as well as risk assessment and brief intervention for high-risk patients (Step 1), fosters symptom monitoring and continued education (Step 2), screens for PTSD and depression 30 days post-injury (Step 3), and provides a referral and warm handoff to mental health services if needed (Step 4)
62744706|NCT05497115|NO_INTERVENTION|Enhanced Usual Care Condition|Patients in the EUC arm will be given education about mental health after traumatic injury, educational materials about mental health recovery, and local referral information to assist treatment-seeking patients in seeking care.
62372785|NCT03965546|EXPERIMENTAL|ET140202-T cell combine with Sorafenib|Sorafenib treatment everyday and autologous ET140202-T cell administered by intravenous (IV) infusion
62744707|NCT02592720|EXPERIMENTAL|Cocktail plus FFR guided group|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
62372786|NCT03965546|EXPERIMENTAL|ET140202-T cell combine with TAE|TAE treatment ahead every two times of autologous ET140202-T cell administered by intravenous (IV) infusion
62372787|NCT03965546|EXPERIMENTAL|solo ET140202-T cell|autologous ET140202-T cell administered by intravenous (IV) infusion
62372788|NCT01116349|ACTIVE_COMPARATOR|Surgical treatment|Patients included in the surgical group will have surgery to treat the fracture.
62372789|NCT01116349|ACTIVE_COMPARATOR|Conservative treatment group|Patients included in the conservative group will be taken to a plaster room where a Hanging Support System(HSS) brace will be installed by a qualified technician.
62372790|NCT03623906|EXPERIMENTAL|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
62372791|NCT03623906|ACTIVE_COMPARATOR|Air insufflation colonoscopy|Room air insufflation colonoscopy
62372792|NCT02507050|EXPERIMENTAL|Intervention|Patients randomised to stop beta blockers and start Ivabradine. Initial dose of 5mg BD, titrated to 7.5mg BD if possible.
62552841|NCT04661644|EXPERIMENTAL|Test Group 1 (Low Dose)|- Administration Method: 1 mL is withdrawn from 1 vial of clusters of adipose-derived mesenchymal stem cells, composed of adipose-derived mesenchymal stem cells and diluted with 20 mL of saline, which is divided into 1 cc pre-filled syringes and administered in 20 divided doses to 15-20 parts of the muscle in divided doses along the working areacourse of the tibial artery and peroneal artery below the knee joint (above the lower ischemic area) of the subject (above the lower ischemic area) of the subjects under general anesthesia or spinal anesthesia so that the entire diluted solution is administered.
62372793|NCT02507050|NO_INTERVENTION|Standard therapy|Bisoprolol given as standard beta blocker treatment i.e. Bisoprolol (maximum dose 10mg OD).
62372794|NCT03793894|ACTIVE_COMPARATOR|Enhanced usual care|"All trial participants will receive smoking cessation counseling (standard of care) and will be given the AHRQ Is Lung Cancer Screening Right for me? patient decision aid to review independently while in the hospital."
62372795|NCT03793894|EXPERIMENTAL|Inpatient SDM + CHW Navigation|In addition to the smoking cessation counseling and decision aid received by all subjects, intervention subjects will receive shared decision making (SDM) + CHW navigation.
62372796|NCT02467660|EXPERIMENTAL|Online Mindfulness Meditation Training|Weekly 1-hr online training and daily meditation for 30-45 min for 6 wks
62372797|NCT02467660|EXPERIMENTAL|Online Health & Wellness Education|6-week training entails completing weekly 1-hour online training and listening to educational podcasts for 30-45 minutes per day
62372798|NCT02467660|NO_INTERVENTION|Wait List Control|No training
62372799|NCT04024202||Patients|"1. Patients with a positive DAT, a positive eluate and signs of hemolysis~2. Patients with a positive DAT with complement only, negative eluate, but with hemolysis"
62744708|NCT02592720|PLACEBO_COMPARATOR|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
62744709|NCT01152047|EXPERIMENTAL|oxytocin, satiety|Oxytocin is given as infusion to examine if this decreases satiety compared to saline during a drinking test
62372800|NCT04024202||Blood donors|Blood donors with a positive direct antiglobulin test and a positive eluate and/or clinically relevant cold auto-antibodies
62372801|NCT03658967|ACTIVE_COMPARATOR|Lymfactin® (1x10E11 vp)|Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
62372802|NCT03658967|PLACEBO_COMPARATOR|Placebo (0.9% physiological saline)|Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
62372803|NCT00498368|EXPERIMENTAL|Rituximab Plus ACE/ARB|Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement
62372804|NCT00498368|ACTIVE_COMPARATOR|ACE/ARB|ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement
62744710|NCT06084637|EXPERIMENTAL|autologous microfat (MG)|Patient will be hospitalized in outpatient surgery. A blood sample will be collected and a lipoaspiration will be performed under local anesthesia during the same operation by the nurses and the surgeon. Then, biological products will be immediately prepared, and a preparation of autologous MG will be injected intra-articularly by th same surgeon.
62744711|NCT06084637|EXPERIMENTAL|Platelet-rich plasma (PRP)|Patient will be hospitalized in outpatient surgery. A blood sample will be collected and a lipoaspiration will be performed under local anesthesia during the same operation by the nurses and the surgeon. Then, biological products will be immediately prepared, and a preparation of autologous PRP will be injected intra-articularly by th same surgeon.
62744712|NCT06084637|EXPERIMENTAL|Microfat autologous-Platelet-rich plasma (MG-PRP)|Patient will be hospitalized in outpatient surgery. A blood sample will be collected and a lipoaspiration will be performed for the preparation during the same operation by the nurses and the surgeon. Then, biological products will be immediately prepared, and autologous microfat associated with a preparation of autologous PRP will be injected intra-articularly by th same surgeon.
62744713|NCT01747343|EXPERIMENTAL|Underwear/Differential Reinforcement|All subjects will wear underwear followed by wearing underwear while receiving differential reinforcement.
62372805|NCT02253160|EXPERIMENTAL|Spectra Optia CMNC first, then COBE Spectra MNC|Spectra Optia CMNC collection procedure followed by COBE Spectra MNC collection procedure.
62372806|NCT02253160|EXPERIMENTAL|COBE Spectra MNC first, then Spectra Optia CMNC|COBE Spectra MNC collection procedure followed by Spectra Optia CMNC collection procedure.
62744714|NCT02402244||Observational (Project: Every Child)|Patients undergo medical data review to create a Childhood Cancer Registry. Patients also undergo collection of biospecimen samples (e.g., tissue, blood, bone marrow, plasma, serum, buccal swab, saliva, cerebrospinal fluid, or urine).
62372807|NCT02654041|EXPERIMENTAL|Hypothyroxinemia induced patients|Combined T3 and Methimazole treatment will be administered. This experimental treatment will be administered adjunct to standard oncological treatment for newly-diagnosed GBM patients e.g. radiation followed by Temozolomide.
62372808|NCT04942522|EXPERIMENTAL|ASD children A|Participants received probiotics PS128 \[6×10\^10 CFU(colony forming unit)/capsule} one capsule orally twice daily for 8 weeks. After a washout period (4 weeks), they then received placebo(450mg/capsule) one capsule orally twice daily for 8 weeks. Stool, urine and blood specimen will be collected at baseline, week 8, week 12 and week 20.
62372809|NCT04942522|EXPERIMENTAL|ASD children B|Participants received placebo(450mg/capsule) one capsule orally twice daily for 8 weeks. After a washout period (4 weeks), they then received probiotics PS128(6×10\^10 CFU/capsule) one capsule orally twice daily for 8 weeks. Stool, urine and blood specimen will be collected at baseline, week 8, week 12 and week 20.
62372810|NCT00509028|EXPERIMENTAL|BUD - Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
62744715|NCT02168049|EXPERIMENTAL|Heart and Lung Function Monitioring|
62744716|NCT03750760|ACTIVE_COMPARATOR|Alirocumab (enhanced care)|"Alirocumab (150 mg) administered by subcutaneous injection, every two weeks for 7 weeks.~Atorvastatin (80 mg), oral administration daily."
62372811|NCT00509028|ACTIVE_COMPARATOR|CONV - Conventional Asthma Therapy|Conventional Asthma Therapy - according to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
62372812|NCT01343849||Suspected Breast cancer subjects|
62372813|NCT06193980||Previously mechanically ventilated|"Patients who have received prolonged mechanical ventilation (7 days or more) within the medical ICU or surgical ICU at Health Sciences Centre Winnipeg.~OR~Patients previously enrolled in Microvascular Monitoring in Circulatory Shock and Sepsis (MiMICSS) research study (NCT05985525)"
62744717|NCT03750760|ACTIVE_COMPARATOR|Atorvastatin (standard care)|Atorvastatin (80 mg), oral administration daily. Ezetimibe (10 mg), oral administration daily, from week 4 if LDL-C is ≥ 70 mg/dL (1.8mmol/L) at week 4.
62744718|NCT03853850|EXPERIMENTAL|Intervention|Participating mothers will receive mobile phone text messages during their babies' first 6 months of life. Messages will educate mothers on breastfeeding and proper infant feeding.
62372814|NCT06193980||Healthy|Healthy volunteers, matched for age and sex, with participants in the previously mechanically ventilated cohort.
62372815|NCT04915105|EXPERIMENTAL|Prescreen on psoriasis and psoriatic arthritis treatment|Prescreen markers from individual PBMCs and choose proper biologics before starting treatment on psoriasis and psoriatic arthritis patients.
62372816|NCT00882362|EXPERIMENTAL|1|
62372817|NCT06201403||COPD Group|Patients diagnosed with COPD at Istanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital
62372818|NCT06201403||Healthy Group|Healthy individuals without any chronic or acute disease
62372819|NCT01828567|EXPERIMENTAL|Intervention|Primary care phone-based prevention coaching using shared decision making following a Healthy Living Assessment
62372820|NCT01828567|NO_INTERVENTION|Control|Usual care
62372821|NCT01589575||Spouses|This group of relatives includes the spouses of ICU patients (over 16 years of age and intubated and under ventilation for at least 48 hours) meeting stated inclusion criteria.
62372822|NCT01589575||Other relatives|This group of relatives includes the non-spouse relatives of ICU patients (over 16 years of age and intubated and under ventilation for at least 48 hours) meeting stated inclusion criteria.
62372823|NCT05849064|ACTIVE_COMPARATOR|Behavioral Control|Participants randomized to the behavioral control group will receive standardized (i.e., all participants in this group will receive the same interventions) behavioral management strategies that include activity, hydration, nutrition, sleep, and stress management strategies.
62372824|NCT05849064|EXPERIMENTAL|Targeted Intervention|Participant receives exercises or strategies based on their clinical concussion domain given to them by their neuropsychologist: 1) Anxiety/Mood, 2)Headache/Migraine, 3)Vestibular, 4)Ocular, 5)Cognitive.
62372825|NCT05984511|EXPERIMENTAL|TACE plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy (TACE-AB-I)|"TACE will be performed for the patients after randomization. Iodion-125 seeds will be implanted into the PVTT under CT guidance within 3-7 days after the first TACE.~Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) will be started at 3-7 days after the first TACE and I-125 Seeds Brachytherapy.~TACE and iodion-125 seeds implantation can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination."
62744719|NCT06308341|OTHER|Group A: (Virtual Reality technique + Motor Imagery technique + Routine Physical Therapy)|"Participants in this group will receive Virtual Reality (VR) for and Motor Imagery (MI) training with routine physical therapy for every alternate day (3 days per week) for 12 weeks. Total 45 minutes of session.~Routine physical therapy protocol will be given for 30 minutes. VR techniques for 10-15 minutes MI techniques for 05-10 minutes"
62744720|NCT06308341|EXPERIMENTAL|Group B: (Virtual Reality + Routine Physical Therapy )|"The VR system consisted of a wall-mounted display, a Nintendo Wii box, a Wii remote, and a Wii Fit board. The participants will be instructed to stand on Wii Fit board while interacting with the VR system and playing the selected games.~Routine physical therapy protocol will be given for 30 minutes along with cycling and walking for 10-15 minutes.~VR techniques for 10-15 minutes."
62744721|NCT06308341|EXPERIMENTAL|Group C: (Motor Imagery +Routine Physical Therapy)|"During the presentation of a video clip, patients will watch the video and afterwards try to do movement as same as shown in video.~Routine physical therapy protocol will be given for 30 minutes along with Cycling and walking for 10-15 minutes MI techniques for 10-15 minutes"
62744722|NCT04627090||LCH Patients|Adult patients with LCH, diagnosed starting from January 2001
62744723|NCT04433741|OTHER|Oxytocin First, then Placebo|Oxytocin administered intravenously for the first half of the study and then will receive intravenous placebo for the second half.
62744724|NCT04433741|OTHER|Placebo, Then Oxytocin|Placebo administered intravenously for the first half of the study and then will receive intravenous oxytocin for the second half.
62744725|NCT05451706|EXPERIMENTAL|YouTube Intervention|Participants assigned to this task were asked to search YouTube for a 5-10 minutes' video promoting mental help-seeking among college students. Then, they were expected to provide the link to the video and describe the content of the video. Next, participants were guided to form rebuttals disapproving three statements that rationalize students' low intention to seek mental help.
62372826|NCT05984511|ACTIVE_COMPARATOR|TACE and Atezolizumab/Bevacizumab (TACE-AB)|"TACE will be performed for the patients after randomization. Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) will be started at 3-7 days after the first TACE.~TACE can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination."
62372827|NCT04447625|ACTIVE_COMPARATOR|CE patients receiving OAA|Patients diagnosed with CE receiving the gold standard treatment of oral antibiotic administration (OAA)
62372828|NCT04447625|EXPERIMENTAL|CE patients receiving OAA and IAI|Patients diagnosed with CE receiving a combination of the gold standard treatment of oral antibiotic administration (OAA) and intrauterine antibiotic infusion (IAI)
62372829|NCT01174940|EXPERIMENTAL|Extracorporeal Photopheresis|Patients will receive 2 ECP treatments on day -10 and day -8 and then for two consecutive days every two weeks starting from post engraftment (ANC \> 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.
62744726|NCT05451706|ACTIVE_COMPARATOR|Facebook Intervention|This task was to draft a Facebook message for the participants' fellow students. In their message, participants were expected to list three reasons for seeking mental help. The length of the message was not pre-determined.
62744727|NCT05451706|PLACEBO_COMPARATOR|YouTube Control Group|Participants in this group were assigned a YouTube task advocating social distancing during a pandemic. The question prompts were modified from the tasks for the experimental groups.
62744728|NCT05451706|PLACEBO_COMPARATOR|Facebook Control Group|Participants in this group were assigned a Facebook task advocating social distancing during a pandemic. The question prompts were modified from the tasks for the experimental groups.
62744729|NCT04673942|EXPERIMENTAL|PART 1: Dose Escalation Safety Run-In (Enrollment Completed)|Subjects will be treated with AdAPT-001 as a single injection, one time.
62744730|NCT04673942|EXPERIMENTAL|PART 2: Dose Expansion Single-Agent (Enrollment Completed)|6 subjects will be enrolled in the Lead In Cohort. A Safety Analysis will be performed after 6 subjects have received at least 24 doses. Upon Safety team review as a continuous reassessment of safety, an additional 19 subjects may be enrolled. All subjects in PART 2 will receive injections of AdAPT-001 on Days 1 and 15 of 28-day cycles.
62744731|NCT04673942|EXPERIMENTAL|PART 3: Expansion (Enrollment Completed)|Up to 45 subjects will be enrolled in the expansion cohort to receive either AdAPT-001 on Days 1 and 15 of 28-day cycles or AdAPT-001 on Days 1 and 15 plus a checkpoint inhibitor of 28-day cycles.
62744732|NCT04673942|EXPERIMENTAL|Phase 2 (Enrollment Open)|Approximately 55 to 80 subjects with advanced solid tumors including sarcoma to receive either AdAPT-001 on Days 1 and 15 of 28-day cycles or AdAPT-001 on Days 1 and 15 plus a checkpoint inhibitor of 28-day cycles..
62744733|NCT05222893|ACTIVE_COMPARATOR|PEEP Pes|PEEP adjustment according to the pressure indicators in the lower third of the esophagus Pes (intervention group)
62744734|NCT05222893|ACTIVE_COMPARATOR|PEEP 5|PEEP constantly set at 5 cmH2O (control group)
62372830|NCT05354973||CAR T Cell Treatment|
62372831|NCT01250301|EXPERIMENTAL|De-nicotinised cigarettes + standard treatment|
62372832|NCT01250301|ACTIVE_COMPARATOR|Standard treatment|
62372833|NCT01678560|ACTIVE_COMPARATOR|Usual Care|Monitoring every 3 months by face-to-face visits:These patients will be monitored on a 3-month, 6-month, 9-month and 12-month intervals with scheduling face-to-face visits. Adherence and efficacy data will only be assessed by the clinician at these intervals.
62372834|NCT01678560|ACTIVE_COMPARATOR|Wireless Care|Frequent remote monitoring:These patients will be monitored using wireless modems as the method to obtain adherence and efficacy data.
62372835|NCT01575249||Asymptomatic group|one hundred patients with a negative exercise stress echo for symptoms/ECG/wall motion abnormalities (WMA), negative spirometry test for pulmonary disease, without known CAD or other valvular diseases, in sinus rhythm and with a LVEF\>55%
62372836|NCT01575249||Symptomatic group|one hundred patients with symptomatic AS (negative pulmonary tests but positive stress echo or prior CAD or other valvular diseases and a LVEF\>55%
62372837|NCT01576991||Oocyte collection|This is an observational study; there are no cohorts or groups
62372838|NCT01525524|SHAM_COMPARATOR|Sham Stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex with the Transcranial Direct Current Stimulation. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp. The device will deliver a charge of 2mA for 1 minute, after that the device will be automatically turned off for 29 minutes.
62372839|NCT01525524|ACTIVE_COMPARATOR|Active Stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex with the transcranial Direct Current Stimulation device. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp. The device will deliver a charge of 2mA for 30 minutes.
62372840|NCT04574674|EXPERIMENTAL|Flexibility exercise group|"Participants will be asked to follow a 12-week flexibility exercise training programme. Participants will be asked to perform a minimum amount of flexibility exercise of 1 set/week for each of six exercises and will have the opportunity to increase their volume of exercise to 2 sets or 3 sets/week per exercise if it is their choice.~Participants will perform 6 flexibility exercises per week (2 different for legs, 1 shoulder and arms, 1 chest, 1 back and 1 core). Passive static stretching exercises will be performed."
62372841|NCT04574674|EXPERIMENTAL|Resistance exercise group|"Participants will be asked to follow a 12-week home-based exercise programme. Participants will be asked to perform a minimum amount of resistance exercise of 1 set/week for each of six exercises and will have the opportunity to increase their volume of exercise to 2 sets or 3 sets/week per exercise if it is their choice.~Participants in the resistance exercise group will be asked to perform a total of 6 exercises per week (2 different leg exercises, 1 shoulder exercise, 1 chest exercise, 1 back exercise and 1 core exercise). Body weight and resistance bands exercises will be used. Participants will be asked to perform each set to complete as many repetitions as possible until fatigue."
62372842|NCT05469152|EXPERIMENTAL|ds-MCE and EGD|All the enrolled participants will undergo the examination of detachable string magnetically controlled capsule endoscopy (ds-MCE) first, followed by EGD within 48 hours.
62552842|NCT04661644|EXPERIMENTAL|Test Group 2 (High Dose)|- Administration Method: 1 mL is withdrawn from 1 vial of clusters of adipose-derived mesenchymal stem cells, composed of adipose-derived mesenchymal stem cells and diluted with 20 mL of saline, then administered to 15-20 parts of the muscle along the working areacourse of the tibial artery and peroneal artery below the knee joint (above the lower ischemic area) of the subject (above the lower ischemic area) of the subjects under general anesthesia or spinal anesthesia.
62552843|NCT02597829|OTHER|Open Label Certolizumab Pegol|Active Treatment
62372843|NCT03908931|EXPERIMENTAL|MRI|
62372844|NCT01395966|ACTIVE_COMPARATOR|DF289|Ear drops
62372845|NCT01395966|ACTIVE_COMPARATOR|DF277|Ear drops
62372846|NCT01395966|EXPERIMENTAL|DF289 plus DF277|Ear drops
62372847|NCT02437721|ACTIVE_COMPARATOR|infant formula containing folic acid|Infant formula including folic acid within the range stipulated by European legislation on infant formula
62372848|NCT02437721|EXPERIMENTAL|infant formula containing MTHF|Infant formula including MTHF instead of folic acid
62372849|NCT02437721|NO_INTERVENTION|Breast milk|non randomized reference group
62372850|NCT02443051|EXPERIMENTAL|Attention Bias Modification|Training in bias modification for 80% of experimental trials
62372851|NCT02443051|ACTIVE_COMPARATOR|Control|Bias modification for 50% of trials
62372852|NCT00122317|EXPERIMENTAL|Eculizumab|600 mg intravenous infusion every week x 4 then 900 mg iv every two weeks
62372853|NCT00467012|EXPERIMENTAL|step 1|6 enrollment for 1 cycle(4 weeks)
62372854|NCT00467012|EXPERIMENTAL|step 2|114 enrollment through to meet the stopping criteria
62372855|NCT01328769|ACTIVE_COMPARATOR|Febuxostat|Investigational
62372856|NCT01328769|PLACEBO_COMPARATOR|Placebo|Placebo
62372857|NCT01787045|EXPERIMENTAL|Intervention Group|"Early and Active Physical Therapy will be performed by physiotherapist twice a day. During first week patients will be positioned in chair or bed and performed cycle-ergometer exercise during 30 min.~Our physiotherapy protocol will be continued until Intensive Care Unit (ICU) discharge."
62372858|NCT01787045|OTHER|Control Group|Routinary Passive Range of Motion will be performed by physiotherapist 20 min and twice a day until ICU discharge.
62372859|NCT03363789|ACTIVE_COMPARATOR|Brisement|Patients will receive a series of brisement injections for treatment of non insertional Achilles tendinosis.
62372860|NCT03363789|ACTIVE_COMPARATOR|Physical Therapy|Patients will undergo physical therapy for treatment of non insertional Achilles tendinosis.
62372861|NCT05605704|ACTIVE_COMPARATOR|atherolive|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
62372862|NCT05605704|PLACEBO_COMPARATOR|placebo atherolive|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
62372863|NCT02863861|EXPERIMENTAL|Group PK|Propofol-Ketamine group: patients in this group will receive IV ketamine at a dose of 1mg.kg-1 in addition to IV propofol 1mg.kg-1 for induction with added doses of propofol 1mg.kg-1 when needed.
62372864|NCT02863861|EXPERIMENTAL|Group DK|Dexmedetomidine-Ketamine group: patients in this group will receive IV ketamine at a dose of 1mg.kg-1 in addition to IV dexmedetomidine 0.5 mcg.kg-1 for induction with additional doses of dexmedetomidine 0.5mcg.kg-1 when required
62372865|NCT05121428||Survey 1|Survey investigating patients' experiences with buprenorphine treatment for Opioid Use Disorder before and during the COVID-19 pandemic
62372866|NCT05121428||Survey 2|Survey investigating the factors that motivate patients to abstain from opioid drug use during buprenorphine treatment for Opioid Use Disorder
62552844|NCT03091179|EXPERIMENTAL|THRIVE|high flow nasal oxygen
62552845|NCT03091179|ACTIVE_COMPARATOR|Endotracheal tube|tracheal intubation
62552846|NCT03439956||Transvaginal specimen extraction (cases)|Pregnant women that underwent previous laparoscopic myomectomy or ovarian cystectomy with transvaginal specimen extraction.
62372867|NCT05121428||Survey 3|Survey investigating patients' attitudes towards and experiences with cannabis use during buprenorphine treatment for Opioid Use Disorder.
62552847|NCT03439956||Controls|Pregnant women that did not undergo previous laparoscopic myomectomy or ovarian cystectomy with transvaginal specimen extraction.
62372868|NCT05121428||Survey 4|Survey investigating patients' attitudes towards and experiences with cigarettes and e-cigarettes use during buprenorphine treatment for Opioid Use Disorder.
62372869|NCT05121428||Survey 5|Survey investigating patients' attitudes towards and experiences with benzodiazepine use during buprenorphine treatment for Opioid Use Disorder.
62372870|NCT04839679|ACTIVE_COMPARATOR|Standard of Care Mayo Clinic booklet|Subjects will receive the standard Mayo Clinic educational booklet in preparation for clinically indicated radiation therapy treatment
62552848|NCT01525017|EXPERIMENTAL|Combig-DC Cancer Vaccine|Two vaccinations of Combig-DC (allogeneic dendritic cells) Cancer Vaccine given before nephrectomy.
62372871|NCT04839679|EXPERIMENTAL|Culturally Oriented Education|Subjects will receive a culturally appropriate educational brochure summarizing pertinent treatment information in a visual manner in addition to the standard Mayo Clinic booklet
62372872|NCT03352869|EXPERIMENTAL|Exenatide|Drug: Byetta Generic name: Exenatide Dosage form: 5ug and 10ug Dosage: 10-20ug/day Frequency: twice a day Duration: 3 months
62372873|NCT03352869|ACTIVE_COMPARATOR|Metformin|Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
62552849|NCT03745079||Group 1|"Participants' temperature measured at 3 places at the same time~* Esophagus~* Skin near to temporal artery~* Skin near to carotid artery"
62552850|NCT02439021|EXPERIMENTAL|CobraPLA|Patients will randomly assign to either LMA or Cobra PLATM
62744735|NCT05761639|EXPERIMENTAL|Telerehabilitation, Education and Telephone Monitoring.|"The effects of a physical exercise program and educational component with telephone follow-up mediated by cardiac telerehabilitation in patients with heart failure on functional capacity, depression and health-related quality of life will be determined.~Each participant will be given a polar FT4 brand frequency monitor to record their HR, an OMRON brand digital blood pressure monitor to monitor blood pressure and the conventional Borg scale will be used for perception of exertion during exercise."
62744736|NCT05761639|EXPERIMENTAL|conventional rehabilitation and Education|The effects of a physical exercise program and a conventional educational component in patients with heart failure on functional capacity, depression and health-related quality of life will be determined. The development of this program will be carried out in person guided by a physiotherapist specializing in cardiac and pulmonary rehabilitation.
62744737|NCT05761639|EXPERIMENTAL|Telerehabilitation and Education|"To determine the effects of a physical exercise program and a conventional educational component mediated by cardiac telerehabilitation in patients with heart failure on functional capacity, depression, and health-related quality of life~Each participant will be given a polar FT4 brand frequency monitor to record their HR, an OMRON brand digital blood pressure monitor to monitor blood pressure and the conventional Borg scale will be used for perception of exertion during exercise."
62744738|NCT03973554|EXPERIMENTAL|pearl powder|natural product, support bone and joint health
62372874|NCT03352869|EXPERIMENTAL|Combination|Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months
62372875|NCT06239701|EXPERIMENTAL|LPA and Fitbit|"The 12-week LPA+Fitbit intervention consists of 3 components:~1. In-Person LPA+Fitbit Orientation~2. Telephone PA counseling sessions.~3. Fitbit activity tracker."
62372876|NCT06239701|ACTIVE_COMPARATOR|Only Fitbit|"The Fitbit Only condition will include 3 components:~1. In-person Fitbit Orientation.~2. Fitbit Activity Tracker.~3. Brief Telephone Check-ins."
62744739|NCT03973554|ACTIVE_COMPARATOR|CPP-ACP|product for professional use containing the active ingredient (CPP-ACP), a special milk-derived protein that has a unique ability to release bio-available calcium and phosphate to tooth surfaces.
62744740|NCT03640325|EXPERIMENTAL|PRISM (Promoting Resilience in Stress Management)|Resilience Skills Training
62744741|NCT03640325|NO_INTERVENTION|Usual Care|Usual psychosocial care (control arm, no intervention)
62744742|NCT03640325|NO_INTERVENTION|Caregivers|Caregivers of participants, no intervention
62744743|NCT00675441|EXPERIMENTAL|Lenalidomide|Lenalidomide 10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
62744744|NCT05055518|EXPERIMENTAL|A Phase I, open-labeled multicenter study|APL-102 Capsules
62372877|NCT04281108|EXPERIMENTAL|APT-1011|APT-1011 3 mg HS
62744745|NCT06659406|EXPERIMENTAL|CoQ-10 supplementation|The experimental arm will consist of fertile females diagnosed with polycystic ovary syndrome aged between 18 to 50 years. Patients with diabetes mellitus, thyroid dysfunction, cardiovascular diseases, impairment of hepatic and renal function, autoimmune and Inflammatory disorders will be excluded.
62744746|NCT05472909|EXPERIMENTAL|Standardized Relaxation Music|
62744747|NCT05472909|ACTIVE_COMPARATOR|Personal Choice of Music|
62372878|NCT04281108|PLACEBO_COMPARATOR|Placebo|HS
62372879|NCT02647372|EXPERIMENTAL|Endocrinological approach|Parkinson patient submitted to DBS surgery target to globus pallidus nucleus or the subthalamic nucleus. Those patients will be endocrinological evaluation including metabolic measures, calorimetric parameters.
62372880|NCT02647372|EXPERIMENTAL|Neurological approach|Parkinson patient submitted to DBS surgery target to globus pallidus nucleus or the subthalamic nucleus. Those patients will be neurological evaluation including UPDRS scale.
62372881|NCT01653756|ACTIVE_COMPARATOR|IPI-145|Capsules
62552851|NCT02439021|EXPERIMENTAL|LMA|Patients will randomly assign to either LMA or Cobra PLATM
62552852|NCT05516862|EXPERIMENTAL|Group 1|Script followed by Dragons Acupuncture (external Dragons points with patient prone for 15 minutes followed by internal Dragons points with patient supine for 15 minutes).
62552853|NCT05516862|SHAM_COMPARATOR|Group 2|Script followed by Dragons sham acupressure placed at the Dragons points (external Dragons points with patient prone for 15 minutes followed by internal Dragons points with patient supine for 15 minutes).
62372882|NCT01653756|PLACEBO_COMPARATOR|Placebo|Capsules
62372883|NCT03765177|EXPERIMENTAL|CLIC-1901|A single Intravenous infusion of CLIC-1901 will be given.
62372884|NCT00002968|EXPERIMENTAL|Arm I (edrecolomab)|Patients receive adjuvant edrecolomab IV over 2 hours on day 1. Treatment repeats every 28 days for 5 courses. Patients must begin therapy no earlier than 7 days and no later than 42 days postsurgical resection. Patients also undergo observation at 3 and 6 months postrandomization.
62552854|NCT05516862|PLACEBO_COMPARATOR|Group 3|Script followed by Acupuncturist lightly touching Dragons points (external Dragons points with patient prone for 15 minutes followed by internal Dragons points with patient supine for 15 minutes).
62552855|NCT03101605|EXPERIMENTAL|e-learning|The intervention for this study will be the completion of an original E-learning module on AOM designed by a team of pediatric residents, pediatricians, a pediatric otolaryngologist, a pediatric emergency physician and a pediatric infectious diseases specialist. The module includes interactive sections on anatomy, epidemiology, pathophysiology, microbiology, diagnostic criteria, treatment options and prognosis. A 5 minute video demonstrating appropriate pediatric ear examination techniques is also included in the module. Throughout the module, many examples of ear pathologies captured on video during a previous study. The E-learning module should take 0.5 hr to complete.
62372885|NCT00002968|NO_INTERVENTION|Arm II (no treatment)|Patients undergo observation at 3 and 6 months postrandomization. .
62372886|NCT03175250|ACTIVE_COMPARATOR|Health Education|This condition included live health education followed by health education videos on HIV risks, testing, and condom use. The videos were presented over laptop.
62372887|NCT03175250|ACTIVE_COMPARATOR|Action Plan|This condition included live health education followed by computerized procedures focusing on action plans for HIV testing and condom use and some of the same health education videos in the Health Education condition.
62372888|NCT03175250|EXPERIMENTAL|Memory Practice|This condition included live health education followed by computerized action plan procedures (as in the Action Plan condition), followed by several memory practice procedures also delivered over laptop. The memory practice procedures were designed to help participants more readily retrieve and use action plans in critical situations.
62372889|NCT06343129|EXPERIMENTAL|Jumpstart Educational Program|"Jumpstart sessions on day 1, 2, 5, 8, 12, and 15. Tests at baseline and week 2 visit: blood pressure, height and weight measurements to calculate a body mass index, urine tests to assess antioxidant activity, quality of life questionnaire (\~8 minutes to complete) about physical and mental symptoms, a 3-day food record to assess if participants are changing their diet over the course of the study, assessment of medication use.~Tests performed at day 1, day 8, and day 15: A small blood draw \[about 1 teaspoon\] to check chemistry levels, cholesterol, and markers of inflammation. Laboratory tests are reviewed once available, and participant contacted by the study team either by telephone or My Chart regarding clinically significant results that require intervention. If potassium levels are higher than 5.2 Meq/L, the study team contacts the participant or their alternate contact directly. For the intervention group, this is in addition to the finger-stick blood collection."
62372890|NCT06343129|NO_INTERVENTION|Control group|Participants randomized to the control group continue to receive medical, dietary, and nutritional advice from their medical team as normal. The testing is the same testing as the intervention group and will be done at day 1, day 8, and day 15 of the study. They do not participate in the educational sessions during the study but will have the opportunity to participate in the program at no charge at the conclusion of the study.
62744748|NCT04683276|ACTIVE_COMPARATOR|small flap medium-sized macular hole (SFMM)|small flap (1-2 disc-diameter) was performed in medium sized macular hole (250-400 um)
62372891|NCT02614261|PLACEBO_COMPARATOR|Placebo|"* Double-blind treatment phase: Participants received placebo once a month by subcutaneous (SC) injection for 3 months.~* Open-label extension phase: After completion of double-blind phase, participants had an option to enter open-label extension phase where they receive 240 milligram (mg) galcanezumab SC at first month, 120mg at second month followed by 120mg or 240mg once a month (at the discretion of the investigator) for the remaining 7 months.~* Follow-up phase: After completion or discontinuation from double-blind or open-label extension phases, participants entered follow-up phase where they were observed for 4 months. No treatments administered."
62372892|NCT02614261|EXPERIMENTAL|Galcanezumab 120 mg|"* Double-blind treatment phase: Participants received loading dose of 240 mg of galcanezumab at first dosing visit followed 120 mg galcanezumab once a month by SC injection for 2 months.~* Open-label extension phase: After completion of double-blind phase, participants had an option to enter open-label extension phase where they received 240mg galcanezumab SC at first month, 120mg at second month followed by 120mg or 240mg once a month (at the discretion of the investigator) for the remaining 7 months.~* Follow-up phase: After completion or discontinuation from double-blind or open-label extension phases, participants entered follow-up phase where they were observed for 4 months. No treatments administered."
62372893|NCT02614261|EXPERIMENTAL|Galcanezumab 240 mg|"* Double-blind treatment phase: Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 3 months.~* Open-label extension phase: After completion of double-blind phase, participants had an option to enter open-label extension phase where they received 240mg galcanezumab SC at first month, 120mg at second month followed by 120mg or 240mg once a month (at the discretion of the investigator) for the remaining 7 months.~* Follow-up phase: After completion or discontinuation from double-blind or open-label extension phases, participants entered follow-up phase where they were observed for 4 months. No treatments administered."
62372894|NCT02614261|EXPERIMENTAL|Israel Addendum|Eligible participants from main study were enrolled in Israel addendum. Participants received 120mg or 240mg galcanezumab SC once a month, at the discretion of the investigator, for up to 3 years or until Israel's Ministry of Health's conditions for continued access cease to be met, whichever occurs first.
62372895|NCT05074394|EXPERIMENTAL|COVI-DROPS|40 mg of COVI-DROPS administered intranasally
62372896|NCT05074394|PLACEBO_COMPARATOR|Placebo|2 mL placebo administered intranasally
62744749|NCT04683276|ACTIVE_COMPARATOR|large flap medium-sized macular hole (LFMM)|large flap (3-4 disc-diameter) was performed in medium sized macular hole (250-400 um)
62744750|NCT04683276|ACTIVE_COMPARATOR|small flap large-sized macular hole (SFLM)|small flap (1-2 disc-diameter) was performed in Large sized macular hole (\>400 um)
62744751|NCT04683276|ACTIVE_COMPARATOR|large flap Large-sized macular hole (LFLM)|large flap (3-4 disc-diameter) was performed in large sized macular hole (\>400 um)
62744752|NCT05807256||pregnant patients with systemic rheumatological diseases|pregnant patients with systemic rheumatological diseases undergoing assisted fertilization techniques
62744753|NCT06350136|EXPERIMENTAL|With Tele-Nursing|With Tele-Nursing
62372897|NCT05769907|EXPERIMENTAL|single arm|The single-arm pilot study will be a feasibility study of the Motivation to Lose Weight version 1 (MLW v.1). The study includes presential and online sessions. Participants will be recruited through advertisements on social media and selected according to the inclusion criteria. Participants will receive 8 sessions of approximately 30-45 minutes of motivational interviewing (MI) according to the processes of change in weight loss, as measured by the S-Weight scale.
62372898|NCT04471168|EXPERIMENTAL|Cryo-Auriculotherapy|Patients benefit from 3 sessions of cryo-auriculotherapy with device with nitrous oxyde on 10 auricular points at one month intervals.
62372899|NCT04471168|SHAM_COMPARATOR|Control group|Patients benefit from 3 sessions of cryo-auriculotherapy with device without nitrous oxyde on 10 auricular points at one month intervals.
62372900|NCT01585168|EXPERIMENTAL|Family history positive, Memantine first, then placebo|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
62372901|NCT01585168|PLACEBO_COMPARATOR|Family history positive, placebo first, then Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
62372902|NCT01585168|EXPERIMENTAL|Family history negative, Memantine first, then placebo|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
62372903|NCT01585168|PLACEBO_COMPARATOR|Family history negative, placebo first, then Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
62552856|NCT03101605|OTHER|Standard teaching|"The control group will receive a 2h lecture on AOM, which is the standard teaching method. Given by a pediatrician or a senior pediatric resident, this lecture, using a PowerPoint© presentation support, encompasses clinical cases, notions of anatomy, epidemiology, pathophysiology, diagnostic criteria, treatment options, and prognosis, describes different ear examination techniques, and shows examples of different pathologies."
62552857|NCT04530955|NO_INTERVENTION|Control Arm|"Patients randomized to the Control Arm that have been implanted with the valve-gated pump will be started on an equivalent dose (without change to the medication concentration) as prior to implant. If at any time during the patients' treatment it is determined by the investigator that the patients' treatment dose needs to be modified, the dose can be modified as clinically indicated. Multiple dosing decreases may be performed if the patient is clinically demonstrating a reduction in spasticity that is profound and negatively impacting function, or if the patient is demonstrating signs of baclofen overdose.~The criteria for dosing decrease will be clinical discretion."
62372904|NCT00895908|EXPERIMENTAL|Friendship Group Intervention|"Participants will receive the Friendship Groups intervention."
62372905|NCT00895908|ACTIVE_COMPARATOR|Individual Tutoring|Participants will receive individual academic tutoring.
62552858|NCT04530955|ACTIVE_COMPARATOR|Study Arm|"Patients randomized to the Study Arm will be started on a 20% dose reduction (without change to the medication concentration) through the newly implanted valve-gated pump. If at any time during the patients' treatment it is determined by the investigator that the patients' treatment dose needs to be increased or decreased, the dose can be increased/decreased as clinically indicated. If the dose increases with the valve-gated pump reach the patients' baseline dose and the patient's spasticity is worse than his or her spasticity at baseline, then the patient will be considered a primary endpoint failure.~The criteria for dosing increase will be clinical discretion."
62552859|NCT02748980||Non- obstructive coronary artery disease, non- diabetic|Clinical evidences such as Holter, Treadmill exercise test and cardiac ECT support myocardial ischemia. CAG showed 20%-70% arterial stenosis. Patients are diagnosed without diabetes.
62552860|NCT02748980||Non- obstructive coronary artery disease, diabetic|Clinical evidences such as Holter, Treadmill exercise test and cardiac ECT support myocardial ischemia. CAG showed 20%-70% arterial stenosis. Patients are diagnosed with type 2 diabetes.
62552861|NCT05308433|EXPERIMENTAL|Experimental|
62744754|NCT06350136|NO_INTERVENTION|Control|no With Tele-Nursing
62744755|NCT03621176|EXPERIMENTAL|Home-based exercise|Home-based intervention in the advanced chronic kidney disease group, hemodialysis or peritoneal dialysis group
62372906|NCT05385913||"Placebo"|AB high group; SUVR \>1.11
62372907|NCT05385913||"Treatment"|AB low group; SUVR ≤1.11
62372908|NCT05385913||Study Partners|Each participant will also have a stud partner that will be enrolled.
62372909|NCT04236531|EXPERIMENTAL|individuals at ultra-high risk for psychosis (UHR)|"30 individuals meeting the UHR criteria according to the Comprehensive Assessment of at-risk mental state (CAARMS) will be recruited and will complete cognitive task and MRI scan"
62372910|NCT04236531|EXPERIMENTAL|patients with first episode psychosis (FEP)|30 patients with first episode psychosis (FEP) will be recruited and will complete cognitive task and MRI scan
62372911|NCT04236531|SHAM_COMPARATOR|healthy controls|30 healthy individuals will be recruited and will complete cognitive task and MRI scan
62372912|NCT01542294|EXPERIMENTAL|treatment|s1+oxaliplatin
62372913|NCT05451602|EXPERIMENTAL|HEC169096|Multiple doses of HEC169096
62372914|NCT00726492|EXPERIMENTAL|CSWD + Hydro|Continuous short wave diathermy and hydrotherapy
62372915|NCT00726492|EXPERIMENTAL|Hydro alone|Hydrotherapy alone
62372916|NCT00726492|EXPERIMENTAL|CSWD alone|Continuous short wave diathermy alone
62372917|NCT00726492|NO_INTERVENTION|Control|No treatment
62372918|NCT04172376|EXPERIMENTAL|Minimally invasive puncture aspiration plus rt-PA|
62372919|NCT04172376|ACTIVE_COMPARATOR|Conservative medical treatment|
62372920|NCT06185062||oART|Patients with pelvic or thoracic tumors with an indication for radiotherapy treated with oART (online Adaptied Radiotherapy).
62372921|NCT06185062||IGRT|Patients with pelvic or thoracic tumors with an indication for radiotherapy treated with conventional IGRT (Image Guided Radiotherapy).
62372922|NCT01637857|SHAM_COMPARATOR|lifestyle counseling|Group of patients treated with sham oligoantigenic diet
62372923|NCT01637857|EXPERIMENTAL|oligoantigenic diet|Treatment with oligoantigenic diat
62744756|NCT02196883|ACTIVE_COMPARATOR|MRI Pathology|
62744757|NCT02196883|ACTIVE_COMPARATOR|Physical Exam Pathology|
62744758|NCT05116319||Chinese people with no known history of diabetes|
62744759|NCT06658210|EXPERIMENTAL|soft tissue mobilization with pelvic floor muscle exercises|soft tissue mobilization with pelvic floor muscle exercises
62372924|NCT03605836|EXPERIMENTAL|Single-blind Run-in Period: Placebo|Placebo-matching tablets BID (twice daily) on Day -7 through Baseline (Day -1).
62372925|NCT03605836|EXPERIMENTAL|Double-blind Treatment Period: Centanafadine SR 200 mg|Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 200 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
62372926|NCT03605836|EXPERIMENTAL|Double-blind Treatment Period: Centanafadine SR 400 mg|Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 400 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
62372927|NCT03605836|PLACEBO_COMPARATOR|Double-blind Treatment Period: Placebo|Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine SR matching placebo tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
62372928|NCT04673461|EXPERIMENTAL|STA363 containing 90 mg (60 mg/mL) lactic acid|"STA363 containing 90 mg (60 mg/mL) lactic acid will be injected into the center of up to two intervertebral discs. Patients with two discs appropriate for treatment will be treated at both affected levels by two separate injections.~Each patient will have 5 visits to study site and 1 telephone call. The patient's total time in the study will be approximately 61 weeks (\~15 months) including an 8-week screening period."
62372929|NCT04673461|EXPERIMENTAL|STA363 containing 180 mg (120 mg/mL) lactic acid|"STA363 containing 180 mg (120 mg/mL) lactic acid will be injected into the center of up to two intervertebral discs. Patients with two discs appropriate for treatment will be treated at both affected levels by two separate injections.~Each patient will have 5 visits to study site and 1 telephone call. The patient's total time in the study will be approximately 61 weeks (\~15 months) including an 8-week screening period."
62372930|NCT04673461|PLACEBO_COMPARATOR|Placebo|"Placebo will be injected into the center of up to two intervertebral discs. Patients with two discs appropriate for treatment will be treated at both affected levels by two separate injections.~Each patient will have 5 visits to study site and 1 telephone call. The patient's total time in the study will be approximately 61 weeks (\~15 months) including an 8-week screening period."
62744760|NCT06658210|EXPERIMENTAL|soft tissue mobilization without pelvic floor muscle exercises|soft tissue mobilization without pelvic floor muscle exercises
62744761|NCT01745744|EXPERIMENTAL|Low dose|- Infusion of mesenchymal stem cells from adipose tissue: 0.5x106 cells / kg of patient weight.
62372931|NCT02325804|ACTIVE_COMPARATOR|Conventional lifestyle counseling|Randomized, open label study to assess effect of 8 weeks of Conventional lifestyle counseling (low calorie diet and exercise) on body composition, physical fitness, and metabolic parameters
62372932|NCT02325804|ACTIVE_COMPARATOR|Unconventional lifestyle counseling|"Randomized, open label study to assess effect of 8 weeks of unconventional lifestyle counseling (low calorie metabolic stairs diet and circuit-based exercise) on body composition, physical fitness, and metabolic parameters"
62372933|NCT01969305|EXPERIMENTAL|Kazakhstani Family Together (KFT)|Usual Care Plus KFT: Family-based multi-media HIV and drug abuse prevention intervention
62372934|NCT01969305|EXPERIMENTAL|Health education curriculum|Usual Care Alone: Health education curriculum on HIV and drug use prevention
62372935|NCT03609710|EXPERIMENTAL|PSTLAR|Combined application of left colic artery preservation, anastomotic reinforcing sutures and postoperative transanal tube placement in robotic low anterior resection for rectal cancer
62372936|NCT03609710|ACTIVE_COMPARATOR|NORLAR|Traditional robotic low anterior resection for rectal cancer without left colic artery preservation, anastomotic reinforcing sutures or postoperative transanal tube placement
62372937|NCT02645136|EXPERIMENTAL|PILATES|Weekly Pilates sessions, guided by a specialized physiotherapist. The duration of the treatment was 10 weeks, and each session lasted 45 to 50 minutes. All subjects received instruction to perform specific daily home exercises.
62372938|NCT02645136|ACTIVE_COMPARATOR|PFMT and AES|For also 10 weeks, the participants went trough anal electrical stimulation (AES) associated with Pelvic Floor Muscle Training (PFMT), supervised by a specialized physiotherapist. All subjects received orientation to perform the same pelvic floor exercises at home.
62744762|NCT01745744|EXPERIMENTAL|High dose|- Infusion of mesenchymal stem cells from adipose tissue: 1x106 cells / kg of patient weight.
62744763|NCT01745744|NO_INTERVENTION|Control|Conventional treatment
62372939|NCT02645136|PLACEBO_COMPARATOR|Control|Control Group
62372940|NCT00004127|EXPERIMENTAL|Arm A|Oxaliplatin (85 mg/m2, day 1 of every 14 day cycle), Leucovorin (500 mg/m2, day 1 and 2 of every 14 day cycle), Fluorouracil (Bolus of 400 mg/m2 followed by 22 hr continuous infusion of 600 mg/m2 on days 1 and 2 of every 14 day cycle)
62372941|NCT01239329||Complex multiple disabilities|People with complex multiple disabilities, living in a care institution participating in the Governor Kremers Centre (GKC.)
62372942|NCT03365440||EP study with transseptal passage|"* 15-30 minute esophageal ECG (using esoECG-3D catheter) \& respiration recording during elective EP study and/or ablation procedure~* Focal pacing maneuvers"
62552862|NCT00694200|EXPERIMENTAL|1|Vinorelbine metronomic + bevacizumab
62744764|NCT06659848|EXPERIMENTAL|Fasted-group|practiced HIIT prebreakfast in the fasted state (8-12 h fasting)
62744765|NCT06659848|EXPERIMENTAL|Post-breakfast|practiced HIIT 2 hours after breakfast
62744766|NCT06659848|EXPERIMENTAL|Post-lunch|practiced HIIT 2 hours after lunch
62744767|NCT06659848|EXPERIMENTAL|Post-dinner|practiced HIIT 2 hours after dinner
62744768|NCT06656117|EXPERIMENTAL|Elliptical training|"* Patients in group A started with a five-minute warm-up, which included cycling on a Star Trac bike and dynamic stretching.~* Following the warm-up, participants were instructed to perform Elliptical training after completing breathing exercises.~* At the end of the training session, participants from both groups engaged in a five-minute gradual cool down."
62372943|NCT03365440||EP study without transseptal passage|- 15-30 minute esophageal ECG (using esoECG-3D catheter) \& respiration recording during elective EP study and/or ablation procedure
62744769|NCT06656117|EXPERIMENTAL|Resistance training|"* Patients in group B started with a five-minute warm-up, which included cycling on a Star Trac bike and dynamic stretching.~* Following the warm-up, participants were instructed to perform Resistance training after completing breathing exercises.~* At the end of the training session, participants from both groups engaged in a five-minute gradual cool down."
62744770|NCT02172573|EXPERIMENTAL|Pramipexole|
62744771|NCT02172573|EXPERIMENTAL|Bromocriptine|
62744772|NCT02172573|PLACEBO_COMPARATOR|Placebo|
62744773|NCT05658796|ACTIVE_COMPARATOR|Control|No intervention (No RxWell). Subjects will receive standard of care and education regarding potential resources for anxiety and depression. Subjects will complete questionnaires via REDCap assessing primary and secondary outcomes
62744774|NCT05658796|EXPERIMENTAL|Intervention: RxWell|RxWell Intervention. Subjects will receive standard of care and digital cognitive behavioral intervention by using the application RxWell. Subjects will complete questionnaires via REDCap assessing primary and secondary outcomes and will complete GAD-7 (Generalized Anxiety Disorder Scale) and PHQ-8 (Patient Health Questionnaire for Depression) every 2 weeks within the RxWell application.
62744775|NCT05658796|NO_INTERVENTION|Control (screen failures)|We will collect data on patient outcomes for patients that did not meet criteria for the RxWell intervention.
62744776|NCT02147730||surgical patients|all surgical patients undergoing gastrectomy, knee-hip-shoulder arthroplasty, hallux valgus surgery, hernia repair, saphenectomy, cesarean section,colectomy, hysterectomy, nephrectomy mastectomy during study period
62744777|NCT01856075||Patients treated with dronedarone|Patients treated with dronedarone at inclusion
62744778|NCT01856075||Patients treated with other antiarrhythmic drugs of interest|"The antiarrhythmic drugs of interest to which dronedarone will be compared are:~* Class 1a/1c antiarrhythmics~* Sotalol~* Amiodarone"
62744779|NCT00804752|EXPERIMENTAL|Vitamin D|An addition of Vitamin D to the standard treatment
62744780|NCT04644237|EXPERIMENTAL|Trastuzumab deruxtecan 6.4 mg/kg|Participants will be randomized to receive trastuzumab deruxtecan 6.4 mg/kg administered by intravenous infusion every 3 weeks (Q3W).
62372944|NCT03365440||Healthy participants|- 60 minute esophageal ECG (using esoECG-3D catheter) \& respiration recording
62372945|NCT00962481|ACTIVE_COMPARATOR|Bimosiamose|
61986311|NCT05243225||open surgical management of post cholecystectomy bile duct injury.|Under general intubation anaesthesia, a generous right subcostal incision is performed and could be extended on demand upward to the xiphoid process and/or to the left subcostal area. Thorough dissection and adhesiolysis is performed to reach the bile duct. Evaluation by intraoperative cholangiogram according to the site and the size of the injury repair will be done. If the injury is small simple repair or repair on T-tube will be done . If the injury is large repair on T-tube or hepaticojejunostomy will be done .If it is a distal injury repair on T-tube or biloenteric shunt will be done .If the injury is proximal biloenteric shunt will be done .Intra-abdominal drains insertion.
62372946|NCT00962481|PLACEBO_COMPARATOR|Placebo|
62372947|NCT00669513|NO_INTERVENTION|1|
62372948|NCT00669513|EXPERIMENTAL|2|Partial sleep deprivation
62372949|NCT04591873||Critical patients in the emergency department|
62372950|NCT01488188|ACTIVE_COMPARATOR|Influenza vaccine-Nasal|Nasal administration
62372951|NCT01488188|ACTIVE_COMPARATOR|Influenza vaccine -Sublingual|Sublingual administration
62372952|NCT02552823|PLACEBO_COMPARATOR|White bread 1|Groups 1 and 2, Visit 1 White bread (equal to 50g available carbohydrate) given to fasting participant
62372953|NCT02552823|EXPERIMENTAL|Pea variety 1 with rice|Group 1,Visit 2-5 Pea variety 1 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
62372954|NCT02552823|EXPERIMENTAL|Pea variety 2 with rice|Group 1, Visit 2-5 Pea variety 2 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
62372955|NCT02552823|EXPERIMENTAL|Pea variety 3 with rice|Group 1, Visit 2-5 Pea variety 3 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
62372956|NCT02552823|EXPERIMENTAL|Rice|Group 1, Visit 2-5 Rice (equal to 50g available carbohydrate) given as breakfast to fasting participants
62372957|NCT02552823|PLACEBO_COMPARATOR|White bread 2|Groups 1 and 2, Visit 6 White bread (equal to 50g available carbohydrate) given to fasting participant
62372958|NCT02552823|EXPERIMENTAL|Pea variety 1 with potato|Group 2, Visit 2-5 Pea variety 1 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
62372959|NCT02552823|EXPERIMENTAL|Pea variety 2 with potato|Group 2, Visit 2-5 Pea variety 2 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
62372960|NCT02552823|EXPERIMENTAL|Pea variety 3 with potato|Group 2, Visit 2-5 Pea variety 3 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
62372961|NCT02552823|EXPERIMENTAL|Potato|Group2, Visit 2-5 Potato (equal to 50g available carbohydrate) given as breakfast to fasting participants
62552863|NCT02295501|EXPERIMENTAL|EBOV convalescent donors|EBOV convalescent donors for passive immune therapy in subjects with acute EVD
62372962|NCT03893851|EXPERIMENTAL|ICC-T|Interactions Competencies with Children - for Teachers (ICC-T) 5.5 days with 8 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
62372963|NCT03893851|NO_INTERVENTION|Control|The control schools do not receive any intervention
62372964|NCT06078306|EXPERIMENTAL|CAR-T therapy|Therapeutic outcomes in adults with Ph- B-ALL have substantially improved in the last decade, with complete remission (CR) and long-term overall survival (OS) rates of around 90% and 40%-50%, respectively. The presence of measurable residual disease (MRD) is the strongest predictor of relapse in B-ALL. In this study, high risk Ph- B-ALL patients receive the induction chemotherapy with Azacitidine+Venetoclax. After induction chemotherapy with Azacitidine+Venetoclax (VA regime), each subject receives CD19CD22 CAR-T cells by intravenous infusion. The patients with MRD negative will undergo HSCT.
62372965|NCT06016335|OTHER|Training|Data from 25-35 participants will be used to train an algorithm to generate synthetic CT images from MRI scans.
62744781|NCT04644237|EXPERIMENTAL|Trastuzumab deruxtecan 5.4 mg/kg|Participants will be randomized to receive trastuzumab deruxtecan 5.4 mg/kg administered by intravenous infusion every 3 weeks (Q3W).
62744782|NCT03278912||IBD|-Patients with IBD without a diagnosed PIDD.-First- or second-degree relatives of patients with a PIDD of interest who do not have a PIDD themselves, but have diagnosed or suspected IBD.
62744783|NCT03278912||Non-PIDD/non-IBD (healthy volunteers)|healthy volunteers
62744784|NCT03278912||PIDD|CGD cohort; IPEX syndrome cohort; CTLA4 haploinsufficiency cohort; LRBA deficiency and hypomorphic RAG deficiency cohorts
62744785|NCT04784052|EXPERIMENTAL|Depleted Stem Cell Transplant with JSP-191 Conditioning|Participants will receive an infusion of donor stem cells which have been depleted of αβ+T cells using the CliniMACS System device. Before the stem cell transplant, they will receive a reduced-intensity preparative regimen containing JSP191 in combination with rATG, cyclophosphamide, fludarabine and rituximab.
62744786|NCT03438279||First-Line Ipilimumab|patients who received ipilimumab as their first-line treatment
62744787|NCT02539199|ACTIVE_COMPARATOR|Misoprostol modified-release pessary|
62744788|NCT02539199|ACTIVE_COMPARATOR|Misoprostol, per-oral tablets|
62744789|NCT04131322|EXPERIMENTAL|switch-cohort|Adalimumab biosimilar
62744790|NCT04131322|ACTIVE_COMPARATOR|non-switchcohort|Adalimumab original
62744791|NCT01760538|EXPERIMENTAL|exercise group|exercise training
62744792|NCT01760538|ACTIVE_COMPARATOR|Control|usual care
62744793|NCT00433966|ACTIVE_COMPARATOR|Pharmacology Arm|"To establish the safety and efficacy of the use of bivalirudin in patients with acute myocardial infarction undergoing a primary angioplasty strategy by showing that compared to unfractionated heparin plus routine use of GP IIb/IIIa inhibitors, bivalirudin (with use of GP IIb/IIIa inhibitors reserved for angioplasty complications) results in:~1. reduced rates of major bleeding events at 30 days~2. similar rates of major adverse ischemic cardiac events at 30 days~3. reduced rates of the composite of major adverse ischemic cardiac events + major bleeding at 30 days."
62744794|NCT00433966|ACTIVE_COMPARATOR|Stent Arm|"To establish the safety and efficacy of the paclitaxel-eluting TAXUS™ stent by showing that compared to an otherwise identical bare metal EXPRESS2™ stent, the TAXUS™ stent results in:~1. reduced rates of target lesion revascularization for ischemia at 1 year~2. similar rates of death, reinfarction, stroke or stent thrombosis at 1 year~3. lower rates of analysis segment binary angiographic restenosis at 13 months"
62744795|NCT04985409|EXPERIMENTAL|Feedback|Participants in the intervention arm will receive a Fitbit upon admission and will receive feedback from the activity tracker and the in-room TV screen as demonstrated by the Study Navigator. Study participants in this arm will be engaging with their physicians around achievement of daily step goals by viewing the in-room TV display of their daily step counts on rounds.
62372966|NCT06016335|OTHER|Testing|Data from remaining participants will be used to test the synthetic CT algorithm, by comparing true CT scans to synthetic CT scans made from MRI.
62552864|NCT05089669|EXPERIMENTAL|interactive e-book|The experimental group will read an interactive e-book for 90 minutes to learn nasogastric tube feeding.
62744796|NCT04985409|NO_INTERVENTION|Control|Subjects in the control arm will receive a Fitbit upon admission for their transplant but neither the physician, nurse, nor patient will receive any feedback from the device. They will be blinded to any data capture by their activity monitor. Nurses and doctors will not monitor ambulation with the activity monitor, they will use standard methods to encourage ambulation.
62744797|NCT03207321||Intervention|In 15 intervention villages, a balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma' - was offered daily to pregnant women and children under six years of age during 1987-1990. The meal provided on average 500 kcal energy and 20-25g of protein to women and half of those amounts to children.
62744798|NCT03207321||Control|No supplement was provided in 14 control villages.
62744799|NCT06407349|EXPERIMENTAL|Communication Board|"customized individualized AAC communication Board with a step command Intervention description: 3 sessions per week, of 30 minutes total of 24 sessions. Both genders will be included.~Children's ages range from 8 to 12 years."
62744800|NCT06407349|OTHER|Traditional Therapy|"Traditional therapy with one-step command Intervention description: 3 sessions per week, of 30 minutes total of 24 sessions. Both genders will be included.~Children's ages range from 8 to 12 years."
62744801|NCT01369472|EXPERIMENTAL|Dilatrend SR capsule 8mg|
62744802|NCT01369472|EXPERIMENTAL|Dilatrend SR capsule 16mg|
62744803|NCT01369472|EXPERIMENTAL|Dilatrend SR capsule 32mg|
62744804|NCT01369472|EXPERIMENTAL|Dilatrend SR capsule 64mg|
62744805|NCT01369472|EXPERIMENTAL|Dilatrend SR capsule 128mg|
62744806|NCT05425732|EXPERIMENTAL|Cohort 1 V116|Pneumococcal vaccine-naïve adult participants (≥50 years of age) receive a single dose of V116 on Day 1.
62744807|NCT05425732|ACTIVE_COMPARATOR|Cohort 1 PCV20|Pneumococcal vaccine-naïve adult participants (≥50 years of age) receive a single dose of PCV20 on Day 1.
62744808|NCT05425732|EXPERIMENTAL|Cohort 2 V116|Pneumococcal vaccine-naïve adult participants (18 to 49 years of age) receive a single dose of V116 on Day 1.
62552865|NCT05089669|ACTIVE_COMPARATOR|comparison group|The comparison group will read a paper textbook for 90 minutes to learn nasogastric tube feeding.
62744809|NCT05425732|ACTIVE_COMPARATOR|Cohort 2 PCV20|Pneumococcal vaccine-naïve adult participants (18 to 49 years of age) receive a single dose of PCV20 on Day 1.
62744810|NCT06361394|EXPERIMENTAL|receive a new elective course|"The experimental group will enroll in the elective course named Mindfulness and Happiness, which will consist of 2 hours every week for a continuous period of 18 weeks."
62744811|NCT06361394|NO_INTERVENTION|not receive a new elective course|"The comparison group do not enroll in the new elective course named Mindfulness and Happiness,"
62744812|NCT04410562|EXPERIMENTAL|Hydroxychloroquine|Participants will be then randomized in a 1:1 ratio to HCQ (400 mg/day for three days, followed by 200 mg/day for 11 days)
62744813|NCT04410562|PLACEBO_COMPARATOR|Placebo|Participants will be then randomized in a 1:1 ratio to placebo (2 tablets for three days, followed by one tablet for 11 days).
62744814|NCT06660056|EXPERIMENTAL|Part 1: Dose Escalation|"The study consists of a total of seven dose groups, with the lowest dose group being 1×10\^6 and the highest dose reaching 1×10\^9 PFU.To avoid exposing too many subjects to an ineffective dose, accelerated titration will be used for the 1 x 10\^6 pfu and 3 x 10\^6 pfu dose groups. The 1×10\^7-1×10\^9 pfu dose group will be dose-escalated using the traditional 3+3 design. In case the maximum dose of 1×10\^9 PFU fails to achieve the Maximum Tolerated Dose (MTD), the sponsor and the investigator will convene to discuss whether to designate it as Maximum Feasible Dose (MFD) or consider escalating further based on current safety and preliminary efficacy data. However, any escalation beyond that of similar drugs' Phase I clinical trials, such as JX-594:NCT00629759 and JX-929:NCT00574977, where the highest administered dose was 3×10\^9 PFU, shall be avoided. This precaution ensures adherence to established safety protocols."
62372967|NCT00632515||Questionnaire|Patients with Colorectal Cancer and their First Degree Relatives (FDRs).
62372968|NCT01512108|EXPERIMENTAL|Liraglutide + an OAD therapy|
62372969|NCT01512108|ACTIVE_COMPARATOR|Two OADs combination therapy|
62372970|NCT04871386|EXPERIMENTAL|Acceptance and commitment therapy (ACT)|"14 consecutive days of exercises (prompted via email every morning) derived from acceptance and commitment therapy (ACT); the instructions were text-based, contained a brief introduction to the general goal and the exercise of the day; the exercises were designed to be completable individually in 20 minutes. Additionally: completion of a daily review questionnaire (online diary) including two open questions (Relevant events during the day? Helpful things for coping positively with the current situation?)"
62372971|NCT04871386|EXPERIMENTAL|Positive psychology intervention (PP)|"14 consecutive days of exercises (prompted via email every morning) derived from positive psychology (PP) interventions; the instructions were text-based, contained a brief introduction to the general goal and the exercise of the day; the exercises were designed to be completable individually in 20 minutes. Additionally: completion of a daily review questionnaire (online diary) including two open questions (Relevant events during the day? Helpful things for coping positively with the current situation?)"
62372972|NCT04871386|NO_INTERVENTION|Control group|"completion of a daily review questionnaire (online diary) including two open questions (Relevant events during the day? Helpful things for coping positively with the current situation?); no additional intervention"
62372973|NCT04722263|EXPERIMENTAL|Radiotherapy for patients with nonresectable keloids|Patients will be seen by a treating radiation oncologist and treatment with the assigned dose schedule will be planned using either EBRT with electrons or high dose-rate radiotherapy (HDR) brachytherapy as deemed appropriate by the treating radiation oncologist. The treatment dose of 15 Gy in 3 fractions will be prescribed to the 90% isodose line.
62372974|NCT02907801|EXPERIMENTAL|Perception-Action Approach|Perception-Action Approach (P-AA) intervention components include environmental set-up for activity and participation in play, manual guidance in the form of light pressure applied to the infant's body in developmentally appropriate positions, and caregiver education in modifications to everyday activities consistent with the P-AA. All components are designed to promote spontaneous exploration of the environment by the infant by suggesting small, incremental changes in his/her perceptual-motor orientation and contact with the support surface. Intervention is progressed by gradually removing the environmental supports and therapist's hands to allow for spontaneous exploration of a newly found contact with the support surface or new body configuration.
62372975|NCT04443868|EXPERIMENTAL|Nitric Oxide Releasing Solution|Daily nasal irrigation (240mL) 14.4ppm
62372976|NCT04443868|PLACEBO_COMPARATOR|Placebo Isotonic Saline|Daily nasal irrigation (240mL) 0.9% saline
62372977|NCT06384300|NO_INTERVENTION|Group A|This is the control group.
62372978|NCT06384300|EXPERIMENTAL|Group B|In the financial incentive group (Group B), participants will receive reimbursement for transportation, accommodation, and food costs, along with RMB 200 (about 30 US dollar) to compensate for potential income loss due to endoscopy, provided they undergo the procedure.
62372979|NCT06384300|EXPERIMENTAL|Group C|For the motivational intervention group (Group C), researchers will provide detailed information about the social norms surrounding endoscopy screening, including the prevalence of screening participation, the potential risks of gastric cancer, and the health benefits of screening.
62372980|NCT06384300|EXPERIMENTAL|Group D|Participants in the mixed intervention group (Group D) will receive both financial incentives and motivational intervention.
62372981|NCT02967562|ACTIVE_COMPARATOR|Inflation Breaths|Five 'inflation breaths' lasting two - three seconds
62372982|NCT02967562|EXPERIMENTAL|Sustained inflation|One fifteen second 'sustained inflation'
62372983|NCT02958033|EXPERIMENTAL|HF WBI-SIB breast radiation|WBI-SIB breast radiation(WBI 2.5Gy x18 and SIB 2.88Gy x18)
62372984|NCT02958033|PLACEBO_COMPARATOR|CF WBI-SIB breast radiation|WBI-SIB breast radiation(WBI 1.8Gy x28 and SIB 2.15Gy x28)
62372985|NCT06340776|EXPERIMENTAL|Acupressure group|Those who received acupressure application were called the experimental group, and patients who received routine post-operative care were called the control group. Acupressure application was applied to the experimental group at the third and twenty-fourth hours after surgery.
61986312|NCT03326492||Patients bitten by a snake|"Any patient over 5 years old going to a participating center for curative care following a snake bite.~Participation to the study does not change usual follow-up of patients. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient."
62372986|NCT06340776|NO_INTERVENTION|Control Group|The control group was evaluated for two days without any application.
62744815|NCT06660056|EXPERIMENTAL|Part 2:metrological amplification stage|Based on the MTD determined during the dose-escalation phase (or the investigator's or sponsor's assessment to select a more appropriate dose), patients with recurrent or progressive gliomas who standard therapy failure or intolerance will be included, and will be enrolled 10 to 30 subjects.
62744816|NCT05366179|EXPERIMENTAL|Single Arm|"CAR.B7-H3 T cells:~Subjects with refractory or recurrent glioblastoma multiforme, have cells collected following their initial surgical resection to manufacture CAR.B7-H3 T cells, preferably before initiation of adjuvant chemoradiation."
62744817|NCT05837611|ACTIVE_COMPARATOR|Monitoring Group Only|Individuals in the Monitoring only group will be required to put down a 200$ deposit but will earn it back non-contingently by attending the weekly study meetings. They will be monitored using the Transdermal Alcohol Monitoring device, but will not be required to meet any Alcohol reduction goals to earn their deposit back.
62744818|NCT05837611|EXPERIMENTAL|Deposit Contract Group|Individuals in the Deposit COntract group will be required to put down a 200$ deposit but will earn it back, as well as a bonus, contingently for meeting alcohol reduction requirements. For this study, this is counted as having a Transdermal Alcohol COntent below equal to .02 g/dl. They will be monitored using the Transdermal Alcohol Monitoring device.
62744819|NCT03296826||BRCA1/2 variant carriers|Japanese women who carry BRCA 1/2 variants.
62744820|NCT04023370|EXPERIMENTAL|BeGraft Peripheral Stent Graft System|Covered stent
62744821|NCT04023370|ACTIVE_COMPARATOR|Bare metal stent system|bare metal stent
62744822|NCT01311128||Heart rate and blood pressure determination|All subjects have the same conditions (T-line, blood pressure cuff, and radial artery catheter), in order to compare them within-subjects.
62744823|NCT02882620|EXPERIMENTAL|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
62744824|NCT02882620|EXPERIMENTAL|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
62744825|NCT02882620|EXPERIMENTAL|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
62744826|NCT05807854|ACTIVE_COMPARATOR|Arthroscopic surgery|The massive degenerative rotator cuff tear are treated by arthroscopy. It consists in reattaching the torn tendon with anchors and sutures.
62372987|NCT05442125|EXPERIMENTAL|PIMS group|Couples in the PIMS group will have up to 6 blastocysts screened with PIMS and a single euploid embryo with the optimal state of whole-genome DNA methylation and the highest morphologic score will be selected for the initial transfer. The optimal state of whole-genome DNA methylation includes methylation level closest to the optimal level (0.26 according to our preliminary results) and proper methylation state for some specific regions.
62372988|NCT05442125|ACTIVE_COMPARATOR|Conventional-IVF group|For women between 20 and 37 years of age,couples in the conventional-IVF group will have a single best blastocyst by morphologic criteria selected for the initial transfer.For women over 37 years old, couples in the PGT-A group will have up to 6 blastocysts tested with PGT-A and a single euploid embryo with the highest morphologic score will be selected for the initial transfer.
62744827|NCT05807854|EXPERIMENTAL|Reverse shoulder arthroplasty|The problems induced by the massive degenerative rotator cuff tear are solved by a complete replacement of the shoulder joint with a prosthesis (reverse design).
62744828|NCT03086707|ACTIVE_COMPARATOR|Cigarette smokers|"Subjects who have smoked at least 20 cigarettes per day for at least the past 5 years.~Subjects will be allowed to use their own brand of non-menthol cigarettes. There will be no smoking restriction after the discharge at Visit 3 and during the 1 day follow-up period."
62744829|NCT03086707|NO_INTERVENTION|Never smokers|"Subjects who have smoked less than 100 cigarettes throughout their lifetime and no cigarettes in the past 3 years.~Subjects will not be allowed to smoke until discharge at Visit 3."
62744830|NCT02998411||AI treatment and dosage|
62372989|NCT02257112|EXPERIMENTAL|Multistage low-energy stimulation|Multistage low-energy electrical pulses as described in Janardhan AH et al. JACC 2014 Jan7-14:63(1):40-8 will be delivered to a patient in atrial fibrillation. The responses to these stimuli will be recorded.
62744831|NCT05457907|EXPERIMENTAL|Parameter testing|In order to test parameters, each individual will be subjected to four interventions with the ultrasound device, one sham intervention and 3 interventions with varying intensity, frequency, and duty cycle.
62744832|NCT05457907|EXPERIMENTAL|Anatomical targeting|In order to test anatomical targeting, each individual will be subjected to four interventions with the ultrasound device, one sham intervention and 2 interventions, varying the anatomical targets.
62744833|NCT03824678|EXPERIMENTAL|Administration of CC-220|All subjects will receive one 1-mg CC-220 capsule administered orally with approximately 240 mL of non-carbonated, room temperature water, and administered by trained clinical staff.
62744834|NCT03227653||Efavirenz|Children using efavirenz-based cART for at least 6 months
62744835|NCT03227653||Non-efavirenz|Children using non-efavirenz-based cART (nevirapine or Lopinavir-Ritonavir Drug Combination) for at least 6 months.
62744836|NCT05732935|EXPERIMENTAL|Time Restricted Eating intervention|In the time restricted eating condition, participants will be instructed to fast for a target of 16 hours per day for a 24 week period.
62552866|NCT00704626||Cohort 1|Subjects with multiple sclerosis and other autoimmune and inflammatory disease of the nervous system
62552867|NCT02965417|EXPERIMENTAL|Sym004|All patients will receive a loading dose of Sym004, followed by weekly (q1w) infusions
62372990|NCT02828995||Comprehensive Diabetes Stigma Survey|Participants in the END STIGMA study will be adult patients who have been receiving diabetes-related medical care for a minimum of 12 months in the Vanderbilt University Medical Center Diabetes Clinic and who take at least 1 medication to manage their diabetes.
62372991|NCT01058057|EXPERIMENTAL|Atorvastatin|Atorvastatin 80mg seven days pre-treatment before PCI
62744837|NCT05732935|ACTIVE_COMPARATOR|Successful Aging Comparison Group (LEARN)|In the LEARN group, participants will be educated on health related topics similar to that of the TRE intervention for 24 weeks.
62372992|NCT01869452|OTHER|therapeutic education class 1|patients in class 1 will have a follow up call with therapeutic education every 3 months. this is the light follow up.
62372993|NCT01869452|OTHER|therapeutic education class 2|patients in class 2 will have a follow up call with therapeutic education every month. this is the moderate follow up
62372994|NCT01869452|OTHER|therapeutic education class 3|patients in class 3 will have a follow up call with therapeutic education twice a month. this is the heavy follow up.
62372995|NCT02752425|EXPERIMENTAL|With visual feedback|Session of speech therapy conducted with the additional use of articulatory visual feedback based on ultrasound echography, which allows to visualize the patient's tongue in real time on a computer screen
62372996|NCT02752425|NO_INTERVENTION|Without visual feedback|Session of speech therapy without use of ultrasound echography
62372997|NCT04602013|EXPERIMENTAL|Immunotherapy combined with chemoradiotherapy|"Immunotherapy combined with chemoradiotherapy~1. Sintilimab Body weight \<60kg: 3mg/kg IV Q3W; Body weight ≥60kg: 200mg IV Q3W.~2. Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).~   Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)~3. Radiotherapy The total dose is 60-66 Gy, divided into 30-33 times (2.0 Gy/f, 5 f per week)."
62372998|NCT03049085|ACTIVE_COMPARATOR|Aspirin group|a 75 mg uncoated aspirin is administered 2 hours prior to OPCAB
62744838|NCT02808052|EXPERIMENTAL|Minocin (minocycline) for Injection|Minocin (minocycline) for Injection will be supplied as a sterile lyophilized powder in single-use 10-mL glass vials. Each vial contains 108 mg of minocycline hydrochloride equivalent to 100 mg of minocycline. Each cohort receives a single 200-mg dose of Minocin (minocycline) for Injection except for the hemodialysis therapy/end stage renal disease cohort, which receives two 200-mg doses.
62372999|NCT03049085|PLACEBO_COMPARATOR|Placebo group|75 mg Vit. C is administered 2 hours prior OPCAB
62373000|NCT05011331|EXPERIMENTAL|MedCline Shoulder Relief System|Patients who will receive the MedCline Shoulder Relief System pillow
62373001|NCT05011331|ACTIVE_COMPARATOR|Control|Patients who will not receive the MedCline Shoulder Relief System pillow
62373002|NCT02062970|EXPERIMENTAL|septic shock patients suffering|blood sample done in a population whom suffer of septic shock
62373003|NCT00935662|EXPERIMENTAL|AZD8329|AZD8329 oral solution
62373004|NCT00935662|PLACEBO_COMPARATOR|Placebo|Placebo for AZD8329 oral solution
62373005|NCT02812329|EXPERIMENTAL|HIV prevention videogame|Participants will play PlayForward on a tablet computer for 1 hour, two times per week for 3 weeks.
62373006|NCT00929422||spinal cord injury 1|
62373007|NCT00929422||spinal cord injury 2|
62373008|NCT00929422||spinal cord injury 3|
62373009|NCT00929422||normal control|
62373010|NCT02095249|OTHER|Pimonidazole|
62373011|NCT01751373|ACTIVE_COMPARATOR|Standard Therapy|Coupling focal BoNT-A injections with a therapy program comprising of functional tasks.
62373012|NCT01751373|EXPERIMENTAL|Optimal Muscle Activation Therapy|Coupling focal BoNT-A injections with a motor training program that focuses on developing and maintaining activation patterns in the muscle treated with BoNT-A.
62373013|NCT01174589|OTHER|6 weeks of physical training|The 6 weeks of physical training consists of muscle strength training of both legs, balance and coordination exercises 2 times a week.
62373014|NCT01174589|OTHER|12 weeks of physical exercise|The 12 weeks of physical training consists of muscle strength training of both legs, balance and coordination exercises 2 times a week.
62373015|NCT03588104|EXPERIMENTAL|POWER2DM support group|Participants in this group will receive access to the POWER2DM system as an adjunct to usual care. The participants have three intervention visits in which they will use the Shared Decision Making Dashboard to set self-management goals and will use the Self-Management Support system for trying to reach those goals in the periods after the intervention visits.
62552868|NCT01964079|ACTIVE_COMPARATOR|CCB (amlodipine)|For patients who fail to respond to 5 mg oral amlodipine daily, the dose will be titrated up to 10 mg amlodipineh. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (\>140 mmHg) or diastolic (\>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
62567186|NCT03076840|NO_INTERVENTION|control group|The student in this group had no treatment in the same position of the previous groups (the hamstring muscle maintained in a stretching position for 15 second)
62373016|NCT03588104|ACTIVE_COMPARATOR|Usual care group|Participants in this group will follow their usual diabetes care with their own diabetes care team.
62373017|NCT02834494|OTHER|3D Shear Wave Elastography (SWE)|
62373018|NCT01711437|EXPERIMENTAL|PEG-S|polyethylene glycol 4000 solution with simethicon
62373019|NCT01711437|EXPERIMENTAL|PEG-CS + Bisacodyl|PEG-CS is a new sulphate-free iso-osmotic formulation of PEG-4000 with citrates and simethicone
62373020|NCT01711437|EXPERIMENTAL|PEG-ASC|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid
62373021|NCT01711437|EXPERIMENTAL|picoprep|sodium picosulphate plus magnesium oxide and citric acid
62373022|NCT02124928||carotid artery stenosis|Patients with symptomatic or asymptomatic carotid artery stenosis indicated for carotid endarterectomy, who provide written informed consent, will be included in this study. The investigators will compare patients ultrasonographic data, serum laboratory analyses and histomorphological preferances to look for biomarkers for the plaque instability.
62567187|NCT02284074|EXPERIMENTAL|Nasal LPS spray - placebo|"This is a 5-way crossover, randomised, placebo-controlled study.~Arms consists of the following nasal challenges:~placebo, 1, 10, 30 and 100µg LPS."
62373023|NCT02772835|ACTIVE_COMPARATOR|nHFOV|Starting treatment mode: nHFOV with Medin-cno. Targeted oxygen saturation: 87-94%. Four 1 h study blocks, alternating from the initial mode to the alternate mode twice. All the data will be recorded at 1-min intervals. The following data will be recorded: tcPCO2, tcPO2, heart rate, respiratory rate, SaO2, Silverman score, cer-rSO2, ren-rSO2. Blood pressure will be taken 30 minutes after the beginning of each treatment block. At the beginning of the first period a BGA will be performed in order to test the reliability of the TcPCO2 data. A second capillary BGA will be performed at the end of second period.
62744839|NCT06121609|EXPERIMENTAL|0-3 years group|Age:\<48 months
62744840|NCT06121609|EXPERIMENTAL|4-6 years group|Age: ≥48 and \<84 months
62744841|NCT06121609|EXPERIMENTAL|7-12 years group|Age: ≥84and \<156 months
62744842|NCT03490591|EXPERIMENTAL|Robotic-assisted intervention|In the Robotic-assisted intervention :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week)
62373024|NCT02772835|ACTIVE_COMPARATOR|nCPAP|Starting treatment mode: nCPAP with Medin-cno. Targeted oxygen saturation of 87-94%. Four 1 h study blocks, alternating from the initial mode to the alternate mode twice. All the data will be recorded at 1-min intervals. The following data will be recorded: tcPCO2, tcPO2, heart rate, respiratory rate, SaO2, Silverman score, cer-rSO2, ren-rSO2. Blood pressure will be taken 30 minutes after the beginning of each treatment block. At the be-ginning of the first period a BGA will be performed in order to test the reliability of the TcPCO2 data. A se-cond capillary BGA will be performed at the end of second period.
62373025|NCT05537506|ACTIVE_COMPARATOR|Bracket slot 0.018|
62744843|NCT06428916|EXPERIMENTAL|Study Group|Consisted of 20 neonates who will receive tucking position during endotracheal suctioning
62744844|NCT06428916|NO_INTERVENTION|Control group|Consisted of 20 neonates who will receive routine care during Endotracheal suctioning
62744845|NCT06275776|ACTIVE_COMPARATOR|Monocryl Smooth Suture|Study arm consisting of participants receiving Monocryl Smooth Suture for closure of the superficial skin. Monofilament suture, placed subcutaneously to approximate the wound edges. Currently used in standard care.
62744846|NCT06275776|ACTIVE_COMPARATOR|Vicryl Rapide + Indermil|Study arm consisting of participants receiving Vicryl Rapide Braided Suture in combination with Indermil Topical Skin Adhesive for closure of the superficial skin. Multifilament suture, placed subcutaneously to approximate the wound edges. Skin glue is applied after the application of the suture to further seal the wound from the external environment. Currently used in standard care.
62744847|NCT06275776|EXPERIMENTAL|Dermabond Prineo|Study arm consisting of participants receiving Dermabond Prineo Skin Closure System for closure of the superficial skin. Relatively novel skin closure system consisting of a self-adhesive transparent mesh, over which skin glue is applied as well. This system approximates the wound edges, shields the wound from the external environment, enables healthcare professionals to still be able to see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
62373026|NCT05537506|ACTIVE_COMPARATOR|Bracket slot 0.022|
62373027|NCT05399602|EXPERIMENTAL|Study group A|Patients with diagnosed hydrocephalus undergoing surgery (VP shunt placement) in general anestezia. Before surgery patients undergo lumbar puncture or external lumbar drainage placement to confirmate the diagnosis and responsivity to VP shunt placement.
62373028|NCT05399602|ACTIVE_COMPARATOR|Study group B|Patients without diagnosed hydrocephalus undergoing short spinal surgery without affecting dural sac (e.g. anterior cervical discectomy and fusion or lumbar disc herniation or lumbar decompression) in general anestezia.
62373029|NCT01191424|EXPERIMENTAL|CHF1535 NEXT DPI|Male and female adolescents and adult patients (≥ 12 years old) treated with CHF1535 NEXT DPI
62744848|NCT06275776|EXPERIMENTAL|Stryker Zip|Study arm consisting of participants receiving Stryker Zip Skin Closure System for closure of the superficial skin. Relatively novel skin closure system consisting of two self-adhesive strips placed parallel to either side of the wound. Zip tie/Cable tie-like structures running perpendicular to the adhesive strips can be tightened to approximate the wound edges and thusly close the wound. This system enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
62744849|NCT01805908|EXPERIMENTAL|111In-Pertuzumab + SPECT-CT|Radiopharmaceutical 111In-labeled Pertuzumab given intravenously prior to SPECT-CT imaging.
62744850|NCT02613494|ACTIVE_COMPARATOR|Hyoscine|Hyoscine hydrobromide
62744851|NCT02613494|ACTIVE_COMPARATOR|Glycopyrrolate|Glycopyrronium bromide
62744852|NCT02613494|PLACEBO_COMPARATOR|Placebo|Placebo
62744853|NCT06658717|EXPERIMENTAL|Group I: Investigational product (IP)|One capsule to be taken with breakfast orally once a day
62744854|NCT06658717|PLACEBO_COMPARATOR|Placebo: Microcrystalline cellulose (MCC)|One capsule to be taken with breakfast orally once a day
62744855|NCT04823923|OTHER|Patients without renal insufficiency under pazopanib|Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.
62744856|NCT04823923|OTHER|Patients without renal insufficiency under cabozantinib|Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.
62744857|NCT04823923|OTHER|Patients with moderate renal impairment under pazopanib|Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.
62744858|NCT04823923|OTHER|Patients with moderate renal impairment under cabozantinib|Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.
62744859|NCT04823923|OTHER|Patients with severe or terminal stage renal impairment under pazopanib|Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.
62744860|NCT04823923|OTHER|Patients with severe or terminal stage renal impairment under cabozantinib|Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.
62744861|NCT03871309||Tigertriever|Male or female patients (age ≥18) who present with an acute ischemic stroke due to a M2 or distal (medium to small) vessel occlusion confirmed by vessel imaging and treated with the Tigertriever 17 or 13 revascularization devices.
62744862|NCT05238207|EXPERIMENTAL|BBI-001|BBI-001: Oral administration immediately prior to a meal enriched with stable iron isotope Fe57
62744863|NCT05238207|PLACEBO_COMPARATOR|Placebo|Placebo: Oral administration immediately prior to a meal enriched with stable iron isotope Fe58
62744864|NCT02479087|EXPERIMENTAL|Plasma-derived FVIII/VWF concentrate|"The drug will be delivered through intravenous slow infusion/injection. The starting dosage can vary between the minimum dosage of 50 IU/Kg 3 times a week up to a maximum of 200 IU/kg per day.~This starting dosage will be decided by the Principal Investigator according to patient's condition and other variables.~The initial dosage can be then adjusted on the base of response."
62744865|NCT05001152|EXPERIMENTAL|Ozanimod|A maximum of 10 healthy adult participants (i.e., sensory panelists) will complete a maximum of 20 taste assessment days, with at least 4 panelists required to evaluate the taste characteristics of ozanimod on each taste assessment day.
62744866|NCT02274480||Breast cancer patients with cardiotoxicity|Each patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete.
62744867|NCT02274480||Breast cancer patients without cardiotoxicity|Each patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete.
62744868|NCT01487174|EXPERIMENTAL|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
62744869|NCT01487174|ACTIVE_COMPARATOR|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
62744870|NCT00884091||Healthy Adults|"1. Chinese in origin~2. Healthy~3. No medication at least two weeks before the study"
62373030|NCT01191424|ACTIVE_COMPARATOR|Free combination BDP and FF|Male and female adolescents and adult patients (≥ 12 years old) treated with a free combination of licenced BDP and FF
62744871|NCT04037449|EXPERIMENTAL|TAP block|Transversus Abdominis Plane (TAP) block technique will be carried out by a restricted group of anaesthesiologists. Standard monitoring will be applied to all patients, which will include pulse oximetry, electrocardiogram and non-invasive monitoring of blood pressure.
62373031|NCT01945788|ACTIVE_COMPARATOR|Teriparatide Forteo|20 micrograms/day plus calcium and vitamin D
62373032|NCT01945788|EXPERIMENTAL|Teriparatide Osteofortil|20 micrograms/day plus calcium and vitamin D
62373033|NCT00832091|ACTIVE_COMPARATOR|1|There are 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were 3 concentrations used for topical administration to the active drug groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
62373034|NCT00832091|PLACEBO_COMPARATOR|2|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
62373035|NCT02669446||Ectoin containing Lozenges|treatment with Ectoin containing lozenges
62373036|NCT02669446||Hyaluronic acid containing lozenges|treatment with hyaluronic acid containing lozenges
62373037|NCT02669446||Saline solution for gargling|Subjects in were requested to gargle with salt water
62373038|NCT03476928|EXPERIMENTAL|Treatment Group A1|4 treatment periods of 12 weeks, each separated by 1 bleeding episode
62373039|NCT03476928|EXPERIMENTAL|Treatment Group A2|2 treatment periods of 24 weeks, separated by 2 bleeding episodes
62373040|NCT04748822|OTHER|Quality of life of patients with AUD.|Patients' demographic data, socioeconomic status, physical diseases, medication use, clinical features of AUD, psychiatric variables, impulsivity, autonomy, sexual functioning, sleep quality, and cognitive functioning will be measured at baseline. The Alcohol Quality of Life Scale (AQoLS) will be completed at baseline and at 6-month follow-up. Alcohol status (relapse/abstinence) will be assessed at 6 months.
62373041|NCT04358913|EXPERIMENTAL|MR Imaging on the Alberta linac-MR P3 system|All participants will undergo a single MR imaging session (30-40 minutes) on the Alberta linac-MR P3 system.
62373042|NCT04459923|ACTIVE_COMPARATOR|Epidural Catheter Group|Patients will be applied with epidural catheter at T 5-6 level and the patient will be injected with an epidural solution containing 15 ml 0.125% bupivacaine through this epidural catheter
62373043|NCT04459923|ACTIVE_COMPARATOR|Erector Spina Block Catheter Groups|Patients will be applied with an erector spina plane block catheter at the T 5-6 level, erector spina plane block will be applied by ultrasound guidance and when the first local anaesthetic dosage block needle is identified under the erector spina muscle 30 ml 0.25% bupivacaine (15 ml bupivacain + 15 ml saline) will be injected.
62373044|NCT05620485|EXPERIMENTAL|prenatally diagnosed CDC|All patients received laparoscopic-assisted CDC excision and hepaticojejunostomy.
62373045|NCT03669146|EXPERIMENTAL|Hyperopic subjects receiving glasses|Randomized +5.00 to +7.00 diopter hyperopic subjects that will receive partial refractive correction and will be instructed to do accommodation exercises on a daily basis.
62373046|NCT03669146|NO_INTERVENTION|Hyperopic subjects uncorrected|Randomized +5.00 to +7.00 diopter hyperopic subjects that will serve as the control to the experimental arm who will receive no correction but be observed for the duration of the study.
62373047|NCT03669146|ACTIVE_COMPARATOR|Highly hyperopic subjects corrected|If a subject is found to be greater than +7.00 diopters hyperopic during the screening phase of the study, they will receive glasses correction and be followed during the study period.
62373048|NCT01251991|EXPERIMENTAL|Combinatorial treatment|
62373049|NCT01251991|ACTIVE_COMPARATOR|Single treatment: Psyllium husks|
62373050|NCT01251991|ACTIVE_COMPARATOR|Single treatment: Isolated soy protein|
62373051|NCT01251991|PLACEBO_COMPARATOR|Control|
62744872|NCT04037449|ACTIVE_COMPARATOR|Conventional analgesia|Patients be given conventional endovenous analgesia, and morphine 2 mg / ev every 15 minutes until the level of pain measured by a Visual Analogue Scale (VAS) ≤ 3
62373052|NCT02630394|EXPERIMENTAL|Azithromycin prophylaxis|Azithromycin will be supplied as a 250-mg tablet. Participants weighing less than 40 mg will be instructed to take 1 tablet 3 days a week (Monday, Wednesday, and Friday), and participants who weigh more than 40 kg will be instructed to take 2 tablets on the same 3 days per week.
62373053|NCT01168375|ACTIVE_COMPARATOR|conventional therapy|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
62373054|NCT01168375|ACTIVE_COMPARATOR|conventional therapy plus umbilical cord serum eye drop|
62373055|NCT05364112|EXPERIMENTAL|Compreflex|Patients recruited for the study will be given one unit of Compreflex (study device) to be worn on the studied leg with a venous ulcer. Once the wound is covered by dressing, the subjects were instructed to wear the study device for 24 hours over the study period. Subjects were allowed to take off the study device during a shower. Subjects were asked to visit the clinic for follow-up purposes at 3 assessment time points after being recruited at the first visit: V2 (3-week), V3 (12-week) and V4 (26-week). Subjects' wound area, leg circumferences were measured and calculated. Patient-centred questionnaires were given to the subjects to assess their compliance and satisfaction with the study device.
62373056|NCT06147336|EXPERIMENTAL|V-LAP™ System|Heart failure subjects - Percutaneous implantation of the V-LAP™ implant by right heart catheterization (RHC) approach and daily LAP measurements at home and will be trained on the use of the device for self-management.
62373057|NCT02165592||Patients with hemophilia|Patients with hemophilia who meet the inclusion criteria
62373058|NCT01512693|EXPERIMENTAL|Moderate Hepatic Insufficiency Group|Single-dose administration of odanacatib 50 mg to participants with moderate hepatic insufficiency.
62373059|NCT01512693|EXPERIMENTAL|Healthy Matched Control Group|Single-dose administration of odanacatib 50 mg to healthy matched control participants.
62373060|NCT06139198|EXPERIMENTAL|SMART-U intervention arm|"SMART-U will consist of 2 main components: a 12-week intensive group format stage and a 12-week remotely accessed telephone follow-up stage."
62373061|NCT06139198|NO_INTERVENTION|Enhanced Treatment as usual|The participants will have usual care supplemented by written materials on epilepsy in their preferred language and tailored to the reading level of most patients at the clinic.
62373062|NCT03368079|EXPERIMENTAL|Negative Pressure Suction Device|
62373063|NCT05415865|ACTIVE_COMPARATOR|Alkalinized Lidocaine, then Placebo|"Participants will have Lidocaine Hydrochloride 20 mg/ml, 20 ml and Sodium hydrogen carbonate 1 mmol/ml, 10 ml (ie a total of 30 ml) installed in the bladder for 15 minutes prior to the BTXA-injection procedure.~When signing up for the next BTXA-injection with a wash out period of minimum three months, participants will have the matching placebo containing Sodium Chloride 9 g/L, 20 ml and Sodium Chloride 9 g/L, 10 ml, a total of 30 ml installed in the bladder for 15 minutes prior to the BTXA-injection procedure."
62373064|NCT05415865|ACTIVE_COMPARATOR|Placebo, then Alkalinized Lidocaine|"Participants will have placebo containing Sodium Chloride 9 g/L, 20 ml and Sodium Chloride 9 g/L, 10 ml, a total of 30 ml installed in the bladder 15 minutes prior to the BTXA-injection procedure.~When signing up for the next BTXA-injection with a wash out period of minimum three months, participants will have Lidocaine Hydrochloride 20 mg/ml, 20 ml and Sodium hydrogen carbonate 1 mmol/ml, 10 ml (ie a total of 30 ml) installed in the bladder for 15 minutes prior to the BTXA-injection procedure."
62373065|NCT03288311|ACTIVE_COMPARATOR|Protocolized Post-extubation Respiratory Support|Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning
62373066|NCT03288311|ACTIVE_COMPARATOR|Usual Care|Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
62373067|NCT04280081|EXPERIMENTAL|Selpercatinib|Selpercatinib 160 milligrams (mg) administered orally twice daily (BID).
62373068|NCT00085644|EXPERIMENTAL|Adalimumab|
62373069|NCT00085644|PLACEBO_COMPARATOR|Placebo|
62373070|NCT00998985|EXPERIMENTAL|400 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 400 mg Grazoprevir or Placebo
62373071|NCT00998985|EXPERIMENTAL|600 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 600 mg Grazoprevir or Placebo
62373072|NCT00998985|EXPERIMENTAL|800 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 800 mg Grazoprevir or Placebo
62373073|NCT00998985|EXPERIMENTAL|400 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 400 mg Grazoprevir or Placebo
62373074|NCT00998985|EXPERIMENTAL|600 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 600 mg Grazoprevir or Placebo
62373075|NCT00998985|EXPERIMENTAL|800 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 800 mg Grazoprevir or Placebo
62744873|NCT03195218|EXPERIMENTAL|HRME examination|HRME will capture images from all areas considered abnormal by VIA (visual inspection with acetic acid) and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
62373076|NCT00998985|EXPERIMENTAL|200 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 200 mg Grazoprevir or Placebo
62373077|NCT00998985|EXPERIMENTAL|100 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 100 mg Grazoprevir or Placebo
62373078|NCT00998985|EXPERIMENTAL|50 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 50 mg Grazoprevir or Placebo
62373079|NCT00998985|EXPERIMENTAL|200 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 200 mg Grazoprevir or Placebo
62373080|NCT00998985|EXPERIMENTAL|100 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 100 mg Grazoprevir or Placebo
62373081|NCT00998985|EXPERIMENTAL|50 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 50 mg Grazoprevir or Placebo
62373082|NCT00998985|EXPERIMENTAL|30 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 30 mg Grazoprevir or Placebo
62373083|NCT00998985|EXPERIMENTAL|10 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 10 mg Grazoprevir or Placebo
62373084|NCT01815905|ACTIVE_COMPARATOR|Traditional therapy|Traditional rehabilitation therapy
62373085|NCT01815905|EXPERIMENTAL|Mobile program|Mobile program for occupational and speech therapy
62744874|NCT01370577||1|Total 300 subjects who was diagnosed with asthma
62744875|NCT00599534|ACTIVE_COMPARATOR|1|4 mg tablet for 16 weeks
62373086|NCT00013104||Group 1|
62373087|NCT05478967|EXPERIMENTAL|IVA group|Received an IVA (0.5 mg/0.05 ml) injection before surgery (1 to 5 days before surgery)
62373088|NCT05478967|NO_INTERVENTION|control group|Did not receive IVA injection before vitrectomy
62373089|NCT05885906|ACTIVE_COMPARATOR|Aloevera group|15 patients suffering from diabetes induced xerostomia that will receive aloe vera as mouthwash (20 ml of aloe vera 50%) 3 times per day for 4 weeks.
62552869|NCT01964079|ACTIVE_COMPARATOR|ARB (losartan)|For patients who fail to respond to 50 mg oral losartan daily, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (\>140 mmHg) or diastolic (\>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
62567188|NCT02284074|EXPERIMENTAL|Nasal LPS spray 1µg|"This is a 5-way crossover, randomised, placebo-controlled study.~Arms consists of the following nasal challenges:~placebo, 1, 10, 30 and 100µg LPS."
62744876|NCT00599534|PLACEBO_COMPARATOR|2|5 mg for 16 weeks
62567189|NCT02284074|EXPERIMENTAL|Nasal LPS spray 10 µg|"This is a 5-way crossover, randomised, placebo-controlled study.~Arms consists of the following nasal challenges:~placebo, 1, 10, 30 and 100µg LPS."
62567190|NCT02284074|EXPERIMENTAL|Nasal LPS spray 30 µg|"This is a 5-way crossover, randomised, placebo-controlled study.~Arms consists of the following nasal challenges:~placebo, 1, 10, 30 and 100µg LPS."
62744877|NCT04622670|EXPERIMENTAL|Group I (yoga group)|Patients attend at least 2 yoga classes per week over 5-6 weeks lasting approximately 60 minutes each for up to 15 classes during the CRT. Patients also complete surveys pre-treatment, once a week, and post-treatment over and receive a yoga manual and DVD during and after CRT.
62744878|NCT04622670|ACTIVE_COMPARATOR|Group II (wait list control)|Patients refrain from participating in any new stress management activities and receive a DVD. Patients are also offered 4 group yoga classes after 3 months of CRT. Patients also complete surveys as in Group I.
62744879|NCT03582553|EXPERIMENTAL|150 mg dose|Blood will be drawn at at 0, 2, 3, 3.5, 4, 4.5, 6, 8,12, and 24 hours to measure serum naringenin concentrations in response to a single 150 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
62744880|NCT03582553|EXPERIMENTAL|300 mg dose|Blood will be drawn at at 0, and 4 hours to measure serum naringenin concentrations in response to a single 300 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
62744881|NCT03582553|EXPERIMENTAL|600 mg dose|Blood will be drawn at at 0, 2, 3, 3.5, 4, 4.5, 6, 8,12, and 24 hours to measure serum naringenin concentrations in response to a single 600 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
62373090|NCT05885906|ACTIVE_COMPARATOR|Thyme honey group|15 patients suffering from diabetes induced xerostomia that will receive thyme honey mouthwash (20 ml of thyme honey diluted in 100 ml of distilled water) 3 times per day for 4 weeks.
62373091|NCT05885906|PLACEBO_COMPARATOR|Saline group|15 patients suffering from diabetes induced xerostomia that will receive saline mouthwash as a control group (20 ml of saline) 3 times per day for 4 weeks.
62744882|NCT03582553|EXPERIMENTAL|900 mg dose|Blood will be drawn at at 0, and 4 hours to measure serum naringenin concentrations in response to a single 900 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
62744883|NCT03582553|PLACEBO_COMPARATOR|Placebo|Subjects in the first cohort will receive 150 mg and 300 mg ascending doses of naringenin and subjects in the second cohort will receive 600 mg and 900 mg ascending doses of naringenin. Each cohort will also have a placebo group.
62744884|NCT03597581|EXPERIMENTAL|Single agent Ompenaclid (RGX-202-01) Dose Escalation|Ompenaclid (RGX-202-01) is administered orally twice or three times daily on days 1-28 of each 28-day cycle. The dose regimen is dependent on the cohort in which the patient is enrolled.
62744885|NCT03597581|EXPERIMENTAL|Ompenaclid (RGX-202-01) in combination with FOLFIRI Dose Escalation|"Ompenaclid (RGX-202-01) is administered orally twice or three times daily on days 1-28 of each 28-day cycle. The dose regimen is dependent on the cohort in which the patient is enrolled.~FOLFIRI is administered as follows: irinotecan 180 mg/m2 intravenously over 90 minutes concurrently with folinic acid (leucovorin) 400 mg/m2 intravenously over 2 hours, followed by 5-FU 400 mg/m2 intravenous bolus and then 5-FU 2400 mg/m2 intravenous infusion over 46 hours, on Days 1 and 15 of each 28-day cycle."
62744886|NCT03597581|EXPERIMENTAL|Expansion: 2nd Line Colorectal Cancer (CRC) KRAS (+)|"2nd Line CRC RAS (+)~Ompenaclid (RGX-202-01) is administered orally twice on days 1-28 of each 28-day cycle.~FOLFIRI is administered as follows: irinotecan 180 mg/m2 intravenously over 90 minutes concurrently with folinic acid (leucovorin) 400 mg/m2 intravenously over 2 hours, followed by 5-FU 400 mg/m2 intravenous bolus and then 5-FU 2400 mg/m2 intravenous infusion over 46 hours, on Days 1 and 15 of each 28-day cycle.~Bevacizumab is administered as follows: 5 mg/kg on Days 1 and 15 of each 28-day cycle."
62373092|NCT05482594||Systemic sclerosis|Patients followed regularly at CHU Brugmann in rheumatology/Dermatology for limited or diffuse systemic sclerosis in accordance with the ACR/EULAR 2013 criteria.
62373093|NCT05482594||Control|Control patients recruited among patients followed for mechanical pathology in rheumatology.
62373094|NCT03595189|EXPERIMENTAL|Cilastatin Dose 1|Starting dose (3g of Cilastatin) Single intravenous administration during 3 hours.
62373095|NCT03595189|EXPERIMENTAL|Cilastatin Dose 2|Dose escalation Single intravenous administration during 3 hours.
62373096|NCT03595189|EXPERIMENTAL|Cilastatin Dose 3|Dose escalation Single intravenous administration during 3 hours.
62373097|NCT03595189|PLACEBO_COMPARATOR|Placebo|Saline solution for infusion
62373098|NCT06070727|OTHER|Metal framework group|group A: Patients will receive metallic framework with obturator for 6 months, then the metallic obturator will be replaced by PEKK obturator for another 6 months.
62373099|NCT06070727|OTHER|PEKK framework group|Group B: Patients will receive PEKK obturator for 6 months, then the same patients will receive metallic framework obturator for another 6 months.
62373100|NCT00184067|EXPERIMENTAL|Peptide vaccine with Montanide ISA 51 + GM-CSF|Peptide vaccine with Montanide ISA 51 GM-CSF
62373101|NCT00184067|ACTIVE_COMPARATOR|Peptide vaccine with Montanide ISA 51|Peptide vaccine with Montanide ISA 51
62744887|NCT03597581|EXPERIMENTAL|Ompenaclid (RGX-202-01) in combination with FOLFOX Dose Escalation|"RGX-201-01 is administered orally twice or three times daily on days 1-28 of each 28-day cycle. The dose regimen is dependent on the cohort in which the patient is enrolled.~The FOLFOX regimen used for this protocol consists of oxaliplatin given at 85 mg/m2 IV together with leucovorin at 400 mg/m2 IV (substitution with levo-leucovorin 200 mg/m2 IV is allowed) (duration per institutional policy), followed by a 5-FU bolus of 400 mg/m2 (over 2-5 minutes), and then continuous infusional 5-FU given at a dose of 2400 mg/m2 over 46-48 hours (1200 mg/m2/day), given on Days 1 and 15 of each 28-day cycle. A minimum of 8 FOLFOX cycles should be received if tolerated per standard of care guidelines."
62744888|NCT03597581|EXPERIMENTAL|Ompenaclid (RGX-202-01) in combination with FOLFOX Dose Expansion|"Ompenaclid (RGX-202-01) is administered orally twice or three times daily on days 1-28 of each 28-day cycle. The dose regimen is dependent on the cohort in which the patient is enrolled.~The FOLFOX regimen used for this protocol consists of oxaliplatin given at 85 mg/m2 IV together with leucovorin at 400 mg/m2 IV (substitution with levo-leucovorin 200 mg/m2 IV is allowed) (duration per institutional policy), followed by a 5-FU bolus of 400 mg/m2 (over 2-5 minutes), and then continuous infusional 5-FU given at a dose of 2400 mg/m2 over 46-48 hours (1200 mg/m2/day), given on Days 1 and 15 of each 28-day cycle. A minimum of 8 FOLFOX cycles should be received if tolerated per standard of care guidelines."
62744889|NCT06661174||Surgical group|
62744890|NCT06661174||Non-surgical group|
62744891|NCT03061721|EXPERIMENTAL|Saroglitazar magnesium 1 mg|Saroglitazar magnesium 1 mg tablet orally once daily in the morning before breakfast for 16 weeks.
62744892|NCT03061721|EXPERIMENTAL|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet orally once daily in the morning before breakfast for 16 weeks.
62744893|NCT03061721|EXPERIMENTAL|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet orally once daily in the morning before breakfast for 16 weeks.
62744894|NCT03061721|PLACEBO_COMPARATOR|Placebos|Placebo tablet orally once daily in the morning before breakfast for 16 weeks.
62744895|NCT06657352|EXPERIMENTAL|ACS Topical Treatment Group|25 participants, measured at Week 0, 2, 4.
62744896|NCT06657352|PLACEBO_COMPARATOR|Topical Placebo Group|25 participants, measured at Week 0, 2, 4.
62744897|NCT06657352|EXPERIMENTAL|ACS Oral Treatment Group|25 participants, measured at Week 0, 2, 4, 8, 12.
62373102|NCT03463109|OTHER|Healthy Volunteers|Electrocutaneous stimulation. A standardized grid will be drawn over the participants' lumbar region. Circular electrodes, connected to a constant current stimulator, will be applied at points on the grid selected at random. Participants will be blinded to the electrode locations. Sets of painful electrocutaneous stimuli will be randomly delivered for each electrode. Participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet the location on which they will perceive each painful stimulation.
62373103|NCT03463109|OTHER|Chronic Low Back Pain|"Assessment + Electrocutaneous stimulation. Patients with chronic low back pain will be asked to provide information about their lifestyle, level of disability, current pain, general pain and to undergo an assessment of kinesiophobia and health status.~After the assessment, a standardized grid will be drawn over the patients' lumbar region. Circular electrodes, connected to a constant current stimulator, will be applied at points on the grid. Patients will be blinded to the electrode locations. Sets of painful electrocutaneous stimuli will be randomly delivered for each electrode. Patients will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation."
62373104|NCT03631394|EXPERIMENTAL|beetroot and anthocyanin|A compound pharmacy will formulate capsules with nitrates extracted from beetroot and anthocyanins from tart cherries. A daily dose of the capsules will be taken for 7 days after the washout period. Each dose will comprise 500 mg of nitrates and 450 mg of anthocyanins. In a meta-review by Dominguez and colleagues, 6-8 mmol of nitrates from beetroot was associated with increased exercise performance. Another review by Kelley et al., showed that marathon runners and resistance trainers ingesting between 450-480 mg of anthocyanins had reduced muscle soreness and decreased oxidative stress. Subject will consume each supplement orally with only water 2 hours pre-prandial.
62373105|NCT03631394|PLACEBO_COMPARATOR|beetroot and placebo|The same compound pharmacy will formulate capsules with nitrate extracted from beetroot and a placebo element made of starch. This product will taste the same as the nitrate and anthocyanin supplementation. A daily dose of the capsules will be taken for 7 days after the washout period. Each supplementation will have 500 mg of nitrate and 450 mg of placebo. Subjects will consume each supplement orally with only water 2 hours pre-prandial.
62373106|NCT01415973|EXPERIMENTAL|3 ounces of cooked, 85% lean ground beef|Subjects would consume 3 ounces of cooked, 85% lean ground beef at one setting on one day.
62567191|NCT02284074|EXPERIMENTAL|Nasal LPS spray 100 µg|"This is a 5-way crossover, randomised, placebo-controlled study.~Arms consists of the following nasal challenges:~placebo, 1, 10, 30 and 100µg LPS."
62567192|NCT00772876|EXPERIMENTAL|P1446A-05|Single arm of the study drug. This being a dose escalation study, patient will receive a dose depending on the stage of the trial.
62373107|NCT01415973|EXPERIMENTAL|20 grams of Beef protein isolate|Subjects would consume 20 grams of beef protein isolate dissolved into 200mL water at one setting on one day.
62744898|NCT06657352|PLACEBO_COMPARATOR|Oral Placebo Group|25 participants, measured at Week 0, 2, 4, 8, 12.
62744899|NCT06657352|EXPERIMENTAL|ACS Oral Treatment + ACS Topical Treatment Group|25 participants, measured at Week 0, 2, 4, 8, 12.
62744900|NCT06657352|PLACEBO_COMPARATOR|ACS Oral Treatment + Topical Placebo Group|25 participants, measured at Week 0, 2, 4, 8, 12.
62744901|NCT04958993|EXPERIMENTAL|Anlotinib combined with concurrent chemoradiotherapy|"Radiotherapy: 1.8-2.0Gy, qd, 54-66Gy, 5 days a week Chemotherapy: squamous cell cancer: paclitaxel + platinum;Adenocarcinoma: pemetrexed + platinum;A cycle of 3W was used, and the appropriate chemotherapy dose was selected by the researcher according to the patient's situation without any restriction on the chemotherapy dose.Pre-induction chemotherapy is allowed.~Anlotinib: QD, take 2 weeks and stop for 1 week (radiotherapy 1, 2, 4, 5 weeks)"
62744902|NCT03566771|ACTIVE_COMPARATOR|Usual care|Usual care according to regular treatment routines at the clinic during 12 months
62744903|NCT03566771|ACTIVE_COMPARATOR|CLOSS|Usual care plus using a web-based support system for self-monitoring weight, physical activity and communication with the clinic during 12 months
62744904|NCT06051318|EXPERIMENTAL|Standardized breakfast A|Consumption order: Participants will initiate the interventional period by eating the low-carb muffin first following the established muffin order for the next days.
62744905|NCT06051318|EXPERIMENTAL|Standardized breakfast B|Consumption order: Participants will initiate the interventional period by eating the vegan muffin first following the established muffin order for the next days.
62744906|NCT06482203|EXPERIMENTAL|Group 1(Trunk Extensor Endurance Training)|Trunk Extensor Endurance Training Level 1: Prone shoulder extension or prone shoulder raises Level 2: Prone back extension Level 3: Prone Ys or Y raises Level 4:Superman pose Level 5:Superman or prone cobra (The given position should be hold for 10 seconds and performs 25 repetitions with 3 sec rests in between the efforts)
62744907|NCT06482203|EXPERIMENTAL|Group 2(Scapular Mobilization)|"Patient side lying. This intervention program includes, supero-inferior, medio-lateral along with circumduction movements.~Procedure:~Patients were side lying with their arms in 90°flexion during scapula mobilization.~The physiotherapist completed 3 sets of 10-15 repetitions of each of the supero-inferior, medio-lateral, and circumduction movements while holding the scapula from the medial border. Between each session, there was a 10 or 30-second break. The length of rests was adjusted depending on the patient's endurance and comfort."
62744908|NCT02997436|EXPERIMENTAL|PAD patients|"Patients referred for vascular ultrasound investigation for suspicion of peripheral artery disease (PAD).~Intervention is measurement of microvascular response to current application on the skin by Laser speckle flowmetry"
62744909|NCT03267719|EXPERIMENTAL|laser therapy|Erbium-laser therapy will be applied
62744910|NCT00954629|EXPERIMENTAL|2PX|Pain medication
62744911|NCT00954629|PLACEBO_COMPARATOR|Placebo|
62373108|NCT03628391|ACTIVE_COMPARATOR|haloperidol|"study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations)."
62373109|NCT03628391|PLACEBO_COMPARATOR|placebo|"study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations)."
62373110|NCT05312385|EXPERIMENTAL|Isoflurane|Inhaled isoflurane administered via Sedaconda ACD-S
62373111|NCT05312385|ACTIVE_COMPARATOR|Propofol|Propofol administered as intravenous infusion
62373112|NCT02661256|ACTIVE_COMPARATOR|on NCPAP|"Once consented, each participant underwent a video fluoroscopic swallow study (VFSS) while NCPAP was administered via a RAM cannula® (intervention). With the NCPAP turned on each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow), a total of 20 swallows were recorded. These swallows were termed on NCPAP swallows. The swallows were assessed in real time for any swallowing dysfunction."
62373113|NCT02661256|ACTIVE_COMPARATOR|Off NCPAP|"Immediately following the on NCPAP condition, an additional 20 swallows were recorded under VFSS with the NCPAP turned off (intervention). These swallows were termed off NCPAP swallows."
62744912|NCT01364454|EXPERIMENTAL|Eligible patients' paper-based reminder|
62744913|NCT01364454|NO_INTERVENTION|Control group|
62744914|NCT06229028|EXPERIMENTAL|verbal explanation group|The treatment by the diagnosis will be explained under the guidance of the therapist and will be repeated at each appointment to the first group.
62744915|NCT06229028|EXPERIMENTAL|patient information and exercise forms group|Treatment by the diagnosis will be provided with patient information and exercise forms containing visual and written information in addition to an explanation under the guidance of the therapist for the second group.
62744916|NCT06229028|EXPERIMENTAL|video recording group|Treatment by diagnosis will be provided with patient information containing visual and written information, exercise forms, and video recording, in addition to narration under the guidance of the therapist for the third group.
62744917|NCT05476887|EXPERIMENTAL|Part 1: Dose escalation Cohort 1|Participants will receive escalating and varying dose intervals of KP104 every week.
62744918|NCT05476887|EXPERIMENTAL|Part 1: Dose escalation Cohort 2|Participants will receive escalating and varying dose intervals of KP104 weekly or biweekly.
62744919|NCT05476887|EXPERIMENTAL|Part 1: Dose escalation Cohort 3|Participants will receive escalating and varying dose intervals of KP104 weekly or biweekly.
62744920|NCT05476887|EXPERIMENTAL|Part 2: Proof-of-concept Cohort 1|Participants will receive escalating and varying dose intervals of KP104 weekly or biweekly.
62744921|NCT05476887|EXPERIMENTAL|Open-label extension (OLE)|Participants will receive KP104, who benefit from KP104 treatment in Part 1 and 2
62744922|NCT02578966|EXPERIMENTAL|Motivational Interview|INTERVENTION GROUP: in this group, composed of 6 UBS, the children and their respective mothers/fathers/responsible adults will be attended by the dentists at least once a year with an approach based on the Motivational Interview.
61986313|NCT03529240|EXPERIMENTAL|Kinesiology taping|After performing the baseline assessments, kinesiology taping with facilitation technique was applied on bilateral quadriceps and tibialis anterior muscles of children. In both applications, the first and last 5 cm section of the bands were used as anchor and no tension was applied.
61986314|NCT00308503|EXPERIMENTAL|1|5 mg/day
62373114|NCT03637894|ACTIVE_COMPARATOR|Infants born by CS-fed fermented formula|Feeding infants with fermented formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
62567193|NCT00404391|EXPERIMENTAL|Arm 1: hydrocodone/acetaminophen extended release|
62567194|NCT00404391|EXPERIMENTAL|Arm 2: hydrocodone/acetaminophen extended release|
61986315|NCT00308503|PLACEBO_COMPARATOR|2|
62373115|NCT03637894|PLACEBO_COMPARATOR|Infants born by CS-fed standard formula|Feeding infants with standard formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
61986316|NCT02315755||Study cohort|Metastatic renal cell carcinoma patients under 3rd line targeted therapy following 1st line interferon alpha and 2nd line TKI. All patients will be ≥ 18 years old and have signed the informed consent document.
62373116|NCT03637894|OTHER|Infants born by CS-breastfed|"Infants born by cesarean section fed with mother milk during were the reference group for all infants born by cesarean section.~The breastfeeding infants were the reference group"
62373117|NCT03637894|ACTIVE_COMPARATOR|Infants born by ED-fed fermented formula|Feeding infants with fermented formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
62373118|NCT03637894|PLACEBO_COMPARATOR|Infants born by ED-fed standard formula|Feeding infants with standard formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
62373119|NCT03637894|OTHER|Infants born by ED-breastfed|"Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life.~The breastfeeding infants were the reference group."
62373120|NCT00821054|EXPERIMENTAL|Period 1|Treatment A, B or C
62373121|NCT00821054|EXPERIMENTAL|Period 2|Treatment A, B or C
62373122|NCT00821054|EXPERIMENTAL|Period 3|Treatment A, B or C
62373123|NCT04829006|OTHER|Speakers|Participants will be recording sentences using a customized app, which is the focus of the current investigation. There is no arm per se, as the current investigation does not involve an intervention. The current investigation aims at developing and pilot testing an app.
62373124|NCT02233491|PLACEBO_COMPARATOR|Control|This group will be counselled in clinic by clinicians about the risks of glucose intolerance and will receive leaflets outlining lifestyle modification advice. The leaflets include advice on healthy eating, exercise and the importance of weight loss. However there will be no dietician referral, psychosocial intervention or focused exercise and weight loss monitoring programme. Follow up will be at routine clinic visits only where lifestyle modification advice will be reinforced as per usual clinical practise.
62373125|NCT02233491|ACTIVE_COMPARATOR|Active intervention|This group will receive active lifestyle modification intervention and will consist of dietician referral, graded exercise programme and weight loss advice. The dietician will be supported by Clinical Psychology services and our collaboration with a recognised expert in behavioural change therapy. The dietician will be trained with motivational interviewing skills and psychological tools will be utilised to support the active lifestyle intervention.
62373126|NCT01770093||Parents of Pediatric Inpatients|
62373127|NCT02573506|EXPERIMENTAL|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-IMRT. Patients are irradiation at a palliative dose in the initial course: 51Gy/17f to PTV-GTV. The disease is re-evaluated three weeks after the end of the initial course using CT. The patient without disease progression according to the RECIST criteria and had a recovery of lung function should get the additional boost. In the second course, the tumor is repositioned and scanned. The residual tumor is then treated with the second course of radiotherapy. A dose of 15-18 Gy/5-6f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
62373128|NCT02111707|ACTIVE_COMPARATOR|Rectal Indomethacin pre-ERCP|Patients will receive rectal indomethacin 100mg 30 minutes before procedure (ERCP).
62373129|NCT02111707|ACTIVE_COMPARATOR|Rectal Indomethacin post-ERCP|Patients will receive rectal indomethacin 100mg immediately after procedure (ERCP)
62373130|NCT02941042|EXPERIMENTAL|NNC9204-1177|
62373131|NCT02941042|PLACEBO_COMPARATOR|Placebo|
62373132|NCT03068052|ACTIVE_COMPARATOR|No incentive|Colon cancer risk assessment and direct access colonoscopy scheduling for those that are eligible.
62373133|NCT03068052|EXPERIMENTAL|Incentive|Loss-framed incentive to participate in risk assessment and additional unconditional pro-social incentive to complete colorectal cancer screening.
62373134|NCT06169644||Chemotherapy-treated GTN Patients|Patients with a diagnosis of Gestational Trophoblastic Neoplasia who completed chemotherapy treatment between 6 weeks and 24 months prior to the study. No IMP intervention to be administered, patients to be involved in a qualitative interview.
62373135|NCT00613340|EXPERIMENTAL|1|Cervical medial branch blocks with 0.25 ml of injectate
62373136|NCT00613340|EXPERIMENTAL|2|Cervical medial branch blocks with 0.5 ml of local anesthetic and contrast
62373137|NCT05329714||Patients with Pulmonary Hypertension|Patients with a diagnosis of pulmonary hypertension typically diagnosed via right heart catheterization.
62373138|NCT05329714||Control Group|Participating PH centers can optionally provide data about patients with exclusion of pulmonary hypertension
62373139|NCT00833612|NO_INTERVENTION|Control arm of study|
62373140|NCT01654393|EXPERIMENTAL|OAR group|Patients with ankle injuries who are assessed by OAR trained triage nurses applying the OAR.
62373141|NCT01654393|NO_INTERVENTION|Control for OAR Triage Nurses|Patients with ankle injuries that are seen by OAR triage nurses but not assessed in accordance with the OAR.
62373142|NCT01594086|EXPERIMENTAL|green tea powder|Natural green tea powder
62373143|NCT03800433|NO_INTERVENTION|control|23 patients will receive their usual dose of erythropoietin stimulating agents and their routine treatment.
62373144|NCT03800433|EXPERIMENTAL|test|23 patients will receive the intervention drug Pentoxifylline (Trental 400 milligram(MG) Extended Release Oral Tablet) twice daily in addition their usual dose of erythropoietin stimulating agents and their routine treatment.
62373145|NCT02698566|EXPERIMENTAL|Ranibizumab PFS|Healthcare professionals (HCPs) will administer ITV injections of ranibizumab 0.5 mg delivered via PFS to enrolled patients (1 injection to each patient) on Day 1.
62373146|NCT06228781|EXPERIMENTAL|Hematopoietic Stem Cell Transplantation|Patients will undergo stem cell transplantation for the treatment of refractory MS
62567195|NCT00404391|PLACEBO_COMPARATOR|placebo|
62567196|NCT05021133|OTHER|Tele-Navi LCS|Tele-Navi of LCS includes: telehealth coaching from a Tele-Navigator for patients undergoing LCS
62567197|NCT01229995|ACTIVE_COMPARATOR|Prefabricated Abutment|
62567198|NCT04446338||Healthcare Worker|Staff of the Department of Ophthalmology, University Tuebingen, Germany
62373147|NCT05367362|EXPERIMENTAL|Intervention|Patients randomized to minocycline will receive 200mg administered once a day for 21 days. The first dose will be administered in the emergency room or the angiography suite prior to endovascular intervention or within the first two hours of endovascular stroke intervention. If the patient is considered able to swallow as per the routine swallow test, the study drug will be administered orally as intact capsules. If the patient is considered to be at any risk for aspiration or is unable to swallow based on swallowing evaluation, study drug may be started using intravenous route and later switched to oral or via feeding tube as it becomes available.
62373148|NCT05367362|NO_INTERVENTION|Control|Patients randomized to control arm will receive look-alike placebo administered once a day for 21 days. The first dose will be administered in the emergency room or the angiography suite prior to endovascular intervention or within the first two hours of endovascular stroke intervention. If the patient is considered able to swallow as per the routine swallow test, the placebo will be administered orally as intact capsules. If the patient is considered to be at any risk for aspiration or is unable to swallow based on swallowing evaluation, placebo may be started using intravenous route and later switched to oral or via feeding tube as it becomes available.
62373149|NCT04835688|EXPERIMENTAL|Ventilation tube insertion|Ventilation tube insertion into the tympanic membrane.
62373150|NCT04835688|SHAM_COMPARATOR|Sham-treatment|Sham-treatment. Manipulation of the tympanic membrane to simulate ventilation tube insertion without performing a ventilation tube insertion.
62373151|NCT04230590||Participants with schizophrenia spectrum disorders|Within 8 weeks post discharge from hospitalization at the Institute of Mental Health
62373152|NCT02216292||Preterm Single Donor Milk Group|The prospective study group = preterm single donor milk group (PSDM-Group) from June 2012 - April 2013
62373153|NCT02216292||Control Group|Retrospective control group receiving no donor milk = control group from March 2011 - May 2012
62373154|NCT03814460||Control Group|A control group of healthy subjects with no previous history of neurological disorders or conditions. This group pf participants will be selected in a similar population based-cohort than the other two study groups.
62373155|NCT03814460||Acute Stroke Group|In this group, participants who suffered a previous stroke within 3 months before data collection will be included.
62373156|NCT03814460||Chronic Stroke Group|In this group, only participants who have suffered a previous stroke of more than 3 months duration before data collection will be included.
62373157|NCT05300958|EXPERIMENTAL|Treatment arm|Deferoxamine：50mg/kg+500ml normal saline (NS) plus chemotherapy
62373158|NCT04531397|PLACEBO_COMPARATOR|ACEI treatment|Drug: ACEI will be given once daily
62373159|NCT04531397|EXPERIMENTAL|Dapagliflozin+ACEI treatment|Drug: ACEI, will be given once daily Drug: Dapagliflozin, will be given once daily
62373160|NCT00861094|EXPERIMENTAL|FOLFOX and radiotherapy|Oxaliplatin (85mg/m2); Folinic Acid (200mg/m2); 5-FU (400mg/m2-Bolus and 1600mg/m2 over 46h)- once every two weeks for six cycles
62373161|NCT00861094|EXPERIMENTAL|5-FU / cisplatin and radiotherapy|5-FU (100mg/m2); Cisplatin (75mg/m2)
62373162|NCT02460172|ACTIVE_COMPARATOR|Zip Surgical Skin Closure|Subject will be randomized to receive one knee (right or left) closed with Zip Surgical Skin Closure and the other knee closed with steel staples.
62373163|NCT02460172|ACTIVE_COMPARATOR|Steel Staples|Subject will be randomized to receive one knee (right or left) closed with steel staples and the other knee closed with Zip Surgical Skin Closure.
62373164|NCT03882866|EXPERIMENTAL|3D-printed non-coplanar template|3D-printed non-coplanar template is used in this group.
62373165|NCT03882866|ACTIVE_COMPARATOR|3D-printed coplanar template|3D-printed coplanar template is used in this group.
62373166|NCT04224987|ACTIVE_COMPARATOR|Azithro 1-11|Biannual weight- or height-based dose of oral azithromycin suspension to children 1-11 months old and oral placebo or no intervention to children 12-59 months old
62373167|NCT04224987|ACTIVE_COMPARATOR|Azithro 1-59|Biannual age, weight- or height-based dose of oral azithromycin suspension to children 1-59 months old
62373168|NCT04224987|PLACEBO_COMPARATOR|Placebo|Biannual weight- or height-based dose of oral placebo to children 1-59 months old
62373169|NCT06392867|SHAM_COMPARATOR|sham group|"MagVenture Cool-B65 A/P sham coil is used for all participants. A butterfly-shaped active/placebo coil, with active cooling, for clinical studies with double-blind experiments. The symmetrical design gives no indication of which is the active side and which is the placebo side.The participants will not receive any benefit from the iTBS if they use the inactive side of the coil.~MagVenture is a privately-owned Danish company which manufactures the TMS machine."
62373170|NCT06392867|ACTIVE_COMPARATOR|iTBS75|The intensity of intermittent theta-burst stimulation (iTBS) applied to the participant will be 75% of their individual rest motor threshold (rMT).
62373171|NCT06392867|ACTIVE_COMPARATOR|iTBS120|The intensity of intermittent theta-burst stimulation (iTBS) applied to the participant will be 120% of their individual rest motor threshold (rMT).
62373172|NCT05509491|EXPERIMENTAL|Postural Awareness Program with Exercises in people with neck pain|Postural education, bad posture, good posture, awareness, their effects in daily life
62373173|NCT04233957|EXPERIMENTAL|High Sodium|Consumption of an extra 3900 mg of dietary sodium per day.
62373174|NCT04233957|PLACEBO_COMPARATOR|Placebo|Control Condition
62373175|NCT04323098|EXPERIMENTAL|valoctocogene roxaparvovec|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg with prophylactic corticosteroids
62373176|NCT02758561|NO_INTERVENTION|Standard of care|Standard of care
62373177|NCT02758561|EXPERIMENTAL|Workshop|90 minute workshop on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (POP)
62373178|NCT04174872|OTHER|Dexmedetomidine|It has a sedative effect without significant respiratory depression , anxiolytic, analgesic, antihypertensive and sympatholytic properties. It is now being used as a neuraxial adjuvant that can be used as an effective adjuvant in epidural anaesthesia as it intensifys the motor block and prolongs the duration of postoperative analgesia.
62373179|NCT04174872|OTHER|Midazolam|Midazolam has been reported to have a spinally mediated analgesic effect. Clinically, single-shot epidural or spinal administration of midazolam has been shown to have an analgesic effect on perioperative pain.
62373180|NCT02940028|EXPERIMENTAL|Expressive writing intervention|The intervention group will participate in a brief expressive writing intervention.
62373181|NCT02940028|OTHER|Control writing intervention|The control group will receive a control writing condition (fact based writing).
62744923|NCT02578966|ACTIVE_COMPARATOR|Traditional health education|CONTROL GROUP: in this group, composed of 6 UBS, the children and their respective mother/fathers/responsible adults will be attended by the dentists at least once a year based on the recommendations by the Brazilian Ministry of Health (BRASIL,2008-a) and on SSC-GHC's protocol (BRASIL, 2008-b). Additionally, the professional guidance script and the parents' booklet of SSC-GHC's oral health Program may be used.
62744924|NCT06452108||Islamabad (Federal) site|Determine community perspective on COVID-19 for identification of relevant, feasible, and effective approaches to promote acceptance, uptake, and adherence of public health measures for COVID-19 prevention and control in Pakistan through generation of high-quality evidence to achieving the goals of the NAP.
62373182|NCT01545414|EXPERIMENTAL|ICBT|Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
62373183|NCT01545414|ACTIVE_COMPARATOR|ICONTROL|Internet-based treatment with a focus on relaxation training
62373184|NCT01545414|NO_INTERVENTION|SMT|Standard Medical Treatment while being on the waitlist for randomization to any of the active treatments
62373185|NCT05651074|EXPERIMENTAL|Vicagrel and omeprazole|D1 single dose of vicagrel was administered. Omeprazole administration was started on D4, once daily for 5 days, and a single dose of vicagrel and omeprazole coadministration on day 9.
62373186|NCT05925829|EXPERIMENTAL|SVF and aaPRP treatment|Patients treated with SVF and aaPRP
62373187|NCT05354869|ACTIVE_COMPARATOR|Usual Care|The current standard, first line treatment for MPP is a program of education, home exercises, and stretching. At enrollment, subjects will be counseled about the origins of myofascial pain in a one-on-one setting with the aid of informational handouts. They will be counseled about specific practices, such as Kegel exercises, volitional holding of urine or stool, and intensive exercise, that aggravate pelvic floor hypertonicity. They will be counseled about appropriate hydration and maintaining an adequate bowel regimen to avoid constipation. A stretching regimen aimed at abdominal and pelvic muscle release with elements of self-massage should be performed three times daily. Lastly, subjects will be prescribed 20 minutes of walking daily. Subjects will be recommended to continue this long-term, self-care program indefinitely.
62373188|NCT05354869|ACTIVE_COMPARATOR|HF-TES by LVN|"In-office pulsed HF-TES will be delivered by licensed vocational nurse using the Urostym® clinic-based Pelvic Floor Rehabilitation System. An LVN will undergo didactic and practical training, which will include a detailed orientation to the device.~Sessions of electric muscle stimulation will be performed at a frequency of 200 Hz (to induce a passive pelvic floor muscle contraction) for 20 min weekly using a pulse duration of 1 ms of stimulation and an interpulse interval of 4.1 ms. Stimulation intensity (current) will be adjusted manually to palpable, but not painful, stimulation. Vaginal and surface abdominal electromyographic monitoring (EMG) will be conducted throughout the treatment session, recording the average pre- and post-treatment values for each session. In subjects whose pelvic floor EMG does not normalize to \<4 millielectronvolts (mV) in a 20-minute session, the subsequent session will be increased to 30 minutes."
62373189|NCT05354869|ACTIVE_COMPARATOR|HF-TES by Physician|"A urogynecologic specialist will deliver HF-TES in office using Urostym® pelvic floor rehabilitation system. A physician will undergo didactic and practical training, which will include a detailed orientation to the device.~Sessions of electric muscle stimulation will be performed at a frequency of 200 Hz (to induce a passive pelvic floor muscle contraction) for 20 min weekly using a pulse duration of 1 ms of stimulation and an interpulse interval of 4.1 ms. Stimulation intensity (current) will be adjusted manually to palpable, but not painful, stimulation. Vaginal and surface abdominal electromyographic monitoring (EMG) will be conducted throughout the treatment session, recording the average pre- and post-treatment values for each session. In subjects whose pelvic floor EMG does not normalize to \<4 millielectronvolts (mV) in a 20-minute session, the subsequent session will be increased to 30 minutes."
62373190|NCT04914468||TMVR|Patients undergoing Transcatheter Mitral Valce Replacement (TMVR)
62373191|NCT04914468||TEER|Patients undergoing mitral Transcatheter Edge-to-Edge Repair (TEER) after screening for TMVR
62373192|NCT04914468||Surgery|Patients undergoing mitral valve surgery (repair or replacement) after screening for TMVR
62373193|NCT04914468||Medical therapy|Patients undergoing medical therapy after screening for TMVR
62373194|NCT04298749|EXPERIMENTAL|GX-P1 dose level 1|GX-P1 dose level 1
62373195|NCT04298749|EXPERIMENTAL|GX-P1 dose level 2|GX-P1 dose level 2
62373196|NCT04298749|EXPERIMENTAL|GX-P1 dose level 3|GX-P1 dose level 3
62373197|NCT05224752||healthcare workers at MRMC|healthcare workers at MRMC
62744925|NCT06452108||Punjab site|Determine community perspective on COVID-19 for identification of relevant, feasible, and effective approaches to promote acceptance, uptake, and adherence of public health measures for COVID-19 prevention and control in Pakistan through generation of high-quality evidence to achieving the goals of the NAP.
62744926|NCT06452108||Sindh site|Determine community perspective on COVID-19 for identification of relevant, feasible, and effective approaches to promote acceptance, uptake, and adherence of public health measures for COVID-19 prevention and control in Pakistan through generation of high-quality evidence to achieving the goals of the NAP.
62744927|NCT06452108||Baluchistan site|Determine community perspective on COVID-19 for identification of relevant, feasible, and effective approaches to promote acceptance, uptake, and adherence of public health measures for COVID-19 prevention and control in Pakistan through generation of high-quality evidence to achieving the goals of the NAP.
62744928|NCT06452108||KPK site|Determine community perspective on COVID-19 for identification of relevant, feasible, and effective approaches to promote acceptance, uptake, and adherence of public health measures for COVID-19 prevention and control in Pakistan through generation of high-quality evidence to achieving the goals of the NAP.
62373198|NCT04819191|EXPERIMENTAL|SHARING Choices|"Components of SHARING Choices include:~A letter from the clinic introducing an initiative to prepare persons and families for Advance Care Planning (ACP); Access to a facilitator trained to lead ACP discussions; Patient-family agenda-setting to align perspectives about the role of family and stimulate discussion about ACP; Facilitated registration to the patient portal (for patient and family) as desired; Education \& resources about Alzheimer's Disease and Related Dementias (ADRD) for clinic staff."
62373199|NCT04819191|NO_INTERVENTION|Usual care|Usual care
62373200|NCT05908929|EXPERIMENTAL|patients treated with SRP and insertion of PRF|
62373201|NCT05908929|ACTIVE_COMPARATOR|patients treated with SRP|
62373202|NCT04724291|OTHER|MAGNET + EGD|Capsule endoscopy followed by traditional endoscopy
62373203|NCT02098928|ACTIVE_COMPARATOR|Hand-acupuncture group|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
62744929|NCT00776672|EXPERIMENTAL|1|fosinopril sodium 40 mg tablets of Ranbaxy
62744930|NCT00776672|ACTIVE_COMPARATOR|2|Monopril® 40mg tablets
62744931|NCT04806776|ACTIVE_COMPARATOR|24hrs dressing change|The first dressing change and sampling were completed 24 hours after catheterization in the operating room or PICU Then the second dressing change and sampling were completed 7days later(if there is no clinical indication occur,such leaking,blood).
62744932|NCT04806776|EXPERIMENTAL|7d change dressing|Dressing change and sampling were completed 7days after catheterization in the operating room or PICU.(if there is no clinical indication occur,such leaking,blood).
62744933|NCT06661486|NO_INTERVENTION|Control group|The control group will not receive any intervention and, is only required to attend 3 timepoints of cognitive assessment: baseline, 12 months and 24 months.
62373204|NCT02098928|PLACEBO_COMPARATOR|Electric-acupuncture group|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
62373205|NCT04285294||RDEB patients with a cSCC|
62373206|NCT04285294||Non-RDEB patients with a SCC induced by ultraviolet radiation|
62373207|NCT04285294||Healthy donors without RDEB nor SCC|
62373208|NCT03864627|PLACEBO_COMPARATOR|Placebo|Participants will receive MOR106 matching placebo via s.c. injection every other week on Day 1, 15, 29 and 43 given concomitantly with a medium potency TCS once daily until Day 57.
62373209|NCT03864627|EXPERIMENTAL|MOR106 320 mg|Participants will receive MOR106 320 milligrams (mg) via s.c. injection every other week on Day 15, 29 and 43 given concomitantly with a medium potency topical TCS once daily until Day 57. A loading dose of MOR106 2 x 320 mg via s.c. injection will be administered on Day 1.
62373210|NCT05232292|ACTIVE_COMPARATOR|Vaccinated|vaccinated ACS \& CHF patients over 65 years
62373211|NCT05232292|NO_INTERVENTION|Not vaccinated|not vaccinated ACS \& CHF patients over 65 years
62373212|NCT00534924|PLACEBO_COMPARATOR|1|No intervention after IR injury
62373213|NCT00534924|EXPERIMENTAL|2|Postconditioning
62373214|NCT00534924|EXPERIMENTAL|3|Vit. C
62744934|NCT06661486|EXPERIMENTAL|Uniformed intervention group|Uniformed intervention groups receive health education sessions in a group setting. Each session is one hour, and lifestyle health-related topics will be delivered to the participants for their knowledge.
61986317|NCT05089682|EXPERIMENTAL|Deep Brain Stimulation (DBS) system|Subjects with existing DBS systems implanted for neurological disease (e.g., Parkinson's, pain, epilepsy) will have targeted stimulation patterns during specific stages of sleep using their existing DBS device.
62373215|NCT03189810|EXPERIMENTAL|Active rTMS (20Hz)|Active rTMS administered with the MagProX100/R30 stimulator equipped with the B65 active coil for dorsolateral prefrontal cortex (DLPFC) stimulator (MagVenture, Farum, Denmark).The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
62373216|NCT03189810|SHAM_COMPARATOR|Sham rTMS|Sham rTMS administered with the MagProX100/R30 stimulator equipped with the B65 placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark). The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
62373217|NCT05013099|EXPERIMENTAL|Subjects with melanoma, Merkel cell, renal cell, or NSCLC|Eligible subjects will receive up to three zirconium Zr 89 crefmirlimab berdoxam PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion or slow bolus injection as follows: First scan within 14 days prior to the onset of IOT, and a second scan 4 to 6 weeks after start of immunotherapy. The second zirconium Zr 89 crefmirlimab berdoxam administration and scan should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third zirconium Zr 89 crefmirlimab berdoxam PET scan at the principal investigator's (PI's) discretion.
62373218|NCT02899104||Radium-223 dichloride|Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC), at least 18 years of age, must have received at least one intravenous injection of Radium-223.
62373219|NCT04583228|EXPERIMENTAL|Sequence 1|Random allocation to HLX71 1 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
62373220|NCT04583228|EXPERIMENTAL|Sequence 2|Random allocation to HLX71 3 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
62744935|NCT06661486|ACTIVE_COMPARATOR|Individualised intervention group|The individualised intervention group receives health education sessions as the uniformed intervention group and receives additional one-on-one health coaching, which besides the group sessions, the participants receive individual sessions every three months.
62744936|NCT00066222|EXPERIMENTAL|Radiation Therapy + Chemotherapy|Accelerated high dose thoracic radiation therapy (RT) with concurrent cisplatin/etoposide chemotherapy, followed by 2 cycles of adjuvant cisplatin/etoposide chemotherapy
62744937|NCT04446624|NO_INTERVENTION|Treatment as usual (TAU)|Patients in the TAU group will receive the treatment routinely offered to patients undergoing RT for breast cancer.
62744938|NCT04446624|EXPERIMENTAL|Music therapy intervention (PSY)|Patients in the PSY group will participate to a short-term group psychotherapy with elements of music therapy; meetings will be 1 / week, for a total of 6 weeks. Beginning of psychotherapy intervention will be 1-2 weeks after recruitment at T0 and will therefore cover the entire duration of the RT cycle.
61986318|NCT01626807|EXPERIMENTAL|Walking school bus|
62744939|NCT01922947|ACTIVE_COMPARATOR|Motivational Interviewing w/Social Network Counseling|Motivational Interviewing integrated with Social Network Counseling, 20-minute session.
62744940|NCT01922947|SHAM_COMPARATOR|Health Counseling|
62744941|NCT03365258|OTHER|High Nutritional Risk|modified NUTRIC score ≥ 5
62744942|NCT03365258|OTHER|Low Nutritional Risk|modified NUTRIC score \< 5
62744943|NCT03228459|EXPERIMENTAL|Mobile Unit Follow-up Group|In the Mobile Unit (MU), clinical, sociodemographic and anthropometric data will be recorded. Patients will be evaluated with artery ultrasound (carotid, femoral, transcranial and abdominal aorta), ankle-brachial index, pulse wave velocity, spirometry, determination of advanced glycation-end products, atrial fibrillation screening, dried blood spot test and urine analysis. Moreover, DNA, RNA, Saliva, blood and urine samples will be collected and stored in the biobank to identify new biomarkers using omic studies. Additionally, climate, air pollutant and airborne pollen data form the entire province of Lleida will be registered. Finally, a report with the exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
62744944|NCT03228459|NO_INTERVENTION|Electronic Medical History Follow-up Group|Participants will be followed through their electronic medical records. Sociodemographic (age, sex, race, marital status, education and labour status), clinical and anthropometric data and will be electronically collected.
62744945|NCT06411769|EXPERIMENTAL|Phase 1. 50K4LIfe Only|Walking Challenge only
62744946|NCT06411769|EXPERIMENTAL|Phase 1. 50K4Life + SMS Text Messages|Walking Challenge + SMS Messages
62744947|NCT06411769|EXPERIMENTAL|Phase 2. 50K4LIfe + Individual|Walking Challenge + Individual level interventions.
62373221|NCT04583228|EXPERIMENTAL|Sequence 3|Random allocation to HLX71 10 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
62744948|NCT06411769|EXPERIMENTAL|Phase 2. 50K4LIfe + School|Walking Challenge + School-level interventions
62744949|NCT06411769|EXPERIMENTAL|Phase 2. 50K4Life + SMS Text Messages + Individual|Walking Challenge + SMS Messages + Individual level interventions
62744950|NCT06411769|EXPERIMENTAL|Phase 2. 50K4Life + SMS Text Messages + Schools|Walking Challenge + SMS Messages + School-level interventions
62744951|NCT06411769|EXPERIMENTAL|Phase 2. Walking Challenge only|Participants meeting the step goal in Phase 1(WC only) will continue into Phase 2 without change.
62744952|NCT06411769|EXPERIMENTAL|Phase 2. Walking Challenge + SMS Text Messages|Participants meeting their step goal in Phase 1 (WC + SMS Text Messages) will continue into Phase 2 without change.
62373222|NCT04583228|EXPERIMENTAL|Sequence 4|Random allocation to HLX71 15 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
62373223|NCT05399589|EXPERIMENTAL|on1 abutment|The on1 abutment was directly used in the operation to protect the soft tissue mucosa. After three months, the mold was taken directly for formal teeth.
62373224|NCT05399589|ACTIVE_COMPARATOR|healing cap|After the operation, the embedded healing is selected. After waiting for three months, the second stage operation is needed to expose the healing cap
62373225|NCT02114398|EXPERIMENTAL|usual treatment|usual treatment
62373226|NCT02114398|EXPERIMENTAL|usual treatment + sophrology|usual treatment + sophrology
62373227|NCT02257060|EXPERIMENTAL|Endocardial Ablation|
62373228|NCT05799911|EXPERIMENTAL|Molecular hydrogen|Hydrogen-rich water supplied in 420-ml packages. 3 days before testing day - 3 packages per day, testing day - 6 packages, 15 packages in total.
62373229|NCT05799911|PLACEBO_COMPARATOR|Placebo|Tap water supplied in 420-ml packages. 3 days before testing day - 3 packages per day, testing day - 6 packages, 15 packages in total.
62373230|NCT06259604|EXPERIMENTAL|PIOMI|Babies in this group will be administered PIOMI once a day, 30-45 minutes before feeding, for 14 days. When the intervention ends, the baby's feeding will be carried out by the researcher neonatal nurse in a semi-elevated side position, taking into account cue-based feeding symptoms, and the transition to full oral feeding will be evaluated by two researchers. These babies will be evaluated with the Early Feeding Skills Assessment Tool for early feeding skills before any intervention is applied (day 0) and on the 14th day of the PIOMI intervention. In addition, the weight of the babies will be monitored every morning for 14 days, on an empty stomach and naked, and will be recorded in the Nutrition Tracking Chart. The time it takes for babies to transition to full oral feeding will be evaluated according to cue-based feeding and recorded in the Feeding Follow-Up Chart.
62373231|NCT06259604|EXPERIMENTAL|PIOMI+kangaroo care|Babies in this group will start using PIOMI once a day, 30-45 minutes before feeding, and kangaroo care for at least 30 minutes during the last 2 minutes of non-nutritive sucking phase of PIOMI, for 14 days. When the intervention ends, the baby's feeding will be carried out by the researcher neonatal nurse in a semi-elevated side position, taking into account cue-based feeding symptoms, and the transition to full oral feeding will be evaluated by two researchers. These babies will be evaluated with the Early Feeding Skills Assessment Tool before any intervention is applied (day 0) and on the 14th day of PIOMI+kangaroo care in terms of early feeding skills. In addition, the weight of the babies will be monitored every morning for 14 days, on an empty stomach and naked, and will be recorded in the Nutrition Tracking Chart. The time it takes for babies to transition to full oral feeding will be evaluated according to cue-based feeding and recorded in the Feeding Follow-Up Chart.
61986319|NCT01626807|NO_INTERVENTION|Usual care|
61986320|NCT02232542|EXPERIMENTAL|Duloxetine - low dose|
62567199|NCT04628247|EXPERIMENTAL|Study group|They will receive the same traditional physical therapy exercise program in addition to gait training on spring gravity bar for one hour
62744953|NCT01180036|ACTIVE_COMPARATOR|Rituximab Treatment Arm|Patients randomized to the RTX arm will receive 1000 mg IV on Days 1 and 15. Patients who achieve complete remission at 6 months will not be retreated. A second course of RTX 1000 mg IV will be administered at study month 6 for individuals who have not achieved a complete remission, but have achieved a minimum of \>25% reduction in Time 0 proteinuria. Dosing at study month 6 will be independent of cluster of differentiation (CD) 19+ B cell count.
61986321|NCT02232542|EXPERIMENTAL|Duloxetine - high dose|
61986322|NCT02232542|PLACEBO_COMPARATOR|Placebo|
62373232|NCT06259604|NO_INTERVENTION|Control|Babies in this group will receive standard care in the clinic. They will be evaluated with the Early Nutrition Skills Assessment Tool in terms of early feeding skills on the day they are included in the study (day 0) and on the 14th day. In addition, the weight of the babies will be monitored every morning for 14 days, on an empty stomach and naked, and will be recorded in the Nutrition Tracking Chart. The time it takes for babies to transition to full oral feeding will be evaluated according to cue-based feeding and recorded in the Feeding Follow-Up Chart. All measurements will be carried out and evaluated separately by two independent researchers. During discharge, discharge time, discharge weight and postmenstrual week at discharge will be recorded in the Baby Information Form.
62373233|NCT01080625|EXPERIMENTAL|phenylephrine|100 mcg of phenylephrine is administered at the time of reperfusion
62373234|NCT01080625|EXPERIMENTAL|epinephrine|10 mcg of epinephrine is administered iv at the time of reperfusion
62373235|NCT01080625|PLACEBO_COMPARATOR|control|10 ml of normal saline is administered at the time of reperfusion
62373236|NCT04282369|ACTIVE_COMPARATOR|HHFNC|In this group patients will receive respiratory support by high flow nasal cannula.
62373237|NCT04282369|ACTIVE_COMPARATOR|nCPAP|In this group patients will receive respiratory support by nasal CPAP.
62744954|NCT01180036|ACTIVE_COMPARATOR|Cyclosporine Treatment Arm|Patients randomized to the Cyclosporine arm will be started at a dose of CsA = 3.5 mg/kg/day p.o. divided into 2 equal doses given at 12 hour intervals. Target trough CsA blood levels are 125 to 175 ng/ml. Patients will have their doses adjusted according to their blood levels of CSA as monitored every 2 weeks until the target trough level is reached. If a complete remission is achieved by 6 months, CSA will be tapered and discontinued over a three-month period. If after 6 months there has not been a reduction in proteinuria of at least 25% of baseline values, the drug will also be discontinued. If there has been a \>25% reduction in baseline proteinuria (but not complete remission) the CSA will be continued for an additional 6 months.
62373238|NCT04282369|ACTIVE_COMPARATOR|nIPPV|In this group patients will receive respiratory support by nasal IPPV.
62373239|NCT04282369|ACTIVE_COMPARATOR|nHFO|In this group patients will receive respiratory support by nasal high frequency oscillatory. ventilation.
62373240|NCT00596895|EXPERIMENTAL|1|Isoflavone treatment
62744955|NCT06510777|EXPERIMENTAL|PICO Treatment Arm|"The maximum duration for treatment with PICO will be 12 weeks.~PICO treatment will be discontinued if the wound does not respond to treatment after 2 weeks according to predefined criteria, if the wound gets worse at any time, if the wound is 100% epithelialized, or if the wound presents advanced healing, which will be assessed using predefined criteria. In the latter case where the VLU is determined sufficiently healed according to the pre-specified criteria in the protocol, subjects will be switched to Standard of Care (SOC).~Wound care treatment at home will be done by home care nurses. Compression therapy will be maintained throughout the entire patient's follow-up."
62744956|NCT06510777|ACTIVE_COMPARATOR|Standard of Care Treatment Arm|Wounds are treated with appropriate traditional dressings throughout the study based on wound condition and healing trajectory. Wound care treatment at home will be done by home care nurses. Compression therapy will be maintained throughout the entire patient's follow-up.
62373241|NCT01776372|ACTIVE_COMPARATOR|Digital thoracic drainage system|Medela Thopaz Thoracic Drainage System
62373242|NCT01776372|ACTIVE_COMPARATOR|Non-digital thoracic drainage system|Atrium Express Dry Seal Chest Drain
62373243|NCT06432491|EXPERIMENTAL|4℃ water drinking group|Volunteers will drink 500ml 4℃ water within 10 minutes at 9a.m., 12p.m., 15p.m., 18p.m. everyday for 6 months.
62373244|NCT06432491|NO_INTERVENTION|37℃ water drinking group|Volunteers will drink 500ml 37℃ water within 10 minutes at 9a.m., 12p.m., 15p.m., 18p.m. everyday for 6 months.
62373245|NCT01654328|EXPERIMENTAL|Arm A: sodium chloride tablets|Arm A: sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
62373246|NCT01654328|ACTIVE_COMPARATOR|B: isotonic saline intravenously|Sodium chloride solution (isotonic saline (NaCl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
62744957|NCT05396222|EXPERIMENTAL|3D-printed|We developed a 3D printed, custom-made, biomimetic prosthesis, with non-rigid structure, which has been tested in biomechanical study and porcine model, showing good bone formation and less stiffness as well. Therefore, we proposed a prospective clinical study to investigate safety, subsidence, and fusion of this prosthesis.
62744958|NCT05963204|ACTIVE_COMPARATOR|Biostimulator and Facial Moisturizer A|"Biostimulator is sterile dry powder poly L-lactic acid with sodium carboxymethylcellulose, non-pyrogenic mannitol. Mode of administration: injection. Dosage: at investigator's discretion for optimal outcome. Frequency and duration: injection at baseline and at week 6.~Facial Moisturizer A is a cream with active TriHex technology. Mode of administration: topical application. Frequency and duration: twice daily on half of the face for the entire study."
62373247|NCT06015191|EXPERIMENTAL|Remote Cardiac Rehabilitation|Following a 2-week ramp-up period, participants will attend group exercise sessions, remotely delivered in their homes, 3 days per week for 45-minutes over 12-weeks led by a live-interactive health coach. There are 4 exercise session types with different modalities: Session A: 75% aerobic, 25% resistance; Session B: 25% aerobic, 75% resistance; Session C: 50% aerobic, 50% resistance; and Session D: Exercise games (mix of modalities). Each participant will rotate through a 5-week set of exercise sessions (20 sessions) twice over the 10-weeks of group exercise period.
62373248|NCT06015191|ACTIVE_COMPARATOR|Active Control|Participants will receive a handout describing physical activities appropriate for their congenital heart disease diagnosis and providing recommendations consistent with the physical activity recommendations for children and adolescents.
62373249|NCT02729402|EXPERIMENTAL|Older Cochlear Implant Subjects|We will assign the study participants to a diagnostic intervention (cognitive testing) before and after their cochlear implant.
62373250|NCT03377829|EXPERIMENTAL|Percutaneous laser ablation(PLA)|Eligible participants with PTMC will be randomly assigned to this group and undergo percutaneous laser ablation(PLA). All the process is under the detection of real-time ultrasound.After surgery, all the patients will accept contrast-enhanced ultrasound(CEUS), regular ultrasound follow-up, thyroid functional detection, fine-needle aspiration biopsy(FNAB), neck CT.Per and post-operative complications, need of drug treatment, length of hospital admission and customer satisfaction will be registered.
62373251|NCT03377829|ACTIVE_COMPARATOR|Surgery|Eligible participants with PTMC will be randomly assigned to this group and undergo total/subtotal thyroid surgery.
62373252|NCT02418728||persons with obesity|
62373253|NCT02418728||lean persons|
62373254|NCT00044694|PLACEBO_COMPARATOR|Placebo 0.01 mL|2 week placebo lead-in followed by Placebo 0.01 mL
62373255|NCT00044694|PLACEBO_COMPARATOR|Placebo 0.02 mL|2 week placebo lead-in followed by Placebo 0.02 mL
62373256|NCT00044694|PLACEBO_COMPARATOR|Placebo 0.03 mL|2 week placebo lead-in followed by Placebo 0.03 mL
62373257|NCT00044694|PLACEBO_COMPARATOR|Placebo 0.04 mL|2 week placebo lead-in followed by Placebo 0.04 mL
62373258|NCT00044694|EXPERIMENTAL|AC2993 2.5 mcg|2 week placebo lead-in (0.01 mL) followed by AC2993 2.5 mcg; 0.01 mL
62373259|NCT00044694|EXPERIMENTAL|AC2993 5.0 mcg|2 week placebo lead-in followed by AC2993 5.0 mcg; 0.01 mL
62373260|NCT00044694|EXPERIMENTAL|AC2993 7.5 mcg|2 week placebo lead-in followed by AC2993 7.5 mcg; 0.03 mL
62744959|NCT05963204|ACTIVE_COMPARATOR|Biostimulator and Facial Moisturizer B|"Biostimulator is sterile dry powder poly L-lactic acid with sodium carboxymethylcellulose, non-pyrogenic mannitol. Mode of administration: injection. Dosage: at investigator's discretion for optimal outcome. Frequency and duration: injection at baseline and at week 6.~Facial Moisturizer B is a neutral, oil-free moisturizing lotion. Mode of administration: topical application. Frequency and duration: twice daily on half of the face for the entire study."
62744960|NCT01099098||Patients with TB sequelae|
62373261|NCT00044694|EXPERIMENTAL|AC2993 10.0 mcg|2 week placebo lead-in period followed by AC2993 10.0 mcg; 0.04 mL
62373262|NCT06198218|EXPERIMENTAL|Scapular mobilization|This Experimental group will be treated with manual scapular mobilization in upward rotation and downward rotation, adduction and abduction of scapula. Sets of 10 repetitions were applied with a rest interval of 30 seconds between set for 20 minutes, activity based scapular mobilization(Codman pendulum exercises, scapular pushups, band wall apart ,wall ball circles and advance study wall pushups) along with conventional physical therapy program(heating,EMS,stretching for tight muscles , strengthening exercises and graduated active exercises) for 25 minutes
62373263|NCT06198218|ACTIVE_COMPARATOR|Conventional physical therapy program|This group will receive conventional physical therapy program including ( heating to improve circulation and release muscle tension ,EMS ,stretching for stiff muscle, weight bearing, strengthening exercises and graduated active exercises)for 20 minutes along with activity based scapular mobilization( Codman pendulum exercises, ban wall apart, wall ball circles, scapular pushups and advance study wall pushups)for 20 minutes with 5 minute resting interval.
62373264|NCT02096471|EXPERIMENTAL|Agent PD-0325901|The primary aim of the study will be to assess quantitative radiographic response in a target lesion. Subjects will receive PD-0325901 by mouth on a bid dosing schedule of 2 mg/m2/dose with a maximum dose of 4 mg bid. Each course is 4 weeks duration, and subjects will receive drug on a 3 week on/1 week off schedule. Subjects may receive additional courses beyond course 8 only if there is at least 15% reduction in volume of the target tumor. Subjects who have a 20% or greater reduction in target tumor volume at the end of 12 courses can continue on therapy for up to an additional year (maximum of 24 total courses). However, subjects who do not achieve at least 15% reduction in volume of the target tumor after 8 courses (\~8 months) will be considered treatment failures and taken off study.
62373265|NCT00747708|EXPERIMENTAL|Peripheral|Patients are randomised in a 1:1 ratio to receive granulocyte-colony stimulating factor (G-CSF) or placebo injection
62744961|NCT01099098||People without TB sequelae|
62744962|NCT02973204||HCC sorafenib|HCC patients referred for Sorafenib treatment
62744963|NCT02973204||HCC curative treatment|HCC patient undergoing potential curative treatment, eg. radiofrequency ablation (RFA) or resection
62744964|NCT02973204||NET everolimus|Pancreatic NET patients referred for Everolimus treatment
62744965|NCT02973204||NET ssta|Small intestinal or unknown primary NET patients referred for treatment with somatostatin analogues, eg. lanreotide and octreotide
62744966|NCT03031626|EXPERIMENTAL|Arm A: Medical air followed by oxygen|
62744967|NCT03031626|EXPERIMENTAL|Arm B: Oxygen followed by medical air|
62744968|NCT01979666|EXPERIMENTAL|study group|the patients that will get a nitrate patch
62373266|NCT00747708|EXPERIMENTAL|Percutaneous intracoronary injection|All patients will receive granulocyte-colony stimulating factor injections followed by a bone marrow aspiration. Patients will be randomised in a 1:1 ratio to receive intracoronary injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
62373267|NCT00747708|EXPERIMENTAL|Percutaneous intramyocardial injection|All patients will receive granulocyte-colony stimulating factor injections followed by a bone marrow aspiration. Patients will be randomised in a 1:1 ratio to receive intramyocardial injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
62744969|NCT01979666|PLACEBO_COMPARATOR|control group|the patients that will get the placebo patch
62744970|NCT03192280|EXPERIMENTAL|All study participants|"Each subject will receive single topical induction application of Leukotriene B4 (LTB4) on the inner arm.~Images of the treated area will be captured using multiple medical devices."
62744971|NCT06017609|EXPERIMENTAL|JTT-861 Dose 1|JTT-861 Capsules Dose 1 orally once daily for 12 weeks
62744972|NCT06017609|EXPERIMENTAL|JTT-861 Dose 2|JTT-861 Capsules Dose 2 orally once daily for 12 weeks
62744973|NCT06017609|EXPERIMENTAL|Placebo|Placebo Capsules orally once daily for 12 weeks
62744974|NCT05859412|EXPERIMENTAL|Neurodynamic exercises|6-weeks home exercise programme of nerve and tendon gliding exercises
62744975|NCT05859412|ACTIVE_COMPARATOR|Steroid injection Steroid injection (Depomedrone 40mg)|Single steroid injection into Carpal Tunnel (positive control group)
62744976|NCT05859412|OTHER|Advice|The advice group will receive advice but no additional intervention during the 6 week intervention period (negative control group)
62744977|NCT03063723||CHC patients|15 treatment-naive CHC patients treated by Ledipasvir-Sofosbuvir orDaclatasvir-Sofosbuvir.
62744978|NCT03063723||Healthy controls|10 Healthy controls without any treatment
62744979|NCT00634725|ACTIVE_COMPARATOR|Arm 1 (A1) - Gemcitabine|Gemcitabine 2 months, then stop until progression
62744980|NCT00634725|EXPERIMENTAL|Arm 2 (B1) Gemcitabine + Erlotinib|B1 Gemcitabine + Erlotinib (100mg/d) 2 months, then erlotinib maintenance (150 mg/d)until progression
62744981|NCT00634725|EXPERIMENTAL|Arm 3 (A2) CRT|A2 CRT then stop until progression
62373268|NCT01875068|EXPERIMENTAL|NPs & PAs referral discussions with a supervising physician|required consultations between NPs and PAs and their supervising physicians
62744982|NCT00634725|EXPERIMENTAL|Arm 4 (B2) CRT then erlotinib|B2 CRT then erlotinib maintenance (150mg/d) until progression
62744983|NCT06474520|EXPERIMENTAL|CBS therapy, CBS dosage: 100mg per day from day 1 to day 84, in IIDD cohort|Subjects in IIDD cohort of this arm will receive general therapy plus CBS.
62744984|NCT06474520|NO_INTERVENTION|Control therapy: no intervention, in IIDD cohort.|Subjects in IIDD cohort of this arm will only receive general therapy.
62744985|NCT06474520|EXPERIMENTAL|CBS therapy, CBS dosage: 100mg per day from day 1 to day 84, in healthy cohort|Subjects in healthy cohort of this arm will only receive CBS.
62744986|NCT00851981|PLACEBO_COMPARATOR|1|
62373269|NCT01875068|OTHER|NPs and PAs - no consultations with supervising physisians|NPs and PAs who are not required to discuss patient referrals
62373270|NCT02904135||first stage|During the first stage, the patient's baseline blood sample will be mainly used for validating and troubleshooting our instrument with clinical samples.
62373271|NCT02904135||second stage|During the second stage, 40 patients will be followed for up to three years after their baseline blood draw to obtain data on their survival status. The CTC results and follow-up data obtained from these samples will help to analyze any correlation with the patient's clinical outcome and further validate the prognosis ability of MiCareo's CTC platform for mBC patients.
62373272|NCT01963962||Copper IUD|Women selecting the copper IUD for emergency contraception and to use for contraception after
62373273|NCT01963962||Levonorgestrel IUD|Women who select oral levonorgestrel for emergency contraception and begin the levonorgestrel IUD for ongoing contraception at the same time.
62373274|NCT01759693||Skin disease|Patients with urticaria or atopic dermatitis
62373275|NCT01759693||Control|Healthy volunteers
62373276|NCT04917731|EXPERIMENTAL|Botox|The patients in this arm will receive Botox injection to the digital arteries of all affected digits.
62373277|NCT04917731|PLACEBO_COMPARATOR|Placebo|The patients in this arm will receive placebo injection of saline to the digital arteries of all affected digits.
62373278|NCT00578890|EXPERIMENTAL|1|
62373279|NCT01216215||Asthmatic sporadic and familial|
62373280|NCT01216215||Control subjects spradic and familial|
62373281|NCT03105375|EXPERIMENTAL|Single ascending dose of X842|Single ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
62373282|NCT03105375|EXPERIMENTAL|Multiple ascending dose of X842|Multiple ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
62373283|NCT03105375|ACTIVE_COMPARATOR|Losec|Standard oral dose of omeprazole administered to subjects in one cohort.
62373284|NCT06041191||Children with GJH|Children who scored above 4 points in the hypermobility assessment made with the Beighton score were included in this group. sensory processing skills assessed with the Test of Sensory Functions in Infants
62373285|NCT06041191||Children without GJH|Children who scored below 4 points in the hypermobility assessment made with the Beighton score were included in this group. sensory processing skills assessed with the Test of Sensory Functions in Infants
62373286|NCT03821350|NO_INTERVENTION|Control Group|The control group was given verbal information
62373287|NCT03821350|EXPERIMENTAL|Leaflet Group|The second group was given verbal information and a detailed information leaflet with written and visual content
62373288|NCT03593564|EXPERIMENTAL|KINDER Participant|The intervention will be provided with a 8-part psychoeducational intervention delivered online on a weekly basis. Online modules will be comprised of a short (approximately 3 minute) videos followed by more specific text-based information and links to additional resources. At the end of the module, participants will complete a short quiz, followed by a reflection exercise to reinforce learning. Each model, participants will be asked to select a goal to complete a pleasurable activity and receive an option to set a text or email reminder to do so.
62373289|NCT04179760|EXPERIMENTAL|SCM-AGH|"* Ingredient: Allogeneic human bone marrow-derived mesenchymal stem cells~* Dose: 1x10\^6 cells/Kg"
62373290|NCT04179760|PLACEBO_COMPARATOR|Placebo|3 times with 2-week intervals by IV infusion.
62373291|NCT06168981|EXPERIMENTAL|Chewing Gum|Before the surgery, the patient will chew gum for 2 minutes and routine nursing care will be applied. Anxiety level will be evaluated before and after chewing gum.
62373292|NCT06168981|NO_INTERVENTION|Control Group|Anxiety level will be evaluated before and after routine nursing care.
62373293|NCT04168151|EXPERIMENTAL|hypoxic group|hypoxic patients (hypoxic index less than 250)
62373294|NCT05155839|EXPERIMENTAL|MRG001|All patients in Phase Ia (dose escalation) and Phase Ib (dose expansion) will be administrated MRG001 on Day 1 of every 3 weeks (21-day cycle).
62373295|NCT05974891|EXPERIMENTAL|Experimental: Simulated group|"Pilot application will be carried out with at least 10 students. A pre-test will be applied to the experimental group. After the scales are applied, the experiment will be applied to the experimental group with the Geriatric Medication Game simulation.~Students simulating the elderly patient role during this simulation will gain a better understanding of age-related health problems and how older adults feel when confronting them. After the application, debriefing, which is the last stage of the simulation training, will be done to evaluate the application. After the application and analysis session is completed, the post-test will be applied to the experimental group. A 3-week clinical practice will be planned for the students in the experimental groups in order to evaluate the continuation of the acquired skills and acquired awareness. In this application, students will be asked to care for the elderly patient and the pre-test will be repeated at the end of the application."
62373296|NCT05974891|NO_INTERVENTION|No Intervention: Control group|The control group will be pre-tested. After the scales are applied, no intervention will be made to the control group. A 3-week clinical practice will be planned for the students in the control group. In this application, students in the control group will be asked to care for the elderly patient and the scales will be repeated at the end of the application.
62744987|NCT00851981|ACTIVE_COMPARATOR|SAMe|
62744988|NCT02141399|EXPERIMENTAL|ALKS 5461|
62744989|NCT02603458|PLACEBO_COMPARATOR|Placebo|Group of enrolled subjects receiving two infusions of intravenous placebo (5% glucose solution)
62744990|NCT02603458|EXPERIMENTAL|NRX-1074 Dose Group|Group of enrolled subjects receiving two infusions of intravenous NRX-1074 (10 mg)
62744991|NCT06249048|EXPERIMENTAL|Phase 1 Monotherapy (STX-001)|A Phase 1, first-in-human (FIH), multiple ascending STX-001 dose administration to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity in patients with advanced cancers. Consists of 4 planned dose escalation cohorts (Cohorts 1m) of STX-001 with new patients enrolled in each dose escalation cohort.
62744992|NCT06249048|EXPERIMENTAL|Phase 1 Combination (STX-001 with Pembrolizumab)|A Phase 1, first-in-human (FIH), multiple ascending STX-001 dose administration, in combination with pembrolizumab, to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity in patients with advanced cancers. Consists of 4 planned dose escalation cohorts (Cohorts 1c) of STX-001 with new patients enrolled in each dose escalation cohort.
62744993|NCT06249048|EXPERIMENTAL|Phase 2 Combination (STX-001 with Pembrolizumab)|Phase 2 consists of dose expansion cohorts in patients with 2 defined cancer types: triple negative breast cancer (TNBC) and melanoma. Phase 2 will evaluate STX-001 in combination with pembrolizumab; the recommended Phase 2 dose (RP2D) of STX-001 will be selected based on analysis of the totality of data from Phase 1.
62744994|NCT03689491|EXPERIMENTAL|rTMS+visual feedback|10-minute rTMS and then a 30-minute visual feedback training ,3 times a week, for 4 weeks
62373297|NCT03424213||white low aggressive|low aggressive = Gleason score \< 7 and stage cT1-cT2 and PSA \< 10 ng/ml
62373298|NCT03424213||white high aggressive|high aggressive = Gleason score ≥ 8 or PSA \> 20 ng/ml or Gleason score = 7 and stage cT3-cT4
62373299|NCT03424213||white intermediate aggressive|intermediate aggressive = all other cases
62373300|NCT03424213||AA low aggressive|low aggressive = Gleason score \< 7 and stage cT1-cT2 and PSA \< 10 ng/ml
62373301|NCT03424213||AA high aggressive|high aggressive = Gleason score ≥ 8 or PSA \> 20 ng/ml or Gleason score = 7 and stage cT3-cT4
62373302|NCT03424213||AA intermediate aggressive|intermediate aggressive = all other cases
62373303|NCT03017833|EXPERIMENTAL|Treatment (metformin, sapanisertib)|Patients receive metformin PO 1-3 times daily on days 1-42 and sapanisertib PO daily on days 15-42 of cycle 1. Patients then receive metformin PO daily and sapanisertib PO daily on days 1-28 of cycle 2 and beyond. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62373304|NCT03894267|EXPERIMENTAL|Experimental Arm|"Self-adhesive silicone bordered foam dressing will be secured to the heels and sacrum.~Daily SEM reading, visual skin assessment. Early Sense placed under study subject's mattress.~Follow up 20 days"
62373305|NCT03894267|NO_INTERVENTION|Control Arm|"Daily SEM reading, visual skin assessment. Early Sense placed under study subject's mattress.~Follow up for 20 days."
62373306|NCT01358006|EXPERIMENTAL|001|JNJ-40411813 Cohort 1: Type=2 to 3 unit=mg number=200 to 300 form=capsule route=oral use.Capsule(s) taken in the fed state Capsule(s) taken in the fed state.,JNJ-40411813 Cohort 2: Type=up to 7 unit=mg number=up to 700 mg form=capsule route=oral use. Capsule(s) taken in the fed state.
62373307|NCT01832389|ACTIVE_COMPARATOR|Group P|PiCCO-controlled group
62373308|NCT01832389|NO_INTERVENTION|Group C|control group
62373309|NCT03236506|EXPERIMENTAL|Daily observed therapy|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a daily, observed basis by either the nurse or a community pharmacist.
62373310|NCT03236506|ACTIVE_COMPARATOR|Fortnightly pick-up|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse.
62373311|NCT03236506|ACTIVE_COMPARATOR|Fortnightly pick-up +psych intervention|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse. In addition, this group will receive a one-off interview with the researcher to complete a psychological intervention designed to improve adherence to the medication regimen.
62744995|NCT03689491|ACTIVE_COMPARATOR|sham rTMS+visual feedback|10-minute sham rTMS and then a 30-minute visual feedback training ,3 times a week, for 4 weeks
62744996|NCT03689491|ACTIVE_COMPARATOR|sham rTMS+traditional training|10-minute sham rTMS and then a 30-minute traditional rehabilitation training,3 times a week, for 4 weeks
62744997|NCT05988528|ACTIVE_COMPARATOR|control group|Control group (Mesalamine group, n =30 ) who will receive 1 g mesalamine three times daily for 6 months
62744998|NCT05988528|ACTIVE_COMPARATOR|Nifuroxazide group|Patients will receive 1 g mesalamine three times daily plus Nifuroxazide 200 mg two times daily for 6 months
62373312|NCT03880123|EXPERIMENTAL|Selinexor/Ixazomib|Patients will receive combination treatment with selinexor and ixazomib. The dose of ixazomib is fixed at 4 mg, whereas several different dose levels of selinexor may be evaluated. No patients will receive a placebo.
62373313|NCT04941976|EXPERIMENTAL|0.3% benzydamine hydrochloride spray oromucosal solution|A single application of 0.3% benzydamine hydrochloride spray oromucosal solution, corresponding to 2.04 mg of benzydamine (4 nebulizations)
62373314|NCT04941976|ACTIVE_COMPARATOR|3 mg lozenge of benzydamine hydrochloride (mint flavour), corresponding to 2.68 mg of benzydamine|A single 3 mg lozenge of benzydamine hydrochloride (mint flavour), corresponding to 2.68 mg of benzydamine.
62373315|NCT01221168||Men with or without Prostate Cancer|"Men with a histological confirmed prostate cancer, and their family members in case of hereditary prostate cancer.~Men with no prostate cancer after a screening procedure for this disease, so that their biological samples can be compared to those of men with prostate cancer."
62373316|NCT03655418|EXPERIMENTAL|Intervention|The prevention program RECUR will be administered.
61986323|NCT00149487|EXPERIMENTAL|Experimental: Tailored Problem Solving Intervention|Participants will be randomized to follow a tailored problem solving intervention for the child.
62744999|NCT04594902|EXPERIMENTAL|Infant Behavior Program (IBP)|Infant Behavior Program (IBP) is a home-based adaptation of the Child-Directed Interaction (CDI) phase of Parent-Child Interaction Therapy (PCIT), an evidence-based intervention for early externalizing problems. Consistent with recommendations we maintained core features of CDI and addressed the unique developmental needs of infants. All IBP sessions will completed remotely.
62745000|NCT04594902|ACTIVE_COMPARATOR|Enhanced Pediatric Primary Care (EPPC)|Families in EPPC will receive six one-hour home visits where they will receive information about normative developmental and health expectations for their infant. Specifically, therapists will provide education on six topics: (1) cognitive and emotional development; (2) language and social development; (3) safety; (4) feeding and nutrition; (5) sleep; and (6) fitness and activity. All EPPC sessions will completed remotely.
62745001|NCT04600505|EXPERIMENTAL|Treatment Sequence ABC|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment A; Treatment B; Treatment C) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
62745002|NCT04600505|EXPERIMENTAL|Treatment Sequence BCA|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment B; Treatment C; Treatment A) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
62745003|NCT04600505|EXPERIMENTAL|Treatment Sequence CAB|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment C; Treatment A; Treatment B) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
62373317|NCT03655418|NO_INTERVENTION|Waitlist control|The prevention program RECUR will be administered after a year of waiting.
62373318|NCT02072733|OTHER|geriatric assessment|"The intervention is individual and based on the Comprehensive Geriatric assessment (CGA) : collection of information on comorbidity, polypharmacy, physical, psychological and cognitive functions, nutrition as well as social status and support.~The results of the CGA, the eventual medical changes and recommendations regarding e.g. initiation of nutritional supplementation, home-care referral or referral to e.g. physiotherapist will be forwarded to the general practitioner and to the oncologist in charge of the treatment"
62373319|NCT00149110|EXPERIMENTAL|A|Sleep deprivation in combination with light and duloxetine
61986324|NCT00149487|ACTIVE_COMPARATOR|Control: Family Education Intervention|Participants will be randomized to follow a family education intervention.
61986325|NCT04851678||Individuals with Tourette syndrome (TS)|Individuals previously diagnosed with Tourette syndrome (TS). Participants must be 18 years of age or older.
62373320|NCT00149110|ACTIVE_COMPARATOR|B|Exercise and duloxetine
62373321|NCT05909462|EXPERIMENTAL|suprascapular verve block|2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine
62373322|NCT05909462|EXPERIMENTAL|intraarticular shoulder injection|2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine
62373323|NCT04246268|EXPERIMENTAL|Treatment Group|"Device: INVOcell Intravaginal Culture System~Intervention: During an IVF/IVC cycle, participants will retain the INVOcell Culture Device with the Retention Device in the vaginal cavity for 5-days vaginal incubation."
62373324|NCT01430949|EXPERIMENTAL|Over-the-Wire Mesh Ablation System|
62373325|NCT03432936|EXPERIMENTAL|MRI guided procedure software evaluation|Evaluate the workflow and effectiveness of the Philips Interventional iSuite software during biopsies and/or ablations versus standard MR imaging in aiding needle placement.
62373326|NCT04063397||Preeclampsia|40 patients diagnosed with preeclampsia with or without severe features
62373327|NCT04063397||Control|20 Control group of patients without hypertensive disorders of pregnancy
62373328|NCT02717676|EXPERIMENTAL|Group A|Episiotomy
62373329|NCT02717676|NO_INTERVENTION|Group B|no episiotomy
61986326|NCT00704535||Subjects with hypercholesterolemia|Subjects with hypercholesterolemia that are using Ezetimibe either alone or in combination with a statin
62373330|NCT00410514|PLACEBO_COMPARATOR|Placebo|Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.
62373331|NCT00410514|EXPERIMENTAL|Mirabegron 50 mg|Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.
62373332|NCT00410514|EXPERIMENTAL|Mirabegron 100 mg|Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.
62373333|NCT05057468|EXPERIMENTAL|Cyclosporine|2.5-5mg/kg of cyclosporine daily for 3 months
62373334|NCT05057468|ACTIVE_COMPARATOR|Rituximab|375 mg/ m2 weekly dose for a maximum of 4 weeks.
62373335|NCT05957328|ACTIVE_COMPARATOR|liposomal iron group|The group would be given liposomal iron syrup at a dose of 1mg per kg per day once a day for 3 months
62373336|NCT05957328|ACTIVE_COMPARATOR|ferrous ascorbate group|The group would be given ferrous ascorbate syrup at a dose of 3mg per kg per day once a day for 3 months
62373337|NCT04892394|EXPERIMENTAL|Video Group|Detailed visual video information was given to the video group patients before endodontic treatment by the clinician.
62373338|NCT04892394|EXPERIMENTAL|Control Group|Basic verbal information was given to the control group patients before endodontic treatment by the clinician.
62373339|NCT00364832|EXPERIMENTAL|Cohort A (0.4/150, 1x/ Week)|Eligible participant will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta \[Mircera\]) SC using a dose conversion factor of 0.4/150 microgram (mcg)/ kilogram (kg) of the previous weekly erythropoiesis stimulating agents (ESA) dose, (equal to 50% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
62373340|NCT00364832|EXPERIMENTAL|Cohort B (0.4/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.4/150 mcg/kg of the previous weekly ESA dose, (equal to 50% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
62373341|NCT00364832|EXPERIMENTAL|Cohort C (0.4/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.4/150 mcg/kg of the previous weekly ESA dose, (equal to 50% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
62745004|NCT04600505|EXPERIMENTAL|Treatment Sequence ACB|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment A; Treatment C; Treatment B) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
62373342|NCT00364832|EXPERIMENTAL|Cohort D (0.8/150, 1x/ Week)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
62373343|NCT00364832|EXPERIMENTAL|Cohort E (0.8/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
62373344|NCT00364832|EXPERIMENTAL|Cohort F (0.8/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
62373345|NCT00364832|EXPERIMENTAL|Cohort G (1.2/150, 1x/ Week)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
62373346|NCT00364832|EXPERIMENTAL|Cohort H (1.2/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
62567200|NCT01994408|EXPERIMENTAL|default intensification arm (all)|all subjects will receive blister packs with weekly increasing blood pressure medications. There is no control arm for this study
62567201|NCT00828217|EXPERIMENTAL|with APA|Children have adapted physical activity during their hospitalization
62567202|NCT00828217|NO_INTERVENTION|without APA|Children don't have adapted physical activity during their hospitalization
62567203|NCT02254317|PLACEBO_COMPARATOR|0 mg placebo|Not containing GSE (Placebo)
62567204|NCT02254317|ACTIVE_COMPARATOR|300 mg GSE|Containing 300 mg of GSE
62567205|NCT02254317|ACTIVE_COMPARATOR|600 mg GSE|Containing 600 mg of GSE
62567206|NCT02254317|ACTIVE_COMPARATOR|900 mg GSE|Containing 900 mg of GSE
62567207|NCT04562168|EXPERIMENTAL|Diagnostic Test: ML model|The diagnostic capacity of the ML model will be compared with that of the general practitioners and with dermatologist.
62567208|NCT06117839||1|"first group is patients will be treated with regular bone cement . Patients will be routinely monitored for clinical signs of infection, including cellulitis or draining sinuses. Radiographs were obtained at 2,6 and 12 months.~* Laboratory tests as CRP and CBC will beused to assess the infection.~* A negative CRP indicate clean field ."
62567209|NCT06117839||2|"the second one is patient will be treated with antibiotic loaded bone cement, commonly used antibiotic includeGentamycin powder.~Patients will beroutinely monitored for clinical signs of infection, including cellulitis or draining sinuses. Radiographs were obtained at 2,6 and 12 months.~* Laboratory tests as CRP and CBC used to assess the infection.~* A negative CRP indicate clean field."
62567210|NCT02647957|EXPERIMENTAL|Group A|Hospital using Code Stroke
62567211|NCT02647957|NO_INTERVENTION|Group B|Hospital not using Code Stroke
62567212|NCT04845750|EXPERIMENTAL|Rodeo Micro Mapping Catheter|Determination of pulmonary vein isoation during cryoablation procedure
62567213|NCT00320710|EXPERIMENTAL|Zoledronic acid every (q) 4 weeks|Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.
62567214|NCT00320710|EXPERIMENTAL|Zoledronic acid q 12 weeks|Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.
62567215|NCT00320710|EXPERIMENTAL|Placebo / zoledronic acid|Participants randomized to this arm received placebo but the arm was later dropped and participants in this arm were swithced to the zoledronic acid q 4 weeks according to a study amendment.
62567216|NCT02021344|NO_INTERVENTION|Pure control|Practice as usual (no MHFA) in all residences on these campuses.
62567217|NCT02021344|EXPERIMENTAL|Intervention residence on mixed campus|Mental Health First Aid delivered to these residences, but not all other residences at the same campus.
62567218|NCT02021344|EXPERIMENTAL|Pure intervention residence|Mental Health First Aid delivered to this residence and all other residences at the same campus
62567219|NCT02021344|NO_INTERVENTION|Control at mixed campus|Practice as usual (no MHFA) at this residence, but some other residences at same campus are in experimental condition (MHFA).
62567220|NCT06577077|EXPERIMENTAL|Product CM9241GRU|
62567221|NCT06577077|PLACEBO_COMPARATOR|Placebo|
62567222|NCT03450317|EXPERIMENTAL|Aspirin|Aspirin 80mg once daily
62567223|NCT03450317|NO_INTERVENTION|Non-treatment group|No intervention
62567224|NCT01535417|EXPERIMENTAL|GCSB|
62567225|NCT01535417|ACTIVE_COMPARATOR|Celebrex|
62567226|NCT02060838||Acute normovolemic hemodilution (ANH)|Patients undergoing acute normovolemic hemodilution (ANH) as part of their cardiac surgery.
62567227|NCT04398238||Pre-PBM|patients screened for surgery before the implementation of PBM program: pre-operative evaluation and treatment according to usual care
62745005|NCT04600505|EXPERIMENTAL|Treatment Sequence BAC|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment B; Treatment A; Treatment C) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
62745006|NCT04600505|EXPERIMENTAL|Treatment Sequence CBA|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment C; Treatment B; Treatment A) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
62745007|NCT05799521|EXPERIMENTAL|Treatment|subjects on Treatment arm will get study drug
62745008|NCT05799521|PLACEBO_COMPARATOR|Placebo|subjects on Treatment arm will get placebo
62745009|NCT03470324|ACTIVE_COMPARATOR|[standard STN] + swallowing therapy|standard stimulation on subthalamic (STN) contacts plus swallowing therapy
62745010|NCT03470324|EXPERIMENTAL|[STN+SNr] + swallowing therapy|Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) plus swallowing therapy
62745011|NCT01250184|ACTIVE_COMPARATOR|Physical Therapy|Twelve sessions, 3 per week.
62373347|NCT00364832|EXPERIMENTAL|Cohort I (1.2/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
62373348|NCT01231672||Septic shock patients|
62373349|NCT06358976|EXPERIMENTAL|Vibration plus anti-spastic hand splint Arm|In this clinical trial, vibration stimulation will be applied to the spastic hand antagonistic muscles using a specific device consisting of a volar anti-spastic hand splint and the arm vibrator. The volar anti-spastic hand splint will be custom-made for each participant at the prosthetic and orthotic clinic, following a standardized protocol. The arm vibrator, designed to fit the arm, will deliver the required vibration parameters. The intervention protocol involves a 30-minute vibration session administered three times weekly for four weeks, accompanied by daily utilization of the custom-made splint for 30 minutes each day.
62373350|NCT06358976|ACTIVE_COMPARATOR|Anti-spastic hand splint Arm|In the anti-spastic hand splint arm , participants will be provided with an anti-spastic splint without vibration. Both vibration plus anti-spastic hand splint arm and anti-spastic hand splint arm will adhere to the same splint standard regime and recommendations, which outlines the specific positioning for the splint.
62373351|NCT06358976|ACTIVE_COMPARATOR|Vibration Arm|In vibration arm , participants will be provided with arm vibrator held in place by appropriate padded harness. A Standardized study protocol will be used each time with no splint.
62373352|NCT06004089|EXPERIMENTAL|V NOTES Sacrocolpopexy arm|V-NOTES sacrocolpopexy was performed who met the eligibility criteria and gave written informed consent. Pelvic organ prolapse quantification (POP-Q) scores were evaluated before and 1 month after surgery. Quality of life was evaluated before and 1 month after surgery with the Turkish-validated Pelvic Floor Impact Questionnaire (PFIQ-7) and Pelvic Floor Distress Inventory (PFDI-20).
62373353|NCT05868460|EXPERIMENTAL|Group A (High Intensity Laser Therapy Group)|patients will receive HILT in addition to traditional physical therapy exercise program
62373354|NCT05868460|PLACEBO_COMPARATOR|Group B (Placebo-Control Group)|patients will receive placebo HILT in addition to traditional physical therapy exercise program
62373355|NCT01386021||Prior recipients of allografts for CABG|
62373356|NCT05615155|EXPERIMENTAL|i-PRF|The sides of the mouth that will be injected with injectable-Platelets Rich Fibrin
62745012|NCT01250184|ACTIVE_COMPARATOR|Lidocaine injection|Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
62745013|NCT01250184|EXPERIMENTAL|Lidocaine injection + physical therapy|Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
62745014|NCT06141538||Experimental group|Adequate and regular anticoagulant therapy. Anticoagulation therapy is determined based on the patient's CHADS₂ or CHA₂DS₂-VASc score. Anticoagulant medications include vitamin K antagonists, novel oral anticoagulants (NOACs), and aspirin.
62745015|NCT06141538||Control group|Patients who have not received regular or continuous anticoagulation therapy due to poor compliance or other reasons.
62745016|NCT02661555|EXPERIMENTAL|Aerobic exercise|Aerobic exercise two times per week for 24 weeks.
62745017|NCT02661555|NO_INTERVENTION|Habitual lifestyle|Habitual lifestyle the first 24 weeks. Will be offered the same exercise intervention after 24 weeks.
62745018|NCT05936840||Regular cycles|To characterize quantitative hormones in the urine using the Mira monitor, along with other menstrual cycle biomarkers, and validate these in reference to serum hormonal measurements and the gold-standard of the ultrasound-day of ovulation in participants with normal menstrual cycles (cycle length 24-38 days).
62745019|NCT05936840||Polycystic ovarian syndrome|To identify hormonal and other menstrual cycle biomarker variations in polycystic ovarian syndrome (PCOS) with oligomenorrhea.
62745020|NCT05936840||Athletes|To identify hormonal and other menstrual cycle biomarker variations in oligomenorrheic athletes.
62745021|NCT04767581|ACTIVE_COMPARATOR|KHK7791|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
62373357|NCT05615155|EXPERIMENTAL|C-PRF|The sides of the mouth that will be injected with Concentrated-Platelets Rich Fibrin
62373358|NCT00584987|PLACEBO_COMPARATOR|Placebo FF + Placebo OXY|Placebo Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
62745022|NCT04767581|PLACEBO_COMPARATOR|Placebo|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
62745023|NCT05806515|EXPERIMENTAL|Treatment (carboplatin)|Patients receive carboplatin IV on study. Patients then undergo surgery on study. Patients who experience PSA progression after surgery undergo CT or MRI of the abdomen and pelvis, CT of the chest or chest X-ray, or PSMA-PET throughout the trial. Patients also undergo collection of blood samples throughout the trial.
62373359|NCT00584987|ACTIVE_COMPARATOR|FF + Placebo OXY|Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
62373360|NCT00584987|ACTIVE_COMPARATOR|Placebo FF + OXY|Placebo Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
62373361|NCT00584987|ACTIVE_COMPARATOR|FF + OXY|Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
62373362|NCT03537937|ACTIVE_COMPARATOR|Lower SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 90% (range 88-92%).
62373363|NCT03537937|ACTIVE_COMPARATOR|Intermediate SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 94% (range 92-96%).
62373364|NCT03537937|ACTIVE_COMPARATOR|Higher SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 98% (range 96-100%).
62373365|NCT00881023|ACTIVE_COMPARATOR|1|Randomized to Microfracture
62373366|NCT00881023|EXPERIMENTAL|2|Randomized to Device
62373367|NCT00881023|EXPERIMENTAL|3|Non-randomized with lesion greater than 6cmˆ2
62373368|NCT01188811|EXPERIMENTAL|Arm 1: lipoic acid|28 subjects receive oral lipoic acid 1200mg daily
62373369|NCT01188811|PLACEBO_COMPARATOR|Arm 2: placebo|28 subjects receive placebo daily
62373370|NCT04472819|EXPERIMENTAL|SHR2285 Part 1A|Participant received one of 7 dose levels of SHR2285 tablet as single-dose oral administration
62373371|NCT04472819|PLACEBO_COMPARATOR|Placebo Part 1A|Single ascending doses of placebo orally
62373372|NCT04472819|EXPERIMENTAL|SHR2285 Part 1B|Participant received one dose of SHR2285 tablet as single-dose oral administration
62373373|NCT04472819|PLACEBO_COMPARATOR|Placebo Part 1B|Single doses of placebo orally
62373374|NCT04472819|EXPERIMENTAL|SHR2285 Part 2|Participant received one of 4 dose levels of SHR2285 tablet as multi-dose oral administration
62373375|NCT04472819|PLACEBO_COMPARATOR|Placebo Part 2|Multiple ascending doses of placebo orally
62373376|NCT04732780||Questionnaire group|Individuals who attend the type 1 diabetes clinic will complete a number of self-report questionnaires and a survey.
62373377|NCT04164849|EXPERIMENTAL|5-ALA photopheresis|All patients will receive 5-aminolevulinic acid (5-ALA) in combination with blue light photopheresis. The investigators will collect mononuclear cells by connecting patient to Spectra Optia with CMNC (continuous mononuclear cell collection protocol), and these cells will include active T-lymphocytes. 5-ALA will be incubated for 1 hour to produce photoactive protoporphyrin-IX (PpIX) before light exposure.
62373378|NCT01699776|ACTIVE_COMPARATOR|Ivabradine|Ivabradine, 7,5 mg b.id. by mouth for 14-16 weeks.
62373379|NCT01699776|ACTIVE_COMPARATOR|Digoxin|Digoxin 0.125 mg once a day, 5 times per week, for 12-14 weeks by mouth.
62373380|NCT01518309|EXPERIMENTAL|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
62373381|NCT01661504|NO_INTERVENTION|Referral Card Only|Women participants at control clinics will be given a referral card containing general information on IPV and a list of resources specific to their community
62373382|NCT01661504|EXPERIMENTAL|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions at 3 months post-baseline / initial counseling
62373383|NCT03458234|EXPERIMENTAL|Focal SBRT with intra-urethral radiotransponder|This study will enroll patients that have a confirmed histology of prostate cancer. They will undergo a 3T MRI scan as well as a CT simulation with 16 French Foley Catheter containing dummy beacons for treatment planning purposes. The patient will then receive focal stereotactic body radiotherapy (SBRT) at a dose of 40 gy in 5 total fractions. Patients will be followed for 24 total months with specific follow-ups at 3, 6, 9, 12, 18, and 24 months.
62373384|NCT00592072|EXPERIMENTAL|Medium chain fatty acid (Octanoic and Decanoic acid)|
62373385|NCT00592072|PLACEBO_COMPARATOR|Splenda (Placebo Control)|
62373386|NCT00262639|EXPERIMENTAL|I|2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.
62373387|NCT00262639|PLACEBO_COMPARATOR|II|20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
62373388|NCT00554346|ACTIVE_COMPARATOR|1|Etoricoxib 90mg
62373389|NCT00554346|PLACEBO_COMPARATOR|2|placebo
62373390|NCT05960786|EXPERIMENTAL|1. Moderate or Worse (MoW) Arm|Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the experimental device.
62373391|NCT05960786|SHAM_COMPARATOR|2. Moderate or Worse (MoW) Arm|Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the sham device.
62745024|NCT04227275|EXPERIMENTAL|Dose Escalation|Dose escalation of intravenous CART-PSMA-TGFβRDN cells for patients with metastatic castration resistant prostate cancer
62745025|NCT03051880|EXPERIMENTAL|Repair Control EGF®|EGF cream was applied. One half side of face and one hand were treated with emollient containing EGF.
62745026|NCT03051880|PLACEBO_COMPARATOR|Cream without rhEGF|Placebo cream without EGF was applied. The other half side of face and the other hand were treated with only emollient which was not containing EGF.
62373392|NCT05960786|EXPERIMENTAL|1. Quality of Life (QoL) Arm|Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the experimental device.
62373393|NCT05960786|SHAM_COMPARATOR|2. Quality of Life (QoL) Arm|Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the sham device.
62373394|NCT00998036|EXPERIMENTAL|Temsirolimus, cisplatin, erlotinib|Cisplatin and temsirolimus will be administered weekly on days one and eight of a three week cycle. Erlotinib will be taken by mouth daily.
62745027|NCT02218697|EXPERIMENTAL|Co-Ad Group|Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of Pneumovax™ 23 vaccine at Day 0 and 1 dose of placebo at Day 28.
62745028|NCT02218697|EXPERIMENTAL|Control Group|Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of placebo at Day 0 and 1 dose of Pneumovax™ 23 vaccine at Day 28.
62745029|NCT03397524|EXPERIMENTAL|optima4BP|optima4BP will receive several types of data to personalize the participant's medication treatment. The data include: remotely measured blood pressure (BP), and information on current medication treatment as well as health updates posted in Epic Electronic Record.
62373395|NCT02909582|NO_INTERVENTION|Pfannenstiel Incision|This curved incision is approximately 10-15 cm long and 2 cm above the pubic symphysis. If a pannus is present, the pannus should be retracted up (see diagram) to allow placement of the Pfannenstiel incision.
62745030|NCT03397524|NO_INTERVENTION|Standard of Care|The participants randomized to the Standard of Care will follow usual care, as currently followed at the University of California San Francisco.
62745031|NCT03090516|EXPERIMENTAL|Arm A ：Donepezil|A：People are randomly divided into three groups according to the educational conditiono，gender and age.
62373396|NCT02909582|EXPERIMENTAL|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
62373397|NCT03872336|EXPERIMENTAL|Experimental labetalol dose|Subjects receive 40mg, 60mg 80mg in succession after each severe BP
62373398|NCT03872336|ACTIVE_COMPARATOR|Current standard of care|Subjects receive 20mg, 40mg 80mg in succession after each severe BP
62373399|NCT02415829|EXPERIMENTAL|Neoadjuvant chemotherapy|A total of 55 cases of locally advanced colon cancer will be enrolled in this arm. After radiological staging, patients were treated first with 3 cycles of neoadjuvant chemotherapy consisting of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen), followed by tumor resection, and then with another 5 cycles of adjuvant chemotherapy with the XELOX regimen. Radiological response was evaluated after 2 cycles of neoadjuvant chemotherapy . A total of 3 cycles neoadjuvant chemotherapy was completed unless there was unacceptable toxicity, emergency operation condition or tumor progression during the period. Tumor responses, toxicities, and surgical complications were recorded. The pathological tumor response in the primary tumor was evaluated according to tumor regression grade (TRG) score.
62373400|NCT04729595|ACTIVE_COMPARATOR|Active Treatment|Tempol (MMB-02) 800 mg per Day (n=124)
62373401|NCT04729595|PLACEBO_COMPARATOR|Placebo|Placebo (n=124)
62373402|NCT05141344|ACTIVE_COMPARATOR|melatonin group|patients in this group will be premedicated One hour before the start of surgery by receiving 0.5mg/kg orally of melatonin (Melatonin 3 mg ), (the tablet will be dissolved in 5 ml of water, to be given by syringe 5ml) in the preoperative unit
62373403|NCT05141344|PLACEBO_COMPARATOR|placebo group|patients in group P (n =25 ) will receive a placebo( sugary tablets dissolved in 5ml of water by syringe 5 ml) one hour before the start of surgery.
62373404|NCT02515773|EXPERIMENTAL|MET and LIFE|Participants randomized to this group will receive both Metformin and lifestyle intervention.Participants randomized to treatment with MET will start at a dose of 500 mg orally at night and slowly titrated in 2-week intervals to ensure that each patient achieves maximum insulin-sensitizing effects of the drug while minimizing the chance of side effects. Investigators will also recommend that MET be taken with food to minimize side effects. If a participant's BMI percentile \<5% (=underweight) his/her treatment with MET will be discontinued. Although the risk of low vitamin B12 while taking MET is associated with age \> 50 years and having type II diabetes, Investigator will monitor B12 levels and a CBC throughout study participation.
62373405|NCT02515773|EXPERIMENTAL|Healthy lifestyle intervention (LIFE)|Participants randomized to this group will receive just lifestyle intervention alone.This healthy lifestyle intervention (LIFE) consists of counseling participants and families regarding a healthy eating plan, physical activity and sedentary activities. Prior to study initiation, clinical site staff will participate in a live (or taped) training session from a dietician to lean to administer LIFE. A trained site staff member (e.g. medical assistant or case manager) will meet with participants and their families for a 15-20 minute session at baseline that will focus on nutritional issues using the Traffic Light Plan (TLP).
62745032|NCT03090516|EXPERIMENTAL|Arm B ：Donepezil and Ginkgo biloba dispersible tablets|B：People are randomly divided into three groups according to the educational conditiono，gender and age.
62745033|NCT03090516|EXPERIMENTAL|Arm C：Ginkgo biloba dispersible tablets|C：People are randomly divided into three groups according to the educational conditiono，gender and age.
62745034|NCT01248039||Total arthroplasty|Patients with osteoarthrosis going for hip or knee arthroplasty
62745035|NCT02309645|EXPERIMENTAL|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
62745036|NCT02309645|OTHER|Sutures Only|Subjects randomized to control will receive additional dural repair sutures as deemed necessary by the surgeon to attempt to achieve a watertight closure.
62373406|NCT01880879|EXPERIMENTAL|helios stent|the group with helios stent implanted
62745037|NCT05850663|OTHER|Ecological Momentary Assessments (EMAs)|Patients will receive one EMA (Ecologic Momentary Assessment) per day for approximately 75 days, through the provided smart phone application.
62373407|NCT03187210|EXPERIMENTAL|Dosis finding (Phase I)|Brentuximab Vedotin at day -8 together with standard BeEAM (Bendamustine, Cytarabine, Etoposide and Melphalan) chemotherapy at days -7 to -1 followed by reinfusion of autologous stem cells at day 0
62373408|NCT03187210|ACTIVE_COMPARATOR|Arm A (Phase II)|"BeEAM Regimen:~Bendamustine intravenously once daily on days -7 and -6 at 200 mg/m2/day; Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day -5 to day-2; Etoposide 200 mg/m2/day intravenously once daily from day -5 to day -2; and Melphalan 140 mg/m2/day intravenously once on day -1, followed by reinfusion of autologous stem cells at day 0"
62745038|NCT05348356|EXPERIMENTAL|Nirogacestat Open-Label|All participants will receive open-label nirogacestat
62745039|NCT05623475|EXPERIMENTAL|experimental group|"1. face-to-face delirium care session (30 minutes in duration);~2. online learning delirium care activities (20 minutes in duration); and~3. delirium care OSCE and reflective activity (30 minutes in duration)."
62745040|NCT05623475|ACTIVE_COMPARATOR|control group|"1. face-to-face delirium care session (30 minutes in duration);~2. online learning delirium care activities (20 minutes in duration)"
62745041|NCT02258971|EXPERIMENTAL|BEA 2180 BR oral|
62745042|NCT02258971|ACTIVE_COMPARATOR|BEA 2180 BR infusion|
62745043|NCT02762656|ACTIVE_COMPARATOR|Lidocaine|Patients will receive Lidocaine drip during spine surgery
62745044|NCT02762656|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo during spine surgery
62745045|NCT06154889|ACTIVE_COMPARATOR|Convention readaptation protocol|Patients have a conventional re-education after surgery for anterior shoulder dislocation (Latarjet procedure)
62745046|NCT06154889|EXPERIMENTAL|Readaptation protocol with psychologic intervention|Patient have a conventional re-education after surgery for anterior shoulder dislocation (Latarjet procedure) with addition of 4 consultations with a sports psychologist
62745047|NCT03203811|EXPERIMENTAL|Low Dose|2mg, HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
62745048|NCT03203811|EXPERIMENTAL|Middle Dose|3.75mg HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
62745049|NCT03203811|EXPERIMENTAL|High Dose|5mg HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
62745050|NCT05868265|EXPERIMENTAL|Enfortumab Vedotin|All patients will receive enfortumab vedotin at 1.25 g/kg on days 1 and 8 of 21 days cycle, for a total of three cycles, followed by radical nephroureterectomy, ureterectomy, or nephrectomy, depending on the site of the tumor and per the clinical decision of the treating urologist.
62745051|NCT00578188||RP100-400|Subjects with Chlamydia. The control group will also be identified with these numbers.
62745052|NCT01320553|EXPERIMENTAL|SPARC1102 I|1334H 0.15% eye drops will be administered in both eyes at 3 occasions
62745053|NCT01320553|EXPERIMENTAL|SPARC1102 II|1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions
62745054|NCT01320553|EXPERIMENTAL|SPARC1102 III|1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions
62745055|NCT01320553|PLACEBO_COMPARATOR|Vehicle|Placebo eye drops (solution)will be administered in both eyes at 3 occasions
62745056|NCT04904276||Initiating treatment with fostamatinib as second-line therapy|
62745057|NCT04904276||Treated with fostamatinib for at least 12 weeks as second-line therapy|
62373409|NCT03187210|EXPERIMENTAL|Arm B (Phase II)|"Brentuximab Vedotin 1.8 mg/kg at day -8 together with standard BeEAM chemotherapy at days -7 to -1~BeEAM Regimen:~Bendamustine intravenously once daily on days -7 and -6 at 200 mg/m2/day; Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day -5 to day-2; etoposide 200 mg/m2/day intravenously once daily from day -5 to day -2; and Melphalan 140 mg/m2/day intravenously once on day -1, followed by reinfusion of autologous stem cells at day 0"
62373410|NCT03942172|EXPERIMENTAL|SpotOn Balance|SpotOn Balance Glasses
62373411|NCT03887052|EXPERIMENTAL|Study Arm|Adult cardiac patients at risk for sudden cardiac arrest otherwise protected with an Implantable Cardioverter Defibrillator (ICD)
62745058|NCT04160286||ECT|Group of patients receiving ECT during their hospitalization.
62745059|NCT04160286||Non-ECT|Group of patients not receiving ECT during their hospitalization.
62745060|NCT04042051|OTHER|Single Arm|This study is a phase Ib open label, single arm, adaptive multi-centre trial. Patients with unresectable locally advanced or metastatic HER2-positive breast cancer who previously received trastuzumab and a taxane, separately or in combination, will be treated with copanlisib (as assigned at registration according to the dose escalation scheme) plus trastuzumab emtansine 3.6mg/kg IV on day 1 of a 21-day cycle.
62745061|NCT02543281|ACTIVE_COMPARATOR|aCRT Off|The adaptive CRT algorithm will be turned off for the CRT device implanted in the patients in this arm.
62745062|NCT02543281|EXPERIMENTAL|aCRT On|The adaptive CRT algorithm will be turned on for the CRT device implanted in the patients in this arm.
62745063|NCT02543281|NO_INTERVENTION|Registry arm|Participants who are not eligible for the randomization because of the implantation of the device that is not capable of delivering aCRT. The team of clinical care providers makes such a clinical decision acting in the patient's best interests.
62745064|NCT06389721||Cohort 1|Participants in Group 1, you will have an EEG and complete one questionnaire prior to your first dose of chemotherapy and once monthly until the end of your chemotherapy (for a maximum of 6 measurements).
62745065|NCT06389721||Cohort 2|Participants in Group 2, you will have an EEG, and complete a questionnaire before and after your chemotherapy regimen. Participants will also have a treatment called closed-loop brain-computer interface (clBCI) training twice a week for the 2 weeks leading up to starting chemotherapy, and then twice a week during chemotherapy, for a maximum of 32 sessions, which you will be able to do at home.
62745066|NCT04150666|EXPERIMENTAL|Hydration|Participants randomized to the hydration-intervention group will be asked to drink 2.0 to 2.5 L of water per day (depending on sex), in addition to usual consumed beverages, for 3 months
62745067|NCT04150666|NO_INTERVENTION|Control|
62745068|NCT05469230||Typically developed children group|Typically developed children will be from both genders. the age range will be (8-16) years old and will be recruited from public governmental schools
62745069|NCT05469230||Beta thalassemia group|children diagnosed with beta thalassemia major and intermedia will be recruited from Abo-El-Rish Pediatric Hospital. the age will be (8-16) years and will be from both genders
62745070|NCT02040350|PLACEBO_COMPARATOR|Placebo|Placebo was given to compare the effects
62745071|NCT02040350|ACTIVE_COMPARATOR|Pralidoxime|Pralidoxime for treating organophosphorous poisoning patients
62745072|NCT05850910|EXPERIMENTAL|Supine practice group|The participant was asked to cross his arms in front of his body while lying on his back.
62745073|NCT05850910|EXPERIMENTAL|Prone application group|The participant positions their hands freely from the side of the treatment table in the prone position.
62745074|NCT05340712|EXPERIMENTAL|IT formula|The test product (IT formula) is an infant formula based on cow's milk proteins containing a high level of lactose, a prebiotic, a high concentration of magnesium and a mix of probiotics.
62745075|NCT05340712|PLACEBO_COMPARATOR|Standard formula|The control product is a standard infant formula based on cow's milk proteins containing usual lactose and magnesium content, no prebiotic nor probiotic.
62745076|NCT02351063|EXPERIMENTAL|Daily BNP|Subjects will be asked to test their BNP at home every day for a period of 180 days using the AlereTM HeartCheck System (the Test System). In addition to BNP, weights and signs and symptoms of HF will be collected each day of testing. The HeartCheck data is transmitted via a secure wireless protocol to the HealthCOM health monitoring portal where it is available to the medical staff. The subject's's physician and medical staff will be required to evaluate the data and determine if a change in HF treatment is advisable. All changes of heart failure medications are at the discretion of the treating physician and medical staff of the institution.
62745077|NCT05143749|EXPERIMENTAL|10 assistant doctors who received video training|10 assistant doctors who receive video training will be the intervention arm
62745078|NCT05143749|NO_INTERVENTION|10 assistant doctors who did not receive video training|10 assistant doctors who did not receive video training will be the control arm
62745079|NCT05655559|EXPERIMENTAL|Treadmill Group|Hemodynamic effects such as heart rate, blood pressure, oxygen saturation (SpO2), dyspnea and fatigue including muscle oxygenation, will be compared during treadmill exercises.
62745080|NCT05655559|EXPERIMENTAL|Cycle Group|Hemodynamic effects such as heart rate, blood pressure, oxygen saturation (SpO2), dyspnea and fatigue including muscle oxygenation, will be compared during cycling exercises.
62745081|NCT06659939||TEST group|"The TEST group's participants will be randomized in order to either wear the dosimeter alone (as usual) or the dosimeter associated with the access badge of the hospital badge-dosi.~The participants are working in the operating room and are exposed to X-rays"
62745082|NCT06659939||LIFE group|"The LIFE group participants will wear a dosimeter associated with the access badge of the hospital badge-dosi.~The participants are working in the same hospital as the TEST group, but they are not exposed to any radiation at work."
62745083|NCT06659939||HOME group|The HOME group participants will have a dosimeter alone which will be stored at home. The participants are working in the same hospital as the TEST group.
62745084|NCT01618045||Fermented Papaya Preparation (FPP)|This a is single arm study - all participants will receive and take fermented papaya preparation (FPP) for a total of 6 weeks. Participants will take 3 grams of FPP three times per day (a total of 9 grams per day).
62745085|NCT03542656|EXPERIMENTAL|amyloid PET|PET/CT
62745086|NCT03069248|EXPERIMENTAL|treatment arm|"Salvage treatment with CHOP or DHAP followed by high dose therapy and stem cell support prior to consolidative immunotherapy with Rituximab and Alpha interferon.~."
62745087|NCT06401889||Observational|Patients complete surveys/questionnaires, undergo skin measurement with the VISIA CA device, undergo facial skin photography, and attend consultations with an aesthetician on study.
62745088|NCT05666934|EXPERIMENTAL|Home-based Augmented Reality Storybook Training Module|The children were entirely involved in this intervention program at home, with 20 minutes each time, 4 times a week for 8 weeks. The caregiver was required to perform the interactive picture book specified by the AR home training modules. During the process, the caregivers could directly contact the researcher by telephone and instant messaging for solving problems that occur during the interaction. The researcher and the caregiver consistently met once every two weeks. On the day of the meeting, the caregiver needs to prepare at least ten minutes of interactive video to discuss with the researcher. The researcher not only provides suggestions for caregiver interaction skills based on the video, in order to facilitate the child's interaction. The interaction strategies were also revised according to the interaction ability and special behavior problems of individual children.
62745089|NCT05359822|NO_INTERVENTION|Clinical Standard Report Only|Participants referred for Coronary Artery Calcium Score Test that receive clinical standard CAC risk report only.
62745090|NCT05359822|EXPERIMENTAL|Clinical Standard Report plus Image-Based Report|Participants referred for Coronary Artery Calcium Score Test that receive clinical standard CAC risk report plus additional image-based report.
62745091|NCT06533501|EXPERIMENTAL|Test Leucine Intake|Randomly assigned one of 7 test leucine intakes that range from deficient to excess (10mg/kg/d to 85mg/kg/d). Participants may complete up to 7 study days in each menstrual phase, at different randomly assigned intakes.
62745092|NCT00361868|EXPERIMENTAL|1|
62745093|NCT00361868|ACTIVE_COMPARATOR|2|
62567228|NCT04398238||post-PBM|patients screened for surgery after the implementation of PBM program (3 months allowed for training/optimization): all patients with pre-operative hemoglobin \< 13g/dl undergo screening for causes and treatment as needed.
62745094|NCT04660851|EXPERIMENTAL|Coached|10 weeks of diet coaching
62745095|NCT04660851|NO_INTERVENTION|Not-coached|No coaching provided
62745096|NCT01985711|EXPERIMENTAL|web-based,CBT,MI,TTM, outpatient|Participants in web-based collaborative care group will receive 24 weekly 40-minute web-based Cognitive Behavioral Therapy (CBT) sessions, undergo structured Transtheoretical Model of Behavior Change or Motivational interviewing to set up proper life-style and healthy behavior to improve their live quality，conducted on the web. Besides, they will receive usual diabetes outpatient care and web-based diabetes care.
62745097|NCT01985711|OTHER|waitlist, usual diabetes outpatient|Participants assigned to the wait-list group will be given usual diabetes outpatient service (diabetic medication guidance and appointment to see doctor as routine, without specific anti-depression therapy). After 6 months, they will receive web-based collaborative care for 6 months too.
62745098|NCT06437288|EXPERIMENTAL|photodynamic therapy|"Receive an intravenous infusion of hematoporphyrin injection at a dose of 3mg/kg over 60 minutes.~Undergo 630nm laser irradiation 48-72 hours after the infusion."
62745099|NCT04999215|EXPERIMENTAL|Main arm|F-choline intravenous injection
62745100|NCT00663884|EXPERIMENTAL|M|Mitiglinide
62745101|NCT00663884|ACTIVE_COMPARATOR|V|Voglibose
62373412|NCT03353441|ACTIVE_COMPARATOR|Glycine (MSG)|Microencapsulated Sublingual Glycine (MSG): 1 tablet prior to TSST; 1 tablet after the TSST
62373413|NCT03353441|PLACEBO_COMPARATOR|Placebo|Lactose: 1 tablet prior to TSST; 1 tablet after the TSST
62373414|NCT03353441|NO_INTERVENTION|No treatment|
62373415|NCT05563259||Groups/Cohorts Interventions Control|patients with steatosis \< 5%
62373416|NCT05563259||non-NASH|patients with steatosis ≥ 5% and did not achieve the criteria for NASH
62373417|NCT05563259||NASH|patients with NAFLD Activity Score (NAS) ≥ 5
62373418|NCT05013385|EXPERIMENTAL|Spesolimab|
62373419|NCT05013385|PLACEBO_COMPARATOR|Placebo|
62373420|NCT04669509||Group 1|Patients with normal ALT, AST and total bilirubin values
62373421|NCT04669509||Group 2|Patients whose ALT, AST or total bilirubin levels are up to 3 times upper limit of normal
62373422|NCT04669509||Group 3|Patients whose ALT, AST or total bilirubin levels are increased more than 3 times upper limit of normal
62373423|NCT00193128|EXPERIMENTAL|Cohort 1|"Oxaliplatin 40 mg/m2 intravenously (IV) over 2 hours and docetaxel 20 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, and 29. Radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).~Patients were to have esophageal resection after completion of preoperative therapy during weeks 9 to 12 and after all treatment-related side effects were resolved."
62373424|NCT00193128|EXPERIMENTAL|Cohort 2|"Oxaliplatin 40 mg/m2 intravenously (IV) over 2 hours and docetaxel 20 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, and 29. Capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35. Radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).~Patients were to have esophageal resection after completion of preoperative therapy during weeks 9 to 12 and after all treatment-related side effects were resolved."
62373425|NCT01480791|ACTIVE_COMPARATOR|Hydrochlorothiazide|Treatment of patients with hydrochlorothiazide and effect on small arteries
62373426|NCT01480791|EXPERIMENTAL|Aliskiren|Treatment of patients with aliskiren and effect on small arteries
62373427|NCT01480791|NO_INTERVENTION|Normotensive non diabetic subjects|A comparator non intervention normotensive non diabetic group of healthy subjects will be used for baseline comparison of primary and secondary endpoints
62373428|NCT03571867||group Sugammadex|After surgery, while the TOF count was 2/4, the residual muscle relaxation was antagonized with 2 mg/kg iv sugammadex + 0.01 ml/kg saline in Group S
62373429|NCT03571867||group Neostigmine|After surgery, while the TOF count was 2/4, the residual muscle relaxation was antagonized with 0.02 mg/kg neostigmin+0.01 mg/kg atropine in Group N.
62373430|NCT04880460|ACTIVE_COMPARATOR|Experimental|45 MDD patients were included in this arm who were received SSRIs and Magnesium tablets
62745102|NCT04261725||Squamous Cell Lung Cancer|Genetic analysis for searching EGFR mutation
62745103|NCT01728558|OTHER|Early Goal Directed Sedation|"Early Goal Directed Sedation process of care involves:~1. Early delivery of proposed intervention, shortly after initiating mechanical ventilation;~2. Effective analgesia provided simultaneously and early (analgesia first).~3. Regular and frequent assessment of patient wakefulness/sedative state;~4. Avoidance of benzodiazepines and minimisation of use of propofol;~5. Reduced overall sedation depth with targeted light sedation; Patients randomised to the EGDS arm will receive a sedative infusion of Dexmedetomidine withor without minimal propofol in order to maintain a RASS of -2 to +1.~Dexmedetomidine infusion will be continued until sedation is no longer clinically indicated up to a maximum of 28 days after enrolment."
62745104|NCT01728558|ACTIVE_COMPARATOR|Standard care Sedation Arm|Patients randomised to the standard care sedation arm will receive process of care sedation directed by the treating clinician. Based on the information from our observational study and the EGDS Pilot trial, most patients in this group are likely to receive midazolam and /or propofol. These agents will be infused to achieve the default target of Light sedation (RASS -2 to +1) whenever clinically appropriate and as specified by the treating clinician. The use remifentanil or dexmedetomidine for initial and maintenance sedation will be precluded.
62745105|NCT03729583|ACTIVE_COMPARATOR|Control group|The control group consisted of 15 patients with a diagnosis of ILD. They received a 12-week Pulmonary Rehabilitation (PR) programme without breathing retraining All patients were medically stable and referred by their caring respiratory consultant
62745106|NCT03729583|EXPERIMENTAL|Active group|The active group consisted of 15 patients with a diagnosis of ILD. They received a 12-week Pulmonary Rehabilitation (PR) programme with breathing retraining exercises. All patients were medically stable and referred by their caring respiratory consultant
62745107|NCT01825486||accidental falls|
62373431|NCT04880460|PLACEBO_COMPARATOR|Control|45 MDD patients were included in this arm who were received SSRIs and placebo tablets
62373432|NCT05939076|ACTIVE_COMPARATOR|Cryoballoon pulmonary vein isolation|Cryoballoon (Arctic Front AdvanceR, Medtronic) for pulmonary vein isolation
62373433|NCT05939076|ACTIVE_COMPARATOR|Antiarrhythmic drug|"Tablet Dronedarone:- 400 mg twice daily or Tablet Flecainide:- (50-)100 (-200) mg twice daily or slow release (100-)200 mg once daily.~If these drugs fail or give side effects:~Tablet Propafenone:- 150 mg 3 times daily increasing to 300 mg twice daily, if necessary max 300 mg three times daily. Dose reduction for patients \<70 kg bodyweight.~Tablet Sotalol:- 80 mg twice daily up to 160 mg twice daily. Dose reduction to half dosage if a creatinine clearance is 30-60 ml/min."
62745108|NCT02766439||Rhupus syndrome, SLE without RA|Rhupus syndrome, SLE without RA
62745109|NCT03936634||Newly Diagnosed (ND)|Recruited within 6 weeks of type 1 diabetes diagnosis. Age between 1 and \<45 years
62745110|NCT03936634||Unaffected Family members (UFM)|"Participants who are not diabetic but have a first degree relative with type 1 diabetes diagnosed \< 45 years of age.~Age between 1 and \<45 years"
62745111|NCT04685005|EXPERIMENTAL|Wake up|Drinking regular formula of Wake Up
62745112|NCT04685005|ACTIVE_COMPARATOR|Caffeine|Drinking 100mg of Caffeine
62745113|NCT04685005|PLACEBO_COMPARATOR|Placebo|Drinking Placebo (only water with sugar)
62552870|NCT03000062|EXPERIMENTAL|Intervention group|"12 Family physicians in primary care will constitute the Intervention group. They will enroll 10 patients each from their ordinary practice. The physicians will be provided with a specific course on the treatment model of the study, including how to collect and register data. They will have a detailed manual indicating the content of each visit.~Following recruitment and consent, the patient will meet for the first visit in the study one week later. At this visit the patient will be provided with detailed information on the content and preparation for all meals. Data will be collected.~The manual describes a diet in accordance with official guidelines providing the patient 1600Kcal per day.~The following visits will take place after 4 weeks, 8 weeks, 4 months, 8 months and 12 months from the first visit. Data will be collected at all visits, and also at 6 and 12 months follow-up."
62745114|NCT04685005|EXPERIMENTAL|Wake up Double Dose|Drinking formula of Wake Up with double doses of guarana, green tea, elderberry and Fruit-up
62745115|NCT04685005|EXPERIMENTAL|Wake up tripple dose|Drinking formula of Wake Up with tripple doses of guarana, green tea, elderberry and Fruit-up
62745116|NCT05103579||Patients with AFib|Patients with AFib
62745117|NCT05103579||Normal patients|Normal patients without AFib
62745118|NCT02227082|EXPERIMENTAL|radiotherapy and olaparib|radiotherapy: 61.18 Gy olaparib: dose escalating
62745119|NCT06030466|OTHER|With physical standardized patients|Medical students practice consultation with physical standardized patients.
62745120|NCT06030466|EXPERIMENTAL|With virtual standardized patients|Medical students practice consultation with virtual standardized patients.
62745121|NCT03913013|EXPERIMENTAL|FFT with MCC App (FFT-MCC)|Youth in this study arm will receive 12 sessions of FFT (psychoeducation, communication skills training, and problem-solving skills training) with their parents and siblings. They and their parents will make regular mobile app ratings of mood, sleep, family functioning, stress, and perceived criticism. Children and parents will call into a voice-activated phone system and be asked to speak freely for 3-5 minutes about their health and family functioning. They will be guided through 12 lesson plans in which they practice skills such as active listening or identifying prodromal signs of episodes, paralleling what they are learning in sessions. The clinician will be able to set a weekly skill training assignment and observe the family's practice of the skill between sessions. They will adapt session content accordingly.
62745122|NCT03913013|ACTIVE_COMPARATOR|FFT with App Assessments only (FFT-Assess)|Youth in this condition will receive the same 12 sessions of FFT, but the app will be limited to daily and weekly assessments of their mood, sleep, stress, and family functioning. The app will not provide the skill training offered in the FFT-MCC condition.
62745123|NCT00374946||A|THA. Bearing of Zirconia head and UHMWPE liner
62373434|NCT03734770|ACTIVE_COMPARATOR|Subcutaneous progesterone|After standard stimulating protocol for IVF, beginning on the day of oocyte retrieval allocated patients receive subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference) for at least 8 gestational weeks or confirmation of a negative pregnancy test performed 14 days after oocyte retrieval.
62373435|NCT03734770|ACTIVE_COMPARATOR|Vaginal progesterone|After standard stimulating protocol for IVF, beginning on the day of oocyte retrieval allocated patients receive micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours) for at least 8 gestational weeks or confirmation of a negative pregnancy test performed 14 days after oocyte retrieval.
62373436|NCT00249912|EXPERIMENTAL|Lapaquistat Acetate 50 mg QD + Rosuvastatin|
62373437|NCT00249912|EXPERIMENTAL|Lapaquistat Acetate 100 mg QD + Rosuvastatin|
62373438|NCT00249912|ACTIVE_COMPARATOR|Rosuvastatin|
62373439|NCT02168660|ACTIVE_COMPARATOR|Control Group|Standard vitamin D3 dose as per IOM (Institute of Medicine) recommendations; actual dose will be 5000 IU per week, which is just slightly higher than the IOM recommendation of 600 IU per day. Length of time proposed to be 4 months at 5000 IU D3 per week. End of study measures at 4 months to be HOMA-IR, BMI Z score, 25-OHD level.
62373440|NCT02168660|EXPERIMENTAL|Low-Normal Group|Initial D3 dose will be 30,000 IU per week; at 6 week intervals serum D3 levels will be checked, and dose adjustments made to reach target 25-OHD level of between 30-50 ng/mL (inclusive). Once within target, D3 dose will be continued for 4 months, and end of study measurements done (HOMA-IR, BMI Z score, 25-OHD level).
62373441|NCT02168660|EXPERIMENTAL|High-Normal Group|Initial D3 dose will be 60,000 IU/week; at 6 week intervals 25-OHD levels will be done, and dose adjustments made to achieve target level of 40-60 ng/mL (inclusive). Once within target range, D3 dose will be continued for 4 months, and end of study measures obtained (HOMA-IR, BMI Z score, 25-OHD level).
62373442|NCT05762965|EXPERIMENTAL|GOS 1|Galacto-oligosaccharide
62373443|NCT05762965|EXPERIMENTAL|GOS 2|Galacto-oligosaccharide
62373444|NCT01498770||Asenapine|
62373445|NCT01498770||Aripiprazole|
62373446|NCT01498770||Quetiapine|
62745124|NCT00374946||B|THA. Bearing of CO-Cr-Mo head and liner
62373447|NCT01498770||Risperidone|
62745125|NCT00374946||C|THA. Head og Zirconia head and UHMWPE moulded in shell (Asian)
62745126|NCT00374946||D|THA. Head and shell og Alumina ceramic
62373448|NCT01498770||Olanzapine|
62373449|NCT01498770||Ziprasidone|
62373450|NCT01498770||Iloperidone|
62373451|NCT01498770||Paliperidone|
62373452|NCT01498770||Lurasidone|
62373453|NCT01498770||Clozapine|
62373454|NCT01498770||Amisulpride|
62373455|NCT01498770||Sertindole|
62373456|NCT01498770||Zotepine|
62373457|NCT01758640|ACTIVE_COMPARATOR|Pregnant|Group of Pregnant patients who will receive either warfarin or phenindione according to the study design
62373458|NCT01758640|ACTIVE_COMPARATOR|Non Pregnant|Group Of Non Pregnant patients who will receive either warfarin or phenindione according to the study design
62373459|NCT05525065||Patients with autoimmune bullous disease receiving glucocorticoids for the duration of the study|Patients with autoimmune bullous disease currently receiving glucocorticoids for their condition, as independently assessed by an appropriately qualified medical professional/dermatologist, for the duration of the study period.
62373460|NCT05525065||Patients with autoimmune bullous disease not currently receiving glucocorticoids|Patients with autoimmune bullous disease who have received glucocorticoids for their condition in the past, but are not currently on steroids.
62745127|NCT04435301|EXPERIMENTAL|Gamma modulation effect|40Hz current is applied by a battery-driven current stimulator(NeuroConn, Germany). Two pairs of electrodes are attached to the middle and lower part of the face to stimulate the maxillary nerve (V2) and the mandibular nerve (V3), respectively. 40Hz acoustic stimuli and 40Hz electric stimuli are synchronously applied for 40min/day, for a total of 5 days.
62373461|NCT05525065||Patients with autoimmune bullous disease ceasing glucocorticoids during the study period|Patients with autoimmune bullous disease who initially had glucocorticoid treatment at the first visit, and had ceased glucocorticoid use during the study period.
62373462|NCT05263011|EXPERIMENTAL|Avocado snack|1 avocado
62373463|NCT05263011|PLACEBO_COMPARATOR|control snack + fiber supplement + vegetable oil|high fat, high fiber control
62373464|NCT05263011|OTHER|control snack|Low-fiber, low-fat
62373465|NCT03948594|PLACEBO_COMPARATOR|plain water|subject drink 250cc plain water
62373466|NCT03948594|ACTIVE_COMPARATOR|resource|subject drink 1 packet resource(237ml)
62373467|NCT03822780|EXPERIMENTAL|HCQ Therapy|"Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg\*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg\*d to 10mg/kg\*d, p.o., bid ; the maximum daily dose is 400mg.~Assess the efficacy and safety of HCQ after 6 months treatment compared with any other routine therapy before HCQ therapy (such as inhaling oxygen, corticosteroid, anti-infection therapy, nutritional support)"
62373468|NCT04197206|EXPERIMENTAL|Costotransverse block|The Costotransverse block will be administrated to this group before induction of anesthesia. An intravenous patient-controlled analgesia device within morphine will be given to the patients postoperatively.
62373469|NCT04197206|NO_INTERVENTION|Control Group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with morphine. No block will be performed.
62373470|NCT01623856||Observational|DNA samples are analyzed by single nucleotide polymorphism and genotyped by fluorogenic polymerase chain reaction (PCR)-based allelic discrimination (Taqman) assays using the ABI Prism 7900HT reverse transcriptase (RT)-PCR system.
62373471|NCT05987514|EXPERIMENTAL|Patients|Patients affected by hepatocellular carcinoma needing to undergo loco-regional treatment
62373472|NCT06424041|ACTIVE_COMPARATOR|Active Treatment - FMT|Participants in this arm will receive a total of 5 real FMT treatments administered weekly, followed by an additional 5 maintenance FMT treatments on a monthly basis. The first induction treatment will consist of 30 grams, with subsequent treatments comprising 15 grams each.
62745128|NCT04435301|EXPERIMENTAL|Beta modulation effect|28Hz current is applied by a battery-driven current stimulator. Two pairs of electrodes are attached to the middle and lower part of the face to stimulate the maxillary nerve (V2) and the mandibular nerve (V3). 28Hz acoustic stimuli and 28Hz electric stimuli are synchronously applied for 40min/day, for a total of 5 days.
62745129|NCT04435301|SHAM_COMPARATOR|Sham modulation group|Sham stimulation was identical to the 40Hz stimulation, except that the acoustic and electric stimulation were ramped down after 0.5 min to remain turned off for the remaining 39.5 min. Sham stimuli are applied for 40min/day, for a total of 5 days.
62373473|NCT06424041|SHAM_COMPARATOR|Sham Treatment - FMT|Participants in this arm will receive a total of 5 sham FMT treatments administered weekly, followed by an additional 5 maintenance sham FMT treatments on a monthly basis. The first induction treatment will consist of 30 grams, with subsequent treatments comprising 15 grams each.
62373474|NCT04759898|ACTIVE_COMPARATOR|Stimulation (noninvasive recording)|Patients with Parkinson's disease or chronic stroke will be assigned to undergo EEG recording and transcranial direct current stimulation.
62745130|NCT00479817|EXPERIMENTAL|Arm A|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 10 mg/kg IV QW
61986327|NCT03281954|PLACEBO_COMPARATOR|Placebo|IV infusion once every 3 weeks for 4 doses (Cycle 1), once every 3 weeks for 4 doses (Cycle 2) and once every 3 weeks after surgery for 1 year after first dose
61986328|NCT03281954|EXPERIMENTAL|Atezolizumab|IV infusion, 1200mg, once every 3 weeks for 4 doses (Cycle 1), once every 3 weeks for 4 doses (Cycle 2) and once every 3 weeks after surgery for 1 year after first dose
61986329|NCT05106244|EXPERIMENTAL|family self-nursing mode|
62373475|NCT04759898|SHAM_COMPARATOR|Sham (noninvasive recording)|Patients with Parkinson's disease or chronic stroke will be assigned to undergo EEG recording and sham transcranial direct current stimulation.
62373476|NCT04759898|EXPERIMENTAL|Stimulation (invasive recording)|Patients with Parkinson's disease undergoing surgery for deep brain stimulation will be studied using electrocorticography combined with transcranial direct current stimulation
62373477|NCT03712995|EXPERIMENTAL|Cutler-Beard modified with graft|Reconstruction of Upper Eyelid With a Newly Modified Cutler-Beard Technique With Tarsoconjunctival Graf
62373478|NCT00682760|ACTIVE_COMPARATOR|1|Korean botulinum toxin A treatment
62373479|NCT00682760|PLACEBO_COMPARATOR|2|Botox treatment
62373480|NCT05642793|EXPERIMENTAL|group 1 (proactive use of conbercept after vitrectomy)|proactive use of conbercept after vitrectomy
62373481|NCT05642793|EXPERIMENTAL|group 2 (passive use of conbercept after vitrectomy)|passive use of conbercept after vitrectomy
62373482|NCT04722380|EXPERIMENTAL|test group|10 infrabony defects treated surgically with Nigella Sativa oil extract Mixed with xenograft
62373483|NCT04722380|PLACEBO_COMPARATOR|control group|10 infrabony defects treated surgically with xenograft alone
62373484|NCT00993980|EXPERIMENTAL|1|qigong
62373485|NCT00993980|ACTIVE_COMPARATOR|2|exercise therapy
62373486|NCT01131130|EXPERIMENTAL|Investigational contact lens|Bausch \& Lomb
62745131|NCT00479817|EXPERIMENTAL|Arm B|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 3 mg/kg IV QW
61986330|NCT05106244|NO_INTERVENTION|hospital nursing mode|
61986331|NCT00940212|EXPERIMENTAL|A|AZD2423
61986332|NCT00940212|EXPERIMENTAL|B|Placebo
62373487|NCT01131130|ACTIVE_COMPARATOR|Acuvue Oasys Contact Lens|Johnson \& Johnson Lens
62373488|NCT01131130|ACTIVE_COMPARATOR|Air Optix Aqua|Ciba Vision
62745132|NCT00479817|ACTIVE_COMPARATOR|Arm C|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 placebo
62745133|NCT02720055|EXPERIMENTAL|Psychological Workbook|Psychological work book containing information and activities aimed at improving outcomes.
62745134|NCT02720055|ACTIVE_COMPARATOR|Basic information workbook|Basic information which represents current practice
62745135|NCT05327842|EXPERIMENTAL|New training simulator|Participants received training with new simulator
62745136|NCT05327842|ACTIVE_COMPARATOR|Traditional method|Participants received traditional training
62745137|NCT01558492|EXPERIMENTAL|All subjects|Carboplatin and Paclitaxel
62745138|NCT00387569|EXPERIMENTAL|Cohort 1|Experimental (20ug); Active Comparator/Placebo
62745139|NCT00387569|EXPERIMENTAL|Cohort 2|Experimental (60ug); Active Comparator/Placebo
62745140|NCT00387569|EXPERIMENTAL|Cohort 3|Experimental (200ug); Active Comparator/Placebo
62745141|NCT05347680|ACTIVE_COMPARATOR|intubating laryngeal Tube Suction|Fiberoptic Intubation through intubating laryngeal Tube Suction
62745142|NCT05347680|ACTIVE_COMPARATOR|Ambu AuraGain Laryngeal Mask|Fiberoptic Intubation through Ambu AuraGain Laryngeal Mask
62373489|NCT02918422|EXPERIMENTAL|High Carbohydrate No Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 55% CHO, 20% PRO and 25% fat with \~6oz Cheese (gouda or cheddar) per day being used as a fat source.
62745143|NCT03541486|EXPERIMENTAL|Investigational Therapy (ASC)|75 grams of pharmacological ascorbate, daily (M-F) 600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique
62745144|NCT03541486|ACTIVE_COMPARATOR|Standard Therapy (ChemoRT)|600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique
62745145|NCT02453945|EXPERIMENTAL|Medical Support Bra|ClearPoint Medical Support Bra worn by patients during their post-cardiac surgery hospital stay (approximately 5-7days).
62745146|NCT02453945|NO_INTERVENTION|Control|Usual Care
62373490|NCT02918422|EXPERIMENTAL|High Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 55% CHO, 20% PRO 25% and Fat 25% with \~6oz Cheese (gouda or cheddar) per day being used as a fat source.
62373491|NCT02918422|EXPERIMENTAL|Mod. Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 30% CHO, 20% PRO and 50% Fat with \~6oz Cheese (gouda or cheddar) per day being used as a fat source.
62373492|NCT02918422|EXPERIMENTAL|Low Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 10% CHO, 20% PRO and 70% Fat with \~6oz Cheese (gouda or cheddar) per day being used as a fat source.
62373493|NCT02587728||Carpal Tunnel Blood Draw|Participants with confirmed diagnosis of Carpal Tunnel Syndrome who will undergo blood draw for laboratory analysis for amyloidosis.
62373494|NCT01289561|EXPERIMENTAL|Alcohol self-administration|All participants will participate in seven sessions. In three sessions, each participant will consume a beverage containing alcohol and caffeine. In three separate sessions, participants will consume a beverage containing alcohol and caffeine-placebo. In the final session, all participants may choose which beverage they consume. Participants and research assistants will be blinded to inclusion of caffeine/caffeine-placebo in beverage, but each beverage will be labeled for identification (e.g., A or B).
62373495|NCT02282488|EXPERIMENTAL|Group 1: Low protein formula|Low protein formula
62745147|NCT02889289|EXPERIMENTAL|Xbox One Kinect Gaming|15 sessions of supervised physical therapy using 2 commercially available Xbox One Kinect game.
62745148|NCT04521686|EXPERIMENTAL|LY3410738|Phase 1 dose escalation - Multiple doses of LY3410738
62745149|NCT04521686|EXPERIMENTAL|LY3410738 alone or in combination with gemcitabine and cisplatin or in combination with durvalumab|Phase 1 dose expansion - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of LY3410738 alone or in combination with gemcitabine plus cisplatin or in combination with durvalumab
62745150|NCT04622891|EXPERIMENTAL|clarithromycin|clarithromycin group
62745151|NCT04622891|ACTIVE_COMPARATOR|Azithromycin|azithromycin group
62745152|NCT04622891|PLACEBO_COMPARATOR|control|control group
62745153|NCT01452061||ASD|Participants with autism spectrum disorder.
62745154|NCT01452061||ADHD/DD|Participants with attention deficit/hyperactivity disorder, developmental delay or psychiatric disorder.
62745155|NCT01452061||Siblings|Siblings without a developmental or psychiatric disorder.
62745156|NCT01452061||Control|Unrelated individuals without a developmental or psychiatric disorder.
62745157|NCT02248441|EXPERIMENTAL|Daily RIC|Daily ischemic conditioning treatment
62745158|NCT02679144|EXPERIMENTAL|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
62745159|NCT02748668||ECMO|No intervention. Blood specimen collection.
62745160|NCT02748668||Control|No intervention. Blood specimen collection.
62745161|NCT03455933|EXPERIMENTAL|Shockwave Light Pain Group|Sham Comparator. It will received a light intensity shockwave in the lateral epicondyle regulated until reach a 3/10 in the Visual Analog Scale (VAS) scale.
62745162|NCT03455933|EXPERIMENTAL|Shockwave Moderate Pain Group|Experimental Intervention. It will received a moderate intensity shockwave in the lateral epicondyle regulated until reach a 6/10 in the Visual Analog Scale (VAS) scale.
62745163|NCT03455933|OTHER|Cold Pressure Group|Control Group. The cold pressure test will be apply to this group. The investigators will use a container with an outer part filled with ice and an inner part filled with water, both separated by a screen that prevents direct contact between the ice and the hand. The water will be regularly stirred to maintain the temperature near to 0.7ºC.
62745164|NCT01411579||Clinical Benefit|The patients responding to the chemotherapy, i.e. who show at least a non progressive disease
62745165|NCT01411579||Non responder|The patients non responding to the chemotherapy, i.e. who show a progressive disease
62745166|NCT04065074|EXPERIMENTAL|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
62745167|NCT03278717|EXPERIMENTAL|Olaparib and Cediranib|"Patients will receive oral olaparib 300mg BD and oral cediranib 20mg OD.~Patients will attend hospital for a 2 weekly review for the first 8 weeks, then 4 weekly for year 1 and 8 weekly for year 2 onwards until discontinuation of all trial drugs. Treatment may continue beyond progression until the next line of treatment if the patient is deemed to still be deriving clinical benefit. QOL instruments will be collected at baseline, every clinic visit and continue to be completed after relapse."
62745168|NCT03278717|ACTIVE_COMPARATOR|Olaparib|"Patients will receive oral olaparib 300mg BD.~Patients will attend hospital for a 2 weekly review for the first 8 weeks, then 4 weekly for year 1 and 8 weekly for year 2 onwards until discontinuation of all trial drugs. Treatment may continue beyond progression until the next line of treatment if the patient is deemed to still be deriving clinical benefit. QOL instruments will be collected at baseline, every clinic visit and continue to be completed after relapse."
62745169|NCT04822896|EXPERIMENTAL|Kinesthetic Motor Imagery|They will be asked to imagine the exercises kinesthetically from a first person perspective (as if they were doing it themselves).
62373496|NCT02282488|EXPERIMENTAL|Group 2: high protein formula|High protein formula
62373497|NCT02282488|NO_INTERVENTION|Group Breastfeeding|Breastfeeding
62373498|NCT02865928|EXPERIMENTAL|Bupivicaine HCl|Ultrasound guided serratus plane block with bupivacaine HCl.
62745170|NCT04822896|EXPERIMENTAL|Visual Motor Imagery|They will be asked to imagine the exercises visually from a third person perspective (as if they were watching from the mirror / from the mirror while doing it themselves).
62745171|NCT04822896|ACTIVE_COMPARATOR|Real Physical Movements|They will be asked to actually do the exercises shown in the video.
62745172|NCT01533337|OTHER|finger|Free dorsal digital flap transferring is used for reconstruction of soft-tissue defects
62745173|NCT01956097|EXPERIMENTAL|HX106 590mg|HX106 590mg/day
62745174|NCT01956097|EXPERIMENTAL|HX106 1180mg|HX106 1180mg/day
62745175|NCT01956097|PLACEBO_COMPARATOR|Placebo|Placebo
62745176|NCT02732795|EXPERIMENTAL|Morphine dosing|Evaluating morphine pharmacokinetics (PK) in 3 groups: normal controls, children with severe OSAS, and obese children with OSAS. Morphine is dosed on ideal body weight in obese children, as recommended by manufacturer. Biomarkers were taken from patients to evaluate their relation to changes in morphine PK.
62745177|NCT03252444|EXPERIMENTAL|Biofeedback group|After 1 minute of rest, participants will perform 6 trials of bilateral, active, weighted arm elevation in the scapular plane and a therapist classifies the scapular motion into specific patterns of scapular dyskinesis. After the evaluation of scapular dyskinesis, the kinematics and surface EMG (sEMG) data will be collected during 5 trials of the same arm movements and 3 selected exercises.
62745178|NCT03252444|ACTIVE_COMPARATOR|Conscious control group|Conscious correction of scapular orientation will be taught to the subjects in the manner described in previous studies. The starting position is determined in each individual by actively positioning the scapula between maximal upward and downward rotation, external and internal rotation, and posterior and anterior tilt. Scapular assistance test (SAT) is also conducted by passively assisting patients' scapula into appropriate position to correct scapula dyskinesis
62745179|NCT01615952||Sitting Position (head of bed 90 degrees)|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
62745180|NCT01615952||Semi-sitting position (45 degrees)|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
62745181|NCT01615952||Supine position|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
62745182|NCT04703270||Exposed|Expectant mothers with a positive nasopharyngeal swab for SARS-CoV-2 at any point during pregnancy from 24 weeks gestation regardless of antibody status.
62745183|NCT04703270||Seropositive|Expectant mothers with a negative nasopharyngeal swab for SARS-CoV-2 at any point during pregnancy from 24 weeks gestation but positive IgM/IgG antibodies against SARS-CoV-2.
62745184|NCT04703270||Unexposed|Expectant mothers with a negative nasopharyngeal swab for SARS-CoV-2 at any point during pregnancy from 24 weeks gestation and negative IgM/IgG antibodies against SARS-CoV-2.
62745185|NCT06661278||Affected|Children diagnosed with Long QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia
62745186|NCT06661278||Unaffected|Healthy children (siblings of affected or those undergoing screening)
62373499|NCT02865928|PLACEBO_COMPARATOR|Normal Saline|Placebo injection on operated side, same technique as experimental group.
62373500|NCT02233582|EXPERIMENTAL|ibuprofen plus ascent to high altitude|subjects randomized to this arm will take ibuprofen 200 mg 3 times daily during ascent and at altitude.
62373501|NCT02233582|PLACEBO_COMPARATOR|sugar pill plus ascent to high altitude|subjects randomized to this arm will receive the placebo
62373502|NCT03014245||Pregnant|Normal pregnant women (first baby) singleton
62373503|NCT03014245||Control|Non pregnant healthy women
62373504|NCT02579863|EXPERIMENTAL|Pembrolizumab + Lenalidomide + Dexamethasone|Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS lenalidomide 25 mg orally (PO) on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
62373505|NCT02579863|ACTIVE_COMPARATOR|Lenalidomide + Dexamethasone|Participants received lenalidomide 25 mg PO on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
62373506|NCT04324476|EXPERIMENTAL|Alternating Bevacizumab plus XELOX and Bevacizumab plus XELIRI|"Induction chemotherapy:~Alternating Bevacizumab plus XELOX and Bevacizumab plus XELIRI:~Bevacizumab: 5mg/kg, iv, 30min, d1, 2w; Oxaliplatin: 85mg/㎡, iv, 120min, d1, 4w; Irinotecan: 150mg/㎡, iv, 90min, d15, 4w; Capecitabine: 1000mg/㎡, bid, d2-8, 2w.~Maintenance chemotherapy:~Bevacizumab: 7.5mg/kg, iv, 30min, d1, q3w; Capecitabine: 1000mg/㎡, bid, d2-15, 2w."
62373507|NCT01440972|ACTIVE_COMPARATOR|Exercise without PBFR|
62373508|NCT01440972|EXPERIMENTAL|exercise with PBFR|
62373509|NCT03001414|EXPERIMENTAL|Placebo followed by Autologous EPCs transfected with eNOS|4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 1 followed by 4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 2
62373510|NCT03001414|EXPERIMENTAL|Autologous EPCs transfected with eNOS followed by Placebo|4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 1 followed by 4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 2
62745187|NCT01794078|PLACEBO_COMPARATOR|Control|Oral placebo, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
62745188|NCT01794078|EXPERIMENTAL|Aminophylline 400 mg|Oral aminophylline 400 mg, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
62745189|NCT01794078|EXPERIMENTAL|ambrisentan 5 mg|Oral ambrisentan 5 mg, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
62745190|NCT01794078|EXPERIMENTAL|Combined aminophylline 400 mg and ambrisentan 5 mg|Oral combined aminophylline 400 mg and ambrisentan 5 mg, administered as single doses during simulated altitude episodes Cycle 1 and Cycle 2
62745191|NCT05896098||Easy laryngoscopy|Cormack Lehane Classification 1-2a
62745192|NCT05896098||Difficult laryngoscopy|Cormack Lehane Classification 2b-3-4
62373511|NCT03001414|EXPERIMENTAL|Autologous EPCs transfected with eNOS|4 monthly IV injections of Autologous EPCs transfected with human eNOS in Course 1 followed by 4 monthly injections of Autologous EPCs transfected with human eNOS in Course 2 (total of 160 million cells)
62373512|NCT00236210|ACTIVE_COMPARATOR|VIP program|Risk assessment, lifestyle counselling, exercise program
62373513|NCT00236210|NO_INTERVENTION|Standard Care|
62373514|NCT01518673||X-rays|
62373515|NCT06507371|EXPERIMENTAL|Treatment Arm|Participants will receive 5\*5Gy node-sparing modified short-course radiation (radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes) concurrently with CAPOX and tislelizumab regimens: Oxaliplatin, 130mg/m2, intravenous infusion,d1 of each cycle; Capecitabine, 1000mg/m2, PO, BID, d1-14 and tislelizumab, 200mg intravenous infusion d1 of each cycle. CAPOX and tislelizumab repeat every 3 weeks for 4 cycles. After treatment, digital rectal examination, pelvic MRI, endoscopy, and biopsy will be performed to evaluate the tumor regression grade. Patients will receive TME surgery after the chemo-immunotherapy, pCR rate and TRG grade will be evaluated.
62373516|NCT06507371|EXPERIMENTAL|Standard Arm|Participants will receive 5\*5Gy standard short-course radiation (radiation targeting the tumor bed and surrounding tumor-draining lymph nodes) concurrently with CAPOX regimens: Oxaliplatin, 130mg/m2, intravenous infusion,d1 of each cycle; Capecitabine, 1000mg/m2, PO, BID, d1-14. CAPOX repeat every 3 weeks for 4 cycles. After treatment, digital rectal examination, pelvic MRI, endoscopy, and biopsy will be performed to evaluate the tumor regression grade. Patients will receive TME surgery after the chemo-immunotherapy, pCR rate and TRG grade will be evaluated.
62552871|NCT03000062|NO_INTERVENTION|Control group|"12 Family physicians in primary care will constitute the Control group. They will enroll 10 patients each from their ordinary practice. The physicians will not be provided with any information of the treatment model of the study but they will have all information about how to collect and register data.~The patients on this group will also sign consent to provide data and therefore they will know about the study but they do not get any specific information about weight loss other than the general information that their physician may tell them.~The patients in the Control Group will be asked to give data on inclusion visit and again 12 months later, and also at 6 and 12 months thereafter (i.e. 0, 12, 18 and 24 months from inclusion)."
62552872|NCT01194401||Cohort|
62552873|NCT03514108|ACTIVE_COMPARATOR|Hydralazine Isosorbide Dinitrate|"Tablet BiDil (Hydralazine 37.5 mg/ isosorbide dinitrate (ISDN) 20 mg) 2 tablets x 3 daily.~Average treatment period 4 years."
62552874|NCT03514108|PLACEBO_COMPARATOR|Placebo (Hydralazine Isosorbide Dinitrate)|Tablet Placebo 2 tablets x 3 daily. Average treatment period 4 years.
62552875|NCT03514108|ACTIVE_COMPARATOR|Metformin|Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily). Average treatment period 4 years.
62552876|NCT03514108|PLACEBO_COMPARATOR|Placebo (Metformin)|Tablet Placebo 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily). Average treatment period 4 years.
62552877|NCT03514095|NO_INTERVENTION|Control Group|The control group shall participate in the usual home-based care provided by their carer.
62552878|NCT03514095|EXPERIMENTAL|Individual Cognitive Stimulation Therapy|The experimental group shall participate in the Making a Difference 3 program (Yates et al., 2015) is aimed at elderly people with mild or major neurocognitive disorder, where informal caregiver (family, friend or neighbour) assume a partnering role in an one-to-one approach. The program is composed by a range of stimulating activities (sessions), each with two levels of difficulty. The carers are introduced to a set of key principles that guides them during individual cognitive stimulation sessions, tailoring the interventions to the needs and reality of the elderly participants.
62552879|NCT04379427|EXPERIMENTAL|Optimization and control 1|The first study part/arm includes 12 patients and will be used for optimization and control of the measurement algorithms of the Sanmina biosensors.
62552880|NCT04379427|EXPERIMENTAL|Optimization and control 2|The second study part/arm includes 12 patients and will be used for optimization and control of the measurement algorithms of the Sanmina biosensors.
62552881|NCT04379427|OTHER|Precision and accuracy|During the third study part with enrolment of 36 patients, the precision and accuracy of the final Sanmina biosensor algorithm will be demonstrated.
62552882|NCT03935698|EXPERIMENTAL|Physiotherapy|12 weekly 60-minute individual sessions of multimodal physiotherapy including education, stretching techniques, pelvic floor muscle biofeedback as well as home exercises.
62552883|NCT04884139|EXPERIMENTAL|Dovato arm|DTG/3TC
62552884|NCT04884139|ACTIVE_COMPARATOR|Biktarvy arm|BIC/FTC/TAF
62745193|NCT06608238|ACTIVE_COMPARATOR|Arm A|D-MNA 200 mcg, intradermal patch, given once weekly for 2 weeks.
62745194|NCT06608238|ACTIVE_COMPARATOR|Arm B|D-MNA 100 mcg intradermal patch, given once weekly for 2 weeks
62745195|NCT06608238|PLACEBO_COMPARATOR|Arm C|P-MNA, intradermal patch, given once weekly for 2 weeks
62745196|NCT00945347|NO_INTERVENTION|Baseline|Visit 1
62745197|NCT00945347|ACTIVE_COMPARATOR|Miglustat|Nasal instillation of Miglustat (visit 2 or 3)
62745198|NCT00945347|PLACEBO_COMPARATOR|Placebo|Nasal instillation of placebo (visit 3 or 2)
62745199|NCT00610350|EXPERIMENTAL|L|
62745200|NCT00610350|EXPERIMENTAL|P|
62745201|NCT06385795|EXPERIMENTAL|NOE-115|Escalating doses of NOE-115 capsules
62745202|NCT05804656|EXPERIMENTAL|CKDB-501A|
62745203|NCT05804656|ACTIVE_COMPARATOR|Botox®|
62745204|NCT02285023||CU-Q2oL|"* Evaluation by the Urticaria Activity Score (UAS7)~* Fill the DLQI and CU-Q2oL questionnaire"
62745205|NCT01916252|ACTIVE_COMPARATOR|MEL-200|bortezomib/lenalidomide/dexamethasone (VRD-GEM) induction treatment followed by high-dose melphalan-200 (MEL-200)
62552885|NCT00725257|ACTIVE_COMPARATOR|1|Low-carbohydrate, energy-restricted, Mediterranean-type diet
62552886|NCT00725257|ACTIVE_COMPARATOR|2|Low-fat diet
62552887|NCT03950154|EXPERIMENTAL|Arm 1|"Bevacizumab \& Oxaliplatin \& Capecitabine \& PD1-T cells~Bevacizumab, 7.5mg/kg, intravenous infusion, d1; Oxaliplatin, 130mg/m2, intravenous infusion, d1; Capecitabine, 1g/m2, oral administration, d1-14; PD1-T cells, 1x10\^10 (10 billion), intravenous infusion, d17; Q3W, 6 cycles. After 6 cycles, Bevacizumab, 7.5mg/kg, intravenous infusion, d1; Capecitabine, 1g/m2, oral administration, d1-14; Q3W, maintenance treatment."
62745206|NCT01916252|ACTIVE_COMPARATOR|BUMEL|bortezomib/lenalidomide/dexamethasone (VRD-GEM) induction treatment followed by busulfan-melphalan (BUMEL) chemotherapy and consolidation with VRD-GEM
62552888|NCT03950154|ACTIVE_COMPARATOR|Arm 2: Control|"Bevacizumab \& Oxaliplatin \& Capecitabine~Bevacizumab, 7.5mg/kg, intravenous infusion, d1; Oxaliplatin, 130mg/m2, intravenous infusion, d1; Capecitabine, 1g/m2, oral administration, d1-14; Q3W, 6 cycles. After 6 cycles, Bevacizumab, 7.5mg/kg, intravenous infusion, d1; Capecitabine, 1g/m2, oral administration, d1-14; Q3W, maintenance treatment."
62552889|NCT05114733|EXPERIMENTAL|InVEST|4 month treatment condition
62552890|NCT05114733|NO_INTERVENTION|delayed invest|participants in delayed invest wait four months and are reassessed before taking part in the intervention
62552891|NCT01694225|EXPERIMENTAL|bubble package for monthly prescription|use of bubble packaging for monthly prescription
62552892|NCT06424197|EXPERIMENTAL|Norm Based Messages|One of 3 messaging entreaties based on normative perceptions of colorectal cancer screening, and one no norm-based messaging arm.
62552893|NCT06424197|EXPERIMENTAL|Fear Reduction Message|Participants randomized to receive (or not receive) messaging entreaty to address colorectal cancer screening fears.
62552894|NCT06424197|EXPERIMENTAL|Commitment|Participants randomized to indicate explicit commitment to return FIT Kits for processing.
62552895|NCT06424197|NO_INTERVENTION|Control|Participants receive no health messages.
62552896|NCT03764618|EXPERIMENTAL|Fostamatinib|Initial dose is 100 mg by mouth (PO) twice a day (bid). At week 4 dose will be increased to fostamatinib 150 mg PO bid if subjects have adequately tolerated the study drug in the opinion of the Investigator.
62552897|NCT03764618|PLACEBO_COMPARATOR|Placebo|Initial dose is 100 mg by mouth (PO) twice a day (bid). At week 4 dose will be increased to placebo 150 mg PO bid if subjects have adequately tolerated the study drug in the opinion of the Investigator.
62745207|NCT03362502|EXPERIMENTAL|PF-06939926|
62745208|NCT04353375|EXPERIMENTAL|HMPL-453|HMPL-453 150mg QD HMPL-453 300mg QD
62745209|NCT04017572|ACTIVE_COMPARATOR|Standard treatment|APD-treatment with a net volume of 12 L 1.36 % anhydrous glucose peritoneal dialysis solution during 540 minutes.
62552898|NCT03719027|EXPERIMENTAL|Study population|Patients followed-up after the diagnosis of pulmonary embolism (PE) Patients who survived after a PE and who consent to participate to the prospective interventional phase of the PREVA-CTEPH study have dyspnea assessment, EKG, and echocardiography to investigate the diagnosis of CTEPH
62552899|NCT05161338|EXPERIMENTAL|FROZEN EMBRYO TRANSFER|Women who undergo an artificial cycle for frozen embryo transfer and receive luteal phase support.
62552900|NCT00005811|EXPERIMENTAL|Treatment (topotecan hydrochloride)|"INDUCTION: Patients receive topotecan hydrochloride IT over 5 minutes twice weekly for 6 weeks.~CONSOLIDATION: Beginning 1 week after completion of induction, patients receive topotecan hydrochloride IT over 5 minutes weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning 2 weeks after completion of consolidation, patients receive topotecan hydrochloride IT over 5 minutes twice monthly for 4 months and then monthly through year 1."
62552901|NCT02907060|EXPERIMENTAL|Mechanical cervical ripening|mechanical cervical ripening with a Cook® Cervical Ripening Balloon
62552902|NCT02907060|ACTIVE_COMPARATOR|Pharmacological cervical ripening|pharmacological cervical ripening with a 10mg slow releasing system of Dinoprostone (Propess®)
62552903|NCT06264063|EXPERIMENTAL|experimental group|patients with dystonia were submitted to a neuropsychological evaluation
62552904|NCT06264063|EXPERIMENTAL|control group|healthy patients were submitted to a neuropsychological evaluation
62552905|NCT00200902|ACTIVE_COMPARATOR|MED|"For medication treatment, three different types were utilized and assigned specifically to each subject depending on their condition:~MED 1: Venlafaxine XR. MED 2: Duloxetine (Cymbalta) MED 3: Escitalopram (Lexapro)"
62745210|NCT04017572|ACTIVE_COMPARATOR|Optimized treatment|APD-treatment with a net volume of 14 L 2.27 % anhydrous glucose peritoneal dialysis solution during 280 minutes followed by a net volume of 10 L 0.1 % glucose dialysis fluid during 200 minutes.
62745211|NCT06660290|EXPERIMENTAL|REFRESH® Classic, then 0.003% AR-15512|One drop of REFRESH® Classic ophthalmic solution administered topically to the eye, followed by 0.003% AR-15512 ophthalmic solution administered topically to the eye
62552906|NCT00200902|PLACEBO_COMPARATOR|Placebo (PBO)|Subjects enrolled will receive interpersonal clinical interaction (ICI) along with a placebo treatment (Interaction and assessment as in ICI plus double blinded treatment with placebo tablets).
62552907|NCT00200902|OTHER|Interpersonal Clinical Interaction (ICI)|Subjects assigned to the interpersonal clinical interaction (ICI) will undergo a one-week waiting period after the initial assessment. Visits will involve a session with a research nurse that will be approximately 20 minutes in length; visits at baseline, end of lead-in, and 1, 2, 4, and 8 weeks also will include a brief (5-10 minutes) meeting with a physician.
62552908|NCT05547997|EXPERIMENTAL|two way traction|The study group will receive 3-point bending cervical extension traction following the protocol of Harrison et al. The duration of each session will starte at approximately three minutes and increased one minute per session until reaching the goal of 20 minutes per session
62552909|NCT05547997|ACTIVE_COMPARATOR|traditional treatment|Stretching exercises: Patients will perform the stretching program 3 times a week; with a single session taking about 10 minutes to perform.
62552910|NCT05999383|EXPERIMENTAL|Placebo marijuana and regular cigarette|Participants will vape a 50/50 mixture of placebo marijuana (0% THC) and regular cigarette (25.94 mg/g nicotine content)
62745212|NCT02589665|EXPERIMENTAL|50 mg Mirikizumab IV Q4W (Induction)|50 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period. Participants who do not have a clinical response may choose to participate in the unblinded study extension period.
62373517|NCT06507371|OTHER|Exploration Arm|Participants will receive 5\*5Gy standard short-course radiation (radiation targeting the tumor bed and surrounding tumor-draining lymph nodes) concurrently with CAPOX and tislelizumab regimens: Oxaliplatin, 130mg/m2, intravenous infusion,d1 of each cycle; Capecitabine, 1000mg/m2, PO, BID, d1-14 and tislelizumab, 200mg intravenous infusion d1 of each cycle. CAPOX and tislelizumab repeat every 3 weeks for 4 cycles. After treatment, digital rectal examination, pelvic MRI, endoscopy, and biopsy will be performed to evaluate the tumor regression grade. Patients will receive TME surgery after the chemo-immunotherapy, pCR rate and TRG grade will be evaluated.
62745213|NCT02589665|EXPERIMENTAL|200 mg Mirikizumab IV Q4W (induction)|"200 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period.~Participants who do not have a clinical response may choose to participate in the unblinded study extension period."
62745214|NCT02589665|EXPERIMENTAL|600 mg Mirikizumab IV Q4W (Induction)|"600 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period.~Participants who do not have a clinical response may choose to participate in the unblinded study extension period."
62745215|NCT02589665|PLACEBO_COMPARATOR|Placebo IV Q4W (Induction)|Placebo administered every 4 weeks (Q4W) intravenously (IV) during the induction period.
62745216|NCT02589665|EXPERIMENTAL|200 mg Mirikizumab SC Q4W (Maintenance)|Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) Q4W during the maintenance period.
62745217|NCT02589665|EXPERIMENTAL|200 mg Mirikizumab SC Q12W (Maintenance)|Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) once every 12 weeks (Q12W) during the maintenance period.
62373518|NCT01915290||1600 elderly participants|Norwegian elderly population
62373519|NCT01641224|ACTIVE_COMPARATOR|TCM (Traditional Chinese medicine)|Formula for pain and diarrhea, Atractylodes (\~10-15g), Paeonia Lactiflora (\~15-30g), Tangerine Peel (\~10g), Ledebouriella Root (\~10g), Radix codonopsitis (\~10-15g), Radix curcumae (\~10g), Fingered citron (\~10g), Tuckahoe (\~15g), etc.
62373520|NCT01641224|ACTIVE_COMPARATOR|Pinaverium|
62373521|NCT01641224|PLACEBO_COMPARATOR|Placebo|Placebo is blindly given to patients
62373522|NCT06267716|ACTIVE_COMPARATOR|PENG block|Immediately after the insurance of general anaesthesia and LFCN block application, PENG block was performed by the primary investigator (B.C) following proper skin disinfection with the patient in the supine position. Under the guidance of a low-frequency curvilinear ultrasound probe, the iliopubic eminence and the psoas tendon were identified, and local anaesthetic (20 ml 0,375% bupivacaine) was injected between the periosteum and psoas tendon following negative aspiration.
62373523|NCT06267716|EXPERIMENTAL|IPP block|After ensuring aseptic conditions, the low-frequency curvilinear ultrasound probe was transversely placed caudad to the anterior superior iliac spine, then rotated anticlockwise and slid along the inguinal ligament to detect the head of the femur, as described by Nielsen et al. The primary investigator (B.C.) directed the needle tip into the iliopsoas plane between the iliopsoas muscle and iliofemoral ligament through an in-plane approach, and 10 ml of 0,375% bupivacaine was injected.
62373524|NCT00796549|EXPERIMENTAL|BIBW 2992|BIBW 2992 in EGFR FISH positive NSCLC patients
62745218|NCT02589665|PLACEBO_COMPARATOR|Placebo SC Q4W (Maintenance)|Induction placebo responders: Placebo administered subcutaneously (SC) Q4W during the maintenance period.
62745219|NCT02589665|EXPERIMENTAL|600mg Mirikizumab IV Q4W Extension Open-Label|Induction non-responders: 600 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
62373525|NCT06120192|EXPERIMENTAL|Research group|Receives the full piano training
62745220|NCT02589665|EXPERIMENTAL|1000mg Mirikizumab IV Q4W Extension Open-Label|Induction non-responders: 1000 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
62745221|NCT02589665|EXPERIMENTAL|200mg Mirikizumab SC Q4W Extension Open-Label|Extension Induction responders: 200 mg mirikizumab administered subcutaneously (SC) once every 4 weeks (Q4W) during the Extension Open-Label
62745222|NCT01858142|EXPERIMENTAL|Preparation intervention|The parental presence decision tool will be delivered as an App shown to families using an iPAD and a set of headphones. This App will include information on what to expect in the operating room as well as the role of the parents. The App incorporates the basic principles of other effective perioperative preparation interventions (e.g., providing both sensory and procedural information) and is tailored to the local context. In addition to preparatory information, the App will also inform parents of the role of parent anxiety on children's outcomes in the operating room.
62745223|NCT01858142|PLACEBO_COMPARATOR|Standard preparation|In standard preparation condition, treating nurses and anesthesiologists will provide information to parents as they standardly do when parents are present at induction; this includes information on logistical issues and safety in the operating room (e.g., where to stand, how to put on gown) and risks of anesthesia induction. Additionally, parents in the standard preparation condition will view a summary of this standard information as text on an iPAD.
62745224|NCT02038140|OTHER|Zimmer TM Total Ankle System|Primary or revision total ankle arthroplasty subjects that receive the Zimmer Trabecular Metal Total Ankle System
62745225|NCT06527144|EXPERIMENTAL|3mg TQC3721 Suspension for Inhalation (Twice a day)|Two syringes of TQC3721 suspension for inhalation (1ml:1.5mg), twice a day for 4 weeks.
62745226|NCT06527144|EXPERIMENTAL|6mg TQC3721 Suspension for Inhalation (Twice a day)|one syringe of TQC3721 suspension for inhalation（1ml:6mg）and one TQC3721 suspension placebo for inhalation (1ml:0mg), twice a day for 4 weeks.
61986333|NCT02885961|OTHER|Dabigatran|"All patients will be entered into the arm, i.e. this is a single arm study. All patients will complete 2 FDG PET scans. All patients will receive dabigatran (direct thrombin inhibitor) at a dose of 110mg twice daily (oral).~The drug will be given for 24 days (+/-3 days). The variation in duration reflects that scans are completed Monday to Friday only."
62373526|NCT01339780|EXPERIMENTAL|Breast Cancer|
62373527|NCT01339780|EXPERIMENTAL|Prostate Cancer|
62373528|NCT01519336|ACTIVE_COMPARATOR|A danoprevir|
62373529|NCT01519336|PLACEBO_COMPARATOR|B darunavir|
62745227|NCT06527144|PLACEBO_COMPARATOR|Placebo for TQC3721 Suspension for Inhalation (Twice a day)|Two syringes of placebo for TQC3721 suspension for inhalation (1ml:0mg), twice a day for 4 weeks.
62373530|NCT01519336|EXPERIMENTAL|C danoprevir/darunavir|
62745228|NCT04130724||Ketogenic diet|Subjects consuming either a ketogenic (\<30g carbohydrate per day) or a low-carb (\<100g carbohydrate per day) diet.
62373531|NCT05976906|EXPERIMENTAL|CNK-UT cells therapy|"1. Dose Escalation： Cohort A：Intravenous injection of CNK-UT cells directly. Cohort B：Intravenous injection of CNK-UT cells after preconditioning by fludarabine and cyclophosphamide.~2. Indications Expansion:~Intravenous injection of CNK-UT cells according to the results of dose escalation."
62373532|NCT03731910|EXPERIMENTAL|HCC group|Participants who are scheduled for TARE for HCC treatment. They undergo MRI three times- before, 1- and 2-week after TARE.
62373533|NCT02269904|ACTIVE_COMPARATOR|Fluorouracil Implants and Xelox regimes|"Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.~Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished."
62373534|NCT02269904|ACTIVE_COMPARATOR|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
62373535|NCT04287205|EXPERIMENTAL|women with endometriosis|
62373536|NCT00515099|EXPERIMENTAL|Antithymocyte globulin|This group received a total of 6.5 mg/kg of antithymocyte globulin (e.g., Thymoglobulin®) divided into four doses as follows: Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.
62373537|NCT00515099|PLACEBO_COMPARATOR|Placebo|This group received a saline solution to match the Thymoglobulin doses given to the active treatment group, on Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.
62373538|NCT06002997||Control Group|Healthy pregnant women
62373539|NCT06002997||Case Group|Pregnant women with Diabetes Mellitus Type 1
62373540|NCT03336203|ACTIVE_COMPARATOR|Hyperurecemia with gout|90 patients with high SUA level (\>8 mg/dL; 480 µmol/L) with gout (EULAR's criteria) are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA \<3 mg/dL (180 µmol/L)
62373541|NCT03336203|ACTIVE_COMPARATOR|Hyperurecemia without gout|90 patients with high SUA level (\>8 mg/dL; 480 µmol/L) withot gout (EULAR's criteria) but with CKD are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA \<3 mg/dL (180 µmol/L)
62373542|NCT00666055||Group 1|30 post-menopausal HIV-infected women
62373543|NCT00666055||Group 2|12 pre-menopausal HIV-infected women
62373544|NCT03050606|EXPERIMENTAL|Pilates|"This group will perform a modified Pilates exercise program, which will be performed using mat, accessories and studio apparatus, in individual sessions, twice a week, lasting 60 minutes.~Both groups will also receive an educational booklet with information on fibromyalgia and self-care strategies for pain management, sleep improvement, depression improvement, stress and fatigue control."
62373545|NCT03050606|ACTIVE_COMPARATOR|Aerobic|"This group will perform aerobic exercise, performed on the treadmill or stationary bike according to the choice of the patient. The training will be performed controlling the heart rate of training. The exercises will be performed individually, twice a week and each session will last 60 minutes.~Both groups will also receive an educational booklet with information on fibromyalgia and self-care strategies for pain management, sleep improvement, depression improvement, stress and fatigue control."
62373546|NCT04557007||Treatment-naive NSCLC patients|Treatment-naive NSCLC patients receiving immunotherapy (pembrolizumab) alone or in combination With chemotherapy divided in groups based on treatment administered. Clinical information will be gathered at start of treatment and at evaluations every 3rd month.
62552911|NCT05999383|EXPERIMENTAL|Placebo marijuana and Very Low Nicotine Content cigarette|Participants will vape a 50/50 mixture of placebo marijuana (0% THC) and Very Low Nicotine Content cigarette (0.42 mg/g nicotine content)
62745229|NCT04130724||High-carbohydrate diet|Subjects consuming a high carbohydrate (\>100g carbohydrate per day) diet.
62745230|NCT04117490|ACTIVE_COMPARATOR|Epiitalis low dose|Two capsules twice daily 30 mins before meals (breakfast \& dinner).
62745231|NCT04117490|ACTIVE_COMPARATOR|Epiitalis mid dose|Two capsules twice daily 30 mins before meals (breakfast \& dinner).
62745232|NCT04117490|ACTIVE_COMPARATOR|Epiitalis high dose|Two capsules twice daily 30 mins before meals (breakfast \& dinner).
62745233|NCT04117490|PLACEBO_COMPARATOR|Placebo|Two capsules twice daily 30 mins before meals (breakfast \& dinner).
62745234|NCT05638802|EXPERIMENTAL|DS-7011a|Participants with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) who will be randomized to receive DS-7011a 20 mg/kg every 4 weeks by intravenous infusion.
62552912|NCT05999383|EXPERIMENTAL|Medium marijuana and regular cigarette|Participants will vape a 50/50 mixture of medium marijuana (\<5% THC) and regular cigarette (25.94 mg/g nicotine content)
62373547|NCT06019390|EXPERIMENTAL|experimental|
62373548|NCT05980611||copd patients with high upper airway symptoms|"The SNOT22 nasal subdomain (SNOT22nasal) consists of seven questions (no. 1-5 + 7-8), which include: need to blow nose, sneezing, runny nose, nasal obstruction, loss of smell or taste, post-nasal discharge and thick nasal discharge. the total SNOT22 has been found to have a median score of 7 points in healthy volunteers"
62552913|NCT05999383|EXPERIMENTAL|Medium marijuana and Very Low Nicotine Content cigarette|Participants will vape a 50/50 mixture of medium marijuana (\<5% THC) and Very Low Nicotine Content cigarette (0.42 mg/g nicotine content)
62552914|NCT05999383|EXPERIMENTAL|High marijuana and regular cigarette|Participants will vape a 50/50 mixture of high marijuana (\>10% THC) and regular cigarette (25.94 mg/g nicotine content)
62745235|NCT05638802|PLACEBO_COMPARATOR|Placebo|Participants with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) who will be randomized to receive placebo every 4 weeks by intravenous infusion.
62373549|NCT05980611||copd patients with low upper airway symptoms|"The SNOT22 nasal subdomain (SNOT22nasal) consists of seven questions (no. 1-5 + 7-8), which include: need to blow nose, sneezing, runny nose, nasal obstruction, loss of smell or taste, post-nasal discharge and thick nasal discharge. the total SNOT22 has been found to have a median score of 7 points in healthy volunteers"
62373550|NCT04371549|ACTIVE_COMPARATOR|Glue|Skin closure after cesarean section using glue
62373551|NCT04371549|ACTIVE_COMPARATOR|Monocryl|Skin closure after cesarean section using running subcuticular sutures using synthetic monofilament
62373552|NCT03366974|EXPERIMENTAL|CYP inhibition + IV/PO midazolam|"Period 1: Administration of Midazolam (IV) on day 1, Co-administration of Midazolam (IV) and Grapefruit juice on day 2~Period 2: Administration of Midazolam (PO) on day 8, Co-administration of Midazolam (PO) and Grapefruit juice on day 9~Period 3: Self-administration of Clarithromycin (PO) bid regimen on day 12-14, Co-administration of Midazolam (IV) and Clarithromycin (PO) on day 15, Co-administration of Midazolam (PO) and Clarithromycin (PO) on day 16"
62373553|NCT02034656||imatinib resistance|All mutation data from CML and Ph positive ALL patients who developed imatinib resistance during the year 2001-2009
62373554|NCT04233840|EXPERIMENTAL|Sequential administration of P1101 and anti-PD1|"Phase I of Study : To determine the safety, tolerability, DLT, and potential phase 2 dose of sequential administration of P1101 and anti-PD1~:Sequential administration 6 doses (450mcg) of P1101 and 3 doses of anti-PD1 (Escalating from 0.3, 0.75, 1.5, 3 mg/kg) for Phase I Study"
62373555|NCT04233840|ACTIVE_COMPARATOR|anti-PD1|Phase II Study Group I: anti-PD1 arm 3mg/kg 3 doses
62373556|NCT04233840|ACTIVE_COMPARATOR|P1101 monotherapy|Phase II Study Group II: P1101 arm 450mcg 12 doses
62373557|NCT04233840|EXPERIMENTAL|sequential administration of P1101 and anti-PD1|Phase II Study GroupIII:Sequential administration of 6 doses of 450mcg P1101 and followed by 3 doses of anti-PD1 dosage (base on Phase I study result)
62373558|NCT03452995|ACTIVE_COMPARATOR|Physiotherapy: LYMPHO DRAINAGE|Patients will be treated on the second postoperative day, on the 4th postoperative day and on the 6th post-operative day by means of Manual lymphodrainage consisting in special massage technique that allows lymphatic drainage, or removal of interstitial fluid stagnation according to Vodder, in association to the standard rehabilitation protocol for TKA (Kinetec, functional rehabilitation and walking training
62373559|NCT03452995|ACTIVE_COMPARATOR|Physiotherapy: KINESIOTAPING|Patients will be treated on the second postoperative day, on the 4th postoperative day and on the 6th post-operative day through the use of patches acting through the sensory system giving stimuli to receptors on the skin, in association to the standard rehabilitation protocol for TKA (kinetec, functional rehabilitation and walking training .
62373560|NCT03452995|EXPERIMENTAL|Physiotherapy:LYMPHO+KINESIO|Patients will ne treated with both kinesiotaping and lymphodreinage on the second post-operative day, on 4 days post-operative and on the 6th post-operative day, in association to the standard rehabilitation protocol for TKA (kinetec, functional rehabilitation and walking training
62373561|NCT05017168|EXPERIMENTAL|CT-P63|Single Ascending Dose
62373562|NCT05017168|PLACEBO_COMPARATOR|Placebo|Single Ascending Dose
62373563|NCT00505544||Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
62373564|NCT00505544||Questionnaire + Actigraphs|Questionnaires that ask about your sleep, symptoms, and mood. Wear actigraph to collect information on activity levels and sleep patterns for one week.
62373565|NCT02227290|EXPERIMENTAL|Naftin Cream, 2%|Once Daily
62373566|NCT02227290|PLACEBO_COMPARATOR|Placebo Cream|Once Daily
62373567|NCT03960385||Hospitalized and controls|Age-matched case of hospitalized dengue and non-dengue control
62373568|NCT03960385||Outpatient and controls|Age-matched dengue case and non-dengue control
62373569|NCT02098148|EXPERIMENTAL|Xenon/Placebo|Participants in this group will receive three treatments of 25% xenon followed by 3 treatments of placebo (room air).
62552915|NCT05999383|EXPERIMENTAL|High marijuana and Very Low Nicotine Content cigarette|Participants will vape a 50/50 mixture of high marijuana (\>10% THC) and Very Low Nicotine Content cigarette (0.42 mg/g nicotine content)
62373570|NCT02098148|EXPERIMENTAL|Placebo/Xenon|Participants in this group will receive three treatments of placebo (room air) followed by three treatments of 25% xenon.
62373571|NCT00357240|ACTIVE_COMPARATOR|A1|
62373572|NCT00357240|ACTIVE_COMPARATOR|A2|
62373573|NCT00357240|EXPERIMENTAL|A3 I|
62373574|NCT00357240|EXPERIMENTAL|A3 II|
62373575|NCT00357240|ACTIVE_COMPARATOR|B1|
62373576|NCT00357240|ACTIVE_COMPARATOR|B2|
62373577|NCT00357240|EXPERIMENTAL|B3 I|
62373578|NCT00357240|EXPERIMENTAL|B3 II|
62373579|NCT00854867|EXPERIMENTAL|Whole brain radiotherapy (WBRT) with concomitant Depocyte|Subjects will receive a total of 38.4 Gray (Gy) WBRT given over 4 weeks. Subjects will receive 3 GyWBRT on Days 1 and 2 and then 1.8 Gy on the third fourth and fifth days of WBRT treatment during Week 1. Subjects will then receive 1.8 Gy WBRT per day; 5 days out of seven, each week for the next 3 weeks. A total of 4 doses of DepoCyte (50 mg of liposomal ARA-C) will be administered intrathecally. The first dose will be administered on Day 3 (or Day 4 or 5) of Week 1, i.e. the third day of radiotherapy treatment when the dosage is reduced to 1.8 Gy. The second dose will be administered on Day 17(+2 days); the third dose will be administered on Day 31 (+2 days); the fourth dose will be administered on Day 45 (+2 days) to complete the induction phase of the protocol. Subjects will continue to receive an additional 6 doses of DepoCyte one dose every 28 days (+2 days) during the maintenance period. The first dose will be given 28 days after the last dose in the induction phase.
62391499|NCT04132817|EXPERIMENTAL|Group A Target Class A-2: Nivolumab+nab-paclitaxel+ipilimumab|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
62552916|NCT05999383|EXPERIMENTAL|High marijuana only|Participants will vape high marijuana (\>10% THC)
62373580|NCT00854867|ACTIVE_COMPARATOR|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|Subjects will receive a total of 38.4 Gy WBRT given over 4 weeks. Subjects will receive 3 Gy (WBRT on Day 1 and Day 2) and then 1.8 Gy on the third fourth and fifth days of WBRT treatment during Week 1. Subjects will then receive 1.8 Gy WBRT per day; 5 days out of seven, each week for the next 3 weeks. A total of 4 doses of DepoCyte (50 mg of liposomal ARA-C) will be administered intrathecally. The first dose will be administered on Day 29 (+2 days); the second dose will be administered on Day 43(+2 days); the third dose will be administered on Day 57 (+2 days); the fourth dose will be administered on Day 71 (+2 days) to complete the induction phase of the protocol. DepoCyte should never be administered more frequently than every 14th day. Subjects will continue to receive an additional 6 doses of DepoCyte one dose every 28 days (+2 days) during the maintenance period. The first dose will be given 28 days after the last dose in the induction phase.
62373581|NCT00194415|OTHER|1|HSV-2 antepartum testing
62373582|NCT00194415|OTHER|2|Subjects will receive safer-sex counseling during pregnancy
62373583|NCT05202002|ACTIVE_COMPARATOR|Educational video|Participants will receive an online video clip, explaining the benefits of breastfeeding.
62373584|NCT05202002|SHAM_COMPARATOR|Control group|Participants will not receive the video clip
62373585|NCT02481323|ACTIVE_COMPARATOR|Group 1|Isosorbide mononitrate 25mg bd
62373586|NCT02481323|ACTIVE_COMPARATOR|Group 2|Cilostazol 100mg bd
62373587|NCT02481323|ACTIVE_COMPARATOR|Group 3|Isosorbide mononitrate 25mg bd and cilostazol 100mg bd start immediately
62373588|NCT02481323|OTHER|Group 4|Isosorbide mononitrate 25mg bd and cilostazol 100mg bd delayed start
62373589|NCT01962467|EXPERIMENTAL|Arm 1|Each subject will receive 7 once daily doses of one of the 3 treatments (FF/LEV FDC or FF or LEV) administered as two 50 µL sprays per nostril in the morning, during each of the 3 treatment periods, as per one of the 6 possible randomization sequences. Each treatment period will be separated by a minimum washout period of 14 days
62373590|NCT03908086||RA patients|Incident patients with rheumatoid arthritis as identified by the Danish National Patient Registry and the rheumatology registry, DANBIO.
62373591|NCT03908086||General population|All other adults, as Identified by the Civil Registration System. Patients who develop RA contribute person-years in the general population cohort until RA diagnosis
62373592|NCT01435122|EXPERIMENTAL|Axitinib Administration|"The investigational drug used in this study is axitinib, and is available as tablets.~You will take the tablet orally with food. Doses should be taken around 12 hours apart continuously, without scheduled breaks. If you vomit anytime after taking a dose do not take another tablet to make up the dose but instead continue taking your next dose as planned.~Any missed dose may be taken late (up to 3 hours before the next scheduled dose); otherwise it should be skipped. If doses are missed or vomited, please keep track of this and report at your next visit."
62373593|NCT02446028|EXPERIMENTAL|BIOD-531|BIOD-531 injected twice daily
62373594|NCT02446028|ACTIVE_COMPARATOR|Humalog® Mix 75/25|Humalog® Mix 75/25 injected twice daily
62373595|NCT04464473|EXPERIMENTAL|FPl-TMS|Transcranial magnetic stimulation to the lateral frontal pole. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold.
62373596|NCT04464473|EXPERIMENTAL|MFG-TMS|Transcranial magnetic stimulation to the middle frontal gyrus. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold..
62373597|NCT04464473|ACTIVE_COMPARATOR|S1-TMS|Transcranial magnetic stimulation to primary somatosensory cortex. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold..
62373598|NCT05388734|NO_INTERVENTION|Before group|Patients in the before group are recruited during the first 4 months of the study and will not benefit from the alternative medicine education consultation
62373599|NCT05388734|ACTIVE_COMPARATOR|After Group|Patients in the front group are recruited from the 5th month of the study and will benefit from the alternative medicine education consultation
62373600|NCT03094494||Double Carbapenem Group|Patients underwent Double carbapenem treatment
62373601|NCT03094494||Standard Treatment Group|Patients who were not treated with the double carbapenem
62373602|NCT02100410|EXPERIMENTAL|Iteration 2-87-1|Delefilcon A toric contact lenses T1 and T2 worn contralaterally (1 in each eye) for approximately 30 minutes
62373603|NCT02100410|EXPERIMENTAL|Iteration 2-87-2|Delefilcon A toric contact lenses T3 and T4 worn contralaterally (1 in each eye) for approximately 30 minutes
62373604|NCT02100410|EXPERIMENTAL|Iteration 2-87-3|Delefilcon A toric contact lenses T5 and T6 worn contralaterally (1 in each eye) for approximately 30 minutes
62373605|NCT04313673||randomized|Patients who were followed up in our clinic with a diagnosis of preterm labor that spontaneously took action and were born before 37 weeks of gestation will form a group.
62373606|NCT01929512|EXPERIMENTAL|HCP1201, Part 1|Participants received a single oral dose of the HCP1201 750/20mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
62373607|NCT01929512|ACTIVE_COMPARATOR|Metformin and Rosuvastatin, Part1|Participants received a single oral dose of coadministration of Metformin SR 750mg and Rosuvastatin 20mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
62373608|NCT01929512|EXPERIMENTAL|HCP1201, Part 2|Participants received a single oral dose of the HCP1201 750/20mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
62552917|NCT05999383|EXPERIMENTAL|Regular cigarette only|Participants will vape a regular cigarette (25.94 mg/g nicotine content)
62373609|NCT01929512|ACTIVE_COMPARATOR|Metformin and Rosuvastatin, Part 2|Participants received a single oral dose of coadministration of Metformin SR 750mg and Rosuvastatin 20mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
62373610|NCT04018105|EXPERIMENTAL|taking metformin 30 or 60 minutes before the OGTT|
62373611|NCT04018105|PLACEBO_COMPARATOR|No metformin before OGTT|
62373612|NCT01957215|EXPERIMENTAL|Indomethacin patch|Indomethacin patch to be applied on the sprained ankle twice a day (BID).
62373613|NCT01957215|PLACEBO_COMPARATOR|Placebo patch|Placebo patch to be applied on the sprained ankle BID.
62373614|NCT04996277|EXPERIMENTAL|Fractional Flow Reserve|Patients with FFR ≤ 0.8 will undergo PCI Patients with FFR \> 0.8 will be treated with medication For study purposes, all patients will undergo OCT (subject's treatment strategy will be based on FFR results, e.g., stent-implanted OCT).
62373615|NCT04996277|EXPERIMENTAL|Optical CoherenceTomography|Patients with MLA \< 4.5mm² will undergo PCI Other patients will be treated with medication For study purposes, all patients will undergo FFR (subject's treatment strategy is based on OCT results; reference to FFR results is not recommended)
62373616|NCT04996277|EXPERIMENTAL|angiography|Appropriate treatment (implantation of stents) will be given according to the evaluation of the physician.
62373617|NCT03996889||Popliteal aneurysm patients with GORE VIABAHN®|The study population will include all popliteal aneurysm patients treated with GORE VIABAHN® stent graft in scheduled elective surgery, whether symptomatic or asymptomatic.
62373618|NCT02484040|EXPERIMENTAL|Two-week course arm|"Experimental arm receive 33 Gy in 10 fractions of radiation for 2 weeks with oral capecitabine.~Two-week course of radiation, 33 Gy/10 fx and oral capecitabine, 825 mg/m2, bid"
62373619|NCT02484040|NO_INTERVENTION|Conventional arm|conventionally fractionated radiation of 50.4 Gy/28 fx and 5-FU, 500 mg/m2 and leucovorin, 20 mg/m2 for 5 days, monthly or Capecitabine, 825 mg/m2, bid
62373620|NCT01581606||Group 1R and 1T AMD Screening|Group 1 patients will be collected through all referrals to any of the physician investigators with a provisional diagnosis of possible wet AMD. Any request for clinical evaluation of a patient for presumed wet AMD will be randomized into Group 1R (Routine Screening) and Group 1T (Tele-ophthalmology screening).
62373621|NCT01581606||Group 2R and 2T Follow up|Group 2 patients will be collected from the patients previously treated for wet AMD within the practices of the physician investigators. All patients in whom the disease is inactive (not receiving active treatment) and who therefore require monitoring will be randomized into Group 2R (Routine Monitoring) and Group 2T (Teleophthalmology Monitoring).
62373622|NCT01886495|ACTIVE_COMPARATOR|nutrition intervention|high protein diet
62373623|NCT01886495|NO_INTERVENTION|control diet|
62373624|NCT03518775||Normal Eyes|Eyes with best-corrected visual acuity of 20/20 or better, and lens opacities of 1.0 or less in the study eye using the LOCS III system, and no prior Laser Vision Correction.
62373625|NCT03518775||Cataract Eyes|Cataract in the study eye greater than Grade 1 using the LOCS III system for one or more: nuclear opacity, nuclear color, cortical opacity, or PSC.
62373626|NCT03518775||Post LVC Eyes|History of Laser Vision Correction (LVC)
62373627|NCT03170492|EXPERIMENTAL|Computerized Cognitive Training|RehaCom for 480 minutes over 12 weeks.
62373628|NCT03170492|ACTIVE_COMPARATOR|Pencil-and-Paper Cognitive Training|Table-top based activities for 480 minutes over 12 weeks.
62373629|NCT02719210|EXPERIMENTAL|High Volume Plasma Exchange with Standard Treatment|
62373630|NCT02719210|ACTIVE_COMPARATOR|Standard Treatment|"Standard Treatment is defined as anti raised Intra-cranial pressure~1. Elective positive pressure ventilation in hepatic encephalopathy grade 3 or 4 and in those with features of raised ICP (Intra-cranial pressure).~2. Mannitol~3. Hypertonic 3% Saline"
62373631|NCT05541250|EXPERIMENTAL|Autologous Human Schwann Cell (ahSC) Group|Participants in this group will undergo a sural nerve biopsy followed by ahSC transplant
62373632|NCT02204059|EXPERIMENTAL|hMAb BIWA 4|Bivatuzumab: 186 Re-labelled humanised monoclonal antibody BIWA 4
62373633|NCT00287755|EXPERIMENTAL|1|
62373634|NCT02259764|EXPERIMENTAL|KUC 7483 CL - single rising dose|"Treatment 1: KUC 7483 CL - low dose~Treatment 2: KUC 7483 CL - medium dose~Treatment 3: KUC 7483 CL - high dose~In treatment 3 the same subjects as in treatment 2 received drug immediately after the ingestion of a standardized high fat meal"
62373635|NCT02259764|PLACEBO_COMPARATOR|Placebo|
62373636|NCT04431141|EXPERIMENTAL|Teneligliptin|
62373637|NCT04431141|EXPERIMENTAL|Empagliflozin|
62373638|NCT04431141|EXPERIMENTAL|Teneligliptin and Empagliflozin|
62373639|NCT02951728|EXPERIMENTAL|Decitabine plus R-CHOP|"Rituximab 375 mg/m2 IV d6; Cyclophosphamide 750mg/m2 IV d7; Doxorubicin 50mg/m2 IV d7; Vincristine 1.4 mg/m2 IV d7; Prednisone 60 mg/m2 PO d7-11;~Decitabine will be administered intravenously at dose levels as follow in Phase 1:~Dose level 1: Decitabine 10 mg/m2 days 1-5; Dose level 2: Decitabine 15 mg/m2 days 1-5; Dose level 3: Decitabine 20 mg/m2 days 1-5 and determine the maximum tolerated dose.~In phase 2, Decitabine will be administered intravenously at MTD."
62373640|NCT04052412|EXPERIMENTAL|NSCLC with Immunotherapy without radiation|The biodistribution and kinetics of the 18F-AraG compound will be assessed in non-small cell lung cancer patients undergoing immunotherapy without adjuvant radiation therapy
62552918|NCT00727012|OTHER|SJM® Rigid Saddle Ring|The SJM® Rigid Saddle Ring is an annuloplasty ring comprised of a titanium core surrounded by a double-velour, polyester fabric sewing cuff.
62373641|NCT04052412|EXPERIMENTAL|NSCLC with Immunotherapy with radiation|The biodistribution and kinetics of the 18F-AraG compound will be assessed in non-small cell lung cancer patients undergoing immunotherapy with adjuvant radiation therapy
62552919|NCT05044195|EXPERIMENTAL|aQIV|Adjuvanted QIV containing 2 influenza type A strains and 2 influenza type B strains
62373642|NCT04251195|EXPERIMENTAL|Cognitive Intervention|
62373643|NCT04251195|ACTIVE_COMPARATOR|Active Control Intervention|
62552920|NCT05044195|ACTIVE_COMPARATOR|Comparator QIV|Non-adjuvanted comparator QIV containing 2 influenza type A strains and 2 influenza type B strains
62552921|NCT03558438||HIV patients older than 50 years|Spanish cohort of patients with HIV infection older tha 50 years old.
62552922|NCT02779166|EXPERIMENTAL|Intervention|Received 400mg celecoxib prior to surgery
62373644|NCT06393413|EXPERIMENTAL|Jiedu Yizhi Formula|The traditional Chinese medicine treatment group received modified Jiedu Yizhi Formula therapy, with no more than 3 flavors, customized based on syndrome differentiation. The herbal composition included 10g of Coptis chinensis Franch (Huanglian, Ranunculaceae, rhizome), 20g of Alpinia oxyphylla Miq.(Yizhiren, Zingiberaceae, fructus), 10g of Chinemys reevesii(Guibanjiao), 10g of Rheum webbianum (Jiu Dahuang, rhizome), 10g of Cornus officinalis (Shanzhuyu, Cornaceae, fructus), 10g of Pheretima aspergillum (Dilong), and 10g of Oreocome striata (Chuanxiong, Apiaceae, rhizome). 300ml of water decoction juice was prepared from each pair of herbs, and 100ml was taken daily after breakfast and dinner.
62373645|NCT06393413|SHAM_COMPARATOR|Donepezil Hydrochloride Tablets|The Western medicine control group, on the other hand, was administered donepezil hydrochloride (Anlishen 5mg/tablet, from Weicai China Pharmaceutical Co., Ltd.) orally before bedtime at a dosage of 5mg per day. After 4 weeks of treatment, clinical reactions were assessed, and no significant abnormal clinical reactions were observed. Subsequently, the dosage was increased to 10mg per day for maintenance therapy, leading to a total of 24 weeks of continuous treatment. Additionally, both patient groups were provided guidance on actively addressing and managing various risk factors associated with Alzheimer's disease, in conjunction with cognitive behavioral training.
62373646|NCT00257322|EXPERIMENTAL|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) 250ug/m\^2 SQ QD with a cap of 500mcg SQ QD
62373647|NCT05118750|EXPERIMENTAL|ALTO-300|ALTO-300 oral (PO) tablet; daily dosing 8 weeks
62373648|NCT00620737|EXPERIMENTAL|Active Arm|Active Treatment
62373649|NCT00620737|PLACEBO_COMPARATOR|Control Arm|Placebo treatment
62373650|NCT00650364|EXPERIMENTAL|1|Midodrine HCl Tablets 5 mg
62373651|NCT00650364|ACTIVE_COMPARATOR|2|ProAmatine® Tablets 5 mg
62373652|NCT05455255|EXPERIMENTAL|Experimental Group|FL will be applied to the intervention group. In this model, short videos of the course will be delivered to students via WhatsApp one week in advance. At the beginning of the lesson, students' deficiencies will be corrected by making kahoot. Afterwards, group work, case scenario, role-play scenario and conceptual map methods will be applied in the course.
62373653|NCT05455255|NO_INTERVENTION|Control Group|The subject of the nursing process will be transferred to the control group with powerpoint presentations by the educator. The activities in the other group will be presented by the trainer as an example.
62373654|NCT02401776|EXPERIMENTAL|small dose monster energy drink|This will be a small dose of monster energy drink
62373655|NCT02401776|EXPERIMENTAL|medium dose monster energy drink|This will be a medium dose of monster energy drink
62373656|NCT02401776|ACTIVE_COMPARATOR|coffee|This will be a coffee group and will drink Starbuck's K-cup Breakfast Blend. This will be mixed according to packing instructions and will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 11 ounce cup of coffee for a person weighing 75 kg).
62373657|NCT03077711|ACTIVE_COMPARATOR|Patients with recurrent UTIs arm 1|Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.
62373658|NCT03077711|ACTIVE_COMPARATOR|Patients with recurrent UTIs arm 2|Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections.
62373659|NCT04450004|EXPERIMENTAL|Vaccine (3.75 µg) unadjuvanted|• Group 1: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine
62373660|NCT04450004|EXPERIMENTAL|Vaccine (3.75 µg) adjuvanted with CpG 1018|• Group 2: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
62373661|NCT04450004|EXPERIMENTAL|Vaccine (3.75 µg) adjuvanted with AS03|• Group 3: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
62373662|NCT04450004|EXPERIMENTAL|Vaccine (7.5 µg) unadjuvanted|• Group 4: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine unadjuvanted
62373663|NCT04450004|EXPERIMENTAL|Vaccine (7.5 µg) adjuvanted with CpG 1018|• Group 5: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
62373664|NCT04450004|EXPERIMENTAL|Vaccine (7.5 µg) adjuvanted with AS03|• Group 6: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
62373665|NCT04450004|EXPERIMENTAL|Vaccine (15 µg) unadjuvanted|• Group 7: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine unadjuvanted
62373666|NCT04450004|EXPERIMENTAL|Vaccine (15 µg) adjuvanted with CpG 1018|• Group 8: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
62373667|NCT04450004|EXPERIMENTAL|Vaccine (15 µg) adjuvanted with AS03|• Group 9: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
62373668|NCT02382770||Open Abdomen patients|All patients underwent to open abdomen procedure
62373669|NCT01525108|EXPERIMENTAL|Home-based blood pressure monitoring|
62373670|NCT01525108|ACTIVE_COMPARATOR|Usual care|
62373671|NCT00673816|EXPERIMENTAL|Sunitinib Malate|Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
62373672|NCT04071808||Coronary angiography group|In diabetic patients without symptoms of myocardial ischemia, coronary angiography showed no stenosis or stenosis less than 75%.
62373673|NCT04071808||Coronary angiographic stent implantation group|Coronary angiographic stenosis was more than 75% in diabetic patients without myocardial ischemia symptoms, and coronary stents were implanted.
62373674|NCT00675129|EXPERIMENTAL|1|Dialectical behavioral therapy
62373675|NCT00675129|ACTIVE_COMPARATOR|2|Enhanced Usual Care (standard care plus monitoring and patient safety protocol implemented)
62373676|NCT05213676|ACTIVE_COMPARATOR|Inhaled Nitric Oxide (iNO) use|The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.
62552923|NCT02779166|PLACEBO_COMPARATOR|Placebo|Received placebo pill prior to surgery
62552924|NCT05734651||Intervention|
62552925|NCT05193955|EXPERIMENTAL|Intervention Group|undergraduate students who practice laughter yoga and simulation education together
62373677|NCT05213676|ACTIVE_COMPARATOR|De-implementation of Inhaled Nitric Oxide (iNO) use|The center will stop using iNO in the initial resuscitation period (defined as birth through stabilization and CDH repair).
62745236|NCT06066021|OTHER|Health education sessions for type 2 diabetic patients|"Patients will be pre-selected according to their risk of developing DR. It will be done through the Retina Risk® application. Will be invited to participate and followed. Retrospective and prospective data will be collected on medical and ophthalmological history (HbA1c value, if performed. 3 questionnaires will be carried out: DM disease, self-care, and emotional state, before and after awareness intervention about self-care through educational sessions in areas of greatest need (physical activity, nutrition, mental health, and self-care). The impact of the previously described sessions on the patients' health status will be assessed using 2 methods: By telephone and by physical examination. Repetition of the 3 questionnaires applied in V1.~The Interventions will be made, through information sessions on the topics: mental health, nutrition, physical exercise, and care that diabetics must take to take care of their body."
62373678|NCT01557127||Group 1|
62373679|NCT03149497|ACTIVE_COMPARATOR|improved anterior approach only in traumatic cervical spine|
62373680|NCT03149497|ACTIVE_COMPARATOR|failed anterior approach only in traumatic cervical spine|
62373681|NCT00053014|EXPERIMENTAL|treatment|patient conditioning - fludarabine 30 mg/m2 IV over 1 hour Days -4, -3, -2; TBI 6-7 cGy/min Day 0 post-transplant immunosuppression - cyclosporine 6.25 mg/kg bid PO D -3 to +180 (begin taper on D+35); mycophenolate mofetil 15mg/kg bid PO D0 to +27
62373682|NCT02145754|ACTIVE_COMPARATOR|MKP media versus BSK-H media|one half of skin specimen obtained from erythema migrans patients was cultivated for Borrelia burgdorferi sensu lato in MKP media and the other half in BSK-H media
62373683|NCT03933306|PLACEBO_COMPARATOR|Placebo+routine blood pressure management|Placebo (normal saline) is administered during anesthesia. Blood pressure is managed according to routine practice.
62373684|NCT03933306|EXPERIMENTAL|Dexmedetomidine+routine blood pressure management|Dexmedetomidine is administered during anesthesia (0.6 mcg/kg for 10 min, then 0.5 mcg/kg/h). Blood pressure is managed according to routine practice.
62373685|NCT03933306|EXPERIMENTAL|Placebo+goal-directed blood pressure management|Placebo (normal saline) is administered during anesthesia. Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
62373686|NCT03933306|EXPERIMENTAL|Dexmedetomidine+goal-directed blood pressure management|Dexmedetomidine is administered during anesthesia (0.6 mcg/kg for 10 min, then 0.5 mcg/kg/h). Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
62373687|NCT02812394|EXPERIMENTAL|CVT-301|"CVT-301 (Dose Level 1): two (low dose) levodopa fine particle dose (FPD) capsules administered to the lung via oral inhalation using the CVT 301 inhaler.~CVT-301 (Dose Level 2): two (high dose) levodopa FPD capsules administered to the lung via oral inhalation using the CVT 301 inhaler.~Sinemet® (carbidopa/levodopa)"
62373688|NCT00976963|ACTIVE_COMPARATOR|TMP/SMX|Sulfamethoxazole-Trimethoprim 800-160 MG Oral Tab; 800mg/160mg BID x 3 days
62373689|NCT00976963|EXPERIMENTAL|Fosfomycin|3g sachet single dose
62373690|NCT01820845||Cohort of children with scoliosis surgery|
62373691|NCT02203942||Vaginal Infections (BV, VVC, trich)|NAAT testing Amsel criteria Nugent score yeast culture TV culture
62373692|NCT03718468|EXPERIMENTAL|GC Flu Quadrivalent|
62373693|NCT03718468|ACTIVE_COMPARATOR|Fluarix tetra|
62373694|NCT02021474|EXPERIMENTAL|AGX-201|Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis.
62373695|NCT02021474|PLACEBO_COMPARATOR|Evan's solution = phenol 0.4%, isotonic sodium chloride|Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis.
62373696|NCT06377436|EXPERIMENTAL|DIVIDAT SENSO GROUP|"40 frail subjects who will undergo the experimental training - DIVIDAT SENSO training on the Locomotor, Sensory and Cognitive domains. Traning wilk be performed at IRCCS Galeazzi-Sant'Ambrogio Hospital (5 non-consecutive sessions every 15 days, for 1 year)"
62373697|NCT06377436|NO_INTERVENTION|STANDARD OF CARE GROUP|40 frail subjects will be subjected to good practice rules for all 5 domains of the intrinsic capacity. Subject will be followed for 1 year. No specific supervised training will be administered to this group.
62373698|NCT02187133|EXPERIMENTAL|Treatment|Patients receive carfilzomib IV over 30 minutes twice weekly on days 1, 2, 8, 9, 15, and 16 or weekly on days 2, 9, and 16; bendamustine hydrochloride IV over 60 minutes on days 1 and 2; and rituximab IV over 30-90 minutes on day 9 (course 1 only) and day 1 (subsequent courses). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62373699|NCT05479136|EXPERIMENTAL|PET study|Single intravenous administration of 18F fluciclovine for PET Scan
62373700|NCT01446991|EXPERIMENTAL|Favorable prostate cancer with pubic arch interference|Men in this arm have chosen brachytherapy for management of localized prostate cancer and do not require androgen ablation for oncologic reasons but have an enlarged prostate causing pubic arch interference and thus require prostate size reduction prior to brachytherapy. They will have 2-3 months of Degarelix with measurement of prostate volume at 8 and 12 weeks.
62373701|NCT01446991|EXPERIMENTAL|Intermediate risk prostate cancer, 6 months Degarelix|Men in this arm have higher risk prostate cancer (upper tier intermediate risk by National Comprehensive Cancer Network \[NCCN\] guidelines) and require 6 months of androgen ablation in conjunction with brachytherapy. Prostate size must be \> 40 cc at baseline so that prostate size reduction measurements are appropriate. Prostate measurements by transrectal ultrasound with be taken at 12 weeks and 20 weeks.
62745237|NCT06483191|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT)|Patients will attend a half-day virtual pre-operative ACT group workshop delivered by physiotherapists. Intervention group patients will also receive booster post-operative ACT text messages once a week for 6 weeks and a telephone follow-up with a physiotherapist at 6-8 weeks. The workshop, text messages and follow-up with a physiotherapist will be in addition to standard care.
62745238|NCT06483191|NO_INTERVENTION|Control|Patients in the control group will receive standard care; All patients should attend a 1-hour face-to-face group pre-operative education class. Patients in either group will have access to a helpline where they can speak to a nurse to discuss any problems or concerns. All patients will also receive a follow-up phone call from a nurse within 5 days of discharge to check their progress and will attend a 6-12 week follow-up clinic with their surgeon.
62552926|NCT05193955|NO_INTERVENTION|Control Group|undergraduate students who practice simulation education
62373702|NCT02188862||Rheumatic heart disease cases|Patients with rheumatic heart disease as defined in the case criteria
62373703|NCT02188862||Population controls|Individuals from the general population divided into new controls (recruited specifically for this study) and existing controls (recruited to previous population genetics studies in the region)
62373704|NCT06149741|EXPERIMENTAL|Left-sided loop colostomy|Left-sided loop colostomy matured in left iliac fossa after complete splenic flexure mobilisation, mesorectal excision and anastomosis
62373705|NCT00623766|EXPERIMENTAL|Ipilimumab, 10 mg/kg, IV in corticosteroid-free patients|Participants who had not received corticosteroid therapy for at least 10 days before starting study drug received ipilimumab,10 mg/kg, as a 90-minute intravenous (IV) infusion every 3 weeks (Weeks 1, 4, 7, and 10) during the Induction Phase. Those eligible (patients who did not discontinue due to toxicity, did not show progression at 24 weeks, and who remained clinically stable) for the Maintenance Phase continued to receive ipilimumab, 10 mg/kg IV, every 12 weeks, beginning at Week 24.
62373706|NCT00623766|EXPERIMENTAL|Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients|Participants who were dependent on corticosteroid therapy received ipilimumab, 10 mg/kg, as a 90-minute intravenous (IV) infusion every 3 weeks (Weeks 1, 4, 7, and 10) during the Induction Phase. Those eligible (patients who did not discontinue due to toxicity, did not show progression at 24 weeks, and who remained clinically stable) for the Maintenance Phase continued to receive ipilimumab, 10 mg/kg IV, every 12 weeks, beginning at Week 24.
62373707|NCT03482193||Adolescents|Adolescents in 2nd or 4th year in secondary school, from 9 different schools in Liège, Belgium.
62552927|NCT02207634|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference. Participants continued with their background statin therapy during the course of the study.
62552928|NCT02207634|EXPERIMENTAL|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference. Participants continued with their background statin therapy during the course of the study.
62745239|NCT04470908|EXPERIMENTAL|Zanubrutinib + Rifabutin|"Day 1: zanubrutinib~Days 3 to 10: rifabutin~Day 11: zanubrutinib and rifabutin"
62373708|NCT03567590|EXPERIMENTAL|Pulsed Radiofrequency Group|This group will undergo pulsed radiofrequency treatment.
62373709|NCT03567590|ACTIVE_COMPARATOR|Nerve Block Group|This group will undergo nerve block treatment.
62552929|NCT00779831|EXPERIMENTAL|1|120 mg Pseudoephedrine hydrochloride extended release tablets of ranbaxy
62552930|NCT00779831|ACTIVE_COMPARATOR|2|(Sudafed ® 12 hour) 120 mg Pseudoephedrine hydrochloride extended - release tablets
62552931|NCT02168192|PLACEBO_COMPARATOR|Traditional Lecture|These subjects received a 10 minute power point lecture on BBN skills.
62552932|NCT02168192|EXPERIMENTAL|Simulation-Debrief|These subjects received a formal debrief process, reviewing their prior baseline simulation.
62552933|NCT00545714|EXPERIMENTAL|Rituximab + Fludarabine + Cyclophosphamide|Participants will receive 6 cycles (cycle length = 28 days) of treatment with rituximab (375 milligrams per square meter \[mg/m\^2\] as intravenous \[IV\] infusion on Day 0 of Cycle 1 and 500 mg/m\^2 as IV infusion on Day 1 of Cycles 2-6); fludarabine (25 mg/m\^2 on Days 1-3) and cyclophosphamide (250 mg/m\^2 on Days 1-3). Participants with a partial or complete response and appropriate neutrophil conditions will receive maintenance treatment with rituximab (375 mg/m\^2 as IV infusion every 2 months) from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
62373710|NCT04207125|NO_INTERVENTION|Without multilevel intervention|patients after liver or kidney transplantation / standard care
62373711|NCT04207125|ACTIVE_COMPARATOR|With multilevel intervention|patients after liver or kidney transplantation / multilevel intervention program
62373712|NCT01805674||isoflavones combined with magnolia|A food supplement containing soy isoflavones, lactobacillus sporogenous, Ca,vitamin D3, magnesium and magnolia extract will be administered once a day during 12 weeks.
62373713|NCT04814706||Group C|Patients drank carbohydrate fluid 2 hours prior to surgery.
62745240|NCT02551094|ACTIVE_COMPARATOR|colchicine|0.5 mg tablet of colchicine taken once a day
62745241|NCT02551094|PLACEBO_COMPARATOR|colchicine placebo|0.5 mg tablet of placebo taken once a day
62373714|NCT02663947||ultrasound group|ultrasonographic measure for optic nerve sheath diameter
62373715|NCT02613338||DePuy Attune PS FB knee system|Patients implanted with a DePuy Attune posterior stabilizing fixed bearing knee system
62373716|NCT02077972|EXPERIMENTAL|High intensity whole-body infrared heating|The participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
62552934|NCT04364178|EXPERIMENTAL|Viral Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system. By this method, viral specific, gamma-secreting T cells, are captured in a closed, sterile system.
62552935|NCT02982291|ACTIVE_COMPARATOR|Standard|
62552936|NCT02982291|EXPERIMENTAL|Individualized|
62552937|NCT04812301||Group 1|Egg-white sandwich is added with 1 mCi Tc-99m sodium phytate, then Abbott Vital® added with 1 mCi Tc-99m sodium phytate
62552938|NCT04812301||Group 2|Abbott Vital® is added with 1 mCi Tc-99m sodium phytate, then egg-white sandwich added with 1 mCi Tc-99m sodium phytate
62745242|NCT05901675|EXPERIMENTAL|DIET|Focus-15 is a 15-week lifestyle change program developed and delivered by the Weight Management Center at the Medical University of South Carolina.
62745243|NCT05901675|EXPERIMENTAL|DIET+Exercise|As above with, the addition of supervised exercise. The investigators developed an innovative rehabilitation approach, Post-stroke Optimization of Walking using Explosive Resistance (POWER) training; a high-velocity, high-intensity lower extremity resistance training intervention that improves post-stroke muscular and locomotor function. POWER training will take place over a 12-week period (3 sessions/week) with exercises including leg press, calf raises, and jump training, all performed at high concentric velocity, as well as trials of fast walking and functional movements.
62745244|NCT05901675|NO_INTERVENTION|Wait-list Control|Participants will undergo pre-, post- and follow-up testing but will not partake in any intervention during the same timeframe as those listed in the other arms. Participants will have the opportunity to be enrolled in one of the other arms once they have completed the WLC group timeframe.
62373717|NCT01251081|EXPERIMENTAL|extra high volume hemofiltration|extra high volume hemofiltration (85 mL/kg/h, EHVHF)
62552939|NCT03631316|EXPERIMENTAL|Generic valganciclovir|Participants will receive generic formulation (Pisa) of valganciclovir, 450 mg tablets, total dosage 900 mg daily for 4 days.
62373718|NCT01251081|SHAM_COMPARATOR|high volume hemofiltration|high volume hemofiltration (50 mL/kg/h, HVHF)
62745245|NCT02130687|ACTIVE_COMPARATOR|Amlodipine|Subjects in this arm will receive calcium channel blocker therapy with amlodipine 5mg daily for 3 days then 10mg daily for 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
62552940|NCT03631316|ACTIVE_COMPARATOR|Innovative valganciclovir|The same participant will receive innovative drug valcyte (roche), 450 mg tablets, total dosage 900 mg daily during 4 days.
62552941|NCT00719186|ACTIVE_COMPARATOR|A|Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
62745246|NCT02130687|EXPERIMENTAL|Ramipril|Subjects will receive ACE-inhibitor therapy with ramipril 5mg daily for 3 days, followed by 10mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
62745247|NCT02130687|ACTIVE_COMPARATOR|Valsartan|Subjects will receive ARB therapy with valsartan 160mg daily for 3 days, followed by 320mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
62745248|NCT04044599|EXPERIMENTAL|Study|THE GROUP THAT WİLL RECİEVE VAGİNAL LACTOBACİLLUS
62745249|NCT04044599|NO_INTERVENTION|Control|Control group
62745250|NCT00895440||1|Diabetic patients without neuropathy
62373719|NCT02583360|ACTIVE_COMPARATOR|Study|Eligible subjects (study) will undergo diagnostic VFSS in combination with manometry, either concurrent or sequential. They will have parental choice of preferred feeding therapy.
62373720|NCT02583360|NO_INTERVENTION|Control|Eligible subjects who had VFSS alone with provider recommendations from the same single center.
62373721|NCT00086242|EXPERIMENTAL|Psychosocial Telephone Counseling (PTC)|Eligible patients are randomized to receive psychosocial telephone counseling (PTC) or usual care.The PTC intervention was specifically designed to help women cope with the stressful events and feelings of distress associated with cervical cancer. The PTC arm of the study received six counseling sessions, \~45 to 50 min in length, in their preferred language, consisting of five consecutive weekly sessions and a 1-month booster session, delivered by a psychologist. A review letter, generated by the counselor after each session, recapitulated the session's contents and reinforced adaptive coping strategies.
62373722|NCT00086242|NO_INTERVENTION|Usual Care|Eligible patients are randomized to receive either psychosocial telephone counseling (PTC) or usual care. The usual care are were only contacted by the study team to collect data in an identical frame to subjects receiving PTC.
62373723|NCT03605225|EXPERIMENTAL|Cellphone application|Train of Four (TOF) ratio displayed by the Cellphone Application
62373724|NCT03605225|ACTIVE_COMPARATOR|Draeger TOF Scan|Train of Four (TOF) ratio displayed by the Draeger TOF Scan
62373725|NCT01609036||Cohort|
62373726|NCT05336019|EXPERIMENTAL|"Diabetes self-management Coaching"|A 12-week Diabetes self-management Coaching program and the usual care
62373727|NCT05336019|ACTIVE_COMPARATOR|"Usual Care"|The control group will be assigned to 12 weeks usual care or routine diabetes service
62373728|NCT01522196|ACTIVE_COMPARATOR|Varespladib|48 hour continuous infusion delivered intravenously (IV)
62373729|NCT01522196|PLACEBO_COMPARATOR|Placebo|48 hour continuous infusion delivered intravenously (IV)
62373730|NCT04840394|EXPERIMENTAL|BDB018 in Monotherapy|"A single subject will be enrolled at each dose level in the single agent arm.~Then dosage escalation will follow a traditional 3+3 dose escalation design.~Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of single agent BDB018 is reached."
62552942|NCT00719186|ACTIVE_COMPARATOR|B|Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
62552943|NCT03578393|EXPERIMENTAL|Intervention|Will visualize an Educational Virtual Reality video in preoperative period to reduce perioperative anxiety.
62552944|NCT03578393|NO_INTERVENTION|Usual treatment|Will be applied the usual treatment (provide information on the anaesthetic-surgical process).
62552945|NCT03231488|EXPERIMENTAL|Mindfulness intervention|
62552946|NCT03231488|ACTIVE_COMPARATOR|Control intervention (unfocused attention)|
62552947|NCT01433367||CerPass® Total Disc Replacement|
62552948|NCT01606774|EXPERIMENTAL|Low risk patients|Patients who agreed to 4 telemedicine obstetrical visits
62745251|NCT00895440||2|Diabetic patients with painless neuropathy
62745252|NCT00895440||3|Diabetic patients with painful neuropathy
62552949|NCT02910804|EXPERIMENTAL|68Ga-BBN-IRDye800CW PET/NIRF|The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.
62552950|NCT00573261|EXPERIMENTAL|Pregabalin|Pregabalin medication
62552951|NCT00573261|PLACEBO_COMPARATOR|Placebo|Placebo
62552952|NCT02934464|EXPERIMENTAL|ARM A|"* RAMUCIRUMAB 8 mg/kg on Days 1 and 15 of every 28-day cycle~* PACLITAXEL 80 mg/m2 on Days 1, 8, and 15 of every 28-day cycle until progressive disease, unacceptable toxicity, informed consent withdrawal or patient's death."
62745253|NCT00895440||4|Diabetic patients with Charcot neuroarthropathy
62745254|NCT00895440||5|Control non-diabetic subjects
62745255|NCT05431387|PLACEBO_COMPARATOR|Placebo + Behavioral Support|one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks
62745256|NCT05431387|EXPERIMENTAL|Cytisinicline + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 12 weeks
62745257|NCT03255967|EXPERIMENTAL|QI program care|DSM-H performance improvement program Patients in the performance improvement group will receive care from a care team who has received the DSM-H performance improvement program
62552953|NCT02934464|ACTIVE_COMPARATOR|ARM B|"* FOLFOX4: Oxaliplatin 85 mg/m2 + l-Leucovorin 100 mg/m2 + 5-fluorouracil 400/600 mg/m2. Cycle length is 2 weeks +/- 3 days.~* mFOLFOX6: Oxaliplatin a 85 mg/m2+ l-Leucovorin 200 mg/m2 + 5-fluorouracil 400 mg/m2 and 2400 mg/m2 46-hours continous infusion. Cycle length is 2 weeks +/- 3 days.~* XELOX:Oxaliplatin130 mg/m2 + Capecitabine will be 2000 mg/m2 for 14 days. Cycle length is 3 weeks +/- 3 days."
62552954|NCT06583070||RT group|In conjunction with targeted and immunotherapy, administer radiation therapy to achieve as complete coverage as possible of all identifiable primary and metastatic lesions.
62552955|NCT06583070||Control group|Targeted and immunotherapy
62552956|NCT01443728|EXPERIMENTAL|Vitamin D3 100,000 IU|Oral vitamin D3, 100,000 IU \[2.5 mg\] given once a month
62552957|NCT01443728|ACTIVE_COMPARATOR|Vitamin D3 12,000 IU|Standard dose oral vitamin D3 12,000 IU \[0.3 mg\] given once a month
62745258|NCT03255967|ACTIVE_COMPARATOR|Control|Receive usual care from a care team who has not received the performance improvement program
62373731|NCT04840394|EXPERIMENTAL|BDB018 in Combination with Pembrolizumab|"In the combination arm of the study, a standard 3+3 dose escalation design will be utilized for all dose levels.~When the MTD or RP2D of single agent BDB018 is reached, the first dose level cohort of the combination arm will begin. Once the MTD or RP2D in combination has been determined, approximately twenty additional subjects will be enrolled in the expansion phase of the study."
62373732|NCT02980991|EXPERIMENTAL|Neoadjuvant chemotherapy group|Two cycles of pemetrexed and cisplatin given to patients before surgery
62373733|NCT03304912||Women who inject drugs who are eligible for PrEP|Women who inject drugs who are eligible for PrEP are provided PrEP Education and option to accept a PrEP prescription.
62373734|NCT03199131|EXPERIMENTAL|CTEPH|Patients undergoing pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
62373735|NCT03199131|OTHER|Control group|Patients undergoing adult cardiac surgery without evidence of pulmonary hypertension.
62373736|NCT01971736||1064nm laser, laxity|split-face single-blind randomized placebo-controlled trial evaluating improvement in facial skin laxity of the side of the face with placebo versus laser
62373737|NCT01428557||Heart Failure patients (Breathe I)|Patients admitted with clinical diagnosis of decompensate heart failure, \> 18 years old.
62373738|NCT01428557||Heart Failure patients (Breathe Extension)|Patients admitted with clinical diagnosis of decompensate heart failure, \> 18 years old.
62373739|NCT05942872||NirAEs, grade ≥ 3 according to CTCAE|Patients treated with ICIs who developed neurologic syndromes consistent with NirAEs, of grade ≥ 3 according to the Common Terminology Criteria for Adverse Events (CTCAE)
62373740|NCT04255992|ACTIVE_COMPARATOR|Calcium arm|1000 mg Calcium tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
62373741|NCT04255992|ACTIVE_COMPARATOR|Vitamin D/Calcium|1000 mg/800UI of VitaminD/Calcium tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
62373742|NCT05080504||Study Population|Subjects with implanted CardioMEMS who are compliant with their measurements.
62373743|NCT03061149|EXPERIMENTAL|Group with low-level laser treatment|"The group received low-level laser therapy (LLLT). The application of a GaAlAs infrared laser with a pencil probe (BTL 5000 Combi, United Kingdom; at 830 nm, 9J/cm2 per point, power output of 100 mW, beam diameter of 5 mm) was performed at five points along the median nerve on the palmar side of the wrist 7. The time of exposure was 10 minutes (2 minutes per point). Both the patient and the therapist wore protective glasses during every session.A total of 10 therapeutic sessions were performed during a period of two weeks (five session times per week).~Additionally, nerve and gliding exercises were administered."
62373744|NCT03061149|ACTIVE_COMPARATOR|Group with ultrasound treament|The group underwent ultrasound treatment. Ultrasound treatment was administered at a frequency of 1 MHz, intensity of 1 W/cm2 ,pulsed mode duty cycle of 1:4 and with a handhold transducer of 5 cm2 (BTL 5000 Combi, UK). The time of application was 6 minutes over the area of the carpal tunnel. Aquasonic gel was used as a couplant. A total of 10 therapeutic sessions were performed during a period of two weeks (five session times per week). Additionally, nerve and gliding exercises were administered.
62373745|NCT04790734|EXPERIMENTAL|Remimazolam|Patients in the remimazolam group received remimazolam besylate at an initial infusion rate of 0.15 mg/kg/h and adjusted to maintain a RASS score of -3 to 0.
62373746|NCT04790734|ACTIVE_COMPARATOR|Propofol|Patients in the propofol group received propofol at an initial infusion rate of 2.0 mg/kg/h and adjusted to maintain a RASS score of -3 to 0.
62373747|NCT01638676|EXPERIMENTAL|Vemurafenib and Metformin|
62552958|NCT01439412|EXPERIMENTAL|Acupuncture and standard treatment|Adults (20-55 years) who contact their general practitioners office because of acute nonspecific low back pain (0-14 days).
62552959|NCT01439412|OTHER|Standard treatment in general practice|Adults (20-55 years) who contact their general practitioners office because of acute nonspecific low back pain (0-14 days).
62552960|NCT02054338|EXPERIMENTAL|vinflunine plus gemcitabine|vinflunine 320 mg/m² D1 plus gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks
62552961|NCT02054338|ACTIVE_COMPARATOR|paclitaxel plus gemcitabine|paclitaxel 175 mg/m² D1 followed by Gemcitabine 1250 mg/m² D1 and D8 every 3 weeks
62552962|NCT06489236|EXPERIMENTAL|Vaccination promotion training program|Pediatric nurses and pediatricians enrolled in the study employed at public primary care centers in Barcelona city and Central Catalonia randomly allocated to the intervention group. Intervention administered: 12-hour, medically accredited, evidence-based training program focused on vaccination promotion.
62552963|NCT06489236|NO_INTERVENTION|Practice as usual|Pediatric nurses and pediatricians enrolled in the study employed at public primary care centers in Barcelona city and Central Catalonia randomly allocated to the control group. No intervention administered. Practice as usual.
62552964|NCT00100828|EXPERIMENTAL|Irinotecan|
62552965|NCT02938143|EXPERIMENTAL|4-stage criteria-based exercise protocol|a progressive 4-stage criteria-based exercise protocol within the limits of pain
62745259|NCT04801225|EXPERIMENTAL|VItalFlow Stimulation Treatment|"Enrolled subjects shall receive a VitalFlow stimulation after other standard-of-care treatments are initiated. VitalFlow treatment is initiated by powering on the System and positioning the two (Left and Right) VItalFlow coils on each side of the head (by the ear).~The operator controls the VItalFlow Stimulation through the accompanying console with simple button operation. Once treatment is initiated, the VitalFlow provides continuous, biphasic pulses at a preset power cycle with the total treatment time under 5 min (fixed time). After treatment is completed, the coils are removed and replaced on the VitalFlow System."
62745260|NCT04652206|EXPERIMENTAL|SCO-101 in combination with gemcitabine and nab-paclitaxel|"Patients receive escalating doses of SCO-101 in combination with the standard recommended dose of gemcitabine and nab-paclitaxel according to local clinical practice. Gemcintabine and nab-paclitaxel is the recommended treatment for the patient group.~Starting dose of SCO-101 is 150 mg. Maximum dose tested is 350 mg. The dose is increased with 50 mg increments between each cohort."
62745261|NCT02890303|EXPERIMENTAL|Zepto Capsulotomy|This study will evaluate outcome in subjects who have elected to have Zepto capsulotomies during cataract surgery. Effectiveness Rate - An effectiveness rate of 95% complete capsulotomies provides reasonable assurance that the Zepto system is effective. Primary Safety Endpoint - Posterior Capsular Rupture \& Vitreous Loss (4% or less)
62745262|NCT00776594|EXPERIMENTAL|Group 1|Androgen Deprivation Therapy Plus Bevacizumab
62745263|NCT00776594|EXPERIMENTAL|Group 2|Androgen Deprivation Therapy Alone
62745264|NCT02617407|EXPERIMENTAL|Livionex® Dental Gel|Study patients assigned to this arm will use Livionex toothpaste for daily teeth brushing from day 1 to day 14. Study participants will be encouraged to continue use study toothpaste and monitored up to 44 days after study enrollment.
62745265|NCT02617407|ACTIVE_COMPARATOR|PreviDent 5000 plus/Tom's of Maine Children's toothpaste|Study patients assigned to this arm will use PreviDent 5000 plus or Tom's of Maine Children's (age 6 years and younger) toothpaste for daily teeth brushing from day 1 to day 14. Study participants will be encouraged to continue use study toothpaste and monitored up to 44 days after study enrollment.
62745266|NCT00615225||Brain dead patients|All patients meeting criteria for brain death
62745267|NCT00615225||Healthy control|Any healthy volunteers accepting to give some blood
62745268|NCT00615225||Volunteers having hip surgery|Patients undergoing hip surgery for degenerative non-inflammatory hip disease
62745269|NCT05501210|EXPERIMENTAL|WBV + PEMF Group|"Patients in WBV + PEMF and WBV only groups will be required to attend the WBV therapy session in Prince of Wales Hospital twice a week, for 8 weeks, fulfilling a total of 16 sessions. Patients in WBV + PEMF groups will receive PEMF after WBV session."
62745270|NCT05501210|NO_INTERVENTION|Control Group|Subjects in control group will perform static squat, single leg squat and lunges without vibration.
62745271|NCT05501210|ACTIVE_COMPARATOR|WBV only|"Patients in WBV + PEMF and WBV only groups will be required to attend the WBV therapy session in Prince of Wales Hospital twice a week, for 8 weeks, fulfilling a total of 16 sessions. Patients in WBV groups will not receive PEMF after WBV session."
62745272|NCT04597359|EXPERIMENTAL|Arm A (green tea catechins)|Patients receive green tea catechins PO BID for up to 6 months in the absence of disease progression or unacceptable toxicity.
62745273|NCT04597359|PLACEBO_COMPARATOR|Arm B (placebo)|Patients receive placebo PO BID for up to 6 months.
62745274|NCT03386136|EXPERIMENTAL|Hospitalized Ileus or Pseudo-Obstruction Patient|Hospitalized inpatient diagnosed with ileus, bowel obstruction or colonic pseudo-obstruction \[clinician interpretation or small bowel diameter ≥3.5 cm, cecal diameter ≥ 9 cm, sigmoid colon diameter ≥ 6 cm\] provided with 100% oxygen via non-rebreather face mask, for 6 hours
62373748|NCT05283499|ACTIVE_COMPARATOR|Opioid|Combination analgesic of hydrocodone 5mg/acetaminophen350 mg
62552966|NCT02938143|ACTIVE_COMPARATOR|Heavy-load eccentric exercise protocol|a 12-week painful heavy-load eccentric exercise protocol
62373749|NCT05283499|ACTIVE_COMPARATOR|Non-Opioid|Combination analgesic of ibuprofen 400mgacademinophen 350mg
62373750|NCT04396106|ACTIVE_COMPARATOR|AT-527 - 550 mg BID|Part A
62373751|NCT04396106|PLACEBO_COMPARATOR|Placebo for 550 mg BID|Part A
62373752|NCT04396106|ACTIVE_COMPARATOR|AT-527 - 1100 mg BID|Part B
62373753|NCT04396106|PLACEBO_COMPARATOR|Placebo for 1100 mg BID|Part B
62373754|NCT03369210|EXPERIMENTAL|Liberal|Liberal group (patients receive a RBC unit each time Hb falls ≤ 9 g/dl (≤ 5.6mmol/l) with a target range for the post-transfusion Hb level of 9-10.5 g/dl (5.6-6.5 mmol/l)).
62552967|NCT00631592|OTHER|GSK1349572|GSK1349572
62552968|NCT02848209|NO_INTERVENTION|Control|No peeling applied on the skin flap
62552969|NCT02848209|EXPERIMENTAL|Drug: TCA 20% Peeling|Trichloroacetic acid 20% applied on the skin flap until even frosting for 2-4 minutes.
62552970|NCT02848209|EXPERIMENTAL|Drug: TCA 40% Peeling|Trichloroacetic acid 40% applied on the skin flap until even frosting for 2-4 minutes.
62745275|NCT02126553|EXPERIMENTAL|Treatment (lenalidomide)|Patients receive lenalidomide PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62745276|NCT02256384|EXPERIMENTAL|Respiratory Acoustic Monitoring|All participants will wear the respiratory acoustic monitoring device.
62745277|NCT05613452|EXPERIMENTAL|Study arm|patients received carbon ion radiotherapy
62745278|NCT02921217|EXPERIMENTAL|ActivBPL1|Active Probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145)
62745279|NCT02921217|EXPERIMENTAL|InactivBPL1|Inactivated probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145)
62745280|NCT02921217|PLACEBO_COMPARATOR|Control|Control
62745281|NCT06658951|EXPERIMENTAL|Anti-HER2 CAR-T cells|All eligible participants will receive a conditioning chemotherapy regimen of fludarabine, cyclophosphamide and ABRAXANE followed by Anti-HER2 CAR-T cell injection.
62745282|NCT01410175|EXPERIMENTAL|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layer.
62745283|NCT01410175|NO_INTERVENTION|Electric scalpel|Use of electric scalpel to incise the skin and subcutaneous layer.
62745284|NCT00625196|EXPERIMENTAL|Subjects receiving fluticasone foroate/ vilanterol|Eligible subjects will receive single dose of fluticasone foroate/ vilanterol combination treatment 800 micrograms/ 50 micrograms administered using a novel powder inhaler. There will be a washout period of 7 to 10 days between treatments.
62745285|NCT00625196|ACTIVE_COMPARATOR|Subjects receiving fluticasone foroate|Eligible subjects will receive single dose of fluticasone foroate 800 micrograms administered using a novel powder inhaler.
62373755|NCT03369210|ACTIVE_COMPARATOR|Restrictive|Restrictive group (patients receive a single RBC unit each time Hb falls ≤ 7.5 g/dl (≤ 4.7 mmol/l) with a target range for the post-transfusion Hb level of 7.5-9 g/dl (4.7-5.6 mmol/l).
62373756|NCT00765830|EXPERIMENTAL|1|50mg qd vildagliptin
62373757|NCT00765830|PLACEBO_COMPARATOR|2|Placebo
62373758|NCT03614702|EXPERIMENTAL|1-dose cIPV + 2-doses bOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences . 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
62373759|NCT03614702|EXPERIMENTAL|1-dose sIPV + 2-doses bOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time;each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
62373760|NCT03614702|EXPERIMENTAL|2-doses cIPV + 1-dose bOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50"
62373761|NCT03614702|EXPERIMENTAL|2-doses sIPV + 1-dose bOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50"
62745286|NCT00625196|ACTIVE_COMPARATOR|Subjects receiving vilanterol|Eligible subjects will receive single dose of vilanterol 50 micrograms administered using a novel powder inhaler.
62373762|NCT03614702|EXPERIMENTAL|2-doses cIPV + 1-dose tOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine（Vero） Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd. 1g/pill,10 pills/pach;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 2 polio virus ≥4.8lgCCID50，type 3 polio virus ≥5.3lgCCID50"
62373763|NCT03614702|EXPERIMENTAL|2-doses sIPV + 1-dose tOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose~tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd.1g/pill,10 pills/pach,one pills each time;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 2 polio virus ≥4.8lgCCID50，type 3 polio virus ≥5.3lgCCID50"
62373764|NCT03614702|EXPERIMENTAL|1-dose cIPV + 2-doses bOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine（Vero） Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
62552971|NCT02848209|EXPERIMENTAL|Drug: Phenol/croton oil Peeling|Phenol/croton oil applied on the skin flap occluded with silicone tape for 24 hours and not neutralized.
62552972|NCT04071314||Cystic fibrosis|Children diagnosed with cystic fibrosis. Children aged between 0 and 18 years.
62745287|NCT00625196|PLACEBO_COMPARATOR|Subjects receiving placebo|Eligible subjects will receive single dose of placebo administered using a novel powder inhaler.
62745288|NCT00227344|EXPERIMENTAL|1|Catheter ablation
62745289|NCT00227344|ACTIVE_COMPARATOR|2|Antiarrhythmic drugs
62552973|NCT04071314||Hirschsprung's disease|Children diagnosed with Hirschsprung's disease. Children aged between 0 and 18 years.
62552974|NCT04071314||Obstructive sleep apnoea|Children diagnosed with obstructive sleep apnoea. Children aged between 0 and 18 years.
62552975|NCT04071314||Healthy controls|Children free of any chronic health condition. Children aged between 0 and 18 years.
62552976|NCT01656057|EXPERIMENTAL|Acetaminophen+saline|Acetaminophen tablet 1500 mg via nasogastric tube + i.v. saline
62552977|NCT01656057|EXPERIMENTAL|Acetaminophen+CCK|Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
62552978|NCT01656057|EXPERIMENTAL|Metformin+saline|Metformin tablet 1500 mg + Acetaminophen tablet 1500 mg via nasogastric tube + i.v. saline
62552979|NCT01656057|EXPERIMENTAL|Metformin+CCK|Metformin tablet 1500 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
62745290|NCT03172884|EXPERIMENTAL|BAY80-6946/Healthy subject|Healthy subjects
62745291|NCT03172884|EXPERIMENTAL|BAY80-6946/moderate hepatically impaired patients|Patients with Child-Pugh B (score 7-9) at the screening visit
62745292|NCT03172884|EXPERIMENTAL|BAY80-6946/severe renal impaired patients|Patients with eGFR 15-29 mL/min/1.73 m\^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation
62745293|NCT03172884|EXPERIMENTAL|BAY80-6946/severe hepatically impaired patients|Patients with Child-Pugh C (score 10-15) at the screening visit
62745294|NCT00223405||metal-ceramic (D'Sign) o|Metal ceramic crown will be placed
62745295|NCT00223405||an all-ceramic crown (IPS Empress2, Eris EXC).|All ceramic crown will be placed
62745296|NCT04639232|PLACEBO_COMPARATOR|Control group|Volunteers will take 6 capsules per day for 28 days a capsule containing maltodextrin.
62745297|NCT04639232|EXPERIMENTAL|Prob-milk|Volunteers will take 6 capsules per day for 28 days a capsule containing the probiotics combination.
62745298|NCT04639232|EXPERIMENTAL|Voluntas-Prob|Volunteers will take 6 capsules per day for 28 days a capsule containing the combination of plant extracts and the inactivated probiotic strain
62745299|NCT06662240|EXPERIMENTAL|Application of vibration anesthesia|In addition to the routine injection protocol performed from the abdominal region, the vibration device was kept on the injection site by the investigator for 3 minutes just before the injection, the vibration device was removed from the injection site, and the injection was performed by the investigator immediately afterwards.
62745300|NCT06662240|NO_INTERVENTION|Subcutaneous Heparin Injection without Vibration Anesthesia (Standard)|"The patient will be informed about the procedure and consent will be obtained. Hands will be washed before the procedure and the abdomen, excluding the 5 cm2 area around the umbilicus, will be used for abdominal SC injection.~During abdominal SC injections, the patient will be given a semi-fowler position that will be comfortable and does not complicate the injection, and the injection site will be cleaned with 70% alcohol cotton wool with circular movements from the center to the outside and left to dry.~After the area dries, the skin and subcutaneous tissue in the injection area will be grasped between the thumb and index fingers.~For injections, a 25 gauge, 1.26 cm needle length, air-locked, ready-to-use syringe containing DMAH (enoxaparin sodium) will be used to enter the tissue at a 90° angle, not aspiration will be performed, the drug will be applied for 10 seconds and the drug will be exited at a 90° angle."
62745301|NCT04727632|EXPERIMENTAL|Treatment: all patients|One session of \[18F\]FES PET/CT Imaging
62745302|NCT00391430|NO_INTERVENTION|Control|Participants assigned to the control condition will receive no treatment
62745303|NCT00391430|ACTIVE_COMPARATOR|Sertraline|Participants will receive treatment with sertraline
62373765|NCT03614702|EXPERIMENTAL|1-dose sIPV + 2-doses bOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
62745304|NCT00391430|ACTIVE_COMPARATOR|CBT|Participants will receive cognitive behavioral therapy
62745305|NCT04647942||Meniscectomy|Patients who underwent a meniscectomy
62373766|NCT03614702|EXPERIMENTAL|2-doses cIPV + 1-dose bOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
62373767|NCT03614702|EXPERIMENTAL|2-doses sIPV + 1-dose bOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle,total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
62373768|NCT03614702|EXPERIMENTAL|2-doses cIPV + 1-dose tOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~tOPV(Liquid) Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml，type1 polio virus≥ 7.0 lgCCID50/ml，type2 polio virus ≥ 6.0lgCCID50/ml，type 3 polio virus≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
62552980|NCT01656057|EXPERIMENTAL|Colesevelam+saline|Colesevelam tablet 3750 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. saline
62745306|NCT06107816|PLACEBO_COMPARATOR|Usual Care Control Group|Will receive usual care
62745307|NCT06107816|ACTIVE_COMPARATOR|F&V Rx Alone Group|Will receive 4 monthly F\&V Rx vouchers regardless of their DSME/S attendance.
62552981|NCT01656057|EXPERIMENTAL|Colesevelam+CCK|Colesevelam tablet 3750 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
62552982|NCT03180281|EXPERIMENTAL|DPP4 group|DPP4 inhibitor,1 pill qd
62552983|NCT03180281|EXPERIMENTAL|insulin group|insulin,glargine or detemir，0.2U/Kg,qd
62745308|NCT06107816|ACTIVE_COMPARATOR|F&V Rx + DSME/S Group|Will receive monthly F\&V Rx vouchers starting at the first group session and they will receive additional F\&V Rx vouchers only when they attend a monthly DSME/S group (up to 4 total)
62745309|NCT04579237||1/All Subjects|Data will be derived from primary studies on all subjects.
62745310|NCT03046095|EXPERIMENTAL|Unilateral Resistance Exercise|One of the participant's legs will be randomized to a unilateral resistance training arm for 10 weeks in duration. The leg chosen to be trained will undergo resistance exercise three days per week (Monday, Wednesday, and Friday) for the entirety of the study.
62745311|NCT03046095|EXPERIMENTAL|Immobilization|One of the participant's legs will be chosen to be immobilized during the last two weeks of the study. Therefore, one leg will be resistance exercising from week 0-10 whereas the other leg will be immobilized during weeks 8-10.
62552984|NCT03180281|PLACEBO_COMPARATOR|SU group|SU,Glimepiride，1-2mg qd
62552985|NCT02962518|ACTIVE_COMPARATOR|A Standard Treatment|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months."
61986334|NCT02981719|EXPERIMENTAL|simultaneous gemcitabine and irreversible electroporation|gemcitabine intravenous infusion prior to irreversible electroporation treatment.
62552986|NCT02962518|EXPERIMENTAL|B Pressure Device|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and are additionally treated with a non-customized pressure device."
62552987|NCT04394039|EXPERIMENTAL|public sp exposures|All participants undergo the procedure of visiting all landscape exposures in a random order.
62745312|NCT05718167|EXPERIMENTAL|TQB2450 Injection and Anlotinib Hydrochloride Capsules|"In the induction stage:~TQB2450 injection: 1200 mg, Intravenous drip on d1; Carboplatin injection: Area Under Curve 5mg/mL/min, Intravenous drip on d1; Paclitaxel injection: 175mg/m2, Intravenous drip on d1. The above schemes are repeated every three weeks.~In the maintenance stage:~TQB2450 injection: 1200 mg, Intravenous drip on d1; Anlotinib Hydrochloride Capsules: 10mg, orally administered every day from d1-d14.~The above schemes are repeated every three weeks."
62745313|NCT05718167|ACTIVE_COMPARATOR|Tislelizumab Injection|"In the induction stage:~Tislelizumab injection: 200 mg, Intravenous drip; Carboplatin injection: Area Under Curve 5mg/mL/min, Intravenous drip; Paclitaxel injection: 175mg/m2, Intravenous drip. The above schemes are repeated every three weeks.~In the maintenance stage:~Tislelizumab injection: 200 mg, Intravenous drip on d1 Placebo capsule: 0mg, orally administered every day from d1-d14. The above schemes are repeated every three weeks."
62745314|NCT01303718|EXPERIMENTAL|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
62373769|NCT03614702|EXPERIMENTAL|2-doses sIPV + 1-dose tOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.0.5ml/dose~Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 2 polio virus ≥ 6.0lgCCID50/ml，type 3 polio virus ≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
62745315|NCT01303718|ACTIVE_COMPARATOR|Standard of Care|Usual care (no CardioFit System implant)
62373770|NCT04299256|EXPERIMENTAL|Benson relaxation combined with music therapy|In the first interview, the patient information delivered a training booklet explaining the definition, purpose, benefits and application techniques of BRT and music therapy to the patients in the intervention group. After patients reviewed the details in the training booklet, a weekly schedule was planned for each patient based on their hemodialysis days. For the initiation of the intervention, patients were invited to the hemodialysis unit at the hospital 45 min prior to their hemodialysis sessions. All the participants wore black eye patches to provide a dim environment and to focus better on their breath and the music piece. Then, the patients information opened the music piece and gave Benson Relaxation Technique comments in a slightly lower voice. Each session lasted for 20 min, and the music piece was switched off as Benson Relaxation Technique ended. The music piece used in the study was Daniel Kobelco's non-verbal classical song.
62373771|NCT04299256|NO_INTERVENTION|Control|Like the intervention group, the control group session (attention-matched education) which composed of 10-12 participants were performed with a booklet containing hemodialysis and its use in a silent room located in the hemodialysis units. The patient information provided in-person training on hemodialysis and its use for 20 min in a group session at the hemodialysis unit, on the first day of the study. During the study period, the participants in the control group were not subjected to any additional intervention.
61986335|NCT02981719|OTHER|IRE group|percutaneous irreversible electroporation for locally advanced pancreatic cancer.
61986336|NCT01572233|EXPERIMENTAL|Patient with HCV Infection|Personalized Physical Activity and Psycho-Education (PPAPE) Program will be tested on this group.
62373772|NCT02352090|EXPERIMENTAL|Synthetic estrogen + progestin|Ethinyl estradiol / dienogest
62373773|NCT02352090|EXPERIMENTAL|Natural estrogen + progestin|Estradiol valerate / dienogest
62373774|NCT02352090|ACTIVE_COMPARATOR|Progestin-Only|Dienogest
62373775|NCT04884386|EXPERIMENTAL|robot-assisted gait training|
62745316|NCT01557257|EXPERIMENTAL|40 mg ALO-02 capsule|Single- and multiple-dose of 40 mg ALO-02 capsule under 50 mg naltrexone block
62373776|NCT04884386|ACTIVE_COMPARATOR|conventional locomotion therapy|
62745317|NCT01557257|EXPERIMENTAL|80 mg ALO-02 capsule|Single- and multiple-dose of 80 mg ALO-02 capsule under 50 mg naltrexone block
62373777|NCT03199014|EXPERIMENTAL|prolonged deployment strategy group|"in deploying the Drug-eluting Stents with a prolonged time group,the inflation time was more than 30 seconds when the Drug-eluting Stents deploying,unless the patients was unstable."
62373778|NCT03199014|ACTIVE_COMPARATOR|rapid deployment strategy group|"in deploying the Drug-eluting Stents with a conventional time group, a conventional method was used to deploying drug-eluting stents,the actual inflation time was within 10s determined by interventional cardiologist."
62373779|NCT00834392|NO_INTERVENTION|Control|
62373780|NCT00834392|EXPERIMENTAL|Exercise|
62373781|NCT04716842||sepsis|In intensive care patients with suspected or proven infection, if the SOFA score ≥2, the patients will be evaluated as sepsis and routine examination, monitoring and treatment will be applied.
62373782|NCT04716842||septic shock|Patients with sepsis who require vasopressor to keep mean arterial pressure above 65 mmHg and lactate\> 2 mmol/l will be included in the septic shock group.
62373783|NCT04716842||control|It will be formed from patients who are hospitalized in the intensive care unit for a reason other than sepsis and septic shock, without suspected or proven infection.
62373784|NCT02111070|EXPERIMENTAL|ILYANG Inactivated split influenza vaccine|IL-YANG FLU Vaccine Vial INJ 0.5mL by intramuscular injection
62373785|NCT00256646||Group 1|"Patients who are enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2."
62552988|NCT02875990|EXPERIMENTAL|patients with invasive cervical cancer|Blood sample
62745318|NCT01557257|EXPERIMENTAL|40 mg OxyContin tablet|Single- and multiple-dose of 40 mg OxyContin tablet under 50 mg naltrexone block
62745319|NCT01579058|ACTIVE_COMPARATOR|bisoprolol|bisoprolol 5mg qd
62745320|NCT01579058|PLACEBO_COMPARATOR|placebo|placebo
62745321|NCT04927156||BALT medical devices|
62745322|NCT05463718|EXPERIMENTAL|children treated by the traditional physical therapy program based on Neurodevelopmental technique|Twenty-five cerebral palsied hemiplegic children will be treated by the traditional physical therapy program ( balance board, single limb support, standing with throwing ball ) based on Neurodevelopmental technique for 6 month
62745323|NCT05463718|EXPERIMENTAL|children treated by Virtual Reality for 15 min. besides the traditional physical therapy program|twenty-five cerebral palsied hemiplegics will be included in this group; they will be receive the regular physical therapy program in addition to training by Virtual reality with use of the HMD helmet allows users to perceive a 3D stereoscopic images that enable participants to interact with different balance games as football Soccer, football heading (known as Soccer Heading), the tight rope walks and the Penguin slide game.
62745324|NCT05463718|EXPERIMENTAL|children treated by Balance Beam for 15 min besides the traditional physical therapy program|Twenty-five cerebral palsied hemiplegics will be included in this group; they will be receive the regular physical therapy program in addition to training by standing and walking in balance beam by differentiate levels of walking balance proficiency as varying widths of beam and walking in different direction (forward or backward).
62745325|NCT00615589|EXPERIMENTAL|Flu-Bu4|Fludarabine Busulfan chemotherapy regimen(Flu-Bu4), followed by allogeneic stem cell transplant from best available, matched donor.
62745326|NCT04888689|EXPERIMENTAL|MS patients|Ambulant patients with multiple sclerosis
62745327|NCT05898776|EXPERIMENTAL|10°C lung preservation|
62745328|NCT05898776|ACTIVE_COMPARATOR|Standard lung preservation|
62745329|NCT06658665||No biliary complication group|The liver transplant patients who did not experience biliary complications within 90 days post-operation.
62745330|NCT06658665||biliary complication group|The liver transplant patients who experience biliary complications within 90 days post-operation.
62745331|NCT04563234|EXPERIMENTAL|COFLEX training|Neurocognitive training, delivered via a mobile device app
62745332|NCT04563234|ACTIVE_COMPARATOR|Crossword group|Access to crossword puzzles via a mobile device app
62745333|NCT00765037||Encore RSP|Subjects who need treatment for rotator cuff deficiency or glenohumeral arthritis, received the Encore Reverse Shoulder Prosthesis and are willing to participate in the study.
62745334|NCT04813614|EXPERIMENTAL|STYLAGE M Lidocaine|"The first injection is performed at visit 1 (V1) on Day 0 (D0). D0 is considered as the baseline. The maximum volume to be injected is 2 mL in total for lower and upper lips. The exact volume per lip will be determined by the physician/injector in order to reach optimal volume correction and/or lips' redefinition, as well as the injection technique(s) to be used. Injection is done into and/or around the lip mucosa by linear threading injection, multipoint injection, or a combination of both techniques with needle or cannula.~One optional touch-up injection is allowed at visit 2 (V2) on Month 1 (M1), with a maximum volume to be injected of 1 mL in total for lower and upper lips. No other touch-up injection is allowed until the end of the study.~A total maximum volume of 2.5 mL is recommended for both initial and touch-up injections combined (upper and lower lips)."
62745335|NCT04813614|ACTIVE_COMPARATOR|Active control group|"The first injection is performed at visit 1 (V1) on Day 0 (D0). D0 is considered as the baseline. The maximum volume to be injected is 2 mL in total for lower and upper lips. The exact volume per lip will be determined by the physician/injector in order to reach optimal volume correction and/or lips' redefinition, as well as the injection technique(s) to be used. Injection is done into the submucosal layer of the lip by linear threading injection or serial puncture techniques injection with needle or cannula.~One optional touch-up injection is allowed at visit 2 (V2) on Month 1 (M1), with a maximum volume to be injected of 1 mL in total for lower and upper lips. No other touch-up injection is allowed until the end of the study.~A total maximum volume of 2.5 mL is recommended for both initial and touch-up injections combined (upper and lower lips)."
62745336|NCT03905031|EXPERIMENTAL|InfraScanner 2000|All participants entered into the study will undergo at least one cranial scanning using the InfraScanner 2000 within 4 hours before or after CT scan. Patients will know the results of the CT scan but not of the InfraScanner 2000. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative.
62745337|NCT04148196|NO_INTERVENTION|Control group|older people's who have a Standard Mini Mental Test score of 23 and above, living in nursing homes.
62745338|NCT04148196|EXPERIMENTAL|Experimental group|Intervention group: older people's who have a Standard Mini Mental Test score of 23 and above, living in nursing homes.The researcher will perform 16 sessions of progressive relaxation exercises twice a week for 8 weeks. Each PMR exercise was conducted under the guidance of the researcher. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate and blood pressure.
62745339|NCT00499512||Spirituality Questionnaire|Patients with newly diagnosed ovarian, primary peritoneal, or fallopian tube cancer.
62745340|NCT03900104|EXPERIMENTAL|Transcervical endometrial injection arm|Tracer injection performed by a transcervical catheter in endometrial cancer patients.
62745341|NCT03900104|ACTIVE_COMPARATOR|Cervical injection arm|Tracer injection was administered via the cervical route in endometrial cancer patients.
62745342|NCT03516773|EXPERIMENTAL|Treatment A|Intervention: EB612 (EBP05) 2.25 mg orally (PO) four times a day (QID) (approximately 5 hours apart) for 4 doses, for a total dose of 9 mg per day
62745343|NCT03516773|EXPERIMENTAL|Treatment B|Intervention: EB612 (EBP05) 2.25 mg PO twice a day (BID) (approximately 10 hours apart) for 2 doses, for a total dose of 4.5 mg per day
62745344|NCT03516773|ACTIVE_COMPARATOR|Treatment C|Intervention: NATPARA/NATPAR PTH(1-84) 100 μg subcutaneous injection once daily (single dose)
62552989|NCT02561325|EXPERIMENTAL|NaCI group|a clinical trial protocol intended to highlight a possible differential effect in the biological effects of the same sodium intake (2.56 g / day) orally, depending on the nature salt.
62552990|NCT02561325|PLACEBO_COMPARATOR|placebo NaCI|a clinical trial protocol intended to highlight a possible differential effect in the biological effects of the same sodium intake (2.56 g / day) orally, depending on the nature salt.
62745345|NCT03516773|EXPERIMENTAL|Treatment D|Intervention: EB612 (EBP05) 2.25 mg PO TID (dose 1 and dose 2 approximately 10 hours apart; dose 2 and dose 3 approximately 5 hours apart- TID schedule option 2), for a total dose of 6.75 mg per day
61986337|NCT01572233|NO_INTERVENTION|usual care|waiting list group with usual care
61986338|NCT05096845|EXPERIMENTAL|V-01 COVID-19 Vaccine|Intramuscular injection into the lateral deltoid of the upper arm Two doses, one each on Day 0 and 21 (+7 days), respectively.
62745346|NCT03516773|EXPERIMENTAL|Treatment E - EB612 (EBP05)|Intervention: EB612 (EBP05) 0.75 mg PO TID (dose 1 and dose 2 approximately 10 hours apart; dose 2 and dose 3 approximately 5 hours apart- TID schedule option 2), for a total dose of 2.25 mg per day
62745347|NCT02179424|EXPERIMENTAL|Health talk + Workshop + Booklet + SMS|Health talk + workshop (Motivational intervention) + booklet + Short Message Service (SMS)
62373786|NCT02705352|EXPERIMENTAL|5-Fluorouracil|Antimetabolite will be injected 2 weeks after periocular reconstruction with full thickness skin graft. Injection will be repeated every 2 weeks for a total of up to 4 injections.
62745348|NCT02179424|EXPERIMENTAL|Face-to-face counseling + Booklet + SMS|Face to Face counseling (Motivational intervention) + Booklet + SMS
62745349|NCT02179424|EXPERIMENTAL|Phone counseling + Health talk + Booklet + SMS|Phone counseling (Motivational intervention) + Health talk + booklet + SMS
62745350|NCT02179424|EXPERIMENTAL|Phone counseling + Booklet + SMS|Phone counseling (Motivational intervention) + booklet + SMS
62745351|NCT04088240|EXPERIMENTAL|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (\~980 mg DPA, 380 mg EPA, 1720 mg DHA)
62745352|NCT04088240|ACTIVE_COMPARATOR|n-3 control|4 g/d n-3 control (\~980 oleic acid, 380 mg EPA, 1720 mg DHA)
62745353|NCT04088240|PLACEBO_COMPARATOR|Placebo|"4 g/d placebo control (light olive oil)"
62745354|NCT06607341|EXPERIMENTAL|Multi-level, community-digital health promotion intervention|"Participants will receive a multi-level, community-digital health promotion intervention.~1. Community-level: Community Health Workers will assess needs of individuals including through a survey and facilitate access to the Medi digital resource platform.~2. Individual level: CHW-delivered coaching on behavior-change goals and facilitation to services via the Medi platform. Participants will also receive tailored social media and in person reinforcements and cues to action based on goal attainment~3. Social network level: Participants will receive tailored recommendations sent via social media on nearby parks, recreational facilities, faith-based ministries, and peer groups to support behavior change goals"
62745355|NCT06607341|ACTIVE_COMPARATOR|Delayed control intervention group|At the individual level, participants will receive standardized 12-month text message (SMS) campaign. At the community-level, the investigators will equip community-based organization partners and community health workers with chronic disease educational content. Participants will also receive recommendations for health events and fairs locally.
62745356|NCT03770325|EXPERIMENTAL|Berberine|berberine (500 mg orally twice a day)
62745357|NCT03770325|PLACEBO_COMPARATOR|Placebo|placebo (500 mg orally twice a day)
62745358|NCT02251834|EXPERIMENTAL|Community Health Worker|Community Health Worker (CHW) home visits, coaching phone calls, group sessions .
62745359|NCT02251834|OTHER|Usual Care|usual care and health education brochures every 4 months.
62745360|NCT03811769|OTHER|Best Medical Therapy (BMT)|Best treatment medical probably associated to the rescue endovascular treatment in case of neurological deterioration
62745361|NCT03811769|OTHER|Mechanical Thrombectomy (MT)|Endovascular treatment (thrombectomy) associated with the best medical treatment
62745362|NCT00142168|EXPERIMENTAL|CC-5103 (Lenalidomide) and Rituximab|Intended therapy consisted of 48 weeks of CC-5103 (lenalidomide)(25 mg/d for 3 weeks and then 1 week off) along with rituximab (375 mg/m(2)/wk) dosed on weeks 2 to 5 and 13 to 16.
62745363|NCT05723562|EXPERIMENTAL|Dostarlimab monotherapy|
62745364|NCT05069077|EXPERIMENTAL|music group|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
62745365|NCT05069077|OTHER|non-music group|Participants in the non-music group will undergo diagnostic outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
62745366|NCT03551405||Intensity accuracy|"The difference of the HU values in corresponding ROIs in the two image sets will be compared with zero using one sample t-test.~In addition, we will also use these patient cases to test the computational efficiency of our algorithm. Based on our preliminary study, it is expected that the computation time will be 5\~10 sec per phase. The reconstruction time will be recorded in these patient cases and will be assessed."
62373787|NCT02705352|PLACEBO_COMPARATOR|Normal saline|Normal saline will be injected 2 weeks after periocular reconstruction with full thickness skin graft. Injection will be repeated every 2 weeks for a total of up to 4 injections.
62373788|NCT04376424|EXPERIMENTAL|Ultra Sound Guided Therapy Group|Hand carried ultrasound will be used in this group to measure IVCd, collapsibility along with internal jugular vein collapsibility. The results of the ultrasound will be unblinded to the treating team.
62745367|NCT04671212||Orthopedic Surgery Patients|Participants receiving orthopedic surgery for clinical management that involve bone marrow containing bone discard.
62745368|NCT00118846|ACTIVE_COMPARATOR|Isoflavone Soy Protein (ISP) Supplementation|25 gm soy protein supplementation administered twice daily in equivalent dosages (12.5 gm)
62745369|NCT00118846|PLACEBO_COMPARATOR|Placebo|Milk protein matching placebo administered twice daily in equivalent dosages
62745370|NCT03316287|EXPERIMENTAL|Hearing aid + mobile phone|
62745371|NCT03316287|EXPERIMENTAL|Hearing aid + mobile phone + biosensor|
62745372|NCT05538312|EXPERIMENTAL|vepdegestrant with and without itraconazole|vepdegestrant administered as a single dose in Period 1 and Period 2. Itraconazole administered once a day for 11 days in Period 2.
62745373|NCT00551148|EXPERIMENTAL|15 mg|
62745374|NCT00551148|EXPERIMENTAL|30 mg|
62745375|NCT00551148|EXPERIMENTAL|5 mg|
62745376|NCT00551148|EXPERIMENTAL|60 mg|
62745377|NCT00551148|PLACEBO_COMPARATOR|Placebo|
62745378|NCT04516499||f-FTLD mutation carriers|All participants must be from a family with f-FTLD mutations. The f-FTLD mutation carrier group members will have their genetic status tested and included in this group if a f-FTLD mutation is observed. Participants do not need to know or be told their genetic status.
62745379|NCT04516499||Non-mutation carriers from families with f-FTLD mutations|All participants must be from a family with f-FTLD mutations. The non-mutation carrier group members will have their genetic status tested and included in this group if they do not have a f-FTLD mutation. Participants do not need to know or be told their genetic status.
62745380|NCT03330483||Female Speedicath nelathon|Evaluation of pain or discomfort in female patients at/during/after Speedicath nelathon-tip catheter insertion
62745381|NCT03330483||Female nelathon|Evaluation of pain or discomfort in female patients at/during/after standard nelathon-tip catheter insertion
62745382|NCT03330483||Male Speedicath tiemann|Evaluation of pain or discomfort in male patients at/during/after Speedicath tiemann-tip catheter insertion
62745383|NCT03330483||Male tiemann|Evaluation of pain or discomfort in male patients at/during/after standard tiemann-tip catheter insertion
62745384|NCT04322331||T1N+|T1 tumor with positive lymph node,N1/N2/N3
62745385|NCT04322331||T2/T3N0|T2/T3 tumor with negative lymph node
62745386|NCT01345513||Solid Tumor Cancer|
62745387|NCT06428058|EXPERIMENTAL|Comprehensive Sexual Health Curriculum|Participants received a four-day comprehensive sexual health curriculum tailored for Africa.
62745388|NCT06428058|NO_INTERVENTION|Waitlist Control|Participants in this arm completed a follow-up survey and scheduled to receive the intervention after the end of the trial.
62745389|NCT05920681|EXPERIMENTAL|Transanal irrigation group|Transanal irrigation will be applied to patients who will enter the experimental group. The patient lies on the left or right side, depending on the main hand, the knees are bent. With the main hand, he carefully introduces the TAI tip lubricated with lubricant. The TAI bag is filled with warm water - it can be boiled or just from the tap. The contents of the TAI bag are slowly administered through the anus. The duration of the TAI is about 15-20 minutes. Afterwards, the subject goes to defecate until the bowel is empty. This action should be repeated daily.
62745390|NCT05920681|ACTIVE_COMPARATOR|Best supportive care group|"The control group will receive best supportive care (diet modification, Loperamidum if needed, diapers, etc).~Loperamidum Dosage form: Loperamide Tablets (2mg of loperamide hydrochloride.). Dosage: Initial dose - 2 tablets immediately, then - 1 tablet after each loose stool, but not earlier than 2-3 hours after the initial dose. Do not exceed the maximum daily dose - no more than 6 tablets for adults (maximum daily dose 12 mg)."
62745391|NCT03786081|EXPERIMENTAL|A: Tisotumab Vedotin + bevacizumab|Dose escalation: Tisotumab vedotin in combination with bevacizumab once every three weeks in previously treated patients
62745392|NCT03786081|EXPERIMENTAL|B: Tisotumab vedotin + pembrolizumab|Dose escalation: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients
62745393|NCT03786081|EXPERIMENTAL|C: Tisotumab vedotin + carboplatin|Dose escalation: Tisotumab vedotin in combination with carboplatin once every three weeks in previously treated patients
62745394|NCT03786081|EXPERIMENTAL|D: Tisotumab vedotin + carboplatin|Dose expansion:Tisotumab vedotin in combination with carboplatin once every three weeks in previously untreated patients
62745395|NCT03786081|EXPERIMENTAL|E: Tisotumab vedotin + pembrolizumab|Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously untreated patients
62745396|NCT03786081|EXPERIMENTAL|F: Tisotumab vedotin + pembrolizumab|Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients
62745397|NCT03786081|EXPERIMENTAL|G: Tisotumab vedotin monotherapy|Dose expansion: Tisotumab vedotin monotherapy weekly for three weeks and 1 week off (28 day treatment cycle) in previously treated patients.
62745398|NCT03786081|EXPERIMENTAL|H: Tisotumab vedotin + pembrolizumab + carboplatin +/- bevacizumab|Dose expansion: Tisotumab vedotin in combination with pembrolizumab and carboplatin with or without bevacizumab once every three weeks in previously untreated patients
62745399|NCT01317576|EXPERIMENTAL|Healthy control|This group will exist of healthy obese that are matched for BMI and age with the type 2 diabetes group and non-alcoholic fatty liver disease group.
62745400|NCT01317576|EXPERIMENTAL|Non-alcoholic fatty liver disease|This group will exist of people that suffer from non-alcoholic fatty liver disease. They will be matched for BMI and age according to the Type 2 diabetes group
62745401|NCT01317576|EXPERIMENTAL|Type 2 diabetes patients|This group will exist of patients that suffer from type 2 diabetes
62745402|NCT02855957|OTHER|Blood sample|A blood collection is carry out in the three populations of patients during the day of their enrolment.
62745403|NCT01738607|PLACEBO_COMPARATOR|Placebo|"basic recipe for juice and muffin recipe~abbreviated PLB"
62745404|NCT01738607|EXPERIMENTAL|Carboxymethylcellulose|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated CMC"
62745405|NCT01738607|EXPERIMENTAL|Gum Arabic|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated GA"
62745406|NCT01738607|EXPERIMENTAL|Psyllium|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated as PSY"
62745407|NCT05317715|OTHER|without device information|this group of patients will complete a questionnaire before receiving information on contraceptive intrauterine devices (copper or hormonal)
62745408|NCT05317715|OTHER|with device information|This group of patients will receive information about contraceptive intrauterine devices (copper or hormonal) before completing a questionnaire
62745409|NCT04943341|EXPERIMENTAL|Eco-guided Triamcinolone-Acetonide injection|Patients affected by medial plica syndrome will be treated with an eco-guided injection of Triamcinolone-Acetonide.
62745410|NCT01237457|EXPERIMENTAL|Treatment|Patients with somatostatin receptor-expressing neuroendocrine neoplasms will receive up to 200 mCi of 177Lu-DOTATATE every 6-11 weeks, preferably 6-9 weeks to a cumulative dose of 800 mCi.
62745411|NCT05808946|EXPERIMENTAL|Alpha-Lipoic Acid Group|
62745412|NCT05808946|ACTIVE_COMPARATOR|Control Group|
62745413|NCT05439993|EXPERIMENTAL|Tepotinib plus paclitaxel arm|
62745414|NCT06661668||Gastroparesis group|Patients scintigraphically proven gastroparesis and failed conservative therapy who undergo laparoscopic gastric pacemaker implantation
62745415|NCT00817570||1|Transfemoral Amputees using the C- Leg knee.
62745416|NCT00817570||2|Transfemoral Amputees using a Multiaxial Knee.
62745417|NCT00817570||3|Able bodied.
62745418|NCT01132534||SE then AFI/NBI|Patients will be randomised to be examined by standard videoendoscopy (SE) then combined AFI/NBI during the esophagogastroduodenoscopy (EGD) examination at same setting.
62745419|NCT01132534||AFI/NBI then SE|Patients will be randomised to be examined by combined AFI/NBI then standard videoendoscopy (SE) during the EGD examination at same setting.
62745420|NCT05705778||Strabismic|
62373789|NCT04376424|NO_INTERVENTION|Conventional Therapy Group|Conventional therapy will occur the use of hand carried ultrasound. The results will be blinded to the treating team. The managing team will analyze the data at the end of the study.
62745421|NCT05705778||Anisometropic|
62373790|NCT04247828|EXPERIMENTAL|Experimental and Generic Communication Interfaces for AAC|Receives both Experimental and Generic AAC systems to communicate. Each participant will receive both devices, with Experimental AAC presented first (Day 1) and Generic AAC presented second (Day 2; reference).
62373791|NCT06353204|EXPERIMENTAL|Experimental group: Halt-intervention|The experimental group will receive the Halt-intervention.
62373792|NCT06353204|NO_INTERVENTION|Control group: No Halt-intervention|The control group will not receive the Halt-intervention, nor will they receive any other intervention or form of punishment.
62373793|NCT01926704||healthy, young subjects|
62373794|NCT05891470|ACTIVE_COMPARATOR|Vaginal Dilatators|Use of vaginal dilatators as standard of care.
62373795|NCT05891470|EXPERIMENTAL|MonaLisa Touch device|Sessions with the MonaLisa Touch device
62373796|NCT02019004|ACTIVE_COMPARATOR|Onabotulinum Toxin A|One side of the face will be randomized to receive Onabotulinum Toxin A injections in the forehead and glabellar region of the face.
62373797|NCT02019004|ACTIVE_COMPARATOR|Incobotulinum Toxin A|The other side of the face will be randomized to receive Incobotulinum Toxin A injections in the glabellar and forehead region of the face.
62373798|NCT00338429|EXPERIMENTAL|Treatment: FHP Sleep Program|Stratified with or without behavior Disorder Diagnosis (ADHD): 50% randomized to receive Better Days, Better Nights- sleep distance intervention
62373799|NCT00338429|NO_INTERVENTION|Control: Usual Care|Stratified with/without behavior diagnosis (ADHD): 50% randomized to receive usual care for sleep disorder
62373800|NCT03566992|ACTIVE_COMPARATOR|Gastric Tube Placement|Nasoenteric tube placed in the stomach.
62373801|NCT03566992|EXPERIMENTAL|Small bowel|Nasoenteric tube placed in the small bowel.
62373802|NCT03104829|ACTIVE_COMPARATOR|DSME|participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later
62373803|NCT03104829|EXPERIMENTAL|DSME+MI|participants in this arm will receive standard care for diabetes plus motivation interviewing (MI) sessions at the beginning of the study and 3 months later, will also receive motivation interviewing sessions by phone at 1, 2, 4, 5 month after the beginning of the study
62373804|NCT03336476|EXPERIMENTAL|Videolaryngoscopy|Videolaryngoscopy the trachea will be intubated using a videolaringoscope
62373805|NCT03336476|ACTIVE_COMPARATOR|Direct laryngoscopy|Direct laringoscopy the trachea will be intubated using a laringoscope
62373806|NCT03338881|EXPERIMENTAL|[14C]-TAK-659 100 mg|\[14C\]-TAK-659 100 mg, solution, orally, once, in the fasted state on Day 1. Participant will have the option to continue treatment with TAK-659 100 mg, tablets, orally, once daily in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, or the start of another anticancer therapy in post-ADME study period.
62745422|NCT05705778||Isoametropic|
62373807|NCT06386367|EXPERIMENTAL|Monastery-based health education intervention|The education sessions were conducted in Burmese by trained monks. They followed the normal teachings of the Buddhist doctrine and typically lasted 30-40 minutes. Our research utilized Burmese as the medium for delivering health messages, and all accompanying materials were meticulously prepared in Burmese. The study team observed at least one to two education sessions in each study village.
62373808|NCT06386367|NO_INTERVENTION|Control|Participants in the control group just received routine malaria control services such as diagnostic, treatment and bed net distribution.
62373809|NCT01685372|EXPERIMENTAL|Fluzone High Dose|Fluzone High Dose 0.5 mL intramuscularly (IM) given once
62373810|NCT01685372|ACTIVE_COMPARATOR|Fluzone|Fluzone 0.5mL IM given once
62373811|NCT03935685|EXPERIMENTAL|mirtazapine in glioma patients treated with Temozolomide|Using the well-known Beck Depression Inventory, we will assess the changes in depression scores from baseline to after four and eight weeks of treatment with mirtazapine. We will also assess the change in nausea, vomiting, and weight at the same time points, and collect information on tolerability of mirtazapine throughout the course of the study.
62373812|NCT04227119|EXPERIMENTAL|Irrigated ablation catheter and 5F balloon tipped PA catheter|Participants undergoing cardiac ablation will have cardiac pressures measured with an irrigated ablation catheter (standard protocol for this procedure) and a 5F balloon tipped pulmonary artery (PA) catheter (for study purposes only).
62745423|NCT05705778||Visual deprivation|
62745424|NCT05705778||Mixed group|
62745425|NCT01106859|ACTIVE_COMPARATOR|zopiclone|Zopiclone is taken at bedtime 9 hours before driving. The middle-of-the-night medication is a placebo matching zolpidem tartrate sublingual tablet.
62373813|NCT04103203|NO_INTERVENTION|New diagnostic results NOT available|Patients with suspected sepsis are included. Blood samples will be collected and analysed with the new diagnostics. However, results will not be communicated. Only the results of routine blood cultures will be availabtle to the treating physician. No intervention will take place, care is provided according to normal routine practices.
62745426|NCT01106859|EXPERIMENTAL|zolpidem 3 hours prior|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is zolpidem tartrate sublingual tablet taken 3 hours prior to driving.
62745427|NCT01106859|EXPERIMENTAL|zolpidem 4 hours prior|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is zolpidem tartrate sublingual tablet taken 4 hours prior to driving.
62745428|NCT01106859|PLACEBO_COMPARATOR|Placebo|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is a placebo matching zolpidem tartrate sublingual tablet.
62745429|NCT01811485|EXPERIMENTAL|LMF237 50/250 mg|Patients took LMF237 50/250 mg twice daily for 14 weeks
62745430|NCT01811485|EXPERIMENTAL|LMF237 50/500 mg|Patients took LMF237 50/500 mg (with a starting dose of LMF 237 50/250 mg for 2 weeks) twice daily for 14 weeks
62745431|NCT01811485|PLACEBO_COMPARATOR|Placebo|Patients took matching placebo of LMF237 (vildagliptin 50 mg) twice daily for 14 weeks
62745432|NCT00501592|ACTIVE_COMPARATOR|25 mg INT-747|
62745433|NCT00501592|ACTIVE_COMPARATOR|50 mg INT-747|
62745434|NCT00501592|PLACEBO_COMPARATOR|Placebo|
62373814|NCT04103203|EXPERIMENTAL|New diagnostic results available|Patients with suspected sepsis are included. Blood samples will be collected and analysed with the new diagnostics. Results will be communicated via telephone by the consultant microbiologist and the electronic medical file to the treating physician. Results of routine blood cultures will also be available for all patients. Results of the new diagnostics are expected earlier, and the treating physician is able to make an earlier decision in terms of antibiotic therapy if he/she deems it necessary.
62745435|NCT00801723|EXPERIMENTAL|1: Budesonide MMX® 6 mg|One Budesonide-MMX® 6 mg tablet self-administered by the patients with a glass of water, in the morning after breakfast.
62745436|NCT00801723|PLACEBO_COMPARATOR|2: Placebo|One placebo tablet self-administered by the patients with a glass of water, in the morning after breakfast.
62373815|NCT06188728|PLACEBO_COMPARATOR|Control group|Group-I comprised of 30 subjects, 15 male and 15 female. The group was assigned no intervention and kept as the control group.
62373816|NCT06188728|EXPERIMENTAL|LSM group|Group II comprised 30 subjects with the equal bifurcation of male and female. Group II was assigned the intervention of lifestyle modification (the combination of diet, physical activity, and behavior therapy)
62745437|NCT02662504|EXPERIMENTAL|multimodal treatment + intrapleural PDT|"* surgery of the MPM: extended pleurectomy/decortication (eP/D)~* intra-operative (intrapleural) photodynamic therapy (PDT). Briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.~then:~* prophylactic chest radiotherapy of surgical scars to prevent tumor seeding (3 x 7 Gray)~* adjuvant standard chemotherapy by (cis)platin 75 mg/m2 and pemetrexed 500 mg/m2 up to 6 cycles (1 cycle every 3 weeks), with oral folic acid (400 μg daily) and vitamin B12 (1000 μg Q9W) supplementation"
62745438|NCT06506188|EXPERIMENTAL|LINK model|Women at these sites receive the LINK model, which includes integrated EPI/HIV testing, screening for HIV risk, support for male partner engagement, and community-facility linkage (CFL) peer moms for breastfeeding women using PrEP for ongoing support and follow-up for breastfeeding women who disengage from PrEP care. This model is integrated into the SOC and does not replace SOC activities.
62745439|NCT06506188|NO_INTERVENTION|Standard of Care|Women at these sites continue to receive the current standard of care (SOC) for postpartum HIV testing, PrEP screening, and PrEP care in Malawi.
62745440|NCT06660537|EXPERIMENTAL|Interventional group|In this group patients will undergo balloon-blowing exercises in the 90/90 bridge position with a ball. In this intervention, patients lie on back with feet against a wall and knee bent at 90 degrees, holding a ball between their knees. While extending one arm overhead and holding a balloon in the other hand, perform a pelvic tilt without lifting their backoff the mat. Inhale through the nose, exhale into the balloon for four breaths, then remove the balloon and repeat the sequence four times. The 4-week protocol includes three supervised sessions per week, each supervised by a physiotherapist. Progress will be monitored regularly to evaluate improvements throughout the intervention.
62745441|NCT06660537|EXPERIMENTAL|Control group|In this group, patient will receive Buteyko breathing exercises consists of two main exercises; the control pause and the maximum pause .For control pause, patient exhale, plug the nose, and hold their breath until they feel the urge to breathe, then inhale and breathe normally for 10 seconds.In Maximum pause, patient exhale,plug their nose ,and hold their breath as long as posiible, aiming for double the control pause time, then inhale and breath normally for 10 seconds.This is a 4-week protocol with three sessions per week.Pre- and post- intervention values will be recorded to assess progress.n.
62745442|NCT03172325|EXPERIMENTAL|CinnaGen adalimumab|CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.
62373817|NCT06188728|EXPERIMENTAL|PSH group|"Group III comprised of 30 subjects, 15 male and 15 female. Group III was assigned the 5gm psyllium husk fiber (in swelled form) two times a day, i.e., 30 minutes before breakfast and 30 minutes before dinner.~All the subjects in the physical demonstration were briefed about the preparation and usage of psyllium husk fiber."
62373818|NCT06188728|EXPERIMENTAL|LSM&PSH|Group IV comprised of 30 subjects, 15 male and 15 female. Group IV was assigned both the intervention of psyllium husk fiber @ 5gm two times a day, 30 minutes before breakfast and dinner in swelled gel form with the combination of lifestyle modification
62373819|NCT06206772||Healthy subjects|
62373820|NCT06206772||Episodic cluster headache, active|
62745443|NCT03172325|ACTIVE_COMPARATOR|AbbVie adalimumab|Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.
62745444|NCT04314999||Patients diagnosed with a chronic spontaneous urticaria|Patients with a chronic spontaneous urticaria who were being treated at the allergology of the university hospital Basel between the 1st of June and the 30th of September
62745445|NCT03091998|ACTIVE_COMPARATOR|Study Drug (CD-NP)|Participants will receive a single subcutaneous injection of CD-NP (5 ug/kg) for 3 days running
62373821|NCT06206772||Episodic cluster headache, remission|
62373822|NCT06206772||Chronic cluster headache|
62373823|NCT02647892|ACTIVE_COMPARATOR|Arm A|10 mg/mL lidocaine; Frequency: 1
62373824|NCT02647892|ACTIVE_COMPARATOR|Arm B|9 mg/mL of 10% sodium bicarbonate-90% lidocaine; Frequency: 1
62373825|NCT02647892|ACTIVE_COMPARATOR|Arm C|7.5 mg/Ml of 25% sodium bicarbonate-75% lidocaine Frequency: 1
62373826|NCT02647892|ACTIVE_COMPARATOR|Arm D|5 mg/mL 50% sodium bicarbonate-50% lidocaine Frequency: 1
62373827|NCT01711476|ACTIVE_COMPARATOR|Lifestyle counseling ARM 1|Arm 1 Breakfast Diet The arm 1 will be assigned to eat High calorie breakfast (800kcal) and reduced dinner (200 kcal) During 90 days from baseline to the end of the trial (day 90)
62373828|NCT01711476|PLACEBO_COMPARATOR|Lifestyle counseling ARM 2|Lean PCOS women in the Arm 2 will be assigned to do a dinner diet from day 0 to day 90 of the trial
62373829|NCT05687253|EXPERIMENTAL|BX1000 0.15 mg/kg|BX1000 0.15 mg/kg IV Bolus
62373830|NCT05687253|EXPERIMENTAL|BX1000 0.25 mg/kg|BX1000 0.25 mg/kg IV Bolus
62373831|NCT05687253|EXPERIMENTAL|BX1000 0.35 mg/kg|BX1000 0.35 mg/kg IV Bolus
62373832|NCT05687253|ACTIVE_COMPARATOR|Rocuronium 0.6 mg/kg|Rocuronium bromide 0.6 mg/kg IV Bolus
62745446|NCT03091998|PLACEBO_COMPARATOR|Placebo (saline)|Participants will receive a single subcutaneous injection (\~1 mL) of normal saline for 3 days running
62745447|NCT03783000|EXPERIMENTAL|All subjects|Treatment T followed by Treatment R
62745448|NCT01311115|EXPERIMENTAL|Group commitment contracts|"In addition to education and counseling, the intervention includes the following components:~1. Each participant is encouraged to deposit his cigarette money on a weekly basis, to be returned only if the smoker quits successfully within three months.~2. The project gives a series of two matching contributions of 150 baht each to participants who meet certain deposit requirements.~3. Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt."
62745449|NCT01311115|ACTIVE_COMPARATOR|Education and counseling|Participants in this group receive educational pamphlets about quitting smoking and one-time, group counseling from a nurse trained in smoking cessation counseling.
62745450|NCT01121445|NO_INTERVENTION|CPAP with heated humidification|Standard of care
62373833|NCT04024449||Celiac Disease|"Celiac disease with the following criteria;~* 13 ≤ Age ≤20~* At least one year after menarche~* Non-obesity or malnutrition, Non-Hyperandogenism symptoms, and blood tests, Non-Hyper or hypothyroidism, Non-Hyperprolactinemia."
62373834|NCT04024449||Control|"The adolescent with the following criteria;~* 13 ≤ Age ≤20~* At least one year after menarche~* Non-obesity or malnutrition, Non-Hyperandogenism symptoms, and blood tests, Non-Hyper or hypothyroidism, Non-Hyperprolactinemia.~* Control group; with normal menstrual period, Non-chronic diseases"
62373835|NCT04432168|EXPERIMENTAL|Fetoscopic Laser Surgery|fetoscopic laser coagulation of the vascular anastomoses at the placental surface
62745451|NCT04277858|EXPERIMENTAL|Neoadjuvant chemotherapy and surgery|"Docetaxel and Cisplatin x 3 cycles followed by Transoral robotic surgery and neck dissection.~Carboplatin may be used instead of Cisplatin."
62745452|NCT02058511|EXPERIMENTAL|Intervention Group|"all enrolled patients undergo the same protocol/ treatment:~Anesthesia Premedication, Induction and Maintenance Pupillometry after administration of anesthetic drugs"
62745453|NCT02110537|EXPERIMENTAL|Active Acupuncture + flecainide|The participants in this group receive verum acupuncture treatment once a week for 10 weeks and flecainide 75 mg twice daily.
62745454|NCT02110537|SHAM_COMPARATOR|Sham acupuncture + flecainide|The participants in this group receive sham acupuncture treatment once a week for 10 weeks and flecainide 75 mg twice daily.
62373836|NCT04432168|OTHER|Standard Treatment|Expectant management, IUT (with or without PET), preterm delivery
62745455|NCT06115473|ACTIVE_COMPARATOR|E group for epinephrine|In Group (E) patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased.
62745456|NCT06115473|PLACEBO_COMPARATOR|Group (F)|In Group (F) patients will receive IV bolus isotonic fluid 500 ml as it is yet the standard method used before intubation
62745457|NCT00835198|ACTIVE_COMPARATOR|1|Dapsone gel 5% and Tretinoin gel 0.025%
62745458|NCT00835198|ACTIVE_COMPARATOR|2|Tretinoin gel 0.025%
62745459|NCT02437630||Patients with COPD|Patients with COPD aged \>40 years with Gold stage II as measured by standard lung function testing or worse and at least 10 pack year history of smoking who will have insertion of an oesophageal balloon to measure intra-thoracic pressure, fibre-optic laryngoscopy to observe movement of the larynx during respiration and facemask pneumotachograph measurement of airflow and volumes at the mouth. The facemask which will be used to deliver a positive airway pressure (continuous positive airways pressure(CPAP) This will provide face mask CPAP with variation of mouth pressure with CPAP
62745460|NCT02437630||normal subjects without copd|Subjects without COPD and normal lung function as measured by standard lung function tests who will have insertion of an oesophageal balloon to measure intra-thoracic pressure, fibre-optic laryngoscopy to observe movement of the larynx during respiration and facemask pneumotachograph measurement of airflows and volumes at the mouth which will be used to deliver a positive airway pressure (continuous positive airways pressure CPAP) This will provide face mask CPAP with variation of mouth pressure with CPAP
62745461|NCT03384355||Class 0|no visible or palpable varicose veins
62745462|NCT03384355||Class 1|telengiectasia ( thread veins, spider veins, broken veins)
62745463|NCT03384355||Class 2|varicose veins
62745464|NCT03384355||Class 3|edema
62745465|NCT03384355||Class 4|skin changes (pigmentation, eczema, lipodermatosclerosis, atrophie blanche)
62745466|NCT03384355||Class 5|healed venous ulcer
62373837|NCT02651376|EXPERIMENTAL|Conventional plus AAIT|Participants received conventional treatment (anti-opportunistic infections and ART) plus a dose (3 times of MNCs) of AAIT.
62373838|NCT03683095||Lymphovenous bypass|Patients with extremity lymphedema treated with lymphovenous bypass.
62373839|NCT04484506|EXPERIMENTAL|Stage I/II nasal ENKTL|2-3 cycles of induction pegaspargase-COEP chemotherapy followed by concurrent chemoradiotherapy, then by 1-2 cycles of pegaspargase-COEP chemotherapy as consolidation
62373840|NCT04484506|EXPERIMENTAL|Stage III/IV or primary extra-nasal ENKTL|6-8 cycles of pegaspargase-COEP chemotherapy with or without local radiotherapy and/or consolidative autologous stem cell transplantation
62373841|NCT00566332|ACTIVE_COMPARATOR|1|Chlorambucil 8mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months
62373842|NCT00566332|ACTIVE_COMPARATOR|2|Fludarabine
62373843|NCT02483065||inpatients with dementia|
62373844|NCT02483065||inpatients without dementia|
62373845|NCT00722475|EXPERIMENTAL|IvIg|Repeated infusions of intravenous immunoglobulin in early pregnancy
62373846|NCT00722475|PLACEBO_COMPARATOR|placebo|infusion of human albumin CSL Behring 5%
62373847|NCT04410913|EXPERIMENTAL|Visual Healing Set and Setting|Participants in this group will receive a single 25 mg dose of open-label psilocybin along with the Visual Healing Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water. Four weeks later all participants will undergo a second open-label psilocybin 25 mg session where participants will choose to receive Visual Healing or standard Set and Setting procedures. All participants will receive Prep and Integration counseling.
62745467|NCT03384355||Class 6|active venous ulcer
62745468|NCT02928302|EXPERIMENTAL|TVU CL screening|TVU CL screening: single TVU CL at 18 0/7 to 23 6/7 every week
62745469|NCT02928302|NO_INTERVENTION|no screening|no TVU CL screening
62745470|NCT03639636|OTHER|interventional prospective study|nonsurgical periodontal therapy(scaling and root planing) surgical therapy( flap surgery)
62745471|NCT00556608|EXPERIMENTAL|Sinovial|3 intra-articular injections of Sinovial®
62745472|NCT00556608|ACTIVE_COMPARATOR|Sinvisc|
62745473|NCT00152477|EXPERIMENTAL|Carboplatin/Paclitaxel|Carboplatin and paclitaxel alone.
62745474|NCT00152477|EXPERIMENTAL|Carboplatin/Paclitaxel/CDP791 10mg|Carboplatin and paclitaxel plus CDP791 10mg/kg
62745475|NCT00152477|EXPERIMENTAL|Carboplatin/Paclitaxel/CDP791 20mg|Carboplatin and paclitaxel plus CDP791 20mg/kg
62745476|NCT03397394|EXPERIMENTAL|Rucaparib|Oral rucaparib (monotherapy)
62745477|NCT02387333|EXPERIMENTAL|Study group|in this arm -study group- : patients will receive mesh stoma reinforcement technique with ileal conduit urinary diversion.
62373848|NCT04410913|ACTIVE_COMPARATOR|Standard Set and Setting|Participants in this group will receive a single 25 mg dose of open-label psilocybin along with the Standard Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water. Four weeks later all participants will undergo a second open-label psilocybin 25 mg session where participants will choose to receive Visual Healing or standard Set and Setting procedures. All participants will receive Prep and Integration counseling.
62373849|NCT03594461|EXPERIMENTAL|2mg IAI q2w|2mg Intravitreal Aflibercept injection will be given every 2 weeks starting at baseline and then at weeks 2, 4, 6, 8, 10 and 12. Patients will then be seen at week 16 (4 weeks following the end of the intensive dosing period), and a treat and extend regimen will be initiated through week 52.
62373850|NCT03594461|EXPERIMENTAL|2mg IAI q3w|2mg Intravitreal Aflibercept injection will be given every 3 weeks starting at baseline and then at weeks 3, 6, 9 and 12. Patients will then be seen at week 16 (4 weeks following the end of the intensive dosing period), and a treat and extend regimen will be initiated through week 52.
62373851|NCT06442085|ACTIVE_COMPARATOR|Medical students - volunteers receiving mannequin based simulation training|volunteers receiving mannequin based simulation training (control), then assessed for primary outcome, analyzed for primary outcome.
62373852|NCT06442085|EXPERIMENTAL|Medical students - volunteers receiving virtual reality simulation training|volunteers receiving virtual reality simulation training (intervention), then assessed for primary outcome, analyzed for primary outcome.
62373853|NCT03052465|EXPERIMENTAL|Feeding|Test soup meal feeding intervention
62373854|NCT01810822||Genesis French-Belgium Study|Cross-sectional, multi-center, binational (Belgian and France) study designed to evaluate the genetic components of diabetic nephropathy. It is a cohort with 501 patients, including 279 individuals (55.7%) with diagnosis of diabetic nephropathy.
62373855|NCT01810822||GENEDIAB|Cross-sectional, multi-center, binational (Belgian and France) study designed to evaluate the genetic components of diabetic nephropathy. It is a cohort with 444 patients, including 310 individuals (69.8%) with diagnosis of diabetic nephropathy.
62745478|NCT02387333|SHAM_COMPARATOR|Control group|in this arm -sham comparator- : patients will not receive mesh stoma reinforcement technique with ileal conduit urinary diversion.
62745479|NCT01271712|EXPERIMENTAL|Regorafenib (Stivarga, BAY73-4506)|Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
62745480|NCT01271712|PLACEBO_COMPARATOR|Placebo|Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
62745481|NCT06362330||muscle-invasive bladder cancer|The postoperative pathology was muscle-invasive bladder cancer
62745482|NCT06362330||non-muscle-invasive bladder cancer|The postoperative pathology was non-muscle-invasive bladder cancer
62745483|NCT01114971|ACTIVE_COMPARATOR|Fentanyl|"Fentanyl 50 micrograms/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or Heart Rate (HR) \> 80 bpm)"
62745484|NCT01114971|EXPERIMENTAL|Labetalol|"Labetalol 5 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
62745485|NCT01114971|EXPERIMENTAL|Esmolol|"Esmolol 10 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
62745486|NCT04850222|EXPERIMENTAL|Subjects randomized to get Fluoxetine therapy|Subjects will be randomized to take Fluoxetine (10mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
62745487|NCT04850222|ACTIVE_COMPARATOR|Subjects randomized to get Calcium Supplmentation|Subjects will be randomized to take Calcium supplementation (1000mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
62373856|NCT01810822||Brazilian cohort|The cohort comprised 451 patients with type 1 diabetes for more than 10 years (56% women; aged 36 ± 11 years, mean ± SD) recruited in diabetes/endocrinology departments of three university hospitals in the cities of São Paulo (SP), Campinas (SP) and Porto Alegre (RS), Brazil.
62373857|NCT04761575||FFQ validation|All participants to complete all aspects of the study.
62373858|NCT03083106|OTHER|Elevoplasty treatment|Single Group Compared to Baseline, Non-Randomized, Multi-Center, Prospective
62373859|NCT05736042|EXPERIMENTAL|Lens fragmentation with miLOOP|Phacoemulsification with adjunctive lens fragmentation with the microinterventional microfilament loop device (miLOOP)
62373860|NCT05736042|NO_INTERVENTION|Controls|Phacoemulsification alone (no adjunctive lens fragmentation)
62373861|NCT04130880||Children with cerebral palsy|Children with CP who aged between 18 months and 6 years will be evaluated.
62373862|NCT04130880||Children with typical development|Children with typical development who aged between 18 months and 6 years will be evaluated.
62373863|NCT00191386|EXPERIMENTAL|Atomoxetine|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
62373864|NCT02052908|EXPERIMENTAL|Arm I (high-dose naproxen)|Patients receive high-dose naproxen PO QD for 6 months.
62373865|NCT02052908|EXPERIMENTAL|Arm II (low-dose naproxen, placebo)|Patients receive low-dose naproxen PO QD and placebo PO QD for 6 months.
62373866|NCT02052908|PLACEBO_COMPARATOR|Arm III (placebo)|Patients receive placebo PO QD for 6 months.
62373867|NCT02840734|EXPERIMENTAL|Kinesio taping|All subjects wore an eye mask and the taped leg was covered by clothes for preventing subjects and researchers from identifying different tapings due to double-blinding. Subjects layed down on the mat in a supine position with the hip flexed 30º and the knee flexed 60º. Y type tape was applied from a point 10 cm below the anterior superior iliac spine, bisected at the junction between quadriceps femoris tendon and the patella, ending at its inferior side. And another Y type tape was applied from the tibial tuberosity, bisected at the junction between patella tendon and the patella, ending at its superior side. The first 5 cm tape was not stretched and acted as the anchor. I type tapes were applied downward and inward to the superior and inferior meniscus of the patella respectively.
62373868|NCT02840734|PLACEBO_COMPARATOR|Placebo taping|Placebo tapes (3M tape) were applied with same method with Kinesio taping.
62373869|NCT02840734|NO_INTERVENTION|No taping|In case of the no taping condition, the subject was treated along the same procedure which was closed subject's eyes with eye mask and covered the legs with clothes although applied anything on their legs. It might be able to minimize the error, because the researchers did not realize which condition the subject had.
62373870|NCT03898323|EXPERIMENTAL|AABM Training|Alcohol Approach Bias Modification (AABM) training is a computer training program that participants interact with by pushing and pulling a joystick. Participants are asked to respond to the format of a presented picture, irrespective of the pictures' content. Training effect is achieved by presenting alcohol pictures in push format only and non-alcoholic drinks in pull format only. AABM training consists of 3 sessions per week over 2 weeks, for a total of 6 sessions.
62373871|NCT04120350|EXPERIMENTAL|R2-MTX-LEN|"Phase Ib：Experimental arm will be treated with R2-MTX regimen for 6 cycles as initiate induction, the dose of lenalidomide was escalated from 15mg， 20mg， 25mg to test DLT by 3+3 design, meanwhile the dose of rituximab and methotrexate is fixed. If the patients achieved CR or PR by MRI and CSF evaluation, they processed to lenalidomide maintenance for 2 years.~Phase II: the patients will be treated by fixed dose of R2-MTX regimen (established lenalidomide dose from phase Ib study) for 6 cycles. the efficiency evaluation will be performed every 2 cycles, the patients who achieved CR or PR will finish the total 6 cycles of induction therapy, then begin the stage of lenalidomide maintenance for 2 years. Follow-ups should be taken for 5 years."
62373872|NCT04713644||Burst Suppression|Patients who present burst suppression after standardized propofol administration during anesthetic induction
62373873|NCT04713644||No Burst Suppression|Patients who did not present burst suppression after standardized propofol administration during anesthetic induction
62373874|NCT00617162|EXPERIMENTAL|DBS Active Treatment Group|Deep Brain Stimulation, Libra Deep Brain Stimulation System: DBS Active Treatment Group - implanted with investigational device and activated for stimulation
62373875|NCT00617162|PLACEBO_COMPARATOR|DBS Control Group|Deep Brain Stimulation, Libra Deep Brain Stimulation System: implanted with investigational device, but will not receive active stimulation for the first 6 months of the study
62373876|NCT03044743|EXPERIMENTAL|PD-1 knockout EBV-CTL|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISP-Cas9 system and EBV-CTL will be generated in the laboratory (PD-1 Knockout EBV-CTL).~Fludarabine at 30mg/m2 and Cyclophosphamide at 300mg/m2 single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10\^7/kg PD-1 Knockout CTL will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.~Interleukin-2 (IL-2) will be given daily( iv) since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit（IU）/day . Patients will receive a total of four cycles of treatment."
62373877|NCT04410835||Psychiatric patients|Psychiatric patients with ICD-10 (International Statistical Classification of Diseases and Related Health Problems) F2/F3/F4 diagnosis
62373878|NCT04410835||Healthy Controls|Participants who do not have a psychiatric disorder or a first degree relative with psychiatric disorder.
62373879|NCT02982642|EXPERIMENTAL|1612 capsule|Subjects will take 1612 capsule 3 capsules per time(0.38g per capsule), 3 times per day for 52 weeks
62373880|NCT02982642|PLACEBO_COMPARATOR|Placebos|Subjects will take palcebo identified to 1612 capsule 3 capsules per time, 3 times per day for 52 weeks
62373881|NCT03272880|EXPERIMENTAL|arts-based programming for cancer survivors and caregivers|This is a 8-week, arts-based, health, resilience, and well-being program.
62373882|NCT03174808|EXPERIMENTAL|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend group sessions led by an instructor experienced in MBSR in an academic setting.
62373883|NCT00108277|EXPERIMENTAL|Raise CO2|Raise CO2 - biofeedback-assisted breathing training to raise baseline pCO2
62373884|NCT00108277|ACTIVE_COMPARATOR|Lower CO2|Lower CO2 - biofeedback-assisted breathing training to lower baseline pCO2
62373885|NCT00108277|NO_INTERVENTION|Waitlist|Waitlist - treatment as usual
62373886|NCT03774836|ACTIVE_COMPARATOR|Tramadol 50 mg|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
62373887|NCT03774836|ACTIVE_COMPARATOR|Morphine 4 mg|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
62373888|NCT03774836|PLACEBO_COMPARATOR|Placebo|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
62373889|NCT04134377|EXPERIMENTAL|Protein Food Snack|Provide a high protein food snack the first 2 weeks of each month for 6 months. Each participant will receive an 8 ounce food snack after dialysis for a total of 6 food snacks for each month.
62373890|NCT05260125|EXPERIMENTAL|Ultrasound-guided Suprascapular Nerve Block|Ultrasound-guided Suprascapular Nerve Block
62373891|NCT05260125|ACTIVE_COMPARATOR|Anatomical Landmark-guided Suprascapular Nerve Block|Anatomical Landmark-guided Suprascapular Nerve Block
62373892|NCT02892305||PAC with LVLM|Patients with pancreatic cancer and low-volume liver metastasis
62373893|NCT01905306|EXPERIMENTAL|computer guided implant planning|radiographic and clinical evaluation of full-arch dental implant rehabilitation
62373894|NCT01905306|EXPERIMENTAL|free hand implants placement|radiographic and clinical evaluation of full-arch dental implant rehabilitation
62373895|NCT04129190|EXPERIMENTAL|Single|
62373896|NCT03192514|EXPERIMENTAL|Electronic Deprescribing tool|GPs of enrolled patients with access to the electronic Deprescribing tool
62373897|NCT03192514|NO_INTERVENTION|Usual Care|Usual care By GP´s
62373898|NCT01111721|EXPERIMENTAL|Project POWER Intervention Group|Intervention group participants will attend the Project POWER intervention sessions, complete a pre-intervention assessment and participate in 3, 6, and 12 month follow-up interviews when they will be asked to provide urine specimens for STI testing. The intervention consists of eight bi-weekly, 1.5 hour sessions. Intervention group participants will also attend one booster group session four weeks after the intervention before being released. Intervention participants will receive booster phone calls from a nurse-interventionist at 2, 6, and 10 weeks after release from prison. Booster phone calls will reinforce intervention content and support participant efforts to reduce risky sex behaviors and make healthy choices.
62373899|NCT01111721|ACTIVE_COMPARATOR|NC DOC Standard of Care for STIs|Control group participants will receive the North Carolina Department of Correction standard of care for Sexually Transmitted Infections, complete one interview in prison and participate in 3, 6, and 12 month follow up interviews when they will be asked to provide urine specimens for STI testing.
62373900|NCT04189640|ACTIVE_COMPARATOR|Group 20 = 20 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20ml will be injected here.
62373901|NCT04189640|ACTIVE_COMPARATOR|Group 30 = 30 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30ml will be injected here.
62373902|NCT04189640|ACTIVE_COMPARATOR|Group 40 = 40 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 40ml will be injected here.
62373903|NCT01045876|EXPERIMENTAL|Dexamethasone|
62373904|NCT01045876|PLACEBO_COMPARATOR|Placebo|
62373905|NCT02236650|EXPERIMENTAL|Primary Care Stepping Stones Triple P|Primary Care Stepping Stones Triple P program (PC-SS Triple P) - a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
62373906|NCT02236650|ACTIVE_COMPARATOR|Wait List Control (WLC)|Wait List Control - Participants who will have access to treatment as usual services during the 4 weeks between baseline and 4 week assessment time points and then will have the opportunity to receive PC-SS Triple P.
62373907|NCT03447041||the keratoplasty group|Patients with limbal dermoid who accepted cornea transplantation surgery after 1 year were performed quick CSF from Adaptive Sensory Technology company
62373908|NCT03447041||the normal group|normal children without ocular disease
62373909|NCT01377324|EXPERIMENTAL|Single arm|Fluoroestradiol-PET is performed at baseline, after 1 month, and 3 months
62373910|NCT02821988|EXPERIMENTAL|Nonstress test|"Subjects will undergo weekly nonstress tests beginning at 32 weeks until delivery in addition to monitoring fetal kick counts.~A nonstress test is a test in which an external fetal monitor is placed on the mother to defect the fetal heart rate for 20 to 40 minutes. A test is considered reactive if there are more than 2 accelerations in fetal heart rate defined as an increase of at least 15 beats per minute lasting at least 15 seconds in a 20 minute period."
62745488|NCT05828394|EXPERIMENTAL|Depithelised Free Gingival Graft, DFGG|The group assignment was communicated through a sealed envelope that was opened just prior to the surgery. The subjects will undergo to a harvesting procedure of a palatal graft using DFGG technique described as following: two horizontal and two vertical incisions will be traced with a 15C blade to delimit the area to be grafted. Along the coronal horizontal incision, the blade will be oriented almost perpendicular to the bone plate and once an adequate soft tissue thickness was obtained, it will be rotated in order to be almost parallel to the superficial surface. The thickness of the graft will be maintained uniform while proceeding apically with the blade. Once the graft is separated, the adipose and glandular tissue as well as the epithelium will be removed extra orally with a new blade. Finally the palate will be sutured with 5-0 monofilament suture and collagen sponges. In this group the palate is suppose to have a secondary intention healing.
62745489|NCT05828394|EXPERIMENTAL|Subepithelial Connective Tissue Graft, SCTG|The group assignment was communicated through a sealed envelope that was opened just prior to the surgery. The subjects will undergo to a harvesting procedure of a palatal graft using SCTG technique described as following: one deep horizontal incision parallel to the gingival margin will be traced at 1.5 mm apical to the gingival margin of the adjacent teeth, according to the palatal pocket depth of the teeth. A deeper incision parallel and deeper to the initial one will be performed. The primary flap will be elevated split-thickness. The horizontal incision will be made almost perpendicular to the underlying bone. Once an adequate soft tissue thickness is obtained, the blade will be rotated in order to be almost parallel to the external surface. The thickness of the graft will be maintained uniform. Finally the palate will be sutured with 5-0 monofilament suture and collagen sponges.In this group the palate is suppose to have a primary intention healing.
62745490|NCT01075867||Control group|Before ELIPS implementation 12 months follow-up
62745491|NCT01075867||Treatment group|After ELIPS implementation 12 months follow-up
62745492|NCT06659458|EXPERIMENTAL|EGFR Positive Lung Cancer|Subjects diagnosed with EGFR positive lung cancer
62745493|NCT06659458|EXPERIMENTAL|Healthy Subjects|Subjects who do not have a cancer diagnosis
62745494|NCT06552546|EXPERIMENTAL|SICO(single-dose icodextrin)|Eligible participants used one icodextrin bag (single-dose icodextrin, SICO) on the first day. Icodextrin solution was left in the peritoneal cavity for a 8-hour dwell. After the icodextrin exchange, the solution was drained from the peritoneal cavity and the patients resumed dialysis using dextrose dialysate with three additional manual exchanges performed for the balance of the 24 hours since the icodextrin dwell was initiated. Patients were discharged and requested to return on days 7 and 14. Blood, urine and dialysate samples are collected at the time-points as required. Icodextrin and metabolites were analyzed and the pharmacokinetics profiles of single-dose icodextrin were provided.
62745495|NCT06552546|EXPERIMENTAL|DICO(double-dose icodextrin)|Eligible participants used two icodextrin bags (double-dose icodextrin, DICO) on the first day. Each icodextrin solution was left in the peritoneal cavity for a 8-hour dwell. The double-dose icodextrin was administered in a sequential way. After the icodextrin exchange, the solution was drained from the peritoneal cavity and the patients resumed dialysis using dextrose dialysate with three additional manual exchanges performed for the balance of the 24 hours since the icodextrin dwell was initiated. Patients were discharged and requested to return on days 7 and 14. Blood, urine and dialysate samples are collected at the time-points as required. Icodextrin and metabolites were analyzed and the pharmacokinetics profiles of double-dose icodextrin were provided.
62745496|NCT03374683|EXPERIMENTAL|RR Digital Tool|Participants in the RR digital tool were provided with a link to the web-based intervention (https://outsideplay.ca) to complete within one week.
62745497|NCT03374683|ACTIVE_COMPARATOR|RR In-Person Workshop|Participants in the in-person workshop attended the 45-90 minute in-person workshop.
62745498|NCT03374683|SHAM_COMPARATOR|Position Statement on Active Outdoor Play|Participants in the control condition were provided with a web link to the Position Statement on Active Outdoor Play, which includes information on research and recommendations for action.
62373911|NCT02821988|EXPERIMENTAL|Biophysical profile|Subjects will undergo weekly biophysical profile testing beginning at 32 weeks until delivery in addition to monitoring fetal kick counts. A Biophysical profile is a test using real time ultrasonography to determine the presence of absence of certain components of fetal well being. There components include: an episode of fetal breathing lasting at least 30 seconds, 3 or more discrete body movements, 1 or more episodes of extension of a fetal extremity with return to flexion, and determination of amniotic fluid volume to detect a maximum vertical pocket of \>2cm. The duration of this test is no more than 30 minutes.
62373912|NCT02821988|NO_INTERVENTION|Kick counts only|Subjects will monitor fetal kick counts only.
62373913|NCT05363618|ACTIVE_COMPARATOR|Product Tolerability Arm|Study Product MHS-1031 1g (1.4 ml) per day
62373914|NCT05363618|PLACEBO_COMPARATOR|Placebo Tolerability Arm|Placebo (Neotame 7.92 mcg/g, phosphoric acid, and sterile water) 1.4 ml per day
62745499|NCT03237494||Participants at risk for hATTR and participants diagnosed with hATTR|Participants 18 years of age or older
62745500|NCT06097533|EXPERIMENTAL|Cannabisextrakt Avextra 10/10 Lösung|Solution with tetrahydrocannabinol and cannabidiol
61986339|NCT05096845|PLACEBO_COMPARATOR|Placebo control|Intramuscular injection into the lateral deltoid of the upper arm Two doses, one each on Day 0 and 21 (+7 days), respectively.
62373915|NCT01606332|NO_INTERVENTION|Single in interscalene block|Single indwelling interscalene block with ropivacaine 0.5% 10ml
62373916|NCT01606332|EXPERIMENTAL|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
62373917|NCT03705468||Ketamine sedation|Ketamine sedation
62373918|NCT03705468||Propofol sedation|Propofol sedation
62552991|NCT03187535|EXPERIMENTAL|Transcutaneous Electrical Acupoint Stimulation|"Subjects in the Transcutaneous Electrical Acupoint Stimulation (TEAS) group will receive 20 minutes of TEAS via ES-130 beginning at the time ondansetron is administered (usually given 30 minutes before the end of surgery), for prevention of PONV."
61986340|NCT03492255|ACTIVE_COMPARATOR|Eurolupus: Cyclophosphamide + Methylprednisolone + oral GC|The EUROLUPUS group will receive Cyclophosphamide (6 doses of 500 mg / fortnightly) + 3 doses of Methylprednisolone (750 mg) initial + oral glucocorticoid (GC) (prednisone) ≤ 30 mg/day with a gradual reduction of 5 mg/month (EUROLUPUS). From the 3rd month, the group will receive oral mycophenolate mofetil (MMF) (2-3 g) until 6 months with gradual reduction of GC from 5 mg/month until the minimum dose of 5 mg/month.
62745501|NCT06097533|PLACEBO_COMPARATOR|Placebo|Sesame oil, Ph.Eur. Linseed oil, Ph.Eur
62745502|NCT03650894|EXPERIMENTAL|Nivolumab, Ipilimumab, and bicalutamide|Participants will receive nivolumab plus ipilimumab combination therapy. Participants should receive nivolumab at a dose of 240 milligrams (mg) fixed dose as a 30-minute intravenous (IV) infusion prepared in 50 milliliter (ml) normal saline (NS) every 2 weeks until progression. Participants should receive ipilimumab at a dose of 1 mg/kilogram as a 30-minute IV infusion prepared in 50 ml NS every 6 weeks. All subjects will take bicalutamide 150mg (3 x 50mg tablets) daily.
62745503|NCT04914481||Classical Low-Flow, Low-Gradient Aortic Stenosis|Classical Low-Flow, Low-Gradient Aortic Stenosis is defined as valve area \<1 cm2, mean gradient \<40 mmHg, ejection fraction \<50% and stroke volume index (SVi) ≤35 mL/m2 by resting transthoracic echocardiography. Dobutamine stress echocardiography is not mandatory for the definition of classical LFLG AS. All patients in this subgroup underwent TAVI and have available data on aortic valve calcification.
62745504|NCT04914481||Paradoxical Low-Flow, Low-Gradient Aortic Stenosis|Paradoxical Low-Flow, Low-Gradient Aortic Stenosis is defined as valve area \<1 cm2, mean gradient \<40 mmHg, ejection fraction ≥50% and SVi ≤35 mL/m2 by resting transthoracic echocardiography. All patients in this subgroup underwent TAVI and have available data on aortic valve calcification.
62745505|NCT04914481||High-Gradient Aortic Stenosis (Control group)|High-Gradient Aortic Stenosis is defined as valve area \<1 cm2 and mean gradient \>40 mmHg by resting transthoracic echocardiography. All patients in this subgroup underwent TAVI. Data on aortic valve calcification is not mandatory for this control group.
62745506|NCT04914481||Conservative treatment (Control group)|The subgroup includes all patients with (severe or non-severe) aortic stenosis, who underwent conservative treatment. Data on aortic valve calcification is not mandatory for this control group.
62745507|NCT06019663|EXPERIMENTAL|Intervention|
62745508|NCT06019663|NO_INTERVENTION|Standard Routine Care|Standard care for self-ham in Pakistan does not usually involve psychiatric or psychotherapy follow-up. Clinical teams in psychiatric departments or family medicine practices provide standard routine care according to their clinical judgment and available resources. We will obtain details of any treatment received by each participant
62745509|NCT05935358|EXPERIMENTAL|Nuwiq|All patients receiving Nuwiq (recombinant FVIII). Nuwiq will be administered intravenously in accordance with the relevant prescribing information. Treatment will be repeated as necessary every 8-24 hours until adequate wound healing, then - if required - for at least another 7 days to maintain FVIII plasma levels of 30-60 IU/dL.
62745510|NCT04630132||Frailty Group|"The 'phenotype' of frailty (cases) is defined as follows: presence of three or more of the following features:~1. Decreased grip strength~2. Self-reported exhaustion~3. Unintentional weight loss of more than 4.5 kg over the past year~4. Slow walking speed~5. Low physical activity"
62745511|NCT04630132||Non-Frailty Group|"The 'phenotype' of non-frailty (control) is defined as follows: presence of less than three of the following features:~1. Decreased grip strength~2. Self-reported exhaustion~3. Unintentional weight loss of more than 4.5 kg over the past year~4. Slow walking speed~5. Low physical activity"
62745512|NCT04353999|EXPERIMENTAL|980 nm diode laser photocoagulation|980 nm diode laser was used to coagulate the blood over the bone graft particles and achieve a socket seal after socket grafting
62373919|NCT05894889|EXPERIMENTAL|Pembrolizumab + Chemotherapy|"Non-squamous NSCLC: pembrolizumab 200mg as at least 30-minute IV infusion on Day 1, followed by pemetrexed at a dose of 500mg/m2 IV over 30 minutes or per institutional standard with Carboplatin at a dose of AUC 5 over 120 minutes or per institutional standard, of a 3-week treatment cycle, for up to 4 cycles.~Squamous NSCLC: pembrolizumab 200mg as at least 30-minute IV infusion on Day 1, followed by nab-paclitaxel at a dose of 135mg/m2 IV over 30 minutes or per institutional standard with Carboplatin at a dose of AUC 5 over 120 minutes or per institutional standard, of a 3-week treatment cycle, for up to 4 cycles. Nab-paclitaxel will also be administered at the dose of 135mg/m2 for over 30 minutes IV infusion or per institutional standard on day 8 of each 3-week treatment cycle."
62373920|NCT04422197|ACTIVE_COMPARATOR|Patients with ultrasound-guided botox injection|Effect of Botox injection on lateral abdominal wall muscles after major open abdominal surgery
62373921|NCT04422197|ACTIVE_COMPARATOR|Patients with no botox injection|Patients with major abdominal surgery without botox injection
62373922|NCT04696172||Patients undergoing cardiopulmonary bypass (CPB) with postoperative ARDS|
62373923|NCT04696172||Patients undergoing cardiopulmonary bypass (CPB) without postoperative ARDS|
62373924|NCT01780207|NO_INTERVENTION|OSA without PFO|
62373925|NCT01780207|OTHER|OSA with PFO|PFO closure
62373926|NCT03422016||autistic spectrum disorder|intelligence quotient IQ\>85 age 4-25yrs
62373927|NCT03422016||control|age 4-25yrs no eye disorder
62373928|NCT01451957|EXPERIMENTAL|Exercise|90 min exercise on Day 1
62373929|NCT01451957|EXPERIMENTAL|Sedentary Control|Subjects remain sedentary on Day 1 and will either consume a hyper-caloric or a caloric balanced diet
62745513|NCT04353999|ACTIVE_COMPARATOR|Dense polytetrafluroethylene membrane|dPTFE membrane was used to seal the socket after grafting
62745514|NCT00483366|OTHER|Imatinib/Gemcitabine/Capecitabine|"Patients will be accrued on cohorts of three per dose level starting at dose level 0. Accrual to higher dose levels will depend on toxicity occurrence.~Dose limiting toxicity (DLT) will be determined after cycle two for each patient.~Schema: Imatinib days 1 - 5 and days 8 - 12 Gemcitabine on days 3 and 10 Capecitabine on days 1 - 14~Doses: Imatinib 400 mg/d fixed dose Gemcitabine 450 mg/m2; 550 mg/m2; 675 mg/m2; 825 mg/m2; 1000 mg/m2 Capecitabine 500 mg/m2; 600 mg/m2 bid; 725 mg/m2; 850 mg/m2~Treatment cycle: 21-days~Treatment duration: Until disease progression or unacceptable toxicity defined in protocol."
62373930|NCT04330989|EXPERIMENTAL|Group 1a: iNSC and Adherence supporter training|HIV-positive women randomly assigned to the intervention arm will receive a multi-component support strategy comprising iNSC and adherence supporter training for ART.
62745515|NCT04570605|ACTIVE_COMPARATOR|Standard Urotherapy|Patients who meet eligibility criteria who will be counselled on standard recommendations for bladder management.
62745516|NCT04570605|EXPERIMENTAL|Standard Urotherapy + PTENS|Patients who meet eligibility criteria who will be counselled on standard recommendations for bladder management AND use parasacral percutaneous TENS as additional treatment.
62745517|NCT02229305|ACTIVE_COMPARATOR|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
62552992|NCT03187535|SHAM_COMPARATOR|No Transcutaneous Electrical Acupoint Stimulation|"Subjects in the No Transcutaneous Electrical Acupoint Stimulation group will not receive any TEAS, although they will have the acupoints identified and ECG patches placed. The device will not be connected to the electrodes of the ES-130 device at the end of surgery, and no TEAS will be delivered."
62745518|NCT02229305|EXPERIMENTAL|Modular Approach to Therapy for Children|Therapists used a modular manual (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita \& Weisz, 2010) to help children with primary problems of anxiety, depression, trauma, and conduct.
62552993|NCT05667376|OTHER|Study group|Study group treated with curcumin gel
62745519|NCT04818827||Ketamine group|This cohort includes patients who received ketamine as a sedative analgesic agent during mechanical ventilation
62552994|NCT06582381|EXPERIMENTAL|Healthy male older adults|Eight predefined, commercially available meal is administered in a randomized fashion. Two meals are consumed 6 hours apart on each study day. Meals are selected to represent a range of fat, protein, and carbohydrate content.
62552995|NCT06582381|EXPERIMENTAL|Healthy female older adults|Eight predefined, commercially available meal is administered in a randomized fashion. Two meals are consumed 6 hours apart on each study day. Meals are selected to represent a range of fat, protein, and carbohydrate content.
62552996|NCT00645970||Group 1|
62552997|NCT02435732|PLACEBO_COMPARATOR|Control group|Standard donor management + vehicle treatment (n=9)- placebo saline solution
62552998|NCT02435732|EXPERIMENTAL|CINRYZE 200 U/Kg IV|Intervention is CINRYZE 200 U/Kg IV single dose
62745520|NCT04818827||Non Ketamine group|This cohort includes patients who received sedatives other than ketamine during mechanical ventilation
62745521|NCT05898672|ACTIVE_COMPARATOR|Treatment A: rosuvastatin|Rosuvastatin tablets
62552999|NCT02435732|EXPERIMENTAL|200 units/kg IV CINRYZE with Heparin 20 U/kg/h IV|CINRYZE 200 units/kg IV single dose with Heparin at 20 units/kg/h IV maintenance until organ recovery
62553000|NCT06017050|EXPERIMENTAL|BullyDown intervention|
62553001|NCT06017050|PLACEBO_COMPARATOR|Healthy lifestyle control|
62553002|NCT04659642|ACTIVE_COMPARATOR|dexmedetomidine group (group A)|will receive Dexmedetomidine 1ug/kg body weight IV diluted to 100ml normal saline (NS) over 15 minutes.
62553003|NCT04659642|ACTIVE_COMPARATOR|Fentanyl group (group B)|will receive Fentanyl 1 ug/kg body weight IV diluted to 100 ml normal saline (NS) over 15 minutes.
62553004|NCT04659642|ACTIVE_COMPARATOR|Both Dexmedetomidine and fentanyl group (group C)|will receive both Dexmedetomidine 1ug/kg body weight mixed with fentanyl 1ug/kg in 100 ml normal saline (NS) over 15 minutes.
62553005|NCT01138787|ACTIVE_COMPARATOR|Reference spread|"2250 mg PS (as PSE) in spread (30 g)~* 50 mg labeled D7-cholesterol,~* 30 mg 3,4-13C-cholesterol, iv dosed at same time."
62553006|NCT01138787|PLACEBO_COMPARATOR|Placebo spread|"regular light margarine (30 g)~* 50 mg labeled D7-cholesterol,~* 30 mg 3,4-13C-cholesterol, iv dosed at same time."
62553007|NCT01138787|EXPERIMENTAL|Test spread|"2250 mg PS in innovatively processed spread (30 g)~* 50 mg labeled D7-cholesterol,~* 30 mg 3,4-13C-cholesterol, iv dosed at same time."
62745522|NCT05898672|EXPERIMENTAL|Treatment B: rosuvastatin + nirmatrelvir/ritonavir|Rosuvastatin + nirmatrelvir/ritonavir tablets
62745523|NCT01766739|EXPERIMENTAL|GL-ONC1|This is an open-label, dose-escalating, non-randomized, single-center Phase I therapeutic study of GL-ONC1 originally administered intrapleurally as a single dose and now escalating to three consecutive daily doses in patients with a diagnosis (histologically or cytologically documented) of malignant pleural effusions.
62745524|NCT00721578||1|
62745525|NCT01424748|PLACEBO_COMPARATOR|Placebo|Placebo juice
62373931|NCT04330989|NO_INTERVENTION|Group 1b: Standard of Care|HIV-positive participants randomly assigned to the control arm will antiretroviral educational material about HIV prevention and treatment (as appropriate to this arm).
62373932|NCT04330989|EXPERIMENTAL|Group 2a: iNSC and Adherence supporter training|HIV-negative women randomly assigned to the intervention arm will receive a multi-component support strategy comprising iNSC and adherence supporter training for PrEP.
62553008|NCT04307888||Study group|Patients undergoing Percutaneous Endovascular Aneurysm Repair (PEVAR), Percutaneous Endovascular Thoracic Aneurysm Repair (PTEVAR) or Transcatheter Aortic Valve Implantation (TAVI) in who percutaneous access closure device is used for implanting devices at aorta level.
62553009|NCT04007198|EXPERIMENTAL|EQ001|EQ001 administered in a blinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 5 doses.
62553010|NCT04007198|PLACEBO_COMPARATOR|EQ001 Placebo|Placebo administered in a blinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 5 doses.
62553011|NCT02263287|OTHER|Alzheimer disease (AD)|Patients with AD according to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria Intervention: LeSCoD scale
62553012|NCT02263287|OTHER|Dementia with Lewy Bodies (DLB)|Patients with probable DLB according to McKeith criteria. Intervention: LeSCoD scale
62553013|NCT02263287|OTHER|Probable AD and possible DLB|Patients with clinical criteria for possible or probable AD and possible DLB Intervention: LeSCoD scale
62745526|NCT01424748|EXPERIMENTAL|30 mL Tahitian Noni Juice|30 mL Tahitian Noni Juice per day dose
62745527|NCT01424748|EXPERIMENTAL|300 mL Tahitian Noni Juice|300 mL Tahitian Noni Juice per day
62745528|NCT01424748|EXPERIMENTAL|750 mL Tahitian Noni Juice|750 mL Tahitian Noni Juice per day
62745529|NCT05128474|EXPERIMENTAL|Group 1|Neuromuscular Control-Based Exercise Training Group
62745530|NCT05128474|ACTIVE_COMPARATOR|Group 2|Conventional Exercise Training Group
62745531|NCT00777985|EXPERIMENTAL|1|
62745532|NCT00777985|ACTIVE_COMPARATOR|2|
62745533|NCT05466955|EXPERIMENTAL|Free eye glasses for un or under-corrected myopia|Free eyeglasses for the correction of uncorrected myopia will be provided to participants at the time of enrolment into the intervention group.
62745534|NCT05466955|NO_INTERVENTION|Control-No treatment|Participants in the control period will not have glasses but the SW-CRT design means that all trial participants with uncorrected myopia will receive free glasses by the trials' completion, and no participant will have glasses withheld after being diagnosed with un- or under-corrected myopia.
62745535|NCT01948765|ACTIVE_COMPARATOR|Xenon and propofol|
62745536|NCT01948765|PLACEBO_COMPARATOR|propofol|
62745537|NCT01595971|EXPERIMENTAL|continuing education|RESPIRANET is a multifaceted intervention directed at professionals of the Family Health Teams in the inner cities.Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
62745538|NCT01595971|PLACEBO_COMPARATOR|Usual Care|usual care
62745539|NCT01779856|OTHER|REVEAL Insertable Cardiac Monitor (ICM)|Monitoring of cardiac arrhythmic events and the relationship between such events and the characteristics.
62745540|NCT00528502|EXPERIMENTAL|Saline|Saline misted into the air breathe during the surgery.
62745541|NCT00528502|EXPERIMENTAL|Lidocaine|Lidocaine misted into the air during the surgery.
62373933|NCT04330989|NO_INTERVENTION|Group 2b: Standard of Care|HIV-negative participants randomly assigned to the control arm will receive educational material about HIV prevention and treatment (as appropriate to this arm).
62553014|NCT01427699|EXPERIMENTAL|T2-18C3 therapeutic antibody|9 subjects will receive the T2-18C3 therapeutic antibody.
62553015|NCT02308995|EXPERIMENTAL|Cystectomy using barbed sutures|Endometrioma bed is sutured with barbed sutures
62745542|NCT00812409|EXPERIMENTAL|1|Control group: non-protein supplement with resistance and aerobic exercise.
62745543|NCT00812409|EXPERIMENTAL|2|Low protein supplement with resistance and aerobic exercise.
62745544|NCT00812409|EXPERIMENTAL|3|Moderate protein supplement with resistance and aerobic exercise.
62745545|NCT00812409|EXPERIMENTAL|4|High protein supplement with resistance and aerobic exercise.
62745546|NCT04832802|EXPERIMENTAL|ACCESS-Vets Intervention Group|This group will receive ACCESS-Vets, a customized employment intervention adapted for use in VA healthcare.
62373934|NCT02117791||Group 1|Riociguat treatment group
62373935|NCT03084432||caffeine group|22 preterm infants received caffeine (starting from day 2 of life and received for more than 7 days) for apnea prophylaxis or treatment according to protocol of Ain Shams University neonatal intensive care unit \[apnea prophylaxis for preterm ≤32 weeks gestation and apnea treatment for those 33 or 34 weeks gestation\]. Dual Energy X-ray Absorptiometry was done 5th-6th week post-natal age
62373936|NCT03084432||control group|20 preterm infants for whom caffeine was not given, either it was not indicated, not available or parents refused its use.Dual Energy X-ray Absorptiometry was done 5th-6th week post-natal age
62373937|NCT00464620|EXPERIMENTAL|Dasatinib, 70 mg, twice daily|Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
62373938|NCT00945269|EXPERIMENTAL|Treatment (cellular adoptive immunotherapy)|Patients receive autologous T-cell IV over 30-60 minutes on days 0 and 28 and low-dose aldesleukin SC twice daily on days 0 to 13 and 28 to 41. Beginning 4-6 days before second T-cell infusion, patients receive denileukin diftitox IV over 30 minutes on days 1-3.
62373939|NCT01165294|EXPERIMENTAL|001|ketamine An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
62373940|NCT01165294|EXPERIMENTAL|002|Placebo An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
62373941|NCT03733106|EXPERIMENTAL|digital breast tomosynthesis|Tomosynthesis and two dimension digital mammography
62373942|NCT03733106|ACTIVE_COMPARATOR|control|standard two dimension digital mammography
62373943|NCT01464398|ACTIVE_COMPARATOR|Stress reduction|Mindfulness-based stress reduction
62373944|NCT01464398|ACTIVE_COMPARATOR|Stress reduction with Health education|General stress management and health education
62373945|NCT02307604||Brain cancer|Patients with diagnosis of brain cancer at any stage
62373946|NCT02169960|ACTIVE_COMPARATOR|Middle School, General|OVK Resiliency Training Program - Cognitive Behavioral Therapy designed to modify negative thoughts and feelings. This program also includes a social problem-solving component.
62373947|NCT02169960|NO_INTERVENTION|High School, General|No intervention - no Resiliency training, no online intervention for high school students who do not score at risk for development of mental health issues
62373948|NCT02169960|ACTIVE_COMPARATOR|Middle School, Top 10%|Smart, Positive, Active, Realistic X-factor thoughts (SPARX), Breaking Free, This Way Up online interventions offered to middle school students who score in the Top 10% of their grade for development of mental health issues. OVK Resiliency Training is also provided.
62373949|NCT02169960|ACTIVE_COMPARATOR|High School, Top 10%|Smart, Positive, Active, Realistic X-factor thoughts (SPARX), Breaking Free, This Way Up online interventions offered to middle school students who score in the Top 10% of their grade for development of mental health issues.
62553016|NCT02308995|ACTIVE_COMPARATOR|Cystectomy using conventional sutures|Endometrioma bed is sutured with conventional sutures
62553017|NCT01106079|EXPERIMENTAL|Intensive management|
62553018|NCT01106079|ACTIVE_COMPARATOR|Standard management|
62553019|NCT04575610|EXPERIMENTAL|PF-06650833 + Standard of Care|Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric \[NG\] tube, orogastric \[OG\] tube, or equivalent) if unable to take tablets by mouth (PO). All dosing of PF-06650833 will be in addition to current hospital SOC therapy.
62373950|NCT00675311|ACTIVE_COMPARATOR|DM-Standard|The conventional disease management group will receive management under the site's usual program offering, which includes, but is not limited to, compliance with the prescribed treatment regimens, dietary management, exercise programs, and other measures recommended by the American Diabetes Association (ADA) and the Association of American Endocrinologists (AACE).
62553020|NCT04575610|ACTIVE_COMPARATOR|Placebo + Standard of Care|Matching placebo tablets will be administered.
62745547|NCT04832802|ACTIVE_COMPARATOR|IPS (Usual Care) Group|This group will receive IPS (Individual Placement and Support), the usual evidence-based supported employment program in VA.
62745548|NCT04494542|EXPERIMENTAL|Sustained Low Efficiency Dialysis|Sustained Low Efficiency Dialysis
62745549|NCT04494542|ACTIVE_COMPARATOR|Continuous Renal Replacement Therapy|continuous renal replacement therapy
62745550|NCT02876523||Patients with a hilar biliary stricture requiring a drainage|Drainage performed by endoscopy, echo-endoscopy or percutaneously
62745551|NCT03772834|EXPERIMENTAL|Group I (methylphenidate, resistance training, walking)|Patients receive methylphenidate PO BID and undergo exercise program consisting of resistance training BIW and walking 15- 40 minutes a day 4 days a week for 12 weeks.
62745552|NCT03772834|ACTIVE_COMPARATOR|Group II (placebo, resistance training, stretching)|Patients receive a placebo PO BID and undergo exercise program consisting of resistance training BIW and walking 15-40 minutes a day for 4 days a week for 12 weeks.
62373951|NCT00675311|ACTIVE_COMPARATOR|DM-Plus|Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology that includes mobile phone client software with web-based companion software, Bluetooth glucose meter cradle, and web-based clinical management software for the clinical management team. The core of the system is the patient's cell phone which is used as an input device and which enables patients to maintain an electronic diary of information such as meal times, blood glucose, insulin use, weight, blood pressure, and exercise. The device is customizable to collect only the information relevant to the patient with diabetes and their healthcare provider. The patient with diabetes enters diary information on his or her mobile phone. No immediate or real-time information is provided to patients as part of this study.
62373952|NCT03052699||vaginal Cesarean Section|patients operated to vaginal Cesarean Section
62373953|NCT06245304|OTHER|DDD-50 followed by AAI-DDD 50|Patients will be programmed to DDD-50 first. After 3 months, patients will be programmed to AAI-DDD 50.
62373954|NCT06245304|OTHER|AAI-DDD 50 followed by DDD-50|Patients will be programmed to AAI-DDD-50 first. After 3 months, patients will be programmed to DDD 50.
62373955|NCT06465355|OTHER|Healthy adults|Pharyngo-esophageal high resolution manometry with affixed single-lumen, end-hole catheter wherein one end of the single lumen catheter is in the pharynx and the other is connected to an external stopcock to vent or not vent the pharynx to atmosphere during twenty dry swallows (10 vented, 10 unvented).
62373956|NCT02279160|EXPERIMENTAL|APD811|Multiple dose titration to maximum tolerated dose.
62373957|NCT02279160|PLACEBO_COMPARATOR|Placebo|Multiple dose titration to maximum tolerated dose.
62373958|NCT00691054|EXPERIMENTAL|Abraxane|One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4.
62373959|NCT04157751|EXPERIMENTAL|Empagliflozin|
62373960|NCT04157751|PLACEBO_COMPARATOR|Placebo|
62373961|NCT01517828|EXPERIMENTAL|Ketamine Arm|Phial of Ketamine (50mg/5ml) will be used and the dose administered will be 2 mg/kg.
62373962|NCT01517828|ACTIVE_COMPARATOR|Midazolam Arm|Phials of midazolam (5mg/5ml)will be used and the dose administered will be 0.2 ml/kg.
62373963|NCT05969262||Head and neck cancer patients|Patients who meet the diagnostic criteria of the Guidelines for Diagnosis and Treatment of Head and Neck Cancer
62373964|NCT05969262||Healthy people|Healthy people without liver related medical history or other diseases known to affect blood lipid/protein metabolism.
62373965|NCT04064944|EXPERIMENTAL|Immunoadsorption group|patients' blood purification treatment protocal is Protain A Immunoadsorption method.
62373966|NCT04064944|EXPERIMENTAL|Plasma exchange group|patients' blood purification treatment protocal is Plasma exchange method.
62373967|NCT04660006||Control|Patients undergoing uneventful cataract surgery with no retinal vascular disease.
62373968|NCT04660006||Diabetic Retinopathy (DR)|Patients with non-proliferative diabetic retinopathy with no diabetic macular edema treatment in the 6 months prior to uneventful cataract surgery.
62373969|NCT04660006||Diabetic Macular Edema (DME)|Patients with diabetic macular edema undergoing active Anti-VEGF treatment (within the last 3 months) undergoing uneventful cataract surgery.
62373970|NCT01789710|EXPERIMENTAL|Active Contingency Management|All participants are assigned to a single arm, active contingency management. In this arm, participants are provided monetary rewards for remaining abstinent from smoking.
62373971|NCT01160224|ACTIVE_COMPARATOR|GW766944|This is the active drug (GW766944)
62373972|NCT01160224|PLACEBO_COMPARATOR|Placebo|Placebo Arm.
62373973|NCT05104749|EXPERIMENTAL|Homeopathic Treatment Group|Individualized homeopathic medicines on impregnated lactose pellets will be prescribed to each participant based on the totality of their physical, emotional, and mental symptoms. All medicines prescribed are listed in the Homeopathic Pharmacopoeia of the United States (HPUS) as outlined in the Food, Drug, and Cosmetics Act of 1939
62373974|NCT05104749|PLACEBO_COMPARATOR|Placebo Group|Identical lactose pellets in size, odor, and taste without the impregnated homeopathic medicines.
62373975|NCT03239262|EXPERIMENTAL|Group GP|Thirty-five patients (35%) from our population underwent concomitant mapping and radiofrequency ablation of ganglionated plexi (Group GP).
62373976|NCT03239262|EXPERIMENTAL|Group LA|Sixty five patients (65%) in whom no intervention related to ganglionated plexi was performed (Group LA).
62373977|NCT05272410||cases|Patients colonized or infected with CPE
62373978|NCT05272410||controls|Patients not colonized or infected with CPE
62373979|NCT06009406|EXPERIMENTAL|Intervention Group|This group will be applied to the soleus, gastrocnemius muscle and Achilles tendon with Graston, an instrumental myofascial mobilization technique, until they feel warmth in the skin and tonus relaxation in the target muscles. The persons treated with graston are applied at a 45° angle parallel to the muscle fibers for approximately 20 seconds. Immediately afterwards, the graston is applied to the muscles in a direction perpendicular to the same muscle fibers at a 45° angle for 20 seconds, resulting in a total treatment time of approximately 40 seconds. This results in an increase in temperature and tonus relaxation on the skin surface. In our study, the application will be performed for Gastarocnemius, Soleus muscle and Achilles tendon.
62373980|NCT06009406|ACTIVE_COMPARATOR|Control Group|The control group will be subjected to 3 repetitions of passive stretching for 30 seconds for the same structures. The static stretching technique is a widely used method that lengthens muscle length by autogenic inhibition that stimulates the Golgi tendon organ. This technique involves passively stretching a specific antagonist muscle by placing it in a position of maximum stretch and holding it there for an extended period of time. Recommendations on the optimal length of time to hold this flexed position typically indicate that a 30-second hold, repeated 3 to 4 times, will provide the most beneficial results. 3 repetitions of passive stretching for 30 seconds will be applied to the same structures.
62373981|NCT01253941|EXPERIMENTAL|Mud Bath therapy|
62373982|NCT01253941|NO_INTERVENTION|no Mud Bath Therapy|
62373983|NCT00268476|ACTIVE_COMPARATOR|Arm A: Standard of Care|Androgen Deprivation Therapy \[ADT\] (plus Radiotherapy for newly-diagnosed non-metastatic disease, plus or minus Docetaxel, plus or minus Abiraterone)\[Control\]
62373984|NCT00268476|EXPERIMENTAL|Arm B: Zoledronic Acid|(ADT + zoledronic acid) NO LONGER RECRUITING
62745553|NCT03772834|ACTIVE_COMPARATOR|Group III (methylphenidate, stretching)|Patients receive methylphenidate PO BID and undergo stretching for 4 days a week for 12 weeks.
62745554|NCT03772834|ACTIVE_COMPARATOR|Group IV (placebo, stretching)|Patients receive a placebo PO BID and undergo stretching for 4 days a week for 12 weeks.
62745555|NCT00579410||A|Patients with Barrett's Esophagus
62745556|NCT00579410||B|Patients with reflux symptoms but no Barrett's Esophagus
62745557|NCT00579410||C|Patients without reflux symptoms and a normal endoscopy
62745558|NCT04158037|EXPERIMENTAL|mHealth App|Participants will receive the gambling disorder mHealth app.
62745559|NCT04158037|NO_INTERVENTION|Wait List Control|Participant will be placed on a wait list for 12 weeks, after which they will be offered the gambling disorder mHealth app.
62745560|NCT06358664|EXPERIMENTAL|Caffeine consumption|Patients with regular caffeine consumption needing pars plana vitrectomy
62745561|NCT06358664|EXPERIMENTAL|No caffeine consumption|Patients with regular caffeine consumption needing pars plana vitrectomy
62745562|NCT05998070|EXPERIMENTAL|Training group|Hip strengthening exercises will be performed in the training group.
62745563|NCT05998070|NO_INTERVENTION|Control group|The control group will continue their training and matches.
62745564|NCT02746887||Preterm cohort|Preterm infants with a gestational age less than 32 weeks or birth weight less than 1,500 g
62745565|NCT02746887||Term control cohort|Healthy term infants
62745566|NCT05959538|EXPERIMENTAL|Building Regulation in Dual Generations (BRIDGE; DBT + Parenting)|The BRIDGE program is a manualized therapy that provides participants with parenting and DBT skills through video training modules and in-group sessions. Participants in the BRIDGE arm will participate in 16 weeks of 20-30 minute DBT and parenting skills training that will be delivered asynchronously via video (participants will access these by logging onto a password protected website). The BRIDGE condition also includes weekly synchronous 1-hour virtual group therapy sessions as well as DBT and parenting skills worksheets to complete between sessions.
62745567|NCT05959538|ACTIVE_COMPARATOR|Dialectical Behavioural Skills Training (DBT)|Participants in the DBT arm will participate in 16 weeks of DBT skills training through weekly, synchronous 1.5-hour virtual group therapy sessions. Participants will also be asked to complete worksheets on the content between sessions.
62745568|NCT05959538|NO_INTERVENTION|Services-As-Usual (SAU)|Participants in the SAU arm will receive a list of local mental health and parenting resources, curated by our research team. Participants can access any intervention or resource participants would like throughout the duration of the program.
62745569|NCT02227069|EXPERIMENTAL|M518101|M518101 is applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks
62553021|NCT03727451|EXPERIMENTAL|PH-Pulmonary Fibrosis|"Part 1: 1st 4 subjects will be treated with iNO 30, 45, 75 mcg/kg IBW/hr~2nd 4 subjects will be treated with iNO 45, 75, 125 mcg/kg IBW/hr~Part 2: Optional open label long term extension at the optimal dose as identified in Part 1"
62553022|NCT03727451|EXPERIMENTAL|PH-Sarcoidosis|"Part 1: 1st 4 subjects will be treated with iNO 30, 45, 75 mcg/kg IBW/hr~2nd 4 subjects will be treated with iNO 45, 75, 125 mcg/kg IBW/hr~Part 2: Optional Open label long term extension at the optimal dose as identified in Part 1"
62553023|NCT06261645|EXPERIMENTAL|Early start|"According to result from the random allocation patients in Early Start will initiate their treatment within two weeks following the Baseline assessment.The intervention consists of a 16 week exercise program with specific exercises to restore total rotator cuff function individually selected during clinical physiotherapy visits and performed 2 - 4 times daily.~According to progression, a mean of 10 visits are anticipated over the 16 weeks In addition, the patient will receive education and guidance in the daily use of the arm to adjust to appropriate load on the shoulder."
62745570|NCT02227069|PLACEBO_COMPARATOR|M518101 Vehicle|M518101 vehicle is applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks
62745571|NCT02227069|ACTIVE_COMPARATOR|sodium lauryl sulfate|A solution of 0.2% sodium lauryl sulfate is applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a positive control.
62745572|NCT02227069|SHAM_COMPARATOR|Saline|A solution of 0.9% saline is applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a negative control.
62745573|NCT03409705|EXPERIMENTAL|Skate Skin group|2,000 mg of low-molecular collagen peptide was orally administered per day for 12 weeks.
62745574|NCT03409705|PLACEBO_COMPARATOR|Control group|2,000 mg of placebo was orally administered per day for 12 weeks.
62745575|NCT04657835|EXPERIMENTAL|Coronary Artery Bypass Grafting|"Patient with indication of Coronary Artery Bypass Grafting will be included. They will have:~* before surgery : cardiac Magnetic Resonance Imaging (MRI), Blood sample~* during surgery : Cardiac muscle biopsy~* after surgery : Holter-electrocardiogram (ECG), medical examination"
62745576|NCT03894982||What is Asthma|"Reviewing asthma is a lung disease. There is no cure, but asthma can be well controlled so that your child can be healthy and join in all their favorite activities.~Asthma causes the airways (breathing tubes in the lungs) to get smaller, making it hard to breathe.Common symptoms of asthma are coughing, wheezing, chest tightness and trouble breathing.~These symptoms are ongoing and get better with asthma medicines."
62745577|NCT03894982||Triggers|Reviewing specifics around children with asthma have extra sensitive airways and many things around them can make their asthma worse. The things around your child that cause an asthma attack are called triggers. Triggers are different for each child. Your doctor can help you figure out your child's triggers. Try to keep your child away from their triggers, especially at home and at school where your child spends most of their time.
62745578|NCT03894982||Medications and Asthma Action Plan|Review what is an asthma action plan, how to use an asthma action and the medications listed on each individuals plan.
62745579|NCT03517839|EXPERIMENTAL|Training Group|
62745580|NCT03517839|SHAM_COMPARATOR|Control Group|
62745581|NCT00301392|OTHER|Pitavastatin|Administration of Pitavastatin
62745582|NCT05551923||Acute cerebral hemorrhage|intestinal flora disturbance To observe the clinical prognosis of acute cerebral hemorrhage after enterobacterial disorder
62745583|NCT05551923||The group without stroke|The group without stroke
62745584|NCT01696019|EXPERIMENTAL|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
62745585|NCT01696019|ACTIVE_COMPARATOR|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
62373985|NCT00268476|EXPERIMENTAL|Arm C: Docetaxel|(ADT + docetaxel + prednisolone) NO LONGER RECRUITING
62373986|NCT00268476|EXPERIMENTAL|Arm D: Celecoxib|(ADT + celecoxib) NO LONGER RECRUITING
62373987|NCT00268476|EXPERIMENTAL|Arm E: Zoledronic Acid & Docetaxel|(ADT + zoledronic acid + docetaxel + prednisolone) NO LONGER RECRUITING
62373988|NCT00268476|EXPERIMENTAL|Arm F: Zoledronic Acid & Celecoxib|(ADT + zoledronic acid + celecoxib) NO LONGER RECRUITING
62373989|NCT00268476|EXPERIMENTAL|Arm G: Abiraterone|(ADT + abiraterone acetate + prednisolone) NO LONGER RECRUITING
62373990|NCT00268476|EXPERIMENTAL|Arm H: M1 RT|(ADT + radiotherapy to the prostate) NO LONGER RECRUITING
62373991|NCT00268476|EXPERIMENTAL|Arm J: Abiraterone * Enzalutamide|(ADT + abiraterone + enzalutamide + Prednisolone) NO LONGER RECRUITING
62373992|NCT00268476|EXPERIMENTAL|Arm K: Metformin|(ADT + Metformin) RECRUITING IN SELECTED SITES
62373993|NCT00268476|EXPERIMENTAL|Arm L: tE2|(Transdermal oestradiol) RECRUITING
62373994|NCT01137448|EXPERIMENTAL|Weight Loss|Subjects will be enrolled in a weight loss program and will receive weight loss and nutritional counseling.
62373995|NCT02737371|EXPERIMENTAL|F901318 Dose level A oral|F901318 adverse events days 1-10
62373996|NCT02737371|PLACEBO_COMPARATOR|Placebo Dose level A oral|Placebo adverse events days 1-10
62373997|NCT02737371|EXPERIMENTAL|F901318 Dose level B oral|F901318 adverse events days 1-10
62373998|NCT02737371|PLACEBO_COMPARATOR|Placebo Dose level B oral|Placebo adverse events days 1-10
62373999|NCT02737371|EXPERIMENTAL|F901318 Dose level C oral|F901318 adverse events days 1-10
62374000|NCT02737371|PLACEBO_COMPARATOR|Placebo Dose level C oral|Placebo adverse events days 1-10
62374001|NCT01478581|EXPERIMENTAL|Cohort 1|PCI-32765 420 mg per day
62374002|NCT01478581|EXPERIMENTAL|Cohort 2|PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week
62374003|NCT01478581|EXPERIMENTAL|Cohort 3|PCI-32765 840 mg per day
62374004|NCT01478581|EXPERIMENTAL|Cohort 4|PCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week
62374005|NCT01466439|OTHER|high frequency rTMS|
62374006|NCT01466439|OTHER|low frequency rTMS|
62374007|NCT03797157|EXPERIMENTAL|H2MF|Human milk-based breast milk fortifier
62374008|NCT03797157|ACTIVE_COMPARATOR|Standard fortifier|Standard care: bovine milk-based breast milk fortifier
62374009|NCT03930277||Pregnant women in labor.|Pregnant women in labor during the 2nd stage of labor.
62374010|NCT04570982||Convalescent Plasma with SOC|All patients will receive CPT and SOC
62374011|NCT01822249|ACTIVE_COMPARATOR|EPI-743 15 mg/kg|Subjects in this arm will receive EPI-743 at a dose of 15 mg/kg three times daily
62374012|NCT01822249|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive placebo at a volume equivalent to the volume of EPI-743 they would receive if in active group based on their weight
62374013|NCT05067114||Observational Cohort|Screening, detection, and referral for atrial fibrillation
62374014|NCT05382806|PLACEBO_COMPARATOR|group Control|participants are administered 2mL of 0.9% placebo at the end of procedure.
62374015|NCT05382806|ACTIVE_COMPARATOR|group Flumazenil|participants are administered 0.2mg (2mL) of flumazenil at the end of procedure.
62374016|NCT06064552||high risk pregnancy|Pregnant women with history of gestational diabetes in previous pregnancies, Polycystic ovaries syndrome, history of Macrosomic baby in previous pregnancies, Past history of late third trimester fetal demise, Past history of polyhydramnios, Overweight /Obese women, Women diagnosed to have other endocrinopathies like suprarenal, thyroid or pituitary disorders, multi fetal pregnancies, Past history of shoulder dystocia, Past history of preeclampsia
62374017|NCT06064552||low risk pregnancy|average risk population like primigravida healthy women or those with normal obstetric history.
62374018|NCT00372294|ACTIVE_COMPARATOR|1|Classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon)
62374019|NCT00372294|ACTIVE_COMPARATOR|2|Intravitreal Clindamycin \& Dexamethasone
62374020|NCT00807443|EXPERIMENTAL|Raltegravir|
62374021|NCT03779906|EXPERIMENTAL|ISOVUE|Isovue will be given to all subjects per the standard of clinical care.The specific iodine concentration and volume of ISOVUE used during the radiologic procedure will depend on the type of procedure and the standards in place at the site where the procedure is performed.
62374022|NCT04630444|EXPERIMENTAL|Intervention Group|30 PTSD patients receiving riluzole 100 mg daily (50 mg bid).
62374023|NCT01404806|EXPERIMENTAL|GSK1349572|
62374024|NCT05628987||Azoospermia|After an abstinence period of 2-7 days, two basic semen analysis, the absence of spermatozoa
62374025|NCT05628987||Oligozoospermia|After an abstinence period of 2-7 days, the total sperm number \<39\*10\^6 per ejaculate or the sperm concentration \< 15 \* 10\^6 per ml
62374026|NCT05628987||Asthenozoospermia|After an abstinence period of 2-7 days, the progressive motility (PR) \< 32%
62374027|NCT05628987||Teratozoospermia|After an abstinence period of 2-7 days, the percentage of morphologically normal spermatozoa \<4%
62374028|NCT05628987||Control|After an abstinence period of 2-7 days, the basic semen analysis is normal.
62374029|NCT03671642|EXPERIMENTAL|Perfusion assessment|Q-ICG: quantitative perfusion assessment with FA White light perfusion assessment FA: fluorescence angiography without quantification
62374030|NCT00597532|EXPERIMENTAL|1|soy (soy protein supplementation 50 grams/day)
62567229|NCT03552978|EXPERIMENTAL|Tech-facilitated IC intervention|After completing an initial 2-hour screening visit that includes a series of questionnaires assessing eligibility criteria and meeting with the study physician to review medical history, participants will be offered nicotine replacement therapy (NRT) at baseline (Week 0), per VA prescribing guidelines, nicotine dependence levels, and participant preference. Participants will then receive 8 counseling sessions (video or telephone). The first session lasts 45-60 min, and the remaining 7 sessions last 20-30 min. Participants will be asked to use the Stay Quit Coach (SQC) app between sessions, and the iCO® Smokerlyzer®
62745586|NCT01696019|ACTIVE_COMPARATOR|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
62745587|NCT01696019|PLACEBO_COMPARATOR|Contact and testing only|The fourth group received no intervention. Contact was maintained by phone during the intervention period to reduce dropout. Participants were called four times during the 40 weeks intervention period by the study coordinator.
62745588|NCT04034719|EXPERIMENTAL|Experimental group|"Newborn hospitalized in the neonatal department with their parent will be included.~They will have a portage scarf to help them to keep their child skin-to-skin"
62745589|NCT04034719|ACTIVE_COMPARATOR|Control group|"Newborn hospitalized in the neonatal department with their parent will be included.~They wont have a portage scarf."
62374031|NCT00597532|PLACEBO_COMPARATOR|2|milk protein supplementation 50 grams/day
62374032|NCT01703715||Patients aged 65 years and over|All patients aged 65 years and over admitted to acutely to medical wards
62374033|NCT05046236|EXPERIMENTAL|Interactive POWER rehabilitation|Participants in this group would be treated with POWER for twice a week, total 12 weeks.
62374034|NCT05046236|ACTIVE_COMPARATOR|Conventical physical training Group|Participants in this group would be treated with traditional exercise rehabilitation for twice a week, total 12 weeks.
62374035|NCT05046236|NO_INTERVENTION|Control group|Usual care
62374036|NCT03273699|EXPERIMENTAL|Mindfulness|"The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the GraphPad Quick Calcs online calculator which offers simple random allocation into equal-sized groups"
62374037|NCT03273699|NO_INTERVENTION|Control|"The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the GraphPad Quick Calcs online calculator which offers simple random allocation into equal-sized groups"
62374038|NCT02324036|EXPERIMENTAL|Coached Care+EMPATHy;|EMPATHy Toolkit: Patient coaching with computer assisted preference assessment
62374039|NCT02324036|ACTIVE_COMPARATOR|Routine Coached Care|Patient coaching only
62374040|NCT01987752||Combigan® Ophthalmic Solution|Patients treated with Combigan® Ophthalmic Solution as per local standard of care in clinical practice.
62374041|NCT05622968|ACTIVE_COMPARATOR|Intervention|Women who are planned for elective delivery for obstetric indication(s) and undergo outpatient induction of labour using Foley catheter
62374042|NCT05622968|PLACEBO_COMPARATOR|Control|Women who are planned for elective delivery for obstetric indication(s) and undergo inpatient induction of labour using intravaginal prostaglandin
62374043|NCT02915692||ERASE Silver Coated Foley Catheters|Subjects given silver catheters from an ERASE CAUTI Tray.
62745590|NCT05221632|EXPERIMENTAL|accelerated continue theta-burst stimulation|Fifty intermittent TBS sessions (1800 pulses per session, 50 minute inter-session interval ) were delivered as ten daily sessions over five consecutive days at 80% resting motor threshold (RMT). The MRI data set should be collected before the first cTBS session and after the last cTBS session.
62745591|NCT05221632|ACTIVE_COMPARATOR|1-HZ repetition transcranial magnetic stimulation Stimulation|The repetition transcranial magnetic stimulation(rTMS) lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 80% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
62745592|NCT05221632|SHAM_COMPARATOR|accelerated continue theta-burst stimulation (sham)|Fifty intermittent TBS sessions (1800 pulses per session, 50 minute inter-session interval ) were delivered as ten daily sessions over five consecutive days at 80% resting motor threshold (RMT). The MRI data set should be collected before the first cTBS session and after the last rTMS session. No actual magnetic stimulation was applied on the head of the volunteers. MRI dataset should be acquired before the first cTBS session and after the last cTBS session.
62374044|NCT02915692||Comparator Silver Coated Catheter|Comparator silver urinary catheter
62374045|NCT01105468||Mamma Carcinoma, no treatment|
62374046|NCT01105468||Mamma Carcinoma, treatment|
62374047|NCT01105468||No Mamma Carcinoma diagnosed by X-ray|
62374048|NCT03875833|EXPERIMENTAL|Collagen Nerve Wrap Conduit|
62374049|NCT03875833|NO_INTERVENTION|Control|
62374050|NCT05322083||HIV patients|All patients will be prescribed treatment drugs in accordance with the national protocol by the doctors of the AIDS centers. The decision to prescribe Doravirine will also be made by doctors.
62374051|NCT04655768|ACTIVE_COMPARATOR|Operative Arm|Radius fractures C1/C2 treated by palmar plate fixation
62374052|NCT04655768|NO_INTERVENTION|Conservative Arm|Radius Fractures C1/C2 treated by cast fixation
62553024|NCT06261645|EXPERIMENTAL|Delayed start|"According to result from the random allocation patients in Delayed Start will delay the start of their treatment with 16 weeks.~Participants in Delayed Start will undergo the same Baseline assessment a second time, and initiate their treatment within 2 weeks thereafter. The intervention consists of a 16 week exercise program with specific exercises to restore total rotator cuff function individually selected during clinical physiotherapy visits and performed 2 - 4 times daily.~According to progression, a mean of 10 visits are anticipated over the 16 weeks In addition, the patient will receive education and guidance in the daily use of the arm to adjust to appropriate load on the shoulder."
62553025|NCT03640494||Neonates with a clinical HIE diagnosis|48 neonates with a clinical diagnosis of HIE will be recruited from the patient populations of Duke University Health System and the University of Utah. All subject will have bedside optical coherence tomography (OCT) imaging performed at various time points while in the intensive care nursery.
62553026|NCT04844593||Participants With CD|Participants with CD diagnosed with or without CPF will be identified from EMRs through medical language application program interface (API) software. The AI will apply NLP and machine learning to identify and analyse text information in EMRs and thereby, extract medical information. The data will be collected retrospectively from January 1st 2015 and December 31st 2021.
62553027|NCT04949412||non-severe COVID19|Patients with mild symptoms (i.e., fever, cough, expectoration, and other upper respiratory tract symptoms), and without abnormalities, or with mild changes on chest radiography, were classified as non-severe types or A mild change in chest radiography is defined by multiple small patchy shadows and interstitial changes, mainly in the outer zone of the lung and under the pleura.
62553028|NCT04949412||Severe Covid19|Severe pneumonia was defined by the presence of any of the following conditions: i) significantly increased respiration rate (RR): RR ≥30 times/minute; ii) hypoxia: oxygen saturation (resting state) ≤93%; iii) blood gas analysis: partial pressure of oxygen/fraction of inspired oxygen (PaO2) /FiO2) ≤ 300 mmHg (millimeters of Mercury); or iv) the occurrence of respiratory or other organ failure that require Intensive care unit (ICU) monitoring and treatment, or shock
62745593|NCT04892550|EXPERIMENTAL|Traction group|"Participants in both groups will complete a 10-week, 3 x per week, 30 sessions total multimodal program consisting of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises.~In addition, the participants in the intervention group will receive the Denneroll™ thoracic traction orthosis. All participants will begin at 3-minutes per session of DTTO application, each visit they will be encouraged to increase the duration by 2-3 minutes, until such time they will be able to reach the goal of 15-20 minutes per session."
62374053|NCT01951911|ACTIVE_COMPARATOR|Ketamine|Ketamine 1 mg per kg per 24 hours as subcutaneous infusion via syringe driver for 48 hours.
62553029|NCT01340131|EXPERIMENTAL|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 40mg/S-Amlodipine 5mg Intervention
62553030|NCT01340131|ACTIVE_COMPARATOR|Free combination Therapy|Co-administration of single oral doses of a 40mg tablet of Telmisatan and a 5 mg tablet of S-Amlodipine
62553031|NCT00613171|EXPERIMENTAL|ST1571|Participants received ST1571 100 mg tablets, orally, once daily. Initiated at an oral dose of 200 mg/day for 4 weeks then titrated up to 400 mg/day for 2 weeks followed by 600 mg/day until Week 24, if well tolerated.
62553032|NCT04782076|EXPERIMENTAL|Dabigatran + Selpercatinib|"Participants received a single oral dose of 150 milligrams (mg) dabigatran on Day 1 and a single oral dose of 150 mg dabigatran coadministered with a single oral dose of 2 x 80 mg (160 mg) selpercatinib on Day 8.~There was a washout period of 7 days between dosing on Days 1 and 8."
62374054|NCT01951911|PLACEBO_COMPARATOR|Placebo|Sodium chloride 0.9% administered as a subcutaneous infusion via syringe driver for 48 hours.
62374055|NCT00242710|EXPERIMENTAL|1|BZA 20mg/CE 0.625
62374056|NCT00242710|EXPERIMENTAL|Arm 2|BZA 20mg/CE 0.45
62374057|NCT00242710|ACTIVE_COMPARATOR|Arm 3|CE 0.45mg/MPA1.5mg
62374058|NCT00242710|PLACEBO_COMPARATOR|Arm 4|Placebo
62374059|NCT05609162||local treatment group vs non-local treatment group|Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group or otherwise into non-local treatment group
62374060|NCT05609162||systemic treatment group vs non-systemic treatment group|Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group or otherwise into non-systemic treatment group
62553033|NCT00246324|EXPERIMENTAL|Single Arm|Interferon beta 1a, oral doxycycline
62553034|NCT01926431|EXPERIMENTAL|Exercise|60 minutes of high intensity treadmill running
62553035|NCT01926431|EXPERIMENTAL|Rest|60 minutes of seated rest (control trial)
62553036|NCT01494116|EXPERIMENTAL|10 mL syringe size|
62553037|NCT01494116|EXPERIMENTAL|20 mL syringe size|
62374061|NCT05609162||local treatment group vs systemic treatment group|Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group
62553038|NCT01494116|EXPERIMENTAL|30 mL syringe size|
62745594|NCT04892550|ACTIVE_COMPARATOR|Control group|Participants in both groups will complete a 10-week, 3 x per week, 30 sessions total multimodal program consisting of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises. The multimodal program will be delivered by the same physiotherapist, with 10 years of experience and training in the specific manual techniques in order to minimize inter-therapist variation and enhance fidelity.
62374062|NCT05609162||local treatment group vs local treatment+systemic treatment group|Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group
62374063|NCT05609162||systemic treatment group vs local treatment+systemic treatment group|Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group; Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group
62553039|NCT01494116|EXPERIMENTAL|60 mL syringe size|
62553040|NCT05361863|EXPERIMENTAL|0.022×0.028-inch slot (Control Group)|Leveling and alignment will be performed with 0.016-inch, 0.016×0.022-inch and 0.019×0.025-inch HANT followed by a working archwire of 0.019×0.025-inch stainless steel (Hangzhou Xingchen 3B Dental Instruments and Materials Co., Hangzhou, China).
62553041|NCT05361863|ACTIVE_COMPARATOR|0.020×0.028-inch slot|Leveling and alignment will be carried out with 0.016-inch, 0.016×0.022-inch and 0.018×0.025-inch HANT followed by a working archwire of 0.018×0.025-inch stainless steel (Hangzhou Xingchen 3B Dental Instruments and Materials Co., Hangzhou, China).
62553042|NCT05361863|ACTIVE_COMPARATOR|0.018×0.028-inch slot for the anterior teeth and 0.022×0.028-inch slot for the posterior teeth|Leveling and alignment will be completed with 0.016-inch, 0.016×0.016-inch, and 0.016×0.022-inch HANT followed by a working archwire of 0.016×0.022-inch stainless steel (Hangzhou Xingchen 3B Dental Instruments and Materials Co., Hangzhou, China).
62745595|NCT00453700||serological testing|In Latin American immigrants diagnosed with nonischemic cardiomyopathy in Los Angeles, serological testing for Trypanosoma cruzi was performed at enrollment.
62745596|NCT04305769|PLACEBO_COMPARATOR|Alanyl-glutamine 0g|
62745597|NCT04305769|EXPERIMENTAL|Alanyl-glutamine 4g|
62745598|NCT04305769|EXPERIMENTAL|Alanyl-glutamine 24g|
62745599|NCT04305769|EXPERIMENTAL|Alanyl-glutamine 44g|
62745600|NCT02427386|ACTIVE_COMPARATOR|dynamized estrogen in alcohol solution|Dynamized estrogen (17-beta estradiol) in the 12cH, 24cH and 18cH potencies.
62745601|NCT02427386|PLACEBO_COMPARATOR|placebo (alcohol solution)|This arm received alcohol solution during the 24-week study duration.
62745602|NCT00640380|EXPERIMENTAL|1|CPVB with NS
62745603|NCT00640380|ACTIVE_COMPARATOR|2|CPVB with LOR
62745604|NCT06477965||Group|For the study to determine efficacy and overall improvement of patients post artery embolization by comparing patient's pain preoperative and post operatively, if there is a decreased use of medication preoperatively compared to post procedure and increased quality of life preoperative and post procedure. Clinical outcomes of improvement will be determined by improvement of Visual Analog Scale (VAS) scores, Western Ontario and McMaster Universities Index (WOMAC), EQ-5D-5L Quality of Life Questionnaire, and to determine if patients had decrease used of medication prescribed preoperatively.
62745605|NCT03951831|EXPERIMENTAL|ADT Followed by Chemoimmunotherapy|"REGN2810 followed by chemoimmunotherapy:~Initiate degarelix 240mg SC once, followed by leuprolide acetate 22.5mg SC every 3 months.~Week 4 start cemiplimab (REGN 2810) 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.~Week 10 start docetaxel 75 mg/m2 every 21 days for up to 6 cycles."
62745606|NCT01513187|EXPERIMENTAL|Pazopanib + interferon|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
62374064|NCT05609162||local treatment+systemic treatment group vs non-local treatment+systemic treatment group|Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group or otherwise into non-local treatment+systemic treatment group
62553043|NCT04254341||patients with OSA|Subjects that underwent regular sleep studies (PSG) and found to have moderate/severe obstructive sleep apnea
62553044|NCT04254341||subjects without OSA|Subjects that underwent regular PSG and found not to have sleep apnea
62745607|NCT05566691|ACTIVE_COMPARATOR|Positive thinking|Videos will describe negative automatic thoughts and then describe positive thinking, its benefits, and how to use it to cope with negative thoughts. A worksheet will then walk participants through applying the strategy to a recent negative thought of their own. Daily surveys will involve a shortened version of this worksheet.
62374065|NCT00951119|EXPERIMENTAL|resperate device|"Resperate© is a device that helps to slow down breathing. This device can measure the breathing patterns through a breathing sensor mounted on the upper abdomen or chest. Furthermore, music-like sound patterns can be composed similar to this breathing pattern, which the patient can hear through the headphones of the Resperate©. By prolonging the expiration, which can be voluntarily used by the user, the frequency of respiration can be slowed down and become more stable (aim\<10 breathings per minute)."
62374066|NCT00951119|SHAM_COMPARATOR|control device|Resperate device without slowing of breathing
62374067|NCT00610714|ACTIVE_COMPARATOR|Active Comparator|carboplatin plus paclitaxel
62553045|NCT01775826|OTHER|All Purposes|All participants.
62553046|NCT04447560|EXPERIMENTAL|Erector Spinae Plane Block|One researcher will record the artery images as explained in the protocol before and after the plane block and two researchers will measure the radius and area of those vessels separately.
62745608|NCT05566691|ACTIVE_COMPARATOR|Positive thinking plus mood induction|The same videos will be used to describe negative automatic thoughts and then describe positive thinking, its benefits, and how to use it to cope with negative thoughts. Participants will then undergo a positive mood induction in which they are asked to recall a pleasant memory and try to re-experience those feelings. A worksheet will then walk participants through applying the strategy to a recent negative thought of their own. Daily surveys will involve the same mood induction and a shortened version of this worksheet.
62745609|NCT05566691|ACTIVE_COMPARATOR|Thought reevaluation|Videos will describe negative automatic thoughts and then describe reevaluating thoughts, its benefits, and how to use it to cope with negative thoughts. A worksheet will then walk participants through applying the strategy to a recent negative thought of their own. Daily surveys will involve a shortened version of this worksheet.
62745610|NCT05566691|ACTIVE_COMPARATOR|Thought reevaluation plus mood induction|The same videos will be used to describe negative automatic thoughts and then describe reevaluating thoughts, its benefits, and how to use it to cope with negative thoughts. Participants will then undergo a positive mood induction in which they are asked to recall a pleasant memory and try to re-experience those feelings. A worksheet will then walk participants through applying the strategy to a recent negative thought of their own. Daily surveys will involve the same mood induction and a shortened version of this worksheet.
62745611|NCT04545723|NO_INTERVENTION|Control group|In every cluster designated as a control group, patients aged 65 or older will be selected according to the inclusion criteria. The difference here is that patients will be given the standard opportunistic screening instead: pulse palpation and a 12-lead ECG when an irregular rhythm is found. This is current best practice.
62374068|NCT00610714|EXPERIMENTAL|2|AZD0530 in combination with carboplatin plus paclitaxel
62745612|NCT04545723|ACTIVE_COMPARATOR|Intervention group|In every cluster designated as an intervention group, patients aged 65 or older will be selected according to the inclusion criteria. Within this group, high-risk patients will be identified using the CHARGE-AF score, and will be prescribed the FibriCheck® app.
62745613|NCT02244840|EXPERIMENTAL|Electronic bidet and sitz bath|Electronic bidet for 3 minutes and sitz bath for 3 minutes, at another day, for each subject
62745614|NCT03883347|ACTIVE_COMPARATOR|Group DEX|Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia. The infusion of the solution will be discontinued and then will be performed in all patients subarachnoid anesthesia. Starting with Tmax, infusion of the solution will be initiated again at a dose of 0.6 mcg / kg / h.
62745615|NCT03883347|ACTIVE_COMPARATOR|Group REMI|Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia. The infusion of the solution will be discontinued and then will be performed in all patients subarachnoid anesthesia. Starting with Tmax, infusion of the solution will be initiated again at a dose of 0.025 mcg / kg / min.
62745616|NCT05610618|EXPERIMENTAL|Healthy adults|A single group of healthy adults will undergo all experimental conditions (within subject design)
62745617|NCT01212679|EXPERIMENTAL|nerve growth factor|Patients who underwent TBI will be chosen to receive NGF randomly.
62745618|NCT01212679|PLACEBO_COMPARATOR|Control|Patients who underwent TBI will be chosen to receive nomral saline randomly.
62745619|NCT06185907||Geriatric gastric cancer patients|
62745620|NCT04685720|EXPERIMENTAL|Inhaled NO delivered using LungFit|Inhaled Nitric Oxide in doses up to 250 ppm
62553047|NCT04740450|EXPERIMENTAL|study side|receive KT technique described by Gozluklu et al in 2020
62745621|NCT04068519|EXPERIMENTAL|Tislelizumab|Tislelizumab 200 mg intravenously (IV) once every 3 weeks (21 days per cycle) until no evidence of continued clinical benefits, unacceptable toxicity, or withdrawal of informed consent at the discretion of the investigator. There were 3 parts in this study: dose verification, pharmacokinetic (PK) sub-study, and indication expansion.
62745622|NCT05929612|EXPERIMENTAL|Ultra Low Dose 4 Gy Radiation|Participants will receive the ultra-low doses of radiation therapy over 1-2 days
62374069|NCT02343952|EXPERIMENTAL|Experimental Arm|Pembrolizumab -200 mg IV 3 weeks
62745623|NCT02976636|ACTIVE_COMPARATOR|Family-based behavioral therapy (FBT)|Family-based behavioral therapy for pediatric weight loss
62745624|NCT02976636|EXPERIMENTAL|Parenting training and FBT|Family-based behavioral therapy for pediatric weight loss + parenting training to enhance outcomes
62374070|NCT02748785|EXPERIMENTAL|Group 1 (No MTX Hold before Vaccination)|Group 1 will continue MTX
62553048|NCT04740450|PLACEBO_COMPARATOR|Control side|tapped with wound tape following the same technique
62745625|NCT05342012|EXPERIMENTAL|Experimental: Beetroot juice then nitrate depleted beetroot juice|Participants will be asked to consume 140ml of beetroot juice prior to their first experimental visit. Participants will then be asked to consume 140ml a day for 2 weeks, and finally visit the investigators once more following another 140ml drink.
62745626|NCT05342012|EXPERIMENTAL|Experimental: Nitrate depleted beetroot juice then beetroot juice|Participants will be asked to consume 140ml of placebo prior to their first experimental visit. Participants will then be asked to consume 140ml a day for 2 weeks, and finally visit the investigators once more following another 140ml drink.
62745627|NCT05529277||Dyad of person with cognitive impairment and caregiver|Households identified in routine care receiving a home-based Dementia Care Management.
62745628|NCT04234529|ACTIVE_COMPARATOR|AMATEA|3x 450mg capsules of AMATEA which contains 270mg of caffeine total
62745629|NCT04234529|ACTIVE_COMPARATOR|Caffeine|3x 450mg capsules each containing 360mg of microcellulose and 90mg of caffeine (270mg caffeine total)
62374071|NCT02748785|EXPERIMENTAL|Group 2 (MTX hold 4 Weeks before vaccination)|Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
62553049|NCT04922723|EXPERIMENTAL|Daratumumab|"Daratumumab, IV, 16 mg/KG -~1 dose prior to surgery or biopsy; Weeks 1 - 8 = 1 dose weekly; Weeks 9 - 24 = 1 dose every other week; Weeks 25 onward (determined by disease progression) = 1 dose every 4 weeks"
62553050|NCT02245087|EXPERIMENTAL|Atorvastatin|Atorvastatin(Lipitor) in addition to the usual guideline based care
62553051|NCT02245087|NO_INTERVENTION|Guideline based care|Current guidelines for lipid-management in healthy middle aged men and women only.
62553052|NCT03889886|PLACEBO_COMPARATOR|Vehicle|Vehicle
62374072|NCT02748785|EXPERIMENTAL|Group 3 (MTX hold 2 Weeks before Vaccination)|Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
62553053|NCT03889886|EXPERIMENTAL|SDP-4 Ophthalmic Solution (0.1%)|Low concentration of SDP-4
62553054|NCT03889886|EXPERIMENTAL|SDP-4 Ophthalmic Solution (1.0%)|Mid concentration of SDP-4
62553055|NCT03889886|EXPERIMENTAL|SDP-4 Ophthalmic Solution (3.0%)|High concentration of SDP-4
62745630|NCT04234529|PLACEBO_COMPARATOR|Placebo|3x 450mg capsules of microcellulose
62745631|NCT01407835|EXPERIMENTAL|1|"* Dactylis glomerata allergen extract at 4 different concentrations~* Positive control~* Negative control"
62745632|NCT06090981|EXPERIMENTAL|Early bolus surfactant replacement therapy|Neonates randomized to this group will receive early bolus surfactant replacement therapy within 2hr of life
62745633|NCT06090981|NO_INTERVENTION|Standard care|Neonates randomized to this group will be managed as per standard protocol in the neonatal unit.
62745634|NCT00607269|NO_INTERVENTION|Control|Control condition receiving minimal incentives for service program attendance and participation.
62745635|NCT00607269|EXPERIMENTAL|Contingency Management|Contingency management (Voucher-Based Reinforcement Therapy) intervention providing positive reinforcement for service program participation and attendance, enactment of prosocial/health behavior, and/or clean urine samples (i.e., no illicit drug use) and clean breathalyzer tests (i.e., BA \< 0.05).
62745636|NCT01394692|ACTIVE_COMPARATOR|intraoperative MRI|tumor resection with intraoperative MRI-guidance
62745637|NCT01394692|ACTIVE_COMPARATOR|conventional group|standard microsurgical tumor resection
62745638|NCT06653751|EXPERIMENTAL|Support by a reminder app|Patients are supported by a Reminder App. The purpose of the app is to remind patients irradiated for prostate cancer in an intuitive, unobtrusive and supportive way to drink 300 ml of water 45 minutes prior to each radiation session. This is supposed to have an impact on the number of bladder volumes \<200 ml. Bladder volumes \<200 ml were previously shown to be associated with increased urinary toxicity.
62553056|NCT03288714|EXPERIMENTAL|Active sTMS|Synchronized Transcranial Magnetic Stimulation (sTMS) treatments to be administered using an active device 5 times per week for six treatment weeks.
62745639|NCT01412450|EXPERIMENTAL|nitinol stent|Protégé EverFlex stent
62745640|NCT03494530|OTHER|Early initiation of edoxaban|Participants will be initiated on edoxaban within ≤ 5 days following ischemic stroke
62745641|NCT03494530|OTHER|Delayed initiation of edoxaban|Participants will be initiated on edoxaban within 6-14 days following ischemic stroke
62745642|NCT01576146|EXPERIMENTAL|Etelcalcetide|Participants received a bolus IV injection of etelcalcetide 3 times a week (TIW) at the end of each hemodialysis session for up to 144 weeks in the extension study. The starting dose was the same as the final dose administered in the parent study (20120331); the dose was adjusted per protocol-specified guidelines to achieve or maintain parathyroid hormone values in the 150 to 300 pg/mL range.
62745643|NCT06587334|ACTIVE_COMPARATOR|Control Group|The control group will receive SRP alone
62745644|NCT06587334|EXPERIMENTAL|Laser Group|The laser group will receive SRP combined with Nd laser-assisted therapy
62745645|NCT01243372||Correlative (BRAF V600E mutation analysis)|Previously collected formalin-fixed and paraffin-embedded baseline tumor samples are analyzed for BRAF V600E mutation. Mutation status is correlated with clinical response and outcome data from patients enrolled on CALGB-C80405.
62745646|NCT06034873|ACTIVE_COMPARATOR|Group A|In the IVAS group, the patients intravenous propofol combined with fentanyl. The sequence will be to inject fentanyl 1 μg•kg-1•min-1 first within 1 min and then inject propofol 2 mg•kg-1•min-1.
62745647|NCT06034873|ACTIVE_COMPARATOR|Group B|Patients will be anesthetized with ultrasound-guided pericapsular nerve group block (PENG block) using 20 ml of 0.25% bupivacaine.
62745648|NCT02043106|EXPERIMENTAL|spinal cord injury|Individuals who have sustained an incomplete spinal cord injury
62745649|NCT02043106|ACTIVE_COMPARATOR|non-spinal cord injury|Individuals who have not sustained a spinal cord injury
62745650|NCT02896491|EXPERIMENTAL|GSM 900 MHz exposure|Radiation: Exposure with non-ionizing electromagnetic fields exposure with GSM 900 MHz (2W/kg)
62745651|NCT02896491|EXPERIMENTAL|TETRA 400 MHz exposure|"Radiation: Exposure with non-ionizing electromagnetic fields:~exposure with TETRA (6W/kg)"
62745652|NCT02896491|SHAM_COMPARATOR|Sham exposure|Radiation: Exposure with non-ionizing electromagnetic fields: exposure with 0 W/kg
62745653|NCT05582018|EXPERIMENTAL|BioTrace|Use of the BioTraceIO 360 device for planning, monitoring and assessment of liver tissue ablations
62374073|NCT02748785|EXPERIMENTAL|Group 4 (MTX hold on Day of Vaccination)|Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
62374074|NCT03345173|EXPERIMENTAL|CI-581a|"CI-581a will be administered during the washout phase when participants are experiencing moderate withdrawal, as well as the following day when the naltrexone titration is initiated.~(0.11 mg/kg 2-min bolus followed by 1.3 mg/kg over 90 min)"
62374075|NCT03345173|PLACEBO_COMPARATOR|CI-581b|"CI-581b will be administered during the washout phase when participants are experiencing moderate withdrawal, as well as the following day when the naltrexone titration is initiated.~(2-min saline bolus followed by 0.0125 mg/kg over 90 min)"
62374076|NCT06379880|EXPERIMENTAL|Patients using CONTINUUM+ CONNECT remote monitoring solution|
62374077|NCT06379880|NO_INTERVENTION|Patients with conventional follow-up without remote monitoring application.|
62374078|NCT02668055|EXPERIMENTAL|TB4|Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells in wound, stick with wound edge skin suture, with vaseline gauze bandaging, controlled side not adding slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitutes
62374079|NCT05333289|EXPERIMENTAL|mRNA-1030 Dose Level A|Participants will receive mRNA-1030 at Dose Level A by intramuscular (IM) injection on Day 1.
62374080|NCT05333289|EXPERIMENTAL|mRNA-1020 Dose Level A|Participants will receive mRNA-1020 at Dose Level A by IM injection on Day 1.
62374081|NCT05333289|EXPERIMENTAL|mRNA-1030 Dose Level B|Participants will receive mRNA-1030 at Dose Level B by IM injection on Day 1.
62374082|NCT05333289|EXPERIMENTAL|mRNA-1020 Dose Level B|Participants will receive mRNA-1020 at Dose Level B by IM injection on Day 1.
62374083|NCT05333289|EXPERIMENTAL|mRNA-1030 Dose Level C|Participants will receive mRNA-1030 at Dose Level C by IM injection on Day 1.
62374084|NCT05333289|EXPERIMENTAL|mRNA-1020 Dose Level C|Participants will receive mRNA-1020 at Dose Level C by IM injection on Day 1.
62374085|NCT05333289|ACTIVE_COMPARATOR|mRNA-1010|Participants will receive mRNA-1010 by IM injection on Day 1.
62745654|NCT00445367||Case|
62745655|NCT00445367||Control|
62745656|NCT01413906|EXPERIMENTAL|Arm 1: BMS-833923 (XL139)|
62374086|NCT05333289|ACTIVE_COMPARATOR|Active Comparator|Participants will receive an active comparator by IM injection on Day 1.
62374087|NCT02444806|ACTIVE_COMPARATOR|Full Polysomnography|Patients will have NIV settings established using overnight full polysomnography.
62374088|NCT02444806|ACTIVE_COMPARATOR|Oximetry-capnography|Patients will have NIV settings established using only Oximetry-capnography and subjective sleep comfort.
62374089|NCT00095810|EXPERIMENTAL|A|
62553057|NCT03288714|SHAM_COMPARATOR|Sham Stimulation|Sham treatments to be administered using a sham device 5 times per week for six treatment weeks.
62553058|NCT02371655|ACTIVE_COMPARATOR|Diet included|Diet is included in bowel preparation
62553059|NCT02371655|EXPERIMENTAL|Diet not included|Diet is not included in bowel preparation
62745657|NCT00292279|EXPERIMENTAL|A|
62745658|NCT00292279|ACTIVE_COMPARATOR|B|
62745659|NCT02428998|EXPERIMENTAL|Korean Red Ginseng|Patients receive oral Korean Red Ginseng twice daily for 24 weeks. Treatment repeats every 4, 12, 24 weeks for 3 courses
62745660|NCT02428998|PLACEBO_COMPARATOR|Placebo|Patients receive oral placebo twice daily for 24 weeks. Treatment repeats every 4, 12,24 weeks for 3 courses
62745661|NCT04331184|EXPERIMENTAL|RFA using combined bipolar and monopolar energy delivery|Control group: The historic cohort is used to compare the results of the conventional alternating unipolar radiofrequency energy transfer mode with RFA.
62745662|NCT03053986|ACTIVE_COMPARATOR|Apple polyphenols|White capsule containing 300 mg of apple extract (Malus Domestica) with glycosilated polyphenols (≥90%) including glycosilated phloritzin (15-30%), chlorogenic acid (10-25%) and quercetin (15-25%)
62553060|NCT05405504||ICU part|Acute heart failure patients with Swan-Ganz catheter and an arterial catheter.
62745663|NCT03053986|PLACEBO_COMPARATOR|Placebo|Indistinguishable capsules with similar dimension, colour, odour and taste
62745664|NCT05534659||Programmable valve(PV) group|Adult patients with hydrocephalus who received programmable ventricular CSF shunts operation.
62745665|NCT05534659||Non-programmable valve(NPV) group|Adult patients with hydrocephalus who received non-programmable ventricular CSF shunts operation.
62745666|NCT00733837|EXPERIMENTAL|A|This is a repeated measures study. All participants experience the same conditions.
62745667|NCT00145184|PLACEBO_COMPARATOR|Placebo|Placebo
62745668|NCT00145184|EXPERIMENTAL|Multivitamins|Multivitamin supplement containing the following vitamins: B1, B2, Niacin, B6, Folate, B12, C, and E
62745669|NCT01910324|EXPERIMENTAL|Multidimensional Family Therapy Cross-Systems|In Stage 1 (in detention) Multidimensional Family Therapy Cross-Systems (MDFT-CS) consists of two major components: standard initial/engagement work with parents in the home and with adolescents in detention, plus a state-of-the-art HIV education prevention module. In Stage 2, MDFT-CS includes the standard MDFT components: 1) interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
62745670|NCT01910324|OTHER|Enhanced Services as Usual|In Stage 1 (in detention) ESAU includes two major components: standard drug treatment services delivered by detention staff, and state-of-the-art HIV education prevention intervention. In Stage 2, community drug treatment providers deliver high quality drug treatment on an outpatient basis.
62745671|NCT03721783||children with soft tissue lesions|All children who undergo cryoablation therapy for benign soft tissue lesions
62745672|NCT02140008|EXPERIMENTAL|I-gel group|
62745673|NCT02140008|ACTIVE_COMPARATOR|Air-Q group|
62745674|NCT02292082|ACTIVE_COMPARATOR|Peri-Articular Injections only|"Intra-Operatively~* Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)~* Surgeon will perform the periarticular injections:~* First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc~* Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine~* Intravenous sedation with midazolam and propofol."
62745675|NCT02292082|EXPERIMENTAL|Peri-Articular Injections and Adductor Canal Block|"Intra-Operatively~* Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)~* Adductor canal block technique:~* Supine position, after IV sedation~* Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches~* Femoral artery will be identified in the adductor canal deep to the Sartorius muscle~* 15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone~* Local anesthetic will be delivered periarterial between 12 and 6 o'clock~* Intravenous sedation with midazolam and propofol.~* First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc~* Second superficial injection prior to closure. 20 ml 0.25% bupivacaine"
62745676|NCT05659407||BAFF-var carrier|
62745677|NCT05659407||No BAFF-var carrier|
62745678|NCT00937729||enfuvirtide|all patients would received enfuvirtide and and optimised background
62553061|NCT05405504||Out-patient part|Chronic heart failure patients with CardioMEMS.
62745679|NCT03758092||SGA vs AGA infants|infants, born at term (37+0/41+3 week gestation), aged 24 months, with a birth weight \<10th percentile or between 10th and 90th percentile for sex, gestational age, and birth order, according to Italian neonatal anthropometric charts
62745680|NCT02082080|ACTIVE_COMPARATOR|Obese and overweight children, education|Overweight and obese school children in grades 5 and 6
62745681|NCT02082080|NO_INTERVENTION|Obese and overweight children|
62745682|NCT03004261|EXPERIMENTAL|CMV-CTL|The donor derived cytomegalovirus specific T lymphocytes (CMV-CTL) will be transfused to the patients. The patients will receive CMV-CTL cells when they are sero-positive for CMV-DNA 30 days after transplant. The CMV-DNA levels will be monitored weekly for at least 60 days after the transplant. If after the initial dose of CMV-CTL cells the patient develops a viral infection, then they may be eligible to receive one additional injection of CMV-CTLs. If the CMV levels in the blood continue to rise after the dose of T cells then the patient will receive treatment with Ganciclovir or Foscarnet.
62745683|NCT03789435||Amputees|Patients underwent trans-tibial and trans-femoral amputation of any etiology at the Rizzoli Orthopedic Institute from 2015 to 2017 with the presence of analgesia data for surgery in a computerized record (SIR, Rizzoli information system). A questionnaire for the detection of residual limb pain will be administrate to all the survivors.
62745684|NCT03865745|EXPERIMENTAL|Korean Red Ginseng|Product: Red ginseng Everytime 1 pack(3g/day)
62553062|NCT03437408|EXPERIMENTAL|Mapping and ablation|Automated Substrate maps with different pacing modes. Validation of collected substrate. Data collection during ablation
62553063|NCT03249532|ACTIVE_COMPARATOR|standard hemodialysis|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 0 Liters (L)
62553064|NCT03249532|ACTIVE_COMPARATOR|cool hemodialysis|prescription of dialysate temperature: 35.5 degrees celsius prescription of convection volume: 0 L
62553065|NCT03249532|ACTIVE_COMPARATOR|low volume hemodiafiltration|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
62553066|NCT03249532|ACTIVE_COMPARATOR|high volume hemodiafiltration|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
62553067|NCT01595347|ACTIVE_COMPARATOR|Hyper-oxigenated fatty acid|Hyper-oxigenated fatty acid,Equisetum arvense, Hypericum perforatum
62553068|NCT01595347|EXPERIMENTAL|Olive oil's Cream|Cream with 60% extra virgin olive oil.
62745685|NCT01476865||Healthy|normal, healthy people
62745686|NCT01476865||RA|rheumatoid arthritis patients
62745687|NCT01549808|EXPERIMENTAL|group 2|"Participants:~100 patients will be included in the observation phase of this project, and another 100 in the intervention phase, according to the following criteria: Patients hospitalized in Unit 4141, at Rigshospitalet or ICU at Slagelse, who have been intubated for more than 48 hours, age ≥18, and after positive confirmation from relatives that the patient before the hospitalization was able to read and understand instructions.~The research is divided in 3 phases:~1. An 8 month observation phase.Current practice relatede to mobilize is measured.~2. An 2 month implementation phase and third: an 8 month intervention phase. The effect is measured as the difference in the functional level between the observation phase and the intervention phase related to primary and secondary outcome.~The effect of the intervention is described by using following test:~walking distance,ADL function, capability to sit and stand"
62745688|NCT01944098|EXPERIMENTAL|Lidocaine|Intraoperative continuous IV infusion of Lidocaine at 2mg/kg/hr
62745689|NCT01944098|ACTIVE_COMPARATOR|Placebo|Intraoperative continuous placebo infusion of dextrose at 2mg/kg/hr
62745690|NCT06104488|EXPERIMENTAL|Dose Level -1|If 0 of 3-6 or no more than 1 of 6 evaluable participants experience a DLT, then the dose will be escalated to Dose Level 2 and the same approach will be repeated. If 2 or more DLTs are observed on Dose Level 1 in 2-6 subjects, then further enrollment to Dose Level 1 will stop, the dose will be de-escalated to Dose Level -1 and the same approach will be repeated. The MTD will be the highest dose with \<2 DLTs in 6 patients.
62745691|NCT06104488|EXPERIMENTAL|Dose Level 1|If 0 of 3-6 or no more than 1 of 6 evaluable participants experience a DLT, then the dose will be escalated to Dose Level 2 and the same approach will be repeated. If 2 or more DLTs are observed on Dose Level 1 in 2-6 subjects, then further enrollment to Dose Level 1 will stop, the dose will be de-escalated to Dose Level -1 and the same approach will be repeated. The MTD will be the highest dose with \<2 DLTs in 6 patients.
62745692|NCT06104488|EXPERIMENTAL|Dose Level 2|If 0 of 3-6 or no more than 1 of 6 evaluable participants experience a DLT, then the dose will be escalated to Dose Level 2 and the same approach will be repeated. If 2 or more DLTs are observed on Dose Level 1 in 2-6 subjects, then further enrollment to Dose Level 1 will stop, the dose will be de-escalated to Dose Level -1 and the same approach will be repeated. The MTD will be the highest dose with \<2 DLTs in 6 patients.
62745693|NCT03469518|SHAM_COMPARATOR|β-Cx plus PS|Fruit and milk based beverage enriched with beta-cryptoxanthin and plant sterols
62745694|NCT03469518|ACTIVE_COMPARATOR|β-Cx plus PS plus GOS|Fruit and milk bases beverage enriched with beta-criptoxanthin, plant sterols and galactooligosaccharides
62745695|NCT00245050|EXPERIMENTAL|Pyridoxine|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine 100 mg twice daily on days 1-28.
62745696|NCT00245050|PLACEBO_COMPARATOR|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo twice 100 mg daily on days 1-28.
62745697|NCT03679858||Platelet function test in patients|Platelet function test in patients on antiplatelet therapy
62745698|NCT03679858||Platelet function test in healthy|Platelet function test in healthy subjects
62745699|NCT06657989|EXPERIMENTAL|High intensity reactive balance training|Participants will complete 5 1-hour training sessions over 11 days. During each training session, participants will complete 36 multi-directional (left-, right-, and forward-fall) perturbations. Participants assigned to high-intensity RBT will experience perturbations at 150% of the multi-step threshold; for example, for a multi-step threshold of 2 m/s\^2 the high intensity perturbation will be 3 m/s\^2.
62745700|NCT06657989|ACTIVE_COMPARATOR|Moderate intensity reactive balance training|Participants will complete 5 1-hour training sessions over 11 days. During each training session, participants will complete 36 multi-directional (left-, right-, and forward-fall) perturbations. Participants assigned to moderate-intensity RBT will experience perturbations at 100% of the multi-step threshold; for example, for a multi-step threshold of 2 m/s\^2 the high intensity perturbation will be 2 m/s\^2.
62553069|NCT05361915|EXPERIMENTAL|Abivertinib - Abiraterone-naive|Abiraterone-naive: Abivertinib 200 mg by mouth twice daily with abiraterone 1000 mg by mouth daily.
62553070|NCT05361915|EXPERIMENTAL|Abivertinib - Abiraterone-progressing|Abiraterone-progressing: Abivertinib 200 mg by mouth twice daily with abiraterone 1000 mg by mouth daily.
62553071|NCT01927900|ACTIVE_COMPARATOR|HMO1|HMO diluted in water
62553072|NCT01927900|PLACEBO_COMPARATOR|Glucose|Glucose diluted in water
62553073|NCT01927900|ACTIVE_COMPARATOR|HMO2|HMO diluted in water
62553074|NCT01927900|ACTIVE_COMPARATOR|HMO3|HMO diluted in water
62553075|NCT01927900|ACTIVE_COMPARATOR|HMO4|HMO diluted in water
62745701|NCT06657989|SHAM_COMPARATOR|Walking control group|Participants assigned to the walking control group will complete 36 trials of unperturbed walking in each training session.
62553076|NCT01927900|ACTIVE_COMPARATOR|HMO5|HMO diluted in water
62553077|NCT01927900|ACTIVE_COMPARATOR|HMO6|HMO diluted in water
62553078|NCT01927900|ACTIVE_COMPARATOR|HMO7|HMO diluted in water
62553079|NCT01927900|ACTIVE_COMPARATOR|HMO8|HMO diluted in water
62553080|NCT01927900|ACTIVE_COMPARATOR|HMO9|HMO diluted in water
62553081|NCT02358902|EXPERIMENTAL|Group A|tDCS (tDCS - DC stimulator, Neurocom, Germany) / AE Group in which will receive active intervention of aerobic exercise training and active tDCS intervention
62553082|NCT02358902|EXPERIMENTAL|Group B|AE group which will receive active intervention of aerobic exercise and placebo tDCS (tDCS - DC stimulator, Neurocom, Germany)
62553083|NCT02358902|EXPERIMENTAL|Group C|tDCS group which will receive placebo AE and active intervention for tDCS (tDCS - DC stimulator, Neurocom, Germany)
62553084|NCT06581952|EXPERIMENTAL|Two poem writing sessions|The intervention consists of two sessions of poem writing. Each session lasts for 3 hours. The instructors for each session will include two experienced Chinese teachers or drama directors from Bestreben Drama Association Limited. Adherence to the protocol will be evaluated by two independent reviewers.
62374090|NCT01461798|EXPERIMENTAL|Benecol|In 2009, the dairy Cooperative Colanta Launches Benecol ® yogurt, a product with optimal daily dose of plant stanol, each portion of 100 g containing 3.4 g of Benecol ®, corresponding to 2 g of plant stanol esters . Skim yogurt with Benecol ® is a product made from pasteurized skim milk, sweetened with sucralose homogenized and fermented by the action of specific lactic culture to obtain the optimal characteristics of texture and acidity. With the addition of fruit pulp and supplemented with plant stanol esters (Benecol ®) to help reduce the risk of cardiovascular disease (31). According to Weiss et al, drinkable yogurt with Benecol ® reduces total cholesterol by 5.8% and 9.8% in LDL cholesterol (32).
62553085|NCT04505527|ACTIVE_COMPARATOR|Recurrent fallers - control group|In this control arm, older adults will have a typical forward walking training that mirror the lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min forward walking. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
62553086|NCT04505527|EXPERIMENTAL|Recurrent fallers - intervention group|In this experimental arm, older adults will have a lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min sideways walking across a 10 m walkway changing body direction at the ends, thus alternating lead and lag limbs. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
62553087|NCT04505527|EXPERIMENTAL|Older non-fallers intervention group|In this experimental arm, older adults will have a lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min sideways walking across a 10 m walkway changing body direction at the ends, thus alternating lead and lag limbs. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
62553088|NCT04505527|ACTIVE_COMPARATOR|Younger adult control group|Outcome measures from a young healthy group will also be measured as a reference. Will be used to compare outcome measured between older and young adults. Young adults will have a lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min sideways walking across a 10 m walkway changing body direction at the ends, thus alternating lead and lag limbs. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
62553089|NCT04139824|EXPERIMENTAL|Cohort|Period 1: LC350189 200mg (QD) Day 1\~ Day 4, Period 2: Naproxen 500 mg (BID) Day 8 \~ Day 12 , Period 3 : LC350189 200mg (QD) + Naproxen 500 mg (BID) Day 13\~19
62553090|NCT00614640|EXPERIMENTAL|1|One 0.8 ml vaccine-containing patch and 1 placebo patch placed on upper back or upper thigh for 24 hours on Days 0, 42, and 84
62553091|NCT00614640|EXPERIMENTAL|2|Four 0.8 ml vaccine-containing patches placed on upper back or upper thigh for 24 hours on Days 0, 42, and 84
62553092|NCT00614640|EXPERIMENTAL|3|Four 0.8 ml vaccine-containing patches placed on upper back or upper thigh for 24 hours on Days 0, 7, 42, 49, 84, and 91
62553093|NCT04107272|EXPERIMENTAL|Experimental group|Real rTMS
62553094|NCT04107272|SHAM_COMPARATOR|Control group|Sham rTMS
62553095|NCT02112851|PLACEBO_COMPARATOR|Orange flavored beverage|240ml orange beverage
62553096|NCT02112851|EXPERIMENTAL|Orange flavored beverage - Test1|240ml processed whole orange low dose
62553097|NCT02112851|EXPERIMENTAL|Orange flavored beverage - Test2|240ml processed whole orange high dose
62553098|NCT02591524|EXPERIMENTAL|Cystic fibrosis airway colonization|Flexible bronchoscopy via the nasal route on the date of baseline visit, nasal lavage at baseline and after 6 month
62553099|NCT01379846|EXPERIMENTAL|TAK-816|
62553100|NCT01379846|ACTIVE_COMPARATOR|ActHIB|
62553101|NCT05866965|ACTIVE_COMPARATOR|control|standard third molar surgery following surgical protocol of Department of Oral Surgery, University of Medicine and Pharmacy
62374091|NCT01461798|PLACEBO_COMPARATOR|yogurt|Yogurt without plant stanols
62374092|NCT02855086|EXPERIMENTAL|50 mg cetuximab-IRDye 800|"Patients receive cetuximab IV over 30 minutes and a lower dose of cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.~All patients undergo standard of care surgical resection of tumor on days 2 to 5."
62553102|NCT05866965|EXPERIMENTAL|PRF|PRF was applied in third molar socket after removal following surgical protocol of Department of Oral Surgery, University of Medicine and Pharmacy
62553103|NCT00910676|EXPERIMENTAL|DIPROSONE|
62374093|NCT02855086|EXPERIMENTAL|100 mg cetuximab-IRDye 800|"Patients receive cetuximab IV over 30 minutes and a higher dose of cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.~All patients undergo standard of care surgical resection of tumor on days 2 to 5."
62374094|NCT01396031|EXPERIMENTAL|Excercise|Cardiovascular exercise Standing Hip Abduction Step-up/Step-down Wall Slide Sit-to-Stand Activity / Exercise Diary 3 times per week x \~1 month
62374095|NCT04062006|EXPERIMENTAL|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU/m2 five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
62374096|NCT04576260|EXPERIMENTAL|CBT-I Group|Participants in the CBT-I group will undertake weekly sessions for a duration of 8 weeks with a trained psychologist through Zoom or Skype Calls.
62374097|NCT04576260|NO_INTERVENTION|Control group|The control group will be asked to maintain the usual lifestyle for the duration of the study
62553104|NCT04044872|EXPERIMENTAL|Single Arm:Diagnosing Cardiotoxicity when on Radiation therapy|
62553105|NCT03763006|EXPERIMENTAL|Ocudox lid wiped|
62553106|NCT03763006|ACTIVE_COMPARATOR|Povidone Iodine|
62553107|NCT06094881|EXPERIMENTAL|Intervention (Obinutuzumab)|60 enrolled subjects: one infusion
62553108|NCT00398866|ACTIVE_COMPARATOR|1|Bupivicaine (local anesthetic)
62553109|NCT00398866|ACTIVE_COMPARATOR|2|Corticosteroid (trimcinolone (Kenalog) 40 mg)
62553110|NCT00398866|EXPERIMENTAL|3|Synvisc
62745702|NCT05333627|EXPERIMENTAL|Fast-Track Course|Clients who select the Fast-Track Course option will receive access to a single ICBT core lesson and Do-It-Yourself guide, followed by three additional Do-It-Yourself guides that they can access in any order. The content includes examples that are tailored to students' experiences. Clients have access to diverse additional resources (e.g., managing panic, assertive communication) throughout the course. Clients will receive up to five weeks of optional therapist support.
62553111|NCT04110210|ACTIVE_COMPARATOR|Group A(Ultrasound guided ESP block after indtiucon of GA).|Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivacaine 0.25% are then injected into the ESP. The procedure is repeated on the contralateral side.
62374098|NCT00378534|EXPERIMENTAL|T Cell Depletion Transplant Participants|Participants with hematological malignancies received a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation followed by an infusion of stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a delayed T cell depletion add back as donor lymphocyte infusion at day 90.
62553112|NCT04110210|ACTIVE_COMPARATOR|Group B(GA with conventional analgesia)|After operation, patients will be transferred to post anesthesia care unit (PACU) for complete recovery and monitoring. The pain VAS scores between the studied groups will be registered every 4 hours for 24 hours postoperatively. A standard postoperative analgesia regimen will be prescribed as paracetamol 1gm every 6 hours and ketorolac 30mg every 8 hours in the first 24 hours postoperatively. Morphine 2.5 mg will be given as a rescue analgesic dose if visual analogue score was ≥ 3 or when patient suffering from pain between the assessment intervals in both groups not exceeding 0.1 mg/kg in a period of 6 hours. Metoclopramide 0.15 mg/kg IV will be prescribed for patients complaining of nausea or vomiting.
62553113|NCT02267018|ACTIVE_COMPARATOR|nCPAP|Nasal continuous positive airway pressure is a frequently used modality for non-invasive respiratory support in preterm infants.
62553114|NCT02267018|ACTIVE_COMPARATOR|NIHFV|Non-invasive high-frequency ventilation is a relatively new modality that is being utilized to support preterm infants and prevent the need for invasive ventilation, but this particular modality is has not been well studied to date.
62553115|NCT06274294|EXPERIMENTAL|SC CT-P13 induction|Experimental arm: SC induction of 240 mg of CT-P13 at week 1, then 120 mg at weeks 2, 3, 4 then every 2 weeks until week 24.
62553116|NCT06274294|OTHER|IV CT-P13 induction|Control arm: IV induction of 5 mg/kg of CT-P13 at weeks 1 and 2 then SC (120 mg) every 2 weeks until week 24.
62553117|NCT04998656|ACTIVE_COMPARATOR|Werewolf FLOW 50 Group|The Werewolf FLOW 50 electrocautery device will be used during surgical treatment for patients assigned to this group.
62553118|NCT04998656|PLACEBO_COMPARATOR|Control Group|No electrocautery device will be used during surgical treatment for patients assigned to this group.
62553119|NCT04584684|PLACEBO_COMPARATOR|0.9% NaCl Saline|Subject participants will rinse mouth one time for 60 seconds with 10 mL of Saline.
62553120|NCT04584684|ACTIVE_COMPARATOR|27% Ethanol plus essential oils|Subject participants will rinse mouth one time for 60 seconds with 10 mL 27% ethanol plus essential oils.
62553121|NCT04584684|ACTIVE_COMPARATOR|0.075% Cetylpyridinium Chloride|Subject participants will rinse mouth one time for 60 seconds with 10 mL 0.075% Cetylpyridinium Chloride.
62553122|NCT04584684|ACTIVE_COMPARATOR|1.5% w/v Hydrogen Peroxide|Subject participants will rinse mouth one time for 60 seconds with 10 mL of 1.5% w/v hydrogen peroxide rinse.
62553123|NCT04584684|ACTIVE_COMPARATOR|0.5% w/v Povidone-iodide|Subject participants will rinse mouth one time for 60 seconds with 10 mL .5% w/v povidone-iodide.
62553124|NCT04584684|ACTIVE_COMPARATOR|0.12% Chlorhexidine Gluconate|Subject participants will rinse mouth one time for 60 seconds with 10 mL of 0.12% Chlorhexidine Gluconate.
62553125|NCT06058104|EXPERIMENTAL|Charades-based mobile digital therapeutic|The mobile app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parents are asked to play with their child for 15 minutes 3-4 times per week for 8 weeks.
62553126|NCT06058104|NO_INTERVENTION|Treatment as Usual|Participants in control group will continue their Applied Behavior Analysis therapy as usual for 8 weeks, and then will be able to cross-over to the treatment condition at week 8.
62553127|NCT04251247||Acute aortic dissection|Patients with a diagnosis of acute aortic dissection.
62553128|NCT04251247||Acute pulmonary embolism|Patients with a diagnosis of acute pulmonary embolism
62553129|NCT04251247||Non-cardiac chest pain|Patients with non-cardiac chest pain
62553130|NCT00896974|EXPERIMENTAL|Arm I|Participants receive a single dose of oral 9cUAB30 on day 1.
62374099|NCT00378534|OTHER|Stem Cell Donors|An HLA 6/6 identical family member will be co-enrolled into this study as a stem cell donor. The stem cell collection aspect of this protocol is not investigational.
62374100|NCT05591430|ACTIVE_COMPARATOR|Ganglion Impar Neurolysis|Block of ganglion impar using neurolytic
62374101|NCT05591430|EXPERIMENTAL|Bilateral S2, S3 and S4 Pulsed radiofrequency|Pulsed radiofrequency of S2-S4
62374102|NCT04868331|EXPERIMENTAL|AIS girls|Girls between the ages of 10-16 will be recruited if they have a diagnosis of AIS.
62374103|NCT04868331|ACTIVE_COMPARATOR|Healthy Controls|Healthy adolescent girls matched in age and puberty maturity without spinal deformity
62553131|NCT03833687|EXPERIMENTAL|Profhilo®|"The 1st treatment was performed during the basal visit and repeated after 1 month.~3 mL of Profhilo® for each brachial zone, 1.5 mL for hemiabdomen was injected into the middle-deep dermis by needle (29 G) using a bolus technique called BAP (Bio Aesthetic Point technique); this technique involves a series of 10 micro-wheals on 3 horizontal-levels for each tested areas (3-4-3 injection points respectively for the 1st, the 2nd and the 3rd horizontal-level). The amount of product to be injected was of 0.3 ml for each point."
62745703|NCT05333627|EXPERIMENTAL|5-Week Course|Clients who select the 5-week course will receive access to an ICBT course which consists of four lessons spread across the span of five weeks. The content includes examples that are tailored to students' experiences. Clients have access to diverse additional resources (e.g., managing panic, assertive communication) throughout the course. Clients will receive five weeks of optional therapist support.
62745704|NCT05333627|EXPERIMENTAL|8-Week Course|Clients who select the 8-week course will receive access to an ICBT course which consists of five lessons spread across the span of eight weeks. The content in this course is not student-specific. Clients have access to diverse additional resources (e.g., managing panic, assertive communication) throughout the course. Clients will receive eight weeks of optional therapist support.
62553132|NCT02163265|EXPERIMENTAL|Surgery|Patients suffering from Pectus excavatum and Pectus carinatum will be surgically treated
62553133|NCT00880178||Simvastatin|Participants in the main AIM-HIGH study who are receiving simvastatin.
62553134|NCT00880178||Simvastatin and Extended-Release Niacin|Participants in the main AIM-HIGH study who are receiving simvastatin and extended-release niacin.
62553135|NCT03816475|EXPERIMENTAL|Hypofractionated radiotherapy|5x5 Gy radiotherapy and delayed surgery (after 6-8 weeks)
62553136|NCT00784004|OTHER|Volunteers|Ten healthy volunteers
62374104|NCT05708729|EXPERIMENTAL|Patients with CPSP which is pharmacorefractory and have a good analgesic response to M1-rTMS|"Diagnosed with definite CPSP (Treede-Klit criteria), which is pharmacorefractory (i.e. amitriptyline 75mg/d 4w, lamotrigine 200mg/d 8w and pregabalin 600mg/d resulting in \<50% VAS reduction and/or intolerable side-effects).~A good analgesic response to M1-rTMS is defined as: ≥50% mean 10-d VAS reduction immediately following vs. before active M1-rTMS minus mean 10-d VAS reduction immediately following vs. pre sham M1-rTMS. A good analgesic response gives a high positive predictive value for pain reduction by MCS."
62374105|NCT05708729|EXPERIMENTAL|Patients with CPSP which is pharmacorefractory with less analgesic M1-rTMS response|"Diagnosed with definite CPSP (Treede-Klit criteria), which is pharmacorefractory (i.e. amitriptyline 75mg/d 4w, lamotrigine 200mg/d 8w and pregabalin 600mg/d resulting in \<50% VAS reduction and/or intolerable side-effects).~Patients with less analgesic M1-rTMS response (n≈20) will be 1:1 randomized to either MCS (≈10) or Vc-DBS (n≈10)."
62374106|NCT00529412|NO_INTERVENTION|control|no Seprafilm
62374107|NCT00529412|ACTIVE_COMPARATOR|Seprafilm|
62374108|NCT00987727|EXPERIMENTAL|1|carboxymethylcellulose 0.5% and glycerin 0.9% (OPTIVE® MD)
62374109|NCT00987727|ACTIVE_COMPARATOR|2|sodium hyaluronate 0.18% (VISMED® Multi)
62374110|NCT00644813||Scapular with glenoid neck fractures|Collect outcome and radiological data on patients with scapular fractures involving the glenoid neck (bone joining the shoulder joint and the scapular body) for a period of 1 year.
62374111|NCT02663115||Arm 1|Patients (age 40 - 70 years) with severe therapy-refractory heart failure caused by ischemic or dilatative myocardiopathy with indication for left ventricular assist device (LVAD) therapy
62374112|NCT02663115||Arm 2|Patients (age 40-70 years) with the indication for elective bypass surgery and normal left ventricular function (EF\>50%)
62374113|NCT06409507||high FKBP12 expression|The immunoreactive score (IRS), calculated by multiplying the staining intensity grades by the proportion of positive cells, was used to assess the expression levels of FKBP12. IRS (8-12) represented high expression levels.
62374114|NCT06409507||low FKBP12 expression|The immunoreactive score (IRS), calculated by multiplying the staining intensity grades by the proportion of positive cells, was used to assess the expression levels of FKBP12. IRS (0-7) represented low expression levels.
62374115|NCT03175952||PCI|
62374116|NCT04868162|EXPERIMENTAL|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight
62374117|NCT04144062|ACTIVE_COMPARATOR|Zirconia crowns|
62374118|NCT04144062|ACTIVE_COMPARATOR|CAD/CAM crowns|
62374119|NCT02291328|EXPERIMENTAL|High Brassica|Participants will be asked to consume 3x 84g portions of frozen broccoli, 3x 84g portions of frozen cauliflower, and 3x 300g portions of frozen broccoli and sweet potato soups a week for a total of 2 weeks.
62374120|NCT02291328|EXPERIMENTAL|Low Brassica|Participants will be asked to consume 1x 84g portion of either frozen broccoli or frozen cauliflower in week one, and the remaining 84g portion of Brassica in week two.
62374121|NCT04946760|SHAM_COMPARATOR|Sham Protocol|The sham protocol will consist of examination of the subject's active and passive range of motion in the spine and extremities, in the joints that would have been treated with OMT. The subject will be positioned in sitting, supine and lateral recumbent in a similar manner to that of the OMT group, but without providing an active intervention. To provide a sham for the OMT-WB protocol, subjects will lie supine with the physician's hands under the occiput, palms toward the table, so that the subject's head rests on the dorsal aspect of the physician's hands. The time used in the sham procedures will be approximately 20-25 minutes.
62374122|NCT04946760|EXPERIMENTAL|Whole-Body Protocol|"The whole-body protocol will include all the techniques in the OMT-ND protocol, but will also include techniques focused on the expected cranial dysfunctions \[Rivera-Martinez 2002\]. The OMT-WB protocol will last approximately 25-30 minutes.~The techniques will include:~* Evaluation for strain pattern(s)~* Occipitolatlantal decompression~* Sphenobasilar synchondrosis decompression~* Occipitomastoid suture V-spread~* Temporal bone balancing~* Venous sinus drainage technique"
62374123|NCT04946760|EXPERIMENTAL|Neck-down protocol|"The neck-down protocol takes into consideration previous relevant studies \[Lopez 2011, Wells 1999\]. OMT will be used bilaterally on the following areas with one or more techniques, including myofascial release, articulatory, muscle energy, and balanced ligamentous tension. The OMT-ND protocol will last approximately 15-20 minutes.~* Cervical spine~* Thoracic spine~* Lumbar spine~* Shoulder girdle~* Sacroiliac joint~* Innominates~* Leg muscles (including psoas, piriformis, hamstring, adductors)~* Ankles"
62374124|NCT04722289|EXPERIMENTAL|Together on Diabetes|The intervention consists of five components: Recruitment of peers and peer supporters; training of peer supporters; matching peers and peer supporters; individual face-to-face meetings between peers and peer supporters; and ongoing supervision and network meetings for peer supporters.
62553137|NCT00784004|OTHER|Patients|Sixteen patients with respiratory insufficiency
62553138|NCT01956201|EXPERIMENTAL|Atorvastatin 20mg, Fenofibrate 160mg|Atorvastatin 20mg, Fenofibrate 160mg: po, q.d.
62553139|NCT01956201|ACTIVE_COMPARATOR|Atorvastatin 20mg, Placebo|Atorvastatin 20mg, Placebo for Fenofibrate 160mg po, q.d.
62553140|NCT00710671||Phase 1|Male, HIV+ participants from ages 16-24 who have had sex with another male in the past year and acquired HIV behaviorally. Participants will be drawn from four participating AMTU sites.
62553141|NCT00710671||Phase 2|Male, HIV+ participants from ages 16-24 who have had sex with another male in the past year and acquired HIV behaviorally. Participants will be drawn from all fifteen AMTU sites.
62553142|NCT02498002|ACTIVE_COMPARATOR|Daily Calorie Restriction (DCR)|During the intervention phase, participants randomised to this treatment condition will be asked to reduce their normal energy intake by 25% on a daily basis.
62745705|NCT05459649|EXPERIMENTAL|Cyclosporin plus Steroid|"Cyclosporin: started orally 1 mg/kg/d in two divided doses for 1 week, increased to 1.5 mg/kg/d for 1week, further increased to 2.5 mg/kg/d and then continued for 24 weeks. After 26 weeks of cyclosporin treatment, the dose for patients who achieved complete response was reduced by 25 mg/d every 2 weeks to ensure continuing the lowest dose that achieved the targeted serum level of cyclosporin and a safe platelet count.~Standard regimen of steroid for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week."
62745706|NCT05459649|ACTIVE_COMPARATOR|Standard steroid|Standard regimen for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
62745707|NCT00489671||pre cancerous condition (pancreatitis)|
62745708|NCT02383888|PLACEBO_COMPARATOR|Matching placebo for each dose groups|
62553143|NCT02498002|EXPERIMENTAL|Fasting with Weight Loss (IMF-WL)|During the intervention phase, participants randomised to this treatment condition will be asked to alternate between 24 hour cycles of feeding (consume 150% of normal energy intake) and fasting (no energy intake).
62745709|NCT02383888|EXPERIMENTAL|BI 425809 Active dose group 1|
62745710|NCT02383888|EXPERIMENTAL|BI 425809 Active dose group 2|
62745711|NCT02383888|EXPERIMENTAL|Bi 425809 Active dose group 3|
62553144|NCT02498002|EXPERIMENTAL|Fasting without Weight Loss (IMF-WS)|During the intervention phase, participants randomised to this treatment condition will be asked to alternate between 24 hour cycles of feeding (consume 200% of normal energy intake) and fasting (no energy intake).
62745712|NCT03539822|EXPERIMENTAL|Cabozantinib plus Durvalumab (Gastric & esophageal cancer cohort)|"Cabozantinib~* By mouth (PO) once daily on days 1-28 of every 28 day cycle~* Dose will be 40mg~Durvalumab~\*Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle"
62745713|NCT03539822|EXPERIMENTAL|Cabozantinib plus Durvalumab (Colorectal cancer cohort)|"Cabozantinib~* By mouth (PO) once daily on days 1-28 of every 28 day cycle~* Dose will be 40mg~Durvalumab~\*Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle"
62745714|NCT03539822|EXPERIMENTAL|Cabozantinib plus Durvalumab (Hepatocellular carcinoma cohort)|"Cabozantinib~* By mouth (PO) once daily on days 1-28 of every 28 day cycle~* Dose will be 40mg~Durvalumab~\*Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle"
62374125|NCT04343391|EXPERIMENTAL|Brief Individual Psychotherapy|"Individual brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in secondary care."
62745715|NCT03539822|EXPERIMENTAL|Cabozantinib plus Durvalumab plus Tremelimumab (Hepatocellular carcinoma cohort)|"Cabozantinib~* By mouth (PO) once daily on days 1-28 of every 28 day cycle~* Dose will be 40mg~Durvalumab \*Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle~Tremelimumab~\*Single dose of 300mg intavenous (IV) infusion on day 1 of cycle 1"
62745716|NCT00144989|ACTIVE_COMPARATOR|1|Etoposide and cisplatin after chemoradiotherapy
62745717|NCT00144989|EXPERIMENTAL|2|Irinotecan and cisplatin after chemoradiotherapy
62745718|NCT05086224|OTHER|Hematoma Block|Inject 20 mL of 1% lidocaine without epinephrine into the hematoma site.
62745719|NCT05086224|OTHER|Bier Block|Intravenous administration a maximum lidocaine dose of 3 mg/kg.
62745720|NCT02024360|EXPERIMENTAL|patient navigation|Patient navigator visits home to encourage health eating, active living and parental skill building
62374126|NCT04343391|EXPERIMENTAL|Brief Group Psychotherapy|"Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in primary care."
62374127|NCT04343391|ACTIVE_COMPARATOR|Treatment as usual|Medication provided by a general practitioner.
62374128|NCT03660280|EXPERIMENTAL|Probiotics|
62374129|NCT03660280|PLACEBO_COMPARATOR|Placebo|
62374130|NCT01899040|ACTIVE_COMPARATOR|active device|A standardized active neuromodulation waveform will be used for all active Device patients at all Study sites. The Device will be used twice daily.
62374131|NCT01899040|PLACEBO_COMPARATOR|placebo device|A standardized placebo neuromodulation waveform will be used for all placebo Device patients at all Study sites. The Device will be used twice daily.
62374132|NCT00804128||Breast Cancer patients|Adult, breast cancer patients with confirmed Ductal Carcinoma in Situ (DCIS) or atypical ductal hyperplasia (ADH)
62374133|NCT05165004|EXPERIMENTAL|Kangaroo Mother Care|Researchers contacted the mother a day before applying KMC, and advised her to take shower and abstain from using perfumes before attending to the NICU. On days of KMC application, the researchers asked the mother to remove the upper clothes in a private room and put on an open-front gown and mask. The mother was assisted to sit in a comfortable chair with a soft backrest and footrest to prevent fatigue. Then, the preterm neonate was carefully put naked except for the head and diaper area on the mothers' bare chest with flexed arms and legs as in froglike position, and the head was turned sideways. The researchers wrapped and secured the mother's gown and put a blanket on the neonates' back to ensure neonatal thermal insulation. The mother was instructed to support the neonate's bottom with the right hand while supporting the head and neck with the other hand.
62374134|NCT05165004|EXPERIMENTAL|Hammock Positioning|Researchers made a hammock by using a rectangular cotton cloth with ropes that passed through the circular openings of the incubator and tied on the upper part of it. After one hour of feeding, the preterm neonate was placed in a supine fetal position in the hammock where the head was supported in a neutral midline position by using rolled towel without neck hyperflexion or hyperextension. Moreover, the spine of the preterm neonate was supported while arms and knees were flexed.
62553145|NCT01149408|EXPERIMENTAL|All patients|All participants enrolled.
62553146|NCT03781687|ACTIVE_COMPARATOR|Bilateral|Bilateral ESP block will be performed
62553147|NCT03781687|ACTIVE_COMPARATOR|Unilateral|Unilateral ESP block will be performed
62745721|NCT05894980|EXPERIMENTAL|active tDCS on left DLPFC|Active tDCS applied on left dorsolateral prefrontal cortex \[DLPFC\]
62745722|NCT05894980|ACTIVE_COMPARATOR|active tDCS on right OFC|Active tDCS applied on right orbitofrontal cortex \[OFC\]
62745723|NCT05894980|SHAM_COMPARATOR|sham tDCS|Sham tDCS applied on left dorsolateral prefrontal cortex \[DLPFC\]
62745724|NCT06179134|EXPERIMENTAL|cognitive rehabilitation group|will be treated by GMT for 5 weeks (two hour sessions per week, one day of rest in between).
62745725|NCT06179134|NO_INTERVENTION|wait-list control group|will be given a list cognitive compensatory strategies that they can do on their own to improve their memory.
62745726|NCT01106651|EXPERIMENTAL|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
62745727|NCT01106651|EXPERIMENTAL|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
62553148|NCT01591083|ACTIVE_COMPARATOR|Double oral dose|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days.
62553149|NCT01591083|ACTIVE_COMPARATOR|Regular oral dose|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole once daily for 25 days.
62745728|NCT01106651|PLACEBO_COMPARATOR|Placebo|Each patient will receive matching placebo once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
62745729|NCT02018848|PLACEBO_COMPARATOR|Attention Training Placebo|"Same procedure, stimulus material, frequency and duration as in experimental group.~The only difference: In the placebo group the probe randomly appears at one of the two locations on the screen so as not to train attention in any direction.~Thus, the placebo training sessions are identical to the bias assessment sessions."
62745730|NCT02018848|EXPERIMENTAL|Attention Training Program|"The Attention Training consists of a modified dot-probe task. In this task pairs of pictures (OCD-relevant/neutral) are presented for 500 ms on a computer screen. Next, a probe appears on one of the two former picture locations. Participants have to react to that probe by pressing the corresponding button on the keyboard. One training session takes approximately 10 minutes in which 160 stimulus pairs are shown.~In the experimental group the probe always appears at the location of the neutral picture so as to train attention away from OCD-relevant stimuli.~Participants are asked to complete at least 2 training sessions per week over a period of 5 weeks. The first and last session are bias assessment sessions (see outcome measures), but participants stay blind to this."
62745731|NCT01891617|EXPERIMENTAL|Exercise-high-fat diet|Two bouts of exercise followed by a high-fat meal
62745732|NCT01891617|EXPERIMENTAL|Exercise-high-carbohydrate diet|Two bouts of exercise followed by a high-carbohydrate meal
62745733|NCT01891617|EXPERIMENTAL|Sedentary-high-fat diet|Sedentary trial with two high-fat meals
62745734|NCT01891617|EXPERIMENTAL|Sedentary-high-carbohydrate diet|Sedentary trial with two high-carbohydrate meals
62745735|NCT04183127||ACP|ACPs, either qualified or in training, working in the South Yorkshire and Bassetlaw area.
62745736|NCT03978052|EXPERIMENTAL|EGCG + multimodal intervention|"EGCG + multimodal intervention (n=50) EGCG: (Font-UP, Laboratoires Grand Fontaine), a daily dose of 5-6 mg/kg up to 500 mg/day for 12 months~+ multimodal lifestyle personalized intervention"
62745737|NCT03978052|PLACEBO_COMPARATOR|Placebo + multimodal intervention|"Placebo Font-Up (n=50)~+ multimodal lifestyle personalized intervention"
62745738|NCT03978052|SHAM_COMPARATOR|Control|Healthy lifestyle recommendations (n=50)
62745739|NCT04147897|ACTIVE_COMPARATOR|Internal Facilitation|mHealth specialist is a trained clinician embedded in the clinical team offering the mHealth intervention, FOCUS.
62745740|NCT04147897|ACTIVE_COMPARATOR|External Facilitation|mHealth specialist is a trained clinician external to the clinical team offering the mHealth intervention, FOCUS.
62745741|NCT06296199|EXPERIMENTAL|Intervention|participants will listen to and watch a concert of musicians playing classical music through a VR headset
62745742|NCT06296199|ACTIVE_COMPARATOR|Control|participants will simply listen to the concert through headphones
62745743|NCT03277430|EXPERIMENTAL|Live donor uterus transplantation|Transplantation of uterus from a living donor. Immunosuppression with tacrolimus.
62745744|NCT03277430|EXPERIMENTAL|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor. Immunosuppression with tacrolimus.
62745745|NCT04771923|EXPERIMENTAL|Tranexamic acid|
62745746|NCT04771923|EXPERIMENTAL|Adrenaline|
62553150|NCT01591083|ACTIVE_COMPARATOR|Control group|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole once daily for 25 days.
62745747|NCT05237791|EXPERIMENTAL|magnesium group|magnesium sulphate 50mg/kg (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
62745748|NCT05237791|PLACEBO_COMPARATOR|control group|normal saline 100ml (loading for 10 minutes), 15mg/kg/hr (continuous infusion)
62745749|NCT05247957|EXPERIMENTAL|NKG2DL-specific CAR-NK cells|Experimental: NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7 After preconditioning with chemotherapy, NKG2DL-specific CAR-NK cells will be evaluated
62745750|NCT02030197|ACTIVE_COMPARATOR|CRISP program|educational and socialization program
62745751|NCT02030197|PLACEBO_COMPARATOR|Control Group|no treatment control group
62745752|NCT04244981|EXPERIMENTAL|PCC group|When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 8～15 IU/kg PCC.
62745753|NCT04244981|ACTIVE_COMPARATOR|FFP group|When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 6～10 mL/kg FFP.
62745754|NCT04486430|EXPERIMENTAL|Neu2000KWL 2750mg dose group|Low dose group
62745755|NCT04486430|EXPERIMENTAL|Neu2000KWL 5250mg dose group|Middle dose group
62745756|NCT04486430|EXPERIMENTAL|Neu2000KWL 6000mg dose group|High dose group
62745757|NCT04486430|PLACEBO_COMPARATOR|Placebo|Placebo
62745758|NCT02813096|EXPERIMENTAL|folfox4 chemotherapy regimen|"details in the Intervention Description"
62745759|NCT02813096|PLACEBO_COMPARATOR|Placebo|"details in the Intervention Description"
62745760|NCT05058690|EXPERIMENTAL|Individuals who had a CCTA as part of their clinical care|Approximately 90 individuals who had a CCTA as part of their clinical care (45 identified as having an abnormal FatHealth algorithm calculation and 45 with a normal FatHealth algorithm calculation) will undergo OGTT which is evaluable;
62745761|NCT05058690|EXPERIMENTAL|Individuals who had a chest CT as part of their clinical care|Approximately 90 individuals who had a chest CT as part of their clinical care (45 identified as having an abnormal FatHealth algorithm calculation and 45 with a normal FatHealth algorithm calculation) will undergo OGTT which is evaluable.
62745762|NCT04452071||prepubertal|patients born in 2012-2011
62553151|NCT02346292||1|Patients of both genders aged 40 years and older, smokers, with smoking history more than 10 pack-years, with severe and very severe COPD who were hospitalized with COPD exacerbation
62553152|NCT03857815|EXPERIMENTAL|SBRT in combined with anti-PD-1 antibody|HCC Patients will be received stereotactic body radiation therapy (SBRT) to primary lesions or metastatic lesions, such as liver, lung, bone, brain or lymph nodes and concurrent anti-PD-1 antibody treatment.
62745763|NCT04452071||pubertal|patients born in 2010-2009-2008-2007
62745764|NCT04452071||postpubertal|patients born in 2006-2005-2004-2003
62745765|NCT02022761|EXPERIMENTAL|40 mg Laninamivir octanoate|Dry Powder Inhaler
62745766|NCT02022761|EXPERIMENTAL|80 mg Laninamivir octanoate|Dry Powder Inhaler
62745767|NCT02022761|PLACEBO_COMPARATOR|Matching placebo|Dry Powder Inhaler
62745768|NCT04976673|EXPERIMENTAL|photodynamic therapy side|On one side, the OLP lesion eligible for treatment was subjected to photodynamic therapy in four sessions every 2 days.Using as photosensitizer Methylen blue for 10min the lesion was irradiated with a 650 nm semiconductor laser at a dose of 120 J / cm2
62553153|NCT03399071|EXPERIMENTAL|FLOT plus Avelumab (FLOT-A)|"Avelumab 10mg/kg (or Maximum Administered Dose established in safety run-in) iv infusion over 1 hour.~Followed by FLOT: Oxaliplatin 85mg/m2 iv infusion day 1 over 2 hours, Folinic acid 200mg/m2 iv infusion day 1 over 2 hours, Docetaxel 50mg/m2 iv day 1 over 1 hour, Fluorouracil 2600mg/m2 over 24 hours iv"
62553154|NCT01949402||Haemodialysis|Patients with end-stage renal failure (ESRF) requiring long-term regular haemodialysis.
62553155|NCT01949402||Chronic Obstructive Pulmonary Disease|Patients with a confirmed diagnosis of COPD based on clinical history, obstructive spirometry (FEV1/VC ratio \<70%) and radiology (e.g. hyperexpansion on plain chest radiograph; evidence of small airways disease or emphysema on cross-sectional imaging).
62553156|NCT01949402||Interstitial Lung Disease|Patients with a confirmed diagnosis of ILD based on clinical history and radiology (evidence of ILD on cross-sectional imaging).
62553157|NCT01949402||Control|Age-matched healthy volunteers with no history of cardiac, respiratory or renal disease.
62553158|NCT01262872|EXPERIMENTAL|10PP-HD 1d Group|This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation at Day 0. The 10PP vaccine was administered intramuscularly in the non-dominant deltoid.
62553159|NCT01262872|ACTIVE_COMPARATOR|Prevnar13 1d Group|This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of Prevnar 13™ at Day 0. Prevnar 13™ was administered intramuscularly in the non-dominant deltoid.
62567230|NCT03552978|ACTIVE_COMPARATOR|VA Quitline|After completing an initial 2-hour screening visit that includes a series of questionnaires assessing eligibility criteria and meeting with the study physician to review medical history, participants will be offered nicotine replacement therapy (NRT) at baseline (Week 0), per VA prescribing guidelines, nicotine dependence levels, and participant preference. Participants will also receive weekly proactive telephone sessions through the VA Quitline, a standard of care, proactive telephone quitline available to all veterans for up to eight weeks. Participants will initiate the first call and subsequent calls will be made by the Quitline counselor.
62745769|NCT04976673|ACTIVE_COMPARATOR|Steroid side|on the other side The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
62745770|NCT04342494|EXPERIMENTAL|Enhanced Feedback + Standard Feedback|Participants will receive enhanced feedback from the MyDataHelps study app in addition to standard feedback from the activity tracker.
62745771|NCT04342494|EXPERIMENTAL|Headspace app + Standard Feedback|Participants will receive an app-based intervention in addition to standard feedback from the activity tracker.
62745772|NCT04342494|EXPERIMENTAL|Headspace app + Enhanced Feedback + Standard Feedback|Participants will receive an app-based intervention, enhanced feedback from the MyDataHelps study app, and standard feedback activity tracker.
62745773|NCT04342494|EXPERIMENTAL|SilverCloud app + Standard Feedback|Participants will receive an app-based intervention in addition to standard feedback from the activity tracker.
62745774|NCT04342494|EXPERIMENTAL|SilverCloud app +Enhanced Feedback +Standard Feedback|Participants will receive an app-based intervention, enhanced feedback from the MyDataHelps study app, and standard feedback from the activity tracker.
62745775|NCT00633633|OTHER|Group 1|Usual Care
62745776|NCT00633633|EXPERIMENTAL|Group 2|Exercise Training + Dietary Counseling
62745777|NCT01700998|PLACEBO_COMPARATOR|Placebo|250 ml saline 0.9% for 24 hours in an infusion rate solution of 10.4 ml / hr for 3 days repeated during ICU stay if hypomagnesemia occurs.
62745778|NCT01700998|EXPERIMENTAL|Magnesium|48 mEq Magnesium diluted in 250 ml saline 0.9% for 24 hours in an infusion rate solution of 10.4 ml / hr. Therapy is continued for 3 days and repeated if hypomagnesemia occurs during ICU stay
62745779|NCT04746924|EXPERIMENTAL|Arm A: Tislelizumab plus Ociperlimab|Participants will receive tislelizumab 200 milligrams (mg) intravenously followed by ociperlimab 900 mg intravenously once every 3 weeks.
62745780|NCT04746924|ACTIVE_COMPARATOR|Arm B: Pembrolizumab plus Placebo|Participants will receive pembrolizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.
62745781|NCT04746924|PLACEBO_COMPARATOR|Arm C: Tislelizumab plus Placebo|Participants will receive tislelizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.
62745782|NCT06661395|OTHER|Evaluation Group|Athletes are first assessed with the classic WAnT protocol in a laboratory environment with the same conditions at least 48 hours apart, then they perform the Wingate test (WAnT-VR) with the scenario integrated into the Oculus virtual reality goggles with the same protocol.
62745783|NCT01152918|EXPERIMENTAL|Linkage-to-Care Component: Financial Incentive (FI)|HIV test sites will provide financial incentives to encourage linkage to HIV care.
62745784|NCT01152918|ACTIVE_COMPARATOR|Linkage-to-Care Component: Standard of Care (SOC)|HIV test sites will provide the standard-of-care to their patients for linkage to HIV care.
62745785|NCT01152918|EXPERIMENTAL|Viral Suppression Component: FI|HIV care sites will provide financial incentives to encourage viral load suppression.
62745786|NCT01152918|ACTIVE_COMPARATOR|Viral Suppression Component: SOC|HIV care sites will provide the standard-of-care to their patients for viral load suppression.
62745787|NCT01152918|EXPERIMENTAL|Prevention for Positives Component: Counseling and SOC|Participants will take part in a computerized HIV risk reduction counseling program and receive SOC for HIV infection.
62745788|NCT01152918|ACTIVE_COMPARATOR|Prevention for Positives Component: SOC|Participants will receive SOC for HIV infection.
62745789|NCT04607213|ACTIVE_COMPARATOR|Advancement-rotation approach|
62745790|NCT04607213|EXPERIMENTAL|Straight-line approach|
62745791|NCT02399540|SHAM_COMPARATOR|Sham|Day 1: sham stimulation Day 2: sham stimulation
62745792|NCT02399540|ACTIVE_COMPARATOR|Conventional Paired tDCS|Day 1: sham stimulation Day 2: conventional tDCS
62745793|NCT02399540|ACTIVE_COMPARATOR|Conventional Unpaired tDCS|Day 1: conventional tDCS Day 2: sham stimulation
62745794|NCT02399540|EXPERIMENTAL|Late LTP-like Plasticity tDCS|Day 1: late LTP-like Plasticity tDCS Day 2: sham stimulation
62745795|NCT00939029|ACTIVE_COMPARATOR|Active|2 nicotine patches each at 21 mg/day for a total of 42 mg/day for 8 weeks
62745796|NCT00939029|PLACEBO_COMPARATOR|placebo|2 patches (containing non active ingredients) per day for 8 weeks
62553160|NCT01262872|EXPERIMENTAL|10PP-LD 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its low-dose (LD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, LD formulation, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
62745797|NCT02524275|EXPERIMENTAL|Treatment (docetaxel, capecitabine)|Patients receive docetaxel IV over 1 hour on day 1 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62553161|NCT01262872|EXPERIMENTAL|10PP-HD 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, HD formulation, co-administered with the Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
62745798|NCT04523818|EXPERIMENTAL|Treatment (CXRT, chemotherapy, surgery)|Patients receive CXRT consisting of radiation therapy 5 days a week (Monday through Friday) for 2 weeks (10 treatments) and standard of care chemotherapy consisting of capecitabine PO BID or fluorouracil IV continuous Monday to Friday of each radiation week. About 2 weeks later, patients receive standard of care chemotherapy for up to 2 months in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery 3-8 weeks post-chemotherapy completion.
62745799|NCT05779241|EXPERIMENTAL|LYN-005 Containing 15-mg Risperidone|During the run-in period (Day -7 to Day -1), participants receive Risperdal® (IR risperidone) daily. During the treatment period, participants receive 5 weekly doses of LYN-005 15 mg (Days 1, 8, 15, 22, and 29) and Risperdal 1 mg from Day 1 to Day 7.
62745800|NCT05779241|EXPERIMENTAL|LYN-005 Containing 45-mg Risperidone|During the run-in period (Day -7 to Day -1), participants receive Risperdal® (IR risperidone) daily. During the treatment period participants receive 5 weekly doses of LYN-005 45 mg (Days 1, 8, 15, 22, and 29) and Risperdal 3 mg from Day 1 to Day 7.
62745801|NCT05587231|EXPERIMENTAL|Dextenza 0.4Mg Ophthalmic Insert|Dextenza (a dexamethasone ophthalmic insert manufactured by Ocular Therapeutix) will be inserted immediately after PRK surgery to administer a post surgery steroid regimen. No steroid drops will be adminstered.
62745802|NCT05587231|ACTIVE_COMPARATOR|Topical Fluorometholone|"Standard of care topical Fluorometholone drops will be used by the subjects after PRK Surgery. There will be a taper as follows:~i. 1 drop in each eye QID for 1st week postop. ii. 1 drop in each eye TID for 2nd week postop. iii. 1 drop in each eye BID for 3rd week postop. iv. 1 drop in each eye qD for 4th week postop."
62745803|NCT04779567|EXPERIMENTAL|Acetaminophen|Acetaminophen 1 gr in 100 ml saline 0,9% iv 4 times a day
62745804|NCT04779567|PLACEBO_COMPARATOR|Placebo|100 ml saline 0.9% iv 4 times a day
62745805|NCT05962632|EXPERIMENTAL|Clinical-based preventive platform|applying of Fluoride varnish every 3 months
62745806|NCT05962632|EXPERIMENTAL|Home-based preventive platform|topical remineralizing agent
62745807|NCT05962632|EXPERIMENTAL|E health platform|Mobile application
62745808|NCT05962632|ACTIVE_COMPARATOR|Basic preventive measures|tooth brushing/fluoridated toothpaste over the counter 1450 ppm, interdental cleaning, fluoride rinse OTC
62745809|NCT05870150|EXPERIMENTAL|ST19|Healthy volunteers will be challenged with Salmonella Typhimurium ST19
62745810|NCT05870150|EXPERIMENTAL|ST313|Healthy volunteers will be challenged with Salmonella Typhimurium ST313
62745811|NCT03402204|EXPERIMENTAL|Simvastatin 10 mg|Simvastatin 10 mg
62745812|NCT03402204|EXPERIMENTAL|Simvastatin 40 mg|Simvastatin 40 mg
62745813|NCT03639623|EXPERIMENTAL|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium tablet once daily in the morning 60 minutes before breakfast
62553162|NCT01262872|ACTIVE_COMPARATOR|Synflorix 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of Synflorix™ and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the Synflorix™, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. Synflorix™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
62553163|NCT01262872|ACTIVE_COMPARATOR|Prevnar13 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of Prevnar 13™ and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of Prevnar 13™, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. Prevnar 13™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
62745814|NCT00845039|ACTIVE_COMPARATOR|Cetuximab + Irinotecan|Participants in Treatment Group 1 will receive intravenous infusions of Cetuximab 500 milligrams per square meter (mg/m²) and Irinotecan 180 mg/m².
62553164|NCT01262872|EXPERIMENTAL|10PP-HD 2+1d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received the GSK 2189242A (or 10PP) vaccine, in its high-dose (HD) formulation, and EPI vaccines according to a 2+1 Schedule. That is, subjects received 2 doses of the 10PP vaccine, HD formulation co-administered with Tritanrix™-Hep B/Hib and Polio Sabin™ at 2-4 months of age (at Day 0 and Month 2), followed by a third dose of the same formulation co-administered with M-Vac™, Stamaril™ and Polio Sabin™ at approximately 9 months of age.. The 2nd doses of Tritanrix™-Hep B/Hib and Polio Sabin™ in EPI vaccines were administered without any pneumococcal vaccine at 3 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
62553165|NCT01262872|ACTIVE_COMPARATOR|Synflorix 2+1d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received Synflorix™ and EPI vaccines according to a 2+1 Schedule. That is, subjects received 2 doses of the Synflorix™ co-administered with Tritanrix™-Hep B/Hib and Polio Sabin™ at 2-4 months of age (at Day 0 and Month 2), followed by a third dose of Synflorix™ co-administered with M-Vac™, Stamaril™ and Polio Sabin™ at approximately 9 months of age. The 2nd doses of Tritanrix™-Hep B/Hib and Polio Sabin™ in EPI vaccines were administered without any pneumococcal vaccine at 3 months of age. Synflorix™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
62553166|NCT02908971||Soy based formula|"soy group will include children from the children who had milk allergy, and consumed a soy-based substitute formula for longer than three months and agreed to participate in this study."
62553167|NCT02908971||Healthy control|The control group will included children (at a rate of 2:1) who will be assigned randomly from the healthy population at the initial cohort, and who will agree to participate.
62745815|NCT00845039|EXPERIMENTAL|Cetuximab + IMC-A12 + Irinotecan|Participants in Treatment Group 2 will receive intravenous infusions of Cetuximab 500 mg/m², IMC-A12 10 milligrams/kilogram (mg/kg) and Irinotecan 180 mg/m².
62745816|NCT02810912||Supraglottic airway device-based anesthesia|Investigators planned to enroll 200 cases who will receive scheduled surgery under supraglottic airway device-based general anesthesia.
62553168|NCT03146104|ACTIVE_COMPARATOR|Group P|Maintenance of anesthesia with 100-150mcg/kg/min propofol, O2 and air and FiO2 of 40%
62553169|NCT03146104|ACTIVE_COMPARATOR|Group I|Maintenance of anesthesia with 1 MAC of isoflurane,O2 and air and FiO2 of 40%
62553170|NCT06581900||Sickle cells patients exposed to MEOPA|Sickle cells patients exposed to MEOPA during an hospitalization for a CVO
62553171|NCT02547532||usual COPD|Patients meeting the diagnostic criteria for COPD and without AATD
62553172|NCT02547532||normal smokers|subjects with a history of smoking, without symptoms, without AATD and with normal lung function
62553173|NCT02547532||normal non smokers|subjects without a history of smoking, without symptoms, without AATD and with normal lung function
62553174|NCT02547532||AATD not treated|patients with COPD, with AATD and not on augmentation therapy for AATD
62553175|NCT02547532||AATD treated|patients with COPD, with AATD on augmentation therapy for AATD
62745817|NCT01450696|ACTIVE_COMPARATOR|Capecitabine + Cisplatin + Herceptin (6 mg/kg)|Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 mg/kg q3w as a standard of care from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m\^2 intravenously q3w plus capecitabine 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
62745818|NCT01450696|EXPERIMENTAL|Capecitabine + Cisplatin + Herceptin (10 mg/kg)|Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 10 mg/kg q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m\^2 intravenously q3w plus capecitabine 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
62745819|NCT04251299|EXPERIMENTAL|Single Arm|All participants will receive the 10-month mentored, vegetable gardening intervention
62745820|NCT04278768|EXPERIMENTAL|Emavusertib (CA-4948) dose escalation|Patients receive emavusertib monotherapy BID daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62567231|NCT03758664|EXPERIMENTAL|ICP-192|The initial dose of ICP-192 is 2 mg, QD, and dose escalation schedule may be modified based on the safety and PK from the previous dose. Tentatively seven dose levels will be evaluated.
62374135|NCT05165004|ACTIVE_COMPARATOR|NICU Routine Care|The preterm neonates in the control group received the routine care of the NICU, which entails; encircling the neonate in a fetal position using rolled towel inside the incubator.
62745821|NCT04278768|EXPERIMENTAL|Emavusertib dose escalation + Venetoclax|"The starting dose for emavusertib will be 200 mg BID for 21 days of a 28-day Cycle. Anticipated emavusertib doses will be 200 and 300 mg BID. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.~This arm of the study has been closed to enrollment."
62745822|NCT04278768|EXPERIMENTAL|Emavusertib monotherapy dose expansion|The Expansion phase will begin once the RP2D from Phase 1 Dose Escalation phase has been identified. There will be 3 Cohorts and patients will be assigned to each Cohort based on baseline disease.
62745823|NCT02516098|ACTIVE_COMPARATOR|Hyoscine butylbromide SCT|
62745824|NCT02516098|EXPERIMENTAL|Hyoscine butylbromide|
62745825|NCT04187144|EXPERIMENTAL|Gepotidacin|Participants will be administered oral doses of 1500 milligrams (mg) gepotidacin plus nitrofurantoin matching placebo BID; approximately every 12 hours for 5 days.
62745826|NCT04187144|ACTIVE_COMPARATOR|Nitrofurantoin|Participants will be administered oral doses of 100 mg nitrofurantoin plus gepotidacin matching placebo BID; approximately every 12 hours for 5 days.
62745827|NCT03784131|EXPERIMENTAL|Personalized Tissue Engineered Vein|P-TEV
62745828|NCT03958747|EXPERIMENTAL|Ultrasound|Undergo peripheral nerve ultrasound
62553176|NCT03684577|EXPERIMENTAL|Hypnotherapy for Agoraphobia|A total of 8-12 individual sessions of hypnotherapy over 12 weeks will be delivered. Hypnotherapy consists of hypnotic activation and reinforcement of the patient's own resources, the use of relevant positive and negative experiences from the biography, and the development of positive solution imagery. The central technique is the work with a symptom regression and the resolution of old and actual experiences. Furthermore, formal trance induction, utilisation techniques, indirect techniques such as the use of metaphors or the representative technique, or work with time progression will be used.
62553177|NCT03684577|NO_INTERVENTION|Wait-list control group|Patients in the wait-list control group will receive 8-12 sessions of individual hypnotherapy after a waiting period for 12 weeks.
62553178|NCT04888832|NO_INTERVENTION|Control Group|No change to work requirements or recertification period
62553179|NCT04888832|ACTIVE_COMPARATOR|Intervention Group 1|Standard 6-month recertification period, additional 6-month work requirement exemption
62553180|NCT04888832|ACTIVE_COMPARATOR|Intervention Group 2|Standard 6-month recertification period, additional 12-month work requirement exemption
62553181|NCT04888832|ACTIVE_COMPARATOR|Intervention Group 3|Standard 6-month recertification period, additional 12-month work requirement exemption
62553182|NCT04888832|ACTIVE_COMPARATOR|Intervention Group 4|12-month recertification period (6-month extension), additional 6-month work requirement exemption
62745829|NCT00734604|EXPERIMENTAL|T(OaD)/S(PRN)/T(PRN)|Tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks, 1 week washout, tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks
62745830|NCT00734604|EXPERIMENTAL|T(OaD)/T(PRN)/S(PRN)|Tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks, 1 week washout, tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks
62745831|NCT00734604|EXPERIMENTAL|S(PRN)/T(OaD)/T(PRN)|Sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks, 1 week washout, tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks, 1 week washout, tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks
62745832|NCT00734604|EXPERIMENTAL|S(PRN)/T(PRN)/T(OaD)|Sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks, 1 week washout, tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks, 1 week washout, tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks
62745833|NCT00734604|EXPERIMENTAL|T(PRN)/T(OaD)/S(PRN)|Tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks, 1 week washout, tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks
62745834|NCT00734604|EXPERIMENTAL|T(PRN)/S(PRN)/T(OaD)|Tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks, 1 week washout, tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks
62553183|NCT03803618||Confirmed dengue case|Dengue cases who are 9-14 years old during the dengue mass vaccination program in Cebu with \<5 days history of fever, admitted in the participating hospitals with dengue virus confirmation by RT-PCR
62553184|NCT03803618||Control|Age and sex matched neighborhood controls
62553185|NCT03495375|EXPERIMENTAL|Treatment with a probiotic|Synbiotic2000Forte (SF) it is composed of 3 LAB species known to have anti-inflammatory effects and restoring the intestinal barrier, and 4 fermentable fibers: Pediococcus pentosaceus 5-33:3, Lactobacillus paracasei subsp paracasei 19, and Lactobacillus plantarum 2362 in combination with the following four fermentable fibres: betaglucan, inulin, pectin and resistant starch, a formula that is currently produced by Synbiotic AB, Sweden.
62553186|NCT03495375|PLACEBO_COMPARATOR|Treatment with placebo powder|Placebo will be a non-digestable carbohydrate with similar texture and flavor to the SF also provided by Synbiotic AB, Sweden.
62553187|NCT03309501|EXPERIMENTAL|Tong-Luo-Qu-Tong Plaster group|Intervention: Tong-Luo-Qu-Tong Plaster, daily 1 time, conventional treatment lasted for 14 days as two courses
62553188|NCT03309501|ACTIVE_COMPARATOR|Qi-Zheng-Xiao-Tong Plaster group|Intervention: Qi-Zheng-Xiao-Tong Plaster, daily 1 time, conventional treatment lasted for 14 days as two courses
62553189|NCT05638191||Experiemental: Surgical Arm|Individuals in this group will receive nerve transfer surgery 6 - 9 months post cervical spine injury and be observed for two years post-operatively.
62553190|NCT05638191||Control: Non-surgical|Individuals in this group will not have undergone nerve transfer surgery. They will be observed for two years post injury while receiving standard of care including medical and rehabilitation. We want to reinforce that individuals are not being randomized to surgery versus non-surgery. Rather individuals this group will either have made the decision not to undergo surgery, independent their participation in this study.
62567232|NCT06576804|EXPERIMENTAL|Eccentric cycling training|Moderate to high intensity cycling training in eccentric type
62745835|NCT05192928|EXPERIMENTAL|All Patients using the Ripple Health Smart Pill Cap|In this single-arm trial, all patients will be using the Ripple Health Smart Pill Cap as a method of medication administration
62745836|NCT01027312||Glaucoma Patients|Glaucoma patients covering the entire range of visual field loss from none to advanced.
62745837|NCT01027312||Control Group|Aged matched people with no eye diseases.
62374136|NCT05155410|EXPERIMENTAL|Experimental|"Participants will consume 15 g of an active oral exogenous ketone monoester supplement 15 minutes prior to each meal of the day for a 14-day period.~Pre-intervention (baseline) and post-intervention measurements will be obtained before and immediately after the 14-day period.~All meals will be provided throughout the supplementation period Participants will wear a continuous glucose monitor for the first 10 consecutive days during the supplementation period."
62553191|NCT05671588|EXPERIMENTAL|Controlled combined program (aerobic-resistant)|Patients randomized into the Experimental arm will undergo controlled exercise on a cycling ergometer in combination with strength training on a multifunctional fitness device for 1-hour duration, twice a week for one month, and once a week for the next month (12 therapies in total).
62553192|NCT05671588|ACTIVE_COMPARATOR|Conventional rehabilitation|Patients randomized into this study arm will undergo conventional rehabilitation.
62374137|NCT05155410|PLACEBO_COMPARATOR|Placebo|Participants will consume a flavor-matched placebo drink and undergo the same procedures described in the Experimental Arm
62553193|NCT05671588|NO_INTERVENTION|No intervention|Patients randomized into this study arm will undergo no intervention and will serve as the control group.
62374138|NCT05804071|ACTIVE_COMPARATOR|150mg QD|Each subject took vitamin C 1 tablet and 150mg polysaccharide iron complex at 20:00 ± 1 hour every day.
62553194|NCT02107924||APPI of TKR-Stimulan|Surgery Stimulan beads 2.4 G Tobramycin 2.0 G Vancomycin
62553195|NCT02107924||APPI of TKR-historical|Surgery 2.4 G Tobramycin 2.0 G Vancomycin
62553196|NCT01753180|EXPERIMENTAL|collagenase|
62553197|NCT01753180|PLACEBO_COMPARATOR|saline|
62745838|NCT01734954|EXPERIMENTAL|Sciatic nerve blockade at bifurcation|Ultrasound-guided block at the bifurcation of the sciatic nerve
62745839|NCT01734954|EXPERIMENTAL|Sciatic block 2 cm beyond bifurcation|Ultrasound-guided block of the sciatic nerve 2 cm beyond of the bifurcation
62745840|NCT05618340|EXPERIMENTAL|Single group target value method|This trial is a prospective, multicenter, single-group target value method study. All subjects are treated uniformly with the pulse ablation system provided in this protocol for paroxysmal AF, and the test results for the main indicators are statistically compared with the target values, a widely accepted standard in professional medicine, and the test results are considered to be attained if the one-sided 95% confidence interval for the test results is not lower than the target values.
62745841|NCT01249781||resilience in caregivers whose child with ALL|
62745842|NCT02099877||Nulliparous requesting epidural|"Nulliparous parturients ≥ 37 weeks gestation, with ASA I or II, with an uncomplicated course of singleton vertex pregnancy requesting epidural analgesia for pain relief will be included.~When the patient requests analgesia, cervical dilatation will be verified by the obstetric resident/attending. Then epidural analgesia will be initiated with a test dose of 3mL of 2% lidocaine and epinephrine 15 µg and a dose of fentanyl 100 µg diluted to a total volume of 10 mL with preservative- free normal saline. Before placement of the epidural, venous blood (2 mL) will be drawn into special tubes. Genotyping of OPRM1: p.118A/G will be also performed."
62374139|NCT05804071|ACTIVE_COMPARATOR|150mg QOD|Each subject took vitamin C 1 tablet and 150mg polysaccharide iron complex at 20:00 ± 1 hour every other day.
62374140|NCT05804071|ACTIVE_COMPARATOR|300mg QD|Each subject took vitamin C 1 tablet and 300mg polysaccharide iron complex at 20:00 ± 1 hour every day.
62553198|NCT04703595||50 non-smoking patients with chronic cough|50 non-smoking patients aged between 30 and 99 years with chronic and / or refractory cough as the only manifestation or associated with gastroesophageal reflux
62374141|NCT05804071|ACTIVE_COMPARATOR|300mg QOD|Each subject took vitamin C 1 tablet and 300mg polysaccharide iron complex at 20:00 ± 1 hour every other day.
62553199|NCT01597973|ACTIVE_COMPARATOR|colistin and meropenem|
62553200|NCT01597973|ACTIVE_COMPARATOR|colistin and placebo|
62374142|NCT05804071|ACTIVE_COMPARATOR|Intravenous iron supplement|Each subject was given intravenous iron supplements according to the instructions
62374143|NCT04272762|ACTIVE_COMPARATOR|Ablation|pulmonary vein isolation
62374144|NCT04272762|PLACEBO_COMPARATOR|Placebo|placebo procedure
62553201|NCT03209843|OTHER|Successfully CTO recanalization|
62553202|NCT03530839|EXPERIMENTAL|Arthrodesis|Arthrodesis of the proximal interphalangeal joint by using a threaded K-wire
62553203|NCT03530839|ACTIVE_COMPARATOR|Resection arthroplasty|Resection arthroplasty of the proximal interphalangeal joint using a normal K-wire
62553204|NCT05076357|EXPERIMENTAL|Only diet group|Dietary energy prescription at -30% of Energy requirements (50% carbohydrate; 30% fat; 20% protein) during 8 weeks. Follow up with a registered dietitian.
62553205|NCT05076357|EXPERIMENTAL|Only cold exposure group|No dietary intervention. Visit at laboratory every 2nd day during the 8-week intervention to undergo the cold exposure as follows: 2 weeks of exposure at 18 degrees, 2 weeks of exposure at 14 degrees and 4 weeks of 10 degrees of exposure during 90 min.
62553206|NCT05076357|EXPERIMENTAL|Combined diet + cold exposure group|Dietary energy prescription at -30% of Energy requirements (50% carbohydrate; 30% fat; 20% protein). Follow up with a registered dietitian. Visit at laboratory every 2nd day during the 8-week intervention to undergo the cold exposure as follows: 2 weeks of exposure at 18 degrees, 2 weeks of exposure at 14 degrees and 4 weeks of 10 degrees of exposure during during 90 min.
62745843|NCT06662084||Temporary mechanical circulatory support group|Male and female patients presenting a refractory cardiogenic shock, requiring temporary mechanical circulatory support (tMCS), with either the use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) or a micro-axial pump device (Impella® CP).
62745844|NCT06662084||Control group|Male and female patients in cardiogenic shock according to the SCAI (Society for Cardiovascular Angiography and Interventions) ESC (European Society of Cardiology) definition and not requiring or not eligible to temporary mechanical circulatory support (tMCS). (e.g. ECMO, Impella®, intra-aortic balloon pump)
62745845|NCT03415451|EXPERIMENTAL|Fiberscope-Guided Nasogastric tube|Fiberscope-Guided Nasogastric tube insertion
62745846|NCT04771416|EXPERIMENTAL|Part 1: Dose Escalation Cohorts designed to identify the optimal dose of PBKR03|"Cohort 1: Subjects aged \>4 to \<9 months Drug: PBKR03 1.5 x 10\^11 GC/g\* Single dose of PBKR03, via intra cisterna magna~Cohort 2: Subjects aged \>4 to \<9 months Drug: PBKR03 5.0 x 10\^11 GC/g\* Single dose of PBKR03, via intra cisterna magna~Cohort 3: Subjects aged \>1 to \<4 months Drug: PBKR03 1.5 x 10\^11 GC/g\* Single dose of PBKR03, via intra cisterna magna~Cohort 4: Subjects aged \>1 to \<4 months Drug: PBKR03 5.0 x 10\^11 GC/g\* Single dose of PBKR03, via intra cisterna magna~\*GC/g: genome copiesy per gram of estimated brain weight"
62745847|NCT04771416|EXPERIMENTAL|Part 2: Expansion Cohort designed to confirm the safety and efficacy of PBKR03|"Cohort 5: Subjects aged \>1 to \<9 months Drug: PBKR03 Single dose of PBKR03, via intra cisterna magna Dose to be used for the confirmatory cohorts in Part 2 will be defined after a review of data from Part 1.~\*GC/g: genome copiesy per gram of estimated brain weight"
62745848|NCT00886886|OTHER|Reboxetine, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
62374145|NCT01652222|EXPERIMENTAL|CONEM-BETA + socio-educational training|"Caregivers will receive 4 socioeducational training sessions during an 8 week period. These sessions will focus on the description and process of the Alzheimer's disease (AD), and will also provide to the caregivers resources and strategies to cope with AD. During the last 4 weeks, they will also systematically play with the patient at home with the CONEM-BETA game.~After that period, caregivers will use the game based on their preference and frequence during a period of 6 more weeks."
62374146|NCT01652222|ACTIVE_COMPARATOR|Socio-educational training only|Caregivers will receive the same 4 socioeducational training sessions as the experimental group, during an 8 week period.
62553207|NCT02180048|ACTIVE_COMPARATOR|400 mg of caffeine/day (Two 200mg pills/day)|One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
62553208|NCT02180048|ACTIVE_COMPARATOR|200 mg of caffeine/day (One 200mg pill and one placebo pill)|This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
62745849|NCT03178123|EXPERIMENTAL|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs for 1 year (27 treatments)
62553209|NCT02180048|PLACEBO_COMPARATOR|Two placebo pills/day|This arm will have participants consume two placebo pills each day.
62553210|NCT03345420|EXPERIMENTAL|Treatment|Within 12 weeks after breast conserving surgery, patients undergo hypofractionated radiation therapy for 9 fractions over 2 weeks.
62553211|NCT03251001|ACTIVE_COMPARATOR|Control|Sites receiving a free gingival graft
62553212|NCT03251001|EXPERIMENTAL|Device - Acellular dermal matrix|Sites receiving acellular dermal matrix
62553213|NCT06551025||Inactive|Individuals with physical activity levels of 0-600 METs according to the results of the International Physical Activity Scale (IPAQ).
62553214|NCT06551025||Minimally/Heavily active|Individuals with physical activity levels of 600-3000 METs or 3000 METs and above according to the results of the International Physical Activity Scale (IPAQ).
62553215|NCT00494702|EXPERIMENTAL|LOX|Low saturation group of premature infants that will be kept within preset limits of 85-89%
62553216|NCT00494702|ACTIVE_COMPARATOR|HOX|HOX group of premature infants will be kept within preset saturation limits of 90-93%
62553217|NCT06280521|OTHER|Women with autistic spectrum disorder|
62745850|NCT03178123|ACTIVE_COMPARATOR|high-dose recombinant interferon a-2B|Patients receive 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5. Treatment repeats weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.Then patients receive 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
62745851|NCT03781895|PLACEBO_COMPARATOR|A0|"A0- On day 0,before intervention placebo,~* Microcrystalline Cellulose (303.8gm)~* Butylated Hydroxy Toluene (0.2mg)~* Magnesium Stearate (3mg)~* Gelatin Capsule Shell (1mg)~weekly,orally,for 90days"
62745852|NCT03781895|PLACEBO_COMPARATOR|A90|"A90- On day 90,after intervention placebo,~* Microcrystalline Cellulose (303.8gm)~* Butylated Hydroxy Toluene (0.2mg)~* Magnesium Stearate (3mg)~* Gelatin Capsule Shell (1mg)~weekly,orally,for 90days"
62745853|NCT03781895|ACTIVE_COMPARATOR|B0|"B0- On day 0,before intervention cholecalciferol,~* Cholecalciferol (40,000IU)~* Microcrystalline Cellulose (58.1 gm)~* Butylated Hydroxy Toluene ( 0.2mg)~* Magnesium Stearate (3mg)~* Gelatin Capsule Shell (1mg)~80.000IU/week,orally,for 90 days"
62745854|NCT03781895|ACTIVE_COMPARATOR|B90|"B90- On day 90,after intervention cholecalciferol,~* Cholecalciferol (40,000IU)~* Microcrystalline Cellulose (58.1 gm)~* Butylated Hydroxy Toluene ( 0.2mg)~* Magnesium Stearate (3mg)~* Gelatin Capsule Shell (1mg)~80.000IU/week,orally,for 90 days"
62553218|NCT06280521|OTHER|Men with autistic spectrum disorder|
62553219|NCT06280521|OTHER|Women without autistic spectrum disorder|
62553220|NCT06280521|OTHER|Men without autistic spectrum disorder|
62553221|NCT05602324|EXPERIMENTAL|Lauric Acid and Berberine|Participants in this arm of the trial will receive 15 ml lauric acid and 1000 mg berberine daily (via feed tube) for the duration of time that they are receiving enteral feeding, up to a maximum time of 14 days
62553222|NCT05602324|NO_INTERVENTION|No-intervention|participants in this arm will receive no additional intervention, beyond standard of care
62553223|NCT02498392|PLACEBO_COMPARATOR|Responders-Placebo|Participants who responded in the placebo lead-in period will be administered with Matching Placebo orally.
62553224|NCT02498392|EXPERIMENTAL|Responders-JNJ-42165279|Participants who responded in the placebo lead-in period will be administered with JNJ-42165279 orally at a dose of 25 milligrams (mg) tablets once daily for 6 weeks.
62553225|NCT02498392|PLACEBO_COMPARATOR|Non Responders-Placebo|Participants who did not respond in the placebo lead-in period will be administered with Matching Placebo orally.
62553226|NCT02498392|EXPERIMENTAL|Non Responders-JNJ-42165279|Participants who did not respond in the placebo lead-in period will be administered with JNJ-42165279 orally at a dose of 25 mg tablets once daily for 6 weeks.
62745855|NCT06375473||prospective observational study|Irinotecan liposome II combination therapy regimen
62745856|NCT06375473||Retrospective observational study|Irinotecan liposome II combination therapy regimen
62374147|NCT01652222|NO_INTERVENTION|Control|Caregivers of this group will behave with his/her patient during the trial as they have been doing so far, but will receive no intervention
62374148|NCT04634318|ACTIVE_COMPARATOR|Respiratory rehabilitation program group (RR).|Post-COVID-19 patients carrying out a respiratory rehabilitation program (RR).
62374149|NCT04634318|EXPERIMENTAL|Respiratory tele-rehabilitation program group (TRR).|Post-COVID-19 patients carrying out a respiratory tele-rehabilitation program (TRR).
62374150|NCT01686347|OTHER|fetal cardiac rhythm abnormally|patient at term, in spontanous labor with fetal cardiac rythm abnormally which occurs 30 minutes after the epidural analgesia induction
62374151|NCT01686347|OTHER|control group|patient at term, spontaneous labor, without any fetal cardiac rhythm abnormalies during the 30 minutes after the epidural analgesia induction
62374152|NCT03739099|ACTIVE_COMPARATOR|Closed-loop insulin delivery 24/7, day and night|Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm
62374153|NCT03739099|OTHER|Closed-loop insulin delivery 7/7, dinner and night|Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm
62374154|NCT06425406|EXPERIMENTAL|Group HFNC|In the HFNC group, the mask ventilation was performed after the patient lost spontaneous breathing until the end-tidal oxygen concentration reached 90 %. The mask was removed and HFNC ( AIRVO2, Fisher Parker Medical Company, Auckland, New Zealand ) was used to record the patient 's safe apnea time. After the end of positive pressure ventilation, intubation or laryngeal mask placement was performed after the end-tidal oxygen concentration reached 90 % or more. During the intubation or placement of the laryngeal mask, the HFNC nasal catheter was kept in the patient 's nose for apnea oxygenation.
62374155|NCT06425406|NO_INTERVENTION|Group control|No intervention
62553227|NCT01117974|EXPERIMENTAL|Liposuction|
62374156|NCT05829915|EXPERIMENTAL|Intervention Group|Subjects in the intervention group will perform 24 sessions of multisensory training using ROXPro© system (A-Champs)
62374157|NCT05829915|ACTIVE_COMPARATOR|Control Group|Subjects in the Control Group will not perform 24 sessions of multisensory training and they will keep doing the current therapy
62374158|NCT05601518||Single Group Assignment|
62374159|NCT05859581|EXPERIMENTAL|Suspected positive RPRM on MRI|
62553228|NCT00451204|ACTIVE_COMPARATOR|Estriol plus Copaxone injections QD|Estriol Capsules (daily) plus Copaxone injections (daily). Progestin capsules given for 2 weeks every 3 months to avoid unopposed estrogens.
62553229|NCT00451204|PLACEBO_COMPARATOR|Placebo plus Copaxone injections QD|Placebo Capsules (daily) plus Copaxone injections (daily). A second placebo capsule given for 2 weeks every 3 months.
62553230|NCT05528978||Inner Engineering Intervention|The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.
62374160|NCT05384990|EXPERIMENTAL|Stochastic Resonance stimulation|During this condition, participants will perform postural transitions like sit to stand, gait initiation, sit to walk and Timed Up and Go test while receiving stochastic resonance stimulation on legs and hip.
62374161|NCT05384990|NO_INTERVENTION|No Stochastic Resonance stimulation|During this condition, participants will perform postural transitions like sit to stand, gait initiation, sit to walk and Timed Up and Go test without receiving any electrical stimulation.
62374162|NCT05462691|EXPERIMENTAL|Patients without tuberosity reconstruction|patients undergoing reverse shoulder arthroplasty because a proximal humeral fracture with suturing of the tuberosities
62374163|NCT05462691|ACTIVE_COMPARATOR|Patients with tuberosity reconstruction|patients undergoing reverse shoulder arthroplasty because a proximal humeral fracture without suturing of the tuberosities
62553231|NCT02581605||Osteotomy Arm|Patients due to undergo an osteotomy around the knee. To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
62553232|NCT02581605||Partial Knee Replacement Arm|Patients due to undergo a partial knee replacement. To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
62553233|NCT01268527|EXPERIMENTAL|Cohort 1|Three concentrations of E6201 topical gel (0.03%, 0.1%, and 0.2%) and active comparator, calcipotriene cream (0.005%), were applied once daily for 12 days to specific test fields determined at Baseline. The 3 concentrations of E6201 gel were dosed first in Cohort 1 to establish the safety and tolerability prior to dosing in Cohort 2.
62374164|NCT05291741|ACTIVE_COMPARATOR|Very Low Calorie Diet (VLCD)|VLCD
62374165|NCT05291741|PLACEBO_COMPARATOR|Standard care|Standard care
62374166|NCT05299502|EXPERIMENTAL|Nutritional Intervention|Intervention promoting healthy eating by a Registered Dietitian.
62374167|NCT05299502|NO_INTERVENTION|Standard Care|Women will have their usual medical pregnancy follow-ups by their MDs without access to nutritional care.
62374168|NCT06263400|EXPERIMENTAL|Psychoeducation|Experimental:Experimental group ın the first meeting with the patients and their caregivers in the experimental group, information about the training was given, information about the patient was obtained, and training days were determined.Structured education and follow-up In the study, we hypothesized that the caregiver psychoeducation program (consisting of six sessions over a 3-week period) would improve depressive symptoms in depressed patients, increase recovery levels, reduce the caregiver's burden, and reduce emotional expression levels in the family.Structured education and follow-up In the study, we hypothesized that the caregiver psychoeducation program (consisting of six sessions over a 3-week period) would improve depressive symptoms in depressed patients, increase recovery levels, reduce the caregiver's burden, and reduce emotional expression levels in the family.
62374169|NCT06263400|NO_INTERVENTION|Control group|The control group continued to receive the routine care
62553234|NCT01268527|EXPERIMENTAL|Cohort 2|Three concentrations of E6201 topical gel (0.005%, 0.01%, and 0.05%) and active comparator, calcipotriene cream (0.005%), were applied once daily for 12 days to specific test fields determined at Baseline. Cohort 2 participants were not dosed until all participants in Cohort 1 completed treatment and safety data were collected and evaluated.
62553235|NCT00987532|EXPERIMENTAL|parent intervention plus gym lessons|Parent-focused participatory preschool intervention in addition to twice weekly gym lessons over 6 months. The participatory intervention includes parents, teachers and children.
62553236|NCT00987532|ACTIVE_COMPARATOR|gym lessons only|Twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
62553237|NCT03710980||Healthy Adult Volunteer|
62745857|NCT03213938|EXPERIMENTAL|Acupuncture|The participants in the acupuncture group will receive treatment that consists of 20 acupuncture sessions over an 8-week (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks) period after baseline, each for 30 minutes. Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Sanyinjiao (SP6), Zhongliao (BL33), Shenshu (BL23), and Huiyang (BL35), were selected as acupoints protocol. SP6 is on the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus; BL32 is in the sacral region, in the second posterior sacral foramen; BL33 is in the third posterior sacral foramen; BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
62745858|NCT03213938|SHAM_COMPARATOR|Sham acupuncture|The participants in the sham acupuncture group will receive shallow needling at bilateral sham BL23, BL33, BL35 and SP6. The protocol includes the same duration and frequency of sessions as for the acupuncture treatment, but the treatment was delivered superficially at non-acupuncture points 10-15 mm to the lateral of corresponding acupuncture and not above a meridian line (15mm to BL23, BL33 and BL35; 10mm to SP6). The Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be inserted with a depth of 2-3 mm without any manipulation.
62745859|NCT04990063|EXPERIMENTAL|adoptive TKC transfer combined with chemotherapy|NK cells and γδT cells are isolated from the patients' PBMCs obtained before standard chemotherapy and then co-cultured ex-vivo. Patients will receive multiple TKC treatments under administration, 3 weeks/cycle. The first infusion will be conducted in 7-10 days after chemotherapy and is assessed by the investigators. TKC cells are transfused to patients in a dosage escalated manner. Dose escalation starts at 1×10\^8 cells/kg (based on the whole body weight). After the safety assurance of the initial administration, the next course, up to 8 courses, is resumed and the dose maybe increased subsequently at the discretion of the investigators, or reduced for safety reason.
62745860|NCT05984407||patients with vasoplegic shock|Application of cytokine hemadsorption therapy in patients with vasoplegic shock without microbiological findings
62745861|NCT00867802|EXPERIMENTAL|Mindfulness- Based Stress Reduction: Active Comparator|Mindfulness-Based Stress Reduction program
62745862|NCT00079391|EXPERIMENTAL|allogeneic hematopoietic SCT|allogeneic hematopoietic stem cell transplantation (SCT) using Nexell Isolex system
62745863|NCT02213848|EXPERIMENTAL|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
62745864|NCT02213848|PLACEBO_COMPARATOR|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
62745865|NCT01668628||Incident PD patients|First treatment for end stage of renal disease (ESRD) by any peritoneal dialysis modality within 30 days prior to or following enrollment (patients may be enrolled prior to commencing first treatment if there is clear indication that the treatment modality is continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dilaysis (APD) and they consent in advance to enter the study) and patients who don't have any experience of dialysis treatment before this study
62745866|NCT01668628||Prevalent PD patients|Prevalent peritoneal dialysis(PD) patients who are under peritoneal dialysis treatment more than 6 months
62745867|NCT01668628||Prevalent HD patients|Prevalent hemodialysis(HD) patients who are under hemodialysis treatment more than 6 months
62745868|NCT02225847|ACTIVE_COMPARATOR|Control|Members of this group will continue with their daily life activities and will not receive gardening intervention. The control group will be given a set of psychometric assessments for health and quality of life evaluations and undergo a Functional Magnetic Resonance Imaging (fMRI) brain scan, followed by a second round of psychometric assessments and a fMRI brain scan administered seven to eight weeks after the initial baseline psychometric assessments and fMRI brain scan.
62553238|NCT01737073|EXPERIMENTAL|IVR self management|cognitive behavioral based self management training for chronic pain delivered by interactive voice response (IVR)
62553239|NCT01737073|EXPERIMENTAL|Opioid monitoring|monthly interactive voice response (IVR) monitoring of prescription opioid use with feedback to the prescribing physician
62553240|NCT01737073|EXPERIMENTAL|IVR self management plus opioid monitoring|Cognitive behavioral based self management training for chronic pain delivered by IVR plus monthly IVR monitoring of prescription opioid use with feedback to the prescribing physician
62553241|NCT01737073|OTHER|Enhanced usual care|Weekly automated wellness tips via IVR
62553242|NCT04355260|EXPERIMENTAL|Hypertrophic Obstructive Cardiomyopathy|
62553243|NCT05900778|EXPERIMENTAL|HABIT-ILE|Hand and arm bimanuel intensive therapy including lowers extremities
62553244|NCT05900778|ACTIVE_COMPARATOR|Conventional intervention|Conventional physical and occupational therapy
62374170|NCT00823186|EXPERIMENTAL|Phyxol,cancer,intra vascular flow|weekly cisplatin plus paclitaxel for 3 cycles as neoadjuvant chemotherapy (NAC) for FIGO IB2 and bulky IIA, squamous cell cervical cancer followed by radical hysterectomy and pelvic lymphedectomy
62553245|NCT04771559|OTHER|Cancer patients|Covid-19 antibody levels of patients will be measured
62553246|NCT04771559|OTHER|Healthy control|Covid-19 antibody levels of healthy controls will be measured
62553247|NCT02961998|EXPERIMENTAL|Celecoxib group|Patients were treated with sorafenib taking capsules celecoxib (Celebrex) at the same time, 200mg/day, last 6 months
62553248|NCT02961998|ACTIVE_COMPARATOR|Control group|Patients take sorafenib only.
62745869|NCT02225847|EXPERIMENTAL|Gardening|Members of this group will be given a set of psychometric assessments for health and quality of life evaluations and a Functional Magnetic Resonance Imaging (fMRI) brain scan prior to receiving the gardening activities intervention. The gardening intervention will consist of twice weekly group sessions lasting 60 minutes in duration that will take place in a greenhouse. The duration of the experimental intervention will be six weeks for a total of 12 individual gardening activity sessions. Following the completion of the gardening intervention, a second round of psychometric assessments and a fMRI brain scan will be administered seven to eight weeks after the initial baseline psychometric assessments and fMRI brain scan.
62745870|NCT05279924|EXPERIMENTAL|Ivoirian Boys with severe Hemophilia A treated with Emicizumab|All Ivoirian boys with severe Hemophilia A (with and without inhibitors) on prophylaxis with Emicizumab
62745871|NCT06257667|ACTIVE_COMPARATOR|"OptiflowTM"|"Patients treated with high flow nasal cannula, using the OptiflowTM Nasal Cannula"
62745872|NCT06257667|EXPERIMENTAL|"Optiflow+DuetTM"|"Patients treated with high flow nasal cannula using the Optiflow+DuetTM Nasal Cannula"
62745873|NCT00925106|ACTIVE_COMPARATOR|Celebrex capsule|Commercial capsule
62745874|NCT00925106|EXPERIMENTAL|D1|Test formulation D1
62745875|NCT00925106|EXPERIMENTAL|D2|Test formulation D2
62745876|NCT00925106|EXPERIMENTAL|D3|Test formulation D3
62745877|NCT00442442|NO_INTERVENTION|1|No treatment control
62745878|NCT00442442|ACTIVE_COMPARATOR|2|LLIN Nets
62374171|NCT04971980|EXPERIMENTAL|hUC-MSC infusion (BC-U001)|Cohort 1: Low-dose BC-U001 Cohort 2: Medium-dose BC-U001 Cohort 3: High-dose BC-U001
62374172|NCT03908268|ACTIVE_COMPARATOR|CLC Program|Half of the mother-child dyads who are enrolled in the study will be randomly assigned to the Standard Children's Learning Center Program group.
62374173|NCT03908268|EXPERIMENTAL|FNI plus CLC Program|Half of the mother-child dyads who are enrolled in the study will be randomly assigned to the Family Nurture Intervention plus Standard CLC Program group.
62374174|NCT03564327||Patients with sinus rhythm|
62374175|NCT03564327||patients with atrial fibrillation|
62374176|NCT04587973|ACTIVE_COMPARATOR|Group Dexmedetomidine|Ropivacaine plus dexmedetomidine group - Preoperative bilateral erector spinae plane block with ropivacaine 0,375% (40 ml) plus dexmedetomidine 1 mcg/kg
62374177|NCT04587973|ACTIVE_COMPARATOR|Group Ropivacaine|Plain ropivacaine group - Preoperative bilateral erector spinae plane block with ropivacaine 0,375% (40 ml)
62374178|NCT04587973|PLACEBO_COMPARATOR|Group Control|Control group - Preoperative bilateral erector spinae plane block with N/S 0,9% (40 ml)
62374179|NCT00852098|ACTIVE_COMPARATOR|1|dividing short gastric vessels
62374180|NCT00852098|ACTIVE_COMPARATOR|2|non-dividing short gastric vessels
62374181|NCT03402360|EXPERIMENTAL|Virtual Reality rehabilitation group|The Virtual Reality group will perform upper extremity motor rehabilitation and neurocognitive rehabilitation based on virtual reality training.
62374182|NCT03402360|ACTIVE_COMPARATOR|Control group|The Control group will perform the same motor and neurocognitive rehabilitation but with the virtual reality turned off.
62745879|NCT00442442|EXPERIMENTAL|3|Mosquito Coils
62745880|NCT00442442|EXPERIMENTAL|4|Mosquito coils \& LLIN
62745881|NCT05354895|EXPERIMENTAL|Intervention: Transcranial Infrared Laser Stimulation (TILS)|Participants receive 10 minutes of TILS treatment to the right prefrontal cortex once a week for 6 weeks. TILS will use an FDA-cleared 1064-nm laser (CG-5000, Cell Gen Therapeutics, LLC, Dallas, TX). The irradiance will be 0.25 W/cm2, and fluence, 60 J/cm2.
62374183|NCT05399836|EXPERIMENTAL|Larger portions|the main meal component (lunch/dinner) served to participants in the laboratory, reflecting 100% portion. All other foods are identical across conditions (e.g. sides, seconds, dessert, snacks).
62374184|NCT05399836|EXPERIMENTAL|Smaller portions|the main meal component (lunch/dinner) served to participants in the laboratory, reflecting 66% portion (i.e. reduced portion size). All other foods are identical across conditions (e.g. sides, seconds, dessert, snacks).
62374185|NCT05841069|ACTIVE_COMPARATOR|Short conservative treatment|Conservative treatment will be performed within no more than 24 h. Surgery will be performed in the absence of contrast in colon according to X-ray examination and if signs of clinical degradation will appear.
62553249|NCT05823857|EXPERIMENTAL|Aquatic Therapy|Aquatic exercise program including trunk stabilization, upper body, lower body strengthening and flexibility exercises and aerobic conditioning. Supervised 10-week program, 2 times a week.
62745882|NCT05851079||1. Stratified experimental design|Relying on the project's clinical multicenter to recruit patients for routine HPV screening in hospital outpatient clinics, for HPV high-risk type-positive subjects. The subjects with positive HPV types will continue to undergo TCT and colposcopic biopsy, and the remaining specimens after routine screening will be collected for high-throughput HPV typing and integrated assays. The sensitivity and accuracy of high-throughput HPV typing and integrated assays were compared with conventional screening methods.
62745883|NCT05851079||2. Parallel experimental design|A multicenter cohort of 12,000 permanent residents was recruited for routine cervical cancer screening(HPV+TCT combined screening), and the remaining specimens were collected after the conventional screening to test the indexes of high-throughput HPV typing and integrated assays. The sensitivity and accuracy of high-throughput HPV typing and integrated assays were compared with conventional screening methods.
62745884|NCT05851079||3. Prospective cohort study design:|Based on a multicenter cohort of cervical cancer screening based on the project group, 3000 cervical cancer patients with HPV-positive routine screening and colposcopic biopsies were enrolled. The cohort was followed up regularly for 3 years with routine HPV+TCT and colposcopy, and cervical biopsy if necessary. And specimens remaining after routine screening will be collected for testing of high-throughput HPV typing and integrated assays.
62745885|NCT06600282|ACTIVE_COMPARATOR|Reference Drug|Active Ingredient: Parecoxib Dosage Form: Lyophilized powder for injection Strength: 40 mg/vial Dose: 40 mg (single intravenous bolus)
62745886|NCT06600282|EXPERIMENTAL|Test Drug|Active Ingredient: Parecoxib Dosage Form: Lyophilized powder for injection Strength: 40 mg/vial Dose: 40 mg (single intravenous bolus)
62745887|NCT06637527|EXPERIMENTAL|Arm A|OK-101, 0.05% - one drop of study drug (0.05%) will be instilled in affected eye(s), four times daily (every 4 hours up to 16 hours, e.g., 9:00 am, 01:00 pm; 05:00 pm, 09:00pm) for 12 weeks
62553250|NCT05823857|EXPERIMENTAL|Standard Care|Standard care program including strengthening, flexibility, aerobic conditioning, modalities and manual mobilization techniques. Supervised 10-week program, 2 times a week.
62745888|NCT06637527|EXPERIMENTAL|Arm B|OK-101, 0.1% - one drop of study drug (0.1%) will be instilled in affected eye(s), four times daily (every 4 hours up to 16 hours, e.g., 9:00 am, 01:00 pm; 05:00 pm, 09:00pm) for 12 weeks.
62745889|NCT06637527|PLACEBO_COMPARATOR|Arm C|Placebo - one drop of placebo will be instilled in affected eye(s), four times daily (every 4 hours up to 16 hours, e.g., 9:00 am, 01:00 pm; 05:00 pm, 09:00pm) for 12 weeks.
62745890|NCT05923931|EXPERIMENTAL|non-cooling blanket group|Cooling body temperature by: control the temperature of the emergency room to 20-24℃, 4℃ fluid infusion, ice packs, evaporation, convection, etc.
62374186|NCT05841069|EXPERIMENTAL|Prolonged conservative treatment|Conservative treatment will be performed within N h, where N = 72 h minus duration of acute intestinal obstruction. Surgery will be performed in the absence of contrast in colon according to X-ray examination and if signs of clinical degradation will appear.
62374187|NCT03019172|EXPERIMENTAL|Lactobacillus reuteri|Women in experimental branch will receive two sachets. Sachet one contains a total of 5\*10\^8 CFU of Lactobacillus reuteri DSM 16666 \& Lactobacillus reuteri DSM 17938, mixed with maltodextrin for flowability during production. Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica.
62374188|NCT03019172|PLACEBO_COMPARATOR|Sachet with cranberry + placebo|Women in control branch will receive two sachets. Sachet one contains only Maltodextrin and sachet two contains instant cranberry drinkcomposed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica Both sachets should be emptied in a glass and mixed with 200 ml of cold water
62374189|NCT01541982||virtual and classic autopsy|"Goldstandard: A group of patients in which virtual and classic autopsy is performed."
62374190|NCT01541982||virtual autopsy only|"Intervention: A group of patients in which for various reasons virtual autopsy only is performed."
62374191|NCT05411224|EXPERIMENTAL|Morton Nuroma|In patients with Morton Neuroma, stride length, stance phase percentage, swing phase percentage, cadence and speed parameters, and fore, mid and hind foot pressure distribution will be recorded with the Zebris FDM-THM-S treadmill system in the analysis of barefoot walking after the physical examination evaluation of the cases.
62374192|NCT03440892||1|
62374193|NCT01784250|EXPERIMENTAL|Propanolol|Propranolol 40mg tablets, one tablet administered 1 hour before surgery
62374194|NCT01784250|PLACEBO_COMPARATOR|Placebo|Placebo tablets, one tablet administered 1 hour before surgery
62374195|NCT01784250|EXPERIMENTAL|Clonidine|clonidine 150mcg tablets, one tablet administered 1 hour before surgery
62374196|NCT05865756|OTHER|Cough and voice analysis in HNC patients|Patients will undergo acoustic cough features analysis.
62374197|NCT05570708|EXPERIMENTAL|Personal experience of substance-assisted therapy using psilocybin, MDMA, and LSD|
62374198|NCT01116674||Glycemic Control|Critically ill children at participating centers who require select vital organ support measure (i.e. mechanical ventilation, vasopressor, or continuous renal replacement therapy) will have routine blood glucose (BG) screening initiated (i.e. at least q 12 hours). If a patient has a BG reading of \> 140 mg/dL, a repeat BG will be obtained in 1-2 hours. If this second BG is \> 140 mg/dL the patient will be diagnosed with critical illness hyperglycemia and an insulin infusion will be started and BG will be maintained between 80-140 using a pediatric specific developed and tested algorithm.
62553251|NCT03591042|EXPERIMENTAL|cervical length screening|cervical length screening
62553252|NCT03591042|NO_INTERVENTION|no screening|no screening
62745891|NCT05923931|ACTIVE_COMPARATOR|Cooling blanket group|On the basis of the cooling methods of non-cooling blanket group, combine the cooling blanket to cool down. The cooling blanket is required to be activated within 30min after admission. The blanket temperature will be set at 4-10℃, and the target body temperature is 38℃.
62374199|NCT05819502|EXPERIMENTAL|Treatment|
62374200|NCT02559115|EXPERIMENTAL|PET/CT imaging with 68Ga-RM2|The intervention is the administration of a single dose of 150-200 MBq 68Ga-RM2 (mass \<= 30 μg) for imaging purposes. This will be followed by a 30-40 min PET/CT study after a waiting period of 60 min (+/- 10 min). Prior clinical experience suggests that imaging can be performed within 1 hour post injection (27, 28). MR imaging and prostatectomy will be performed as standard of care at MSKCC.
62374201|NCT03409575|OTHER|5 minutes stimulation|The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 5 minutes.
62374202|NCT03409575|OTHER|10 minutes stimulation|The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 10 minutes.
62374203|NCT06437639|ACTIVE_COMPARATOR|Main (Mexidol and standard therapy)|Mexidol IV 300 mg for 14 days, then Mexidol FORTE 250 orally 250 mg 1 tablet 3 times a day for 8 weeks
62374204|NCT06437639|NO_INTERVENTION|Control (standard therapy)|IOP normalizing therapy
62745892|NCT05286658|EXPERIMENTAL|Healthy Adult Speakers|healthy adult participants across the lifespan in three groups:18-35, 36-55, and 56+
62374205|NCT06106685|EXPERIMENTAL|High-dose group|The participant will receive a high dose of the washed microbiota suspension, with a bacterial quantity that is 10 times higher than the conventional clinical treatment dose, once daily for a duration of 4 days.
62374206|NCT06106685|EXPERIMENTAL|Low-dose group|The participant will receive a low-dose washed microbiota suspension, with a bacterial quantity equivalent to the conventional clinical treatment dose. The washed microbiota suspension will be administered once on the first day, followed by placebo of equal volume for the next 3 days.
62553253|NCT02663843|EXPERIMENTAL|i-gel airway|I-gel inserted for the low skill fibreoptic intubation technique
62553254|NCT02663843|EXPERIMENTAL|air-Q airway|Air-Q inserted for the low skill fibreoptic intubation technique
62567233|NCT06576804|EXPERIMENTAL|Concentric cycling training|Moderate to high intensity cycling training in concentric type (intensity matched the eccentric training)
62745893|NCT00791453||I|Established patients at the Clarksdale Diabetes and Metabolism Center
62745894|NCT02615938|EXPERIMENTAL|Start HCQ block Verum|During trial: Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.
62745895|NCT02615938|PLACEBO_COMPARATOR|Start HCQ block Placebo|At the beginning of the trial: Placebo for 4 weeks then Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.
62745896|NCT02615938|EXPERIMENTAL|Stop HCQ block Verum|Individual dose, usually Hydroxychloroquine Sulfate (HCQ, Quensyl) 6-10 mg/kg bw/d, p.o., one daily dose in the evening; the maximum daily dose is 400 mg. The dose, on which the patient is included into the trial, should be continued for 3 months. After therapy of 3 months the medication will be stopped. The patients will be followed up for additional 3 months.
62745897|NCT02615938|PLACEBO_COMPARATOR|Stop HCQ block Placebo|Patients will receive Placebo for 3 months and will be followed up for additional 3 months.
62745898|NCT02490995|NO_INTERVENTION|Group A|Information given by the anaesthetist during the consultation
62745899|NCT02490995|EXPERIMENTAL|Group B|Movie + Information given by the anaesthetist during the consultation
62374207|NCT06106685|PLACEBO_COMPARATOR|Control group|The patient will receive a placebo of equal volume once daily for a duration of 4 days.
62374208|NCT03317912|ACTIVE_COMPARATOR|Lidocaïne 2%|Bolus 0.075ml/kg/h, following by continuous infusion 0.1ml/kg/h during surgery and 0.066ml/kg/h during 24h
62374209|NCT03317912|PLACEBO_COMPARATOR|Placebo (for Lidocaïne)|Bolus 0.075ml/kg/h, following by continuous infusion 0.1ml/kg/h during surgery and 0.066ml/kg/h during 24h
62374210|NCT02455843|EXPERIMENTAL|Microwave plus chemotherapy|In combination group, patients will be treated with microwave ablation in primary tumor sites followed by chemotherapy （For non-squamous cell lung cancer，patients will be treated with pemetrexed，500mg/m2, d1, ivdrip, or docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, ivdrip,or novelbine 25mg/m2 d1 d8, ivdrip, paclitaxel 175mg/m2 d1 ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip. For squamous cell lung cancer，patients will be treated with docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip；repeated every 3 weeks and up to 6 cycles are administrated ）
62374211|NCT02455843|PLACEBO_COMPARATOR|chemotherapy|In chemotherapy group,patients will be treated with chemotherapy alone（For non-squamous cell lung cancer，patients will be treated with pemetrexed，500mg/m2, d1, ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with a area uder the curve of 5 d1 ivdrip. For squamous cell lung cancer，patients will be treated with docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, novelbine 25mg/m2 d1 d8, ivdrip, paclitaxel 175mg/m2 d1 ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip；repeated every 3 weeks and up to 6 cycles are administrated ）
62374212|NCT03687827|EXPERIMENTAL|Insulin degludec|Participants will receive insulin degludec in period 1 and 2 in a cross-over manner.
62374213|NCT03687827|ACTIVE_COMPARATOR|Insulin glargine|Participants will receive insulin glargine in period 1 and 2 in a cross-over manner.
62374214|NCT01902836|EXPERIMENTAL|Conventional Treatment plus DLE|"Conventional treatment plus DLE~Conventional treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend;~Dialyzed Leukocyte Extracts as Adjuvant Treatment: oral DLE (Transferon) (2mg/5mL), then every day for 5 days, and then every 72hrs to complete one month."
62374215|NCT01902836|PLACEBO_COMPARATOR|Conventional treatment plus placebo|"Conventional treatment plus placebo:~oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend; plus oral placebo, every day for 5 days, then every 72hrs to complete one month."
62374216|NCT04901390|EXPERIMENTAL|Yogurt with B. lactis and added cane sugar|Participants will consume yogurt with B. lactis and added cane sugar twice daily for 14 days.
62374217|NCT05539924|ACTIVE_COMPARATOR|Group P|The patients in this group will receive 150 mg pregabalin tablets P.O 1 hours before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.
62374218|NCT05539924|ACTIVE_COMPARATOR|Group G|The patients in this group will receive 400 mg Gababentin4 tablets P.O 1 hours before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.
62374219|NCT05539924|PLACEBO_COMPARATOR|Group C|The patients in this group will receive vitamin B12 (100µg) as placebo tablets P.O hours before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.
62374220|NCT06139094||CMD negative|Participants in this group exhibit no signs of Coronary Microvascular Disease (CMD), as evidenced by a CFR measurement equal to or greater than 2.5. This group serves as the comparative reference, representing individuals without CMD-related myocardial ischemia.
62374221|NCT06139094||CMD positive|This group comprises participants demonstrating signs of Coronary Microvascular Disease (CMD), defined by a coronary flow reserve (CFR) measurement of less than 2.5. Participants in this category are experiencing myocardial ischemia without significant blockages in their coronary arteries.
62374222|NCT04961502|EXPERIMENTAL|Elderly person|Three blood sample: the first carried out before the anti-COVID-19 vaccination; the second shortly before the vaccination booster injection and the third approximately two months after the first vaccine injection
62567234|NCT06576804|NO_INTERVENTION|Control group|without receiving any exercise training
62567235|NCT06139471|EXPERIMENTAL|study group (VR-enhanced Gagne's Instructional Model)|receive VR-enhanced Gagne's Instructional Model
62745900|NCT02994472|EXPERIMENTAL|Healthy volunteers|"Each participant will have to eat scrambled egg on day 1 and porridge on day 2; both meals will contain the radioactive tracer 99mTc-DTPA.~Participants will be scanned by a trained technologist. The scans will be carried out using a General Electric, Discovery 360 Gamma Camera.The scanning process will take approximately three hours in total, however the imaging will be carried out in stages."
62745901|NCT06396169|ACTIVE_COMPARATOR|Yoga Exercise Group|Yoga Exercises
62745902|NCT06396169|ACTIVE_COMPARATOR|Calisthenic Exercise Group|Calisthenic Exercises
62745903|NCT03418311|NO_INTERVENTION|Control-Group|Control-group-women receive management as usual; i.e. expectant management with interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications.
62553255|NCT03416829|EXPERIMENTAL|100% frequency|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (100% frequency - vibrotactile cueing every time the participant exceeds a vocal intensity threshold). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
62745904|NCT03418311|EXPERIMENTAL|Cervical Pessary-Group|placement of the cervical pessary (non-invasive) at enrollment; removal of the cervical pessary (non-invasive) in a regular preventive examination at WoG 37.
62745905|NCT02241655|EXPERIMENTAL|EEG guided protocol|Participants will have a pragmatic EEG-guided anesthetic protocol during their surgery. Practitioners will modify administration of anesthesia in an attempt to limit the occurrence of EEG burst suppression or persistent suppression.
62745906|NCT02241655|NO_INTERVENTION|Control Arm|Participants will have the standard anesthetic protocol.
62745907|NCT06362655|EXPERIMENTAL|ACTIBESE Invervention Group|Group that will receive the intervention from teachers to improve physical activity behaviors.
62745908|NCT06362655|NO_INTERVENTION|Traditional Physical Education Classes Group (Comparative group)|Group that won't receive the intervention from teachers for improving physical activity behaviours. This group will receive traditional physical education classes according to the national curriculum.
62374223|NCT04961502|ACTIVE_COMPARATOR|Younger adults (priority caregivers)|Three blood sample: the first carried out before the anti-COVID-19 vaccination; the second shortly before the vaccination booster injection and the third approximately two months after the first vaccine injection
62553256|NCT03416829|EXPERIMENTAL|25% frequency|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (25% frequency - vibrotactile cueing every 4th time the participant exceeds a vocal intensity threshold). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
62553257|NCT03416829|EXPERIMENTAL|Summary feedback|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (summary - no cueing, statistics shown every 2 minutes of voicing). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
62553258|NCT02630576|EXPERIMENTAL|Men - Left Hand|5 healthy male volunteers undergoing 4 types of neuromuscular stimulation protocols on the left hand
62553259|NCT02630576|EXPERIMENTAL|Men - Right Hand|5 healthy male volunteers undergoing 4 types of neuromuscular stimulation protocols on the right hand
62553260|NCT02630576|EXPERIMENTAL|Women - Left Hand|5 healthy female volunteers undergoing 4 types of neuromuscular stimulation protocols on the left hand
62553261|NCT02630576|EXPERIMENTAL|Women - Right Hand|5 healthy female volunteers undergoing 4 types of neuromuscular stimulation protocols on the right hand
62374224|NCT04958525||Endoscopic Surgery Group|After a full evaluation of the patient's condition, the informed consent was signed to perform keyhole neuroendoscopic ultrasound-guided hematoma removal for the patient.
62374225|NCT04958525||Microsurgery group|After a full evaluation of the patient's condition, the informed consent was signed to perform small bone window craniotomy for hematoma removal under microscope for the patient.
62374226|NCT04093206|EXPERIMENTAL|EpiCor and Vitamin C|EpiCor (90mg/5ml) and Vitamin C (25mg/5ml) given at dose of 5ml to children 1-2 years old, 7.5ml to children 3-4 years old and 10ml to children 5-6 years old
62374227|NCT04093206|ACTIVE_COMPARATOR|Vitamin C|Vitamin C (25mg/5ml) given at dose of 5ml to children 1-2 years old, 7.5ml to children 3-4 years old and 10ml to children 5-6 years old
62553262|NCT02121652|ACTIVE_COMPARATOR|Healthy eating control|Healthy eating control involves healthy eating content delivered in a 90 minute group session with two follow up phone calls.
62553263|NCT02121652|EXPERIMENTAL|Cognitive behavioral therapy|Cognitive behavioral therapy for insomnia includes content on sleep restriction, stimulus control, relaxation, cognitive restructuring and sleep hygiene content delivered in a 90 minute group intervention with two follow up phone calls.
62745909|NCT04161092|OTHER|Liver transplantation + best alternative care|"Patients subjected to Ltx will during the waiting time receive individualized chemotherapy, with the aim to avoid side effect that make them not transplantable.~If possible, patients randomized to Ltx should be treated within 12 weeks after randomization.~If the patients progress systemically they will be treated with best alternative care.~If they progress only within the liver they continue to be transplantable until they are deemed technically not transplantable by the transplant surgeon."
62745910|NCT04161092|OTHER|Best alternative care|The treating physician will together with the patient decide the treatment.
62745911|NCT00448851|EXPERIMENTAL|1|inhaled allergen challenge
62745912|NCT06272838|EXPERIMENTAL|Experimental Group|In addition to conventional balance exercises, the exercise program, which includes games to improve balance, performed with the help of a Biodex balance device, will be given in a total of 20 sessions, 5 days a week, for 4 weeks..
62745913|NCT06272838|ACTIVE_COMPARATOR|Control Group|The conventional balance exercise program will be applied by a physiotherapist for 4 weeks, 5 days a week, in a total of 20 sessions.
62745914|NCT03225118||HIV/ATI|HIV-infected Adults (age 18-65 years) on ART with suppressed viremia willing to interrupt treatment and then restart once criteria is met.
62745915|NCT06151639||Surgery under general anesthesia|13 patients were anesthetized intravenous with routine general anesthesia.
62374228|NCT01510561|EXPERIMENTAL|90Y-hPAM4|90Y-hPAM4 is administered weekly for 3 weeks
62374229|NCT01510561|EXPERIMENTAL|90Y-hPAM4 + gemcitabine|90Y-hPAM4 is administered weekly for 3 weeks, while gemcitabine is administered weekly for 4 weeks.
62374230|NCT00955344|EXPERIMENTAL|Web-based intervention (eToolbox)|This arm will allow diplomats of the American Board of Internal Medicine to complete the Practice Improvement Module that will embed a link to the web-based intervention (eToolbox).
62374231|NCT00955344|ACTIVE_COMPARATOR|Practice Improvement Module|This arm will allow diplomats of the American Board of Internal Medicine to complete the Practice Improvement Module without any link to the Web-based eToolbox.
62553264|NCT05806996|EXPERIMENTAL|Magnesium Group|Subjects having urology surgery per standard of care will receive intravenous magnesium during the surgery.
62745916|NCT06151639||Surgery with Pecs block|13 patients underwent surgery with PECS block
62745917|NCT01377610|ACTIVE_COMPARATOR|Buprenorphine|Standard 7-day buprenorphine induction and gradual taper from 8 mg to 0 mg followed on day 15 by Vivitrol injection
62745918|NCT01377610|ACTIVE_COMPARATOR|Oral naltrexone|The naltrexone arm is a modification of our current inpatient naltrexone induction procedure, consisting of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses. Followed on day 8 by Vivitrol injection.
62745919|NCT04884035|EXPERIMENTAL|Administration of CC-220 with R-CHOP-21|CC-220 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment
62745920|NCT04884035|EXPERIMENTAL|Administration of CC-99282 with R-CHOP-21|CC-99282 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment
62745921|NCT04884035|EXPERIMENTAL|Administration of CC-220 with polatuzumab-R-CHP|CC-220 to be administered orally in combination with Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (polatuzumab-R-CHP) for 6 cycles of treatment
62374232|NCT05298410|EXPERIMENTAL|Limitless|Participants will be instructed to take Limitless capsules for 30 days starting with the first dose to be administered in clinic on Visit 2 (Day 1, Baseline). The last dose will occur in clinic on Visit 3 (Day 30). Participants will be instructed to take two capsules two hours with water after breakfast, and two capsules two hours after dinner. Do not take food after evening dose before bed. (i.e. no snacking or desserts.). If a dose is missed participants are instructed to skip that dose. Participants will be advised not to exceed four capsules daily.
62745922|NCT04884035|EXPERIMENTAL|Administration of CC-99282 with polatuzumab-R-CHP|CC-99282 to be administered orally in combination with Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (polatuzumab-R-CHP) for 6 cycles of treatment
62745923|NCT03647150|OTHER|Moderate Acute Malnutrition (MAM)|"MAM children at control clinics or MAM children at intervention clinics that do no have high rick characteristics. Control treatment is Mother Care counselling, delivered by a respected elder in the local community."
62745924|NCT03647150|EXPERIMENTAL|High Risk Moderate Acute Malnutrition (MAM)|The intervention treatment incorporates Mother Care counselling, provision of one packet (508 calories) of ready-to-use therapeutic food (RUTF) daily and a 1 week course of amoxicillin. This provision will continue until the child has reached a mid-upper arm circumference (MUAC) equal to or greater than 12.5 cm or 12 weeks have elapsed.
62745925|NCT05016661|EXPERIMENTAL|ABP-450 - Low Dose|ABP-450 Low Dose - intramuscular injections into specified muscles.
62745926|NCT05016661|EXPERIMENTAL|ABP-450 - High Dose|ABP-450 High Dose - intramuscular injections into specified muscles
62745927|NCT05215808|EXPERIMENTAL|RBN-3143|RBN-3143 in single ascending dose followed by multiple ascending dose cohorts, randomized 3:1 ratio
62745928|NCT05215808|ACTIVE_COMPARATOR|Placebo|Placebo randomized in 1:3 ratio with ascending RBN-3143 single and multiple dosing
62745929|NCT05215808|OTHER|Pantoprazole|Open Label PPI cohort to evaluate concurrent administration of pantoprazole on RBN-3143 pharmacokinetics
62374233|NCT02421640|EXPERIMENTAL|Cisplatin+TIL|Cisplatin concurrent chemoradiotherapy(CCRT) combined with tumor-infiltrating lymphocyte (TIL)
62374234|NCT02421640|ACTIVE_COMPARATOR|Cisplatin|Cisplatin concurrent chemoradiotherapy(CCRT) only
62745930|NCT05215808|OTHER|Midazolam|Open Label DDI Cohort (12 subjects) to evaluate the effect of RBN-3143 on the exposure of midazolam, a sensitive CYP3A4 substrate
62553265|NCT05806996|PLACEBO_COMPARATOR|Placebo Group|Subjects having urology surgery per standard of care will receive intravenous placebo during the surgery.
62745931|NCT02340247|EXPERIMENTAL|Placebo|150mL water
62745932|NCT02340247|EXPERIMENTAL|Ursodeoxycholic acid|Ursodeoxycholic acid (750mg) dissolved in 150mL water
62745933|NCT02340247|EXPERIMENTAL|Chenodeoxycholic acid|Chenodeoxycholic acid (1250mg) dissolved in 150mL water
62745934|NCT00907530|ACTIVE_COMPARATOR|MULTIHANCE|gadobenate dimeglumine
62745935|NCT00907530|ACTIVE_COMPARATOR|GADOVIST|gadobutrol
62745936|NCT03789513|OTHER|Triage with different options|"All women will have an HPV test, partial genotyping (16/18/45 versus other high-risk HPV \[hr-HPV\]) and VIA. The different options for triage that will be compared are:~* Participants hr-HVP+ and VIA+ participants selected for treatment;~* Participants HPV 16/18/45+ selected for treatment;~* Participant HPV 16/18/45+ and/or VIA+ selected for treatment;"
62745937|NCT04445883|EXPERIMENTAL|Study Group A|Study group A will include patients from the medical unit on 6S100 in addition to the Rehab units on 6N400/500. Participants in Study Group A will be receiving mealtime assistance from volunteers via the Eating Matters Program.
62745938|NCT04445883|NO_INTERVENTION|Control Group B|Control Group B will include participants from the Rehab Unit on 4N400 and the Medical unit on 6S200.
62745939|NCT04200196|EXPERIMENTAL|"Fabrique à histoire"|"Children 3 to 6 years in pediatric emergency needing to venous puncture and randomized in the fabrique à histoire (Lunii(R)) arm in addition to the routine anaesthetic cream patch."
62745940|NCT04200196|ACTIVE_COMPARATOR|Usual care|Children 3 to 6 years in pediatric emergency needing to venous puncture and randomized in the habitual care arm in addition to the routine anaesthetic cream patch.
62374235|NCT04687436||Foley catheter group|mechanical cervical ripening
62374236|NCT04687436||Double-balloon group|mechanical cervical ripening
62374237|NCT04687436||Cook cervical ripening balloon|mechanical cervical ripening
62567236|NCT06139471|NO_INTERVENTION|STUDY group|doesn't VR-enhanced Gagne's Instructional Model
62567237|NCT05602220|EXPERIMENTAL|Brain training and paced breathing to stimulate alertness|
62567238|NCT05602220|EXPERIMENTAL|Brain training and paced breathing to relax|
62567239|NCT04687137|EXPERIMENTAL|TAK-743|
62567240|NCT04553601|EXPERIMENTAL|8F-FDG PET/CT and PET/CT-guide targeted biopsy|Each subject receive a single intravenous injection of 18F-FDG PET/CT and PET/CT-guide targeted biopsy within the specified time.
62567241|NCT06402318||COVID-19 positive patients|Participants screened with known COVID-19 positive results obtained within 48 hours of recruitment.
62745941|NCT00984165|EXPERIMENTAL|Donor Lymphocyte Infusion/Radiation|Subjects will receive a unmanipulated donor lymphocyte infusion (DLI) on Day 1 after radiation (single, 8-Gy fraction to the maximum number of lesions).
62745942|NCT00984165|ACTIVE_COMPARATOR|Radiation/No Donor Lymphocyte Infusion|Subjects will receive radiation (single, 8-Gy fraction to the maximum number of lesions).
62745943|NCT00984165|ACTIVE_COMPARATOR|Donor Lymphocyte Infusion - Control|Subjects will receive a unmanipulated donor lymphocyte infusion (DLI) on Day 0.
62745944|NCT00984165|ACTIVE_COMPARATOR|Donor Lymphocyte Infusion - Donor|Healthy subjects who donated lymphocytes for infusion on a treatment Arm.
62745945|NCT04723641|EXPERIMENTAL|STUDY GROUP|they received progressive resistive functional strength training from plantigrade foot position conducted for one hour, 3 days/week. The therapist will replace the conventional physical therapy with the progressive resistive functional strength training, when this is consistent with the objectives of the strength training.
62745946|NCT04723641|NO_INTERVENTION|control group|received a designed physical therapy program
62745947|NCT03967028||Study group|primigravida scheduled for cesarean section
62745948|NCT03029078|EXPERIMENTAL|Fecal transplantation|"Patient will be transplanted with a healthy donor microbiota, free from XDR bacteria, in order to evaluate the impact on the digestive tract colonization Whole process of feces screening and reconstitution was under the responsibility of the pharmacists in charge of the study.~Patient will benefit of a naso-duodenal tube in order to perform a bowel lavage prio to the fecal microbiota transplant.~Patient will be monitored for 24h to rule out potential adverse events."
62745949|NCT00946764|EXPERIMENTAL|1|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)
62745950|NCT00946764|ACTIVE_COMPARATOR|2|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)
62745951|NCT05056922|EXPERIMENTAL|Tele-PCIT (Parent-Child Interaction Therapy)|
62745952|NCT05056922|ACTIVE_COMPARATOR|Treatment as Usual|
62745953|NCT03003182||in clinical trials|
62745954|NCT03003182||out of clinical trials|
62745955|NCT02643615|EXPERIMENTAL|VEP under TIVA|Patients undergoing prone spine surgery will receive an anesthesia regimen using propofol (TIVA) for maintenance
62745956|NCT02643615|EXPERIMENTAL|VEP under balanced anesthesia|Patients undergoing prone spine surgery will receive an anesthesia regimen using Desflurane as part of balanced general anesthesia
62745957|NCT04726592|PLACEBO_COMPARATOR|Control arm|"placebo and standard care :~* Placebo IV~* Ketoprofen 100 mg IV (if nausea-vomiting)~* Metoclopramide 10 mg IV(if nausea-vomiting)"
62745958|NCT04726592|EXPERIMENTAL|Experimental arm|"clorazepate and standard care :~* Clorazepate 20 mg IV~* Ketoprofen 100 mg IV (if nausea-vomiting)~* Metoclopramide 10 mg IV(if nausea-vomiting)"
62745959|NCT02315807|EXPERIMENTAL|dlPFC|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in dorsolateral prefrontal cortex
62745960|NCT02315807|EXPERIMENTAL|CON|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in cingulo-opercular network
62745961|NCT02315807|ACTIVE_COMPARATOR|M1|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in motor primary cortex
62745962|NCT03433833|EXPERIMENTAL|Intervention|Patients will be given digoxin orally daily for 24 weeks. The initial dose will be selected with the goal of achieving a serum digoxin concentration of 0.5-0.9 ng/ml, a dose range recommended for heart failure patients. A dose of 0.0625, 0.125 or 0.25 mg daily will be selected based on a normogram.
62745963|NCT01643252|PLACEBO_COMPARATOR|Placebo and UVA light exposure|
62745964|NCT01643252|ACTIVE_COMPARATOR|Riboflavin drops and UVA light exposure|
62745965|NCT00368381|ACTIVE_COMPARATOR|Hydrocortision and fludrocortisone|Study is comparing hydrocortisone alone versus the combination of hydrocortisone and fludrocortisone in the treatment of adrenal insufficiency of septic patients.
62745966|NCT03939767||wAMD patients|Patients with a diagnosis of wAMD and naïve to any treatment in the study eye will be enrolled after the decision by treating physician for IVT aflibercept therapy according to the local label.
62745967|NCT05409053|ACTIVE_COMPARATOR|screw fixation|lateral condyle humerus fracture open reduction and internal fixation by canullated screws
62745968|NCT05409053|ACTIVE_COMPARATOR|k wire fixation|lateral condyle humerus fracture open reduction and internal fixation by K wire
62745969|NCT05409053|OTHER|Conservative management|Undisplaced fractured treated conservatively by above elbow slab
62745970|NCT05409053|OTHER|Closed reduction and percutaneous pinning|Undisplaced fractured treated closed reduction and percutaneous pinning
62745971|NCT03136146|EXPERIMENTAL|Treatment (combination chemotherapy)|See detailed description
62745972|NCT06292416|EXPERIMENTAL|Mirror therapy with sensory motor training.|"1. Visual perception activities~2. Body awareness~3. Tactile perception.~4. Visual-motor coordination training~The child will be seated on a chair and a 30\*30 cm mirror will set up on a table in front of them. The affected hand will be placed behind the mirror so that the image of a healthy hand can be seen clearly"
62745973|NCT06292416|EXPERIMENTAL|Mirror Therapy with motor training.|supination-pronation, wrist flexion-extension, finger flexion-extension, abduction, adduction, opposition
62745974|NCT06292416|OTHER|Motor Training|"1. Holding objects~2. Stabilize objects~3. manipulate objects"
62745975|NCT01372943|EXPERIMENTAL|synthetic stool|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
62745976|NCT03271372|EXPERIMENTAL|Arm I (avelumab)|Patients receive avelumab IV over 1 hour once every 15 days for the first 120 days (Induction Phase 1), once every 30 days for the next 120 days (Induction Phase 2), and then once every 120 days (Maintenance Phase) for a maximum of 720 days (approximately 24 months or 2 years total) in the absence of disease progression or unacceptable toxicity.
62745977|NCT03271372|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo IV over 1 hour once every 15 days for the first 120 days (Induction Phase 1), once every 30 days for the next 120 days (Induction Phase 2), and then once every 120 days (Maintenance Phase) for a maximum of 720 days (approximately 24 months or 2 years total) in the absence of disease progression or unacceptable toxicity.
62745978|NCT00108303||Diagnostic|A diagnostic was performed
62745979|NCT06661057|EXPERIMENTAL|Vivally system|
62745980|NCT06415812|EXPERIMENTAL|Psychotherapy|All the participants receive as active treatment a form of psychotherapy for personality disorders (Evolutionary Systems Therapy). The treatment last 6 months (24 weekly sessions, each lasting 50-60 minutes).
62553266|NCT04030208|OTHER|Sequence A|If patient is randomly assigned to Sequence A, they will be placed on a traditional ventilator for the first period. This period will be 1 hour in duration. Delivered tidal volume, respiratory rate (RR), and peak pressure will be recorded throughout the period using the ventilator. Heart rate (HR), Blood Pressure (BP), and oxygen (O2) saturation measurements will be recorded every 5 minutes. Arterial blood gas (ABG) data will be taken at t = 1 hour if the patient is stable on the traditional ventilator. ABGs may be taken more frequently if the patient is destabilizing. Next, the study participant will be transitioned to the Umbulizer to begin Period 2. This period will also be 1 hour in duration. Delivered tidal volume, RR, and peak pressure will be recorded throughout the period using Umbulizer. HR, BP, O2 saturation measurements will be taken every 5 minutes. ABG data will be taken at t = 30 minutes and 1 hour.
62553267|NCT04030208|OTHER|Sequence B|If patient is randomly assigned to Sequence B, they will be shifted to the Umbulizer for the first period. This period will be 1 hour in duration. Delivered tidal volume, RR, and peak pressure will be recorded throughout the period using Umbulizer. HR, BP, O2 saturation measurements will be recorded every 5 minutes. ABG data will be taken at t = 30 minutes and 1 hour. Next, the study participant will be transitioned to a traditional ventilator to begin Period 2. This period will also be 1 hour in duration. Delivered tidal volume, RR, and peak pressure will be recorded throughout the period using the ventilator. HR, BP, O2 saturation measurements will be recorded every 5 minutes. ABG data will be taken at t = 1 hour if the patient is stable on the traditional ventilator. ABGs may be taken more frequently if the patient is destabilizing.
62553268|NCT00080145|ACTIVE_COMPARATOR|risperidone plus parent management training|
62553269|NCT00080145|ACTIVE_COMPARATOR|risperidone only|
62553270|NCT03752697||Neurological injury|Paper and pencil/computerized assessments of cognitive functioning and metacognitive performance will be administered.
62745981|NCT02664168|ACTIVE_COMPARATOR|Aquacel Ag Surgical Dressing|
62745982|NCT02664168|ACTIVE_COMPARATOR|Single-Use Negative Pressure Wound Therapy (PICO)|
62553271|NCT03752697||Healthy control|Paper and pencil/computerized assessments of cognitive functioning and metacognitive performance will be administered.
62745983|NCT01208961|ACTIVE_COMPARATOR|Epanova-Lovaza-Epanova-Lovaza|
62745984|NCT01208961|ACTIVE_COMPARATOR|Lovaza-Epanova-Lovaza-Epanova|
62745985|NCT05043792|ACTIVE_COMPARATOR|Dose 1 (Low dose)|TT-00920, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.
62745986|NCT05043792|ACTIVE_COMPARATOR|Dose 2 (High dose)|TT-00920, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.
62745987|NCT05043792|PLACEBO_COMPARATOR|Placebo|TT-00920 Placebo, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.
62745988|NCT04491019|EXPERIMENTAL|Balance exercise group|Balance exercises will be carried out with a physiotherapist.
62745989|NCT04491019|EXPERIMENTAL|Strengthening exercise group|Strengthening exercises will be performed with a physiotherapist.
62745990|NCT00639041|PLACEBO_COMPARATOR|placebo|
62745991|NCT00639041|ACTIVE_COMPARATOR|n-3 LC-PUFA|
62745992|NCT00491036|ACTIVE_COMPARATOR|Intraaortic balloon pump|Patients in cardiogenic shock get an intraaortic balloon pump in the cath lab
62745993|NCT00491036|NO_INTERVENTION|No intraaortic balloon pump|Patients in cardiogenic shock in this group get no intraaortic balloon pump
62745994|NCT03065621|EXPERIMENTAL|Palbociclib with Endocrine Therapy|All subjects will receive palbociclib 125 mg for 4 cycles, orally, once a day, for 21 days followed by 7 days of rest (4 cycles of 28 day long). After the final rest week (therefore post cycle 4), subjects will receive 3 to 7 additional days of palbociclib, as necessary, at the same dose and posology, until the day before curative intent surgery. Depending upon the menopausal status, the patient will receive either letrozole or tamoxifen continuously during the palbociclib treatment (which consists of 4 cycles of 28 days).
62745995|NCT06241638|ACTIVE_COMPARATOR|Dapagliflozin group|Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months
62745996|NCT06241638|EXPERIMENTAL|Vitamin B12 and Dapagliflozin group|Vitamin B12 and Dapagliflozin group received orally Vit. B12 supplements methylcobalamin 500 µg once daily with their usual anti-diabetic therapy Dapagliflozin 10 mg/daily for twelve months.
62745997|NCT01335893|EXPERIMENTAL|ICG injection group|This group will receive a single dose of ICG, diluted in saline solution, prior to surgery. Then, during their surgery, they will be imaged with the camera and imaging probe we have developed.
62745998|NCT04982328||NAFLD|patients diagnosed with NAFLD and hospitalized due to the severe COVID-19
62745999|NCT04982328||non-NAFLD|patients hospitalized due to the with severe COVID-19 without NAFLD
62746000|NCT05076409|EXPERIMENTAL|All participants|
62746001|NCT05742516|EXPERIMENTAL|GOS|Galactooligosaccharide consumption through the prebiotic product Bimuno.
62746002|NCT05742516|PLACEBO_COMPARATOR|Placebo|Maltodextrin powder
62746003|NCT02305849|EXPERIMENTAL|Peficitinib 100 mg|Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.
62746004|NCT02305849|EXPERIMENTAL|Peficitinib 150 mg|Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.
62746005|NCT02305849|PLACEBO_COMPARATOR|Placebo|Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.
62746006|NCT06010758|EXPERIMENTAL|Arm 1: Brush / Listerine Experimental Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Experimental Mouthwash twice a day.
62746007|NCT06010758|EXPERIMENTAL|Arm 2: Brush / Listerine Cool Mint Zero|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with experimental mouthwash twice a day.
62746008|NCT06010758|EXPERIMENTAL|Arm 3: Brush / Listerine Total Care Zero|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with experimental mouthwash twice a day.
62746009|NCT06010758|OTHER|Arm 4: Brush only|Participants will brush their teeth using a soft bristled toothbrush and Colgate Cavity Protection Toothpaste twice daily for 1 timed minute and then rinse with water for 1 minute.
62746010|NCT05981001|EXPERIMENTAL|Phase I and phase II: LNL treatment + Camrelizumab + Chemotherapy|Participants in both phase I and phase II portions receive LNL treatment, which consists of non-myeloablative lymphocyte depleting regimen of chemotherapy with cyclophosphamide and fludarabine, followed by infusion of LNL and interleukin-2. After LNL treatment, participants receive camrelizumab PLUS one of two background chemotherapy regimens at investigator's discretion: (1) nab-paclitaxel, OR (2) gemcitabine/carboplatin.
62746011|NCT05981001|ACTIVE_COMPARATOR|Phase II: Camrelizumab + Chemotherapy|The single-arm phase I study did not have this arm. Participants in phase II portion receive camrelizumab PLUS one of two background chemotherapy regimens at investigator's discretion: (1) nab-paclitaxel, OR (2) gemcitabine/carboplatin.
62746012|NCT03115203|OTHER|Facial paralysis|
62746013|NCT03115203|OTHER|Healthy subject|
62746014|NCT03257202|NO_INTERVENTION|Control|No topical treatment
62746015|NCT03257202|EXPERIMENTAL|Clindamycin alone|topical clindamycin alone using Clindamycin 1% Gel
62746016|NCT03257202|EXPERIMENTAL|Benzoyl peroxide alone|topical benzoyl peroxide alone using Benzoyl Peroxide 5% Gel
62746017|NCT03257202|EXPERIMENTAL|Clindamycin and benzoyl peroxide|Topical clindamycin and topical benzoyl peroxide together using BenzaClin 5%-1% Topical Gel
62746018|NCT05791565|EXPERIMENTAL|Salbutamol HFA-152a MDI followed by Salbutamol HFA-134a MDI|Participants will receive Salbutamol HFA-152a MDI in treatment period 1 followed by Salbutamol HFA-134a MDI in treatment period 2. There will be a minimum washout period of 72 hours between each treatment period.
62746019|NCT05791565|EXPERIMENTAL|Salbutamol HFA-134a MDI followed by Salbutamol HFA-152a MDI|Participants will receive Salbutamol HFA-134a MDI in treatment period 1 followed by Salbutamol HFA-152a MDI in treatment period 2. There will be a minimum washout period of 72 hours between each treatment period.
62746020|NCT06067100|EXPERIMENTAL|Indacaterol + mometasonefluroate|
62746021|NCT06067100|PLACEBO_COMPARATOR|Placebo|
62746022|NCT01539733|EXPERIMENTAL|Olanzapine|
62374238|NCT01529827|EXPERIMENTAL|Treatment (reduced intensity allogeneic PBSCT)|PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan IV over 30 minutes on day -2. Patients undergo low-dose TBI BID on day -1. TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0. GvHD PROPHYLAXIS: Patients receive tacrolimus IV or PO BID on days -1 to 100 with taper over 4-6 months, MMF PO or IV every 6-8 hours on days -1 to 60, and methotrexate IV over 15 to 30 minutes on days 1, 3, and 6.
62374239|NCT05498792|EXPERIMENTAL|CBL0137 (Dose level 1) +Ipilimumab + Nivolumab|Dose level 1 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
62374240|NCT05498792|EXPERIMENTAL|CBL0137 ( Dose level 2) +Ipilimumab + Nivolumab|Dose level 2 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
62374241|NCT05498792|EXPERIMENTAL|CBL0137 ( Dose level -1) +Ipilimumab + Nivolumab|Dose level -1 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
62374242|NCT05576415|EXPERIMENTAL|OC-01|
62746023|NCT01539733|ACTIVE_COMPARATOR|Haloperidol|
62746024|NCT03174405|EXPERIMENTAL|AVELUMAB|
62746025|NCT03183258|EXPERIMENTAL|Sentinel Skin Flap|
62746026|NCT05305118|EXPERIMENTAL|Acute Inpatients With Spinal Cord Injury|Inpatient participants undergoing rehabilitation after acute traumatic SCI.
62374243|NCT00307892|ACTIVE_COMPARATOR|A|TRAUMEEL S
62746027|NCT03686306|EXPERIMENTAL|Experimental group|Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks.
62746028|NCT03686306|PLACEBO_COMPARATOR|Control group|Placebo (single morning oral dose) for a total duration of 24 weeks.
62746029|NCT03055728||Group 1 / Study Group|Subjects presenting with signs or symptoms of acute pharyngitis, with a history of culture-proven GAS infection and subsequent 10-day antibiotic treatment within the preceding 28 days. Subjects will have a rapid strep antigen detection test and a throat culture to determine presence of strep.
62746030|NCT03055728||Group 2 / Control Group|Subjects presenting with signs or symptoms of acute pharyngitis, without a recent history of GAS infection. Subjects will have a rapid strep antigen detection test and a throat culture to determine presence of strep.
62374244|NCT00307892|PLACEBO_COMPARATOR|B|comparable placebo remedy (injection and oral)
62553272|NCT02251600|EXPERIMENTAL|Deflazacort|This is an open label and single period study , dosed with 0.9mg/kg Deflazacort.
62567242|NCT06402318||COVID-19 negative patients|Participants screened with known COVID-19 negative results obtained within 48 hours of recruitment.
62746031|NCT02497144|ACTIVE_COMPARATOR|NMES Group|"Intervention: NMES group will receive neuromuscular electrical stimulation using high frequency galvanic stimulation and breathing exercises.~Neuromuscular electrical stimulation will be applied bilaterally to quadriceps femoris muscle for 3days/6 weeks by a physiotherapist.~NMES group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks."
62746032|NCT02497144|SHAM_COMPARATOR|Control Group|"Sham: Control group will receive breathing exercises. Control group will perform breathing exercises 120 times/day, 7 days/week, for 6 weeks.~Control group will be followed-up by telephone once a week."
62746033|NCT06327074|NO_INTERVENTION|Control Group|Sites in the control condition will be asked to complete appropriate/relevant surveys and interviews with minor modifications as needed and use the same Electronic Health Record Data Abstraction process.
62746034|NCT06327074|EXPERIMENTAL|Experimental Group|Sites randomized to use the EA-LCS materials will be given password-protected access to the program/toolkit web portal and encouraged to use any materials that fit the normal flow of clinic procedures. Materials available include both staff-facing and LCS candidate-facing materials.
62746035|NCT04909008|EXPERIMENTAL|Exercise Training|Two sets of exercise testing (before and after) 10 weeks of supervised exercise training (3 sessions per week) at Mayo Clinic Florida.
62746036|NCT04909008|NO_INTERVENTION|Control Groups|Two sets of exercise testing while continuing with standard medical care in between.
62746037|NCT03849820|ACTIVE_COMPARATOR|Robotic-assisted partial nephrectomy|da Vinci surgical robotic assisted partial nephrectomy
62746038|NCT03849820|ACTIVE_COMPARATOR|Open partial nephrectomy|Open partial nephrectomy surgery
62746039|NCT05465798|EXPERIMENTAL|Beta-Glucans|Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans daily for up to three consecutive days.
62746040|NCT05465798|PLACEBO_COMPARATOR|Placebo|Participants allocated to this arm will receive a placebo that will be identical in form to the MC 3x3 pills used the interventional arm. These doses will be scheduled daily and administered orally for up to three consecutive days.
62746041|NCT03161912||DME/naïve|patients with pre-treatment in diabetic macular edema (DME)
62746042|NCT03161912||DME/pre-treatment|patients without pre-treatment in DME
62746043|NCT03161912||RVO/pre-treatment|Macular edema secondary to RVO with prior treatment
62746044|NCT03161912||RVO/naïve|Macular edema secondary to RVO without prior treatment
62746045|NCT05348993|EXPERIMENTAL|50 mg dose of G03-52-01|150 subjects randomized to 50 mg of G03-52-01
62746046|NCT05348993|EXPERIMENTAL|100 mg dose of G03-52-01|150 subjects randomized to 100 mg of G03-52-01
62746047|NCT05348993|PLACEBO_COMPARATOR|Placebo|75 subjects randomized to placebo
62746048|NCT05348993|OTHER|100 mg dose of G03-52-01 or Placebo|250 subjects randomized to 100 mg of G03-52-01 or placebo
62746049|NCT04953819||Revascularization group|This group includes patients with dialysis who have received revascularization by percutaneous coronary intervention or coronary artery bypass grafting for coronary artery disease.
62746050|NCT04953819||Medical treatment group|This group includes patients who have received medical therapy for coronary artery disease, not percutaneous coronary intervention or coronary artery bypass grafting.
62746051|NCT04945707|ACTIVE_COMPARATOR|Arm 1|Ferric derisomaltose (Monoferric®) 1000 mg X 1 (for subject \<50 kg, 20 mg/kg X1)
62746052|NCT04945707|PLACEBO_COMPARATOR|Arm 2|Normal Saline
62746053|NCT05160168|EXPERIMENTAL|Dose Escalation|Participants with unresectable or metastatic GIST who will receive orally administered THE-630.
62746054|NCT05160168|EXPERIMENTAL|Expansion Cohort 1|Patients with unresectable or metastatic GIST who have progressed on or are intolerant to imatinib, sunitinib, regorafenib and ripretinib who will receive orally administered THE-630 at the recommended Phase 2 dose based on the dose escalation phase.
62746055|NCT05160168|EXPERIMENTAL|Expansion Cohort 2|Patients with unresectable or metastatic GIST who have progressed on or are intolerant to imatinib, sunitinib and 0-1 additional lines of therapy in the advanced/metastatic setting, who will receive orally administered THE-630 at the recommended Phase 2 dose based on the dose escalation phase.
62746056|NCT05160168|EXPERIMENTAL|Expansion Cohort 3|Patients with unresectable or metastatic GIST who have progressed on or are intolerant to imatinib (including in the adjuvant setting) and who have not received additional systemic therapy for advanced GIST, who will receive orally administered THE-630 at the recommended Phase 2 dose based on the dose escalation phase.
62746057|NCT03628482|ACTIVE_COMPARATOR|CRF group|Patients were assigned to receive continuous radiofrequency (CRF) treatment of genicular nerves
62746058|NCT03628482|EXPERIMENTAL|PRF group|Patients were assigned to receive pulsed radiofrequency (CRF) treatment of genicular nerves
62746059|NCT01343186|OTHER|Arm 1|
62746060|NCT01343186|OTHER|Arm 2|
62746061|NCT01343186|OTHER|Arm 3|
62746062|NCT01343186|OTHER|Arm 4|
62746063|NCT02281110||iFR/FFR assessment|Patients enrolled into this prospective registry will be derived from Stable Coronary Artery disease or Acute Coronary Syndrome (ACS) population undergoing cardiac catheterization. Patients with ACS may be evaluated by functional assessment in the non-culprit stenosis during the index PCI revascularization or in a staged procedure. The registry will enroll patients in whom physiological assessment (iFR/FFR) is particularly helpful in identifying haemodynamically significant stenosis: MVD patients defined by patients with lesions \> 40% and \<100% in 2 or more vessels.
62746064|NCT00003783|EXPERIMENTAL|Complete Response and no CNS 3|See detailed description.
62553273|NCT00417170|EXPERIMENTAL|Aliskiren 300 mg|Eligible participants received oral Aliskiren 300 mg + Placebo Amlodipine once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed.
62746065|NCT00003783|EXPERIMENTAL|Complete Response and CNS 3|See detailed description.
62746066|NCT03006848|EXPERIMENTAL|Avelumab|"All participants with recurrent/refractory osteosarcoma who consent to the study.~Interventions: Avelumab and quality of life questionnaires."
62746067|NCT06438471|EXPERIMENTAL|EC5026|Multiple oral doses of EC5026
62746068|NCT06438471|PLACEBO_COMPARATOR|Placebo|Matching oral placebo
62746069|NCT02503358|EXPERIMENTAL|Arm I (continuous selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-21 and paclitaxel IV over a fixed rate on days 1 and 8.
62746070|NCT02503358|EXPERIMENTAL|Arm II (intermittent selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-5, 8-12, and 15-19 and paclitaxel as in Arm I.
62746071|NCT02503358|EXPERIMENTAL|Arm III (pulsatile selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-3, 8-10, and 15-17 and paclitaxel as in Arm I.
62746072|NCT01895439|EXPERIMENTAL|MSCs injection|Autologous bone marrow derived stem cells injected intrathecally to enrolled MS patients
62746073|NCT05570110|EXPERIMENTAL|enoxolone|100 mg enoxolone in a capsule
62746074|NCT05570110|PLACEBO_COMPARATOR|placebo|Placebo in a capsule
62746075|NCT05873153|EXPERIMENTAL|Treatment Group|Participants will be given access to health education, home blood pressure monitor, and referral to a primary care provider.
62746076|NCT05873153|NO_INTERVENTION|Control Group|Participants receive referrals only to a primary care provider (PCP) for blood pressure monitoring.
62746077|NCT05058196|OTHER|Whole breast radiotherapy after surgery|WBRT will be delivered at 50 Grays (2 Grays x 25 fractions), 5 days/week for 5 weeks after breast surgery
62374245|NCT03288623|EXPERIMENTAL|Dark Chocolate|Dark chocolate (85% cocoa) 40 mg per day for 30 days
62746078|NCT05058196|OTHER|Intra Operative Radiotherapy|IORT will be delivered at a single dose of 20 grays to the tumor bed during breast surgery
62746079|NCT05058196|NO_INTERVENTION|no radiotherapy|No radiotherapy will be administrated to the patients during or after breast surgery
62746080|NCT05467839|EXPERIMENTAL|vitillgo patients|
62746081|NCT00680355|OTHER|Golden rice meal with 10g fat|10 g corn oil in the Golden Rice meal
62746082|NCT00680355|OTHER|Golden Rice with 0g fat|0g corn oil eating with the Golden Rice meal
62746083|NCT00680355|OTHER|Golden Rice meal with 5 g fat|5 g corn oil in the Golden Rice meal
62746084|NCT06396429|EXPERIMENTAL|Treatment group A: HRS9531 injection|
62746085|NCT06396429|EXPERIMENTAL|Treatment group B: HRS9531 injection|
62746086|NCT06396429|EXPERIMENTAL|Treatment group C: HRS9531 injection|
62746087|NCT06396429|PLACEBO_COMPARATOR|Placebo injection|
62746088|NCT04011566||ShuntCheck|Participants will be administered the ShuntCheck diagnostic test.
62746089|NCT01404793||Liver transplant recipient|
62746090|NCT03112512|EXPERIMENTAL|EIT|PEEP titration is performed where EIT is measured at the same time. After PEEP titration, EIT data is analyzed. Global inhomogeneity index and regional compliance based on EIT are calculated. PEEP level is selected when ventilation distribution is most homogeneous.
62746091|NCT03112512|EXPERIMENTAL|G5 VENTILATOR|Protective Ventilation Tool by G5(MV) to determine the optimal PEEP on ARDS patients. The results are delivered by the ventilator automatically.
62746092|NCT01681069|ACTIVE_COMPARATOR|IQP-VV-102|2 tablets twice a day
62553274|NCT00417170|ACTIVE_COMPARATOR|Amlodipine 5 mg|Eligible participants received oral Amlodipine 5 mg + Placebo Aliskiren once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed.
62746093|NCT01681069|PLACEBO_COMPARATOR|Placebo|2 tablets twice a day
62746094|NCT03327220|EXPERIMENTAL|iovera° Device Treatment Group|Iovera° device presurgical cryoneurolysis treatment, 5 (+/- 2) days prior to TKA. Additionally, all participants received treatment as per all the standard pre-, peri-, and post-operative surgical protocols.
62746095|NCT03327220|NO_INTERVENTION|Standard of Care Treatment Group|All participants received treatment as per all the standard pre-, peri-, and post-operative surgical protocols.
62746096|NCT00289068||Phacoemulsification Sleeve 2.2mm|Phacoemulsification Sleeve setting 2.2 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
62746097|NCT00289068||Phacoemulsification Sleeve 2.8mm|Phacoemulsification Sleeve setting 2.8 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
62746098|NCT00289068||Phacoemulsification Sleeve 3.0mm|Phacoemulsification Sleeve setting 3.0 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
62746099|NCT06084754|EXPERIMENTAL|Group A (Study group)|pulsed electromagnetic field and medical treatment ( vancomycin IV injection 1gm divided 250mg every 6hours )
62746100|NCT06084754|ACTIVE_COMPARATOR|Group B(control group)|medical treatment only (vancomycin IV injection 1gm divided 250mg every 6hours )
62374246|NCT03288623|PLACEBO_COMPARATOR|White/Milk Chocolate|White chocolate or Milk chocolate administration in tablet (\<35% cocoa) per day for 30 days
62746101|NCT06655558|EXPERIMENTAL|medial gonarthrosis|Patients with medial gonarthrosis
62746102|NCT03020134|EXPERIMENTAL|PKGroup(Ravidasvir/Danoprevir/Ritonavir)|Ravidasvir + Danoprevir/ Ritonavir
62746103|NCT03020134|PLACEBO_COMPARATOR|Placebo Group|Placebo
62746104|NCT04807088|EXPERIMENTAL|Intervention Group|Tactile-kinesthetic stimulation (TKS) was performed with a specific baby oil provided by the investigator. Tactile stimulation was performed while the neonate was in prone position. Light massage was applied in the head, shoulder, back, legs and arms of the infants. Every massage was performed for 2 × 5 seconds, with a total duration of 5 minutes. Kinesthetic stimulation, including elbow flexion-extension movement, palm massages, flexion-extension of the knees and legs and plantar massages, was applied while the neonate was in supine position. Each kinesthetic stimulation was performed for 2 × 5 seconds. Each movement was repeated six times, with a total duration of 5 minutes. Tactile stimulation was repeated once after kinesthetic stimulation. The total duration of TKS was 15 minutes which was performed three times daily preferably between breastfeeding or bottle feeding for 10 consecutive days.
62746105|NCT04807088|PLACEBO_COMPARATOR|Control Group|Control group was not given TKS.
62746106|NCT05489172|OTHER|A Single arm study to evaluate the effectiveness of Hola Bebe application|"Participants will receive the handout It's never too early to prevent diabetes and will meet with the health educator at their CHC and download the Hola Bebe app. The health educator will advise participants to watch one module and complete an action plan for each of the first 12 weeks of study and encourage participants to weigh themselves weekly. The app includes the following features:1) educational/ behavioral audio visual modules, with automatic prompting to complete an action plan at the end of each module; 2) a motivational message library so that participants can chose which motivational texts they wish to receive, how often and time of day; 3) a community forum where participants can interact with each other and ask questions to the health educator; 4) tracking of weights to allow participants to see a graphic of their weight over time by inputting weekly weights; and 5) awards program where participants can earn badges for completing modules."
62746107|NCT01127607|EXPERIMENTAL|stimulant medication|blinded lisdexamfetamine at the optimal dose for the individual participant as previously determined during the med optimization portion of the study
62374247|NCT02308904|OTHER|Laboratory Studies for Pituitary-Gonadal Function|"Females: We expect to enroll approximately 15 females ages 12 years and older.~Males: We expect to enroll approximately 15 males ages 12 years and older."
62553275|NCT03911830|EXPERIMENTAL|Exercise followed cold water immersion|Exercise program on cycloergometer and its submerged recovery
62746108|NCT01127607|PLACEBO_COMPARATOR|placebo pill|placebo medication identical in appearance to active med
62746109|NCT00075725|ACTIVE_COMPARATOR|Arm I|Patients in arm I receive intrathecal cytarabine in week 1; infusions of vincristine and daunorubicin once a week in weeks 1-4; dexamethasone by mouth or infusion twice a day in weeks 1 and 2; intrathecal methotrexate in weeks 2 and 5 or 2-5; and an injection of pegaspargase in week 1.
62374248|NCT02308904|OTHER|Data on iron burden and chelation history|"Retrospective data, as listed in this section, will be obtained from chart review and results of relevant clinical data.~1. Iron burden data~2. Assay for non-transferrin bound iron (NTBI)~3. Chelation data~4. Oxidant stress~5. History or presence of hypogonadism"
62374249|NCT02308904|OTHER|Pituitary MRI|MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland.
62374250|NCT04594889|EXPERIMENTAL|Sirolimus|Sirolimus eluting balloon will be inflated in the target vessel after optimal balloon angioplasty for at least 2 minutes
62374251|NCT04594889|ACTIVE_COMPARATOR|Paclitaxel|Paclkitaxel eluting balloon will be inflated in the target vessel after optimal balloon angioplasty for at least 2 minutes
62374252|NCT05505539|EXPERIMENTAL|5-fluorouracil|Participants will receive up to 3 intralesional 5-fluorouracil injections (0.25 mL of a 50mg/mL solution) once every 2 weeks into an oral leukoplakia lesion.
62553276|NCT01654692|EXPERIMENTAL|Single arm of ipilimumab and fotemustine|Ipilimumab in combination with Fotemustine
62746110|NCT00075725|ACTIVE_COMPARATOR|Arm II|Patients in arm II will receive intrathecal cytarabine in week 1; infusions of vincristine and daunorubicin once a week in weeks 1-4; dexamethasone by mouth or infusion twice a day in weeks 1 and 2; intrathecal methotrexate in weeks 2 and 5 or 2-5; and an injection of pegaspargase in week 1.
62746111|NCT00075725|EXPERIMENTAL|Arm III|"Patients in arm III will receive cytarabine, vincristine, daunorubicin, and pegaspargase as in groups one and two. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and intrathecal methotrexate in weeks 2 and 5.~Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning in week 6 or 7, patients may receive combination chemotherapy by infusion, injection, intrathecally, and by mouth for up to 8 weeks."
62746112|NCT00075725|EXPERIMENTAL|Arm IV|"Patients in arm IV will receive cytarabine, vincristine, daunorubicin, and pegaspargase as in groups one and two. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and intrathecal methotrexate in weeks 2 and 5.~Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning in week 6 or 7, patients may receive combination chemotherapy by infusion, injection, intrathecally, and by mouth for up to 8 weeks."
62746113|NCT01196468||Anal/cervical dyplasia|Any patient presenting for care with any degree of anal or cervical dysplasia
62746114|NCT01196468||STI|Any patient presenting for care with any non-HIV sexually transmitted infection
62746115|NCT01196468||Lymphoma|Any patient presenting for care with malignant lymphoma of any histological type
62746116|NCT01196468||Seborrhoeic dermatitis/exanthema|Any patient presenting for care with seborrhoeic dermatitis/exanthema
62746117|NCT01196468||Thromobocytopaenia/Leucopaenia, or hypergammaglobulinaemia|Any patient presenting for care with unexplained thromobocytopaenia/leucopaenia of more than four weeks duration, or with hypergammaglobulinaemia
62746118|NCT02035436|EXPERIMENTAL|Non-sedation|Non-sedation supplemented with pain management during mechanical ventilation.
62746119|NCT02035436|ACTIVE_COMPARATOR|Sedation|Current gold standard: Sedation with a daily wake-up trial.
62746120|NCT06662032|EXPERIMENTAL|Test Intervention|In the intervention arm, participants will follow the standard rehabilitation programme at a frequency of ideally 2 times a week. LumbaCure® device will be used in addition to the standard programme. A session of 15 min will be performed at each rehabilitation session. The device is to be used by the Physiotherapist at the rehabilitation centre. In total, the participant should perform 26 LumbaCure® sessions during the intervention period, this corresponds to the number of rehabilitation sessions considered in the intervention period.
62746121|NCT06662032|ACTIVE_COMPARATOR|Control Intervention|Participants in the control arm will follow the standard rehabilitation programme at a frequency of ideally 2 times a week. To align with the duration of the intervention arm, participants in the control arm will also perform an additional 15 minutes of exercises (following standard care of the site).
62553277|NCT01951924|EXPERIMENTAL|Group A: I10E then Kiovig®|1 g/kg for 1-3 days up to 2 g/kg for 2-5 days every 4 to 8 weeks (±7 days)
62746122|NCT04216784|ACTIVE_COMPARATOR|Furosemide (Lasix) alone|Cohort 1 will receive furosemide (Lasix) 40 to 80 mg IVP BID for at least 48 hours
62374253|NCT05389306|EXPERIMENTAL|MRI Scanning and CEUS for detection of small cervical lymph node metastases.|All patients enrolled will undergo an MRI Scanning and CEUS to evaluate their cervical lymph nodes. Ultrasound-guided lymph node aspiration and pathologic examination will be performed subsequently to obtain definitive diagnosis of the lymph nodes. The pathologic results of the lymph nodes will be adopted as gold standard to evaluate the diagnostic performance of MRI Scanning, CEUS, and the combined diagnostic criteria.
62746123|NCT04216784|ACTIVE_COMPARATOR|Combination of furosemide (Lasix) and albumin|Cohort 2 will receive combination of furosemide (Lasix) 40 to 80 mg IVP BID and albumin (25%) 12.5 grams IV BID for at least 48 hours
62746124|NCT00979342|EXPERIMENTAL|Cervical Block, 6 injection sites|Subject will receive a cervical block of 1% lidocaine and 0.25% bupivacaine, with injections in the following locations: 2cc at 12:00, 10cc at 3:00, 10 cc at 9:00, 5 cc at 4:00, 5 cc at 8:00, and 5 cc at 6:00.
62746125|NCT00979342|EXPERIMENTAL|Cervical Block, 2 injection sites|Subject will receive a cervical block of 1% lidocaine and 0.25% bupivacaine, with injections in the following locations: 10 cc at 4:00, and 10 cc at 8:00.
62746126|NCT00979342|EXPERIMENTAL|Ibuprofen q. 8 hours|Subjects will receive a post procedure pain management regimen of ibuprofen 800 mg every 8 hours, for the first 24 hours and then PRN.
62746127|NCT00979342|EXPERIMENTAL|Ibuprofen PRN|Subjects will receive a post procedure pain management regimen of ibuprofen 800 mg PRN.
62746128|NCT03242564|EXPERIMENTAL|Active Device|"Active Device: Vevazz LED red light therapy system~Vevazz LED red light therapy system is a treatment regimen using the Vevazz LED device for fat removal using LED red light therapy."
62746129|NCT06357091|EXPERIMENTAL|ACL reconstruction with human allogeneic cortical bone screw (Shark Screw®)|The sugery techniqueis the same for both arms. An allograft screw (Shark Screw ACL®; Surgebright GmbH, A-4040 Lichtenberg, Austria) is used. At the beginning of the operation, the diagnosis is confirmed arthroscopically. The tendon is prepared. The bone tunnels will be created due to the size of the graft. The graft is pulled in and fixed with the intereference screw (Shark Screw ACL®). The tibial bone tunnel will be filled with cancellous chips. Finally, the graft is checked for strength and possible anterior or lateral pinching. The arthroscopic fluid is aspirated and the wound is closed.
62746130|NCT06357091|ACTIVE_COMPARATOR|ACL reconstruction with Mecta Composite interference screw|The sugery techniqueis the same for both arms. A Mecta-composite-screw, (Medacta, Castello San Pietro, Swiss) is used. At the beginning of the operation, the diagnosis is confirmed arthroscopically. The tendon is prepared. The bone tunnels will be created due to the size of the graft. The graft is pulled in and fixed with the intereference screw (Mecta-composite-screw, Medacta). The tibial bone tunnel will be filled with cancellous chips. Finally, the graft is checked for strength and possible anterior or lateral pinching. The arthroscopic fluid is aspirated and the wound is closed.
62746131|NCT06076252|EXPERIMENTAL|Modified Blumgart Anastomosis of LPD|The effect of modified Blumgart technique in the treatment of periampulltrary carcinoma on postoperative pancreatic fistula
62374254|NCT01287988||Ocriplasmin|Subjects who were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study (TG-MV-006 or TG-MV-007)
62746132|NCT06076252|OTHER|Conventional Blumgart Anastomosis of LPD|The effect of Conventional Blumgart Anastomosis in the treatment of periampulltrary carcinoma on postoperative pancreatic fistula
62746133|NCT01995994||RT-CGM|
62746134|NCT06601517|EXPERIMENTAL|HDM1002 with Repaglinide, Atorvastatin, Digoxin and Rosuvastatin|"Period 1: Single dose of repaglinide, atorvastatin, digoxin and rosuvastatin~Period 2: Once daily dose of HDM1002~Period 3: Single dose of repaglinide, atorvastatin, digoxin and rosuvastatin with once daily dose of HDM1002"
62746135|NCT06314958||Stage II/III Colorectal Cancer, with Recurrence (Training)|Stage II/III Colorectal Cancer patients who received treatment with surgery and adjuvant chemotherapy, and experienced recurrence within five years.
62746136|NCT06314958||Stage II/III Colorectal Cancer, without Recurrence (Training)|Stage II/III Colorectal Cancer patients who received treatment with surgery and adjuvant chemotherapy, and did not experience recurrence within five years.
62746137|NCT06314958||Stage II/III Colorectal Cancer, with Recurrence (Validation)|Stage II/III Colorectal Cancer patients who received treatment with surgery and adjuvant chemotherapy, and experienced recurrence within five years.
62746138|NCT06314958||Stage II/III Colorectal Cancer, without Recurrence (Validation)|Stage II/III Colorectal Cancer patients who received treatment with surgery and adjuvant chemotherapy, and did not experience recurrence within five years.
62374255|NCT01287988||Placebo|Subjects who were exposed to a single intravitreal injection of placebo in a previous phase III study (TG-MV-006 or TG-MV-007)
62746139|NCT02964559|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62746140|NCT05711381|EXPERIMENTAL|Severe renal impairment|
62746141|NCT05711381|EXPERIMENTAL|Normal renal impairment|
62746142|NCT05711381|EXPERIMENTAL|Moderate renal impairment|
62746143|NCT05711381|EXPERIMENTAL|Mild renal impairment|
62746144|NCT02125851|EXPERIMENTAL|Xanthan Gum|"A total of 12 subject will be administered sucralose slurry and the xanthan gum slurry. Six will get sucralose first (then an hour later the xanthan gum) and 6 will receive the xanthan gum first (then an hour later the sucralose slurry).~The sucralose slurry will which will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 10 grams of sucralose and 1 millicurie (mCi) of Tc99m-Sulfur Colloid.~The xanthan gum-budesonide slurry will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 1ml of xanthan gum gel, crystallized orange flavoring agent, and 1mCi of Tc99-Sulfur colloid."
62746145|NCT02125851|EXPERIMENTAL|Honey|"A total of 12 subject will be administered sucralose slurry and the honey slurry. Six will get sucralose first (then an hour later the honey) and 6 will receive the honey first (then an hour later the sucralose slurry).~The sucralose slurry will which will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 10 grams of sucralose and 1 millicurie (mCi) of Tc99m-Sulfur Colloid.~The honey-budesonide slurry will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 6ml of honey and 1mCi of Tc99-Sulfur Colloid."
62746146|NCT00771043|EXPERIMENTAL|TYSABRI|
62746147|NCT00771043|EXPERIMENTAL|AVONEX|
62746148|NCT03926572|OTHER|Patients with Pulmonary arterial hypertension|Pulmonary arterial hypertension or non-operable chronic thromboembolic pulmonary hypertension established by right cardiac catheterization prior to inclusion in the study
62746149|NCT04894344|EXPERIMENTAL|Educational program|"Participants will be randomly assigned. Intervention Group: 57 participants Each participant will receive the same educational information throughout the study, each week a newsletter will be provided with recommendations and information that teaches them to choose low-sodium foods for 4 weeks.~Urine samples of 24 h before and after the Intervention will be analyzed."
62746150|NCT04894344|NO_INTERVENTION|Control group|Participants will be randomly assigned. Control group:57 participants Follow-up for 4 weeks. Urine samples of 24 h before and after the educational program will be analyzed.
62746151|NCT01184638|NO_INTERVENTION|Local anesthesia|Patients received local anesthesia without any intervention of general anesthetics
62746152|NCT01184638|ACTIVE_COMPARATOR|Inhalational anesthesia|Patients received sevoflurane anesthesia during general anesthesia
62746153|NCT01184638|ACTIVE_COMPARATOR|Intravenous anesthesia|Patients received intravenous anesthetic (Propofol) during general anesthesia
62746154|NCT02863172||Consenting Proband Group|Questionnaires completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
62746155|NCT02863172||Family Members (MDA Registered Patients) Group|Health questionnaire completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
62746156|NCT02863172||Family Members (Not MDA Registered Patients) Group|Health questionnaire completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
62374256|NCT03053973|EXPERIMENTAL|NIV directly started arm|Patients randomised to this arm will start noninvasive ventilation after baseline measurements are performed.
62553278|NCT01951924|EXPERIMENTAL|Group B : Kiovig® then I10E|1 g/kg for 1-3 days up to 2 g/kg for 2-5 days every 4 to 8 weeks (±7 days)
62746157|NCT03289663|ACTIVE_COMPARATOR|Control|The arm will receive bednets treated with conventional insecticide (Pyrethroid)
62746158|NCT03289663|EXPERIMENTAL|Experimental|The arm will receive bednets treated with new generation of insecticides (synergistic combination of insecticides)
62746159|NCT01942668|EXPERIMENTAL|Treatment 1|Combined Estradiol 1 mg / Progesterone 100 mg softgel capsule formulation and placebo taken orally once a day for twelve months.
62746160|NCT01942668|EXPERIMENTAL|Treatment 2|Combined Estradiol 0.5 mg / Progesterone 100 mg softgel capsule formulation and placebo taken orally once a day for twelve months.
62746161|NCT01942668|EXPERIMENTAL|Treatment 3|Combined Estradiol 0.5 mg / Progesterone 50 mg softgel capsule formulation and placebo, taken orally once a day for twelve months.
62746162|NCT01942668|EXPERIMENTAL|Treatment 4|Combined Estradiol 0.25 mg / Progesterone 50 mg softgel capsule formulation and placebo, taken orally once a day for twelve months.
62746163|NCT01942668|PLACEBO_COMPARATOR|Placebo|Two Placebo softgel capsules taken orally once a day for twelve months.
62746164|NCT06249555||Vedolizumab|"Group one will include participants who will be starting Vedolizumab as part of routine care.~Dose, frequency and duration are not mandated as part of the study and are determined by the health care provider."
62553279|NCT02553772|EXPERIMENTAL|OM3 Tear|Carboxymethylcellulose based eye drop \[Omega-3 (OM3) Tear\] administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
62746165|NCT06249555||IL-23 Antagonists|"Group two will include participants who will be starting an IL-23 antagonist as part of routine care.~Dose, frequency and duration are not mandated as part of the study and are determined by the health care provider."
62746166|NCT01194089|ACTIVE_COMPARATOR|Nasal Nicotine Spray|3 mg of nasal nicotine will be administered postoperatively.
62374257|NCT03053973|OTHER|NIV postponed arm|Patients randomised to this arm will, after baseline measurements have been done, first be followed for 3 months while on standard care, and thus serve as the control arm. After this 3 months period, measurements are repeated and patients will also be initiated on noninvasive ventilation.
62553280|NCT02553772|ACTIVE_COMPARATOR|REFRESH OPTIVE® ADVANCED|Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
62553281|NCT05237778|EXPERIMENTAL|TMR group|Patients will receive a sound while they generate a positive outcome of imagery rehearsal therapy (IRT). They will also receive the sound during REM sleep.
62553282|NCT05237778|ACTIVE_COMPARATOR|Control group|Patients will not receive a sound while they generate a positive outcome of imagery rehearsal therapy (IRT). They will receive the same sound as the experimental group during REM sleep under the same conditions.
62553283|NCT06291194|EXPERIMENTAL|Test group(AJU-S56 5%)|QID(4 times in a day) for 24 Weeks after Randomization
62746167|NCT01194089|PLACEBO_COMPARATOR|Nasal Normal Saline Spray|1 ml of nasal normal saline spray will be administered postoperatively.
62746168|NCT00370760|ACTIVE_COMPARATOR|1|
62746169|NCT00370760|PLACEBO_COMPARATOR|2|
62746170|NCT03321864|EXPERIMENTAL|Study arm|All patients recruited to the study (this arm) will have an additional transrectal ultrasound whilst already under GA for TP biopsy.
62746171|NCT06325046|EXPERIMENTAL|Arm I (near margin-less ART)|Patients undergo near margin-less ART for 2 treatments at least 3 days apart in the absence of disease progression or unacceptable toxicity. Patients also undergo CBCT and may undergo CT and/or MRI on study.
62746172|NCT06325046|ACTIVE_COMPARATOR|Arm II (standard SABR)|Patients undergo standard SABR for 5 treatments at least 2 days apart in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI on study.
62746173|NCT03150966|EXPERIMENTAL|Patients who received nanocurcumin|Patients who received nanocurcumin
62746174|NCT03150966|PLACEBO_COMPARATOR|Patients who received placebo|Patients who received placebo
62746175|NCT06658678|EXPERIMENTAL|Receiving an educational intervention|Receiving the educational video link on their mobile device
62746176|NCT06658678|NO_INTERVENTION|No educational intervention|
62746177|NCT05834933|NO_INTERVENTION|Standard care (SC)|Participants received one-on-one breast cancer awareness education; one-on-one monthly Breast Self-Examination (BSE) training; general breast cancer screening recommendations; and general lifestyle modification recommendations
62746178|NCT05834933|EXPERIMENTAL|SC + Risk assessment and counselling|Participants received Standard care as described in the SC arm above in addition to individualized breast cancer risk assessment, individualized breast cancer risk counseling, and lifestyle risk reduction recommendations
62746179|NCT04842630|EXPERIMENTAL|SHR-1916|
62746180|NCT03892668|EXPERIMENTAL|tranexamic acid|Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/ kg/h infusion in 500 ml Ringer's by infusion pump till the end of the procedure.
62746181|NCT03892668|ACTIVE_COMPARATOR|oxytocin|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one ampoule of oxytocin (10 U/mL/amp) (Syntocinon; Aventis Pharmaceutical Co.) will be added to 500 mL Ringer's solution running at a rate of 400 mU/min by infusion pump till the end of the procedure.
62746182|NCT03892668|PLACEBO_COMPARATOR|placebo|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
62746183|NCT04654611|OTHER|Treatment group|The intervention will be preservative free tafluprost 0.0015% topical ophthalmic solution given once daily for the study duration.
62746184|NCT03804463|EXPERIMENTAL|radical surgery group|Endometrial cancer radical surgery to be administered in this arm.
62746185|NCT03804463|EXPERIMENTAL|fertility preservation group|Fertility-sparing surgery to be administered in this arm.
62746186|NCT03804463|EXPERIMENTAL|ovarian preservation group|Ovarian preservation surgery to be administered in this arm.
62746187|NCT03575065|EXPERIMENTAL|Cohort 1: Triple-negative breast cancer (TNBC)|Locally advanced or metastatic TNBC
62746188|NCT03575065|EXPERIMENTAL|Cohort 2: HR(+)/HER2(-) breast cancer|Locally advanced or metastatic Hormone receptor-positive(HR+) human epidermal growth factor receptor2 Negative(HER2-) breast cancer
62746189|NCT04883125|ACTIVE_COMPARATOR|Interventional no|Patients treated with both drugs ( imatinib and pioglitazone)
62746190|NCT04883125|NO_INTERVENTION|Control|Historical control (treated with imatinib only)
62746191|NCT01557777|EXPERIMENTAL|Navitoclax, ABT-263|
62374258|NCT03505957|EXPERIMENTAL|SafeBreak Vascular Intervention|Every study participant will have SafeBreak Vasculars installed in each of their IV lines.
62374259|NCT04724772|EXPERIMENTAL|Blepharoplasty patient|Patient receives LA in one eye and LA with TXA in the other eye. They are blinded. They compare eyes without knowing which one received the TXA.
62374260|NCT01917591|ACTIVE_COMPARATOR|MariGen Wound|Fish derived extra cellular matrix
62553284|NCT06291194|PLACEBO_COMPARATOR|Placebo group(Vehicle)|QID(4 times in a day) for 24 Weeks after Randomization
62746192|NCT06411912|EXPERIMENTAL|NIDO-361|Participants receive 100 mg of NIDO-361 given orally once daily.
62746193|NCT06411912|PLACEBO_COMPARATOR|Placebo|Participants receive matched dose placebo given orally once daily.
62746194|NCT01151059|OTHER|Group 1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
62746195|NCT04835194||Phenotype 1 (from LCA)|
62746196|NCT04835194||Phenotype 2 (from LCA)|
62746197|NCT04835194||Phenotype 3 (from LCA)|
62746198|NCT00557310|EXPERIMENTAL|Teriparatide|20 micrograms (mcg) teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
62746199|NCT03181425||Imaging assessment|All subject of the study have a knee osteoarthritis (OA) and are going to have a knee prosthetic surgery with cartilage excision. Imaging measurements are conducted on human cartilage samples (2 samples per patient are selected : healthy and severely degraded).
62746200|NCT03299881|EXPERIMENTAL|Treatment|The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatone for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.
62553285|NCT06030375|ACTIVE_COMPARATOR|KAND567 in ascending doses|In each of the 3 cohorts, 6 subjects were planned to be randomised to receive KAND567. The dose levels were 33.8 mg/6 h (cohort 1), 67 mg/6 h (cohort 2), or 134 mg/6 h (cohort 3).
62746201|NCT03299881|ACTIVE_COMPARATOR|Control|Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
62746202|NCT05627258|EXPERIMENTAL|Group 1|5 mg/kg IV single administration
62746203|NCT05627258|EXPERIMENTAL|Group 2|5 mg/kg SC single administration
62746204|NCT05627258|EXPERIMENTAL|Group 3|20 mg/kg IV single administration
62746205|NCT05627258|EXPERIMENTAL|Group 4|40 mg/kg IV single administration
62374261|NCT01917591|ACTIVE_COMPARATOR|Oasis Sheet|Pig intestine derived extra cellular matrix
62374262|NCT06186622|EXPERIMENTAL|Orforglipron (Part 1)|Participants will receive Orforglipron capsule and tablet formulation with Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, Midazolam and Sodium Bicarbonate administered orally.
62746206|NCT05627258|EXPERIMENTAL|Group 5|5 mg/kg SC repeat dosing
62746207|NCT05627258|EXPERIMENTAL|Group 6|20 mg/kg IV repeat dosing
62746208|NCT01642498|EXPERIMENTAL|Group A|ROX Coupler + continuing standard antihypertensive medications
62746209|NCT01642498|NO_INTERVENTION|Group B|Continuing standard antihypertensive medications
62746210|NCT04120753|EXPERIMENTAL|Treatment 1|OLOMAX 20/5/5mg
62746211|NCT04120753|EXPERIMENTAL|Treatment 2|OLOMAX 20/5/10mg
62746212|NCT04120753|ACTIVE_COMPARATOR|Treatment 3|Olmesartan 20 mg/Amlodipine 5 mg
62746213|NCT01740466||Ocular diseases|Observational
62746214|NCT01453751|EXPERIMENTAL|Intravenous Injection of AD-SVF|Intravenous administration of AD-SVF.
62746215|NCT03951493|EXPERIMENTAL|RSHF + zoledronic acid|Patients receive RSHF according to : 30 Gy in 5 fractions of 6 Gy spaced 48 hours or 27 Gy in 3 fractions of 9 Gy spaced 48 hours or 20 Gy in 1 fraction. combined with zoledronic acid (4 mg IV slow monthly for 12 months, dose adjusted according to creatinine clearance).
62746216|NCT03951493|ACTIVE_COMPARATOR|RSHF|Patients receive only RSHF according to : 30 Gy in 5 fractions of 6 Gy spaced 48 hours or 27 Gy in 3 fractions of 9 Gy spaced 48 hours or 20 Gy in 1 fraction.
62374263|NCT06186622|EXPERIMENTAL|Orforglipron (Part 2)|Participants will receive Orforglipron capsule and tablet formulation with Simvastatin, Digoxin and Sodium Bicarbonate administered orally.
62746217|NCT05064176|EXPERIMENTAL|Reconstructive lymphatic surgery|"The intervention treatment is reconstructive lymphatic surgery and consists of the application of lymphovenous anastomosis (LVA), lymph node transfer (LNT) or a combination of both. The choice of reconstructive technique(s) is determined by the surgeon and is based on the algorithm for reconstructive lymphatic surgery of lymphoedema.~Additionally, all patients receive usual care (i.e. maintenance decongestive lymphatic therapy)"
62746218|NCT05064176|ACTIVE_COMPARATOR|No surgery|All patients receive usual care (i.e. maintenance decongestive lymphatic therapy)
62746219|NCT03926533|EXPERIMENTAL|Telehealth ICU Recovery Program|Components of the ICU RC telehealth visit will be structured parallel to what is done during a typical in-person clinic visit. The telehealth intervention consists of 5 chronological components conducted during two 1.5 hour telehealth clinic visits (the same time required for an in-person visit). Upon completion of the pre-intervention baseline assessment, the study coordinator will contact patients randomized to the intervention arm to schedule the first telehealth visit. Study visits will occur at 3 weeks and 3 months following hospital discharge.
62746220|NCT03926533|NO_INTERVENTION|Standard Recovery Conditions|participants assigned to the standard of care control group will be contacted by the study coordinator to ensure the patient has a primary care and/or specialist appointment scheduled. At this time, patients will also receive an electronic PICS guide for ICU survivors created by the Society of Critical Care Medicine. Patients will be directed to use the information provided in the PICS guide for ICU survivors to connect with resources.
62746221|NCT06107842|ACTIVE_COMPARATOR|Gerofit exercise|Participants enrolled in the Gerofit program
62746222|NCT06107842|PLACEBO_COMPARATOR|Health education|Participants enrolled in monthly in-person health education sessions which do not include a physical activity/exercise promotion session
62746223|NCT05594927|EXPERIMENTAL|Icaritin soft capsule|
62746224|NCT05594927|ACTIVE_COMPARATOR|Huachansu tablet|
62746225|NCT01581034|ACTIVE_COMPARATOR|Padma|
62553286|NCT06030375|PLACEBO_COMPARATOR|Placebo|In each of the 3 cohorts, 2 subjects were planned to be randomised to receive Placebo.
62553287|NCT03513991|EXPERIMENTAL|IF-VLP (very low protein)|Participants were exclusively fed with an infant formula containing 1g of protein/dL, 26% alpha lactoalbumin, and 100% A2 casein for 4 months.
62746226|NCT01581034|PLACEBO_COMPARATOR|Placebo|
62374264|NCT04543630|ACTIVE_COMPARATOR|Particulated autogenous bone|Particulated autogenous bone is considered the gold standard for sinus floor augmentation. The bone will be harvested locally
62553288|NCT03513991|OTHER|IF-LP (low protein)|Participants were exclusively fed with an infant formula containing 1.3 g of protein/dL, 26% alpha lactoalbumin, 100% A2 casein for 4 months.
62553289|NCT03513991|OTHER|IF-CSP (control standard protein)|Participants were exclusively fed with an infant formula containing 1.5 g of protein/dL, 50% A1 casein and 50% A2 casein for 4 months.
62553290|NCT03513991|NO_INTERVENTION|HM (human milk)|Participants were exclusively breastfed
62746227|NCT00916838||Type 1 Diabetes Mellitis|Children with Type 1 Diabetes Mellitis (T1DM) between 4 and 16 were recruited.
62746228|NCT00916838||Non diabetic Control|62 healthy siblings also enrolled in the study between the ages of 4 and 17.
62746229|NCT03241940|EXPERIMENTAL|Treatment (CD19/CD22-CAR T cells, chemotherapy)|Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and cyclophosphamide IV over 60 minutes on day -2. Patients then receive CD19/CD22-CAR T cells IV over 10-20 minutes on day 0. Patients that benefited from the first dose of CD19/CD22-CAR T cells, had no unacceptable side effects, and have enough cells left over may receive 2 or 3 additional doses of CD19/CD22-CAR T cells.
62746230|NCT02522585||Conservative management|Patients diagnosed of CIN-II by directed biopsy
62746231|NCT01224340|EXPERIMENTAL|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
62746232|NCT01224340|EXPERIMENTAL|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path. The player got points for collected fishes but also credits for time of flying and speed.
62746233|NCT01224340|EXPERIMENTAL|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
62746234|NCT03888040|EXPERIMENTAL|Blood Flow Restriction Training|This leg will then perform low-load resistance training (30% of 1-RM) including 3 sets of 15 knee extensions performed as fast as possible while seated upright in a knee extension weight machine. Sets will be interspersed with 30 seconds rest. This leg will always perform the training with blood flow restriction.
62746235|NCT03888040|EXPERIMENTAL|Resistance Training Only|This leg will then perform low-load resistance training (30% of 1-RM) including 3 sets of 15 knee extensions performed as fast as possible while seated upright in a knee extension weight machine. Sets will be interspersed with 30 seconds rest. This leg will always perform the training without blood flow restriction.
62746236|NCT04173260|EXPERIMENTAL|Intervention arm - Oral Deutetrabenazine|This is the only arm for this trial. All subjects will receive oral Deutetrabanazine.
62746237|NCT01321918|OTHER|Case subjects|
62746238|NCT01321918|OTHER|Control subjects|
62746239|NCT02431910|NO_INTERVENTION|Control group|The control group remains at rest for 10 minutes, which is not applied KT in the RF, VL and VM muscles. The volunteers of this group perform all evaluation without the application of KT
62746240|NCT02431910|PLACEBO_COMPARATOR|Placebo group|The Kinesio Taping (KT) is applied on the vastus lateralis (VL), vastus medialis (VM) and rectus femoris (RF) muscles longitudinally from proximal to the distal. For the RF proximal anchor is applied 5cm below the anterior superior iliac spine and the distal anchor the upper edge of the patella. VL in the proximal and distal anchor will be fixed in greater trochanter of the femur and the lateral edge of the patella. As for the VM muscle proximal anchor will be applied to the middle third from the medial region of the thigh and the distal anchor on the medial edge of the patella. The anchors are applied with 0% tension and therapy area will follow on the belly of the muscles with a 0%.
62746241|NCT02431910|EXPERIMENTAL|Kinesio Taping group|The Kinesio Taping (KT) is applied on the vastus lateralis (VL), vastus medialis (VM) and rectus femoris (RF) muscles longitudinally from proximal to the distal. For the RF proximal anchor is applied 5cm below the anterior superior iliac spine and the distal anchor the upper edge of the patella. VL in the proximal and distal anchor will be fixed in greater trochanter of the femur and the lateral edge of the patella. As for the VM muscle proximal anchor will be applied to the middle third from the medial region of the thigh and the distal anchor on the medial edge of the patella. The anchors are applied with 0% tension and therapy area will follow on the belly of the muscles with a 50%. This application will be held with subjects standing on one foot, with the hip of the non-dominant limb at 0º and knee flexed at 90º.
62746242|NCT00853242|PLACEBO_COMPARATOR|Placebo|Placebo matched to Genz-644470 tablet orally three times a day (TID) with meals for 3 weeks.
62746243|NCT00853242|EXPERIMENTAL|Genz-644470 2.4 Grams Per Day (g/day)|Genz-644470 2.4 g/day tablets dosed orally TID with meals for 3 weeks.
62746244|NCT00853242|EXPERIMENTAL|Genz-644470 4.8 g/day|Genz-644470 4.8 g/day tablets dosed orally TID with meals for 3 weeks.
62746245|NCT00853242|EXPERIMENTAL|Genz-644470 7.2 g/day|Genz-644470 7.2 g/day tablets dosed orally TID with meals for 3 weeks.
62746246|NCT00853242|ACTIVE_COMPARATOR|Sevelamer Carbonate 2.4 g/day|Sevelamer Carbonate 2.4 g/day tablets dosed orally TID with meals for 3 weeks.
62746247|NCT00853242|ACTIVE_COMPARATOR|Sevelamer Carbonate 4.8 g/day|Sevelamer Carbonate 4.8 g/day tablets dosed orally TID with meals for 3 weeks.
62553291|NCT04335513|EXPERIMENTAL|Intervention|Early diabetes management and education including focused education based on pathophysiology of type 1 diabetes, factors which impact blood glucose, and effects of insulin using data from continuous glucose monitoring device (CGM) worn unblinded at least 20 days per month with interpretation and education on results. Early initiation of insulin therapy, when warranted based on a pattern of prolonged or repeated high blood glucose values.
62746248|NCT00853242|ACTIVE_COMPARATOR|Sevelamer Carbonate 7.2 g/day|Sevelamer Carbonate 7.2 g/day tablets dosed orally TID with meals for 3 weeks.
62746249|NCT01380197|ACTIVE_COMPARATOR|Randomizing particiipants to Morphine|Randomizing participants to Morphine or Nubain for treatment of Sickle Cell Pain Crisis
62746250|NCT01380197|ACTIVE_COMPARATOR|Randomization to Nubain|Randomization toNubain or Morphine for the management of Pain Crisis in Sickle Cell patients
62746251|NCT00951080|EXPERIMENTAL|SNaP Wound Care System|
62746252|NCT00951080|ACTIVE_COMPARATOR|Traditional NPWT System|
62746253|NCT06265792|EXPERIMENTAL|The experimental group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy.The experimental group was given Stellate Ganglion Block.
62746254|NCT06265792|ACTIVE_COMPARATOR|The control group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy.
62746255|NCT00006253|EXPERIMENTAL|Nurse|Receives symptom management assistance from an oncology nurse via the telephone
62746256|NCT00006253|EXPERIMENTAL|Non-nurse coach|Receives symptom management assistance from a non-nurse coach via telephone
62553292|NCT04335513|ACTIVE_COMPARATOR|Control|Usual education and advice on glycemic surveillance based on protocols of TEDDY/DAISY/ASK (ongoing studies at BDC). This includes: blood glucose checks 2-3 times per month, participant-led contact with study personnel when abnormalities are noted and transition to clinical care when criteria for clinical type 1 diabetes are met.
62746257|NCT05475483|EXPERIMENTAL|SOM3355 300 mg BID|Administration of SOM3355 in up-titration for 3 weeks up to the maintenance dose of 300 mg BID (twice daily) administered for 7 additional weeks, and down-titration for 2 weeks.
62746258|NCT05475483|EXPERIMENTAL|SOM3355 200 mg BID|Administration of SOM3355 in up-titration for 2 weeks up to the maintenance dose of 200 mg BID (twice daily) administered for 8 additional weeks, and down-titration for 2 weeks.
62746259|NCT05475483|PLACEBO_COMPARATOR|Placebo BID|Administration of matching Placebo BID (twice daily) for 12 weeks.
62746260|NCT03570918|EXPERIMENTAL|MGD014 0.1 micrograms/kilogram (mcg/kg)|a single 2-hour infusion
62746261|NCT03570918|EXPERIMENTAL|MGD014 0.3 mcg/kg|a single 2-hour infusion
62746262|NCT03570918|EXPERIMENTAL|MGD014 1.0 mcg/kg|a single 2-hour infusion
62746263|NCT03570918|EXPERIMENTAL|MGD014 3.0 mcg/kg|a single 2-hour infusion
62746264|NCT03570918|EXPERIMENTAL|MGD014 10.0 mcg/kg|a single 2-hour infusion
62746265|NCT03570918|EXPERIMENTAL|MGD014 30.0 mcg/kg|a single 2-hour infusion
62746266|NCT03570918|EXPERIMENTAL|MGD014 100.0 mcg/kg|a single 2-hour infusion
62746267|NCT03570918|EXPERIMENTAL|MGD014 300.0 mcg/kg|a single 2-hour infusion
62746268|NCT03570918|EXPERIMENTAL|MGD014 300.0 mcg/kg multiple doses|2-hour infusion every 2 weeks for 3 infusions
62746269|NCT03333096|OTHER|Glaucoma and mild cognitive impairment|"Device: Ocusweep test battery Neuropsychological test battery~Ocusweep system compared to neuropsychological testing"
62746270|NCT04193865||Extracorporeal Life Support with Renal Replacement Therapy|"This cohort will include all subjects receiving extracorporeal life support with concurrent continuous renal replacement therapy.~Two blood samples and one ultrafiltration sample will be obtained for the study protocol twice per day (every 12 hours) for the duration of each participants's CRRT course."
62374265|NCT04543630|EXPERIMENTAL|Advanced platelet-rich fibrin|Advanced platelet-rich fibrin will be be obtained through a blood sample from the participant
62746271|NCT04193865||Renal Replacement Therapy|"This cohort will include all subjects receiving continuous renal replacement therapy (no extracorporeal life support).~Two blood samples and one ultrafiltration sample will be obtained for the study protocol twice per day (every 12 hours) for the duration of each patient's CRRT course."
62746272|NCT05577312|EXPERIMENTAL|BRL-101|BRL-101 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Subjects will receive a single infusion of BRL-101.
62374266|NCT04485936|EXPERIMENTAL|Epitomee Device|the participants receive the device which is non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of early satiation and prolonged satiety
62374267|NCT00205946|PLACEBO_COMPARATOR|Placebo|
62746273|NCT00185380|EXPERIMENTAL|LCS12|Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro
62374268|NCT00205946|ACTIVE_COMPARATOR|Bupropion|
62374269|NCT05387135|SHAM_COMPARATOR|sham Transcutaneous Vagus Nerve Stimulation|For sham-t-VNS device was turned 180°, stimulating the outer earlobe which does not contain fibers of the ABVN. A similar protocol as for active stimulation was used.
62746274|NCT00185380|EXPERIMENTAL|LCS16|Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro
62746275|NCT00185380|ACTIVE_COMPARATOR|IUS20 (Mirena)|Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro
62746276|NCT01359241|EXPERIMENTAL|closed-loop insulin delivery|Subcutaneous insulin delivery adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
62746277|NCT01359241|ACTIVE_COMPARATOR|Usual diabetes treatment regimen|Usual non-insulin glucose-lowering medications
62746278|NCT04047875|EXPERIMENTAL|Norethisterone 10mg/day|NET-only pill (Norethisterone, Primolut-Nor®), 10 mg/day, 1 pill per day until 2 consecutive days without bleeding/spotting (maximum use of 1 box of Primolut-Nor® per bleeding episode)
62746279|NCT04047875|PLACEBO_COMPARATOR|Placebo|Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting (maximum use of 1 box of Placebo per bleeding episode)
62746280|NCT03966963|EXPERIMENTAL|Eye Movement Desensitization Reprocessing (EMDR)|Subjects with trauma-related symptomology resultant from CSA will undertake EMDR; they will be systematically observed through use of their quantitative treatment outcome measures at both pre- and post- treatment alongside one-month follow-up interview data to determine outcomes of interest (namely emotional, behavioural and neuropsychological functioning).
62746281|NCT06414135|EXPERIMENTAL|Relma-cel arm|All participants will receive Relma-cel once at different dose levels
62746282|NCT03479294||Exposure group|Exposure group patients are those who voluntarily choose to use Shenlingcao Oral Liquid recommended by the doctor in NSCLC patients receiving adjuvant chemotherapy. Jiangzhong Group will donate the first 30 bottles of medicine, and afterwards, patients may purchase if they still need to take it. The length of time and dose of Shenlingcao Oral Liquid are unlimited and other adjunctive treatments may be used at the same time.
62746283|NCT03479294||Control group|Control group patients are those who voluntarily choose not to use Shenlingcao Oral Liquid recommended by the doctor in NSCLC patients receiving adjuvant chemotherapy.
62746284|NCT00964665|EXPERIMENTAL|Group 1 ABF656 900ug Q2w|
62746285|NCT00964665|EXPERIMENTAL|Group 2 ABF656 900ug Q4w|
62746286|NCT00964665|EXPERIMENTAL|Group 3 AB656 1200ug Q4w|
62746287|NCT00964665|EXPERIMENTAL|Group 4 ABF656 1500ug Q4w|
62746288|NCT00964665|ACTIVE_COMPARATOR|Group 5 Pegasys® 180µg qw|
62746289|NCT00559429|ACTIVE_COMPARATOR|C1|
62746290|NCT00559429|ACTIVE_COMPARATOR|C2|
62746291|NCT00559429|ACTIVE_COMPARATOR|C3|
62746292|NCT00559429|ACTIVE_COMPARATOR|C4|
62746293|NCT01381276|EXPERIMENTAL|Cassava Treatment 1|Single meal containing bio-fortified, high carotenoid cassava without oil.
62746294|NCT01381276|EXPERIMENTAL|Cassava Treatment 2|Single meal containing bio-fortified, high carotenoid cassava with oil.
62746295|NCT01381276|ACTIVE_COMPARATOR|Cassava Treatment 3|Single meal containing low carotenoid cassava with oil and retinyl palmitate.
62553293|NCT00556244|ACTIVE_COMPARATOR|2|
62746296|NCT00820859|EXPERIMENTAL|1|
62746297|NCT00820859|ACTIVE_COMPARATOR|2|
62746298|NCT04553744||Observational (survey)|Participants complete an online survey over 5-10 minutes asking how they would manage lymph node basins in the extremity sarcoma.
62746299|NCT01205061|EXPERIMENTAL|Emervel Deep Lidocaine|NLFs (Nasolabial Folds) were injected with Emervel Deep Lidocaine (20 mg/mL with 0.3% lidocaine).
62746300|NCT01205061|ACTIVE_COMPARATOR|Juvederm Ultra Plus|NLFs were injected with Juvéderm Ultra Plus (24 mg/mL).
62746301|NCT01337843|ACTIVE_COMPARATOR|Control Group|Control Group participants will receive a well-regarded book for back pain patients.
62553294|NCT02186002|EXPERIMENTAL|Group 1|A single oral dose of 10 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo.
62553295|NCT02186002|EXPERIMENTAL|Group 2|A single oral dose of 50 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 50 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
62746302|NCT01337843|EXPERIMENTAL|Wellnes Workbook|Participants will receive the Wellness Workbook, a web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase their physical activity and manage stress with relaxation and mindfulness training
62746303|NCT01683747|EXPERIMENTAL|Tranexamic acid|Study group receives enteral tranexamic acid in normal saline in addition to usual care.
62746304|NCT01683747|PLACEBO_COMPARATOR|Control group|Control group receives vehicle (normal saline) without study drug and usual care.
62746305|NCT01287390|ACTIVE_COMPARATOR|standard radiotherapy treatment|These patients receive the normal standard treatment.
62746306|NCT01287390|EXPERIMENTAL|adaptive radiotherapy|These patients receive the adaptive image-guided intensity-modulated radiotherapy (IMRT) for head and neck cancer.
62746307|NCT06660771|EXPERIMENTAL|Herbst|The Herbst appliance is fixed and rigid functional appliance. It consists of attachments (casted splints) in the lateral segments of both jaws which are connected by a telescoping mechanism from the upper posterior to the lower anterior region resulting in mandibular bite jumping.
62746308|NCT06660771|EXPERIMENTAL|Twin Block|"Twin-block appliance is used with two separate acrylic plates for the lower and upper jaw.~It consists of acrylic bite blocks that lock together at a 70° angle, allowing the mandible to be positioned in front."
62746309|NCT04522336|EXPERIMENTAL|Treatment (pembrolizumab, chemoradiotherapy)|See Detailed Description
62746310|NCT02643563|EXPERIMENTAL|Ropivacaine 0.5%|Low volume (5 ml) Interscalene Block with Ropivacaine 0.5%
62746311|NCT02643563|ACTIVE_COMPARATOR|Ropivacaine 1%|Low volume (5 ml) Interscalene Block with Ropivacaine 1%
62746312|NCT02643563|ACTIVE_COMPARATOR|Bupivacaine 0.5% + epinephrine 1:200,000|Low volume (5 ml) Interscalene Block with Bupivacaine 0.5% + epinephrine 1:200,000
62746313|NCT06435364|EXPERIMENTAL|Vagus nerve|This non-invasive system is activated by the cutaneous distribution of vagus nerve afferents via the external ear.
62567243|NCT05045443|ACTIVE_COMPARATOR|Curcumin|Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement (composed of Tumeric (curcuma longa)root 450mg and Tumeric extract (curcuma longa )root 50mg ) standardized to contain 95%curcuminoids, it will given twice daily for 1 month starting at week 1 of maintenance phase of chemotherapy (Time 1) . It is preferably to be taken with meals but may be opened and prepared as a tea
62746314|NCT06435364|ACTIVE_COMPARATOR|Manual therapy|Manual therapy is effective in the treatment of musculoskeletal pain.
62746315|NCT01217879||Group 1|
62746316|NCT01295840|NO_INTERVENTION|CRT therapy|Cardiac Resynchronization Therapy Defibrillator (CRT-D)
62746317|NCT01803191|EXPERIMENTAL|Fosfomycin 3 g|Unique oral dosis of 3 g of fosfomycin 1hour before of biopsy
62746318|NCT01803191|ACTIVE_COMPARATOR|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg before biopsy
62746319|NCT06485856|OTHER|Experimental group|During the procedural procedures applied to patients who are monitored in intensive care and who are conscious but unable to express themselves verbally, their pictures will be taken 12 times for one minute. This procedure will be applied to the same patient during 4 different procedures. After the procedure, the patient will be asked to score his/her pain numerically between 0-10 (0-no pain, 10-severe/unbearable pain). In addition, the images obtained will be evaluated by three expert nurses and they will be asked to estimate the patient's pain based on their facial expressions. Meanwhile, the pain assessment based on the patient's pictures will be evaluated numerically between 0-10 by the Facial Action Coding system. As the final process, all data will be compared and the patient's pain expression will be compared with the Facial Action Coding system and the pain evaluations of the experts. The assessment closest to the patient's pain expression will be determined.
62567244|NCT05045443|PLACEBO_COMPARATOR|Standard of nutritional care|Standard of nutritional support care
62746320|NCT05243745|EXPERIMENTAL|Test Product|Participants will dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion. Test product is a combination toothpaste of 3% methyl vinyl ether/maleic anhydride co-polymer (PVM/MA) + 5% Potassium Nitrate (KNO3). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for one timed minute, twice daily (morning and evening); Participants will be permitted to rinse with water post-brushing.
62746321|NCT05243745|ACTIVE_COMPARATOR|Comparator 1|Participants will dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion. Comparator 1 toothpaste is containing 3% PVM/MA. Participants will brush their two selected 'test teeth' first, followed by the whole mouth for one timed minute, twice daily (morning and evening); participants will be permitted to rinse with water post-brushing.
62746322|NCT05243745|ACTIVE_COMPARATOR|Comparator 2|Participants will dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion. Comparator 2 toothpaste is containing 5% KNO3. Participants will brush their two selected 'test teeth' first, followed by the whole mouth for one timed minute, twice daily (morning and evening); participants will be permitted to rinse with water post-brushing.
62746323|NCT05243745|OTHER|Negative Control|Participants will dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion. Negative control is regular fluoride toothpaste. Participants will brush their two selected 'test teeth' first, followed by the whole mouth for one timed minute, twice daily (morning and evening); participants will be permitted to rinse with water post-brushing.
62746324|NCT05514756|ACTIVE_COMPARATOR|Active t-VNS|Active t-VNS at 8 Hz to the left cymba conchae, acutely for up to 60 minutes
62746325|NCT05514756|SHAM_COMPARATOR|Sham t-VNS|Sham t-VNS at 8 Hz to the left earlobe, acutely for up to 60 minutes
62746326|NCT05514756|PLACEBO_COMPARATOR|Baseline assessments|Baseline assessments of neurocardiovascular stability, cognition and serum and plasma inflammatory markers per participant serve to act as their own control in this three-part crossover design
62746327|NCT05866679|EXPERIMENTAL|Hyperpolarized 13-C-pyruvate|
62746328|NCT04738760||Group 1|Moderate and severe patients who were infected with SARS-CoV-2 and who were already receiving treatment with standard dose vitamin D in addition to standard COVID-19 management.
62746329|NCT04738760||Group 2|Moderate and severe patients who were infected with SARS-CoV-2 and who were already receiving treatment with high dose vitamin Din addition to standard COVID-19 management.
62746330|NCT01605604|EXPERIMENTAL|recieves Buddhist mindfullness|
62746331|NCT04009694|EXPERIMENTAL|Pelvic Floor Muscle Training|"Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist.~Participants will be assessed at weeks 0 / 4 / 10 \& 16 and the outcome measures will be recorded at week 0 \& week 16.~During each assessment, participants will be educated regarding the anatomy of pelvic organ prolapses and the pelvic floor muscles. They will be taught how to contract their pelvic floor, offered a vaginal examination, given a personalised pelvic floor muscle training programme (including the Knack) - up to a ten second hold long contractions (x 10 repitations) and up to 10 quick contractions. They will also be taught a sub max contraction for up to 30 seconds, offered lifestyle management advice including avoiding heavy lifting or straining. A leaflet explaining the aforementioned information will also be provided at the initial assessment."
61986341|NCT03492255|EXPERIMENTAL|Cyclones Group: Cyclophosphamide+Methylprednisolone no oral GC|CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg / fortnightly) + Methylprednisolone \[500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)\] without oral glucocorticoid (GC). From the third month, the group will receive only oral MMF (2-3 g) until the 6th month. Patients using GC ≤ 20 mg/day may enter the protocol with immediate reduction to 15 mg/day with a reduction of 5mg/month until complete withdrawal.
61986342|NCT03713203|EXPERIMENTAL|Pagetex PDT|"PAGETEX medical device for photodynamic therapy (PDT). Composed of the association: Laser source + optical fiber + diffuser support incorporating luminous textiles + drug photosensitizer (Metvixia®)"
61986343|NCT06095323|EXPERIMENTAL|Prophylactic compression sleeves group|The intervention group will wear compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg) during the day for 12 months.
61986344|NCT06095323|NO_INTERVENTION|routine care group|The routine care group will proceed as an observation and receive standard lymphedema education during the clinical trial.
62374270|NCT05387135|ACTIVE_COMPARATOR|Transcutaneous Vagus Nerve Stimulation|Afferents of the Auricular branch of vagus nerve (ABVN) were stimulated using a t-VNS device (TENS 7000TM) made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000). The electrode was placed in the left cymba concha with direct contact on the skin after cleaning with an alcohol swab. The stimulation for both groups will last for 30 minutes once a day for 3 days per week for 12 weeks. The amplitude of the output current was between 0.25-2.0 mA as tolerated and 250 µs width at 10 Hz.
62374271|NCT03371589|EXPERIMENTAL|no P.O corticosteroids|Steroids injection
62553296|NCT02186002|EXPERIMENTAL|Group 3|A single oral dose of 200 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 200 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
62553297|NCT02186002|EXPERIMENTAL|Group 4|A single dose of 500 mg ACT-451840 or placebo to be administered to subjects in the fasted state, followed by an observation period of 4 days. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 500 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
61986345|NCT04708938|EXPERIMENTAL|Treatment group|High voltage electrical stimulation + exercise therapy
61986346|NCT04708938|ACTIVE_COMPARATOR|Control group|Exercise therapy
62374272|NCT02949687|EXPERIMENTAL|ileal interposition sleeve sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
62374273|NCT01071291|EXPERIMENTAL|Arm A|Arm A will receive a Niaspan treatment in Period 1 and Placebo treatment in Period 2
62374274|NCT01071291|EXPERIMENTAL|Arm B|Arm B will receive a Placebo treatment in Period 1 and Niaspan treatment in Period 2
62374275|NCT02249260|EXPERIMENTAL|Behavioral|Group-based high intensity interval training and lifestyle counseling
62374276|NCT04427410||pregnancy|
62374277|NCT04427410||postpartum|
62374278|NCT00520091|ACTIVE_COMPARATOR|Cohort 1|Induction chemotherapy and chemoradiation without celecoxib
62374279|NCT00520091|EXPERIMENTAL|Cohort 2|Induction chemotherapy and chemoradiation with celecoxib
62746332|NCT02050802|EXPERIMENTAL|Treatment sequence BCAD|Subjects received study medication in the sequence BCAD. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
62746333|NCT02050802|EXPERIMENTAL|Treatment sequence ABDC|Subjects received study medication in the sequence ABDC. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
62746334|NCT02050802|EXPERIMENTAL|Treatment sequence DACB|Subjects received study medication in the sequence DACB. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
62746335|NCT02050802|EXPERIMENTAL|Treatment sequence CDBA|Subjects received study medication in the sequence CDBA. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
62553298|NCT02186002|EXPERIMENTAL|Group 5|A single oral dose of 1000 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 1000 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
62553299|NCT02186002|EXPERIMENTAL|Group 6|A single oral dose of ACT-451840 or placebo to be administered to subjects in the fed state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. The dose of ACT-451840 to be determined on the basis of the pharmacokinetic results for the previous groups
62553300|NCT01974531||Preterm birth/ Timely birth|
62553301|NCT01974531||Women/men|
62374280|NCT02455440|ACTIVE_COMPARATOR|Esmolol|500 mcg/kg of esmolol bolus 10 min before induction of anesthesia, followed by additional 200 mcg/kg/min of esmolol until 30 minutes after extubation.
62553302|NCT01546428|EXPERIMENTAL|INC280|
62553303|NCT03112473|ACTIVE_COMPARATOR|Bilateral TENS (Bi-TENS) group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with bilateral electrical stimulation
62553304|NCT03112473|PLACEBO_COMPARATOR|Unilateral TENS (uni-TENS) group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with unilateral electrical stimulation on paretic side and sham electrical stimulation on the non-paretic side
62553305|NCT03112473|PLACEBO_COMPARATOR|Placebo group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with bilateral sham electrical stimulation
62553306|NCT03112473|NO_INTERVENTION|Control group|No Active intervention
62553307|NCT02964247|EXPERIMENTAL|liraglutide + SGLT2i ± metformin|
62553308|NCT02964247|PLACEBO_COMPARATOR|liraglutide placebo + SGLT2i ± metformin|
62553309|NCT00727103|ACTIVE_COMPARATOR|1 Varenicline|Varenicline will be dispensed in 0.5 mg (blue capsules containing a 0.5 mg varenicline tablet) and 1 mg (red capsules containing a 1 mg varenicline tablet) capsules taken orally. During the first 3 days of medication, participants will take one blue capsule (0.5 mg tablet) of varenicline daily. If the medication is well-tolerated, the dose will be increased to one blue capsule (0.5 mg) po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 red capsule (1 mg) po twice daily. At the end of the 8th week, varenicline will be discontinued.
62553310|NCT00727103|PLACEBO_COMPARATOR|2 Placebo|Placebo will be dispensed in blue and red color coded capsules. During the first 3 days, participants will take one blue capsule po daily. If the medication is well-tolerated, the dose will be increased to one blue capsule po twice daily for 4 days. On day 8, the patients will take 1 red capsule po twice daily. At the end of the 8th week, placebo will be discontinued.
62553311|NCT04118491|SHAM_COMPARATOR|sham1st|40 sham HBO2 treatments (air at near normal pressure (1.2 ATA)). Treatments will be done once daily for 2 hours, Monday through Friday. The second block will be treated similarly except that they will receive sham treatments in the first block and oxygen treatments in the second block.
62374281|NCT02455440|PLACEBO_COMPARATOR|control|Control group did not receive esmolol or other b-blocker in the perioperative period.
62746336|NCT02050802|EXPERIMENTAL|Treatment sequence DBAC|Subjects received study medication in the sequence DBAC. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
62746337|NCT02050802|EXPERIMENTAL|Treatment sequence ADCB|Subjects received study medication in the sequence ADCB. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
62746338|NCT02050802|EXPERIMENTAL|Treatment sequence CABD|Subjects received study medication in the sequence CABD . Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
62746339|NCT02050802|EXPERIMENTAL|Treatment sequence BCDA|Subjects received study medication in the sequence BCDA. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
62746340|NCT00473668|EXPERIMENTAL|TRITANRIX-HEPB/HIBERIX KFT. GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ Kft. vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
62746341|NCT00473668|ACTIVE_COMPARATOR|TRITANRIX-HEPB/HIBERIX LD GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ low-dose (LD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
62746342|NCT00473668|ACTIVE_COMPARATOR|TRITANRIX-HEPB/HIBERIX HD GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ high-dose (HD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
62746343|NCT05806541|NO_INTERVENTION|control group|At the beginning of the study, data collection tools Personal Information Form, Academic Self-Efficacy Scale and Psychological Well-Being Scale will be applied to the control group. No intervention will be made in the control group. Measurement tools will be applied for the post-test.
62746344|NCT05806541|EXPERIMENTAL|experimental group|"Arm: Experimental: experimental group Personal Information Form, Academic Self-Efficacy Scale and Psychological Well-Being Scale will be applied to all 4th year nursing students studying at Sinop University Health Sciences in the autumn term of 2023-2024.~Laughter therapy session will be applied face to face for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. Psychological Well-Being Scale and Academic Self-Efficacy Scale will be applied again after the application and in the follow-up (after the application is over)."
62746345|NCT05337111||Chinese men|Chinese men based on self-identity for three generations (parents and grandparents), age 25 - \<45 years, who are physically inactive (\< 150 minutes moderate or \< 75 minutes vigorous leisure-time physical activity per week), with elevated body mass index (\>23-\<30 kg/m2) for Asians. Single measure of CRF, resting fat oxidation and fat oxidation during graded exercise.
62374282|NCT02022891||systematic psychological care|Systematic psychological treatment plan added to medical care for children with SCD. Bio-psychosocial paradigm applied at pediatric consultations.
62746346|NCT05337111||Indian men|Indian men based on self-identity for three generations (parents and grandparents), age 25 - \<45 years, who are physically inactive (\< 150 minutes moderate or \< 75 minutes vigorous leisure-time physical activity per week), with elevated body mass index (\>23-\<30 kg/m2) for Asians. Single measure of CRF, resting fat oxidation and fat oxidation during graded exercise.
62746347|NCT05337111||Malay men|Malay men based on self-identity for three generations (parents and grandparents), age 25 - \<45 years, who are physically inactive (\< 150 minutes moderate or \< 75 minutes vigorous leisure-time physical activity per week), with elevated body mass index (\>23-\<30 kg/m2) for Asians. Single measure of CRF, resting fat oxidation and fat oxidation during graded exercise.
62746348|NCT01027234|EXPERIMENTAL|1|
62746349|NCT01027234|PLACEBO_COMPARATOR|2|
62746350|NCT04099719||Anyone (>16 years old) registered with services providing drug|retrospective data, no intervention to be administered
62746351|NCT00678769|EXPERIMENTAL|Group A (temsirolimus on days 15 and 22 course 1)|Patients receive temsirolimus IV over 30 minutes on days 15 and 22 for course 1 and on days 1, 8, 15, and 22 for all subsequent courses. Patients also receive cixutumumab IV over 60 minutes on days 1, 8, 15, and 22.
62374283|NCT02022891||Control|medical care only at routine pediatric consultations for SCD. Psychological support provided only when the pediatrician consider it appropriate.
62374284|NCT01703429||Individuals with MS|
62374285|NCT03563586|ACTIVE_COMPARATOR|Bowel Preparation plus antibiotics|Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
62374286|NCT03563586|OTHER|Bowel Preparation|Preoperative mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
62746352|NCT00678769|EXPERIMENTAL|Group B (cixutumumab on days 15 and 22 of course 1)|Patients receive cixutumumab IV over 60 minutes on days 15 and 22 for course 1 and on days 1, 8, 15, and 22 for all subsequent courses. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
62746353|NCT00678769|EXPERIMENTAL|Group C (temsirolimus on days 1, 8, 15, and 22)|Patients receive temsirolimus IV over 30 minutes and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22.
62746354|NCT05379218|EXPERIMENTAL|Intervention Arm - Remote Ischemic Conditioning|Remote Ischemic Conditioning
62746355|NCT05379218|NO_INTERVENTION|Control Arm - No Remote Ischemic Conditioning|No intervention. A blood pressure cuff will be placed on the infant's arm but will not be inflated.
62746356|NCT04823455|EXPERIMENTAL|Allo Omero 2020|Humeral allograft group 12 patients were surgically treated for a locked posterior glenohumeral dislocation with a humeral head defect affecting at least 30% of the head diameter. During surgery, the bone defect was substituted with a fresh-frozen humeral head osteochondral allograft.Included patients were clinically and radiographically re-evaluated for the purpose of this study by examiners not involved in the primary treatment at a mean of 66 months postoperatively. The clinical examination consisted of a physical examination and structured interview. Computed tomography (CT) was carried out at the medium follow-up of 66 months in all patients to evaluate OA progression and allograft resorption.
62746357|NCT01162824|OTHER|No endothelial dysfunction|
62374287|NCT05679440|NO_INTERVENTION|Control group|Patients in the control group are ventilated in a comfortable position according to the principles of treatment and their wishes
62374288|NCT05679440|EXPERIMENTAL|Intervention group|Patients are ventilated in prone position (for patients with bilateral lung lesions), left/right lateral position, semi-prone position (for patients with unilateral lung lesions or those who cannot tolerate prone ventilation, so that the diseased lung is above and the healthy lung is below), supine position (for patients who cannot tolerate prone ventilation or lateral ventilation, etc.) according to the pulmonary imaging data.
62374289|NCT02447068|NO_INTERVENTION|Non-treatment Control|Control arm will not have any intervention
62374290|NCT02447068|ACTIVE_COMPARATOR|Occlusive Dressing|An off-the-shelf dressing occlusive dressing will be used as an active comparator.
62374291|NCT02447068|ACTIVE_COMPARATOR|Luma Light|A NBUVB light will be used as an active comparator.
62374292|NCT02447068|EXPERIMENTAL|Luma Light System|The experimental arm will be a combination of an occlusive dressing and NBUVB light.
62374293|NCT03858686|ACTIVE_COMPARATOR|400 mg FP-025 capsules|Based on a double-blind randomized schedule, 16 subjects will receive FP-025 capsules in Period 1 and matching placebo FP-025 capsules in Period 2. Both study periods will follow the same schedule of procedures, with a washout period of at least 3 weeks and up to 7 weeks between study periods.
62746358|NCT01162824|OTHER|Endothelial Dysfunction|Definition of abnormal epicardial and microvascular vasoreactivity Abnormal epicardial vasoreactivity is defined as a reduction of the baseline coronary diameter ≥75% after glyceryltrinitrate i.c. together with a reproduction of the angina symptoms reported by the patient and/or ischemic ECG-changes. Abnormal microvascular vasoreactivity is defined as the reproduction of the angina symptoms together with ischaemic ECG-changes, but without changes in epicardial vasomotion.
62746359|NCT05250635||Patients underwent thoracic surgery|Patients underwent thoracic surgery and general anesthesia with usage of DLET are included. Those patients with abnormal breath sound, pulmonary disease or history of cardiothoracic surgery are excluded.
62746360|NCT05688215|EXPERIMENTAL|Treatment (zimberelimab, quemliclustat, chemotherapy)|Patients receive zimberelimab IV, quemliclustat IV, oxaliplatin IV, leucovorin calcium IV, and inrinotecan IV on study. Patients undergo collection of blood samples and CT throughout the trial. Patients with borderline-resectable pancreatic cancer undergo collection of tissue samples. Patients with locally advanced pancreatic cancer undergo core biopsy.
62746361|NCT05525052||Cohort|Patients having a history of spinal surgery such as laminectomy and/or classic surgical arthrodesis, and subsequent focal spinal, treated by transfacet arthrodesis under CT scan guidance
62746362|NCT05158335|EXPERIMENTAL|MBX 2109 (Part A)|Single ascending SC doses
62746363|NCT05158335|EXPERIMENTAL|MBX 2109 (Part B)|Repeated ascending SC doses
62746364|NCT05158335|PLACEBO_COMPARATOR|Placebo|
62746365|NCT02043912||patients treated with haloperidol|
62374294|NCT03858686|PLACEBO_COMPARATOR|FP-025 Placebo Capsules|Based on a double-blind randomized schedule, 16 subjects will receive matching placebo FP-025 capsules in Period 1 and FP-025 capsules in Period 2. Both study periods will follow the same schedule of procedures, with a washout period of at least 3 weeks and up to 7 weeks between study periods.
62374295|NCT05126654|EXPERIMENTAL|COPD with PHGG|COPD patient PHGG 5g/day for 1 month
62374296|NCT05126654|NO_INTERVENTION|COPD without PHGG|COPD patient without PHGG 5g/day for 1 month
62374297|NCT05126654|ACTIVE_COMPARATOR|Healthy with PHGG|Healthy PHGG 5g/day for 1 month
62374298|NCT05126654|NO_INTERVENTION|Healthy without PHGG|Healthy without PHGG 5g/day for 1 month
62374299|NCT04246489|EXPERIMENTAL|Bintrafusp alfa|
62374300|NCT03583112|ACTIVE_COMPARATOR|Dapoxetine|In this group, patients received one dapoxetine hydrochloride tablet before MRI scan.
62374301|NCT03583112|PLACEBO_COMPARATOR|Placebo|In this group, patients received placebo tablet before MRI scan.
62374302|NCT00776581||1|Records regarding combined spinal-epidural analgesia (CSEA) with patient-controlled analgesia (PCA) pump
62374303|NCT00776581||2|Records regarding combined spinal-epidural analgesia with intermittent bolus injection (IBI)
62374304|NCT00776581||3|Records regarding epidural analgesia (EA) with patient-controlled pump
62374305|NCT00776581||4|Records regarding epidural analgesia with intermittent bolus injection
62374306|NCT03250819||Corticosteroid responders|Patients who develop an increase in eye pressure after the use of corticosteroids
62746366|NCT01904474|EXPERIMENTAL|Next.Step|"Experimental group participants, in addition to the standard treatment program are invited to get restricted access to the e-therapeutic platform (Next.Step), which includes a diverse set of resources, such as: educational resources (videos, brochures, menus, weekly tips, access to other links), self-monitoring (food, weight and physical activity records), social support (chats, discussion forums and personalized messages), interactive training modules (self-assessment quizzes, making their own diets) and motivational tools (personal goals planning, treatment progression registry, positive reinforcement).~Intervention length will be 36 weeks (24 weeks of direct intervention with a follow-up of 12 weeks), being based on case management methodology."
62746367|NCT01904474|ACTIVE_COMPARATOR|Standard protocol|The control group will follow the POC/HSM standard treatment protocol, which includes a baseline evaluation session with a paediatrician for initial screening, followed by appointments with the nutritionist and exercise physiologist. The second set of appointments will take place one month after for adjustments. After this, the adolescent will have appointments at 3, 6, 9 and 12 months. These adolescents will join a waiting list and nine months (36 weeks) after having started the standard treatment, they will receive the personal codes for accessing Next.Step.
62746368|NCT05557851|EXPERIMENTAL|Open Label Study of Minnelide in Patients with Metastatic Adenocarcinoma of the Pancreas|This is an open-label, Phase 1b study of MinnelideTM given once a day on Days 1 to 5, Days 8 to12 and Days 15 to 19 in combination with SOC (nab-paclitaxel \[Abraxane\] plus gemcitabine). The study will be conducted in patients with disease progression while on FOLFIRINOX as first treatment and who have had no prior treatment with nab-paclitaxel (Abraxane) plus gemcitabine or single agent nab paclitaxel or gemcitabine or in any other combinations. The total number of treatment cycles administered will be dependent on drug tolerability by patient.
62746369|NCT00812006|EXPERIMENTAL|A|Treatment Sequence A: rizatriptan, rizatriptan, placebo
62746370|NCT00812006|EXPERIMENTAL|B|Sequence B: rizatriptan, placebo, rizatriptan
62746371|NCT00812006|EXPERIMENTAL|C|Sequence C: placebo, rizatriptan, rizatriptan
62746372|NCT01743313||Hip and knee replacement recipients|"Hip and knee replacement recipients (with osteoarthritis) enrolled previously into Perioperative Hyperglycaemia in Primary Total Hip and Knee Replacement study (NCT01021826)."
62746373|NCT04463186|EXPERIMENTAL|Experimental|subjects participated in three experimental trials: Static stretching for 2 minutes (SS2), static stretching for 4 minutes (SS4), and static stretching for 8 minutes (SS8). Strength was measured before (pre), immediately after (post), and at 10- and 20- minutes post stretching.
62746374|NCT03922347|NO_INTERVENTION|routine care|
62553312|NCT04118491|ACTIVE_COMPARATOR|sham second|"iii. We will divide the subjects into two groups of five. One group will receive 40 Hyperbaric Oxygen (HBO2) treatments (100% oxygen at twice normal air pressure (2 ATA)) followed by 40 sham HBO2 treatments (air at near normal pressure (1.2 ATA)). Treatments will be done once daily for 2 hours, Monday through Friday. The second block will be treated similarly except that they will receive sham treatments in the first block and oxygen treatments in the second block.~iv. Neurological and psychologic assessments will be done prior to starting treatments, after the first block of 40 and again after the second block of 40."
62553313|NCT01174693|ACTIVE_COMPARATOR|Clopidogrel|Plavix® 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014
62553314|NCT01174693|EXPERIMENTAL|Triflusal|Disgre® 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014
62553315|NCT05305066|ACTIVE_COMPARATOR|Sub-study 1 TNFi|TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein), adalimumab (monoclonal antibody), golimumab (monoclonal antibody), or certolizumab (pegylated fragment of a monoclonal antibody)
62553316|NCT05305066|ACTIVE_COMPARATOR|Sub-study 1 Anti-IL6|Anti-IL6 receptor monoclonal antibodies - tocilizumab or sarilumab
62553317|NCT05305066|ACTIVE_COMPARATOR|Sub-study 2 Anti-IL6|Anti-IL6 receptor monoclonal antibodies - tocilizumab or sarilumab
62746375|NCT03922347|ACTIVE_COMPARATOR|Screening program including 2 consecutive tests|
62746376|NCT03922347|ACTIVE_COMPARATOR|Screening program with mobile health|
62746377|NCT01893411|EXPERIMENTAL|16 Units per kg body weight incobotulinumtoxinA (Xeomin)|
62746378|NCT01893411|EXPERIMENTAL|12 Units per kg body weight incobotulinumtoxinA (Xeomin)|
62553318|NCT05305066|ACTIVE_COMPARATOR|Sub-study 2 JAKi|JAKi - tofacitinib (JAK1/3 inhibitor), baricitinib (JAK 1/2 inhibitor) or upadacitinib (JAK1 inhibitor)
62553319|NCT02267044|ACTIVE_COMPARATOR|Ropivacaine Single Shot Block|Single Shot Interscalene block patients will receive a single shot of 30ml of 0.5% Ropivacaine prior to surgery
62746379|NCT01893411|EXPERIMENTAL|4 Units per kg body weight incobotulinumtoxinA (Xeomin)|
62746380|NCT05137197|NO_INTERVENTION|TAU|Treatment as Usual: The treating clinician will decide on what antidepressant to prescribe based on the clinical evaluation.
62746381|NCT05137197|ACTIVE_COMPARATOR|PGT|Predictix Guided Treatment: The treating clinician will decide on what antidepressant to prescribe based on clinical evaluation and the Predictix report
62746382|NCT04105348||IBD with DM|
62746383|NCT04105348||IBD without DM|
62746384|NCT01879462|EXPERIMENTAL|Cohort A|Subjects in this cohort will receive 3 treatments (either active drug or placebo for each dose level) in 3 treatment periods (one per period). Subjects will receive GSK2878175 5 mg, GSK2878175 50 mg, and GSK2878175 200 mg in treatment period 1, 2, and 3 respectively in fasted state (with 1:3 ratio of placebo to active treatment at each treatment period).
62746385|NCT01879462|EXPERIMENTAL|Cohort B|Subjects in this cohort will receive 3 treatments (either active drug or placebo for each dose level) in 3 treatment periods (one per period). Subjects will receive GSK2878175 15 mg in fasted state, GSK2878175 100 mg in fasted state, and GSK2878175 100 mg in fed state in treatment period 1, 2, and 3 respectively (with 1:3 ratio of placebo to active treatment at each treatment period).
62746386|NCT01879462|EXPERIMENTAL|Cohort C|Subjects in this cohort will receive GSK2878175 15 mg single dose or placebo for 7 days in fasted state (with 1:4 ratio of placebo to active treatment).
62746387|NCT01879462|EXPERIMENTAL|Cohort D|Subjects in this cohort will receive placebo and GSK2878175 50 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
62746388|NCT01879462|EXPERIMENTAL|Cohort E|Subjects in this cohort will receive placebo and GSK2878175 100 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
62746389|NCT01879462|EXPERIMENTAL|Cohort F|Subjects in this cohort will receive placebo and GSK2878175 200 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
62746390|NCT04324996|EXPERIMENTAL|NK cells|The NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week) .
62746391|NCT04324996|EXPERIMENTAL|IL15-NK cells|The NK cells secreting super IL15 superagonist are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week) .
62746392|NCT04324996|EXPERIMENTAL|NKG2D CAR-NK cells|The NKG2D CAR-NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
62374307|NCT03250819||Non-corticosteroid responders|Patients who use/used corticosteroids but didn't develop an increase in eye pressure
62374308|NCT04694794|EXPERIMENTAL|Interventional|Single arm, interventional. All participants will be administered Educational Brochure to educate them regarding management of side effects experienced during chemotherapy treatment
62746393|NCT04324996|EXPERIMENTAL|ACE2 CAR-NK cells|The ACE2 CAR-NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
62746394|NCT04324996|EXPERIMENTAL|NKG2D-ACE2 CAR-NK cells|The NKG2D-ACE2 CAR-NK cells secreting IL15 superagonist and GM-CSF-neutralizing scFv are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
62746395|NCT00676520||1|Single-arm study
62746396|NCT02363361|EXPERIMENTAL|Imatinib|Day 1. 800 mg, Day 2-14: 2 \* 400 mg per day
62746397|NCT03305081|EXPERIMENTAL|Immediate or early placement|Immediate or early placement of levonorgestrel IUD, copper IUD, or etonorgestrel sub dermal implant (within 48 hours) postpartum
62746398|NCT03305081|ACTIVE_COMPARATOR|Interval placement|Interval (4-6 weeks) postpartum placement of levonorgestrel IUD, copper IUD, or etonorgestrel sub dermal implant
62746399|NCT05958953|EXPERIMENTAL|active management|early IOL within 8 hours of rupture of membranes. Center-specific IOL protocols will be used.
62374309|NCT06179355|EXPERIMENTAL|manual Astigmatic Keratotomy|manual limbal Astigmatic Keratotomy using a diamond knife group
62374310|NCT06179355|EXPERIMENTAL|femtosecond laser Astigmatic Keratotomy|Femtosecond laser-guided astigmatic keratotomy group
62374311|NCT05127356||Laser fluorescence|"DIAGNOdent is a laser fluorescence device that detects and quantify stages of development of incipient carious lesions~0-4 healthy tooth structure; 5-10 Outer half enamel caries; 11-20 Inner half enamel caries; 21+ Dentin caries"
62374312|NCT05127356||Visual examination|"ICDAS II~Code 0: Sound tooth surface; Code 1: First visual change in enamel; Code 2:Distinct visual change in enamel when viewed wet; Code 3: Localized enamel breakdown due to caries with no visible dentin; Code 4: Underlying dark shadow from dentin with or without localized enamel breakdown; Code 5: Distinct cavity with visible dentin; Code 6: Extensive distinct cavity with visible dentin."
62746400|NCT05958953|NO_INTERVENTION|Expectant management|monitoring until 24 hours from rupture of membranes, with subsequent induction of labor (IOL).
62746401|NCT05352516|EXPERIMENTAL|Treatment group|
62746402|NCT05352516|ACTIVE_COMPARATOR|Control group|
62746403|NCT01190761|EXPERIMENTAL|A|Galantamine 4 mg Tablet, single dose
62746404|NCT01190761|ACTIVE_COMPARATOR|B|Reminyl 4 mg Tablet, single dose
62746405|NCT02918461|EXPERIMENTAL|Emerging from the Haze class|A 6-week psycho-educationally-based, cognitive behavioral program to help patients with subjective cognitive complaints after cancer treatment, titled Emerging from the Haze™ (Haze). Each series meets once a week for 2-2.5 hours for 6 weeks.
62746406|NCT04399863|EXPERIMENTAL|ETOILE therapeutic education|ETOILE is a patient education program, in accordance with French recommendations, which offers to patients and caregivers the opportunity to follow a customized educational training on their disease. Better quality of life and enhanced autonomy are the aim of this program.
62746407|NCT01087658|EXPERIMENTAL|Glutamine and calcium magnesium|"Glutamine 10g p.o. 3-times a day beginning at day -2 for 7 consecutive days during each chemotherapy cycle. 1g of calcium and 1g of magnesium i.v. over 30 minutes just before the chemotherapy and repeated at the same dose after the completion of the oxaliplatine infusion.~All patients will receive an oxaliplatin based chemotherapy with XELOX, FOLFOX-4 or mFOLFOX-6."
62746408|NCT01087658|ACTIVE_COMPARATOR|Calcium magnesium|"1g of calcium and 1g of magnesium i.v. over 30 minutes just before the chemotherapy and repeated at the same dose after the completion of the oxaliplatine infusion.~All patients will receive an oxaliplatin based chemotherapy with XELOX, FOLFOX-4 or mFOLFOX-6."
62746409|NCT00754949|EXPERIMENTAL|1|
62746410|NCT00754949|ACTIVE_COMPARATOR|2|
62746411|NCT00754949|ACTIVE_COMPARATOR|3|
62746412|NCT05723731|EXPERIMENTAL|Treatment group|patients will receive taVNS at left tragus for four weeks.
62746413|NCT05723731|SHAM_COMPARATOR|Sham-treatment group|patients will receive sham-taVNS at left earlobe for four weeks.
62374313|NCT05399160|EXPERIMENTAL|Nurse-led Supportive Care Group|
62374314|NCT05399160|NO_INTERVENTION|Control Group|The control group did not receive any intervention during the study period.
62374315|NCT02543606|EXPERIMENTAL|Esomelone|powder for injection/ infusion Esomeprazole 40mg
62374316|NCT02543606|ACTIVE_COMPARATOR|Nexium|powder for injection/ infusion Esomeprazole 40mg
62374317|NCT06305819|EXPERIMENTAL|Intervention|Participants assigned to intervention arm will receive the self-management support program. The program consists of 2.5-hour sessions and is delivered to groups of 5-7 participants. The intervention is provided over a period of eight weeks with one session per week and is delivered by a multidisciplinary team. A tele-health version of the intervention will be offered to those who prefer to participate via electronic devices.
62746414|NCT00445211|ACTIVE_COMPARATOR|Intra-Aortic balloon Pump with Heparin|Intra-Aortic Balloon Pump (IABP) with Heparin
62746415|NCT00445211|ACTIVE_COMPARATOR|Intra-Aortic balloon Pump without Heparin|Intra-Aortic balloon Pump (IABP) without Heparin
62746416|NCT02998203|NO_INTERVENTION|Conventional phase|During the conventional phase, participants are asked to maintain their usual dietary choices for 40 days.
62746417|NCT02998203|EXPERIMENTAL|Organic phase|During the organic phase, participants are asked to follow strictly the two 20-day organic dietary menus provided to them for 40 days. The organic dietary menus were prepared by a certified dietitian. The meals of the organic phase are prepared by a certified organic restaurant and are delivered to school every day except Sunday. For the meals of breakfast and afternoon snacks, children choose their preferred options for the week on the Friday of the previous week according to a list of organic food items and the products for these meals are delivered on Saturday along with the rest meals. Parents are responsible to pick-up the organic meals from school and ensure that the participating children have access to them.
62746418|NCT06659276||patients with new diagnosis of symptomatic multiple myeloma|fdg pet/CT and Whole body MRI with DWI
62746419|NCT05846425|EXPERIMENTAL|Nose-breathing|Controlled nose-breathing
62746420|NCT05846425|ACTIVE_COMPARATOR|Mouth-breathing|Controlled mouth-breathing
62746421|NCT05846425|NO_INTERVENTION|Control group|no intervention
62746422|NCT04489147|ACTIVE_COMPARATOR|metformin|Group A ( involve 200 patients ) will receive metformin 850 mg twice daily along the cycle of ICSI
62746423|NCT04489147|NO_INTERVENTION|No Metformin|Group B ( involve 200 patients) will not receive metformin
62746424|NCT05464641|ACTIVE_COMPARATOR|preoperative|preoperative The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse.
62746425|NCT05464641|ACTIVE_COMPARATOR|postoperative|postoperative The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse.
62746426|NCT03126058|EXPERIMENTAL|enhanced recovery after surgery|"enhanced recovery after surgery includes:~1. Multimodal analgesia~2. Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet~3. Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally. B: Remove catheter early.~4. Early activity~5. Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation for right hemicolectomy, Miles rectectomy and Hartman rectectomy, simple cleansing enema for left hemicolectomy,sigmoidectomy and Dixon rectectomy; C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken"
62746427|NCT04659499|EXPERIMENTAL|Nab-paclitaxel in combination with pyrotinib treatment group|Nab-paclitaxel 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib 240mg daily for one year
62746428|NCT01049230|EXPERIMENTAL|Proton beam radiation|Radiation therapy with proton beam
62746429|NCT03629340|EXPERIMENTAL|Drug: Metformin|500mg PO (by mouth) BID (two times daily) x 1 week then increase to 1000mg PO BID x 11 weeks
62746430|NCT03629340|PLACEBO_COMPARATOR|Placebo Oral Capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
62746431|NCT03831191|EXPERIMENTAL|50 mg LY3375880|"Induction Period:~Participants received 50 mg LY3375880 administered SC Q4W."
62553320|NCT02267044|ACTIVE_COMPARATOR|Ropivacaine Continuous block|Continuous Interscalene block patients will receive a shot of up to 30ml of 0.5% Ropivacaine and then a catheter is placed. The catheter is secured with Dermabond and Tegaderm. Once surgery is complete, the catheter is connected to a pain ball system which holds 400ml of 0.2% Ropivacaine local anesthetic. The rate is locked in at 8ml/hr. Catheter is pulled once the pain ball is empty.
62553321|NCT04825912|EXPERIMENTAL|Adults with Advanced Lung Cancer|Older adults with stage III or stage IV lung cancer will be enrolled in the Self-System Therapy intervention to treat illness-related distress, depression, and to enhance self-efficacy via delivery of behavioral coping skills across a period of 10 weeks.
62553322|NCT05027152|EXPERIMENTAL|traditional resistance exercises|The resistance training group will perform traditional resistance exercises with an intensity of 30%-60% of a voluntary repetition maximum and 1 to 2 sets of 10 repetitions each exercise.
62553323|NCT05027152|EXPERIMENTAL|repetitive task training|The repetitive task training group will carry out exercises involving upper and lower limbs.
62553324|NCT05107947|EXPERIMENTAL|Intervention biocentric light environment|In all study rooms, a biocentric lighting environment will be able to be created by activating a special lighting system. In these rooms, light will change dynamically both in spectral distribution and intensity during the day. During the day, color temperature and intensity are high (1000 lux and up to 6500 K) to decrease both intensity and color temperature during the evening.
62553325|NCT05107947|NO_INTERVENTION|Control standard light environment|Standard static light environment.
62553326|NCT04051346|EXPERIMENTAL|Low Oxalate Diet Followed by High Oxalate Diet|Subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the high oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet.
62553327|NCT04051346|EXPERIMENTAL|High Oxalate Diet Followed by Low Oxalate Diet|Subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the low oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet.
62567245|NCT01982617|EXPERIMENTAL|Motivational Interviewing|The Cognitive Behavioral Therapy/Motivational Interviewing group consisted of four group sessions focused on using motivational interviewing to enhance motivation to quit smoking and on presenting cognitive-behavioral techniques for preparing to cut down or quit smoking. The following four topics were covered in this program: 1) Positive and Negative Aspects of Smoking, 2) Concerns and Hopes about Cutting Down or Quitting, 3) Small Changes that Can Help You Get Motivated, and 4) Planning for the Future.
62746432|NCT03831191|EXPERIMENTAL|150 mg LY3375880|"Induction Period:~Participants received 150 mg LY3375880 administered SC Q4W."
62746433|NCT03831191|EXPERIMENTAL|600 mg LY3375880|"Induction Period:~Participants received 600 mg LY3375880 administered SC Q4W."
62746434|NCT03831191|PLACEBO_COMPARATOR|Placebo|"Induction Period:~Participants received placebo administered subcutaneously (SC) every 4 weeks (Q4W)."
62746435|NCT06629220|OTHER|Co-creation meetings|All participants will be invited to participate in the co-creation meetings.
62746436|NCT06560554|ACTIVE_COMPARATOR|Control|The subjects in the control arm will only complete the baseline and week 13 visits. They will not be asked to make any changes to their diet, only to document their regular diet 3 days a week.
62553328|NCT00709995|EXPERIMENTAL|Part 1 Arm A: Enzastaurin + Sunitinib|"(Cohort 1): On cycle 1, day 1 a loading dose 125 milligram (mg) of Enzastaurin was administered by mouth orally, (BID) twice a day, followed by Enzastaurin 125 mg administered, twice a day, Days 2 through 42 of a 6-week cycle.~(Cohort 2): Cycle 1, Day 1 loading dose 375 mg of Enzastaurin administered po three times a day (TID), followed by 250 mg, po, BID continuously until disease progression, unacceptable toxicity, death, or discontinuation from the study for any other reason.~Sunitinib 50 mg was administered orally, once daily, Days 1-28, then rest (no drug given) days 29-42.~Phase 2 (Part 2): Randomized Double-Blind: Dosing was determined by Part 1. Part 2 was not activated per recommendation of safety review committee.~Enzastaurin: Cycle 1, Day 1 loading dose 375 mg administered orally, (TID) three times a day, followed by Part 1 dose twice a day on Days 2-42 of 6 week cycle.~Sunitinib: 50 mg administered orally, once daily, on Days 1-28, then rest Days 29-42."
62746437|NCT06560554|EXPERIMENTAL|Treatment|Will receive an in-person teaching session delivered by a trained team member including introductory education on microbiome and a description on a variety of probiotic fermented foods commercially available (fermented dairy products, fermented vegetables, fermented non-alcoholic drinks). Participants will be able to choose their own probiotic fermented foods based on this education and taste preference. Subjects will be contacted weekly to ensure they are tolerating and adhering to the study protocol.
62746438|NCT03495310|EXPERIMENTAL|Mindfulness|"In this group, children and their parents will receive a mindfulness session once a week, with a duration of 90 minutes, during 8 weeks (sessions will be separated for children and parents). Mindfulness sessions will be coordinated by experts in mindfulness techniques in children and adults respectively from the collaborator Institution Spanish School of Transpersonal Development Previous to the session, a 24-hour food recall questionnaire will be applied to offer a meal plan restricted in 500 kcal. The 24-R will be repeated at each session in order to make adjustments to the meal plan if necessary. Also a 60-minute walk 3 times a week will be recommended"
62746439|NCT03495310|NO_INTERVENTION|Control|In this group, children and their parents will receive information regarding what is a healthy diet and physical activity attached to the World Health Organization recommendations. The session will be coordinated by a pediatric endocrinologist. Previous to the session, a 24-hour food recall questionnaire will be applied to offer a meal plan restricted in 500 kcal. The 24-R will be repeated at each session in order to make adjustments to the meal plan when necessary. Also a 60-minute walk 3 times a week will be recommended
62746440|NCT01687088||chronic migraineurs|At least 8 migraine days per week and headache at least 15 days per month.
62746441|NCT01687088||controls|No significant headache or disability as defined by migraine disability scale.
62746442|NCT05611567|EXPERIMENTAL|POSE2.0|This is the arm that got the POSE2.0 procedure. The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA). This device is registered and commercially available in the United Arab Emirates for the management of obesity.
62746443|NCT05611567|ACTIVE_COMPARATOR|Life style and behavioral intervention|This is the comparator arm that received lifestyle modification alone for weight loss and NAFLD management (representing the comparative control group). This group underwent the same lifestyle program and clinical follow-up as the POSE2.0, but under a parallel standard clinical care pathway, which is the standard clinical pathway in the hospital this study was conducted in.
62746444|NCT01538979|EXPERIMENTAL|BM32 low dose|7 subcutaneous injections of 20 micrograms over two grass pollen seasons
62746445|NCT01538979|EXPERIMENTAL|BM32 high dose|7 subcutaneous injections of 40 micrograms over two grass pollen seasons
62746446|NCT01538979|PLACEBO_COMPARATOR|Placebo|7 subcutaneous injections over a time span of two pollen seasons
62746447|NCT03070171|EXPERIMENTAL|Dabigatran Etexilate Capsule|
62746448|NCT03070171|EXPERIMENTAL|Dabigatran Etexilate Tablet|
62746449|NCT01293630|EXPERIMENTAL|Cohort - 1 through 5|AVE8062 combined with paclitaxel and carboplatin will be administered once every 3 weeks
62746450|NCT01110330|EXPERIMENTAL|Ketoconazole 2% cream (formulation F126)|ketoconazole 2% cream (formulation F126) A topical white homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
62746451|NCT01110330|EXPERIMENTAL|Ketoconazole 2% cream (formulation F012) (Nizoral)|ketoconazole 2% cream (formulation F012) (Nizoral) A topical white homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
62746452|NCT01110330|PLACEBO_COMPARATOR|Placebo cream|Placebo cream A topical white homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
62746453|NCT03269968|EXPERIMENTAL|Negative pressure wound therapy (NPWT)|Women receiving NPWT will have a PREVENA Incision Management Therapy System applied directly onto their skin over the closed incision after delivery.
62746454|NCT03269968|PLACEBO_COMPARATOR|Standard dressing|Standard dressing
62746455|NCT05153369|EXPERIMENTAL|Level 1|At enrollment, participants will be categorized according to the following criteria related to suicidality, emotion dysregulation, risk behaviors, and participant preference: No lifetime suicidal behaviors on the Columbia-Suicide Severity Rating Scale (C-SSRS) AND no active suicidal ideations with method/plan/intent in the past month on the C-SSRS (cannot score 'yes' on items \> 3).
62746456|NCT05153369|EXPERIMENTAL|Level 2|At enrollment, participants will be categorized according to the following criteria related to suicidality, emotion dysregulation, risk behaviors, and participant preference: No non-suicidal self-injurious (NSSI) behaviors in the past 3 months on the C-SSRS AND no suicide attempts (actual, interrupted and/or aborted) in the past year on the C-SSRS AND no preparatory act or behavior in the past year as measured by the C-SSRS OR participant preference.
61986347|NCT04474951|EXPERIMENTAL|Anemia|Metastatic patients with grade 1 anemia and on treatment with anti-CDK 4/6 or PARP Inhibitors (10 patients) or on adjuvant therapy with hormonal therapy (10 patients) will be enrolled. The control of the event will be evaluated during treatment with 40 drops TID of Stinging Nettle Fluid Extract; hemoglobin levels will be assessed every 4 weeks for a maximum period of 6 months.
62746457|NCT05153369|EXPERIMENTAL|Level 3|At enrollment, participants will be categorized according to the following criteria related to suicidality, emotion dysregulation, risk behaviors, and participant preference: NSSI behaviors in the past 3 months on the C-SSRS OR at least 1 suicide attempt in the past year (actual, interrupted, and/or aborted) on the C-SSRS OR at least 1 preparatory act or behavior in the past year as measured by the C-SSRS OR Meets youth threshold for at least 2 impulsive behavior categories on question #4 from the Structured Interview for DSM-IV Personality Disorders Borderline Personality Disorder (SIDP-IV) or 1 category is identified as severe OR participant preference during the course of treatment.
62746458|NCT02010333|EXPERIMENTAL|Ha44 Gel 0.74% w/w|Open label, one arm
62746459|NCT05359081|EXPERIMENTAL|SEP-363856|SEP-363856 (50 or 75 mg/day, flexible dose)
62746460|NCT04361409|EXPERIMENTAL|Rituximab plus chemotherapy|"* Drug:Rituximab~* Drug:Cisplatin~* Drug:Gemcitabine"
62746461|NCT02312999|EXPERIMENTAL|Volulyte|A baseline crystalloid infusion (plasmalyte®) will be set by the attending physician at 3 cc/kg/hr (standard patient care) for each of the randomized groups. The patient will receive fluid management via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to standardize the way fluids are administered intra-operatively and eliminate variation between clinical providers. The liquid perfused will be bolus amounts of volulyte.
62746462|NCT02312999|ACTIVE_COMPARATOR|Plasma-Lyte|A baseline crystalloid infusion (plasmalyte®) will be set by the attending physician at 3 cc/kg/hr (standard patient care) for each of the randomized groups. The patient will receive fluid management via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to standardize the way fluids are administered intra-operatively and eliminate variation between clinical providers. The liquid perfused will be bolus amounts of plasma-lyte.
62746463|NCT05305833|EXPERIMENTAL|umbilical cord derived mesenchymal stem cells transplantation group|taking umbilical cord derived mesenchymal stem cells
62746464|NCT05305833|EXPERIMENTAL|stromal vascular fraction cells application group|taking stromal vascular fraction cells
62746465|NCT05321758|ACTIVE_COMPARATOR|FMT group|Repeated and multiple FMTs plus PEN(80%) in the treatment of pediatric CD. Patients received PEN (80% of total calories as a polymeric diet, Peptamen, Nestle, Vevey, and Switzerland) and FMT intervention. In the induction stage of CD, FMT was given 1-3 courses, 3-6 times per course.
62374318|NCT06305819|ACTIVE_COMPARATOR|Control|Participants assigned to the control group will receive the usual health and rehabilitation services provided in the municipality or other rehabilitation settings. These services will potentially vary greatly from no services to specialized or local rehabilitation teams. All services received by participants in the control group will be registered at the follow-ups.
62746466|NCT05321758|SHAM_COMPARATOR|Immunosuppressive group|Patients received PEN (80% of total calories as a polymeric diet, Peptamen, Nestle, Vevey, and Switzerland) combined with Immunosuppressants (hormones, azathioprine, thalidomide) treatment.
62746467|NCT02793817|ACTIVE_COMPARATOR|KPI-121 1.0% Ophthalmic Suspension|dosed BID
62746468|NCT02793817|PLACEBO_COMPARATOR|Vehicle of KPI-121 Ophthalmic Suspension|dosed BID
62746469|NCT02450448||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
62746470|NCT02450448||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
62746471|NCT02450448||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
62746472|NCT02450448||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
62746473|NCT05049707|PLACEBO_COMPARATOR|Control|The control arm will receive an equivalent volume of normal saline as the treatment group
62746474|NCT05049707|EXPERIMENTAL|IV magnesium|We will randomize patients in the treatment group to receive either a 50 mg/kg bolus of intravenous magnesium preoperatively followed by a magnesium infusion of 15mg/kg/hr, to be given after intraoperative neuromonitoring staff have been able to record baseline neurological data.
62746475|NCT05511727|ACTIVE_COMPARATOR|single Foley's catheter group|
62746476|NCT05511727|ACTIVE_COMPARATOR|Double Foley's catheter group|
62746477|NCT01817699|NO_INTERVENTION|Low Hb target without cholecalciferol|Target Hemoglobin level: ≥9.5 and \<10.5 g/dL
62746478|NCT01817699|ACTIVE_COMPARATOR|Low Hb target with cholecalciferol|Target Hemoglobin level: ≥9.5 and \<10.5 g/dL Cholecalciferol: 1,000 IU/day
62746479|NCT01817699|ACTIVE_COMPARATOR|High Hb target without cholecalciferol|Target Hemoglobin level: ≥12.5 and \<13.5 g/dL
62746480|NCT01817699|EXPERIMENTAL|High Hb target with cholecalciferol|Target Hemoglobin level: ≥12.5 and \<13.5 g/dL Cholecalciferol: 1,000 IU/day
62746481|NCT04397939||Patients with Acute Cardiac Injury|Patients with acute cardiac injury
62746482|NCT04397939||Patients without cardiac injury|Patients without cardiac injury
62374319|NCT00528840|EXPERIMENTAL|AA4500 0.58 mg|
62374320|NCT01378091|EXPERIMENTAL|Lenalidomide, Docetaxel, Prednisone|Subjects will receive this drug combination during a treatment phase and an extension phase.
62553329|NCT00709995|PLACEBO_COMPARATOR|Part 2 Arm B: Sunitinib + Placebo|"Part 2 was not activated per recommendation of safety review committee.~Sunitinib: 50 mg administered orally, once daily, Day 1-28, then rest Days 29-42.~Placebo: Cycle 1 Day 1 loading dose 3 tablets on Day 1, then 2 tablets daily, days 2-42."
62746483|NCT04397939||Patients with Chronic Cardiac Injury|Patients with chronic cardiac injury
62746484|NCT01517165|EXPERIMENTAL|Group 1|
62746485|NCT01517165|PLACEBO_COMPARATOR|Group 2|
62746486|NCT00962741|EXPERIMENTAL|1|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
62746487|NCT03378609|OTHER|Vocal Fatigue Index (VFI)|Standardized Questionnaire assessing vocal fatigue
62746488|NCT05633459|EXPERIMENTAL|QRL-201: Sporadic ALS|Multiple-ascending doses of QRL-201 will be intrathecally administered to individuals with ALS.
62746489|NCT05633459|PLACEBO_COMPARATOR|Placebo: Sporadic ALS|Multiple-ascending doses of placebo comparator will be intrathecally administered to individuals with ALS.
62746490|NCT05633459|EXPERIMENTAL|QRL-201: C9orf72-ALS|QRL-201 will be intrathecally administered to individuals with C9orf72-ALS.
62746491|NCT05633459|PLACEBO_COMPARATOR|Placebo: C9orf72-ALS|Placebo comparator will be intrathecally administered to individuals with C9orf72-ALS.
62746492|NCT01181999|EXPERIMENTAL|rituximab|
62746493|NCT05852158|EXPERIMENTAL|Single Dose|Single pre-operative dose of 2g IV Cefazolin given prior to first incision for orthognathic surgical procedure
62746494|NCT05852158|ACTIVE_COMPARATOR|24-Hour Dosing|Single pre-operative dose of 2g IV Cefazolin given prior to first incision for orthognathic surgical procedure, as well as 2g IV Cefazolin q8h post-operatively for 24 hours (3 total doses)
62746495|NCT00281099|ACTIVE_COMPARATOR|VVI 40 pacing|Backup ventricular pacing (VVI) at 40 beats per minute
62746496|NCT00281099|ACTIVE_COMPARATOR|MVP pacing|Managed ventricular pacing (MVP) at 60 beats per minute
62746497|NCT03656848|EXPERIMENTAL|QFR-guided PCI group|If the patient is assigned to QFR-guided PCI, QFR is first measured in all coronary arteries with DS% ≥ 50% and ≤ 90%. Then PCI treatment is performed in lesions with QFR ≤ 0.80, and optimal medicine treatment is prescribed to those with QFR \> 0.80. It is strongly recommended to select the device size based on the 3D-QCA measurements in this group.
62746498|NCT03656848|ACTIVE_COMPARATOR|Angiography-guided PCI group|If the patient is assigned to angiography-guided PCI, then the investigator performs PCI according to the stenosis severity based on visual assessment of the angiogram. No other functional tests such as FFR/iFR can be used for further assessment of the lesion before PCI.
62746499|NCT01139411|EXPERIMENTAL|Behavioral Weight Control with Enhanced Parent Involvement|This treatment arm included periodic dyadic sessions with adolescents and their parents, focusing on weight-related communication combined with standard behavioral weight control.
62746500|NCT01139411|PLACEBO_COMPARATOR|Behavioral Weight Control with Minimal Parent Involvement|This treatment arm included standard behavioral weight control delivered to the adolescent with minimal parent involvement.
62746501|NCT04103944|EXPERIMENTAL|Osteonecrotic Repair Device|A biphasic osteochrondral composite method to support the regeneration of articular cartilage in vivo. With its concept that could be securely installed by press-fit without additional fixation, this approach can present an alternative to perform graft harvest and implantation in a single surgery.
62746502|NCT04103944|ACTIVE_COMPARATOR|Core Decompression|Core decompression is a common surgical procedure that aims to improve vascular inflow by decreasing intraosseous pressure in the femoral head. It is performed that involves removing a cylindrical core of bone from the proximal femur.
62746503|NCT00924430|OTHER|1|
62746504|NCT00924430|OTHER|2|
62746505|NCT01314807||patients with COPD|patients who were defined as COPD, based on post-bronchodilator spirometry (GOLD criteria). Patients will have at least 10 pack years
62746506|NCT01314807||smoking controls|patients with at least 10 pack years who have no COPD (based on post-bronchodilator spirometry)
62746507|NCT01314807||non-smoking controls|patients with \< 1 pack year who have no COPD (based on post-bronchodilator spirometry)
62746508|NCT03325296|EXPERIMENTAL|LEO 124249 ointment 30 mg/g|Ointment to be applied on the eyebrow twice daily.
62374321|NCT06099808|EXPERIMENTAL|Audit and Feedback (AF)|Pharmacists randomized to audit and feedback will receive a monthly email containing information including their total medication titration encounters over a 3 month period, as well as the site and VISN level for comparison. The audit and feedback email will also contain rates of medical therapy and percentage of patients on \>50% of the target dose of medical therapy stratified by site, VISN and national. This data will be obtained from VHA national HF dashboard. Pharmacists in AF will also receive invitations to monthly educational sessions and access to shared resources on HF medication management.
62374322|NCT06099808|EXPERIMENTAL|Audit and Feedback with Patient Specific Targets (AF+)|Pharmacists randomized to the AF+ group will receive the audit and feedback intervention described above with the addition of a list of 5-7 HF patients who are potentially eligible for pharmacist HF medication titration. These patients will be identified using the VHA national HF dashboard.
62746509|NCT03325296|PLACEBO_COMPARATOR|LEO 124249 ointment vehicle|Ointment to be applied on the eyebrow twice daily.
62374323|NCT06099808|ACTIVE_COMPARATOR|Usual Care|Pharmacists randomized to the usual care arm will have access to monthly educational sessions and to shared resources on HF medication management. They will receive no additional feedback.
62374324|NCT01335438|EXPERIMENTAL|Cementless Nexgen CR|Cementless fixation of Nexgen CR TKR
62374325|NCT01335438|ACTIVE_COMPARATOR|Cemented Nexgen CR|Cemented fixation of Nexgen CR TKR
62374326|NCT00004205|EXPERIMENTAL|Tamoxifen|Tamoxifen for 5 years after randomization.
62374327|NCT00004205|EXPERIMENTAL|Letrozole|Letrozole for 5 years after randomization.
62553330|NCT02962986|ACTIVE_COMPARATOR|norepinephrine 6mcg|norepinephrine, given as 1mL IV boluses, to treat post-spinal hypotension
62553331|NCT02962986|ACTIVE_COMPARATOR|phenylephrine 100mcg|phenylephrine, given as 1mL IV boluses, to treat post-spinal hypotension
62746510|NCT01040988||Pacemaker|Patients meeting entry criteria with a pacemaker in place.
62746511|NCT01040988||ICD|Patients meeting entry criteria with an ICD in place.
62746512|NCT01694121|EXPERIMENTAL|MEN Count|3 session HIV intervention including a) HIV risk reduction, inclusive of gender equity and healthy relationship counseling and b) case management support for stable employment and housing.
62746513|NCT01694121|ACTIVE_COMPARATOR|Comparison|An attention comparison program similar to the MEN Count intervention in structure (3 one-on-one sessions delivered over 60-90 days) but focused on stress reduction and healthy lifestyle.
62746514|NCT06481371|EXPERIMENTAL|rabeprazole sodium enteric-coated tablets or mosapride citrate|"For epigastric pain syndrome, Rabeprazole sodium enteric-coated tablets were given as 20mg/dose, 2 times/day.~Postprandial discomfort syndrome was treated with mosapride citrate, 5mg/dose, 3 times/day, orally before meals.~The treatment lasted for 4 weeks."
62746515|NCT06481371|EXPERIMENTAL|Chinese medicine combination group|In the Chinese medicine combination group, 3g of Zuojinwan was added to the western medicine group twice a day for 4 weeks.
62746516|NCT05706155|ACTIVE_COMPARATOR|Control|Hypocaloric diet with predominance of animal protein
62746517|NCT05706155|EXPERIMENTAL|Intervention|Hypocaloric diet with predominance of plant protein
62746518|NCT03772028|NO_INTERVENTION|conventional surgery|Primary cytoreductive surgery without HIPEC
62746519|NCT03772028|EXPERIMENTAL|HIPEC|Primary cytoreductive surgery with HIPEC with cisplatin
62746520|NCT01406938|EXPERIMENTAL|AIN457150 mg- Induction period Only(IPO)|secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)
62746521|NCT01406938|EXPERIMENTAL|AIN457 300 mg - IPO|secukinumab- 2 x 150mg injections per dose
62746522|NCT01406938|EXPERIMENTAL|AIN457 150 mg - Fixed Interval (FI)|1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection
62746523|NCT01406938|EXPERIMENTAL|AIN457 300 mg FI|2 s.c. secukinumab 150 mg injections
62746524|NCT01406938|EXPERIMENTAL|AIN457 150 mg- Start of relapse (SoR)|1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection
62746525|NCT01406938|EXPERIMENTAL|AIN457 300 mg- SoR|2 s.c. secukinumab 150 mg injections
62746526|NCT03389724|EXPERIMENTAL|Group capoten (Intervention arm)|Patients will receive prophylactic ACE-I(Capoten®) at day 1 of initiation of chemotherapy and is to be continued for 1 year after the end of treatment. Patients will remain on this arm until they experience any of the study primary or secondary end-point where they will be off-study and will receive cardiotoxicity treatment independently.
62746527|NCT03389724|NO_INTERVENTION|Group standard treatment (Control arm)|Patients will not receive ACE-I as prophylaxis, and will be monitored and evaluated for first signs of cardiotoxicity based on the above mentioned end-points.
62746528|NCT04516538|EXPERIMENTAL|Young people|Men or Women under 35 years old
62746529|NCT04516538|EXPERIMENTAL|Old people|Men or Women between 60 and 80 years old
62374328|NCT00004205|EXPERIMENTAL|Tamoxifen, then letrozole|Tamoxifen for 2 years after randomization, then letrozole for the next 3 years.
62374329|NCT00004205|EXPERIMENTAL|Letrozole, then tamoxifen|Letrozole for 2 years after randomization, then tamoxifen for the next 3 years.
62374330|NCT05379933|EXPERIMENTAL|C-PRIME|Participants will wear an activity tracker for 8 weeks. During the 8 weeks of the study, participants will complete weekly survey questions about health and well-being and engage in weekly, 15-20 minute telephone/videoconference coaching sessions with a health coach.
62374331|NCT02652572|EXPERIMENTAL|Granexin® gel plus standard-of-care|Granexin® gel will be applied topically to diabetic foot ulcer(s) on Day 0 (baseline), Day 3, and Day 7. In addition, standard-of-care treatment will be applied to the ulcer(s) at Screening, Day 0, Day 3, and Day 7.
62374332|NCT04949776|EXPERIMENTAL|Double reading of all cases with and without Transpara software|Double reading of all cases with and without Transpara software
62374333|NCT06444997|EXPERIMENTAL|Oxycodone Hydrochloride|Continuous infusion therapy
62374334|NCT06444997|ACTIVE_COMPARATOR|Remifentanil|Continuous infusion therapy
62374335|NCT05947695|EXPERIMENTAL|Intervention|The oncology nurse-specialist-led multidisciplinary early intervention arm includes standard of care with additional coordination of services, patient education, and referral to treatment and other resources aligned with comprehensive best practice models for multidisciplinary care teams.
62374336|NCT05947695|ACTIVE_COMPARATOR|Standard of Care|The standard of care comparator arm is usual clinical care using NCCN guidelines and evidence-based practice for palliative and survivorship care for patients treated with distant metastases.
62746530|NCT04516538|EXPERIMENTAL|Very old people|Men or Women over 80 years old
62746531|NCT06661707|ACTIVE_COMPARATOR|Quadratus Lumborum block (QL) group|
62746532|NCT06661707|ACTIVE_COMPARATOR|Ilioinguinal/Iliohypogastric block (ILI/IHG) group|
62746533|NCT06102200|ACTIVE_COMPARATOR|Standard of care|Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly, bi-weekly or monthly visits (at the discretion of the provider) in-person or virtually. This condition will be matched with the other conditions in terms of the number of research visits.
62746534|NCT06102200|EXPERIMENTAL|Standard of care + CBT4CBT|This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise.
62746535|NCT06102200|EXPERIMENTAL|Standard of care + CBT4CBT+ RC|This condition will integrate the standard of care, CBT4CBT, and recovery coaching services with Assertive Community Engagement (ACE) model interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs Peer recovery coaching services involve a form of nonclinical, peer support aimed at helping individuals with substance use disorders to achieve and maintain recovery. Recovery coaches are individuals with experience with substance use and successful recovery. In addition to their lived experience, recovery coaches obtain formal training on substance use coaching and receive ongoing supervision. The recovery coaches use an assertive engagement approach to provide holistic, person-centered, and strength-based support.
62746536|NCT01568450|EXPERIMENTAL|GL2907 XL 20mg (Oxycodone 20mg, fasted)|
62746537|NCT01568450|EXPERIMENTAL|GL2907 XL 20mg (Oxycodone 20mg, after high fat meal)|
62746538|NCT01568450|ACTIVE_COMPARATOR|Oxycontin CR 10mg (Oxycodone 10mg, fasted)|
62746539|NCT04342806||HCWs currently working in the US, and their families and communities|"The HERO Registry will include HCWs currently working across the United States, and their families and communities. For the purposes of this study, a healthcare worker is defined as an individual who currently works in a setting where individuals receive healthcare. (Note: individuals do not have to work directly with patients, but may have any role within a setting where individuals receive healthcare, such as housekeeping, food service, etc.)"
62746540|NCT01405352|ACTIVE_COMPARATOR|Non obese/ vitamin A|Non obese individuals with body mass index 18.5-24.9 kg/m2 who receive 25000 IU/day vitamin A for 4 months .
62374337|NCT04990531|EXPERIMENTAL|Covid-19 subjects|Childrens and adolescent with PCR-proven previous SARS-CoV-2 infection
62374338|NCT04990531|ACTIVE_COMPARATOR|Healthy controls|Healthy controls negative for previous SARS-CoV-2 infection
62374339|NCT01397513|ACTIVE_COMPARATOR|Aspirin 75mg|
62374340|NCT01397513|ACTIVE_COMPARATOR|Aspirin 320mg|
62746541|NCT01405352|PLACEBO_COMPARATOR|obese/ placebo|obese individuals with body mass index greator than 30 kg/m2 who receive 1 cap placebo per day for 4 months .
62746542|NCT01405352|ACTIVE_COMPARATOR|Obese/ vitamin A|obese individuals with body mass index greater than 30 kg/m2 who receive 25000 IU/day vitamin A for 4 months
62746543|NCT03149354|OTHER|Patients with HIV|Patients with HIV
62746544|NCT03745365|EXPERIMENTAL|sleeve gastrectomy|"The greater omentum is divided 5 cm from the pylorus with an energy device. The antral pouch is measured 2-6cm from the pylorus along greater curve as risk benefit ratio is best within these limits.~Devascularization is continued up the greater curve of the stomach to the short gastric vessels with the help of the assistant who maintains traction and exposure during this process. Eventually, one reaches the left crus which is an important landmark of dissection. We selectively explore the hiatus of the symptomatic and endoscopically proven hiatus hernia , and the hernia should be reduced and repaired."
62746545|NCT03745365|EXPERIMENTAL|sleeve gastrectomy with loop bipartition|Sleeve gastrectomy is performed first, then a loop gastro-ileostomy 200-250 cm from doudeno-jejunal junction was created at the dependent part of the antrum with 2 layers of with stapler but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastro-ileostomy. The staple line and anastomosis was tested with methylene blue. A drain is inserted.
62746546|NCT05151445||mHealth dietary app + health coaching intervention|A feasibility study will be utilized to establish the recruitment, retention, and adherence with post-kidney transplant recipients using a consumer-based mHealth dietary app + health coaching.
62746547|NCT05987605|EXPERIMENTAL|1A46 Drug Substance|One cycle is defined as 21 days. Patients will be scheduled to receive weekly infusions of 1A46 for the first cycle and then for the remaining 15 cycles of the study, patients will receive a single infusion of 1A46 per cycle (Q3W)
62746548|NCT06645457|EXPERIMENTAL|stress ball|group applying the stress ball for 20 minute before endoscopy
62746549|NCT06645457|EXPERIMENTAL|4-7-8 breathing technique|group applying the 4-7-8 breathing technique for 6 sets before endoscopy
62746550|NCT06645457|NO_INTERVENTION|Control group|The group in which no intervention was performed before endoscopy and routine care was given
62374341|NCT00487994|EXPERIMENTAL|Lapaquistat Acetate 100 mg QD|
62746551|NCT06225375|OTHER|Treatment with Restorelle Flat Mesh|Subjects shall undergo transvaginal mesh surgery per the surgeon's specifications. Briefly, a sheet of Restorelle® Flat Mesh-(XL) shall be cut to the dimensions of the former Restorelle® Direct Fix Anterior and Posterior Mesh
62746552|NCT02174029||Ventilation- mandatory mode only|those patient ventilator days during which they had only received a mandatory mode of ventilation
62746553|NCT02174029||Ventilation- voluntary mode only|Those patient days on a mechanical ventilator who have not received prior mandatory ventilation during this episode of mechanical ventilation.
62746554|NCT02174029||voluntary with preceding mandatory|Those patient ventilator days where the patient had at least one prior day of mandatory mechanical ventilation during this episode of respiratory support.
62746555|NCT01491789|EXPERIMENTAL|Virtual Sailing|you will be doing 60 minutes of Virtual Sailing training, 1 time a week for 12 weeks
62374342|NCT00487994|EXPERIMENTAL|Lapaquistat Acetate 100 mg QD + Atorvastatin 10 mg QD|
62553332|NCT05626205|EXPERIMENTAL|Experimental Group|The Experimental Group will receive for 12 weeks a robotic training with Paro robot combined with traditional training.
62746556|NCT01103544||Patients with advanced / metastatic TCCU after CDDP-failure|
62746557|NCT02502435||Patients with Night-Eating Syndrome|Individuals diagnosed with Night Eating Syndrome (NES); 18-65 years of age; eating 30% of their caloric intake after dinner with nocturnal awakenings to eat at a frequency of ≥ 5 times per week
62746558|NCT02502435||Matched Healthy Controls|Healthy volunteers; 18-65 years of age; eating \<25% of their caloric intake after dinner; no nocturnal ingestions
62553333|NCT05626205|NO_INTERVENTION|Control Group|The Control Group will receive only the traditional therapy.
62746559|NCT03571009|EXPERIMENTAL|utilization of PAAS|conventional treatment utilization of PAAS
62746560|NCT03571009|NO_INTERVENTION|Conventional care|conventional treatment only
62746561|NCT06662097|EXPERIMENTAL|Dose Defining|A dose defining phase for each surgical setting.
62746562|NCT06662097|EXPERIMENTAL|Dose Expansion|A dose expansion phase for each surgical setting.
62746563|NCT05904236|EXPERIMENTAL|ICVB-1042|Part A: Dose escalation Part B: Dose expansion
62553334|NCT04964102|EXPERIMENTAL|Workshop|Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills
62746564|NCT01285570|EXPERIMENTAL|Experimental 2|
62746565|NCT01285570|EXPERIMENTAL|experimental 1|
62746566|NCT01285570|PLACEBO_COMPARATOR|Placebo|Placebo comparator daily (QD)
62374343|NCT00487994|ACTIVE_COMPARATOR|Atorvastatin 10 mg QD|
62374344|NCT06251544|EXPERIMENTAL|Arm A: HTR2 T Cells (without lymphodepletion)|Two dose levels will be evaluated in Arm A (without lymphodepletion)
62374345|NCT06251544|EXPERIMENTAL|Arm B: HTR2 T Cells (with lymphodepletion)|Two dose levels will be evaluated in Arm B (with lymphodepletion)
62374346|NCT04881110|EXPERIMENTAL|Liraglutide group|Patients in this arm will receive liraglutide, according to the current clinical practice.
62374347|NCT04881110|OTHER|Control group|Patients in this arm will be strictly monitored with optimization of the therapy for atherosclerosis major risk factors.
62553335|NCT02411825|EXPERIMENTAL|SAR425899 (healthy subjects)|Once daily SC doses of SAR425899
62553336|NCT02411825|PLACEBO_COMPARATOR|Placebo (healthy subjects)|Once daily SC doses of placebo
62553337|NCT02411825|EXPERIMENTAL|SAR425899 (T2DM Patients)|Once daily SC doses of SAR425899 and two up titration steps in each dose cohort with metformin as background therapy
62553338|NCT02411825|PLACEBO_COMPARATOR|Placebo (T2DM Patients)|Once daily SC doses of placebo and two up titration steps in each dose cohort with metformin as background therapy
62553339|NCT00137501|OTHER|A|High dose Nifedpine arm
62746567|NCT02982434|EXPERIMENTAL|Group 1|All patients underwent conventional CABG surgery. After the main stage of the surgery new pharmaceutical composition containing botulinum toxin (50 U/1 mL) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right ganglionated plexi (GP); second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior pulmonary vein (PV) and left inferior PV (between the PVs and left atrial appendage (LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
62746568|NCT02982434|ACTIVE_COMPARATOR|Group 2|All patients underwent conventional cardiac surgery. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
62746569|NCT03900130|EXPERIMENTAL|Full group|"There is only one arm in this study. The group of 25 subjects all undergo a repeated measures 2 x 2 factorial design, fully crossed such that all subjects are tested under all four combinations of factors.~The intervention Preload amounts to two factors, caloric load and protein to carbohydrate ratio of the preload, both of which can take on two levels high or low."
62746570|NCT05725005|EXPERIMENTAL|Group 1|Group 1 will receive 10 mg once-daily (QD) doses of ASN51, by mouth, for 14 days.
62746571|NCT05725005|EXPERIMENTAL|Group 2|Group 2 will receive 20 mg once-daily (QD) doses of ASN51, by mouth, for 14 days.
62553340|NCT00137501|OTHER|B|Low dose Nifedipine arm
62553341|NCT05310071|EXPERIMENTAL|Aducanumab|Participants will receive aducanumab, up to 10 milligrams per kilograms (mg/kg), monthly (once every four weeks), administered as intravenous (IV) infusion.
62746572|NCT00054327|EXPERIMENTAL|Regimen A|Patients receive cytarabine 3.0gm/M² IV over 1 hour twice daily on days -9 to -7 and cyclophosphamide 45mg/kg IV over 2 hours on days -6 and -5. Patients also undergo total body irradiation (TBI), 165 cGY, twice daily on days -4 to -1 for a total of 1320 cGY.
62746573|NCT00054327|EXPERIMENTAL|Regimen B-1|Patients receive cyclophosphamide 60 mg/kg IV on days -6 and -5. Patients also undergo total body irradiation (TBI) twice daily on days -4 to -1 for a total of 1320 cGY..
62553342|NCT05310071|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo, monthly (once every four weeks), administered as IV infusion.
62553343|NCT03744247|EXPERIMENTAL|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62553344|NCT03744247|ACTIVE_COMPARATOR|Lenvatinib alone|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received placebo intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62553345|NCT05546437||Subjects with Ion Endoluminal dye marking of pulmonary nodule for resection|Subjects in which a pulmonary lesion dye marking procedure was attempted or performed with the Ion Endoluminal System in anticipation of resection of the lesion
62553346|NCT05462041|OTHER|DBD Donor Heart Transplantation|If the heart offer is from a DBD donor, the heart will be retrieved per standard of care.
62553347|NCT05462041|OTHER|DCD Donor Heart Transplantation|If the heart offer is from a DCD donor, the heart will be retrieved using one of two strategies: Normothermic Regional Perfusion (NRP) or Direct Procurement and Perfusion (DPP). NRP procedures will be used to procure all DCD hearts unless contraindicated or prohibited by the donor hospital. In the event the donor hospital does not allow NRP for cardiac organ procurement, or the target number of eight DCD transplants with NRP has been achieved, DPP with the Organ Care System (OCS) should be utilized.
62553348|NCT05203783|ACTIVE_COMPARATOR|Control Group|The control group will receive only McKenzie exercises for 7 days.
62553349|NCT05203783|EXPERIMENTAL|Experimental Group|The experimental group will receive Kinesio tape application in addition to McKenzie exercises for 7 days.
62553350|NCT05396898|EXPERIMENTAL|LCP-tacrolimus (Envarsus®)|"Patients in this arm start (after randomization) on LCP-tacrolimus therapy.~At midterm of study participation (16 weeks), a switch is made to twice-daily tacrolimus (Prograf® ) therapy.~The duration of the trial for each subject is expected to be 32 weeks."
62553351|NCT05396898|ACTIVE_COMPARATOR|twice-daily tacrolimus (Prograf®)|"Patients in this arm start (after randomization) on twice daily tacrolimus (Prograf®) therapy.~At midterm of study participation (16 weeks), a switch is made to LCP-tacrolimus (Envarsus®) therapy. The duration of the trial for each subject is expected to be 32 weeks."
62746574|NCT00054327|EXPERIMENTAL|Regimen B-2|Patients receive cyclophosphamide 60 mg/kg IV over 2 hours on days -5 and -4. Patients also undergo TBI twice daily on days -3 to -1 for a total of 1200 cGY.
62746575|NCT00054327|EXPERIMENTAL|Regimen C|Patients receive oral busulfan 1mg/kg/dose (or 40mg/m2/dose for young children)4 times daily on days -8 to -5 and cyclophosphamide 60 mg/kg IV over 2 hours on days -4 to -2.
62746576|NCT00054327|EXPERIMENTAL|Regimen B-3|Patients undergo total body irradiation (TBI) twice daily on days -7 to -5 for a total of 1200 cGY. Patients then receive cyclophosphamide 60 mg/kg IV on days -4 and -3.
62746577|NCT00054327|EXPERIMENTAL|Regimen D|Patients receive total body irradiation (TBI) on days T -6, -5 and -4 for a total of 1320 cGy , then etoposide (60mg/kg/dose) on day -3.
62553352|NCT04814173|EXPERIMENTAL|One jaw mechanic|Mini-implants anchored total-maxillary-arch-distalization using a one-jaw mechanic (mini-implants in the maxillary arch).
62746578|NCT01667224|EXPERIMENTAL|Actiponin|Actiponin(extract of Gynostema pentaphyllum, 450mg/day) for 12weeks
62746579|NCT01667224|PLACEBO_COMPARATOR|Placebo|Placebo(450mg/day) for 12weeks
62746580|NCT00666588|EXPERIMENTAL|Bortezomib 1.3mg/m2-assess efficacy-low anthracycline exposure|Bortezomib 1.3mg/m2 to assess efficacy in low prior anthracycline exposure. Patients receive idarubicin IV (12 mg/m2/day) over 15 minutes on days 1-3, low-dose cytarabine IV (100 mg/m2/day) continuously over days 1-7, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity (closed as of 08/01/10). Dosage modification based on age \< 3 years old.
62746581|NCT00666588|EXPERIMENTAL|Bortezomib 1.0mg/m2-assess feasibility high anthracycline exp|Bortezomib 1.0 mg/m2 to assess feasibility in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.0 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62746582|NCT00666588|EXPERIMENTAL|Bortezomib 1.3 mg/m2-assess feasibility high anthracycline exp|Bortezomib 1.3 mg/m2 to assess feasibility in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity (dose-finding phase closed as of 10/10).
62553353|NCT04814173|EXPERIMENTAL|Two-jaw mechanic|Mini-implants anchored total-maxillary-arch-distalization using a two-jaw mechanic (mini-implants in the mandibular arch with class II elastics).
62553354|NCT04814173|EXPERIMENTAL|Traditional treatment|traditional en-mass retraction with first premolars extraction with mini-implants in the maxillary arch.
62553355|NCT01094015|ACTIVE_COMPARATOR|Lidocaine-Prilocaine cream|
62553356|NCT01094015|PLACEBO_COMPARATOR|placebo|
62553357|NCT02732873|EXPERIMENTAL|FibroFix|
62553358|NCT03996811|EXPERIMENTAL|exercise group|exercise education: A 12-week regimen of home-based walking exercises, include moderate intensity for 40 min, three times a week on non-dialysis days. We explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. Participants were instructed that the exercises would be effective only if they reached 40%-60% of the target heart rate, as determined by the Karvonen method, and 12-13 on the RPE.
62553359|NCT03996811|NO_INTERVENTION|usual-care group|Hospital routine care
62553360|NCT04177407|EXPERIMENTAL|BPF group|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.
62553361|NCT04177407|NO_INTERVENTION|control group|Regarding to the pelvic peritoneum reconstruction, in control group, the pelvic peritoneum will be closed with running suturing. If not possible, the peritoneum covering the surface of the bladder will be secured on the anterior surface of the sacrum with nonabsorbable sutures at the level where the anatomic structure obliterates the pelvic entrance. If neither method was feasible, the pelvic peritoneum defect will be left unclosed.
62553362|NCT02276807|EXPERIMENTAL|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques. Emphasis is placed upon understanding the individuals values and increasing the number of pleasurable activities aligned with the individuals values.
62553363|NCT02276807|ACTIVE_COMPARATOR|Usual Care|This is the usual care condition, where participants often times will be provided with brief treatment in primary care that can take many forms.
62553364|NCT03145415|EXPERIMENTAL|Bilateral Pudendal block|0.25 cc per kg of 0.2% ropivacaine will be injected once for right pudendal N block and the same volume for the left pudendal N block before the start of the surgery
62553365|NCT03145415|ACTIVE_COMPARATOR|Caudal block|1 cc per kg of 0.2% ropivacaine in the caudal space given before the start of surgery
62553366|NCT06429293|EXPERIMENTAL|Cognitive processing therapy|12 week treatment period of cognitive processing therapy followed by a post-treatment visit.
62553367|NCT06429293|NO_INTERVENTION|Control waitlist|Participants randomized to waitlist are offered CPT upon completion of the post-treatment visit.
62567246|NCT01982617|EXPERIMENTAL|Psychoeducation|The education group also consisted of four group sessions that were co-led by a doctoral-level clinical psychologist and at bachelors-level research assistant. However, the focus of the education group was to present factual information about health risks of smoking, benefits of quitting, pharmacological smoking cessation aides, and smoking cessation programs in the area. The four group topics included: 1) Health Risks of Smoking, 2) Benefits of Quitting, 3) Nicotine Replacement Therapy and Bupropion (Zyban), and 4) Options for Treatment Programs.
62567247|NCT02062450||Primary surgery with Dual Mobility Cup|Patients having a Primary Hip acetabular replacement, using a Dual Mobility Cup.
62567248|NCT02062450||Revision surgery with Dual Mobility Cup|Patients having a Revision Hip acetabular replacement, using a Dual Mobility Cup.
62567249|NCT00634803|EXPERIMENTAL|CBT for POD|Integrated cognitive behavioral therapy for chronic pain and opioid dependence
62567250|NCT00634803|ACTIVE_COMPARATOR|Educational Counseling for POD|Educational Counseling is a didactic, lecture-discussion format to supplement the information and advice provided by physicians in physician management (PM)
62567251|NCT00634803|ACTIVE_COMPARATOR|Physician Management|PM is a relatively brief intervention that approximates the medically focused advice and brief counseling about medical issues that is typically provided by physicians to patients with chronic pain or other chronic medical conditions, such as diabetes or asthma.
62567252|NCT06392022|EXPERIMENTAL|Experimental group|Children in this group were shown musical cartoons during rectal irrigation.
62567253|NCT06392022|NO_INTERVENTION|Control group|No additional intervention
62567254|NCT01579097|ACTIVE_COMPARATOR|compounded ternary parenteral nutrition|compounded ternary Parenteral Nutrition admixture
62746583|NCT00666588|EXPERIMENTAL|Bortezomib 1.3 mg/m2-assess efficacy high anthracycline exp|Bortezomib 1.3 mg/m2 to assess efficacy in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity
62746584|NCT02987361|EXPERIMENTAL|treatment group 1|anodal stimulation on the lesioned primary motor cortex DC-STIMULATOR PLUS
62746585|NCT02987361|EXPERIMENTAL|treatment group 2|cathodal stimulation on the non-lesioned primary motor cortex DC-STIMULATOR PLUS
62553368|NCT00467974|EXPERIMENTAL|1|TEA with LEM
62746586|NCT02987361|EXPERIMENTAL|treatment group 3|dual stimulation such as anodal stimulation on the lesioned side and cathodal stimulation on the non-lesioned side DC-STIMULATOR PLUS
62746587|NCT02987361|SHAM_COMPARATOR|sham group|sham group
62553369|NCT00467974|ACTIVE_COMPARATOR|2|TACE
62746588|NCT02740062|ACTIVE_COMPARATOR|Active treatment|Active tDCS treatment
62746589|NCT02740062|SHAM_COMPARATOR|Sham treatment|Sham tDCS treatment
62746590|NCT01644006|EXPERIMENTAL|Device: Teleconsultation|"In cases of suspected acute coronary syndrome (including STEMI), if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. Also 12-lead-ECGs can be transmitted to the tele-EMS physician. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, ECG diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene.~The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
62746591|NCT01644006|NO_INTERVENTION|Historical Matched Pairs|Historical matched pairs were searched from local protocols. During this phase no teleconsultation system was existent.
62746592|NCT02021617|NO_INTERVENTION|Intraosseous Access|This study will evaluate the proximal humerus and proximal tibia IO infusion sites for infusion flow rates attainable at specified infusion pressures. We will evaluate the IO infusion pathway to determine the mean time from IO contrast injection at the proximal humerus and proximal tibia sites to delivery to central circulation. This study will provide additional data regarding the relationship between IO and IV blood when used for routine laboratory analysis, adding to the current sample size. Lastly, this study will provide data to determine the average time from IO needle insertion to access of the IO space for immediate drug administration, and the average time from IO needle insertion to the ability to infuse fluids in the conscious subject. Intraosseous access.
62746593|NCT02612103||Active Crohns disease|Verified Crohns disease diagnosis according to clinical, endoscopic and histological standard criteria and Harvey Bradshaw index \> 4.
62746594|NCT02612103||Crohns disease in remission|Verified Crohns disease diagnosis according to clinical, endoscopic and histological standard criteria and Harvey Bradshaw index ≤ 4.
62746595|NCT02612103||Active ulcerative colitis|Verified ulcerative colitis diagnosis according to clinical, endoscopic and histological standard criteria and Simple Clinical Colitis Activity Index \> 3.
62746596|NCT02612103||Ulcerative colitis in remission|Verified ulcerative colitis diagnosis according to clinical, endoscopic and histological standard criteria and Simple Clinical Colitis Activity Index ≤ 3.
62746597|NCT02612103||Irritable bowel syndrome|Verified irritable bowel syndrome according to standard criteria.
62746598|NCT02612103||Healthy controls|No known chronic diseases which needs continuously medication.
62746599|NCT06243003|EXPERIMENTAL|HA-WBRT with SRS|hippocampal-sparing WBRT combined with SRS will be used to treat SCLC patients with baseline brain metastases during standard first-line chemotherapy combined with immunotherapy.
62746600|NCT02975999|EXPERIMENTAL|Vasopressin|Vasopressin at 0.4mU/kg/min
62746601|NCT02975999|PLACEBO_COMPARATOR|Normal saline|Normal saline will be provided on a drip infusion to the selected group once coming off cardiopulmonary bypass following the Fontan operation.
62746602|NCT03429985|EXPERIMENTAL|FRRM Intervention|The experimental arm will receive the FRRM intervention.
62746603|NCT03429985|NO_INTERVENTION|Control|The control arm will not receive the FRRM intervention.
62553370|NCT01689883|OTHER|Current stimulator|The investigators have developed a device to deliver very small currents to the arm. The device will be used while subjects perform upper-limb movements using a device for upper-limb rehabilitation. Subjects will perform multiple trials of movement. During half of the trials, they will receive actual stimulation. During the other half, they will receive sham stimulation.
62553371|NCT02051348|PLACEBO_COMPARATOR|Placebo|Placebo - 2 doses per day for 4 weeks
62746604|NCT02398422|EXPERIMENTAL|Filtered Music Intervention|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
62746605|NCT02398422|EXPERIMENTAL|Nonfiltered Music Intervention|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention (nonfiltered music). The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
62553372|NCT02051348|ACTIVE_COMPARATOR|Pylopass|Probiotic - 2 doses per day for 4 weeks
62553373|NCT03929068|ACTIVE_COMPARATOR|carbidopa-levodopa|Each tablet of carbidopa-levodopa in this study will be equivalent to half of a standard carbidopa-levodopa 25/100mg tablet. Participants will take one tablet three times a day for the first week of the study period, increasing to two tablets three times a day for the remainder of the study period.
62553374|NCT03929068|PLACEBO_COMPARATOR|Placebo|Participants will take one placebo tablet three times a day for the first week of the study period, increasing to two tablets three times a day for the remainder of the study period.
62553375|NCT06223802|EXPERIMENTAL|trained group|women group with a number of 29 women receiving 3-time biodex training per week, every time will be 10 minutes for 12 weeks
62746606|NCT02398422|NO_INTERVENTION|Assessment-only|The assessment-only group will participate in all pre- and post-intervention assessments, but will not receive the Listening Project Protocol.
62746607|NCT02441491|EXPERIMENTAL|Cyclophosphamide|"Cyclophosphamide will be given by vein once a day for four straight days.~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, will be given by vein once every day to try to help your blood cells grow faster."
62746608|NCT06661525|EXPERIMENTAL|Participants|Data collection from Participants and evaluate their feedback by filling a questioner
62746609|NCT06661525|ACTIVE_COMPARATOR|Care providers|Care providers will provide their feedback via questioner
62746610|NCT02533986|PLACEBO_COMPARATOR|Control drink|Dietary supplement: Control drink As control, subjects are asked to consume 150 ml control drink containing equal amount of insoluble fiber (cellulose) and sugar for 28 days. In addition, on days-1 and 28, subjects will receive an acute challenge of placebo drink at our clinical facility. After 30 min. control drink intake, subjects will be given standardized breakfast corresponding to 50 g available carbohydrates.
62746611|NCT02533986|EXPERIMENTAL|Berry peel drink|Dietary supplement: Berry peel drink Subjects are asked to consume 150 ml experimental drink containing a berry peel fruit powder. In addition, on days-1 and 28, subjects will receive an acute challenge of test drink at our clinical facility. After 30 min. berry drink intake, subjects will be given standardized breakfast corresponding to 50 g available carbohydrates.
62746612|NCT03883919|EXPERIMENTAL|Group 1: Paricalcitol 75 mcg Days 1 and 8|"* 5-FU, LV, and nal-IRI will be administered at standard fixed doses. Briefly, 5-FU will be given at a dose of 2400 mg/m\^2 continuous IV infusion over 46 hours, LV will be given at 400 mg/m\^2 IV over 30 minutes, and liposomal irinotecan will be given at a dose of 70 mg/m\^2 IV over 90 minutes (unless homozygous for the UGT1A1\*28 7/7 allele, in which case the dose will start at 50 mg/m\^2 and escalate to 70 mg/m\^2 in subsequent cycles if no excessive toxicity is experienced) on Day 1 of each 14-day cycle.~* Paricalcitol 75 mcg on Days 1 and 8~* Treatment with liposomal irinotecan plus 5FU/ LV may continue indefinitely, and treatment with paricalcitol may continue for up to 10 cycles (20 weeks)"
62553376|NCT06223802|NO_INTERVENTION|non trained group|this group will serve as a control group that will receive no intervention
62553377|NCT02252354|EXPERIMENTAL|Part 1: [14C]-TAK-385|\[14C\]-TAK-385 80 mg, solution, orally, once on Day 1.
62553378|NCT02252354|EXPERIMENTAL|Part 2: TAK-385 + [14C]-TAK-385 IV|TAK-385 80 mg, tablets, orally, and \[14C\]-TAK-385 80 μg, infusion, intravenous once on Day 1.
62567255|NCT01579097|EXPERIMENTAL|Oliclinomel N4 formulation|Oliclinomel N4 is a ready-to-use PN product presented as a triple chamber bag
62567256|NCT01491568|EXPERIMENTAL|Investigational|
62567257|NCT02598050||older surgical patients|Patients 65 years of age and older having lower extremity joint replacement surgery.
62567258|NCT02501122||Adenotonsillectomy|Measuring quality of care in patients undergoing adenotonsillectomy.
62567259|NCT04968730|PLACEBO_COMPARATOR|control group A|routine nursing after operation
62567260|NCT04968730|EXPERIMENTAL|intervention group B|Nursing care after operation with stage intervention
62567261|NCT02509507|EXPERIMENTAL|Phase Ib/II Talimogene Laherparepvec|Talimogene Laherparepvec
62567262|NCT02509507|EXPERIMENTAL|Phase Ib/II Talimogene Laherparepvec + Pembrolizumab|Combination treatment of Talimogene Laherparepvec and Pembrolizumab
62567263|NCT02641743|EXPERIMENTAL|Inslow|Each participant was requested to consume one of is energetic test meals (200 kcal per serving 200ml) Inslow at 7:00 AM.
62567264|NCT02641743|PLACEBO_COMPARATOR|standard balanced formula|Each participant was requested to consume one of is energetic test meals (200 kcal per serving 200ml) standard balanced formula at 7:00 AM.
62567265|NCT01286467|EXPERIMENTAL|1|
62567266|NCT03015337|EXPERIMENTAL|New Physical Education Instructions|
62567267|NCT05923801|ACTIVE_COMPARATOR|BT ECT|Participants showing no response will be switched to BT ECT until remission is achieved.
62567268|NCT05923801|ACTIVE_COMPARATOR|RUL ECT|Participants showing no response will continue with RUL ECT until remission is achieved.
62567269|NCT04750499|EXPERIMENTAL|Treatment|Patients with complex anal fistulas, non related to Crohn's disease.
62567270|NCT02153177|ACTIVE_COMPARATOR|NSAID and pain medication arm|After a rotator cuff repair procedure subjects in the NSAID and pain medication arm will receive both Ibuprofen and Hydrocodone/Acetaminophen, and also Omeprazole.
62567271|NCT02153177|ACTIVE_COMPARATOR|pain medication arm|Patients in the pain medication arm will receive Hydrocodone/Acetaminophen after the rotator cuff repair procedure.
62567272|NCT03379727|EXPERIMENTAL|Midostaurin|"Patients went through 3 phases:~Induction phase - Day (D)8 to D28 in combination with standard of care (7+3 or 5+2 chemotherapy) up to 2 cycles; Consolidation phase - D8 to D28 in combination with cytarabine up to 4 cycles; Maintenance phase - D1 to D28 up to 12 cycles"
62567273|NCT06370546|EXPERIMENTAL|Low Intensity|The low-intensity group undergoes a strength training program using barbells, weights and dumbbells, consisting of 6 sets of 12 repetitions each, with an execution speed below 55% of the maximum velocity used in the one-repetition maximum
62567274|NCT06370546|EXPERIMENTAL|high intensity|The low-intensity group undergoes a strength training program using barbells, weights and dumbbells consisting of 6 sets of 6 repetitions each, with an execution speed equal to or greater than 80% of the maximum velocity used in the one-repetition maximum
62567275|NCT02354677|EXPERIMENTAL|Heathy volunteers, smokers and COPD|
62567276|NCT03190993|ACTIVE_COMPARATOR|Sugar Sweetened Solid Treatment|A solidified food that is made with the SSB syrup concentrate and gelatin. It is equivalent to one 20 oz. soft drink.
62567277|NCT03190993|ACTIVE_COMPARATOR|Sugar Sweetened Beverage Treatment|20 oz. carbonated sugar sweetened beverage. Added ingredients include: \~2.1g whey protein powder.
62567278|NCT05348460|OTHER|Ketone - Placebo treatment|Patients will first receive a supplemental drink containing a ketone ester before performing the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time after receiving the placebo treatment.
62746613|NCT03883919|EXPERIMENTAL|Group 2: Paricalcitol 7 mcg/kg Days 1 and 8|"* 5-FU, LV, and nal-IRI will be administered at standard fixed doses. Briefly, 5-FU will be given at a dose of 2400 mg/m\^2 continuous IV infusion over 46 hours, LV will be given at 400 mg/m\^2 IV over 30 minutes, and liposomal irinotecan will be given at a dose of 70 mg/m\^2 IV over 90 minutes (unless homozygous for the UGT1A1\*28 7/7 allele, in which case the dose will start at 50 mg/m\^2 and escalate to 70 mg/m\^2 in subsequent cycles if no excessive toxicity is experienced) on Day 1 of each 14-day cycle.~* Paricalcitol 7 mcg/kg on Days 1 and 8~* Treatment with liposomal irinotecan plus 5FU/ LV may continue indefinitely, and treatment with paricalcitol may continue for up to 10 cycles (20 weeks)"
62746614|NCT03466281|ACTIVE_COMPARATOR|IBS School|Patient education provided in a group setting
62746615|NCT03466281|ACTIVE_COMPARATOR|Internet patient education|Patient education provided via the internet
62553379|NCT04581993|EXPERIMENTAL|Intervention|Pregnant and lactating women (PLW) will receive Super Cereal - wheat soya blend with sugar and children aged 6-23 months will receive lipid-based nutrient supplement-medium quantity (LNS-MQ). Social and behavior change communication (SBCC), community mobilization, referrals, identification of model families, food demonstrations, local recipe) ration/beneficiary entitlement cards will be provided for easy verification and tracking during delivery of intervention.
62746616|NCT02739763|EXPERIMENTAL|Plasmodium falciparum sprozoite (PfSPZ) challenge|Challenge agent
62746617|NCT03874741|EXPERIMENTAL|Arm - Experimental|Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
62746618|NCT01257568|OTHER|Rejuvenate Modular Hip System|Rejuvenate Modular Hip
62746619|NCT01748461|ACTIVE_COMPARATOR|Structured intervention|Supervised cycle ergometer program
62746620|NCT01748461|ACTIVE_COMPARATOR|Coach intervention|Non-supervised cycle ergometer program
62746621|NCT01748461|NO_INTERVENTION|Control group|No cycle ergometer program
62746622|NCT01054560|EXPERIMENTAL|SOLITAIRE™ Device|The SOLITAIRE™ Device (investigational device) is the experimental arm
62746623|NCT01054560|ACTIVE_COMPARATOR|MERCI® Device|The MERCI® Device (control device) is commercially available.
62746624|NCT02225483||Hemophilia A|Boys with Factor VIII coagulant activity less than or equal to 1%.
62553380|NCT04581993|NO_INTERVENTION|Control|Control districts will receive routine health care services available in the study area.
62553381|NCT05606783|EXPERIMENTAL|Home blood pressure monitoring|"* Smart Phones with Apple Health Software will be used to monitor blood pressure once a day, and results will be sent automatically to the patients EHR (Epic)~* The Omron 10 Series Wireless Upper Arm Blood Pressure Device will be given to the patient to monitor blood pressure at home daily~* Patients will be scheduled for a one-hour in-person appointment for the initial study visit where informed consent will be obtained, and for the final study visit"
62746625|NCT02106949|EXPERIMENTAL|SMS|The patients of the test group receive a first SMS 48 hours after their discharge from the hospital then a total of 10 messages distributed over six months: 48 hours, S1, S2, M1, M2, M3, M4, M5, M6 and M13.
62746626|NCT02106949|NO_INTERVENTION|Without SMS|The patients of the group benefit from the usual care.
62746627|NCT02302092|EXPERIMENTAL|Flomoxef|Flomoxef, 2g, injection, intravenously, twice daily (every 12 hours), for up to 12 days.
62746628|NCT02302092|ACTIVE_COMPARATOR|Cefepime|Cefepime, 1g, injection, intravenously, twice daily (every 12 hours) for up to 14 days.
62746629|NCT01551576||photoacoustic imaging (PAI)|Men seen in the urology clinic for elevated PSA and/or abnormal digital rectal exam (DRE) will be offered PAI at the time of transrectal ultrasound guided biopsy, which is standard of care. In addition, patients with a biopsy proven prostate cancer may also be approached for this PAI scan
62746630|NCT01005316||Cohort A: Non-Sensitized|"Cohort A will include participants who are alloantibody Luminex(TM) LABScreen. There is no study mandated care or treatment. All care given is clinical site standard of care. All sites follow a similar standard of care regimen. Non-sensitized recipients receive steroid-free maintenance immunosuppression:~1. Induction Therapy (anti-T cell antibody induction)~2. Tacrolimus (Prograf®)~3. Mycophenolate Mofetil- MMF (CellCept®)."
62746631|NCT01005316||Cohort B: Sensitized|"Cohort B will include participants who are alloantibody positive (Sensitized) as determined by Luminex LabScreen for Class I or Class II with specificities identified by single antigen testing.~There is no study mandated care or treatment. All care given is clinical site standard of care. All sites follow a similar standard of care regimen.~Sensitized recipients receive:~1. Induction Therapy (anti-T cell antibody induction)~2. Intraoperative plasma exchange/pheresis~3. Short-term post-operative plasmapheresis~4. Post-transplant course of intravenous immunoglobulin (IVIG) therapy~5. Maintenance corticosteroids (Prednisone)~6. Tacrolimus (Prograf®)~7. Mycophenolate Mofetil-MMF (CellCept®)."
62746632|NCT06660199|NO_INTERVENTION|Standard ED care|
62746633|NCT06660199|EXPERIMENTAL|Standard ED care with a text-based intervention|"This arm incorporates adolescent-centered (A-C) and parent-centered (P-C) texting components~Parents in the intervention arm will receive up to 3 text messages per day over six weeks after ED discharge: daily A-C text and up to two P-C messages. The P-C component includes an embedded micro-randomized trial (MRT), and parents will be randomized twice each day over the six-week intervention to either receive or not receive a P-C message."
62746634|NCT01540630|EXPERIMENTAL|CNV1014802|
62746635|NCT01540630|PLACEBO_COMPARATOR|Placebo|
62746636|NCT06318078|EXPERIMENTAL|Intervention|570 children will be allocated to the intervention arm and children in this arm will be assessed using the eCHIS digital tool.
62746637|NCT06318078|NO_INTERVENTION|Control|570 children will be allocated to the intervention arm and children in this arm will be assessed using the standard care and paper based tools.
62746638|NCT06523608||Control group|Patients in the control group are examined according to standard protocol (with a biannual follow-up) or more frequently when there is a development of decompensation or HCC.
62374348|NCT01847872|EXPERIMENTAL|IPV IM (Visit 1)|IM IPV vaccine using syringe and needle pair is given at visit 1 followed by MR vaccine at visit 2 and YF vaccine at visit 3
62746639|NCT06523608||Group with stratified surveillance|"Patients in the study group will be stratified for the risk of decompensation/mortality and de novo-HCC-risk, based on the M10S20 (\[Liver stiffness and MELD combined\]) and PLEASE (\[Platelet, Etiology, Age, Sex und Elastography\]) scores.~High-risk patients are allocated for a further CT/MRI examination and an AFP examination to exclude HCC and receive another appointment for a hospital visit within 3 months.~Low-risk patients receive an appointment in one year."
62746640|NCT05798936|EXPERIMENTAL|Polidocanol group|Polidocanol is injected in the thyroid cyst under ultrasound guidance.
62746641|NCT05798936|EXPERIMENTAL|Alcohol group|Alcohol is injected in the thyroid cyst under ultrasound guidance.
62746642|NCT05529264|EXPERIMENTAL|Invasive EEG (electrodes are implanted in a participant's brain)|Patients with intracranial electrodes (electrodes are implanted in a participant's brain) undergoing pre-surgical evaluation for clinical reasons will be asked to participate in various study tasks with the recording of intracranial EEG (recording of brain waves via electrodes implanted in a participant's brain) during these tasks.
62746643|NCT05529264|EXPERIMENTAL|Scalp EEG (electrodes are placed on a participant's scalp)|Patients with non-invasive scalp electrodes who are admitted to the hospital for clinical reasons will be asked to participate in various study tasks with the recording of their EEG (recording of brain waves via electrodes attached to a participant's scalp) during these tasks.
62746644|NCT05529264|ACTIVE_COMPARATOR|Normal Controls|Normal controls will be recruited from family members of patients, from advertisements, or from online tools. There will be no EEG recordings obtained from these participants.
62746645|NCT05529264|ACTIVE_COMPARATOR|Online Controls|Certain control subjects will be recruited through Amazon Mechanical Turk. These participants will be given their task on the online platform using Qualtric survey function. The task design will be identical to normal controls who are recruited in-person, with the exception of identifiers. There will be no EEG recordings obtained from these participants.
62746646|NCT05926349|EXPERIMENTAL|Andexanet Alfa Group|Patients will receive andexanet alfa as IV bolus followed by an infusion.
62746647|NCT05926349|ACTIVE_COMPARATOR|Usual Care Group|Patients will receive treatment based on the Investigator's discretion, according to regional, local/institutional guidelines or practices.
62746648|NCT06654505|NO_INTERVENTION|Villages where Village Health Volunteers/Workers work as individuals|
62746649|NCT06654505|EXPERIMENTAL|Villages where Community Health Workers work in pairs|
62553382|NCT02269098|EXPERIMENTAL|Intervention|"Diabetes survival skills self-management education; plus diabetes medication management using medication algorithm by diabetes educator supervised by endocrinologist, plus health system naviagation.~Metformin, sulfonylureas and basal insulin were included in the algorithm. Survival skills DSME included: BG meter instruction if the patient did not already have a meter or confirmation of self-BG monitoring technique if they did; instructions on how to self-inject insulin if prescribed; and information on BG targets, signs and treatment of hypoglycemia and hyperglycemia, basic nutrition information and when to call the doctor or go to the ED."
62553383|NCT02269098|NO_INTERVENTION|Control|Usual ED care was provided to controls. Hyperglycemia was treated with rapid acting insulin and with IV hydration, if indicated. DM medications were added and/or doses were adjusted at the discretion of the ED physician and prescriptions provided. Insulin, however, was not prescribed as a new medication due to staff concerns regarding post-discharge hypoglycemia and lack of certainty of timely medical follow-up. Follow-up with primary care was recommended.
62374349|NCT01847872|EXPERIMENTAL|IPV IM (Visit 2)|MR vaccine at visit 1 followed by IM IPV vaccine using syringe and needle pair at visit 2, then YF vaccine at visit 3
62374350|NCT01847872|EXPERIMENTAL|IPV IM (Device - Visit 2)|YF vaccine at visit 1 followed by IPV given IM using a Jet injector device at visit 2 and MR vaccine at visit 3
62374351|NCT01847872|EXPERIMENTAL|IPV IM and MR (Visit1)|IM IPV using syringe and needle pair is given alongside MR at visit 1 followed by YF vaccine at visit 2
62553384|NCT02827955|EXPERIMENTAL|bilateral thalamotomy radiosurgery|Gamma Knife radiosurgery bilateral
62553385|NCT05469334|EXPERIMENTAL|Experimental: DeStress for Health Program Participants|Rural residents 18 years and older of Granville and Vance counties (n=40) will be recruited to participate.
62553386|NCT02571699|ACTIVE_COMPARATOR|Subgluteal sciatic block|Subgluteal block with similar volume
62553387|NCT02571699|EXPERIMENTAL|Subgluteal block|Subgluteal block with decreasing volume
62553388|NCT00591773|EXPERIMENTAL|Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD|
62553389|NCT00591773|EXPERIMENTAL|Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD|
62746650|NCT00336284|ACTIVE_COMPARATOR|Home Monitoring|Home Monitoring programmed on.
62746651|NCT00336284|OTHER|In-Office Conventional Follow-up|Home Monitoring programmed off.
62746652|NCT01942161|EXPERIMENTAL|Low (2 mg/day)|Subjects in the 2 mg/day group will be administered 2 mg once daily for 6 weeks (42 days).
62746653|NCT01942161|EXPERIMENTAL|Mid (6 - 12 mg/day)|Subjects in the 6-12 mg/day group will be administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg in accordance with the criteria below.
62746654|NCT01942161|EXPERIMENTAL|High (24 - 30 mg/day)|Subjects in the 24-30 mg/day group will be administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg in accordance with the criteria below.
62746655|NCT00748397|EXPERIMENTAL|A|
62746656|NCT04783779|EXPERIMENTAL|STARgraft-2|Participants will be implanted with 6mm diameter STARgraft-2 grafts as an upper arm Brachial Artery to Axillary Vein shunt for hemodialysis access.
62746657|NCT00964912|ACTIVE_COMPARATOR|BMS-820836 (Part 1, Panel 1)|
62746658|NCT00964912|ACTIVE_COMPARATOR|BMS-820836 (Part 1, Panel 2)|
62746659|NCT00964912|ACTIVE_COMPARATOR|BMS-820836 (Part 1, Panel 3)|
62746660|NCT00964912|ACTIVE_COMPARATOR|BMS-820836 (Part 1, Panel 4)|
62746661|NCT00964912|ACTIVE_COMPARATOR|BMS-820836 (Part 1, Panel 5)|
62746662|NCT00964912|ACTIVE_COMPARATOR|BMS-820836 (Part 1, Panel 6)|
62746663|NCT00964912|ACTIVE_COMPARATOR|BMS-820836 (Part 1, Panel 7)|
62746664|NCT00964912|ACTIVE_COMPARATOR|BMS-820836 (Part 1, Panel 8)|
62746665|NCT00964912|ACTIVE_COMPARATOR|BMS-820836 (Part 1, Panel 9)|
62746666|NCT00964912|ACTIVE_COMPARATOR|BMS-820836 (Part 2, Panel A)|
62746667|NCT00964912|ACTIVE_COMPARATOR|BMS-820836 (Part 2, Panel B)|
62553390|NCT00591773|ACTIVE_COMPARATOR|Chlorthalidone 25 mg QD|
62553391|NCT04505969||SCD patients|
62553392|NCT04505969||Healthcare professionals|
62553393|NCT05472246|EXPERIMENTAL|VR group|VR group will be shown relaxing videos (nature scenes) by wearing a VR headset in addition to the routine anesthesia procedure.
62553394|NCT05472246|NO_INTERVENTION|Control group|Control group will undergo the routine anesthesia procedure.
62553395|NCT03347201|EXPERIMENTAL|Intervention Group|"1. Initial heparin bolus before CPB to be calculated using HMS Plus.~2. Following commencement of CPB further heparin requirements will be determined using the HMS Plus. ACT's will also be checked whilst on CPB and if falls below 480 seconds, additional heparin will also be given.~3. Following cessation of CPB the dose of protamine required to reverse residual heparin will be calculated using the HMS Plus."
62553396|NCT03347201|NO_INTERVENTION|Control Group|Patients in the control arm will undergo routine heparin anticoagulation using a weight based initial dose of 400 units/kg, aiming for an ACT of \>480 seconds. Further heparin doses (5000 to 10000 units) will be given if the ACT falls below 480 seconds whilst on bypass. At the end of CPB heparin will be reversed with protamine using 1:1 ratio based on the initial dose of heparin given pre-bypass. HMS Plus measures will also be conducted in this group for study purposes, but the results will not be made available to the clinicians.
62553397|NCT03304301|EXPERIMENTAL|experimental group|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and expose to sunlight (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months.
62553398|NCT03304301|NO_INTERVENTION|control group|Participants will receive routine care.
62553399|NCT01358461||Patients with vagal syncopes|Patients with vagal syncopes (n=120 : 60 adults \& 60 children)
62746668|NCT03229772|OTHER|Subjects indicated for dynamic nuclear medicine scanning|The trial will consist of a single arm composed of subjects with preexisting indications for dynamic nuclear medicine scanning at the site. All patients will undergo nuclear medicine scintigraphy using the GE Discovery 670 NM/CT device with and without CZT enabled during a single visit.
62374352|NCT01847872|EXPERIMENTAL|IPV IM and YF (Visit 1)|IM IPV using syringe and needle pair is given alongside YF vaccine at visit 1 followed by MR at visit 2
62374353|NCT01847872|EXPERIMENTAL|IPV ID (Visit 2)|MR and YF vaccines are co-administered at visit 1 followed by ID IPV using syringe and needle pair is given at visit 2
62374354|NCT01847872|EXPERIMENTAL|IPV IM and MR and YF (Visit 1)|IM IPV using syringe and needle pair is given alongside YF vaccine and MR vaccine at visit 1
62374355|NCT01847872|EXPERIMENTAL|IPV (ID Device Visit 2)|MR vaccine is given at visit 1 followed by IPV vaccine by ID Jet injector device at visit 2 and YF vaccine at visit 3
62374356|NCT04273568|EXPERIMENTAL|Group1 (PNF group)|Scapular PNF and exercise program was applied to the PNF group.
62374357|NCT04273568|ACTIVE_COMPARATOR|Group 2 (Exercise group)|Exercise program was applied to the exercise group
62374358|NCT05843344|ACTIVE_COMPARATOR|ropivacaine and morphine group|erector spinae plane block with a combination of ropivacaine and morphine
62374359|NCT05843344|ACTIVE_COMPARATOR|ropivacaine and dexmedetomidine group|erector spinae plane block with a combination of ropivacaine and dexmedetomidine
62374360|NCT05843344|ACTIVE_COMPARATOR|ropivacaine group|erector spinae plane block with ropivacaine only
62374361|NCT04362852||Cancer|No intervention
62374362|NCT04362852||Atopic Dermatitis/Eczema|No intervention
62374363|NCT00934713|ACTIVE_COMPARATOR|montelukast|montelukast 4 mg once per day for 8 weeks
62374364|NCT00820963|EXPERIMENTAL|Arm I|Patients undergo standard radiotherapy 5 days a week for 6 weeks.
62374365|NCT00820963|EXPERIMENTAL|Arm II|Patients undergo hypofractionated radiotherapy 5 days a week for 2 weeks.
62374366|NCT00820963|EXPERIMENTAL|Arm III|Patients receive oral temozolomide on days 1-5. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62374367|NCT06261840|EXPERIMENTAL|Oral Multi-Dose Metronidazole|Multi-dose oral MTZ (500 mg twice daily for 7 days) for the treatment of T. vaginalis infection in women and men
62374368|NCT06261840|EXPERIMENTAL|Single-Dose Secnidazole|Single-dose 2 g oral SEC for the treatment of T. vaginalis infection in women and men
62374369|NCT03961139|EXPERIMENTAL|Continuous feeding (CF)|"Infants fed through a naso or orogastric tube in a continuous fashion using syringe pump. Each feed cycle is of 4 hours (3 hrs continuous feeding and 1 hour rest). 6 feed cycles in a day.~Feed volume increment per day is as per departmental protocol and same as comparator arm."
62374370|NCT03961139|ACTIVE_COMPARATOR|Bolus feeding (BF)|"Infants fed through a naso or orogastric tube in a gravity dependent bolus feeding every 2-3 hours. Each feed would take approximately 10 minutes.~Feed volume increment per day is as per departmental protocol and same as experimental arm."
62374371|NCT05961397|EXPERIMENTAL|Normal hepatic function group|Subjects with normal hepatic function
62374372|NCT05961397|EXPERIMENTAL|Moderate hepatic impairment group|Subjects with a Child-Pugh score of 7 to 9 (Category B) at screening
62374373|NCT05678504||Application Group|"* Filling out the pre-initiative volunteering form and sociodemographic data~* Preparation of the individual for the transaction~* Monitoring the vein with a vein imaging device and operating a stopwatch~* Implementation of the initiative~* Stopping the stopwatch at the end of the process~* Application of VAS Pain and VAS satisfaction Scale"
62553400|NCT01358461||Subjects controls without vagal syncopes|Subjects controls without vagal syncopes (n=120:60 adults \& 60 children
62553401|NCT04655547|NO_INTERVENTION|Control|The participants will follow the usual offered course on the outpatient clinic of Hammel Neurocenter. They wil anticipate in data collection three times in line with the intervention group.
62553402|NCT04655547|EXPERIMENTAL|Intervention|The participants will receive dietary guidance from an dietician, with focus on energy intake and food texture. This guidance will include two sessions on site and three phone meetings. The last on site meeting, will be concluding.
62746669|NCT04330391|NO_INTERVENTION|Usual Care|Individuals randomized to the usual care group will receive standard care. This may include a physical therapist and/or nutritionist referral. Brigham and Women's Hospital offers several programs for patients interested in losing weight, including the Nutrition Wellness Service (NWS) and Program for Weight Management (PWM). Insurance coverage for these programs varies by patient insurance.
62746670|NCT04330391|EXPERIMENTAL|Intervention|Intervention subjects will use the Nutrimedy mobile app and be connected at enrollment with a registered dietitian who will contact intervention participants weekly or bi-weekly via video calls and unlimited in-app text messaging for up to three months. The first week will include either one 55-minute video session or two 25-minute sessions. Weeks 2-4 will have weekly 25-minute video calls, and weeks 5-12 will have biweekly 25-minute sessions for a total of 8-9 sessions over 12 weeks. Together, participants and dietitians will come up with goals for the 12 weeks, and dietitians will check on progress toward these goals using in-app tools such as food logs and messaging between video calls. All patients will be encouraged to lose at least 20 pounds with a goal BMI\<40 kg/m2 after 12 weeks. The intervention group will also receive all aspects of the usual care arm including the opportunity to have a physical therapist and/or nutritionist referral.
62746671|NCT00904462|EXPERIMENTAL|Lidocaine 5% patch|Lidocaine 5% patch (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied on each affected knee once every 24 hours
62746672|NCT00904462|PLACEBO_COMPARATOR|Placebo patch|Matching placebo patch, 1⅓ patches applied on each affected knee once every 24 hours
62746673|NCT06662370|EXPERIMENTAL|Esophagus replacement|
62746674|NCT02518087|EXPERIMENTAL|CPB-oXiris®|Non emergent cardiac surgery patients requiring expected CPB time \> 90 minutes: double valve replacement or valve replacement plus coronary arterial bypass graft (CABG).
62746675|NCT02518087|NO_INTERVENTION|CPB-Standard|Non emergent cardiac surgery patients requiring expected CPB time \> 90 minutes: double valve replacement or valve replacement plus coronary arterial bypass graft (CABG).
62746676|NCT06608654|EXPERIMENTAL|fetal distress|
62746677|NCT01034969||Participants with hereditary angioedema (HAE)|All participants with hereditary angioedema (HAE) who are administered Cinryze (C1 inhibitor \[human\]) or Firazyr (Icatibant) for the treatment or prevention of angioedema attacks in routine clinical practice will be included into the study.
62746678|NCT04086693|ACTIVE_COMPARATOR|Standard IV dressing|Polyurethane dressing with clear tape
62553403|NCT05114213|EXPERIMENTAL|Arm A: SBRT|mPDAC patients not progressing after 8 weeks of standard of care systemic therapy (SoC-CT: minimum doublet chemotherapy). The primary tumor is treated with SBRT (6.6Gy x 5) on a MR-LINAC in breath-hold technique. For this purpose, daily adaptive planning is performed aiming to maintain stringent dose constraints for organs at risk (duodenum / stomach / bowel / kidney). Chemotherapy will be continued after SBRT.
62553404|NCT05114213|ACTIVE_COMPARATOR|Arm B: SOC|Continuing SoC-CT (according to clinical routine appr. 2 weeks after the previous cycle) without SBRT.
62553405|NCT04943133|ACTIVE_COMPARATOR|3rd-term group: Pregnant women included in the last 3 months of pregnancy|Comparison of the profile of the curve according to whether there is presence or absence of blood pressure disorders.
62553406|NCT04943133|ACTIVE_COMPARATOR|Before 20 weeks group. Pregnant women (normal blood pressure) included before 20 weeks of pregnancy.|Comparison of the profile of the curve according to the presence or absence of risk factors for pre-eclampsia
62553407|NCT02417987|ACTIVE_COMPARATOR|High Volume injection|"A total volume of 50 ml:~* 10 mls 0.5% bupivacaine hydrochloride and~* 20 mg of Depomedrol (hydrocortisone)~* 40 mls saline (NaCl) HVI is injected one time at baseline and thereafter the group received sham treatment at 2 weeks, 4 weeks and after 6 weeks."
62553408|NCT02417987|ACTIVE_COMPARATOR|Autologous conditioned plasma (ACP)|"Whole blood was drawn from the patients using arthrex system (total of 10 mls whole blood). After that the whole blood is spined for 5 minutes and ACP with platelets and growth factors is separated from the red and white blood cells (4 mls).~The ACP is injected 4 times (at baseline, 2 weeks, 4 weeks and after 6 weeks)"
62553409|NCT02417987|SHAM_COMPARATOR|Placebo|A few drops of saline is injected in the soft tissue away from the tendon.
62553410|NCT03749889|EXPERIMENTAL|100 g carbs|100 grams of carbohydrate allowance for the day
62553411|NCT03749889|ACTIVE_COMPARATOR|MyPlate|Carbohydrate suggestions based on standard MyPlate. 45-65% kcal intake from carbs.
62553412|NCT01228617|EXPERIMENTAL|A1 Short, no buffer|Nicotine / not yet marketed
62553413|NCT01228617|EXPERIMENTAL|A2 Short, low buffer|Nicotine / not yet marketed
62553414|NCT01228617|EXPERIMENTAL|A3 Short, high buffer|Nicotine / not yet marketed
62553415|NCT01228617|EXPERIMENTAL|B1 Long, no buffer|Nicotine / not yet marketed
62374374|NCT05678504||Control Group|"* Filling out the pre-initiative volunteering form and sociodemographic data~* Preparation of the individual for the transaction~* Starting routine blood collection and starting the stopwatch~* Implementation of the initiative~* Stopping the stopwatch at the end of the process~* Application of VAS Pain and VAS satisfaction Scale"
62553416|NCT01228617|EXPERIMENTAL|B2 Long, low buffer|Nicotine / not yet marketed
62553417|NCT01228617|EXPERIMENTAL|B3 Long, high buffer|Nicotine / not yet marketed
62553418|NCT01228617|ACTIVE_COMPARATOR|R = Nicotine Gum|Nicorette® Gum
62553419|NCT02380326||Lung transplant recipients|Lung transplant recipients with diffuse parenchymal abnormalities subjected to advanced endoscopic imaging modalities
62553420|NCT02380326||Diffuse intersitial lung disease|Patients suffering from diffuse intersitial lung disease without a certain diagnosis subjected to advanced endoscopic imaging modalities
62553421|NCT04389372|EXPERIMENTAL|Mindfulness by Smartphone|mindfulness therapy by smart phone
62553422|NCT01625091|ACTIVE_COMPARATOR|naltrexone|The investigators will administer Naltrexone to women with hazardous drinking and assess the study outcomes.
62746679|NCT04086693|EXPERIMENTAL|Standard IV dressing plus Adhezion SecurePortIV|Polyurethane dressing with clear tape plus Adhezion Biomedical SecurePortIV (a tissue adhesive peripheral IV securement device).
62746680|NCT05876299|ACTIVE_COMPARATOR|Low-Fat Pork|This condition will consist of consuming 90.2 g of low-fat (4.90% crude fat) ground pork.
62746681|NCT05876299|EXPERIMENTAL|High-Fat Pork|This condition will consist of consuming 109.6 g of high-fat (18.84% crude fat) ground pork.
62746682|NCT05876299|PLACEBO_COMPARATOR|Carbohydrate Control|This condition will consist of a carbohydrate beverage.
62746683|NCT01980836|ACTIVE_COMPARATOR|Seasonal influenza vaccine in tocilizumab treated RA patients|RA patients treated with tocilizumab
62746684|NCT01980836|ACTIVE_COMPARATOR|Seasonal influenza vaccine to Healthy controls|Healthy controls will be vaccinated against seasonal influenza
62746685|NCT02591758||Stable Angina with coronary angiogram|This study aims to correlate the biometric data collected and derived from the Hexoskin with the standard physiological assessment, in patients referred for coronary angiography for limiting angina. Afterwards, the clinician will decide of the best treatment strategy for the patient: coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) or no revascularization.
62746686|NCT06606522||Derivation cohort|Patients from Peking University First Hospital
62746687|NCT06606522||External Validation Cohort|Patients from other four centers
62746688|NCT03647410||lumbopelvic fixation|sacral fractures fixed with lumbopelvic fixation
62746689|NCT03647410||novel adjustable plate|sacral fractures fixed with novel adjustable plate
62746690|NCT00949754|ACTIVE_COMPARATOR|histamine|histamine in saline administered ID as active control for Apitox
62746691|NCT00949754|EXPERIMENTAL|Apitox pure honeybee venom|ID study drug
62746692|NCT04689490||Dyspnea|Patients with prior hospitalization because of COVID-19, with succesful hospital discharge, who underwent at least a first-time follow-up from the index event, and present persistent dyspnea.
62746693|NCT04689490||Control|Patients with prior hospitalization because of COVID-19, with succesful hospital discharge, who underwent at least a first-time follow-up from the index event, fully recovered, without persistent dyspnea.
62746694|NCT00685269|ACTIVE_COMPARATOR|A|eszopiclone 3 mg QD
62374375|NCT05937490|EXPERIMENTAL|Group 1 (Long)|COH will be performed using a long GnRH agonist protocol(administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle). COH will be commenced when pituitary desensitization was achieved(\~14 days after the initiation of GnRH agonists) as evidenced by the absence of ovarian follicles \&gt;10 mm and endometrial thickness \&lt;4 mm on TV-US examination.
62553423|NCT01625091|PLACEBO_COMPARATOR|placebo pill|The investigators will administer an inert placebo that looks similar to Naltrexone, to women with hazardous drinking and assess the study outcomes.
62553424|NCT03018678||Patients with HOFH|No intervention
62553425|NCT06248125|EXPERIMENTAL|Singing intervention (music with enrichment)|The goal of this intervention is to improve the frequency and quality of active parent-infant interaction via infant-directed singing. Throughout the 20-week intervention period, parents will be offered a weekly, smartphone- based, music intervention program featuring video-recorded music classes specifically designed for parents with infants. The video classes, which are part of Music Together Wiggle \& Sing curriculum, introduce new songs and demonstrate hands-on activities with the songs that parents can easily incorporate into their daily routines. The activities are highly interactive, emphasizing physical contact, gross-motor play, eye contact, cuddling, and rocking. Recordings of these songs will be also provided to supplement parents' learning in the instructional videos with audio-only content (e.g., for parents to use when viewing a video is not convenient). Parents will use the Music Together app and receive a weekly access code for a fresh set of intervention resources.
62567279|NCT05348460|OTHER|Placebo - Ketone treatment|Patients will first receive a placebodrink before performing the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time after receiving the supplemental drink containing a ketone ester.
62567280|NCT02374970|EXPERIMENTAL|Intervention group|Actual Lumbar stability exercises involving co-contraction of the transversus abdominis and Protocolized Physiotherapy (therapeutic exercises and thermotherapy during 12 sessions)
62567281|NCT02374970|ACTIVE_COMPARATOR|Control group|Protocolized Physiotherapy treatment: therapeutic exercises and thermotherapy during 12 sessions.
62746695|NCT00685269|PLACEBO_COMPARATOR|B|placebo tablet
62746696|NCT05905835|EXPERIMENTAL|Cryoablation Balloon|The Synaptic Cryo Balloon will be used to isolate all targeted pulmonary veins.
62746697|NCT03514511|EXPERIMENTAL|Cohort 1 in healthy subjects|LEO 138559 (dose regiment 1) or LEO 138559 placebo
62746698|NCT03514511|EXPERIMENTAL|Cohort 2 in healthy subjects|LEO 138559 (dose regiment 2) or LEO 138559 placebo
62746699|NCT03514511|EXPERIMENTAL|Cohort 3 in healthy subjects|LEO 138559 (dose regiment 3) or LEO 138559 placebo
62746700|NCT03514511|EXPERIMENTAL|Cohort 4 in healthy subjects|LEO 138559 (dose regiment 4) or LEO 138559 placebo
62746701|NCT03514511|EXPERIMENTAL|Cohort 5 in healthy subjects|LEO 138559 (dose regiment 5) or LEO 138559 placebo
62746702|NCT03514511|EXPERIMENTAL|Cohort 6 in healthy subjects|LEO 138559 (dose regiment 6) or LEO 138559 placebo
62746703|NCT03514511|EXPERIMENTAL|Cohort 7 in healthy subjects|LEO 138559 (dose regiment 7) or LEO 138559 placebo
62746704|NCT03514511|EXPERIMENTAL|Cohort 8 in subjects with atopic dermatitis|LEO 138559 (dose regiment 8) or LEO 138559 placebo
62746705|NCT03514511|EXPERIMENTAL|Cohort 9 in subjects with atopic dermatitis|LEO 138559 (dose regiment 9) or LEO 138559 placebo
62746706|NCT05190315|EXPERIMENTAL|Chlorpromazine with standard of care chemoradiation|"Each patient will undergo 3 phases of treatment.~Concurrent Phase: includes concurrent radiation Monday - Friday (60 Gy total radiation dose in 2 Gy fractions), oral temozolomide (75 mg/m2/day) daily for a maximum 49 days starting Day 1 of radiation, and oral chlorpromazine (25 mg for first 3 patients, then escalate to 50 mg if no DLT) daily starting 7 days prior to radiation start.~Interim Phase: Continue oral chlorpromazine daily dose post-radiation and prior to beginning adjuvant temozolomide.~Adjuvant Phase: 28 days after radiation fini (+/- 5 business days), Start oral temozolomide (starting dose 150 mg/m2/day and escalated to 200 mg/m2/day if no treatment related adverse events noted) once daily for 5 consecutive days of a 28 day cycle, and continue oral daily chlorpromazine seven days a week per cycle. The adjuvant phase treatment will continue for up to 6 cycles. Cycle length is 28 days."
62746707|NCT04549779|EXPERIMENTAL|Group I (low volume)|patients will receive 5 ml levobupivacaine 0.25% in ultrasound-guided interscalene brachial plexus block
62746708|NCT04549779|EXPERIMENTAL|Group II (intermediate volume)|patients will receive 10 ml levobupivacaine 0.25% in ultrasound-guided interscalene brachial plexus block
62746709|NCT04549779|EXPERIMENTAL|Group III (high volume)|patients will receive 15 ml levobupivacaine 0.25% ultrasound-guided interscalene brachial plexus block.
62746710|NCT03852992|EXPERIMENTAL|Safety Group|"will participate in one visit, receiving laser assisted delivery of minoxidil and PK data. The safety group treatments will follow dose escalation as follows:~* Safety Participant 1: Post-laser 5mg minoxidil (0.25ml of 20mg/ml sterile solution, applied post-laser procedure)~* Safety Participant 2: Post-laser 10mg minoxidil (0.5ml of 20mg/ml sterile solution, applied post-laser procedure)~* Safety Participant 3: Post-laser 20mg minoxidil (1mL of 20mg/mL sterile solution, applied post-laser procedure)"
62746711|NCT03852992|PLACEBO_COMPARATOR|Placebo|"Laser: Fractional ablative, deep mode, 5% fractional coverage~Post-Laser Saline 0.9%: 2ml of sterile saline solution applied post-laser procedure"
62746712|NCT03852992|EXPERIMENTAL|Treatment A|"Laser: Fractional ablative, deep mode, 5% fractional coverage~Post-Laser Minoxidil 2%: 2ml of 20mg/ml sterile solution, applied post-laser procedure"
61986348|NCT04474951|EXPERIMENTAL|Fatigue|Patients on treatment with Epirubicin and Cyclophosphamide or Carboplatin and Taxane and showing fatigue not associated to anemia or with anemia grade 1 (10 patients) or associated to anemia grade 2 (10 patients) will be enrolled. The control of the event will be evaluated during treatment with 40 drops TID of Stinging Nettle Fluid Extract; the assessment of fatigue will be performed at every chemotherapy cycle, for a maximum period of 6 months.
62374376|NCT05937490|EXPERIMENTAL|Group 2 (Long + high dose DNG)|Before COH, patients will be treated with DNG at high dose (2 mg+2 mg/day) for 28 days, from the first day of previous menstrual cycle. COH will be performed using a long GnRH agonist protocol (administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle). COH will be commenced when pituitary desensitization was achieved (\~14 days after the initiation of GnRH agonists), as defined above.
62374377|NCT05937490|EXPERIMENTAL|Group 3 (ultra-long):|COH will be performed using a ultra-long GnRH agonist protocol (administration of the first depot leuprorelin 3.75 mg on day 21 of menstrual cycle, repeated after 28 days for other two times). COH will be commenced when pituitary desensitization was achieved (\~14 days after the initiation of GnRH agonists), as described above.
62374378|NCT05937490|OTHER|Control group (without adenomyosis)|COH will be performed by using a long GnRH agonist protocol as previous described or using a flexible GnRH antagonist protocol. During TV-US monitoring, when at least one follicle reached 14 mm in diameter, to achieve LH (luteinizing hormone) suppression avoiding spontaneous ovulation, GnRH antagonist 0.25 mg/day will be added subcutaneously until the day of HCG administration.
62374379|NCT03935594|EXPERIMENTAL|PRP injection right half|"The scar to be treated will first be wiped with an alcohol swab, then measured and marked out with a marking pen such that the entirety of the scar will fit into a symmetric ellipse that is drawn, and the ellipse is filled entirely with the scar tissue. A ruler will be used to measure the scar in its greatest horizontal span, and the midway point will be marked with a vertical line. A coin flip will determine if the PRP injection (the experimental half) will be on the right half of the scar (as opposed to the left half). The half of the scar that will not receive PRP will be the control half.~After finishing the VSS and POSAS, the area inside the control half of the ellipse will then be subdivided with a marking pen into 1cm x 1cm square boxes, with the plan of injecting 1mL normal saline into each 1 square cm box at 0 months, 1 month, 4 months, and 6 months.~Punch biopsies from each scar will be will be obtained at both six months and one year from enrollment."
62374380|NCT03935594|EXPERIMENTAL|PRP injection left half|"The scar to be treated will first be wiped with an alcohol swab, then measured and marked out with a marking pen such that the entirety of the scar will fit into a symmetric ellipse that is drawn, and the ellipse is filled entirely with the scar tissue. A ruler will be used to measure the scar in its greatest horizontal span, and the midway point will be marked with a vertical line. A coin flip will determine if the PRP injection (the experimental half) will be on the right half of the scar (as opposed to the left half). The half of the scar that will not receive PRP will be the control half.~After finishing the VSS and POSAS, the area inside the experimental half of the ellipse will then be subdivided with a marking pen into 1cm x 1cm square boxes, with the plan of injecting 1mL PRP into each 1 square cm box at 0 months, 1 month, 4 months, and 6 months.~Punch biopsies from each scar will be will be obtained at both six months and one year from enrollment."
62374381|NCT05833061||Stroke Patients|Stroke patients giving written informed consent.
62374382|NCT04618549|ACTIVE_COMPARATOR|Direct anterior approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by direct anterior approach, using a regular OR table, without hip hyperextension.
62374383|NCT04618549|ACTIVE_COMPARATOR|Mini Posterior Approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by a mini posterior approach.
62374384|NCT04618549|ACTIVE_COMPARATOR|Lateral approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by a lateral (Hardinge) approach.
62374385|NCT03592173|EXPERIMENTAL|SAS20|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 20ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
62746713|NCT03852992|EXPERIMENTAL|Treatment B|"Laser: Fractional ablative, deep mode, 5% fractional coverage~Post-Laser Minoxidil 2%: 2ml of 20mg/ml sterile solution, applied post-laser procedure~At-Home Minoxidil 5%: 2ml of 50mg/ml foam q24 h for duration of study"
62746714|NCT05698017|ACTIVE_COMPARATOR|Low dose hOMSC300|Single IT administration of low dose hOMSC300
62746715|NCT05698017|ACTIVE_COMPARATOR|High dose hOMSC300|Single IT administration of high dose hOMSC300
62746716|NCT05698017|OTHER|Sham Procedure|Lumbar puncture only
62746717|NCT02777606|EXPERIMENTAL|Si-Ni-Tang (a Chinese Herbal Formula)|Treatment for severe sepsis adheres to the International guidelines for management of sepsis and septic shock 2012 and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015. Besides, 150ml of Si-Ni-Tang will be given by p.o. or a nasogastric tube once per day for 3 days in the treatment group.
62746718|NCT02777606|NO_INTERVENTION|Control|Treatment for severe sepsis adheres to the International guidelines for management of sepsis and septic shock 2012 and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015.
62553426|NCT06248125|ACTIVE_COMPARATOR|Music listening intervention (music with limited enrichment)|This intervention follows the same structure as the singing intervention but focuses on the use of passive music listening rather than live singing. On a weekly basis, parents will be provided with a carefully curated music playlist, along with tips on how to effectively incorporate recorded music into their daily lives. These weekly playlists will feature 10 music recordings suitable for everyday scenarios commonly experienced together by parents and infants (e.g., calming lullabies for naptime, exciting play songs for free play). The playlists are intended to serve as background music, thus creating a very different musical experience compared to that of the singing intervention. Each week, parents will receive a link to access a new playlist, along with an information sheet about the music and tips on how to use them. Parents will use Spotify to access the playlists on their smartphones and computers.
62567282|NCT03526861|EXPERIMENTAL|Tralokinumab(Dose1) initial-> Tralokinumab(Dose1) maintenanceA|"Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 1) maintenance SC injection regimen A."
62567283|NCT03526861|EXPERIMENTAL|Tralokinumab(Dose1) initial-> Tralokinumab(Dose1) maintenanceB|"Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 1) maintenance SC injection regimen B."
62746719|NCT06349460|EXPERIMENTAL|Increase healthy eating behaviors - Assigned|Individuals will be assigned to increase healthy eating behaviors that week.
62746720|NCT06349460|EXPERIMENTAL|Increase healthy eating behaviors - Recommended|Individuals will be recommend to increase healthy eating behaviors that week.
62746721|NCT06349460|EXPERIMENTAL|Increase physical activity - Assigned|Individuals will be assigned to increase physical activity that week.
62746722|NCT06349460|EXPERIMENTAL|Increase physical activity - Recommended|Individuals will be recommended to increase physical activity that week.
62746723|NCT06349460|EXPERIMENTAL|Limit unhealthy dieting behaviors - Assigned|Individuals will be assigned to limit unhealthy dieting behaviors that week.
62746724|NCT06349460|EXPERIMENTAL|Limit unhealthy dieting behaviors - Recommended|Individuals will be recommended to limit unhealthy dieting behaviors that week.
62746725|NCT06349460|EXPERIMENTAL|Improve self-image - Assigned|Individuals will be assigned to improve self-image that week.
62746726|NCT06349460|EXPERIMENTAL|Improve self-image - Recommended|Individuals will be recommended to improve self-image that week.
62746727|NCT06349460|EXPERIMENTAL|Improve mood - Assigned|Individuals will be assigned to improve mood that week.
62374386|NCT03592173|ACTIVE_COMPARATOR|SAS0|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 0ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
62746728|NCT06349460|EXPERIMENTAL|Improve mood - Recommended|Individuals will be recommended to improve mood that week.
62746729|NCT04177953|ACTIVE_COMPARATOR|Carboplatin or Cisplatin and Pemetrexed|"Four cycles (q4w) platinum-based adjuvant chemotherapy i.v.:~* carboplatin AUC5 or cisplatin 75 mg/m2~* pemetrexed 500 mg/m2"
62746730|NCT04177953|EXPERIMENTAL|Carboplatin or Cisplatin and Pemetrexed + Nivolumab|"Four cycles (q4w) of a combination of platinum-based adjuvant chemotherapy and immunotherapy i.v.:~* carboplatin AUC5 or cisplatin 75 mg/m2~* pemetrexed 500 mg/m2~* nivolumab 480 mg flat-dose.~Followed by up to 12 cycles (q4w) maintenance immunotherapy:~- nivolumab 480 mg flat-dose i.v."
62374387|NCT03592173|ACTIVE_COMPARATOR|SAS50|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 50ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
62374388|NCT00713557||1|patients with acute ST-elevation myocardial infarction and receiving primary percutaneous coronary intervention Subgroup: Patient Transferring vs. Physician Transferring strategy
62374389|NCT00713557||2|patients with acute ST-elevation myocardial infarction treated by thrombolysis or facilitated PCI Subgroup: upstream use of Tirofiban + primary PCI vs. downstream use of tirofiban + primary PCI
62746731|NCT05967741|EXPERIMENTAL|Erythritol-sweetened beverage|1-gram erythritol/kg body weight/day, divided into three beverage servings and fruit-flavored with Kool-Aid® unsweetened drink mix.
62746732|NCT05967741|PLACEBO_COMPARATOR|Aspartame-sweetened beverage|Control beverages will be made from a noncaloric aspartame-sweetened, fruit-flavored drink mix at the concentration needed to match the sweetness (\~3 mg aspartame/kg/day) and flavoring of the erythritol beverages on a per volume basis.
62746733|NCT05980104|EXPERIMENTAL|1-Session pain relief skills class (online Empowered Relief)|Empowered Relief is a 2-hour one session pain relief skills intervention that is delivered to a group of patients by a certified instructor using a standardized treatment manual and electronic slide deck. Content includes completion of a pain survey, pain neuroscience education, information on pain and stress responses, experiential exercises, information on three core pain management skills, completion of a personalized plan for empowered relief, and receipt of a binaural app for daily use.
62746734|NCT05844098|EXPERIMENTAL|With K-wire|arthroscopic assisted CC-stabilization with K-wire
62746735|NCT05844098|NO_INTERVENTION|No K-wire|arthroscopic assisted CC-stabilization
62374390|NCT00713557||3|patients with non-ST-elevation ACS treated by immediate PCI
62374391|NCT00713557||4|patients with non ST-elevation ACS treated by elective PCI
62374392|NCT00713557||5|STEMI patient with multivessel disease, complete revascularization is planned to achieve during the index hospitalization.i.e.P-PCI for culprit lesion,combined with staged PCI for remaining diseased vessel.
62746736|NCT06659328|EXPERIMENTAL|Walking Intervention with Varying Speeds and Social Interaction in Children with Autism Spectrum Dis|"This arm of the study focuses on a single group of participants consisting of 30 children aged 4 to 6 years diagnosed with ASD. The objective is to evaluate how varying walking speeds and social interactions influence gait parameters.~Participants will engage in a structured walking intervention under three conditions: normal speed (120 bpm), slow speed (100 bpm), and fast speed (140 bpm). Each child will walk with two different types of adult companions: a familiar adult (e.g., caregiver) and an unfamiliar adult. This design allows for a comprehensive assessment of gait characteristics in response to different social contexts and pacing.~Each child will complete a 10-meter walking task, with gait parameters such as stride length, step time, cadence, velocity, and joint amplitudes being recorded using video analysis software (Kinovea©).The results will contribute to understanding how children with ASD adapt their locomotion to social cues and varying speeds"
62746737|NCT00803400|ACTIVE_COMPARATOR|Alprazolam|Patients assigned to the pharmacological plan
62746738|NCT00803400|ACTIVE_COMPARATOR|Alprazolam + Aerobic exercise|Patients assigned to mix plan
62374393|NCT00713557||6|STEMI patient with multivessel disease, complete revascularization is planned to achieve at 6 weeks after STEMI onset.i.e.P-PCI for culprit lesion during index hospitalization,combined with staged PCI for remaining diseased vessel at 6-week's follow-up(secondary hospitalization).
62374394|NCT01782612|ACTIVE_COMPARATOR|General Ansethesia|Subjects undergoing Total uni-Hip Replacement will receive standard General Anesthesia with Laryngeal Mask Airway and Multimodal analgesic techniques
62374395|NCT01782612|EXPERIMENTAL|Peripheral Nerve Blocks|Subjects undergoing Total uni-Hip Replacement will receive Lumbar plexus block and Sciatic nerve block with 0.4% Ropivacaine and Multimodal analgesic techniques
62374396|NCT03177954|EXPERIMENTAL|Patient Oriented Discharge Summary|A one hour patient oriented discharge summary meeting will take place with participants.
62374397|NCT02183610|EXPERIMENTAL|[14C] BI 1356 as oral (p.o.) solution|
62374398|NCT02183610|EXPERIMENTAL|[14C] BI 1356 solution for i.v. infusion|
62374399|NCT02411006|NO_INTERVENTION|Usual care control|No intervention, just usual care from the insurance company
62374400|NCT02411006|EXPERIMENTAL|Reminder control|Send a reminder to subjects every month
62374401|NCT02411006|EXPERIMENTAL|Anonymous prediction|Ask subjects to anonymously predict their upcoming medication adherence
62374402|NCT02411006|EXPERIMENTAL|Anonymous commitment|Ask subjects to anonymously commit to their upcoming medication adherence
62374403|NCT02411006|EXPERIMENTAL|Identified prediction|Ask subjects to predict their upcoming medication adherence and report it
62567284|NCT03526861|EXPERIMENTAL|Tralokinumab(Dose2) initial-> Tralokinumab(Dose2) maintenanceA|"Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 2) maintenance SC injection regimen A."
62567285|NCT03526861|EXPERIMENTAL|Tralokinumab(Dose2) initial-> Tralokinumab(Dose2) maintenanceB|"Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 2) maintenance SC injection regimen B."
62746739|NCT02327390|EXPERIMENTAL|X-ACT lymph node cell dose and schedule|"All patients will begin at dose level 1 and will be moved to higher dosing levels as long as the patient does not experience two or more dose limiting toxicities and maintains an acceptable performance status. A minimum of three patients will be enrolled per dose level and no patients will be enrolled on higher dose levels if dose limiting toxicities are encountered.~Dose level 1: 0.5 x 10\^10 X-ACT cells. 2 infusions 4 weeks apart~Dose level 2: 1.0 x 10\^10 X-ACT cells. 1 infusion~Dose level 3: 0.5 x 10\^10 X-ACT cells. 4 infusions 4 weeks apart~Dose level 4: 1.0 x 10\^10 X-ACT cells. 2 infusions 4 weeks apart~Dose level -1: 0.5 x 10\^10 X-ACT cells. 1 infusion (if necessary)"
62746740|NCT06056895|EXPERIMENTAL|Treatment (retifanlimab, tuparstobart, and verzistobart)|"INDUCTION PHASE: Patients receive retifanlimab IV over 30 minutes every 4 weeks and tuparstobart and verzistobart IV over 30 minutes every 2 weeks. Treatment continues for up to day 169 in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography CT/MRI during screening and on study and blood sample collection on study and may undergo during screening. Patients may also undergo a tumor biopsy during screening and on study.~MAINTENANCE PHASE: Patients receive retifanlimab, tuparstobart and verzistobart IV over 30 minutes every 6 weeks. Treatment continues for up to day 715 in the absence of disease progression or unacceptable toxicity. Patients undergo CT/MRI on study and blood sample collection on study and may undergo during follow-up. Patients may also undergo tumor biopsy on study and during follow-up."
61986349|NCT04474951|EXPERIMENTAL|Nausea|20 patients on treatment with Epirubicin and Cyclophosphamide or Carboplatin and Taxane and showing nausea of any grade (without vomiting) will be enrolled. The control of the event will be evaluated during treatment with 40 drops TID of Peppermint Fluid Extract, associated to antiemetic therapy prescribed as per clinical practice; the assessment of nausea will be performed at every chemotherapy cycle, for a maximum period of 6 months.
62374404|NCT02411006|EXPERIMENTAL|Identified commitment|Ask subjects to commit to their upcoming medication adherence and report it
62374405|NCT03603574|EXPERIMENTAL|EWA through the needle|EWA through the needle group, 5 mL of normal saline are injected through the epidural needle after the occurrence of LOR. The needle is subsequently connected to the pressure transducer (leveled with the heart) via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations.
62374406|NCT03603574|EXPERIMENTAL|EWA through the catheter|EWA through the catheter group, the epidural catheter is advanced 5 cm beyond the needle tip after the occurrence of LOR. Subsequently, the operator injects 5 mL of normal saline through the catheter and the latter is connected to the pressure transducer via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations.
62374407|NCT02158962|EXPERIMENTAL|Behavioral - Education|"3 Educational Sessions~Session 1 - Reducing Risk for Intimate Partner Violence (IPV); Session 2 - Reducing risk for Sexually Transmitted Infections including HIV (STI/HIV) Session 3 - A group session which reinforces skills for reducing IPV and STI/ HIV risk reduction."
62746741|NCT00914446|OTHER|morbid obese subject|
62746742|NCT00914446|OTHER|overweight and NASH subjects|
62746743|NCT00914446|OTHER|control subjects|
61986350|NCT05188209|EXPERIMENTAL|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight
62746744|NCT04019106|EXPERIMENTAL|Dosing Level 1|0.0625 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
62746745|NCT04019106|EXPERIMENTAL|Dosing Level 2|0.125 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
62746746|NCT04019106|EXPERIMENTAL|Dosing Level 3|0.25 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
62746747|NCT06606197||Men who have sex with men|
62746748|NCT05482529||colorectal cancer with metastasis|colorectal cancer patients with at least one distant metastasis(liver, lung)
62746749|NCT04851119|EXPERIMENTAL|Treatment (tegavivint)|Tegavivint will be administered IV over 4 hours on days 1, 8, and 15 of each cycle. Administer D5W flush after completion of each tegavivint infusion. Treatment repeats every 28 days for up to 26 cycles or 24 months in the absence of disease progression or unacceptable toxicity. Drug doses should be adjusted based on the weight (height and BSA will also be captured) measured within 7 days prior to the beginning of each cycle. The starting dose will be 5 mg/kg with dose levels for subsequent cohorts increasing to 6.5 mg/kg and 8 mg/kg if excessive toxicity does not occur. If the MTD has been exceeded at the first dose level, then the subsequent cohort of patients will be treated at a dose of 4 mg/kg. Patients undergo an x-ray at baseline, after cycle 1, and then every 3 cycles while on treatment and DEXA scan at baseline and every 6 cycles while on treatment, then at 12 months, 24 months, and annually up to 60 months following end of therapy.
62746750|NCT05425446|EXPERIMENTAL|SAD Cohort 1|All randomized patients will receive one dose of either DONQ52 Dose A or placebo
62746751|NCT05425446|EXPERIMENTAL|SAD Cohort 2|All randomized patients will receive one dose of either DONQ52 Dose B or placebo
62746752|NCT05425446|EXPERIMENTAL|SAD Cohort 3|All randomized patients will receive one dose of either DONQ52 Dose C or placebo
62746753|NCT05425446|EXPERIMENTAL|SAD Cohort 4|All randomized patients will receive one dose of either DONQ52 Dose D or placebo
62746754|NCT05425446|EXPERIMENTAL|MAD Cohort 1|All randomized patients will receive multiple dose of either DONQ52 Dose E or placebo
62746755|NCT05425446|EXPERIMENTAL|MAD Cohort 2|All randomized patients will receive multiple dose of either DONQ52 Dose F or placebo
62746756|NCT05425446|EXPERIMENTAL|MAD Cohort 3|All randomized patients will receive multiple dose of either DONQ52 Dose G or placebo
62746757|NCT06540105||Opioid Use Disorder|Subjects with a history of opioid use disorder
62746758|NCT06232018|EXPERIMENTAL|Skin adhesive|2-octylcyanoacrylate glue (DERMABOND ADVANCED®, Ethicon, johnson \& johnson, Somerville, NJ)
62746759|NCT06232018|ACTIVE_COMPARATOR|skin adhesive Plus polyester mesh|2-octylcyanoacrylate glue + polyester mesh ( DERMABOND PRINEO®, Ethicon, johnson \& johnson, Somerville, NJ)
62746760|NCT05456373|EXPERIMENTAL|SoC+ClearEdge device - Standard of Care + study device|Standard assessment of the surgical margins of the excised breast specimen during lumpectomy surgery plus the use of the study device to assess for breast cancer cells at the the margins
62746761|NCT05456373|NO_INTERVENTION|SoC - Standard of Care|Standard assessment of the surgical margins of the excised breast specimen during lumpectomy surgery
62746762|NCT02731677|EXPERIMENTAL|Experimental|Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
62746763|NCT02731677|NO_INTERVENTION|Control|The control group no suffered intervention.
62746764|NCT04547335||Voriconazole|All eligible patients will be followed up for voriconazole related adverse drug events and efficacy
62746765|NCT01519791|EXPERIMENTAL|Certolizumab Pegol + Methotrexate|
62746766|NCT01519791|PLACEBO_COMPARATOR|Placebo + Methotrexate|
62746767|NCT04850196|EXPERIMENTAL|TEAS group|TEAS treatment was performed for 30 mins before anesthesia on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints And TEAS treatment for 30 mins was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints at the end of surgery as well as on the each night before sleeping after surgery until discharged from the hospital
62746768|NCT04850196|SHAM_COMPARATOR|Control group|Patients in the Control group received electrical stimulation at a non-acupoint which was located 2 cm interior to the bilateral Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints similar to patients in group TEAS.
62746769|NCT04845009|EXPERIMENTAL|progressive muscle relaxation|progressive muscle relaxation tape guided
62746770|NCT04845009|PLACEBO_COMPARATOR|usual care|usual care
62746771|NCT02191150||Cohort 1|Patients with CKD
62746772|NCT04281225|PLACEBO_COMPARATOR|Placebo only condition|Participants in this condition will be told at the time of the initial assessments (T1) that the device they will be testing will improve their hearing. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will be asked if they perceive their hearing to be changed by the device in addition to qualitative descriptions of the audio. This group will allow researchers to investigate the main effect of the placebo hearing aid - without calling participant's attention to variability in their symptoms.
62746773|NCT04281225|EXPERIMENTAL|Placebo and ATV condition|Participants in this condition at the time of the initial assessments (T1) will be told that the device they will be testing will improve their hearing. They will then be told that in-order to receive the maximum benefit from the hearing device, they should focus on instances in which they can hear better and worse. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will asked 1) if they perceive their hearing to be changed by the device; 2) to note any changes in what they heard in the audio focusing on the story in the ballad; and 3) whether their hearing is possibly impacted by activities and behavior and what they were doing.This condition will enable researchers to test the effects of the interaction between attention to variability and the placebo effect.
62746774|NCT04281225|EXPERIMENTAL|ATV only condition|Participants in this condition will be told that the device they will be testing is merely a prototype that they are testing for design purposes. However, these participants will also be told that their input while wearing the device will help the team in developing the final device and allow the team to focus on how to best improve hearing. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will be asked 1) to note any changes in what they heard in the audio focusing on the story in the ballad and 2) whether their hearing might possibly be impacted by activities and behavior. They will also be asked 3) about their general health and wellness, as compared to the last time they were contacted by email. This condition will enable researchers to test the main effect of attention to variability, without an explicit placebo effect.
62746775|NCT04281225|NO_INTERVENTION|Control condition- no ATV or Placebo effect.|Participants in this condition will be told that the device they will be testing is merely a prototype that they are testing for ergonomic purposes. They will listen to the audio and record volume levels at the start and at the end of the audio and provide feedback on the design. They will be told that each day they will listen to a brief audio (ballad of under 3 minutes) and will be asked a few similar questions twice daily for 6 days. After the 2nd audio of the day, they will be asked for feedback on the hearing device design. They will also be asked about their general health and wellness, as compared to the last time they were contacted.This group will allow researchers to test for the effects of having any device at all.
62746776|NCT00712036|ACTIVE_COMPARATOR|Interim|Methadone maintenance for up to 4 months with emergency counseling only for individuals on program waiting lists.
62746777|NCT00712036|ACTIVE_COMPARATOR|Comprehensive|Methadone Treatment provided with counseling as usual.
62746778|NCT00712036|ACTIVE_COMPARATOR|Restored|Methadone Treatment with counseling provided by a clinician with a lower caseload than counseling as usual.
62746779|NCT05555953||Phase-1|The draft CORONATE questionnaire will be administered to participants to create the final version of the questionnaire.
62746780|NCT05555953||Phase-2|The questionnaire created in Phase 1 will be administered to a new group of participants for validation. All partners who are in a relationship with the participants since at least 3 years will be asked to participate in the study for the comparison between participants' and partners' perspectives on the impact of long-term psoriasis on participants' life.
62746781|NCT02039219|PLACEBO_COMPARATOR|Placebo|Placebo
62746782|NCT02039219|EXPERIMENTAL|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 6 weeks.
62746783|NCT06543849|SHAM_COMPARATOR|24-hour treatment|
62746784|NCT06543849|ACTIVE_COMPARATOR|72-hour treatment|
62746785|NCT00654836|EXPERIMENTAL|Carboplatin, ABI-007 and Bevacizumab|Participants will receive combination carboplatin, nanoparticle albumin-bound paclitaxel (ABI-007-Abraxane), and bevacizumab (Avastin)
62746786|NCT00223808|EXPERIMENTAL|Robot-Low|low-dose mechanically-assisted upper limb therapy
62746787|NCT00223808|EXPERIMENTAL|Robot-High|high-dose mechanically-assisted upper limb therapy
62746788|NCT00223808|ACTIVE_COMPARATOR|Control|additional traditional therapy
62746789|NCT05635396|EXPERIMENTAL|Wearable, non invasive sensor for vital signs recording.|All included patients will be provided with a wearable, non invasive sensor for vital signs recording.
62746790|NCT02776462||Potential Traumatic Brain Injury|This group will consist of people admitted to the ER, Trauma Bay, or Neurosurgery for potential traumatic brain injury.
62746791|NCT06606249|EXPERIMENTAL|Self-Help Plus (SH+)|"The intervention is available in its individual online self-help version called Doing What Matters in Time of Stress. It composed of an illustrate guide, divided into sessions, and pre-recorded audio.~Participants will be required to access an online platform for attending the sessions. A total of 5 sessions of approximately an hour each are planned. Participants will be guided by facilitators with minimal qualifications and skills in providing psychosocial support. They will receive regular reminders and instructions from helpers at the beginning of the program and before any sessions via phone call, teleconferencing meeting, or message. Facilitators will receive brief training from specialized mental health professionals trained by WHO."
62746792|NCT06606249|ACTIVE_COMPARATOR|Psychological First Aid (PFA)|Psychological First Aid will also be delivered by facilitators through a phone call or teleconferencing meeting, for an approximate ranging from 20 to 45 minutes. Participants will also receive an information sheet with details about mental health services available for students experiencing distress at each of the centers.
62746793|NCT01748188|ACTIVE_COMPARATOR|Ultrasound + Exercises + Cryotherapy|Ultrasound of 1 Megahertz (MHz), intensity 2 W/cm2, 5 minutes, for 20 sessions.
62746794|NCT01748188|EXPERIMENTAL|Phonophoresis + Exercises + Cryotherapy|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
62746795|NCT01748188|EXPERIMENTAL|Iontophoresis + Exercices + Cryotherapy|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 milliamperes (mA), 20 minutes, for 20 sessions.
62746796|NCT04245670|EXPERIMENTAL|Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5|Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.
62746797|NCT00283803|EXPERIMENTAL|IAS and Exisulind|Patients will receive intermittent dosing of hormone therapy with commercially supplied luteinizing hormone-releasing hormone (LHRH) agonist and anti-androgen to be chosen by physician per standard of care. Exisulind will be started 3 months prior to the end of the second cycle of hormone therapy. Patients will continue treatment with Exisulind beyond the completion of the second cycle of hormone therapy until they meet criteria for discontinuation.
61986351|NCT02636868|EXPERIMENTAL|Aerosolized lucinactant (low dose)|Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.
61986352|NCT02636868|EXPERIMENTAL|Aerosolized lucinactant (high dose)|Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.
61986353|NCT02636868|ACTIVE_COMPARATOR|nasal CPAP|nCPAP alone
62567286|NCT03526861|EXPERIMENTAL|Placebo initial-> Placebo maintenance|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 52 (maintenance period):~Placebo continuation SC injection regimen A."
62746798|NCT03481166|EXPERIMENTAL|Education on breastfeeding pain|Both the experimental and control groups will receive usual prenatal education offered through our regional public health program. In addition to usual prenatal education, the experimental group will also receive a one-hour, nurse led (a Registered Nurse specially trained in perinatal care), small group-based education session with specific focus on breastfeeding pain. The goals of this educational intervention are to provide pregnant women with anticipatory guidance around pain which is commonly experienced while breastfeeding in the first two weeks postpartum. Education will include the prevalence, etiology and management of various types of breastfeeding-related pain experienced postpartum.
62746799|NCT03481166|NO_INTERVENTION|Usual prenatal education|Women allocated to the usual prenatal education group will receive prenatal classes through their local public health unit. Women enrolled in classes will receive approximately 12 hours of combined in-class and online prenatal content. Topics include: discomforts of pregnancy, labor and birth, medical interventions, adjustment to parenting, breastfeeding, and caring for the newborn. Breastfeeding-related material includes basic mechanisms of milk production, benefits of breastfeeding, benefits of skin-to-skin, correct breastfeeding latch, breastfeeding positions, timing of feeds, responding to infant cues, and caring for nipples. Women in the usual prenatal education group will not receive education on the prevalence and etiology of nipple pain, nor specific pain management strategies.
62746800|NCT01089413||Cohort|
62746801|NCT02202213|EXPERIMENTAL|Lu AF11167 hard capsules; 0.25, 0.5 and 1 mg|"Part A: Lu AF11167 monotherapy Part B: Lu AF11167 adjunctive therapy to risperidone~Three times daily oral dosing for 14 days."
62746802|NCT02202213|PLACEBO_COMPARATOR|Matching placebo|Daily oral dosing matching the experimental arm.
62746803|NCT03082183|EXPERIMENTAL|All participants|BI 425809 given alone in first period, then in combination with Rifampicin in second period
62374408|NCT02158962|ACTIVE_COMPARATOR|Behavioral - Education|"3 Educational Sessions~Session 1 - Breast Health Education and Developing A Breast Cancer Risk Reduction Plan Session 2 - Reducing risk for overweight and obesity and Developing a Healthy Eating and Activity Plan Session 3 - A group session which integrates and reinforces skills from Sessions 1 and 2."
62553427|NCT06248125|ACTIVE_COMPARATOR|Book reading intervention (enrichment with limited music)|This intervention follows the same structure as the singing intervention, but without the musical elements, while emphasizing enriched parent-infant interaction in non-musical (or less-musical) contexts. Throughout the intervention period, parents will be provided with developmentally appropriate books, carefully selected to encourage increased parent interaction. Along with each book, a demonstration video analogous to the Wiggle and Sing videos used in the singing intervention will be offered. These videos demonstrate techniques to create a rich listening experience for young infants, such as using infant-directed speech and highlighting aspects of illustrations to engage the infant. In line with the singing intervention, the activities will be highly interactive, emphasizing the use of infant-directed speech and physical interactions with their infants.
62553428|NCT06248125|NO_INTERVENTION|No intervention|No intervention will be provided.
62553429|NCT01433055|ACTIVE_COMPARATOR|Minocycline|
62553430|NCT01433055|PLACEBO_COMPARATOR|Sugar Pill|
62553431|NCT05543083|EXPERIMENTAL|Cognitive-Behavioral Therapy followed by Exercise Training|6-week cognitive-behavioral therapy intervention of 6 weekly 1-hour group sessions followed by a 6-week exercise training intervention of 6 weekly 1-hour group sessions
62553432|NCT05543083|ACTIVE_COMPARATOR|Exercise Training followed by Cognitive-Behavioral Therapy|6-week exercise training intervention of 6 weekly 1-hour group sessions followed by a 6-week cognitive-behavioral therapy intervention of 6 weekly 1-hour group sessions
62553433|NCT05543083|ACTIVE_COMPARATOR|Exercise Training Only|6-week exercise training intervention of 6 weekly 1-hour group sessions followed by an additional 6-week exercise training intervention of 6 weekly 1-hour group sessions
62553434|NCT05543083|ACTIVE_COMPARATOR|Cognitive-Behavioral Therapy Only|6-week cognitive-behavioral therapy intervention of 6 weekly 1-hour group sessions followed by an additional 6-week cognitive-behavioral therapy intervention of 6 weekly 1-hour group sessions
62553435|NCT00897182||Group 1|This is a CALGB Leukemia Tissue Bank project makes use of tissue from patients who have previously provided their consent. Diagnostic samples from patients enrolled on CALGB AML treatment studies (eg, CALGB 9621, 9710, and 19808) and who have been registered on the companion Leukemia Tissue Bank Protocol CALGB 9665 were used.
62746804|NCT02585024|EXPERIMENTAL|1.5 mg cytisine|1.5 mg cytisine given as a single dose
62746805|NCT02585024|EXPERIMENTAL|3 mg cytisine|3 mg cytisine given as a single dose
62746806|NCT02585024|EXPERIMENTAL|4.5 mg cytisine|4.5 mg cytisine given as a single dose
62746807|NCT02585024|EXPERIMENTAL|1.5 mg cytisine six times a day|1.5 mg (1 capsule) is given six times a day (0, 2, 4, 6, 8 and 10 hours) for 5 days
62746808|NCT02585024|EXPERIMENTAL|3 mg cytisine three times a day|3 mg (2 capsules) are given three times a day (0, 4 and 8 hours) for 5 days
62746809|NCT02585024|EXPERIMENTAL|4.5 mg cytisine two times a day|4.5 mg (3 capsules) are given two times a day (0 and 6 hours) for 5 days
62746810|NCT01686425|ACTIVE_COMPARATOR|Percutaneous Transhepatic cholangiography|
62746811|NCT01686425|ACTIVE_COMPARATOR|Endoscopic Ultrasound guided biliary drainage|
62746812|NCT01801436|EXPERIMENTAL|Bortezomib|Bortezomib 1.3 milligram (mg) per meter square (m\^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
62746813|NCT05638269||disease group|no intervention
62746814|NCT05638269||control group|no intervention
61986354|NCT02034461|EXPERIMENTAL|Acute surgical implantation|The investigators will conduct three acute surgeries where a Utah slanted Electrode Array (USEA) will be implanted in volunteers who are about to undergo limb amputations. These acute implantations will provide the PI with human surgical experience in implanting USEAs and evaluating the containment system the investigators will be using to immobilize the implanted USEA in the nerve.
62374409|NCT04853056|EXPERIMENTAL|Virtual Reality Group|watching the application by wearing virtual glasses to the child during the peripheral IV line insertion
62746815|NCT05480215|EXPERIMENTAL|Experimental: TAPS delivered by Cala device with Trio band|Two 40-minute TAPS sessions daily for 14 days
62746816|NCT05480215|EXPERIMENTAL|Experimental: TAPS delivered by Cala device with Trio+ band|Two 40-minute TAPS sessions daily for 14 days
62746817|NCT00426816|EXPERIMENTAL|Crossover population|All study population receive placebo and doses of SB-649868 at 10mg, 30mg and 60mg in a crossover desing
62746818|NCT04734418|EXPERIMENTAL|Remifentanil group|
62746819|NCT04734418|ACTIVE_COMPARATOR|Dexmedetomidine|
62746820|NCT06429397|EXPERIMENTAL|Drug|Patients receive Penpulimab and anlotinib
62746821|NCT01011491|EXPERIMENTAL|Medifast 5 & 1 Plan|Medifast's 5 \& 1 Plan is a meal replacement plan for weight loss and weight maintenance.
62746822|NCT01011491|ACTIVE_COMPARATOR|Food-based|The food-based arm followed a meal plan of self-selected foods that provided the same number of calories as the Medifast 5 \& 1 plan.
62746823|NCT00535704|EXPERIMENTAL|1|The Strong AFrican American FAmilies-Teen program is a five part educational program has been designed to help teens and their parents create successful futures and avoid the risky behaviors that sometimes keep teens from reaching their goals.
62746824|NCT00535704|OTHER|2|The FUEL program is a family-based adaptation of a curriculum designed to assist teens to develop lifestyles that prevent health problems such as heart disease, diabetes, and being overweight. This program deals with diet and exercise, the influence of TV and magazines on eating habits, and handling stress.
62746825|NCT05202574|ACTIVE_COMPARATOR|dexamethasone|
62746826|NCT05202574|ACTIVE_COMPARATOR|ondanestrone|
62746827|NCT05202574|PLACEBO_COMPARATOR|control group|
62746828|NCT02200588||Patients|Patients followed in the First Episode Psychosis Clinical Program (PAFIP) with psychotic disorder
62746829|NCT02200588||Controls|Healthy subjects without psychotic disorder
62746830|NCT05664958|EXPERIMENTAL|ESP Block|Standard of care analgesic regimen with ESP Block
62746831|NCT05664958|NO_INTERVENTION|Control|Standard of care analgesic regimen
62746832|NCT05758389|EXPERIMENTAL|immunotherapy combined with chemotherapy|
62746833|NCT03403361|EXPERIMENTAL|Dual-Energy CT scan|Patients enrolling in this study will undergo additional sequential DECT scan in addition to their routine SECT or DECT scan.
62746834|NCT06205355|EXPERIMENTAL|goal-directed analgesia using ANI monitoring|
62746835|NCT06205355|ACTIVE_COMPARATOR|Standard monitoring|
62746836|NCT06606652|EXPERIMENTAL|Caffeine - Morning|
62746837|NCT06606652|EXPERIMENTAL|Caffeine - Evening|
62746838|NCT06606652|PLACEBO_COMPARATOR|Placebo - Morning|
62746839|NCT06606652|PLACEBO_COMPARATOR|Placebo - Evening|
62746840|NCT04355442||contained patients|contained patients
62746841|NCT04355442||Comparative patients|Comparative patients
62746842|NCT00794105||Normal ears|
62746843|NCT00794105||Otitis media ears.|
62746844|NCT03028844|NO_INTERVENTION|Sucrose alone|"These infants will receive an oral sucrose solution (Sweetease) only prior to venepuncture"
62746845|NCT03028844|EXPERIMENTAL|Music intervention plus sucrose|These infants will receive both oral sucrose solution and music therapy prior to venepuncture.
62746846|NCT05130632|EXPERIMENTAL|The community working group|Female participants over the age of 15 randomized to the intervention group will participate in working group sessions over 12 weeks' time that addresses plastic waste and introduce strategies to reduce use, recycle, and repurpose plastic. Community members of participants in the intervention group will also be invited to participate in the working groups.
62746847|NCT05130632|NO_INTERVENTION|Control Group.|No specific activities
62746848|NCT00098748|EXPERIMENTAL|1|
62746849|NCT00098748|EXPERIMENTAL|2|
62746850|NCT00098748|EXPERIMENTAL|3|
62746851|NCT01382355||Kidney transplant|
62746852|NCT04236024|EXPERIMENTAL|Experimental group|The students in this group will learn medication knowledge by using board game.
62746853|NCT04236024|ACTIVE_COMPARATOR|Comparison group|The students in this group will learn medication knowledge through tradition lecture.
62746854|NCT00441142|ACTIVE_COMPARATOR|Phase II: Arm A (Control Group: RT + TMZ)|"The Induction Phase:~Temozolomide (75 mg/m2 daily for 6 weeks) with concurrent fractionated radiation therapy for approximately 6 weeks (XRT must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy), followed by 4-6 weeks rest.~Followed by the Maintenance Phase:~12 cycles of adjuvant temozolomide \[at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle; if 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given\]."
62746855|NCT00441142|EXPERIMENTAL|Phase I + Phase II: Arm B (RT + TMZ + Vandetanib)|"The Induction Phase:~ZD6474 (Vandetanib) daily (to begin 5-7 days prior to starting participant's RT) Temozolomide (75 mg/m2 daily for 6 weeks) with concurrent fractionated radiation therapy for approximately 6 weeks (XRT must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy), followed by 4-6 weeks rest.~Followed by the Maintenance Phase:~12 cycles of adjuvant temozolomide \[at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle; if 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given\].~ZD6474 (Vandetanib) daily for the twelve (12) 28-day cycles of adjuvant temozolomide, with the option to continue until participant experiences an unacceptable toxicity or his/her tumor progresses."
62746856|NCT06552949||Study group|Patient undergoing emergent laparoscpic cholecystectomy guided by indocyanine green cholangiography (ELC-ICGC)
62746857|NCT06552949||Control group|Patient undergoing emergent conventional laparoscopic cholecystectomy
62746858|NCT04511871|EXPERIMENTAL|CCT303-406|"To determine the safety, tolerability, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of CCT303-406 cell therapy in patients with HER2-positive (IHC 3+ in ≥50% tumor cells) relapsed or refractory solid tumors.~Dose cohorts:~* Dose 1: 3x10\^5 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion~* Dose 2: 1x10\^6 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion~* Dose 3: 1x10\^7 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion"
62746859|NCT02172131|EXPERIMENTAL|BI 1744 CL|Single rising dose of BI 1744 CL as intravenous (i.v.) infusion
62746860|NCT02172131|PLACEBO_COMPARATOR|Placebo|
62746861|NCT06582693|EXPERIMENTAL|Intervention Arm|Adult intervention arm participants will receive motivational counseling provided by the study staff member enrolling them. The study team member will offer 4 evidence-based treatment options (varenicline, NRT, quitline, and/or smokefreeTXT), emphasizing that the combination is often more effective than one treatment alone, and that they could start treatment even if they are not ready to quit.
62746862|NCT06582693|NO_INTERVENTION|Control Arm|Adult control arm participants will receive a handout listing tobacco treatment options that they can connect to on their own
62746863|NCT04628169||group A|30 placental specimens of PAS
62746864|NCT04628169||group B|30 placental specimens of heaithy women with normal pregnancy
62746865|NCT05108454||Intervention group|Pregnant women who received MMS from the SMC program
62553436|NCT06076733|EXPERIMENTAL|active group|Twenty 2-mA sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 20 minutes per session, twice daily over 10 consecutive days, and the stimulus frequency was set as 6Hz.
62746866|NCT05108454||Comparison|Pregnant women who did not receive MMS
62746867|NCT03119181|EXPERIMENTAL|Active Tymbion Iontophoresis|Unilateral treatment with active iontophoresis of Tymbion (2% lidocaine HCl/ 1:100,000 epinephrine) using the Tusker Medical Tula Iontophoresis System.
62746868|NCT03119181|SHAM_COMPARATOR|Sham Tymbion Iontophoresis|The sham iontophoresis procedure will be identical to the active Tymbion iontophoresis in that Tymbion (2% lidocaine/ 1:100,000 epinephrine solution) will be placed in the external ear canal, however the iontophoresis current delivery (which facilitates penetration of drug into the tympanic membrane tissue) will not be activated.
62746869|NCT05401929|EXPERIMENTAL|Active|
62746870|NCT05401929|SHAM_COMPARATOR|Sham|
62746871|NCT00646763|ACTIVE_COMPARATOR|Abdomen|These subjects will have their cytokine injections administered only to their abdomen.
62746872|NCT00646763|ACTIVE_COMPARATOR|Extremities|The extremity arm will have their injections administered to their upper and/or lower extremities.
62746873|NCT04193345|ACTIVE_COMPARATOR|Early cord clamping|The umbilical cord will be clamped within 15 seconds from delivery of the baby
62746874|NCT04193345|ACTIVE_COMPARATOR|Delayed cord clamping|The umbilical cord will be clamped after 60 seconds from delivery of the baby
62746875|NCT03350958|EXPERIMENTAL|Group 1|Participants received experimental test meal first and placebo comparator meal at the next study visit. Participants to fill out visit questionnaire prior to meal and every 30 minutes thereafter for 5 hours. Samples of ileostomy fluid taken at these time-points, along with blood samples in a subset of participants
62746876|NCT03350958|PLACEBO_COMPARATOR|Group 2|Participants received placebo comparator meal first and experimental test meal at the next study visit. Participants to fill out visit questionnaire prior to meal and every 30 minutes thereafter for 5 hours. Samples of ileostomy fluid taken at these time-points, along with blood samples in a subset of participants
62746877|NCT05073003|PLACEBO_COMPARATOR|ST1_Adults_Placebo_GR1 Group|Adults 18 to 50 years of age in Stage 1 (Europe) randomized to receive two doses of altSonflex Placebo, one each at Day 1 and Day 85.
62746878|NCT05073003|EXPERIMENTAL|ST1_Adults_Dose C_GR1 Group|Adults 18 to 50 years of age in Stage 1 (Europe) randomized to receive two doses of altSonflex1-2-3 Dose C vaccine, one each at Day 1 and Day 85.
62553437|NCT06076733|SHAM_COMPARATOR|sham group|Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
62553438|NCT00919295|PLACEBO_COMPARATOR|placebo|placebo
62746879|NCT05073003|PLACEBO_COMPARATOR|ST1_Adults_Placebo_GR2 Group|Adults 18 to 50 years of age in Stage 1 (Europe) randomized to receive two doses of altSonflex Placebo, one each at Day 1 and Day 169.
62553439|NCT00919295|PLACEBO_COMPARATOR|mirtazapine 15|mirtazapine 15 mg
62746880|NCT05073003|EXPERIMENTAL|ST1_Adults_Dose C_GR2 Group|Adults 18 to 50 years of age in Stage 1 (Europe) randomized to receive two doses of altSonflex1-2-3 Dose C vaccine, one each at Day 1 and Day 169.
62746881|NCT05073003|ACTIVE_COMPARATOR|ST2_Adults_Control C Group|Adults 18 to 50 years of age in Stage 2 (Africa) randomized to receive one dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine at Day 1 and one dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine at Day 85.
61986355|NCT02034461|EXPERIMENTAL|Implantation of a Utah Electrode Array|The arm which has been amputated or has peripheral nerve trauma. Intervention include insertion of the Utah Slanted Electrode Arrays which will interact with nerve endings in order to gain knowledge about device feasibility and nerve stimulation.
62553440|NCT00919295|PLACEBO_COMPARATOR|mirtazapine 30|mirtazapine 30mg
62553441|NCT01059461|EXPERIMENTAL|Cerebrolysin®, neuroregeneration|Injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
61986356|NCT01591291|EXPERIMENTAL|Ondansetron|
61986357|NCT01591291|PLACEBO_COMPARATOR|Placebo|
61986358|NCT02227342|EXPERIMENTAL|Fecal Microbiota Transplantation|serial Fecal Microbiota Transplantation
61986359|NCT01485640|EXPERIMENTAL|Lurasidone|Lurasidone flexibly dosed
62553442|NCT02398864|EXPERIMENTAL|endobronchial ultrasound bronchoscopy|EBUS with TBNA
62553443|NCT00501995|EXPERIMENTAL|IV Cyclophosphamide (50 mg/kg)|This is an open-labeled single arm study of Cyclophosphamide (50 mg/kg) administered intravenously over 1 hour daily for four consecutive days (200 mg/kg total) through a Hickman catheter .
62553444|NCT06171399|EXPERIMENTAL|"All Natural descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor All Natural."
62746882|NCT05073003|EXPERIMENTAL|ST2_Adults_Dose C Group|Adults 18 to 50 years of age in Stage 2 (Africa) randomized to receive two doses of altSonflex1-2-3 Dose C vaccine, one each at Day 1 and Day 85.
62746883|NCT05073003|ACTIVE_COMPARATOR|ST2_Children_Control B Group|Children 24 to 59 months of age in Stage 2 (Africa) randomized to receive one dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine at Day 1 and one dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine at Day 85. This group is a control group for children receiving altSonflex1-2-3 Dose B vaccine.
61986360|NCT01759108|EXPERIMENTAL|Rebamipide|Patients will be randomized 1:1 to receive 300mg/d (100mg x3/day) of rebamipide for 12 weeks together with their usual therapy
61986361|NCT01759108|PLACEBO_COMPARATOR|Placebo|Patients will be randomized 1:1 to receive 300mg/d (100mg x3/day) of placebo for 12 weeks together with their usual therapy.
61986362|NCT03811431|EXPERIMENTAL|CEUS guidance|SonoVue 2, 4 ml
61986363|NCT03811431|EXPERIMENTAL|Conventional US guidance|No drugs
62746884|NCT05073003|EXPERIMENTAL|ST2_Children_Dose B Group|Children 24 to 59 months of age in Stage 2 (Africa) randomized to receive two doses of altSonflex1-2-3 Dose B vaccine, one each at Day 1 and Day 85.
62553445|NCT06171399|EXPERIMENTAL|"Gluten-free descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor Gluten-free"
62746885|NCT05073003|ACTIVE_COMPARATOR|ST2_Children_Control C Group|Children 24 to 59 months of age in Stage 2 (Africa) randomized to receive one dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine at Day 1 and one dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine at Day 85. This group is a control group for children receiving altSonflex1-2-3 Dose C vaccine.
62746886|NCT05073003|EXPERIMENTAL|ST2_Children_Dose C Group|Children 24 to 59 months of age in Stage 2 (Africa) randomized to receive two doses of altSonflex1-2-3 Dose C vaccine, one each at Day 1 and Day 85.
62746887|NCT05073003|ACTIVE_COMPARATOR|ST2_Infants_Control A_Safety Group|Infants 9 months of age in Stage 2 (Africa), part of the safety cohort, randomized to receive two doses of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine, one each at Day 1 and Day 85, and one dose of GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine at Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 29 and Day 281, as concomitant vaccination. This group is a control group for infants receiving altSonflex1-2-3 Dose A vaccine.
62746888|NCT05073003|EXPERIMENTAL|ST2_Infants_Dose A_Safety Group|Infants 9 months of age in Stage 2 (Africa), part of the safety cohort, randomized to receive three doses of altSonflex1-2-3 Dose A, one each at Day 1, Day 85 and Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 29 and Day 281, as concomitant vaccination.
62553446|NCT06171399|EXPERIMENTAL|"Vegan descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor Vegan"
62553447|NCT06171399|EXPERIMENTAL|"100% Organic descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor 100% Organic"
62553448|NCT06171399|EXPERIMENTAL|"Handcrafted descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor Handcrafted"
62553449|NCT06171399|EXPERIMENTAL|"Made with live resin descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor Made with live resin"
62553450|NCT06171399|EXPERIMENTAL|"Fast-acting descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor Fast-acting"
62553451|NCT06171399|EXPERIMENTAL|"Relax descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor Relax"
62553452|NCT06171399|EXPERIMENTAL|"Energy Boost descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor Energy Boost"
62553453|NCT06171399|EXPERIMENTAL|No descriptor (control)|Four edible product packages (gummies, chocolate, mints, cookies) without any product descriptors
61986364|NCT03559140|EXPERIMENTAL|Group A|"The R25 (size 25/ .08) instrument was used in thin and curved root canals, and R40 files (40/ .06) were used in wide root canals. Three in-and-out pecking motions were used with an amplitude of not more than 3 mm until reaching the estimated working length.~After the procedure cryotherapy will be applied as follows:~Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes"
62374410|NCT04853056|EXPERIMENTAL|Cold Vibration Group|Buzzy, connecting and operating 5 cm above the area to be inserted peripheral IV line
62374411|NCT04853056|NO_INTERVENTION|Control group|Standart care
62374412|NCT05742789|OTHER|Propofol|Anesthesia
62374413|NCT05742789|OTHER|Isofluran|Anesthesia
62374414|NCT05742789|OTHER|Sevofluran|Anesthesia
62553454|NCT02382003|EXPERIMENTAL|Positive Training+Anxious Imagery Prime|Positive Cognitive Bias Modification - Interpretation training paired with a preceding Anxious Imagery Prime
62553455|NCT02382003|EXPERIMENTAL|Positive Training+Neutral Imagery Prime|Positive Cognitive Bias Modification - Interpretation training paired with a preceding Neutral Imagery Prime
62553456|NCT02382003|ACTIVE_COMPARATOR|50/50 Training+Anxious Imagery Prime|50/50 Cognitive Bias Modification - Interpretation (half positive \& half negative scenarios) paired with a preceding Anxious Imagery Prime
62553457|NCT02382003|ACTIVE_COMPARATOR|50/50 Training+Neutral Imagery Prime|50/50 Cognitive Bias Modification - Interpretation (half positive \& half negative scenarios) paired with a preceding Neutral Imagery Prime
62553458|NCT02382003|OTHER|No Scenario+Anxious Imagery Prime|No scenarios paired with a preceding Anxious Imagery Prime
62553459|NCT02382003|OTHER|No Scenario+Neutral Imagery Prime|No scenarios paired with a preceding Neutral Imagery Prime
62553460|NCT04685512|EXPERIMENTAL|TDF / FTC|2 tablets on Day-1 then 1 tablet/day for 6 days
62553461|NCT04685512|NO_INTERVENTION|usual care|Standard of Care
62553462|NCT01348256|NO_INTERVENTION|Observation|Observation after standard treatment
62553463|NCT01348256|EXPERIMENTAL|Dendritic cells vaccine|Adjuvant treatment with dendritic cells vaccine after standard treatment
62553464|NCT01023503||1|Adults, with a new statin prescription or a change in their stain treatment
62553465|NCT01602822|OTHER|Atazanavir, Ritonavir, Truvada|Open Label
62553466|NCT01026194|PLACEBO_COMPARATOR|Placebo / Teneli + Pio|
62553467|NCT01026194|EXPERIMENTAL|Teneli / Teneli + pio|
62553468|NCT00003126|EXPERIMENTAL|Interleukin-2 (IL-2)|Patients randomized to this arm will receive one course of IL-2 \[600,000 U/kg every 8 hours on post-operative days 1 to 5 and days 15 to 19 (maximum 28 doses)\].
62553469|NCT00003126|NO_INTERVENTION|Observation|Patients randomized to this arm will receive their normal medical care
62553470|NCT02118545||vWF and postoperative Outcome|An independent prospective validation cohorts will be obtained from 4 different Institutions: 2 in Vienna , 1 in Salzburg and 1 in Bern
62553471|NCT00316290|EXPERIMENTAL|1|Participants will receive integrated parent training.
62553472|NCT00316290|ACTIVE_COMPARATOR|2|Parents will receive behavioral parent training.
62746889|NCT05073003|ACTIVE_COMPARATOR|ST2_Infants_Control B_Safety Group|Infants 9 months of age in Stage 2 (Africa), part of the safety cohort, randomized to receive two doses of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine, one each at Day 1 and Day 85, and one dose of GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine at Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 29 and Day 281, as concomitant vaccination. This group is a control group for infants receiving altSonflex1-2-3 Dose B vaccine.
62746890|NCT05073003|EXPERIMENTAL|ST2_Infants_Dose B_Safety Group|Infants 9 months of age in Stage 2 (Africa), part of the safety cohort, randomized to receive three doses of altSonflex1-2-3 Dose B vaccine, one each at Day 1, Day 85 and Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 29 and Day 281, as concomitant vaccination.
62746891|NCT05073003|ACTIVE_COMPARATOR|ST2_Infants_Control C_Safety Group|Infants 9 months of age in Stage 2 (Africa), part of the safety cohort, randomized to receive two doses of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine, one each at Day 1 and Day 85, and one dose of GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine at Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 29 and Day 281, as concomitant vaccination. This group is a control group for infants receiving altSonflex1-2-3 Dose C vaccine.
62746892|NCT05073003|EXPERIMENTAL|ST2_Infants_Dose C_Safety Group|Infants 9 months of age in Stage 2 (Africa), part of the safety cohort, randomized to receive three doses of altSonflex1-2-3 Dose C vaccine, one each at Day 1, Day 85 and Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 29 and Day 281, as concomitant vaccination.
62746893|NCT05073003|ACTIVE_COMPARATOR|ST2_Infants_Control_Dose find Group|"Infants 9 months of age in Stage 2 (Africa), part of the dose-finding cohort, randomized to receive two doses of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine, one each at Day 1 and Day 85, and one dose of GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine at Day 253.~These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 1 and Day 253, as concomitant vaccination. This group is a control group for infants in dose-finding groups receiving either altSonflex1-2-3 Dose A, Dose B or Dose C vaccine."
62746894|NCT05073003|EXPERIMENTAL|ST2_Infants_Dose A_Dose find Group|Infants 9 months of age in Stage 2 (Africa), part of the dose-finding cohort, randomized to receive three doses of altSonflex1-2-3 Dose A vaccine, one each at Day 1, Day 85 and Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 1 and Day 253, as concomitant vaccination.
62746895|NCT05073003|EXPERIMENTAL|ST2_Infants_Dose B_Dose find Group|Infants 9 months of age in Stage 2 (Africa), part of the dose-finding cohort, randomized to receive three doses of altSonflex1-2-3 Dose B vaccine, one each at Day 1, Day 85 and Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 1 and Day 253, as concomitant vaccination.
62746896|NCT05073003|EXPERIMENTAL|ST2_Infants_Dose C_Dose find Group|Infants 9 months of age in Stage 2 (Africa), part of the dose-finding cohort, randomized to receive three doses of altSonflex1-2-3 Dose C vaccine, one each at Day 1, Day 85 and Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 1 and Day 253, as concomitant vaccination.
62746897|NCT01829633||Rotator cuff tears|Patients who were diagnosed with a symptomatic full-thickness tear of the rotator cuff. Tear examination by sonography and MRI showed a repairable tear. All patients were initially treated conservatively by physiotherapy.
62746898|NCT02943330||Hemodialysis|Hemodialysis patients
62746899|NCT02943330||Hepatitis C|Patients receiving interferon treatment for hepatitis C
62746900|NCT02480166|EXPERIMENTAL|8 weeks SOF/LED|Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.
62746901|NCT02480166|EXPERIMENTAL|12 weeks SOF/LED|Patients that are either treatment experienced or are cirrhotic will be assigned to 12 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.
62746902|NCT01709422|ACTIVE_COMPARATOR|Propofol|both midazolam (1mg if aged \<= 70 years or 0.5mg in age \>70 years) and meperidine 20 mg were given intravenously at the initiation of sedation, Thereafter, an initial bolus of propofol 20 mg intravenously. Sedation was maintained with repeated dose of 5 to 10 mg propofol.
62746903|NCT01709422|ACTIVE_COMPARATOR|Conventional|both midazolam 2 to 5 mg and meperidine 25 to 50 mg were given intravenously at the initiation of sedation. Sedation was maintained with repeated doses of 0.5 to 1.0 mg midazolam and 5 to 10 mg meperidine.
62746904|NCT04338139|EXPERIMENTAL|Bio-oss Collagen|90% xengeneic bovine bone partciles + 10% collagen type I
62746905|NCT05761106|EXPERIMENTAL|Oculomotor Therapy|The procedures for oculomotor therapy will be arranged sequentially, from easiest to most difficult. It will consist of a convergence technique (Brock Cord and Barrille Cartouche) and an accommodative technique (Eccentric circles or lifesaving cards) and Eye Relaxation.
62746906|NCT05761106|ACTIVE_COMPARATOR|Therapy for Temporomandibular Disorder|"Extra-oral and intra-oral massage: The main objective is to reduce pain as well as re-establish proper muscle length and flexibility. The patient will be instructed to use diaphragmatic breathing to promote relaxation during these massage procedures.~Myofascial release of the masseter, temporalis and sternocleidomastoid muscles, release of neck soft tissues, cervical pomp, suboccipital inhibition, passive anteroposterior mobilization of the upper cervical, cervical exercises, Temporomandibular Joint exercises (mouth opening exercise with tongue on palate) , Proprioceptive exercises)."
62746907|NCT00597987||1|RNA samples
62553473|NCT00074308|EXPERIMENTAL|Arm I|Patients receive oral imatinib mesylate once or twice daily on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62553474|NCT00908544|EXPERIMENTAL|PHI-patients|"Patients with primary HIV infection (PHI) (see also Eligibility) are immediately treated with 2 NRTI + 1 PI/r + Maraviroc + Raltegravir"
62553475|NCT00908544|EXPERIMENTAL|CHI-patients|"Patients with chronic HIV infection (CHI) and with suppressed plasma viral load for at least three years under continuous HAART (2 NRTI + 1 PI/r see also Eligibility) intensified by Maraviroc + Raltegravir"
62746908|NCT02539173|EXPERIMENTAL|Experimental|Ultrasound scan of diaphragm is made preoperatively during the pre-anesthetic visit, patients are informed of the purpose of the study. Written consent is collected after oral and written information.
62746909|NCT01882426|ACTIVE_COMPARATOR|Enhanced treatment algorithm|Treatment algorithm featuring the early use of combination therapy, treatment intensification guided by objective assessments of inflammation and the use of remission as a therapeutic goal
62746910|NCT01882426|PLACEBO_COMPARATOR|Usual Care|These subjects will be managed according to local treatment guidelines for the treatment of UC.
62746911|NCT06659198|EXPERIMENTAL|minimally invasive posterior approach|minimally invasive posterior approach total hip replacement
62746912|NCT06659198|EXPERIMENTAL|direct anterior approach|direct anterior approach total hip replacement
62746913|NCT06108193|EXPERIMENTAL|topical minoxidil in Acne Vulgaris|Split face: 2% or 5% topical minoxidil solution applied and no treatment Description: Subjects will apply the 2% or 5% topical minoxidil solution to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face twice a day for 4 weeks.
62746914|NCT05840952|EXPERIMENTAL|ALG-097558|Oral doses of ALG-097558 in Healthy Volunteers, up to 20 doses over 10 days
62746915|NCT05840952|PLACEBO_COMPARATOR|Placebo|Oral doses of placebo in Healthy Volunteers, up to 20 doses over 10 days
62553476|NCT01459783|ACTIVE_COMPARATOR|Dementia care management in person|The dementia care management protocol will be delivered via face-to-face interactions in participants' homes or in mutually convenient locations between a trained care manager and the care recipient/informal family caregiver dyad, supplemented by telephone.
62553477|NCT01459783|ACTIVE_COMPARATOR|Dementia care management telephone only|The dementia care management protocol will be delivered via telephonic meetings only. Assessment, education, counseling, and social support procedures as well as referral and follow-ups will follow the same procedural content as stipulated for the face-to-face intervention, however, contact will not be planned in person.
62553478|NCT02143544|ACTIVE_COMPARATOR|Preoperative intra-aortic balloon pump.|Intervention: Preoperative placement of the intra-aortic balloon pump.
62553479|NCT02143544|NO_INTERVENTION|Control|No preoperative placement of the intra-aortic balloon pump.
62553480|NCT02126826|PLACEBO_COMPARATOR|Placebo to BI 1026706|Multiple Rising Doses Placebo to BI 1026706
62553481|NCT02126826|EXPERIMENTAL|BI 1026706|Multiple Rising Doses BI 1026706
62746916|NCT05840952|EXPERIMENTAL|ALG-097558 and Midazolam|Oral doses of ALG-097558, up to 14 doses over 7 days and oral dose of Midazolam, up to 2 doses, over 2 days, in Healthy Volunteers
62746917|NCT05840952|EXPERIMENTAL|ALG-097558, Placebo, and, Itraconazole|Oral doses of placebo, up to 2 doses over 2 days, followed by ALG-097558, up to 2 doses over 2 days, and itraconazole up to 10 doses over 10 days, in Healthy Volunteers.
62746918|NCT05840952|EXPERIMENTAL|ALG-097558 and Carbamazepine|Oral doses of ALG-097558, up to 2 doses over 2 days and oral doses of Carbamazepine, up to 30 doses, over 15 days, in Healthy Volunteers
62746919|NCT05840952|EXPERIMENTAL|ALG-097558 Bioavailability|Oral doses of ALG-097558, up to 3 doses over 3 days, both solution and tablet formulations dosed in fasted state, and tablet formulation dosed in fed state, in Healthy Volunteers
62553482|NCT00754078|OTHER|1|anal cancer patients treated with tomotherapy and chemotherapy
62553483|NCT03225001|EXPERIMENTAL|Failing surgical valve|Patients with a failing surgical bioprosthetic valve in the aortic position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN XT transcatheter valve.
62746920|NCT06608758||Patients with disabilities|"Cases with disabilities are patients aged 3 - 89 years old with the following secondary (or primary) diagnoses (using associated ICD-10 codes)~Mobility impairments: Spinal cord diseases, Spinal cord injuries, Injury to spinal cord nerves, Multiple sclerosis, Cerebral palsy, Dependence on enabling machines or devices, Need for caregiver related to mobility impairments~Severe Vision impairments:~Severe Hearing impairments:~Mental health: Person history mental and behavioral disorders, Major Depression, Severe bipolar disorder, Severe schizophrenia, Paranoia, Psychosis~Intellectual Disabilities:~Autism"
62746921|NCT06608758||Patients without disabilities|"Patients without disabilities are patients age 3-89 without the following secondary (or primary) diagnoses:~Mobility impairments: Spinal cord diseases, Spinal cord injuries, Injury to spinal cord nerves, Multiple sclerosis, Cerebral palsy, Dependence on enabling machines or devices, Need for caregiver related to mobility impairments~Severe Vision impairments:~Severe Hearing impairments:~Mental health: Person history mental and behavioral disorders, Major Depression, Severe bipolar disorder, Severe schizophrenia, Paranoia, Psychosis~Intellectual Disabilities:~Autism"
62746922|NCT03103698|OTHER|Monitoring of perioperative analgesia by the ANI device|
62746923|NCT03103698|OTHER|conventional monitoring based on hemodynamic variations.|
62746924|NCT05242224|EXPERIMENTAL|Experimental Group|Receives evolutionary nutrition package \[high quality diet plus nutrition messaging + standard of care (iron-folic acid and calcium supplements)\]
62746925|NCT05242224|NO_INTERVENTION|Control Group|Receives standard-of-care, iron-folic acid and calcium supplements.
62746926|NCT03726918||Osteoarthritis|Surgery for implantation of a prosthesis in case of Osteoarthritis
62746927|NCT03726918||Non Osteoarthritis|Surgery for implantation of a prosthesis fon non Osteoarthritis cases
62746928|NCT00590174|EXPERIMENTAL|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
62746929|NCT00590174|ACTIVE_COMPARATOR|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
62746930|NCT02305472|EXPERIMENTAL|NeoVas BCS|The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA-based polymer scaffold and contains the antiproliferative drug sirolimus.
62746931|NCT06588530|EXPERIMENTAL|All participants|All participants will be vaccinated during their first study visit using TENIVAC (Tetanus and Diphtheria Toxoids Adsorbed).TENIVAC will be administered intramuscularly as recommended in the subject's deltoid muscle at a dose of 0.5 mL.
62746932|NCT01835574|OTHER|Conditional Cash Transfer and Cognitive-behavioral aftercare|Pre- and post- CCT+AC intervention comparison
62746933|NCT01792375|ACTIVE_COMPARATOR|Concurrent membrane sweeping with Dinoprostone|
62746934|NCT01792375|ACTIVE_COMPARATOR|Dinoprostone|
62746935|NCT04463693|EXPERIMENTAL|Intervention|Insertion of the etonogestrel contraceptive implant subdermally over the non-dominant scapula
62567287|NCT03526861|EXPERIMENTAL|Tralokinumab (Dose1) initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
62746936|NCT06112821||APL negative|Patients without persistent antiphospholipid antibodies (aPL) positivity
62746937|NCT06112821||APL positive|Patients with persistent antiphospholipid antibodies (aPL) positivity
62746938|NCT01192269|EXPERIMENTAL|Docosahexaenoic Acid Supplement|"DHA supplement: Experimental~1 x 950 mg capsules per day orally, each capsule providing \~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric)."
62746939|NCT03988699|EXPERIMENTAL|Subject with severe tinnitus|Subjects diagnosed with severe tinnitus for at least six months, and it has not responded to conventional management will have surgical implantation of the device Tinnitus Implant System.
62746940|NCT04117581|ACTIVE_COMPARATOR|Vitamin D3 supplement|Participant will be asked to take one capsule of vitamin D3 supplement (5000 IU) (125 μg) daily for a total duration of 12 weeks.
62746941|NCT04117581|PLACEBO_COMPARATOR|Placebo|Participants will be asked to take one capsule of placebo (inert filler) daily for a total duration of 12 weeks.
62746942|NCT06329063|EXPERIMENTAL|Vasopressin group|Drug: Vasopressin (20IU)
62746943|NCT06329063|PLACEBO_COMPARATOR|Placebo group|Drug: Placebo
62746944|NCT05858853|EXPERIMENTAL|Group 1|The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days
62746945|NCT05858853|EXPERIMENTAL|Group 2|The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days
62746946|NCT05858853|ACTIVE_COMPARATOR|Group 3|Control drug (human blood albumin injection) 10 g/ day for 14 days
62746947|NCT05858853|ACTIVE_COMPARATOR|Group 4|Control drug (human blood albumin injection) 20 g/ day for 7 days
62746948|NCT02534558|EXPERIMENTAL|miR-29a precursor oligonucleotide|Effects of IL-1β, miR-29a precursor oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
62746949|NCT02534558|EXPERIMENTAL|miR-29a antisense oligonucleotide|Effects of IL-1β, miR-29a antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
62746950|NCT06151886||Patients|
62746951|NCT06151886||Relatives|
62746952|NCT06151886||Trained respiratory patient caregiver|
62746953|NCT01060449|OTHER|LV lead low output|"Low output on left ventricular pacing lead.~Intervention: LV stimulus intensity"
62746954|NCT01060449|OTHER|LV lead high output|"High output on left ventricular lead~Intervention: LV stimulus intensity"
62746955|NCT00436423|EXPERIMENTAL|1|Gemcitabine with TS-1
62746956|NCT05474638|OTHER|Controlateral and simultaneous comparison of neuromuscular transmission monitors|Controlateral and simultaneous comparison of responses from acceleromyography- and mechanomyography-based neuromuscular transmission monitors in the same patients.
62746957|NCT01630928|EXPERIMENTAL|Renal sympathetic denervation|Patients with treatment resistant hypertension
62746958|NCT04930276|EXPERIMENTAL|GDM group|After participants are enrolled, they would be given medical nutrient treatment. Besides, they need have a follow-up visit every two weeks. Blood glucose, body weight, lifestyle and clinical information are collected. Blood samples and stool samples are collected in 28 and 32 pregnant weeks, respectively.
62746959|NCT04930276|OTHER|non-GDM group|After participants enrollment, they also would be given medical nutrient treatment. And the other conditions are same as the group of GDM.
62746960|NCT01543399|EXPERIMENTAL|Tibolone use|climacteric women will use Tibolone for 30 days
62746961|NCT01543399|PLACEBO_COMPARATOR|Placebo use|climacteric women will use placebo for 30 days
62746962|NCT05052814|EXPERIMENTAL|Calcium hydroxide ( Ca(OH)2 )|Root canal medicament which was placed into root canals with a lentulo spiral.
62746963|NCT05052814|EXPERIMENTAL|Chlorhexidine gel (CHX gel)|Root canal medicament which was placed into root canals with a lentulo spiral.
62746964|NCT05052814|EXPERIMENTAL|Calcium hydroxide+ CHX gel|Root canal medicament which was placed into root canals with a lentulo spiral.
62746965|NCT02130830|EXPERIMENTAL|Topical anesthesia|Application of topical 2,5% lidocaine + 2,5% prilocaine gel to the anal canal before the procedure
62746966|NCT02130830|PLACEBO_COMPARATOR|Placebo|Application of placebo gel into the anal canal before the procedure
62746967|NCT04848220|EXPERIMENTAL|Stage A (Dose Cohort 1) and Stage B (Dose Group 1)|
62746968|NCT04848220|EXPERIMENTAL|Stage A (Dose Cohort 2) and Stage B (Dose Group 2)|
62746969|NCT04848220|PLACEBO_COMPARATOR|Stage A (Dose Cohort 1 and Dose Cohort 2) and Stage B (Dose Group 1 and Dose Group 2)|
62746970|NCT02816021|EXPERIMENTAL|Arm A: Metastatic Melanoma - PD-1 Naive|"Thirty-six participants with metastatic melanoma that are PD-1 naïve enrolled in treatment Arm A.~Treatment consists of 3-week cycles and continues until disease progression. Oral Azacitidine administered by mouth daily for 15 days (Days 1-15) of every cycle. Pembrolizumab administered by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days."
62746971|NCT02816021|EXPERIMENTAL|Arm B: Metastatic Melanoma - Post PD-1 Progression|"Thirty-five participants with metastatic melanoma that have progressed on PD-1 directed therapy enrolled in treatment Arm B.~Treatment consists of 3-week cycles and continues until disease progression. Oral Azacitidine administered by mouth daily for 15 days (Days 1-15) of every cycle. Pembrolizumab administered by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days."
62746972|NCT04765644|ACTIVE_COMPARATOR|Celecoxib|"Phase 1: Twenty volunteers will receive celecoxib 200 mg, 2 times/day (total 400 mg/day) for 7 days. At this point, the study team will perform an interim analysis of the data. If our primary endpoint is not achieved we may revise our endpoints and/or if additional power is required, we may recruit up to an additional n=20 volunteers per group. This analysis may also serve as a stop-go checkpoint for continuation of the second phase of the study. If we do not see any effects of celecoxib on endothelial or cardiovascular function, we will not proceed to phase 2. If we do see a negative effect, we will proceed to phase 2.~In phase 2 participants will be re-invited to the study site following a 4-8 week washout period. Participants will then receive either treatment with placebo + 10g L-arginine supplementation (20 participants) or celecoxib + 10g arginine supplementation (20 participants) for a total of 7 days"
62746973|NCT04765644|PLACEBO_COMPARATOR|Placebo|"Phase 1: Twenty volunteers will receive a placebo capsule, 2 times/day (total 400 mg/day) for 7 days. At this point, the study team will perform an interim analysis of the data. If our primary endpoint is not achieved we may revise our endpoints and/or if additional power is required, we may recruit up to an additional n=20 volunteers per group. This analysis may also serve as a stop-go checkpoint for continuation of the second phase of the study. If we do not see any effects of celecoxib on endothelial or cardiovascular function, we will not proceed to phase 2. If we do see a negative effect, we will proceed to phase 2.~In phase 2 participants will be re-invited to the study site following a 4-8 week washout period. Participants will then receive either treatment with placebo + 10g L-arginine supplementation (20 participants) or celecoxib + 10g arginine supplementation (20 participants) for a total of 7 days"
62746974|NCT02141633|EXPERIMENTAL|smokers|participants with smoking history ( \> 10 pack/year) will be enrolled and perform airway blood flow and echocardiogram before and 15 minutes after albuterol inhalation
62746975|NCT02141633|EXPERIMENTAL|non-smokers|healthy life-time non smokers will be enrolled and perform airway blood flow and echocardiogram before and 15 minutes after albuterol inhalation
62553484|NCT00932672|EXPERIMENTAL|Atkins group|Men assigned to the Atkins diet will be asked to restrict carbohydrate intake to \<20 grams/day. We will use an established clinical program directed by Dr. Eric Westman which implements this diet using a trained clinical nutritionist. No other dietary restrictions will be placed on the subjects. They will measure their urinary ketones at home weekly using urinary ketone strips. Subjects will meet with the nutritionist monthly during the 6 months of the study. Subjects in the Atkins arm will also be asked to walk at a brisk pace for 30 minutes a day, 5 days a week and will be provided a pedometer to measure the number of steps taken per day.
62553485|NCT00932672|NO_INTERVENTION|Control group|Subjects assigned to the control group will be asked to make no changes in their dietary habits. At the completion of the study subjects will meet with the nutritionist and receive standard nutrition AHA recommendations.
62746976|NCT05587062|EXPERIMENTAL|Aflibercept (CinnaGen Co, Iran)|Aflibercept (CinnaGen Co, Iran) 2 mg (0.05 mL) by intravitreal injection every 4 weeks for the first 3 injections, followed by 2 mg every 8 weeks until week 48 of study
62374415|NCT02118402|ACTIVE_COMPARATOR|Fortified maize porridge (MNP)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, maltodextrin carrier (added up to 11g)
62553486|NCT06199284|OTHER|Patient|Usual care and gait training with the Atalante exoskeleton
62553487|NCT00133965||1|Dignity Psychotherapy
62553488|NCT00133965||2|Supportive Psychotherapy
62553489|NCT00133965||3|Standard Palliative Care
62553490|NCT05008874||Males with AMN|Adult males with confirmed diagnosis of ALD and symptoms of AMN.
62374416|NCT02118402|ACTIVE_COMPARATOR|Fortified maize porridge (MNP+Fe)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g)
62553491|NCT02078700|EXPERIMENTAL|early palliative care programme|Patients will be proposed to be followed by the Palliative Care Team
62553492|NCT03095664|EXPERIMENTAL|Intervention group|6 months after surgical treatment, women in the experimental group will attend a counseling program to promote healthy eating and physical activity.
62553493|NCT03095664|NO_INTERVENTION|Control group|Control group will receive usual care (verbal nutritional counseling after surgical treatment, at discharge).
62746977|NCT05587062|ACTIVE_COMPARATOR|Aflibercept (Regeneron, USA)|Aflibercept (Regeneron, USA) 2 mg (0.05 mL) by intravitreal injection every 4 weeks for the first 3 injections, followed by 2 mg every 8 weeks until week 48 of study
62746978|NCT01801748|EXPERIMENTAL|oral wheat challenge|
62746979|NCT03018795|ACTIVE_COMPARATOR|Ozone Group|Decontamination of implant surfaces with saline irrigation and additional ozone therapy in combination with regenerative surgery
62746980|NCT03018795|ACTIVE_COMPARATOR|Control Group|Decontamination of implant surfaces with saline irrigation alone in combination with regenerative surgery
62746981|NCT03441997|EXPERIMENTAL|Full mind-body exercises|Participants will be trained to perform a type of mind-body exercise that involves low intensity exercise and body movements similar to Tai Chi. Participants will be asked to exercise 2 times per day for 8 weeks.
62374417|NCT02118402|ACTIVE_COMPARATOR|Fortified maize porridge (MNP+Fe+GOS)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA plus 7.5 g of galactooligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g)
62374418|NCT03209986|EXPERIMENTAL|MSC group|mesenchymal stem cell transplantation via peripheral vein: 1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8.
62567288|NCT03526861|EXPERIMENTAL|Tralokinumab (Dose2) initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
62553494|NCT03338530|EXPERIMENTAL|Comprehensive School-Based Intervention|Children with HFASD assigned to the CSBI received social skills groups, computer instruction in emotion recognition, therapeutic activities, and a behavioral reinforcement system (individual daily note) during the school year and their parents participated in monthly parent training. School staff received training prior to the school year and demonstrated fidelity with the protocol. Fidelity was also monitored during the school year by research assistants.
62746982|NCT03441997|ACTIVE_COMPARATOR|Light mobility exercises: Control Group|The Light mobility exercises group will perform a similar exercise as the experimental group. However without a few components. Participants will be asked to exercise two times per day for 8 weeks.
62746983|NCT03441997|NO_INTERVENTION|Healthy Controls|Healthy females will be asked to make one visit to complete aerobic exercise test, questionnaires, and provide blood samples.
62374419|NCT03209986|NO_INTERVENTION|control|Standard medication for viral hepatitis and cirrhosis
62374420|NCT02170558||Patients implanted w/TM-Ardis|Patients who are receiving a TM-Ardis implant for degenerative disc disease will have a CT scan immediate post op (2 weeks) and again at 6 months to determine if fusion can be assessed with the study metal reduction software. Will utilize TM- Ardis implant and Metal Reduction CT software
62374421|NCT02916199|EXPERIMENTAL|Needle knife fistulotomy|"Device: Needle knife fistulotomy Disease: Common bile duct stone, Malignant biliary stricture, Benign biliary stricture, Benign pancreatic disease, biliary sphincter of Oddi dysfunction Indication: High risk of post-endoscopic retrograde cholangiopancreatography pancreatitis~- Intervention: canulation of ampulla of Vater Intervention: canulation of ampulla of Vater"
62374422|NCT02916199|ACTIVE_COMPARATOR|conventional cannulation|"Device: conventional canulation catheter Disease: Common bile duct stone, Malignant biliary stricture, Benign biliary stricture, Benign pancreatic disease, biliary sphincter of Oddi dysfunction Indication: High risk of post-endoscopic retrograde cholangiopancreatography pancreatitis~- Intervention: canulation of ampulla of Vater Intervention: canulation of ampulla of Vater"
62374423|NCT04460300|EXPERIMENTAL|Aromatherapy-inhalation group|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is carried out through the essential oil inhalation method. Individuals who can distinguish odors in the odor sense test before the application is included in the study. Aromatherapy inhalation is applied for three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week. Intervention is made between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~In this method, 5 drops of lavender oil is dropped directly on a sterile gauze and individuals is allowed to breathe from a distance of 10 cm for 5 minutes."
62374424|NCT04460300|EXPERIMENTAL|Aromatherapy-foot massage group|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is applied through foot massage. Swedish massage protocol is followed in foot massage intervention.The foot massage is performed on three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week.The intervention is performed between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~Foot massage is done with 10 drops (5 drops per foot) of lavender for 10 minutes for each foot for 20 minutes. During the intervention, 20 techniques is used and the application time of each technique is 30 seconds (total 10 minutes per foot)."
62374425|NCT04460300|NO_INTERVENTION|Control group|Interviews is held with the control group while performing the routine treatment and care of the clinic. No intervention is made by the researchers to the control group during the interview.
62374426|NCT04683133|OTHER|Single arm|Optical coherence tomography evaluation of coronary arteries with intermediate to severe stenosis.
62374427|NCT01382667||GLP-2 and symptom evaluation|Before starting and at the end of the chemotherapy, along with a blood withdrawal for GLP-2 evaluation, a GSRS (gastrointestinal symptom rate scale) questionnaire will be filled by each patient to account for GI symptoms. In addition, minor complaints such as warm sensation after chemotherapy, susceptibility to nausea under specific condition, sweating and weakness will scored by visual analog score (VAS). Lastly, the NCI-CTC score for mucositis will be performed.
62374428|NCT04731194|EXPERIMENTAL|performance-based financial incentive program|Village doctors in villages of the intervention group will promote policy awareness, support registration, follow-up patients, and receive financial incentives based on their performance.
62374429|NCT04731194|NO_INTERVENTION|current situation|Village doctors in villages of the control group will not be contacted. The control group would serve as a natural baseline and do not receive any intervention.
62567289|NCT03526861|EXPERIMENTAL|Placebo initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
62567290|NCT00696423|EXPERIMENTAL|Infanrix/Hib Single Injection Group|Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.
62746984|NCT05093595|NO_INTERVENTION|Group A|The tracheal tube was routinely fixed with a teeth pad and adhesive tape (3M).
62746985|NCT05093595|EXPERIMENTAL|Group B|The tracheal tube was fixed by the trans-nasal Silicone Foley Catheter (SFC) and adhesive tape.
62746986|NCT01120236|EXPERIMENTAL|Arm I (androgen deprivation and cixutumumab)|Patients receive androgen deprivation therapy comprising bicalutamide PO QD on days 1-28 and either goserelin acetate SC or leuprolide acetate IM every 1, 3, 4, 6, or 12 months. Patients also receive cixutumumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for 7 courses in the absence of disease progression or unacceptable toxicity.
62746987|NCT01120236|ACTIVE_COMPARATOR|Arm II (androgen deprivation therapy)|Patients receive androgen deprivation therapy comprising bicalutamide and either goserelin acetate or leuprolide acetate as in arm I.
62746988|NCT00801788|EXPERIMENTAL|Egalet® oxycodone Treatment A|Single Dose Administration
62746989|NCT00801788|EXPERIMENTAL|Egalet® oxycodone Treatment B|Single Dose Administration
62746990|NCT00801788|EXPERIMENTAL|Egalet® oxycodone Treatment C|Single Dose Administration
62746991|NCT00801788|ACTIVE_COMPARATOR|Active comparator|Single Dose Administration
62746992|NCT03744468|EXPERIMENTAL|Phase 1 Dose Escalation|Dose escalation of BGB-A425 in combination with Tislelizumab in participants with advanced solid tumors
62746993|NCT03744468|EXPERIMENTAL|Phase 2 Safety Lead-in|Dose escalation for Cohort A (LBL-007 + Tislelizumab) and Cohort B (BGB-A425 + LBL-007 + Tislelizumab) in participants with advanced solid tumors
62567291|NCT00696423|ACTIVE_COMPARATOR|Infanrix + Hiberix Separate Injection Group|Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.
62567292|NCT03068377|PLACEBO_COMPARATOR|Placebo|Soft gel capsules without test material
62567293|NCT03068377|EXPERIMENTAL|Experimental|Soft gel capsules containing a mixture of tomato extract, lutein, zeaxanthin as well as other phytonutrients and vitamins
62746994|NCT03744468|EXPERIMENTAL|Phase 2 Dose Expansion|Further explore the safety and clinical activity of BGB-A425 and LBL-007 in combination with Tislelizumab in participants with NSCLC, HNSCC and RCC
62746995|NCT00002705|EXPERIMENTAL|Arm I|Single-Agent Chemotherapy. Topotecan, TOPO, NSC-609699.
62746996|NCT01175486|EXPERIMENTAL|Actos|Actos 30 mg for 6 months
62746997|NCT01175486|ACTIVE_COMPARATOR|Acarbose|Acarbose 50mg tid for 6 months
62746998|NCT06454825|ACTIVE_COMPARATOR|Granisetron group|one group received granisetron 3 mg drug
62746999|NCT06454825|EXPERIMENTAL|Granisetron and Metoclopramide group|one group received a combination of granisetron 3 mg and metoclopramide 10 mg drugs
62747000|NCT01611116|PLACEBO_COMPARATOR|sodium chloride solution 0.9%|
62747001|NCT01611116|EXPERIMENTAL|temsirolimus|
62747002|NCT02342457|EXPERIMENTAL|Child suspected of Hirschsprung disease|Children admitted for biopsy, so that Hirschsprungs desease may be ruled out or diagnosed, whom are planned for rectal biopsy, by clinical decision.
62747003|NCT04023591||Surgery|Surgery/ Occupational Therapy
62747004|NCT00907608|EXPERIMENTAL|1|Receive Darbepoetin alfa
62747005|NCT00907608|NO_INTERVENTION|2|
62747006|NCT01823159|ACTIVE_COMPARATOR|Retigabine|Administration of a single dose of 400 mg retigabine, two hours before the measures
62747007|NCT01823159|PLACEBO_COMPARATOR|placebo|Randomized administration of a single dose of placebo, two hours before the measures.
62374430|NCT03632304|NO_INTERVENTION|Brachial plexus block (infraclavicular)|The standard of care at our institution. Performed by experienced regional anesthetists.
62374431|NCT03632304|ACTIVE_COMPARATOR|Local anesthesia with minimal sedation|The comparison group. Performed by the operating surgeon.
62374432|NCT01834638|EXPERIMENTAL|ABT-126 low dose|ABT-126 low dose
62374433|NCT01834638|EXPERIMENTAL|ABT-126 middle dose|ABT-126 middle dose
62374434|NCT01834638|EXPERIMENTAL|ABT-126 high dose|ABT-126 high dose
62374435|NCT04178434|ACTIVE_COMPARATOR|Internet-based CBT intervention|A nine step internet-based intervention with focus on stress and anxiety
62374436|NCT04178434|NO_INTERVENTION|Treatment as usual|Regular follow-up with two doctor and one nurse appointment
62374437|NCT06111404|ACTIVE_COMPARATOR|Group A (central group)|A metal catheter was then inserted in the bladder. The catheter was rotated so the tip was pointing upward, to stretch the bladder pillars. The bladder was dissected with monopolar scissors with the catheter in place. Then opening the posterior leaflet of the broad ligament to the cervix, opening of the vesico-vaginal space and dissecting the bladder downwards will be done (Poojari et al., 2014). Coagulation and section of the uterine pedicles: performed on the ascending segment of the uterine artery, will be carried out in a progressive manner on both sides.
62374438|NCT06111404|ACTIVE_COMPARATOR|Group B (lateral group)|The broad ligament is dissected down till the uterine bundle is identified. Once the uterine vascular bundle is identified the space can be dissected just above these vessels to reach the lateral margins of cervix. Any fatty tissue should be moved with the bladder. Uterine vessels are then tackled by desiccation or ligation. Similar procedure is done on the opposite side. Once the bladder is completely dissected and lifted off from the cervix below, midline adhesions of the bladder and pillars can be gradually separated using sharp dissection or Ligasure staying near to cervix (Chen et al., 2007).
62374439|NCT05471024|ACTIVE_COMPARATOR|Digitized Mounted Articulator Scan|"Conventional articulator facebow mounting will be digitized using extraoral digital 3d scanner and used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
62374440|NCT05471024|EXPERIMENTAL|Average Positioning on Virtual Bonwill Triangle|"Virtual Bonwill triangle will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
62374441|NCT05471024|EXPERIMENTAL|Digital Face Scan|"Digital face scan will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
62374442|NCT02870244|EXPERIMENTAL|Escalating Doses|Three patients will be treated at the first \& each subsequent dose level. Patients will be observed for 30 days post T cell infusion. If there was one DLT in the first 3 patients, an additional 3 patients will be treated at that level. If no additional DLTs are observed (for a total of 1 DLT in 6 patients) then the dose will be escalated. If two patients in the first 3 patients at a dose level experience a DLT, the dose will be de-escalated to the previous level \& an additional 3 patients will be enrolled at that level if 6 have not yet been treated at that level. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a DLT. If 2 or 3 patients in the first 3 patients experience a DLT at the first dose level, the study will terminate.
62374443|NCT06407336|EXPERIMENTAL|Contrast sensitivity|
62374444|NCT06407336|OTHER|Refraction|
62374445|NCT01223690|PLACEBO_COMPARATOR|Placebo|250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
62374446|NCT01223690|ACTIVE_COMPARATOR|Clarithromycin|1000 mg of clarithromycin diluted in 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
62374447|NCT02723019|EXPERIMENTAL|Intervention Group|Volunteer Peer Mentor + Behavioral Health Nurse
62374448|NCT02723019|NO_INTERVENTION|Control|Care as Usual
62374449|NCT02048657|EXPERIMENTAL|Foley group|The Foley Airway Stylet Tool was used to guide ProSeal LMA insertion
62374450|NCT02048657|EXPERIMENTAL|I-Tool group|the ProSeal LMA was inserted with a standard introducer-tool
62374451|NCT02259127|ACTIVE_COMPARATOR|SOC arm|SOC for ODYSSEY A is defined as a PI or non nucleoside transcriptase inhibitors + 2 or 3 nucleoside transcriptase inhibitor SOC for ODYSSEY B is defined as a PI or non nucleoside transcriptase inhibitor+ 2 nucleoside transcriptase inhibitors
62374452|NCT02259127|EXPERIMENTAL|DTG arm|DTG + 2 nucleoside transcriptase inhibitors
62553495|NCT03338530|NO_INTERVENTION|Business-As-Usual (BAU) Control|Children with HFASD in the BAU schools received their typical special education programming as legally-mandated. The programming received by each was carefully monitored per the following: 1) Each student's IEP was reviewed to document the legally mandated services received; 2) For those receiving counseling or speech-language services, the related-service provider completed a survey indicating specific treatment targets and the protocol for service provision; 3) Parents completed a monthly survey of any external therapeutic programming their child may have received; and 4) Fidelity measures designed for the intervention group (with sequencing requirements removed) were completed for the control condition during two 60-minute classroom observations per week by research assistants.
62553496|NCT04092140||diabetic complaining of neuropathy or not|using of ultrasound in examination and nerve conduction study
62553497|NCT04092140||carpal tunnel syndrome|using of ultrasound in examination and nerve conduction study
62553498|NCT04607135|EXPERIMENTAL|Acoustic radiation force impulse (ARFI)|Patients with suspected PCa who are scheduled to undergo an ultrasound fusion-MR prostate biopsy.
62553499|NCT04607135|ACTIVE_COMPARATOR|MR-ultrasound fusion|Patients with suspected PCa who are scheduled to undergo an ultrasound fusion-MR prostate biopsy.
62553500|NCT03806010||Quantitative sensory testing|QST will be performed at baseline two weeks and 2 months
62553501|NCT04534452|EXPERIMENTAL|Phenylephrine HCl|Subjects have a documented and/or self-reported history of allergic rhinitis with nasal congestion for at least 2 years.
62553502|NCT02922127|OTHER|Ulipristal Acetate|20 women will randomized to daily use of 10mg of ulipristal acetate
62553503|NCT02922127|OTHER|Combined Oral Contraceptive|20 women will be randomized to daily use of a combined oral contraceptive pill
62553504|NCT02934399||Healthy controls (HC)|Definition of the normal circadian and ultradian profiles of pituitary and adrenal hormones in healthy subjects:Each subject (total number 200, anticipated 50 per study centre) will be sampled by the ULTRADIAN sampling device for 27 hours. Day to day hormonal variability:A subgroup of 20 subjects will be asked to undergo sampling on three occasions to assess reproducibility of hormonal levels over time. Comparison of tissue and blood concentrations of hormones: 20 subjects will be asked to participate in the study comparing hormonal tissue level and blood levels.
62747008|NCT01663818|EXPERIMENTAL|Treatment group|Treatment with Tack-IT Endovascular Staple
62747009|NCT04880629|EXPERIMENTAL|Sleep rectriction|Participants in METWI2 undergo both a baseline (unrestricted) sleep and sleep restriction condition. On the morning following each condition, participants complete an oral glucose tolerance test to measure changes in glucose and insulin following ingestion of a glucose load.
62747010|NCT01900171|EXPERIMENTAL|10 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
62747011|NCT01900171|EXPERIMENTAL|50 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
62747012|NCT01900171|EXPERIMENTAL|125 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
62747013|NCT01900171|EXPERIMENTAL|250 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
62747014|NCT01900171|EXPERIMENTAL|500 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
62747015|NCT01900171|EXPERIMENTAL|750 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
62747016|NCT01900171|EXPERIMENTAL|1,000 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
62747017|NCT01900171|EXPERIMENTAL|1,250 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
62747018|NCT01900171|PLACEBO_COMPARATOR|Placebo|The placebo was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
62747019|NCT01329653|EXPERIMENTAL|aerobic training|12 weeks of aerobic training, 4X/week
62747020|NCT01329653|PLACEBO_COMPARATOR|wait list control|wait list control condition, 12 weeks to parallel the active intervention group
62747021|NCT05289817|EXPERIMENTAL|Transcutaneous Vagus Electrical Nerve Stimulation (t-VNS)|Transcutaneous electrical stimulation will be delivered by trains for twenty minutes to the right cymba conchae at the ear.
62747022|NCT05289817|ACTIVE_COMPARATOR|Transcutaneous Sympathetic Ganglion Electrical Nerve Stimulation (t-SNS)|Transcutaneous electrical stimulation will be delivered continuously for twenty minutes to the cervicothoracic region.
62747023|NCT05289817|SHAM_COMPARATOR|Sham Transcutaneous Vagus Electrical Nerve stimulation (sham t-VNS)|Transcutaneous electrical stimulation will be delivered by trains for twenty minutes to the right scapha at the ear.
62553505|NCT02934399||Cushing syndrome (CS)|"Diagnosis of Cushing's syndrome by ULTRADIAN dynamic cortisol measurements The primary objective is to establish circadian and ultradian hormonal profiles of patients with Cushing's from 24 hour ambulatory sampling of subcutaneous fluid.~A secondary aim is to compare the pre and post-operative hormonal profiles of patients with Cushings and to compare these results to age/sex matched control~Study subjects: Subjects with established clinical and biochemical Cushing's syndrome (ACTH-producing pituitary adenoma or ACTH-independent adrenal source)."
62553506|NCT02934399||Adrenal insufficiency (AI)|"Monitoring of adrenal insufficiency (AI) by ULTRADIAN dynamic cortisol and ACTH measurements Aims and objectives: to compare hormonal profiles of patients with Adrenal insufficiency on conventional replacement regimes to age/sex matched controls.~Study subjects: Subjects with established primary (adrenal) AI"
62553507|NCT02934399||Congenital adrenal hyperplasia (CAH)|"Monitoring of congenital adrenal hyperplasia (CAH) by ULTRADIAN dynamic cortisol, ACTH, and androgen measurements Aims and objectives: to compare hormonal profiles of patients with CAH on conventional replacement regimes to age/sex matched controls.~Study subjects: Individuals with established CAH either salt- wasting or simple virilisation forms on glucocorticoid replacement therapy"
62747024|NCT02613468|PLACEBO_COMPARATOR|Periodontally healthy|"Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.~Intervation: Collection of periodontal records and pregnancy parameters."
62747025|NCT02613468|PLACEBO_COMPARATOR|Periodontally diseased, untreated|"This group is comprised of individuals who do not accept treatment Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit were evaluated.~Birth weight was recorded at the end of pregnancy."
62747026|NCT02613468|ACTIVE_COMPARATOR|Periodontally diseased, treated|"This group is comprised of individuals who agree to treatment. Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit were evaluated.~Initial Periodontal Therapy is completed (calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.~Birth weight was recorded at the end of pregnancy. Intervation: Collection of periodontal records and pregnancy parameters."
62747027|NCT05475665|EXPERIMENTAL|Irbesartan/Amlodipine|
62747028|NCT05475665|ACTIVE_COMPARATOR|Irbesartan|
62747029|NCT04067297|NO_INTERVENTION|Control Arm|The 14 communities that are in the control arm of the trial will receive usual standard of care. The usual standard of care will follow clinical daily practice patterns provided by family physicians in Ontario for CVD prevention. This follows the periodic standard of care provided by Canadian cholesterol, hypertension, and diabetes best practice guideline recommendations utilized based on each physician's clinical judgement, physical assessment, and discretion. Patients also typically have access to existing cardiovascular prevention materials offered online through publicly available websites.
62553508|NCT02934399||Primary hyperaldosteronism (PHA)|"Diagnosis of primary hyperaldosteronism (PHA) by ULTRADIAN dynamic aldosterone and renin measurements Aims and objectives: The primary objective is to establish circadian and ultradian profiling of free aldosterone and renin in subcutaneous tissue.~Secondary objectives are (1) to compare pre and post-operative profiles (2) to identify profiles typical for adenoma as opposed to bilateral hyperplasia and (3) to compare profiles to age/sex matched controls.~Study subjects: Subjects with suspected PHA."
62553509|NCT02934399||Growth hormone insufficiency (GHD)|"Diagnosis of growth hormone deficiency (GHD) by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal circadian and ultradian profiles of adult GHD by analysing the growth hormone profile in the subcutaneous tissue fluid.~Study subjects: Adult subjects with established clinical and biochemical GHD."
62553510|NCT02934399||Acromegaly (A)|"Diagnosis and treatment of acromegaly by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal profiles of patients with Acromegaly A secondary objective is to compare pre and post-operative profiles and to compare these profiles to age/sex matched controls.~Study subjects: Patients with established clinical and biochemical Acromegaly by current diagnostic criteria"
62553511|NCT02486237||Type 2 diabetes mellitus|Type 2 diabetes mellitus patients, no intervention is performed besides usual clinical practice
62553512|NCT01221415||Interscalene Ultrasound|Subjects having orthopedic surgery requiring an interscalene peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
62553513|NCT01221415||Interscalene Nerve Stimulator|Subjects having orthopedic surgery requiring an interscalene peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
62553514|NCT01221415||Popliteal Ultrasound|Subjects having orthopedic surgery requiring an popliteal peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
62553515|NCT01221415||Popliteal Nerve Stimulator|Subjects having orthopedic surgery requiring an popliteal peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
62553516|NCT01221415||Femoral Ultrasound|Subjects having orthopedic surgery requiring an femoral peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
62374453|NCT02339441||Methotrexate|Patients treated with Methotrexate at the entry of the study.
62374454|NCT02339441||Mycophenolate Mofetil|Patients treated with Mycophenolate Mofetil at the entry of the study.
62553517|NCT01221415||Femoral Nerve Stimulator|Subjects having orthopedic surgery requiring an femoral peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
62553518|NCT02654028|EXPERIMENTAL|Autotransfusion group|These group of patients will receive autotransfusion before liver resection.
62553519|NCT02654028|ACTIVE_COMPARATOR|Control group|These group of patients will not receive autotransfusion before liver resection.
62553520|NCT00002528|EXPERIMENTAL|Surgery w/ axillary clearance, tamox|Either a total mastectomy with axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy with radiotherapy to the conserved breast) with axillary lymph node dissection, and tamoxifen (20 mg) given after surgery for the duration of 5 years or until relapse.
62374455|NCT02339441||Cyclophosphamide|Patients treated with Cyclophosphamide at the entry of the study
62374456|NCT02339441||No Immunosuppressant|Patients without immunosuppressant treatment at the entry of the study
62374457|NCT01492738|NO_INTERVENTION|Control Group|Participants will be asked to make themselves comfortable lying on a massage table for 20 minutes.
62747030|NCT04067297|EXPERIMENTAL|Intervention Arm|The 14 communities that are in the intervention arm of the trial will receive a multicomponent intervention that provides both physicians and patients with access to a 'toolbox' of lipid management resources. The components planned for the 'toolbox' are all evidence-based interventions and chosen after consultations with Canadian family physicians and implementation science experts based on their potential for scalability to the entire population, cost and practicality. Online tools will be used and the trial will leverage pre-existing implementation initiatives (e.g., newsletters, listservs) wherever possible to minimize study costs and increase accessibility.
62747031|NCT04587414|EXPERIMENTAL|eHealth + counselling contacts|6-month eHealth physical activity intervention complemented by face-to-face and telephone counselling contacts on physical activity..
62747032|NCT04587414|EXPERIMENTAL|eHealth|6-month eHealth physical activity intervention
62553521|NCT00002528|EXPERIMENTAL|Surgery w/o axillary clearance, tamox|Either a total mastectomy without axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy with radiotherapy to the conserved breast) without axillary lymph node dissection, and tamoxifen (20 mg) given after surgery for the duration of 5 years or until relapse.
62553522|NCT04141774|ACTIVE_COMPARATOR|Passive FES|Subjects randomized to this control group will be asked to participate in a passive FES intervention or non-EEG guided muscle stimulation. Participation will include behavioral assessments, functional magnetic resonance imaging, and functional electric stimulation (FES) treatment.
62553523|NCT04141774|EXPERIMENTAL|Active FES|Subjects randomized to this experimental group will be asked to complete the active FES intervention which include EEG guided muscle stimulation. Participation will include behavioral assessments, functional magnetic resonance imaging, functional electric stimulation (FES) treatment, and EEG.
62553524|NCT04349202||Beaumont employees|Beaumont employees (employees and affiliated non-employed physicians and advanced practice providers) undergoing serology testing for SARS-CoV-2 antibodies, their immediate family members, and members of other high-risk groups.
62553525|NCT03564158|EXPERIMENTAL|meropenem 2 g- vaborbactam 2 g|Approved Dose
62553526|NCT03564158|EXPERIMENTAL|meropenem-vaborbactam (dose TBD)|Supratherapeutic Dose
62553527|NCT03564158|ACTIVE_COMPARATOR|Moxifloxacin 400 mg|Active Control
62553528|NCT03564158|PLACEBO_COMPARATOR|Normal Saline (placebo)|Placebo
62553529|NCT05688917|EXPERIMENTAL|green been extract treated group|Participants included in the study were maintained on a balanced diet and supplemented with Green Coffee Bean (Coffea Arabica) extract capsules (800 mg/capsule
62553530|NCT05688917|PLACEBO_COMPARATOR|Placebo group|Participants included in the study were maintained on a balanced diet and supplemented with placebo capsules.
62553531|NCT05292807|EXPERIMENTAL|Imaginal exposure for memories|A behavioral intervention in imagery for memories
62553532|NCT05292807|EXPERIMENTAL|Imaginal exposure for future events|A behavioral intervention in imagery for future events
62553533|NCT05292807|EXPERIMENTAL|Imagery rescripting for memories|A different behavioral intervention in imagery for memories
62553534|NCT05292807|EXPERIMENTAL|Imagery rescripting for future events|A different behavioral intervention in imagery for future events
62553535|NCT04061239|EXPERIMENTAL|CPX-351 Arm|"CPX-351 is a liposomal formulation with a fixed 5:1 molar ratio of cytarabine and daunorubicin. It will be administered as a 90-minute intravenous infusion.~The treatment includes up to 2 cycles of induction as follows:~* 1 x CPX-351 1st induction: daunorubicin 44 mg/m² and cytarabine 100 mg/m² in liposomes on days 1, 3, and 5~* 1 x CPX-351 2nd induction: daunorubicin 44 mg/m² and cytarabine 100 mg/m² in liposomes on days 1 and 3~Each induction cycle will last 28 days. Depending on the type and extent of response as well as toxicity, the patient may continue on to consolidation therapy after induction or be discontinued from the treatment phase and transferred directly to alloHCT, if applicable. CPX-351 consolidation is with daunorubicin 29 mg/m² and cytarabine 65 mg/m² in liposomes on days 1 and 3. For patients \< 60 years up to 3 consolidation cycles and for patients ≥ 60 years up to 2 consolidation cycles are allowed."
62553536|NCT04061239|OTHER|CCR Arm|"The conventional care regimens (CCR) arm has 2 options according to the discretion of the investigator:~1. conventional 7+3 cytarabine/daunorubicin chemotherapy regimen~2. treatment with s.c. Azacitidine"
62747033|NCT04587414|OTHER|Usual care|Usual care of type 2 diabetics within the primary health care setting.
62747034|NCT04368494|NO_INTERVENTION|Control|Continue with normal activity.
62747035|NCT04368494|EXPERIMENTAL|Exercise|12-weeks of home based exercise involving 30 minutes of brisk walking on 5 days per week.
62747036|NCT02511093|EXPERIMENTAL|TBC intervention|"A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:~* BP measurements;~* an educational and counselling intervention on patient adherence;~* an educational and counselling intervention on lifestyle (physical activity and diet).~Physicians adjust antihypertensive medications based on nurse and pharmacist feedback."
62747037|NCT02511093|NO_INTERVENTION|Usual care|
62553537|NCT06011447||Patients with diabetes and wound ulcers|
62747038|NCT02697227|ACTIVE_COMPARATOR|Group I (NRT, SC)|Patients receive NRT patch daily for 8 weeks. Patients receive individual behavioral treatment sessions consisting of behavioral treatment strategies for smoking cessation and health education information over 45 minutes for 8 sessions.
62553538|NCT04762472|ACTIVE_COMPARATOR|Montelukast|Montelukast 10mg daily (tablet) orally x 26 weeks
62747039|NCT02697227|ACTIVE_COMPARATOR|Group II (NRT, BATS)|Patients receive NRT patch daily for 8 weeks. Patients complete individual treatment sessions consisting of SC strategies and BA strategies over 45 minutes for 8 sessions.
62553539|NCT04762472|PLACEBO_COMPARATOR|Montelukast-matched placebo|Placebo (Montelukast identical) tablet 1 daily orally x 26 weeks
62553540|NCT02856555|EXPERIMENTAL|Firsocostat 5 mg|Participants will receive firsocostat 1 x 5 mg + 1 x placebo matched to firsocostat 5 mg + 2 x placebo matched to firsocostat 10 mg for 12 weeks.
62553541|NCT02856555|EXPERIMENTAL|Firsocostat 20 mg|Participants will receive firsocostat 2 X 10 mg + 2 x placebo matched to firsocostat 5 mg for 12 weeks.
62553542|NCT02856555|EXPERIMENTAL|Placebo|Participants will receive 2 x placebo matched to firsocostat 5 mg + 2 x placebo matched to firsocostat 10 mg for 12 weeks.
62553543|NCT03270839|ACTIVE_COMPARATOR|Responsive to Scopolamine (Active)|Scopolamine administration - subject will take 1 tablet per os (Kwells, Hyoscine Hydrobromide 0.3mg, 1\*day )
62747040|NCT01541943|EXPERIMENTAL|HL-040XC|Once daily, administered orally, 8 week
62553544|NCT03270839|PLACEBO_COMPARATOR|Responsive to Scopolamine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
62553545|NCT03270839|ACTIVE_COMPARATOR|Non-responsive to Scopolamine (Active)|Scopolamine administration - subject will take 1 tablet per os (Kwells, Hyoscine Hydrobromide 0.3mg, 1\*day )
62553546|NCT03270839|PLACEBO_COMPARATOR|Non-responsive to Scopolamine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
62553547|NCT03270839|ACTIVE_COMPARATOR|Responsive to Meclizine (Active)|Meclizine administration - subject will take 1 tablet per os (Bonine 25Mg Chewable Tablet, Meclizine Hydrochloride 25mg, 1\*day )
62553548|NCT03270839|PLACEBO_COMPARATOR|Responsive to Meclizine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
62553549|NCT03270839|ACTIVE_COMPARATOR|Non-responsive to Meclizine (Active)|Meclizine administration - subject will take 1 tablet per os (Bonine 25Mg Chewable Tablet, Meclizine Hydrochloride 25mg, 1\*day )
62553550|NCT03270839|PLACEBO_COMPARATOR|Non-responsive to Meclizine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
62553551|NCT01851083|EXPERIMENTAL|autologous bone marrow mononuclear cells|a bone marrow harvest will be performed, followed by a single intravenous infusion of autologous bone marrow mononuclear cells within 48 hours of injury.
62553552|NCT01851083|PLACEBO_COMPARATOR|placebo infusion|a sham harvest will be performed, followed by a single intravenous placebo infusion within 48 hours of injury.
62553553|NCT01289678|EXPERIMENTAL|interleukin-2|interleukin-2 therapy during lymphocyte recovery
62553554|NCT01980030|EXPERIMENTAL|Romiplostim|Weekly Romiplostim for 12 weeks with intra-patient weekly dose escalation from 1µg/Kg to a maximum dose of 10 µg/Kg with a dose reduction schema in case of platelet overshoot
62553555|NCT05854914|EXPERIMENTAL|Hypnosis video to control postoperative pain.|
62553556|NCT01491360|EXPERIMENTAL|LaserACE(R) procedure performed|The LaserACE(R) procedure (partial depth scleral micro-excisions with an Er:YAG laser in a specified pattern) will be performed.
62553557|NCT00247312|ACTIVE_COMPARATOR|125Gy prescription dose Pd-103|125Gy prescription dose Pd-103
62553558|NCT00247312|ACTIVE_COMPARATOR|110 Gy prescription dose Pd-103|110 Gy prescription dose Pd-103
62553559|NCT03314909|EXPERIMENTAL|Hemodialysis (HD)|Patients in this group would receive hemodialysis for 3 days consecutively besides conservative therapy.
62553560|NCT03314909|EXPERIMENTAL|Hemoperfusion (HP)|Patients in this group would receive hemoperfusion for 3 days consecutively besides conservative therapy.
62553561|NCT03314909|EXPERIMENTAL|HP-HD|Patients in this group would receive hemoperfusion and hemodialysis concurrent therapy for 3 days consecutively besides conservative therapy.
62553562|NCT03314909|NO_INTERVENTION|Conservative|Patients in this group would receive basic supportive treatment, gastric lavage, glucosteroid and immunosuppressive drugs without any hemopurification.
62553563|NCT06487793|EXPERIMENTAL|Enhanced Insomnia Coach Mobile App Intervention|Participants assigned to the experimental condition are asked to view the modules within the app for 8 weeks. The mobile app contains content based on cognitive behavioral therapy for insomnia (CBT-I) enhanced with content from brief alcohol interventions.
62553564|NCT06487793|ACTIVE_COMPARATOR|Sleep Hygiene Control|Participants assigned to the control condition are asked to view sleep hygiene modules delivered by email once per week for 8 weeks.
62553565|NCT02333942||Alzheimer's Disease|Nautilus NeuroWaveTM System'
62553566|NCT02333942||Mild Cognitive Impairment|Nautilus NeuroWaveTM System'
62553567|NCT02333942||Frontotemporal Lobar Degeneration|Nautilus NeuroWaveTM System'
62553568|NCT02333942||Age-Matched Controls|Nautilus NeuroWaveTM System'
62553569|NCT06134726||RA group|
62553570|NCT06134726||Control group|
62747041|NCT01541943|ACTIVE_COMPARATOR|Atorvastatin|Once daily, administered orally, 8 week
62374458|NCT01492738|ACTIVE_COMPARATOR|Acupuncture group|Acupuncture group will receive one acupuncture treatment for twenty minutes.
62553571|NCT00580788|EXPERIMENTAL|PTHrP(1-36) 2 pmol/kg/hr|PTHrP(1-36) at 2 picomoles/kg/hr for one week.
62553572|NCT00580788|EXPERIMENTAL|PTHrP (1-36) 4 pmol/kg/hr|PTHrP(1-36) at 4 picomoles/kg/hr for one week.
62553573|NCT00580788|EXPERIMENTAL|PTHrP(1-36) 5 pmol/kg/hr|PTHrP(1-36) at 5 picomoles/kg/hr for one week.
62553574|NCT00580788|EXPERIMENTAL|PTHrP(1-36) 6 pmol/kg/hr|PTHrP(1-36) at 6 picomoles/kg/hr for one week.
62553575|NCT06132373|EXPERIMENTAL|Single arm study|We will apply evidence-based Problem Solving Therapy (PST), a transdiagnostic, low-intensity approach shown to improve mental health problems among adolescents with demonstrated effectiveness in global settings. PST for adolescents is a brief 5 session individual treatment with demonstrated efficacy when delivered by lay providers. PST is theorized to function by increasing adolescent capacity to cope with perceived and experienced stress through the use of problem- and emotion- focused coping skills that then allow engagement in positive, healthy activities.
62553576|NCT05606406|ACTIVE_COMPARATOR|Healthy Control Group|Individuals without lung disease will receive oxygen for a period of four hours
62553577|NCT05606406|ACTIVE_COMPARATOR|Nocturnal hypoxemia group|Individuals with lung disease will receive oxygen for a period of four hours
62553578|NCT00124917|EXPERIMENTAL|Radiation Therapy|Radiation to tumor area as per protocol
62553579|NCT04190121|EXPERIMENTAL|GROUP A|
62553580|NCT04190121|NO_INTERVENTION|GROUP B|
62553581|NCT01622829|EXPERIMENTAL|group1|"Usual Physiotherapy, additional: Prescription for Activity with a structured fitness program and individual instructions to become more active in the daily living situation"
62553582|NCT01622829|EXPERIMENTAL|group 2|"usual Physiotherapy , additional: Prescription for Activity without instructions"
62747042|NCT01541943|ACTIVE_COMPARATOR|Losartan|Once daily, administered orally, 8 week
62747043|NCT01541943|PLACEBO_COMPARATOR|Placebo|Once daily, administered orally, 8 week
62747044|NCT00960011|EXPERIMENTAL|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
62747045|NCT00960011|ACTIVE_COMPARATOR|POLYPROPYLENE|Use of Polypropylene mesh for open inguinal hernia repair
62747046|NCT06108726|EXPERIMENTAL|envafolimab plus chemotherapy|Local injection of Envafolimab 5mg/kg plus platinum-based chemotherapy under fiberoptic bronchoscopy, Q2W.
62747047|NCT00978380|EXPERIMENTAL|A|
62553583|NCT01622829|NO_INTERVENTION|group 3|control, usual physiotherapy
62553584|NCT06486870|EXPERIMENTAL|gonadotropin|Human menopausal gonadotrophin (hMG) is given starting on cycle day three in a dose of 75 IU alternate days. The aim of treatment is to achieve mono-ovulation. Monitoring of treatment is achieved by serial transvaginal ultrasound scanning every other day starting from cycle day nine. Size and number of follicles is recorded in patients follow up sheets. The dose of hMG is reviewed around stimulation day 10 and if follicular development is unsatisfactory, the dose is increased to 75 IU daily .If a good response is not achieved day16 ; the cycle is cancelled. A new cycle is commenced with a higher starting dose of hMG (75 IU per day). When one follicle reached a size of \> =18 mm a single dose of 10,000 IU human chorionic gonadotrophin (hCG, Pregnyl, Epifasi, Choriomon) is given.
62747048|NCT02589652||Switch group|Patients who have been assigned to pegylated interferon alfa-2a.
62747049|NCT02589652||Sequential combination group (S-C group)|Patients who have been assigned to pegylated interferon alfa-2a plus entecavir.
62747050|NCT02589652||ETV group|Patients who have been assigned to entecavir monotherapy.
62747051|NCT02429557|EXPERIMENTAL|Abdominal compression and placebo pill|Abdominal compression with an inflatable abdominal binder (up to 40 mmHg) during head up tilt, and placebo pill given 1 hour before the second head up tilt
62747052|NCT02429557|SHAM_COMPARATOR|Sham abdominal compression and placebo|Sham abdominal compression with an inflatable abdominal binder (\~5 mmHg) during head up tilt, and placebo pill given 1 hour before the second head up tilt
62747053|NCT02429557|EXPERIMENTAL|Abdominal compression and midodrine|Abdominal compression with an inflatable abdominal binder (up to 40 mmHg) during head up tilt, and midodrine 2.5-10 mg PO given 1 hour before the second head up tilt
62374459|NCT03616470|EXPERIMENTAL|Uproleselan (GMI-1271)|Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)
62374460|NCT03616470|PLACEBO_COMPARATOR|Placebo (Saline, 0.9% Sodium Chloride)|Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)
62374461|NCT03669107|EXPERIMENTAL|Gum chewing|"Gum type was standardized with all subjects receiving sugar-free peppermint-flavored gum.~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (one stick) 3 times daily in the morning, afternoon, and evening at 30 min. The administration of the therapy was implemented by ward nursing staff and recorded in the patients file. All gum-chewing patients completed their course of gum chewing until bowel function."
62553585|NCT06486870|EXPERIMENTAL|letrozole|: 5 mg LE oral tablets are administered on the fifth day of menses and then every day for 5 days. Treatment is repeated for up to six cycles
62553586|NCT06486870|EXPERIMENTAL|unilateral laparoscopic ovarian drilling|"Laparoscopic ovarian drilling will be done according to the following:~Electrocautery using a mixed current in monopolar electrosurgical needle will be into introduced through the ovarian ipsilateral parts and applied up to 4 point cauterisation of the ovarian capsule, each for 4 second, at 40 W and for a diameter of 3mm and a depth of 4 mm in the antimesentric surface . (Amer et al 2003, Sawant S et al 2019) ,the procedure will be applied for one ovary .~The patient under the study will be followed up to six months of continuous marital life after the procedure"
62747054|NCT02429557|ACTIVE_COMPARATOR|Sham abdominal compression and midodrine|Sham abdominal compression with an inflatable abdominal binder (\~5 mmHg) during head up tilt, and midodrine 2.5-10mg PO given 1 hour before the second head up tilt
62747055|NCT06094218|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|TAU may include (1) routine suicide risk screening and assessment; (2) safety planning with means restriction; and (3) the Collaborative Assessment and Management of Suicidality (CAMS), an evidence-based approach to managing and treating suicidal patients.
62747056|NCT06094218|EXPERIMENTAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT consists of 12 outpatient individual psychotherapy sessions scheduled weekly or biweekly. The first session is 90 minutes and subsequent sessions are 60 minutes. BCBT is divided into three phases. In phase 1 (5 sessions), the therapist conducts a detailed assessment of the patient's most recent suicidal episode or suicide attempt, identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase 2 (5 sessions), the therapist teaches cognitive restructuring skills to build cognitive flexibility. In phase 3 (2 sessions), a relapse prevention task is conducted, and participants must demonstrate the ability to successfully complete this task in order to terminate the treatment. Additional sessions are conducted until participants demonstrate the ability to successfully complete this task.
62747057|NCT04049266|EXPERIMENTAL|KSI-301 5 mg|"Drug: KSI-301 5 mg. KSI-301 5 mg will be administered by intravitreal injection into the study eye at 12, 16, and 20 weeks intervals as specified in the study protocol.~Drug: Sham Procedure. The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking."
62747058|NCT04049266|ACTIVE_COMPARATOR|Aflibercept 2 mg|"Drug: Aflibercept 2 mg. Aflibercept 2 mg will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks.~Drug: Sham Procedure. The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking."
62747059|NCT02954406|EXPERIMENTAL|Dose Escalation Phase Cohort A: TAK-659 60 mg + Bendamustine 90 mg/m^2|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m\^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 in a 21-day treatment cycle, for up to 8 cycles. Participants continued to receive TAK-659 monotherapy until they experienced progressive disease (PD) or unacceptable toxicities or up to 39 cycles.
62374462|NCT03669107|NO_INTERVENTION|Control group|no gum
62374463|NCT00004889|EXPERIMENTAL|Rituxan|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
62553587|NCT03028116|ACTIVE_COMPARATOR|Allantoic split inactivated seasonal influenza vaccine|Allantoic split inactivated seasonal influenza vaccine
62747060|NCT02954406|EXPERIMENTAL|Dose Escalation Phase Cohort A: TAK-659 80 mg + Bendamustine 90 mg/m^2|TAK-659 80 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m\^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 was escalated to 80 mg once daily after safety and tolerability of 60 mg dose was determined. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 39 cycles.
62747061|NCT02954406|EXPERIMENTAL|Dose Escalation Phase Cohort A: TAK-659 100 mg + Bendamustine 90 mg/m^2|TAK-659 100 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine mg/m\^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 was escalated to 100 mg once daily after safety and tolerability of 60 mg dose was determined. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 39 cycles.
62747062|NCT02954406|EXPERIMENTAL|Dose Escalation Phase Cohort B: TAK-659 60 mg + Bendamustine 90 mg/m^2 + Rituximab 375 mg/m^2|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m\^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 along with rituximab 375 mg/m\^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 12 cycles.
62553588|NCT03028116|PLACEBO_COMPARATOR|Placebo|Water for Injection
62553589|NCT01935830|EXPERIMENTAL|LAAM arm|"1. \[11C\]LAAM 15-20 mCi (maximum administered mass of 10 ug)~2. Efavirenz, oral capsules, 600 mg~3. Ritonavir, oral capsules, 100 mg"
62553590|NCT02890602|EXPERIMENTAL|Darbepoietin alfa|Hemoglobin level will be checked at every cycle's day 0 or 1(1cycle is 21days) after starting Darbepoietin alfa. It will be applied to chemotherapy until increment of hemoglobin 12.0 g/dL.
62553591|NCT01586507|EXPERIMENTAL|Group 1|
62553592|NCT01586507|EXPERIMENTAL|Group 2|
62553593|NCT05516186|EXPERIMENTAL|Scapular-focused exercise protocol supported by real-time EMGBF|The scapular-focused exercise protocol followed the protocol described by dos Santos et al. (2021). The protocol uses sequential stages of motor relearning (cognitive, associative, and autonomous) as a framework, while promoting the integration of local and global muscle function in weekly sessions divided into three phases. The main purpose of the protocol is to increase scapular neuromuscular activity and control.
62553594|NCT05516186|EXPERIMENTAL|Scapular-focused exercise protocol without EMGBF|The same protocol described above was applied without EMGBF
62553595|NCT05516186|OTHER|Control therapy group|The control therapy group underwent conservative physical therapy, which included both manual and exercise therapy
62553596|NCT01111955|ACTIVE_COMPARATOR|BMS-823778 (2 mg)|+ metformin
62553597|NCT01111955|ACTIVE_COMPARATOR|BMS-823778 (10 mg)|+ metformin
62553598|NCT01111955|ACTIVE_COMPARATOR|BMS-823778 (20 mg)|+ metformin
62553599|NCT01111955|PLACEBO_COMPARATOR|Placebo|+ metformin
62553600|NCT02898376|EXPERIMENTAL|combination tocopherol/pentoxifylline + spa care|pentoxifylline (400 mg bid) + tocopherol (500 mg x bid) during at least 6 months AND skin-oriented spa care (18 days)
62553601|NCT02898376|ACTIVE_COMPARATOR|combination tocopherol/pentoxifylline|pentoxifylline (400 mg bid) + tocopherol (500 mg x bid) during at least 6 months
62553602|NCT00017095|ACTIVE_COMPARATOR|non taxane based chemotherapy|either FEC 100 or Canadian CEF or Tailored FEC for 6 cycles
62553603|NCT00017095|EXPERIMENTAL|taxane based chemotherapy|Docetaxel for 3 cycles followed by Epirubicin/Docetaxel for 3 cycles
62553604|NCT04940572|EXPERIMENTAL|Depakine (VPA)|"Depakine Chrono 500 mg (VPA)~VPA will be administered orally:~* From D1 to D3: During the first week 10-15 mg sodium valproate/kg bodyweight per day will be taken daily.~* From D3 to W156: The dose will be increased every 3 days in steps of 10 mg sodium valproate/kg bodyweight per day with VPA plasma concentration monitoring until the total daily dose corresponding to the optimal plasma level between 40 and 100 mg/l (ie, 300 to 700 micromol/l) is reached, till the 156 weeks corresponding to the end of treatment (EOT) visit.~The total daily dose will be taken in one or two doses during meals."
62553605|NCT00699426|ACTIVE_COMPARATOR|Nexium + Yoghurt|
62553606|NCT00699426|PLACEBO_COMPARATOR|Nexium + Placebo|
62553607|NCT00699426|PLACEBO_COMPARATOR|Placebo+ Yoghurt|
62553608|NCT00699426|PLACEBO_COMPARATOR|placebo+placebo|
62553609|NCT04579900|EXPERIMENTAL|Type 2 Diabetes patients|Upper gut biopsies and lower gut samples
62553610|NCT04579900|ACTIVE_COMPARATOR|Non Type 2 Diabetes patients|Upper gut biopsies and lower gut samples
62553611|NCT00795262|PLACEBO_COMPARATOR|placebo comparator|Quinapril 40 mg (Accupril)plus placebo will be given for 8 weeks.
62553612|NCT00795262|ACTIVE_COMPARATOR|Active comparator|Quinapril 40 mg plus Alpha Lipoic Acid (ALA)on vascular effects of patients with diabetes and hypertension
62553613|NCT03732430|EXPERIMENTAL|Anti-PD-1 antibody|IBI308 200mg intravenous drip every three weeks following adaptive radiation therapy.
62553614|NCT01207583||healthy children after vaccination|healthy children after vaccination
62553615|NCT05212077|EXPERIMENTAL|Advanced Care at Home (ACH)|Patients will receive inpatient hospitalization at home.
62553616|NCT05212077|ACTIVE_COMPARATOR|Traditional Inpatient (Brick-and-Mortar) Hospital Care|Patients will receive inpatient hospitalization at the hospital.
62553617|NCT02304393|EXPERIMENTAL|Part IA: Selicrelumab (IV) + Atezolizumab|Selicrelumab at a dose of 16 milligrams (mg) will be administered intravenously (IV) on Day 1 of Cycle 1 (first cycle in this group was of 42 days, and subsequent 21-day cycles); and atezolizumab 1200 mg will be administered IV after 6 weeks on Day 1 of Cycle 2, followed by every 3 weeks during Part IA until disease progression, death, loss of follow-up, or withdrawal of consent.
62747063|NCT02954406|EXPERIMENTAL|Dose Escalation Phase Cohort B: TAK-659 80 mg + Bendamustine 90 mg/m^2 + Rituximab 375 mg/m^2|TAK-659 80 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m\^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 along with rituximab 375 mg/m\^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 was escalated to 80 mg once daily after safety and tolerability of 60 mg dose was determined. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 12 cycles.
62747064|NCT02954406|EXPERIMENTAL|Dose Escalation Phase Cohort B: TAK-659 100 mg + Bendamustine 90 mg/m^2 + Rituximab 375 mg/m^2|TAK-659 100 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m\^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 along with rituximab 375 mg/m\^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 was escalated to 100 mg once daily after safety and tolerability of 60 mg dose was determined. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 12 cycles.
62553618|NCT02304393|EXPERIMENTAL|Part IA: Selicrelumab(SC) + Atezolizumab|Selicrelumab at a starting dose of 1 mg will be administered subcutaneously (SC) on Day 1 of Cycle 1 (21-day cycle) which will follow escalation in sequential cohorts; and atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 2, and followed by every 3 weeks during Part IA as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
62553619|NCT02304393|EXPERIMENTAL|Part IB: Selicrelumab + Atezolizumab|Selicrelumab will be administered at a starting dose of 1 mg SC on Day 2 of Cycle 1 (21-day cycle) which will follow escalation in sequential cohorts; and atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 1, and followed by every 3 weeks during Part IB as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
62553620|NCT02304393|EXPERIMENTAL|Part II: Selicrelumab + Atezolizumab|Atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 1, and followed by every 3 weeks; and Selicrelumab will be administered at the dose defined in Part IB (not exceeding 80 mg SC \[unless IV administration in Part IB demonstrates better benefit/risk ratio\]) on Day 2 (1 day after atezolizumab administration) of every second cycle from Cycles 1 to 7, and every fourth cycle thereafter during Part II as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
62553621|NCT05513833|OTHER|Sequence 1|"Standard School Screening: All counties in Sequence 1 will receive standard hearing screening in the control period, Year 1~Standard Referral: All counties in Sequence 1 will receive standard referral in control period, Years 1 and 2.~Enhanced mHealth screening component: Counties randomized to Sequence 1 will receive the enhanced mHealth screening in Years 2, 3, and 4.~Specialty telemedicine referral component: Counties randomized to Sequence 1 will receive the specialty telemedicine referral component in addition to the enhanced mHealth screening in Years 3 and 4."
62553622|NCT05513833|OTHER|Sequence 2|"Standard Hearing Screening: All counties in Sequence 2 will receive standard hearing screening in the control period, Years 1 and 2~Standard Referral: All counties in Sequence 2 will receive standard referral in control period, Years 1, 2 and 3.~Enhanced mHealth screening component: Counties randomized to Sequence 2 will receive the enhanced mHealth screening in Years 3 and 4.~Specialty telemedicine referral component: Counties randomized to Sequence 2 will receive the specialty telemedicine referral component in addition to the enhanced mHealth screening in Year 4."
62553623|NCT06449976|EXPERIMENTAL|Blue Light 0D Defocus Group|This is the group that performs visual evoked tasks using videos and texts that are not defocused in the blue channel. In this group, the impact of standard video modes on the axial length of the eye, refractive fatigue, and visual function is assessed, including but not limited to indicators such as reading efficiency, blinking detection, and retinal fundus blood flow.
62374464|NCT05990140|EXPERIMENTAL|Experimental|"Consent of all patients will be obtained the night before surgery. Biochemical parameter levels and state trait anxiety scale and apfel risk scale will be recorded.~As it will be difficult for the experimental group to be oriented while giving mouthwash training after the surgery, mouthwash training will be given at a time when it is available the night before the operation. State anxiety scale, visual comparison scale and nausea and vomiting effect scale will be administered before discharge (approximately 48 hours). After discharge, he will continue to gargle in the same way 3 times a day. At the end of the first week, all patients will be called by the researcher and the state anxiety scale, visual comparison scale and nausea and vomiting effect scale shared on the digital environment will be filled and recorded. This process will continue for 4 weeks. In the last measurement, visual comparison scale, nausea vomiting and state trait anxiety scale will also be filled."
62374465|NCT05990140|NO_INTERVENTION|Control|"Consent of all patients will be obtained the night before surgery. Biochemical parameter levels and state trait anxiety scale and apfel risk scale will be recorded.~The state anxiety scale, visual comparison scale and nausea and vomiting effect scale will be administered to the control group before they are discharged (approximately at the 48th hour). At the end of the first week, all patients will be called by the researcher, and the state anxiety scale, visual comparison scale and nausea and vomiting effect scale will be filled and recorded. This process will continue for 4 weeks. In the last measurement, visual comparison scale, nausea vomiting and state trait anxiety scale will also be filled. At the end of the first month, the biochemical parameters taken during the routine hospital control will be recorded."
62374466|NCT02111954||F-18-FCH & Ga-68-NODAGA-MJ9|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9
62374467|NCT05135182|EXPERIMENTAL|furazolidone-tetracycline-containing quadruple|patients in furazolidone-tetracycline-containing quadruple group will receive vonoprazan fumarate 20mg po bid, tetracycline 500mg po qid , bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone 100mg po bid for 14d
62747065|NCT02954406|EXPERIMENTAL|Dose Escalation Phase Cohort C: TAK-659 60 mg + Gemcitabine 1000 mg/m^2|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with gemcitabine 1000 mg/m\^2, infusion, intravenously, over 30 minutes on Days 1 and 8 in a 21-day treatment cycle. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 2 cycles.
62747066|NCT02954406|EXPERIMENTAL|Dose Escalation Phase Cohort D: TAK-659 40 mg + Lenalidomide 25 mg|TAK-659 40 mg, immediate-release tablet, orally, once daily on Days 1 to 28 along with lenalidomide 25 mg, capsules orally, once daily on Days 1 to 21 in a 28-day treatment cycle. The TAK-659 60 mg dose was de-escalated to 40 mg in case of dose limiting toxicity or if the starting dose was determined to be not tolerable. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 26 cycles.
62747067|NCT02954406|EXPERIMENTAL|Dose Escalation Phase Cohort D: TAK-659 60 mg + Lenalidomide 25 mg|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 28 along with lenalidomide 25 mg, capsules orally, once daily on Days 1 to 21 in a 28-day treatment cycle. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 26 cycles.
62553624|NCT06449976|EXPERIMENTAL|Blue Light 1D Defocus Group|Group using blue channel defocused 1D videos and texts for visual evoked tasks. Participants will engage in a 50-minute visual evoked task using videos and texts processed with 1D blue channel. The impact of standard video mode on axial length of the eye, refractive labor, and visual function will be assessed, including but not limited to indicators such as reading efficiency, blinking detection, and retinal fundus blood flow.
62553625|NCT06449976|EXPERIMENTAL|Blue Light 2D Defocus Group|The group uses blue channel defocused 2D videos and texts for visual evoked tasks. Participants will undergo a 50-minute visual evoked task using videos and texts processed with the 2D blue channel. The effects of standard video mode on the eye's axial length, refractive labor, and visual function are assessed, including but not limited to indicators such as reading efficiency, blinking detection, and retinal fundus blood flow.
62553626|NCT06449976|EXPERIMENTAL|Blue Light 1D Defocus with Partial Filtration Group|The group uses videos and texts processed with the blue channel 1D defocus and 30% blue light filtering for visual evoked tasks. Participants will engage in a 50-minute visual evoked task using videos and texts that have been processed with the 1D blue channel and partially filtered for blue light. The impact of the standard video mode on the eye's axial length, refractive labor, and visual function is evaluated, including but not limited to indicators such as reading efficiency, blinking detection, and retinal fundus blood flow.
62553627|NCT04447040|EXPERIMENTAL|Acetaminophen/naproxen sodium Dose A|Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
62553628|NCT04447040|EXPERIMENTAL|Acetaminophen/naproxen sodium Dose B|Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
62553629|NCT04447040|EXPERIMENTAL|Acetaminophen/naproxen sodium Dose C|Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
62553630|NCT04447040|EXPERIMENTAL|Acetaminophen/naproxen sodium Dose D|Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
62553631|NCT04447040|EXPERIMENTAL|Acetaminophen/naproxen sodium Dose E|Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.
62553632|NCT04447040|PLACEBO_COMPARATOR|Placebo|Placebo tablets administered as a single two-tablet dose.
62553633|NCT04108286|EXPERIMENTAL|TEST/CONTROL|Eligible subjects that are habitual wearers of spherical soft contact lenses will be randomly assigned to 1 of 2 contralateral lens sequences (Right: TEST/ Left: CONTROL) or (Right: CONTROL/ Left: TEST).
62553634|NCT04108286|EXPERIMENTAL|CONTROL/TEST|Eligible subjects that are habitual wearers of spherical soft contact lenses will be randomly assigned to 1 of 2 contralateral lens sequences (Right: TEST/ Left: CONTROL) or (Right: CONTROL/ Left: TEST).
62553635|NCT00725491|EXPERIMENTAL|1|ganirelix
62553636|NCT00725491|ACTIVE_COMPARATOR|2|triptorelin
62553637|NCT03234543|EXPERIMENTAL|Remote Ischemic Conditioning|The RIC intervention consists of 5 minutes of inflation of a pneumatic tourniquet placed mid-thigh followed by 5 minutes of deflation, repeated for 3 cycles. The pressure used will be 250 mmHg for the pre-operative intervention. Subsequent tourniquet pressures will be 50 mmHg above the patient's systolic blood pressure.
62553638|NCT03234543|SHAM_COMPARATOR|No Remote Ischemic Conditioning|The No RIC group will receive a sham intervention at all the same time points. The thigh tourniquet will be inflated to only 20 mmHg (to mask the intervention from the subject).
62553639|NCT02952469|EXPERIMENTAL|(68Ga)PSMA-HBED-CC|Intervention: positron emission tomography / computed tomography (PET/CT) scan using a experimental radiotracer for imaging prostate-specific membrane antigen
62553640|NCT01195610|EXPERIMENTAL|New Nordic Diet|New Nordic Diet
62553641|NCT01195610|EXPERIMENTAL|Average Danish Diet|Average Danish Diet
62553642|NCT02223988|EXPERIMENTAL|subglottic secretion drainage|
62553643|NCT01104623||ADHD - Patients|Adults (18-50 years old). All eligible subjects will experience the voice recording procedure followed by the assessment of adult ADHD diagnostics. The diagnostic guidelines for ADHD in adulthood will be accomplished as outlined by expert consensus of the German Society for Psychiatry, Psychotherapy and Neurology, with a semi-structured clinical interview following the DSM-IV-TR criteria and the ADHD-Checklist (ADHD-CL) for DSM-IV (Hesslinger et al., 2002) to assess the severity of ADHD-Symptoms. Childhood ADHD symptoms will be rated retrospectively amongst others by using the short version (WURS-k) of the Wender Utah Rating Scale (Ward et al., 1993), German version (Retz-Junginger et al., 2002). To strengthen the validity of the ADHD diagnosis the reported symptoms were corroborated by second party reports.
62553644|NCT01104623||Healthy Controls|Adults(18-50 years old). All eligible subjects will experience the voice recording procedure followed by the ADHD-Checklist (ADHD-CL) for DSM-IV (Hesslinger et al., 2002. To assess the severity of Non-ADHD, the absence of childhood ADHD symptoms will be rated retrospectively amongst others by using the short version (WURS-k) of the Wender Utah Rating Scale (Ward et al., 1993), German version (Retz-Junginger et al., 2002).
62747068|NCT02954406|EXPERIMENTAL|Dose Escalation Phase Cohort E: TAK-659 60 mg + Ibrutinib 560 mg|TAK-659 60 mg, immediate-release tablet, orally, once daily along with ibrutinib 560 mg capsules, orally, once daily on Days 1 to 28 in a 28-day treatment cycle. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 3 cycles.
62747069|NCT02954406|EXPERIMENTAL|Safety Expansion Phase Cohort B: TAK-659 + Bendamustine 90 mg/m^2 + Rituximab 375 mg/m^2|TAK-659 immediate-release tablet, at the MTD/maximally administered dose (MAD)/RP2D determined from Dose Escalation Phase, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m\^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 along with rituximab 375 mg/m\^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles in participants (who were to be entered in Phase 2) with advanced FL or MZL. Treatment could then be continued until they experienced PD or unacceptable toxicities or up to 12 cycles in participants who were to be enrolled in the Safety Expansion Phase Cohort.
62747070|NCT04956315||Examiner effect group|Two examiners performed the test on one healthy subject with both devices for ten consecutive days. We measured the AD of both knees and calculated the ADD of every test. We evaluated the contralateral-side effect by comparing the AD standard deviations of each knee with both devices, and compared the average ADD tested by different examiners with the same device, to estimate examiner effect.
62553645|NCT06499532|EXPERIMENTAL|Gow-gates anesthesia, distance to inferior alveolar nerve is more than 1 mm|The extraction of impacted wisdom teeth in patients forming this study arm was performed using the Gow-Gates anesthesia technique. In these patients, the distance between the wisdom teeth and the inferior alveolar nerve is greater than 1 mm.
62553646|NCT06499532|EXPERIMENTAL|Gow-gates anesthesia, distance to inferior alveolar nerve is less than 1 mm|The extraction of impacted wisdom teeth in patients forming this study arm was performed using the Gow-Gates anesthesia technique. In these patients, the distance between the wisdom teeth and the inferior alveolar nerve is less than 1 mm.
62553647|NCT06499532|EXPERIMENTAL|İnferior alveoler nerve block,distance to inferior alveolar nerve is more than 1 mm|The extraction of impacted wisdom teeth in patients forming this study arm was performed using the inferior alveolar nerve block technique and supplemental anesthesia (buccal- mylohyoid). In these patients, the distance between the wisdom teeth and the inferior alveolar nerve is greater than 1 mm.
62553648|NCT06499532|EXPERIMENTAL|İnferior alveoler nerve block, distance to inferior alveolar nerve is less than 1 mm|The extraction of impacted wisdom teeth in patients forming this study arm was performed using the inferior alveolar nerve block technique and supplemental anesthesia (buccal- mylohyoid). In these patients, the distance between the wisdom teeth and the inferior alveolar nerve is less than 1 mm.
62747071|NCT04956315||Method effect group|The experienced examiner performed tests on 20 healthy subjects using both devices. The means and standard deviations of both knees were calculated. We examined the difference in measurements using each device to determine the method effect.
62747072|NCT04956315||Equipment effectiveness group|The experienced examiner performed tests on 200 ACL ruptureand 200 healthy subjects using each device. Effectiveness was analyzed using 1.5 mm and 3 mm threshold values in ACL tears.
62747073|NCT03350256|EXPERIMENTAL|Microdosing group|Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
62747074|NCT00926419|EXPERIMENTAL|Varicella (1/5 dose) - ID - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
62553649|NCT00054405|EXPERIMENTAL|Treatment (IL-12, aldesleukin)|"Cohort A: Patients receive interleukin-12 (IL-12) IV over 5-15 seconds on days 1, 3, 5, 8, 10, and 12.~Cohort B: Patients receive interleukin-2 (IL-2) IV over 15 minutes twice daily on days 1 and 8 and IL-12 IV as in cohort A.~Treatment in both cohorts repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Some patients may receive additional courses at the discretion of the principal investigator.~Cohorts of 3-6 patients in both cohorts receive escalating doses of IL-2 and IL-12 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Once the MTD is determined, an additional cohort of 8 patients receives IL-12 and IL-2 at the MTD."
62553650|NCT04384094||Test subjects|Test subjects according to the inclusion / exclusion criterias.
62553651|NCT00819663||Crohns patients|Established Crohn's disease patients who underwent CTE imaging before and after initiating infliximab therapy
62553652|NCT01090414|EXPERIMENTAL|Idelalisib|Participants will receive up to 350 mg of idelalisib twice daily until disease progression or unacceptable toxicity.
62374468|NCT05135182|ACTIVE_COMPARATOR|metronidazole-tetracycline-containing quadruple group|patients in metronidazole-tetracycline-containing quadruple group will receive vonoprazan fumarate 20mg po bid,tetracycline 500mg po qid , bismuth potassium citrate(Lizhudele) 220mg po bid, and metronidazole 400mg po qid for 14d.
62374469|NCT03973567|EXPERIMENTAL|refractory FD patients using antidepressants|Sixty FD patients who met the criteria were selected as the experimental group after more than two kinds of treatment, including acid-making, proton pump inhibitors (PPI), motivation and anti-Helicobacter pylori（HP） treatment, including 30 in the conventional treatment group and 30 in the combined antidepressant treatment group.
62374470|NCT03973567|PLACEBO_COMPARATOR|refractory FD patienTS using conventional treatment|Sixty FD patients who met the criteria were selected as the experimental group after more than two kinds of treatment, including acid-making, PPI, motivation and anti-HP treatment, including 30 in the conventional treatment group and 30 in the combined antidepressant treatment group.
62374471|NCT03973567|NO_INTERVENTION|normal control|Age, sex and education matched, right-handed 30 normal people.
62374472|NCT06361706|EXPERIMENTAL|VR-Enhanced Chronic Pain Management Program|Participants in this arm will undergo a comprehensive psychoeducational program tailored for chronic pain and central sensitization management, significantly enhanced with Virtual Reality (VR) experiences.
62374473|NCT02587104|EXPERIMENTAL|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
62553653|NCT05857683|ACTIVE_COMPARATOR|extension pin block|this is the technique for mallet finger where 2 pins are used, one for the extension block and other intramedullary for the extension posture
62374474|NCT06388356|EXPERIMENTAL|Intervention group|Receives the educational intervention
62374475|NCT06388356|NO_INTERVENTION|control group|The comparison group will not perform the educational intervention and will continue to work as normal standard according to their own organization's instructions.
62374476|NCT03266367||patients|NGAL and renal functions will be measured two hours after Percutaneous coronary intervention and two days later as a follow up
62374477|NCT03266367||Healthy Group|control group
62747075|NCT00926419|EXPERIMENTAL|Varicella (1/5 dose) - ID - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
62747076|NCT00926419|EXPERIMENTAL|Varicella (2/5 dose) - ID - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.25 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
62747077|NCT00926419|EXPERIMENTAL|Varicella (2/5 dose) - ID - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.25 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
62747078|NCT00926419|ACTIVE_COMPARATOR|Varicella (full dose) - SC - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.5 ml Subcutaneous administration with Disposable Needle-free Syringe Jet Injector
62747079|NCT00926419|ACTIVE_COMPARATOR|Varicella (full dose) - SC - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.5 ml Subcutaneous administration with Disposable Needle Syringe
62553654|NCT05857683|ACTIVE_COMPARATOR|pin orthosis- extension block pin|this is the technique for mallet finger where only 1 pin is used for extension block and an orthosis is applied for the extension posture
62553655|NCT05416840|EXPERIMENTAL|Clonidine|Patients will receive clonidine controlled-release patch (2.5 mg), once a week
62747080|NCT00926419|EXPERIMENTAL|Hepatitis A (1/5 dose) ID - Injector|Hepatitis A virus vaccine, inactivated, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
62747081|NCT00926419|EXPERIMENTAL|Hepatitis A (1/5 dose) ID - Syringe|Hepatitis A virus vaccine, inactivated, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
62747082|NCT00926419|ACTIVE_COMPARATOR|Hepatitis A (full dose) IM - Injector|Hepatitis A virus vaccine, inactivated, Single dose, 0.5 ml Intramuscular administration with Disposable Needle-free Syringe Jet Injector
62747083|NCT00926419|ACTIVE_COMPARATOR|Hepatitis A (full dose) IM - Syringe|Hepatitis A virus vaccine, inactivated, Single dose, 0.5 ml Intramuscular administration with Disposable Needle Syringe
62747084|NCT04957992|ACTIVE_COMPARATOR|Control Feeding Group|Milk based product
62747085|NCT04957992|EXPERIMENTAL|Experimental Feeding Group|Milk based product with oligosaccharides
62747086|NCT04957992|OTHER|Human Milk Reference Group|Human Milk
62747087|NCT01242696||Coronary artery stenting|All subjects who are candidates for coronary artery stenting, signed the Informed Consent Form and are eligible to receive a TAXUS Element stent will be evaluated for enrollment in this study.
62747088|NCT06058247|EXPERIMENTAL|Active nutritional supplementation|The participants in active nutritional supplementation arm received nutritional support targeting specific protein (over 1.5 g/kg/day) and calorie intake (over 20 kcal/kg/day), with consultation from the nutritional support team and the initiation of nutritional supplementation on the same day as intensive care unit admission.
62747089|NCT06058247|EXPERIMENTAL|Conventional nutritional supplementation|The participants in conventional nutritional supplementation arm underwent conventional nutrition management without specific protein or caloric targets.
62747090|NCT03695614|EXPERIMENTAL|Cognitive Remediation|CR is a form of group therapy that uses a hybrid approach of restorative and strategy based methods to improve areas of cognition (ie. attention, memory, processing speed and learning) through the use of computerized exercises. CR is administered in groups consisting of 2-8 participants and one or two therapists. The CR groups meet twice per week for two hours per session over twelve weeks, for a total of 24 sessions.
62374478|NCT03824457|EXPERIMENTAL|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours). The period of the treatment with the study drug lasts 3 days.
62374479|NCT03824457|ACTIVE_COMPARATOR|Ringer lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
62747091|NCT05495841||Face Mask Alone|40 patients receiving the pre-oxygenation face mask alone method during clinical routine will be studied. As per clinical standard, the standard oxygen facemask will be tightly applied on the face of the patient at 100% FiO2 for 3 to 4 minutes. In case of suspected full stomach, it is recommended to perform a rapid sequence induction and the patient does not receive bag-mask ventilation during the apnea period (45-60s). In the other case, a standard pre-oxygenation will be performed (see figure 1: experimental design of the study).
62374480|NCT05203744|EXPERIMENTAL|Standard Dose (200 mg)|Participants will receive the standard 200 mg tafenoquine dose (200 mg daily for 3 days) followed by 200 mg weekly for two weeks to check for tolerability and adverse effects.
62374481|NCT05203744|EXPERIMENTAL|Low Monthly Dose (600 mg)|"The same participants from Part 1 will be administered a monthly dose of tafenoquine (600 mg total, given as 300 mg split over 2 days) for two consecutive months. This monthly dose of 600 mg tafenoquine is designated the low monthly tafenoquine dose."
62374482|NCT05203744|EXPERIMENTAL|High Monthly Dose (800 mg)|The same participants from Parts 1 and 2 will be administered a monthly dose of tafenoquine (800 mg total, given as 400 mg split over 2 days) for two consecutive months. This monthly dose of 800 mg tafenoquine is designated the high monthly tafenoquine dose
62553656|NCT05416840|ACTIVE_COMPARATOR|Amlodipine|Patients will receive amlodipine (5 mg), once daily
62553657|NCT04894370|EXPERIMENTAL|Experimental|"Phase 1: Radiotherapy (8 Gy on target lesions)~Phase 2: Combination immunotherapy and mDCF regimen mDCF regimen every 2 weeks for 8 cycles~* Docetaxel (40 mg/m², day 1),~* Cisplatin (40 mg/m², day 1)~* 5-FU (1200 mg/m²/day for 2 days) Spartalizumab: 400 mg intravenous will be administrated every 4 weeks~Phase 3 : Multimodal treatment of residual disease The multimodal treatment is recommended in oligometastatic anal cancer. The support by ablative treatment (surgery, hypofractionnated radiotherapy or by radiofrequency) improve survival.~In absence of progression disease:~* Ablative treatment: surgery, hypofractionnated radiotherapy or by radiofrequency of residual metastases~* and Chemo-radiotherapy (CRT) for local disease~Phase 4: Maintenance treatment with Spartalizumab 400 mg intravenous every 4 weeks for 12 months from enrolment maximum"
62747092|NCT05495841||Face Mask and Nasal Cannula|40 patients using the pre-oxygenation combined facemask + HFNO technique as part of routine clinical care will be studied. As to clinical standards, the standard oxygen facemask will be tightly applied on the face of the patient at 100% FiO2 for 3 to 4 minutes and HFNO at 100% with a flow at 40 L/minutes during the pre-oxygenation (the flow can be decreased to less than 40 L/minutes if no tolerance by the patient). Then, after a general anesthesia induction and/or a rapid sequence induction is performed, the patient receives HFNO at 100% FiO2 and the flow of HFNO is increased to up to 80 L/minutes (which corresponds to a close delivered FiO2 at 80%) during the apnea period (1 to 2 min) until correct position of the endotracheal tube is confirmed with capnography.
62747093|NCT05527353||Women with PCOS|Women born in Northern Finland during 1985-1987 fulfilling ≥2 Rotterdam criteria.
62747094|NCT05527353||Controls|Women born in Northern Finland during 1985-1987 who are PCOM negative with no other diagnostic features of PCOS according to the Rotterdam criteria.
62747095|NCT01753869|ACTIVE_COMPARATOR|ACTs after HTS inhalation:|ACTs after HTS inhalation: Patients will take a bronchodilator (Salbutamol, 2 puffs) wait 15 minutes, and then take a single inhalation (4 mls) of 7% HTS (Nebusal™) via updraft nebulizer (Portex) (approximately 20 minutes) immediately followed by an airways clearance session of 10 supervised cycles of Active Cycle of Breathing Technique (ACBT) using the acapella® (approximately 20 minutes).
62747096|NCT01753869|ACTIVE_COMPARATOR|ACTs during HTS inhalation|ACTs during HTS inhalation: Patients take a bronchodilator (Salbutamol, 2 puffs), wait 15 minutes, and then take a single inhalation (4mls) of 7% HTS (Nebusal™) through the acapella® duet (with portex updraft nebulizer attached) device. During inhalation, an airways clearance session of 10 supervised cycles of ACBT using the acapella® will be carried out (approximately 20 minutes).
62747097|NCT03475706|EXPERIMENTAL|Solabegron immediate release tablets low dose|
62747098|NCT03475706|EXPERIMENTAL|Solabegron immediate release tablets high dose|
62747099|NCT03475706|PLACEBO_COMPARATOR|Placebo Comparator|
62747100|NCT01730365||Histological biopsy procedures|Patients with a suspicious lesion in lung or liver or breast who are planned for a standard core biopsy procedure. And patients planned for percutaneous RFA (Radiofrequency Ablation) of colorectal liver metastasis
62747101|NCT04221737|ACTIVE_COMPARATOR|Conventional ventilation|Protective lung conventional strategy with volume-controlled ventilation (VCV) or pressure-controlled ventilation (PCV) mode, with low tidal volume and adequate positive end expiratory pressure (PEEP) level.
62747102|NCT04221737|EXPERIMENTAL|Time-controlled adaptive APRV|Airway Pressure Release Ventilation with Time-controlled adaptive ventilation method. Allowing for spontaneous breathing.
62747103|NCT03815695|EXPERIMENTAL|Single ascending dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 6:2 receiving a single dose of FT-4202 or placebo. The first cohort will receive 200 mg of FT-4202 or placebo. Dose escalation will occur if FT-4202 or placebo is tolerated. The maximum dose of FT-4202 or placebo will be 1500 mg.
62747104|NCT03815695|EXPERIMENTAL|Multiple ascending dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 9:3 to receive FT-4202 or placebo for 14 days continuous dosing. The first cohort will receive 100 mg of FT-4202 or placebo daily X 14 days. The maximum dose of FT-4202/placebo will be 600 mg FT-4202/placebo daily for 14 days.
62747105|NCT03815695|EXPERIMENTAL|Food Effect Cohort in healthy subjects|Health Volunteer subject cohort of 10 subjects who will receive a single dose of FT-4202 with food and without food. Dose will be administered per the protocol defined dose.
62747106|NCT03815695|EXPERIMENTAL|Single ascending dose cohorts in SCD subjects|Sickle cell disease subject cohort randomized 6:2 receiving a single dose of FT-4202 or placebo. The dose of FT-4202/placebo administered will be a dose that was found to be safe in healthy subjects.
62747107|NCT03815695|EXPERIMENTAL|Multiple ascending dose cohorts in SCD subjects|Sickle cell disease subject cohorts randomized 9:3 to receive FT-4202 or placebo for 14 days continuous dosing. The dose of FT-4202/placebo administered will be a dose less than the maximum tolerable dose evaluated in MAD healthy volunteers.
62747108|NCT03815695|EXPERIMENTAL|12-week dosing cohort in SCD subjects|Sickle cell disease subjects cohort to receive up to 84 consecutive daily doses of open-label FT-4202. The dose of FT-4202 administered will not exceed the highest dose evaluated in the MAD SCD subject cohorts
62553658|NCT00064987|EXPERIMENTAL|Group 1 (FSH)|Patients in Group 1 will receive subcutaneous follicle stimulating hormone (FSH) injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.
62747109|NCT02946567|EXPERIMENTAL|Noisy City|Participant will play the Noisy City game developed by this project.
62747110|NCT02946567|PLACEBO_COMPARATOR|Control|Participant will play a generic game.
62747111|NCT00730041|ACTIVE_COMPARATOR|Palatal Implants|Pillar(R) Palatal Implants in combination with continuous positive airway pressure (CPAP) in subjects diagnosed with obstructive sleep apnea (OSA)
62747112|NCT00730041|SHAM_COMPARATOR|Sham procedure|Sham (procedure but no implants inserted) in combination with continuous positive airway pressure (CPAP) in subjects diagnosed with obstructive sleep apnea (OSA)
62553659|NCT00064987|ACTIVE_COMPARATOR|Group 2 (GnRH)|Patients in Group 2 will receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.
62553660|NCT00695474||A|The cohort consists of type 2 diabetics from the outpatient clinic at Silkeborg Hospital.
62747113|NCT00574730|EXPERIMENTAL|Arm 1|Participants will receive 6 cycles of combination chemotherapy with the standard CHOP regimen given in conjunction with rituximab. Cycles are repeated at 21-day intervals for six to eight cycles. Participants achieving at least a partial response to chemotherapy will begin PEG Intron at a dose of 2g/kg/week subcutaneously. PEG Intron treatment will be continued for 12 months in the absence of signs of progressive/recurrent disease, or unacceptable toxicity/intolerance of therapy.
62747114|NCT04969601|EXPERIMENTAL|Anti Covid with COMIRNATY® (BNT162b2) vaccine|Two injections of COMIRNATY® (BNT162b2) vaccine 21-28 days apart
62747115|NCT02493803|EXPERIMENTAL|Receive detailed dietary advice|Half of the participants will be randomly allocated to receive detailed dietary advice
62553661|NCT05233462|ACTIVE_COMPARATOR|control group|"intrathecal administration of a solution containing~* bupivacaine 10 mg~* morphine 100 micrograms~* sufentanil 3 micrograms"
62747116|NCT02493803|NO_INTERVENTION|Receive standard of care dietary advice|These patients will receive dietary advice which is the current standard of care
62747117|NCT03603587|EXPERIMENTAL|Patients who will benefit from the removal of a scalp tumour|"Patients who will benefit from the removal of a scalp tumour in the alopecic zone will be recruited in the dermatology department of the St-Etienne University Hospital.~They will have biopsy, blood sample, examination of the scalp, questionnaire on sun exposure, Norwood scale, scinexa score, questionnaire of clinicals signs and questionnaire of the history of the hair loss."
62747118|NCT00006003|EXPERIMENTAL|Treatment (semaxanib)|Patients receive SU5416 IV over 60 minutes twice weekly for 4 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
62747119|NCT01983384|PLACEBO_COMPARATOR|Anesthetic Depth: standard care|A cohort of older patients undergoing major non-cardiac surgery will be randomized to receive routine anesthetic management not guided by the processed electroencephalogram
62747120|NCT01983384|EXPERIMENTAL|Anesthetic Depth: interventional|A cohort of older patients undergoing major non-cardiac surgery will be randomized to receive anesthetic management guided by the processed electroencephalogram (processed EEG-guided anesthetic depth)
62747121|NCT00244933|EXPERIMENTAL|Gemcitabine, genistein (Novasoy), Tumor biopsy|Gemcitabine IV-1000mg/m2: Days 1 \& 8 every 21 days Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
62747122|NCT03195348|EXPERIMENTAL|HBF Bed Rest|7 days control period followed by a washout period, then 7 days of HBF.
62747123|NCT02805751|ACTIVE_COMPARATOR|Control|This constitutes the currently accepted regime and is therefore consider the control group (CTRL) with early range of motion and early weight bearing. The control group was allowed to have weight-bearing as tolerated from day 0. They are also instructed to perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
62747124|NCT02805751|EXPERIMENTAL|Early loading|The patients in the early loading group are also allowed to have weight-bearing as tolerated from day 0 and perform tendon strain exercises 3 times each day from 2 weeks after the rupture. The patients in this group will also remove the walker twice a day and use a special training pedal for 5 weeks (until walker removal).
62747125|NCT02403817|EXPERIMENTAL|Eye Movement Game Control|Cognitive Training Eye Motor Training
62747126|NCT02403817|ACTIVE_COMPARATOR|Hand Movement Game Control|Cognitive Training Hand Motor Training
62747127|NCT00003191|EXPERIMENTAL|Arm I|Patients receive oral fenretinide 3 times a day on days 1-7. Treatment repeats every 3 weeks for up to 8 courses. Patients may receive an additional 22 courses of therapy in the presence of stable or responding residual tumor. Patients with recurrent neuroblastoma, after prior myeloablative therapy with no measurable disease, will stop treatment after 8 courses. Cohorts of 3-6 patients receive escalating doses of fenretinide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
62747128|NCT05455918|EXPERIMENTAL|TIP treatment arm|
62747129|NCT01457014|ACTIVE_COMPARATOR|servo ventilation auto mode|Inspiratory and expiratory pressures automatically determined by the servo ventilation device.
62747130|NCT01457014|ACTIVE_COMPARATOR|Continuous positive airway pressure|Airway pressure delivered at a constant pressure level.
62747131|NCT01457014|ACTIVE_COMPARATOR|servo ventilation manual|Inspiratory and expiratory pressures automatically determined by the servo ventilation device with mandatory minimal inspiratory minus expiratory pressure difference.
62747132|NCT05609994|EXPERIMENTAL|PEPIDH1M vaccine + vorasidenib|Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids) intramuscularly into the deltoid muscle. Patients will then receive vorasidenib 40mg orally once a day for 28 days. After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15. The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid. This will be administered twelve hours to one day prior to receiving PEPIDH1M vaccine i.d. to the RIGHT groin area. Vaccines #3 and #4 will be given on day 1 and day 15 of cycle 4. Starting on 6th cycle of 28-day vorasidenib, subjects will receive PEPIDH1M vaccine (i.d. to alternating groin regions) every 28 days on day 1 for vaccine #5-#12. Patients will receive up to a total of 14 cycles of vorasidenib.
62747133|NCT04703608|EXPERIMENTAL|Arm 1 of Cohort 1|Index Case / Household members Ivermectin / Ivermectin (with preventative package)
62747134|NCT04703608|EXPERIMENTAL|Arm 2 of Cohort 1|Index Case / Household members Ivermectin / Placebo (with preventative package)
62747135|NCT04703608|PLACEBO_COMPARATOR|Arm 3 of Cohort 1|Index Case / Household members Placebo / Placebo (with preventative package)
62747136|NCT04703608|EXPERIMENTAL|Arm 1 of Cohort 2|Aspirin 150mg daily for 28 days or until hospital discharge or death (whichever is sooner)
62747137|NCT04703608|PLACEBO_COMPARATOR|Arm 2 of Cohort 2|Non identical placebo; doses as per above
62747138|NCT05300568||post-menopausal women|post-menopausal women with moderate to severe VMS associated with menopause
62747139|NCT05406219|EXPERIMENTAL|Group 1: moderately impaired renal function|Participants with moderately impaired renal function will receive a single dose of BAY2395840.
62747140|NCT05406219|EXPERIMENTAL|Group 2: normal renal function matched to Group 1|Participants with normal renal function matched to Group 1 will receive a single dose of BAY2395840.
62747141|NCT05406219|EXPERIMENTAL|Group 3: normal renal function aiming to balance out Group 2|Participants with normal renal function aiming to balance out Group 2 for the age and gender investigations will receive a single dose of BAY2395840.
62747142|NCT03840824||Cancer Survivor|Pre-menopausal women who are cancer survivors ages 18-45 years with normal menstrual cycles.
62747143|NCT03840824||Similar aged healthy controls|Pre-menopausal, healthy women ages 18-45 years with normal menstrual cycles
62747144|NCT03840824||Late Reproductive Age|Pre-menopausal, healthy women of late reproductive age
62553662|NCT05233462|EXPERIMENTAL|individualized group|"intrathecal administration of a solution containing~* bupivacaine 0.05 mg per cm of patient's height~* morphine 100 micrograms~* sufentanil 3 micrograms"
62553663|NCT01893515|EXPERIMENTAL|PRC-4016|PRC-4016, oral administration once daily, capsule
62553664|NCT01893515|PLACEBO_COMPARATOR|Placebo|Placebo, oral administration once daily, capsule
62747145|NCT06349083|EXPERIMENTAL|Oral high-dose of psilocybin|Participants will receive a single IP administration session of psilocybin (30 mg total) and three supportive therapy sessions.
62747146|NCT06349083|PLACEBO_COMPARATOR|Placebo control|Participants will receive a single IP administration session of matching placebo capsules and three supportive therapy sessions.
62747147|NCT04801433|EXPERIMENTAL|Boleda Supramolecular Active Zinc|Boleda Supramolecular Active Zinc (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
62747148|NCT04801433|ACTIVE_COMPARATOR|Capotetriol scalp solution|30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
62747149|NCT04801433|PLACEBO_COMPARATOR|Supramolecular Hydrogel|30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
62374483|NCT03676465|EXPERIMENTAL|Experimental Group|"Subjects will wear their personal pump (if appropriate), use a study insulin pen (if appropriate), a study CGM and study activity tracker (i.e. Fitbit). Participants will receive a weekly CloudConnect Report based on analysis of the weekly data gathered for each participant. The report will be sent via email once a week to both the subject and their parent(s). Subjects and parents will have weekly contact with the study team. Subjects will complete questionnaires at the beginning and end of the study. These questionnaires will ask subjects about:~* the communication within the family about the information shared in this report~* how subjects feel when blood sugar is high or low~* who takes responsibility of how diabetes care is managed"
62374484|NCT03676465|ACTIVE_COMPARATOR|Control Group|"Subjects will wear their personal pump (if appropriate), use a study insulin pen (if appropriate), a study CGM and study activity tracker (i.e. Fitbit). Participants will not receive a CloudConnect Report. Subjects and parents will have weekly contact with the study team. Subjects will complete questionnaires at the beginning and end of the study. These questionnaires will ask subjects about:~* the communication within the family about the information shared in this report~* how subjects feel when blood sugar is high or low~* who takes responsibility of how diabetes care is managed"
62374485|NCT04781725|EXPERIMENTAL|INT230-6 Treated Arm|"Part I: Patients will receive up to 3 doses of INT230-6 injected weekly prior to breast surgery~Part II: Patients will receive up to 2 intratumoral doses of INT230-6 (over a 15-day period) prior to breast surgery"
62374486|NCT04781725|PLACEBO_COMPARATOR|Control Arm|"Part I: No intervention while awaiting surgery~Part II: Placebo saline injection"
62374487|NCT00997828|EXPERIMENTAL|everolimus-eluting stent|everolimus-eluting stent
62374488|NCT00997828|ACTIVE_COMPARATOR|coronary artery bypass graft surgery|coronary artery bypass graft surgery
62374489|NCT03827967|EXPERIMENTAL|1x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
62553665|NCT05495243|EXPERIMENTAL|ARINA-1|ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH); fixed dose, 4 mL solution inhaled twice daily via nebulization for 28 days
62553666|NCT05495243|PLACEBO_COMPARATOR|Placebo|Isotonic saline (0.9%); 4 mL solution inhaled twice daily via nebulization for 28 days
62553667|NCT05780060|EXPERIMENTAL|Intervention arm|standard stroke clinic follow, combined with remote patient blood pressure monitoring and an added patient-facing smartphone application with educational modules and adherence incentives (n=30).
62553668|NCT05780060|ACTIVE_COMPARATOR|Control arm|standard stroke clinic follow up combined with remote blood pressure monitoring
62747150|NCT04731480|ACTIVE_COMPARATOR|CLADS group|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anesthesia.
62747151|NCT04731480|ACTIVE_COMPARATOR|Marsh model group|The target-controlled infusion (TCI) pump will be programmed to marsh model with the target plasma site concentration of 3-µg/ml. The plasma concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
62747152|NCT04731480|ACTIVE_COMPARATOR|Schnider model group|The TCI-pump will be programmed to will be programmed to Schnider model with the target effect site concentration of 3-µg/ml. The effect-site concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia.
62747153|NCT04731480|ACTIVE_COMPARATOR|Manual group|Propofol administration will be controlled manually using an intravenous infusion pump to maintain a target BIS of 50 during induction and maintenance of anesthesia.
62747154|NCT03736993|OTHER|Additional blood sampling|non-small cell lung cancer (NSCLC)
62747155|NCT06230510|EXPERIMENTAL|Whole Milk|Whole Milk consumption for one year
62747156|NCT06230510|EXPERIMENTAL|1% Milk|1% Milk consumption for one year
62747157|NCT04497857|PLACEBO_COMPARATOR|CSC-SD|Standard clinic-based CSC model treatment. Treatment will be delivered largely in clinic for 12 months.
62553669|NCT02524847|EXPERIMENTAL|Methoxsalen with ECP|Participants receive methoxsalen 20 µg/ml in conjunction with ECP procedure three times per week for Weeks 1 to 4, and two times per week for Weeks 5 to 12.
62553670|NCT04245800||Observational|All participants will be part of the prospective observational cohort. If participants develop flu-like symptoms, they will be prompted to complete the flu@home self-test kit. Analysis will be conducted for various subgroups (e.g. age, vaccination status)
62747158|NCT04497857|EXPERIMENTAL|CSC-TH|Telehealth based CSC model treatment. Treatment will be delivered largely through telehealth for 12 months.
62747159|NCT05099705|EXPERIMENTAL|Intervention Group (Access to an FSN/TSS)|40 participants will be randomly assigned to the intervention group (i.e., to receive an FSN and have access to the TSS). The FSN may meet with the participant at least twice and provide navigation support.
62747160|NCT05099705|NO_INTERVENTION|Control Group (Access to Information, training and referral)|15 participants will be randomly assigned to the non-personalized comparison group (i.e., information, training, and referral).
62747161|NCT03265002|PLACEBO_COMPARATOR|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
62747162|NCT03265002|EXPERIMENTAL|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
62747163|NCT03265002|ACTIVE_COMPARATOR|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
62747164|NCT03265002|ACTIVE_COMPARATOR|Inulin and Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
62747165|NCT02543177|EXPERIMENTAL|group A|direct coronary angiography
62553671|NCT00560820|EXPERIMENTAL|Deferasirox|30 mg/kg/day
62747166|NCT02543177|EXPERIMENTAL|group B|direct coronary angiography plus ischemic precondition
62747167|NCT02543177|EXPERIMENTAL|group C|delayed coronary angiography; the kidneys will be irrigated prior to coronary angiography
62747168|NCT02543177|EXPERIMENTAL|group D|delayed coronary angiography plus ischemic precondition; the kidneys will be irrigated prior to coronary angiography
62747169|NCT03983265|OTHER|computer guided condylar reposition device|surgical procedure : under general anesthesia after BSSO condyle will be repositioned by computer guided repostioning device
62747170|NCT05258578|EXPERIMENTAL|Tele-CBT Group|"Participants will receive 6 weekly Tele-CBT sessions and 1 final booster session 1 month later, all approximately 55-minutes in duration. Briefly, the Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and problem solving and challenging negative thoughts. Participants are encouraged to complete CBT homework between sessions (i.e., completing food records, pleasurable activities and worksheets). Five clinical psychology graduate students will work as study therapists under the supervision of Drs. Cassin and Sockalingam and will have biweekly case supervision meetings."
62747171|NCT05258578|ACTIVE_COMPARATOR|Self-Help Resources Group|Participants will be directed to the CAMH COVID-19 Self-Help webpage (www.camh.ca/covid19) to access coping tools to help with COVID-19 associated stress and anxiety, loss, grief and healing, stigma, and physical isolation. Participants in the control arm will receive weekly check-in/reminder emails for the duration of the intervention period.
62747172|NCT01074463|EXPERIMENTAL|1|Pramipexole Dihydrochloride 0.25 mg Tablets
62747173|NCT01074463|ACTIVE_COMPARATOR|2|Mirapex® 0.25 mg Tablets
62747174|NCT02609841||Cardiac rhythm remote monitoring system|Subjects use non-invasive wearable BodyGuardian remote monitoring system throughout 12 days of study.
62747175|NCT05820568|EXPERIMENTAL|Treatment|Patients receiving ICBT-IU
62747176|NCT03825146|EXPERIMENTAL|Treatment Arm (AMPC)|AMPC will be intravenously infused.
62747177|NCT04526951|ACTIVE_COMPARATOR|Tenecteplase|The total dose of tenecteplase is 0.25 mg/kg body weight, maximum 25 mg. The total dose will be given as an intravenous bolus
62553672|NCT01434914|ACTIVE_COMPARATOR|verum|
62553673|NCT01434914|PLACEBO_COMPARATOR|Placebo|
62553674|NCT01565889|EXPERIMENTAL|Part A: SOF+EFV/FTC/TDF (Cohort 1)|Participants with a prestudy regimen of EFV/FTC/TDF will receive SOF+EFV/FTC/TDF FDC for 7 days, followed by EFV/FTC/TDF FDC (or EFV+FTC/TDF) for 7 days, coadministered once daily in the evening under fasting conditions.
62553675|NCT01565889|EXPERIMENTAL|Part A: SOF+EFV+ZDV/3TC (Cohort 2)|Participants with a prestudy regimen of EFV+ZDV/3TC will receive SOF+EFV+ZDV/3TC for 7 days followed by EFV+ZDV/3TC for 7 days. Sofosbuvir and EFV will be administered once daily in the evening under fasting conditions; ZDV/3TC will be administered twice daily, in the morning without regard to food and in the evening on an empty stomach.
62553676|NCT01565889|EXPERIMENTAL|Part A: SOF+RTV+ATV+FTC/TDF (Cohort 3)|Participants with a prestudy regimen of RTV+ATV+FTC/TDF will receive SOF+RTV+ATV+FTC/TDF for 7 days followed by RTV+ATV+FTC/TDF for 7 days coadministered once daily in the morning with food.
62747178|NCT04526951|ACTIVE_COMPARATOR|acetylsalicylic acid|one tablet of aspirin 300 mg Other Name: Aspirin
62747179|NCT03267043|ACTIVE_COMPARATOR|Standard Care|Participants enrolled in Phase 1 will be receiving the current standard of care in the NICU at The Valley Hospital.
62747180|NCT03267043|EXPERIMENTAL|Family Nurture Intervention (FNI)|Participants enrolled in Phase 2 will be receiving family nurture intervention (FNI) that focuses on supporting the parents and facilitating emotional connection between mother and infant during the infant's NICU stay.
62747181|NCT03267043|ACTIVE_COMPARATOR|Standard Care - Case Studies|Participants enrolled as case studies in Phase 1 will be receiving the current standard of care in the NICU at The Valley Hospital. These participants will be those who fall outside the inclusion criteria.
62553677|NCT01565889|EXPERIMENTAL|Part A: SOF+RTV+DRV+FTC/TDF (Cohort 4)|Participants with a prestudy regimen of RTV+DRV+FTC/TDF will receive SOF+RTV+DRV+FTC/TDF for 7 days followed by RTV+DRV+FTC/TDF for 7 days coadministered once daily in the morning with food.
62553678|NCT01565889|EXPERIMENTAL|Part A: SOF+RAL+FTC/TDF (Cohort 5)|Participants with a prestudy regimen of RAL+FTC/TDF will receive SOF+RAL+FTC/TDF for 7 days followed by RAL+FTC/TDF for 7 days. Sofosbuvir and FTC/TDF will be administered once daily in the morning with food; RAL will be administered twice daily, in the morning with food and in the evening without regard to food.
62553679|NCT01565889|EXPERIMENTAL|Part B: SOF+PEG+RBV|Participants will receive SOF+PEG+RBV for 12 weeks.
62553680|NCT03809689|OTHER|acute infarction|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT at 1, 4 and 12 weeks after cardiac event
62553681|NCT03809689|OTHER|acute infarction requiring reperfusion|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT at 1, 4 and 12 weeks after cardiac event
62747182|NCT03267043|EXPERIMENTAL|FNI - Case Studies|Participants enrolled in Phase 2 will be receiving family nurture intervention (FNI) that focuses on supporting the parents and facilitating emotional connection between mother and infant during the infant's NICU stay. These fall outside the inclusion criteria but act as a comparator to the case studies of Phase 1.
62747183|NCT03955224|ACTIVE_COMPARATOR|Basic Oral Care + active LLLT (experimental arm)|
62747184|NCT03955224|PLACEBO_COMPARATOR|Basic oral Care + inactive LLLT (control arm)|
62747185|NCT03955224|OTHER|Basic Oral Care (control arm)|
62553682|NCT03809689|OTHER|chronic ischemic occlusion|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT before and 2 months after reperfusion treatment
62553683|NCT01895777|EXPERIMENTAL|dabigatran etexilate|Dabigatran etexilate capsules, pellets or liquid formulation given BID in an open label fashion for 3 months
62747186|NCT02645877||Prehospital care|All pre-hospital service data were collected from January 2005 to December 2014 from the Beijing Emergency Center and Beijing Red Cross Emergency Center, which oversee all pre-hospital care in Beijing. The major illnesses were classified into 34 disease spectrum categories according to the Medical Priority Dispatch System (MPDS) which total includes 34 diseases. Data on pre-hospital emergency demand and first aid-related time intervals were analyzed to determine trends over the period.
62747187|NCT03167112|EXPERIMENTAL|FOLFIRINOX|Oxaliplatin, Irinotecan, Leucovorin, Fluorouracil
62747188|NCT03911752||People with Acquired Brain Injury|People with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=8).
62747189|NCT03911752||Partners of people with Acquired Brain Injury|Partners of people with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=2).
62747190|NCT03911752||Relatives of people with Acquired Brain Injury|Relatives of people with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=2).
62747191|NCT01471028|EXPERIMENTAL|ELAD Treatment|This group will receive treatment with ELAD plus standard of care treatment.
62747192|NCT01471028|OTHER|Standard of care (Control)|This group will receive standard of care treatment as defined in the protocol.
62747193|NCT02975011||Lumbar stenosis group|Lumbar stenosis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manipulation, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
62747194|NCT03927235|SHAM_COMPARATOR|the freezing time of 3s|Transbronchial cryobiopsy in the freezing time of 3s
62747195|NCT03927235|EXPERIMENTAL|the freezing time of 4s|Transbronchial cryobiopsy in the freezing time of 4s
62747196|NCT03927235|EXPERIMENTAL|the freezing time of 5s|Transbronchial cryobiopsy in the freezing time of 5s
62747197|NCT03927235|EXPERIMENTAL|the freezing time of 6s|Transbronchial cryobiopsy in the freezing time of 6s
62747198|NCT03764566||Trauma control group|Individuals with adverse childhood experiences (e.g.childhood abuse or neglect) will be included as the experimental group of participants. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
62747199|NCT03764566||Healthy control group|Individuals with no trauma history will be added as the healthy control group of participants. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
62747200|NCT03764566||Clinical control group|Individuals with Borderline Personality Disorder (BPD) will be added as a clinical control group. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
62747201|NCT01294306|EXPERIMENTAL|Treatment (Akt inhibitor MK2206, erlotinib hydrochloride)|Patients receive Akt inhibitor MK2206 PO QOD of a 28-day course, and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62747202|NCT04659174|EXPERIMENTAL|KarXT|
62747203|NCT03537248|EXPERIMENTAL|Asepticys investigational ASP-57 Multi-Purpose Solution|ASP-57 Multi-Purpose contact lens care solution used as a rub care regimen (Test)
62553684|NCT01895777|ACTIVE_COMPARATOR|standard of care|Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
62553685|NCT00634699|EXPERIMENTAL|One|Ischemic Compression on Triggers Points on Muscles along the Median Nerve. Active Comparator
62553686|NCT02525900|PLACEBO_COMPARATOR|Wound Infiltration|0.5mg/kg of 0.25% bupivacaine will be injected around the incision for wound infiltration
62553687|NCT02525900|EXPERIMENTAL|TAP Blocks|20mL of 0.25% bupivacaine will be injected on each side of the abdomen for ssTAP procedures
62747204|NCT03537248|ACTIVE_COMPARATOR|ReNu® Multiplus Contact Lens Solution|ReNu® Multiplus Contact Lens Solution used as rub care regimen (Control)
62747205|NCT06605586|EXPERIMENTAL|Tasquinimod|Patients will be treated with tasquinimod capsules 0.5 mg/day for 14 days (half cycle) and then capsules of 1 mg/day for the remaining 14 days in the first cycle. In consecutive 28-day cycles 1 mg/day (or if 1 mg/day is not tolerated, reduction to 0.75 or 0.5 mg/day is allowed, followed by dose re-escalation whenever possible). Patients will be treated for a maximum period of 24 weeks (6 cycles).
62747206|NCT00692614|EXPERIMENTAL|1|100 mcg triamcinolone acetonide
62747207|NCT00692614|EXPERIMENTAL|2|500 mcg triamcinolone acetonide
62747208|NCT00692614|EXPERIMENTAL|3|925 mcg triamcinolone acetonide
62747209|NCT00692614|NO_INTERVENTION|4|sham control - not implanted, no medication
62747210|NCT00918775||Observational (follow-up)|After metastasectomy, patients are followed up every 6 months for up to 5 years.
62747211|NCT02821442|EXPERIMENTAL|Acupuncture|Acupuncture will consist of acupuncture points ST36, LR3, LI4 bilaterally x 30 minutes, once a week over 6 weeks. ST36 will have EA with 2Hz at the maximum tolerated intensity (ES-130 Portable Japanese Electro-Acupuncture Device, UPC Medical Supplies Inc. South El Monte, CA, USA).
62747212|NCT02821442|SHAM_COMPARATOR|Sham Acupuncture|Sham acupuncture (Streitberger Placebo Needles, Asiamed) uses the same points and treatment parameters but the placebo needle does not penetrate the skin and the current for EA is not turned on.
62747213|NCT06588647|EXPERIMENTAL|Improving Participation after Stroke Self-Management Program (IPASS)|The IPASS-R intervention consists of 6 weekly 90-minute sessions delivered by an occupational therapist and stroke survivor peer facilitator. All sessions will be delivered remotely via videoconferencing.
62747214|NCT06588647|ACTIVE_COMPARATOR|Chronic Disease Self-Management Program (CDSMP)|The CDSMP will consist of 6, weekly 90-minute sessions. All sessions will be delivered remotely via videoconferencing.
62747215|NCT01795495|ACTIVE_COMPARATOR|Remifentanil|This arm will receive remifentanil alone as is the current practice.
62747216|NCT01795495|EXPERIMENTAL|Remifentanil plus methadone|This arm will receive the current analgesic remifentanil plus and adjunct dose of methadone hydrochloride.
62553688|NCT02525900|EXPERIMENTAL|TAP Catheters|20mL of 0.25% bupivacaine will be injection on each side of the abdomen and catheters placed for repeat bolus every 12 hours with 20mL of 0.25% Bupivacine until 48 hours post procedure or hospital discharge.
62747217|NCT01795495|EXPERIMENTAL|Remifentanil plus magnesium|This arm will receive the current analgesic remifentanil plus an adjunct dose of magnesium sulfate.
62747218|NCT02959853|PLACEBO_COMPARATOR|weight loss|Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
62747219|NCT02959853|EXPERIMENTAL|aromatase inhibitor (anastrazole) plus weight loss|Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
62747220|NCT06117969|EXPERIMENTAL|Tibolone|take Tibolone 1.25mg/day orally for 8 weeks
62747221|NCT06117969|EXPERIMENTAL|Xiangshao granules|take Xiangshao granules orally 3 times a day, 4g each time
62747222|NCT06117969|EXPERIMENTAL|Tibolone plus Xiangshao granules|take Tibolone 1.25mg/day and Xiangshao granules 3 times a day, 4g each time orally for 8 weeks
62747223|NCT03618732|EXPERIMENTAL|Bilateral movement-based computer training|"All subjects underwent 16 sessions of assigned treatment (2 times per week; for 8 weeks; 3 hours standardized rehabilitation program per visit) There was 1.5 hours standardized conventional physiotherapy training a 1.5 hours multi-disciplinary program which consisted of standardized occupational therapy, speech therapy and nursing care.~Subjects in Intervention Group will be assigned an additional 30 minutes bilateral movement-based computer games(Able-X) training program of upper limb."
62747224|NCT03618732|OTHER|Video-directed conventional training|All subjects underwent 16 sessions of assigned treatment (2 times per week; for 8 weeks; 3 hours standardized rehabilitation program per visit) There was 1.5 hours standardized conventional physiotherapy training a 1.5 hours multi-disciplinary program which consisted of standardized occupational therapy, speech therapy and nursing care.
62747225|NCT04974346|EXPERIMENTAL|study arm|"External beam radiotherapy:~Pelvic and para-aortic radiotherapy 45-50.4Gy/25-28 fractions. PET-CT positive lymph node should be boost to a dose of 60Gy or higher. Parametrium(both) should be boost to a dose from 50Gy to 60Gy.~Concurrent chemotherapy:~Weekly cisplatin 40mg/m2 during external beam radiotherapy.~Brachytherapy:~High dose rate(HDR) Brachytherapy. The dose of high-risk clinical target volume(HR CTV) D90 or Point A should be 85Gy+/-10%. The dose of intermediate-risk clinical target volume(IR CTV) D98 should be 60Gy at least."
62747226|NCT04974346|ACTIVE_COMPARATOR|control arm|"External beam radiotherapy:~Pelvic radiotherapy 45-50.4Gy/25-28 fractions. PET-CT positive lymph node should be boost to a dose of 60Gy or higher. Parametrium(both) should be boost to a dose from 50Gy to 60Gy.~Concurrent chemotherapy:~Weekly cisplatin 40mg/m2 during external beam radiotherapy.~Brachytherapy:~HDR Brachytherapy. The dose of HR CTV D90 or Point A should be 85Gy+/-10%. The dose of IR CTV D98 should be 60Gy at least."
62747227|NCT02694276|EXPERIMENTAL|Internet-based cognitive behavior therapy|10 sessions of ICBT during 10 weeks.
62747228|NCT06073912|EXPERIMENTAL|Autogenous corticocancellous block|Autogenous bone graft harvested as a block from the chin area
62747229|NCT06073912|ACTIVE_COMPARATOR|Mineralized plasmatic matrix|Mix of patient's PRP and autogenous particulate graft
62747230|NCT04345861|ACTIVE_COMPARATOR|monotherapy hydroxychloroquine|Hydroxychloroquine 800mg (Day 1), 600mg (from Day 2 to Day 10) + placebo from Day 1 to Day 5
62747231|NCT04345861|EXPERIMENTAL|combination hydroxychloroquine + azithromycin|Hydroxychloroquine 800mg (Day 1), 600mg (from Day 2 to Day 10) and azithromycin 500mg (Day 1 ), 250 mg (from day 2 to Day 5)
62747232|NCT04778631|EXPERIMENTAL|Heat therapy|Local perineal heat therapy during active second stage of labor
62747233|NCT04778631|EXPERIMENTAL|Cryotherapy|Local perineal cryotherapy during the immediate postpartum period
62747234|NCT04778631|NO_INTERVENTION|Active second stage usual car|Standard obstetrical care and perineal protection during active second stage of labor
62553689|NCT02905604|EXPERIMENTAL|dmPFC iTBS|Repetitive transcranial magnet stimulation (rTMS) over the dorsomedial prefrontal cortices at 90% of the resting motor threshold of the foot flexors. The rTMS is given in 20 trains to the left and right dmPFC, respectively. Each train consists of 10 bursts at 5 Hz (theta-frequency), and each burst consists of 3 pulses at 50 Hz. The stimulation is intermittent with 2 seconds of stimulation, 8 seconds off. After a 15 minute break the whole protocol i applied again, resulting in 2400 pulses/day. Treatment is delivered daily at 10 week days.
62747235|NCT04778631|NO_INTERVENTION|Postpartum usual care|Standard immediate (\<2 hours) postpartum care
62747236|NCT02674919|EXPERIMENTAL|Nordic Hamstring|The Nordic Hamstring group performs a progressive strengthening program (Mjolsnes et al., 2004) comprising of the Nordic Hamstring exercise during a period of 10 weeks. The training load increases from one session per week in week 1 to 3 sessions per week in week 3-10. Number of sets and repetitions progressively increase from 2 to 3 and 5 to 12, respectively. The exercise program is performed in the end of a regular football training session.
62747237|NCT02674919|OTHER|Control|The control group are asked not to perform the exercise or any other specific strength training for the hamstring muscles and to continue to play football as usual.
62747238|NCT00256035|OTHER|Unstable coronary artery disease|Patients with unstable coronary artery disease will have daily IL6 levels
62567294|NCT02746250|ACTIVE_COMPARATOR|Tension type headache|The investigator measures the muscle soreness and muscle stiffness before the patients starts their prescribed treatment with amitriptyline - and again after they have reached their optimal dosage of amitriptyline.
62567295|NCT02746250|NO_INTERVENTION|Healthy controls|The investigator measures the muscle soreness and muscle stiffness once.
62747239|NCT00256035|OTHER|Coronary Angioplasty Patients|Patients having coronary angioplasty will have levels taken before and immediately after the proceedure and 24 hours post.
62747240|NCT00256035|OTHER|Coronary bypass grafts patients|Patients will have levels collected immediately after and 24 hours post procedure
62747241|NCT00256035|OTHER|Stable coronary Artery Diseaese Patients|Once the patients are commenced on treatment with statins and or angiotensin converting enzyme they will have twice weekly levels taken
62567296|NCT01105169|ACTIVE_COMPARATOR|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate.
62747242|NCT01549886|EXPERIMENTAL|MGD + Rituximab + Y-90-Zevalin|"Moxtezafin Gadolinium: Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m\^2 intravenous infusion.~Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 8 only) by Day 8 Rituximab 250 mg/m\^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 millicurie / kilogram (mCi/kg) 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL."
62747243|NCT01549886|ACTIVE_COMPARATOR|Rituximab + Y-90-Zevalin|Day 1 Rituximab 250 mg/m\^2 intravenous infusion. Day 8 Rituximab 250 mg/m\^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
62747244|NCT00721760|EXPERIMENTAL|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment \[SRI\]) once daily for 7-10 days with an initial dose given 8 hours after surgery~Placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind"
62747245|NCT00721760|ACTIVE_COMPARATOR|Enoxaparin|"Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment \[SRI\]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
62553690|NCT02905604|SHAM_COMPARATOR|dmPFC Sham iTBS|A sham treatment protocol by using a sham coil with two identical sides where one side give active treatment as described above while on the other side the coil is insulated so very little magnetic energy is delivered. The coil has a built in positioning sensors and a software handling the randomization codes prompts the operator which side of the coil that should be directed towards the patient. Superficial transcutaneous electrical nerve stimulation (TENS) is applied over the stimulation site of the dmPFC synchronous wiht the TMS pulses to further mimic the sensation of the active stimulation.
62747246|NCT04301128|EXPERIMENTAL|EXPERIMENTAL GROUP|Patients in the experimental group were able to install and set up mobile application on android phones via Bluetooth and were informed about the sick android application. Patients were reminded and guided by subcutaneous anti-TNF drug treatments from mobile application. Both groups of patients were then assessed using face-to-face interviews for 6 months, 6 weeks after using the Subcutaneous Anti-TNF Treatment Questionnaire , BASDAI, ASQoL, BASFI scales.
62747247|NCT04301128|ACTIVE_COMPARATOR|BOOKLET GROUP|An anti-TNF drug administration training booklet were given to patients in the control group and were required to take advantage of the booklet on subcutaneous anti-TNF drug production. Both groups of patients were then assessed using face-to-face interviews for 6 months, 6 weeks after using the Subcutaneous Anti-TNF Treatment Questionnaire , BASDAI, ASQoL, BASFI scales. At the end of the study (twenty forth week) was applied to all patients.
62747248|NCT05864950|EXPERIMENTAL|Middle-Aged Adults|Middle-Aged Adults between 55-69 years of age.
62747249|NCT04500080|EXPERIMENTAL|PE intervention|Aerobic, resistance, and neuromotor exercise
62747250|NCT01140997|EXPERIMENTAL|Group 1|Ypeginterferon alfa-2b 90mcg per Week, with Ribavirin 1000-1200mg/d
62747251|NCT01140997|EXPERIMENTAL|Group 2|Ypeginterferon alfa-2b 135mcg per Week, with Ribavirin 1000-1200mg/d
62747252|NCT01140997|EXPERIMENTAL|Group 3|Ypeginterferon alfa-2b 180mcg per Week, with Ribavirin 1000-1200mg/d
62747253|NCT01140997|ACTIVE_COMPARATOR|Group 4|Pegasys 180mcg per Week, with Ribavirin 1000-1200mg/d
62747254|NCT05726981|EXPERIMENTAL|Patients with nodules treated by thermal ablation|"The study population is a monocentric cohort of patients who underwent thermoablation treatment for benign thyroid nodules 3 years ago. These patients aged \>18 years-old were carriers of a benign but troublesome thyroid nodule before thermal ablation, either unique or dominant, i.e. associated with one or more other non-significant nodules (\<20 mm) that were subjected to simple ultrasound surveillance. Patients refused, after clear and fair information, surgical management of their nodule. On average, 2 patients have been treated for TA per week in the Thyroid Disease and Endocrine Tumor Department since 2016. Patients systematically benefit from annual clinical and ultrasound monitoring as part of their follow-up in our Department."
62747255|NCT01713673|EXPERIMENTAL|Active Treatment|Subjects receive Ulthera System Treatments according to the pre-defined Ulthera® System energy settings.
62747256|NCT01713673|SHAM_COMPARATOR|Sham Treatment|Subjects will receive Sham treatments using the Ulthera® System with the energy set to 0.00 Joules.
62747257|NCT06138015|EXPERIMENTAL|Exercise and Time-Restricted Eating|
62747258|NCT06138015|ACTIVE_COMPARATOR|Exercise only|
62747259|NCT00726037|EXPERIMENTAL|1|Three doses of Ontak 9 mcg/Kg IV over 30 minutes every other day for 1 week
62747260|NCT02627547|EXPERIMENTAL|Experimental tests|2 sets of experimental tests; once, during a period of normal training and repeated following one week of de-training
62747261|NCT04717648||Patients with anastomotic leakage|Post operative anastomotic leakage
62747262|NCT04717648||Patients without anastomotic leakage|Post operative without anastomotic leakage
62747263|NCT03563677|NO_INTERVENTION|Usual care|Standard evaluation process for patients approaching a center for rare diseases with an unclear diagnosis. The process includes the evaluation of complete medical records byan experienced physician, an outpatient visit to the center, and case discussion between experts. The process may also include an inpatient stay, a local case conference and a case conference between centers for rare diseases from different cities
62747264|NCT03563677|EXPERIMENTAL|New Innovative Care|The innovative evaluation process includes the additional involvement of a psychiatrists/psychosomatic expert in all of the processes described for the usual care arm plus the option to use telemedicine in the process of evaluation in addition to outpatient and inpatient visits and to transfer the patient back into standard care (i.e., primary care physician, rehabilitation, psychological/psychosomatic specialized care, etc.)
62747265|NCT00733291|ACTIVE_COMPARATOR|Nelfilcon A soak / Nelfilcon A no-soak|Nelfilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution, followed by nelfilcon A contact lenses inserted directly from the blister package. Each pair of lenses worn for 2 hours.
62747266|NCT00733291|ACTIVE_COMPARATOR|Nelfilcon A no soak / nelfilcon A soak|Nelfilcon A contact lenses inserted directly from the blister package, followed by nelfilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution. Each pair of lenses worn for 2 hours.
62747267|NCT00733291|ACTIVE_COMPARATOR|Etafilcon A soak / etafilcon A no soak|Etafilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution, followed by etafilcon A contact lenses inserted directly from the blister package. Each pair of lenses worn for 2 hours.
62747268|NCT00733291|ACTIVE_COMPARATOR|Etafilcon A no soak / etafilcon A soak|Etafilcon A contact lenses inserted directly from the blister package, followed by etafilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution. Each pair of lenses worn for 2 hours.
62747269|NCT01352221|EXPERIMENTAL|ST10|ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day
62747270|NCT01352221|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day
62747271|NCT06232850||Multiple sclerosis patient|According to EDSS should be between 0-3, not having had an attack in the last 3 months and without spasticity according to MAS in patient with MS will assesment KFORCE Sens® device and Purdue Pegboard Test.
62553691|NCT03197623|EXPERIMENTAL|LLP2A-ALENDRONATE|50, 150, 400, 750 or 1200 μg/kg or placebo given as a one time intravenous administration over 120 minutes.
62747272|NCT06232850||Healthy group|Healthy people of similar age who agree to participate in the study will evaluate the KFORCE Sens® device and the Purdue Pegboard Test.
62553692|NCT03197623|PLACEBO_COMPARATOR|Placebo|Placebo given as a one time intravenous administration over 120 minutes.
62747273|NCT03231917|EXPERIMENTAL|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
62747274|NCT03231917|EXPERIMENTAL|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion.
61986365|NCT03559140|EXPERIMENTAL|Group B|"Canals were prepared as in group A, Patients assigned to this group receive (application of criotherapy)~A final irrigation will be applied with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes. was applied. as follows:~Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes"
62374490|NCT03827967|EXPERIMENTAL|2x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
62553693|NCT02107131|ACTIVE_COMPARATOR|Monthly Intravitreal ranibizumab 0.3mg|Monthly Intravitreal ranibizumab 0.3mg injections.
62553694|NCT02107131|ACTIVE_COMPARATOR|PRN Intravitreal ranibizumab 0.3mg|PRN Intravitreal ranibizumab 0.3mg injections.
62553695|NCT05383612|EXPERIMENTAL|Group I:3% diquafosol|70 people, 70 eyes.
62553696|NCT05383612|OTHER|Group II:3% diquafosol and warm compresses and lid massage|70 people, 70 eyes.
62553697|NCT00886509|EXPERIMENTAL|Collateral promotion; PCI after 6 months|First pegGCSF or placebo; PCI after 6 months
62553698|NCT00886509|EXPERIMENTAL|Collateral promotion after PCI at baseline|Collateral promotion with pegGCSF after PCI at baseline
62567297|NCT01105169|PLACEBO_COMPARATOR|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
62374491|NCT03827967|EXPERIMENTAL|4x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
62374492|NCT03827967|EXPERIMENTAL|8x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
62374493|NCT03363568|EXPERIMENTAL|Adaptive Inhibitory Control Training|Participants played a set of three modified stop-signal reaction time tasks designed by NeuroScouting, LLC at home for approximately 5 days a week (25 min/day) for 4-weeks. This condition involved real-time adaptive gameplay that increased in difficulty as performance increased.
62374494|NCT03363568|ACTIVE_COMPARATOR|Non-Adaptive Inhibitory Control Training|Participants played a set of three modified stop-signal reaction time tasks designed by NeuroScouting, LLC at home for approximately 5 days a week (25 min/day) for 4-weeks. This condition had no change in difficulty (non-adaptive gameplay).
62374495|NCT02485860|NO_INTERVENTION|standard dressings|"In general, the dressings made are either of the type :~* Algosteril® (round or flat wick) + Mepilex® border~* or AquacelTM ExtraTM + AquacelTM Foam"
62374496|NCT02485860|EXPERIMENTAL|standard dressings with sterile honey|Melectis G
62374497|NCT06409104|ACTIVE_COMPARATOR|Propofol|will receive 1-2 mgkg-1 propofol injection over 30s followed by of propofol a 0.05 to 0.1 mg /kg/min infusion .
62374498|NCT06409104|ACTIVE_COMPARATOR|Dexmedetomidine|will receive dexmedetomidine at a loading dose of 1 μg/kg over 10 min, followed by a 0.2-0.7-μg/kg/h infusion.
62374499|NCT04146129|EXPERIMENTAL|CDX-0159|Eligible subjects will receive a single dose of CDX-0159
62374500|NCT04146129|PLACEBO_COMPARATOR|Normal saline|Subjects assigned to receive placebo will receive a single dose of normal saline
62374501|NCT01003067|NO_INTERVENTION|No Mesh|
62374502|NCT01003067|EXPERIMENTAL|Mesh Implementation|
62374503|NCT04383535|EXPERIMENTAL|Convalescent SARS COVID-19 plasma|Convalescent SARS COVID-19 plasma from a pool of 10 donor plasma, in addition to standard care.
62374504|NCT04383535|PLACEBO_COMPARATOR|Placebo|Single infusion of saline solution, in addition to standard care.
62374505|NCT05440344|EXPERIMENTAL|Imlunestrant (Mild Hepatic Impairment)|Imlunestrant administered orally.
62374506|NCT05440344|EXPERIMENTAL|Imlunestrant (Moderate Hepatic Impairment)|Imlunestrant administered orally.
62374507|NCT05440344|EXPERIMENTAL|Imlunestrant (Severe Hepatic Impairment)|Imlunestrant administered orally.
62374508|NCT05440344|EXPERIMENTAL|Imlunestrant (Normal Hepatic Function)|Imlunestrant administered orally.
62374509|NCT03520894|EXPERIMENTAL|Neoadjuvant radiotherapy arm|Early breast cancer patients eligible for breast conservative surgery will undergo neoadjuvant radiotherapy with Cyberknife robotic system
62374510|NCT05395728|EXPERIMENTAL|Group 1|Deflate the cuff at the beginning of the mechanical ventilation weaning protocol
62374511|NCT05395728|ACTIVE_COMPARATOR|Group 2|Deflate the cuff after complete weaning from mechanical ventilation
62374512|NCT02044367|EXPERIMENTAL|Test 1 (Treatment A)|multiple dose of dabigatran
62374513|NCT02044367|EXPERIMENTAL|Test 2 (Treatment B)|multiple dose of dabigatran
62374514|NCT02044367|EXPERIMENTAL|Reference|multiple dose of dabigatran
62374515|NCT02721654|EXPERIMENTAL|Plasma-Lyte 148®|Following randomisation, each study participant will receive either Plasma-Lyte 148® or 0.9% saline alone for all resuscitation episodes and for all compatible intravenous crystalloid therapy while in ICU (for up to 90 days).
62374516|NCT02721654|ACTIVE_COMPARATOR|0.9% sodium chloride|Following randomisation, each study participant will receive either Plasma-Lyte 148® or 0.9% saline alone for all resuscitation episodes and for all compatible intravenous crystalloid therapy while in ICU (for up to 90 days).
62374517|NCT03946644|ACTIVE_COMPARATOR|EVLA with keeping of security distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance 2 cm below the SFJ.
62374518|NCT03946644|EXPERIMENTAL|EVLA without keeping a distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance without keeping a distance to the SFJ.
62747275|NCT03368053|EXPERIMENTAL|GSKSB732461 Group|Healthy HIV uninfected volunteers who participated in study PRO HIV-002 between February 2003 and February 2005 and who were vaccinated with at least 3 doses of the GSKSB732461 vaccine candidate in the PRO-HIV-002 study.
62553699|NCT05156671|EXPERIMENTAL|Adrecizumab (HAM 8101)|Adrecizumab (HAM 8101) on top of standard of care. Adrecizumab (HAM8101) is a humanized IgG1 monoclonal antibody (mAb). 2 mg/kg body weight Adrecizumab diluted in up to 100 mL saline as single dose infusion.
62553700|NCT05156671|PLACEBO_COMPARATOR|Placebo/ control substance (NaCl 0.9%)|100 mL saline as single dose infusion
62553701|NCT05976100|EXPERIMENTAL|Group 1 (15 volunteers)|"Single use:~Single 200-mg oral dose of NIOCH-14"
62747276|NCT01031316|EXPERIMENTAL|Nondisclosure|
62747277|NCT01031316|ACTIVE_COMPARATOR|Disclosure|
62747278|NCT02164357||EVT|Patients receiving endovascular treatment (EVT) within 4.5 hours after onset because intravenous thrombolytic therapy (IVT) is contraindicated
62553702|NCT05976100|EXPERIMENTAL|Group 2 (15 volunteers)|"Single use:~Single 600-mg oral dose of NIOCH-14"
62747279|NCT02164357||IVT + EVT|Patients receiving intravenous thrombolytic therapy (IVT) followed by endovascular treatment (EVT) within 4.5 hours after onset
62747280|NCT02164357||IVT (intravenous thrombolytic therapy)|Patients that will received IVT only within 4.5 hours after onset
62747281|NCT06383247|EXPERIMENTAL|Real rTMS group|Participants will receive active transcranial magnetic stimulation (TMS) daily for 1 week.
62553703|NCT05976100|EXPERIMENTAL|Group 3 (15 volunteers)|"Single use:~Single 1200-mg oral dose of NIOCH-14 (on the same day in the morning 600 mg and in the evening 600 mg)"
62553704|NCT05976100|EXPERIMENTAL|Group 4 (15 volunteers)|"Multiple application:~Daily 200-mg oral dose of NIOCH-14 once a day for 6 days"
62747282|NCT06383247|PLACEBO_COMPARATOR|Sham rTMS group|Participants will receive sham transcranial magnetic stimulation (TMS) daily for 1 week
62747283|NCT05339490|EXPERIMENTAL|Progenitor Biological Bandages|"Donor Site Wound (DSW) is created with a dermatome. PBB are placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days.~Dressing's changes are performed at Day 5 ± 1 and Day 10 ± 1."
62747284|NCT05339490|ACTIVE_COMPARATOR|Jelonet|"Donor Site Wound is created with a dermatome. Jelonet® are placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days.~Dressing's changes are performed at Day 5 ± 1 and Day 10 ± 1."
62747285|NCT02604654|EXPERIMENTAL|Yiqitongluo group|Yiqitongluo granule 12g each time, 3 times a daily for 4 weeks.
62747286|NCT06146751||patients with ventricular aneurysm and after percutaneous ventricular reconstruction|Patients with ventricular aneurysm and after percutaneous ventricular reconstruction undergo a novel ferumoxytol-enhanced cardiac magnetic resonance imaging and transthoracic echocardiography.
62747287|NCT00438763||1|Subjects using the neoprene splint.
62747288|NCT00438763||2|Subjects using the orthoplast splint.
62747289|NCT00194584|EXPERIMENTAL|1|
62747290|NCT00194584|NO_INTERVENTION|0|
62747291|NCT01500915|EXPERIMENTAL|ranibizumab|
62747292|NCT04164017|EXPERIMENTAL|EUS-guided FNB with syringe suction|
62747293|NCT04164017|ACTIVE_COMPARATOR|EUS-guided FNB without syringe suction|
62747294|NCT02899650|EXPERIMENTAL|Young Fit|Young (18-39 yrs) people who have endurance training habit
62747295|NCT02899650|EXPERIMENTAL|Young Unfit|Young (18-39 yrs) people who have sedentary lifestyle.
62747296|NCT02899650|EXPERIMENTAL|Older Fit|Older (50-80 yrs) people who have endurance training habit
62747297|NCT02899650|EXPERIMENTAL|Older Unfit|Older (50-80 yrs) people who have sedentary lifestyle
62747298|NCT05045807|EXPERIMENTAL|Meat with added nitrate|Prosciutto/pancetta/Parma ham/salami (all derived from pork) prepared by a commercial butcher with sodium nitrate as an additive.
62747299|NCT05045807|EXPERIMENTAL|Meat with added nitrate plus vegetables|"The same intervention as of Arm meat with added nitrate consumed together with mixed vegetables."
62747300|NCT01793337|OTHER|Cold first|temperature is measured in cold (-20°C) environment first, and warm (23°C) environment afterwards
62747301|NCT01793337|OTHER|Warm first|temperature is measured in warm (23°C) environment first, and cold (-20°C) environment afterwards
62747302|NCT04039750|EXPERIMENTAL|Antibiotic irrigation with suction|Group A: You will receive antibiotic irrigation with suction if a PA is found during surgery
62747303|NCT04039750|ACTIVE_COMPARATOR|suction only|Group B: You will receive suction alone if a PA is found during surgery
62747304|NCT06157177|ACTIVE_COMPARATOR|Active M640|Metaxalone micronized 640 mg over encapsulated tablet Taken orally every 6 hours for 7 days
62747305|NCT06157177|PLACEBO_COMPARATOR|Placebo|Inactive placebo capsule 640 mg Taken orally every 6 hours for 7 days
62553705|NCT05976100|EXPERIMENTAL|Group 5 (15 volunteers)|"Multiple application:~Daily 600-mg oral dose of NIOCH-14 once a day for 6 days"
62553706|NCT05976100|EXPERIMENTAL|Group 6 (15 volunteers)|"Multiple application:~Daily 600-mg oral dose of NIOCH-14 twice a day for 6 days"
62553707|NCT01231776|NO_INTERVENTION|control group|
62553708|NCT01231776|ACTIVE_COMPARATOR|acupuncture preoperative|acupuncture before operation for one week
62553709|NCT01231776|ACTIVE_COMPARATOR|acupuncture in hospital|acupuncture all the time in hospital
62553710|NCT05983354|EXPERIMENTAL|Oral medications|10 mg oral metoclopramide, 400 mg oral ibuprofen with 2 x 50 ml NS administered over 15 minutes.
62553711|NCT05983354|ACTIVE_COMPARATOR|IV medications|2 x placebo tablets, 10 mg metoclopramide in 50 cc NS and 10 mg ketorolac in 50 ml NS administered over 15 min.
62553712|NCT02021162||Gilenya|MS patients taking Gilenya
62553713|NCT02021162||Healthy Controls|Healthy controls age and gender matched to MS patients taking Gilenya
62553714|NCT01875328|EXPERIMENTAL|Telemedicine|Telemedicine group
62553715|NCT01875328|ACTIVE_COMPARATOR|Clinic|Clinic group
62553716|NCT01626690|EXPERIMENTAL|Pre-Warming|
62553717|NCT01626690|ACTIVE_COMPARATOR|Control|
62553718|NCT00710268|EXPERIMENTAL|1|Dose Escalation Study 50, 100, 200, 400 mg
62553719|NCT02345876||Dyslexic children|Longitudinal follow-up without intervention
62553720|NCT02345876||Normal reading children|Longitudinal follow-up without intervention
62747306|NCT03655301|EXPERIMENTAL|Copanlisib (Aliqopa, BAY80-6946)|All subjects will receive a single dose of metformin 1000 mg on Days 1 and 8 in a fasting state. Subjects will also receive a single i.v. dose of 60 mg copanlisib on Day 8 as part of the combination with metformin.
62747307|NCT02276352|EXPERIMENTAL|Meloxicam low dose - one tablet|
62553721|NCT04659369|EXPERIMENTAL|CMAB819|CMAB819 480 mg intravenous (IV) solution for Injection every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
62747308|NCT02276352|EXPERIMENTAL|Meloxicam high dose - two tablets|
62747309|NCT02276352|ACTIVE_COMPARATOR|Meloxicam high dose - one tablet|
62747310|NCT01751906|EXPERIMENTAL|Absorb BVS|Subjects receiving Absorb BVS
62747311|NCT01751906|ACTIVE_COMPARATOR|XIENCE|Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
62553722|NCT04659369|ACTIVE_COMPARATOR|Nivolumab|Nivolumab 480 mg intravenous (IV) solution for injection every 4 weeks until documented disease progression, discontinuation, withdrawal of consent, or the study ends or up to 4 doses in subjects without disease progression, whichever occurs earlier. After completing 4 doses of Nivolumab therapy, administer of CMAB819 480 mg intravenous (IV) solution for injection every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
62747312|NCT04809818|EXPERIMENTAL|Part A - LT3001 Drug Product|Multiple doses of LT3001 administered by intravenous infusion
62747313|NCT04809818|PLACEBO_COMPARATOR|Part A - Placebo|Multiple doses of Placebo administered by intravenous infusion
62747314|NCT04809818|EXPERIMENTAL|Part B - LT3001 and Aspirin|Multiple doses of LT3001 and Aspirin administered
62747315|NCT04809818|EXPERIMENTAL|Part B - LT3001 and Clopidogrel|Multiple doses of LT3001 and Clopidogrel administered
62747316|NCT04809818|EXPERIMENTAL|Part B - LT3001 and Apixaban|Multiple doses of LT3001 and Apixaban administered
62747317|NCT04809818|EXPERIMENTAL|Part B - LT3001 and Dabigatran|Multiple doses of LT3001 and Dabigatran administered
62747318|NCT06157632|OTHER|Patients with thyoid nodules|Patients with thyroid nodules that will do thyroidectomy
62747319|NCT05559840|ACTIVE_COMPARATOR|Group I|The control group (Group I) will be treated with condom catheter tamponade by inflating the condom with saline according to national protocol.
62747320|NCT05559840|EXPERIMENTAL|Group II|The study group (Group II) will receive condom catheter that will be inflated with air
62747321|NCT06324422|EXPERIMENTAL|Aerobic exercise group|Participants must be clinically fatigued when enrolled and furthermore meet additional inclusion criteria.
62553723|NCT02711631|NO_INTERVENTION|Control: Standard therapy|Participants in this arm of the study will receive standard therapy.
62553724|NCT02711631|EXPERIMENTAL|MedBIKE|Participants in this arm will be using the new MedBIKE system as their method of rehabilitation.
62747322|NCT06324422|EXPERIMENTAL|Waitlist control group/resistance exercise group|Participants must be clinically fatigued when enrolled and furthermore meet additional inclusion criteria.
62747323|NCT05078515||Patients with recurrence after TME|Patients who developed local recurrence after TME of rectal cancer
62747324|NCT05078515||Patients without recurrence after TME|Patients who did not develop local recurrence after TME of rectal cancer
62747325|NCT04544930|EXPERIMENTAL|therapist-guided|Therapist-guided Internet treatment based on cognitive behavior therapy (ICBT).
62747326|NCT05487040|EXPERIMENTAL|PF-07321332 (nirmatrelvir)/ritonavir participants with severe renal impairment on hemodialysis|Patients with Covid-19 infection and severe renal impairment. Capsule and tablet once a day by mouth.
62747327|NCT05487040|EXPERIMENTAL|PF-07321332 (nirmatrelvir)/ritonavir participants with severe renal impairment not on hemodialysis|Patients with Covid-19 infection and severe renal impairment. Capsule and tablet once a day by mouth.
62747328|NCT06046612|EXPERIMENTAL|heart failure with preserved ejection fraction|Empagliflozin 10mg, tablet, once daily
62747329|NCT06662162|EXPERIMENTAL|Active i-Lumen AMD therapy|Active transpalpebral microcurrent therapy
62747330|NCT06662162|SHAM_COMPARATOR|Sham i-Lumen AMD therapy|Sham transpalpebral microcurrent therapy
62747331|NCT01536665|EXPERIMENTAL|Low|
62747332|NCT01536665|EXPERIMENTAL|Medium|
62747333|NCT01536665|EXPERIMENTAL|High|
62747334|NCT01741025|EXPERIMENTAL|iFuse Implant System|Surgical placement of iFuse implants in the affected SI joint
62747335|NCT01741025|ACTIVE_COMPARATOR|conservative management|Medications, physical therapy, information
62553725|NCT03417778|EXPERIMENTAL|Moderate Hepatic Impairment|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
62553726|NCT03417778|EXPERIMENTAL|Severe Hepatic Impairment|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
62553727|NCT03417778|EXPERIMENTAL|Mild Hepatic Impairment|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
62567298|NCT01105169|ACTIVE_COMPARATOR|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
62747336|NCT03525301|ACTIVE_COMPARATOR|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fractions
62747337|NCT03525301|EXPERIMENTAL|short course treatment|patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
62747338|NCT05073796|EXPERIMENTAL|Interventional arm|Participants will receive the intervention as descibed in the respective section.
62747339|NCT06606002|EXPERIMENTAL|Group schema therapy|The group schema therapy intervention includes 30 group sessions and 8 individual sessions for the participants, and 9 group sessions for the participants' parents.
62747340|NCT06606002|ACTIVE_COMPARATOR|Control|Treatment as usual
62747341|NCT05440591|ACTIVE_COMPARATOR|Metformin|Metformin XR 500 mg tablets - up-to twice daily orally.
62747342|NCT05440591|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10 mg tablets - once daily
62747343|NCT05440591|EXPERIMENTAL|MetforminXR 500/Dapagliflozin 5mg|MetforminXR 500/Dapagliflozin 5mg , tablets- once daily
62747344|NCT01761591|EXPERIMENTAL|Acrobat|Device: PCI with Svelte Acrobat
62747345|NCT01761591|ACTIVE_COMPARATOR|Control BMS|Device: PCI with other BMS
62747346|NCT03897153|EXPERIMENTAL|Experimental:Diagnostic|Diagnostic Test: SONAS® Ultrasound Device
62747347|NCT02447250|EXPERIMENTAL|Single Arm: varied albuterol dose response|Subjects will be evaluated in 3 sessions. The sessions will occur within a 7 day time span, beginning after 14 days of age and at 28w0d to 33w6d corrected gestational age. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a single dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
62747348|NCT04605497|EXPERIMENTAL|Intervention Arm|Use of Dexcom G6 real-time CGM to monitor blood glucose levels continually.
62747349|NCT04605497|OTHER|Referent Arm|Self-capillary blood glucose monitoring (SCBG) testing 4x/day with blinded CGM every 2 weeks.
62747350|NCT00920387|EXPERIMENTAL|Full Dose LSD (200 mcg)|200 mcg LSD administered once during each of two LSD-assisted therapy sessions, scheduled two to four weeks apart.
62747351|NCT00920387|ACTIVE_COMPARATOR|Active Placebo LSD (20 mcg)|20 mcg LSD administered once during each of two LSD-assisted therapy sessions, scheduled two to four weeks apart.
62553728|NCT05584384|EXPERIMENTAL|Active group|The investigators aim for six sessions of anodal stimulation over the right primary motor area contralateral to the orofacial pain (C3 or C4 in 10-20 EEG system) with cathode above the frontal area ipsilateral to the orofacial pain (Fp1 or Fp2) using HDCstim by Newronika S.r.l., Italy. The therapy will be administered over two weeks (Mon, Wed, Fri) to ensure a washout period of 48 to 72 hours between applications. The current of 2 mA will be delivered via silicone electrodes inserted into saline (0.9%) filled cellulose sponges, anode 5x5cm, cathode 6x8cm, for 20 minutes with 20 seconds of both ramp-up and ramp-down. An International 10-20 EEG system will be used to determine the stimulation location, and dedicated EEG caps will be used to ensure consistency between applications.
62553729|NCT05584384|PLACEBO_COMPARATOR|Sham group|The sham (placebo) will be administered using the same devices with a preprogrammed sham protocol (using HDCprog by Newronika S.r.l., Italy) of 20 minutes to be virtually indistinguishable from the active stimulation.
62553730|NCT05594706||Newly diagnosed patients with T1DM|The investigators will do prospective measures in 10 to 15 children aged 2 to 18 years, at the time of diagnosis, four months after diagnosis and one year after diagnosis.
62553731|NCT05594706||Patients with T1DM of different duration|As the functional beta-cell mass gradually declines as disease duration increases, the investigators will do measurements in a cohort of children aged ≤ 18 years, with increasing diabetes duration. The investigators plan to analyze groups of 5 patients with a disease duration of 3 (36 - 47 months), 5 (60 - 71 months) and 10 years (120 - 131 months), respectively.
62553732|NCT02726659|EXPERIMENTAL|Celecoxib|Adjunct celecoxib in 6 week treatment
62553733|NCT02726659|PLACEBO_COMPARATOR|Placebo|Adjunct placebo in 6 week treatment
62553734|NCT03362814|EXPERIMENTAL|Experimental Group|Ravidasvir + Danoprevir + Ritonavir + Ribavirin
62553735|NCT03362814|PLACEBO_COMPARATOR|Placebo Group|Ravidasvir placebo + Danoprevir placebo + Ritonavir placebo + Ribavirin placebo
62553736|NCT05327933|EXPERIMENTAL|Surgery plus endovascular MMA embolization|
62553737|NCT05327933|ACTIVE_COMPARATOR|Surgery alone|
62553738|NCT00717717|NO_INTERVENTION|Control|No intervention except repeated measurements of physical capacity
62553739|NCT00717717|EXPERIMENTAL|Intervention|Intervention: One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
62553740|NCT04272788||CD patients|CD patients about to start Infliximab treatment, gives as i.v. injection of 5 mg/kg at baseline, after 2 weeks, 6 weeks, and then every 8th week.CD patients are followed for 14 weeks after the first administration of infliximab. At week 14 of Infliximab treatment, CD patients are classified as remission group (CDAI\<150 and endoscopic mucosal healing, R group) and non-remission group (CDAI≥150 and/or mucosal non-healing group, N group).
62553741|NCT04272788||Healthy controls|Healthy controls without Crohn's Disease.
62553742|NCT06351111|EXPERIMENTAL|Upper limb|Participants in this arm will receive up to 36 sessions of VNS paired with upper limb rehabilitative exercises
62553743|NCT06351111|EXPERIMENTAL|Lower limb|Participants in this arm will receive up to 36 sessions of VNS paired with lower limb rehabilitative exercises
62747352|NCT01498393|OTHER|Laser treatment|Laser treatment to Improve the Appearance of Onychomycosis
62747353|NCT05608395|EXPERIMENTAL|11C-Methionine PET/CT Arm|"The cohort consists of patients:~* diagnosed with GB~* with confirmed REP~* indicated for adjuvant chemoradiotherapy~* will undergo the 11C-MET PET/CT"
62747354|NCT05608395|NO_INTERVENTION|Arm A-historical|"The cohort consists of a historical group of patients collected in the period 2014-2018:~* with diagnosed GB~* with confirmed REP~* were indicated for adjuvant chemoradiotherapy"
62747355|NCT02761187||Relapsed/refractory (R/R) MM|Patients who have received 1 to 3 prior lines of therapy
62747356|NCT02761187||Newly diagnosed (ND) MM|Patients within 3 months from initiation of treatment
62747357|NCT02138409|EXPERIMENTAL|ON FSS 100 µg|Participants classified as opioid-naïve (ON), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, and further randomized to a dose of 100 µg
62747358|NCT02138409|EXPERIMENTAL|ON FSS 200 µg|Participants classified as opioid-naïve (ON), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, and further randomized to a dose of 200 µg
62747359|NCT02138409|EXPERIMENTAL|OE FSS 400 µg|Participants classified as opioid-experienced (OE), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, at a dose of 400 µg
62747360|NCT02138409|PLACEBO_COMPARATOR|ON PSS|Participants classified as opioid-naïve (ON) and randomized to receive one dose of matching placebo sublingual spray (PSS) 10 minutes before treatment procedure
62747361|NCT02138409|PLACEBO_COMPARATOR|OE PSS|Participants classified as opioid-experienced (OE) and randomized to receive one dose of matching placebo sublingual spray (PSS) 10 minutes before treatment procedure
62747362|NCT03074292|ACTIVE_COMPARATOR|conventional phototherapy|neonates with unconjugated hyperbilirubinemia exposed to conventional phototherapy
62747363|NCT03074292|ACTIVE_COMPARATOR|extensive phototherapy|neonates with unconjugated hyperbilirubinemia exposed to extensive phototherapy
62747364|NCT03074292|ACTIVE_COMPARATOR|LED phototherapy|neonates with unconjugated hyperbilirubinemia exposed to LED phototherapy
62747365|NCT06220864|EXPERIMENTAL|Dose Escalation|
62747366|NCT06220864|EXPERIMENTAL|Dose Expansion|
62747367|NCT06608082|OTHER|Totale hysterectomy with indocyanine green and fluorescence intensity analysis|"Patient scheduled to undergo total hysterectomy through a surgically accessible laparoscopic procedure.~The difference from standard care is that during the intraoperative period, at the end of the procedure, the patient will receive a diluted bolus of indocyanine green. The collected images will be analyzed using the TRACKER software in order to assess intraoperative vascularization of the area (fluorescence intensity value different from 0)."
62747368|NCT02258750|EXPERIMENTAL|Polydextrose|Tomato soup enriched with added polydextrose
62747369|NCT02258750|PLACEBO_COMPARATOR|Control|Tomato soup without added polydextrose
62747370|NCT05312632|EXPERIMENTAL|Safinamide Mesilate|Participants with parkinson's disease will be administered Safinamide Mesilate 50 milligram (mg) tablet, orally, once daily as add-on therapy to levodopa for up to 2 weeks. After 2 weeks, at the discretion of an investigator, dose of Safinamide Mesilate will be increased to 100 mg tablets (two tablets of 50 mg each), orally, once daily for up to 18 weeks.
62747371|NCT02220855|EXPERIMENTAL|BKM120|BKM120, 100mg capsule for oral use, taken once daily for two or more months for a maximum of one year. Each cycle is 28 days.
62747372|NCT06056336|EXPERIMENTAL|Adjuvant tislelizumab plus chemothearpy|Tislelizumab：200mg d1, q3w × 2 cycles，up yo 1 year; Nad-paclitaxel 260 mg/m2 d1 q3w 2 cycles;carboplatin AUC = 5 d1, q3w × 2 cycles.
62747373|NCT05917496||Patients|Children aged 11 months to 21 months on the day of inclusion in the study, with profound congenital deafness and having benefited from unilateral or bilateral cochlear implantation before 18 months of life inclusive, followed at Necker-Enfants Malades hospital and who receive a speech therapy.
62747374|NCT05311449|EXPERIMENTAL|Acupressure Group (experimental)|The experimental group will be given acupressure.
62747375|NCT05311449|PLACEBO_COMPARATOR|Placebo Acupressure Group (control)|The placebo group will be given placebo acupressure.
62374519|NCT06250504|EXPERIMENTAL|Intervention: Choice of long-acting PrEP and PEP added to Thetha Nami ngithethe nawe|"Tailored peer-led psychosocial support and social mobilisation into community based SRH and differentiated HIV care and prevention, including a choice of effective PrEP or PEP.~At the mobile AYFS in the intervention clusters nurses will offer the choice of either daily oral tenofovir/emtricitabine or injectable long acting cabotegravir (CAB LA) to be delivered to adolescents and young adults at risk of HIV acquisition. Those who decline will have the option of three monthly dapivarine vaginal rings or Post Exposure Prophylaxis (PEP) packs (tenofovir/lamuvidine/dolutegravir) to take home.~Peer navigators will promote long-acting PrEP in addition to oral PrEP. As part of the peer mentorship package, the peer naviators will remind young people of their follow-up visits."
62374520|NCT06250504|ACTIVE_COMPARATOR|Control (Enhanced SoC): Thetha Nami ngithethe nawe|"Tailored peer-led psychosocial support and social mobilisation into community based SRH and differentiated HIV care and prevention, including oral tenofovir/emtricitabine PrEP.~In the mobile AYFS, young people are offered self-taken vaginal swabs or urine testing for sexually transmitted infections (STIs), family planning support and syndromic and aetiological management for STIs; HIV counselling and two POCT; immediate initiation of ART if living with HIV and oral tenofovir/emtricitabine PrEP if HIV test is negative and they are suitable.~Peer navigators in control clusters will promote oral PrEP during their community based health promotion activities. As part of the peer mentorship package, the peer naviators will remind young people of their follow-up visits and if required accompany young people to the mobile clinics."
62747376|NCT04945850||Covid negative|"20 patients undergoing ocular surgery who are COVID negative will be included as control patients and undergo the same procedures.~All patients will get a vitreous tap from operative eye 0.1-0.2 ml fluid. This fresh sample will be tubed to the lab using a unique marked label. This will be performed after the trocar is placed~At the end of surgery, the BSS bag will be tubed to the lab using the same label."
62747377|NCT04945850||Covid positive|"60 patients undergoing ocular surgery with previous COVID infection will be stratified into three groups by time since diagnoses: 3, 6, 12 months \~ 20 patients per group.~All patients will get a vitreous tap from operative eye 0.1-0.2 ml fluid. This fresh sample will be tubed to the lab using a unique marked label. This will be performed after the trocar is placed~At the end of surgery, the BSS bag will be tubed to the lab using the same label."
62747378|NCT06662058|ACTIVE_COMPARATOR|Group I (audiometry)|Patients undergo audiometry at WEM at baseline and at 3 and 12 months after chemotherapy and/or radiation treatment.
62747379|NCT06662058|ACTIVE_COMPARATOR|Group II, Arm I (audiometry)|Patients undergo audiometry at WEM at baseline and at 3 and 12 months after chemotherapy and/or radiation treatment as in Group I.
62747380|NCT06662058|EXPERIMENTAL|Group II, Arm II (close to home audiometry, remote audiometry)|Patients undergo audiometry at WEM at baseline and are offered closer to home audiometry or self-administered remote audiometry at 3 and 12 months after chemotherapy and/or radiation treatment.
62747381|NCT02531425|EXPERIMENTAL|IT-pIL12-EP|intratumoral injection of plasmid-IL12 following immediately by electroporation
62747382|NCT02689739||Obese Pregnant cohort|Women will be consented to participate and then separated into a study group of obese women (BMI \>/= 30).
62747383|NCT02689739||Non-obese Pregnant cohort|This will be the control group of non-obese women (BMI \<30).
62747384|NCT01792713|ACTIVE_COMPARATOR|Sertaconazole 2% cream|2x daily treatment with Sertaconazole 2% cream for 4 weeks, 2 weeks follow-up
62747385|NCT01792713|PLACEBO_COMPARATOR|Placebo Arm|2x daily treatment with Placebo cream for 4 weeks, 2 weeks follow-up
62747386|NCT02617394|ACTIVE_COMPARATOR|Control group|
62747387|NCT02617394|EXPERIMENTAL|Study group|
62747388|NCT02052726|EXPERIMENTAL|Arm Label: Month 0, 1 and 3 Schedule|
62747389|NCT02052726|EXPERIMENTAL|Day 1, 8, and 30 Schedule|
62747390|NCT06178848|ACTIVE_COMPARATOR|propofol group|During induction, the propofol group initiates with a target-controlled infusion (TCI) of propofol, starting at an effect site concentration of 4.0 ng/ml. After intubation, it is adjusted to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
62747391|NCT06178848|EXPERIMENTAL|remimazolam group|The remimazolam group begins with a continuous infusion of remimazolam at 6 mg/kg/hr, which is then adjusted to 1 mg/kg/hr after loss of consciousness to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
62747392|NCT02666651|EXPERIMENTAL|Test group|Administration of oral tolvaptan (15-60mg PO titration) during admission for decompensated heart failure
62747393|NCT02666651|OTHER|Control group|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority
62747394|NCT03960411|EXPERIMENTAL|Doxycycline|Doxycycline 100 mg capsule by mouth every 12 hours for 7 days, administered early after primary PCI
62747395|NCT03960411|PLACEBO_COMPARATOR|Placebo|Placebo capsule by mouth every 12 hours for 7 days, administered early after primary PCI
62747396|NCT03584841|EXPERIMENTAL|Patients with mucoviscidosis|For patients with cystic fibrosis: clinically stable, all genotypes included.
62747397|NCT03584841|EXPERIMENTAL|Parents of patients with confirmed diagnosis of mucoviscidosis|The parents are heterozygous subjects
62747398|NCT03584841|ACTIVE_COMPARATOR|Healthy volunteers|
62747399|NCT00585494||Preoperative orthopedic|Patients undergoing elective total hip, knee and spinal surgery at University of Wisconsin hospital, having their preoperative visit between December 1, 2007 and November 30, 2008.
62553744|NCT06351111|EXPERIMENTAL|Bladder control|Participants in this arm will receive up to 36 sessions of VNS paired with bladder control rehabilitative exercises
62553745|NCT05588479|PLACEBO_COMPARATOR|Control|Capsules with no pomegranate extract One capsule to be administered once a day for 12 weeks.
62747400|NCT05259137|NO_INTERVENTION|Intra-lesional triamcinolone acetonide|This arm will will be our control. They will receive current standard of care of a single intra-lesional injection of 1 mL of 10mg/mL triamcinolone acetonide at 0 weeks, 6 weeks, and 12 weeks.
62747401|NCT05259137|EXPERIMENTAL|Intra-lesional triamcinolone acetonide + enalaprilat|This will be our intervention experiment. They will receive a single intra-lesional injection of 1.0 mL of 1.25 mg/mL of enalaprilat at 0 weeks, 6 weeks, and 12 weeks.
62747402|NCT00948857|EXPERIMENTAL|DHEA active treatment|Dehydroepiandrosterone 25 mg tid po
62553746|NCT05588479|EXPERIMENTAL|Intervention|Capsules with 500 mg of pomegranate extract One capsule to be administered once a day for 12 weeks.
62747403|NCT00948857|PLACEBO_COMPARATOR|DHEA Placebo|Blinded placebo
62747404|NCT05145764|EXPERIMENTAL|Suvorexant|Nightly dosing of suvorexant
62747405|NCT05145764|PLACEBO_COMPARATOR|Placebo|Nightly dosing of placebo
62553747|NCT00916383|EXPERIMENTAL|Upper Back|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of the upper back.
62553748|NCT00916383|EXPERIMENTAL|Upper Arm|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite arms.
62553749|NCT00916383|EXPERIMENTAL|Side of Torso|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of torso.
62553750|NCT02000726|EXPERIMENTAL|Placebo and Citalopram|4 weeks of 1 placebo pill/day and 12 weeks of citalopram 20-40 mg/day
62747406|NCT01434043||Myocardial ischemia patients|
62747407|NCT00142805|ACTIVE_COMPARATOR|AC-1202|Tricaprilin formulation, once daily. Administered orally
62747408|NCT00142805|PLACEBO_COMPARATOR|Matching Placebo to AC-1202|Placebo formulation, once daily. Administered orally
62747409|NCT02969291|OTHER|Reduced Sedentary Time Intervention|Reduced Sedentary Time Intervention (RSTI)
62747410|NCT04670458||CA group|Patients with In-Hospital Cardiac Arrest
62747411|NCT04670458||CONTROL group|Patients without In-Hospital Cardiac Arrest
62747412|NCT05707078|OTHER|Surgery|Based on PET/CT scan patients will undergo neck dissection.
62747413|NCT01159925||Possible hepatitis A Cohort|Children with an acute disease characterized by discrete onset of symptoms and jaundice
62747414|NCT01159925||Probable hepatitis A Cohort|Children with an increase in serum levels of transaminase 2.5 times higher than the maximum limit of the normal interval
62747415|NCT01159925||Confirmed hepatitis A Cohort|Children presenting a positive result for Immunoglobulin M for hepatitis A virus
62747416|NCT05275608|EXPERIMENTAL|VLCKD|"20 Patients recruited from our endocrinology department that will keep the same medical visits frequency and drugs and accept to be randomized to one of the two groups.~Inclusion criteria:~* Age 25-65~* BMI 30-40 mg/m2~* NAFLD~* DM2 drug-treated (metformin, SGLT2 inhibitors, GLP-1 analogues, DPPIV inhibitors, insulin) and HbA1c \> 7 and \< 10 %."
62747417|NCT05275608|ACTIVE_COMPARATOR|Hypocaloric Mediterranean Diet|"20 Patients recruited from our endocrinology department that will keep the same medical visits frequency and drugs and accept to be randomized to one of the two groups.~Inclusion criteria:~* Age 25-65~* BMI 30-40 mg/m2~* NAFLD~* DM2 drug-treated (metformin, SGLT2 inhibitors, GLP-1 analogues, DPPIV inhibitors, insulin) and HbA1c \> 7 and \< 10 %."
62747418|NCT06010641|EXPERIMENTAL|Head-down position|head-down position as an adjunct to guideline-based treatment
62747419|NCT06010641|OTHER|control|guideline-based treatment
62747420|NCT06404320|EXPERIMENTAL|PA program|Participants in the PA group will receive a 4-week remotely delivered one-on-one individualized PA program adjunct to TAU.
62747421|NCT06404320|NO_INTERVENTION|TAU|Participants in the TAU group will be given a handout with the Canadian 24-hour movement guidelines and be told that they are encouraged to engage in PA.
62747422|NCT06287515|EXPERIMENTAL|SRS hypophysectomy|Once the radiation plan is ready, you will be brought to the radiation treatment room and positioned for treatment. You will be lying on your back on the treatment table during the radiation treatment. You will not see, hear, or feel the radiation during the treatment. The treatment time varies but may range from 1-3 three hours. Once the treatment is completed, the headframe/mask will be removed and you will be brought to a recovery area.
62747423|NCT00176488|EXPERIMENTAL|Sequential epirubicin/vinorelbine|For patients with stage IIB (T3N0), IIIA, or IIIB breast cancer, epirubicin and vinorelbine will be administered for up to 5 cycles. For patients with stage IV breast cancer, epirubicin and vinorelbine will be administered as long as there is evidence of continued response or stable disease and no evidence of cardiac or other serious toxicities.
62747424|NCT01331382|EXPERIMENTAL|250mg trans- resveratrol|
62747425|NCT01331382|EXPERIMENTAL|250mg trans-resveratrol with 20mg piperine|
62747426|NCT01331382|PLACEBO_COMPARATOR|Placebo|
62747427|NCT01518998|PLACEBO_COMPARATOR|Placebo|Take one double-blind capsule filled with a placebo tablet in the every morning
62747428|NCT01518998|ACTIVE_COMPARATOR|Fimasartan 60mg|Take one double-blind capsule filled with of Fimasartan 60mg in the every morning
62747429|NCT01518998|ACTIVE_COMPARATOR|Fimasartan 30mg|Take one double-blind capsule filled with Fimasartan 30mg in the every morning
62374521|NCT02921906|EXPERIMENTAL|Neonatal diabetes|People with neonatal diabetes due to mutations in the KCNJ11 gene who are treated with sulphonylureas and not on insulin.
62553751|NCT06443229|EXPERIMENTAL|Graded Activity based in exercises and educational approach|Exercises for warming up, strengthening, and relaxation, along with informational sessions incorporating an educational approach for low back pain using Telerehabilitation platform.
62553752|NCT06443229|SHAM_COMPARATOR|Educational Approach|Educational approach for low back pain using Telerehabilitation platform.
62747430|NCT01518998|ACTIVE_COMPARATOR|Amlodipine 5mg|Take one double-blind capsule filled with Amlodipine 5mg in the every morning
62553753|NCT03474874|OTHER|Collagen Dressing and Comparator|NeoMatriX Collagen Dressing and Comparators - positive control and normal saline will be applied to the absorbent pad portion of the exclusive dressing.
62553754|NCT03757858|EXPERIMENTAL|HT+ACT|
62553755|NCT03757858|EXPERIMENTAL|HT+ACT+PD-1|
62553756|NCT03757858|EXPERIMENTAL|HT+ACT+CT|
62553757|NCT03757858|ACTIVE_COMPARATOR|HT+CT|
62553758|NCT01962818|EXPERIMENTAL|HFOV-sigh at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~Frequency 3 breaths/min Ti = 1s Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP\*Tinsp+PEEP\*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
62553759|NCT01962818|EXPERIMENTAL|HFOV-only at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~Frequency 3 breaths/min Ti = 1s Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP\*Tinsp+PEEP\*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
62553760|NCT03073824|EXPERIMENTAL|vSculpt, model #VS1100|A novel intravaginal device for females
62567299|NCT01105169|PLACEBO_COMPARATOR|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
62567300|NCT06033027|NO_INTERVENTION|Baseline phase|
62567301|NCT06033027|EXPERIMENTAL|Soft-robotic glove phase|
62567302|NCT06033027|NO_INTERVENTION|Retention phase|
62567303|NCT03211676|ACTIVE_COMPARATOR|Theranova-500|
62567304|NCT03211676|SHAM_COMPARATOR|Elisio-21H|
62747431|NCT01518998|ACTIVE_COMPARATOR|Amlodipine 10mg|Take one double-blind capsule filled with Amlodipine 10mg in the every morning
62747432|NCT01518998|EXPERIMENTAL|Fimasartan 60mg/ Amlodipine 5mg|Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 5mg in the every morning
62747433|NCT01518998|EXPERIMENTAL|Fimasartan 60mg/Amlodipine 10mg|Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 10mg in the every morning
62747434|NCT01518998|EXPERIMENTAL|Fimasartan 30mg/Amlodipine 5mg|Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 5mg in the every morning
62747435|NCT01518998|EXPERIMENTAL|Fimasartan 30mg/Amlodipine 10mg|Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 10mg in the every morning
62374522|NCT02921906|ACTIVE_COMPARATOR|Non-diabetic controls|People without diabetes.
62747436|NCT03554941|EXPERIMENTAL|noise stimulation|noise stimulation
62747437|NCT06398730|EXPERIMENTAL|A non-radiolabeled GEH200520 - 1 mg|
62747438|NCT06398730|EXPERIMENTAL|A non-radiolabeled GEH200520 - 2 mg|
62747439|NCT06398730|EXPERIMENTAL|A non-radiolabeled GEH200520 - 4 mg|
62747440|NCT06398730|EXPERIMENTAL|A non-radiolabeled GEH200520 - 6 mg|
62374523|NCT02921906|ACTIVE_COMPARATOR|Controls with Type 2 Diabetes|People with Type 2 diabetes who are treated with sulphonylurea medication.
62374524|NCT01739374|EXPERIMENTAL|Device - Reduced mesh implants|Patients treated with reduced mesh implants for POP reconstruction
62374525|NCT02698852|EXPERIMENTAL|BuMA Supreme group|Totally 1000 subjects combined the 220 subjects from randomized controlled trial(RCT) group
62374526|NCT05077280|EXPERIMENTAL|one arm|see below
62374527|NCT01446549|EXPERIMENTAL|Deep Brain Stimulation|
62374528|NCT01446549|EXPERIMENTAL|Locomotor Exercise|
62747441|NCT06398730|EXPERIMENTAL|A non-radiolabeled GEH200520 - 8 mg|
62747442|NCT06398730|EXPERIMENTAL|A non-radiolabeled GEH200520 - 10 mg|
62747443|NCT06398730|EXPERIMENTAL|A non-radiolabeled GEH200520 - 12 mg or 15 mg|
62747444|NCT05096234|EXPERIMENTAL|[18F]F-AraG PET|"Subjects will undergo PET imaging at the following time points:~* Baseline, prior to lymphodepleting chemotherapy: \[18F\]F-AraGPET/CT, followed the next day by FDG-PET/CT~* At peak CAR expansion: Day 4 (± 2 days) post-CAR infusion:~  \[18F\]F-AraG PET~* At Day +28 (± 4 days) post-CAR infusion: FDG-PET/CT Subjects will have a paired biopsy after each imaging time point, if possible. Subjects will be followed for safety of \[18F\]F-AraG for 30 days after last dose"
62747445|NCT02156284|EXPERIMENTAL|Empathic behaviour by nurses|Patients who received empathic behaviour was performed by a trained nurse.
62747446|NCT02450461||Asthma|20 patients with asthma
62553761|NCT05747651||Active SLE|"Patients will undergo regular follow-up where routine clinical examination and laboratory assessments will be conducted, and biological samples will be obtained. The patients will be instructed to contact their center whenever they develop a symptom suspicious of flare. In such cases, an unscheduled visit will be conducted for clinical examination, assessment and sampling similar to the last visit.~If a patient needs a major change in therapy at one of the scheduled visits or at an unscheduled visit, an early termination (ET) visit will be planned. Patients requiring a major change in therapy due to active disease (defined as BILAG A or B) from week 12 through week 52 will undergo two additional evaluations at week +26 and at week +52 from the time of early termination/new therapy initiation in order to determine biomarkers of secondary response after the change in therapy (herein termed secondary response) and persistent non- response (herein termed refractory disease)."
62553762|NCT05585203|EXPERIMENTAL|Contingency management|In addition to receiving usual care at the recovery house, participants assigned to this arm will receive contingency management by trained recovery house staff in addition to their usual care. Contingency management sessions will be led by a trained recovery house staff member who is also a research participant in the study. Contingency management will occur once weekly for sessions of approximately 10-15 minute duration for up to 12 weeks. Participants will plan three recovery-oriented activities with the staff member each week, and upon verification of completion of the tasks, the resident participant can earn prize draws of varying monetary amounts.
62747447|NCT02450461||Controls|20 control subjects with no apparent lung disease and normal lung function testing. Matched for gender, age and smoking history.
62747448|NCT05180799|EXPERIMENTAL|BA3071|Conditionally active biologic (CAB) antibody that binds to CTLA-4
62747449|NCT05180799|EXPERIMENTAL|Combination Therapy|Conditionally active biologic (CAB) antibody that binds to CTLA-4 with PD-1 inhibitor
62747450|NCT05180799|EXPERIMENTAL|Combination Therapy + Chemotherapy|Conditionally active biologic (CAB) antibody that binds to CTLA-4 with PD-1 inhibitor + Chemotherapy
62553763|NCT05585203|ACTIVE_COMPARATOR|Usual Care|Participants in this arm will receive usual care that they would normally receive at the recovery houses. Recovery houses are safe, healthy, family-like substance-free living environments that support individuals in recovery from addiction. Although recovery residences vary considerably, this form of housing benefits individuals in recovery by reinforcing a substance-free lifestyle and providing direct connections to other peers in recovery, mutual support groups and recovery support services.
62553764|NCT04818983||NSCLC cohort|Patients with locally advanced or metastatic non-small cell lung cancer who are planning to provide atezolizumab combination therapy as the most appropriate medical care
62747451|NCT05180799|EXPERIMENTAL|Neoadjuvant Combination Therapy + Chemotherapy|Conditionally active biologic (CAB) antibody that binds to CTLA-4 with PD-1 inhibitor + Chemotherapy prior to surgical resection
62747452|NCT03319953|EXPERIMENTAL|Treatment Sequence 1: TAK-041 40 mg/Placebo + Antipsychotics|TAK-041 40 milligram (mg), suspension, orally on Day 1 of Treatment Period 1, followed by 35 day Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
62747453|NCT03319953|EXPERIMENTAL|Treatment Sequence 2: Placebo/TAK-041 40 mg + Antipsychotics|TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 40 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
62747454|NCT03319953|EXPERIMENTAL|Treatment Sequence 3: TAK-041 160 mg/Placebo + Antipsychotics|TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
62747455|NCT03319953|EXPERIMENTAL|Treatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics|TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
62747456|NCT03096795|PLACEBO_COMPARATOR|Part 1: Placebo|Healthy participants with a history of mild atopy and proven sensitivity to house dust mite (HDM) will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously.
62747457|NCT03096795|EXPERIMENTAL|Part 1: MEDI3506 SC Dose 1|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 subcutaneously.
62747458|NCT03096795|EXPERIMENTAL|Part 1: MEDI3506 SC Dose 2|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 2 subcutaneously.
62747459|NCT03096795|EXPERIMENTAL|Part 1: MEDI3506 SC Dose 3|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 3 subcutaneously.
62553765|NCT04818983||ED-SCLC cohort|Patients with extensive disease small cell lung cancer who are planning to provide atezolizumab combination therapy as the most appropriate medical care
62567305|NCT04924361||Early onset dementia|Dementia patients with onset age lower than 65y/o
62747460|NCT03096795|EXPERIMENTAL|Part 1: MEDI3506 SC Dose 4|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 4 subcutaneously.
62747461|NCT03096795|EXPERIMENTAL|Part 1: MEDI3506 SC Dose 5|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 5 subcutaneously.
62747462|NCT03096795|EXPERIMENTAL|Part 1: MEDI3506 SC Dose 6|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 6 subcutaneously.
62747463|NCT03096795|EXPERIMENTAL|Part 1: MEDI3506 IV Dose 6|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 6 intravenously.
62747464|NCT03096795|PLACEBO_COMPARATOR|Part 2: Placebo|Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
62567306|NCT04924361||Late onset dementia|Dementia patients with onset age between 65y/o and 85y/o
62747465|NCT03096795|EXPERIMENTAL|Part 2: MEDI3506 SC Dose 4|Participants with COPD will receive 3 administration of MEDI3506 Dose 4 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
62747466|NCT03096795|EXPERIMENTAL|Part 2: MEDI3506 SC Dose 5|Participants with COPD will receive 3 administration of MEDI3506 Dose 5 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
62374529|NCT02419586|EXPERIMENTAL|bubble gum chewing and routine care|Start chewing gum on postoperative day at three times daily with no more than 30 minutes till discharged
62374530|NCT02419586|NO_INTERVENTION|routine care|Non interventional group will receive existing routine care as usual
62553766|NCT02286843|EXPERIMENTAL|HER2-targeted PET/CT|Pts with confirmed HER2- breast cancer will then undergo HER2-targeted PET/CT. 89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. 89Zr-pertuzumab is a novel radiotracer which may allow for specific visualization of HER2+ lesions. PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions, rather than evaluation of only single lesions by biopsy. Avid lesions will be considered suspicious for HER2+ malignancy. Pts with at least one 89Zr-trastuzumab or 89Zr-pertuzumab avid lesion will be biopsied to confirm HER2+ pathology. From these 50 pts, we will determine the proportion of HER2- primary breast cancer pts that express HER2+ malignancy imagable by HER2-targeted PET/CT. Pts recruited to the protocol, but then drop out prior to HER2-targeted PET/CT due HER2+ disease being identified on retesting of the patient's archived tissue samples, will be replaced with newly recruited pts.
62553767|NCT02275169|EXPERIMENTAL|Treated|Urofollitropin 150 IU ampoules three times a week for three months
62553768|NCT02275169|PLACEBO_COMPARATOR|Controls|Placebo ampoules three times a week for three months
62553769|NCT00989482|EXPERIMENTAL|Computer Kiosk Eduction|
62553770|NCT01226927|ACTIVE_COMPARATOR|Continuous infusion rate|Patients received a continuous infusion of 0.2% ropivacaine at 10.1 mL/hr via their femoral nerve catheter.
62553771|NCT01892956||Healthy volunteers|
62374531|NCT01029665||CDH survivors|School age (ages 4-6) Congenital Diaphragmatic Hernia survivors treated at Duke University Medical Center.
62374532|NCT05988086|ACTIVE_COMPARATOR|Group 1: platelet rich fibrin|Group 1: This will include 12 children in whom nasal layer of alveolar cleft will be repaired using autologous platelet rich fibrin with autogenous chin bone.
62374533|NCT05988086|ACTIVE_COMPARATOR|Group 2:collagen membrane|Group 2: This will include 12 children in whom nasal layer of alveolar cleft will be repaired using collagen membrane with autogenous chin bone.
62374534|NCT04474392||At-Risk (N=180)|"1. No evidence of inflammatory arthritis on clinical examination AND~2. At elevated risk for RA based on familial or serologic risk~   * Familial risk includes having a first degree relatives (FDRs) with RA~  * Serologic risk includes asymptomatic serum ACPA positivity~There will be 1 study visit per year for 3 years; for a subset of 30 of these participants, there will be an additional 3 quarterly visits in one year.~Study Procedures (Baseline \& Follow-up):~* Questionnaires~* Physical and joint exam~* Measurement of participants' height, weight~* Blood and sputum collection"
62374535|NCT04474392||Healthy Controls (N=120)|"1. No history of RA~2. No FDRs with RA~3. No systemic use of immunosuppressants for autoimmune disease~Participants will return for 1 follow-up visit, approximately 1 year after their baseline visit.~Study Procedures (Baseline \& Follow-up):~* Questionnaires~* Physical and joint exam~* Measurement of participants' height, weight~* Blood and sputum collection"
62553772|NCT01892956||Newly diagnosed T2DM|Newly diagnosed T2DM, who have not started yet medical treatment with glucose lowering medications
62553773|NCT04436601|ACTIVE_COMPARATOR|Lactulose|90 ml of Lactulose dissolved in 750 ml of water administered orally by mouth or nasogastric tube (three doses within 24 hrs) continued up to 72 hours or until patient discharge, whichever comes first.
62553774|NCT04436601|EXPERIMENTAL|PEG: Polyethylene Glycol|Three or four sachet of Movicol(PEG) will be dissolved in 750 ml of water and will be given over 24 hrs as 3 doses orally by mouth or Nasogastric tube and will continue up to 72 hours or until patient discharge, whichever comes first
62747467|NCT03096795|EXPERIMENTAL|Part 2: MEDI3506 SC Dose 6|Participants with COPD will receive 3 administration of MEDI3506 Dose 6 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
62747468|NCT03096795|PLACEBO_COMPARATOR|Part 3: Placebo|Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously.
62747469|NCT03096795|EXPERIMENTAL|Part 3: MEDI3506 IV Dose 6|Healthy Japanese participants will receive a single MEDI3506 Dose 6 intravenously.
62747470|NCT03932864|PLACEBO_COMPARATOR|Single Ascending Dose of MGTA-145 or placebo|MGTA-145 or placebo dose escalation as single agent, single dose
62747471|NCT03932864|PLACEBO_COMPARATOR|Single Dose MGTA-145 or placebo plus plerixafor|MGTA-145 or placebo in combination with plerixafor, single dose
62747472|NCT03932864|EXPERIMENTAL|Single dose MGTA-145 plus plerixafor for 2 sequential d|MGTA-145 in combination with plerixafor on two consecutive days; single dose per day
62553775|NCT00290550|OTHER|1|MK-0457
62553776|NCT01112059|PLACEBO_COMPARATOR|Placebo|Patients given placebo twice a day for 8 days at beginning of inpatient CF exacerbation
62553777|NCT01112059|ACTIVE_COMPARATOR|doxycycline|Patients given doxycycline 100 mg tablet twice a day for 8 days at the beginning of inpatient CF exacerbation
62553778|NCT02271932||Surgery|Surgical management with appendectomy consists of hospital admission with initiation of intravenous antibiotics and urgent appendectomy .
62747473|NCT03932864|EXPERIMENTAL|Single dose MGTA-145 plus plerixafor followed by apheresis|MGTA-145 in combination with plerixafor followed by apheresis
62747474|NCT01059682|EXPERIMENTAL|Dalcetrapib|
62747475|NCT01059682|PLACEBO_COMPARATOR|Placebo|
62747476|NCT03319563|EXPERIMENTAL|local anesthetic-epinephrine group|"after general anesthesia, the Infiltration cocktail was done by the surgeon at three levels:~1. Subcutaneous: before incision at a volume 20 ml/10 cm/side.~2. Muscular Paravertebral: before opening the thoracolumbar fascia, using the same previous volume.~3. Neural paravertebral: after exposure of the transverse processes. A volume of 5 ml/per each process of the same cocktail, 1 cm deep to the surface of the corresponding process before pedicular screws fixation after negative blood aspiration."
62747477|NCT03319563|PLACEBO_COMPARATOR|saline group|after general anesthesia, the same infiltration volume and technique using normal saline.
62747478|NCT01858857||Geriatric psychiatric in patients|
62747479|NCT06110156|EXPERIMENTAL|Patient-tailored deprescribing assessment and intervention (MCI and Dementia diagnosis)|Patients are identified for enrollment via a risk prediction model and enrolled in a pharmacist-led polypharmacy clinic. The pharmacist will conduct a comprehensive medication review, which will include: medication reconciliation, assessment of patient risk factors, identification of potentially inappropriate medications, identification of potential prescribing omissions, shared decision-making with the patient and/or caregiver, and confirmation of the results with the primary care clinician (PCP). Once the PCP has approved the recommendations, the pharmacist will make the appropriate changes to the medication regimen, will provide tailored medication education and counseling and will follow-up with the patient at least once per month to assess side effects, adverse effects, and provide support. This arm specifically includes only patients with a diagnosis of Mild Cognitive Impairment (MCI) or Alzheimer's Disease and Related Dementias (ADRD) at enrollment.
62747480|NCT06110156|NO_INTERVENTION|Usual care (MCI and Dementia diagnosis)|Patients in the comparator arm will see their primary care clinician as needed. This arm specifically includes patients with a diagnoses of Mild Cognitive Impairment (MCI) or Alzheimer's Disease and Related Dementias (ADRD) at enrollment.
62553779|NCT02271932||Non-operative|Non-operative management consists of hospital admission for observation with a minimum of 24 hours of intravenous antibiotics and a minimum of 12 hours nil per os (NPO). With clinical improvement, patients are switched to oral antibiotics and discharged home with a prescription for oral antibiotics to complete a total antibiotic course of 7 days (including the duration of intravenous antibiotics).
62553780|NCT01176513|EXPERIMENTAL|GE 148-002|
62553781|NCT04829669||Participants with Major Depressive Disorder (MDD) and Active Suicidal Ideation with Intent|Participants with MDD (moderate or severe) and active suicidal ideation with intent as defined/confirmed by healthcare team will be enrolled and treated in accordance with routine clinical practice. The primary data source for this study will be the medical chart review, carer and clinician-reported outcome measures records of each participant.
62553782|NCT01277783|EXPERIMENTAL|Endocardial Left Ventricular pacing|All patients will undergo the intervention, and are followed at 1, 3, 6, and 12 months (minimum) and biannually thereafter until 1 year after enrollment of the last patient.
62553783|NCT04292444|EXPERIMENTAL|RAGE polymorphism (TT)|30 participants with the RAGE polymorphism (-374 T/A: rs1800624; TT) will be selected and scanned twice.
62747481|NCT06110156|EXPERIMENTAL|Patient-tailored deprescribing assessment and intervention (no MCI and Dementia diagnosis)|Patients are identified for enrollment via a risk prediction model and enrolled in a pharmacist-led polypharmacy clinic. The pharmacist will conduct a comprehensive medication review, which will include: medication reconciliation, assessment of patient risk factors, identification of potentially inappropriate medications, identification of potential prescribing omissions, shared decision-making with the patient and/or caregiver, and confirmation of the results with the primary care clinician (PCP). Once the PCP has approved the recommendations, the pharmacist will make the appropriate changes to the medication regimen, will provide tailored medication education and counseling and will follow-up with the patient at least once per month to assess side effects, adverse effects, and provide support. This arm specifically includes only patients with NO diagnosis of Mild Cognitive Impairment (MCI) or Alzheimer's Disease and Related Dementias (ADRD) at enrollment.
62747482|NCT06110156|NO_INTERVENTION|Usual care (no MCI and Dementia diagnosis)|Patients in the comparator arm will see their primary care clinician as needed. This arm specifically includes patients with NO diagnoses of Mild Cognitive Impairment (MCI) or Alzheimer's Disease and Related Dementias (ADRD) at enrollment.
62747483|NCT05898308|NO_INTERVENTION|"standard-of-care arm"|"Patients will be initially treated according to the French guidelines (PNDS) based on the Ritux-3 regimen: 1000 mg of rituximab on Day1-Day14, and 500 mg at Month 12 and Month 18, plus oral prednisone 1 mg/kg/day initially, with the aim to stop prednisone after 6 months.~The prednisone dose could be increased up to 1.5 mg/kg/day in patients who do not achieve disease control with the initial 1 mg/kg/day dose."
62374536|NCT04474392||RA Diagnosis (N=40)|"1. Classified RA by 1987 ACR and/or 2010 ACR/EULAR RA classification criteria (confirmed by medical chart review) OR~2. Diagnosed with RA by a board-certified rheumatologist (confirmed by medical chart review)~Participants will return for 1 follow-up visit, approximately 1 year after their baseline visit.~Study Procedures (Baseline \& Follow-up):~* Questionnaires~* Physical and joint exam~* Measurement of participants' height, weight~* Blood and sputum collection"
62391500|NCT04132817|EXPERIMENTAL|Group A Target Class A-3: Nivolumab+nab-paclitaxel+ipilimumab|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
62553784|NCT04292444|EXPERIMENTAL|RAGE polymorphism (TA/AA)|30 participants with the RAGE polymorphism (-374 T/A: rs1800624; TA/AA) will be selected and scanned twice.
62553785|NCT04108299|PLACEBO_COMPARATOR|Wait-list Control|Standard of care
62553786|NCT04108299|EXPERIMENTAL|SMS Intervention|The SMS group will receive brief lifestyle counseling videos via SMS links. At the end of the study, the wait-list control group will be provided the opportunity to receive the counseling videos.
62567307|NCT04924361||Oldest old dementia|Dementia patients with onset age older than 85y/o
62567308|NCT04924361||Cognitive normal control|cognitive normal control
62747484|NCT05898308|EXPERIMENTAL|"personalized maintenance treatment arm"|Patients will be treated with the same regimen (1000 mg of rituximab on Day1-Day14, and 500 mg at Month 12 and Month 18, plus oral prednisone 1 mg/kg/day initially, with the aim to stop prednisone after 6 months), which will then be adapted according to the evolution of anti-Dsg Abs: During the initial phase of treatment: patients i) whose serum anti-Dsg Abs have not sufficiently decreased ii) and/or those who initially had a severe pemphigus (at the inclusion visit) defined by a PDAI score \> 45) will receive 1 g of rituximab at Month 6 ; Beyond the second year from Month 22 (4 months after the Month 18 infusion of 500 mg of rituximab) until the end of the study: patients whose anti-Dsg3 Abs re-increase \>50 UI/ml and/or anti-Dsg1Abs re-increase\>20 UI/ml) will receive 1 g of rituximab. A maximum of 2 additional maintenance infusions of rituximab per year will be allowed during the study.
62374537|NCT04513106|EXPERIMENTAL|Advance care planning programme|It is a theory-driven advance care planning programme specifically designed for PWEDs and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model. Each dyad of participants will receive a 3-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 1 group-based sessions and 2 dyadic discussions. One hour for each session, and once weekly. Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. They will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participant will be given an ACP booklet documenting the ACP process.
62374538|NCT04513106|PLACEBO_COMPARATOR|Attention control|Dyads of participants in the control group will receive 3-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants.
62374539|NCT01979380|EXPERIMENTAL|KD101|
62374540|NCT01979380|PLACEBO_COMPARATOR|placebo|
62374541|NCT02092324|EXPERIMENTAL|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO every other day, QD, or BID on days 1-28. Each patient will be followed for a maximum of 96 weeks (24 cycles, 1 cycle is 4 weeks long). If the study drug continues to be effective, the patient may be eligible to continue on study drug past 24 cycles.
62374542|NCT01069094|EXPERIMENTAL|progenta 12.5 mg|Progenta (CDB-4124) 12.5 mg capsule
62374543|NCT01069094|EXPERIMENTAL|progenta 25 mg|Progenta (CDB-4124) 25 mg capsule
62374544|NCT01069094|EXPERIMENTAL|progenta 50 mg|Progenta (CDB-4124) 50 mg capsule
62374545|NCT01069094|ACTIVE_COMPARATOR|Lucron Depot|Lucron Depot, Leuprolide acetate for depot suspension
62374546|NCT01069094|PLACEBO_COMPARATOR|placebo|Placebo capsule
62374547|NCT02971072|EXPERIMENTAL|Patients|Subjects with shoulder tendinopathy who will undergo both a subacromial injection and physical therapy
62374548|NCT05752461|EXPERIMENTAL|Treatment group A: SHR-2004 injection|
62553787|NCT04124445|ACTIVE_COMPARATOR|Pulsed Radiofrequency Ablation|Radiofrequency ablation of sensory nerves at minimum 3 levels of cervical spine with Maximum allowable temperature 50° rotation: 90.; Pulse rate: 3 Hz; pulse duration: 50 ms; 3 minutes
62553788|NCT04124445|ACTIVE_COMPARATOR|Continuous Radiofrequency Ablation|Radiofrequency ablation of sensory nerves at minimum 3 levels of cervical spine, burn will be made at 80° for 60 seconds.
62553789|NCT04109144|EXPERIMENTAL|Large Volume Paracentesis (LVP) with Fresh Frozen Plasma (FFP)|All participants who are scheduled for a LVP and meet the eligibility criteria will be monitored for 3 consecutive periods. At the second drainage participants will receive 2 units, or about 500 ccs, of fresh frozen plasma intravenously, plus 1 bottle, or 50 ccs, of 25% albumin if more than 4 liters of fluid are removed
62553790|NCT04109144|ACTIVE_COMPARATOR|Large Volume Paracentesis (LVP) with Albumin|All participants who are scheduled for a LVP and meet the eligibility criteria will be monitored for 3 consecutive periods. At the first and third drainage participants will receive 1 bottle, or 50 ccs, of 25% albumin intravenously for every two liters of fluid removed
62747485|NCT06053112|EXPERIMENTAL|Test group|New infant formula with 6 HMOs blend
62747486|NCT06053112|ACTIVE_COMPARATOR|Control group|Standard infant formula without 6 HMOs blend
62747487|NCT06053112|NO_INTERVENTION|Reference group|Breastfeeding
62747488|NCT03811925|OTHER|DCB|
62747489|NCT03811925|OTHER|Stenting|
62747490|NCT02345772|EXPERIMENTAL|Treatment Protocol|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery. Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
62747491|NCT04328753|EXPERIMENTAL|super oxidized water group|
62747492|NCT04328753|ACTIVE_COMPARATOR|chlorhexidene group|
62374549|NCT05752461|EXPERIMENTAL|Treatment group B: SHR-2004 injection|
62374550|NCT05752461|EXPERIMENTAL|Treatment group C: SHR-2004 injection|
62374551|NCT05752461|ACTIVE_COMPARATOR|Treatment group D: Enoxaparin sodium injection|
62374552|NCT03930927|EXPERIMENTAL|Self Assembling peptide|intervention
62374553|NCT03930927|EXPERIMENTAL|Fluoride|Comparator
62374554|NCT00777257|EXPERIMENTAL|Study Group A|Tdap vaccine + placebo concomitantly on Day 0; Menactra® vaccine 28 days later
62374555|NCT00777257|EXPERIMENTAL|Study Group B|Tdap vaccine + Menactra® vaccine concomitantly on Day 0; placebo 28 days later
62747493|NCT04328753|PLACEBO_COMPARATOR|distilled water|
62747494|NCT01708265|ACTIVE_COMPARATOR|Early mitral valve repair|Early mitral valve repair
62747495|NCT01708265|ACTIVE_COMPARATOR|Watchful waiting|Watchful waiting
62747496|NCT00412685||TGA group|The TGA group consists of 15 patients treated withMustard or Senning procedures for surgical repaired of D-TGA atrial switch operation.
62747497|NCT00412685||TOF group|The TOF group consists of 15 patients with surgically corrected TOF.
62747498|NCT00412685||Control group|The control group C consists of 15 control subjects (AH) with normal Doppler Echocardiographic echocardiographic examinations.
62747499|NCT03971240|EXPERIMENTAL|outcome of surgically evacuated traumatic ASDH|we will operate patients with traumatic acute subdural hematoma with some criteria and evaluate the outcome of surgery
62747500|NCT03541967|OTHER|ADHEAR-PONTO|The ADHEAR system will be fitted to the patient who will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the ADHEAR system. Then the patient will be fitted with the PONTO 3 SUPER POWER on softband and will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the PONTO 3 SUPER POWER on softband.
62747501|NCT03541967|OTHER|PONTO-ADHEAR|The PONTO 3 SUPER POWER on softband will be fitted to the patient who will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the PONTO 3 SUPER POWER on softband. Then the patient will be fitted with the ADHEAR system and will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the ADHEAR system.
62747502|NCT04608409|EXPERIMENTAL|Lapatinib - Group 1|Patients in this group will receive Lapatinib (500mg PO BID) and Paclitaxel (80mg/m2).
62747503|NCT04608409|EXPERIMENTAL|Lapatinib - Group 2|Patients in this group will receive Lapatinib (750mg PO BID) and Paclitaxel (80mg/m2).
62747504|NCT04608409|EXPERIMENTAL|Lapatinib - Group 3|Patients in this group will receive Lapatinib (1500mg PO BID) and Paclitaxel (80mg/m2).
62747505|NCT04608409|EXPERIMENTAL|Lapatinib - Group 4|Patients in this group will receive Lapatinib (2000mg PO BID) and Paclitaxel (80mg/m2).
62747506|NCT00883285||1|conventional aortic valve replacement
62747507|NCT00883285||2|transfemoral aortic valve replacement
62747508|NCT00883285||3|transapical aortic valve replacement
62747509|NCT06283940|EXPERIMENTAL|Physiotherapist-led exercise based cardiac rehabilitation (PT-X)|PT-X consists of centralcirculatory aerobic exercise and muscular endurance training in an existing PT-X group at Alingsas Hospital in Sweden. The patients will follow an individually tailored exercise program, twice a week for 60 minutes each session over 12 weeks. The physiotherapist guides and progresses the program based on the patient's exercise capacity throughout the intervention. Additionally, two sessions of home-based exercise will be added and recorded in an exercise diary. The exercise programs are prescribed after the patient's individual exercise capacity, with perceived exertion graded 13-17 on Borg's 6-20 scale.
62747510|NCT06283940|NO_INTERVENTION|Control group|The patient will continue with their usual activities during the control period
62374556|NCT00777257|EXPERIMENTAL|Study Group C|Menactra® vaccine + placebo concomitantly on Day 0; Tdap vaccine 28 days later
62374557|NCT06305923|PLACEBO_COMPARATOR|placebo cream|everyday using of placebo cream
62747511|NCT02007135||Healthy|Healthy persons, without non-specific low back pain
62747512|NCT00597623|EXPERIMENTAL|1|2 injections of Adalimumab (Humira®)
62747513|NCT00597623|PLACEBO_COMPARATOR|2|2 injection of Placebo
62747514|NCT03295383|EXPERIMENTAL|Rituximab treatment|"Rituximab at a dose of 1000 mg (or matching placebo) will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197~cyclophosphamide placebo will be administered orally once daily"
62747515|NCT03295383|ACTIVE_COMPARATOR|Cyclophosphamide treatment|"cyclophosphamide will be administered orally once daily at the following initial doses:~patients younger than 75 years: 1.5 mg/kg/day, orally. patients older than 75 years: 1 mg/kg/day, orally.~Rituximab placebo (NaCl 0.9 %) will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197"
62747516|NCT01841125|EXPERIMENTAL|escitalopram|escitalopram 15mg
62553791|NCT05124470|EXPERIMENTAL|musical training sessions|24 musical training sessions over the 6 months + 3 months of follow-up post cognitive remediation.
62553792|NCT04179318||low risk|BCT Score \<4
62553793|NCT04179318||high risk|BCT Score ≥4
62553794|NCT01424007|EXPERIMENTAL|Lower fat diet|Participants in this group will be individually counseled and receive print materials on a higher-carbohydrate, lower-fat diet.
62747517|NCT01841125|PLACEBO_COMPARATOR|Placebo|placebo 15mg
62747518|NCT03713398|EXPERIMENTAL|T4C-SMI Group|Participants will receive the T4C-SMI intervention, in addition to standard prison mental health services
62747519|NCT03713398|NO_INTERVENTION|Control Group|The control group receives standard prison mental health services
62553795|NCT01424007|EXPERIMENTAL|Lower carbohydrate diet|Participants in this group will be individually counseled and receive print materials on a lower-carbohydrate, higher-monounsaturated fat diet.
62553796|NCT01424007|EXPERIMENTAL|Walnut-rich diet|Participants in this group will be individually counseled and receive print materials on a lower-carbohydrate, walnut-rich higher-fat diet.
62747520|NCT06608680|EXPERIMENTAL|iTBS/Sham|Adults age 18-30 with typical reading and language abilities
62747521|NCT06608680|EXPERIMENTAL|cTBS/Sham|Adults age 18-30 with typical reading and language abilities
62747522|NCT05434065|EXPERIMENTAL|Celebrex treatment arm|Celecoxib 200 mg/dose, started within 6 h after onset, then one dose per day for 21 days.
62747523|NCT05434065|NO_INTERVENTION|Control arm|No trial medication will be given.
62374558|NCT06305923|ACTIVE_COMPARATOR|colostrum cream|everyday using of colostrum cream
62374559|NCT05238558|EXPERIMENTAL|FMPV-1 vaccination|"GM-CSF (0.03 mg) + FMPV-1 (0.15 mg/injection: low dose) administered as 2 separate intradermal injections.~Total of 8 administrations intradermally; GM-CSF + FMPV-1 on 5 separate occasions and FMPV-1 (without GM-CSF) on 3 occasions for the DTH skin reactivity assessment."
62374560|NCT03414268|EXPERIMENTAL|Micronized dHACM|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
62553797|NCT04016454|EXPERIMENTAL|Intervention group|No handover of anesthesia care
62553798|NCT04016454|NO_INTERVENTION|Control group|Complete handover of anesthesia care
62553799|NCT02449850|NO_INTERVENTION|Observation only|Observation only
62553800|NCT02449850|EXPERIMENTAL|Food intervention|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age
62553801|NCT02449850|EXPERIMENTAL|Skin care|Intervention: regular baths with bath-oil 0.5-9 months of age
62747524|NCT01325454||Patients with parapneumonic effusions|Patients with pleural effusions of unknown causes admitted to Taipei Medical University Hospital were included if parapneumonic effusion was diagnosed as one associated with pneumonia according to the criteria of the American Thoracic Society (ie, patients with newly acquired respiratory symptoms, fever, and abnormal breath sounds, plus a new lung infiltrate seen on a chest radiograph).
62747525|NCT03941457|EXPERIMENTAL|anti-tumor response of BiCAR-NK cells (ROBO1 CAR-NK cells)|Patients with relapsed and refractory pancreatic cancer of ROBO1 expression will be treated with BiCAR-NK cells (ROBO1 CAR-NK cells).
62747526|NCT06507436|EXPERIMENTAL|Treatment group 1|
62374561|NCT03414268|PLACEBO_COMPARATOR|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
62374562|NCT01818765|EXPERIMENTAL|Procedure|"Pre-procedure speckle-tracking echocardiography assessment of latest activation~Trans-ventricular-septal placement of LV pacing lead~Acute response assessment"
62374563|NCT06143228||Whiplash Associated Disorder with Directional Preference|Movements that reduce, abolish, or centralize the patient symptoms are recognized as a directional preference. Directional preference is ultimately used to guide the treatment of neck pain related to derangement syndrome.If the patient neck impairments are related to a Derangement syndrome, the patient will be instructed to perform the movements in the identified directional preference every 2-3 hours for 10-12 repetitions or to hold the cervical spine in a sustained position for 1-2 minutes. If the response to the intervention plateaus, the exercise intensity is progressed through the application of patient self-overpressure. If warranted clinician overpressure and mobilization may be utilized as a progression beyond patient generated forces. to achieve a favorable response.
62553802|NCT02449850|EXPERIMENTAL|Food intervention and skin care|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age Intervention: regular baths with bath-oil 0.5-9 months of age
62553803|NCT05881434|EXPERIMENTAL|Expectations Questionnaire|Provision of expectations questionnaire and associated instructions to patient.
62747527|NCT06507436|EXPERIMENTAL|Treatment group 2|
62747528|NCT06558422|EXPERIMENTAL|Maintenance hyperinsulinemia (MH) Protocol then Reduction toward Euinsulinemia (RE) Protocol|On Pancreatic Clamp Visit 1 (MH Protocol), the insulin infusion rate (IIR) will be set to approximately replicate participants' endogenous fasting serum insulin levels based on screening visit data for the duration of the pancreatic clamp. On Pancreatic Clamp Visit 2 (RE Protocol), the IIR will be set to reduce serum insulin levels to roughly 50% of the screening fasting serum insulin for the duration of the pancreatic clamp. In both cases, plasma glucose will be clamped to approximately 140 mg/dL +/- 10%.
62374564|NCT06143228||Whiplash Associated Disorder without Direction Preference|Patients with WADs that do not demonstrate directional preference will be managed based on the published Clinical Practice Guidelines (2017) for management of WADs with related movement coordination deficits. Treatment and progression of care for this group will be determined by the treating therapist but will consist of education, multimodal care inclusive of therapeutic exercise, mobilization, aerobic exercise, flexibility, and postural education. In addition, if the patient symptoms are chronic in nature treatment may include exercise progression, education and reassurance, transcutaneous nerve electrical stimulation, and cognitive behavioral therapy are recommended.
62374565|NCT01595308|EXPERIMENTAL|Pomegranate juice|Pomegranate juice
62391501|NCT03579862||Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|
62391502|NCT03579862||Pulmonary Embolism (PE)|
62391503|NCT03579862||Pulmonary Arterial Hypertension (PAH)|
62553804|NCT05881434|NO_INTERVENTION|Control|Usual care (no expectations questionnaire or further instruction)
62553805|NCT03321149|EXPERIMENTAL|RiseTx|Participants were given access to the RiseTx application and an activity monitor to participate in the five phase intervention.
62553806|NCT04264325||Malignant pleural effusions : diaphragmatic ultrasound measure|
62553807|NCT02627690||Islet transplanted|patients who underwent islet transplantation
62747529|NCT06558422|EXPERIMENTAL|Reduction toward euinsulinemia (RE) protocol|On Pancreatic Clamp Visit 1 (RE Protocol), the insulin infusion rate (IIR) will be set to produce serum insulin levels of approximately 50% that of the screening fasting serum insulin level for the full duration of the pancreatic clamp. On Pancreatic Clamp Visit 2 (MH Protocol), the IIR will be set to approximately replicate the full fasting serum insulin for the duration of the pancreatic clamp. In both cases, plasma glucose will be clamped to approximately 140 mg/dL +/- 10%.
62747530|NCT05021302|PLACEBO_COMPARATOR|Kegel exercises group|20 women in this group
62374566|NCT02845440|ACTIVE_COMPARATOR|Treatment as Usual (TAU) - Cohort 1|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services. Participants in this arm will receive no other study-related intervention.Cohort 1 (AD-eligible) comprised participants seen in primary care clinics serving ≥3 enrolled participants.
62374567|NCT02845440|EXPERIMENTAL|AD + CHW - Cohort 1|"Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. The aim of AD is to help clinicians understand and adopt targeted evidence-based practices.~Community Health Worker (CHW) will offer to support patients and prescribers to implement smoking cessation treatments that may be requested by patients and/or recommended by prescribers."
62553808|NCT02627690||non islet transplanted|patients who refused or were non selected for islet transplantation for a non nephrologic reason
62553809|NCT05820464||Control group|"Standard care:~* Doppler velocimetry: UA \& MCA PI, DV PIV, CPR;~* Indirect cardiotocography (CTG)~* Biophysical profile (BPP)"
62553810|NCT05820464||DDA Doppler group|Standard care plus DDA Doppler monitoring
62553811|NCT06364059||Surgery Group|Adult patients who underwent surgery due to acute subdural hematoma
62553812|NCT03719625|EXPERIMENTAL|norepinephrin group|The patients of this group will recieve 0.5 micro gr/kg of norepinephin intravenously, the infusion will start during the intrathecal injection and during 10 minutes
62553813|NCT03719625|EXPERIMENTAL|Ephedrin group|The patients of this group will recieve 0,3mg/kg of Ephedrin intravenously, the infusion will start during the intrathecal injection and during 10 minutes
62553814|NCT01662778|ACTIVE_COMPARATOR|Monodisperse FP 1.5um|50 mg of monodisperse Fluticasone Propionate delivered as 1.5 microns aerosol followed by AMP PC20 challenge test
62374568|NCT02845440|EXPERIMENTAL|AD - Cohort 1|Participant in this arm will have Academic Detailing offered to their primary care clinical staff as described above. Participants who are randomized to this condition will not be offered Community Health Worker support.
62553815|NCT01662778|ACTIVE_COMPARATOR|Monodisperse FP 6.0um|50 mg of monodisperse Fluticasone Propionate delivered as 6.0 microns aerosol followed by AMP PC20 challenge test
62553816|NCT01662778|PLACEBO_COMPARATOR|Placebo STAG|No active drug, just solvent delivered from STAG followed by AMP PC20 challenge test
62553817|NCT01662778|ACTIVE_COMPARATOR|MDI FP|Fluticasone Propionate , Metered dose inhaler, 250 mg dose followed by AMP PC20 challenge test
62553818|NCT00082277|EXPERIMENTAL|1|High-Risk Fragility Fracture-Open-Label, Non-Comparative Stratum
62553819|NCT00082277|EXPERIMENTAL|2|Moderate-Risk of Fragility Fracture-Randomised, Double-Blind Stratum
62553820|NCT00082277|EXPERIMENTAL|3|Low-Risk of Fragility Fracture - Open-Label, Non-Comparative Stratum
62553821|NCT06054321|EXPERIMENTAL|Good responder group-stepwise pharmacotherapy group|"Using multimodal serum biomarker scores, patients will be divided into good/poor responder. Then good responder group will be randomized into stepwise pharmacotherapy group vs antidepressant monotherapy(escitalopram) group.~In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks."
62567309|NCT05799833||Athletes with low QRS voltage|"Cohort (anticipated N = 60) will undergo testing with 12 lead ECG, blood test, cardiac MRI, 24 hour holter monitoring and cardiopulmonary exercise testing.~A subgroup of those identified to have low QRS voltage and myocardial scar on CMR will undergo genetic testing (anticipated number to be tested, N= 25)"
62747531|NCT05021302|EXPERIMENTAL|Electromagnetic stimulation group|20 women in this group
62747532|NCT05092282||TBI Patients|TBI participants 13 to 45 years of age, recruited from patients at a clinical research facility who present with head trauma. Clinical evaluation for the patient can be positive (target condition present) or negative (target condition absent) for mTBI. Enrollment is to occur within 2 weeks of the incident injury.
62747533|NCT05092282||Controls|Participants should not be part of the Intended Use Population. Subjects that present to the hospital, clinic or emergency department, either as a patient or non-patient, with no history of head trauma.
62747534|NCT03802344|EXPERIMENTAL|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks
62747535|NCT03802344|ACTIVE_COMPARATOR|Cal/BDP combination|Calcipotriene/betamethasone (Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks
62747536|NCT03802344|PLACEBO_COMPARATOR|Vehicle|One application daily for 8 weeks
62374569|NCT02845440|EXPERIMENTAL|CHW - Cohort 2|Community Health Worker (CHW) will offer to support patients and prescribers to implement smoking cessation treatments that may be requested by patients and/or recommended by prescribers.
62374570|NCT02845440|ACTIVE_COMPARATOR|Treatment as Usual (TAU) - Cohort 2|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services. Participants in this arm will receive no other study-related intervention. Cohort 2 (AD-ineligible) comprised participants whose primary care clinic served ≤2 enrolled participants
62374571|NCT01183481|EXPERIMENTAL|Aprepitant and Granisetron|Patients will be given a single dose of Granisetron 2 mg orally and Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the Palliative radiation therapy.
62374572|NCT02374359||atrial tachycardia group|Patients diagnosed of cryptogenic stroke with atrial tachycardia in holter
62374573|NCT02374359||Non atrial tachycardia group (control group)|Patients diagnosed of cryptogenic stroke with a normal holter
62374574|NCT00608491|ACTIVE_COMPARATOR|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
62374575|NCT00608491|EXPERIMENTAL|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
62374576|NCT05187494|OTHER|Conventional local palatine injection|Conventional palatal injection with anesthetic (lidocaine 2% with Epinephrine 1:80000, Korea) will be performed and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.
62374577|NCT05187494|EXPERIMENTAL|EMLA cream only|The palatine mucosa will be dried with a cotton ball 2\*2 and then 0,2 g of Emla cream will be applied for 3 minutes . During this period and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.
62391504|NCT01248429||Patient treated by TKI|Any patient with solid tumor and treated by Thyrosine Kinase Inhibitor for at least 1 week
62553822|NCT06054321|ACTIVE_COMPARATOR|Good responder group-antidepressant monotherapy group|"Using multimodal serum biomarker scores, patients will be divided into good/poor responder. Then good responder group will be randomized into stepwise pharmacotherapy group vs antidepressant monotherapy(escitalopram) group.~In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks."
62567310|NCT05799833||Young healthy individuals (non-athletes) with low QRS voltage|"Cohort (anticipated N = 60) will undergo testing with 12 lead ECG, blood test, cardiac MRI, 24 hour holter monitoring and cardiopulmonary exercise testing.~A subgroup of those identified to have low QRS voltage and myocardial scar on CMR will undergo genetic testing (anticipated number to be tested, N= 25)"
62747537|NCT05287841|EXPERIMENTAL|Batten graft, plus septoplasty and inferior turbinate reduction|In the intervention arm, a portion of the quadrangular cartilage of the nasal septum is also removed, but will be refashioned and re-implanted into the patient as an autologous batten graft. This will be performed together with standard septoplasty and turbinate reduction.
62747538|NCT05287841|ACTIVE_COMPARATOR|Septoplasty and inferior turbinate reduction alone|In the control arm, a portion of the quadrangular cartilage of the nasal septum is removed. This will be performed as a standard septoplasty and turbinate reduction.
62747539|NCT04467658||ADHD|
62747540|NCT04467658||NT NeuroTypical|
62747541|NCT04467658||ADHD NOS|
62747542|NCT05141708||Talazoparib-treated adults with HER2- gBRCAm mBC|Adult patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations who initiated talazoparib treatment in first-line or later line of therapy between January 1, 2018 and September 30, 2020.
62747543|NCT05915416|EXPERIMENTAL|Experiment Group|The participants in the experiment group were first administered the pre-test and then CANPP. A Child abuse and neglect Training Booklet was sent to the participants after the pre-test and before the program. Trainings within the scope of CANPP were provided over the Google Meet application in four sessions. A link was sent to the pregnant women via WhatsApp just before the specified training hours so that they could participate in the online training which is carried out individually.
62747544|NCT05915416|NO_INTERVENTION|Control group|Participants in control group does not receive intervention. They were then applied CANPP and were given the training booklet after the finalization the program.
62747545|NCT00615446|EXPERIMENTAL|A|
62747546|NCT06322745|ACTIVE_COMPARATOR|suture renorrhaphy group|involves cases of laparoscopic partial nephrectomy done with suture renorrhaphy only for hemostasis of the tumor bed.
62747547|NCT06322745|ACTIVE_COMPARATOR|thulium beam coagulation group|involves cases of laparoscopic partial nephrectomy with thulium beam coagulation and suture renorrhaphy for hemostasis of the tumor bed
62747548|NCT03199326|EXPERIMENTAL|Collaborative Care|CPS caseworkers will be randomized to collaborative or comparison practice. For any infant investigated by a caseworker in the collaborative practice, the caseworkers will conduct a standard CPS investigation. Additionally, caseworkers will seek parental permission to contact an identified primary health care provider at two points in the CPS investigation for information sharing related to health needs, social risks, and recommended interventions.
62374578|NCT05187494|EXPERIMENTAL|chemical permeability enhancer DMSO with EMLA cream|The palatine mucosa will be dried with a cotton ball and then EMLA cream will be mixed with a permeability enhancer in the laboratory of pharmaceutical industries at the Faculty of Pharmacy at Damascus University according to the following: Adding 10 g of EMLA cream 5%, 1,026 g of DMSO 100% and it will be applied with cotton bud for a period of 3 minutes. During this period and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.
62374579|NCT05187494|EXPERIMENTAL|Oral patches with EMLA Cream|The palatine mucosa will be dried with a cotton ball and then 0.2 g of EMLA cream 5% will be applied by using an oral patch 14\*14 mm for 3 minutes. During this period and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.
62374580|NCT05187494|EXPERIMENTAL|Micro-needle patches dissolved with EMLA Cream|The palatine mucosa will be dried with a cotton ball 2\*2 and then 0.2 g of EMLA cream 5% will be applied by using an micro-needle patch 14\*14 mm, 0,25 micron for 3 minutes.
62374581|NCT00906828|ACTIVE_COMPARATOR|1. Duodopa, optimised dose|
62553823|NCT06054321|EXPERIMENTAL|Poor responder group-stepwise pharmacotherapy group|"Using multimodal serum biomarker scores, patients will be divided into good/poor responder. Then poor responder group will be randomized into stepwise pharmacotherapy group vs antidepressant monotherapy(escitalopram) group.~In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks."
62747549|NCT03199326|NO_INTERVENTION|Comparison Care|CPS caseworkers will be randomized to collaborative or comparison practice. For any infant investigated by a caseworker in the comparison practice, the caseworkers will conduct a standard CPS investigation.
62747550|NCT01730326|EXPERIMENTAL|Paracetamol|Paracetamol which will be given after randomization will be diluted in serum physiologic and will be given as intravenous rapid infusion.
62747551|NCT01730326|ACTIVE_COMPARATOR|Dexketoprofen|Dexketoprofen which will be given after randomization will be diluted in serum physiologic and will be given as intravenous rapid infusion.
62747552|NCT06608862||Female soldiers|Female soldiers from the university of the Bundeswehr in Munich, which are all of German nationality and between 18 and 35 years of age.
62747553|NCT02407340|ACTIVE_COMPARATOR|Oxytocin|intranasal oxytocin - 40 International Units (IU) dose administered 3 times daily for 1 week
62747554|NCT02407340|PLACEBO_COMPARATOR|Placebo|Intranasal placebo administered 3 times daily for 1 week
62374582|NCT00906828|EXPERIMENTAL|2. 80% Duodopa + entacapone|80% of optimised Duodopa dose + two tablets of entacapone at t=0 hours and at t= 6 hours
62374583|NCT00906828|EXPERIMENTAL|3. 80% Duodopa + tolcapone|80% of optimised Duodopa dose + two tablets of tolcapone at t=0 hours and at t= 6 hours
62747555|NCT05858450||Same day|Pfizer-BioNTech mRNA bivalent COVID and flu on the same day
62747556|NCT05858450||COVID alone|Pfizer-BioNTech bivalent COVID only
62747557|NCT05858450||flu alone|influenza vaccine of any type only
62747558|NCT04505553|EXPERIMENTAL|Arm I (acupuncture, acupressure, cryotherapy)|Patients undergo acupuncture during chemotherapy infusion on day 1 and fluorouracil pump disconnect on day 3 of each biweekly chemotherapy infusion over 12 weeks. Patients also undergo self-administered acupressure over 11 minutes daily for 12 weeks and undergo standard of care oral cryotherapy.
62374584|NCT01675323||RLS Patients|Participants who have diagnosed RLS with diagnosis confirmed by study investigators.
62747559|NCT04505553|ACTIVE_COMPARATOR|Arm II (cryotherapy)|Patients undergo standard of care oral cryotherapy.
62747560|NCT03830476|EXPERIMENTAL|Acceptance- and Commitment therapy group|Experiment group that receives the treatment direct after the baseline measurement.
62747561|NCT03830476|ACTIVE_COMPARATOR|Treatment as usual|Comparison group that receives treatment as usual and the Navigator ACT intervention appr 6 months later.
62747562|NCT05305222|EXPERIMENTAL|Japanese Participants Receiving Risankizumab|Participants will receive single dose of risankizumab.
62747563|NCT05305222|EXPERIMENTAL|Japanese Participants Receiving Placebo|Participants will receive single dose of placebo.
62747564|NCT05305222|EXPERIMENTAL|Caucasian Participants Receiving Risankizumab|Participants will receive single dose of risankizumab.
62747565|NCT05305222|EXPERIMENTAL|Caucasian Participants Receiving Placebo|Participants will receive single dose of placebo.
62747566|NCT00349921|ACTIVE_COMPARATOR|clonidine first, then adenosine|clonidine given in first injection adenosine given in second injection
62747567|NCT00349921|ACTIVE_COMPARATOR|adenosine first, then clonidine|adenosine given in first injection clonidine given in second injection
62747568|NCT00349921|PLACEBO_COMPARATOR|clonidine given first, then placebo|placebo
62747569|NCT00349921|PLACEBO_COMPARATOR|adenosine given first, then placebo|placebo
62553824|NCT06054321|ACTIVE_COMPARATOR|Poor responder group-antidepressant monotherapy group|"Using multimodal serum biomarker scores, patients will be divided into good/poor responder. Then poor responder group will be randomized into stepwise pharmacotherapy group vs antidepressant monotherapy(escitalopram) group.~In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks."
62567311|NCT05799833||Age and sex matched control group of athletes with normal QRS voltage|Cohort (anticipated N = 60) will undergo testing with 12 lead ECG, blood test, cardiac MRI, 24 hour holter monitoring and cardiopulmonary exercise testing.
62747570|NCT01892436|EXPERIMENTAL|Secukinumab 75mg|Subjects continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator
62747571|NCT01892436|EXPERIMENTAL|Secukinumab 150mg|Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator
62747572|NCT01892436|EXPERIMENTAL|Placebo - AIN457A 75mg|Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5 mL solution solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg
62747573|NCT01892436|EXPERIMENTAL|Placebo - AIN457 150mg|Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg
62747574|NCT06303089||Questionnaires assessed Chronic Kidney Disease patients|"Participants who met the inclusion criteria below will be invited to fill in tobacco exposure questionnaires, smokers will be invited to complete smoking cessation questionnaires set.~1. Participants aged 18 years or older;~2. Participants with a confirmed diagnosis of Chronic Kidney Disease;"
62747575|NCT02382029|ACTIVE_COMPARATOR|clonazepam|Twenty two patients took clonazepam two times a day (0.5 mg) in the morning and after two weeks one tablet (0.5 mg) in the morning and another tablet (0.5 mg) in the evening during the next two weeks.
62747576|NCT02382029|EXPERIMENTAL|acupuncture|"Traditional Chinese acupuncture was performed on 20 participants 3 times during one week for four weeks. Intervention was performed on acupuncture points as follows: the points ST 8 (stomach- tou wei), GB 2, TE 21, SI 19 (small intestine- ting gong), SI 18 (small intestine- quan liao), LI 4 (large intestine-Yuan) on both sides of the body as well as GV 20 (Governing vessel-bai hui).~Each session lasted half an hour. Sterile acupuncture needles made from surgical stainless steel silicone coated with spring handle were used. The dimensions of the chosen needles were 0.25 in diameter and 30 mm length, inserted at the depth of the 0.5-1 cm. The elicited response was of the type de qi accompanied by redness and a feeling of numbness around the needles."
62747577|NCT06606548|NO_INTERVENTION|general oral hygiene|
62747578|NCT06606548|EXPERIMENTAL|comprehensive oral care|including cleaning, facial massage, oral muscle massage and stretching, and oral moisturizing.
62747579|NCT02584231|EXPERIMENTAL|Patients needing an urinary concentration test|Patients who need a urinary concentration test because of uro- or nephropathy (age: 6 months - 8 year)
62747580|NCT02584231|EXPERIMENTAL|Patients suffering from treatment resistant nocturnal enuresis|Patients suffering from treatment resistant nocturnal enuresis (age: 5 - 8 year)
62747581|NCT00770497|EXPERIMENTAL|Pioglitazone 15 mg to 30 mg QD|
62747582|NCT00770497|ACTIVE_COMPARATOR|Pioglitazone 15 mg to 30 mg QD + Ramipril 2.5 mg to 5 mg QD|
62747583|NCT00770497|ACTIVE_COMPARATOR|Ramipril 2.5 mg to 5 mg QD|
62747584|NCT01671293|EXPERIMENTAL|Multicomponent remote care model|A remote intervention based on counseling (telephone-based).
62747585|NCT01671293|ACTIVE_COMPARATOR|Usual care|Usual care.
62747586|NCT06229431|EXPERIMENTAL|CSNAT intervention|District nurses will be trained to use the CSNAT-I on family caregivers to persons with multimorbidity at home.
62747587|NCT06229431|NO_INTERVENTION|Control|Standard support and care.
62747588|NCT02592616|EXPERIMENTAL|CON|Control (CON).
62747589|NCT02592616|EXPERIMENTAL|CW|Continuous Walking (CW).
62747590|NCT02592616|EXPERIMENTAL|IW|Interval Walking (IW).
62747591|NCT06397651|EXPERIMENTAL|Test Group|Live 1:1 Coaching program, focusing on Exercise and Meditation, along with app-guided evidence-based information on Diet, Sleep, and other lifestyle practices for 24 weeks
62747592|NCT06397651|ACTIVE_COMPARATOR|Control Group|24 weeks access to Digital application with expert guidelines on lifestyle modification focusing on exercise, meditation, as well as information on diet, sleep and other lifestyle practices. Does not include live coaching and personalization.
62747593|NCT04357730|NO_INTERVENTION|Control|Patients randomized to Control arm will receive no study medication; the treatment will be standard of care according to the institution's protocol for ARDS.
62747594|NCT04357730|EXPERIMENTAL|Alteplase-50 bolus|Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours. Re-bolusing of Alteplase, at the same dose, is permitted in those patients who show an initial transient response. The repeat dose will be given between 24 and 36 hours after the initial Alteplase administration.
62747595|NCT04357730|EXPERIMENTAL|Alteplase-50 bolus plus drip|Patients randomized to Alteplase-50 plus drip group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours. Immediately following this initial Alteplase infusion, a drip of 2 mg/hr of Alteplase will be initiated over the ensuing 24 hours (total 48 mg infusion).
62747596|NCT02479685|EXPERIMENTAL|SORD-BILL|PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) for subtotal hysterectomy and uterine morcellation, respectivelly, during sacral colpopexy for Pelvic Organ Prolapse.
62747597|NCT02479685|ACTIVE_COMPARATOR|STANDARD|Conventional monopolar hook and conventional mechanic morcellator for subtotal hysterectomy and uterine morcellation, respectivelly, during sacral colpopexy for Pelvic Organ Prolapse.
62747598|NCT04042142|ACTIVE_COMPARATOR|Healthy overweight subjects|MR spectroscopy verified no steatosis
62747599|NCT04042142|ACTIVE_COMPARATOR|Subjects with non-alcoholic fatty liver disease|MR spectroscopy verified steatosis, no steatohepatitis on liver biopsy
62747600|NCT04042142|ACTIVE_COMPARATOR|Subjects with non-alcoholic steatohepatitis|MR spectroscopy verified steatosis, steatohepatitis on liver biopsy
62747601|NCT01560637|EXPERIMENTAL|UT-15C|Open label access
62374585|NCT01675323||Healthy Controls|Participants without RLS who are generally healthy and matched for gender, age, educational level, and race to patients in the RLS group.
62747602|NCT03135158||Women in labor|All participants who have a vaginal delivery
62747603|NCT03802305|EXPERIMENTAL|Computerized intraosseous technique (Quicksleeper™)|patients will receive the anesthetic solution with computerized intraosseous technique anesthesia near the tooth roots involved.
62747604|NCT03802305|ACTIVE_COMPARATOR|loco-regional anesthesia (IANB technique)|patients will receive the anesthetic solution with the loco-regional anesthesia technique: near the place where the nerve goes into the jaw, based on osteo muscular markers.
62747605|NCT04588857|EXPERIMENTAL|Active drug|dexamethasone 24 mg i.v., single dose
62747606|NCT04588857|PLACEBO_COMPARATOR|Placebo|saline i.v., single dose
62747607|NCT05488548|EXPERIMENTAL|Part 1|Patients will be assigned escalated dose according to BOIN design. The starting dose is 5 mg orally once a day for 7 consecutive days followed by 14 days of rest.
62747608|NCT05488548|EXPERIMENTAL|Part 2|Patients will be assigned escalated dose according to BOIN design. The starting dose is 20 mg orally once a day for 14 consecutive days followed by 14 days of rest.
62747609|NCT05488548|EXPERIMENTAL|Part 3|Patients will be assigned escalated dose according to BOIN design. The starting dose is 10 mg orally once a day for 14 consecutive days in combination with ruxolitinib or momelotinib followed by 14 days of rest according to the traditional 3 + 3 design by the modified Fibonacci sequence
62747610|NCT06453941|EXPERIMENTAL|Yizhi Baduanjin group|The Yizhi Baduanjin group will practice Yizhi Baduanjin as intervention for 6 months, and the participants will be examined for assessment indicators on the 1st, 3rd, 6th month after the intervention started.
62747611|NCT06453941|NO_INTERVENTION|Control group|The control group has no intervention until 6 months after the intervention of the experimental group started, but the participants will be examined for the same assessment indicators together with the experimental group.
62374586|NCT02391298|EXPERIMENTAL|Mindfulness Meditation|All participants will complete baseline assessments of variables of interest (i.e., levels of mindfulness, contrast sensitivity, cognitive inhibition, and emotional regulation skills). Participants will then undergo 8 weeks of self-directed mindfulness training with re-assessments of variables of interest completed at week 4 and week 8. All participants will be given access to meditation recordings and asked to practice the exercises in a progressive manner from mindfulness of breath to a loving/kindness meditation (each exercise twice per week). Participants will be asked at the end of study for feedback on the acceptability of the program.
62374587|NCT02214446||primary caregivers of children newly diagnosed with cancer|Explore Factors related to Truth Telling in Primary Caregivers of Children Newly Diagnosed with Cancer
62553825|NCT06581445|EXPERIMENTAL|Depressed group|"The participants were categorized into two groups using the Patient Health Questionnaire (PHQ-9) and the 17-item Hamilton Depression Rating Scale (HAM-D). PHQ-9 is a self-report scale. PHQ-9 scores of 5 or higher represent mild and severe depression, while PHQ-9 scores of lower than 5 mean normal condition. HAM-D is a scale administered by a healthcare professional. The cut-off point of the HAM-D scale is 8, which divides normal conditions from depressive conditions. The participants first completed PHQ-9. For those with PHQ-9 scores of 5 or higher, the trained researchers interviewed them and rated their severity of depression on the HAM-D. The participants first completed PHQ-9.~For those with PHQ-9 scores ≥ 5, the trained researchers interviewed them and rated their severity of depression on the HAM-D. Those with HAM-D scores \> 8 were classified into the depressed group."
62747612|NCT04122183|EXPERIMENTAL|Program Group|Following a failed hearing screening, participants will be offered the standard of care (information sheet recommending a comprehensive hearing evaluation) and asked to complete the iManage Program. Six months after the screening participants will be asked if they visited an audiologist.
62747613|NCT04122183|NO_INTERVENTION|Delayed Program Group|Following a failed hearing screening, participants will be offered the standard of care (information sheet recommending a comprehensive hearing evaluation). Six months after the screening participants will be asked if they visited an audiologist and they will be given the opportunity to complete the iManage Program.
62747614|NCT02450383|ACTIVE_COMPARATOR|Control|Autologous subepithelial connective tissue graft
62747615|NCT02450383|EXPERIMENTAL|Experimental|Acellular Dermal Matrix
62747616|NCT03501004|EXPERIMENTAL|The Acupuncture Group|Sterile acupuncture needles for single use will be used.The intervention is going to be executed using the acupuncture points GV14（Dazhui）and GB20 (Fengchi) for 20 minutes.The acupuncture needles will be inserted to a depth of 0.8 to 1 cm using GV14（Dazhui）and GB20 (Fengchi).
62747617|NCT03501004|SHAM_COMPARATOR|The Sham Acupuncture Group|Sterile acupuncture needles for single use will be used.The sham acupuncture group's acupuncture needles will be inserted to a depth of 0.1 to 0.2 cm with nonacupuncture points located 0.5 cm in lateral to the real acupoint or to the right for midline points for 20 minutes.
62747618|NCT01431014|ACTIVE_COMPARATOR|"Dexamethasonelow-dose"|5mg
62747619|NCT01431014|EXPERIMENTAL|"Dexamethasonehigh-dose"|15mg
62747620|NCT03240367|EXPERIMENTAL|coutery|Stapler bloom will be stopped with cautery
62747621|NCT03240367|NO_INTERVENTION|clips|Stapler bloom will be stopped with clipping
62747622|NCT03048890||Patients with PAD|Patients with PAD will be in 1 cohort and will have their physical activity levels closely monitored by researchers and physicians.
62747623|NCT03048890||Patients without PAD|Patients without PAD will be allowed to contribute their data to the application, but they will not be as closely monitored.
62747624|NCT02323685|EXPERIMENTAL|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
62747625|NCT06437613|EXPERIMENTAL|Group 1|"Week 1 Passive Hip Flexion Test Straight leg Raise Modified Knee Extension Test Passive Static Stretching 3-4 reps 3-5 second hold in each activity Week 2 Passive Hip Flexion Test Straight leg Raise Modified Knee Extension Test Passive Static Stretching 3-4 reps 3-5 second hold in each activity~Week 3 Passive Hip Flexion Test Straight leg Raise Modified Knee Extension Test Passive Static Stretching 3-4 reps 3-5 second hold in each activity~Week 4 Passive Hip Flexion Test Straight leg Raise Modified Knee Extension Test Passive Static Stretching 3-4 reps 3-5 second hold in each activity"
62747626|NCT06437613|EXPERIMENTAL|Group 2|"Week 1 Passive Hip Flexion Test Straight leg Raise Modified Knee Extension Test Passive Static Stretching 3-4 reps 3-5 second hold in each activity Week 2 Passive Hip Flexion Test Straight leg Raise Modified Knee Extension Test Passive Static Stretching 3-4 reps 3-5 second hold in each activity Week 3 Passive Hip Flexion Test Straight leg Raise Modified Knee Extension Test Passive Static Stretching 3-4 reps 3-5 second hold in each activity~Week 4 Passive Hip Flexion Test Straight leg Raise Modified Knee Extension Test Passive Static Stretching 3-4 reps 3-5 second hold in each activity"
62747627|NCT05441683|EXPERIMENTAL|HEI|PAOO with horizontally extending incisions on both sides
62747628|NCT05441683|ACTIVE_COMPARATOR|VRI|PAOO with vertical releasing incisions on both sides
62747629|NCT01341808|EXPERIMENTAL|IBD patients|"Patients diagnosed with IBD~-\> receive Epaxal Berna (virosomal hepatitis A vaccine)"
62747630|NCT05743842|EXPERIMENTAL|TriSalus™ TriNav™Infusion System (catheter)|TriNav Infusion System (TriNav catheter) for the injection of the surrogate/test dose during the planning part of the radioembolization procedure and your actual treatment with the radioactive microspheres match each other better than the standard catheter
62747631|NCT05695261|EXPERIMENTAL|antibiotic / MTT|"Study subjects randomized to the experimental arm will receive oral antibiotics for 7 days as a way to modulate the composition of the gastrointestinal microbiota.~Upon completion of oral antibiotics, subjects randomized to the experimental arm will be administeredf MTT under medical supervision. Subjects will be monitored and then discharged. Subjects will be instructed to take MTT capsules daily for 27 days."
62747632|NCT05695261|ACTIVE_COMPARATOR|placebo / placebo|"Study subjects randomized to the placebo arm will receive oral placebo capsules instead of oral antibiotics, for 7 days, at the same frequency and capsule amount per dose.~Upon completion of 7 days of placebo (matching the antibiotics given in the experimental arm), subjects randomized to the placebo arm will be administered capsules of placebo (matching the MTT capsules given in the experimental arm) under medical supervision. Subjects will be monitored and then discharged. Subjects will be instructed to take placebo capsules daily for 27 days."
62747633|NCT00003675|EXPERIMENTAL|Oral Topotecan 5 days|Patients receive intervention twice daily for 5 days
62553826|NCT06581445|EXPERIMENTAL|Non-depressed group|Those with PHQ-9 scores \< 5 or HAM-D scores ≤ 8 were classified into the non-depressed group.
62747634|NCT00003675|EXPERIMENTAL|Oral Topotecan 10 days|Patients receive intervention once daily for 10 days
62747635|NCT06423495|EXPERIMENTAL|low-intensity laser treatment group|This is an intervention study. The sample will consist of 30 individuals who will be allocated to the low-intensity laser treatment group.
62747636|NCT04867720|EXPERIMENTAL|CertiroBell Tablet|Use in combination with Tacrolimus at least 6 months after liver transplantation.
62747637|NCT06556095|EXPERIMENTAL|Ridge preservation test group|Patients will be randomized to one of the experimental treatment group immediately following tooth extraction and debridement of the socket (test: hydration of allograft with 4mg/1ml dexamethasone solution)
62747638|NCT06556095|NO_INTERVENTION|Ridge preservation control group|Patients will be randomized to the control group immediately following tooth extraction and debridement of the socket (control: hydration of allograft with normal saline solution)
62747639|NCT00538967|NO_INTERVENTION|1|
62747640|NCT00538967|ACTIVE_COMPARATOR|2|doxycycline 50 mg/day
62747641|NCT00538967|ACTIVE_COMPARATOR|3|doxycycline 100 mg
62747642|NCT00538967|ACTIVE_COMPARATOR|4|doxycycline 300 mg
62747643|NCT04726280|EXPERIMENTAL|10 ml single-shot injection|"In the 10ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 10 ml ropivacaine 0.75% at the level of C5-C6 nerves roots.~Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg\^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution."
62747644|NCT04726280|ACTIVE_COMPARATOR|20 ml single-shot injection group|"In the 20ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 20 ml ropivacaine 0.75% at the level of C5-C6 nerves roots.~Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg\^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution."
62747645|NCT01439971|EXPERIMENTAL|1|
62747646|NCT01439971|EXPERIMENTAL|2|
62747647|NCT01439971|EXPERIMENTAL|3|
62747648|NCT01439971|EXPERIMENTAL|4|
62747649|NCT01439971|EXPERIMENTAL|5|
62747650|NCT03898466|EXPERIMENTAL|Fluticasone Furoate|"Daily inhalation of 100mcg fluticasone furoate for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.~The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints"
62553827|NCT02862015|EXPERIMENTAL|Oncothermia|Patients with oncothermia treatment and palliative chemotherapy
62553828|NCT02862015|ACTIVE_COMPARATOR|Control|Patients with palliative chemotherapy only
62567312|NCT05799833||Age and sex matched young healthy controls (non-athletes) with normal QRS voltage|Cohort (anticipated N = 60) will undergo testing with 12 lead ECG, blood test, cardiac MRI, 24 hour holter monitoring and cardiopulmonary exercise testing.
62747651|NCT03898466|PLACEBO_COMPARATOR|Matching Placebo|"Daily inhalation of inactive placebo comparator for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.~The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints"
62747652|NCT01775579|EXPERIMENTAL|Crestor tablet 20 mg|Crestor tablet 20 mg single---\>wash out----\>Glucophage SR tablet 750 mg single----\>washout---\>Glucophage SR tablet 750 mg, Crestor tablet 20 mg both
62747653|NCT01775579|EXPERIMENTAL|Glucophage SR tablet 750 mg and Crestor tablet 20 mg both|Glucophage SR tablet 750 mg, Crestor tablet 20 mg both---\>wash out----\>Glucophage SR tablet 750 mg single------\>washout---\>Crestor tablet 20 mg single
62747654|NCT01775579|EXPERIMENTAL|Glucophage SR tablet 750 mg|Glucophage SR tablet 750 mg single ---\>wash out----\>Crestor tablet 20 mg single----\>washout---\>Glucophage SR tablet 750 mg, Crestor tablet 20 mg both
62747655|NCT03641768|ACTIVE_COMPARATOR|Healthy volunteers|Volunteers with no trauma history
62747656|NCT03641768|ACTIVE_COMPARATOR|Trauma only|Volunteers that do not have PTSD but have had similar trauma to those with PTSD
62553829|NCT03054701|EXPERIMENTAL|Sidelying hip abduction exercise|"Participants will be lying on the side with both legs stretched and with their head resting on a pillow. Participants will be allowed to place their hand in front of them to fixate their body and maintain balance. The participants will be instructed to abduct their hip to 45 degrees and return to the resting position afterwards. An elastic band will be used as resistance. This exercise will be applied only on the test limb. A digital metronome will be used to maintain the pace during the exercise.~Load: 12 repetition maximum; Nr. of repetition: 12; Nr. of sets: 3; Rest between sets: 120 seconds; Time under tension: 8 seconds; Distribution of load: Concentric (3 seconds), Eccentric (3 seconds), Isometric (2 seconds)."
62553830|NCT03054701|ACTIVE_COMPARATOR|Sitting knee extension exercise|"Participants will be seated at the end of an examination couch with the hip and knee relaxed in a 90 degrees angel. Participants will be allowed to place their hands on the side of the couch and the stabilizing foot may have contact with the floor. The participants will be instructed to extend their knee to a 180-degree angle and return to the resting position afterwards. An elastic band will be used as resistance. This exercise will be applied only on the test limb. A digital metronome will be used to maintain the pace during the exercise.~Load: 12 repetition maximum; Nr. of repetition: 12; Nr. of sets: 3; Rest between sets: 120 seconds; Time under tension: 8 seconds; Distribution of load: Concentric (3 seconds), Eccentric (3 seconds), Isometric (2 seconds)."
62553831|NCT01751256|EXPERIMENTAL|Continuous wound infiltration|Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
62553832|NCT01751256|NO_INTERVENTION|Control|Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
62553833|NCT03551821|EXPERIMENTAL|ATI-50002 Topical Solution|ATI-50002 Topical Solution
62553834|NCT02229435||eGFR <60ml/min|Patients with CKD with eGFR \<60 ml/min (CKD-EPI or MDRD) 12/2004-08/2014 of Medical Laboratory, Prof. Schenk / Dr. Ansorge and Colleagues, GbR, Am Neustädter Feld 47, 39124 Magdeburg, Germany.
62553835|NCT03073876|EXPERIMENTAL|Drug|Participants in the Drug group received oral 5mg of Donepezil Hydrochloride daily for 6 months. The Drug group was assessed at baseline, after approximately 6 weeks and after 6 months of treatment. The baseline to 6 weeks phase was part of the double-blind, placebo controlled portion of the trial.
62553836|NCT03073876|PLACEBO_COMPARATOR|Placebo|"Participants in the placebo group first received oral administration of a placebo pill for approximately 6 weeks. After that initial interval, the study was unblinded and participants in the placebo group then received 5mg of donepezil hydrochloride treatment for 6 months.~The Placebo group was evaluated at baseline, after 6 weeks of placebo, after 6 weeks of donepezil hydrochloride drug treatment, and 6 months of donepezil hydrochloride treatment."
62553837|NCT04413019||Group (D): Planned domiciliary care.|Patients within this group will be counseled for home care with self-monitoring for any symptoms suggestive of preterm labor, maternal or fetal distress.
62553838|NCT04413019||Group (H): Planned hospital care.|Patients within this group will be admitted at hospital for close monitoring of maternal \& fetal wellbeing \& finally the neonatal outcome
62553839|NCT04317092|EXPERIMENTAL|tocilizumab treatment|All the patients enrolled are treated with tocilizumab.
62553840|NCT02189837|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
62553841|NCT02189837|ACTIVE_COMPARATOR|Atorvastatin|Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
62553842|NCT02189837|EXPERIMENTAL|Evolocumab|Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
62553843|NCT02189837|EXPERIMENTAL|Evolocumab and Atorvastatin|Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
62553844|NCT04898452||Patients needing antibiotics infusion|Patients needing antibiotics infusion A new model of interaction across health services with use of welfare technology and telemedicine Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
62747657|NCT03641768|ACTIVE_COMPARATOR|PTSD only|Volunteers with PTSD but no traumatic brain injury
62747658|NCT03641768|ACTIVE_COMPARATOR|PTSD and TBI|Volunteers with PTSD and mild traumatic brain injury
62747659|NCT06145633|EXPERIMENTAL|Treatment (vorinostat, 177Lu-PSMA-617)|Patients receive vorinostat PO QD for 28 days and then receive gallium Ga 68 gozetotide IV and undergo a PET scan on trial. Patients may go on to receive 177Lu-PSMA-617 IV per SOC on day 1 of each cycle. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT and bone scan on trial and during follow-up, as well as a SPECT/CT and FDG PET/CT during screening and on trial. Patients undergo blood sample collection on trial and may also optionally undergo biopsy during screening and on trial.
62747660|NCT03197987|EXPERIMENTAL|Endocuff colonoscopy|Endocuff-assisted colonoscopy
62747661|NCT03197987|ACTIVE_COMPARATOR|Cap colonoscopy|Cap-assisted colonoscopy
62553845|NCT04898452||Next of kin|Next of kin A new model of interaction across health services with use of welfare technology and telemedicine Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
62747662|NCT01542697|ACTIVE_COMPARATOR|Magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline at the end of surgery before closure
62747663|NCT01542697|PLACEBO_COMPARATOR|normal saline|intraperitoneal nebulisation of 5 ml of normal saline after end of surgery before closure
62747664|NCT00620256|EXPERIMENTAL|AL-37807|AL-37807 ophthalmic suspension, 0.1%, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
62747665|NCT00620256|ACTIVE_COMPARATOR|Timolol|Timolol gel forming solution, 0.5%, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
62747666|NCT00620256|PLACEBO_COMPARATOR|AL-37807 vehicle|AL-37807 ophthalmic solution vehicle, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
62747667|NCT04110951|EXPERIMENTAL|Pranayama group|Kapalbhati, Ujjayi and Anuloma-Viloma pranayama techniques were applied to the experimental group. Within this scope, a three days of applied training program was prepared and a guide involving the steps of Pranayama breathing technique was formed. The patients in of pranayama group were trained by the researcher who had yoga trainer certificate. After completing three days of training and observations regarding their accomplishment of applications properly, a pranayama breathing technique video showing how the pranayama breathing technique is done with its details was downloaded to their smartphones and a guide including the application steps was distributed to the patients. The patients were required to apply pranayama technique, in company with the video, 20 min every day and a month in total.
62374588|NCT04990102|EXPERIMENTAL|CPX-351|Dose Level 1: CPX-351 administered through intravenou infusion on Day 1 and Day 3 of 28 day cycle for 6 cycles or Dose Level -1: CPX-351 administered through intravenous infusion on Day 1 of each 28 day cycle for 6 cycles.
62747668|NCT04110951|ACTIVE_COMPARATOR|Relaxation group|As there was not placebo breathing control treatment appropriate to yoga breathing technique, relaxation technique was decided to apply in the second group to equalize psychological effects of the treatment. Progressive relaxation technique was taught to the relaxation group during the same training span.A three days of applied training program and Relaxation Technique Application Guide, including steps of progressive relaxation technique, were prepared within this scope. After completing three days of training and observations regarding their accomplishment of applications properly, a relaxing music to listen during applications and a training video involving progressive relaxation directives were downloaded to smartphones of the patients. Also, Relaxation Technique Application Guide involving application steps were distributed to the patients. The patients were required to apply relaxation technique, in company with the video, 20 min every day and a month in total.
62747669|NCT01367418|EXPERIMENTAL|Thoracic Epidural Analgesia (TEA)|TEA is used for perioperative pain management, having been used both intra- and postoperatively, up to 48 h.
62747670|NCT01367418|ACTIVE_COMPARATOR|Patient controlled analgesia (PCA)|PCA is the standard of pain management and is usually used for up to 48 h postoperative for pain management following radical prostatectomy.
62747671|NCT02584543|EXPERIMENTAL|HEV vaccine and HBV vaccine Co-administration group|
62747672|NCT02584543|ACTIVE_COMPARATOR|HEV vaccine control group|
62747673|NCT02584543|ACTIVE_COMPARATOR|HBV vaccine control group|
62374589|NCT00878644|EXPERIMENTAL|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia after experiencing cardiac arrest.
62374590|NCT00878644|ACTIVE_COMPARATOR|Therapeutic Normothermia|Participants will receive therapeutic normothermia after experiencing cardiac arrest.
62374591|NCT03632551|ACTIVE_COMPARATOR|Symmetrical hearing|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
62374592|NCT03632551|EXPERIMENTAL|Single-sided deafness|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
62374593|NCT03632551|EXPERIMENTAL|Bilateral profound hearing loss treated|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
62374594|NCT04137055|EXPERIMENTAL|ZSP0678-10mg (single dose)-Cohort 1|ZSP0678/Placebo 10mg
62374595|NCT04137055|EXPERIMENTAL|ZSP0678-30mg (single dose)-Cohort 2|ZSP0678/Placebo 30 mg Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1.
62374596|NCT04137055|EXPERIMENTAL|ZSP0678-60mg (single dose)-Cohort 3|ZSP0678/Placebo 60mg Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2.
62374597|NCT04137055|EXPERIMENTAL|ZSP0678-120mg (single dose)-Cohort 4|ZSP0678/Placebo 120mg Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3.
62374598|NCT04137055|EXPERIMENTAL|ZSP0678-180mg (single dose)-Cohort 5|ZSP0678/Placebo 180mg Enrollment into Cohort 5 will begin upon assurance of safety for Cohort 4.
62374599|NCT04137055|EXPERIMENTAL|ZSP0678-240mg (single dose)-Cohort 6|ZSP0678/Placebo 240mg Enrollment into Cohort 6 will begin upon assurance of safety for Cohort 5.
62374600|NCT04137055|EXPERIMENTAL|ZSP0678-320mg (single dose)-Cohort 7|ZSP0678/Placebo 320mg Enrollment into Cohort 7 will begin upon assurance of safety for Cohort 6.
62747674|NCT05994703|EXPERIMENTAL|DCS with Juul e-cigarette|"d-cycloserine (DCS) 100 mg taken orally, once a day for six weeks. There will be a 50 mg dose taken the afternoon/evening prior to the first switch date (after enrollment) to ensure serum levels of the medication are available for the first switch to e-cigarette attempt.~Participants will be instructed to use the Juul as often as they like during the 12 week period, and to switch completely to the Juul within 1 week. If, however, they do smoke any combustible cigarettes (CC), they will also be instructed to use the Juul immediately before each CC to relieve their craving as much as possible before smoking their usual brand. The Juul will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute Juul for CCs by the end of the first week of use."
62747675|NCT04155086|EXPERIMENTAL|Exposed group (patient with an autoimmunise disease)|Any patient with an autoimmune disease followed at one of the 14 centres who wants to be screened for T21.
62747676|NCT04155086|OTHER|Non Exposed group (patient without an autoimmunise disease)|
62747677|NCT04348149|EXPERIMENTAL|Intervention group|
62747678|NCT04348149|NO_INTERVENTION|Wait-list|
62747679|NCT00951236|ACTIVE_COMPARATOR|One injection|
62747680|NCT00951236|ACTIVE_COMPARATOR|Two Injections|
62747681|NCT01689012|EXPERIMENTAL|Facial Exercise|
62747682|NCT02637414|NO_INTERVENTION|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
62747683|NCT02637414|EXPERIMENTAL|Flourishing App Program|This group will receive the intervention Flourishing App Program and after that it will not receive any other intervention.
62747684|NCT04899999|EXPERIMENTAL|Financial reward graphic message|
62747685|NCT04899999|EXPERIMENTAL|Health reward graphic message|
62747686|NCT04899999|EXPERIMENTAL|Self-efficacy graphic message|
62747687|NCT04899999|EXPERIMENTAL|Social norms graphic message|
62747688|NCT02375841||Physicians, Patients, and Caregivers|This is a longitudinal study of patients with GBM with recurrent or multi-recurrent disease as determined by their neuro-oncologist (on the basis of clinical and/or radiological findings). Patients will indicate a single caregiver who will consent separately and perform separate assessments. The study assessments will evaluate the content of the discussion in which this change in disease status was communicated, as well as include patient-reported and caregiver-reported outcomes. We intend to accrue 160 total participants (80 patients and 80 caregivers) with complete post-discussion visit follow-ups over 18-24 months.
62747689|NCT03735628|EXPERIMENTAL|Dose escalation|"Copanlisib:~45 mg (dose level -1) or 60 mg (dose level 1) on Day 1, Day 8 and Day 15 (28 day cycle)~Nivolumab:~240 mg on Day 15 of Cycle 1 and on Day 1 and Day 15 of subsequent cycles (28 day cycle)."
62747690|NCT03735628|EXPERIMENTAL|Dose expansion|"Copanlisib:~Recommended phase 2 dose established in the phase 1b part on Day 1, Day 8 and Day 15 (28 day cycle)~Nivolumab:~240 mg on Day 15 of Cycle 1 and on Day 1 and Day 15 of subsequent cycles (28 day cycle)."
62747691|NCT04913168|EXPERIMENTAL|Control Group|Control Group; no intervention
62747692|NCT04913168|EXPERIMENTAL|Intervention Group|Intervention Group; receives 13 month intervention
62374601|NCT04137055|EXPERIMENTAL|ZSP0678 (food effect)-Cohort FE|"Period 1: Group A and Group B receive ZSP0678/Placebo under the fasting or fed condition ,respectively on Day1.~Period 2: Group A and Group B receive ZSP0678/Placebo under the fed or fasting condition ,respectively on Day8.~Enrollment into Cohort FE will begin upon assurance of safety for Cohort 4."
62553846|NCT04898452||Health professionals|A new model of interaction across health services with use of welfare technology and telemedicine Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
62747693|NCT05960331|EXPERIMENTAL|Self-control group|Participants will be able to choose over feedback schedule when practicing finger-pressing trajectory matching task.
62747694|NCT05960331|ACTIVE_COMPARATOR|Yoked group|Participants will receive feedback, which was determined by their counterpart in self-control group, with no-choice when practicing finger-pressing trajectory matching task.
62747695|NCT00918320|EXPERIMENTAL|Toptecan + temozolomide|
62747696|NCT05645978||Patients who underwent pacemaker insertion during study period|Patients who underwent pacemaker insertion between January 2015 and December 2020
62747697|NCT06214130|EXPERIMENTAL|Test|Orfiril long 500 mg (sodium valproate) prolonged-release minitablets
62374602|NCT04137055|EXPERIMENTAL|ZSP0678 Dose1 (multiple doses)-Cohort 8|ZSP0678/Placebo Dose1 will be administrated according to the results of Cohort 2\&3
62374603|NCT04137055|EXPERIMENTAL|ZSP0678 Dose2 (multiple doses)-Cohort 9|ZSP0678/Placebo Dose2 will be administrated according to the results of Cohort 3\&4
62747698|NCT06214130|ACTIVE_COMPARATOR|Reference|Ergenyl chrono 500 mg (valproic acid) prolonged -release tablets
62747699|NCT06179277|EXPERIMENTAL|Treatment/experimental group|Patients undergoing surgical crown lengthening of a single site with application of PrefGel® + Emdogain®
62374604|NCT04137055|EXPERIMENTAL|ZSP0678 Dose3 (multiple doses)-Cohort 10|ZSP0678/Placebo Dose3 will be administrated according to the results of Cohort 4\&5
62553847|NCT05235373||group A: (mild cases): with no progression of the respiratory symptoms.|multislice CT finding,The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive.
62553848|NCT05235373||group B: (moderate cases): who have worsened disease but not requiring ICU admission.|multislice CT finding,The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive.
62747700|NCT06179277|PLACEBO_COMPARATOR|Control group|Patients undergoing surgical crown lengthening of a single site with application of PrefGel® only
62747701|NCT02135328|EXPERIMENTAL|Radio Story|Participants listen to a radio story about a family's' success with preventing or managing type 2 diabetes through diet and physical activity; the focus was for the entire family to implement healthful lifestyle behaviors so the children can learn as well.
62747702|NCT02135328|ACTIVE_COMPARATOR|Audio brochure|Participants received an audio version of a standard brochure about type 2 diabetes prevention and management.
62553849|NCT05235373||Group C: (sever cases): patient who needed ICU admission.|multislice CT finding,The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive.
62747703|NCT05555797|EXPERIMENTAL|group of patients with psoriasis vulgaris|"in each patient lesions will be divided into 3 groups; Group 1: treated with Excimer laser alone(1-2 sessions/ week for 12 sessions according to induration protocol\*).~Group 2: treated with Excimer laser combined with topical tazarotene gel 0.1% Group3: treated with Excimer laser combined with topical betamethasone valerate ointment 0.1%"
62747704|NCT02084706|ACTIVE_COMPARATOR|Triamcinolone (20 g) and 2% Lidocaine injection over A1 pulley|Group one subjects will receive an injection of 0.5mL (20 g) of Triamcinolone and 0.5 mL of 2% Lidocaine over the A1 pulley.
62747705|NCT02084706|EXPERIMENTAL|J-tip lidocaine administration, then steroid injection|"Group two subjects will receive a needle free J-tip administration of 0.5mL of 2% lidocaine prior (2-10 minutes) to needle injection of 0.5mL of Triamcinolone (20 g) over the A1 pulley."
62747706|NCT01461265|OTHER|Cryoablation|All subjects will have cryoablation on one or two painful metastatic bone tumors.
62747707|NCT05208515|OTHER|stardard group|wowen who need emergency cesarean section will be send to the general operating center.
62747708|NCT05208515|EXPERIMENTAL|new group|women who need emergency cesarean section will be send to the obstetric operating center
62747709|NCT01847066|ACTIVE_COMPARATOR|Erbium plus cosmetics plus Impact|Erbium 2940 plus cosmetics plus Impact Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
62747710|NCT01847066|ACTIVE_COMPARATOR|Erbium 2940 plus cosmetics|Erbium 2940 plus cosmetics Patient shall be treated with erbium 2940nm laser, cosmetics
62374605|NCT03698929|ACTIVE_COMPARATOR|Dietary Effect of Cholesterol - Egg Phase|In a randomized, 9-week crossover trial, we will test the effects of dietary cholesterol in individuals without baseline cholesterol intake through two 4-week dietary intervention periods, using baked goods containing egg yolks or egg-free baked goods. During the egg phase participants will consume two egg yolks a day for four weeks. Each week, participants will be given a week's worth of baked goods containing two egg yolks each.
62374606|NCT03698929|PLACEBO_COMPARATOR|Dietary Effect of Cholesterol - No-Egg Phase|In a randomized, 9-week crossover trial, we will test the effects of dietary cholesterol in individuals without baseline cholesterol intake through two 4-week dietary intervention periods, using baked goods containing egg yolks or egg-free baked goods. During the no-egg phase participants will consume an egg-free product for four weeks. Each week participants will be given a week's worth of egg-free baked goods.
62374607|NCT05297383|ACTIVE_COMPARATOR|n-3 PUFA and flexibility- Control|Participants will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for 6 weeks. Alongside supplementation, participants will be instructed to maintain their normal level of physical activity but will participate in a time-matched control consisting of flexibility training (low-intensity exercise) for 6 weeks.
62374608|NCT05297383|PLACEBO_COMPARATOR|Placebo and flexibility- Control|Participants will take Placebo (safflower oil, AlaskOmega®, from Organic Technologies Inc.) will be taken by participants in placebo groups for 6 weeks. Alongside supplementation, participants will be instructed to maintain their normal level of physical activity but will participate in a time-matched control consisting of flexibility training (low-intensity exercise) for 6 weeks.
62553850|NCT05235373||Group D: (fatality cases): cases who died with or without ICU admission).|multislice CT finding,The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive.
62553851|NCT06516211||Lay User|
62553852|NCT06516211||HCP Predicate Device|
62553853|NCT02244281|EXPERIMENTAL|FLOMAX®|
62747711|NCT01847066|ACTIVE_COMPARATOR|Erbium 2940 plus cosmetics plus Impact|Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
62747712|NCT01847066|ACTIVE_COMPARATOR|Erbium 2940nm plus cosmetics|Patients shall be treated with Erbium 2940nm laser plus cosmetics only.
62747713|NCT01186926|EXPERIMENTAL|HGNS Treatment|
62747714|NCT04268329|OTHER|Educational website: Patient|Patients with a head and neck cancer will be asked to complete an 8 item questionnaire during their clinic visit. Patients will be shown the head and neck website (available in both English and Spanish) by a member of the study investigation team on a computer and also given the URL address to the study website. Patients will be asked to review the material on the website between their initial visit and there second follow-up visit. The time between visits will be between 1 and 4 weeks. Patients will be asked to record the number of times they visit the website and the time spent during each visit. Patients will be given a log sheet to document their use/time on the website. During the 2nd clinic visit patients will be asked to complete the same questionnaire that they completed during their initial study visit along with an additional 7 item survey. Following completion of the 2 documents, the patient's participation in the study will be completed.
62374609|NCT05297383|ACTIVE_COMPARATOR|n-3 PUFA and HIIT- Test|Participants will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for 6 weeks. Alongside supplementation, participants will engage in a 4 x 4 HIIT exercise (4 intervals for 4 min at 85-95% HRmax with 3min active recovery at 50-70% HRmax) program, 3 days/week, for 6 weeks.
62553854|NCT02244281|PLACEBO_COMPARATOR|Placebo|
62553855|NCT04612907|ACTIVE_COMPARATOR|Moderate hypo-fractionation|Radiotherapy to the prostate delivered in 3Gy fractions x 19
62553856|NCT04612907|EXPERIMENTAL|Ultra hypo-fractionation|Radiotherapy to the prostate delivered in 6.1Gy fractions x 6
62553857|NCT01625650||Rheumatology|Patients who present at enrolling sites across the US are invited to enroll if eligible.
62553858|NCT04089449|EXPERIMENTAL|PRT811|PRT811 will be administered orally
62553859|NCT03899909|EXPERIMENTAL|GLPG3121 SAD|Single doses of GLPG3121 at up to 6 dose levels in ascending order
62553860|NCT03899909|PLACEBO_COMPARATOR|Placebo SAD|Single doses of placebo
62553861|NCT03899909|EXPERIMENTAL|GLPG3121 MAD|Multiple doses of GLPG3121 at up to 4 dose levels in ascending order
62553862|NCT03899909|PLACEBO_COMPARATOR|Placebo MAD|Multiple doses of placebo
62553863|NCT06217913|NO_INTERVENTION|control group|routine delivery examination group
62747715|NCT04268329|OTHER|Educational website: Family member|A family member of a patient with a head and neck cancer will be asked to complete an 8 item questionnaire during their clinic visit. They will be shown the head and neck website (available in both English and Spanish) by a member of the study investigation team on a computer and also given the URL address to the study website. They will be asked to review the material on the website between their relatives initial visit and there second follow-up visit. The time between visits will be between 1 and 4 weeks. The family member will be asked to record the number of times they visit the website and the time spent during each visit. They will be given a log sheet to document their use/time on the website. During the 2nd clinic visit the family member will be asked to complete the same questionnaire that they completed during their initial study visit along with an additional 7 item survey. Following completion of the 2 documents, their participation in the study will be completed.
62747716|NCT03215303|EXPERIMENTAL|Continuous Positive Airway Pressure (CPAP)|Participants in the intervention group will use CPAP device, for a period of 40 minutes, with the following parameters: PEEP of 10cmH2O and FiO2 0.21.
62747717|NCT03215303|PLACEBO_COMPARATOR|CONTROL|Participants in the control group will use CPAP device, for a period of 40 minutes, with the following parameters: PEEP of 1cmH2O and FiO2 0.21.
62747718|NCT03116828|EXPERIMENTAL|eslicarbazepine acetate (arm 1)|eslicarbazepine acetate (as first add-on)mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
62747719|NCT03116828|EXPERIMENTAL|eslicarbazepine acetate (arm 2)|eslicarbazepine acetate (as later add-on)
62747720|NCT00790647|EXPERIMENTAL|Stem Cell Transplant with Bortezomib and Melphalan|Mobilization with Filgrastim Stem Cell Collection Bortezomib Melphalan Stem Cell infusion
62747721|NCT00742989|EXPERIMENTAL|A|OLT administration
62747722|NCT00742989|SHAM_COMPARATOR|B|placebo-OLT
62747723|NCT06294574|EXPERIMENTAL|Hydromark plus clip placement|Patients with a previously placed HydroMARK T3 coil clip or a clip made by another manufacturer and will have a HydroMARK Plus clip placed during the scout localization procedure for this study. Breast surgeons will perform retrieval and then complete a satisfaction survey to compare the two clips.
62747724|NCT00686426|ACTIVE_COMPARATOR|1|Low Dairy
62747725|NCT00686426|EXPERIMENTAL|2|Adequate Dairy
62747726|NCT02284529|EXPERIMENTAL|Orectalip® (Oxaliplatin)|High-risk Stage-Ⅱ Colorectal Cancer treatment with Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1 to execute 8\~12 cycles
62747727|NCT01113008|EXPERIMENTAL|Remote postcondtioning|Patients assigned to remote ischemic postconditioning (randomized controlled trial)
62747728|NCT01113008|PLACEBO_COMPARATOR|Control group|
62747729|NCT01129713|ACTIVE_COMPARATOR|Nexium|Comparing 40 mg.once daily in healing erosive esophagitis.
62747730|NCT01129713|ACTIVE_COMPARATOR|Secretol|Comparing the efficacy of 80/80 Secretol once daily in healing erosive esophagitis.
62747731|NCT04971239|ACTIVE_COMPARATOR|topical methotrexate microemulsion|Group(A): topical methotrexate micro emulsion formulation, each patient will be instructed to apply a very thin film of 0.5 ml of it over the three psoriatic plaques three times weekly .
62747732|NCT04971239|EXPERIMENTAL|combination of topical methotrexate microemulsion and excimer light|Group(B) : excimer laser will be done twice weekly on a different psoriatic plaques in combination with topical methotrexate micro emulsion for a total treatment course of 12 weeks.
62374610|NCT05297383|PLACEBO_COMPARATOR|Placebo and HIIT- Test|Participants will take Placebo (safflower oil, AlaskOmega®, from Organic Technologies Inc.) will be taken by participants in placebo groups for 6 weeks. Alongside supplementation, participants will engage in a 4 x 4 HIIT exercise (4 intervals for 4 min at 85-95% HRmax with 3min active recovery at 50-70% HRmax) program, 3 days/week, for 6 weeks.
62374611|NCT03712670|ACTIVE_COMPARATOR|AM group|Intravitreal aflibercept monotherapy
62374612|NCT03712670|EXPERIMENTAL|AP group|Intravitreal aflibercept along with 0.1% pranoprofen
62374613|NCT03712670|EXPERIMENTAL|AN group|Intravitreal aflibercept plus daily supplementation of nutraceutical tablets
62374614|NCT04498390|EXPERIMENTAL|LY3493269|LY3493269 administered orally.
62374615|NCT04498390|PLACEBO_COMPARATOR|Placebo|Placebo administered orally.
62374616|NCT01100658|ACTIVE_COMPARATOR|Methylphenidate|Administered 1 capsule each day for 1 week, .3 mg/kg dose.
62553864|NCT06217913|EXPERIMENTAL|intervention group|routine delivery examination group + use of wearable blood pressure monitoring device group
62553865|NCT02665221|PLACEBO_COMPARATOR|Control group|
62553866|NCT02665221|EXPERIMENTAL|Treatment group|
62553867|NCT03158922||Stage 1|Caucasian men aged 55-69 to undergo genetic profiling.
62747733|NCT04971239|EXPERIMENTAL|combination of topical methotrexate microemulsion and narrow band-ultraviolet B|Group(C) : Narrow band ultraviolet B will be done twice weekly on a different psoriatic plaques in combination with topical methotrexate micro emulsion for a total treatment course of 12 weeks
62747734|NCT02984241|ACTIVE_COMPARATOR|eHealth Coping Skills Training + Coach|Access to StopSpinningMyWheels.org + Coach Support
62747735|NCT02984241|ACTIVE_COMPARATOR|eHealth Coping Skills Training Only|Access to StopSpinningMyWheels.org
62747736|NCT02984241|ACTIVE_COMPARATOR|eHealth Usual Web Care|Access to StopSpinningMyWheels.org usual care
62747737|NCT03720041|ACTIVE_COMPARATOR|R1: IRD induction therapy (reactive)|In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol.
62553868|NCT03158922||Stage 2|Men from Stage 1 identified as having a higher genetic risk score (top 10%) for prostate cancer.
62553869|NCT05370105||Stroke patients|80 post-stroke patients will be asked to undergo three samples of biological material (10 ml of blood): the first collection on the second day of hospitalization at IRCCS S. Maria Nascente (Milano) or at IRCCS Don Gnocchi (Florence) of Fondazioen Don Gnocchi (t0) and a second withdrawal at discharge (t1), or approximately 2 months after the first withdrawal. Where possible, a third sampling (t2 - follow up) will be performed 6 months after the event.
62553870|NCT05370105||Healthy Controls|The healthy controls will be volunteers recruited at Fondazione Don Gnocchi, who are not affected by neurodegenerative and cardiovascular diseases and who have not taken anti-inflammatory drugs in the week prior to recruitment.
62553871|NCT01974973|EXPERIMENTAL|Stem cell|autologous bone marrow mononuclear cell transplantation
62553872|NCT05311189|EXPERIMENTAL|HLX10, Trastuzumab and Chemotherapy|HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer
62553873|NCT02562066|EXPERIMENTAL|amifampridine phosphate -placebo|Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive amifampridine in Period I and then crossed over to receive placebo in Period II. Each randomized treatment period is 7 days in duration and is separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
62747738|NCT03720041|EXPERIMENTAL|R1: IRD induction therapy (adaptive)|In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail.
62747739|NCT03720041|ACTIVE_COMPARATOR|R2: Lenalidomide plus placebo maintenance|Participants randomised to this arm at Randomisation 2 will receive lenalidomide plus placebo maintenance.
62747740|NCT03720041|EXPERIMENTAL|R2: Lenalidomide + ixazomib maintenance|Participants randomised to this arm at Randomisation 2 will receive lenalidomide plus ixazomib maintenance.
62747741|NCT04202224|EXPERIMENTAL|Study|Receives pre-emptive analgesia 30min. prior to third molar extraction. NSAID: Ibuprofen 400mg and Acetaminophen 500mg/
62747742|NCT04202224|PLACEBO_COMPARATOR|Placebo|Receives glucose tablets as pre-emptive analgesia 30min. prior to third molar extraction.
62747743|NCT04202224|ACTIVE_COMPARATOR|Control|Receives no medication prior to third molar extraction.
62747744|NCT00995397|EXPERIMENTAL|Dexchlorpheniramine 1% lotion|
62747745|NCT00995397|ACTIVE_COMPARATOR|Dexchlorpheniramine 1% cream|
62747746|NCT05396924|ACTIVE_COMPARATOR|Room Group|Room temperature irrigation fluids will be used routinely for Group 1. Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer, whose batteries will be changed every two operations.
62374617|NCT01100658|PLACEBO_COMPARATOR|Placebo|Administered 1 capsule each day for 1 week.
62553874|NCT02562066|EXPERIMENTAL|placebo - amifampridine phosphate|Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive placebo in Period I and then crossed over to receive amifampridine in Period II. Each randomized treatment period is 7 days in duration and separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
62553875|NCT01604616||PCFL GROUP|patients in this group had the PFCL for a period of 7-10 days before it was replaced by SF6 gas or silicone oil
62553876|NCT01604616||control group|in thos group no PFCL was left in the eye and either SF6 or silicone oil was the definitive treatment at the time of the retinal detachment surgery repair.
62747747|NCT05396924|ACTIVE_COMPARATOR|Warmed Group|Irrigation fluids heated up to 36-38 degrees will be used for Group 2.Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer, whose batteries will be changed every two operations.
62747748|NCT03509363|EXPERIMENTAL|Intervention|Participants allocated to the intervention group will be prescribed a set of exercise video with QR code provided in home exercise pamphlets and they have to perform the prescribed exercises under the guidance of video.The content of home exercise program in both groups is the same and is based on the recommendations from the National Stroke Foundation Clinical Guidelines, including mobilization exercise, strengthening exercise and balance training which is tailor-made for different mobility level of stroke patients. Suitability of participating home exercise program will be assessed by physiotherapists based on environmental risk, fall risk and competence of patients or carers in performing exercise with patients. The number of exercises prescribed, frequency and intensity of exercise varies from participants and will be determinated by physiotherapists
62747749|NCT03509363|NO_INTERVENTION|Control|Participants in control group will be given instructions for their home exercise program in a traditional pamphlet includes photographs and instructions of exercise demonstration.
62747750|NCT06061263||PCR patients with eaophageal squamous cell carcinomas|patients with esophageal squamous cell carcinoma (ESCC) patients who achieved pathologic complete response after neoadjuvant chemoradiotherapy (nCRT).
62747751|NCT02769338|EXPERIMENTAL|QI with External Facilitation|Receive external facilitation to support implementation of the quality improvement program
62747752|NCT02769338|NO_INTERVENTION|Control|Non-Intervention VA Medical Centers
62747753|NCT01579565|EXPERIMENTAL|OMS302|OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
62747754|NCT01579565|PLACEBO_COMPARATOR|Placebo|Placebo diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
62747755|NCT05048836|EXPERIMENTAL|Food subsidy, no lifestyle support, 6 months|Participant will receive $40 healthy food subsidy for 6 months.
62374618|NCT06250933|EXPERIMENTAL|Experiment group|The experimental group will receive education on postpartum maternal care and premature infant care, in addition to routine care provided by healthcare professionals, based on nursing care grounded in Meleis' Transition Theory.
62747756|NCT05048836|EXPERIMENTAL|Food delivery, no lifestyle support, 6 months|Participant will receive twice monthly healthy food delivery for 6 months.
62747757|NCT05048836|EXPERIMENTAL|Food subsidy, with lifestyle support, 6 months|Participants will receive food subsidy and healthy lifestyle support for 6 months.
62747758|NCT05048836|EXPERIMENTAL|Food delivery, with lifestyle support, 6 months|Participants will receive twice monthly food box deliveries and lifestyle support for 6 months.
62747759|NCT05048836|EXPERIMENTAL|Food subsidy, no lifestyle support, 12 months|Participants will receive food subsidy for 12 months.
62747760|NCT05048836|EXPERIMENTAL|Food delivery, no lifestyle support, 12 months|Participants will receive twice monthly food box deliveries for 12 months.
62747761|NCT05048836|EXPERIMENTAL|Food subsidy, with lifestyle support, 12 months|Participant will receive food subsidy and lifestyle support for 12 months.
62747762|NCT05048836|EXPERIMENTAL|Food delivery, with lifestyle support, 12 months|Participants will receive twice monthly food box deliveries and lifestyle support for 12 months.
62747763|NCT04424628|ACTIVE_COMPARATOR|Radiotherapy 3 Gy|"Patiens will receive low dose gonarthrosis or coxarthrosis radiotherapy (0.5 Gy in 6 fractions alternating days).~Evaluation of pain releave and quality of live in 8-12 weeks If no effect the patient will be randomized to 3 or 6 Gy again"
62374619|NCT06250933|NO_INTERVENTION|Control group|The control group will continue to receive routine care
62374620|NCT00260936||HIV-negative|HIV-infected and -uninfected males, ages 12 to 24 years, of Tanner Stage 4 or 5
62374621|NCT00260936||HIV-positive, has never been on ART|HIV-positive, has never been on ART
62374622|NCT00260936||HIV-positive, non PI containing NNRTI-based regimen|HIV-positive, currently on a non-PI-containing NNRTI-based regimen for at least 12 weeks. Must never have received a total of more than 6 months of PI-containing regimen, and at least one year must have passed since receipt of last PI-containing regimen
62374623|NCT00260936||HIV-positive, non-NNRTI-containing PI-based regimen|HIV-positive, currently on a non-NNRTI-containing PI-based regimen for at least 12 weeks. Must never have received a total of more than 6 months of NNRTI-containing regimen, and at least one year must have passed since receipt of last NNRTI-containing regimen.
62374624|NCT01565460||pancreatic/biliary strictures|Sample Collection: Patients with pancreatic/biliary stricture undergoing intervention will have samples of brushings and bile taken during the procedure.
62747764|NCT04424628|ACTIVE_COMPARATOR|Radiotherapy 6 Gy|"Patiens will receive low dose gonarthrosis or coxarthrosis radiotherapy (1 Gy in 6 fractions alternating days).~Evaluation of pain releave and quality of live in 8-12 weeks If no effect the patient will be treated with 6 Gy again"
62747765|NCT04717336|EXPERIMENTAL|PERIOD 1: Sodium Chloride then Placebo|Participant will take Sodium Chloride at 3 pills per day for a total of 3 grams for two weeks, followed by a wash-out period for three-weeks, then ending with a cross-over to the Placebo at 3 pills per day for a total of 3 grams for two weeks.
62747766|NCT04717336|EXPERIMENTAL|PERIOD 2: Placebo then Sodium Chloride|Participant will take Placebo at 3 pills per day for a total of 3 grams for two weeks, followed by a wash-out period for three-weeks, then ending with a cross-over to the Sodium Chloride at 3 pills per day for a total of 3 grams for two weeks.
62747767|NCT05322512|EXPERIMENTAL|124I-EV|Imaging cohort All enrolled participants will be allocated to undergo three 124I-EV PET/CT scans.
62747768|NCT05678816|EXPERIMENTAL|BREATHER GROUP|"1)respiratory muscle training for inspiratory and expiratory muscles by the breather device 2)physiotherapy prgramme for stroke rehabilitation which include:~* Passive stretching exercise, strengthening exercise.~* Postural control and balance exercise from different positions as quadruped, kneeling, sitting and standing.~* Gait training."
62747769|NCT05678816|OTHER|CONTROL|"physiotherapy prgramme for stroke rehabilitation which include:~* Passive stretching exercise, strengthening exercise.~* Postural control and balance exercise from different positions as quadruped, kneeling, sitting and standing.~* Gait training."
62747770|NCT03366558||PD patients: early stage|Parkinson Disease patients with early stage of the disease: potentially hypokinesia, but no dyskinesia and motor fluctuations
62747771|NCT03366558||PD patients: developed stage|"PD patients having dyskinesia and motor fluctuations (described as developed stage of the disease)"
62747772|NCT03366558||No PD|Subjects not having diagnosed Parkinson Disease
62747773|NCT01397773||Hemodialysis group|Patients on chronic hemodialysis program
62374625|NCT04672317|EXPERIMENTAL|Neoadjuvant arm|"Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible.~Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy"
62374626|NCT02020304|EXPERIMENTAL|Room temperature|room temperature combined spinal epidural dose (60-75 degrees F)
62374627|NCT02020304|ACTIVE_COMPARATOR|refrigerated temperature|refrigerated temperature combined spinal epidural dose (\~\<43 degrees F)
62553877|NCT01101412|EXPERIMENTAL|Arm I: Antimicrobial Solution|Antimicrobial solution into central or peripheral venous catheter (CVC or PVC) once daily for 90 days. Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug infusion or blood aspiration.
62553878|NCT01101412|ACTIVE_COMPARATOR|Arm II: Saline Solution|Saline solution into CVC or PVC once daily for 90 days. Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug infusion or blood aspiration.
62553879|NCT02203357|ACTIVE_COMPARATOR|20μg, 0-1-6|117 young adults were administered with 20μg of hepatitis B vaccine according to the 0-1-6 mon schedule.
62553880|NCT02203357|EXPERIMENTAL|60μg, 0-1|112 young adults were administered with 60μg of hepatitis B vaccine according to the 0-1 mon schedule.
62747774|NCT01397773||Peritoneal dialysis group|Patients on chronic peritoneal dialysis program
62747775|NCT01397773||Pre-dialysis group|Patients with chronic kidney disease stage-4
62747776|NCT01397773||Control group|Healthy subjects
62553881|NCT02203357|EXPERIMENTAL|60μg, 0-2|125 young adults were administered with 60μg of hepatitis B vaccine according to the 0-2 mon schedule.
62747777|NCT01229254|EXPERIMENTAL|Amiodarone|Participants on betrixaban 30 mg and concomitant baseline amiodarone
62747778|NCT01229254|EXPERIMENTAL|Betrixaban 60 mg|Participants with lower weights
62747779|NCT01229254|EXPERIMENTAL|Betrixaban 90 mg|Participants with higher weights
62747780|NCT06607783||Single Group Males|Men with clinically suspected prostate cancer and referred for prostate MRI with Likert/PIRADS 3 or above and prior decision made to perform targeted biopsy.
62747781|NCT06626061|EXPERIMENTAL|CBSM Intervention in In-Person Group Format|"* 8 CBSM sessions~* The sessions will take place in a group setting, face-to-face, within the institution."
62747782|NCT06626061|EXPERIMENTAL|Hybrid CBSM Intervention|"* 8 CBSM sessions~* This format combines podcasts to listen to, along with three online sessions via video conferencing (at the beginning, middle, and end of the program)."
62747783|NCT06626061|NO_INTERVENTION|Delayed CBSM Intervention|Participants will participate in the program at a delayed time to form a control group.
62747784|NCT03170115|EXPERIMENTAL|Aspirin|Induction chemotherapy followed by chemoradiotherapy with aspirin Aspirin 100mg daily during the chemoradiotherapy
62747785|NCT03170115|PLACEBO_COMPARATOR|Placebo Oral Tablet|Induction chemotherapy followed by chemoradiotherapy without aspirin Placebo daily during the chemoradiotherapy
62747786|NCT01611688|EXPERIMENTAL|Active|
62747787|NCT01611688|PLACEBO_COMPARATOR|Placebo|
62747788|NCT04871412|EXPERIMENTAL|Integrative Care (Treatment)|Participants in the Integrative arm will receive standard surgical and oncologic care at The Ottawa Hospital plus complementary care guided by a naturopathic doctor at The Centre for Health Innovation
62747789|NCT04871412|NO_INTERVENTION|Standard Care (Control)|Participants in the control arm will receive standard surgical and oncologic care at The Ottawa Hospital
62374628|NCT04285177||Horizontal muscle surgery|Patients suffering from esotropia or exotropia, will have medial/lateral rectus recession/resection
62747790|NCT03960086|EXPERIMENTAL|Custom-made foot orthoses|"Children in the experimental group received as treatment intervention custom-made polypropylene foot orthoses (Podoactiva®, Spain). They were advised pragmatically to wear the orthoses at least 8 to 10 hours per day for the daily life and during sport activity.~Treatment period of 12 weeks"
62747791|NCT03960086|ACTIVE_COMPARATOR|Heel Lifts|"Children in the experimental group received as treatment intervention custom-made polypropylene foot orthoses (Podoactiva®, Spain). They were advised pragmatically to wear the orthoses at least 8 to 10 hours per day for the daily life and during sport activity.~Treatment period of 12 weeks"
62747792|NCT05951075|EXPERIMENTAL|Power Prenatal for Sperm|This is a single arm study. Participants will take supplements for 4 months. The supplements is Power Prenatal for Sperm (active ingredients - https://birdandbe.com/the-power-prenatal-for-sperm)
62374629|NCT04285177||Patients with Inferior Oblique Overaction|Will undergo inferior Oblique Myectomy
62374630|NCT04285177||Patients with combined horizontal and oblique muscle surgery|Having combined surgery
62553882|NCT03442439|ACTIVE_COMPARATOR|Nutrition and Play Intervention (NPI)|Half of the mother-child dyads who are enrolled into the study will be randomly assigned to the Nutrition and Play Intervention group.
62553883|NCT03442439|EXPERIMENTAL|Family Nurture Intervention (FNI)|Half of the mother-child dyads who are enrolled into the study will be randomly assigned to the Family Nurture Intervention group.
62553884|NCT05731518|EXPERIMENTAL|SC0245 and irinotecan combination|SC0245 and irinotecan combination are administered one cycle that is consisted of 28 days until disease progression or death or loss of follow-up or withdrawal.
62747793|NCT06655532|SHAM_COMPARATOR|Usual care|Patients allocated to this arm will receive the standard medical treatment plus explicit recommendations for 12-week home-based moderate-intensity aerobic and strength training.
62747794|NCT06655532|ACTIVE_COMPARATOR|Supervised aerobic plus moderate to high-intensity strenght training|Patients allocated to this arm will receive the usual care plus supervised aerobic and moderate to high-intensity strength training.
62747795|NCT06493357|EXPERIMENTAL|PAC-Man Model|"PAC-Man represents an integrated DSD model for mothers and infants that brings the following three evidence-based practices into the community for EMTCT: 1) pediatric active case finding using novel POC EID technology; 2) same-day ART initiation for infants newly diagnosed with HIV infection; and 3) mVL testing and back-to-care services. PAC-Man uses a mobile approach to offer EMTCT services in the community and reach high risk MIPs. Delivering the PAC-Man model will be done under the auspices of routine care, applying an overarching implementation strategy of creating new mobile care teams equipped with new diagnostic technology who deploy the m-PIMA in community settings."
62747796|NCT06493357|ACTIVE_COMPARATOR|Standard of care (control arm)|Routine care as provided by the Ministry of Health.
62747797|NCT04700345|EXPERIMENTAL|Embolization|Middle meningeal artery(MMA) embolization
62747798|NCT04700345|ACTIVE_COMPARATOR|No embolization|Traditional treatment group
62747799|NCT04017923||20-29 age group|
62747800|NCT04017923||30-39 age group|
62747801|NCT04017923||40-64 age group|
62747802|NCT04017923||65 and older age group|
62747803|NCT05991115|NO_INTERVENTION|Standard of Care|Control arm will receive the standard of care (SOC) after hospital discharge.
62747804|NCT05991115|EXPERIMENTAL|Hospital to Home Transition (H2H)|The intervention for this study is a multi-component navigation-supported intervention for children hospitalized with asthma. Navigators will work with families for 12-months post-discharge. Trained asthma educator/navigators will work to address challenges with asthma care after discharge; will include maximum 15 contacts/12 months. The asthma navigators within this study will attempt to maintain direct contact with participants primary care doctors through email, fax, and/or postal mail as means for delivering asthma action plans, prescription updates, and patient appointment scheduling. The asthma navigators for intervention participants will attempt to maintain contact with the school nurse in efforts to have a line of communication with the school. Asthma navigators will assist families in all home-based needs pertaining to their child's asthma.
62747805|NCT05093673|ACTIVE_COMPARATOR|Cathodal Cerebellar tDCS and SFA|Cathodal cerebellar tDCS, 2 milliamp (mA) plus Semantic Feature Analysis (SFA) naming treatment for 15 sessions (25-minutes per each 60-minute treatment session) over the course of 3-5 weeks. The electrical current will be administered to the right cerebellum. The stimulation will be delivered at an intensity of 2 mA for a maximum of 25 minutes. SFA will be delivered by a Speech and Language Pathologist to improve naming
62747806|NCT05093673|SHAM_COMPARATOR|Sham Cerebellar tDCS and SFA|Sham cerebellar tDCS plus SFA for 15 sessions (25-minutes per each 60-minute treatment session) over the course of 3-5 weeks. Current will be administered in a ramp-like fashion, but after the ramping, the intensity will drop to 0 mA. SFA will be delivered by a Speech and Language Pathologist to improve naming.
62747807|NCT01271010|EXPERIMENTAL|Rituximab + Fludarabine + Cyclophosphamide|Participants received rituximab 375 milligrams per square meter (mg/m\^2) intravenously (IV) on Day 1 of Cycle 1, then 500 mg/m\^2 IV on Day 1 of each subsequent cycle; fludarabine 25 mg/m\^2 IV or 40 mg/m\^2 orally on Days 1-3 of each cycle and cyclophosphamide 250 mg/m\^2 IV or 250 mg/m\^2 orally on Days 1-3 of each cycle. Treatment duration was 6 cycles, 28 days each.
62747808|NCT03424967|EXPERIMENTAL|ABM therapy|The attention bias modification treatment comprises of six computerized sessions, twice a week, in purpose of modulate biases in attention for threat stimuli.
62747809|NCT06606808|EXPERIMENTAL|4.5 mg risankizumab-800CW|Patients receive 4.5 mg risankizumab-800CW and undergo a Fluorescence Molecular Imaging procedure
62747810|NCT06606808|EXPERIMENTAL|15 mg risankizumab-800CW|Patients receive 15 mg risankizumab-800CW and undergo a Fluorescence Molecular Imaging procedure
62747811|NCT06606808|EXPERIMENTAL|25 mg risankizumab-800CW|Patients receive 25 mg risankizumab-800CW and undergo a Fluorescence Molecular Imaging procedure
62747812|NCT06606808|EXPERIMENTAL|14 weeks or more of risankizumab therapy and optimal dose risankizumab-800CW|Patients who are treated with risankizumab for at least 14 weeks are enrolled in this arm. This can be patients who already joined in the dose finding part of the study or new patients. These patients will receive the optimal dose risankizumab-800CW and will undergo aFluorescence Molecular Imaging procedure
62747813|NCT03130621||Adenocarcinoma of upper digestive tract|Early-onset carcinomas ; Family History of Malignancy; Special pathological type; MSI or dMMR; Multiple primary malignant tumors;
62747814|NCT03130621||Esophageal squamous cell carcinoma|Family History of Malignancy; Multiple primary malignant tumors; MSI or dMMR;
62747815|NCT01670786|EXPERIMENTAL|Iodopovidone 1%|The patients enrolled in this arm were submitted to pleurodesis with iodopovidone 1% administration into pleural cavity.
62747816|NCT01670786|EXPERIMENTAL|Iodopovidone 2%|The patients enrolled in this arm were submitted to pleurodesis with iodopovidone 2% administration into pleural cavity.
62747817|NCT06493305|NO_INTERVENTION|control group|No intervention before, after pregnancy termination, pain scores and pain evaluation by questionnaires will be done.
62747818|NCT06493305|ACTIVE_COMPARATOR|intervention|Neurolinguistic programme will be done before uterine curettage for pregnancy termination, after this, pain scores and pain evaluation by questionnaires will be done.
62747819|NCT03300271|OTHER|No intervention (Education)|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
62747820|NCT03300271|EXPERIMENTAL|Mobile Application (Self monitoring)|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
62747821|NCT03300271|EXPERIMENTAL|Mobile Application (Personal coaching)|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
62747822|NCT02047591|EXPERIMENTAL|Relaxing-touch method|
62747823|NCT02047591|NO_INTERVENTION|Usual care|
62747824|NCT04717297|EXPERIMENTAL|Tailored Medication Management Remote Intervention Treatment Arm|Participants receive a total of three visits (one evaluation/pre-treatment visit and 2 treatment visits) that last 75 minutes each over 4 weeks. Sessions/visits are spaced 1 week apart and will be delivered remotely.
62747825|NCT04717297|SHAM_COMPARATOR|Waitlist Attention Control Arm|The attention control group will receive two, 75-minute attention visits with a trained research assistant. Upon completion of waitlist period, the participants in the waitlist group will be offered the intervention in person.
62553885|NCT03435887|ACTIVE_COMPARATOR|Alere q HIV-1/2 Detect for point of care infant testing|POC testing with Alere q HIV-1/2 Detect at birth and 6-weeks postnatal in parallel with standard of care HIV DNA PCR testing
62747826|NCT04717297|EXPERIMENTAL|Tailored Medication Management In-Person Intervention Treatment Arm|Participants receive a total of three visits (one evaluation/pre-treatment visit and 2 treatment visits) that last 75 minutes each over 4 weeks. Sessions/visits are spaced 1 week apart and will be delivered in-person.
62747827|NCT05740163|EXPERIMENTAL|Egg allergy with asthma with intervention|Immunotherapy Egg product including egg white and yolk allergens
62747828|NCT05740163|EXPERIMENTAL|Egg allergy without asthma with intervention|Immunotherapy Egg product including egg white and yolk allergens
62747829|NCT05740163|NO_INTERVENTION|Egg allergy with asthma without intervention|No intervention, control
62747830|NCT05740163|NO_INTERVENTION|Egg allergy without asthma without intervention|No intervention, control
62747831|NCT02545517|EXPERIMENTAL|Conv-R/JE Group|Participants who completed the Rabies PrEP regimen on days 1, 8 and 29, and Japanese Encephalitis (JE) primary series regimen on days 1 and 29 in the parent study (V49_23) and who received at least one booster dose of purified chick embryo cell culture (PCEC) rabies vaccine in this extension study, if Rabies Virus Neutralizing Antibody (RNVA) concentrations were less than (\<)0.5 IU/mL at scheduled visits.
62747832|NCT02545517|EXPERIMENTAL|Acc-R/JE Group|Participants who completed the Rabies PrEP regimen on days 1, 4 and 8 and JE primary series regimen on days 1 and 8 in the parent study (V49_23) and who received at least one booster dose of PCEC rabies vaccine in this extension study, if RNVA concentrations were \<0.5 IU/mL at scheduled visits.
62747833|NCT02545517|EXPERIMENTAL|Conv-R Group|Participants who completed the Rabies PrEP regimen on days 1, 8 and 29 in the parent study (V49_23) and who received at least one booster dose of PCEC rabies vaccine in this extension study, if RNVA concentrations were \<0.5 IU/mL at scheduled visits.
62747834|NCT04085458|OTHER|Severe hemophilia A patients|Prophylactic treatment regimens should be guided by clinical judgement based on individual patient characteristics and treatment response.
62747835|NCT06039930|EXPERIMENTAL|Tele-PROTECT (Effectiveness Aim, Abuse Impact Aim)|This group of participants will receive the Tele-PROTECT intervention, a behavioral intervention for depressed elder abuse (EA) victims designed to work in synergy with EA resolution services that provide safety planning, support services, and links to legal services.
62747836|NCT06039930|ACTIVE_COMPARATOR|Depression Education (DepEd) (Effectiveness Aim, Abuse Impact Aim)|This group of participants will receive the Depression Education intervention, an intervention designed with active therapeutic ingredients (education, support, empathy) and designed to be what a good clinician providing education would do with an individual with depression.
62747837|NCT06039930|NO_INTERVENTION|Stakeholder Groups (Implementation Aim)|To address the Implementation Aim of the study, investigators will conduct qualitative data via surveys, interviews, and focus groups. Qualitative data from NAPSA surveys, interviews, and focus groups will be analyzed to identify barriers and facilitators to the implementation of Tele-PROTECT in elder abuse agencies nation-wide using a mixed methods design with multiple stakeholder groups (e.g., EA directors, staff) in collaboration with the National Adult Protective Services Association (NAPSA).
62747838|NCT05009641|EXPERIMENTAL|carnitine2|2000 mg L-carnitine per day for 24 weeks
62747839|NCT05009641|ACTIVE_COMPARATOR|carnitine|1000 mg L-carnitine per day for 24 weeks
62747840|NCT05009641|NO_INTERVENTION|control|no supplementation
62747841|NCT00882583|EXPERIMENTAL|Dasatinib/Cetuximab/RT|"In Cohort A , there will be an initial run-in period of single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8 and oral dasatinib at specific dose level from day 8-14.~Cohort A will consist of patients with AJCC stage II (T2N0) and III (T1-2N1) SCCHN of oral cavity, oropharynx, T2N0 hypopharynx, T2N0-1 supraglottic larynx. Treatment will be dasatinib at specific dose level in combination with cetuximab 250mg/m2 IV and radiation therapy (RT) 70Gy at 2Gy/fn."
62747842|NCT00882583|EXPERIMENTAL|Dasatinib/Cetuximab/cisplatin/RT|"In Cohort B, there will be an initial run-in period of single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8 and oral dasatinib at specific dose level from day 8-14.~Cohort B will include patients with AJCC stage III (T3N0-1) and IV (T1-4N2-3M0, T4N0-1M0) squamous cell carcinoma of Oral Cavity, Oropharynx, Hypopharynx, and Larynx. Treatment will be daily dasatinib at specific dose level, in combination with q 3 week cisplatin 75mg/m2, weekly cetuximab 250mg/m2 IV and RT 70Gy ( 2gy per fraction)."
62747843|NCT04669938||Patients hospitalized for COVID-19|
62553886|NCT03435887|ACTIVE_COMPARATOR|GeneXpert HIV-1 Qual for point of care infant testing|POC testing with GeneXpert HIV-1 Qual at-birth and at 6-weeks postnatal in parallel with standard of care HIV DNA PCR testing
62553887|NCT02478229|EXPERIMENTAL|SOF and LDV|Single arm: All participants will be started on Sofosbuvir (SOF) 400 mg and Ledipasvir (LDV) 90 mg as a fixed dose combination (FDC) tablet p.o. once daily with or without food starting at the time of liver transplantation (OLT), i.e. first doses given immediately prior to OLT, and continuing for 12 weeks.
62553888|NCT01609790|EXPERIMENTAL|Arm I (bevacizumab and trebananib)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62747844|NCT01824654|EXPERIMENTAL|Rigid and Elastic registration softwares|
62553889|NCT01609790|ACTIVE_COMPARATOR|Arm II (bevacizumab and placebo)|Patients receive bevacizumab as in Arm I and placebo IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm I.
62553890|NCT04247373|EXPERIMENTAL|laparoscopic gastrectomy with pneumoperitoneum|
62553891|NCT02248311||Patients/Control Group|Observational
62553892|NCT02248311||Patients/Group Control|Observational
62553893|NCT01739712|EXPERIMENTAL|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
62553894|NCT01739712|SHAM_COMPARATOR|Fixed Sleep Duration|All youth in this condition are asked to maintain their baseline sleep duration.
62747845|NCT00919750||Ancillary-Correlative (tissue and blood sample collection)|Brain tumor tissue and blood specimens are collected from patients and banked for future study.
62747846|NCT02439151|EXPERIMENTAL|New Strategy|New Strategy: use transpulmonary pressure guide new lung ventilation strategy in ECMO for severe ARDS patients
62553895|NCT00815464|EXPERIMENTAL|Antiviral Therapy|Liquid Acupuncture(Herb Acupoints Injection) Therapeutics was researched and developed by Herbalist Yu Ru Lin in early of 1950s and used by Yu Medical Garden till now. It is an integrated therapeutics,according to individual condition, select the Acupoints(not limit to current used common acupoints) and proper herbs made individually.It is a special medical treatment conception, which theory is utilizing patients' condition, mobilizing their individual internal curability,therefore the final efficacy can be retrieved.
62747847|NCT02439151|OTHER|Conventional Strategy|Conventional Strategy: use conventional ventilation strategy (ELSO guide ventilation strategy) in ECMO for severe ARDS patients
62747848|NCT03487588|EXPERIMENTAL|A-101 Topical Solution|Open Label Arm
62374631|NCT03247218|EXPERIMENTAL|Single group of patients|"In this study 40 patients with SCD will be included. Twenty patients aged 18 years or older (cohort 1) and twenty patients 10 - 17 years old (cohort 2).~All the patients will receive Memantine Teva® film-coated tablets (Memantine hydrochloride) produced by Teva Pharma AG and will be provided as 5 mg, 10 mg, and 20 mg tablets packed in blister.~The study drug will be taken once a day per os, during one year."
62374632|NCT05774574|EXPERIMENTAL|CBD|1 mL hemp oil containing 60 mg/mL CBD, daily.
62374633|NCT05774574|PLACEBO_COMPARATOR|Placebo|1 mL hemp oil containing 0 mg/mL CBD, daily.
62374634|NCT00329459|EXPERIMENTAL|arm 1|Treximet (sumatriptan/naproxen sodium)
62374635|NCT00329459|PLACEBO_COMPARATOR|arm 2|placebo to match
62374636|NCT05375240|NO_INTERVENTION|Blank-control group|Patients will receive standard treatment.
62374637|NCT05375240|EXPERIMENTAL|Oropranolol group|Propranolol will be administered at a dose of 10mg\*3/day over a course of 7 consecutive days after stroke onset.
62374638|NCT05375240|EXPERIMENTAL|Propranolol + ceftriaxone group|Propranolol will be administered at a dose of 10mg\*3/day combined with 2g/day ceftriaxone over a course of 7 consecutive days after stroke onset.
62374639|NCT05554744|EXPERIMENTAL|MEN1-1-related pNETs|The patients with MEN1-1-related pNETs will undergo EUS-FNI with ethanol or lauromacrogol
62374640|NCT00926185|PLACEBO_COMPARATOR|Placebo|Placebo Ophthalmic Solution
62374641|NCT00926185|EXPERIMENTAL|0.1% Lifitegrast|Lifitegrast
62374642|NCT00926185|EXPERIMENTAL|1.0% Lifitegrast|Lifitegrast
62374643|NCT00926185|EXPERIMENTAL|5.0% Lifitegrast|Lifitegrast
62374644|NCT03722992|OTHER|Mindfulness Cohort|Mindfulness-based stress reduction (MBSR) treatment group
62747849|NCT01024972|EXPERIMENTAL|Dantrolene|Dantrolene 1.25mg/kg IV every 6 hours x 7 days
62747850|NCT01024972|PLACEBO_COMPARATOR|Placebo|Equiosmolar volume (5% Mannitol)
62747851|NCT06608134|ACTIVE_COMPARATOR|2cc WJ Allograft (Low Dose)|The 2cc Whartons Jelly Allograft group receives an intra-articular knee injection and is considered the Low Dose Group.
62747852|NCT06608134|ACTIVE_COMPARATOR|3cc WJ Allograft (Medium Dose)|The 3cc Whartons Jelly Allograft group receives an intra-articular knee injection and is considered the Medium Dose Group.
62747853|NCT06608134|ACTIVE_COMPARATOR|4cc WJ Allograft (High Dose)|The 4cc Whartons Jelly Allograft group receives an intra-articular knee injection and is considered the High Dose Group.
62747854|NCT05834088|EXPERIMENTAL|Myofascial techniques with Thiele massage|Group A will receive myofascial techniques with Thiele massage. 12 treatment sessions will be given in 12 weeks
62747855|NCT05834088|ACTIVE_COMPARATOR|Myofascial techniques without Thiele massage|Group B will receive myofascial techniques without Thiele massage. 12 treatment sessions will be given in 12 weeks
62374645|NCT01602744|NO_INTERVENTION|Controll|The medications in this arm will not be screened.
62374646|NCT01602744|ACTIVE_COMPARATOR|Intervention screening medication group|STOPP/START screening tools are used for medication intervention
62747856|NCT06106724|ACTIVE_COMPARATOR|group A|sphencterotomy of papilla by conventuional methodes
62374647|NCT02827487|ACTIVE_COMPARATOR|Tramadol|Women will receive oral Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) and an oral placebo similar to Celecoxib 2 hours before IUD insertion.
62374648|NCT02827487|ACTIVE_COMPARATOR|Celecoxib|Women will receive oral Celecoxib 200mg (Celebrex® 200, Pfizer, USA) and an oral placebo similar to Tramadol 2 hours before IUD insertion.
62374649|NCT02827487|PLACEBO_COMPARATOR|Placebo 1|Women will receive a placebo similar to Tramadol and a placebo similar to Celecoxib orally 2 hours before IUD insertion.
62374650|NCT03971019|EXPERIMENTAL|Statin therapy (experimental group)|"On the basis of guiding patients to control their diet and improve their lifestyle, etc.~Simvastatin 20mg/d QN Po (dosage can be adjusted according to the blood lipid level of each reexamination) Atorvastatin 10mg/d QN Po (patients who cannot tolerate the side effects of simvastatin may consider replacing this drug)"
62374651|NCT03971019|OTHER|Dietary intervention group (control group)|Guiding patients to control diet, improve lifestyle, etc.
62374652|NCT00991536||Chronic respiratory failure|Patients with restrictive pulmonary disorders leading to progressive hypercapnic respiratory failure and requiring nocturnal non-invasive ventilation
62374653|NCT02353325|EXPERIMENTAL|non-encapsulated FeSO4|Maize porridge with salt fortified with non-encapsulated FeSO4
62374654|NCT02353325|EXPERIMENTAL|encapsulated FeSO4, before cooking|Maize porridge with salt fortified with non-encapsulated FeSO4, added before cooking
62374655|NCT02353325|EXPERIMENTAL|encapsulated FeSO4, after cooking|Maize porridge with salt fortified with non-encapsulated FeSO4, added after cooking
62374656|NCT02353325|EXPERIMENTAL|non-encapsulated FeSO4 + ascorbic acid|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid
62374657|NCT02353325|EXPERIMENTAL|encapsulated FeSO4 + ascorbic acid, before cooking|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid, added before cooking
62374658|NCT02353325|EXPERIMENTAL|encapsulated FeSO4 + ascorbic acid, after cooking|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid, added after cooking
62374659|NCT01518140|EXPERIMENTAL|VapoTherm|"Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
62747857|NCT06106724|ACTIVE_COMPARATOR|group B|precutting of the papilla by knife needle
62747858|NCT01814319|EXPERIMENTAL|Probenecid|Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate therapy.
62747859|NCT01814319|PLACEBO_COMPARATOR|placebo|Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate (placebo) therapy.
62747860|NCT00811005|ACTIVE_COMPARATOR|Acitretin-PUVA combination|"Acitretin-PUVA combination:~Acitretin monotherapy: Patients randomized to the acitretin group will receive acitretin in a dose of 1mg /kg daily two weeks prior to additional PUVA treatment.~PUVA treatment (see below) will be applied thrice weekly in addition to acitretin until (near) complete clearance or over a maximum period of 12 weeks. (Near) complete clearance is defined by improvement of the clinical baseline score (see below) by ≥90%.~PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation."
62747861|NCT00811005|EXPERIMENTAL|Fumaric acid ester -PUVA combination|"FAE monotherapy:~Patients randomized to this group will receive FAE in weekly incremental doses (initial daily dose: 30 mg dimethylfumarate (DMF), highest daily dose: 720 mg DMF) starting two weeks prior to additional PUVA treatment.~FAE-PUVA combination:~PUVA treatment will be applied thrice weekly in addition to FAE until (near) complete clearance or over a maximum period of 12 weeks. (Near) complete clearance is defined by improvement of the clinical baseline score (see below) by ≥90%.~PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation."
62374660|NCT01518140|EXPERIMENTAL|BiPAP|"Participants receive air through bilevel positive airway pressure (BiPAP) for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through VapoTherm for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
62747862|NCT04300517|EXPERIMENTAL|protein supplement|Intervention patients will be received protein diet (1.2 g/kg/day) and protein supplement (36 g/day) for 1 month after surgery.
62747863|NCT04300517|PLACEBO_COMPARATOR|maltodextrin|Control patients will be received protein diet (1.2 g/kg/day) and maltodextrin for 1 month after surgery.
62747864|NCT04466631||Observative longitudinal|The participants won't receive any support during the post surgery period.
62747865|NCT05046002||Prospective (cases)|Patients who develop new symptoms of suspected myocarditis/pericarditis within 42 days of receiving a COVID-19 vaccination. The clinical symptoms include chest pain, pressure, or discomfort; dyspnea, shortness of breath, or pain with breathing; palpitations; diaphoresis or sudden death. The symptoms can also be non-specific, including fatigue, abdominal pain, dizziness or syncope, edema, cough or irritability, vomiting, poor feeding, tachypnea or lethargy in young children
62747866|NCT05046002||Prospective (Control Negative)|"Family members/relatives who have been vaccinated in a similar timeframe with the participants but did not experience myocarditis side-effects.~If a relative is not available, then a voluntary control who has received the same COVID-19 vaccine in a similar time frame can be recruited."
62747867|NCT05046002||Retrospective|Identified patients, previously diagnosed with the condition, at participating centers
62747868|NCT04071262|EXPERIMENTAL|Abemaciclib + Abiraterone Acetate + Prednisolone|Abemaciclib, abiraterone acetate and prednisolone given orally.
62747869|NCT03263130||COPD, Emphysema, Asthma-COPD Overlap|Based on clinical, pathologic, laboratory, physiologic and radiologic differences, patient groups can be described.
62747870|NCT05470179|ACTIVE_COMPARATOR|Hybrid hyrax distalizer|Inverted hyrax with 2 miniscrews for 6 months for maxillary molar distal movement in class II angle malocclusion
62747871|NCT05470179|ACTIVE_COMPARATOR|Pendulum distalizer device|Modified pendulum with miniscrews for 6 months for maxillary molar distal movement in class II angle malocclusion
62747872|NCT05099055|EXPERIMENTAL|Test group|Monitoring will be installed upon arrival.Metoclopramide 10 mg IV and Dexamethasone 4 mg will be given for nausea-prophylaxis. Patients may be given ondansetron 4 mg as rescue. Cefazoline 2G or clindamycin 900 mg will be given.A sterile spinal technique will be performed with a 25G Whitacre. Bupivacaine 12 mg (1.6 ml) will be drawn and given, along with dexmedetomidine 3 mcg (0.75 mL) previously blindly prepared for a total of 2.35 ml.Adequate blood pressure will be maintained with phenylephrine infusion or ephedrine IV. Glycopyrrolate 0.2 mg may be given for bradycardia.Once an adequate sensory block is obtained, the obstetrics team can perform the surgery.The patient will receive a dose of ketorolac 30 mg IV before leaving the PACU and then Naproxen 500 mg PO every 12 hours.She will receive acetaminophen 975 mg PO every 6 hours and hydromorphone 2-4 mg PO every 3 hours prn. Patients will also have access to a protocol for treatment of nausea and pruritus.
62747873|NCT05099055|ACTIVE_COMPARATOR|Control group|Monitoring will be installed upon arrival.Metoclopramide 10 mg IV and Dexamethasone 4 mg will be given for nausea-prophylaxis. Patients may be given ondansetron 4 mg as rescue. Cefazoline 2G or clindamycin 900 mg will be given.A sterile spinal technique will be performed with a 25G Whitacre. Bupivacaine 12 mg (1.6 ml) will be drawn and given, along with morphine 100 mcg, fentanyl 15 mcg and normal saline 0.25 ml previously blindly prepared for a total of 2.35 ml.Adequate blood pressure will be maintained with phenylephrine infusion or ephedrine IV. Glycopyrrolate 0.2 mg may be given for bradycardia.Once an adequate sensory block is obtained, the obstetrics team can perform the surgery.The patient will receive a dose of ketorolac 30 mg IV before leaving the PACU and then Naproxen 500 mg PO every 12 hours.She will receive acetaminophen 975 mg PO every 6 hours and hydromorphone 2-4 mg PO every 3 hours prn. Patients will also have access to a protocol for treatment of nausea and pruritus.
62747874|NCT02028117|EXPERIMENTAL|Enadenotucirev|
62747875|NCT02478697|EXPERIMENTAL|Tobacco Treatment|The tobacco treatment includes: (a) the ProChange ExpertSystem, a Transtheoretical-model (TTM) tailored, computer-assisted web-delivered program focused on increasing intrinsic motivation, (b) a stage-tailored treatment manual with goal setting for quitting tobacco, and (c) education on proper use of nicotine replacement therapy (NRT, patch plus gum or lozenge) with guidance on obtaining low-cost or free NRT through MediCal, private insurance plans, and community programs.
62747876|NCT02478697|NO_INTERVENTION|Usual Care|"Usual care includes: completing the study assessments at baseline, 3- and 6-months and receiving referrals to tobacco treatment in the community, including the state quitline, in line with the public health Ask, Advise, Refer model of tobacco cessation intervention."
62747877|NCT00737568|EXPERIMENTAL|Tenofovir DF|TDF plus placebo to match FTC/TDF
62747878|NCT00737568|EXPERIMENTAL|FTC/TDF|FTC/TDF plus placebo to match TDF
62747879|NCT04867187|EXPERIMENTAL|rTMS active and active mirror-based therapy using virtual reality|The patient will have an amount of 4 sessions (S3, S5, S7 and S9) for 1.5 months: 1 session every 2 weeks. The patient will receive rTMS active and active mirror-based therapy using virtual reality.
62747880|NCT04867187|SHAM_COMPARATOR|rTMS active and sham mirror-based therapy using virtual reality|The patient will have an amount of 4 sessions (S3, S5, S7 and S9) for 1.5 months: 1 session every 2 weeks. The patient will receive rTMS active and sham mirror-based therapy using virtual reality.
62747881|NCT05598125||Smoker_1|Begins with e-cigarette crosses over to conventional cigarette
62747882|NCT05598125||Non smoker|never smoking participants as control group
62374661|NCT01518140|EXPERIMENTAL|Non-Rebreather Mask|"Participants receive air through Non-Rebreather Mask for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through VapoTherm for up to 30 minutes, followed by 30 minutes using bilevel positive airway pressure (BiPAP)."
62553896|NCT05262387|EXPERIMENTAL|Treatment Sequence 1: ADBC|"Period 1: Lyumjev with 50% basal rate reduction (Treatment A)~Period 2: Humalog with 100% basal rate reduction (Treatment D)~Period 3: Lyumjev with 100% basal rate reduction (Treatment B)~Period 4: Humalog with 50% basal rate reduction (Treatment C)~Participants received their assigned treatments in each of the above treatment period on Day 1 subcutaneously."
62553897|NCT05262387|EXPERIMENTAL|Treatment Sequence 2: BACD|"Period 1: Lyumjev with 100% basal rate reduction (Treatment B)~Period 2: Lyumjev with 50% basal rate reduction (Treatment A)~Period 3: Humalog with 50% basal rate reduction (Treatment C)~Period 4: Humalog with 100% basal rate reduction (Treatment D)~Participants received their assigned treatments in each of the above treatment period on Day 1 subcutaneously."
62553898|NCT05262387|EXPERIMENTAL|Treatment Sequence 3: CBDA|"Period 1: Humalog with 50% basal rate reduction (Treatment C)~Period 2: Lyumjev with 100% basal rate reduction (Treatment B)~Period 3: Humalog with 100% basal rate reduction (Treatment D)~Period 4: Lyumjev with 50% basal rate reduction (Treatment A)~Participants received their assigned treatments in each of the above treatment period on Day 1 subcutaneously."
62553899|NCT05262387|EXPERIMENTAL|Treatment Sequence 4: DCAB|"Period 1: Humalog with 100% basal rate reduction (Treatment D)~Period 2: Humalog with 50% basal rate reduction (Treatment C)~Period 3: Lyumjev with 50% basal rate reduction (Treatment A)~Period 4: Lyumjev with 100% basal rate reduction (Treatment B)~Participants received their assigned treatments in each of the above treatment period on Day 1 subcutaneously."
62553900|NCT06366763|EXPERIMENTAL|gradient pressure elastic stocking treatment after endovenous radiofrequency ablation.|Among the 210 patients to assess the clinical efficacy of different compression methods within 48 hours after endovenous radiofrequency ablation (RFA) in terms of great saphenous vein closure rate, postoperative complications, quality of life, time to return to normal work, and patient satisfaction.
62553901|NCT04808674|EXPERIMENTAL|Group-based cognitive remediation program|Patients are admitted to the day hospital 2 days a week for 6 weeks and participate in a group-based (4 patients per group) rehabilitation program conducted by a multidisciplinary team including a PMR doctor, a neuropsychologist, an occupational therapist, and a physical activity monitor).
62553902|NCT04808674|EXPERIMENTAL|One-on-one cognitive remediation program|Patients are admitted to the day hospital 5 days a week for 6 weeks and participate in a one-on-one intensive rehabilitation program conducted by a multidisciplinary team including a speech therapist, neuropsychologist, occupational therapist, physiotherapist, physical activity monitor and a psychologist.
62553903|NCT06477094|ACTIVE_COMPARATOR|Stratus Nimbus|Patients will receive their radiofrequency ablation procedure of the lumbar medial branch nerves with the Stratus Nimbus Electrode.
62747883|NCT05598125||Smoker_2|Begins with conventional cigarette crosses over to e-cigarette
62747884|NCT06420856||Lisfranc injury patients|"Sense of light touch will be used with the Semmes-Weinstein Monofilament test, Proprioception evaluation will be used with the Dr.Goniometer application, Muscular strength and endurance will be evaluated with the cybex isokinetic device, Weight-Bearing Lunge test will be used to evaluate ankle mobility and Modified Star Excursion Balance Test will be used to evaluate dynamic balance.~Patients' functional levels will be evaluated under two headings:~1. Questionnaire-based functional evaluation: American Orthopedic Foot and Ankle Society (AOFAS) midfoot score and foot and ankle functions Rating Foot and Ankle Outcome Score (FAOS) will be used and will be evaluated.~2. Physical performance evaluation: Heel raise test would be used"
62374662|NCT02436915|EXPERIMENTAL|Real tDCS|"The real tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation (tDCS) targeting left prefrontal cortex at a target current intensity of 1.5 mA."
62374663|NCT02436915|SHAM_COMPARATOR|Sham tDCS|"The sham tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation with same montage as the real tDCS, except current will only be applied for the first 60 seconds of each session."
62374664|NCT05391295||6 CTCL patients, and 6 chronic cluster headache patients|The patients will be treated according to standard regular care, which is a corticosteroid treatment regime.
62374665|NCT03667573|EXPERIMENTAL|tsDCS Dosage A and textured insoles|"tsDCS dosage A and textured shoe insoles"
62374666|NCT03667573|EXPERIMENTAL|tsDCS Dosage B and textured insoles|"tsDCS dosage B and textured shoe insoles"
62374667|NCT03667573|EXPERIMENTAL|tsDCS Dosage A and smooth insoles|"tsDCS dosage A and smooth shoe insoles"
62747885|NCT06420856||Healthy Volunteers|"Sense of light touch will be used with the Semmes-Weinstein Monofilament test, Proprioception evaluation will be used with the Dr.Goniometer application, Muscular strength and endurance will be evaluated with the cybex isokinetic device, Weight-Bearing Lunge test will be used to evaluate ankle mobility and Modified Star Excursion Balance Test will be used to evaluate dynamic balance.~Patients' functional levels will be evaluated under two headings:~1. Questionnaire-based functional evaluation: American Orthopedic Foot and Ankle Society (AOFAS) midfoot score and foot and ankle functions Rating Foot and Ankle Outcome Score (FAOS) will be used and will be evaluated.~2. Physical performance evaluation: Heel raise test would be used"
62747886|NCT04758884|EXPERIMENTAL|Telemedicine group|"Visits by videoconference in months 0, 1, 2, 3, 4 and 6. Additionally, availability to send intermediate messages with a response from the endocrine in less than 72 hours.~The videoconference will be held safely through the SocialDiabetes® App. Patients will be provided with a glucometer that transfers the data directly to the App without the patient having to enter it to avoid bias in time and value. Videoconferences will NOT be recorded.~Patients with CGM will additionally have all their values on the platform that corresponds to their sensor (Libreview® for the Freesyle libre® sensor and Clarity® for the Dexcom G5 sensor)."
62747887|NCT04758884|NO_INTERVENTION|Conventional management group|Initial visit, 3 and 6 months.
62747888|NCT00877786|ACTIVE_COMPARATOR|Face-to-face group therapy|
62747889|NCT00877786|ACTIVE_COMPARATOR|Online chat group therapy|
62747890|NCT05658627|ACTIVE_COMPARATOR|1- control group|conventional physical therapy (ultrasound therapy- stretching exercise- strengthening exercise)
62747891|NCT05658627|EXPERIMENTAL|2- Experimental group|Active release technique for hamstring+ conventional physical therapy(ultrasound therapy- stretching exercise- strengthening exercise)
62747892|NCT03928938|EXPERIMENTAL|Electronic follow-up|Follow-up of cancer patients treated with immune checkpoint inhibitor therapy using electronic patient reported outcomes-tool
62747893|NCT04092894|ACTIVE_COMPARATOR|Suvorexant|Suvorexant 20 mg will be administered p.o. once a day between 9:00pm and 10:00pm for 7 days starting the night after extubation in the ICU.
62747894|NCT04092894|PLACEBO_COMPARATOR|Placebo|Placebo will be administered p.o. once a day between 9:00pm and 10:00pm for 7 days starting the night after extubation in the ICU.
62747895|NCT06313502|EXPERIMENTAL|75gm HDAA + Melphalan 100mg/m2|Subjects will receive HDAA alone (75gm) on day -4, HDAA combined with melphalan 100 mg/m2 on day -1, and ASCT on day 0. Four additional HDAA doses (75gm) will then be administered 3 days apart on D+2, D+5, D+8 and D+11, followed by weekly doses of the corresponding dose of HDAA for four additional weeks. On day, D-1, when both drugs are given, melphalan should be given first
62747896|NCT06313502|EXPERIMENTAL|100gm HDAA + Melphalan 100mg/m2|Subjects will receive HDAA alone (100gm) on day -4, HDAA combined with melphalan 100 mg/m2 on day -1, and ASCT on day 0. Four additional HDAA doses (100gm) will then be administered 3 days apart on D+2, D+5, D+8 and D+11, followed by weekly doses of the corresponding dose of HDAA for four additional weeks. On day, D-1, when both drugs are given, melphalan should be given first
62747897|NCT06313502|EXPERIMENTAL|125gm HDAA + Melphalan 100mg/m2|Subjects will receive HDAA alone (125gm) on day -4, HDAA combined with melphalan 100 mg/m2 on day -1, and ASCT on day 0. Four additional HDAA doses (125gm) will then be administered 3 days apart on D+2, D+5, D+8 and D+11, followed by weekly doses of the corresponding dose of HDAA for four additional weeks. On day, D-1, when both drugs are given, melphalan should be given first
62747898|NCT01050920||Blood Collection|
62747899|NCT05137288|ACTIVE_COMPARATOR|patients receiving intrathecal atropine|Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% ) with morphine 250mic and atropine sulphate 100 micwith total volume = 2.5 ml .
62374668|NCT03667573|EXPERIMENTAL|tsDCS Dosage B and smooth insoles|"tsDCS dosage B and smooth shoe insoles"
62374669|NCT00273806|EXPERIMENTAL|1|Medical assistant identification and referral for behavioral risk factors.
62374670|NCT00273806|NO_INTERVENTION|2|Usual care for behavioral risk factors.
62374671|NCT01165463|EXPERIMENTAL|Clinic-based SOPT basic training|Clinic-based SOPT basic training for 10 hours.
62374672|NCT01165463|EXPERIMENTAL|Home-based SOPT basic training|Home-based SOPT basic training for 10 hours.
62374673|NCT01165463|ACTIVE_COMPARATOR|Crossword Puzzles Training|Crossword puzzles training for 10 hours in our lab.
62747900|NCT05137288|ACTIVE_COMPARATOR|patients receiving preoperative intravenous ondasetron|Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% with 0.5 ml normal saline with morphine 250 mic ) with total volume = 2.5 ml with giving 4 mg IV ondansetron before anesthesia ( patients with body weight more than 80 Kg may need additional 4 mg IV ) .
62747901|NCT01734395||Galantamine|Patients will receive galantamine 8 mg/day for the first 4 weeks and the dose of galantamine will be increased up to 24 mg (if tolerable).
62747902|NCT02178852|EXPERIMENTAL|TNS-active|TRIGEMINAL NERVE STIMULATION (TNS)
62747903|NCT02178852|PLACEBO_COMPARATOR|TNS-sham|TRIGEMINAL NERVE STIMULATION (TNS) - sham
62747904|NCT03542903|ACTIVE_COMPARATOR|Short ECT arm|In the short arm, bitemporal ECT is administered twice a week during the first 6 weeks. Afterwards, it is administered once a week during 4 weeks. After that, the patients will have one ECT every 3 weeks during 6 weeks. Lastly, patients will receive one ECT each month during 2 months.
62747905|NCT03542903|ACTIVE_COMPARATOR|Long ECT arm|In the long arm, bitemporal ECT is administered twice a week during the first 12 weeks. Afterwards, it is administered once a week during 8 weeks. After that, the patients will have one ECT every 3 weeks during 12 weeks. Lastly, patients will receive one ECT each month during 4 months.
62747906|NCT05377450|ACTIVE_COMPARATOR|Cemented Engage Partial Knee|Engage partial knee implanted with bone cement for fixation.
62747907|NCT05377450|ACTIVE_COMPARATOR|Cementless Engage Partial Knee|Engage partial knee implanted with cementless fixation.
62374674|NCT01165463|EXPERIMENTAL|SOPT basic and SOPT booster-training|Clinic-based SOPT basic training and SOPT booster training.
62374675|NCT03644316|EXPERIMENTAL|BandGrip|Topical skin closure device
62747908|NCT06177197|EXPERIMENTAL|Physiomer|"It is a sterile, isotonic seawater-based solution, with a concentration equivalent to 9 g/L sodium chloride. This solution is packaged in 5 mL single-dose units.~It is a Class IIa medical device manufactured by Laboratoire de la mer, and is CE marked.~Electrodialyzed seawater solution is administered via the nasal passage, in line with current recommendations. Dosage varies according to age, and the pressure exerted on the unit dose enables the product to be administered into the nostril."
62747909|NCT06177197|ACTIVE_COMPARATOR|Saline solution|"It is a sterile, isotonic seawater-based solution, with a concentration egal to 0,9 g/L sodium chloride. This solution is packaged in 5 mL single-dose units.~It is a Class IIa medical device manufactured by GiLBERT, and is CE marked. The saline solution is administered via the nasal passage, in line with current recommendations. Dosage varies according to age, and the pressure exerted on the unit dose enables the product to be administered into the nostril."
62747910|NCT06153849||BCG instillation patient|Patients with pathology-confirmed median to high risk urothelial carcinoma defined by 2023 EAU guideline, underwent transurethral resection of bladder tumor and receiving BCG instillation therapy.
62747911|NCT03979456|ACTIVE_COMPARATOR|6-month dosing interval|This arm is receiving standard dose rituximab 500 mg every 6 months
62747912|NCT03979456|EXPERIMENTAL|12-month dosing interval|This arm is receiving the comparator dose rituximab 500 mg every 12 months
62747913|NCT05909410||Patients with Lynch syndrome|Certain genetic diagnosis o fLynch syndrome
62747914|NCT05909410||Healthy patients of reproductive age|
62747915|NCT01739686|EXPERIMENTAL|CASA Intervention|"The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~* A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~* A social worker provides structured counseling targeting adjustment to illness and depression if present.~* A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone."
62747916|NCT01739686|NO_INTERVENTION|Usual Care|Patients in the control group will continue to receive care at the discretion of their providers, which may include referral to cardiology, palliative care, or mental health. If patients self-report depression on baseline surveys, this information will be given to their provider, and patients will be given resources. Patients will have the same amount of interaction with research assistants as the intervention patients, completing questionnaires and participating in study visits at the same frequency.
62374676|NCT03954184|NO_INTERVENTION|TAU/Control|Sites in the Treatment as Usual (TAU)/Control Arm will receive product training/online support. Sites in the TAU/Control Arm will participate in a one-day product implementation or training session.
62747917|NCT00350870|PLACEBO_COMPARATOR|Placebo|Placebo (plus Cognitive Behavioral Therapy- CBT)
62747918|NCT00350870|ACTIVE_COMPARATOR|Disulfiram|Disulfiram (plus CBT)
62747919|NCT00350870|PLACEBO_COMPARATOR|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance (in addition to CBT).
62374677|NCT03954184|EXPERIMENTAL|NIATx-TI Framework|Sites in the NIATx-TI Arm will receive product training/online support, and training in the NIATx-TI framework. The NIATx-TI framework will include a pre-implementation (planning) phase, and post-implementation (problem-solving) phase, with training delivered by a NIATx-TI coach.
62747920|NCT00350870|ACTIVE_COMPARATOR|Disulfiram plus Contingency Management|Disulfiram plus Contingency Management for cocaine abstinence and medication compliance (in addition to CBT).
62747921|NCT05743556|EXPERIMENTAL|HILT group|Therapy of muscle hypertonus by Hight intensive laser applied on cervical muscles.
62747922|NCT05743556|ACTIVE_COMPARATOR|TRT group|Muscle hypertonus of the cervical area treated by Target radio frequency current.
62747923|NCT05743556|NO_INTERVENTION|Control group|Group of patients with muscle cervical hyper tone without any therapy.
62747924|NCT04185402|ACTIVE_COMPARATOR|Azithromycin Continuation|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. Oral azithromycin, 20 mg/kg for children and 1 g for adults, will be offered to all households identified on the preceding census in the communities randomized to continuing treatment. Study drug will be distributed by health extension workers and organized by PNSO. Individuals with a known macrolide allergy will be offered a two-week course of daily ophthalmic tetracycline ointment (two tubes).
62747925|NCT04185402|NO_INTERVENTION|Azithromycin Discontinuation|In study communities randomized to the Azithromycin Discontinuation arm, individuals will receive no treatment.
62747926|NCT05839730|EXPERIMENTAL|Pacemaker with multiple pacing therapies enabled|Device will be programmed for personalized lower rate pacing (PLR) and tachycardiac remodeling pacing (TRT).
62747927|NCT05839730|ACTIVE_COMPARATOR|Pacemaker with no pacing therapies enabled|Device will be programmed to a non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.
62747928|NCT02924207|EXPERIMENTAL|Intervention|Path Electronic decision support arm
62747929|NCT04966494|EXPERIMENTAL|BOSB Group|This group consumed a common beans and oats snack bar (BOSB) for 8 weeks.
62747930|NCT04966494|NO_INTERVENTION|Control Group|This group corresponded to hypertriglyceridemic women who does not consume BOSB
62747931|NCT04730869|EXPERIMENTAL|Standard treatment in conjunction with MTP|"Standard:~* Concurrent chemoradiation - Radiation (60-Gy in 30 fractions over 6 weeks) with daily oral temozolomide.~* Adjuvant chemotherapy - Daily oral temozolomide (5 days per 4-week cycle, starting 4 weeks after completion of chemoradiation, with at least 6 cycles intended).~MTP:~- Two 5-day fasts (allowing water, salt, tea, coffee, and a magnesium supplement) during chemoradiation followed by a 5-day fast during each adjuvant chemotherapy cycle, with a time-restricted modified ketogenic diet (one or two 1-hour eating windows per day, allowing oils, meats, vegetables, nuts, seeds, limited berries, and a multivitamin) between fasts."
62747932|NCT01289288|EXPERIMENTAL|Mailed printed materials and in-office training|
62747933|NCT01289288|NO_INTERVENTION|Control|Usual care
62747934|NCT04743752||Group OSA+NSCLC|According to the baseline sleep monitor results, participants will be divided into Group OSA+NSCLC if apnea hypopnea index(AHI) no less than 15.
62747935|NCT04743752||Group NSCLC|According to the baseline sleep monitor results, participants will be divided into Group NSCLC if apnea hypopnea index(AHI) less than 15.
62747936|NCT06659068|EXPERIMENTAL|Seluang fish oil (Rasbora argyrotaenia) and Synbiotic|"Seluang fish oil (Rasbora argyrotaenia) and Synbiotic~The patients were given a capsule containing seluang fish oil (Rasbora argyrotaenia) once a day and also synbiotic once a day"
62747937|NCT06659068|PLACEBO_COMPARATOR|Placebo|"Placebo~The patients were given placebo capsules of seluang fish oil (Rasbora argyrotaenia) and synbiotics once a day"
62747938|NCT04413656|EXPERIMENTAL|ablation group|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ). Meanwhile, post-treatment response will be evaluated and follow up will be carried out according to the standard procedure.
62747939|NCT04413656|EXPERIMENTAL|surgery group|Patients with stage IA operable peripheral lung tumor will be performed surgery. cfDNA methylation would be monitored at different time(before surgery , after surgery 1month, 3month). Post-treatment response will be evaluated and follow up will be carried out according to the standard procedure.
62747940|NCT02079831|EXPERIMENTAL|Higher protein and energy restriction|Participants in this arm will consume 30% of energy as protein with 25% energy restriction.
62747941|NCT02079831|EXPERIMENTAL|Lower protein and energy restriction|Participants in this arm will consume 15% of energy as protein with 25% energy restriction.
62747942|NCT05134285||control|pregnancy without preeclampsia
62747943|NCT05134285||preeclampsia|pregnancy complicated with preeclampsia at the first delivery or at the second delivery
62747944|NCT05134285||recurrent preeclampsia|pregnancy complicated with preeclampsia at two deliveries
62747945|NCT01345968|PLACEBO_COMPARATOR|NaCl 0.9%|
62747946|NCT01345968|EXPERIMENTAL|Ferinject|
62747947|NCT03702348|EXPERIMENTAL|Resistance exercise group|Progressive resistance exercise protocol with elastic resistance to strengthen the muscle groups that stabilize the main joints affected by Chikungunya Fever. The sessions will be 2 times a week for 12 weeks.
62747948|NCT03702348|NO_INTERVENTION|Control group|No intervention during the 12 weeks, being contacted through telephone calls. After the reevaluation at the end of the 12 weeks, this group will perform the same protocol as the experimental group
62747949|NCT03887455|EXPERIMENTAL|Core Study: Lecanemab 10 mg/kg biweekly|
62747950|NCT03887455|PLACEBO_COMPARATOR|Core Study: Placebo|
62747951|NCT03887455|EXPERIMENTAL|Extension Phase: Lecanemab 10 mg/kg biweekly|
62747952|NCT03887455|EXPERIMENTAL|Extension Phase: Lecanemab 720 mg Subcutaneous Injection Weekly|This will include approximately 40 de novo participants (those that did not participate in the core study) with early Alzheimer disease (AD).
62747953|NCT03887455|EXPERIMENTAL|Extension Phase: Lecanemab 360 mg Subcutaneous Autoinjector Injection Weekly|
62747954|NCT05295784|ACTIVE_COMPARATOR|Arm 1: Low dose caffeine|Each neonate will receive a single dose of caffeine citrate in the first 24 hours of life. Arm 1 neonates will receive low dose intravenous caffeine citrate (5 mg/kg).
62747955|NCT05295784|ACTIVE_COMPARATOR|Arm 2: Medium dose caffeine|Each neonate will receive a single dose of caffeine citrate in the first 24 hours of life. Arm 2 neonates will receive medium dose intravenous caffeine citrate (15 mg/kg).
62747956|NCT05295784|ACTIVE_COMPARATOR|Arm 3: High dose caffeine|Each neonate will receive a single dose of caffeine citrate in the first 24 hours of life. Arm 3 neonates will receive high dose intravenous caffeine citrate (25 mg/kg).
62747957|NCT01177618||Probands|Severe, early-onset COPD subjects that bring the family into the study
62747958|NCT01177618||Relatives|Relatives of early-onset COPD probands, including first-degree relatives (parents, siblings, and children), second-degree relatives (aunts, uncles, grandparents, half-siblings), spouses, and other affected individuals.
62747959|NCT00459875|EXPERIMENTAL|Sunitinib|The treatment will include Sunitinib malate 50 mg self-administered orally, once daily in the evening, without regard to meals, for 4 consecutive weeks (28 days) followed by 2 weeks (14 days) off, to comprise a complete cycle of 6 weeks.
62747960|NCT03487419||patients develop atrial fibrillation|patients post coronary artery bypass grafting who develop atrial fibrillation post operative
62747961|NCT03487419||patients who not develop atrial fibrillation|patients post coronary artery bypass grafting who don't develop atrial fibrillation post operative
62747962|NCT01510366|EXPERIMENTAL|Cohort 1|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections.
62747963|NCT01510366|EXPERIMENTAL|Cohort 2:|Inactivated Poliomyelitis Vaccine (Salk strains) 3 x 0.5ml intramuscular injections.
62747964|NCT00052091|EXPERIMENTAL|1 Problem Solving Therapy|12 weekly sessions of problem solving therapy (PST)
62747965|NCT00052091|EXPERIMENTAL|2 Brief Supportive Therapy|12 weekly sessions of brief supportive therapy (BST)
62747966|NCT01369641|EXPERIMENTAL|Experimental Ear - Sodium Thiosulfate (STS)|Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.
62747967|NCT01369641|PLACEBO_COMPARATOR|Comparator Ear - Placebo|Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.
62747968|NCT02111876||AHRF follow-up|
62747969|NCT05605275||Gram negative|Patients who had at least one blood culture with a gram- isolate during hospitalisation in the surgical ICU
62374678|NCT01665040|EXPERIMENTAL|Neurostimulation for chronic pain|Neurostimulation (spinal cord stimulation with or without peripheral nerve stimulation of the trunk) for chronic intractable pain of the trunk and/or limbs.
62374679|NCT00883649|PLACEBO_COMPARATOR|1|
62747970|NCT05605275||Gram positive|Patients who had at least one blood culture with a gram+ isolate during hospitalisation in the surgical ICU
62747971|NCT06267469|OTHER|Grip strength|Using a hydraulic handgrip dynamometer by Saehan according to the procedure to measure grip strength
62747972|NCT06267469|OTHER|DASH Questionnaire|The DASH questionnaire assesses upper limb disability and consists of 30 questions in the general section and an additional work module with 4 questions and a sport/instrument playing module with 4 questions. Assess symptoms and the inability to perform certain activities based on health status.
62747973|NCT06267469|OTHER|Likert scale|Measurement strategy, used in surveys to gain knowledge about the degree of acceptance of the orthosis
62747974|NCT06267469|OTHER|Kapandji score|Is a tool useful for assessing the opposition of the thumb
62747975|NCT06267469|OTHER|NRS scale|Requires the patient to rate their pain on a defined scale
62747976|NCT06267469|OTHER|Pinch strength|Using a hydraulic handgrip dynamometer by Saehan according to the procedure to measure grip strength
62747977|NCT05447195|EXPERIMENTAL|CAN008|CAN008 IV infusion weekly
62747978|NCT05447195|PLACEBO_COMPARATOR|placebo|Placebo IV infusion weekly
62747979|NCT02966964|EXPERIMENTAL|Tenofovir 300mg qd + DWPUR001 500mg bid|Tenofovir 300mg qd + DWPUR001 500mg bid for up to 12 months
62747980|NCT02966964|EXPERIMENTAL|Tenofovir 300mg qd + DWPUR001 300mg bid|Tenofovir 300mg qd + DWPUR001 300mg bid for up to 12 months
62747981|NCT02966964|PLACEBO_COMPARATOR|Tenofovir 300mg qd + DWPUR001 Placebo bid|Tenofovir 300mg qd + DWPUR001 Placebo bid for up to 12 months
62747982|NCT02765113|ACTIVE_COMPARATOR|Facial nerve combing|Facial nerve combing and Microvascular Decompression(MVD) was performed in all the patients in this group.
62747983|NCT02765113|ACTIVE_COMPARATOR|Facial and Trigeminal nerve combing|Facial nerve combing、trigeminal nerve combing and Microvascular Decompression(MVD) was performed in all the patients in this group.
62747984|NCT03650803|EXPERIMENTAL|3D MR Fingerprinting scan|Three separate 3D MR fingerprinting scans: Before the start of chemotherapy, 7-10 days after the first cycle of chemotherapy, and within 1 month of the end of chemotherapy treatment.
62747985|NCT03549208|EXPERIMENTAL|LBVE01|Multivalent pneumococcal conjugate vaccine
62747986|NCT03549208|EXPERIMENTAL|LBVE02|Multivalent pneumococcal conjugate vaccine
62747987|NCT03549208|ACTIVE_COMPARATOR|Prevnar13|Multivalent pneumococcal conjugate vaccine Prevnar13
62747988|NCT01468207|PLACEBO_COMPARATOR|Placebo|Placebo for 12 weeks.
62747989|NCT01468207|EXPERIMENTAL|Adalimumab Every Week (EW)|Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
62747990|NCT01468207|EXPERIMENTAL|Placebo/Adalimumab Every Week (EW)|Participants randomized to receive placebo in Period 1 received adalimumab 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to Week 35 in Period 2 (up to 24 weeks).
62747991|NCT01468207|EXPERIMENTAL|Adalimumab Every Week (EW)/Placebo|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
62747992|NCT01468207|EXPERIMENTAL|Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive adalimumab 40 mg eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
62747993|NCT01468207|EXPERIMENTAL|Adalimumab Every Week (EW)/Adalimumab Every Week (EW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
62747994|NCT01467050|ACTIVE_COMPARATOR|Application of STOPP/START criteria|
62374680|NCT00883649|ACTIVE_COMPARATOR|2|
62553904|NCT06477094|ACTIVE_COMPARATOR|Stryker Venom|Patients will receive their radiofrequency ablation procedure of the lumbar medial branch nerves with the Stryker Venom Cannula.
62747995|NCT01467050|NO_INTERVENTION|Control|
62747996|NCT03292887||Elaprase Treated|Participants with Hunters Syndrome received or receiving treatment with Elaprase as prescribed by their physician following locally approved prescribing information.
62747997|NCT03292887||Elaprase Non-Treated|Participants received no treatment for Hunters Syndrome.
62747998|NCT01418703|EXPERIMENTAL|Closed Loop Control (CLC)|"The CLC used a computer to make recommendations for their insulin treatment. This study arm was designed to demonstrate management of glucose using a modular insulin management system based on continuous glucose monitoring and targeted towards the avoidance of hypoglycemic and prolonged hyperglycemic episodes (i.e. control to range). This system was designed to both:~* monitor the meal boluses of the patient and correct it in case of observed/predicted under insulinization (avoidance of prolonged hyperglycemia), based on a coarse and subjective knowledge of the meal amount, a precise understanding of the subject's day to day insulin treatment, continuous glucose monitoring, and past insulin injections;~* predict and avoid hypoglycemic events, based on continuous glucose reading and past insulin injection."
62747999|NCT01418703|PLACEBO_COMPARATOR|Open Loop|The subject were in charge of their insulin treatment.
62748000|NCT04916366|EXPERIMENTAL|Kinesio taping|In this arm, patients will be treated with blue Kinesio taping in a muscle relaxation position during 4 days.
62748001|NCT04916366|PLACEBO_COMPARATOR|Placebo|In this arm, patients will be treated with conventional bandage in a muscle relaxation position during 4 days.
62748002|NCT04916366|NO_INTERVENTION|Control|In this arm, patients will be not treated but the outcomes will be measure after 4 days.
62748003|NCT00642434|ACTIVE_COMPARATOR|1|study drug- carvedilol
62748004|NCT00642434|ACTIVE_COMPARATOR|2|study drug metorprolol
62374681|NCT00474136|EXPERIMENTAL|1|
62553905|NCT05004883|EXPERIMENTAL|Regulation of Cues Enhanced Treatment|The ROC program provides psychoeducation, coping skills, self-monitoring and experiential learning, and it will be combined with aspects of BWL to capitalize on the strengths of both treatments.
62748005|NCT06658054|ACTIVE_COMPARATOR|Group A (control)|Patients will receive an erector spinae plane block (ESPB) with 20 cc solution per single-shot injection comprised of 0.25% bupivacaine and 0.9% normal saline under ultrasound guidance to be administered bilaterally (40 cc total).
62748006|NCT06658054|ACTIVE_COMPARATOR|Group B (Intervention)|Patients will receive ESPB with 20cc solution per single-shot injection comprised of 0.25% bupivacaine, 25mcg dexmedetomidine, and 5mg dexamethasone under ultrasound guidance to be administered bilaterally (40 cc total). This is in addition to the bupivacaine.
62748007|NCT01414101|EXPERIMENTAL|Group A|Dose 1 ISIS CRP Rx versus Placebo
62748008|NCT01414101|EXPERIMENTAL|Group B|Dose 2 ISIS CRP Rx versus Placebo
62748009|NCT01414101|EXPERIMENTAL|Group C|Dose 3 ISIS CRP Rx versus Placebo
62748010|NCT04939181|EXPERIMENTAL|Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
62748011|NCT04939181|PLACEBO_COMPARATOR|Placebo Non-invasive Neuromodulation|Placebo microcurrents Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
62748012|NCT06332768|ACTIVE_COMPARATOR|NIV|Non-invasive ventilation
62553906|NCT05004883|ACTIVE_COMPARATOR|Behavioral Weight Loss|The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
62748013|NCT06332768|ACTIVE_COMPARATOR|HFO|High Flow Oxygenation
62748014|NCT05260073||Tirbanibulin|Participants will receive tirbanibulin ointment 2.5 mg in 250 mg (single dose packet). The participants will be observed for 24 weeks to gather participant reported outcomes (PROs) and clinical profile.
62748015|NCT06607510|EXPERIMENTAL|Experimental HIIT.|Subjects belonging to this group perform a 12-week supervised exercise. Treadmill walking exercise. Participants must complete four four-minute blocks at an intensity of 85-95% of peak heart rate.
62748016|NCT06607510|EXPERIMENTAL|Experimental HIFT.|Subjects belonging to this group perform a 12-week supervised exercise. Four blocks of 4 minutes each of the highest number of repetitions/rounds possible (AMRAP) at an intensity of 85-95% of peak heart rate.
62748017|NCT06607510|NO_INTERVENTION|No intervention: Control.|These patients do not receive training sessions.
62748018|NCT06404866|EXPERIMENTAL|eMotion Intervention|This is a single-group study assessing participation satisfaction with the 10-week eMotion intervention. The eMotion intervention is based on feasibility testing of the successful in-person program with critical refinement to improve accessibility. eMotion has undergone subsequent content validity testing with intervention development, self-management, cardiovascular health, and health information technology delivery experts. eMotion teaches a carefully selected repertoire of emotion regulation strategies well suited for adults following a first cardiac event.
62748019|NCT00996515|EXPERIMENTAL|Cohort 5|Erlotinib 150mg/day PO Day 1-28 and Vidaza 100mg/m2/day SQ Day 1-4 and 15-18
62748020|NCT00996515|EXPERIMENTAL|Cohort 4|Erlotinib 200 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day SQ 1-4 and 15-18
62748021|NCT00996515|EXPERIMENTAL|Cohort 3|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-3 and 15-17
62748022|NCT00996515|EXPERIMENTAL|Cohort 2|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-2 and 15-16
62748023|NCT00996515|EXPERIMENTAL|Cohort 1|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1 and 15
62748024|NCT04567706||Ancillary-correlative (biospecimen collection)|Patients undergo collection of blood samples at the time of the initial diagnostic work-up, and possibly prior to the initiation of surgery, chemotherapy, immunotherapy, or radiation therapy, at tumor progression or recurrence, and annually during routine follow-up (no more than 4 blood draws per year). Patients may also undergo collection of tissue sample during standard of care surgical or radiologic procedures. Healthy individuals undergo collection of blood samples up to 4 times over 1 year.
62748025|NCT02576041|EXPERIMENTAL|Placebo (run-in); Bilastine|At V0, the enrolled patient received the complete drug-kit and started a 7 (+3)-day wash-out period with placebo. At the end of the 7 (+3)-days of placebo-treatment period, patients repeated the F1-high speed simulator test at Visit V1, and afterwards initiated the 7 (+3)-day treatment period with active treatment (bilastine).
62748026|NCT00742287|PLACEBO_COMPARATOR|1|placebo
62748027|NCT00742287|ACTIVE_COMPARATOR|2|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)
62748028|NCT04103307|NO_INTERVENTION|Control: Standard of care|Participants in the control group will receive standard-of-care CRRT prescriptions, and have the returning venous blood warmed with an external blood warmer to a temperature of 37°C. The blood warmer temperature will be adjusted by the CRRT nurse as per usual practice to maintain normothermia.
62748029|NCT04103307|EXPERIMENTAL|Intervention: Cooling|Participants in the intervention group will receive standard of care CRRT prescriptions and have the blood warmer set to 35.5°C, as long as the nasopharyngeal temperature remains above 35.5°C.
62374682|NCT00474136|EXPERIMENTAL|2|
62374683|NCT00474136|ACTIVE_COMPARATOR|3|
62374684|NCT05051527||Legalon®|Legalon® 140 mg
62374685|NCT06286267||Breast phyllodes tumor|Patients diagnosed with phyllodes tumor of breast
62748030|NCT04210362|EXPERIMENTAL|Educational intervention for 30 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 30 months.
62748031|NCT04210362|EXPERIMENTAL|Educational intervention for 24 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 24 months.
62748032|NCT04210362|EXPERIMENTAL|Educational intervention for 12 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 12 months.
62748033|NCT04210362|NO_INTERVENTION|Comparison group|Group comprised of children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca, Mexico. Children and their caregivers will not be exposed to the intervention at the moment of their measurements.
62748034|NCT05249933|PLACEBO_COMPARATOR|Control group|All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of two liters of polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at the hospital in the morning after an overnight fast (\>8hours). Then they would be randomly assigned to the control group or pronase group randomly. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg dimethicone. And 25 minutes before swallowing the capsule, the patient was asked to take 200ml warm water. There is still have 800-1000ml water for gastric filling 10 minutes before swallowing the capsule.
62553907|NCT05004883|ACTIVE_COMPARATOR|Nutrition, Stress Management, and Social Support|Nutrition Education, Stress Management and Social Support will be covered. Mindfulness will be practiced in every session.
62553908|NCT00371436|ACTIVE_COMPARATOR|Progressive Audiologic Tinnitus Management (PATM)|"The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment."
62553909|NCT00371436|OTHER|Usual Care (UC)|Typical audiologic care that would be received in a VA Audiology Clinic.
62553910|NCT01761383|EXPERIMENTAL|Nintendo Wii and Chronic Schizophrenia|Participants enrolled in the study will be provided with the Nintendo Wii console and Nintendo Wii Fit Plus video games to use for the duration of the study (6 months) with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life with the use of self report questionnaires and psychiatric assessment.
62748035|NCT05249933|EXPERIMENTAL|Pronase group|All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of two liters of polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at the hospital in the morning after an overnight fast (\>8hours). Then they would be randomly assigned to the control group or pronase group randomly. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg dimethicone. And 25 minutes before swallowing the capsule, the patient was asked to take 20000 IU pronase Granules Combined with 1 g NaHCO3 dissolved in 200ml warm water to maintain the intragastric pH at 6 - 8. There is still have 800-1000ml water for gastric filling 10 minutes before swallowing the capsule.
62553911|NCT01482312|ACTIVE_COMPARATOR|Lotrafilcon A / Comfilcon A / Glasses|Lotrafilcon A contact lenses worn first, followed by comfilcon A contact lenses, followed by habitual glasses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
62553912|NCT01482312|ACTIVE_COMPARATOR|comfilcon A / glasses / lotrafilcon A|Comfilcon A contact lenses worn first, followed by glasses, followed by lotrafilcon A contact lenses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
62553913|NCT01482312|ACTIVE_COMPARATOR|glasses / lotrafilcon A / comfilcon A|Glasses worn first, followed by lotrafilcon A contact lenses, followed by comfilcon A contact lenses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
62553914|NCT02485093|ACTIVE_COMPARATOR|No pacing|Ventricular intrinsic conduction enhanced
62748036|NCT01186042||Aging in HIV|20-40 years of age or older than 50
62748037|NCT03484156|EXPERIMENTAL|Volunteers|"The Installation of 3PEGASE Sensor in elders volunteers to monitor clinical indicators at home.The instrument is for monitoring functional and cognitive autonomy in frail or disable elderly persons living alone at home.~The volunteers will have 70 years old or more, living alone at home, frail of disable (ADL\> or =3) and able to walk by themselves."
62553915|NCT02485093|EXPERIMENTAL|Pacing|Septal ventricular pacing with optimized AV delay
62553916|NCT00462904|EXPERIMENTAL|BPI infusion group|BPI will be infused by bolus for 30 minutes followed by continuous infusion for 47.5 hours
62553917|NCT01108614|EXPERIMENTAL|Intervention|Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
62553918|NCT01108614|NO_INTERVENTION|Usual|Routine HIV prevention, including health education, counseling and testing, condom promotion.
62553919|NCT04524208|EXPERIMENTAL|Treatment-Arm|
62553920|NCT02766114|EXPERIMENTAL|Issa1|After local anesthesia, through transverse approach on the middle of dorsal wrist crease the incision is made for 1.5 cm length, then the subcutaneous fat is dissected, soon we see the the palmaris longus tendon or its connection with the carpal ligament , take the ulnar side of the palmaris longus tendon and cut the carpal ligament axillary by scalpel, not going deep with the scalpel to avoid medial nerve injury, soon we see the nerve, we use the scissors to cut the proximal part then the distal part of the carpal ligament by enclosing it between the blades of the scissors, now the full released carpal tunnel most be observed, and one stitch is enough, in this operation most be an assistant exist.
62553921|NCT02577991|NO_INTERVENTION|Control group|No steroid
62553922|NCT02577991|EXPERIMENTAL|IV steroid|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
62553923|NCT02577991|EXPERIMENTAL|Local steroid|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
62553924|NCT04540653|OTHER|Standard vaccination schedule|To evaluate the immunogenicity of the monovalent hepatitis B vaccine, expressed in Hansenula polymorpha, aged ≥50 years old, using a standard vaccination schedule (three doses of 20 μg, in months 0, 1, 6).
62553925|NCT04540653|EXPERIMENTAL|Reinforced vaccination schedule|To evaluate the immunogenicity of the monovalent hepatitis B vaccine, expressed in Hansenula polymorpha, in individuals aged ≥50 years, using a reinforced vaccination schedule (three doses of 40 μg, in months 0, 1, 6).
62553926|NCT02421055||Group 1|Roux-en-Y Gastric Bypass
62748038|NCT04033887||HCV-only infected|"Archived frozen plasma samples from individuals that were characterised to be HCV-antibody positive or HCV-antibody negative (HCV-only infected). These samples are characterised for their HIV status (negative)."
62748039|NCT04033887||HCV/HIV co-infected|"Archived frozen plasma samples from HCV-positive or HCV-negative individuals who are HIV infected (HCV/HIV co-infected)."
62748040|NCT02183480|EXPERIMENTAL|Linagliptin, low dose|
62748041|NCT02183480|EXPERIMENTAL|Linagliptin, medium dose|
62748042|NCT02183480|ACTIVE_COMPARATOR|Linagliptin, high dose|
62748043|NCT02306863|EXPERIMENTAL|whole-body vibration|40 Hz Whole-body vibration applied via physioaccoustic method for 12 weeks, 3 times a week
62748044|NCT02306863|SHAM_COMPARATOR|sham treatment|simulated whole-body vibration applied 3 times a week for 12 weeks
62748045|NCT04925076|EXPERIMENTAL|Family History Positive|People reporting at least one parent with a history of alcohol problems.
62748046|NCT04925076|EXPERIMENTAL|Family History Negative|People who do not report having a parent with a history of alcohol problems.
62748047|NCT05352061|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT) for Syndemic and Adherence Factors Group|Participants in this group will receive the CBT for Syndemics and Adherence Factors intervention for a total of 14 sessions over 4 months.
62553927|NCT02421055||Group 2|Sleeve Gastrectomy
62553928|NCT04470063|EXPERIMENTAL|group A|
62553929|NCT04470063|EXPERIMENTAL|group B|
62553930|NCT04470063|EXPERIMENTAL|group C|
62553931|NCT00707616||A|Subjects without type 2 diabetes living in Olmsted County, MN
62748048|NCT00952445|EXPERIMENTAL|T0903131 Besylate|1.0 mg
62748049|NCT00952445|EXPERIMENTAL|T0903131 Besylate (higher dose)|10.0 mg
62748050|NCT00952445|PLACEBO_COMPARATOR|Placebo|Once daily, oral
62748051|NCT01364558|EXPERIMENTAL|Diazepam Nasal Spray Suspension|Diazepam Nasal Suspension - 10 mg
62748052|NCT01364558|EXPERIMENTAL|Diazepam Nasal Spray Solution|Diazepam Nasal Spray Solution - 10 mg
62748053|NCT01364558|ACTIVE_COMPARATOR|Diazepam injection|Diazepam injection IV - 5 mg
62748054|NCT04301076|EXPERIMENTAL|Treatment (lenalidomide, EPOCH)|"INDUCTION THERAPY: Patients receive lenalidomide PO QD on days 1-14 of 21 day cycles or days 1-21 or 1-28 of 28 day cycles. Patients receive doxorubicin hydrochloride IV continuously on days 1-4, vincristine sulfate IV continuously on days 1-4, etoposide IV continuously on days 1-4, prednisone PO on days 1-5, and cyclophosphamide IV over 1-4 hours on day 5. Treatment repeats every 21 or 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients with CR, PR, or SD may receive up to 2 additional cycles of lenalidomide, doxorubicin hydrochloride, vincristine sulfate, etoposide, prednisone, and cyclophosphamide at the discretion of the investigator and/or up to an additional 2 years of lenalidomide in the absence of disease progression or unacceptable toxicity.~Patients undergo bone marrow biopsy at baseline and as clinically indicated. Patients undergo PET/CT or CT, tissue and blood sample collection throughout."
62748055|NCT04309305|EXPERIMENTAL|Stroke RE|After discharge from the acute rehabilitation facility, participants in the stroke RE group will participate 3 days a week for 10 weeks in robotic exoskeleton gait training provided by a trained, licensed physical therapist. Participants will be permitted to participate in additional prescribed standard physical therapy on their own.
62748056|NCT04309305|ACTIVE_COMPARATOR|Stroke SOC|After discharge from the acute rehabilitation facility, participants in the stroke SOC group will participate 3 days a week for 10 weeks in standard of care gait training provided by a licensed physical therapist. Participants will be permitted to participate in additional prescribed standard physical therapy on their own.
62748057|NCT04309305|OTHER|Healthy Control|Participants in the healthy control group will not participate in any gait training. Healthy control participants will only be asked to complete 3 testing sessions.
62748058|NCT03677466|EXPERIMENTAL|Pharmaco-invasive strategy|Fibrinolytic therapy (Streptokinase, Alteplasa, Tenecteplasa in standard dose) is conducted within 12 h of symptom onset in the pre-hospital setting if primary PCI cannot be performed within 120 min from STEMI diagnosis. Then PCI is performed to all of patients.
62748059|NCT03677466|ACTIVE_COMPARATOR|Primary PCI|Primary percutaneous coronary intervention (PCI) in patients with primary STEMI
62748060|NCT04011826|EXPERIMENTAL|Experimental: Experimental trial nasal mask|Experimental trial nasal mask: Participants will be placed on this arm for a total of 14±3 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm. Participants on the extension will use this trial mask for a further six months after Visit 3.
62748061|NCT02266251||Surgical AVR|No interventions will be administered. Retrospective data analysis will be completed to compare health outcomes among patients with a similar baseline health satus who are eligible for both procedures (operative transcatheter AVR patients enrolled in the Transcatheter Valve Therapies (TVT) Registry (Nov 2011-Dec 2013) and surgical AVR patients with STS perioperative risk of mortality whose index procedure is included in the STS Adult Cardiac Surgical DAtabase (ACSD) (Jan 2011-Dec 2013).
62748062|NCT02266251||Transcatheter AVR|No interventions will be administered. Retrospective data analysis will be completed to compare health outcomes among patients with a similar baseline health satus who are eligible for both procedures (operative transcatheter AVR patients enrolled in the TVT Registry (Nov 2011-Dec 2013) and surgical AVR patients with STS perioperative risk of mortality whose index procedure is included in the STS ACSD (Jan 2011-Dec 2013).
62748063|NCT05349409|EXPERIMENTAL|Treatment group|SHR-A1811, Fluzoparib
62748064|NCT04495257|EXPERIMENTAL|Dose Level 1 (DL1)|DL1 will include ipilimumab at 1mg/kg and nivolumab at 3 mg/kg with APX005M of 0.1mg/kg for the induction phase. After 4 cycles, participants will be treated with 360mg of nivolumab and APX005M every 3 weeks.
62748065|NCT04495257|EXPERIMENTAL|Dose Level 2 (DL2)|DL2 will include ipilimumab at 1mg/kg and nivolumab at 3 mg/kg with APX005M of 0.3mg/kg for the induction phase. After 4 cycles we will treat with 360mg of nivolumab and APX005M every 3 weeks.
62374686|NCT06388460|EXPERIMENTAL|Asthma Link|Practices in the Asthma Link condition will receive brief training on how to identify, refer and arrange for children with poorly controlled asthma to receive school-supervised therapy with the child's school health staff. Participants will receive an educational asthma workbook.
62374687|NCT06388460|ACTIVE_COMPARATOR|Enhanced Usual Care|Practices in the Enhanced Usual Care condition will receive brief training on how to identify and refer the same group of children with poorly controlled asthma and these children will receive an educational asthma workbook.
62748066|NCT06458530|EXPERIMENTAL|Vivo intervention|Participants will meet virtually twice a week for 12 weeks with their small group and certified trainer for 45 minutes.
62748067|NCT06458530|NO_INTERVENTION|Waitlist control|Participants randomized to this arm will be asked to maintain their baseline physical activity for 12-weeks. They will be scheduled for the baseline and 12-week assessment and following the 12-week assessment, they will be offered enrollment into Vivo.
62374688|NCT01281774|EXPERIMENTAL|CSL112|Multiple ascending intravenous doses of CSL112
62374689|NCT01281774|PLACEBO_COMPARATOR|Placebo|Multiple intravenous infusions of placebo
62374690|NCT01855204|ACTIVE_COMPARATOR|Conventional|Computed tomographic urography was done with conventional protocols.
62374691|NCT01855204|EXPERIMENTAL|Reduced|Computed tomographic urography was done with the protocols of low voltage and low iodine concentration.
62748068|NCT00633074|EXPERIMENTAL|Thiomersal-free FluAS25 adjuvanted vaccine group|Subjects received 1 dose of thiomersal-free FluAS25 adjuvanted vaccine
62748069|NCT00633074|EXPERIMENTAL|Thiomersal reduced FluAS25 adjuvanted vaccine group|Subjects received 1 dose of thiomersal reduced FluAS25 adjuvanted vaccine
62748070|NCT03532854|EXPERIMENTAL|Sequence A|Ezetimibe/Rosuvastatin -\> Valsartan -\> Valsartan and Ezetimibe/Rosuvastatin
62748071|NCT03532854|EXPERIMENTAL|Sequence B|Valsartan -\> Valsartan and Ezetimibe/Rosuvastatin-\> Ezetimibe/Rosuvastatin
62748072|NCT03532854|EXPERIMENTAL|Sequence C|Valsartan and Ezetimibe/Rosuvastatin -\> Ezetimibe/Rosuvastatin -\> Valsartan
62748073|NCT03532854|EXPERIMENTAL|Sequence D|Ezetimibe/Rosuvastatin -\> Valsartan and Ezetimibe/Rosuvastatin-\> Valsartan
62748074|NCT03532854|EXPERIMENTAL|Sequence E|Valsartan -\> Ezetimibe/Rosuvastatin -\> Valsartan and Ezetimibe/Rosuvastatin
62748075|NCT03532854|EXPERIMENTAL|Sequence F|Valsartan and Ezetimibe/Rosuvastatin -\> Valsartan -\> Ezetimibe/Rosuvastatin
62748076|NCT05108272|ACTIVE_COMPARATOR|Silicone Sheeting|After explaining and taking consent from the patient about the intervention, pre intervention assessment will be made. Silicone gel sheet (Rystoraº) will be used at scar wound for 16 hours every day for 3 months. After 3 months post intervention assessment will be made.
62748077|NCT05108272|EXPERIMENTAL|Microneedling|After explaining and taking consent from the patient about the intervention, pre- intervention assessment will be made. Derma pen (Dr.Pen auto Microneedle system Ultima-A6) with 36 needles per cm2 will be used with adjustable depth of 0.5mm to 2mm. Micro-needling will be performed in 3 axis,1st in vertical, then horizontal and then oblique direction to the point of uniform petechial bleed. Four sessions at 3 weekly intervals will be performed. Final assessment will be made after 3 months of first intervention
62748078|NCT02060630|OTHER|Available vein, open surg. revasc.|Subjects with an available SSGSV cohort randomized to open surgical revascularization
62748079|NCT02060630|OTHER|Available vein, endovasc. revasc.|Subjects with an available SSGSV cohort randomized to endovascular revascularization
62748080|NCT02060630|OTHER|Alternative conduit, open surg. revasc.|Subjects with an alternative conduit cohort randomized to open surgical revascularization
62748081|NCT02060630|OTHER|Alternative conduit, endovasc. revasc.|Subjects with an alternative conduit cohort randomized to endovascular revascularization
62748082|NCT06346691|EXPERIMENTAL|Doxofylline arm|Doxofylline 400 mg oral twice daily for 4 weeks
62748083|NCT06346691|ACTIVE_COMPARATOR|Procaterol arm|Procaterol 50 mcg oral twice daily for 4 weeks
62748084|NCT00585221|EXPERIMENTAL|All patients|All participants enrolled in the study.
62748085|NCT02083848|OTHER|7T MRI|All subjects are entered into a single arm.
62748086|NCT01865994||Pediatric cardiac surgery|Children scheduled for elective cardiac surgery
62748087|NCT03924063|OTHER|conservative treatment|conservative treatment with physical therapy and non steroidal anti-inflammatory drugs
62748088|NCT02247011|OTHER|fracture group|Fracture group included participants with new fractures during the 5 year follow-up visit. Fracture consists of non-vertebral fracture and vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
62748089|NCT02247011|OTHER|non-fracture group|Fracture group included participants without new fractures during the 5 year follow-up visit. Fracture consists of vertebral fracture and non-vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
62748090|NCT03894410||Continuing Lapatinib|Patients continued using treatment containing Lapatinib after progression on Lapatinib.
62748091|NCT03894410||Change HER-2 treatment|Patients changed to another HER-2 targeted treatment after progression on Lapatinib (ado-trastuzumab emtansine, trastuzumab, etc.).
62748092|NCT03894410||Lapatinib plus capetabine|Patients used lapatinib plus capetabine.
62748093|NCT03894410||Lapatinib plus Trastuzumab and one chemotherapy|Patients used lapatinib plus trastuzumab and one chemo regimen.
62748094|NCT05410171|EXPERIMENTAL|AI group|patients evaluated by early warning platform
62748095|NCT05410171|NO_INTERVENTION|usual care group|patients not evaluated by early warning platform
62748096|NCT04352088||Allergic rhinitis patients|
62748097|NCT04352088||Allergic rhinitis and asthma patients|
62748098|NCT04352088||Healthy individuals|
62748099|NCT03236259|ACTIVE_COMPARATOR|Brainport high dose|
62748100|NCT03236259|ACTIVE_COMPARATOR|Brainport low dose|
62748101|NCT03236259|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62748102|NCT02153424||NVAF patients in Mexico treated with Apixaban|All patients with NVAF at the sentinel site for the CNFV in Mexico who received at least 1 dose of Apixaban to reduce the risk of stroke or systemic embolism during the specified 24-month study period
62748103|NCT02899507|EXPERIMENTAL|Prophylactic antibiotic|Amoxicillin-Clavulanic acid 1.2g every 8h
62748104|NCT02899507|NO_INTERVENTION|Clinically-driven antibiotics|Administration of antibiotics in clinically-driven group was at the discretion of attending intensivist. Selection of antibiotic in clinically-driven group was empirical or based on the results of bacterial cultures if already available.
62748105|NCT01155739||procalcitonine monitoring|PCT group: antibiotic use is tailored by serum procalcitonin values, determined every 48houres.
62748106|NCT01155739||control group|control group: antibiotic use and length of treatment as defined by guidelines
62748107|NCT00388388|EXPERIMENTAL|1|Losartan treatment
62748108|NCT00388388|ACTIVE_COMPARATOR|2|Hydrochlorothiazide, 12.5-25 mg per day once a day for 6 months
62748109|NCT04502264|EXPERIMENTAL|Botulinum toxin, hand robot training, occupational therapy|Patient would receive Botulinum toxin (Injections of 100\~400U of Botox in the upper limb muscle with a 2ml/100U dilution), robot-assisted therapy (Hand of Hope training), and standard occupational therapy.
62748110|NCT04502264|ACTIVE_COMPARATOR|Botulinum toxin, occupational therapy|Patient would receive Botulinum toxin (Injections of 100\~400U of Botox in the upper limb muscle with a 2ml/100U dilution) and standard occupational therapy.
62748111|NCT04014881|EXPERIMENTAL|CD123+ Acute Myeloid Leukemia|Patients will receive CD123-targeted CAR-T cells in the dose-climbing trial. Each dose group has 3 patients and the the maximum dose can be extended.
62748112|NCT04611958|EXPERIMENTAL|Bupivacaine arm|Participants undergoing ERCP as part of routine clinical care will be consented for this study.
62748113|NCT00064259|EXPERIMENTAL|Treatment (oblimersen sodium)|"Phase I: Patients receive oblimersen IV continuously on days 1-7, fluorouracil IV continuously on days 4-8, and cisplatin IV on day 4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 12 patients are treated at the MTD.~Phase II: Patients receive treatment as in phase I with oblimersen at the MTD."
62748114|NCT03426462|EXPERIMENTAL|Age 1-6 years|"Induction of anesthesia with propofol using infusion pumps that are programmed with a pharmacokinetic model to achieve a calculated plasma concentration of the drug; this is followed by two anesthetic deepening episodes.~The target plasma concentrations achieved, as calculated by the programmed pump, is exactly the same in both age groups."
62748115|NCT03426462|EXPERIMENTAL|Age 8-13 years|"Induction of anesthesia with propofol using infusion pumps that are programmed with a pharmacokinetic model to achieve a calculated plasma concentration of the drug; this is followed by two anesthetic deepening episodes.~The target plasma concentrations achieved, as calculated by the programmed pump, is exactly the same in both age groups."
62748116|NCT06331286|EXPERIMENTAL|dulaglutide injection treatment group|0.75mg Subcutaneous injection once a week for 24 weeks
62748117|NCT06331286|OTHER|diet and exercise guidance treatment|diet and exercise guidance treatment for 24 weeks
62748118|NCT02367001|OTHER|1: standard invitation|"Group 1: sending a standard invitation signed by the coordinating doctor (send by the structure responsible for organized screenings)~Intervention : Normal invitation"
62748119|NCT02367001|EXPERIMENTAL|2: Revised invitation|"Group 2: Sending a revised invitation ( text, layout) signed by the coordinating doctor (send by the structure responsible for organized screenings)~Intervention : revised invitation signed by the coordinating doctor"
62748120|NCT02367001|EXPERIMENTAL|3 : revised invitation signed by the attending physician|"Group 3: Sending a revised invitation signed by the attending physician (send by the structure responsible for organized screenings)~Intervention : Revised invitation signed by the attending physician"
62748121|NCT01747408|EXPERIMENTAL|25% human albumin|Subjects will be entered into one of 4 increasing dosages of 25% human albumin sequentially. Once the first 20 subjects have been enrolled and the DSMB reviews data and approves moving to the next dosage tier patients will be entered into the following dosage tier.
62748122|NCT00500058|EXPERIMENTAL|SB-485232+Rituximab|Rituximab 375 milligrams per square meter (mg/m\^2) will be administered to subjects with CD20+ B cell lymphoma by intravenous (IV) infusion once a week for four consecutive weeks on Day 1 of Weeks 1 to 4. SB-485232 will be administered by IV infusion over a 2 hour period, at doses ranging from 1 microgram (μg)/kilogram (kg) to 100 μg/kg. SB-485232 will be given once a week for 12 consecutive weeks on Day 2 of Weeks 1 to 4 and Day 2 (± 1 day) of Weeks 5 to 12. SB-485232 will be infused at least 24 hours after the Rituximab infusion was started.
62374692|NCT00939055|EXPERIMENTAL|StomaphyX|Post-Roux-en-Y revisional surgery using the StomaphyX device.
62374693|NCT00939055|SHAM_COMPARATOR|Sham Procedure|No intervention
62374694|NCT04797494|NO_INTERVENTION|Control Group|No acrylic Removable Appliance (RA) was prescribed for patients prior to restorative treatment of generalized severe tooth wear.
62374695|NCT04797494|EXPERIMENTAL|Experimental Group|A acrylic Removable Appliance (RA) was prescribed for patients prior to restorative treatment of generalized severe tooth wear. Patients were asked to wear the RA 3 weeks prior to restorative treatment for 24h per day, except for when eating.
62374696|NCT05766267|EXPERIMENTAL|2BMZRb/2 BMRb|"Eight weeks of daily treatment with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), plus rifabutin (Rb), followed by nine weeks of daily treatment with bedaquiline (B or BDQ), moxifloxacin (M) and Rifabutin (Rb)~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered once daily.~Study drug doses: Bedaquiline (B): 200 mg once daily x 56 days, then 100 mg daily; Moxifloxacin (M): 400 mg once daily; Pyrazinamide (Z) 1500 mg (weight \<75kg) or 2000mg(\> 75kg) once daily x 56 days; Rifabutin (Rb): 300 mg once daily"
62374697|NCT05766267|EXPERIMENTAL|2 BMZD/2 BMD|"Eight weeks of daily treatment with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), plus delamanid (D or DLM) followed by nine weeks of daily treatment with bedaquiline (B or BDQ), moxifloxacin (M) and delamanid (D or DLM)~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered once daily.~Study drug doses: Bedaquiline (B): 200 mg once daily x 56 days, then 100 mg daily; Moxifloxacin (M): 400 mg once daily; Pyrazinamide (Z) 1500 mg (weight \<75kg) or 2000mg(\> 75kg) once daily x 56 days; Delamanid (D):300 mg once daily"
62374698|NCT05766267|ACTIVE_COMPARATOR|2RHZE/4RH|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by eighteen weeks of daily treatment with rifampin and isoniazid~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered once daily~study drug doses: Rifampin (R), 600 mg daily; Isoniazid (H), 300 mg daily; Pyrazinamide (Z) 1500 mg (weight \<75kg) or 2000mg(\> 75kg) once daily ; Ethambutol, 15 mg/kg once daily rounded up to nearest 400 mg dose"
62374699|NCT03844139||Feeding pump group(continous)|Using the feeding pump to give patients prescribed enteral nutrient solution through nasogastric tube in 24 hours
62374700|NCT03844139||Glycerin syringe group(intermittent)|Using the glycerin syringe to give patients prescribed enteral nutrient solution through nasogastric tube in 4-5 times
62374701|NCT03846076|EXPERIMENTAL|Internet-delivered CBT|10 weeks of CBT delivered via the Internet.
62374702|NCT02410746|ACTIVE_COMPARATOR|standard chirocaine infiltration|non-targeted infiltration of 10ml 0.25% Chirocaine into breast pocket
62374703|NCT02410746|EXPERIMENTAL|targeted chirocaine pec block|pectoral muscle block with 10ml 0.25% chirocaine
62374704|NCT01601873|EXPERIMENTAL|PROPATEN|patients with heparin-bonded graft implantation
62374705|NCT01601873|ACTIVE_COMPARATOR|Standard Graft|patients undergoing ePTFE hemodialysis graft implantation
62374706|NCT00886691|EXPERIMENTAL|Arm I (bevacizumab and everolimus)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and everolimus PO QD on days 1-28.
62374707|NCT00886691|EXPERIMENTAL|Arm II (bevacizumab and placebo)|Patients receive bevacizumab as in Arm I and placebo PO QD on days 1-28.
62374708|NCT03991468|EXPERIMENTAL|NanoZoomer Whole Slide Imaging|All cases will be assessed via Whole Slide Imaging using the Hamamatsu NanoZoomer S360MD Digital Slide Scanner System to assess pathological characteristics of scanned slides.
62374709|NCT03991468|ACTIVE_COMPARATOR|Glass Slide Light Microscopy|All cases will be assessed via the use of traditional light microscopy to assess pathological characteristics of glass slides.
62374710|NCT02886338|EXPERIMENTAL|capsule endoscopy examination|Capsule endoscopic examination for the esophagus, stomach and duodenum.
62748123|NCT00753103|EXPERIMENTAL|1|Patients with active vasculitis who receive infliximab in addition to standard immunosuppressive therapy
62748124|NCT00753103|ACTIVE_COMPARATOR|2|Patients with active ANCA associated vasculitis who receive standard immunosuppression but no infliximab
62748125|NCT04545190|ACTIVE_COMPARATOR|Glucose|"Glucose will be ingested at three time points during resistance training (RT): 30 min prior to RT (30 g glucose mixed with 300 ml sugar-free Fun light lemonade), immediately prior to RT (30 g, 300 ml), and immediately after completion of training (30 g, 300 ml).~Protein supplement will be ingested at two time points: 2 hours prior to RT (e.g. at 0700 hrs, 25 g) and immediately after completion of training (25 g).~Placebo will be ingested during the afternoon (i.e. not during training; between 1800 hrs and 1900 hrs): 3 x 100 mg Stevia powder mixed with 3 x 300 ml sugar-free Fun light lemonade.~(The dietary intervention spans from 2200 hrs on the evening prior to RT sessions to \~2.5 hrs after completion of RT. During this time frame, participants will ingest glucose and protein supplements only)"
62748126|NCT04545190|PLACEBO_COMPARATOR|Placebo|"Placebo will be ingested at three time points during resistance training (RT): 30 min prior to RT (100 mg Stevia powder mixed with 300 ml sugar-free Fun light lemonade), immediately prior to RT (100 mg, 300 ml), and immediately after completion of training (100 mg, 300 ml).~Protein supplement will be ingested at two time points: 2 hours prior to RT (e.g. at 0700 hrs, 25 g) and immediately after completion of training (25 g).~Glucose will be ingested during the afternoon (i.e. not during training; between 1800 hrs and 1900 hrs): 3 x 30 g glucose mixed with 3 x 300 ml sugar-free Fun light lemonade.~(The dietary intervention spans from 2200 hrs on the evening prior to RT sessions to \~2.5 hrs after completion of RT. I.e.: during this period, participants will ingest placebo and protein supplements only)"
62748127|NCT03593343|EXPERIMENTAL|Short overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 11 pm and stay overnight fasted afterwards for (9.5h).
62748128|NCT03593343|EXPERIMENTAL|Long overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 4.30 pm and stay overnight fasted afterwards for (16h).
62374711|NCT03705741|EXPERIMENTAL|Exercise group|Resistance exercise twice a week
62553932|NCT02766270|EXPERIMENTAL|Chemoradiotherapy with Temozolomide|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks (for a total of 60 Gy) and receive temozolomide PO QD (75 mg/m2/day, 7 days/week) for up to 7 weeks. Beginning 4 weeks after completion of chemotherapy and radiation therapy, patients receive temozolomide PO QD on days 1-5 (150-200 mg/m2). Treatment with temozolomide repeats every 28 days for up to 12 courses
62553933|NCT02766270|ACTIVE_COMPARATOR|Radiotherapy alone|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks (for a total of 60 Gy)
62553934|NCT06052046|EXPERIMENTAL|Total30 for Astigmatism Contact Lenses|TOTAL30 for Astigmatism Monthly Replacement Contact Lenses
62553935|NCT02906670|EXPERIMENTAL|1 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 1 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
62553936|NCT02906670|EXPERIMENTAL|2 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 2 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
62553937|NCT02906670|EXPERIMENTAL|4 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 4 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
62553938|NCT02906670|EXPERIMENTAL|6 mg/kg Q1W + Prophylaxis|"Phase 1a: Patients are administered a weekly dose of 6 mg/kg of Sym013 + premedication until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
62553939|NCT02906670|EXPERIMENTAL|9 mg/kg Q1W + Prophylaxis|"Phase 1a: Patients are administered a weekly dose of 9 mg/kg of Sym013 + premedication until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
62553940|NCT02906670|EXPERIMENTAL|6 mg/kg Q2W|Phase 1a: Patients are administered a dose of 6 mg/kg of Sym013 every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
62553941|NCT02906670|EXPERIMENTAL|9 mg/kg Q2W|Phase 1a: Patients are administered a dose of 9 mg/kg of Sym013 every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
62748129|NCT05935878|EXPERIMENTAL|Cementless Oxford Unicompartmental Knee Arthroplasty|Phase III Cementless Oxford Unicompartmental Knee Replacement (Biomet)
62748130|NCT05935878|ACTIVE_COMPARATOR|Cemented Oxford Unicompartmental Knee Arthroplasty|Phase III Cemented Oxford Unicompartmental Knee Replacement (Biomet)
62748131|NCT02606981|EXPERIMENTAL|Chlorination|Device: Water chlorination by the Flogenic Primary drinking water source will be outfitted with automatic dosing device supplied with chlorine tablets. The device is called the Flogenic.
62748132|NCT02606981|PLACEBO_COMPARATOR|Control|Active control: Vitamin C dosing into water. Primary drinking water source will be outfitted with automatic dosing device supplied with vitamin C tablets. The device is not commercially available.
62748133|NCT00581269|ACTIVE_COMPARATOR|1|low-impact aerobic exercise group
62748134|NCT00581269|ACTIVE_COMPARATOR|2|dietary restriction group
62748135|NCT00581269|NO_INTERVENTION|3|control group
62748136|NCT05191888|ACTIVE_COMPARATOR|14-day vonoprazan high-dose two-in-one therapy|vonoprazan 20mg bid and amoxicillin 750mg qid
62374712|NCT03705741|NO_INTERVENTION|Control group|
62374713|NCT03581045||ALL Survivors|Adult survivors of Acute Lymphoblastic Leukemia (ALL) enrolled on the SJLIFE protocol
62374714|NCT03581045||Control Group|Healthy Individuals with no history of childhood or adult onset cancer, matched on age- and sex
62374715|NCT00444951|EXPERIMENTAL|Menactra® group|Have received previously a dose of an A, C, Y, W 135 and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, will receive a booster dose of Menactra® (Meningococcal \[serogroups A, C, Y, W-135\] polysaccharide diphtheria toxoid conjugate) vaccine.
62748137|NCT05191888|ACTIVE_COMPARATOR|14-day vonoprazan triple therapy|vonoprazan 20mg bid and amoxicillin 1gm bid and clarithromycin 500mg bid
62748138|NCT05191888|ACTIVE_COMPARATOR|14th Rabeprazole reverse mixed therapy|first 7 days rabeprazole 20mg bid and amoxicillin 1gm bid and clarithromycin 500mg bid and metronidazole 500mg bid Next 7 days rabeprazole 20mg bid and amoxicillin 1gm bid
62748139|NCT04144699||Wheezing 3~11months|Patient has wheezing, age 3 to 11 months
62748140|NCT04144699||Wheezing 12~23months|Patient has wheezing, age 12 to 23 months
62748141|NCT04144699||Wheezing 24~35months|Patient has wheezing, age 24 to 35 months
62748142|NCT04144699||Wheezing 36~107months|Patient has wheezing, age 36 to 107 months
62748143|NCT04144699||No wheezing 3~11months|Patient do not have wheezing, age 3 to 11 months
62748144|NCT04144699||No wheezing 12~23months|Patient do not have wheezing, age 12 to 23 months
62748145|NCT04144699||No wheezing 24~35months|Patient do not have wheezing, age 24 to 35 months
62748146|NCT04144699||No wheezing 36~107months|Patient do not have wheezing, age 36 to 107 months
62748147|NCT03556592|EXPERIMENTAL|All subjects|"Tralokinumab - investigational medicinal product:~Week 0: subcutaneous (SC) injection of tralokinumab loading dose.~Week 2 to Week 14: SC injection of tralokinumab maintenance dose.~CYP substrates - non-investigational medicinal products:~Week -1, Week 1, and Week 15: oral administration of caffeine 100 mg, warfarin sodium 5 mg x2, omeprazole 20 mg, metoprolol tartrate 100 mg, and midazolam hydrochloride 2 mg."
62748148|NCT04987996|EXPERIMENTAL|GR-MD-02 + pembrolizumab|4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
62748149|NCT04987996|PLACEBO_COMPARATOR|Pembrolizumab Monotherapy|4 mg/kg placebo in combination with standard pembrolizumab treatment.
62748150|NCT02628431||General anesthesia|Patients that will recieve general anesthesia for elective surgery
62748151|NCT02628431||Regional or neuraxial anesthesia|Patients that will revieve regional or neuraxial anesthesia for elective surgery
62748152|NCT04186195||Diabetic children aged 1-16 years and their families|Diabetic children aged 1-16 years and their families. A child's disease duration must be over 1 year so that possible remission period is over.
62748153|NCT04347213||omnivors|Participants who habitually consume all food groups in their diet.
62374716|NCT00444951|EXPERIMENTAL|Mencevax® group|Have received previously a dose of an A, C, Y, W 135 and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, will receive a booster dose of Mencevax ACWY (serogroups A, C, Y, W-135) polysaccharide meningococcal vaccine.
62567313|NCT01582490|ACTIVE_COMPARATOR|Infiltration - EXPAREL|Group 2 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be administered via local infiltration into each surgical site per the surgeon's normal practice at the beginning of surgery.
62748154|NCT04347213||vegetarian|Participants who habitually avoid meat in their diet.
62748155|NCT04347213||vegan|Participants who habitually avoid all animal source food in their diet.
62748156|NCT04347213||low-carbohydrate high-fat diet|Participants who habitually avoid carbohydrate in their diet.
62748157|NCT02213185|EXPERIMENTAL|EMLA patches and SWI|EMLA patches 1.5 hrs before sterile water injections
62748158|NCT02213185|ACTIVE_COMPARATOR|EMLA patches and isotonic saline|EMLA patches 1.5 hrs before isotonic saline
62748159|NCT02213185|PLACEBO_COMPARATOR|Placebo patches and SWI|PLACEBO patches 1.5 hrs before sterile water injections
62748160|NCT02213185|PLACEBO_COMPARATOR|Placebo patches and isotonic saline|PLACEBO patches 1.5 hrs before isotonic saline
62748161|NCT05472675|EXPERIMENTAL|local anesthetic and botulinum toxin group|patients who have vestibular migraine and who accepted for study gruoup as local anesthetic and botulinum toxin group
62748162|NCT05472675|NO_INTERVENTION|beta-blocker control group|patients who have vestibular migraine and who have standard migraine treatment as beta-blocker
62748163|NCT00883870|EXPERIMENTAL|mesenchymal stem cells|Intramuscular injection
62748164|NCT00883870|EXPERIMENTAL|Placebo|Intramuscular injection
62748165|NCT01116024|EXPERIMENTAL|3f Enable Aortic Bioprosthesis Model 6000|Single arm study
62748166|NCT04434625|NO_INTERVENTION|control group|Colonoscopy was performed in the control group directly.
62748167|NCT04434625|EXPERIMENTAL|model-based interference group|Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score\<3 in IM group colonoscopy directly.
62748168|NCT00561002|EXPERIMENTAL|Influenza vaccine Naive/Inadequately Primed|Participants had no more than one previous lifetime dose of influenza vaccine and received two doses of Fluzone®, on Days 0 and 14.
62748169|NCT00561002|EXPERIMENTAL|Influenza Vaccine Primed|Participants had previously received 2 injections of Influenza vaccine in the same season and received a single dose of Fluzone® on Day 0.
62748170|NCT02652208|ACTIVE_COMPARATOR|Online decision aid|This group will receive the access to an online decision aid that covers the main treatment options for stable chest discomfort.
62748171|NCT02652208|ACTIVE_COMPARATOR|Video decision aid|This group will receive the DVD and booklet decision aid describing stable chest discomfort and the main treatment options including medical therapy and stents.
62748172|NCT04161443|EXPERIMENTAL|Experimental|"Following physiotherapy treatment will be given to the participants in this group for 4 weeks and each session last for 30 minutes.~i. MET Quadratus lumborum ii. Ultrasound iii. Gluteus medius exercises iv. Hamstring stretch Posture advice and home exercise program"
62748173|NCT04161443|ACTIVE_COMPARATOR|Comparator|"Following physiotherapy treatment will be given to the participants in this group for 4 weeks and each session last for 30 minutes.~i. Ultrasound ii.Gluteus medius exercises iii.Hamstring stretch"
62748174|NCT03913026|EXPERIMENTAL|Main intervention|Eligible patients will receive an ablative conditioning regimen and be infused with an ECT-001 expanded cord-blood. The ECT-001 expanded CB could be infused fresh, or cryopreserved.
62748175|NCT00643786|EXPERIMENTAL|A|Oxygène
62748176|NCT00643786|PLACEBO_COMPARATOR|B|Air Médical
62748177|NCT03200275||HOSPITALISED PNEUMONIA PATIENTS|"All patients of more than 18 years of age, hospitalized consecutively for pneumonia irrespective of it being community or hospital acquired. All the patients included in this study will need to have acute symptoms of less than 2 weeks and radiological features which are compatible to pneumonia.~They will undergo testing for Legionella pneumophila serogroup 1 urine antigen using a qualitative rapid assay following manufacturer's instructions at baseline. The diagnosis of Legionella pneumonia is made if the Immunocatch™ Legionella Urine Antigen Test is positive."
62748178|NCT03929653||Advanced Refractory Solid Tumors|Patients with advanced refractory solid tumors receive personalized therapy with the guidance of Molecular Tumor Board after the NGS(next generation sequencing).
62748179|NCT00791479|EXPERIMENTAL|0.1 milligram (mg) LY2189265|LY2189265: 0.1 milligram (mg), subcutaneous (SC), once weekly (QW)
62748180|NCT00791479|EXPERIMENTAL|0.5 milligram (mg) LY2189265|LY2189265: 0.5 milligram (mg), subcutaneous (SC), once weekly (QW)
62748181|NCT00791479|EXPERIMENTAL|1.0 milligram (mg) LY2189265|LY2189265: 1.0 milligram (mg), subcutaneous (SC), once weekly (QW)
62374717|NCT00444951|EXPERIMENTAL|Control group|Participants have not previously received any meningococcal vaccine, will receive a booster dose of Menactra® (Meningococcal \[serogroups A, C, Y, W-135\] polysaccharide diphtheria toxoid conjugate) vaccine.
62748182|NCT00791479|EXPERIMENTAL|1.5 milligram (mg) LY2189265|LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
62748183|NCT00791479|PLACEBO_COMPARATOR|Placebo|Placebo: subcutaneous (SC) once weekly (QW)
62748184|NCT03761017|EXPERIMENTAL|Cohort 1|0.03 mg/kg administered IV every 3 weeks.
62748185|NCT03761017|EXPERIMENTAL|Cohort 2|0.1 mg/kg administered IV every 3 weeks.
62748186|NCT03761017|EXPERIMENTAL|Cohort 3|0.3 mg/kg administered IV every 3 weeks.
62748187|NCT03761017|EXPERIMENTAL|Cohort 4|1.0 mg/kg administered IV every 3 weeks.
62748188|NCT03761017|EXPERIMENTAL|Cohort 5|30. mg/kg administered IV every 3 weeks.
62748189|NCT03761017|EXPERIMENTAL|Cohort 6|6.0 mg/kg administered IV every 3 weeks.
62748190|NCT03761017|EXPERIMENTAL|Cohort 7|10.0 mg/kg administered IV every 3 weeks.
62748191|NCT00365105|ACTIVE_COMPARATOR|Zoledronic acid|Zoledronic acid, vitamin D and calcium supplements.
62748192|NCT00365105|EXPERIMENTAL|Zoledronic acid + Radiopharmaceuticals|Zoledronic acid, vitamin D and calcium supplements, plus Sr-89 or Sm-153.
62748193|NCT01426152||Low level progesterone group (1)|Progesterone \< 1.50 ng/mL on day of ovulation induction
62748194|NCT01426152||Medium level progesterone group (2)|Progesterone 1.51-1.99 ng/mL on the day of ovulation induction
62748195|NCT01426152||High level progesterone group (3)|Progesterone \> 1.99 ng/mL on the day of ovulation induction
62374718|NCT03973502|EXPERIMENTAL|18F-DOPA PET|PET/CT
62374719|NCT04017624|EXPERIMENTAL|Fresh Truck with stipend|Referral to Fresh Truck mobile market
62374720|NCT04017624|ACTIVE_COMPARATOR|THRIVE-Basic|Screening-and-referral usual care model
62374721|NCT06435494|EXPERIMENTAL|Intervention|All patients will be asked to complete a number of questionaires: EQ5D-5L, a study specific questionaire (designed specifically for this study) and a shoulder-disease-specific questionaire (the Oxford Shoulder Score). For patients in the intervention group, the results of the questionaires will be accessable for patient and health-care professionals and will be used to illustrate the problems, make a prognostic model for the specific patient based on previous PRO results from other patients and will be used in monitoring the treatment of the patient.
62374722|NCT06435494|NO_INTERVENTION|Control|All patients will be asked to complete a number of questionaires: EQ5D-5L, a study specific questionaire and a shoulder-disease-specific questionaire. For patients int he control group, this will be collected, but not accessed or used during the treatment of the patient. The data will be used in the final analyses of the study.
62374723|NCT03178175|EXPERIMENTAL|"acupuncture with De Qi"|all participants in this group will receive the standard procedure of acupuncture.
62374724|NCT03178175|SHAM_COMPARATOR|Sham acupuncture|In this group, all participants will receive acupuncture needle insertion but not exact acupoint's location and depth.
62374725|NCT04739995|EXPERIMENTAL|Low-Dose-Naltrexone (LDN)|The LDN treatment will consist of one 4.5 mg naltrexone tablet (lactose-free) taken daily for 12 months before going to sleep.
62748196|NCT01631747|ACTIVE_COMPARATOR|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
62748197|NCT01631747|EXPERIMENTAL|Lifestyle Intervention Group|Women in the Intervention group will participate in a lifestyle program based on Moms'adopting a healthier diet and becoming more active for 24 months. Implementation is at approximately 15 weeks.Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet \& activity and use of pedometer
62748198|NCT02689466||cervical dystonia|clinically documented cervical dystonia (focal cervical or segmental with neck involvement) established by history and physical/neurological examination, at least 18 years old.
62748199|NCT02689466||healthy volunteers|age and sex matched healthy volunteers, at least 18 years old.
62748200|NCT01905228|EXPERIMENTAL|CBL0137|"* Dose Level 9: 150 mg/m2, IV~* Dose Level 10: 180 mg/m2, IV~* Dose Level 11: 240 mg/m2, IV~* Dose Level 12: 320 mg/m2, IV~* Dose Level 13: 400 mg/m2, IV~* Dose Level 14: 540 mg/m2, IV~* Dose Level 15: 700 mg/m2, IV~* Dose Level 16: 920 mg/m2, IV~* Dose Level 17: 1200 mg/m2, IV~* Dose Level 18: 1600 mg/m2, IV~* Dose Level 19: 2100 mg/m2, IV~* Dose Level 20: 2700 mg/m2, IV"
62748201|NCT03558334|EXPERIMENTAL|Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be given to preterm infants with BPD.
62748202|NCT03558334|ACTIVE_COMPARATOR|No Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be not given to preterm infants with BPD.
62748203|NCT03902457|EXPERIMENTAL|test site|The sinus mucosa will be elevated and, at the test sites, a collagen membrane will be placed subjacent the sinus mucosa
62748204|NCT03902457|EXPERIMENTAL|control site|The sinus mucosa will be elevated and, at the control sites, a collagen membrane will not be placed subjacent the sinus mucosa
62748205|NCT01703208|EXPERIMENTAL|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
62748206|NCT01703208|PLACEBO_COMPARATOR|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
62374726|NCT04739995|PLACEBO_COMPARATOR|Placebo|The control group will take the placebo daily (a film-coated tablet, identical to the LDN, filled with a lactose-free excipient), for 12 months, following the same guidelines.
62374727|NCT04009824|PLACEBO_COMPARATOR|Group 1: Saline Placebo|Participants received placebo on days 1 and 22 by subcutaneous injection
62374728|NCT04009824|EXPERIMENTAL|Group 2: AGS-v PLUS Non-Adjuvanted|Participants received 1012 µg of unadjuvanted AGS-v PLUS vaccine on days 1 and 22 by subcutaneous injection
62748207|NCT03540537|OTHER|PCA for Open Hepatectomy|Patient-controlled intravenous analgesia in Open hepatectomy (PCA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing)
62748208|NCT03540537|EXPERIMENTAL|QLB for Open Hepatectomy|Bilateral quadratus lumborum block with 20 ml 0.375% ropivacaine each side(maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
62748209|NCT03540537|EXPERIMENTAL|TPVB for Open hepatectomy|T6+T8 of thoracic paravertebral block with 15 ml 0.375% ropivacaine each segment (maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
62374729|NCT04009824|EXPERIMENTAL|Group 3: AGS-v PLUS + Adjuvant Montanide ISA-51 + Placebo|Participants received 1012 µg of AGS-v PLUS and Montanide ISA-51 on day 1 and placebo on day 22 by subcutaneous injection
62374730|NCT04009824|EXPERIMENTAL|Group 4: AGS-v PLUS + Montanide ISA-51|Participants received 1012 µg of AGS-v PLUS + Montanide ISA-51 on days 1 and 22 by subcutaneous injection
62553942|NCT02906670|EXPERIMENTAL|9 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 9 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
62553943|NCT02906670|EXPERIMENTAL|12 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 12 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
62553944|NCT02906670|EXPERIMENTAL|15 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 15 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
62748210|NCT03540537|OTHER|PCA for Laparoscopic Hepatectomy|Patient-controlled intravenous analgesia in Laparoscopic hepatectomy (same as PCA for Open hepatectomy Arm)
62374731|NCT04009824|EXPERIMENTAL|Group 5: AGS-v PLUS + Alhydrogel® Adjuvant|Participants received 1012 µg of AGS-v PLUS and Alhydrogel® on days 1 and 22 by subcutaneous injection
62553945|NCT02906670|EXPERIMENTAL|Phase 2a Dose-Expansion Cohort A|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
62553946|NCT02906670|EXPERIMENTAL|Phase 2a Dose-Expansion Cohort B|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
62748211|NCT03540537|EXPERIMENTAL|QLB for Laparoscopic Hepatectomy|Bilateral quadratus lumborum block 20 ml 0.375% ropivacaine each side(maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
62748212|NCT03540537|EXPERIMENTAL|TPVB for Laparoscopic Hepatectomy|T6+T8 of thoracic paravertebral block with 15 ml 0.375% ropivacaine each segment (maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
62748213|NCT05010122|EXPERIMENTAL|Treatment (decitabine, cedazuridine, venetoclax, gilteritib)|"INDUCTION (CYCLE 1): Patients receive decitabine and cedazuridine PO QD on days 1-5, venetoclax PO QD on days 1-28, and gilteritinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity~CONSOLIDATION (CYCLES 2-24): Patients receive decitabine and cedazuridine PO QD on days 1-5, gilteritinib PO QD on days 1-28, and venetoclax PO QD on days 1-21. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE (CYCLES 24+): Patients receive gilteritinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62748214|NCT06572891|ACTIVE_COMPARATOR|Conventional maxillary obturator|conventional acrylic obturator for each patient
62748215|NCT06572891|ACTIVE_COMPARATOR|Implant supported maxillary obturator|Implant-supported maxillary obturator (compressive implants)
62748216|NCT04694352|EXPERIMENTAL|Jumping Exercises|Jumping in place Jump and clap Jump and reach Jump and twist Jump and turn Half jumping jack Jumping side to side
62748217|NCT04694352|ACTIVE_COMPARATOR|Conventional|"Drop and catch a ball Squeeze ball between legs, jump up and catch the ball Walking on a straight line Stand on one leg try to pick object from floor without using hands (do this on both legs) Drop the ball and catch it with both hands Jump up stair with both limbs off the floor simultaneously while holding railing.~Skipping."
62748218|NCT01595230|EXPERIMENTAL|Inertervention group_Clips to avoid internal herniation|LRYGB with closure of the defects with simple hernia stapler clips. Aim of this study is to evaluate the benefits and disadvantages of closing the mesenteric defects during gastric bypass in order to avoid internal herniation.
62748219|NCT01595230|NO_INTERVENTION|Control group|conventional LRYGB without closure of the mesenteric defects
62748220|NCT02696733|EXPERIMENTAL|UG - ONB|Patients with the bladder tumor located on the lateral wall, with the high risk of adductor muscles contraction during TURBT under spinal anesthesia.
62748221|NCT02691624||sentinel lymph node biopsy|Patients of the group is diagnosed with breast cancer and receive lymphoscintigraphy before operation, and will receive sentinel lymph node biopsy
62748222|NCT02691624||axillary lymph node dissection|Patients of the group is diagnosed with breast cancer and receive lymphoscintigraphy before operation, and will receive axillary lymph node dissection
62748223|NCT05552261||Group Long-term follow-up|All eligible patients, after completing enrollment in the original DEFENDO Study, will be invited to enter the DEFENDO Long-Term Follow-Up Study (all standard of care is permitted), according to inclusion and exclusion criteria.
62748224|NCT04245267|NO_INTERVENTION|Control|Patients in the wait-list being attended with the standard model of care for diabetes in primary care units.
62748225|NCT04245267|EXPERIMENTAL|DIABEMPIC program|Intervention comprised by an interdisciplinary team care, patient-centered care approach, structured diabetes education program, promotion of self-management, audit, and guaranteed supply of anti-diabetic medication.
62748226|NCT06493097|EXPERIMENTAL|Treatment with hypnotherapy audio files|Participants get access to a website, where they can find information about the diagnosis DGBI and mechanisms leading to symtoms. On the website they also get access to a tretament protocoll for self-hypnosis with audio files (5 different audio files, age-adjusted). Participants listen to audio files min 5 times/week for 12 weeks. They answer the study questionnaries before, after and every 3 weeks during the treatment.
62748227|NCT01302834|ACTIVE_COMPARATOR|IMRT + Cisplatin|Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin
62748228|NCT01302834|ACTIVE_COMPARATOR|IMRT + Cetuximab|Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab
62748229|NCT04309370|EXPERIMENTAL|20 Hz rTMS targeting the LDLPFC first, then 20 Hz rTMS targeting the LSPC|
62748230|NCT04309370|EXPERIMENTAL|20 Hz rTMS Targeting the LSPC first, then 20 Hz rTMS Targeting the LDLPFC|
62374732|NCT06154759|EXPERIMENTAL|experimental caregiver group|33 of whom were in the experimental group and 33 in the control group, were included in the study. In the study, quantitative data were collected using Descriptive Characteristics Form, Beck Hopelessness Scale, Templer Death Anxiety Scale and Caregiver Strain Index, while qualitative data were collected using Structured Interview Form-1 and Structured Interview Form-2. Quantitative data collection tools were applied to the relatives of the patients in the experimental and control groups after the randomization group assignment within the scope of the pre-test. Psychoeducation was given to the relatives of the patients in the experimental group for 45-60 minutes once a week for eight weeks. Qualitative data were collected in sessions (sessions 2,3,5,7,8) and for this purpose, Structured Interview Form-1, Structured Interview Form-2, and audio recording were used. The same data collection tools were applied to the Experiment group for the post-test measurements after eight weeks.
62374733|NCT06154759|NO_INTERVENTION|control caregiver group|In the study, quantitative data were collected using Descriptive Characteristics Form, Beck Hopelessness Scale, Templer Death Anxiety Scale and Caregiver Strain Index in control group. The control group received no intervention for eight weeks. The same data collection tools were applied to the Control group for the post-test measurements after eight weeks.
62374734|NCT01599949|EXPERIMENTAL|Ibrutinib|
62374735|NCT05233423|EXPERIMENTAL|Intervention Group|The patients in the intervention group were applied 9 cold applications with 30 mmHg pressure for 20 minutes and 40 minutes of rest.
62374736|NCT05233423|NO_INTERVENTION|Control Group|The patients in the control group were applied 9 times of cold gel in the form of 20 minutes of application and 40 minutes of rest after surgery.
62374737|NCT01846208|EXPERIMENTAL|Egg OIT Randomized|Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
62374738|NCT01846208|EXPERIMENTAL|Baked Egg Randomized|"Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and safe commercial products with up to four oral food challenges as directed by the protocol."
62748231|NCT01791049|EXPERIMENTAL|Active|Single escalating doses of TD-1607, administered intravenously
62748232|NCT01791049|PLACEBO_COMPARATOR|Placebo|Placebo
62748233|NCT06571591|ACTIVE_COMPARATOR|Group 1|
62748234|NCT06571591|ACTIVE_COMPARATOR|Group 2|
62374739|NCT01846208|EXPERIMENTAL|Egg OIT Assigned|Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
62553947|NCT02906670|EXPERIMENTAL|Phase 2a Dose-Expansion Cohort C|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
62748235|NCT06571591|PLACEBO_COMPARATOR|Placebo|
62748236|NCT06606821|EXPERIMENTAL|Tirzepatide|Tirzepatide is administered sc. once-weekly.
62748237|NCT06606821|PLACEBO_COMPARATOR|Placebo|Placebo is administered sc. once-weekly.
62748238|NCT05384106|EXPERIMENTAL|Avela™ (R)-1,3-Butanediol|3 servings of Avela™, with consumption of each serving separated by 30 minutes and each serving providing 11.5 g of (R)-1,3-butanediol \[total intake of 34.5 g of (R)-1,3-butanediol\].
62748239|NCT01493102|ACTIVE_COMPARATOR|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
62748240|NCT01493102|ACTIVE_COMPARATOR|Norepinephrine|Norepinephrine: Norepinephrine will be reduced first (0.1 microgram/kg/hour)
62748241|NCT04556955|PLACEBO_COMPARATOR|post isometric relaxation and exercises|Group A included Post Isometric Relaxation, 5 rep , 20% isometric contraction 10 sec , 20 sec of stretch hold beyond resistance barrier and conventional exercise program ; this program included Hot pack placed over the painful area in cervical region before the treatment ( 20 minutes).Strengthening exercises for deep neck flexors, rhomboids, lower trapezius and serratus anterior due to weak muscles (2 sets of 10 repetitions once a day) Stretching exercises for pectoralis muscles (20-second hold, 5 repetitions).This exercise protocol was for 4 weeks and 3 sessions per week. Measurements taken at baseline level and at the End of treatment, i.e. ROM, pain intensity by NPRS and PPT , functional disability.
62748242|NCT04556955|EXPERIMENTAL|Graston technique and exercises|Group B included Graston Technique to Upper Trapezius and Levator Scapulae.This instrumented-assisted soft tissue massage applied with deeper pressure to the area of concern.The protocol consist of Longitudinal stroking parallel to muscle fiber for 1min , spin over trigger points for 1 min using knob of instrument and fanning for 2 min Hot pack placed over the painful area in cervical region before the treatment ( 20 minutes).Strengthening exercises for deep neck flexors, rhomboids, lower trapezius and serratus anterior due to weak muscles (2 sets of 10 repetitions once a day) Stretching exercises for pectoralis muscles (20-second hold, 5 repetitions). This exercise protocol was for 4 weeks and 3 sessions per week. Measurements taken at baseline level and at the END of treatment , i.e. ROM, pain intensity by NPRS and PPT , functional disability.
62748243|NCT06270836|EXPERIMENTAL|Tarcocimab 5 mg (Treatment Group A)|Tarcocimab 5 mg via intravitreal injection at Day 1, Week 4, Week 8, Week 20, and Week 44.
62748244|NCT06270836|SHAM_COMPARATOR|Treatment Group B|Sham injection on the same schedule as Treatment Group A
62748245|NCT00035607|ACTIVE_COMPARATOR|Darbepoetin alfa SC|
62748246|NCT00035607|EXPERIMENTAL|Darbepoetin alfa IV|
62374740|NCT03638362|PLACEBO_COMPARATOR|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 2 week washout then switch over to the alternate beverage. Approximately half of participants began study consuming placebo beverage and the other half TCJ.
62374741|NCT03638362|EXPERIMENTAL|Tart cherry juice (TCJ)|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 2 week washout then switch over to the alternate beverage. Approximately half pf participants began study consuming placebo beverage and the other half TCJ.
62391505|NCT02377401|EXPERIMENTAL|Zanamivir 300 mg|Subjects will receive a single dose of IV zanamivir 300 mg on Day 1 morning. The repeat dose session will begin on Day 3 evening. Subjects will receive IV zanamivir 300 mg every 12 hours for 5 days. Each dose will be administrated intravenously at a constant rate over 30 minutes (500 milliliter per hour \[mL/hr\]).
62553948|NCT02906670|EXPERIMENTAL|Phase 2a Dose-Expansion Cohort D|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
62553949|NCT06301074|EXPERIMENTAL|HS-10509 in healthy adults|In SAD, participants in each dose-escalation cohort will orally receive a single dose of HS-10509 or a matching placebo on Day 1
62553950|NCT06301074|PLACEBO_COMPARATOR|Placebo in healthy adults|In SAD, participants in each dose-escalation cohort will orally receive a single dose of HS-10509 or a matching placebo on Day 1
62553951|NCT06301074|EXPERIMENTAL|HS-10509 in patients|In MAD, patient with schizophrenia in each dose-escalation cohort will orally receive HS-10509 or a matching placebo once daily for 28 days.
62553952|NCT06301074|PLACEBO_COMPARATOR|Placebo in patients|In MAD, patient with schizophrenia in each dose-escalation cohort will orally receive HS-10509 or a matching placebo once daily for 28 days.
62553953|NCT02037425|OTHER|onabotulinumtoxinA|At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
62553954|NCT02321059||No incisional hernia group|Healthy volunteers with an intact abdominal wall.
62553955|NCT02321059||Incisional hernia group|Patients with a ventral incisional hernia.
62553956|NCT02054052|EXPERIMENTAL|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating maliganant pleural or percardial effusion
62553957|NCT00332670|ACTIVE_COMPARATOR|1|10.000lux bright blue light 1hour every morning 1 hour after wake-up time during three weeks
62553958|NCT00332670|PLACEBO_COMPARATOR|2|50lux dim red light 1 hour every morning 1 hr after wake-up time during 3 weeks
62567314|NCT01582490|EXPERIMENTAL|Instillation - EXPAREL|Group 1 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be instilled into each breast pocket at the beginning of surgery.
62567315|NCT02512302|EXPERIMENTAL|SUN-101 via eFlow nebulizer|50 mcg glycopyrrolate via Electronic Nebulizer
62567316|NCT02512302|EXPERIMENTAL|SUN-101 via eFlow nebulizer with activated charcoal|50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
62567317|NCT02512302|ACTIVE_COMPARATOR|Seebri® Breezhaler®|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
62567318|NCT02512302|ACTIVE_COMPARATOR|Seebri® Breezhaler® with activated charcoal|: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
62567319|NCT02512302|ACTIVE_COMPARATOR|: Glycopyrrolate Injection|50 mcg glycopyrrolate via IV infusion
62567320|NCT00985387||Solifenacin treatment|Male and female OAB patients who were treated with solifenacin
62567321|NCT03138213|EXPERIMENTAL|TLPD|Ttotal laparoscopic pancreaticoduodenectomy
62567322|NCT03138213|EXPERIMENTAL|OPD|Open pancreaticoduodenectomy
62567323|NCT06123091||Congenital ichthyosis patients|Questionnaires
62567324|NCT02433184|EXPERIMENTAL|Etanercept|Treatment Arm 1 will receive etanercept and methotrexate combination therapy administered for a total duration of 48 weeks.
62567325|NCT02433184|ACTIVE_COMPARATOR|Methotrexate-treat to target|Treatment Arm 2 will receive initial methotrexate monotherapy with adoption of a treat to target protocol (standard care involving monthly DAS28-ESR assessment with escalation to combination sDMARD therapy if not achieving LDA at, or after, 8 weeks) and step-up to etanercept and methotrexate at 24 weeks if failing to achieve clinical remission
62567326|NCT02611895|EXPERIMENTAL|HIV DNA|Blood test : Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
62567327|NCT05607784||Adolescent Advisory Board Male|This board consisted of 9 male adolescents recruited from the schools.
62567328|NCT05607784||Adolescent Advisory Board Female|This board consisted of 9 female adolescents recruited from the schools.
62567329|NCT05607784||Health Education Professionals Panel (HEPP)|This panel consisted of 6 health teachers and other school health professionals such as nurses and counselors. They were recruited at each participating school.
62748247|NCT05300230||Patients with Zti Opticon Cochlear Implant|Patients that are users of Neuro Zti and Neuro 2 processor with a minimum of 6 months of habituation after the implementation.
62748248|NCT00904930||no periodontal disease|33 dental students (13 male, 20 female) with a mean age of 24.7 years (min. 19.8; max. 36.5) with no periodontal disease or dental trauma
62374742|NCT01878175|EXPERIMENTAL|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
62374743|NCT03219554|EXPERIMENTAL|palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
62553959|NCT04125485||Person with Parkinson's|"Inclusion criteria for interview/focus group with people with PD: people with PD living at home, Hoehn \& Yahr stage 1-4 (Hoehn and Yahr, 1967), cognitively able to participate, able to speak a conversational level of English, and at different stages of PD (early, mid, later by years of diagnosis) and ages (younger and older).~Exclusion criteria: any hospital admission within the last 1 year, whether for Parkinson's or anything else, that was for more than 24 hours i.e. not day surgery/brief checks in the emergency department after falls; patients diagnosed with PD less than 6 months ago to confirm the diagnosis and allowed them to have time for using the resources for people with PD; unwillingness to participate."
62553960|NCT04125485||Healthcare professional|"Inclusion criteria for interview/focus group for health professionals: Professionals from different disciplines (physician, neurologist, General Practitioners, nurses/specialist nurses, social worker, occupational therapist, mental health workers, physiotherapist, pharmacist, speech therapist) that provide support directly or indirectly to patients with PD and family carers.~Exclusion criteria: Not involved in direct care or support of people with PD or unwillingness to participate."
62553961|NCT04125485||Family carer|"Inclusion and exclusion criteria for all are the same for Interviews and Focus Groups.~Family carers:~Inclusion criteria: family caregivers of PD patients at different stages (early, mid, late) or friends involved in the care process. Also, family caregivers of patients with cognitive impairment will be included.~Exclusion criteria: not being involved in the care of the person with PD or unwillingness to participate in the project, and an ability to speak a conversational level of the English language.~Family carers do not need to have the person they care for in the study also and vice-versa."
62748249|NCT04664972|PLACEBO_COMPARATOR|TAC regimen group|The control group was treated with TAC (docetaxel 75mg/m2 + adriamycin 50mg /m2 + cyclophosphamide 500mg/m2) for 6 cycles, 21 days as a cycle.
62748250|NCT04664972|EXPERIMENTAL|TP regimen group|The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.
62748251|NCT05427448|EXPERIMENTAL|Prospective multisite clinical trial with consecutive recruitment.|Patients consulting in memory clinics from Montpellier, Nîmes, or Perpignan. CSF AD biomarkers performed for diagnostic purpose in clinical routine practice
62748252|NCT04098432|EXPERIMENTAL|Arm 1|4-weeks stereotactic radiotherapy followed by nivolumab 3 mg/kg every two weeks
62748253|NCT02489708|EXPERIMENTAL|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
62374744|NCT06119568|EXPERIMENTAL|Patients surgically treated with Bitrack System and ESE/ NESE instruments and accessories|
62374745|NCT02074397|EXPERIMENTAL|Distant extrafascial injection|Injection away from the brachial plexus with the needle tip positioned in the middle scalene muscle
62374746|NCT02074397|ACTIVE_COMPARATOR|Subfascial injection|Injection within the brachial plexus, with the needle tip positioned between C5 and C6
62374747|NCT01536938|ACTIVE_COMPARATOR|Calcipotriol|"Calcipotriol aerosol foam: calcipotriol 50 mcg/g.~Applied once daily for up to 4 weeks"
62374748|NCT01536938|ACTIVE_COMPARATOR|Betamethasone|"Betamethasone dipropionate aerosol foam: betamethasone 0.5 mg/g (as dipropionate)~Applied once daily for up to 4 weeks"
62374749|NCT01536938|EXPERIMENTAL|LEO 90100|"LEO 90100 aerosol foam: calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)~Applied once daily for up to 4 weeks"
62374750|NCT03461705|EXPERIMENTAL|Primary|All patients who are referred for coronary angiography and require physiological assessment of intermediate lesions will have both RFR and iFR measured during their standard of care procedure. Both the RFR wire (St. Jude Medical (SJM) Aeris Pressure Wire System) and iFR (Volcano Verrata Pressure Wire) wire will be advanced across the lesion with the sensor located at least 3 cm distal from the lesion.
62374751|NCT04366128|EXPERIMENTAL|CAPA indution immunotherapy|CAPA regimen, repeat every 3 week for 4 cycles.
62374752|NCT00604357|EXPERIMENTAL|1|Prior to reperfusion 500 mg Prednisolone will be administered i.v.. After the transplantation, a combination of anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure), and MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake) will be applied. Earliest, on day 10 after LT Sirolimus will be introduced aiming at 24 hours trough-levels for Sirolimus between 4 and 8 ng/mL. Steroids will be started on day 1 after transplantation with 1mg/kg BW and will be tapered every 2 days for 5 mg to a dosage of 20 mg and for 2.5 mg every two days to 7.5 mg. Thereafter the dosage will be reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter. Additionally, every patient with risk constellation will receive cytomegalovirus (CMV) prophylaxis and prophylaxis against Pneumocystis carinii infection during the first 3 months after liver transplantation.
62374753|NCT06423001|EXPERIMENTAL|PostbiotiX Slowing (Treatment A) Sequence AB|Each patient will be supplied with the investigational product at Visit 0 (V0, Kit V0, PostibiotiX Slowing) and at visit 3 (V3, Kit V3, Placebo), based on the outcome of the randomization at V0 (Sequence AB, PostbiotiX Slowing/Placebo).
62374754|NCT06423001|EXPERIMENTAL|Placebo (Tratment B) Sequence BA|Each patient will be supplied with the investigational product at Visit 0 (V0, Kit V0, Placebo) and at visit 3 (V3, Kit V3, PostibiotiX Slowing), based on the outcome of the randomization at V0 (Sequence BA, Placebo/PostbiotiX Slowing).
62748254|NCT00656149|ACTIVE_COMPARATOR|Telerehabilitation of hand function|Intervention: for one hour per day participants perform exercise therapy on a home-based tele-rehabilitation workstation, the Rehabilitation Joystick for Computerized Exercise (ReJoyce) with which participants play computer games associated with activities of daily life. A remote therapist coaches each one-hour session over the Internet, with the use of the ReJoyce tele-rehabilitation system. Hand grasp-release is assisted with functional electrical stimulation (FES) triggered voluntarily by the participant with the use of a wireless earpiece with a sensor that detects toothclicks.
62748255|NCT00656149|ACTIVE_COMPARATOR|Conventional exercise therapy|Intervention: for one hour per day participants perform conventional range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 with the use of the ReJoyce tele-rehabilitation min). A remote therapist coaches each one-hour session A remote therapist coaches each one-hour session over the Internet, with the use of the ReJoyce tele-rehabilitation system.
62748256|NCT03620578|EXPERIMENTAL|DA-EPOCH-R followed by Nivolumab|5 cycles of DA-EPOCH-R protocol induction, followed with one year Nivolumab consolidation for end-of-induction patients who are in complete metabolic response
62748257|NCT06608615|EXPERIMENTAL|Kinesio Taping Group|Persons who will undergo kinesio taping
62748258|NCT06608615|EXPERIMENTAL|Rigid Taping group|Persons to whom rigid taping will be performed
62748259|NCT02554149||stem anteversion|a hip lateral radiograph and CT scan were taken to measure stem anteversion
62748260|NCT04714203||cohort|Sarcopenia assessment
62748261|NCT03199053|EXPERIMENTAL|Low dose Dapagliflozin|Oral route. Start with a low dose of dapagliflozin administered once daily and remain on the low dose regardless of your HbA1c at week 12.
62748262|NCT03199053|EXPERIMENTAL|Low dose/high dose Dapagliflozin|Oral route. Start with a low dose of Dapagliflozin administered once daily and up titrate to the high dose Dapagliflozin administered once daily if HbA1c \>= 7% at week 12
62748263|NCT03199053|EXPERIMENTAL|Low dose Saxagliptin|Oral route. Start with a low dose of saxagliptin administered once daily and remain on the low dose regardless of your HbA1c at week 12
62748264|NCT03199053|EXPERIMENTAL|Low dose/high dose Saxagliptin|Oral route. Start with a low dose of saxagliptin administered once daily and up titrate to the high dose if HbA1c \>= 7% at week 12
62748265|NCT03199053|PLACEBO_COMPARATOR|Placebo arm|Oral route. Placebo tablets administered for 52 weeks
62748266|NCT04271371||Prototype intervention|To be developed through Phase 1 and 2
62748267|NCT06661772||All pediatric Patients less than 16 years old who were diagnosed with sepsis & admitted to PICU|All consecutively hospitalized children (less than 16 years old) admitted to 30 beds in PICU who were treated with the first course of vancomycin as empirical therapy for suspected sepsis without AKI by the time of the start of treatment were enrolled in the study.
62748268|NCT05617066|ACTIVE_COMPARATOR|therapy vs psychological support and usual care|Comparison between therapy groups vs psychological support and usual care. Only one group receive therapy.
62748269|NCT05617066|NO_INTERVENTION|therapy and psychological support versus control group|Comparison between therapy groups vs psychological support and usual care. Only one group receive therapy.
62748270|NCT05858632|EXPERIMENTAL|Guselkumab treatment|Guselkumab treatment for \~ 9 months
62748271|NCT00613002|EXPERIMENTAL|testosterone gel|1% testosterone transdermal gel
62748272|NCT00613002|PLACEBO_COMPARATOR|placebo gel|placebo transdermal gel
62748273|NCT00338208|NO_INTERVENTION|No training|Subjects will be fitted with low vision devices; no extra training will be provided.
62748274|NCT00338208|EXPERIMENTAL|Training in the Use of Low Vision Devices|Subjects will be fitted with low vision devices and will receive 6 training sessions with prescribed devices for up to 1 hour each time
62748275|NCT01672463|EXPERIMENTAL|All patients|All participants enrolled in this study
62748276|NCT05925452|EXPERIMENTAL|GenaKumab|15 subjects: GenaKumab 3.0mg/kg dose group and 4.0 mg/kg dose group, Subcutaneous injection, Q4w
62553962|NCT04125485||Stakeholder|"Stakeholders:~Inclusion criteria: non-NHS professionals or volunteers involved in policy making or working or collaborating in voluntary organisations or from different sectors; (non-NHS) Health Care, Social Services, voluntary sector, employment, food, Pharmaceutical, Education, Political, that have an impact directly or indirectly in the management of PD and development of care pathways for PD or other long-term conditions (when relevant). Exclusion criteria: unwillingness to participate in the project or lack of involvement in strategic planning or involvement in provision of community PD care."
62553963|NCT05843669|EXPERIMENTAL|N/A. Only one arm.|Single arm. During the 12-week period of receiving treatment, patient participants will take Mucinex® 12h, 2 x 600 mg (1200 mg total) twice daily and complete weekly bespoke surveys and the CASA-Q instrument.
62748277|NCT03307603|EXPERIMENTAL|Yttrium-90 + Nivolumab|240 mg Nivolumab intravenously, beginning at 2 weeks after Yttrium-90 treatment and given every 2 weeks until progression or toxicity. Additional dose at 2 weeks prior to Y-90 will be given if the first 3 patients do not have toxicity. If any of the first 3 patients have toxicity, the schedule can be relaxed to begin 3 weeks after Y-90 treatment.
62553964|NCT01446172||cognitive, schema focused, guided mastery, exposure|
62748278|NCT03352557|EXPERIMENTAL|Low-dose BIIB092|Intravenous (IV) infusion once every 4 weeks OR once every 12 weeks and placebo at the other 4-week dosing visits to maintain the treatment blind.
62748279|NCT03352557|EXPERIMENTAL|Medium-dose BIIB092|Intravenous (IV) infusion once every 4 weeks.
62748280|NCT03352557|EXPERIMENTAL|High-dose BIIB092|Intravenous (IV) infusion once every 4 weeks.
62748281|NCT03352557|PLACEBO_COMPARATOR|Placebo|Intravenous (IV) infusion once every 4 weeks.
62748282|NCT05372731|EXPERIMENTAL|RM after BAL|patients underwent RM after BAL
62748283|NCT05372731|NO_INTERVENTION|Non-RM after BAL|patients did not undergo RM after BAL
62748284|NCT05901480|EXPERIMENTAL|Treatment Arm|Patients with OTOF mutation-related deafness
62748285|NCT05615675|EXPERIMENTAL|Virtual Reality|Patients undergo prone pain procedure with virtual reality distraction
62748286|NCT05615675|NO_INTERVENTION|Control|Patients undergo prone pain procedure without virtual reality distraction
62748287|NCT06135896|EXPERIMENTAL|Treatment Group|"* Premedication: depending on the center (Ondansetron 8 mg +Dextrose 5% 50 mL, MIV, Dexamethason 10 mg IV, and Atropine sulfate 0.25 mg \[0.5 amp\] SC)~* Onivyde 70 mg/m2 + Dextrose 5% 500 mL (bag), and MIV for 90 min~* Leucovorin 400 mg/m2 + Dextrose 5% 500 mL (bag), and MIV for 30 min~* 5-FU (2400 mg/m2) + Dextrose 5% 500 mL (bag) and MIV for 46 h~* Tripegfilgrastim 6 mg SC administered 24 h after completing 5-FU infusion The above chemotherapy will be administered every two weeks"
62748288|NCT06135896|NO_INTERVENTION|Control Group|"* Premedication: depending on center (Ondansetron 8 mg+Dextrose 5% 50 mL, MIV, Dexamethason 10 mg IV, and Atropine sulfate 0.25 mg \[0.5 amp\] SC)~* Onivyde 70 mg/m2 + Dextrose 5% 500 mL (bag), and MIV for 90 min~* Leucovorin 400 mg/m2 + Dextrose 5% 500 mL (bag), and MIV for 30 min~* 5-FU (2400 mg/m2) + Dextrose 5% 500 mL (bag), and MIV for 46 h The following medication will be provided in the event that the patient develops febrile neutropenia after the above chemotherapy~* Tripegfilgrastim 6 mg SC administered 24 h after stopping 5-FU. In the event of neutropenia, chemotherapy will be paused until the patient recovers, and then restarted after recovery.~* The above chemotherapy will be administered every two weeks."
62553965|NCT01221701|EXPERIMENTAL|In-Home Cognitive Behavioral Therapy|Mothers will receive 15 weekly sessions of IH-CBT plus one booster session scheduled 1 month later.
62553966|NCT01221701|NO_INTERVENTION|typical home visitation|Standard of care in home visitation in which mothers can receive treatment in the community if they choose.
62553967|NCT05115175|EXPERIMENTAL|Intervention immediately|The intervention was delivered via a teen MBSR workbook and online communication across the 10-week intervention period. Participants were assigned weekly readings and activities from an MBSR workbook for teens. Topics included understanding stress, introduction to mindfulness, mindful eating and other mindfulness-based intervention principles and were recommended to be completed daily. Mindfulness-based exercises were either self-led per instructions provided in the workbook or to be completed using an audio recording directing participants' behaviors during the exercise.
62553968|NCT05115175|EXPERIMENTAL|Intervention in ten weeks following waitlist|This group received the same intervention as the first arm, however, the participants in arm 2 received the intervention after a 10-week waitlist period. The intervention was delivered via a teen MBSR workbook and online communication across the 10-week intervention period. Participants were assigned weekly readings and activities from an MBSR workbook for teens. Topics included understanding stress, introduction to mindfulness, mindful eating and other mindfulness-based intervention principles and were recommended to be completed daily. Mindfulness-based exercises were either self-led per instructions provided in the workbook or to be completed using an audio recording directing participants' behaviors during the exercise.
62553969|NCT01139229|OTHER|HE group|
62553970|NCT01139229|OTHER|HS group|
62553971|NCT01139229|OTHER|SA group|
62553972|NCT04680572|ACTIVE_COMPARATOR|Bipolar hemiarthroplasty group|
62553973|NCT04680572|ACTIVE_COMPARATOR|Dual mobility cups total hip replacement group|
62553974|NCT04074850||TBI group|"A cohort of patients admitted to UZ Leuven from 1999 to 2019 due to Traumatic Brain Injury and fulfilling our inclusion and exclusion criteria will be recruited.~Inclusion criteria will be: ≥ 65 years old at the time of the accident, admitted to UZ Leuven from 1999 and 2019, all injury severities, classified by the Glasgow Coma Scale (GCS) (mild (GCS 13-15), moderate (GCS 9-12) or severe (GCS ≤8)), and having signed the informed consent to participate in the study.~Exclusion criteria will be: \< 65 years old, admitted to UZ Leuven in a different period from 1999-2019, diagnosis of other neurodegenerative diseases before the TBI, cognitive and motor disturbances caused by any other pathology before the TBI, previous alcohol/drugs abuse, and not having signed the informed consent to participate in the study."
62553975|NCT02636478||reference group|therapy naive patients with a sleep related breathing disorder
62553976|NCT02636478||therapy group|patients with devices treating their sleep related breathing disorder
62553977|NCT02649712|ACTIVE_COMPARATOR|Unilateral stent|Patients undergo placement of unilateral biliary stent on day 1.
62553978|NCT02649712|ACTIVE_COMPARATOR|Bilateral stents|Patients undergo placement of bilateral biliary stents on day 1.
62748289|NCT06595823|ACTIVE_COMPARATOR|Group A (Povidone-Iodine10%)|About 100 patients women who underwent elective caesarian section with subcutaneous tissue irrigation with Povidone iodine 10% solution.
62748290|NCT06595823|ACTIVE_COMPARATOR|Group B (Saline0.9%)|About 100 patients women who underwent elective caesarian section with subcutaneous tissue irrigation with normal saline0.9%
62748291|NCT06595823|PLACEBO_COMPARATOR|Group C (the control group)|About 100 patients women who underwent elective caesarian section without irrigation of the subcutaneous tissue with betadine or saline.
62748292|NCT01614834||chronic urticaria patients|all patients suffering from chronic forms of urticaria (chronic spontaneous urticaria as well as chronic inducible forms such as cold contact urticaria)
62748293|NCT01372072|ACTIVE_COMPARATOR|Humidification|Patients in this arm of the trial will receive humidification with the non-invasive ventilation.
62748294|NCT01372072|NO_INTERVENTION|NIV without humidifivation|As per usual practice patients in this arm will not have humidification with their NIV
62748295|NCT06607380|EXPERIMENTAL|Group 1|TNM002
62748296|NCT06607380|ACTIVE_COMPARATOR|Group 2|Adsorbed tetanus vaccine
62748297|NCT06607380|EXPERIMENTAL|Group 3|TNM002 + adsorbed tetanus vaccine
62748298|NCT03723720||Patients after colonoscopy over 50 years|All colonoscopies in patients over 50 years of age (screening, surveillance, diagnostic) excluding therapeutic, IBD, management of complications and sigmoidoscopies
62748299|NCT01302223||Minor Burns|Total burn surface area less than 5% of second and third degree.
62748300|NCT01302223||Major Burns.|Total Burn Surface Area more than 25% of second and third degree, and less than 50%.
62748301|NCT04775862|EXPERIMENTAL|RAS wild type; investigator choice re-challenge with anti EGFR Rx|
62748302|NCT04775862|ACTIVE_COMPARATOR|RAS mutant; investigator choice of SOC third line Rx|
62748303|NCT04149977|EXPERIMENTAL|blood flow restriction therapy (pressure cuff)|The cuff will be placed around the upper thigh of the injured leg and set at a pressure that will prevent approximately 80% arterial blood flow. The machine will determine what pressure is required to reach that 80%, when placed on the leg and turned on.
62748304|NCT04149977|PLACEBO_COMPARATOR|blood flow restriction therapy (placebo)|Patients with a placebo pressure will have a pressure setting, 50% lower than the effective setting as stated in the experimental arm
62748305|NCT04348747|EXPERIMENTAL|Treatment (anti-HER2/3 dendritic cell vaccine)|"TREATMENT PHASE: Patients receive anti-HER2/HER3 dendritic cell vaccine ID on days 1, 22, and 43. Patients will also receive pembrolizumab IV on the same days.~MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients may also receive a booster dose of anti-HER2/3 dendritic cell vaccine ID, every 3-6 months in the opinion of principal investigator."
62748306|NCT06304181|EXPERIMENTAL|Paracetamol and Mannitol Injection group|Paracetamol and Mannitol Injection 500mg was given intravenously 30 minutes before the end of the operation
62553979|NCT01027325|EXPERIMENTAL|High CHO/Low Amylose|55% Carbohydrate (11.2% Amylose, 26.3% Amylopectin) 20% Protein 25% Fat
62553980|NCT01027325|EXPERIMENTAL|Low Carbohydrate/Hi Amylose|40% Carbohydrate (26.3% Amylose, 11.2% Amylopectin) 20% Protein 40% Fat
62553981|NCT01027325|EXPERIMENTAL|High CHO/High Amylose|55% Carbohydrate (26.3% Amylose, 11.2% Amylopectin) 20% Protein 25% Fat
62553982|NCT01027325|EXPERIMENTAL|Low Carbohydrate/Low Amylose|40% Carbohydrate (11.2% Amylose, 26.3% Amylopectin) 20% Protein 40% Fat
62553983|NCT01027325|ACTIVE_COMPARATOR|Baseline|40% Carbohydrate 20% Protein 40% Fat
62553984|NCT02294214|PLACEBO_COMPARATOR|Placebo|Placebo Repellent product with no active ingredient
62553985|NCT02294214|ACTIVE_COMPARATOR|Intervention|Spatial Repellent product with active ingredient
62553986|NCT02141607||Hemorrhagic Shock|"Hypovolemic shock characterized by:~* Hypotension: systolic blood pressure \< 90 mm Hg or a drop of \> 40 mm Hg from baseline or mean arterial pressure \< 70 mm Hg persisting despite adequate fluid resuscitation.~* Rapid loss of significant amount of blood~* Lactate levels ≥ 2 mmol/L"
62553987|NCT02141607||Cardiogenic shock|"State of inadequate circulation of blood because of ventricular failure due to acute cardiac conditions, concomitant presence of:~* Hypotension: systolic blood pressure \< 90 mm Hg or a drop of \> 40 mm Hg from baseline or mean arterial pressure \< 70 mm Hg persisting despite adequate fluid resuscitation.~* Need for a continuous infusion of inotropic drugs~* Cardiac Index \<2.2 L/min/m2 or use of inotropic drugs (dobutamine/isoprenaline/phosphodiesterase inhibitors or levosimendan)~* Signs of reduced heart function~* Cardiac overload or altered left/right ventricular function"
62553988|NCT02141607||Septic shock|"Septic shock is defined as sepsis-induced hypotension, defined as systolic blood pressure \< 90 mm Hg or a drop of \> 40 mm Hg from baseline or mean arterial pressure \< 70 mm Hg persisting despite adequate fluid resuscitation.~Only community medical acquired sepsis with a sepsis onset within 48 hours from hospital admission (i.e. different from nosocomial infection).~Lactate levels ≥ 2mmol/L."
62553989|NCT02141607||control group|"The control group will consist on:~1. 5 healthy blood donors: serving only for the purposes of obtaining reference values for proteomics analysis~2. a cohort of 20 patients hospitalized for sepsis OR cardiac syndromes not developing shock: will be recruited from patients admitted to the hospital during the study period. The clinical status of the patients will be assessed during hospitalization to ascertain shock and AHF development. Shock development will be an exclusion criteria."
62748307|NCT06304181|ACTIVE_COMPARATOR|Parecoxib group|40mg of parecoxib was given intravenously 30min before the end of the operation
62748308|NCT00480558|ACTIVE_COMPARATOR|1|Group 1: M. tb
62748309|NCT00480558|ACTIVE_COMPARATOR|2|Group 2: HIV (not on antiretrovirals \[ARV\])
62748310|NCT00480558|ACTIVE_COMPARATOR|3|Group 3: M. tb and HIV (not on ARV)
62748311|NCT00480558|ACTIVE_COMPARATOR|4|Group 4: M. tb and HIV (on ARV)
62748312|NCT03221868|EXPERIMENTAL|Physical exercise intervention|Exercise group. Physical exercise intervention with sessions carried out as circuit-training, three times a week for 12 weeks to improve physical fitness and metabolic control. The sessions will last between 10 and 45 minutes.
62748313|NCT03221868|ACTIVE_COMPARATOR|Control|Control group consisting of women who underwent the same measurements for future comparisons and were assigned to receive information about health and counseling to practice of physical activity.
62553990|NCT05373108|EXPERIMENTAL|Intervention Arm|A consecutive subset of eligible patients based on inclusion/exclusion criteria will receive a 1-week course of Macitentan (10 mg po daily) prior to their routine 1-year coronary angiogram (7th and final dose of Macitentan will occur on the day of the angiogram).
62553991|NCT06392854|OTHER|obesity status|obesity
62748314|NCT02422836|EXPERIMENTAL|Three Product Anti-Aging Regimen|"Three Product Anti-Aging Treatment Regimen:~Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks"
62553992|NCT06392854|OTHER|lean|non-obese
62553993|NCT03330873|EXPERIMENTAL|Foley catheter|After the completion of hysteroscopic adhesiolysis, Foley catheter was inserted and inflated with normal saline which was removed on the 7th day after surgery.
62553994|NCT03330873|EXPERIMENTAL|Disposable balloon uterine stent|After the completion of hysteroscopic adhesiolysis, disposable balloon uterine stent was inserted and inflated with normal saline which was removed on the 7th day after surgery.
62553995|NCT00632346||1 group|200 patients presenting to the Adolescent Medicine Clinic at Brooke Army Medical Center between the ages of 18 and 23 years-old.
62567330|NCT04964050|EXPERIMENTAL|Treatment sequence TRR|Participants will receive Capozide (T) in period 1 followed by ACE-Hemmer-Ratiopharm (R) in period 2 followed by ACE-Hemmer-Ratiopharm (R) in period 3.
62567331|NCT04964050|EXPERIMENTAL|Treatment sequence RTR|Participants will receive ACE-Hemmer-Ratiopharm (R) in period 1 followed by Capozide (T) in period 2 followed by ACE-Hemmer-Ratiopharm (R) in period 3.
62567332|NCT04964050|EXPERIMENTAL|Treatment sequence RRT|Participants will receive ACE-Hemmer-Ratiopharm (R) in period 1 followed by ACE-Hemmer-Ratiopharm (R) in period 2 followed Capozide (T) by in period 3.
62567333|NCT00966992|NO_INTERVENTION|Arm 1 (No Zometa)|Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. All interventions on this arm are standard of care.
62567334|NCT00966992|EXPERIMENTAL|Arm 2 (Zometa)|Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. Women randomized to zoledronic acid will receive 4 mg intravenously (IV) with their first dose chemotherapy and 3, 6 and 9 months after completion of radiation (total of 4 doses) along with scheduled follow-up dual-energy X-ray absorptiometry (DEXA) and biomarker studies.
62748315|NCT01009437|ACTIVE_COMPARATOR|Control Arm - No Ritonavir|Five ER+, HER2- breast cancer patients meeting all study eligibility will be enrolled prior to the start of phase I recruitment to act as controls (no ritonavir will be given-will receive therapeutic conventional surgery) to confirm that anesthesia does not affect EET levels. Core biopsies, surgical tumor/normal tissue and pre- and post- surgery blood samples will be collected for comparison with the treatment group.
62748316|NCT01009437|EXPERIMENTAL|Ritonavir - Escalating Doses (I)|"Standard phase I dose escalation (with therapeutic conventional surgery) will be used with 3 levels of ritonavir given - 200 mg bid, 400 mg bid, and 600 mg bid for the following groups:~1. ER+, HER2-~2. ER+, HER2+~3. ER-, HER2+~4. ER-, PR+, HER2-~5. ER-, PR-, HER2-"
62748317|NCT01009437|EXPERIMENTAL|Ritonavir - Maximum Tolerated Dose (II)|Phase II: Once the maximum tolerated dose (MTD) of ritonavir is established, 19 ER+, HER2- patients will be enrolled at MTD during the phase II component along with therapeutic conventional surgery.
62748318|NCT01190475|EXPERIMENTAL|BGS649 high dose|1 BGS649 1.0mg capsule with three 0.1 mg placebo capsules.
62748319|NCT01190475|EXPERIMENTAL|BGS649 low dose|1 BGS649 1.0 mg placebo capsule and 3 BGS649 0.1 mg capsules
62748320|NCT01190475|PLACEBO_COMPARATOR|Placebo to BGS649|1 matching placebo 1.0mg matching and three matching 0.1 mg placebo capsules
62748321|NCT01126268|EXPERIMENTAL|Retapamulin ointment 1%|
62748322|NCT06163183||Extubation failure|
62748323|NCT06163183||Extubation success|
62748324|NCT03614481||AMD patient|"During the AMD consultation, patients have their imaging exams including OCT, retinophotography, and fluorescein angiography.~After the interview with the doctor on pathology diagnosis and follow-up, they will meet the clinical research associate nurse to complete the questionnaire and perform anthropometric measurements (weight, height, abdominal perimeter measurement and blood pressure measurement). Patients recruited at Créteil will benefit from a venous blood sample (20 mL) in 2 EDTA tubes for DNA extraction after light reading and signature of consent. For patients recruited from other ophthalmic centers, the Clinical Research Associate will perform salivary sampling for DNA extraction after light reading and signature of consent."
62748325|NCT03614481||control without AMD|"898/5000 Given the observation of a mutation in an unaffected control individual, it is not excluded that this individual may be suffering from AMD at a later age. The observation of the mutation could thus be considered as a pre-clinical test. None of the teams were able to obtain a control population of the same age and sex ratio, which could have benefited from fluorescein angiography or at least a fundus examination, to ensure the absence of warning signs of AMD. This requires cooperation from healthy elderly volunteers not only for blood sampling but also for pupillary dilatation.~The controls may be the accompanying persons or spouses of AMD patients. It may also be people seen in general consultation without maculopathy or retinopathy with an age greater than 55 years."
62748326|NCT03515226|ACTIVE_COMPARATOR|Traditional Training|20 hours of didactic education and training in CBT principles, depression assessment and cultural competency and 25 hours in dyad role playing of CBT manualized treatment sessions with supervision.
62748327|NCT03515226|EXPERIMENTAL|ITS based training|Traditional training plus the addition of an algorithmic based training computer program that trains clinicians in clinical micro-competencies.
62748328|NCT06606496||Group Control (Group K)|
62748329|NCT06606496||Group Testosterone (Group T)|
62553996|NCT00003744|EXPERIMENTAL|Intercalcated Duct|"The first group, referred to as intercalated duct will include Aadenoid cystic carcinoma, acinic cell carcinoma, malignant mixed tumor, polymorphous low grade adenocarcinoma, undifferentiated carcinoma, and adenocarcinoma.~- Gemcitabine iv 30 min infusion on days 1,8, and 15 of each 28 day cycle.~-- Participants will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
62553997|NCT00003744|EXPERIMENTAL|Excreatory Duct|"The second group, referred to as excretory duct, will include: squamous cell carcinoma and mucoepidermoid carcinoma.~* Gemcitabine iv 30 min infusion on days 1,8, and 15 of each 28 day cycle.~* Participants will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
62553998|NCT02198937||Smokers|Healthy smokers
62748330|NCT01424891|PLACEBO_COMPARATOR|Placebo|Treatment with placebo over 8 weeks
62748331|NCT01424891|ACTIVE_COMPARATOR|Simvastatin 80 mg|treatment with 80 mg of simvastatin over 8 weeks
62553999|NCT02198937||Non-Smokers|Healthy non-smokers
62748332|NCT01424891|ACTIVE_COMPARATOR|Sim10/Eze10|treatment with 10 mg of simvastatin in combination with 10 mg ezetimibe over 8 weeks
62748333|NCT03505788|PLACEBO_COMPARATOR|high-dose loop diuretics+placebo|"* At the moment of randomization (day 1), oral loop diuretics are stopped and the patient receives IV loop diuretics at a dose equal to the double of his oral daily maintenance dose + 500 mg IV bolus of placebo.~* If the patient still have signs of volume overload the next mornings (day 2 and day 3), the patient will receive IV loop diuretics at a dose equal to the oral daily maintenance dose + 500 mg IV bolus of placebo. It the patient has no sign of volume overload at these time points, the study treatment will be stopped."
62748334|NCT03505788|EXPERIMENTAL|high-dose loop diuretics+acetazolamide|"* At the moment of randomization (day 1), oral loop diuretics are stopped and the patient receives IV loop diuretics at a dose equal to the double of his oral daily maintenance dose + 500 mg IV bolus of acetazolamide.~* If the patient still have signs of volume overload the next mornings (day 2 and day 3), the patient will receive IV loop diuretics at a dose equal to the oral daily maintenance dose + 500 mg IV bolus of acetazolamide. It the patient has no sign of volume overload at these time points, the study treatment will be stopped."
62748335|NCT06130449|PLACEBO_COMPARATOR|Placebo|Participant-blinded (Ayr Saline Gel)
62748336|NCT06130449|ACTIVE_COMPARATOR|Intranasal TRT|Participant-blinded (11 mg of Natesto)
62748337|NCT06339242|EXPERIMENTAL|Experimental group|Patients who met the inclusion criteria were given Furmonertinib tablets 160mg daily for continuous oral administration, and combined with Ommaya capsule technology lateral ventricle chemotherapy for local treatment until the disease progression of meningeal metastases or intolerance or death.
62748338|NCT02222909|EXPERIMENTAL|Intervention CBOs|"Will receive co-developed IT intervention developed together with intervention group community based members. Set of primarily web based tools to improve connection with clients, Johns Hopkins Medicine and one another, referrals, and volunteer services."
62748339|NCT02222909|NO_INTERVENTION|Control CBOs|Community Based Organizations that are being followed for data collection only for the period of one year
62748340|NCT01952548|EXPERIMENTAL|Dose 1 Active|
62748341|NCT01952548|EXPERIMENTAL|Dose 2 Active|
62748342|NCT01952548|EXPERIMENTAL|Dose 3 Active|
62748343|NCT01952548|EXPERIMENTAL|Dose 4 Active|
62748344|NCT01952548|EXPERIMENTAL|Dose 5 Active|
62748345|NCT01952548|EXPERIMENTAL|Dose 6 Active|
62748346|NCT01952548|EXPERIMENTAL|Dose 7 Active|
62748347|NCT01952548|PLACEBO_COMPARATOR|Dose 1 Placebo|
62748348|NCT01952548|PLACEBO_COMPARATOR|Dose 2 Placebo|
62748349|NCT01952548|PLACEBO_COMPARATOR|Dose 3 Placebo|
62748350|NCT01952548|PLACEBO_COMPARATOR|Dose 4 Placebo|
62748351|NCT01952548|PLACEBO_COMPARATOR|Dose 5 Placebo|
62374755|NCT03700086|EXPERIMENTAL|Negative wound pressure device (PICO)|The disposable negative wound pressure device (PICO) will be used to cover the midline incision. The dressing is changed on POD3 and removed on POD7. Data are collected on POD3, POD7 and POD30.
62554000|NCT04564092|EXPERIMENTAL|DaTSCAN™ ioflupane (123I) injection|Participants will receive a single intravenous (IV) injection of DaTSCAN™ ioflupane (123I) injection into an arm vein, followed by planar whole-body imaging at prespecified time points over a period of 48 hours after administration. Brain SPECT imaging will be acquired at 3 and 6 hours after administration.
62554001|NCT06302569|EXPERIMENTAL|Pembrolizumab + Enfortumab Vedotin|"Patients will be treated with Pembrolizumab q21 plus Enfortumab Vedotin 1,8q21 for 3 cycles (3 infusion of Pembrolizumab and 6 infusion of Enfortumab Vedotin) then radiological imaging will be repeated and patients with SD, PR or CR will continue pembrolizumab until disease progression, or unacceptable toxicities or completion of treatment (17 cycles). Patients with progressive disease after 3 cycles of study intervention will be treated as per clinical practice.~Patients who will experience progressive disease during pembrolizumab monotherapy treatment could restart Enfortumab Vedotin."
62554002|NCT03099109|EXPERIMENTAL|LY3321367 Dose Escalation|LY3321367 given intravenously (IV).
62554003|NCT03099109|EXPERIMENTAL|LY3321367 + LY3300054 Dose Escalation|LY3321367 and LY3300054 given IV.
62554004|NCT03099109|EXPERIMENTAL|LY3321367 Dose Expansion|LY3321367 given IV.
62554005|NCT03099109|EXPERIMENTAL|LY3321367 + LY3300054 Dose Expansion|LY3321367 and LY3300054 given IV.
62554006|NCT03099109|EXPERIMENTAL|Japanese Arm D LY3321367|LY3321367 given IV.
62554007|NCT03099109|EXPERIMENTAL|Japanese Arm E LY3300054|LY3300054 given IV.
62748352|NCT01952548|PLACEBO_COMPARATOR|Dose 6 Placebo|
62374756|NCT03700086|ACTIVE_COMPARATOR|Standard sterile dressing|The OPsite post-op visible standard sterile dressing will be used to cover the midline incision. Dressing is changed q48h. Data are collected on POD3, POD7 and POD30.
62554008|NCT03099109|EXPERIMENTAL|Japanese Arm F LY3321367 + LY3300054|LY3321367 and LY3300054 given IV.
62567335|NCT01542242|EXPERIMENTAL|Liraglutide|Treatment of Diabetes Mellitus Type 2 with Liraglutide in the setting of Prader Willi Syndrome
62567336|NCT03909230||Day 2 post ovulation|Ultrasound of the endometrium, Endometrial fluid sample, Blood sample
62567337|NCT03909230||Day 4 post ovulation|Ultrasound of the endometrium, Endometrial fluid sample, Blood sample
62567338|NCT01391858|ACTIVE_COMPARATOR|pregabalin|pregabalin (lyrica)
62567339|NCT01391858|PLACEBO_COMPARATOR|placebo|placebo
62567340|NCT02338323|EXPERIMENTAL|Febuxostat|take orally, 40mg per day, for 1 year
62748353|NCT01952548|PLACEBO_COMPARATOR|Dose 7 Placebo|
62748354|NCT04695600|EXPERIMENTAL|Botulinum toxin arm|100 units of botulinum toxin (Botox, Allergan, CA) diluted in 2.5 mL of normal saline will be injected into the cricopharyngeus muscle under direct endoscopic vision using an esophago-gastro-duodenoscope (GIF 190,Olympus). The procedure will be done under general anesthesia in the endoscopy suite as the position of the endoscope is unstable at cricopharynx and the muscle needs to be relaxed during the procedure. Pre-procedure a Ryle's tube will be placed into the stomach under endoscopic guidance which will be kept a day post procedure. Cricopharyngeus muscle will be identified as the muscle at the upper esophageal sphincter located just behind the laryngeal opening. Botulinum toxin will be injected into the muscle in four aliquots into each quadrant using 23 G needle (160cm). Post procedure patient will be observed for an hour for any untoward adverse event
62748355|NCT04695600|PLACEBO_COMPARATOR|Placebo arm|2.5 mL of Normal saline will be injected into the cricopharyngeus muscle under direct endoscopic vision using an esophago-gastro-duodenoscope (GIF 190,Olympus). The procedure will be done under general anesthesia in the endoscopy suite as the position of the endoscope is unstable at cricopharynx and the muscle needs to be relaxed during the procedure. Pre-procedure a Ryle's tube will be placed into the stomach under endoscopic guidance which will be kept a day post procedure. Cricopharyngeus muscle will be identified as the muscle at the upper esophageal sphincter located just behind the laryngeal opening. Post procedure patient will be observed for an hour for any untoward adverse event
62748356|NCT01069263|ACTIVE_COMPARATOR|Intravesical DMSO instillation|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
62748357|NCT01069263|EXPERIMENTAL|Hyperbaric Oxygen Therapy (HBOT)|Overall 60 treatments (5 days per weeks for 12 weeks). 90 minutes every session. Pressure of 2 atm. Inhalation of 100% oxygen.
62748358|NCT03896724|EXPERIMENTAL|Group 1|"n=150. Age 5-17 month-old. 5mcg R21/25mcg Matrix-M at Day 0, 28 and 56 and 1 year.~Following the initial booster, Group 1 will be randomised 2:1 into Groups1a and 1b for 5ug R21/50ug Matrix-M: control. Groups 1a and 1b will receive these second and third booster vaccinations each year prior to the malaria season"
62748359|NCT03896724|EXPERIMENTAL|Group 2|"n=150. Age 5-17 month-old. 5mcg R21/50mcg Matrix-M at Day 0, 28 and 56 and 1 year.~Following the initial booster, Group 2 will be randomised 2:1 into Groups 2a and 2b or 5ug R21/50ug Matrix-M:ccontrol. Groups 2a and 2b will receive these second and third booster vaccinations each year prior to the malaria season"
62748360|NCT03896724|PLACEBO_COMPARATOR|Group 3 (control group)|n=150. Age 5-17 month-old. Rabies Vaccine by the end of the trial.
62567341|NCT02338323|EXPERIMENTAL|Benzbromarone|take orally, 50mg per day, for 1 year
62567342|NCT04145128|EXPERIMENTAL|AG-881|Participants will receive AG-881 10 mg, tablet orally, once in Period 1 followed by AG-881 50 mg, tablet orally, once in Period 2. Period 1 and Period 2 will be separated by a washout period of 20 days between doses.
62567343|NCT04513444|OTHER|Standard arm (A): music listening therapy|
62748361|NCT06331364|EXPERIMENTAL|Intervention Arm|Clinicians will be asked to use the diagnostic portion of the electronic clinical decision tool (eCDST) on their mobile phones, into which they will enter inputs and receive a diagnostic plan. Point of care (POC) testing as advised by the eCDST will be conducted by either clinical staff or trained research staff. If performed by research staff, results will be delivered on paper within 6 hours of testing to ≥ 2 primary clinicians on the team (including the consultant/ attending-level physician or senior registrar). THK, DGM, and DGH do not have an electronic medical record system. Clinicians will be asked to input the results from diagnostic testing and to follow the treatment recommendations as per the eCDST, but will be advised that the final decision regarding prescription of antimicrobials is entirely at their discretion.
62748362|NCT06331364|NO_INTERVENTION|Usual Care Arm|"Study staff will inform the treating clinicians to diagnose and treat patients according to usual practice. Clinicians will be able to order routine diagnostic testing as per standard practice.~These tests may include complete blood count, chemistries, C-reactive protein (CRP) testing, erythrocyte sedimentation rate (ESR) testing, blood and sputum cultures, and chest x-ray or chest CT imaging."
62748363|NCT05852652|EXPERIMENTAL|cryolipolysis and aerobic exercise|in this arm we combined between Three Max cool shaping Cryolipolysis device (ESM-8l00MO; EunSung global, Korea) was utilised. Vacuum controllable heads with cold temperatures ranging from (-10to 5)°C were adjusted according to each patient's tolerance, after careful patient sensation examination and vital sign evaluation before and after each session ,they got two sessions and walked from 30 to 60 minutes in nearby park.Two Cryolipolysis treatments totaling 45 minutes each were administered to each patient in the experimental group at the hypogastrium region, 5 cm below the umbilicus, using an anti-freezing membrane to prevent cold burn, in order to conduct the treatment
62554009|NCT06343753|ACTIVE_COMPARATOR|Opioid free anesthesia (OFA) group|"Analgesia will be provided by syringe containing ketamine, Lidocaine and Dexmedetomidine in induction and maintenance according to lean body weight (LBW).~Induction :~Ketamine: 0.5 mg/kg (IBW), Lidocaine 1 mg/kg and dexmedetomidine 0.5 mg/kg (LBW) for induction to be given in 10 ml syringe over 10 minutes.~Maintenance : The maintenance mixture - 50 cc syringe containing:~50 mcg Dexmedetomidine (0.5 cc of standard 100 mcg/ml solution) 50 mg Ketamine 500 mg Lidocaine (25 ml of standard 2% solution) NaCl up to total 50 ml"
62554010|NCT06343753|ACTIVE_COMPARATOR|Opioid based anesthesia( OBA )group|Fentanyl 2 g/kg (LBW) as induction dose in 10 ml syringe to be given over 10 minutes, and 1 g/kg/h in 50 ml syringe as infusion during operation starting before skin incision for Group TBA.
62554011|NCT00917774|ACTIVE_COMPARATOR|Standard LPS Flex|Nexgen LPS-Flex total knee design used for TKA
62554012|NCT00917774|EXPERIMENTAL|Gender specific LPS-Flex|Gender specific LPS flex design used for TKA in female patients
62554013|NCT03282955|EXPERIMENTAL|Lipidem|i.v. lipid emulsion containing fractionated fish oil (n-3 fatty acid triglycerides)
62554014|NCT03282955|ACTIVE_COMPARATOR|Lipofundin MCT|i.v. lipid emulsion
62554015|NCT01289483|ACTIVE_COMPARATOR|fospropofol 6.5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 6.5 mg/kg.
62554016|NCT01289483|ACTIVE_COMPARATOR|fospropofol 5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 5 mg/kg.
62554017|NCT01289483|ACTIVE_COMPARATOR|fospropofol 3.5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 3 mg/kg.
62554018|NCT01289483|ACTIVE_COMPARATOR|fospropofol 2 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 2 mg/kg.
62554019|NCT03618017|EXPERIMENTAL|CCC Website|The intervention, ConnectedCancerCare (CCC) Website is a personalized, navigation tool that is tailored to patients' preferences for provider roles in follow-up care, their satisfaction with their current primary care provider, and their worry about cancer recurrence. It involves a personalized, patient-facing website which includes a baseline survey, tailored educational modules, and a guide for their survivorship care, as well as a text or email based reminder system. The intervention also includes a provider-facing summary document, which will be faxed to both the oncology and primary care teams.
62554020|NCT03618017|OTHER|Static care plan|"The control arm will receive is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as standard of care."
62748364|NCT02959541|OTHER|Calciumfolinat 60 mg/m²|Intravenous infusion of Calciumfolinat 60 mg/m²given to patients with colon cancer at the time for the operation of the colon cancer.
62748365|NCT02959541|OTHER|Calciumfolinat 200 mg/m²|Intravenous infusion of Calciumfolinat 200 mg/m² given to patients with colon cancer at the time for the operation of the colon cancer.
62748366|NCT02959541|OTHER|Calciumfolinat 500 mg/ m²|Intravenous infusion of Calciumfolinat 500 mg/ m² given to patients with colon cancer at the time for the operation of the colon cancer.
62748367|NCT06102122|OTHER|Patients well established on tube feeds will act as their own control|Patients will switch from current to new tube feed.
62748368|NCT05137171|EXPERIMENTAL|AK105 and anlortinib|AK105 200mg iv q3w;anlotinib 12mg 2w on/1w off po qd;21 days as a cycle until PD,intolerable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.
62748369|NCT02132923||Patients with respiratory syncytial virus (RSV) infection|The RSV infection is laboratory confirmed
62748370|NCT06607679||Patients Receiving ECT|
62748371|NCT05732506||Patients|Elderly patients diagnosed with nonvalvular atrial fibrillation who meet the frailty criteria and who had been receiving anticoagulant treatment with Edoxaban for no more than 6 months prior to inclusion in the study.
62748372|NCT04640558||Group 1. Latent Myofascial Trigger Point Group|24 participants who will be clinically diagnosed with unilateral latent myofascial trigger point in the dominant side gluteus medius muscle.
62554021|NCT05883124|EXPERIMENTAL|Rivastigmine twice-weekly 9,5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
62554022|NCT05883124|ACTIVE_COMPARATOR|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
62554023|NCT06387420|EXPERIMENTAL|AK117+Azacitidine+Venetoclax|"Phase Ib: Subjects will receive: A117: different doses on every 2 weeks, azacitidine: 75 mg/m\^2 on Days 1-7 each cycle, venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter;~Phase II: Subjects will receive: AK117: the recommended Phase 2 dose (RP2D) on every two weeks, azacitidine: 75 mg/m\^2 on Days 1-7 each cycle, venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter."
62748373|NCT04640558||Group 2. Non-Latent Myofascial Trigger Point Group|24 participants who don't have latent myofascial trigger point.
62554024|NCT06387420|PLACEBO_COMPARATOR|Placebo+Azacitidine+Venetoclax|Phase II: Subjects will receive: placebo: the recommended Phase 2 dose (RP2D) on every two weeks, azacitidine: 75 mg/m\^2 on Days 1-7 each cycle, venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter.
62748374|NCT05525091|EXPERIMENTAL|Feeding Assessment|Feeding assessment of High-risk premature infants
62748375|NCT05091697|EXPERIMENTAL|Multicomponent treatment VIRTUAL FIBROWALK + TAU|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
62748376|NCT05091697|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
62748377|NCT06355947|NO_INTERVENTION|Stage 1:Healthy people|To establish a baseline and ensure reliability, and to explore the relationship between dual-task gait performance and dual-task cycling
62748378|NCT06355947|NO_INTERVENTION|No Intervention: Stage 2:PD people|To explore the relationship between dual-task gait and dual-task cycling performances in individuals with Parkinson's Disease (PD)
62748379|NCT06355947|EXPERIMENTAL|Stage 3:PD cycling training group|Cycling training conducted with cognitive tasks
62554025|NCT03722589|ACTIVE_COMPARATOR|Flublok (Recombinant)|Flublok® Quadrivalent by Sanofi Pasteur, 45µg of HA per strain
62554026|NCT03722589|ACTIVE_COMPARATOR|Flucelvax (Cell-based)|Flucelvax™ Quadrivalent by Seqirus, Inc., 15µg of HA per strain
62554027|NCT03722589|ACTIVE_COMPARATOR|Fluarix (Egg-based)|Fluarix® Quadrivalent by GlaxoSmithKlein, 15µg of HA per strain
62554028|NCT03722589|ACTIVE_COMPARATOR|Fluzone (Egg-based)|Fluzone® Quadrivalent by Sanofi Pasteur, 15µg of HA per strain
62748380|NCT06355947|EXPERIMENTAL|Stage 3: PD treadmill training group|Treadmill training conducted with cognitive tasks
62748381|NCT06355947|NO_INTERVENTION|Stage 3:PD Control group|Control group
62748382|NCT04052763||High-risk ACS patients|High-risk ACS patients admitted to the emergency departement witch chest pain.
62748383|NCT03915574|EXPERIMENTAL|Dural Puncture Epidural|Participants will receive a dural puncture epidural block with a 25 gauge spinal needle followed by a standard epidural infusion (0.0625% bupivacaine + 2mcg/ml fentanyl)
62748384|NCT03915574|ACTIVE_COMPARATOR|Standard Epidural|Participants will have standard epidural infusion followed by a standard epidural infusion (0.0625% bupivacaine + 2mcg/ml fentanyl)
62748385|NCT02383654|OTHER|Compassionate Treatment|ALS patients are received Intravenous and intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells (ADSCs), Rehabilitation.
62748386|NCT03907865|EXPERIMENTAL|intense|Patients have been randomized to receive Softacort eye drops for 12 days 4 times daily followed by 2 days twice daily treatment resulting in a total time of 14 days
62748387|NCT03907865|EXPERIMENTAL|standard|Patients have been randomized to receive Softacort eye drops for 8 days 3 times daily followed by 3 days twice daily treatment resulting in a treatment time of 11 days total
62748388|NCT02481648|EXPERIMENTAL|ARM1: Exercise Intervention|"The exercise program is a 4-12 weeks progressive combined resistance and aerobic exercise for participants from time of diagnosis to RP.~Participants will undergo twice weekly group-training (four-six participants/group) combined aerobic-resistance sessions (1hr per session), supervised by trained exercise therapists. In addition, participants will undergo home-based aerobic exercise independently three times a week with the goal to meet the current physical activity guidelines for cancer survivors (150min/week of moderate intensity aerobic activity and two resistance training sessions per week). Participants will also be supplied with the Canadian Physical Activity and Sedentary Behavior Guidelines Handbook and accompanying Log Sheets."
62748389|NCT02481648|NO_INTERVENTION|ARM2: Control Group|Participants will be asked to exercise as they normally would and will be asked to record their exercise activity on provided activity logs.
62748390|NCT04950712||Overall Study Group|Patients aged 18 years old or above, with HSV-2 genital herpes, who are recruited in specific community settings in the United States and in Europe.
62748391|NCT00096174|EXPERIMENTAL|Cisplatin, C225, Radiation|"* Cetuximab therapy: Patients receive an initial loading dose of cetuximab intravenously (IV) over 2 hours on day 1. Patients then receive cetuximab IV over 1 hour on days 8, 15, 22, 29, 36, 43, 50, and 57.~* Chemoradiotherapy: Beginning on day 15 of cetuximab therapy, patients undergo radiotherapy once daily, 5 days a week, for at least 7 weeks. Patients also receive cisplatin IV over 1-2 hours on days 15, 36, and 57.~* Cetuximab maintenance therapy: After the completion of chemoradiotherapy, patients continue to receive cetuximab IV over 1 hour once weekly for 6-12 months."
62748392|NCT01384448|EXPERIMENTAL|Initial Stress Echocardiography|
62748393|NCT01384448|EXPERIMENTAL|Initial Coronary CT Angiography|
62748394|NCT06607536|EXPERIMENTAL|Calcium Chloride|Mini implant immersed in the calcium chloride 0.1M solution
62748395|NCT06607536|ACTIVE_COMPARATOR|Acid Etch|mini implant etched with hydrochloric acid
62748396|NCT06607536|NO_INTERVENTION|machined mini implant|non surface treated mini implant
62748397|NCT02392390|EXPERIMENTAL|The study population|"A total of 10 leg ulcer patients will be recruted for this study. All will have the experimental treatment.~Intervention: Topical Dynamic Phototherapy (TDP)"
62748398|NCT00227669|ACTIVE_COMPARATOR|Arm I: Gemcitabine|"Gemcitabine at Day 1, Day 8 and Day 15. No treatment at Day 22.~1 cycle = 28 days.~Treatment duration: 8 months"
62748399|NCT00227669|EXPERIMENTAL|Arm II: Gemcitabine + Docetaxel|"Gemcitabine at Day 1 and Day 8. No treatment at Day 15. Docetaxel at Day 8.~1 cycle = 21 days.~Treatment duration: 6 months"
62748400|NCT05921682||Patients with heat stroke|Patients with heat stroke presenting to the emergency department at the study site
62748401|NCT05148013|EXPERIMENTAL|Pilates exercise group|Pilates exercise group will receive a total of 20 sessions of 30 minute Pilates exercises 5 days a week which will be performed under the supervision of a physiotherapist.
62748402|NCT05148013|EXPERIMENTAL|PNF exercise group|A total of 20 sessions of PNF exercises for 30 minutes, 5 days a week, will be performed individually with a physiotherapist.
62748403|NCT03287024|EXPERIMENTAL|BeGrow Stent System|All enrolled subjects will receive the BeGrow Stent System
62748404|NCT05553340|EXPERIMENTAL|Technology Educational|The intervention will be carried out by nurses and will consist of a virtual educational action through a massive, open and online course (MOOC) that seeks to equip the family caregiver to assist the elderly at home in care, such as hygiene, feeding, positioning and transfer, based on in the Guidance Manual for Family Caregivers of Elderly People with Stroke. A hotline will also be available for participants to contact if they have any questions.
62374757|NCT05949463|EXPERIMENTAL|Intermittent group|The intermittent group students performed an intermittent teaching unit twice a week for eight weeks aimed at promoting healthy physical activity habits. Specifically, the last 15 minutes of each lesson were used. The rest of lessons' time other contents were worked on with no relation to any health physical activity habit (i.e., acrosport, badminton, basketball, volleyball, soccer and athletics).
62554029|NCT03722589|ACTIVE_COMPARATOR|Fluzone (Egg-based) High-Dose|Fluzone® Trivalent High-Dose by Sanofi Pasteur, 60µg of HA per strain
62554030|NCT04048291|EXPERIMENTAL|Brisk walking and balance training|"1. Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session~2. Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session~3. Participants practice own balance exercise and brisk walking 2-3 times/week (to aim at 150 min of moderate intensity of brisk walking per week at 40-60% of heart rate reserve)"
62554031|NCT04048291|ACTIVE_COMPARATOR|Upper limb exercise|"1. Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session~2. Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session~3. Participants practice own upper limb exercise 2-3 times/week (to aim at 150 min of exercise per week)"
62554032|NCT02719184||Healthy subjects|All eligible healthy subjects were included in this group. The observational period is 156 weeks.
62554033|NCT02719184||COPD GOLD I|All eligible patients with Chronic Obstructive Pulmonary Disease (COPD) grade 1 according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) were included in this group. The observational period is 156 weeks.
62554034|NCT02719184||COPD GOLD II|All eligible patients with Chronic Obstructive Pulmonary Disease (COPD) grade 2 according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) were included in this group. The observational period is 156 weeks.
62748405|NCT05553340|NO_INTERVENTION|Usual|Control group participants will receive initial and final assessments, but will not have access to the course.
62374758|NCT05949463|ACTIVE_COMPARATOR|Control group|The control group students also carried out two Physical Education lessons a week during the intervention period. During these lessons, contents of handball, basketball, alternative sports and traditional games were developed. However, this group did not wear physical activity activity wristbands or receive any behavior modification specific strategy developed in the intermittent group.
62374759|NCT01834469|OTHER|ICG NIR imaging|see Summary and description iv injection of ICG
62374760|NCT02809391|ACTIVE_COMPARATOR|Orthotic|Recruited participants will be asked to wear the customizable foot orthotic, from baseline testing to a follow-up at 6 weeks post-baseline. Outcome measures at 6 weeks will be compared to those at baseline.
62374761|NCT02809391|ACTIVE_COMPARATOR|Orthotic+Textured Top Cover|At 6 weeks post-baseline, participants will received a different orthotic which has a textured material used as its top cover. Testing at 6 weeks post-baseline will determine if acute changes occur as a result of wearing the orthotic with textured top cover. Testing at 12 weeks post-baseline will determine if long-term changes occur as a result of the orthotic with textured top cover.
62374762|NCT01341860||controls|control group with a BMI of less thatn 25kg/m2
62374763|NCT01341860||obese group|Obese patients with BMI 25-30 kg/m2
62374764|NCT04849676|EXPERIMENTAL|Upper limb subacute spinal cord injury (sUL)|"Intervention: neurofeedback. Participants will receive visual feedback on a screen.~Diagnostic Tests:~Modified Ashworth Scale grading muscle resistance to movement (all limbs tested)~Perceived Spasticity level questionnaire on impact of spasticity~Spinal Cord Independence Measure questionnaire on level of independence of patients~Diary of spastic episodes~Grip strength - measure of hand and forearm muscle strength using dynamometer~Instrumented Pendulum test - oscillations when forearm is dropped from a resting position~Hand grip - closing and opening the fist recorded with Kinect (Microsoft) device~EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria)~Brief Visual Analog Scale self-assessment of performance and mental strategies~Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)"
62554035|NCT02719184||COPD GOLD III|All eligible patients with Chronic Obstructive Pulmonary Disease (COPD) grade 3 according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) were included in this group. The observational period is 156 weeks.
62554036|NCT02719184||COPD and A1AT Deficiency|All eligible patients with Chronic Obstructive Pulmonary Disease (COPD) and Alpha one anti-trypsin (A1AT) deficiency were included in this group. The observational period is 156 weeks.
62567344|NCT04513444|EXPERIMENTAL|Experimental arm (B): music listening and hypnosis therapy|
62748406|NCT00305032|EXPERIMENTAL|1|
62748407|NCT02379221|EXPERIMENTAL|Injectable / Topical|Half of the face is injected with local anesthesia (lidocaine-epinephrine), the other half is treated with topical anesthesia (topicaine gel) per randomize method.
62748408|NCT03800446|OTHER|Intervention|All patients will undergo testing with the study intervention (point of care) and routine testing with serum ferritin (venous blood sample).
62748409|NCT01683006|ACTIVE_COMPARATOR|Neuromuscular blocker group|"Continuous application of neuromuscular blockers during therapeutic hypothermia.~Bolus application of placebo in case of shivering."
62748410|NCT01683006|PLACEBO_COMPARATOR|Placebo group|"Continuous application of placebo during therapeutic hypothermia.~Bolus application of neuromuscular blockers in case of shivering."
62391506|NCT02377401|EXPERIMENTAL|Zanamivir 600 mg|Subjects will receive a single dose of IV zanamivir 600 mg on Day 1 morning. The repeat dose session will begin on Day 3 evening. Subjects will be receive IV zanamivir 600 mg every 12 hours for 5 days. Each dose will be administrated intravenously at a constant rate over 30 minutes (500 mL/hr).
62554037|NCT01811472|PLACEBO_COMPARATOR|Placebo|Patients randomized to Placebo arm, received matching placebo to 5 mg, 10 mg and 20 mg pradigstat (LCQ908) once daily for 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
62554038|NCT01811472|EXPERIMENTAL|pradigastat (LCQ908) 5mg/10mg|Patients, randomized to pradigastat 5/10 mg, initially began with pradigastat (LCQ908) 5 mg once daily and then were up-titrated, if pradigastat (LCQ908) 5 mg once daily was tolerated, to pradigastat 10 mg once daily at Week 2. Total treatment duration was 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
62748411|NCT04469920|EXPERIMENTAL|Group 1- mild hepatic impairment without evidence of PHT|Subject with mild hepatic impairment without evidence of portal hypertension (PHT) based on Class A CPT score 5-6 points
62748412|NCT04469920|EXPERIMENTAL|Group 2- mild hepatic impairment with evidence of PHT|Subjects with mild hepatic impairment with evidence of portal hypertension based on Class A CPT score 5-6 points
62748413|NCT04469920|EXPERIMENTAL|Group 3-moderate hepatic impairment|Subjects with moderate hepatic impairment based on Class B CPT score 7-9 points
62748414|NCT04469920|EXPERIMENTAL|Group 4- severe hepatic impairment|Subjects with severe hepatic impairment based on Class C CPT score 10-14 points)
62748415|NCT04469920|EXPERIMENTAL|Group 5-cholestatic liver disease|Subjects with cholestatic liver disease
62748416|NCT04469920|EXPERIMENTAL|Group 6-Non-cirrhotic Advanced Fibrosis secondary to NASH|Subjects with Non-cirrhotic Advanced Fibrosis secondary to NASH
62748417|NCT04469920|EXPERIMENTAL|Group 7- normal hepatic function|Subjects with normal hepatic function
62748418|NCT04323137|NO_INTERVENTION|Control|This group receives no additional pro-vaccination intervention beyond the health system's normal efforts. Although some patients are currently targeted for flu vaccination encouragement due to a non-ML assessment that they are at high risk for complications, these patients are not told that they are at high risk or that they have been targeted.
62748419|NCT04323137|EXPERIMENTAL|High risk only|This group receives messages telling them they have been identified to be at high risk for flu complications without specifying how or why the health system believes this to be the case.
62748420|NCT04323137|EXPERIMENTAL|High risk based on medical records|This group receives messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records.
62748421|NCT04323137|EXPERIMENTAL|High risk based on algorithm|This group receives messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records by an AI/ML system.
62748422|NCT04323137|NO_INTERVENTION|Sub-threshold patients|Patients in this group is in the top 11-20% of risk for flu and complications, slightly lower risk than those included in the intervention, who are in the top 10% of risk for flu and complications. This group of patients does not receive an intervention, but are monitored for flu shots as a comparison to target patients.
62748423|NCT04323137|NO_INTERVENTION|Household members|This group of patients share an address with target high-risk patients (in arms 1-4). This group does not receive an intervention but is monitored for spillover effects of the intervention.
62748424|NCT06140940|EXPERIMENTAL|active stimulation group: 20 participants with aphantasia will receive a session of active HD-tDCS|Participants will receive a session of active HD-tDCS at a current intensity of 4 mA for a duration of 15min. The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task).
62748425|NCT06140940|PLACEBO_COMPARATOR|placebo stimulation group: 20 participants with aphantasia will receive a session of sham HD-tDCS|"High-definition transcranial direct current (HD-tDCS), sham condition. Participants will receive a session of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 4mA during the 30 first seconds at the beginning of the 15-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation.~The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task)."
62748426|NCT02668900|EXPERIMENTAL|Decision support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
62748427|NCT02668900|NO_INTERVENTION|Usual care|The control group will not receive the decision support intervention prior to consultation with the physician.
62748428|NCT02087618|ACTIVE_COMPARATOR|Kodro+|Will begin Kodro program at baseline
62748429|NCT02087618|PLACEBO_COMPARATOR|Kodro+D|Will begin Kodro program 12-weeks post baseline
62748430|NCT00308412|EXPERIMENTAL|1|Two 10\^5 PFU doses of rHPIV3cp45 vaccine given as nose drops to healthy infants and children aged 6 to 36 months of age. The two doses are given 4 to 10 weeks apart.
62748431|NCT00308412|PLACEBO_COMPARATOR|2|Two placebo vaccinations given as nose drops to healthy infants and children aged 6 to 36 months of age. The two doses are given 4 to 10 weeks apart.
62748432|NCT03195244|NO_INTERVENTION|Observation|
62748433|NCT03195244|ACTIVE_COMPARATOR|One-on-one Aquatic Therapy|
62748434|NCT03195244|EXPERIMENTAL|Group Aquatic Therapy|
62748435|NCT01950793|ACTIVE_COMPARATOR|steroid|"used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
62554039|NCT01811472|EXPERIMENTAL|pradigastat (LCQ908) 10mg/20mg|Patients, randomized to pradigastat 10/20 mg, initially began with pradigastat (LCQ908) 10 mg once daily and then were up-titrated, if pradigastat (LCQ908) 10 mg once daily was tolerated, to pradigastat 20 mg once daily at Week 2. Total treatment duration was 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
62748436|NCT01950793|EXPERIMENTAL|Hyaluronic acid|"used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
62748437|NCT03014310|EXPERIMENTAL|Arm 1: 3.75 mcg A/H5N8 + AS03|3.75 mcg A/H5N8 + AS03 given IM on Day 1 and 22, n=30
62748438|NCT03014310|EXPERIMENTAL|Arm 2: 15 mcg A/H5N8 + AS03|15 mcg A/H5N8 + AS03 given IM on Day 1 and 22, n=30
62748439|NCT03014310|ACTIVE_COMPARATOR|Arm 3: 15 mcg A/H5N8 unadjuvanted|15 mcg A/H5N8 unadjuvanted given IM on Day 1 and 22, n=15
62748440|NCT03014310|EXPERIMENTAL|Arm 4: 3.75 mcg A/H5N8 + MF59|3.75 mcg A/H5N8 + MF59 given IM on Day 1 and 22, n=30
62748441|NCT03014310|EXPERIMENTAL|Arm 5: 15 mcg A/H5N8 + MF59|15 mcg A/H5N8 + MF59 given IM on Day 1 and 22, n=30
62748442|NCT03014310|ACTIVE_COMPARATOR|Arm 6: 15 mcg A/H5N8 unadjuvanted|15 mcg A/H5N8 unadjuvanted given IM on Day and 22, n=15
62748443|NCT05969756|EXPERIMENTAL|Fluoride varnish group|5% sodium fluoride varnish, 3M, USA
62748444|NCT05969756|EXPERIMENTAL|Conventional etch and rinse sealant group|Resin-based composite sealant, 3M, USA
62554040|NCT03308214||septic shock|Patients with septic shock treat with Imipenem
62554041|NCT03308214||non-septic shock|Patients with infection but not septic shock treat with Imipenem
62554042|NCT01897428|ACTIVE_COMPARATOR|Reference arm|Treated with Reference (bepotastine besilate 10 mg)
62554043|NCT01897428|EXPERIMENTAL|Test arm|Treated with Test (bepotastine salicylate 9.64 mg)
62748445|NCT05969756|ACTIVE_COMPARATOR|Self-etch sealant group|Self-etch primed sealant, Shofu, Japan
62554044|NCT06263192||AMH < 1.1 ng/ml|
62748446|NCT03447899|EXPERIMENTAL|ABC Intervention|"The investigators will deliver the Attachment and Biobehavioral Catch-up (ABC) in the home weekly using live, in-room coaching, to give caregivers feedback as they use targeted skills during interactions with the child. The intervention will last 10 sessions. Study participants in both groups will complete study measures at baseline, 1 month, 3 months, post-intervention, 6 months, and 12 months."
62748447|NCT03447899|NO_INTERVENTION|Standard of Care|"Subjects will receive normal standard of care without the Attachment and Biobehavioral Catch-up (ABC)."
62748448|NCT00266214|EXPERIMENTAL|Lidocaine Patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.
62748449|NCT00266214|PLACEBO_COMPARATOR|Placebo|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.
62554045|NCT06263192||AMH > 1.1 ng/ml|
62554046|NCT02404480|EXPERIMENTAL|Cohort 1|PTC 596 administered twice daily- Dose level 0.65mg/kg
62748450|NCT03625830|EXPERIMENTAL|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|
62748451|NCT03625830|ACTIVE_COMPARATOR|Rapid exchange PTCA Balloon Catheter (SeQuent® Neo)|
62748452|NCT02937298|EXPERIMENTAL|Control Meal|Control meal using standard breakfast foods.
62748453|NCT02937298|EXPERIMENTAL|Berry Treatment|This will consist of standard breakfast foods plus a berry smoothie.
62748454|NCT02937298|EXPERIMENTAL|Sea Buckthorn Treatment|This will consist of standard breakfast foods plus a sea buckthorn berry smoothie.
62748455|NCT02937298|EXPERIMENTAL|Wild Garlic Treatment|This will consist of standard breakfast foods plus a wild garlic dip.
62748456|NCT00395135|EXPERIMENTAL|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
62748457|NCT00395135|PLACEBO_COMPARATOR|Matching Placebo BID|Matching placebo tablet each morning and evening
62748458|NCT00695955|EXPERIMENTAL|Azilsartan Medoxomil|
62748459|NCT00567671|EXPERIMENTAL|Treatment|Corneal collagen cross-linking
62748460|NCT00567671|SHAM_COMPARATOR|Control|Sham Treatment
62748461|NCT06092216|EXPERIMENTAL|Spesolimab|900 mg of spesolimab intravenously (IV)
62748462|NCT00347438|EXPERIMENTAL|Capecitabine|Capecitabine will be given at 1000mg/m2 twice daily for 2 weeks x 8 cycles, with a one-week pause in-between cycles.
62748463|NCT05704621|EXPERIMENTAL|secondary cytoreductive surgery followed by chemotherapy|surgery arm
62748464|NCT05704621|ACTIVE_COMPARATOR|chemotherapy|no surgery arm
62748465|NCT02569372|EXPERIMENTAL|GC1102 80,000 IU(Single does)|GC1102 80,000 IU(Single does) I.V.
62748466|NCT02569372|EXPERIMENTAL|GC1102 120,000 IU(Single does)|GC1102 120,000 IU(Single does) I.V.
62748467|NCT02569372|EXPERIMENTAL|GC1102 180,000 IU(Single does)|GC1102 180,000 IU(Single does) I.V.
62748468|NCT02569372|EXPERIMENTAL|GC1102 240,000 IU(Single does)|GC1102 240,000 IU(Single does) I.V.
62748469|NCT02569372|EXPERIMENTAL|GC1102 80,000 IU(Multiple does)|GC1102 80,000 IU(Multiple does) I.V.
62748470|NCT02569372|EXPERIMENTAL|GC1102 120,000 IU(Multiple does)|GC1102 120,000 IU(Multiple does) I.V.
62748471|NCT02569372|EXPERIMENTAL|GC1102 180,000 IU(Multiple does)|GC1102 180,000 IU(Multiple does) I.V.
62748472|NCT02569372|EXPERIMENTAL|GC1102 240,000 IU(Multiple does)|GC1102 240,000 IU(Multiple does) I.V.
62748473|NCT02309983|ACTIVE_COMPARATOR|Electrical Stimulation Alone Group|Group 1 will receive 1hr of electrical stimulation while lying down followed by 15 min of overground training. Electrical stimulation will be applied through leads and self-adhesive electrodes over muscles of both legs. Two electrodes will be used for each muscle. Electrical stimulation will be induced by using the EMPI, Inc., St. Paul, MN \[Respond Select Neuromuscular Stimulation\]. There will be 60 sessions/3x week for 20 weeks.
62748474|NCT02309983|PLACEBO_COMPARATOR|Stand Retraining Alone with BWS|Group 2 will receive standing retraining with BWS alone on a treadmill without functional electrical stimulation. Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. The duration of stand retraining sessions will be up to 1 hour or determined by subject's fatigue. There will be 60 sessions/3x week for 20 weeks.
62554047|NCT02404480|EXPERIMENTAL|Cohort 2|PTC 596 administered twice daily-Dose level 1.3mg/kg
62748475|NCT02309983|EXPERIMENTAL|Stand Retraining and ES Group|Group 3 will receive standing retraining with BWS with electrical stimulation, followed by 15 min of overground training. Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. Electrical stimulation will start while participant is seated and before he/she is brought up to full standing. There will be 60 sessions/3x week for 20 weeks.
62748476|NCT02997553|EXPERIMENTAL|sentinel lymph node detection|"Each patient receive both injections of Technetium99 (standard care) and indocyanine green.~The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery."
62748477|NCT06309017|EXPERIMENTAL|Nutrition specialist|Participants will be assigned to this arm if the subject is determined malnourished. They will be sent to a nutrition specialist for a nutrition focused visit and will be provided standard of care intervention prior surgery.
62748478|NCT06309017|ACTIVE_COMPARATOR|Standard of Care|Participants that show no signs of malnutrition will be assigned to this arm. The subject will be provided with education and schedule of Ensure® Surgery Immunonutrition shakes for prior to surgery as per standard of care.
62748479|NCT04984265|EXPERIMENTAL|Stereotactic Body rRadiotherapy (SBRT)|SBRT targeting the area of the circuit of Ventricular Tachycardia
62748480|NCT04451564|EXPERIMENTAL|MORE Mindfulness oriented recovery enhancement group|MORE Mindfulness oriented recovery enhancement group
62748481|NCT04451564|NO_INTERVENTION|Control|wait-list
62748482|NCT05076279|EXPERIMENTAL|Single port or reduced ports|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection
62748483|NCT04613557|EXPERIMENTAL|CYAD-211|Infusion post preconditioning non-myeloablative chemotherapy
62748484|NCT04246437|EXPERIMENTAL|[18F]F-DOPA|All patients will receive \[18F\]F-DOPA for PET imaging to measure pre-synaptic dopamine in the brain.
62748485|NCT02704702|OTHER|Sequence 1 (ABC)|"Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment C)~There will be a washout of at least 7 days between the each period."
62748486|NCT02704702|OTHER|Sequence 2 (ACB)|"Period 1(Treatment A) → Period 2(Treatment C) → Period 3(Treatment B)~There will be a washout of at least 7 days between the each period."
62748487|NCT02704702|OTHER|Sequence 3 (BAC)|"Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment 3)~There will be a washout of at least 7 days between the each period."
62748488|NCT02704702|OTHER|Sequence 4 (BCA)|"Period 1(Treatment B) → Period 2(Treatment C) → Period 3(Treatment A)~There will be a washout of at least 7 days between the each period."
62748489|NCT02704702|OTHER|Sequence 5 (CAB)|"Period 1(Treatment C) → Period 2(Treatment A) → Period 3(Treatment B)~There will be a washout of at least 7 days between the each period."
62748490|NCT02704702|OTHER|Sequence 6 (CBA)|"Period 1(Treatment C) → Period 2(Treatment B) → Period 3(Treatment A)~There will be a washout of at least 7 days between the each period."
62391507|NCT06354075||Patient who receives a consultation before an interventional procedure|Any patient who receives a consultation before an interventional procedure will be included. Questionary will be administrated.
62748491|NCT02734771|EXPERIMENTAL|BV+mini-R-CHP|Brentuximab vedotin 1.8 mg/kg IV day 1 for six cycles Rituximab 375 mg/m2 IV day 1 for six cycles Cyclophosphamide 400 mg/m2 IV day 1for six cycles Doxorubicin 25 mg/m2 IV day 1 for six cycles Prednisone 40 mg/m1 PO days 1-5 for six cycles
62748492|NCT03998670|EXPERIMENTAL|Prism Group|Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by prism and alternate cover test (PACT) at distance or near) equally divided between the 2 lenses will be prescribed to the participant
62748493|NCT03998670|PLACEBO_COMPARATOR|Non-Prism Group|Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism will be prescribed to the participant
62748494|NCT03379857|OTHER|Cannabis User|
62748495|NCT02324205|EXPERIMENTAL|DBT and FFDM|Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT). Digital Breast Tomosynthesis: 3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device. Full-Field Digital Mammography: 2D imaging of the breast using Full-Field Digital Mammography (FFDM) device.
62748496|NCT06608056|EXPERIMENTAL|Tramadol|Patients received injection tramadol 50 mg intravenously every 8 hourly following surgery
62748497|NCT06608056|EXPERIMENTAL|Ketorolac|Patients received injection tramadol 30 mg intravenously every 8 hourly following surgery
62748498|NCT04736368|EXPERIMENTAL|EDIP Group|CD participants will receive EDIP diet information
62748499|NCT04736368|PLACEBO_COMPARATOR|Control Group|CD participants will be given diet suggestions according to routine experience.
62748500|NCT06399432|ACTIVE_COMPARATOR|Mediterranean Diet|Participants in this arm will follow the Mediterranean Diet.
62748501|NCT06399432|NO_INTERVENTION|No Dietary Intervention|Participants in this arm will have no dietary intervention.
62748502|NCT01895543|EXPERIMENTAL|EBX10|Elobixibat 10 mg
62748503|NCT05557539|OTHER|all patients|The intervention consists of taking blood samples, urine sample and naso-pharyngeal sample at two different time points (at inclusion and at week8-12).
62748504|NCT05364970|EXPERIMENTAL|VR_1PP|Virtual training with an avatar observed from the first-person perspective
62748505|NCT05364970|ACTIVE_COMPARATOR|VR_3PP|Virtual training with an avatar observed from the third-person perspective
62391508|NCT03458351|ACTIVE_COMPARATOR|Remote ischemic preconditioning|"Remote ischemic conditioning after anesthesia induction~- four cycles of 5 min of ischemia followed by 5 min of reperfusion by inflation to 200 mm Hg and deflation of a blood pressure cuff on the upper arm"
62554048|NCT02404480|EXPERIMENTAL|Cohort 3|PTC 596 administered twice daily-2.6mg/kg
62554049|NCT02404480|EXPERIMENTAL|Cohort 4|PTC 596 administered twice daily-Dose level 5.2mg/kg
62554050|NCT02404480|EXPERIMENTAL|Cohort 5|PTC 596 administered twice daily-Dose level 10mg/kg
62554051|NCT02404480|EXPERIMENTAL|Cohort 6|PTC 596 administered twice daily-Dose level 7mg/kg
62554052|NCT02404480|EXPERIMENTAL|Cohort 7 (Bio Marker cohort)|PTC 596 administered twice daily-Dose level 5.2mg/kg
62554053|NCT03078686|ACTIVE_COMPARATOR|Control ARM 1|Control: 1) HD-PRP + Matristem Matrix (ACell) (Current Standard of Care); 2) Platelet Rich Plasma Concentrate)
62554054|NCT03078686|EXPERIMENTAL|Emulsification tSVF + PRP ARM 2|HD-PRP + Emulsified AD-tSVF; Intervention: Platelet Rich Plasma Concentrate
62554055|NCT03078686|EXPERIMENTAL|Emulsification tSVF + PRP + cSVF ARM 3|tSVF; PRP; cSVF cell enriched biocellular therapeutic mix
62554056|NCT03078686|EXPERIMENTAL|cSVF in Normal Saline IV ARM 4|cSVF + Normal Saline IV (500 cc) Infusion
62554057|NCT04028557|EXPERIMENTAL|Customized CDS|The customized CDS will be designed and implemented with comprehensive application of known best practice principles in CDS design. The recommendation will be to initiate an evidence-based beta blocker for heart failure.
62554058|NCT04028557|ACTIVE_COMPARATOR|Commercial CDS|The commercial CDS is available to all institutions using the Epic electronic health record vendor, but violates some CDS design best practices, notably not being tailored to the end users of a given health system. The recommendation will be to initiate an evidence-based beta blocker for heart failure.
62748506|NCT05364970|NO_INTERVENTION|NO_VR|No VR training administered
62748507|NCT01115894|EXPERIMENTAL|active medication + psychotherapy|
62748508|NCT01115894|EXPERIMENTAL|placebo + psychotherapy|
62748509|NCT01115894|EXPERIMENTAL|active medication+brief supportive counseling|
62748510|NCT01115894|EXPERIMENTAL|placebo + brief supportive counseling|
62748511|NCT02429219|ACTIVE_COMPARATOR|Transurethral Resection|Transurethral Resection of the Prostate in Saline irrigation with ethanol
62748512|NCT02429219|EXPERIMENTAL|Photoselective vaporisation|Photoselective vaporisation of the Prostate in Saline irrigation with ethanol
62748513|NCT01940250|PLACEBO_COMPARATOR|Sterile water|"Sterile water will be packaged identically to the active comparator.~Each patient randomized to the placebo arm of the trial will receive a loading dose of 0.5ml/kg intravenous over 20 minutes , followed by a maintenance dose of 0.3 ml/kg/hr to 0.5 ml/kg/hr randomly adjusted by an independent doctor to mimic adjustments made in the active comparator arm for 72 hrs."
62748514|NCT01940250|ACTIVE_COMPARATOR|Magnesium sulphate|"Each patient randomized to the treatment arm of the trial will receive a loading dose of 50mg/kg intravenous over 20 minutes (0.5ml/kg), followed by a maintenance dose of 30-50 mg/kg/hr (0.3 ml/kg/hr to 0.5 ml/kg/hr) for 72 hrs.~The maintenance dose will be determined by increasing the loading infusion dose 0.1 ml/kg/hr (10mg/kg/hr) every 15 minutes to a maximum dose of 0.5 ml/kg/hr (50 mg/kg/hr), with the following caveats:~* If the systolic BP decreases to \< 90th percentile for age, gender and length the dose will be reduced by 1 stage every 15 mins~* If the systolic BP increases to the levels detailed in the study protocol for treatment failure, action will be taken as indicated~* If the systolic BP decrease rapidly more than 25% over 15 minutes~* If the plasma Mg level \> 2.5 mmol/l or \< 1.8 mmol/l a 25% increase or decrease in the infusion rate will be implemented as appropriate."
62748515|NCT03575845|EXPERIMENTAL|Occupational therapy informed yoga|Occupational therapists adapted postures to meet the abilities and rehabilitation needs of individual breast cancer survivors engaging in group-delivered yoga sessions
62748516|NCT06232564|EXPERIMENTAL|Open Label, Single Arm, Phase II Study|This is an open label, single arm, phase II multicentre study designed to evaluate the efficacy and safety of pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy in patients with HG-NETs who are chemotherapy-naïve for their metastatic disease. The study will be conducted in up to 10 sites and will recruit up to a maximum of 20 evaluable participants.
62748517|NCT03290417|NO_INTERVENTION|Unmodified Diet|Patients are under active surveillance with no modification to their diet, as is standard of care for low risk prostate cancer
62748518|NCT03290417|EXPERIMENTAL|Diet modification|Patients receive Vitamin D, Omega-3 and turmeric curcumin as dietary supplements
62748519|NCT06605547|ACTIVE_COMPARATOR|Test group|Test sites receiving the subgingival application of i-PRF after NSPT.
62748520|NCT06605547|PLACEBO_COMPARATOR|Control group|Control sites treated with saline after NSPT.
62748521|NCT01415479|EXPERIMENTAL|Quantitative|"Subjects view:~1. Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~2. Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)"
62748522|NCT01415479|EXPERIMENTAL|Default|"Subjects view:~1. Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~2. Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT)."
62748523|NCT01415479|EXPERIMENTAL|Quantitative + Default|"Subjects view:~1. Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~2. Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)~3. Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT)."
62748524|NCT01415479|ACTIVE_COMPARATOR|Control|Subjects view a computer-based presentation regarding colorectal cancer (CRC) and available screening tests for CRC, primarily a video produced by the American Cancer Society.
62748525|NCT01552551|ACTIVE_COMPARATOR|Healthy Steps|Healthy Steps program as currently implemented by the PA Department of Aging
62748526|NCT01552551|EXPERIMENTAL|Healthy Steps with Falls Case Management|Healthy Steps program augmented with research interventionist guidance on seeking physician care and home safety assessment
62748527|NCT01552551|EXPERIMENTAL|Healthy Steps in Motion|Healthy Steps program augmented with Healthy Steps in Motion, a 4-week, twice a week program of group exercise.
62748528|NCT01166373|EXPERIMENTAL|Enrollment video arm|Arm of subjects that will be shown a standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process.
62748529|NCT01166373|NO_INTERVENTION|No video intervention arm|This group of subjects will not view a standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process.
62748530|NCT01166373|EXPERIMENTAL|ULS|Uterosacral Ligament Suspension was one of the randomized surgical treatments in the OPTIMAL study
62554059|NCT05488093|EXPERIMENTAL|total knee replacement surgery group|"The study will be conducted in 4 visits:~* a pre-inclusion visit during a routine care consultation where the patient will be informed about the study~* a V1 inclusion visit (pre-surgery of the knee) during which informed consent, clinical examination, VAS, self-questionnaires, DXA, X-SENS sensor, MRI, isokinetism will be collected~* a V2 visit during the operation, during which biological samples will be taken (muscle biopsy, collection of osteoarticular parts, and serum collection)~* a V3 visit at 12 months with a clinical examination, EVA, self-questionnaires, DXA, isokinetics, X-SENS sensor, serum collection, and collection of adverse events."
62554060|NCT01595685|EXPERIMENTAL|Telbivudine|Telbivudine 600 mg Daily Oral
62748531|NCT01166373|EXPERIMENTAL|SSLF|Sacrospinous Ligament Fixation was one of the randomized surgical treatments in the OPTIMAL study.
62748532|NCT01166373|EXPERIMENTAL|PMT|Perioperative Behavioral Therapy/Pelvic Muscle Training was one of the randomized non-surgical (behavioral) interventions in the OPTIMAL study.
62748533|NCT01166373|OTHER|Usual Care|No Perioperative Behavioral Therapy/Pelvic Muscle Training (i.e., usual care) was one of the randomized non-surgical (behavioral) interventions in the OPTIMAL study.
62748534|NCT03643341|EXPERIMENTAL|Family Healthy Living Intervention|Children aged 8-12 and at least one caregiver will meet for 10 weekly face-to-face and online intervention sessions (1.5 hours per session). Four biweekly maintenance sessions will follow the main program.
62748535|NCT03643341|NO_INTERVENTION|Wait-list control group|Children aged 8-12 will be randomly assigned to the wait-list control group until after the study.
62748536|NCT00005605||Tamoxifen group|
62748537|NCT00005605||Chemotherapy group|
62748538|NCT03017677||Group|
62748539|NCT03643315|EXPERIMENTAL|Exercise and Meal (EX)|The EX protocol will involve a 30 minute acute bout of high intensity intermittent exercise on a stationary exercise bike followed by an ad-libitum test meal.
62748540|NCT03643315|EXPERIMENTAL|No-Exercise and Meal (NEX)|The NEX protocol will involve a 30 minute period of rest (to match the exercise period in EX) where participants will be provided a video/movie. Following this, participants will be provided ad-libitum access to a test meal (as per EX energy intake assessment protocol)
62748541|NCT04732130|ACTIVE_COMPARATOR|Time-Restricted Feeding|Participants in the time-restricted feeding are instructed to eat ad libitum from 12:00 to 20:00 daily, and fast from 20:00 to 12:00 daily for 4 weeks.
62748542|NCT04732130|ACTIVE_COMPARATOR|Alternate Day Fasting|Participants in the alternate day fasting group are instructed to eat every second day ad libitum, but to abstain from calorie intake on fast days (100 % restriction) for 4 weeks.
62748543|NCT04732130|NO_INTERVENTION|Control|Participants in the control group are instructed to maintain their habitual diet regimen.
62748544|NCT01064102|EXPERIMENTAL|Cetirizine|Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys Laboratories Limited
62748545|NCT01064102|ACTIVE_COMPARATOR|Zyrtec|Zyrtec Tablets 10 mg of Pfizer Labs
62554061|NCT01595685|ACTIVE_COMPARATOR|Entecavir|Entecavir 0.5 mg Daily Oral
62554062|NCT05256186|EXPERIMENTAL|Basketball pre-injury attack program|The intervention group carried out a program for 24 weeks. The participant had to perform the program 3 days per week for 12-15' each day (training days with the team, prior to group activation).
62554063|NCT05256186|NO_INTERVENTION|Control|The control group performed only the initial, follow-up (12 weeks) and final (24 weeks) evaluations.
62554064|NCT03930537|ACTIVE_COMPARATOR|Hip replacement with cemented femoral component|A special device that measure the pressure will be used to measure the change of pressure before, during and after implantation of cemented femoral component of hip prothesis.
62748546|NCT03305549|ACTIVE_COMPARATOR|TIW Dialysis Strategy|Conventional thrice-weekly acute intermittent hemodialysis treatment schedule.
62748547|NCT03305549|EXPERIMENTAL|Conservative Dialysis Strategy|Conservative acute intermittent hemodialysis strategy, in which hemodialysis is not continued unless specific metabolic or clinical indications for RRT are present.
62748548|NCT04378998|EXPERIMENTAL|Acupuncture|The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Ying Tang were used.
62748549|NCT04378998|NO_INTERVENTION|Usual care|
62748550|NCT03013101|EXPERIMENTAL|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
62748551|NCT01587261|PLACEBO_COMPARATOR|Placebo|Victims of severe thermal injury receiving placebo Lactated Ringers solution for the first 24 hours
62748552|NCT01587261|EXPERIMENTAL|Vitamin C|Victims of severe thermal injury receiving high-dose vitamin C 66 mg/kg/hr for the first 24 hours
62748553|NCT00006441|EXPERIMENTAL|A|Patients beginning IL-2 treatment regimens after 4 weeks of study
62748554|NCT00006441|ACTIVE_COMPARATOR|B|Patients beginning IL-2 treatment after some delay based on specified criteria
62748555|NCT05156099||ScanNav Anatomy PNB unaided|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance without the device.
62748556|NCT05156099||ScanNav Anatomy PNB-aided|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance with the device.
62748557|NCT04261400|EXPERIMENTAL|MAMAACT|Post graduate training of midwives in intercultural communication and health education materials for the pregnant women.
62748558|NCT04261400|NO_INTERVENTION|Control|Care as usual
62748559|NCT01895231|EXPERIMENTAL|Iron isomaltoside 1000|Monofer® 1000 mg IV infusion over 15 minutes
62748560|NCT01895231|PLACEBO_COMPARATOR|Placebo|0.9 % saline Infusion over 15 min
62748561|NCT02671903|ACTIVE_COMPARATOR|Pacemaker: AV optimised, His pacing|Subjects will remain in this arm for 6 months before being crossed-over. See below intervention details.
62748562|NCT02671903|NO_INTERVENTION|No pacing|Subjects will remain in this arm for 6 months before being crossed-over. The pacemaker will be programmed to VVI 30 bpm. Dynamic AV delay will be programmed off throughout the study.
62748563|NCT02862483|EXPERIMENTAL|Experimental|Tamsulosin 0.2mg and Tadalafil 5mg
62748564|NCT02862483|ACTIVE_COMPARATOR|Comparator|placebo for Tamsulosin 0.2mg and Tadalafil 5mg
62748565|NCT05195957||rTAR|All consecutive patients undergoing bilateral robotic transversus abdominis release operation in the treatment of their ventral incisional hernia, are considered eligible for inclusion.
62748566|NCT05195957||oTAR|All consecutive patients undergoing bilateral open transversus abdominis release operation in the treatment of their ventral incisional hernia, are considered eligible for inclusion.
62748567|NCT04018976|EXPERIMENTAL|Heat and Vacuum|AVACEN 100 applies heat and vacuum to hand
62748568|NCT04018976|ACTIVE_COMPARATOR|Heat Only|AVACEN 100 applies heat only
62748569|NCT04018976|SHAM_COMPARATOR|Sham|AVACEN 100 applies neither heat nor vacuum
62748570|NCT05354609|EXPERIMENTAL|MR-enterography|
62748571|NCT03055325||Surgical patients|Cognitive testing, testing of heart rate variability and collection of blood samples
62748572|NCT05705375|EXPERIMENTAL|waterpipe regular smokers|waterpipe regular smokers will be invited for 3 lab visits where they are allocated (random order) to smoke 3 waterpipe different sizes.
62748573|NCT05120570|EXPERIMENTAL|PTCy/sirolimus plus VIC-1911|Patients enrolled and treated with PTCy/sirolimus plus VIC-1911
62748574|NCT03905265|EXPERIMENTAL|Moxidectin 2 mg|Moxidectin 2 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
62748575|NCT03905265|EXPERIMENTAL|Moxidectin 8 mg|Moxidectin 8 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
62748576|NCT03905265|EXPERIMENTAL|Moxidectin 20 mg|Moxidectin 20 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
62748577|NCT03905265|EXPERIMENTAL|Moxidectin 36 mg|Moxidectin 36 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
62748578|NCT03957499|PLACEBO_COMPARATOR|the control group|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
62748579|NCT03957499|ACTIVE_COMPARATOR|Group dexamethasone/Bupivacaine:|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml).(
62748580|NCT03957499|ACTIVE_COMPARATOR|Group Magnesium sulphate/Bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
62748581|NCT06607757|EXPERIMENTAL|Arm A|Capivasertib (400 mg po twice daily d1-4 followed by 3 days off) for 2 weeks followed by capivasertib (400 mg po twice daily d1-4 followed by 3 days off) and fulvestrant (500 mg i.m. q28d, with an additional 500 mg dose given two weeks after the initial dose) for additional 8 weeks (overall 4 administrations of fulvestrant)
62748582|NCT06607757|ACTIVE_COMPARATOR|Arm B|Fulvestrant (500mg i.m. q28d, with an additional 500 mg dose given two weeks after the core biopsy and the initial dose) for 10 weeks (overall 4 administrations)
62748583|NCT02750345|EXPERIMENTAL|Sequence TP 1 - TP 2 - Reference|Subjects will receive a single 10 mg tablet of Nitisinone (Test Product 1 (TP 1)) in treatment period 1, 10 mg tablet of Nitisinone Baked Tablet (Test Product 2 (TP 2)) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
62748584|NCT02750345|EXPERIMENTAL|Sequence TP 1 - Reference - TP 2|Subjects will receive a single 10 mg tablet of Nitisinone (Test Product 1) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
62748585|NCT02750345|EXPERIMENTAL|Sequence TP 2 - TP 1 - Reference|Subjects will receive a single 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
62748586|NCT02750345|EXPERIMENTAL|Sequence TP 2 - Reference - TP 1|Subjects will receive a single 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
62748587|NCT02750345|EXPERIMENTAL|Sequence Reference - TP 1 - TP 2|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
62748588|NCT02750345|EXPERIMENTAL|Sequence Reference - TP 2 - TP 1|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 2, and 10 mg tablet of Nitisinone (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
62748589|NCT04746235|EXPERIMENTAL|Treatment (decitabine and cedazuridine, venetoclax)|Patients receive decitabine and cedazuridine PO daily on days 1-5 and venetoclax PO daily on days 1-28 of the first cycle and on days 1-21 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62391509|NCT03458351|SHAM_COMPARATOR|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10mm Hg.
62391510|NCT01768624||Stage 5 chronic kidney disease|Patients receiving home hemodialysis Patients receiving home peritoneal dialysis Patients receiving center-based hemodialysis Patients who had a pre-emptive kidney transplant Patients who planned for renal conservative care
62554065|NCT03930537|ACTIVE_COMPARATOR|Hip replacement with non-cemented femoral component|A special device that measure the pressure will be used to measure the change of pressure before, during and after implantation of non-cemented femoral component of hip prothesis.
62748590|NCT06608264|NO_INTERVENTION|Control arm:|Patients who did not receive any intervention other than standard treatment and care during continuous passive motion exercise after total knee arthroplasty were defined as the control arm.
62748591|NCT06608264|EXPERIMENTAL|stress ball arm|Patients who underwent stress ball intervention during continuous passive motion exercise after total knee arthroplasty were defined as stress ball arms.
62748592|NCT06608264|EXPERIMENTAL|hand holding arm|Patients who underwent hand-holding intervention during continuous passive range of motion exercise after total knee arthroplasty were defined as hand-holding arm.
62748593|NCT02665351|ACTIVE_COMPARATOR|Peramivir 300mg Q12H|Peramivir 300 mg, administered intravenously, twice daily (every 12 hours)
62748594|NCT02665351|ACTIVE_COMPARATOR|Peramivir 600mg Q24H|Peramivir 600 mg, administered intravenously, once daily (every 24 hrs)
62748595|NCT06251661|ACTIVE_COMPARATOR|Group 1 (GA)|20 Egyptian ischemic stroke patients receive 12 sessions of CMR and traditional physical therapy each session lasts for 40 minutes of CMR and 30 minutes of traditional physical therapy.
62748596|NCT06251661|SHAM_COMPARATOR|Group 2 (GB)|20 Egyptian ischemic stroke patients receive 12 sessions of traditional physical therapy each session lasts for 30 minutes.
62748597|NCT05365061|EXPERIMENTAL|Periosteal electrical dry needling followed by no maintenance treatments|Periosteal electrical dry needling followed by no maintenance treatments
62748598|NCT05365061|ACTIVE_COMPARATOR|Periosteal electrical dry needling followed by maintenance treatments every other month|Periosteal electrical dry needling followed by maintenance treatments every other month
62554066|NCT03240029|EXPERIMENTAL|Children in cancer remission|Children in cancer remission sent to ordinary schools: primary (3rd, 4th, 5th grade) and middle (6th, 7th grade) schools.
62554067|NCT03240029|OTHER|Control children|Children (not in cancer remission) sent to ordinary schools (age and sex matched): primary (3rd, 4th, 5th grade) and middle (6th, 7th grade) schools.
62554068|NCT02018991|ACTIVE_COMPARATOR|Everolimus-Eluting-Stent (EES)|Patients treated with EES
62554069|NCT02018991|ACTIVE_COMPARATOR|Zotarolimus-Eluting-Stent (ZES)|Patients treated with ZES
62748599|NCT05365061|ACTIVE_COMPARATOR|Periosteal electrical dry needling followed by monthly maintenance treatments|Periosteal electrical dry needling followed by monthly maintenance treatments
62748600|NCT02030717|EXPERIMENTAL|Spinal anesthesia|The drugs used in the spinal injection are: 12 mg bupivacain, 160 ug morfin och klonidin( \< 60 years 75 ug, 60 - 85 years old 60 ug and older than 85 years 45 ug)
62391511|NCT01129219|EXPERIMENTAL|Usual care|Subjects in the control group were asked to maintain their current lifestyle. No restrictions were placed on their exercise activities.
62554070|NCT02018991|ACTIVE_COMPARATOR|Biolimus-Eluting-Stent (BES)|Patients treated with BES
62554071|NCT04123405|EXPERIMENTAL|Group A: 600 mg acetylcysteine|one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)
62554072|NCT04123405|EXPERIMENTAL|Group B: 1200 mg acetylcysteine|two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)
62554073|NCT04123405|EXPERIMENTAL|Group C: 2400 mg acetylcysteine|four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)
62554074|NCT04123405|PLACEBO_COMPARATOR|Group D: Placebo|four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)
62554075|NCT05531864|EXPERIMENTAL|Continuous serratus anterior plane block|Ultrasound-guided continuous serratus anterior plane block.
62554076|NCT05531864|ACTIVE_COMPARATOR|Single serratus anterior plane block combined with rectus sheath nerve block|Ultrasound-guided single serratus anterior plane block combined with rectus sheath nerve block.
62554077|NCT01876225|NO_INTERVENTION|No coughing|Cervical punch biopsy without forced coughing intervention
62554078|NCT01876225|EXPERIMENTAL|coughing|Forced coughing during cervical punch biopsy
62554079|NCT05898971|EXPERIMENTAL|Group A|received robotic gloves training
62554080|NCT05898971|EXPERIMENTAL|Group B|received mirror therapy
62554081|NCT05898971|ACTIVE_COMPARATOR|Group C|received traditional physical therapy
62748601|NCT02030717|ACTIVE_COMPARATOR|Epidural anesthesia|Epidural anesthesia patients group gets an epidural catheter at level Th 8- 10 with per- and postoperative infusion with a routine mixture of: bupivacain 1 mg/ml, fentanyl 1 ug/ml, and adrenalin 1 ug/ml) until termination.
62748602|NCT01684709|EXPERIMENTAL|Telemonitoring + self-management support|Automated assessment calls with follow-up by a Care Manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up.
62748603|NCT01684709|NO_INTERVENTION|Usual Care|Usual Care
62748604|NCT00541866|EXPERIMENTAL|Voreloxin injection and cytarabine|"Dose-escalation Phase~* Schedule A:~* Schedule B:~Expansion Phase~* Schedule A:~* Schedule B:"
62748605|NCT02080481|EXPERIMENTAL|Infiniti Plus needle guidance system|ultrasound guidance with the InfinitiPlus (TM) needle guidance system
62748606|NCT02080481|OTHER|conventional block needle|ultrasound guidance with a conventional block needle
62748607|NCT06606717|EXPERIMENTAL|Creatine Whey Protein|
62748608|NCT06606717|EXPERIMENTAL|Whey Protein|
62748609|NCT04691141|EXPERIMENTAL|ATG-016|5 mg QD×Days 1-5/week will be the initial dose of this study.
62748610|NCT00053976|EXPERIMENTAL|Daclizumab|"Patients are randomized to 1 of 2 treatment arms.~Arm I:~* Patients receive methylprednisolone or equivalent corticosteroid IV or orally~* Daclizumab IV on days 0, 3, 7, 14, and then weekly as indicated until day 100.~Arm II: Patients receive methylprednisolone or equivalent corticosteroid as in arm I and placebo.~Patients are followed at 1 year and then annually thereafter."
62748611|NCT00053976|PLACEBO_COMPARATOR|Placebo|"Patients are randomized to 1 of 2 treatment arms.~* Patients receive methylprednisolone or equivalent corticosteroid as in Daclizumab arm~* Placebo IV on days 0, 3, 7, 14, and then weekly as indicated until day 100."
62748612|NCT02779088|EXPERIMENTAL|Early exercise and nutrition|Enrolled participants with sarcopenia will be randomized to receive either strengthening exercise and nutrition or education courses (DVD and handbook) first and then will receive the opposite intervention subsequently. The study will consist of two periods of 12 weeks separated by a washout period of 2 weeks. It's the AB/BA study. Subjects in the AB arm receive exercise and nutrition intervention first, followed by the education course.
62748613|NCT02779088|ACTIVE_COMPARATOR|Delayed exercise and nutrition|Enrolled participants with sarcopenia will be randomized to receive either strengthening exercise and nutrition or education courses (DVD and handbook) first and then will receive the opposite intervention subsequently. The study will consist of two periods of 12 weeks separated by a washout period of 2 weeks. It's the AB/BA study. Subjects in the BA arm receive the education course first, followed by exercise and nutrition.
62748614|NCT03179254|EXPERIMENTAL|Oral hypoglycemic agent continue|Metformin continue on the day of surgery
62748615|NCT03179254|ACTIVE_COMPARATOR|Oral hypoglycemic agent discontinue|Metformin discontinue on the day of surgery
62748616|NCT01945216||Alogliptin 25mg, tablets, orally, once daily, up to 36 months|
62748617|NCT04739618|EXPERIMENTAL|Single arm. Subjects receiving treatment.|Efficacy of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy as determined by overall response rate of radiographic changes according to iRECIST criteria
62748618|NCT00415428||1.|
62748619|NCT01007435|EXPERIMENTAL|(A) Tocilizumab 8 mg/kg + placebo to methotrexate|Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.
62748620|NCT01007435|EXPERIMENTAL|(B) Tocilizumab 8 mg/kg + methotrexate|Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
62748621|NCT01007435|EXPERIMENTAL|(C) Tocilizumab 4 mg/kg + methotrexate|Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
62748622|NCT01007435|ACTIVE_COMPARATOR|(D) Placebo to tocilizumab + methotrexate|Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.
62748623|NCT01022957|EXPERIMENTAL|Study group|Neurological, ophthalmological, olfactive exams and cerebral MRI
62748624|NCT04378465||ERP group|A prospective series of consecutive patients undergoing elective colorectal surgery completing a standardized Enhanced Recovery Program (ERP) protocol at the S. Anna University Hospital in Ferrara (Italy) in 2013-2015
62748625|NCT04378465||Non-ERP group|A retrospective series of consecutive patients operated at the same hospital (S. Anna University Hospital in Ferrara), in the same period of time (2013-2015), but with a traditional perioperative care protocol.
62748626|NCT01714037|EXPERIMENTAL|Cisplatin, Pemetrexed, Debio 0932|Cisplatin, Pemetrexed, Debio 0932
62748627|NCT01714037|EXPERIMENTAL|Cisplatin, Gemcitabine, Debio 0932|Cisplatin, Gemcitabine, Debio 0932
62748628|NCT01714037|EXPERIMENTAL|Docetaxel, Debio 0932|Docetaxel, Debio 0932
62748629|NCT02693054|EXPERIMENTAL|Hybrid Fractional Laser Treatment|Halo (1470nm and 2940 nm) laser
62748630|NCT03263728|EXPERIMENTAL|Stress Cardiac MR|
62748631|NCT00096226|EXPERIMENTAL|Chemoradiation, Surgery, Chemotherapy|Induction paclitaxel(50 mg/m2 I.V. in a one-hour infusion) and induction carboplatin (AUC 2.0 I.V. in a thirty-minute infusion): 1x/week for 6 weeks. Concurrent radiation therapy (RT): 1.8 Gy/day, 5 fx/week, for a total of 50.4 Gy in 28 fractions plus a boost of 1.8 Gy/day, 5 fx/week, for a total of 10.8 Gy in 6 fractions. Followed by an assessment to determine whether patient will undergo a resection or not. Followed by consolidation paclitaxel (200 mg/m2 I.V. over three hours) and consolidation carboplatin (AUC 6.0 over one hour) q 21 days x 2.
62748632|NCT01044212|ACTIVE_COMPARATOR|Docusate|Docusate is the standard of care regimen
62748633|NCT01044212|EXPERIMENTAL|Bowel medications|Docusate, Miralax, Metamucil wafers, Bisacodyl suppository
62374765|NCT04849676|EXPERIMENTAL|Upper limb chronic spinal cord injury (sUL)|"Intervention: neurofeedback. Participants will receive visual feedback on a screen.~Diagnostic Tests:~Modified Ashworth Scale grading muscle resistance to movement (all limbs tested)~Perceived Spasticity level questionnaire on impact of spasticity~Spinal Cord Independence Measure questionnaire on level of independence of patients~Diary of spastic episodes~Grip strength - measure of hand and forearm muscle strength using dynamometer~Instrumented Pendulum test - oscillations when forearm is dropped from a resting position~Hand grip - closing and opening the fist recorded with Kinect (Microsoft) device~EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria)~Brief Visual Analog Scale self-assessment of performance and mental strategies~Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)"
62748634|NCT01972308|EXPERIMENTAL|Patient advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to carrying out medical advice, and transfer of information between providers and patients.
62748635|NCT01972308|OTHER|usual care|Patient receives asthma care as usual from their asthma provider
62748636|NCT01185418||risperidone|
62748637|NCT01185418||aripiprazole|
62391512|NCT01645449|EXPERIMENTAL|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
62391513|NCT01645449|ACTIVE_COMPARATOR|Lipitor 80 mg Tablets|Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
62748638|NCT01185418||haloperidol|
62748639|NCT01185418||amisulpride|
62748640|NCT01185418||lactose|
62748641|NCT03315897|ACTIVE_COMPARATOR|Erythropoietin|12 intravenous infusions of recombinant human erythropoietin (EPO)
62748642|NCT03315897|PLACEBO_COMPARATOR|Saline|12 intravenous infusions of saline (1 ml NaCl)
62748643|NCT04816656|EXPERIMENTAL|Experimental arm|All patients were presented the digital PROMs platform during their chemotherapy
62748644|NCT03262571|EXPERIMENTAL|Group A|Group A includes patients undergoing lung ultrasound and physical examination.
62748645|NCT03262571|PLACEBO_COMPARATOR|Group B|Group B includes patients undergoing physical examination only.
62748646|NCT02555813||Abraxane + Gemcitabine|Abraxane 125mg by intravenous( IV) infusion + Gemcitabine 1000mg by intravenous on Days 1, 8, 15 of every 21 day cycle until progression
62748647|NCT04751409|EXPERIMENTAL|Group 1, Arm I (intense follow up)|Patients undergo intense follow-up every 3 months for 2 years consisting of restaging with CT-chest and imaging of the primary site.
62748648|NCT04751409|EXPERIMENTAL|Group 1, Arm II (limited follow-up)|Patients undergo limited follow-up every 6 months for 2 years consisting of restaging with either CT-chest or CXR and imaging of the primary site.
62748649|NCT04751409|EXPERIMENTAL|Group 2 (intense follow up)|Patients undergo intense follow-up every 3 months for 2 years as in Group 1, Arm I.
62748650|NCT05514938|EXPERIMENTAL|Polypill|Patients will be randomized to receiving a fixed-dose polypill in addition to other guideline-directed medical therapies prescribed by their physician. Polypill formulations will include rosuvastatin 40 mg, aspirin 81 mg, and prasugrel 10 mg daily or rosuvastatin 40 mg, aspirin 81 mg, and clopidogrel 75 mg.
62748651|NCT05514938|ACTIVE_COMPARATOR|Usual Care (individual medications prescribed by primary cardiologist)|Patients will receive usual post-ACS care and medications prescribed by their provider. All of the individual components will be available at low- or no-cost to participants as individual pill formulations.
62748652|NCT06606977||Elite Greco-Roman Wrestlers|Elite senior wrestlers in the Greco-Roman style participated in the study. These wrestlers had not participated in field training for a minimum of 14 weeks due to the Covid-19 epidemic, and this study focuses on their performance and autonomous system response after resuming field training.
62748653|NCT00519376|EXPERIMENTAL|GW642444M 25mcg|
62748654|NCT00519376|EXPERIMENTAL|GW642444M 50mcg|
62748655|NCT00519376|EXPERIMENTAL|GW642444M 100mcg|
62748656|NCT00519376|EXPERIMENTAL|GW642444H 100mcg|
62748657|NCT00519376|EXPERIMENTAL|placebo|
62748658|NCT05223231|EXPERIMENTAL|LBL-019|singal -arm
62748659|NCT04885322|EXPERIMENTAL|DLPFC Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex.
62748660|NCT04885322|EXPERIMENTAL|Occipital Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the occipital cortex.
62748661|NCT04885322|SHAM_COMPARATOR|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
62391514|NCT03876509||Impedance Cardiography|Impedance Cardiography
62748662|NCT02649374|NO_INTERVENTION|Gestational diabetes mellitus|women diagnosed with GDM during pregnancy, either treated by diet or pharmacological therapy
62748663|NCT02649374|ACTIVE_COMPARATOR|No GDM, Dietary Modifications|Women without GDM, will be advised and monitored for dietary, Exercise and lifestyle modifications
62748664|NCT02649374|NO_INTERVENTION|No GDM, free diet|Women without GDM, for whom diet. exercise are continued regulary without any modifications
62748665|NCT05526664||Gaucher Type 1|"* The participant was diagnosed with Gaucher type 1 disease~* Adults only"
62748666|NCT05526664||Gaucher Type 3|"* The participant was diagnosed with Gaucher type 3 disease~* Adults only"
62748667|NCT05526664||Healthy Volunteer|"* Healthy participants~* Adults only"
62748668|NCT05125718|EXPERIMENTAL|test group (antimicrobial peptide)|Half of the dentition will receive scaling and root surface debridement within a week followed by the application of antimicrobial peptide gel Ace Helper™ into the site with pocket depth \>5mm until overflow noticed. Antimicrobial peptide (AMP) will be reapplied for 2 more times at an interval of 3 days. Antimicrobial peptide gel Ace Helper™ contained 0.85% synthetic AMP (TAPS-18) designed based on the basic structure of cathelicidin, hydroxyethyl cellulose, and purified water.
62748669|NCT05125718|SHAM_COMPARATOR|control group (normal saline)|Half of the dentition will receive scaling and root surface debridement within a week followed by the irrigation of 0.9% normal saline into the site with pocket depth \>5mm. Normal saline irrigation will be repeated for 2 more times at an interval of 3 days.
62391515|NCT05604781||Symfony & Synergy IOL combination|
62748670|NCT04971538|EXPERIMENTAL|HCV self-testing|the study staff will leave an HCV ST and instructions for use (IFU) with the household. The study team will also explain the HCVST process to the most senior member of the household, as well as leave a mobile number for the participant to contact for help conducting the test. The study team will follow up with the participant to inquire about if testing was completed, collect any testing results, and conduct a brief survey.
62748671|NCT04971538|NO_INTERVENTION|Referral to clinic for HCV RDT|the study staff will leave information on HCV testing and direct them to the nearest clinic with screening services, the participant will not be left a HCVST. Study staff will also leave a mobile number for the participant to contact for further information on HCV testing. The study team will follow up with the participant to inquire about if testing was completed, collect any testing results, and conduct a brief survey
62748672|NCT06608953|EXPERIMENTAL|Enhanced external counterpulsation (intervention) group|Recieving enhanced external counterpulsation application during hemodialysis
62748673|NCT06608953|NO_INTERVENTION|Controlled group|Recieve standard hemodialysis with optimal medical care
62391516|NCT05043896|EXPERIMENTAL|Combination therapy|Li-ESWT + tadalafil
62391517|NCT05043896|SHAM_COMPARATOR|Single Therapy|tadalafil only
62748674|NCT05763901|EXPERIMENTAL|Paramorphisms/dysmorphisms of spine and/or lower limbs|Only one arm of patients assessed for motor competence and balance without controls
62748675|NCT03590626|EXPERIMENTAL|Dulaglutide group|receive dulaglutide 0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks plus standard treatment for type 2 diabetes
62748676|NCT03590626|NO_INTERVENTION|Control group|receive standard treatment for type 2 diabetes and up titration of treatment will be done by anti-diabetic medicines other than the GLP-1 receptor agonist
62748677|NCT06604936||Fibromyalgia group|Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Functional status of the patients will be evaluated with the Fibromyalgia Impact Questionnaire. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
62748678|NCT06604936||Healthy group|individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
62748679|NCT02681796|EXPERIMENTAL|Study: Bupivacaine Epidural + standard of care pain regimen|-The study group will receive a T6 to T8 level epidural catheter in addition to the standardized pain regimen. Epidurals used in this study will contain a 0.125% bupivacaine-only infusion
62748680|NCT02681796|NO_INTERVENTION|Control: Standard of care pain regimen|-The control group will receive a standardized pain regimen including an opioid patient controlled analgesia (PCA), IV acetaminophen, and IV ketorolac per surgeon's preference
62748681|NCT02292758|EXPERIMENTAL|Arm I (cetuximab, bevacizumab, irinotecan)|Patients receive cetuximab IV over 90-120 minutes, bevacizumab IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62748682|NCT02292758|ACTIVE_COMPARATOR|Arm II (cetuximab, placebo, irinotecan)|Patients receive cetuximab IV over 90-120 minutes, placebo IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62748683|NCT03835754|EXPERIMENTAL|OCS Preservation|
62748684|NCT01218750|EXPERIMENTAL|edematous tractional epimacular membrane|Diabatic maculopathy comes to the edematous or tractional form. It is believed that epiretinal membranes are comprised from glial components. The processes of these cells may invade through the internal limiting membrane of the retina to the vitreous causing the vitreoretinal adhesion and anomalous posterior detachment of vitreous (APVD). In the macula, APVD causes vitreo-macular traction syndrome, which results in diffuse diabetic macular edema. If vitreoschisis is present, a place of dissection is crucial. If break occurs in front of the hyalocytes remaining on the retinal surface, the vitreous layer is thick and easily shrinks concentrically, which results in the formation of epimacular membrane.
62748685|NCT01522521|EXPERIMENTAL|1.|
62748686|NCT01522521|PLACEBO_COMPARATOR|2.|
62748687|NCT01824199|EXPERIMENTAL|Omeprazole|Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire 30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
62748688|NCT05289271|EXPERIMENTAL|Group 1: V, V, V|Participants who received a 2-dose regimen of Vaxelis™ as infants prior to enrollment will receive a Vaxelis™ booster at \~11 months of age.
62748689|NCT05289271|EXPERIMENTAL|Group 2: H, H, V|Participants who received a 2-dose regimen of Hexyon™ as infants prior to enrollment will receive a Vaxelis™ booster at \~11 months of age.
62748690|NCT01328834|EXPERIMENTAL|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase
62748691|NCT04314765|EXPERIMENTAL|bayonet flap|Bayonet flap is performed to extract the the lower third molar
62748692|NCT04314765|EXPERIMENTAL|envelope flap|Envelope flap is performed to extract the the lower third molar
62748693|NCT05340621|EXPERIMENTAL|OKI-179 + binimetinib|
62748694|NCT01274923|SHAM_COMPARATOR|shock wave treatment|
62748695|NCT01274923|SHAM_COMPARATOR|"MEDISPEC Sham"|"MEDISPEC Probe does not deliver energy but creates same noise and sensation of active probe"
62748696|NCT03307161|ACTIVE_COMPARATOR|Parkinsons fwd posture manual treatment|Subject will receive the intervention, osteopathic manual treatment protocol.
62748697|NCT03307161|NO_INTERVENTION|Parkinsons forward posture|Subjects will receive counseling.
62748698|NCT03307161|NO_INTERVENTION|Parkinsons without forward posture|Subjects will receive counseling.
62391518|NCT06151743|EXPERIMENTAL|Neoadjuvant therapy+Surgery+Adjuvant therapy|Participants receive three cycles of neoadjuvant therapy (toripalimab+cetuximab+platinum), followed by radical surgery. After surgery, participants receive radiotherapy or chemoradiotherapy according to the pathological results of the operation.
62554082|NCT04841837|EXPERIMENTAL|Time-restricted feeding|Restrict all calorie intake within a self-selected 10-hours window for 12 weeks, without necessarily altering diet quality and quantity
62554083|NCT05317819|EXPERIMENTAL|Drug: ADI-PEG 20|Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)
62748699|NCT02442310|EXPERIMENTAL|Delayed release, fed conditions|A single 1200 mg dose of deferiprone delayed release tablet formulation administered following a high-fat breakfast
62554084|NCT05317819|PLACEBO_COMPARATOR|Drug: Placebo|Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)
62748700|NCT02442310|EXPERIMENTAL|Delayed release, fasting conditions|A single 1200 mg dose of deferiprone delayed release tablet formulation, administered following a 10-hour fast
62748701|NCT02442310|EXPERIMENTAL|Delayed release half-tablets|A single 1200 mg dose of deferiprone delayed release tablet formulation, following a high-fat breakfast
62748702|NCT02442310|ACTIVE_COMPARATOR|Oral solution, fasting conditions|A single 1200 mg dose of deferiprone oral solution, administered following a 10-hour fast
62748703|NCT06542601||Total|All subjects
62748704|NCT03549676|EXPERIMENTAL|HSCT patients with refractory GVHD|Patients will accept FilmArray Gastrointestinal (GI) panel test before pre-treatment of HSCT and 28±3 days post-HSCT. Patients will receive 50ml fecal microbiota from unrelated healthy donors through nasojejunal tube and monitored under gastroscopy. Patients receiving FMT treatment will be followed for at least 6 months. The ideal follow up time is 2 year. Stool and blood samples will be serially collected and tested (before pre-treatment, 1/3/6/12 months after FMT).
62748705|NCT00798629|EXPERIMENTAL|Vaccine Dose Escalation|Dose Escalation: Intradermal DC Injection. Level 1: Cell Dose: 2 x 10\^6 Level 2: Cell Dose: 1 x 10\^7 Level 3: Cell Dose: 2 x 10\^7
62748706|NCT05386550|EXPERIMENTAL|Arm A: Xevinapant (Debio 1143) + IMRT|
62748707|NCT05386550|PLACEBO_COMPARATOR|Arm B: Placebo + IMRT|
62554085|NCT06582316|EXPERIMENTAL|Intervention Arm|"Participants will undergo 8 sessions of digital Train Your Brain programme lead by a trained clinical neuropsychologist over 2 months."
62554086|NCT06582316|NO_INTERVENTION|Control Arm|"Participants will not undergo any sessions of digital Train Your Brain programme for 2 months when intervention arm's brain health training programme is ongoing."
62554087|NCT05187104|EXPERIMENTAL|Patients with age-related macular degeneration receiving standard treatment and retinal stem cells|Patients with age-related macular degeneration receiving standard treatment and autologous retinal stem and progenitor cells
62748708|NCT06389331||defect closure|the fascia transversalis (pseudo sac) was pulled and incorporated into closure with a non-absorbable polypropylene barbed monofilament size-0 suture
62748709|NCT06389331||non closure group|defect was left open
62554088|NCT05187104|ACTIVE_COMPARATOR|Patients with age-related macular degeneration receiving standard treatment|Patients with age-related macular degeneration receiving standard treatment
62554089|NCT04172935|EXPERIMENTAL|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal working distance as measured before intervention.
62554090|NCT04172935|NO_INTERVENTION|Control Group|Will be deferred to receive spectacles as above, after the 4 weeks evaluation period.
62554091|NCT02245607|EXPERIMENTAL|Compensatory Cognitive Training|Compensatory Cognitive Training
62748710|NCT05893771|PLACEBO_COMPARATOR|Placebo control|With ultrasound guidance, 20 ml plain normal saline will be injected to spread lateral to the femoral artery and deep to the sartorius muscle, or more distal, below the knee after arrival to the theatre.
62748711|NCT05893771|EXPERIMENTAL|Depomedrol group|With ultrasound guidance, a mixture of 5 ml Bupivacaine 0.5%, 1 ml (20 mg) depomedrol, and 14 ml normal saline is injected to spread lateral to the femoral artery and deep to the sartorius muscle, or more distal, below the knee after arrival at the theatre.
62748712|NCT05893771|ACTIVE_COMPARATOR|Bupivacaine group|A mixture of 5 ml Bupivacaine 0.5%- and 14-ml normal saline is injected to spread lateral to the femoral artery and deep to the sartorius muscle, or more distal, below the knee, after arrival at the theatre.
62748713|NCT03604588|OTHER|Patients with oropharyngeal cancer|"Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test.~Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results."
62748714|NCT03232645|OTHER|Rhythmia HDx and DirectSense technology|"Subjects will undergo ablation treatment of the pulmonary veins with the Rhythmia HDx mapping system with DirectSense technology. Subjects indicated for ablation treatment of de-novo PAF will be selected based on the inclusion/exclusion criteria and if deemed to be eligible for participation, will be asked to sign the Informed Consent Form.~For all enrolled subjects who undergo the ablation procedure, the subjects will be treated with the commercial Rhythmia HDx System with commercially available Software Version 2.0 with DirectSense technology (or any commercially available updates that are released during the course of the study); the IntellaMap Orion mapping catheter and the IntellaNav MiFi OI ablation catheter."
62748715|NCT01598337|ACTIVE_COMPARATOR|Aspirin alone|
62391519|NCT01127529||Subjects with severe congenital protein C deficiency|Registry subjects will be identified by working with Hemophilia Treatment Centers and Thrombosis Centers known to have subjects with severe congenital protein C deficiency, as well as by working with centers that use Ceprotin in emergency care situations.
62554092|NCT02245607|ACTIVE_COMPARATOR|Recreational Therapy|Recreational Therapy
62748716|NCT01598337|EXPERIMENTAL|Tirofoban|Patient assigned to this arm will receive tirofiban infusion starting approximately six hours post bypass surgery once hemomstasis established and no evidence of bleeding
62748717|NCT01598337|EXPERIMENTAL|Clopidogrel|Patients receive oral clopidogrel 75 mg 6-8 hours before coronary bypass surgery and continue daily mentenance dose as per instruction by investigators
62748718|NCT01598337|EXPERIMENTAL|Prasugrel|Patients started on prasugrel 6 hours post surgery 10 mg then continue on daily 10mg as per instruction by investigators
62748719|NCT05875753|EXPERIMENTAL|68Ga-FAPI-FS PET/CT|Each patient will receive one dose of 68Ga-FAPI-FS by intravenous route. Dedicated whole-body PET/CT imaging will be performed.
62748720|NCT00737854|EXPERIMENTAL|1 ARM|Otherwise healthy patients with oral lichen planus (precancerous/erosive OLP)
62748721|NCT03916185|EXPERIMENTAL|RSV ΔNS2/Δ1313/I1314L Vaccine|Participants will receive a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
62748722|NCT03916185|EXPERIMENTAL|RSV 6120/ΔNS2/1030s Vaccine|Participants will receive a single dose of the RSV 6120/ΔNS2/1030s vaccine at study entry (Day 0).
62748723|NCT03916185|EXPERIMENTAL|RSV 276 Vaccine|Participants will receive a single dose of the RSV 276 vaccine at study entry (Day 0).
62748724|NCT03916185|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
62748725|NCT02308527|ACTIVE_COMPARATOR|Temozolomide|Temozolomide Days 1-5 every 4 weeks
62748726|NCT02308527|EXPERIMENTAL|Bevacizumab + Temozolomide|Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 every 4 weeks
62748727|NCT02308527|EXPERIMENTAL|Irinotecan + Temozolomide|Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
62748728|NCT02308527|EXPERIMENTAL|Bevacizumab + Irinotecan + Temozolomide|Bevacizumab Day 1 + Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
62748729|NCT02308527|EXPERIMENTAL|Temozolomide + Topotecan|Temozolomide Days 1-5+ Topotecan Days 1-5 every 4 weeks
62748730|NCT02308527|EXPERIMENTAL|Bevacizumab + Temozolomide + Topotecan|Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
62748731|NCT02308527|EXPERIMENTAL|Dinutuximab beta + Temozolomide|Dinutuximab beta Days 1-7 + Temozolomide Days 1-5 every 4 weeks
62748732|NCT02308527|EXPERIMENTAL|Dinutuximab beta + Temozolomide + Topotecan|Dinutuximab beta Days 1-7 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
62748733|NCT02308527|OTHER|Dinutuximab beta + Topotecan + Cyclophosphamide|Dinutuximab beta Days 1-7 + Topotecan Days 1-5 + Cyclophosphamide Days 1-5 every 4 weeks
62748734|NCT06278506|EXPERIMENTAL|Ablation|Ablative treatment of small kidney cancer lesion, could be given with radiofrequency, microwawe or cryoablation
62748735|NCT06278506|ACTIVE_COMPARATOR|Partial nephrectomy|Surgical resection with open or laparoscopic technique
62748736|NCT00759265|EXPERIMENTAL|resistance training|"During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).~During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home."
62748737|NCT00759265|NO_INTERVENTION|control|No intervention was prescribed
62748738|NCT01165112|EXPERIMENTAL|Treatment (chemotherapy and monoclonal antibody therapy)|Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60 minutes on days 1-3, and carboplatin IV over 60 minutes on day 1. Patients with CD20+ T-cell lymphoma disease also receive rituximab IV on day 2 or 3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
62748739|NCT05758181|NO_INTERVENTION|Linear Wound Closure|A cutaneous layer of sutures will be placed on one side, as is standard of care.
62748740|NCT05758181|EXPERIMENTAL|Linear Wound Closure with Apical Undermining|The other side of the wound will have a cutaneous layer of sutures, as is standard of care, and will receive apical undermining.
62748741|NCT06608641|EXPERIMENTAL|Endoxifen Arm|Endoxifen enteric-coated tablet (8 mg). Patients will continue treatment with their initial randomized medication for 3 weeks
62748742|NCT06608641|PLACEBO_COMPARATOR|Placebo Arm|Placebo tablets. Patients will continue administration with their initial randomized medication for 3 weeks
62748743|NCT06605300|EXPERIMENTAL|oxytocin|A single dose of 24 international units (IU) of OT will be administered with 3 puffs of treatment to each nostril.
62748744|NCT06605300|EXPERIMENTAL|vasopressin|A single dose of 20 international units (IU) of AVP will be administered with 3 puffs of treatment to each nostril.
62748745|NCT06605300|PLACEBO_COMPARATOR|placebo|A single dose of PLC will be administered with 3 puffs of treatment to each nostril.
62748746|NCT05223348|EXPERIMENTAL|Body Scan Meditation|The experimental condition involves participants listening to a 16-minute recording of a body scan meditation. The body scan condition guides participants to focus on their bodily sensations separately, then together as a whole.
62748747|NCT05223348|ACTIVE_COMPARATOR|Listening Task|The active comparer condition involves participants listening to a 16-minute recording of text that describes the human musculoskeletal system. The text will be narrated by a female voice to match the body scan meditation. In addition, the focus on the body in the text of the active condition matches the focus on the body in the body scan meditation and, as such, controls for demand characteristics.
62748748|NCT03857360|ACTIVE_COMPARATOR|Pentabiocel|Oral administration of one sachet of Pentabiocel for 12 consecutive weeks.
62748749|NCT03857360|PLACEBO_COMPARATOR|Placebo|Oral administration of one sachet of Placebo per day for 12 consecutive weeks.
62748750|NCT01923363|EXPERIMENTAL|Standard Dose to High Dose Piperacillin/Tazobactam|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Then, they will be switched to higher dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
62748751|NCT00569244|EXPERIMENTAL|Arm 1|
62554093|NCT05207891|EXPERIMENTAL|Intervention mattress|"At every shift during the seven days project period, the nurses will check for pressure wounds, and mark identified pressure wounds and their category on a pressure injury body map. At every shift the nurses will use a custom made form to register resources needed in each position changing of the patient, the number of times the position is changed, as well as the level of physical strain in the nurses. All participants will start with seven days use of the newly developed intervention mattress. At the end of the testing period, the participants will register their feeling of quality of life, bedrest comfort, sleep-wellness, pain and satisfaction in the study period.~A custom made semi-structured interview guide has been conducted asking in more details of experienced quality in use and in managing the mattress. One participant and one nurse will be asked to participate in in-depth interviews after testing both mattresses."
62554094|NCT05207891|NO_INTERVENTION|Regulare care mattress|"At every shift during the seven days project period, the nurses will check for pressure wounds, and mark identified pressure wounds and their category on a pressure injury body map. At every shift the nurses will use a custom made form to register resources needed in each position changing of the patient, the number of times the position is changed, as well as physical strain in the nurses. At the end of the testing period, the participants will register their feeling of quality of life, bedrest comfort, sleep-wellness, pain and satisfaction in the test period.~A custom made semi-structured interview guide has been conducted asking in more details of experienced quality in use and in managing the mattress. One participant and one nurse will be asked to participate in in-depth interviews after testing both mattresses."
62748752|NCT00569244|ACTIVE_COMPARATOR|Arm 2|
62748753|NCT04893629|EXPERIMENTAL|intervention group|children diagnosed with dilated cardiomyopathy , will undergo trans endocardium injection of mono nuclear cells
62748754|NCT04893629|ACTIVE_COMPARATOR|control group|children diagnosed with dilated cardiomyopathy ,will continue the classic medical treatment
62748755|NCT04376840|EXPERIMENTAL|adults with severe SARS-CoV2 pneumonia|adult with severe SARS-CoV2 pneumonia
62567345|NCT06353373||Pre-Modified DeVTEcare Group|In our hospital, routine use of DeVTEcare system (a CDSS for VTE risk assessment and integrated care) for in-hospital management of VTE has been launched since 2021. By retrospectively collecting information on discharged patients, all patients discharged from our hospital between April 2023 and April 2024 will be included in the pre-modified DeVTEcare group.
62748756|NCT05645406|ACTIVE_COMPARATOR|EstroGel® 0.06%|EstroGel® 0.06% (1.25 g of gel/dose)
62748757|NCT05645406|ACTIVE_COMPARATOR|Compounded estradiol product|Compounded estradiol product (equivalent to EstroGel®/dose)
62748758|NCT04322305|EXPERIMENTAL|Pregabalin|Treatment with pregabalin administered in 75 mg and 100 capsules in dosages up to 600 mg per day for up to 8 weeks (including a 3 week titration run up) followed by a one week taper.
62748759|NCT04322305|PLACEBO_COMPARATOR|Placebo|Individuals will receive the placebo capsules that appear identical to the pregabalin capsules and will receive the same number of capsules.
62748760|NCT03409211|ACTIVE_COMPARATOR|Pso|with or without PsA
62748761|NCT03409211|ACTIVE_COMPARATOR|Healthy Subjects|Without PsA
62748762|NCT05088746||Non-surgical periodontal therapy|
62748763|NCT02864186|ACTIVE_COMPARATOR|control|Women wont use support bra for six months
62748764|NCT02864186|ACTIVE_COMPARATOR|surgical support bra|Women will use surgical support bra 24 hours a day for six months
62748765|NCT02864186|ACTIVE_COMPARATOR|common support bra|Women will use common support bra 24 hours a day for six months
62748766|NCT03165240|EXPERIMENTAL|BI 690517 Dose 1|
62748767|NCT03165240|EXPERIMENTAL|BI 690517 Dose 2|
62748768|NCT03165240|EXPERIMENTAL|BI 690517 Dose 3|
62748769|NCT03165240|EXPERIMENTAL|Eplerenone|
62748770|NCT03165240|PLACEBO_COMPARATOR|Placebo|
62748771|NCT00798239|ACTIVE_COMPARATOR|Control|The control arm is Iliac Crest Autograft
62748772|NCT00798239|EXPERIMENTAL|Prefix 150|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
62748773|NCT00798239|EXPERIMENTAL|Prefix 750|Prefix (AMPLEX) B2A Enhanced Ceramic Granules
62748774|NCT03718572||Scoring factors|
62748775|NCT03718572||Difficulty criteria|
62748776|NCT00885586|SHAM_COMPARATOR|Sham-laser acupuncture|Sham laser acupuncture (c) is applied at equivalent points as needle acupuncture. Laser irradiation is faked.
62748777|NCT00885586|ACTIVE_COMPARATOR|gabapentine|standard analgesic treatment
62748778|NCT00885586|ACTIVE_COMPARATOR|Acupuncture|Acupuncture treatment is semi-standardized, i.e. beside a scheme of basic points, individual points can be chosen according to the TCM diagnostic pattern.
62748779|NCT05306561|EXPERIMENTAL|Arm 1|Single arm trial
62391520|NCT00113321|EXPERIMENTAL|Decitabine|20 mg/m2 by vein (IV) over 1 hour daily x 5 days.
62748780|NCT02813135|EXPERIMENTAL|Arm A. Ribociclib + Topotecan and Temozolomide|Topotecan iv QD and temozolomide capsules orally QD Days 1 to 5; Ribociclib capsules or oral solution orally QD from Day 6 to 20 of a 28 day cycle.
62554095|NCT02500043|EXPERIMENTAL|TAS-102+BSC|Participants received 35 milligrams per meter square (mg/m\^2) of TAS-102 tablets orally twice daily (BID) for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until a discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.
62748781|NCT02813135|EXPERIMENTAL|Arm B. Ribociclib + Everolimus|Ribociclib capsules or oral solution orally QD for 21 days of each 28 day cycle; Everolimus orodispersible tablets orally QD for 28 days.
62748782|NCT02813135|EXPERIMENTAL|ARM C. Adavosertib + Carboplatin|Adavosertib capsules orally BID 3 days on / 4 days off in week 1; Carboplatin iv QD AUC 5 on Day 1 of a 21 day cycle.
62748783|NCT02813135|EXPERIMENTAL|Arm D. Olaparib + Irinotecan|Olaparib tablets orally BID on Day 1-10 of a 21 day cycle Irinotecan iv QD on Day 4-8 of a 21 day cycle.
62554096|NCT02500043|EXPERIMENTAL|Placebo+BSC|Participants received 35 mg/m\^2 of matching placebo for TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.
62748784|NCT02813135|EXPERIMENTAL|Arm E. Vistusertib single agent|Vistusertib tablets orally BID 2 days on/5 days off per week of a 28 day cycle.
62748785|NCT02813135|EXPERIMENTAL|Arm F. Vistusertib + Topotecan and Temozolomide|Topotecan iv QD and temozolomide capsules orally QD Days 1 to 5; Vistusertib tablets orally BID 3 days on/4 days off per week of a 28 day cycle.
62748786|NCT02813135|EXPERIMENTAL|Arm G. Nivolumab + Cyclophosphamide +/- Radiotherapy|Nivolumab iv QD every 2 weeks of a 28 day cycle (Days 1 and 15); Cyclophosphamide tablets or oral solution orally BID, 1 week on/1 week off; Palliative irradiation/radiofrequency/cryotherapy starting 2 weeks after the first nivolumab injection.
62748787|NCT02813135|EXPERIMENTAL|Arm H. Selumetinib + Vistusertib|Selumetinib capsules twice daily on a continous administration. Vistusertib orally twice daily on an intermittent schedule : 2 days on / 5 days off per week of a 28 day cycle.
62748788|NCT02813135|EXPERIMENTAL|Arm I. Enasidenib|Enasidenib tablets or sprinkle solution orally on a continuous dosing once daily (QD) per 28 day cycle.
62748789|NCT02813135|EXPERIMENTAL|Arm J. Lirilumab + Nivolumab|Nivolumab iv QD on Day 1 and 15 of a 28 day cycle; Lirilumab iv QD on Day 1 of a 28 day cycle
62391521|NCT03480334|EXPERIMENTAL|Arm A|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
62554097|NCT02846571|OTHER|Human Pancreatic Islet Transplantation|Islet transplantation into the anterior chamber of the eye single arm
62554098|NCT05238610||Experimental: intervention group|"This group will receive PFO-closure and standard antiplatelet treatment PFO-closure will be performed after 3-6 months of observation and monitoring for paroxysmal atrial fibrillation Standard antiplatelet treatment will be prescribed - aspirin 100mg and clopidogrel 75mg, once daily, principally. However, the final decision of antiplatelet treatment will be made by the physician. If paroxysmal atrial fibrillation is detected, anticoagulation will be considered.~Intervention : PFO closure Drug: aspirin 100mg/day Drug: clopidogrel 75mg/day"
62554099|NCT05238610||Active comparator: control group|"This group will receive standard antiplatelet treatment only Dual antiplatelet treatment with Aspirin 100mg and Clopidogrel 75mg, once daily, or single antiplatelet treatment with those agents can be considered. If paroxysmal atrial fibrillation is detected, anticoagulation will be considered.~Drug: aspirin 100mg/day Drug: clopidogrel 75mg/day"
62554100|NCT05450419|ACTIVE_COMPARATOR|Vitamin D3|Patient received enteral supplementation of 576,000 IU vitamin D3 on week 1, then enteral supplementation of 72,000 IU vitamin D3 on week 2, week 3 \& week 4.
62554101|NCT05450419|PLACEBO_COMPARATOR|Placebo|Patient received enteral supplementation of placebo on week 1, then enteral supplementation of placebo on week 2, week 3 \& week 4.
62554102|NCT04479787|ACTIVE_COMPARATOR|Spinal Cord Stimulation (SCS)|An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
62554103|NCT04479787|ACTIVE_COMPARATOR|Conventional Medical Management (CMM)|CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
62554104|NCT05177185|EXPERIMENTAL|SRS with hippocampal-sparing|Stereotactic radiosurgery with hippocampal-sparing
62554105|NCT04495569|EXPERIMENTAL|Group/Cohort A|A single intramuscular injection of SYN023 at 0.3mg/kg
62748790|NCT02813135|EXPERIMENTAL|Arm K. Fadraciclib (CYC065) + Temozolomide|Fadraciclib iv QD on Day 1 (+/- 15) of a 28 day cycle Temozolomide capsules orally QD on Day 1-5 of a 28 day cycle
62748791|NCT02813135|EXPERIMENTAL|Arm L. Fadraciclib (CYC065) + Cytarabine|Fadraciclib iv QD on Day 1 (+/- 15) of a 28 day cycle Cytarabine iv or sc on Day 2-5 and Day 8-11 of a 28 day cycle
62391522|NCT00829920||Bladder cancer|Patients with muscle invasive or metastatic bladder cancer who will be planning for treatment with surgery or chemotherapy.
62748792|NCT02813135|EXPERIMENTAL|Arm M. Ribociclib + Everolimus +/- Dexamethasone|"Ribociclib capsules or tablets orally QD on Day 1-21 of a 28 day cycle. Everolimus dispersible tablets orally QD on a continuous dosing per 28 day cycle.~For patients with leukemia and lymphoma:~Dexamethasone orally or iv on Day 1-7 of each 28 day cycle. For patients with ALL, AML and Non-Hodgkin Lymphoma (NHL), Intrathecal chemotherapy will be administered additionally as per standard practice depending on CNS status."
62748793|NCT02813135|EXPERIMENTAL|Arm N. Ceralasertib (AZD6738) + Olaparib|Olaparib tablets orally BID per 28 days Ceralasertib tablets QD or BID per 28 day cycle
62748794|NCT02813135|EXPERIMENTAL|Arm O. Futibatinib (TAS-120)|Futibatinib tablets orally on a continuous dosing QD per 28 day cycle
62554106|NCT04495569|EXPERIMENTAL|Group/Cohort B|A single intramuscular injection of SYN023 at 0.3mg/kg combined with the Chinese licensed Vero Cell Rabies Vaccine (following the PEP (Post-exposure Prophylaxis) recommendation)
62374766|NCT04849676|EXPERIMENTAL|Lower limb subacute spinal cord injury (sLL)|"Intervention: neurofeedback. Participants will receive visual feedback on a screen.~Diagnostic Tests:~Modified Ashworth Scale grading muscle resistance to movement (all limbs tested)~Perceived Spasticity level questionnaire on impact of spasticity~Spinal Cord Independence Measure questionnaire on level of independence of patients~Diary of spastic episodes~Instrumented Pendulum test - oscillations when lower leg is dropped from a resting position~10m walking test - patient walks 10 meters in a straight line, recorded with Kinect (Microsoft) device~EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria)~Brief Visual Analog Scale self-assessment of performance and mental strategies~Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)"
62374767|NCT04849676|EXPERIMENTAL|Lower limb chronic spinal cord injury (cLL)|"Intervention: neurofeedback. Participants will receive visual feedback on a screen.~Diagnostic Tests:~Modified Ashworth Scale grading muscle resistance to movement (all limbs tested)~Perceived Spasticity level questionnaire on impact of spasticity~Spinal Cord Independence Measure questionnaire on level of independence of patients~Diary of spastic episodes~Instrumented Pendulum test - oscillations when lower leg is dropped from a resting position~10m walking test - patient walks 10 meters in a straight line, recorded with Kinect (Microsoft) device~EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria)~Brief Visual Analog Scale self-assessment of performance and mental strategies~Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)"
62554107|NCT05810103|EXPERIMENTAL|DP303c|Eligible patients will be treated with DP303c at 3.0 mg/kg every 3 weeks.
62374768|NCT05747664|EXPERIMENTAL|DWP16001 to normal haptic function|Normal hepatic function
62374769|NCT05747664|EXPERIMENTAL|DWP16001 to Child-Pugh Class A|Child-Pugh Class A
62374770|NCT05747664|EXPERIMENTAL|DWP16001 to Child-Pugh Class B|Child-Pugh Class B
62374771|NCT00408772|EXPERIMENTAL|Unresectable colorectal liver mets|
62554108|NCT02287714|ACTIVE_COMPARATOR|Instep without Gastrocnemius Recession|Patient will receive an instep plantar fascial release but not a gastrocnemius recession.
62554109|NCT02287714|EXPERIMENTAL|Instep with Gastrocnemius Recession|Patient will receive an instep plantar fascial release as well as a gastrocnemius recession.
62554110|NCT02131987||Dislocation|Patients operated with hip hemiarthroplasty for a femoral neck fracture with a postoperative dislocation of the prosthesis
62554111|NCT02131987||Non-dislocated|Patents without dislocation of a hemiarthroplasty for a femoral neck fracture
62554112|NCT01231646||Lamotrigine|No intervention
62554113|NCT01231646||Valproate|No intervention
62554114|NCT02879344|OTHER|Patient undergoing ECMO|
62554115|NCT02998697|EXPERIMENTAL|Treated Group|Systolic heart failure patients received Ferrous Sulfate 200 mg t.i.d for 90 days
62554116|NCT02998697|PLACEBO_COMPARATOR|Control Group|Systolic heart failure patients received placebo oral capsule t.i.d for 90 days
62554117|NCT02037412|EXPERIMENTAL|Ticagrelor Arm|Ticagrelor Arm
62554118|NCT02037412|ACTIVE_COMPARATOR|Clopidogrel Arm|Clopidogrel Arm
62748795|NCT02813135|EXPERIMENTAL|Arm P. Capmatinib (INC280) + Everolimus|Capmatinib tablets orally on a continuous dosing BID per 28 day cycle. Everolimus dispersible tablets orally QD on a continuous dosing per 28 day cycle.
62748796|NCT02074345|EXPERIMENTAL|TAK-816 0.5 mL|Primary immunization: TAK-816 0.5 mL, intramuscular injection, once on Day 1 and every 28 days for 2 intervals (Days 29 and 57). Booster immunization: TAK-816 0.5 mL, intramuscular injection, once, 52 weeks after the third dose of primary immunization.
62748797|NCT01939002|EXPERIMENTAL|BIIB017 plus current FLS therapy|Following a 4-week run-in period (starting 1 day after the Screening Visit) in which participants administer non-pegylated IFN therapy, participants receive BIIB017 at an initial dose of 63 μg followed by 94 μg dose at Week 2 and 125 μg every 2 weeks from Week 4 to Week 46, plus current FLS management regimen as determined by the clinician.
62748798|NCT01939002|EXPERIMENTAL|BIIB017 plus naproxen|Following a 4-week run-in period (starting 1 day after the Screening Visit) in which participants administer non-pegylated IFN therapy, participants receive BIIB017 at an initial dose of 63 μg followed by 94 μg dose at Week 2 and 125 μg every 2 weeks from Week 4 to Week 46, plus 500 mg naproxen administered twice daily up to 24 hours prior to BIIB017 treatment and continuing for 48 hours following the BIIB017 injection for the first 8 weeks of treatment, and as recommended by the treating physician subsequently.
62748799|NCT00793559|ACTIVE_COMPARATOR|terlipressin bolus|1 mg of terlipressin received one time only
62748800|NCT00793559|EXPERIMENTAL|terlipressin drip|
62374772|NCT04372979|EXPERIMENTAL|SARS-CoV-2 patients treated with convalescent plasma|Subjects will receive an intravenous injection of SARS-CoV-2 Convalescent Plasma.
62374773|NCT04372979|ACTIVE_COMPARATOR|SARS-CoV-2 patients treated with standard plasma|Subjects will receive an intravenous injection of standard Plasma.
62374774|NCT03787901|EXPERIMENTAL|Morula Vitrification Arm|
62374775|NCT03787901|ACTIVE_COMPARATOR|Blastocyst Vitrification Arm|
62554119|NCT00207883||Landmark|Procedure/Surgery: Use of landmarks for central line placement
62554120|NCT00207883||Ultrasound guided|Procedure/Surgery: Use of ultrasound for central line placement
62554121|NCT04987151|EXPERIMENTAL|Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups.
62554122|NCT04987151|EXPERIMENTAL|Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking,
62374776|NCT06077136|ACTIVE_COMPARATOR|regular physical therapy group|this group will receive regular physical therapy 3 -5 times per week. this program will be designed according to the needs of each child. strength, stretch, facilitation, splinting, coordination, and functional exercises are examples of the components of the programs.
62374777|NCT06077136|EXPERIMENTAL|whole body vibration|"in addition to the regular exercises, selected arm exercises will be performed while the child is under whole-body vibration. using (Galileo® MED 25 TT, Germany; 2021 model) with the following parameters:~* WBV session duration: 10 minutes (rest periods can be incorporated~* frequency: 12 Hz~* Amplitude: 2 (fixed)~* duration of each exercise: 2-3 minutes"
62554123|NCT04987151|EXPERIMENTAL|Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups
62554124|NCT04987151|NO_INTERVENTION|Control Group|All the patients in the wait-list control group will receive one of the three trainings immediately after the intervention.
62554125|NCT04248530|EXPERIMENTAL|Renal denervation therapy group|The subject treated by renal denervation by using DENEX system.
62554126|NCT05649527||Main sample|Sample of 880 children spontaneously recruited and representative of the French population according to the criteria defined for the study. Includes breastfed children.
62554127|NCT05649527||Additional sample|Children in the appropriate age group selected because of their specific consumption in order to increase the number of children in the concerned age group to allow a statist test.
62554128|NCT05005052|EXPERIMENTAL|Sulodexide arm|Name: Vessel (medicinal product registered in Italy) Dosage form: soft capsules Active substance: sulodexidum 250 LSU Dosage: 2 x 2 soft capsules daily (oral use), in line with the labelled posology (500 LSU twice a day) Duration: 24 ± 4 weeks
62554129|NCT05005052|PLACEBO_COMPARATOR|Placebo arm|Dosage form: soft capsules Appearance: undistinguishable from the active Dosage regimen: 2 x 2 soft capsules daily Duration of placebo intake: a total of 24 ± 4 weeks
62554130|NCT05927870|EXPERIMENTAL|pyocele|obstructed gallbladder with infection on top
62554131|NCT02765256|EXPERIMENTAL|Fluconazole|Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
62374778|NCT01160042|EXPERIMENTAL|Metformin|Metformin Hydrochloride 1000 mg tablets of Dr. Reddy's Laboratories Limited
62374779|NCT01160042|ACTIVE_COMPARATOR|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
62374780|NCT03832023|NO_INTERVENTION|Facility-based model|Standard of care of each country
62374781|NCT03832023|EXPERIMENTAL|Community-based model|Screening and initiating preventive therapy in communities
62748801|NCT00503581|EXPERIMENTAL|Regimen 1 (megestrol acetate, surgery)|Patients receive oral megestrol twice daily every day for 24 weeks. Approximately twelve weeks after treatment starts, clinical blood tests are obtained and research serum and plasma collected. Twenty-four weeks constitutes one course of treatment and a pill count is performed during the 12-week f/u visit and at the completion of the treatment course to determine compliance. After progestin therapy the patient has an induced-withdrawal bleed. Patients in this arm undergo a re-evaluation biopsy and hysterectomy a minimum of two weeks and a maximum of eight weeks after completing the megestrol treatment.
62748802|NCT00503581|EXPERIMENTAL|Regimen 2 (megestrol acetate, surgery)|Patients receive oral megestrol twice daily for two weeks continuously followed by no treatment for two weeks. This course is repeated for a total of 24 weeks. Approximately twelve weeks after treatment starts, clinical blood tests are obtained and research serum and plasma collected. Twenty-four weeks constitutes one course of treatment and a pill count is performed during the 12-week f/u visit and at the completion of the treatment course to determine compliance. After progestin therapy the patient has an induced-withdrawal bleed. Patients in this arm undergo a re-evaluation biopsy and hysterectomy a minimum of two weeks and a maximum of eight weeks after the megestrol treatment.
62748803|NCT00503581|ACTIVE_COMPARATOR|Regimen 3 (surgery/biopsy)|(Closed as of 6/3/2010) Patients do not receive megestrol. At the discretion of the managing physician, patients undergo the re-evaluation biopsy and hysterectomy anytime between 2-20 weeks after enrollment and randomization.
62748804|NCT02360137||Patients with carotid plaque|Patients with carotid plaque treated using only drugs
62748805|NCT02360137||Patients with carotid stenosis|Patients with carotid stenosis indicated to carotid endarterectomy
62748806|NCT00252694|EXPERIMENTAL|candesartan|candesartan cilexetil 32 mg once daily
62748807|NCT00252694|NO_INTERVENTION|placebo|control
62748808|NCT03956277||Observational PUG|Patients receive gastrostomy via percutaneous ultrasound gastrostomy.
62748809|NCT00788099|EXPERIMENTAL|1|Plitidepsin and Sorafenib
62748810|NCT00788099|EXPERIMENTAL|2|Gemcitabine and Plitidepsin
62748811|NCT02121106|EXPERIMENTAL|Cognitive Remediation|Participants in this group will receive active cognitive remediation.
62554132|NCT02765256|PLACEBO_COMPARATOR|Placebo|Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo for fluconazole. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
62554133|NCT00782314||1|patients with maintenance only treatment with Symbicort Turbuhaler for at least 1 month
62748812|NCT02121106|SHAM_COMPARATOR|Sham Cognitive Remediation|Participants in this group will receive a sham comparison, which is a computerized exposure to the same exercises as the active intervention, but with cognitively complex elements removed and no titration of the difficulty of tasks.
62748813|NCT00521391|EXPERIMENTAL|A|a tailored physical activity intervention involving moderate-intensity exercise
62748814|NCT00521391|NO_INTERVENTION|B|
62748815|NCT00555763|ACTIVE_COMPARATOR|1|
62748816|NCT01607333||Completed suicide|Patients who completed suicide
62748817|NCT01607333||Suicide attempt|Patients who have attempted suicide, or performed preparatory acts toward imminent suicidal behavior, suicidal ideation plus indeterminate or potentially suicidal events
62748818|NCT01607333||Not completed suicide|Patients who have not completed suicide
62748819|NCT04027049|EXPERIMENTAL|Supine cycle ergometry of the lower extremities|Patients will receive two 20 minute cycle ergometry sessions separated by at least 4 hours in addition to usual care. The cycle will be set to a gear of zero and will begin in passive mode, the patient will be able to actively cycle if patients are able.
62748820|NCT04027049|NO_INTERVENTION|Control|Patients will receive usual care only.
62748821|NCT02974959|EXPERIMENTAL|gammaCore active device|Patients in this arm will be using an active device which delivers a treatment dose of current to the vagus nerve twice daily for 120 seconds
62748822|NCT02974959|SHAM_COMPARATOR|gammaCore Sham device|Patients in this arm will be using a sham device which does not deliver a treatment dose of current, but will deliver enough current to cause tingling on the skin.
62748823|NCT00948233||Intervention|Educational video game
62748824|NCT00948233||Standard Care|Pamphlets on stopping tobacco use
62748825|NCT00234871|ACTIVE_COMPARATOR|1|
62374782|NCT01401985|EXPERIMENTAL|Cohort 1|5 mg TD-1211 once daily for 4 days followed by 10 mg for 14 days
62554134|NCT00782314||2|patients with SMART treatment with Symbicort Turbuhaler for at least 1 month
62554135|NCT01437839|EXPERIMENTAL|1|Period I: fasting state, Period II: fed state
62554136|NCT01437839|EXPERIMENTAL|2|Period I: fed state, Period II: fasting state
62374783|NCT01401985|EXPERIMENTAL|Cohort 2|5 mg TD-1211 once daily for 4 days followed by 15 mg for 14 days
62554137|NCT03899246|EXPERIMENTAL|Capsaicin Arm|Single arm to receive eight percent topical capsaicin applied to up to 4 sites of recurrent pain over one hour on an every three month schedule. Participants in this arm will receive pretreatment with topical five percent lidocaine.
62554138|NCT03135015|OTHER|Lean Participants|Participants with BMI \>18.5 and \<25.0kg/m²
62554139|NCT03135015|OTHER|Overweight/Obese Participants|Participants with BMI ≥25.0 and \<35.0kg/m²
62554140|NCT06237296|EXPERIMENTAL|RSV/hMPV mRNA / LNP 1 Group 1|Participants will be randomized to receive a single IM injection of RSV/hMPV mRNA / LNP vaccine 1 dose 1.
62554141|NCT06237296|EXPERIMENTAL|RSV/hMPV mRNA / LNP 1 Group 2|Participants will be randomized to receive a single IM injection of RSV/hMPV mRNA / LNP vaccine 1 dose 2.
62748826|NCT00234871|ACTIVE_COMPARATOR|2|
62748827|NCT05783310|EXPERIMENTAL|Psychoeducation Intervention|The intervention group will receive six sessions of a psychoeducation intervention delivered face-to-face
62748828|NCT05783310|NO_INTERVENTION|Control group|No psychoeducation intervention will be given
62748829|NCT05299996|EXPERIMENTAL|all patients having stones in the upper tract of anomalous kidney|"patients having stones in abnormal anatomy , example horse-shoe kidney ,malrotation, crossed fusion , duplex collecting system. The stone size is 1 cm to 2.5 cm or 3.5 cm with variable density , located in calyx or the pelvis , single or multiple.~the patient complain may be abdominal pain , loin pain, uremic symptoms .ct-kub non contrast , full lab \& fitness before the operation."
62554142|NCT06237296|EXPERIMENTAL|RSV/hMPV mRNA / LNP 1 Group 3|Participants will be randomized to receive a single IM injection of RSV/hMPV mRNA / LNP vaccine 1 dose 3.
62554143|NCT06237296|EXPERIMENTAL|RSV/hMPV mRNA / LNP 2 Group 4|Participants will be randomized to receive a single IM injection of RSV/hMPV mRNA / LNP vaccine 2 dose 1.
62554144|NCT06237296|EXPERIMENTAL|RSV mRNA / LNP 1 Group 5|Participants will be randomized to receive a single IM injection of RSV mRNA / LNP vaccine 1 dose 1.
62748830|NCT06132425|EXPERIMENTAL|Positive Rehearsal|After every two exposure trials, participants will complete a rehearsal exercise prompting reflection of expectancy violation and rehearsal of the inhibitory association between the conditional stimulus (i.e., speech) and the unconditional stimulus (i.e., rejection). During rehearsal, participants are prompted to identify positive emotional experiences associated with exposure trial outcomes.
62748831|NCT06132425|ACTIVE_COMPARATOR|Neutral Rehearsal|After every two exposure trials, participants will complete a rehearsal exercise prompting reflection of expectancy violation and rehearsal of the inhibitory association between the conditional stimulus (i.e., speech) and the unconditional stimulus (i.e., rejection). During rehearsal, participants are prompted to maintain a neutral, non-emotional stance and focus on overall exposure trial outcomes.
62748832|NCT01376063|EXPERIMENTAL|FG-4592|
62748833|NCT05403593||Participants with Intracranial Stenosis|Patients with Intracranial Stenosis who undergo Mechanical Thrombectomy will be added to the registry given they meet the age inclusion criteria.
62374784|NCT01401985|EXPERIMENTAL|Cohort 3|5 mg TD-1211 once daily for 2 days followed by 10 mg for 14 days
62374785|NCT01401985|EXPERIMENTAL|Cohort 4|5 mg TD-1211 once daily for 2 days followed by 15 mg for 14 days
62374786|NCT01401985|EXPERIMENTAL|Cohort 5|2 mg TD-1211 once daily for 14 days
62374787|NCT01401985|EXPERIMENTAL|Cohort 6|2.5 mg TD-1211 every 6 hours for 14 days
62374788|NCT00542217|PLACEBO_COMPARATOR|Cohort 1|Single dose of 0.5 mg/kg Imprime PGG administered over 1 hr
62374789|NCT00542217|PLACEBO_COMPARATOR|Cohort 2|Single dose of 1.0 mg/kg Imprime PGG administered over 1 hr
62748834|NCT04049253|EXPERIMENTAL|Acidic phosphate buffer solution|pH5.2 phosphate buffer solution
62748835|NCT04049253|PLACEBO_COMPARATOR|Neutral phosphate buffer solution|pH7.4 phosphate buffer solution
62748836|NCT06036017|NO_INTERVENTION|Control groups|"T1: TBF, GCS, GKS, RCUOS, RASS, CAM-ICU forms will be filled out from the patients and blood samples will be taken.~T2: GCS, GKS, RCUOS, RASS, CAM-ICU forms will be filled out from the patients and blood samples will be taken. Additionally, durations of anesthesia, intubation and sedation as well as the amount of medication used for sedation will be recorded. The care package prepared will be applied to this group by the nurses working at the ward.~T3: GCS, GKS, RCUOS, RASS, CAM-ICU forms will be filled out from the patients and blood samples will be taken. Their length of stay in the intensive care unit will be noted."
62748837|NCT06036017|EXPERIMENTAL|Study groups|"T1: TBF, GCS, GKS, RCUOS, RASS, CAM-ICU forms will be filled out from the patients and blood samples will be taken.~T2: GCS, GKS, RCUOS, RASS, CAM-ICU forms will be filled out from the patients and blood samples will be taken. Additionally, durations of anesthesia, intubation and sedation as well as the amount of medication used for sedation will be recorded.~T3: GCS, GKS, RCUOS, RASS, CAM-ICU forms will be filled out from the patients and blood samples will be taken. Their length of stay in the intensive care unit will be noted."
62748838|NCT00712725|EXPERIMENTAL|1|MK3207- 2.5 mg
62748839|NCT00712725|EXPERIMENTAL|2|MK3207- 5 mg
62748840|NCT00712725|EXPERIMENTAL|3|MK3207- 10 mg
62748841|NCT00712725|EXPERIMENTAL|4|MK3207- 20 mg
62748842|NCT00712725|EXPERIMENTAL|5|MK3207- 50 mg
62748843|NCT00712725|EXPERIMENTAL|6|MK3207- 100 mg
62748844|NCT00712725|PLACEBO_COMPARATOR|7|Placebo
62748845|NCT01676753|EXPERIMENTAL|Treatment (Dinaciclib, Pembrolizumab)|Pembrolizumab will be administered on Day 1, every 3 weeks at a fixed dose of 200 mg IV. Dinaciclib will be administered D1 and D8 of a 21 day cycle by 2-hour intravenous infusion starting at Dose Level (DL) 1 of 12 mg/m\^2. Further dose escalation cohorts are defined as follows: DL 2: 18 mg/m\^2, DL 3: 25 mg/m\^2, DL 4: 33 mg/m\^2, and DL 5: 50 mg/m\^2
62554145|NCT06237296|EXPERIMENTAL|hMPV mRNA / LNP 1 Group 6|Participants will be randomized to receive a single IM injection of hMPV mRNA / LNP vaccine 1 dose 1.
62748846|NCT02260778|EXPERIMENTAL|Phase I Intervention|The learning collaborative as designed will be delivered to this arm during phase I, which will last a period of approximately 9 months. After the 9 months, there will be passive follow-up of this arm to see if outcomes following the first 9 months are sustained.
62748847|NCT02260778|NO_INTERVENTION|Phase II Intervention|This arm will serve as a control for the Phase I intervention arm during the first 9 months of the study for primary analysis. After the first 9 months, the Phase II intervention arm will receive the learning collaborative during the following 9 months.
62554146|NCT06237296|EXPERIMENTAL|RSV/hMPV mRNA / LNP 1 Group 7|Participants will be randomized to receive a single IM injection of RSV/hMPV mRNA / LNP vaccine 1 dose 4.
62554147|NCT03806673|ACTIVE_COMPARATOR|primipara|primipara subjected to their first epidural block
62748848|NCT05049213|EXPERIMENTAL|Topical medical treatment|Intranasal spray and oral gargling
62748849|NCT05767346|EXPERIMENTAL|Aficamten up to 20 mg plus placebo for metoprolol|Patients will receive doses of 5 mg, 10 mg, 15 mg or 20 mg of aficamten (CK-3773274) plus placebo for metoprolol succinate with dose levels guided by echocardiography assessments for up to 24 weeks.
62748850|NCT05767346|ACTIVE_COMPARATOR|Metoprolol succinate up to 200 mg plus placebo for aficamten|Patients will receive 50 mg, 100 mg, 150 mg or 200 mg of metoprolol succinate plus placebo for aficamten (CK-3773274) with dose levels guided by echocardiography and heart rate assessments for up to 24 weeks.
62748851|NCT00090233|EXPERIMENTAL|1|RotaTeq
62748852|NCT00090233|PLACEBO_COMPARATOR|2|Placebo
62748853|NCT06272084||TPE Treatments|Patients with indication for TPE treatment according to American Society for Apheresis (ASFA) guideline
62748854|NCT06067685||Pregnancies with GDM and BMI > 30|Pregnancies with GDM diagnosed between 24-32 weeks and BMI \> 30.
62748855|NCT04467229|EXPERIMENTAL|Focus group with chronically painful adolescents|Adolescents with chronic pain
62748856|NCT01628679|EXPERIMENTAL|physical therapy treatment|
62748857|NCT03526237|EXPERIMENTAL|The 24-week treatment|The 24-week treatment, Sisters Health And Primary CarE Uniting and Preventing Diabetes (SHAPE UP) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.
62748858|NCT03526237|OTHER|Wait-list Control|Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.
62374790|NCT00542217|PLACEBO_COMPARATOR|Cohort 3|Single dose of 2.0 mg/kg Imprime PGG administered over 1 hr
62374791|NCT00542217|PLACEBO_COMPARATOR|Cohort 4|Single dose of 4.0 mg/kg Imprime PGG administered over 2 hr
62554148|NCT03806673|ACTIVE_COMPARATOR|multipara|multipara subjected to their repeated epidural block.
62554149|NCT04213495||Patients undergoing anesthesia in Czech Republic|Patients undergoing anesthesia in Czech Republic in the selected period from the confirmed Anesthesia Center
62554150|NCT03679689|NO_INTERVENTION|Control group|no changes in their alimentary habits
62554151|NCT03679689|EXPERIMENTAL|intervention group|no intake of artificially sweetened beverages
62554152|NCT01295398|OTHER|conventional jet-nebulizer|(particles diameter of 4-5 µm)
62748859|NCT05818956|EXPERIMENTAL|Sequence 1: (Treatment A + Treatment B + Treatment C)|TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 under fasting condition as Treatment A, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C. There will be a washout period of at least 4 days between each dosing.
62748860|NCT05818956|EXPERIMENTAL|Sequence 2: (Treatment B + Treatment C + Treatment A)|TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 under fasting condition as Treatment A . There will be a washout period of at least 4 days between each dosing.
62748861|NCT05818956|EXPERIMENTAL|Sequence 3: (Treatment C + Treatment A + Treatment B)|TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 under fasting condition as Treatment A, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B. There will be a washout period of at least 4 days between each dosing.
62748862|NCT05818956|EXPERIMENTAL|Sequence 4: (Treatment A + Treatment C + Treatment B)|TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 under fasting condition as Treatment A, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B. There will be a washout period of at least 4 days between each dosing.
62374792|NCT00542217|PLACEBO_COMPARATOR|Cohort 5|Single dose of 6.0 mg/kg Imprime PGG administered over 3 hr
62374793|NCT00941707|EXPERIMENTAL|JNJ-38518168|
62374794|NCT00941707|PLACEBO_COMPARATOR|Placebo|
62554153|NCT01295398|EXPERIMENTAL|a jet-nebulizer adapted for infants|(particles diameter of 2-2.5 µm),
62748863|NCT05818956|EXPERIMENTAL|Sequence 5: (Treatment B + Treatment A + Treatment C)|TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 under fasting condition as Treatment A, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C. There will be a washout period of at least 4 days between each dosing.
62748864|NCT05818956|EXPERIMENTAL|Sequence 6: (Treatment C + Treatment B + Treatment A)|TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 under fasting condition as Treatment A. There will be a washout period of at least 4 days between each dosing.
62748865|NCT00518648|EXPERIMENTAL|I|Multifactorial fall prevention program
62748866|NCT00518648|OTHER|II|Usual care
62748867|NCT02250807|EXPERIMENTAL|Simeprevir and Sofosbuvir|Subjects will receive oral capsule of Simeprevir 150 milligram (mg) along with oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
62748868|NCT03994887|EXPERIMENTAL|Experimental group|Patients under general anesthesia will be included.
62748869|NCT01643161|EXPERIMENTAL|TAU+GSH|Treatment As Usual plus Guided Self Help.
62748870|NCT01643161|ACTIVE_COMPARATOR|TAU|Treatment AS Usual.
62374795|NCT02736474|EXPERIMENTAL|Naltrexone and Bupropion|Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.
62374796|NCT02736474|PLACEBO_COMPARATOR|Placebo Naltrexone and Bupropion|Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.
62374797|NCT00939094|EXPERIMENTAL|A|
62374798|NCT00939094|PLACEBO_COMPARATOR|B|
62554154|NCT01295398|EXPERIMENTAL|a mesh-nebulizer adapted for infants|(particles diameter of 2-2.5 µm).
62554155|NCT01495000|EXPERIMENTAL|Arm 1|denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind treatment
62554156|NCT01495000|PLACEBO_COMPARATOR|Arm 2|placebo subcutaneous injection, single dose at the start of the 6-month double-blind treatment
62748871|NCT03326401||Case (AMD group)|Case group including 100 patients diagnosed with age-related macular degeneration (50 women, 50 men).Demographic data and dietary intake of different food groups were assessed by a standardized interviewer-assisted questionaire with the method of face-to-face interview. The body weight of the individuals were measured with a calibrated electronic scale,anthropometric measurements were measured by the researcher. Participants' dietary intake was assessed using food frequency questionaire (FFQ). The FFQ included 65 food items traditionally consumed in Turkey. Foods were classified into the following food categories: milk and dairy products, meat and meat products, fruits, vegetables, breads and cereals, beverages, and desserts.
62554157|NCT04435834|EXPERIMENTAL|Propofol|"Subject will receive propofol anesthesia during their MRI. Dosage form: injectable solution. Dosage: 100-300 mcg/kg/min, or as per clinical standard of care appropriate for specific subjects.~Frequency and duration: continuous infusion while undergoing MRI."
62554158|NCT04435834|EXPERIMENTAL|Sevoflurane|"Subject will receive sevoflurane anesthesia during their MRI. Dosage form: volatile liquid for inhalation Dosing: 0-1 month full term neonate (3.3% in oxygen), 1-6 months old (3% in oxygen), 6 months to \<3 years old (2.8% in oxygen), or as per clinical standard of care appropriate for specific subjects.~Frequency and duration: continuous infusion while undergoing MRI."
62554159|NCT02861924|EXPERIMENTAL|microcirculatory responses|"Measure microcirculatory responses after localized ischemia obtained by local application of pressure (laser speckle).~A pressure is applied to the subject's arm. this causes a localized ischemia. the measures responses to this ischemia will be made by the imager speckle (LSCI) give the microvascular perfusion data."
62554160|NCT03652337|EXPERIMENTAL|BlephEx|The subjects who are enrolled in this arm will undergo electronic lid margin debridement using the BlephEx instrument.
62554161|NCT03652337|EXPERIMENTAL|Manual debridement|The subjects who are enrolled in this arm will undergo manual lid margin debridement using a stainless steel ophthalmic golf spud.
62554162|NCT02574598|EXPERIMENTAL|Docetaxel + MK-3475|"Docetaxel 75 mg/m2 every 3 weeks until progression of disease~MK-3475 (administered on day 8) 200mg every 3 until progression of disease"
62554163|NCT02574598|ACTIVE_COMPARATOR|Docetaxel|Docetaxel 75 mg/m2 every 3 weeks until progression of disease followed by MK-3475 200mg every 3 until progression of disease
62554164|NCT02255331||Retrieval Analysis|"You qualify for this Retrieval Analysis study if you:~1. Have a total hip replacement with a ceramic component undergoing revision for any reason, including recurrent dislocation.~2. Have a metal-on-polyethylene total hip replacement and have repeated dislocation, or~3. Have a metal-on-polyethylene total hip replacement greater than 1 year old, or~4. Have an infected total hip replacement (any surface bearing)~You do not qualify for this arm of the study if you:~1. Have occupational exposure to cobalt or chromium~2. Presence of a metal-on-metal (MOM) implant, or a recalled implant~3. Have had a prior revision of your total hip~4. Standard contra-indications to MRI (e.g. cardiac pacemaker, etc.)"
62554165|NCT02255331||Longitudinal Evaluation|"You qualify for this arm of the study if you:~1. Have a total hip replacement with a ceramic component~2. Have a metal-on-polyethylene total hip replacement.~3. Have your original or revised total hip replacement.~You do not qualify for this arm of the study if you:~1. Have occupational exposure to cobalt or chromium~2. Have cemented components.~3. Presence of a metal-on-metal (MOM) implant, or a recalled implant~4. Standard contra-indications to MRI (e.g. cardiac pacemaker, etc.)"
62748872|NCT03326401||Control (Non-AMD group)|Case group including 100 patients not diagnosed with age-related macular degeneration (50 women, 50 men).Demographic data and dietary intake of different food groups were assessed by a standardized interviewer-assisted questionaire with the method of face-to-face interview. The questionaire form, prepared to determine socio-demographic features of individuals participating in the research, was applied by the research with the method of face-to-face interview. The body weight of the individuals were measured with a calibrated electronic scale,anthropometric measurements were measured by the researcher. Participants' dietary intake was assessed using food frequency questionaire (FFQ). The FFQ included 65 food items traditionally consumed in Turkey. Foods were classified into the following food categories: milk and dairy products, meat and meat products, fruits, vegetables, breads and cereals, beverages, and desserts.
62748873|NCT00139542|ACTIVE_COMPARATOR|CONTROL|AED Treatment protocol following AHA Guidelines 2000 recommendations for cardiac arrest resuscitation.
62554166|NCT03995277|OTHER|Healthy cohort - high dose|Apparently healthy subjects, who take 10 mg/d of biotin at the same time each morning for 10 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), and 10 days after participants stopped taking biotin (day 20).
62748874|NCT00139542|EXPERIMENTAL|STUDY|AED treatment protocol with prolonged CPR intervals, single shocks, fewer rhythm analysis and pulse checks.
62748875|NCT06161636||Patients with Parkinson Disease (PD)|"Participants will then have to perform three blocks of tests: the first focused on the scripted motor signature, a second on the voice signature, and a complementary block aimed at capturing the motor signature using gestures of greater amplitude.~All the tests were designed to allow the characterization of the motor signature according to different aspects of motor control, but also to reproduce the same concepts in the three fields (scripted signature, voice signature and large amplitude motor signature), while allowing an acquisition of an approximate total duration of 30 minutes.~For retinal photos, the subject's pupils will be dilated using eye drops (1% tropicamide and 2.5% phenylephrine) 15-20 minutes before taking the measurement. These drugs are considered the standard used by optometrists and ophthalmologists during pupil dilation."
62374799|NCT01728766||Infants under-6 months and their mothers|Small for gestational age at delivery. Post-term Infant, Not Heavy-for-dates.
62374800|NCT05754372||Hyperammonaemia|
62374801|NCT03857464|OTHER|Crossover Arm One|Hospital wards in this arm will use C. DIFF QUIK CHEK COMPLETE® for near-patient testing for the first phase of the crossover. For the second phase of the crossover, Arm One will utilize standard operating procedure testing for C. difficile infections using the centralized testing facilities.
62748876|NCT06161636||Patients with atypical Parkinsonian Syndromes (PS)|"Participants will then have to perform three blocks of tests: the first focused on the scripted motor signature, a second on the voice signature, and a complementary block aimed at capturing the motor signature using gestures of greater amplitude.~All the tests were designed to allow the characterization of the motor signature according to different aspects of motor control, but also to reproduce the same concepts in the three fields (scripted signature, voice signature and large amplitude motor signature), while allowing an acquisition of an approximate total duration of 30 minutes.~For retinal photos, the subject's pupils will be dilated using eye drops (1% tropicamide and 2.5% phenylephrine) 15-20 minutes before taking the measurement. These drugs are considered the standard used by optometrists and ophthalmologists during pupil dilation."
62554167|NCT03995277|OTHER|Hypothyroid cohort|Subjects under thyroid medication, who take 10 mg/d of biotin at the same time each morning for 10 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), and 10 days after participants stopped taking biotin (day 20).
62554168|NCT03995277|OTHER|Healthy cohort - low dose|Apparently healthy subjects, who take 50 µg/d of biotin at the same time each morning for 20 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), after 20 days of biotin supplementation (day 20), and 10 days after participants stopped taking biotin (day 30).
62554169|NCT01306266|ACTIVE_COMPARATOR|rizatriptan|initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo
62554170|NCT01306266|PLACEBO_COMPARATOR|Placebo|Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg
62554171|NCT00932191|ACTIVE_COMPARATOR|Ultrasound phacoemulsification|Cataract nucleus is removed using standard amounts of ultrasound energy.
62554172|NCT00932191|ACTIVE_COMPARATOR|Reduced ultrasound phacoemulsification|Cataract nucleus removal using less ultrasound energy and more mechanical energy.
62554173|NCT03044028|EXPERIMENTAL|NMES preoperative and postoperative|Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use preoperative and will continue to use postoperatively until end of study
62554174|NCT03044028|EXPERIMENTAL|NMES postoperative only|Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use postoperatively and will continue to use until end of study
62554175|NCT03044028|NO_INTERVENTION|No intervention|Subject will not be given device and will undergo the standard rehab protocol alone
62554176|NCT01436955|EXPERIMENTAL|A|
62554177|NCT01436955|PLACEBO_COMPARATOR|B|
62374802|NCT03857464|OTHER|Crossover Arm Two|Hospital wards in this arm will utilize testing for C. difficile infections using the centralized testing facilities in phase 1 and will switch to using C. DIFF QUIK CHEK COMPLETE® for near-patient testing in phase 2 of the crossover design.
62374803|NCT05529862|EXPERIMENTAL|Locally advanced or metastatic Breast Cancer Women|"Study Procedures:~* Additional tumour sampling during the pre-treatment biopsy scheduled as per routine care,~* A post-treatment tumour biopsy,~* One pre-treatment and one post-treatment blood sampling."
62374804|NCT05008549|EXPERIMENTAL|First Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence.
62554178|NCT04365803||patient with radiological complete response|patient with radiological complete response after neoadjuvant chemotherapy
62554179|NCT03691766|EXPERIMENTAL|Photobiomodulation Therapy|Experimental: Photobiomodulation Therapy comprising 640 nm, 875 nm, and 905 nm light (red lights)
62554180|NCT03691766|PLACEBO_COMPARATOR|Control|Placebo device with different wavelengths of light without known physiologic effect.
62554181|NCT04873596|ACTIVE_COMPARATOR|nebulized dexmedetomidine|parturient will receive nebulized 3ug/kg dexmedetomidine diluted in normal saline (0.9%) solution till total volume of nebulized solution will become 5 ml and will be nebulized by a standard hospital jet nebulizer via mouthpiece, with a continuous flow of 100% oxygen at 6 L/min. for 15 minutes, and the treatment will be stopped when the nebulizer will be began to sputter.
62554182|NCT04873596|ACTIVE_COMPARATOR|nebulized midazolam|parturient will receive nebulized 0.2 mg/kg midazolam diluted in normal saline (0.9%) solution till total volume of nebulized solution will become 5 ml and will be nebulized by a standard hospital jet nebulizer via mouthpiece, with a continuous flow of 100% oxygen at 6 L/min. for 15 minutes, and the treatment will be stopped when the nebulizer will be began to sputter.
62554183|NCT03956394|OTHER|Active Takayasu disease|UltraFast ultrasound will be performed in the usual health care, with the evaluation of carotid artery disease by Doppler ultrasound in patients hospitalized for Takayasu Arteritis Assessment.
62554184|NCT03956394|OTHER|Non-active Takayasu disease|UltraFast ultrasound will be performed in the usual health care, with the evaluation of carotid artery disease by Doppler ultrasound in patients hospitalized for Takayasu Arteritis Assessment.
62554185|NCT05351931|ACTIVE_COMPARATOR|SPC-flakes with or without Salovum|SPC-flakes flat dose of 75 g/d divided in 2 - 4 doses started 5 days prior to start of RCT and continued during the RCT. Salovum egg powder 4 g/sachet. Four sachets, ie 16 g q 8 h for 5 days prior to start of RCT. The appropriate amount of Salovum is mixed with 100 - 200 ml of suitable liquid, eg fruit juice, and ingested orally.
62554186|NCT05351931|PLACEBO_COMPARATOR|SPC-flakes placebo with or without Salovum placebo|SPC-placebo flat dose of 75 g/d divided in 2 - 4 doses started 5 days prior to start of RCT and continued during the RCT. Salovum placebo egg powder 4 g/sachet. Four sachets, ie 16 g q 8 h for 5 days prior to start of RCT. The appropriate amount of Salovum placebo is mixed with 100 - 200 ml of suitable liquid, eg fruit juice, and ingested orally.
62554187|NCT04886661||PATIENTS WITH CHRONIC NECK PAIN|Patients between the ages of 18-65 who are eligible for the inclusion criteria will be included in the study who have cervical X-RAY and cervical MRIs taken in the last 3 months.
62554188|NCT03383523|EXPERIMENTAL|Part 1a - treatment A|5 mg emodepside LSF, fasted
62554189|NCT03383523|EXPERIMENTAL|Part 1a - treatment B|5 mg emodepside IR-tablet #406, fasted
62554190|NCT03383523|EXPERIMENTAL|Part 1a - treatment C|5 mg emodepside IR-tablet #416, fasted
62554191|NCT03383523|EXPERIMENTAL|Part 1b - treatment D|5 mg emodepside IR-tablet #406, fed
62554192|NCT03383523|EXPERIMENTAL|Part 1b - treatment E|5 mg emodepside IR-tablet #416, fed
62554193|NCT03383523|EXPERIMENTAL|Part 2 - treatment F|2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
62554194|NCT03383523|EXPERIMENTAL|Part 2 - treatment G|2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
62554195|NCT03590210|EXPERIMENTAL|Group A - L-sarcoma|Patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen will receive drug treatment with trabectedin (1 cycle mono-therapy) followed by trabectedin/nivolumab combination (up to 15 additional cycles); 16 cycles in total
62374805|NCT05008549|EXPERIMENTAL|Second Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
62554196|NCT03590210|EXPERIMENTAL|Group B - non-L-sarcoma|Patients with unresectable or metastatic soft tissue sarcoma other than liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen (GIST excluded) will receive drug treatment with trabectedin (1 cycle mono-therapy) followed by trabectedin/nivolumab combination (up to 15 additional cycles); 16 cycles in total
62554197|NCT02604407|EXPERIMENTAL|SHP465 12.5 mg|Subjects will receive SHP465 12.5 mg
62554198|NCT02604407|EXPERIMENTAL|SHP465 37.5 mg|Subjects will receive SHP465 titrated up to 37.5 mg
62554199|NCT02604407|PLACEBO_COMPARATOR|Placebo|Subjects will receive matching placebo
62554200|NCT02735109|OTHER|description|photographies and biopsy on normal area
62554201|NCT04867343|EXPERIMENTAL|HR020602 injection|
62554202|NCT04867343|ACTIVE_COMPARATOR|fentanyl injection + remifentanil injection|
62554203|NCT00575237|NO_INTERVENTION|Control|In the control group, CO2 was removed by passive deflation of the abdominal cavity through the holes of the trocar.
62554204|NCT00575237|EXPERIMENTAL|Intervention|
62391523|NCT03672006|EXPERIMENTAL|alteplase|patients will receive 30 min-4 hours dwells of alteplase (recombinant t-PA) (2mg/2ml, up to 2mg per dose) to central venous catheter every 3 days (maximum 10 doses)
62748877|NCT06161636||Healthy volunteers|"Participants will then have to perform three blocks of tests: the first focused on the scripted motor signature, a second on the voice signature, and a complementary block aimed at capturing the motor signature using gestures of greater amplitude.~All the tests were designed to allow the characterization of the motor signature according to different aspects of motor control, but also to reproduce the same concepts in the three fields (scripted signature, voice signature and large amplitude motor signature), while allowing an acquisition of an approximate total duration of 30 minutes.~For retinal photos, the subject's pupils will be dilated using eye drops (1% tropicamide and 2.5% phenylephrine) 15-20 minutes before taking the measurement. These drugs are considered the standard used by optometrists and ophthalmologists during pupil dilation."
62748878|NCT04679922|ACTIVE_COMPARATOR|Peri Implant mucosal thickness connective tissue graft|
62748879|NCT04679922|EXPERIMENTAL|Peri Implant mucosal thickness fascia lata graft|
62748880|NCT04703816|EXPERIMENTAL|Intervention arm|Physicians in the intervention arm will receive the training program consisting of two half-day group workshops with a review of the skills needed to build effective patient relationships and a discussion of difficult consultations.
62748881|NCT04703816|NO_INTERVENTION|Control arm|Physicians in the control group will not receive any specific intervention at this stage.
62748882|NCT06035575|EXPERIMENTAL|Intervention (video)|Educational Video: Participants in this arm will watch an interactive pain management video, sent as a link to their email. Participants will send back answers to the multiple-choice questions posed during the video and/or confirm having watched the video within 5 days (at most) of their acute care visit or discharge from the ED.
62748883|NCT06035575|NO_INTERVENTION|Usual Care|Participants will receive the typical care provided by medical personnel for their acute pain.
62748884|NCT05211804||Treatment-naïve|15 patients not previously receiving anti-VEGF treatment for nAMD.
62748885|NCT05211804||Undergoing treatment|15 patients already undergoing treatment with anti-VEGF for nAMD.
62748886|NCT01265563|PLACEBO_COMPARATOR|NAC placebo and Silibin placebo|Drug: N-acetylcysteine placebo and Drug: Silibin placebo
62748887|NCT01265563|EXPERIMENTAL|NAC active and Silibin placebo|Drug: N-acetylcysteine and Drug: Silibin placebo
62374806|NCT05008549|EXPERIMENTAL|Third Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
62374807|NCT05008549|EXPERIMENTAL|Fourth Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
62374808|NCT05008549|EXPERIMENTAL|Fifth Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
62374809|NCT05008549|EXPERIMENTAL|Sixth Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
62374810|NCT01961999|ACTIVE_COMPARATOR|Early RRT|"In the early arm renal replacement therapy was started on the basis of refractory oliguria: urine output \<0,5ml/Kg/h for \> 6 hours"
62374811|NCT01961999|ACTIVE_COMPARATOR|Late RRT|"In the late arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:~* persistent and refractory oliguria (\<0,5 ml/Kg/h \>12h), despite therapy~* refractory extravascular fluid overload~* azotemia \> 40mmol/L or 240 mg/dL~* metabolic acidosis (pH\<7,2)~* hyperkaliemia (k+\>6 mmol/L)"
62554205|NCT06239077|EXPERIMENTAL|Identifai Genetics Analytic Validity - Compound Heterozygosity and Samples Collection|
62374812|NCT02325128|EXPERIMENTAL|Post-Exposure Nap|Sleep-enhancement of extinction memory: At the end of the third and fourth of 5 exposure therapy sessions, all participants deliver a speech designed to elicit significant social anxiety. Following this speech, this arm will be given a 2-hour sleep opportunity with polysomnographic (PSG) monitoring.
62554206|NCT01656980|EXPERIMENTAL|Carmustine Sustained Release Implant|For subjects in this group, they will accept intracranially implanted carmustine intraoperatively.
62554207|NCT01656980|SHAM_COMPARATOR|Tumor Resection Surgery|For subjects in this control group, they accept no implants while gliomas maximally be resected.
62554208|NCT02816606||Standard Reconstruction Technique|ACL reconstruction using hamstring autograft Using 30-degree arthroscope Using rigid femoral tunnel reamer (Rigid Reamers)
62554209|NCT02816606||Alternative Reconstruction Group|ACL reconstruction using hamstring autograft Using 30-degree and 70-degree arthroscopes Using flexible femoral tunnel reamer (Flexible Reamers)
62748888|NCT01265563|EXPERIMENTAL|NAC placebo and Silibin active|Drug: N-acetylcysteine placebo and Drug: Silibin active
62748889|NCT01265563|EXPERIMENTAL|NAC active and Silibin active|Drug: N-acetylcysteine active and Drug: Silibin active
62748890|NCT01265563|EXPERIMENTAL|NAC active and High-dose Silibin active|Drug: N-acetylcysteine active and Drug: Silibin higher dose active
62748891|NCT01034566|EXPERIMENTAL|Arm I|Patients undergo proton beam radiotherapy 5 days a week for 6 (preoperative patients) or 8 (post-operative patients) weeks in the absence of disease progression or unacceptable toxicity.
62748892|NCT03354546||Elective noncardiac surgery|Individuals having major noncardiac surgery following an elective hospital admission
62748893|NCT03354546||Emergency general surgery|Individuals having general surgery following an urgent hospital admission
62748894|NCT06405737|EXPERIMENTAL|oxytocin|a single dose of 24 international units (IU) of OT will be administered with 3 puffs of treatment to each nostril.
62748895|NCT06405737|EXPERIMENTAL|placebo|a single dose of 24 international units (IU) of placebo will be administered with 3 puffs of treatment to each nostril.
62748896|NCT02513485|ACTIVE_COMPARATOR|Sinemet/Placebo|Subjects with major depression will be given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet will be given first followed by placebo at the subsequent visit.
62748897|NCT02513485|ACTIVE_COMPARATOR|Placebo/Sinemet|Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit.
62748898|NCT00769925|EXPERIMENTAL|Therapist Assisted Bibliotherapy-Primary Care (TAB-PC)|
62748899|NCT00769925|EXPERIMENTAL|Cognitive Behavior Therapy-Primary Care (CBT-PC)|
62748900|NCT01451931|EXPERIMENTAL|Point-of-care Ultrasound|Patient with suspected urolithiasis will receive ultrasonography performed in the emergency department. Perform ultrasonography in the ED (physician).
62748901|NCT01451931|EXPERIMENTAL|Radiology Ultrasound|Patient with suspected urolithiasis will receive diagnostic ultrasonography in the radiology department. Diagnostic ultrasound completed in the radiology department at time 0.
62748902|NCT01451931|EXPERIMENTAL|Radiology CT|Patient with suspected urolithiasis will receive computed tomography in the radiology department. Computed tomography of abdomen completed in the radiology department at time 0.
62748903|NCT02399280|EXPERIMENTAL|Lunch|Lunch as main meal(LM)+ Diet
62748904|NCT02399280|EXPERIMENTAL|Dinner|Dinner as main meal(DM)+ Diet
62748905|NCT01327079|EXPERIMENTAL|Group 1|"Gestational age less than 29 weeks We will substitute for one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
62748906|NCT01327079|EXPERIMENTAL|Group 2|"Gestational age greater then 29 weeks We will substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
62748907|NCT03628144|EXPERIMENTAL|A: Intervention Group - Impact®|A: Intervention Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Impact® Advanced Recovery: Three times daily for the 5 days just prior to the start of each cycle of chemotherapy. Participants will undergo pre- and post-treatment assessments.
62748908|NCT03628144|ACTIVE_COMPARATOR|B: Control Group - Boost®|B: Control Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Boost® High Protein: Identical schedule of a supplement with similar calorie and protein content, Boost® High Protein. Participants will undergo pre- and post-treatment assessments.
62748909|NCT02549625|EXPERIMENTAL|Single-arm|Intracoronary delivery of autologous bone marrow-derived mononuclear cells using catheterization procedure
62748910|NCT01743235|EXPERIMENTAL|Placebo|30 subjects administered a placebo
62748911|NCT01743235|EXPERIMENTAL|Testosterone + Buspirone hydrochloride combination drug|30 subjects are given combination drug (0.25 mg Testosterone + 5 mg Buspirone hydrochloride)
62748912|NCT01743235|EXPERIMENTAL|Testosterone + Buspirone hydrochloride combinat|30 subjects are given combination drug (0.25 mg Testosterone + 10 mg Buspirone hydrochloride)
62748913|NCT01743235|EXPERIMENTAL|Testosterone + Buspirone Combination Drug|30 subjects are given combination drug (0.5 mg Testosterone + 5 mg Buspirone hydrochloride)
62748914|NCT01743235|EXPERIMENTAL|Testosterone +Buspirone Combination Drug|30 subjects are given combination drug (0.5 mg Testosterone + 10 mg Buspirone hydrochloride)
62748915|NCT01743235|EXPERIMENTAL|Testosterone|30 subjects are given 0.5 mg Testosterone
62748916|NCT01743235|EXPERIMENTAL|Buspirone|30 subjects are given 10 mg Buspirone hydrochloride
62554210|NCT03173157|EXPERIMENTAL|Value Feedback Arm|A weekly email will be sent to all inpatient, resident-staffed cardiology teams outlining best use practices from AHA/ACC statements on trans-thoracic echoacardiography and data feedback on in-hospital charges, running 13 week average usage and previous week usage of full and limited trans thoracic echocardiograms
62748917|NCT00733161|ACTIVE_COMPARATOR|1|Passive leg cycle exercise with stretching and resistance training
62748918|NCT00733161|ACTIVE_COMPARATOR|2|Stretching and resistance training
62554211|NCT06582979|EXPERIMENTAL|Combined Intervention Group|This group will experience both computer-based game therapy and also high-intensity interval training for 7 weeks.
62554212|NCT04076163|NO_INTERVENTION|control group|group of students participating to a face-to-face learning
62554213|NCT04076163|OTHER|intervention group|group of students using serious game
62554214|NCT03697824|EXPERIMENTAL|GSK3377794+pembrolizumab|After screening, eligible subjects will enter a leukapheresis phase, followed by lymphodepletion phase where they will be administered fludarabine and cyclophosphamide. On Day 1, subjects will receive a single dose of GSK3377794 administered as an intravenous infusion of 1 to 6 x10\^9 total transduced cells. On Day 22, subjects will be administered pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks for adults and 2 mg/kilogram (kg) (up to 200 mg) once every 3 weeks for children for up to 35 cycles (2 years) or until subsequent disease progression.
62748919|NCT03479268|EXPERIMENTAL|Treatment (pevonedistat, ibrutinib)|Participants receive pevonedistat IV over 1 hour on days 1, 3, and 5, and ibrutinib PO daily on days 2-21 of course 1 and days 1-21 of subsequent courses. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Participants then receive only ibrutinib PO daily on days 1-21. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
62748920|NCT02823054|NO_INTERVENTION|Standard group|bi lung ventilation usual practice
62748921|NCT02823054|EXPERIMENTAL|EZ-Blocker group|one lung ventilation 'EZ-Blocker'
62748922|NCT04433689||Pregnant women|Pregnant woman, age 18 to 38 yo, with uncomplicated singleton pregnancy and no ocular diseases.
62748923|NCT01480804|EXPERIMENTAL|Geriatric diabetes team intervention group|The subjects in this group underwent evaluation for barriers to self care by a diabetes educators well versed with age specific barriers. After consideration of patients clinical, functional, and psychosocial background a geriatric diabetes team devised strategy to help patients cope respective barriers. A care manager then implemented the coping strategies by educating patients and caregivers. She also made home visits to assess any safety issues not know to clinic based geriatric team. She helped the patients and caregivers with all aspects of care coordination. Patients in this group received phone contact from care managers as many times as needed over the six month intervention period.
62748924|NCT01480804|NO_INTERVENTION|Attention Control Group|The subjects in the group received similar, in person, contact as the intervention group. An educator, separate from the one involved in the intervention team, called patents in this group for a total of eleven time within the first six months. The phone calls were forces toward general discussion without any diabetes related advice.
62748925|NCT02519894|EXPERIMENTAL|Intervention group|Intensive low sodium education and immediate sodium intake feedback by dietary scanning calculator
62748926|NCT02519894|PLACEBO_COMPARATOR|Controlled group|Standard education
62748927|NCT06072300|EXPERIMENTAL|Intervention|The placement of physical activity calorie equivalent labelling on beverage vending machines
62374813|NCT02325128|ACTIVE_COMPARATOR|Post-Exposure Wake|At the end of the third and fourth of 5 exposure therapy sessions, all participants deliver a speech designed to elicit significant social anxiety. Following this speech, this arm will be instrumented for PSG but, instead of napping, will undergo 2 hours of quiet wakefulness. Therefore, this arm will not undergo sleep-enhancement of extinction memory.
62748928|NCT06072300|NO_INTERVENTION|Comparator|No physical activity calorie equivalent labelling on beverage vending machines
62748929|NCT05980091|OTHER|Group A|Embryo transfer is scheduled on the 6th full day of progesterone administration, following the initial commencement of progesterone (120 hours)
62748930|NCT05980091|OTHER|Group B|Embryo Transfer is scheduled on the 7th full day of progesterone administration, following the initial commencement of progesterone (144 hours)
62748931|NCT05940363||Liaoning Provincial Maternal and Child Health Hospital|Liaoning Provincial Maternal and Child Health Hospital
62748932|NCT05940363||Shenyang Maternal and Infant Hospital|Shenyang Maternal and Infant Hospital
62748933|NCT05940363||Guangdong Women and Children's Hospital|Guangdong Women and Children's Hospital
62748934|NCT05940363||Guangzhou Women and Children's Medical Center|Guangzhou Women and Children's Medical Center
62748935|NCT05940363||Guangdong Provincial People's Hospital|Guangdong Provincial People's Hospital
62748936|NCT05940363||Shandong Maternal and Child Health Hospital|Shandong Maternal and Child Health Hospital
62748937|NCT05940363||Fujian Provincial Maternal and Child Health Hospital|Fujian Provincial Maternal and Child Health Hospital
62374814|NCT02369211|EXPERIMENTAL|Intravenous acetaminophen|Patient receives 1g intravenous acetaminophen after the incision
62374815|NCT02369211|PLACEBO_COMPARATOR|Placebo|Patient receives saline injection instead of the study drug
62374816|NCT00376675|EXPERIMENTAL|Arm I|Patients receive oral methylphenidate hydrochloride daily on days 1-28.
62374817|NCT00376675|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo daily on days 1-28.
62748938|NCT05940363||Maternal and Child Health Hospital of Hubei Province|Maternal and Child Health Hospital of Hubei Province
62748939|NCT05940363||Anhui Provincial Maternal and Child Health Hospital|Anhui Provincial Maternal and Child Health Hospital
62748940|NCT05940363||Peking University First Hospital, Ningxia Women and Children's Hospital|Peking University First Hospital, Ningxia Women and Children's Hospital
62748941|NCT05940363||Sichuan Maternal and Child Health Hospital|Sichuan Maternal and Child Health Hospital
62374818|NCT05823376||Avatrombopag group|The duration of the study is 4 weeks, from +1 day to +28 days after UCBT, patients will be given Avatrombopag with a recommended dose of 40mg per day. After 28 days of administration, the patients may continue, change or discontinue medication based on the patients' platelet status.
62374819|NCT01679704|OTHER|Food products|Ten food products will be given to all subjects
62374820|NCT04760691|ACTIVE_COMPARATOR|Pre-Exposure Prophylaxis (PrEP) only|Truvada one tablet by mouth daily
62374821|NCT04760691|EXPERIMENTAL|PrEP plus Gonadotropin Releasing Hormone (GnRH) Agonist|Truvada one tablet by mouth daily Leuprolide 11.25 milligrams (mg) intramuscular (im) injection once
62748942|NCT02553200|ACTIVE_COMPARATOR|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
62748943|NCT02553200|EXPERIMENTAL|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
62748944|NCT02553200|SHAM_COMPARATOR|BreatheMAX (unload and non-oscillated)|inspiratory and expiratory breathing exercise for 10 breathes/set, 10 sets/day and rest 1 minute between set
62748945|NCT02784119|EXPERIMENTAL|temporary porto-caval shunt|patients in whom temporary porto-caval shunt is performed during orthotopic liver transplantation
62748946|NCT02784119|NO_INTERVENTION|no temporary porto-caval shunt|patients in whom temporary porto-caval shunt is not performed during orthotopic liver transplantation
62748947|NCT05413785|EXPERIMENTAL|Participants with Hepatitis C|Participants will be clients at the Lexington Probation and Parole office who are Hepatitic C positive.
62748948|NCT05865340|OTHER|oral health + MED diet|oral health + MED diet education
62748949|NCT05865340|OTHER|oral health|oral health education
62748950|NCT05865340|OTHER|MED diet|MED diet education
62748951|NCT05865340|NO_INTERVENTION|compare|
62748952|NCT02141698|EXPERIMENTAL|Cohort 1: TAK-438 1 mg|TAK-438 1 mg, tablets, orally, once on Day 1.
62748953|NCT02141698|EXPERIMENTAL|Cohort 2: TAK-438 5 mg|TAK-438 5 mg, tablets, orally, once on Day 1.
62748954|NCT02141698|EXPERIMENTAL|Cohort 3: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once on Day 1.
62748955|NCT02141698|EXPERIMENTAL|Cohort 4: TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once on Day 1.
62748956|NCT02141698|EXPERIMENTAL|Cohort 5: TAK-438 15 mg|TAK-438 15 mg, tablets, orally, once on Day 1.
62748957|NCT02141698|EXPERIMENTAL|Cohort 6: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once on Day 1.
62748958|NCT02141698|EXPERIMENTAL|Cohort 7: TAK-438 30 mg|TAK-438 30 mg, tablets, orally, once on Day 1.
62748959|NCT02141698|EXPERIMENTAL|Cohort 8A: Food-effect|TAK-438 20 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 20 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
62748960|NCT02141698|EXPERIMENTAL|Cohort 8B: Food-effect|TAK-438 20 mg, tablets, orally, under fed conditions, once on Day 1, Period 1.
62748961|NCT02141698|EXPERIMENTAL|Cohort 9: TAK-438 Multiple Dose 1|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
62748962|NCT02141698|EXPERIMENTAL|Cohort 10: TAK-438 Multiple Dose 2|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
62748963|NCT02141698|EXPERIMENTAL|Cohort 11: TAK-438 Multiple Dose 3|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
62748964|NCT02141698|EXPERIMENTAL|Cohort 12: Ethnic Bridging|TAK-438 tablets, dose 1, orally, on Days 1-7 of Period 1, followed by a 4-week washout period followed by TAK-438 tablets, dose 2, orally, Days 1-7 of Period 2, followed by a 4-week washout period, followed by esomeprazole tablets, 40 mg, orally, on Days 1-7 of Period 3. TAK-438 doses to be determined from data collected in Cohorts 9-11.
62748965|NCT02141698|PLACEBO_COMPARATOR|Cohorts 1-7: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1
62748966|NCT02141698|PLACEBO_COMPARATOR|Cohorts 9-11: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1, where available, if required.
62748967|NCT02537587|ACTIVE_COMPARATOR|Control 1|67g of Control energy bar containing 4g protein, 15g fat, 42g carbohydrate, 2g fiber, and 24g sugar.
62748968|NCT02537587|ACTIVE_COMPARATOR|Control 2|86g of Control energy bar containing 5g protein, 20g fat, 55g carbohydrate, 3g fiber and 30g sugar
62748969|NCT02537587|EXPERIMENTAL|15/0|Experimental bar with 15% added resistant starch and 0% added protein; 66g portion containing 3g protein, 7g fat, 50g carbohydrate, 10g fiber and 16g sugar
62748970|NCT02537587|EXPERIMENTAL|15/0-LS|Experimental bar with 15% added resistant starch and 0% added protein with reduced sugar; 84g portion containing 4g protein, 8g fat, 55g carbohydrate, 15g fiber and 15g sugar
62748971|NCT02537587|EXPERIMENTAL|15/5|Experimental bar with 15% added resistant starch and 5% added protein; 75g portion containing 9g protein, 7g fat, 52g carbohydrate, 12g fiber and 17g sugar
62748972|NCT02537587|EXPERIMENTAL|10/5|Experimental bar with 10% added resistant starch and 5% added protein; 72g portion containing 10g protein, 8g fat, 49g carbohydrate, 9g fiber and 19g sugar
62748973|NCT02537587|EXPERIMENTAL|10/10|Experimental bar with 10% added resistant starch and 10% added protein; 80g portion containing 17g protein, 7g fat, 49g carbohydrate, 9g fiber and 18g sugar
62748974|NCT04903873|EXPERIMENTAL|EU101: Dose Escalation Cohort|Participants with advanced solid tumors will receive EU101 intravenously once every 3 weeks (3 weeks = 1 cycle) with escalating doses starting from 0.05 milligrams per kilogram (mg/kg) to 10 mg/kg until disease progression, unacceptable toxicities or death, withdrawal of consent, end of study, or physician's decision, whichever occurs first.
62748975|NCT04903873|EXPERIMENTAL|EU101: Dose Expansion Cohort 1|Participants with CRC will receive EU101 intravenously once every 3 weeks (3 weeks = 1 cycle) with a determined recommended phase 2 dose until disease progression, unacceptable toxicities or death, withdrawal of consent, end of study, or physician's decision, whichever occurs first.
62748976|NCT04903873|EXPERIMENTAL|EU101: Dose Expansion Cohort 2|Participants with NSCLC will receive EU101 intravenously once every 3 weeks (3 weeks = 1 cycle) with a determined recommended phase 2 dose until disease progression, unacceptable toxicities or death, withdrawal of consent, end of study, or physician's decision, whichever occurs first.
62748977|NCT04222634|OTHER|MDT for oligoprogressive lesions in CRPC|"metastasis-directed therapy:~* radiotherapy (SBRT or conventional radiotherapy in case of local recurrence or untreated primary tumor)~* metastasectomy~* salvage lymphadenectomy~* salvage prostatectomy in case of local recurrence or untreated primary tumor"
62374822|NCT04760691|EXPERIMENTAL|PrEP plus Low Dose Estrogen|Truvada one tablet by mouth daily Estradiol 1 milligram by mouth daily x 2 weeks
62748978|NCT05486572|ACTIVE_COMPARATOR|Abdominal Ultrasound Screening with serum AFP|abdominal ultrasound (US)+serum alpha fetoprotein (AFP) every 6 months from the time of recruitment until the end of year 8
62748979|NCT05486572|OTHER|Abbreviated Magnetic Resonance Imaging with serum AFP|Abdominal aMRI+ serum AFP every 6 months from the time of recruitment until the end of year 8
62748980|NCT02585063||Dual assessment|Where there is time and space, participants will be allocated to have a clinical assessment by the IP optometrist during their wait for the clinical assessment with the ophthalmologist. Both clinical assessments are needed to obtain measurement of agreement. There is no intervention. but participants have two clinical assessments rather than just one.
62748981|NCT02752958|EXPERIMENTAL|stannous fluoride|This was a non-comparative design study, all the participants applied dentifrice containing stannous fluoride for 1 timed minute, twice daily (morning and evening) for 24 weeks.
62748982|NCT01957241||Hepatocellular Carcinoma and Esophageal Cancer|
62748983|NCT03143907|OTHER|Group-A - Immediate Intervention|Immediate Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
62748984|NCT03143907|OTHER|Group-B - Delayed Intervention|6 month treatment as usual waitlist followed by Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
62374823|NCT04760691|EXPERIMENTAL|PrEP plus High Dose Estrogen|Truvada one tablet by mouth daily Estradiol 6 milligrams (mg) by mouth daily x 2 weeks
62374824|NCT04760691|EXPERIMENTAL|High Dose Estrogen|Estradiol 6 mg by mouth daily x 2 weeks
62374825|NCT00058773|EXPERIMENTAL|CTL Administration|Infusion of EBV Specific Cytotoxic T-Lymphocytes
62374826|NCT02578095|PLACEBO_COMPARATOR|Placebo|Placebo QD
62748985|NCT01711489|EXPERIMENTAL|isavuconazole and mycophenolate mofetil|Single dose of MMF on Day 1, isavuconazole three times daily (TID) on Days 9 and 10, isavuconazole once daily (QD) Days 11-16, a single dose of MMF on Day 13
62374827|NCT02578095|EXPERIMENTAL|VK5211- 0.5mg|0.5mgQD
62374828|NCT02578095|EXPERIMENTAL|VK5211- 1.0mg|1.0mg QD
62374829|NCT02578095|EXPERIMENTAL|VK5211- 2.0mg|2.0mg QD
62374830|NCT04684849||Healthy subjects|Subjects who are healthy without disease
62748986|NCT03184935|EXPERIMENTAL|Experimental group|Basic medication: Decitabine; Allogeneic umbilical cord mesenchymal stem cells.
62748987|NCT03184935|PLACEBO_COMPARATOR|Control group|Basic medication: Decitabine; placebo: saline.
62748988|NCT06315231|EXPERIMENTAL|Group of edaravone dexborneol sublingual tablet|Patients will receive edaravone dexborneol sublingual tablet twice daily of 24 weeks.
62748989|NCT06315231|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo twice daily of 24 weeks.
62748990|NCT01157325|ACTIVE_COMPARATOR|Non-neuraxial analgesia|Parturients will not receive neuraxial analgesia
62748991|NCT01157325|ACTIVE_COMPARATOR|Neuraxial analgesia|Parturients will receive neuraxial analgesia
62748992|NCT03581695||Pulmonary Hypertension and Congenital Heart Disease|Pulmonary Hypertension and Congenital Heart Disease
62748993|NCT03581695||Congenital Heart Disease|Congenital Heart Disease
62748994|NCT03581695||Healthy Controls|Healthy Controls
62748995|NCT03159169|EXPERIMENTAL|study patients|Single arm study. Patients will receive Spinal Cord Stimulation (SCS) according to standard clinical procedures.
62748996|NCT02200003|EXPERIMENTAL|Attention Bias Modification|640 Trials (20 minutes) four times over four weeks
62748997|NCT02200003|SHAM_COMPARATOR|Sham Attention bias modification|640 Trials (20 minutes) four times over four weeks
62748998|NCT06599255|ACTIVE_COMPARATOR|one puncture|one-puncture technique of RSB combined with TAPB.
62748999|NCT06599255|ACTIVE_COMPARATOR|Multipoint|multipoint technique of RSB combined with TAPB.
62749000|NCT06599255|NO_INTERVENTION|control|nalbuphine (2 mg/kg) and normal saline to a total volume of 150 mL, with a background infusion rate of 2 mL/h, a bolus dose of 2 mL, a lockout interval of 15 min, and a maximum limit of 10 mL within 1 h.
62749001|NCT05680480|EXPERIMENTAL|Telitacicept 240 mg|Telitacicept 240 mg given SC weekly plus standard therapy through week 48.
62749002|NCT05680480|EXPERIMENTAL|Telitacicept 160 mg|Telitacicept 160 mg given SC weekly plus standard therapy through week 48.
62749003|NCT05680480|PLACEBO_COMPARATOR|Placebo|Placebo given SC weekly plus standard therapy through week 48.
62749004|NCT06172803|EXPERIMENTAL|RESToRE|Participants will receive RESToRE, an interdisciplinary, hybrid 8- week intervention.
62749005|NCT06172803|ACTIVE_COMPARATOR|Light Stretching Exercise|The control group will receive 8-week, attention-matched, stretching and breathing exercises, supervised by a rehabilitation clinician.
62749006|NCT03387007|EXPERIMENTAL|Intervention|Two teachers from each of the schools included in this arm received training on providing psycho-social support to their students to be implemented in their regular routine school activities
62749007|NCT03387007|NO_INTERVENTION|Control|The teachers from the schools in this arm did not receive training on psycho-social support
62749008|NCT04741958|EXPERIMENTAL|ultra sound guided percutaneous core needle biopsy|60 patients that had radiographic evidence of thoracic mass suspected of malignancy .Twenty masses were in the lung, seventeen lesions were in the pleura, ten masses were in the mediastinum, eleven enlarged palpable lymph nodes, and two masses were in chest wall. The sensitivity, PPV and accuracy for detection of chest tumors in chest wall, mediastinum, lung, and pleura were (100 %) for all, and in LN (88.9, 100 and 90.9 %) respectively. The overall diagnostic performance of sonar guided true cut needle biopsy in diagnosis was 97.78 % sensitivity, 98.18% accuracy, and 100 % PPV
62749009|NCT01289353|EXPERIMENTAL|ChemoRT|Concurrent Carboplatin and Radiotherapy
62749010|NCT02460354|EXPERIMENTAL|Metformin|Subjects with congenital nephrogenic diabetes insipidus (NDI) will receive one metformin 500 mg pill orally
62749011|NCT00937144|EXPERIMENTAL|viagra|viagra versus placebo will be given to patients with sickle cell anemia
62749012|NCT00937144|PLACEBO_COMPARATOR|placebo|viagra versus placebo will be given to patients with sickle cell anemia
62749013|NCT05071872||Rotarex®S|Treatment performed with Rotarex®S
62749014|NCT05071872||Aspirex®S|Treatment performed with Aspirex®S
62554215|NCT03301545|ACTIVE_COMPARATOR|Fast-Track to Bariatric Surgery|Patients will undergo standard of care for bariatric surgery patients in Manitoba and receive preoperative evaluation by the Centre for Metabolic and Bariatric Surgery (CMBS) team of nurses, dietitians, psychologist, and kinesiologist. Patients must attend the standard appointments and achieve the personalized program goals to be approved for laparoscopic Roux-En-Y gastric bypass surgery. Once approved, one of four surgeons performs surgery (within 12 months of randomization). Patients are followed post-operatively (by surgeon) at 6 weeks, and at 6 and 12 months. Pharmacologic glycemic control will be determined by an endocrinologist as per a standardized post-operative protocol. Post-procedural multidisciplinary follow-up occurs based on established CMBS guidelines (phone call 1 week post-operatively and an appointment at 3 and 12 months). Patients receive surgery within the current publically funded bariatric surgery program; no additional direct costs incurred by the patients.
62567346|NCT06353373||Post-Modified DeVTEcare Group|The modified DeVTEcare system, which incorporates bundled guideline-based VTE prevention measures, will be utilized to assist healthcare providers in VTE prophylaxis after September 2024. By retrospectively collecting information on discharged patients, all patients discharged from our hospital between September 2024 and February 2025 will be included in the post-modified DeVTEcare group.
62749015|NCT05497349|EXPERIMENTAL|Leukocyte Rich-PRP Injection|"Three infiltrations of Leukocyte Rich Platelet Rich Plasma~1 infiltration weekly, for 3 weeks"
62749016|NCT05497349|ACTIVE_COMPARATOR|Leukocyte Poor- PRP Injection|"Three infiltrations of Leukocyte Poor-Platelet Rich Plasma~1 infiltration weekly, for 3 weeks."
62749017|NCT02513290|EXPERIMENTAL|Bilastine group|Bilastine 20 mg administered once a day for ten days.
62749018|NCT02513290|EXPERIMENTAL|Loratadine group|Loratadine 10 mg administered once a day for ten days.
62749019|NCT01610557|EXPERIMENTAL|Group 1 - Ranibizumab-Ranibizumab-Bevacizumab Injection Series|"Group 1 eyes were assigned to Ranibizumab-Ranibizumab-Bevacizumab (RRB) treatment sequence and received intravitreal injections of ranibizumab at baseline, Weeks 4, and 8 (period 1), and Weeks 12, 16 and 20 (period 2), then crossed over to receive intravitreal injections of bevacizumab at Weeks 24, 28 and 32 (period 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
62749020|NCT01610557|EXPERIMENTAL|Group 2 - Ranibizumab-Bevacizumab-Bevacizumab Injection Series|"Group 2 eyes were assigned to Ranibizumab-Bevacizumab-Bevacizumab (RBB) treatment sequence and received intravitreal injections of ranibizumab at baseline and Weeks 4 and 8 (period 1), then crossed over to receive intravitreal injections of bevacizumab at Weeks 12, 16, 20, 24, 28 and 32 (periods 2 and 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
62749021|NCT01610557|EXPERIMENTAL|Group 3 - Bevacizumab-Bevacizumab-Ranibizumab Injection Series|"Group 3 eyes were assigned to Bevacizumab-Bevacizumab-Ranibizumab (BBR) treatment sequence and received intravitreal injections of bevacizumab at baseline and Weeks 4, 8, 12, 16 and 20 (periods 1 and 2), then crossed over to receive intravitreal injections of ranibizumab at Weeks 24, 28 and 32 (period 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
62749022|NCT01610557|EXPERIMENTAL|Group 4 - Bevacizumab-Ranibizumab-Ranibizumab Injection Series|"Group 4 eyes were assigned to Bevacizumab-Ranibizumab-Ranibizumab (BRR) treatment sequence and received intravitreal injections of bevacizumab at baseline and Weeks 4 and 8 (period 1), then crossed over to receive intravitreal injections of ranibizumab at Weeks 12, 16, 20, 24, 28 and 32 (periods 2 and 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
62749023|NCT06260436||pelvic organ prolapse patients with lower urinary tract symptoms|this group for patient who have pelvic organ prolapse and lower urinary tract symptoms
62749024|NCT06260436||pelvic organ prolapse patients without lower urinary tract symptoms|this group for patient who have pelvic organ prolapse but do not have any lower urinary tract symptoms
62749025|NCT03969056|EXPERIMENTAL|Artificial Intelligence (AI) Activity group|Participants in this group receive an AI based intervention (automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning and message)
62749026|NCT03969056|ACTIVE_COMPARATOR|Control group|Participants in this group receive a standardized and fixed 10,000 daily steps goal intervention.
62749027|NCT06252961|EXPERIMENTAL|Levamisole 3 days|Participants randomized in this arm will receive 3 days of levamisole 2.5mg/kg, followed by 2 days of placebo
62749028|NCT06252961|EXPERIMENTAL|Levamisole 5 days|Participants randomized in this arm will receive a 5-day course of levamisole 2.5mg/kg
62749029|NCT06252961|PLACEBO_COMPARATOR|Placebo|Participants randomized in this arm will receive 5 days of placebo
62749030|NCT02019108|EXPERIMENTAL|Gait Modification Group|Participants will complete 4 months of a home-based progressive walking program with toe-out gait modification aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with a study therapist and will be instructed to perform a toe-out gait, with the aid of a mirror during walking. Focus will also be on increasing the time and distance of walking. These goals will be emphasized for the home-based portion of the intervention as well.
62749031|NCT02019108|ACTIVE_COMPARATOR|Walking Only Group|Participants will complete 4 months of a home-based progressive walking program aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with the study therapist with focus on increasing the time and distance of walking. This goal will be emphasized for the home-based portion of the intervention as well.
62554216|NCT03301545|NO_INTERVENTION|Best Diabetic Care Group|Patients will receive the best available medical practice for the treatment, education, and follow-up T2DM based on Manitoba Diabetes Care Recommendations and Diabetes Canada's clinical practice guidelines. Patients will have access to a general physician, endocrinologist, and a diabetes education nurse. An Endocrinologist will deliver the program to patients. Diabetes care, education and self-management support services will be provided by the Victoria General Hospital (VGH) Diabetes Education Centre; led by a registered nurse and dietitian. Patients will undergo individual diabetes management instruction which may include counseling on topics such as diet, exercise, smoking cessation, medications, diabetic complications, and blood sugar testing. Medical therapies, including pharmaceutical agents, will be determined on an individual basis as per standard protocol. There will be no direct patient-related medication costs (publicly funded).
62749032|NCT06137378|NO_INTERVENTION|A - Control|"Standard-Arm:~Short Induction (IC-1):~T = Docetaxel 75 mg/m\^2 i.v. day 1 P = Cisplatin 75 mg/m\^2 i.v. day 1 Response evaluation will be performed in week 4 after IC-1 by endoscopic estimation of tumor-surface shrinkage (ETSS) to select nonresponders for early total laryngectomy (TL). Responders receive further 2 cycles TP followed by radiotherapy (RT) starting week 11.~ETSS \< 30% (Nonresponder):~- TL + adjuvant RT or chemo-radiotherapy (CRT) according the decision of the tumor board~ETSS \>=30% (Responder):~2 further TP cycles (IC-2 in week 5-7 and IC-3 in week 8-10; same doses as IC-1) Radiotherapy (RT) is accelerated IMRT with concomitant boost with total dose of 69.6 Gy applied over 5.5 weeks to all tumor localizations; clinically non-affected neck levels receive 51.6 Gy.~\* protocol is according exactly to the DeLOS-II protocol arm A in Dietz et al. Ann Oncol. 2018 Oct 1;29(10):2105-2114"
62749033|NCT06137378|EXPERIMENTAL|B - KEYTRUDA®|"Intervention arm aka Experimental-Arm:~Treatment same as for patients randomized into the standard arm A + application of KEYTRUDA® (pembrolizumab), i.v., in 3-week cycle (q3w) 200 mg, starting day 1; for 17 cycles (12 months). Treatment with pembrolizumab will continue in the experimental arm regardless of ETSS status after IC-1 in both responders and laryngectomized nonresponders, independent from subsequent decision on adjuvant therapy after TL."
62749034|NCT05867433|EXPERIMENTAL|STHS Intervention|Participants in this group (10 schools) will participate in the STHS program.
62749035|NCT05867433|OTHER|Usual Care|Participants in this group (10 schools) will continue with usual care, as they will not be asked to add or remove any of their current, physical activity, healthy eating, or positive youth development programming.
62749036|NCT00573040||1|"Inclusion criteria~* Histological or cytological proven NSCLC~* UICC stage I-III~* Performance status 0-2~* FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~* Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)~* Stage IV~* Performance status 3 or more~* FeV 1 or DLCO \< 30% of the age-predicted value"
62749037|NCT00075114|OTHER|1 Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
62749038|NCT00075114|NO_INTERVENTION|2 Control Group|Participants randomized to this arm did not receive any interventions.
62374831|NCT04684849||Gas and Bloating patients|Patients with symptoms of gas and bloating
62374832|NCT06336447|EXPERIMENTAL|Group #1: Virtual Reality Headset|Group 1 will be assigned to the Virtual Realtity Headset. Participants will wear the headset for at least 10 minutes prior to the planned procedure. Subjects will receive standard procedure. The VR Headset will be removed 10 minutes after the planned procedure.
62374833|NCT06336447|ACTIVE_COMPARATOR|Group 2 No Virtual Reality Headset|Group 2 will receive standard care without the use of the Virtuality Reality Headset.
62374834|NCT05011409||Newly diagnosed breast cancer patients|Newly diagnosed breast cancer patients referred to Kazakh Institute of Oncology and Radiology or Almaty Oncology Center will be assessed on the prevalence of depression and anxiety symptoms.
62554217|NCT03301545|NO_INTERVENTION|Retrospective Cohort|A retrospective cohort of non-Indigenous bariatric surgery patients from the Centre for Metabolic and Bariatric Surgery Program will allow comparison with the intervention group. The cohort will be age and gender matched.
62554218|NCT06272721|OTHER|Group 1: Children of women with overt hypothyroidism during pregnancy|31 children undergoing neuropsychological testing for clinical practice, having their 31 mothers exhibited overt hypothyroidism during pregnancy.
62554219|NCT06272721|ACTIVE_COMPARATOR|Group 2: Children of women without overt hypothyroidism during pregnancy|21 children undergoing neuropsychological testing outside of clinical practice, as their 21 mothers did not exhibit overt hypothyroidism during pregnancy.
62554220|NCT03057821|NO_INTERVENTION|Control|The control group will not receive any hydrogen peroxide skin preparation
62749039|NCT05499455|ACTIVE_COMPARATOR|Control|Active Control
62749040|NCT05499455|EXPERIMENTAL|Positional Sleep Belt|Rematee Positional Sleep Belt
61986366|NCT03559140|EXPERIMENTAL|Control Group (CG)|"The R25 (size 25/ .08) instrument was used in thin and curved root canals, and R40 files (40/ .06) were used in wide root canals. Three in-and-out pecking motions were used with an amplitude of not more than 3 mm until reaching the estimated working length. Reciproc instruments were used in one tooth only (single use).~The group will receive the irrigant solution at room temperature. as follows:~they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes."
62749041|NCT06428942|EXPERIMENTAL|Intervention group|The participants in the intervention group would receive their daily low-potassium vegetables 3 to 5 serving according to their daily suggested requirement and routine CKD dietary education for 8 weeks.
62749042|NCT06428942|NO_INTERVENTION|Control group|The participants in the control group would receive routine CKD dietary education for 8 weeks.
62749043|NCT03173976|EXPERIMENTAL|Zoledronic Acid|1 cycle of Zoledronic Acid (ZA) at 4mg IVP prior to surgery and a second cycle of ZA at 4 mg IVP 3 weeks after surgery
62749044|NCT05478434|EXPERIMENTAL|Robot and stimulation PPC-M1|Combined paired pulse stimulation (PAS) with robot-assisted therapy
62749045|NCT05478434|SHAM_COMPARATOR|Robot and sham stimulation PPC-M1|Combined sham PAS with robot-assisted therapy
62749046|NCT05868928||Brain metastases patients who received stereotactic radiosurgery|Patients with brain metastases who received stereotactic radiosurgery
62749047|NCT01610713|EXPERIMENTAL|GW-1000-02|Active treatment.
62749048|NCT03298984|EXPERIMENTAL|Alvocidib and Cytarabine/Daunorubicin|The starting dose of alvocidib will be 20 mg/m2 as a 30-minute intravenous (IV) bolus followed by 30 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3 of Induction. Patients will have a one day drug holiday (Day 4) before initiation of the 7+3 regimen. Beginning on Day 5, cytarabine will be administered as a 100 mg/m2/day continuous IV infusion for seven consecutive days (Days 5-11) plus daunorubicin administered at a dosage of 60 mg/m2 IV on Days 5-7.
62749049|NCT04754191|EXPERIMENTAL|Treatment: all patients|Enfortumab will be administered in monotherapy on days 1, 8, and 15 as part of a 28-day cycle at 1.25 mg/kg up to 125 mg.
62749050|NCT04270942|EXPERIMENTAL|Teplizumab treated|Administration of teplizumab by intravenous infusion
62749051|NCT04749758|EXPERIMENTAL|SVF treatment|SVF treatment is developed by Cellab Laboratory (Celstem®). It is approved by Andorra's Government authorities.
62749052|NCT00086801|EXPERIMENTAL|doxorubicin + vinblastine + gemcitabine|"Patients receive doxorubicin IV over 3-5 minutes, vinblastine IV over 3-5 minutes, and gemcitabine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo fludeoxyglucose F 18 positron-emission tomography (PET) scanning and CT scan before treatment and after courses 2 and 6 of therapy to assess response. Patients with a positive PET scan after completion of study therapy may undergo biopsy. A PET scan is performed 3 months later if biopsy is negative or biopsy is unable to be performed.~Patients are followed every 3 months for 1 year, every 4 months for 2 years, every 6 months for 2 years, and then annually for 5 years."
62749053|NCT03030495||Overt microvascular disease|Fractional flow reserve\>0.80, coronary flow reserve\<2 \& Index of microvascular resistance\>25U
62749054|NCT03030495||No Overt microvascular disease|Fractional flow reserve\>0.80, coronary flow reserve\>2 \& Index of microvascular resistance\<25U
62749055|NCT06482697|ACTIVE_COMPARATOR|total colpocleisis|
62554221|NCT03057821|EXPERIMENTAL|Treatment|The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
62749056|NCT06482697|EXPERIMENTAL|partial colpocleisis (LeFort)|
62749057|NCT03702920|EXPERIMENTAL|SMT+ PE-A 5%|PE-A 5% will be performed using 5% albumin (Albutein 5%) as the main replacement fluid administered intravenously.
62554222|NCT01613768|EXPERIMENTAL|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62554223|NCT05908227|EXPERIMENTAL|NHF high|Nasal high flow therapy 8L/min
62554224|NCT05908227|EXPERIMENTAL|NHF low|Nasal high flow therapy 6L/min
62554225|NCT05908227|ACTIVE_COMPARATOR|NCPAP|Nasal continuous positive airway pressure 6 cm H20
62554226|NCT03676218||Elderly cancer patients|
62749058|NCT03702920|ACTIVE_COMPARATOR|Standard Medical Treatment (SMT)|Standard medical treatment (SMT) will be administered according to institution standards.
62749059|NCT03979014|EXPERIMENTAL|Vaccinated Arm|Add vaccine
62749060|NCT03979014|NO_INTERVENTION|Control|No intervention
61986367|NCT00566150|ACTIVE_COMPARATOR|Levetiracetam|
61986368|NCT00566150|PLACEBO_COMPARATOR|Placebo|
62554227|NCT05870189|EXPERIMENTAL|Remote CMR|adults with SCI without restriction for race, sex or socio-economic status randomized to CMR intervention.
62554228|NCT05870189|PLACEBO_COMPARATOR|Remote exercises|adults with SCI without restriction for race, sex or socio-economic status randomized to remote exercise intervention.
62554229|NCT03848494||Gastroesophageal reflux disease|Patients submitted to primary minimally invasive surgery for gastroesophageal reflux disease or hiatus hernia
62749061|NCT00043017|EXPERIMENTAL|MRI/MRS|MRI and MRS examinations with standard imaging, with contrast enhancement using an agent (gadopentetate dimeglumine).
62749062|NCT05935891|EXPERIMENTAL|Violet|Patients receiving CBD-dominant balm
62749063|NCT05935891|EXPERIMENTAL|Red Xs|Patients receiving THC-dominant balm
62374835|NCT02479386||Cohort Geographic Atrophy|Cohort of participants with GA secondary to AMD will be evaluated for changes in GA over time.
62374836|NCT03986476|EXPERIMENTAL|Lactobacillus reuteri strain 1|Probiotic compound
62374837|NCT03986476|EXPERIMENTAL|Lactobacillus reuteri strain 2|Probiotic compound
62374838|NCT03986476|PLACEBO_COMPARATOR|Placebo|Placebo
62374839|NCT04573491|EXPERIMENTAL|Pharmacogenetic test|Medication review including results from pharmacogenetic testing
62374840|NCT05661175|EXPERIMENTAL|Experimental group(group 1)|Percutaneous nephrolithotripsy was performed using one - hand lithotripsy
62374841|NCT05661175|NO_INTERVENTION|Control group(group 2)|Percutaneous nephrolithotripsy was performed using traditional techniques
62374842|NCT05310942||A|The fluid management of patients in this group will be assessed by IVC collapsibility index (IVC CI) calculated by ultrasound through maximum IVC diameter - minimum IVC diameter divided by maximum diameter then multiplied by 100. If it is less than 50% means that the patient is volume non- depleted while if it is more than 50% means the reverse.
62374843|NCT05310942||B|All patients in this group with sepsis will be evaluated by the electrical cardiometry monitor.
62374844|NCT00996541|EXPERIMENTAL|Intervention|
62374845|NCT00996541|PLACEBO_COMPARATOR|Control|
62374846|NCT02109549||Diabetes and metformin|Patients with diabetes mellitus treated with metformin only.
62374847|NCT02109549||Insulin-diabetes without metformin|Patients with insulin-dependent diabetes mellitus not treated with metformin
62374848|NCT02109549||Controlgroup|The remaining patients serve as control group.
62374849|NCT02329860|EXPERIMENTAL|Apatinib|750 mg orally (p.o.) every day (qd), 28 days as one cycle
62374850|NCT02329860|PLACEBO_COMPARATOR|Placebo|orally (p.o.) every day (qd), 28 days as one cycle
62374851|NCT03774706|ACTIVE_COMPARATOR|Misoprostol with TA|two tablets sublingual misoprostol plus IgM tranexamic acid in 100 ml saline by slow iv
62374852|NCT03774706|ACTIVE_COMPARATOR|Misoprostol with placebo to TA|two tablets sublingual misoprostol plus placebo to tranexamic acid ( 110 ml saline) by slow iv
62374853|NCT04699240|ACTIVE_COMPARATOR|Clotrimazole vaginal tablets|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
62374854|NCT04699240|ACTIVE_COMPARATOR|Clotrimazole vaginal tablets+ Lactobacillus|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times + Lactobacillus Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
62374855|NCT05162833|EXPERIMENTAL|Maintenance group|"Subjects that completed the clinical study Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms that were in the active treatment group will be offered to extend treatment for 3 months."
62374856|NCT00658450|EXPERIMENTAL|Cognitive rehabilitation training|Children in this arm will the receive the intervention comprising of 16 cognitive rehabilitation training (CRT) exercises for 8 weeks. These exercises will train different cognitive skills including attention, visual spatial processing, logical skills and memory.
62374857|NCT00658450|NO_INTERVENTION|Treatment as usual|Children in this group will not receive any intervention, they will undergo the usual post discharge treatment for brain injured children at Mulago Hospital (the study site). This is the treatment as usual (TAU) group.
62374858|NCT01222416|EXPERIMENTAL|fluorodeoxyglucose PET/CT (FDG-PET/CT)|A PET/CT scan prior to the initiation of therapy, and then two additional scans following the initiation of therapy. Each patient will have up to three scans in a 6 month time frame.
62374859|NCT01222416|EXPERIMENTAL|fluorodeoxythymidine PET/CT (FLT-PET/CT)|A PET/CT scan prior to the initiation of therapy, and then two additional scans following the initiation of therapy. Each patient will have up to three scans in a 6 month time frame.
62374860|NCT06153628|EXPERIMENTAL|Virtual reality glasses|"First of all, the State Anxiety Inventory will be applied to all women (60 women).Then, milk will be expressed from both breasts once a day (10:00) for the first 3 days and the amount of milk expressed will be recorded in the Breast Milk Amount Tracking Form. After the first 3 days, all women will be relaxed by watching virtual reality glasses (10 minutes) once a day (10:00 in the morning) for 3 days, and the State Anxiety Inventory will be applied at the end of the video. Then, milk will be expressed from both breasts and recorded in the Breast Milk Amount Tracking Form."
62374861|NCT03086148|EXPERIMENTAL|ketamine group|
62374862|NCT03086148|PLACEBO_COMPARATOR|normal saline group|
62374863|NCT03140722|EXPERIMENTAL|vadadustat|Vadadustat daily oral dose, adjustable based on Hb level
62374864|NCT03140722|ACTIVE_COMPARATOR|epoetin alfa|Epoetin alfa, dose adjustable based on Hb level, as clinically indicated throughout the study
62374865|NCT05477251|EXPERIMENTAL|microwave ablation|
62374866|NCT05477251|ACTIVE_COMPARATOR|lobectomy|
62374867|NCT03189563|PLACEBO_COMPARATOR|Placebo|placebo, tid
62374868|NCT03189563|EXPERIMENTAL|DA-9805 low|DA-9805 45mg
62374869|NCT03189563|EXPERIMENTAL|DA-9805 high|DA-9805 90mg
62554230|NCT06568510||Patients with continuous sciatic nerve block|Patients were placed in the lateral position (with the injured leg uppermost) and a US-guided sciatic nerve block was performed under aseptic conditions . The sciatic nerve was visualized at the upper third of the posterior thigh (short axis view) and a Tuohy needle (21 G × 10 mm, was inserted in a lateral to medial direction. The needle was placed underneath the sciatic nerve and 10 ml of ropivacaine (0.1%) were injected. A perineural catheter (with retracted integral stylet by 6 cm) was then threaded through the needle tip and coiled behind the sciatic nerve. Confirmation of correct catheter tip placement was defined as adequate spread and contact of ropivacaine injectate (3 ml, 0.1%) with the sciatic nerve
62554231|NCT01200173|ACTIVE_COMPARATOR|1 = Tested product|
62554232|NCT01200173|SHAM_COMPARATOR|2 = Control product|
62554233|NCT04553393|ACTIVE_COMPARATOR|Decitabine-primed Tandem CAR19/20 engineered T cells|Tandem dual Specificity targeting CD19 and CD20 decitabine-primed CAR-T cells can recognize and kill the CD19 negative malignant cells through recognition of CD20 and improve the possibility of killing lymphoma tumor cells.
62554234|NCT04553393|EXPERIMENTAL|Decitabine-primed Tandem CAR19/20 engineered T cells plus chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
62554235|NCT04553393|EXPERIMENTAL|Decitabine-primed Tandem CAR19/20 engineered T cells plus decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
62554236|NCT04553393|EXPERIMENTAL|Decitabine-primed Tandem CAR19/20 engineered T cells plus chidamide+decitabine|The combination of chidamide and decitabine can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function, induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance
62374870|NCT00606229|EXPERIMENTAL|1|
62374871|NCT01662128|EXPERIMENTAL|Xeloda|Xeloda
62554237|NCT04849871|EXPERIMENTAL|Arm S_APBI (External Beam Accelerated Partial Breast Irradiation (APBI) 20 Gy-1 fraction)|-External Beam APBI 20 Gy to surgical bed surface (7 Gy to 1 cm from surgical bed in 1 fraction)
62554238|NCT04849871|EXPERIMENTAL|Arm F_APBI (External Beam Accelerated Partial Breast Irradiation (APBI) 30 Gy-5 fractions)|-External Beam APBI 30 Gy in 5 fractions over 5 days.
61986369|NCT06245291|EXPERIMENTAL|Cohort A|Imdusiran 60 mg SC Q8 weeks + nucleos(t)ide analog for 48 weeks + durvalumab at early and mid-treatment period timepoints
62374872|NCT00398086|EXPERIMENTAL|100 mg/m^2|Participants received albumin-bound paclitaxel 100 mg/m\^2 followed by gemcitabine 1000 mg/m\^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level one). Treatment continued until progressive disease or unacceptable toxicity.
62374873|NCT00398086|EXPERIMENTAL|125 mg/m^2|Participants received albumin-bound paclitaxel 125 mg/m\^2 followed by gemcitabine 1000 mg/m\^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level two). Treatment continued until progressive disease or unacceptable toxicity.
62374874|NCT00398086|EXPERIMENTAL|150 mg/m^2|Participants received albumin-bound paclitaxel 150 mg/m\^2 followed by gemcitabine 1000 mg/m\^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level three). Treatment continued until progressive disease or unacceptable toxicity.
62374875|NCT04105595||ASD patients|
62374876|NCT04105595||PFO patients|
62374877|NCT03477344|ACTIVE_COMPARATOR|Dexmédétomidine|Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
62374878|NCT03477344|PLACEBO_COMPARATOR|Sodium Chloride 0,9%|Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
62374879|NCT03827070|EXPERIMENTAL|Talcum powder & Afatinib|Talcum powder 4 g + Afatinib 0,4 g. Is entered once
62374880|NCT04778865|EXPERIMENTAL|Vitamin D-correction|Subjects will receive one capsule with 50.000 IU cholecalciferol weekly for 3 months.
62374881|NCT04778865|ACTIVE_COMPARATOR|Vitamin D-RDA|Subjects will receive one capsule with 4.200 IU cholecalciferol weekly for 3 months.
62749064|NCT03277898|EXPERIMENTAL|Aerobic Exercise|Participants will complete three supervised aerobic exercise sessions each week using the treadmill, stationary bicycle or elliptical training for the duration of their chemotherapy (12-18 weeks). Aerobic exercise will be performed for 20-40 minutes at 50-75% of heart rate reserve. Participants will wear heart rate monitors during all supervised sessions (Polar Electro Inc., Lake Success, NY) and will be provided with target heart rates that will be individualized using their baseline (i.e., week 0) assessment data. Home-based exercise will be introduced in week 3. For the home-based sessions, participants will be asked to complete at least 1 session per week of 30 minutes of aerobic exercise (an activity of their choosing; e.g., walking).
62749065|NCT03277898|OTHER|Usual Care (Wait-list Control)|Participants randomly assigned to UC group will be advised to continue with their regular activities of daily living. Following their chemotherapy, the UC group will receive the exercise intervention (lasting 12 weeks).
62749066|NCT03114579|OTHER|Measure of the cardiac output obtained by a reference methode|
62749067|NCT03114579|OTHER|Measurement of cardiac output obtained by NEXFIN HD.|
62749068|NCT05080855|ACTIVE_COMPARATOR|the cleft lip will be repaired by modified Millard technique|In the modified Millard technique, points (nasal and Vermilion border points) and lines (rotational and advancement flap lines and mucosal lines) were drawn. Then, we cut the submucosal layer and created three flaps: advancement flap, rotational flap, and c flap. The orbicular muscle was dissected and freed from the columellar base on the non-cleft side and from the alar base on the cleft side. Using a vicryl 5-0, we sutured the anterior nasal floor; then, using vicryl 4-0, we sutured the alar base and muscle. Using vicryl 6-0, we sutured top of philtral column with point a, the peak of Cupid's bow, and tip of c flap with alar base. The suturing of mucosal lip was carried out using a vicryl 5-0.
62749069|NCT05080855|ACTIVE_COMPARATOR|the cleft lip will be repaired by Tennison-Randall technique.|In the Tennison-Randall technique, points (nasal and Vermilion border points) and lines (Skin triangle flap lines and mucosal lines) were drawn. Then, we cut the submucosal layer and created equilateral triangle flap and releasing incision. The orbicular muscle was dissected and freed from the columellar base on the non-cleft side and from the alar base on the cleft side. The suturing of the anterior nasal floor, alar base, and muscle followed the same principles of the modified Millard technique. The cutaneous repair was done by suturing the top of philtral column, the peak of Cupid's bow, point a, the line between the top of philtral column and the peak of Cupid's bow with b-8 and 3-a with b-a.
62749070|NCT01184313||aortic valve surgery|
62749071|NCT06145165|PLACEBO_COMPARATOR|RP group:Nerve block with ropivacaine and intravenous analgesia group|The ropivacaine group will use ultrasound high-frequency line array probe for ACB and convex array probe for iPACK block before induction of general anesthesia
62749072|NCT06145165|EXPERIMENTAL|LP group ：Nerve block with liposomal bupivacaine and intravenous analgesia group|The liposomal bupivacaine group will use ultrasound high-frequency line array probe for ACB and convex array probe for iPACK block before induction of general anesthesia
62749073|NCT06145165|PLACEBO_COMPARATOR|control group：Intravenous analgesia group|General anesthesia was induced directly
62749074|NCT00608023|EXPERIMENTAL|Tesamorelin 12 months (T-T)|Tesamorelin 2 mg/day for 12 months
62749075|NCT00608023|EXPERIMENTAL|Tesamorelin-Placebo (T-P)|Tesamorelin 2 mg/day for 6 months - Placebo for 6 months
62749076|NCT00608023|EXPERIMENTAL|Placebo-Tesamorelin (P-T)|Placebo 6 months - Tesamorelin 2 mg/day for 6 months
62749077|NCT03469986||Autism Spectrum Disorder|Children who meet criteria based on expert clinical diagnosis for autism spectrum disorder will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.
62749078|NCT03469986||Non-autism Spectrum Disorder|Children who do not meet criteria for autism spectrum disorder based on expert clinical diagnosis will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.
62749079|NCT04828577|EXPERIMENTAL|Real Time Neurofeedback|Real time neurofeedback will be based on a classifier of increasing or decreasing delay discounting fMRI patterns. Participants will try to modulate their discounting rate based on neurofeedback via a visual dial, during an fMRI scan. Participants will be told they will be controlling the visual dial.
62749080|NCT04828577|SHAM_COMPARATOR|"Idealized/Sham Neurofeedback"|"Rather than using the output of a classifier, the visual dial will display perfect modulation of increasing and decreasing delay discounting and participants will told that they will not be controlling the visual dial."
62749081|NCT06193408|EXPERIMENTAL|VR-AD-1005|
62749082|NCT06193408|PLACEBO_COMPARATOR|Placebo|
62374882|NCT02945852|EXPERIMENTAL|refractory SCLC|Patients receive apatinib 500mg/d until progressive Disease(PD).
62749083|NCT00385944|EXPERIMENTAL|Prasugrel|Open label lead-in one time dose of Clopidogrel 900 mg oral tablets (a single or cumulative dose) and 250 mg to 500 mg aspirin loading dose (LD), either orally or intravenously. Patients are then assigned to maintenance dose (MD) prasugrel 10 mg and two placebo tablets, matched to clopidogrel, and 100 mg aspirin, all taken orally once a day for 14 days. Patients cross-over to MD of clopidogrel two 75 mg tablets and one placebo matched to prasugrel and 100 mg aspirin, all taken orally once a day for the next 14 days.
62749084|NCT00385944|ACTIVE_COMPARATOR|Clopidogrel|Open label lead-in one time dose of Clopidogrel 900 mg oral tablets (a single or cumulative dose) and 250 mg to 500 mg aspirin loading dose (LD), either orally or intravenously. Patients are then assigned to maintenance dose (MD) Clopidogrel two 75 mg and one placebo tablet, matched to prasugrel, and 100 mg aspirin, all taken orally once a day for 14 days. Patients cross-over to MD of prasugrel one 10 mg tablet and two placebo tablets matched to clopidogrel and 100 mg aspirin, all taken orally once a day for the next 14 days.
62374883|NCT02000544|OTHER|Modular Cardiopulmonary Bypass Circuit|Patients undergoing open heart surgery with a modular hybrid extracorporeal circulation circuit.
62374884|NCT02820480||Patients/health professionals|Stroke AND cerebral palsy PATIENTS: greater than 18 years of age, who are more than 3 months post stroke, as well as health professionals who have considerable experience in stroke rehabilitation will be asked to evaluate the design of the Rehab in a Crate system. The aim is to survey stroke survivors and healthcare professionals on the design, ease of use, utility, and various features of, both existing and those yet-to-be-developed.
62749085|NCT02649218|EXPERIMENTAL|Ligelizumab|QGE031 240 mg s.c. q4w x 13 treatments
62749086|NCT05082051|ACTIVE_COMPARATOR|CDX-7108|CDX-7108, an oral recombinant lipase. It is a modified version of a triacylglycerol lipase enzyme derived from the bacteria Bacillus thermoamylovans (btLIP) and produced by fermentation of recombinant Escherichia coli.7
62749087|NCT05082051|PLACEBO_COMPARATOR|Placebo|Excipients only
62749088|NCT01637636|EXPERIMENTAL|Rifampin|
62749089|NCT01637636|EXPERIMENTAL|Ketoconazole|
62374885|NCT03145506||Mohs Surgery Patients|Adult patients undergoing Mohs surgery for treatment of BCC or SCC
62374886|NCT02870348|EXPERIMENTAL|Alpha-1 MP|Participants received IV infusion of 60 mg/kg Alpha-1 MP administered weekly for mean duration of 213 weeks.
62374887|NCT01321658|EXPERIMENTAL|Geriatric intervention|
62374888|NCT01321658|NO_INTERVENTION|Control|
62554239|NCT03523455|PLACEBO_COMPARATOR|Sugar Pill|Maltodextrin (matches the weight of the active treatment) Taken once each day after breakfast, but before lunch.
62749090|NCT00797745|ACTIVE_COMPARATOR|Standard of Care|"PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily for 48 weeks.~* Subjects with \>= 1 log decrease from baseline in HCV-RNA levels after 12 weeks, but still above the lower limit of quantitation, have the option of crossing over to PegIntron, ribavirin plus SCH 900518 400 mg and ritonavir 100 mg daily for 12 weeks. This is followed by standard of care, PegIntron and ribavirin, for a total treatment duration of up to 48 weeks."
62749091|NCT00797745|EXPERIMENTAL|2|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
62749092|NCT00797745|EXPERIMENTAL|3|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 400 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
62749093|NCT00797745|EXPERIMENTAL|4|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
62749094|NCT00797745|EXPERIMENTAL|5|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 400 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
61986370|NCT06245291|EXPERIMENTAL|Cohort B|Imdusiran 60 mg SC Q8 weeks + nucleos(t)ide analog for 48 weeks + durvalumab at mid and late-treatment period timepoints
62554240|NCT03523455|ACTIVE_COMPARATOR|Iron Aid IPS (Iron Protein Succinylate)|IronAid Iron Protein Succinylate 30 mg Taken once each day after breakfast, but before lunch.
62554241|NCT00590616||1|
61986371|NCT06245291|EXPERIMENTAL|Cohort C|Imdusiran 60 mg SC Q8 weeks + nucleos(t)ide analog for 48 weeks + durvalumab at 2 late treatment period timepoints
62554242|NCT06028295|EXPERIMENTAL|Wheat Polar Lipid Complex Oil|Dietary supplement - Wheat Polar Lipid Complex (Oil)
62554243|NCT06028295|EXPERIMENTAL|Wheat Polar Lipid Complex Powder|Dietary supplement - Wheat Polar Lipid Complex (Powder)
62554244|NCT06028295|PLACEBO_COMPARATOR|Placebo|Dietary supplement - Placebo
62554245|NCT01030302||001|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
62554246|NCT02753361|NO_INTERVENTION|Traditional|This will utilize the traditional method of performance of regional block
62554247|NCT02753361|EXPERIMENTAL|US-guided|In this arm, regional block will be performed under the ultrasound guidance
62554248|NCT05608876|EXPERIMENTAL|Single Arm, Open Label|Single or multiple Intratumoural injections of tigilanol tiglate at up to a fixed dose of 3.6 mg/m2 (Body Surface Area \[BSA\]) per treatment.
62554249|NCT05197543||BRRA group|Rupture risk of asymptomatic AAAs in this group was estimated using Biomechanical rupture rist assessment (BRRA). BRRA considers an AAA as a pressure vessel and estimates its risk of rupture by comparing its wall stress to wall strength
62554250|NCT05197543||Maximal diameter group|Rupture risk of asymptomatic AAAs in this group was estimated by a classical approach based on a maximal diameter.
61986372|NCT00763347|EXPERIMENTAL|SYR-619 12.5 mg QD|
62554251|NCT03003351||Fistula|Patients with Fistulaê that are not caused by Crohn's disease
62554252|NCT03003351||Fistula and Crohn's disease|Patients with Fistulae that are caused by underlying Crohn's disease
62554253|NCT01507311|EXPERIMENTAL|NNC 90-1170|
62554254|NCT01507311|PLACEBO_COMPARATOR|Placebo|
62554255|NCT04081909|ACTIVE_COMPARATOR|Opioid Based Anesthesia(OBA)|
62554256|NCT04081909|EXPERIMENTAL|Opioid Free Anesthesia(OFA)|
62554257|NCT04745221|EXPERIMENTAL|with auto-FMT|The patients in the experimental group took autologous fecal bacteria capsule about 3 weeks after bone marrow transplantation.
62554258|NCT04745221|NO_INTERVENTION|empty capsule|The patients in this group took empty capsule about 3 weeks after bone marrow transplantation
62554259|NCT03027960|EXPERIMENTAL|Placebo, then empagliflozin|"Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy."
62749095|NCT00797745|EXPERIMENTAL|6|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 100 mg twice daily plus ritonavir 100 mg twice daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
62749096|NCT00797745|EXPERIMENTAL|7|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 600 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
62749097|NCT06377696|EXPERIMENTAL|Group A (metformin)|Patients receive metformin PO BID for 12 months. Treatment repeats every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients also wear a wearable device to monitor health and undergo neurocognitive test throughout the study.
62749098|NCT06377696|ACTIVE_COMPARATOR|Group B (usual care)|Patients receive SOC treatment for 12 months. Patients also wear a wearable device to monitor health and undergo neurocognitive test throughout the study.
62749099|NCT02839187|EXPERIMENTAL|Patients with Alzheimer Disease|Patients will have Neuroimaging by Florbetapir (AV-45)-positron emission tomography
62749100|NCT02839187|ACTIVE_COMPARATOR|Controls patients|Controls will have neuroimaging by AV45-positron emission tomography
62749101|NCT03596047|EXPERIMENTAL|Standard treatment + Radial wave therapy|Sildenafil according to the degree of patient involvement + 6 sessions of radial waves.
62749102|NCT03596047|PLACEBO_COMPARATOR|Standard treatment + Placebo therapy|Sildenafil according to the patient's degree of affectation + 6 sessions of placebo therapy.
62749103|NCT00898300||Patients with confirmed or suspected head and neck cancer|
62749104|NCT06277700|EXPERIMENTAL|Chiropractic Manipulation (CM) Group|In the side lying position, lumbar chiropractic manipulation will be performed over the transverse process of the vertebra thought to have vertebral subluxation. A total of 8 sessions of chiropractic manipulation will be performed 2 times a week.
62749105|NCT06277700|EXPERIMENTAL|Dynamic Neuromuscular Stabilization (DNS) Group|Participants in the groups receiving DNS exercise therapy will be given individualized exercises under the supervision of a physiotherapist. Firstly, the participants will be taught the skill of posterior diaphragm activation in the supine position and the ability to direct the intra-abdominal pressure caudally, while preventing the cranial movement of the thorax, so that the chest and pelvis are in a neutral position and the thoracic diaphragm and pelvis are aligned in parallel. Our aim in this alignment is that with the correct diaphragm movement pattern, the deep stabilizers will be activated as a reflex response to intra-abdominal pressure change. Participants will be asked to focus on and maintain this alignment throughout the entire DNS exercise pattern. Exercises will be done 2 times a week for 50 minutes for 4 weeks.
62749106|NCT06277700|EXPERIMENTAL|CM + DNS Group|This group receives a treatment as a combination of the treatments described above.
62749107|NCT06277700|NO_INTERVENTION|Control Group|No treatment will be applied to the control group.
62749108|NCT06605768|PLACEBO_COMPARATOR|Group Placebo|
62749109|NCT06605768|ACTIVE_COMPARATOR|Group Treatment|
62749110|NCT01407471|EXPERIMENTAL|Clobetasol + Spironolactone|0.05% clobetasol and 5% spironolactone
62749111|NCT01407471|ACTIVE_COMPARATOR|Clobetasol + Placebo|0.05% clobetasol + inert excipient
62749112|NCT01407471|ACTIVE_COMPARATOR|Placebo + Spironolactone|Inert excipient + 5% spironolactone
62749113|NCT01407471|PLACEBO_COMPARATOR|Placebo + placebo|Inert excipient
61986373|NCT00763347|EXPERIMENTAL|SYR-619 50 mg QD|
62374889|NCT04111185|EXPERIMENTAL|Receive Blood Volume Analysis Guided Treatment|The health care team will be provided with BVA results and may use the information to make decisions regarding the participant's treatment.
62554260|NCT03027960|EXPERIMENTAL|Empagliflozin, then Placebo|"Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy."
62749114|NCT00529230||Chronic opioid therapy + Gonadal function|Males on chronic opioid therapy for cancer-related pain syndromes
62749115|NCT04816136||patients with a sleep recording performed|patients with a sleep recording performed in the sleep unit in Montpellier University Hospital, who had an ischemic stroke before the recording.
62749116|NCT02180919|NO_INTERVENTION|Control period|All patients with receive standard optimal medical care according to ESC Heart Failure guidelines, NICE COPD guidelines or other best practice care pathways as relevant to their condition.
62749117|NCT02180919|EXPERIMENTAL|Telemonitoring|telemonitoring will be carried out in the patient's home using the conformity European (CE) marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a television (TV) channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
62749118|NCT03666780||Subject|"All patients who signed informed consent and are implanted with a Lifetech LAmbre occluder device will undergo follow-up (FU) evaluations as per local hospital standards and corresponding IFU which is expected to be at the following time points post-implant:~* At discharge (+/- 1 day)~* 1-3 months (+/- 1 week)~* 6 months (+/- 2 weeks)~* 12 months (+/- 1 month)~* 2 years (+/- 3 month)~* 3 years(+/- 3 month)~Patients who have undergone a LAmbre explant should remain in the study and adhere to the above-mentioned follow-up time point until completion of 3-year follow-up period.~After the patient has completed the 3-year follow-up assessments, the patient is considered to have completed the study. A study exit eCRF needs to be completed and the patient will receive routine care."
62391524|NCT03672006|ACTIVE_COMPARATOR|Heparin|patients will receive 30 min-4 hours heparin (10U/ml, up to 2 ml per dose) dwells to central venous catheter every 3 days (maximum 10 doses)
61986374|NCT00763347|EXPERIMENTAL|SYR-619 100 mg QD|
61986375|NCT00763347|EXPERIMENTAL|SYR-619 200 mg QD|
61986376|NCT00763347|PLACEBO_COMPARATOR|Placebo QD|
62374890|NCT04111185|NO_INTERVENTION|Receive Standard of Care Treatment|The health care team will not be provided with the BVA results. The participant will receive the same treatment they would have received if they weren't in the study.
62554261|NCT01088958|EXPERIMENTAL|Micronutrient Sprinkles|Sales of Sprinkles in these groups of villages by community vendors
62749119|NCT06008418|EXPERIMENTAL|The LINE Chatbot|"Participants of the experimental group are required to use the Chatbot before discussing with their physicians.~Outcome variables are mainly measured at three points: baseline (immediately before the outpatient visit), 24 hours within the outpatient visit, and a week after. At baseline, participants provide their demographic information and complete questionnaires to evaluate their communication self-efficacy and quality of life. After 24 hours, participants are invited to evaluate their satisfaction, communication self-efficacy, shared-decision making process, and the experience of illness invalidation. After a week, the research assistant will remind the participant to evaluate their quality of life. Finally, a retrospective chart review will be conducted one month after the visit to confirm any emergency department visits. Except for the demographic variables (i.e., age, sex, educational level, and diagnosis) and emergency visits."
62374891|NCT01307046|EXPERIMENTAL|MK-0954A|Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks.
62374892|NCT01307046|ACTIVE_COMPARATOR|Losartan|Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks.
62374893|NCT00721357||Stroke|Stroke subjects
62554262|NCT03298542|EXPERIMENTAL|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
62554263|NCT03298542|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will receive a SC matching placebo to golimumab.
62554264|NCT01243957|EXPERIMENTAL|LY2216684 + fluoxetine|"LY2216684: 18 milligrams (mg) oral (po) once daily (QD) on Days 1, 2, and 3 and Days 25-27~Fluoxetine: 60 mg po QD for 7 days (Days 4-10) then 20 mg po QD for 17 days (Days 11-27)"
62554265|NCT02271347|EXPERIMENTAL|CMX001|CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
62554266|NCT05010265||Use of advanced neurotechnologies to detect consciousness and predict recovery|Treating clinicians, family members (caregivers) and patients recovering from a diagnosis of coma, vegetative state, or minimally conscious state minus (i.e. minimally conscious state without language function)
62554267|NCT02569190|EXPERIMENTAL|Walkbot|Receive conventional physical therapy (session I for 30 min/day) with Walkbot training 3 days a week for 8 weeks, 20 session in all.
62554268|NCT04353635||Patients with class III dentofacial deformity|No intervention as it will be a retrospective study
62554269|NCT01092858|EXPERIMENTAL|Arm 1|
62554270|NCT01092858|PLACEBO_COMPARATOR|Arm 2|
62554271|NCT02713685|EXPERIMENTAL|Subarachnoid block|Subarachnoid block will be given in lateral position
62554272|NCT02713685|ACTIVE_COMPARATOR|Peripheral nerve block|Combined Femoral and Sciatic nerve block will be given using nerve stimulation technique
62554273|NCT03106324||TNE NDMM patients treated with lenalidomide regimen|Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen containing lenalidomide
62554274|NCT03106324||TNE NDMM patients treated with non-lenalidomide|Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen not containing lenalidomide
62554275|NCT02122991||Able-Bodied Controls|Subjects must be between the ages of 30 and 64 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 22 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (\<6 months), unstable/uncontrolled seizures, neurodegenerative disease, Severe Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, any significant systemic illness or unstable medical condition (uncontrolled diabetes, hypo- or hyperthyroidism, systemic cancer), history of schizophrenia or bipolar disorder or any active psychosis, or alcohol/substance abuse or dependence (\<6 months).
62567347|NCT06242431|ACTIVE_COMPARATOR|Group pectoralis nerve block (PECS-II)|PECS II; The block will be performed in the supine position of the patient, just anterior to the axillary line at the level of the 4th rib. After visualizing the serratus anterior, pectoralis major, and pectoralis minor muscles along with the ribs and pleura, the needle will be directed in-plane from cranial to caudal into the fascia of the serratus anterior muscle. Subsequently, 30 ml of bupivacaine with a 0.25% concentration will be applied.
61986377|NCT00763347|ACTIVE_COMPARATOR|Alogliptin 25 mg QD|
62749120|NCT06008418|NO_INTERVENTION|Routine|"The comparison group participants will receive routine care (i.e., oral instruction regarding the overall process of outpatient department visits).~Outcome variables are mainly measured at three points: baseline (immediately before the outpatient visit), 24 hours within the outpatient visit, and a week after. At baseline, participants provide their demographic information and complete questionnaires to evaluate their communication self-efficacy and quality of life. After 24 hours, participants are invited to evaluate their satisfaction, communication self-efficacy, shared-decision making process, and the experience of illness invalidation. After a week, the research assistant will remind the participant to evaluate their quality of life. Finally, a retrospective chart review will be conducted one month after the visit to confirm any emergency department visits. Except for the demographic variables (i.e., age, sex, educational level, and diagnosis) and emergency visits."
62749121|NCT05945602||Biomarker Optimization - Patients|Veterans currently enrolled for healthcare services at the VA San Diego Healthcare System who have a diagnosis of a chronic psychotic disorder (e.g., schizophrenia or schizoaffective disorder).
62749122|NCT05945602||Biomarker Optimization - Healthy Comparison Subjects|Veterans currently enrolled for healthcare services at the VA San Diego Healthcare System who have no history of mental illness.
62749123|NCT05945602||Biomarker Validation in Chronic Psychotic Disorders|Veterans currently enrolled for healthcare services at the VA San Diego Healthcare System with a diagnosis of a chronic psychotic disorder (e.g., schizophrenia or schizoaffective disorder).
62749124|NCT06455891||Group 1|Patients with generalized AD defined by AD skin lesion involved more or equal 50% of total body surface area with head and neck involvement. (15 patients)
62749125|NCT06455891||Group 2|Patients with head and neck AD (HNAD) defined by AD involving at least 80% of the head and neck area with or without AD involvement outside the head and neck area but \<20% of total body surface area. (15 patients)
62749126|NCT06455891||Group 3|Healthy control without chronic skin disease. Healthy control will be recruited from non-atopic patients explored in ours departments for drug allergy after resolution of acute events. (15 healthy controls)
62749127|NCT02891148|EXPERIMENTAL|BI 690517|
62749128|NCT06372171|OTHER|Stage 1|Day 14
62749129|NCT06372171|OTHER|Stage 2|Day 28
62749130|NCT01588340|ACTIVE_COMPARATOR|MRI|The patient will have a rapid noncontrast MRI (magnetic resonance imaging) that will take approximately 15 minutes to complete.
62749131|NCT01588340|ACTIVE_COMPARATOR|Ultrasound exam|A noncontrast ultrasound examination
62749132|NCT05771441|ACTIVE_COMPARATOR|neck stabilization exercise (NSE)|the patients who had NSE
62749133|NCT05771441|ACTIVE_COMPARATOR|NSE + HOT PACK THERAPY|the patients who had NSE+ hot pack
62749134|NCT05771441|ACTIVE_COMPARATOR|NSE + infrared therapy|the patients who had NSE+ infrared therapy
62749135|NCT05771441|ACTIVE_COMPARATOR|NSE + ultrasound therapy|the patients who had NSE+ ultrasound therapy
62749136|NCT02901054|EXPERIMENTAL|open label infusion ondansetron|"1. A single 4-mL CSF sample per subject.~2. Serial blood sampling at 0 (pre-infusion), 15, 30, 60, 120, and 180 min after ondansetron administration"
62749137|NCT04154449||Control group.|
62749138|NCT04154449||Surgical group Received intranasal insulin.|
62749139|NCT04154449||Surgical group Received placebo.|
62749140|NCT01282307|EXPERIMENTAL|Method Guided Self-Determination|The Method Guided Self-Determination consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
62749141|NCT01282307|NO_INTERVENTION|Treatment as usual|
62749142|NCT03484507|ACTIVE_COMPARATOR|Chlorhexidine monotherapy|Topical chlorhexidine 0.04%
62749143|NCT03484507|EXPERIMENTAL|Chlorhexidine plus povidone iodine|Topical chlorhexidine 0.04% plus povidone iodine 2.5%
62749144|NCT03484507|EXPERIMENTAL|Early corticosteroids|Topical prednisolone sodium phosophate 1% for weeks 4-11
62749145|NCT03484507|EXPERIMENTAL|Late corticosteroids|Artificial tears for weeks 4-5, then topical prednisolone sodium phosophate 1% for weeks 6-11
62749146|NCT03484507|PLACEBO_COMPARATOR|Placebo|Artificial tears for weeks 4-11
62749147|NCT03092830||1-arm, 500 participates|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
62749148|NCT05841004|EXPERIMENTAL|Investigational device - newly developed intermittent compact catheter|Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (CH12 and CH14) for urinary drainage. The investigational device is for single use.
62749149|NCT05841004|ACTIVE_COMPARATOR|Hollister Infyna Chic|The comparator is Hollister Infyna Chic, a CE-marked single-use compact catheter.
62749150|NCT01352442|EXPERIMENTAL|AcuFocus Corneal Inlay|The AcuFocus Corneal Inlay ACI 7000PDT, which is a small medical device, will be surgically implanted in one eye of each subject.
62749151|NCT03015649|EXPERIMENTAL|SCOUT device|"The study population consists of 25 - 35 adult surgical patient volunteers who plan to have definitive breast cancer surgery at Memorial Healthcare System (MHS) Hospitals after neoadjuvant treatment.~The investigator will identify subjects who meet inclusion/exclusion criteria, obtain patient's consent and schedule the subject for the SAVI SCOUT Surgical Guidance System procedure. All study participants will receive the same treatment assignment, i.e. lesion localization with the SCOUT device 31 - 365 days prior to surgery. Neoadjuvant treatment decisions will be determined by patient's medical oncologist."
62749152|NCT04710550|EXPERIMENTAL|Safety/Dosimetry Cohort|
62749153|NCT04710550|EXPERIMENTAL|Traumatic Brain Injury|
62749154|NCT04710550|EXPERIMENTAL|AD/MCI|
62749155|NCT04710550|ACTIVE_COMPARATOR|Healthy Controls|
62749156|NCT02178254|EXPERIMENTAL|Sequence 3|N=10 subjects receive 3grams oral sachet of Monurol in Period 1; 1.0gram of Intravenous (IV) ZTI-01 for Period 2 (1-hour infusion); and 8.0 grams IV ZTI-01 for Period 3.
62749157|NCT02178254|EXPERIMENTAL|Sequence 1|N=10 subjects receive 1.0gram of Intravenous (IV) ZTI-01 for Period 1 (1-hour infusion); 8.0 grams IV ZTI-01 for Period 2 (1-hour infusion); and 3grams oral sachet of Monurol in Period 3.
62749158|NCT02178254|EXPERIMENTAL|Sequence 2|N=10 subjects receive 8.0 grams IV ZTI-01 for Period 1(1-hour infusion); 3grams oral sachet of Monurol in Period 2 and 1.0gram of IV ZTI-01 for Period 3 (1-hour infusion)
62749159|NCT05878327||Thrombophilia screening|Patients with livedoid vasculopathy. Investigated by thrombophilia screening
62554276|NCT02122991||Spinal Cord Injury|Subjects must be between the age of 30 and 64 years old, be English-literate and able to provide informed consent. They must be at least 1 year from the date of their spinal cord injury. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 22 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (\<6 months), unstable/uncontrolled seizures, neurodegenerative disease, Severe Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, any significant systemic illness or unstable medical condition (uncontrolled diabetes, hypo- or hyperthyroidism, systemic cancer), history of schizophrenia or bipolar disorder or any active psychosis, or alcohol/substance abuse or dependence (\<6 months).
62554277|NCT03188796|PLACEBO_COMPARATOR|Placebo|oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days
62749160|NCT02831738|EXPERIMENTAL|Active Treatment|Polydextrose 12 g
62749161|NCT02831738|PLACEBO_COMPARATOR|Control Treatment|No polydextrose
62749162|NCT05980273||school children, their mothers and teachers|educational session program
62749163|NCT04817137|OTHER|All Enrolled Patients|Patients will wear the Caretaker Pulse Decomposition Analysis (PDA) Device, which will record the patient's blood pressure.
62749164|NCT04924530|SHAM_COMPARATOR|Maltodextrin|Glucose polymer; a common sugar substitute
62749165|NCT04924530|ACTIVE_COMPARATOR|Sucrose|Fructose-glucose disaccharide
62749166|NCT04924530|EXPERIMENTAL|Lactose|Galactose-glucose disaccharide
62749167|NCT06598514|EXPERIMENTAL|Chlorhexidine Lavage|2% chlorhexidine perineal lavage following defecation
62749168|NCT06598514|ACTIVE_COMPARATOR|Sterile Water Lavage|Sterile water perineal lavage following defecation
62749169|NCT04587843|EXPERIMENTAL|Contrave 8mg/90mg Extended Release Tablet|Group treated with Contrave Extended Release Tablets
62749170|NCT04587843|PLACEBO_COMPARATOR|Placebo|Group given placebo
62749171|NCT05066581|NO_INTERVENTION|Philips band|It is a medical device that collects, among other things, movement data by means of an accelerometer, from which it accelerometer, from which it estimates the total time of sleep (TTS) and wakefulness, and waking time, also offering the efficiency of the same (time asleep in relation to time in bed). time in bed). In addition, it collects data not related to sleep, such as energy expenditure (in kilocalories), energy expenditure (in kilocalories) (in kilocalories), heart rate, and daily activity (in steps), among others.
62374894|NCT00721357||Control|neurologically healthy subjects
62374895|NCT00902512|ACTIVE_COMPARATOR|Treatment A|Viagra® 100 mg tablet, administered with water
62374896|NCT00902512|ACTIVE_COMPARATOR|Treatment B|Sildenafil 100 mg CT administered with water
62749172|NCT05066581|ACTIVE_COMPARATOR|Philips Band + Live chat|In the Intervention group, in addition to having the philips band, the subjects will interact through the live chat system that they will have to download to their mobile phones. This live chat offers the possibility to consult in real time, thus initiating a process of relationship between researcher/subject.
62749173|NCT01789060||p-AKT|p-AKT immunohistochemical staining,high p-AKT expression (upper quartile), low p-AKT expression (lower 3 quartiles)
62749174|NCT05556135||group1|NAFLD patients
62749175|NCT05556135||group 2|non NAFLD patients
62749176|NCT03587701|EXPERIMENTAL|Group A|This group will be randomized to receive intervention of 42 consecutive days of anakinra (100mg/0.67ml) in period 1 followed by an additional 42 consecutive days of anakinra (100mg/0.67ml) in period 2
62749177|NCT03587701|EXPERIMENTAL|Group B|This group will be randomized to receive intervention of 42 consecutive days of anakinra (100 mg/0.67ml) in period 1 followed by 42 consecutive days of placebo in period 2
62554278|NCT03188796|EXPERIMENTAL|High Dose Vitamin D3|"oral/enteral pharmacological dose of cholecalciferol (vitamin D3) - total dose 900,000~* loading dose of 540,0000 (dissolved in 37.5 ml of medium chain triglycerides - MCT)~* followed by 4000 IU daily (10 drops) for the entire active study period (90 days)"
62749178|NCT03587701|EXPERIMENTAL|Group C|This group will be randomized to receive intervention of placebo for 42 consecutive days in period 1 followed by 42 consecutive days of anakinra (100mg/0.67ml) in period 2
62749179|NCT05507021|EXPERIMENTAL|Lactobacillus plantarum DSM 33464, MegaMetalliQ|Subjects will take 1 sachet of Lactobacillus plantarum DSM 33464 (2 g) per day for 8 weeks
62749180|NCT05507021|PLACEBO_COMPARATOR|placebo group|Subjects will take 1 sachet of Placebo (2 g) per day for 8 weeks
62749181|NCT05723965||rectal cancer lesion images for training|"Rectal cancer lesion images. Images with threatened (\<2mm) circumferential margin of rectal cancer were labeled as diseased. Otherwise, images were labeled as normal. Using these materials as training materials for AI deep learning model buildup."
62749182|NCT05723965||rectal cancer lesion images for testing.|Using the buildup AI deep learning models from training cohort. Evaluating prediction rate of the model and analysis survival outcomes.
62749183|NCT03619707|EXPERIMENTAL|Oral Dydrogesterone|Oral dydrogesterone (Duphaston 10 mg) will be given orally four times daily : will be continued till the pregnancy test, and till at least 12 weeks of gestation in case of a positive pregnancy test.
62749184|NCT03619707|EXPERIMENTAL|Vaginal microprogesterone|Vaginal progesterone (Utrogestan 200 mg) will be given vaginally four times daily: will be continued till the pregnancy test, and till at least 12 weeks of gestation in case of a positive pregnancy test
62749185|NCT03127774|EXPERIMENTAL|Surgery with HIPEC|Cytoreductive surgery followed by HIPEC with cisplatin and sodium thiosulfate
62749186|NCT00963716|EXPERIMENTAL|Hot biopsy|Hot biopsy i.e. Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
62749187|NCT00963716|ACTIVE_COMPARATOR|Cold biopsy|Cold biopsy i.e. Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
62749188|NCT05209802|EXPERIMENTAL|A: Exercise|High intensity interval exercise training (4 x 4 minutes of intensity above 17 on the Borg Rating of Perceived Exertion)
62749189|NCT05209802|ACTIVE_COMPARATOR|B: Exercise|Moderate intensity exercise training
62749190|NCT03300154|EXPERIMENTAL|Financial incentives|
62554279|NCT04763954|EXPERIMENTAL|Game|Group that receives the game intervention (the trial version and the access to level 2 and level 7
62554280|NCT04763954|NO_INTERVENTION|Control|Group without intervention
62554281|NCT04763954|EXPERIMENTAL|Guidance|Group that receives the game (the same levels as group 1) and email coaching one day after completing the game.
62749191|NCT03300154|EXPERIMENTAL|Framing (SMS)|
62749192|NCT03300154|NO_INTERVENTION|Usual care|
62749193|NCT06447623|EXPERIMENTAL|Arm-A|Apatinib combined with cdk4/6i and Endocrine therapy.
62749194|NCT06447623|ACTIVE_COMPARATOR|Arm-B|cdk4/6i and Endocrine therapy.
62749195|NCT00588172|SHAM_COMPARATOR|1|Individuals with no nsSNPs or mutations known to alter oct1 function
62749196|NCT00588172|ACTIVE_COMPARATOR|2|Individuals with nsSNPs or mutations known to alter oct1 function
62749197|NCT01259648|EXPERIMENTAL|0.5 µg / kg remifentanil|Induction anesthesia includes 0.5 µg/kg remifentanil in addition to classic induction anesthesia protocol.
62749198|NCT01259648|EXPERIMENTAL|1.0 µg/kg remifentanil|Induction anesthesia includes 1.0 µg/kg remifentanil in addition to the classic induction protocol.
62749199|NCT01259648|PLACEBO_COMPARATOR|NaCl|An equivalent volume (1 ml for 10 kg of weight) of isotonic 0.9% NaCl is injected in addition to the classic anesthesia induction protocol
62374897|NCT00902512|ACTIVE_COMPARATOR|Treatment C|Sildenafil 100 mg CT administered without water
62749200|NCT02664649|EXPERIMENTAL|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight \<60 kg, serum creatinine ≥1.5 mg/dL \[133 μMol/L\].~- Also, subjects with severe renal insufficiency \[calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min\] will take apixaban 2.5 mg tablets orally twice daily"
62749201|NCT02664649|ACTIVE_COMPARATOR|Standard of care|VKA or Antiplatelet therapy
62749202|NCT06061276|EXPERIMENTAL|bTAE-HAIC combined with Lenvatinib and Camrelizumab|bTAE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin every 4 weeks.
62391525|NCT06150404|EXPERIMENTAL|Intervention Group|Those in the intervention group will receive the administration of white noises and maternal and/or paternal voice recording.
62749203|NCT06106009|EXPERIMENTAL|Part A Cohort 1|Single dose administration of PF-07976016 and placebo. Participants will receive up to 4 dose levels of PF-07976016 or matching placebo.
62749204|NCT06106009|EXPERIMENTAL|Part A Cohort 2|Single dose administration of PF-07976016 and placebo. Participants will receive up to 4 dose levels of PF-07976016 or matching placebo.
62391526|NCT06150404|NO_INTERVENTION|Control Group|Those enrolled in the control group will receive standard care and will be subjected to the usual level of ambient noise.
62749205|NCT06106009|EXPERIMENTAL|Part A Optional Cohort 3|Single dose administration of PF-07976016 and placebo. Participants will receive up to 2 dose levels of PF-07976016 or matching placebo.
62749206|NCT06106009|EXPERIMENTAL|Part A Optional Cohort 4|Single dose administration of PF-07976016 and placebo. Participants will receive up to 4 dose levels of PF-07976016 or matching placebo.
62749207|NCT06106009|EXPERIMENTAL|Part B Cohort 5|Multiple dose administration of PF-07976016 or matching placebo.
62749208|NCT06106009|EXPERIMENTAL|Part B Cohort 6|Multiple dose administration of PF-07976016 or matching placebo.
62749209|NCT06106009|EXPERIMENTAL|Part B Cohort 7|Multiple dose administration of PF-07976016 or matching placebo.
62749210|NCT06106009|EXPERIMENTAL|Part B Cohort 8|Multiple dose administration of PF-07976016 or matching placebo.
62749211|NCT06106009|EXPERIMENTAL|Part B Cohort 9|Multiple dose administration of PF-07976016 or matching placebo.
62749212|NCT06106009|EXPERIMENTAL|Part B Optional Cohort 10|Multiple dose administration of PF-07976016 or matching placebo.
62749213|NCT06106009|EXPERIMENTAL|Part C Optional Cohort 11|Single dose midazolam administered alone or in combination with multiple doses of PF-07976016.
62749214|NCT06106009|EXPERIMENTAL|Part C Optional Cohort 12|Single dose midazolam administered alone or in combination with multiple doses of PF-07976016.
62749215|NCT06106009|EXPERIMENTAL|Part D Optional Cohort 13|Multiple dose administration of PF-07976016 or matching placebo.
62374898|NCT01800162|ACTIVE_COMPARATOR|Uterine evacuation, then MTX for some|Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
62374899|NCT01800162|ACTIVE_COMPARATOR|Empiric treatment with MTX for all|Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
62554282|NCT03473184|EXPERIMENTAL|Single Cohort (Healthy Volunteers)|Single cohort received diacerein 1% ointment
62374900|NCT01800162|ACTIVE_COMPARATOR|Expectant Management|Subjects will have their PPUL expectantly managed using serum hCG monitoring.
62749216|NCT02523157|EXPERIMENTAL|Intervention|Wellbeing Plan
62749217|NCT02523157|ACTIVE_COMPARATOR|Control|Control task. Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
62749218|NCT05721326|EXPERIMENTAL|Sequential Communications|This sequential arm contains three types of communication to be employed following non-response to the previous type. The initial communication will be a direct message to the patient via the MyPennMedicine. The subsequent message will be sent as a text via the Way To Health app(lication). The final communication will be a nudge to the patient's physician which will send upon opening the patient's chart and will remain as a flag thereafter.
62749219|NCT03351816|EXPERIMENTAL|Cardioversion group|Patients with persistent atrial fibrillation who are oriented for cardioversion in the course of routine care.
62374901|NCT03486769|EXPERIMENTAL|Dual Stimulation 1|i) anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex, ii) anodal stimulation on ipsilesional premotor cortex and cathodal stimulation on contralesional supraorbital area.
62374902|NCT03486769|EXPERIMENTAL|Dual Stimulation 2|i) anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex, ii) anodal stimulation on ipsilesional anterior intraparietal sulcus and cathodal stimulation on contralesional supraorbital area.
62374903|NCT03486769|EXPERIMENTAL|Single stimulation|anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex
62554283|NCT00923897|EXPERIMENTAL|RT for Liver Mets and HCC|
62554284|NCT04810715||Patient Group|Anklyosing Spondilitis
62554285|NCT01017835||statin treatment, isolated hypertension|treatment with statins, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking
62749220|NCT03351816|EXPERIMENTAL|Ablation group|Patients with persistent or paroxystic atrial fibrillation who are oriented for ablation of AF in the course of routine care.
62749221|NCT04005560|OTHER|patient|Score of PedSQL who is the Pediatric Quality of Life Questionnaire
62749222|NCT06301828|EXPERIMENTAL|Experimental group|Enrolled patients were treated with endostar combined with stereotactic body radiation therapy and Envafolimab.
62749223|NCT04279821||Colonic diverticulosis and macroscopic signs of inflammation|No interventional study
62554286|NCT01017835||placebo treatment, isolated hypertension|treatment with placebo, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking
62554287|NCT05698914|EXPERIMENTAL|Telehealth mindfulness-based intervention (MBI)|Eight, weekly telehealth mindfulness sessions delivered one-on-one with mindfulness instructor
62554288|NCT05698914|ACTIVE_COMPARATOR|Telehealth Education (EDU)|Eight, weekly post-surgical educational sessions delivered one-on-one with physical therapist
62749224|NCT02553980|EXPERIMENTAL|Physical activity promotion I|"Participants in this group attended the VT3 program (with Automatic HR detection)"
62749225|NCT02553980|EXPERIMENTAL|Physical activity promotion II|"Participants in this group attended the VT2 program (self PA report)"
62749226|NCT02553980|PLACEBO_COMPARATOR|Control|Participants in this group did not receive any VT treatment, and live as usual.
62749227|NCT05952765|EXPERIMENTAL|Partially demineralized dentin matrix graft|"* A high-speed fine finishing stone and saline irrigation will be used to clean extracted teeth from periodontal ligaments, soft tissue attachments, caries, and restorations if present.~* Teeth particles will be partially demineralized using nitric acid 2% for fifteen minutes.~* Finally, the prepared partially demineralized dentin matrix graft granules will be washed twice with distilled water and phosphate buffered saline~* Immediate implant of appropriate dimensions will be placed and the previously prepared partially demineralized dentin matrix graft will be used to graft the jumping gap.~* Customized healing abutment will be used.~* In Osseo integrated implants temporary abutment will be removed and impressions for final restoration will be performed after 3 months."
62749228|NCT05952765|ACTIVE_COMPARATOR|xenograft|"* After tooth extraction, thorough curettage will be performed.~* Immediate implant of appropriate dimensions will be placed, and the jumping gap will be grafted with xenograft Cerabone .~* Customized healing abutment will be used.~* In Osseo integrated implants temporary abutment will be removed and impressions for final restoration will be performed after 3 months."
62749229|NCT06267937||hip fracture|patients that were diagnosed with a hip fracture between 2012 and 2017
62749230|NCT01961284|ACTIVE_COMPARATOR|Zygomatic Implants|2-4 zygomatic implants inserted into edentulous maxilla with no augmentation/grafting prior to providing patient with dental prosthesis
62749231|NCT01961284|ACTIVE_COMPARATOR|Bone Graft and Conventional implants|Edentulous maxilla which is deficient in bone is first grafted using bone grafting material derived from cows and then ordinary implants are placed into the augmented jaw bone approximately 6 monhts after grafting. Patients will be provided with a dental prosthesis following osseointegration.
62749232|NCT01103154|ACTIVE_COMPARATOR|Carvedilol|carvedilol 6.25mg per day
62749233|NCT01103154|ACTIVE_COMPARATOR|N+I|nadolol 40mg per day, ISMN 10 mg per day
62749234|NCT01945411|EXPERIMENTAL|Experimental|the length between incisor and mandible angle
62749235|NCT01945411|ACTIVE_COMPARATOR|Active comparator|the length between mouth corner-mandible angle
62749236|NCT03619096|ACTIVE_COMPARATOR|Test Group (tunnel technique)|It Will be performed root coverage of multiple recessions using porcine collagen matrix with a tunnel Technique
62749237|NCT03619096|PLACEBO_COMPARATOR|Control Group (extended flap technique)|It Will be performed root coverage of multiple recessions using porcine collagen matrix with a extended flap technique
62749238|NCT01863173|ACTIVE_COMPARATOR|metoprolol|patient or intervention group
62749239|NCT01863173|ACTIVE_COMPARATOR|placebo group|control group
62374904|NCT04270565|EXPERIMENTAL|Intervention Group|The intervention group will receive real-time gait-training interventions along with a home exercise program. Participants in this group will be given a pair of sensors to wear on their shoes to wear during runs throughout the study period, and wear a Garmin watch to get information from the sensors to the watch for feedback. They will also do home exercises during the study, and to come into the laboratory weekly for about 30 minutes per visit to progress the home exercises and get instructions on feedback for the next week.
62554289|NCT06382532||Healthy control group|"1. M.I.N.I scale rating without any mental disorder;~2. Patient Health Questionnaire (PHQ-9) \< 5;~3. No history of mental illness, no family genetic history;~4. Age 18-60 years old, Males;~5. Voluntary informed consent form."
62374905|NCT04270565|ACTIVE_COMPARATOR|Control Group|The control group will receive only a home exercise program. Participants in this group will be given a pair of sensors to wear on their shoes to wear during runs throughout the study period, and do home exercises during the study. Participants will be asked to come into the laboratory weekly for about 30 minutes per visit to progress the home exercises.
62374906|NCT04075955|EXPERIMENTAL|Study treatment group|Olanzapine in combination with ondansetron and dexamethasone
62374907|NCT04075955|ACTIVE_COMPARATOR|Standard treatment group|Aprepitant in combination with ondansetron and dexamethasone
62374908|NCT05418140||Women with diagnosis of adenomyosis on ultrasound scan|"The cohort group (375 participants) will comprise of women diagnosed with adenomyosis on pre-treatment baseline ultrasound scan before ART treatment who satisfy the eligibility criteria and consent to participate in the study.~September 2022: Amendments to the protocol: Some of the methodological aspects of the AdAPT-ART study have been revisited to ensure timely delivery of the study to a full sample size. These amendments have been approved by the local ethics committee.~Amendment sample size:~Sample size of 276 women with adenomyosis and 552 women with normal uterus with 2:1 control: cohort design. Power remains 80%"
62374909|NCT05418140||Control group: Women with normal uterus on baseline ultrasound scan|"Women with normal uterus on baseline ultrasound scan during the study duration will be used as control (375 participants) and will be matched for the following variables: age, embryo quality, type of ART cycle (donor or self and IVF or ICSI) and number of embryos transferred. The eligibility criteria will be applicable to the controls as well.~September 2022: Amendments to the protocol: Some of the methodological aspects of the AdAPT-ART study have been revisited to ensure timely delivery of the study to a full sample size. These amendments have been approved by the local ethics committee.~Amendment sample size:~Sample size of 276 women with adenomyosis and 552 women with normal uterus with 2:1 control: cohort design. Power remains 80%"
62374910|NCT04440085|ACTIVE_COMPARATOR|Intervention group|Midodrine will be administered every 8 hours, increasing the dose gradually until a maximum of 30 mg a day is reached. It will be given orally in the following sequence: 2.5 mg - 5 mg - 7.5 mg - 10 mg. The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) \> 65 mmHg, with unchanged dose of midodrine after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.
62374911|NCT04440085|PLACEBO_COMPARATOR|Control group|By placebo group will be followed the same strategy.The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) \> 65 mmHg, with unchanged dose of placebo after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.
62374912|NCT04574141|EXPERIMENTAL|spray before tablet|
62374913|NCT04574141|EXPERIMENTAL|tablet before spray|
62374914|NCT05078086||Patients undergoing cardiac surgery with CPB|\>18 y/o patients who undergo cardiac surgery with cardiopulmonary bypass and with a preoperative additive EuroSCORE I≥ 6
62374915|NCT02762123|EXPERIMENTAL|Cohort 1 (BMS-986142: 200 mg)|200mg BMS-986142 administered orally once daily on specified days.
62374916|NCT02762123|EXPERIMENTAL|Cohort 2 (BMS-986142: 350 mg)|350mg BMS-986142 administered orally once daily on specified days.
62374917|NCT06442176||Control Healthy group|
62374918|NCT06442176||Coronary Artery Disease Group|
62554290|NCT06382532||Depressive disorder group|"1. Patients with a first depressive disorder meeting DSM-5 criteria;~2. Age 18-60 years, Males;~3. Voluntary informed consent."
62554291|NCT06382532||Depressive disorder malinger group|"1. Clinical complaints meeting Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for the diagnosis of depressive disorder;~2. Patients with first-episode fraudulent disease who meet the DSM-5 criteria for the diagnosis of Z76.5;~3. Age 18-60 years, Males;~4. Voluntary informed consent."
62749240|NCT05475210|EXPERIMENTAL|Peptide Receptor Radionucleotide Therapy (PRRT)|The treatment regimen will consist of a single-dose intravenous administration of 177Lu-DOTA-EB-TATE per 6-week cycle, for a total of 2 cycles. The dose per cycle will be fixed for each patient and will be escalated in 3 different dose levels, from 50 mCi to 150 mCi (1.85 -5.55 GBq). Each dose of 177Lu-DOTA-EB-TATE will be administered in association with intravenous renal protective amino acid solutions.
62749241|NCT03324334||Study group|Patients with ulcerative colitis Interventions to be administered: Thyroid antibodies and Thyroid sonography
62749242|NCT03324334||Control group|normal control subjects selected from general population at random Interventions to be administered: Thyroid antibodies and Thyroid sonography
62749243|NCT06003543|EXPERIMENTAL|Virtual Reality|virtual glasses will be applied
62749244|NCT06003543|NO_INTERVENTION|Control|no application will be made
62749245|NCT03603899|EXPERIMENTAL|Hp 129Xenon|Participants will inhale up to 4 doses of Hp129Xenon; each dose will be no more than 1 liter.
62749246|NCT03195660|EXPERIMENTAL|ASV Therapy|ASV Therapy
62749247|NCT01971749||Unprotected left main coronary artery stenosis patients|
62749248|NCT00808613|ACTIVE_COMPARATOR|Optetrak Posterior Stabilized TKR|Subjects in this arm will receive an Optetrak Posterior Stabilized total knee system.
62749249|NCT00808613|ACTIVE_COMPARATOR|Optetrak Hi-Flex TKR|Subjects in this arm will receive an Optetrak Hi-Flex total knee system.
62749250|NCT01578642|OTHER|Single Arm open label|EndoStim LES Stimulation System
62749251|NCT04627324|EXPERIMENTAL|The smart toothbrush and smart mirror (STM) system toothbrushing instruction (TBI)|Participants received using the STM system TBI. The plaque indexes were evaluated at baseline, immediately after TBI (day 0), 1 week, 1 month and 10 month (1st study only) after TBI.
62749252|NCT04627324|ACTIVE_COMPARATOR|conventional toothbrushing instruction (TBI)|Participants received using conventional TBI. The plaque indexes were evaluated at baseline, immediately after TBI (day 0), 1 week, 1 month and 10 month (1st study only) after TBI.
62749253|NCT05083013||COVID-19 with DM|"All patients will be screened for diabetes according to history and blood glucose measurements as well as HbA1C.~Accordingly, the patients will be divided into two groups, diabetic and non-diabetic group."
62749254|NCT05083013||COVID-19 without DM|"All patients will be screened for diabetes according to history and blood glucose measurements as well as HbA1C.~Accordingly, the patients will be divided into two groups, diabetic and non-diabetic group."
62749255|NCT04599959|EXPERIMENTAL|Overall (Swab/Saliva)|
62749256|NCT03831516||Non Invasive Electroanatomical Mapping|Patients will undergo non invasive electroanatomical mapping (CardioInsight by Medtronic) prior and during an invasive electrophysiology study and ablation of ventricular Arrhythmias.
62749257|NCT03222973|EXPERIMENTAL|BIIB033 (opicinumab) 750 mg|Participants with relapsing multiple sclerosis (RMS) will receive BIIB033 750 milligram (mg) intravenously (IV) as an add-on therapy to a background disease-modifying therapy (DMT) once every 4 weeks over 72 weeks in Part 1 and once every 4 weeks over 96 weeks in Part 2.
62749258|NCT03222973|PLACEBO_COMPARATOR|Placebo|Participants with RMS will receive placebo IV as an add-on therapy to a background DMT once every 4 weeks over 72 weeks in Part 1 and BIIB033 once every 4 weeks over 96 weeks in Part 2. The placebo looks like BIIB033 but does not contain the active ingredient that is thought to have an effect on MS disease. The placebo used in this study is sterile normal saline (water with a small amount of sodium chloride \[salt\]).
62749259|NCT05716178|EXPERIMENTAL|Maternal health education|participants in the intervention group will receive behavioral change communication on maternal health from trained religious leaders. The local religious leaders from each clustered kebele will be recruited based on religious educational status (educational status greater than or equal to diploma), acceptance by their followers and popularity, in collaboration with religious organization leaders, health extension workers, and kebele leaders. Then after the potential religious leaders are recruited, the two days training will be given for them. Recruited religious leaders are expected to give training on the topics (maternal health) for four sessions to promote healthy maternal behaviors for the members of their religion. After training sessions, every participant will receive a copy of the visual materials (posters) containing the key messages for promoting prenatal health behaviors.
62554292|NCT04973566|EXPERIMENTAL|Part 1: Etanercept and Nipocalimab|Participants will receive a single subcutaneous (SC) dose of etanercept on Day 1 in Period 1 followed by single intravenous (IV) infusion of nipocalimab on Day 29, SC administration of etanercept followed by an IV infusion of nipocalimab on Day 43 and then a single dose of nipocalimab IV infusion on Day 57 in Period 2 of Part 1. There will be a wash-out period of 28 days between Day 1 of Period 1 and Day 29 of Period 2 in Part 1.
62554293|NCT04973566|EXPERIMENTAL|Part 2 (Cohort 1): Nipocalimab|Participants will receive a single IV infusion of nipocalimab on Day 1 in Cohort 1 of Part 2.
62554294|NCT04973566|EXPERIMENTAL|Part 2 (Cohort 2): Nipocalimab and Hydroxychloroquine (HCQ)|Participants will receive a single oral dose of HCQ film-coated tablets once daily from Day 1 to Day 22 and a single IV infusion of nipocalimab on Day 8 in Cohort 2 of Part 2.
62749260|NCT05716178|NO_INTERVENTION|Usual or routine care|The control group in this study will be on the existing routine maternal service without a provision of religious leaders' training intervention. In this arm, there will be no intervention by the researchers, rather baseline and end line data will be collected.
62749261|NCT04052789|ACTIVE_COMPARATOR|Zirconia single posterior crowns veneered with ceramics|'In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits
62749262|NCT04052789|EXPERIMENTAL|BioHpp PEEK single posterior crowns veneered with compos|In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits
62749263|NCT05128513|EXPERIMENTAL|DELP|Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) is a non-pharmacological therapy for acute stroke, which is approved by China Food and Drug Administration
62749264|NCT05128513|NO_INTERVENTION|control group|
62749265|NCT04452435|EXPERIMENTAL|C21 100 mg twice daily|Oral C21 treatment 100 mg twice daily for 7 days
62554295|NCT01488773||ICS + salmeterol|"Patients treated with both inhaled glucocorticosteroid (ICS) and salmeterol (long-acting β2-agonist).~90 patients met the inclusion criteria for this group."
62554296|NCT01488773||ICS + montelukast|"Patients treated with both inhaled glucocorticosteroid (ICS) and montelukast (leukotriene receptor antagonist).~42 patients met the inclusion criteria for this group."
62554297|NCT00778388|ACTIVE_COMPARATOR|IC43 50|IC43 50 mcg with AI(OH)3
62554298|NCT00778388|ACTIVE_COMPARATOR|IC43 100 with|IC43 100 mcg with AI(OH)3
62554299|NCT00778388|ACTIVE_COMPARATOR|IC43 100 w/o|IC43 100 mcg w/o AI(OH)3
62554300|NCT00778388|ACTIVE_COMPARATOR|IC43 200|IC43 200 mcg with AI(OH)3
62554301|NCT00778388|PLACEBO_COMPARATOR|Placebo|Placebo (0,9% NaCl)
62554302|NCT03660176|ACTIVE_COMPARATOR|routine management|Children in the control group receive no additional treatment
62554303|NCT03660176|EXPERIMENTAL|EXP GROUP|children receiving butyrate enemas + routine management butyrate enemas every day before Curative surgery
62554304|NCT02234102|ACTIVE_COMPARATOR|Paroxysmal Atrial Fibrillation (PAF)|Endoscopically guided laser ablation
62749266|NCT04452435|PLACEBO_COMPARATOR|Placebo|Oral placebo treatment 100 mg twice daily for 7 days
62374919|NCT04363723||patients with an acute exacerbation during Rehabilitation|Patients with severe chronic obstructive pulmonary disease awaiting lung Transplantation that developed an acute exacerbation during a pulmonary Rehabilitation program but continued the Rehabilitation program
62374920|NCT04363723||patients without an acute exacerbation during Rehabilitation|Patients with severe chronic obstructive pulmonary disease awaiting lung Transplantation that did not develop an acute exacerbation during a pulmonary Rehabilitation program and completed the Rehabilitation program regularly.
62554305|NCT02234102|ACTIVE_COMPARATOR|Persistent Atrial Fibrillation|Endoscopically guided laser ablation
62554306|NCT05012020|EXPERIMENTAL|mHealth Remote Monitoring|Use of the Clinic Portal by Healthcare professionals and use of the Mobile App by patients/caregivers
62554307|NCT06036186|EXPERIMENTAL|BaroPacing treatment|Group 1 will use BaroPacing for the first 3 weeks (day 8 to day 28) and then switch to standard treatment for another 3 weeks (day 29 to day 49).
62554308|NCT06036186|ACTIVE_COMPARATOR|Standard treatment|Group 2 will use standard treatment for the first 3 weeks (day 8 to day 28) and then switch to BaroPacing for another 3 weeks (day 29 to day 49).
62554309|NCT01070953||EZETROL® 10 mg|Participants with Hypercholesterolemia treated with EZETROL®
62554310|NCT04470648||hosted in the center and HCWs at the epidemic period|"people hosted in the health care or in the women center and health care workers working in one these centers during the epidemic time.~People with initial positive SARS-COV2 serology will have a second blood test to mesure atibodies kinetic"
62554311|NCT02351661||medica/surgical|Medical or surgical patients from 18 hospitals
62554312|NCT02152605|EXPERIMENTAL|Umeclidinium/Vilanterol 62.5/25 mcg once daily|The subjects will receive UMEC/VI 62.5/25 mcg, administered as one inhalation once-daily in the morning via a dry powder inhaler (DPI)
62554313|NCT02152605|PLACEBO_COMPARATOR|Placebo once daily|The subjects will receive placebo, administered as one inhalation once-daily in the morning via a DPI
62554314|NCT03353701|OTHER|Adults with or without HIV infection|Participants will be asked to stop drinking for at least 30 and up to 90 days. The study will use Contingency Management (CM) with financial incentives to encourage participants to maximally reduce alcohol consumption.
62554315|NCT03282500|EXPERIMENTAL|Mindfulness Based Cognitive Therapy|In the experimental condition, participants will receive 12 sessions including the instruction of mindfulness skills and cognitive behavioral therapy.
62554316|NCT03282500|NO_INTERVENTION|Psychoeducation on brain injury and treatment|In the control condition, participants will receive 12 sessions on the psychoeducation of brain injuries, outcomes, treatment, and support.
62554317|NCT00185588|EXPERIMENTAL|Stage 1 Dose Exploration 0 - Gemcitabine 700 + vatalanib 1250|Gemcitabine 700 mg/m2 + vatalanib 1250 mg daily
62749267|NCT02961933|EXPERIMENTAL|Apneic oxygenation|
62749268|NCT02961933|ACTIVE_COMPARATOR|non-apneic oxygenation|
62554318|NCT00185588|EXPERIMENTAL|Stage 1 Dose Exploration 1 - Gemcitabine 850 + vatalanib 1250|Gemcitabine 850 mg/m2 + vatalanib 1250 mg
62749269|NCT06581731|EXPERIMENTAL|group remimazolam-remifentanil|Administer 5 mg of remimazolam intravenously, followed by a continuous infusion at a rate of 0.5 mg/kg/h to maintain anesthesia.
62749270|NCT06581731|EXPERIMENTAL|group dexmedetomidine-remifentanil|Administer 1 μg/kg of dexmedetomidine as an intravenous bolus over 10 minutes, followed by a continuous infusion at 0.5 μg/kg/h to maintain anesthesia.
62749271|NCT03648177|ACTIVE_COMPARATOR|Treatment as Usual|"Active Comparator: (n=15) Treatment as Usual~The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain which allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic, non-pharmacologic approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group."
62749272|NCT03648177|EXPERIMENTAL|IPGT|"Experimental: IPGT (n=15) Integrated Psychosocial Group Treatment~IPGT consists of 6 weekly group sessions of motivational interviewing and behavioral change, self-management, and pain education focused on appropriate adherence to treatment and resisting urges to misuse prescription medications. The intervention also entails an education session on knowledge pertaining to overdose education and naloxone distribution. Topics covered in IPGT include: Pacing and goal setting, negative thinking, coping with stress and anxiety, sleep enhancement techniques, managing set-backs, and chronic pain and your life."
62749273|NCT02607475|EXPERIMENTAL|Robotic telesonography compared to conventional sonography|All participants will receive two imaging studies: (1) Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix), and (2) conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare).
62749274|NCT04286841||Neoadjuvant immunotherapy|
62749275|NCT03401021||Crrent Male smokers|"Male smokers met the inclusion criteria below will be invited to fill in the questionnaires set, part of them will be invited to attend a semi-structured interview(optional).~1. be aged 18 or above,~2. have a history of smoking at least one cigarette per day before their partners became pregnant,~3. be involved with partners whose pregnancies could be confirmed,~4. able to read Chinese and communicate in the Mandarin dialect."
62749276|NCT01257230|PLACEBO_COMPARATOR|placebo|once daily, delivered with Respimat inhaler
62554319|NCT00185588|EXPERIMENTAL|Stage 1 Dose Explrtion2 - Gemcitabine850+vatalanib 2x250/2x500|Gemcitabine 850 mg/m2 + vatalanib 250 mg Q12 hours x 1 week then 500 mg Q12 hours thereafter
62554320|NCT00185588|EXPERIMENTAL|Stage 2 Dose Expansion - Gemcitabine850+vatalanib 2x250/2x500|Gemcitabine 850 mg/m2 + vatalanib 250 mg Q12 hours x 1 week then 500 mg Q12 hours thereafter
62374921|NCT05302804|EXPERIMENTAL|Menthol Gel first, then hypoallergenic gel|"Participants randomized to receive menthol gel first then hypoallergenic gel after 7 day washout.~Gel is applied to the skin (arm and thigh). Participants walk on a treadmill for 30 minutes (3.5 mph at 5% grade) in 38°C and 60% relative humidity."
62374922|NCT05302804|EXPERIMENTAL|Hypoallergenic Gel first, then menthol|"Participants randomized to receive hypoallergenic gel first then menthol gel after 7 day washout.~Gel is applied to the skin (arm and thigh). Participants walk on a treadmill for 30 minutes (3.5 mph at 5% grade) in 38°C and 60% relative humidity."
62374923|NCT03157999|EXPERIMENTAL|Intervention group (CAST)|Participants in the intervention group will receive the CAST hospital-to-home transition intervention in addition to usual care.
62374924|NCT03157999|NO_INTERVENTION|Control group (usual care)|Participants assigned to the control group will receive usual care at discharge from hospital to home.
62374925|NCT05687292||CDSS Ventilator Weaning Group|This group will be exposed to the CDSS to inform weaning and discontinuation of mechanical ventilation.
62374926|NCT04037462|EXPERIMENTAL|Lead in Dexamethasone followed by immunotherapy|escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
62554321|NCT05630417|EXPERIMENTAL|Geriatric Massage Group|The fragility of the elderly, the sensitivity of skin, muscle and bone tissue necessitate modification of massage techniques according to the individual characteristics of the elderly. Geriatric massage is a form of massage applied according to the characteristics of the elderly individual and can be applied to all body parts according to the needs of the elderly. However, since diabetic neuropathy, which is a long-term complication that is common in individuals with Type 2 diabetes and can affect all body parts, shows more symptoms in the feet, foot massage as a geriatric massage may be effective in reducing diabetes symptoms and improving blood parameters. Because of its more systemic effects, back massage was preferred.
62554322|NCT05630417|NO_INTERVENTION|Control Group|No attempt will be made by the researcher on the elderly with Type 2 diabetes in the control group. The elderly in this group will benefit from the standard care practices offered by the institution.
62554323|NCT03783325|OTHER|UV Counseling|Evaluate the effectiveness of dosimetry feedback on sun exposure behaviors, attitudes, and awareness in patients diagnosed with melanoma.
62554324|NCT03783325|EXPERIMENTAL|Visual Analysis - UV Photo|Assess the relationships between UV camera score, silicone mold of a skin patch, phenotypic evaluation and sun-exposure behaviors. Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
62554325|NCT03783325|EXPERIMENTAL|Biological Sample|Determine the relationship between measures of sun exposure and genomic characteristics of tumors in melanoma patients. Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
62554326|NCT03396003|EXPERIMENTAL|GALILEI G6 Lens Professional|The GALILEI G6 Lens Professional will measure anterior segment geometry and axial intra-ocular distances of the eye.
62554327|NCT03396003|ACTIVE_COMPARATOR|Oculus Pentacam AXL|The Oculus Pentacam AXL will measure anterior segment geometry and axial intra-ocular distances of the eye.
62554328|NCT00890617|EXPERIMENTAL|Prednisone & Cryotherapy|"Prednisone taken:~20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure"
62554329|NCT03803969|OTHER|ConfirmRx (Insertable Cardiac Monitor)|This is a single arm study where in patients with an approved indication for a cardiac monitor will receive a ConfirmRx Device.
62554330|NCT01214577|EXPERIMENTAL|1|Up to three days of treatment
62554331|NCT05934227|PLACEBO_COMPARATOR|control|1) scaling and root planing (SRP) plus systemic administration of placebo (n=25)
62554332|NCT05934227|EXPERIMENTAL|antibiotics|2) scaling and root planing (SRP) plus systemic administration of amoxicillin and metronidazole (n=25).
62554333|NCT05807204|EXPERIMENTAL|Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine|Participants will daily consume the multi-ingredient (L-Histidine, L-Serine, L-Carnosine and N-Acetylcysteine) for 12 weeks.
62554334|NCT05807204|PLACEBO_COMPARATOR|Placebo|Participants will daily consume the placebo (maltodextrin) for 12 weeks.
62554335|NCT02386293|PLACEBO_COMPARATOR|Placebo|Sugar pill identical to Avapro provided for 7 day prescription
62554336|NCT02386293|ACTIVE_COMPARATOR|Irbesartan|150 mg of Avapro once daily for 7 days.
62554337|NCT06048276||Drug exposure|Herbal medicines
62554338|NCT01994785|ACTIVE_COMPARATOR|EGD capnography open|Capnographic monitoring during EGD - Data made available to study staff throughout procedure
62554339|NCT01994785|ACTIVE_COMPARATOR|EGD capnography blinded|Capnographic monitoring during EGD - Data made available to study staff only if necessary for safety reasons
62749277|NCT01257230|EXPERIMENTAL|tiotropium low dose|once daily, delivered with Respimat inhaler
62749278|NCT01257230|EXPERIMENTAL|tiotropium high dose|once daily, delivered with Respimat inhaler
62749279|NCT04883294||Disease Group|A disease group including patients older than 18 years old with any kind of histopathologically proven malignancy of the thyroid gland (including Papillary thyroid cancer (PTC), Follicular thyroid cancer (FTC), Medullary thyroid cancer (MTC), and Anaplastic thyroid cancer);
62749280|NCT04883294||Control|A control group including patients older than 18 years old with any kind of histopathologically proven benign thyroid gland disease (including adenoma, hyperplasia).
62749281|NCT01679548|EXPERIMENTAL|Single-port LAVH group|single-port laparoscopic assisted vaginal hysterectomy
62749282|NCT01679548|ACTIVE_COMPARATOR|Three-port LAVH group|three-port laparoscopic assisted vaginal hysterectomy
62374927|NCT04416191|OTHER|Limb immobilization|Participants will undergo a 2-week leg immobilization period
62374928|NCT02300506||Cohort 1|Patients with diagnosed malignant glioma treated by surgery, implanted Gliadel wafers 7.7mg, and enrolled in study GLI01S.
62554340|NCT01994785|ACTIVE_COMPARATOR|Colonoscopy capnography open|Capnographic monitoring during Colonoscopy - Data made available to study staff throughout procedure
62749283|NCT00123279|EXPERIMENTAL|1|
62749284|NCT00123279|EXPERIMENTAL|2|
62749285|NCT00123279|EXPERIMENTAL|3|
62749286|NCT00123279|EXPERIMENTAL|4|
62749287|NCT00123279|EXPERIMENTAL|5|
62749288|NCT00123279|EXPERIMENTAL|6|
62749289|NCT00003234|EXPERIMENTAL|Stratum 1 - Soft Tissue Sarcoma|See detailed description.
62749290|NCT00003234|EXPERIMENTAL|Stratum 2 - CNS Tumors|See detailed description.
62749291|NCT00003234|EXPERIMENTAL|Stratum 3 - Neuroblastoma|See detailed description.
62749292|NCT00433160|EXPERIMENTAL|Teriparatide|20 micrograms for 104 weeks
62749293|NCT00433160|PLACEBO_COMPARATOR|Placebo|Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks
62749294|NCT00072293|ACTIVE_COMPARATOR|Axillary Dissection|Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.
62749295|NCT00072293|EXPERIMENTAL|No Axillary Dissection|Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.
62374929|NCT00686699|EXPERIMENTAL|Preladenant 25 mg BID→Placebo BID|Participants received one preladenant 25 mg capsule twice daily (BID) for 14 days during the first treatment period and received one matching placebo capsule BID during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.
62374930|NCT00686699|PLACEBO_COMPARATOR|Placebo BID→Preladenant 25 mg BID|Participants received one matching placebo capsule BID for 14 days during the first treatment period and received one preladenant 25 mg capsule during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.
62554341|NCT01994785|ACTIVE_COMPARATOR|Colonoscopy capnography blinded|Capnographic monitoring during Colonoscopy - Data made available to study staff only if necessary for safety reasons
62749296|NCT06605716|EXPERIMENTAL|Maxilla|Presence of cystic structures larger than 1 cm in the maxilla with a surgical indication for enucleation Healthy adults
62749297|NCT06605716|EXPERIMENTAL|Mandibula|Presence of cystic structures larger than 1 cm in the mandible with a surgical indication for enucleation Healthy adults
62749298|NCT04964986|EXPERIMENTAL|Apraglutide SC injections, once weekly|Peptide analogue of GLP-2
62749299|NCT04379479|EXPERIMENTAL|Dialyzable Leukocyte Extract|"Oral administration 2 mg/5 mL every 24 hours for 14 days, following by 2 mg/5 mL twice a week for 3 weeks.~All patients will receive paracetamol as symptomatic treatment, 500 mg oral administration 3 times per day."
62749300|NCT04379479|PLACEBO_COMPARATOR|Placebo|"Oral administration 5 mL every 24 hours for 14 days, following by 5 mL twice a week for 3 weeks.~All patients will receive paracetamol as symptomatic treatment, 500 mg oral administration 3 times per day."
62749301|NCT05807087|ACTIVE_COMPARATOR|Mechanical Osteotomy|
62749302|NCT05807087|EXPERIMENTAL|Piezosurgery|
62749303|NCT02760173|EXPERIMENTAL|Single intervention arm|This is the only arm in this study, measuring verticality perception after prolonged roll-tilt over 5min.
62554342|NCT01051362|NO_INTERVENTION|PLD and Carboplatin|Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
62554343|NCT00620386|EXPERIMENTAL|1|Intubation with Bonfils intubating fiberscope
62554344|NCT00620386|ACTIVE_COMPARATOR|2|Intubation with Macintosh laryngoscopy
62554345|NCT01207180|EXPERIMENTAL|Follow-up phone call from Nurse|Patients in this are will receive a phone call follow-up from a nurse 1-3 days after their discharge from the ED.
62554346|NCT01207180|PLACEBO_COMPARATOR|Satisfaction survey|This group of patients will receive a phone call from a student who will conduct a brief satisfaction survey of the patient's experience in the ED.
62554347|NCT01207180|PLACEBO_COMPARATOR|Control group|Patients in this group will receive no phone call at 1-3 days.
62554348|NCT05181046|ACTIVE_COMPARATOR|Standard eyedrops of 0.5% timolol maleate|Participants randomized to this arm will receive one standard drop of 0.5% timolol maleate in each eye.
62749304|NCT00873041|EXPERIMENTAL|5 mg/kg/day deferasirox|Participants received a starting dose of 5 mg/kg/day deferasirox tablets orally each day in the morning for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
62749305|NCT00873041|EXPERIMENTAL|10 mg/kg/day deferasirox|Participants received a starting dose of 10 mg/kg/day deferasirox tablets orally each day in the morning for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
62749306|NCT00873041|PLACEBO_COMPARATOR|5 mg/kg/day placebo|Placebo tablet matching 5 mg/kg/day orally in the morning each day for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
62749307|NCT00873041|PLACEBO_COMPARATOR|10 mg/kg/day placebo|Placebo tablet matching 10 mg/kg/day orally in the morning each day for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
62749308|NCT01762735|ACTIVE_COMPARATOR|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
62749309|NCT01762735|EXPERIMENTAL|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .All the patients were examined without sedation during the whole procedure.
62749310|NCT04583787|EXPERIMENTAL|Patients with suspected CAD|
62749311|NCT00290771|EXPERIMENTAL|Imatinib 600 mg + hydroxyurea 1000 mg|Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.
62749312|NCT00290771|EXPERIMENTAL|Imatinib 1000 mg + hydroxyurea 1000 mg|Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.
62749313|NCT01635673|NO_INTERVENTION|Control Group|A group that continues with their normal daily activities for the duration of the study
62749314|NCT01635673|EXPERIMENTAL|Exercise Group|This group exercises 3 times each week
62749315|NCT04054869|EXPERIMENTAL|Bio-mechanically correct manual therapy (received first) arm|Participants will be randomized to receive manual therapy directed at the cervical spine atlanto-axial joints in the bio-mechanically correct direction followed by instruction in a home program to maintain this motion. Outcome measures will be assessed. Participants will return in 2-3 days and receive the opposite treatment and home program followed by outcomes assessment. Participants will return again in 2-3 days, outcomes will be assessed and the study will conclude. Participants will then be given the option to continue in formalized physical therapy if desired.
62749316|NCT04054869|EXPERIMENTAL|Bio-mechanically incorrect manual therapy (received first) arm|Participants will be randomized to receive manual therapy directed at the cervical spine atlanto-axial joints in the bio-mechanically incorrect direction followed by instruction in a home program to maintain this motion. Outcome measures will be assessed. Participants will return in 2-3 days and receive the opposite treatment and home program followed by outcomes assessment. Participants will return again in 2-3 days, outcomes will be assessed and the study will conclude. Participants will then be given the option to continue in formalized physical therapy if desired.
62749317|NCT02559934|EXPERIMENTAL|SR-T100 gel|A single dose of 0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract) in 25 cm2 skin area covered by an occlusive dressing at least 20 hours a day and will be given once daily for sixteen consecutive weeks.
62749318|NCT02224287|OTHER|Fluoroscopy|Technologist control of fluoroscopy Surgeon control of fluoroscopy
62749319|NCT03729037|EXPERIMENTAL|Serious game|Intervention: CPR self-training with serious game.
62749320|NCT03729037|ACTIVE_COMPARATOR|Training video|Intervention: CPR self-training with Keynote presentation with the addition of voice-over narration.
62749321|NCT03217877|ACTIVE_COMPARATOR|No Routine stress testing after PCI|
62749322|NCT03217877|EXPERIMENTAL|Routine stress testing at 9~15 months after PCI|
62749323|NCT05382468|EXPERIMENTAL|Intradialytic exercise|In this study intradialytic exercise comprised of a set warm up, aerobic, active, passive \& cool down activities performed by patients during dialysis for a period of 30 min twice or thrice a week regularly for one month \& supervised by principle investigator.
62749324|NCT06535230|ACTIVE_COMPARATOR|Patients who were assigned to have manual anesthesia induction group with propofol|Patients who were assigned to have a manual anesthesia induction group, propofol was administered 1-2 mg/kg in 1-2 minutes to achieve a level of hypnosis measured by bispectral index ( BIS ) of 35-60
62749325|NCT06535230|ACTIVE_COMPARATOR|Patients who were assigned to have target controlled infusions ( TCI) induction with propofol|Patients who were assigned to have TCI induction had the target effect site concentration (Ce) of propofol (Ce) set at 1 μg ml-1 using the Schneider model and subsequently modified to achieve and maintain a level of hypnosis measured by BIS of 35-55
62749326|NCT05005845|ACTIVE_COMPARATOR|0.5% NFX-179 gel|Topical gel applied once daily to target cNFs
62749327|NCT05005845|ACTIVE_COMPARATOR|1.5% NFX-179 gel|Topical gel applied once daily to target cNFs
62749328|NCT05005845|PLACEBO_COMPARATOR|Vehicle gel|Topical gel applied once daily to target cNFs
62749329|NCT03537365|EXPERIMENTAL|Bovine Colostrum / intervention group|Preterm infants are supplemented with bovine colostrum (BC) as a fortifier to human milk. BC is the first milk from cows after parturition and is a rich source of protein (80-150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and growth factors. The product is supplied in a sterile, powdered form and consists of unmodified, intact BC.
62749330|NCT03537365|ACTIVE_COMPARATOR|FM85 / control group|Preterm infants are supplemented with PreNAN FM85 as fortifier to human milk. PreNAN FM85 contains partially hydrolyzed protein and maltodextrin including vitamins and minerals. The product is supplied in a powdered form.
62749331|NCT04776187|ACTIVE_COMPARATOR|Gadodiamide|"Patients who have undergone contrast-enhanced MRI using Gadodiamide contrast agent for clinical purposes.~Generic name: Gadodiamide Injection; Product name: OMNISCAN; Sample specifications: 15ml: 4.305g (a sterile solution containing 287mg/ml gadodiamide)."
62749332|NCT04776187|EXPERIMENTAL|Gadoteric Acid Meglumine Salt|"Patients who have undergone contrast-enhanced MRI using Gadoteric Acid Meglumine Salt contrast agent for clinical purposes.~Generic name: Gadoteric Acid Meglumine Salt Injection; Commodity name: Jia Di Xian; Sample specifications: 15ml: 5.654g (a sterile solution containing 377mg/ml gadoteric acid meglumine salt)."
62554349|NCT05181046|EXPERIMENTAL|Nanodropper-mediated microdrops of 0.5% timolol maleate|Participants randomized to this arm will receive one microdrop of 0.5% timolol maleate in each eye. Microdrops will be dispensed from bottles with installed Nanodropper adaptors.
62749333|NCT04077346|EXPERIMENTAL|Transcutaneous Spinal Stimulation- Acute and with Training.|"For Aim 1: Participants will receive transcutaneous stimulation (TcStim) in supine or side lying position at a single or multi site spinal levels to produce stepping/locomotor activity in lower limbs.~For Aim 2: TcStim will be delivered while participants are stepping on a computerized treadmill with an overhead partial body weight support (BWS) system and while stepping overground.~For Aim 3: Participants will first receive a combination of Activity-based locomotor training (AB-LT)+TcStim for 60 sessions."
62749334|NCT06605651|EXPERIMENTAL|Active Arm|Anti-Staphylococcus aureus Bacteriophages (PP1493 and PP1815) intra-articular injection with 0.9% NaCl solution
62749335|NCT06605651|PLACEBO_COMPARATOR|Control Arm|0.9% NaCl solution
62749336|NCT06660498|ACTIVE_COMPARATOR|Pomalidomide|This arm will receive pomalidomide 2 mg oral capsules
62749337|NCT06660498|PLACEBO_COMPARATOR|Placebo|This arm will receive placebo (oral capsules with no active drug)
62749338|NCT02115022||Potentially resectable pancreatic cancer|Patients with a confirmed pancreatic mass (suspected neoplastic) deemed resectable or borderline resectable on multislice (at least 16 simultaneously acquired slices) pancreatic protocol computed tomography (CT), fit and willing to undergo surgery with a curative (R0) intent.
62749339|NCT04147390|ACTIVE_COMPARATOR|usage mycophenolate mofetil|
62749340|NCT04147390|ACTIVE_COMPARATOR|usage tacrolimus|
62749341|NCT00470093|EXPERIMENTAL|Interleukin-6 and Interferon-α|Subjects will be started on recombinant interferon-α at a dose of 3 million units SQ daily, escalating the dose by 1 million units every week as tolerated to a maximum dose of 3 million units/m2/day. Following a minimum of one month of interferon therapy with two weeks on a stable dose, subjects will begin recombinant interleukin-6 therapy at a dose of 2.5 ug/kg/day.
62374931|NCT02489851|ACTIVE_COMPARATOR|Quadratus Lumborum block group|"Quadratus Lumborum block group (QL)~patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%"
62554350|NCT00312338|EXPERIMENTAL|Infected Patient treated with Vigamox|Conjunctivitis-Infected Patient receiving Vigamox 0.5% in both eyes three times daily for 7 days.
62554351|NCT00312338|NO_INTERVENTION|Healthy Subjects|Healthy Subjects receiving no treatment
62554352|NCT02802813|ACTIVE_COMPARATOR|Intervention arm|Dihydroartemisinin-piperaquine (DP) therapy plus 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
62554353|NCT02802813|PLACEBO_COMPARATOR|Control arm|Dihydroartemisinin-piperaquine therapy plus 14 days identical placebo not containing primaquine.
62554354|NCT00580450|NO_INTERVENTION|2|
62554355|NCT00580450|EXPERIMENTAL|1|
62749342|NCT01180894|ACTIVE_COMPARATOR|Iron sucrose|100 mg IV TIW
62749343|NCT01180894|PLACEBO_COMPARATOR|Placebo|Pacebo - Normal Saline
62749344|NCT01935583|EXPERIMENTAL|Resilience/Adjustment Counseling|Intervention to promote resilience and adjustment (RAI) - The RAI was developed based upon considerable clinical experience and research review. The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment to injury. The RAI is implemented in seven, 60-minute, in-person sessions.
62749345|NCT01935583|NO_INTERVENTION|Waitlist Control|Individuals are randomly assigned to the treatment group or waitlist control (WLC) group. Individuals will complete the study measures on 2 occasions, 5 weeks apart. In fairness, WLC participants will then be offered the opportunity to participate in the intervention.
62749346|NCT00211835|EXPERIMENTAL|Treatment Arm 1|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
62749347|NCT00211835|EXPERIMENTAL|Treatment Arm 2|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
62749348|NCT05550870|EXPERIMENTAL|Group 1|Group 1 will be given Raw Fenugreek seed powder. The dose will be 7.5grams two times a day i.e, before breakfast and before dinner for the period of three months.
62749349|NCT05550870|EXPERIMENTAL|Group 2|Group 2 will be given Roasted Fenugreek seed powder, 7.5 grams twice a day before breakfast and dinner for the period of three months.Total number of arms will be 2.
62749350|NCT05311943|EXPERIMENTAL|olverembatinib|40mg, taken orally once every other day of a 28-day cycle
62554356|NCT05346042||Confirmed Covid-19|All adult COVID-19 patients and health care workers tested positive in the 7 participating hospitals identified between the end of February 2020 and December 2021.
62554357|NCT02281825||Control|Adolescents without any psychiatric disorder
62554358|NCT02281825||Study|Adolescents with psychiatric disorder of the following: Attention-Deficit and Hyperactivity Disorder, Conduct, Oppositional defiant Disorder, Anxiety, Depression, Disruptive Mood Dysregulation Disorder
62554359|NCT02570620|EXPERIMENTAL|Observational cohort of patients|Patients will benefit from an ultrasonography of the cervix through endovaginal before induction of prostaglandins
62554360|NCT03405025|OTHER|Safety and Feasibility|All patients will undergo endoscopic US guided radiofrequency ablation, to assess safety and feasibility.
62554361|NCT02814344||pregnant women not in labour|"from 24 weeks of gestation until term, provided that they are not in labour~Electrohysterography"
62749351|NCT06140498|EXPERIMENTAL|Intervention|Digital Self-Efficacy Training with 3 trainings daily and Ecological Momentary Assessment
62749352|NCT06140498|ACTIVE_COMPARATOR|Control|Ecological Momentary Assessment
62749353|NCT06517394|EXPERIMENTAL|Intervention|Dyads will participate in 6 30-minute skills-based sessions. Sessions will also include provision of anticipatory guidance and and resources to manage cardiac arrest-specific stressors. A clinical psychologist will deliver all of the sessions. The main intervention goal is to provide dyads with resiliency skills and resources to reduce emotional distress and prevent chronic distress.
62749354|NCT06006507|ACTIVE_COMPARATOR|control group|no exercise will be given
62749355|NCT06006507|EXPERIMENTAL|exercise group|exercise training will be given and they will be asked to exercise regularly.
62554362|NCT02814344||women in labour|Electrohysterography
62554363|NCT03345693|EXPERIMENTAL|Treated with MoTrack Therapy|Patients receive the MoTrack Therapy device to assist them in their at-home therapy exercises. The patient is instructed to use the MoTrack Therapy device when they want to do their at-home therapy exercises. The patients therapy in the clinic is not affected.
62554364|NCT01542801|ACTIVE_COMPARATOR|Norfloxacin|norfloxacin 400 mg once daily administration
62554365|NCT01542801|EXPERIMENTAL|Ciprofloxacin|Ciprofloxacin 750 mg per week
62554366|NCT06579625|OTHER|experimental group|The effect of cancer education on cancer knowledge burden, information about cancer screenings, and attitudes will be evaluated by providing cancer education to 39 patients in the experimental group.
62554367|NCT06579625|NO_INTERVENTION|Control group|The control group will not receive any intervention.
62749356|NCT06018493|EXPERIMENTAL|intervention group|In intervention group, participants will receive the whole peri-renal fat modification therapy (including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting and initiating) Intervention: Device: focused power ultrasound mediate inferior perirenal adipose tissue modification
62374932|NCT02489851|ACTIVE_COMPARATOR|Transversus abdominis plane block group|"Transversus abdominis plane block (TAP)~patients will receive a bilateral TAP block using Bupivicaine 0.125%"
62749357|NCT06018493|SHAM_COMPARATOR|sham-control group|"In sham control group, participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.~Intervention: Device: sham-control group"
62749358|NCT00653848|EXPERIMENTAL|Docetaxel arm|six of docetaxel every third week + hormonal treatment
62749359|NCT00653848|NO_INTERVENTION|Control|hormonal treatment only
62749360|NCT04694521|EXPERIMENTAL|antegrade colorectal single stapler anastomosis|open Side to end antegrade colorectal anastomosis colo rectal cancers.
62749361|NCT04694521|EXPERIMENTAL|open end to end colorectal stapler anastomosis|open end to end colorectal single anastomosis in non-emergent colo rectal cancers.
62749362|NCT02853812|OTHER|single sided tinnitus|patients with single sided tinnitus on which functional brain MRI is assessed
62749363|NCT01443364|EXPERIMENTAL|Certolizumab pegol|
62749364|NCT00883012|EXPERIMENTAL|Influenza vaccine|Two doses of trivalent sub-unit influenza vaccine (2009) to be administered one month apart
62749365|NCT00883012|PLACEBO_COMPARATOR|Placebo|Two doses of saline administered one month apart
62749366|NCT00132691|ACTIVE_COMPARATOR|1|Immunosuppressant medication implant
62749367|NCT00132691|ACTIVE_COMPARATOR|2|Systemic corticosteroids with immunosuppressant drugs as needed
62749368|NCT02080897||Palliative Surgery Group|Patients who present to clinic with soft tissue sarcoma with metastatic lung disease who opt to proceed with palliative surgical treatment
62749369|NCT02080897||Non-surgical Group|Patients who present to clinic with soft tissue sarcoma with metastatic lung disease who opt not to pursue palliative surgery
62749370|NCT06607874||Observational aim 1 & aim 3|Patients may choose to undergo HPV vaginal swab self-collection on study in the research clinic or at home. Patients may choose to complete an interview on study. In addition, patients have their medical records reviewed on study.
62374933|NCT02557815|EXPERIMENTAL|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial Magnetic Stimulation: Active 10hz stimulation over the right dorsolateral Prefrontal Cortex (dlPFC)
62374934|NCT02557815|SHAM_COMPARATOR|Sham stimulation|Repetitive Transcranial Magnetic Stimulation: sham stimulation over the right dlPFC
62554368|NCT02486874|EXPERIMENTAL|Treatment group|PoreSkin, a human acellular dermal matrix, were used for scar contracture treatment
62554369|NCT04247100|EXPERIMENTAL|Active Stimulation (8)|"Participants will receive active auricular microstimulation via TENS unit for 8 weeks.~Under guidance from the study team, participants will self-administer the TENS therapy for two 1-hour periods a day for 8 weeks."
62749371|NCT06607874||Observational aim 2|Patients are contacted by the study Clinical Research Coordinator (CRC) by phone on study and informed of HPV vaccination eligibility, asked interest in being vaccinated, and informed of sites for HPV vaccination. Patients are then contacted again by the CRC to determine if HPV vaccination occurred.
62749372|NCT06606379|ACTIVE_COMPARATOR|C (comparator)|Nickel titanium 3D-fusion ring (Garrison, USA)
62749373|NCT06606379|EXPERIMENTAL|I1 (Intervention)|Resin ring (DR- Resin ring, Egypt)
62749374|NCT06606379|EXPERIMENTAL|I2 (Intervention)|Elliot separator (Pfingst \& Co, South Plainfield, NJ, USA)
62749375|NCT06606379|EXPERIMENTAL|I3 (Intervention)|Stainless Steel Metal ring (TOR VM ring, Moscow, Russia)
62749376|NCT00888524|EXPERIMENTAL|General Practice (GP) in Physio plus Deep water running|A supplementation of Deep Water running exercises of 20 minutes in high intensity around aerobic thresholds estimated in individual land and water test
62749377|NCT00888524|EXPERIMENTAL|General Practice in Physio|A procedure of evidence-based physiotherapy is usual care in pragmatic trial
62749378|NCT02185014|OTHER|Adalimumab|Participants received open-label adalimumab 40 mg by subcutaneous injection every other week for 40 weeks.
62749379|NCT05206188|EXPERIMENTAL|Experimental|Study participants randomized to the experimental condition will receive IPS services as usual in conjunction with the MWW intervention.
62749380|NCT05206188|NO_INTERVENTION|Control|Study participants randomized to the control condition will receive IPS services as usual.
62749381|NCT01888536|EXPERIMENTAL|Limaprost & Placebo|Limaprost 5㎍ tablet and a capsule of Pegabalin-Placebo thrice a day for 8 weeks.
62749382|NCT01888536|ACTIVE_COMPARATOR|Pregabalin & Placebo|Pregabalin 75mg capsule and a tablet of Limaprost-Placebo thrice a day for 8 weeks.
62749383|NCT01888536|ACTIVE_COMPARATOR|Limaprost+Pregabalin|Limaprost 5㎍ tablet and Pregabalin 75mg capsule thrice a day for 8 weeks.
62554370|NCT04247100|SHAM_COMPARATOR|Sham Stimulation (4), Active (4)|"Participants will receive sham therapy via inactive TENS unit for 4 weeks, followed by active auricular microstimulation via TENS for 4 weeks.~Under guidance from the study team, participants will self-administer the TENS therapy for two 1-hour periods a day for 8 weeks (4 weeks of therapy with inactive TENS, 4 weeks with active TENS)."
62554371|NCT03670615|EXPERIMENTAL|Exercise and tDCS|Patients randomized to this group will attend Toronto Rehabilitation Institute - University Health Network (TRI-UHN) for an individualized exercise program and active tDCS intervention.
62554372|NCT03670615|OTHER|Exercise Education and tDCS|Patients randomized to this group will undergo treatment as usual, receiving routine advice about physical activity and active tDCS intervention.
62554373|NCT03670615|OTHER|Exercise and Sham tDCS|Patients randomized to this group will attend TRI-UHN for an individualized exercise program and sham tDCS intervention.
62554374|NCT01508884|ACTIVE_COMPARATOR|IM vaccine and placebo cream|A single dose of intramuscular influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream
62554375|NCT01508884|ACTIVE_COMPARATOR|ID vaccine and placebo cream|A single dose of intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream
62554376|NCT01508884|EXPERIMENTAL|ID vaccine and imiquimod cream|A single dose intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with imiquimod cream applied to the skin before vaccination
62554377|NCT05484492|EXPERIMENTAL|demineralized and mineralized combination putty bone allograft|Fifteen test patients will receive an intrasocket demineralized and mineralized combination putty allograft (MinerOss Putty, BioHorizons) with a regenerative tissue matrix membrane (AlloDerm GBR, BioHorizons) following tooth extraction.
62554378|NCT05484492|ACTIVE_COMPARATOR|calcium phosphosilicate putty alloplast graft|The positive control group of fifteen patients will receive an intrasocket synthetic resorbable calcium phosphosilicate putty alloplast graft (NovaBone, Osteogenics) covered with a regenerative tissue matrix membrane (AlloDerm GBR, BioHorizons) following tooth extraction.
62554379|NCT02589730|EXPERIMENTAL|online mutual management|The patients received the online coaching of a doctor and diabetes educator via smart phone based welltang app.
62554380|NCT02589730|EXPERIMENTAL|online self-management|The patients received the online coaching of a doctor alone via smart phone based welltang app.
62374935|NCT06175104|EXPERIMENTAL|HeartGPS (Treatment Arm)|"Participants will receive usual fetal cardiac care plus the HeartGPS intervention. This is a novel psychological intervention leveraging virtual technology and user-centered design to reduce maternal psychological stress and anxiety after prenatal cardiac diagnosis and improve neurodevelopmental outcomes for infants with single ventricle CHD.~GPS stands for: Guiding through emotions, Providing information and support, and Strengthening connections.~The intervention includes sessions with a trained psychologist, coupled with tailored educational resources, and a personalized care plan to support longer-term parent, child, and family wellbeing."
62554381|NCT02589730|NO_INTERVENTION|hospital regular management|The patients received usual care and did not use smart phone.
62554382|NCT03788343|EXPERIMENTAL|Phenylalanine|"Capsules containing 250 mg Phenylalanine (Phe). The daily dose will be chosen according to gender and weight at the time of T1 and will be divided in 3 separate doses. The assigned dose of the IMP will be kept throughout the whole study and weight fluctuations will not be considered.~Female~\<60 kg: 1500 mg per day (divided in 3 doses): 250 mg 2-2-2-0~≥60 kg: 2000 mg per day (divided in 3 doses): 250 mg 2-2-4-0~Male~\<60 kg: 2500 mg per day (divided in 3 doses): 250 mg 4-2-4-0~≥60 kg: 3000 mg per day (divided in 3 doses): 250 mg 4-4-4-0~Phe capsules can be ingested before, during or after a meal or together with other amino acid supplements. The last capsule of the given intervention period will be timed to be ingested with the last meal before the study visit.~Patients will take Phe for 4 weeks."
62749384|NCT04261972||CHARM|Patients identified with hereditary breast and ovarian cancer syndrome (germline BRCA1 or BRCA2 carrier) or Lynch syndrome (germline variant in EPCAM, MLH1, MSH2, MSH6, or PMS2).
62749385|NCT05012631|EXPERIMENTAL|Losartan|Participants will receive oral losartan as tablets or oral solution one time daily. The dosing will depend on age and will be based on drug label and dosing used in studies on patients with SCD.
62749386|NCT03661905|EXPERIMENTAL|Cognitive Therapy|A modularized, cognitive-behavioural therapy intervention that incorporates evidence gathering and behavioural experiments. Our CT protocols rely heavily on behavioural experiments which are typically targeted and brief exercises designed to permit clients/patients to gather disconfirmatory evidence about their beliefs.
62749387|NCT03661905|ACTIVE_COMPARATOR|Behavioural Therapy|Method of behavioral therapy and form of exposure and response prevention therapy in which individuals confront their fears and discontinue their escape response. Exposures in this protocol are prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
62749388|NCT06315036|EXPERIMENTAL|Developmental gymnastics (DG)|Developmental gymnastics group of participants
62749389|NCT06315036|NO_INTERVENTION|Control (CG)|Control group of participants
62374936|NCT06175104|NO_INTERVENTION|Usual Fetal Cardiac Care (Control Arm)|In the usual care arm, participants will receive the information, support, and resources currently offered by their fetal heart care team. This can include support from their doctor or nurse, a social worker, psychologist, or support group, as well as information booklets, websites, and other resources to help parents learn more about their baby's heart condition.
62374937|NCT00596349||A|epithelial ovarian cancer survivors (women disease-free at 5 to 10 years from diagnosis of ovarian cancer)
62374938|NCT00596349||B|women in second- or greater remission (women who have had one or more relapses from ovarian cancer but are considered to be currently clinically disease-free 5 to 10 years from original diagnosis of ovarian cancer).
62554383|NCT03788343|PLACEBO_COMPARATOR|Placebo|"Capsules containing 250mg Placebo. Placebo capsules will be administered in identical manner to Phe capsules.~Patients will take the Placebo for 4 weeks."
62554384|NCT04958655|OTHER|Tetris, Positive Image|Participants randomised to order of intervention: this arm has; Tetris (Active Comparator) then Positive Future Image (Intervention).
62554385|NCT04958655|OTHER|Positive Image, Tetris|Participants randomised to order of intervention: this arm has; Positive Future Image (Intervention) then Tetris (Active Comparator).
62554386|NCT03252067|EXPERIMENTAL|azithromycin eyedrop|Each of the subjects' eyes will receive single dose of azithromycin eyedrops and then attribute the time for tear sampling at seven time points up to 24 hours.
62374939|NCT00596349||C|women surviving with epithelial ovarian cancer (women alive with disease 5 to 10 years from original diagnosis of ovarian cancer)
62374940|NCT03592589|NO_INTERVENTION|control group|standard general anesthesia using sevoflurane delivered by a pediatric high concentration mask
62374941|NCT03592589|EXPERIMENTAL|Intervention group|sevoflurane will be deliver by a pediatric high flow nasal canula (2L/KG/min)
62374942|NCT03462030|EXPERIMENTAL|Baked Milk Immunotherapy|Subjects will receive baked milk oral immunotherapy with baked non-fat cow's milk powder as the intervention. Subjects will undergo an initial dose escalation, build-up, and then a maintenance period.
62374943|NCT03462030|PLACEBO_COMPARATOR|Placebo|Subjects will receive oral immunotherapy with the placebo control (tapioca powder). Subjects will undergo an initial dose escalation, build-up, and then a maintenance period.
62374944|NCT04861506||acute or subacute thromboembolic occlusions of lower extremity|The patients are confirmed with acute or subacute thromboembolic occlusions of lower extremity, and which are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods such as PMT pharmacomechanical thrombectomy (PMT) and catheter-directed thrombolysis (CDT) for thrombus removal according to the characteristics of the lesions and hospital conditions.
62374945|NCT02909920|EXPERIMENTAL|Telerehabilitation|The Telerehabilitation group receives a standardized and customized exercises through a web application that allows the Physiotherapist generate videos, images and parameters of each exercise program and send them via email for each patient. Patients are initially supervised by a physiotherapist who will conduct videoconference sessions to ensure proper execution of exercises and encourage patient adherence.
62554387|NCT03068117|EXPERIMENTAL|RESSCT plus Standard Care/Therapy|"Regular Early Specialist Symptom Control Treatment (RESSCT) and Standard Therapy.~Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
62554388|NCT03068117|NO_INTERVENTION|Standard Care/Therapy|The standard care/therapy control group will continue to receive all appropriate, standard treatment for Malignant Pleural Mesothelioma (MPM) currently available to them and will be initiated by the patient's General Practitioner (GP), the cancer MDT or lead respiratory physician as required.
62554389|NCT06058624|EXPERIMENTAL|Veteran ACT for Chronic Pain (VACT-CP)|Participants will complete seven modules (each approximately 15 minutes) over seven weeks. The purpose of VACT-CP is to assist with at home therapeutic and behavioral self-management of chronic pain, based on the principles of acceptance and commitment therapy. Following the end of treatment (7 weeks), participants will complete post-treatment surveys at Week 7, Month 3, and Month 6 to provide feedback and information regarding 1) the intervention and 2) the potential impact of the intervention on functioning, quality of life, and other mental and physical health factors.
62554390|NCT06058624|ACTIVE_COMPARATOR|Online Pain School|Participants will complete seven modules (each approximately 15 minutes) over seven weeks. Online Pain School is designed to balance for time participating in the intervention, and is also an active online attention control. The goal of this program will be to provide Veterans with more tools and options for pain management, and the online format will allow us to monitor website use/dose. Following the end of treatment (7 weeks), participants will complete post-treatment surveys at Week 7, Month 3, and Month 6 to provide feedback and information regarding 1) the intervention and 2) the potential impact of the intervention on functioning, quality of life, and other mental and physical health factors.
62554391|NCT00943748|ACTIVE_COMPARATOR|deferiprone|deferiprone 30 mg/kg/day
61997497|NCT01488097|EXPERIMENTAL|Open-Label Sebelipase Alfa|Participants were administered sebelipase alfa once weekly (qw) as an intravenous (IV) infusion at the same dose received in Study LAL-CL01 (0.35, 1, or 3 milligrams per kilogram \[mg/kg\]) for 4 weeks. After the initial 4 qw doses, participants transitioned to dosing every other week (qow) at either 1 mg/kg (participants who initiated treatment at 0.35 or 1 mg/kg qw) or 3 mg/kg (participants who initiated dosing at 3 mg/kg qw). Subsequent modifications to the dose and dosing frequency were permitted for individual participants based on observed safety, tolerability, and clinical response to treatment. Participants could continue to receive treatment with sebelipase alfa for up to 5 years.
62554392|NCT00943748|PLACEBO_COMPARATOR|placebo|placebo : 30 mg/kg/day, in 2 liquid doses
62554393|NCT00604682|EXPERIMENTAL|Administration of CC10004|
61997498|NCT06116331||Participants|Participants will complete 3 online questionnaires at 6 month intervals. At the first two time points they will also be asked to submit 2 at home stool sample tests, to assess fecal calprotectin.
62749390|NCT05974618||First arm (primary objective):|"First arm (primary objective): Adnexal mass scanned at 11-14 weeks. If the decision is to manage the adnexal mass conservatively, the patient is to be re-scanned once more: 0 - 90 days postpartum. In addition, the patient will be asked to enter into the third arm of the study (see below) knowing that she can opt out from that arm at any point. If she consents to participate in the third arm, she will participate in a series of longitudinal examinations as described for the third arm.~All patients with a mass detected before 11 weeks will also be scanned at 11-14 weeks and can enter all three arms of the study. In this scenario, if more than one scan is performed during pregnancy before 11 weeks, only the first of several scans before 11 weeks will be included for the second and third arms of the study."
62554394|NCT01808547|EXPERIMENTAL|ISV-303|
62554395|NCT01808547|PLACEBO_COMPARATOR|Durasite Vehicle|
62554396|NCT04343157|EXPERIMENTAL|Image-guided cognitive sparing brain SRS|This is a single arm phase II study where enrolled subjects will receive intracranial SRS will performed identically to standard of care, except for implementing additional imaging techniques and software for additional regional avoidance for cognitive sparing (specifically sparing white matter and the bilateral hippocampus)
62554397|NCT06275438|ACTIVE_COMPARATOR|experimental group|The group consists of mothers who meet the inclusion criteria specified in the study, have an 8cm dilation at term, and undergo cesarean section delivery.
62554398|NCT06275438|NO_INTERVENTION|control group|The group comprises healthy mothers who meet the inclusion criteria specified in the study, have an 8cm dilation at term, and give birth vaginally.
62554399|NCT01806194|ACTIVE_COMPARATOR|Educational control arm|Control group receives 16 mailings of diabetes educational materials but no regular contact with community health workers
62554400|NCT01806194|EXPERIMENTAL|Lifestyle counseling|Small changes behavioral counseling and social support, delivered in 16 sessions by community health workers.
62554401|NCT05247229|EXPERIMENTAL|Middle school education program|"The education intervention centers around teaching children about local traditional ecological knowledge and traditional harvesting and gathering practices, including those for shellfish.~The education program is divided into three units, following other tribal education programs. Primary data collection will be conducted by unit to assess student learning for each unit. The first unit will cover an introduction to shellfish, harmful algal blooms (HAB), and paralytic shellfish poisoning (PSP). The second unit will cover herring and how herring relates to Tlingit culture. The third unit will focus on intertidal zones as zones relate to Tlingit culture."
62554402|NCT05034016|EXPERIMENTAL|HM experimental group|Intraocular implant test product
62554403|NCT05034016|NO_INTERVENTION|Natural observation control group|Natural observation of the disease changes, no surgical intervention
62554404|NCT02705261|EXPERIMENTAL|Cognitive-behavior therapy|Cognitive-behavior therapy to teach parents the skills to help their children. Participants will have access to the program as often as they wish and have the post assessment at week 12.
62554405|NCT05187728||adenomyosis group|CSD with adenomyosis
62749391|NCT05974618||Second arm (secondary objective):|"Second arm (secondary objective): Adnexal mass is seen for the first time during that pregnancy at any gestation. If the decision is to manage the adnexal mass conservatively, the patient is to be re-scanned once more: 0 - 90 days postpartum. For patients with a mass detected before 11 weeks, see also above (they will be re-scanned at both 11-14 weeks and at 0-90 days postpartum).~In addition, the patient will be asked to enter into the third arm of the study knowing that she can opt out from that arm at any point. If she consents to this, she will participate in a series of longitudinal examinations as described for the third arm."
62749392|NCT05974618||Third arm (secondary objective):|"Third arm (secondary objective): Patients from the first and second arms who agree to enrol into the third arm i.e. longitudinal examination of an adnexal mass during pregnancy. For the purposes of the longitudinal evaluation, the time points for the ultrasound examination are:~* initial presenting scan if \<11 weeks;~* 11-14 weeks;~* 16 week scan - endometriomas ONLY;~* second trimester routine scan (18-22 weeks);~* 30-34 weeks;~* any additional scans during pregnancy which resulted in either conservative management with extra scans or surgical intervention (with reason for the extra scan or for surgery documented);~* 0-90 days postpartum."
62749393|NCT02979509||Endoscopic ultrasound- (EUS) guided tissue sampling|All patients scheduled to undergo EUS with tissue sampling (TS) as medically indicated will be considered for the study. Patients in whom EUS-TS is considered as part of their standard medical care will be offered to participate in this study.
62749394|NCT03775343||General Anesthesia|"General anesthesia:~25 patients older than 65 years, undergoing elective eye surgery under general anesthesia.~Intervention: neurocognitive testing (Neurocognitive Test Battery) preoperative, 6 and 24 hours postoperative.~Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery."
62554406|NCT05187728||non-adenomyosis group|CSD without adenomyosis
62749395|NCT03775343||Local anesthesia with sedoanalgesia|"25 patients older than 65 years, undergoing elective eye surgery under local anesthesia in combination with sedoanalgesia.~Intervention: neurocognitive testing (Neurocognitive Test Battery) preoperative, 6 and 24 hours postoperative Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery."
62749396|NCT03775343||Control Group|"25 patients, not undergoing any operative intervention. To determine a normal reference value of cognitive functions, a group of 25 individuals without an operative intervention will be recruited as a control group.~Intervention: neurocognitive testing (Neurocognitive Test Battery) at 3 determined time points (0, 6 and 24 hours)"
62374946|NCT02909920|ACTIVE_COMPARATOR|Traditional Physiotherapy|Traditional Physiotherapy group receives assistance in a physiotherapy center through the usual procedure of rehabilitation in Spain consisting in personalized therapy 1 to 1 with a physical therapist and exercise programs for home.
62374947|NCT03025516||Adults with pulmonary TB symptoms|"All patients will be tested with both the reference and index TB diagnostic tests. Index test results will not be used to inform case management.~All samples must be collected before the patient starts any form of TB treatment. Patients will be randomized to receive either the TB Breathalyser or AeonoseTM on Day 1, and will be tested with the remaining breath-test on Day 2. A follow-up evaluation will be required after 8 weeks for all patients who do not have microbiologic confirmation of TB (smear or culture). Two additional breath samples may also be collected upon follow-up."
62554407|NCT03157479|EXPERIMENTAL|Protective ventilation|Volume controlled ventilation with tidal volume 6-7 ml/kg of predicted body weight (45.5 + 0.91 (height \[cm\] -152.4)), FiO2 0.4 and PEEP 10 cmH2O during the whole study period. Respiratory rate will be titrated to keep end-tidal CO2 values between 30 and 40 mmHg. I:E ratio will be set in order to obtain an inspiratory time of 0.8 seconds and an inspiratory pause of 0.3 seconds and FiO2 will be kept unchanged during the whole study period. In patients in this group, recruiting maneuvers will be performed throughout a stepwise 5 cmH2O PEEP increase every 30 seconds to achieve a PEEP of 35 cmH2O during Pressure Controlled Ventilation (10 cmH2O of inspiratory pressure while keeping respiratory rate unmodified), followed by a stepwise 5 cmH2O PEEP reduction every 30 seconds until the baseline set peep is reached.
62749397|NCT06441071|EXPERIMENTAL|Group S|After completion of the erector spinae plane block, patients in group S remained in the supine position for 30 minutes.
62749398|NCT06441071|EXPERIMENTAL|Group L|After completion of the erector spinae plane block, patients in group L remained in the lateral position for 30 minutes.
62749399|NCT06441071|EXPERIMENTAL|Group P|After completion of the erector spinae plane block, patients in group P remained in the prone position for 30 minutes.
62749400|NCT06441071|OTHER|Group C|After completion of the paravertebral block, patients in group C remained in the supine position for 30 minutes.
62749401|NCT02947178|ACTIVE_COMPARATOR|Bupivicaine|Bupivicaine fascial iliaca regional soft tissue infiltration blockade
62749402|NCT02947178|ACTIVE_COMPARATOR|Bupivacaine plus liposomal bupivacaine|Bupivacaine plus liposomal bupivacaine fascial iliaca regional soft tissue infiltration blockade
62749403|NCT06607640|EXPERIMENTAL|Intervention: Increase outdoor activity time during specific time periods.|The intervention group received an additional 1 hour of outdoor activity during a specific time period on each school day, with the intervention lasting for one year.
62749404|NCT06607640|NO_INTERVENTION|continued their regular indoor or outdoor routine|The control group continued their regular indoor or outdoor routine.
62749405|NCT00294645|ACTIVE_COMPARATOR|Control|Transtelephonic monitoring at 2 month intervals
62749406|NCT00294645|ACTIVE_COMPARATOR|Remote|Medtronic CareLink® Network remote pacemaker interrogation at 3 month intervals
62749407|NCT06037096|EXPERIMENTAL|Attend-PE|
62374948|NCT01561872||intervention group|"Rooms of the patient of the intervention group will be equipped of cameras"
62374949|NCT01561872||reference group|"Patient in the non-equipped group will have usual care"
62374950|NCT05437692|EXPERIMENTAL|zimberelimab plus concurrent radiotherapy and chemotherapy|19 patients will treated with zimberelimab plus concurrent radiotherapy and chemotherapy
61986378|NCT05953454|EXPERIMENTAL|Group Pain Neuroscience Education|"A single face-to-face group session of approximately 60-80 minutes provided through active participation. Five key domains will be structured from the Fear and Belief Avoidance Questionnaire that will serve as a guide for the sessions through a Powerpoint presentation. In addition, participants will be encouraged to be active by walking for 20-30 minutes 3-5 times a week and will be taught an exercise to improve transverse abdominis activation (abdominal corset or follow-through).~With the main ones, a brochure will be delivered and informative capsules will be made to which the participants will have access (5 videos of 15 minutes, one per domain). Participants will be instructed to record on a calendar the days they read the brochure and/or reviewed the information capsules to assess treatment compliance and for each domain invent a metaphor or script for how they would explain it to another person. This activity must be delivered in the second evaluation."
61997499|NCT01352494|EXPERIMENTAL|docetaxel/gemcitabine|All the patients are locally advanced breast cancer. Patients with a measurable lesion at chest CT. (at least 1 measurable lesion)
62374951|NCT01608555|EXPERIMENTAL|inhaled tobramycin once-a-day|Adult patients, with cystic fibrosis, requiring inhaled tobramycin prophylaxis. Patient will be treated with a single dose of 300 mg tobramycin od for 28 days.
62374952|NCT04114773|EXPERIMENTAL|SCARF|"The participants will take part in a rehabilitation intervention focused on the physical, mental, and social consequences of cardiac arrest with an overarching theme of managing fatigue. This will consist of:~* a 5-day residential rehabilitation stay~* followed by a 12 week home-based programme including one telephone call by a member of the clinical rehabilitation team,~* after the 12 week home intervention there will be a further 2-day rehabilitation stay."
62374953|NCT01564485|EXPERIMENTAL|Cardiac CT|Patients randomized to cardiac CT will obtain a non-invasive assessment of their coronary arteries.
62554408|NCT03157479|ACTIVE_COMPARATOR|Standard Ventilation|Volume controlled ventilation with tidal volume 10 ml/kg of PBW (45.5 + 0.91 (height \[cm\] -152.4)), FiO2 0.4 and PEEP 5 cmH2O during the whole study period. Respiratory rate will be titrated to keep end-tidal CO2 values between 30 mmHg and 40 mmHg. I:E ratio will be set in order to obtain an inspiratory time of 0.8-1 seconds and an inspiratory pause of 0.3 second
62374954|NCT01564485|ACTIVE_COMPARATOR|Usual Care|Patients randomized to usual care will be assigned to continuing usual medical care with their primary care physician
62554409|NCT00428233|NO_INTERVENTION|Leukemia Cell Harvest|Procedure/Surgery: Leukemia cell harvest Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
62554410|NCT01747954|EXPERIMENTAL|Bag Squeezing|"* 20% increase in FiO2~* Inflation pressure of 30 cm H2O + 10l O2/min~* 0.5 ml saline 0.9%~* 10 Manual Hyperinflation~* 10 vibrocompression~* Aspiration Tracheal"
62554411|NCT01747954|ACTIVE_COMPARATOR|Thoracic vibrocompression|"* 20% increase in FiO2~* 0.5 ml saline~* 10 vibrocompression toracica on the right and left~* Aspiration Tracheal"
62554412|NCT02370238|EXPERIMENTAL|paclitaxel+reparixin|"paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + reparixin oral tablets 1200 mg t.i.d.~continuing from D 1 to Day 21 of 28-day cycle"
62554413|NCT02370238|ACTIVE_COMPARATOR|paclitaxel+placebo|paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
62554414|NCT05215951|EXPERIMENTAL|Osimertinib plus standard chemotherapy|single-arm
62554415|NCT06029543||Gambian Women|Gambian women aged 15 and older with lung function impairment as measured by spirometry
62554416|NCT01410903|EXPERIMENTAL|TheraSorb Ig|
62554417|NCT05642598|EXPERIMENTAL|Pivot for Vape|A commercially available mobile phone app and program for vaping cessation
62554418|NCT05066880|EXPERIMENTAL|Yoga|Participants allocated to the yoga group will receive the yoga-based intervention through an internet-based video conference remotely in real-time. Each class will accommodate a maximum of 5 subjects. A qualified physiotherapist who was a certificated yoga instructor will teach in these classrooms. The 8-week exercise intervention consists of three times per week sessions of yoga.
62554419|NCT05066880|EXPERIMENTAL|Aerobic exercise|Participants of the aerobic exercise group will be requested to perform unsupervised aerobic training in the home environment (e.g., at home, park, backyard, or in the local gym). The 8-week exercise intervention consists of three times per week sessions of aerobic exercise. Training will consist of a 10-min warm-up period, aerobic activity, and 5-min cool-down period.
62374955|NCT03017040|EXPERIMENTAL|Scapholunate tear|Subjects with a full scapholunate tear will have a CT scan and fluoroscopy images taken
62374956|NCT03017040|ACTIVE_COMPARATOR|Control Wrist|Subjects will have a CT scan and fluoroscopy image taken of the contralateral wrist serve as the control.
62374957|NCT02465762|EXPERIMENTAL|ultrashape fat reduction treatment|all patient undergo non-invasive fat and circumference reduction at the flanks area
62374958|NCT00611416|EXPERIMENTAL|1|Active treatment A
62374959|NCT00611416|EXPERIMENTAL|2|Active treatment B
62374960|NCT00611416|EXPERIMENTAL|3|Active treatment C
62374961|NCT00611416|ACTIVE_COMPARATOR|4|Positive control
62374962|NCT00611416|PLACEBO_COMPARATOR|5|Placebo
62554420|NCT05066880|NO_INTERVENTION|Wait-list|Participants in the wait-list group will be advised to continue their habitual physical activity next to usual medical care. A yoga or aerobic exercise program of 8 weeks will be offered after the ending of the study period.
62374963|NCT05393544|EXPERIMENTAL|Intervention|The intervention utilizes an existing care coordination smartphone app to allow participants to engage with a recovery coach during and after an inpatient admission to an inpatient withdrawal management facility (i.e. detox).
62374964|NCT03100006|EXPERIMENTAL|Nivolumab and Oregovomab|
62374965|NCT00561301|NO_INTERVENTION|1|
62374966|NCT03227094|OTHER|Standard OGTT|OGTT standard test at hospital (75g glucose beverage; 2-h test with plasma glucose collection)
62374967|NCT03227094|EXPERIMENTAL|Home-based OGTT (Beverage)|Home-based OGTT with CGM device, without glucose collection (75g glucose beverage; 2-h test: glycemia measured by CGM)
62374968|NCT03227094|EXPERIMENTAL|Home-based OGTT (Candy)|Home-based OGTT with CGM device, without glucose collection (75g of glucose (Jelly Beans); 2-h test: glycemia measured by CGM)
62374969|NCT03885076||Acute myeloid leukaemia|Patients with Acute Myeloid Leukaemia (excluding M3) at presentation, remission or with refractory or relapsed disease. There is no intervention. This is an observational tissue collection study.
62374970|NCT02482389|EXPERIMENTAL|Single arm 7 Gray (Gy) fraction of radiotherapy|All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
62374971|NCT04226144|ACTIVE_COMPARATOR|Breath Stacking Group|The lungs are inflated as fully as possible by stacking successive breaths without expiration until the patients' maximal inspiratory capacity (MIC). The participant will be instructed to sustain the air in the lung, closing the glottis. Once the lungs are maximally inflated, the compressed air volume is released under expiratory muscle force, thus generating a cough with lung and chest wall recoil. They will perform 5-8 cycles of breath stacking per session, stacking 3-5 breaths per cycle.
62374972|NCT04226144|EXPERIMENTAL|Breath stacking and EMT|This group will perform the breath stacking technique in addiction with EMT. It will change the one-way valve in this group to VUP (Lumiar, Sao Paulo, Brazil) one-way valve, which allows the patients blow out the air with a counter resistance during all expiratory phase. The initial expiratory pressure will be 8 cmH2O, and could be changed at each visit according to participants' tolerance (either report easy or difficult to exhale assessed by research coordinators. The participants are encouraged to blow out the most slowly that they can do it.
62374973|NCT02894788||ICU|patients postoperatively admitted to ICU
62374974|NCT02894788||no ICU|patients who didn't required ICU admission postoperatively
62554421|NCT05583695|EXPERIMENTAL|mindfulness-based music therapy|
62554422|NCT05583695|EXPERIMENTAL|mindfulness-based therapy|
62554423|NCT05583695|ACTIVE_COMPARATOR|routine care|
62554424|NCT02088801|EXPERIMENTAL|Airtraq, blade without channel for tracheal tube|intubation
62374975|NCT06246136|ACTIVE_COMPARATOR|Arm 1|ELIOS
62374976|NCT06246136|ACTIVE_COMPARATOR|Arm 2|Competitor Device
62374977|NCT03643198|SHAM_COMPARATOR|CONTROL|The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
62374978|NCT03643198|ACTIVE_COMPARATOR|TREATMENT|In the study group, patients will receive oral treatment with Ciprofloxacin at a dose of 500 mg every 12 hours and Metronidazole 500 mg every 8 hours for a period of 7 days.
62374979|NCT03566498|EXPERIMENTAL|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements.
62554425|NCT02088801|EXPERIMENTAL|KingVision , blade without channel for tracheal tube|intubation
62554426|NCT02088801|EXPERIMENTAL|A.P. Advance, blade without channel for tracheal tube|intubation
62554427|NCT02088801|EXPERIMENTAL|Macintosh|intubation
62554428|NCT05712239|OTHER|Advices Group|Patients in this group will take only advices about their postures and activities of daily living
62554429|NCT05712239|ACTIVE_COMPARATOR|Cervical and scapular stabilization Group|Patients in this group will take advices and stability exercises for neck and scapula
62554430|NCT05712239|EXPERIMENTAL|Neck, scapular and lumber stabilization Group|Patients in this group will take advices, and stability exercises for neck, scapula and lumber spine
62554431|NCT04759807|PLACEBO_COMPARATOR|Placebo|The placebo designed for administration in the proposed clinical study consists of a dry powder composed of the same excipients as the active (sodium sulfate, mannitol and polysorbate 80), pre-metered into HPMC capsules at the same 5 mg powder fill weight as the active formulations. Subjects will receive 14 doses administered once daily in the morning.
62374980|NCT03566498|ACTIVE_COMPARATOR|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
62374981|NCT01047462|ACTIVE_COMPARATOR|Laparoscopic lavage|
62374982|NCT01047462|ACTIVE_COMPARATOR|Primary resection|
62374983|NCT00343395|ACTIVE_COMPARATOR|Avandamet|AVANDAMET 2/500 mg
62374984|NCT00343395|PLACEBO_COMPARATOR|Placebo|
62374985|NCT02269982||men with mCRPC prior to enzalutamide/abiraterone|
62749408|NCT06518317|EXPERIMENTAL|Short treatment|Single antiplatelet therapy 75 to 100 mg aspirin for 3 months after TAVI followed by aspirin discontinuation
62749409|NCT06518317|ACTIVE_COMPARATOR|long treatment|Long term (lifetime) single antiplatelet therapy75 to 100 mg aspirin therapy after TAV
62749410|NCT02802423|EXPERIMENTAL|BLEX 404 Oral Liquid|During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Docetaxel monotherapy among 6 patients in the Phase I study.
62749411|NCT04293926|NO_INTERVENTION|Control|This group will receive routine recommendations by the pediatrician, including specific lifestyle advises.
62749412|NCT04293926|EXPERIMENTAL|Exercise|This group will receive routine recommendations by the pediatrician, including specific lifestyle advises. In addition, a 8-week resistance exercise training program will be performed.
62749413|NCT01032954|ACTIVE_COMPARATOR|"125 to 170 IU of 'Botulinum toxin' "|group with intervention of 125 to 170 IU of 'Botulinum toxin'
62749414|NCT01032954|ACTIVE_COMPARATOR|171 to 210 IU of 'Botulinum toxin'|Patients who have received 171 to 210 IU of 'Botulinum toxin'
62749415|NCT01032954|ACTIVE_COMPARATOR|211 to 250 IU of Botulinum toxin|Patients who have received 211 to 250 U of Botulinum toxi'
62554432|NCT04759807|ACTIVE_COMPARATOR|PUR1800 250 μg|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to 250 μg and 500 μg nominal dose strengths of RV1162. Subjects will receive 14 doses administered once daily in the morning.
62554433|NCT04759807|ACTIVE_COMPARATOR|PUR1800 500 μg|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to 250 μg and 500 μg nominal dose strengths of RV1162. Subjects will receive 14 doses administered once daily in the morning.
62554434|NCT01960660|EXPERIMENTAL|Investigational Product|Omega-3 fatty acids in the form of triglycerides
62749416|NCT05577598|ACTIVE_COMPARATOR|Subjects in this arm will receive active stimulation.|The Medtronic DBS system will be implanted in subjects in both study arms. Stimulation will vary depending on the study arm assignment. All subjects will receive therapeutic settings at the end of the blinded period.
62749417|NCT05577598|SHAM_COMPARATOR|Subjects in this arm will receive sham stimulation with DBS being turned off.|The Medtronic DBS system will be implanted in subjects in both study arms. Stimulation will vary depending on the study arm assignment. All subjects will receive therapeutic settings at the end of the blinded period.
62749418|NCT06608420||Melanoma patients|The training dataset will consist of 6000 adult melanoma patients while the adaptation dataset for children, adolescents and young adults (CAYA) will be of N = 120.
62749419|NCT03466099|EXPERIMENTAL|KVD001 Injection (high dose)|
62749420|NCT03466099|EXPERIMENTAL|KVD001 Injection (low dose)|
62749421|NCT03466099|SHAM_COMPARATOR|Sham Procedure|
62749422|NCT00724854||Mono-infected with HCV|Participants infected with Hepatitis C Virus (HCV).
62374986|NCT03531762|EXPERIMENTAL|Sequence 1: Treatment A-B-C|Participants received single oral dose of 500 milligrams (mg) of Tepotinib alone in fed state on Day 1 of Treatment period 1 (Treatment A) followed by single oral dose of 500 mg Tepotinib in fasted state on Day 5 of Treatment period 2 with 40 mg of omeprazole once daily on Day 1 to 5 of Treatment period 2 (Treatment B) followed by single oral dose of 500 mg Tepotinib in fed state on Day 5 of Treatment period 3 with 40 mg omeprazole once daily on Day 1 to 5 of Treatment period 3 (Treatment C). A washout period of at least 14 days was maintained between the Tepotinib single dose administrations.
62554435|NCT01960660|ACTIVE_COMPARATOR|Comparator Product 1|Omega-3 fatty acids in the form of ethyl esters.
62554436|NCT01960660|ACTIVE_COMPARATOR|Comparator Product 2|Omega-3 fatty acids in the form of phospholipids from krill oil.
62749423|NCT00724854||Co-infected with HCV and HIV|Participants co-infected with HCV and Human Immunodeficiency Virus (HIV).
62749424|NCT05072223|EXPERIMENTAL|Group A|
62749425|NCT05072223|ACTIVE_COMPARATOR|Group B|
62749426|NCT06607224|EXPERIMENTAL|Decision making guided by CGM|Hospitalized patients with T2D in non-critical medical and surgical wards. The participants use FreeStyle 2-CGM and therapeutic decisions will be made based on CGM and GC parameters; with the presence of alarms for hypoglycemia or hyperglycemia activated for timely action. Blinded will be applied to patients; while the data will be open to the physicians in charge of the research in order to make daily modifications of insulin therapy. The CG controls will be of 6 points (before each meal and two hours after meals) with a standard Abbott FreeStyle Optium Neo glucometer. Basal-bolus scheme with basal insulin Glargine U-100 and prandial insulin Aspart will be used. Daily adjustments will be made based on protocol based of our department according to the international guidelines and previous research
62749427|NCT06607224|NO_INTERVENTION|Decision making guided by CG|Hospitalized patients with T2D admitted in non-critical medical and surgical wards. The participants use FreeStyle 2-CGM with deactivated alarms. Blind will be applied for patients, nurses and physicians in charge of the investigation. Concomitant 6-point CG controls will be performed (before each meal and two hours after meals) with Abbott FreeStyle Optium Neo glucometer. Insulin therapy adjustments will be carried out by GC only. The CGM values in this group will be evaluated a posteriori. Basal-bolus schedule with basal insulin Glargine U-100 and prandial insulin Aspart will be used. Daily adjustments will be made based on protocols of our department according to the international guidelines.
62554437|NCT01960660|ACTIVE_COMPARATOR|Comparator Product 3|Omega-3 fatty acids from salmon oil.
62554438|NCT02896712|ACTIVE_COMPARATOR|ACT plus CM|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered to help decrease experiential avoidance while increasing acceptance and willingness to experience unpleasant thoughts, feelings, and physical symptoms.
62749428|NCT05426031|EXPERIMENTAL|Fixed Dose Protamine group|Participants in the group will receive a one time dose of 250 mg Protamine to reverse heparin during the standard cardiopulmonary bypass management during cardiac surgery.
62749429|NCT05426031|ACTIVE_COMPARATOR|Ratio Dose Protamine Group|Participants in the group will receive a ratio dose of Protamine in a 1mg per 100 units of heparin ratio to reverse heparin during the standard cardiopulmonary bypass management during cardiac surgery.
62749430|NCT02013206|EXPERIMENTAL|Never Smokers|Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib \[Tarceva\] 150 mg orally daily until disease progression or unacceptable toxicity.
62749431|NCT02013206|EXPERIMENTAL|Current/Former Smokers|Current Smokers (participants who smoked \> 100 cigarettes in entire lifetime and either quit smoking \< 1 year ago or were currently smoking) or Former Smokers (participants who smoked \> 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib \[Tarceva\] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity.
62749432|NCT05846880|EXPERIMENTAL|Maintenance Vitamin D|In this arm, patients will receive maintenance Vitamin D3 prior to autologous transplantation (ASCT). Within 120 days after ASCT the following will be assessed: vitamin D level, Overall Response Rate (ORR) and Measurable Residual Disease (MRD). Then patients will receive lenalidomide and continuation of maintenance Vitamin D.
62749433|NCT05846880|ACTIVE_COMPARATOR|No Maintenance Vitamin D|In this arm, patients will receive no maintenance vitamin D prior to ASCT. Within 120 days after ASCT the following will be assessed: vitamin D level, ORR, and MRD. Then patients will receive the standard lenalidomide dose along with no maintenance vitamin D.
62749434|NCT05694312|EXPERIMENTAL|Ibrutinib|Patients will receive ibrutinib 420 mg/day orally for up to 12 cycles of 28 days.
62391527|NCT04169620|EXPERIMENTAL|variable aquatic Ai Chi|"The 15 patients assigned to the aquatic therapy group (experimental group) received 20 twice-weekly sessions in total, during the same period of time as the control group. These 20 sessions consisted of group sessions lasting 45-minutes.~The sessions were designed with a gradual increase in difficulty. Initially, a recreational warm-up activity was performed, followed by 30 minutes dedicated to practicing the Ai Chi Program. At the end of the session there was a calming down activity. The exercises were performed in a specific order, until completion of the 19 possible movements."
62554439|NCT02896712|ACTIVE_COMPARATOR|ACT plus CM, with Placebo|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered and augmented with a placebo capsule during Phase 2 (weeks 5-12).
62554440|NCT02896712|EXPERIMENTAL|ACT plus CM, with Modafinil|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered and augmented with a Modafinil (300mg) capsule during Phase 2 (weeks 5-12).
62554441|NCT02896712|ACTIVE_COMPARATOR|DC plus CM|Drug Counseling and Contingency Management for cocaine use will be administered to help educate patients about important concepts in addiction recovery.
62554442|NCT02896712|ACTIVE_COMPARATOR|DC plus CM, with Placebo|Drug Counseling and Contingency Management for cocaine use will be administered and augmented with a placebo capsule during Phase 2 (weeks 5-12).
62554443|NCT02896712|EXPERIMENTAL|DC plus CM, with Modafinil|Drug Counseling and Contingency Management for cocaine use will be administered and augmented with a Modafinil (300mg) capsule during Phase 2 (weeks 5-12).
62554444|NCT02854527|EXPERIMENTAL|R1 (Reference 1) Digoxin|1 tablet (0.25 mg) digoxin as single dose
62554445|NCT02854527|EXPERIMENTAL|R2 Furosemide|0.1 mL (1 mg) furosemide oral solution as single dose
62554446|NCT02854527|EXPERIMENTAL|R3 Metformin hydrochloride|0.1 mL (10 mg) metformin oral solution as single dose
62554447|NCT02854527|EXPERIMENTAL|R4 Rosuvastatin|1 tablet (10 mg) rosuvastatin as single dose
62554448|NCT02854527|EXPERIMENTAL|T (Test)|1 tablet (0.25 mg) digoxin, 0.1 mL (1 mg) furosemide oral solution, 0.1 mL (10 mg) metformin oral solution, and 1 tablet (10 mg) rosuvastatin, all together as a single dose ('cocktail')
62554449|NCT03987997|ACTIVE_COMPARATOR|Association electrical muscle stimulation with cyclo-ergometer|Randomized leg with receive electrical muscle stimulation of the quadriceps in addition to early mobilization of lower limbs with cyclo-ergometer.
62554450|NCT03987997|OTHER|Cyclo-ergometer only|This control group correspond to the leg which don't receive electrical muscle stimulation (as usually supported)
62554451|NCT04789551||Multiple Sclerosis Stable Conditions|Multiple sclerosis patients presenting for a routine clinic visit.
62554452|NCT04789551||Multiple Sclerosis Acute Flare Up|Multiple sclerosis patients admitted to the hospital with acute symptoms.
62554453|NCT04789551||Control patients|Patients without any immunological diseases who present for elective surgery.
62749435|NCT05064020||Polypharmacy|"Polypharmacy: patient is using five or more medications will be considered polypharmacy.~Subjects having polypharmacy condition with taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir/Alafenamide 150MG-150MG-200MG-10MG Oral Tablet \[Genvoya\] or Elevitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate 150MG-150MG-200MG-300MG Oral Tablet \[Stribild\] will switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet \[BIKTARVY\]"
62749436|NCT05064020||Nonpolypharmacy|"Nonpolypharmacy: patient is using less than five medications will be considered nonpolypharmacy~Nonpolypharmacy Subjects taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir/Alafenamide 150MG-150MG-200MG-10MG Oral Tablet \[Genvoya\] or Elevitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate 150MG-150MG-200MG-300MG Oral Tablet \[Stribild\] will switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet \[BIKTARVY\]"
62749437|NCT03354312|EXPERIMENTAL|Lidocaine/Articaine|Lidocaine Hydrochloride 1% Gel anesthesia / Articaine hydrochloride/epinephrine (adrenaline) hydrochloride anesthesia
62749438|NCT03354312|EXPERIMENTAL|Articaine/Lidocaine|Articaine hydrochloride/epinephrine (adrenaline) hydrochloride anesthesia / Lidocaine Hydrochloride 1% Gel anesthesia
62749439|NCT02803177|EXPERIMENTAL|BMC2012 + beta-TCP Chronos® Synthes|The large bone defect will be bridged as per clinical standard, filled with a clinically established scaffold (beta-TCP Chronos® Synthes), and loaded with 1.3 x 10E6 BMC/ml TCP per 1 ml beta-TCP in situ.
62749440|NCT02803177|PLACEBO_COMPARATOR|beta-TCP Chronos® Synthes|The large bone defect will be bridged as per clinical Standard and filled with a clinically established scaffold (beta-TCP Chronos® Synthes).
62749441|NCT03785249|EXPERIMENTAL|Phase 1 Dose Exploration|Dose escalation of MRTX849 to determine maximum tolerated dose
62749442|NCT03785249|EXPERIMENTAL|Phase 1b Expansion|Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 to recommend Phase 2 regimens
62374987|NCT03531762|EXPERIMENTAL|Sequence 2: Treatment A-C-B|Participants received single oral dose of 500 mg of Tepotinib alone in fed state on Day 1 of Treatment period 1 (Treatment A) followed by single oral dose of 500 mg Tepotinib in fed state on Day 5 of Treatment period 2 with 40 mg omeprazole once daily on Day 1 to 5 of Treatment period 2 (Treatment C) followed by single oral dose of 500 mg Tepotinib in fasted state on Day 5 of Treatment period 3 with 40 mg of omeprazole once daily on Day 1 to 5 of Treatment period 3 (Treatment B). A washout period of at least 14 days was maintained between the Tepotinib single dose administrations.
62374988|NCT03531762|EXPERIMENTAL|Sequence 3: Treatment B-A-C|Participants received single oral dose of 500 mg Tepotinib in fasted state on Day 5 of Treatment period 1 with 40 mg of omeprazole once daily on Day 1 to 5 of Treatment period 1 (Treatment B) followed by single oral dose of 500 mg of Tepotinib alone in fed state on Day 1 of Treatment period 2 (Treatment A) followed by single oral dose of 500 mg Tepotinib in fed state on Day 5 of Treatment period 3 with 40 mg omeprazole once daily on Day 1 to 5 of Treatment period 3 (Treatment C). A washout period of at least 14 days was maintained between the Tepotinib single dose administrations.
62374989|NCT03531762|EXPERIMENTAL|Sequence 4: Treatment B-C-A|Participants received single oral dose of 500 mg Tepotinib in fasted state on Day 5 of Treatment period 1 with 40 mg of omeprazole once daily on Day 1 to 5 of Treatment period 1 (Treatment B) followed by single oral dose of 500 mg Tepotinib in fed state on Day 5 of Treatment period 2 with 40 mg omeprazole once daily on Day 1 to 5 of Treatment period 2 (Treatment C) followed by single oral dose of 500 mg of Tepotinib alone in fed state on Day 1 of Treatment period 3 (Treatment A). A washout period of at least 14 days was maintained between the Tepotinib single dose administrations.
62554454|NCT03965195|EXPERIMENTAL|RIV4|Nursing homes randomized to receive quadrivalent recombinant influenza vaccine (Flublok) for the residents and staff
62374990|NCT03531762|EXPERIMENTAL|Sequence 5: Treatment C-A-B|Participants received single oral dose of 500 mg Tepotinib in fed state on Day 5 of Treatment period 1 with 40 mg omeprazole once daily on Day 1 to 5 of Treatment period 1 (Treatment C) followed by single oral dose of 500 mg of Tepotinib alone in fed state on Day 1 of Treatment period 2 (Treatment A) followed by single oral dose of 500 mg Tepotinib in fasted state on Day 5 of Treatment period 3 with 40 mg of omeprazole once daily on Day 1 to 5 of Treatment period 3 (Treatment B). A washout period of at least 14 days was maintained between the Tepotinib single dose administrations.
62374991|NCT03531762|EXPERIMENTAL|Sequence 6: Treatment C-B-A|Participants received single oral dose of 500 mg Tepotinib in fed state on Day 5 of Treatment period 1 with 40 mg omeprazole once daily on Day 1 to 5 of Treatment period 1 (Treatment C) followed by single oral dose of 500 mg Tepotinib in fasted state on Day 5 of Treatment period 2 with 40 mg of omeprazole once daily on Day 1 to 5 of Treatment period 2 (Treatment B) followed by single oral dose of 500 mg of Tepotinib alone in fed state on Day 1 of Treatment period 3 (Treatment A). A washout period of at least 14 days was maintained between the Tepotinib single dose administrations.
62374992|NCT00853112|EXPERIMENTAL|PF-00489791 1 mg|
62374993|NCT00853112|EXPERIMENTAL|PF-00489791 2 mg|
62374994|NCT00853112|EXPERIMENTAL|PF-00489791 4 mg|
62374995|NCT00853112|EXPERIMENTAL|PF-00489791 10 mg|
62374996|NCT00853112|EXPERIMENTAL|PF-00489791 20 mg|
62374997|NCT00853112|PLACEBO_COMPARATOR|Placebo|
62749443|NCT03785249|EXPERIMENTAL|Phase 2|Separate cohorts of patients stratified by histological diagnosis, prior treatment history or co-mutation status (e.g., STK11) for evaluation of clinical activity of MRTX849
62374998|NCT00853112|ACTIVE_COMPARATOR|Sildenafil|Observational comparator arm
62374999|NCT00822640|EXPERIMENTAL|1|Columbus Knee Prosthesis with rotating Platform
62375000|NCT00822640|ACTIVE_COMPARATOR|2|Columbus Knee Prosthesis with fixed platform
62554455|NCT03965195|ACTIVE_COMPARATOR|IV4|Nursing homes randomized to receive standard dose quadrivalent influenza vaccine for the residents and staff
62554456|NCT02225431|ACTIVE_COMPARATOR|Standard saline infusion|All patients received standard intravenous saline hydration (0.9% sodium chloride, 1 ml/kg/h for 12 hours before and after procedure)
62554457|NCT02225431|EXPERIMENTAL|Double saline infusion|All patients received double dose of intravenous saline hydration (0.9% sodium chloride, 2 ml/kg/h for 12 hours before and after procedure)
62749444|NCT03785249|EXPERIMENTAL|Pilot Phase 1b Combination with Pembrolizumab|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with pembrolizumab in patients with NSCLC
62749445|NCT03785249|EXPERIMENTAL|Pilot Phase 1b Combination with Cetuximab|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with CRC
62749446|NCT03785249|EXPERIMENTAL|Pilot Phase 1b Combination with Afatinib|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with afatinib in patients with NSCLC
62749447|NCT03785249|EXPERIMENTAL|Phase 2 Combination with Cetuximab|Phase 2 evaluation of the clinical activity of MRTX849 in combination with cetuximab in patients with CRC
62749448|NCT03785249|EXPERIMENTAL|Pilot Phase 1b Combination with Cetuximab in NSCLC|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with NSCLC
62749449|NCT03785249|EXPERIMENTAL|Pilot Phase 1b Combination with Cetuximab in PDAC|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with pancreatic adenocarcinoma (PDAC)
62749450|NCT01535599|EXPERIMENTAL|AL-60371|AL-60371, 0.3% Otic Suspension, 4 drops to the affected ear(s) twice daily for 7 days
62749451|NCT01535599|PLACEBO_COMPARATOR|Vehicle|AL-60371 Vehicle, 4 drops to the affected ear(s) twice daily for 7 days
62749452|NCT01777217|ACTIVE_COMPARATOR|solifenacin succinate|Solifenacin succinate, 5mg or 10 mg once daily
62749453|NCT01777217|PLACEBO_COMPARATOR|Placebo|Drug: Placebo oral
62749454|NCT02965183|EXPERIMENTAL|Temperature measurements|
62749455|NCT03040011|EXPERIMENTAL|Bupivacaine/Dexamethasone Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of a mixture of 20 milliliters of 0.25% bupivacaine (2.5mg/milliliter ) and 2 milliliters of dexamethasone (4mg/milliliter). The total amount of the bupivacaine/dexamethasone solution will be divided equally between the four injection sites.
62749456|NCT03040011|ACTIVE_COMPARATOR|Bupivacaine Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.25% bupivacaine (2.5mg/milliliter). The total amount will be divided equally between the four injection sites.
62749457|NCT03040011|PLACEBO_COMPARATOR|Placebo Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.9% saline (normal saline). The total amount will be divided equally between the four injection sites.
62749458|NCT04444778|ACTIVE_COMPARATOR|Continuous positive airway pressure|Diet and general life style recommendations plus continuous positive airway pressure (CPAP).
62749459|NCT04444778|NO_INTERVENTION|Conservative treatment|Diet and general life style recommendations.
62749460|NCT01700374||Women without Prepubertal Adversity|"At 8-17 weeks gestational age, 1,500 pregnant women will complete:~* Adverse Childhood Events (ACE) Questionnaire;~* Perceived Stress Scale (PSS);~* A general health and demographic questionnaire.~All women who are screened will be asked if they would be willing to allow the study team to access their delivery report.~Women who report 0 or 1 adverse childhood experiences will be invited to continue in the study as part of the Women without Prepubertal Adversity cohort. We aim to have 125 women in this cohort."
62749461|NCT01700374||Women with Prepubertal Adversity|"At 8-17 weeks gestational age, 1,500 pregnant women will complete:~* Adverse Childhood Events (ACE) Questionnaire;~* Perceived Stress Scale (PSS);~* A general health and demographic questionnaire.~All women who are screened will be asked if they would be willing to allow the study team to access their delivery report.~Women who report 2 or more adverse childhood experiences will be invited to continue in the study as part of the Women without Prepubertal Adversity cohort. We aim to have 125 women in this cohort."
62554458|NCT01838850|EXPERIMENTAL|CS8635 20/5/12.5mg and placebo|Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this triple fixed dose combination therapy (CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5mg) + placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 40/5/12.5mg (OM/AML/HCTZ 40/5/12.5 mg).
62554459|NCT01838850|ACTIVE_COMPARATOR|Olmetec® Plus 20/12.5mg and placebo|Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this dual fixed dose combination therapy (Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5mg) + Placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5 mg).
62554460|NCT01446341|ACTIVE_COMPARATOR|Immobilization|50 patients will be randomly assigned to have their lateral ankle sprain immobilized in a below knee cast
62554461|NCT01446341|ACTIVE_COMPARATOR|Functional Rehabilitation|50 patients will be randomly assigned to a functional rehabilitation program for their lateral ankle sprain
62554462|NCT00708110|EXPERIMENTAL|Treatment A|GSK1349572 2 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
62554463|NCT00708110|EXPERIMENTAL|Treatment B|GSK1349572 10 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
62554464|NCT00708110|EXPERIMENTAL|Treatment C|GSK1349572 50 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
62554465|NCT01842529|ACTIVE_COMPARATOR|CABG+ Botulinum toxin|All patients underwent conventional CABG. After the main stage of the surgery botulinum toxin (Xeomin, incobotulinumtoxin A, Merz Pharma GmbH \& Co KGaA, Germany; 50 U/1 mL at each fat pad; botulinum toxin group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
61997500|NCT06368453|EXPERIMENTAL|Performance|INSTI® HIV ST devices are provided to the enrolled participants to conduct the self test using the provided instruction for use while being observed by an operator. The operator records the INSTI® HIV ST results interpreted by the subjects. The operator then performs the comparator test to compare the results with the INSTI® HIV ST.
62749462|NCT00491855|EXPERIMENTAL|Bevacizumab + Oxaliplatin + Paclitaxel|One cycle of treatment is 21 days. Bevacizumab starting dose level 2.5 mg/kg given intravenously on day 1. Oxaliplatin starting dose level 25 mg/m\^2 given intraperitoneally on day 2. Paclitaxel starting dose level 110 mg/m\^2 given continuous infusion on day 1 and 30 mg/m\^2 given intraperitoneally on day 8.
62749463|NCT01239381|EXPERIMENTAL|SBRT-Proton|Stereotactic body radiotherapy by proton radiation
62749464|NCT01781650|ACTIVE_COMPARATOR|Air insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
62375001|NCT03080701|NO_INTERVENTION|Group 1 - Automated Mailing|The mailing process will be identical to those used in the SOS study. Mailing 1 includes an introductory letter on CRC screening and a pamphlet on CRC testing choices (colonoscopy every 10 years, FIT testing yearly, or flexible sigmoidoscopy every 10 years combined with interval FIT testing), and pros and cons of each. The letter will state that they will soon be receiving a FIT kit in the mail, and a number to call if they prefer another option. Mailing 2 includes a brief letter reaffirming the importance of screening, a FIT kit (the one used by Group Health), pictograph instructions, and a postage-paid return envelope. Mailing 3 a reminder letter, is sent to participants not completing the FIT kit after 3 weeks. The intervention for Group 1 includes no incentive.
62554466|NCT01842529|ACTIVE_COMPARATOR|Control|All patients underwent conventional CABG. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad; placebo group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
62375002|NCT03080701|EXPERIMENTAL|Group 2 - Auto Mailing Plus Money|Receives the same number of mailings and materials as group 1 with the following modifications. In Mailing 1 the letter will include the intervention notification that they will receive a monetary thank you gift for completing testing (FIT colonoscopy or flex sig within 6 months). Mailing 2 and mailing 3 (reminder letters for those still not returning kits) will include the same information about the monetary thank you gift for CRC screening completion. Mailing 4 will include the money with a thank you letter for those who complete the screening
62554467|NCT04859829||Patients with autoimmune dysmotility receiving IVIG infusions|
62554468|NCT04859829||Patients with autoimmune dysmotility without IVIG infusions|
62554469|NCT04168892||Female age ≤ 35 years: 150 IU of HMG|For controlling the effect of the starting dose on the number of retrieved oocytes, the patients will be divided in two groups based on their age. For the patients with an age ≤ 35 years, COS will be carried out by daily injections of 150 IU of Human Menopausal Gonadotropins (HMG) and will be started on the 3rd day of the cycle. The starting dose will be maintained for the first 5 days and followed by individual dose-adjustments according to the patient's follicular response. The pituitary suppression will be obtained by the administration of the Gonadotropin-releasing Hormone (GnRH) antagonist ganirelix (0.25 mg per day), starting from the 6th day of the ovarian stimulation until the day of the induction of the final oocyte maturation. Highly purified urinary human Chorionic Gonadotropin (hCG) 10.000 IU will be used to induce final oocyte maturation. In case of OHSS risk, the final oocyte maturation will be obtained by using a GnRH agonist (buserelin acetate), 0.5 mg subcutaneously.
62375003|NCT03080701|EXPERIMENTAL|Group 3 - Auto Mailing Plus Lottery|Receives the same number of mailings and materials as group 1 with the following modifications. In Mailing 1 the letter will include the intervention notification that they will have a 1 in 10 chance of winning money (FIT, colonoscopy or flex sig within 6 months). Mailing 2 and mailing 3 (reminder letters for those still not returning kits) will include the same information about the 1 in 10 chance of winning the lottery for CRC screening completion. Mailing 4 will include a thank you letter with money for those who complete their screening and win the lottery. Participants who do not win the lottery will receive a thank you letter.
62749465|NCT01781650|EXPERIMENTAL|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
62749466|NCT01781650|EXPERIMENTAL|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
62749467|NCT06605365||CXC-SP|Subjects affected by dry eye disease are treated with the new ophthalmic solution containing cross-linked CMC (CX-CMC) and Silk Proteins (SP).
62749468|NCT06373926|EXPERIMENTAL|case|APS patients
62749469|NCT06373926|ACTIVE_COMPARATOR|control|healthy individuals
62749470|NCT05963412|EXPERIMENTAL|Online Individual Intervention Program|The online intervention program (namely, Meaning-Centered Coping Program) consists of eight individual sessions, each lasting approximately 60 min. Sessions were conducted per week.
62749471|NCT05963412|NO_INTERVENTION|No Intervention: Waitlist Control Group|A wait-list control group was used. Participants assigned to the wait-list control group did not receive the intervention immediately. After the final assessment was administered (eight weeks later since the initial assessment), they were able to participate in the same intervention program if they wanted.
62749472|NCT01220973|EXPERIMENTAL|Atorvastatin and Celecoxib|
62749473|NCT03504540||Case (with pseudo-drusen-like deposits)|"Patients with lupus, treated or not with antimalarial drugs, with pseudo-drusen-like deposits"
62749474|NCT03504540||Control (without pseudo-drusen-like deposits)|"Patients with lupus, treated or not with antimalarial drugs, without pseudo-drusen-like deposits"
62749475|NCT06604910|EXPERIMENTAL|BCAA|patients undergoing branched chained amino acid
62749476|NCT06604910|NO_INTERVENTION|patients undergoing no BCAA|patients undergoing no branched chained amino acid
62749477|NCT05832515|EXPERIMENTAL|AHSCT: FluCy200|"AHSCT with reduced intensity condition regimen (RIC):~cyclophosphamide intravenously at a dose of 50 mg/kg/day from -5 to day -2 inclusive; fludarabine intravenously at a dose of 30 mg/m2 from -5 to day -2 inclusive. Immunotherapy: ATG - ATGAM intravenously 20 mg/kg from -3 to -1 or Thymoglobulin 2.5 mg/kg from -3 to -1 day.~Also, within the framework of immunotherapy, instead of ATG, it is allowed to use anti-B-cell therapy - Rituximab 500 mg / m2 per day +12 AHSCT."
62749478|NCT02376725|ACTIVE_COMPARATOR|Phaco/IOL|Cataract extraction using phacoemulsification technique with intraocular lens implant
62749479|NCT02376725|ACTIVE_COMPARATOR|Phaco/IOL + goniosynechialysis|Cataract extraction using phacoemulsification technique with intraocular lens implant with goniosynechialysis
62375004|NCT02968966|EXPERIMENTAL|Therapy regime|Two medical drugs will be administered in a predefined order (1. Phenhydan® (Phenytoin), 2. Lacosamide (Vimpat®) to investigate whether this enables an effective reduction of seizures in early onset epileptic encephalopathies..
62375005|NCT03298048|ACTIVE_COMPARATOR|Low fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
62749480|NCT06303440|OTHER|Group A (Routine Physical Therapy+ Balance Training)|"The children will be provided with Routine Physical Therapy and Balance Training.~Balance exercises will be provided for 15 minutes and 30 minutes of Routine physical therapy will be as strengthening and stretching exercises."
62749481|NCT06303440|EXPERIMENTAL|Group B (Virtual Reality + Routine Physical Therapy)|The VR system consisted of a wall-mounted display, a Nintendo Wii box, a Wii remote, and a Wii Fit board. The participants will be instructed to stand on Wii Fit board while interacting with the VR system and playing the selected games and routine physical therapy of 30 minutes will be provided.
62749482|NCT06303440|EXPERIMENTAL|Group C (Motor Imagery+ Routine Physical Therapy)|During the presentation of a video clip, patients will watch the video and afterwards try to do movement as same as shown in video
62749483|NCT00688324|EXPERIMENTAL|Single Arm|All subjects will have baseline measures, receive acamprosate for 2 weeks, then have measures repeated.
62749484|NCT05825430|EXPERIMENTAL|Control group|Patients will not receive any block
62749485|NCT05825430|EXPERIMENTAL|Direct pecs block group|Pec I block will be given with 10 ml bupivacaine 0.25% which injected between two pectoral muscles and pecs II block will be given with 20 ml bupivacaine 0.25%.which given between pectoralis minor muscle and serratus muscle. Patients will receive direct pecs block by surgeon after closure of pectoralis muscle under direct vision and before skin closure.
62749486|NCT05825430|EXPERIMENTAL|Ultrasound guided pecs|Pec I block will be given with 10 ml bupivacaine 0.25% which injected between two pectoral muscles and pecs II block will be given with 20 ml bupivacaine 0.25%.which given between pectoralis minor muscle and serratus muscle. Patients will receive ultrasound guided pecs block done after induction and before skin incision.
62375006|NCT03298048|ACTIVE_COMPARATOR|Mid fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
62375007|NCT03298048|ACTIVE_COMPARATOR|High fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
62749487|NCT03840772|EXPERIMENTAL|Eribulin|"Eribulin will be administered at the dose of 1.23 mg/m², intravenously over 2-5 min on day 1 and day 8 of every 21 day cycle.~Study treatment will be administered until evidence of progression or unacceptable toxicity, patient's own willingness, non-compliance or according to clinical investigator's decision."
62749488|NCT01035463|EXPERIMENTAL|Treatment (stem cell transplantation)|"PRE-CONDITIONING (patients with CD20+ NHL): Patients receive rituximab IV per standard of care.~PREPARATIVE REGIMEN: Patients receive carmustine IV on day -6, etoposide IV BID and cytarabine IV BID on days -5 through -2, and melphalan IV on day -1.~AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: Patients undergo stem cell infusion on day 0.~MAINTENANCE THERAPY: Beginning approximately 100 days post-transplant, patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity."
62749489|NCT03759886||Oral Antibiotics|The patients get mechanical bowel preparation and oral antibiotic prophylaxis with 4g Paromomycin (Paromomycin Sulfate Powder) and 1 g Metronidazole p.o. and perioperative i.v. antibiotic prophylaxis with Ertepanem 1g i.v.
62554470|NCT04168892||Female age >35 years: 225 IU of HMG|In order to control the effect of the starting dose on the number of retrieved oocytes, the patients will be divided in two groups based on their age. For the patients with an age \>35 years, the controlled ovarian stimulation will be carried out by daily injections of 225 IU of HMG and will be started on the 3rd day of the cycle. The starting dose will be maintained for the first 5 days and followed by individual dose-adjustments according to the patient's follicular response. The pituitary suppression will be obtained by the administration of the GnRH antagonist ganirelix (0.25 mg per day), starting from the 6th day of the ovarian stimulation until the day of the induction of the final oocyte maturation. Highly purified urinary hCG 10.000 IU will be used to induce final oocyte maturation. In case of OHSS risk, the final oocyte maturation will be obtained by using a GnRH agonist (buserelin acetate), 0.5 mg subcutaneously.
62749490|NCT03759886||iv Antibiotics|The patients get mechanical bowel preparation and perioperative i.v. antibiotic prophylaxis with Ertepanem 1g i.v.
62749491|NCT03222154|NO_INTERVENTION|Control|20 volunteers without intervention. At the end of the study they received an application of shock wave therapy.
62749492|NCT03222154|PLACEBO_COMPARATOR|Placebo|20 volunteers who received simulation of the application of shock wave therapy
62749493|NCT03222154|EXPERIMENTAL|Experimental|20 volunteers who received shock wave therapy
62182813|NCT01502306|EXPERIMENTAL|Phone counseling & nicotine patches|"One-on-one, proactive telephone counseling to quit smoking; The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls.~Nicotine patches (four weeks' worth) are sent directly to clients the day after the screening intake. Dosage is 21 mg if smoking 11 or more per day, 14 mg if smoking 6-10 per day and 7mg if smoking \<6 per day."
62375008|NCT04111926|EXPERIMENTAL|Intervention group|A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.
62554471|NCT05669534|ACTIVE_COMPARATOR|Condition 1|Standard CHRP Intervention Components
62749494|NCT05527587|EXPERIMENTAL|Nature Connections Group|Participants will be screened to confirm their eligibility to partake in the study. Participants who meet the study criteria will then be invited to participate in the nature connections intervention. At the start of the intervention, mid-intervention and post intervention, participants will be invited to participate in assessments of their behaviour and mood symptoms, cognition, quality of life, caregiver burden and stress levels using different measures and questionnaires at the University of Calgary. Participants will be provided with a visit passport to record a log of activities completed during the park visits.
62749495|NCT04736004||Athletes with COVID-19|
62749496|NCT04736004||Athletes without COVID-19 (control)|
62749497|NCT03784599|EXPERIMENTAL|Trastuzumab-emtansine and osimertinib|"Trastuzumab-emtansine 3.6 mg/kg, intravenously, every 3 weeks~Osimertinib 80 mg once daily, orally, continuous~Treatment will be continued until tumor progression (according to RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs."
62375009|NCT04111926|PLACEBO_COMPARATOR|Control group|Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.
62375010|NCT04741204|EXPERIMENTAL|White women|White women on metformin Extended release 750 mg BID
62375011|NCT04741204|EXPERIMENTAL|Black women|Black women on metformin Extended release 750 mg BID
62554472|NCT05669534|EXPERIMENTAL|Condition 2|Standard CHRP Intervention Components and Information Processing Components
62749498|NCT05296824||Pulmonary vein isolation (PVI) only|Patients with symptomatic paroxysmal atrial fibrillation who received cryoballoon pulmonary vein isolation (PVI) only
62749499|NCT05296824||Pulmonary vein isolation (PVI) with posterior wall isolation (PWI)|Patients with symptomatic paroxysmal atrial fibrillation who received cryoballoon pulmonary vein isolation (PVI) with posterior wall isolation (PWI)
62749500|NCT01304069|PLACEBO_COMPARATOR|Placebo|
62749501|NCT01304069|ACTIVE_COMPARATOR|Selecoxib|
62375012|NCT04347252|EXPERIMENTAL|Glucagon at basal glycemia|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 240 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 30 or 60 minutes.
62375013|NCT04347252|EXPERIMENTAL|Glucagon at hyperglycemia|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 120 an infusion of 20% glucose, labeled to 2% with deuterated glucose, will be started and adjusted to raise the blood glucose to 8.3 mM for the remainder of the study. At time 240 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 30 or 60 minutes.
62375014|NCT04347252|EXPERIMENTAL|Glucagon at hyperglycemia with GLP-1R blockade|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 120 an infusion of 20% glucose, labeled to 2% with deuterated glucose, will be started and adjusted to raise the blood glucose to 8.3 mM for the remainder of the study; concurrently exendin-(9-39) will be infused at 750 pmol/kg/min, also for the remaining 180 minutes. At time 240 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 30 or 60 minutes.
62554473|NCT05669534|EXPERIMENTAL|Condition 3|Standard CHRP Intervention Components and Memory Components
62554474|NCT05669534|EXPERIMENTAL|Condition 4|Standard CHRP Intervention Components, Information Processing Components, and Memory Components
62554475|NCT05669534|EXPERIMENTAL|Condition 5|Standard CHRP Intervention Components, Executive Functioning Components
62375015|NCT00372489|EXPERIMENTAL|Peginesatide|
62554476|NCT05669534|EXPERIMENTAL|Condition 6|Standard CHRP Intervention Components, Information Processing Components, and Executive Functioning Components
62749502|NCT01304069|ACTIVE_COMPARATOR|Etoricoxib|
62749503|NCT04225052|OTHER|Group1|16 subjects, Cross-over, Single dose of comparator on day1, Single dose of YHP1903 on day8
62749504|NCT04225052|OTHER|Group2|16 subjects, Cross-over, Single dose of YHP1903 on day1, Single dose of comparator on day8
62749505|NCT03695627|EXPERIMENTAL|Meditation Group|Participants in the meditation group will use a digitally-based mindfulness intervention Headspace app (Basics + Stress packs) will be used for 10 minutes a day over the course of 8 weeks
62749506|NCT03695627|NO_INTERVENTION|Control Group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
62749507|NCT05055323|EXPERIMENTAL|Treatment (pyrvinium pamoate)|Patients receive pyrvinium pamoate PO QD for 3 days in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
62375016|NCT02213081|EXPERIMENTAL|Ulipristal|1 patient with chronic, endometriosis-related pelvic pain refractory to medical and/or surgical therapies will receive 15mg ulipristal every other day (three times a week- Monday, Thursday, Saturday) for three months.
62375017|NCT01531933|EXPERIMENTAL|DLBS3233|
62375018|NCT01531933|PLACEBO_COMPARATOR|Placebo of DLBS3233|
62375019|NCT01089751|EXPERIMENTAL|Sanctura XR®|Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks.
62375020|NCT01089751|PLACEBO_COMPARATOR|Placebo|Placebo once daily on an empty stomach for 14 weeks.
62749508|NCT01854632|EXPERIMENTAL|SIIL Live Attenuated Influenza Vaccine|Single 0.5 mL dose of trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
62749509|NCT01854632|PLACEBO_COMPARATOR|Matched placebo|Single 0.5mL inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
62554477|NCT05669534|EXPERIMENTAL|Condition 7|Standard CHRP Intervention Components, Memory Components, and Executive Functioning Components
62554478|NCT05669534|EXPERIMENTAL|Condition 8|Standard CHRP Intervention Components, Information Processing Components, Memory Components, and Executive Functioning Components
62554479|NCT05669534|EXPERIMENTAL|Condition 9|Standard CHRP Intervention Components and Attention Components
62554480|NCT05669534|EXPERIMENTAL|Condition 10|Standard CHRP Intervention Components, Information Processing Components, and Attention Components
62554481|NCT05669534|EXPERIMENTAL|Condition 11|Standard CHRP Intervention Components, Memory Components, and Attention Components
62554482|NCT05669534|EXPERIMENTAL|Condition 12|Standard CHRP Intervention Components, Information Processing Components, Memory Components, and Attention Components
62554483|NCT05669534|EXPERIMENTAL|Condition 13|Standard CHRP Intervention Components, Executive Functioning Components, and Attention Components
62749510|NCT06607419|EXPERIMENTAL|Blinatumomab|Patients in this group should receive Blinatumomab
62749511|NCT02251561|EXPERIMENTAL|FID 109182|Senofilcon A contact lens pre-soaked in FID 109182 worn in the right or left eye as randomized for 2 hours
62749512|NCT02251561|ACTIVE_COMPARATOR|Opti-Free Plus|Senofilcon A contact lens pre-soaked in Opti-Free Plus worn in the fellow eye for 2 hours
62749513|NCT02076308|EXPERIMENTAL|Electroacupuncture|Electroacupuncture and physical therapy
62749514|NCT02076308|SHAM_COMPARATOR|Sham-electroacupuncture|Sham-electroacupuncture and physical therapy
62749515|NCT05947565|ACTIVE_COMPARATOR|Group 1|Invasive urodynamic study will be performed firstly in sitting position. Then, repeated in standing position.
62375021|NCT04344015|OTHER|Convalescent Plasma Donation|The goal of this study is to identify individuals who have previously been infected with COVID-19 and collect plasma from those who meet inclusion criteria for convalescent plasma donation. This protocol will allow for the collection, manufacturing, and storage of convalescent plasma that may be administered to patients with COVID-19 in the near future. In addition, it allows for testing of SARS-COV-2 antibody titers in the plasma that has been collected to inform studies assessing outcomes for patients currently infected with COVID-19 who have received convalescent plasma infusions.
62375022|NCT03793270||patients|"1. Group 1: 30 diseased with Early Rheumatoid Arthritis from 6months to 1 year).~drugs described in the clinic."
62554484|NCT05669534|EXPERIMENTAL|Condition 14|Standard CHRP Intervention Components, Executive Functioning Components, Attention Components, and Information Processing Components
62554485|NCT05669534|EXPERIMENTAL|Condition 15|Standard CHRP Intervention Components, Executive Functioning Components, Attention Components, and Information Processing Components
62554486|NCT05669534|EXPERIMENTAL|Condition 16|Standard CHRP Intervention Components, Executive Functioning Components, Attention Components, Information Processing Components, and Memory Components
62749516|NCT05947565|ACTIVE_COMPARATOR|Group 2|Invasive urodynamic study will be performed firstly in standing position. Then, repeated in sitting position.
62749517|NCT05067023|EXPERIMENTAL|MRI scan|All participants will undergo 1 DCE-MRI scan before surgery or puncture.
62375023|NCT03793270||patients 2|2. Group 2: 30 diseased with late/chronic Rheumatoid Arthritis. drugs described in the clinic.
62554487|NCT05711420|EXPERIMENTAL|Gamification method group|"The group to be trained by gamification method; A gamification application was made every week. Points are given in the table prepared for those who are successful in weekly participation in gamification, coming to the lesson with their homework done, participating in the discussions in the lesson, and in the evaluation at the end of the lesson. Every week, the winner was given a gift. At the end of the lesson, the points in the headings of Leaderboard, Badge and Status, which are the elements of the gamification method, were added weekly. And in the last week, a meeting was held with the students according to all scores and a post-test was applied."
62554488|NCT05711420|EXPERIMENTAL|Flipped learning group|"Before the study, videos were found each week that lecture on the relevant subject, videos were shot on the subject, and the videos were transferred to the students via a platform. At the end of each video, they were told to complete the homework on the subject and come to the lesson.~In the lesson, the lesson was processed with activities according to the videos."
62554489|NCT05711420|NO_INTERVENTION|Control group|Lessons were taught with traditional learning method.
62554490|NCT05714878|EXPERIMENTAL|Prehabilitation arm|Patient receives prehabilitation intervention including exercise, nutrition and psychological support.
62554491|NCT05714878|NO_INTERVENTION|Control arm|Patient receives regular care recommended by the WHO without supervision and support.
62749518|NCT02687685|EXPERIMENTAL|Skin to skin contact immediate|At birth, the baby will be placed and dried on the breast of his mother where thermoregulation manoeuvres will be applied and once the cord clamping procedure has taken place; the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least one hour or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, it will be allowed again after these interventions. During immediate SSC, mother and baby receive continuous monitoring by the health staff
62749519|NCT02687685|ACTIVE_COMPARATOR|skin to skin contact early|At birth, the baby will be dried and placed on the abdomen and chest of his mother where thermoregulation manoeuvres are applied once there is an indication that the cord clamp procedure has been completed. At this time the baby will go to the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby who has 60 minutes of life, will proceed with the initiation of SSC for at least one hour or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC the mother and baby will receive monitoring by health personnel
62554492|NCT02666261||Breast Cancer Pathology Samples|Data on the epidemiology and HER2 testing of breast cancer will be collected from pathology routine diagnostics.
62375024|NCT03793270||healthy donors|3. Group 3: 30 healthy controls. No drugs.
62749520|NCT01796119|EXPERIMENTAL|Ridge Splitting|"Dental implants placed using ridge splitting technique. To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length."
62749521|NCT01796119|ACTIVE_COMPARATOR|Implants placed using drilling technique|"Dental implants placed in the ridge with sufficient thickness using drilling technique.~To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length."
62554493|NCT02561117|ACTIVE_COMPARATOR|q8h|Metronidazole given every 8 hours
62554494|NCT02561117|EXPERIMENTAL|q24h|Metronidazole given once daily
62554495|NCT06370611|ACTIVE_COMPARATOR|Early mobile health intervention|ICURA app and sensor-based technology, individualized training plan, and weekly calls from a physiotherapist in addition to standard care
62554496|NCT06370611|NO_INTERVENTION|Control|Standard care consists of physiotherapy group education of about 10-15 minutes regarding mobilization, respiratory therapy, and sternal precautions after surgery. After surgery, phase I in-hospital rehabilitation consists of respiratory therapy, mobilization from supine and sitting position, and walking down a corridor. Prior to discharge, all patients are encouraged to undertake daily walks and resume activities of daily living, and engage in recommended moderate physical activity (Borg's scale 12-14). All patients are referred to CR in their municipality.
62554497|NCT01081327||Patients receiving Warfarin|
62554498|NCT04020523|EXPERIMENTAL|Patient with an injected breast MR exam|
62554499|NCT00784108|OTHER|Diagnostic tool|Modulated Imaging measure effect of Photodynamic therapy treatment
62554500|NCT00784108|OTHER|Photodynamic therapy|Modulated Imaging measure effect of Photodynamic therapy treatment
62554501|NCT03586089|EXPERIMENTAL|Phenobarbital|Patients will receive a single dose of phenobarbital (7.5 mg/kg of ideal body weight, IV) in addition to usual therapy.
62554502|NCT03586089|PLACEBO_COMPARATOR|Placebo|Patients will receive an inactive placebo (IV).
62554503|NCT03003195|EXPERIMENTAL|Vaccination: P10s-PADRE/MONTANIDE ISA 51 VG|100mL vaccination on Weeks 1, 2, 3 and 8
62554504|NCT05616793|EXPERIMENTAL|Dose Group 1|A single, unilateral, subretinal injection of low dose (1E10 vg/eye) OPGx-001 is injected into two LCA5 adults (18 yo or above) in a sentinel fashion. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, a subsequent LCA5 adolescent (13-17) may be treated in a sentinel fashion, with a unilateral, subretinal injection of OPGx-001. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, two remaining adolescents (13-17) are eligible to be treated with a single, unilateral, subretinal injection of a low dose of OPGx-001. Total cohort size is 5 (2 adults and 3 adolescents).
62554505|NCT05616793|EXPERIMENTAL|Dose Group 2|A single, unilateral, subretinal injection of an intermediate dose (3E10 vg/eye) OPGx-001 is injected into two LCA5 adults (18 yo or above) in a sentinel fashion. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, a subsequent LCA5 adolescent (13-17) may be treated in a sentinel fashion, with a unilateral, subretinal injection of OPGx-001. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, two remaining adolescents (13-17) are eligible to be treated with a single, unilateral, subretinal injection of an intermediate dose of OPGx-001. Total cohort size is 5 (2 adults and 3 adolescents).
62554506|NCT05616793|EXPERIMENTAL|Dose Group 3|A single, unilateral, subretinal injection of high dose (1E11 vg/eye) OPGx-001 is injected into two LCA5 adults (18 yo or above) in a sentinel fashion. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, a subsequent LCA5 adolescent (13-17) may be treated in a sentinel fashion, with a unilateral, subretinal injection of OPGx-001. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, two remaining adolescents (13-17) are eligible to be treated with a single, unilateral, subretinal injection of a high dose of OPGx-001. Total cohort size is 5 (2 adults and 3 adolescents).
62554507|NCT04834609|EXPERIMENTAL|Injection with adipose tissue|Injection of freshly collected autologous adipose tissue
62749522|NCT06243939|EXPERIMENTAL|Education|24-26 weeks for pregnant women diagnosed with gestational diabetes mellitus. A total of motivational interviews will be held for 4 weeks with the pregnant women. Personal Information Form, Health Management Self-Efficacy Scale and Quality of Life Scale will be administered before the motivational interview, and the Health Management Self-Efficacy Scale and Quality of Life Scale will be administered at the end of the motivational interview.
62375025|NCT05444829|EXPERIMENTAL|specific screw holes locating surgical guide and pre-bent plates|Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the pre-bent plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa.
62375026|NCT05444829|OTHER|classical reduction and fixation|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
62554508|NCT03229226||2016 OPPE|All faculty participating in yearly ongoing professional Practice evaluation were eligible for enrollment
62554509|NCT05411146|EXPERIMENTAL|[14C]-etrumadenant|Participants will receive a single dose of \[14C\]-etrumadenant.
62749523|NCT06243939|NO_INTERVENTION|Control|24-26 weeks for pregnant women diagnosed with gestational diabetes mellitus. Personal Information Form, Health Management Self-Efficacy Scale and Quality of Life Scale will be applied to the pregnant patient.
62749524|NCT02349607|EXPERIMENTAL|PF-05089771 300 mg|
62749525|NCT02349607|EXPERIMENTAL|PF-05089771 300 mg + pregabalin 300 mg|
62749526|NCT02349607|PLACEBO_COMPARATOR|Placebo|
62375027|NCT01437059|ACTIVE_COMPARATOR|ALN-PCS02|
62749527|NCT02349607|ACTIVE_COMPARATOR|pregabalin 300 mg|
62749528|NCT02349607|ACTIVE_COMPARATOR|ibuprofen 600 mg|
62749529|NCT01732939||AT|Docetaxel 75 mg/m2, day 1 or paclitaxel 175mg/m2 day 1 plus Epirubicin 75 mg/m2, day 1 or doxorubicine 50mg/m2 day 1 for 6-8 cycles
62749530|NCT01732939||AT-NP|docetaxel 75mg/m2,day 1 or paclitaxel 175mg/m2,day 1 plus doxorubicine 50mg/m2,day 1 or epirubicin 75mg/m2, day 1,for3-4 cycles then switch to vinorelbine 25mg/m2, day 1 and day 8 plus cisplatinum 75mg/m2, day 1 for 3-4 cycles
62749531|NCT05579301||PSP patients|Patients with PSP according to the inclusion and exclusion criteria
62749532|NCT05579301||healthy controls|age-matched healthy controls according to the inclusion and exclusion criteria
62749533|NCT03341364|EXPERIMENTAL|ACT group treatment|Participants receiving the ACT-based group therapy.
62749534|NCT03341364|ACTIVE_COMPARATOR|ACT individual|Participants receiving individual ACT-based therapy.
62749535|NCT00686985|EXPERIMENTAL|A|
61986379|NCT05953454|EXPERIMENTAL|Individual Pain Neuroscience Education|"A single one-on-one face-to-face session of approximately 60-80 minutes provided through active participation. Five key domains will be structured from the Fear and Belief Avoidance Questionnaire that will serve as a guide for the sessions through a Powerpoint presentation. In addition, participants will be encouraged to be active by walking for 20-30 minutes 3-5 times a week and will be taught an exercise to improve transverse abdominis activation (abdominal corset or follow-through).~With the main ones, a brochure will be delivered and informative capsules will be made to which the participants will have access (5 videos of 15 minutes, one per domain). Participants will be instructed to record on a calendar the days they read the brochure and/or reviewed the information capsules to assess treatment compliance and for each domain invent a metaphor or script for how they would explain it to another person. This activity must be delivered in the second evaluation."
62749536|NCT06607029|ACTIVE_COMPARATOR|the opioid-based control group|
62749537|NCT06607029|EXPERIMENTAL|the opioid-free anaesthesia group|
62749538|NCT01530035|ACTIVE_COMPARATOR|soccer training intervention|
61986380|NCT05953454|NO_INTERVENTION|Control|no intervention
62375028|NCT01437059|PLACEBO_COMPARATOR|Sterile Normal Saline (0.9% NaCl)|
62375029|NCT02196090|EXPERIMENTAL|Single arm|Study uses the single case series design with only one arm. All participants in the one arm will have procedures with treatment as usual (Exposure and Response Prevention) alternating with procedures including the vagal maneuver (Cold Face Gel Mask).
62749539|NCT01530035|OTHER|strength training intervention|
62749540|NCT01530035|NO_INTERVENTION|control group|elderly men with no change in daily activities
62749541|NCT01530035|NO_INTERVENTION|active soccer control group|veteran soccer players with a 40 year history of continues soccer playing
62749542|NCT04601428|EXPERIMENTAL|Investigational Arm|
62749543|NCT01897350||CMR following ST segment myocardial infarction|
62749544|NCT05979220|EXPERIMENTAL|Dalpiciclib combined with Letrozole|"Dalpiciclib combined with Letrozole,28 days as one cycle.~1. Dalpiciclib: 150 mg (p.o.) was given once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~2. Letrozole: 2.5mg, p.o., once a day, continuous administration."
62749545|NCT04036474|EXPERIMENTAL|Smoking Prevention Education Program|In addition to the lecture on the hazards of smoking, students received the SPEP intervention. The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. The SPEP intervention was delivered to participants in their usual classroom setting, during school hours combined with relevant school subjects such as physical education class. The duration of SPEP intervention took approximately one month.
62749546|NCT04036474|NO_INTERVENTION|Control|Immediately after the collection of baseline data, students received a one-time lecture on the hazards of smoking by the research assistant.
62749547|NCT02582073|PLACEBO_COMPARATOR|Placebo (0.5ml)|Six 0.5ml injections of placebo consisting of L-Tyrosine, Ph. Eur 2%
62749548|NCT02582073|PLACEBO_COMPARATOR|Placebo (1.0ml)|Six 1.0ml injections of placebo consisting of L-Tyrosine, Ph. Eur 2%
62749549|NCT02582073|EXPERIMENTAL|Grass MATA MPL (0.5ml) 5100SU|Six 0.5 mL injections sequentially of placebo, placebo, 300, 800, 2000 and 2000 SU of Grass MATA with 50 µg/0.5 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 5100SU).
62749550|NCT02582073|EXPERIMENTAL|Grass MATA MPL (1.0ml) 10200SU|Six 1.0 mL injections sequentially of placebo, placebo, 600, 1600, 4000 and 4000 SU of Grass MATA per 1.0 mL and 50 µg/1.0 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 10200 SU).
62749551|NCT02582073|EXPERIMENTAL|Grass MATA MPL (1.0ml) 18200SU|Six 1.0 mL injections sequentially of placebo, 600, 1600, 4000, 4000, 4000 and 4000 SU of Grass MATA per 1.0 mL and 50 µg/1.0 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 18200 SU).
62554510|NCT05626842|EXPERIMENTAL|Single-arm|Single-arm real-world evaluation with a matched control group from comparable GP practices
62554511|NCT03511027|EXPERIMENTAL|Intervention (SME + Karie Device)|Patients randomly assigned to receive SME+Karie will 1) undergo Screening for Self Medication Readiness to determine self-management capacity, 2) will receive self-medication education (SME) by a study Occupational Therapist, and 3) receive a 5-day self-medication performance assessment by an Registered Nurse prior to discharge. In addition, this group will receive orientation to the Karie Automated Medication Delivery by the study Occupational Therapist. The participants in the intervention arm will use the Karie device for all applicable medications for the study duration.
62554512|NCT03511027|ACTIVE_COMPARATOR|Control (SME only)|"West Park has a Self-Medication Education Program policy in place which seeks to establish independent medication self-medication capacity during the inpatient stay. Eligibility criteria for SME include a need to manage medications independently at home; stabilized on medication (as per pharmacist/physician discretion); and mild-moderate cognitive/physical impairments (as per an OT assessment). During SME participants receive training by an Occupational Therapist, followed by a 5-day self-medication performance assessment by an Registered Nurse prior to discharge. Participants in the SME group will fill prescriptions as usual for the duration of study."
62554513|NCT01547390|EXPERIMENTAL|Aspirin|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first
62554514|NCT01547390|PLACEBO_COMPARATOR|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
62554515|NCT03774355|EXPERIMENTAL|CG1801|Dosing 'CG1801' followed by dosing 'CGL1802'
62554516|NCT03774355|EXPERIMENTAL|CGL 1802|Dosing 'CGL1802' followed by dosing 'CG1801'
62554517|NCT04211831|EXPERIMENTAL|Cohort 1: URO-902 24 mg; Placebo|Participants will receive either a single treatment of URO-902 24 milligrams (mg) or matching placebo.
62554518|NCT04211831|EXPERIMENTAL|Cohort 2: URO-902 48 mg; Placebo|Participants will receive either a single treatment of URO-902 48 mg or matching placebo.
62554519|NCT04101409|EXPERIMENTAL|DAs group|Shared decision making using decision aids
62554520|NCT04101409|NO_INTERVENTION|Control group|Standard oral explanation guided with booklets
62554521|NCT00249431|PLACEBO_COMPARATOR|Placebo and Relapse Prevention|Patients will be treated with Relapse Prevention Therapy plus placebo
62554522|NCT00249431|ACTIVE_COMPARATOR|Sertraline and Relapse Prevention|Patients will be treated with Relapse Prevention Therapy plus Sertraline.
62554523|NCT04359147|ACTIVE_COMPARATOR|Yohimbine|10 mg
62554524|NCT04359147|ACTIVE_COMPARATOR|Hydrocortisone|10 mg
62554525|NCT04359147|ACTIVE_COMPARATOR|Yohimbine + Hydrocortisone|10 mg each
62554526|NCT04359147|PLACEBO_COMPARATOR|Placebo|
62554527|NCT01261897|ACTIVE_COMPARATOR|Adductor-Canal-Blockade with Ropivacaine|
62554528|NCT01261897|PLACEBO_COMPARATOR|Adductor-Canal-blockade with saline|
62554529|NCT04362670|EXPERIMENTAL|OTX-CSI-Cohort 1|Formulation 2A-.36 mg
62554530|NCT04362670|EXPERIMENTAL|OTX-CSI-Cohort 2|Formulation 1- .36 mg
62749552|NCT02582073|ACTIVE_COMPARATOR|Grass MATA (0.5ml) 5100SU|Six 0.5ml injections sequentially of placebo, placebo, 300, 800, 2000 and 2000 SU of Grass MATA adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 5100SU).
62749553|NCT01611363|EXPERIMENTAL|Part A|Ipragliflozin (low dose) \& Placebo
62749554|NCT01611363|EXPERIMENTAL|Part B|Ipragliflozin (high dose)
62749555|NCT01182805|OTHER|Single arm study.|
62554531|NCT04362670|PLACEBO_COMPARATOR|HV|"Cohort 2:~Formulation 2B"
62554532|NCT04362670|EXPERIMENTAL|OTX-CSI- Cohort 2|Formulation 2A- .36 mg
62554533|NCT04362670|PLACEBO_COMPARATOR|HV-2|"Cohort 2:~Formulation 3"
62554534|NCT03648229|EXPERIMENTAL|SLT|The study eye will undergo 360-degree selective laser trabeculoplasty (SLT), followed, if needed, by repeat 360-degree SLT.
62749556|NCT03520348|EXPERIMENTAL|PRO-167|Dose: a strip approximately 1 cm long, 4 times a day during the period of vigil, in the bottom
62749557|NCT03520348|ACTIVE_COMPARATOR|Corneregel®|Dose: a strip approximately 1 cm long, 4 times a day during the period of vigil, in the bottom of the right eye sac.
62749558|NCT06459089||Group1|The children will select the parent who acoompany theim during anesthesia induction
62749559|NCT06459089||Group 2|The children will select the parent who accompany them dring anesthesia induction and bring their favorite toy also to the operating room.
62554535|NCT03648229|ACTIVE_COMPARATOR|MED|The study eye will receive latanoprost ophthalmic solution 0.005% once daily, followed, if needed, by adjunctive timolol ophthalmic solution 0.5% twice daily. Medications will be provided at no cost to the subject.
62554536|NCT03648229|ACTIVE_COMPARATOR|RX|The study eye will receive latanoprost ophthalmic solution 0.005% once daily, followed, if needed, by adjunctive timolol ophthalmic solution 0.5% twice daily. Medications will be provided by prescription to be obtained at the subject's expense. This represents usual care for glaucoma in Africa and other regions of the world.
62554537|NCT02841501||Candidemia patients|These patients are included in the study after the reception of a positive blood culture for Candida sp.
62554538|NCT02841501||Control patients|"These patients are matched on case patients on the following criteria:~* Age+/-5 years~* length of hospitalisation~* type of ward~* type of surgery for surgical patients~* IGS2 for intensive care patients"
61986381|NCT03630809|ACTIVE_COMPARATOR|Previously enrolled in study or have been previously treated with DC1 Vaccines - Arm A|Participants currently enrolled into arm A will offered randomization into arms C or D. If study participants decline randomization or are ineligible, they will complete study follow up visits as stated in the schedule of events per Arm A.
61986382|NCT03630809|ACTIVE_COMPARATOR|Participants receiving first 3 boosters at 3 month intervals - Arm B|A history and physical exam will be taken at 3-month intervals. Any changes in history or physical condition will be documented. Patient currently enrolled into arm B will offered randomization into arms C or D once finished with arm B. If patients decline randomization or are ineligible, they will complete study follow up visits as stated in the schedule of events per Arm B.
62375030|NCT04120480|EXPERIMENTAL|Testing|Participants randomized to this arm will be sent a kit to collect a genetic sample from a swab of their mouths. The kit will have instructions on how to collect the genetic sample and how to send it in a postage-paid envelope to the testing laboratory (OneOme). OneOme will process the sample and The study pharmacist will scan the results and enter any related information into the participant's KPCO electronic health record. If any changes to the participant's medication(s) are recommended (for example: a dose decrease or increase, stop taking your current medication and start another), the study pharmacist will contact the participant's KPCO prescriber directly to discuss the recommendations. The prescriber may contact the participant to change the participant's medication(s).
62375031|NCT04120480|NO_INTERVENTION|Usual Care|Participants randomized to this arm will NOT be tested. They will receive usual care and the research will not involve study visits or in-person contact.
62375032|NCT03279146|ACTIVE_COMPARATOR|Regimen A|Immediate release tablet Tenofovir exalidex (TXL)
62375033|NCT03279146|EXPERIMENTAL|Regimen B|New Formulation 1 Tenofovir exalidex (TXL)
62375034|NCT03279146|EXPERIMENTAL|Regimen C|New formulation 2 Tenofovir exalidex (TXL)
62375035|NCT03257306|ACTIVE_COMPARATOR|Magnetic double-J ureteric stent|Double-J ureteric stent removed using magnet
62375036|NCT03257306|ACTIVE_COMPARATOR|Standard double-J ureteric stent|Double-J stent removed using cystoscopy
62375037|NCT06098794|EXPERIMENTAL|Sodium Bicarbonate - Placebo|First exercise performance assessment after ingesting sodium bicarbonate. Second exercise performance assessment after ingesting placebo
62375038|NCT06098794|EXPERIMENTAL|Placebo - Sodium Bicarbonate|First exercise performance assessment after ingesting placebo. Second exercise performance assessment after ingesting sodium bicarbonate
62375039|NCT01512329|EXPERIMENTAL|pacing|The pacing self-management program (3 one-on-one sessions weekly for 3 consecutive weeks) focused on teaching the patient to estimate their current physical capabilities prior to commencing an activity. In order to appropriately pace activities (daily activities and exercise bouts), MS patients were learned to estimate their current physical capabilities prior to commencing an activity, keeping in mind the regular fluctuating nature of their symptoms. The activity duration used within the program was less than that reported by the patient so to account for typical overestimations made by the patient. Each activity block was interspersed with breaks, with the length of this break equating to the duration of the activity.
62554539|NCT06582537||Adult carriers of the LAMA2 c.5562+5G>C mutation|
62554540|NCT06582537||Healthy controls|
62554541|NCT05578209|EXPERIMENTAL|Active|"Participants received the intervention of iTBS (The total pulse of every session is 1200 pulses) over bilateral posterior superior temporal sulcus for 4 weeks (5 days/week).~\*iTBS = intermittent theta burst stimulation"
62554542|NCT05578209|SHAM_COMPARATOR|Sham|Participants received the sham intervention of iTBS (sham-coil) over bilateral posterior superior temporal sulcus for 4 weeks (5 days/week).
62554543|NCT05123378|EXPERIMENTAL|Phase 1 Implementation|Campwood District and District 3C begin NCHAP implementation in May 2018.
62554544|NCT05123378|EXPERIMENTAL|Phase 2 Implementation|District 3AB and District 2 begin NCHAP implementation in November 2018.
61986383|NCT03630809|EXPERIMENTAL|Participants receiving 3 booster vaccines at 3-month intervals (+/- 30 days window) - Arm C|A history and physical exam will be taken at 3-month intervals. Any changes in history or physical condition will be documented
61986384|NCT03630809|EXPERIMENTAL|Participants receiving 6 booster vaccines at 3-month intervals (+/- 30 days window) - Arm D|A history and physical exam will be taken at 3-month intervals. Any changes in history or physical condition will be documented.
62554545|NCT05123378|EXPERIMENTAL|Phase 3 Implementation|District 4 begins NCHAP implementation in September 2020.
62554546|NCT05123378|EXPERIMENTAL|Phase 4 Implementation|Owensgrove District and Commonwealth District begin NCHAP implementation in April 2021.
62554547|NCT05123378|EXPERIMENTAL|Phase 5 Implementation|District 1 begins NCHAP implementation in January 2022.
62554548|NCT01644240|EXPERIMENTAL|TD-8954 Dose 1|
62554549|NCT01644240|PLACEBO_COMPARATOR|Placebo|
62554550|NCT01644240|EXPERIMENTAL|TD-8954 Dose 2|
62554551|NCT03264807|ACTIVE_COMPARATOR|D2 lymphadenectomy|Subtotal gastrectomy with D2 lymphadnectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) could be performed in this arm
62554552|NCT03264807|EXPERIMENTAL|D2 and #14v lymphadenectomy|Subtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and lymph node #14v lymphadnectomy could be performed in this arm
62554553|NCT00850811|EXPERIMENTAL|1|
62554554|NCT04789837|EXPERIMENTAL|Cilostazol|Cilostazol 50 mg twice daily plus Celecoxib 200mg capsule
62554555|NCT04789837|PLACEBO_COMPARATOR|Placebo|Placebo tablet twice daily plus Celecoxib 200mg capsule
62554556|NCT01807065|EXPERIMENTAL|Arm A (sipuleucel-T)|Patients receive sipuleucel-T IV over 60 minutes days 22, 36, and 50.
62554557|NCT01807065|EXPERIMENTAL|Arm B (radiation therapy, sipuleucel-T)|Patients undergo external beam radiation therapy in weeks 1-2. Patients also receive sipuleucel-T as in Arm A.
62554558|NCT01956474|OTHER|Theralight crosslinking and Riboflavin|ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using UVA light and the photo- mediator riboflavin
62554559|NCT01728844|ACTIVE_COMPARATOR|beta-tricalcium phosphate alone|beta-tricalcium phosphate alone
62554560|NCT01728844|EXPERIMENTAL|GFeBGS 0.1%|GFeBGS consisting of beta-tricalcium phosphate + 0.1% recombinant human basic fibroblast growth factor (rh-bFGF)
62554561|NCT01728844|EXPERIMENTAL|GFeBGS 0.3%|GFeBGS consisting of beta-tricalcium phosphate + 0.3% rh-bFGF
62749560|NCT02373436|EXPERIMENTAL|Constraint Induced Therapy|"All participants will receive a glove that limits the use of the fingers and wrist, and can be placed by the participant. They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.~The intervention training will consist of 30 minutes of exposure of the transfer package, the interview with the items in the MAL, and 2 hours and 30 minutes with about four task Shaping, which may vary according to the needs of each individual, and Task Practice, standardized to be the same for all individuals."
62749561|NCT02373436|OTHER|Control|They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
62554562|NCT01728844|EXPERIMENTAL|GFeGBS 0.4%|GFeBGS consisting of beta-tricalcium phosphate + 0.4% rh-bFGF
62554563|NCT06581094|PLACEBO_COMPARATOR|Control group|Control group use UCII.
62554564|NCT06581094|EXPERIMENTAL|Test group|Test group use UCII, glucosamine and curcumin.
62554565|NCT06134037||Aminophylline|Patients who received Aminophylline bolus (4 mg/kg) at Burst Suppression occurence during induction of general anesthesia conducted with Eleveld TCI model
62554566|NCT06134037||Not Aminophylline|Patients who did not received Aminophylline bolus (4 mg/kg) at Burst Suppression occurence during induction of general anesthesia conducted with Eleveld TCI model
62554567|NCT01320293|EXPERIMENTAL|Adalimumab 40mg|Adalimumab 40 MG/0.8 ML Subcutaneous Solution \[HUMIRA\] Dose administered every other week for 6 months
62554568|NCT02877225|EXPERIMENTAL|Treatment Sequence 1 : ABAB|Participants will receive 140 milligram (mg) of ibrutinib administered as one IMBRUVICA 140-mg oral capsule (Treatment A) in Period 1, 140 mg of ibrutinib administered as one ibrutinib 140-mg oral tablet (Treatment B) in Period 2, then Treatment A in period 3 and then followed by Treatment B in Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
62554569|NCT02877225|EXPERIMENTAL|Treatment Sequence 2 : BABA|Participants will receive (Treatment B) Period 1, then Treatment A in Period 2, then Treatment B in Period 3 and then followed by Treatment A in Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
62554570|NCT05639582|EXPERIMENTAL|periodontally healthy individuals|50 subject without any periodontal disease
62554571|NCT05639582|EXPERIMENTAL|Stage 1 periodontitis|50 subject diagnosed with stage 1 in the periodontal disease classification
62554572|NCT05639582|EXPERIMENTAL|Stage 2 periodontitis|50 subject diagnosed with stage 2 in the periodontal disease classification
62554573|NCT05639582|EXPERIMENTAL|Stage 3 periodontitis|50 subject diagnosed with stage 3 in the periodontal disease classification
62554574|NCT04940988||See alert|The intervention group refers to medication orders placed by prescribers when practicing in an outpatient department randomly assigned to receive the intervention, which is implementation of the RTPB tool.
62554575|NCT04940988||Do not see alert|The non intervention group refers to medication orders placed by prescribers when practicing in an outpatient department randomly selected to not receive the intervention.
62554576|NCT02020278|EXPERIMENTAL|Tolvaptan|"Participants enrolled in this trial were eligible to receive open-label tolvaptan if they had a clinical need as determined by the investigator and met the eligibility criteria for optional tolvaptan treatment.~Daily dose levels would have included 3.75 milligrams (mg), 7.5 mg, 15 mg, 30 mg, and 60 mg."
62554577|NCT01727752|ACTIVE_COMPARATOR|Surgical decompression|Surgical decompression
62375040|NCT01512329|ACTIVE_COMPARATOR|relaxation|Relaxation therapy (3 one-on-one sessions weekly for 3 consecutive weeks) comprised of education about the role of stress in MS biology, and the opportunities stress management provides to handle this issue. Patients were then taught how to apply stress management techniques like Jacobson relaxation skills, Schultz relaxation skills, visualization, etc.
62375041|NCT04446494|EXPERIMENTAL|Axillary dissection with DEPART technique|In the experimental group, 1 ml (2.5 mg) indocyanine green (ICG) and methylene blue (MB) was intradermally injected into the internal bicipital sulcus of ipsilateral arm. During axillary dissection, the identified arm sentinel nodes were carefully injected with 0.1 ml methylene blue (MB) using a 1-cc syringe with a 32-gauge needle. MB could then flow from the nodes along several lymphatic channels toward the infraclavicular nodes. Subsequent-echelon nodes and lymphatics were identified. Sentinel lymph nodes (SLNs) were removed after the identification of the arm sentinel nodes and the procedure of MB injection. When patients harbored positive SLNs, axillary lymph node dissection (ALND) was performed subsequently. All discernible arm lymphatics and lymph nodes were preserved, except that gross arm lymph nodes (major axis larger than 10 mm or node firm on palpation) were sent for immediate partial frozen section (pFS) to determine their resection during ALND.
62554578|NCT01727752|ACTIVE_COMPARATOR|coflex Interlaminar Technology|Surgical decompression followed by implantation of coflex Interlaminar Technology.
62554579|NCT04529135|EXPERIMENTAL|Dexmedetomidine|IV,0.2\~0.8 µg/kg/hr
62375042|NCT04446494|NO_INTERVENTION|Standard axillary dissection|In the control group (no intervention), ALND was performed with complete resection of at least Berg's levels I and II. Resection of level III was performed only in cases with gross disease in level II and/or III
62375043|NCT00446225|EXPERIMENTAL|A|"Erlotinib (Tarceva)150 mg /day~Patients will receive treatment until disease progression or unacceptable toxicity.~For all practical effects a treatment cycle will be defined as three weeks of continuous treatment with erlotinib"
62554580|NCT04529135|ACTIVE_COMPARATOR|Remifentanil|IV,0.05\~0.2 µg/kg/min
62554581|NCT03985540|EXPERIMENTAL|memory experimental group|Experimental group will receive memory retraining exercises administered on a lab top computer twice a week for 5 weeks.
62554582|NCT03985540|PLACEBO_COMPARATOR|Placebo comparator memory|Placebo controlled group will receive placebo memory retraining exercises administered on a lab top computer twice a week for 5 weeks.
62554583|NCT03985540|EXPERIMENTAL|Processing speed|Processing speed group will receive processing speed training exercises administered on a lab top computer twice a week for 5 weeks.
62554584|NCT03985540|PLACEBO_COMPARATOR|Processing speed placebo|Placebo controlled group will receive placebo processing speed training exercises administered on a lab top computer twice a week for 5 weeks.
62554585|NCT01225250|EXPERIMENTAL|Polydioxanone (PDS) plates|15 subjects will be randomized to receive a caudal septal extension graft using a PDS plated cartilagenous graft
62554586|NCT01225250|OTHER|Non-plated cartilagenous graft|15 subjects will be randomized to receive a cartilagenous caudal septal extension fgraft
62554587|NCT02091856|EXPERIMENTAL|Conventional-CBT (C-CBT)|This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the mindfulness paradigm.
62554588|NCT02091856|EXPERIMENTAL|Religious CBT (R-CBT)|This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the general Christian belief.
62554589|NCT02091856|NO_INTERVENTION|Wait List Control Group (WLCG)|This arm represents the wait-list comparison group.
62554590|NCT05620446|ACTIVE_COMPARATOR|endoscopic managment of sigmoid volvulus|patients are subjected to untwist the volvulus first by endoscopy then one or two days later are subjected to sigmoid colon fixation by endoscopy using 2-shot anchor device
62554591|NCT05620446|NO_INTERVENTION|surgical management of sigmoid volvulus|patients aresubjected for surgical colostomy ( hartman's procedure ) , then later on after 6 weeks , they are subjected for surgical sigmoid fixation or excision either by open or laparoscopic approach
62554592|NCT00370552|EXPERIMENTAL|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|
62554593|NCT00370552|EXPERIMENTAL|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|
62554594|NCT00370552|ACTIVE_COMPARATOR|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|
62554595|NCT00445432|EXPERIMENTAL|DB Adalimumab 40 mg eow|Subjects received double-blind (DB) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the DB treatment period lasting 52 weeks.
62554596|NCT00445432|PLACEBO_COMPARATOR|Placebo eow|Subjects received placebo subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
62554597|NCT00445432|EXPERIMENTAL|OL Adalimumab 40 mg eow|Subjects received open-label (OL) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
62554598|NCT06033391|EXPERIMENTAL|GGOC-AD (GG Obsessive-Compulsive Disorder - Adolescents)|The experimental group will use the GGOC-AD module for 14 days after the first assessment.
62554599|NCT06033391|ACTIVE_COMPARATOR|GGN-AD (GG Neutral - Adolescents)|The control group will use the GGN-AD module for 14 days after the first assessment.
62554600|NCT01068145|EXPERIMENTAL|Very low dose SCH 527123|
62554601|NCT01068145|EXPERIMENTAL|Low dose SCH 527123|
62554602|NCT01068145|EXPERIMENTAL|Medium dose SCH 527123|
62554603|NCT01068145|EXPERIMENTAL|High dose SCH 527123|
62554604|NCT01068145|PLACEBO_COMPARATOR|Placebo to match SCH 527123|
62554605|NCT01068145|EXPERIMENTAL|Low dose SCH 527123 (Part 2)|
62554606|NCT01068145|EXPERIMENTAL|Medium dose SCH 527123 (Part 2)|
62554607|NCT01068145|EXPERIMENTAL|High dose SCH 527123 (Part 2)|
62554608|NCT01068145|PLACEBO_COMPARATOR|Placebo (Part 2)|
62554609|NCT01379157|ACTIVE_COMPARATOR|Conventional arm|Infusion of 0.5 g of imipenem for 0.5 hr every 6 hr for 3-5 days
62554610|NCT01379157|EXPERIMENTAL|Extended infusion arm|Infusion of 1 g of imipenem for 4 hr every 8 hr for 3-5 days
62554611|NCT03219827|EXPERIMENTAL|Patients allergic to wasp venom|"Patient with major allergic reaction to wasp venom.~* Blood samples collection at visit 1, at visit 2 (4 weeks after visit 1), at visit 3 (one year after treatment onset)~* After visit 1, an allergen-specific immunotherapy will be conducted as part of the classical patient care program."
62554612|NCT03219827|EXPERIMENTAL|Patients allergic to penicillin|"Patient with major allergic reaction to penicillin.~- Blood samples collection at visit 1 and at visit 2 (4 weeks after visit 1= end of study, none treatment will be evaluated in this arm)"
62554613|NCT02585414||85 healthy subjects with no history of DES|
62554614|NCT02585414||255 subjects with DES|
62554615|NCT06128408||schizophrenia|
62554616|NCT00795652|EXPERIMENTAL|Distance Treatment|50% randomized to receive Distance Treatment for postpartum depression
62554617|NCT00795652|NO_INTERVENTION|Usual Care Services|50% randomized to receive usual care services for postpartum depression
62554618|NCT02912182|PLACEBO_COMPARATOR|Placebo|Day 1: Intravenous sodium-chloride 2ml Day 2-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
62554619|NCT02912182|ACTIVE_COMPARATOR|Short treatment|Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-3: 10 tablets prednisolone 5 mg Day 4-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
62554620|NCT02912182|ACTIVE_COMPARATOR|Standard treatment|Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-6: 10 tablets prednisolone 5 mg Day 7: 8 tablets prednisolone 5 mg Day 8: 6 tablets prednisolone 5 mg Day 9: 4 tablets prednisolone 5 mg Day 10: 2 tablets prednisolone 5 mg Day 11: 1 tablet prednisolone 5 mg
62749562|NCT02513407|EXPERIMENTAL|Group I (EML)|Participants complete an assessment on knowledge, attitudes, and behaviors at baseline and attend 2 weekday sessions comprised of interactive education segment that is culturally responsive, and based on the community EML program, and topics including: nutrition guideline, nutrition label reading, comparison shopping/grocery store tour, recipe modification and healthy food preparation, eating healthy on a budget, and making healthy choices outside the home (e.g., restaurants) and physical activity over 1 hour led by CHE, a physical activity conducted by Duarte Fitness Centers instructors over 30 minutes, and cooking/taste test demonstration co-led by the CHE and local chef over 30 minutes over 12 weeks. Participants are also prescribed and encouraged to participate in 3 days a week exercise classes (for \> 30 minutes) including salsa, Zumba and other aerobic exercises that are provided at Duarte Fitness Center.
62749563|NCT02513407|ACTIVE_COMPARATOR|Group II (control)|Participants receive a fitness tracker to track their physical activity and be wait listed to receive the intervention during month 10-12.
62554621|NCT00495573||1|HSV-2 seropositive subjects who will receive a 5-day course of acyclovir for treatment of a genital herpes recurrence.
62749564|NCT00364572|PLACEBO_COMPARATOR|1|Two injections of epidural saline 2 weeks apart
62749565|NCT00364572|EXPERIMENTAL|Epidural injection of etanercept|Two injections of epidural etanercept 2 weeks apart
62749566|NCT05223907|EXPERIMENTAL|Group Etomidate|Etomidate will be used for general anesthesia
62749567|NCT05223907|EXPERIMENTAL|Group Propofol|Propofol will be used for general anesthesia
62749568|NCT02192060|EXPERIMENTAL|Test|Using of a suspension containing Triclosan
62749569|NCT02192060|PLACEBO_COMPARATOR|Control|Using of a suspension without Triclosan or other active ingredient
62749570|NCT00328562|EXPERIMENTAL|Iressa and RT|"Iressa plus thoracic RT at the following dose levels:~* Level 1: 42.0 Gy in 10 fractions of 4.2 Gy~* Level 2: 50.4 Gy in 12 fractions of 4.2 Gy~* Level 3: 63.0 Gy in 15 fractions of 4.2 Gy"
62554622|NCT00495573||2|HSV-2 seropositive subjects who will be observed during a genital herpes recurrence but not receive acyclovir.
62554623|NCT00429429|EXPERIMENTAL|Peanut protein solution|Subjects receiving the peanut sublingual peanut protein drops. Sublingual Immunotherapy.
62554624|NCT03583476||CLA triple therapy|Patients with clarithromycin-containing triple therapy
62554625|NCT03583476||MET triple therapy|Patients with metronidazole-containing triple therapy
62749571|NCT02251704|OTHER|Study Group|Subjects 6 months to \<10 years of age enrolled in HDSS catchment areas at the sites participating in the EPI-MAL-002 and EPI-MAL-003 studies of the candidate malaria vaccine RTS,S/AS01E in sub-Saharan Africa.
62554626|NCT03583476||Concomitant therapy|Patients with concomitant therapy
62554627|NCT03583476||Sequential therapy|Patients with sequential therapy
62554628|NCT01972399|EXPERIMENTAL|Laser|A laser will be used to clean out the area around the diseased implant to try to regain bone.
62554629|NCT01972399|ACTIVE_COMPARATOR|Mechanical|Mechanical debridement will be used to clean out the area around the diseased implant to try to regain bone.
62554630|NCT02094417|EXPERIMENTAL|AMG531 (Dose 1)|
62554631|NCT02094417|EXPERIMENTAL|AMG531 (Dose 2)|
62749572|NCT01097642|ACTIVE_COMPARATOR|Ixabepilone|Brand name is Ixempra ®; it is an epothilone B analog used in combination with other chemotherapeutics against cancer.
62554632|NCT02094417|EXPERIMENTAL|AMG531 (Dose 3)|
62554633|NCT02094417|EXPERIMENTAL|AMG531 (Dose 4)|
62554634|NCT03942601|ACTIVE_COMPARATOR|Group 1 - temsirolimus injection|Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1
62554635|NCT03942601|ACTIVE_COMPARATOR|Group 2 - temsirolimus and dexamethasone injection|Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2
62554636|NCT01159730|EXPERIMENTAL|Multiple doses of VB-201|
62554637|NCT01159730|PLACEBO_COMPARATOR|Placebo|
62554638|NCT01602393|EXPERIMENTAL|CHF 5074 1x|oral tablet, multidose
62554639|NCT01602393|EXPERIMENTAL|CHF 5074 2x|oral tablet, multidose
62749573|NCT01097642|EXPERIMENTAL|Ixabepilone plus Cetuximab|Cetuximab, brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor and monoclonal antibody used with Ixabepilone against cancer.
62375044|NCT00446225|ACTIVE_COMPARATOR|B|"4 cycles of Chemotherapy:~Cisplatin / Gemcitabine; Cisplatin /Docetaxel; Carboplatin / Gemcitabine; Carboplatin / Docetaxel.~- Cisplatin plus docetaxel: cisplatin 75 mg/m2 i.v. day 1 and docetaxel 75 mg/m2 i.v.~day 1. Repeat cycles every 3 weeks.~- Cisplatin plus gemcitabine: Cisplatin 75 mg/m2 i.v. on day 1 and gemcitabine 1250 mg/m2 on days 1 and 8. Repeat cycles every 3 weeks.~In the case of patients not eligible for treatment with cisplatin, cisplatin can be replaced by carboplatin. The schedules will be the following:~Docetaxel 75 mg/m2 day 1 and carboplatin AUC = 6 day 1, every 21 days.~Gemcitabine 1000 mg/m2 days 1 and 8 and carboplatin AUC = 5 day 1, every 21 days.~Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given."
62554640|NCT01602393|EXPERIMENTAL|CHF 5074 3x|oral tablet, multidose
62554641|NCT01042769|EXPERIMENTAL|Aleglitazar|
62554642|NCT01042769|PLACEBO_COMPARATOR|Placebo|
62554643|NCT02636517|OTHER|C. Difficile without IBD|Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile
62554644|NCT02636517|OTHER|C. Difficile with IBD|Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile with Inflammatory Bowel Disease
62554645|NCT02574182||Control subjects under 40 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
62554646|NCT02574182||Control subjects over 60 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
62554647|NCT02574182||MCI subjects over 60 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
62554648|NCT03927456|EXPERIMENTAL|SHR6390 + Fulvestrant|Intervention Drug: SHR6390, Fulvestrant
62554649|NCT03927456|PLACEBO_COMPARATOR|Placebo + Fulvestrant|Intervention Drug: Placebo, Fulvestrant
62749574|NCT05658848|EXPERIMENTAL|women cases|
62749575|NCT05658848|NO_INTERVENTION|women control|
62749576|NCT06485973||All Participants|Participants who are involved in the treatment planning of any of the following treatments: filling, root canal treatment, scaling, implant treatment and tooth extraction.
62554650|NCT00956111|EXPERIMENTAL|split-virion, adjuvanted H1N1 vaccine of 7.5 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
62554651|NCT00956111|EXPERIMENTAL|split-virion, adjuvanted H1N1 vaccine of 15 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
62554652|NCT00956111|EXPERIMENTAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
62554653|NCT00956111|EXPERIMENTAL|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
62554654|NCT00956111|EXPERIMENTAL|whole-virion, adjuvanted H1N1 vaccine of 5 μg|100 adults to receive whole-virion, adjuvanted H1N1 vaccine of 5 μg on day 0 and 21.
62554655|NCT00956111|EXPERIMENTAL|whole-virion, adjuvanted H1N1 vaccine of 10 μg|"200 participants: 100 adults to receive whole-virion, adjuvanted H1N1 vaccine of 10 μg on day 0 and 21.~100 elders to receive whole-virion, adjuvanted H1N1 vaccine of 10 μg on day 0 only."
62554656|NCT00956111|PLACEBO_COMPARATOR|Placebo control|100 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
62749577|NCT05887544||Type 2 diabetes|Overall study population. In addition, a subset of volunteer participants (up to 20 participants) will be asked to consume extra portions of fermented dairy products (skyr, ymer and yogurt) 1-2 days before the spot urine sample to be able to validate markers for specific foods.
62749578|NCT01234740|EXPERIMENTAL|Arm I|Patients undergo intracerebral microdialysis during debulking craniotomy or stereotactic biopsy. Beginning 24 hours later, patients receive oral bafetinib twice daily for 1 day. Beginning at least 2 weeks after surgery, patients continue to receive oral bafetinib twice daily in the absence of disease progression or unacceptable toxicity.
62749579|NCT05345574|ACTIVE_COMPARATOR|dexmedetomidine infusion group|dexmedetomidine infusion (loading dose of 1 ㎍/kg over 10 min and continuous infusion of 0.3-0.6 ㎍/kg/h) during the surgery
62749580|NCT05345574|ACTIVE_COMPARATOR|remifentanil infusion group|remifentanil of 0.05 ㎍/kg/h during induction, followed by remifentanil infusion (0.05-0.3 ㎍/kg/h) during the surgery
62749581|NCT03194568|EXPERIMENTAL|Anterior Vertebral Tethering|Subjects receiving Anterior Vertebral Tethering intervention.
62749582|NCT06115486|OTHER|Control Arm / ACSM Guidelines|The control group will follow resistance training guidelines from the American College of Sports Medicine (ACSM) with the goal of promoting hypertrophy
62749583|NCT06115486|EXPERIMENTAL|Experimental Arm / EOC Guidelines|The experimental group will use a regimen that is often used by strength and conditioning coaches to maximize hypertrophy, and is part of the standard regimens at the Exercise Oncology Center (EOC)
62749584|NCT02120300|EXPERIMENTAL|LDV/SOF GT 1 or 4|Participants with chronic genotypes (GT) 1 or 4 HCV infection will receive LDV/SOF for 12 or 24 weeks. Treatment-experienced cirrhotic participants with genotype 1 HCV infection will receive LDV/SOF for 24 weeks.
62749585|NCT02120300|EXPERIMENTAL|SOF+RBV 12 wks GT 2|Participants with chronic genotype 2 HCV infection will receive SOF+RBV for 12 weeks.
62749586|NCT02120300|EXPERIMENTAL|SOF+RBV 24 wks GT 3|Participants with chronic genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
62749587|NCT06562660|EXPERIMENTAL|Smoking group|In the Smoking group, the HFNC was performed after the patient lost spontaneous breathing until the end-tidal oxygen concentration reached 95 %. record the patient 's safe apnea time.
62749588|NCT06562660|NO_INTERVENTION|never smoking|no intervention
62749589|NCT06606678|EXPERIMENTAL|excercise|supervised excercise training; twice a week for 12 months
62749590|NCT00503776|ACTIVE_COMPARATOR|Arm IA|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
62749591|NCT00503776|ACTIVE_COMPARATOR|Arm IB|Patients undergo SNT and low weight resistance training (LWRT).
62749592|NCT00503776|EXPERIMENTAL|Arm IIA|Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.
62749593|NCT00503776|EXPERIMENTAL|Arm IIB|Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.
62749594|NCT03478475|EXPERIMENTAL|Vitamin D group|The vitamin D group received three times per week a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada)
62749595|NCT03478475|PLACEBO_COMPARATOR|Placebo group|The placebo group received three times per week a tablet containing microcrystalline cellulose (66.3%), starch (33.2%), and magnesium stearate (0.5%), per serving.
62749596|NCT03183323|EXPERIMENTAL|Telerehabilitation|In addition to optimal medical treatment: 3 months of twice weekly group-based telerehabilitation through a video-conferencing on a tablet platform. In addition access to instruction videos for further self-training through the same platform and throughout the whole 2-year period. Electronic devices to trace activity.
62749597|NCT03183323|NO_INTERVENTION|Standard care|In addition to optimal medical treatment: Advice on physical activity. Electronic devices to trace activity.
62749598|NCT06607614||Prospective cohort|All FIT+ patients of participating centers that are active in the CRC regional screening programs, with follow up colonscopies scheduled according to the developed scoring system.
62749599|NCT01357135||Metformin + Sitagliptin|Participants taking metformin + sitagliptin (Januvia®/Xelevia®) as prescribed in routine clinical practice.
62749600|NCT01357135||Metformin + Sulfonylurea|Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride.
62749601|NCT01357135||Sitagliptin +/- Other Antihyperglycemic Medication|Participants taking sitagliptin +/- other antihyperglycemic medication (other than metformin) as prescribed in routine clinical practice. These other antihyperglycemic medications could include: insulin, glinides, sulfonylurea, glitazone, an alpha-glucosidase inhibitor, or combinations thereof.
62749602|NCT04715802||PAAG removal + Immediate implant reconstruction|Patients who had a one-stage operation comprising gel removal and immediate breast reconstruction.
62749603|NCT04715802||PAAG removal + Delayed implant reconstruction|Patients who had a two-stage operation comprising gel removal and delayed breast reconstruction at least 3 months later. The first included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.
62749604|NCT04715802||PAAG removal + No breast reconstruction|Patients who only underwent surgical PAAG removal without breast reconstruction.
62749605|NCT04715802||PAAG removal + Delayed autologous fat grafting reconstruction|Patients who underwent a two-stage operation comprising surgical PAAG removal and autologous fat injection at least 3months later. Usually, the amount of transplanted fat was 150-200mL/side. A multilayer and multi-tunnel injection method was commonly used.
62749606|NCT04715802||PAAG removal + breast reconstruction with implants|Patients who underwent surgical PAAG removal with immediate or delayed implant breast reconstruction.
62749607|NCT04715802||Primary breast augmentation with implants|Patients who had undergone conventional breast augmentation(BA) with implants during the study period who matched the study cohort by age(±5 years).
62749608|NCT01478685|EXPERIMENTAL|Arm A: CC-486 plus Carboplatin|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability. Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
62749609|NCT01478685|EXPERIMENTAL|Arm B: CC-486 plus ABI-007|"CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability~ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m\^2"
62375045|NCT01487928|EXPERIMENTAL|Human Milk Cream Group|For infants randomized to the human milk cream group, the human milk (either mother's own or donor) being provided to the infant will be tested each time a new container is used to prepare feedings. The test will be for the caloric content of the milk using a commercially available device provided for this purpose. If the caloric level falls below 20 kcal/oz for any test, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. The amount added will be calculated to the nearest mL rounding down for 0.1-0.4mL and up for 0.5-0.9 mL to avoid imprecision due to the measuring device used in the nutrition preparation area.
62554657|NCT03288064|EXPERIMENTAL|Corinthian currant supplementation|Corinthian currant supplementation: 1.5 g CHO/kg BW prior to exercise
62554658|NCT03288064|EXPERIMENTAL|Glucose supplementation|Glucose drink (Top Star 100, Esteriplas, Portugal) supplementation: 1.5 g CHO/kg BW prior to exercise
62554659|NCT03288064|PLACEBO_COMPARATOR|Water ingestion|Water ingestion: 7 ml/kg BW prior to exercise
62554660|NCT01610492|EXPERIMENTAL|Cohort 1|10mg/kg belimumab intravenous (IV) administered at weeks 0 and 2, and then every 4 weeks, over a 24-week treatment period, resulting in a total of 8 doses, and will be assessed for the primary endpoint at week 28. Subjects will then enter the long term phase of the study and receive 10mg/kg belimumab every 4 weeks until week 100,or until they have been in complete remission for at least 3 months, resulting in up to 27 doses.
62554661|NCT02312414|NO_INTERVENTION|IVIR|Patients given IV iron (Sodium ferric gluconate, \[125 mg/100 ml\] from week 1 to week 4
62554662|NCT02312414|EXPERIMENTAL|IVIR Carnitine|Patients given Carnitine (20mg/kg, IV) perior to IV iron (Sodium ferric gluconate, \[125 mg/100 ml\] from week 4 to week 8.
62554663|NCT01264510|OTHER|patients implanted with a Bone-anchored hearing aid(Baha)|
62554664|NCT00302653|EXPERIMENTAL|1|Rasburicase 0,20mg/Kg/Day once a day 3-7 days
62554665|NCT04018651|EXPERIMENTAL|PrEP Master Adherence Intervention|The intervention consists of an introductory session and 4 individual sessions led by the PrEP Master, over an 8 week period. Between the sessions, the PrEP Master will conduct weekly check-in calls to participants to encourage adherence and assist with difficulties. During the weekly check-in, side effects and their impact will be assessed using assessment measures.
62554666|NCT06103578||Non-smoker periodontitis|
62749610|NCT01478685|EXPERIMENTAL|Arm C: CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
62375046|NCT01487928|NO_INTERVENTION|Control Group|For infants randomized to the Control group, human milk and human milk derived fortifier will be provided according to the institutional standard of care and there will be no use of the milk analysis (mother's own or donor), which is typical for the vast majority of neonatal intensive care units.
62749611|NCT02690428|EXPERIMENTAL|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
62749612|NCT05720858|EXPERIMENTAL|Hospital group|A total of 36 sessions (3 days a week) will be applied. Training intensity will be performed at the level of 4-6 according to the modified Borg scale, and rest will be allowed between exercises according to the tolerance of the patients. In the hospital-based group, a supervised aerobic exercise program will be applied in the hospital. There will be warm-up exercises before the exercise and cool-down exercises after. At the beginning of the session, warm-up exercises will begin. Flexibility exercises will be applied during the warm-up period. Warm-up and cool-down exercises will be performed for 10 minutes with 3 repetitions, including the upper and lower extremities and distal joints. Exercises will be performed for 3 months, with 10 repetitions in the first 6 weeks and 15 repetitions in the next 6 weeks.
61986385|NCT02809690|EXPERIMENTAL|Diagnostic (18F-FMAU PET/CT)|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT on day 1. Patients then undergo standard of care multiparametic MRI and standard of care transrectal ultrasound-guided biopsy.
62375047|NCT01528618|EXPERIMENTAL|gemcitabine and cisplatin|gemcitabine 1,000 mg/m2 over 30 to 60 minutes on days 1, 8, and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
62375048|NCT01528618|ACTIVE_COMPARATOR|5-Fluorouracil and cisplatin|5-Fluorouracil 4,000 mg/m2 CIV over 96 hours and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
62375049|NCT00662285|OTHER|A: Niferex|100 mg Fe++
62554667|NCT06103578||Smoker periodontitis|
62554668|NCT06103578||Control|
62554669|NCT01068483|EXPERIMENTAL|BKM120|Dose escalation followed by dose expansion
62554670|NCT03732963|PLACEBO_COMPARATOR|Placebo (Group P)|Group P: 20 patients will receive a placebo tablet preoperatively.
62554671|NCT03732963|ACTIVE_COMPARATOR|Melatonin (Group M)|Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
62554672|NCT03443531|EXPERIMENTAL|TCM|Patients in this group will receive two types of TCM treatment, which are Bufei Huatan granule, Yifei Qinghua granule. The herbal extract twice daily for 24 weeks for lower dosage. The two granules are corresponding to the two traditional Chinese syndromes in sequence, which are syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung, Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung.
62375050|NCT05454241|EXPERIMENTAL|anti-CD7 UCAR-T cells|
62554673|NCT03443531|PLACEBO_COMPARATOR|placebo TCM|Patients in this group will be given two placebo TCM treatment, which are which are placebo Bufei Huatan granule, placebo Yifei Qinghua granule, corresponding to the two traditional Chinese syndromes in sequence, which are syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung, Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung.
62554674|NCT01850134|PLACEBO_COMPARATOR|Control Study Product|1 serving of control beverage.
62749613|NCT05720858|EXPERIMENTAL|Telerehabilitation group|"A total of 36 sessions (3 days a week) will be applied. Training intensity will be performed at the level of 4-6 according to the modified Borg scale, and rest will be allowed between exercises according to the tolerance of the patients. Supervised sessions will be held with the telerehabilitation group via phone or computer video conference (For patients who agree to participate, the physiotherapist will initially conduct the first session face-to-face).~There will be warm-up exercises before the exercise and cool-down exercises after. At the beginning of the session, warm-up exercises will begin. Flexibility exercises will be applied during the warm-up period. Warm-up and cool-down exercises will be performed for 10 minutes with 3 repetitions, including the upper and lower extremities and distal joints. Exercises will be performed for 3 months, with 10 repetitions in the first 6 weeks and 15 repetitions in the next 6 weeks."
62749614|NCT05720858|NO_INTERVENTION|Control group|They will continue their routine activities. After the study, those who wish will be included in the exercise program.
62749615|NCT06307522|EXPERIMENTAL|MRG-001 (0.005 mL/kg)|Lowest dose of dose-escalation arm
62749616|NCT06307522|EXPERIMENTAL|MRG-001 (0.007 mL/kg)|Intermediate dose of dose-escalation arm
62375051|NCT05346380|EXPERIMENTAL|During Minimally Invasive Pulmonary Segmentectomy (Group 2)|
62554675|NCT01850134|EXPERIMENTAL|Experimental Study Product|1 serving of a nutritional supplement for people with diabetes.
62375052|NCT05346380|EXPERIMENTAL|During Minimally Invasive Esophagectomy (Group 1)|
62375053|NCT00865202|EXPERIMENTAL|L-Tryptophan|L-tryptophan supplementation (1 gram enterally three times per day) starting post-operatively and continuing for a maximum of 9 doses or the time of discharge from ICU (whichever occurs first)
62375054|NCT00865202|PLACEBO_COMPARATOR|Placebo|Similar appearing placebo administered post-operatively (1 enterally three times per day) for a total of nine doses or discharge from ICU (whichever occurs first)
62554676|NCT01542814||Fujifilm 3Dimensional Mammography|Group of subjects being given Fujifilm 3D Mammography Imaging
62554677|NCT01542814||2D FFDM|Group of Subjects receiving FujiFilm or other FDA Approved 2D Mammography Imaging
62554678|NCT05933044||Durvalumab cohort|All stage III non-small cell lung cancer (NSCLC) patients who received durvalumab
62554679|NCT05933044||Non-durvalumab cohort|All stage III non-small cell lung cancer (NSCLC) patients who did not receive durvalumab
62554680|NCT01029743||Group 1|
62554681|NCT01029743||Group 2|
62375055|NCT01879475|EXPERIMENTAL|032-11|032-11 topical haemostat.
62554682|NCT04837144|EXPERIMENTAL|Intervention Group|The Intervention Group will receive 9 physical rehabilitation sessions using the MAK device. Each session will consist of approximately 90 minutes.
62749617|NCT06307522|EXPERIMENTAL|MRG-001 (0.01 mL/kg)|High dose of dose-escalation arm
62375056|NCT01879475|ACTIVE_COMPARATOR|Floseal (R)|Floseal(R) topical haemostat
62749618|NCT05121220|EXPERIMENTAL|fixed mandibular lingual rectangular retainer 0.673 x 0.268 mm|0.673 x 0.268 mm 8-stranded wire Bond A Braid (Reliance Orthodontic Products, USA) will be bonded in mandible canine to canine on each tooth using Filtek flowable composite (Ivoclar Vivadent, Lichtenstein) and Multilink adhesive (3M, USA).
62375057|NCT06049628|EXPERIMENTAL|FIFA 11+ group|The experimental group will apply FIFA 11+ training 3 times a week for 9 weeks.
62375058|NCT06049628|ACTIVE_COMPARATOR|control group|The control group members will be advised to continue their routine warm-up program 3 times a week for 9 weeks.
62567348|NCT06242431|ACTIVE_COMPARATOR|Group serratus posterior superior intercostal plane block (SPSIPB)|SPSIPB; The procedure will be carried out with the patient in the lateral decubitus position. After gently shifting the scapula laterally, the US probe is held sagittally at the upper corner of the scapula, and the 3rd rib and serratus posterior superior muscle are visualized. The block needle will be advanced in the cranio-caudal direction to enter between the serratus posterior superior and the 3rd rib. After confirming the block site, 30 ml of 0.25% concentration of marcaine (bupivacaine) will be used.
62567349|NCT05941507|EXPERIMENTAL|LCB84 monotherapy|IV infusion Q3W
62749619|NCT05121220|EXPERIMENTAL|fixed mandibular lingual round retainer 0.40 mm|0.40 mm round 6-stranded wire (Forestadent, Germany) will be bonded on 6 mandibular frontal teeth, canine to canine on each tooth using Filtek flowable composite (Ivoclar Vivadent, Lichtenstein) and Multilink adhesive (3M, USA).
62749620|NCT05121220|ACTIVE_COMPARATOR|removable mandibular retainer|Group without fixed retainer will be wearing removable thermoplastic vacuum-formed Essix retainer
61986386|NCT03311659|EXPERIMENTAL|dTpa group|Healthy female and male subjects with age 4 years and above and who received a single dose of Boostrix vaccine at Day 1.
62375059|NCT06218628|EXPERIMENTAL|Dose Level -1|0.25 mg (PO, QD) Talazoparib (Days 1-7) 200 mg (PO, BID) Pacritinib (Day 1-28, Lead in dosing of Pacritinib day -7 for the first cycle of treatment)
62375060|NCT06218628|EXPERIMENTAL|Dose Level 1|0.25 mg (PO, QD) Talazoparib (Days 1-14) 200 mg (PO, BID) Pacritinib (Day 1-28, Lead in dosing of Pacritinib day -7 for the first cycle of treatment)
62375061|NCT06218628|EXPERIMENTAL|Dose Level 2|0.5 mg (PO, QD) Talazoparib (Days 1-14) 200 mg (PO, BID) Pacritinib (Day 1-28, Lead in dosing of Pacritinib day -7 for the first cycle of treatment)
62375062|NCT06218628|EXPERIMENTAL|Dose Level 3|0.75 mg (PO, QD) Talazoparib (Days 1-14) 200 mg (PO, BID) Pacritinib (Day 1-28, Lead in dosing of Pacritinib day -7 for the first cycle of treatment)
62375063|NCT06218628|EXPERIMENTAL|Dose Level 4|1 mg (PO, QD) Talazoparib (Days 1-14) 200 mg (PO, BID) Pacritinib (Day 1-28, Lead in dosing of Pacritinib day -7 for the first cycle of treatment)
62375064|NCT01212120||All patients|All patients
62375065|NCT02142712|ACTIVE_COMPARATOR|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
62749621|NCT06162663|EXPERIMENTAL|Suvorexant with information on sleep hygiene|Participants randomized to this arm will receive 10 mg of suvorexant daily with a dose increase to 20 mg after day 7. Medication will be administered as an oral medication. Total duration of 28 days.
62375066|NCT02142712|ACTIVE_COMPARATOR|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
62375067|NCT02142712|EXPERIMENTAL|Dextromethorphan|"Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care.~If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration."
62375068|NCT02142712|EXPERIMENTAL|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
62375069|NCT01017666|EXPERIMENTAL|Rosiglitazone 8mg PO|Cohort 1
62554683|NCT04852523|EXPERIMENTAL|18F fluciclovine Administration|"* Initial normal standardized uptake values (SUV) of the pancreas, liver, and blood pool will be obtained from 50archived previous 18F-Fluciclovine studies, as there are no normal ranges in the literature. This will be done by retrospective medical record review after a waiver of consent/authorization is obtained from the local IRB.~* Informed consent will be obtained from 10 patients with pancreatic allografts, and each will undergo an 18F-Fluciclovine study. These patients will not be suspected of having current rejection or allograft dysfunction. Timing of 18F-Fluciclovine PET/CT scans will be planned to coincide with standard-of-care imaging studies and laboratory tests.~* The 18F-Fluciclovine study will be compared with the patients' standard-standard-of-care US and/or CT with the assessment of ease of visualization of the pancreatic allograft."
62554684|NCT03772717|EXPERIMENTAL|Non-invasive vagus nerve stimulation (nVNS)|Participants will use the electrical neuromuscular stimulator device, VitalStim 400, which has been used in previous clinical studies for modulation of pain and has received FDA approval. Participants will also continue to take their standard of care medication.
62554685|NCT04827498||Myocardial ischemia without obstructive coronary stenosis|
62749622|NCT06162663|PLACEBO_COMPARATOR|Placebo with information on sleep hygiene|Participants randomized to this arm will receive 10 mg of suvorexant daily with a dose increase to 20 mg after day 7. Medication will be administered as an oral medication. Total duration of 28 days.
62749623|NCT06561880|EXPERIMENTAL|Triple Regimen Induction Including Gilteritinib, Venetoclax and Azacitidine|Patients will receive 2 courses of induction with a triple regimen therapy consisting of Gilteritinib, Venetoclax, and Azacitidine. Patients who achieved complete remission will receive 3 courses of intermediate-dose cytarabine for consolidation. After consolidation therapy, dose-adjusted triple regimen therapy including Gilteritinib, Venetoclax, and Azacitidine will be applied for 6 courses as maintenance treatment.
62749624|NCT02626234|EXPERIMENTAL|INC280|
62749625|NCT01476189|EXPERIMENTAL|Experimental paracetamol formulation|test formulation
62749626|NCT01476189|ACTIVE_COMPARATOR|Marketed paracetamol|Marketed paracetamol
62749627|NCT01476189|ACTIVE_COMPARATOR|Higher dose marketed paracetamol|higher dose marketed paracetamol
62749628|NCT05295901|EXPERIMENTAL|experimental group|"In the pre-test phase (first interview) - Patient Diagnosis Form, COPD Self-efficacy Scale, Chronic Disease Care Assessment Scale-Patient Form, COPD Assessment Test (CAT), Modified Medical Research Council (mMRC) Dyspnea Scale average 15-20 min. will be implemented.~After the pre-test, the mCOPD mobile application will be installed on the phones of the patients and it will be checked whether the mobile application is working. mobile application content will be explained. In addition, a pulse oximeter device will be given to the patients by the researcher to record their pulse and saturation values and its use will be explained.~In the final test phase (final interview); The COPD Self-Efficacy Scale, the Chronic Disease Care Assessment Scale-Patient Form, the COPD Assessment Test (CAT), the Modified Medical Research Council (mMRC) Dyspnea Scale and the Satisfaction Questionnaire will be applied to determine the degree of satisfaction"
62749629|NCT05295901|NO_INTERVENTION|control group|"In the pre-test phase (first interview); Patient Diagnosis Form, COPD self-efficacy scale, Chronic Disease Care Assessment Scale-Patient Form, COPD Assessment Test (CAT), Modified Medical Research Council (MRC) Dyspnea Scale will be applied. No action will be taken after the interview.~In the final testing phase (final interview); After applying the COPD Self-Efficacy Scale, the Chronic Disease Care Assessment Scale-Patient Form, the COPD Assessment Test (CAT), the Modified Medical Research Council (MRC) Dyspnea Scale, the mCOPD application will be installed on their phones and training"
62749630|NCT06457776||Antiresorptive Drugs|Patients treated by means of Antiresorptive drugs due to either bone metastasis or metabolic diseases
62375070|NCT01017666|EXPERIMENTAL|Midazolam 2mg PO, Warfarin 25mg PO|Cohort 2
62375071|NCT06200870||aortic valvular sclerosis group|
62554686|NCT04040556||anesthesia residence|anesthesia residences who currently study in the department of Anesthesia and voluntarily enrolled into the study
62749631|NCT05804513|PLACEBO_COMPARATOR|Placebo, healthy volunteers|Sodium chloride 0.9% solution. Subcutaneous injection administered once.
62749632|NCT05804513|ACTIVE_COMPARATOR|Lixisenatide 10 micrograms, healthy volunteers|Lixisenatide 10 micrograms. Subcutaneous injection administered once.
62749633|NCT05804513|PLACEBO_COMPARATOR|Placebo, type 1 diabetic patients|Sodium chloride 0.9% solution. Subcutaneous injection administered once.
62749634|NCT05804513|ACTIVE_COMPARATOR|Lixisenatide 10 micrograms, type 1 diabetic patients|Lixisenatide 10 micrograms. Subcutaneous injection administered once.
62375072|NCT06200870||non-aortic valvular sclerosis group|
62567350|NCT05941507|EXPERIMENTAL|LCB84 + anti-PD-1|IV infusion Q3W
62567351|NCT02604043|EXPERIMENTAL|supraglottic impendence/pH probe|
62567352|NCT05078892||Adolescents (12-17)|Adolescents 12-17 with Turner Syndrome
62567353|NCT05078892||Parents of Adolescents (12-17)|Parents of Adolescents (12-17)with Turner Syndrome
62567354|NCT05078892||Young Adults (18-25)|Young Adults (18-25)with Turner Syndrome
62567355|NCT05531123|EXPERIMENTAL|Arm1(cCR=cT0, cTa)|
62567356|NCT05531123|EXPERIMENTAL|Arm2 (non-cCR)|
62567357|NCT04465669|ACTIVE_COMPARATOR|Orsiro|Implantation of a Orsiro® biolimus a9 eluting coronary stent (drug-eluting stent, DES)
62567358|NCT04465669|ACTIVE_COMPARATOR|Resolute Integrity|Implantation of a Resolute Integrity® zotarolimus eluting coronary stent (drug-eluting stent, DES)
62567359|NCT03776357|EXPERIMENTAL|Experimental|The application used is build upon the company's category-defining, FDA- cleared Virtual Exercise Rehabilitation Assistant (VERA™) and create a platform that streamlines the performance and management of post-acute care physical therapy. The rehab tool will provide us with functional outcome score.
62567360|NCT02441738|ACTIVE_COMPARATOR|Hybrid Ablation|Epicardial surgical ablation performed thoracoscopically with occlusion/removal of the LAA combined with percutaneous endocardial ablation (one-stage).
62567361|NCT02441738|ACTIVE_COMPARATOR|Catheter Ablation|Percutaneous endocardial catheter ablation, with optional repeated catheter ablation(s).
62567362|NCT04142073||Children under 18 years of age|
62567363|NCT03785522||Tresiba®|Patients with type 2 diabetes in Saudi Arabia are to receive Tresiba® (Insulin degludec) for 26 weeks.
62567364|NCT02641795|EXPERIMENTAL|Experimental|Minimally invasive robotic cochlear implantation with custom device
62567365|NCT04655560||Women living with HIV|
62567366|NCT06088680||Open Label- Glycar Pericardial Patch|patients undergoing cardiovascular repair or reconstruction surgery under standard clinical care with the commercially available Glycar Pericardial Patch.
62567367|NCT00840749|EXPERIMENTAL|CyberKnife Stereotactic Radiotherapy|
62567368|NCT00840749|ACTIVE_COMPARATOR|Surgery|
62567369|NCT03364660|EXPERIMENTAL|Acute Epidural Stimulation for Cardiovascular Stability.|Participants are assessed both with and without epidural stimulation for cardiovascular stability for persistent hypotension, orthostatic hypotension and autonomic dysreflexia.
62567370|NCT03364660|EXPERIMENTAL|Epidural Stimulation for Cardiovascular stability during daily activities|Participants assigned to this arm will receive be randomized to receive epidural stimulation specific for cardiovascular function alone or cardiovascular function and standing, or voluntary movement alone or voluntary movement and standing.
62567371|NCT03364660|EXPERIMENTAL|Voluntary Movement ES + Stand Training|Participants assigned to this group will receive epidural stimulation specific for voluntary movement and will also receive stand training.
62567372|NCT03364660|EXPERIMENTAL|Cardiovascular ES + Stand Training|Participants assigned to this group will receive epidural stimulation specific for cardiovascular function and will also receive stand training.
62567373|NCT03364660|EXPERIMENTAL|Epidural Stimulation for Voluntary Movement|Participants assigned to this group receive epidural stimulation specifically for voluntary movement.
62567374|NCT02382575|ACTIVE_COMPARATOR|Tacrolimus|Tacrolimus: Standard dose with oral Tacrolimus 0.2 mg/kg/day in two divided doses till 6 month of relapse free survival.
62567375|NCT02382575|EXPERIMENTAL|Rituximab|Two to four rituximab infusions (over 2-4 weeks) will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2)depending on circulating B cells level.
62749635|NCT05055388||Group with sepsis complicated with multidrug-resistant bacteria|Obstetrics diagnosed with sepsis were divided to group with sepsis complicated with multidrug-resistant bacteria if microbial culture results showed multidrug-resistance.
62554687|NCT06188221|EXPERIMENTAL|Corticosteroid with Lidocaine|"The group with the lidocaine will get a combined injection with a steroid and lidocaine. The dosages depend on the disease. The steroid dosage will be the same as for the group without lidocaine.~* Trigger finger/De Quervain's tenosynovitis/Tendonitis: 20mg kenalog (0.5mL of kenalog 40mg/mL suspension) + 5mg lidocaine (0,5mL 10mg/mL lidocaine solution)~* Carpal tunnel injections: 6mg betamethasone (1mL of betamethasone 6mg/mL suspension) + 20mg lidocaine (2mL 10mg/mL lidocaine solution)~* CMC/Basal joint arthritis: 3mg betamethasone (0.5mL of betamethasone 6mg/mL suspension) + 5mg lidocaine (0,5mL 10mg/mL lidocaine solution)"
62554688|NCT06188221|ACTIVE_COMPARATOR|Corticosteroid without Lidocaine|"The group without the lidocaine will get an injection with only steroids. The steroid dosage depends on the disease and will be the same as for the group with the lidocaine:~* Trigger finger/De Quervain's tenosynovitis/Tendonitis: 20mg kenalog (0,5mL of kenalog 40mg/mL suspension)~* Carpal tunnel injections: 6mg betamethasone (1mL of betamethasone 6mg/mL suspension)~* CMC/Basal joint arthritis: 3mg betamethasone (0,5mL of betamethasone 6mg/mL suspension)"
62554689|NCT03646994||Cohorts 1|ROS1 fusion positive NSCLC patients who received crizotinib
62554690|NCT02531529|EXPERIMENTAL|D group|intraoperative dexmedetomedine infusion
62554691|NCT02531529|SHAM_COMPARATOR|F group|Intraoperative fentanyl infusion
62749636|NCT05055388||Group with sepsis complicated with none multidrug-resistant bacteria|Obstetrics diagnosed with sepsis were divided to group with sepsis complicated with none multidrug-resistant bacteria if microbial culture results showed none-multidrug-resistance or no positive result of microbial culture.
62749637|NCT02911740|EXPERIMENTAL|Urine LAM Ag test|Patients will be enrolled prospectively and tested for TB using the urine LAM Ag test
62749638|NCT02911740|NO_INTERVENTION|Retrospective arm|Charts of retrospectively selected patients from the Hospital Santo Tomas database who presented within the last five years meeting inclusion criteria will be used as controls
62375073|NCT02572089|EXPERIMENTAL|2mg Intranasal Naloxone|Administer 0.1mL spray of the 20 mg/mL formulation in one nostril
62375074|NCT02572089|EXPERIMENTAL|4mg(a) Intranasal Naloxone|Administer 0.1mL spray of the 20 mg/mL formulation in both nostrils
62554692|NCT04115215|EXPERIMENTAL|Arm 1|Physical exercise (PE)
62749639|NCT04028765|ACTIVE_COMPARATOR|Oral Misoprostol|
62554693|NCT04115215|EXPERIMENTAL|Arm 2|Transcranial current stimulation (tCS)
62554694|NCT04115215|ACTIVE_COMPARATOR|Control|Educational sessions on healthy aging
62554695|NCT03390335|EXPERIMENTAL|Altitude Dive Altitude profile|Subjects are exposed to Pressure profiles (Altitude followed by a Dive with a return to Altitude) and Breathing Gases during dive exposures.
62554696|NCT02277535|EXPERIMENTAL|E-mail intervention|"ICU clinicians caring for patients who have not yet been initiated on nutrition 48 hours after ICU admission will receive a reminder email.~ICU clinicians caring for patients who accumulate a caloric deficit greater than 4000 calories or 150 g protein deficit will receive a feedback email"
62554697|NCT02277535|NO_INTERVENTION|No E-mail intervention|Nutrition status of patients will be assessed but no reminder or feedback emails will be sent
62554698|NCT01458353|EXPERIMENTAL|Handsewn ileocolonic anastomosis|Swabs obtained from patients undergoing handsewn ileocolonic anastomosis
62554699|NCT01458353|EXPERIMENTAL|Stapled ileocolonic anastomosis|Swabs obtained for culture in those patients undergoing stapled ileocolonic anastomosis
62554700|NCT04060056|OTHER|Standardized breakfast|Egg (50g), whole-wheat bread (35g), celery (30g), and dried bean curd (10g)
62554701|NCT04060056|OTHER|Standardized snack|Tomato (50g) and skim milk (200g)
62554702|NCT04060056|OTHER|Standardized lunch|Rice (40g), oats (40g), shrimp (70g), lettuce (80g), lean pork (30g), carrot (10g), soaked auricularia auricula (20g), broccoli (80g), cucumber (10g), tomato egg drop soup (200g), salt (3g), and oil (8g)
62554703|NCT06281951|EXPERIMENTAL|Facial Nebulization|Fentanyl's facial nebulization in healthy volunteers.
62554704|NCT06281951|EXPERIMENTAL|Intranasal|Fentanyl's intranasal inhalation in healthy volunteers.
62554705|NCT00344448|EXPERIMENTAL|Raptiva|At the beginning of the first (week 1) and second (week 13) phases, all patients will receive reduced dose of the study medication determined at 0.7 mg/kg/week. During all the subsequent administrations, all patients will receive full dose of the study medication determined at 1 mg/kg/week.
62554706|NCT00344448|PLACEBO_COMPARATOR|placebo|Weekly subcutaneous injection of a placebo (formulated to match the commercial vial of Raptiva in appearance and content except for the active ingredient) for the first 12 weeks of the study.
62554707|NCT02439216|EXPERIMENTAL|Dose 1|Edasalonexent 67 mg/kg/day. Capsules taken by mouth two times per day
62554708|NCT02439216|EXPERIMENTAL|Dose 2|Edasalonexent 100 mg/kg/day. Capsules taken by mouth three times per day
62554709|NCT02439216|PLACEBO_COMPARATOR|Placebo|Matching placebo
62554710|NCT02102854|ACTIVE_COMPARATOR|Standard dose rATG|Standard dose rATG given as daily infusions of 1.5 mg/kg x 4-5 days
62554711|NCT02102854|EXPERIMENTAL|Single dose rATG|Single dose rATG give as 2 consecutive 3 mg/kg IV infusions to be completed over a 24-36 hour duration
62554712|NCT06404918|EXPERIMENTAL|Erector spinae plane group|The patients were placed in lateral decubitus position with the operation site up. The probe was placed vertically 3 cm lateral to the T5 spinous process, and the transverse process was identified as an oval hyperechoic sonographic structure. The needle was introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. 0.5 mL of normal saline was injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. A total of 0.4 mL kg-1 of 0.25% bupivacaine was injected. between the erector spinae muscle and transverse process.
62567376|NCT03622125||1|Patients who apply anti-scorpion venom serum Birmex at the discretion of the attending physician were given vital signs.
62567377|NCT03622125||2|Patients who apply anti-scorpion venom serum Alacramyn at the discretion of the attending physician were given vital signs.
62567378|NCT02755103|EXPERIMENTAL|Women receiving MBRP plus TAU|Women will receive the Mindfulness Based Relapse Prevention (MBRP) plus treatment as usual (TAU less trauma focused group).
62567379|NCT02755103|NO_INTERVENTION|Women receiving TAU|Women will only receive treatment as usual (TAU less trauma focused group).
62567380|NCT02896634||group with inflammation|Selection of samples from biobank with groups with inflammation
62567381|NCT02896634||group with denutrition|Selection of samples from biobank with groups with denutrition
61986387|NCT00668941|EXPERIMENTAL|1|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will receive a continuous regimen of daily teriparatide (20 mcg subcutaneously) for 48 months, in addition to alendronate. Biopsies will be performed at Week 7 or Month 7.5. The participants will then have the option to be followed while taking alendronate alone for 24-48 months.
62749640|NCT04028765|ACTIVE_COMPARATOR|Oxytocin|
62749641|NCT04823702|EXPERIMENTAL|Child-Pugh A (Mild Hepatic Impairment) & Healthy Matched|Administered by subcutaneous injection
62554713|NCT06404918|EXPERIMENTAL|Serratus anterior plane group|Serratus anterior plane block was administered to patient in the supine position with ipsilateral arm abducted to 90°. Under aseptic precautions, linear probe was placed over the midclavicular region in the sagittal plane. Ribs were counted inferiorly and laterally until the fifth rib was identified in midaxillary line. Latissimus dorsi, teres major, and serratus anterior muscles were identified overlying the fifth rib. The intended puncture site was infiltrated with 2 mL of 2% lignocaine, and using ultrasound-guided in-plane approach, the needle was introduced in caudal to cranial direction until the tip was placed between the serratus anterior muscle and external intercostal muscle.
62749642|NCT04823702|EXPERIMENTAL|Child-Pugh B (Moderate Hepatic Impairment) & Healthy Matched|Administered by subcutaneous injection
62749643|NCT04823702|EXPERIMENTAL|Child-Pugh C (Severe Hepatic Impairment) & Healthy Matched|Administered by subcutaneous injection
62749644|NCT05723081||Native Americans|Native Americans / American Indians
62749645|NCT06397937|EXPERIMENTAL|Intervention|The SHIFT intervention team, comprising a community health worker (CHW), community social worker (CSW), and community nurse (CN),will make a first home visit within 72 hours of hospital discharge, and make regular visits to address SDOH barriers identified for each patient, provide individualized counseling, and assist with medication management, risk factor control, and health literacy.
62375075|NCT02572089|EXPERIMENTAL|4mg(b) Intranasal Naloxone|Administer 0.1mL spray of the 40mg/mL formulation in one nostril
62554714|NCT05894837|EXPERIMENTAL|Serplulimab in combination with Regorafenib and hepatic artery bicarbonate infusion|Serplulimab: once every two weeks; Regorafenib: from the first day to the 21th day; hepatic artery bicarbonate infusion: once every four weeks
62554715|NCT04256915|EXPERIMENTAL|CBT-I + Bright Light|n = 50
62375076|NCT02572089|EXPERIMENTAL|8mg Intranasal Naloxone|Administer 0.1mL spray of the 40mg/mL formulation in both nostrils
62375077|NCT02572089|EXPERIMENTAL|Intramuscular Naloxone|Administer 1mL of 0.4mg/mL formulation intramuscularly
62375078|NCT02954861||Cardiac surgery|Patients who develop delirium following cardiac surgery
62554716|NCT04256915|ACTIVE_COMPARATOR|CBT-I + Placebo Light|n = 50
62554717|NCT04256915|NO_INTERVENTION|Wait-list Control|n = 50
62554718|NCT05977023|EXPERIMENTAL|NMDAE|An NMDA enhancer
62554719|NCT05977023|PLACEBO_COMPARATOR|Placebo|Placebo
62554720|NCT05134415|EXPERIMENTAL|Product Use Sequence 1|Period 1 - RELX ENDS tobacco flavor 1 Period 2 - RELX ENDS tobacco flavor 2
62554721|NCT05134415|EXPERIMENTAL|Product Use Sequence 2|Period 1 - RELX ENDS tobacco flavor 2 Period 2 - RELX ENDS tobacco flavor 1
62554722|NCT05134415|EXPERIMENTAL|Product Use Sequence 3|Period 1 - RELX ENDS menthol flavor 1 Period 2 - RELX ENDS menthol flavor 2
62554723|NCT05134415|EXPERIMENTAL|Product Use Sequence 4|Period 1 - RELX ENDS menthol flavor 2 Period 2 - RELX ENDS menthol flavor 1
62567382|NCT02896634||group with none|Selection of samples from biobank with groups with none
62554724|NCT04842760||No platelet disorders or no HIT|Patients without platelet disorders or without HIT, without anti-PF4/H antibodies, without anti-aggregant treatment.
62554725|NCT04842760||HIT patients with anti-PF4/H antibodies|patients with anti-PF4/H antibodies but for whom HIT was ruled out.
62554726|NCT04842760||platelet dysfunction or HIT|Patients with platelet dysfunction or suffering from HIT
62554727|NCT04999657|ACTIVE_COMPARATOR|Active|Device: Non-invasive low-frequency tibial nerve stimulator
62554728|NCT04999657|SHAM_COMPARATOR|Sham|Device: Non-invasive low-frequency tibial nerve stimulator (same device operation without real current output)
62554729|NCT05352750|EXPERIMENTAL|Dose Level 1|SON-1010 Dose Level 1
62554730|NCT05352750|EXPERIMENTAL|Dose Level 2|SON-1010 Dose Level 2
62749646|NCT06397937|NO_INTERVENTION|Usual Care|All patients will be given standard discharge information, including culturally/racially sensitive stroke education materials for post-stroke care, signs and symptoms of acute stroke, and management of stroke risk factors. Homecare referrals and other rehabilitation services will continue to be provided to discharged patients according to standard-of-care and treating physician referrals. Follow up clinic appointments at 4-6 weeks post discharge will be made with a stroke neurologist per clinical protocol. Thus the only difference between intervention and usual care will be the SHIFT intervention.
62749647|NCT01391780||Group 1|Patients with stress urinary incontinence
62554731|NCT05352750|EXPERIMENTAL|Dose Level 3|SON-1010 Dose Level 3
62554732|NCT05352750|EXPERIMENTAL|Dose Level 4|SON-1010 Dose Level 4
62749648|NCT01391780||Group 2|Patients with urgency urinary incontinence.
62749649|NCT01363921|EXPERIMENTAL|Dialysis treatment with HCO1100|
62749650|NCT06236984||AKI patients|Patients with an indication for the extracorporeal blood treatment suffering from AKI who received CKRT adult mode treatment
62749651|NCT00612417|EXPERIMENTAL|1|recombinant FVIII
62749652|NCT00612417|PLACEBO_COMPARATOR|2|Placebo
62749653|NCT05734001|ACTIVE_COMPARATOR|Conventional Haemostatic Tests|"Conventional Haemostatic Tests:~1. If INR: \> 2.5 FFP will be transfused at 15 ml/kg~2. If Platelet Count is 20,000/mm3-50,000/mm3 RDPC will be transfused at 10 ml/kg~3. If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg"
62749654|NCT05734001|EXPERIMENTAL|ROTEM Based tests|"The second group will undergo ROTEM based correction. ROTEM correction will be based on the following protocol :~1. EXTEM CT \> 80 sec - FFP will be transfused at 15 ml/kg MCF \< 35 mm- Platelet will be transfused at 10 ml/kg~2. FIBTEM MCF \< 7 mm- Cryoprecipitate will be transfused at 5 ml/kg"
62749655|NCT06481228|EXPERIMENTAL|TKI Combined With Chemotherapy and Sequential CAR-T Cells|Ph+ALL patients receiving CAR-T cells as consolidation therapy after achieving complete remission (CR) with overembatinib, venetoclax and reduced-intensity chemotherapy.
62749656|NCT06607601||Exposed|Patients initiating treatment with palbociclib and letrozole as first-line treatment for metastatic ER+/HER2- breast cancer
62749657|NCT06607601||Comparator|Patients initiating treatment with letrozole as first-line treatment for metastatic ER+/HER2- breast cancer
62749658|NCT04089241|EXPERIMENTAL|all cohort|Patients will perform CTA 1 months after the EVAR procedure. Following CTA, an ultrasound examination which will include a 3D reconstruction and CEUS will be performed using SONOVIEW contrast agent. The dimensions and volume of the aorta will be compared to the measurements in CTA using the fusion method. In the case of endoleak type 1 or 3 the patient will be urgently refered to endovascular repair . In the case of endoleak type 2 or a normal exam the patient will undergo another fused exam with CEUS at 6 month . In the case of endoleak type 2 with a growth of more than 1 cm in the aneurysm diameter , the patient will be refered to endovascular repair. In the case of a normal exam or an endoleak type 2 with a shrinkage of 1 cm or more ,the patient will undergo another fused exam with CEUS at 12 months. At any case of a new endoleak type 1 or 3 the patient will undergo CTA.
62749659|NCT03888404||Underlying Cohort|"The study will recruit and follow a prospective cohort of women at risk of pregnancy for one year."
62749660|NCT03888404||Pregnancy Match Cohort, Pregnant Group|Women from the Underlying Cohort who become pregnant will be transferred into the Pregnancy Match Cohort to be followed for two years.
62554733|NCT05352750|EXPERIMENTAL|Dose Level 5|SON-1010 Dose Level 5
62554734|NCT05352750|EXPERIMENTAL|RP2D Expansion|RP2D Dose of SON-1010
62749661|NCT03888404||Pregnancy Match Cohort, Not Pregnant Group|The study will also follow a comparison cohort of non-pregnant women from the Underlying Cohort, frequency matched to the pregnant participants on Desire to Avoid Pregnancy score and time at risk of pregnancy.
62749662|NCT05422365|EXPERIMENTAL|Main Group|"Patients included in the study will receive the intravenous immunoglobulin (IVIG, Bioven), 10% solution for infusion according to the protocol for the use of IVIG in ITP treatment - at a dose of 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.~The next day after the administration of the drug, the patient undergoes blood sampling to determine the level of platelets, the level of immunoglobulin G (IgG), and the Coombs test.~This procedure will also be carried out on days 7, 14, 21, and 28 after the first injection of the drug to monitor the patient's performance."
62749663|NCT03336801|ACTIVE_COMPARATOR|Sevoflurane|Intervention Back surgery and sevoflurane.
62749664|NCT03336801|ACTIVE_COMPARATOR|Propofol|Intervention Back surgery and propofol.
62749665|NCT01772524|EXPERIMENTAL|ALD403|Single IV Dose on Day 0
62749666|NCT01772524|PLACEBO_COMPARATOR|Saline|Single IV infusion on Day 0
62749667|NCT01340625|EXPERIMENTAL|Investigational Test Product|Norethindrone/Ethinyl Estradiol 0.4 mg/35 mcg Chewable Tablets (Teva)
62749668|NCT01340625|ACTIVE_COMPARATOR|Reference Listed Drug|Ovcon® 35 Fe 0.4 mg/35 mcg Chewable Tablets (Warner Chilcott)
62749669|NCT06607653|EXPERIMENTAL|OT grroup|Olfactory training used repeated stimulation of different olfactory substances at high concentrations, combined with odor association and odor identification training, twice in the morning and evening, each time for 5 minutes, for 15 weeks.
62749670|NCT06607653|NO_INTERVENTION|No intervention group|There were only pre-test and post-test without any intervention
62749671|NCT01693341|ACTIVE_COMPARATOR|Care-giver mediated training|Each patient and the caregiver of the intervention group received weekly home training and exercise counseling by a physical therapist about the caregiver mediated home exercise skill for stroke patient. The training program were progress weekly based on the patient's need.
62749672|NCT01693341|NO_INTERVENTION|Standard-care|Maintain the inherent standard-care
62554735|NCT04762004|EXPERIMENTAL|Maternal speech|During the intervention, mothers were asked to speak to their preterm infants in the incubators for 5 min preceding the heel prick procedure and for the subsequent 5 min.
62554736|NCT04762004|EXPERIMENTAL|Maternal singing|During the intervention, mothers were asked to sing to their preterm infants in the incubators for 5 min preceding the heel prick procedure and for the subsequent 5 min.
62554737|NCT04762004|ACTIVE_COMPARATOR|Standard care|During the control condition (without the mother), the newborn was placed by the nurse in the incubator in the standard care conditions recommended for painful procedures (supine position, wrapped and contained by the nest).
62554738|NCT04402411|ACTIVE_COMPARATOR|Control Group|Patients will receive general anesthesia with intravenous opioid
62749673|NCT01537159||Acute Myelogenous Leukemia (AML)|Patients who have been diagnosed with AML
62749674|NCT00561158|EXPERIMENTAL|A|
62749675|NCT00561158|NO_INTERVENTION|2|
62749676|NCT01448785|ACTIVE_COMPARATOR|abiliti Group|Subjects will receive implanted abiliti System. The device will be activated to deliver therapy at implant. Gastric stimulation performance testing, therapy adjustment and dietary/exercise counseling will be conducted at each visit.
62749677|NCT01448785|ACTIVE_COMPARATOR|Gastric Band Group|Subjects will receive an implanted laparoscopic adjustable gastric band. The subjects will have their band adjusted following the standard of care. Dietary/exercise counseling will be conducted at each visit.
62749678|NCT02338895||acutly oliguric patients with ultrasound|Patients with septic shock and acute oliguria that will undergo bedside ultrasonographic assessment of inferior vena caval diameter, respiratory variation and renal perfusion.
62749679|NCT00562497|PLACEBO_COMPARATOR|Placebo|Participants will receive 6 infusions of placebo-matching Prochymal® intravenously (IV) during the first 4 weeks of the study. The first infusion will be administered within 72 hours of the start of systemic corticosteroid therapy. Participants will receive 4 infusions during the first 2 weeks (twice weekly at least 3 days apart), followed by 2 infusions administered once weekly over the subsequent 2 weeks up to Day 28.
62749680|NCT00562497|ACTIVE_COMPARATOR|Prochymal® 2x10^6 hMSC/kg|Participants will receive 6 infusions of Prochymal® 2x10\^6 human mesenchymal stem cells (hMSC)/kg IV during the first 4 weeks of the study. The first infusion will be administered within 72 hours of the start of systemic corticosteroid therapy. Participants will receive 4 infusions during the first 2 weeks (twice weekly at least 3 days apart), followed by 2 infusions administered once weekly over the subsequent 2 weeks up to Day 28.
62749681|NCT03359785|EXPERIMENTAL|Luvadaxistat 500 mg, then Placebo|Participants first received luvadaxistat 500 mg orally once daily (QD) for 8 days during treatment period 1. After a washout of 14 to 21 days, participants then received matching placebo orally QD for 8 days during treatment period 2.
62375079|NCT05780229||Massive Rotator Cuff Tears: Mixed Methodology|"Phase 1: A theoretical sampling of maximum variation was carried out using a segmentation criterion, being the evaluation before or after the treatment in those patients who attended the visit in 5 Spanish hospitals.~Phase 2: A consecutive sample of patients with massive rotator cuff tears, treated with conservative treatment, arthroscopy decompression surgery, or reverse prosthesis in 5 Spanish hospitals."
62554739|NCT04402411|EXPERIMENTAL|Quadratus lumborum|Patients will receive bilateral quadratus lumborum block
62749682|NCT03359785|EXPERIMENTAL|Placebo, then Luvadaxistat 500 mg|Participants first received matching placebo orally QD for 8 days during treatment period 1. After a washout of 14 to 21 days, participants then received luvadaxistat 500 mg orally QD for 8 days during treatment period 2.
62749683|NCT03359785|EXPERIMENTAL|Luvadaxistat 50 mg, then Placebo|Participants first received luvadaxistat 50 mg orally QD for 8 days during treatment period 1. After a washout of 14 to 21 days, participants then received matching placebo orally QD for 8 days during treatment period 2.
62749684|NCT03359785|EXPERIMENTAL|Placebo, then Luvadaxistat 50 mg|Participants first received matching placebo orally QD for 8 days during treatment period 1. After a washout of 14 to 21 days, participants then received luvadaxistat 50 mg orally QD for 8 days during treatment period 2.
62554740|NCT04402411|EXPERIMENTAL|Transversus abdominis plane|Patients will receive bilateral transversus abdominis plane block
62554741|NCT00829725|ACTIVE_COMPARATOR|screws-internal fixation|3-4-screws-internal fixation
62567383|NCT02896634||group with both|Selection of samples from biobank with groups with both.
62567384|NCT06524050|EXPERIMENTAL|Puppet Show and Storytelling Effect among Children with Cancer|puppet show and storytelling interventions
62567385|NCT06524050|NO_INTERVENTION|standard care|standard care
62749685|NCT01326156|EXPERIMENTAL|Avon patellofemoral replacement|Knee arthroplasty with insertion of patellofemoral joint replacement.
62749686|NCT01326156|ACTIVE_COMPARATOR|PFC Sigma CR total knee replacement|Knee arthroplasty with total (tricompartmental) knee replacement.
62749687|NCT05519449|EXPERIMENTAL|Dose Escalation|IV dosing during 21- or 28-day cycles. Dosage per cohort will increase to determine the maximum tolerable dose.
62749688|NCT05519449|EXPERIMENTAL|Backfill Expansion|IV dosing during 21- or 28-day cycles. Subjects will be dosed at levels previously declared tolerable.
62749689|NCT05519449|EXPERIMENTAL|Expansion|IV dosing during 21- or 28-day cycles. Subjects will be dosed at preliminary recommended phase 2 dose (RP2D).
62749690|NCT02833090|OTHER|Group 1|Control group had biomarkers.
62749691|NCT02833090|EXPERIMENTAL|Group 2|Biomarkers
62749692|NCT02833090|EXPERIMENTAL|Group 3|Biomarkers
62749693|NCT02833090|EXPERIMENTAL|Group 4|Biomarkers
62749694|NCT01057576|EXPERIMENTAL|PMI 5011|An experimental group randomized to PMI 5011
62749695|NCT01057576|PLACEBO_COMPARATOR|Placebo|Placebo
62749696|NCT06446856||VR study group|20 patients with depressive disorder
62749697|NCT06446856||VR active control group|20 patients with psychotic disorder.
62749698|NCT06446856||VR healthy control group|20 patients with no psychiatric disorder
62554742|NCT00829725|EXPERIMENTAL|TARGON FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
62567386|NCT03535792|ACTIVE_COMPARATOR|Fentanyl/Hyperbaric Bupivacaine|"Group F:~Patients will receive intrathecal injection of 2 ml of 0.5% hyperbaric bupivacaine plus 1 ml fentanyl (50μg) and will have Tibial internal fixation."
62749699|NCT02882789|EXPERIMENTAL|LCB01-0371 200mg|LCB01-0371 IV 200 mg
62749700|NCT02882789|EXPERIMENTAL|LCB01-0371 400mg|LCB01-0371 IV 400 mg
62749701|NCT02882789|EXPERIMENTAL|LCB01-0371 800mg|LCB01-0371 IV 800 mg
62749702|NCT06346353||Chess players|Chess players who play tournament chess and have a DWZ (deutsche Wertungszahl) and/or ELO rating
62749703|NCT06346353||Non-chess players|Non-chess players or hobby chess players who do not have a DWZ or ELO rating
62749704|NCT06571708|EXPERIMENTAL|Group 1: Gemcitabine/Cisplatin/Cemiplimab|"* Gemcitabine 1000 mg/m\^2 IV (days 1 and 8 of 21 day for 4 cycles)~* Cisplatin 70 mg/m\^2 IV (day 1 of 21 day cycle for 4 cycles) or renally-dosed split-dose -cisplatin 35 m/m\^2 IV (day 1 and 8 of 21 day cycle for 4 cycles)~* Cemiplimab (REGN 2810) 350 mg IV every 3 weeks (17 cycles)"
62749705|NCT06571708|EXPERIMENTAL|Group 2: Gemcitabine/Cisplatin/Cemiplimab/Fianlimab|"* Gemcitabine 1000 mg/m2 IV (days 1 and 8 of 21 day cycle for 4 cycles)~* Cisplatin 70 mg/m2 IV (day 1 of 21 day cycle for 4 cycles) or renally-dosed split-dose cisplatin 35 m/m2 IV (day 1 and 8 of 21 day cycle for 4 cycles )~* Cemiplimab (REGN 2810) 350mg IV every 3 weeks (4 cycles)~* Fianlimab (REGN3767) 1600mg IV every 3 weeks (4 cycles)"
62749706|NCT00621556|EXPERIMENTAL|1|Drug + MR with MRCP
62749707|NCT05617924||Conventional Physiotherapy|Treatment method using physical agents such as analgesic currents and superficial-deep heaters
62749708|NCT05617924||Mechanical Traction|It is a stretching process for the spine with a weight and pulling system for the spine.
62749709|NCT05617924||Nonsurgical Spinal Decompression|Non-surgical spinal decompression is a technique that uses a precision computerized mechanism and opens spinal nerve roots through segmental distraction.
62749710|NCT04849312||Training|A subset of patients that are used to train the machine learning algorithm.
62749711|NCT04849312||Validation|"A subset of patients that are held back and used to validate the algorithm's accuracy."
62749712|NCT04155918|EXPERIMENTAL|AR882/FBX|
62749713|NCT04155918|EXPERIMENTAL|AR882/ALLO|
62749714|NCT05610826|OTHER|Arm 1- Control Arm - Standard Of Care - no peptide receptor radionuclide therapy|Arm 1 is the control arm, which will undergo standard of care cytoreductive surgery (for the tumor). Participants in this arm will not receive peptide receptor radionuclide therapy (PRRT).
62749715|NCT05610826|EXPERIMENTAL|Arm 2 (peptide receptor radionuclide therapy + cytoreductive surgery)|Arm 2 will undergo four cycles of peptide receptor radionuclide therapy (PRRT) before cytoreductive surgery.
62749716|NCT01441908|NO_INTERVENTION|Control Group|Control Group
62749717|NCT01441908|ACTIVE_COMPARATOR|Statin|Receiving Statin
62749718|NCT04850391|ACTIVE_COMPARATOR|Lean-overweight|BMI 18.5 - 30 kg/m2
62749719|NCT04850391|ACTIVE_COMPARATOR|Obese|BMI \> 30 kg/m2
62749720|NCT04850391|ACTIVE_COMPARATOR|Obese OSA|OSAS patients with BMI \> 30 kg/m2
62749721|NCT02684812|ACTIVE_COMPARATOR|Tranexamic Acid|Eligible subjects are randomly assigned to immediate administration of TXA (1 g i.v.) after a diagnosis of SAH, as confirmed by CT-scan of the brain, continued by continuous infusion of 1 g per 8 hours to a maximum of 24 hours after start of medication. A maximum of 4 g TXA (1 g bolus + 3x 1 g continuous infusion) can be administered to one patient.
62749722|NCT02684812|NO_INTERVENTION|Control|Standard care
62749723|NCT01368692|ACTIVE_COMPARATOR|neutral shoulder|neutral shoulder position during subclavian vein catheterization
62749724|NCT01368692|EXPERIMENTAL|shoulder retraction|position of shoulder retraction during subclavian vein catheterization
62749725|NCT01044745|EXPERIMENTAL|Treatment (Rituximab and allogeneic HCT transplant)|"CONDITIONING REGIMEN: Patients receive one of the following conditioning regimens as per the transplant physician: cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive rituximab IV on days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Patients also receive tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.~TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0."
62749726|NCT02782052|EXPERIMENTAL|Nebulized ipratropium bromide|Administration in a random order nebulized ipratropium bromide at V3 or V4 or V5
62749727|NCT02782052|EXPERIMENTAL|Nebulized combination ipratropium bromide with salbutamol|Administration in a random order combination Ipratropium bromide and Salbutamol at V3 or V4 or V5
62749728|NCT02782052|PLACEBO_COMPARATOR|Placebo|Administration in a random order placebo at V3 or V4 or V5
62749729|NCT00875485|EXPERIMENTAL|Twinrix Adult Group|Subjects received 2 doses of Twinrix™ Adult intramuscularly according to a 0, 6 month schedule in the primary study
62749730|NCT00875485|EXPERIMENTAL|Twinrix Junior Group|Subjects received 3 doses of Twinrix™ Junior (= half dose Twinrix™ Adult) intramuscularly according to a 0, 1, 6 month schedule in the primary study
62749731|NCT04151927|EXPERIMENTAL|Normobaric Hypoxia (NH)|Overnight exposure (8 hours) to NH conditions (\~15% oxygen; achieved with nitrogen dilution, equivalent to \~8500 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
62749732|NCT04151927|SHAM_COMPARATOR|Normobaric Normoxia (NN)|Overnight exposure (8 hours) to NN conditions (\~20% oxygen; achieved with nitrogen dilution, equivalent to \~1000 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
62749733|NCT03051412||Current Patellofemoral Pain|This group has current patellofemoral pain
62749734|NCT03051412||Recovered|This group has a previous history of patellofemoral pain, but currently self reports as recovered.
62749735|NCT03051412||Control|This is a control group with no history of knee pain.
62749736|NCT01380535|EXPERIMENTAL|ECP Methoxsalen + Standard of Care|Participants receive methoxsalen administered via ECP in addition to standard of care
62749737|NCT01380535|ACTIVE_COMPARATOR|Standard of Care|Participants receive standard of care only
62749738|NCT01796990|ACTIVE_COMPARATOR|REF group|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
62749739|NCT01796990|OTHER|ACT group|"The ACT group gets the same procedure as the REF group. In addition, they will participate the ACT based program. The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
62749740|NCT06356935|EXPERIMENTAL|Resistance training|Assigned to heavy-load undulating resistance training.
62749741|NCT06356935|ACTIVE_COMPARATOR|Control|Training-as-usual off-season strength and conditioning training, programs provided by respective clubs
62749742|NCT05131867|ACTIVE_COMPARATOR|triple H group|The patients will receive nimodipine (60 mg/4 hours) orally or via nasogastric tube from the first day of admission, then after the diagnosis of vasospasm is confirmed, Triple H therapy (hypertension, hypervolemia and hemodilution) will be started. norepnnephrine (0.01-0.2ug/kg/min) to mentain main arterial blood pressure \>100mmhg and hypervolemia to maintain the CVP around 12---14 mmHg and hemodilution to maintain the haematocrit between 30% and 33%.
62375080|NCT03653585||Lesion negative hemisphere in Healthy Controls (HC)|Data grouped as an un-lesioned primary sensorimotor cortical hemisphere in age and sex matched healthy voluntary participants
62375081|NCT03653585||Lesion negative hemisphere in patients (PT-N)|Data grouped as an un-lesioned primary sensorimotor cortical hemisphere in MS patients
62554743|NCT06365528|EXPERIMENTAL|Tunneled PICC|The intervention group will consist of adult patients who will have PICCs inserted using the catheter tunneling technique. The technique involves the catheter being exteriorized through the skin at a site different from the blood vessel puncture site, thus traversing a subcutaneous tunnel.
62375082|NCT03653585||Lesion positive hemisphere in patients (PT-P)|"Lesion positive hemisphere in patients:~Data grouped as a lesioned primary sensorimotor cortical hemisphere in MS patients"
62375083|NCT06411106|EXPERIMENTAL|Arm|CDLE patients and healthy volunteers In part B of this study, 5 mg imiquimod (100 mg Aldara®) per skin area (in total two skin areas) will be applied for two consecutive days under occlusion.
62749743|NCT05131867|ACTIVE_COMPARATOR|Milrinone group|"The patients will receive oral Nimodipine (60 mg/4) will be given orally or in the gastric tube also from the first day of admission, then after the diagnosis of vasospasm is confirmed, start milrinone bolus of 0.1-0.2 mg/kg followed by 0.75mcg/k/min, if no response after 30min increase the infusion to 1-25mcg/kg/min with maintaining CVP 5:8.~Norepinephrine (0.01-0.2ug/kg/min) is used only to restore the mean arterial pressure (MAP) to its previous values If there was no recurrence of symptoms after 72 h, we decreased the milrinone infusion by 0.25 mcg/kg/min every 24 or 48 h until discontinuation. If there are any recurrent of symptoms of vasospasm, the patients are placed back on the dose they were previously receiving. If required, another Milrinone bolus is administered if the patient's deficits do not revert12."
62554744|NCT06365528|ACTIVE_COMPARATOR|Non-tunneled PICC|The control group will consist of adults patients who will have PICCs inserted using the conventional technique
62554745|NCT06582797|EXPERIMENTAL|treatment withdraw|patient with discontinue standard of care treatment for their HIV infection
62554746|NCT05627843|EXPERIMENTAL|Trial group|Children on regular hemodialysis whose weight 30 kg or above
62749744|NCT00568373|EXPERIMENTAL|Treatement|All subjects that meet the requirement for gastric stimulator placement
62375084|NCT03152175|EXPERIMENTAL|Propranolol Hydrochloride|1mg / kg of propranolol hydrochloride administered as a capsule 60 minutes prior to memory reactivation
62554747|NCT05627843|PLACEBO_COMPARATOR|Placebo group|Children on regular hemodialysis whose weight 30 kg or above
62554748|NCT03198338|EXPERIMENTAL|TAP group|Drug: 0.25% Bupivacaine, 0.5mL/kg
62554749|NCT03198338|SHAM_COMPARATOR|Placebo group|Drug: 0.9% Normal Saline, 0.5mL/kg
62554750|NCT02528773||HIV positive|Persons newly diagnosed with HIV.
62554751|NCT02593617|OTHER|University students who use alcohol|In Addiction Profile Index, university students who use alcohol in last year.
62554752|NCT02593617|OTHER|University students who don't use alcohol|In Addiction Profile Index, university students who don't use alcohol in last year.
62554753|NCT02593617|OTHER|University students who use energy drinks|In energy drink consumption questionnaire, university students who use energy drinks in last year.
62749745|NCT00342550||Pregnant Women|Pregnant women aged 15 and older between 20 and 35 weeks with singleton gestation
62749746|NCT05775549||Retrospective Cohort|Patients with newly diagnosed AOC BRCAwt with known HRD status who have been prescribed 1L olaparib maintenance treatment.
62749747|NCT04487535|OTHER|Standard Total Knee Arthroplasty Surgery|Surgery performed by one orthopedic surgeon
62749748|NCT06174454|EXPERIMENTAL|Inervention group|The intervention group will be subject to RPP. Techniques of slow expiration will be used and slow inspiration for the sweeping of secretions, during its expulsion forced expiratory techniques will be used (tracheal reflex). 10 sessions will be performed, one a day from Monday to Friday, with a duration of 10 to 15 minutes.
62749749|NCT06174454|PLACEBO_COMPARATOR|Control Group|Will be subject to PD plus muscle belly compressions of the upper limbs for 10 sessions, one session a day from Monday to Friday, with a duration de 10 to 15 minutes per patient. Both groups will receive the usual treatment for pneumonia prescribed by their treating doctor.
62749750|NCT05335187|EXPERIMENTAL|micro-macro electrode|In this single-arm, open-label study, all patients receive one or a handful of micro-macro electrode (MME) in place of conventional intracranial EEG electrodes.
62749751|NCT02984150|EXPERIMENTAL|fatty acid|the nutrient that can be widely found in daily food.
62749752|NCT02984150|SHAM_COMPARATOR|saline|saline
62749753|NCT05952011|ACTIVE_COMPARATOR|The first group (A)(Left internal mammary artery diameter before left stellate ganglion block ).|control group
62749754|NCT05952011|ACTIVE_COMPARATOR|The second Group (B)(Left internal mammary artery diameter after left stellate ganglion block )|same group but after intervention
62749755|NCT04219319|EXPERIMENTAL|Experimental: LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor|An open label, multi center, single arm Phase I study to evaluate the safety, tolerability, and efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor.
62749756|NCT04399473||Control group: Usual PT Care|
62749757|NCT04399473||Experimental group: PNE + Usual PT Care|Participants in this arm will receive PNE education in addition to Usual PT Care
62749758|NCT02352272|EXPERIMENTAL|Sleep extension|Subject spend 10 hours Time in bed per day during 6 nights. This period is follow by a total sleep deprivation intervention (i.e. 39 hours awaking) in laboratory.
62749759|NCT02352272|SHAM_COMPARATOR|Habitual sleep|Subject respect their habitual Time in bed during 6 nights. This period is follow by a total sleep deprivation intervention (i.e. 39 hours awaking) in laboratory.
62749760|NCT05643196|EXPERIMENTAL|Pulsed Low-Intensity Focused Ultrasound (PLIFUS), then Sham|Participants will receive PLIFUS sonication on the first intervention visit, then sham sonication on the second intervention visit. Visits will be separated by 1 week. Sonication at both visits will be preceded and followed by fMRI and an exit medical examination. Sonication will be delivered in a pulse pattern over 10 minutes.
62749761|NCT05643196|EXPERIMENTAL|Sham, then Pulsed Low-Intensity Focused Ultrasound (PLIFUS)|Participants will receive sham sonication on the first intervention visit, then PLIFUS sonication on the second intervention visit. Visits will be separated by 1 week. Sonication at both visits will be preceded and followed by fMRI and an exit medical examination. Sonication will be delivered in a pulse pattern over 10 minutes.
62749762|NCT01490736|EXPERIMENTAL|LTS/Vehicle|Within subject control study
62749763|NCT00704483|EXPERIMENTAL|1|1g tid
62749764|NCT00704483|ACTIVE_COMPARATOR|2|Sevelamer HCl
62749765|NCT00704483|EXPERIMENTAL|3|SBR759 1.5 g tid
62749766|NCT00704483|ACTIVE_COMPARATOR|4|Sevelamer HCl
62749767|NCT00904098|EXPERIMENTAL|Frovatriptan|Frovatriptan 2.5 mg oral tablet
62749768|NCT00904098|ACTIVE_COMPARATOR|Usual Care|Usual care includes the current treatment used to treat all episodes of migraine headache
62749769|NCT04895293|EXPERIMENTAL|RBM-007 Injectable Solution - 2.0 mg|Single intravitreal injection in study eye
62749770|NCT02715024|EXPERIMENTAL|Tamsulosin alone|
62749771|NCT02715024|EXPERIMENTAL|Tamsulosin + solifenacin|
62749772|NCT04136327|EXPERIMENTAL|GLPG1972 oral and [14C]-GLPG1972 IV|GLPG1972 film-coated tablet followed by \[14C\]-GLPG1972 solution for infusion
62749773|NCT04136327|EXPERIMENTAL|[14C]-GLPG1972 oral solution|\[14C\]-GLPG1972 oral solution
62749774|NCT03732495|EXPERIMENTAL|Trial arm|"Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.~Study drugs will be continued until a treatment discontinuation criterion is met."
62749775|NCT02239835|EXPERIMENTAL|TPV low dose + RTV low dose|
62749776|NCT02239835|EXPERIMENTAL|TPV high dose + RTV low dose|
62749777|NCT02239835|ACTIVE_COMPARATOR|SQV + RTV high dose|
62749778|NCT03010137|PLACEBO_COMPARATOR|Standard Closure|After surgical closure is complete, the patient receives standard of care operative incision treatment (dermabond/topical skin adhesive).
62554754|NCT02593617|OTHER|University students who don't use energy drinks|In energy drink consumption questionnaire, university students who don't use energy drinks in last year.
62554755|NCT02593617|OTHER|University students who use substance|In Addiction Profile Index, university students who use substance in last year.
62554756|NCT02593617|OTHER|University students who don't use substance|In Addiction Profile Index, university students who don't use substance in last year.
62554757|NCT06405035||patients with resectable gastroesohageal adenocarcinoma|patients with resectable GEA (including Siewert I) which are candidate to receive either peri-op treatments or upfront surgery followed by adjuvant treatments, if recommended.
62554758|NCT02521415|EXPERIMENTAL|ketamine|ketamine (1mg/kg)
62554759|NCT02521415|ACTIVE_COMPARATOR|fentanyl|fentanyl (1.5 micrograms/kg)
62554760|NCT05048329|EXPERIMENTAL|Ileostomy Cohort|The study will include ten eligible patients into the cohort to conduct the study.
62375085|NCT03152175|PLACEBO_COMPARATOR|Placebo|Placebo manufactured as a capsule to mimic 1mg/kg of propranolol hydrochloride administered 60 minutes prior to memory reactivation
62375086|NCT00912639|EXPERIMENTAL|Genexol-PM|"All the patients are recurrent breast cancer after taxane treatment. Patients with a measurable lesion (at least 1 measurable lesion)~1. Spiral CT : lesion ≥ 10mm (unidimension)~2. X-ray, MRI, ultrasound : lesion ≥ 20 mm (unidimension)"
62554761|NCT05015829||Classical low-flow low-gradient aortic stenosis|LVEF\<50% SVi \< 35.0 mL/m2 Aortic mean gradient \< 40 mmHg AVA \< 1.0 cm2.
62554762|NCT05015829||Paradoxical low-flow low-gradient aortic stenosis|LVEF\>50% SVi \< 35.0 mL/m2 Aortic mean gradient \< 40 mmHg AVA \< 1.0 cm2.
62554763|NCT01957514||Ancillary-Correlative (sample collection)|Patients undergo collection of tissue biopsy, blood, buccal swab, saliva, and urine at baseline.
62554764|NCT05024825|EXPERIMENTAL|Gabapentin|Patients in the gabapentin group will receive gabapentin preoperatively, one time dose of 10 mg/kg PO (maximum dose 600 mg) and will resume scheduled doses postoperatively of PO gabapentin, 300 mg PO every 8 hours, in addition to acetaminophen and ibuprofen for 7 days postoperative. Acetaminophen 15mg/kg PO (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; gabapentin, 10 mg/kg standing every 8 hours (22).
62554765|NCT05024825|ACTIVE_COMPARATOR|Hydrocodone|Patients in the hydrocodone group will receive scheduled doses of hydrocodone, acetaminophen and ibuprofen at scheduled doses. Acetaminophen 15mg/kg (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain.
62554766|NCT02493660|EXPERIMENTAL|InSpace implantation|Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation
62554767|NCT02493660|ACTIVE_COMPARATOR|Tendon Repair|Arthroscopic partial repair of rotator cuff
62554768|NCT03623191||Patients with erosive pustular dermatosis of the leg|
62554769|NCT05913544|EXPERIMENTAL|SINTYA group|
62749779|NCT03010137|ACTIVE_COMPARATOR|Incisional Negative Pressure Wound Therapy|After surgical closure is complete, an incisional negative pressure wound therapy device is applied to the incision in its entirety. This device is placed on the wound, sterilely, in the operating room, at the conclusion of the procedure. The incisional negative pressure wound therapy device is to remain in place for 7 days, and is removed in clinic after completion.
62749780|NCT00350363|ACTIVE_COMPARATOR|1 hour gatifloxacin|presence of conjunctival bacteria 1 hour after administration of topical gatifloxacin
62749781|NCT02438384|NO_INTERVENTION|Usual care|Pts will receive education and follow-up based on judgment of emergency provider.
62749782|NCT02438384|EXPERIMENTAL|Video|Patients will watch 10 minute educational video
62749783|NCT02438384|EXPERIMENTAL|Video plus Phone Follow-up|Patients will watch 10 minute educational video and receive phone call follow-up at 3 days to assess pain symptoms. Patients with a pain score of 4 or more will receive another call with advice from a geriatric pain specialist.
62749784|NCT02511834|EXPERIMENTAL|VEST supported|Vein graft supported by VEST
62749785|NCT02511834|ACTIVE_COMPARATOR|Control|Vein grafts unsupported by VEST
62749786|NCT04243577|OTHER|Group A: Conventional Sensors First, Then Experimental (Tele-EaT) Sensors|Group A participants will complete the experimental protocol (swallow trials) with the conventional (commercially available) electrodes/sensors first. After a break of 10 minutes, they then will repeat the exact same experimental protocol (exact same swallow trials) with the experimental sensors (i.e., a wearable surface EMG sensors patch we are developing).
62749787|NCT04243577|OTHER|Group B: Experimental (Tele-EaT) Sensors First, Then Conventional Sensors|Group B participants will complete the experimental protocol (swallow trials) with the experimental sensors (i.e., a wearable surface EMG sensors patch we are developing) first. After a break of 10 minutes, they then will repeat the exact same experimental protocol (exact same swallow trials) with the conventional (commercially available) electrodes/sensors.
62375087|NCT02798640|ACTIVE_COMPARATOR|Active|Subject wearing Celliant garment
62375088|NCT02798640|PLACEBO_COMPARATOR|Control|Subject wearing non-celliant control garment
62554770|NCT05913544|NO_INTERVENTION|Control|
62554771|NCT02462863|EXPERIMENTAL|Immunonutrient treatment|Administration of arginine and fish oil.
62749788|NCT06142513||Grup I|Subjects with obesity hypoventilation syndrome (30 \< body mass index \< 45 kg/m2)
62375089|NCT00440102|ACTIVE_COMPARATOR|1|ketamine
62375090|NCT00440102|ACTIVE_COMPARATOR|2|Etomidate
62375091|NCT00854568|EXPERIMENTAL|CEOP regimen|CEOP regimen
62375092|NCT00854568|ACTIVE_COMPARATOR|CHOP regimen|CHOP regimen
62375093|NCT04602611|NO_INTERVENTION|Standard of Care|Standard of Care
62554772|NCT04442399|EXPERIMENTAL|Intervention|The intervention was based on the WHO-endorsed manual entitled Positive Connections: Leading Information and Support Groups for Adolescents Living with HIV. For Family Connections, a caregiver companion guide was developed. In brief, adolescent/caregiver pairs attended 10 intervention sessions held every other Saturday at their HIV clinic over a six-month period.
62749789|NCT06142513||Grup II|Age and sex-matched obese subjects (30 \< body mass index \< 45 kg/m2) with low risk of obstructive sleep apnea (STOP-BANG score \< 3)
62749790|NCT00760435|EXPERIMENTAL|1|Infliximab plus Intravenous immunoglobulin (IVIG)
62749791|NCT00760435|PLACEBO_COMPARATOR|2|Placebo plus IVIG
62749792|NCT05515588|EXPERIMENTAL|Part A: BI 690517 (C-14)|
62749793|NCT05515588|EXPERIMENTAL|Part B: BI 690517 fasted (test treatment, T) / BI 690517 (C-14) (reference treatment, R)|
62554773|NCT04442399|NO_INTERVENTION|Comparison|The comparison arm consisted of standard of care for adolescents as offered at the HIV clinics.
62554774|NCT05902338|EXPERIMENTAL|Group with music|"L400 Over Ear Music Headset Glowing Cat Ear Headphones 7 branded headphones will be used for music intervention."
62375094|NCT04602611|EXPERIMENTAL|Oncology Nurse Navigation|Standard of Care + Oncology Nurse Navigation
62375095|NCT03209791||Alcoholic Steatosis|This group will have 10 patients with alcoholic steatosis which is milder disease and muscle biopsies will be performed
62375096|NCT03209791||Cirrhosis|This group will consist of 10 patients with cirrhosis. We anticipate a 50% difference in these patients and the controls in the autophagy readouts and muscle biopsies will be performed
62375097|NCT03209791||Steatohepatitis|This group will have 10 patients with alcoholic steatohepatitis that have more severe necroinflammation in the liver but for a shorter duration of illness and muscle biopsies will be performed
62375098|NCT03209791||controls|This group will consist of 10 patients who are healthy and have no liver disease diagnosis and muscle biopsies will be performed
62375099|NCT00579462||1|Patients with advanced lung cancer.
62375100|NCT00339950||1|Asymptomatic women between the ages of 40 and 75 referred to regional military medical centers for routine colorectal screening
62375101|NCT01925482|OTHER|Group 1 -- no history of otitis media|no history of otitis media
62375102|NCT01925482|OTHER|Group 2 --patent tympanostomy tube|at least 1 patent tympanostomy tube
62375103|NCT02033291||Cortical stroke or primary intracerebral hemorrhage patients:|patients who have a clear clinical presentation of either cortical stroke or primary intracerebral hemorrhage confirmed on brain CT. The patients are eligible when the DCE-MRI scans can be performed within 0-6 weeks of the vascular event and on two subsequent days as the vascular permeability may change significantly on the timescale of weeks.
62375104|NCT02033291||cSVD patients|patients who present with a transient ischemic attack (TIA) and cSVD related abnormalities on brain MRI. TIA patients are defined as patients with stroke like symptoms that last no longer than 24 hours. MRI abnormalities include extended white matter lesions, (asymptomatic) lacunar infarcts, microbleeds and enlarged Virchow-Robin spaces. The patients are eligible when the first DCE-MRI scan can be performed 8-12 weeks after the TIA to avoid the acute phase, and the second MRI-scan within four weeks after the first.
62375105|NCT05522543|EXPERIMENTAL|Conventional treatment with manual segmental lumber traction|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• Manual lumbar Traction (L1-L5) for 15-20 sec x5 sets • Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets) • .Core stability exercises (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan"
62375106|NCT05522543|ACTIVE_COMPARATOR|Conventional treatment with passive translatoric intervertebral glides|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets • Core stabilization exercise (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan (bridges, knee to chest, cat and camel stretch and prone press ups"
62375107|NCT06355206||recurrent acute pancreatitis|Recurrent acute pancreatitis is generally defined as a condition in which at least two well documented episodes of acute pancreatitis have occurred, with resolution of symptoms between each episode, and absence of morphological criteria for chronic pancreatitis.
62375108|NCT00038142|EXPERIMENTAL|Arm A: VACdxr With ImmTher|Chemotherapy repeated every 3 weeks for 6 cycles: Vincristine 2.0 mg/m\^2 (max 2.0 mg) intravenous (IV), Doxorubicin 90 mg/m\^2 IV over 30 minutes, Cyclophosphamide 2.0 g/m\^2 IV daily for 2 days. Dexrazoxane 900 mg/m\^2 IV (30 minutes prior to doxorubicin). ImmTher 900 mcg/m\^2 IV over 1 hour every week x 50-52 weeks.
62375109|NCT00038142|ACTIVE_COMPARATOR|Arm B: VACdxr|Chemotherapy repeated every 3 weeks for 6 cycles: Vincristine 2.0 mg/m\^2 (max 2.0 mg) IV. Doxorubicin 90 mg/m\^2 IV over 30 minutes, Cyclophosphamide 2.0 g/m\^2 IV daily for 2 days, Dexrazoxane 900 mg/m\^2 IV (30 minutes prior to doxorubicin).
62554775|NCT05902338|NO_INTERVENTION|Group without music|Music will not be used while performing motor skills.
62554776|NCT04151680||Intermittent anticoagulation|Patients receiving anticoagulation only if continuous electrocardiographic monitoring detects an atrial fibrillation episode
62554777|NCT04151680||Chronic anticoagulation|Patients receiving chronic oral anticoagulation regardless findings at continuous electrocardiographic monitoring
62554778|NCT03561038|ACTIVE_COMPARATOR|Franseen Needle|2 strokes within the mass with Franseen Needle, and then 2 strokes with the Fork-tip Needle
62749794|NCT02985892|EXPERIMENTAL|SSASG|Stabilization and stretching group, 12 session, 60 minutes each. This group will perform stretching for back muscles in different positions, associated with stabilization exercises using a protocol developed by Richardson, 2005.
62749795|NCT02985892|EXPERIMENTAL|SSPSG|Stabilization Group, 12 session, 60 minutes each. This group will perform placebo stretching for upper limb muscles (the muscle is not stretched in it maximum extent) with stabilization exercises, using a protocol developed by Richardson, 2005.
62749796|NCT01913028|EXPERIMENTAL|MEDI9929|Solution of MEDI9929, SC
62749797|NCT01913028|PLACEBO_COMPARATOR|Placebo|Placebo solution for MEDI9929, SC
62749798|NCT04351464|ACTIVE_COMPARATOR|Physical therapy and Reflexology group|Received reflexology implementation for 20-30 minutes on the sole along with the physical treatment involving NDT approaches. Within the scope of the implementation, all the reflex points on the sole were stimulated. The pituitary gland, which is related to sleep and control of salivation, oromotor area and areas of muscular and skeletal system were stimulated with further repetitions.
62749799|NCT04351464|EXPERIMENTAL|Just Physical therapy group|The group received a 45-minute physical therapy program involving NDT approaches as the control group. Within the scope of this program, the children were treated with intramuscular stretching and soft tissue mobilization, exercises that improved balance and that supported the development of postural control, position shifts, and stretching and reinforcement exercises in the necessary muscle groups.
62375110|NCT02110472|OTHER|Presbia Flexivue Microlens Corneal Inlay|Presbia Flexivue Microlens implanted in corneal pocket in nondominant eye
62375111|NCT04851223||Pre Diabetics|
62375112|NCT03304769|NO_INTERVENTION|IV placement no Virtual reality|Patient will have IV placed in traditional manner, with no virtual reality headset
62554779|NCT03561038|ACTIVE_COMPARATOR|Fork-tip Needle|2 strokes within the mass with Fork-Tip needle, and then 2 strokes with the Franseen Needle
62554780|NCT00690066|EXPERIMENTAL|Prochymal|PROCHYMAL®
62554781|NCT00690066|PLACEBO_COMPARATOR|Placebo|Placebo
62554782|NCT02665156|EXPERIMENTAL|Robotic Stapled orthotopic neobladder|Intracorporeal stapled neobladder using robotic staplers: Partly stapled orthotopic neobladder: robotic staplers applied to create the neobladder neck and to suture the left side of the posterior aspect of neobladder. Right side of the posterior aspect of neobladder and the anterior aspect of the neobladder hand sewn.
62554783|NCT03263676|EXPERIMENTAL|Icon reusable underwear|
62554784|NCT03263676|PLACEBO_COMPARATOR|Disposable pad|
62554785|NCT06582199|EXPERIMENTAL|Exploratory group|
62554786|NCT02253004|EXPERIMENTAL|Active|Cilostazol 200 mg single dose
62554787|NCT02253004|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62554788|NCT01772043||Duchenne muscular dystrophy|
62554789|NCT04477291|EXPERIMENTAL|Dose Escalation and Expansion|Dose Escalation and Expansion; CG-806 will be given orally in ascending doses in patients with relapsed or refractory AML or higher-risk MDS (escalation cohort), until the maximum tolerated dose or candidate recommended Phase 2 dose is reached. Followed up by up to 50 patients enrolled in the expansion cohort at the recommended dose.
62554790|NCT04875351||Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Testing|Female patients diagnosed with hormone receptor-positive (HR+), lymph node-negative (LN-) or lymph node-positive (LN+, with 1-3 positive nodes) early-stage invasive breast cancer, who are distant recurrence-free.
62554791|NCT02072980|OTHER|16hrs/15mins|Delefilcon A contact lenses worn bilaterally (in both eyes) for 16 waking hours (1 day) in Period 1, followed by 15 minutes in Period 2. A fresh pair of lenses was dispensed for Period 2.
62749800|NCT06605820||Patients|
62749801|NCT06605820||Healthcare workers|
62749802|NCT03771131|EXPERIMENTAL|Experimental group|Group receiving the multi-domain cognitive training
62749803|NCT03771131|NO_INTERVENTION|Control group|Passive control group
62554792|NCT02072980|OTHER|15mins/16hrs|Delefilcon A contact lenses worn bilaterally for 15 minutes in Period 1, followed by 16 waking hours (1 day) in Period 2. A fresh pair of lenses was dispensed for Period 2.
62554793|NCT00404287|ACTIVE_COMPARATOR|fluvastatin|fluvastatin 80 mg
62554794|NCT00404287|PLACEBO_COMPARATOR|placebo|
62749804|NCT02839447||Normal Semen|"Semen that meet the criteria for normal on sperm number, motility, and morphology as described by the current WHO manual."
62749805|NCT02839447||Abnormal Semen|"Semen that fail to achieve one or more of the criteria for normal on sperm number, motility, and morphology as described by the current WHO manual."
62749806|NCT01988662|EXPERIMENTAL|Ranibizumab|104 patients with an eligible study eye were randomized to be treated with Ranibizumab IVT. 0.5 mg of commercially available Ranibizumab were used for intravitreal injection adminstered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).
62749807|NCT01988662|ACTIVE_COMPARATOR|Aflibercept|101 patients with an eligible study eye were randomized to be treated with Aflibercept IVT. 2.0 mg of commercially available Aflibercept were used for intravitreal injection admistered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).
62375113|NCT03304769|EXPERIMENTAL|IV placement with Virtual Reality|Patient will have IV placed with Virtual Reality headset distraction
62375114|NCT02204111||Control Cluster|Care as usual
62554795|NCT00786214|EXPERIMENTAL|Acupuncture|Patients given acupuncture treatment
62375115|NCT02204111||Treatment Cluster|Care as usual and patient directed, multidimensional treatment proposals
62375116|NCT06371209||Ewing Amputees|Amputees who have previously undergone Agonist-Antagonist Myoneural Interface construction at the trans-tibial level
62375117|NCT06371209||Standard Amputees|Amputees who have previously undergone trans-tibial level amputations without the construction of Agonist-Antagonist Myoneural Interfaces
62375118|NCT04950933|EXPERIMENTAL|Test group|
62375119|NCT04950933|PLACEBO_COMPARATOR|Control group|
62375120|NCT04488991||the woman who has just HPV infection|the woman who is between 30-65 years old, who is participate this research, and has just HPV infection in cervix.
62375121|NCT04488991||the woman who has just nabothian cyst|the woman who is between 30-65 years old, who is participate this research, and has just nabothian cyst in cervix.
62749808|NCT04225676|EXPERIMENTAL|Tisagenlecleucel|"Tisagenlecleucel Cell Dispersion for Infusion given once during the study.~The approved dose range for tisagenlecleucel is: 0.2 to 5.0×106 CAR positive viable T cells / kg for patients' ≤ 50 kg body weight or 0.1 to 2.5×108 CAR-positive viable T cells for patients \> 50 kg body weight."
62554796|NCT00786214|SHAM_COMPARATOR|Sham acupuncture|Patients given sham acupuncture treatment
62749809|NCT02703012|EXPERIMENTAL|Adjustment of ventilator settings by EIT|Individual Adjustment of Ventilator settings using an algorithm based on electrical impedance tomography.
62749810|NCT02199314|EXPERIMENTAL|desflurane MEP's|Transcranial motor evoked potentials are obtained under total intravenous anesthesia (TIVA) and again after desflurane at 3%, for at least 5 minutes.at two different time points. Each subject is his/her own control
62749811|NCT00987428|EXPERIMENTAL|groupe 1|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
62749812|NCT00987428|ACTIVE_COMPARATOR|Groupe 2|usual procedure
62749813|NCT02138305|OTHER|Patients referred for CABG|"* Patients who after undergoing standard of care diagnostic coronary angiography will be referred for CABG~* ComboMap XT Guidewire~* 'SPY' NIRF During CABG"
62749814|NCT06065059|EXPERIMENTAL|Single Agent Dose Escalation|Participants with BRCA 1/2 mutant or HRD+ solid tumors will receive escalating doses of TNG348 to estimate the MTD
62749815|NCT06065059|EXPERIMENTAL|Combination Dose Escalation|Participants with BRCA 1/2 mutant or HRD+ solid tumors will receive escalating doses of TNG348 in combination with olaparib to estimate the MTD
62749816|NCT06065059|EXPERIMENTAL|Single agent dose expansion in breast cancer|Participants with BRCA 1/2 mutant breast cancer will receive TNG348 at the identified RP2D
62749817|NCT06065059|EXPERIMENTAL|Single agent dose expansion in ovarian cancer|Participants with BRCA 1/2 mutant ovarian cancer will receive TNG348 at the identified RP2D
62375122|NCT04488991||the woman who has both nabothian cyst and HPV infection|the woman who is between 30-65 years old, who is participate this research, and has both nabothian cyst in cervix.
62554797|NCT02038257|ACTIVE_COMPARATOR|MKTP with CO2 Laser/Collagen Dressing|Each Subject will have a depigmented patch of skin treated with MKTP using the carbon dioxide laser for de-epithelialization and a collagen dressing for the wound dressing.
62554798|NCT02038257|ACTIVE_COMPARATOR|MKTP with CO2 laser/vaseline gauze|Each subject will have a depigmented patch of skin treated with MKTP using the carbon dioxide laser for de-epithelialization and vaseline impregnated gauze as the wound dressing.
62554799|NCT02038257|ACTIVE_COMPARATOR|MKTP with dermabrasion/collagen dressing|Each subject will have a depigmented patch of skin treated with MKTP using dermabrasion for de-epithelialization and a collagen dressing for the wound dressing.
62554800|NCT02038257|ACTIVE_COMPARATOR|MKTP with dermabrasion/vaseline gauze|Each subject will have a depigmented patch of skin treated with MKTP using dermabrasion for de-epithelialization and vaseline impregnated gauze as a wound dressing.
62554801|NCT01001754|EXPERIMENTAL|PEG-rIL-29 at 120 µg|
62749818|NCT06065059|EXPERIMENTAL|Combination therapy dose expansion in breast cancer|Participants with BRCA 1/2 mutant breast cancer will receive TNG348 in combination with olaparib at the identified RP2D
62749819|NCT06065059|EXPERIMENTAL|Combination therapy dose expansion in ovarian cancer|Participants with BRCA 1/2 mutant ovarian cancer will receive TNG348 in combination with olaparib at the identified RP2D
62749820|NCT06065059|EXPERIMENTAL|Combination therapy dose expansion in pancreatic or prostate cancer|Participants with BRCA 1/2 mutant pancreatic or prostate cancer will receive TNG348 in combination with olaparib at the identified RP2D
62749821|NCT06065059|EXPERIMENTAL|Combination therapy dose expansion in HRD+ advanced or metastatic solid tumors|Participants with HRD+ advanced or metastatic solid tumors will receive TNG348 in combination with olaparib at the identified RP2D
62749822|NCT01818739|EXPERIMENTAL|sentinel lymph node detection|Patients undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue and sentinel lymph node biopsy.
62749823|NCT05627011|EXPERIMENTAL|Clinical Decision Support Tool|Practices assigned to iPOP-UP intervention which involves EHR-based CDS tools refined through a formative evaluation and user-centered design.
62749824|NCT05627011|NO_INTERVENTION|Control|Practices assigned to usual care that will not have access to the iPOP-UP CDS tool but will have access to many opportunities available to all pediatric clinicians nationally around the release of the new American Academy of Pediatrics guidelines for obesity management.
62554802|NCT01001754|EXPERIMENTAL|PEG-rIL-29 at 180 µg|
62749825|NCT03118427|EXPERIMENTAL|Zero-fluoroscopy implantation|Pacemaker implantation performed for all patients in this group with zero-fluoroscopy 3D navigation.
62749826|NCT03118427|ACTIVE_COMPARATOR|Conventional fluoroscopy implantation|Pacemaker implantation performed for all patients with conventional x-ray navigation.
62749827|NCT04271748|EXPERIMENTAL|Time Restricted Feeding|Subjects will be required to fast for 16 consecutive hours daily for 4 weeks. The registered dietitian will provide subjects counseling on the intermittent fasting regimen.
62749828|NCT00099944|EXPERIMENTAL|LAF237 50 mg qd + glimepiride 4 mg qd|LAF237 50 mg qd + glimepiride 4 mg qd
62749829|NCT00099944|EXPERIMENTAL|LAF237 50 mg bid + glimepiride 4 mg qd|LAF237 50 mg bid + glimepiride 4 mg qd
62749830|NCT00099944|PLACEBO_COMPARATOR|LAF237 placebo + glimepiride 4 mg qd|LAF237 placebo + glimepiride 4 mg qd
62749831|NCT04234789|OTHER|Cardiopulmonary exercising test|All patients underwent to diagnostic tests protocol
62375123|NCT02777034|EXPERIMENTAL|Enhanced Recovery|"Preoperative protocols：Multidisciplinary patient information、no bowel preparation、no fasting（drink 10% glucose 1000 at 21：30 night before the surgery）.~Intraoperative protocols：Laparoscopic standardized technique、fluid restriction (max 500 ml/h)、no abdominal drains.~Postoperative protocols：no nasogastric tube、early solid dietary intake and mobilization、urinary catheter removal on postoperative day 1、restrictive fluid management（\<2000ml/d）."
62375124|NCT02777034|OTHER|Unenhanced Recovery|"Preoperative protocols：Patient information、Mechanical bowel preparation、Fasting since midnight before operation.~Intraoperative protocols：Laparoscopic standardized technique、fluid overload (over 500 ml/h) 、place abdominal drains.~Postoperative protocols：no nasogastric tube、mobilization from postoperative day 1、fluids and solids intake after first passage of stool、Urinary catheter removal on postoperative day 2/3、no restrictive fluid management（\>2000ml/d）."
62375125|NCT01228786||Group A|\~ 20 sporadic PHPT patients
62375126|NCT01228786||Group B|\~10 normocalcemic euthyroid patients (control tissue)
62375127|NCT00921570|EXPERIMENTAL|Amlodipine|
62375128|NCT00921570|EXPERIMENTAL|Valsartan|
62375129|NCT00921570|EXPERIMENTAL|Valsartan+Amlodipine|
62375130|NCT05190757||Laryngeal Mask Airway|
62554803|NCT01001754|ACTIVE_COMPARATOR|Peginterferon alfa-2a at 180 µg|
62375131|NCT05190757||Face Mask|
62375132|NCT03973632|EXPERIMENTAL|Group A|Fasting at last 10h before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 1，Feeding with high-fat diet within 30 minutes before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 2. Each cycle is 4 days with a 3-days interval.
62567387|NCT03535792|ACTIVE_COMPARATOR|Nalbuphine/Hyerbaric Bupivacaine|"Group N:~Patients will receive intrathecal injection of 2 ml of 0.5% hyperbaric bupivacaine plus 1ml nalbuphine hydrochloride (1.6 mg); (nalufin 20 mg in 1 ml ampoule, Amoun Pharmaceutical Co. Cairo, Egypt) and will have Tibial internal fixation."
62749832|NCT01349361|EXPERIMENTAL|Daylight-PDT|
62749833|NCT03440736|ACTIVE_COMPARATOR|Secukinumab 300 mg subcutaneous (s.c.)|Patients in arm A received therapy with Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24).
62749834|NCT03440736|EXPERIMENTAL|Secukinumab 300 mg subcutaneous (s.c.) and lifestyle intervention|Patients in arm B received therapy with Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24). In addition they participated in a lifestyle intervention program.
62749835|NCT05540249|EXPERIMENTAL|Group CHO|Patients in Group CHO will orally consume CHO 355ml containing 50 g of carbohydrates 8-12 hours before operation (20:00 -24:00 the evening before operation).
62375133|NCT03973632|EXPERIMENTAL|Group B|Feeding with high-fat diet within 30 minutes before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 1，Fasting at last 10h before taking 200mg（two pills） of SH-1028 tablets on Day 1 of cycle 2. Each cycle is 4 days with a 3-days interval.
62375134|NCT00420212|PLACEBO_COMPARATOR|Placebo|Participants received two placebo capsules orally three times daily (TID)
62375135|NCT00420212|EXPERIMENTAL|BG00012 240 mg Twice Daily (BID)|Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
62375136|NCT00420212|EXPERIMENTAL|BG00012 240 mg 3 Times Daily (TID)|Participants received two 120 mg BG00012 capsules orally three times daily (TID)
62375137|NCT04770025|EXPERIMENTAL|MI with tACS|Motivational interviewing with concurrent active stimulation
62375138|NCT04770025|SHAM_COMPARATOR|MI with sham|Motivational interviewing with concurrent sham stimulation
62554804|NCT03251170|EXPERIMENTAL|Ketamine group|This group of patients will receive: 1 mg/Kg ketamine + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
62375139|NCT04770025|ACTIVE_COMPARATOR|MI-only|Motivational interviewing only, delayed treatment control
62375140|NCT00233324|EXPERIMENTAL|Surfactant and Low Oxygen|Administration of surfactant by endotracheal tube and supplemental oxygen with target saturation of 85% to 89%
62375141|NCT00233324|EXPERIMENTAL|Surfactant and High Oxygen|Administration of surfactant by endotracheal tube and supplemental oxygen with target saturationof 91% to 95%
62375142|NCT00233324|EXPERIMENTAL|CPAP and Low Oxygen|Administration of continuous positive airway pressure (CPAP) and supplemental oxygen with target saturation of 85% to 89%
62375143|NCT00233324|EXPERIMENTAL|CPAP and High Oxygen|Administration of continuous positive airway pressure (CPAP)and supplemental oxygen with target saturation of 91% to 95%
62375144|NCT03592927|EXPERIMENTAL|Order A|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
62375145|NCT03592927|EXPERIMENTAL|Order B|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
62375146|NCT03988790|EXPERIMENTAL|VOC analysis|VOC analysis in exhaled air in patients with severe asthma treated by monoclonal antibody
62375147|NCT06362928|EXPERIMENTAL|Patients with Acute Pulmonary Embolism|Patients undergoing mechanical thrombectomy for acute pulmonary embolism.
62375148|NCT01245127|EXPERIMENTAL|Canakinumab|"* Canakinumab 150 mg (or 2 mg/kg for patients weighing \<40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).~* At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing \<40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing \<40 kg) every 8 weeks beginning at Week 8.~* Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.~* If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks."
62375149|NCT04801355|OTHER|laparoscopic resection|patients with colonic adenomas who will undergo to laparoscopic segmental resection
62375150|NCT04801355|EXPERIMENTAL|full-thickness laparo-endoscopic colon adenomas excision|patients with colonic adenomas who will undergo to laparo-endoscopic full-thickness colon resection
62375151|NCT00011492||1/All Patients|All eligible patients
62375152|NCT00792857|EXPERIMENTAL|CTAP201 Injection at dose a|CTAP201 at dose a
62567388|NCT00142831|EXPERIMENTAL|1|Bupropion-SR, 150 mg/day x 3 days, then 300 mg/day for 13 weeks
62567389|NCT00142831|PLACEBO_COMPARATOR|2|Identical Placebo
62567390|NCT04785482||Parents of infants with single ventricle heart disease|All participants
62375153|NCT00792857|EXPERIMENTAL|CTAP201 Injection|CTAP201 at dose b or dose c
62554805|NCT03251170|ACTIVE_COMPARATOR|Fentanyl|2.5 mg/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
62554806|NCT01268410||acute respiratory failure|
62375154|NCT00792857|ACTIVE_COMPARATOR|Doxercalciferol at dose a|Active at dose a
62375155|NCT00792857|ACTIVE_COMPARATOR|Doxercalciferol|Active at dose b or dose c
62375156|NCT01829867|EXPERIMENTAL|sNN0031|
62375157|NCT04330040|EXPERIMENTAL|Single Arm|Intervention: Drug: Olaparib
62375158|NCT02272244|ACTIVE_COMPARATOR|Standard|SI Group participants will be mailed a set of standard materials. The materials will include a letter from the participant's primary care practice encouraging selection and performance of either (1) colonoscopy screening, or (2) stool blood test (SBT) screening. Accompanying the letter will be instructions for arranging a colonoscopy appointment and instructions for completing an enclosed immunochemical SBT kit. Print materials and contacts will be provided, in both English and Spanish, after the baseline survey. At 45 days following random assignment that encourages screening.
62554807|NCT01392963|EXPERIMENTAL|Botox, Then Placebo|At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).
62749836|NCT05540249|NO_INTERVENTION|Group CTRL|Patients in Group CTRL will consume no food or drink 12 hours before operation (20:00 the evening before operation).
62749837|NCT01969396|EXPERIMENTAL|SonoBiopsy Catheter|
62554808|NCT01392963|EXPERIMENTAL|Placebo, Then Botox|At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).
62554809|NCT05451524|EXPERIMENTAL|Insomnia prevention program|"The preventive program has been developed and modified as based on the evidence-based CBT-I insomnia treatment.~Active intervention group will be conducted in group size with 6-8 subjects who are from the same education level (i.e. secondary vs university). Youths in the intervention group will receive 4 weekly insomnia prevention program conducted by the sleep therapists who has received training in conducting CBT-I under close supervision of sleep experts. Each session will last for about 60-90 mins."
62554810|NCT05451524|ACTIVE_COMPARATOR|General health education|In order to control for placebo effect and other non-specific factors such as contact time, youths in the control group will be provided with group-based general health education with same dosage (4 weeks) as intervention group. Modules will contain information about general well-being, diet, nutrition, and activity. It is expected that this health education will be an active control group to account for most of the non-specific effects including time, attention, therapist, and peer support.
62554811|NCT03517501|ACTIVE_COMPARATOR|ART-123|
62554812|NCT03517501|PLACEBO_COMPARATOR|Placebo|
62554813|NCT04864028|EXPERIMENTAL|Healthy volunteer|
62554814|NCT00682812|ACTIVE_COMPARATOR|1|125 womens with normal cervix
62554815|NCT00682812|OTHER|2|105 womens with an intraepithelial lesion
62554816|NCT00682812|OTHER|3|105 womens with a cancer of the cervix
62554817|NCT04606160|EXPERIMENTAL|Single Session Problem-Solving Intervention|Participants will receive a single session problem-solving intervention during visit 2 of the 4 visit research study. During visit 3, participants will receive a review of the intervention from visit 2. During visits 1, 3, and 4, participants will complete measures.
62749838|NCT01969396|ACTIVE_COMPARATOR|Endometrial biopsy catheter|
62749839|NCT00391469|NO_INTERVENTION|control treatment|
62749840|NCT01368172|EXPERIMENTAL|Physical Activity Guidelines|Participants randomized to this arm received training/guidance on following the physical activity guidelines for adults with spinal cord injury
62749841|NCT01368172|NO_INTERVENTION|Control|
62749842|NCT05964530|EXPERIMENTAL|Watch and wait group|In this group, the patients with clinically complete response will undergo non-surgical treatment (watch-and-wait group)
62749843|NCT05964530|ACTIVE_COMPARATOR|Surgical group|In this group, the patients with clinically complete response will undergo surgical treatment (LAR with anal preservation or APR)
62749844|NCT02597218||Patients following hepatectomy|"Patients following hepatectomy of any type, any gender. Roughly, we will describe: type of resection, presence of cancer,use of mechanical/pharmacological prophylaxis, major/minor bleedings ocurring during observation period.~Outcomes: Venous thromboembolism (VTE)\[deep vein thrombosis (DVT) and pulmonary embolism (PE)\] and portal thrombosis (PT)."
62375159|NCT02272244|EXPERIMENTAL|Decision Support & Navigation|DSNI Group will be mailed print materials, including a letter from the practice on CRC screening, an informational booklet, and instructions for arranging a colonoscopy appointment and for completing an enclosed immunochemical SBT kit. All materials will be provided in both English and Spanish. Within 7 days after this mailing, participants will receive a telephone call from a trained bilingual study navigator. Following the call, the navigator will enter the participant's screening plan into the participant's electronic medical record, send the participant a letter describing the screening plan, and send the participant's primary care provider a copy of that same letter. At 45 days following random assignment, research staff will send participants a reminder letter encouraging the participant's preferred test. At 6 months after randomization, the navigator will send the provider and their office manager a participant CRC screening status report.
62567391|NCT04698395|EXPERIMENTAL|HABIT-ILE|Baby HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) intervention during two weeks
62749845|NCT05906758|ACTIVE_COMPARATOR|Immediate intervention arm|Immediate angiography will be performed within 24 hours of enrollment. Omnipaque contrast will be administered. Serum creatinine will be collected on enrollment, within 6 hours before coronary angiography, and at 24h, 48h and 1-week after the angiography, as expected in common practice. Pre- and post-hydration administration will be at the discretion of the treating physician. In case percutaneous coronary intervention is indicated it will be schedule for 7 days after angiography.
62749846|NCT05906758|PLACEBO_COMPARATOR|Delayed intervention arm|Delayed angiography will be performed after kidney function stabilizes.
62749847|NCT06584331|EXPERIMENTAL|1 dose of beetroot juice|The volunteers will ingest 70 ml of beetroot juice with 400 mg of nitrate every morning for 10 days
62749848|NCT06584331|EXPERIMENTAL|2 doses of beetroot juice|This group will ingest 2 shots of 70 ml of beetroot juice with 400mg of nitrate, in each shot, for 10 days.
62749849|NCT06584331|PLACEBO_COMPARATOR|Placebo|In this group, the participants will receive a low-nitrate beetroot juice dose to consume in the morning.
62749850|NCT05978492|EXPERIMENTAL|Dose-escalation part|TXN10128 will be administered orally once daily.
62749851|NCT01482169|ACTIVE_COMPARATOR|Adenoscan|Subjects will have the FFR Measurement with IV Adenoscan®
62749852|NCT01482169|EXPERIMENTAL|Regadenoson|Subjects will have the FFR Measurement with IV Regadenoson
62749853|NCT06364813|EXPERIMENTAL|COMPANION Group|eHealth education: participants receive family caregiving education through the COMPANION eHealth program.
62749854|NCT06364813|NO_INTERVENTION|No Intervention|Control group participants will receive the usual care available at their local rehabilitation clinic.
62554818|NCT04606160|NO_INTERVENTION|Control - Non Single Session Problem-Solving Intervention|These participants will complete measures at visits 1,2,3, and 4. They will also receive a visit during visit 2 of the 4 visit study, where they will only complete measures.
62554819|NCT03633825|NO_INTERVENTION|Control|
62554820|NCT03633825|EXPERIMENTAL|Intervention|
62554821|NCT02135614|EXPERIMENTAL|Presatovir|Participants will receive a single dose of presatovir.
62554822|NCT02135614|PLACEBO_COMPARATOR|Presatovir placebo|Participants will receive a single dose of presatovir placebo.
62749855|NCT02934880|EXPERIMENTAL|Immediate APA|intervention: 10 sessions of APA within the 5 weeks (2 sessions per week) following the randomization
62749856|NCT02934880|ACTIVE_COMPARATOR|Delayed APA|intervention: 10 sessions of APA in 5 weeks (2 sessions per week) , 3 months after randomization
62749857|NCT02200328|EXPERIMENTAL|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
62749858|NCT02200328|PLACEBO_COMPARATOR|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
62554823|NCT00799058|ACTIVE_COMPARATOR|dapivirine gel 4789|will be applied by participants once daily for 12-weeks treatment period
62567392|NCT04698395|ACTIVE_COMPARATOR|Regular care|Usual customary care intervention during two weeks
62749859|NCT03172962|EXPERIMENTAL|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks
62749860|NCT03172962|ACTIVE_COMPARATOR|Usual care (control)|Will receive the usual care at the hospital
62749861|NCT02872896|EXPERIMENTAL|ClearSight device|Patients having orthopedic, urologic or general surgery will have blood pressure monitored by the ClearSight device second by second throughout surgery.
62375160|NCT01344304|NO_INTERVENTION|Standard therapy|The patients are treated with 5HT3-receptor antagonist + dexamethasone during the first course, then treated with aprepitant / fosaprepitant + 5HT3-receptor antagonist + dexamethasone
62375161|NCT01344304|EXPERIMENTAL|Aprepitant / Fosaprepitant therapy|The patients are treated with aprepitant / fosaprepitant + 5HT3-receptor antagonist + dexamethasone during first and second courses.
62375162|NCT03339089||Participants with Rheumatoid Arthritis (RA)|This group/ cohort includes participants with RA.
62554824|NCT00799058|ACTIVE_COMPARATOR|dapivirine gel 4759|Will be applied by participants once daily for12-weeks treatment period
62375163|NCT03339089||Participants with Plaque Psoriasis (Ps)|This group/ cohort includes participants with Ps.
62375164|NCT03339089||Participants with Ankylosing spondylitis (AS)|This group/ cohort includes participants with AS.
62554825|NCT00799058|PLACEBO_COMPARATOR|HEC-based placebo gel, 2.5g containing no Dapivirine|Will be applied once daily for 12-weeks treatment period
62554826|NCT01867528|EXPERIMENTAL|Laparoscopic adhesiolysis|
62554827|NCT01867528|ACTIVE_COMPARATOR|Open adhesiolysis|
62554828|NCT02691325|EXPERIMENTAL|Part A (Sequence 1) - Placebo, GSK2269557 200 mcg|Subjects will receive a single dose of GSK2269557 matching placebo (one inhalation) in treatment period 1, and single dose of GSK2269557 200 microgram (mcg) (2 inhalations of GSK2269557 100 mcg) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
62554829|NCT02691325|EXPERIMENTAL|Part A (Sequence 2) - GSK2269557 100 mcg, Placebo|Subjects will receive a single dose of GSK2269557 100 mcg (one inhalation) in treatment period 1, and single dose of GSK2269557 matching placebo (two inhalations) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
62554830|NCT02691325|EXPERIMENTAL|Part A (Sequence 3) - GSK2269557 100 mcg, GSK2269557 200 mcg|Subjects will receive a single dose of GSK2269557 100 mcg (one inhalation) in treatment period 1, and single dose of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
62554831|NCT02691325|EXPERIMENTAL|Part B- GSK2269557 200 mcg|Subjects will receive repeated doses of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) once daily via the ELLIPTA DPI for 10 days. Doses of GSK2269557 may be modified based on emerging data from Part A.
62554832|NCT02691325|EXPERIMENTAL|Part B- GSK2269557 matching Placebo|Subjects will receive repeated doses of GSK2269557 matching Placebo (2 inhalations) once daily via the ELLIPTA DPI for 10 days.
62554833|NCT02691325|EXPERIMENTAL|Part C- GSK2269557 200 mcg with and without activated charcoal|Subjects will receive a single dose of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) via the ELLIPTA DPI with activated charcoal in one treatment period and without ingestion of activated charcoal in another treatment period. The washout period between each dosing day will be at least 14 days. Dose of GSK2269557 may be modified based on emerging data from Part A.
62554834|NCT01392846||Resolute Integrity|Patients receiving Resolute-Integrity stent
62749862|NCT02872896|SHAM_COMPARATOR|Non-ClearSight|Patients having orthopedic, urologic or general surgery will have blood pressure monitored by the Non-ClearSight (the clinical team) every 5 minutes throughout surgery.
62749863|NCT01858545|EXPERIMENTAL|Experimental|MatriStem MicroMatrix and MatriStem Wound Matrix
62749864|NCT01858545|ACTIVE_COMPARATOR|Comparator|Cellular Dermal Replacement Tissue
62749865|NCT05845333||Stimulant Use Severity High|
62749866|NCT05845333||Stimulant Use Severity Medium|
62749867|NCT05845333||Stimulant Use Severity Low|
62749868|NCT05845333||Psychopathic Traits High|
62749869|NCT05845333||Psychopathic Traits Medium|
62749870|NCT05845333||Psychopathic Traits Low|
62749871|NCT05845333||Community (Healthy) Controls|
62749872|NCT02110329|NO_INTERVENTION|stage II-III colon cancer treated with surgery|stage II-III colon cancer treated with surgery
62749873|NCT06163495|EXPERIMENTAL|Intervention group|"Participants will engage in the Screen Free Time with Friends intervention that includes the following components:~1. For each participating class, children and parents will be invited to two family workshops.~2. In the beginning of 4th grade, parents will engage in a short exercise focusing on screen media use.~3. Children will engage in school hour workshops focusing on the class culture related to screen media use and face-to-face interaction with peers.~4. Afterschool club personal will engage in a training program consisting of three workshops aimed to increase participation rate in the afterschool club.~5. Local stakeholders relevant to children's leisure time will engage in two workshops to develop local actions focusing on children's engagement in face-to-face interactions with peers."
62749874|NCT06163495|NO_INTERVENTION|Control group|Participants are encouraged to continue as usual.
62749875|NCT01421303||AS patients who are working and treated with Enbrel|
62749876|NCT03587025|ACTIVE_COMPARATOR|Amitryptyline|Patients who will be take amitryptyline, 75mg, only use, 30min before surgery.
62749877|NCT03587025|PLACEBO_COMPARATOR|Placebo|Patients who will be take placebo 30min before surgery.
62749878|NCT06386302|EXPERIMENTAL|Chidamide combined with venetoclax, azacitidine group|"Chidamide (C): 30 mg/d orally on d1, 4, 8, 11 or 10 mg QD, d1-d14, adjusted according to patient tolerance Azacitidine (A): 75 mg/m 2 /d subcutaneous injection d1-d7 Venetoclax (V): 100 mg d1 200 mg d 2 400 mg d3-d28 Orally~A treatment cycle is 28 days , and subjects will continue to receive treatment allocation according to the investigator's assessment until documented disease progression, intolerable toxicity, withdrawal of consent, or the subject meets other conditions for terminating treatment. Program Standards (whichever occurs first)."
62749879|NCT06386302|ACTIVE_COMPARATOR|venetoclax, azacitidine group|azacitidine: 75 mg/m 2 /d subcutaneous injection d1-d7 Venetoclax: 100 mg day 1, 200 mg day 2, 400 mg day 3-d28 orally A treatment cycle is 28 days , and subjects will continue to receive treatment allocation according to the investigator's assessment until documented disease progression, intolerable toxicity, withdrawal of consent, or the subject meets other conditions for terminating treatment. Program Standards (whichever occurs first).
62749880|NCT04053946|EXPERIMENTAL|Next Science|Following amputation, SurgX™ will be applied directly to the surgical incision in the operating room under sterile conditions and covered with SOC dressing. The surgical dressing will not be removed until post-operative day 3, except if deemed necessary by the treating surgeon. At that time, direct application of the BlastX™ to the incision will be placed, then covered with a SOC dressing. BlastX™ will be applied every day and covered with SOC dressing.
62749881|NCT04053946|NO_INTERVENTION|Control|Post-op SOC dressing as per treating research doctor to include dressing changes post-op day 3 and daily thereafter.
62375165|NCT00068822|EXPERIMENTAL|Vertebroplasty|Participants will receive percutaneous vertebroplasty
62554835|NCT04443972|EXPERIMENTAL|PD VitalOs cement® alone|class II furcation defects that will be treated with PD VitalOs cement® alone
62554836|NCT04443972|EXPERIMENTAL|PD VitalOs cement® plus Bone graft and membrane|PD VitalOs cement® and Hydroxyapatite bone graft and biodegradable collagen membrane in the treatment of class II furcation defects.
62554837|NCT03888742||ADT Group|Participants received continue ADT treatment for at least more than 6 months
62554838|NCT03888742||RRP Group|Participants have radical prostatectomy performed more than 6 months ago.
62554839|NCT06361927|EXPERIMENTAL|cohort A：dose level 1 of SSGJ-707|
62554840|NCT06361927|EXPERIMENTAL|cohort A：dose level 2 of SSGJ-707|
62554841|NCT06361927|EXPERIMENTAL|cohort A：dose level 3 of SSGJ-707|
62554842|NCT06361927|EXPERIMENTAL|cohort B：dose level 1 of SSGJ-707|
62554843|NCT06361927|EXPERIMENTAL|cohort B：dose level 2 of SSGJ-707|cohort B
62554844|NCT06361927|EXPERIMENTAL|cohort B：dose level 3 of SSGJ-707|
62554845|NCT03708094||molecular diagnosis confirmed|Whole exome sequencing is applied to children and the molecular diagnosis was identified before renal transplantation.
62554846|NCT03708094||molecular diagnosis unconfirmed|Whole exome sequencing is applied to children and the molecular diagnosis was not identified before renal transplantation.
62554847|NCT00908635||survivor|survivors of patients
62749882|NCT06040008||healthy volunteers|Healthy status is defined by the absence of evidence of any active or chronic disease at the beginning of the study
62749883|NCT03241823||Patients with hepatitis c virus related liver cirrhosis|"Patients with chronic hepatitis C virus whose ultrasound shows liver cirrhosis, fibroscan F3 and F4, Child score A and B, of any MELD score, who achieved Sustained Virological Response after direct acting antiviral drugs (Sofosbuvir, Daclatasvir ± Ribavirin)."
62749884|NCT00417378|ACTIVE_COMPARATOR|1|Intraaortic balloon counterpulsation (IABP)
62749885|NCT00417378|EXPERIMENTAL|2|Left Ventricular Assist Device (Impella LP2.5)
62554848|NCT00908635||fatalities|non-survivors of patients
62749886|NCT06606015||Responders group:|included 26 preterm infants who successfully responded to medical PDA closure
62749887|NCT06606015||Non responders group:|included 17 preterm infants who didn't respond to medical PDA closure
62749888|NCT00660413|EXPERIMENTAL|AMG|Acceleromygraphy monitoring
62749889|NCT00660413|ACTIVE_COMPARATOR|MMG|Mechanomyography monitoring
62749890|NCT02330666|NO_INTERVENTION|Comparison|Standard care
62749891|NCT02330666|EXPERIMENTAL|Intervention|Communication skills training Mission Possible: Parents \& Kids Who Listen
62749892|NCT04574414||Children with Attention Deficit Hyperactivity Disorder|Cases
62749893|NCT04574414||Children without Attention Deficit Hyperactivity Disorder|Population controls
62749894|NCT02104596|EXPERIMENTAL|Xylitol injection|Intraarticular injection of Xylitol
62749895|NCT02104596|PLACEBO_COMPARATOR|Control|
62749896|NCT04804631||Gastrostomy tube|Prophylactic gastrostomy placed prior to bone marrow transplant.
62749897|NCT04804631||Nasogastric tube|Nasogastric tube placed during admission.
62749898|NCT03252249|ACTIVE_COMPARATOR|3 months dual anti-platelet therapy|3 months dual anti-platelet therapy.
62749899|NCT03252249|ACTIVE_COMPARATOR|12 months dual anti-platelet therapy|12 months dual anti-platelet therapy.
62749900|NCT06605859||GlucoTab Prospective Group|
62749901|NCT06605859||Retrospective Control Group|
62749902|NCT03023774|OTHER|neupogen|neupogen (granulocyte colony-stimulating factor) 30 IU once intrauterine at the time of ovum pickup
62749903|NCT01310543|EXPERIMENTAL|Teens and Toddlers|The T\&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
62749904|NCT01310543|NO_INTERVENTION|Comparison|Girls in the comparison group will continue with their normal afternoon of schooling, which is missed by girls attending the T\&T intervention for the 20 weeks of their attendance.
62749905|NCT05655325|EXPERIMENTAL|Home-based walking exercise|A 6-month partially supervised walking exercise training using a tapered approach. Participants begin with exercising (walking) in person, on-site one time per week and 3 times per week at home for a minimum exercise dosage of 30 minutes of accumulated exercise per session during month 1. During month 2, participants will exercise on-site once every other week and 3-4 times per week at home a minimum exercise dosage of 30 minutes of accumulated exercise per session. During months 2-6, participants will exercise at home 4 times per week for a minimum exercise dosage of 30 minutes of accumulated exercise per session and they will receive a phone call every two weeks to help coach and address any problems. Participants will receive a Fitbit fitness tracker that will be used to deliver their personalized exercise program, exercise monitoring, feedback, and motivational messages.
62375166|NCT00068822|PLACEBO_COMPARATOR|Control Group|Participants will receive sham vertebroplasty without PMMA
62375167|NCT00678249|EXPERIMENTAL|FLAIR|Primary PTA followed by placement of the FLAIR Endovascular Stent Graft
62554849|NCT03171376|ACTIVE_COMPARATOR|Intraorifice Group|After root canal treatment intraorifice barrier of glass-ionomer cement (Ketac™ Molar, 3M ESPE ) placed 3mm inside canals from root canal orifice.
62554850|NCT03171376|ACTIVE_COMPARATOR|Base Group|2mm thick base of glass-ionomer cement (Ketac™ Molar, 3M ESPE ) applied uniformly on the floor of the pulp chamber after completion root canal treatment.
62554851|NCT03171376|ACTIVE_COMPARATOR|Control Group|Neither intraorifice barrier nor base applied after completion of root canal treatment.
62554852|NCT01860235|EXPERIMENTAL|sextant 1|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (EMLA)
62554853|NCT01860235|ACTIVE_COMPARATOR|sextant 2|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (Injectable anesthesia)
62554854|NCT01860235|ACTIVE_COMPARATOR|sextant 3|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (2% Benzocaine)
62375168|NCT00678249|ACTIVE_COMPARATOR|PTA Only|Percutaneous Transluminal Angioplasty
62375169|NCT00678249|EXPERIMENTAL|FLAIR Roll-in Participants|Primary Patency followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
62375170|NCT03828864|ACTIVE_COMPARATOR|Active Pulsed Shortwave therapy|Application of the medical device emitting pulsed shortwave therapy. The medical device is used over the site of pain.
62375171|NCT03828864|PLACEBO_COMPARATOR|Placebo Pulsed Shortwave therapy|Application of the medical device that does not emit pulsed shortwave therapy. The medical device is used over the site of pain.
62375172|NCT05375786||COVID-19 infections|"* SARS-Cov-2 RNA positive~* without symptom or with mild clinical manifestations"
62375173|NCT05148429||Fetuses with abnormal positionning of mesenteric vessels|All pregnant women with abnormal positionning of mesenteric vessels during second trimester scan
62375174|NCT00290355|EXPERIMENTAL|GSK 249553 Group|Male and female patients at least 18 years of age, with resectable non-small-cell lung cancer (NSCLC), who received 13 doses of GSK 249553 vaccine, administered intramuscularly in the deltoid or lateral regions of the thighs, alternatively on the right and left sides, according to the following schedule: 5 doses at 3-week intervals, followed by 8 doses at 3-month intervals.
62375175|NCT00290355|PLACEBO_COMPARATOR|Placebo Group|Male and female patients at least 18 years of age, with resectable non-small-cell lung cancer (NSCLC), who received 13 doses of placebo, administered intramuscularly in the deltoid or lateral regions of the thighs, alternatively on the right and left sides, according to the following schedule: 5 doses at 3-week intervals, followed by 8 doses at 3-month intervals.
62375176|NCT03160066|ACTIVE_COMPARATOR|Active|Capsules containing 1x10\^9 colony forming units of Lactobacillus Rhamnosus (JB-1) will be given once per day for 4 weeks.
62375177|NCT03160066|PLACEBO_COMPARATOR|Placebo|Placebo capsules identical to the probiotic in taste, smell, colour, and comprised only of the same non-active ingredients (corn starch, magnesium stearate and silicon dioxide) in the probiotic supplement will be given once per day for 4 weeks.
62554855|NCT01860235|PLACEBO_COMPARATOR|sextant 4|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (Placebo)
62554856|NCT05365802|EXPERIMENTAL|68Ga-FAPi-46|Patients receive 68Ga-FAPi-46 IV and undergo PET/CT scan over 20-50 minutes
62567393|NCT06351891|EXPERIMENTAL|14-day bismuth quadruple regimen containing cefuroxime and tetracycline|14-day bismuth quadruple regimen containing cefuroxime and tetracycline:Tegoprazan (50mg twice/day before breakfast and supper), Bismuth potassium citrate capsule (0.6g twice/day before breakfast and supper), Cefuroxime tablets (500mg twice/day after breakfast and supper), Tetracycline (500mg three times/day after three meals);14 days.
62749906|NCT05655325|PLACEBO_COMPARATOR|Health education|The health education group will receive the same amount of contact hours as the intervention group. The attention control group will receive health education and stretching exercises. Participants will be in person, on-site one time per week during month 1 for about 30 minutes. During month 2, participants will attend the health education on-site once every other week for about 30 minutes. During months 2-6 participants will receive a phone call every two weeks to help remind about the health education. Participants will receive a Fitbit fitness tracker that will be used for exercise monitoring.
62749907|NCT04072601|EXPERIMENTAL|Atorvastatin|Atorvastatin 10-20 mg for 18 months of treatment. Start dose is 10 mg, adjusted to 20 mg after 15-30 days if no sideeffects occurs.
62749908|NCT04072601|PLACEBO_COMPARATOR|Control|Placebo of atorvastatin 10 mg, 1-2 tablets for 18 months of treatment. Start dose is 1 tablet (10 mg placebo), adjusted to 2 tablets (20 mg placebo) after 15-30 days if no side effects occurs.
62749909|NCT04726150||Mildly of Asymptomatic COVID|Athletes with prior COVID-19 that had a mildly or asymptomatic course
62749910|NCT04726150||Moderate to Severe Symptoms, Cardiac Symptoms|Athletes with prior COVID-19 that had a moderate to severely symptomatic course, or who experience(d) cardiac symptoms
62554857|NCT04359589||Acute myocardial infarction (AMI) group|"700 patients with AMI;several demographics, clinical and analytical parameters were collected, and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in acute ischemic cardiovascular disease of different severity. Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established circulatory integration diagnosis and treatment evaluation system of acute ischemic cardiovascular with DSS as the core was used to predict the prognosis of patients with acute ischemic cardiovascular diseases."
62554858|NCT04359589||Acute ischemic stroke group|"500 patients with acute ischemic; several demographics, clinical and analytical parameters were collected,and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in acute ischemic cerebrovascular disease of different severity.Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established circulatory integration diagnosis and treatment evaluation system of acute ischemic cardiovascular with DSS as the core was used to predict the prognosis of patients with acute cerebrovascular diseases."
62749911|NCT04726150||Hospitalized for|Athletes that were hospitalized for COVID-19
62749912|NCT02465788|EXPERIMENTAL|755nm alexandrite laser with bipolar RF|GentleTouch (Helos) combines 755nm alexandrite laser energy with bipolar RF energy.
62749913|NCT05800028||AD group|30 individuals aged between 50 and 85 years with probable Alzheimer's disease dementia with amnestic presentation and documented decline following the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
62749914|NCT05800028||SPPA group|16 individuals aged between 50 and 85 years with the semantic variant of primary progressive aphasia following the classification of primary progressive aphasia and its variants.
62749915|NCT05800028||HC group|46 individuals without cognitive complain.
62749916|NCT05800028||Partners|92 individuals without cognitive complaints. Each of these individuals will partner with one of the members of the experimental groups to carry out learning in social contexts.
62749917|NCT01896076||Pediatric patients in urologic surgery|Pediatric patients undergoing caudal block for urologic surgery were included in this study.
62749918|NCT03139981|EXPERIMENTAL|ASN002 40 mg|40 mg ASN002
62749919|NCT03139981|EXPERIMENTAL|ASN002 80 mg|80 mg ASN002
62749920|NCT03139981|EXPERIMENTAL|ASN002 20 mg|20 mg ASN002
62749921|NCT03139981|EXPERIMENTAL|ASN002 120 mg|120 mg ASN002
62749922|NCT02030080|ACTIVE_COMPARATOR|Feedback 50th Percentile|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 50th percentile in their arm.
62749923|NCT02030080|EXPERIMENTAL|Feedback 75th Percentile|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 75th percentile in their arm.
62554859|NCT04359589||Acute lower limb ischemia group|"500 patients with acute lower limb ischemia; several demographics, clinical and analytical parameters were collected,and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in lower limb ischemia disease of different severity.Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established circulatory integration diagnosis and treatment evaluation system of lower limb ischemia disease with DSS as the core was used to predict the prognosis of patients with acute cerebrovascular diseases."
62554860|NCT04359589||Control group|200 healthy volunteers were included as controls
62554861|NCT00974922|ACTIVE_COMPARATOR|Phase I: Aliskiren|Two weeks of single-blind placebo, followed by randomization in a double-blind fashion to Aliskiren 150 mg to 300 mg once daily for 6 weeks
62554862|NCT00974922|ACTIVE_COMPARATOR|Phase I: Cholecalciferol|Two weeks of single-blind placebo, followed by randomization in a double-blind fashion to Cholecalciferol (3000 I.U.) once daily for 6 weeks
62554863|NCT00974922|ACTIVE_COMPARATOR|Phase II: Aliskiren and Vitamin D3|Aliskiren 150-300 mg orally once daily and Cholecalciferol 3000 I.U. in combination once daily for 6 weeks
62554864|NCT01901926|ACTIVE_COMPARATOR|Periodontal Treatment|"Periodontal Treatment in the form of Full mouth scaling and root planning will be given at one time only i.e. at baseline after full mouth dental checkup.~Checkup will be repeated at 3, 6 \& 9 month interval along with HbA1C levels"
62554865|NCT01901926|NO_INTERVENTION|Non treatment group|this group will only receive detailed dental check ups at the specified time 0, 3, 6 and 9 months respectively and there will be no scaling done. HbA1C levels will be estimated at the above specified times
62554866|NCT03595956||Medical Gender Affirmation (MGA) Cohort|Patients engaged in gender-affirming care.
62554867|NCT05237323|EXPERIMENTAL|main group|Group 1 included 25 patients who received mycophenolate mofetil 2 g per day per os and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day per os and standard drug therapy for heart failure (beta-blockers, angiotensin converting enzyme inhibitors or angiotensin II receptor blocker, mineralocorticoid receptor antagonist angiotensin receptor-neprilysin inhibitor (if required), diuretics (if required)).
62554868|NCT05237323|ACTIVE_COMPARATOR|control group|Group 2 included 25 patients who received azathioprine at an average dose of 150 \[75; 150\] mg per day per os and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day per os and standard drug therapy for heart failure (beta-blockers, angiotensin converting enzyme inhibitors or angiotensin II receptor blocker, mineralocorticoid receptor antagonist angiotensin receptor-neprilysin inhibitor (if required), diuretics (if required))
62554869|NCT02636218|ACTIVE_COMPARATOR|0.9% NaCl control|Normal saline
62554870|NCT02636218|EXPERIMENTAL|Ketamine|Anesthetic
62554871|NCT01184430|ACTIVE_COMPARATOR|advanced hemodynamic monitoring|advanced hemodynamic monitoring with pulse contour analysis ( LiDCO rapid) and goal-directed therapy
62554872|NCT01184430|NO_INTERVENTION|standard monitoring|hemodynamic monitoring based on the standard operating procedures of our clinic
62375178|NCT06092840|EXPERIMENTAL|Transform Burn|Participants were supplied with one bottle of study product (Transform Burn) for each visit, labeled with their participant number. They were required to take the product consisting of 4 capsules per day, taken on an empty stomach at least 30 minutes prior to eating each morning, 5 days on Monday through Friday. Product was taken at the beginning of each visit, except for Week 0 visit for a total of 12 weeks and bottles were returned at each visit.
62749924|NCT02030080|EXPERIMENTAL|Feedback 50th Percentile + Lottery|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 50th percentile in their arm. If their team's average daily step count is ≥ 7000 steps, they'll be eligible to collect winnings from a weekly lottery. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
62749925|NCT02030080|EXPERIMENTAL|Feedback 75th Percentile + Lottery|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 75th percentile in their arm. If their team's average daily step count is ≥ 7000 steps, they'll be eligible to collect winnings from a weekly lottery. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
62749926|NCT06385392||People with Parkinson's disease and Freezing of Gait using experimental insole and haptic module|
62554873|NCT02807337|EXPERIMENTAL|Caphosol rinse group|Caphosol consists of two solutions (A and B) which are mixed immediately before use. Caphosol mouth rinse will begin concomitantly (the same day) with the beginning of chemotherapeutic drugs. It will be continued for seven consecutive days.
62554874|NCT02807337|ACTIVE_COMPARATOR|0,9% NaCl group.|0,9% NaCl consists of two solutions (A and B). Two vials of 0.9% NaCl will be mixed to maintain blinding. The study mouth rinse will begin concomitantly (the same day) with the beginning of chemotherapeutic drugs. It will be continued for seven consecutive days.
62554875|NCT01026246|EXPERIMENTAL|Group B: 20 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 20 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
62554876|NCT01026246|EXPERIMENTAL|Group A: 5 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 5 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
62554877|NCT01026246|EXPERIMENTAL|Group C: 80 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 80 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
62554878|NCT02235454|OTHER|Glaucoma arm|Consecutive patients with glaucoma will undergo non-invasive OCT imaging
62554879|NCT01147068|EXPERIMENTAL|PanBlok 135µg No Adjuvant|135µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
62554880|NCT01147068|EXPERIMENTAL|PanBlok 45µg No Adjuvant|45µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
62749927|NCT04053400||Ketamine Group|Active duty military service member injured in theater, AEROVAC-ED out, and received ketamine.
62749928|NCT04053400||Non-Ketamine Comparison Group|Active duty military service member injured in theater, AEROVAC-ED out, and did NOT receive ketamine treatment for pain.
62749929|NCT06607471||Arrhythmic and Inflammatory (AINICM)|"The AINICM group will include presentation with ventricular fibrillation (VF), either sustained or non-sustained ventricular tachycardia (VT; NSVT), frequent premature ventricular complexes (PVC), supraventricular arrhythmias (SVA) and bradyarrhythmias (BA).~The arrhythmogenic and the inflammatory non-ischemic cardiomyopathies (AINICM) will be characterized by means of a multimodal diagnostic workup, which is a combination ofgenetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry."
62749930|NCT06607471||Non-arrhythmic and inflammatory (INICM)|The inflammatory component will be diagnosed by means of a multidisciplinary workup (i.e. EMB, PET).
62749931|NCT06607471||Arrhythmic and Non-inflammatory (ANICM)|The arrhythmic component will be diagnosed by means of a multidisciplinary work-up (i.e. SAECG, Arrhythmia monitoring, Stress test, CT scan, EAM, Electrophysiological test)
62749932|NCT06607471||Non-arrhythmic and Non-inflammatory (NICM)|NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
62749933|NCT03197714|EXPERIMENTAL|OPB-111077|Level 1: 200 mg daily Level 2: 250 mg daily
62749934|NCT00895752|EXPERIMENTAL|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
62749935|NCT04308460|ACTIVE_COMPARATOR|arthrocentesis group|the group of internal derangement patients which was treated with arthrocentesis procedure
62749936|NCT04308460|ACTIVE_COMPARATOR|operative arthroscopy group|the group of internal derangement patients which was treated with operative arthroscopy procedure
62554881|NCT01147068|EXPERIMENTAL|PanBlok 45µg and GLA 1.0µg, SE 2%|45µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
62554882|NCT01147068|EXPERIMENTAL|PanBlok 15µg and GLA 1.0µg, SE 2%|15µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
62554883|NCT01147068|EXPERIMENTAL|PanBlok 7.5µg and GLA 1.0µg, SE 2%|7.5µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
62749937|NCT01814878|EXPERIMENTAL|Tramadol Hydrochloride/Acetaminophen ER|Participants will be administered 2 oral tablets of extended release (ER) tramadol HCl (75 milligram \[mg\])/acetaminophen (650 mg) and 2 tablets of placebo matching to immediate release (IR) tramadol HCl/acetaminophen orally every 12 hours up to 36 hours, and 2 tablets of placebo matching to IR tramadol HCl/acetaminophen every 6 hours up to 42 hours.
62749938|NCT01814878|ACTIVE_COMPARATOR|Tramadol HCl/Acetaminophen IR|Participants will be administered 2 oral tablets of IR tramadol HCl (37.5 mg)/acetaminophen (325 mg) and 2 tablets of placebo matching to ER tramadol HCl/acetaminophen at 0, 12, 24 and 36 hours, and 2 tablets of IR tramadol HCl/acetaminophen at 6, 18, 30 and 42 hours.
62749939|NCT01467037||Rotavirus-negative|Patients with a negative result for rotavirus via enzyme immunoassay (EIA). No intervention done.
62749940|NCT01467037||Rotavirus-positive|Patients with a positive result for rotavirus via enzyme immunoassay (EIA). Rotavirus-positives were confirmed via real-time reverse-transcriptase polymerase chain reactions (RT-PCR). RT-PCR results were used in the event of discordant EIA results. Rotavirus genotyping was performed. No intervention done.
62749941|NCT06606093|PLACEBO_COMPARATOR|Placebo|
62749942|NCT06606093|EXPERIMENTAL|Enavogliflozin 0.3 mg once daily|
62749943|NCT02706275|EXPERIMENTAL|Warming Group|External warming via forced air warming
62749944|NCT02706275|NO_INTERVENTION|Control Group|Standard of care body temperature management
62749945|NCT04077671|EXPERIMENTAL|SAD - Cohort A - CHF6467 0.3 µg/mm2|Cohort A: will be administered with CHF6467 0.3 µg/mm2 ulcer area as single dose.
62749946|NCT04077671|EXPERIMENTAL|SAD - Cohort B - CHF6467 1 µg/mm2|Cohort B: will be administered with 1 µg/mm2 ulcer area as single dose.
62749947|NCT04077671|EXPERIMENTAL|SAD - Cohort C - CHF6467 3 µg/mm2|Cohort C: will be administered with 3 µg/mm2 ulcer area as single dose.
62749948|NCT04077671|EXPERIMENTAL|SAD - Cohort D - CHF6467 6 µg/mm2|Cohort D: will be administered with 6 µg/mm2 ulcer area as single dose.
62749949|NCT04077671|EXPERIMENTAL|MAD - Cohort E - CHF6467 0.3 or 1 µg/mm2|Cohort E: will be administered with 0.3 or 1 µg/mm2 ulcer area (total daily dose) as multiple dose (14 days). The dose will be selected based on the SAD results.
62554884|NCT01147068|EXPERIMENTAL|PanBlok 3.8µg and GLA 1.0µg, SE 2%|3.8µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
62554885|NCT01147068|PLACEBO_COMPARATOR|Placebo|0.9% Sodium Chloride; Two 0.5 mL IM injections 21 days apart
62554886|NCT02115490||Osteoporosis_with_Bisphosphonates|This group of patients are taking Bisphosphonates orally in their treatment
62554887|NCT02115490||Osteoporosis-without-Bisphosphonates|This group of patients has not taken Bisphosphonates in the course of treatment
62554888|NCT04563936|EXPERIMENTAL|LY01005 3.6 mg|Intramuscular injections of LY01005 3.6 mg every 28 days for a maximum of 3 consecutive doses.
62554889|NCT04563936|ACTIVE_COMPARATOR|ZOLADEX® 3.6 mg|Subcutaneous injections of ZOLADEX® 3.6 mg every 28 days for a maximum of 3 consecutive doses.
62749950|NCT04077671|EXPERIMENTAL|MAD - Cohort F - CHF6467 1 or 3 µg/mm2|Cohort F: will be administered with 1 or 3 µg/mm2 ulcer area (total daily dose) as multiple dose (14 days). The dose will be selected based on the SAD results.
62554890|NCT04166201|OTHER|modified chevrel technique|hernioplasty done with double mesh modification of chevrels technique
62749951|NCT06598228||the group without acute kidney injury|Patients not diagnosed with acute kidney injury according to KDIGO(Kidney Disease: Improving Global Outcomes) criteria
62749952|NCT06598228||the group with transient acute kidney injury|Patients diagnosed with acute kidney injury according to KDIGO(Kidney Disease: Improving Global Outcomes) criteria and recovered within 48h
62749953|NCT06598228||the group with persistent acute kidney injury|Patients diagnosed with acute kidney injury according to KDIGO(Kidney Disease: Improving Global Outcomes) criteria and sustained over 48h
62749954|NCT02978547|EXPERIMENTAL|Metformin|All patients will receive metformin 500 mg per oral twice daily with food for at least 7 days, until 2 days prior to surgery. Metformin therapy should be discontinued 2 days before surgery to reduce the risk of lactic acidosis associated with fasting.
62749955|NCT03866603||Parkinson´s disease individuals|"* The participant has been clinically diagnosed with Parkinson's disease within the last 5 years (≤ 5 years)~* The participant is between 30 and 80 years old"
62749956|NCT02350413||Endometriosis|Women referred to five Obstetrics and Gynecological Department for the treatment of endometriosis
62749957|NCT05523128|EXPERIMENTAL|ZS802|Single intravenous (i.v.) infusion of ZS802 Intervention: Gene Therapy / Gene Transfer
62749958|NCT05215223|EXPERIMENTAL|whole body vibration|the patient will be received whole body vibration for three times/ week in addition to aerobic exercise for 3 times per week, 45 minutes per session for eight weeks
62749959|NCT05215223|ACTIVE_COMPARATOR|Aerboic exercise|Moderate intensity aerobic exercise in form of walking on treadmill for 3 times per week, 45 minutes per session for eight weeks
62749960|NCT05927675|EXPERIMENTAL|Exercise intervention|
62749961|NCT05594017|EXPERIMENTAL|Scopolamine (0.4mg)|"Subjects will receive a dose of scopolamine (0.4mg) on each day. Approximately 15 minutes after administration, the participant will then complete either an episodic or a spatial memory task session.~If the patient completed the sham session already, this session will take place the day following the initial session, or at least four half-lives after the first session."
62749962|NCT05594017|PLACEBO_COMPARATOR|Placebo|"Subjects will receive saline (0.4mg) via IV on each day. Approximately 15 minutes after administration, the participant will then complete either an episodic or a spatial memory task session.~If the patient completed the scopolamine session already, this session will take place the day following the initial session, or at least four half-lives after the first session."
62749963|NCT04913181||Sepsis prediction model|This group of people was used for the clinician's decision, and the sepsis prediction model was used simultaneously for the prediction, but the model was not involved in the decision, and was only used for verification
62749964|NCT04913181||Daily clinical judgment of doctors|This group of people was used for the clinician's decision without sepsis prediction model.
62554891|NCT01588288|EXPERIMENTAL|Galectin 3 dosage|Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy
62554892|NCT05183880|ACTIVE_COMPARATOR|Crystalline vitamin C supplementation|1000 mg of vitamin C ingested in crystalline form
62749965|NCT00509860|EXPERIMENTAL|Irinotecan|Irinotecan 16 mg/m2 by vein daily over 1 hour for 5 Days
62554893|NCT05183880|EXPERIMENTAL|Phosphatidylcholine-lipid encapsulated vitamin C supplementation|1000 mg of vitamin C ingested in phosphatidylcholine-lipid encapsulated form
62554894|NCT00425321|EXPERIMENTAL|RWJ-445380 100 mg|
62749966|NCT00584090|EXPERIMENTAL|1|
62554895|NCT00425321|EXPERIMENTAL|RWJ-445380 200 mg|
62554896|NCT00425321|EXPERIMENTAL|RWJ-445380 300 mg|
62554897|NCT00425321|PLACEBO_COMPARATOR|Placebo|
62554898|NCT06328933|EXPERIMENTAL|Intermittent Oro-esophageal Tube Feeding+comprehensive rehabilitation therapy|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
62554899|NCT06328933|ACTIVE_COMPARATOR|Nasogastric Tube Feeding+comprehensive rehabilitation therapy|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the control group was given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements."
62554900|NCT03917251|OTHER|Right ventricular Pacemaker|Patients with right ventricular pacing and evidence of coronary ischemia who have evidence of coronary ischemia who are to undergo coronary angiogram.When an intermediate stenosis (40-80%) has been identified angiographically, this lesion will undergo further hemodynamic assessment, All data including resting flow, FFR, CFR, vital signs, arrhythmias and patient symptoms will be recorded twice: once when the pacemaker is programmed to pace, and once when the PPM is reprogrammed such that the pacemaker is no longer pacing.
62749967|NCT00584090|PLACEBO_COMPARATOR|2|
62749968|NCT02022215|EXPERIMENTAL|ME1111 Solution, Low strength|
62749969|NCT02022215|EXPERIMENTAL|ME1111 Solution, High strength|
62749970|NCT02022215|PLACEBO_COMPARATOR|Matching Vehicle Solution|
62749971|NCT02725814|EXPERIMENTAL|Sucrose|
62749972|NCT04557514|ACTIVE_COMPARATOR|platelet rich plasma injection in post burn facial scar|"prp in subgroup allocation 1:1 Obtain WB by venipuncture in acid citrate dextrose (ACD) tubes~Do not chill the blood at any time before or during platelet separation.~Centrifuge the blood using a 'soft' spin.~Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).~Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate.~The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.~Remove PPP and suspend the platelet pellets in a minimum quantity of plasma (2-4 mL) by gently shaking the tube."
62749973|NCT04557514|ACTIVE_COMPARATOR|fat injection in post burn facial scar|After aspiration of the fatty tissue, it is important that nonviable components of the aspirate, such as oil, blood, and local anesthetics are removed and, at the same time, the quality, integrity, and viability of the adipocytes and the inherent mesenchymal stem cells in the aspirate be maintained. Processing techniques are sedimentation , filtering and washing There is no consensus as to the optimal method of fat graft preparation.
62749974|NCT01273116|EXPERIMENTAL|CWS in Hospital|CWS in Hospital in addition to usual care
62749975|NCT04096820|EXPERIMENTAL|Open Label|Uromune will be taken by the participant for 90 days.
62749976|NCT05173948|EXPERIMENTAL|Kinesio taping and Conventional Physical therapy|Kinesio taping with Transcutaneous Electrical Nerve Stimulation and Supervised Exercise therapy
62749977|NCT05173948|EXPERIMENTAL|Conventional Physical therapy|Transcutaneous Electrical Nerve Stimulation and Supervised Exercise therapy
62749978|NCT01444625|EXPERIMENTAL|Dark chocolate|Flavanol-rich chocolate
62749979|NCT01444625|PLACEBO_COMPARATOR|Placebo chocolate|Flavanol-free chocolate
62749980|NCT04083508|EXPERIMENTAL|Malaria challenge|Malaria Sporozoite Challenge by mosquito bites.
62749981|NCT01980303|EXPERIMENTAL|Cohort 1: Treatment A|Japanese participants will receive 1 spray of esketamine solution in each nostril (total dose: 28 mg).
62749982|NCT01980303|EXPERIMENTAL|Cohort 1: Treatment B|Japanese participants will receive 1 spray of esketamine solution in each nostril at time 0 and 5 minutes (total dose: 56 mg).
62749983|NCT01980303|EXPERIMENTAL|Cohort 1: Treatment C|Japanese participants will receive 1 spray of esketamine solution in each nostril at time 0, 5, and 10 minutes (total dose: 84 mg).
62749984|NCT01980303|EXPERIMENTAL|Cohort 2: Treatment A|Caucasian participants will receive 1 spray of esketamine solution in each nostril (total dose: 28 mg).
62749985|NCT01980303|EXPERIMENTAL|Cohort 2: Treatment B|Caucasian participants will receive 1 spray of esketamine solution in each nostril at time 0 and 5 minutes (total dose: 56 mg).
62749986|NCT01980303|EXPERIMENTAL|Cohort 2: Treatment C|Caucasian participants will receive 1 spray of esketamine solution in each nostril at time 0, 5 and 10 minutes (total dose: 84 mg).
62749987|NCT03474900|EXPERIMENTAL|PLGA implant, Bioretec ltd. Finland|Treatment with biodegradable elastic stable intramedullary nail in unstable forearm shaft fracture in paediatric population
62749988|NCT03474900|ACTIVE_COMPARATOR|Titanium elastic stable nail|Treatment with titanium elastic stable intramedullary nail in unstable forearm shaft fracture in paediatric population
62749989|NCT00564863|OTHER|CS19 expressing ETEC strain|Ascending dose finding study in 5-10 subjects per dose; to identify the dose able to give a diarrheal attack rate greater than or equal to 80%.
62749990|NCT01222091|ACTIVE_COMPARATOR|Propranolol, Then Placebo|Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
62749991|NCT01222091|PLACEBO_COMPARATOR|Placebo, Then Propranolol|Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
62749992|NCT06289920|EXPERIMENTAL|BR3005|
62749993|NCT06289920|ACTIVE_COMPARATOR|BR3005-1+BR3005-2|
62749994|NCT06306963||Cirrhosis With Gastric Antral Vascular Ectasia|Patients with Gastric Antral Vascular Ectasia with cirrhosis will undergo gastric motor function testing. This will be measured by radioscintigraphy after overnight fast using a radiolabeled meal.
62749995|NCT06306963||Cirrhosis Without Gastric Antral Vascular Ectasia|Patients without Gastric Antral Vascular Ectasia with cirrhosis will undergo gastric motor function testing. This will be measured by radioscintigraphy after overnight fast using a radiolabeled meal.
62375179|NCT05400811|EXPERIMENTAL|Group I: MM09 allergoid-mannan conjugates SC (3.000 UTm/mL) + sublingual placebo|"Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3,000 UTm/mL subcutaneous immunotherapy + sublingual placebo.~Subcutaneous active treatment will be administered once a month for 12 months. Sublingual placebo will be administered daily (2 subsequent administrations) for 12 months."
62749996|NCT02471560|EXPERIMENTAL|dimethyl fumarate|As prescribed by the Investigator according to the local Summary of Product Characteristics.
62749997|NCT02471560|ACTIVE_COMPARATOR|injectable MS DMT|As prescribed by the Investigator according to the local Summary of Product Characteristics.
62749998|NCT06601868|NO_INTERVENTION|100 patients without R-Support supplementation (control group)|These patients will have no intervention, will not take the nutritional supplements
62749999|NCT06601868|ACTIVE_COMPARATOR|100 patients with R-Support supplementation (intervention group)|"The treatment period for the intervention group will last 28 days, divided into two phases: 14 days preoperative and 14 days postoperative.~During the preoperative phase, participants will consume one shake per day. Each shake will consist of 35 grams (3 scoops) of R-Support Prepare mixed with 250 milliliters of water or milk. This regimen will be followed for 14 days leading up to the surgery.~During the postoperative phase, participants will consume one shake per day. Each shake will consist of 35 grams (3 scoops) of R-Support After mixed with 250 milliliters of water or milk. This regimen will be followed for 14 days following the surgery."
62750000|NCT06102135|OTHER|Patients well established on tube feeds will act as their own control|Patients in the control group will switch from current feed to new tube feed to assess tolerance and acceptability.
62750001|NCT02449889|EXPERIMENTAL|HP-hCG IM|highly purified human chorionic gonadotropin, intramuscularly (IM)
62750002|NCT02449889|EXPERIMENTAL|HP-hCG SC|highly purified human chorionic gonadotropin, subcutaneously (SC)
62750003|NCT02449889|ACTIVE_COMPARATOR|rhCG|recombinant human chorionic gonadotropin
62750004|NCT01827774|EXPERIMENTAL|Surgisis® Soft Tissue Graft|
62750005|NCT05008575|EXPERIMENTAL|antiCD33 CAR NK cells|After preconditioning with chemotherapy, the antiCD33 CAR NK cells will be evaluated
62750006|NCT00005901|ACTIVE_COMPARATOR|Pamidronate every 3 months for 3 years|Subjects who received Pamidronate every 3 months for 3 years.
62375180|NCT05400811|EXPERIMENTAL|Group II: MM09 allergoid-mannan conjugates SL (3.000 UTm/mL) + subcutaneous placebo|"Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan sublingual immunotherapy at 3.000 UTm/mL + subcutaneous placebo.~Sublingual active treatment will be administered daily (2 subsequent administrations) for 12 months.~Subcutaneous placebo will be administered once a month for 12 months."
62375181|NCT05400811|EXPERIMENTAL|Group III: MM09 allergoid-mannan conjugates SL (9.000 UTm/mL) + subcutaneous placebo|"Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan sublingual immunotherapy at 9.000 UTm/mL + subcutaneous placebo.~Sublingual active treatment will be administered daily (2 subsequent administrations) for 12 months.~Subcutaneous placebo will be administered once a month for 12 months."
62375182|NCT05400811|PLACEBO_COMPARATOR|Group IV: Placebo|"Mixture of sublingual placebo + subcutaneous placebo. Sublingual placebo will be administered daily (2 subsequent administrations) for 12 months.~Subcutaneous placebo will be administered once a month for 12 months"
62375183|NCT03413228||Influenza-like illness group|
62375184|NCT03870893|EXPERIMENTAL|Intervention group|Intervention is administered to patients in this Arm.
62375185|NCT03870893|NO_INTERVENTION|control group|No intervention
62750007|NCT00005901|ACTIVE_COMPARATOR|Pamidronate every 6 months for 3 years|Subjects who received Pamidronate every 6 months for 3 years.
62750008|NCT05634746|EXPERIMENTAL|APT-1011|APT-1011 3 mg HS
62750009|NCT05634746|PLACEBO_COMPARATOR|Placebo|Placebo HS
62750010|NCT04224636|EXPERIMENTAL|Up-front Atezo/Bev, then TACE|Patients will receive atezolizumab and bevacizumab iv every three weeks for up to 24 months. Upon detection of at least one unequivocal progressive hepatic lesion, selective TACE directed against progressive lesion(s) (sdTACE) will be performed. RFA or MWA are permitted as alternative to TACE to treat one or more lesion that cannot be reasonably selectively targeted by TACE
62750011|NCT04224636|EXPERIMENTAL|Atezo/Bev combined with TACE|First TACE will be performed as selectively as possible against all viable tumor lesions. Atezo/Bev will be initiated within three days from TACE. Upon detection of at least one unequivocal progressive hepatic lesion, treatment with Atezo/Bev will be continued if RFA or MWA can be used to treat this/these progressive lesion.
62750012|NCT03585036|ACTIVE_COMPARATOR|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
62750013|NCT03585036|ACTIVE_COMPARATOR|tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure~."
62750014|NCT03585036|PLACEBO_COMPARATOR|placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
62750015|NCT04312360|EXPERIMENTAL|intervention track 1|"14 patient with right-sided colon cancer receive intervention before the hemicolectomi.~both arms of this study use the same intervention."
62750016|NCT04312360|EXPERIMENTAL|intervention track 2a|"14 patient with right-sided colon adenoma receive intervention before the endoscopic mucosa resection.~both arms of this study use the same intervention."
62750017|NCT00700544|ACTIVE_COMPARATOR|B|"* Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR~* maintenance therapy every 3 months = 6 courses of reinduction with :~  -idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5 ), subcutaneously~* between the courses, a continuous regimen of methotrexate and 6-mercaptopurine."
62750018|NCT00700544|EXPERIMENTAL|A|"* Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR~* maintenance therapy every 3 months = 6 courses of reinduction with :~  * idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5, subcutaneously)~ * 10 to 20 mg (according to body weigh) of norethandrolone daily~* between the courses, a continuous regimen of methotrexate and 6-mercaptopurine."
62750019|NCT02509052|EXPERIMENTAL|Arm 1: 20 mg leflunomide|Patients receive 20 mg leflunomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62750020|NCT02509052|EXPERIMENTAL|Arm 2: 40 mg leflunomide|Patients receive 40 mg leflunomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62554901|NCT03917251|OTHER|Biventricular Pacemaker|Patients with Biventricular pacing and evidence of coronary ischemia who have evidence of coronary ischemia who are to undergo coronary angiogram.When an intermediate stenosis (40-80%) has been identified angiographically, this lesion will undergo further hemodynamic assessment, All data including resting flow, FFR, CFR, vital signs, arrhythmias and patient symptoms will be recorded twice: once when the pacemaker is programmed to pace, and once when the PPM is reprogrammed such that the pacemaker is no longer pacing.
62750021|NCT02509052|EXPERIMENTAL|Arm 3: 60 mg leflunomide|Patients receive 60 mg leflunomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62750022|NCT01416103|EXPERIMENTAL|Intervention group|Intervention group
62750023|NCT01416103|PLACEBO_COMPARATOR|Intervention control|Control group
62554902|NCT04835857||Experimental-Arm|"For the same subject,~1. ViTrack wrist cuff is applied on one of the wrist~2. Standard Oscillometric cuff is applied to the brachial artery / wrist of the same arm~3. Auscultatory cuff is applied to the brachial artery of the same arm"
62554903|NCT01414673|OTHER|spontaneous LH|
62554904|NCT01414673|EXPERIMENTAL|HCG|
62750024|NCT01975519|EXPERIMENTAL|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose pazopanib or every two week administration during cycle 1, and starting on cycle 2 day 1 and beyond, TRC105 may be administered every two weeks. This is also in combination with standard dose pazopanib.
62750025|NCT03589664||Non-Sternotomy Group|Subjects who have no prior sternotomy
62750026|NCT03589664||Sternotomy Group|Subjects who previously underwent a sternotomy procedure.
62750027|NCT01661777|OTHER|Nasal steroid and Antihistamine|Patients with ETD will be given nasal steroid and antihistamine for 8 weeks.
62750028|NCT01661777|ACTIVE_COMPARATOR|Myringotomy tubes|Patients who fail nasal steroid and antihistamine treatment will have myringotomy tubes placed.
62750029|NCT01661777|ACTIVE_COMPARATOR|Low salt diet and diuretic|Patient's who fail to improve with myringotomy tubes will be treated with low salt det and diuretic
62750030|NCT04627623||Screened arm|"6000 peoples (3x2000) in all ages randomly selected from the general population of three towns (Katowice, Sosnowiec, Gliwice).~From all invited is collected a venous blood samples (5ml) to assay IgM and IgG antibodies."
62750031|NCT04899258|OTHER|Pre-surgery and post-surgery|femtosecond assisted LASIK
62750032|NCT02375737|EXPERIMENTAL|m-health|Patients will receive text message, emails, and monthly phone calls
62750033|NCT01728506|EXPERIMENTAL|Weight Loss & Exercise|Single arm intervention of a 24 week weight loss and exercise intervention.
62554905|NCT01907230|EXPERIMENTAL|Entecavir, Prophylactic group|Participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
62554906|NCT01907230|NO_INTERVENTION|Control group (pre-emptive treatment)|Patients will start entecavir therapy, 0.5 mg/day orally, when reactivation of HBV (defined as detectable HBV viral loads for 2 consecutive visits with at least one month apart), and continued entecavir treatment until undetectable HBV viral loads for 1 year (consistent with current APASL recommendation).
62554907|NCT06499675||Group 1|obese patients
62554908|NCT02738138|EXPERIMENTAL|ABT-493/ABT-530 for 8 weeks|HCV Genotype (GT)1-6/HIV-1 co-infected non-cirrhotic subjects treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 8 weeks
62750034|NCT03070860|EXPERIMENTAL|PXE Patient|positron emission tomography scanner (PET scan) 18-FDG and 18-NAF: conventionnal use.
62750035|NCT04540666|EXPERIMENTAL|VR group|VR program will be displayed throughout the surgery.
62750036|NCT04540666|PLACEBO_COMPARATOR|Non-VR group|VR program will be turned off throughout the surgery.
62750037|NCT01741324|EXPERIMENTAL|Umeå, vitamin D 25 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
62750038|NCT01741324|ACTIVE_COMPARATOR|Umeå, vitamin D 10 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 10 microg vitamin D3 per dag.
62750039|NCT01741324|ACTIVE_COMPARATOR|Umeå, vitamin D 10 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per dag.
62750040|NCT01741324|EXPERIMENTAL|Malmö, vitamin D 25 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
62750041|NCT01741324|EXPERIMENTAL|Malmö, vitamin D 25 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
62750042|NCT01741324|ACTIVE_COMPARATOR|Malmö, vitamin D 10 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
62750043|NCT01741324|ACTIVE_COMPARATOR|Malmö, vitamin D 10 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
62750044|NCT01741324|PLACEBO_COMPARATOR|Malmö, placebo, dark skin,|Participants with dark skin will be randomized to a milk drink without added vitamin D (placebo).
62750045|NCT01741324|PLACEBO_COMPARATOR|Malmö, placebo, light skin|Participants with light skin will be randomized to a milk drink without added vitamin D (placebo).
62750046|NCT01741324|EXPERIMENTAL|Umeå, vitamin D 25 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
62750047|NCT02498886|EXPERIMENTAL|Iron deficient anaemic: IDA|"Iron deficient anaemic women.~Interventions: two iron supplements will be used:~IHAT- iron hydroxide adipate tartrate: an analogue of natural food iron. Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.~Each compound will be labelled with a stable isotope of iron:~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
62750048|NCT02498886|EXPERIMENTAL|Iron sufficient: non-IDA|"Women that are not anaemic or iron deficient.~Interventions: two iron supplements will be used:~IHAT- iron hydroxide adipate tartrate: an analogue of natural food iron. Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.~Each compound will be labelled with a stable isotope of iron:~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
62750049|NCT02498886|EXPERIMENTAL|Iron deficient anaemic (IDA): IHAT new manufacture|"Iron deficient anaemic women.~Interventions: two iron supplements will be used:~IHAT new manufacture- iron hydroxide adipate tartrate: an analogue of natural food iron.~Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.~Each compound will be labelled with a stable isotope of iron:~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
62750050|NCT05513872|EXPERIMENTAL|Condition #1|NRT Sampling = On Behavioral Counseling = Practice Quitting
62750051|NCT05513872|EXPERIMENTAL|Condition #2|NRT Sampling = Off Behavioral Counseling = Practice Quitting
62750052|NCT05513872|EXPERIMENTAL|Condition #3|NRT sampling = On Behavioral counseling = Motivational Interviewing
62750053|NCT05513872|EXPERIMENTAL|Condition #4|NRT sampling = Off Behavioral counseling = Motivational Interviewing
62750054|NCT06130774|EXPERIMENTAL|Retro walking and conventional|Patient will start retro walking with first he/she will raise his/her one foot with toe off first then heel will be off from ground. swing phase of same leg would be done in backward direction with flexion on knee and extension will be performed on hip. Then patient will place the same foot on ground behind the other foot, with toe touch first on ground, and so this way patient would continue for 20 minutes continue his retro-walk for 20 minutes.
62750055|NCT06130774|ACTIVE_COMPARATOR|conventional therapy|Hot pack in supine lying (10min) TENS (10min ) Tibiofemoral mobilization (grade 1,2 ,3) (10rep) Static quadriceps exercise in supine (10rep x 3sec x2set) hip abduction in side lying(10repx 2set) knee bending exercise in prone lying ( 10rep x 2set) Hamstring stretch in supine ( 10 rep x 2 set)
62750056|NCT05997992|EXPERIMENTAL|Electroacupuncture group|"The Electroacupuncture group received electroacupuncture at Baihui(GV20), bilateral Sanyinjiao(SP-6) and Fuliu points(KP-7).20 minutes of acupuncture.~Twice a week."
62750057|NCT05997992|PLACEBO_COMPARATOR|Sham acupuncture group|The control group received placebo acupuncture.Except for placebo acupuncture, which won't penetrate the skin, the rest is the same as the Electroacupuncture group.
62750058|NCT03610945|EXPERIMENTAL|EDP-305 and fluconazole interaction (Part 1)|
62750059|NCT03610945|EXPERIMENTAL|EDP-305 and quinidine interaction (Part 2)|
62750060|NCT02199951||Dihydroartemisinin and piperaquine|The patients will take Eurartesim® (DHA/PQP) with a dose regimen of one administration every 24 hours over a period of three days, i.e. at Day 1, then after 24 hours (Day 2) and after 48 hours (Day 3) from the first administration. The dose will be based on body weight. Two strengths of Eurartesim® will be provided for dosing in children and adults: 20/160mg and 40/320mg of DHA and PQP respectively. Body weight (kg) Daily dose (mg) Number of tablets per dose 20/160mg DHA/PQ 40/320mg DHA/PQ 5 to \<7 10 mg DHA and 80 mg PQP ½ tablet 7 to \<13 20 mg DHA and 160 mg PQP 1 tablet 13 to \< 24 40 mg DHA and 320 mg PQP 1 tablet 24 to \< 36 80 mg DHA and 640 mg PQP 2 tablets 36 to \< 75 120 mg DHA and 960 mg PQP 3 tablets 75 to \< 100 160 mg DHA and 1280 mg PQP 4 tablets \> 100.
62554909|NCT02738138|EXPERIMENTAL|ABT-493/ABT-530 for 12 weeks|HCV GT1-6/HIV-1 co-infected subjects with compensated cirrhosis treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 12 weeks
62554910|NCT05191485||Patients of decision making need assessment|"We will conduct semi-structured interviews with target patients and patients' representatives to assess their decisional needs. Decisional needs including difficult decision type /timing, unreceptive decisional stage, decisional conflict (uncertainty), inadequate knowledge \& unrealistic expectations, unclear values, inadequate support \& resources, and Personal \& clinical needs. All interviews will be conducted one-to-one or one-to-many (including families) and be audio-recorded for further analysis. Written informed consent will be obtained prior to each interview.~Nonrandom purposive sampling will be used to select key respondents to conduct in depth interview. Snowball sampling, where potential participants are asked to identify others who may be willing to participate, as well as convenience sampling, will be utilized. For patients, aiming for diversity regarding age, sex, education level and annual household income. All participants should be Chinese-speaking."
62567394|NCT06351891|ACTIVE_COMPARATOR|14-day bismuth quadruple regimen containing cefuroxime and levofloxacin|14-day bismuth quadruple regimen containing cefuroxime and levofloxacin:Tegoprazan (50mg twice/day before breakfast and supper), Bismuth potassium citrate capsule (0.6g twice/day before breakfast and supper), Cefuroxime tablets (500mg twice/day after breakfast and supper), Levofloxacin (500mg once/day after breakfast);14 days.
62567395|NCT06059287|EXPERIMENTAL|Henagliflozin|Henagliflozin 10mg qd po
62567396|NCT06059287|ACTIVE_COMPARATOR|Metformin|Metformin 1000mg bid po
62567397|NCT01326260||THAM Patients|Patients who were managed with the use of THAM
62567398|NCT01326260||Non-THAM Patients|Patients who did not use THAM but were resuscitated with crystalloids and colloids and may have received sodium bicarbonate for the treatment of acidosis
62567399|NCT05391347|EXPERIMENTAL|Intervention|3 ml of orange oil were dripping onto the sponge, and the patient was told to breathe slowly at a distance of 3 cm and to smell during the process
62567400|NCT05391347|NO_INTERVENTION|Control|
62567401|NCT02444208|EXPERIMENTAL|Cocaine Inhibitory Control Training|This group will receive active inhibitory control training.
62567402|NCT02444208|PLACEBO_COMPARATOR|Neutral Inhibitory Control Training|This group will receive neutral inhibitory control training.
62567403|NCT01731132||Group 1|
62567404|NCT01768026||No treatment|Subjects diagnosed with Dystrophic Epidermolysis Bullosa
62567405|NCT05171504||I , Infertile males with varicocele|Lactoferrin , iron in seminal plasma and semen analysis from Infertile patients with varicocele
62567406|NCT05171504||II , infertile males due to other causes than varicocele|Lactoferrin , iron in seminal plasma and semen analysis from infertile patients due to other causes than varicocele
62567407|NCT05171504||III , fertile males|Lactoferrin , iron in seminal plasma and semen analysis from fertile males with history of childbirth within the previous year
62567408|NCT03274388|EXPERIMENTAL|Control|Intervention of protein-rich nutritional therapy and counseling
62567409|NCT03274388|EXPERIMENTAL|Intervention|Intervention of protein-rich nutritional therapy and counseling combined with whole body electromyostimulation exercise training
62567410|NCT01999920|EXPERIMENTAL|Vilazodone|Vilazodone treatment. Dosage will begin at 10mg/day and will be increased to 20mg/day after 1 week, and 40mg/day after two weeks (optional). Dosage can be held steady or lowered at any time during the study as clinically indicated in the event of adverse effects. Twelve weeks of treatment, total.
62567411|NCT01999920|PLACEBO_COMPARATOR|Placebo|Pill placebo.
62750061|NCT02936310|EXPERIMENTAL|mindfulness intervention|"The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.The proposed topics include: 1) mindfulness: dealing with stress in a new way, 2) mindful awareness of stress: listening to our body, 3) mindful working with thoughts, 4) mindful working with emotions, 5) mindful interactions, and 6) dealing with obstacles of mindful practices and wrap-up. Mindfulness practices embedded in the program will include mindfulness breathing meditation, sitting meditation, standing meditation, walking meditation, movement meditation (Taichi or Yoga), body scan meditation and daily life meditation.~Data will be collected at pre-intervention (one week before the first session) and post-intervention (one week after the last session) to assess stress, burnout, mindfulness, anxiety,depression,the feedback on the MLWS intervention and the feedback on the influence of MLWS intervention."
62750062|NCT06605690|EXPERIMENTAL|experimental|Dalpiciclib and Letrozole Combined With Anlotinib
62750063|NCT02746601|EXPERIMENTAL|Risk Assessment, Counselling & Resources|Patients complete an electronic preconception health risk assessment tool. Results from the tool are directly uploaded or scanned into the patients' electronic medical record. A healthcare provider provides behavioural counselling, based on results of the risk assessment. Patients are given a customized handout that includes health recommendations and resources based on the patient's identified risk factors.
62750064|NCT01124123|EXPERIMENTAL|Bilastine 20 mg|Single dose 20 mg bilastine oral tablet. Test drug
62750065|NCT01124123|ACTIVE_COMPARATOR|Bilastine 10 mg|Single dose 10 mg Bilastine endovenous. Control drug
62750066|NCT01168791|EXPERIMENTAL|doxorubicin plus palifosfamide-tris|
62750067|NCT01168791|ACTIVE_COMPARATOR|doxorubicin plus placebo|
62567412|NCT04211688|EXPERIMENTAL|Combined individual + group Schema therapy|Those who will receive both individual plus group schema therapy
62567413|NCT04211688|ACTIVE_COMPARATOR|Only group Schema therapy|Those who will receive group schema therapy
62567414|NCT03993626|EXPERIMENTAL|CXD101 and Nivolumab combination|"* CXD101 will be presented as 10mg HPMC capsules and will be taken orally for 5 consecutive days repeated every three weeks on an outpatient basis.~* Nivolumab will be presented as a 10 mg/mL solution in a single-dose vial, administered as iv infusion over 60 mins, repeated every two weeks.~* CXD101 in combination with nivolumab will be administered in the Phase II component of the trial at doses determined in the Phase Ib component."
62750068|NCT05076916|EXPERIMENTAL|Intervention group|The web-based education program was introduced to the patients with cancer in the intervention group during face-to-face interviews. They were asked to examine the program for at least two hours a week for three months. During the follow-up period, the patients in the intervention group were called twice a week and reminded to use the education program. The researchers get in contact with the patients online via the website. During the follow-up period, the patients contact the research team by calling or writing messages via the website 24/7. An e-mail account was created by the research team using the email system of the university, and it was shared with the patients. The clinical researchers of the team answered the patients' questions via this e-mail account. In the third month, after the follow-up stage of the study was completed, the post-tests were administered to the patients in the intervention group who came to the hospital for follow-up or treatment.
62750069|NCT05076916|NO_INTERVENTION|Control group|The control group received routine patient education and routine hospital follow-ups given by Oncology Education Nurses during the three-month follow-up period. In the third month, after the follow-up stage of the study was completed, the post-tests were administered to the patients in the control group who came to the hospital for follow-up or treatment.
62750070|NCT01790282|EXPERIMENTAL|estradiole - progesterone arm|Cases are given estradiole valerate 2mg 3 times /day from day of ovum pick up until the time of pregnancy test two weeks together with daily IM injection of 100 progesterone starting . Single intramuscular 0.1 mg decapeptyl are given on day of transfer
62750071|NCT01790282|ACTIVE_COMPARATOR|Progesterone only arm|Patient are given 100 mg progesterone daily starting on day of pickup plus single dose of decapeptyl 0.1 mg on day of embryo transfer
62750072|NCT03398642|EXPERIMENTAL|French Lifestyle Redesign|16 older adults, 10 without and 6 with disabilities, participated to weekly 2-hour group sessions, including outings, and monthly 1-hour individual sessions led by a occupational therapist over 6-month period and promoting healthy lifestyle and involvement in meaningful activities.
62750073|NCT05343130|EXPERIMENTAL|Brain-Computer Interface controlled functional electrical stimulation feedback|
62750074|NCT05343130|SHAM_COMPARATOR|Sham Brain-Computer Interface controlled functional electrical stimulation feedback|
62750075|NCT03297073|EXPERIMENTAL|major hepatic surgery|resection greater than or equal to three hepatic segments
62750076|NCT03297073|EXPERIMENTAL|hepatic surgery|resection less than three hepatic segments
62750077|NCT03297073|EXPERIMENTAL|hepatic surgery recovery|
62750078|NCT03666897|OTHER|DTI Outcomes and Biomarkers|Imaging and Lab Collection
62750079|NCT00874458|EXPERIMENTAL|MRI|
62750080|NCT00920218|EXPERIMENTAL|GSK 1437173A F1 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 1 (F1) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
62750081|NCT00920218|EXPERIMENTAL|GSK 1437173A F2 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 2 (F2) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
62750082|NCT00920218|EXPERIMENTAL|Placebo-GSK 1437173A F1 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 1 dose of the placebo followed by 2 doses of GSK 1437173A F1 vaccine. For some safety analyses, this Group was split into Placebo 1D Group (results following placebo administration) and GSK 1437173A 2D Group (results following HZV administration). All vaccines were administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
62750083|NCT00920218|PLACEBO_COMPARATOR|Placebo Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of placebo, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
62750084|NCT06606964||Football players with genu varum|Football players with genu varum leg alignment
62750085|NCT06606964||Football players without genu varum|Football players with normal lower extremity alignment
62750086|NCT00322023|EXPERIMENTAL|D-serine 30 mg/kg|D-serine 30 mg/kg
62750087|NCT00322023|EXPERIMENTAL|D-serine 60 mg/kg|D-serine 60 mg/kg
62750088|NCT00322023|EXPERIMENTAL|D-serine 120 mg/kg|D-serine 120 mg/kg
62750089|NCT04236908|EXPERIMENTAL|Group 1 (NSAIDS only)|NSAIDs only (naproxen 500mg by mouth twice a day as needed)
62750090|NCT04236908|EXPERIMENTAL|Group 2 (Acupuncture+GV26)|Acupuncture to include use of GV 26 with manual tonification (twisting or rotating the needle) plus NSAIDs (naproxen 500mg by mouth twice a day as needed)
62750091|NCT04236908|EXPERIMENTAL|Group 3 (Battlefield Acupuncture+NSAIDS)|Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men) plus NSAIDs (naproxen 500mg by mouth twice a day as needed)
62750092|NCT04236908|EXPERIMENTAL|Group 4 (Battlefield Acupuncture+GV26+NSAIDS)|GV26 with manual tonification + Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men) plus NSAIDs (naproxen 500mg by mouth twice a day as needed).
62750093|NCT04979767||Sepsis|I. ≥ 50 years with ≥ 2 chronic comorbidities II. Highly suspected bacterial infection based on clinical or radiologic evidence III. ≥ 2 systemic inflammatory response syndrome (SIRS) criteria IV. Actual/anticipated admission to intensive care unit (ICU) V. Anticipated length of hospital stay ≥ 5 days
62750094|NCT04979767||Control|I. ≥ 50 years with ≥ 2 chronic comorbidities II. No suspected bacterial infection III. Actual/anticipated admission to intensive care unit (ICU) IV. Anticipated length of hospital stay ≥ 5 days
62750095|NCT05039164|ACTIVE_COMPARATOR|Initial training|School personnel will implement CATS or CPP and CICO with students in the school setting. They will participate in an initial live remote training to learn about implementing the three EBPs (CC).
62750096|NCT05039164|EXPERIMENTAL|Initial training plus video|School personnel will implement CATS or CPP and CICO with students in the school setting. They will participate in an initial live remote training and receive access to asynchronous video training modules about the EBPs (RV).
62750097|NCT05039164|EXPERIMENTAL|Initial training plus video, plus coaching|School personnel will implement CATS or CPP and CICO with students in the school setting. They will participate in an initial live remote training, receive access to asynchronous video training modules about the EBPs, and receive coaching support by study staff (RV+). The coaching will be from a study consultant regarding the implementation of EBPs.
62750098|NCT00090142|EXPERIMENTAL|1|Montelukast - Placebo
62750099|NCT00090142|EXPERIMENTAL|2|Placebo - Montelukast
62554911|NCT05191485||Other stakeholders of decision making need assessment|"We will conduct semi-structured interviews with other stakeholders to assess their decisional needs. All interviews will be conducted one-to-one and be audio-recorded for further analysis. Written informed consent will be obtained prior to each interview.~Nonrandom purposive sampling will be used to select key respondents to conduct in depth interview. Snowball sampling, where potential participants are asked to identify others who may be willing to participate, as well as convenience sampling, will be utilized. For other stakeholders (including thoracic surgeons, nurses, psychoanalyst, hospital administrators, molecular testing company staffs and insurance company staffs), region, seniority, position, and attitude toward both molecular testing and SDM are considered. All participants should be Chinese-speaking."
62567415|NCT06254716||Disc resection of rectal endometriosis|Patients who underwent disc resection and anastomosis for rectal endometriosis involving the full thickness of the rectum reaching the mucosa or submucosa during preoperative evaluation or intraoperative exploration, and who were diagnosed pathologically.
62750100|NCT04852705|EXPERIMENTAL|candidate vaccine|
62750101|NCT04852705|PLACEBO_COMPARATOR|Placebo|
62750102|NCT05377658|EXPERIMENTAL|AK104+albumin-bound paclitaxel+carboplatin|Participants receive 3 cycles of AK104 in combination with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy prior to surgery; followed by surgery; followed by adjuvant AK104 for 9 cycles.
62750103|NCT01828619||modified BuFlu, HSCT, elder/intolerable|The study group is the hematlogic malignant patients that older than 55years and/or with severe concurrent medical conditions, who will undergo HLA-matced allogenic HSCT to cure the disease. The patients will received a modified BuFlu conditioning.
62750104|NCT03371511||MiLC Cohort|"Participants donated HM from two consecutive pumping sessions at home. Women pumped once with their own pump and milk collection kit, and once with a sterile and sterile collection kit. Both pumping sessions occurred at participants' homes between 0700 and 1100 hours. The second pumping session occurred within 3 hr (+/- 30 min) after the beginning of the first. Randomization was used to determine which pump was used first. Women elected from which breast they donated their HM and were asked not to nurse on that side 2 hr before the first pumping session and not until after the second. Before women pumped with their own pump, swabs were taken of the breast from which HM was donated, the women's dominant hand, their own bottle/flange, their own pumps (port of pump and tubing), and their babies' mouths.~There was only one group but stratified enrollment was used to ensure equal numbers of women whose infants consumed HM only and women whose infants consumed HM and complementary foods."
62750105|NCT03135769|EXPERIMENTAL|Avelumab|Avelumab administration at 10 mg/kg every 14 days during 6 months maximum
62750106|NCT04193761|ACTIVE_COMPARATOR|Control|
62750107|NCT04193761|ACTIVE_COMPARATOR|Chronic hepatitis|
62750108|NCT04193761|ACTIVE_COMPARATOR|Cirrhosis|
62750109|NCT04193761|ACTIVE_COMPARATOR|Hepatocellular carcinoma|
62750110|NCT05762250|EXPERIMENTAL|Auricular Acupuncture|"Intervention group: Ear acupressure is performed on both ears with permanent pellets according to the NADA (National Acupuncture Detoxification Association) protocol over a period of 8 weeks (presentation at the study center 1x/week, application of the acupressure patches there; these remain on both ears for 5 days and should be massaged 3x/day by the patients themselves according to the instructions provided).~In addition, patients receive a 30-minute psychoeducational talk at the first treatment appointment to promote their own health competence."
62750111|NCT05762250|NO_INTERVENTION|Waitlist|Control group: standard treatment / waiting list Patients in the control group will also receive a one-time 30-minute psychoeducational interview at baseline.
62750112|NCT05124652|NO_INTERVENTION|Focus Group Testing|Focus group testing of key-fob device to control adjusting socket system
62750113|NCT05124652|EXPERIMENTAL|In-Lab, Crossover Study|Testing of auto-adjusting algorithm in-lab. Participants will carry out a structured protocol wearing the socket in all modes. Order will be randomly assigned.
62750114|NCT05124652|EXPERIMENTAL|Out-of-Lab Crossover Study|Evaluate socket performance in user free-living environments. Participants will use the prosthesis in all modes by end of study, order will be randomly assigned.
62750115|NCT00368836|EXPERIMENTAL|BreathScreen PE + D-dimer|CO2/O2 ratio will be measured using the Breath Screen PE device. D-dimer levels will also be collected.
62750116|NCT03341078|PLACEBO_COMPARATOR|Placebo|Placebo Group will be dosed with a placebo oral tablet twice daily for 6 weeks. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
62750117|NCT03341078|ACTIVE_COMPARATOR|Ibudilast|Ibudilast Group will be dosed with ibudilast twice daily for 6 weeks. The first 2 weeks will be 20 mg twice daily followed by 4 weeks of 50 mg twice daily. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
62750118|NCT03341078|NO_INTERVENTION|Controls|Healthy controls will only undergo baseline evaluations and will not be enrolled in the drug portion of the study.
62750119|NCT06488612|EXPERIMENTAL|Cases|A Prospective Half-side Comparative Study, Minced skin grafts will be used on a half of donor site of the same patient
62750120|NCT02348879|EXPERIMENTAL|AMG 403|AMG 403 administered as subcutaneous and intravenous doses
62750121|NCT02348879|PLACEBO_COMPARATOR|Placebo|No active drug
62750122|NCT06155656|EXPERIMENTAL|Pea concentrate|Participants randomized to receive a soup containing 25 g of protein from pea protein concentrate
62750123|NCT06155656|EXPERIMENTAL|Pea isolate|Participants randomized to receive a soup containing 25 g of protein from pea protein isolate
62750124|NCT06155656|EXPERIMENTAL|Pea extrudate|Participants randomized to receive a soup containing 25 g of protein from pea protein extrudate
62750125|NCT06155656|ACTIVE_COMPARATOR|Whey|Participants randomized to receive a soup containing 25 g of protein from whey protein
62750126|NCT01960998|EXPERIMENTAL|Telehealth with Pelvic Floor Muscle Training|Participants in this group will participate in an evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 1 month before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively. In addition to the pelvic floor muscle training, content will also include general perioperative care; wetness, odor and skin care management; and outcome measures.
62750127|NCT01960998|ACTIVE_COMPARATOR|Telehealth without Pelvic Floor Muscle Training|Participants in this group will receive a telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 3 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
62750128|NCT04482530|EXPERIMENTAL|Original recipe|Normal fruit paste
62750129|NCT04482530|EXPERIMENTAL|maltodextrin recipe|fruit pastes in which some of the simple sugars in the recipe will be replaced by maltodextrin with a low glycemic index (DE12).
62750130|NCT04482530|EXPERIMENTAL|fructose recipe|fruit pastes in which some of the simple sugars in the recipe (25% min) will be replaced by fructose
62750131|NCT04482530|EXPERIMENTAL|isomaltulose recipe|fruit pastes with some of the sugars will be replaced (25% min) by isomaltulose
62750132|NCT04482530|EXPERIMENTAL|mixed recipe|fruit pastes with some of the sugars will be replaced (25% min) by fructose / isomaltulose
62750133|NCT02193386|ACTIVE_COMPARATOR|Usual Care|No intervention, no follow-up, only registration of usual therapy
62750134|NCT02193386|EXPERIMENTAL|Intervention period|Predefined, evidence-based program and support
62750135|NCT02921555|EXPERIMENTAL|methylprednisolone & prednisone|Intravenous bolus of methylprednisolone followed by a decreasing conventional course of oral prednisone
62750136|NCT02921555|ACTIVE_COMPARATOR|prednisone|A decreasing conventional course of oral prednisone
62750137|NCT06215703|EXPERIMENTAL|Order 1|Participants randomized to Order 1 will complete the four music playing tasks in the following order: (1) No improvisation (maintain beat), no live accompaniment (recorded accompaniment); (2) Improvisation, no live accompaniment (recorded accompaniment); (3) No Improvisation (maintain beat), live accompaniment; (4) Improvisation, live accompaniment.
62750138|NCT06215703|EXPERIMENTAL|Order 2|Participants randomized to Order 2 will complete the four music playing tasks in the following order: (1) Improvisation, no live accompaniment (recorded accompaniment); (2) No improvisation (maintain beat), no live accompaniment (recorded accompaniment); (3) Improvisation, live accompaniment; (4) No improvisation (maintain beat), live accompaniment.
62750139|NCT06215703|EXPERIMENTAL|Order 3|Participants randomized to Order 3 will complete the four music playing tasks in the following order: (1) No improvisation (maintain beat), live accompaniment; (2) Improvisation, live accompaniment; (3) No improvisation (maintain beat), no live accompaniment (recorded accompaniment); (4) Improvisation, no live accompaniment (recorded accompaniment).
62750140|NCT06215703|EXPERIMENTAL|Order 4|Participants randomized to Order 3 will complete the four music playing tasks in the following order: (1) Improvisation, live accompaniment; (2) No improvisation (maintain beat), live accompaniment; (3) Improvisation, no live accompaniment (recorded accompaniment); (4) No improvisation (maintain beat), no live accompaniment (recorded accompaniment).
62750141|NCT03659903||younger patients (age < 80)|age \< 80 patients， All the variables' definitions are encoded in the SEER database. To identify the PDAC cases, site codes (C25 pancreas, C25.0-C25.9) and histology codes (8140 adenocarcinoma, 8500 infiltrating duct carcinoma) based on the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) were used.11 Only cases that underwent PD and microscopically confirmed were included.
62750142|NCT03659903||older patients (age≥ 80 )|age ≥ 80 years-old patients，All the variables' definitions are encoded in the SEER database. To identify the PDAC cases, site codes (C25 pancreas, C25.0-C25.9) and histology codes (8140 adenocarcinoma, 8500 infiltrating duct carcinoma) based on the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) were used.11 Only cases that underwent PD and microscopically confirmed were included.
62750143|NCT02657681|EXPERIMENTAL|tSMS|30 min of tSMS, one session per day, for 9 days over 2 weeks
62750144|NCT02657681|PLACEBO_COMPARATOR|sham|30 min of sham, one session per day, for 9 days over 2 weeks
62750145|NCT01655121|EXPERIMENTAL|Autoimmune hepatitis (Non-cirrhotic)|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
62750146|NCT01655121|EXPERIMENTAL|Autoimmune hepatitis (Cirrhotic)|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
62750147|NCT03448666|EXPERIMENTAL|pembrolizumab and elettrochemiotherapy|drug: Pembrolizumab 200 mg flat dose every three weeks procedure: elettrochemiotherapy once after first pembrolizumab dose
62750148|NCT02152371|EXPERIMENTAL|Dulaglutide + Insulin Glargine|1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
62750149|NCT02152371|PLACEBO_COMPARATOR|Placebo + Insulin Glargine|Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
62567416|NCT06254716||Segmental resection of rectal endometriosis|Patients who underwent segmental resection and anastomosis for rectal endometriosis involving the full thickness of the rectum reaching the mucosa or submucosa during preoperative evaluation or intraoperative exploration, and who were diagnosed pathologically.
62750150|NCT06604819|ACTIVE_COMPARATOR|closed sinus lifting using osteotomes with simultaneous implant placement|Full thickness mucoperiosteal flap was elevated.• The pilot drill of the implant system was used to create an osteotomy 1 mm short of the subantral floor. • The insertion of the osteotome were repeated several times until the required membrane lift was achieved then the osteotome corresponding in size to the last drill was used.After that, placement of the implant was done .Healing abutment was placed to allow for multiple times measurements of implant stability and primary closure was done and the flap was sutured in an interrupted manner using 4/0 prolene suture .
62750151|NCT06604819|EXPERIMENTAL|closed sinus lifting using osteotomes with simultaneous implant placement with ozone gel placement|Full thickness mucoperiosteal flap was elevated.• The pilot drill of the implant system was used to create an osteotomy 1 mm short of the subantral floor. • The insertion of the osteotome were repeated several times until the required membrane lift was achieved then the osteotome corresponding in size to the last drill was used.Ozone gel was delivered into the osteotomy . To obtain the ozone gel, pure olive oil was blasted with 25 μ/ml O3 gas for two days, or until the oil changed from a greenish-colored liquid to a whitish gel. The longevity Ext 120 ozone generator executed out this process. After that, placement of the implant was done .Healing abutment was placed to allow for multiple times measurements of implant stability and primary closure was done and the flap was sutured in an interrupted manner using 4/0 prolene suture .
62750152|NCT02042053|EXPERIMENTAL|PET/MR|Patients treated with SipT (standard of care) undergo FDG-PET/MRI, NaF-PET/CT and blood drawing at 3 time points: baseline, Day 7 after the last SipT infusion, Week 10 after the last SipT infusion.
62750153|NCT04132076||Group A: Osteochondral lesion of talus (OLT)|Patients with OLT treated operatively (debridement, microfracture, allograft, mesenchymal stem cells implantation) in Department of Orthopaedic Surgery, University Medical Centre Ljubljana (UMC).
62750154|NCT04132076||Group B: Ankle joint osteoarthrosis|Patients with ankle joint osteoarthrosis treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
62750155|NCT04132076||Group C: Ankle Impingement syndrome|Patients with ankle impingement syndrome treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
62750156|NCT04132076||Group D: Ankle instability syndrome|Patients with ankle instability syndrome treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
62750157|NCT04428190|ACTIVE_COMPARATOR|Human Milk Oligosaccharide (HMO)|"10 g sachet, self-administered for 3 months.~2'-O-fucosyllactose and lacto-N-neotetraose, novel human milk oligosaccharide (HMO) sugars have been shown to stimulate the production of short chain fatty acids, especially propionate. Propionate has been shown to be important in attenuating hypertrophy, fibrosis, vascular dysfunction and hypertension (Bartolomaeus H et al 2019Mar12) and extremely important for the gut kidney axis (Li L et al 2017Dec11)."
62750158|NCT04428190|PLACEBO_COMPARATOR|Placebo|"10 g sachet, self-administered for 3 months.~Placebo sachets are identical to the HMO sachets in color, taste, smell, size and shape"
62750159|NCT03851120|EXPERIMENTAL|Intervention|150 pregnant women will be given Probiotics and 480 mg DHA, psychosocial stimulation, and healthy eating education
62750160|NCT03851120|PLACEBO_COMPARATOR|Control|150 pregnant women will be given placebo probiotics and 240 mg DHA, psychosocial stimulation, and healthy eating education
62750161|NCT03100240|EXPERIMENTAL|Experimental group|Modified Supper Long Protocol
62750162|NCT03100240|NO_INTERVENTION|control group|long protocol
62750163|NCT05943392||Healthy volunteers|EEG recordings; behavioural data (psychophysics)
62554912|NCT05191485||Participants of cognitive debriefing/alpha tests|The purpose of Alpha test is to test the understandability of Decision Aid for Lung Cancer Molecular Testing version 1.0 (DA_LCMT 1.0). All debriefing interviews will be conducted one-on-one with structured probing questions. Participants will be encouraged to comment on DA_LCMT 1.0 and give recommendations to replace any unclear wording. At the start, the interviewer will explain the aim of the study and the procedures of the cognitive debriefing to participants. Then a paper-based DA_LCMT 1.0 will be given to participants, and sufficient time will be guaranteed to allow them to read DA_LCMT 1.0. The cognitive debriefing interview will start afterwards, and participants will answer questions probing questions asked by interviewers about DA_LCMT 1.0. Each cognitive debriefing interview will last for about 20 minutes. DA_LCMT 2.0 will be generated after the completion of the cognitive debriefing (Alpha test).
62567417|NCT01872312|OTHER|treatment|Loading IBV® Valve System
62567418|NCT00730483|EXPERIMENTAL|DEB-TACE|PVA microporous hydrospheres loaded with doxorubicin hydrochloride used for the treatment of unresectable liver metastases from neuroendocrine tumors.
62750164|NCT03262766|ACTIVE_COMPARATOR|Acute intermittent hypoxia (AIH)|"Subjects will be exposed to acute intermittent hypoxia, daily for 5 days. Each session will consist of up to 90 seconds of 9-10% Oxygen (FiO2 0.09), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for up to 45 minutes, to maintain SpO2 at 80-90%. If the SpO2 drops below 75%, hypoxia exposure will be terminated immediately.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2)."
62750165|NCT03262766|EXPERIMENTAL|AIH+ Upper extremity training|"Subjects will be exposed to acute intermittent hypoxia, daily for 5 days. Each session will consist of up to 90 seconds of 9-10% Oxygen (FiO2 0.09), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for up to 45 minutes, to maintain SpO2 at 80-90%. If the SpO2 drops below 75%, hypoxia exposure will be terminated immediately.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2).~Following the AIH protocol, subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®."
62554913|NCT05191485||Patients of Field testing /β tests|"Then the investigators will conduct the field testing (Beta test) with patient and clinician facing the decision in real time. The purpose of Beta test is to test the usability of DA_LCMT 2.0 in real-world setting. Clinician and patients will use the DA_LCMT 2.0 for real-time decision making. The conversation of decision progress will be audio-recorded. After the decision is made by patients, structured interview will be conducted and audio-recorded separately between clinician and patients. All the field testing interviews will conducted one-on-one and written informed consent will be obtained prior to each interview. Each field testing interview will last for about 20 minutes."
62554914|NCT05191485||Clinician of Field testing /β tests|"Then the investigators will conduct the field testing (Beta test) with patient and clinician facing the decision in real time. The purpose of Beta test is to test the usability of DA_LCMT 2.0 in real-world setting. Clinician and patients will use the DA_LCMT 2.0 for real-time decision making. The conversation of decision progress will be audio-recorded. After the decision is made by patients, structured interview will be conducted and audio-recorded separately between clinician and patients. All the field testing interviews will conducted one-on-one and written informed consent will be obtained prior to each interview. Each field testing interview will last for about 20 minutes."
62554915|NCT02224989|EXPERIMENTAL|Mind-Body Bridging|An awareness training program using mindfulness-based techniques.
62554916|NCT01674218|EXPERIMENTAL|Treatment E|PA-824 400 mg plus moxifloxacin 400 mg
62554917|NCT01674218|ACTIVE_COMPARATOR|Treatment D|PA-824 placebo plus moxifloxacin 400 mg
62554918|NCT01674218|EXPERIMENTAL|Treatment C|PA-824 1000 mg plus moxifloxacin placebo
62554919|NCT01674218|EXPERIMENTAL|Treatment B|PA-824 400 mg plus moxifloxacin placebo
62554920|NCT01674218|PLACEBO_COMPARATOR|Treatment A|PA-824 placebo and moxifloxacin placebo
62554921|NCT00714194|OTHER|1|Patients in the control group will receive continuous sedative infusions without daily interruption of sedatives based on the standard clinical practice of the TICU.
62554922|NCT00714194|EXPERIMENTAL|2|Patients in the intervention group will receive daily interruption of sedative.
62554923|NCT01555346||High risk pregnant subjects undergoing an invasive procedure|Women with one or more high risk factors for fetal chromosome 21 aneuploidy scheduled to undergo an invasive procedure for fetal karyotype determination.
62554924|NCT01555346||High risk subjects electing not to undergo invasive procedure|Women with one or more high risk factors for fetal chromosome 21 aneuploidy who elect not to undergo an invasive procedure for fetal karyotype determination.
62554925|NCT01891630||AA children|African-American children with moderate-to-severe asthma living in a defined geographical area whose asthma is poorly controlled, and up to 30 moderate-to-severe African-American asthmatic children living in the same defined geographical area whose asthma is well controlled.
62554926|NCT06470191|EXPERIMENTAL|B007|
62554927|NCT06470191|ACTIVE_COMPARATOR|Cyclosporin Capsules|
62554928|NCT05122169|EXPERIMENTAL|chlorhexidine|Pre-vaginal delivery skip prep using chlorhexidine-alcohol
62554929|NCT05122169|ACTIVE_COMPARATOR|Povidone-iodine|Pre-vaginal delivery skip prep using Povidone-iodine
62554930|NCT04206917|EXPERIMENTAL|Multi Pulse Therapy|Subjects will have AF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia.
62554931|NCT02063750|EXPERIMENTAL|Strengthening group|This group perform muscle strengthening exercises using a Swiss ball of 65 cm diameter.
62554932|NCT02063750|ACTIVE_COMPARATOR|Stretching group|Performed stretching exercises
62554933|NCT00805324|EXPERIMENTAL|Arm 1|
62554934|NCT01095302|EXPERIMENTAL|Ombrabulin/ docetaxel/cisplatin|AVE8062 combined with docetaxel and cisplatin will be administered once in every 3 weeks, with 30-minute intravenous infusion
62554935|NCT05460702||Luminal A|Breast cancer patients with immunohistochemically luminal A
62554936|NCT05460702||Luminal B|Breast cancer patients with immunohistochemically luminal B
62554937|NCT05460702||Triple negative|Breast cancer patients with immunohistochemically triple negative
62554938|NCT05460702||Control|The absence of any pathology in the breasts of healthy volunteers by mammography and/or ultrasound
62554939|NCT03520556||docosahexaenoic acid (DHA)|Adults supplemented with DHA in a randomized controlled trial of ≥7 days duration
62554940|NCT03520556||eicosapentaenoic acid (EPA)|Adults supplemented with EPA in a randomized controlled trial of ≥7 days duration
62554941|NCT03520556||control|Adults supplemented with control fatty acids in a randomized controlled trial of ≥7 days duration assessing the effects of EPA and/or DHA
62554942|NCT05681598|EXPERIMENTAL|Hydroxyurea treatment|participants were treated with hydroxyurea
62554943|NCT03346096|EXPERIMENTAL|Thiotepa|Thiotepa for reduce toxicity and improve outcome following transplantation
62554944|NCT05675098|EXPERIMENTAL|Methylphenidate|Participants in this group will receive 2.5mg Methylphenidate and 100mg placebo (Modafinil shape) in addition to physical therapy program
62554945|NCT05675098|EXPERIMENTAL|Modafinil|Participants in this group will receive 100mg Modafinil and 2.5mg placebo (Methylphenidate shape) in addition to physical therapy program
62554946|NCT05675098|PLACEBO_COMPARATOR|Placebo|Participants in this group will receive 2.5mg placebo (Methylphenidate shape) and 100mg placebo (Modafinil shape) in addition to physical therapy program
62567419|NCT01211834|EXPERIMENTAL|Tocilizumab 8mg/kg+DMARDs|
62567420|NCT01211834|PLACEBO_COMPARATOR|Placebo+DMARDs|
62375186|NCT04691349|EXPERIMENTAL|Chimeric antigen receptor T cell|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells
62375187|NCT03316742|EXPERIMENTAL|Intervention 1|Participants randomized to intervention 1 will complete baseline and endline outcomes and participate in version 1 of a weight loss program. Each participant will attend twelve one hour classes discussing weight loss adherence in addition to barriers experienced. Changes in weight will be recorded throughout the study.
62375188|NCT03316742|EXPERIMENTAL|Intervention 2|Participants randomized to intervention 2 will complete baseline and endline outcomes and participate in version 2 of a weight loss program. Each participant will attend 12 one hour classes discussing weight loss adherence in addition to barriers experienced. Changes in weight will be recorded throughout the study.
62554947|NCT02134652||Suspected Dengue|Children with an acute febrile illness, and two of the following: headache, retro-orbital pain, myalgias, arthralgia, rash, hemorrhagic manifestations, or plasma leakage (i.e. shortness of breath, abdominal distention/pain) will all receive a diagnostic bedside ultrasound.
62375189|NCT04426240|ACTIVE_COMPARATOR|Cyclosporine|Subject who use cyclosporine and hyaluronate artificial tear 1 month before cataract surgery
62375190|NCT04426240|NO_INTERVENTION|non-Cyclosporine|Subject who use only hyaluronate eye drop 1 month before cataract surgery
62554948|NCT02431377|EXPERIMENTAL|S-26 Gold|Standard Infant Formula containing enriched with alpha-lactalbumin
62375191|NCT01983683|EXPERIMENTAL|Cadazolid|Subjects receive oral cadazolid 250 mg twice daily (bid) and oral vancomycin-matching placebo 4 times per day (qid) for 10 days
62375192|NCT01983683|ACTIVE_COMPARATOR|Vancomycin|Subjects receive oral vancomycin 125 mg qid and oral cadazolid-matching placebo bid for 10 days
62375193|NCT04070092||TBI group|"A cohort of patients admitted to UZ Leuven from 2019 to 2023 due to Traumatic Brain Injury and fulfilling our inclusion and exclusion criteria will be recruited.~* Inclusion criteria will be: ≥ 65 years old, admitted to UZ Leuven between 2019 and 2023 due to TBI, all injury severities (mild (GCS 13-15), moderate (GCS 9-12) or severe (GCS ≤8)), and having signed the informed consent to participate in the study.~* Exclusion criteria will be: \< 65 years old, admitted to UZ Leuven before 2019, diagnose of neurodegenerative diseases before the TBI, cognitive and motor disturbances caused by any other pathology, previous alcohol/drugs abuse, and not having signed the informed consent to participate in the study."
62554949|NCT05623501|EXPERIMENTAL|Cohort 1|DHM 300mg x1 dose
62554950|NCT05623501|EXPERIMENTAL|Cohort 2|DHM 900mg x1 dose
62554951|NCT05623501|EXPERIMENTAL|Cohort 3|DHM 300mg x1 dose + Lysine 140mg x1 dose
62554952|NCT05623501|EXPERIMENTAL|Cohort 4|DHM 900mg x1 dose + Lysine 420mg x1 dose
62554953|NCT03333941||RES (Regenerative Epithelial Suspension)|
62554954|NCT03194269|EXPERIMENTAL|EARFOLD®|EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic
62554955|NCT00307398|EXPERIMENTAL|AL-3789|One injection to the study eye by the posterior juxtascleral depot procedure at 6-month intervals for 42 months.
62554956|NCT00307398|SHAM_COMPARATOR|Anecortave Acetate Vehicle|One sham injection to the study eye at 6-month intervals for 42 months. Syringe containing AA vehicle was not inserted into the eye.
62750166|NCT03262766|ACTIVE_COMPARATOR|Sham AIH + Upper extremity training|"Subjects will be exposed to sham hypoxia daily for 5 days. Each session will consist of up to 90 seconds of 21% Oxygen (FiO2 0.21), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery will be repeated up to 18 times per session each, for a total of up to 45 minutes.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2).~Following the sham AIH protocol, subjects will receive 45 minutes of task-specific, high repetition upper extremity training. Upper extremity training will be given using an upper-limb robotic rehabilitation device, the Armeo Spring®."
62750167|NCT03262766|SHAM_COMPARATOR|Sham Acute intermittent hypoxia|"Subjects will be exposed to sham hypoxia daily for 5 days. Each session will consist of up to 90 seconds of 21% Oxygen (FiO2 0.21), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery will be repeated up to 18 times per session each, for a total of up to 45 minutes.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2)."
62750168|NCT03886337|NO_INTERVENTION|Control|The control arm will be surgical care according to usual practice with usual ambient lighting
62750169|NCT03886337|EXPERIMENTAL|Treatment Arm|The treatment arm will include surgical care according to usual practice with germicidal ambient lighting
62750170|NCT04915170|EXPERIMENTAL|High intensity group|Intervention is administrated with an inspiratory muscle trainer (IMT). High intensity group: 10 cycles, 1 minute each one, 40% MIP with IMT. 1 minute to rest between cycles.
62750171|NCT04915170|EXPERIMENTAL|Low intensity group|Intervention is administrated with an inspiratory muscle trainer (IMT). Low intensity group: 10 cycles, 1 minute each one, 20% MIP with IMT. 1 minute to rest between cycles.
62750172|NCT06116539|EXPERIMENTAL|Cyanoacrylate Group|In the test group, a cyanoacrylate-based tissue adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
62750173|NCT06116539|ACTIVE_COMPARATOR|Suture Group|In the control group, the edges will be approximated with 4/0 monofilament non-absorbable nylon suture (Aragó, Barcelona, Spain).
62750174|NCT04660825|EXPERIMENTAL|High intensity resistance band exercise|Randomly assigned as exercise group, exercise intervention. This will be a progressive exercise programme with the aim being to participate three times per week, one in a group session and two in-home sessions.
62750175|NCT04660825|EXPERIMENTAL|Non resistance band exercise|Randomly assigned non-exercise group
62750176|NCT00724685|PLACEBO_COMPARATOR|Placebo|
62750177|NCT00724685|EXPERIMENTAL|Active|
62750178|NCT02938832|ACTIVE_COMPARATOR|Traditional low-fat diet advice|Advice on traditional low-fat diet by dietician
62375194|NCT04070092||Control group|"A cohort of healthy volunteers with similar demographic characteristics will be recruited as a control group.~* Inclusion criteria will be: ≥ 65 years old and having signed the informed consent to participate in the study.~* Exclusion criteria will be: \< 65 years old, diagnose of neurodegenerative diseases, cognitive and motor disturbances caused by any pathology, previous alcohol/drugs abuse, and not having signed the informed consent to participate in the study."
62554957|NCT04099004|OTHER|Neural Imaging|Females with PFP attending a single study visit where neural imaging is acquired via MRI.
62554958|NCT05091970|EXPERIMENTAL|In-Person|Manualized cognitive rehabilitation for mild traumatic brain injury (mTBI) delivered face-to-face.
62554959|NCT05091970|EXPERIMENTAL|Telehealth|Manualized cognitive rehabilitation for mild traumatic brain injury (mTBI) delivered via telehealth.
62554960|NCT06032078|EXPERIMENTAL|Patients with keratosis pilaris|Patients treated with 3 sessions of 1064nm Nd: YAG laser at 4-weekly intervals. Results are compared with baseline.
62554961|NCT02710721|EXPERIMENTAL|Fasting|60h-modified fasting (36h before and 24h after chemotherapy)
62554962|NCT02710721|ACTIVE_COMPARATOR|Control|mediterranean diet
62554963|NCT06227767|ACTIVE_COMPARATOR|exercise group twice a week|Spinal stabilization exercises determined by the authors will be applied 2 days a week for 40 minutes.
62554964|NCT06227767|ACTIVE_COMPARATOR|exercise group four times a week|Spinal stabilization exercises determined by the authors will be applied 4 days a week for 40 minutes.
62554965|NCT06227767|NO_INTERVENTION|control group|Patients will be followed with a home exercise program
62554966|NCT04763629|EXPERIMENTAL|Interval Training (IT)|Patients randomized to this group will perform 45 minutes of exercise on treadmill, alternating intervals of ten minutes at 50-60% of VO2 peak and two intervals five miutes at 85-90% of VO2 peak
62750179|NCT02938832|ACTIVE_COMPARATOR|Mediterranean diet advice|Advice on a Mediterranean dietary regime with reduced carbohydrates
62750180|NCT06330103|ACTIVE_COMPARATOR|LV function from cardiologist|Certified Cardiologist will access and interpreted LV function by used traditional Echocardiography then separate result into three group Preserved LV ejection fraction(EF\>50%), mildly reduce ejection fraction(EF40-49%), reduced LV ejection fraction(EF\<40%)
62375195|NCT03606707|EXPERIMENTAL|corticosteroid|steroid group, received intra-articular steroid injection for atlantoaxial joint. , in addition to methotrexate and chloroquine 400 mg per day.
62554967|NCT04763629|EXPERIMENTAL|Compbined Training (CT)|Patients randomized to this group will perform 45 minutes of exercise in which they will perform aerobic continuous training on tradmill (20 minutes) and resistance training (25 minutes)
62554968|NCT05778812|EXPERIMENTAL|Full Sleep|"With Full Sleep, the app provides daily lessons about sleep and skills that can help with sleep. In the app, participants also record information about each night's sleep in their sleep log. Every seven nights, they also complete the Sleep Needs Questionnaire. At the beginning, middle, and end of the study, they additionally complete the Insomnia Severity Inventory in the app. At the end of every week, a sleep schedule and weekly summary are calculated via automated formulas. The app also contains access to messaging a coach. The intent of coach access is for participants to ask questions about their daily lessons and application of the skills and to feel supported and accountable.~The REST (Radar Enabled Sensing Technology) device in the Full Sleep program uses radar to passively track sleep patterns and nighttime awakenings. It also offers white noise options and audio guidance for relaxation techniques and stimulus control."
62554969|NCT05778812|ACTIVE_COMPARATOR|Path to Better Sleep|Path to Better Sleep is a self-management tool for insomnia. It is available as a web-based program at https://www.veterantraining.va.gov/apps/insomnia/index.html#dashboard. Path to Better Sleep is intended to be completed over six weeks, and includes weekly educational lessons about sleep which include videos, visual depictions, and interactive activities, in addition to sleep check-ins (e.g., knowledge checks, self reflections about sleep). It also includes sleep logging. Participants in this condition will be asked to share their sleep log weekly via email, as Stanford and Koko Labs do not receive access to the data.
62554970|NCT03856801|EXPERIMENTAL|Whole-body vibration in normoxia condition|Training session in normoxia condition
62375196|NCT03606707|NO_INTERVENTION|oral steroid|systemic group, received systemic steroid 20 mg/d , in addition to methotrexate and chloroquine 400 mg per day.
62554971|NCT03856801|EXPERIMENTAL|Whole-body vibration in hypoxia condition|Training session in hypoxia condition
62554972|NCT01742897|EXPERIMENTAL|TTS-fentanyl|Transdermal therapeutic system (TTS) fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
62554973|NCT01521650|EXPERIMENTAL|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria
62750181|NCT06330103|EXPERIMENTAL|LV function By artificial intelligence|AI will access VDO clips in only parasternal long axis view and separate into three group Preserved LV ejection fraction(EF\>50%), mildly reduce ejection fraction(EF40-49%), reduced LV ejection fraction(EF\<40%)
62375197|NCT00648492|EXPERIMENTAL|1|Metformin Hydrochloride ER Tablets 500 mg
62375198|NCT00648492|ACTIVE_COMPARATOR|2|Glucophage® XR 500 mg
62375199|NCT03210467||experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
62554974|NCT01521650|NO_INTERVENTION|Control|No intervention. What has been the standard procedure so far
62554975|NCT05291338||HCC patients|116 hepatocellular carcinoma patients underwent TACE
62554976|NCT05855603|EXPERIMENTAL|Cardioneuroablation|Bi-atrial ablation of GPs: CARDIONEUROABLATION (Group A, n = 45)
62375200|NCT03210467||control group|patients who were untreated ever in immune-active phase took entecavir(ETV) for maintenance treatment.
62375201|NCT02812615|EXPERIMENTAL|Malnourished participants|After screening the participants for any organic diseases and application of inclusion/exclusion criteria, stunted children, children who are at risk of stunting and malnourished adult cases will receive one egg, 150 ml of milk 6 days a week for 3, 2 and 2 months respectively. Along with that participants will also get Anti-helminthic treatment (Albendazole/Pyrantel Pamoate) and nutritional counselling. Children will get one sachet of multiple micro-nutrient sprinkles per day to be administered at home with the mid-day meal for two months.
62375202|NCT03302624||Patients who were included in ELVIS study|
62375203|NCT01508793|NO_INTERVENTION|Control|
62375204|NCT01508793|EXPERIMENTAL|Optimize Sleep|
62375205|NCT03769389|EXPERIMENTAL|assessing the GI + GL of Birhi + YEO 0% fat yoghurt|47g of total carbohydrate in which contains 43.6g of Freeze-dried of Birhi powder+ 150g of 0% fat yoghurt
62375206|NCT03769389|EXPERIMENTAL|assessing the GI + GL of Khassab + YEO 0% fat yoghurt|47g of total carbohydrate in which contains34.6g of freeze-dried Khassab powder+ 150g of 0% fat yoghurt
62375207|NCT03769389|EXPERIMENTAL|assessing the GI + GL of 50g of Glucose in 100 ml of water|50g of pure glucose dissolved in 100ml of water
62375208|NCT02138162|EXPERIMENTAL|1:Single dose of enzalutamide in hepatically impaired subjects|Single dose of enzalutamide
62554977|NCT05855603|ACTIVE_COMPARATOR|Dual-chamber pacemaker|"Implant of a dual-chamber CLS PACEMAKER\* (Group B, n = 45).~\*or failing this, a dual-chamber pacemaker with RDR algorithm"
62554978|NCT03980652|OTHER|Intervention|Change of gloves and use of separate, sterile instruments before closing the abdominal wall
62554979|NCT03980652|NO_INTERVENTION|Current routine hospital practice|No change of gloves or use of separate, sterile instruments before closing the abdominal wall
62554980|NCT01256879|EXPERIMENTAL|CimTest-A|200mg cimetidine (as 2 capsules)
62554981|NCT01256879|EXPERIMENTAL|CimTest-B|200mg cimetidine (as 2 capsules)
62750182|NCT03587831|EXPERIMENTAL|VSG + LSM|"Procedure/Surgery: Vertical Sleeve Gastrectomy will be performed using five laparoscopic ports. The short gastric and epiploic vessels will be taken down With a 40 French Bougie in place, the greater curvature will be excised starting 6 cm proximal to the pylorus.~Behavioral: Lifestyle Modification Counseling - The intensive lifestyle intervention will align with methods listed in the LSM arm description. However, participants assigned to the VSG will not have calorie ceilings during the first 6 months of rapid weight loss, and they will receive additional instruction regarding food volume and adequate protein intake."
62750183|NCT03587831|ACTIVE_COMPARATOR|LSM|Behavioral: Lifestyle Modification Counseling - The intensive lifestyle intervention is modeled after the LookAHEAD trial, with modules modified for participants undergoing surgery, and designed to produce maximum achievable weight loss. Both groups will increase their level of moderate-intensity physical activity (such as walking) to a total of 325 minutes per week. All lifestyle-medical management participants will be given calorie intake targets of 1200, 1500, or 1800 kilocalories per day, depending on body weight, with the goal of producing a weight loss of 1 to 2 pounds per week. There will be 24 weekly counseling meetings during the first 6 months, bi-weekly meetings between months 7 and 9, and monthly meetings between months 10 and 12.
62750184|NCT00634712|ACTIVE_COMPARATOR|1|
62750185|NCT00634712|PLACEBO_COMPARATOR|2|
62750186|NCT06605898|EXPERIMENTAL|Standard MIND diet|Participants in the active MIND diet group will be asked to consume one ready-to-eat meal per day from Daily Harvest® meal delivery service. This will be a standard treatment arm without prior selection through predictive analytics. The treatment meals will follow MIND diet guidelines and include leafy green vegetables, nuts, legumes, whole grains, berries, and extra virgin olive oil.
62750187|NCT06605898|EXPERIMENTAL|Predictive Analytics informed MIND Diet|Participants in the active MIND diet group informed by predictive analytics will be pre-identified based on the results of a machine learning model that predicts who will most likely benefit from the MIND diet. The participants in this group will be asked to consume one ready-to-eat meal per day from Daily Harvest® meal delivery service. The treatment meals will follow MIND diet guidelines and include leafy green vegetables, nuts, legumes, whole grains, berries, and extra virgin olive oil.
62750188|NCT06605898|ACTIVE_COMPARATOR|Control Diet|Participants in the control diet group will be asked to consume one ready-to-eat meal per day from Daily Harvest® meal delivery service. The Control group will receive daily meals that are isocaloric with the active/experimental meals but will follow a general diet based on the average American diet and Dietary Guidelines for Americans (i.e., vegetables, fruits, nuts, whole grains, and unsaturated fats).
62750189|NCT02290691|EXPERIMENTAL|Needle- Free|Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.
62750190|NCT02290691|ACTIVE_COMPARATOR|Needle and Syringe|Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.
62375209|NCT02138162|EXPERIMENTAL|2:Single dose of enzalutamide in healthy subjects|Single dose of enzalutamide
62750191|NCT00634257||Patients|Patients with advanced cancer receiving palliative care.
62750192|NCT00634257||Caregivers|Primary caregivers of Patients with advanced cancer receiving palliative care.
62750193|NCT00484393|EXPERIMENTAL|Tetracaine|Tetracaine 4% gel 1g applied to injection site
62750194|NCT00484393|PLACEBO_COMPARATOR|Placebo|Placebo cream (Aquatain) 1g applied to inejction site
62375210|NCT01199198|EXPERIMENTAL|Tolvaptan Group|Tolvaptan Group: Starting dose 15 mg by mouth once a day for 14 days.
62375211|NCT01199198|PLACEBO_COMPARATOR|Placebo Group|Placebo Group: Placebo by mouth once a day for 14 days.
62375212|NCT04487795||under 18 years old|
62375213|NCT04487795||18-40 years old|
62375214|NCT04487795||41-60 years old|
62375215|NCT04487795||over 60 years old|
62554982|NCT01256879|ACTIVE_COMPARATOR|Sorbitol-free cimetidine solution|200mg cimetidine (as oral liquid)
62750195|NCT02899234|ACTIVE_COMPARATOR|Nicotine-free e-cigarette|Subjects will actively inhale nicotine-free vapor prior to blood samples and various non-invasive cardiopulmonary tests.
62750196|NCT02899234|ACTIVE_COMPARATOR|Nicotine e-cigarette|Subjects will actively inhale nicotine containing vapor prior to blood samples and various non-invasive cardiopulmonary tests.
62750197|NCT02645643|EXPERIMENTAL|intervention group|Medical students rolled into this group would accept education of medical humanities.
62750198|NCT02645643|NO_INTERVENTION|control group|Medical students rolled into this group would not gain education of medical humanities.
62750199|NCT03505723|ACTIVE_COMPARATOR|Tranexamic Acid (TXA)|Patients will receive a 1g loading dose of intravenous TXA before surgery and a 1g loading dose of intravenous TXA at the end of surgery (wound closure).
62750200|NCT03505723|PLACEBO_COMPARATOR|Placebo (0.9% normal saline)|Patients will receive a 1g loading dose of placebo (0.9% normal saline) before surgery and a 1g loading dose of placebo (0.9% normal saline) at the end of surgery (wound closure).
62750201|NCT03505723|ACTIVE_COMPARATOR|Hypotension-avoidance strategy|Aims to avoid hypotension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).
62750202|NCT03505723|PLACEBO_COMPARATOR|Perioperative hypertension-avoidance strategy|Aims to avoid hypertension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).
62750203|NCT04193085||Spinal Muscular Atrophy (SMA)|ambulatory children and adults at least 5 years old by the time of enrollment with genetically confirmed SMA
62750204|NCT04193085||Duchenne / Becker Muscular Dystrophy (DMD/BMD)|ambulatory children and adults ages at least 5 years old by the time of enrollment with genetically confirmed Duchenne or Becker muscular dystrophy or evidence on muscle biopsy with a clinical presentation consistent with DMD /BMD.
62750205|NCT04193085||Healthy Control|The healthy control group will be age and gender-matched to the SMA and DMD groups as best as possible
62750206|NCT01885208|EXPERIMENTAL|Semaglutide 1.0 mg|
62375216|NCT06238089||Eligible patients who have had a psychiatric review by specialist adult ID services in 2017.|Adults with an intellectual disability who are under the care of ID services in receipt of \>2 oral and/or long-acting intra-muscular (IM) injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2017.
62375217|NCT06238089||Eligible patients who have had a psychiatric review by specialist adult ID services in 2018.|Adults with an intellectual disability who are under the care of ID services in receipt of \>2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2018.
62375218|NCT06238089||Eligible patients who have had a psychiatric review by specialist adult ID services in 2019.|Adults with an intellectual disability who are under the care of ID services in receipt of \>2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2019.
62750207|NCT01885208|ACTIVE_COMPARATOR|Exenatide ER 2.0 mg|
62750208|NCT02354131|EXPERIMENTAL|Niraparib monotherapy|Niraparib mono therapy until progression
62750209|NCT02354131|EXPERIMENTAL|Niraparib-bevacizumab combination|Niraparib-bevacizumab combination therapy until progression
62750210|NCT01648296|EXPERIMENTAL|Dosimetry Group|A total of 12 subjects will receive a single intravenous injection of\[18F\]FluorbetaOx followed by PET-CT imaging. Four normal healthy volunteer subjects and 8 subjects with or without Type 2 Diabetes Mellitus with Chronic Dilated Cardiomyopathy.
62750211|NCT01648296|EXPERIMENTAL|Kinetic Dynamic Group|A total of 38 subjects will receive a single intravenous injection of \[18F\]FluorbetaOx, \[11C\]Palmitate, and \[15O\]Water followed by PET-CT imaging. Ten normal healthy volunteer subjects and 28 subjects with or without Type 2 Diabetes Mellitus of which 18 subjects will have Chronic Dilated Cardiomyopathy and 10 obese subjects with a Body Mass Index of ≥ 30kg/m2.
62750212|NCT01384669||Group 1|papillary thyroid microcarcinoma without lymph node metastasis
62750213|NCT01384669||Group 2|papillary thyroid microcarcinoma with lateral lymph node metastasis
62750214|NCT00778258|EXPERIMENTAL|Milk-allergic; Non-consumption|Subjects in this arm reacted to the lowest baseline dose of baked milk (muffin) and will continue strict milk avoidance, returning for re-evaluation with laboratory tests at 12 and 24 months and baked milk challenge at 36 months. Individual participants may be challenged at 12 and or 24 months.
62750215|NCT00778258|EXPERIMENTAL|Tolerated Muffin, Reacted to Pizza|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin but react to ingesting the amount of baked milk in a standardized portion of pizza. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
62750216|NCT00778258|EXPERIMENTAL|Reacted to Rice Pudding|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin and a standardized portion of pizza but react to a standardized dose of baked milk in rice pudding. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
62750217|NCT00778258|EXPERIMENTAL|Reacted to Non-baked Milk|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin, pizza and rice pudding but react to a standardized dose of non-baked milk. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
62750218|NCT00778258|EXPERIMENTAL|Tolerant to Baked and Non-baked Milk|"Biological/Vaccine: Baked Milk At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.~Biological/Vaccine: Non-baked Milk Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk."
62750219|NCT00778258|NO_INTERVENTION|Non-Interventional Comparison|Thirty subjects who fulfill inclusion criteria but are unwilling to participate in the full protocol will be enrolled as a comparison group to the active arms.
62750220|NCT02421406|EXPERIMENTAL|Internet Behavioral Intervention|Participants receive a 12-week Internet-based eating and activity intervention including multimedia lessons and enhanced self-monitoring of weight loss behaviors with automated feedback
62750221|NCT02421406|ACTIVE_COMPARATOR|Internet Education Intervention|Participants receive 12 weekly Internet-based weight loss lessons containing information for modification of diet and activity behaviors, but not behavioral strategies for changing these behaviors.
62554983|NCT01256879|EXPERIMENTAL|Commercial cimetidine solution|200mg cimetidine (as oral liquid)
62750222|NCT01984463|ACTIVE_COMPARATOR|Fentanyl|Patients will be randomized to receive by the epidural catheter a bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL.
62750223|NCT01984463|EXPERIMENTAL|Morphine|Patients will be randomized to receive by the epidural catheter a bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL.
62750224|NCT00673205|PLACEBO_COMPARATOR|A|
62750225|NCT00673205|ACTIVE_COMPARATOR|B|
62750226|NCT02567370|PLACEBO_COMPARATOR|Placebo|
62750227|NCT02567370|ACTIVE_COMPARATOR|AMG 581|
62750228|NCT04446507|EXPERIMENTAL|Group 1|Subjects in severe renal impairment group will be enrolled and dosed consecutively (i.e. first 8 subjects of group 1 will receive 2 mg dose, followed by another 8 subjects who will receive 4 mg dose).
62750229|NCT04446507|EXPERIMENTAL|Group 2|Subjects (Normal renal function eGFR ≥90) will be matched according to age (± 10 years), sex, and weight (± 20 kg) with participants in Group 1 (Severe renal impairment not on HD) on a one to one basis based on demographic characteristic. Here, 8 participants will be administered single dose of 2 mg Saroglitazar Magnesium and 8 participants will be administered single dose of 4 mg Saroglitazar Magnesium.
62554984|NCT04996979|PLACEBO_COMPARATOR|Control|Only standard care
62554985|NCT04996979|EXPERIMENTAL|Intervention group|The PENG block was performed for intervention group with local anaesthetic solution composed of 20 ml of ropivacaine 0.5%.
62554986|NCT03284723|EXPERIMENTAL|PF-06804103|Study Treatment
62554987|NCT03284723|EXPERIMENTAL|PF-06804103+Combination Regimen|Study Treatment
62750230|NCT03505294|EXPERIMENTAL|Task-oriented training|"Task-oriented training consisting of 10 different motor tasks will be applied."
62750231|NCT03505294|NO_INTERVENTION|Control group|The control group will be taught relaxation exercises and will be asked to perform.
62750232|NCT02557100|EXPERIMENTAL|Treatment A|Abatacept Single Blind Treatment Period
62554988|NCT05355870|EXPERIMENTAL|Cognitive Training|"Participants in the experimental arm will be provided a brochure that included information on basic knowledge of ADRD, signs and symptoms related to ADRD, the definition and the potential benefits of cognitively stimulating activities in maintaining cognitive function, and examples of cognitively stimulating activities.~Participants in this arm will complete a series of cognitive training exercises on a smartphone/tablet. The anticipated training will last for 12 weeks and involve 3-4 sessions per week (20-30 min/ session)."
62750233|NCT02557100|ACTIVE_COMPARATOR|Treatment B|Adalimumab Single Blind Treatment Period
62750234|NCT02557100|ACTIVE_COMPARATOR|Treatment C|Abatacept Cumulative Treatment Period
62750235|NCT01163357|EXPERIMENTAL|Group I (bortezomib, fludarabine phosphate, TMI, melphalan)|Patients receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. Patients also undergo TMI BID on days -9 to -7. If no DLT is observed in the first cohort, bortezomib IV will be added on days -6 and -3 for subsequent cohorts.
62750236|NCT01163357|EXPERIMENTAL|Group II (bortezomib, fludarabine phosphate, melphalan|Patients receive fludarabine phosphate IV and melphalan IV as in Stratum I. Patients also receive bortezomib IV on days -6, -3, 1, and 4.
62750237|NCT03836833|EXPERIMENTAL|4in1 granules|Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination in granules formulation administered twice daily for at least 3 weeks, Followed by Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets) administered twice daily for at least 3 weeks.
62750238|NCT03836833|EXPERIMENTAL|LPV/r Pellets Plus ABC/3TC|"Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets) administered twice daily for at least 3 weeks.~Followed by Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination in granules formulation administered twice daily for at least 3 weeks"
62750239|NCT02321189|PLACEBO_COMPARATOR|LONGEVINEX|The Effect of LONGEVINEX on Choroidal Thickness
62750240|NCT02321189|PLACEBO_COMPARATOR|placebo|The Effect of placebo on Choroidal Thickness
62750241|NCT03658200|ACTIVE_COMPARATOR|FAST software|Patient referred for chest CT and scanned with delay based on bolus tracking with FAST software. intervention: FAST START Software delay
62375219|NCT06238089||Eligible patients who have had a psychiatric review by specialist adult ID services in 2020.|Adults with an intellectual disability who are under the care of ID services in receipt of \>2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2020.
62554989|NCT05355870|NO_INTERVENTION|Passive Control|A passive control group will be included in this pilot trial. Participants in this passive control arm will be provided a brochure that included information on basic knowledge of ADRD, signs and symptoms related to ADRD, the definition and the potential benefits of cognitively stimulating activities in maintaining cognitive function, and examples of cognitively stimulating activities.
62750242|NCT03658200|ACTIVE_COMPARATOR|Control|Patient referred for chest CT and scanned with delay based on bolus tracking without FAST software. Intervention: Manual bolus tracking delay
62750243|NCT02570152|EXPERIMENTAL|AFI Group|Population living in randomly selected households in geographically-defined communities. Households including at least one member aged less than 18 years will be considered eligible if at least one adult (aged no more than 50 years) and one child (aged less than 18 years) consent (and assent if applicable) to participate in the study.
62750244|NCT01920568|EXPERIMENTAL|Denosumab 120 mg|Subjects will be administered with Denosumab 120 mg subcutaneous (SC) injection for a maximum of 13 doses and placebo IV infusion over \&gt;=15 minutes once every 4 weeks.
62750245|NCT01920568|EXPERIMENTAL|Zoledronic acid 4 mg|Subjects will be administered with Zoledronic acid 4 mg IV infusion over a minimum of 15 minutes for a maximum of 13 doses and placebo SC once every 4 weeks.
62750246|NCT04332497|ACTIVE_COMPARATOR|Group CPB = Clavipectoral fascia plane block group|In group CPB, CPB will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third of the clavicle. A 22-gauge block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 20 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
62750247|NCT04332497|NO_INTERVENTION|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
62375220|NCT06238089||Eligible patients who have had a psychiatric review by specialist adult ID services in 2021.|Adults with an intellectual disability who are under the care of ID services in receipt of \>2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2021.
62375221|NCT06238089||Eligible patients who have had a psychiatric review by specialist adult ID services in 2022.|Adults with an intellectual disability who are under the care of ID services in receipt of \>2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2022.
62554990|NCT01596790|OTHER|CTC assay|Detection \& characterization of viable CTC in the peripheral blood.
62554991|NCT01398046|ACTIVE_COMPARATOR|Dasatinib|
62554992|NCT01398046|EXPERIMENTAL|Dasatinib plus Rabeprazole|
62554993|NCT01398046|EXPERIMENTAL|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|
62750248|NCT04332497|ACTIVE_COMPARATOR|Group ISCB = ISCB group|In group ISCB, ISCB will be performed with patients in the supin position. US probe will be placed in transverse plane at the level of cricoid cartilage. The prob will be moved laterally when the artery is visualized. The needle will be inserted in a medial-to-lateral direction after the brachial plexus between the scalen muscles is visualized. Then, 5 ml normal saline will be enjected for correction of the needle with in-plane technique. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
62750249|NCT01380470||Chronic Obstructive Pulmonary Disease|Group of patients seen in consultation not previously diagnosed with COPD, both sexes, aged between 40 and 70 years.
62750250|NCT04056520||Arm 1|Subjects undergoing posterior cervicothoracic fusions between C2 and upper thoracic will be enrolled
62750251|NCT05229211||New Onset Atrial Fibrillation|Patients admitted to an adult intensive care unit for more than 24 hours who develop new onset atrial fibrillation during their ICU admission will be included. After discharge from ICU patients will undergo continuous ECG monitoring via VitalConnect patch for 14 days or until hospital discharge, whichever is shortest. They will undergo a further 7 days of continuous ECG monitoring via VitalConnect patch as an outpatient at 3 months post hospital discharge.
62750252|NCT01958697||AG-BMI < 10 pct|Patients who's peroperative BMI is less than the 10th centile
62750253|NCT01958697||AG-BMI >= 10th pct|Patients who's peroperative BMI equals or is greater than the 10th centile
62554994|NCT02297997|EXPERIMENTAL|1.5mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 1.5mg will be taken daily for two weeks.
62554995|NCT02297997|EXPERIMENTAL|3mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 3mg will be taken daily for two weeks.
62554996|NCT02297997|EXPERIMENTAL|4.5mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 4.5mg will be taken daily for two weeks.
62750254|NCT01144975|ACTIVE_COMPARATOR|XOMA 052|
62750255|NCT01144975|PLACEBO_COMPARATOR|Placebo|
62375222|NCT06238089||Eligible patients who have had a psychiatric review by specialist adult ID services in 2023.|Adults with an intellectual disability who are under the care of ID services in receipt of \>2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2023.
62375223|NCT03665987||properative assessment clinic group|The treatment group will be seen in the preoperative clinic before hospitalization.
62375224|NCT03665987||Control group|The control group will get anesthetic consultation after hospitalization without clinic service.
62750256|NCT02352454|EXPERIMENTAL|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
62750257|NCT02352454|NO_INTERVENTION|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
62750258|NCT04693273||Carpal Tunnel Release surgical patients|This is the group the investigators survey who are candidates for carpal tunnel release (CTR) surgery: patients should be 18 years or older, comprehend and read English, and patients who consent to do the survey.
62750259|NCT02335047|OTHER|lower back pain|
62750260|NCT01414023|EXPERIMENTAL|CCT|Cognitive Control Training - Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
62750261|NCT01414023|PLACEBO_COMPARATOR|PVT|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
62750262|NCT01941979|EXPERIMENTAL|Adjuvant therapy|"5-FU, Leucovorin and Oxaliplatine (FLOX) OR Capecitabine and Oxaliplatin (CAPOX)~NOTE: If the patient was randomized for the arm experimental, the investigator can choose between intravenous (IV) treatment or oral treatment (PO). Both are considered equal by the principal investigator."
62750263|NCT01941979|NO_INTERVENTION|Observation|
62750264|NCT05365568|EXPERIMENTAL|LBBAP|
62750265|NCT05365568|ACTIVE_COMPARATOR|BiV|
62375225|NCT01135004||Pneumothorax patients|Primary spontaneous pneumothorax patients undergoing thoracoscopic bullectomy
62375226|NCT05874947||Dental Cast Digitization techniques:(CBCT 3D model scanning module )|Scanning the plaster model using CBCT 3d model scanning module to generate a digital model
62375227|NCT05874947||Dental Cast Digitization techniques :Desktop Optical 3D Scanner|Scanning the plaster model using Desktop Optical 3D Scanner to generate a digital model
62375228|NCT05874947||plaster cast|linear measurments on the plaster cast as the gold standard (using the digital caliper )
62375229|NCT05903391|EXPERIMENTAL|3D-Printed Finger Splints|Participants who wear the experimental customizable 3D-printed finger splints
62375230|NCT05903391|ACTIVE_COMPARATOR|Conventional Finger Splints|Participants who wear the control, conventionally made finger splints
62750266|NCT05875636||Patients taking a GLP-1 agonist medication|Participants meeting all inclusion/exclusion criteria who are taking a GLP-1 agonist medication
62750267|NCT05875636||Controls|Participants meeting all inclusion/exclusion criteria and are NOT taking a GLP-1 agonist medication.
62750268|NCT01314170|NO_INTERVENTION|Susanna Implant|Patients with refractory glaucoma neovascular type or that failed in trabeculectomy will undergo surgery to place implants Susana.
62375231|NCT02158728||ICD indicated subjects|"Subjects indicated for implantable cardioverter defibrillator (ICD)/ cardiac resynchronization therapy defibrillator (CRT-D) implant, ICD/CRT-D change-out, or indicated for an ICD/CRT-D and undergoing ablation or electrophysiology (EP) study (including Non-Invasive ElectroPhysiology Study \[NIPS\]).~Enrolled subjects are prepared for the indicated procedure as per investigational center's standard practice. The investigator will determine the best methodology for inducing or simulating SVT within the indicated procedure. Data is recorded by a data acquisition recording system. Recording should begin just before the indicated procedure and continue until completion of the procedure.The recorded data are collected."
62375232|NCT01585909|OTHER|Septic Shock|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients with septic shock
62750269|NCT03758079|ACTIVE_COMPARATOR|Doxepin|10 mg Doxepin daily for 4 weeks
62375233|NCT01585909|OTHER|SIRS|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients with SIRS
62750270|NCT03758079|ACTIVE_COMPARATOR|Gabapentin|Gabapentin 100mg after each dialysis session
62750271|NCT03025672||clostridium difficile|Patients that have been infected by clostridium difficile during their stay in hospital
62750272|NCT03025672||no clostridium difficile|Patients that have not been infected during their stay in hospital.
62750273|NCT05491070|EXPERIMENTAL|Dual Proglide|Use Two Progilde for closure of femoral artery with large sheath in transfemoral TAVI
62750274|NCT05491070|EXPERIMENTAL|Progilde + AngioSeal|Use Progilde + AngioSeal for closure of femoral artery with large sheath in transfemoral TAVI
62375234|NCT01585909|OTHER|healthy/controls|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients without SIRS/septic shock
62554997|NCT02297997|EXPERIMENTAL|6mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 6mg will be taken daily for two weeks.
62750275|NCT04070716|EXPERIMENTAL|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
62375235|NCT01347073|EXPERIMENTAL|HPN-100|Switch over from sodium phenylbutyrate to open label HPN-100 oral liquid over 10 days then open label, long term treatment for 12 months
62554998|NCT02297997|PLACEBO_COMPARATOR|Control|Placebo will be taken daily for two weeks.
62554999|NCT02535689|ACTIVE_COMPARATOR|1|ARM 1: 10 of SLE patients will be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily.
62555000|NCT02535689|ACTIVE_COMPARATOR|2|ARM 2: 10 of SLE patients will NOT be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily.
62750276|NCT04070716|EXPERIMENTAL|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
62750277|NCT01887015|EXPERIMENTAL|Standard oxygen therapy|Our hypothesis is that, compared with standard oxygen therapy, early application of nasal high flow oxygen therapy can reduce the need for postoperative NPPV for postoperative hypoxemia (defined as PaO2/FiO2 ratio \<300).
62750278|NCT01887015|OTHER|nasal high flow oxygen therapy|Our hypothesis is that, compared with standard oxygen therapy, early application of nasal high flow oxygen therapy can reduce the need for postoperative NPPV for postoperative hypoxemia (defined as PaO2/FiO2 ratio \<300).
62750279|NCT00580580|ACTIVE_COMPARATOR|1 Intravenous Optison Followed by Contrast Pulse Sequencing|"Administration of Optison (0.1-0.4 mL) intravenously followed by Contrast Pulse Sequencing to image both the coronary and carotid arteries.~Use will depend on availability of the contrast for the given study Optison will not be used on patients with blood allergies or Jehovah Witnesses"
62750280|NCT00580580|ACTIVE_COMPARATOR|2 Intravenous Definity followed by Contrast Pulse Sequencing|Intravenous injection of Definity (0.05-0.20 mL) followed by Contrast Pulse Sequencing to image both coronary and carotid arteries
62750281|NCT00580580|ACTIVE_COMPARATOR|3 Intravenous PESDA followed by Contrast Pulse Sequencing|Intravenous injection of PESDA at a rate of 0.05-0.20 mL followed by Contrast Pulse Sequencing image of coronary and carotid arteries PESDA will be used exclusively in patients who are eligible for other IRB studies
62750282|NCT04254367|EXPERIMENTAL|Intervention group - experimental TAU + intervention|Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
62750283|NCT04254367|NO_INTERVENTION|TAU - no intervention|Treatment as usual following local routines on each primary care center
62750284|NCT05706233||Erector Spina Plane Block (ESPB)|
62750285|NCT05706233||Intravenous Group (IV)|
62750286|NCT02797665|ACTIVE_COMPARATOR|Steroids group|The patients will be treated with oral corticosteroids (prednisone 0.6mg/kg/d) alone.
62750287|NCT02797665|ACTIVE_COMPARATOR|Stent group|The patients will be treated with oral corticosteroids and biliary stent.
62750288|NCT02778555||Sample 1|In Sample 1 (N=186), our 14-item Daily PCS was administered daily for 14 days to replicate the 3-factor structure at the daily level, and to select the ideal 5 items for a brief Daily PCS.
62750289|NCT02778555||Sample 2|In Sample 2 (N=209), the 5-item Daily PCS was administered daily for 14 days with short forms for PROMIS Pain Intensity, Depression, Anger, and Anxiety included on days 1, 7, and 14.
62750290|NCT02778555||Sample 3|In Sample 3 (N=318), the 5-item Daily PCS was administered daily for 14 days with short forms for PROMIS Pain Intensity, Depression, Anger, and Anxiety included on days 1, 7, and 14. In addition, assessments of pain, mood, activity, sleep, energy level, and positive affect were administered daily for the 14-day period.
62555001|NCT02535689|PLACEBO_COMPARATOR|3|ARM 3: 10 of SLE patients will be with variable genotypes will receive placebo twice daily.
62555002|NCT03271684|EXPERIMENTAL|intervention group|Will receive one session of up to one-hour per week over a six-week period in self-management in addition to their usual rehabilitation and workbook.
62555003|NCT03271684|OTHER|control group|Will receive booklet consist of home exercises and education besides the usual care
62567421|NCT05519917|EXPERIMENTAL|Afatinib|Subject meeting the inclusion criteria will take afatinib (40 mg daily) orally, 4 weeks for a cycle.
62567422|NCT00486746|EXPERIMENTAL|Lifestyle intervention|
62567423|NCT00486746|ACTIVE_COMPARATOR|General health counseling|
62750291|NCT04407026||Healthy|Healthy control group (n=25) consisted of the volunteers having clinically healthy gingiva, PD≤3 mm, BOP\<10% and no sign of clinical attachment loss and radiographic alveolar bone destruction.
62750292|NCT04407026||Gingivitis|Gingivitis group (n=25) had PD≤3 mm with BOP\>50% in the entire mouth, and no clinical attachment loss or alveolar bone loss.
62750293|NCT04407026||Stage 3 periodontitis|Stage 3 periodontitis group included the patients exhibiting PD ≥6 mm and interdental CAL ≥5 mm at %30 or more teeth. They had no more than four teeth loss.
62750294|NCT02521753|ACTIVE_COMPARATOR|Metformin|Metformin 850mg twice a day for six months
62750295|NCT02521753|EXPERIMENTAL|Magnesium|Magnesium chloride 250mg daily for six months
62750296|NCT02521753|EXPERIMENTAL|PUFA omega 3|Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) 1.1mg daily for six months
62750297|NCT00404755|EXPERIMENTAL|escitalopram|escitalopram 10 mg/d for 1 week, then increasing by 10 mg/week if tolerated and not remitted to maximal dose of 40 mg/d
62750298|NCT00404755|EXPERIMENTAL|bupropion|bupropion extended release (XL) 150 mg/d for a week, then 300 mg/d for a week and then 450 mg/d; all dose increases if tolerated and not remitted
62750299|NCT00404755|EXPERIMENTAL|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then by 50 mg/week to a maximum dose of 300 mg/d; all dose increases if tolerated and not remitted
62750300|NCT00236990|EXPERIMENTAL|001|pentosan polysulfate sodium
62750301|NCT05332587|EXPERIMENTAL|Rituximab Treated|rituximab
62750302|NCT06290167|EXPERIMENTAL|360° media|All participants will be randomly assigned to 360° media or TAU condition
62750303|NCT06290167|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|All participants will be randomly assigned to TAU or 360° media condition
62750304|NCT06290167|OTHER|In hospital sessions|all participants will perform session in hospital
62750305|NCT06290167|OTHER|at home sessions|all participants will perform session at home
62750306|NCT06290167|OTHER|Mild Cognitive Impairment|half of the patients will have MCI
62750307|NCT06290167|OTHER|Subjective Memory Complain|half of the patients will have SMC
62750308|NCT01663701|ACTIVE_COMPARATOR|Usual care|Patients are managed according to admitting doctors' orders. Blood cultures are drawn in all patients. Antibiotics are specified by the admitting doctors.
62750309|NCT01663701|EXPERIMENTAL|Simplified Severe Sepsis Protocol|This protocol consists of an early aggressive fluid strategy, early blood cultures and antibiotics, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings. Antibiotics are specified by the admitting doctors.
62750310|NCT01746511|ACTIVE_COMPARATOR|Glycerin Suppository|"Based on our institution's protocol, infant will receive a glycerin shave within one hour of initiation of phototherapy and then every eight hours while under phototherapy.~Subjects will be block randomized (varying block sizes of 2 to 8). Babies in both groups will be fed according to NICU standard birth weight protocols. Stratified enrollment will occur with 2 separate groups:~1. Infants who are NPO (\< 20 mL/kg/day of fluids enterally at the time of therapy) vs.~2. Those being enterally fed at least 20 mL/kg/day of total fluids at the time of therapy."
62555004|NCT00629018|EXPERIMENTAL|SC Group|"SC therapy,'Bone Marrow Stimulation','CD34+ autologous stem cell transplantation':~In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect"
62750311|NCT01746511|EXPERIMENTAL|No Glycerin Suppository|"Infants will receive no scheduled glycerin suppositories, while under phototherapy (unless otherwise directed by attending physician).~Subjects will be block randomized (varying block sizes of 2 to 8). Babies in both groups will be fed according to NICU standard birth weight protocols. Stratified enrollment will occur with 2 separate groups:~1. Infants who are NPO (\< 20 mL/kg/day of fluids enterally at the time of therapy) vs.~2. Those being enterally fed at least 20 mL/kg/day of total fluids at the time of therapy."
62750312|NCT00002938|OTHER|Surgery|Salvage prostatectomy
62750313|NCT03201926|EXPERIMENTAL|mealworms|mealworms
62750314|NCT03201926|PLACEBO_COMPARATOR|grain powder|grain powder
62750315|NCT00759356|OTHER|1|Treatment A (test product) followed by Treatment B (reference product)
62750316|NCT00759356|OTHER|2|Treatment B (reference product) followed by Treatment A (test product)
62555005|NCT00629018|NO_INTERVENTION|Controls|Patients receiving no cell therapy.
62555006|NCT02079597||Healthy|Healthy individuals no infection
62555007|NCT02079597||SIRS|SIRS patients no included in an interventional study no peroperative infection
62567424|NCT03775525|EXPERIMENTAL|Experimental: monotherapy|GZ17-6.02 given orally on a daily x 28 day schedule. This will be a dose escalation study.
62750317|NCT04774536|EXPERIMENTAL|CRISPR_SCD001 Drug Product|CRISPR_SCD001 Drug Product (autologous CD34+ cell-enriched population that contains cells modified by the CRISPR-Cas9 ribonucleoprotein) dose will be ≥3.0×106 CD34+ cells/kg recipient weight for each subject and the upper limit cell dose is 20 ×106 CD34+ cells/kg.
62750318|NCT05638334|EXPERIMENTAL|89Zr-S095012 tracer with S095012|
62750319|NCT06434766|SHAM_COMPARATOR|Sham stimulation|A sham coil with exactly the same appearance of active coil is used to compare with active coil. Stimulation dose and frequency is the same as active stimulation.
62750320|NCT06434766|ACTIVE_COMPARATOR|Active stimulation|An active coil is used to deliver iTBS. The stimulation dose is 20 sessions (1800 pulses per session; 2 sessions a day, at least 1 hour apart) over the course of 2 weeks (10 days to 14 days, allow at most three breaks and only once of the longest interval of 2 days).
62750321|NCT01425450|EXPERIMENTAL|HF1020|
62750322|NCT01425450|PLACEBO_COMPARATOR|Placebo|
62555008|NCT04507295|ACTIVE_COMPARATOR|volume controlled group|"15 patients in is this group will be ventilated during capnothorax using volume controlled ventilation with the following parameters:~* FIO2 of 60 %.~* Tidal Volume (TV) of 6-8 ml/kg.~* Respiratory rate of 30 breathes/min then the respiratory rate will be modified to maintain the ETCO2 between 30-35 mm Hg.~* inspiratory to expiratory ratio (I: E) 1:2.~* using a minimal Positive End Expiratory Pressure (PEEP) of 2 cm H2O."
62375236|NCT01092364|EXPERIMENTAL|Cell phone intervention|Behavioral lifestyle intervention for weight loss, delivered by cell phone.
62375237|NCT01092364|EXPERIMENTAL|Personal counseling intervention|Behavioral lifestyle intervention for weight loss, delivered by personal counseling.
62375238|NCT01092364|NO_INTERVENTION|Advice only|Advice only control group.
62375239|NCT05746689|EXPERIMENTAL|glucocorticoid and sirolimus combination therapy|"Prednisone acetate 0.8mg/Kg/d (maximum dose 60mg/d), reduced by 5mg every 14 days, reduced by 2.5mg every 2 weeks after 30mg/d until discontinuation. At the same time, treatment for prevention or control of osteoporosis was given.~Sirolimus: 2mg/day for the first three days and 1mg/day thereafter. The plasma drug concentration was monitored at 14 days, 12 weeks, and 48 weeks of medication to maintain a plasma drug concentration of 4-15 ug/L."
62375240|NCT06001892|EXPERIMENTAL|Be in Charge|The 7 units of curriculum fit in with the theory of planned behavior where the educational components of the BiC intervention are designed to impact knowledge, attitudes, norms, and perceived control over sexual health related outcomes (i.e., sexual intercourse and contraception usage), ultimately influencing intention and behavior. The curricula is trauma-informed and integrate a PYD approach through creation of safe environments, engagement of youth through creative activities, and facilitation of progressive skill-building.
62375241|NCT06001892|ACTIVE_COMPARATOR|Adolescent Health Curricula|Adolescent Health Curriculum which is designed to navigate youth through the emotional components of adolescence in preparation for adulthood.
62375242|NCT04162262|EXPERIMENTAL|Stretching, Strengthening, and IASTM|This group will attend eight weekly sessions, which will include initial screening tests and exercise education on visit 1 and strengthening and stretching exercise progression on visits 1-8. Data measurements will occur at weeks 0, 4, 8, and 12. This group will perform a 5-minute, self-paced warmup on a stationary bicycle followed by a 10-minute IASTM treatment. Test measurements will be performed before and immediately following the warmup and IASTM treatment. They will then perform stretching and strengthening exercises under the supervision of an investigator masked to treatment group weekly for eight visits. Exercise resistance will be increased as needed each week. In addition, participants will perform daily stretching and strengthening exercises at home.
62375243|NCT04162262|ACTIVE_COMPARATOR|Strengthening and Stretching|This group will attend eight weekly sessions, which will include initial screening tests and exercise education on visit 1 and strengthening and stretching exercise progression on visits 1-8. Data measurements will occur at weeks 0, 4, 8, and 12. To equalize visit time with the Stretching, Strengthening, and IASTM group, subjects will perform 15 minutes of self-paced bicycle riding at the beginning of each session. They will then perform stretching and strengthening exercises under the supervision of an investigator masked to treatment group weekly for eight visits. Exercise resistance will be increased as needed each week. In addition, participants will perform daily stretching and strengthening exercises at home.
62375244|NCT04162262|OTHER|Pain-free Comparison Group|The third group is a pain-free comparison group. This group will come to the laboratory once. They will perform a 5-minute, self-paced warmup on a stationary bicycle followed by a 10-minute IASTM treatment. Test measurements will be performed before and immediately following the warmup and IASTM treatment. These measurements will be compared to the same measures from the Stretching, Strengthening, and IASTM group to examine outcome measure differences in those with and without plantar fasciopathy following a single IASTM treatment.
62375245|NCT01023516|EXPERIMENTAL|1|
62375246|NCT01023516|PLACEBO_COMPARATOR|2|
62375247|NCT06147232|ACTIVE_COMPARATOR|Sotagliflozin|In the active arm, participants will be treated with Sotagliflozin 200mg as an oral tablet once daily for 12 weeks.
62375248|NCT06147232|PLACEBO_COMPARATOR|Placebo|In the placebo arm, participants will be treated with a matched placebo as an oral tablet once daily for 12 weeks.
62375249|NCT01424306|EXPERIMENTAL|Fructose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days.
62750323|NCT01644695||Candidate for BARS procedure.|The subjects selected for this trial were over 18 years of age with an appropriate complex, incisional hernia. These patients were consented and treated with the BARS(bony anchoring reinforcement system)procedure.
62750324|NCT00616811|EXPERIMENTAL|Vildagliptin|
62375250|NCT01424306|EXPERIMENTAL|Glucose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days.
62375251|NCT01424306|EXPERIMENTAL|High-fructose corn syrup-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days.
62375252|NCT02039128|EXPERIMENTAL|Krill oil|1 gram per day in 12 weeks
62375253|NCT02039128|ACTIVE_COMPARATOR|Fish oil|1 gram per day in 12 weeks
62555009|NCT04507295|ACTIVE_COMPARATOR|pressure controlled group|"15 patients in is this group will be ventilated during capnothorax using pressure controlled ventilation with the following parameters:~* FIO2 60 %.~* inspiratory pressure adjusted to fulfil the required TV according to the weight of the patient (6-8 ml /kg) then the insufflation pressure will be added to the driving pressure.~* respiratory rate of 30 breathes/min then the respiratory rate will be modified to maintain the ETCO2 between 30-35 mm Hg.~* I:E ratio of 1:1.5 .~* Using a minimal PEEP of 2 cm H2O."
62555010|NCT02297399|EXPERIMENTAL|PEG-ascorbate 2L|Subjects will take 2 liters of a polyethylene glycol 3500 (sodium sulphate, sodium chloride, postassium chloride), ascorbic acid and sodium ascorbate solution.
62555011|NCT02297399|ACTIVE_COMPARATOR|PEG 4L|Subjects will take 4 liters of a polyethylene glycol 4000 (sodium sulphate, sodium chloride, postassium chloride and sodium bicarbonate) solution.
62555012|NCT04942678||Pediatric patients ages 4-7 years old in the Pediatric Emergency Department|Patients will receive a 10-minute visit with therapy dog and child life handler
62750325|NCT00616811|ACTIVE_COMPARATOR|Sitagliptin|
62750326|NCT00246051|OTHER|Sleep Hygiene Education|
62750327|NCT00246051|OTHER|Expert-Led Sleep Disorders Screening and Treatment|
62750328|NCT00246051|OTHER|Online Sleep Disorders Screening|
62555013|NCT04942678||Pediatric patients ages 8-12 years old in the Pediatric Emergency Department|Patients will receive a 10-minute visit with therapy dog and child life handler
62750329|NCT03856476||Dyslipidemia group|Children and adolescents with dyslipidemia
62375254|NCT02039128|PLACEBO_COMPARATOR|Placebo|1 gram per day in 12 weeks
62750330|NCT03856476||Control group|Children and adolescents without dyslipidemia
62750331|NCT05890170||Short-term|"Patients treated at the Department of Oral Surgery and Stomatology at the University of Bern will be potentially be recruited. Patients treated with a dental implant with contour augmentation procedure and required post-operative follow-ups as standard of care (short-term group) will be invited to participate in this study. Patients who expressed an interest to participate in this study at the clinical/phone screening examination, would be informed of the purpose and timeline of the study. All potential subjects will be required to read, understand, and sign the consent form, which included a thorough explanation of the study design, as well as expected benefits and possible risks of participating in the study without limit of time.~Patients would received questionnaires. Data from questionnaires would be extracted by an independent investigator. Different variables would be included: 1) age, sex, systemic factors, date of the procedure; location and extension of the procedure..."
62555014|NCT06488534|OTHER|Fructose|A solution of 10 g fructose in 200 mL of tap water will be infused once over a period of 20min. during 1 of the 3 investigation days.
62555015|NCT06488534|OTHER|Fructan|A solution of 30 g fructan in 200 mL of tap water will be infused once over a period of 20min. during 1 of the 3 investigation days.
62750332|NCT05890170||Mid-term|"Patients treated at the Department of Oral Surgery and Stomatology at the University of Bern will be potentially be recruited. Patients treated with a dental implant with contour augmentation procedure done 1 to 5 years ago (mid-term group) will be invited to participate in this study. Patients who expressed an interest to participate in this study at the clinical/phone screening examination, would be informed of the purpose and timeline of the study. All potential subjects will be required to read, understand, and sign the consent form, which included a thorough explanation of the study design, as well as expected benefits and possible risks of participating in the study without limit of time.~Patients would received questionnaires. Data from questionnaires would be extracted by an independent investigator. Different variables would be included: 1) age, sex, systemic factors, date of the procedure; location and extension of the procedure..."
62750333|NCT05890170||Long-term|"Patients treated at the Department of Oral Surgery and Stomatology at the University of Bern will be potentially be recruited. Patients treated with a dental implant with contour augmentation procedure done \>5 years ago (mid-term group) will be invited to participate in this study. Patients who expressed an interest to participate in this study at the clinical/phone screening examination, would be informed of the purpose and timeline of the study. All potential subjects will be required to read, understand, and sign the consent form, which included a thorough explanation of the study design, as well as expected benefits and possible risks of participating in the study without limit of time.~Patients would received questionnaires. Data from questionnaires would be extracted by an independent investigator. Different variables would be included: 1) age, sex, systemic factors, date of the procedure; location and extension of the procedure..."
62750334|NCT06283823||Retainer with high margins|Thermoformed retainers with modified cutout and high margins in the posterior region of the retainer
62750335|NCT06283823||Retainer with low margins|Thermoformed retainer with conventional festooned cutout and low margins
62750336|NCT06537557|EXPERIMENTAL|experimental group|Using the early in-hospital temperature management protocol for heat stroke patients developed in our previous research, we will implement early identification, rapid cooling, and precise target temperature management for this group of patients.
62750337|NCT06537557|NO_INTERVENTION|control group|We will retrospectively collect data on heat stroke patients who were visited before the implementation of the early in-hospital temperature management protocol between 2021 and 2022, meaning this group of patients received temperature management according to the original methods used by their respective hospitals.
62750338|NCT02538419|ACTIVE_COMPARATOR|CPAP + Peer Support|"Participants randomized to this arm will receive support from a 'CPAP Peer Leader', delivered as part of a group of other participants as well as targeted one-on-one support throughout the study.~All participants will receive CPAP in addition to this intervention."
62750339|NCT02538419|ACTIVE_COMPARATOR|CPAP + Individual Education|"Participants randomized to this arm will receive individual support and education from a trained investigator.~All participants will receive CPAP in addition to this intervention."
62750340|NCT00998751|EXPERIMENTAL|masitinib (AB1010)|oral masitinib 7.5 mg/kg/day
62750341|NCT06372522|EXPERIMENTAL|continuous oxytocin infusion|continuous oxytocin infusion - women will continue to receive a continuous oxytocin infusion from start of labor augmentation until delivery.
62750342|NCT06372522|ACTIVE_COMPARATOR|intermittent oxytocin infusion|"intermittent oxytocin infusion - oxytocin transfusion will be discontinued after 8 hours if the woman does not go into active labor, or does not deliver in that period of time.~The second course of oxytocin will be renewed after 6 hours if the woman hasn't progressed into labor or hasn't given birth yet."
62750343|NCT05122260|PLACEBO_COMPARATOR|Placebo|
62750344|NCT05122260|EXPERIMENTAL|Q-Griffithsin|
62750345|NCT04577300|EXPERIMENTAL|Dual Implantation|Two NT-501 devices will be implanted in the study eye.
62750346|NCT04577300|EXPERIMENTAL|Single Implantation|One NT-501 device will be implanted in the study eye.
62750347|NCT04577300|SHAM_COMPARATOR|Sham Implantation|No NT-501 devices will be implanted in the study eye.
62750348|NCT05522244|NO_INTERVENTION|standard CTA|Standard CTA performed as standard of care for Stroke Workup
62750349|NCT05522244|EXPERIMENTAL|extended CTA|The standard CTA will be extended 6 cm below the carina
62750350|NCT01145352||Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis during registered period (2.5 year).
62750351|NCT05751590|ACTIVE_COMPARATOR|Glidescope + Fiberoptic broncscopy|
62750352|NCT05751590|ACTIVE_COMPARATOR|Fiberoptic broncscopy|
62750353|NCT05600816|OTHER|Pounce Venous Thrombectomy System|Subjects admitted for endovascular thrombus removal using the Pounce Venous Thrombectomy System
62750354|NCT04182321|EXPERIMENTAL|Combination Therapy|Metformin as add-on to entecavir therapy in patients with chronic hepatitis B
62750355|NCT04182321|PLACEBO_COMPARATOR|Standard Therapy|Entecavir monotherapy in patients with chronic hepatitis B
62750356|NCT02692040|EXPERIMENTAL|12-24 mg (B1) dose of G3215|"G3215 multiple dose, subcutaneous injection:~5 doses over a 4 week treatment period at escalating doses to a max of 24 mg."
62750357|NCT02692040|EXPERIMENTAL|6-10 mg (B2) dose of G3215|"G3215 multiple dose, subcutaneous injection:~5 doses over a 4 week treatment period at escalating doses to a max of 10 mg."
62750358|NCT02692040|EXPERIMENTAL|5-16 mg (B3) dose of G3215|"G3215 multiple dose, subcutaneous injection:~5 doses over a 4 week treatment period at escalating doses to a max of 16 mg."
62750359|NCT02692040|EXPERIMENTAL|3.2mg (C) infusion pump dose of G3215|G3215 subcutaneous infusion over a 4 day treatment period at escalating doses to a max of 3.2 mg (with either the first or last day administering infusion of placebo \[saline\]).
62750360|NCT02692040|PLACEBO_COMPARATOR|Placebo (B) - saline|5 subcutaneous injections of 0.9% saline, over a 4 week treatment period
62750361|NCT02692040|PLACEBO_COMPARATOR|Placebo (A) - saline|Single subcutaneous injection of 0.9% saline
62750362|NCT02692040|EXPERIMENTAL|0.1 mg dose G3215 (A1)|0.1 mg G3215 single dose, subcutaneous injection
62750363|NCT02692040|EXPERIMENTAL|0.5 mg dose G3215 (A1)|0.5 mg G3215 single dose, subcutaneous injection
62555016|NCT06488534|OTHER|Mannitol|A solution of 10 g mannitol in 200 mL of tap water will be infused once over a period of 20min. during 1 of the 3 investigation days.
62375255|NCT00949104|ACTIVE_COMPARATOR|Sucrose|1 ml of 24% sucrose was administered 2 minutes before the procedure
62375256|NCT00949104|PLACEBO_COMPARATOR|Placebo|Double distilled water
62375257|NCT04856215|EXPERIMENTAL|90-Yttrium-labelled anti-CD66 monoclonal antibody|"The medicinal product consists of the murine IgG1 anti-CD66 monoclonal antibody radio-labelled with 111In for imaging and dosimetry and with 90Y for therapy.~Dosage indications The \[111In\]-labeled anti-CD66 monoclonal antibody (MAb) will be given at an infused activity of 100MBq/sqm between 1-4 weeks before the therapeutic dose of radiolabelled antibody.~\[90Y\]-yttrium-labeled anti-CD66 MAb will be given as a single infusion on day - 14 prior to transplant. \[90Y\]-yttrium labelled anti-CD66 MAb will be given to target an absorbed dose to the bone marrow of 45 Gy +/- 10%. The maximum dose to be delivered to the liver and the kidneys is 15 Gy and 10 Gy, respectively."
62375258|NCT02252068|OTHER|I-CBT feasibility pilot|Open trial of I-CBT
62375259|NCT02252068|EXPERIMENTAL|I-CBT randomized trial|I-CBT in randomized trial.
62375260|NCT02252068|ACTIVE_COMPARATOR|IDC randomized trial|Comparison condition (Individualized Drug Counseling) in randomized trial.
62375261|NCT04739917|EXPERIMENTAL|Arm N Vaccine|30 malaria-naïve subjects from non-endemic areas of Cali, Colombia.
62555017|NCT03706482|EXPERIMENTAL|Postnatal|"15 participants.~Administration of four postnatal doses of BOOST cells with the first dose as soon as possible after birth and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10\^6 MSC/kg body weight."
62375262|NCT04739917|PLACEBO_COMPARATOR|Arm N Placebo|30 malaria-naïve subjects from non-endemic areas of Cali, Colombia.
62375263|NCT04739917|EXPERIMENTAL|Arm S Vaccine|30 semi-immune subjects from malaria endemic areas of Chocó, Colombia.
62375264|NCT04739917|PLACEBO_COMPARATOR|Arm S Placebo|30 semi-immune subjects from malaria endemic areas of Chocó, Colombia.
62555018|NCT03706482|EXPERIMENTAL|Prenatal|"3 participants.~Administration of one prenatal dose of BOOST cells followed by three postnatal doses at +4, +8 and +12 months after the first dose. Each dose is 3x10\^6 MSC/kg body weight."
62555019|NCT03706482|NO_INTERVENTION|Prospective control (untreated)|"1-30 participants.~Subjects eligible for the trial but not willing/able to participate in any of the experimental arms."
62555020|NCT03706482|NO_INTERVENTION|Historic control|"18-90 participants (1-5 per included and treated subject).~Matched historical controls. Subjects will be identified in historical registries and data will be retrieved from national OI registers and the OI Variant Database (Dalgleish 2018)."
62555021|NCT00062530|EXPERIMENTAL|1|All participants will receive oral vaccine at study entry, although dosage will vary
62555022|NCT00505830||1|50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ \>85.
62555023|NCT00505830||2|50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70\<IQ\<84.
62555024|NCT00505830||3|50 adolescents with psychiatric disorders but no autism syndrom.
62555025|NCT00505830||4|Sample of 50 healthy adolescents selected randomly from 200.
62750364|NCT02692040|EXPERIMENTAL|1.5 mg dose G3215 (A1)|1.5 mg G3215 single dose, subcutaneous injection
62750365|NCT02692040|EXPERIMENTAL|4 mg dose G3215 (A2) with varied formulation|4 mg G3215 single dose, subcutaneous injection
62750366|NCT02692040|EXPERIMENTAL|4 mg dose G3215 (A3) with varied formulation|4 mg G3215 single dose, subcutaneous injection
62750367|NCT02692040|EXPERIMENTAL|4 mg dose G3215 (A4) with varied formulation|4 mg G3215 single dose, subcutaneous injection
62750368|NCT02692040|EXPERIMENTAL|4 mg dose G3215 (A5) with varied formulation|4 mg G3215 single dose, subcutaneous injection
62750369|NCT02692040|EXPERIMENTAL|8 mg dose G3215 (A7)|8 mg G3215 single dose, subcutaneous injection
62750370|NCT02692040|EXPERIMENTAL|10 mg dose G3215 (A6)|10 mg G3215 single dose, subcutaneous injection
62750371|NCT02692040|EXPERIMENTAL|12 mg dose G3215 (A8)|12 mg G3215 single dose, subcutaneous injection
62750372|NCT02692040|EXPERIMENTAL|16 mg dose G3215 (A9)|16 mg G3215 single dose, subcutaneous injection
62750373|NCT02692040|EXPERIMENTAL|32 mg dose G3215 (A10)|32 mg G3215 single dose, subcutaneous injection
62750374|NCT02692040|EXPERIMENTAL|48 mg dose G3215 (A11)|48 mg G3215 single dose, subcutaneous injection
62750375|NCT00978055|EXPERIMENTAL|1|Liothyronine Sodium Tablets, 50 mcg
62750376|NCT00978055|ACTIVE_COMPARATOR|2|Cytomel® Tablets, 50 mcg
62750377|NCT02186379|EXPERIMENTAL|RePace Intervention Group|"Re-Pace intervention-five weekly intervention sessions lasting about 1 hour each.~Lab Test Meal-2 test meals 6-8 weeks apart."
62555026|NCT05081050||10-year Patients|Clinical and image examination to assess single crowns on short (6-mm) implants in the posterior region of the maxilla and mandible, according to functional, biological and technical variables, patient's satisfaction and quality of life.
62555027|NCT02850692|EXPERIMENTAL|Cystic fibrosis with portal hypertension|Mucoviscidosis with portal hypertension. Blood sample (21ml). Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®). Injected abdominal CT scan.
62555028|NCT02850692|EXPERIMENTAL|Muco without portal hypertension|Mucoviscidosis without portal hypertension. Blood sample (21ml). Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®). Injected abdominal CT scan.
62555029|NCT02850692|EXPERIMENTAL|Portal hypertension without muco|Portal hypertension without Mucoviscidosis. Blood sample (21ml) . Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®). Injected abdominal CT scan.
62750378|NCT02186379|ACTIVE_COMPARATOR|Usual Care Control Group|One 25 minute education session (week 6) 2 lab test meals 6-8 weeks apart (baseline and week 6)
62750379|NCT01872195|EXPERIMENTAL|* Before checklists|The comprehensive patient safety checklist system
62555030|NCT02850692|EXPERIMENTAL|Healthy volunteers|Healthy volunteers. Blood sample (21ml) . Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®).
62555031|NCT05084924|EXPERIMENTAL|Delta-beta tACS|The study is investigating the use of transcranial alternating current stimulation (tACS). The stimulation is delivered at 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA zero to-peak amplitude at the return electrode. For the experimental arm, the tACS will be delivered using the cross-frequency stimulation waveform delta-beta (3-20Hz).
62750380|NCT01872195|EXPERIMENTAL|* After checklists|Without the comprehensive patient safety checklist system
62750381|NCT03645421|PLACEBO_COMPARATOR|placebo|Placebo per day,SC injection on 48 days.
62750382|NCT03645421|EXPERIMENTAL|MEDI0382 100μg|50 μg/day,SC injection on the first 5 days and 100 μg/day,SC injection on 43 days
62750383|NCT03645421|EXPERIMENTAL|MEDI0382 200μg|50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days and 200 μg/day,SC injection on 36 days.
62750384|NCT03645421|EXPERIMENTAL|MEDI0382 300μg|50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days, 200 μg/day,SC injection on 7 days and 300 μg/day,SC injection on 29 days
62750385|NCT06608719||Receiving the study drug|Patients diagnosed with ALS who visited our hospital and were administered SHED-CM between January 1, 2022, and November 30, 2023.
62750386|NCT01342354|EXPERIMENTAL|Stereotactic Radiation|Escalating doses of SBRT in three doses over ten days.
62750387|NCT06605287||Supaglutide Treatment|Type 2 diabetes patients without any hypoglycemic drugs after 52 or 28 weeks of Supaglutide treatment
62555032|NCT05084924|ACTIVE_COMPARATOR|Theta-gamma tACS|This arm serves as an active control where tACS will be delivered using the cross-frequency stimulation waveform theta-gamma (5-50Hz).
62750388|NCT03661424|EXPERIMENTAL|Test dose then 8 doses HER2 Bi-armed activated T-cells (BATs)|Approximately 4 weeks following registration and blood collection, participants are given a test dose of HER2 BATs followed by 8 weekly infusions. Infusions are given intraventricularly.
62555033|NCT05084924|SHAM_COMPARATOR|Active-sham tACS|For active sham stimulation, either delta-beta or theta-gamma stimulation is delivered for 10 seconds and then returns to baseline. This is intended to mimic the skin sensations (e.g., itching, burning, tingling) that are experienced at the onset of stimulation, assisting with blinding the participant's assignment.
62555034|NCT04650594|EXPERIMENTAL|case group|Patients with knee bone malignancy
62555035|NCT04654793|EXPERIMENTAL|Intervention group|Robot assisted inclined bed treatment and FES
62555036|NCT04654793|ACTIVE_COMPARATOR|Control group|conventional inclined bed treatment
62555037|NCT00154154|ACTIVE_COMPARATOR|A|General Psychiatric Management
62555038|NCT00154154|EXPERIMENTAL|2|Dialectal Behaviour Therapy
62567425|NCT03775525|EXPERIMENTAL|Experimental: Combination with Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer|GZ17-6.02 given orally twice daily x 21 day schedule in combination with Capecitabine 825 mg/m2 orally twice daily for 14 days x 21 day schedule.
62567426|NCT03775525|EXPERIMENTAL|Experimental: Combination with Capecitabine in Metastatic Colorectal Cancer|GZ17-6.02 given orally twice daily x 21 day schedule in combination with Capecitabine 850 mg/m2 orally twice daily for 14 days x 21 day schedule.
62567427|NCT05888662|EXPERIMENTAL|Endo-epicardial ablation|
62567428|NCT05888662|ACTIVE_COMPARATOR|endocardial ablation only|
62567429|NCT02805920|ACTIVE_COMPARATOR|GROUP 1 : G20|Postoperative pain for ACLR : G20 : received ACB with 20 ml 0.25% Bupivacaine
62567430|NCT02805920|ACTIVE_COMPARATOR|GROUP 2 : G25|Postoperative pain for ACLR : G25: received ACB with 25 ml 0.25% Bupivacaine
62567431|NCT02805920|ACTIVE_COMPARATOR|GROUP 3 : G30|Postoperative pain for ACLR : G30 received ACB with 30 ml 0.25% Bupivacaine
62567432|NCT02604992|EXPERIMENTAL|Group 1 (A,B,C)|With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment B, and then Treatment C.
62567433|NCT02604992|EXPERIMENTAL|Group 2 (B,C,A)|With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment C, and then Treatment A.
62567434|NCT02604992|EXPERIMENTAL|Group 3 (C,A,B)|With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment A, and then Treatment B.
62567435|NCT02604992|EXPERIMENTAL|Group 4 (C,B,A)|With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment B, and then Treatment A.
62567436|NCT02604992|EXPERIMENTAL|Group 5 (A,C,B)|With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment C, and then Treatment B.
62555039|NCT02185339|EXPERIMENTAL|dNMB group|For patients randomized to the dNMB group, intravenous infusion of 0.6 mg/kg/h rocuronium will be administered 10 minutes after the administration of intubation dose or after the return of post-tetanic count (PTC), whichever comes first. Then, the infusion rate will be titrated according to PTC (target to keep PTC between 1 to 2). Infusion rate will be increased or be reduced at a rate of 0.1 mg/kg/h if PTC is \> or \< than 1-2 to maintain deep muscle relaxation throughout the surgery. Neuromuscular monitoring will be carried out by monitoring the adductor pollicis muscle in response to ulnar nerve stimulation. A dose of sugammadex (4 mg/kg) will be administered at the end of the surgery. Patients will be extubated when the train of four ratio is ≥0.9.
62555040|NCT02185339|ACTIVE_COMPARATOR|mNMB group|For patients randomized to the mNMB group, intravenous infusion of 0.2 mg/kg/h rocuronium will be administered 30 minutes after the administration of intubation dose or after the appearance of train-of-four (TOF) count \>2, whichever comes first. Then, the infusion rate will be titrated according to TOF (target to keep TOF between 1 to 2). Infusion rate will be increased or reduced at a rate of 0.1 mg/kg/h if TOF is \> or \< than 1-2. A dose of sugammadex (2 mg/kg) will be administered at the end of the surgery. Patients will be extubated when the train of four ratio is ≥0.9.
62750389|NCT05763381|ACTIVE_COMPARATOR|The Usual Care + PBM Group|Participants that are assigned to this group will receive active treatment with PBM 3 times a week for 3 weeks for a total of 9 treatments.
62750390|NCT05763381|PLACEBO_COMPARATOR|The Usual Care + Sham (Placebo) PBM Group|Participants that are assigned to this group will receive Sham PBM therapy 3 times a week for 3 weeks for a total of 9 treatments. Sham PBM therapy is an inactive harmless treatment that is intended to mimic the active PBM treatment.
62750391|NCT04655755|EXPERIMENTAL|Treatment (venetoclax, ASTX727)|Patients receive venetoclax orally PO QD on days 1-14. Patients also receive ASTX727 PO QD on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62750392|NCT06319469|EXPERIMENTAL|group B|8 mg silodosin
62750393|NCT06319469|EXPERIMENTAL|group A|silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet
62750394|NCT05742906|OTHER|Group A: Adults treated with SIS 1.0 Cor TRICUSPID ECM Valve|Adults (\>/= 21 years of age) treated with the SIS 1.0 Cor TRICUSPID ECM Valve
62750395|NCT05742906|OTHER|Group B: Pediatrics treated with SIS 1.0 Cor TRICUSPID ECM Valve|Pediatrics (\<21 years of age) treated with SIS 1.0 Cor TRICUSPID ECM Valve
62750396|NCT05742906|OTHER|Group C: Adults treated with SIS 2.0 Cor TRICUSPID ECM Valve|Adults (\>/= 21 years of age) treated with the SIS 2.0 Cor TRICUSPID ECM Valve
62750397|NCT05742906|OTHER|Group D: Pediatrics treated with SIS 2.0 Cor TRICUSPID ECM Valve|Pediatrics (\<21 years of age) treated with SIS 2.0 Cor TRICUSPID ECM Valve
62750398|NCT01872039|ACTIVE_COMPARATOR|Weight-based adjustment group|Dosage regimen according to the current Package Insert approved by SFDA
62750399|NCT01872039|EXPERIMENTAL|Non-weight-based adjustment group|Dosage regimen according to the Package Insert approved by FDA
62750400|NCT03582865||responding|patients who received Tamoxifen 20 mg daily for at least 3 years with good response (no relapse) to tamoxifen. Both genotyping assessment and TDM of tamoxifen and its metabolites will be performed and correlated with the records. Follow up for these patients for further assessment of tamoxifen effectiveness will be carried out for 1- 2 years.
62750401|NCT03582865||relapse|patients who received Tamoxifen 20 mg daily for at least 3 years who were good responder to the drug but then the response has been diminished (relapse) and they have been shifted to another therapy. They will be exposed to genotyping study of CYP 2D6 to recognize the phenotyping style of that patient that may explain diminishing of response to tamoxifen therapy.
62750402|NCT03582865||tamoxifen resistant|patients who received Tamoxifen 20 mg daily for not more than 1 year with poor response to tamoxifen (early relapse) and clinically will be shifted to use another medication as they were diagnosed as tamoxifen resistant. Like the second group, they will be exposed to genotyping study of CYP2D6 with the same concept.
62750403|NCT04941807|EXPERIMENTAL|Platelet-rich plasma|The proximal nail fold is cleansed with alcohol and platelet-rich plasma obtained from the patient is injected using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.
62750404|NCT04941807|PLACEBO_COMPARATOR|Platelet-poor plasma|The proximal nail fold is cleansed with alcohol and platelet-poor plasma obtained from the patient is injected using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.
62555041|NCT04385537|NO_INTERVENTION|Control|Participants in this group avoid all nuts for 4-weeks
62555042|NCT04385537|EXPERIMENTAL|PECAN|Participants in this group consume 68 g of pecans/d with no other changes to their habitual diet and avoid all other nuts.
62555043|NCT01549405|NO_INTERVENTION|Control group|Control group: Group that without intercostal nerve block
62555044|NCT01549405|EXPERIMENTAL|nerve block|Group that performing intercostal block
62555045|NCT02635984|PLACEBO_COMPARATOR|Triplet Therapy Plus Placebo|All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
62555046|NCT02635984|ACTIVE_COMPARATOR|Triplet Therapy Plus Olanzapine|All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
62555047|NCT02271295|EXPERIMENTAL|Enoxaparine|69 Child Pugh B7-C10, cirrhotic patients receiving anticoagulation treatment (daily subcutaneous injection of enoxaparin 4000UI/day) during 24 months
62555048|NCT02271295|NO_INTERVENTION|Control|69 Child Pugh B7-C10, cirrhotic patients not receiving anticoagulation treatment
62750405|NCT02507180||Pregnant women with suspected DVT|Pregnant women presenting with suspected DVT will have the LEFt clinical decision rule applied by the attending physician and will have a clinical D-dimer test done.
62750406|NCT01261442||Diabetic patients with DSPN|
62750407|NCT01261442||Diabetic patients without DSPN|
62750408|NCT05077995|EXPERIMENTAL|Healthy adult group|Sixty healthy adults, aged 18-65 years, will be included following written informed consent.
62750409|NCT03550170|ACTIVE_COMPARATOR|Teleconference|Teleconference Intervention arm
62750410|NCT03550170|ACTIVE_COMPARATOR|Internet|Internet Intervention arm
62750411|NCT03550170|ACTIVE_COMPARATOR|I-to-1, in-person or videoconference|1-to-1, in-person or videoconference intervention arm
62750412|NCT05470101|EXPERIMENTAL|Cohort A1: ITI-333 2.25 mg|
62750413|NCT05470101|EXPERIMENTAL|Cohort A2: ITI-333 dose to be determined based on Cohort A1|
62750414|NCT05470101|EXPERIMENTAL|Cohort A3: ITI-333 dose to be determined based on Cohort A1 and A2|
62750415|NCT05470101|EXPERIMENTAL|Cohort A4: ITI-333 dose to be determined based on Cohort A1, A2 and A3|
62750416|NCT05476237|ACTIVE_COMPARATOR|TAU|Psychologists or PsyTechs in mental health services of primary care clinics will provide individual psychotherapy to depressed adolescents in the TAU arm. Local mental health professionals providing depression treatment in the TAU arm will not have been trained on IPT for adults or adolescents. Also, the two Ministry of Health psychologists trained as trainers of IPT-AG will not provide treatment in the TAU Arm.
62750417|NCT05476237|EXPERIMENTAL|IPT-AG|Group IPT-AG will be facilitated by the trained providers at each YFHS using the IPT-AG manual adapted to the Mozambican context. Adolescents will participate in 12 weekly sessions. The first and last sessions will be one-on-one with the provider. The first session is used for the participant and provider to develop a treatment plan and the last session is to prepare for treatment termination. All other sessions will be conducted in groups of 6-8 adolescents.
62750418|NCT06606184|EXPERIMENTAL|Inspiratory Muscle Training group|Participants received a 12-week inspiratory muscle training and incentive spirometry therapy after discharged from hospital
62750419|NCT06606184|SHAM_COMPARATOR|Routine care|Participants received incentive spirometry therapy only
62750420|NCT02767089|OTHER|Sequence A|Period 1: Placebo Period 2: Prednisone 2.5 mg Period 3: Prednisone 10 mg
62750421|NCT02767089|OTHER|Sequence B|Period 1: Prednisone 2.5 mg Period 2: Prednisone 5 mg Period 3: Prednisone 20 mg
62750422|NCT02767089|OTHER|Sequence C|Period 1: Prednisone 5 mg Period 2: Prednisone 10 mg Period 3: Prednisone 40 mg
62750423|NCT02767089|OTHER|Sequence D|Period 1: Prednisone 10 mg Period 2: Prednisone 20 mg Period 3: Prednisone 60 mg
62750424|NCT02767089|OTHER|Sequence E|Period 1: Prednisone 20 mg Period 2: Prednisone 40 mg Period 3: Placebo
62750425|NCT02767089|OTHER|Sequence F|Period 1: Prednisone 40 mg Period 2: Prednisone 60 mg Period 3: Prednisone 2.5 mg
62750426|NCT02767089|OTHER|Sequence G|Period 1: Prednisone 60 mg Period 2: Placebo Period 3: Prednisone 5 mg
62750427|NCT05470543|EXPERIMENTAL|Nurse-led Supportive Care Group|
62750428|NCT05470543|NO_INTERVENTION|Control Group|The control group received only usual care. They did not receive any intervention during the study period.
62375265|NCT02516891|EXPERIMENTAL|hydrophilic wire/Drug-Eluting Stents|Will include 100 patients with coronary bifurcation lesions in that they will be treated with stents and in which the technique is used jailed guide.
62555049|NCT02929888|EXPERIMENTAL|Lysine Acetilsalicilate (LA)|Loading dose (LD) of intravenous LA 450mg plus oral prasugrel 60mg/ticagrelor 180mg in patients with ST-segment elevation myocardial infarction
62555050|NCT02929888|ACTIVE_COMPARATOR|Aspirin|Loading dose (LD) of oral aspirin 300mg plus oral prasugrel 60mg/ticagrelor 180mg in patients with ST-segment elevation myocardial infarction
62555051|NCT04921917|NO_INTERVENTION|Control|Standard of care: neoadjuvant radiation therapy (NRT).
62555052|NCT04921917|EXPERIMENTAL|Neoadjuvant Exercise Regimen|Subjects will receive conventional NRT in conjunction with a prescribed exercise regimen during the usual 10-week duration of NRT treatment prior to tumor resection.
62555053|NCT00145951||1|
62555054|NCT00145951||2|
62555055|NCT00145951||3|
62555056|NCT00549575|EXPERIMENTAL|A|Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories). Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venous was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
62555057|NCT00549575|PLACEBO_COMPARATOR|B|After double blind randomization, patients received a placebo. Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venous was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
62555058|NCT01936350|EXPERIMENTAL|Sildenafil|12 patients will be in this group. They will take a sildenafil 50mg.
62555059|NCT01936350|PLACEBO_COMPARATOR|Placebo|12 patients will be in this group, they will take placebo
62555060|NCT01373138|EXPERIMENTAL|Desloratadine and pseudoephedrine ER tablets 5/240 mg|Desloratadine and pseudoephedrine ER tablets 5/240 mg of Dr. Reddy's Laboratories Limited
62555061|NCT01373138|ACTIVE_COMPARATOR|Clarinex D 24-hour|Clarinex D-24 of Schering Corporation Inc USA
62555062|NCT00763633|ACTIVE_COMPARATOR|highB6|high vitamin B6
62555063|NCT00763633|ACTIVE_COMPARATOR|lowB6|low vitamin B6
62555064|NCT03667638|EXPERIMENTAL|PRP Intervention|PRP injection into wound border
62555065|NCT05489302|ACTIVE_COMPARATOR|(MSE) Alt-RAMEC protocol|
62555066|NCT05489302|ACTIVE_COMPARATOR|(MSE) conventional protocol|
62555067|NCT00825786|ACTIVE_COMPARATOR|Group 1|combined group: ropivacaine and mepivacaine mixture: 1:1 volume mixture of 1.5% mepivacaine and 0.5% ropivacaine in 2 syringes (labeled 1 and 2) with 15 mL in each (total, 30 mL) injected in immediate sequence;
62555068|NCT00825786|ACTIVE_COMPARATOR|Group 2|sequential group: mepivacaine followed by ropivacaine: syringe 1 containing 15 mL of 1.5% mepivacaine, syringe 2 containing 15 mL of 0.5% ropivacaine (total, 30 mL); syringe 2 was injected with a 90-sec delay after injection of syringe 1.
62555069|NCT03778138|EXPERIMENTAL|Anlotinib plus Pemetrexed|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2 IV d1)
62555070|NCT01288963||IL-2 subjects|Subjects receiving IL-2 for advanced melanoma
62750429|NCT04503083||Migraine patients|"* Excellent responder, a patient who experiences a \>75% decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days during the last 4 weeks of treatment as compared to baseline;~* Responder, a patient who experiences a \>50% decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days during the last 4 weeks of treatment as compared to baseline;~* Non responder, a patient who experiences a decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days ranging from 26 to 49% during the last 4 weeks of treatment as compared to baseline;~* Full non responder, a patient who experiences a \<25% decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days during the last 4 weeks of treatment as compared to baseline."
62750430|NCT00664313|EXPERIMENTAL|1|Linezolid 600 mg po QD
62750431|NCT00664313|PLACEBO_COMPARATOR|2|Placebo
62750432|NCT02101684|EXPERIMENTAL|Orteronel 300mg b.i.d.|Orteronel 300mg BID (600mg per day) will be administered to all included patients in a 28 days cycle schedule.
62750433|NCT06390696|EXPERIMENTAL|Microbial intervention|Children receive an indoor sandbox and cultivation set including soil- and plant-based material with high microbial diversity.
62750434|NCT06390696|PLACEBO_COMPARATOR|placebo|Children receive an indoor sandbox and cultivation set including placebo material with low microbial diversity.
62750435|NCT04829799|ACTIVE_COMPARATOR|Control Group|Subjects will receive intracameral 1% preservative-free lidocaine following paracentesis
62750436|NCT04829799|EXPERIMENTAL|Study Experimental Group|Subject will receive Omidria (phenylephrine and ketorolac (1.0%/0.3%) added to the ophthalmic irrigating solution during the cataract extraction procedure
62750437|NCT00230802|ACTIVE_COMPARATOR|2 tablet increase|Patients will increase their current levothyroxine dose by 2 extra tablets per week (\~29% increase)
62750438|NCT00230802|ACTIVE_COMPARATOR|3 tablet increase|Patients will increase their levothyroxine dosage by 3 extra tablets per week (\~43%).
62750439|NCT01931488|OTHER|MIBG label with I123 or I124|evaluate the added value of PET-CT with 124I-MIBG tracer, compared to planar and SPECT imaging with the routine 123I-MIBG tracers/
62750440|NCT06605248|EXPERIMENTAL|App-based self-management tool plus usual care|App-based self-management tool consisting of pain education and clinical hypnosis delivered after usual care.
62750441|NCT06605248|EXPERIMENTAL|Patient information digital fact-sheet plus usual care|The intervention consists of a fact-sheet delivered after usual care.
62750442|NCT00530829|EXPERIMENTAL|1|Mothers recieve a blister pack of zinc tablets in home every two months for use when child in home under 5 years has diarrhea. ORS satchets also given. Instructions on when and how to use zinc and ORS and when to take child in clinic are given by community health worker. Zinc will also be given in clinic if child visits clinic with diarrhea and has not yet started zinc at home.
62750443|NCT00530829|ACTIVE_COMPARATOR|2|Mothers recieve ORS satchets at home every two months for use when child in home under 5 years has diarrhea. Instructions on when and how to use ORS and when to take child in clinic are given by community health worker. Zinc will be given in clinic if child visits clinic with diarrhea.
62750444|NCT06345482|EXPERIMENTAL|MHB039A|MHB039A IV every 2 weeks or every 3 weeks (including 5mg/kg、10mg/kg、20mg/kg and 30mg/kg)
62750445|NCT05226780|EXPERIMENTAL|NBI-921352|NBI-921352 administered for up to 164 weeks.
62750446|NCT03994250|ACTIVE_COMPARATOR|Kinematic Arm|Kinematic Alignment for TKR surgery
62750447|NCT03994250|PLACEBO_COMPARATOR|Control Arm|Mechanical alignment for TKR surgery
62750448|NCT05350930||R-CHOP or G-CHOP chemotherapy|Patients with hematological malignancies receiving R-CHOP or G-CHOP chemotherapy
62750449|NCT05316233|EXPERIMENTAL|VOLITE XC|Participants will receive VOLITE XC for initial treatment and followed for up to 14 Months. Participants will have the opportunity to receive optional touch-up and optional repeat treatment of VOLITE XC during the follow-up duration period.
62750450|NCT05316233|OTHER|Control Group|The control group received no treatment and will be followed for up to 6 months after randomization. Participants can then opt to receive VOLITE XC and followed for 6 Months.
62750451|NCT06126718|EXPERIMENTAL|BR201|
62750452|NCT06126718|ACTIVE_COMPARATOR|Cosentyx (Secukinumab)|
62750453|NCT02053207|EXPERIMENTAL|Cog-Train Intervention|
62750454|NCT02850861|EXPERIMENTAL|The experimental group|In this group, the condylar reductor was applied in the surgical treatment of mandibular condylar fractures.
62750455|NCT02850861|NO_INTERVENTION|The control group|In this group, traditional surgical instruments were applied in the surgical treatment of mandibular condylar fractures.
62750456|NCT05132361|EXPERIMENTAL|SELUTION SLR™ 018 DEB|Treatment with Selution SLR drug eluting balloon to apply long term (\>90 days) local treatment with sirolimus
62750457|NCT05132361|ACTIVE_COMPARATOR|Plain (Uncoated) Balloon Angioplasty (PTA)|Opening artery only by dilatation with an temporary inserted and inflated balloon.
62750458|NCT02235675|EXPERIMENTAL|Tack-It|Implant of the Intact Vascular Tack-It Endovascular System to repair post angioplasty dissections.
62750459|NCT03568253|ACTIVE_COMPARATOR|Bulk fil composite|
62750460|NCT03568253|ACTIVE_COMPARATOR|High viscosity glass ionomer|
62750461|NCT05220319|PLACEBO_COMPARATOR|Placebo|"100 ml of NaCl 0,9%, not containing corticosteroids, given at induction of anaesthesia, before surgery.~If a patient will receive cardiopulmonary bypass (CPB) during his operation, a repeat dose of 100 ml of NaCl 0,9% will be administered at the beginning of CPB."
62750462|NCT05220319|ACTIVE_COMPARATOR|Methylprednisolone|"250 mg of methylprednisolone made up with 100 ml NaCl 0,9%, given at the induction of anaesthesia, before surgery.~If a patient will receive cardiopulmonary bypass (CPB) during his operation, a repeat dose of 250 mg methylprednisolone will be administered at the beginning of CPB."
62750463|NCT00611442|ACTIVE_COMPARATOR|1|split-dose PEG solution without dietary restrictions plus lubiprostone 24mcg gelcap pretreatment
62750464|NCT00611442|PLACEBO_COMPARATOR|2|split-dose PEG solution without dietary restrictions plus placebo pretreatment
62750465|NCT00701142|ACTIVE_COMPARATOR|Haemocomplettan® P|Intravenous infusion during aortic surgery
62750466|NCT00701142|PLACEBO_COMPARATOR|Saline solution|
62750467|NCT04983485||Observational Group|Individuals who were diagnosed with COPD by Bolu Abant İzzet Baysal University Medical Faculty Chest Diseases Department and referred to Bolu Abant İzzet Baysal University Health Sciences Faculty Physiotherapy and Rehabilitation Department will be included in the study.
62750468|NCT00531557|OTHER|1|Darunavir 600mg BID with ritonavir 100mg BID administered orally.
62750469|NCT06608823|EXPERIMENTAL|Transcatheter Aortic Valve Replacement (TAVR)|Transcatheter Aortic Valve Replacement (TAVR) using the Trilogy THV System
62750470|NCT06608823|OTHER|SAVR|SAVR using commercially available surgical prosthetic valve
62750471|NCT06609044||Anti-NMDAR encephalitis patients.|Patients over 18 years old with NMDAR encephalitis.
62750472|NCT06604533|EXPERIMENTAL|Intervention: MRI-Linac SABR|The treatment planning protocol follows the UK SABR Consortium Guidelines. Patients will be prescribed the maximum isotoxic dose achievable while meeting normal organ tolerances (normal liver, kidney, spinal cord, stomach, duodenum, small and large bowel, heart, lungs, chest wall). The lowest acceptable SABR doses are indicated in the dose range Table within the protocol. The maximum dose/fraction also indicates the maximum the dose can be escalated to for each adaptive session on the MRI-Linac.
62375266|NCT02516891|NO_INTERVENTION|Non hydrophilic wire/Drug-Eluting Stents|Will include 100 patients with coronary bifurcation lesions in that they will be treated with stents and in which the technique is used jailed guide.non hydrophilic guide.
62375267|NCT06118190|EXPERIMENTAL|mesotherapy|All participants who received mesotherapy were monitored regularly for the following three months to assess their prognosis and ensure patient adherence to treatment.
62375268|NCT04115891|EXPERIMENTAL|Lavender oil group|"100 % pure, high strength lavender oil inhalation in a separate room for 3 minutes, prior to tooth extractions.~Anxiety scale (FIS) Pain scale 1 (FLACC) Pain scale 2 (WBS) Vital signs 1 (systolic and diastolic blood pressure) Vital signs 2 (heart rate) Vital signs 3 (saturation)"
62375269|NCT04115891|SHAM_COMPARATOR|Control group|"No application prior to interventions. No lavender oil inhalation.~Anxiety scale (FIS) Pain scale 1 (FLACC) Pain scale (WBS) Vital signs 1 (systolic and diastolic blood pressure) Vital signs 2 (heart rate) Vital signs 3 (saturation)"
62375270|NCT04955652|ACTIVE_COMPARATOR|Standard of Care|A health maintenance topic, actionable sidebar item, and a single-click best practice alert are presented.
62375271|NCT04955652|EXPERIMENTAL|Silent Best Practice Alert|A health maintenance topic and an actionable sidebar item are presented. The best practice alert is set to be silent and will not appear in the patient's chart.
62375272|NCT03234075||Control group|Patients supported without regional organization for promotion of renal transplantation Setting : French Auvergne Rhone Alpes region and French Center region
62375273|NCT03234075||Intervention group|Patients supported with the regional organization for promotion of renal transplantation Setting : French Auvergne Rhone Alpes region
62375274|NCT01129414|EXPERIMENTAL|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~* Day 1: clopidogrel 600 mg loading dose~* Day 2 to Day 5: clopidogrel 150 mg, once daily~Period 2:~* Day -5 to Day -1: omeprazole 80 mg, once daily~* Day 1: clopidogrel 600 mg loading dose + omeprazole 80 mg concomitantly~* Day 2 to Day 5: clopidogrel 150 mg + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
62375275|NCT01129414|PLACEBO_COMPARATOR|Group placebo - placebo + omeprazole|"Period 1:~* Day 1: placebo loading dose~* Day 2 to Day 5: placebo, once daily~Period 2:~* Day -5 to Day -1: omeprazole 80 mg, once daily~* Day 1: placebo loading dose + omeprazole 80 mg concomitantly~* Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
62375276|NCT01129414|EXPERIMENTAL|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~* Day -5 to Day -1: omeprazole 80 mg, once daily~* Day 1: clopidogrel 600 mg loading dose + omeprazole 80 mg concomitantly~* Day 2 to Day 5: clopidogrel 150 mg + omeprazole 80 mg concomitantly, once daily~Period 2:~* Day 1: clopidogrel 600 mg loading dose~* Day 2 to Day 5: clopidogrel 150 mg, once daily~Each intake is under fasted conditions"
62375277|NCT01129414|PLACEBO_COMPARATOR|Group placebo + omeprazole placebo|"Period 1:~* Day -5 to Day -1: omeprazole 80 mg, once daily~* Day 1: placebo loading dose + omeprazole 80 mg concomitantly~* Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Period 2:~* Day 1: placebo loading dose~* Day 2 to Day 5: placebo, once daily~Each intake is under fasted conditions"
62375278|NCT04966806|OTHER|Percentage of Coma and SA to Total ocular HOA|
62555071|NCT04012788|ACTIVE_COMPARATOR|probiotic arm|inulin, 15 g Lactobacillus rhamnosus (LGG®) Lactobacillus acidophilus (LA-5®) Lactobacillus paracasei (L. casei 431®) Bifidobacterium lactis (BB-12®), Total cell counts 150 billion/day
62555072|NCT04012788|PLACEBO_COMPARATOR|placebo arm|placebo powder, 15 g
62555073|NCT04855968|ACTIVE_COMPARATOR|control (CON)|will receive the usual standard of care post-operative pain pills for the involved shoulder (Control Group)
62555074|NCT04855968|EXPERIMENTAL|Mindfulness/Meditation (MM)|will receive the usual standard of care post-operative pain pills for the involved shoulder with the addition of access to the Headspace application for mindfulness/meditation (Mindfulness/Meditation Group)
62555075|NCT03275142|EXPERIMENTAL|Icare Applanation|"Evaluation of corneal stability post-applanation with Icare tonometer via pre and post applanation keratometry readings with IOL Master, topography with Pentacam, fluorescein corneal staining. Patient's OD and OS are randomized into study or control, then undergo applanation with Icare. Investigator is masked as to which eye has undergone applanation."
62555076|NCT03275142|ACTIVE_COMPARATOR|No ICare Applanation|"Evaluation of corneal stability post-applanation with Icare tonometer via pre and post applanation keratometry readings with IOL Master, topography with Pentacam, fluorescein corneal staining. Patient's OD and OS are randomized into study or control, then undergo applanation with Icare. Investigator is masked as to which eye has undergone applanation."
62555077|NCT01047254|ACTIVE_COMPARATOR|Bupropion|Buproprion 150-300 mg in a flexible dose
62555078|NCT01047254|PLACEBO_COMPARATOR|placebo capsule|Placebo
62555079|NCT03301649|EXPERIMENTAL|Generic Ivermectin Lotion 0.5%|Infested household participants will administer a single application of up to 117 grams (1 tube) of generic ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
62555080|NCT03301649|ACTIVE_COMPARATOR|Sklice (Ivermectin) Lotion 0.5%|Infested household participants will administer a single application of up to 117 grams (1 tube) of Sklice ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
62555081|NCT03301649|PLACEBO_COMPARATOR|Vehicle Lotion|Infested household participants will administer a single application of up to 117 grams (1 tube) of vehicle topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
62555082|NCT06461000||Survey|Usual survey
62555083|NCT01867918|EXPERIMENTAL|Cheomotherapy and local treatment|Standard chemotherapy + local treatment
62555084|NCT01867918|PLACEBO_COMPARATOR|Cheomotherapy|Standard chemotherapy
62567437|NCT02604992|EXPERIMENTAL|Group 6 (B,A,C)|With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment A, and then Treatment C.
62375279|NCT01998906|EXPERIMENTAL|HER-2+ Trastuzumab, Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene positive breast cancer (HER2+) were treated with trastuzumab 8 milligrams per kilogram (mg/kg), intravenous (IV), on Day 1 of Cycle 1, followed by 6 mg/kg, IV, on Day 1 of Cycle 2 to up a maximum of Cycle 17. Participants also received doxorubicin 60 mg/ square meter (m\^2), IV, and paclitaxel 150 mg/m\^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m\^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF: cyclophosphamide 600 mg/m\^2, IV; methotrexate 40 mg/m\^2, IV; and 5-fluorouracil 600 mg/m\^2, IV, on Day 1 of Cycles 8 through 10.
62375280|NCT01998906|ACTIVE_COMPARATOR|HER-2+ Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene positive breast cancer were treated with doxorubicin 60 mg/m\^2, IV, and paclitaxel 150 mg/m\^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m\^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
62375281|NCT01998906|ACTIVE_COMPARATOR|HER-2- Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene negative breast cancer were treated with doxorubicin 60 mg/m\^2, IV, and paclitaxel 150 mg/m\^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m\^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
62375282|NCT05553652|ACTIVE_COMPARATOR|ASTARTE™ oral capsule|"The capsule will contain a mixture of four probiotic strains with a combined potency of 5 x10\^9 (CFU)/capsule:~Lactobacillus crispatus LBV88, 2 x10\^9 CFU/g Lactobacillus rhamnosus LBV96, 2 x10\^9 CFU/g Lactobacillus gasseri LBV150N , 0.6 x10\^9 CFU/g Lactobacillus jensenii LBV116, 0.4 x10\^9 CFU/g Corn starch 79 mg, Magnesium salts of fatty acid 3 mg, Silicon dioxide 3 mg, Vegetal capsule size 1 DR white 75 mg, Fructooligosaccharides 30mg"
62375283|NCT05553652|PLACEBO_COMPARATOR|Placebo oral capsule|The placebo oral capsules is identical to the ASTARTE™ capsules and contains Corn starch 79 mg, Magnesium salts of fatty acid 3 mg, Silicon dioxide 3 mg, Vegetal capsule size 1 DR white 75 mg, Fructooligosaccharides 30mg
62375284|NCT02778425|EXPERIMENTAL|Secondary prevention-1|Endoscopic therapy+ beta blockers
62375285|NCT02778425|EXPERIMENTAL|Secondary prevention-2|Endoscopic therapy+ PSE+beta blockers
62375286|NCT02778425|EXPERIMENTAL|Primary prevention-1|Beta blockers
62375287|NCT02778425|EXPERIMENTAL|Primary prevention-2|Endoscopic therapy
62375288|NCT02778425|EXPERIMENTAL|Primary prevention-3|Endoscopic therapy+ PSE
62375289|NCT02778425|EXPERIMENTAL|Acute bleeding-1|Somatostatin+endoscopic therapy
62375290|NCT02778425|EXPERIMENTAL|Acute bleeding-2|Somatostatin+endoscopic therapy+PSE
62750473|NCT06604533|NO_INTERVENTION|Control: Standard SABR|The treatment planning protocol follows the UK SABR Consortium Guidelines. Patients will be prescribed the maximum isotoxic dose achievable while meeting normal organ tolerances (normal liver, kidney, spinal cord, stomach, duodenum, small and large bowel, heart, lungs, chest wall). The lowest acceptable SABR doses are indicated in the dose range Table within the protocol. The maximum dose/fraction also indicates the maximum the dose can be escalated to for each adaptive session on the MRI-Linac.
62555085|NCT02953119|EXPERIMENTAL|Prehabilitation|"The patients will undergo an exercise test on a cycle ergometer (VO2 max), a grip strength test (Jamar dynamometer), a Time Up and Go (TUG) test and a 6 Minutes Walking Test (6-MWT), before and after prehabilitation. Intervention involves 3 training sessions per week during 3 weeks preoperatively, according to the high intensity interval training model, wich consists of:~* 5 minute warm-up (50% of Cardiopulmonary exercise testing, CPET)~* Two 10 minute series of 15 sec sprint intervals (100%) interspersed by 15 sec pauses and a 4 min rest between the two series~* Cool down with a 5 min active recovery period (30%) The grip strength test (Jamar dynamometer), TUG-test and 6-MWT will be repeated between 4 and 6 weeks and 8 and 10 week postoperatively."
62555086|NCT02953119|NO_INTERVENTION|Controls|The patients will also undergo an exercise test on a cycle ergometer, a grip strength test (Jamar dynamometer), a TUG-test and a 6-MWT, but only once preoperatively, and between 4 and 6 weeks and 8 and 10 week postoperatively.
62555087|NCT02087657|EXPERIMENTAL|Hyperbaric Oxygen Treatment|Administration of hyperbaric oxygen on the morning of stem cell transplant (Day 0).
62567438|NCT00209261|ACTIVE_COMPARATOR|1|
62750474|NCT05849714|ACTIVE_COMPARATOR|Usual Care|Patients will receive usual care for their diabetes during their peri-procedural period.
62750475|NCT05849714|EXPERIMENTAL|DIAPI|Patients will receive the care for their diabetes recommended by the DIAPI algorithm during their peri-procedural period.
62750476|NCT06605144|OTHER|Vasopressors|
62750477|NCT03420391|PLACEBO_COMPARATOR|Placebo PBMT|Participants will be treated with placebo PBMT in different time-points before the eccentric exercise protocol (5 minutes, 3 hours, 6 hours or 24 hours). Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
62555088|NCT04791137|NO_INTERVENTION|Monitoring|Participants complete weekly questionnaires (QIDS-SR, PMH, GAD-7) on a weekly basis but receive no intervention.
62555089|NCT04791137|EXPERIMENTAL|Standard imagery cognitive bias modification|Participants are scheduled to complete a first introductory session then 12 further training sessions of a 'standard' imagery cognitive bias modification (CBM) intervention derived from that implemented in previous studies.
62555090|NCT04791137|EXPERIMENTAL|Standard imagery cognitive bias modification plus additional rationale and transfer instructions|Participants are scheduled to complete a first introductory session then 12 further training sessions of a 'standard' imagery cognitive bias modification (CBM) intervention, but in addition are first presented with a more extended rationale for completing the training, and during each training session are provided with instructions to practice retrieval and rehearsal of the training contents in between sessions.
62555091|NCT04791137|EXPERIMENTAL|Standard imagery cognitive bias modification with frequent brief sessions|"Participants are scheduled to complete a first introductory session then 40 brief (\~5 min) sessions of a 'standard' imagery cognitive bias modification (CBM) intervention, with 2 per day five days per week for each of the four training weeks. In addition, as with the arm Standard imagery cognitive bias modification plus additional rationale and transfer instructions, participants are first presented with a more extended rationale for completing the training, and during many of the training sessions are provided with instructions to practice retrieval and rehearsal of the training contents in between sessions. This arm was added into the ongoing trial on 30.05.21."
62555092|NCT04791137|EXPERIMENTAL|Standard imagery cognitive bias modification with a less intensive schedule|"Participants are scheduled to complete a first introductory session then 11 further sessions of a 'standard' imagery cognitive bias modification (CBM) intervention, with 3 sessions scheduled for each of the four training weeks. Sessions have fewer training scenarios than the Standard imagery cognitive bias modification condition and more varied task instructions. In addition, as with the arm Standard imagery cognitive bias modification plus additional rationale and transfer instructions, participants are first presented with a more extended rationale for completing the training, and during many of the training sessions are provided with instructions to practice retrieval and rehearsal of the training contents in between sessions. This arm was added into the ongoing trial on 09.06.21."
62555093|NCT04900181|EXPERIMENTAL|the same-day discharge surgery|Patients in the the same-day discharge surgery group were admitted to hospital, operated and discharged within 24 hour
62555094|NCT04900181|NO_INTERVENTION|inpatient surgery|Patients in inpatient surgery follow routine procedures and do not need to be discharged on the same day.
62750478|NCT03420391|ACTIVE_COMPARATOR|5 Minutes|"Participants will be performed the eccentric exercise protocol 5 minutes after PBMT.~Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol."
62750479|NCT03420391|ACTIVE_COMPARATOR|3 Hours|"3 hours: Participants will be performed the eccentric exercise protocol 3 hours after PBMT.~Assessments will be performed before at baseline, 1 minute, 1 hour and 24, 48 hours after the end of exercise protocol."
62750480|NCT03420391|ACTIVE_COMPARATOR|6 Hours|"6 hours: Participants will be performed the eccentric exercise protocol 6 hours after PBMT.~Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol."
62555095|NCT03640338|EXPERIMENTAL|Cold-therapy system|Patients will receive a cold-therapy system postoperatively (Polar Care Kodiak, Breg®) and will use the system during inpatient stay and during the first 14 days post-discharge.
62750481|NCT03420391|ACTIVE_COMPARATOR|24 hours|24 hours: Participants will be performed the eccentric exercise protocol 24 hours after PBMT. Assessments will be performed before at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
62750482|NCT03420391|NO_INTERVENTION|Control|Participants will not receive intervention. Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
62750483|NCT06600243|EXPERIMENTAL|Resistance training + deep sea water|Resistance training with elastic bands prior intake of deep sea water (20ml) twice weekly during 32 weeks.
62750484|NCT06600243|ACTIVE_COMPARATOR|Resistance training + Placebo|Resistance training with elastic bands prior placebo water (20ml) twice weekly during 32 weeks.
62750485|NCT06600243|ACTIVE_COMPARATOR|Control + Deep sea water|No exercise and intake of deep sea water (20ml) twice weekly during 32 weeks.
62750486|NCT06600243|PLACEBO_COMPARATOR|Control + Placebo|No exercise and intake of placebo water (20ml) twice weekly during 32 weeks.
62750487|NCT00052611|EXPERIMENTAL|Celecoxib|Celecoxib will be given at a pre-determine dose twice daily for 3 months. If there is a favorable change in biomarker expression on biopsy at 3 months, treatment will continue to complete a 12-month treatment period.
62750488|NCT03345160|EXPERIMENTAL|Peanut Flour: Open label peanut OIT|This is an open label treatment for subjects who had previously received placebo treatment in a prior peanut OIT study
62750489|NCT00612547||Observation|Children under the age of five years (2 months to 5 years) residing in the zone covered by the community-based service provider throughout the entire follow-up period
62555096|NCT03640338|NO_INTERVENTION|Standard care (ice-pack)|Patients will use disposable ice-pack as per standard of care
62555097|NCT00858273|ACTIVE_COMPARATOR|Antioxidant Supplement|Vitamin C 250 mg; beta-carotene 6 mg; vitamin E 30 mg; selenium 100 mcg; zinc 20 mg
62555098|NCT00858273|PLACEBO_COMPARATOR|Placebo|
62555099|NCT00912938|EXPERIMENTAL|Zoledronic acid|Patients with advanced breast cancer with radiographic confirmation of bone metastases. This arm will be receiving zoledronic acid administration. The primary endpoint is to find the correlation between bone turnover markers and the frequency of skeletal-related-events for one year. Skeletal related events are defined as pathologic fractures, the need for radiation therapy, orthopaedic surgery, hypercalcemia of malignancy and spinal cord compression. A total of 237 patients will be included.
62555100|NCT04142086|EXPERIMENTAL|Group 1|1 injection of vYF vaccine Dosage 1
62555101|NCT04142086|EXPERIMENTAL|Group 2|1 injection of vYF vaccine Dosage 2
62555102|NCT04142086|EXPERIMENTAL|Group 3|1 injection of vYF vaccine Dosage 3
62375291|NCT03542890||Baska Mask|It has a non-inflatable cuff, which is moulded to take up the shape of the supraglottic airway, potentially reducing the risk of oropharyngeal tissue and/or nerve damage induced by cuff over inflation, a known complication with other supraglottic airways.
62375292|NCT03542890||I-gel|The I-gel is a single use (SADs) composed of a soft ,gel-like, non-inflatable cuff made from a thermoplastic elastomer. It has a widened , flattened stem with a rigid bite block that acts as a buccal stabilizer to reduce axial rotation and mal-positioning and a port for gastric tube insertion. It is a latex free device that does not require digital insertion into mouth of patient.
62375293|NCT02233608|NO_INTERVENTION|Usual Care|The usual care group will receive generic pelvic floor muscle exercise (PMFX) instructions and demonstrations by the research coordinator at the initial post-operative time point. This will include instruction on how to engage the pelvic floor and specific PFMX prescription. Repetition volume will start at 20 repetitions per day during weeks 1-2; 60/day during weeks 3-4; and 90/day during weeks 5-6, and 100+/day for weeks 7-26. The total number of repetitions will be divided equally between rhythmic (contract and relaxed over one second) and sustained contractions (contract and hold for up to 10 seconds).
62567439|NCT00209261|ACTIVE_COMPARATOR|2|
62750490|NCT02187276||Alzheimer disease or mixed dementia|Patients were evaluated four times. In the first consultation, without taking cholinesterase inhibitors (ChEI), after three, six and 12 months taking ChEI.
62750491|NCT03993990|EXPERIMENTAL|Experimental group|Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation).
62555103|NCT04142086|ACTIVE_COMPARATOR|Group 4|1 injection of YF-VAX
62555104|NCT00625820|EXPERIMENTAL|6R BH4|Subjects will receive 6R-BH4 400mg bid for 6 weeks, sequentially followed by 6R-BH4 plus Vitamin C 500mg bid for another 6 weeks. Patients will have scheduled visits at Weeks 0,3,6,9 and 12, with an exit-visit at week 16. Albuminuria will be assessed in 24-hour urine collections as well as early morning spot urine samples for albumin:creatinine ratio. Blood and urine will be tested for routine clinical laboratory tests, blood nitric oxide (NO), and also archived for later assays for special biomarkers. The primary outcome will be level of albuminuria as measured in a 24-hour urine collection at 6 and 12 weeks of therapy. Secondary outcomes will include urine albumin/creatinine ratio, estimated glomerular filtration rate (eGFR), and blood pressure .
62555105|NCT02347059|EXPERIMENTAL|L-dopa|L-dopa will be administered as monotherapy. The dosage and the frequency of intakes are not pre-specified and will be individualized.
62750492|NCT03993990|NO_INTERVENTION|Control group|Participants will receive routine care of the research setting only. The counseling will be provided if participants request.
62555106|NCT02347059|ACTIVE_COMPARATOR|Dopamine agonist|Dopamine agonists (either pramipexole or ropirinole) will be administered as monotherapy. The dosage and the frequency of intakes are not pre-specified and will be individualized.
62750493|NCT05238142|EXPERIMENTAL|MiniMed 780G System|Adult participants with insulin-requiring type 2 diabetes age 18-80 using the MiniMed 780G system for a combined run-in period and study period will be approximately 135 days long.
62555107|NCT02480101|ACTIVE_COMPARATOR|H7N9 LAIV|H7N9 live influenza vaccine
62555108|NCT02480101|PLACEBO_COMPARATOR|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers
62750494|NCT02451683|OTHER|Electrophysiology Assessment of Time Domain|Assessment of electrophysiology in the time domain to examin temporal organization of corticospinal function
62750495|NCT02451683|EXPERIMENTAL|Electrophysiology Assessment of Location|Assessment of electrophysiology to examine spatial organization of corticospinal function
62750496|NCT02451683|ACTIVE_COMPARATOR|Training with some stimulation|Training with non-invasive stimulation and training with sham stimulation
62750497|NCT02739529|EXPERIMENTAL|Cohort 1|Genexol-PM 100mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1
62750498|NCT02739529|EXPERIMENTAL|Cohort 2|Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1
62750499|NCT02739529|EXPERIMENTAL|Cohort 3|Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 6 AUC IV infusion D1
62750500|NCT03933410|EXPERIMENTAL|KB195|KB195 is a novel glycan
62750501|NCT03945721|EXPERIMENTAL|Niraparib|"* Niraparib will be administered orally on a daily basis~* Radiation Therapy will be administered concurrently with Niraparib"
62750502|NCT03730961|EXPERIMENTAL|Placebo+Diuretic to BMS-986231+Diuretic|Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods
62750503|NCT03730961|EXPERIMENTAL|BMS-986231+Diuretic to Placebo+Diuretic|Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods
62750504|NCT00562276|EXPERIMENTAL|1|Immediate IUD insertion following suction aspiration between 5 and 12 weeks gestation
62750505|NCT00562276|NO_INTERVENTION|2|Delayed IUD insertion 2-6 weeks following suction aspiration between 5 and 12 weeks gestation
62750506|NCT05014464|EXPERIMENTAL|Cohort A, first line ALK-TKIs|All the patients were treated with first line ALK-TKis including Crizotinib, Alectinib, Brigatinib and Lorlatinib etc. Approximately 30 patients.
62750507|NCT05014464|EXPERIMENTAL|Cohort B, second line ALK-TKIs|All the patients were treated with second line ALK-TKis including Crizotinib, Alectinib, Brigatinib and Lorlatinib etc. Approximately 30 patients.
62750508|NCT05014464|EXPERIMENTAL|Cohort C, post second line ALK-TKIs|All the patients were treated with post second ALK-TKis including Crizotinib, Alectinib, Brigatinib and Lorlatinib etc. Approximately 30 patients.
62750509|NCT00134654|ACTIVE_COMPARATOR|Group A|Premarin once a day
62750510|NCT00134654|ACTIVE_COMPARATOR|Group B|Premarin 3 times a day
62750511|NCT02545660|EXPERIMENTAL|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the QLF group will be shown the QLFD images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
62750512|NCT02545660|EXPERIMENTAL|White light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown the White light images.Standardized oral hygiene reinforcement shall be given based on the White light images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
62750513|NCT01856049|OTHER|Umbilical Cord Blood Collection|Umbilical Cord Blood is drawn from the umbilical cord of newborn babies diagnosed with Hypoplastic Left Heart Syndrome, before placental detachment. Cord blood is packaged in a Credo Cube, and sent at a temperate state to the manufacturer immediately after draw. At least 65 mL of cord blood is needed to produce a stem cell product during manufacturing. Once processed, the patient's autologous cord blood stem cells will be frozen for their potential future use in a clinical trial.
62750514|NCT01358812|EXPERIMENTAL|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
62750515|NCT01637363|NO_INTERVENTION|Regular treatment|This group is offered regular treatment from the job center i.e. exercise, mindfulness
62750516|NCT01637363|EXPERIMENTAL|Psychoeducation|6 x 2 hours of psychoeducation
62750517|NCT01713283|EXPERIMENTAL|SOF+RBV 12 Weeks|Treatment-naive and treatment-experienced participants will receive SOF+RBV for 12 weeks.
62750518|NCT01713283|EXPERIMENTAL|SOF+RBV 24 Weeks|Treatment-naive and treatment-experienced participants will receive SOF+RBV for 24 weeks.
62750519|NCT04074018|EXPERIMENTAL|Experimental group|Self-rehabilitation guided program with investigator PMR specialist
62750520|NCT04074018|ACTIVE_COMPARATOR|Control group|Conventional rehabilitation with a speech therapist or physiotherapist specialized in facial rehabilitation
62750521|NCT04081753|EXPERIMENTAL|TMD Group|Temperature Monitoring Device Group - The interventional group, who will be given the temperature monitoring device and will be monitored remotely.
62750522|NCT04081753|NO_INTERVENTION|Historic cohort Group|Historic cohort group will be enrolled from medical record
62750523|NCT01457170|EXPERIMENTAL|Apelin/Saline|Apelin infusion then crossover to Saline infusion
62750524|NCT01457170|EXPERIMENTAL|Saline/Apelin|Saline infusion then crossover to Apelin infusion
62750525|NCT01461928|OTHER|Maintenance II Period Observation Only|Participants will receive standard chemotherapy regimen in combination with 375 mg/m\^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); no treatment in Maintenance II period until disease progression or end of study, whichever occurs first.
62555109|NCT03182426|EXPERIMENTAL|Treated arm|"For participants assigned to the treated arm, they will follow study regime below: Intervention treatment will last from Day 0 up to Month 24.~Day 0: Subjects will receive alemtuzumab (30mg iv single dose); anakinra (100 mg sc.); etanercept (50 mg sc.) and liraglutide (0.6 mg sc.).~Day 1: Subjects will receive plerixafor (0.24 mg/kg/day) sc. to mobilize CD34+ stem cells to peripheral blood.~Day 1: Continuing with anakinra 100mg sc. daily for 12 month; etanercept 50mg sc. twice weekly for first 3 months, and 50mg sc. weekly for another 9 months; liraglutide 0.6 mg sc. daily for 7 days, then 1.2 mg sc. daily (or up to 1.8mg daily) as tolerated for 24 months."
62555110|NCT03182426|EXPERIMENTAL|Control arm|"For participant assigned to the control arm, they will be monitored and tested for the first 12 months, and receive intervention treatment from Month 12 up to Month 24.~Month 12: Subjects will receive alemtuzumab (30mg iv single dose); anakinra (100 mg sc.); etanercept (50 mg sc.) and liraglutide (0.6 mg sc.).~Month 12 + 1 day: Subjects will receive plerixafor (0.24 mg/kg/day) sc.. Month 12 + 1 day: Continuing with anakinra 100mg sc. daily for 12 month; etanercept 50mg sc. twice weekly for first 3 months, and 50mg sc. weekly for another 9 months; liraglutide 0.6 mg sc. daily for 7 days, then 1.2 mg sc. daily (or up to 1.8mg daily) as tolerated for 12 months."
62555111|NCT03888066|EXPERIMENTAL|Group 1: Patiromer|Subjects will be randomized to receive a daily dose of patiromer with possible dose adjustments based on subsequent local serum potassium levels.
62555112|NCT03888066|PLACEBO_COMPARATOR|Group 2: Placebo|Subjects will be randomized to receive a daily dose of placebo with possible dose adjustments based on subsequent local serum potassium levels.
62750526|NCT01461928|EXPERIMENTAL|Maintenance II Period Rituximab|Participants will receive standard chemotherapy regimen in combination with 375 mg/m\^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); 1400 mg rituximab SC every 8 weeks until disease progression or end of study, whichever occurs first (Maintenance II period).
62750527|NCT02429492|EXPERIMENTAL|ALS patients|Patients with amyotrophy lateral sclerosis (ALS)
62750528|NCT02429492|EXPERIMENTAL|Control subjetcs|Neurologically intact subjects sex and age-matched to ALS patients
62555113|NCT06022068|EXPERIMENTAL|Rapamycin|Sirolimus tablets will be administered orally, 7 mg once per week during 26 weeks
62555114|NCT06209840|ACTIVE_COMPARATOR|Control Group|Classical physiotherapy program will be applied for gross motor functions and upper extremity functions.
62555115|NCT06209840|EXPERIMENTAL|Study (Music) Group|In addition to the classical physiotherapy program for gross motor functions, will be applied in the Neuro-Creative Music Therapy (NCMT) program for upper extremity.
62555116|NCT06582017|EXPERIMENTAL|Phase 1a Dose Escalation in Solid Tumors - Part A1|Dose escalation of QXL138AM in participants with locally advanced un-resectable and/or metastatic solid tumors.
62555117|NCT06582017|EXPERIMENTAL|Phase 1a Dose Escalation in Multiple Myeloma - Part A2|Dose escalation of QXL138AM in participants with multiple myeloma.
62555118|NCT06582017|EXPERIMENTAL|Phase 1b Dose Expansion in Solid Tumors - Part B1|Dose expansion in solid tumors using the recommended dose for expansion from Part A1
62555119|NCT06582017|EXPERIMENTAL|Phase 1b Dose Expansion in Multiple Myeloma - Part B2|Dose expansion in Multiple Myeloma using the recommended dose for expansion from Part A2
62555120|NCT01444261|ACTIVE_COMPARATOR|Intervention|Fer-in-Sol drops and iron-fortified cereal
62555121|NCT01444261|OTHER|Control|No intervention
62555122|NCT06512792|EXPERIMENTAL|Patients undergoing telemedicine interventions|Participants in the intervention group received telemedicine management from researchers through the mobile app platform (establishing electronic health records, health management monitoring, risk warning and intervention, health education).
62555123|NCT06512792|NO_INTERVENTION|IBD patients receiving traditional medical care|The control group received no guidance and only standard traditional care services (i.e., prescribed medication and regular outpatient follow-up).
62555124|NCT05895201|EXPERIMENTAL|Sitagliptin + Bortezomib + Cyclophosphamide|
62555125|NCT01564537|EXPERIMENTAL|Ixazomib + Lenalidomide + Dexamethasone|Ixazomib 4 mg, capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until progressive disease (PD) or unacceptable toxicity, whichever occurred first up to end of treatment (EOT) up to approximately 42.9 months.
62555126|NCT01564537|PLACEBO_COMPARATOR|Placebo + Lenalidomide + Dexamethasone|Ixazomib placebo-matching capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until PD or unacceptable toxicity, whichever occurred first up to approximately 41 months.
62555127|NCT04877847|EXPERIMENTAL|Low-Frequency Therapeutic Ultrasound|LOTUS system will be operated per operated per normal instructions
62555128|NCT04877847|SHAM_COMPARATOR|Sham Control|LOTUS system will be set to Control setting
62555129|NCT01917682||Study Cohort|Subjects treated with CorPath-assisted Percutaneous Coronary Intervention (PCI)
62555130|NCT05345106||Premenopausal women with obesity|
62555131|NCT05345106||Postmenopausal women with obesity|
62750529|NCT01328535|EXPERIMENTAL|Treatment (individualized chemotherapy)|Patients with an established biorhythm receive TMZ PO on recommended day for 5 days. Treatment repeats every 21-42 days until disease progression or unacceptable toxicity. Patients without an established biorhythm receive TMZ PO on days 1-5. Courses repeat every 28 days until disease progression or unacceptable toxicity.
62555132|NCT05345106||Men with obesity|
62555133|NCT05345106||Premenopausal women without obesity|
62555134|NCT05345106||Postmenopausal women without obesity|
62555135|NCT05345106||Men without obesity|
62555136|NCT02350816|ACTIVE_COMPARATOR|HGT-1410 Q2W in Study HGT-SAN-093 randomized to HGT-1410 Q2W|"Patients in Group 1 will continue HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 50, with a cumulative treatment period of up to 42 months (168 weeks) . HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).~HGT-SAN-093 = NCT02060526"
62555137|NCT02350816|ACTIVE_COMPARATOR|HGT-1410 Q4W in Study HGT-SAN-093 randomized to HGT-1410 Q4W|Patients in Group 2 will continue HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 52, with a cumulative treatment period of up to 42 months (168 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
62555138|NCT02350816|ACTIVE_COMPARATOR|no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q2W|Patients in Group 3A will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
62567440|NCT05503537|ACTIVE_COMPARATOR|Basic Cardiac Rehabilitation protocol|ankle pumps and leg slides, 2 sets of 10 repetitions of each exercise. Walk for 10 minutes.
62750530|NCT06527248|ACTIVE_COMPARATOR|Nitrate group|Daily consumption of 70 mL nitrate-rich beetroot juice concomitant with 12 weeks of exercise training
62750531|NCT06527248|PLACEBO_COMPARATOR|Placebo group|Daily consumption of 70 mL nitrate-depleted beetroot juice (placebo) concomitant with 12 weeks of exercise training
62750532|NCT01170065|EXPERIMENTAL|BIBF 1120 low qd|Low dose BIBF 1120 once daily
62750533|NCT01170065|EXPERIMENTAL|BIBF 1120 low bid|Low dose BIBF 1120 twice daily
62750534|NCT01170065|EXPERIMENTAL|BIBF 1120 medium bid|Intermediate dose BIBF 1120 twice daily
62750535|NCT01170065|EXPERIMENTAL|BIBF 1120 high bid|High dose BIBF 1120 twice daily
62750536|NCT01703689|EXPERIMENTAL|strong intervention group (SIG)|Nursing homes that received audit and feedback information on quality indicators and benefited of cooperative work meetings with hospital geriatricians
62750537|NCT01703689|ACTIVE_COMPARATOR|intervention group (LIG)|Nursing homes that only received audit and feedback information on quality indicators
62750538|NCT04552639|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual is offered. This includes; individual therapy, group therapy, dietetic support, occupational therapy, nursing and psychiatry, excluding the NEAT group.
62750539|NCT04552639|EXPERIMENTAL|Treatment as usual and NEAT group|Treatment as usual is offered. This includes; individual therapy, group therapy, dietetic support, occupational therapy, nursing and psychiatry, alongside NEAT group.
62750540|NCT04092881|ACTIVE_COMPARATOR|Short pulsed Nd-YAG laser treatment side|"Neodymium-Doped Yttrium Aluminum Garnet (Nd-YAG) (Fotona XP®) laser is a successful therapeutic modality and is characterized by its safe profile compared to other lasers.~Short pulsed Nd-YAG laser (Fotona XP® Accelera mode) results in a non-ablative dermal heating with intact overlying epidermis which has shown a potential for dermal collagen remodeling in histological sections."
62750541|NCT04092881|ACTIVE_COMPARATOR|Fractional ablative CO2 laser treatment side|"Carbon dioxide (CO2) (Deka SmartXide DOT®) laser is one of the well-tolerated therapeutic modalities used for treatment of different skin disorders including striae alba.~CO2 laser targets mainly water content in both epidermis and dermis causing vaporization of target cells.~Fractional ablative CO2 laser creates columns of focal dermo-epidermal tissue loss known as (microablative columns) with thermal damage, hemostatic effect and incomplete coagulation of tissues. This ablation of dermal tissues (including collagen and elastin) has the potential for stimulation of new tissue formation in striae distensae."
62750542|NCT06600633|PLACEBO_COMPARATOR|Placebo product (PP)|Active ingredient: none Instructions for use: Supplement should be consumed once per day during the intervention period, about one hour to bedtime.
62750543|NCT06600633|ACTIVE_COMPARATOR|Active control (AC)|Active ingredient: 1 mg of melatonin per dosage Instructions for use: Supplement should be consumed once per day during the intervention period, about one hour to bedtime.
62750544|NCT06600633|EXPERIMENTAL|Test product (TP)|Active ingredient: 0.3 mg of melatonin per dossage Instructions for use: Supplement should be consumed once per day during the intervention period, about one hour to bedtime.
62750545|NCT06607328||Prehypertensive Group (PHTG)|The prehypertensive group (PHTG) was formed from the prehypertensive individuals with similar characteristics.
62750546|NCT06607328||Hypertensive Group (HTG)|In line with the Holter results hypertensive group (HTG) was formed from the individuals who were followed up with the diagnosis of hypertension.
62555139|NCT02350816|ACTIVE_COMPARATOR|no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q4W|Patients in Group 3B will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
62555140|NCT06435689||Patients undergoing surgery for the treatment of primary and/or metastatic colorectal cancers|
62555141|NCT01519310|ACTIVE_COMPARATOR|Group 1|Group 1 (Antibiotics/probioitic):
62555142|NCT01519310|ACTIVE_COMPARATOR|Group 2|Group 2 (Antibiotics/no-probiotic):
62555143|NCT01519310|ACTIVE_COMPARATOR|Group 3|Group 3 (no-Antibiotics/probiotic):
62555144|NCT02513225|EXPERIMENTAL|Intervention|The adapted Project EMPWR will be comprised of 2 sessions delivered approximately 7-10 days apart by a trained Apache paraprofessional interventionist. In the first session, interventionists will use curriculum to help participants understand their personal risk factors for STDs including HIV/AIDS (i.e., substance use, mental and emotional health, sexual health, etc.) and develop an achievable personalized risk-reduction plan that emphasizes individual and community-based strengths and resources.The second counseling session will consist of the disclosure of results (if tested) and the provision of social support to help participants develop a longer-term risk-reduction plan. At visit two, participants in both groups will be offered a STD screening protocol test.
62750547|NCT04308434|EXPERIMENTAL|CSD190601-11|Subjects will self-assign to flavor variant CSD190601-11 of 1.5% ENDS products based on their preferred flavor.
62750548|NCT04308434|EXPERIMENTAL|CSD190601-12|Subjects will self-assign to flavor variant CSD190601-12 of 1.5% ENDS products based on their preferred flavor.
62750549|NCT04308434|EXPERIMENTAL|CSD190601-13|Subjects will self-assign to flavor variant CSD190601-13 of 1.5% ENDS products based on their preferred flavor.
62750550|NCT04308434|EXPERIMENTAL|CSD190601-14|Subjects will self-assign to flavor variant CSD190601-14 of 1.5% ENDS products based on their preferred flavor.
62750551|NCT04308434|EXPERIMENTAL|CSD190601-15|Subjects will self-assign to flavor variant CSD190601-15 of 1.5% ENDS products based on their preferred flavor.
62750552|NCT04308434|EXPERIMENTAL|CSD190601-16|Subjects will self-assign to flavor variant CSD190601-16 of 1.5% ENDS products based on their preferred flavor.
62555145|NCT02513225|OTHER|Control|The comparison condition will consist of Optimized Standard Care (OSC) alone. All participants will receive OSC at the first visit. OSC includes the distribution of educational pamphlets and provision of information on substance use, signs and symptoms of mental health problems, and information about STD screening resources. At visit two, participants in both groups will be offered a STD screening protocol test.
62555146|NCT05514223||Males of couples seeking fertility treatment|The study population will consist of males of couples that visit the Center reproductive Medicine of the UMCG where a semen analysis is planned for clinical purposes.
62555147|NCT01295320|EXPERIMENTAL|GSK1437173A Group|Subjects who received 2 doses of HZ vaccine in the intermediate dose study group in study 108494 (NCT00434577). No treatment was given in this current study (NCT01295320).
62555148|NCT04627792|OTHER|Waitlist Group|We will use a switching replication design in which fifty guardians will be randomly assigned using a lottery to receive the intervention and fifty will be assigned to a group who will receive the intervention at a later time point
62555149|NCT01870089|EXPERIMENTAL|Study group|
62555150|NCT03159247|EXPERIMENTAL|eyeGuide|Two personalized eHealth interventions aimed to improve glaucoma medication adherence.
62555151|NCT03894644|EXPERIMENTAL|Group A: simulation training before instruments|Group A performed simulation training before the recognition of real surgical instruments.
62375294|NCT02233608|EXPERIMENTAL|Advanced Pelvic Floor Exercise (APFX)|Participants in this group will receive detailed week-by-week description of the program. The program progresses participants through stages of training every two weeks, starting the introduction of basic PFMX, and slowly incorporates Pfilates and Hypopressives exercises until week 8, where patients will maintain the final stage of training until week 26 or urinary incontinence is completely resolved.
62555152|NCT03894644|ACTIVE_COMPARATOR|Group B:instruments before simulation training|Group B performed the recognition of real surgical instruments without prior simulation training.
62555153|NCT04667624|ACTIVE_COMPARATOR|Reference|TWYNSTA Tablet 80/5mg(Telmisartan/Amlodipine)
62555154|NCT04667624|EXPERIMENTAL|Test|LodienT Tablet 80/2.5mg(Telmisartan/S-amlodipine)
62375295|NCT01392014|ACTIVE_COMPARATOR|dihydroartemisinin-piperaquine|
62375296|NCT01392014|ACTIVE_COMPARATOR|Dihydroartemisininpiperaquine primaquine|
62555155|NCT04092309|OTHER|ACE group|patients after bone marrow transplantation will be treated with ACE inhibitor
62555156|NCT04092309|OTHER|Sacubitril Valsartan group|patients after bone marrow transplantation will be treated with sacubitril valsartan
62555157|NCT04092309|OTHER|Control group|patients after bone marrow transplantation will be treated neither with ACE i nor with sacubitril valsartan
62555158|NCT00742209|PLACEBO_COMPARATOR|Placebo|PBO
62555159|NCT00742209|ACTIVE_COMPARATOR|GSK 1838262 1200 mg/day|600 or 1200 mg/day
62555160|NCT00742209|ACTIVE_COMPARATOR|GSK 1838262 1800 mg/day|600 or 1200 or 1800 mg/day
62555161|NCT00742209|ACTIVE_COMPARATOR|GSK 1838262 2400 mg/day|600 or 1200 or 1800 or 2400 mg/day
62555162|NCT00742209|ACTIVE_COMPARATOR|GSK 1838262 3000 mg/day|600 or 1200 or 1800 or 2400 or 3000 mg/day
62555163|NCT03716856|EXPERIMENTAL|CAR-BCMA T cells|"In this study, autologous T cells transduced with a BCMA-targeted chimeric antigen receptor (CAR-BCMA T cells) are used to treat patients with refractory or relapsed multiple myeloma.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to CAR-BCMA T cells infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
62555164|NCT00470392|OTHER|Imiquimod|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
62555165|NCT00470392|OTHER|Clobetasol|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
62375297|NCT04905836|EXPERIMENTAL|COVI-MSC|Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4
62555166|NCT03335826|EXPERIMENTAL|Combined epidural-general anesthesia|Patients assigned to this group receive combined epidural-general anesthesia and postoperative patient-controlled epidural analgesia.
62555167|NCT03335826|ACTIVE_COMPARATOR|General anesthesia|Patients assigned to this group receive general anesthesia and postoperative patient-controlled intravenous analgesia.
62555168|NCT03151174|EXPERIMENTAL|Vitamin D - 10000IU|These individuals have been categorized as Vitamin D deficient and will receive 10000IU of Vitamin D per day.
62555169|NCT03151174|EXPERIMENTAL|Vitamin D - 5000IU|These individuals have been categorized as Vitamin D insufficient and will receive 5000IU of Vitamin D per day.
62555170|NCT03151174|NO_INTERVENTION|Placebo|These individuals have been categorized as Vitamin D sufficient and will receive placebo.
62555171|NCT01057680|EXPERIMENTAL|creatine|This arm will involve creatine supplementation 0.1 g per kg body mass per day while participating in a resistance training program (1 hour per day, 3 days per week).
62555172|NCT01057680|PLACEBO_COMPARATOR|Sugar|This arm will involve placebo (maltodextrin) given every day while the participant does a resistance training program (1 hour per day, 3 days per week).
62750553|NCT04308434|EXPERIMENTAL|CSD190601-17|Subjects will self-assign to flavor variant CSD190601-17 of 1.5% ENDS products based on their preferred flavor.
62750554|NCT04308434|EXPERIMENTAL|CSD190601-21|Subjects will self-assign to flavor variant CSD190601-21 of 3.0% ENDS products based on their preferred flavor.
62750555|NCT04308434|EXPERIMENTAL|CSD190601-22|Subjects will self-assign to flavor variant CSD190601-22 of 3.0% ENDS products based on their preferred flavor.
62750556|NCT04308434|EXPERIMENTAL|CSD190601-23|Subjects will self-assign to flavor variant CSD190601-23 of 3.0% ENDS products based on their preferred flavor.
62750557|NCT04308434|EXPERIMENTAL|CSD190601-24|Subjects will self-assign to flavor variant CSD190601-24 of 3.0% ENDS products based on their preferred flavor.,
62555173|NCT00934167|EXPERIMENTAL|Test|Hipolabor
62555174|NCT00934167|ACTIVE_COMPARATOR|Comparator|5.000 USP/mL - APP
62555175|NCT02495662|EXPERIMENTAL|Liposomal prednisolone|Treatment with polyethylene glycol (PEG)-liposomal prednisolone sodium phosphate 150mg in 500ml saline intravenously at 1 and 15 days post surgery.
62750558|NCT04308434|EXPERIMENTAL|CSD190601-25|Subjects will self-assign to flavor variant CSD190601-25 of 3.0% ENDS products based on their preferred flavor.
62750559|NCT04308434|EXPERIMENTAL|CSD190601-26|Subjects will self-assign to flavor variant CSD190601-26 of 3.0% ENDS products based on their preferred flavor.
62555176|NCT02495662|PLACEBO_COMPARATOR|Placebo|Treatment with 500ml normal 0.9% saline intravenously at 1 and 15 days post surgery.
62555177|NCT04599075|EXPERIMENTAL|Intravenous Insulin Infusion|Patients will be randomized to discontinuation of the CSII pump intrapartum and initiation of IV insulin infusion per hospital protocol.
62555178|NCT04599075|EXPERIMENTAL|Continuous Subcutaneous Insulin Infusion (CSII)|Patients will be randomized to continuation of their CSII pump intrapartum and will be managed in accordance with the CSII hospital protocol.
62750560|NCT04308434|EXPERIMENTAL|CSD190601-27|Subjects will self-assign to flavor variant CSD190601-27 of 3.0% ENDS products based on their preferred flavor.
62750561|NCT05565573|EXPERIMENTAL|Medroxyprogesterone acetate|Administered MPA at a dosage of 500 mg/d concurrently
62750562|NCT05565573|EXPERIMENTAL|LNG-IUS|Go through LNG-IUS insertion
62750563|NCT01746121||Amelogenesis Imperfecta|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth
62750564|NCT01746121||healthy family members|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth
62750565|NCT04577716||Endoleak Group|Participants with a previous Endovascular Aneurysm Repair (EVAR) who have developed an endoleak
62750566|NCT04577716||No Endoleak Group|Participants with a previous Endovascular Aneurysm Repair (EVAR) who have not developed an endoleak
62750567|NCT04577716||Pre-EVAR Group|Participants who have an abdominal aortic aneurysm and who are undergoing an Endovascular Aneurysm Repair as standard of care
62750568|NCT01809145|OTHER|metal hypersensitivity|peripheral blood test for metal hypersensitivity (MELISA test)
62555179|NCT03309098||Ankle Injury|Person who injures their ankle
62555180|NCT06513481||Early initiation of drug prophylaxis (within 24 hours after surgery)|Patients who underwent surgery received prophylactic administration of low molecular weight heparin (nardraparin calcium injection) at a time point of 24 hours after surgery，this group carries out early initiation of drug prophylaxis (within 24 hours after surgery)
62750569|NCT04000308|EXPERIMENTAL|Quadratus Lumborum Block type 2|The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
62750570|NCT04000308|ACTIVE_COMPARATOR|Wound Infiltration|Patricipants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
62750571|NCT03730831|EXPERIMENTAL|Intervention (second work program)|Narrative Exposure Therapy Narrative Exposure Therapy (NET) is a brief manualized trauma-focussed psychotherapeutic treatment and will be performed according to the manual of Schauer et al., 2011. In NET, traumatic experiences are worked through and placed in the context of the entire life story.
62750572|NCT01813552|EXPERIMENTAL|Samatasvir + Ritonavir|Days 1, 9 and 13: Healthy Volunteers will take samatasvir in the mornings under fed or fasted conditions with water. Days 5-16: Healthy Volunteers will take ritonavir in the mornings under fasted or fed conditions with water.
62375298|NCT04905836|PLACEBO_COMPARATOR|Placebo|Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4
62375299|NCT03833349|EXPERIMENTAL|Spinning Class|Subjects randomly selected for the spinning group will participate in spinning classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
62555181|NCT06513481||Late initiation of drug prophylaxis (24 hours after surgery)|Patients who underwent surgery received prophylactic administration of low molecular weight heparin (nardraparin calcium injection) at a time point of 24 hours after surgery，this group carries out late initiation of drug prophylaxis ( 24 hours after surgery)
62375300|NCT03833349|EXPERIMENTAL|Yoga Class|Subjects randomly selected for the yoga group will participate in yoga classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
62555182|NCT05334641|EXPERIMENTAL|Experimental Group|
62555183|NCT05334641|ACTIVE_COMPARATOR|Control Group|
62375301|NCT03833349|EXPERIMENTAL|Dance Class|Subjects randomly selected for the dance group will participate in dance classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
62375302|NCT03164122|EXPERIMENTAL|Intra-articular injection|
62375303|NCT02144090|EXPERIMENTAL|Fractional flow reserve|Fractional flow reserve measurement
62555184|NCT04700137|ACTIVE_COMPARATOR|Caring Contacts + Introductory Phone Call (CC+)|"Healthcare provider and staff participants who are randomized to both caring text messages and an introductory phone call.~Adult and adolescent participants who are randomized to both caring text messages and an introductory phone call."
62555185|NCT04700137|ACTIVE_COMPARATOR|Caring Contacts (without phone call) (CC)|"Healthcare provider and staff participants who are randomized to only caring text messages.~Adult and adolescent patient participants who are randomized to only caring text messages."
62555186|NCT02854384||Epilepsy Patients|males and females whose age more than 18 years, diagnosed with epilepsy, regardless of whether symptomatic,idiopathic ,focal or generalized
62555187|NCT02854384||Healthy Control|males and females whose age more than 18 years
62750573|NCT01813552|EXPERIMENTAL|Samatasvir + Omeprazole|Days 1, 9 and 13: Healthy Volunteers will take samatasvir in the mornings under fasted conditions with water or Coke. Days 5-16: Healthy Volunteers will take omeprazole in the mornings under fasted conditions with water or Coke.
62750574|NCT00986401|EXPERIMENTAL|Glucophage® then Sanctura XR® (AB)|Treatment Period 1: Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD) for 4 days + Glucophage® (500 mg, BID) for 3.5 days.
62750575|NCT00986401|EXPERIMENTAL|Sanctura XR® then Glucophage® (BA)|Treatment Period 1: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD for 4 days) + Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Glucophage® (500 mg, BID) for 3.5 days.
62750576|NCT03474848|EXPERIMENTAL|HABIT|Protocol of 90-hour of Hand-Arm Bimanual Intensive Training - 6 hours/day; 5 days/week, for 3 weeks
62555188|NCT00181714|EXPERIMENTAL|OROS MPH|Single arm- open treatment with extended duration methylphenidate (OROS MPH)
62555189|NCT04222426|EXPERIMENTAL|89Zr-atezolizumab PET scan|All patients will undergo two 89Zr-atezolizumab PET scans, one at baseline and one after two doses carboplatin induction treatment. The 89Zr-atezolizumab PET scan will be performed 4 days after tracer injection. Procedures within the ImaGelato study will be completed after the two 89Zr-atezolizumab PET scans, but patients will continue treatment with carboplatin combined with atezolizumab in the GELATO trial.
62555190|NCT03525886|EXPERIMENTAL|Cohort 1 (50 mg QHS)|NBI-74788 50 mg once daily at bedtime (QHS) administered orally for 14 consecutive days.
62555191|NCT03525886|EXPERIMENTAL|Cohort 2 (100 mg QHS)|NBI-74788 100 mg once daily at bedtime (QHS) administered orally for 14 consecutive days.
62555192|NCT03525886|EXPERIMENTAL|Cohort 3 (100 mg QPM)|NBI-74788 100 mg once daily in the evening (QPM) administered orally for 14 consecutive days.
62555193|NCT03525886|EXPERIMENTAL|Cohort 4 (100 mg BID)|NBI-74788 100 mg twice daily (BID) administered orally for 14 consecutive days.
62750577|NCT03474848|ACTIVE_COMPARATOR|Conventional Occupational Therapy (OT)|Provision of 2 sessions/week (45 minutes), for 3 weeks
62750578|NCT02046226|EXPERIMENTAL|OxyGenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
62750579|NCT02046226|NO_INTERVENTION|Standard Wound Care|Standard wound care using gauze dressings per institutional standard of care.
62750580|NCT03018418|EXPERIMENTAL|Proton Therapy and Chemotherapy|Standard chemoradiation using 5-FU, Mitomycin, with pencil beam proton radiotherapy
62750581|NCT01177748||Patients on the Stroke Unit|
62750582|NCT05676151|EXPERIMENTAL|Music Therapy in Pain Rehabilitation|Subjects undergoing care at the Mayo Clinic Florida Pain Rehabilitation Center (PRC) to address pain will receive a 20-minute music therapy intervention
62750583|NCT02867813|EXPERIMENTAL|evolocumab (AMG 145)|All subjects are randomized to a single arm and will receive evolocumab 140mg every two weeks (Q2W) or 420mg monthly (QM) according to subject's preference.
62750584|NCT03546595|EXPERIMENTAL|Auricular acupoints acupressure|
62750585|NCT03546595|SHAM_COMPARATOR|Sham auricular acupoints acupressure|
62555194|NCT05387889|EXPERIMENTAL|Treatment Arm|"This treatment Arm will receive MMPH intervention first, while the wait-listed group waits until this group is complete.~Then the wait-listed group will receive the same intervention after the first group completes it."
61986388|NCT00668941|EXPERIMENTAL|2|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will receive a cyclical regimen of teriparatide, in addition to alendronate. Teriparatide will be administered subcutaneously in 20-mcg doses daily for 3 months. They will receive no teriparatide for the following 3 months, and then teriparatide treatment will continue for the 3 months after that. This schedule will continue for 24 months with an aption to all participants to continue cyclic teriparatide for another 24 months. Biopsies will be performed at Week 7 or Month 7.5.
62375304|NCT02574520|PLACEBO_COMPARATOR|Part 1|SABER-Bupivacaine and Saline Placebo
62375305|NCT02574520|ACTIVE_COMPARATOR|Part 2|SABER-Bupivacaine and Bupivacaine HCl
62555195|NCT05387889|ACTIVE_COMPARATOR|Comparison Arm or Waited List Arm|This active comparator Arm will not receive MMPH intervention at the beginning. They will receive the intervention once the Treatment Group completed the intervention.
62555196|NCT03682107|EXPERIMENTAL|Arm 1 (2 mg ANDV - 3-dose regimen)|"1 sentinel subject assigned to the 3-dose regimen will receive 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine on Days 29, 169, and matching placebo on Day 57 in double-blind manner.~11 subjects assigned to the 3-dose regimen will receive either 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169, and matching placebo on Day 57 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
62750586|NCT01516580|ACTIVE_COMPARATOR|LMB chemo|"Prephase (COP) for all groups followed by:~* in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m²~* in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
62750587|NCT01516580|EXPERIMENTAL|LMB chemo + Rituximab|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
62750588|NCT02436707|ACTIVE_COMPARATOR|R-GDP|"Rituximab - 375 mg/m2 IV, 1.5 - 6 hours D1 (prior to cisplatin);~Gemcitabine - 1000 mg/m2, IV 30 min D1, D8;~Dexamethasone - 40 mg daily PO D1 - D4;~Cisplatin - 75 mg/m2 IV, 1 hour D1;"
61986389|NCT00668941|ACTIVE_COMPARATOR|3|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will continue taking alendronate alone. Biopsies will be performed at Week 7 and then participants in this group will be offered teriparatide as part of Group 2 or 3.
62555197|NCT03682107|EXPERIMENTAL|Arm 2 (2 mg ANDV - 4-dose regimen)|"1 sentinel subject assigned to the 4-dose regimen will receive 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and Days 29, 57 and 169 in double-blind manner.~11 subjects assigned to the 4-dose regimen will receive either 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
61986390|NCT00668941|EXPERIMENTAL|4|Participants in this group will receive a continuous regimen of teriparatide (20 mcg delivered subcutaneously) daily for 48 months. Biopsies will be performed at Week 7 or Month 7.5. At 24 months the participants will then have the option of taking alendronate and remaining in the study for another 24 months.
62375306|NCT02098044||Professional footballers|Retired professional footballers
62375307|NCT02098044||Control Population|members of the general public recruited from the east midlands region
62375308|NCT02430389|EXPERIMENTAL|Remifentanil|Intravenous bolus of 10 mL of remifentanil (0.7 mcg/kg based on ideal body weight) will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
62375309|NCT02430389|PLACEBO_COMPARATOR|Normal Saline|Intravenous bolus of 10 mL normal saline from study syringe will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
62375310|NCT04733664|EXPERIMENTAL|Cohort 1|Patients will receive one dose of visible fluorescent injectate (VFI)™ and one dose of iohexol approximately 4 hours prior to undergoing dialysis followed by a second dose of VFI and iohexol approximately 1 hour after completing dialysis.
62375311|NCT00302055|ACTIVE_COMPARATOR|one-on-one lifestyle|Clinical referral to diabetes prevention lifestyle intervention at School of Medicine campus
62375312|NCT00302055|EXPERIMENTAL|group-based community lifestyle|Clinical referral to group diabetes prevention lifestyle intervention program in community
62567441|NCT05503537|EXPERIMENTAL|post-isometric relaxation technique with basic cardiac protocol|ankle pumps and leg slides, 2 sets of 10 repetitions of each exercise. Walk for 10 minutes. Post-isometric relaxation technique: contraction time 10 second using 20% of strength with 15 second rest period in between contractions + 4 repetitions.
62567442|NCT05503537|EXPERIMENTAL|static stretching with basic cardiac protocol|Ankle pumps and leg slides, 2 sets of 10 repetitions of each exercise. Walk for 10 minutes. Static stretching: 5 repetitions with 15 sec hold time of stretch.
62750589|NCT02436707|EXPERIMENTAL|Ibrutinib plus R-GDP (ACCRUAL COMPLETE)|"Ibrutinib 560 mg PO -- D1 - D21~Rituximab 375 mg/m2 IV 1.5 - 6 hours D1 (prior to cisplatin)~Gemcitabine 1000 mg/m2 IV 30 min D1, D8~Dexamethasone 40 mg daily PO -- D1 - D4~Cisplatin 75 mg/m2 IV 1 hour D1"
61986391|NCT00668941|EXPERIMENTAL|5|Participants in this group will receive a cyclical regimen of teriparatide. Teriparatide will be administered subcutaneously in 20-mcg doses daily for 3 months. They will receive no teriparatide for the following 3 months, and then teriparatide treatment will continue for the 3 months after that. This schedule will continue for 24 months with an option to all participants to continue cyclic teriparatide for another 24 months. Biopsies will be performed at Week 7 or Month 7.5.
62750590|NCT02436707|EXPERIMENTAL|R-DICEP (ACCRUAL COMPLETE)|"Rituximab 375 mg/m2 IV 1.5-6hrs Day 1 and Day 5 prior to Cisplatin~Mesna 1.75 g/m2 IV 24 hour Cycle 1, Day 2, Day 3 and Day 4~Cyclophosphamide, 1.75 g/m2 IV 2 hours, Day 2, Day 3 and Day 4~Etoposide 350 mg/m2 IV 2 hours, Day 2, Day 3 and Day 4~Cisplatin 35 mg/m2 IV, 2 hours, Day 2, Day 3 and Day 4~G-CSF 300 mcg (\<60kg); 480 mcg (60-90kg); 600 mcg (\>90kg); SC, Daily, starting Day 15 until apheresis completed."
62750591|NCT02436707|EXPERIMENTAL|Selinexor + R-GDP|"Selinexor - 40mg PO, D1, D3, D8~Rituximab - 375 mg/m2 IV, 1.5 - 6 hours D1 (prior to cisplatin);~Gemcitabine - 1000 mg/m2, IV 30 min D1, D8;~Dexamethasone - 40 mg daily PO D1 - D4;~Cisplatin - 75 mg/m2 IV, 1 hour D1;"
62750592|NCT04480190|EXPERIMENTAL|Research Treatment|Gemcitabine/Cisplatin/ChemoRT
62750593|NCT01491386|EXPERIMENTAL|rhBMP-2/ACS|
62567443|NCT04622605|EXPERIMENTAL|Treatment Group|Cataract extraction and intraocular lens placement with combined placement of glaucoma microstent
62750594|NCT01491386|ACTIVE_COMPARATOR|Autogenous Bone|
61986392|NCT00668941|ACTIVE_COMPARATOR|6|Participants in this group will take only calcium and vitamin D supplements. Biopsies will be performed at Week 7. Participants will then be offered the standard care for osteoporosis or they may enter the study in Group 4 or 5.
61986393|NCT04295512|NO_INTERVENTION|Usual Care|Community therapists delivering routine care to participant children with no training in UOT
62750595|NCT04478916||Geriatric evaluation Group|Geriatric evaluation of the proportion of elderly patients in which the treatment is modified based on the complete geriatric assessment (CGA)
62750596|NCT04478916||Control Group|
62750597|NCT00527683|ACTIVE_COMPARATOR|A|Subjects will receive vigabatrin in escalating doses to 3 grams per day over three weeks, continued for 4 weeks and then tapered to zero over the next 2 weeks.
62750598|NCT00527683|PLACEBO_COMPARATOR|B|Orange juice and administration identical to Arm A.
62750599|NCT02885740|EXPERIMENTAL|Atrial fibrillation in normal heart|Patients having atrial fibrillation in normal heart
62750600|NCT02885740|ACTIVE_COMPARATOR|Control|Patients having a junctional supraventricular tachycardia in normal heart
62750601|NCT02613117|OTHER|potassium oxalate gel|potassium oxalate gel self applied
61986394|NCT04295512|EXPERIMENTAL|UOT Training|Therapists enrolled in UOT Training
61986395|NCT01683981|EXPERIMENTAL|L-Citrulline, Exercise Capacity|L-Citrulline malate, 1gr, oral, divided 3 times a day,for 2 weeks
61986396|NCT01434238|EXPERIMENTAL|Intervention participant|
61986397|NCT05031182|PLACEBO_COMPARATOR|Laparoscopy|In this Arm, patient will have the traditional hysterectomy by laparoscopy. This is the type of surgery that we realize everyday.
62750602|NCT02613117|OTHER|oxalate liquid, SnF2 paste|Potassium oxalate liquid professionally applied, Stannous fluoride paste self applied
62750603|NCT04465032|ACTIVE_COMPARATOR|Autologous gut microbiome transplantation|Three autologous (own) fecal transplantations (at baseline, 3 and 6 weeks)
62750604|NCT04465032|EXPERIMENTAL|Allogenic gut microbiome transplantation|Three allogenic (lean donor) fecal transplantations (at baseline, 3 and 6 weeks)
62750605|NCT01933438|EXPERIMENTAL|Sup-ER protocol|Early shoulder repositioning (Sup-ER Splint)
62750606|NCT01933438|ACTIVE_COMPARATOR|Control|Standard treatment
62750607|NCT05319899|EXPERIMENTAL|Sequence 1: ABC|"Participants received each treatment on 1 occasion:~Period 1 (Treatment A): ALXN1840 following an overnight fast. Period 2 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
61986398|NCT05031182|ACTIVE_COMPARATOR|vNOTES|In this Arm, patient will have the hysterectomy by vNOTES (vaginal natural orifices Transluminal surgery). It's the new type of surgery that we want prove the no-inferiority.
62750608|NCT05319899|EXPERIMENTAL|Sequence 2: ACB|"Participants received each treatment on 1 occasion:~Period 1 (Treatment A): ALXN1840 following an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast. Period 3 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
62555198|NCT03682107|EXPERIMENTAL|Arm 3 (4 mg ANDV - 3-dose regimen)|"1 sentinel subject assigned to the 3-dose regimen will receive 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine on Days 29, 169, and matching placebo on Day 57 in double-blind manner.~11 subjects assigned to the 3-dose regimen will receive either 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169, and matching placebo on Day 57 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
62555199|NCT03682107|EXPERIMENTAL|Arm 4 (4 mg ANDV - 4-dose regimen)|"1 sentinel subject assigned to the 4-dose regimen will receive 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and Days 29, 57 and 169 in double-blind manner.~11 subjects assigned to the 4-dose regimen will receive either 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
62555200|NCT04451148||Obese subjects|Subjects with obesity
62555201|NCT04451148||Obese plus metabolic syndrome subjects|Subjects with obesity and metabolic syndrome
62750609|NCT05319899|EXPERIMENTAL|Sequence 3: BAC|"Participants received each treatment on 1 occasion:~Period 1 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast. Period 2 (Treatment A): ALXN1840 following an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
62750610|NCT05319899|EXPERIMENTAL|Sequence 4: BCA|"Participants received each treatment on 1 occasion:~Period 1 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast. Period 3 (Treatment A): ALXN1840 following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
62750611|NCT05319899|EXPERIMENTAL|Sequence 5: CAB|"Participants received each treatment on 1 occasion:~Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast. Period 2 (Treatment A): ALXN1840 following an overnight fast. Period 3 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
62750612|NCT05319899|EXPERIMENTAL|Sequence 6: CBA|"Participants received each treatment on 1 occasion:~Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast. Period 2 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast. Period 3 (Treatment A): ALXN1840 following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
62750613|NCT01082874|EXPERIMENTAL|Active Clonidine and Active ASA|
62750614|NCT01082874|EXPERIMENTAL|Active Clonidine and Placebo ASA|
62750615|NCT01082874|EXPERIMENTAL|Placebo Clonidine and Active ASA|
62750616|NCT01082874|PLACEBO_COMPARATOR|Placebo Clonidine and Placebo ASA|
62555202|NCT04451148||Healthy controls|Otherwise healthy subjects
62555203|NCT06254040|PLACEBO_COMPARATOR|Control Group|Volunteers will take 1 dissolving powder pack with maltodextrin daily for 6 months.
62555204|NCT06254040|EXPERIMENTAL|Experimental Group|Volunteers will take 1 dissolving powder pack with the mixture of extracts and DHA daily for 6 months.
62555205|NCT00528047|EXPERIMENTAL|PRLX 93936|
62555206|NCT05623423|EXPERIMENTAL|Organically Modified Ceramic (ORMOCER) Resin Composite.|(Admira Fusion, Voco GmbH, Germany)
62555207|NCT05623423|ACTIVE_COMPARATOR|Methacrylate Based Composite|(Ceram.X Spectra ST, Dentsply Sirona, UK)
62750617|NCT06597994|EXPERIMENTAL|Amber UI Therapy|Participants will receive optimised recharge accessories and device firmware upgrades
62750618|NCT03082534|EXPERIMENTAL|Cohort 1|"PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
62750619|NCT03082534|EXPERIMENTAL|Cohort 2|"PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
62750620|NCT03082534|EXPERIMENTAL|Cohort 3|"PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
62375313|NCT05518136|EXPERIMENTAL|Recovery group|Recovery group was given home-based rehab exercise periodically supervised by cellphone APP. Left ventricular ejection fractions (LVEF), the rate of increase in heart rate (rHRI), and the rate of recovery heart rate (rHRR) were measured for representing cardiopulmonary capacity. The Alberta test and Neuro-intelligence Scale were used to evaluate their motor developmental outcomes.
62375314|NCT05518136|NO_INTERVENTION|Control group|General post-operative care for control group. Left ventricular ejection fractions (LVEF), the rate of increase in heart rate (rHRI), and the rate of recovery heart rate (rHRR) were measured for representing cardiopulmonary capacity. The Alberta test and Neuro-intelligence Scale were used to evaluate their motor developmental outcomes.
62375315|NCT05306795||Observational cohort|Observational prospective cohort of kidney transplant allograft biopsies
62375316|NCT05564754|ACTIVE_COMPARATOR|Sedation, temperature device and high MAP|Continuous deep sedation for 36 hours Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of \>85mmHg.
62375317|NCT05564754|ACTIVE_COMPARATOR|Sedation, no temperature device and high MAP|Continuous deep sedation for 36 hours. Fever management without a feedback-controlled device. A mean arterial pressure target of \>85mmHg.
62375318|NCT05564754|ACTIVE_COMPARATOR|Sedation, temperature device and low MAP|Continuous deep sedation for 36 hours. Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of \>65mmHg.
62375319|NCT05564754|ACTIVE_COMPARATOR|Sedation, no temperature device and low MAP|Continuous deep sedation for 36 hours. Fever management without a feedback-controlled device. A mean arterial pressure target of \>65mmHg.
62750621|NCT03082534|EXPERIMENTAL|Cohort 4|"cutaneous HNSCC~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
62750622|NCT04782050|EXPERIMENTAL|Study arm|
62750623|NCT05974475||SBRT Cohort|Radiation: Stereotactic Body Radiotherapy (SBRT)
62750624|NCT05974475||Surgery Cohort|Procedure: Surgery
62750625|NCT05062304||Fluticasone furoate-vilanterol|Reference group
62750626|NCT05062304||Fluticasone furoate-umeclidinium-vilanterol|Exposure group
62750627|NCT06115382|EXPERIMENTAL|Self cueing|Self-cueing training using singing, one hour sessions twice weekly for 12 weeks.
62750628|NCT06115382|EXPERIMENTAL|External cueing|External cueing using music, one hour sessions twice weekly for 12 weeks.
61986399|NCT05133687|EXPERIMENTAL|Group (0.8-G)|This group will receive general anesthesia and caudal block with 0.8 ml/kg of bupivacaine 0.25%
62375320|NCT05564754|ACTIVE_COMPARATOR|Minimal sedation, temperature device and high MAP|Minimal sedation (and early extubation if possible). Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of \>85mmHg.
62750629|NCT06604546|EXPERIMENTAL|hyaluronidase group|
61986400|NCT05133687|EXPERIMENTAL|Group (1.2-G)|This group will receive general anesthesia and caudal block with 1.2 ml/kg of bupivacaine 0.25%
62750630|NCT06604546|PLACEBO_COMPARATOR|Placebo self control group|
62750631|NCT05201430|EXPERIMENTAL|A: FOLFOXIRI|Neoadjuvant chemotherapy with 3-4 cycles of FOLFOXIRI regimen, followed by surgery
62750632|NCT05201430|EXPERIMENTAL|B: CapeOX|Neoadjuvant chemotherapy with 2-3 cycles of CapeOX regimen, followed by surgery
62750633|NCT06188650|EXPERIMENTAL|experimental group|
62750634|NCT06174688|EXPERIMENTAL|BOTOX|BOTOX will be injected on Day 1
62750635|NCT06174688|PLACEBO_COMPARATOR|Placebo|Placebo will be injected on Day 1
62750636|NCT05437562|OTHER|Ewing Amputation|Single Arm Pilot Study : To implement lead-in surgeon training and test the feasibility of recruiting and retention of veterans undergoing Ewing Amputation in a single arm study at Atlanta VAMC.
62750637|NCT05462444||Children with food allergy|
62750638|NCT05462444||Children with food intolerance|
62750639|NCT05462444||Children with other allergies (reference group)|
62750640|NCT01321216||Hospitalized Gastroenteritis|Children under 5 years of age hospitalized with gastroenteritis
62750641|NCT03464357|ACTIVE_COMPARATOR|Symptomatic patients with dry eye|8 symptomatic patients with dry eye (mild to severe) assessed using a validated questionnaire (OSDI score, Appendix 1) associated with a disabling photophobia (need to wear sunglasses permanently outside, restriction of the outputs in case of significant brightness, restriction of the use of the screens because of the visual embarrassment ...). The fMRI will be carried out following the inclusion visit after all the necessary checks
62750642|NCT03464357|ACTIVE_COMPARATOR|Asymptomatic patient|"8 asymptomatic patients presenting neither photophobia (even minimal) or dry eye.~The fMRI will be carried out following the inclusion visit after all the necessary checks"
62750643|NCT05120765|EXPERIMENTAL|Intervention|"Intervention to be administered is The CONNECT Program. This is a 6-week, group-based, telephone-based, mental health intervention for socially isolated older adults. This group-therapy intervention is based on principles of Acceptance and Commitment Therapy (ACT)."
62750644|NCT05120765|NO_INTERVENTION|Waitlist|Waitlist intervention requires participants to wait 6 weeks. This waitlist group will receive the intervention after this 6 week waiting period, due to the exploratory nature of this Pilot Randomized Controlled Trial (RCT).
62750645|NCT04599023||MS patients including CIS|Patients with a diagnosis of MS, including Clinically Isolated Syndrome (CIS), who have the ability to understand the audio and visual instructions for the MSPT modules and whose visual function that does not preclude an ability to see the screen of the MSPT tool.
62750646|NCT00368615||1|Subjects ages 18-85 years old with biopsy proven melanoma. Peripheral blood will be collected from adults ages 18-85 years old. These samples will then be used for PCR analysis and to generate melanoma-specific T cell clones. If the participant requires a palliative resection of a melanoma tumor(s) then tissue from the tumor will be used to characterize the melanoma's interaction with the immune system and to generate melanoma-specific cell lines. T cell clones isolated from participant's peripheral blood will then be assayed for in-vitro responsiveness to these cell lines. All experiments will be conducted in-vitro.
62750647|NCT00368615||2|Age-matched controls (no evidence of melanoma)
62750648|NCT02476084||Conventional synthetic DMARD naïve|"Naive RA patients commencing Methotrexate and Hydroxychloroquine.~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
62750649|NCT02476084||DMARD-IR: anti-TNF|"Conventional synthetic DMARD inadequate responders commencing Anti-TNF~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
62750650|NCT02476084||DMARD-IR: anti-IL6|"Conventional synthetic DMARD inadequate responders commencing anti-IL6~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
62750651|NCT02476084||DMARD-IR: anti-CTLA-4|"Conventional synthetic DMARD inadequate responders commencing anti-CTLA-4~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
62750652|NCT02476084||DMARD-IR: anti-CD20|"Conventional synthetic DMARD inadequate responders commencing anti-CD20~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
62750653|NCT04233307|OTHER|Wound photographs|Telethermographic photographs of fracture wound and contralateral limb before and after propofol infusion.
62750654|NCT00460759|EXPERIMENTAL|Moxifloxacin and Rifapentine|
62375321|NCT05564754|ACTIVE_COMPARATOR|Minimal sedation, no temperature device and high MAP|Minimal sedation (and early extubation if possible). Fever management without a feedback-controlled device. A mean arterial pressure target of \>65mmHg.
62375322|NCT05564754|ACTIVE_COMPARATOR|Minimal sedation, temperature device and low MAP|Minimal sedation (and early extubation if possible). Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of \>65mmHg.
62375323|NCT05564754|ACTIVE_COMPARATOR|Minimal sedation, no temperature device and low MAP|Minimal sedation (and early extubation if possible). Fever management without a feedback-controlled device. A mean arterial pressure target of \>65mmHg.
62375324|NCT05802290|EXPERIMENTAL|nivolumab|nivolumab monotherapy at 240mg flat dose as a 30-minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death or withdrawal of consent
62555208|NCT01290549|EXPERIMENTAL|Polatuzumab Vedotin|Polatuzumab vedotin will be administered by an IV infusion of escalating doses (starting dose of 0.1 mg/kg, potentially to be followed by 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, and 4.0 mg/kg doses) every 3 weeks (q3w) (Day 1 of each 21 day cycle).
62375325|NCT03231228|ACTIVE_COMPARATOR|Cefazolin 1 g Infusion|Pediatric surgical subjects weighing at least 25 kg to less than 60 kg will receive a single 30-minute infusion of 1 g cefazolin.
62375326|NCT03231228|ACTIVE_COMPARATOR|Cefazolin 2 g Infusion|Pediatric surgical subjects weighing at least 60 kg will receive a single 30-minute infusion of 2 g cefazolin.
62375327|NCT05575583|EXPERIMENTAL|Intervention group|Subjects underwent repetitive transcranial magnetic stimulation for five consecutive days from day 2 to day 6 after surgery. The stimulation target area was the posterior cingulate gyrus, and the neuronavigation system was used to accurately locate the stimulation target in this project. Continuous theta short rapid pulse mode (cTBS) was used. CTBS mode consisted of a slave stimulus delivered every 0.2 seconds (5Hz), and each slave stimulus consisted of three bursts of 50Hz. A single stimulus lasts about 40 seconds and totals 600 pulses. Stimulation sessions are from 8 to 10 a.m. daily.
62375328|NCT05575583|SHAM_COMPARATOR|Control group|Subjects underwent repetitive transcranial magnetic stimulation for five consecutive days from day 2 to day 6 after surgery，but the machine does not turn on.
62375329|NCT05981755|EXPERIMENTAL|Breathing tasks and Brain mapping with stimulation|
62375330|NCT01118585|OTHER|TIF Procedure|Intervention: Transoral incisionless fundoplication procedure using the EsophyX device. During general anesthesia the EsophyX device is introduced trans orally into the stomach and used to created a 270 degree, 3cm in length, wrap at the distal end of the esophagus to treat GERD.. .
62375331|NCT04224350|EXPERIMENTAL|Once-Daily Tacrolimus|Experimental arm: TacroBell SR Cap.
62375332|NCT04224350|ACTIVE_COMPARATOR|Twice a Day Tacrolimus|Active Comparator arm: TacroBell Cap.
62375333|NCT02515851|ACTIVE_COMPARATOR|Active Group|Group that receives actual liposomal bupivacaine injections
62375334|NCT02515851|PLACEBO_COMPARATOR|Placebo Group|Group that receives placebo injections
62375335|NCT00762528|ACTIVE_COMPARATOR|Total Toothpaste|Triclosan/Copolymer/fluoride toothpaste
62375336|NCT00762528|PLACEBO_COMPARATOR|Fluoride toothpaste|sodium monofluorophosphate toothpaste
62375337|NCT02721290|ACTIVE_COMPARATOR|Femoral nerve block using Ultrasound and neurostimulator|Femoral block using the standard technique of ultrasound for femoral nerve identification and neurostimulator set at between 0.3-0.5 mA with quads muscle response for needle placement confirmation before injecting 20cc of Ropivacaine 0.5%.
62375338|NCT02721290|EXPERIMENTAL|Femoral nerve block using femoral artery target|Femoral block using the alternate technique of aiming for the inferolateral aspect of the femoral artery and injecting 20cc of Ropivacaine 0.5%.
62375339|NCT04725604|EXPERIMENTAL|pH Probe|Softcell pH monitoring system: designed to measure intramuscular pH levels in patients with fracture or crush injuries sufficiently severe to be at risk of developing ACS.
62375340|NCT00026195|EXPERIMENTAL|irinotecan|"Patients receive irinotecan IV over 90 minutes once weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed for survival."
62375341|NCT02462889|EXPERIMENTAL|Intravitreal aflibercept injection|Subjects will be randomized to receive intravitreal aflibercept injection every three months for 24 months.
62375342|NCT02462889|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to receive sham injection every three months for 24 months.
62375343|NCT05084768||Rejection of kidney transplant|Diagnostic test: measurement of regulatory T cell and donor-derived cell-free DNA
62555209|NCT01290549|EXPERIMENTAL|Polatuzumab Vedotin + Rituximab|Polatuzumab vedotin will be administered by an IV infusion q3w (Day 1 of each 21 day cycle). Rituximab was administered by an IV infusion at 375 milligrams per square meter (mg/m\^2) body surface area dose q3w.
62555210|NCT06194708||Mid-low rectal cancer patients with temporary stoma after radical surgery|
62750655|NCT02780635|EXPERIMENTAL|App + Couples Coach Intervention|Both members of the couple will receive a mobile app for PTSD: PTSD Coach for the Veteran and PTSD Family Coach for the partner/spouse. Those assigned to this arm will also receive mailed materials that are designed to help increase positive communication strategies.
62555211|NCT03145675|EXPERIMENTAL|Enoxaparin (Staged-dose PCI Group)|Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and additional enoxaparin 0.25 mg/kg at the beginning of PCI (i.e., insertion of guiding catheter).
62375344|NCT05084768||No rejection of kidney transplant|Diagnostic test: measurement of regulatory T cell and donor-derived cell-free DNA
62555212|NCT03145675|ACTIVE_COMPARATOR|Enoxaparin (Single-dose PCI Group)|Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and NO additional enoxaparin at the beginning of PCI (i.e., insertion of guiding catheter).
62555213|NCT03145675|EXPERIMENTAL|Enoxaparin (High-dose Group)|Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).
62555214|NCT03145675|ACTIVE_COMPARATOR|Enoxaparin (Standard-dose Group)|Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).
62555215|NCT01795950|EXPERIMENTAL|0.5 M PLX-PAD|0.5 million (M) PLX-PAD cells per kg body weight
62555216|NCT01795950|EXPERIMENTAL|1 M PLX-PAD|1.0 million (M) PLX-PAD cells per kg body weight
62555217|NCT01795950|EXPERIMENTAL|2 M PLX-PAD|2.0 million (M) PLX-PAD cells per kg body weight
62555218|NCT00247715|OTHER|Step-up|"Stepwise treatment:~* step1: antacid (+placebo proton pump inhibitor)~* step2: H2-receptor antagonist~* step3: proton pump inhibitor (+ placebo antacid)"
62375345|NCT00634751|EXPERIMENTAL|Phase I: 200mg Sorafenib+2DOC|"Cohort 1: 200mg Sorafenib+2DOC~Oxaliplatin + Oral Capecitabine + Sorafenib"
62375346|NCT00634751|EXPERIMENTAL|Phase I: 400mg Sorafenib BID+2DOC|"Cohort 2: 400mg Sorafenib+2DOC~Oxaliplatin + Oral Capecitabine + Sorafenib"
62375347|NCT00634751|EXPERIMENTAL|Phase II: Pancreatic Cancer|Oxaliplatin + Oral Capecitabine + Sorafeni
62555219|NCT00247715|OTHER|step-down|"Stepwise treatment:~* step1: proton pump inhibitor (+placebo antacid)~* step2: H2-receptor antagonist~* step3: antacid (+proton pump inhibitor)"
62750656|NCT02780635|ACTIVE_COMPARATOR|App Alone|Both members of the couple will receive a mobile app for PTSD: PTSD Coach for the Veteran and PTSD Family Coach for the partner/spouse.
62555220|NCT04981717|EXPERIMENTAL|REGN1908-1909|Randomized 1:1
62555221|NCT04981717|PLACEBO_COMPARATOR|Placebo|Randomized 1:1
62555222|NCT03125798|EXPERIMENTAL|LigaSure|In this arm, LigaSure™ will be used for mediastinal lymph nodes dissection, according to standard surgical technique.
62555223|NCT03125798|ACTIVE_COMPARATOR|Monopolar electrocautery|In this arm, conventional monopolar electrocautery will be used for mediastinal lymph nodes dissection, according to standard surgical technique.
62555224|NCT03845686||Subacute Stroke Sample|Participants with first-ever left-brain stroke, \< 4 weeks post stroke, age \>18 years, right-handed, fluent and literate in English prior to stroke, no prior neurological disorders or clinical stroke event, \<4 weeks post-stroke; able to undergo an MRI and complete study tasks, and presence of reading deficits.
62555225|NCT03845686||Chronic Stroke Sample|The same group of participants examined in the chronic post-stroke period (\>3 months post-stroke)
62750657|NCT00866034|EXPERIMENTAL|CD2|Early fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2, together with the initiation of daily treatment with exogenous gonadotropins.
62375348|NCT00634751|EXPERIMENTAL|Phase II: Biliary Tract Cancer|Oxaliplatin + Oral Capecitabine + Sorafeni
62555226|NCT01949246||CRT patients|Patients undergoing CRT device implantation
62750658|NCT00866034|EXPERIMENTAL|CD6|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6. As in the other arm of the study, exogenous gonadotropins will commence on cycle day 2.
62750659|NCT04761679|EXPERIMENTAL|Intervention Group|
62750660|NCT04761679|NO_INTERVENTION|Control Group|
62750661|NCT06078202|EXPERIMENTAL|Part 1, Sequence A|Participants will receive 1 dose of ABBV-903.
62750662|NCT06078202|EXPERIMENTAL|Part 1, Sequence B|Participants will receive 1 dose of ABBV-903.
62750663|NCT06078202|EXPERIMENTAL|Part 1, Sequence C|Participants will receive 1 dose of ABBV-903.
62750664|NCT06078202|EXPERIMENTAL|Part 2, Sequence A|Participants will receive 1 dose of ABBV-903.
62750665|NCT06078202|EXPERIMENTAL|Part 2, Sequence B|Participants will receive 1 dose of ABBV-903.
62750666|NCT02725593|EXPERIMENTAL|Dapagliflozin|
62750667|NCT02725593|PLACEBO_COMPARATOR|Dapagliflozin placebo|
62375349|NCT03330093|EXPERIMENTAL|Sleep Extension|1-month educational and problem solving behavioral intervention about sleep.
62555227|NCT01949246||Healthy patients|Healthy controls
62375350|NCT03330093|ACTIVE_COMPARATOR|Health and Safety|1-month educational and problem solving behavioral intervention about health and safety.
62375351|NCT01803529|EXPERIMENTAL|heat-pack with massage|deep friction massage and standard heat-pack given a maximum of 8 treatments
62375352|NCT01803529|ACTIVE_COMPARATOR|heatpack only|standard heat-pack given a maximum of 8 treatments
62375353|NCT02449512||complete|individuals with somato-sensory complete spinal cord injury
62375354|NCT02449512||incomplete|individuals with somato-sensory incomplete spinal cord injury
62555228|NCT03975933|EXPERIMENTAL|Free pregnancy tests at baseline but not for the future|We offer free pregnancy test service at baseline but the respondents do not have an opportunity to receive or buy a pregnancy test.
62375355|NCT00784459|EXPERIMENTAL|Treatment with Abatacept|Administration of Abatacept intravenously 10 mg/kg every 2 weeks for 3 doses, followed by every 4 weeks for 2 doses.
62375356|NCT00784459|PLACEBO_COMPARATOR|Placebo|Administration of placebo (normal saline) intravenously 10 mg/kg every 2 weeks for 3 doses, followed by every 4 weeks for 2 doses.
62375357|NCT02458352|OTHER|Standard dose CT, Ultra-low dose CT|Standard dose non-contrast enhanced CT (clinically indicated) and Ultra low dose non-contrast enhanced CT (as part of the trial)
62375358|NCT02611934|EXPERIMENTAL|Mild Therapeutic Hypothermia|OHCA survivors with diagnosed or suspected ACS
62555229|NCT03975933|EXPERIMENTAL|Free pregnancy tests at baseline and for the future|We offer free pregnancy test service at baseline and a free pregnancy test for future use.
62555230|NCT03975933|EXPERIMENTAL|Free pregnancy tests at baseline and future use (random price)|We offer free pregnancy test service at baseline and the respondents have an opportunity to buy a pregnancy test.
62555231|NCT03975933|NO_INTERVENTION|Control Group|Control group. No intervention is implemented.
62555232|NCT03975933|EXPERIMENTAL|Pregnancy test for the future use|No free pregnancy tests at baseline, but receive a free pregnancy test for the future.
62750668|NCT02034682|EXPERIMENTAL|Volulyte 6%|"- Volulyte 6% (HES 130/0.4 in an isotonic composition). In 1000 ml:~* Maize starch 60 gr. Molar substitution 0.38-0.45. 130000 Da~* Na acetate trihydrate 4.63 gr~* Sodium Chloride 6.02 gr~* Potassium Chloride 0.3 gr~* MgCl 0.3 gr~* Sodium hydroxide-hydrochloric acid \& H2O"
62750669|NCT02034682|ACTIVE_COMPARATOR|Geloplasma|"In 1000 ml:~* Modified fluid gelatin 30 gr~* Sodium Chloride 5.4 gr~* Potassium Chloride 0.37 gr~* MgCl 0.14 gr~* Sodium lactate 3.36 gr"
62750670|NCT00737711|EXPERIMENTAL|Mircera|
62555233|NCT03975933|EXPERIMENTAL|Pregnancy test for the future with random price|No free pregnancy tests at baseline, but receive an opportunity to buy a pregnancy test for the future (ranodmized price).
62555234|NCT06105528|EXPERIMENTAL|Cohort 1 PMN310 175mg or placebo|PMN310 175mg or placebo administered as a 60-minute infusion.
62750671|NCT01316757|EXPERIMENTAL|Treatment|Patients receive cetuximab IV over 60 minutes, paclitaxel IV over 1 hour, and carboplatin IV over 30 minutes on day 1. Beginning in course 2, patients also receive erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62750672|NCT02858986|EXPERIMENTAL|3D laparoscopy|Patients will undergo laparoscopic cholecystectomy using a 3D laparoscopic system
62750673|NCT02858986|EXPERIMENTAL|4K laparoscopy|Patients will undergo laparoscopic cholecystectomy using a 4K laparoscopic system
62750674|NCT02041975|EXPERIMENTAL|Prebiotic|Nutriose FB06 14g/day
62750675|NCT02041975|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62750676|NCT03729258|EXPERIMENTAL|Cefpodoxime 200 (b.i.d)|
62750677|NCT03729258|ACTIVE_COMPARATOR|Cefpodoxime 400 (q.d)|
62750678|NCT00571870|ACTIVE_COMPARATOR|A|Stimulated as conventional protocol
62750679|NCT00571870|EXPERIMENTAL|B|GnRH antagonist stopped one day earlier than conventional protocol
62750680|NCT02027818|EXPERIMENTAL|Indocyanine Green|study of the correlation between fluorescence and margins of the tumours after iv injection of Indocyanine Green
62750681|NCT03073018|EXPERIMENTAL|Fosinopril + Pravastatin|Fosinopril (20 mg) + pravastatin (40 mg) once daily for 4 years
62750682|NCT03073018|ACTIVE_COMPARATOR|Fosinopril + Placebo|Fosinopril (20 mg) + pravastatin placebo once daily for 4 years
62375359|NCT02611934|NO_INTERVENTION|no-Mild Therapeutic Hypothermia|OHCA survivors with diagnosed or suspected ACS
62375360|NCT02132689|ACTIVE_COMPARATOR|Actilyse|Thrombolytic therapy: Patients treated with initial thrombolytic therapy (Actilyse) followed with anticoagulant therapy (unfractionated/low-molecular weight heparin).
62375361|NCT02132689|ACTIVE_COMPARATOR|UHF/LMWH|Anticoagulation therapy: Patients treated with anticoagulation therapy only (unfractionated/low-molecular weight heparin).
62375362|NCT02807155|NO_INTERVENTION|Non-Intervention Control|No intervention will be delivered.
62750683|NCT03073018|ACTIVE_COMPARATOR|Pravastatin + Placebo|Pravastatin (40 mg) + fosinopril placebo once daily for 4 years
62750684|NCT03073018|PLACEBO_COMPARATOR|Double Placebo|Fosinopril placebo and pravastatin placebo once daily for 4 years
62750685|NCT05928117|EXPERIMENTAL|Experimental|Intervention: Mobile education given in the line of coping with fear The first one is 28-30th of pregnancy. week, the second is 36-38. It will meet in three meetings in total, the third of which will be within 12-24 hours postpartum.
62750686|NCT05928117|NO_INTERVENTION|Control|Standart care
62750687|NCT02581956|EXPERIMENTAL|Walking Exercise|For the exercise group, subjects were asked to follow a simple walking regimen. Walk normally with stable and comfortable stride rates during their exercise. The duration and frequency was initiated at a 30-minute or more daily exercise at least five days per week and gradually increased to a maximum of 60 minutes within subject's comfort zone.
62375363|NCT02807155|EXPERIMENTAL|Continuity Group|"Continuity Group participants aged 20-21 (i.e. the last year of the LEAP Program) will be seen at one of the 2 study centers - 1) the newly established LAC+USC Diabetes Transition Clinic; or 2) Children's Hospital Los Angeles Pediatric Endocrinology Clinic, and will receive the full 1-year Transition Empowerment Program - Continuity Group"
62750688|NCT02581956|PLACEBO_COMPARATOR|No Intervention|No exercise required
62750689|NCT06605274|OTHER|Web-Based Education Group|"The technology-based education program prepared for women experiencing perinatal loss was prepared based on current literature and care theories related to perinatal loss. The program consisted of five modules, namely What I am experiencing, I am ready to learn, I have a loss and I am ready to experience my mourning process, I am experiencing my loss and I do not have to be alone, I am ready to look back and explore, and create a memory, move on. Expert opinions were obtained for the content of the program. Necessary adjustments were made to the program in line with expert opinions."
62375364|NCT02807155|EXPERIMENTAL|Rescue Group|"Rescue Group participants aged 21-25 will be connected to a diabetes healthcare home (medical clinic or doctor's office) in Los Angeles County based on geography and personal preference. Those individuals connected to the LAC+USC Diabetes Transition Clinic will receive the full 1-year Transition Empowerment Program - Rescue Group (TEP-RG). Those assigned to other providers in LA County will have access to the web-based curriculum."
62555235|NCT06105528|EXPERIMENTAL|Cohort 2 PMN310 350mg or placebo|PMN310 350mg or placebo administered as a 60-minute infusion.
62555236|NCT06105528|EXPERIMENTAL|Cohort 3 PMN310 700mg or placebo|PMN310 700mg or placebo administered as a 60-minute infusion.
62555237|NCT06105528|EXPERIMENTAL|Cohort 4 PMN310 1400mg or placebo|PMN310 1400mg or placebo administered as a 60-minute infusion.
62555238|NCT06105528|EXPERIMENTAL|Cohort 5 PMN310 2800mg or placebo|PMN310 2800mg or placebo administered as a 60-minute infusion.
62555239|NCT02531048|EXPERIMENTAL|healthy volunteers|"Healthy volunteers are able to participate to this study. They must not have neurological troubles. They will have different stimulations :~* laser stimulations on lower limbs~* laser stimulations cervical~* 20 laser stimulations for each site on the upper limbs~* laser stimulations on face and neck"
62555240|NCT03855982||myocarditis induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of myocarditis of patient treated by a drug, with a chronology compatible with the drug toxicity
62555241|NCT00233948|EXPERIMENTAL|Arm I|Patients receive oral nelfinavir mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62555242|NCT05978401|EXPERIMENTAL|Phase I Dose-Escalation Stage：GLS-012+GLS-010|Participants will be treated with escalating doses of GLS-010 + GLS-012 to determine the MTD
62555243|NCT05978401|EXPERIMENTAL|Phase I Expansion Stage：GLS-012+GLS-010|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of GLS-012+GLS-010 in Advanced Non-Small Cell Lung Cancer.
62555244|NCT05978401|EXPERIMENTAL|GLS-012+GLS-010+pemetrexed + carboplatin|Participants will be enrolled in the expansion stage to better characterize the safety, PK variability, and preliminary efficacy of GLS-012+GLS-010+pemetrexed+carboplatin in Advanced Non-Small Cell Lung Cancer.
62750690|NCT06605274|ACTIVE_COMPARATOR|Control Group|A conventional post discharge follow up was performed on control group no other intervention was applied.
62750691|NCT04880044|EXPERIMENTAL|EC/EG & EGD|"Participants will complete a study questionnaire about reflux symptoms. Performance of an EsoCheck (EC) procedure; the EC sample will subsequently be tested with the EsoGuard (EG) assay~If EG assay results come back positive, participant is requested to complete standard of care (SOC) upper endoscopy (tissue samples collected)~If EG assay results come back negative, selected participants (100 volunteers) will also undergo a research EGD if they consent"
62375365|NCT01197495|EXPERIMENTAL|Treatment|Juvederm(R) Ultra XC Injectable Gel
62375366|NCT01197495|EXPERIMENTAL|Control|No treatment for 3 months followed by Juvederm(R) Ultra XC Injectable Gel at Month 3.
62375367|NCT05699044||Amyloidosis Screening|Patients fulfilling eligibility criteria will screened for Cardiac Amyloidosis.
62555245|NCT05978401|EXPERIMENTAL|GLS-012+GLS-010+paclitaxel+carboplatin|Participants will be enrolled in the expansion stage to better characterize the safety, PK variability, and preliminary efficacy of GLS-012+GLS-010+paclitaxel+carboplatin in Advanced Non-Small Cell Lung Cancer.
62750692|NCT01100710||healthy volunteers|
62750693|NCT03865108|EXPERIMENTAL|Pessary and Progesterone|Women already receiving a pessary in addition to the standard progesterone through the TOPS trial will undergo ultrasound imaging and cervical speculum examination for information collection.
62750694|NCT03865108|PLACEBO_COMPARATOR|Progesterone only|Women already receiving the standard progesterone only will undergo ultrasound imaging and cervical speculum examination for information collection.
62750695|NCT04442126|EXPERIMENTAL|NM21-1480 Treatment arm|
62750696|NCT05159492|EXPERIMENTAL|PEF Arm|PEF is a non-thermal ablation modality using extremely short high voltage pulses to induce cell death, with tissue selectivity, cardiomyocytes being much more sensitive to this energy than Phrenic nerve or Esophageal cells. Energy (2000 V) will be delivered 8 times per vein with 2 different catheter configurations and rotations
62750697|NCT05159492|ACTIVE_COMPARATOR|Pulmonary vein isolation using Contact Force RF|The PVI strategy using RF is very standard. The CARTO© platform will be used, with a contact force catheter (SmartTouch), aiming at an ablation index value of 300 to 400 on the posterior wall, and at least 500 on the anterior wall. Power will be limited to 35/45 W, with a distance between consecutive deliveries of 6 mm or less (CLOSE protocol).
62750698|NCT01330628|EXPERIMENTAL|Laser atherectomy and PTA|laser, then balloon angioplasty
62750699|NCT01330628|ACTIVE_COMPARATOR|Balloon angioplasty|
62750700|NCT00198393|EXPERIMENTAL|A|Gefitinib
62750701|NCT00198393|EXPERIMENTAL|B|Gemcitabine
62750702|NCT00198393|EXPERIMENTAL|C|Docetaxel
62750703|NCT05272137||ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
62750704|NCT03038607|ACTIVE_COMPARATOR|Aspirin group|
61986401|NCT05133687|ACTIVE_COMPARATOR|Group G|This group will receive general anesthesia with local infiltration of the wound or transversus abdominis plan block (TAPB) at the end of the procedure.
61986402|NCT05420207||MSM patients|
61986403|NCT05420207||Physician treating MSM patients|
62750705|NCT03038607|NO_INTERVENTION|No intervention|
62750706|NCT06608771||Out-of-hospital cardiac arrest (OHCA) and In-hospital cardiac arrest (IHCA) patients|The study population includes all adult patients resuscitated from cardiac arrest and subsequently admitted to the Intensive Care Unit over a 14-year-period
62750707|NCT02200419|OTHER|Transfusion Algorithm|Hospitals will be randomized to the intervention arm of the study in a stratified manner.
62750708|NCT02563535|EXPERIMENTAL|Drug-eluting balloon|angioplasty with Litos drug-eluting balloon
62750709|NCT02563535|ACTIVE_COMPARATOR|conventional PTA|angioplasty with conventional balloon
62375368|NCT02147106||Videoconsultation|Performing two videoconsulations with the treating medical oncologist
62375369|NCT02162264||E2020|
62375370|NCT04933253|EXPERIMENTAL|Experimental|this cohort will receive 2 L of warm 37celsius saline irrigation of the mediastinum prior to closure of the chest
62375371|NCT04933253|NO_INTERVENTION|Control|this cohort will receive the normal standard of care as established by the primary surgeon
62375372|NCT06412640|ACTIVE_COMPARATOR|high dose amoxicillin with keverprazan group|Patients need to take keverprazan 20mg bid and amoxicillin 1000mg tid for 14 days.
62375373|NCT06412640|EXPERIMENTAL|low dose amoxicillin with keverprazan group|Patients need to take keverprazan 20mg bid and amoxicillin 1000mg bid for 14 days.
62375374|NCT02327728|EXPERIMENTAL|medial lower eyelid waived|Botulinum toxin A 10U per eye subcutaneous injection at orbicularis oculi
62375375|NCT02327728|ACTIVE_COMPARATOR|full injection pattern|Botulinum toxin A 12.5U per eye subcutaneous injection at orbicularis oculi
62375376|NCT04488601|EXPERIMENTAL|Rapamycin 5|Rapamycin 5 mg/week
62375377|NCT04488601|EXPERIMENTAL|Rapamycin 10|Rapamycin 10 mg/week
62375378|NCT04488601|PLACEBO_COMPARATOR|Placebo 1|Placebo once per week
62375379|NCT04680104||Cohort A|Infusion of Na-Lev plus 5-FU (unique administration by one 48h-infusional pump)
62375380|NCT04680104||Cohort B|Infusion of Ca-Lev followed by infusion of 5-FU (two separated administrations by using one plastic bag followed by one 48h-infusional pump)
62375381|NCT05756894|EXPERIMENTAL|Neurostimulation for respiratory function after spinal cord injury|Efficacy of STDP on respiratory function.
62375382|NCT05345704||Lay rescuers|Volunteer participants in a role lay rescuers
62375383|NCT05345704||Health care professionals (HCPs)|Health care professionals (HCPs) trained in advanced life support
62375384|NCT05622656|PLACEBO_COMPARATOR|Placebo|Intraperitoneal instillation of normal saline
62375385|NCT05622656|ACTIVE_COMPARATOR|Dexmedetomidines|Intraperitoneal instillation Dexmedetomidine 5ug/ml (10ml,50ug)
62375386|NCT04555811|EXPERIMENTAL|FT596 + Rituximab Dose Level 1: 9x10^7 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 administration: (Dose Level 1: 9x10\^7 cells/dose, Dose Level 2: 3x10\^8 cells/dose, Dose Level 3: 9x10\^8 cells/dose with a Dose Level -1: 3x10\^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
62555246|NCT04187755|ACTIVE_COMPARATOR|Group I|Participants were given ceftazidime as the antibiotic therapy with standard regimens and dose of antibiotic
62375387|NCT04555811|EXPERIMENTAL|FT596 + Rituximab Dose Level 2: 3x10^8 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 administration: (Dose Level 1: 9x10\^7 cells/dose, Dose Level 2: 3x10\^8 cells/dose, Dose Level 3: 9x10\^8 cells/dose with a Dose Level -1: 3x10\^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
62555247|NCT04187755|EXPERIMENTAL|Group II|Participants were given cefepime as the antibiotic therapy with standard regimens and dose of antibiotic
62555248|NCT05457777|EXPERIMENTAL|Motivational interview group|Motivational interviews will be held to the participants with digital game addiction in this group.
62555249|NCT05457777|NO_INTERVENTION|Control group|This group will be control group and any motivational interviews will not be held to the participants with digital game addiction in this group.
62750710|NCT05058573|EXPERIMENTAL|Myofascial relaxation technique + Temporomandibular joint release techniques group (n=22)|medical treatment + temporomandibular joint relaxation (temporalis, masseter, and suboccipital muscles) + myofasial release/trigger points (trapezius, rhomboideus, and levator scapulae, sternocleidomastoideus muscles),
62750711|NCT05058573|EXPERIMENTAL|Temporomandibular joint release techniques group (n=22)|only temporomandibular joint relaxation will be performed in this group (temporalis, masseter, and suboccipital muscles).
62750712|NCT05058573|EXPERIMENTAL|Control group (n=22)|only medication treatment will be applied
62750713|NCT02281474|ACTIVE_COMPARATOR|150mg dosing|This arm will take 150mg of Nilotinib by mouth daily for the 6 month drug period to establish a safe and efficacious dose.
62375388|NCT04555811|EXPERIMENTAL|FT596 + Rituximab Dose Level 3: 9x10^8 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 administration: (Dose Level 1: 9x10\^7 cells/dose, Dose Level 2: 3x10\^8 cells/dose, Dose Level 3: 9x10\^8 cells/dose with a Dose Level -1: 3x10\^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
62375389|NCT04507490|EXPERIMENTAL|Whole body vibration 6 Hz|application of whole body vibration in the following parameters:frequency 6 Hz, amplitude 4 mm, five cycles lasting 1 minutes and interval between cycles of 1 minute
62375390|NCT04507490|EXPERIMENTAL|Whole body vibration 25 Hz|application of whole body vibration in the following parameters: 25 Hz frequency, 4 mm amplitude, five cycles lasting 1 minute and interval between 1 minute cycles
62375391|NCT04507490|SHAM_COMPARATOR|Whole body vibration sham|application of whole body vibration in the following parameters: The sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to that of the connected platform for a time equivalent to that of the treatment protocol.
62375392|NCT04060433|EXPERIMENTAL|ROCKETLAUNCH project|Intensive treatment program with focusing on the implementation of evidence based family therapy
62375393|NCT02726204|ACTIVE_COMPARATOR|Healthy Subjects|Seven healthy patients will serve as controls based on preliminary data in healthy volunteers using CAREX with gravity elimination alone versus gravity elimination plus path assistance.
62375394|NCT02726204|ACTIVE_COMPARATOR|Chronic Post Stroke Right Side Hemiparesis|Radiologically verified unilateral stroke patients with at least 4 months previously.
62375395|NCT03028532|EXPERIMENTAL|Clomid|All participants will be receiving Clomid and will follow the same study procedures.
62375396|NCT05130229|EXPERIMENTAL|Sleep Well Bee Well|Sleep program to help toddlers sleep better
62375397|NCT05130229|PLACEBO_COMPARATOR|Wait-list Control|The wait-listed group will begin the intervention after the intervention group
62375398|NCT04449718|EXPERIMENTAL|Experimental|Patients will receive 200,000 IU of vitamin D3 on admission + conventional care
62375399|NCT04449718|PLACEBO_COMPARATOR|Placebo|Patients will receive an equivalent amount of a placebo solution on admission + conventional care
62375400|NCT05371132|EXPERIMENTAL|Basic science (zirconium Zr 89-Df-crefmirlimab, PET, SBRT)|Patients receive zirconium Zr 89-Df-crefmirlimab IV over 5-10 minutes and then under PET imaging 24 hours after infusion before and after SBRT. Patients undergo SBRT every 2-5 days for a total of 5 fractions. For lymphoma patients only, IMRT on consecutive days may be used.
62750714|NCT02281474|ACTIVE_COMPARATOR|300mg dosing|This arm will take 300mg of Nilotinib by mouth daily for the 6 month drug period to establish a safe and efficacious dose.
62555250|NCT02776943|EXPERIMENTAL|Mesenchymal stem cell treatment|Umbilical Cord Mesenchymal stem cells (UCMSC) expanded and treated for 1-2 weeks. Then administer 5x10\^6 of UCMSC per cm\^2 of the cartilage defect.
62555251|NCT02776943|ACTIVE_COMPARATOR|Hyaluronic acid treatment|Administer hyaluronic acid (30 mg) in a single injection
62555252|NCT04904250|EXPERIMENTAL|Emboshield NAV6|using Emboshield NAV6 distal embolism protection device during CAS
62375401|NCT01677676|ACTIVE_COMPARATOR|Group 2|FP-01.1 (250µg/peptide)
62375402|NCT01677676|ACTIVE_COMPARATOR|Group 3|FP-01.1-Adjuvant (150µg/peptide / 10.8mg)
62375403|NCT01677676|ACTIVE_COMPARATOR|Group 4|FP-01.1-Adjuvant (250µg/peptide / 18mg)
62375404|NCT01677676|ACTIVE_COMPARATOR|Group 1|FP-01.1 (150µg/peptide)
62375405|NCT04022291|EXPERIMENTAL|Biocon Insulin 70/30|0.4 IU/kg Dose per administration, Subcutaneous Route of administration
62375406|NCT04022291|ACTIVE_COMPARATOR|Humulin® 70/30|0.4 IU/kg Dose per administration, Subcutaneous Route of administration
62375407|NCT03741140|OTHER|medial frontal stroke|20 patients (up to 10 patients can be replaced) with a stroke in the medial frontal lobe will be included in this arm, and will undergo motivation phenotyping.
62375408|NCT03741140|OTHER|lateral frontal stroke|20 patients (up to 10 patients can be replaced) with a stroke in the lateral frontal lobe will be included in this arm, and will undergo motivation phenotyping.
62375409|NCT03741140|OTHER|Healthy participants|20 healthy participants (up to 10 healthy participants can be replaced) will be included in this arm, and will undergo motivation phenotyping.
62555253|NCT04904250|ACTIVE_COMPARATOR|SpiderFX|using SpiderFX distal protection device during CAS
62555254|NCT03811691|OTHER|1.5 Tesla MRI Scan|Subjects will undergo 1.5T MRI exam
62555255|NCT03811691|OTHER|3 Tesla MRI Scan|Subjects will undergo 3T MRI exam
62555256|NCT03532529||experiencing the composit outcome|"Average values of LV longitudinal strain\^ (Midesophageal 4 chamber view) in patients who developed the composite outcome including the following outcomes of interest:~* death within 30 days from VA ECMO liberation~* the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation~  o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal~* heart transplantation within 30 days from VA ECMO liberation"
62555257|NCT03532529||not experiencing the composit outcome|"Average values of LV longitudinal strain\^ (Midesophageal 4 chamber view) in patients who did not develop the composite outcome including the following outcomes of interest:~* death within 30 days from VA ECMO liberation~* the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation~  o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal~* heart transplantation within 30 days from VA ECMO liberation"
62375410|NCT01453686|EXPERIMENTAL|Hydrocortisone 1%|
62375411|NCT01453686|EXPERIMENTAL|Clobetasol Propionate 0.05%|
62375412|NCT00777686||MRI/MRS Scanning|Magnetic resonance imaging with magnetic resonance spectroscopy (MRI/MRS Scanning)
62375413|NCT04759612|EXPERIMENTAL|Self-Action Observation (s-AO Group)|Participants will watch their own actions during an upper extremity functionality test.
62375414|NCT04759612|EXPERIMENTAL|Action Observation (AO Group)|Participants will watch another person's actions during an upper extremity functionality test.
62375415|NCT04371913|OTHER|Radiation Therapy|Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for RT naïve patients at New York Presbyterian using External Beam Radiation Therapy (EBRT).
62555258|NCT01050439|EXPERIMENTAL|UDAlloSCT + Therapy|This is a non-randomized study to test the safety and response of unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT) with either myleoablative (full intensity) or reduced intensity conditioning therapy in patients with selected malignant and non-malignant disorders. UDAlloSCT has been performed in both adults and children as an alternative transplant for patients who lack and HLA-matched family donor in both malignant and non-malignant disease with varying degrees of response.
62555259|NCT04167553|EXPERIMENTAL|HM15136|
62555260|NCT04167553|PLACEBO_COMPARATOR|Placebo|
62375416|NCT05870397|PLACEBO_COMPARATOR|Recheck time is at 4 to 6 weeks after the eradication therapy|All cases are administered the same eradication regimen: amoxicillin 1000 mg, clarithromycin 500mg, rabeprazole 10mg, and colloidal bismuth 200 mg each given twice a day for 14 days. Urea breath tests were administered at 4 to 6 weeks( as guildeline suggested) after the treatment.
62375417|NCT05870397|ACTIVE_COMPARATOR|Recheck time is at 6 to 8 weeks after eradication therapy|All cases are administered the same eradication regimen: amoxicillin 1000 mg, clarithromycin 500mg, rabeprazole 10mg, and colloidal bismuth 200 mg each given twice a day for 14 days. Urea breath tests were administered at 6 to8 weeks after the treatment.
62375418|NCT05870397|ACTIVE_COMPARATOR|Recheck time is at 8 to 10 weeks after eradication therapy|All cases are administered the same eradication regimen: amoxicillin 1000 mg, clarithromycin 500mg, rabeprazole 10mg, and colloidal bismuth 200 mg each given twice a day for 14 days. Urea breath tests were administered at 8 to 10 weeks after the treatment.
62567444|NCT01660633|OTHER|High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)|Subjects will receive only High-Dose Melphalan HCL for Injection (Propylene Glycol-free) at 200mg/m2 (100mg/m2/day for two days).
62375419|NCT04773964|EXPERIMENTAL|MET642 high dose|
62555261|NCT01776710|EXPERIMENTAL|Structured education|The structured education intervention will comprise a 3-hour education workshop delivered by two trained facilitators and a follow-up telephone call 2 weeks later. The aims of the education programme are to enhance patients' understanding of peripheral arterial disease and intermittent claudication, and to support patients in increasing their daily walking activity. Key behaviour change techniques that will be incorporated will include goal setting, action planning, barrier identification/problem solving, prompt review of behavioural goals, prompt self-monitoring of behaviour, and instructions on how to perform the behaviour.
62555262|NCT01776710|NO_INTERVENTION|Standard care control|Standard care will consist of general advice to increase walking and an information sheet on peripheral arterial disease, plus a consultation with a Consultant Vascular Surgeon.
62555263|NCT05570864||Study group (with CS)|A population of patients acquired from multiple national registries aged \> 18 years, admitted for ACS without CS and proceeding to coronary angiography who developed cardiogenic shock (CS).
62567445|NCT00916669|ACTIVE_COMPARATOR|Group A|Cisplatin and Etoposide
62750715|NCT01175434|EXPERIMENTAL|School-Based Medication Group|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse will begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
62750716|NCT01175434|NO_INTERVENTION|Usual Care Group|Children in the Usual Care group will not receive preventive medications delivered at school. These children will continue to receive all of their asthma care from their parents and primary care physicians.
62750717|NCT03117790|EXPERIMENTAL|Dexmedetomidine group|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
62750718|NCT03117790|PLACEBO_COMPARATOR|Placebo group|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
62750719|NCT06489158||Benign breast disease|The accuracy of VOCs indicators and ultrasound 4a/4b/4c diagnosis will be compared in determining benign and malignant diseases based on pathological gold standards.
62750720|NCT06489158||Breast Cancer|The accuracy of VOCs indicators and ultrasound 4a/4b/4c diagnosis will be compared in determining benign and malignant diseases based on pathological gold standards.
62750721|NCT04886544|EXPERIMENTAL|Test group|Hyaluronic acid dermal filler at Week 0
62750722|NCT04886544|NO_INTERVENTION|Control group|Remain untreated until Week 26
62750723|NCT04140695|EXPERIMENTAL|Tradipitant|Oral Capsule
62750724|NCT04140695|PLACEBO_COMPARATOR|Placebo|Oral Capsule
62750725|NCT04206254|EXPERIMENTAL|gp96 group|"Patients only receive autologous gp96 vaccination after surgery (do not accept other anti-tumor treatments)~6 times of gp96 vaccination are administered via subcutaneous injection in 25μg doses within 8 weeks after surgery. gp96 is administered once a week."
62750726|NCT04206254|NO_INTERVENTION|Control group|Patients do not accept any anti-tumor treatmentsafter surgery
62750727|NCT05771636|EXPERIMENTAL|Experimental G1 - imagery of planned activity|In this condition, the participant will have to think about 4 activities he will plan to do during the next 2 weeks. He will then complete a questionnaire about all the activities he identified and think about the major obstacle that could prevent him to do each activity, and a solution for each one. Then he will proceed to a mental imagery exercise where he imagines doing the activity as vividly as possible. He then will proceed to go home and repeat the imagery practice every day for the next two weeks, and do the planned activities. He will report in a booklet ratings of the mental imagery exercise and the activities he did.
62375420|NCT04773964|EXPERIMENTAL|MET642 low dose|
62555264|NCT05570864||Control group (without CS)|A population of patients acquired from multiple national registries aged \> 18 years, admitted for ACS without CS and proceeding to coronary angiography who did not develop cardiogenic shock (CS).
62750728|NCT05771636|EXPERIMENTAL|Experimental G2 - imagery of best possible self|In this condition, the participant will first have to do a mental imagery exercise where he imagines his best possible self, having accomplished all his big life goals, as vividly as possible. He will then have to think about 4 activities he will plan to do during the next 2 weeks, in line with the imagery exercise. He will then complete a questionnaire about all the activities he identified. He then will proceed to go home and repeat the imagery practice every day for the next two weeks, and do the planned activities. He will report in a booklet ratings of the mental imagery exercise and the activities he did.
62750729|NCT05771636|ACTIVE_COMPARATOR|Control G3 - activity planification alone|In this condition, the participant will have to think about 4 activities he will plan to do during the next 2 weeks. He will then complete a questionnaire about all the activities he identified. There is no mental imagery exercise in this condition. He then will proceed to go home and receive the assignment to do the planned activities in the course of the next two weeks. He will report in a booklet ratings of the activities he did.
62750730|NCT02163967|OTHER|Dose sequence: Sham, Low, High|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- Sham stimulation; Day 2 -1 milliamp stimulation intensity, Day 3 - 2milliamp stimulation intensity
62750731|NCT02163967|OTHER|Dose sequence: Sham, High, Low|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- Sham stimulation; Day 2 -2 milliamp stimulation intensity, Day 3 - 1milliamp stimulation intensity
62555265|NCT04756661|EXPERIMENTAL|Carbetocin|Patient received 100 mcg of carbetocin intravenous over one minute immediately after delivery of the baby.
62555266|NCT04756661|ACTIVE_COMPARATOR|Oxytocin plus misoprostol|Patient received 10 units of oxytocin IV drip and 400 mcg of misoprostol rectally after anesthesia.
62555267|NCT02015143||Bipolar Disorder|
62555268|NCT02015143||Unipolar Disorder|
62555269|NCT03354598|EXPERIMENTAL|Sulopenem-etzadroxil/probenecid|Sulopenem-etzadroxil/probenecid 500 mg PO twice daily for 5 days
62375421|NCT04773964|PLACEBO_COMPARATOR|MET642 Placebo|
62555270|NCT03354598|ACTIVE_COMPARATOR|Ciprofloxacin|Ciprofloxacin 250 mg PO administered twice daily for 3 days
62555271|NCT00947921|ACTIVE_COMPARATOR|Plasty|Patients treated with restrictive Annuloplasty
62555272|NCT00947921|ACTIVE_COMPARATOR|Prosthesis|Patients treated with valve replacement
62555273|NCT01679990|EXPERIMENTAL|PLX-PAD Low dose|PLX-PAD double low doses
62555274|NCT01679990|ACTIVE_COMPARATOR|PLX-PAD high doses|PLX-PAD double high dose
62555275|NCT01679990|PLACEBO_COMPARATOR|Placebo|Double Placebo doses
62555276|NCT01679990|EXPERIMENTAL|PLX-PAD high dose +Placebo|High dose+Placebo
62555277|NCT05573958|EXPERIMENTAL|Arm A: Rivaroxaban, Clopidogrel, and Aspirin|Rivaroxaban 2.5 mg tablet twice daily orally, Clopidogrel 75 mg tablet once daily orally, and Aspirin 81 mg tablet once daily
62750732|NCT02163967|OTHER|Dose sequence: Low, Sham, High|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 1milliamp stimulation intensity; Day 2 -Sham stimulation; Day 3 - 2milliamp stimulation intensity
62750733|NCT02163967|OTHER|Dose sequence: Low, High, Sham|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 1milliamp stimulation intensity; Day 2 - 2milliamp stimulation intensity; Day 3 - Sham stimulation
62750734|NCT02163967|OTHER|Dose sequence: High, Sham, Low|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 2 milliamp stimulation intensity; Day 2 - Sham stimulation; Day 3 - 1 milliamp stimulation intensity
62750735|NCT02163967|OTHER|Dose sequence: High, Low, Sham|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 2 milliamp stimulation intensity; Day 2 - 1 milliamp stimulation intensity; Day 3 - Sham stimulation
62750736|NCT01748136||Single Arm|CT Scan Arm
62750737|NCT00394251|EXPERIMENTAL|AC --> ABI-007|Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 260 mg/m\^2 ABI-007 (Abraxane) plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
62750738|NCT00394251|EXPERIMENTAL|AC --> Taxol|Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 175 mg/m\^2 Taxol plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
62750739|NCT04485611|EXPERIMENTAL|Prehabilitation|This pilot cohort will undergo an intervention and will be followed for up to 6 months. The study does not include a comparator group.
62750740|NCT06517251|EXPERIMENTAL|Arm-hand BOOST (Aha BOOST)|Aha BOOST consist of 20 one-hour group sessions (spread over 4 weeks, 5 days a week) and one hour of individual therapy per week (divided in two times 30 minutes). This group will receive therapy for the upper extremity.
62750741|NCT06517251|ACTIVE_COMPARATOR|Lower limb BOOST (L-BOOST)|L-BOOST consist of 20 one-hour group sessions (spread over 4 weeks, 5 days a week) and one hour of individual therapy per week (divided in two times 30 minutes). This group will receive therapy for strengthening exercises the lower limbs and general reconditioning.
62750742|NCT05879770||Wire group|Patients who underwent Shouldice inguinal hernia repair using wire.
62555278|NCT05573958|ACTIVE_COMPARATOR|Arm B: Clopidogrel and Aspirin|Clopidogrel 75 mg tablet once daily, and Aspirin 81 mg tablet once daily
62555279|NCT03658044|EXPERIMENTAL|Participation in the internet forum|Other: Patients will be encouraged to participate in an internet forum communicating with other patients at least once per week. Participation in the internet forum
62555280|NCT03658044|ACTIVE_COMPARATOR|No participation in the internet forum|"Placebo Patients will not be able to enter or read in the forum, but will be able to read general information on the webpage where the forum is placed."
62555281|NCT02392585|ACTIVE_COMPARATOR|Single tourniquet|
62750743|NCT05879770||prolene group|Patients who underwent Shouldice inguinal hernia repair using prolene.
62750744|NCT00998673|EXPERIMENTAL|Arm 1|
62750745|NCT00998673|OTHER|Arm 2|
62555282|NCT02392585|ACTIVE_COMPARATOR|Triple tourniquet|
62555283|NCT01710787|EXPERIMENTAL|Kovacaine Mist, 3 sprays unilateral|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
62555284|NCT01710787|EXPERIMENTAL|Tetracaine Only, 3 sprays unilateral|Tetracaine HCl 3%
62555285|NCT01710787|PLACEBO_COMPARATOR|Placebo, 3 sprays unilateral|Placebo
62555286|NCT03561077|EXPERIMENTAL|Mindfulness program|To study the feasibility in France of a mindfulness program with mindfulness-based interventions (MBI's) dedicated for adolescents with chronic pain.
62555287|NCT03610230|EXPERIMENTAL|Monofer|Iron Isomaltoside as a single intravenous dose 1000mg over 60 minutes
62375422|NCT02349776|EXPERIMENTAL|All patients for allograft transplant|For the testimonial part all patients who have received an allograft transplant in the last five years will be eligible for participation if they have capacity to consent and can speak English fluently.
62555288|NCT03610230|ACTIVE_COMPARATOR|Venofer|Iron Sucrose 200mg weekly intravenous infusions over 2 hours for 5 weeks
62555289|NCT03884985|EXPERIMENTAL|Normal Vision|This study examines high-acuity vision, oculomotor behavior recorded using high-resolution eyetracking. Healthy participants are asked to perform different types of visual tasks, ranging from letter identification to judging facial expressions while their eye movements will be recorded with high-precision together with their behavioral performance in the task.
62555290|NCT01598961|ACTIVE_COMPARATOR|TOF count-guided group|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
62375423|NCT03938558|EXPERIMENTAL|Dance intervention group|"* Dancers at beginners level~* Dancers at advanced level"
62375424|NCT03938558|ACTIVE_COMPARATOR|Art intervention group|"* Paint artists~* Word artists~* Film artists~* Photographers"
62375425|NCT04412668|EXPERIMENTAL|Efzofitimod 1 mg/kg|Participants will receive single dose of efzofitimod 1 milligrams/kilograms (mg/kg) IV infusion on Day 1.
62375426|NCT04412668|EXPERIMENTAL|Efzofitimod 3 mg/kg|Participants will receive single dose of efzofitimod 3 mg/kg IV infusion on Day 1.
62375427|NCT04412668|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to efzofitimod IV infusion on Day 1.
62555291|NCT01598961|ACTIVE_COMPARATOR|T1/Tc amplitude group|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
62555292|NCT01598961|EXPERIMENTAL|No neuromuscular blockade group|to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
62555293|NCT04104178|ACTIVE_COMPARATOR|Clindamycin|600 mg clindamycin, 3 times daily for 10 days, orally
62555294|NCT04104178|PLACEBO_COMPARATOR|Placebo|Arm consumes placebo capsules identical to clincamycin capsuls from the other arm,3 times daily for 10 days, orally
62555295|NCT04728802|ACTIVE_COMPARATOR|Proxalutamide + Usual Care|Proxalutamide + usual care as determined by care provider
62555296|NCT04728802|PLACEBO_COMPARATOR|Placebo + Usual Care|Placebo + usual care as determined by care provider
62555297|NCT04262648|EXPERIMENTAL|Treatment|
62375428|NCT03793790|EXPERIMENTAL|Group 1|Conditioning nocebo effects on pain with a partial reinforcement schedule (induction) and counterconditioning of the previously induced nocebo effect (attenuation).
62375429|NCT03793790|EXPERIMENTAL|Group 2|Conditioning nocebo effects on pain with a partial reinforcement schedule (induction) and extinction of the previously induced nocebo effect (attenuation).
62375430|NCT03793790|EXPERIMENTAL|Group 3|Conditioning nocebo effects on pain with a continuous reinforcement schedule (induction) and counterconditioning of the previously induced nocebo effect (attenuation).
62375431|NCT03793790|EXPERIMENTAL|Group 4|Conditioning nocebo effects on pain with a continuous reinforcement schedule (induction) and extinction of the previously induced nocebo effect (attenuation).
62375432|NCT03793790|SHAM_COMPARATOR|Group 5|Sham conditioning of nocebo effects on pain (induction) and extinction (attenuation).
62375433|NCT00510575|ACTIVE_COMPARATOR|1|Subjects in this arm will receive the 5.5mm stainless steel instrumentation rod.
62750746|NCT04127357|OTHER|A - Control|Brushing with 1450 ppm fluoride toothpaste.
62375434|NCT00510575|ACTIVE_COMPARATOR|2|Subjects in this arm will receive a 6.35mm stainless steel instrumentation rod.
62375435|NCT02332876|EXPERIMENTAL|Exercise Intervention|This arm will receive a 12-week individually tailored phone and email-based exercise program.
62375436|NCT02332876|ACTIVE_COMPARATOR|Wellness Waitlist Control|This arm will receive emails on the same schedule as the exercise arm, that cover a variety of health and wellness topics. At the end of the 12 weeks, participants will be able to start the exercise program.
62375437|NCT01674972||NAFLD|Patients with biopsy proven NAFLD
62375438|NCT01674972||Control|Matched healthy control subjects
62750747|NCT04127357|EXPERIMENTAL|B - Test|Resin sealing (FluroShield, Dentsply, Brazil).
62750748|NCT05179668|EXPERIMENTAL|Intervention arm|Hemodialysis patients receiving dapagliflozin 10 mg once daily
62750749|NCT05179668|PLACEBO_COMPARATOR|Placebo|Hemodialysis patients receiving placebo oral tablet once daily
62750750|NCT06604286|ACTIVE_COMPARATOR|8 mg IM dexamethasone injection into the masseter muscle|"Group 1 (Masseter Injection) (n=20): 8 mg IM dexamethasone injection into the masseter muscle of the patients in this group was performed.~Dexamethasone injection in group 1 was made into the masseter muscle. Injection; The margo anterior of the mandible was palpated and horizontally parallel to the occlusal level of the mandibular second molar tooth and 1 cm behind the margo anterior towards the mandibular ramus. Bone contact was not taken during the injection and the injection was made by taking negative aspiration.Similar to the mandibular anesthesia technique"
62750751|NCT06604286|ACTIVE_COMPARATOR|8 mg IM dexamethasone injection into the pterygomandibular cavity|"Group 2 (Pterygomandibular Space Injection) (n=20): 8 mg IM dexamethasone injection into the pterygomandibular cavity of the patients in this group was performed.~The injection given to Group 2 was directed to the region between the margo anterior of the mandible and the raphe pterygomandibularis, 1 cm above the occlusal level of the mandibular 2nd molar tooth, and the direction of the syringe from the incisal top of the opposing mandibular canine tooth to this region, and then entering the pterygomandibular cavity. Bone contact was not taken during the injection and the injection was made by taking negative aspiration"
62750752|NCT00831740|EXPERIMENTAL|Speech Therapy|
62750753|NCT00831740|ACTIVE_COMPARATOR|ACT NoW Visitor|
62555298|NCT04262648|PLACEBO_COMPARATOR|Control|
62750754|NCT00945529|NO_INTERVENTION|No Intervention/ historical control group|historical controls group of patients who did not receive iNO.
62750755|NCT00945529|EXPERIMENTAL|Intervention|Prospective group who received iNO.
62750756|NCT01465217|EXPERIMENTAL|text message medication reminders|
62750757|NCT01465217|NO_INTERVENTION|control|
62555299|NCT00525980|EXPERIMENTAL|Group 1: Written Materials|One group asked to read educational materials.
62555300|NCT00525980|EXPERIMENTAL|Group 2: Computer Program Only|Group 2 use an educational computer program to learn about breast cancer risk and genetic testing without guidance.
62555301|NCT00525980|EXPERIMENTAL|Group 3: Computer Program + Promotora|Group 3 use the computer program with the guidance of a promotora.
62750758|NCT03761888||Labetalol|Patients who will receive labetalol in IV route in first intention
62750759|NCT03761888||Nicardipine|Patients who will receive nicardipine in IV route in first intention
62750760|NCT04762043|EXPERIMENTAL|Experimental and Reference Devices for Communication|"Each participant listens to speech produced by an experimental (MyoVoice) and reference (electrolarynx) systems that are used to communicate. Participants rate the naturalness of the speech produced from each device (audio files presented in a randomized order). Duration: 30 mins to 1 hour."
62555302|NCT03804957|ACTIVE_COMPARATOR|CT-guided core needle biopsy (CNB)|18 gauge ct-guided lung biopsy
62555303|NCT03804957|EXPERIMENTAL|CNB followed by ABPI.|17 gauge coaxial needle for a 18g ct-guided lung biopsy followed by autologous blood patch injection
62555304|NCT00961857|ACTIVE_COMPARATOR|Treatment A|Individual Tablets of 50 mg sitagliptin and 500 mg metformin
62555305|NCT00961857|EXPERIMENTAL|Treatment B|Sitagliptin/metformin 50 mg/500 mg tablet
62750761|NCT04762043|NO_INTERVENTION|Development of Speech Corpora|Each participant produces a list of speech tasks that include syllables, phrases, reading passages, and open-ended questions using the MyoVoice system. Myovoice pitch and loudness recognition accuracy of speech is evaluated. Duration: 30 mins to 2 hours.
62750762|NCT06443177|EXPERIMENTAL|Spinal Cord Stimulation|Participants randomized to receive temporary electrode inserted through the skin into the epidural space of participants upper back/lower neck.
62750763|NCT06443177|SHAM_COMPARATOR|Sham Comparator|Participants randomized to not receive temporary electrode.
62375439|NCT03968211|EXPERIMENTAL|Vaccine|Subjects who meet enrollment criteria will be administered a single intramuscular dose of the Salmonella typhi polysaccharide vaccine
62750764|NCT03846726||observation group|Pathologically confirmed stage II/III rectal adenocarcinoma patients who received neoadjuvant chemoradiotherapy followed by a clinical complete response, and refused surgery but went on with the watch and wait approach.
62750765|NCT03846726||surgery group|Pathologically confirmed stage II/III rectal adenocarcinoma patients who received neoadjuvant chemoradiotherapy followed by a clinical complete response, and received radical resection.
62750766|NCT05401695|NO_INTERVENTION|The historical control group|The historical control group was composed of patients treated septic shock between May 2019 and May 2021. They was received routine treatment for septic shock including intravenous fluid resuscitation, antibiotics, removal of source of infection and inotropic drugs within 6 hours after the diagnosis of sepsis.
62750767|NCT05401695|ACTIVE_COMPARATOR|The HA-treated group|The HA-treated group will be enrolled between July 2021 and May 2022. This group included children with sepsis, who were admitted to our PICU during the study period. All children initially received routine treatment for septic shock as the historical control group. An HA330 disposable hemoperfusion cartridge (HA330; Jafron, Zhuhai City, China) was used with a continuous renal replacement therapy (CRRT) machine (Aquarius® or Primaflex®) in this intervention group.
62750768|NCT02349191|EXPERIMENTAL|Interventional cohort|Omental transposition for mild Alzheimers Disease
62750769|NCT04138914|EXPERIMENTAL|Focal Cryotherapy|Focal Cryotherapy using 2 freeze-thaw cycles
62750770|NCT05609877|ACTIVE_COMPARATOR|Fentanyl group|"Patients will receive 0.5-1 mcg/kg fentanyl intravenously as pre-procedure analgesia for Less Invasive Surfactant Administration (LISA).~The staff will perform LISA using standard pre- and post-procedure care, including non-pharmacological treatment and the use of atropine, caffeine, and naloxone at the clinician's discretion, based on local protocols and guidelines. All medications will be registered."
62750771|NCT05609877|SHAM_COMPARATOR|Saline group|"Patients will receive a placebo (isotonic saline) instead of pre-procedure analgesia for Less Invasive Surfactant Administration (LISA).~The staff will perform LISA using standard pre- and post-procedure care, including non-pharmacological treatment and the use of atropine, caffeine, and naloxone at the clinician's discretion, based on local protocols and guidelines. All medications will be registered."
62750772|NCT05087927||Focus Group|There will be 4 focus groups of up to 12 women in each focus group.
62750773|NCT05087927||Survey Group|There will be up to 200 women who complete the survey for this study.
62750774|NCT02520258|EXPERIMENTAL|Aspartame Consumers - Cohort 1|"Experimental Group/Arm~Phase I - Questionnaires and fasting oral glucose tolerance test (OGTT).~Phase II - (If OGTT results are abnormal, participants will be invited to participate in Phase II) Five (5) week study phase with Prudent Metabolic Diet and Intervention of diet soda containing aspartame only; Week 1: Prudent Metabolic Diet and 36oz diet soda po daily, Week 2-4: Prudent Metabolic Diet and no diet soda, Week 5: Prudent Metabolic Diet and 36 oz diet soda po daily."
62375440|NCT01919086|EXPERIMENTAL|Patients with Multiple Myeloma|This is a phase II, single center clinical trial designed to evaluate the response rate and toxicity of a response-adapted, sequential therapy, using bortezomib and dexamethasone, followed by the addition of lenalidomide in non-responders, in patients with untreated MM.
62375441|NCT01336257|EXPERIMENTAL|Electronic Reminder|alert from SEBASTIAN decision support system
62375442|NCT01336257|NO_INTERVENTION|control|
62375443|NCT03729908|EXPERIMENTAL|Animal assisted mindfulness based intervention|"The intervention is the AAMI. Trained animals that live in the Therapie-Tiergarten of REHAB Basel will function as therapy animals. Trained psychologists will lead the AAMI."
62375444|NCT03729908|ACTIVE_COMPARATOR|Anti-stress program|The active control intervention consists of the same program, however without the inclusion of animals (Anti-Stress program, ASP).
62375445|NCT00638274|ACTIVE_COMPARATOR|Air|Air 3 ml used to identify epidural space
62750775|NCT02520258|ACTIVE_COMPARATOR|Aspartame Naive Participants - Cohort 2|"Control Group/Arm~Phase I - Questionnaires and fasting oral glucose tolerance test (OGTT).~Phase II - Not applicable for this cohort."
62750776|NCT02342717|EXPERIMENTAL|Reference|single dose BI 425809
62750777|NCT02342717|EXPERIMENTAL|Test|multiple doses of Itraconazole + single dose BI 425809
62750778|NCT05721365||Pre-Infusion|Participants prior to commencing Adoptive Cell Therapy (ACT).
62750779|NCT05721365||Acute|Participants either receiving ACT or up to 30 days post treatment.
62750780|NCT05721365||Sub-acute|Up to 12 months post ACT.
62750781|NCT05721365||Long term follow up|From 12 months post ACT onwards
62750782|NCT06606938|EXPERIMENTAL|Faecal Microbiota Transplantation|FMT will be reconstituted from healthy donor's stool
62750783|NCT06606938|SHAM_COMPARATOR|Placebo|Subjects will receive 0.9% sodium chloride solution (normal saline) as placebo identical looking with FMT
62750784|NCT06581614||prospective group|Patients who have lost their second molar, are scheduled to undergo single-implant reconstruction at the Prosthodontics Department of National Taiwan University Hospital, and do not have any major physical or mental health conditions
62750785|NCT06581614||retrospective group|Patients who have lost their second molar, have undergone single-implant-supported fixed restoration reconstruction at the Prosthodontics Department of National Taiwan University Hospital, and do not have any major physical or mental health conditions.
62750786|NCT06009237|EXPERIMENTAL|Part 1: Han-Chinese Participants ABBV-903|Han-Chinese participants will receive a single dose of ABBV-903.
62750787|NCT06009237|EXPERIMENTAL|Part 1: Japanese Participants ABBV-903|Japanese participants will receive a single dose of ABBV-903.
62375446|NCT00638274|ACTIVE_COMPARATOR|Saline|Saline 3 ml used to identify epidural space
62375447|NCT02015104|EXPERIMENTAL|Bacillus Calmette-Guerin (BCG) + PANVAC|Intravesical TICE BCG (50mg) once weekly starting in week 3 for a total of 6 weeks. PANVAC-V 2 x 10\^8 pfu subcutaneous (SQ) at week 0 only; PANVAC-F 1 x 10\^9 pfu SQ at weeks 3, 7, 11, and 15
62375448|NCT02015104|EXPERIMENTAL|Bacillus Calmette-Guerin (BCG) Alone|Intravesical TICE BCG (50mg) once weekly starting in week 3 for a total of 6 weeks
62750788|NCT06009237|EXPERIMENTAL|Part 1: Placebo|Participants will receive a single dose of Placebo for ABBV-903.
62750789|NCT06009237|EXPERIMENTAL|Part 2: Japanese Participants ABBV-903|Japanese participants will receive ABBV-903 daily for 10 days.
62750790|NCT06009237|EXPERIMENTAL|Part 2: Japanese Participants Placebo|Japanese participants will receive placebo daily for 10 days.
62375449|NCT04956237||Tenonian surgery|Hospital recruitment with outpatient surgery without the presence of an anesthesiologist, without loco-regional anesthesia and without intravenous route
62750791|NCT03803670||acute lymphoblastic leukemia patients|We observed within adult patients with ALL three groups of patients: patients without central nervous system (CNS) involvement, patients with manifest CNS involvement and patients with occult CNS involvement.
62375450|NCT04956237||Peribulbar surgery|Gold standard: City recruitment with outpatient surgery with the presence of an anesthesiologist and with loco-regional anesthesia
62375451|NCT05379764|EXPERIMENTAL|Embodiment group|This group this group will view the VR scenario being 'embodied' in the avatar who is experiencing the VR scenario. This implies first persons perspective, agency over the avatar, multi-sensorial integration and co-location.
62750792|NCT06521515||TLP group|Patients were grouped into TLP if they exhibited a tissue-like pattern in any region
62750793|NCT06521515||DBP group|Patients were grouped into DBP if they displayed diffuse B-lines and shred signs in most regions.
62750794|NCT05755256|EXPERIMENTAL|Probiotic|The product contains the probiotic strain and no other ingredients.
62750795|NCT05755256|PLACEBO_COMPARATOR|Placebo|The control product is a placebo with the same characteristics of appearance and packaging as the tested product.
62750796|NCT01646645|EXPERIMENTAL|Group I|This is a single-arm non-randomized single institution phase 2 trial, designed to evaluate the therapeutic activity of CMVpp65-CTLs generated from seropositive HSCT donors when adoptively transferred into transplant recipients with persistent CMV infection or viremia. Patients eligible for this trial will be consenting recipients of related or unrelated HSCT who have an active CMV infection or persistent CMV viremia for ≥ 2 weeks despite treatment with anti-viral agents or who cannot be maintained on anti-viral therapy due to treatment related toxicity.
62750797|NCT03806556|EXPERIMENTAL|Tranexamic Acid|Doses will be given intravenous (IV). Doses are administered every 8 hours or three times daily (TID) per the discretion of the treating investigator. TXA dose will be 10mg/kg, diluted in normal saline to a total volume of 15 milliliters (mL).
62750798|NCT03806556|PLACEBO_COMPARATOR|Placebo|Doses will be given intravenous (IV). Doses are administered every 8 hours or TID per the discretion of the treating investigator. Normal saline will be administered at a total volume of 15mL.
62750799|NCT05120973||A|Tc-ICG in the prostate (SN procedure) and fluorescein unlilateral in leg or abdominal wall
62750800|NCT05120973||B|Free ICG bilateral in the abdominal wall
62750801|NCT04972708||Bipolar Disorder|100 patients after COVID-19 infection 100 patients without COVID-19 infection
62750802|NCT04972708||Healthy controls|100 controls after COVID-19 infection 100 controls without COVID-19 infection
62750803|NCT04303078|EXPERIMENTAL|Children with Cerebral Palsy (Cases)|Children meeting inclusion/exclusion criteria with a diagnosis of cerebral palsy.
62750804|NCT04303078|OTHER|Typically Developing Children (Controls)|Children meeting inclusion/exclusion criteria without a diagnosis of cerebral palsy or other condition.
62750805|NCT03692377||Children Aged 2-6|Children 2 to 6 years of age who are arriving with a guardian to the Emergency Department with a low acuity condition (Canadian Triage scale (CTAS) 4 or 5) and are waiting to be seen by the doctor, or are waiting for test results.
62567446|NCT00916669|EXPERIMENTAL|Group B|Cisplatin and etoposide, plus low-dose enoxaparin sodium
62375452|NCT05379764|SHAM_COMPARATOR|observation group|This group will view the VR scenario from a third persons perspective , as an observer.
62375453|NCT03773601|EXPERIMENTAL|Athletes|Athletes will undergo a 4-days sleep monitoring with the use of the Sleep Profler. At the same time, they will fill the Total Quality of Recovery (TQR) scale and the Pittsburgh Sleep Quality Index (PSQI).
62375454|NCT03692195|EXPERIMENTAL|Week WHOOP is worn|Participants will wear the WHOOP strap 2.0 either 7 days prior to or 7 days after their sleep study.
62375455|NCT03692195|PLACEBO_COMPARATOR|Week WHOOP is not worn|Participants will not wear the WHOOP strap 2.0 either 7 days prior to or 7 days after their sleep study.
62375456|NCT02381262|EXPERIMENTAL|Intervention|"At the 2 week post-surgical visit, subjects will receive and be trained in the use of the Fitbit and data interface and meet with the exercise physiologist or research coordinator to initiate MyLGHealth, lifestyle/activity data collection.~Subsequent data collection time-points correspond with follow-up post-surgical appointments either at each visit or the 2 week, 1 month, 4 month, 8 month or 12 month visit."
62375457|NCT02381262|NO_INTERVENTION|Control|"At the 2 week post-surgical visit, all subjects will then meet with the exercise physiologist or research coordinator to initiate MyLGHealth, lifestyle/activity data collection.~Subsequent data collection time-points correspond with follow-up post-surgical appointments either at each visit or the 2 week, 1 month, 4 month, 8 month or 12 month visit.~The control group will receive a current version of the Fitbit device at the end of their completion of the 12 month visit."
62375458|NCT02381262|NO_INTERVENTION|Historical Control|The investigators will extract historical control data from the electronic health record using electronic queries and manual data extraction. Historical controls will have surgery and 12-month follow-up completed prior to the start of the RCT.
62375459|NCT01840280||Carcinoma, Irinotecan onkovis (Irinotecan)|Treatment in mono- or combination therapy with Irinotecan of advanced colorectal carcinoma.
62375460|NCT04849195||Model training and test group|Data set will be split into training group and test group, where training group will be used for model building, and test group for subsequent evaluation and verification.
62555306|NCT00961857|ACTIVE_COMPARATOR|Treatment C|Individual Tablets of 50 mg sitagliptin and 1000 mg metformin
62555307|NCT00961857|EXPERIMENTAL|Treatment D|sitagliptin/metformin 50 mg/1000 mg tablet
62750806|NCT02052336|EXPERIMENTAL|CJ-12420 200 mg + Clarithromycin 500mg|CJ-12420 200mg QD for 5 days + Clarithromycin 500mg BID for 5 days
62750807|NCT02052336|ACTIVE_COMPARATOR|CJ-12420 200mg|CJ-12420 200mg QD for 5 days
62750808|NCT02052336|ACTIVE_COMPARATOR|Clarithromycin 500mg|Clarithromycin 500mg BID for 5 days
62750809|NCT01774253|EXPERIMENTAL|Vismodegib|Vismodegib will be dosed at 150mg-300mg orally (max dose: 300mg) once a day on days 1 to 28 of a 28-day cycle. In the absence of unacceptable toxicity or disease progression, treatment may continue for as long as tolerated.
62750810|NCT02987907|EXPERIMENTAL|treatment group|use dexamethasone 10mg (2ml) I.A. during TACE
62750811|NCT02987907|PLACEBO_COMPARATOR|control group|use normal saline 2ml I.A. during TACE
62750812|NCT01909180|EXPERIMENTAL|Cardiac|Revolution CT Cardiac Imaging Scan
62750813|NCT01909180|EXPERIMENTAL|Body/Extremity|Revolution CT Body and/or Extremity Imaging Scan
62750814|NCT01909180|EXPERIMENTAL|Neuro|Revolution CT Brain and Spinal Cord Imaging Scan
62750815|NCT03438955|EXPERIMENTAL|Cohort A|Administration of omacor soft capsule 4000mg for 16 days, and followed by omacor soft capsule 4000mg and Pritor tablet 40mg in combination for 7 days.
62750816|NCT03438955|EXPERIMENTAL|Cohort B|Administration of Pritor tablet 40mg for 7 days, and followed by Pritor tablet 40mg and Omacor soft capsule 4000mg in combination for 16 days.
61986404|NCT06502236||Control Group|"The present study was conducted with individuals aged 18 to 65 years with cervical disc herniation, who were suffered from neck pain lasting for at least 3 months, had a resting pain between 3-7 according to the Visual Analog Scale \[4\], and could follow the instructions of a physiotherapist. All individuals initially diagnosed as cervical disc lesion either one level or multilevel lesions, as diagnosed by the neurologist and confirmed by MRI imaging. The individuals with disk degeneration without cervical disk herniation, cervical stenosis and cervical spondylosis were excluded. In addition, individuals who had a history of spinal tumor or head trauma, had a spinal deformity or congenital malformation, had a cervical instability and cervical artery dysfunction, underwent any cervical surgery in the preceding 6 months, musculoskeletal disorders and neuromuscular diseases in the upper extremity and shoulders."
62375461|NCT02583464|EXPERIMENTAL|Test-Reference|A new formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).
62375462|NCT02583464|EXPERIMENTAL|Reference-Test|A branded formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (R) followed by a new formulation (T).
62375463|NCT01269827|EXPERIMENTAL|pentoxifylline|
62375464|NCT01269827|PLACEBO_COMPARATOR|placebo|
62375465|NCT02255955|EXPERIMENTAL|550 mg naproxen sodium and 30mg codeine|Preoperatively patients received oral naproxen sodium codeine, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
62555308|NCT05089591|ACTIVE_COMPARATOR|Study eyes|Study eye receives the standard energy dose as recommended by the manufacturer (between 8 and 12J/cm2, in accordance with the manufacturer's recommendations).
62555309|NCT05089591|SHAM_COMPARATOR|Control eyes|The control eye is treated using low energy dose energy (1J/ cm2) as sham treatment, ensuring blinding of the respective patient.
62555310|NCT00214383|EXPERIMENTAL|CHESS + Case Mgt|Case Management (with monthly support calls) and CHESS services were available for a 12 month intervention period. Support calls refer to check in calls by a nurse to the parents to see how the child is doing. CHESS services include access to a website with information on asthma management, discussion groups and a case manager. The website also include a management tool for asthma symptoms check in, and the case manager used the information entered to tailor the homepage to individual clients.
62555311|NCT00214383|NO_INTERVENTION|Control|Control-usual care. Usual care refers to the manner in which clients generally manage their asthma.
62555312|NCT03454503||First cohort|Newly diagnosed patients
62555313|NCT03454503||Second cohort|Patients switched from reference product (Glivec® )
62555314|NCT03423797|ACTIVE_COMPARATOR|NaF without fTCP|25% AgNO3 solution followed by 5% NaF.
62750817|NCT01310179|EXPERIMENTAL|Ad/PNP and fludarabine monophosphate|Ad/PNP will be injected three times into the tumor over 2 days followed by three daily intravenous infusions of F-araAMP (fludarabine monophosphate). Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
62555315|NCT03423797|EXPERIMENTAL|NaF with fTCP|25% AgNO3 solution followed by 5% NaF with fTCP.
62555316|NCT03099031||Tinzaparin|Patients with objectively confirmed cancer associated venous thromboembolism receiving tinzaparin treatment to prevent recurrence of venous thromboembolism
62555317|NCT02492867|EXPERIMENTAL|Response-driven Adaptive RT|Patients will receive treatment 5 days per week, in once daily fractions, for 30 treatments with dose per fraction individually adapted over the final 9 treatments. Patients may also receive concurrent chemotherapy with Carboplatin and Paclitaxel. Patients may receive consolidation chemotherapy (carboplatin and paclitaxel) or immunotherapy (durvalumab) at the discretion of the medical oncologist.
62555318|NCT04742829|EXPERIMENTAL|GROUP 1|Patients treated with INTRAVIT® tablets
62555319|NCT04742829|NO_INTERVENTION|GROUP 2|patients who will not take any medical therapy to overlap with the activity described for INTRAVIT® tablets.
62555320|NCT01130662|EXPERIMENTAL|Decitabine Midostaurin combination|
62555321|NCT01564043|EXPERIMENTAL|website and pedometer|
62555322|NCT05839314|EXPERIMENTAL|Huaier group|Patients will take Huaier granule and renin-angiotensin-aldosterone system inhibitors (RASI).
62750818|NCT03554057||Intervention Group|All low-risk patients referred for invasive coronary angiography through the Hamilton General Hospital's Heart Investigation Unit Triage will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification with CCTA at HHS and NHS as an alternative to upfront invasive angiography.
62555323|NCT05839314|ACTIVE_COMPARATOR|Ciclosporin soft capsules group|Patients will take Ciclosporin soft capsules and RASI.
62555324|NCT00681421|EXPERIMENTAL|A|
61986405|NCT01888796|ACTIVE_COMPARATOR|Linagliptin|Linagliptin 5 mg (tablets) once daily for 6 month
62375466|NCT02255955|ACTIVE_COMPARATOR|300 mg paracetamol and 30 mg codeine|Preoperatively patients received oral paracetamol codeine, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
62375467|NCT02255955|PLACEBO_COMPARATOR|Placebo|Preoperatively patients received oral placebo tablet, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
62375468|NCT05855421|EXPERIMENTAL|Experimental: Specific Auricular Acupuncture|12 sessions in 6 weeks, 6 ear points of Chinese Tradicional Medicine - liver, kidney, shenmen, subcortex, heart and lung, with a semi-permanent needle (0,2x2,5mm). Participants will be instructed to stimulate the area 3 times a day.
62375469|NCT05855421|SHAM_COMPARATOR|Inespecific Auricular Acupuncture|12 sessions in 6 weeks, 6 ear points not related to chinese specific points - cheek, outer ear, 4 points non-reactive on the ear helix, with a semi-permanent needle (0,2x1,0mm). Participants will be instructed to stimulate the area 3 times a day.
62391528|NCT04169620|PLACEBO_COMPARATOR|variable dry land|These sessions consisted of group sessions of supervised training lasting 45 minutes each. These comprised a 10-minute warm-up that included exercises for gait, trunk mobility and exercises involving the upper and lower limbs. The central part of the sessions consisted of 30-40 minutes of strength training and aerobic exercises, both individual and in groups. Each session was performed with a specific intensity goal, in order to end with a cooling down period, comprising 20 minutes of functional exercises based on activities of daily living, balance exercises, facial muscle exercises, proprioceptive exercises, muscle relaxation and stretching.
62555325|NCT04749225||45° group|Uses the video stylet with 45 degree(The tip of the trachway in 45°-55°) to assist the nasotracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
62555326|NCT04749225||70° group|Uses the video stylet with 70 degree(The tip of the trachway in 60°-70°)to assist the nasotracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
62555327|NCT04749225||90° group|Uses the video stylet with 90 degree(The tip of the trachway in 80°-90°)to assist the nasotracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
62555328|NCT02801123|EXPERIMENTAL|Preference: MBCR (im)|Individuals with a preference for 'Mindfulness-Based Cancer Recovery (MBCR)' randomized to immediate treatment
62555329|NCT02801123|EXPERIMENTAL|Preference: TCQ (im)|Individuals with a preference for 'Tai Chi/Qigong (TCQ) for Cancer Patients' randomized to immediate treatment
62555330|NCT02801123|ACTIVE_COMPARATOR|Preference: MBCR (wl)|Individuals with a preference for 'Mindfulness-Based Cancer Recovery (MBCR)' randomized to waitlist
62555331|NCT02801123|ACTIVE_COMPARATOR|Preference: TCQ (wl)|Individuals with a preference for 'Tai Chi/Qigong (TCQ) for Cancer Patients' randomized to waitlist
62391529|NCT01642823||retinablastoma tumor tissue|
62391530|NCT05487807|NO_INTERVENTION|Standard of Care|This is the baseline group receiving advice to quit.
62555332|NCT02801123|EXPERIMENTAL|No Preference: MBCR (im)|Individuals with no preference randomized to 'Mindfulness-Based Cancer Recovery (MBCR)' - immediate
62555333|NCT02801123|EXPERIMENTAL|No Preference: TCQ (im)|Individuals with no preference randomized to 'Tai Chi/Qigong (TCQ) for Cancer Patients' - immediate
62555334|NCT02801123|ACTIVE_COMPARATOR|No Preference: MBCR (wl)|Individuals with no preference randomized to 'Mindfulness-Based Cancer Recovery (MBCR)' - waitlist
62555335|NCT02801123|ACTIVE_COMPARATOR|No Preference: TCQ (wl)|Individuals with no preference randomized to 'Tai Chi/Qigong (TCQ) for Cancer Patients' - waitlist
62555336|NCT02174627|EXPERIMENTAL|Roxadustat|
62555337|NCT02174627|PLACEBO_COMPARATOR|Placebo|
62555338|NCT00981487|EXPERIMENTAL|Fed|A single oral dose of EUR-1025 (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The Ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast.
62555339|NCT00981487|EXPERIMENTAL|Fasting|A single oral dose of EUR-1025 (1 x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.
62555340|NCT04688645|EXPERIMENTAL|Balanced crystalloid solution|Balanced crystalloid solution - Plasmalyte.
62750819|NCT03554057||Control Group|Intervention sites will act as their own controls: outcomes of all eligible patients in the 24-months prior to the implementation of the intervention will be assessed from a routinely collected health administrative database. Eligible patients not undergoing CCTA (patient or physician refusal, or CCTA not available) will be captured and included in the control group as part of a sensitivity analysis during the intervention period
62750820|NCT06511674|EXPERIMENTAL|Cancer patients|500 cancer patients: 100 women with breast cancer, 100 women with gynecological cancer, 150 patients with lung cancer (100 men, 50 women) and 150 patients with colorectal cancer (100 men, 50 women).
62555341|NCT04688645|ACTIVE_COMPARATOR|Normal saline|0.9% sodium chloride solution.
62750821|NCT06511674|EXPERIMENTAL|Healthy volunteers controls|125 healthy control volunteers from the volunteer database
62750822|NCT02105844||Atrial Fibrillation|Cohort Study on patients with atrial fibrillation in Switzerland
62750823|NCT01685801|EXPERIMENTAL|Ivacaftor, Placebo, Ivacaftor, Placebo (IPIP)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and Cycle 2 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
62750824|NCT01685801|EXPERIMENTAL|Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and Cycle 2 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
62555342|NCT04708704|EXPERIMENTAL|Erythrosine, prepared in drinking water|One point-of-use technology in development that has demonstrated potential for inactivating viruses in drinking water is the application of an edible photosensitizing dye to the water for disinfection. When exposed to sunlight, the photosensitizing dye produces singlet oxygen, a reactive oxygen species capable of inactivating a wide range of viruses. Erythrosine, an FDA-approved dye, has proven its ability to disinfect drinking water, achieving 4-log inactivation of bacteriophage MS2 in under 10 minutes of sunlight exposure. Furthermore, the dye photobleaches upon exposure to light, and the accompanying distinct color change (e.g., red to transparent) occurs at a rate comparable to the disinfection, providing a safety indication that disinfection has completed, a much-needed function lacking in other point-of-use technologies.
62555343|NCT03896698|EXPERIMENTAL|TUS treatment|AD patients with TUS treatment
61986406|NCT01888796|PLACEBO_COMPARATOR|Placebo|Placebo (tablets) once daily for 6 month
62555344|NCT03896698|NO_INTERVENTION|Non-TUS treatment|AD patients with Non-TUS treatment
62555345|NCT00428272|EXPERIMENTAL|1|Lexatumumab alone dose escalation
62555346|NCT00428272|EXPERIMENTAL|2|Lexatumumab with interferon - dose escalation
62555347|NCT00428272|OTHER|3|Lexatumumab 10mg/kg with interferon expansion at
62555348|NCT05131672|EXPERIMENTAL|Operative reduction w/ fixation|open reduction and internal fixation (ORIF)
62555349|NCT05131672|ACTIVE_COMPARATOR|Non-operative immobilization|immobilization in a cast without reduction
62555350|NCT01494259|EXPERIMENTAL|Bupivacaine (Treatment) Group|The Symbios GOPump is the Food and Drug Administration-approved delivery device used to infuse the bupivacaine. The pump is attached to catheters placed in the patient's breast reconstruction site. A 10cm long 16-guage needle is provided to aid insertion of the catheter into the patient. The entire catheter will pass through the bore of the introducer needle. A 60cc syringe is used to fill the Symbios GOPump through the fill port. After filling the 60cc syringe with up to 300cc of 0.5% bupivacaine, the syringe is attached to the port and the medication injected into the infusion pump. The steady-flow pressure regulator maintains a constant 6 psi pressure in the outflow chamber ensuring a uniform flow of medication through each catheter inserted into the Symbios GOPump.
62567447|NCT00916669|EXPERIMENTAL|Group C|Cisplatin and etoposide, plus high-dose enoxaparin sodium
62567448|NCT01321749|EXPERIMENTAL|RIPC+stroke secondary prevension|"Procedure/Surgery: Remote Ischemic Preconditioning (RIPC) The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.~Procedure:stroke secondary prevention(Such as Antiplatelet therapy, Cholesterol-lowering therapymaintain blood pressure and blood sugar normal)"
62750825|NCT01685801|EXPERIMENTAL|Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and Cycle 2 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
62750826|NCT01685801|EXPERIMENTAL|Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and Cycle 2 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
62750827|NCT05971030|EXPERIMENTAL|CBS for mPFC and dlPFC|Case series of AD patients who accept CBS for mPFC and dlPFC
62750828|NCT00846417||Case|Patients with ICDs who attend the ICD Support Groups.
62750829|NCT00846417||Control|Patients with ICDs who do not attend the ICD support groups.
62750830|NCT04920630|EXPERIMENTAL|CBT-I|5-weekly Cognitive Behavioral Therapy for Insomnia group therapy sessions conducted virtually.
62750831|NCT04048707|ACTIVE_COMPARATOR|Midodrine/Octreotide|This arm will receive standard of care treatment of midodrine, octreotide, and albumin.
62750832|NCT04048707|EXPERIMENTAL|Angiotensin 2|This arm will receive the experimental treatment of angiotensin 2 infusion and albumin.
62750833|NCT03746600|EXPERIMENTAL|Immediate Intervention Group|"Receives the eight-week intervention, Project TRAC: Tracking and Reducing Alcohol Consumption, immediately upon enrollment. This intervention focuses on skill building and motivational enhancement for reducing alcohol consumption."
62750834|NCT03746600|OTHER|Waitlist Control Group|"Receives the Project TRAC: Tracking and Reducing Alcohol Consumption alcohol reduction intervention after an 8-week, assessment-only period. This 8-wek intervention focuses on skill building and motivational enhancement for reducing alcohol consumption."
62750835|NCT01891799||PMTCT Options Evaluation|All HIV positive pregnant women not on ART engaging in PMTCT services at the study sites will be included. This will include HIV+ women not on ART enrolling in PMTCT services and pregnant women newly testing HIV+ in the ANC. All women will eventually receive the intervention of Option B+ as each clinic transitions from Option A to B+.
62750836|NCT03193814|EXPERIMENTAL|Chemotherapy + Apatinib|chemotherapy regimens include: Folfox (Oxaplatin 85 mg/m2 IV over 2 hours, day 1; Leucovorin 400 mg/m2 over 2 hours, day 1; 5-FU 400 mg/m2 IV bolus on day 1, then 1200mg/m2/day x 2 days; repeat every 2 weeks) or Folfiri (Irinotecan 150-180 mg/m2 IV over 30-90 minutes, day 1; Leucovorin 400 mg/m2 over 2 hours, day 1; 5-FU 400 mg/m2 IV bolus on day 1, then 1200mg/m2/day x 2 days; repeat every 2 weeks)； apatinib 500mg po qd
62567449|NCT01321749|NO_INTERVENTION|stroke secondary prevention|Procedure:stroke secondary prevention(Such as Antiplatelet therapy, Cholesterol-lowering therapymaintain blood pressure and blood sugar normal)
62567450|NCT00514215|EXPERIMENTAL|Sargramostim, Flow Cytometry, Biopsy. Cryosurgery|Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 \& 32 Immunoenzyme technique-Days 1 \& 32 CT guided biopsy-Days 1 \& 32 Cryosurgery-Days 1 and 32
62750837|NCT00918164|EXPERIMENTAL|Healthy adult volunteers|Standard Phase 1 normal healthy adult volunteers, age range 21-55 years and of either sex
62750838|NCT03479177|EXPERIMENTAL|High Intensity Interval Training|The exercise group will participate in a home and telephone-based program consisting of a 12-week high intensity interval training workout (HIIT). The home-based exercise sessions will be prescribed by the program exercise counselor, with a goal to exercise three times per week. The program will be tailored to meet specific fitness and strength needs of the participant. The participant will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. At 12 weeks, participants in both the exercise and wait-list control group will complete online questionnaires. The ActiGraph will be returned to the University of Minnesota research staff via a pre-paid postage envelope.
62750839|NCT03479177|NO_INTERVENTION|Wait-List Control Group|Participants in the wait-list control condition will have the option of receiving the exercise intervention program after completion of the final assessment.
62750840|NCT02154100|EXPERIMENTAL|Tart Cherry|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
62750841|NCT02154100|PLACEBO_COMPARATOR|Placebo|12 weeks tart cherry juice taken in two doses of 240 ml per day.
62750842|NCT05538832|EXPERIMENTAL|Visual Perception Training|Contains targeted visual perception exercises from BrainHQ's suite of cognitive exercises. This training paradigm is designed to improve state estimation processes at the perceptual input level.
62750843|NCT05538832|EXPERIMENTAL|Visual Cognitive Control Training|Contains targeted visual cognitive control exercises from BrainHQ's suite of exercises. This training paradigm is designed to enhance state representation stability of visual information.
62750844|NCT03468816|EXPERIMENTAL|A-B-A|Investigational device is Absorbest moisture sensor in variant A and variant B, placed on the backside of the wound dressing DryMax Extra Soft. Participants performed three dressing changes. They first received variant A, at next dressing change they received variant B, and on the third dressing change they received variant A again. No washout periods.
62750845|NCT03468816|EXPERIMENTAL|B-A-B|Investigational device is Absorbest moisture sensor in variant A and variant B, placed on the backside of the wound dressing DryMax Extra Soft. Participants performed three dressing changes. They first received variant B, at next dressing change they received variant A, and on the third dressing change they received variant B again. No washout periods.
62750846|NCT05347225|EXPERIMENTAL|Nemtabrutinib|Participants receive nemtabrutinib at specified dose orally once daily (QD) until progressive disease (PD) or discontinuation.
62375470|NCT01833026|EXPERIMENTAL|COPD assessment and management recommendations|"Patients with a physician-diagnosed COPD or asthma suspicious for COPD being managed by the physician randomized to the intervention group will perform a spirometry test and provide information regarding their medical history on their initial visit, which is 90 minutes before their doctor's appointment. A letter containing the interpretation of spirometry test results, and recommendations for guideline based therapy based on GOLD guidelines will be available to the primary care doctor at the time of the patient's clinic visit. The doctor may review the results and use his or her own judgment in moving forward with the subject's diagnosis and management. A copy of the spirometry results and assessment based on the GOLD criteria at the time of the test of your subject will be uploaded to his or her electronic health record for future reference.~Outcomes will be assessed every 3 months for up to one year through patient telephone calls and medical chart reviews."
62555351|NCT01494259|PLACEBO_COMPARATOR|Saline (Placebo) Group|The Symbios GOPump is the Food and Drug Administration-approved delivery device used to infuse the saline. The pump is attached to catheters placed in the patient's breast reconstruction site. A 10cm long 16-guage needle is provided to aid insertion of the catheter into the patient. The entire catheter will pass through the bore of the introducer needle. A 60cc syringe is used to fill the Symbios GOPump through the fill port. After filling the 60cc syringe with up to 300cc of normal saline, the syringe is attached to the port and the medication injected into the infusion pump. The steady-flow pressure regulator maintains a constant 6 psi pressure in the outflow chamber ensuring a uniform flow of medication through each catheter inserted into the Symbios GOPump.
62375471|NCT01833026|PLACEBO_COMPARATOR|Usual Care|"Patients with a physician-diagnosed COPD or physician-diagnosed asthma suspicious for COPD being managed by the physician randomized to the usual care group will provide medical history, not initially have a spirometry, and will be observed as usual care.~Outcomes will be assessed every 3 months for up to one year through patient telephone calls and medical chart reviews. At the conclusion of the research study which will be 12 months from the patients' initial visit, patients being managed by the physician randomized to the usual care group will have a spirometry test and these results will not be shared with the doctor or the patients during the study but will be uploaded to the electronic health record after the end of the study for future reference."
62375472|NCT01213511|ACTIVE_COMPARATOR|MECC Group|Patients operated for elective coronary artery bypass grafting with the use of minimal extracorporeal circulation.
62375473|NCT01213511|ACTIVE_COMPARATOR|CECC Group|Group of patients undergoing elective coronary bypass grafting with the use of conventional extracorporeal circulation.
62375474|NCT02453139|EXPERIMENTAL|Exercise group|6 month supervised and home based moderate intensity aerobic exercise programme
62375475|NCT02453139|NO_INTERVENTION|Control|Non-exercising control group receiving usual care
62375476|NCT00374127|EXPERIMENTAL|marijuana blunt|marijuana blunt (0%, 1.8%, or 3.6% THC)
62375477|NCT00374127|EXPERIMENTAL|marijuana cigarette|marijuana cigarette (0%, 1.8%, or 3.6% THC)
62375478|NCT03714256|EXPERIMENTAL|Children 6-17 months|"Device, patient mobility, powered:~Usability of the pediatric mobility device by both parent/guardian and occupational/physiological therapist, performed according to instructions for use at a one time occasion."
62375479|NCT03714256|EXPERIMENTAL|Children 18 - 36 months|"Device, patient mobility, powered:~Usability of the pediatric mobility device by both parent/guardian and occupational/physiological therapist, performed according to instructions for use at a one time occasion."
62375480|NCT00824967|NO_INTERVENTION|1- The reference group|one will take care of the patient in a habitual way: no consultation additional, step of exam on top of that...
62375481|NCT00824967|OTHER|2- The intervention group|Training and valuation of the treating personnel
62375482|NCT02385591|EXPERIMENTAL|Telephone Support|Participants will receive bi-weekly 20 minute telephone calls from a trained professional facilitator offering physical activity advice with the goal of increasing moderate-to-vigorous intensity physical activity.
62555352|NCT05965375||Occasional premature ventricular contractions group|Premature ventricular contractions (PVCs) occur when an electrical impulse originates from an ectopic focus within the ventricle or the interventricular septum, causing premature depolarization of the ventricle before the impulse from the sinoatrial node has reached the ventricle. Occasional PVCs refer to PVCs that occur less than 6 times per minute.
62750847|NCT04907773|OTHER|Potassium measurement|
62750848|NCT03564522||Pulmonary Hypertension|Participants diagnosed with pulmonary hypertension that will undergo a clinically indicated cardiac catheterization and cMRI.
62750849|NCT03564522||Heart Transplant|Successful cardiac transplant recipient without evidence of pulmonary hypertension, that will undergo clinically indicated cardiac catheterization.
62750850|NCT01814098|EXPERIMENTAL|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
62555353|NCT05965375||Frequent premature ventricular contractions group|Premature ventricular contractions (PVCs) occur when an electrical impulse originates from an ectopic focus within the ventricle or the interventricular septum, causing premature depolarization of the ventricle before the impulse from the sinoatrial node has reached the ventricle. Frequent PVCs refer to PVCs that occur more than 6 times per minute.
62555354|NCT05965375||Short runs of ventricular tachycardia group|Premature ventricular contractions (PVCs) occur when an electrical impulse originates from an ectopic focus within the ventricle or the interventricular septum, causing premature depolarization of the ventricle before the impulse from the sinoatrial node has reached the ventricle. Short runs of ventricular tachycardia refer to three or more consecutive PVCs that occur within 30 seconds.
62555355|NCT05965375||Sustained ventricular tachycardia group|Sustained ventricular tachycardia (VT) is defined as ventricular arrhythmia that lasts for at least 30 seconds and has a heart rate exceeding 100 bpm, or requires termination before 30 seconds due to hemodynamic instability.
62555356|NCT05965375||Ventricular fibrillation group|Ventricular fibrillation refers to the complete disappearance of QRS waves, ST segments, and T waves in the ECG, replaced by different shapes, varying amplitudes, and extremely irregular ventricular fibrillation waves.
62555357|NCT02325492|EXPERIMENTAL|Aramchol 400 mg|• One tablet of Aramchol 400 mg and one tablet of Placebo
62555358|NCT02325492|EXPERIMENTAL|Aramchol 600 mg|• One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
62555359|NCT02325492|PLACEBO_COMPARATOR|Placebo|• Two tablet of Aramchol matching placebo.
62555360|NCT06182371|EXPERIMENTAL|Disengagement of the breathing circuit|When the patient's position is changed from the supine position to the lateral decubitus position, the anesthesiologist disengages the breathing circuit.
62555361|NCT06182371|NO_INTERVENTION|Connect the breathing circuit|When the patient's position is changed from the supine position to the lateral decubitus position, the anesthesiologist maintains the normal connection of the breathing line.
62555362|NCT01756183|EXPERIMENTAL|S-1 + Paclitaxel Chemotherapy|"S-1: 60mg twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~Paclitaxel: 150 mg/m2, iv, 3h, at D1"
62555363|NCT02267681|EXPERIMENTAL|Group A|The patients in Group A will be given 100 mcg/kg/min propofol infusion and 10 mcg/kg loading dose of alfentanil and 5 mcg/kg additional bolus of alfentanil whenever FPS (Faces Pain Scale) is greater than 3 or the patients can not tolerate the procedure.
62555364|NCT02267681|EXPERIMENTAL|Group F|The patients in Group F will be given 100 mcg/kg/min propofol infusion and 1 mcg/kg loading dose of fentanyl and 5 mcg/kg additional bolus of fentanyl whenever FPS (Faces Pain Scale) is greater than 3 or the patients can not tolerate the procedure.
62555365|NCT02267681|ACTIVE_COMPARATOR|Group P|Group P is designated as the control group and the patients will be given 100mcg/kg/min infusion and sedation will be achieved via 1 mg/kg propofol loading dose and 0.5 mg/kg propofol additional bolus will be given whenever the patients can not tolerate the procedure or FPS is greater than 3.
62555366|NCT00548639|EXPERIMENTAL|Statin Choice|Statin Choice Decision Aid The provider will introduce the patient to the choice of statins using the decision aid. The patient may make a choice then or defer this choice; in all cases, the patient goes home with the Statin Choice decision aid and pamphlet.
62555367|NCT00548639|SHAM_COMPARATOR|Usual Care|Control Pamphlet the provider meets with the patient to discuss treatment options in the usual fashion.
62555368|NCT01257620|PLACEBO_COMPARATOR|Placebo|Placebo
62555369|NCT01257620|EXPERIMENTAL|Probiotic|Life Start Two
62555370|NCT06203613|EXPERIMENTAL|patients with gastric cancer|Subjects were recruited from the Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
62750851|NCT02609750|EXPERIMENTAL|Structured care & workplace intervention|Through a flow chart the investigators in detail specify the medical and work place interventions (all according to evidence-based guidelines). Red, yellow and blue flags, and motivational factors are identified in a screening investigation. The aim of the screening is to individually tailor the rehabilitation interventions. Physiotherapy interventions are based on a bio-psychosocial and cognitive behavioural therapy perspective. Behavioural medicine treatment principles include careful examination and treatments such as advice to stay active, instructions, OMI, OMT, MDT. The investigators apply interventions based on ergonomics, motivational factors and work place changes according to Convergence Dialogue Meetings (CDM).
62555371|NCT06203613|EXPERIMENTAL|patients with pancreatic cancer|Subjects were recruited from the Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
62555372|NCT02489188||ankle osteoarthritis|patients with ankle osteoarthritis scheduled for arthroplasty
62555373|NCT02489188||knee osteoarthritis|patients with knee osteoarthritis scheduled for arthroplasty
62375483|NCT02385591|EXPERIMENTAL|SMS Support|Participants will receive weekly text messages (3-5 text messages per week) offering physical activity advice with the aim of increasing moderate-to-vigorous intensity physical activity.
62555374|NCT02489188||hip osteoarthritis|patients with hip osteoarthritis scheduled for arthroplasty
62555375|NCT02489188||lumbar spinal stenosis|patients with lumbar spinal stenosis scheduled for lumbar spinal stenosis decompression
62555376|NCT02489188||muscle contracture|patients with functionally limited range of motion at the knee because of muscle contracture scheduled for manual therapy
62750852|NCT02609750|ACTIVE_COMPARATOR|Treatment as Usual|Patients follows the PHCs standard schedule and procedures including the so called rehabilitation guarantee
62750853|NCT05774223|ACTIVE_COMPARATOR|Active iTBS on working memory|Participants will receive active 80% rMT iTBS over the left DLPFC in this arm. The working memory assessments will be performed pre-stimulation and at 0-, 10-, 20-, 30-, and 40-min post-stimulation. The working memory assessment is measured using a 2-minute 3-back task. The fNIRS will monitor the prefrontal hemoglobin change throughout the whole procedure.
62750854|NCT05774223|SHAM_COMPARATOR|Sham iTBS on working memory|Participants will receive sham 80% rMT iTBS over the left DLPFC (by putting the coil perpendicular to the left DLPFC) in this arm. The working memory assessments will be performed pre-stimulation and at 0-, 10-, 20-, 30-, and 40-min post-stimulation. The working memory assessment is measured using a 2-minute 3-back task. The fNIRS will monitor the prefrontal hemoglobin change throughout the whole procedure.
62750855|NCT03267667||obstructive sleep apnea patients|number of 90 patients will be investigated by 2D echocardiography and cardiac MRI to determine the right ventricle function
62555377|NCT02489188||healthy subjects|healthy subjects
62555378|NCT01041144|EXPERIMENTAL|Lifestyle counseling|
62555379|NCT01037452|EXPERIMENTAL|Combination product|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg tablet
62555380|NCT01037452|ACTIVE_COMPARATOR|PPI alone|Lansoprazole
62750856|NCT03267667||healthy volunteers|number of 10 subjects will be investigated by 2D echocardiography and cardiac MRI to determine right ventricular function in healthy persons have risk factors other than cardiac or lung diseases
62750857|NCT01529983|EXPERIMENTAL|Fractional photothermolysis|Fractional photothermolysis (FP) for treatment of photo- damaged skin is an FDA-approved method for treating facial rhytids. Fractionated treatment with 1550-nm laser is a safe, nonsurgical method for improvement of periorbital rhytides, photodamage, and scarring
62750858|NCT01529983|ACTIVE_COMPARATOR|High-intensity focused ultrasound|High-intensity focused ultrasound (HIFUS) is an FDA-approved method for periorbital treatment and nonablative tissue tightening. Ultrasound waves induce a vibration in the tissue, generating heat and increasing the tissue temperature within a focal area. The tissue changes depend on amount of heat and exposure duration. These findings are similar to the thermally induced changes within the skin after CO2 laser fractional ablative treatments.
61986407|NCT02360384|PLACEBO_COMPARATOR|Sham diet|The placebo intervention will be healthy eating advice in patients with irritable bowel syndrome of the alternating subtype for 28 days.
61986408|NCT02360384|ACTIVE_COMPARATOR|Lincalotide|All patients with constipation predominant IBS will receive linaclotide 280mcg po od for 28 days.
61986409|NCT02360384|EXPERIMENTAL|FODMAP diet|The FODMAP diet will be introduced in patients with irritable bowel syndrome of the alternating subtype for 28 days.
62555381|NCT01037452|ACTIVE_COMPARATOR|Antacid alone|Calcium carbonate/magnesium hydroxide
62555382|NCT01037452|PLACEBO_COMPARATOR|Placebo|Placebo
62555383|NCT00894621|EXPERIMENTAL|Norepinephrine|
62555384|NCT00894621|PLACEBO_COMPARATOR|Placebo|
62555385|NCT01410214|EXPERIMENTAL|Erlotinib arm|In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
62555386|NCT01410214|ACTIVE_COMPARATOR|Chemo arm|In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
62555387|NCT00667680|ACTIVE_COMPARATOR|1|anodal tDCS
62555388|NCT00667680|SHAM_COMPARATOR|2|Sham tDCS
62555389|NCT03241641|EXPERIMENTAL|Maintaining TAF monotherapy|- Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 96 weeks
62555390|NCT03241641|ACTIVE_COMPARATOR|Switching from TDF to TAF|"* Tenofovir Disoproxil Fumarate (Viread) Tablet, 300mg, Daily Oral, 48 weeks~* Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 48 weeks"
62555391|NCT03482245|EXPERIMENTAL|Pneumonia: Blue Light|a 12 hours:12 hours light:dark photoperiod cycle of bright (1700 lux) blue (peak 442 nm) enriched light for a total of 3 days after the initial diagnosis and informed consent. The photoperiod is 12 hours: 0800 to 2000. At the transition from light to dark (2000), the blue-enriched light is turned off, and additional blue wavelength light removed with an amber filter.
62555392|NCT03482245|EXPERIMENTAL|Intraabdominal infection: Blue Light|a 12 hours:12 hours light:dark photoperiod cycle of bright (1700 lux) blue (peak 442 nm) enriched light for a total of 3 days after the initial diagnosis and informed consent. The photoperiod is 12 hours: 0800 to 2000. At the transition from light to dark (2000), the blue-enriched light is turned off, and additional blue wavelength light removed with an amber filter.
62555393|NCT03482245|EXPERIMENTAL|Necrotizing Soft Tissue Infection: Blue Light|a 12 hours:12 hours light:dark photoperiod cycle of bright (1700 lux) blue (peak 442 nm) enriched light for a total of 3 days after the initial diagnosis and informed consent. The photoperiod is 12 hours: 0800 to 2000. At the transition from light to dark (2000), the blue-enriched light is turned off, and additional blue wavelength light removed with an amber filter.
62555394|NCT03482245|NO_INTERVENTION|Pneumonia: Ambient Light|a 12 hours:12 hours light:dark photoperiod cycle of the standard white fluorescent ambient light of the hospital for a total of 3 days after the initial diagnosis and informed consent. The photoperiod is 12 hours: 0800 to 2000. At the transition from light to dark (2000), the ambient white lights are turned off.
62555395|NCT03482245|NO_INTERVENTION|Intraabdominal infection: Ambient Light|a 12 hours:12 hours light:dark photoperiod cycle of the standard white fluorescent ambient light of the hospital for a total of 3 days after the initial diagnosis and informed consent. The photoperiod is 12 hours: 0800 to 2000. At the transition from light to dark (2000), the ambient white lights are turned off.
62555396|NCT03482245|NO_INTERVENTION|Necrotizing Soft Tissue Infection: Ambient Light|a 12 hours:12 hours light:dark photoperiod cycle of the standard white fluorescent ambient light of the hospital for a total of 3 days after the initial diagnosis and informed consent. The photoperiod is 12 hours: 0800 to 2000. At the transition from light to dark (2000), the ambient white lights are turned off.
62555397|NCT03482245|EXPERIMENTAL|Infected Joint: Blue Light|a 12 hours:12 hours light:dark photoperiod cycle of bright (1700 lux) blue (peak 442 nm) enriched light for a total of 3 days after the initial diagnosis and informed consent. The photoperiod is 12 hours: 0800 to 2000. At the transition from light to dark (2000), the blue-enriched light is turned off, and additional blue wavelength light removed with an amber filter.
62555398|NCT03482245|NO_INTERVENTION|Infected Joint: Ambient Light|a 12 hours:12 hours light:dark photoperiod cycle of the standard white fluorescent ambient light of the hospital for a total of 3 days after the initial diagnosis and informed consent. The photoperiod is 12 hours: 0800 to 2000. At the transition from light to dark (2000), the ambient white lights are turned off.
62555399|NCT03203122|EXPERIMENTAL|Study group|Patients are randomized to treatment of either right or left side. The other side works as control
62750859|NCT02655523|ACTIVE_COMPARATOR|Bupivacaine+Triamcinolone|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL 40 mg of triamcinolone.
61986410|NCT04828512||normal glucose tolerance (NGT)|In the 75-g OGTT, an FPG level of \< 100 mg/dL or a 120-min PG level of \< 140 was diagnosed as NGT.
61986411|NCT04828512||impaired glucose intolerance (IGT)|In the 75-g OGTT, an FPG level of 100-125 mg/dL (5.6-6.9 mmol/L) or a 120-min PG level of 140-200 mg/dL (7.8-11.1 mmol/L) was diagnosed as IGT.
62555400|NCT03203122|SHAM_COMPARATOR|Comparator Group|Patients are randomized to treatment in either right or left side. The other side works as control
62555401|NCT05093075|EXPERIMENTAL|Treatment Arm|Participants randomized to the Treatment Arm will received 1.0 plasma exchanges daily until discontinuation of vasopressors, death or to a maximum of 5 daily treatments. Solvent detergent plasma (SDP) or frozen plasma (FP) depending on availability will be used as the replacement fluid.
62750860|NCT02655523|ACTIVE_COMPARATOR|Bupivacaine+Dexamethasone|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL 4 mg of dexamethasone.
62750861|NCT02655523|PLACEBO_COMPARATOR|Bupivacaine+Saline|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL of preservative free normal saline.
62750862|NCT01983605|EXPERIMENTAL|Treatment|LAA exclusion with the LARIAT Suture Delivery Device
62750863|NCT01880749|EXPERIMENTAL|RAD001|RAD001 taken by mouth 10mg daily for 10 days before surgery
62750864|NCT01938508|EXPERIMENTAL|Test|Minocycline 100 mg capsules Darier SA Dermatological Laboratories de CV (Micromycin ®).
62555402|NCT05093075|NO_INTERVENTION|Standard of Care Arm|Participants randomized to the Control Arm will receive standard of care for the treatment of septic shock in accordance with local practice and informed by national and international guidelines.
62555403|NCT04677335|EXPERIMENTAL|Nutraceutical|Nutraceutical capsules taken once daily for 12 weeks
62555404|NCT04677335|PLACEBO_COMPARATOR|Control|Placebo capsules taken once daily for 12 weeks
62555405|NCT00033397||Arm A|"Patients receive an injection of gadopentetate dimeglumine and undergo magnetic resonance imaging (MRI) of the breast before initiation, 1-3 days after initiation, and then after completion of neoadjuvant anthracycline-based chemotherapy and prior to surgery. Patients who previously received a taxane also undergo an additional contrast-enhanced MRI scan.~Mammograms and possibly ultrasounds are performed prior to and after chemotherapy (before surgery).~Patients are followed every 6 months for 5 years and then annually for up to 10 years."
62555406|NCT02876341||No chronic antihypertensives|Not on either a chronic β-blocker or ACE-Inhibitor
62555407|NCT02876341||Chronic antihypertensives|On a chronic β-blocker, on chronic ACE-Inhibitor, or on both chronic β-blocker and ACE-inhibitor
62555408|NCT03793764|ACTIVE_COMPARATOR|Group T|At the end of the surgery USG guided TAP block will be performed with 20 mL of 0.25% isobaric bupivacaine.
62555409|NCT03793764|ACTIVE_COMPARATOR|Group Q|At the end of the surgery USG guided QL block will be performed with 20 mL of 0.25% isobaric bupivacaine.
62555410|NCT03793764|NO_INTERVENTION|Group C|In this group no intervention will be performed after the end of operation.
62555411|NCT01927120|EXPERIMENTAL|GVHD Regimen|Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).
62555412|NCT03692507|EXPERIMENTAL|HMB only|Taking HMB supplements three times a day
62750865|NCT01938508|EXPERIMENTAL|Reference|Minocycline 100 mg capsules (Micocin ®) Marketed and distributed by Triax Pharmaceuticals
62750866|NCT02253563|EXPERIMENTAL|Resistance Training|Group performing resistance training.
62750867|NCT02253563|EXPERIMENTAL|Balance Training|Group performing balance training.
62750868|NCT04981366|NO_INTERVENTION|Control group (CTRL)|Patients allocated to this arm will not receive any intervention.
62555413|NCT03692507|EXPERIMENTAL|Protein and HMB|Drinking Ensure Enlive shakes
62555414|NCT03692507|EXPERIMENTAL|Current ERAS (High Protein)|Drinking Ensure surgery shakes + Ensure pre-surgery
62555415|NCT00836407|EXPERIMENTAL|Arm 1: Ipilimumab Alone|Ipilimumab alone
62555416|NCT00836407|EXPERIMENTAL|Arm 2: Ipilimumab + Pancreatic Cancer Vaccine|Ipilimumab + Pancreatic Cancer Vaccine
62567451|NCT04980430||Primary Care and Ophthalmology clinic patients|Participants will be recruited from primary care and ophthalmology clinics in New York City
62750869|NCT04981366|EXPERIMENTAL|Caloric Restriction associated to exercise training plus protein supplementation (CREX+PTN)|Patients allocated to this arm will be submitted to caloric restriction associated with exercise training program plus protein supplementation.
62750870|NCT04981366|PLACEBO_COMPARATOR|Caloric Restriction associated to exercise training plus isocaloric placebo (CREX+PLA)|Patients allocated to this arm will be submitted to caloric restriction associated with exercise training program plus isocaloric placebo.
62750871|NCT06352892|EXPERIMENTAL|Group 1: Maridebart Cafraglutide Dose 1|Participants will receive a single SC lower dose of Maridebart Cafraglutide.
62750872|NCT06352892|EXPERIMENTAL|Group 2: Maridebart Cafraglutide Dose 2|Participants will receive a single SC higher dose of Maridebart Cafraglutide.
62750873|NCT06195969|EXPERIMENTAL|Intervention group|Participants in intervention group will receive the EMI for 4 weeks. Based on the steps of mobile message development recommended by Abroms, et al. , we will develop a message content library and protocol for EMI delivery.
62750874|NCT06195969|NO_INTERVENTION|Control group|The control group will receive instant messages about general stroke management including hypertension management from the Hospital Authority of HK SAR Government website, which is open to the public (https://www21.ha.org.hk/smartpatient/SPW/en-US/Disease-Information/Disease/?guid=29ac1219-3d68-4378-a2bd-09e111da3650), with reminder text messages of importance follow-up surveys.
62750875|NCT05578638|EXPERIMENTAL|aloe Vera group|10 ml of the spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
62750876|NCT05578638|EXPERIMENTAL|rosemary group|10 ml of the spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
62750877|NCT05578638|EXPERIMENTAL|aloe Vera rosemary compound|10 ml of the spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
62750878|NCT05578638|NO_INTERVENTION|control group|
62375484|NCT02385591|ACTIVE_COMPARATOR|Attention-control|Participants will receive telephone-based general nutrition advice.
62555417|NCT04209283|EXPERIMENTAL|Trauma exposed women|"No Intervention: Baseline phase ('A'):~Measurements collected in a daily diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.~Experimental: Intervention phase ('B'):~A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game-play with mental rotation) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a daily diary four times a day following the intervention for the primary outcome (occurrence of intrusive memories of trauma).~Intervention: Behavioral: Brief cognitive intervention"
62750879|NCT04040595|EXPERIMENTAL|Adipocyte measurement|Abdominal fat biopsy
62375485|NCT04132128|EXPERIMENTAL|study|6 meetings with a dietician diabetes educator assimilating simple CC tool
62375486|NCT04132128|OTHER|control|meeting with dietician as needed with regular education of CC
62375487|NCT03552900|ACTIVE_COMPARATOR|App 1 Study group (7cups)|"Participants assigned to this group will be assigned a behavioral intervention, the mobile app (7cups) which allows participants access to direct online social support via the app."
62375488|NCT03552900|ACTIVE_COMPARATOR|App 2 Study Group (Bliss|"Participants assigned to this group will be assigned to a behavioral intervention, the mobile app ( Bliss ) which provides participants an informational app about mental health resources at Harvard."
62391531|NCT05487807|ACTIVE_COMPARATOR|Nicotine Replacement|This group will receive the standard of care and be prescribed nicotine replacement therapy
62391532|NCT05487807|ACTIVE_COMPARATOR|Text Messaging|This group will receive the standard of care and receive text message support
62391533|NCT05487807|ACTIVE_COMPARATOR|Nicotine replacement and text messaging|This group will receive the standard of care, be prescribed nicotine replacement therapy, and receive text message support
62750880|NCT01322399|EXPERIMENTAL|Structural Integration plus usual care|Each subject in this arm will receive ten Structural Integration treatments at intervals of between one and three weeks, and will also receive usual care for chronic low back pain as standard practice at Spaulding Medford Rehabilitation Clinic, which may include pain medication, exercise and physical therapy. Usual care will be provided on average twice weekly for between 3 and 7 weeks, at the discretion of the clinic's medical director
62750881|NCT01322399|ACTIVE_COMPARATOR|Usual care|Each subject in this arm will receive care for chronic low back pain as standard practice at Spaulding Medford Rehabilitation Clinic, which may include pain medication, exercise and physical therapy. Usual care will be provided on average twice weekly for between 3 and 7 weeks, at the discretion of the clinic's medical director
62750882|NCT06102590|EXPERIMENTAL|Individualized RBCT|Requires daily assessment of hemoglobin (Hb) levels. Prescription of RCBT is restricted to patients who present Hb ≤ 9.0 g/dL and O2ER ≥ 30%. If O2ER \< 30%, transfusion will take place only when Hb falls below 7.0 g/dL. Further O2ER measurements during the day in this group are allowed, and the clinician should not be blinded of the results. To tolerate Hb levels below 7.0 g/dL with O2ER \< 30% remains a clinical decision, documented in the CRF. Transfusion with Hb below 6.0 g/dL is mandatory
62750883|NCT06102590|ACTIVE_COMPARATOR|Control group|Requires daily assessment of hemoglobin levels. Prescription of RCBT is restricted to patients who present Hb ≤ 7.0 g/dL, despite of O2ER values. Indeed, O2ER calculation takes place at least once daily in this group but does not interfere with clinical decision to prescribe RBCT. A liberal transfusion threshold (i.e. 9.0 g/dL) is still possible in critically ill adults with acute coronary syndromes, as indicated by the European current guidelines
62750884|NCT03783468|EXPERIMENTAL|light sedation pressure support ventilation|
62750885|NCT02142517|ACTIVE_COMPARATOR|Duct to mucosa PJ group|Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
62750886|NCT02142517|ACTIVE_COMPARATOR|Invagination PJ group|Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
62750887|NCT04123912|EXPERIMENTAL|KT-FMPT group|
62555418|NCT04838730|EXPERIMENTAL|single-arm|Hanita CleaRing device (CE approved; AMAR Certificate)
61986412|NCT04828512||newly diagnosed DM (subclinical DM)|In the 75-g OGTT, a basal FPG level ˃126 mg/dL (7.0 mmol/L) or a 120-min PG level ˃200 mg/dL (11.1 mmol/L) was considered as newly diagnosed DM (hereafter referred to as subclinical DM).
62391534|NCT02534181|ACTIVE_COMPARATOR|Intervention group|"Patients will undergo a caloric management protocol:~Days 1 and 2:~1. Reduction of caloric intake to 5kcal/kg/day;~2. Replacement of serum phosforus, potassium and magnesium;~3. Administration of 100mg intravenous thiamine, vitamins and microelements.~From day 3:~1. If serum phosphorus \< 2.5mg/dL, protocol will be followed according to day 2;~2. If serum phosphorus \> 2.5mg/dL, a gradual increase to target caloric intake will ensue."
62555419|NCT01950221|EXPERIMENTAL|POMx|POMx is a 1,000 milligram capsule of natural pomegranate polyphenol extract.
62555420|NCT01950221|PLACEBO_COMPARATOR|Placebo|Composition of the Drug Placebo Component/Function/Weight/Percentage of Fill Weight = Cellulose/Bulk agent/658 mg/64.5% Caramel/Colorant/79mg/7.8% Beet root/Flavor Ingredient/263mg/25.8% Magnesium stearate/USP Lubricant/10mg/1.0% Silica Dioxide/FCC Glidant/10mg/1.0% Total = 1020 mg/100% The method of manufacture of the placebo is identical to that of the drug product, except cellulose, caramel, and beet root are added in place of the active ingredient.
62555421|NCT04555187||Covid19-positive|Covid19 test positive. age \>= 18 y.
62555422|NCT04555187||Covid19-negative|Covid19 test negative. age \>=18y
62391535|NCT02534181|NO_INTERVENTION|Control group|"1. Nutritional management will be followed according to institutional protocol.~2. Electrolyte replacement will be provided at the clinician's discretion."
62555423|NCT06581354|ACTIVE_COMPARATOR|no provisional prosthesis, pekkton is a definitive framework.|Implant-supported, full-arch maxillary prosthesis utilizing 6 implants, for constructing PEKKTON framework without provisionalization
62555424|NCT06581354|EXPERIMENTAL|Glass fiber composite framework for provisionalization then pekkton framework.|Implant-supported full arch maxillary provisional prosthesis protocol utilizing 6 implants for constructing a resin glass fiber composite framework followed by a definitive PEKKTON framework.
62555425|NCT05215444||survivors|
62555426|NCT05215444||non survivors|
62555427|NCT06582550|EXPERIMENTAL|Audiovisual Instruction Group|Patients who require a hand surgery presenting to the clinic will be divided randomly; each participant is assigned by opening a prepared envelope with a dedicated group randomly, if the patient is assigned to group 1, they will receive standard printed instructions regarding their expected postoperative care, but if the patient is assigned to group 2, they will be provided with a barcode to scan to view audiovisual instructions regarding their post-operative course
62555428|NCT06582550|ACTIVE_COMPARATOR|Written Instruction Group|Patients who require a hand surgery presenting to the clinic will be divided randomly; each participant is assigned by opening a prepared envelope with a dedicated group randomly, if the patient is assigned to group 1, they will receive standard printed instructions regarding their expected postoperative care, but if the patient is assigned to group 2, they will be provided with a barcode to scan to view audiovisual instructions regarding their post-operative course
62555429|NCT03573154|OTHER|e-liquid 1|
62555430|NCT03573154|OTHER|e-liquid 2|
62555431|NCT02484937|ACTIVE_COMPARATOR|Group 1 (PMS Treatment)|Subjects will be treated monthly for 6 months by Pain Medicine Specialist (PMS) per standard protocol. The PCP will not be involved in the treatment.
62555432|NCT02484937|EXPERIMENTAL|Group 2 (PCP Treatment)|Subjects will be treated monthly for 6 months by the Primary Care Provider (PCP).The PCP will be involved and a multimodal therapeutic strategy will be communicated to the PCP by the PMS. The PCP will make dosage based on an algorithm provided by the PMS on how to adjust drug doses over time. It is not intended that the PCP may have ongoing engagement with the PMS. A direct line of communication will be set up between the PCP and the data integration clinical coordinator to handle serious medical concerns.
62555433|NCT04128930|EXPERIMENTAL|Fixed CPAP titration at home|"Patients will start CPAP treatment with a pressure that is calculated by the following formula (predicted pressure = (0.13 x BMI) + (0.16x neck circumference in cm) + (0.04 x AHI)) with a maximal pressure of 10 cmH2O. After 3 nights and after 7 nights, CPAP data will be remotely evaluated and pressure will be adapted based on the following rules:~* After 3 nights: median obstructive AHI\<5/h: decrease pressure with 2 cmH2O; median obstructive AHI\>5/h: increase with 2cmH2O~* After 7 nights: median obstructive AHI\>5/h of 4 nights after last adaptation: increase with 2 cmH2O"
62555434|NCT04128930|ACTIVE_COMPARATOR|APAP titration at home|Patients will start CPAP treatment with an auto-adjusting CPAP device with pressure levels between 4 and 12 cmH2O. After 7 nights of titration, the optimal pressure will be determined by analyzing the median of the nightly pressure that included 95% of the periods (percentile 95). CPAP treatment will be continued with this fixed optimal pressure.
62391536|NCT05814965|EXPERIMENTAL|Diabetic patients with Apical periodontitis|Diabetic patients with Apical periodontitis received Endodontics treatment in form of Root canal treatment and assessment of inflammatory and metabolic markers
62391537|NCT05814965|EXPERIMENTAL|Healthy patients with Apical periodontitis|systemically healthy participants patients with Apical periodontitis received Endodontics treatment in the form of root canal treatment and assessment of inflammatory markers
62555435|NCT01215773|EXPERIMENTAL|BI 671800 HEA medium dose|Tablet, oral administration with 240 mL of water for each treatment
62555436|NCT01215773|EXPERIMENTAL|BI 671800 HEA high dose|2 Tablets, oral administration with 240 mL of water for each treatment
62555437|NCT01215773|PLACEBO_COMPARATOR|Placebo|Matching to HEA 200 mg tablets, oral administration
62555438|NCT04774484|EXPERIMENTAL|All subjects will be in one arm|Both Lean and Obese, End-Stage Renal Disease (ESRD) patients and normal volunteers will be in one arm, that will receive the High Intensity Interval Training intervention.
62750888|NCT04123912|PLACEBO_COMPARATOR|Control group|
62750889|NCT01375803|EXPERIMENTAL|1|3g/day
62750890|NCT01375803|EXPERIMENTAL|2|6g/day
62750891|NCT01375803|PLACEBO_COMPARATOR|Placebo beverage|0g/day
62750892|NCT04177485|EXPERIMENTAL|Standard of Care + SMS text reminders|Standard of Care + SMS text reminders to be sent to caregivers for each of their subsequent vaccination visits, as per the EPI schedule (Penta2/OPV2/PCV2, Penta3/OPV3/PCV3, and MCV)
62750893|NCT04177485|NO_INTERVENTION|Standard of Care|\*Standard of care was defined as the health worker providing vaccination cards (home based records) to caregivers, as available, and providing verbal instruction of when to return for the next visit.
62750894|NCT04681833|EXPERIMENTAL|Cohort 1: BARS13 low repeat dose|Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of one arm, and one dose of placebo by IM injection to the deltoid region of the other arm, given sequentially (10 μg rRSV G protein/10 μg CsA in total for each vaccination) on Day 1 and 29.
62750895|NCT04681833|PLACEBO_COMPARATOR|Cohort 1: BARS13 placebo low repeat dose|Placebo: One dose administered by IM injection to both arms, on Day 1 and 29.
62750896|NCT04681833|EXPERIMENTAL|Cohort 2: BARS13 high repeat dose|Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1 and 29.
62750897|NCT04681833|PLACEBO_COMPARATOR|Cohort 2: BARS13 placebo high repeat dose|Placebo: One dose administered by IM injection to both arms, on Day 1 and 29.
62750898|NCT04681833|EXPERIMENTAL|Cohort 3: BARS13 high repeat multiple dose|Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1, Day 29 and Day 57.
62750899|NCT04681833|PLACEBO_COMPARATOR|Cohort 3: BARS13 placebo high repeat multiple dose|Placebo: One dose administered by IM injection to both arms, on Day 1, Day 29 and Day 57.
62750900|NCT03362060|EXPERIMENTAL|PVX-410|"* PVX-410 vaccine at W0, 1, 2, 3, 4, and 5 followed by booster PVX-410 vaccine doses at W10 and 28~* Pembrolizumab will be administered every 3 weeks intravenously starting with week 1"
62750901|NCT03472664|EXPERIMENTAL|Modified Mediterranean Ketogenic Diet|"The MMKD is a low carbohydrate/high fat diet aimed at inducing ketosis, as the experimental diet in the proposed study. Participants on the MMKD will keep their daily carbohydrate consumption below 20 grams per day throughout the 4 month intervention.The MMKD group will be supplied with extra virgin olive oil during their in person visits to use as a source of fat in their diet, and will be encouraged to eat plentiful fish, lean meats, and nutrient rich foods that meet the requirement of \<20 grams total carbohydrates per day.~Participants will receive a daily multivitamin (Centrum Silver) over the course of the study and instructed to take 1 tablet each day while on the diet."
62750902|NCT03472664|EXPERIMENTAL|American Heart Association Diet|The American Heart Association Diet (AHAD), is a low fat/high carbohydrate diet (\<40 grams/day) will be used as the control diet. Participants on the AHAD will be encouraged to limit their amount of fat intake to \<40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber. Participants will receive the same daily multivitamin supplement (Centrum Silver) over the course of the study and instructed to take 1 tablet each day while on the diet.
62750903|NCT00651950||Operator Dependence|
62750904|NCT05824923|EXPERIMENTAL|Pulmonary Artery Denervation (PADN)|Patients in the PADN group will receive pulmonary artery denervation procedure.
62750905|NCT05824923|ACTIVE_COMPARATOR|Guideline-directed medical therapy (GDMT) for heart failure|Patients in the control group will take their baseline anti-heart failure medications at the original doses according to 2023 ESC Guidelines for heart failure, without any changes except when medically required. The anti-heart failure drugs treatment is consistent in both arms.
62375489|NCT05405855|EXPERIMENTAL|Experimental Group|"The eLIFEwithIBD intervention is an ACT, mindfulness and compassion eHealth intervention for people with inflammatory bowel disease (IBD). The eLIFEwithIBD intervention is delivered through 9 sessions available on an online platform throughout a 9-week period. Each session is composed of real-image videos, texts with illustrative images, exercises in editable text format, and audio files with the experiential exercises and practices targeting topics such as acceptance, mindfulness, compassion, and gratitude.~Participants in this group also continue to receive a standard, personalised treatment for IBD."
62555439|NCT04016519||Gastrostomie|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
62555440|NCT05264883|EXPERIMENTAL|Venetoclax combined with Decitabine/Azacitidine and Aclarubicin|"Venetoclax (Ven): oral once daily (100 mg d1, 200 mg d2, 400 mg d3-28);~Decitabine (DAC): 20mg/m2 intravenous for 1 hour daily (d1 to d5);~Azacitidine (AZA): 75mg/m2 subcutaneous at two different sites daily (d1 to d7);(Choose decitabine or azacitidine according to the patient's wishes)~Aclarubicin (Acla): 10mg/m2 intravenous daily (d1 to d3);"
62555441|NCT05264883|ACTIVE_COMPARATOR|Venetoclax combined with Decitabine/Azacitidine|"Venetoclax (Ven): oral once daily (100 mg d1, 200 mg d2, 400 mg d3-28);~Decitabine (DAC): 20mg/m2 intravenous for 1 hour daily (d1 to d5);~Azacitidine (AZA): 75mg/m2 subcutaneous at two different sites daily (d1 to d7);(Choose decitabine or azacitidine according to the patient's wishes)"
62750906|NCT00408655|EXPERIMENTAL|Arm I|"PART A: Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1 and temsirolimus IV over 30 minutes on days 8 and 15. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive paclitaxel and carboplatin as in part A. They also receive temsirolimus IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
62750907|NCT05592366|NO_INTERVENTION|Standard of Care|Participants in this arm will only receive standard of care.
62375490|NCT05405855|NO_INTERVENTION|Control Group|Treatment as Usual (TAU) - Standard, personalised treatment for inflammatory bowel disease.
62375491|NCT04331210|ACTIVE_COMPARATOR|Group 1|Using diclofenac sodium suppository 50 mg immediately after suturing and then every 8 hours
62375492|NCT04331210|ACTIVE_COMPARATOR|Group 2|Using diclofenac sodium tablets 50 mg every 8 hours after birth
62375493|NCT00948194|NO_INTERVENTION|No nitric oxide|This arm will not receive nitric oxide, but will receive other standard inhaled anesthetics
62375494|NCT00948194|EXPERIMENTAL|Nitric Oxide|Will receive Nitric oxide and other standard inhaled anesthetics
62375495|NCT06019091|ACTIVE_COMPARATOR|Group 1, low frequency group, 20 Hz.|Compass Health TENS 3000, 3 mode Analog Unit. Normal Mode (N), pulse width of 200 microseconds and an intensity to be determined in the office based upon when the participant feels sensitive to the TENS unit. Frequency (pulse rate) 20 Hz
62375496|NCT06019091|ACTIVE_COMPARATOR|Group 2, medium frequency, 50 Hz.|Compass Health TENS 3000, 3 mode Analog Unit. Normal Mode (N), pulse width of 200 microseconds and an intensity to be determined in the office based upon when the participant feels sensitive to the TENS unit. Frequency (pulse rate) 50 Hz
62375497|NCT06019091|ACTIVE_COMPARATOR|Group 3, high frequency, 100 Hz.|Compass Health TENS 3000, 3 mode Analog Unit. Normal Mode (N), a pulse width of 200 microseconds and an intensity to be determined in the office based upon when the participant feels sensitive to the TENS unit. Frequency (pulse rate) 100 Hz
62375498|NCT01885104|EXPERIMENTAL|PEG 3350|Participants will receive a 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment.
62375499|NCT01885104|PLACEBO_COMPARATOR|Placebo|Participants will receive a 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment.
62375500|NCT05648006|EXPERIMENTAL|OH2+Capecitabine|OH2: 10\^7 CCID50/mL intratumoral injection, once every 2 weeks; Capecitabine: 1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks
62375501|NCT05648006|ACTIVE_COMPARATOR|Capecitabine/Capecitabine+Bevacizumab|Capecitabine: 1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks Bevacizumab: 7.5 mg/kg, intravenously, once every 3 weeks.
62375502|NCT02144376|PLACEBO_COMPARATOR|Maltodextrin|7 days without use of laxatives other than standardised rescue therapy 7 grams maltodextrin taken 3 times daily, at least 4 hours apart, for up to 7 days
62375503|NCT02144376|ACTIVE_COMPARATOR|Ispaghula|7 days without use of laxatives other than standardised rescue therapy 7 grams ispaghula/ psyllium taken 3 times daily, at least 4 hours apart, for up to 7 days
62375504|NCT03508245|OTHER|Wearable short wavelength light therapy|Wearable short wavelength light therapy
62375505|NCT03285061|NO_INTERVENTION|Standard Disposal Instructions|These patients will receive standard instructions on proper disposal of excess pain medication following orthopedic foot and ankle surgery. They will be asked complete a survey at their 6 post operative follow-up on excess medication disposal.
62750908|NCT05592366|EXPERIMENTAL|Adjusted CHAT-AD|Using CHAT, participants will be asked questions about their needs to fully support and care for their loved one after the loved one is released from the hospital.
62555442|NCT00868920|EXPERIMENTAL|1|"The Graseby 3300 PCA pump will be loaded with a mixture of propofol 10 mg/cc containing 10 µg/cc remifentanil. The loading and demand doses will be individualized based on patient weight, height, age, and gender.~The initial loading phase of sedation will be performed by the anesthesiologist to permit estimation of patient sensitivity. Following the initial loading dose, a series of button presses will be issued by the anesthesiologist to achieve a state of moderate sedation, as determined by a decrease in BIS to the range of 75-80. Once this state has been reached, the button will be transferred to the patient for Patient C0ntrolled Sedation."
62555443|NCT00868920|EXPERIMENTAL|2|"The Graseby 3300 PCA pump will be loaded with a mixture of propofol 10 mg/cc containing 10 µg/cc remifentanil. The loading and demand doses will be individualized based on patient weight, height, age, and gender.~The initial loading phase of sedation will be performed by the anesthesiologist to permit estimation of patient sensitivity. Following the initial loading dose, a series of button presses will be issued by the anesthesiologist to achieve a state of moderate sedation, as determined by a decrease in BIS to the range of 75-80. Once this state has been reached,the anesthesiologist will control the sedation."
62555444|NCT03593889|EXPERIMENTAL|Intervention group|The intervention group will receive a collaborative stepped care programme provided by registered social workers and trained peer supporters from elderly or mental health service units (NGOs) according to level of risks, symptom severity, and intervention response. Home visits or other format of contact will be delivered by trained peer supporters employed by NGOs to detect and engage hidden cases.
62750909|NCT02279771|ACTIVE_COMPARATOR|transanal anastomotic reinforcement|Low anterior resection with TME plus anastomotic transanal reinforcement without protective ileostomy/colostomy (transanal anastomotic reinforced arm:TAR-LAR)
62555445|NCT03593889|OTHER|Control group|The control group will receive treatment as usual, which will be determined by the responsible worker from NGO units.
62375506|NCT03285061|EXPERIMENTAL|At Home Disposal|With patients' prescription for post operative pain medication, a Deterra portable drug deactivation system will be provided, along with instructions on proper use. They will be asked complete a survey at their 6 post operative follow-up on excess medication disposal.
62375507|NCT03445611|EXPERIMENTAL|Group 1|These patients will receive a corticosteroid solution with lidocaine containing parabens.
62375508|NCT03445611|ACTIVE_COMPARATOR|Group 2|These patients will receive corticosteroid solution with paraben free lidocaine.
62375509|NCT03105869|EXPERIMENTAL|fluorocholine PET/CT|all patients will undergo a second PET/CT with fluorocholine
62391538|NCT05814965|ACTIVE_COMPARATOR|Diabetic patients with out Apical periodontitis|systemic inflammatory markers along with metabolic markers will be assessed
62750910|NCT02279771|ACTIVE_COMPARATOR|protective ileostomy group|Standard low anterior resection with TME plus protective ileostomy/colostomy (S-LAR)
62750911|NCT06606132|EXPERIMENTAL|Exercise with virtual reality|The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person's condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
62750912|NCT04901442|ACTIVE_COMPARATOR|Running with an Orthotic|Group A will receive an L700 Speed Orthotic (https://www.aetrex.com/running-orthotic/?lang=en_US) according to participants shoe size and will run with this Orthotic in the participants normal running shoes. The investigators will send an instruction sheet along with the Orthotic in the post, explaining how to use it. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. The group will be asked to run as normal over the 8-week trial period
62750913|NCT04901442|NO_INTERVENTION|Running without an Orthotic|Group B will not be provided with the Orthotic and will run in the participants normal running shoes during the course of the study. The group will be asked to run as normal over the 8-week trial period. At the end of the study and following collection of data participants in Group B will also be provided with an L700 Speed Orthotic.
62750914|NCT06464185|EXPERIMENTAL|Bispecific antibody-based therapy combined with CAR-T cell therapy|
62555446|NCT02465398|OTHER|Fracture device|Patient were treated with an Anatomical Shoulder Fracture device.
62750915|NCT02574650|EXPERIMENTAL|Open Label|Non-randomized, open label clinical study that intends to treat up to 30 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.
62555447|NCT02183779|EXPERIMENTAL|Reynaud|patients with reynaud phenomena
62555448|NCT02183779|EXPERIMENTAL|Healthy|Healthy volunteers
62750916|NCT03741946|OTHER|Triangle of Sedillot identification using ultrasonography|USG probe placed upright at the top of triangle of Sedillot at cricoid level
62750917|NCT01758224|EXPERIMENTAL|Functional Magnetic Stimulation|This group will receive magnetic stimulation of the respiratory (breathing) muscles that may improve the breathing function in subjects with MS. The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes).
62750918|NCT01758224|ACTIVE_COMPARATOR|Resistive Expiratory Muscle Training|Participants in this group will perform breathing exercises using a resistive breathing device. The training will take place in the FMS lab. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home.
62375510|NCT02866773|EXPERIMENTAL|PA1:Education sessions, Reminders, Whataps group|The intervention includes Physical activity knowledge enhancement session, Physical activity anti-inertia Reminders , Physical activity ambassadors' electronic communication group.
62375511|NCT02866773|ACTIVE_COMPARATOR|PA2:Education sessions, Reminders|The intervention includes Physical activity knowledge enhancement session and Physical activity anti-inertia Reminders
62555449|NCT01060072|EXPERIMENTAL|Loteprednol etabonate|Loteprednol etabonate 0.5% ophthalmic suspension
62555450|NCT01060072|PLACEBO_COMPARATOR|Vehicle|Vehicle of loteprednol etabonate ophthalmic suspension
62555451|NCT06486714|EXPERIMENTAL|Kinematic Total Knee Arthroplasty|KA-TKAs recreate the native joint line, hip-knee-ankle angle, and rotation of the pre-arthritic joint.
62750919|NCT02098499|ACTIVE_COMPARATOR|Haloperidol and Diphenhydramine|Haloperidol 5mg IV X1 and Diphenhydramine 25mg IV X1
62750920|NCT02098499|ACTIVE_COMPARATOR|Metoclopramide and Diphenhydramine|Metoclopramide 10mg IV X1 and Diphenhydramine 25mg IV X1
62750921|NCT06077240|EXPERIMENTAL|E-cigarettes|Adults who smoke cigarettes will be randomized to receive e-cigarettes for a duration of 4 weeks and to 1 of 4 possible regulatory scenarios within products where flavor availability is either menthol and tobacco/unflavored available or tobacco/unflavored only available, and nicotine concentration is either higher (5% e-cig) or lower (2.4% e-cig). Participants will return for bi-weekly research visits (in person or remote videocall) to complete measures for study aims. They will complete a final follow-up at Week 6 to assess maintenance of cigarette reduction and willingness to continue using products once they are no longer provided.
62750922|NCT06077240|EXPERIMENTAL|Nicotine Pouches|Adults who smoke cigarettes will be randomized to receive nicotine pouches for a duration of 4 weeks and to 1 of 4 possible regulatory scenarios within products where flavor availability is either menthol and tobacco/unflavored available or tobacco/unflavored only available, and nicotine concentration is either higher (6mg pouch) or lower (3mg pouch). Participants will return for bi-weekly research visits (in person or remote videocall) to complete measures for study aims. They will complete a final follow-up at Week 6 to assess maintenance of cigarette reduction and willingness to continue using products once they are no longer provided.
62750923|NCT06040918|EXPERIMENTAL|Healthy Subjects|Subjects will be scheduled for first apheresis collection on study Day 1. All subjects will receive N-803 at a fixed dose of 1 mg by subcutaneous (SC) injection 4 to 5 days prior to the second apheresis collection. The study day for N-803 administration will be determined based on the planned date of the second apheresis collection.
62750924|NCT02974855|EXPERIMENTAL|PF-06741086 (Cohort 1)|
62750925|NCT02974855|EXPERIMENTAL|PF-06741086 (Cohort 2)|
62750926|NCT02974855|EXPERIMENTAL|PF-06741086 (Cohort 3)|
62750927|NCT02974855|EXPERIMENTAL|PF-06741086 (Cohort 4)|
62750928|NCT04930549|EXPERIMENTAL|Dapagliflozin 10Mg Tab|Dapagliflozin 10 mg film-coated tablets
62555452|NCT06486714|ACTIVE_COMPARATOR|Mechanical Total Knee Arthroplasty|MA-TKAs are performed by which the distal femur and proximal tibia cuts are made perpendicular to the mechanical axis, a line connecting the center of the femoral head to the center of the ankle. These cuts are classically described as a 6-degree valgus cut of the distal femur and a 0-degree cut of the proximal tibia in relation to the mechanical axis. MA-TKAs create a 0-degree hip-knee-ankle angle.
62555453|NCT01744639|EXPERIMENTAL|HCC under treatment with radioablation|Assessment of nutritional status by anthropometry, bioelectrical impedance, blood sampling and application of psychometric hepatic encephalopathy score and critical flicker frequency, to assess the presence of hepatic encephalopathy.
62555454|NCT05725681|EXPERIMENTAL|High protein ramen|
62555455|NCT05725681|ACTIVE_COMPARATOR|Standard ramen|
62750929|NCT04930549|PLACEBO_COMPARATOR|Placebo|Identical film-coated tablets without dapagliflozin
62750930|NCT05585684||Oncology Patients|All participants in the study.
62750931|NCT00405964|EXPERIMENTAL|5-mg Desloratadine tablet|
62750932|NCT00405964|PLACEBO_COMPARATOR|Placebo tablet|
62750933|NCT04025502||Healthy Volunteer Subjects (HV)|"Male and female subjects 21-50 years of age, who are in good and stable health with no history or evidence of clinically relevant medical or neuropsychiatric illness.~Healthy Volunteer Subjects will undergo Event-Related Potential (ERP)/electroencephalogram (EEG) testing with the COGNISION® System."
62750934|NCT04025502||Subjects with Schizophrenia (SZ)|"Otherwise healthy male and female subjects 21-50 years of age, who have a current diagnosis of Schizophrenia with a duration of illness greater than or equal to one year.~Subjects with Schizophrenia (SZ) will undergo Event-Related Potential (ERP)/electroencephalogram (EEG) testing with the COGNISION® System."
62750935|NCT03727646|EXPERIMENTAL|Open-label nicotinamide riboside|"Participants scheduled to receive an LVAD will be prescribed nicotinamide riboside (NR) according to the following administration schedule:~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg)~Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily~Washout Day of LVAD Surgery and/or Day 15: None"
62750936|NCT03727646|NO_INTERVENTION|Baseline controls|Patients previously receiving LVADs, in whom blood and myocardial tissue assays for NAD+ levels and mitochondrial function were performed.
62750937|NCT02124018||Post-MI patients|"Asymptomatic post-MI patients late after MI or 40 days after STEMI-NSTEMI with preserved ejection fraction and absence of active ischemia Programmed ventricular stimulation (PVS) will be performed in high-risk patients based on non-invasive evaluation.~ICD implantation will be performed in patients with induced ventricular tachycardia (VT) upon PVS"
61986413|NCT00003799|EXPERIMENTAL|Treatment (chemotherapy, radiotherapy, surgery)|"Patients receive fluorouracil IV continuously with concurrent radiotherapy for 5.5 weeks. Patients also receive oxaliplatin IV over 2 hours on day 1 of weeks 1, 3, and 5.~Patients undergo surgery 6-8 weeks after completing preoperative chemotherapy and radiotherapy. The surgical procedure is determined by the extent of the tumor before preoperative therapy. The type of operative procedure may be abdominoperineal resection, low anterior resection (LAR), or LAR/coloanal anastomosis.~Postoperative chemotherapy begins within 6 weeks after surgery, comprising leucovorin calcium and fluorouracil IV on days 1-5. Treatment repeats every 21 days for 4 courses."
61986414|NCT04816695|EXPERIMENTAL|VOC analysis|VOC analysis in exhaled air in patients hospitalised for COPD exacerbation
62375512|NCT02866773|ACTIVE_COMPARATOR|PA3:Education sessions, Whataps group|The intervention includes Physical activity knowledge enhancement session and Physical activity ambassadors' electronic communication group.
62375513|NCT02866773|ACTIVE_COMPARATOR|PA4:Education sessions|The intervention includes Physical activity knowledge enhancement session only.
62375514|NCT02866773|EXPERIMENTAL|HD1:Education sessions, Reminders, Whataps group|The intervention includes Health diet knowledge enhancement session, Health diet anti-inertia Reminders , Health diet ambassadors' electronic communication group.
62375515|NCT02866773|ACTIVE_COMPARATOR|HD2:Education sessions, Reminders|The intervention includes Health diet knowledge enhancement session, Health diet anti-inertia Reminders , and Health diet ambassadors' electronic communication group.
62555456|NCT04967326|EXPERIMENTAL|Patients with epilepsy|The therapies of patients with epilepsy were optimized using pharmacists' interventions, including medication consultation, dosage adjustment, medication switching/discontinuation, or combination therapy.
62750938|NCT05266872||PD patients|Subjects with neurodegenerative disease or having degenerative parkinsonism (typical PD or atypical parkinsonism)
62750939|NCT05266872||Healthy controls|Gender- and age-matched healthy controls
62750940|NCT02839226|ACTIVE_COMPARATOR|AR/101|AR/101 will be administered topically once daily for up to 28 days concomitantly with standard of care as advised by treating physician. After randomization, patients will be treated for up-to 28 days, or until granulation tissue formation has reached maximal score on the granulation scale, or until the wound is ready for skin grafting, whichever occurs first.
61986415|NCT03987061|EXPERIMENTAL|MOTIV bioresorbable vascular scaffold|MOTIV bioresorbable vascular scaffold for below-the-knee artery disease
62375516|NCT02866773|ACTIVE_COMPARATOR|HD3:Education sessions, Whataps group|The intervention includes Health diet knowledge enhancement session and Health diet ambassadors' electronic communication group.
62375517|NCT02866773|ACTIVE_COMPARATOR|HD4:Education sessions|The intervention includes Health diet knowledge enhancement session only.
62375518|NCT03862586|EXPERIMENTAL|N-acetyl cysteine|Twenty two infertile women with the onset of endometrial preparation for evaluating genes expression, received 1200 mg of oral N-acetyl cysteine for at-least six weeks before starting ovarian stimulation
62375519|NCT03862586|PLACEBO_COMPARATOR|Placebos|Eighteen infertile women with the onset of endometrial preparation for evaluating genes expression, received placebo effervescent tablet for at-least six weeks before starting ovarian stimulation
62555457|NCT03745209|EXPERIMENTAL|Ultrasound-guided peripheral IV.|Ultrasound-guided peripheral IV cannulation
62555458|NCT03745209|NO_INTERVENTION|Traditional landmark technique|Traditional landmark technique
61986416|NCT04657614|EXPERIMENTAL|Neutral Alignment Group|A straight pylon with the ankle at neutral.
61986417|NCT04657614|EXPERIMENTAL|Anterior Alignment Group|An anteriorly displaced pylon with ankle dorsiflexion at 5 degrees.
62375520|NCT01429155||Liver transplant recipeints|Patients suffering from chronic hepatitis C that required a living donor liver transplant.
62375521|NCT01429155||Liver Donors|Patients who donated part of their liver to a patient suffering from chronic hepatitis C
62375522|NCT01490333|EXPERIMENTAL|2500 IU Vitamin D3|
62375523|NCT01490333|ACTIVE_COMPARATOR|400 IU Vitamin D3|
62375524|NCT01511640|EXPERIMENTAL|Pregabalin 1|Dose 1
62375525|NCT01511640|PLACEBO_COMPARATOR|Placebo 1|Placebo 1
62375526|NCT01511640|EXPERIMENTAL|Pregabalin 2|Dose 2
62375527|NCT01511640|PLACEBO_COMPARATOR|Placebo 2|Placebo 2
62375528|NCT05939193|EXPERIMENTAL|Urine-guided hydration|The target is to maintain urine output at 200 ml/h (3 ml/kg/h) or higher by intravenous injection/infusion of furosemide throughout surgery. That is, a loading dose of 20 mg is injected at the beginning of surgery; if the urine output does not reach the target value, furosemide will be continuously infused at 10 mg/h until the end of the surgery as needed, with a maximum cumulative dose not exceeding 250 mg. Intravenous hydration is performed to balance urine output and to maintain the SVV≤10%.
62375529|NCT05939193|ACTIVE_COMPARATOR|Routine hydration|The target is to maintain urine output at 0.5 ml/kg/h or higher as per current medical practice. That is, furosemide is only administered when clinically necessary or at the discretion of attending anesthesiologists. Intravenous hydration is performed to maintain the SVV≤10%.
62375530|NCT03934489|EXPERIMENTAL|PERSIST|Participants will receive Partnered Emotion Regulation Skills Intervention and Support.
62375531|NCT03934489|ACTIVE_COMPARATOR|Facilitated Peer Support|Participants will undergo a 12-week group intervention, adapted from community-based peer support groups, that focuses on participant-generated topics and facilitated discussion.
62375532|NCT05002582||patients with hematological diseases|to clarify the intestinal carriage rate of carbapenem-resistant Organisms (CRO) in patients with hematological diseases
62375533|NCT01378676|PLACEBO_COMPARATOR|Matching Placebo|
62375534|NCT01378676|EXPERIMENTAL|Active Drug Low Dose (CK-2017357 125 mg)|
62375535|NCT01378676|EXPERIMENTAL|Active Drug Mid Dose (CK-2017357 250 mg)|
61986418|NCT04657614|EXPERIMENTAL|Posterior Alignment Group|A posteriorly displaced pylon with 5 degrees of plantarflexion at the ankle.
62375536|NCT01378676|EXPERIMENTAL|Active Drug High Dose (CK-2017357 375 mg)|
62375537|NCT05692986|ACTIVE_COMPARATOR|povidone betadine|
62375538|NCT05692986|ACTIVE_COMPARATOR|chlorhexidine|
62375539|NCT02961400|EXPERIMENTAL|PUSH text messages|Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE).
62375540|NCT02961400|EXPERIMENTAL|PULL text messages|Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE). Text messages will request a response from the participant.
62375541|NCT02961400|OTHER|No text messages|No text messages will be sent in this condition to participants in either treatment condition (i.e., TranS-C or PE).
62375542|NCT00311090|EXPERIMENTAL|Idrabiotaparinux|"Idrabiotaparinux sodium , 3.0 mg, once-weekly for 6 months.~In avidin sub-study, participants receive on Day 183, avidin 100 mg or placebo (for avidin) (4 hours after Idrabiotaparinux administration)"
62375543|NCT00311090|ACTIVE_COMPARATOR|Idraparinux|"Idraparinux sodium, 2.5 mg, once-weekly for 6 months~In avidin sub-study, participants receive on Day 183, placebo (for avidin) (4 hours after Idrabiotaparinux administration)"
62375544|NCT01758172|ACTIVE_COMPARATOR|Albumin|albumin was administered to reach CVP up to 7mmHg
62375545|NCT01758172|EXPERIMENTAL|6% hydroxyethyl starch 130/0.4|6% hydroxyethyl starch 130/0.4 was administered to reach CVP up to 7mmHg
62391539|NCT05814965|ACTIVE_COMPARATOR|Healthy participants without Apical periodontitis|systemic inflammatory markers will be assessed
62391540|NCT06103773|EXPERIMENTAL|SAD-TollB-001 50mg Dosage groups|drug：TollB-001 tablets（50mg，single-dose, on the first day）
62750941|NCT02839226|PLACEBO_COMPARATOR|Placebo|placebo will be administered topically once daily for up to 28 days concomitantly with standard of care as advised by treating physician. After randomization, patients will be treated for up-to 14 days or until granulation tissue formation has reached maximal score on the granulation scale, or until the wound is ready for skin grafting, whichever occurs first.
62750942|NCT05411588|EXPERIMENTAL|Active|PF-07275315
62750943|NCT05411588|PLACEBO_COMPARATOR|Placebo|Placebo
62375546|NCT00944476||Pts/volunteers getting regular MRI exam|Fat-free MRI images utilizing standard magnetization transfer imaging will be acquired on 10 patients known or suspected sarcoma of the of the extremity or trunk, in addition to their traditional clinical MRI. In addition, we will perform the same scans on 4 volunteers who have no history of sarcoma.
62375547|NCT04574076||N8-GP|Patients with haemophilia A
62555459|NCT03232593||Participants who Receive Atezolizumab|Participants who are administered with atezolizumab as per the local label and standard of care at physician's discretion will be observed for approximately 6 years.
62555460|NCT01404546|EXPERIMENTAL|Cost Free Pharmacotherapy|Participants assigned to the CF group received a starter kit (4-week supply) of cost-free quit smoking medication (nicotine replacement therapy, bupropion, or varenicline) and a pre-printed prescription to be filled by the patient at the end of the 4-weeks.
62555461|NCT01404546|ACTIVE_COMPARATOR|Usual Care Group|Participants assigned to the prescription only usual care group received a prescription for smoking cessation pharmacotherapy to be filled at their own cost at their local community pharmacy.
62555462|NCT01442597|ACTIVE_COMPARATOR|Individual clinician-provided CBT|Individual treatment provided by a trained Cognitive Behavioral Therapy (CBT)clinician who will cover the same skills provided by the CBT4CBT computer program.
62555463|NCT01442597|EXPERIMENTAL|CBT4CBT|A computerized program that teaches skills for stopping drug use and increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc.
62555464|NCT01442597|ACTIVE_COMPARATOR|Standard Treatment as Usual (TAU)|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on substance abuse.
62555465|NCT00525681|OTHER|CsA|Investigation of systemic exposure of cyclosporine before and after 2 moths of co-adminiastration of rimonabant.
62555466|NCT00525681|OTHER|Tac|Investigation of systemic exposure of tacrolimus before and after 2 moths of co-adminiastration of rimonabant.
62567452|NCT06070467||children and teenagers affected by Rare Eye Diseases|A Mixed Methods Research (MMR) using quantitative (QUAN) Vision Related-QoL (VR-QoL = FVQ-CYP and VQoL-CYP) tools and psychosocial PEM-CY, and qualitative (QUAL) socio-anthropologic investigations can capture reliably children's and teenagers' Patient-Reported Outcome (PRO).
62750944|NCT03117374|EXPERIMENTAL|Team Nutriathlon intervention|Participants were invited to participate in the Team Nutriathlon for an 8-week period
62750945|NCT03117374|NO_INTERVENTION|Control|Participants were invited to follow the regular school curricular for an 8-week period
62555467|NCT01937078|ACTIVE_COMPARATOR|active|Famotidine will be administered at total daily doses of 80, 120mg, or 160mg per day. Each patient will be randomized to receive each active dose of famotidine (80, 120, or 160mg/d and placebo). Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo.
62555468|NCT01522456|ACTIVE_COMPARATOR|Epiduo Gel|Adapalene 0.1% and benzoyl peroxide 2.5% gel
62555469|NCT01522456|ACTIVE_COMPARATOR|Retin-A Micro Microsphere 0.1%|Tretinoin gel, 0.1%
62750946|NCT04675658|ACTIVE_COMPARATOR|Classroom Intervention|"Physical activity support is provided by integrating daily structured activities in the classroom delivered by physical activity leaders through a video conferencing platform in partnership with the classroom teacher. Activities last about 10 minutes or less and have the flexibility of being integrated with academic lessons or serving as a break from academics.~The activities are simple and get kids moving in place. The activities will be delivered by a research staff member via video conferencing (using the schools preferred platform). A combination of live activities led by the research team and pre-recorded videos will be used (see example below). If live videos do not work for the teacher, they will have the option to only use the pre-recorded videos or receive a list of resources to promote CBPA in their classrooms."
62555470|NCT02179060||Cooling group|The RhinoChill® cooling is started as soon as possible to the patients with Cardiac arrest, and before the return of spontaneous circulation
62555471|NCT02179060||Control group|Standard care, no cooling during pre-hospital care
62555472|NCT00558597||1|30 patients with stable graft function
62555473|NCT00558597||2|30 patients with acute rejection after lung transplantation
62555474|NCT01354210|NO_INTERVENTION|Standard of care only|The SOC for ART adherence consists of viewing a 20-minute animated tutorial which explains the importance of adherence to antiretroviral medication. It is specifically designed for viewers who have no science background and is appropriate for adolescents and young adults.
62375548|NCT03640728||ETV|patients receive entecavir 0.5 mg/day orally.
62567453|NCT01109537||RLS Diagnosis|
62567454|NCT01109537||Healthy Controls|
62567455|NCT03386552|EXPERIMENTAL|Isifera+|Subjects are pertubated with Isifer+ solution containing lidocaine 0.5 mg/ml
62555475|NCT01354210|EXPERIMENTAL|Intervention|This study will test a tailored, personalized SMS Text Message Reminder intervention to improve adherence to ART among non-adherent YLH. Participants will use their own cell phones for receipt of the intervention. Participants will have the option to choose a tailored personalized message that may be changed as requested throughout the study period (six months). Taking advantage of the Intelecare technology, participants will be asked to send a text message response indicating that that have successfully (or not) taken their meds per schedule. No identifying patient information will be included in the SMS text to protect patient confidentiality.
62750947|NCT04675658|EXPERIMENTAL|Classroom Intervention plus family support|"Same components as the Classroom Intervention Arm plus the following:~Family Component: A newsletter will be sent to parents or guardians once every two weeks over the semester and posted on the study website. The newsletters include physical activity information related to safety/protection, skills building, motivation, overcoming barriers, and goal setting and monitoring (all newsletters are included as an appendix). As part of the program, children also receive a Garmin wearable physical activity monitor. Parents or guardians will receive text messages with behavior change messages based on the Garmin data (text message content is included as an appendix). Text messages also contain links to website materials.~Texts will be sent out using the Twilio platform."
62567456|NCT03386552|PLACEBO_COMPARATOR|Buffer|Subjects are pertubated with a buffer solution without lidocaine
62375549|NCT03640728||TDF|patients receive Tenofovir Disoproxil Fumarate 300 mg/day orally.
62375550|NCT03640728||TAF|patients receive Tenofovir alafenamide 25 mg/day orally.
62555476|NCT03106428|EXPERIMENTAL|acute myeloid leukemia|Patients with R/R AML by World Health Organization (WHO) classification (Arber et al, 2016) who have failed prior standard therapy and for whom no standard therapies are available
62555477|NCT03106428|EXPERIMENTAL|Multiple Myeloma|Patients with R/R MM who have failed prior standard therapy(ies) which should include immunomodulatory agents and proteasome inhibitors and for whom there is no standard salvage regimen.
61986419|NCT06113133||Maximal oxygen uptake|Measurement of maximal oxygen uptake using \< 50-millilitre and 100 millilitre oxygen as a cut-off
62391541|NCT06103773|EXPERIMENTAL|SAD-TollB-001 100mg Dosage groups|drug：TollB-001 tablets （100mg，single-dose, on the first day）
62555478|NCT03106428|EXPERIMENTAL|Diffuse Large B-cell Lymphoma|Patients with R/R DLBCL who have failed prior standard therapy(ies) and for whom there is no standard salvage regimen.
62567457|NCT05673980|EXPERIMENTAL|vitamin D2|Oral dose of Vitamin D2 every two weeks
62567458|NCT05673980|PLACEBO_COMPARATOR|Placebo|Without any intervention
62567459|NCT02130362||Immunosuppressant Therapy|Pediatric patients who are being prescribed and treated with immunosuppressant therapy
61986420|NCT05872581|EXPERIMENTAL|Hand scanner instant feedback|Hand scanner results only but no training videos will be provided.
62567460|NCT02130362||Adalimumab (Humira) Treatment|Pediatric patients who are prescribed and treated with adalimumab
62567461|NCT02775682||patients with epilepsy|
62750948|NCT01534260|EXPERIMENTAL|sorafenib, vorinostat and bortezomib|Escalating cohorts of sorafenib, vorinostat and bortezomib
62750949|NCT03100916|EXPERIMENTAL|Dose Ranging Arm|
62750950|NCT03100916|EXPERIMENTAL|Food Effect arm|
62750951|NCT05325749||unaffected|newborns without developmental features having no variations according to an inherited diseases screening;
62750952|NCT05325749||affected|newborns showing either phenotypic features or deviations according to MS screening
62750953|NCT05325749||refused families|parents refused to enroll their newborns to the study
62375551|NCT01563406|EXPERIMENTAL|Alcohol with 5 second scrub|70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 5 seconds.
62375552|NCT01563406|EXPERIMENTAL|Alcohol with 15 second scrub|70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 15 seconds.
62375553|NCT01563406|EXPERIMENTAL|Chlorhexidine with 5 second scrub|3.15% chlorhexidine/70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 5 seconds.
62375554|NCT01563406|EXPERIMENTAL|Chlorhexidine with 15 second scrub|3.15% chlorhexidine/70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 15 seconds.
62375555|NCT05178680|EXPERIMENTAL|relaxation session combining music and soft light|
62375556|NCT05178680|NO_INTERVENTION|usual rest session|
62567462|NCT02775682||normal individuals without epilepsy|
62567463|NCT03468517|NO_INTERVENTION|Control group|Standard preoperative evaluation process will continue without any intervention.
62750954|NCT05325749||unaffected born prematurely|newborns without specific developmental features having no variations according to an inherited diseases screening, born before term
62750955|NCT05325749||unaffected wirh family history|newborns without developmental features having no variations according to an inherited diseases screening but with affected relative(s)
62750956|NCT05325749||unaffected wirh prenatal phenotype|newborns without developmental features at birth and on, having no variations according to an inherited diseases screening which had been observed to show signs of developmental features during prenatal ultrasound examination
62555479|NCT02497586|EXPERIMENTAL|MRS|Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. This is a prospective feasibility study, aiming to recruit 15 consecutive patients with lung cancer to undergo proton MRS. The feasibility and repeatability of the technique will be assessed by analysis of the MR spectra obtained.
62555480|NCT06295523|EXPERIMENTAL|Experimental: Very hot and dry|Subjects will be exposed to 3 hours in a climate chamber set to approximately 47 deg C and 15% relative humidity, which reflects a very hot and dry heat wave condition similar to the 2018 Los Angeles heat wave. Two visits will be required to complete this arm, with one visit including water spray for cooling.
62750957|NCT04606199|EXPERIMENTAL|Mindfulness-based intervention|Participants will be randomly assigned to an app-based intervention that includes brief (\<5 min) audio-guided mindfulness and compassion-based practices.
62750958|NCT04606199|NO_INTERVENTION|No intervention|Participants will continue their normal activities and not practice any form of mindfulness mediation at the time of app-notification.
62750959|NCT05946291|EXPERIMENTAL|Standardized Patient Group|Standardized Patient: A pressure wound similar to reality will be created with the application of mulage on a standardized patient. In accordance with the scenario of a patient with a pressure wound, students will perform pressure wound evaluation and maintenance on a standardized patient in a simulation laboratory. Following the simulation application, student groups of eight to ten individuals will participate in a debriefing session.
62750960|NCT05946291|ACTIVE_COMPARATOR|Simulated Manneqquin Group|Simulated Mannequin: A pressure wound similar to reality will be created with the simulated mannequin mulage application. In accordance with the same scenario used in the experimental group, pressure wound evaluation and maintenance will be performed on the simulated mannequin in the simulation laboratory. Following the simulation application, student groups of eight to ten individuals will participate in a debriefing session.
62750961|NCT02314065|EXPERIMENTAL|Conventional CBT|Cognitive Behavioural Therapy delivered in a conventional manner
62750962|NCT02314065|EXPERIMENTAL|Internet-delivered CBT|Cognitive Behavioural Therapy delivered via the Internet
62750963|NCT04285866||Durvalumab Group|Patients who have participated in the EAP between 1 September 2017 up to 21 December 2018 and have received at least 1 dose of durvalumab.
62750964|NCT03109093|EXPERIMENTAL|Blinatumomab|"Patients will receive four cycles of treatment, unless criteria for treatment discontinuation apply. The duration of one cycle is 6 weeks, including a four week continuous intravenous infusion and a two week infusion free interval, which may be extended by a maximum of 7 days.~Patients entered with MRD level \<10-4 (non quantifiable/MolNE1, quantifiable/MolNE2) or positive MRD, non quantifiable (MolNE3) will receive up to two cycles of Blinatumomab.~Transfer of patients to alloHSCT after one cycle or after subsequent cycles is considered as per protocol discontinuation and as premature treatment discontinuation In case of hematological or extramedullary relapse, the study treatment will be permanently discontinued."
62750965|NCT06495229|EXPERIMENTAL|CM310 group|
62750966|NCT04992065|EXPERIMENTAL|Oral NNC0385-0434 15 mg once-daily (OD)|15 mg NNC0385-0434 co-formulated with 500 mg Salcaprozate sodium (SNAC) tablet once daily
62750967|NCT04992065|PLACEBO_COMPARATOR|Oral placebo (NNC0385-0434 15 mg)|15 MG placebo administered as tablets (without SNAC) once daily
62750968|NCT04992065|EXPERIMENTAL|Oral NNC0385-0434 40 mg OD|40 mg study drug co-formulated with 500 mg SNAC tablet once daily
62750969|NCT04992065|PLACEBO_COMPARATOR|Oral placebo (NNC0385-0434 40 mg)|placebo administered as tablets (without SNAC) once daily
62750970|NCT04992065|EXPERIMENTAL|Oral NNC0385-0434 100 mg|100 mg NNC0385-0434 co-formulated with 500 mg SNAC tablet once daily (51 participants)
62750971|NCT04992065|PLACEBO_COMPARATOR|Oral placebo (NNC0385-0434 100 mg)|placebo administered as tablets (without SNAC) once daily
62750972|NCT04992065|ACTIVE_COMPARATOR|Subcutaneous evolocumab 140 mg Q2W|140 mg evolocumab Subcutaneous (s.c.) injections every 2 weeks (51 participants). The s.c. evolocumab arm is open-label to limit unnecessary injections
62750973|NCT03576066|EXPERIMENTAL|ABI-H0731 + SOC NUC|Virologically suppressed participants will receive ABI-H0731 along with SOC NUC (ETV, TDF or TAF) tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.
62750974|NCT03576066|ACTIVE_COMPARATOR|Placebo + SOC NUC|Virologically suppressed participants will receive matching placebo tablets and continue their SOC NUC (ETV, TDF or TAF) for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.
62750975|NCT04015284|EXPERIMENTAL|SSNB + PCB|Single shot US-guided suprascapular nerve block (SSNB) with 5 mL ropivacaine 0.5%, then single shot US-guided posterior cord block (PCB) with 10 ml ropivacaine 0.5%.
62750976|NCT04015284|ACTIVE_COMPARATOR|ISBPB|Single shot US-guided interscalene brachial plexus block (ISBPB) with 15 mL ropivacaine 0.5%.
62750977|NCT05993312||A bras actif|
62750978|NCT05763186|EXPERIMENTAL|Sampling|"* On the PiccLine: a collection of 6 consecutive heparinized tubes with 3.5ml gel corresponding to the usual purge volume~* In the periphery : one 3.5ml heparin-gel tube as a reference."
61986421|NCT05872581|EXPERIMENTAL|Video training|A training video only but no hand scanner results will be provided.
62750979|NCT05763186|EXPERIMENTAL|Sampling and rinsing|"* On the PiccLine: a 10 ml pre-rinsing with 0.9% NaCl and then a sampling of 6 consecutive heparinized tubes with 3.5ml gel corresponding to the usual purge volume.~* In the periphery: one 3.5 ml heparin-gel tube as a reference."
62750980|NCT03854526||Patients without Gougerot Sjogren disease|New patient, or patient, with no history of a dental examination in the last six months and with at least one tooth with coronal dental restoration
62555481|NCT06295523|EXPERIMENTAL|Experimental: Hot and humid|Subjects will be exposed to 3 hours in a climate chamber set to approximately 41 deg C and 40% relative humidity, which reflects hot and humid heat wave similar to the 1995 Chicago heat wave. Two visits will be required to complete this arm, with one visit including water spray for cooling.
62555482|NCT00965887|ACTIVE_COMPARATOR|1|MK0974 Ethanolate
62555483|NCT00965887|ACTIVE_COMPARATOR|2|MK0974 Hydrate
62555484|NCT00684281|OTHER|1|Subject control
62555485|NCT00684281|EXPERIMENTAL|2|40 patients before hand include in a program
62555486|NCT00291317|EXPERIMENTAL|RT 300-P FES Cycle|Participants exercised using functional electrical stimulation cycling (FES) using the RT 300-P FES cycle (Restorative Therapies, Baltimore, MD).
62555487|NCT02846610||regional anesthesia|surgical patients (age: 0-100 years) having regional anesthesia along with the procedure and postoperative course
62555488|NCT02846610||systemic analgesia|surgical patients (age: 0-100 years) having systemic analgesia along with the procedure and post procedure course
62555489|NCT04108897|EXPERIMENTAL|Doxycycline 40mg/day|Doxycycline 40mg will be administered once a day per oral for 28 days.
62555490|NCT04108897|EXPERIMENTAL|Doxycycline 50mg/day|Doxycycline 50mg will be administered once a day per oral for 28 days.
62555491|NCT04108897|EXPERIMENTAL|Doxycycline 100mg/day|Doxycycline 100mg will be administered once a day per oral for 28 days.
62750981|NCT03854526||Patients with Gougerot Sjogren disease|New patient, or patient, with no history of a dental examination in the last six months, with at least one tooth with coronal dental restoration and presenting a Gougerot Sjogren disease
62555492|NCT04108897|EXPERIMENTAL|Doxycycline 200mg/day|Doxycycline 100mg will be administered twice a day per oral for 28 days.
62555493|NCT04108897|EXPERIMENTAL|Topical ivermectin(1%)|Topical ivermectin will be applied once a day for 28 days.
62555494|NCT04108897|NO_INTERVENTION|Control|No intervention will be performed.
62555495|NCT03632369||Optimization Group|The primary objective of this study is to determine an optimized set of scan parameters for HP 129Xe MR diffusion-weighted imaging, HP 129Xe MR ventilation imaging, HP 129Xe Chemical Shift Saturation Recovery (CSSR) and Xenon polarization Transfer Contrast (XTC) MRI that will produce clear, anatomically and clinically relevant images of the lungs in up to 10 healthy participants and up to 10 participants with NSCLC. The primary objective will be completed before moving onto the secondary objective.
62555496|NCT03632369||Delineate Functional vs. non-functional lung tissue|The secondary objective of this study is to delineate functional versus non-functional lung tissue and the effects of radiotherapy. This objective will be explored by performing these five optimized techniques with up to 10 participants with NSCLC at three time points: before radiotherapy begins, at the end of radiotherapy, and at least 10-weeks post-radiation treatment. These results will be correlated with those from PFTs and CT scans performed at corresponding time points.
62555497|NCT04156581|ACTIVE_COMPARATOR|ESPB with Bupivacaine and Dexamethasone|23 complex spine surgery patients will be randomized to receive intraoperative ultrasound-guided bilateral ESPB with 0.375% bupivacaine plus 2 mg preservative free dexamethasone, 25-30 mL total per side according to patient weight.
62555498|NCT04156581|PLACEBO_COMPARATOR|ESPB with saline placebo|23 complex spine surgery patients will be randomized to receive intraoperative ultrasound-guided bilateral ESPB with saline placebo, 25-30 mL total per side according to patient weight.
62555499|NCT00994812|EXPERIMENTAL|Metformin|
62555500|NCT05560607|EXPERIMENTAL|Intervention/ Drug|Investigation of the knockdown of hepatic HSD17B13 mRNA expression, PK, safety, and tolerability following multiple dose administration of AZD7503 in male participants and female participants of non-childbearing potential with NAFLD or NASH
62555501|NCT01777178|EXPERIMENTAL|Low bicarbonate dialysis|
62555502|NCT03564457||One group of 20.000 patients|No interventions will take place as this is an observational study
62555503|NCT02817659|EXPERIMENTAL|Glucagon Infusion|Glucagon infusion in escalating manner at 12.5, 25, 37.5 and 50 ng/kg/min (each step for 60 min). At 30 and 60 mins of each infusion rate, we will administer a previously established questionnaire to assess overall nausea intensity.
62555504|NCT00546663|EXPERIMENTAL|Open-label|
62555505|NCT04944173|EXPERIMENTAL|MRD Negative|All subjects will receive four cycles of durvalumab with SABR concurrent at cycle 2, then will be evaluated for MRD. Subjects in this arm have no detectable ctDNA at MRD landmark and will receive no further therapy.
62555506|NCT04944173|EXPERIMENTAL|MRD Positive, no further therapy|All subjects will receive four cycles of durvalumab with SABR concurrent at cycle 2, then will be evaluated for MRD. Subjects in this arm have detectable ctDNA at MRD landmark and are randomized to no further therapy.
62555507|NCT04944173|EXPERIMENTAL|MRD Positive, consolidation durvalumab|All subjects will receive four cycles of durvalumab with SABR concurrent at cycle 2, then will be evaluated for MRD. Subjects in this arm have detectable ctDNA at MRD landmark and are randomized to eight additional cycles of durvalumab
62555508|NCT05259527|EXPERIMENTAL|Vitamin D Replacement|Participants will receive prescribed oral vitamin D2 to achieve a serum vitamin D level between 30 ng/mL to 50 ng/mL.
62555509|NCT05259527|ACTIVE_COMPARATOR|Standard of Care|Participants will receive standard-of-care advice to take over the counter vitamin D.
62555510|NCT05259527|NO_INTERVENTION|Observation Arm|Observation only
62555511|NCT05616338|EXPERIMENTAL|Eligible patients|
62555512|NCT04109092|EXPERIMENTAL|Dose Escalation: NMIBC And BCG Unresponsive NMIBC|
62750982|NCT03428581|EXPERIMENTAL|ALND with ARM +/- LVB|Axillary Lymph Node Dissection (ALND) using Axillary Reverse Mapping (ARM) with Lympho-venous bypass (LVB) will be performed.
62750983|NCT03428581|ACTIVE_COMPARATOR|ALND without ARM +/- LVB|Axillary Lymph Node Dissection (ALND)
61986422|NCT05872581|EXPERIMENTAL|Hand scanner and Video training|Both hand scanner results and a training video will be provided.
62555513|NCT04109092|EXPERIMENTAL|Dose Expansion: CIS With/Without Ta or T1|
62555514|NCT04109092|EXPERIMENTAL|Dose Expansion: High-grade Ta or T1, Without CIS|
62555515|NCT04203134|EXPERIMENTAL|Treatment Group|Patients in the randomly assigned treatment group will receive a mouthguard at first visit along with standard treatment of BMS.
62555516|NCT04203134|NO_INTERVENTION|Control Group|Control group will proceed through treatment for BMS in an otherwise standard treatment protocol and will not receive a mouthguard.
62555517|NCT04957823||Diseased|type II diabetic patients with documented coronary artery disease.
62555518|NCT04957823||Control|type II diabetic patients without coronary artery disease.
62375557|NCT01001143|EXPERIMENTAL|Dose Level 1|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.~Bexarotene 100 mg/m2 PO daily for each 28 day cycle."
62375558|NCT01001143|EXPERIMENTAL|Dose Level 2|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.~Bexarotene 200 mg/m2 PO daily for each 28 day cycle."
62375559|NCT01001143|EXPERIMENTAL|Dose Level 3|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.~Bexarotene 300 mg/m2 PO daily for each 28 day cycle."
62375560|NCT01122823|EXPERIMENTAL|On-line workshop|The online CDSMP is an internet-based program for people with 1 or more chronic conditions. It's built on self-efficacy theory, facilitated by lay leaders, and uses a curriculum emphasizing problem solving, decision making, and confidence building in weekly sessions over six weeks. It addresses generic topics and skills relevant to managing any chronic condition, including: action plans; problem solving; nutrition; exercise; fatigue; breathing; managing medications; managing stress and emotions; working with health care providers. The structure includes: 1) password-protected, interactive web-based instruction; 2) web-based bulletin board discussion groups to enable participatory learning and support; 3) and a reference book that contains the program content and supplemental information.
62375561|NCT00050570|EXPERIMENTAL|Intervention|An 8-week, Internet- based, structured cognitive- behavioral program combined with an online, asynchronous, moderated discussion group.
62391542|NCT06103773|EXPERIMENTAL|SAD-TollB-001 200mg Dosage groups|drug：TollB-001 tablets （200mg，single-dose, on the first day）
62750984|NCT01004731|EXPERIMENTAL|Cetuximab in combination with Carboplatin/Gemcitabine|Approximately 30 patients with advanced NSCLC will be enrolled. Patients will receive 3-week cycles of Cetuximab in combination with Carboplatin/Gemcitabine.
62750985|NCT06605404||Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)|Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)
62750986|NCT06605404||Esophageal|Esophageal cancer
62750987|NCT06605404||Gastric and Gastroesophageal Junction (GEJ)|Gastric and Gastroesophageal Junction (GEJ)
62750988|NCT06605404||Melanoma|Melanoma
62750989|NCT06605404||Non-small cell lung (NSCLC)|Non-small cell lung (NSCLC)
62750990|NCT06605404||Pancreatic (exocrine only)|Pancreatic (exocrine only)
62750991|NCT06605404||Mix of Solid Tumors (MOST)|Mix of Solid Tumors (MOST)
62750992|NCT01023555|NO_INTERVENTION|0.5cc 2 Bottles|
62750993|NCT01023555|ACTIVE_COMPARATOR|1cc single bottle|
62750994|NCT01384500|EXPERIMENTAL|Saline in tube cuff|Use of sterile saline to inflate tracheal tube cuff
62750995|NCT01384500|NO_INTERVENTION|Air in tube cuff|No intervention (control) - patient cohort, using air to inflate tracheal tube cuff.
62750996|NCT02227953|EXPERIMENTAL|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 7 days a week for 12 weeks (total of 84 applications)
62750997|NCT02227953|SHAM_COMPARATOR|sham-Yband (YDT-201N)|sham-tDCS application 7 days a week for 12 weeks (total of 84 applications)
62750998|NCT04865731|EXPERIMENTAL|Dermaprazole|30 HNC patients who will be using Dermaprazole twice daily for 7 weeks
62750999|NCT04865731|ACTIVE_COMPARATOR|Aquaphor|15 HNC patients using Aquaphor, the current clinical standard of care
62751000|NCT05381441|EXPERIMENTAL|SAFE Loop Arm|Nursing units involved in the intervention arm will participate in an iterative educational and quality improvement process that encourages improved reporting of medication safety events deemed important to their individual nursing units.
62751001|NCT05381441|NO_INTERVENTION|Control Arm|Nurses in this study will continue standard practice protocol.
62751002|NCT06464900|PLACEBO_COMPARATOR|Routine Care|Implementation of routine diabetes health education.
62751003|NCT06464900|EXPERIMENTAL|Based on BCW Theory of Health Education|A FoH intervention program based on BCW theory was implemented on top of the routine care.
62751004|NCT01940575|ACTIVE_COMPARATOR|Restylane®|Inject Restylane® on right or left nasolabial fold
62751005|NCT01940575|EXPERIMENTAL|SkinPlus-Hyal®|Inject SkinPlus-Hyal® on right or left nasolabial fold
62751006|NCT03036683|EXPERIMENTAL|Anodal stimulation|Participants in the active stimulation group will undergo anodal transcranial direct current stimulation (tDCS). tDCS will be delivered by a battery-driven, constant-current stimulator connected to two saline-soaked surface sponge electrodes. An anodal electrode (25cm2) will be placed over the right dorsolateral prefrontal cortex and one cathodal electrode (100cm2) will be placed over the left supraorbital area at least 5cm from the anode. Scalp electrodes will be positioned according to the 10-20 EEG international system. A current of 2mA will be applied for 20 minutes and the current will be ramped up and down over 20 seconds at the beginning and end of the stimulation period.
62751007|NCT03036683|SHAM_COMPARATOR|Sham stimulation|The sham tDCS condition will involve the same placement of the electrodes, current intensity, and ramp-up/down time as the active tDCS condition, but stimulation will only last for 30 seconds.
62751008|NCT05383443|EXPERIMENTAL|Intervention|"Multidomain non-pharmacological intervention, including cognitive training, physical exercise, nutrition education, capacitation to deal with cognitive decline, and diagnosis and correction of hearing impairment.~The intervention plan includes home training activities of identical intensity for participants with and without access or autonomy to use computer/internet. It will comprise individual and group sessions over three months, possibly extensible up to 12 months.~Caregivers or partners of all participants will be invited to participate in the activities of nutrition education and capacitation to deal with cognitive decline."
62751009|NCT05383443|ACTIVE_COMPARATOR|Control group|"Multidomain non-pharmacological intervention, including cognitive training, physical exercise, nutrition education, capacitation to deal with cognitive decline, and diagnosis and correction of hearing impairment.~It will comprise individual and group sessions, over three months (possibly extensible up to 12 months), conducted with a lower frequency in comparison with the intervention group.~Caregivers or partners of all participants will be invited to participate in the activities of nutrition education and capacitation to deal with cognitive decline."
61986423|NCT05872581|NO_INTERVENTION|Control group without intervention|No hand scanner results or training videos will be provided.
62375562|NCT00050570|NO_INTERVENTION|Control|The waitlist control group was only contacted at the time of assessments and was offered the intervention at the end of the study, after the 2-year follow-up assessment was completed.
62751010|NCT00515294|EXPERIMENTAL|1Caffeinated Alcoholic Beer|Caffeinated Alcoholic beer
62751011|NCT00515294|ACTIVE_COMPARATOR|2Non-Caffeinated Alcoholic Beer|Non-Caffeinated Alcoholic beer
62751012|NCT00515294|ACTIVE_COMPARATOR|3Caffeinated Non-Alcoholic Beer|Caffeinated Non-Alcoholic Beer
62751013|NCT00515294|PLACEBO_COMPARATOR|4Non-Caffeinated, Non-Alcoholic Beer|Non-Caffeinated, Non-Alcoholic Beer
62751014|NCT02629848|EXPERIMENTAL|Motesanib + Paclitaxel + Carboplatin|Motesanib 125 mg, (5 x 25 mg) tablets, orally, once daily and paclitaxel 200 mg/m\^2, intravenous, once on Day 1 and carboplatin at a dose to achieve a target Area Under the Curve (AUC) of 6.0 mg/mL x minute, once on Day 1 of a 3 week Cycle for up to 6 Cycles. After 6 Cycles, motesanib 125 mg, tablets, orally, once daily alone until disease progression, drug intolerability, study withdrawal or death for up to 36 months.
62751015|NCT02629848|PLACEBO_COMPARATOR|Placebo + Paclitaxel + Carboplatin|Motesanib placebo-matching tablets, orally, once daily and paclitaxel 200 mg/m\^2, intravenous, once on Day 1 and carboplatin at a dose to achieve a target AUC of 6.0 mg/mL x minute, once on Day 1 of a 3 week Cycle for up to 6 Cycles. After 6 Cycles, motesanib placebo-matching, tablets, orally, once daily alone until disease progression, drug intolerability, study withdrawal or death for up to 36 months.
62751016|NCT05502107|EXPERIMENTAL|PRESS Intervention|Study sites will participate in the intervention phase for 6 to 18 months, depending on the order of cluster randomization. Sites will switch from the baseline phase in approximately 6 month blocks, with all sites delivering the intervention for the final 6 months of the study.
62751017|NCT05502107|NO_INTERVENTION|Standard of Care|Study sites will participate in the standard of care phase to collect baseline data for 6 to 18 months, depending on the order of cluster randomization. All sites are in the baseline phase for the first 6 months then sites will switch one at a time, every 6 months, to the intervention phase of the study.
62751018|NCT05032690|EXPERIMENTAL|Treatment B: Bosutinib four 25 mg capsule after meal|Bosutinib four 25 mg capsule taken after a high-fat and high-calorie breakfast for comparison 1
62751019|NCT05032690|ACTIVE_COMPARATOR|Treatment A: Bosutinib 100 mg capsule after meal (active comparator)|Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast for comparison 1
62751020|NCT05032690|EXPERIMENTAL|Treatment A: Bosutinib 100 mg capsule after meal (experimental)|Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast for comparison 2
62751021|NCT05032690|ACTIVE_COMPARATOR|Treatment C: Bosutinib 100 mg capsule after fasting|Bosutinib 100 mg capsule taken after an overnight fast of at least 10 hours for comparison 2
62751022|NCT00837265|EXPERIMENTAL|Pilot Phase: Balugrastim Low Dose|Participants will receive balugrastim low dose administered by subcutaneous (SC) injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days).
62751023|NCT00837265|EXPERIMENTAL|Pilot Phase: Balugrastim Medium Dose|Participants will receive balugrastim medium dose administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days).
62751024|NCT00837265|EXPERIMENTAL|Pilot Phase: Balugrastim High Dose|Participants will receive balugrastim high dose administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days).
62751025|NCT00837265|ACTIVE_COMPARATOR|Pilot Phase: Pegfilgrastim|Participants will receive pegfilgrastim 6 mg administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days).
62751026|NCT00837265|EXPERIMENTAL|Main Phase: Balugrastim Medium Dose|Participants will receive balugrastim medium dose administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days).
62751027|NCT00837265|EXPERIMENTAL|Main Phase: Balugrastim High Dose|Participants will receive balugrastim high dose administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days).
62751028|NCT00837265|ACTIVE_COMPARATOR|Main Phase: Pegfilgrastim|Participants will receive pegfilgrastim 6 mg administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days).
62751029|NCT03252886|ACTIVE_COMPARATOR|DL user|Experienced emergency physicians who primarily use the direct laryngoscopy (DL) for endotracheal intubation during cardio-pulmonary resuscitation.
62751030|NCT03252886|ACTIVE_COMPARATOR|VL user|Experienced emergency physicians who primarily use the videolaryngoscopy (VL) for endotracheal intubation during cardio-pulmonary resuscitation.
62391543|NCT06103773|EXPERIMENTAL|SAD-TollB-001 400mg Dosage groups|drug：TollB-001 tablets （400mg，single-dose, on the first day）
62391544|NCT06103773|EXPERIMENTAL|SAD-TollB-001 800mg Dosage groups|drug：TollB-001 tablets （800mg，single-dose, on the first day）
62751031|NCT00592228|OTHER|1|Fractional flow guided drug-eluting stent implantation arm
62751032|NCT00592228|OTHER|2|Routine drug-eluting stent implantation
62751033|NCT03233334|EXPERIMENTAL|Purpose Project Group|Group receiving Purpose Project intervention.
62751034|NCT04018820|EXPERIMENTAL|Training program|
62751035|NCT00820794|EXPERIMENTAL|Cohort 1a|Subjects are treated with single dose lithium first. Then after at least 7 day washout, the subjects start PD 0332334 treatment from day 1 to day 9. At day 4 of PD 0332334 treatment, single dose lithium is given to subjects.
62751036|NCT00820794|EXPERIMENTAL|Cohort 1b|Subjects are treated with PD 0332334 from day 1 to 9 and a single dose of lithium is given at day 4. After at least 7 day washout, the subjects are treated with single dose of lithium.
62751037|NCT00907803|EXPERIMENTAL|ST-246 400 mg|ST-246 400mg (2 x 200 mg Capsules) Orally Once Daily for 14 days
62751038|NCT00907803|EXPERIMENTAL|ST-246 600 mg|ST-246 600 mg (3 x 200 mg Capsules) Orally Once Daily for 14 days
62751039|NCT00907803|PLACEBO_COMPARATOR|Placebo|Matching Placebo capsules, Orally Once Daily for 14 days
62751040|NCT04373408||ACL rupture without indication for ALL surgery|Patients with an ACL rupture undergoing surgical repair of the ACL only
62751041|NCT04373408||ACL rupture with indication for ALL surgery|Patients with an ACL rupture undergoing surgical repair of the ACL and the ALL
62751042|NCT04420572|EXPERIMENTAL|ozone injection group|ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
62751043|NCT04420572|EXPERIMENTAL|steroid injection group|1ml betamethasone will be used for steroid injection.
62751044|NCT06443710|EXPERIMENTAL|Patients with malignant tumors of the gastrointestinal tract or healthy subjects|Each patient will receive 10 or 20 mCi ± 20% technetium \[99mTc\]-H7ND injection intravenously
62751045|NCT01576419|EXPERIMENTAL|PG201 tablet|
62751046|NCT01576419|ACTIVE_COMPARATOR|Celecoxib capsule|
62751047|NCT06606535||Cases|Breast cancer patients undergoing endocrine adjuvant therapy with Aromatase Inhibitors (+ GnRH analogues if they are premenopausal)
62751048|NCT06606535||Controls|Healthy age-matched women who are not using hormonal contraception or hormonal replacement therapy at the time of the study.
62751049|NCT01370200|ACTIVE_COMPARATOR|4% citrate|4% trisodium citrate, starting infusion rate 180 ml/h Interventions according to postfilter ionized calcium, change in 10 ml/h step
62751050|NCT01370200|ACTIVE_COMPARATOR|15% citrate|15% trisodium citrate, starting infusion rate 50 ml/h Interventions according to postfilter ionized calcium, change in 10 ml/h step
62751051|NCT04265729|OTHER|single test product arm|use of Neocate Infant and Junior marketed products (product type depending on subject's age and condition)
62751052|NCT00167141|EXPERIMENTAL|testosterone injections|injections of testosterone to normal men (arm 1) and two men with subnormal semen parameters (arm 2)
62751053|NCT04545164|NO_INTERVENTION|Usual Care|Participants in the usual care arm will receive no specific trial intervention. Usual care includes tests routinely available at Zomba Central Hospital, including (but not limited to) conventional (plain film) chest X-ray, urine Alere LAM and sputum Xpert Mtb/Rif on treating clinician request.
62751054|NCT04545164|EXPERIMENTAL|DCXR-CAD and FujiLAM and usual care|Participants randomized to the intervention arm will receive TB screening using DCXR-CAD and urine FujiLAM. The CAD score and FujLAM results will be appended into their medical notes for treating clinicians to see. If patients have a CAD score above a pre-determined threshold the study team will attempt to collect sputum for Xpert Mtb/Rif. Chest X-ray images will be available for clinicians to view. This is in addition to usual care (detailed above).
62751055|NCT04545164|OTHER|Diagnostic cohort|Patients in the observational enhanced diagnostic arm will receive an enhanced package of diagnostics. This is a smaller arm (1 in 9 of all clusters) and is observational only - participants in this arm do not contribute to trial outcomes.
62751056|NCT04236180|ACTIVE_COMPARATOR|Intervention Group|Patients enrolled in the Specialised Paediatric Palliative Care (SPPC) programme at the University Children's Hospital Zurich.
62751057|NCT04236180|NO_INTERVENTION|Comparison Group|Patients treated at the Children's Hospital Aarau, University Children's Hospital Basel, and the University Hospital Inselspital Bern.
62751058|NCT06605313|EXPERIMENTAL|SQ-Kyrin-T Transcatheter Tricuspid Valve Repair System|Subjects who received treatment with the experimental device will be included in this arm.
62751059|NCT01612286|EXPERIMENTAL|endostatin|chemotherapy concurrently with endostatin
62751060|NCT06238843|ACTIVE_COMPARATOR|control arm|Treatment of Investigator's choice irinotecan or paclitaxel
62751061|NCT06238843|EXPERIMENTAL|experimental arm|IBI343 monotherapy
62555519|NCT05943717||50 children and adolescents with end stage renal disease on regular hemodialysis|50 children and adolescents with end stage renal disease on regular hemodialysis for three times weekly
62555520|NCT01990248||Cohort|
62555521|NCT02042118|EXPERIMENTAL|Laryngeal Mask Airway|Laryngeal mask airway (LMA) ventilation will be provided for newborns in this arm during the first 2.5 minutes.
62555522|NCT02042118|ACTIVE_COMPARATOR|Face mask ventilation|Face-mask ventilation (FMV) will be provided for newborns in this arm during the first 2.5 minutes.
62555523|NCT06354517|EXPERIMENTAL|SENSE group|Parents of babies in this group will be given SENSE program training. After the training, parents will care for their babies within the scope of the SENSE program. These babies will receive care from their parents with positive sensory exposures within the scope of the SENSE program from admission to the clinic until discharge. Data collection forms will be administered to babies and their parents.
62567464|NCT03468517|ACTIVE_COMPARATOR|Bathe Group|In the comparator group of patients, Bathe method will be applied at preoperative evaluation process.
62751062|NCT03224507|EXPERIMENTAL|KRdD followed by auto-HCT|Cycle 1-Dexamethasone 40mg orally days 1/8/15/22; Lenalidomide 25mg orally days 1-21; Carfilzomib 20mg/m2 days 8/9 then 36mg/m2 venous days 15/16; Daratumumab 16mg/kg venous days 1/8/15/22 (KRd-Dara). Cycle 2 the same except Carfilzomib 36mg/m2 venous days 1/2/8/9/15/16. Cycles 3,4 the same but no Daratumumab Days 8 and 22. Dosage adjusted for last tolerated dose (LTD). Following induction therapy, auto-HCT is done (consolidation 1), then up to two 4-cycle blocks of KRd-Dara consolidation (consolidations 2 and 3). Minimum residual disease (MRD) checked after each phase. Patients with confirmed MRD(-) at or after consolidation 1 will not undergo maintenance and will be actively monitored for resurgence of MRD or clinical relapse. After consolidation if MRD+ patients will undergo standard of care lenalidomide maintenance.
62375563|NCT01018251|EXPERIMENTAL|Arm I|Patients undergoing definitive surgery after cancer diagnosis undergo 3'-deoxy-3'-\[18F\] fluorothymidine (FLT)-PET prior to definitive surgery. Patients undergoing neoadjuvant chemotherapy prior to definitive surgery undergo FLT-PET prior to and after completion of neoadjuvant chemotherapy
62375564|NCT03350802||procalcitonin pneumonia cohort|Patients who are suspected of acute pneumonia due to symptoms and imaging findings compatible with pneumonia can be enrolled in this cohort.
62375565|NCT02463227|EXPERIMENTAL|VRC01|Participants received an IV infusion of 40 mg/kg of VRC01 on study days 0, 21, and 42.
62375566|NCT03988894|NO_INTERVENTION|Control: Usual Care|All participants will (a) receive a general hypertension health education booklet from the Heart and Stroke Foundation of Ontario;(b) be encouraged to see their family physicians or primary health care providers regarding their blood pressure status; those who do not have a primary health care provider will be referred to a walk-in clinic or a community health centre; and (c) have access to family physicians, tele-health, emergency care, hospital and other health care facilities in the Greater Toronto Area as required.
62375567|NCT03988894|ACTIVE_COMPARATOR|Intervention: mDASHNa-CC app use|In addition to usual care, those participants randomized to the intervention group will be offered use of the app.Then, they will load the app in their smartphones and be requested to review educational contents, conduct dietary self-assessment, and monitor blood pressure for 8 weeks.By the end of eight weeks post randomization, seniors will be prompted by phone using an audible alert to complete the app Evaluation Questionnaire on the smartphone, which ascertains likes and dislikes with the app.
62375568|NCT02330601|NO_INTERVENTION|control group|The papilla orifice could be enlarged by asphincterotomeif necessary. The stones were retrieved by a basket or a retrieval balloon
62751063|NCT03224507|EXPERIMENTAL|KRdD only|Cycle 1-Dexamethasone 40mg orally days 1/8/15/22; Lenalidomide 25mg orally days 1-21; Carfilzomib 20mg/m2 days 8/9 then @ 36mg/m2 venous days 15/16; Daratumumab 16mg/kg venous days 1/8/15/22. Cycle 2 the same except Carfilzomib 36mg/m2 venous days 1/2/8/9/15/16. Cycles 3,4 the same but no Daratumumab Day 22. Dosage adjusted for last tolerated dose (LTD). Following induction therapy, Following induction therapy, patients will receive up to three 4-cycle blocks of KRd-Dara consolidation (consolidations 1, 2 and 3). Minimum residual disease (MRD) checked after each phase. Patients with confirmed MRD(-) at or after consolidation 1 will not undergo maintenance and will be actively monitored for resurgence of MRD or clinical relapse. After consolidation if MRD+ patients will undergo standard of care lenalidomide maintenance.
62555524|NCT06354517|NO_INTERVENTION|Control group|The SENSE program will not be applied to the parents of babies in this group. These babies will receive the routine care of the clinic. These babies will be monitored from admission to the clinic until discharge. Data collection forms will be administered to infants and parents.
62391545|NCT06103773|EXPERIMENTAL|SAD-TollB-001 1000mg Dosage groups|drug：TollB-001 tablets （1000mg，single-dose, on the first day）
62751064|NCT01771848|EXPERIMENTAL|Grp 1-10ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 1 (n=6): 2,500 PfSPZ administered IM in a volume of 10 µL in 2 sites (one injection of 10µL containing 1,250 PfSPZ in each deltoid)."
62391546|NCT06103773|EXPERIMENTAL|MAD- TollB-001 100mg Dosage groups|drug：TollB-001 tablets （100mg，Multiple-dose, once per day for 5 days）
62567465|NCT01729390|EXPERIMENTAL|Std ED Control|100% energy density and 133% portion size
62751065|NCT01771848|EXPERIMENTAL|Grp 2-50ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 2 (n=6): 2,500 PfSPZ administered IM in a volume of 50 µL in 2 sites (one injection of 50µL containing 1,250 PfSPZ in each deltoid)."
62751066|NCT01771848|EXPERIMENTAL|Grp 3-250ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 3 (n=6): 2,500 PfSPZ administered IM in a volume of 250 µL in 2 sites (one injection of 250 µL containing 1,250 PfSPZ in each deltoid)."
62751067|NCT01771848|EXPERIMENTAL|Grp 4-50ul x 2; 25,000 PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 4 (n=6) (control group) 25,000 PfSPZ administered IM in a volume of 50 µL in 2 sites (one injection of 50 µL containing 12,500 PfSPZ in each deltoid)."
62751068|NCT01771848|EXPERIMENTAL|Grp 5-Optimal vol Part A x 2; 25,000 PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 5 (n=6) 25,000 PfSPZ administered IM in the optimum volume determined in Part A in 2 sites (one injection of the optimum volume containing 12,500 PfSPZ in each deltoid).~If the optimal volume in Part A is 50µL, then Group 5 will be modified to avoid duplication of regimens between groups 4 and 5. In this case, volunteers in group 5 will be administered a dose of 25,000 PfSPZ administered intradermally in four 10 µL injections. (Every volunteer will receive 4 ID injections of 6,250 PfSPZ in a volume of 10 µL each, with 2 injections in each arm respectively)."
62391547|NCT06103773|EXPERIMENTAL|MAD- TollB-001 200mg Dosage groups|drug：TollB-001 tablets （200mg，Multiple-dose, once per day for 5 days）
62567466|NCT01729390|EXPERIMENTAL|Inc ED Control|133% energy density and 133% portion size
62567467|NCT01729390|EXPERIMENTAL|Std ED and Std PS|100% energy density and 100% portion size
62567468|NCT01729390|EXPERIMENTAL|Std ED and Inc PS|100% energy density and 133% portion size
62567469|NCT01729390|EXPERIMENTAL|Inc ED and Inc PS|133% energy density and 133% portion size
62567470|NCT01729390|EXPERIMENTAL|Inc ED and Std PS|133% energy density and 100% portion size
62567471|NCT05067413|SHAM_COMPARATOR|Total mesorectal excision approach|Patients of the control group who are to receive the traditional approach-- total mesorectal excision approach to transect the distal rectum are assigned into this arm.
62567472|NCT05067413|EXPERIMENTAL|Transanterior obturator nerve gateway approach|Patients of the experimental group who are to receive the novel approach-- transanterior obturator nerve gateway approach to transect the distal rectum are assigned into this arm.
62567473|NCT05118672|EXPERIMENTAL|Experimental drug (paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg)|Group 1: paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg FDC (experimental drug).
62567474|NCT05118672|PLACEBO_COMPARATOR|Placebo group|Group 2: Placebo
62567475|NCT00803608|ACTIVE_COMPARATOR|02|Current standard of care insole
62567476|NCT00803608|EXPERIMENTAL|01|TrueContour® insole
62567477|NCT01620138|ACTIVE_COMPARATOR|Pasireotide|"For non-cured patients with prolactinomas resistant to cabergoline, MRI will be performed immediately before and six months after the onset of pasireotide treatment. The anti-secretory effect will be evaluated by prolactin dosage every month.~For patients harboring a NFPA, treatment will be started at least 3 months after neurosurgery, when a pituitary MRI clearly shows the presence of a residual tumor without any possible misinterpretation of postsurgical changes. In this case, the drug efficacy will be evaluated clinically by visual field and by MRI six months after pasireotide treatment."
62375569|NCT02330601|OTHER|EPLBD group|a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
62555525|NCT06515119|EXPERIMENTAL|Resources-oriented Salutogenic Intervention|"Intervention contents: Participants in the intervention group (IG) will receive online Resources-oriented Salutogenic intervention in the form of group lectures and in-session activity via Zoom meetings, and home activity via Facebook. Each group will have 7-8 participants. The intervention contents will provide information about resources and their utilization skills on health literacy related to prediabetes, healthy diet, exercise training, stress management, social support, and peer support. They will receive a) a resources booklet, b) My Salutogenic Diary for daily life recording, c) receive monthly telephone follow-ups.~Intervention form: online group courses via Zoom meetings and Facebook. Intervention frequency and duration: 90 minutes per week, 8 weeks and two telephone follow-ups, once a month."
62555526|NCT06515119|NO_INTERVENTION|Usual Care|The control group (CG) will receive usual care (that is, general health education about lifestyle) on Facebook and undergo monthly educational follow-ups via Facebook messages to check the practical application of healthy lifestyle.
62555527|NCT01796600|EXPERIMENTAL|Conventional and a cone-beam scanner 5G|The patients will have a conventional scanner, a reference examination, and a cone-beam scanner Newtom 5G just after the conventional scanner
62751069|NCT01771848|EXPERIMENTAL|Grp 6-Optimal vol Part A x 2; 125,000* PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 6 (n=6) 125,000 PfSPZ administered IM in the optimum volume determined in Part A in 2 sites (one injection of the optimum volume containing 62,500 PfSPZ in each deltoid) if the volume is 50 µL or 250 µL.~\*If the optimal volume in Part A is 10 µL, then Group 6 will receive 100,000 PfSPZ (2 inoculations of 50,000 PfSPZ) instead of 125,000 PfSPZ."
62751070|NCT00072930|ACTIVE_COMPARATOR|1|MEDI-522 + Docetaxel + Prednisone + Zoledronic Acid (N=55)
62555528|NCT05423132|ACTIVE_COMPARATOR|Physiological serum Group|"The cluneal nerve block is performed under ultrasound using the Thomas Dahl Nielsen and Thomas Fichtner Bendtsen method.~The patients are placed in ventral decubitus. A sensor of high linear frequency is moved toward the middle and posterior to where the aponeurosis of the transverse muscle and the thoraco-lumbar fascia meet, following the appearance of the thoracolumbar fascia and then the appearance of the posterior ilio-costalis muscle under the fascia lumbar area. The infiltration is carried out in-plane, with a lateral towards the median axis direction, in a way, that it penetrates perpendicularly the fascia~The physiological serum (NaCl 0.9%) will be injected, on each side, into the aponeurosis and the muscle in the area where the superior cluneal nerves pass. An easy separation of the thoraco- lumbar fascia and the ilio-costalis muscle is achieved during injection by slightly raising the needle towards the median axis as the space opens up gradually."
62567478|NCT01620138|ACTIVE_COMPARATOR|cabergoline|In patients with non-functioning pituitary adenoma, treatment will be started at least 3 months after neurosurgery, when a pituitary MRI clearly shows the presence of a residual tumor without any possible misinterpretation of postsurgical changes. The drug response will be evaluated clinically by visual field and by Magnetic resonance imaging (MRI) before medical treatment and after six months of cabergoline treatment at maximum dose.
62567479|NCT03131843|EXPERIMENTAL|Alcohol|Alcohol will be wiped on the vaccine injection site immediately before vaccine injection.
62751071|NCT00072930|OTHER|2|Docetaxel + Prednisone + Zoledronic Acid (N=55)
62751072|NCT06599554||patients|patients suffering from fibula fracture treated surgically through reduction and synthesis with an anatomical fibula plate
62391548|NCT06103773|EXPERIMENTAL|MAD-TollB-001 400mg Dosage groups|drug：TollB-001 tablets （400mg，Multiple-dose, once per day for 5 days）
62391549|NCT06103773|EXPERIMENTAL|MAD-TollB-001 800mg Dosage groups|drug：TollB-001 tablets （800mg，Multiple-dose, once per day for 5 days）
62751073|NCT01773551||Optical Index of Breast Density|Breast Density
62751074|NCT04404036|EXPERIMENTAL|SinuSonic Device|"Aim 1: SinuSonic device used once a day over a 2 day period.~Aim 2: SinuSonic device used twice daily for 3 minutes in the home setting for 6 weeks.~Aim 3: SinuSonic device used twice daily for 3 minutes in the home setting for 4 weeks."
62751075|NCT05996055|ACTIVE_COMPARATOR|control group|initially using the Type A device (the NTUH version_support device)
61986424|NCT05726396|EXPERIMENTAL|RMT group|16 patients will be randomized to Oral restorative microbiota therapy (RMT). Consenting eligible participants receive a loading dose of RMT capsules.
61986425|NCT05726396|PLACEBO_COMPARATOR|active placebo|participants in the placebo arm will receive an identical looking placebo capsules
62375570|NCT03286634|EXPERIMENTAL|SR|"Standard Risk (SR) :~CNS 3 or CNS 2 regardless of response OR Time-point #1 (Day 15 induction) Flow MRD ≥ 1% (treatment will not be de-escalated even MRD \<0.01% by TP#2) OR Time-point #2 (Day 1 IDMTX/MP of Consolidation) ≥0.01%~SR strategy:~All SR patient will have to receive two doses of anthracycline and 12 L-asparaginase doses during induction except those who are escalated to SR at time point 2 when MRD ≥0.01%.~During the first year of maintenance phase (48 weeks; 4x12 weeks blocks), cyclophosphamide and cytarabine bolus will be administered at 4 weekly interval."
62375571|NCT03286634|EXPERIMENTAL|LR|"Low Risk (LR):~Time-point #1 (Day 15 induction) Flow MRD \<1% AND Time-point #2 (Day 1 IDMTX/MP of Consolidation) \<0.01% AND CNS 1 only~LR strategy:~For LR patients, one dose of anthracycline and 3 doses of L-asparaginase will be omitted during induction.~Following re-induction I, interim maintenance and additional block of re-induction ie. re-induction II prior to maintenance phase will be omitted for LR patients."
62375572|NCT03659708|EXPERIMENTAL|Lyon-VTE score|"300 adult pregnant women with a personal history of VTE and/or known thrombophilia, will be randomly included in this group and their VTE risk during pregnancy will be managed according to the Lyon-VTE score :~The Lyon score classifies patients into 3 risk categories and directs the preventive LMWH prescription:~* A score strictly less than 3 indicates a moderate thrombotic risk: the patient does not receive LMWH in ante-partum;~* A score between 3 and 5 indicates a high thrombotic risk: a preventive dose LMWH is introduced in the third trimester (from the beginning of the 7th month);~* A score greater than or equal to 6 indicates a very high thrombotic risk: LMWH at a preventive dose is prescribed throughout the ante-partum.~All patients receive an elasto-compression prescription and daily physical activity is recommended throughout pregnancy (except obstetric contraindication).~All patients also receive systematic preventive LMWH treatment postpartum for 6 weeks."
62375573|NCT03659708|EXPERIMENTAL|recommendations currently available|300 adult pregnant women with a personal history of VTE and/or known thrombophilia, will be randomly included in this group and their VTE risk during pregnancy will be managed according to the last ACCP guidelines or UK guidelines or Canadian recommendations or French recommendations, according to the habits of the center.
62375574|NCT06006143|EXPERIMENTAL|Varenicline|Participants will receive a prescription for generic varenicline
62375575|NCT00102336|EXPERIMENTAL|AMG 531|Active investigational product
62375576|NCT00102336|PLACEBO_COMPARATOR|Placebo|
62375577|NCT00005629|EXPERIMENTAL|Group A - first dosing group|Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides (100 ug dose) emulsified in 2 ml of Montanide ISA-51.
61986426|NCT01187927||Female subjects|Subjects received Cervarix® as per routine practice
61986427|NCT00238121|EXPERIMENTAL|Treatment|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61986428|NCT01369576|PLACEBO_COMPARATOR|Placebo|Usual sleep apnea and CPAP care Sleep apnea OSR Medical Treatment Plan©
61986429|NCT01369576|EXPERIMENTAL|zopiclone|Sleep apnea OSR Medical Treatment plan ©
62751076|NCT05996055|EXPERIMENTAL|experimental group|initially using the Type B device (improved version_support device)
62751077|NCT01349322|ACTIVE_COMPARATOR|Whole breast irradiation + sequential boost|Standard fractionation whole breast irradiation (WBI) with sequential boost.
62751078|NCT01349322|EXPERIMENTAL|Hypofractionated whole breast irradiation + concurrent boost|Hypofractionated whole breast (H-WBI) irradiation with a concurrent boost
62751079|NCT06236542|EXPERIMENTAL|Automated tracheostomy suctioning device|Participants in this group will receive tracheostomy suctioning using an automated robotic suctioning device.
62751080|NCT06236542|EXPERIMENTAL|Mixed-reality tracheostomy tube change system|Participants in this group will receive tracheostomy tube changes using a mixed-reality tracheostomy tube change device.
62751081|NCT06236542|EXPERIMENTAL|NextGen Tracheostomy Toolkit|Participants in this group will receive tracheostomy care using the NextGen Tracheostomy Toolkit. Providers will be trained using virtual reality educational modules. Participants in this group will receive tracheostomy suctioning using an automated robotic suctioning device and tracheostomy tube changes using a mixed-reality tracheostomy tube change device.
62751082|NCT06236542|NO_INTERVENTION|Control group|Participants in this group will receive usual tracheostomy care.
62751083|NCT05707351|EXPERIMENTAL|Adynovate 45±5 IU/kg|Participants will receive prophylactic treatment with Adynovate (45 \[±5\] international units per kilogram \[IU/kg\]), infusion, intravenously, twice-weekly, over a period of 26 weeks or at least 50 EDs, whichever occurs last.
62751084|NCT03315273|EXPERIMENTAL|Traumatic brain injury|"Patients who have suffered a traumatic brain injury will be assessed with a test battery including~* a motor imagery ability questionnaire (MIQ-rs)~* a mental rotation test~* a chronometry test (TDMI)"
62375578|NCT00005629|EXPERIMENTAL|Arm B - dosing group 2|Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides (500 ug dose) emulsified in 2 ml of Montanide ISA-51.
62375579|NCT00005629|EXPERIMENTAL|Group 3 - dosing level 3|Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides (1000 ug dose) emulsified in 2 ml of Montanide ISA-51.
62375580|NCT03309241|EXPERIMENTAL|Cohort 1|Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
62567480|NCT03131843|PLACEBO_COMPARATOR|No alcohol|Alcohol will be wiped adjacent to the vaccine injection site immediately before vaccine injection.
62567481|NCT03596801|EXPERIMENTAL|Group 1: RSV 6120/∆NS1 Vaccine|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of 10\^6.0 plaque-forming units (PFUs) of RSV 6120/∆NS1 vaccine at Day 0.
62567482|NCT03596801|EXPERIMENTAL|Group 1: RSV 6120/F1/G2/∆NS1 Vaccine|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of 10\^5.8 PFUs of RSV 6120/F1/G2/∆NS1 vaccine at Day 0.
62567483|NCT03596801|PLACEBO_COMPARATOR|Group 1: Placebo|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of placebo at Day 0.
62567484|NCT03596801|EXPERIMENTAL|Group 2: RSV 6120/∆NS1 Vaccine|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of 10\^5.0 PFUs of RSV 6120/∆NS1 vaccine at Day 0.
62567485|NCT03596801|EXPERIMENTAL|Group 2: RSV 6120/F1/G2/∆NS1|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of 10\^5.0 PFUs of RSV 6120/F1/G2/∆NS1 vaccine at Day 0.
62567486|NCT03596801|PLACEBO_COMPARATOR|Group 2: Placebo|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of placebo at Day 0.
62567487|NCT03225469|EXPERIMENTAL|reinforced family member education group|Regular instructions will be given to all patients during the colonoscopy appointment. At least one family member who lives with the patient together will be given instruction at the basis of patent education.
62567488|NCT03225469|NO_INTERVENTION|regular education group|Regular instructions will be given to the patients during the colonoscopy appointment. There will be nothing specially for family members.
62567489|NCT04744194|ACTIVE_COMPARATOR|Nordic hamstring exercise program|Participants are required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. When they can no longer lower themselves as such, they are instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touches the ground they are instructed to immediately return to the starting position by pushing up with their hands
62751085|NCT03315273|ACTIVE_COMPARATOR|Control|"Healthy volunteers matched for age, sex and educational level will be assessed with the same test battery including~* a motor imagery ability questionnaire (MIQ-RS)~* a mental rotation test~* a chronometry test (TDMI)"
62751086|NCT04633811|EXPERIMENTAL|Controlled Diet and Weight Loss Program|Subjects will consume a low oxalate diet with blood and urine collections to establish baseline levels before undergoing a weight loss program with Optifast VLCD products. After completing the weight loss program, subjects will once again consume a low oxalate diet with blood and urine collections to observe any changes that may have occurred due to the weight loss.
62751087|NCT01663324|EXPERIMENTAL|single site rTMS|"Low frequency temporoparietal transcranial magnetic stimulation~Intervention: Device: rTMS intervention 1"
62751088|NCT01663324|EXPERIMENTAL|multisite rTMS|"Combined high frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation~Intervention: Device: rTMS Intervention 2"
62751089|NCT00497549|ACTIVE_COMPARATOR|1|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
62751090|NCT00497549|ACTIVE_COMPARATOR|2|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
62751091|NCT05146713|EXPERIMENTAL|Propolis nanoparticles extract solution|
62751092|NCT05146713|ACTIVE_COMPARATOR|sodium hypochlorite|
62751093|NCT04543266||Patients with Progressive Disease|Patients with metastasis and/or recurrent OSCC were considered as a group of subjects with progressive disease
62751094|NCT04543266||Patients without Progressive Disease|Patients without metastasis and/or recurrent OSCC were considered as a group of subjects without progressive disease
62751095|NCT03373890|EXPERIMENTAL|Short burst Interval Treadmill Training High Frequency|Participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 5x/week for 4 weeks
62751096|NCT03373890|ACTIVE_COMPARATOR|Short Burst Interval Treadmill Training Low Frequency|Participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 2x/week for 10 weeks
62751097|NCT03404531|EXPERIMENTAL|Social Media Messages Intervention Group|Participants randomized to this condition will have access to a newly developed, culturally-tailored interactive website and theoretically-grounded social media messages.
62751098|NCT03404531|ACTIVE_COMPARATOR|Website Only Group|Participants randomized to this condition will have access to a newly developed, culturally-tailored interactive website only.
62375581|NCT03309241|EXPERIMENTAL|Cohort 2|Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
62555529|NCT05423132|EXPERIMENTAL|Ropivacaine Group|"The cluneal nerve block is performed under ultrasound using the Thomas Dahl Nielsen and Thomas Fichtner Bendtsen method.~The patients are placed in ventral decubitus. A sensor of high linear frequency is moved toward the middle and posterior to where the aponeurosis of the transverse muscle and the thoraco-lumbar fascia meet, following the appearance of the thoracolumbar fascia and then the appearance of the posterior ilio-costalis muscle under the fascia lumbar area. The infiltration is carried out in-plane, with a lateral towards the median axis direction, in a way, that it penetrates perpendicularly the fascia~The local anaesthetic (Ropivacaine) will be injected into the aponeurosis and the muscle in the area where the superior cluneal nerves pass. An easy separation of the thoraco- lumbar fascia and the ilio-costalis muscle is achieved during injection by slightly raising the needle towards the median axis as the space opens up gradually."
62751099|NCT01131429|EXPERIMENTAL|first-line erlotinib|erlotinib in first-line treatment and docetaxel/cisplatin in second-line treatment
62751100|NCT01131429|ACTIVE_COMPARATOR|second-line erlotinib|docetaxel/cisplatin in first-line treatment and erlotinib in second-line treatment
62751101|NCT04902924|EXPERIMENTAL|Repeated cold-water immersion|In this arm, the participants undergo repeated cold water immersion at 10°C for 2 x 5 min. Between the immersion, a break will be conducted 2.5 min. Participants will be immersed up to the iliac crest
62751102|NCT04902924|ACTIVE_COMPARATOR|Repeated warm-water immersion|In this arm, the participants undergo repeated warm water immersion at 40°C for 2 x 5 min. Between the immersion, a break will be conducted 2.5 min. Participants will be immersed up to the iliac crestParticipants will be immersed up to the iliac crest.
62375582|NCT03309241|EXPERIMENTAL|Cohort 3 (optional)|Single Ascending Dose administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
62555530|NCT01702064|EXPERIMENTAL|Nilotinib with Ruxolitinib|"The starting dose of ruxolitinib will be 5mg by mouth (PO) twice a day (BID) and will increase by 5 mg increments in each cohort, to a maximum dose of 15 mg PO BID. Nilotinib will be given at a dose ranging from 300 mg PO BID to 400 mg PO BID, depending on the participant's dose prior to enrollment on the trial.~Dose Level 1: Ruxolitinib 5 mg twice a day (BID); Nilotinib 300 mg or 400 mg BID.~Dose Level 2: Ruxolitinib 10 mg BID; Nilotinib 300 mg or 400 mg BID.~Dose Level 3: Ruxolitinib 15 mg BID; Nilotinib 300 mg or 400 mg BID."
62751103|NCT04902924|OTHER|Control|In this arm, the participants undergo the control intervention which comprises to remain seated for 12.5 min. The participants, that will perform the muscle damaging protocol under hypoxia will also be treated with the control condition.
62751104|NCT01975662|EXPERIMENTAL|Daptomycin|"Daptomycin will be dosed intravenously at 6-8mg/kg every 24 hours.~Patients with uncomplicated bacteremia will receive a dose of 6mg/kg every 24 hours. Patients with suspected complicated bacteremia or endocarditis, or receipt of at least two doses of vancomycin in the last 90 days (apart from vancomycin received for their current MRSA bacteremia) will receive a dose of 8mg/kg every 24 hours.~In patients with a creatinine clearance less than 30ml/min, or on intermittent or continuous hemodialysis, daptomycin will be dosed at 6-8mg/kg every 48 hours. The same criteria as above applies as to whether they receive 6mg/kg or 8mg/kg every 48hours. Daptomycin will be administered after hemodialysis in patients undergoing intermittent hemodialysis."
62751105|NCT01975662|ACTIVE_COMPARATOR|Vancomycin|Vancomycin will be dosed at 15mg/kg every 12 hours with appropriate dose adjustments by a pharmacist in patients with a creatinine clearance less than 50 ml/min, so as to achieve a vancomycin trough level of 15-20ug/ml.
62751106|NCT05404347||Gallbladder Cancer|Patients with confirmed diagnosis of gallbladder cancer
62751107|NCT05271032||Septic Patients|
62751108|NCT05807100||Stage I|Stage I Alzheimer's Group (n=42): Individuals diagnosed with probable Alzheimer's disease with mild (early stage) dementia according to the Clinical Dementia Rating Scale.
62751109|NCT05807100||Stage II|Stage II Alzheimer's Group (n=29): Individuals diagnosed with probable Alzheimer's disease with moderate (moderate stage) dementia according to the Clinical Dementia Rating Scale.
62751110|NCT05807100||Stage III|Stage III Alzheimer's Group (n=19): Individuals diagnosed with probable Alzheimer's disease with severe (advanced stage) dementia according to the Clinical Dementia Rating Scale.
62751111|NCT06607016|EXPERIMENTAL|Experimental Group|KJ103 +SOC(SoC consists of a standardized combination of PE, Cyclophosphamide, and glucocorticoids)
62751112|NCT02310230|OTHER|Blinded Group|Data from the ExSpiron Respiratory Variation Monitor (minute ventilation, tidal volume, and respiratory rate) will not be displayed. The anesthesia provider will care for the patient in the usual manner.
62751113|NCT02310230|EXPERIMENTAL|Monitor Group|The ExSpiron Respiratory Variation Monitor will display continuous real-time measurements of minute ventilation, tidal volume, and respiratory rate, and the anesthesia provider will be instructed to utilize this information in the care of the patient as they deem appropriate.
61986430|NCT02726256||Diabetes and Impaired glucose Tolerance (G-CREDIT)|Patients with either type 2 diabetes or impaired glucose tolerance who are older than 20 years old and have attended Gangnam Severance hospital for regular follow up.
62751114|NCT06601647|ACTIVE_COMPARATOR|ropivacaine|0.6% ropivacaine, control
62751115|NCT06601647|EXPERIMENTAL|ropivacaine + dexamethasone|0.6% ropivacaine + 2mg dexamethasone
62751116|NCT06601647|EXPERIMENTAL|ropivacaine + dexmedetomidine|0.6% ropivacaine + 025ug/kg dexmedetomidine
62751117|NCT06601647|EXPERIMENTAL|ropivacaine + dexamethasone + dexmedetomidine|0.6% ropivacaine + 2mg dexamethasone + 0.25/ug/kg dexmedetomidine
62751118|NCT01833195||Heart transplant recipients|Heart transplant rejection surveillance including AlloMap testing
62751119|NCT01022372||control group|
62751120|NCT01022372||endometriosis group|
62751121|NCT01022372||endometrioma group|
62555531|NCT03808480|EXPERIMENTAL|CA and Nivolumab|"After 1 cycle of cyclophosphamide and doxorubicin (CA) induction therapy, Nivolumab 360mg flat dose will be given on day 1 with CA chemotherapy in a 21-day cycle.~After the completion of 4 cycles of CA chemotherapy, Nivolumab will be continued as a single agent at a dose of 480mg flat dose every 4 weeks until loss of clinical benefit"
62555532|NCT02254265|EXPERIMENTAL|OTX-101 0.05%|OTX-101 0.05% ophthalmic solution 1 drop in both eyes BID for 84 days
62555533|NCT02254265|EXPERIMENTAL|OTX-101 0.09%|OTX-101 0.09% ophthalmic solution 1 drop in both eyes BID for 84 days
62555534|NCT02254265|PLACEBO_COMPARATOR|Vehicle|Vehicle of OTX-101 ophthalmic solution 1 drop in both eyes BID for 84 days
62555535|NCT01350271|PLACEBO_COMPARATOR|Placebo|Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
62555536|NCT01350271|ACTIVE_COMPARATOR|Mebendazole polymorph A and C 500 mg|Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
62555537|NCT01350271|EXPERIMENTAL|Mebendazole polymorph C 500 mg|Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
62555538|NCT05291273|EXPERIMENTAL|Intervention|All subjects will perform the same tests.
62555539|NCT03126448|OTHER|Group 1: Closed Index Fractures|Group 1 is clean, closed fractures undergoing index open reduction internal fixation (ORIF), intramedullary nailing (IMN) where the fracture site is accessible, or staged treatment of a pilon or plateau that was initially treated by joint spanning external fixation. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
62751122|NCT00926731|EXPERIMENTAL|1|AZD1152 variable dose in combination with 20 mg of LDAC. (The LDAC is given twice daily.)
62751123|NCT04388319|EXPERIMENTAL|Combination zonisamide and bupropion with e-cigarette|Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. After the first week of e-cigarette use, (at V3) participants will be given zonisamide and bupropion in addition to continued use of the G6. Use of these study drugs will continue for 12- weeks with a target complete switch date (from combustible cigarettes to e-cigarettes) one week after study drug initiation.
62751124|NCT04686851|EXPERIMENTAL|Intervention|Comprehensive Geriatric Assessment and follow-up as add on to standard oncologic care
62751125|NCT04686851|NO_INTERVENTION|Control|standard oncologic care according to national guidelines
62751126|NCT06477146|EXPERIMENTAL|Milk Thistle|Patients will be given Milk Thistle capsules based on weight by mouth once or twice daily for 12 weeks.
62751127|NCT06477146|EXPERIMENTAL|Placebo|Patients will be give 500mg capsule based on weight by mouth once or twice daily for 12 weeks.
62751128|NCT03657563|EXPERIMENTAL|Intervention group|Nurses with burnout are recruited in the intervention group and participate in positive psychological intervention.
61986431|NCT06299566||People with experience of cystic fibrosis|Adults or children with experience of CF.
62555540|NCT03126448|OTHER|Group 2: Hardware Removal from Healed Fractures|Group 2 will include patients having a plate removed from a healed fracture without clinical evidence of infection and excluding history of open fracture. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
62555541|NCT03126448|OTHER|Group 3: Index Treatment of Fracture Nonunions|Group 3 will be patients that are undergoing an index procedure for fracture nonunion at a site where prior surgery has been undertaken for the fracture. Exclusions include bone grafting of 'critical' defects, active clinical infection, or \< 3 months from index fracture fixation. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
62555542|NCT03212027||Patients with low-risk thymomas|low-risk thymomas include types A, AB, and B1 thymomas
62555543|NCT03212027||Patients with high-risk thymomas|high-risk thymomas include types B2 and B3 thymomas
62555544|NCT03212027||Patients with thymic carcinomas|thymic carcinomas also called types C thymomas
62555545|NCT06081478|EXPERIMENTAL|CD19/CD22 CAR-T group|Patients would receive autologous CAR-T cell therapy targeting both CD19 and CD22. The dosage for CD19-CAR-T cell was 2×10e6/kg and CD22-CAR-T cell was 1×10e6/kg. Both CAR-T cells were infused at the same day.
62555546|NCT05131555|PLACEBO_COMPARATOR|1: Placebo|lactose
61986432|NCT06299566||Health professionals|Health professionals with experience of caring for people with experience of CF.
61986433|NCT00736008||A|Patients with thromboembolic events
62555547|NCT05131555|EXPERIMENTAL|H1 blockade|540 mg Fexofenadine
62555548|NCT05131555|EXPERIMENTAL|H2 blockade|40 mg Famotidine
62751129|NCT03657563|NO_INTERVENTION|Control group|Nurses with burnout are recruited in the control group and none interventions are conducted to them.
62751130|NCT02881112|EXPERIMENTAL|Active Treatment Arm|Treatment with Provant Therapy System
62555549|NCT03583307|EXPERIMENTAL|Sirolimus|
62751131|NCT01432340||Vaccinated group|Children between 6months- 10years of age who have received the influenza vaccine
62751132|NCT01432340||Unvaccinated group|Eligible children between 6months and 10years who didn't receive the influenza vaccine
62751133|NCT06343870|ACTIVE_COMPARATOR|Testosterone|Subdermal implant-bioabsorbable testosterone pellet (100 mg of testosterone)
62751134|NCT06343870|PLACEBO_COMPARATOR|Placebo|Subdermal implant-bioabsorbable placebo pellet (cholesterol)
62751135|NCT02029807||Blood donors|Healthy adult volunteers donating blood
62751136|NCT00420004|EXPERIMENTAL|LY2216684|"LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks.~For the first week of treatment, participants received a starting dose of 3 mg/day. Then, based on tolerability, for the next 7 weeks, the dose could remain at 3 mg/day; it could be increased 3 mg at a time (scheduled visit) to a maximum dose of 12 mg/day; or it could be decreased 3 mg at any time (scheduled or unscheduled visits) to a minimum dose of 3 mg/day.~All participants were required to take an equal number of tablets (2) and capsules (2) per day. Therefore, participants on 3 mg/day and 6 mg/day of LY2216684 also received 1 LY2216684-matching placebo tablet + 2 escitalopram-matching placebo capsules. Participants on 9 mg/day and 12 mg/day of LY2216684 also received 2 escitalopram-matching placebo capsules."
62751137|NCT00420004|PLACEBO_COMPARATOR|Placebo|Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks.
62751138|NCT00420004|ACTIVE_COMPARATOR|Escitalopram|"Escitalopram: flexible dose of 10 or 20 milligram (mg), capsules, administered orally, once daily for 8 weeks.~For the first week of treatment, participants received a starting dose of 10 mg/day. Then, based on tolerability, for the next 7 weeks, the dose could remain at 10 mg/day; it could be increased up to a maximum dose of 20 mg/day; or it could be decreased back to 10 mg/day.~All participants were required to take an equal number of tablets (2) and capsules (2) per day. Therefore, participants on 10 mg/day of escitalopram also received 1 escitalopram-matching placebo capsule + 2 LY2216684-matching placebo tablets. Participants on 20 mg/day of escitalopram also received 2 LY2216684-matching placebo tablets."
62751139|NCT01255813|PLACEBO_COMPARATOR|Placebo|
62751140|NCT01255813|EXPERIMENTAL|Sub-perception|
62751141|NCT01255813|EXPERIMENTAL|Full Stimulation|
62751142|NCT04929002||McArdle Disease|
62751143|NCT04929002||Pompe disease|
62751144|NCT04929002||Controls|
62751145|NCT02275715|EXPERIMENTAL|Parent Training Program (PT-F)|Treatment group
62751146|NCT02275715|NO_INTERVENTION|Waitlist|Control group in which parents randomized to this group will be offered the PT-F at the end of the 20 week study period to address their child's feeding issues.
62751147|NCT05047029||Patients with cirrhosis|Patients with cirrhosis and transjugular intrahepatic portosystemic shunt implantation.
62751148|NCT05433051|ACTIVE_COMPARATOR|Buccal miniscrews with TPA|active comparator double center
62555550|NCT01707290|EXPERIMENTAL|Ivacaftor|Participants who received Ivacaftor 150 milligram (mg) tablet and/or Placebo matched to Ivacaftor tablet orally, every 12 hours (q12h) in the previous study VX11-770-110 (Study 110; NCT01614457), VX12-770-111 (Study 111; NCT01614470) or VX12-770-113 (Study 113; NCT01685801); received Ivacaftor 150 mg tablet q12h in this VX12-770-112 (Study 112; NCT01707290) up to 104 weeks.
62555551|NCT01707290|NO_INTERVENTION|Observational|Participants who received Ivacaftor 150 mg tablet and/or Placebo matched to Ivacaftor tablet, orally, q12h in the previous Study 110 (NCT01614457) or Study 111 (NCT01614470), were observed (did not receive study drug) in this Study 112 (NCT01707290) for up to 2 years.
62555552|NCT02517008|EXPERIMENTAL|Mama kits intervention|"Health facilities randomized to this arm provided mama kits - packages of childcare materials including a cloth (chitenge), baby blanket, and diaper - to all mothers who delivered at these facilities between June 1, 2013 - Aug 31, 2013."
62555553|NCT02517008|NO_INTERVENTION|No intervention|Health facilities randomized to this arm provided obstetric services as normal.
62555554|NCT01326845|EXPERIMENTAL|Deferasirox am|Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food
62751149|NCT05433051|ACTIVE_COMPARATOR|vertical holding appliance|active comparator double center
62751150|NCT05757154|EXPERIMENTAL|Coffee A|Coffee type A. All intervention arms are coffee. Three different types of coffee is tested. Differences in type of bean, degree of roasting and preparation method.
62751151|NCT05757154|EXPERIMENTAL|Coffee B|Coffee type B. All intervention arms are coffee. Three different types of coffee is tested. Differences in type of bean, degree of roasting and preparation method.
62751152|NCT05757154|EXPERIMENTAL|Coffee C|Coffe type C. All intervention arms are coffee. Three different types of coffee is tested. Differences in type of bean, degree of roasting and preparation method.
62751153|NCT02185430|PLACEBO_COMPARATOR|Control group|saline solution
62751154|NCT02185430|ACTIVE_COMPARATOR|dexmedetomidine group|dexmedetomidine
62751155|NCT01073397|EXPERIMENTAL|Behavioral|Weekly Integral Yoga sessions lasting 90 minutes for 10 weeks with home practice.
62751156|NCT01073397|ACTIVE_COMPARATOR|Health and Wellness Classes|Weekly classes on health and wellness lasting 90 minutes for 10 weeks, with additional home practice
62751157|NCT01073397|NO_INTERVENTION|Waitlist|This group receives usual care for 10 weeks and is then randomized to one of the study arms.
62751158|NCT01869530||Healthy children|
62751159|NCT01707433||Diagnosis of hip disease|Diagnosed with spondyloepiphyseal dysplasia or multiple epiphyseal dysplasia or bilateral Legg-Calve-Perthes disease, or bilateral proximal femoral epiphyseal dysplasia
62751160|NCT05838027|NO_INTERVENTION|Control|No intervention
62751161|NCT05838027|EXPERIMENTAL|Cash Transfer|Participants will receive $125 every 2 weeks for 8 payments via ClinCard, for a total of $1000.
62555555|NCT01326845|EXPERIMENTAL|Deferasirox pm|Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal
62555556|NCT01668290||Stress Echocardiography|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Stress Echocardiography.
62555557|NCT01668290||SPECT|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Single Photon Emission Computed Tomography (SPECT)
62555558|NCT01668290||CCTA|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Cardiac Computed Tomographic Angiography (CCTA)
62751162|NCT01430962||General Anesthesia|Patients will receive Total Intravenous Anesthesia (TIVA) with a combination of Propofol, Ketamine and neuromuscular blockade by anesthesia. Either an LMA or an ETT will be used to secure airway.
62751163|NCT01430962||Moderate Sedation|Patients will receive moderate sedation given by the physician performing EBUS with a combination of Versed and Fentanyl per hospital protocol.
62555559|NCT01660425|NO_INTERVENTION|treatment as usual with MPH|In the first twelve months of intervention the children receive treatment as usual with MPH and do not get any further intervention. Afterwards, the families get the opportunity to take part in the program which is then conducted for a duration of four months. Measurements are performed at the beginning of the program, after six moths, after 12 months and additionally after 16 months.
62555560|NCT01660425|ACTIVE_COMPARATOR|Psychosocial intervention|Parenting Enhancement Training as a form of psychosocial intervention is a guided program. Parents get the opportunity to discuss written information with a therapist in 20 minutes telephone calls. 14 telephone calls are offered. The whole intervention lasts for a period of one year. Booklets are mailed via post within the first 4 months. First 9 telephone calls are also within the first 4 months, usually every two weeks. Telephone calls 10 and 11 are within 5th or 6th month, telephone calls 12 to 14 are within 7th to 12th month with a two monthly time period in between.
62555561|NCT01510951|PLACEBO_COMPARATOR|PLACEBO|
62555562|NCT01510951|EXPERIMENTAL|AMG 811|
62555563|NCT02177461|EXPERIMENTAL|Telmisartan|
62555564|NCT02177461|ACTIVE_COMPARATOR|Enalapril|
62555565|NCT02177461|EXPERIMENTAL|Telmisartan + clonidine TTS1|
62555566|NCT02177461|ACTIVE_COMPARATOR|Enalapril + clonidine TTS1|
62555567|NCT00619723|ACTIVE_COMPARATOR|Citicoline|Participants will receive active medication throughout the study. Citicoline will be given beginning at two capsules (500 mg/day) with an increase to four capsules (1000 mg/day) at week 2, six capsules (1500 mg/day) at week 4, and eight capsules (2000 mg/day) at week 6. Doses will be decreased, based on clinician judgment, due to side effects.
62555568|NCT00619723|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo identical in appearance to Citicoline throughout the study. Placebo will be given beginning at two capsules (500 mg/day) with an increase to four capsules (1000 mg/day) at week 2, six capsules (1500 mg/day) at week 4, and eight capsules (2000 mg/day) at week 6. Doses will be decreased, based on clinician judgment, due to side effects.
62555569|NCT01834534|EXPERIMENTAL|CarePartners for depression|For one year, patients receive weekly automated telemonitoring of mood and self-management, while their CarePartners receive weekly reports of the patient's assessment results with tailored instructions on supporting the patient's depression self-management.
62555570|NCT01834534|NO_INTERVENTION|Usual care|Usual medical care.
62555571|NCT01802021|EXPERIMENTAL|Qingshu-Yiqi-Tang+standard therapy|"Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy, maximal for 6 months.~1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD."
62555572|NCT01802021|NO_INTERVENTION|1st line doublet chemotherapy|1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD.
62555573|NCT02868957|ACTIVE_COMPARATOR|Impression data from reference scanner|desktop scanner was used as a reference scanner. According to the data of the manufacturer, the accuracy is less than 20 µm and the scan points more than 100,000.
62555574|NCT02868957|EXPERIMENTAL|Trios|"Trios is a scanner with real time rendering type adopting the confocal principle, and scans the object while showing the scanned area on a screen.~Interventions: Assigned intervention to participants in this clinical study was in the form of repetitive learning of Trios intra-oral scanner."
62555575|NCT02868957|EXPERIMENTAL|iTero|"iTero captures teeth and periodontal soft tissue using a red laser beam and parallel confocal imaging technology. This system with a focal depth of 300 can capture up to 100,000 of laser points, and each of such laser points is separated at a 50 mm gap.~Interventions: Assigned intervention to participants in this clinical study was in the form of repetitive learning of iTero intra-oral scanner."
62555576|NCT05255731|ACTIVE_COMPARATOR|Laser Group (GL)|Patients will be submitted to a low power laser application immediately after suturing of the surgical area. The radiation emission shall be conducted according to protocol.
62555577|NCT05255731|PLACEBO_COMPARATOR|Control Group (CG)|In these patients the investigators will use the same protocol applied in the experimental group (time and application values) but the laser device will be turn off.
62751164|NCT03477851|PLACEBO_COMPARATOR|Placebo|Patients randomized to receive 0,9% sodium hydrochloride solution 5ml i.m. (gluteus muscle) after spinal anesthesia, simultaneously with the sciatic nerve block.
62555578|NCT02848001|EXPERIMENTAL|CC-90009 - Part A|Will be administered intravenously per dosing schedule in a 28-day cycle.
62555579|NCT02848001|EXPERIMENTAL|CC-90009 - Part B - AML and MDS patients|Relapsed or refractory AML and MDS subjects. IP will be administered intravenously per dosing schedule determined in Part A
62555580|NCT03412695|EXPERIMENTAL|Arm A|Use of the MyFood tool among patients and nurses (intervention group)
62751165|NCT03477851|EXPERIMENTAL|Tramadol|Patients randomized to receive 100mg of Tramadol hydrochloride in 5ml 0,9% sodium hydrochloride i.m. (gluteus muscle) after spinal anesthesia, simultaneously with the sciatic nerve block.
62555581|NCT03412695|NO_INTERVENTION|Arm B|No intervention. Regular hospital routines
62751166|NCT04002284|EXPERIMENTAL|anlotinib|anlotinib 12mg qd p.o. d1-14/21day/cycle
62751167|NCT02885454|EXPERIMENTAL|OC + AL-335 + ODV + 3-DAA combination|Participants will receive single dose of 3 milligram (mg) drospirenone/0.02 mg ethinylestradiol \[OC\] on Day 1, AL-335 800 mg once daily on Days 5 and 6, a single dose of AL-335 800 mg + a single dose of OC on Day 7, ODV 25 mg once daily on Days 12 to 24, followed by a single dose of ODV 25 mg and a single dose of OC on Day 25, followed by ODV 25 mg + AL-335 800 mg + simeprevir (SMV) 75 mg \[3-DAA combination\] once daily on Days 26 to 31, followed by a single dose of 3-DAA combination and a single dose of OC on Day 32.
62751168|NCT04251767|EXPERIMENTAL|Observational group|5u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.
62555582|NCT02936908||Ventilatory support|Adult patients presenting a neuromuscular disease, with involvement of respiratory or bulbar muscles
62555583|NCT04447131||COVID-19|Confirmation of the diagnosis of COVID-19 by laboratory method (RT-PCR and / or positive serology for SARS-CoV-2 - COVID group).
62555584|NCT04447131||Healthy Individuals|Asymptomatic and with negative SARS-CoV-2 serology
62555585|NCT04447131||Respiratory symptoms but negative for COVID-19|Negative for SARS-CoV-2. But with respiratory symptoms
62555586|NCT05756582||Health-care workers and students|The study will involve all health-care workers of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome - a tertiary reference hospital with over 1,500 beds - and all students of all three-year and single-cycle degree courses, master's degree courses, graduate schools of the faculty of Medicine and Surgery of the Catholic University of Sacred Heart in Rome, trained at the Fondazione Policlinico Universitario A. Gemelli IRCCS.
62375583|NCT01942395|ACTIVE_COMPARATOR|DASH/Sodium-Restricted Diet Intervention|Each patient will eat 3 weeks of the provided DASH/SRD diet for 21 days. The diet is patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants. At enrollment patients will be randomized to the DASH/SRD or Control Diet for 21 days and then cross over to the other for 21 days. Immediately following the provided DASH/SRD and Control Diet, patients will be instructed to adhere to the DASH/SRD for an additional eight weeks with dietary support.
62555587|NCT02729571|EXPERIMENTAL|MTBVAC Group 1|Intervention: MTBVAC live vaccine (low dose)
62751169|NCT04251767|PLACEBO_COMPARATOR|Control group|5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.
62751170|NCT05487651|EXPERIMENTAL|Cohort A, non-ALL relapsed/refractory|"These dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by CD19.CAR-aNKT cell infusion.~Genetic: CD19.CAR-aNKT cells Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose.~Dose level 1: 1×107/m2. Dose level 2: 3×107/m2. Dose level 3: 1×108/m2).~Drug: Cyclophosphamide:~Lymphodepletion chemotherapy. Patients will receive 3 daily doses of cyclophosphamide (500mg/m2/day finishing at least 24 hours before T-cell infusion. The drug will be given intravenously (through an IV needle) Other name: Cytoxan~Drug Fludarabine Lymphodepletion chemotherapy. Patient will receive 3 daily dose of fludarabine (30mg/m2/day) finishing at least 24 hours before T-cell infusion. the drug will be given intravenously (through an IV needle) Other name: Fludara"
62555588|NCT02729571|EXPERIMENTAL|MTBVAC Group 2|Intervention: MTBVAC live vaccine (middle dose)
62555589|NCT02729571|EXPERIMENTAL|MTBVAC Group 3|Intervention: MTBVAC live vaccine (high dose)
62555590|NCT02729571|ACTIVE_COMPARATOR|BCG Control Group|Intervention: commercially available BCG live vaccine
62555591|NCT00920491||patients with non-specific complaints|patients who do not have specific presenting symptoms (e.g. dyspnea, chest pain etc.)
62555592|NCT02608411|EXPERIMENTAL|ARQ-197|ARQ-197 360 mg twice/day by mouth (PO), with meals, continuously as maintenance treatment until disease progression or unacceptable toxicity.
62555593|NCT03661645|ACTIVE_COMPARATOR|Methylprednisolone Treated Group|Subjects in this group will receive single intraoperative course of 10 mg IV dexamethasone \& 6 day oral methylprednisolone taper that is 10 mg Intravenous IV dexamethasone and 6 day oral methylprednisolone taper course
62555594|NCT03661645|OTHER|Control Group|Subjects in this group will receive single intraoperative dose of 10 mg IV dexamethasone; that is 10 mg Intravenous (IV) dexamethasone
62555595|NCT06331182|EXPERIMENTAL|Ketamine group|Patients will receive external oblique intercostal plane block using 29 ml bupivacaine 0.25% + 1 ml ketamine (50 mg) after induction of general anesthesia.
62555596|NCT06331182|EXPERIMENTAL|Dex group|Patients will receive external oblique intercostal plane block using 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg after induction of general anesthesia.
62555597|NCT02456740|PLACEBO_COMPARATOR|Placebo|Participants received placebo once a month (QM) by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
62555598|NCT02456740|EXPERIMENTAL|Erenumab 70 mg QM|Participants received erenumab 70 mg QM by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
62555599|NCT02456740|EXPERIMENTAL|Erenumab 140 mg QM|Participants received erenumab 140 mg QM by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
62555600|NCT05314231|EXPERIMENTAL|ALXN1720|Participants will receive a single dose of ALXN1720, given as a SC infusion at a dose of 1500 mg.
62555601|NCT03153358|EXPERIMENTAL|icotinib+SBRT|icotinib 125 milligram,three times a day for 28 days oral administration,12weeks later given the SBRT treatment depended on the outcome of icotinib
62555602|NCT05219448|EXPERIMENTAL|Education and self-efficacy coaching|This arm will receive education, behavior change support in the form of self-efficacy coaching, and introduction of sugar-free water enhancers.
62555603|NCT05219448|NO_INTERVENTION|Comparison|This arm will have the outcomes assessed but will not receive relevant parts of the intervention (education, behavior change support, and introduction of sugar-free water enhancers) until the end of the study.
62555604|NCT02280200|EXPERIMENTAL|AFO to improve outcomes|Patients completed graded treadmill testing, followed by 12 weeks of unstructured community-based walking using the AFO ad libitum
62555605|NCT02280200|NO_INTERVENTION|Historical Controls|Historical PAD control group (n = 10) received upfront advice to walk at home with no intervention
62555606|NCT01974622|EXPERIMENTAL|Visudyne|Visudyne half fluence- 1 treatment with the possibility of a second treatment.
62555607|NCT04653649|EXPERIMENTAL|HSP-CAR30 (anti-CD30 CAR T cells)|"Phase I:~Ten patients will be treated with HSP-CAR30 (anti-CD30 CAR T-cells) with an escalation approach to define maximum tolerated dose (MTD) from 3 x 106/kg to 10 x 106/kg.~Phase IIa:~Twenty patients will be treated with HSP-CAR30 at MTD to evaluate efficacy."
62751171|NCT05487651|EXPERIMENTAL|Cohort B, ALL releapsed/refractory|"This cohort is for patients with relapsed or refractory B-cell ALL afer 2 or more lines of therapy. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.~Genetic: CD19.CAR-aNKT cells Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose.~Dose level 1: 1×107/m2. Dose level 2: 3×107/m2. Dose level 3: 1×108/m2).~Drug: Cyclophosphamide:~Lymphodepletion chemotherapy. Patients will receive 3 daily doses of cyclophosphamide (500mg/m2/day finishing at least 24 hours before T-cell infusion. The drug will be given intravenously (through an IV needle) Other name: Cytoxan~Drug Fludarabine Lymphodepletion chemotherapy. Patient will receive 3 daily dose of fludarabine (30mg/m2/day) finishing at least 24 hours before T-cell infusion. the drug will be given intravenously (through an IV needle)"
62391550|NCT06103773|EXPERIMENTAL|FE-Low Dosage groups|drug：TollB-001 tablets（Subjects in the fasting-fed sequence group will be administered with TollB-001 under fasting condition in the first period and under fed condition in the second period; subject in the fed-fasting sequence group will be administered with TollB-001 under fed condition in the first period and under fasting condition in the second period. The two periods of cross-administration will have a washout period of 5-10 days）
62751172|NCT02924194|EXPERIMENTAL|nbM stimulation ON for 3 months (GPi also on)|Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation ON for a period of 3 months (GPi also on). No usual treatment is withheld. PD drug doses will be stable unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor Unified Parkinson's Disease Rating Scale (UPDRS) rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
62751173|NCT02924194|EXPERIMENTAL|nbM stimulation OFF for 3 months (GPi is on)|Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation OFF for a period of 3 months (GPi is on). No usual treatment is withheld. PD drug doses will be stable during blinded parts of the assessment unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor UPDRS rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
62751174|NCT01070693|EXPERIMENTAL|Prolene Hernia System device|Inguinal hernia repair either with a bilayer mesh (PHS)
62751175|NCT01070693|EXPERIMENTAL|Lichtenstein|Inguinal hernia repair with the Lichtenstein technique
62751176|NCT04812119||Patients with the CTNNB1 mutation|Patient with a diagnosed CTNNB1 mutation.
62751177|NCT00993512|EXPERIMENTAL|TPCS2a|No comparative treatment is given in this open-label phase I, dose escalating safety study
62751178|NCT05462834|EXPERIMENTAL|Compressed Air then Supplemental Oxygen|
62751179|NCT05462834|EXPERIMENTAL|Supplemental Oxygen then Compressed Air|
62751180|NCT01702090|EXPERIMENTAL|TMC114/ritonavir|
62751181|NCT03897725|EXPERIMENTAL|Telehealth Intervention|Study participants will be randomized into either the control or experimental group. Participants in the intervention group will receive routine care which will follow the schedule from previous adolescent PrEP studies where participants are recommended to follow up at 4, 8, and 12 weeks and then every 3 months following initiation of PrEP. This group will also receive SMS texting every 4 weeks between in-person visits (weeks 16, 20, 28,32, 40, 44) reminding them to pick up their medication. The experimental group will also be seen in follow up every month for the first 3 months and then spaced out to visits every 3 months. The SMS texting will occur every 4 weeks between in-person visits, the experimental group will also have 2 tele-health visits (which will be conducted within a participant's home using an app) that will occur every 4 weeks between each of the traditional in-person visits to provide more frequent monitoring and counseling regarding adherence.
62751182|NCT03897725|NO_INTERVENTION|Routine Care|The control group will follow the schedule from previous adolescent PrEP studies where participants are recommended to follow up at 4, 8, and 12 weeks and then every 3 months following initiation of PrEP.
62751183|NCT06012500||Control|Healthy Controls
62375584|NCT01942395|ACTIVE_COMPARATOR|Control Diet Intervention|Patients will consume 3 weeks of a specially prepared diet that will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants. At enrollment patients will be randomized to the DASH/SRD or Control Diet for 21 days and then cross over to the other for 21 days. Immediately following the provided DASH/SRD and Control Diet, patients will be instructed to adhere to the DASH/SRD for an additional eight weeks with dietary support.
62375585|NCT01942395|NO_INTERVENTION|Healthy Control|Fifteen healthy age-matched and 10 young healthy control patients will be recruited. Age-matched healthy control subjects will undergo testing before and after 3 weeks of eating their habitual diet. Young healthy control subjects will only require 1 study visit with no dietary intervention.
62751184|NCT06012500||ILD|Participants with diagnosed ILD
62751185|NCT03102047|EXPERIMENTAL|durvalumab|IV infusion once every 2 weeks for 4 total doses
62751186|NCT06012019||Periodontitis Cases|Patients with stage 3 or 4 periodontitis (Chicago 2017) ; BOP ≥ 10%, PD≥ 4mm Patients requiring surgical care such as dental avulsion or pre-prosthetic periodontal surgeries
62751187|NCT06012019||Gingivitis Cases|BOP ≥ 10%, PD≤ 3mm according to Chicago 2017 Patients requiring surgical care such as dental avulsion or pre-prosthetic periodontal surgeries
62751188|NCT06012019||Control|BOP \< 10%, PI \< 20%, PD≤ 3mm Patients with gingival health on intact or reduced periodontium without a history of periodontitis and requiring surgical care such as dental avulsion or aesthetic surgeries
62751189|NCT03172806||Study Group|All patients included in the study. First: clinical scores were collected in all patients. Second: all patients underwent a polysomnography in order to compare this results with these of the clinical scores.
62751190|NCT01028534|ACTIVE_COMPARATOR|ARB plus increased ARB|angiotensin II receptor blockers for the first 3 months and increasing dose of angiotensin II receptor blockers for the next 3 months
62751191|NCT01028534|ACTIVE_COMPARATOR|ARB plus CCB|angiotensin II receptor blockers for the first 3 months and adding calcium channel blockers for the next 3 months
62751192|NCT01028534|ACTIVE_COMPARATOR|CCB plus ARB|calcium channel blockers for the first 3 months and adding angiotensin II receptor blockers for the next 3 months
62751193|NCT04022785|EXPERIMENTAL|Treatment (BRD4 Inhibitor PLX51107, azacitidine)|Patients receive PLX51107 PO QD on days 1-21 and azacitidine SC or IV over 15 minutes on days 8-14 and 22-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62555608|NCT03311204|EXPERIMENTAL|Microblepharon Exfoliation|This treatment is provided using BlephEx tool from Optimed Pty Ltd.
62751194|NCT03478176||Patients|
62751195|NCT03832855|EXPERIMENTAL|Treatment|4 mg pING-hHER3FL ID or IM
62751196|NCT04098367|EXPERIMENTAL|VIVITY|VIVITY IOL implanted in the eye during cataract surgery
62751197|NCT04098367|ACTIVE_COMPARATOR|SYMFONY|SYMFONY IOL implanted in the eye during cataract surgery
62751198|NCT04098367|ACTIVE_COMPARATOR|AT LARA|AT LARA implanted in the eye during cataract surgery
62751199|NCT03986580|OTHER|Annular closure device|Single arm study; all patients treated with an annular closure device
62751200|NCT03807297|OTHER|TIVA - total intravenous anaesthesia|only intravenous type of anaesthesia using Injection propofol, 10 mg and Injection dexmedetomidine drug infusion will be infused for maintenance of anaesthesia
62751201|NCT03807297|OTHER|Inhalational anaesthesia|In this group, both nitrous oxide and sevoflurane will be given for maintenance of anaesthesia
62555609|NCT03311204|EXPERIMENTAL|Eyelid cleansing using Lid Hygenix|Foam-based hypoallergenic cleanser used as a control treatment in this study.
62555610|NCT04530643|EXPERIMENTAL|HY209 0.3%|multiple dose of HY209 0.3% gel
62751202|NCT01338350|EXPERIMENTAL|1|
62751203|NCT01338350|PLACEBO_COMPARATOR|2|
62751204|NCT01844102|EXPERIMENTAL|PrePex|PrePex circumcision procedures will be offered as part of the minimum package of HIV prevention services recommended by the Zambian Ministry of Health (MOH)
62751205|NCT04864626||patient with eating disorder|
62375586|NCT05219006|EXPERIMENTAL|ketogenic dieting + conventional treatment|Nutrition team will help patients implement an Atkins-type ketogenic diet. The diet should be continued for at least 6 weeks. They will be able to continue with the pharmacological-based treatment but without any changes having been made in the last 6 weeks or during the time they are in the study. To ensure adherence to the diet, urine ketones will be determined twice a week.
62751206|NCT06511557|EXPERIMENTAL|Non immersive virtual reality (Xbox kinetic)|"* Track and field.~* Skiing.~* Dance Central.~* Kinect sports."
62751207|NCT06511557|ACTIVE_COMPARATOR|Kinetic Chain Exercises|"Closed chain:~Terminal Knee Extension.~* Semi squat.~* Forward step up and down.~Open chain:~* SLR in lying.~* Knee extension in sitting."
62375587|NCT05219006|ACTIVE_COMPARATOR|Healthy dieting + conventional treatment|In addition to their basic (pharmacological) treatment, the nutrition team will help them implement a low-calorie, non-ketogenic diet. The presence of ketones will also be determined in urine to avoid bias
62375588|NCT05528562|EXPERIMENTAL|PrEP Rapid Access|Participants who are at risk of HIV and being seen at the Victory Program's Mobile Prevention Services Van.
62375589|NCT02587975|EXPERIMENTAL|Evogliptin 10 mg|Single oral administration of 2 tablets of evogliptin 5 mg with water 250 mL
62375590|NCT05581927|EXPERIMENTAL|modified Whole-Body Hypothermia|patients were allocated to modified Whole-Body Hypothermia with normal base excess and blood pressure.
62375591|NCT05581927|ACTIVE_COMPARATOR|standard Whole-Body Hypothermia|patients were allocated to standard Whole-Body Hypothermia.
62751208|NCT00129701|EXPERIMENTAL|Patients attending|Patients recruited to have a telephone consultation and then at the next appointment a face-to-face appointment
62751209|NCT06373653|ACTIVE_COMPARATOR|Manzanilla Sophia®|"Matricaria recutita 0.025%, Ophthalmic solution.~* Dosage: 1 drop every 4 hours (4 daily applications \[QID\]), during 7 days.~* Route of administration: Topical ophthalmic."
62375592|NCT04764305||Patients|Patients with Fontan circulation. No intervention planned (observational study)
62375593|NCT04764305||Controls|Healthy, biventricular controls. No intervention planned (observational study)
62751210|NCT06373653|ACTIVE_COMPARATOR|Meticel Ofteno®|"Hypromellose 0.5%. Ophthalmic solution.~* Dosage: 1 drop every 4 hours (4 daily applications \[QID\]), during 7 days~* Route of administration: Topical ophthalmic."
62751211|NCT04793451|EXPERIMENTAL|Group A|Endurance training
62751212|NCT04793451|EXPERIMENTAL|Group B|Endurance-strength training
62751213|NCT02826421|EXPERIMENTAL|UltraSert Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
62751214|NCT02826421|ACTIVE_COMPARATOR|iTec Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
62375594|NCT02518568|EXPERIMENTAL|Drug|
62375595|NCT02017067|NO_INTERVENTION|control|Maintain regular physical activity as usual, and received health education material about their disease, importance of nutrition and risks factors.
62375596|NCT02017067|EXPERIMENTAL|hydraulic resistance circuit training|12 weeks resistance training
62375597|NCT01339676|EXPERIMENTAL|1|Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D
62555611|NCT04530643|EXPERIMENTAL|HY209 0.5%|multiple dose of HY209 0.5% gel
62555612|NCT04530643|PLACEBO_COMPARATOR|Placebo|multiple dose of Placebo
62555613|NCT00676702|EXPERIMENTAL|001|Pancrelipase in combination with Ensure Plus 3 pancrelipase MT 21 capsules containing a total of 63 000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
62555614|NCT00676702|ACTIVE_COMPARATOR|002|Ensure Plus A high-fat liquid meal of 500 ml of Ensure Plus
62375598|NCT01339676|PLACEBO_COMPARATOR|2|Identically appearing once weekly peroral capsules
62375599|NCT03644589|EXPERIMENTAL|Treatment (pembrolizumab, cisplatin)|"Participants receive pembrolizumab and cisplatin once every 3 weeks for a total of 6 doses. Both drugs are given by vein (IV). Participants that are responding to the study treatment will continue to receive pembrolizumab alone beyond 6 cycles for up to 24 months until disease gets worse, having bad side effects, no longer wish to be in the study, or have become pregnant (whichever comes first).~Participants receive pembrolizumab over 30 minutes and cisplatin on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants without disease progression after 6 courses may continue on pembrolizumab IV on day 1 every 21 days for up to 24 months (or 35 courses) in the absence of disease progression or unacceptable toxicity."
62375600|NCT02798445|EXPERIMENTAL|tapirs|this group will have surgery with endovascular laser treatment (EVLT) in the axial vein and foam sclerotherapy echo-guided in perforator veins and veins in relation with the ulcer, after the surgery the patients will have conventional wound care plus juxta cure system that give a continuous compression in the leg.
62375601|NCT02798445|ACTIVE_COMPARATOR|multilayer bandage|multilayer bandage and conventional wound care (grade 1A) recommendation in management of vein ulcers. gold standard
62375602|NCT02626806||patients with hemodynamic significant CAD;|
62375603|NCT02626806||patients without hemodynamic significant CAD|
62375604|NCT01847560||Dabigatran|
62375605|NCT01847560||Warfarin or other New Oral Anticoagulant (NOAC)|
62375606|NCT04080349|EXPERIMENTAL|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
62375607|NCT04080349|ACTIVE_COMPARATOR|misoprostol|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
62375608|NCT04080349|PLACEBO_COMPARATOR|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
62375609|NCT04461145|OTHER|ACL group|
62375610|NCT02928081|EXPERIMENTAL|Extended lymphadenectomy|In addition to the standard lymphadenectomy, the nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1) must be dissected. Retroperitoneal lymphatic tissue, nerves and connective tissue range from the hepatic portal down to the beginning part of the inferior mesenteric artery, the right to the right renal hilus, left to the left edge of the abdominal aorta is included.
62375611|NCT02928081|OTHER|Standard lymphadenectomy|Lymph node dissection includes the superior and inferior pyloric nodes (LN5, LN6), anterior and posterior nodes along the common hepatic artery (CHA) (LN8a, 8b), nodes along the common hepatic duct, common bile duct and cystic duct (LN12b1, 12b2, 12c), posterior pancreatoduodenal nodes (LN13a, 13b), nodes along the superior mesenteric artery (SMA) (LN14a, 14b), anterior pancreatoduodenal nodes (LN17a, 17b), but excluding the nerve tissues around common hepatic artery and the superior mesenteric artery.
62555615|NCT06469723|EXPERIMENTAL|INFA Intervention|Participants sorted into this arm will receive care under the INFA program, which includes standard care, along with early detection of geriatric syndromes or symptoms using the INFA screening tool. This will include potential early referrals to allied health professionals, care plans, and comprehensive early discharge planning and systematic follow-ups.
62555616|NCT06469723|NO_INTERVENTION|Standard Care - Control|Participants sorted into this arm will continue to receive standard care in the wards.
62555617|NCT05348083||ESPB|A prospective cohort of 25 patients ASA 2 (according to American Society of Anesthesiologists physical status classification) with normal singleton pregnancy, scheduled for elective caesarean section under spinal anesthesia without intrathecal morphine, who underwent bilateral echo-guided ESPB at T9 level at the end of surgery.
62751215|NCT02826421|ACTIVE_COMPARATOR|iSert Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
62751216|NCT02826421|ACTIVE_COMPARATOR|Monarch III D Manual IOL Delivery System|Manually loaded IOL delivered via a 2.4 mm clear corneal incision during cataract surgery
62751217|NCT02816593|EXPERIMENTAL|Group 1 - HP 6%|Group 1: Experimental: Office; hydrogen peroxide 6%,
62751218|NCT02816593|EXPERIMENTAL|Group 2 - HP 15%|Group 2: Experimental: Office; hydrogen peroxide 15%,
62751219|NCT02816593|ACTIVE_COMPARATOR|Group 3 - CP 10%|Group 3: Control: Homemade; Carbamide Peroxide 10%,
62751220|NCT01069159|ACTIVE_COMPARATOR|Propranolol|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive propranolol.
62751221|NCT01069159|PLACEBO_COMPARATOR|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
62751222|NCT00858741|EXPERIMENTAL|8 Gy arm|8.0 Gy in 1 fraction to 8.0 Gy total dose.
62751223|NCT00858741|ACTIVE_COMPARATOR|30 Gy arm|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
62751224|NCT01559922|PLACEBO_COMPARATOR|Placebo|Normal Saline
62751225|NCT01559922|EXPERIMENTAL|Artefill|Dermal Filler
62751226|NCT05733611|EXPERIMENTAL|RP2 and atezolizumab plus bevacizumab in advanced MSS and pMMR CRC|RP2 will be injected by direct (including via colonoscope) or image-guided injection into injectable tumors (including subcutaneous, visceral, and nodal tumors).
62751227|NCT05733611|EXPERIMENTAL|RP3 and atezolizumab plus bevacizumab in advanced MSS and pMMR CRC|RP3 will be injected by direct (including via colonoscope) or image-guided injection into injectable tumors (including subcutaneous, visceral, and nodal tumors).
62751228|NCT02638389|EXPERIMENTAL|Patients with vascular malformations|Patients with venous, lympathic or complex vascular malformations (KTS, PTEN, etc.) will receive sirolimus after completion of inclusion criteria
62751229|NCT05662761||symptomatic chronic obstruction|patients with symptomatic chronic obstruction of the femoroiliac and caval vein segments (VFC, VIE, VIC, VCI) treated with stent angioplasty.
62751230|NCT01415648|EXPERIMENTAL|open NIRS|continuous per operative cerebral oximetry monitoring (using INVOS™ cerebral oximeter) associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
62751231|NCT01415648|SHAM_COMPARATOR|Blinded NIRS|Continuously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre
62751232|NCT03638908|OTHER|Fluoxetine|"Dosing will be~* Week 1-4: 20 mg daily~* Week 5-8: 40 mg daily~* Week 9-12: 60 mg daily~* Week 13-24: 80 mg daily"
62751233|NCT01608217|ACTIVE_COMPARATOR|Namisol|Namisol is a tablet containing delta-9-tetrahydrocannabinol, the main cannabinoid from Cannabis sativa L. Namisol is added to a standardized treatment with acetaminophen.
62751234|NCT01608217|PLACEBO_COMPARATOR|Placebo|The control product is placebo, consisting of a tablet with similar appearance and taste of the test product. Placebo is added to a standardized treatment with acetaminophen.
62375612|NCT02839590||HiFu (ultrasound)|Manufacturer Name Eyehope Principle intended use Surgical treatment of uncontrolled glaucoma and OHT The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study.
62555618|NCT05348083||p-QLB|A historical cohort of 25 patients ASA 2 (according to American Society of Anesthesiologists physical status classification) with normal singleton pregnancy, scheduled for elective caesarean section under spinal anesthesia without intrathecal morphine, who underwent bilateral echo-guided p-QLB at the end of surgery.
62555619|NCT04941092||patients with ARDS induced by SARS CoV 2|
62751235|NCT01714206|ACTIVE_COMPARATOR|Treatment A|Each volunteer will receive digoxin once daily on Days 1 through 7.
62751236|NCT01714206|EXPERIMENTAL|Treatment B|Each volunteer will receive digoxin once daily on Days 1 through 7 in combination with canagliflozin (JNJ-28431754) once daily on Days 1 through 7.
62751237|NCT06162546||ARREST NEPHROSIS Participants|
62751238|NCT00881998|ACTIVE_COMPARATOR|1|Minimally invasive total hip arthroplasty
62555620|NCT04941092||patients with ARDS induced by influenza|
62555621|NCT03575377|EXPERIMENTAL|Deterra Bag|These families will receive a Deterra® bag (a drug Disposal Aid) and instructions on its use by a research team member.
62555622|NCT03575377|NO_INTERVENTION|Control|These families will receive routine postoperative instructions only.
62555623|NCT02641652|ACTIVE_COMPARATOR|Sertraline|sertraline, 25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial
62555624|NCT02641652|PLACEBO_COMPARATOR|Placebo|placebo
62751239|NCT00881998|ACTIVE_COMPARATOR|2|
62751240|NCT02288546||Vegans|Vegans' data are compared with those of sex-and age-matched non vegetarians
62751241|NCT02288546||Non-vegans|Non-vegans are age and sex-matched controls
62751242|NCT02023801|EXPERIMENTAL|Aurora Treatment Arm|Endometrial Ablation
62751243|NCT02182440|PLACEBO_COMPARATOR|Placebo|1 hour IV infusion once daily for 3 days
62751244|NCT02182440|EXPERIMENTAL|0.4 mg/kg (250 U/kg) recAP|1 hour IV infusion once daily for 3 days
62751245|NCT02182440|EXPERIMENTAL|0.8 mg/kg (500 U/kg) recAP|1 hour IV infusion once daily for 3 days
62751246|NCT02182440|EXPERIMENTAL|1.6 mg/kg (1000 U/kg) recAP|1 hour IV infusion once daily for 3 days
62751247|NCT04199273|EXPERIMENTAL|Magnetic stimulation and electric stimulation|The patient receive first the magnetic stimulation with MagStim 200 tool. Then 15 min after he will receive the electric stimulation with the SonoStim tool : ultrasonography phrenic nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)
62751248|NCT04199273|EXPERIMENTAL|Electric stimulation and magnetic stimulation|The patient receive first electric stimulation with the SonoStim tool : ultrasonography phrenic nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager). Then 15 min after he will receive the magnetic stimulation with MagStim 200 tool
62751249|NCT05055297|EXPERIMENTAL|SELUTION SLR™ DEB 014|
62555625|NCT05049850|EXPERIMENTAL|Imlifidase|Imlifidase is administered intravenously as one dose of 0.25 mg/kg over 15 minutes within the 24-hour period prior to transplantation. (A second dose may be given if the crossmatch test at 4 hours after the first dose remains positive.)
62555626|NCT00555165|EXPERIMENTAL|I|
62555627|NCT02063568|ACTIVE_COMPARATOR|Low dose oxytocin infusion|oxytocin will be administered as an intravenous infusion at a rate of 0.33 units/min starting after fetal delivery upon umbilical cord clamping and continuing for a total of 30 minutes
62555628|NCT02063568|ACTIVE_COMPARATOR|High dose oxytocin infusion|oxytocin will be administered as an intravenous infusion at a rate of 1.33 units/min starting after fetal delivery upon umbilical cord clamping and continuing for a total of 30 minutes
62555629|NCT05988580|EXPERIMENTAL|Experimental group|Subjects will consume a pasta dish with 20-22% of resistant starch
62555630|NCT05988580|PLACEBO_COMPARATOR|Control group|Subjects will consume the original version of pasta dish
62555631|NCT06150339|EXPERIMENTAL|Long-term Care Stream or Rehab Stream Intervention Arm|"Intervention Dose: Up to 45 minutes per session, 5 sessions per week, for 6 weeks. Approximately up to 30 minutes will be spent walking; up to 15 minutes will be spent performing sit-to-stands.~Intervention Components:~Component 1: Patient-Centered Communication Care Plan. A patient-centered communication care plan will be created, to promote enjoyment and engagement during the sessions. The care plan will be informed by interviews with the participant and their care partner.~Component 2: Sit to Stand Activity. A target number of sit to stands per session will be determined based on a baseline assessment and according to an algorithm; the target will be progressed halfway into the intervention.~Component 3: Walking Program. Based on the findings from the patient-centered assessment interviews as well as the performance of the participants on a walk test at baseline (Time 1), an individualized walking program will be carried out with participants."
62751250|NCT05055297|ACTIVE_COMPARATOR|Plain (Uncoated) Balloon Angioplasty (PTA)|
62751251|NCT03571802|EXPERIMENTAL|intervention arm|simvastatin 20mg once
62751252|NCT02214225|EXPERIMENTAL|Quadrivalent Influenza Vaccine (QIV)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
62751253|NCT02214225|ACTIVE_COMPARATOR|Trivalent Influenza Vaccine (TIV-1)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
62751254|NCT02214225|ACTIVE_COMPARATOR|Trivalent Influenza Vaccine (TIV-2)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the recommended influenza A (H1N1-, H3N2-like) strains and the alternate B strain for the Northern Hemisphere 2014/2015 influenza season).
62751255|NCT02867943||respiratory rate is 10 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
62751256|NCT02867943||respiratory rate is 12 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
62751257|NCT02867943||respiratory rate is 14 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
62751258|NCT02867943||respiratory rate is 16 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
62751259|NCT05576168|EXPERIMENTAL|T2DM group|patients with T2DM
62751260|NCT05576168|ACTIVE_COMPARATOR|control group|patients without T2DM
62751261|NCT02387905|ACTIVE_COMPARATOR|Arm I (standard of care)|Patients undergo stereotactic spinal radiosurgery per standard of care.
62751262|NCT02387905|EXPERIMENTAL|Arm II (vertebral body cement augmentation)|Patients undergo vertebral body cement augmentation within 4 weeks before or after standard stereotactic spinal radiosurgery.
62751263|NCT03866785|OTHER|STEP 1: Patient with prostate cancer|First, patients with prostate cancer will be included during step 1. They will have an interview.
62567490|NCT04744194|EXPERIMENTAL|Assisted nordic hamstring exercise program|Participants are required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. During this exercise, participants are attached to a weighted pulley cable system via a chest attachment. A sufficient amount of assistance is given to allow the participant to lower to 30 degrees of knee flexion. When they can no longer lower themselves as such, they are instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touches the ground they are instructed to immediately return to the starting position by pushing up with their hands
62751264|NCT03866785|OTHER|STEP 2: Patient with prostate cancer and a physical activity|"Secondly, patient with prostate cancer and a physical activity will be included during step 2. They are called peer.~They will have a questionnaire Adult Physical Activity Questionnaire (APAQ), an activity actigraph and a peer training. The peer will help patients to realize the Physical Activity Program during step 3."
62751265|NCT03866785|OTHER|STEP 3: Physical Activity Program|"Finally, patients with prostate cancer (different from step 1) and who agrees to participate at the Physical Activity Program will be included during step 3.~They will have an activity actigraph and a questionnaire Adult Physical Activity Questionnaire (APAQ) at inclusion and 3 months later.~They will receive the Physical Activity Program."
62751266|NCT06126952|EXPERIMENTAL|Treatment A (Azelair)+Treatment B (Placebo)+Treatment C (Ryaltris), min. 14 days wash-out period|Cross-over design
62751267|NCT06126952|EXPERIMENTAL|Treatment B (Placebo)+Treatment C (Ryaltris)+Treatment A (Azelair), min. 14 days of wash-out period|Cross-over design
62751268|NCT06126952|EXPERIMENTAL|Treatment C (Ryaltris)+Treatment A (Azelair)+Treatment B (Placebo), min. 14 days of wash-out period|Cross-over design
62751269|NCT06126952|EXPERIMENTAL|Treatment A (Azelair)+Treatment C (Ryaltris)+Treatment B (Placebo), min. 14 days of wash-out period|Cross-over design
62751270|NCT06126952|EXPERIMENTAL|Treatment B (Placebo)+Treatment A (Azelair)+Treatment C (Ryaltris), min.14 days of wash-out period|Cross-over design
62751271|NCT06126952|EXPERIMENTAL|Treatment C (Ryaltris)+Treatment B (Placebo)+Treatment A (Azelair), min. 14 days of wash-out period|Cross-over design
62375613|NCT02839590||Baerveldt implant|"Manufacturer Name Abbott Medical Optics Inc., Abbott Laboratories Inc., Abbott Park, Illinois, USA.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
62751272|NCT05129904||Double plasma molecular absorption system treatment|Patients treat with DPMAS alone or in combination with plasma exchange
62375614|NCT02839590||Ahmed Implant|"Manufacturer Name New World Medical, Inc., 10763 Edison Court, Rancho Cucamonga, CA 91730, USA.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
62375615|NCT02839590||STARflo|"Manufacturer Name iSTAR Medical SA, Parc Créalys, Rue Phocas Lejeune, Bâtiment Regain 25/3, 5032 Isnes, Belgium.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
62567491|NCT02303795|ACTIVE_COMPARATOR|Rivaroxaban 20mg|Oral Rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
62751273|NCT05129904||Standard medical therapy|Patients with standard medical therapy except for DPMAS treatment or other artificial liver support system
62751274|NCT04381637|EXPERIMENTAL|NIPE|
62751275|NCT02182206|EXPERIMENTAL|BIBF 1120|
62375616|NCT02839590||Hydrus Microstent implant|"Manufacturer Name Ivantis, Inc., 38 Discovery, Suite 150, Irvine, CA 92618, USA.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
62375617|NCT02839590||iStent implant|"Manufacturer Name Glaukos Corporation, 26051 Merit Circle, Suite 103, Laguna Hills, CA 92653, USA.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
62375618|NCT02839590||Kahook Dual Blade|Manufacturer: New World Medical. Inc. Single use, ophthalmic blade Utilizes ab interno approach through a clear cornea micro incision Dual blades positioned for precise parallel incisions of the trabecular meshwork with minimal residual leaflets Maintains natural physiologic outflow pathways
62375619|NCT05906914|EXPERIMENTAL|Experimental Group|Intervention: CHA
62567492|NCT02303795|ACTIVE_COMPARATOR|Warfarin|Warfarin Warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.
62567493|NCT02127151|EXPERIMENTAL|BMN 673|BMN 673 daily until progression, death, unacceptable toxicity, withdrawal of consent or any other criterion felt by the Investigator to preclude continuation of treatment.
62751276|NCT00169234|EXPERIMENTAL|0.1mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 0.1mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
62751277|NCT00169234|EXPERIMENTAL|0.5mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 0.5mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
62751278|NCT00169234|EXPERIMENTAL|1.0mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 1.0mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
62751279|NCT00169234|EXPERIMENTAL|2.0mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 2.0mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
62751280|NCT00169234|EXPERIMENTAL|0.5mL Pneumococcal Polysacc Vaccine|Participants in this group were randomized at enrollment to receive 0.5mL Pneumovax 23 at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
62375620|NCT02709941|ACTIVE_COMPARATOR|IMST Training Group|Subjects in inspiratory muscle strength training group will complete 30 breaths against a resistance set at 75% of Maximal Inspiratory Pressure (PI Max) everyday for period of 6 weeks.
62375621|NCT02709941|PLACEBO_COMPARATOR|Placebo Training Group|Subjects in placebo training group will complete 30 breaths against a resistance set at 15% of Maximal Inspiratory Pressure (PI Max) everyday for period of 6 weeks.
62375622|NCT06245395|ACTIVE_COMPARATOR|Virtual Reality Arm|Pediatric patient receiving Virtual Reality during the otologic procedure.
62375623|NCT06245395|NO_INTERVENTION|Standard of Care Arm|
62375624|NCT05488106|PLACEBO_COMPARATOR|Placebo|
62375625|NCT05488106|ACTIVE_COMPARATOR|Dose 1|
62375626|NCT05488106|ACTIVE_COMPARATOR|Dose 2|
62567494|NCT05536973|EXPERIMENTAL|Dose 1|A single intravitreal injection of ADVM-022 2E11 vg/eye
62567495|NCT05536973|EXPERIMENTAL|Dose 2|A single intravitreal injection of ADVM-022 6E10 vg/eye
62751281|NCT04694755|PLACEBO_COMPARATOR|Heart lung qi deficiency syndrome placebo group|Buyixinfei placebo was given.Tianjiang brand formula granules were used. One dose a day, two times orally, five days a week.
62751282|NCT04694755|PLACEBO_COMPARATOR|Deficiency of lung and Kidney Qi placebo group|Tonifying kidney and protecting lung prescription placebo was given. Tianjiang brand granule was used as the drug, one dose a day, twice orally, five days a week.
62751283|NCT04694755|EXPERIMENTAL|Heart lung qi deficiency syndrome drugs group|Buyixinfei formula was given. Tianjiang brand granule was used as the drug, one dose a day, twice orally, five days a week.
62375627|NCT05488106|ACTIVE_COMPARATOR|Dose 3|
62375628|NCT02956031||HIV pos|those who serologically tested positive for HIV
62375629|NCT02956031||HIV neg|those who serologically tested negative for HIV
62375630|NCT02956031||HIV unk|those with no available serological test for HIV
62375631|NCT01079208|PLACEBO_COMPARATOR|standard starter infant formula|standard starter infant formula
62375632|NCT01079208|EXPERIMENTAL|test starter formula|test infant formula
62375633|NCT01079208|EXPERIMENTAL|test starter formula with synbiotics|starter formula with synbiotics and adapted protein levels
62751284|NCT04694755|EXPERIMENTAL|Deficiency of lung and Kidney Qi drugs group|The prescription of invigorating the kidney and protecting the lung was given. The drug was Tianjiang brand granule, one dose a day, two times orally, five days a week
62751285|NCT05131399|EXPERIMENTAL|Self-comparison|"Patients will be fitted with 2 types of ankle foot orthoses, alternately, divided into 4 phases, in the following order:~Phase A1: Standard Plastic ankle foot orthosis Phase B1: carbon medical device ankle foot orthosis Phase A2: Standard Plastic ankle foot orthosis Phase B2: carbon medical device ankle foot orthosis Each patient is his own comparator. For all patients, the total duration of the study will be the same, and will correspond to 12 weeks."
62375634|NCT03518463|EXPERIMENTAL|Intervention|"ERAS arm received;~Preoperative:1. Intravenous (IV) cefazoline 1g 2. IV metoclopromide 10mg, dexamethasone 8mg, ranitidine 150mg~Intraoperative: 1. Hyperbaric bupivacaine 10-15mg plus intrathecal morphine 100mcg 2. Adrenaline 100mcg in 500ml of ringers lactate 3. Individualized goal directed fluid therapy 4. Reinforced counseling and education 5. wound infiltration with isobaric bupivacaine 2mg/kg 6. Rectal diclofenac 100mg and misoprostol 400mcg stat~Postoperative:~1. Feeding within 1 hour~2. urethral catheter removal at 6-8 hours~3. Mobilization at 8-10 hours~4. A single fixed dose combination of ibuprofen 400 mg and paracetamol 500 mg 8 hourly~5. Tablets Amoxicillin-clavulunate 850mg 12 hourly"
62375635|NCT03518463|ACTIVE_COMPARATOR|Control|"Standard care arm received;~1. IV ceftriaxone 2g or ampiclox 2g~2. Anesthetists administered IV fluids, vasopressors, and managed hypothermia based on their clinical impressions.~3. Oral feeding and breastfeeding were allowed any time after transfer to postnatal ward.~4. Urethral catheters were removed between 12-24 hours after surgery.~5. Ward nurses and obstetricians made decisions regarding treatment without study staff input or oversight."
62375636|NCT05529134|EXPERIMENTAL|PTW-002 10 mg/g gel|PTW-002 poloxamer hydrogel for topical administration (cutaneous use), 10 mg/g gel
62375637|NCT05529134|PLACEBO_COMPARATOR|Placebo|Matching placebo poloxamer hydrogel for topical administration (cutaneous use)
62375638|NCT01748903||Target 360°, 2D, Nano Coils|Subjects will undergo embolization using Target 360°, 2D, Nano Coils for the treatment of their intracranial aneurysm.
62375639|NCT06488014|ACTIVE_COMPARATOR|Group E|Erector spina plan block : Under USG guidance, local anaesthetic will be administered to the fascial plane between the erector spinae muscle and the transverse process.
62751286|NCT04676165|EXPERIMENTAL|SAM Group|At discharge from hospital, patients (and/or caregivers) will receive access to Smart About Meds (SAM), a medication management mobile application that has been developed by the McGill Clinical and Health Informatics (MCHI) Research Group.
62751287|NCT04676165|NO_INTERVENTION|Usual Care Group|At discharge from hospital, patients will be provided with a written discharge prescription to be filled at their community pharmacy, and may or may not receive written or verbal instructions about changes made to therapy.
62751288|NCT03978637|EXPERIMENTAL|Itacitinib 300 mg|Phase 1: Itacitinib 300 mg twice daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration.
62751289|NCT03978637|EXPERIMENTAL|Itacitinib 400 mg|Phase 1: Itacitinib 400 mg once daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration.
62751290|NCT03978637|EXPERIMENTAL|Itacitinib 600 mg|Phase 1: Itacitinib 600 mg once daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration
62751291|NCT03978637|EXPERIMENTAL|Itacitinib|Phase 2: Itacitinib administered orally at the recommended dose from Phase 1.
62751292|NCT05964465|EXPERIMENTAL|Treatment|The treatment group will receive dupilumab at 300mg SC Q2weeks. The first dose will be administered via subcutaneous injection in clinic at baseline. Subjects will self-administer study drug (dupilumab 300 mg) subcutaneous every 2 weeks after initial dosing at visit 2.
62751293|NCT06399510|ACTIVE_COMPARATOR|Normal Saline|If patients were randomized to the control arm, the fluid regime for the first 24 hours in ICU will be normal saline.
62751294|NCT06399510|EXPERIMENTAL|Sterofundin|If patients were randomized to the interventional arm, the main fluid therapy during the first 24 hours of ICU stay will be Sterofundin.
62751295|NCT05803863|EXPERIMENTAL|Myatro|Prescribing one 0,01% Myatro (Atropine) drop/eye/night , in 12 months Then wash-out in next 12 months
62751296|NCT05803863|EXPERIMENTAL|Myatro XL|Prescribing one 0,05% Myatro XL (Atropine) drop/eye/night , in 12 months Then wash-out in next 12 months
62751297|NCT05803863|NO_INTERVENTION|Conventional spectacles|Prescribing conventional spectacles and follow-up in 24 months.
62751298|NCT02664051|PLACEBO_COMPARATOR|placebo|mannitol
62751299|NCT02664051|ACTIVE_COMPARATOR|disodium cromoglycate|disodium cromoglycate
62751300|NCT00050531|EXPERIMENTAL|Gleevec|Gleevec 400 mg orally twice daily.
62555632|NCT06150339|EXPERIMENTAL|Reactivation Stream Intervention Arm|"Intervention Dose: up to 45 minutes per session, five sessions per week, for 3 weeks. Approximately up to 30 minutes will be spent walking with the participant and up to 15 minutes will be spent performing the sit-to-stands.~Component 1: Patient-Centered Communication Care Plan. A patient-centered communication care plan will be created, to promote enjoyment and engagement during the sessions. The care plan will be informed by interviews with the participant and their care partner.~Component 2: Sit to Stand Activity. A target number of sit to stands per session will be determined based on a baseline assessment and according to an algorithm; the target will be progressed halfway into the intervention.~Component 3: Walking Program. Based on the findings from the patient-centered assessment interviews as well as the performance of the participants on a walk test at baseline (Time 1), an individualized walking program will be carried out with participants."
62555633|NCT03074344|EXPERIMENTAL|XLHA+CoQ10|XLHA+CoQ10 eye drop administered four times a day for 12 weeks (90 days).
62555634|NCT03074344|ACTIVE_COMPARATOR|Hyaluronic acid (HA)|Hyaluronic acid (HA) eye drop administered four times a day for 12 weeks (90 days).
62751301|NCT00050531|EXPERIMENTAL|Gleevec + Peg-Intron + GM-CSF|Gleevec 400 mg orally twice daily. Peg-Intron 0.5 mcg/kg each week subcutaneously. GM-CSF 125 mcg/m\^2 three times per week subcutaneously.
62751302|NCT01953549|EXPERIMENTAL|physical fitness training|aerobic physical fitness training
62555635|NCT05047666||Cases Group|Also called in our study 'Case-Positives'. These are those with respiratory symptoms suspected of COVID-19 that actually test positive (PCR).
62567496|NCT01669863|EXPERIMENTAL|Use of ECMO in non-intubated patients|ECMO will be used in non-intubated patients with ARDS
62751303|NCT01953549|ACTIVE_COMPARATOR|relaxation|non-aerobic training
62751304|NCT00682071||1|transabdominal ultrasound (TAS) guided embryo transfer
62751305|NCT00682071||2|transvaginal ultrasound (TVS) guided embryo transfer
62751306|NCT01048307|EXPERIMENTAL|Prontosan wound irrigation solution|"Prontosan® Wound Irrigation Solution (experimental group):~* cleansing the wound bed at dressing change with Prontosan® Wound Irrigation Solution; a sterile gauze dressing impregnated with the Prontosan® solution will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~* placing the primary dressing (Profore® WCL): the dressing will be impregnated with Prontosan® Wound Irrigation Solution;~* fixing the dressing to the wound using multilayered elastic compression bandaging (Profore®bandaging system)."
62751307|NCT01048307|PLACEBO_COMPARATOR|Saline irrigation (standard care control)|"Saline (control group):~* cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~* placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~* fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system)."
62751308|NCT00697866|EXPERIMENTAL|Group A|HBV-MPL Lot A
62751309|NCT00697866|EXPERIMENTAL|Group B|HBV-MPL Lot B
62751310|NCT00697866|EXPERIMENTAL|Group C|HBV-MPL Lot C
62751311|NCT00697866|ACTIVE_COMPARATOR|Group D|Engerix™-B
62375640|NCT06488014|ACTIVE_COMPARATOR|Group P|Paravertebral block: USG-guided local anaesthetic administration to the side of the vertebral body close to where the spinal nerves exit from the intervertebral foramen.
62555636|NCT05047666||Symptomatic Control Group|Also called in our study 'Case-Negatives'. These are those with respiratory symptoms suspected of COVID-19 that actually test negative for SARS-CoV-2 but positive for any other pathogen included in our respiratory PCR-based panel.
62555637|NCT05047666||Healthy Control Group|At the community.
62555638|NCT03015987|EXPERIMENTAL|diode laser activated irrigation|Laser-activated irrigation (LAI) has been introduced as a powerful method enhancing irrigant action; The laser radiation produces transient cavitation in the liquid through optical breakdown by strong absorption of the laser energy. The high-power diode laser has been tested in several areas of dentistry such as bleaching, depigmentation and gingivectomy, with promising results in dentinal disinfection. The diode laser has proved to be a resource worth testing, because of the it's properties and its low cost and availability in comparison to most lasers used in endodontics.
62555639|NCT03015987|ACTIVE_COMPARATOR|ultrasonic activated irrigation|"ultrasonics have been developed to improve the penetration and effectiveness of irrigation in peripheral areas of the root canal space. The efficiency of sonic and ultrasonic devices is based on the creation of hydrodynamic phenomenon in well-shaped canals filled with an irrigant.~Such active root canal irrigation has been shown to facilitate the disruption of biofilms and make the cell membrane of bacteria more permeable to NaOCl."
62375641|NCT01312285|PLACEBO_COMPARATOR|Placebo|
62375642|NCT01312285|EXPERIMENTAL|Resonator Device|
62555640|NCT04258592|EXPERIMENTAL|Patients|A single dose of 18F-MFBG will be intravenously injected in 10 patients with neural crest tumors or neuroendocrine tumors. Adult patients will first undergo a dynamic PET scan, followed by whole-body PET/CT scans at various time points for a pharmacokinetics study and efficacy assessment. Pediatric patients will undergo, depending on what is feasible for the child, at least 1 and up to 2 static whole-body PET/CTs. In patients 12 years or older, also a dynamic PET scan can be performed.
62555641|NCT01772329|EXPERIMENTAL|4 weekly CT sessions - in person|4 weekly CT sessions; all will be 1-hr individual cognitive therapy sessions with the psychology staff (under the supervision of John Burns, PhD).
62555642|NCT01772329|EXPERIMENTAL|8 weekly CT sessions|"8 weekly CT sessions; 1st and 8th will be 1-hr individual cognitive therapy session with the psychology staff (under the supervision of John Burns, PhD). The intermediate CT sessions will be by telephone call or video/Skype. Our group will purchase and setup a web camera and headphone/microphone for the subjects in the CT groups that use Skype. The 1-hr CT protocol was adapted from Dr. Beverly E. Thorn's CT manual (Cognitive Therapy for Chronic Pain: A Step-by-Step Guide; Thorn, 2004; with the Client and Therapy Workbooks."
62555643|NCT01772329|EXPERIMENTAL|4 weekly CT sessions - Tele-video|"4 weekly CT sessions; 1st and 4th will be 1-hr individual cognitive therapy session with the psychology staff. The intermediate CT sessions will be by telephone call or video/Skype."
62555644|NCT01772329|PLACEBO_COMPARATOR|Routine care|Routine care; no CT sessions
62555645|NCT03499444|EXPERIMENTAL|Oral Rucaparib monotherapy|Part I: Dose Escalation, Part II: Dose Expansion (Additional patients will be enrolled at the recommended dose as defined in Part I of the study.)
62555646|NCT04330664|EXPERIMENTAL|Phase 1 Dose Exploration|Dose escalation of TNO155 to determine maximum tolerated dose of TNO155 in combination with MRTX849
62375643|NCT04453618|EXPERIMENTAL|Food effect|Healthy subjects receive a single dose of SYHA1402 (100mg) in either a fasted state or with a meal.
62375644|NCT04453618|EXPERIMENTAL|Multiple doses 25mg|Healthy subjects receive multiple doses of SYHA1402 (25mg) or Placebo(25mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.
62375645|NCT04453618|EXPERIMENTAL|Multiple doses 50mg|Healthy subjects receive multiple doses of SYHA1402 (50mg) or Placebo (50mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.
62555647|NCT04330664|EXPERIMENTAL|Phase 1b Expansion|Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with TNO155 to recommend Phase 2 regimens
62555648|NCT04330664|EXPERIMENTAL|Phase 2|Separate cohorts of patients stratified by histological diagnosis for evaluation of clinical activity to evaluate clinical activity of MRTX849 and TNO155 in combination
62555649|NCT04015167||T2 Alpha Tibia|Subjects in the clinical investigation will undergo placement of the Tibial Nail of the T2 Alpha Tibia Nailing System, according to the approved Instructions for Use and Operative Technique Manual.
62555650|NCT03581019|EXPERIMENTAL|Uterus transplantation|Uterus transplantation
62555651|NCT00042601|PLACEBO_COMPARATOR|Placebo|A clear, colorless, sterile solution for SC injection manufactured by Amylin Pharmaceuticals, Inc. Placebo solution is the same, sterile preserved formulation, except the active ingredient, pramlintide, is omitted.
62751312|NCT05696353|NO_INTERVENTION|Control Group|The Control Group will have an in-vehicle device installed in the teen's car, but all feedback features will be disabled. Parents assigned into this group will receive no communication training on how to motivate their teen to adopt safe driving habits.
62751313|NCT05696353|EXPERIMENTAL|Feedback and Expert-Delivered Parent Communication Intervention Group|Teens will have an in-vehicle device installed in their car and the smart phone app downloaded on their smart phone. Teens will receive real-time and cumulative driving feedback generated by the in-vehicle device and app; parents will have access to their teen's cumulative driving data at any time via study web portal. Parents will also receive communication training on how to motivate their teen to adopt safe driving habits via online modules and a video call with a teen driving safety communication expert. A second booster session will occur two months after the initial training. Both teens and parents will also receive a biweekly summary report of the teen's driving events prepared by the research team.
62751314|NCT05696353|EXPERIMENTAL|Feedback and Peer-Delivered Parent Communication Intervention Group|Teens will have an in-vehicle device installed in their car and the smart phone app download on their smart phone. Teens will receive real-time and cumulative driving feedback generated by the in-vehicle device and app; parents will have access to their teen's cumulative driving data at any time via study web portal. Parents will also receive communication training on how to motivate their teen to adopt safe driving habits via online modules and a video call with a peer trainer who is a parent of teen with a traffic violation and who has received the Expert-delivered Intervention and met the defined peer trainer criteria. A second booster session delivered by the peer trainer will also occur two months after the initial training. Both teens and parents will also receive a biweekly summary report of the teen's driving events prepared by the research team.
62751315|NCT01730664|EXPERIMENTAL|ertapenem|single dose ertapenem
62751316|NCT01118520|ACTIVE_COMPARATOR|perindopril|ACE inhibitor blood pressure lowering agent
62751317|NCT01118520|ACTIVE_COMPARATOR|amlodipine|calcium channel blocker blood pressure lowering agent
62751318|NCT01118520|PLACEBO_COMPARATOR|placebo|inactive substance identical in appearance to the othe two comparators
62751319|NCT05890794|EXPERIMENTAL|0.8 mg/kg ilofotase alfa|Single dose administered intravenously over 1 hour
62751320|NCT05890794|EXPERIMENTAL|3.2 mg/kg ilofotase alfa|Single dose administered intravenously over 1 hour
62751321|NCT05827549|EXPERIMENTAL|Single group study|Apply Blinatumomab Cycle 1,2, S cycle 1, 2 (High Risk Group)- 4 weeks to patients before transplantation
62751322|NCT06315283|ACTIVE_COMPARATOR|Oral olanzapine|
62751323|NCT06315283|EXPERIMENTAL|TV-44749|
62751324|NCT05802082||Group P: n: 32patients|Group P: Patients administered iv 10mg/kg paracetamol 30 minutes before surgery
62751325|NCT05802082||Group K:n:32 patients|Group K: Patients administered iv 10mg/kg paracetamol 15 minutes before the end of surgery
62751326|NCT05581082||Routine Clinical Care with PCP|All individuals will be seen by their primary care physician (PCP) in Geriatric Clinic. Patients previously diagnosed with frailty per their PCP. Their PCP visit will include independent assessment and physical therapy referral, and will begin a physical therapy-based strengthening intervention. Patients will be independently managed (assessment and intervention) by a Physical Therapist (PT). The PT will initiate an intervention plan (e.g., education and exercise)
62751327|NCT04376684|EXPERIMENTAL|Part 1: Participants receiving otilimab|Participants (age \>=18 years and \<=79 years) will receive a single dose of otilimab administered as an IV infusion in addition to standard of care in Part 1.
62375646|NCT04453618|EXPERIMENTAL|Multiple doses 150mg|Healthy subjects receive multiple doses of SYHA1402 (150mg) or Placebo (150mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.
62751328|NCT04376684|PLACEBO_COMPARATOR|Part 1: Participants receiving placebo 1|Participants (age \>=18 years and \<=79 years) will receive a single dose of matching placebo administered as an IV infusion in addition to standard of care in Part 1.
62751329|NCT04376684|EXPERIMENTAL|Part 2: Participants receiving otilimab|Participants (age 70 years or above) will receive a single dose of otilimab administered as an IV infusion in addition to standard of care in Part 2.
62751330|NCT04376684|PLACEBO_COMPARATOR|Part 2: Participants receiving placebo 2|Participants (age 70 years or above) will receive a single dose of matching placebo administered as an IV infusion in addition to standard of care in Part 2.
62751331|NCT01588314|ACTIVE_COMPARATOR|gabapentin|
62751332|NCT01588314|PLACEBO_COMPARATOR|placebo|
62751333|NCT06416657|EXPERIMENTAL|Local anesthesia group|Patients in the local anesthesia group received only local anesthesia at the femoral artery puncture site without anesthesia drugs such as conscious sedation.
62751334|NCT06416657|ACTIVE_COMPARATOR|General anesthesia group|Patients in the general anesthesia group received not only local anesthesia at the femoral artery puncture site, but also fast-induction anesthesia with tracheal intubation or laryngeal mask insertion using isoproterenol, remifentanil, and muscle relaxants.
62375647|NCT06256094|EXPERIMENTAL|a2 Platinum Premium Infant Formula Stage 1|a2 Platinum Premium Stage 1 (0-6 months) cow's milk based powder infant formula
62555652|NCT00042601|ACTIVE_COMPARATOR|Pramlintide|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection manufactured by Amylin Pharmaceuticals, Inc. It consists of pramlintide (AC137) 0.6 mg/mL in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative.
62555653|NCT00678210|EXPERIMENTAL|1|
62375648|NCT06256094|ACTIVE_COMPARATOR|Frisolac Infant Formula Stage 1 (Dutch Edition)|Dutch Edition of the Frisolac Stage 1 (0-6 months) cow's milk based powder infant formula
62375649|NCT04511429||Kidney transplant patients|Patients submitted to kidney transplantation.
62375650|NCT04511429||Liver transplant patients|Patients submitted to liver transplantation.
62375651|NCT04511429||Oncological patients|Oncological patients submitted to chemotherapy.
62375652|NCT04347902|EXPERIMENTAL|PN with SMOFLipid|Parenteral nutrition with MCT/LCT/olive oil/fish oil (SMOFLipid, Fresenius Kabi, Germany, SMOF group)
62375653|NCT04347902|ACTIVE_COMPARATOR|PN with Olive oil|Parenteral nutrition with Olive oil/LCT 80:20 (ClinOleic, Baxter Healthcare, USA, OO group)
62375654|NCT04347902|ACTIVE_COMPARATOR|PN with MCT/LCT|Parenteral nutrition with - Medium/long-chain triglycerides 50:50 (Lipofundin, B Braun Germany, MCT/LCT group)
62375655|NCT04451395|EXPERIMENTAL|Multiple micronutrients (UNIMMAP composition)|"The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet..The supplement is provided within the parent trial.~Other Name: UNICEF, Micronutrient tabs, pregnancy/PAC-1000"
62375656|NCT04451395|NO_INTERVENTION|Standard of care|Daily iron and folic acid supplementation provided through the existing public health system.
62375657|NCT01438775|EXPERIMENTAL|Open Label Injection of NX-1207|Intraprostatic injection of 2.5 mg NX-1207
62375658|NCT06380556|NO_INTERVENTION|Control|The heel lance procedure of the infants in the control group was performed according to the routine heel lance procedure of the clinic.
62375659|NCT06380556|EXPERIMENTAL|ShotBlocker|ShotBlocker was applied to the infants in this group before and during the heel lance procedure.
62375660|NCT06380556|EXPERIMENTAL|Mechanical vibration|Mechanical vibration was applied to the infants in this group before and during the heel lance procedure.
62375661|NCT01841086|ACTIVE_COMPARATOR|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
62375662|NCT01841086|EXPERIMENTAL|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
62375663|NCT04295668||Usual care|A contemporaneous control group of patients was build using propensity score matching (PSM) methodologies taking into account the following matching variables: type of surgery, age, sex, American Society of Anesthesiologists Index (ASA) and adjusted morbidity groups (GMA) grading.
62375664|NCT04295668||Prehabilitation|"Prospective sample of risk patients who are candidates for major surgery attended in the outpatient offices of the Hospital Clínic de Barcelona.~Inclusion criteria: i) American Society of Anesthesiologists Index (ASA) 3-4; and / or, ii) age ≥ 75 years; and / or iii) major aggressive surgery; and, iv) solid organ transplant candidate.~Exclusion criteria: i) Non-elective surgery; ii) Known metastatic disease before surgery; iii) Unstable respiratory or heart disease; or, iv) Locomotive or cognitive limitations that prevent adherence to the program."
62375665|NCT02100813|OTHER|Part 1: LEO 43204|Open-label, dose escalation, 2 days treatment
62555654|NCT00678210|EXPERIMENTAL|2|
62555655|NCT00678210|EXPERIMENTAL|3|
62555656|NCT00678210|PLACEBO_COMPARATOR|4|
62555657|NCT00266630|EXPERIMENTAL|Olanzapine Monotherapy|"Olanzapine extension for Study BMAC patients who completed Visit 8.~Patients received olanzapine 5-20 mg for 18 weeks."
62751335|NCT01783314|ACTIVE_COMPARATOR|Normal liver function|Control group. Subjects will obtain MRI of liver.
62751336|NCT01783314|EXPERIMENTAL|Hepatitis C|Subjects with hepatitis C. Subjects will obtain both MRI of liver and limited CT of liver.
62751337|NCT01384630|OTHER|Single group|
62555658|NCT00266630|EXPERIMENTAL|Olanzapine + Mood Stabilizer|"Olanzapine extension for Study BMAC patients who discontinued at Visit 4 or 5.~Patients received an initial dose of olanzapine 10 mg for 1 week and subsequent doses of olanzapine 5-20 mg for 17 weeks.~Patients received one (1) mood stabilizer (lithium, valproate or carbamazepine) for 18 weeks."
62555659|NCT06408181|ACTIVE_COMPARATOR|Double low-dose aspirin|Participants will take 2 81mg aspirin tablets daily from entrance into the trial until delivery.
62751338|NCT03262350|EXPERIMENTAL|Yoga Group|Participants are required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, body image, sleep habits, and loneliness and have their height and weight measured. Participants are also required to attend 50-minute yoga classes on Mondays, Wednesdays, and Fridays from 1:25-2:15pm for 10 weeks. The overall time commitment for Yoga Group participants is 3 hours of assessments and 50-minute yoga classes 3X week for 10 weeks.
62751339|NCT03262350|NO_INTERVENTION|Control Group|Participants will be required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, health habits, body image, sleep habits and loneliness and have their height and weight measured. The overall time commitment for Control Group participants is 3 hours of assessments total.
62751340|NCT06109051||EndeavorOTC Users|All users who subscribe to EndeavorOTC for any duration
62751341|NCT06164496|EXPERIMENTAL|control group|A control group will be formed using a manual brush with a classic head.
62751342|NCT06164496|EXPERIMENTAL|study group|A study group will be formed using a 360-degree bristle brush.
62751343|NCT05977309|EXPERIMENTAL|Effect of Topical Ozone on The Healing Diabetic Foot Ulcer|The topical ozone therapy group received standard wound care with modern dressings every three days for thirty days.
62555660|NCT06408181|PLACEBO_COMPARATOR|Standard of Care|Participants will take 2 placebo pills from entrance into the study until 12 weeks gestational age, they will then take 1 placebo pill and 1 81mg aspirin until delivery.
62751344|NCT05977309|PLACEBO_COMPARATOR|Effect of Standart Wound Care on The Healing Diabetic Foot Ulcer|The placebo group received standard wound care with modern dressings thrice weekly for thirty days.
62751345|NCT03863470|NO_INTERVENTION|Pre-Intervention (Control)|There is no trial-driven approach to care. All hospitals contribute a minimum of 12 weeks of outcomes data prior to adopting the intervention. Pre-specified outcomes data will be electronically extracted for patients meeting eligibility criteria but there will be no attempt to influence delivery of usual care within the ICU. The length of the control phase will differ for each ICU cluster, depending on the sequence in which ICU-clusters are assigned to switch to the intervention phase.
62751346|NCT03863470|ACTIVE_COMPARATOR|Early mobilization intervention|The clinical team will set a standardized mobility goal for each patient during morning rounds and display the goal on the patient's door. A facilitator will be established in the ICU to communicate mobility goals and activities across clinical personnel shifts. Patient mobility scores will be displayed to clinical and administrative staff in the ICU via the ICU board.
62375666|NCT02100813|ACTIVE_COMPARATOR|Part 2: LEO 43204 x dose|X dose for 2 days treatment
62375667|NCT02100813|ACTIVE_COMPARATOR|Part 2: LEO 43204 Y dose|Y dose for 2 days treatment
62375668|NCT02100813|PLACEBO_COMPARATOR|Part 2: Placebo|Placebo for 2 days treatment
62375669|NCT02521168|EXPERIMENTAL|Oral triiodothyronine|Oral T3 (triiodothyronine) is given 1 mcg/kg every 6 hourly through naso-gastric tube since induction of anaesthesia for 60 hours
62375670|NCT02521168|PLACEBO_COMPARATOR|Placebo|Placebo (saccharin lactic) is given every 6 hourly through naso-gastric tube since induction of anaesthesia for 60 hours
62375671|NCT05822284||Patients with stage IIIB-C driver-negative NSCLC receiving induction chemoimmunotherapy|
62375672|NCT05740267|NO_INTERVENTION|Conventional laparoscopy group|The investigators can select either the intracorporeal or extracorporeal method to create bowel anastomoses. For the extracorporeal way, a mini-laparotomy wound is created and exteriorizes the bowel to do the anastomosis. The specimen is removed via the mini-laparotomy wound after the anastomosis is accomplished for the intracorporeal approach.
62375673|NCT05740267|EXPERIMENTAL|NOSE group|After bowel resection, all bowel anastomoses are created via side-to-side intracorporeal anastomosis, either isoperistaltic or antiperistaltic. The surgical steps of NOSE with the transrectal method are illustrated in Figure 1. First, the rectosigmoid colonic lumen is blocked with a bowel clamp. After rectal irrigation with povidone-iodine water, a transanal endoscopic microsurgery (TEM) scope or Alexis wound protector is inserted through the anus, reaching the upper rectum. Enterotomy is performed at the upper rectum, and a suction device is used to clean any fecal spillage. The TEM scope is pushed forward beyond the rectal opening, and the specimen is extracted with the TEM scope. The rectal opening is closed with a barbed suture, and an air leak test is performed to identify anastomotic leakage.
62375674|NCT05181215|EXPERIMENTAL|Bafiertam|190 mg (2 x 95 mg) delayed-release capsules
62375675|NCT05181215|ACTIVE_COMPARATOR|Vumerity|462 mg (2 x 231 mg) delayed-release capsules
62375676|NCT01786278|EXPERIMENTAL|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
62375677|NCT01786278|OTHER|Endoscopic Stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
62375678|NCT01944254|ACTIVE_COMPARATOR|random to respiration|Cardiac output measurement at random to respiration
62375679|NCT01944254|EXPERIMENTAL|timed with expiration start|Cardiac output measurement synchronised at start of expiration.
62375680|NCT01944254|EXPERIMENTAL|timed to instructed exhalation|Cardiac output measurement timed to instructed exhalation. The patient will receive instructions to exhale slowly using a peak expiratory flow (PEF)-flute and the cardiac output measurement will be started (i.e bolus given) at the start of expiration.
62375681|NCT00032110|EXPERIMENTAL|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after CR is confirmed.
62375682|NCT04090515|EXPERIMENTAL|Project Health|Project Health has three aims: 1) encourage participants to explore the costs of obesity, an unhealthy diet, and sedentary behavior and the benefits of physical fitness, a healthy diet, and regular exercise; 2) help participants gradually reduce caloric intake and increase physical activity, such that the participant reaches energy balance (i.e., is not eating more calories than they need); and 3) reduce attitudinal and behavioral risk factors for eating disorders and obesity. The intervention will be administered in Spanish.
62375683|NCT04090515|PLACEBO_COMPARATOR|Educational Video Control|The educational video control condition will include an educational video series on obesity in Spanish.
62375684|NCT03786276|EXPERIMENTAL|Exercise-Only|Exercise-Only condition, 12 exercise sessions on a stationary recumbent bicycle over 4 weeks. After 4 weeks, the participants will have a 1-week washout followed by Active VR-WMR arm.
62375685|NCT03786276|EXPERIMENTAL|VR-WMR-Only|Virtual Reality Working Memory Retraining-Only condition, 12 working memory retraining sessions over 4 weeks. After 4 weeks, the participants will have a 1-week washout followed by Active VR-WMR arm.
62375686|NCT03786276|EXPERIMENTAL|Active VR-WMR|After 4 weeks in one of the first two arms, the participants will have a 1-week washout followed by the Active VR-WMR arm. Participants will complete 12 Active VR-WMR sessions on a stationary recumbent bicycle over 4 weeks.
62375687|NCT01314404||KAP/WTP study population|"The participants will range in age from 12 to 50 and will be selected randomly. The study population will be representative of the following categories: men, women, adolescent boys, and adolescent girls.~As our study seeks to take a broad-based view of knowledge related to cervical cancer and HPV, our study population is necessarily wide-ranging. Adolescent boys and girls will be between the ages of 12 and 18; men and women will be older than 18, with at least one child that falls within the adolescent age range."
62555661|NCT05850117|ACTIVE_COMPARATOR|Tetracycline combined with levofloxacin quadruple therapy|esomeprazole 40mg twice a day + tripotassium dicitrate bismuthate 300mg four times a day+ tetracycline 500mg four times a day+ levofloxacin 500mg once a day
62555662|NCT05850117|ACTIVE_COMPARATOR|standard tincture quadruple therapy|"esomeprazole 40mg twice a day + tripotassium dicitrate bismuthate 300mg four times a day~+ tetracycline 500mg four times a day + metronidazole 250mg four times a day"
62555663|NCT05850117|ACTIVE_COMPARATOR|amoxicillin combined with levofloxacin quadruple therapy|esomeprazole 40mg twice a day + tripotassium dicitrate bismuthate 300mg four times a day+ amoxicillin 500mg four times a day+ levofloxacin 500mg once a day
62555664|NCT00726193||1 - standard films|Tibia reconstruction surgery with OsteoGen™ with standard radiographs
62555665|NCT00726193||2 - Standard films plus CT|Tibia reconstruction surgery with OsteoGen™ with standard radiographs and additional CT scan at 10 and 18 weeks.
62555666|NCT03979391|EXPERIMENTAL|Children with CIS or RIS|The detection of supernumerary oligoclonal bands (OCBs) in tears will be performed
62555667|NCT03196336|OTHER|Intervention|The intervention is the pharmacotherapeutic follow-up care. This service is performed according to the Pharmacotherapy Workup method, which is a protocol for the pharmacotherapeutic follow-up. This service identify, prevent and solve drug-related problems. It consiste of five pharmaceutical consultations (every up to 2-3 months) with the patient.
62555668|NCT03196336|OTHER|Control|The intervention is the usual procedure of dispensation of drugs. It is performed in five meetings (every up to 2-3 months) between the investigator and the patient.
62555669|NCT02196402||study population|"Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy for routine indications (screening, symptoms, surveillance).~Exclusion criteria:~* patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer~* patients with inadequate bowel preparation~* patients in which cecal intubation was not achieved or scheduled for partial examinations~* polyps could not be resected due to ongoing anticoagulation or could not be retrieved for pathologic assessment"
62555670|NCT03692832|EXPERIMENTAL|Group L|40 patients undergoing laparoscopic hysterectomy
62555671|NCT03692832|ACTIVE_COMPARATOR|Group V|40 patients undergoing vaginal hysterectomy
62555672|NCT05289869|EXPERIMENTAL|High-dose oxytocin regimen|Starting dose 6 mU/min and increased by 6 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
62555673|NCT05289869|EXPERIMENTAL|Low-dose oxytocin regimen|Starting dose 2 mU/min and increased by 2 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
62555674|NCT04506034|EXPERIMENTAL|lidocaine patches|for every port entry site from the three in ports of laparoscope, patients received three lidocaine patches 5% (Lidoderm® , Endo Pharmaceuticals, Chadds Ford, PA). Each patch measured 10 cm × 14 cm and contains (700 mg), was divided into two equal parts, six parts applied two of it around one port entry site that marked before sterilization and just before induction of anesthesia. The patches not changed until removed after return of bowel function or on the maximum at fifth postoperative day.
62555675|NCT04506034|ACTIVE_COMPARATOR|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight \>70 kg or 1 mg/min if body weight \<70 kg.
62555676|NCT04506034|PLACEBO_COMPARATOR|IV saline infusion|received i.v. saline infusion.
62555677|NCT00241670|EXPERIMENTAL|5-aminolevulinic acid|
62555678|NCT00241670|NO_INTERVENTION|Conventional resection|
62555679|NCT02023931|EXPERIMENTAL|Broccoli Sprout Extract Drink|Three different regimens of BSE delivery will be evaluated in each participant, with participants serving as their own controls. Each regimen will involve a 3 day exposure, with daily collection of buccal cell scrapings. Between regimens, a minimum 3 day (72 hour) washout period will occur.
62555680|NCT03067025||30 youth with MS|
62555681|NCT03067025||30 healthy control participants|
62555682|NCT00867659|EXPERIMENTAL|Cetrotide acetate|oocyte donors will receive cetrotide acetate on the day of oocyte retrieval. The incidence of OHSS will be assessed.
62555683|NCT03693417|ACTIVE_COMPARATOR|Control|
62555684|NCT03693417|EXPERIMENTAL|Heat|
62555685|NCT04445831|PLACEBO_COMPARATOR|Placebo|Placebo administered at predefined time points over a 48-week period.
62555686|NCT04445831|EXPERIMENTAL|ACI-35.030 - Low dose|Active vaccine administered at predefined time points over a 48-week period.
62555687|NCT04445831|EXPERIMENTAL|ACI-35.030 - Medium dose|Active vaccine administered at predefined time points over a 48-week period.
62555688|NCT04445831|EXPERIMENTAL|ACI-35.030 - High dose|Active vaccine administered at predefined time points over a 48-week period.
62555689|NCT04445831|EXPERIMENTAL|JACI-35.054 - Low dose|Active vaccine administered at predefined time points over a 48-week period.
62555690|NCT04445831|EXPERIMENTAL|JACI-35.054 - Medium dose|Active vaccine administered at predefined time points over a 48-week period.
62555691|NCT04133012|OTHER|Single Arm|Single arm composed by 34 HIV-1 infected male subjects
62555692|NCT05941312|ACTIVE_COMPARATOR|CONTROL GROUP (GROUP 1)|"Only open flap debridement (OFD):~Conventional OFD surgery was applied to patients in all groups which began with local anesthesia (4% articaine with 1:100 000 epinephrine) after the surgical area was disinfected. Defects were thoroughly debrided firstly by using periodontal curettes and then cleaned by piezoelectric ultrasonic scaler. For the control group, the defects were left without adding any products."
62555693|NCT05941312|ACTIVE_COMPARATOR|GROUP 2|Conventional OFD surgery was applied to patients in all groups which began with local anesthesia (4% articaine with 1:100 000 epinephrine) after the surgical area was disinfected. Defects were thoroughly debrided firstly by using periodontal curettes and then cleaned by piezoelectric ultrasonic scaler. After the operation area was washed thoroughly with saline, platelet-rich fibrine (PRF) was placed inside defects
62555694|NCT05941312|ACTIVE_COMPARATOR|GROUP 3|Conventional OFD surgery was applied to patients in all groups which began with local anesthesia (4% articaine with 1:100 000 epinephrine) after the surgical area was disinfected. Defects were thoroughly debrided firstly by using periodontal curettes and then cleaned by piezoelectric ultrasonic scaler. After the operation area was washed thoroughly with saline, Consantrated Growth Factor (CGF) was placed inside defects
62555695|NCT05941312|ACTIVE_COMPARATOR|GROUP 4|Conventional OFD surgery was applied to patients in all groups which began with local anesthesia (4% articaine with 1:100 000 epinephrine) after the surgical area was disinfected. Defects were thoroughly debrided firstly by using periodontal curettes and then cleaned by piezoelectric ultrasonic scaler. After the operation area was washed thoroughly with saline, autologous bone graft (ABG) was placed inside defects
62555696|NCT00473590|EXPERIMENTAL|Bortezomib + bevacizumab|Participants received bortezomib 1.3 mg/m\^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and bevacizumab 15 mg/kg administered by intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. After completion of 8 cycles, participants could continue to receive bevacizumab as monotherapy until disease progression.
62555697|NCT00473590|ACTIVE_COMPARATOR|Bortezomib + placebo|Participants received bortezomib 1.3 mg/m\^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and placebo intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. At the completion of the 8-cycle treatment phase, participants entered the observation phase until disease progression.
62555698|NCT03360383|EXPERIMENTAL|grade 1|percutaneous vertebroplasty
62555699|NCT03360383|ACTIVE_COMPARATOR|grade 2|conservative treatment
62555700|NCT05244122|EXPERIMENTAL|Feedback X Prevalence Using Dermatology Stimuli|"In this experiment, observers (Os) completed blocks of 80 trials. On each trial, they saw an image of a spot on the skin. They classified this as a melanoma (cancer) or a nevis (benign). Blocks could be of low prevalence (20% cancer cases, 16 images) or high prevalence (50%, 40 images). Os either did received trial by trial Feedback about their performance accuracy, or they did not. Thus, there were four types of block.~Low prevalence, No Feedback Low prevalence, Feedback High prevalence, No Feedback High prevalence, Feedback Each of these four types of block was made available to Os on each of 6 days. Os could elect to view each of the four blocks each day. Our particular interest was in the effect of performing one block on performance on an immediately subsequent block."
62751347|NCT06370962||Children and adolescents with cystic fibrosis treated with Kaftrio-Kalydeco|Patients with cystic fibrosis Aged from 2 to 17 years and 11 months Treated with CFTR modulator Kaftrio-Kalydeco for at least 2 months Followed in a participating Cystic Fibrosis Resource and Skill national Centre
62751348|NCT05678205|EXPERIMENTAL|Phase 1 Dose Confirmation|Dose Confirmation of AB-201 in advanced metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression
62751349|NCT05678205|EXPERIMENTAL|Phase 2 Cohort A|AB-201 given to patients with advanced/unresectable or metastatic breast cancer with HER2 overexpression (IHC ≥2+) that is refractory to or intolerant of standard treatment, or for which no standard treatment is available
62751350|NCT05678205|EXPERIMENTAL|Phase 2 Cohort B|AB-201 given to patients with advanced/unresectable or metastatic breast cancer with HER2 overexpression (IHC 3+ or IHC 2+/ISH+) that is relapsed to, refractory to, or intolerant of previous trastuzumab deruxtecan (T-DXd) based therapy
62751351|NCT05678205|EXPERIMENTAL|Phase 2 Cohort C|AB-201 given to patients with advanced/unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression (IHC ≥ 2+) that is refractory to or intolerant of standard treatment, or for which no standard treatment is available
62751352|NCT05482620|EXPERIMENTAL|Study Group|Study group following Nordic walking program and educational sessions and usual care (medical visits, medication, etc).
62751353|NCT05482620|ACTIVE_COMPARATOR|Control Group|Group that will only receive educational sessions and usual care (medical visits, medication, etc).
62555701|NCT03696290|ACTIVE_COMPARATOR|Aztreonam lysine, 3 doses per day|3 doses per day of nebulised Aztreonam lysine (75 mg) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
62751354|NCT00496483|ACTIVE_COMPARATOR|LCP-Tacro (tacrolimus)|Experimental: LCP Tacro; investigational product LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.
62751355|NCT01636063|EXPERIMENTAL|Mifepristone|Subjects will receive 200 mg of capsulized mifepristone orally for the purpose of cervical preparation before surgical abortion
62751356|NCT01636063|ACTIVE_COMPARATOR|Misoprostol|Subjects will receive 400 mcg of buccal misoprostol for the purposes of cervical preparation.
62375688|NCT01314404||Prevalence study population|"We plan to identify and recruit women diagnosed with cervical cancer who are being treated by a doctor from the department of gynecology of the Hospital Gabriel Touré in Bamako, Mali. These patients will have been previously identified and diagnosed by clinical exam by an obstetrician-gynecologist at Gabriel Touré, and will have been identified as surgical candidates by a doctor.~The subject has expressed a willingness to have a biopsy or other gynecological operation and have a doctor collect tissue samples during a standard medical appointment, has agreed to have blood drawn, was older than 18, and has the capacity to give informed consent."
62375689|NCT01376505|EXPERIMENTAL|HER-2 Vaccine|"combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with nor-MDP and ISA 720~This escalation arm has completed. The trial has moved on to the extension arm"
62375690|NCT01376505|EXPERIMENTAL|EXTENSION HER-2 Vaccine at OBD|"Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with nor-MDP and ISA 720 at dose level cohort 2~This extension arm is ongoing"
62375691|NCT05835167|EXPERIMENTAL|Inferior part-sternotomy CABG|A midline skin incision of 8 to 10cm in length is made over the sternum, starting from 2-3cm below the sternal angle inferiorly and extending slightly beyond the xiphoid process. A sternal saw is used to split the sternum from the xiphoid process to the second intercostal space where the sternum is partially transected by turning the saw rightward. Left internal mammary artery (LIMA)-left anterior descending branch bypass is the first choice for all patients. Remaining coronary bypassing techniques are according to clinical practice and preference of the operator. If it is difficult to perform CABG via inferior part-sternotomy, the treatment strategy convert to full median sternotomy, which is deemed to be failed to achieve complete revascularization via inferior part-sternotomy.
62375692|NCT05835167|ACTIVE_COMPARATOR|Full median sternotomy CABG|A midline skin incision is made over the sternum, starting from the sternal angle and extending slightly beyond the xiphoid process. The sternum is fully split by a sternal saw. Remaining coronary bypassing techniques are same in both groups according to clinical practice and preference of the operator.
62555702|NCT03696290|PLACEBO_COMPARATOR|Placebo, 3 doses per day|3 doses per day of nebulised placebo (5 mg lactose monohydrate) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
62555703|NCT03696290|ACTIVE_COMPARATOR|Aztreonam lysine, 2 doses per day|2 doses per day of nebulised Aztreonam lysine (75 mg) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
62751357|NCT05025098|ACTIVE_COMPARATOR|Standard therapy|"This study is a randomization between treatment principles, not treatments, i.e., standard therapy vs precision therapy (tumor board determined).~Standard treatment for AML patients is Azacitidine + Venetoclax.\*~\*Only if venetoclax is available to the study at the time-point of study start. If venetoclax is not available AML patients will receive Azacitidine alone similar to MDS patients.~Standard treatment for MDS is Azacitidine."
62751358|NCT05025098|EXPERIMENTAL|Precision therapy|This study is a randomization between treatment principles, not treatments, i.e., standard therapy vs precision therapy (tumor board determined). The precision therapy arm will receive standard therapy + tumor board decided precision therapy. The tumor board decided precision therapy can in principle be any therapy with marketing authorization in Norway.
62751359|NCT04854525||One Stage Reconstruction With pre-reconstruction Radiotherapy|
62751360|NCT04854525||Two Stage Reconstruction With pre-reconstruction Radiotherapy|
62751361|NCT04854525||Autologous Reconstruction With pre-reconstruction Radiotherapy|
62751362|NCT04854525||One Stage Reconstruction Without pre-reconstruction Radiotherapy|
62751363|NCT04854525||Two Stage Reconstruction Without pre-reconstruction Radiotherapy|
62751364|NCT04854525||Autologous Reconstruction Without pre-reconstruction Radiotherapy|
62751365|NCT05118464|EXPERIMENTAL|Children with cancer|The arm of the research will consist of pediatric patients aged 6-18 years who have been diagnosed with cancer in Afyonkarahisar Health Sciences University, Health Application and Research Center, Department of Pediatric Hematology-Oncology Clinics and who come for outpatient treatment.
62751366|NCT05634733||Patients with Sepsis|These are patients who present to the emergency department with sepsis. They will have a MAPSE at the time of enrollment and then after initial treatment.
62751367|NCT01818258|ACTIVE_COMPARATOR|Severe Malnutrition|ZDV+3TC+LPV/r Zidovudine (ZDV, Retrovir®) 10 mg/ml oral syrup administered twice daily at WHO weight band dose for 48 weeks; Lamivudine (Epivir®, 3TC) 10 mg/ml for oral solution administered twice daily at WHO weight band dose for 48 weeks; Lopinavir/ritonavir (Kaletra®, LPV/r) 80/20 mg/ml oral solution administered twice daily at the WHO weight band dose for 48 weeks
62751368|NCT01818258|ACTIVE_COMPARATOR|Normal Nutrition/Mild Malnutrition|ZDV+3TC+LPV/r Zidovudine (ZDV, Retrovir®) 10 mg/ml oral syrup administered twice daily at WHO weight band dose for 48 weeks; Lamivudine (Epivir®, 3TC) 10 mg/ml for oral solution administered twice daily at WHO weight band dose for 48 weeks; Lopinavir/ritonavir (Kaletra®, LPV/r) 80/20 mg/ml oral solution administered twice daily at the WHO weight band dose for 48 weeks
62751369|NCT03384563|ACTIVE_COMPARATOR|Dexmedetomidine 0.5 mcg/kg 1-6 months|Precedex 0.5mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
62751370|NCT03384563|ACTIVE_COMPARATOR|Dexmedetomidine 1 mcg/kg 1-6 months|Precedex 1 mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
62751371|NCT03384563|ACTIVE_COMPARATOR|Dexmedetomidine 0.5 mcg/kg 6-12 months|Precedex 0.5mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
62751372|NCT03384563|ACTIVE_COMPARATOR|Dexmedetomidine 1 mcg/kg 6-12 months|Precedex 1 mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
62751373|NCT03384563|PLACEBO_COMPARATOR|Placebo 6-12 months|Saline intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
62751374|NCT03384563|ACTIVE_COMPARATOR|Dexmedetomidine 0.5 mcg/kg 1-3 years|Precedex 0.5mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
62751375|NCT03384563|ACTIVE_COMPARATOR|Dexmedetomidine 1 mcg/kg 1-3 years|Precedex 1 mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
62751376|NCT03384563|PLACEBO_COMPARATOR|Placebo 1-3 years|Saline intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
62751377|NCT03384563|PLACEBO_COMPARATOR|Placebo 1-6 months|Saline intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
62751378|NCT05449379|EXPERIMENTAL|Post COVID experimental group|Safe protocol of 6 week physical training (aerobic training, resistance training, general improvement training, stretching training and respiratory rehabilitation) adjusted to the clinical state of patients plus additional resistance respiratory training with the use of respiratory muscle trainer (Philips Respironics Threshold IMT).
62555704|NCT03696290|PLACEBO_COMPARATOR|Placebo, 2 doses per day|2 doses per day of nebulised placebo (5 mg lactose monohydrate) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
62555705|NCT04456140|EXPERIMENTAL|Prevention (pre-genetic test counseling, genetic testing)|Patients watch a pre-recorded genetic counseling video and those who consent to genetic testing undergo collection of blood samples. Patients also complete surveys over 5-15 minutes each prior to receiving their genetic test results and following the receipt of genetic test results.
62375693|NCT01314456|EXPERIMENTAL|NaviGo|Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
62375694|NCT05393895|EXPERIMENTAL|CSF-1|One drop bilaterally twice daily for approximately 6 weeks
62375695|NCT05393895|PLACEBO_COMPARATOR|Vehicle|One drop bilaterally twice daily for approximately 6 weeks
62375696|NCT04770428|EXPERIMENTAL|Cohort 1: Japanese MEDI7352|Randomized Japanese participants will receive single doses of MEDI7352 subcutaneously.
62375697|NCT04770428|PLACEBO_COMPARATOR|Cohort 1: Japanese Placebo|Randomized Japanese participants will receive matching placebo subcutaneously.
62375698|NCT04770428|EXPERIMENTAL|Cohort 2: Caucasian MEDI7352|Randomized Caucasian participants will receive single doses of MEDI7352 subcutaneously.
62375699|NCT04770428|PLACEBO_COMPARATOR|Cohort 2: Caucasian Placebo|Randomized Caucasian participants will receive matching placebo subcutaneously.
62375700|NCT00599222|ACTIVE_COMPARATOR|TTT|TTT is given every three months
62375701|NCT00599222|SHAM_COMPARATOR|Sham TTT|Sham TTT is given every three months
62375702|NCT06169891|EXPERIMENTAL|SSGJ-613 200 mg|SSGJ-613 200 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh. Randomized patients will receive one s.c. injection of SSGJ-613 and placebo matching compound betamethasone injection (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection is recommended to be administered deeply into the gluteal muscle.
62375703|NCT06169891|ACTIVE_COMPARATOR|Compound Betamethasone Injection 1 mL|Compound betamethasone injection 1 mL intramuscularly (i.m) once. The i.m. injection is recommended to be administered deeply into the gluteal muscle. Randomized patients will receive compound betamethasone injection 1 mL i.m. once and placebo matching SSGJ-613 s.c. once, on Day 1.
62375704|NCT03031990|EXPERIMENTAL|Yoga intervention|The participants who elect to include yoga as part of their infertility treatments will self select one of three groups: 1) In person yoga for fertility group; 2) Online yoga for fertility group; 3) In person discussion only group
62375705|NCT03031990|NO_INTERVENTION|Control|These are patients that have a history of IVF failure or who are undergoing elective egg freezing who elect to be included in the study but are not interested in including yoga as a part of their treatment.
62375706|NCT01228695||steroid treatment|
62375707|NCT03709940|EXPERIMENTAL|Placebo, MPH|"Dose order: placebo, methylphenidate (MPH)~Participants receive a placebo tablet (ascorbic acid 50 mgs) on DAY 1 and a clinically effective dose of short-acting MPH (20 mgs) on DAY 2."
62375708|NCT03709940|EXPERIMENTAL|MPH, Placebo|"Dose order: methylphenidate (MPH), placebo~Participants receive a clinically effective dose of short-acting MPH (20 mgs) on DAY 1 and a placebo tablet (ascorbic acid 50 mgs) on DAY 2."
62375709|NCT05544214|EXPERIMENTAL|Sequence 1|"Period 1 - A single dose of 2 tablets(D745, D759) under fasting condition.~Period 2 - A single dose of 1 tablets(CKD-371) under fasting condition."
62375710|NCT05544214|EXPERIMENTAL|Sequence 2|"Period 1 - A single dose of 1 tablets(CKD-371) under fasting condition.~Period 2 - A single dose of 2 tablets(D745, D759) under fasting condition."
62555706|NCT03143790|ACTIVE_COMPARATOR|ESWT|500 shockwave 3 different points on penis bilateral
62555707|NCT03143790|PLACEBO_COMPARATOR|Placebo|500 shockwave 3 different points on penis bilateral
62555708|NCT04198194||Participants with events|Individuals who have experienced any of the listed outcomes
62555709|NCT04198194||Participants without events|Individuals who have not experienced any of the listed outcomes
62375711|NCT05725161|EXPERIMENTAL|Acceptance and commitment therapy (ACT) group|8 weekly ACT sessions individually guided by a trained coach through Zoom videoconferencing with psychoeducation materials provided
62375712|NCT05725161|OTHER|Wait-list control group with psychoeducation materials provided|Care as usual with psychoeducation materials provided during the study period and ACT sessions provided after the study period ends
62375713|NCT01500421|EXPERIMENTAL|TH - Endovacular alone|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with an endovascular groin catheter (Copenhagen only).
62375714|NCT01500421|EXPERIMENTAL|TH - Endovascular + nasopharyngeal induction|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with endovascular catheter along with nasopharyngeal induction (Copenhagen only).
62375715|NCT01500421|NO_INTERVENTION|Standard Treatment|Patients are treated with standard care in the stroke ward.
62375716|NCT01500421|EXPERIMENTAL|TH - Surface Cooling|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with cold saline infusion followed by surface cooling with Arctic Sun Cooling system, Medivance, USA (Malmø only)
62555710|NCT06031558|EXPERIMENTAL|SY-5007|SY-5007 will be given orally 160 mg twice daily in 28-day cycle continuously until disease progression, death, unacceptable toxicity, or withdraw consent in this study.
62751379|NCT05449379|PLACEBO_COMPARATOR|Post COVID control group|Safe protocol of 6 week physical training (aerobic training, resistance training, general improvement training, stretching training and respiratory rehabilitation) adjusted to the clinical state of patients. No resistance set on respiratory muscle trainer (Philips Respironics Threshold IMT).
62375717|NCT04839328|EXPERIMENTAL|60mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 60mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 60mg of Hemay005.
62375718|NCT04839328|PLACEBO_COMPARATOR|Placebo|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with placebo in first phase. Then will be treated BID for 36-week extension followed with 60mg of Hemay005.
62375719|NCT00608803|EXPERIMENTAL|Single arm|Once the maximum tolerated dose (MTD) is determined, an expanded cohort of 20 subjects with advanced, ifosfamide and doxorubicin naive soft-tissue sarcoma subjects will be dosed at the MTD and evaluated for efficacy.
62375720|NCT01315080||Saline|Percutaneous drainage and saline solution irrigation
62375721|NCT01315080||Triamcinolone|Percutaneous drainage and saline solution irrigation plus percutaneous triamcinolone
62375722|NCT01336231||patients group|Patients with a metastatic kidney cancer and must beginning a treatment by antiangiogenic
62375723|NCT01388491|EXPERIMENTAL|Treatment I: (DR-102)|21 days of combination active pills (containing 150 mcg desogestrel \[DSG\]/20 mcg ethinyl estradiol \[EE\]), followed by 7 days of 10 mcg EE, taken orally for 6 consecutive 28-day cycles
62375724|NCT01388491|ACTIVE_COMPARATOR|Treatment II|21 days combination active pills (containing 150 mcg DSG/20 mcg EE), taken orally and followed by 7 days of no treatment for a total of 6 consecutive 28-day cycles
62751380|NCT04299945|EXPERIMENTAL|Dietary nitrate supplementation|The dietary nitrate supplement will be a concentrated, nitrate-rich beetroot juice (70 ml providing ∼400mg nitrate per serving)
62751381|NCT04299945|PLACEBO_COMPARATOR|Placebo|The placebo will be a concentrated, nitrate-depleted beetroot juice (70 ml with trace amounts of nitrate)
62751382|NCT04171596|EXPERIMENTAL|Primary care coordination|
62751383|NCT03058315||Low back pain patients|Cohort of 800 consecutive low back pain patients, 18 years +, who have been referred from general practice to the secondary sector for further examination and MR scan.
62751384|NCT06298617||Study group|
62751385|NCT05192499|OTHER|Case|"Patients aged to 1 to 3 years with severe asthma (i.e. resistant to inhaled corticosteroid doses less than or equal to 200μg fluticasone equivalent).~Severe asthma patients (cases) are defined by poor asthma control under doses of inhaled corticosteroids ≤200μg fluticasone equivalent."
62751386|NCT05192499|OTHER|Control|"Patients aged to 1 to 3 years with low or moderate asthma (controlled with mild to moderate doses of inhaled corticosteroids less than or equal to 200μg of fluticasone equivalent).~Mild to moderate asthma patients (controls) are defined by disease control by first-line treatment in asthma, i.e. corticosteroids inhaled at mild to moderate doses of ≤200 micrograms/day of fluticasone equivalent."
62751387|NCT01858805||detection of circulating tumors cells|This prospective, single-institution study conducted at the University Hospital Hamburg-Eppendorf (Hamburg, Germany) enrolled 123 patients with ECs that were initially considered resectable. Only patients with histologically proven EC were included. Peripheral blood samples for CTC analysis were collected immediately before surgery.
62751388|NCT06183294||: adult subjects who underwent a clinically indicated invasive coronary angiography|"adult subjects with stable angina, unstable angina or NSTEM1 who underwent a clinically indicated invasive coronary angiography and on whom invasive FFR has been measured in vessels with coronary lesions.~Interventions:~Other: Collecting invasive FFR measurements."
62751389|NCT03374267||aRCC|Patients with advanced renal cell carcinoma
62751390|NCT03374267||aUBC|Patients with advanced urothelial carcinoma (locally advanced and inoperable, or metastatic)
62751391|NCT03374267||High-risk MIUC|Patients with muscle-invasive urothelial carcinoma classified as high-risk after radical surgery (ypT2-ypT4 and/or ypN+,M0 for patients with prior neoadjuvant chemotherapy; pT3-pT4 and/or pN+, M0 for patients without prior neoadjuvant chemotherapy)
62751392|NCT01344681|EXPERIMENTAL|Arm A|Micafungin sodium
62751393|NCT01344681|ACTIVE_COMPARATOR|Arm B|Itraconazole
62751394|NCT06608745|ACTIVE_COMPARATOR|conventional total knee arthroplasty surgery|
62751395|NCT06608745|EXPERIMENTAL|computer-assisted total knee arthroplasty surgery|
62751396|NCT05430191||Qualitative Interviews|Conduct 15 interviews with patients diagnosed with FH. Interviews will be 30-60 minutes in length and will focus on how individuals understand cascade screening, barriers to engagement including reasons why individuals do and do not share health information with family members, and preferred approaches to engaging family members, with a focus on acceptability, appropriateness, and feasibility of the planned implementation strategies. Interviewers will also attend to structural factors such as medical mistrust and experiences of racism in health care, and ask about preferences and logistics to incorporate preference into the future clinical trial design.
62751397|NCT05430191||Penn-mediated implementation strategy|The Penn-mediated implementation strategy will be designed and then iterated upon during mini-pilots. As part of this strategy, the patients would receive text messages and/or emails containing information about FH and cascade screening from Penn Medicine. This would include a request for the patient to identify first-degree biological relatives. They would be given a choice of either contacting their family members directly or sharing their contact information so someone from Penn Medicine can contact them. If the proband chooses to contact their family members, they receive educational information to share with them. Family members would be offered FH screening at no cost by blood lipid panel.
61986434|NCT03745144|EXPERIMENTAL|Sequence 1: First Cladribine, Then Placebo|"Period 1: Participants received a single once daily dose of Microgynon® tablet from Day 1-8 followed by 5-day once-daily Cladribine 10 to 20 milligram(mg) depending on body weight along with Microgynon® tablet once daily from Day 9-28.~Period 2: Participants received a single once daily dose of Microgynon® tablet from Day 1-8 followed by 5-day once-daily Cladribine matched Placebo along with Microgynon® from Day 9-14. From Day 15-28 participants received once daily Microgynon® along with 5-day once-daily Cladribine 10 to 20 mg depending on body weight."
62375725|NCT03283891|EXPERIMENTAL|educational intervention|Various pedagogical activities to mobilise Watson's ten Carative Factors
62375726|NCT03283891|NO_INTERVENTION|control|No intervention during the different times of measurement. Educational intervention will be delivered after the last measure.
62751398|NCT05430191||Family Heart Foundation-mediated implementation strategy|The Family Heart Foundation (FHF)-mediated implementation strategy will be designed and then iterated upon during mini-pilots. As part of this strategy, the patient would be contacted by a FHF patient navigator. The patient navigator would ask to set up a time to talk to the patient to talk about options for contacting family members, introduce them to the services they can provide to the patient and/or family members and obtain some details about the patient's family. The patient would come up with a plan to either contact their family members directly or have the patient navigator contact them. Family members will be offered FH screening at no cost by blood lipid panel. The patient and/or family members will be able to contact the patient navigator at any time with questions.
62751399|NCT00583414|EXPERIMENTAL|Endovascular Aneurysm Repair|Investigational stent-graft implant to exclude aneurysm
62751400|NCT00782171|ACTIVE_COMPARATOR|Immediate Loading|SLActive dental implant(s) will be restored with a temporary restoration on the day of surgery.
62751401|NCT00782171|ACTIVE_COMPARATOR|Early Loading|Healing caps will be placed on the SLActive dental implant(s) immediately after surgery. A provisional restoration will be placed between day 28 to day 34 post surgery
62751402|NCT04834154|ACTIVE_COMPARATOR|Mindfulness group visit|Participants will attend 6 weekly educational and mindfulness sessions
62751403|NCT04834154|PLACEBO_COMPARATOR|Wait list control|Participants will be placed on a wait list
62751404|NCT05115240|EXPERIMENTAL|Audio-guided mindfulness-based intervention (body scan)|
62751405|NCT05115240|EXPERIMENTAL|Enhanced Audio-guided mindfulness-based intervention (body scan)|Participants undergo the same audio-guided body scan intervention. However, in this arm the instruction focuses on the positive effects of mindfulness-based interventions and body scan aiming to optimize participants' interventions outcome expectations of the intervention. The idea of this arm is to assess whether the effects of the mindfulness-based intervention can be augmented by boosting participants positive expectations prior to the intervention.
62751406|NCT05115240|ACTIVE_COMPARATOR|Audio-Book|Participants in this group listen to an audio-book for the same duration as the participants in the two experimental groups.
62751407|NCT05010369|EXPERIMENTAL|non-hodgkin lymphoma|patients diagnosed with non-hodgkin lymphoma
62375727|NCT05937399|EXPERIMENTAL|Intervention Arm|This arm includes patients who view the integrated health video that provides information about both smoking and environmental risk.
62751408|NCT05010369|EXPERIMENTAL|hodgkin lymphoma|patients diagnosed with hodgkin lymphoma
62751409|NCT05010369|EXPERIMENTAL|squamous cell carcinoma|patients diagnosed with squamous cell carcinoma
62751410|NCT05010369|EXPERIMENTAL|reactive|patients diagnosed with a reactive (non-cancerous) lymph node
62751411|NCT05010369|EXPERIMENTAL|other|none of the above. Other cancer and non-cancer conditions
62751412|NCT05257460|ACTIVE_COMPARATOR|Closed-loop using standard rapid-acting insulin lispro|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using standard rapid-acting insulin lispro.~The CamAPS FX closed-loop system comprises Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA), an Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system."
62555711|NCT03266796||Patients & Physical therapists|First consultations of peoples with musculoskeletal disorders and their physical therapists will be audiotaped. Audiotapes will be used to analyse the communication between the patients and their physicaltherapists to explore how much physical therapists involve their patients in the goal setting process, to see if there is a shared decision making existing.
62751413|NCT05257460|EXPERIMENTAL|Closed-loop using ultra-rapid insulin lispro|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using ultra-rapid insulin lispro.~The CamAPS FX closed-loop system comprises Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA), an Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system."
61986435|NCT03745144|EXPERIMENTAL|Sequence 2: First Placebo, Then Cladribine|"Participants 5-day once daily Period 1: Participants received a single once daily dose of Microgynon® tablet from Day 1-8 followed by 5-day once-daily Cladribine matched Placebo along with Microgynon® tablet once daily from Day 9-28.~Period 2: Participants received a single once daily dose of Microgynon® tablet from Day 1-8 followed by 5-day once-daily Cladribine 10 to 20 mg depending on body weight along with Microgynon® tablet once daily from Day 9-28."
62555712|NCT02534389|EXPERIMENTAL|fish oil group|4 soft gel with omega-3 fish oil
62555713|NCT02534389|NO_INTERVENTION|control group|without intervention
62555714|NCT04807010|ACTIVE_COMPARATOR|Prostate artery embolization|
62555715|NCT04807010|SHAM_COMPARATOR|Sham|
62555716|NCT00651274|EXPERIMENTAL|Ezetimibe|
62555717|NCT00651274|PLACEBO_COMPARATOR|Placebo|
62555718|NCT01851044|PLACEBO_COMPARATOR|Vehicle (Saline)|2 ml of saline is injected to the proximal insertion of extensor carpi radialis brevis (ECRB) muscle.
62555719|NCT01851044|ACTIVE_COMPARATOR|Whole Blood|2 ml of patient own venous blood is injected to the proximal insertion of ECRB.
62555720|NCT01851044|EXPERIMENTAL|Platelet Rich Plasma|9 ml of patient own venous blood is centrifuged using The Arthrex ACP® Double Syringe System and 2 ml of platelet rich plasma is injected to the proximal insertion of ECRB.
62555721|NCT05193838||Allopurinol|we plan to follow up effect of Allopurinol on left ventricular function in children with dilated cardiomyopathy for 6 months
62555722|NCT03415646|ACTIVE_COMPARATOR|Block Group|Erector Spinae Plane Block administered group
62555723|NCT03415646|SHAM_COMPARATOR|Control Group|Control group
62555724|NCT02436161|EXPERIMENTAL|"Care management program PROMIC"|care management program provided by a multidisciplinary team that optimizes care with the main role of nurses acting as coaches of patients and carers, within the primary care teams
62555725|NCT02436161|NO_INTERVENTION|Usual care|Patients in the control group belongs to different Primary health care centres from the intervention group and are treated as usual by their Primary Care team and by cardiologists different from the intervention group
62555726|NCT06269458|EXPERIMENTAL|Baby Massage|"In the baby massage application, mothers were trained on baby massage and the massage applied by the mother to her baby was observed once. The baby massage video prepared by the researchers was shared with mothers. Baby massage application was performed 90 minutes after feeding and each application was performed at the same time. Mothers massaged their babies for 15 minutes three times a week for a month. The Massage Application Content included one minute face, two minutes chest, four minutes arm, two minutes abdominal, four minutes leg and two minutes back massage (Virgian and Setiawati, 2021; Yenigün 2020; Yılmaz, 2019). All mothers were called once a week by a researcher to provide counseling and follow-up of the process.~At the end of four weeks, measurement tools were applied to all mothers and the groups were changed, massage was applied to the yoga group, and yoga intervention was applied to the massage group, as in the beginning of the research."
61986436|NCT03745144|EXPERIMENTAL|Microgynon®|Participants received Microgynon® for 21 days, starting on the first day of the menstrual cycle.
62555727|NCT06269458|EXPERIMENTAL|Mother-Baby Yoga|The mothers in the Mother-Baby Yoga group were given a 10-minute training on mother-baby yoga before the application, and then a session was applied together. Mothers were asked to choose the most suitable time of day for themselves and the baby, to ensure that the baby was fed at least 45 minutes before yoga, and to practice yoga in a calm and dimly lit environment, listening to music or white noise of their choice. One yoga session lasted approximately 20 minutes. Mothers and their babies did mother-baby yoga three times a week for four weeks. Mother baby yoga content; Mood regulation: belly breathing, warm touch from the heart, chair pose, scoop hug, bukka bukka, vortex creation, lush falls one hand two hands, tiny stretches, here and now awareness and dolphin pose.
62555728|NCT03879785|ACTIVE_COMPARATOR|Self-Administration followed by Interviewer-Administered|
62751414|NCT03822312|EXPERIMENTAL|DBT-TOBI|"* Subjects will be imaged using DBT-TOBI at the time points indicated in the Study Calendar (Baseline, before cycle 2, and additional optional time points).~* Both breasts will be measured in turn.~* Each breast is symmetrically centered on the x-ray detector/optical illuminator and is first compressed according to standard mammography procedures to determine the amount of force needed for each given patient~* An optional Magnetic Resonance Imaging TOBI (MRI-TOBI) scan will also be performed."
62751415|NCT05451290|EXPERIMENTAL|treatment arm|
62751416|NCT03425006|EXPERIMENTAL|Itacitinib and Pembrolizumab|
62555729|NCT03879785|ACTIVE_COMPARATOR|Interviewer-Administered followed by Self-Administration|
62555730|NCT05467501|EXPERIMENTAL|Ultrasound group|Therapeutic ultrasound application. US parameters are 0.8 W/cm for intensity, 3 MHz for frequency and 5 min application. The device that will be used is medserve, England (the head of the device is 5cm). The physical therapy will by 6 sessions (every day). PT sessions will be done by the same physical therapist.
62555731|NCT05467501|ACTIVE_COMPARATOR|placepo group|group B will have a non-steroidal anti-inflammatory drug as prescribed by the same orthopedist and 2 session of massage with the head of ultrasound.
62555732|NCT03707574||Ancillary-correlative (genetic analysis)|Patients undergo collection of blood and tumor prior to starting treatment and upon disease progression (second collection of blood and tumor only for patients who do not continue to progress and achieve either an OR or SD after 6 months of treatment). Samples are banked and analyzed via next generation sequencing.
62555733|NCT00748761|EXPERIMENTAL|OCD Active CBT|Children with obsessive-compulsive disorder (OCD) will be treated with cognitive behavioral therapy (CBT) from the time of enrollment.
62555734|NCT00748761|ACTIVE_COMPARATOR|OCD Waitlist|Children with OCD will receive waitlist treatment at enrollment. Nonresponders will cross over to CBT.
62555735|NCT00748761|NO_INTERVENTION|Healthy Controls|Healthy control children will be given no intervention.
62555736|NCT02159313|EXPERIMENTAL|BAY63-2521 with Non sparkling water|Single dose of a whole 2.5 mg riociguat tablet (fasted) with 240 mL of non-sparkling water at room temperature
62555737|NCT02159313|EXPERIMENTAL|BAY63-2521 with applesauce|Single dose of a crushed 2.5 mg riociguat tablet suspended in 50 mL applesauce, to be eaten with a spoon (fasted)
62555738|NCT02159313|EXPERIMENTAL|BAY63-2521 with water|Single dose of a crushed 2.5 mg riociguat tablet suspended in a glass with 25 mL water, to be drunk and flushed twice with 25 mL water in the same glass (fasted)
62751417|NCT05419128|ACTIVE_COMPARATOR|ACHESS-C|In ACHESS-C, both the drinker and the partner will receive a smartphone, but only the drinker will receive the ACHESS-C app. The partner will receive a smartphone with contact information for standard AUD, SUD, and crisis support.
62751418|NCT05419128|EXPERIMENTAL|FamCHESS-C|In the FamCHESS-C arm, drinker and partner will both receive a smartphone with the FamCHESS-C app, which contains ACHESS-C services plus ABCT/ PartnerCHESS services.
62751419|NCT05419128|NO_INTERVENTION|Control|Both the drinker and family partner will receive a smartphone with pre-programmed contact information for Alcoholics Anonymous (AA), Narcotics Anonymous (NA), Al-Anon, Adult Children of Alcoholics (ACOA), and crisis hot lines.
62751420|NCT01213147|EXPERIMENTAL|clomiphene citrate,pregnancy,poor responders|Woman in clomiphene citrate arm are administered 100mg/day oral from day 3 of menstrual cycle until day 7 of cycle
62751421|NCT01213147|ACTIVE_COMPARATOR|buserelin,pregnancy,poor responder|women in control arm are administered Buserelin buserelin 50 µg SC twice a day from cycle day 2 of menstrual cycle
62555739|NCT02159313|EXPERIMENTAL|BAY63-2521 after breakfast|Single dose of a whole 2.5 mg riociguat tablet taken within 5 minutes after the last bite of a continental breakfast (fed) with 240 mL of non-sparkling water at room temperature
62555740|NCT03888469|OTHER|DDT2, then 1DAVM|Verofilcon A contact lenses worn first, with etafilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
62555741|NCT03888469|OTHER|1DAVM, then DDT2|Etafilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
62751422|NCT04363697|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10 mg administered orally once daily for 2 months
62751423|NCT04363697|PLACEBO_COMPARATOR|Placebo|Matching placebo administered orally once daily for 2 months
62555742|NCT05273411|ACTIVE_COMPARATOR|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester|1 x 20 mL
62555743|NCT05273411|EXPERIMENTAL|Beta-hydroxybutyric acid|1 x 237 mL
62555744|NCT05273411|EXPERIMENTAL|1,3-Butanediol|1 x 35 mL
62555745|NCT04623047||Adults 18 years of age and up|The study will recruit any adult over the age of 18 years.
62555746|NCT03523936|ACTIVE_COMPARATOR|Prebiotic|
62555747|NCT03523936|PLACEBO_COMPARATOR|Placebo|
62751424|NCT05639153|EXPERIMENTAL|DR30303|DR30303 injection treatment. This phase 1 trial will include two stages, a dose escalation stage and an expansion stage.
62751425|NCT01713660|OTHER|FS Corneal Incisions|
62751426|NCT03548753||Patients with Agatston score > 399|"1. Coronary computed tomography angiography with FFR-CT~2. Invasive coronary angiography with FFR"
62751427|NCT05375396|ACTIVE_COMPARATOR|Streptococcus salivarius M18 lozenges|Streptococcus salivarius M18 lozenges containing dairy based Streptococcus salivarius M18
62751428|NCT05375396|ACTIVE_COMPARATOR|Streptococcus salivarius M18 dairy free lozenges|Streptococcus salivarius M18 lozenges containing dairy free Streptococcus salivarius M18
62751429|NCT03454399|NO_INTERVENTION|TEE image before suction|Suction orogastric tube which is attached to TEE probe
62751430|NCT03454399|EXPERIMENTAL|TEE image after suction|Suction orogastric tube which is attached to TEE probe
62751431|NCT01183052|OTHER|Training|20 sessions of training
62751432|NCT00944814|EXPERIMENTAL|LNS with zinc|LNS containing 10 mg zinc per 20 g dose of LNS
62751433|NCT00944814|PLACEBO_COMPARATOR|LNS without zinc|LNS containing no zinc
62751434|NCT00813865|EXPERIMENTAL|Afegostat Tartrate Treatment Regimen 1|Afegostat tartrate was administered orally at a dose of 225 mg QD for 3 or 7 consecutive days followed by no study medication for 4 or 7 consecutive days (consecutive 3-days-on/4-days-off or 7-days-on/7-days-off, respectively). Amendment 2 added a MWF 3-days-on/4-days-off regimen. After Amendment 2 was implemented, all participants were assigned to one of the two 3-days-on/4-days-off regimens. Amendment 4 removed the consecutive 3-days-on/4-days-off regimen, and all participants were assigned to the MWF 3-days-on/4-days-off regimen. Participants were to receive afegostat tartrate for 30 months and be followed for 6 months after EOT.
62751435|NCT01598558|EXPERIMENTAL|64Cu-DOTA|Subjects will be injected with less than 14 mCi of 64Cu-DOTA-Rituximab. This is a slow infusion, done over 20 minutes.
62751436|NCT02370485|EXPERIMENTAL|LY2801653 Reference - Fasted|Single oral dose of LY2801653 (Reference Formulation) administered in fasted state in one of three study periods.
62555748|NCT03266601|EXPERIMENTAL|Recombinant Human Interferon α-2b Spray|
62555749|NCT03266601|ACTIVE_COMPARATOR|Ribavirin|
62555750|NCT06109155|ACTIVE_COMPARATOR|High dose tranexamic acid + high ACT level|high dose tranexamic acid: 50mg/kg ACT level: \> 600 sec
62555751|NCT06109155|ACTIVE_COMPARATOR|High dose tranexamic acid + low ACT level|high dose tranexamic acid: 50mg/kg ACT level: 400\~ 600 sec
62751437|NCT02370485|EXPERIMENTAL|LY2801653 Test - Fasted|Single oral dose of LY2801653 (Test Formulation) administered in fasted state in one of three study periods.
62751438|NCT02370485|EXPERIMENTAL|LY2801653 Test - Fed|Single oral dose of LY2801653 (Test Formulation) administered with a high fat meal in one of three study periods.
62555752|NCT06109155|ACTIVE_COMPARATOR|Low dose tranexamic acid + low ACT level|Low dose tranxeamic acid: 20mg/kg ACT level: 400\~ 600 sec
62751439|NCT06606054|PLACEBO_COMPARATOR|No intervention|This group will not receive any of the educational and/or implementation Neurocardiology until the data collection is completed.
62751440|NCT06606054|ACTIVE_COMPARATOR|Intervention arm|Sites randomized in this arm will receive the educational and implementation Neurocardiology tool with the aim of improving adherence to best practice recommendations for secondary stroke prevention of cardioembolic strokes, as defined by the WSO Systematic Review and Synthesis of Global Stroke Guidelines or more recent high-quality evidence published after the last stroke guidelines.
62751441|NCT04027803|EXPERIMENTAL|BCD-148|39 healthy subjects received BCD-148, 900 mg, a single drip infusion over 25-45 min
62751442|NCT04027803|ACTIVE_COMPARATOR|Soliris|39 healthy subjects received Soliris, 900 mg, a single drip infusion over 25-45 min
62751443|NCT04960904||In-Kone® UNIVERSAL|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges In-Kone® UNIVERSAL, including the former 3.0 range now named In-Kone® Universal NR (narrow), and including the In-Kone® Universal WD (wide).
62751444|NCT04960904||In-Kone® PRIMO|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges In-Kone® PRIMO
62751445|NCT04960904||twinKon®|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges twinKon®
62751446|NCT04960904||EVL® S|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges EVL® S
62375728|NCT05937399|EXPERIMENTAL|Control Video Arm|This arm includes patients who view the integrated health video that provides information ONLY about smoking risk.
62375729|NCT06505681|EXPERIMENTAL|Pharmacopuncture|20 patients with pharmacoacupuncture
62555753|NCT06109155|PLACEBO_COMPARATOR|Low dose tranexamic acid + high ACT level|Low dose tranxeamic acid: 20mg/kg ACT level: \> 600 sec
62555754|NCT00721071|EXPERIMENTAL|1|
62751447|NCT04960904||EVL® K|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges EVL® K
62375730|NCT06505681|ACTIVE_COMPARATOR|Physical therapy|20 patients with physical therapy
62375731|NCT02936115|EXPERIMENTAL|TruSkin®|Cryopreserved skin allograft
62375732|NCT02936115|ACTIVE_COMPARATOR|Wound Cover|Active Comparator for Diabetic Foot Ulcers
62375733|NCT01601990|PLACEBO_COMPARATOR|Placebo|
62375734|NCT01601990|EXPERIMENTAL|LC15-0444|
62375735|NCT04856969|ACTIVE_COMPARATOR|Arm A|ATB-1011: 1tab/d for 5days , ATB-1011+ATB-1012: each 1tab/d for 5days
62375736|NCT04856969|ACTIVE_COMPARATOR|Arm B|ATB-1012: 1tab/d for 5days / ATB-1011+ATB-1012: each 1tab/d for 5days
62375737|NCT02525809|OTHER|mobility insert with tripod attachment (Novae E®)|mobility insert with tripod attachment (Novae E®)
62375738|NCT02525809|OTHER|mobility insert with press fit pure (Sunfit®)|mobility insert with press fit pure (Sunfit®)
62375739|NCT02525809|OTHER|fixed insert (Quartz®).|fixed insert (Quartz®).
62375740|NCT03610867|EXPERIMENTAL|Furaprevir capsule (SAD)|single ascending oral dose (100 mg, 200 mg, 400 mg, and 600 mg) of TG-2349 (Furaprevir capsule)
62375741|NCT03610867|PLACEBO_COMPARATOR|Placebo (SAD)|"Single ascending oral dose of Furaprevir similar capsule.~."
62375742|NCT03610867|EXPERIMENTAL|Furaprevir capsule (MAD)|multiple ascending oral doses (200 mg, 400 mg, and 600 mg) of TG-2349 (Furaprevir capsule)
62375743|NCT03610867|PLACEBO_COMPARATOR|Placebo (MAD)|Multiple ascending oral doses of Furaprevir similar capsule
62375744|NCT00683774|EXPERIMENTAL|PCOS subjects|PCOS subjects given diazoxide
62375745|NCT00683774|ACTIVE_COMPARATOR|Normal subjects|Normal subjects given diazoxide
62375746|NCT05565066||FNB group|FNB needles adpted to acquire lesion tissues according patients' advice and patients' willings.
62375747|NCT05565066||FNA group|FNA needles adpted to acquire lesion tissues according patients' advice and patients' willings.
62375748|NCT04161313||Cystic fibrosis|children with cystic fibrosis
62375749|NCT04161313||primary ciliary dyskinesia|children with primary ciliary dyskinesia
62375750|NCT04161313||healthy controls|Age-matched healthy volunteers
62375751|NCT06014021|EXPERIMENTAL|Experimental group 1|All participants will use an Smartphone application with access to information about pelvic floor and communication with healthcare team, and a strengthening program for PF, while using an intracavitary biofeedback device.
62375752|NCT06014021|ACTIVE_COMPARATOR|Experimental group 2|All participants will use an Smartphone application with access to information about pelvic floor and communication with healthcare team, and a strengthening program for PF.
62375753|NCT06014021|ACTIVE_COMPARATOR|Control group|All participants will use an Smartphone application with access to information about pelvic floor and communication with healthcare team.
62375754|NCT00192465|EXPERIMENTAL|1|MEDI-524 (Numax-TM)
62375755|NCT00192465|EXPERIMENTAL|2|MEDI-524 (Numax-TM)
62555755|NCT05049395|ACTIVE_COMPARATOR|Control group|The patients are administered oxygen of 3L-6L/min until the end of the hysteroscopy operation.
62555756|NCT05049395|EXPERIMENTAL|HFNO group|The patients are administered oxygen of 30L-60L/min until the end of the hysteroscopy operation.
62555757|NCT05975411||telemedecine cabin|Anesthesia Consultation with telemedicine cabin installed in Dozulé
62375756|NCT00192465|EXPERIMENTAL|3|MEDI-524 (Numax-TM)
62375757|NCT00192465|EXPERIMENTAL|4|MEDI-524 (Numax-TM)
62375758|NCT00192465|EXPERIMENTAL|5|MEDI-524 (Numax-TM)
62375759|NCT03011528|OTHER|VDC - IE x2 & Surgery|"Patients in Arm A receive~* VDC-IE x2: Intensified induction phase:~  * 4 cycles of VDC (Vincristine Doxorubicine Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if good response after the 4th treatment, followed by:~ * 4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association~* Consolidation BuMel High dose chemotherapy (Busulfan Melphalan) followed by Peripheral Blood Stem Cell Infusion~* Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added~* Maintenance phase~  * 1st year : VC (Vincristine Cyclophosphamide) association~ * 2nd year : Cyclophosphamide po 25 mg/m²"
62555758|NCT05975411||telemedicine trolley|Anesthesia Consultation with telemedicine by way of the telemedicine trolley installed in a center close to their place of residence
62555759|NCT05975411||standard|Anesthesia Consultation at the CHU de Caen as usual.
62555760|NCT04364893|OTHER|Group 1|Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
62555761|NCT04364893|OTHER|Group 2|Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
62751448|NCT04960904||EVL® C|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges EVL® C
62375760|NCT03011528|OTHER|VDC - IE & TEMIRI & Surgery|"Patients in Arm B receive~* VDC-IE \& TEMIRI: Intensified induction phase:~  * 4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if poor response after the 4th treatment, followed by:~ * 4 cycles of TEMIRI (Temozolomide-Irinotecan) association~* Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added~* Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~* Maintenance phase~  * 1st year : VC (Vincristine Cyclophosphamide) association~ * 2nd year : Cyclophosphamide po 25 mg/m²"
62375761|NCT03011528|OTHER|VDC - IE x2 & Radiotherapy|"Patients in Arm C receive~* VDC-IE x2: Intensified induction phase:~  * 4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if good response after the 4th treatment, followed by:~ * 4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association~* Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~* Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.~* Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~* Maintenance phase~  * 1st year : VC (Vincristine Cyclophosphamide) association~ * 2nd year : Cyclophosphamide po 25 mg/m²"
62375762|NCT03011528|OTHER|VDC - IE & TEMIRI & Radiotherapy|"Patients in Arm D receive~* VDC-IE \& TEMIRI: Intensified induction phase:~  * 4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if poor response after the 4th treatment, followed by:~ * 4 cycles of TEMIRI (Temozolomide-Irinotecan) association~* Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.~* Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~* Maintenance phase~  * 1st year : VC (Vincristine Cyclophosphamide) association~ * 2nd year : Cyclophosphamide po 25 mg/m²"
62375763|NCT04173481|EXPERIMENTAL|Rood's Group|Rood's sensory motor training along with CIMT
62555762|NCT01791309|EXPERIMENTAL|combination panitumumab and vemurafenib|This will be a pilot study of the combination panitumumab and vemurafenib in patients with metastatic colorectal cancer with a BRAF V600E mutation. Patients participating in this study must have BRAF V600E mutated metastatic colorectal cancer and not previously received treatment with an anti-EGFR targeting antibody (cetuximab or panitumumab).
62555763|NCT01756027|ACTIVE_COMPARATOR|Group A|Ulthera System providing one treatment per cheek
62555764|NCT01756027|ACTIVE_COMPARATOR|Group B|Ulthera System providing two treatments per cheek
62751449|NCT01575938|EXPERIMENTAL|HIV group-based prevention intervention|The HIV prevention intervention is a 6-session group-based and manualized intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
61986437|NCT00798109|EXPERIMENTAL|Motivational Therapy|Four motivational interview for cannabis abuse in schizophrenia population during one month
62751450|NCT01575938|ACTIVE_COMPARATOR|Diet and nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
62751451|NCT01575938|NO_INTERVENTION|Standard-of-care|This arm will receive HIV and STI testing and counseling only.
62751452|NCT04695054|EXPERIMENTAL|Buzzy and EMLA Cream|In the experimental group children will receive the application of EMLA cream 60 minutes before the needle procedure and the use of Buzzy device during the procedure.
62375764|NCT04173481|ACTIVE_COMPARATOR|Conventional Physical Therapy Group|Conventional Physical Therapy including Proprioceptive Neuromuscular Facilitation technique.
62375765|NCT02074761||SImmetry Implant|Subjects who are indicated for the SImmetry device and meet the inclusion/exclusion criteria will receive a SImmetry implant.
62375766|NCT03148899|EXPERIMENTAL|Visit 1 Randomization|At visit 1 (PSG 1) subjects will receive one of two interventions: either Oxytocin Intranasal Spray (40 IU) or Placebo Intranasal Spray. Subjects will be blinded as to which drug they are receiving.
62375767|NCT03148899|EXPERIMENTAL|Visit 2: Crossover Randomization|At visit 2 (PSG 2) subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal Spray (40 IU) or Placebo Intranasal Spray. Subjects will be blinded as to which drug they are receiving.
62375768|NCT02946151|EXPERIMENTAL|Implantation|Implantation of a subcutaneous electrode and connection to the external logging device
62375769|NCT03943940|EXPERIMENTAL|BM-MNC and UC-MSC|30 patients with Type 2 Diabetes Mellitus will be enrolled and received mononuclear cells and mesenchymal stem cells by intravenous infusion.
62375770|NCT03943940|OTHER|Stand medicines|30 patients with Type 2 Diabetes Mellitus will be enrolled and treated by standard medicines.
62375771|NCT01541540|EXPERIMENTAL|e-Counseling plus Usual Care|
62375772|NCT01541540|ACTIVE_COMPARATOR|e-Info Control plus Usual Care|
62751453|NCT04695054|ACTIVE_COMPARATOR|EMLA Cream|In the control group children will receive the application of EMLA cream 60 minutes before the needle procedure
62751454|NCT06157996|EXPERIMENTAL|Intensive treatment of lenvatinib and tislelizumab plus CapeOX chemotherapy|Efficacy of lenvatinib and tislelizumab plus CapeOX as first-line treatment
62751455|NCT06157996|ACTIVE_COMPARATOR|Conventional treatment of tislelizumab plus CapeOX chemotherapy|Efficacy of tislelizumab plus CapeOX as first-line treatment
62751456|NCT06466941||Thoracic surgery and open abdominal surgery|Patients who underwent surgery thoracic surgery or open abdominal surgery
62751457|NCT06466941||Orthopedic surgery|Patients who underwent orthopedic surgery
62375773|NCT02387450|ACTIVE_COMPARATOR|Treated group|Sildenafil, oral, 100mg per day
62375774|NCT02387450|PLACEBO_COMPARATOR|Control group|placebo oral
62751458|NCT06466941||Spine surgery|Patients who underwent spine surgery
62751459|NCT01426919||Suspected traumatic brain injury with head CT|
62751460|NCT03012139||Cancer with cachexia|Men and women (ages 35-80 years) with cancer cachexia (≥5% drop in body mass in less than 12 months)
62751461|NCT03012139||Cancer without cachexia|Men and women (ages 35-80 years) with cancer but without cachexia of similar age and sex as the group with cachexia
61986438|NCT00798109|OTHER|Usual Care|Usual care with intensive psychotherapy
62375775|NCT00478595|EXPERIMENTAL|Rimonabant|Rimonabant 20 mg once daily
62375776|NCT00478595|PLACEBO_COMPARATOR|Placebo|Placebo (for Rimonabant) once daily
62375777|NCT03875872||Group propofol|Patients who had surgeries and were anaesthetized with propofol at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
62375778|NCT03875872||Group inhalation anaesthetics|Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
62375779|NCT04189380|EXPERIMENTAL|Cohort 1|liver transplanted patient
62375780|NCT01902927|EXPERIMENTAL|COPD patients|COPD patients will perform a constant workrate treadmill exercise test until exhaustion with positve/neutral/negative visual distraction images during the exercise test assigned in a randomized order
62375781|NCT03455504|EXPERIMENTAL|Cohort 1|FLAI + V400 mg
62375782|NCT03455504|EXPERIMENTAL|Cohort 2|FLAI + V600 mg
62555765|NCT01042093|ACTIVE_COMPARATOR|ROP/EPI/TOR/CLO|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
62555766|NCT01042093|ACTIVE_COMPARATOR|ROP/EPI/TOR|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml)
62555767|NCT01042093|ACTIVE_COMPARATOR|ROP/EPI/CLO|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
62375783|NCT01877291||Nonsmokers|Young healthy nonsmokers
62375784|NCT01877291||Smokers<2.5 pack years|"Young healthy or asymptomatic smokers (aged \< 35 y.o.) with smoking history \<2.5 pack years"
62375785|NCT01877291||Smokers≥ 2.5 pack-years|"Young healthy or asymptomatic smokers (aged \< 35 y.o.) with smoking history ≥ 2.5 pack-years"
62375786|NCT02969213||Genetic|patients with Gene detection (+)
62375787|NCT02969213||Metabolism|patients with Metabolic disturbance
62375788|NCT02969213||Immune|patients with Immunological marker and Immunotherapy (+)
62375789|NCT02969213||infection|patients with the Infection of central nervous system
62555768|NCT01042093|ACTIVE_COMPARATOR|ROP/EPI|Ropivacaine 5mg/ml (49.25ml) Epinephrine 1 mg/ml (0.5 ml)
62751462|NCT03012139||No cancer|Men and women (ages 35-80 years) without cancer, but similar age and sex as groups with cancer.
62751463|NCT06283810|EXPERIMENTAL|psychotherapy of interpersonal relationships|"Informed Consent Form and Voluntary Consent Form will be presented to the students assigned to Group 1 in the first interview and their consent will be obtained, Student Information Form (ANNEX-1), CIBS (ANNEX-3), PCI (ANNEX-4), CPI (ANNEX-5) and SB3S (ANNEX-6) will be applied.~After the initial data are collected, 2-3 sessions of individual interviews will be conducted to assess the student's suitability for Group CIPT."
62751464|NCT06283810|EXPERIMENTAL|laughter therapy|"In the first interview, Informed Consent Form and Voluntary Consent Form will be presented to the students assigned to Group 2 and their consent will be obtained, and Student Information Form (ANNEX-1), CIBS (ANNEX-3), PCI (ANNEX-4), CPI (ANNEX-5) and SB3S (ANNEX-6) will be applied.~After the initial data were collected, the students in Experiment 2 will be informed about Laughter Therapy and Group IPT. An agreement will be made with the students about the points to be considered regarding laughter therapy"
62751465|NCT06283810|PLACEBO_COMPARATOR|Plasebo group|"Informed Consent Form and Voluntary Consent Form were presented to the students in the placebo group in the first interview and their consent was obtained, Student Information Form (ANNEX-1), CIBS (ANNEX-3), PCI (ANNEX-4), CPI (ANNEX-5) and SB3S (ANNEX-6) were applied."
62751466|NCT06283810|NO_INTERVENTION|control group|The students assigned to G4 will be informed that they are in the control group and that no application will be made. After the completion of the study data (by giving information about Group CIPT and laughter therapy), it will be stated that they can receive Group CIPT or laughter therapy if they wish.
62751467|NCT05659719||Recifercept cohort|Achondroplasia patients enrolled in the recifercept phase 2 clinical trial
62751468|NCT05659719||Natural history cohort|Achondroplasia patients enrolled in the achondroplasia natural history study
62555769|NCT01514747||ELBW infants|
62555770|NCT03617666|EXPERIMENTAL|Avelumab|Patients with newly diagnosed cHL will receive single agent avelumab in 2 cycles
62555771|NCT05047224|EXPERIMENTAL|Tele-assessment + in-person assessment|Participants in this group will receive a tele-assessment using the TAP and will attend a traditional, in-person evaluation for autism spectrum disorder in a clinic setting.
62555772|NCT05047224|ACTIVE_COMPARATOR|Tele-assessment only|Participants in this group will receive a tele-assessment using the TAP, followed by a second, shorter tele-assessment.
62555773|NCT03944941|ACTIVE_COMPARATOR|Arm I (Avelumab)|Patients receive avelumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with avelumab failure will crossover to Arm II.
62555774|NCT03944941|EXPERIMENTAL|Arm II (Avelumab, cetuximab)|Patients receive cetuximab IV over 1-2 hours on days 1, 8,15, and 22 and avelumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles for cetuximab and 24 cycles for avelumab in the absence of disease progression or unacceptable toxicity.
62555775|NCT00593892||Observation|All patients who are admitted to UAB for trauma, are 19 years of age and older, and whose Injury Severity Score (ISS) is greater than 9.
62555776|NCT00578266|OTHER|No Arms|
62751469|NCT05143307|EXPERIMENTAL|Long Term Follow Up|Participants who received EBT-101 in a parent study will undergo long term follow up
62751470|NCT04333511|EXPERIMENTAL|Sequence 1|TPS first with crossover to Sham-TPS
62751471|NCT04333511|EXPERIMENTAL|Sequence 2|Sham-TPS first with crossover to TPS
62751472|NCT00348699|EXPERIMENTAL|Treatment (AFP464)|Patients receive AFP464 IV over 3 hours on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62555777|NCT03305848|OTHER|Oral nitroglycerin solution|Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes
62751473|NCT03972345||Paediatric patients with iGHD or SGA|Children with one of the following confirmed diagnoses: isolated growth hormone deficiency (iGHD) or small for gestational age (SGA)
62555778|NCT03654833|EXPERIMENTAL|MiST1 Rucaparib|BRCA1/BAP1 negative mesothelioma; 600mg twice daily (BID) every 28 days.
62555779|NCT03654833|EXPERIMENTAL|MiST2 Abemaciclib|p16INK4A negative mesothelioma; 200mg orally twice daily every 28 days.
62555780|NCT03654833|EXPERIMENTAL|MiST3 Pembrolizumab & Bemcentinib|"No specific biomarker requirement: Pembrolizumab 200mg IV infusion on Day 1 only:~Bemcentinib loading dose of 400mg on days 1-3, on day 4 on-wards 200mg daily every 21-days."
62555781|NCT03654833|EXPERIMENTAL|MiST4 Atezolizumab & Bevacizumab|PDL1 expression positive mesothelioma: Atezolizumab 1200 milligrams via intravenous nfusion; Bevacizumab 15 milligrams per kilogram via IV infusion both on Days 1 every 21-days.
62751474|NCT04853160||All Participants With Gout|Participants with gout, initiating febuxostat therapy on or after 01 June 2016 will be included in the study.
62751475|NCT03374800|PLACEBO_COMPARATOR|Placebo (0.9% saline)|Withholding Stress ulcer prophylaxis (intravenous 0.9% saline as placebo)
62555782|NCT03654833|EXPERIMENTAL|MiST 5 Dostarlimab and Niraparib|Platinum sensitive mesothelioma: Niraparib 200-300mg daily every 21 days; Dostarlimab 500mg on day 1 of each 21 day cycle for 4 cycles, then 1000mg on day 1 of each 42 day cycle.
62555783|NCT05690932|EXPERIMENTAL|Capsule|Study drug will be administered with water after an overnight fast.
62555784|NCT05690932|EXPERIMENTAL|Tablet|Study drug will be administered with water after an overnight fast.
62555785|NCT05690932|EXPERIMENTAL|Suspension|Study drug will be administered with water after an overnight fast.
62555786|NCT05690932|EXPERIMENTAL|Fasted|Study drug will be administered with water after an overnight fast.
62555787|NCT05690932|EXPERIMENTAL|Low-fat Meal|Study drug will be administered with water after an overnight fast, after which time a standard low-fat breakfast will be given.
62751476|NCT03374800|ACTIVE_COMPARATOR|Stress Ulcer Prophylaxis (Pantoprazole)|pantoprazole 40mg powder for injection reconstituted with 0.9% saline
62751477|NCT00121524|EXPERIMENTAL|IV yes|Intravenous needle Epinephrine q 3 min during CPR Atropine 3 mg in initial asystole Amiodarone 300 mg iv after repeated failed defibrillation attempts
62375790|NCT02969213||structure|patients with abnormal image of brain
62555788|NCT05690932|EXPERIMENTAL|High-fat Meal|Study drug will be administered with water after an overnight fast, after which time a standard high-fat breakfast will be given.
62555789|NCT06157008||healthy volunteers|
62751478|NCT00121524|NO_INTERVENTION|IV no|The patient will not have an intravenous needle placed or given any drugs during CPR. If patient obtains spontaneous circulation, an intravenous needle is placed and patient can receive any drugs that are appropriate during the following treatment.
62555790|NCT06157008||patients with prolonged disorders of consciousness|
62555791|NCT05509530|EXPERIMENTAL|anti BCMA/GPRC5D CAR-T|Enrolled patients will receive prespecified dose of autologous anti BCMA/GPRC5D CAR-T cells.
62555792|NCT00419497|ACTIVE_COMPARATOR|Paleolithic diet vs Mediterranean diet|Prudent diets with or without grains and dairy
62555793|NCT01863914|PLACEBO_COMPARATOR|Placebo|Placebo tablet contains only inactive ingredient. The placebo tablets will be taken once daily for 4 weeks (1 week before operation and 3 weeks after creation of AV fistula)
62751479|NCT00646321|EXPERIMENTAL|1|budesonide/formoterol
62751480|NCT00646321|ACTIVE_COMPARATOR|2|budesonide
62751481|NCT06031428|ACTIVE_COMPARATOR|Control|All participants in the study will receive diabetes education mailers. This includes monthly mailings of diabetes education, based off the American Diabetes Association guidelines for Diabetes Education.
62751482|NCT06031428|EXPERIMENTAL|MANAGe-DM|Participants assigned to MANAGe-DM will receive the standard diabetes education mailing in addition to a novel nurse case management intervention. MANAGe-DM will include NCM services tailored to the health needs of Black men with recent release from incarceration and T2DM. MANAGe-DM will include three components: 1) diabetes education and skills training; 2) healthcare navigation and 3) basic needs navigation. . Each month of the study period, the NCM will conduct two phone call intervention sessions with individual participants.
62751483|NCT01425359|PLACEBO_COMPARATOR|Placebo|"Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period.~Treatment Period: Placebo to match ranolazine (Day 1: 1 tablet in the evening; Days 2-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 8 weeks."
62751484|NCT01425359|EXPERIMENTAL|Ranolazine|"Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period.~Treatment period: Ranolazine tablets (Day 1: 1 × 500 tablet in the evening; Days 2-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 8 weeks."
62375791|NCT02969213||unknown|patients not found any reason
62555794|NCT01863914|ACTIVE_COMPARATOR|Rosuvastatin|Rosuvastatin (CrestorÒ, Astrazeneca) 5mg once daily for 4 weeks (1 week before operation and 3 weeks after creation of AV fistula)
62555795|NCT01226030|EXPERIMENTAL|M2ES 7.5mg|M2ES 7.5mg
62375792|NCT05010863||Patients with early gastric cancer|
62375793|NCT05010863||Patients with advanced gastric cancer|
62375794|NCT05010863||healthy person|
62555796|NCT01226030|EXPERIMENTAL|M2ES 15mg|M2ES 15mg
62555797|NCT01226030|EXPERIMENTAL|M2ES 30mg|M2ES 30mg
62555798|NCT01226030|EXPERIMENTAL|M2ES 60mg|M2ES 60mg
62555799|NCT04215237|OTHER|Atorvastatin regulates intestinal flora|
62555800|NCT06509113|OTHER|Intervention|Nursing students will be assigned to the intervention group and will receive online HIV-related stigma training.
62555801|NCT06509113|OTHER|Control|Nursing students will be assigned to the online HIV epidemiology training with no specific content on stigma.
62555802|NCT05117346|EXPERIMENTAL|To Establish the Safety and Efficacy of CARDIX-101 in Chronic Bradycardia Patients|"Treatment Regimen: A total of 20±4 chronic bradycardia subjects with a heart rate (H.R.) average of less than 60 bpm will be enrolled in the study (6±3/cohort). A clinical study period of 14±2-days is planned for each enrollment of patients.~Route of Administration: Each subject will receive, via oral administration, one capsule of study medicine per dose and three doses per day for 14±2-days treatment."
62751485|NCT03489434|EXPERIMENTAL|Intervention Group|Preliminary prevention program component content is based on evidence-based prevention programs and will integrate prevention content for substance use, sexual assault, and sexual risk behaviors.
62751486|NCT03489434|NO_INTERVENTION|Control|Assessment only control.
62751487|NCT02174367||Psoriasis|Patients with moderate to sever psoriasis attending a tertiary referral center. patients will be evaluated with a questionnaire, measurement of height,weight, waist circumference, fasting bloods, abdominal ultrasound and transient elastography.
62751488|NCT04964648||Inflammatory pancreatic lesions|older than 18 years with a diagnosis of acute or chronic pancreatitis
62751489|NCT04964648||Malignant pancreatic lesions|older than 18 years with a diagnosis of pancreatic neoplasm
62751490|NCT04964648||Control group|Healthy adult subjects
62751491|NCT04956731|EXPERIMENTAL|Pharmacist provision of medication abortion|This is a single arm study with 10 participants undergoing start to finish medication abortion provided by a pharmacist.
62751492|NCT04712760||Transient congenital hypothyroidism|- children with congenital hypothyroidism who are no longer treated with Levothyroxine at an age of 3 years and 6 months
62751493|NCT04712760||Permanent congenital hypothyroidism|- children with congenital hypothyroidism who are still treated with Levothyroxine at an age of 3 years and 6 months
62751494|NCT05470842|EXPERIMENTAL|Continuous glucose monitoring|Continuous Glucose Monitoring Device for up to 10 days
62751495|NCT00559845|EXPERIMENTAL|Bevacizumab|Participants will receive FEC, followed by paclitaxel, given concomitantly with bevacizumab for approximately 3-12 months.
62751496|NCT00374569|EXPERIMENTAL|Gymnastics|Gymnasts stand on a computerized dynamic posturography Force Plate and Stability is measured and gymnastic routines performed
62751497|NCT00374569|EXPERIMENTAL|Non Gymnasts|Non Gymnasts stand on a computerized dynamic posturography Force Plate and Stability is measured and gymnastic routines performed
62751498|NCT04200443|EXPERIMENTAL|Treatment (cabozantinib, temozolomide)|Patients receive cabozantinib PO QD on days 1-28 and temozolomide PO QD on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62751499|NCT05825534|EXPERIMENTAL|EIT monitoring|
62751500|NCT00441779||1|Traumatic injury
61986439|NCT01480076|EXPERIMENTAL|(BIIB041) Fampridine|All participants take 10 mg fampridine twice daily for the first 4 weeks. If deemed a treatment responder, a participant continues 10 mg fampridine twice daily for 44 weeks. Treatment non-responders can continue without treatment by completing quality of life questionnaires.
62375795|NCT05010863||Patients with colorectal cancer|
62555803|NCT05452018|EXPERIMENTAL|First intervention group|Recordings of muscle activity during swallowing
62751501|NCT00441779||2|Elective orthopedic surgery
62751502|NCT00441779||3|Burn injury
62375796|NCT05010863||Liver cancer patients|
62375797|NCT05010863||Breast cancer patient|
62555804|NCT05920837||Stroke|Sample of stroke patients
62555805|NCT01569867||statin|
62555806|NCT02029118|EXPERIMENTAL|Herbal application on acupoint group|Containing the herbal medicine application on the specific acupoints plus foundation treatment
62555807|NCT02029118|PLACEBO_COMPARATOR|Placebo application on acupoint|Not containing herbal medicine application on the specific acupoints plus foundation treatment
62751503|NCT00405509||Confirmed respiratory virus|
62751504|NCT00405509||Unconfirmed respiratory infection|
62751505|NCT02453165|EXPERIMENTAL|TRANSVAGINAL SUTURE|INTERVENTION: Transvaginal suturE of the vaginal vault at the end of a total laparoscopic hysterectomy using vaginal valves and needleholders.
62751506|NCT02453165|ACTIVE_COMPARATOR|LAPAROSCOPIC SUTURE|INTERVENTION: Laparoscopic suturE of the vaginal vault at the end of a total laparoscopic hysterectomy using with laparoscopic needleholders.
62751507|NCT02508272||Trauma patients|age ≥18 y ISS ≥ 17 points admission \< 6 h.
62751508|NCT02472418|EXPERIMENTAL|DFN-15 120 mg (treatment A)|DFN-15 120 mg (treatment A)
62751509|NCT02472418|EXPERIMENTAL|DFN-15 240 mg (treatment B)|DFN-15 240 mg (treatment B)
62375798|NCT05010863||Patients with atrophic gastritis|
62375799|NCT03782467|EXPERIMENTAL|ATOR-1015|ATOR-1015 administered by intravenous infusions every 2 weeks until confirmed progressive disease, unacceptable toxicity or withdrawal of consent.
62375800|NCT03344562|EXPERIMENTAL|CES Active|Active cranial electrical stimulation device
62555808|NCT02029118|PLACEBO_COMPARATOR|Herbal application on non-acupoint group|Containing the herbal medicine application on the non-acupoints plus foundation treatment
62751510|NCT02472418|PLACEBO_COMPARATOR|Placebo (treatment C)|Placebo (treatment C)
62751511|NCT03968575|EXPERIMENTAL|Laser|
62751512|NCT04372147|EXPERIMENTAL|intervention group|MMA embolization procedure within 7 days of the burr-hole surgery in addition to standard medical care
62751513|NCT04372147|NO_INTERVENTION|control group|standard medical care
62751514|NCT03156686|NO_INTERVENTION|Control|Patients will be randomly assigned to conventional hospital care
62751515|NCT03156686|EXPERIMENTAL|Home care treatment|Patients will be randomly assigned to the HOME-based hospitalization and treated with intravenous diuretics. Following discharge within 48 hours from the hospital, patients in the HC group will be treated at home.
62751516|NCT03395691|ACTIVE_COMPARATOR|The distal approach|The first two attempts via the distal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the proximal approach.
62751517|NCT03395691|ACTIVE_COMPARATOR|The proximal approach|The first two attempts via the proximal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the distal approach.
62751518|NCT04845659|EXPERIMENTAL|Intervention|Avatrombopaq administration
62751519|NCT00790868|EXPERIMENTAL|D-cycloserine|DCS-augmented CBT
62751520|NCT00790868|PLACEBO_COMPARATOR|Placebo|placebo-augmented CBT
62751521|NCT04549116|EXPERIMENTAL|Investigational|Progesterone-IBSA 25mg, twice daily (BID) subcutaneous (SC) injection every 12 hours and Crinone Placebo, once daily (QD) intravaginally.
62751522|NCT04549116|ACTIVE_COMPARATOR|Comparator|Crinone 8%, 90 mg, QD intravaginally and Progesterone-IBSA Placebo, BID SC Injection every 12 hours
62751523|NCT01657344||ED Patients|All patients (age 0-18 regardless of race, ethnicity, or gender and of diagnosis or chronic health condition) who are registered in the ED.
62751524|NCT03215758|ACTIVE_COMPARATOR|QAW039|QAW039 once daily
62751525|NCT03215758|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62751526|NCT02091531|EXPERIMENTAL|MLN0128|Patients will be treated with the established phase II dose of MLN0128 (4mg po daily continuously; 1 cycle=4 weeks) to assess mechanisms of sensitivity and resistance in men with CRPC who have received either enzalutamide and/or abiraterone.
62751527|NCT06305715|EXPERIMENTAL|Radiation therapy followed by mutation-matched TKI treatment|Part 1 will enroll subjects who will be given radiation doses at the discretion of the treating physicians. Subjects with actionable driver mutation will continue to Part 2 and receive a standard-of-care TKI at the discretion of the treating oncologist.
62751528|NCT02017938|NO_INTERVENTION|Stage 1: Health group|To establish non-invasive fatigue monitoring method via testing healthy individuals.
62751529|NCT02017938|EXPERIMENTAL|Stage 2: PD group|To find the optimal feedback variables for anti-fatigue training on individuals with PD.
62751530|NCT02017938|EXPERIMENTAL|Stage 2: Health group|Stage 2 controlled group
62751531|NCT02017938|EXPERIMENTAL|Stage 3: PD group|To evaluate the effect of four weeks of VR anti-fatigue ergo cycling training on various fatigue components and functional abilities in individuals with PD.
62375801|NCT03344562|SHAM_COMPARATOR|CES Sham|Inactive device identical to the active device.
62555809|NCT02029118|SHAM_COMPARATOR|Placebo application on non-acupoint|Not containing herbal medicine application on the non-acupoints plus foundation treatment
62555810|NCT05775887|EXPERIMENTAL|UQSC2 vaccine|15mcg of UQSC2 (SARS-CoV-2 Sclamp2 antigen) adjuvanted with MF59
62751532|NCT02017938|NO_INTERVENTION|Stage 3: PD controlled group|Stage 3 controlled group
62751533|NCT05190354|EXPERIMENTAL|Xtremity Prosthesis|Xtremity Prosthesis fitting
62751534|NCT02870075|ACTIVE_COMPARATOR|Fed exercise|Fed prior to exercise
62751535|NCT02870075|ACTIVE_COMPARATOR|Fasted exercise|Fasted prior to exercise
62751536|NCT01129089|EXPERIMENTAL|LNS-PLW|There will be 48 pregnant or lactating women (PLW) in this arm. They will be randomized to receive cumin flavored LNS-PLW or LNS-PLW with no added flavor on day 2. On day 3, the PLW getting a test-dose of cumin flavored LNS-PLW on day 2 will receive LNS-PLW with no added flavor and the PLW getting a test-dose of LNS-PLW with no added flavor on day 2 will receive cumin flavored LNS-PLW.
62751537|NCT01129089|EXPERIMENTAL|LNS-Child|There will be 48 infant and young children(IYC) in this arm. They will be randomized to receive cardamom flavored LNS-Child or LNS-Child with no added flavor on day 2. On day 3, the IYC getting a test-dose of LNS-Child with no added flavor on day 2 will receive cardamom flavored LNS-Child and the IYC getting a test-dose of cardamom flavored LNS-Child on day 2 will receive LNS-Child with no added flavor.
62375802|NCT05405569||Group 1|Manikin laying on the ground and rescuer kneeled on the floor
62555811|NCT05775887|ACTIVE_COMPARATOR|NVX-CoV2373 vaccine|5 mcg SARS-CoV-2 spike protein adjuvanted with Matrix-M
62555812|NCT03797807|EXPERIMENTAL|MINST|Minimally invasive non surgical treatment
62555813|NCT03797807|ACTIVE_COMPARATOR|MIST|Minimally invasive surgical treatment
62555814|NCT03797807|ACTIVE_COMPARATOR|GTI + MINST|Minimally invasive non surgical treatment + Geometric/Thermal Imaging (GTI subgroup)
62555815|NCT03797807|ACTIVE_COMPARATOR|GTI + MIST|Minimally invasive surgical treatment + Geometric/Thermal Imaging (GTI subgroup)
62751538|NCT01129089|EXPERIMENTAL|MNP-Child|There will be 48 infant and young children(IYC) in this arm. They will receive MNP on day 2 and day 3.
62751539|NCT03372434|EXPERIMENTAL|Investigational Lens Device #1|Investigational Intraocular Lens Device #1: Model ZFR00
62751540|NCT03372434|EXPERIMENTAL|Investigational Lens Device #2|Investigational Intraocular Lens Device #1: Model ZYR00
62555816|NCT01493869|EXPERIMENTAL|Group 1|Subjects with normal hepatic function: healthy normal adult subjects
62555817|NCT01493869|EXPERIMENTAL|Group 2|Subjects with mild hepatic impairment: adult subjects with a Child-Pugh grade A (score 5-6).
62555818|NCT01493869|EXPERIMENTAL|Group 3|Moderate hepatic impairment: adult subjects with a Child-Pugh grade B (score 7-9).
62555819|NCT01493869|EXPERIMENTAL|Group 4|Severe hepatic impairment: adult subjects with a Child-Pugh grade C (score 10-15).
62555820|NCT02698163|ACTIVE_COMPARATOR|Gutta Percha|For all the patients in the control arm of the study, standard treatment of care procedures will be given. Root canal therapy will be given according to the vertical obturation technique. The root canals will be filled with standard root canal filler material: gutta percha at the apical third up to and including the coronal third. The tooth will be restored with a crown for posterior teeth, or a composite filling for anterior teeth.
62555821|NCT02698163|EXPERIMENTAL|Nanodiamond reinforced Gutta Percha|For all the patients in the treatment arm of the study, standard treatment of care procedures will be given. Root canal therapy will be given according to the vertical obturation technique. The difference between the two arms will be the root canal filler material used. The root canals for the treatment arm of the study will be filled with gutta percha at the apical third, Nanodiamond gutta percha (NDGP) in the middle third, and again with gutta percha at the coronal third. The tooth will be restored with a crown for posterior teeth, or a composite filling for anterior teeth.
62555822|NCT03215927|PLACEBO_COMPARATOR|Placebo|Subcutaneous placebo injection weekly for 24 weeks.
62555823|NCT03215927|EXPERIMENTAL|Abatacept|Subcutaneous injection of abatacept 125 mg weekly for 24 weeks. 24 week optional follow up phase all subjects receive abatacept 125 mg weekly.
62555824|NCT04464850|EXPERIMENTAL|Intravenous iron|Iron sucrose 200 mg every 2 weeks Folic acid 5 mg/day B6 10 mg/day
62555825|NCT04464850|ACTIVE_COMPARATOR|Oral iron|Ferrous fumarate 600 mg/day Folic acid 6.5 mg/day B6 15 mg/day
62555826|NCT03673917|EXPERIMENTAL|Educational video|The educational video on skin cancer for cosmetologists
62751541|NCT03372434|ACTIVE_COMPARATOR|Control Device|Control TECNIS Multifocal Intraocular Lens Model ZLB00
62751542|NCT02660671|ACTIVE_COMPARATOR|Usual care|Email outreach
62751543|NCT02660671|EXPERIMENTAL|Active choice|Email outreach + active choice
62751544|NCT02660671|EXPERIMENTAL|Financial incentive + Active choice|Email outreach + active choice + financial incentive
62751545|NCT01215643|EXPERIMENTAL|ALV 1000 mg|Alisporivir (ALV) 600 mg twice daily (BID) for 1 week, followed by ALV 1000 mg once daily (QD) during Weeks 2 to 24.
62751546|NCT01215643|EXPERIMENTAL|ALV 600 mg+RBV|Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with ribavirin (RBV) during Weeks 2 to 24.
62751547|NCT01215643|EXPERIMENTAL|ALV 800 mg+RBV|Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
62751548|NCT01215643|EXPERIMENTAL|ALV 600 mg+PEG|Alisporivir (ALV) 600 mg BID with Peginterferon alfa-2a (PEG) for 1 week, followed by ALV 600 mg QD with PEG once weekly during Weeks 2 to 24.
62751549|NCT01215643|ACTIVE_COMPARATOR|PEG+RBV|Peginterferon alfa-2a (PEG) and RBV during Weeks 1 to 24.
62751550|NCT02408861|EXPERIMENTAL|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1. Patients in dose level 2 also receive ipilimumab IV over 90 minutes on day 1 of every third cycle of nivolumab, and patients in dose level -2 also receive ipilimumab IV over 90 minutes on day 1 of every sixth cycle of nivolumab. Treatment repeats every 14 days for up to 46 cycles of nivolumab (with ipilimumab if receiving dose level 2 or -2) in the absence of disease progression or unacceptable toxicity.Patients undergo blood sample collection throughout the study. Patients undergo PET and CT scan during screening and on study. Patients undergo bone marrow biopsy on screening and may undergo it during follow up.
62751551|NCT01572363|EXPERIMENTAL|Sildenafil|All patients will be given Sildenafil 50 mg with evaluation of pulmonary vascular resistance and systemic ventricular function at rest and during exercise after 30 minutes.
62751552|NCT02209545|EXPERIMENTAL|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
62751553|NCT02209545|PLACEBO_COMPARATOR|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
62751554|NCT06318806|ACTIVE_COMPARATOR|Exposure and Response Prevention|ERP will be delivered in accordance with published guidelines and protocols that employ inhibitory learning principles. Following the creation of a hierarchy of feared situations, patients are encouraged to confront their fears (both during and in-between treatment sessions) while abstaining from engaging in compulsions and other neutralizing strategies (i.e., response prevention). Exercises consist of exposure in vivo (i.e., exposure in real life situations) and/or imaginal exposure that are initially conducted in sessions under the therapist's guidance, and then as daily homework designed by the therapist in collaboration with the patient. In accordance with an inhibitory learning model, rather than focusing on habituation to anxiety, exercises aim to maximize outcomes through expectancy violation, deepened extinction, elimination of safety behaviors during exposure, exposure in multiple contexts, and affect labeling during exposure.
62751555|NCT06318806|EXPERIMENTAL|Inference-based Cognitive Behavioral Therapy|CBT will be delivered in accordance with published guidelines and protocols that target the dysfunctional reasoning giving rise to obsessional doubts. The first learning point in I-CBT is that the compulsions, anxiety and discomfort are driven by an initial obsessional doubt. The principal focus of treatment is to show that the doubt is 100% irrelevant in the here and now. To this end the reasoning narrative is identified, including the reasoning distortions contained therein, giving undue credibility to the obsessional doubt. The selective nature of the doubt is underlined by showing the client how under most everyday circumstances his/her reasoning is entirely different from the obsessional situation. This stage also educates the client in the thematic nature of the obsessional doubt and how personal themes dictate the idiosyncratic nature of the person's obsession. The final stage of therapy consists of training the client in the proper use of the senses.
62751556|NCT03757650|ACTIVE_COMPARATOR|HP eradication therapy positive-HP positive|who has HP positive endoscopic biopsy will take HP eradication therapy one month before the surgery
62555827|NCT03673917|ACTIVE_COMPARATOR|Control video|A publicly accessible healthy lifestyle video on YouTube, which did not contain any information on skin cancer
62555828|NCT05888857|EXPERIMENTAL|Cohort A: patients with TLS+ IO-naïve solid tumors|Participants with TLS+ IO-naïve solid tumors will be treated by MEDI5752
62555829|NCT05888857|EXPERIMENTAL|Cohort B: patients with TLS+ PD1/PDL1-experienced solid tumors|Participants with TLS+ PD1/PDL1-experienced solid tumors will be treated by MEDI5752
62555830|NCT05765500|EXPERIMENTAL|Arm A: Relugolix|"55 participants will be randomized in a 1:1 fashion to Relugolix and stratified by intent to treat with radiation and will complete study procedures as outlined:~* Surveys at baseline and at months 3, 6, 9, and 12.~* Medication diary entries.~* Cycles 1 - 6:~  --Days 1 - 28 of 28 day cycle: Predetermined dose of Relugolix. Participant will self-administer at home.~* Follow up visits every 3 months for 12 months."
62555831|NCT05765500|ACTIVE_COMPARATOR|Arm B: Leuprolide|"55 participants will be randomized in a 1:1 fashion to Leuprolide and stratified by intent to treat with radiation and will complete study procedures as outlined:~* Surveys at baseline and at months 3, 6, 9, and 12.~* Cycle 1 and Cycle 4:~  --Day 1 of 28 day cycle: Predetermined dose of Leuprolide. Injection will be administered in clinic.~* Follow up visits every 3 months for 12 months."
62555832|NCT05661370|ACTIVE_COMPARATOR|Intervention|Access to educational mobile application for 8 days, diagnosing 500 digital patient-cases.
62555833|NCT05661370|NO_INTERVENTION|Control|Control group receiving no intervention, continuing daily practice.
62555834|NCT04214977|EXPERIMENTAL|group S|Patients in group S had spinal anesthesia in the sitting position under complete aseptic technique through a standard mid-line approach. The patient was then asked to turn him- or herself into the prone position on the surgical table with the help of the surgical and anesthetic teams.
62555835|NCT04214977|EXPERIMENTAL|group L|Patients in group L received standard general anesthesia. Proper (weight-based) classic laryngeal mask airway was then blindly inserted.
62555836|NCT03247569||Edoxaban|Patients treated with Edoxaban
62555837|NCT02248987||Clozapine|stable patients treated with clozapine
62555838|NCT02248987||Other antipsychotics|stable patients treated with risperidone or paliperidone or olanzapine
62555839|NCT02248987||Healthy volunteer|healthy controls
62555840|NCT03422614||Patient|Patients with Primary Immunodeficiency
62555841|NCT03422614||Control|Healthy Controls
62555842|NCT03588143|ACTIVE_COMPARATOR|Electrical stimulation with TENS|TENS with 100 Hz frequency, 65 microseconds pulse duration, in continuous pattern
62555843|NCT03588143|EXPERIMENTAL|Electrical stimulation with HVPS|HVPS with twin spiked monophasic current at 100 pps frequency, in continuous pattern
62555844|NCT03588143|PLACEBO_COMPARATOR|Placebo electrical stimulation|same electrode placement with other interventions, using the same electrotherapy device, without activating the device except its time unit.
62555845|NCT06342687||Group 1|with a compliance rate with ERAS below 80%
62555846|NCT06342687||Group 2|with a compliance rate with ERAS of 80% or above
62555847|NCT05637216|EXPERIMENTAL|Breast Conservation Surgery with Losartan|Participants who underwent breast conservation surgery will take losartan in a 25 milligram oral capsule once daily starting day one of radiation therapy until one year following the completion of radiation therapy.
62555848|NCT05637216|PLACEBO_COMPARATOR|Breast Conservation Surgery with Placebo|Participants who underwent breast conservation surgery will take placebo in a 25 milligram oral capsule once daily starting day one of radiation therapy until one year following the completion of radiation therapy.
62555849|NCT05637216|EXPERIMENTAL|Mastectomy with Losartan|Participants who underwent a mastectomy will take losartan in a 25 milligram oral capsule once daily starting day one of radiation therapy until one year following the completion of radiation therapy.
62555850|NCT05637216|PLACEBO_COMPARATOR|Mastectomy with Placebo|Participants who underwent a mastectomy will take placebo in a 25 milligram oral capsule once daily starting day one of radiation therapy until one year following the completion of radiation therapy.
62555851|NCT02490631|NO_INTERVENTION|Control Arm|Standard of care pre-operative cleansing with soap and water the night before and morning of surgery
62555852|NCT02490631|EXPERIMENTAL|Intervention Arm|2% chlorhexidine gluconate cloths the night before and morning of surgery
62555853|NCT03087500||Down Syndrome (DS)|120 clinically confirmed full trisomy 21, age 3-50 years of both sexes will be recruited as the target study population. Half of the individuals (n=60) will be children (3-17 years of age) while half (n=60) will be adults (18-50 years of age)
62751557|NCT03757650|ACTIVE_COMPARATOR|HP eradication therapy negative-HP positive|who has HP positive endoscopic biopsy and will not take any medication about HP
62751558|NCT03757650|NO_INTERVENTION|HP negative-Control group|who has HP negative endoscopic biopsy and will not take any medication. (control group)
62751559|NCT01938924|NO_INTERVENTION|No intervention|No intervention
62751560|NCT01938924|ACTIVE_COMPARATOR|GekoTM|geko applied to bypass limb
62751561|NCT00656188|PLACEBO_COMPARATOR|Arm 2|
62555854|NCT03087500||Typically Developing Controls|60 typically developing individuals age 3-50, age and gender matched to at least one participant with DS. Half of the controls (n=30) will be age and gender match to children with DS and half (n=30) will be age and gender matched to adults with DS.
62555855|NCT04797026|EXPERIMENTAL|Penpal Program to Alleviate Loneliness|A social program connecting patients in residential care facilities with high school students through monthly letter writing would positively impact quality of life for both, reducing quantitative and qualitative measures of loneliness
62751562|NCT00656188|ACTIVE_COMPARATOR|Arm 1|
62751563|NCT03213782|EXPERIMENTAL|Experimental group|Nature based sounds are administered via head phones continuously for 20 minutes.
62751564|NCT03213782|NO_INTERVENTION|Control group|Usual routine care was continued
62751565|NCT05007496|EXPERIMENTAL|AV-COVID-19 (0.1 mcg S-protein)|DCL previously incubated with 0.1 mcg spike protein
62555856|NCT05629715|ACTIVE_COMPARATOR|ROSA|Subjects randomly assigned to this arm will undergo a primary total knee arthroplasty procedure using the ROSA Knee System.
62555857|NCT05629715|ACTIVE_COMPARATOR|KneeAlign|Subjects randomly assigned to this arm will undergo a primary total knee arthroplasty procedure using the KneeAlign navigation system.
62555858|NCT05629715|NO_INTERVENTION|Conventional|Subjects randomly assigned to this arm will undergo a primary total knee arthroplasty procedure using conventional instrumentation.
62751566|NCT05007496|EXPERIMENTAL|AV-COVID-19 (0.33 mcg S-protein)|DCL previously incubated with 0.33 mcg spike protein
62751567|NCT05007496|EXPERIMENTAL|AV-COVID-19 (1.0 mcg S-protein)|DCL previously incubated with 1.0 mcg spike protein
62751568|NCT01402076|EXPERIMENTAL|Steady State PK Group|
62751569|NCT01402076|EXPERIMENTAL|No steady state PK|
62751570|NCT06280872|EXPERIMENTAL|Physiological Based Cord Clamping (PBCC)|In the intervention group, newborns will receive PBCC. The resuscitation table will be placed as close as possible to the mother's pelvis. Stabilization will start as soon as the infant is placed on the platform. The nurse will place the oximeter sensor on the right wrist, electrocardiogram electrodes on the chest of the newborn. Local resuscitation guidelines will be in respect of the Newborn Life support European Resuscitation Council 2021 guidelines. Stabilization of the newborn will be performed while the cord is intact and the cord will be clamped after respiratory stabilization will be achieved, de ﬁned as the establishment of regular spontaneous breathing, a heart rate above 100 bpm and oxygen saturation by pulse oximetry above 85% while using supplemental oxygen less than 0,4. If the infant does not reach the criteria for being stable, the maximum clamping time will be 10 min. After clamping, the platform will be withdrawn and placed next to the bed of the mother.
62555859|NCT03845192|OTHER|ORI measurement by Radical-97|"In this arm ORI measurement is done from the beginning of the induction of anaesthesia until the end of the induction of anaesthesia or until the end of the stay in the operating theatre. The measurement to ORI is done by the Radical-97 device by Masimo®"
62751571|NCT06280872|ACTIVE_COMPARATOR|Differed Cord Clamping (DCC)|In the control group, newborns will receive standard DCC defined as time based and performed at 60 seconds after birth, depending on the clinical condition of the infant, in accordance with the ERC guidelines 2021.Then infants will be transferred to a standard resuscitation table located in a stabilization room next to the operating room. Further treatment and intervention required for cardiopulmonary stabilization will be provided on the standard resuscitation table. Stabilization will start as soon as the infant is placed on the resuscitation table. The nurse will place the oximeter sensor on the right wrist, ECG electrodes on the chest and temperature probe on the right hypochondrium of the newborn. Local resuscitation guidelines will be in respect of the Newborn Life support European Resuscitation Council 2021 guidelines. The time to reach the stabilisation described above (a HR above 100 bpm and SpO 2 above 85% while using supplemental oxygen less than 0,4) is recorded.
62375803|NCT05405569||Group 2|Manikin laying on a bed at the level of the rescuer knees and rescuer standing on the side of the bed
62555860|NCT06252883|EXPERIMENTAL|GROUP A (intervention group)|"Parents in this group will receive bedside video call 2-3 days a week in addition to the routine NICU phone update and/or bedside update using the NICU iPad w/ Doximity app."
62751572|NCT01077999|ACTIVE_COMPARATOR|Carboplatin + paclitaxel + radiotherapy|Carboplatin AUC = 2, Paclitaxel 50 mg/m2 (both weekly) , a total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
62751573|NCT01077999|EXPERIMENTAL|Carboplatin+ paclitaxel+ panitumumab+ radiotherapy|Carboplatin AUC = 2, Paclitaxel 50 mg/m2 (both weekly) , a total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy. Panitumumab panitumumab: 6mg/kg in weeks 1-3-5.
62751574|NCT06044909||Patients undergoing minimally invasive hepatectomy by conventional or robot-assisted laparoscopy|Patients undergoing minimally invasive hepatectomy by conventional or robot-assisted laparoscopy will be included.
62751575|NCT01368783|EXPERIMENTAL|atazanavir|400 mg/day for 2 days
62751576|NCT01368783|EXPERIMENTAL|Atazanavir and Tenofovir|
62555861|NCT06252883|NO_INTERVENTION|Group B (control group)|Parents in this group will receive the routine phone and/or bedside updates done in our NICU already without the intervention (serial video calls).
62751577|NCT01368783|EXPERIMENTAL|Atazanavir and Ritonavir|
62375804|NCT05405569||Group 3|Manikin laying on a higher bed and rescuer standing on a step stool on the side of the bed (the manikin should be at the level of rescuers knees)
62375805|NCT05405569||Group 4|Manikin laying on a bed and rescuer kneeled on the bed, on the side of the manikin.
62375806|NCT04692896|EXPERIMENTAL|0.1% lidocaine|
62375807|NCT04692896|EXPERIMENTAL|0.2% lidocaine|
62375808|NCT04692896|EXPERIMENTAL|0.3% lidocaine|
62555862|NCT05718934|ACTIVE_COMPARATOR|"Group N for Standard reversal"|Standard reversal of 50 µg.kg-1 neostigmine (up to a maximum dose of 5mg) and 7 µg.kg-1 glycopyrrolate at the end of surgery (when surgeons finish deep tissues closure) with starting TOF 1-3.
62555863|NCT05718934|EXPERIMENTAL|"Group S for Sugammadex"|Sugammadex 0.5 mg.kg-1 IV will be performed at the end of surgery (when surgeons finish deep tissues closure) with starting TOF 1-3.
62555864|NCT02779244|EXPERIMENTAL|Early Weight Bearing + Cam boot|
62555865|NCT02779244|ACTIVE_COMPARATOR|Standard Treatment Cam boot|
62751578|NCT01368783|EXPERIMENTAL|Atazanavir + tenofovir + ritonavir|
62751579|NCT06403306|ACTIVE_COMPARATOR|Ferric Sulfate|Ferric Sulfate (FS), widely used in pulpotomy treatment of primary teeth, provides hemostasis through a chemical reaction with blood. The FS solution was kept in the cavity for 15 seconds using cotton pellets in the FS group.
62375809|NCT01731756|EXPERIMENTAL|Palmer arsenical keratosis (study)|Leaf extract of A. indica plus salicylic acid (6%) in petroleum jelly base will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks
62375810|NCT01731756|PLACEBO_COMPARATOR|Palmer arsenical keratosis (control)|Salicylic acid (6%) in petroleum jelly base will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks
62375811|NCT00342667||1|patients with preterm labor/contractions and preterm premature rupture of membranes
62375812|NCT05186363|ACTIVE_COMPARATOR|Intervention|SMC eligible kids aged 3-59 months who will receive a standard SMC intervention of 4 cycles of SPAQ over 4 months.
62555866|NCT05276362||Typical Sleepers|This will be a single arm study of approximately 70 typical sleepers that will wear the Study Watch(es) and Actiwatch for one night in a sleep laboratory.
62751580|NCT06403306|EXPERIMENTAL|Ankaferd Blood Stopper|Ankaferd Blood Stopper (ABS), recently introduced to clinical practice as an alternative to FS, is a herbal hemostatic agent. The ABS solution drawn from the 1 ml ampoule to the syringe according to the manufacturer's instructions, was kept in the cavity for 15 seconds using cotton pellets in the ABS group.
62751581|NCT06403306|EXPERIMENTAL|Er,Cr:YSGG laser|Er,Cr:YSGG laser was applied in a non-contact manner on the pulp tissue from a distance of 3-4 mm for ten seconds, with an energy intensity of 25 mL, output power of 0.5 W, and frequency of 20 Hz. The MZ6 laser tip was used for application.
62751582|NCT05725486|EXPERIMENTAL|n-3 PUFA|Intake of n-3 PUFAs enriched chicken meet for three weeks
62375813|NCT05186363|ACTIVE_COMPARATOR|Control|SMC eligible kids aged 3-59 months who will not receive a standard SMC intervention of 4 cycles of SPAQ over 4 months.
62375814|NCT00667940|EXPERIMENTAL|Workshop|Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
62751583|NCT05725486|EXPERIMENTAL|Control|Intake of regular chicken meet for three weeks
62751584|NCT02780856|OTHER|Sound and unsound teeth|Sound (ICDAS 0) canines or incisors and unsound (ICDAS 2 or 3) molars or pre-molars - imaging with the Calcivis System
62751585|NCT05924698|ACTIVE_COMPARATOR|Control group|This arm only received the Neuromuscular and Muscular Electrical Stimulation (NMES) intervention.
62751586|NCT05924698|EXPERIMENTAL|Experimental group|This arm received the intervention with NMES and Blood flow restriction (BFR).
62375815|NCT00667940|NO_INTERVENTION|Delayed workshop|No specific intervention until after follow-up assessment, then receives same workshop.
62375816|NCT02311140||Cystic Fibrosis patients with G551D mutation|Cohort Description Ten participants (6 Jena/4 Innsbruck) were included, of whom 6 were female and 4 were male. At the start of the study, patients were aged 7-45 years (mean age: 16.55 ± 13.42 years). Results of sweat tests and lung function FEV1 were available only from 8 patients. Lung function at baseline, as obtained from those patients, ranged from 0.96 to 4.07 L (mean FEV1: 99.7 ± 20.3% predicted, median: 103.6% predicted, IQR=20.4% predicted).
62555867|NCT05276362||Sleepers with Elevated Insomnia Symptoms|This will be a single arm study of at least 15 participants with elevated insomnia symptoms that will wear the Study Watch(es) and Actiwatch for one night in a sleep laboratory.
62555868|NCT05276362||Sleepers withObstructive Sleep Apnea Sleepers|This will be a single arm study of at least 15 participants with obstructive sleep apnea that will wear the Study Watch(es) and Actiwatch for one night in a sleep laboratory.
62555869|NCT00462917|EXPERIMENTAL|Pleiotropic info, in-person disclosure|Incidental pleiotropic risk information, in addition to AD risk information, is disclosed in-person during an APOE-based genetic risk assessment
62555870|NCT00462917|EXPERIMENTAL|AD-only info, phone disclosure|Alzheimer's disease risk information only is disclosed via telephone during an APOE-based genetic risk assessment
62555871|NCT00462917|EXPERIMENTAL|Pleiotropic info, phone disclosure|Incidental pleiotropic risk information, in addition to AD risk information, is disclosed via telephone during an APOE-based genetic risk assessment
62555872|NCT00462917|ACTIVE_COMPARATOR|AD-only info, in-person disclosure|Alzheimer's disease risk information only is disclosed in-person during an APOE-based genetic risk assessment
62555873|NCT04722497||Physicians and nurses|All physicians, nurses, involved in a cesarean births are included in the cohort.
62555874|NCT04722497||Patients undergoing cesarean births|All patients undergoing cesarean births
62555875|NCT02333903|EXPERIMENTAL|Personalized Physical Activity|Patients will undergo a personalized physical activity program after sleeve gastrectomy.
62555876|NCT02333903|NO_INTERVENTION|Regular Activity|Patients will have regular physical activity after sleeve gastrectomy.
62555877|NCT02761668|EXPERIMENTAL|ParS+Ortho 4W|Orthodontic alignment starts 4 weeks post surgical
62555878|NCT02761668|ACTIVE_COMPARATOR|ParS+Ortho 6M|Orthodontic alignment starts 6 months post surgical
62555879|NCT00723502|EXPERIMENTAL|1|
62555880|NCT00723502|EXPERIMENTAL|2|
62555881|NCT02477956|EXPERIMENTAL|vitamin D3|subjects taking the standard vitamin D protocol with added monthly high dose cholecalciferol of 100,000 IU cholecalciferol
62555882|NCT02477956|ACTIVE_COMPARATOR|Control|group of subjects taking the standard vitamin D
62555883|NCT02163057|OTHER|Cohort 1: Surgery Cohort|Participants received up to two doses of INO-3112 immunotherapy 3 weeks (± 3 days) apart before surgery and up to three doses of INO-3112 immunotherapy 3 weeks (± 3 days) apart after surgery for a total of no more than four doses of INO-3112 immunotherapy delivered IM followed by EP with CELLECTRA™-5P device.
62555884|NCT02163057|OTHER|Cohort 2: Chemoradiation|Participants received four doses of INO-3112 immunotherapy delivered IM followed by EP with CELLECTRA™-5P device 3 weeks (± 3 days) apart beginning approximately 2 to 6 months after chemoradiation therapy.
62555885|NCT02166567|EXPERIMENTAL|YoPro and FACS|Spermatozoa to be used for ICSI will be stained with the YoPro Dye and then be sorted with FACS to select non-YoPro stained spermatozoa, known to have significantly less fragmented DNA.
62555886|NCT02166567|ACTIVE_COMPARATOR|Swim-up|Spermatozoa will be processed using the conventional swim-up me
62555887|NCT00488189|NO_INTERVENTION|1|baseline, collecting rectal swab samples
62555888|NCT00488189|ACTIVE_COMPARATOR|2|use pipercill/tazobact to replace 3rd generation cephalosporin and collect rectal swab
62555889|NCT02540005||Aneurysmatic subarachnoid haemorrhage|Acute subarachnoid haemorrhage (confirmed by computed tomography, CT, or cerebrospinal fluid erythrocyte count over 1000 x 106/l) AND confirmed origin either with computed angiography (CTA) or digital subtraction angiography (DSA)
62555890|NCT02540005||Control patients|Elective craniotomy due to non-ruptured intracranial aneurysm
62555891|NCT02570464|EXPERIMENTAL|Patients undergoing aortic aneurysm surgery with RIPC|Blood drawn is done for patient undergoing elective open infrarenal abdominal aortic aneurysm repair surgery with Remote ischemic preconditioning (RIPC)
62555892|NCT02570464|SHAM_COMPARATOR|Patients undergoing aortic aneurysm surgery without RIPC|Blood drawn is done for patient undergoing elective open infrarenal abdominal aortic aneurysm repair surgery without Remote ischemic preconditioning (RIPC)
62555893|NCT03524651|ACTIVE_COMPARATOR|Ferrous sulfate|Patients will take every day for 12 weeks two oral capsules of 150 mg ferrous sulfate delivering 47 mg of active elemental iron. Capsules should be taken orally either two hours before meal or two hours after meal. The same patients will take every day on exactly the same time for 12 weeks two placebo vials of 15 ml volume with excipients contained in the commercially available formulation Fe-Asp Omalin (Uni-Pharma SA).
62555894|NCT03524651|ACTIVE_COMPARATOR|Fe-ASP|Patients will take every day for 12 weeks two oral placebo capsules. Capsules should be taken orally either two hours before meal or two hours after meal. The same patients will take every day on exactly the same time for 12 weeks two vials of 15 ml volume of the Fe-Asp preparation Omalin (Uni-Pharma SA) delivering 40 mg of elemental iron.
62555895|NCT02810925|EXPERIMENTAL|PENS T6 and 1200 Kcal/day diet|Patients undergo 12 sessions of percutaneous electrical stimulation of dermatome T6 (PENS T6), weekly, during 12 weeks. During this period they follow a hypocaloric 1200 Kcal/day diet.
62555896|NCT02810925|ACTIVE_COMPARATOR|PENST6 + Normocaloric 2000 Kcal/day diet|Patients undergo 12 sessions of percutaneous electrical stimulation of dermatome T6 (PENS T6), weekly, during 12 weeks. During this period they follow a normocaloric 2000 Kcal/day diet.
62555897|NCT02810925|PLACEBO_COMPARATOR|TENS T11/ T12 + 1200 Kcal/day diet|Patients undergo 12 sessions of transcutaneous electrical stimulation of dermatomes T11-T12 , weekly, during 12 weeks. During this period they follow a hypocaloric 1200 Kcal/day diet.
62555898|NCT02810925|ACTIVE_COMPARATOR|1200 Kcal/day diet|Patients follow only a hypocaloric 1200 Kcal/day diet.
62555899|NCT03290963|ACTIVE_COMPARATOR|Ketamine plus Lithium|Lithium will be used in conjunction to Ketamine infusions for the treatment of major depression disorder or bipolar disorder type I or II. Before the first ketamine infusion, subjects will be randomized to 2 weeks of lithium treatment. All subjects will receive three IV ketamine infusions (0.5 mg/kg, over 100 min.) over 7 days. Those who achieve positive response (\>50% decrease in MADRS total score from baseline) will be given 4 additional once-weekly ketamine infusions (same dose and infusion rate) and lithium treatment .
62555900|NCT03290963|PLACEBO_COMPARATOR|Ketamine plus Placebo|Placebo tablets will be used in conjunction to Ketamine infusions for the treatment of major depression disorder or bipolar disorder type I or II. Before the first ketamine infusion, subjects will be randomized to 2 weeks of placebo treatment. All subjects will receive three IV ketamine infusions (0.5 mg/kg, over 100 min.) over 7 days. Those who achieve positive response (\>50% decrease in MADRS total score from baseline) will be given 4 additional once-weekly ketamine infusions (same dose and infusion rate) and placebo treatment.
62555901|NCT02329509|ACTIVE_COMPARATOR|one stage cleft palate surgery|Subjects submitted to one stage palate surgical repair after 9 months old and before 24 months old ,
62555902|NCT02329509|ACTIVE_COMPARATOR|two stage palate repair|Subjects submitted to two stage palate surgical repair (first soft palate repair between 6 and 12 months old and hard palate closure at 3 to 4 years old)
62555903|NCT06147648|EXPERIMENTAL|Experimental: Single arm observational registry study Drug: Tacrolimus Sustained-release Capsules|"Drug: Tacrolimus Sustained-release Capsules~After liver transplantation, immediate-release tacrolimus was administered for acute rejection prevention, and after 3 months, it was converted into tacrolimus sustained-release capsules in a ratio of 1:1 to 1:1.2; (The specific medication plan is decided by the clinician according to the actual situation)"
62555904|NCT00820781|ACTIVE_COMPARATOR|Portacaval shunt|Undergo portacaval shunt surgery
62555905|NCT00820781|ACTIVE_COMPARATOR|Sclerotherapy|Undergo endoscopic sclerotherapy
62555906|NCT02631486|EXPERIMENTAL|Early|"The first group will use sling for comfort only. Active assisted exercises in closed chain and in safe zone are allowed in the first 4 weeks.~The rehabilitation stages will start from active assisted progressing to more active stages phases until full recovery. The whole program will last about 3 months."
62555907|NCT02631486|ACTIVE_COMPARATOR|Conservative|The second group will use a sling for 6 weeks. The rehabilitation stages will start with active assisted/closed chain movements with short levers, it will progress to more active stages phases until full recovery. The whole program will last about 3 months.
62555908|NCT02881502||healthy control group|Mainly from students, family members of patients without chronic lung disease, healthy population, age 18-75 years old, the gender is not limited.
62375817|NCT04166955|EXPERIMENTAL|(Intervention)|Participants will be provided with weekly messages including information for promoting physical activity.
62555909|NCT02881502||mild and moderate asthma group|Patients diagnosed with asthma in the outpatient clinic, in accordance with the inclusion criteria and exclusion criteria.
62751587|NCT02743949|ACTIVE_COMPARATOR|Esomeprazole 40 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by esomeprazole 40 mg, over encapsulated tablets, orally, once daily for 4 weeks during the active treatment period.
62751588|NCT02743949|EXPERIMENTAL|Vonoprazan 20 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 20 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the treatment period.
62751589|NCT02743949|EXPERIMENTAL|Vonoprazan 40 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 40 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the active treatment period.
62375818|NCT04166955|NO_INTERVENTION|(Control)|Participants will be evaluated without providing any intervention.
62375819|NCT01573286|EXPERIMENTAL|Intestinal Failure in children (>1 year)|Children requiring parenteral nutrition for \>30% of calories more than 1 year (365) days post surgery will be eligible for treatment with Glucagon-like peptide 2 (20 ug/kg/day) for 6 weeks
62555910|NCT02881502||severe asthma group|Outpatient patients with severe asthma diagnosis, in accordance with the inclusion criteria and exclusion criteria.
62555911|NCT01007669|ACTIVE_COMPARATOR|Reference|Health check only
62555912|NCT01007669|EXPERIMENTAL|Intervention|Physical activity and Health check
62555913|NCT02689583|EXPERIMENTAL|Successful treatment|The patients with H. pylori infection have successful treatment based on the results from antibiotic susceptibility testing，CYP2C19 gene polymorphism，drug resistance gene sequencing and 16SrRNA sequencing.
62555914|NCT02689583|EXPERIMENTAL|refractory infection|The patients with H. pylori infection have failed treatment based on the results from antibiotic susceptibility testing，CYP2C19 gene polymorphism，drug resistance gene sequencing and 16SrRNA sequencing.
62555915|NCT02335697|OTHER|Intervention|Attitude change towards female circumcision
62751590|NCT03208907|ACTIVE_COMPARATOR|CQ coadministered with PQ|Chloroquine was administered for 3 days according to the brazilian protocol and Primaquine was administered for 14 days (0.50mg/kg/day)
62751591|NCT03208907|EXPERIMENTAL|DHA-PQP coadministered with PQ|Dihydroartemisinin/Piperaquine was administered according to the weight and Primaquine (0.50mg/kg/day)
62751592|NCT03208907|EXPERIMENTAL|CQ and PQ starting on Day 42|Chloroquine was administered for 3 days according to the brazilian protocol and Primaquine started on Day 42 for 14 days (0.50mg/kg/day) \[arm halted after preliminary analysis\]
62751593|NCT03208907|EXPERIMENTAL|DHA-PQP and PQ starting on Day 42|Dihydroartemisinin/Piperaquine was administered for 3 days according to the weight and Primaquine started on Day 42 for 14 days (0.50mg/kg/day) \[arm halted after preliminary analysis\]
62555916|NCT02335697|OTHER|No intervention|No intervention
62555917|NCT04981418|ACTIVE_COMPARATOR|Control group|will receive standardised advice on management of pelvic girdle pain, through a discussion centred around 'Guidance for Mothers-to-be and New Mothers: Pregnancy-related Pelvic Girdle Pain' booklet (https://pogp.csp.org.uk/system/files/pogp-pgppat_3.pdf). This publicly available, specialist physiotherapy approved, standardised leaflet, provides information reflective of current best practice. The participant can use this as an ongoing resource. The physiotherapist will teach participants a standardised programme of exercises, typical of those provided within usual physiotherapy practice. Written explanation/illustrations of these exercises will be provided and the women asked to undertake these at home, three times/week.
62751594|NCT02660450|EXPERIMENTAL|Prescription for Workload|Prescription from 65% VO2max for 5 min of exercise
62751595|NCT02660450|EXPERIMENTAL|Prescription for Heart Rate|Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
62751596|NCT02660450|EXPERIMENTAL|Prescription Self Selected|Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
62751597|NCT01288846||Acutly ill, Medical ward, consent|group of acutely ill patient who uses three or more drugs, must be able to give consent.
62555918|NCT04981418|EXPERIMENTAL|Intervention group|"In addition to the control groups intervention of exercise and advice, women in the intervention group will be fitted with the customised pelvic support shorts (DM Orthotics Ltd, https://www.dmorthotics.com).~Prior to the first physiotherapy session, those women allocated to the intervention group will have recieved the support shorts in the post together with standardised written information on wear time/washing. At the first physiotherapy session (one hour), the woman will be asked to try them on so that the physiotherapist can review the fit and comfort of the shorts. The physiotherapist will reinforce the written advice about wear time and care of the shorts, and answer any queries / brainstorm any issues. At session two (30 minutes), \~10 days later, the physiotherapist will review the fit and wearing of the shorts, problem solve any issues that have arisen, and review exercises to ensure they are being performed correctly."
62555919|NCT00618488|EXPERIMENTAL|1|Bifidobacterium lactis
62751598|NCT05098964|EXPERIMENTAL|Study Group (pedometer)|Participants received an Omron HJ 321 pedometer (Omron Healthcare Co Ltd, Kyoto, Japan) and were asked to walk at home at the fastest step pace as possible, for at least 30 minutes every day, up to 6 weeks.
62751599|NCT05098964|EXPERIMENTAL|Control Group|participants received supervised exercise training at outpatient clinics for total 18 sessions (3 weekly sessions for 6 weeks).
62751600|NCT03842345||Psychiatric patients|Major depression, Bi-polar, schizophrenia, ADHD, OCD, PTSD
62751601|NCT03842345||healthy controls|young healthy controls to serve as norm.
62751602|NCT05917990|EXPERIMENTAL|Dyadic Text-Messaging Micro-Intervention|The proposed micro-intervention will consist of 4 modules: welcome and overview module, sharing thoughts and feelings module, problem-solving skills module, and meaningful experiences and resources module. Each of the modules contain information and skills relevant to improving dyadic communication and relationship functioning in couples coping with advanced cancer.
62751603|NCT05917990|NO_INTERVENTION|Waitlist Control|Couples in the waitlist control group will not initially receive any intervention materials; after completing post-assessment, couples in this arm will be offered the dyadic micro-intervention.
62751604|NCT03981887|EXPERIMENTAL|Nafithromycin 200 mg as IV infusion|Nafithromycin 200 mg administered as IV infusions twice daily (q12h) over a period of 3 hours for 3 days.
62751605|NCT03981887|PLACEBO_COMPARATOR|placebo administered as IV infusion|Placebo administered as IV infusions twice daily (q12h) over a period of 3 hours for 3 days.
62751606|NCT01428037|EXPERIMENTAL|Misoprostol Vagianl Tablet|Misoprostol Vaginal Tablet 25 mcg.
62751607|NCT01428037|PLACEBO_COMPARATOR|Placebo|Tablet without active ingredient
62751608|NCT00532740||All Patients|Patients with metastatic cancer of the liver who are not surgical resection candidates and who will be treated with TheraSphere per institutional standard of care.
62751609|NCT05901051|EXPERIMENTAL|dual therapy A|Vonoprazan 20mg bid ac and amoxicillin 0.75g qid pc
62751610|NCT05901051|EXPERIMENTAL|dual therapy B|Vonoprazan 20mg bid ac and amoxicillin 1g tid pc
62751611|NCT05901051|EXPERIMENTAL|dual therapy C|Vonoprazan 20mg bid ac and amoxicillin 1g tid ac
62751612|NCT01573221||stroke|
62375820|NCT01573286|EXPERIMENTAL|GLP-2 in Infants (<1 year of age)|Infants under one year of age with congenital anomalies, or intestinal resection, leaving them with anatomic short bowel syndrome (total remaining small intestine less than 40 % of predicted for gestational age) or with intestinal resection or repaired gastroschisis who have demonstrated dependence on parenteral nutrition at 45 days post operation with the requirement for \>50% of calories by PN (independent of the length of remnant small intestine) will be eligible for treatment with Glucagon-like peptide 2, at a dose of 5, 10 or 20 ug/kg/day.
62375821|NCT05319886||Anlotinib and Penpulimab|
62751613|NCT05734053||Nilotinib|patients prescribed with nilotinib in routine medical practice
62555920|NCT00618488|PLACEBO_COMPARATOR|2|Placebo
62751614|NCT05149040||very elderly outpatients|outpatients (eyes, ear-nose-and throat, orthopaedic outpatient clinics at Haukeland University Hospital, Bergen, Norway) aged 80 years and older
62751615|NCT05149040||proxy|next of kin who likely would act as a proxy in a medical emergency, identified by the very elderly respondent
62751616|NCT00222430|ACTIVE_COMPARATOR|A|Usual standard coronary angiographic procedure
62751617|NCT00222430|EXPERIMENTAL|B|Fluoroscopy-guided coronary angiography
62751618|NCT03120260|EXPERIMENTAL|Short Sleep|Diet+ have 5 hour sleep at night (SS)
62751619|NCT03120260|EXPERIMENTAL|Normal Sleep|Diet+ have 7-8 hour sleep at night (NS)
62751620|NCT01398319|EXPERIMENTAL|Group Brief Alcohol Booster Intervention|The 1-hour booster intervention was delivered using MI to extend the effective elements found in the original BAI intervention with elements from behavioral economic theory. A behavioral economic approach to alcohol use suggests that decisions to drink are more likely when 1) there is a lack of access to or engagement in alternative alcohol-free reinforcing activities, and 2) there is a greater relative focus on immediate, relative to delayed, rewards (i.e., steep delayed reward discounting). The intent of the intervention is to bring important long-term goals into the present so that the immediate awareness of this goal might diminish the relative benefit of drinking. Another goal was to have the Airmen identify enjoyable and goal-consistent alcohol-free activities they could engage in during their free time. The booster also included a reminder of the U.S. Air Forces rules and policies on alcohol use and harm reduction drinking strategies.
62751621|NCT01398319|ACTIVE_COMPARATOR|Bystander Intervention|"The 1-hour Bystander intervention was a non-alcohol related briefing that served as the control condition. The intervention focused on increasing Airmen's awareness of the qualities of being a good wingman (e.g., watching for their peers) and how those are tied to the Air Force Core Values. It aimed to increase participants' perceived responsibility to act in certain situations. The intervention draws on the philosophy that members in a community have a role in shifting social norms to prevent violence. While the intervention did not directly discuss alcohol use, the focus on military values and taking responsibility for one's self and others could contribute to healthier drinking-related choices."
62375822|NCT03062670|EXPERIMENTAL|Retreat|A full day off-site training session
62375823|NCT03062670|NO_INTERVENTION|Control|Care teams normal process
62375824|NCT05592444|EXPERIMENTAL|Low concentration|"Patients receive a contrast medium with an iodine concentration of 140 mg/ml. The volume is 1 ml/kg which result in a dose of 140 mg/kg.~Maximal dose of contrast medium is 90 ml i.e. 12.6 g of iodine."
62751622|NCT05291988|EXPERIMENTAL|Screening (S2S education, FIT kit)|Participants receive S2S online screening education and FIT kit for sample collection.
62751623|NCT03381365|EXPERIMENTAL|investigational arm|
62751624|NCT01865812|EXPERIMENTAL|OCA: 10 mg|Obeticholic acid, oral administration, 10 milligrams (mg), 8 weeks
62375825|NCT05592444|EXPERIMENTAL|Low volume|"Patients receive a contrast medium with an iodine concentration 350 of mg/ml. The volume is 0.4 ml/kg which result in a dose of 140 mg/kg.~Maximal dose of contrast medium is 36 ml i.e. 12.6 g of iodine."
62375826|NCT05592444|EXPERIMENTAL|Saline Dilution|"Patients receive a contrast medium with an iodine concentration of 350 mg/ml. The contrast medium is diluted 1:1 with saline.~The injected volume is 0.8 ml/kg which result in a dose of 140 mg/kg. Maximal dose of contrast medium is 72 ml i.e. 12.6 g of iodine."
62375827|NCT02585635||Families|Families of children with haemophilia
62375828|NCT02585635||Clinicians|Haemophilia physicians
62391551|NCT06103773|EXPERIMENTAL|FE-High Dosage groups|drug：TollB-001 tablets Subjects in the fasting-fed sequence group will be administered with TollB-001 under fasting condition in the first period and under fed condition in the second period; subject in the fed-fasting sequence group will be administered with TollB-001 under fed condition in thefirst period and under fasting condition in the second period. The two periods of cross-administration will have a washout period of 5-10 days）
62555921|NCT03799432|EXPERIMENTAL|TF-CBT Learning collaborative + COAST-IS|In addition to participating in a learning collaborative for implementing trauma-focused cognitive behavioral therapy (TF-CBT) with periodic coaching calls, organizations will receive additional training and tailored implementation support.
62751625|NCT01581749|OTHER|36.25Gy to prostate in 5 fractions|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
62751626|NCT01915121|ACTIVE_COMPARATOR|Education Intervention|In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer.
62751627|NCT01915121|PLACEBO_COMPARATOR|Nutrition Intervention|In this session, participant will be provided with information about nutrition information directly related to bladder cancer recovery
62751628|NCT06398431|EXPERIMENTAL|Gait group|
62751629|NCT01606683|EXPERIMENTAL|GROUP 1|Infant formula supplemented with with functional ingredients (galacto-oligosaccharides, beta-palmitate, fermented milk). Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae.
62555922|NCT03799432|ACTIVE_COMPARATOR|TF-CBT Learning collaborative|Organizations will participate in a learning collaborative for implementing trauma-focused cognitive behavioral therapy (TF-CBT) with periodic coaching calls.
62751630|NCT01606683|OTHER|GROUP 2|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
62751631|NCT01606683|OTHER|CONTROL GROUP|Breast milk
62751632|NCT04667520|EXPERIMENTAL|LPA+Fitbit|Participants in this group receive a Lifestyle Physical Activity intervention and are provided with a Fitbit to collect activity data
62555923|NCT03272178||Triathlon knee total knee arthroplasty|50 Patients who are assigned to Triathlon knee, half cemented/half cementless
62555924|NCT03272178||Depuy knee total knee arthroplasty|50 Patients who are assigned to Depuy knee, half cemented/half cementless
62555925|NCT05523115|EXPERIMENTAL|Heights Smart Supplement|Participants will take the supplement over a 12 week period. There will be both biomarker outcomes and subjective outcomes reported by the participants via questionnaires.
62751633|NCT04667520|ACTIVE_COMPARATOR|Fitbit Only|Participants in this group are provided with a Fitbit to collect activity data
62751634|NCT02072460|EXPERIMENTAL|vestibular signals determination|vestibular signals determination by electromyography and electroencephalography associated to approaches from psychophysics
62751635|NCT05882864|ACTIVE_COMPARATOR|Topical 6-Gingerol Group|Group I Will include 14 patients receiving topical ginger extract 1% four times per day (after every meal and before going to bed) for eight weeks (Zakaria et al., 2020).
62751636|NCT05882864|ACTIVE_COMPARATOR|Topical Steroid Group|"Group II Will include 14 patients receiving topical steroid (triamcinolone acetonide 0.1%) four times per day for eight weeks (Laeijendecker et al., 2006)~In the fourth and eighth weeks, topical anti-fungal will be applied by a third-party medical personnel to avoid 2ry candidiasis for this group."
62751637|NCT01025076|EXPERIMENTAL|StomaphyX Group|"* Primary Roux-en-Y gastric bypass with evidence of enlarged gastric pouch volume or enlarged stoma diameter of ≥ 20 mm via endoscopy or fluoroscopy.~* Patients also demonstrate a weight regain of 15% of excess body weight loss."
62751638|NCT02687555|EXPERIMENTAL|Intervention|Computerized Cognitive Bias Modification of Appraisals (CBM-App), developed from that used by Woud et al. (2012,2013). The intervention comprises 8 sessions completed over a period of 2 weeks. The training takes place while participants are also receiving specialized inpatient treatment for PTSD at the Clinic for Psychosomatic Medicine and Psychotherapy, LWL University Clinic of Ruhr University of Bochum.
62751639|NCT02687555|SHAM_COMPARATOR|Control|Computerized Peripheral Vision Task (PVT), developed from that used by Calkins et al. (2015). The intervention comprises 8 sessions completed over a period of 2 weeks. The training takes place while participants are also receiving specialized inpatient treatment for PTSD at the Clinic for Psychosomatic Medicine and Psychotherapy, LWL University Clinic of Ruhr University of Bochum.
62751640|NCT01117740||Thoracoscopy Group|
62751641|NCT01117740||Indwelling Pleural Catheters|
62751642|NCT06438445|EXPERIMENTAL|Real Jelly Group|Patients with chronic kidney disease on hemodialysis will receive capsules containing 500mg of royal jelly/day for two months.
62751643|NCT06438445|PLACEBO_COMPARATOR|Placebo group|Patients with chronic kidney disease on hemodialysis will receive capsules containing 500mg of placebo/ day for two months.
62751644|NCT02186652|OTHER|Pantoprazole|
62751645|NCT06605482||Operative|Humeral shaft fracture is surgically managed with open reduction internal fixation or intramedullary nailing.
62751646|NCT06605482||Non-operative|Humeral shaft fracture is conservatively managed with bracing or splinting
62751647|NCT01528891|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine
62375829|NCT05254925|ACTIVE_COMPARATOR|Phototoxicity evaluation of sunscreen oil with 6% BEMT (SU E 101413 85)|"Assessment of the phototoxicity potential of sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer a test material (formulation: SU E 101413 85).~The phototoxic response of the investigational product: SU E 101413 85 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject."
62555926|NCT01841593|EXPERIMENTAL|Group A|DAYS 1 to 7: raltegravir 400 mg BID DAYS 8 to 14: raltegravir 400 mg BID PLUS amlodipine 5 mg OD DAYS 15 to 21: amlodipine 5 mg OD
62555927|NCT01841593|EXPERIMENTAL|Group B|DAYS 1 to 7: amlodipine 5 mg OD DAYS 8 to 14: raltegravir 400 mg BID PLUS amlodipine 5 mg OD DAYS 15 to 21: raltegravir 400 mg BID
62751648|NCT01528891|PLACEBO_COMPARATOR|placebo|Normal saline
62751649|NCT00597311|EXPERIMENTAL|1|preoperative short term radiation group 5x5 Gy and surgery after 6 weeks
62751650|NCT00597311|EXPERIMENTAL|2|preoperative chemoradiotherapy group 50Gy + 5FU/Lv and surgery after 6 weeks.
62751651|NCT06002854|EXPERIMENTAL|GROUP A Microneedling with PRP(platelete rich plasma)|
62555928|NCT03081832|EXPERIMENTAL|Oxytocin|Groups of children with Prader Willi Syndrome treated by oxytocin for 7 days during their first 6 months of life.
62555929|NCT03081832|EXPERIMENTAL|Control|Groups of children with Prader Willi Syndrome not treated by oxytocin for 7 days during their first 6 months of life.
62751652|NCT06002854|EXPERIMENTAL|GROUP B Microneedling with topical INSULIN|
62751653|NCT06602388||Healthy volunteers (Bioaster employees)|Collection of biological samples from healthy volunteers: Stool, urine, saliva, buccal swab, nasal swab, superficial skin swab, hair
62751654|NCT06218251|EXPERIMENTAL|BOTOX|Participants will receive injections in the glabellar complex, in each of the lateral canthal area, and in the frontalis muscle on Day 1.
62555930|NCT05810233|EXPERIMENTAL|Vitamin C|Commercially available Tablet Vitamin C 1000mg per day for 7 days
62555931|NCT05810233|PLACEBO_COMPARATOR|Placebo|Glucose chewable table 1x per day for seven days
62555932|NCT05436730||"Escape Phenomenon of the Antihypertensive Therapy Efficacy"|Men and women aged 18-90 years with arterial hypertension grade 1-3, stage I-II and initially achieved target BP levels while taking 2-3-component AHT.
62751655|NCT04960930|EXPERIMENTAL|FMX101|FMX101 4% minocycline foam
62751656|NCT04960930|PLACEBO_COMPARATOR|Vehicle Foam|Vehicle Foam
62751657|NCT02685748|EXPERIMENTAL|Aspirin & pantoprazole|"Aspirin 1000 mg/pd per os in two doses~Pantoprazole 40 mg/pd per os in two doses for gastric protection"
62751658|NCT02685748|PLACEBO_COMPARATOR|Placebo|"Two pills in the morning and two in the evening~All pills (aspirin, pantoprazole an placebo) will be the same looking- in the same capsules."
62751659|NCT01098604|ACTIVE_COMPARATOR|32mm ceramic head group|patients performed with THA using 32mm ceramic head
62751660|NCT01098604|ACTIVE_COMPARATOR|28mm ceramic head group|patients performed with THA using 28mm ceramic head
62751661|NCT01235923|ACTIVE_COMPARATOR|three times weekly Epo|Epo 400 units/kg three times weekly given subcutaneously for 4 weeks
62751662|NCT01235923|ACTIVE_COMPARATOR|weekly Epo|1,200 units/kg given once a week subcutaneously for 4 weeks
62751663|NCT02794844|EXPERIMENTAL|Genotype Guided PPI Dosing|"Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.~No other ARM will be studied."
62751664|NCT06311136|EXPERIMENTAL|Intervention group|"Participants complete a valence-specific ecological momentary intervention twice daily over 14 consecutive days.~The ecological momentary intervention is presented as the Positive Everyday Affect Knowledge (PEAK) diary and includes valence-specific emotion regulation strategy instructions. Participants receive reminders to complete surveys on their strongest emotions since the last assessment. Depending on the valence of this emotion, they receive instructions on how to use the strategy savoring (for positive emotions) or reappraisal (for negative emotions)."
62555933|NCT03730207|EXPERIMENTAL|Xpede™ Bone Cement|The subjects in this group will be injected the Xpede™ Bone Cement into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body.
62555934|NCT03730207|ACTIVE_COMPARATOR|Mendec Spine Bone Cement|The subjects in this group will be injected the Mendec Spine Bone Cement into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body.
62751665|NCT06311136|NO_INTERVENTION|Monitoring-only control group|"Participants complete a valence-specific ecological momentary assessment twice daily over 14 consecutive days.~The ecological momentary assessment is presented as the Positive Everyday Affect Knowledge (PEAK) diary, and only involves monitoring participants' emotional experiences and regulation. Participants receive reminders to complete surveys on their strongest emotions since the last assessment. Depending on the valence of this emotion (positive versus negative), they are asked about their emotion regulation strategies."
62751666|NCT05752942|EXPERIMENTAL|Treatment: Student Intervention Matching System|In the treatment condition, the students received a performance-based interventions matched to their individual needs and characteristics based on Student Intervention Matching System (SIMS).
62751667|NCT05752942|ACTIVE_COMPARATOR|Active control: group-based social skills training|In the control condition, students received an unconditionally mismatched acquisition-based EBI (group-based social skills training).
62751668|NCT00813605|EXPERIMENTAL|Arm A|AMG 655 10 mg/kg plus AMG 479 placebo in combination with FOLFIRI every 14 days
62751669|NCT00813605|ACTIVE_COMPARATOR|Arm C|AMG 479 Placebo plus AMG 655 Placebo in combination with FOLFIRI every 14 days
62751670|NCT00813605|EXPERIMENTAL|Arm B|AMG 479 12 mg/kg plus AMG 655 placebo in combination with FOLFIRI every 14 days
62751671|NCT06604988|EXPERIMENTAL|Intervention group of videofeedback to promote positive parenting|Biweekly sessions will be held for 6 months (a total of 12 sessions per family) via videoconference with the family at home. Each session will last approximately 1 hour to 1 hour and 30 minutes and will work with the primary caregiver. The intervention protocol mixes coaching strategies based on observation and video-feedback. This arm will provide with measurements at waves 0,1, and 2 over a time period of approximately 12 months.
62751672|NCT06604988|NO_INTERVENTION|Control Group|This arm will only provide the measurements at the different time points (waves 0,1, and 2) over 12 months. After the follow-up planned in the study, feedback as well as recommendations concerning parenting will be provided.
62751673|NCT00537667|ACTIVE_COMPARATOR|A|anakinra
62751674|NCT00537667|EXPERIMENTAL|B|anakinra and PEGsTNF-R1
62751675|NCT04315792|EXPERIMENTAL|Endoxifen Arm|Endoxifen enteric-coated tablet (8 mg). Patients will continue treatment with their initial randomized medication for 3 weeks
62751676|NCT04315792|PLACEBO_COMPARATOR|Placebo Arm|Placebo tablets of endoxifen. Patients will continue administration with their initial randomized medication for 3 weeks
62555935|NCT02000791|EXPERIMENTAL|cLMA insertion via laryngoscopic technique|Comparison of cLMA insertion via laryngoscope view by fiberscope
62555936|NCT02000791|ACTIVE_COMPARATOR|cLMA insertion via standart technique|Comparison of cLMA insertion via standart technique view by fiberscope
62555937|NCT02920801|EXPERIMENTAL|saxagliptin group|saxagliptin group consumed saxagliptin 5mg per day for 12 week
62555938|NCT02920801|ACTIVE_COMPARATOR|metformin group|metformin group consumed metformin 1500mg per day for 12 week
62751677|NCT05280002|EXPERIMENTAL|Adipose Tissue derived Total-Stromal-Cells (TOST)|Adipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cells plus standard conservative care.
62751678|NCT05280002|NO_INTERVENTION|Control|Standard Conventional Treatment
62751679|NCT00809991|EXPERIMENTAL|Hypofractionated radiation therapy in prostate adenocarcinoma|Participants with histologically confirmed, locally confined adenocarcinoma of the prostate receive 3.6 Gy per day to a total dose of 57.6 Gy (16 fractions).
62751680|NCT02884167||Patients with constipation|
62751681|NCT02884167||Healthy individuals without constipation|
62751682|NCT00931723|ACTIVE_COMPARATOR|1|Seroquel XR and Lithium
62555939|NCT02074150|EXPERIMENTAL|Biceps Brachii|"Biceps Brachii (elbow flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62555940|NCT02074150|EXPERIMENTAL|Flexor Carpi Radialis|"Flexor Carpi Radialis (wrist flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62751683|NCT00931723|PLACEBO_COMPARATOR|2|Seroquel XR and placebo
62751684|NCT05230108|NO_INTERVENTION|Phase 1 (F1): retrospective control.|Phase 1, retrospective, will include all patients who attended the ED from January 2018 to December 2022.
62751685|NCT05230108|EXPERIMENTAL|Phase (F2): prospective intervention of Advanced Triage|Phase 2, prospective, where advanced triage based on advanced practice nurse will be implemented. Will include patients from January 2023 to December 2024.
62751686|NCT06598072|EXPERIMENTAL|CPC+Zn mouthwash and brushing|A regimen composing of a CPC+Zn mouthwash, brushing with a commercially available toothbrush and a stannous fluoride-based toothpaste
62751687|NCT06598072|ACTIVE_COMPARATOR|Essential oils mouthwash and brushing|A regimen composing of an essential oils mouthwash, brushing with a commercially available toothbrush and a fluoride-based toothpaste
62751688|NCT06598072|ACTIVE_COMPARATOR|Flossing and brushing|A regimen composing of flossing and brushing with a commercially available toothbrush and a fluoride-based toothpaste
62375830|NCT05254925|OTHER|Phototoxicity evaluation of sunscreen oil vehicle (SU E 101413 91)|"Vehicle Control: Assessment of the phototoxicity potential of sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (formulation: SU E 101413 91).~The phototoxic response of the investigational product: SU E 101413 91 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject."
62555941|NCT02074150|EXPERIMENTAL|Flexor carpi ulnaris|"Flexor carpi ulnaris (wrist flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62555942|NCT02074150|EXPERIMENTAL|Flexor digitorum profundus|"Flexor digitorum profundus (finger flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62555943|NCT02074150|EXPERIMENTAL|Flexor digitorum sublimis|"Flexor digitorum sublimis (finger flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62555944|NCT02074150|EXPERIMENTAL|Adductor pollicis|"Adductor pollicis (thumb flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62751689|NCT01408550|ACTIVE_COMPARATOR|NPB-01|Active Comparator: 1 Intravenous immunoglobulin
62751690|NCT01408550|PLACEBO_COMPARATOR|Placebo|Placebo Comparator: 2 Physiological saline
62751691|NCT01261013||keratoconus stage I in whom KeraRing ICRS were implanted|
62751692|NCT01261013||keratoconus stage II in whom KeraRing ICRS were implanted|
62751693|NCT01261013||keratoconus stage III in whom KeraRing ICRS were implanted|
62751694|NCT00191724|EXPERIMENTAL|1|
62751695|NCT00191724|EXPERIMENTAL|2|
62751696|NCT00191724|EXPERIMENTAL|3|
62751697|NCT00191724|EXPERIMENTAL|4|
62751698|NCT00191724|PLACEBO_COMPARATOR|5|
62751699|NCT03227952|ACTIVE_COMPARATOR|Active treatment|Vibrotactile sensory stimulation
62751700|NCT03227952|SHAM_COMPARATOR|Sham|Identical device. No vibration
62751701|NCT06606509||T1DM patients|Patients with Type 1 Diabetes Mellitus (T1DM) will undergo a series of examinations, including physical examinations, surveys, continuous glucose monitoring, and subcutaneous fat ultrasonography.
62555945|NCT02074150|EXPERIMENTAL|Flexor pollicis longus|"Flexor pollicis longus (thumb flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62751702|NCT05986968|EXPERIMENTAL|Treatment arm|Ticagrelor monotherapy instead of dual antiplatelet therapy (aspirin plus ticagrelor)
62751703|NCT05986968|ACTIVE_COMPARATOR|Control arm|Dual antiplatelet therapy (aspirin plus ticagrelor) for 12 months.
62751704|NCT05293613|EXPERIMENTAL|Cases|
62751705|NCT04397159|EXPERIMENTAL|Combination Exercise|Flywheel resistance exercise plus aerobic exercise
62555946|NCT02074150|EXPERIMENTAL|Change from Baseline in Elbow Ashworth|"Change from Baseline in Elbow Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):~0 = No increase in muscle tone (none)~1. = Slight increase~2. = Moderate increase~3. = Considerable increase~4. = Limb rigid (very severe)."
62751706|NCT04397159|NO_INTERVENTION|Standard-of-care|Participants will maintain standard-of-care and current activity levels during the course of the study.
62751707|NCT06224439|ACTIVE_COMPARATOR|spinal anaesthesia|25 gauge quincke needle will be used for spinal anaesthesia. After the lateral position is given to the patient with the side to be operated on, the patient will be entered through the appropriate interval (L3-4 or L4-5) to apply hypobaric spinal anaesthesia, and after the feeling of falling in the subdural area is obtained, Cerebro Spinal Fluid arrival will be seen and the drug consisting of 0.5% Bupivacain and distilled water with bupivacaine hydrochloride active ingredient will be applied in the range of 2-4cc according to the patient's height and weight.
62751708|NCT06224439|ACTIVE_COMPARATOR|lumbar plexus block|A 10-15 cm peripheral block needle, ultrasound and nerve stimulator will be used for lumbar plexus block. Buvicaine with 0.5% Bupivacaine Hydrochloride active substance will be used. It will be diluted half and half with saline. It will be applied in accordance with the patient's height and weight, not exceeding 2mg/kg.
62751709|NCT02762240|ACTIVE_COMPARATOR|DHQP 2016|This group consists of general practices allocated to undergo accreditation scheme in 2016.
62751710|NCT02762240|PLACEBO_COMPARATOR|DHQP 2018|This group consists of general practices allocated to undergo accreditation scheme in 2018.
62751711|NCT01949025|EXPERIMENTAL|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
62751712|NCT01949025|NO_INTERVENTION|Control group|
62751713|NCT05894096|EXPERIMENTAL|Cold Athmospheric Plasma Jet+Alginate patch|Leg Venous Ulcers will be treated in all patients belonging to the experimental arm using the PlasmAction Med cold plasma generator at atmospheric air pressure and alginate (Melgisorb Ag®) will be used after the plasma has been applied.
62751714|NCT05894096|ACTIVE_COMPARATOR|Alginate patch|For patients included in the control arm, alginate (Melgisorb Ag®) will be used as a cure for ulcers, size 10 X 10 cm and 5x5 (3 units), whose replacements will also be carried out twice a week.
62751715|NCT04975919|EXPERIMENTAL|Treatment (decitabine and cedazuridine, venetoclax)|Patients receive decitabine and cedazuridine PO QD on days 1-10. Patients who achieve CR/CRi during consolidation/maintenance may receive decitabine and cedazuridine PO QD on days 1-5. Patients also receive venetoclax PO QD on days 1-28 of cycle 1 and days 1-21 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62751716|NCT02446704|EXPERIMENTAL|Olaparib and Temozolomide|"- Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation. Once the MTD is determined, the study will move to the phase II portion.~* Olaparib- Oral, on determined days per cycle~* Temozolomide- Oral, on determined days per cycle"
62751717|NCT02455661|EXPERIMENTAL|Radial PCI with TR Band (TM)|Patients with a PCI using the radial approach and the above radial compression device.
62751718|NCT02455661|ACTIVE_COMPARATOR|Femoral PCI with AngioSeal device|Patients with a PCI using the femoral approach and the above femoral vascular closure device.
62751719|NCT02455661|ACTIVE_COMPARATOR|Femoral PCI with StarClose device|
62751720|NCT02825966|OTHER|AUDICOR then LifeVest then AUDICOR|First, assigned to wear AUDICOR device for 15 minutes. Then assigned to wear the WCD, including 6 hours of overnight wear. Total anticipated wear time with WCD is 12-16 hours. Finally, assigned to wear the AUDICOR device for another 15 minutes after finishing the WCD wear.
62751721|NCT02419196||abdominal surgery|27 patients undergoing abdominal surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
62751722|NCT02419196||limb surgery|27 patients undergoing upper and lower limb surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
62751723|NCT02419196||flail chest|10 patients undergoing an operative stabilization of a flail chest will be examined by perioperative pulmonary function tests
62751724|NCT00842946|EXPERIMENTAL|Exposure w/ Acceptance-Based Rationale|Behavioral exposure within the context of psychological acceptance.
62751725|NCT00842946|ACTIVE_COMPARATOR|Exposure w/ Habituation-Based Rationale|Behavioral exposure within the context of habituation.
62751726|NCT02873065|EXPERIMENTAL|Ilaprazole|Ilaprazole -based quadruple therapy for 7days：Ilaprazole -based quadruple therapy for 7days: Ilaprazole 5mg bid.
62751727|NCT02873065|ACTIVE_COMPARATOR|Esoprazole|Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid.
62751728|NCT03294174||Opioid naive|Patients who have not been exposed to opioids, but will receive ropivacaine injection
62555947|NCT02074150|EXPERIMENTAL|Change from Baseline in Wrist Ashworth|"Change from Baseline in Wrist Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.Ashworth score (the force required to move an extremity around a joint):~0 = No increase in muscle tone (none)~1. = Slight increase~2. = Moderate increase~3. = Considerable increase~4. = Limb rigid (very severe)."
62751729|NCT03294174||Opioid exposure|Patients who have been exposed to(\> 6months), but not currently taking opioids, but will receive ropicacaine injection
62751730|NCT03294174||opioid tolerance|Patients who have been actively taking opioids with a tolerant dose based on FDA guideline, but will receive ropivacaine injection
62751731|NCT05897190|EXPERIMENTAL|SARS-CoV-2 mRNA vaccine (RBMRNA-405) adult group|One dose was administered by intramuscular injection on day 1
62751732|NCT05897190|EXPERIMENTAL|SARS-CoV-2 mRNA vaccine (RBMRNA-405) older adult group|One dose was administered by intramuscular injection on day 1
62751733|NCT05897190|ACTIVE_COMPARATOR|CoronaVac® adult group|One dose was administered by intramuscular injection on day 1
62751734|NCT05897190|ACTIVE_COMPARATOR|CoronaVac® older adult group|One dose was administered by intramuscular injection on day 1
62751735|NCT03923621|EXPERIMENTAL|Experimental - EPSiT|Endoscopic Pilonidal Sinus Treatment
62751736|NCT03923621|ACTIVE_COMPARATOR|Control - excision|Excision treatment
62751737|NCT00797446||Photon/Proton Radiation Therapy|Data collection will be obtained from the patient's medical records including initial evaluation, pathology report, dosimetry information, radiotherapy completion records and follow-up.
62375831|NCT05254925|ACTIVE_COMPARATOR|Phototoxicity evaluation of dispersion of 6% BEMT in petrolatum (SU E 101413 82)|"Assessment of the phototoxicity potential of a dispersion of 6% BEMT (PARSOL® Shield) in petrolatum (formulation: SU E 101413 82).~The phototoxic response of the investigational product: SU E 101413 82 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject."
62567497|NCT02673736|EXPERIMENTAL|PLX73086|"Part 1: Open-label, sequential PLX73086 dose escalation in approximately 36 solid tumors subjects.~Part 2: Extension cohort at the recommended phase 2 dose (RP2D) of PLX73086 in approximately 30 subjects with histologically confirmed, unresectable, locally advanced or refractory TGCT (including metastatic disease)."
62567498|NCT02172443|EXPERIMENTAL|tiotropium inhalation capsules|
62567499|NCT02172443|ACTIVE_COMPARATOR|Atrovent MDI|
62567500|NCT05488977|EXPERIMENTAL|Exercise training|8 weeks of supervised high-intensity interval training (HIIT) that is 4×4 min intervals at 85-95% of maximal heart rate (HRmax) with 3-minute active breaks (\~60 % HRmax) in between intervals, twice a week) on treadmills. In addition, the participants will perform exercise once a week on their own following the correct exercise intensity.
62567501|NCT05488977|NO_INTERVENTION|Control|No intervention. Carry on their normal life.
62567502|NCT02413905||Senegal|Stool samples on Children with and without severe acute malnutrition in Senegal recruited in 3 locations (Dakar, Dielmo and Ndiop)
62567503|NCT02413905||Niger|Stool samples Children with and without severe acute malnutrition in Niger recruited in Niamey
62567504|NCT04302870|EXPERIMENTAL|Memantine|
62567505|NCT04302870|EXPERIMENTAL|Trazodone|
62567506|NCT04302870|PLACEBO_COMPARATOR|Placebo|
62567507|NCT04302870|EXPERIMENTAL|Amantadine|
62567508|NCT01694160|EXPERIMENTAL|Paricalcitol|Paricalcitol 2 ug/daily for 48 weeks
62567509|NCT01694160|NO_INTERVENTION|no intervention|
62567510|NCT02183324|EXPERIMENTAL|Low dose of BI 1356 BS|
62567511|NCT02183324|EXPERIMENTAL|Medium dose of BI 1356 BS|
62567512|NCT02183324|EXPERIMENTAL|High dose of BI 1356 BS|
62567513|NCT02183324|PLACEBO_COMPARATOR|Placebo|
62567514|NCT05694780|EXPERIMENTAL|Experimental|Women in the intervention group will receive standard obstetric care plus the STEP intervention which is a 8-week program based on sleep hygiene education and cognitive-behavioral training.
62567515|NCT05694780|NO_INTERVENTION|Control|Women in the control group will receive standard obstetric care.
62567516|NCT06575712|EXPERIMENTAL|Step Up|Step Up participants will complete 7 sessions over 7-14 weeks (45 min/session). Of the 7 sessions, participants will complete 3 in-person in the hospital/outpatient clinic (1 coping skills training for symptom management \[45 min\] and 2 activity coaching \[45 min\]) followed by 4 via videoconferencing (coping skills training for symptom management and activity coaching \[45 min each\]) once the patient has been discharged home from the outpatient clinic.
62567517|NCT06575712|OTHER|Usual Care Plus (UC+)|Usual Care Plus (UC+) participants will complete all assessments at time intervals corresponding to Step Up, and otherwise continue to receive their usual medical care plus 7 videos delivering educational content (1 video/week for 7 weeks; 5-10 minutes/video) via a study app (free download), but not the Step Up protocol.
62567518|NCT04868825|EXPERIMENTAL|Experimental (Intervention)|
62567519|NCT04868825|ACTIVE_COMPARATOR|Active Comparator|
62567520|NCT03765489|EXPERIMENTAL|electrical muscle stimulation|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al. plus electrical muscle stimulation: The parameters used in biceps were: 35 Hz, 250 μs and in quadriceps were: 50 Hz, 400 μs. In both, biphasic wave was used, 45 minutes of total work, 5 seconds of contraction and 10 seconds of relaxation and the intensity was adjusted to present a visible contraction"
62751738|NCT00387179|EXPERIMENTAL|Dim Light Melatonin and/or methylxanthine|Dim Light Melatonin and/or methylxanthine
62375832|NCT05254925|OTHER|Phototoxicity evaluation of petrolatum vehicle (SU-E-101413-83)|"Vehicle Control: Assessment of the phototoxicity potential of petrolatum vehicle (SU-E-101413-83).~The phototoxic response of the investigational product: SU E 101413 83 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject."
62375833|NCT04542395|EXPERIMENTAL|Increasing Uptake of COVID-19 Testing and Vaccination|"This is a pre-experimental one group pretest-posttest design to improve COVID-19 associated health outcomes and willingness and uptake toward testing and vaccination among 310 Hispanic and African American public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by our COVID-19 health ambassadors and our researchers. We will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention."
62567521|NCT03765489|ACTIVE_COMPARATOR|conventional physical therapy|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al"
62567522|NCT03231072|EXPERIMENTAL|Electrical Impedance Tomography record|Electrical Impedance Tomography monitoring of the pleural effusion evacuation.
62751739|NCT00387179|EXPERIMENTAL|Placebo and Dim Light or bright light|Placebo and Dim Light or bright light
62751740|NCT00387179|EXPERIMENTAL|Bright light melatonin and/or methylxanthine|Bright light, melatonin, and/or methylxanthine
62751741|NCT02973542|EXPERIMENTAL|ethosuximide|A responder will correspond to a decrease in abdominal pain score (11-points NRS pain) of at least 30% compared to the score before treatment and a score of 6 or 7 on the SGA scale. At endpoint (12-weeks treatment period), it will be compared the responder rate between the 2 treatment arms (ethosuximide vs placebo).
62751742|NCT02973542|PLACEBO_COMPARATOR|placebo|A responder will correspond to a decrease in abdominal pain score (11-points NRS pain) of at least 30% compared to the score before treatment and a score of 6 or 7 on the SGA scale. At endpoint (12-weeks treatment period), it will be compared the responder rate between the 2 treatment arms (ethosuximide vs placebo).
62751743|NCT00762138|OTHER|Autologel System|Autologel System produces platelet rich plasma gel
62751744|NCT03524690|ACTIVE_COMPARATOR|SUSOPS Balance|Volunteers provided sufficient food to maintain energy balance.
62751745|NCT03524690|EXPERIMENTAL|SUSOPS Negative Balance|Volunteers provided insufficient food to maintain energy balance resulting in negative energy balance.
62751746|NCT05929001||Lymphedema Risk Group|"Participants in this group will:~1. Completed questionnaires about daily function and mood,~2. Undergo arm circumference measurement conducted by medical staff, and~3. Undergo Lymphedema Index Test (L-DEX) or measurement of tissue water content, conducted standard of care.~Total expected participation is about six months."
62751747|NCT01318278|ACTIVE_COMPARATOR|Dopamine treatment|Dopamine treatment beginning at 5 mcg/kg/min and titrated by 5 mcg/kg/min to effect up to maximum of 20 mcg/kg/min
62751748|NCT01318278|ACTIVE_COMPARATOR|Vasopressin treatment|Arginine Vasopressin treatment beginning at 0.01 units/kg/hr and titrated up by 0.01 units/kg/hr to effect up to a maximum of 0.04 units/kg/hr
62751749|NCT01318278|NO_INTERVENTION|Comparison Arm|Infants who did not require vasopressor support for hypotension during the first 24 hours of life
62375834|NCT04830657|EXPERIMENTAL|Distant reiki group|The application will be carried out by the researcher who has received level 2 reiki training. Reiki energy will be sent to the individuals who have undergone hemodialysis with the intention of healing. The Reiki practitioner is enabled to send the Reiki remotely in a quiet and lonely room. The practitioner moves to the right side of the individual, imagining as if he is next to the individual, and his aura (the energy that exists around the body) is corrected 3 times from above and from the head to the feet. The practitioner's hands are held side by side. Starting from the beginning of the application, reiki energy is sent to the 7 main chakras in an average of 3 minutes, from top to bottom. Each session is approximately 21-25 minutes. After the session, the chakra equalization process is applied to help the frequencies of the chakras to work in harmony with each other. 15 minutes in total. Balancing is done.
62375835|NCT04830657|OTHER|Control|Patients will receive routine treatment in accordance with the institution policy without any intervention in the control group.
62375836|NCT01234311|PLACEBO_COMPARATOR|placebo|Matching placebo
62375837|NCT01234311|EXPERIMENTAL|tasquinimod|Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
62375838|NCT06101680||Children in intensive care with rhabdomyosis|
62375839|NCT02960308||Diagnostic (WNCTP scan)|Patients undergo WNCTP scan over 2-3 minutes during standard of care CT.
62375840|NCT03826992|EXPERIMENTAL|Venetoclax and Vyxeos combination|"Venetoclax will be given orally on Days per the assigned dose level. A single course consisting of 3 doses of Vyxeos and 7-21 doses of venetoclax depending on the assigned dose level will be administered to participants in this study. Vyxeos will be administered by central venous catheter over 90 minutes on Day 1, 3, and 5.~Venetoclax is given daily by mouth per assigned dose level."
62375841|NCT04112745|EXPERIMENTAL|Experimental group|
62375842|NCT04112745|PLACEBO_COMPARATOR|Control group|
62375843|NCT02828189|ACTIVE_COMPARATOR|Physical Exercise|"The protocol consists in:~* Physical Exercise according to their preferences.~* Therapeutic Education related to Health Habits and Physical Exercise."
62375844|NCT02828189|EXPERIMENTAL|Therapeutic Exercise-Physiotherapy|"The protocol consists in:~* Cardiovascular exercise.~* Force-Resistance Exercises of the principals muscle groups of the lower limbs, upper limbs and trunk.~* Muscle Stretches.~* Therapeutic Education related to Health Habits and Physical Exercise."
62375845|NCT01755260|NO_INTERVENTION|oral intake|The patients at this arm were allowed to take food through mouth
62375846|NCT05714254|ACTIVE_COMPARATOR|MEDI0618|A human immunoglobulin antibody to the Protease Activated Receptor 2 (PAR2)
62375847|NCT05714254|PLACEBO_COMPARATOR|Placebo|Histidine/histidine HCl, sucrose and polysorbate
62375848|NCT03615664|EXPERIMENTAL|BGD therapy|Bendamustine, Gemcitabine, Dexamethasone
62375849|NCT03931590|EXPERIMENTAL|Healthy Male Subjects|Single oral dose of 150 mg of \[14C\] omaveloxolone containing approximately 90 μCi as a capsule after an overnight fast of at least 10 hours.
62375850|NCT02165644|EXPERIMENTAL|Acetazolamide|"Acetazolamide 250 mg QID oral for 4 days along with current standard of care which is Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.~If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration."
62375851|NCT02165644|ACTIVE_COMPARATOR|Standard of care|Subjects will receive only standard of care for subarachnoid hemorrhage which will include Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.
62375852|NCT01228838|EXPERIMENTAL|NGX-1998, 10% w/w capsaicin|
62375853|NCT01228838|EXPERIMENTAL|NGX-1998, 20% w/w capsaicin|
62375854|NCT01228838|PLACEBO_COMPARATOR|Placebo liquid|
62375855|NCT01938768||Tranexamic acid|patients with multiple trauma who received tranexamic acid on the scene
62375856|NCT01938768||Non tranexamic acid|patients with multiple trauma who did not receive tranexamic acid on the scene
62375857|NCT03733132|PLACEBO_COMPARATOR|Placebo|Participants in placebo group will receive Placebo Oral Tablets identical to the metformin tablets for 10 months.
62375858|NCT03733132|ACTIVE_COMPARATOR|Metformin|Participants in placebo group will receive an escalating dose of Metformin hydrochloride tablets up to a dose of 2500mg for 10 months.
62375859|NCT02177786|EXPERIMENTAL|Selonsertib 2 mg|Participants will receive selonsertib 2 mg for 48 weeks.
62375860|NCT02177786|EXPERIMENTAL|Selonsertib 6 mg|Participants will receive selonsertib 6 mg for 48 weeks.
62375861|NCT02177786|EXPERIMENTAL|Selonsertib 18 mg|Participants will receive selonsertib 18 mg for 48 weeks.
62375862|NCT02177786|PLACEBO_COMPARATOR|Placebo to match selonsertib|Participants will receive placebo to match selonsertib for 48 weeks.
62375863|NCT00402285|ACTIVE_COMPARATOR|lycopene supplement|Two 15mg lycopene capsules daily for 3 months.
62375864|NCT00402285|ACTIVE_COMPARATOR|fish oil supplement|1g fish oil capsule daily for 3 months.
62375865|NCT00402285|PLACEBO_COMPARATOR|placebo|placebos for lycopene and fish oil.
62375866|NCT04904640||CLS stem|CLS Zimmer stem implantation (single wedge, tapered stem) using the 3D CT based software for surgical pre-operative planning
62375867|NCT04904640||Wagner cone stem|Wagner cone Zimmer stem implantation (conical tapered stem) using the 3D CT based software for surgical pre-operative planning
62375868|NCT04904640||Aptafix stem|Aptafix Ortho stem implantation (anatomical stem) using the 3D CT based software for surgical pre-operative planning
62375869|NCT02530827||LIPO-HIPO-|HIV-seropositive without lipodystrophy and no use of lipid-lowering drugs.
62375870|NCT02530827||LIPO+HIPO-|HIV-seropositive with lipodystrophy and no use of lipid-lowering drugs.
62375871|NCT02530827||LIPO+HIPO+|HIV-seropositive with lipodystrophy and use of lipid-lowering drugs.
62375872|NCT06491992|EXPERIMENTAL|study group|Chitosan Phonophresis intervention
62375873|NCT06491992|EXPERIMENTAL|control group|the selected exercise program
62375874|NCT03520426|EXPERIMENTAL|Votiva RF|Patients will undergo radiofrequency treatment using the Votiva FormaV and FractoraV hand pieces, using the device's standard protocol. Patients will have 3 treatments spaced 3-4 weeks apart and two follow-up visits. Duration of each treatment visit is approximately 1-1.5 hours. Prior to treatment and follow-up visit, each patient will be assessed using standardized photos, perineometry, and validated questionnaires.
62375875|NCT03520426|SHAM_COMPARATOR|Votiva RF Sham|Patients will undergo the acts of receiving radiofrequency treatment with the Votiva FormaV and FractoraV hand pieces, but no direct energy will be applied. Patients will have 3 treatments spaced 3-4 weeks apart and 2 follow-up visits. Duration of each treatment visit is approximately 1-1.5 hours. Prior to treatment and follow-up visit, each patient will be assessed using standardized photos, perineometry, and validated questionnaires.
62375876|NCT03261037|OTHER|Participants With Suspicion of IPF/ILD|A participant will be eligible for inclusion if the Investigator has a suspicion that the participant may have IPF/ILD based on symptoms and radiological evidence.
62375877|NCT02049294|ACTIVE_COMPARATOR|Omalizumab (Xolair)|Dosage/frequency is dependent on body weight (kg) and baseline blood IgE level.
62375878|NCT02049294|PLACEBO_COMPARATOR|Placebo (Normal Saline)|0.9% normal saline equivalent to the dosage/frequency/duration of Omalizumab
62375879|NCT04366739|EXPERIMENTAL|CHLORPROMAZINE (CPZ)|Standard of Care (SOC) plus CHLORPROMAZINE (CPZ)
62375880|NCT04366739|ACTIVE_COMPARATOR|standard of care (SOC)|"In the absence of a reference treatment in COVID-19, the standard of care (SOC) is the comparator arm"
62375881|NCT04081051|EXPERIMENTAL|Intervention|Diagnostic algorithm( paper and electronic) utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change training for healthcare workers
62375882|NCT04081051|NO_INTERVENTION|control|Standard of care practices for acute febrile illness
62375883|NCT01958710||Embolisation|(preoperative) embolisation of the bronchial circulation
62375884|NCT01958710||Surgery|Any surgically treated patient with a functional lung resection (at least wedge resection)
62375885|NCT04096404|NO_INTERVENTION|Control|no advice
62375886|NCT04096404|ACTIVE_COMPARATOR|Non genetic personalised advice|dietary and physical activity advice based on reported dietary intake and physical activity
62375887|NCT04096404|EXPERIMENTAL|Genotype- based personalised advice|dietary and physical activity advice based on genotype, reported dietary intake and physical activity
62375888|NCT04700228|PLACEBO_COMPARATOR|Group C|0.25% bupivacaine at a total volume of 0.5ml/kg.
62375889|NCT04700228|ACTIVE_COMPARATOR|Group BD1|0.25% bupivacaine + 1mcg/kg dexmedetomidine at a total volume of 0.5ml/kg.
62375890|NCT04700228|ACTIVE_COMPARATOR|Group BD2|0.25% bupivacaine + 0.5mcg/kg dexmedetomidine at a total volume of 0.5ml/kg.
62751750|NCT02105493|ACTIVE_COMPARATOR|500 microgram of Nitroglycerin|500 mcg nitroglycerin was given intra-arterially through the sheath at the end of a transradial procedure
62751751|NCT02105493|PLACEBO_COMPARATOR|Saline 5 mL|0,9% Saline 5 mL was given intra-arterially through the sheath at the end of a transradial procedure
62751752|NCT01280058|EXPERIMENTAL|Arm I (wild-type reovirus, carboplatin, paclitaxel)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and wild-type reovirus IV over 60 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62751753|NCT01280058|EXPERIMENTAL|Arm II (carboplatin, paclitaxel)|Patients receive paclitaxel and carboplatin as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.
62375891|NCT00621244|EXPERIMENTAL|Arm 1, Group X|
62375892|NCT00621244|EXPERIMENTAL|Arm 1, Group Y|
62375893|NCT00621244|EXPERIMENTAL|Arm 2, Group X|
62375894|NCT00621244|EXPERIMENTAL|Arm 2, Group Y|Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week, as part of a 28-day treatment cycle. Group Y is a sub-arm, based on disease indication.
62375895|NCT03450486|EXPERIMENTAL|affected limb|measurements of balance from the affected side of individuals with unilateral knee osteoarthritis following an exercise session
62751754|NCT02281786|EXPERIMENTAL|Cohort 1|8 volunteers (6 active, 2 placebo)
62751755|NCT02281786|EXPERIMENTAL|Cohort 2|8 volunteers (6 active, 2 placebo)
62751756|NCT02281786|EXPERIMENTAL|Cohort 3|8 volunteers (6 active, 2 placebo)
62751757|NCT02281786|EXPERIMENTAL|Cohort 4|8 volunteers (6 active, 2 placebo)
62375896|NCT03450486|ACTIVE_COMPARATOR|unaffected limb|measurements of balance from the unaffected side of individuals with unilateral knee osteoarthritis following an exercise session
62375897|NCT03333512|EXPERIMENTAL|Nap|After each night with a 5-hour sleep opportunity, participants have a daytime nap opportunity of 1.5 hours.
62375898|NCT03333512|NO_INTERVENTION|No nap|After each night with a 6.5-hour sleep opportunity, participants do not have a daytime nap opportunity, but instead watch documentaries.
62375899|NCT02896751|EXPERIMENTAL|3D Printed NIV Mask|3D imaging and use of a custom mask from 3D printer
62375900|NCT03338452|EXPERIMENTAL|participants|The participants will be subjected to low energy ketogenic diet.
62375901|NCT00547989|ACTIVE_COMPARATOR|1|control
62567523|NCT05182060|EXPERIMENTAL|Transition Intervention|"We will implement a bundle of care transition safety resources with the assistance of home health coordinators at the study site.~These resources include a link to a video about home health services, a caregiver assessment, a care task role assignment sheet, and a shopping list."
62375902|NCT00547989|EXPERIMENTAL|2|PVB with ropivacaine and postoperative pump 5ml/h
62375903|NCT00547989|EXPERIMENTAL|Experimental 1|PVB with ropivacaine, 10 patients included but not analysed
62375904|NCT03797144|EXPERIMENTAL|Fenestrated Screw System|
62375905|NCT02663245|EXPERIMENTAL|Intervention 1|Diabetes specific consultation + multicomponent intervention aimed at professionals and patients
62375906|NCT02663245|EXPERIMENTAL|Intervention 2|Multicomponent intervention aimed at professionals and patients minus the diabetes specific consultation.
62375907|NCT02663245|NO_INTERVENTION|Control group|No intervention. Data of the control groups will be retrieved from the SIDIAP.
62375908|NCT06164743|EXPERIMENTAL|VVN461 1.0%|VVN461 Ophthalmic Solution, 1.0%
62375909|NCT06164743|EXPERIMENTAL|VVN461 0.5%|VVN461 Ophthalmic Solution, 0.5%
62375910|NCT06164743|PLACEBO_COMPARATOR|Vehicle|VVN461 Vehicle
62751758|NCT02281786|EXPERIMENTAL|Cohort 5|8 volunteers (6 active, 2 placebo)
62751759|NCT02281786|EXPERIMENTAL|Cohort 6|8 volunteers (6 active, 2 placebo)
62375911|NCT03042195|ACTIVE_COMPARATOR|Intervention group|Supplementary parenteral nutrition
62375912|NCT03042195|NO_INTERVENTION|Control group|The control group will receive standard nutritional care
62567524|NCT05182060|NO_INTERVENTION|Control|"We will select other home health provider teams that provide care to similar populations to serve as concurrent controls.~No interventions will be administered."
62751760|NCT02109432|OTHER|Pedal Desk|"Participants will complete three 2-week conditions in the following order:~1. Self-directed Pedal Desk~2. Facilitated Pedal Desk~3. Facilitated Pedal Desk with Pedometer"
62375913|NCT00369408|EXPERIMENTAL|1|naltrexone (50 mg orally) for 12-week treatment period
62375914|NCT00369408|PLACEBO_COMPARATOR|2|placebo for 12-week treatment period
62375915|NCT00081263|EXPERIMENTAL|Arm I (celecoxib)|Patients receive oral celecoxib once daily for 14-18 weeks.
62375916|NCT00081263|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive oral placebo once daily for 14-18 weeks.
62567525|NCT00605618|EXPERIMENTAL|Single Arm|
62567526|NCT02224651|EXPERIMENTAL|(1-1000mg) Immediate Release formulation|
62567527|NCT02224651|PLACEBO_COMPARATOR|Immediate Release Placebo arm|
62751761|NCT02927704||case (Aggressive periodontitis)|Single intervention has been performed for each subject. Gingival crevicular fluid sample was obtained in conjunction with clinical measurements in this intervention.
62751762|NCT02927704||control (Periodontally healthy subjects)|Single intervention has been performed for each subject. Gingival crevicular fluid sample was obtained in conjunction with clinical measurements in this intervention.
61986440|NCT04989400|EXPERIMENTAL|ulipristal group|received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal according to FIGO guidelines 2017,Then women had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy
62751763|NCT01025349|EXPERIMENTAL|metastatic breast cancer|Patients with histological or cytological proven metastatic breast cancer were recruited. The previous hormonal therapy for metastatic breast cancer or cytotoxic therapy was allowed. The Her2/Neu over-expressive status should be negative. Patients with brain metastasis are excluded.
62751764|NCT03584997|EXPERIMENTAL|PRF , ABB & Autogenous Particulate|Platelets rich fibrin + anorganic bovine bone + autogenous particulate graft
62751765|NCT03584997|ACTIVE_COMPARATOR|ABB And Autogenous Particulate|anorganic bovine bone +autogenous particulate graft
62751766|NCT02829736|ACTIVE_COMPARATOR|Chest tube group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with a standard post-operative chest tube.
62751767|NCT02829736|EXPERIMENTAL|No chest tube group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with intraoperative chest tube removal.
62751768|NCT04149158|PLACEBO_COMPARATOR|Placebo|
62751769|NCT04149158|EXPERIMENTAL|Verum|Sinetrol® Xpur
62751770|NCT06170346|EXPERIMENTAL|Antioxidant|30 drops of topical antioxidants (Gluconolactone 4%, Hyaluronic acid 0,01%, Allantoin 0,1%, Ferulic acid 3%, Acetyl heptapeptide 0,001%, Silver vine extract 1%, Ectoine 0,01%, Hydroxyectoine 0,01%, and vehicle) will be applied on tested area on each participant for four consecutive days. On the fifth day, the subject will be irradiated on the tested area. After irradiation, erythema intensity and skin biopsy will be taken. Furthermore, skin tissue will be stained to see sunburn cells and assesses the expression of MMP-9, Thymine Dimer, and p-53 by immunohistochemistry.
62751771|NCT06170346|PLACEBO_COMPARATOR|Vehicle|30 drops of topical vehicle (Aqua, Dipropylene glycol, Hydroxypropyl cyclodextrin, Polydextrose, 1,2-hexanediol, Butylene glycol, Propanediol, Caprylhydroxamic acid, Ethylhexylglycerin, Xanthan gum, Benzyl alcohol, Glyceryl caprylate, and Benzoic acid) will be applied on tested area on each participant for four consecutive days. On the fifth day, the subject will be irradiated on the tested area. After irradiation, erythema intensity and skin biopsy will be taken. Furthermore, skin tissue will be stained to see sunburn cells and assesses the expression of MMP-9, Thymine Dimer, and p-53 by immunohistochemistry.
62751772|NCT06170346|NO_INTERVENTION|Control|Skin without intervention and irradiation. Skin biopsy will be taken as a control. Skin tissue will be stained to see sunburn cells and assesses the expression of MMP-9, Thymine Dimer, and p-53 by immunohistochemistry.
62751773|NCT02657655|EXPERIMENTAL|Kinesia 360 Users|Parkinson's patients will be monitored continuously using wearable Kinesia 360 sensors.
62751774|NCT03905239|EXPERIMENTAL|algorithm arm|Patient management is based on clinical examination and procalcitonin assessment. From 48 hours after initiation of conservative management in the case of absence of bowel function, operative management (adhesiolysis or bowel resection) will be performed. In the event of discordance between procalcitonin values and clinical examination, management will always be based on clinical examination.
62751775|NCT03905239|NO_INTERVENTION|no algorithm arm|Patient management is based on clinical examination. Conservative management will be continued for 48 hours in the absence of signs of bowel ischemia (clinical and laboratory assessment other than procalcitonin, as procalcitonin will not be assayed in this arm). Gastrografin will not be used in this arm. Operative management (adhesiolysis or bowel resection) will be performed 48 hours after initiation of conservative management or in the case of absence of bowel function.
62751776|NCT00489424|EXPERIMENTAL|Acetaminophen|2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
62751777|NCT00489424|EXPERIMENTAL|Fluvastatin|2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
62751778|NCT00489424|PLACEBO_COMPARATOR|Placebo|2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
62751779|NCT03828422||patients with essential thrombocythemia|"* essential thrombocythemia with JAK2 V617F positive mutation~* patients from the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F positive ET between 2011 and 2014~* no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)~* all signed the informed consent~* examined twice, the first time in the years 2014-2015 and for the second time in the years 2018-2019~* blood for laboratory tests~* imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning"
62751780|NCT03828422||control group|"* the control group is selected among healthy employees of the University Medical Centre Ljubljana and their relatives~* they are matched with the patient group for age and sex distribution and classical risk factors for cardiovascular disease~* no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)~* all signed the informed consent~* blood for laboratory tests~* examined twice, the first time in the years 2014-2015 and for the second time the in years 2018-2019~* imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning"
62375917|NCT05126550||Immunogenicity|Group 1 constitutes the immunogenicity group which will be evaluated regarding immunogenicity, safety, and effectiveness of the SARS-CoV-2 vaccine (Vero cell) inactivated produced by Sinopharm
62375918|NCT05126550||Non-Immunogenicity|Group 2 that constitutes the non-immunogenicity group which will be evaluated regarding only safety and effectiveness of the aforementioned vaccine
62375919|NCT00218452|EXPERIMENTAL|Lifestyle counseling|
62375920|NCT04721275||Sepsis on the elderly population in ED|The elderly population is defined as patients over 65 years old of age.
62375921|NCT04721275||Sepsis on the non-elderly population in ED|The non-elderly population is defined as patients aged of 18 to 64 years old.
62375922|NCT01940549|SHAM_COMPARATOR|Trauma Focused Therapy + Sham tDCS|Trauma Focused Therapy will be conducted during the delivery of sham Transcranial Direct Current Stimulation
62375923|NCT01940549|ACTIVE_COMPARATOR|Trauma Focused Therapy + active tDCS|Trauma focused therapy will be conducted while active Transcranial Direct Current Stimulation is applied
62375924|NCT03817749|EXPERIMENTAL|Experimental|"* Participants will consume 20 g of an active oral exogenous ketone monoester supplement 15 minutes prior to each meal of the day for a 14-day period.~* Pre-intervention (baseline) and post-intervention measurements will be obtained before and immediately after the 14-day period.~* All meals will be provided throughout the supplementation period~* Participants will wear a continuous glucose monitor for 6 consecutive days during the supplementation period."
62375925|NCT03817749|PLACEBO_COMPARATOR|Placebo|Participants will consume a flavor matched placebo drink and undergo the same procedures described in the Experimental Arm
62751781|NCT06020066|EXPERIMENTAL|3rd generation EGFR-TKI+SRS|The experimental arm will undergo stereotactic radiotherapy targeting all residual lesions in the brain (completed in a single or multiple treatment courses within one month), while continuing EGFR-TKI therapy until disease progression or intolerable toxicity occurs.
62751782|NCT06020066|ACTIVE_COMPARATOR|3rd generation EGFR-TKI|The control group will receive 3rd generation EGFR-TKI until disease progression or intolerable toxicity occurs.
62751783|NCT02918396|ACTIVE_COMPARATOR|Conventional PVI|Conventional PVI by Radio-frequency Ablation: Wide area circumferential pulmonary vein isolation (PVI) only (current standard of care) using radio-frequency ablation catheters.
62751784|NCT02918396|EXPERIMENTAL|PVI + Scar-based ablation|Scar-Based Radio-frequency Ablation: Pulmonary vein isolation followed by targeting, using radio-frequency ablation, of dense LGE sites on MRI, which are confirmed on bipolar mapping to have voltage \<0.3 mV.
62751785|NCT02918396|EXPERIMENTAL|PVI + Modeling-predicted rotors ablation|Rotor Anchors Radio-frequency Ablation: Pulmonary vein isolation followed by radio-frequency ablation of rotor anchors predicted by modeling.
62751786|NCT00675818|EXPERIMENTAL|1|CVVH: Patients in this arm will receive CVVH at a replacement fluid rate of 35 mL/kg/h.
62375926|NCT05465967|SHAM_COMPARATOR|Group I: Control Group|Patients in this group will receive ipsilateral sham ultrasound-guided block via subcutaneous injection of 1 ml of normal saline after surgery.
62375927|NCT05465967|ACTIVE_COMPARATOR|Group II:( transverse trans muscular Quadratus lumborum group).|patients in this group will receive an ipsilateral single-shot of paraspinous sagittal approach of Quadratus lumborum BLOCK(30 ml of plain bupivacaine 0.25%) after surgery using ultrasonographic guidance.
62375928|NCT05465967|ACTIVE_COMPARATOR|Group III : paraspinous sagittal approach of Quadratus lumborum BLOCK|patients in this group will receive an ipsilateral single-shot of paraspinous sagittal approach of Quadratus lumborum BLOCK (30 ml of plain bupivacaine 0.25%) after surgery using ultrasonographic guidance.
62375929|NCT01551485|EXPERIMENTAL|Zolpidem|
62375930|NCT01551485|PLACEBO_COMPARATOR|Placebo|
62375931|NCT02844322|EXPERIMENTAL|Bortezomib|Patients in this group will receive bortezomib+ cyclophosphamide+ dexamethasone as introduction chemotherapy regimen. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better response achieves, addition 3 cycles will be given. If not, patients will cross to RCD group for another 3 cycles. If a PR or better response comes out, addition 3 cycles will be given, otherwise, the patient will quit this study.
62567528|NCT02224651|EXPERIMENTAL|(10-500) mg Modified Release formulation|
62567529|NCT02224651|PLACEBO_COMPARATOR|Modified Release Placebo arm|
62567530|NCT06578793|EXPERIMENTAL|Catheter ablation combined with Marshall vein ethanol ablation group|"Participants in this group will undergo standard catheter ablation, which involves the isolation of the pulmonary veins and may include additional ablation of other atrial areas as necessary, guided by fluoroscopy and/or 3D electroanatomical mapping. In addition to the standard ablation procedure, participants will receive Marshall vein ethanol ablation. This involves the injection of absolute ethanol into the Marshall vein via a specialized catheter, aiming to ablate the vein's myocardial sleeves and adjacent autonomic fibers. The ethanol ablation targets arrhythmogenic substrates and aims to enhance the efficacy of the overall ablation procedure by reducing atrial fibrillation triggers.~This combined approach is hypothesized to improve clinical outcomes by providing a more comprehensive treatment of atrial fibrillation substrates, particularly in patients with persistent atrial fibrillation and concomitant heart failure."
62567531|NCT06578793|ACTIVE_COMPARATOR|Catheter ablation alone group|"Participants in this group will undergo standard catheter ablation, which primarily involves the isolation of the pulmonary veins, a common trigger site for atrial fibrillation. The procedure may include additional ablation of other atrial areas based on the patient's specific arrhythmogenic substrate. The catheter ablation will be performed under fluoroscopic guidance and/or with the assistance of 3D electroanatomical mapping to ensure precision. This procedure is designed to eliminate or reduce the arrhythmogenic tissue within the atria to restore and maintain normal sinus rhythm.~This intervention is the comparator arm in the study, representing the current standard treatment for persistent atrial fibrillation, particularly in patients with concomitant heart failure."
62567532|NCT04825691||cases diagnosed as prostatic acinar adenocarcinoma|
62567533|NCT04888793||Cancer Patients on active treatment|
62375932|NCT02844322|EXPERIMENTAL|rituximab|Patients in this group will receive rituximab+cyclophosphamide+ dexamethasone as introduction chemotherapy regimen. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better response achieves, addition 3 cycles will be given. If not, patients will cross to BCD group for another 3 cycles. If a PR or better response comes out, addition 3 cycles will be given, otherwise, the patient will quit this study.
62375933|NCT06282302|EXPERIMENTAL|Group control|The control session will consist of keeping the volunteer sitting in a calm, air-conditioned environment for 40 minutes.
62375934|NCT06282302|EXPERIMENTAL|Isometric Exercise|The intervention with isometric exercise for the lower limbs, the volunteers will start in a vertical position, with shoulders and hips in contact with the wall, feet parallel and shoulder-width apart and hands at the sides of the body. Then (second phase), the volunteers, maintaining contact with the wall, squatted and advanced their feet in the desired position until the knee joint angle reached the previously determined value. The third phase referred directly to the isometric effort of the isometric exercise session. For the isometric wall squat exercise session, volunteers will be asked to perform 4 repetitions of 2 minutes, with a 2-minute rest interval in a seated position for adequate rest between each repetition.
62375935|NCT06282302|EXPERIMENTAL|Aerobic Exercise|Volunteers will perform 50 minutes of horizontal exercise cycling (brand: pro-user), continuously and at moderate intensity (50% to 60% of HR reserve).
62375936|NCT05704595|OTHER|Initial outpatient management strategy, including outpatient IV diuretics in clinic|
62375937|NCT05704595|OTHER|Initial hospitalization-based management strategy|
62375938|NCT05613491|EXPERIMENTAL|Intranasal insulin group|Before anesthesia induction, give the first insulin nasal spray, once per hour, 20 IU each time, until the end of the operation
62375939|NCT05613491|PLACEBO_COMPARATOR|Saline group|Before anesthesia induction, give the equal volumes'saline nasal spray, once per hour, 20 IU each time, until the end of the operation
62375940|NCT00381108|EXPERIMENTAL|Pomegranate Tablet|
62375941|NCT00381108|PLACEBO_COMPARATOR|Placebo Tablet|
62375942|NCT02181504|EXPERIMENTAL|abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
62375943|NCT02181504|EXPERIMENTAL|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
62375944|NCT02181504|ACTIVE_COMPARATOR|ranibizumab 0.5 mg|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
62751787|NCT00675818|ACTIVE_COMPARATOR|2|CVVHD: Patients in this arm will receive CVVHD at a dialysate flow rate of 35 mL/kg/h.
62751788|NCT06439433|EXPERIMENTAL|ALA A Group|ALA 500mg Group
62751789|NCT06439433|EXPERIMENTAL|ALA B Group|ALA 750mg Group
62751790|NCT06439433|PLACEBO_COMPARATOR|Placebo|Placebo Group
62751791|NCT06314477|ACTIVE_COMPARATOR|Conservative treatment|Subjects allocated to this arm will receive hygienic and dietary measures counselling
62751792|NCT06314477|EXPERIMENTAL|CPAP treatment|Subjects allocated to this arm will receive treatment with continuous positive airway pressure (CPAP)
62751793|NCT03600636|OTHER|Control|
62751794|NCT03600636|OTHER|antiphospholipid syndrome patients|
62751795|NCT05166278|EXPERIMENTAL|EXPER|Deescalation training.
62751796|NCT05166278|NO_INTERVENTION|CONTR|Management of aggressive behaviour as usual.
62751797|NCT06367686||Chronic obstructive pulmonary disease|3 Chronic obstructive pulmonary disease patients monitored with IscAlert sensor at nasal mucosa for 8-14 hours during the night
62751798|NCT06367686||Neuromuscular disease|3 Neuromuscular disease patients monitored with IscAlert sensor at nasal mucosa for 8-14 hours during the night
62751799|NCT06367686||Obesity hypoventilation syndrome|3 Obesity hypoventilation syndrome patients monitored with IscAlert sensor at nasal mucosa for 8-14 hours during the night
62751800|NCT06367686||Healthy volunteers|2 healthy volunteers monitored with IscAlert sensor at nasal mucosa for approximately 8 hours during daytime
62375945|NCT04248556|EXPERIMENTAL|subjects, 18-59 y, healthy|patch test with investigation product
62375946|NCT05997173||Control|Normal control group
62375947|NCT05997173||Non erosive OLP|Non erosive oral lichen planus
62375948|NCT05997173||Erosive OLP|Erosive oral lichen planus
62375949|NCT02238236||Patients with allergic rhinitis, eczema/dermatitis, urticaria|
62567534|NCT04888793||Bone marrow transplant patients|
62567535|NCT04888793||Solid organ transplant recipients|
62567536|NCT04888793||HIV patients|
62567537|NCT04888793||Rheumatic disease patients|
62567538|NCT04888793||Healthy controls|
62567539|NCT05820815|EXPERIMENTAL|in-bed self-exercises based on EMG-sensor feedback intervention|Conventional rehabilitation corresponds to general rehabilitation for lower extremity motor function in stroke patients and is mainly performed according to functional mobility with a range of motion. This includes lying down, standing, walking, and balance training. Additional in-bed self-exercises based on EMG-sensor feedback with conventional rehabilitation.
62567540|NCT05820815|NO_INTERVENTION|Conventional rehabilitation|Conventional rehabilitation corresponds to general rehabilitation for lower extremity motor function in stroke patients and is mainly performed according to functional mobility with a range of motion. This includes lying down, standing, walking, and balance training.
62567541|NCT01672502|EXPERIMENTAL|Intervention|Firefighters in this group will receive at the beginning of the study an introduction to the study, sleep education, sleep disorder screening survey, health survey, increased sleep opportunities at their fire department, followed later by physiological monitoring of a portion of the firefighters, and then finally an 'end of year' survey at the end of the study.
62567542|NCT01672502|ACTIVE_COMPARATOR|Control|Firefighters in this group will only receive an introduction to the study and a health survey, followed later by physiological monitoring of a portion of the firefighters, and then at the end of the study will receive the sleep disorders screening survey, sleep education (Intervention group received screening survey and education much earlier at the beginning of the study), and an 'end of year' survey. None of these firefighters will receive the increased sleep opportunities as the Intervention group will.
62375950|NCT01408732|EXPERIMENTAL|Standard Treatment then Sclerotherapy Intervention|"The standard treatment group will continue their pre-study standard treatment methods to treat epistaxis on the first 6 weeks of the study, followed by intervention with sclerotherapy on the second 6 weeks of the study, plus any additionally needed standard treatments for breakthrough epistaxis. Wash out period 2 weeks"
62375951|NCT01408732|EXPERIMENTAL|Sclerotherapy Intervention then Standard Treatment'|This group will receive, on the first 6 weeks of the study, sclerotherapy with STS to any visible lesions in the nose at the outset, followed by any needed standard treatments for breakthrough epistaxis. On the second 6 weeks of the study this group will continue with standard treatments that they had been receiving for epistaxis prior to the study. Wash out period of two weeks
62375952|NCT03540641|ACTIVE_COMPARATOR|1500 pulses|This group will receive 1500 pulses of transcranial magnetic stimulation at 5Hz over the left dorsolateral prefrontal cortex, until completing 15 sessions
62375953|NCT03540641|SHAM_COMPARATOR|1500 pulses sham|this group will receive the sham modality of the protocol of 1500 pulses at 5Hz of transcranial magnetic stimulation during 15 sessions.
62375954|NCT03540641|ACTIVE_COMPARATOR|5000 pulses|This group will receive 5000 pulses of transcranial magnetic stimulation at 5Hz over the left dorsolateral prefrontal cortex, until completing 15 sessions.
62375955|NCT03540641|SHAM_COMPARATOR|5000 pulses sham|this group will receive the sham modality of the protocol of 5000 pulses at 5Hz of transcranial magnetic stimulation during 15 sessions.
62375956|NCT01200563|ACTIVE_COMPARATOR|Group 1|Subjects assigned to receive MIST Therapy will be treated 3 times per week. The duration of each MIST treatment will be dependent on the wound's area measured at baseline and at each weekly assessment.
62375957|NCT01200563|ACTIVE_COMPARATOR|Group 2|Subjects assigned to receive Negative Pressure Wound Therapy will be treated with the Vacuum Assisted Closure system. For administration of this study treatment, e.g., treatment cycle, target pressure and dressing changes, the manufacturer's recommended guidelines will be followed.
62375958|NCT01200563|ACTIVE_COMPARATOR|Group 3|Subjects assigned to this group will receive MIST Therapy treatments and Negative Pressure Wound Therapy.
62375959|NCT00705380|EXPERIMENTAL|1|Participants will receive cognitive behavioral therapy with panic control treatment.
62375960|NCT00705380|ACTIVE_COMPARATOR|2|Participants will receive cognitive behavioral therapy with panic control treatment after a 12-week waitlist period.
62751801|NCT05285618|EXPERIMENTAL|Predicting the perceptual experience of retinal prosthesis patients|This intervention will assess the effect of different stimulation strategies on the perceptual experience of retinal prosthesis patients. We will produce visual percepts in patients either by directly stimulating electrodes (using FDA-approved pulse trains) or by asking them to view a computer or projector screen and using standard FDA-approved stimulation protocols (as is standardly used for their devices) to convert the computer or projector screen image into pulse trains on their electrodes. Existing blind users of the Argus II will be recruited for this study. Performance of Argus II users will be compared to performance of sighted subjects viewing a prosthetic vision simulation in virtual reality.
62375961|NCT06220188|EXPERIMENTAL|Biochemical recurrent prostate cancer but not radio-morphological local recurrence|Patients with prostate cancer and confirmed biochemical recurrence with PSA of ≥ 0.2 ng/ml after radical prostatectomy or PSA \> nadir + 2ng/ml after radiotherapy but not radio-morphological local recurrence after primary therapy with curative intent will receive systemic therapy with \[177Lu\]Lu-PSMAI\&T radioligand therapy
62375962|NCT06225141||Patients|
62375963|NCT06225141||Controls|
62375964|NCT04116619||Individuals with Cannabis Use Disorder|Participants who meet criteria for Cannabis Use Disorder will complete three guided imagery conditions (stress, cannabis, neutral) in an inpatient research unit. During the guided imagery, repeated measurements of subjective (i.e., craving, negative affect), neuroendocrine (i.e., cortisol), and physiological variables (i.e., heart rate variability \[HRV\]) will be collected.
62567543|NCT02863185|EXPERIMENTAL|Pitavastatin group|Use of 2mg or 4mg Pitavastatin
62567544|NCT02863185|ACTIVE_COMPARATOR|Atorvastatin group|Use of 10mg or 20mg Atorvastatin
62567545|NCT04491825||Mycosis fungoides (MF)|
62567546|NCT04491825||Eczema (Atopic Dermatitis)|
62567547|NCT04491825||Chronic Plaque-Psoriasis|
62567548|NCT04491825||Healthy Control Skin|
62375965|NCT04116619||Light Cannabis Users|Participants who are light cannabis users (\<1 joint/week) will complete three guided imagery conditions (stress, cannabis, neutral) in an inpatient research unit. During the guided imagery, repeated measurements of subjective (i.e., craving, negative affect), neuroendocrine (i.e., cortisol), and physiological variables (i.e., heart rate variability \[HRV\]) will be collected.
62751802|NCT03457142|EXPERIMENTAL|Treatment (abatacept, ixazomib citrate, dexamethasone)|Patients receive abatacept IV over 30 minutes on day 1 of course 1, then SC on days 2, 8, 15, and 22 of course 1, and then on days 1, 8, 15, and 22 of subsequent courses. Patients also receive ixazomib citrate PO QD on days 1, 8, and 15 and dexamethasone on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62751803|NCT01304212|ACTIVE_COMPARATOR|femoral block|
62751804|NCT01304212|EXPERIMENTAL|local infiltration + femoral nerve block|Combination of local infiltration with drugs and femoral nerve block
62375966|NCT02361073||Takotsubo|
62375967|NCT02361073||Healthy|
62375968|NCT02361073||ACS|
62375969|NCT03163940|EXPERIMENTAL|Laughter Yoga (LY) Group|The LY session will be offered twice weekly, for 45 minutes each time. Each participant will be asked to attend a total of 8 groups (over 4 weeks).
62375970|NCT03163940|NO_INTERVENTION|Treatment-as-usual (TAU)|The TAU will receive their usual routine community mental health care (including medications) and attend medical outpatient appointments as determined by their individual needs.
62375971|NCT03735017|ACTIVE_COMPARATOR|Non-Interactive|Participants will receive non-interactive virtual reality walking sessions.
62375972|NCT03735017|EXPERIMENTAL|Interactive|Participants will receive interactive virtual reality walking sessions.
62375973|NCT03114462|EXPERIMENTAL|Stereotactic Hypofractionated Radioablation (HYDRA)|"Participants receive HYDRA radiation on up to 5 days over the course of about 2 weeks, and for a total of 5 times.~Questionnaires completed at Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years."
62375974|NCT04576663|PLACEBO_COMPARATOR|Control group|Normal saline infusion simultaneous with subarachnoid block
62375975|NCT04576663|EXPERIMENTAL|0.3125 μg/kg/min group|A maintenance dose of phenylephrine (0.3125 μg/kg/ min) infusion simultaneous with subarachnoid block
62751805|NCT01304212|ACTIVE_COMPARATOR|several drugs local infiltration|
62751806|NCT04131387|EXPERIMENTAL|Test Group|After installing the disposable treatment head coat, the pelvic floor muscles, ligaments, etc. were treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Treated twice a week for 6 weeks.
62751807|NCT04131387|PLACEBO_COMPARATOR|Control Group|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
62751808|NCT03526809||Ovarian cancer patients|MRI and FDG-PET imaging
62751809|NCT04549805||Patients without myocardial injury|Patients without myocardial injury will be recruited in a 2:1 fashion stratified by peak high-sensitivity cardiac troponin I concentration above and below a threshold of 5 ng/L.
62751810|NCT02727387|EXPERIMENTAL|TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL|2cycles of Temozolomide(500 mg/m2)+Irinotecan(250 mg/m2) and 2cycles of Vincristine(1.4mg/m2)+ Adriamycin(90mg/m2)+Ifosfamide (9gr/m2) alternes with 2 cycles of Ciclofosfamide(4g/m2)+Etoposide (600mg/m2) followed by radiotherapy (42-54 Gy) and 2cycles of Ifosfamide (9gr/m2) + Etoposide(300mg/m2) alternes with to 2cycles of Vincristine (1.4mg/m2)+ Adriamycin (80mg/m2)+ Ciclofosfamide(1.2g/m2) and Busulfan(0.8-1.2 mg/Kg)+Melfalan(140 mg/m2)+PBSCT and 6 months with Celecoxib (500mg/m2/die for\<14 years old ,800 mg/die for\>14 years old) Ciclofosfamide (oral therapy 35mg/m2/die for\<14 years old, 50 mg/m2 for\>14 years old)
62751811|NCT03752346|NO_INTERVENTION|control group|Control group maintained their regular lifestyle and received the routine care
62751812|NCT03752346|EXPERIMENTAL|exercise group|Participants in the exercise group (EG) were instructed to engage performed exercise at least 3 times per week (30-50 minutes) or 10-15 minutes per section every day to accumulate 150 minutes per week for 8 weeks using disc (DVD) at home. Main exercise was moderate intensity aerobic exercise, an intensity of 55-70% of the heart rate reserve (HR max).
62751813|NCT05921695|ACTIVE_COMPARATOR|Normal Saline infusion group|During the emergency department, the normal saline infusion was not restricted.
62751814|NCT05921695|EXPERIMENTAL|Ringer lactate infusion group|Use ringer lactate or other balanced crystallographic solution instead of normal saline. Strictly limit the amount of normal saline infusion. Normal saline will only be infused by medical advice if the patient has hypochloremia or needs saline as solvent.
62751815|NCT05392790|EXPERIMENTAL|Aerobic exercise plus progressive resisted exercise group|Will receive aerobic exercise, progressive resisted exercise in addition to traditional care.
62751816|NCT05392790|EXPERIMENTAL|Aerobic exercise group|Will receive aerobic exercise plus traditional care.
62751817|NCT05392790|EXPERIMENTAL|Progressive resisted exercise group|Will receive progressive resisted exercise
62751818|NCT05392790|OTHER|Control group|Will receive traditional medical treatment in the form of Calcium, Vit D and Bi phosphnate.
62751819|NCT06514664|EXPERIMENTAL|Group 1|Use of probiotic toothpaste + smoking patient
62751820|NCT06514664|NO_INTERVENTION|Group 2|Use of regular toothpaste + smoking patient
62375976|NCT04576663|EXPERIMENTAL|0.625 μg/kg/min group|A maintenance dose of phenylephrine (0.625 μg/kg/ min) infusion simultaneous with subarachnoid block
62375977|NCT04576663|EXPERIMENTAL|0.9375 μg/kg/min group|A maintenance dose of phenylephrine (0.9375 μg/kg/ min) infusion simultaneous with subarachnoid block
62375978|NCT04707027|SHAM_COMPARATOR|complete polypoidal regression arm|follow up monthly with color fundus photography and OCT at each visit
62375979|NCT04707027|ACTIVE_COMPARATOR|incomplete polypoidal regression arm|continue treatment with aflibercept injection (treat and extend regimen)
62567549|NCT04305327|EXPERIMENTAL|Brodalumab|Brodalumab for 52 weeks. The dose will be determined by the participant's body weight.
62567550|NCT04305327|ACTIVE_COMPARATOR|Ustekinumab|Ustekinumab for 52 weeks. The dose will be determined by the participant's body weight.
62567551|NCT04305327|PLACEBO_COMPARATOR|Placebo/brodalumab|Placebo for the first 12 weeks and brodalumab for the following 40 weeks. The dose will be determined by the participant's body weight.
62567552|NCT04305327|PLACEBO_COMPARATOR|Placebo/ustekinumab|Placebo for the first 12 weeks and ustekinumab for the following 40 weeks. The dose will be determined by the participant's body weight.
62567553|NCT04656821|ACTIVE_COMPARATOR|Control Group|Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed.
62567554|NCT04656821|EXPERIMENTAL|Erector Spinae Block (ESB) group|Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography. The concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.
62567555|NCT04656821|EXPERIMENTAL|Thoracic Paravertebral Block group|Patients will receive 25 mg bupivacaine 0.5%, plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at the desired level under ultrasonography
62567556|NCT04087993|EXPERIMENTAL|Polyglucoferron|once intravenously, dosing according to Hb-levels and body weight, 500 - 2000 mg
62567557|NCT04087993|ACTIVE_COMPARATOR|Ferric Carboxymaltose|Once intravenously (a second administration is allowed), dosing according to Hb-levels and body weight (500 - 2000 mg, max. single dose of 1000 mg)
62567558|NCT04087993|ACTIVE_COMPARATOR|Ferrous sulfate|capsules, orally, dosing 50 mg - 200 mg (50 mg: 1 capsule in total, 200 mg: 4 capsules in total, taken as 2 capsules twice daily), duration of treatment 28 days
62751821|NCT06514664|EXPERIMENTAL|Group 3|Use of probiotic toothpaste + non-smoking patient
62751822|NCT06514664|NO_INTERVENTION|Group 4|Use of regular toothpaste + non-smoking patient
62751823|NCT05480189||patients in breast cancer with bone metastasis|patients in breast cancer with bone metastasis
62751824|NCT01593995|EXPERIMENTAL|EGF ointment|
62751825|NCT04472117|EXPERIMENTAL|Usual care and usual care plus video|Phase I (completed 3/31/2021): A sample of patients in phase I will complete a qualitative interview prior to or after surgery. Twenty-five evaluable patients (15 pre-operatively and a separate 10 post-operatively) will be selected to participate in an in-person/phone interview. Phase II: A separate group of women will compose phase II. All patients (N = 100) in phase II will complete discrete-choice surveys. Patients in phase III of the study will be randomized evenly to usual care plus video or usual care only. Phase III: One hundred participants will be randomized via CRDB to receive standard pre-operative counseling or standard pre-operative counseling with the additional of an educational video. Those randomized to view the video will also complete the post-video survey. All patients will complete the post-op survey.
62751826|NCT00201448|ACTIVE_COMPARATOR|Placebo (hepatitis A)|Placebo group
62375980|NCT01369069|EXPERIMENTAL|IV insulin drip with target glucose 80 mg/dL - 130 mg/dL|The intervention arm will have a targeted glucose concentration of 80-130 mg/dL. IV insulin drip will be titrated to keep glucose concentration in this range.
62375981|NCT01369069|ACTIVE_COMPARATOR|Sub Q insulin to keep glucose less than 180 mg/dL|This standard care arm will get sub q insulin sliding scale to keep glucose concentration less than 180 mg/dL
62751827|NCT00201448|EXPERIMENTAL|Towne vaccine|Towne vaccine given at 3000 pfu/subject
62751828|NCT03147612|EXPERIMENTAL|Treatment (chemotherapy, ponatinib, blinatumomab)|See Detailed Description.
62751829|NCT02346331|EXPERIMENTAL|WHO intervention|This arm will be treated with the 2011 WHO sepsis recommendations for the first 6 hours of their hospitalization. The WHO recommendations involve fluid boluses guided by vital signs and physical exam, frequent patient monitoring, rapid and early administration of empiric antibiotics, oxygen delivery, correction of hypoglycemia, and correction of severe anemia.
62751830|NCT02346331|NO_INTERVENTION|Standard care|This arm will be managed per standard care by the hospital clinicians.
62751831|NCT05369520|EXPERIMENTAL|Group 1 - Thoracic stimulation|Participants will receive 8 weeks TCSCS at the mid/low thoracic spinal cord levels.
62751832|NCT05369520|EXPERIMENTAL|Group 2- Lumbosacral stimulation|Participants will receive 8 weeks TCSCS at the lumbosacral spinal cord levels.
62751833|NCT06410261|EXPERIMENTAL|Exercise rehabilitation program|• Participants will take part in a personalized, one-hour, one-on-one muscle therapy session, two days a week, for 6 months.
62751834|NCT06410261|NO_INTERVENTION|Control|• Participants will complete the study measures on three separate occasions and will have the option to complete the exercise rehabilitation intervention once the study reaches completion.
62375982|NCT04942769|EXPERIMENTAL|selenium|selenium was administered to patients with autoimmune thyroiditis
62375983|NCT04717167|EXPERIMENTAL|DN group|All identified MTrPs were inserted with a sterile filiform needle (0,30mm x 40mm or 0,30mm x 75mm, depending on the muscle) that moved up- and downwards until a local twitch response was elicited. When the repeated local twitch response fade away or the subject reported too much pain, the needle was removed. After the treatment, a 15 minutes break(51) was set up and the subjects were not permitted to use a hot pack or to stretch the muscle.
62751835|NCT03100981|EXPERIMENTAL|Internet-delivered MBCT|The intervention group will immediately receive 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy.
62751836|NCT03100981|OTHER|Waitlist control|The control group will be on a waiting list to participate in Internet-delivered MBCT after the 6-months follow-up time has passed.
62751837|NCT01571050|EXPERIMENTAL|Fresh NaF/SiO2 toothpaste|
62751838|NCT01571050|PLACEBO_COMPARATOR|Purified water|
62751839|NCT01571050|EXPERIMENTAL|Aged NaF/SiO2 toothpaste|
62751840|NCT01571050|EXPERIMENTAL|Fresh MFP/CaCO3 toothpaste|
62751841|NCT01571050|EXPERIMENTAL|Aged MFP/CaCO3 toothpaste|
62751842|NCT04256668|ACTIVE_COMPARATOR|good embryo development in assisted reproduction|20 infertile men treated with assisted reproduction with normal embryo development in vitro, as demonstrated in a previous treatment with assisted reproductive technology (defined by normal fertilization rate \>50% and normal blastocyst development rate \>50%).
62751843|NCT04256668|ACTIVE_COMPARATOR|poor embryo development in assisted reproduction|20 infertile men treated with assisted reproduction with poor embryo development in vitro, as demonstrated in a previous treatment with assisted reproductive technology (defined by normal or slightly reduced fertilization rate \<50% and low or absent blastocyst development (0 or only 1 blastocyst).
62751844|NCT04256668|PLACEBO_COMPARATOR|natural conception|20 previously infertile men, normal history, normal genital status, normal sperm count, DNA fragmentation rate \<20% (as given by TUNEL) and achieving pregnancy naturally (without medical intervention).
62567559|NCT04994769|EXPERIMENTAL|Epitomee Capsule|Epitomee Capsule combined with lifestyle counseling
62375984|NCT04717167|SHAM_COMPARATOR|Sham needling (SN) group|The SN technique was similar to DN, except for penetrating the muscle. In this technique, the needle only penetrated the skin and was therefore impossible to provoke a local twitch response.
62375985|NCT01555541|EXPERIMENTAL|Single-arm study|
62751845|NCT02333682|EXPERIMENTAL|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 10 mcg, 1 capsule/day before breakfast, Duration: 6 months
62375986|NCT05212467|ACTIVE_COMPARATOR|AIR-program|• The Amygdala and insula retraining program consists of novel brain retraining approaches focused on hypothetically interrupting and retraining the conditioned defensive hyper-stimulation of the sympathetic nervous system and aspects of the immune system by the amygdala and insula, to bring the brain and body back to homeostasis. It includes supportive techniques such as breathing, meditation, and neurolinguistic programming. The patients are invited to an online program of video session and eight weekly 2 h webinar sessions followed by three monthly sessions. The patients are assigned to do daily homework that takes approximately 15 to 20 min to complete
62567560|NCT01236508|EXPERIMENTAL|Nuclear imaging|PET/CT imaging with F-18 fluorodeoxyglucose
62567561|NCT00686608|EXPERIMENTAL|Glucose|IV glucose
62751846|NCT02333682|EXPERIMENTAL|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 15 mcg, 1 capsule/day before breakfast, Duration: 6 months
62567562|NCT00686608|ACTIVE_COMPARATOR|Fructose|
62567563|NCT00686608|PLACEBO_COMPARATOR|Saline|
62751847|NCT02333682|EXPERIMENTAL|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 20 mcg, 1 capsule/day before breakfast, Duration: 6 months
62751848|NCT02333682|ACTIVE_COMPARATOR|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol), Dose: 20 mcg, 1 capsule/day before breakfast, Duration: 6 months
62751849|NCT02368912|EXPERIMENTAL|1. Single ascending dose (SAD), ASP1707 dose levels 1-7|healthy young male
62751850|NCT02368912|EXPERIMENTAL|2. Single ascending dose (SAD), placebo dose levels 1-7|healthy young male
62751851|NCT02368912|EXPERIMENTAL|3. Food effect (FE), ASP1707 fasted|Fasted healthy young male
62751852|NCT02368912|EXPERIMENTAL|4. Food effect (FE), ASP1707 fed|Fed healthy young male
62751853|NCT02368912|EXPERIMENTAL|5. Multiple ascending dose (MAD), ASP1707 dose levels 1-4|healthy elderly male
62751854|NCT02368912|EXPERIMENTAL|6. Multiple ascending dose (MAD), Placebo, dose levels 1-4|healthy elderly male
62751855|NCT02368912|EXPERIMENTAL|7. Multiple ascending dose (MAD), ASP1707, dose levels 1-2|healthy pre-menopausal female
62751856|NCT02368912|EXPERIMENTAL|8. Multiple ascending dose (MAD), Placebo dose levels 1-2|healthy pre-menopausal female
62751857|NCT02368912|EXPERIMENTAL|9. Parallel multiple dose, ASP1707 dose levels 1-3|healthy pre-menopausal female
62751858|NCT02368912|EXPERIMENTAL|10. Parallel multiple dose, Placebo|healthy pre-menopausal female
62751859|NCT06457230|EXPERIMENTAL|Paired-pulse rTMS based on cerebellum and FPC for substance use disorder|Randomly assigned cerebellar + FPC sequential intervention group (20 people). The cerebellar + FPC sequential intervention group was designed with a block programme of cerebellar and FPC stimulation at 100 ms intervals (each block: cerebellar 10 Hz rTMS stimulation - 100 ms interval - frontal pole 10 Hz rTMS stimulation).
62751860|NCT06457230|EXPERIMENTAL|Single pulse rTMS based on cerebellar or FPC for substance use disorder|Participants will be subjected to 10 Hz rTMS based on cerebellar or FPC (20 people). The randomised intervention group randomly intervened in either the cerebellum or the FPC, with the stimulation parameters remaining the same as in the experimental group.
62751861|NCT04742348|PLACEBO_COMPARATOR|Control, Placebo|Similar looking tablet(s) to active drug will be administered in a single dose to those who are randomly assigned to this group.
62751862|NCT04742348|EXPERIMENTAL|Active Drug, Carbidopa + Levodopa|Single dose of immediate release carbidopa-levodopa (50mg/500mg).
62751863|NCT00709293|PLACEBO_COMPARATOR|1|
62375987|NCT05212467|ACTIVE_COMPARATOR|HUS Internet therapy|The HUS internet therapy for bodily stress syndromes (iHUSbss) includes psychoeducation about autonomic nervous system and of the effects of patient's own thinking and action on the nervous system. The exercises aim at relaxing the body, at novel ways to observe the symptoms, and at developing acceptance and self-compassion. The program includes exercises that are done regularly in everyday life.
62375988|NCT05212467|PLACEBO_COMPARATOR|Treatment as usual|The patients may have appointments with their physician, physiotherapist, or another health professional, and they may attend group interventions. If possible, medication is kept the same during the intervention and three months afterwards. If there is need to change the medication during the trial, the changes will be recorded. Appointments with health professionals and attendance in group interventions are monitored.
62751864|NCT00709293|ACTIVE_COMPARATOR|2|
62375989|NCT03075930||Extended Electrocardiogram|Elective patients receiving an AF ablation receiving a extended ECG
62375990|NCT03075930||Body surface potential map|Elective patients receiving an AF ablation receiving a body surface potential map
62375991|NCT05608200|EXPERIMENTAL|Len-Sin-TACE|Lenvatinib, Sintilimab Plus TACE
62375992|NCT05608200|ACTIVE_COMPARATOR|Len-TACE|Lenvatinib Plus TACE
62375993|NCT04532281|EXPERIMENTAL|Administration of Murine CD19 CAR T-cells|
62375994|NCT03479658|EXPERIMENTAL|HIIT two sessions|Two sessions per week of HIIT + nutritional education (1 session/week)
62751865|NCT05333172|ACTIVE_COMPARATOR|balance exercise group|The balance program was performed on soft and hard surface. Firstly the participants started the exercises on hard ground while standing. Postural balance program consisted of static and dynamic functional balance exercises (hıp flexion, hıp abduciton, semitandem stance, one leg stance, toe tips lifting). Afterwards exercises were performed on soft surface. Three sets of eight to ten repetitions of each exercise in a slow, controlled manner were performed. This section was completed 30 minitues.
62751866|NCT05333172|EXPERIMENTAL|Dual task exercises|"Dual task exercises are in two forms as motor dual task and cognitive dual task. In this study we used cognitive secondary task exercises. In addition to the exercises applied by the balance exercise group, a cognitive task was added. Participants in this group tried to count 4, 5 and 7 back from 100 while practicing balance exercises.~The balance program was performed on soft and hard surface. Firstly the participants started the exercises on hard ground while standing. Postural balance program consisted of static and dynamic functional balance exercises (hıp flexion, hıp abduciton, semitandem stance, one leg stance, toe tips lifting). Afterwards exercises were performed on soft surface. Three sets of eight to ten repetitions of each exercise in a slow, controlled manner were performed. This section was completed 30 minitues."
62375995|NCT03479658|EXPERIMENTAL|HIIT one session|One session per week of HIIT + nutritional education (1 session/week)
62751867|NCT04894305|EXPERIMENTAL|Group 1 (Test Group): Ad26.COV2.S (0.3 mL)|Participants will receive single dose Ad26.COV2.S 0.3 milliliter (mL) intramuscular (IM) injection on Day 1 in test group.
62751868|NCT04894305|ACTIVE_COMPARATOR|Group 2 (Reference Group): Ad26.COV2.S (0.5 mL)|Participants will receive single dose Ad26.COV2.S 0.5 mL IM injection on Day 1 in reference group.
62751869|NCT05826418|EXPERIMENTAL|MEND diet|patients being treated with FMT
62751870|NCT05826418|ACTIVE_COMPARATOR|mNICE (modified NICE) diet|patients being treated with FMT
62751871|NCT03396367|EXPERIMENTAL|PARTNER Intervention|This intervention is a four-session intervention designed to increase PrEP uptake, increase PrEP adherence, and reduce drug use and HIV transmission risk behaviors of individuals in relationships.
62751872|NCT03396367|ACTIVE_COMPARATOR|Education Intervention|This intervention is a four-session intervention that discussed drug use and its effect on physiological social functioning.
62375996|NCT03479658|ACTIVE_COMPARATOR|Nutritional education|Nutritional education (1 session/week)
62751873|NCT05210699|EXPERIMENTAL|Product usage order A B N C E D|Subjects will use each of the 5 products sequentially (A B N C E D) during an evaluation period, followed by a 4 hour Test Session.
62751874|NCT05210699|EXPERIMENTAL|Product usage order B C A D N E|Subjects will use each of the 5 products sequentially (B C A D N E) during an evaluation period, followed by a 4 hour Test Session.
62555948|NCT02074150|EXPERIMENTAL|Change from Baseline in Finger Ashworth|"Change from Baseline in Finger Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):~0 = No increase in muscle tone (none)~1. = Slight increase~2. = Moderate increase~3. = Considerable increase~4. = Limb rigid (very severe)."
62567564|NCT06574659|EXPERIMENTAL|Assigned Interventions|Noninvasive Ventilation Breathing Test guiding sequential invasive Ventilation and noninvasive ventilation weaning group with Ventilators.
62751875|NCT05210699|EXPERIMENTAL|Product usage order C D B E A N|Subjects will use each of the 5 products sequentially (C D B E A N) during an evaluation period, followed by a 4 hour Test Session.
62567565|NCT06574659|ACTIVE_COMPARATOR|The standard SBT guiding weaning group|The standard SBT guiding weaning protocol with Ventilators.
62751876|NCT05210699|EXPERIMENTAL|Product usage order D E C N B A|Subjects will use each of the 5 products sequentially (D E C N B A) during an evaluation period, followed by a 4 hour Test Session.
62751877|NCT05210699|EXPERIMENTAL|Product usage order E N D A C B|Subjects will use each of the 5 products sequentially (E N D A C B) during an evaluation period, followed by a 4 hour Test Session.
62751878|NCT05210699|EXPERIMENTAL|Product usage order N A E B D C|Subjects will use each of the 5 products sequentially (N A E B D C) during an evaluation period, followed by a 4 hour Test Session.
62751879|NCT03418649|EXPERIMENTAL|Experimental|Eplerenone 50 Mg Tab
62751880|NCT03418649|PLACEBO_COMPARATOR|Control|Placebo Oral Tablet
62751881|NCT00592163|EXPERIMENTAL|Single Arm|
62751882|NCT01774097|EXPERIMENTAL|ALD-301|Participants will receive ALD-301 via intramuscular injection
62751883|NCT01774097|PLACEBO_COMPARATOR|Placebo (vehicle)|Participants will receive placebo (vehicle)via intramuscular injection
62751884|NCT00570037|ACTIVE_COMPARATOR|Immunization Program|Intervention Hospital - Standing postpartum vaccine orders, influenza vaccine clinic on postpartum ward for household contacts, mailed vaccine reminders
62751885|NCT00570037|NO_INTERVENTION|No Immunization Program|Comparison Hospital - Receipt of vaccine through routine clinical care
62751886|NCT02596958||Bevacizumab|Patients will receive six 3-weeks cycle of IV bevacizumab along with platinum-based chemotherapy, followed by maintenance therapy of bevacizumab until progression (approximately 7 months).
62751887|NCT05966363||CBCT|Patients receiving a Cone Beam of the rocks as part of a cochlear implant position check at Besançon University Hospital
62751888|NCT05966363||CT|Patients receiving a CT scan of the rocks at Besançon University Hospital, all indications combined
62751889|NCT05379517|NO_INTERVENTION|Control Group (CG)|Patients in the control group will receive a booklet with general information on a health education program where they will be taught global stretching exercises to be performed themselves at least twice a week at home for 20 minutes. In addition, hygienic postural care will be included.
62751890|NCT05379517|EXPERIMENTAL|Experimental group 1|People will receive a three times-weekly 60 min pulmonary rehabilitation program (PRP) for 8 weeks. Exercise training will be structured in three stages. Exercise will start with a warm-up period (4 minutes); followed by the core phase of aerobic exercises (15-18 minutes), upper and lower limb strength (9 minutes), exercises of the respiratory muscles with diaphragmatic breaths with retentions (10 minutes) and the final cooling-stretching (4 minutes) for a total 45 min, coupled with 15 minutes of breathing retraining with the Threshold Inspiratory Muscle Training® (IMT) device (Philips Respironics). Respiratory muscle training will start at 10% of the initial MIP achieved at startup and will increase by 5% every two weeks until reaching 20% of the initial MIP. The intensity of the exercise training will be at 60-75% of the maximum heart rate rate achieved in the exercise capacity test.
62751891|NCT05379517|EXPERIMENTAL|Experimental group 2|Patients will receive a pulmonary rehabilitation program (PRP) supplemented with pulsed electromagnetic field therapy. The latter will be applied for 5 weeks, a total of 3 sessions per week. The BTL-6000 Super Inductive System (SIS) will be used with the 'focus field' type manual applicator. The parameters will be: intensity of the magnetic field up to 2.5 Tesla (T), the frequency range to achieve the analgesic effect will vary between 10-20 Hz and, finally, an adjustable relative intensity up to 100%, depending on the perception subjective of the patients. Sessions will last 10 minutes. The parameters and procedure of therapy follow the manufacturer's recommendations. The SIS will be applied in the area where the patient presents the highest level of pain.
62751892|NCT00932269||Seroimmunity 2007|Cord blood from 400 newborns, 1800 children (2 - 18 years) and 2400 adults (above 18 years), randomly selected and stratified in age groups, from which blood samples are taken.
62751893|NCT00932269||Sub Study|800 immigrated children (14 - 16 years) from which blood samples are taken.
62751894|NCT05311995|ACTIVE_COMPARATOR|Group 1|trocar entry areas:Periumblical, left lower quadrant, suprapubic
62751895|NCT05311995|ACTIVE_COMPARATOR|Group 2|trocar entry areas: Periumblical, left lower quadrant, right lower quadrant
62375997|NCT06217640||Patients with Heart Failure|Patient diagnosed with heart failure with reduced ejection fraction (HFrEF): EF less than or equal to 40% and heart failure with preserved EF (HFpEF): EF is greater than or equal to 50%.
62375998|NCT06217640||Healthy Control|older people without HF.
62375999|NCT01172990|EXPERIMENTAL|Conventional Group|Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- Percutaneous Coronary Intervention PCI between 24 to 48 hours from randomisation according to local policy and guidelines
62376000|NCT01172990|ACTIVE_COMPARATOR|Immediate Invasive Group|Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (\< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting Percutaneous Coronary Intervention(PCI) will be performed according to local policy and guidelines
62376001|NCT04323917||Cases|Subjects affected by Pancreatic carcinoma (PC) confirmed by tissue biopsy
62376002|NCT04323917||Controls|Healthy Subject enrolled following colon cancer screening via colonoscopy
62376003|NCT03450824||The study group|The participants with patellofemoral pain.
62376004|NCT03450824||The control group|The participants without patellofemoral pain.
62376005|NCT00736450|EXPERIMENTAL|Arm I|See Detailed Description
62376006|NCT00910936|EXPERIMENTAL|Intervention|
62751896|NCT05311995|ACTIVE_COMPARATOR|group 3|trocar entry areas: Periumblical, right lower quadrant, suprapubic
62751897|NCT05311995|ACTIVE_COMPARATOR|Group 4|trocar entry areas: Periumblical, left lower quadrant, left upper quadrant
62376007|NCT00910936|NO_INTERVENTION|Control|
62376008|NCT06097975|EXPERIMENTAL|Experimental arm|
62751898|NCT06454448|EXPERIMENTAL|Study arm|"1. Decitabine: RP2D dose, continuous infusion over 1 hr, D1-D3.~2. Albumin paclitaxel: dose of 125 mg/m2, IV infusion over 30-40min, D1, D8, D15~3. Gemcitabine: dose of 1000 mg/m2, IV infusion over at least 30min, D1, D8, D15~4. Adebrelimab: 1200 mg by IV infusion over 30-60 min, D15, Q3W In case of AG (albumin paclitaxel + gemcitabine) treatment-related adverse events during the treatment period, dose adjustment of the AG regimen may be appropriately allowed, with the gemcitabine dose adjusted from 1000 mg/m2 to 800 mg/m2. chemotherapy is administered in 1 treatment cycle every 28 days."
62751899|NCT03769818|ACTIVE_COMPARATOR|bupivacaine and dexamethasone|Bilateral ESP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
62751900|NCT03769818|ACTIVE_COMPARATOR|bupivacaine and placebo to dexamethasone|Bilateral ESP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
62751901|NCT03769818|PLACEBO_COMPARATOR|control group|Bilateral ESP block with placebo to bupivacaine bilaterally plus placebo to dexamethasone
62751902|NCT03075488|ACTIVE_COMPARATOR|Conventional landmark-guided technique|In this arm spinal anesthesia will be performed by using conventional cutaneous landmarks
62751903|NCT03075488|EXPERIMENTAL|Accuro device guided technique|In this arm spinal anesthesia will be performed only after having detected the intralaminar space, the mid-line, the depth and the orientation for spinal needle insertion with pre-procedural scan performed with Accuro device
62751904|NCT01969383|EXPERIMENTAL|heated pool|After selection, all volunteers will be asked to attend two exercise protocols performed on the ground and in the heated pool and the minimum interval of 24 hours between each protocol. Data collection will be performed only with the dominant member of each volunteer.
62751905|NCT02607917|EXPERIMENTAL|Mass Media plus clinic intervention.|These geographic areas will receive the media plus clinic intervention over a two year period.
62751906|NCT02607917|EXPERIMENTAL|Media|These geographic areas will receive the media intervention over a two year period.
62751907|NCT02607917|NO_INTERVENTION|No Intervention|Adjacent states will receive no intervention.
62751908|NCT06608433|EXPERIMENTAL|Semaglutide/Rybelsus|
62751909|NCT06608433|PLACEBO_COMPARATOR|Placebo|
62751910|NCT05083546|EXPERIMENTAL|Intervention|MGO cocktail containing a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine
62751911|NCT05083546|PLACEBO_COMPARATOR|Control|sugar pill
62751912|NCT02357082||MRI Scan|Patients with a previously implanted Cardiac Implantable Electronic Device who are undergoing an MRI Scan for clinically indicated, diagnostic purposes.
61986441|NCT04989400|PLACEBO_COMPARATOR|placebo|received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal according to FIGO guidelines 2017. Then women in had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy
61986442|NCT00593671|ACTIVE_COMPARATOR|PGS group|
61986443|NCT00593671|NO_INTERVENTION|control group|
61986444|NCT04162028|EXPERIMENTAL|Nebulized Ketamine|sub-dissociative dose ketamine administered prehospitally via breath-actuated nebulizer at 1.0 mg/kg for patients with acute pain
62751913|NCT03822598|EXPERIMENTAL|Intervention group|Teaching Recovery Techniques implemented 1- 3 weeks after recruitment
62751914|NCT03822598|ACTIVE_COMPARATOR|Wait-list control group|Delayed implementation of Teaching Recovery Techniques (after the experimental group has completed the program)
62751915|NCT06608914|EXPERIMENTAL|Testosterone arm|The testosterone group will receive a 200mg dose of intramuscular testosterone cypionate (also known as Nandrolone) weekly for 8 weeks beginning 2 weeks prior to surgery.
62751916|NCT06608914|PLACEBO_COMPARATOR|Saline Arm|The saline group will receive a 200mg dose of intramuscular saline weekly for 8 weeks beginning 2 weeks prior to surgery.
62751917|NCT02647541|EXPERIMENTAL|Nutritional intervention|Consultation with a dietitian, including nutritional recommendations and supplementation.
62751918|NCT02647541|NO_INTERVENTION|Standard therapy|No specific nutritional recommendations.
62376009|NCT01910649|EXPERIMENTAL|Drisapersen|Extension phase of treatment. Intravenous dosing of drisapersen will be investigated as an alternative route of administration
62567566|NCT05339373|OTHER|Sequence TR|18 subjects assigned to the sequence TR will receive a single 100 mg dose of the test product Aceclofenac (1 x 100 mg tablet), marked as T in the sequence, in Period 1 and a single 100 mg dose of the reference product Airtal ® (1 x 100 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62751919|NCT03910738|EXPERIMENTAL|Testosterone treatment (Nebido®)|"Treatment/Nebido® arm: in this experimental arm, each patient will be injected intramuscularly with 1000 mg / 4 ml of testosterone undecanoate (Nebido®).~Treatment will be injected at baseline, week 6, 18, 30, 42 and 54"
62751920|NCT03910738|PLACEBO_COMPARATOR|Placebo|"Placebo arm: In this arm, each patient will be injected intramuscularly with 4 ml of placebo solution.~Placebo will be injected at baseline, week 6, 18, 30, 42 and 54"
62751921|NCT06244082|EXPERIMENTAL|AOC 1044 Multiple Dose Levels|AOC 1044 will be IV infused every 6 weeks or 8 weeks for approximately 2 years.
62751922|NCT03895398|EXPERIMENTAL|nutrition and psychosocial intervention arm|"12 selected ECE centers will be selected to be the intervention group. ECE teachers will be trained on psychosocial and nutrition care for children and expected to deliver the information and parenting class to mother.~Community health officers will be trained on how to monitored the activities regularly and providing technical assistance to ECE teachers if needed.~mothers will received weekly parenting class. in the parenting class mothers will be informed on how to provide appropriate feeding and psychosocial stimulus to their children. nutrient dense food supplementation in the form of liver and fish floss will be prepared together and distributed.~underfive children will received nutrient dense food supplementation in the form of liver and fish floss and expected to be eaten everyday for 6 months"
62751923|NCT03895398|NO_INTERVENTION|control arm|no intervention is given to this arm
62751924|NCT05783245|EXPERIMENTAL|Experimental Ice Therapy|Postoperative care with experimental ice therapy
62751925|NCT05783245|ACTIVE_COMPARATOR|Standard of Care Ice Therapy|Postoperative care with standard of care ice therapy
62751926|NCT04809558|ACTIVE_COMPARATOR|Max intensity with no visual biofeedback|Tongue resistance exercises completed at maximum intensity with no visual biofeedback.
62751927|NCT04809558|ACTIVE_COMPARATOR|Progressive intensity with no visual biofeedback.|Tongue resistance exercises completed at a progressive intensity with no visual biofeedback.
62751928|NCT04809558|ACTIVE_COMPARATOR|Max intensity with visual biofeedback|Tongue resistance exercises completed at maximum intensity with visual biofeedback of performance.
62751929|NCT04809558|ACTIVE_COMPARATOR|Progressive intensity with visual biofeedback.|Tongue resistance exercises completed at a progressive intensity with visual biofeedback of performance.
62751930|NCT03260894|EXPERIMENTAL|Pembrolizumab + Epacadostat|
62751931|NCT03260894|ACTIVE_COMPARATOR|SoC (Sunitinib or Pazopanib)|Standard of care (SoC) (sunitinib or pazopanib monotherapy).
62751932|NCT05504304|ACTIVE_COMPARATOR|Group A: open reduction and internal fixation plus primary subtalar arthrodesis.|they will be scheduled to surgery after resolution of the edema and appearance of wrinkle sign. Lateral position and lateral extensile approach will be used. A 4 mm schanz will be inserted in the calcaneal tuberosity from lateral side to control varus and to restore calcaneal height. Lateral wall of the calcaneus will be lifted keeping it attached inferiorly. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. tricortical iliac bone autograft will be inserted the subtalar joint. A lateral nonlocked plate will be applied to reduce the lateral wall blow out and broadening then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
62376010|NCT05017987|ACTIVE_COMPARATOR|Sequence A=Reference-Test|"T(Test drug): ATB-101 R1(Reference drug1): ATB-1011 R2(Reference drug2): ATB-1012~First stage: co-administration of R1 and R2, single dose and then Washout: 7days and then Second stage: administration of T, single dose"
62376011|NCT05017987|ACTIVE_COMPARATOR|Sequence B=Test-Reference|First stage: administration of T, single dose and then Washout: 7days and then Second stage: co-administration of R1 and R2, single dose
62376012|NCT03737396|ACTIVE_COMPARATOR|Electronic health screening|Self-administered electronic health screening on tablet
62376013|NCT03737396|NO_INTERVENTION|Paper-based health screening|Routine-care nurse-administered, paper-based health screening
62376014|NCT02689544|EXPERIMENTAL|static stretching|Group of 15 volunteers (gSS)
62376015|NCT02689544|EXPERIMENTAL|dynamic stretching|Group of 15 volunteers (gDS)
62376016|NCT02689544|OTHER|control|Group of 15 volunteers (gC)
62376017|NCT03194204|ACTIVE_COMPARATOR|RA patients treated with methotrexate|"Disease activity score(DAS28) matrix metalloproteinase-3(MMP-3) and matrix metalloproteinase-9(MMP-9), Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid Rheumatoid factor (RF IgM, U/L) Anti- cyclic citrullinated peptide . Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views .~Cardiac assessment :By electrocardiogram ( ECG ) and echocardiography , Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound."
62376018|NCT03194204|ACTIVE_COMPARATOR|RA patients treated with methotrexate plus doxycycline|"Disease activity score(DAS28) Matrix Metalloproteinase-3 (MMP-3) and Matrix Metalloproteinase-9 (MMP-9) Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid , Rheumatoid factor (RF IgM(immunoglobulin M), U/L) Anti- cyclic citrullinated peptide. Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views.~Cardiac assessment :~By electrocardiogram ( ECG ) and echocardiography Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound."
62376019|NCT00348075|EXPERIMENTAL|Neurovision|
62376020|NCT00809614|EXPERIMENTAL|AIN457 (2x 10mg/kg)|Each patient received 10 mg/kg AIN457 intravenously, on Day 1 and Day 22.
62376021|NCT00809614|PLACEBO_COMPARATOR|Placebo|Each patient received 10 mg/kg of matching placebo intravenously, on Day 1 and Day 22.
62376022|NCT05225792|EXPERIMENTAL|Injured Service Members|
62376023|NCT06220240|ACTIVE_COMPARATOR|Modified Training Group|It is a training program that will be carried out under the supervision of a physiotherapist. There will be 3-minute breaks between sets. A training program will be applied to the athletes based on revising the training program they use in their routine with eccentric contractions.
62376024|NCT06220240|ACTIVE_COMPARATOR|Routine Training Group|The training program that the athlete uses in her normal routine will be implemented under the supervision of a physiotherapist.
62376025|NCT00532064||Ancillary-correlative (biospecimen collection)|Patients receive sunitinib malate or sorafenib chemotherapy then undergo blood collection 2 weeks later, and then every 4-6 weeks for up to 6 months to test for troponin I and BNP.
62376026|NCT00004141|EXPERIMENTAL|Arm A|CDDP (75 mg/m2) and DTIC (660 mg/m2) will be administered sequentially by intravenous infusion in day 1. Subsequently, GM-CSF (450 mg/ m2) will be administered SC days 2-7; IL-2 (11 MU daily) will be given SC days 8-14, and IFN-2b (9 MU) will be given SC days 8, 10, 12, and 14.
62751933|NCT05504304|ACTIVE_COMPARATOR|Group B: conservative management then calcaneoplasty and subtalar arthrodesis.|they will be assessed upon 1st clinic visit. After at least three months patients will be scheduled for subtalar arthrodesis. A new preoperative ankle CT scan will be done. Lateral position and lateral extensile approach will be used. Lateral wall and plantar exostosis will be resected. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. Hind foot deformity (mostly varus) will be corrected through the subtalar joint manually and checked clinically. Loss of calcaneal height will be corrected by tricortical iliac bone autograft to distract the subtalar joint then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
62751934|NCT06602050||HG and NIF|The cohort will consist of cooperative mechanically ventilated (MV) patients. In this patient group, the relationships between negative inspiratory force (NIF), handgrip strength (HG), and physical functional status will be examined.
62751935|NCT00835640|EXPERIMENTAL|1|
62751936|NCT00835640|ACTIVE_COMPARATOR|2|
62751937|NCT02059889|EXPERIMENTAL|Diagnostic (diffusion-weighted MRI, 4D CT, FDG-PET)|Patients undergo 15 imaging studies: 5 chest CT scans, 5 chest MRI scans, 5 PET scans. Each scan will be obtained before treatment begins, weeks 2 and 4 during radiation therapy, 3 months and 1 year following radiation therapy. THe chest CT obtained pre-treatment, at 3 months post treatment and 1 year post treatment are considered routine and would be obtained regardless of study participation. The pre-treatment PET scan is also considered routine. All other scans are being done for the purposes of this research.
62751938|NCT02968160|EXPERIMENTAL|Telmisartan+Rosuvastatin|"Duowell ® tablet (Telmisartan 40mg + Rosuvastatin 20mg) 1 tablet, once daily, Oral administration/ 8 weeks~\* But, the increased Duowell ® tablet (Telmisartan 80mg + Rosuvastatin 20mg) will get administrated orally one tablet once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit."
62376027|NCT03442933|ACTIVE_COMPARATOR|Road Cycling first, then Mountain Biking|First Intervention (3 hours: Road cycling), followed by a 7 days washout, and the second Intervention (3 hours: Mountain Biking).
62555949|NCT02074150|EXPERIMENTAL|Change from Baseline in Thumb Ashworth|"Change from Baseline in Thumb Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):~0 = No increase in muscle tone (none)~1. = Slight increase~2. = Moderate increase~3. = Considerable increase~4. = Limb rigid (very severe)."
62751939|NCT02968160|ACTIVE_COMPARATOR|Telmisartan/Rosuvastatin|"Telmisartan 40mg + Rosuvastatin 20mg 2 tablets, once daily, Oral administration/ 8 weeks~\* But, the increased Telmisartan 80mg + Rosuvastatin 20mg will get administrated orally 2 tablets once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit."
62751940|NCT02654288||single arm|The pancreatic cancer patients without history of chemotherapy who will receive gemcitabine-based chemotherapy will be recruited and the sera IgG4 and IL-10 will be detected before and after chemotherapy.
62376028|NCT03442933|ACTIVE_COMPARATOR|Mountain Biking first, then Road Cycling|First Intervention (3 hours: Mountain Biking), followed by a 7 days washout, and the second Intervention (3 hours: Road cycling).
62376029|NCT02057276|ACTIVE_COMPARATOR|Active rTMS|Participants will receive daily active rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
62751941|NCT04837209|EXPERIMENTAL|Niraparib + Dostarlimab + Radiation therapy|"Study cycle length is 3 weeks. Participants will receive:~* Niraparib 1x daily during each study cycle~* Dostarlimab 1x every 3 weeks for 4 study cycles, then 1x every 6 weeks beginning on Cycle 5~* Radiation therapy will be given on Days 1, 2, and 3 of Cycle 1."
62751942|NCT04172415||Retrospective cohort|Patients that received procedural sedation in a community Emergency Department.
62376030|NCT02057276|SHAM_COMPARATOR|Sham rTMS|Participants will receive daily sham rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
62376031|NCT01245972|NO_INTERVENTION|Control|No treatment administered
62376032|NCT01245972|EXPERIMENTAL|PDL Setting 1|PDL Setting 1: 15 J/cm2, 3ms pulse length, no dynamic cooling, 7mm spot size, 10% overlap between the pulses, 2 passes
62376033|NCT01245972|EXPERIMENTAL|PDL Setting 2|PDL Setting 2: 7.5 J/cm2, 3ms pulse length, no dynamic cooling, 10mm spot size, 10% overlap between the pulses, 2 stacked pulses
62376034|NCT02299206|EXPERIMENTAL|CeraVe Baby Diaper Rash Cream|Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
62376035|NCT02299206|EXPERIMENTAL|Desitin Maximum Strength Original Paste|Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
62376036|NCT06338813|NO_INTERVENTION|Kron Technique|Intraabdominal pressure measurement with Kron Technique
62376037|NCT06338813|ACTIVE_COMPARATOR|Digital Manometry|Intraabdominal pressure measurement with Digital Manometry
62376038|NCT05973240||Sample derived from the first data collection round (MSA)|Patients have to be aged 18 years and older, cross in an anticoagulation clinic for at least three months, have appropriate cognitive functioning as determined by the six-item screener, and have the ability to give informed consent will be the inclusion criteria. Patients will be excluded if their Charlson Comorbidity Index (CCI) is high (CCI \> 4) to account for any comorbidity-related variability and assure the homogeneity of the study sample.
62376039|NCT05973240||Sample derived from the second data collection round (CFA)|Patients have to be aged 18 years and older, cross in an anticoagulation clinic for at least three months, have appropriate cognitive functioning as determined by the six-item screener, and have the ability to give informed consent will be the inclusion criteria. Patients will be excluded if their Charlson Comorbidity Index (CCI) is high (CCI \> 4) to account for any comorbidity-related variability and assure the homogeneity of the study sample.
62376040|NCT05685849||Trial group|A total of 200 pregnant women in the first trimester (gestational age of 6-13 weeks+6 days), who had cardiovascular disease and experienced regular obstetric examinations throughout the pregnancy, were selected from the obstetric outpatients in 10 centers, with 20 cases in each center.
62376041|NCT01538433||biopsy-proven IgA nephropathy|
62376042|NCT02706795|EXPERIMENTAL|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
62376043|NCT05483764||Paraplegia|
62751943|NCT03991403|EXPERIMENTAL|Atezolizumab group|
62751944|NCT03991403|ACTIVE_COMPARATOR|Control group|
61986445|NCT04886986|EXPERIMENTAL|All Subjects|Patients enrolled in the study will receive the study drugs 225Ac-J591 and 177Lu-PSMA-I\&T, along with 68Ga-PSMA-11.
61986446|NCT01633892|EXPERIMENTAL|Fat Grafting|
61986447|NCT04286607|EXPERIMENTAL|ARQ-151 Cream 0.3%|
62376044|NCT05483764||Control|
62376045|NCT05847387||Keratoplasty group|Patients undergoing keratoplasty and their respective donor tissue
62376046|NCT03851224|ACTIVE_COMPARATOR|control group|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced with no graft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
62376047|NCT03851224|ACTIVE_COMPARATOR|study group|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced with autogenous bone graft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
62376048|NCT03851224|ACTIVE_COMPARATOR|study group 2|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced withxenograft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
62376049|NCT01189838||Low Cyr61|Low Cyr61 immunohistochemical stain in patients' TCC tumor
62376050|NCT01189838||High Cyr61|High Cyr61 immunohistochemical stain in patients' TCC tumor
62376051|NCT05010395|NO_INTERVENTION|Control|Individuals in this arm did not receive a letter.
62376052|NCT05010395|EXPERIMENTAL|Arm 1: Basic Letter|Individuals received a letter with information about the benefits of enrolling, the February 15th sign-up deadline, the HealthCare.gov website, and the call center phone number.
62376053|NCT05010395|EXPERIMENTAL|Arm 2: Action|"Individuals in this arm received a letter that emphasized only minimal marginal effort is required; and used adjectives and verbs connoting action (e.g., almost done, quick, act now, and fast)."
62376054|NCT05010395|EXPERIMENTAL|Arm 3: Action, Implementation|Individuals in this arm received a letter similar to Arm 2, but with the addition of a calendar that draws attention to the February 15th deadline; and provided fill-in blanks in which the recipient can write the planned month, day, and time when they intend to enroll.
62751945|NCT06607952|EXPERIMENTAL|The experimental group with scenario-based case videos teaching method.|The students in the experimental group will receive a new teaching method of five scenario-based case videos. These scenarios include Triage, SDH (Subdural Hemorrhage) and ETTC (Emergency Trauma Training Course), AMI (Acute Myocardial Infarction) and D2B (Door to Balloon), COPD AE (Chronic Obstructive Pulmonary Disease with Acute Exacerbation) and TOCC (Travel, Occupation, Contact, and Cluster History Review), and Sepsis and CVC Procedure (Central Venous Catheter Procedure).
62376055|NCT05010395|EXPERIMENTAL|Arm 4: Action, Implementation, Picture|Individuals in this arm received a letter similar to Arms 2 and 3, but with the addition of an image of then HealthCare.gov Chief Executive Officer Kevin Counihan
62376056|NCT05010395|EXPERIMENTAL|Arm 5: Norm|"Individuals in this arm received a letter that included the following social norm sentence: Americans are enrolling but you haven't joined them."
62751946|NCT06607952|ACTIVE_COMPARATOR|The control group with traditional lecture-based teaching method.|The students in the control group will receive traditional lecture-based teaching on the five topics: Triage, SDH and ETTC, AMI and D2B, COPD AE and TOCC, and Sepsis and CVC Procedure.
62751947|NCT01079546||Sq.CC of head and neck TASMC|
62376057|NCT05010395|EXPERIMENTAL|Arm 6: Norm, Pledge|"Individuals in this arm received a letter that included a statement, to be checked in agreement, that I pledge to Get Covered at Healthcare.gov."
62376058|NCT05010395|EXPERIMENTAL|Arm 7: Loss Aversion|"Individuals in this arm received a letter that warned You risk paying a fee of $325 or 2% of your income-whichever is higher."
62376059|NCT05010395|EXPERIMENTAL|Arm 8: Kitchen Sink|Individuals in this arm received a letter that includes all behavioral dynamics except for the pledge (due to space limitations).
62376060|NCT02551328||Sevofluorane|Patients preconditioned with Sevo
62376061|NCT02551328||Propofol|Patients with no preconditioning
62376062|NCT01731808|NO_INTERVENTION|Standard care|All participants received three specially-developed brochures with information regarding the diabetic foot condition. The brochures contained explanations to a) the cause and warning signs of diabetic foot ulcers, b) the precautions patients can take in their daily life, and c) helpful foot gymnastics to be practiced at home. The participants who were randomized in the control group received standard care. Standard care consisted of either physician-prescribed inpatient or outpatient wound care.
62376063|NCT01731808|EXPERIMENTAL|Nursing counseling|
62376064|NCT03381352|EXPERIMENTAL|Chemo-radiotherapy with IMRT technique|Radiotherapy with IMRT technique concurrent with Capecitabine and MMC chemotherapy
62376065|NCT04547491|OTHER|GDT group|Cardiac optimization with goal-directed therapy, liberal use of vasopressor agents.
62376066|NCT04547491|EXPERIMENTAL|HPI group|Hemodynamic management HPI-based, protocol-based use of fluids, vasopressors and inotropes.
62376067|NCT00518336|EXPERIMENTAL|Cervarix Group|Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.
62751948|NCT01079546||hadassa Jerusalem|
62751949|NCT01079546||sheba hospital|
62751950|NCT01079546||rambam Haifa|
62376068|NCT00518336|PLACEBO_COMPARATOR|Placebo Group|Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.
62376069|NCT04065815|EXPERIMENTAL|Resistance Training (RT)|Individualized, protein-rich nutritional therapy combined with resistance training
62376070|NCT04065815|EXPERIMENTAL|WB-EMS|Individualized, protein-rich nutritional therapy combined with whole-body electromyostimulation (WB-EMS)
62751951|NCT01079546||belinson Petah Tikva|
62751952|NCT01079546||Nazeret|
62751953|NCT01079546||soroka beer sheva|
62751954|NCT04404114||Normal renal function|Normal renal function
62751955|NCT04404114||Acute kidney injury in normal kidney|Acute kidney injury in normal kidney
62751956|NCT04404114||Acute kidney injury in chronic kidney disease|Acute kidney injury in chronic kidney disease
62751957|NCT04404114||Chronic kidney disease|Chronic kidney disease
62751958|NCT01815554||DPS Cohort|All patients implanted with a DPS within the past 5 years at one of 6 collaborating sites will be included. Patients will be interviewed as they cross their 1st, 3rd, 5th or 7th anniversary with the DPS.
62751959|NCT01632475||Pneumostem®|Low Dose Group (3 subjects): 1.0 x 10\^7 cells/kg, High Dose Group (6 subjects): 2.0 x 10\^7 cells/kg
62751960|NCT05907954|EXPERIMENTAL|darovasertib|IDE196 (darovasertib) oral open label
62376071|NCT04065815|EXPERIMENTAL|High-intensity interval training (HIIT)|Individualized, protein-rich nutritional therapy combined with high-intensity interval training (HIIT)
62376072|NCT04065815|EXPERIMENTAL|Combined HIIT and Resistance Training (Combi)|Individualized, protein-rich nutritional therapy combined with a combined high-intensity interval training (HIIT) and resistance training
62376073|NCT03740139|EXPERIMENTAL|Intervention|"The Police-Mental Health Linkage System~In the case of an encounter between law enforcement and subjects randomized to this group, the officer will receive a notice disclosing that the participant receives services in a mental health clinic and that he/she has the opportunity to call to speak with a mental health professional."
62751961|NCT05731908|EXPERIMENTAL|BI 690517 mild hepatic impairment (Child-Pugh A)|
62751962|NCT05731908|EXPERIMENTAL|BI 690517 normal hepatic function|control group
62751963|NCT05731908|EXPERIMENTAL|BI 690517 moderate hepatic impairment (Child-Pugh B)|
62751964|NCT03817463||New users of SGLT-2i|Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i) including empagliflozin.
62751965|NCT03817463||New users of DPP-4i|Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i).
62751966|NCT02906449|EXPERIMENTAL|Mindfulness Training|Daily Mindfulness Training - both in-class lectures (weekly) and self-study (daily) over 3 weeks
62376074|NCT03740139|NO_INTERVENTION|No Intervention|In the case of an encounter between law enforcement and subjects randomized to this arm of the study, the officer will not receive any notice.
62376075|NCT03727776|EXPERIMENTAL|H.P. Acthar ®|Subjects will self-administer subcutaneous injections of 80 units of adrenocorticotropic hormone analog starting on post-operative day 1 for twice a week until week 8.
62751967|NCT02906449|ACTIVE_COMPARATOR|Relaxation Meditation Training|Daily Relaxation Meditation Training - both in-class lectures (weekly) and self-study (daily) over 3 weeks
62751968|NCT05519436||Morbid obesity individuals|
62751969|NCT05519436||Healthy individuals|
62751970|NCT05772663|EXPERIMENTAL|personalized program group|people with chronic stroke
62751971|NCT05772663|ACTIVE_COMPARATOR|routine rehabilitation care group|people with chronic stroke
62751972|NCT06596954|EXPERIMENTAL|lymphocyte-sparing radiotherapy|Firstly, ensure coverage of the PTV (Planning Target Volume). Secondly, limit the doses to the heart, bilateral lungs, and spinal cord to meet the required dose constraints. While maintaining target coverage and traditional OAR (Organs At Risk) dose constraints, also address dose limits for the TVB1-12 thoracic vertebral bodies, ribs, spleen, and major thoracic blood vessels to protect the lymphocyte
62751973|NCT06596954|ACTIVE_COMPARATOR|conventional radiotherapy|ensure coverage of the PTV (Planning Target Volume) and limit the doses to the heart, bilateral lungs, and spinal cord to meet the required dose constraints. do not limits the dose for lymphocyte-related organs
62751974|NCT00599391|OTHER|1|Far Infrared Radiation
62751975|NCT03424954|EXPERIMENTAL|EpxOstomy|Post-operative ileostomy patients will receive the study intervention for 30 days following discharge from the hospital.
62751976|NCT03620552|EXPERIMENTAL|18F-S16 injection and PET/CT scan|The subjects were intravenously injected with 370MBq 18F-S16 and underwent PET/CT scan immediately after the injection.
62751977|NCT02715882|EXPERIMENTAL|1 injection of CBLB502 0.35 μg/kg|One subcutaneous injection of CBLB502 0.35 μg/kg (not more 30 μg/injection) or Placebo at Day 1 before tumor removal
62751978|NCT02715882|EXPERIMENTAL|1 injection of CBLB502 0.45 μg/kg|One subcutaneous injection of CBLB502 0.45 μg/kg (not more 40 μg /injection) or Placebo at Day 1 before tumor removal
62751979|NCT02715882|EXPERIMENTAL|2 injections of CBLB502 0.35 μg/kg|Two subcutaneous injections of CBLB502 0.35 μg/kg (not more 30 μg/injection) or Placebo at Day 1 and Day 4 before tumor removal
62751980|NCT02715882|EXPERIMENTAL|2 injections of CBLB502 0.45 μg/kg|Two subcutaneous injections of CBLB502 at 0.45 μg/kg (not more 40 μg /injection) or Placebo at Day 1 and Day 4 before tumor removal
62751981|NCT06599710|OTHER|AndoSan 6 week intervention|Intervention; AndoSanTM, 60 ml/day for 6 weeks
62751982|NCT00884039|ACTIVE_COMPARATOR|30 mg anecortave acetate|
62751983|NCT00884039|ACTIVE_COMPARATOR|15 mg anecortave acetate|
62751984|NCT04620382|ACTIVE_COMPARATOR|Midodrine|Single oral dose of midodrine (5-10mg) combined with sham abdominal compression
62751985|NCT04620382|EXPERIMENTAL|Abdominal Compression|Abdominal compression (up to 40 mmHg) combined with a placebo pill
62751986|NCT00516893|EXPERIMENTAL|Natalizumab High Titer|natalizumab high titer 300 mg administered as intravenous (IV) infusion over 60 minutes once every 4 weeks for up to 9 doses
62751987|NCT06489821|EXPERIMENTAL|Stereotactic body radiotherapy (SBRT) plus continuation of first line systemic therapy|SBRT in 5 or 2 (or 4) fractions for body and spine respectively over 2 weeks, while continuing first line systemic therapy
62751988|NCT02378012|ACTIVE_COMPARATOR|GROUP A (participants provide own computer or tablet device)|A member of the research personnel helps the participants install Netflix, Spotify, and Skype applications on their computers if they wish to do so. Participants will be given subscriptions to each application and usernames for access on days -5 to 10.
62751989|NCT02378012|EXPERIMENTAL|GROUP B (Apple BuckiPad)|Participants receive an iPad for days -5 to 10. Participants also receive the BuckiPad manual for instructions on how to use the iPad and Netflix, Skype, and Spotify applications. Participants are also directed to the official Apple's iPad user's manual on their device and have questions answered by research personnel on day -5.
62751990|NCT02378012|NO_INTERVENTION|GROUP C (no intervention)|Participants do not receive an iPad for days -5 to 10.
62751991|NCT04527237|EXPERIMENTAL|acupressure|"The person will be given 2 applications a day at 12-hour intervals and 6 applications in 72 hours in total.Physiological measurements will be made before and after the acupressure application. Physiological measurements 10-15 min. From acupressure application. will be taken before and the same measurements after acupressure 20-30. Will be taken again in the min interval. In addition, the Continuous Anxiety Scale will be applied once before application, the State Anxiety Scale will be applied once before the application and 3 times in total after the application at the end of every 24 hours. Sleep Scale will be applied 3 times in total before the next day after application.~Application to acupressure points in a certain order; Baihui, Susanli, Hegu, Shenmen and Quchi will be held.~After 2-3 minutes of approach to the patient and proper positioning, 20 seconds of preparation of each of the notes will be prepared and then 2 minutes acupressure application will be applied to each point."
62751992|NCT04527237|PLACEBO_COMPARATOR|placebo|The false acupressure application steps (temperature of the environment, patient's position, application time, frequency and repetition, evaluation period etc.) will be the same as the acupressure application steps. Unlike acupressure, it will only be in contact with wearing gloves to reduce the electrical effect of touch, away from the actual acupressure points. Touching any part of the body or making skin contact can be an effect alone, as well as other meridians and points are located near the existing meridian and selected points, and entering their area of influence, pressing or scrubbing can cause other effects to be activated.
62751993|NCT01723293|NO_INTERVENTION|Control|Sedentary pregnant women
62751994|NCT01723293|EXPERIMENTAL|Exercise group|
62751995|NCT05745987|EXPERIMENTAL|Smallpox vaccine|Participants will receive the Bavarian Nordic smallpox vaccine 0.5 ml single-dose
62751996|NCT05745987|ACTIVE_COMPARATOR|Typhoid vaccine|Participants will receive the Typhim Vi® typhoid vaccine 0.5 ml single-dose
62751997|NCT01029990|EXPERIMENTAL|Telephone arm|A midwife tries to contact the woman by telephone and offer her an appointment for a PAP-smear
62751998|NCT01029990|EXPERIMENTAL|Self-test arm|
62751999|NCT01029990|NO_INTERVENTION|Control arm|No intervention other than what is routine in the screening program
62752000|NCT00340860||Norweigian Population-Based Pregnancy Cohort|Norwegian-speaking pregnant women, their children born post enrollment, and enrolled children's fathers
62752001|NCT02591667|EXPERIMENTAL|Active treatment|"Patients will first undergo upfront staging laparoscopy with retrieval of tumor tissue for standard pathology.~Two to 4 weeks after initial surgical exploration, patients will receive 4 cycles of FOLFOXIRI + bevacizumab, q2w. The last chemotherapy cycle will be given without bevacizumab.~Five to 7 weeks after the last administration of bevacizumab (i.e., 3 to 5 weeks after completion of chemotherapy), patients will undergo surgery with the intent to perform complete surgical cytoreduction of all peritoneal tumor deposits. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, will be given at the discretion of the investigator."
62376076|NCT03727776|NO_INTERVENTION|Controls|Subjects will be managed per the standard of care.
62376077|NCT01337791|NO_INTERVENTION|control|
62376078|NCT01337791|NO_INTERVENTION|telbivudine|
62376079|NCT00164788|ACTIVE_COMPARATOR|IV Nexium|Intravenous bolus injection of esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
62376080|NCT00164788|ACTIVE_COMPARATOR|Oral Nexium|Oral esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 40mg every 12 hours for 24 hours
62376081|NCT01316835||Type 2 Diabetes Mellitus, No treatment|
62376082|NCT00802880|EXPERIMENTAL|Dacarbazine|Dacarbazine 850 mg/m\^2 IV Day 1 of each 21 day cycle.
62376083|NCT01700140|EXPERIMENTAL|SyB D-0701: high dose group|
62376084|NCT01700140|EXPERIMENTAL|SyB D-0701: low dose group|
62376085|NCT01700140|PLACEBO_COMPARATOR|placebo group|
62376086|NCT02240524|EXPERIMENTAL|D2 lymphadenectomy and HIPEC and Systemic chemotherapy|"Intraoperative and postoperative hyperthermic intraperitoneal chemotherapy (twice HIPEC) were performed after radical gastrectomy with D2 lymphadenectomy, followed by 8 cycles of systemic chemotherapy.~HIPEC was conducted within 48 h after surgery: Normal saline 3000ml-4000ml, Paclitaxel 75mg/m\^2, 43°C, 60min.~Systemic chemotherapy (XELOX):~Oxaliplatin: 130mg/m\^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m\^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance."
62376087|NCT02240524|PLACEBO_COMPARATOR|D2 lymphadenectomy+Systemic chemotherapy|"8 cycles of systemic chemotherapy were performed after radical gastrectomy with D2 lymphadenectomy.~Systemic chemotherapy (XELOX):~Oxaliplatin: 130mg/m\^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m\^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance."
62376088|NCT03344874|EXPERIMENTAL|Stethee (new stethoscope)|"Test 1: Use Stethee® to auscultate and identify a set of 10 manikin-simulated heart sounds.~Test 2: After a 10-minute break, use 3MTM Littmann® Classic IIITM to auscultate and identify the same set of 10 manikin-simulated heart sounds but played in a different sequence to Test 1."
62555950|NCT02074150|EXPERIMENTAL|Change from Baseline in PGAS|Change from Baseline in PGAS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The Physician Global Assessment Scale or PGAS is a 9 category scale scoring the physician's evaluation of the patients' status compared to baseline, ranging from -4 to +4 (very marked worsening to complete improvement), with 0 indicating no change from baseline and +1 slight improvement.
62555951|NCT02074150|EXPERIMENTAL|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30
62752002|NCT04934709|EXPERIMENTAL|PBMT-sMF|Volunteers underwent intervention (active PBMT-sMF) in the non-dominant lower limb. A single application was performed at each phase of the trial, between the first and second set of the exercise protocol.
62752003|NCT04934709|PLACEBO_COMPARATOR|Placebo|Volunteers underwent intervention (placebo PBMT-sMF) in the non-dominant lower limb. A single application was performed at each phase of the trial, between the first and second set of the exercise protocol.
62376089|NCT03344874|ACTIVE_COMPARATOR|Littmann (conventional stethoscope)|"Test 1: Use 3MTM Littmann® Classic IIITM to auscultate and identify a set of 10 manikin-simulated heart sounds.~Test 2: After a 10-minute break, use Stethee® to auscultate and identify the same set of 10 manikin-simulated heart sounds but played in a different sequence to Test 1."
62376090|NCT00794469||Water|obese children (body mass index \> 95th percentile for age and sex) that will drink cold water
62752004|NCT02203383||Pts with CSA for CRT implantation|Patients with heart failure (EF\<40%) and moderate to severe CSA (\>15 events per hour, \>50% Central)
62752005|NCT02203383||No Sleep Apnoea for CRT implantation|Heart failure (EF \< 40%) but no significant sleep apnoea (\<5 events per hour).
62752006|NCT06542575|EXPERIMENTAL|DTx-guided HBCR group|
62752007|NCT06542575|NO_INTERVENTION|Usual care group|
62752008|NCT00284557|EXPERIMENTAL|Group-based behavioral intervention|"The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter."
62376091|NCT03140488|ACTIVE_COMPARATOR|Lean-Control|"1) Control group: Lean cohort: BMI ≤25, at \<20 weeks gestation or BMI ≤28 at a term gestation, low dose oxytocin protocol~Low dose oxytocin regimen (the standard at Banner University Labor and Delivery, as well as across the United States): 30 units in 500cc 0.9% normal saline bag (60 milliunit/cc). Starting rate would be 2 milliunit/minute, or 2cc/hour. The medication will be increased by 2 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 20 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
62376092|NCT03140488|EXPERIMENTAL|Lean-Intervention|"2) Intervention group: Lean cohort: BMI ≤25, at \<20 weeks gestation or BMI ≤28 at a term gestation, high dose oxytocin protocol~High dose oxytocin regimen (endorsed by American College of Obstetricians and Gynecologists): 90 units in 500cc 0.9% normal saline bag (180 milliunit/cc). Starting rate would be 6 milliunit/minute, or 2cc/hour. The medication will be increased by 6 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 60 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
62376093|NCT03140488|ACTIVE_COMPARATOR|Obese-Control|"3) Control group: Obese cohort: BMI ≥30, at \<20 weeks gestation or BMI ≥35 at a term gestation, low dose oxytocin protocol~Low dose oxytocin regimen (the standard at Banner University Labor and Delivery, as well as across the United States): 30 units in 500cc 0.9% normal saline bag (60 milliunit/cc). Starting rate would be 2 milliunit/minute, or 2cc/hour. The medication will be increased by 2 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 20 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
62555952|NCT02074150|EXPERIMENTAL|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62555953|NCT02074150|EXPERIMENTAL|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62555954|NCT02074150|EXPERIMENTAL|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62555955|NCT02074150|EXPERIMENTAL|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62752009|NCT00284557|ACTIVE_COMPARATOR|Health education materials only|Those allocated to Group 2 were provided with a standardized packet of health education materials addressing the recommended items from the expert committee guidelines (e.g., dietary recommendations using the Food Guide Pyramid and the Traffic Light Diet, a general prescription to increase physical activity to 60 minutes daily). They were also given a community resource list that provides contact and program information for community-based obesity treatment activities in their area.
62752010|NCT05353712|EXPERIMENTAL|Group T: ABCDEF|Participants will receive all six blind-coded samples, in the order A, B, C, D, E, F. There will be a minimum of 7 days washout between samples.
62752011|NCT05353712|EXPERIMENTAL|Group V: FABCDE|Participants will receive all six blind-coded samples, in the order F, A, B, C, D, E. There will be a minimum of 7 days washout between samples.
62752012|NCT05353712|EXPERIMENTAL|Group W: EFABCD|Participants will receive all six blind-coded samples, in the order E, F, A, B, C, D. There will be a minimum of 7 days washout between samples.
62752013|NCT05353712|EXPERIMENTAL|Group X: DEFABC|Participants will receive all six blind-coded samples, in the order D, E, F, A, B, C. There will be a minimum of 7 days washout between samples.
62555956|NCT02074150|EXPERIMENTAL|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62555957|NCT02074150|EXPERIMENTAL|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62752014|NCT05353712|EXPERIMENTAL|Group Y: CDEFAB|Participants will receive all six blind-coded samples, in the order C, D, E, F, A, B. There will be a minimum of 7 days washout between samples.
62752015|NCT05353712|EXPERIMENTAL|Group Z: BCDEFA|Participants will receive all six blind-coded samples, in the order B, C, D, E, F, A. There will be a minimum of 7 days washout between samples.
62752016|NCT02359045|EXPERIMENTAL|Part 1: Treatment A-B-C-D|Subjects received a single dose of D1400147 (Treatment A: Omega-3-carboxylic acids 2000 mg uncoated capsules), D14000136 (Treatment B: Omega-3-carboxylic acids 2000 mg coated capsules coat 1), D14000137 (Treatment C: Omega-3-carboxylic acids 2000 mg coated capsules coat 2) and Epanova® (Treatment D: Epanova capsules 1000 mg) under fasted condition.
62752017|NCT02359045|EXPERIMENTAL|Part 2: Treatment A-B/C-D|Subjects received a single dose of D1400147 (Treatment A: Omega-3-carboxylic acids 2000 mg uncoated capsules), D14000136 (Treatment B: Omega-3-carboxylic acids 2000 mg coated capsules coat 1) or D14000137 (Treatment C: Omega-3-carboxylic acids 2000 mg coated capsules coat 2) and Epanova® (Treatment D: Epanova capsules 1000 mg) under fed condition.
62752018|NCT06474507|EXPERIMENTAL|CBS therapy, CBS dosage: 100mg per day from day 1 to day 84, in ICVD cohort|Subjects in ICVD cohort of this arm will receive general therapy plus CBS.
62752019|NCT06474507|NO_INTERVENTION|Control therapy: no intervention, in ICVD cohort.|Subjects in ICVD cohort of this arm will only receive general therapy.
62752020|NCT06474507|EXPERIMENTAL|CBS therapy, CBS dosage: 100mg per day from day 1 to day 84, in healthy cohort|Subjects in healthy cohort of this arm will only receive CBS.
62752021|NCT03167970||Pill cam and EGD|Patients in this arm is requested to swallow the esophageal capsule and then undergo standard EGD.
62752022|NCT00882037||Meth Dependence|Methamphetamine Dependence in residential Substance Abuse Treatment Program
62752023|NCT04274049|EXPERIMENTAL|investigational produc|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
61986448|NCT03558399|EXPERIMENTAL|FET according to ERA|In preparation for frozen embryo transfer (FET), estradiol will be administered for approximately 10 to 14 days or until endometrial criteria are met. These endometrial criteria will be assessed with transvaginal ultrasound and serum estradiol levels. Women will then begin intramuscular progesterone injection and if assigned to the study arm, a single euploid embryo will be transferred at the time indicated by the ERA test results. Merely the timing of embryo transfer will distinguish the study from the control group.
62752024|NCT04274049|PLACEBO_COMPARATOR|Placebo|Patients in this group will receive normal saline respective in D0、14、18
62752025|NCT05210803||Roll over|No intervention All subjects that previously received RGX-314 in a parent study
62752026|NCT05133622|ACTIVE_COMPARATOR|Covid-19 group|"Individuals between the ages of 20-30 Individuals who were diagnosed with COVID-19 positive in the last 3-10 months and were treated with home isolation and whose last PCR test was negative Individuals who had not to get vaccinated Individuals whose physical activity level is between 600-3000 MET min/week according to International Physical Activity Questionnaire-Short form (IPAQ-SF) (sedentary)"
62752027|NCT05133622|ACTIVE_COMPARATOR|Control group|Individuals between the ages of 20-30 Individuals who have not been diagnosed with COVID-19 positive Individuals who had not to get vaccinated Individuals whose physical activity level is between 600-3000 MET min/week according to the IPAQ-SF (sedentary)
62752028|NCT06414148|EXPERIMENTAL|Arm A|EPCORITAMAB (EPCOR-ONLY)
62752029|NCT06414148|EXPERIMENTAL|Arm B|EPCORITAMAB, LENALIDOMIDE AND RITUXIMAB (EPCOR-R2)
62752030|NCT00713349|OTHER|1|Xenaderm Vehicle
62752031|NCT00713349|PLACEBO_COMPARATOR|2|Placebo Comparator
62752032|NCT03317626|EXPERIMENTAL|Cold Stimulus|The study procedure will beto use a coldstimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted
62376094|NCT03140488|EXPERIMENTAL|Obese-Intervention|"4) Intervention group: Obese cohort: BMI ≥30, at \<20 weeks gestation or BMI ≥35 at a term gestation, high dose oxytocin protocol~High dose oxytocin regimen (endorsed by American College of Obstetricians and Gynecologists): 90 units in 500cc 0.9% normal saline bag (180 milliunit/cc). Starting rate would be 6 milliunit/minute, or 2cc/hour. The medication will be increased by 6 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 60 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
62376095|NCT04316286|EXPERIMENTAL|Tele-multidisciplinary participants|Patients undergoing televisit
62752033|NCT05370963|ACTIVE_COMPARATOR|hyalase group|Bupivacaine 5 mg (1 mL) + Triamcinolone 40 mg (1 mL) + Saline solution (2 mL) + Hyaluronidase 1,500 IU reconstituted in 1 mL distilled water (HYL)
62752034|NCT05370963|ACTIVE_COMPARATOR|dexmedtemodine group|Bupivacaine 5 mg (1 mL) + Triamcinolone 40 mg (1 mL) + Saline solution (2 mL) + Dexmedetomidine 0.5 mic/kg
62555958|NCT02074150|EXPERIMENTAL|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62555959|NCT02074150|EXPERIMENTAL|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62376096|NCT04316286|OTHER|In-office standard participants|Patients undergoing in-office visits
62376097|NCT02411669||Health care professionals|Physicians, nurses and managerial staff
62376098|NCT00369928|PLACEBO_COMPARATOR|Placebo|Placebo, oral dose, BID
62376099|NCT00369928|EXPERIMENTAL|25 mg PG-760564|25 mg BID, of oral PG-760564
62376100|NCT00369928|EXPERIMENTAL|100 mg PG-760564|100 mg BID, of oral PG-760564
62376101|NCT03952689|EXPERIMENTAL|Post cardiac surgery patients|For all patients, readings of the urine output from both the Serenno system and the collection bag (urinometer) (by camera) will be recorder every 10 minutes, for the duration of 24 hours.
62376102|NCT03416517|EXPERIMENTAL|Anlotinib and Irinotecan(phase 1b)|Anlotinib 12 or 8 mg/d PO on days 1-14 q3w. Irinotecan 20 or 15mg/m\^2/d over 60 minutes on days 1-5 and 8-12 q3w. Vincristine 1.4mg/m\^2/d IV on days 1,8 q3w. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
62376103|NCT03416517|EXPERIMENTAL|Anlotinib and Irinotecan(phase 2)|Anlotinib 12 or 8 mg/d PO on days 1-14 q3w. Irinotecan 20 or 15 mg/m\^2/d IV over 60 minutes on days 1-5 and 8-12 q3w. The final dose of anlotinib and irinotecan depends on the result from previous phase Ib study. Vincristine 1.4mg/m\^2/d IV on days 1,8 q3w. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
62376104|NCT05565599|EXPERIMENTAL|Treatment|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure system.
62376105|NCT01166386|EXPERIMENTAL|First steps treatment intervention|"A brief 10-session manualized acute neurobehavioral intervention program will be individually implemented with randomly assigned treatment participants. Session components include injury-related education, enhancement of self-awareness of deficits from the TBI, coping and cognitive skills training, and supported practice. The acronym FANCI refers to the name of the program which is First Steps Acute Neurobehavioral and Cognitive Intervention."
62376106|NCT01166386|PLACEBO_COMPARATOR|standard rehabilitation care|The controls will spend 10 one-half hours with a therapist viewing videos they choose from a menu, some of which have to do with brain injury. The therapist will interact naturally with the controls and occasionally relate the movie or film to brain injury rehabilitation.
62376107|NCT01875666|ACTIVE_COMPARATOR|Trastuzumab|single dose intravenous infusion administration of trastuzumab (8 mg/kg)
62376108|NCT01875666|ACTIVE_COMPARATOR|pertuzumab|single dose infusion of pertuzumab (840 mg)
62376109|NCT01875666|ACTIVE_COMPARATOR|trastuzumab plus pertuzumab|single dose infusion of combination trastuzumab (8 mg/kg) plus pertuzumab (840 mg)
62376110|NCT01875666|ACTIVE_COMPARATOR|trastuzumab plus lapatinib|combination of single dose infusion of trastuzumab (8 mg/kg) plus oral lapatinib (1000 mg daily for 7 days)
62376111|NCT01351714|OTHER|D3 resection|Radical D3 resection of the right colon through the use of preoperative MDCT angiography
62376112|NCT04451694||Covid-19 unit outgoing patients|nutritional evaluation and intervention
62376113|NCT04989595||Women_Kyleena|
62376114|NCT04989595||Women_Jaydess|
62376115|NCT04989595||Women_Mirena|
62376116|NCT05776355|EXPERIMENTAL|Ovarian cancer|
62376117|NCT03401216|EXPERIMENTAL|SYNERGY 48 PCI + 3 month OCT follow-up|Synergy 48 mm stent implantation followed by 3 month OCT imaging
62555960|NCT02074150|EXPERIMENTAL|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62555961|NCT02074150|EXPERIMENTAL|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62555962|NCT06488287|EXPERIMENTAL|Real stimulation|Participants in this arm will receive 6 sessions of real tDCS.
62752035|NCT05594121|EXPERIMENTAL|Extended-release subcutaneous buprenorphine (SC-BPN-XR)|For eligible patients randomly allocated to SC-BPN-XR, the first dose will be administered at the time of randomization (Day 0). SC-BPN-XR comes in two formulations, 100 mg and 300 mg buprenorphine doses in a pre-filled syringe. SC-BPN-XR administration is by subcutaneous injection in the abdomen. SC-BPN-XR is administered at intervals ≥26 days. For patients randomly allocated to SC-BPN-XR, they will receive the 300 mg dose for the first 2 months, followed by the 100 mg dose every month until the end of the 12-month period. All SC-BPN-XR doses will be administered in clinics by trained personnel. All patients receiving SC-BPN-XR will have their vital signs monitored every 5 minutes for 15 minutes after the injection before leaving the clinic.
62752036|NCT05594121|ACTIVE_COMPARATOR|Immediate-release sublingual buprenorphine/naloxone (SL-BPN/NX)|For eligible patients randomly allocated to SL-BPN/NX, the first study dose will be administered at the time of randomization (Day 0) and will match the SL-BPN/NX type (tablet versus film), route (sublingual versus buccal) and dose used for stabilization prior to study enrollment. For the first 2 weeks of the study period, all SL-BPN/NX administration will be directly observed at community pharmacies by trained personnel according to the usual standard of care. Subsequent to this period, healthcare providers and participants will develop a care plan for ongoing directly observed therapy vs unsupervised take-home dosing according to usual standard of care.
62752037|NCT05460364|EXPERIMENTAL|Sequence 1|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 1: A-B-C"
62752038|NCT05460364|EXPERIMENTAL|Sequence 2|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 2: A-C-B"
62752039|NCT05460364|EXPERIMENTAL|Sequence 3|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 3: B-A-C"
62752040|NCT05460364|EXPERIMENTAL|Sequence 4|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 4: B-C-A"
62752041|NCT05460364|EXPERIMENTAL|Sequence 5|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 5: C-A-B"
62752042|NCT05460364|EXPERIMENTAL|Sequence 6|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 6: C-B-A"
62752043|NCT04686084|EXPERIMENTAL|CT scan|CT scan (MDCT, standard of care) and DE-CBCT (Investigational)
62752044|NCT01320319|PLACEBO_COMPARATOR|Placebo|
62555963|NCT06488287|PLACEBO_COMPARATOR|Sham stimulation|Participants in this arm will receive 6 sessions of sham tDCS.
62752045|NCT01320319|EXPERIMENTAL|Nutritional Supplementation with EPA|This arm will receive the nutritional supplementation of EPA 960mg Three times a day.
62752046|NCT04342026||Parent of patient with cryptorchidism|parent exposition of endocrine disruptors
62752047|NCT04342026||Parent of patient without cryptorchidism|Parent exposition of endocrine disruptors
62752048|NCT04801238|ACTIVE_COMPARATOR|LCBDE + LC|Laparoscopic common bile duct exploration with laparoscopic cholecystectomy
62376118|NCT03401216|EXPERIMENTAL|SYNERGY 48 PCI + 6 month OCT follow-up|Synergy 48 mm stent implantation followed by 6 month OCT imaging
62376119|NCT05102344|ACTIVE_COMPARATOR|Psychosocial Treatment as Usual|Participants assigned to the active comparator arm will receive active non-pharmacological treatment utilizing behavioral social skills training strategies previously found to be effective in reducing symptoms of ADHD and improving social skills for children with ADHD
62376120|NCT05102344|EXPERIMENTAL|Animal Assisted Intervention|Participants assigned to the experimental arm will receive active non-pharmacological treatment utilizing behavioral social skills training strategies previously found to be effective in reducing symptoms of ADHD and improving social skills for children with ADHD accompanied by live therapy dogs
62376121|NCT01271595|ACTIVE_COMPARATOR|acupuncture|12 sessions of acupuncture according to TCM
62376122|NCT01271595|SHAM_COMPARATOR|sham acupuncture|superficial acupuncture at non acupuncture sites
62752049|NCT04801238|ACTIVE_COMPARATOR|ERC + LC|Endoscopic retrograde cholangiography with laparoscopic cholecystectomy
62752050|NCT04484896|EXPERIMENTAL|Gain-frame Message|"Short messaging service (SMS) message: Dear group O/A Rh-D negative blood donor:~Hello! The inventory of group O/A Rh-D negative blood product is low at present, but patients with such blood group are in urgent need of blood. If you can, please consider donating blood again to save lives. Thank you for your support.~Please bring your identification (ID) card and show this message to our staff. Thank you."
62752051|NCT04484896|EXPERIMENTAL|Loss-frame Message|"SMS message: Dear group O/A Rh-D negative blood donor:~Hello! The inventory of group O/A Rh-D negative blood product is low at present, but patients with such blood group are in urgent need of blood. If you can, please consider donating blood again to prevent the loss of life. Thank you for your support.~Please bring your ID card and show this message to our staff. Thank you."
62752052|NCT04484896|EXPERIMENTAL|Information Message|"SMS message: Dear group O/A Rh-D negative blood donor:~Hello! The inventory of group O/A Rh-D negative blood product is low at present, if you can, please consider donating blood again. Thank you for your support.~Please bring your ID card and show this message to our staff. Thank you."
62752053|NCT04484896|NO_INTERVENTION|Control group|Donors in this group were not received SMS reminders.
62752054|NCT01824823|EXPERIMENTAL|Arm A (afatinib)|Patients receive afatinib PO QD on days 1-28.
62752055|NCT01824823|PLACEBO_COMPARATOR|Arm B (placebo)|Patients receive placebo PO QD on days 1-28.
62752056|NCT05925413|EXPERIMENTAL|Cadonilimab+TACE|Cadonilimab (15mg/kg Q3W D1)+TACE
62752057|NCT01345591|EXPERIMENTAL|Fat Grafting|Twenty (20) subjects who have had severe facial trauma, 18 years of age and older enrolled to clinical trial will receive Fat grafting intervention procedure
62752058|NCT04275271|EXPERIMENTAL|Intervention group|Intervention group will be received sexuality teaching skills for promotion of professional competence based on information, motivation and behavioral skills model for adolescent sexuality after signing informed consent form and being informed about the goals and details of intervention for 6 sessions (one two hour session per week).
62376123|NCT03053713|ACTIVE_COMPARATOR|Mediterranean Diet Pattern|Mediterranean diet pattern x 12 weeks.
62376124|NCT03053713|PLACEBO_COMPARATOR|Habitual Diet|Habitual diet (control) x 12 weeks.
62376125|NCT04065295|EXPERIMENTAL|Single Rising Dose Part|
62376126|NCT04065295|EXPERIMENTAL|Bioavailability Part|
62376127|NCT02789800|ACTIVE_COMPARATOR|Group A|Intervention group (n = 163) Intervention: Participates in DIMAC02 Program
62376128|NCT02789800|NO_INTERVENTION|Group B|Control group (n = 163)
62376129|NCT02789800|NO_INTERVENTION|Group C|Health Administrative Data Group (n = 1630) Number of matched data controls. Not taking part in intervention.
62376130|NCT04317898|ACTIVE_COMPARATOR|serratus plane block|20 ml of Bupivacine 0.25% +80mg triamcinlone will be injected in serratus plane under ultrasound.
62752059|NCT04275271|NO_INTERVENTION|Control group|The control group will not receive any intervention until the end of the research.
62752060|NCT00241631|PLACEBO_COMPARATOR|Placebo|Inhaled Theophylline placebo capsule, then placebo, then active Theophylline
62752061|NCT00241631|ACTIVE_COMPARATOR|Steroid|Inhaled Theophylline placebo capsule, then Fluticasone Propionate 500 ug bid, then active Theophylline
62752062|NCT06607133||surgery group|patients treated with thyroidectomy for benign thyroid nodules
62752063|NCT06607133||thermal ablation group|patients treated with staged thermal ablation for benign thyroid nodules
62752064|NCT03453762|ACTIVE_COMPARATOR|Recruitment maneuver group|After anesthetic induction, recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
62752065|NCT03453762|EXPERIMENTAL|Lung ultrasonography group|After anesthetic induction, recruitment maneuver is performed, being guided by ultrasonography.
62752066|NCT03699059|OTHER|Health Care Professionals|A purposeful sample of 5 HCP's from the transplant team will test the online intervention and be interviewed using qualitative methods. This data will be analysed and used to plan a second study (feasibility RCT).
62752067|NCT03699059|OTHER|Kidney Transplant Patients|A purposeful sample of 10 kidney transplant patients will test the online intervention and be interviewed using qualitative methods. This data will be analysed and used to plan a second study (feasibility RCT).
62752068|NCT05864365|EXPERIMENTAL|ATH434|
62376131|NCT04317898|ACTIVE_COMPARATOR|paravertebral block|10 ml of bubivacine 0.25% +80 mg triamcinlone will be injected at T2 level (paravertebral) under ultrasound.
62376132|NCT01256606||Positive for fetal aneuploidy|
62376133|NCT01256606||Negative for fetal aneuploidy|
62376134|NCT01572480|EXPERIMENTAL|Group A - (closed) - Carfilzomib with Revlimid and Dexamethasone|Carfilzomib (intravenous (IV), Days 1, 2, 8, 9, 15, and 16 of the 28-day cycle); Revlimid (by mouth (PO), Days 1-21 of the 28-day cycle; exception: not given on cycle 1 day 1); and Dexamethasone (PO or IV, Days 1, 2, 8, 9, 15, 16, 22, and 23 of the 28-day cycle; exception: not given on cycle 1 day 1)
62376135|NCT01572480|EXPERIMENTAL|Group B - Carfilzomib with Revlimid and Dexamethasone|Carfilzomib (intravenous (IV), Days 1, 2, 8, 9, 15, and 16 of the 28-day cycle); Revlimid (by mouth (PO), Days 1-21 of the 28-day cycle); and Dexamethasone (PO or IV, Days 1, 2, 8, 9, 15, 16, 22, and 23 of the 28-day cycle)
62376136|NCT00656994|EXPERIMENTAL|Ramelteon 16 mg QD|
62752069|NCT05231577|EXPERIMENTAL|Experimental: Patients in Group 0 undergo 7.5fr ultra-fine ureteroscopy|
62376137|NCT00656994|PLACEBO_COMPARATOR|Placebo|
62752070|NCT05231577|EXPERIMENTAL|Experimental: Patients in Group 2 undergo 9.2fr ureteroscopy|
62752071|NCT04043234|EXPERIMENTAL|Single-Case Experimental Design|Participants act as their own controls. They first use the Control device, which includes the pattern recognition controller, 8 electrodes, batteries, socket, frame, and prosthesis terminal device (hand/wrist/elbow). Participants are then transitioned to the Experimental device, which includes the RESCU controller, Apple iPad, 8 electrodes, batteries, socket, frame, and prosthesis terminal device (hand/wrist/elbow).
62752072|NCT05557552|EXPERIMENTAL|standar thoracic RT dose|Sequential chemo-immunotherapy plus standard dose of thoracic radiotherapy followed by anti-PD-1/PD-L1 maintenance therapy
62752073|NCT05557552|EXPERIMENTAL|decreased thoracic RT dose|Sequential chemo-immunotherapy plus decreased thoracic radiotherapy followed by anti-PD-1/PD-L1 maintenance therapy
62752074|NCT03103204|EXPERIMENTAL|Normal weight full-mouth disinfection|"* Normal weight (body mass index 18.5 - 24.9 kg/m2) individuals with chronic periodontitis~* Full-mouth manual scaling and root planing within 24 hours~* tongue cleaning with chlorhexidine gel 1% for 1 minute~* tonsils disinfection with chlorhexidine spray 0.2%~* rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~* subgingival irrigation of all periodontal pockets with 1% chlorhexidine solution~* daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
62752075|NCT03103204|EXPERIMENTAL|Overweight full-mouth disinfection|"* Overweight (body mass index 25.0 - 29.9 kg/m2) individuals with chronic periodontitis~* Full-mouth manual scaling and root planing within 24 hours~* tongue cleaning with chlorhexidine gel 1% for 1 minute~* tonsils disinfection with chlorhexidine spray 0.2%~* rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~* subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~* daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
62752076|NCT03103204|EXPERIMENTAL|Obesity I full-mouth disinfection|"* Obesity I (body mass index 30.0 - 34.9 kg/m2) individuals with chronic periodontitis~* Full-mouth manual scaling and root planing within 24 hours~* tongue cleaning with chlorhexidine gel 1% for 1 minute~* tonsils disinfection with chlorhexidine spray 0.2%~* rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~* subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~* daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
62752077|NCT03103204|EXPERIMENTAL|Obesity II full-mouth disinfection|"* Obesity II (body mass index 35.0 - 39.9 kg/m2) individuals with chronic periodontitis~* Full-mouth manual scaling and root planing within 24 hours~* tongue cleaning with chlorhexidine gel 1% for 1 minute~* tonsils disinfection with chlorhexidine spray 0.2%~* rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~* subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~* daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
62376138|NCT04844892|EXPERIMENTAL|PROTECT Diaphragm Pacing Therapy|
62376139|NCT01930669|OTHER|All patients|To measure the autonomic nervous system activity elicited by a gravitational sympathetic stimulus in critically ill
62376140|NCT00732472|EXPERIMENTAL|7 day repeat dose|7 day repeat dose
62376141|NCT04974411||Infection|Patients diagnosed with infection but did not reach the sepsis marker.
62376142|NCT04974411||sepsis|The patient was diagnosed with sepsis but did not develop septic shock
61986449|NCT03558399|ACTIVE_COMPARATOR|FET according to standard protocol|In preparation for frozen embryo transfer (FET), estradiol will be administered for approximately 10 to 14 days or until endometrial criteria are met. These endometrial criteria will be assessed with transvaginal ultrasound and serum estradiol levels. Women will then begin intramuscular progesterone injection and if assigned to the control arm, a single euploid embryo will be transferred according to our standard FET protocol.
62376143|NCT04974411||sepsis shock|The patient was diagnosed with sepsis shock
62376144|NCT03488706||Gray Zone Group|The gray zone group PSA between 4.00 to 10.99 ng/ml.
61986450|NCT01140321|EXPERIMENTAL|Neridronato|Thalassemia Major or Severe Thalassemia Intermedia
61986451|NCT01140321|NO_INTERVENTION|Placebo|Thalassemia Major or Severe Thalassemia Intermedia
62752078|NCT03103204|EXPERIMENTAL|Obesity III full-mouth disinfection|"* Obesity III (body mass index ≥ 40.0 kg/m2) individuals with chronic periodontitis~* Full-mouth manual scaling and root planing within 24 hours~* tongue cleaning with chlorhexidine gel 1% for 1 minute~* tonsils disinfection with chlorhexidine spray 0.2%~* rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~* subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~* daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
62752079|NCT01678573|EXPERIMENTAL|Sequence 1: abiraterone acetate|"Randomly assigned participants in Sequence 1 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule ABC under fasted conditions."
61986452|NCT01899534|NO_INTERVENTION|Paper-based screening|Paper-based screening. Women will complete a mental health screening tool on paper (usual care).
62752080|NCT01678573|EXPERIMENTAL|Sequence 2: abiraterone acetate|"Randomly assigned participants in Sequence 2 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule BAC under fasted conditions."
62376145|NCT06102291|EXPERIMENTAL|Acupoint application with Yanqing Zhitong Ointment|"Acupoint selection: Ashi points, Shenshu (BL23), Guanyuanshu (BL26) Operation: Stick to each acupoint for about 4 hours. If there is a burning sensation or obvious itching or other discomfort on the part after application, it can be removed in advance.~Treatment Duration: Three times a week( Monday, Wednesday, and Friday), for four weeks"
62376146|NCT06102291|ACTIVE_COMPARATOR|Acupuncture|"Acupoint selection: Ashi points, Shenshu (BL23), Guanyuanshu (BL26) Operation: Disposable stainless steel needles (0.25mm×25mm) are used. The needles are retained for 20 mins afte Deqi.~Treatment Duration: Three times a week( Monday, Wednesday, and Friday), for four weeks"
62376147|NCT01178190||lung cancer|
62376148|NCT00471276|EXPERIMENTAL|1|
62376149|NCT01697189|EXPERIMENTAL|Fatigue management training|Experimental group subjects participated in a single half-day fatigue management training session.
62376150|NCT01697189|NO_INTERVENTION|No fatigue management training|The control group subjects did not participate in the fatigue management training.
62555964|NCT05446558|EXPERIMENTAL|Intracorporeal anastomosis (IA)|Experimental: Intracorporeal anastomosis Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen is retrieved through a Pfannenstiel incision.
61986453|NCT01899534|EXPERIMENTAL|E-screening|Women will complete mental health screening on a tablet
61986454|NCT03836196|EXPERIMENTAL|Combined radiation treatment|Combined low-dose-rate brachytherapy and external beam radiation therapy
62376151|NCT01897259|ACTIVE_COMPARATOR|Corticosteroid Injections|Patients will receive 1 cc Kenalong 10 mg injection to the site every 6 weeks until clinical symptoms have resolved. They will also receive an anesthetic of 1cc 1% lidocaine in conjunction with the corticosteroid injection.
62376152|NCT01897259|ACTIVE_COMPARATOR|Prolotherapy|Participants receive 1cc 50% Dextrose and 1 cc Sodium Morrhuate to the site every 6 weeks until symptoms resolve. These participants will also receive an anesthetic of 1cc 1% lidocaine.
62376153|NCT01897259|PLACEBO_COMPARATOR|Placebo|Participants will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
62376154|NCT01897259|ACTIVE_COMPARATOR|Physical Therapy|Participants will be prescribed NSAIDS (Diclofenac 75 mg BID) for 2 weeks. Participants will attend therapy for muscle stretches, soft tissue mobilization, and gradual strengthening.
62376155|NCT03542292|EXPERIMENTAL|placental drainage group|In study group; umbilical cord was clamped from fetal side but unclamped from maternal side. After that unclamped side of umblical cord was left open to drain the blood until the flow ceased. The blood was collected in the metal bowl and measured using a measuring jar. Care was taken not to mix the drained blood from the cord with the blood lost during the third stage.
62376156|NCT03542292|ACTIVE_COMPARATOR|no placental drainage group|In control group the umblical cord was clamped both sides.
62376157|NCT00128362|EXPERIMENTAL|Radio guided Sentinle node biopsy|The radiolabeled Tc-99 colloid or phytate (500 Mbq) will be injected into the primary tumor 2 hours before surgery. A localized scintiscan will then be performed to confirm the radiolabeling of the sentinel node before surgery and for documentation. Isosulphan blue dye will be injected subdermal (0.5ml) over the tumor and intraparenchymal (3-4ml) towards the axilla 10-15mins before incision.
62376158|NCT06277609|EXPERIMENTAL|Part A: Lu AF28996 with Enzyme Inhibitors|Participants will receive repeated single doses of Lu AF28996 and enzyme inhibitors.
62555965|NCT05446558|ACTIVE_COMPARATOR|Extracorporeal anastomosis (EA)|A transverse incision in the right upper quadrant is performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Rel Stapler
61986455|NCT05933928|EXPERIMENTAL|İntervention group (High validity simulation application group) (n:40)|"Practices will be carried out with the students in the intervention group with the NOELLA Birth Simulator, which is a high-reality simulator located in the Simulation laboratory of the Department of Midwifery of the Faculty of Health Sciences of Hamidiye. A simulator will be practiced with a separate scenario including early, late, variable deceleration, reactive, sinusoidal and non-reactive trace interpretation and intervention."
62376159|NCT06277609|EXPERIMENTAL|Part B: Lu AF28996 with Antibiotics|Participants will receive single doses of Lu AF28996 and amoxicillin/clavulanic acid.
62376160|NCT01030991||HFpEF|HFpEF cohort (observational study)
62376161|NCT03185325||Non hodgkin lymphoma patients|bone marrow puncture and venous blood samples
62376162|NCT03185325||healthy voulnteers|venous blood samples
62376163|NCT04222257|EXPERIMENTAL|Short course|Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
62376164|NCT04222257|ACTIVE_COMPARATOR|Standard course|Those patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
62376165|NCT02094612|ACTIVE_COMPARATOR|Usual Care|Usual clinic ADHD care
62376166|NCT02094612|EXPERIMENTAL|Usual Care plus Assessment|Usual clinic ADHD care plus the Quotient®
62555966|NCT05889429||brain ischemic stroke patients|"Participants who meet the inclusion criteria.~All participants will undergo four testing sessions spanning the acute and subacute post-stroke phases:~Session 1 (t1) - 2-14 days from stroke onset Session 2 (t2) - 4 weeks (± 7 days) after the stroke Session 3 (t3) - 8 weeks (± 7 days) after the stroke Session 4 (t4) - 12 weeks (± 7 days) after the stroke"
62376167|NCT04519476|EXPERIMENTAL|Selinexor/Lenalidomide/Steroids|All subjects enrolled will receive: 1) selinexor, PO, at 60 mg once weekly on days 1-28 of a 28-day cycle, 2) lenalidomide, PO, 10 mg daily on days 1-21 of 28-days cycle and 3) methylprednisolone at the same dose and schedule as the last lenalidomide-containing regimen if it contained steroids. If patient's qualifying lenalidomide-containing regimen contained different type of steroid (e.g. prednisone, dexamethasone, etc.) then patient on this study will receive methylprednisolone at the equivalent dose and schedule.
62376168|NCT04841681|EXPERIMENTAL|Video-based Psychotherapy|The group received the intervention of video-based psychotherapy.
62376169|NCT01814449||Hypoxic Group|Higher 18FMISO uptake (Target to background Ratio, TBR\>1.2) in Primary breast cancer by 18FMISO PET/CT scan.Primary endocrine therapy Letrozole was given to the patients.
62376170|NCT01814449||Non-Hypoxic Group|Lower 18FMISO uptake (TBR\<1.2)in primary breast cancer by 18FMISO PET/CT scan.Primary endocrine therapy letrozole was given to the patients.
62555967|NCT05889429||Control group|"Participants with healthy age and gender-matched with no history of neurological impairments.~Each participant will visit the testing sites 4 times within one month between different sessions."
62555968|NCT01719614|EXPERIMENTAL|Rilpivirine+Metformin|All participants will receive study medications in two sessions in a fixed, sequential order as a session 1 (a single dose of metformin on Day 1) followed by washout period (period when no treatment is received) of 4 days and then session 2 (rilpivirine on Day 5 to Day 17 with a single dose of metformin on Day 15).
62376171|NCT03808844|EXPERIMENTAL|HSK3486|0.4mg/kg/0.2 mg/kg
62376172|NCT03808844|ACTIVE_COMPARATOR|Propofol|2.0mg/kg/1.0mg/kg
62376173|NCT02596425|EXPERIMENTAL|Passive deflation|In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
62376174|NCT02596425|EXPERIMENTAL|40 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.
62376175|NCT02596425|EXPERIMENTAL|60 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.
62376176|NCT01855139||Rivaroxaban|
62376177|NCT03237390|EXPERIMENTAL|Treatment (gemcitabine hydrochloride, ribociclib)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and ribociclib PO QD on days 8-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62376178|NCT03517735|EXPERIMENTAL|Automated postoperative sedation|Automated administration of Propofol and Remifentanil.
62376179|NCT03517735|ACTIVE_COMPARATOR|Manual postoperative sedation|Manual administration of Propofol and Remifentanil.
62376180|NCT04883099|EXPERIMENTAL|APIOC for Presbyopia and Presbyopia with Astigmatism|Presbyopic Spherical or Toric Contact Lens
62376181|NCT01370772|ACTIVE_COMPARATOR|Standard R-FC arm|"Standard R-FC arm 6 cycles every 28 days~* Cycle 1:~  * Rituximab : 375 mg/m² i.v on day 1~ * Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~ * Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days For patients with Leucocyte count \> 25\* G/L : rituximab in two equal doses at D1, D2~* Cycle 2-6:~  * Rituximab: 500 mg/m² i.v on day 1, repeated every 28 days~ * Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~ * Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days"
62555969|NCT06528379|EXPERIMENTAL|Physical Activity intervention|"This Physical Activity intervention arm is a 6-month excercise protocol for SCI people, delivered 3 times per week, comprising of 2 supervised group-based exercise sessions \& one home-based (unsupervised) one.~The exercise programme is a progressive evidence-based tailored exercise regime comprising aerobic, resistance and balance exercises, applied at a moderate intensity (60-80% of targeted heart rate)."
62555970|NCT00547586|PLACEBO_COMPARATOR|Placebo|
62376182|NCT01370772|EXPERIMENTAL|DenseR-FC arm|"DenseR-FC arm =1 prephase R Dense course +6 R-FC courses~* Prephase:~  - Rituximab: 500 mg on day 0, 2000 mg on days 1, 8, and D15 For patients with Leucocyte count \> 25\* G/L : rituximab 250 mg D-1, D0 prephase~* Cycle 1-6 (cycle 1 beginning at D22):~  * Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days~ * Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~ * Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days"
62376183|NCT05956028|EXPERIMENTAL|(group S)|receive ultrasound guided subclavian vein cannulation
62376184|NCT05956028|ACTIVE_COMPARATOR|(group I)|receive ultrasound guided internal jugular vein cannulation
62555971|NCT00547586|EXPERIMENTAL|150 mg|
62555972|NCT00547586|EXPERIMENTAL|300 mg|
62555973|NCT00547586|EXPERIMENTAL|450 mg|
62555974|NCT00547586|EXPERIMENTAL|600 mg|
62555975|NCT01044550|OTHER|Treatment|Laparoscopy on a group of randomly selected patients with left thoracoabdominal stab wounds to obtain the incidence of occult diaphragm injury
62555976|NCT01044550|ACTIVE_COMPARATOR|Control|Assess the incidence and clinical outcome of delayed diaphragm visceral herniation in the study group.
62376185|NCT03128255||Regular Thyroid Work-up|Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics. Data and images of patient characteristics, laboratory results, ultrasonography loops and planar 99mTcO4 scintigraphy are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
62376186|NCT03128255||Regular Thyroid Work-up and I-124 PET/US|Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics and additional I-124 PET/CT, followed by I-124 PET/US (administration of I-124 was not subject of this study). Data and images of patient characteristics, laboratory results, ultrasonography loops, planar 99mTcO4 scintigraphy as well as I-124 PET/US loops are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
62376187|NCT01315340|EXPERIMENTAL|Glaucoma Patients|
62376188|NCT01315340|ACTIVE_COMPARATOR|Control subjects|
62376189|NCT01808365||Study cohort|
62376190|NCT02136329|EXPERIMENTAL|Sildenafil|All subjects in groups 1-6 will receive SIldenafil but in escalating doses.
62376191|NCT00002590|EXPERIMENTAL|Regimen A|See detailed description.
62376192|NCT03248817|EXPERIMENTAL|single shot|spinal anesthesia will be performed using intrathecal bupivacaine. Then, a single shot phenylephrine (1.5 ug/Kg) will be administered
62376193|NCT03248817|ACTIVE_COMPARATOR|fixed infusion|spinal anesthesia will be performed using intrathecal bupivacaine. Then, fixed infusion phenylephrine will be administered at a dose of (0.75 mcg/Kg/min). the infusion will stop if reactive hypertension occurred
62376194|NCT03248817|ACTIVE_COMPARATOR|variable infusion|spinal anesthesia will be performed using intrathecal bupivacaine. Then, variable infusion phenylephrine will be administered at a starting dose of (0.75 mcg/Kg/min). the infusion will be titrated according to blood pressure
62376195|NCT05098808||Dysphagia mild|Able to start oral feeding after assessment
62376196|NCT05098808||Dysphagia severe|Non oral feeding and high risk of aspiration
62376197|NCT00654576|ACTIVE_COMPARATOR|1|the comparator arm will only receive one of the seven antipsychotic
62376198|NCT00654576|EXPERIMENTAL|2|the experimental group will receive one of the seven study drugs combination with psychosocial intervention
62376199|NCT00355615|ACTIVE_COMPARATOR|rosuva 5|rosuvastatin 5 mg
62376200|NCT00355615|ACTIVE_COMPARATOR|rosuva 10|rosuvastatin 10 mg
62376201|NCT00355615|ACTIVE_COMPARATOR|rosuva 20|rosuvastatin 20 mg
62376202|NCT00355615|PLACEBO_COMPARATOR|Placebo|Placebo
62376203|NCT00355615|OTHER|rosuva ol|rosuvastatin open label
62376204|NCT01675141|EXPERIMENTAL|Lenalidomide Maintenance Therapy for Multiple Myeloma|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
62376205|NCT00676728|EXPERIMENTAL|JNJ-26481585|
62555977|NCT04080739|EXPERIMENTAL|Experimental Group|US-guided ipsilateral sciatic nerve block for fibula free flap patients utilizing ropivacaine 0.2% at 2-8 cc/hr for fibula free flap patients; US-guided infraclavicular brachial plexus nerve block for forearm free lap patients utilizing ropivacaine 0.2% at 2-8cc/hr for forearm free flap patients.
62555978|NCT04080739|NO_INTERVENTION|Control Group|No regional anesthetic of any kind during the surgical procedure.
62555979|NCT03334435|PLACEBO_COMPARATOR|Responders and Partial Responders (RPR)-Placebo|Responders or partial responders (RPR) \[Investigator's Global Assessment (IGA) of (0,1, or 2) at entry to study JAHN and never rescued in originating study\] participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY were assigned to remain in this arm to receive placebo orally.
62376206|NCT03727386|EXPERIMENTAL|Coconut oil|A dietary intervention that relies on the administration of 30 ml of extra virgin coconut oil per day for six months will be utilized in this study. Coconut oil administered will replace the cooking/vegetable oil usually used by the participants. .
62376207|NCT03727386|PLACEBO_COMPARATOR|Sunflower oil|A dietary intervention that relies on the administration of 30 ml of sunflower oil per day for 6 months will be utilized in this study. The oil administered will replace the cooking/vegetable oil usually used by the participants.
62376208|NCT01620801|EXPERIMENTAL|Low dose|AAV8-hFIX19
62376209|NCT01620801|EXPERIMENTAL|Middle dose|AAV8-hFIX19
62376210|NCT01620801|EXPERIMENTAL|High dose|AAV8-hFIX19
62376211|NCT05307965|ACTIVE_COMPARATOR|Standalone Percutaneous Coronary Intervention|Participants will have standard of care treatment. They will undergo PCI with devices and techniques driven by clinical decision making at the patient level and institutional level, and carried out in accordance with the Oxford University Hospitals NHS Foundation Trust department guidelines.
62555980|NCT03334435|EXPERIMENTAL|RPR-Bari 1-milligram (mg)|RPR participants from previous Baricitinib monotherapy studies-JAHL and JAHM were assigned to remain in this arm to receive Baricitinib 1 mg orally.
62376212|NCT05307965|ACTIVE_COMPARATOR|Percutaneous Coronary Intervention and Thrombus Aspiration|Participants will have standard of care treatment with manual thrombectomy catheter and PCI. They will undergo PCI with devices and techniques driven by clinical decision making at the patient level and institutional level, and carried out in accordance with the Oxford University Hospitals NHS Foundation Trust department guidelines.
62376213|NCT05307965|EXPERIMENTAL|Percutaneous Coronary Intervention and Retriever Thrombectomy|Participants randomised to the stent-retriever thrombectomy arm of the RETRIEVE AMI trial will undergo stent-retriever thrombectomy with the SolitaireTM X Revascularisation Device.
62376214|NCT04218513|EXPERIMENTAL|Compound Edaravone|30 mL (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg)
62376215|NCT04218513|EXPERIMENTAL|Edaravone|30 mL (containing edaravone 30 mg)
62376216|NCT04218513|EXPERIMENTAL|2-Aminoethanesulfonic Acid|30 mL (containing 2-aminoethanesulfonic acid 600 mg)
62376217|NCT04994275||Patients admitted to undergo a major elective surgery|
62376218|NCT02315833|EXPERIMENTAL|Acetium|Patient will administer Acetium capsules (100mg l-cysteine) twice a day for three months
62376219|NCT02315833|PLACEBO_COMPARATOR|Placebo|Patient will administer placebo capsules twice a day for three months
62376220|NCT04683952|EXPERIMENTAL|Rehabilitation with HHFNC|"15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, and with Humified High Flow Nasal Cannula (HHFNC).~The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months."
62376221|NCT04683952|ACTIVE_COMPARATOR|Control Group rehabilitation without HHFNC|"15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, without Humified High Flow Nasal Cannula (HHFNC).~The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months."
62376222|NCT04631016|EXPERIMENTAL|MEDI3506|Approximately 72 participants will be randomized to receive MEDI3506
62376223|NCT04631016|PLACEBO_COMPARATOR|Placebo|Approximately 72 participants will be randomized to receive placebo
62376224|NCT05724147|EXPERIMENTAL|Mandala Activity|There will be a total of 5 sessions, including the Mandala activity once a week, meeting (1), working (3) and ending (1).
62376225|NCT04693312|EXPERIMENTAL|Group I|scalene muscle level injection of depomedrol
62376226|NCT04693312|EXPERIMENTAL|Group II|Rheumboid muscle level injection of depomedrol
62376227|NCT05027776|EXPERIMENTAL|Experimental: 2-doses Group|Subjects aged 9-14 years, received 2 doses of q-HPV vaccine, which was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 6-month schedule.
62376228|NCT05027776|EXPERIMENTAL|Experimental: 3-doses Group|Subjects aged 9-19 years, received 3 doses of q-HPV vaccine, which was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 2，6-month schedule.
62376229|NCT05027776|ACTIVE_COMPARATOR|Acitve Group|Subjects aged 20-26 years, received 3 doses of q-HPV vaccine, which was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 2，6-month schedule.
62376230|NCT01238705|ACTIVE_COMPARATOR|Felodipine,Irbesartan,Sexual Dysfunction|
62376231|NCT01238705|ACTIVE_COMPARATOR|Felodipine,Metoprolol,Sexual Dysfunction|
62376232|NCT00706264|NO_INTERVENTION|1|Expectant management
62376233|NCT00706264|EXPERIMENTAL|2|Placement of arabin pessary since 23 weeks until 37 weeks
62376234|NCT02407665|EXPERIMENTAL|Tai Chi|Participants who practice Tai Chi 2X/week for 12-weeks
62376235|NCT02407665|NO_INTERVENTION|Healthy Control|24 healthy controls
62376236|NCT02443233||Maternal hepatitis B carrier|
62376237|NCT02443233||Paternal hepatitis B carrier|
62376238|NCT05091918|OTHER|MotionSense Wearable|Using MotionSense from pre-op to 90 days post-op during the recovery after primary TKA
62376239|NCT04835051|OTHER|Breastfeeding promotion|The breastfeeding promotion intervention included training for health workers, interpersonal communication (in person and digital) between providers and pregnant/breastfeeding women, and mass media.
62376240|NCT04835051|NO_INTERVENTION|Comparison|
62376241|NCT06146140|EXPERIMENTAL|Oral Herbal Supplement|Oral supplement containing an herbal blend
62376242|NCT06146140|PLACEBO_COMPARATOR|Oral Placebo Supplement|Oral placebo supplement
62376243|NCT01935570|EXPERIMENTAL|Magnesium|
62376244|NCT00298311|EXPERIMENTAL|mci guidance & peer social support|home visits to promote maternal-child interaction \& social support
62376245|NCT00298311|SHAM_COMPARATOR|peer social support|social support
62376246|NCT04395989|EXPERIMENTAL|LAR-HER2mut|If patients were LAR subtype with HER2 gene activated mutation
62376247|NCT04395989|EXPERIMENTAL|LAR-PI3K/AKTmut|If patients were LAR subtype without HER2 gene activated mutation, but had PI3K/AKT/mTOR pathway mutation
62376248|NCT04395989|EXPERIMENTAL|IM|If patients were IM subtype (CD8 positive T cell more than 10%)
62376249|NCT04395989|EXPERIMENTAL|BLIS/MES-PI3K/AKTWT|If patients were BLIS subtype or MES subtype without PI3K/AKT/mTOR pathway activation
62376250|NCT04395989|EXPERIMENTAL|MES-PI3K/AKTmut|If patients were MES subtype and had PI3K/AKT/mTOR pathway activation
62376251|NCT02268760|EXPERIMENTAL|BILN 2061 ZW single rising doses|
62376252|NCT02268760|PLACEBO_COMPARATOR|Placebo|
62376253|NCT02268760|EXPERIMENTAL|BILN 2061 ZW fixed dose fed|
62376254|NCT02268760|ACTIVE_COMPARATOR|BILN 2061 ZW fixed dose fasted|
62376255|NCT02514213|EXPERIMENTAL|Arm A|2mg INO-5150 and electroporation device CELLECTRA®-5P
62376256|NCT02514213|EXPERIMENTAL|Arm B|8.5mg INO-5150 and electroporation device CELLECTRA®-5P
62376257|NCT02514213|EXPERIMENTAL|Arm C|2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
62376258|NCT02514213|EXPERIMENTAL|Arm D|8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
62376259|NCT02233140|EXPERIMENTAL|Shockwave with manual manipulation|A shockwave (EPAT) therapy with two supervised manual manipulation per week
62376260|NCT02233140|ACTIVE_COMPARATOR|Manual manipulation|A Placebo (no) shockwave with two supervised manual manipulations per week
62376261|NCT03602638|EXPERIMENTAL|Sitagliptin|
62376262|NCT03602638|ACTIVE_COMPARATOR|CONTROL|Acarbose
62376263|NCT02837055|EXPERIMENTAL|VivaSight intubation|Patients are intubated with the VivaSight-SL endotracheal tube
62376264|NCT02837055|ACTIVE_COMPARATOR|conventional intubation|Patients are intubated with a conventional endotracheal tube
62376265|NCT01738074|EXPERIMENTAL|trivalent rotavirus genetic reassortment vaccine|2ml of rotavirus genetic reassortment vaccine by mouth every month for three month
62752081|NCT01678573|EXPERIMENTAL|Sequence 3: abiraterone acetate|"Randomly assigned participants in Sequence 3 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule CBA under fasted conditions."
62752082|NCT06425939|OTHER|Single group|Healthy adults moderately trained in resistance exercises
62376266|NCT01738074|PLACEBO_COMPARATOR|Placebo|2ml of placebo by mouth every month for three month
62376267|NCT04682795|EXPERIMENTAL|Needle-free injector group|To evaluate the efficacy and safety of the needle-free injector in T2DM
62376268|NCT04682795|ACTIVE_COMPARATOR|Insulin pen group|To evaluate the efficacy and safety of the insulin pen in T2DM
62752083|NCT04734522|EXPERIMENTAL|The specified PAL design wearers|Subjects who have been already wearing any from specified design type of PAL
62376269|NCT06134076|EXPERIMENTAL|Unfermented Chickpea|
62376270|NCT06134076|EXPERIMENTAL|Fermented Chickpea|
62752084|NCT04734522|ACTIVE_COMPARATOR|The other PAL design wearers|Subjects who have been already wearing any from the other design type of PAL
62376271|NCT01637844|EXPERIMENTAL|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation start to orally take telbivudine (600 mg/day) until 4 weeks after delivery. Newborn infants receive standard immunoprophylaxis.
62376272|NCT01637844|NO_INTERVENTION|Control|Infants of HBsAg- and HBeAg-positive women who are not treated with telbivudine and any other antiviral agents serve as controls. The infants are administered standard immunoprophylaxis against mother-to-infant transmission of HBV, 100-200 IU hepatitis B immunoglobulin (HBIG) within 12 hours after birth and three doses hepatitis B vaccine at 0, 1 and 6-month schedule.
62376273|NCT02148952|EXPERIMENTAL|Intervention Health Facility|WHO Safe Childbirth Checklist Program
62555981|NCT03334435|EXPERIMENTAL|RPR-Bari 2-mg|RPR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY were assigned to remain in this arm to receive Baricitinib 2 mg orally.
62752085|NCT03416920|EXPERIMENTAL|Wellframe|Subjects in this arm will use the Wellframe application for 90 days
62752086|NCT02534935|EXPERIMENTAL|rLP2086 vaccine|"Arm stratified by age:~≥12 to \<18 months and ≥18 to \<24 months"
62752087|NCT02534935|ACTIVE_COMPARATOR|Control|"Arm stratified by age:~≥12 to \<18 months and ≥18 to \<24 months"
62376274|NCT02148952|NO_INTERVENTION|Control Health Facility|Matched control facilities providing comparison for intervention facilities
62376275|NCT04854785||DNP-mild|Participants that have recovered from mild COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
62752088|NCT02495246|ACTIVE_COMPARATOR|Group 1|ChAd3-EBO-Z (1x10\^11 vp) and Ad26.ZEBOV (5x10\^10 vp) 28 days later.
62752089|NCT02495246|ACTIVE_COMPARATOR|Group 2|Ad26.ZEBOV (5x10\^10 vp) and ChAd3-EBO-Z (1x10\^11 vp) 28 days later.
62752090|NCT02495246|ACTIVE_COMPARATOR|Group 3|ChAd3-EBO-Z (1x10\^11 vp) and Ad26.ZEBOV (5x10\^10 vp) 56 days later.
62376276|NCT04854785||DNP-moderate|Participants that have recovered from moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
62376277|NCT04854785||Healthy Control Participants|Participants in good physical health, age- and sex-matched to Group 1 and 2 participants.
62376278|NCT00789659|EXPERIMENTAL|VAC dressing|The patients whose postoperative wound will be dressed with a negative pressure (V.A.C.) dressing.
62376279|NCT06135142|EXPERIMENTAL|Connective Tissue Massage Group|The patient was positioned in sitting position and their feet were supported.The basic region consisted of short and long strokes to the anterior superior iliac spine, the sacrolumbar angle, the ilium, L5 to T12, the pectoral muscles.After,the transition was made to the lower thoracic region.Short strokes were applied from lateral to medial on the latissimus dorsi muscle.Short strokes were executed between the transverse processes of the vertebrae from T12 to T7.Following this,long strokes were initiated from the axilla and continued up to the vertebrae.Finally,long strokes continued beneath the scapular angles.At the end of the lower thoracic region massage,the pectoral muscles were subjected to three stroking motions.After concluding the massage of the lower thoracic region,the application was finalized with long strokes performed subcostally and under the iliac crest.
62376280|NCT06135142|EXPERIMENTAL|Classic Massage Group|The patient positioned themselves face down with their upper clothing removed. The massage initiation involved employing a general stroking motion. Commencing from the sacrolumbar region, paravertebral long sweeping strokes were executed bilaterally, progressing upwards along the vertebrae's lateral edges. In the area spanning from the lumbothoracic boundary to the gluteals, a general stroking motion was iterated thrice. Subsequently, the erector spinae, latissimus dorsi, and gluteus maximus muscles were sequentially subjected to a series of actions: three cycles of stroking, followed by three cycles of kneading, concluding with three more cycles of stroking. As a concluding step, the initial general stroking movements were replicated thrice prior to finalizing the massage session.
62376281|NCT06135142|ACTIVE_COMPARATOR|Control Group|The standardized physiotherapy program included the application of superficial thermal heat, transcutaneous electrical nerve stimulation (TENS) and therapatic Ultrasound. TENS at a frequency of 100 Hz (250-μsec pulses) was applied for 15 min using two 4- to 6-cm electrodes placed bilaterally on each side of the spinous process of the L4 to S1 vertebrae with thermal therapy. While the TENS application was in progress, the heat treatment was also applied. Topical moist heat treatment at 40°C applied directly on the skin to increase both tissue temperature and blood flow. Then, continuous ultrasound was applied at an intensity of 1.5 to 2.5 W/cm2 for a period of 5 minutes.
62376282|NCT01551628|EXPERIMENTAL|Recombinant Human Arginase 1 Peg5000|
62376283|NCT04468464|ACTIVE_COMPARATOR|Control Group|Occlusal Splint
62376284|NCT04468464|EXPERIMENTAL|Study Group|Osteopathic Manuel Therapy
62376285|NCT02407691|EXPERIMENTAL|Primary Care 101 Enhanced guideline|Primary Care 101 guideline with enhanced mental health
62376286|NCT02407691|ACTIVE_COMPARATOR|Standard of care|Primary Care 101 standard version guideline
62376287|NCT01140464|ACTIVE_COMPARATOR|Enhanced Usual Care|Usual care treatment of depression in primary care settings. Usual care considered enhanced as patients and their parents were given screening results and encouraged to seek care from their primary care doctor and behavioral health services.
62376288|NCT01140464|ACTIVE_COMPARATOR|Collaborative Care|Collaborative care intervention for depression. Involves care management, evidence based treatments in primary care setting, symptom monitoring and stepped care design
62376289|NCT01487863|EXPERIMENTAL|Concurrent Arm|Subjects received sipuleucel-T concurrent with abiraterone acetate plus prednisone. Abiraterone acetate plus prednisone treatment started the next day after the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
62376290|NCT01487863|EXPERIMENTAL|Sequential Arm|Subjects received sipuleucel-T therapy followed by abiraterone acetate plus prednisone. Abiraterone acetate plus prednisone started at week 10 from the start of the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
62376291|NCT04563624|EXPERIMENTAL|ceramic cad cam blocks|
62752091|NCT02495246|ACTIVE_COMPARATOR|Group 4|Ad26.ZEBOV (5x10\^10 vp) and ChAd3-EBO-Z (1x10\^11 vp) 56 days later.
62752092|NCT04170504|EXPERIMENTAL|Qing Re Huo Xue (QRHX) granule plus methotrexate (MTX)|QRHX granule 10g bid and methotrexate (MTX) 10 mg once a week for 24 weeks
62752093|NCT04170504|PLACEBO_COMPARATOR|Qing Re Huo Xue (QRHX) granule placebo plus Methotrexate (MTX)|QRHX granule placebo 10g bid plus Methotrexate (MTX) 10mg once a week for 24 weeks
62752094|NCT00619424|EXPERIMENTAL|pazopanib + erlotinib|Pazopanib and erlotinib are to be combined at different specified dose levels until an optimally tolerated dose level is identified. Pazopanib, a multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, and -3, PDGFR-alpha and beta, and c-kit and erlotinib, an epidermal growth factor (EGFR) inhibitor, are to be combined in an effort to simultaneously block two tightly woven cell signaling pathways.
62752095|NCT00619424|EXPERIMENTAL|pazopanib + pemetrexed|Pazopanib and pemetrexed are to be combined at different specified dose levels until an optimally tolerated dose regimen is identified. Combination of an anti-VEGF therapy (such as bevacizumab) with systemic chemotherapy has demonstrated increased clinical efficacy in comparison with systemic chemotherapy alone in several malignancies. Hence, pazopanib, a multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, and -3, PDGFR-alpha and beta, and c-kit, was chosen to be combined with pemetrexed, a chemotherapeutic agent that inhibits the enzyme thymidylate synthase, in an effort to determine if an anti-angiogenesis inhibitor would enhance the activity of the approved chemotherapeutic agent pemetrexed.
62752096|NCT04983875|EXPERIMENTAL|BAC-enhanced group|944 participants will receive a post-mammography results letter which includes information on their BAC results.
62752097|NCT04983875|OTHER|Waitlist control group|944 participants will receive a post-mammography results letter without BAC information, which is the current standard of care. These patients will receive BAC information following study completion (approximately 6 months after mammography).
62752098|NCT02808195|EXPERIMENTAL|constraint-induced therapy|training of the more affected arm and restraint the less affected arm
62752099|NCT02808195|EXPERIMENTAL|kinect-based constraint-induced therapy|training of the more affected arm and restraint the less affected arm by kinect-game
62752100|NCT05837403|ACTIVE_COMPARATOR|Nitroglycerin only|application of local Nitroglycerin ointment 2% (Recto-Relief Nitroglycerin Ointment, 30 g) applied twice daily.
62752101|NCT05837403|EXPERIMENTAL|platelet rich plasma injection|injection of platelet rich plasma under fissure base and edges
62752102|NCT00510718|EXPERIMENTAL|1|MDV3100
62752103|NCT02154620|NO_INTERVENTION|Plaster cast|The patient will be treated in a dorsal plaster cast for 4 weeks following the injury to the wrist
62752104|NCT02154620|EXPERIMENTAL|Volar plate|The patient will undergo surgery to the injured wrist with a Synthes Two-column plate (TCP) with a volar approach. Cast will be worn 2 weeks after surgery.
62752105|NCT00446953|EXPERIMENTAL|1|2x 12 mg betamethazone
62752106|NCT00446953|PLACEBO_COMPARATOR|2|no drugs
62376292|NCT04563624|ACTIVE_COMPARATOR|composite cad cam blocks|
62752107|NCT05726565||LNNB-S >=10|As one of the core components of multidisciplinary CR, psychiatrist and psychologist consultation was delivered to all patients. Cognitive function was assessed with the Luria-Nebraska Neuropsychological Battery-Screening test (LNNB-S) Chinese version by an experienced psychologist. The evaluation would be completed during admission. The initial LNNB was condensed to fifteen items for the screen test by Golden. LNNB-S Chinese version focuses on 3 domains, including number calculation, cognitive function, and rhythm control. In our participants' cohort, investigators choose LNNB-S \>=10 as a cutoff point. That is, participants may have cognitive impairment when their LNNB-S \>=10.
62752108|NCT05726565||LNNB-S <10|As one of the core components of multidisciplinary CR, psychiatrist and psychologist consultation was delivered to all patients. Cognitive function was assessed with the Luria-Nebraska Neuropsychological Battery-Screening test (LNNB-S) Chinese version by an experienced psychologist. The evaluation would be completed during admission. The initial LNNB was condensed to fifteen items for the screen test by Golden. LNNB-S Chinese version focuses on 3 domains, including number calculation, cognitive function, and rhythm control. In our participants' cohort, investigators choose LNNB-S \>=10 as a cutoff point. That is, participants may have cognitive impairment when their LNNB-S \>=10.
62376293|NCT01359527||Hip Resurfacing|
62376294|NCT01359527||Total Hip Arthroplasty|
62376295|NCT06435117|OTHER|People with mental ill-health|All people with mental ill-health aged 18 or older who visit one of the recruitment sites will be asked to participate. Further participants will be recruited through partner organizations (non-governmental organisations, patient groups and professional organisations) involved in care for individuals with mental ill-health, as well as personal contacts. Additionally, healthcare professionals involved in care of people with mental ill-health will be asked to participate in the qualitative part of the study.
62376296|NCT06101355|EXPERIMENTAL|Telerehabilitation Group Based on Home Exercises|Intervention group is home exercise program supplemented with visual and video resources using telerehabilitation.
62376297|NCT06101355|ACTIVE_COMPARATOR|Standard Home Exercise Group|Standard home based exercise group
62376298|NCT02835235|EXPERIMENTAL|NNC9204-0530|Dose-escalation within the cohort before reaching final dose
62376299|NCT02835235|PLACEBO_COMPARATOR|Placebo|
62376300|NCT01557140|PLACEBO_COMPARATOR|RASi plus placebo|RAS inhibition was optimized and after patients were randomly assigned to receive placebo
62376301|NCT01557140|EXPERIMENTAL|RASi plus carvedilol|RAS inhibition was optimized and after patients were randomly assigned to receive carvedilol
62376302|NCT03463044|PLACEBO_COMPARATOR|Placebo|
62376303|NCT03463044|EXPERIMENTAL|MOTREM 1|
62376304|NCT03463044|EXPERIMENTAL|MOTREM 2|
62376305|NCT03463044|EXPERIMENTAL|MOTREM 3|
62376306|NCT03463044|EXPERIMENTAL|MOTREM 4|
62376307|NCT03463044|EXPERIMENTAL|MOTREM 5|
62376308|NCT03463044|EXPERIMENTAL|MOTREM 6|
62752109|NCT04576039|EXPERIMENTAL|presenting with thickened endometruim|women presenting with thickened endometrium after the use of ulipristalacetate will undergo a saline infusion in the uterus and immediate ultrasonographic control to visualise the morphology of the endometrium.
62376309|NCT03463044|EXPERIMENTAL|MOTREM 7|
62376310|NCT03463044|EXPERIMENTAL|MOTREM 8|
62376311|NCT00113555|EXPERIMENTAL|Experimental|Open Label Study, ACT (Adjustable Continence Therapy)
62376312|NCT03258450|EXPERIMENTAL|Psycho-behavioural intervention arm (PBI)|Participants will receive 4 sessions(PBI) that lasts approximately 60 mins.
62376313|NCT03258450|NO_INTERVENTION|Waitlist Control Arm (WLC)|The WLC group receives standard usual care before being offered the same PBI protocol and assessment thereafter.
62376314|NCT05032287|ACTIVE_COMPARATOR|tamsulosin|tamsulosin 0.4 mg once daily
62376315|NCT05032287|PLACEBO_COMPARATOR|Placeb|Placebo once daily
62376316|NCT04076813||STEMI/NSTEMI|Patients in the registry will be 18 years of age or older and underwent coronary angiography for a ST-elevation myocardial infarction (STEMI) or NSTEMI Non-ST-elevation myocardial infarction
62376317|NCT03582839|EXPERIMENTAL|PROTECT+|The PROTECT+ intervention group is a self-selected sample, which receives the PROTECT+ group therapy (4 modules in 4 subsequent weeks à 100 min). Participants are assessed at T1 (baseline), T2 (post treatment, 1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
62376318|NCT06330766||No preoperative dental screening|No preoperative dental screening in patients undergoing TAVI
62752110|NCT06592495|EXPERIMENTAL|Sequence A: RTRT|T: DWJ1589 R: DWC202315
62752111|NCT06592495|EXPERIMENTAL|Sequence B: TRTR|T: DWJ1589 R: DWC202315
62376319|NCT06330766||Mandatory preoperative dental screening|Mandatory preoperative dental screening in patients undergoing TAVI
62376320|NCT04143789|EXPERIMENTAL|Tablets to be taken orally daily for 14 of 21 day cycle|AP-002 (4 mg and 20 mg tablets) to be taken orally daily for 14 days
62376321|NCT03352167||ED Hjoerring|
62376322|NCT03352167||ED Aalborg|
62376323|NCT03352167||ED Aarhus|
62376324|NCT03352167||ED Herning|
62376325|NCT03352167||ED Aabenraa|
62376326|NCT03352167||ED Odense|
62376327|NCT03352167||ED Slagelse|
62376328|NCT03352167||ED Koege|
62376329|NCT02935595|EXPERIMENTAL|Ketamine|Slow infusions of ketamine will take place over a time period of 40 minutes.
62376330|NCT01243203|PLACEBO_COMPARATOR|Placebo|patient will receive placebo pills
62376331|NCT05790915||Group 1|Patients with SOFA score \< 2 at admission. No intervention
62376332|NCT05790915||Group 2|"Patients with SOFA score equal to or \> 2 on admission and who improved after 48 hours of treatment.~Intervention focused on identified organ dysfunction(s)"
62752112|NCT04824768|EXPERIMENTAL|Experimental group|30 min session of Tecar Therapy with functional massage on the rectus femoris, and gastrocnemius. Tecar therapy in the resistive modality (80W) on lower back and hamstrings and in rectus femoris and gastrocnemius with resistive mode (100-120W), and then in capacitive mode(180-200VA)
62376333|NCT05790915||Group 3|"Patients with SOFA score equal to or \> 2 on admission and who did not improve after 48 hours of treatment.~Intervention focused on identified organ dysfunction(s)"
62376334|NCT04023344|ACTIVE_COMPARATOR|Humalog® Mix 25|Insulin Humalog® Mix 25 twice daily, individually glucose-level based administered doses +/- 1 or 2 OADs in stable doses, started before enrollement
62376335|NCT04023344|EXPERIMENTAL|Insulin Lispro Biphasic 25|Insulin Lispro Biphasic 25 twice daily, individually glucose-level based administered doses +/- 1 or 2 OADs in stable doses, started before enrollement
62752113|NCT04824768|SHAM_COMPARATOR|Control group|30 min session of Tecar Therapy with functional massage on the rectus femoris, and gastrocnemius. Sham stimulation was provided by only turn on the device but dose is 0.
62752114|NCT01656993||ASA activity|Participants (age 2.0 days to 12 months) undergoing cardiac surgery for a shunt and planned treatment with aspirin
62752115|NCT01792817|SHAM_COMPARATOR|Sham GammaCore device|The Sham GammaCore device looks and operates like the Active GammaCore device, but does not deliver a therapeutic stimulation treatment.
62752116|NCT01792817|EXPERIMENTAL|GammaCore Device|Non-Invasive Vagus Nerve Stimulator
62752117|NCT01460875|EXPERIMENTAL|Treatment (interferon therapy)|Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
62752118|NCT04282265|PLACEBO_COMPARATOR|Placebo|
62752119|NCT04282265|EXPERIMENTAL|Red Spinach Extract|
62752120|NCT05482477|EXPERIMENTAL|preoperative TEAS group|Receive a TEAS on bilateral Neiguan (PC6) Yintang (GV29) and Zusanli (ST36) by the transcutaneous electrical stimulators to provide an altered frequency 2/100 Hz, disperse-dense waves, and adjusted intensity which was less than 10 mA, 30 min before anesthesia.
62752121|NCT05482477|EXPERIMENTAL|Intraoperative TEAS group|Receive a TEAS on bilateral Neiguan (PC6) Yintang (GV29) and Zusanli (ST36) by the transcutaneous electrical stimulators to provide an altered frequency 2/100 Hz, disperse-dense waves, and adjusted intensity which was less than 10 mA, from 30 min before anesthesia to the end of surgery
62752122|NCT05482477|EXPERIMENTAL|Postoperative TEAS group|Receive a TEAS on bilateral Neiguan (PC6) Yintang (GV29) and Zusanli (ST36) by the transcutaneous electrical stimulators to provide an altered frequency 2/100 Hz, disperse-dense waves, and adjusted intensity which was less than 10 mA, once a day, 30 minutes each time for 7 consecutive days after operation
62752123|NCT05482477|EXPERIMENTAL|Pre-and post-operative TEAS group|Receive a TEAS on bilateral Neiguan (PC6) Yintang (GV29) and Zusanli (ST36) by the transcutaneous electrical stimulators to provide an altered frequency 2/100 Hz, disperse-dense waves, and adjusted intensity which was less than 10 mA, from 1 day before operation to 7 days after operation, once a day, 30 minutes each time.
62752124|NCT05482477|EXPERIMENTAL|Perioperative TEAS group|Receive a TEAS on bilateral Neiguan (PC6) Yintang (GV29) and Zusanli (ST36) by the transcutaneous electrical stimulators to provide an altered frequency 2/100 Hz, disperse-dense waves, and adjusted intensity which was less than 10 mA, 30 min before the induction of anesthesia to the end of the surgery, 1 day before operation, and on the 1st, 2nd and 3rd days after surgery, 30 min once a day.
62752125|NCT05482477|SHAM_COMPARATOR|Sham TEAS group|the electrodes were placed at the same time as the perioperative TEAS group, but the electronic stimulation was not applied and they were told that the TEAS treatment have no feeling
62752126|NCT05482477|NO_INTERVENTION|Control group|receive standardised perioperative management such as preoperative health education, optimize anaesthesia scheme, intraoperative heat preservation, and reduce surgical trauma.
62752127|NCT05958394|EXPERIMENTAL|Treatment|This arm will receive the intervention. This intervention is access to the SkillFlix for Parents Microskills video library, about 60 minute in duration. The library includes a curriculum covering skills such as seizing teachable moments, talking about identities, and using a conversation tone.
62752128|NCT05958394|NO_INTERVENTION|Control|During the intervention period arm 2 will receive written conversation guides for the assigned conversations. This arm will receive the intervention upon completion of follow-up study activities.
62752129|NCT05838053||Lobectomy with systemic lymph node dissection|lobectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively.
62752130|NCT05838053||Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed after a comprehensive evaluation. As with lobectomy, systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated in the same manner as with lobectomy.
62752131|NCT01419613|EXPERIMENTAL|Motivational Interviewing|
62376336|NCT04576390|ACTIVE_COMPARATOR|Group O|On the day of procedure, the recruited patients in Group O will be given Ondansetron 4 mg diluted for up to 5ml using normal saline by a colleague not participating to the study or the patient care \& will label the syringes as antiemetic.
62376337|NCT04576390|ACTIVE_COMPARATOR|Group P|On the day of procedure, the recruited patients in Group P will be given Palonosetron 75 mcg diluted for up to 5ml using normal saline by a colleague not participating to the study or the patient care \& will label the syringes as antiemetic.
62376338|NCT01432665|EXPERIMENTAL|Placebo|30 subjects administered a placebo
62376339|NCT01432665|EXPERIMENTAL|sildenafil + testosterone combination drug 1|30 subjects are given combination drug 1 (sildenafil 25mg and testosterone 0.25mg)
62376340|NCT01432665|EXPERIMENTAL|Sildenafil and testosterone combination drug 2|Sildenafil 50mg and testosterone 0.25mg
62376341|NCT01432665|EXPERIMENTAL|Sildenafil and testosterone combination drug 3|30 subjects are given sildenafil 25mg and testosterone 0.50mg
62376342|NCT01432665|EXPERIMENTAL|Sildenafil and Testosterone Combination drug 4|30 subjects are given sildenafil 50mg and testosterone 0.50mg
62376343|NCT01432665|EXPERIMENTAL|Sildenafil 50mg|30 subjects are given sildenafil 50mg
62752132|NCT01419613|ACTIVE_COMPARATOR|Physical Activity Counseling|
62376344|NCT01432665|EXPERIMENTAL|Testosterone 0.50mg|30 subjects are given testosterone 0.5mg
62376345|NCT03233672|OTHER|Hypo-fractionated postoperative IMRT-SIB|All patients underwent combined, intensified and modulated radiotherapy for five days a week with the following doses: 62.5 Gy to the prostate bed and 45 Gy to pelvis nodes in 25 fractions.
62555982|NCT03334435|EXPERIMENTAL|RPR-Bari 4-mg|RPR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY were assigned to remain in this arm to receive Baricitinib 4 mg orally.
62752133|NCT04041466|EXPERIMENTAL|Atrial fibrillation (AF)|Patients diagnosed with AF during reference ECG
62752134|NCT04041466|EXPERIMENTAL|Sinus Rhythm (SR)|Patients diagnosed with SR during reference ECG
62752135|NCT04041466|EXPERIMENTAL|Other Arrythmia|Patients diagnosed with an arrhythmia other than AF during the reference ECG
62752136|NCT05540561||Subjects consuming nitrous oxide with clinical outcomes|Subjects who consume nitrous oxide and who have been hospitalized in this context and who present clinical signs determined during a neurological evaluation according to the PND (Peripheral Neuropathy Disability) score or who have had a thrombotic accident related to the consumption of nitrous oxide.
62752137|NCT05540561||Subjects consuming nitrous oxide without clinical outcomes|Subjects who consume nitrous oxide who do not present clinical signs related to this consumption and recruited during a routine medical consultation.
62376346|NCT02766049|ACTIVE_COMPARATOR|(a) DC|Autologous dendritic cells (3x10e7)
62376347|NCT02766049|ACTIVE_COMPARATOR|(b) DC 10e6+HIV-AT2|Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
62376348|NCT02766049|ACTIVE_COMPARATOR|(c) DC 10e7+HIV-AT2|Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
62752138|NCT02300558|EXPERIMENTAL|Eleclazine (Single-blind treatment phase)|Eleclazine and/or eleclazine placebo up to Week 24
62376349|NCT00654394|EXPERIMENTAL|1|
62376350|NCT05281549|ACTIVE_COMPARATOR|Alteplase|Patients will receive intravenous Alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
62376351|NCT05281549|EXPERIMENTAL|Tenecteplase 0.25mg/kg|Patients will receive intravenous Tenecteplase, 0.25mg/kg, maximum 25mg, administered as a bolus over 5\~10 seconds
62376352|NCT05281549|EXPERIMENTAL|Tenecteplase 0.4mg/kg|Patients will receive intravenous Tenecteplase, 0.4mg/kg, maximum 40mg, administered as a bolus over 5\~10 seconds
62376353|NCT02473016|EXPERIMENTAL|Treatment|All subjects will receive both Active (Carbon Dioxide Drug Delivery System) and Placebo. This is a single-blind study so subjects will not know the order. Subjects will receive 3 doses of active and 3 doses of placebo. One dose is a 60 second delivery of CO2 or placebo. At the discretion of the investigator, subjects may receive up to 3 additional doses of CO2.
62376354|NCT03419351|OTHER|Main group|Main study group including all individuals that underwent the study procedures
62376355|NCT00935961|EXPERIMENTAL|RAD001 + docetaxel + cisplatin|In this phase I trial, the primary endpoint will be considered to be reached when we have described a phase II recommended dose of RAD001 given with docetaxel + cisplatin as induction chemotherapy for head and neck cancer. Up to 3 dose levels of daily RAD001 will be studied. A standard 3 + 3 phase I dose escalation design will be used. The phase II recommended dose will be determined according to the dose escalation plan.
62376356|NCT03659240|EXPERIMENTAL|Cranberry beverage|
62376357|NCT03659240|PLACEBO_COMPARATOR|Placebo beverage|
62376358|NCT00397631|EXPERIMENTAL|1|sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.
62376359|NCT00397631|ACTIVE_COMPARATOR|2|sitagliptin 100 mg placebo q.d./pioglitazone 30 mg q.d.
62376360|NCT00169338|EXPERIMENTAL|deep brain stimulation|Paladin deep brain stimulation
62376361|NCT00169338|PLACEBO_COMPARATOR|sham deep brain stimulation|no stimulation
62376362|NCT06380036|EXPERIMENTAL|seton|loose seton will be placed in the pts with fistula in ano. All patients in Group A underwent the loose seton technique. The procedures were performed in the operating room with the patient in the lithotomy position. Probing of the fistula tract was done with a metallic malleable probe. The incision was given from the external opening of the fistula to the anal verge, involving the skin, subcutaneous tissue, superficial part of the external sphincter, and superficial part of the internal sphincter. After the insertion of loose Seton, a non-absorbable suture was left loosely and kept in situ for three months.
62752139|NCT02300558|EXPERIMENTAL|Open-label Extension Phase|Eligible participants will continue to receive open-label eleclazine until this drug is commercially available for the treatment of patients with LQT3, or until Gilead terminates development of eleclazine for the treatment of patients with LQT3, or the investigator deems it no longer in the participant's best interest.
62752140|NCT04015609|EXPERIMENTAL|Meaning Centered Psychotherapy for Latinos (MCP-L)|
62376363|NCT06380036|EXPERIMENTAL|VAAFTS|"In group B, video-assisted fistula tract surgery (VAAFTS) was performed. The patients were positioned in the lithotomy position. The fistuloscope was then introduced into the external opening and the procedure was performed, except for the closure of the internal opening, which was performed with either a figure of eight suture or an advancement flap, rather than using a stapler. The tracts were destroyed using electrocautery, the necrotic tissues were removed, and the external openings were cored out and left open for drainage"
62376364|NCT02992912|EXPERIMENTAL|Cohort 1: metastatic colorectal cancer|
62376365|NCT02992912|EXPERIMENTAL|Cohort 2: metastatic non-small lung cancer|
62376366|NCT02992912|EXPERIMENTAL|Cohort 3: metastatic renal cell carcinoma|
62376367|NCT02992912|EXPERIMENTAL|Cohort 4: metastatic sarcoma|
62376368|NCT01594411||All subjects|Subjects are enrolled at multiple participating primary care practices. The main inclusion criterion for enrollment is the occurrence of chest pain (or anginal equivalent) in a patient without known significant coronary artery disease (CAD) or a history of prior myocardial infarction.
62752141|NCT04015609|ACTIVE_COMPARATOR|Control|
62752142|NCT06327555|OTHER|the traditional rehabilitation group|The traditional rehabilitation group takes a face-to-face approach, with therapists providing outpatient rehabilitation instruction twice a week for six weeks.
62752143|NCT06327555|EXPERIMENTAL|the remote rehabilitation group|The remote rehabilitation group uses software and sensors to provide remote postoperative rehabilitation guidance.
62752144|NCT05811520|EXPERIMENTAL|Scapular stabilization exercises with conventional therapy|The patient will sit on the knees in 90° flexion position, and a Swiss ball will be placed between the chest and stomach. From the side, the earlobe, acromion of scapula, and pelvis should made a straight line. Four general exercises will be included with 2 sets of 15 repetitions, holding for 10 sec.
62376369|NCT02676050|EXPERIMENTAL|Imaging agents and imaging devices|All participants in Cohort 1 will be dosed on one occasion with the optical imaging agents and Cohort 2 can be dosed twice per agent. The final dosage will be \<100ug per agent. The agents will be delivered using a novel delivery catheter and imaged with a novel imaging fibre and microendoscopy system.
62376370|NCT02477540|EXPERIMENTAL|2-time injection group : Cellgram-CLI|Within 30 days after extracting bone marrow, autologous bone marrow-derived mesenchymal stem cells is directly injected into the lesion. Then the second cell is injected within 30 days after the first cell injection.
62376371|NCT04275492|EXPERIMENTAL|Fasting group|Subjects were randomly assigned to one of two sequential groups (t-r group, r-t group) in a 1:1 ratio.In the first cycle, 15 subjects were given 1 tablet of test preparation (T) orally and 240mL warm water on an empty stomach, and the other 15 subjects were given 1 tablet of reference preparation (R, Siforl®) orally and 240mL warm water on an empty stomach.Cross-administration at 7±1 days.The authorized drug dispenser assigned the study drug to each phase of the study according to a randomized protocol.
62376372|NCT04275492|EXPERIMENTAL|Feeding group|Subjects were randomly assigned to one of two sequential groups (t-r group, r-t group) in a 1:1 ratio.In the first cycle, 15 subjects took 1 tablet of the test preparation (T) orally and 240mL warm water about 30min after the high-fat meal, and another 15 subjects took 1 tablet of the reference preparation (R, Siforl®) orally and 240mL warm water about 30min after the high-fat meal.Cross-administration at 7±1 days.The authorized drug dispenser assigned the study drug to each phase of the study according to a randomized protocol.
62555983|NCT03334435|EXPERIMENTAL|Non-responders (NR): Bari 1 mg to 2 mg|Non-responder (NR) \[those not meeting definition of RPR\] participants from previous Baricitinib monotherapy studies-JAHL and JAHM who received Baricitinib 1 mg and were re-randomized to this arm to receive Baricitinib 2 mg orally.
62555984|NCT03334435|EXPERIMENTAL|NR: Bari 1 mg to 4 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM who received Baricitinib 1 mg and were re-randomized to this arm to receive Baricitinib 4 mg orally.
62555985|NCT03334435|EXPERIMENTAL|NR: Bari 2 mg to 2 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received Baricitinib 2 mg and were re-randomized to this arm to receive Baricitinib 2 mg orally.
62752145|NCT05811520|EXPERIMENTAL|Thoracic extension exercises with conventional therapy|Thoracic extension exercises consist of three exercise types
62376373|NCT02058706|EXPERIMENTAL|Arm A (enzalutamide and LHRH analogue therapy)|Patients receive enzalutamide orally PO QD and undergo orchiectomy or receive LHRH analogue therapy (leuprolide acetate, goserelin acetate, or any other FDA approved preparation). Treatment continues in the absence of disease progression or unacceptable toxicity.
62752146|NCT02356419|EXPERIMENTAL|experimental 0.5 ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
62752147|NCT02356419|EXPERIMENTAL|experimental 1.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
62752148|NCT02356419|EXPERIMENTAL|experimental 2.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
62752149|NCT02356419|EXPERIMENTAL|experimental 3.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
62376374|NCT02058706|ACTIVE_COMPARATOR|Arm B (bicalutamide and LHRH analogue therapy)|Patients receive bicalutamide PO QD and undergo orchiectomy or receive LHRH analogue therapy as in Arm A. Treatment continues in the absence of disease progression or unacceptable toxicity.
62376375|NCT05844254|EXPERIMENTAL|NORD group|After undergoing phase one of periodontal therapy, patients will be recalled after four weeks for root coverage surgery. NORD group will undergo NORD flap for root coverage. Patients will be followed up after 1 month,6, 12 and 15 months. Patients belonging to thin phenotype will be followed up as separate cohort for period of one year to evaluate phenotype modification.
62376376|NCT05844254|ACTIVE_COMPARATOR|Sub epithelial connective tissue group|After undergoing phase one of periodontal therapy, patients will be recalled after four weeks for root coverage surgery. Sub epithelial connective tissue group will receive sub epithelial connective tissue graft. Patients will be followed up after 1 month,6, 12 and 15 months. Patients belonging to thin phenotype will be followed up as separate cohort for period of one year to evaluate phenotype modification.
62752150|NCT06350942||Complete duplicated collecting system|The presence of two pelvicalyceal systems within a single kidney, with either obstructed or ectopic ureter
62752151|NCT04752566|EXPERIMENTAL|Eculizumab|Participants will receive eculizumab.
62752152|NCT04752566|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62752153|NCT06605040|EXPERIMENTAL|Social Media|The group will receive scientific content via social media
62752154|NCT06605040|ACTIVE_COMPARATOR|Email|The group will receive scientific content via email
62752155|NCT06605781|EXPERIMENTAL|Experimental group|The experimental group will receive AR/VR technology-based group training within a virtual clinical environment during their practicum
62752156|NCT06605781|ACTIVE_COMPARATOR|Control group|The control group will watch educational videos and participate in a general discussion group focused on auditory hallucinations.
62752157|NCT05215860|ACTIVE_COMPARATOR|Habit cessation counselling with management for OPMD|n=100; Habit cessation counselling with general and medical management for OPMD
62752158|NCT05215860|EXPERIMENTAL|Habit cessation counselling, management for OPMD and intraoral photographs|n=100; Habit cessation counselling with standard management for OPMD and visual exposure to personal intraoral photographs of oral lesions at baseline and review
62752159|NCT02241811|PLACEBO_COMPARATOR|Control|After wound dressing we applied hydrogel without any active ingredient everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
62752160|NCT02241811|EXPERIMENTAL|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
62752161|NCT04024332|EXPERIMENTAL|Group A (healthy)|On Day 1, 8 healthy subjects will receive a single oral dose of 25 mg ACT-541468 in fasted condition.
62752162|NCT04024332|EXPERIMENTAL|Group B (severe renal function impairment)|On Day 1, 8 subjects with severe renal function impairment will receive a single oral dose of 25 mg ACT-541468 in fasted condition.
62752163|NCT04290793|EXPERIMENTAL|Experimental group|Patients will receive the test drug (Pyrotinib) combined with Epirubicin and Cyclophosphamide followed by Taxanes and Trastuzumab
62752164|NCT04290793|ACTIVE_COMPARATOR|Control group|Patients will only receive Epirubicin and Cyclophosphamide followed by Taxanes and Trastuzumab
62376377|NCT01762592|EXPERIMENTAL|Iodine (124I) Girentuximab|Single infusion of radio labeled antibody: 30 mL will be infused using an infusion pump at a rate of 2mL/min over 15 minutes on study day 0.
62752165|NCT01846676|ACTIVE_COMPARATOR|Program counseling|Active branch, subject to the rehabilitation program
62752166|NCT01846676|PLACEBO_COMPARATOR|No counseling|Passive branch, which was control, with usual management (no intervention).
62752167|NCT06233201|EXPERIMENTAL|Sequence 1-Sitagliptin and Metformin Hydrochloride Tablets test product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg test product, treatment 2= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg reference product.
62752168|NCT06233201|EXPERIMENTAL|Sequence 2-Sitagliptin and Metformin Hydrochloride Tablets reference product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg test product, treatment 2= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg reference product.
62752169|NCT05611229||Population 1: BRAF+ melanoma patients treated with either TT or IO in the adjuvant setting|Included patients were aged more than or equal to 18 years, were required to have a diagnosis of melanoma (ICD-9 172.x \& ICD-10 C43.x or D03.x), pathologic stage III disease, evidence of resection, adjuvant treatment with IO (e.g., nivo or pembro) or TT (e.g., dab+tram) on or after January 1, 2014, and prior to August 30,2020 (data cut-off), and any evidence of a BRAF+ result.
62752170|NCT05611229||Population 2: BRAF+ melanoma patients with LTB treated with TT or IO in the metastatic setting|Included patients were aged more than or equal to 18 years, and were required to have a diagnosis of melanoma (ICD-9 172.x \& ICD-10 C43 or D03x), a pathologic stage IV diagnosis, treatment with IO (e.g. ipi, nivo, pembro, ipi+nivo) or TT (dab+tram, vem+cobi, enco+bini) on or after January 1, 2014 and prior to May 31, 2020 (data cut-off), and evidence of a BRAF+ result after therapy initiation. Patients were required to be classified as LTB at the time of stage IV diagnosis. LTB was defined as having normal LDH and \<3 metastatic sites at the time of stage IV diagnosis.
62752171|NCT02673476|PLACEBO_COMPARATOR|Placebo|Identical Placebo Comparator
62376378|NCT02186535|OTHER|Daily dosing|Daily oral capsule of Vitamin D in 4000 IU/day with daily oral capsules of 1000mg of calcium
62376379|NCT02186535|OTHER|weekly dosing|Oral capsule Vitamin D 50,000 IU/week with a oral capsule of 1000mg of calcium, daily
62555986|NCT03334435|EXPERIMENTAL|NR: Bari 2 mg to 4 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received Baricitinib 2 mg and were re-randomized to this arm to receive Baricitinib 4 mg orally.
62752172|NCT02673476|EXPERIMENTAL|ALS-008176|ALS-008176 tablets
62752173|NCT03466619|EXPERIMENTAL|inflatable penile prosthesis (IPP)|inflatable penile prosthesis (IPP)
62752174|NCT03843385|EXPERIMENTAL|faecal microbiota filtrate|Encapsulated faecal microbiota filtrate . 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or cool drink.
62752175|NCT03843385|ACTIVE_COMPARATOR|faecal microbiota|Encapsulated faecal microbiota. 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or cool drink.
62376380|NCT02528799|EXPERIMENTAL|Nexvax2 DQ2.5 Homozygotes (Cohort 1)|Nexvax2 by ID injections for a total of 14 doses over 46 days.
62752176|NCT03843385|SHAM_COMPARATOR|Placebo|Placebo: Encapsulated sterile saline. 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or cool drink.
62752177|NCT01926171|EXPERIMENTAL|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus concurrent icotinib, which was administered orally three times per day.
62752178|NCT04114643|ACTIVE_COMPARATOR|Prothrombin Complex Concentrate|
62752179|NCT04114643|ACTIVE_COMPARATOR|Frozen Plasma|
62752180|NCT02480491||Third day embryos|embryos culture media during third day after fertilization
62376381|NCT02528799|PLACEBO_COMPARATOR|Nexvax2 Placebo DQ2.5 Homozygotes (Cohort 1)|Nexvax2 Placebo by ID injections for a total of 14 doses over 46 days.
62376382|NCT02528799|EXPERIMENTAL|Nexvax2 DQ2.5 Non-homozygotes (Cohort 2)|Nexvax2 by ID injections for a total of 14 doses over 46 days.
62555987|NCT03334435|EXPERIMENTAL|NR: Bari 4 mg to 4 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received Baricitinib 4 mg and were re-randomized to this arm to receive Baricitinib 4 mg orally.
62376383|NCT02528799|PLACEBO_COMPARATOR|Nexvax2 Placebo DQ2.5 Non-homozygotes (Cohort 2)|Nexvax2 Placebo by ID injections for a total of 14 doses over 46 days.
62376384|NCT02528799|EXPERIMENTAL|Nexvax2 DQ2.5 Non-homozygotes (Cohort 3)|Nexvax2 by ID injections for 18 doses (up to 27 doses) over 60 days (maximum of 91 days).
62752181|NCT02480491||Fifth day embryos|embryos culture media during fifth day after fertilization
62376385|NCT02528799|PLACEBO_COMPARATOR|Nexvax2 Placebo DQ2.5 Non-homozygotes (Cohort 3)|Nexvax2 Placebo by ID injections for 18 doses (up to 27 doses) over 60 days (maximum of 91 days).
62376386|NCT04605458|EXPERIMENTAL|Contingency Management|
62376387|NCT04605458|ACTIVE_COMPARATOR|Standard Care|
62752182|NCT00812201||1|
62752183|NCT06179628|ACTIVE_COMPARATOR|Low Concentration and Volume|0.15% bupivacaine 10 ml boluses for continuous adductor canal block
62752184|NCT06179628|PLACEBO_COMPARATOR|Standard Concentration and Volume|0.25% bupivacaine 20 ml boluses for continuous adductor canal block
62376388|NCT02626299|PLACEBO_COMPARATOR|200 mg/day DHA|Participants will receive 2 placebo pills/day that do not contain DHA. Like the experimental group, they will be given a supplement of Docosahexaenoic acid - 200mg/day , a common amount in prenatal vitamins.
62376389|NCT02626299|EXPERIMENTAL|1000 mg/day DHA|The intervention includes Docosahexaenoic acid - 800mg/day per day provided in two 400 mg capsules. The intervention group as well as the active comparator group will be given 1-200 mg/capsule per day of DHA that is a common amount in prenatal vitamins.
62752185|NCT00211393|EXPERIMENTAL|Drug: ketoconazole|"Drug: ketoconazole~Other Names:~ketoconazole~600mg. /day for 6 weeks~--------------------------------------------------------------------------------"
62752186|NCT00529126|EXPERIMENTAL|SKY0402 high dose|SKY0402, single administration
61986456|NCT05933928|NO_INTERVENTION|Control group (Case-based teaching technique group) (n:40)|To the control group students; Cases on early, late, variable deceleration, reactive, sinusoidal and non-reactive tracing will be prepared by dividing into groups of 5 people. Semi-structured cases will be evaluated and clinical intervention will be discussed with group work. Practice will be done in the basic skills laboratory of the midwifery department.
62376390|NCT00854685|EXPERIMENTAL|1|
62376391|NCT00854685|EXPERIMENTAL|2|
62752187|NCT00529126|EXPERIMENTAL|SKY0402 middle dose|SKY0402, single administration
62752188|NCT00529126|EXPERIMENTAL|SKY0402 low dose|SKY0402, single administration
62752189|NCT00529126|ACTIVE_COMPARATOR|Bupivacaine HCl|Bupivacaine HCl
62752190|NCT06052254|ACTIVE_COMPARATOR|12 cm2 - 2 Active DMTS Patches|2 Active DMTS patches will be applied to the upper back and worn for 4 days (96 hours)
62752191|NCT06052254|ACTIVE_COMPARATOR|6 cm2 - 1 Active and 1 Placebo DMTS Patches|1 Active and 1 Placebo DMTS patches will be applied to the upper back and worn for 4 days (96 hours)
62752192|NCT06052254|PLACEBO_COMPARATOR|Placebo - 2 Placebo DMTS Patches|2 Placebo DMTS patches will be applied to the upper back and worn for 4 days (96 hours)
62376392|NCT00854685|EXPERIMENTAL|3|
62376393|NCT00854685|EXPERIMENTAL|4|
62376394|NCT00854685|PLACEBO_COMPARATOR|5|
62376395|NCT00854685|PLACEBO_COMPARATOR|6|
62376396|NCT05817591||Patients with peripheral neuropathic pain and having an indication of capsaicin patches|"All patients will receive as part of routine care:~* Three consecutive patches of 8% capsaicin in localized application for 30 to 60 minutes once every 3 months : at M0 (study inclusion), M3 and M6, or until pain scale \< 4/10 (between 0 and 10),~* Pain assessment every 1.5 months (+/-7 days), to evaluate clinical response,~* 8% capsaicin patches if the pain assessment rises again to pain scale \> 4/10, after an initial response to treatment"
62752193|NCT06497777||Pancreatic adenocarcinoma|Pancreatic adenocarcinoma which are proven by pathology, before initiation of anti-cancer treatment.
62752194|NCT06497777||Healthy control|People who do not have pancreatic disease.
62752195|NCT04955483||Virtual single-energy imaging reconstruction group|Rebuild a virtual single energy map (70-140Kev, interval 10Kev)
62752196|NCT04955483||Virtual single energy (70-140Kev, interval 10Kev) combined with MAR reconstruction group|Rebuild a virtual single energy map (70-140Kev, interval 10Kev) combined with MAR reconstruction group
62752197|NCT06264219|ACTIVE_COMPARATOR|FMT (Fecal microbiota transplantation)|Mother-to-infant fecal microbiota transplantation
62752198|NCT06264219|ACTIVE_COMPARATOR|FVT (Fecal virome transplantation)|Mother-to-infant fecal virome transplantation
62752199|NCT06264219|PLACEBO_COMPARATOR|Placebo|Inactive solution buffer placebo
62752200|NCT06264219|OTHER|Vaginal control group|Non-randomized control group used for secondary outcomes comparisons.
62376397|NCT02668328|EXPERIMENTAL|Behavioral Intervention|The proposed study involves a 2-phase randomized clinical trial in adults with recently diagnosed T2D. Participants will be randomized to a wait-list Control group, BI, or Tailored-BI. In Phase 1, wait-list Control participants will receive 6 months of standard care; BI and Tailored-BI participants will receive 6 months of Active Intervention. In Phase 2, wait-list Control group participants will cross-over to the delayed Tailored-BI, and the BI and Tailored-BI participants will enter a 6-month observation phase to examine maintenance effects of the intervention.
62376398|NCT01941212|ACTIVE_COMPARATOR|Music therapy and Behavioral therapy|Music and behavioral therapy
62376399|NCT01941212|ACTIVE_COMPARATOR|Music only|Music therapy without behavioral therapy
62752201|NCT06116552|EXPERIMENTAL|More and Less Social Comprehension|Participants listen to more social and less social comprehension stories and answer comprehension questions about the stories.
62752202|NCT05254132||aRECIST|Treatment naive patients with metastatic NSCLC (stage four) with life expectancy of more than three months.
62752203|NCT05254132||rATLAS|Treatment naive patients diagnosed with NSCLC.
62752204|NCT00422149|ACTIVE_COMPARATOR|1|SUBLIVAC® Grasses treatment
62752205|NCT00422149|PLACEBO_COMPARATOR|2|Placebo treatment
61986457|NCT03479307|EXPERIMENTAL|Bilastine Ophthalmic Solution 0.6%|"Bilastine Ophthalmic Solution 0.6%~1 drop in each eye at 2 separate times during an 8 day period."
62376400|NCT01941212|NO_INTERVENTION|Control|Patients will not listen to music neither will get music therapy
62376401|NCT00976261|EXPERIMENTAL|GSK1614235|Glucose lowering agent under investigation.
62376402|NCT00976261|ACTIVE_COMPARATOR|Sitagliptin|Glucose lowering comparator
62376403|NCT00976261|PLACEBO_COMPARATOR|Placebo|Placebo to match GSK1614235 and placebo to match Sitagliptin
62376404|NCT00901394|EXPERIMENTAL|Treatment 1|B12-Folic acid, nitrous oxide
62376405|NCT00901394|ACTIVE_COMPARATOR|Treatment 2|Nitrous oxide (NO) and placebo
62752206|NCT06039436||ATG group|Patients in the ATG group will be treated with conditioning regimen containing ATG 2mg/kg on day -7 prior to transplant.
62376406|NCT00901394|PLACEBO_COMPARATOR|Control group|oxygen nitrogen
62376407|NCT05743413|EXPERIMENTAL|Armeo Spring|Study subjects randomized into this group will undergo physiotherapy sessions using the Armeo Spring device.
62752207|NCT05019742|EXPERIMENTAL|Placebo|2 placebo tablets, 1 in the morning and 1 in the evening, daily for 8 weeks. After 8 weeks, optional randomization to 1 of 2 SPH3127 daily treatment arms for an additional 10 months
62752208|NCT05019742|EXPERIMENTAL|SPH3127 50 mg|"1 50 mg SPH3127 tablet in the morning and 1 placebo tablet in the evening daily for 8 weeks.~After 8 weeks, optional continuation of daily treatment for an additional 10 months."
62752209|NCT05019742|EXPERIMENTAL|SPH3127 100 mg|"1 50 mg SPH3127 tablet in the morning and 1 50 mg SPH3127 tablet in the evening daily for 8 weeks.~After 8 weeks, optional continuation of daily treatment for an additional 10 months."
62752210|NCT01574157|ACTIVE_COMPARATOR|Sodium Bicarbonate|Participants were prescribed 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily for six months
62376408|NCT05743413|ACTIVE_COMPARATOR|Standard physiotherapy|Study subjects randomized into this control group will undergo standard physiotherapy sessions.
62376409|NCT02274766|EXPERIMENTAL|ADS-5102 (amantadine HCl extended release)|ADS-5102 (amantadine HCl extended release)
62376410|NCT02274766|PLACEBO_COMPARATOR|Placebo|Placebo
62376411|NCT01487694|EXPERIMENTAL|Cimicifuga racemosa|patients receive cimicifuga racemosa rhizome and root extract 40 mg/day (equivalent to triterpene glycosides 12.3 mg)
62376412|NCT01487694|PLACEBO_COMPARATOR|Placebo|Placebo containing no active ingredient which match the drug in bottle, shape, color and smell
62376413|NCT05585983|EXPERIMENTAL|Influenza vaccination|Influenza vaccine, 0.5 mL.
62376414|NCT05585983|PLACEBO_COMPARATOR|Placebo|Placebo, 0.5 mL saline.
62376415|NCT04771390|EXPERIMENTAL|Part 1: Group A|Participants will receive 3 single doses of selitrectinib in adult tablet formulation sequentially in 3 treatment periods. The washing-out period between each dose is at least 3 days
62376416|NCT04771390|EXPERIMENTAL|Part 1: Group B|Participants will receive 3 single doses of selitrectinib in pediatric tablet formulation sequentially in 3 treatment periods. The washing-out period between each dose is at least 3 days
62376417|NCT04771390|EXPERIMENTAL|Part 2 (Group A): Dose A-B-C-D|Participants will receive dose A, B, C and D sequentially. The washing-out period between each dose is at least 3 days
62555988|NCT03334435|EXPERIMENTAL|NR: Placebo to Bari 2 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received placebo and were re-randomized to this arm to receive Baricitinib 2 mg orally.
62555989|NCT03334435|EXPERIMENTAL|NR: Placebo to Bari 4 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received placebo and were re-randomized to this arm to receive Baricitinib 4 mg orally.
62555990|NCT03334435|PLACEBO_COMPARATOR|Placebo|Participants from previous Baricitinib monotherapy studies (JAHL, JAHM) and combination therapy study (JAIY) were randomized or assigned to this arm to receive placebo orally.
62555991|NCT03334435|EXPERIMENTAL|Bari 1 mg|Participants from previous Baricitinib monotherapy studies (JAHL, JAHM) were randomized or assigned to this arm to receive Baricitinib 1 mg orally.
62555992|NCT03334435|EXPERIMENTAL|Bari 2 mg|Participants from previous Baricitinib monotherapy studies (JAHL, JAHM) and combination therapy study (JAIY) were randomized or assigned to this arm to receive Baricitinib 2 mg orally.
62555993|NCT03334435|EXPERIMENTAL|Bari 4 mg|Participants from previous Baricitinib monotherapy studies (JAHL, JAHM) and combination therapy study (JAIY) were randomized or assigned to this arm to receive Baricitinib 4 mg orally.
62555994|NCT03334435|EXPERIMENTAL|Bari 2-mg Open-Label Addendum|Participants were directly enrolled to this open-label arm to receive Baricitinib 2-mg orally.
62555995|NCT05204992|EXPERIMENTAL|Hydrodissection|ultrasound guided hydrodissection
62555996|NCT02937311|EXPERIMENTAL|NMES group|This group of patients received Neuromuscular Electrical Stimulation (NMES) and standardized physiotherapy and rehabilitation protocol
62555997|NCT02937311|EXPERIMENTAL|Kinesiotape Group|This group of patients received standardized physiotherapy and rehabilitation protocol and at the same time kinesiotape was applied to their affected shoulder
62555998|NCT02937311|EXPERIMENTAL|Control|This group of patients received only a standardized physiotherapy and rehabilitation protocol
62555999|NCT04658914|NO_INTERVENTION|rotarix only|Rotarix will be administered at 6 and 10 weeks of age following the national Expanded Program for Immunization (EPI) schedule. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 \& 9 days later.
62556000|NCT04658914|EXPERIMENTAL|P2 VP8 only|Parenteral P2-VP8 subunit vaccine will be administered at 6, 10 and 14 weeks of age. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 \& 9 days later.
62556001|NCT04658914|EXPERIMENTAL|Rotarix + 1 dose P2-VP8|Rotarix will be administered at 6 and 10 weeks of age, followed by parenteral P2-VP8 subunit vaccine at 14 weeks of age. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 \& 9 days later.
62556002|NCT04658914|EXPERIMENTAL|Rotarix + 3 doses P2-VP8|Rotarix and parenteral P2-VP8 subunit vaccine will be coadministered at 6 and 10 weeks of age, with an additional dose of P2-VP8 subunit vaccine administered at 14 weeks of age. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 \& 9 days later.
62556003|NCT06460805|EXPERIMENTAL|Axial Spondyloarthritis|
62556004|NCT06460805|EXPERIMENTAL|Healthy Volunteers|
62556005|NCT04356989||Rivaroxaban|Adult NVAF patients with renal impairment, who are prescribed with rivaroxaban to prevent stroke or non-central nervous system (CNS) systemic embolism (SE).
62556006|NCT01210105||Macintosh #3 Laryngoscope|
62556007|NCT01210105||Glidescope|
62556008|NCT01210105||Ambu Pentax AWS|
62556009|NCT01210105||McGrath|
62556010|NCT01210105||Airtraq|
62556011|NCT01210105||Storz C-MAC|
62556012|NCT01375946|EXPERIMENTAL|AG200-15 location|The subject will wear AG200-15 for 7 days and be exposed to one of 5 external conditions (normal, treadmill, cold water, whirlpool, dry sauna).
62556013|NCT01531088|NO_INTERVENTION|Usual care|Recommendations made by consultant pharmacists as part of their federally-mandated medication regimen review process
62556014|NCT01531088|EXPERIMENTAL|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events
62556015|NCT00408525|EXPERIMENTAL|1|Donepezil
62556016|NCT00811967|EXPERIMENTAL|Treatment Arm|
62556017|NCT00811967|NO_INTERVENTION|Control Arm|
62556018|NCT03738072|EXPERIMENTAL|StiMic stimulation condition|StiMic stimulation condition will be evaluate during stereo-electro-encephalography and this condition will be compare to standard stimulation condition
62752211|NCT01574157|PLACEBO_COMPARATOR|Placebo|Participants were prescribed an identical number of placebo tablets had they been assigned to the intervention, and took this daily for six months.
62752212|NCT05460273|EXPERIMENTAL|Dato-DXd Arm|This single-arm study consists of multiple cohorts, divided by indication.
62752213|NCT03390478|NO_INTERVENTION|Control Group|The participants that will be assign to the control group will receive institutional usual care.
62752214|NCT03390478|EXPERIMENTAL|Combined Intervention Group|The participants that will be assigned to the experimental group will receive the Combined Intervention Program
62752215|NCT02362516|EXPERIMENTAL|BI 425809|
62752216|NCT01182740||glidescope|
62752217|NCT01182740||storz c-mac|
62752218|NCT01182740||mcgrath vl|
62752219|NCT01182740||ambu pentax aws|
62752220|NCT01182740||macintosh laryngoscope|
62752221|NCT01182740||others|
62752222|NCT02952482||newborns testing for ALD|newborns testing for ALD
61986458|NCT03479307|ACTIVE_COMPARATOR|Ketotifen Ophthalmic Solution 0.025% (Zaditen)|"Ketotifen Ophthalmic Solution 0.025% (Zaditen)~1 drop in each eye at 2 separate times during an 8 day period."
61986459|NCT03479307|PLACEBO_COMPARATOR|Vehicle of Bilastine Ophthalmic Solution|"Vehicle of Bilastine Ophthalmic Solution~1 drop in each eye at 2 separate times during an 8 day period."
62376418|NCT04771390|EXPERIMENTAL|Part 2 (Group A): Dose B-C-A-D|Participants will receive dose B, C, A and D sequentially. The washing-out period between each dose is at least 3 days
62752223|NCT01689870|EXPERIMENTAL|Phase 1 Cohort 1|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.1 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
62752224|NCT01689870|EXPERIMENTAL|Phase 1 Cohort 2|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.2 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
62752225|NCT01689870|EXPERIMENTAL|Phase 1 Cohort 3|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.4 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
62752226|NCT01689870|EXPERIMENTAL|Phase 2 Cohort 4|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered i.v. at the Phase 1 Maximum Tolerated Dose over 60 minutes only in the first week on Days 1, 3 and 5.
62752227|NCT00027378|EXPERIMENTAL|1|fluoxetine plus Treatment As Usual (TAU)
62752228|NCT00027378|PLACEBO_COMPARATOR|2|placebo plus Treatment As Usual (TAU)
62752229|NCT01177553|ACTIVE_COMPARATOR|Surgery Group|"Patients randomized to surgery will have hospital arrangements (laboratory tests and anesthesia assessment) finalized for a surgery the next day. Patients will sign the informed consent form.~Patients undergoing surgery will be admitted to Tampa General Hospital and will complete usual hospital admission procedures."
62752230|NCT01177553|ACTIVE_COMPARATOR|Expectant Management Group|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
62752231|NCT03833986|EXPERIMENTAL|Stress management program|The stress program will be delivered to experimental group in a six-sessions for two weeks, each session will take 2 hours (2 hours/six sessions /two weeks).
62752232|NCT03833986|NO_INTERVENTION|Control|There is no intervention for controlled group during workshop but they are put on a waiting-list to receive the intervention after the active treatment group does.
62752233|NCT04080219||Normal|Patients with Oxygen desaturation index \<5
62752234|NCT04080219||Sleep-disordered breathing|Patients with Oxygen desaturation index ≥5
62376419|NCT04771390|EXPERIMENTAL|Part 2 (Group A): Dose C-A-B-D|Participants will receive dose C, A, B and D sequentially. The washing-out period between each dose is at least 3 days
62376420|NCT04771390|EXPERIMENTAL|Part 2 (Group B): Dose A-B-C-D|Participants will receive dose A, B, C and D sequentially. The washing-out period between each dose is at least 3 days
62376421|NCT04771390|EXPERIMENTAL|Part 2 (Group B): Dose B-D-A-C|Participants will receive dose B, D, A and C sequentially. The washing-out period between each dose is at least 3 days
62376422|NCT04771390|EXPERIMENTAL|Part 2 (Group B): Dose C-A-D-B|Participants will receive dose C, A, B and D sequentially. The washing-out period between each dose is at least 3 days
62376423|NCT04771390|EXPERIMENTAL|Part 2 (Group B): Dose D-C-B-A|Participants will receive dose D, C, B and A sequentially. The washing-out period between each dose is at least 3 days
62376424|NCT02447952|EXPERIMENTAL|Pilot and Core Study Phase|During Pilot phase,subjects will attend clinic at least once to perform a series of set reference tasks while wearing the accelerometer and electrode. Subjects will also continuously wear the accelerometer and electrode in their routine home-life setting for approximately 3 days after the clinic visit (home monitoring). During 48 week Core Study, subjects will attend 5 clinic visits to perform gold standard measures of function (ALS Functional Rating Scale-Revised and Forced Vital Capacity) and perform a series of set reference tasks while wearing the accelerometer and electrode. Subjects will also continuously wear the accelerometer and electrode in their routine home-life setting for approximately 3 days after the clinic visits (home monitoring). In between clinic visits, subjects will attach the accelerometer and electrode and wear it for approximately 3 days in their home. A telephone contact with the subject will be made by the site at the end of each 3-day home monitoring period
62376425|NCT03245944|ACTIVE_COMPARATOR|early angioplasty|Patients who initiated hemodialysis with a CVC, then had a new AVF created after commencing dialysis, and then had a 6-week postoperative ultrasound that revealed an immature AVF (diameter \< 4 mm diameter or blood flow \< 500 ml/min). These patients who an early angioplasty intervention group that will undergo a routine Angioplasty at 6 weeks after AVF creation
62376426|NCT03245944|EXPERIMENTAL|late Angioplasty|Patients who initiated hemodialysis with a CVC, then had a new AVF created after commencing dialysis, and then had a 6-week postoperative ultrasound that revealed an immature AVF (diameter \< 4 mm diameter or blood flow \< 500 ml/min). These patients who a late angioplasty intervention group in which early Angioplasty will be avoided and subsequently be performed only if the 3-month ultrasound indicates persistent AVF immaturity
62376427|NCT00957034|PLACEBO_COMPARATOR|placebo|placebo patch
62376428|NCT00957034|EXPERIMENTAL|300 µg/day testosterone|300 micrograms/day transdermal testosterone patch
62376429|NCT00957034|EXPERIMENTAL|450 µg/day testosterone|450 micrograms/day transdermal testosterone patch
62556019|NCT04696536|EXPERIMENTAL|Group 1: Listerine Cool Mint Mouth Rinse (Marketed product)|Participants will receive Alcohol-containing Essential Oil (AEO) containing mouth rinse (Listerine Cool Mint, marketed) orally for 12 weeks. Participant will brush their teeth and rinse once daily under supervision during the week (five days) for 30 seconds with 20 milliliter (mL) of mouth rinse and brush their teeth and rinse a second time each day during the week at home. During the weekends, participants will brush twice daily in their usual manner, following rinsing with their assigned mouth rinse, unsupervised at home.
62752235|NCT01932151|OTHER|Terlipressin and albumin|Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.
62752236|NCT01382303|ACTIVE_COMPARATOR|Pentoxifylline|Pentoxifylline 400mg three times a day
62752237|NCT01382303|PLACEBO_COMPARATOR|Placebo|placebo tablet
62752238|NCT05497102|EXPERIMENTAL|Single arm of Lenalidomide maintenance|"\[KRd #1\~6, Every 4 weeks\] D1, 2, 8, 9, 15,16 Carfilzomib 20mg/m2 + 5% dextrose in water 50 mL over 10 mins (From Cycle1Day8 27mg/m2) D1 - 21 Lenalidomide 25mg P.O. D1, 8, 15, 22 Dexamethasone 40mg IV or PO~\[Autologous stem cell transplantation phase\]~\[Lenalidomide maintenance phase, Every 4 weeks\] D1-28 Lenalidomide 10 mg"
62752239|NCT06292754|EXPERIMENTAL|Intervention group|The intervention groups receives treated using magnesium pin in additional to the suture anchor used routinely in clinical practice.
62752240|NCT06292754|ACTIVE_COMPARATOR|Control group|The control group receives routine suture anchor for the treatment-as-usual (TAU).
62752241|NCT06432192||APOE E|The cohort will be genotyped to determine the phenotype of the APOE allele
62752242|NCT03921619|NO_INTERVENTION|No Sling|Participants will perform the balance tests without any added equipment.
62752243|NCT03921619|EXPERIMENTAL|Sling (Dominant)|Participants will perform the balance tests with a sling on the dominant arm.
62556020|NCT04696536|EXPERIMENTAL|Group 2: Negative Control (5 Percent (%) Hydroalcohol Mouth Rinse)|Participants will receive negative control mouth rinse (5% Hydroalcohol mouth rinse) orally for 12 weeks. Participant will brush their teeth and rinse once daily under supervision during the week (five days) for 30 seconds with 20 milliliter (mL) of mouth rinse and brush their teeth and rinse a second time each day during the week at home. During the weekends, participants will brush twice daily in their usual manner, following rinsing with their assigned mouth rinse, unsupervised at home.
62752244|NCT04642560||Usual practice|Any child hospitalized in Pediatric or Neonatal ICU and receiving systemic (intravascular, intramuscular or oral) antibiotic treatment for an episode of suspected or proven community-acquired or nosocomial bacterial infection
62752245|NCT00522314|ACTIVE_COMPARATOR|1|NIV \& ACBT
62752246|NCT00522314|PLACEBO_COMPARATOR|2|Active cycle of breathing techniques
62752247|NCT04750694|EXPERIMENTAL|RT + BFRE|High intensity Resistance training combined with Blood Flow
62752248|NCT04750694|ACTIVE_COMPARATOR|RT|Resistance training alone
62752249|NCT05254275|EXPERIMENTAL|Peri-implant mucositis sites|Peri-implant mucositis sites will be randomly assigned to ozone treatment.
62752250|NCT05254275|EXPERIMENTAL|Contralateral peri-implant mucositis sites|Contralateral peri-implant mucositis sites with respect to those treated with ozone will be assigned to chlorhexidine treatment.
62752251|NCT00006164|EXPERIMENTAL|1|Peg-interferon alfa-2a 90 mcg/week
62752252|NCT00006164|ACTIVE_COMPARATOR|2|Standard of care followup
62752253|NCT02482194|EXPERIMENTAL|Autologous mesenchymal stem cells|use of mesenchymal stem cells as therapeutic intervention for spinal cord injury patients by autologous transplantation
62752254|NCT06606145|EXPERIMENTAL|Lymphovenous Anastomoses (LVA)|Patients with BCRL recieve one ore more Lymphovenous Anastomoses (LVA) on the affected limb. This involves connecting functional lymphatic vessels to nearby veins, allowing for the rerouting of lymphatic fluid into the venous system, thus improving lymphatic drainage. All patients had CDT pre- and post-op.
62752255|NCT06606145|EXPERIMENTAL|Vascularized Lymph Node Transfer (VLNT)|Patients with BCRL recieve a Vascularized Lymph Node Transfer (VLNT) on the affected limb. This involves transferring healthy lymph nodes along with their blood supply to the affected lymphoedematous area, aiding in lymphatic fluid transport and potentially promoting lymphangiogenesis. All patients had CDT pre- and post-op.
62752256|NCT06606145|EXPERIMENTAL|LVA + VLNT|Patients with BCRL recieve a combined simultaneous surgical intervention during which both VLNT and one or more LVA are performed on the affected limb. All patients had CDT pre- and post-op.
62752257|NCT06606145|ACTIVE_COMPARATOR|Complex Decongestive Therapy (CDT)|Patients with BCRL who refuse to undergo further surgical treatment after breast cancer surgery are offered conservative therapy. The current standard of care for most BRCL patients includes conservative measures known as Complex Decongestive Therapy (CDT) consisting of compression therapy with low-stretch bandages, manual lymphatic drainage, exercise, and skincare.
62752258|NCT04873167|EXPERIMENTAL|Low Fat Diet|subjects subjected to a low-fat dietary regime
62752259|NCT04873167|EXPERIMENTAL|Mediterranean Diet|subjects subjected to a mediterranean dietary regime
62752260|NCT01271075|ACTIVE_COMPARATOR|Bilastine A|A: Crossover Bilastine 20 mg, Bilastine 40 mg, Placebo, Bilastine 80 mg
62556021|NCT04696536|EXPERIMENTAL|Group 3: Flossing Performed by Dental Hygienist|Participants will brush their teeth and then undergo instructions on flossing technique using reach dental floss orally for 12 Weeks. Dental hygienist will floss participant's teeth at the site once daily during the week (five days). The second brushing will be done unsupervised at home. The remaining weekend days flossing and brushing will be done unsupervised at home.
62556022|NCT04696536|EXPERIMENTAL|Group 4: Flossing under Supervision|Participants will brush their teeth and then undergo instructions on flossing technique using reach dental floss orally for 12 Weeks. Participants floss their teeth under supervision at the site once daily during the week (five days). The second brushing will be done unsupervised at home. The remaining weekend days flossing and brushing will be done unsupervised at home.
62556023|NCT03766815|PLACEBO_COMPARATOR|Placebo|Fiber supplement mixed with jelly will be ingested for 18 days with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
62556024|NCT03766815|EXPERIMENTAL|BCAA 200mg/kg/day|Branched-chain amino acid supplement mixed with jelly will be ingested for 18 days. The amount of supplement provided will be based on body weight (200mg/kg/day) with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
62556025|NCT03766815|EXPERIMENTAL|BCAA 400mg/kg/day|Branched-chain amino acid supplement mixed with jelly will be ingested for 18 days. The amount of supplement provided will be based on body weight (400mg/kg/day) with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
62556026|NCT00102622|EXPERIMENTAL|Arm 1: Paclitaxel + tgDCC-E1A|80 mg/m\^2 intravenous Paclitaxel and intraperitoneal (IP) tgDCC-E1A starting dose 1.8 mg DNA/m\^2 weekly for six treatments every 7 days.
62556027|NCT00102622|ACTIVE_COMPARATOR|Arm 2: Paclitaxel Alone|Weekly single agent intravenous Paclitaxel 80 mg/m\^2 for six treatments every 7 days.
62752261|NCT01271075|ACTIVE_COMPARATOR|Bilastine B|B: Crossover Bilastine 80 mg, Placebo, Bilastine 40 mg, Bilastine 20 mg
62752262|NCT00473967|EXPERIMENTAL|10 mcg Na-ASP-2/Alhydrogel|Na-ASP-2 Hookworm Vaccine
62752263|NCT00473967|ACTIVE_COMPARATOR|Butang hepatitis B vaccine|Hepatitis B Vaccine - comparator vaccine
62752264|NCT02320812|EXPERIMENTAL|Treated subjects|human retinal progenitor cells
62752265|NCT01035437|EXPERIMENTAL|HPPH|HPPH
62752266|NCT00394901|PLACEBO_COMPARATOR|Placebo|
62752267|NCT00394901|EXPERIMENTAL|Pregabalin 150mg/day|
62752268|NCT00394901|EXPERIMENTAL|Pregabalin 300mg/day|
62752269|NCT00394901|EXPERIMENTAL|Pregabalin 600mg/day|
62752270|NCT05205538|EXPERIMENTAL|Females|Female participant group
62752271|NCT05205538|EXPERIMENTAL|Males|Male participant group
62752272|NCT03311139||AF and ACS patients: No PCI|Patients with Atrial Fibrillation and Acute Coronary Syndrom who did not undergo a Percutaneous Coronary Intervention
62752273|NCT03311139||AF and ACS patients: PCI without stent|Patients with Atrial Fibrillation and Acute Coronary Syndrom who underwent PCI without stent implantation (NOMESCO code FNG00-96 except FNG05)
62752274|NCT03311139||AF and ACS patients: PCI with stent|Patients with Atrial Fibrillation and Acute Coronary Syndrom who underwent PCI with stent implantation (NOMESCO code FNG05)
62752275|NCT01510145|EXPERIMENTAL|TRAVATAN® BAK-free|Travoprost 0.004% BAK-free, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks.
62752276|NCT04158141|EXPERIMENTAL|Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)|"STEP 1: Patients undergo P/D then within 4 to 8 weeks receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1. Patients may instead receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1 then undergo P/D within 4 to 8 weeks after chemotherapy. The order of surgery and chemotherapy is at the discretion of the treating physician.~STEP 2: Patients receive no treatment."
62752277|NCT04158141|EXPERIMENTAL|Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)|"STEP 1: Patients undergo P/D then within 4 to 8 weeks receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1. Patients may instead receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1 then undergo P/D within 4 to 8 weeks after chemotherapy. The order of surgery and chemotherapy is at the discretion of the treating physician.~STEP 2: Within 4-8 weeks from the end of Step 1 treatment, patients undergo 25-28 fractions IMRT or PBS proton therapy 5 days per week over 6 weeks."
62752278|NCT03027856|EXPERIMENTAL|Magmaris|Implantation of sirolimus eluting bioresorbable magnesium stent
62752279|NCT01184833||Group 1|
62752280|NCT03098251|EXPERIMENTAL|3D typing|typing the patient with 3D typing system and give treatment according preestablished algorism in our center.
62752281|NCT03098251|ACTIVE_COMPARATOR|routine typing|typing the patient with routine typing system and give treatment according preestablished algorism in our center.
62752282|NCT03010891|ACTIVE_COMPARATOR|control condition|Preterm infants in the control condition will receive only usual NICU care, plus positioning and gentle touch during intrusive procedures.
62752283|NCT03010891|EXPERIMENTAL|experimental condition|The bundle of supportive interventions will be designed to alleviate preterm infants' stress/pain from birth to discharge from the hospital NICU.
62752284|NCT06607107|EXPERIMENTAL|mFOLFOX7 combined with Apatinib and Camrelizumab|mFOLFOX7(Oxaliplatin, Calcium Levofolinate, Fluorouracil) combined with Apatinib and Camrelizumab
62752285|NCT03326414|OTHER|Constant PEEP - low tidal volume|PEEP is 10mbar, tidal volume is set to 4-5ml/kg IBW
62752286|NCT03326414|OTHER|Constant PEEP - high tidal volume|PEEP is 10mbar, tidal volume is set to 8-10ml/kg IBW
62752287|NCT03326414|OTHER|constant tidal volume - low PEEP|tidal volume is 8ml/kg IBW, PEEP is set to 3mbar
62752288|NCT03326414|OTHER|constant tidal volume - high PEEP|tidal volume is 8ml/kg IBW, PEEP is set to 12mbar
62752289|NCT05304117|EXPERIMENTAL|Advance Care Planning Experimental|Community Information Session on advance care planning and private one-on-one Sharing Session about advance care planning.
62752290|NCT05304117|OTHER|Advance Care Planning Waitlist|Waitlist Group- Baseline control measures will be collected at the same time as Cohort 1 completes their pretest. Six Months after Cohort 1, participants will be pretested again before attending a Community Information Session on advance care planning and an one-on-one Sharing Session about Advance Care Planning.
62752291|NCT03878030||Subjects with spinal muscular atrophy types 2 and 3|Intrathecal nusinersen will be administered to all subjects per FDA approved label.
62752292|NCT03842969|EXPERIMENTAL|RO7234292 (RG6042) Q8W|Participants who received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q8W. Participants who previously received open-label of RO7234292 Q8W in a preceding study or are currently receiving RO7234292 Q8W in this study will receive RO7234292 Q8W. Participants who previously received placebo, or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q8W. Participants who previously received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q8W will receive open-label RO7234929 Q8W. Participants who received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q8W.
62752293|NCT03842969|EXPERIMENTAL|RO7234292 (RG6042) Q16W|Participants who previously received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q16W. Participants who previously received placebo in a preceding study or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q16W. Participants who previously received blinded placebo Q8W will receive RO7234292 Q8W. Participants who previously received blinded RO7234292 Q16W will receive open-label RO7234292 Q16W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q16W. Participants who previously received open-label RO7234292 Q16W will receive open-label RO7234292 Q16W.
62752294|NCT00869804|EXPERIMENTAL|Exercise|combination aerobic (walking) and resistance (strength training) exercise
62752295|NCT00869804|SHAM_COMPARATOR|attention control|attention control with daily journal and cancer-related education
62752296|NCT02694068||Discovery for Aim One|2173 subjects will be involved in the discovery cohort.
62752297|NCT02694068||Replication for Aim One|1673 subjects will comprise the replication cohort.
62752298|NCT02694068||Discovery for Aim Two|824 subjects will be involved in the discovery cohort.
62752299|NCT02694068||Replication for Aim Two|538 subjects will comprise the replication cohort.
62752300|NCT04804657|ACTIVE_COMPARATOR|Sage extract|Two hours before the endurance test, participants were asked to absorb two capsules of sage extracts (600mg each - cognivia™)
62752301|NCT04804657|PLACEBO_COMPARATOR|placebo|Two hours before the endurance test, participants were asked to absorb two capsules of placebo (similar appearance than active comparator).
62376430|NCT01640067|EXPERIMENTAL|Human Neural Stem Cells Suspension|50,000 cells/µl. Patients received either unilateral or bilateral hNSCs microinjections (3 microinjections on each side) into the lumbar spinal cord. Each microinjection consisted of 15 µl of the above 50,000cells/µl suspension, yielding a total of 750,000 cells per injection site.
62376431|NCT03750344|EXPERIMENTAL|ChroniSense Polso Respiratory Rate|
62752302|NCT01839591|EXPERIMENTAL|Bronchial Thermoplasty|bronchoscopy bronchial thermoplasty catheter ALAIR Boston SCientific asthma
62752303|NCT06605092|EXPERIMENTAL|Young Adults|Adults from 18 to 35 years old
62376432|NCT00603876|EXPERIMENTAL|2|Step 1 dietary counseling plus 100-110 grams of almonds daily
62376433|NCT00603876|NO_INTERVENTION|1|Step 1 dietary counseling
62376434|NCT06508697||Patients who underwent CTA within 90 days before ICA with FFR pressure|A consecutive series of patients who underwent Coronary computed tomography angiography (CTA) within 90 days before invasive coronary angiography (ICA) with fractional flow reserve (FFR) pressure measurement were candidates for this study at Fujita Health University Hospital, Bantane Hospital, and Nagoya First Red Cross Hospital.
62556028|NCT01121250|EXPERIMENTAL|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
62556029|NCT01121250|ACTIVE_COMPARATOR|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
62752304|NCT06605092|EXPERIMENTAL|Elderly|Adults aged 65 years ol or more
62752305|NCT01744613||Group A|Will include patients with PRU values above the optimal cut-off value determined by ROC analysis
62752306|NCT01744613||Group B|Will include patients with PRU values below the optimal cut-off value determined by ROC analysis.
62752307|NCT05064293|OTHER|Control Arm|"Data will be collected at baseline and 6-month follow-up from the standardized instruments and automated sources for all eligible subjects randomized to the control arm.~Families who agree to participate will first be offered a formal assessment in order to ascertain the primary mental health diagnosis and any co-occurring mental health disorders. After completing the online parent/guardian self-assessment, parents/guardians will meet for 30 minutes with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to their primary care provider.~Study clinicians will document clinically relevant information from their assessment in a telephone encounter and route these to the child's KP primary care provider in Epic as well as the site navigator.~Control arm participants do not receive navigation."
62752308|NCT05064293|EXPERIMENTAL|Navigation Arm|"6-months of telephonic support from a mental health (MH) navigator to promote early access, engagement, coordination, and personalization of mental health treatment and services as soon as early symptoms of mental health problems are detected in children.~The navigator model and implementation to be tested include:~* Automated identification of early symptoms for children~* Virtual collection of self-reported, standardized assessment scores~* Psychologists interpreting assessment scores and providing feedback to families and PCPs~* Trained clinicians serving as MH navigators to conduct family outreach, engage them in MH care, and coordinate with and between clinicians for up to 6-months~* Up to 4 video-based behavioral health sessions with the MH navigator, as needed, while barriers to initiation of ongoing mental health services can be explored and addressed over the 6-month period."
62752309|NCT02076269|OTHER|Arm 1|Subjects will receive no treatment in this study. Each subject will attend the clinic on 2 occasions, initially for a screening visit and then for further assessments (Visit 1). Subjects will remain in the study for maximum 33 days from the screening visit to follow up.
62752310|NCT03549871|EXPERIMENTAL|Fitusiran|Cohort A \[inhibitor\]: participants with severe hemophilia A/B and inhibitory antibodies to coagulation factor VIII (FVIII)/factor IX (FIX) previously received BPA prophylaxis. Cohort B \[non-inhibitor\]: participants with severe hemophilia A/B without inhibitory antibodies to FVIII/FIX previously received factor prophylaxis. Participants from both cohorts was enrolled into 6-month factor/BPA prophylaxis period and continued their pre-study, regularly scheduled prophylaxis regimen with factor/BPAs. This period could be skipped by subgroup of Cohort A (hemophilia B with inhibitors to FIX and historical annualized bleeding rate \[ABR\] \>=20) that started directly with fitusiran. Post completing factor/BPA prophylaxis period, participants entered 7-month fitusiran treatment period (1-month onset+6-month efficacy) followed by AT follow-up/roll-over into LTE15174 (NCT03754790). Throughout study, participants could receive on-demand treatment for breakthrough BE with factor/BPAs, as appropriate.
62752311|NCT02631174|NO_INTERVENTION|cohort 1|Cohort 1 (Aim 1) - 6 participants Cohort 1 will be comprised of 6 neonates (≤28 days of age) admitted to the CICU or NICU who are neither undergoing ECMO nor CPB. Cohort 1 will receive a single dose of ATIII by short 15 minute infusion.
62752312|NCT02631174|ACTIVE_COMPARATOR|cohort 2.1|"• Cohort 2.1 - 6 neonates undergoing ECMO.~* Three participants will receive a single dose 15 minute infusion of hpATIII that is dose adjusted to account for additional circuit volume followed by a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume~* Three participants will receive a single dose 15 minute infusion of hpATIII that is not dose adjusted to account for circuit volume followed by a single dose 15 minute infusion of hpATIII that is dose adjusted to account for additional circuit volume"
62752313|NCT02631174|ACTIVE_COMPARATOR|cohort 2.2|"• Cohort 2.2 - 12 neonates who will undergo open-heart surgery with CPB~* Six participants will receive a single dose 15 minute infusion of ATIII that is dose adjusted to account for additional circuit volume.~* Six participants will receive a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume"
62752314|NCT02631174|ACTIVE_COMPARATOR|cohort 2.3|"• Cohort 2.3 - 12 infants who will undergo open-heart surgery with CPB~* Six participants will receive a single dose 15 minute infusion of ATIII that is dose adjusted to account for additional circuit volume.~* Six participants will receive a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume"
62752315|NCT02631174|ACTIVE_COMPARATOR|cohort 3|Cohort 3 (Aim 3) - 6 participants Six participants (neonates or infants) who will undergo ECMO and receive ATIII as standard of care will be enrolled and have a baseline ATIII level measured within 6 hours of ATIII administration and repeated within 15 minutes of initiation of extracorporeal support. If post-support level is \< 80% normal activity then an ATIII level will be repeated and participants will be assigned to one of two hpATIII dosing regimens in which one formula accounts for additional circuit volume and one formula does not account for additional circuit volume, as described in section 7.4. Upon completion and 120 hr follow up after the first dose, participants still having ATIII activity less than 80% will then receive a second dose
62556030|NCT01121250|NO_INTERVENTION|Usual Care|Participants do not receive any services.
62376435|NCT02449915|EXPERIMENTAL|Bupivacaine Arm|Those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
62752316|NCT04086537||BMPR2-mutation carriers|Patients affected by pulmonary arterial hypertension (PAH) with already determined BMPR2 mutation status (hereditary PAH, HPAH) or patients with idiopathic PAH (IPAH) and other forms of PAH who are newly diagnosed within the duration of the study and resulted positive for mutation at the routinely-performed (according to current guidelines) BMPR2 analysis.
62752317|NCT04086537||non-BMPR2 mutation carriers|Patients affected by Pulmonary arterial hypertension (PAH) who resulted negative at the routinely-performed (according to current guidelines) BMPR2 analysis (Idiopathic PAH, IPAH) or patients with Idiopathic PAH (IPAH) and other forms of PAH who are newly diagnosed within the duration of the study and resulted negative for mutation at the routinely-performed (according to current guidelines) BMPR2 analysis.
62752318|NCT04086537||healthy controls|Healthy controls free of heart and lung disease or any comorbidities affecting iron metabolism. This control group will be age and gender matched to non-BMPR2 mutation carriers.
62752319|NCT03935724|EXPERIMENTAL|1A Intervention group 8 patients|Neuro-Cells treatment at day 1-2 (= 6-10 weeks after TSCI incident). N=8
62752320|NCT03935724|PLACEBO_COMPARATOR|1B Placebo group 8 patients|Placebo treatment at day 1-2 (= 6-10 weeks after TSCI incident) Neuro-Cells treatment at day 181-182 (= 32-34 weeks after TSCI incident) N=8
62752321|NCT03935724|EXPERIMENTAL|2A Intervention group 27 patients|Neuro-Cells treatment at day 1-2 (= 6-10 weeks after TSCI incident) N=27
62752322|NCT03935724|PLACEBO_COMPARATOR|2B Placebo group 27 patients|Placebo treatment at day 1-2 (= 6-10 weeks after TSCI incident) Neuro-Cells treatment at day 181-182 (= 32-34 weeks after TSCI incident) N=27
62752323|NCT04073784|EXPERIMENTAL|Gemcitabine combined with Apatinib and Toripalimab|Subjects receive Apatinib for oral administration, 250mg, once a day, gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) and Apatinib 250mg once a day maintenance for the remainder of the study or until documented PD.
62752324|NCT05420714|EXPERIMENTAL|Professional CGM Trial|Participants will be asked to wear Dexcom Professional Continuous Glucose Monitoring (Pro-CGM) Device for 10 days. They will have 2 clinic visits with a certified diabetes care and education specialist (CDCES): initial visit for placement of the Pro-CGM and final visit to review the data with CDCES and their diabetes clinic provider. They will be asked to complete a short survey at the end of the 10 days about their experience using the Pro-CGM device and how it impacts their diabetes self-care practices.
62752325|NCT05385887|ACTIVE_COMPARATOR|Antibiotic treatment|Two kinds of antibiotics: Ciprofloxacine 500mg 2dd \& Metronidazole 500mg 3dd
62752326|NCT05385887|PLACEBO_COMPARATOR|Placebo|Placebo tabletes
62752327|NCT04362475|ACTIVE_COMPARATOR|Family Youth Intervention (FYI)|The primary objective of FYI is to evaluate the effectiveness of a theory-based, peer-supported family strengthening intervention on the primary outcomes in a sample of 120 parent-child pairs living in resource-poor urban neighborhoods in Birmingham. For FYI, we will utilize community health advisors (CHAs) to implement the intervention. CHAs will be recruited from each FYI neighborhood and will be trained in research ethics. CHAs will assist and support FYI participants in mastering the sequential skills of the 12 modules designed to improve maternal, youth, and family functioning. Additionally, CHAs will provide emotional social support that is helpful, hopeful, and trustful.
62752328|NCT04362475|ACTIVE_COMPARATOR|ESPI Environment: Social and Physical Intervention (ESPI)|ESPI will enroll 500 community members to examine the effect of blight elimination through lot recovery on primary outcomes of improved social interaction, social cohesion around common neighborhood norms, and collective efficacy to effect change in the neighborhoods . Neighborhood residents will select a cluster of lots (2-3) for lot recovery that are highly visible in the neighborhood (e.g. on a main thoroughfare). The community residents will lead the neighborhood projects. In some cases, neighborhood residents will personally undertake all or part of the greening projects.
62752329|NCT04362475|OTHER|Wait-List Control|The two communities will get ESPI, upon completion of the study.
62752330|NCT04362475|ACTIVE_COMPARATOR|FYI and ESPI|Two of the eight neighborhoods will receive both FYI and ESPI intervention.
62752331|NCT01447485|EXPERIMENTAL|Valsartan 20 mg or 40 mg|
62752332|NCT03066726||CPR less than the 10%le|Group of patients with fetuses with cerebroplacental ratio less than 10%le
62752333|NCT03066726||CPR greater or equal than 10%le|Group of patients with fetuses with cerebroplacental ratio greater or equal than 10%le
62752334|NCT01329796|EXPERIMENTAL|Pertubation with Endole® (lignocaine)|Three treatments were to be given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
62752335|NCT01329796|PLACEBO_COMPARATOR|Placebo|Pertubation with Ringer solution, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
62752336|NCT04796324|EXPERIMENTAL|Ixabepilone|Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle
62752337|NCT00182052|ACTIVE_COMPARATOR|Group 1|
62752338|NCT00182052|PLACEBO_COMPARATOR|Group 2|
62752339|NCT03179111|EXPERIMENTAL|Low Pressure Group|Participants will undergo elective bariatric surgery. Participants under this group will be given intra-abdominal pressure of 8-10mmHg. The number of subjects anticipated for this arm will be 47. Participants in this low pressure group are expected to encounter lesser shoulder tip pain and abdominal pain. Operating field for surgeons also expected to be better.
62752340|NCT03179111|EXPERIMENTAL|Standard Pressure Group|Participants will undergo elective bariatric surgery. Participants under this group will be given intra-abdominal pressure of 12-15mmHg. The number of subjects anticipated for this arm will be 47. Participants in this group are expected to have an increased amount of shoulder tip pain and higher pain score postoperatively compared to low pressure group. Operating fields for surgeons are expected to be less clear.
62752341|NCT01991080|ACTIVE_COMPARATOR|Wheatgerm juice|patients will drink Wheatgerm juice
62752342|NCT01991080|ACTIVE_COMPARATOR|Biofeedback|The patients will undergo biofeedback relaxation therapy
62556031|NCT04245254|EXPERIMENTAL|Intervention Arm|Single arm study. Receives collagen protein powder.
62752343|NCT05575492|EXPERIMENTAL|mRNA-1647 Dose A|CMV-seronegative or CMV-seropositive participants 9 to 15 years of age will receive mRNA-1647 at Dose Level A by intramuscular (IM) injection given as a 3-injection series on Day 1, Month 2, and Month 6.
62752344|NCT05575492|EXPERIMENTAL|mRNA-1647 Dose B|CMV-seronegative or CMV-seropositive participants 9 to 15 years of age will receive mRNA-1647 at Dose Level B by IM injection given as a 3-injection series on Day 1, Month 2, and Month 6.
62752345|NCT05575492|EXPERIMENTAL|mRNA-1647 Dose C|CMV-seronegative or CMV-seropositive participants 9 to 15 years of age and 16 to 25 years of age will receive mRNA-1647 at Dose Level C by IM injection given as a 3-injection series on Day 1, Month 2, and Month 6.
62752346|NCT05575492|EXPERIMENTAL|Dose Expansion: mRNA-1647|CMV-seronegative or CMV-seropositive participants 9 to 15 years of age will receive mRNA-1647 at selected dose level by IM injection given as a 3-injection series on Day 1, Month 2, and Month 6.
62752347|NCT05575492|PLACEBO_COMPARATOR|Dose Expansion: Placebo|Participants will receive placebo by IM injection given as a 3-injection series on Day 1, Month 2, and Month 6.
62752348|NCT05718752||Healthy men|no intervention
62752349|NCT05718752||Healthy women|no intervention
62752350|NCT04740281||Medical Doctors at Aarhus University Hospital, Denmark|Medical Doctors from different subspecialties at Aarhus University Hospital, Denmark. Blinded for the purpose of the trial, their footwear will be evaluated by trial responsible personal.
62752351|NCT01925495|EXPERIMENTAL|healthy adults|Experiment 1 -- variation of ear-canal pressure; Experiment 2 -- varied middle-ear gas compositions; Experiment 3 -- variation of middle-ear pressure
62752352|NCT03130660|EXPERIMENTAL|Short Axis Ultrasonography|one person does both ultrasound and line insertion
62752353|NCT03130660|EXPERIMENTAL|Long Axis Ultrasonography|one person does ultrasound and another inserts the central line
62376436|NCT02449915|PLACEBO_COMPARATOR|Placebo Arm|Those subjects in the placebo arm will have 30 mL sterile normal saline injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected into the port site wounds in the abdomen (5 sites, 4 mL per incision).
62752354|NCT02082457|PLACEBO_COMPARATOR|Placebo|Two tablets of YKP10811 placebo are administered orally once a day for 12 weeks.
62752355|NCT02082457|EXPERIMENTAL|YKP10811 10mg|Two tablets of YKP10811 5mg are administered orally once a day for 12 weeks.
62752356|NCT02082457|EXPERIMENTAL|YKP10811 20mg|One tablet of YKP10811 20mg and one tablet of placebo are administered orally once a day for 12 weeks.
62752357|NCT02082457|EXPERIMENTAL|YKP10811 40mg|Two tablets of YKP10811 20mg are administered orally once a day for 12 weeks.
62752358|NCT01657890|EXPERIMENTAL|Arm 1: Isavuconazole in healthy non-elderly male subjects|age 18 to 45 years
62376437|NCT00740818|NO_INTERVENTION|A|The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.
62376438|NCT00740818|SHAM_COMPARATOR|B|A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.
62376439|NCT00740818|EXPERIMENTAL|C|Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
62376440|NCT03817931|PLACEBO_COMPARATOR|Placebo|Placebo pill identical will be identical to tablets in the other 2 arms.
62376441|NCT03817931|ACTIVE_COMPARATOR|Anticholinergic|Solifenacin 5 mg tablet orally once daily for 30 days
62376442|NCT03817931|ACTIVE_COMPARATOR|Beta-3 agonists, adrenergic|Mirabegron 25 mg tablet orally once daily for 30 days
62376443|NCT04340687||IP group|All patients recevied pancreatic duct stent during ERCP and one single dose of 100mg rectal indomethacin after ERCP.
62376444|NCT04340687||IN group|All patients received one single dose of 100mg rectal indomethacin after ERCP.
62556032|NCT01306305|EXPERIMENTAL|Elderly|Elderly subjects aged over 60 years
62556033|NCT01306305|EXPERIMENTAL|Adults|Adults from 18 to 60 years old inclusive
62556034|NCT04269993|PLACEBO_COMPARATOR|Vaporized cannabis: placebo|Vaporized cannabis: placebo dose
62752359|NCT01657890|EXPERIMENTAL|Arm 2: Isavuconazole in healthy non-elderly female subjects|age 18 to 45 years
62752360|NCT01657890|EXPERIMENTAL|Arm 3: Isavuconazole in healthy elderly male subjects|age 65 years and older
62752361|NCT01657890|EXPERIMENTAL|Arm 4: Isavuconazole in healthy elderly female subjects|age 65 years and older
62752362|NCT02180256|EXPERIMENTAL|Endoscratching, non-RIF|Endometrial scratching. Women with no more than 1 previous unsuccessful embryo transfer. Pipelle in the first seven days of the menstrual cycle, just before starting controlled ovarian stimulation.
61986460|NCT01809873|EXPERIMENTAL|Performance based incentives|Performance based incentives: The Incentive arm will receive monthly visits and external quality assurance of malaria diagnostic accuracy, identical to the comparison. Incentive arm will also receive quarterly incentives linked to performance of the facility around six indicators of appropriate malaria case management
62376445|NCT02906098|EXPERIMENTAL|Patient centered oral health education|The program is based on cognitive behavioral theory and principles. Hence, the intervention is adapted to each individual's problem, capacity and goals were the dental hygienist use motivational interviewing skills in communication and act as a guiding resource during the process of behavioral change. The program follows a specific structure including components such as formulation of personal goals, continuous self-monitoring by diary and planning of behavior. The initial intervention phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
62556035|NCT04269993|EXPERIMENTAL|Vaporized cannabis: medium THC/medium CBD|Vaporized cannabis: medium THC/medium CBD dose
62556036|NCT04051203|EXPERIMENTAL|Autologous Platelet Rich Plasma Injection|PRP contains high concentrations of platelets, growth factors, and anti-inflammatory molecules.
62556037|NCT04051203|ACTIVE_COMPARATOR|Standard Treatment|Steroid and anesthetic injection: the clinical standard.
62752363|NCT02180256|NO_INTERVENTION|Control, non-RIF|No intervention. Women with no more than 1 previous unsuccessful embryo transfer.
62752364|NCT02180256|EXPERIMENTAL|Endoscratching, RIF|Endometrial scratching. Women with 2 or more previous unsuccessful embryo transfers. Pipelle in the first seven days of the menstrual cycle, just before starting controlled ovarian stimulation.
62752365|NCT02180256|NO_INTERVENTION|Control, RIF|No intervention. Women with 2 or more previous unsuccessful embryo transfers.
62752366|NCT00770042|EXPERIMENTAL|Group 1|Ketoconazole 400 mg qd for 5 days (Days 2-6) plus a single dose of 50 mg avanafil on Days 1 and 6
62752367|NCT00770042|EXPERIMENTAL|Group 2|Erythromycin 500mg every 12 hours for 5 days (Days 2-6) plus a single dose of 200 mg Avanafil on Days 1 and 6.
62752368|NCT00770042|EXPERIMENTAL|Group 3|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8) plus a single dose of 50 mg avanafil on Days 1 and 8
62752369|NCT01798173|EXPERIMENTAL|Cases: cirrhotic patients with hepatocellular carcinoma|
62752370|NCT01798173|ACTIVE_COMPARATOR|Controls: cirrhotic patients without hepatocellular carcinoma|
62376446|NCT02906098|ACTIVE_COMPARATOR|Standard educational intervention|The subjects in the control group receive educational intervention by a dental hygienist in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
62752371|NCT05788783|EXPERIMENTAL|Experimental|Active intervention. 8 youth will be assigned to the active Recovery \& Care Canine-Assisted Therapy intervention arm.
62752372|NCT05788783|OTHER|Active control|Active control intervention. 8 youth will be assigned to the active Canine Education \& Bonding arm.
62752373|NCT04644796|PLACEBO_COMPARATOR|Placebo Group|Patients in this group will be given the placebo (sterile saline).
62376447|NCT05481944|ACTIVE_COMPARATOR|Patients with insulinotherapy introduction|Injected MRI
62376448|NCT05481944|SHAM_COMPARATOR|Healthy volunteers|No injected MRI
62376449|NCT06415916||patient|Patients admitted to intensive care who require volume expander
62376450|NCT01960556||Simulation|Simulation Training part of education
62376451|NCT01960556||Non-Simulation Based Education|Did not receive simulation based education
62376452|NCT04063540|OTHER|placebo-amiloride|Patients will be treated for 12 weeks with placebo and then after a 4 week wash-out period, will be treated for 12 weeks with amiloride.
62376453|NCT04063540|OTHER|amiloride -placebo|Patients will be treated for 12 weeks with amiloride and then after a 4 week wash-out period, will be treated for 12 weeks with placebo.
62376454|NCT00669591|EXPERIMENTAL|1|Patients will receive up to six (6) 28-day cycles of docetaxel plus weekly bavituximab during the treatment phase. During the follow-up phase, patients will continue to receive weekly bavituximab until disease progression
62376455|NCT03042585|EXPERIMENTAL|Dose Level 1|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.64 Gy per Fraction for a total of 8 Fractions. The total amount would be 13.12 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
62376456|NCT03042585|EXPERIMENTAL|Dose Level 2|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.76 Gy per Fraction for a total of 8 Fractions. The total amount would be 14.08 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
62376457|NCT03042585|EXPERIMENTAL|Dose Level 3|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.88 Gy per Fraction for a total of 8 Fractions. The total amount would be 15.04 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
62376458|NCT03042585|EXPERIMENTAL|Dose Level 4|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 2.00 Gy per Fraction for a total of 8 Fractions. The total amount would be 16 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
62556038|NCT04051203|PLACEBO_COMPARATOR|Normal Saline|Placebo injection, with no known treatment effects.
62556039|NCT06583200|OTHER|End Expiratory Occlusion Test|Pulse pressure variation before and after end expiratory occlusion test
62752374|NCT04644796|ACTIVE_COMPARATOR|Liposomal bupivacaine|Patients in this group will be given the study drug (liposomal bupivacaine).
62752375|NCT04114604||Spinal Cord Injury|Adults who have sustained a spinal cord injury at the cervical or upper thoracic level (T6 or higher).
62752376|NCT01174004|EXPERIMENTAL|1|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
62752377|NCT01174004|PLACEBO_COMPARATOR|2|placebo, tablet, once daily by mouth for 6 weeks
62752378|NCT01725230|EXPERIMENTAL|Rosuvastatin|Single, oral dose of rosuvastatin 20mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of rosuvastatin 20 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily
62752379|NCT01725230|EXPERIMENTAL|Simvastatin|Single, oral dose of simvastatin 40 mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of simvastatin 40 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily
62752380|NCT02120092|ACTIVE_COMPARATOR|Clopidogrel + ASA|
62752381|NCT02120092|PLACEBO_COMPARATOR|Clopidogrel + Placebo|
62752382|NCT02120092|ACTIVE_COMPARATOR|Ticagrelor + ASA|
62752383|NCT02120092|PLACEBO_COMPARATOR|Ticagrelor + Placebo|
62752384|NCT03350087|EXPERIMENTAL|iTBS group|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
62752385|NCT03350087|EXPERIMENTAL|cTBS group|In continuous theta burst stimulation (cTBS group), they received cTBS (80% of active motor threshold) on unaffected hemisphere.
62752386|NCT03350087|EXPERIMENTAL|iTBS+cTBS group|Continuous theta burst stimulation (cTBS group) at first followed by intermittent theta burst stimulation (iTBS group).
62752387|NCT03350087|SHAM_COMPARATOR|sham TBS group|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
62376459|NCT02117492|EXPERIMENTAL|Vertical Cuff|Vaginal cuff closure will be done vertically.
62556040|NCT06583200|OTHER|Passive leg raising test|Pulse pressure variation before and after passive leg raising test
62752388|NCT03350087|EXPERIMENTAL|VCT group|VCT group received the VCT training in addition to traditional rehabilitation. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise.
62752389|NCT03350087|EXPERIMENTAL|VCT+optimal rTMS group|VCT+optimal rTMS group received the VCT training and optimal rTMS in addition to traditional rehabilitation.
62752390|NCT02238431|EXPERIMENTAL|Lucrin depot, artificial cycle start|intramuscular administration of Lucrin depot (half dose of 3.75mg) on the 5th day following oocyte retrieval
62752391|NCT02238431|ACTIVE_COMPARATOR|OCP active, artificial cycle start|to take active OCP tablets (1 per day) from the 10th day following oocyte retrieval for at least 21 days
62376460|NCT02117492|EXPERIMENTAL|Horizontal Cuff|Vaginal cuff closure will be done horizontally.
62376461|NCT05042570|EXPERIMENTAL|Instrument Assisted Soft Tissue Mobilization|Group 1 (n=13): Each session will consist of 40 minutes. An additional 10 minutes of IASTM will be performed to the 30-minute NDT program.
62376462|NCT05042570|EXPERIMENTAL|Stretching Exercises|Group 2 (n=13): Each session will consist of 40 minutes. In addition to the NDT program applied for 30 minutes, 10 minutes of Stretching Exercises will be performed.
62556041|NCT01805843||chronic meloid leukemia|echo, exercise echo, and if indicated, right heart catheter
62556042|NCT02076087||Normal Weight (BMI: 18.5-24.9 kg/m²)|Liposuction/lipectomy
62556043|NCT02076087||Overweight (BMI: 25.0-29.9 kg/m²)|Liposuction/lipectomy
62752392|NCT02238431|EXPERIMENTAL|Natural, menstrual period|to wait for the second bleed to commence the artificial FET cycle
62752393|NCT06585904|EXPERIMENTAL|1 dose of beetroot juice|The volunteer will ingest 1 dose of beetroot juice containing 400mg of inorganic nitrate for 10 days.
62752394|NCT06585904|ACTIVE_COMPARATOR|Exercise|The volunteer will perform moderate aerobic exercise for 10 consultative days on a cycle ergometer.
62752395|NCT06585904|NO_INTERVENTION|Control|The volunteer will undergo initial assessments, will carry out the control without any intervention, for 10 consecutive days and will carry out the assessments afterwards.
62752396|NCT03790436|EXPERIMENTAL|Betaquik|
62752397|NCT03047356|EXPERIMENTAL|"First-person if-then plan"|"Participants are asked to form if-then plans and the instructions are presented in the first person (if I...then I...). Ifs are critical situations, thens are appropriate responses."
62752398|NCT03047356|EXPERIMENTAL|"Second-person if-then plan"|"Participants are asked to form if-then plans and the instructions are presented in the second person (if you...then you...). Ifs are critical situations, thens are appropriate responses."
62752399|NCT03047356|PLACEBO_COMPARATOR|Control|"Participants are presented with ifs (critical situations) and thens but are not asked to form if-then plans."
62376463|NCT05042570|ACTIVE_COMPARATOR|Control|Group 3 (n=13): Each session will consist of 40 minutes. There will be no additional application to the NDT program, which is applied for 40 minutes, and it will be included as a control group in the study.
62376464|NCT02054663|EXPERIMENTAL|Bolus|Patients randomized to this arm will receive a 600mg bolus dose of clopidogrel at the time of switching from ticagrelor to clopidogrel, followed by 75mg daily.
62376465|NCT02054663|EXPERIMENTAL|no bolus|Individuals randomized to this arm will receive 75mg of clopidogrel at the time of the transition followed by a daily dose of 75mg orally.
62376466|NCT03790267||Hip arthroplasty|
62376467|NCT03790267||Knee arthroplasty|
62376468|NCT03790267||Shoulder arthroplasty|
62376469|NCT01381731|EXPERIMENTAL|Diquafosol tetrasodium ophthalmic solution 2%|topical ophthalmic solution
62376470|NCT01381731|PLACEBO_COMPARATOR|Placebo|saline ophthalmic solution
62376471|NCT04299750|EXPERIMENTAL|Alveolar Ridge Preservation|Patients in this arm will undergo atraumatic extraction of an hopeless tooth and a socket preservation procedure. Alveolar ridge preservation will be performed using a slow-resorption bone substitute and a collagen membrane that covers the graft.
62376472|NCT04299750|ACTIVE_COMPARATOR|Natural healing|Patients in this arm will undergo atraumatic extraction of an hopeless tooth. The socket will follow natural healing.
62376473|NCT01855191||Standard|
62376474|NCT01855191||Standard + saliva collection|
62376475|NCT00958191|OTHER|Trident® X3 Polyethylene Insert|Participants who received the Trident® X3 Polyethylene Insert.
62376476|NCT00912496|EXPERIMENTAL|Group 9: 2 dose prime|Received two doses of A/Vietnam/1203/04 90mcg vaccine as prime (on Days 0, 28 in DMID 07-0019), will receive a booster dose of A/Anhui/05 vaccine (A) with or without MF59 adjuvant in DMID 08-0013 on Day 0.
62376477|NCT00912496|EXPERIMENTAL|Group 8: 1 dose prime|Received A/Vietnam/1203/04 90mcg vaccine as prime (Day 0 in DMID 07-0019), will receive a booster dose of A/Anhui/05 vaccine (A) with or without MF59 adjuvant in DMID 08-0013 on Day 0.
62376478|NCT00912496|EXPERIMENTAL|Group 10: unprimed control/dose response group|Unprimed control and dose response group of H5 vaccine naive volunteers will be added in DMID 08-0013 to receive two doses of A/Anhui/05 vaccine (A) with or without MF59 adjuvant or placebo on Day 0 and Day 28.
62376479|NCT06136910|EXPERIMENTAL|H101 combined with tirilizumab and platinum-containing two-drug chemotherapy|"1. Recombinant human adenovirus type 5 injection(H101), intratumoural, administered for 4 cycles, 1 injection on day 1 (d1) of each cycle.The number of injections should be determined according to the patient's tolerance and the ease of manipulation of the injection site, and should be no less than 2 times.~2. Tirilizumab injection, 200 mg, IV, d1, Q21d, administered until disease progression or intolerable side effects occur~3. Platinum-containing two-agent chemotherapy Adenocarcinoma: pemetrexed plus carboplatin Non-adenocarcinoma: paclitaxel/gemcitabine combined with carboplatin"
62376480|NCT02726607|EXPERIMENTAL|HITSystem 2.0|Pregnant women who are eligible for PMTCT services will be enrolled in the HIV Infant Tracking System 2.0 (HITSystem 2.0) intervention during their first PMTCT appointment and followed until 12 weeks postpartum.
62376481|NCT02726607|ACTIVE_COMPARATOR|Standard of PMTCT Care|Pregnant women who are eligible for PMTCT services will receive standard of care PMTCT services at the control hospital. The records of women enrolled during their first PMTCT appointment will be used to assess outcomes during the same follow-up period.
62376482|NCT01670825|EXPERIMENTAL|Pulsed radiofrequency + local anesthetic injection|Local anesthetic injection plus pulsed radiofrequency over each affected occipital nerve
62556044|NCT02076087||Obese (BMI: >30.0kg/m²)|Liposuction/lipectomy
62556045|NCT00835302|EXPERIMENTAL|Manipulation + Exercise Group|Cervicothoracic manipulation and ROM exercises
62556046|NCT00924300||patients|children and/or adolescents with psychiatric disorder
61986461|NCT01809873|NO_INTERVENTION|Comparison|The comparison arm will receive monthly visits and monthly external quality assurance of malaria diagnostic accuracy.
62556047|NCT00924300||controls|typically-developing children/adolescents
62376483|NCT01670825|ACTIVE_COMPARATOR|Corticosteroid injection + sham pulsed radiofrequency|"Injection with corticosteroid and local anesthetic over the occipital nerve(s)plus sham pulsed radiofrequency"
62376484|NCT01430689|EXPERIMENTAL|Inactivated Influenza Vaccine Trivalent Types A and B|Women will be vaccinated with Influenza vaccine: Inactivated Influenza Vaccine Trivalent Types A and B
62376485|NCT01430689|ACTIVE_COMPARATOR|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate|Women will be vaccinated with IM injection of Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine
62376486|NCT05008367|ACTIVE_COMPARATOR|Treatment A|24 mg dexamethasone i.v. perioperatively and 24 mg dexamethasone i.v. on the first postoperative day
62376487|NCT05008367|ACTIVE_COMPARATOR|Treatment B|24 mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
62376488|NCT05008367|PLACEBO_COMPARATOR|Placebo|Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
62376489|NCT04813549||Rheumatoid Arthritis patients|Rheumatoid arthritis patients will be evaluated in terms of the presence of secondary fibromyalgia and its effect on the quality of life, at their admission.
62376490|NCT02483611|EXPERIMENTAL|Group M|"Magnesium Sulfate. In this group, the patients received magnesium sulfate 40 mg/Kg as a bolus and 20 mg/kg/h by continuous IV infusion during surgery.~After the bolus of magnesium sulfate, 0.15 mg/kg of cisatracurium was infused over 5 seconds."
62556048|NCT02035111|EXPERIMENTAL|Tianshu capsule|Four Tianshu capsules (0.34 g per capsule) by oral three times a day for 12 weeks.
62752400|NCT01845324||Diabetes Mellitus in pregnancy|Our cohort will include all consequtive women with Diabetes Mellitus atending our clinic
62752401|NCT01955434|EXPERIMENTAL|Treatment (SMAC mimetic LCL161 and cyclophosphamide)|Patients receive SMAC mimetic LCL161 PO QD on days 1, 8, 15, and 22. Patients lacking a minor response by end of course 2 or partial response by end of course 4 may also receive cyclophosphamide PO QD on days 1, 8, 15, and 22 at the discretion of the treating physician. Patients taking cyclophosphamide with less than a 25% interval reduction in paraprotein receive SMAC mimetic LCL161 on days 2, 9, 16, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62376491|NCT02483611|EXPERIMENTAL|Group ML|"Magnesium Sulfate plus Lidocaine. In this group, the patients received 40 mg/kg of Magnesium Sulfate plus 3 mg kg-1 lidocaine as a bolus and 20 mg/kg/h and 3 mg/kg/h, respectively, by infusion continuously during the surgery.~After the bolus of magnesium sulfate and lidocaine, 0.15 mg/kg of cisatracurium was infused over 5 seconds"
62376492|NCT02483611|PLACEBO_COMPARATOR|Group C|"Isotonic Solution. In this group, the patients received the volume of isotonic solution equivalent to the volume of solution infused into experimental groups.~After the bolus of the isotonic solution , 0.15 mg/kg of cisatracurium was infused over 5 seconds"
62376493|NCT00985140||12 Gy TSEBT|Prospective assignment to receive 12 Gy total skin electron beam therapy (TSEBT) for mycosis fungoides
62376494|NCT02510976|ACTIVE_COMPARATOR|Prucalopride|Prucalopride tablet 2 mg
62752402|NCT05664347|ACTIVE_COMPARATOR|Control|Standard verbal teach to goal inhaler technique education
62376495|NCT02510976|PLACEBO_COMPARATOR|Placebo|matching placebo tablet
62376496|NCT00860704|ACTIVE_COMPARATOR|Ringerlactate lean|fluidtherapy with crystalloids in lean patients
62376497|NCT00860704|ACTIVE_COMPARATOR|Ringerlactate overweight|fluidtherapy with crystalloids in overweight patients
62376498|NCT00860704|ACTIVE_COMPARATOR|Ringerlactate obese|fluidtherapy with crystalloids in obese patients
62376499|NCT02098655||30 patients with PD|30 patients (12 M, 18 F, mean age 66,8 ± 8,7) with PD in stage 3 of H\&Y will undergo training of balance using a stabilometric platform
62376500|NCT02098655||12 healthy volunteers|12 healthy volunteers (3 M, 9 F, mean age 66,5 ± 6,0) served as controls will undergo training of balance using a stabilometric platform
62376501|NCT04170491|NO_INTERVENTION|control|The standard medical care (Control) group will receive sequential portable EEGs, performed according to clinical demand. These patients usually have 2 recordings of 20-30 minutes each within 24 or 48 hours. The studies include baseline recoding and recording after auditory, tactile and nociceptive stimulation. The EEGs will be visually reviewed and reported within 4 hours after the recording completion by a Consultant Clinical Neurophysiologist or other doctor with equivalent qualifications.
62556049|NCT02035111|PLACEBO_COMPARATOR|Sugar pill|Four sugar pills (0.34 g per capsule) by oral three times a day for 12 weeks.
62752403|NCT05664347|ACTIVE_COMPARATOR|Intervention|Video based teach to goal inhaler technique education
62376502|NCT04170491|EXPERIMENTAL|cEEG|The treatment (cEEG) group will have cEEG applied within 12 hours of RSE diagnosis, which will continue until 24 hours after cessation of clinical and electrical seizure activity. Reactivity testing with auditory, tactile and nociceptive stimulation will be repeated at least once daily. The cEEG will be visually interpreted twice daily by a Consultant Clinical Neurophysiologist and the results will be communicated within two hours of their completion to the treating clinical team.
62376503|NCT05295836|NO_INTERVENTION|CONTROL|In this phase of the study, the rectangular test will be performed in conditions of 16°C and 25-30% humidity, intaking 26 mL/kg/body weight of water one and a half hours before the test.
61986462|NCT05225142|EXPERIMENTAL|Modified minimally invasive surgery alone|Modified minimally invasive surgery alone for access and debridement of intrabony defect. This approach maximises wound stability. No application of regenerative biomaterial.
62376504|NCT05295836|PLACEBO_COMPARATOR|PLACEBO (PLA)|In this intervention, subjects will perform the rectangular test at 28°C and 25-30% humidity, ingesting 26 mL/kg/body weight of water and placebo one and a half hours before the test.
62376505|NCT05295836|EXPERIMENTAL|GLYCEROL (GLY)|In this intervention, subjects will perform the rectangular test at 28°C and 25-30% humidity, ingesting 1.2 g + 26 mL/kg/body weight of water one and a half hours before the test.
62376506|NCT04696328|EXPERIMENTAL|Group of subjects undergoing cell transplantation|Human (allogeneic) iPS cell derived-cardiomyocyte sheet transplantation (only once)
62376507|NCT06138392||Experimental group|
62376508|NCT03034109|EXPERIMENTAL|tDCS conventional stimulation|"Transcranial Direct Current Stimulation:~The anode will be placed over the left dorsal lateral prefrontal cortex (DLPFC) and the cathode will be placed over the right supraorbital cortex. This is the standard 1 anode by 1 cathodal convention. Stimulation will last 20 minutes."
62376509|NCT03034109|EXPERIMENTAL|High Definition (HD)-tDCS stimulation|"Transcranial Direct Current Stimulation:~The anode will be placed over the left DLPFC and 4 cathodes will be placed surrounding the anode. This is the 4 cathode by 1 anode HD-tDCS montage for more focal stimulation. Stimulation will last 20 minutes."
62376510|NCT03034109|SHAM_COMPARATOR|tDCS sham stimulation|"Transcranial Direct Current Stimulation:~The anode will be placed over the left DLPFC and the cathode over the right supraorbital cortex. A short stimulation will be given to the subjects that will mimic the sensation of an actual stimulation but will last much shorter. The session will still last 20 minutes in total to blind both subjects and investigators."
62376511|NCT02339454|ACTIVE_COMPARATOR|Active treatment group|"Patients in this group receive actual shockwave therapy. Study treatment consists of 9 sessions, with 3 sessions per week 1, 5 and 9. 100 shocks are delivered per spot, 1200 shocks per session.~During 1st treatment week ESMR will be delivered 3 times (every other day) to basal segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).~During 2nd treatment week ESMR will be delivered 3 times (every other day) to middle segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).~During 3rd treatment week ESMR will be delivered 3 times (every other day) to apical segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions)."
62376512|NCT02339454|PLACEBO_COMPARATOR|Placebo group|This group of patients undergoes the same procedure as the treatment group; however shockwaves are not delivered to the heart.
62376513|NCT00262561|ACTIVE_COMPARATOR|Aspirin|All participants get Aspirin, and platelet reactivity measurements are performed.
62376514|NCT00756821||SMA cohort|Subjects between the ages of 2-12 years diagnosed with SMA Type I, II, or III.
62376515|NCT00756821||Control cohort|Healthy children between the ages of 2-12 years. These children may be either genetically-related siblings of SMA children (genetically confirmed non-carriers of SMA),or unrelated children.
62376516|NCT03826316|EXPERIMENTAL|Mutonpain Injection 10 mg/ml|
62376517|NCT04491292||Observational (questionnaire)|Participants complete 2 online questionnaires over 10 minutes each at baseline and at 3 months after the pandemic ends.
62376518|NCT01657214|EXPERIMENTAL|Dose escalation|SAR125844 will be administered as weekly IV infusion. Four weekly administrations are considered as 1 cycle. The starting dose will be either 1 dose level (DL) below the highest cleared dose level in a European TED11449 ongoing study or DL4 (260 mg/m\^2), if the highest cleared dose in TED11449 is \>340 mg/m\^2.
62376519|NCT01646151||Bimatoprost|Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
62376520|NCT04840849|EXPERIMENTAL|Nirsevimab|Nirsevimab single dose IM injection
62376521|NCT04840849|PLACEBO_COMPARATOR|Placebo|Placebo single dose IM injection
62376522|NCT04085991|EXPERIMENTAL|131I-PSMA-1095 Radioligand Therapy (RLT)|Intravenous injection of 100 mCi of 131I-PSMA-1095 RLT, Q8 weeks up to a maximum of 4 doses
62376523|NCT00411879|PLACEBO_COMPARATOR|Control Group|Patients with refractory cardiac arrest (as defined in methods) treated according to the latest guidelines for resuscitation and receiving placebo instead of vasopressin and corticosteroids
62556050|NCT01144429|ACTIVE_COMPARATOR|100 DPP/mL|Concentration of solution fo s.c. injection: 100 DPP/mL
62752404|NCT01480713|EXPERIMENTAL|Monotherapy with IPs+ Raltegravir 400 mg|Lopinavir/r 400/100 mg every 12 hours + Raltegravir 400 mg every 12 hours or Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
62752405|NCT04080986|NO_INTERVENTION|Standard Arm|All defibrillation attempts will occur using the standard defibrillation method, i.e. defibrillation pads will be placed in the anterior-anterior configuration. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
62376524|NCT00411879|EXPERIMENTAL|Study Group|Patients with refractory cardiac arrest treated with combined vasopressin, epinephrine, and methylprednisolone during resuscitation. Patients receive stress-dose hydrocortisone for postresuscitation shock
62376525|NCT01594463|EXPERIMENTAL|late ultrasound examination|late examination between 34+1 weeks to 35+6 weeks.
62752406|NCT04080986|ACTIVE_COMPARATOR|Double Sequential Defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. For all further shocks, a second set of defibrillation pads (via a second on scene EMS or fire defibrillator) will be applied in the anterior-posterior position, and defibrillation will be carried out by sequential defibrillation shocks provided by the two defibrillators (i.e. with a short delay between the two defibrillators). The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
61986463|NCT05225142|ACTIVE_COMPARATOR|Modified minimally invasive surgery with enamel matrix derivative|Modified minimally invasive surgery access and debridement of intrabony defect combined with local application of enamel matrix derivative (regenerative biomaterial)
62376526|NCT01594463|EXPERIMENTAL|early ultrasound examination|early examination between 30+1 weeks to 31+6 weeks
62376527|NCT01138293|EXPERIMENTAL|motion sensor integrated in a mobile phone|A motion sensor integrated in a mobile phone. The system analyses kind, intensity and duration of physical activity and eating habits.
62376528|NCT00470873||Group 1|
62556051|NCT01144429|ACTIVE_COMPARATOR|1000 DPP/mL|Concentration of solution fo s.c. injection: 1000 DPP/mL
62376529|NCT02461849|EXPERIMENTAL|Imatinib|Imatinib 400mg qd daily Until disease progression, patient's refusal
62376530|NCT03061227|ACTIVE_COMPARATOR|Intravenous glucagon|Low-dose glucagon infusion (0.5 pmol/min/kg body weight) over 150 minutes during a standardized 75 g oral glucose tolerance test
62752407|NCT04080986|ACTIVE_COMPARATOR|Vector Change Defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. All further shocks will occur with the pads placed in the anterior-posterior position. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
62752408|NCT04692168||Entire group|The group will be test prior and three months after a neurotoxic chemotherapy for gynecological cancer.
62752409|NCT02095665|ACTIVE_COMPARATOR|Narcotic analegesic only|"Drug:~Tylenol #3 1 tablet every six hours as necessary"
62752410|NCT02095665|ACTIVE_COMPARATOR|Mirabegron and narcotic analgesia|"Drug :~Mirabegron 50 mg oral daily~Drug:~Tylenol #3 1 tablet every six hours as necessary"
62752411|NCT02095665|ACTIVE_COMPARATOR|Tamsulosin and narcotic analgesia|"Drug:~Tamsulosin 0.4mg oral daily Drug: Tylenol #3 1 tablet every six hours as necessary"
62752412|NCT02095665|EXPERIMENTAL|Mirabegron, Tamsulosin and narcotic|"Drug:~Mirabegron 50 mg oral daily~Drug:~Tamsulosin 0.4mg oral daily~Drug:~Tylenol #3 1 tablet every six hours as necessary"
62752413|NCT06604780|EXPERIMENTAL|Intervention group|The intervention program is based on the Discharge Transition Model for the prevention of hospital readmission in Mental Health. This is a multicomponent program that initially involves the development of a scale to assess the risk of readmission for each patient, followed by its systematic application. This allows for stratification of patients according to their risk of early readmission and adaptation of the intervention to the needs of each risk level. The intervention includes elements aimed at promoting continuity of care after discharge, transitioning back to the community setting, as well as elements aimed at enhancing personal and emotional resources through psychotherapeutic approaches.
62752414|NCT06604780|NO_INTERVENTION|Control group I|To assess the effectiveness of the Multicomponent Discharge Transition Program, users from Málaga East Axarquía Hospital and North Málaga Health Management Area will be employed as the control group. Participants in the control group will continue with their usual treatment.
62752415|NCT06604780|NO_INTERVENTION|Control group II|Additionally, users from the Mental Health Management Unit of Regional Hospital of Málaga who were admitted the previous year and thus did not participate in the intervention program will also be used as a control group.
62752416|NCT02334683|EXPERIMENTAL|Electrophysiologic guidance|Electrophysiologic guidance, using electrical stimulation
62752417|NCT02334683|ACTIVE_COMPARATOR|Ultrasound guidance|Ultrasound guidance,using sound waves through a wand directed towards the targeted muscles.
62376531|NCT03061227|PLACEBO_COMPARATOR|Intravenous saline|Saline infusion over 150 minutes during a standardized 75 g oral glucose tolerance test
62376532|NCT04307589||Caregiving grandparents|
62556052|NCT01144429|ACTIVE_COMPARATOR|5000 DPP/mL|Concentration of solution fo s.c. injection: 5000 DPP/mL
62556053|NCT01144429|ACTIVE_COMPARATOR|10000 DPP/mL|Concentration of solution fo s.c. injection: 10000 DPP/mL
62556054|NCT00685217|EXPERIMENTAL|TVT Secur surgical device|Single incision tape device
62556055|NCT00685217|ACTIVE_COMPARATOR|TVT surgical device|Usual care retropubic tape device
62376533|NCT04307589||Non-caregiving grandparents|
62376534|NCT04307589||Middle-aged and older adults not being a grandparent|
62376535|NCT05749874|EXPERIMENTAL|berberine group|Berberine hydrochloride plus lifestyle intervention
62376536|NCT05749874|PLACEBO_COMPARATOR|placebo group|Placebo plus lifestyle intervention
62376537|NCT03832166|EXPERIMENTAL|Fruits and Vegetables Only|This group will receive a prescribed amount of free fruits and vegetables (F \& V) for 6 weeks through pick-up at a farm stand, or direct delivery. After 6 weekly pick-up/deliveries, participants will be provided vouchers and reminders to obtain F\&V at farm stands for an additional 18 weeks with minimal contact
62376538|NCT03832166|EXPERIMENTAL|Fruits and Vegetables and Cook|"In addition to the prescribed amount of free F\&V, participants will receive 6 weekly, group nutrition and cooking education classes based on The Happy Kitchen curriculum. Participants will also receive free ingredients to complete the recipe from each weekly session at home."
62376539|NCT02788851|ACTIVE_COMPARATOR|Medication only|Stimulant or non-stimulant medication only - Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine. Investigators will be using a product approved for clinical use in Canada), with dose optimized for each participant based on report of efficacy and side effects. Once on an optimal dose of stimulant or non-stimulant medication they will attend 8 weekly education sessions about ADHD.
62376540|NCT02788851|EXPERIMENTAL|Aerobic Exercise only|Participants attend a structured aerobic exercise class, twice a week for 8 weeks.
62376541|NCT02788851|ACTIVE_COMPARATOR|Combination Group|Participants assigned to this group will be optimally medicated (either stimulant or non-stimulant medication - approved for clinical use in Canada) and will attend a structured aerobic exercise class, twice a week for 8 weeks.
62376542|NCT05337735|EXPERIMENTAL|XmAb20717|Participants will receive XmAb20717 by vein over 1 hour on Days 1 and 15 of each cycle.
62752418|NCT06209593||Patients well established on tube feeds will act as their own control|Each participant will receive the new trial feed a nutritionally complete standard enteral tube feed for a period of 7 days. The new trial feed is a food for special medical purposes for use under medical supervision. The Health Care Professional/ dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube.
62752419|NCT03207178|EXPERIMENTAL|Mixed CD19/CD20 CAR-T Transfer|Subjects with CD19+/CD20+ B-cell lymphomas will be infused with CD19-targeting CAR T Cells and CD20-targeting CAR T Cells in one time or in parts
62556056|NCT05260294|ACTIVE_COMPARATOR|18 Gauge Tuohy group|In the 18G group, all CESIs were performed utilizing the fluoroscopy only method when the needle was navigated from the skin toward the epidural space under contralateral oblique fluoroscopy, and the contrast spread technique was employed for epidural space identification. After radiological confirmation of the epidural spread, LOR was tested using an Epidrum® device (Exmoor Innovations Ltd., Somerset, UK).
62752420|NCT04218838|ACTIVE_COMPARATOR|CornerLoc SI Joint Stabilization Group|Patient will receive the CornerLoc minimally invasive SI Joint Stabilization procedure. This procedure will be performed in an outpatient surgery center under local sedation or general anesthesia, and normally takes around 45 minutes. During the procedure, the physician will make two small incisions in the patient's lower back to access the SI joint, and place four small cadaveric bone grafts into the SI joint to help stabilize the SI joint.
62752421|NCT04218838|ACTIVE_COMPARATOR|SI Joint Steroid Injections Group|Patient will receive an injection of steroid medication directly into their SI joint. The area around the SI joint will be numbed with an injection of local anesthetic and then ultrasound guidance will be used to guide the needle of steroid medication directly into the SI joint. This procedure will be performed in the physician's office or an outpatient surgery center, and normally takes around 30 minutes.
62752422|NCT04253106|EXPERIMENTAL|Unaffected carriers of constitutional mutations|Patients with CDH1 or CTNNA1 germline pathogenic variant. No history of diffuse gastric cancer.
62752423|NCT04253106|ACTIVE_COMPARATOR|All patients with FOGD|without observation of macroscopic lesions paired with cases (age and sex)
62752424|NCT00605098|ACTIVE_COMPARATOR|1|
62752425|NCT00605098|EXPERIMENTAL|2|
62752426|NCT05292911|EXPERIMENTAL|ALT-801 Dose Level 1|Administered once a week for 12 weeks
62556057|NCT05260294|ACTIVE_COMPARATOR|25 Gauge Tuohy group|In the 25G group, all CESIs were performed utilizing the fluoroscopy only method when the needle was navigated from the skin toward the epidural space under contralateral oblique fluoroscopy, and the contrast spread technique was employed for epidural space identification. After radiological confirmation of the epidural spread, LOR was tested using an Epidrum® device (Exmoor Innovations Ltd., Somerset, UK).
62556058|NCT00646334|EXPERIMENTAL|A|Optilene® Mesh Elastic
62752427|NCT05292911|EXPERIMENTAL|ALT-801 Dose Level 2|Administered once a week for 12 weeks
62752428|NCT05292911|EXPERIMENTAL|ALT-801 Dose Level 3|Administered once a week for 12 weeks
62752429|NCT05292911|PLACEBO_COMPARATOR|Placebo|Administered once a week for 12 weeks
62752430|NCT03216304|EXPERIMENTAL|rosuvastatin|Film-coated tablets Rosuvastatin will be administered at the dose of 20 mg (single dose at day 1)
62752431|NCT03216304|EXPERIMENTAL|safinamide + rosuvastatin|Film-coated tablets Safinamide will be administered at the dose 100 mg (once a day for 11 days) Film-coated tablets Rosuvastatin will be administered at the dose of 20 mg (single dose at 12)
62752432|NCT01500603|EXPERIMENTAL|Experimental|Patients will receive AdvanceXP retrourethral male sling implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route
62752433|NCT01500603|ACTIVE_COMPARATOR|Active comparator|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
62752434|NCT05682287|EXPERIMENTAL|Experimental group|"Participants in the experimental group will be treated with a combination of 448kHz capacitive resistive monopolar radiofrequency and Proprioceptive neuromuscular facilitation (PNF) over the course of two weeks.~1. 448 kHz radio frequency therapy will be carried for a duration of 15 min. Contact cream will be applied beforehand to increase the electrical conductivity in the treated area.~2. After the radiofrequency therapy, participants will exercise for exactly 20 minutes using the PNF concept exercises to mobilize the pelvis and lumbar spine, primarily strengthening the muscles of the abdomen, back and hips.~Therapy will be administered for a total of 5 times in two weeks. Three times in week 1 and two times in week 2."
62752435|NCT05682287|ACTIVE_COMPARATOR|Control group|"Participants will exercise for exactly 20 minutes, over the course of two weeks, using the PNF concept exercises to mobilize the pelvis and lumbar spine, primarily strengthening the muscles of the abdomen, back and hips.~Therapy will be administered for a total of 5 times in two weeks. Three times in week 1 and two times in week 2.~This is identical intervention and the second intervention in the experimental group."
62752436|NCT02313727|ACTIVE_COMPARATOR|pamidronate|pamidronate
62752437|NCT02313727|PLACEBO_COMPARATOR|placebo|placebo
62752438|NCT01894880|ACTIVE_COMPARATOR|early SSC|Early SSC: bonding straight after birth
62752439|NCT01894880|OTHER|late SSC|late SSC: bonding after termination of operation
62752440|NCT02533765|EXPERIMENTAL|Olaparib|Olaparib 300mg twice daily continuously
62752441|NCT05950516|EXPERIMENTAL|QLG2065|"Up to 1.0 mg semaglutide (QLG2065)~Metformin ≥ 1500 mg/day (or maximum tolerated dose ≥ 1000 mg/day)."
62752442|NCT05950516|ACTIVE_COMPARATOR|Ozempic|"Up to 1.0 mg semaglutide (Ozempic)~Metformin ≥ 1500 mg/day (or maximum tolerated dose ≥ 1000 mg/day)."
62752443|NCT04301479|ACTIVE_COMPARATOR|Steroid|Patients assigned for steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal, defined by systolic arterial pressure \> 90 mmHg for 12 hours after vasopressor weaning without fluid expansion.
62752444|NCT04301479|PLACEBO_COMPARATOR|Control|Patients assigned for control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal, defined by systolic arterial pressure \> 90 mmHg for 12 hours after vasopressor weaning without fluid expansion.
62752445|NCT01083979|EXPERIMENTAL|Liposomes|Intravesical instillation of Liposomes in sterile water totally 40 cc at four weekly treatments.
62752446|NCT06017921|ACTIVE_COMPARATOR|Eszopiclone|Eszopiclone 3mg at bed time for 14 days
62752447|NCT06017921|PLACEBO_COMPARATOR|Placebo|Placebo at bed time for 14 days
62752448|NCT02230761|EXPERIMENTAL|XOPH5 Ointment|XOPH5 Ointment is the investigational drug to be studied.
62752449|NCT02230761|PLACEBO_COMPARATOR|Placebo Ointment|Placebo is an ointment that matches XOPH5 Ointment but lacks the active ingredient.
62752450|NCT02435407|EXPERIMENTAL|SOS arm|The Sequential Oral Sensory (SOS) approach treatment protocol, involving systematic desensitization hierarchy of skills needed to build feeding skills.
62752451|NCT02435407|ACTIVE_COMPARATOR|Education arm|Parents will participate in educational talks around the cause and management of feeding difficulties in children with autism spectrum disorder.
62752452|NCT05379712|EXPERIMENTAL|Multimodal Nutrition Therapy|"To assess a multimodal nutrition therapy (primary nutrition intervention+ adjuvant nutrition therapy) with features adapted for patients with cancers of the head and neck receiving chemo-radiotherapy treatment, to maintain oral dietary intake during treatment. The regimen consists of 2 medical foods, each taken on an unrestricted basis (as and when preferred by each patient).~Resource® Support Plus, a nutritionally complete Medical Food specifically for the dietary management of oncology patients with (risk of) malnutrition.~BOOST® Soothe, a Medical Food formulated as a clear oral nutritional supplement for cancer patients with sensory alterations or oral discomfort due to cancer treatments, in particular chemo- and/or radiotherapy."
62752453|NCT05379712|NO_INTERVENTION|Standard of Care|In this setting patients rely on oral dietary intake. Ordinary, commercially available ingredients and food products are consumed. The standard of care includes weekly consultation with specialist oncology Registered Dietitian.
62752454|NCT05354466|EXPERIMENTAL|Sugammadex as reversal agent|
62752455|NCT05354466|ACTIVE_COMPARATOR|Neostigmine as reversal agent|
62752456|NCT06415981|EXPERIMENTAL|Hypoglossal nerve and/or Ansa Cervicalis stimulation|
62752457|NCT06411886|EXPERIMENTAL|Allergen Challenge|Inhaled allergen
62752458|NCT06411886|PLACEBO_COMPARATOR|Diluent Challenge|Inhaled saline
62556059|NCT00646334|ACTIVE_COMPARATOR|B|Ultrapro® Mesh
62752459|NCT04082390|EXPERIMENTAL|RELEASE Supplement|
62752460|NCT04082390|PLACEBO_COMPARATOR|Placebo|
62752461|NCT00803517||Photodynamic therapy (PDT)|
62752462|NCT00803517||Focal laser photocoagulation (focal)|
62752463|NCT04316611|EXPERIMENTAL|Potassium chloride|Potassium chloride
62752464|NCT03739489|ACTIVE_COMPARATOR|rTMS-PSI|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the posterior superior insula right.
62752465|NCT03739489|ACTIVE_COMPARATOR|rTMS-M1|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the right primary motor cortex.
62752466|NCT03739489|ACTIVE_COMPARATOR|rTMS-F3|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the left pre frontal dorsolateral cortex.
62752467|NCT04580368|EXPERIMENTAL|CFTR modulator or other therapies|CFTR modulator or active therapy
62752468|NCT02916641|EXPERIMENTAL|Fuzhenghuayu+UDCA|Regular UDCA treatment combination with Fuzhenghuayu
62752469|NCT02916641|ACTIVE_COMPARATOR|Monotherapy|UDCA monotherapy
62752470|NCT05820152|EXPERIMENTAL|NFS-02 Injection|"Potential doses at the dose-finding stage:~5.0×107 vg, 0.05 mL/eye/dose (low dose) 1.5×108 vg, 0.05 mL/eye/dose (starting dose) 5.0×108 vg, 0.05 mL/eye/dose (intermediate dose) 1.5×109 vg, 0.05 mL/eye/dose (high dose)"
62752471|NCT03057041|EXPERIMENTAL|Fentanyl|
62752472|NCT03057041|PLACEBO_COMPARATOR|Placebo|
62752473|NCT05647343|EXPERIMENTAL|ATL-001 0.2 mg/kg vs Placebo|Cohort 1: ATL-001 at 0.2 mg/kg or Placebo (depending on randomization) will be administered during 5 days
62752474|NCT05647343|EXPERIMENTAL|ATL-001 0.5 mg/kg vs Placebo|Cohort 2: ATL-001 at 0.5 mg/kg or Placebo (depending on randomization) will be administered during 5 days
62376543|NCT02721446|OTHER|VHA Cohort|Investigators will use Veteran Health Administration (VHA) electronic health record (EHR) data to construct patient-level Framingham stroke risk scores using previously validated methodology. Investigators will establish a cohort of live patients with at least one primary care visit 12 months prior to study initiation (Oct 1, 2015). Investigators will obtain EHR data for Framingham measurements of age, sex, systolic blood pressure (SBP), blood pressure treatment (yes/no), total cholesterol, high-density lipoprotein cholesterol, and smoking status in the prior 12 month period. SBP will be obtained from outpatient primary care visits only; if \> 1 SBP is available the investigators will use the average of the last 2 outpatient SBPs prior to study initiation.
62376544|NCT02721446|OTHER|Eskenazi Health System Cohort|Investigators will use EHR data from Indiana Network for Patient Care (INPC) to identify a cohort of live patients with at least one primary care visit in the prior 12 months. Investigators will use identical methods to construct Framingham risk score variables from the EHR data.
62376545|NCT01266421||Dienogest (DNG)|Women using DNG) for the treatment of endometriosis
61986464|NCT05225142|ACTIVE_COMPARATOR|Modified minimally invasive surgery with enamel matrix derivative and bone replacement graft|Modified minimally invasive surgery access and debridement of intrabony defect combined with local application of enamel matrix derivative and bone replacement graft (regenerative biomaterial)
61986465|NCT01421758|EXPERIMENTAL|online social network|
61986466|NCT01421758|ACTIVE_COMPARATOR|web education control|
62376546|NCT01266421||Other approved endometriosis drugs (OAED)|Women using hormonal medications approved for endometriosis treatment in all particiapting countries other than DNG.
62752475|NCT05647343|EXPERIMENTAL|ATL-001 1 mg/kg vs Placebo|Cohort 3: ATL-001 at 1 mg/kg or Placebo (depending on randomization) will be administered during 5 days
62752476|NCT05647343|EXPERIMENTAL|ATL-001 2 mg/kg vs Placebo|Cohort 4: ATL-001 at 2 mg/kg or Placebo (depending on randomization) will be administered during 5 days
62752477|NCT05647343|EXPERIMENTAL|ATL-001 4 mg/kg vs Placebo|Cohort 5: ATL-001 at 4 mg/kg or Placebo (depending on randomization) will be administered during 5 days
62376547|NCT01266421||Non-approved endometriosis drugs (NAED)|Women using hormonal medications not approved for endometriosis treatment in all particiapting countries.
62376548|NCT05098249|EXPERIMENTAL|Verum|
62752478|NCT00369174|EXPERIMENTAL|Treatment (rosiglitazone maleate)|Patients receive oral rosiglitazone once daily. Treatment continues for 12 weeks in the absence of unacceptable toxicity.
62752479|NCT06110858|EXPERIMENTAL|Tinkering Activities|
62752480|NCT03372460|ACTIVE_COMPARATOR|Active Stimulation|Active stimulation (tDCS) will be used in the dose of 2mA /25 min per day, for 6 sessions over the course of 2 weeks (3 sessions per week).
62376549|NCT05098249|PLACEBO_COMPARATOR|Placebo|
62376550|NCT03731975|ACTIVE_COMPARATOR|CTZ Paste|Endodontic treatment with CTZ paste.
62376551|NCT03731975|EXPERIMENTAL|GP Paste|Endodontic treatment with Guedes-Pinto paste.
62752481|NCT03372460|SHAM_COMPARATOR|Sham Stimulation|Sham tDCS uses the device study mode (10 µA over 15 ms current pulse applied every 550 ms, 3ms peak current). This process will be used for each of the 6 sessions during a 2 week period.
62752482|NCT03093207|PLACEBO_COMPARATOR|Control group|In this group (n = 17), patients will take placebo pills and open flap debridement will be performed to treat residual pockets.
62752483|NCT03093207|EXPERIMENTAL|Test Group|In this group (n = 17), patients will take 3 g of omega-3 polyunsaturated fatty acids plus 100 mg of aspirin daily supplementation over a period of 180 days and open flap debridement will be performed to treat residual pockets.
62376552|NCT02828462||Experimental|Patients using the device
62376553|NCT02828462||Control|Patients not using the device
62376554|NCT00884936||Group 1|Young age: 20 to 30 years old
62752484|NCT03586323|EXPERIMENTAL|L-SLNB|performed a superior laryngeal nerve block with lidocaine
62752485|NCT03586323|PLACEBO_COMPARATOR|S-SLNB|performed a superior laryngeal nerve block with saline
62752486|NCT06022965|EXPERIMENTAL|ARM I (GAIN-S)|Patients complete the CARG-GA at baseline and 3 months and receive GA-based interventions using telemedicine over 6 months.
62376555|NCT00884936||Group 2|Middle Age: 38 to 48 years old (pre-menopausal only)
62376556|NCT00884936||Group 3|Elderly Age: 60 to 75 years old (Post-menopausal only)
62376557|NCT01486940|EXPERIMENTAL|Basal/bolus regimen 1|
62376558|NCT01486940|ACTIVE_COMPARATOR|Basal/bolus regimen 2|
62376559|NCT01061827||Dementia|
62376560|NCT01061827||Depression|
62376561|NCT01061827||Control|
62376562|NCT05680090||Eligible participants for AI-based ophthalmic emergency triage and primary diagnosis|
62376563|NCT02846766|EXPERIMENTAL|Lenvatinib|The starting dose of lenvatinib will be 24 mg orally per day. The duration of one cycle is defined as 28 days (4 weeks). Subjects will be treated for 2 cycles (8 weeks) and then restaged. Subjects will continue study drug until progression or unacceptable toxicity occurs.
62376564|NCT03196973|EXPERIMENTAL|DF289 plus DF277|Otic solution
62376565|NCT03196973|ACTIVE_COMPARATOR|DF289|Otic solution
62376566|NCT03196973|ACTIVE_COMPARATOR|DF277|Otic solution
62376567|NCT04583267|EXPERIMENTAL|PrEP|
62752487|NCT06022965|ACTIVE_COMPARATOR|ARM II (SOC)|"Receive SOC over the first 3 months, then switch to receive GA-based interventions using telemedicine for the following 3 months.~Patients complete the CARG-GA at baseline and 3 months and receive SOC over 6 months."
62752488|NCT05263986|EXPERIMENTAL|Assigned Interventions|In the 5-day PK lead-in period, patients will receive a single oral dose of 600 mg MRTX849 on Day 1 and there will be no drug administration in the subsequent 4 days. Following the PK lead-in period, patients will receive MRTX849 600 mg BID (an interval of approximate 12 hours between 2 doses) orally in 3-week cycles until disease progression, unacceptable AEs, patient refusal, or death. Dosing schedules may be adjusted depending on safety results.
62752489|NCT06608576|ACTIVE_COMPARATOR|Standard Treatment|participants will receive face-to-face early intervention treatment on physical therapy area once a month for two months.
62752490|NCT06608576|EXPERIMENTAL|Telematic Support|Participants will receive weekly telematic early intervention sessions at home via video conferencing for two months.
62752491|NCT03965884|EXPERIMENTAL|lumbal stabilization exercise group|
62752492|NCT03965884|EXPERIMENTAL|connective tissue massage group|
62752493|NCT03965884|NO_INTERVENTION|control group|
62752494|NCT04720040|EXPERIMENTAL|YMS-201B|transcranial Direct Current Stimulation (tDCS) application 5 \~7 days a week for 6 weeks (total of 30\~42 applications)
62376568|NCT06267495||Epithelium-on corneal cross-linking group|Patients in this group underwent epithelium-on accelerated corneal cross-linking (epi-on CXL) for the eye with no clinical signs of keratoconus.
62376569|NCT06267495||Follow-up group|Patients in this group were planned to have regular follow-up visits, without intervention, for the eye with no clinical signs of keratoconus.
62376570|NCT05422833||Before|"Children and adults with FD/MAS who visited at least once in our center (outpatient and hospitalized patients).~and with the first visit in the center included between 1996 and 2006 - before certification of our center."
62376571|NCT05422833||After|"Children and adults with FD/MAS who visited at least once in our center (outpatient and hospitalized patients).~and with the first visit in the center included between 2007 and 2019 - after certification of our center."
62376572|NCT01836029|EXPERIMENTAL|chemotherapy and cetuximab plus VTX-2337|"VTX-2337 (3.0 mg/m2) will be administered on Day 8 and Day 15 of a 21-day cycle for 6 cycles, followed by dosing on Days 8 and 22 of 28-day cycles until disease progression.~Cisplatin (100 mg/m2) OR carboplatin (AUC 5 mg/mL/min) will be administered on Day 1 of a 21-day cycle for a maximum of 6 cycles.~5-FU (1000 mg/m2) will be administered on Days 1-4 of a 21-day cycle for a maximum of 6 cycles.~Cetuximab (initial dose: 400 mg/m2; remaining doses: 250 mg/m2) will be administered weekly until disease progression."
62376573|NCT01836029|ACTIVE_COMPARATOR|chemotherapy and cetuximab plus placebo|"Placebo (3.0 mg/m2) will be administered on Day 8 and Day 15 of a 21-day cycle for 6 cycles, followed by dosing on Days 8 and 22 of 28-day cycles until disease progression.~Cisplatin (100 mg/m2) OR carboplatin (AUC 5 mg/mL/min) will be administered on Day 1 of a 21-day cycle for a maximum of 6 cycles.~5-FU (1000 mg/m2) will be administered on Days 1-4 of a 21-day cycle for a maximum of 6 cycles.~Cetuximab (initial dose: 400 mg/m2; remaining doses: 250 mg/m2) will be administered weekly until disease progression."
62376574|NCT01728649|NO_INTERVENTION|Normothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using current FDA approved devices. After which patient will be started on normothermia attempting to keep core body temp between 38 and 36.5 degrees centigrade. Patients will also undergo blood draws for biomarkers before reperfusion is achieved the immediately, 6 hours then 24 hours after reperfusion.
62376575|NCT01728649|EXPERIMENTAL|Mild Hypothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using current FDA cleared device. Patient will also have a Quattro catheter placed in the femoral vein and temperature brought to 33 degrees centigrade as quickly as possible. They will stay in mild hypothermia for 12 hours and then be rewarmed very slowly. Patients will also undergo blood draws for biomarkers before reperfusion is achieved the immediately, 6 hours then 24 hours after reperfusion.
62376576|NCT00491751|EXPERIMENTAL|Atorvastatin|Atorvastatin 40 or 80 mg/day
62376577|NCT00491751|EXPERIMENTAL|Ascorbic Acid|Ascorbic Acid 500 mg/day
62376578|NCT00491751|PLACEBO_COMPARATOR|Placebo|Placebo atorvastatin and Placebo ascorbic acid
62752495|NCT01568151|ACTIVE_COMPARATOR|Intervention Clinics|Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions(Clinic-directed intervention program)including: 1)provider-directed interventions; 2)office-based systems; and 3) waiting room materials. If the subjects have not undergone colorectal cancer screening after 12 months, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
62752496|NCT01568151|NO_INTERVENTION|Usual Care Clinics|Subjects recruited at the Usual Care Clinics (Control Clinics) will not receive any study intervention. The results of how many subjects undergo colorectal cancer screening at the Usual Care Clinics will be compared to the number that undergo colorectal cancer screening at the Intervention Clinics.
62752497|NCT04750473|EXPERIMENTAL|Diagnostic (Ga PSMA, fluciclovine F18, PET/CT)|Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan over 30 minutes. On a separate day, patients receive fluciclovine F18 IV and undergo a PET/CT scan over 30 minutes.
62376579|NCT02159365|EXPERIMENTAL|Elotuzumab + Lenalidomide/Dexamethasone|Elotuzumab 10 mg/kg solution intravenously weekly in cycle 1 and 2, then every other week, Lenalidomide 25 mg tablet by mouth Days 1-21 of each cycle / Dexamethasone 40 mg tablet by mouth / solution intravenously weekly until progression or discontinuation of Elotuzumab
62556060|NCT01027702|EXPERIMENTAL|Infusion of donor lymphocytes|Patients will receive an infusion of donor lymphocyte after T-cell depleted transplant.
62556061|NCT03730220||Induction of labour|
61986467|NCT06011681||Depression|Seniors diagnosed with late life depression or with a concern of late life depression.
62752498|NCT01388439||Oseltamivir exposure|One infant in the Neonatal Intensive Care Unit (NICU) at St. Louis Children's Hospital experienced respiratory decompensation and tested positive for influenza virus type A by fluorescent antibody stain performed on a nasopharyngeal swab. This infant received treatment doses of oseltamivir. Subsequently, 27 other infants received oseltamivir prophylaxis for exposure to influenza virus type A. Exposed infants were those who shared a primary medical team, nursing care, respiratory therapist, physical therapist, or occupational therapist with the influenza A positive infant. Prophylaxis was deemed necessary by the attending neonatologist after consultation with the Infectious Diseases Division of the Department of Pediatrics at the Washington University School of Medicine.
62752499|NCT05791994|EXPERIMENTAL|Intervention group|
62752500|NCT05791994|ACTIVE_COMPARATOR|Comparator group|
62752501|NCT02540330|ACTIVE_COMPARATOR|Intramuscular Fulvestrant|500mg fulvestrant administered intramuscularly
62752502|NCT02540330|EXPERIMENTAL|Intraductal Fulvestrant|up to 500mg fulvestrant administered intraductally
62752503|NCT00301600|ACTIVE_COMPARATOR|Mycophenolate mofeti|
62376580|NCT01642004|EXPERIMENTAL|Arm A: Nivolumab|Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
62376581|NCT01642004|EXPERIMENTAL|Arm B: Docetaxel|Docetaxel 75 mg/m\^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
62376582|NCT03607240|EXPERIMENTAL|LUS-guided alveolar recruitment|Lung ultrasound-guided alveolar recruitment maneuver will be performed
62376583|NCT03607240|ACTIVE_COMPARATOR|conventional alveolar recruitment|Alveolar recruitment maneuver will be provided with positive pressure of 30 cmH2O for 10 seconds.
62752504|NCT00620178||1|Candesartan
62752505|NCT00620178||2|Losartan
62752506|NCT03371134||Sarcopenic group|Harvesting of muscular biopsies Muscular biopsies will be harvested from old sarcopenic patients undergoing hip replacement surgery
62752507|NCT03371134||Control group|Harvesting of muscular biopsies Muscular biopsies will be harvested from young patients undergoing Anterior Cruciate Ligament (ACL) reconstruction surgery
62752508|NCT00218582|EXPERIMENTAL|1|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
62752509|NCT00218582|ACTIVE_COMPARATOR|2|Standard psychiatric day treatment
62752510|NCT05573399||Early oral feeding|No enteral feeding tube was placed after pancreaticoduodenectomy and oral nutrition was given early. Patients were given liquid drinks on the second day after pancreaticoduodenectomy, and solid food from the fifth day.
62752511|NCT05573399||Early nasojejunal enteral nutrition|Early enteral nutrition was given early through nasojejunal tube. 5% glucose saline was given on the first day after pancreaticoduodenectomy through nasojejunal tube. Enteral nutrition was given from the second day after pancreaticoduodenectomy. When oral intake was adequate, the nasojejunal tube was removed on the sixth day.
62752512|NCT05978960|EXPERIMENTAL|Resistance training with high quality low-carbohydrate nutrition regimen|The regimen will consist of an intense resistance training program with linear progression and the goal of increase strength, mobility, muscle mass, and functional capacity. The nutrition program will avoid calorie counting, and instead focus on quality, while maximizing protein and limiting carbohydrates.
62752513|NCT03162510|EXPERIMENTAL|SOLAR|Albumin-Bound Paclitaxel /nab-Paclitaxel (Abraxane®) 150 mg/m2 IVD 30 min followed by Oxaliplatin 60\~ 85 mg/m2 IVD 2hr at D1, plus Tegafur,oral S-1 35mg/m2 and Folinic acid/LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
62752514|NCT05178030||GALLOP-11|Patients with a proven KIT exon 11 mutated GIST covered by our in-house designed ddPCR assay.
62376584|NCT02061163|EXPERIMENTAL|Subjects with Crohn's disease|Contrast Enhanced Ultrasound Optison
62376585|NCT04272814|EXPERIMENTAL|Compression therapy|compression therapy
62752515|NCT01783574|ACTIVE_COMPARATOR|Testosterone|Testosterone cream will be applied to skin for 8 weeks. Starting dose is 10 mg daily and will be titrated based on blood levels.
62752516|NCT01783574|PLACEBO_COMPARATOR|Placebo|Placebo cream will appear identical to the testosterone cream and will be applied to skin for 8 weeks.
62752517|NCT01892787|EXPERIMENTAL|Formoterol (Atimos Modulite)|Atimos Modulite 1 puff (12 micrograms) twice a day
62376586|NCT04272814|ACTIVE_COMPARATOR|Standard treatment|standard treatment
62376587|NCT03307473||e-bike|During 3 months in a the geographic area of Clermont-Ferrand (France), new e-bike buyers and renters are invited to take part in VELONAPS study before starting to use their e-bike
62752518|NCT01892787|ACTIVE_COMPARATOR|Salmeterol (Serevent Accuhaler)|Serevent Accuhaler 1 puff (50 micrograms) of twice a day
62752519|NCT02080039|EXPERIMENTAL|Electrical Stimulation|
62376588|NCT03184766|EXPERIMENTAL|1|Treatment Order: Test, Comparator 1, Comparator 2
62376589|NCT03184766|EXPERIMENTAL|2|Treatment Order: Test, Comparator 2, Comparator 1
62752520|NCT01753219|EXPERIMENTAL|Onstep|Participants in this group will have a inguinal hernia repair ad modum Onstep.
62752521|NCT01753219|ACTIVE_COMPARATOR|Lichtenstein|Participants in this group will receive a inguinal hernia repair ad modum Lichtenstein.
62752522|NCT02802241|EXPERIMENTAL|open-label placebo|
62752523|NCT02802241|EXPERIMENTAL|double-blind placebo|
62752524|NCT02802241|EXPERIMENTAL|double-blind peppermint oil|
62752525|NCT02802241|NO_INTERVENTION|no additional treatment|
62752526|NCT03234855||LMD|Physician uses LMD during procedure.
62376590|NCT03184766|EXPERIMENTAL|3|Treatment Order: Comparator 1, Test, Comparator 2
62376591|NCT03184766|EXPERIMENTAL|4|Treatment Order: Comparator 1, Comparator 2, Test
62376592|NCT03184766|EXPERIMENTAL|5|Treatment Order: Comparator 2, Test, Comparator 1
62376593|NCT03184766|EXPERIMENTAL|6|Treatment Order: Comparator 2, Comparator 1, Test
62376594|NCT05085327|EXPERIMENTAL|ChapStick Lip Moisturizer Original|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg per square centimeter \[mg/cm\^2\]) of ChapStick Lip Moisturizer Original will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
62376595|NCT05085327|EXPERIMENTAL|ChapStick Lip Moisturizer Mint|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm\^2) of ChapStick Lip Moisturizer Mint will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
62556062|NCT06581978|EXPERIMENTAL|Whole-Body Vibration Intervention Group|Enrolled children will be trained at home using a vertical rhythm device under the guidance of researchers and parental supervision. WBV training lasted for four weeks, five days a week, 15 minutes a day, each movement lasted for 30 seconds, and 30 seconds of rest between groups.
62556063|NCT06581978|NO_INTERVENTION|Control Group|Children were instructed to rest and not participate in physical activity
62752527|NCT04958044|EXPERIMENTAL|Calcium electroporation|Calcium gluconate 0.23 mmol/ml Maxium dosage 20 ml Intra tumoral injection
62752528|NCT01562522|EXPERIMENTAL|Intervention group|
62752529|NCT01562522|NO_INTERVENTION|Control group|
62752530|NCT03483038|EXPERIMENTAL|Liposomal irinotecan with FOLFOX|Subjects will receive 8 cycles and each cycle is 14 days.
62752531|NCT01133405|EXPERIMENTAL|LY2886721 Part 1: Cohort A/B|Single (7 milligram (mg), 15 mg, 25 mg, 35 mg) doses of LY2886721 administered orally in up to three of three study periods
62752532|NCT01133405|PLACEBO_COMPARATOR|Placebo Part 1: Cohort A/B|Single dose in up to 1 period
62752533|NCT01133405|EXPERIMENTAL|LY2886721 Part 2: Cohort C|Single 10 mg dose of LY2886721, dose determined by Part 1
62752534|NCT01133405|EXPERIMENTAL|LY2886721 Part 2: Cohort D|Single 35 mg dose of LY2886721, dose determined by Part 1
62752535|NCT01133405|PLACEBO_COMPARATOR|Placebo Part 2: Cohort C/D|Single dose
62752536|NCT05852262|EXPERIMENTAL|High Dose Cephalexin|The intervention is high-dose cephalexin (1000mg PO QID) for seven days
62752537|NCT05852262|ACTIVE_COMPARATOR|Standard Dose Cephalexin|The comparator is standard-dose cephalexin (500mg PO QID) plus oral placebo for seven days
62752538|NCT01973387|EXPERIMENTAL|Treatment Arm A|
62752539|NCT01973387|EXPERIMENTAL|Treatment Arm B|
62752540|NCT02421731|EXPERIMENTAL|Robot-assisted gait training|This group will receive rehabilitation treatment based on robot-assisted gait training.
62752541|NCT02421731|ACTIVE_COMPARATOR|Conventional therapy|This group will receive conventional rehabilitation therapy.
62752542|NCT04748757|PLACEBO_COMPARATOR|Placebo|Normal saline, 50 ml infusion over 30 minutes every 12 hours for 7 days
62376596|NCT05085327|EXPERIMENTAL|ChapStick Lip Moisturizer Black Cherry|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm\^2) of ChapStick Lip Moisturizer Black Cherry will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
62376597|NCT05085327|ACTIVE_COMPARATOR|SPF Standard|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm\^2) of SPF Standard will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
62376598|NCT02393989|EXPERIMENTAL|Active comparator|posterior restorations
62376599|NCT01961128|EXPERIMENTAL|Exercise Intervention|220 minutes of exercise per week, including 2-3 supervised sessions for 6 weeks
62376600|NCT03249441|EXPERIMENTAL|Compassion-focused therapy|Compassion-Focused Therapy (CFT) Participants were taught the main compassion-focused exercises as outlined in 'The Compassion-Mind Guide to Ending Overeating: Using Compassion-Focused Therapy to overcome Bingeing and Disordered Eating' manual (Goss, 2011) over a ten session period (weekly for 2 hours), offered over a 3 month period. Self-criticism and shame were key foci across sessions. Participants in the CFT arm also received Treatment as Usual.
62376601|NCT03249441|NO_INTERVENTION|Treatment as Usual|Treatment As Usual Treatment as usual was based in the Diabetes, Endocrinology and Metabolism Clinic in Galway University Hospital. The Weight Management Service provides assessment by a multi-disciplinary team of endocrinologists, dieticians, nurse specialists and clinical psychologists. Dietary advice is given by a specialist dietician regarding weight management, assessment by the Consultant Endocrinologist with possible medication for management of diabetes and weight, and participation in a healthy lifestyle education program.
62376602|NCT06186895|EXPERIMENTAL|Dexmedetomidine group|Group D, received an intravenous loading dose of DEX (1 μg/kg) over 15 minutes prior to the anesthetic induction. Following the intubation procedure, a maintenance infusion of DEX was delivered at a rate of 0.6 μg/kg/h. The infusion was discontinued upon trocars removal
62376603|NCT06186895|ACTIVE_COMPARATOR|Fentanyl group|Group F were administered fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. Following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. The infusion was discontinued upon the removal of the trocars.
62376604|NCT06235229|EXPERIMENTAL|GC012F|GC012F will be administered in one infusion
62376605|NCT01266070|EXPERIMENTAL|Dovitinib|500 mg/day on a 5 day on, 2 day off schedule
62376606|NCT03439722||Patients|Episodic cluster headache patients will be admitted for 1 night where a polysomnography will be performed by the Danish Center of Sleep Medicine.
62376607|NCT03439722||Controls|Controls will be admitted for 1 night where a polysomnography will be performed by the Danish Center of Sleep Medicine.
62376608|NCT02564562|EXPERIMENTAL|Treatment|Radiolabeled PF-06463922 in healthy volunteers
62376609|NCT06011785|EXPERIMENTAL|Intervention Group|Participants have Silicosis and wish to be included in the intervention group
62376610|NCT01726504|EXPERIMENTAL|electro-acupuncture|"1. The electric stimulator is applied to bilateral ST25andSP14 with dilatational wave10/50 Hz and electric current0.1-1.0mA.They are given acupuncture with 0.3×50mm or 0.35×75mm needles by inserting30-70mm and twirling lifting andthrusting 3 times.Dosage:The needle arrives the abdominal muscle layer(patients feel painful and acupuncturists feel touching hard).~2. Bilateral ST37 are given conventional acupuncture with 0.30mm×40mm needles by inserting 25-30mm and twirling lifting and thrusting for 3.Dosage:Local sour and heavy feeling is the appropriate dose.~Every session lasts for 30min/day.The participants are treated continuously for 8 weeks.During 8-week treatment the first 2 weeks,5 sessions per week,and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total."
62376611|NCT01726504|SHAM_COMPARATOR|sham electro-acupuncture|"1. The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave, 10/50 Hz and electric current 0.5mA. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. The needle is inserted by 3mm-5mm (the needle can be vertically fixed on the skin).~2. Bilateral ST37 are given acupuncture with 3mm-5mm (the needle can be vertically fixed on the skin).~Length of Treatment and the treatment sessions are the same as treatment group."
62376612|NCT04142762|EXPERIMENTAL|Cohort 1: ABI-H2158 + Itraconazole|Oral ABI-H2158 on Days 1 and 9; oral itraconazole once-daily (QD) on Days 6 through 13
62752543|NCT04748757|EXPERIMENTAL|Low dose|50 microg/kg SY-005 in 50 ml saline infused over 30 minutes every 12 hours for 7 days
62752544|NCT04748757|EXPERIMENTAL|High dose|100 microg/kg SY-005 in 50 ml saline infused over 30 minutes every 12 hours for 7 days
62752545|NCT03200639|ACTIVE_COMPARATOR|Physical training, CT|Combined Trained with no cancer (CT): Post menopausal women with no cancer submitted to 12 weeks of combined training (i.e. aerobic training plus resistance training)
62376613|NCT04142762|EXPERIMENTAL|Cohort 2: ABI-H2158 + Rifampin|Oral ABI-H2158 on Days 1 and 12; oral rifampin QD on Days 6 through 16
62376614|NCT04142762|EXPERIMENTAL|Cohort 3: ABI-H2158 + Esomeprazole|Oral ABI-H2158 on Days 1 and 11; oral esomeprazole QD on Days 6 through 11
62376615|NCT04142762|EXPERIMENTAL|Cohort 4: ABI-H2158 + Midazolam|Oral midazolam on Days 1 and 11; oral ABI-H2158 QD on Days 2 through 11
62376616|NCT04142762|EXPERIMENTAL|Cohort 5: ABI-H2158 + Oral Contraceptive|Cycle 1: active oral contraceptive (ethinyl estradiol/levonorgestrel) QD on Days 1 through 21 and oral placebo QD on Days 22 through 28; Cycle 2: active oral contraceptive QD on Days 1 through 21, oral placebo QD on Days 22 through 26, and oral ABI-H2158 QD on Days 11 through 24
62376617|NCT01938391|OTHER|OAS + BA|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS), is used prior to adjunctive balloon angioplasty (BA)
62376618|NCT03551392|ACTIVE_COMPARATOR|NIR -Older Adult|Older adult participants receive the Medx Console System and the Vielight 810 intranasal stand alone unit. These interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
62376619|NCT03551392|SHAM_COMPARATOR|No Dose NIR-Older Adult|Older adult participants receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
62376620|NCT03551392|ACTIVE_COMPARATOR|NIR -Parkinson|Participants with Parkinson disease receive the Medx Console System and the Vielight 810 intranasal stand alone unit. These interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
62376621|NCT03551392|SHAM_COMPARATOR|No Dose NIR-Parkinson|Participants with Parkinson disease receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
62376622|NCT05472376||3-month follow-up|
62376623|NCT05472376||6-month follow-up|
62556064|NCT06581978|EXPERIMENTAL|Traditional Chinese medical exercises training Intervention Group|The enrolled children will be supervised by their parents and follow the teaching of the self-developed APP for Yi Jin Jing exercises. The training lasts for 4 weeks, 5 days a week, 15 minutes a day, 12 movements in total, each movement is 1 minute, and the rest between groups is 15 seconds.
62376624|NCT05472376||12-month follow-up|
62376625|NCT05472376||24-month follow-up|
62376626|NCT05472376||36-month follow-up|
62376627|NCT00342472||1|Two of the oldest individuals (a male and a female greater than 18 years of age) from each of 10-15 nonsmoking households from the high-risk region of Linxian, China
62376628|NCT02734849|EXPERIMENTAL|25 mg AK001|25 mg AK001 will be administered as multiple doses
62376629|NCT02734849|EXPERIMENTAL|250 mg AK001|250 mg AK001 will be administered as multiple doses
62376630|NCT02734849|PLACEBO_COMPARATOR|Placebo|A placebo comparator consisting of inactive excipients will be administered as multiple doses
62376631|NCT04684706|OTHER|Compressed iTBS schedule|Stimulation 3-pulse 50-Hz bursts at 5-Hz for 2-s trains, with trains every 10 s, for 10 minutes, 10 times a day, for 5 consecutive days.
62376632|NCT03842761|EXPERIMENTAL|Dose group 1|Low Dose
62376633|NCT03842761|EXPERIMENTAL|Dose group 2|Medium Dose
62376634|NCT03842761|EXPERIMENTAL|Dose group 3|High Dose
62376635|NCT03842761|EXPERIMENTAL|Dose Group 4|Dose for healthy volunteers dependent on results from prior dose groups with patients
62376636|NCT00767494|EXPERIMENTAL|1|Travoprost/Brinzolamide AM, Vehicle PM
62376637|NCT00767494|EXPERIMENTAL|2|Travoprost/Brinzolamide PM, Vehicle AM
62556065|NCT03853031|ACTIVE_COMPARATOR|LVEDA guided intraoperative fluid therapy|Patients in TEE group will be given crystalloid fluids during surgery guided by LVEDA cm2 to be maintained between 10 -18 cm2 , if LVEDA \< 10 cm2 then 200ml colloid bolus will be given and increase in LVEDA noted.
62556066|NCT03853031|ACTIVE_COMPARATOR|CVP guided intraoperative fluid therapy|Patients in CVP group will be given crystalloid fluids during surgery guided by CVP values to be maintained between 10 -16 cms of water H2O ,if CVP value \< 10 cms H2O then 200 ml colloid bolus will be given and increase in CVP value noted.
62752546|NCT03200639|ACTIVE_COMPARATOR|Physical training, HIITBW|High intensity interval training with body weight with no cancer (HIITBW): Post menopausal women with no cancer submitted to 12 weeks of high intensity interval training with body weight (i.e. step climbing plus squats)
62752547|NCT03200639|EXPERIMENTAL|Physical training, CTc|Combined Trained with gynecological and/or breast cancer (CTc): Post menopausal women with with gynecological and/or breast cancer submitted to 12 weeks of combined training (i.e. aerobic training plus resistance training)
62752548|NCT03200639|EXPERIMENTAL|Physical training, HIITBWc|High intensity interval training with body weight with gynecological and/or breast cancer (HIITBWc): Post menopausal women with gynecological and/or breast cancer submitted to 12 weeks of high intensity interval training with body weight (i.e. step climbing plus squats)
62752549|NCT06029673|EXPERIMENTAL|Cabergoline|After the completion of the surgical procedure or medical induction for the early second-trimester abortion or fetal loss, the participant will be administered cabergoline 1mg orally with juice or water by the clinician or study investigator.
62752550|NCT06029673|PLACEBO_COMPARATOR|Placebo|After the completion of the surgical procedure or medical induction for the early second-trimester abortion or fetal loss, the participant will be administered a placebo pill orally with juice or water by the clinician or study investigator.
62752551|NCT03142399|EXPERIMENTAL|whey protein|The whey protein group will receive whey protein supplementation 30g/day of whey protein during three months (12 weeks)
62752552|NCT03142399|PLACEBO_COMPARATOR|placebo group|The placebo group (maltodextrin) will receive 30g/day of maltodextrin during three months (12 weeks)
62752553|NCT02169024|EXPERIMENTAL|Expect With Me group prenatal care|receiving prenatal care through an Expect With Me group
62752554|NCT02169024|ACTIVE_COMPARATOR|Individual Care Only|Standard of Care- individual prenatal care
62376638|NCT00767494|ACTIVE_COMPARATOR|3|AZOPT AM and PM
62376639|NCT00767494|ACTIVE_COMPARATOR|4|TRAVATAN PM, Vehicle AM
62752555|NCT06605872||GlucoTab Prospective Group|
62752556|NCT06605872||Retrospective control group|
62376640|NCT04419597|EXPERIMENTAL|HEMOPATCH Collagen Patch and PEG Haemostatic Sealant|Two units of the large patch are applied as reinforcement of the primary dural seal (HEMOPATCH 4,5x9cm, 1506253).
62376641|NCT04419597|ACTIVE_COMPARATOR|Standard of care treatment|Usual clinical practice techniques for reinforcing primary dural closure.
62376642|NCT05939700||Cohort 1|Pregnant or breastfeeding women exposed to mavacamten
62376643|NCT03491852|EXPERIMENTAL|BOOST Intervention|"The BOOST intervention consists of 8 group-based, weekly one-hour sessions. While every BOOST session is different, in general they will focus on helping participants fight back against stigmatizing thoughts and develop a sense of self-worth and empowerment. BOOST sessions are group-based and facilitated by trained clinicians, with the aid of a peer support worker to provide unique insights on living with and overcoming self-stigma. Content of sessions involve group discussions, exercises conducted in session, and between-session missions (i.e., home practice activities)."
62376644|NCT03491852|ACTIVE_COMPARATOR|Waitlist Controls|Participants on the waitlist will still receive treatment as usual, which includes medical, psychosocial, and occupational interventions to help maximize patients' integration within the community and support recovery from a first episode of psychosis. Frequency of contact largely depends on the individual needs of patients. Waitlist controls will be offered the BOOST intervention 3 months post-enrollment.
62376645|NCT00821756|EXPERIMENTAL|1|Assertive intervention in OPAC-style: Outreach,problem solving,adherence,continuity
62556067|NCT02291991|EXPERIMENTAL|Group A|"Drug : GX-E2 - Intravenously injection once day at dose 8 ug/kg Drug : Placebo~(1 subject : GX-E2, 1 subject : Placebo)~Subjects in group A will be injected drug, So we observe safety. After three days, Subject in group B will be injected drug."
62752557|NCT05092763|EXPERIMENTAL|FIT4SURGERY Intervention|The Fit4Surgery intervention consists of the FitBit Inspire HR device, the Fit4Surgery mobile app, and weekly coaching calls.
62752558|NCT05092763|ACTIVE_COMPARATOR|Healthy Lifestyle Control|The Healthy Lifestyle Control group engages in their usual activities and receives education about physical activity and a healthy lifestyle for ovarian cancer patients. They receive weekly check in calls.
62752559|NCT05118789|EXPERIMENTAL|Phase 1 dose escalation|NVL-520 oral daily dosing
62752560|NCT05118789|EXPERIMENTAL|Cohort 2a|ROS1+ NSCLC naïve to TKI therapy and up to 1 prior chemotherapy and/or immunotherapy
62752561|NCT05118789|EXPERIMENTAL|Cohort 2b|ROS1+ NSCLC treated with 1 prior ROS1 TKI and no prior chemotherapy or immunotherapy
62752562|NCT05118789|EXPERIMENTAL|Cohort 2c|ROS1+ NSCLC treated with 1 prior ROS1 TKI and 1 prior platinum-based chemotherapy with or without immunotherapy
62752563|NCT05118789|EXPERIMENTAL|Cohort 2d|ROS1+ NSCLC treated with ≥2 prior ROS1 TKIs and up to 1 prior chemotherapy and/or immunotherapy
62752564|NCT05118789|EXPERIMENTAL|Cohort 2e|ROS1+ solid tumor and progressed on any prior therapy
62752565|NCT01671501|EXPERIMENTAL|Motivational Interviewing|The intervention consists of one 45-minute in-person session followed by two 20-minute telephone sessions.The first telephone MI session will occur approximately 10 days after the in-person session. The second call will occur 30 days after the first call. The same research clinician will conduct both the in-person session and phone sessions. The calls will include a review of material covered in the initial session, questions on alcohol use, open-ended questions regarding patients' current motivational level, and a review of the patient's initial goals regarding alcohol consumption and will last about 20 minutes. If after six months hazardous drinking is noted, three more motivational interviewing phone sessions will be delivered by the research clinician.
62376646|NCT00821756|NO_INTERVENTION|2|Control arm: Treatment as usual
62376647|NCT02074475||Control group|The control group of three sites for larger Adequacy of Anaesthesia study. Total 150 patients
62376648|NCT05204108||Contrast-enhanced Ultrasonography|To evaluate the diagnostic accuracy of CEUS for the preoperative staging of bladder cancer, which would benefit the implementation of efficient therapeutic strategies.
62376649|NCT06161324|EXPERIMENTAL|Tele-rehabilitation group (TeleG)|The participants of the tele-rehabilitation group(TeleG), will remotely perform a pelvic floor muscle (PFM) exercises program at home in cooperation with a PFM superficial sensor. At the same time, the participants will be supervised remotely by the physiotherapist. Participants and therapist will communicate through the mobile app, either synchronously (i.e. through video calls) or asynchronously (i.e. through emails), regarding the execution of the PFM exercises (direction of the PFM contraction, frequency of the PFM exercise program etc.)
62376650|NCT06161324|ACTIVE_COMPARATOR|Traditional treatment group (TrG)|"In the Traditional (classic) treatment group (TrG), participants will follow the usual care treatment of pelvic floor muscles, based on the pragmatic treatment of urinary incontinence, which is used today in rehabilitation clinics, centers etc."
62376651|NCT06161324|OTHER|Control Group (CG)|The participants of the control group (CG), will follow a pelvic floor muscle exercise program at home (via leaflet), without any supervision.
62376652|NCT04535258|OTHER|First-movers|The first four alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
62376653|NCT04535258|OTHER|Second-movers|After three months, the next five alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
62376654|NCT04535258|OTHER|Third-movers|After three months, the next five alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
62376655|NCT04535258|OTHER|Fourth-movers|After three months, the last four alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
62376656|NCT02021149|OTHER|Psychotherapy and Questionnaire Group|Participants in this arm will have their regular psychotherapy sessions with their psychotherapist and will, prior to each session, fill out study related questionnaires.
62376657|NCT02021149|EXPERIMENTAL|High intensity whole-body infrared heating and Psychotherapy.|Subjects will have weekly psychotherapy sessions and fill out study questionnaires. The participant's 4th psychotherapy session will be conducted while the patient undergoes the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
62376658|NCT02021149|SHAM_COMPARATOR|Low intensity whole-body infrared heating and Psychotherapy|Subjects will have weekly psychotherapy sessions and fill out study questionnaires. The participant's 4th psychotherapy session will be conducted while the patient undergoes WBH-control where subjects will be induced to levels of heat that causes only a minor increase in body temperature.
62376659|NCT03186040|OTHER|Lacosamide|
62376660|NCT01620658|ACTIVE_COMPARATOR|standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
62376661|NCT01620658|EXPERIMENTAL|0.3mm XPF cap|Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.
62376662|NCT01620658|EXPERIMENTAL|0.5mm XPF cap|Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.
62376663|NCT06408987|ACTIVE_COMPARATOR|1 .Arthroscopically assisted|Arthroscopically assisted in surgical reduction of the hip in patients with irreducible DDH before the walking age arm 1
62376664|NCT06408987|ACTIVE_COMPARATOR|2.open surgical reduction arm 2|open surgical reduction of the hip in patients with irreducible DDH before the walking age arm 2
62376665|NCT00893763|EXPERIMENTAL|Pre-intubation CHX|Chlorhexidine applied to oral cavity prior to intubation
62376666|NCT00893763|ACTIVE_COMPARATOR|Control|No chlorhexidine applied to oral cavity prior to intubation
62376667|NCT02334137||iPad app|This group will have unlimited access to educational iPad app while waiting for ophthalmology visits.
62376668|NCT02334137||Educator sessions|This group will have unlimited access to educational iPad app AND at least one appointment with a certified diabetes educator or registered dietitian while waiting for ophthalmology visits.
62376669|NCT02334137||Educator sessions + retinal photos|"This group will have same access as iPad app + education sessions and in addition will be able to briefly review their own retinal photos (compared to normal retina) with a resident ophthalmologist during timeline of pilot program."
62376670|NCT01326910|EXPERIMENTAL|19306-127|Experimental Topical cream applied twice daily (or as needed)
62376671|NCT01326910|OTHER|19306-137|Marketed Topical cream applied twice daily (or as needed)
62376672|NCT01076270|EXPERIMENTAL|Filgrastim and plerixafor for PBSC mobilization|"Donors receive filgrastim subcutaneously (SC) and plerixafor SC on day -14 and undergo leukapheresis to collect peripheral blood stem cells (PBSC) on day -13. These cells are frozen to preserve them. Treatment modifications may apply according to sufficient collection of PBSC. Patients receive standard high-dose conditioning and undergo allogeneic PBSC transplantation on day 0 using the previously frozen cells.~After completion of study treatment, donors are followed up 1 day after the last stem cell donation."
62376673|NCT00859716|EXPERIMENTAL|1|vaccination with ACE393 followed by challenge with campylobacter jejuni
62376674|NCT00859716|PLACEBO_COMPARATOR|2|Placebo vaccination followed by challenge with campylobacter jejuni
62556068|NCT02291991|EXPERIMENTAL|Group B|Drug : GX-E2 - Intravenously injection once day at dose 8 ug/kg Drug : Placebo (7 subjects : GX-E2, 1 subject : Placebo)
62376675|NCT02672644|EXPERIMENTAL|Emervel Classic|Subjects treated with Emervel Classic (moderate NLFs; WSRS = 3/3). Subjects receiving bilateral treatment of NLFs following approved product labeling.
62376676|NCT02672644|EXPERIMENTAL|Emervel Deep|Subjects treated with Emervel Deep (severe NLFs; WSRS = 4/4). Subjects receiving bilateral treatment of NLFs following approved product labeling.
62752566|NCT01671501|EXPERIMENTAL|Email Feedback|Each participant will receive up to three detailed emails, (if participants respond to a first, initial email with information on alcohol use risks). The initial and subsequent emails will be brief in length, and will include specific information on hazardous drinking levels, standard drink size; as well as advice to reduce drinking to non-hazardous levels. Each email will conclude with contact numbers for patients to receive further information and assistance if needed, including information on how to easily access SU treatment; and will encourage participants to respond to the research clinician with questions. If after six months hazardous drinking is detected, up to 3 more detailed emails will be delivered to the participant.
62376677|NCT02084316|EXPERIMENTAL|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
62556069|NCT01358214||Patients treated with a surgical mesh|This arm of study patients is defined by patients treated with a TiLOOP® Tape mesh between 2007 and 2009 at the Franziskus Krankenhaus, Berlin. The sample of the treated population represents the patient population for which the medical device is intended. To minimize selection bias without compromising patients' rights and welfare, all treated patients will be invited. These patients will be asked to participate in the validation of the questionnaire on quality of life. In addition to this safety and effectiveness of the surgical mesh implantation will be collected
61986468|NCT06011681||Mild cognitive impairment|Seniors with self-reported decline in cognitive function or with a diagnosis of mild cognitive impairment.
62376678|NCT02084316|ACTIVE_COMPARATOR|Standard of Care|"The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.~After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.~Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling."
62376679|NCT01994109|ACTIVE_COMPARATOR|MYOBLOC 2500 U|Subjects will receive specified dose of MYOBLOC
62376680|NCT01994109|ACTIVE_COMPARATOR|MYOBLOC 3500 U|Subjects will receive specified dose of MYOBLOC
62376681|NCT01994109|PLACEBO_COMPARATOR|Placebo|Subjects will receive volume matched Placebo
62376682|NCT01614522|EXPERIMENTAL|HER-2 Amplified|
62376683|NCT01614522|EXPERIMENTAL|HER-1 & HER-2 Co-expression|
62376684|NCT02797288||Acute CDI cohort|Hospitalized patients diagnosed with Acute CDI
62376685|NCT02797288||FMT cohort|Patients undergoing FMT for recurrent CDI
62376686|NCT02797288||Past CDI Control Cohort|Hospitalized patients with past CDI diagnosis without recurrence
62752567|NCT01671501|OTHER|Usual Care|Participants in this arm will receive routine primary care services only. Usual care in this health care setting may include alcohol screening, brief intervention and referral to treatment (SBIRT) delivered by usual care clinic staff
62752568|NCT06038526|EXPERIMENTAL|Prevention (canakinumab, bronchoscopy)|Patients undergo bronchoscopy over 30-60 minutes and receive canakinumab SC 60 minutes and 2 weeks after the initial bronchoscopy. Patients undergo an additional bronchoscopy on day 77. Patients undergo buccal, nasal, and blood sample collection and CO testing on study.
62752569|NCT04417218|EXPERIMENTAL|Normal Lysine Diet|Participants will complete two one-week dietary interventions, in a randomized order. For the normal lysine diet, participants will be asked to adhere to a specific diet for 1 week. Each study subject will receive 3 meals and 1-2 snacks per day during the study period.
62752570|NCT04417218|EXPERIMENTAL|High Lysine Diet|Participants will complete two one-week dietary interventions, in a randomized order. For the high lysine diet, participants will be asked to consume the same foods as in the normal lysine diet, but with the addition of lysine supplements (5g/day).
62752571|NCT04431310||Serial seroconversion measurements in hospital employees|Serial seroconversion measurements in hospital employees during the COVID-19 pandemic
62752572|NCT01088165|EXPERIMENTAL|Adalimumab treatment group|
62752573|NCT01088165|ACTIVE_COMPARATOR|Fumaric acid esters treatment group|
62752574|NCT04397003|EXPERIMENTAL|Neoantigen DNA vaccine+durvalumab|"* Patients will receive durvalumab (1500mg Q3W) in combination with standard of care carboplatin and etoposide for a total of 4 cycles given every 3 weeks~* Beginning 4 weeks following Cycle 4 of carboplatin/etoposide/durvalumab, patients on will then receive 6 cycles of durvalumab 1500 mg with the polyepitope neoantigen DNA vaccine, both administered once every 4 weeks~* Patients may then receive durvalumab every 4 weeks until disease progression or drug toxicity~* Should a delay in vaccine preparation occur, patients will begin durvalumab and the vaccine will be added with the subsequent cycle."
62752575|NCT02829892|OTHER|Light therapy|Innovative ambient lighting
62752576|NCT04808947|EXPERIMENTAL|Local infiltration analgesia|Patients in this group will receive LIA intraoperatively, as per institutional standard. The injected solution will be comprised of 100cc Ropiv 2%, + Ketorolac 30 mg + Epinephrine 25 ug.
61986469|NCT06011681||Healthy controls|Seniors with no neurological or psychiatric symptoms or conditions.
62376687|NCT03380169|EXPERIMENTAL|Advance dressing|Prophylactic advance wound dressing
62376688|NCT03380169|ACTIVE_COMPARATOR|Conventional gauze dressing|Prophylactic conventional wound dressing
62376689|NCT02052154|EXPERIMENTAL|Prime-boost pneumococcal immunization|
62376690|NCT01308489|EXPERIMENTAL|Arm I (posterior spinal tumor resection)|Patients undergo posterior spinal tumor resection on day 0.
62376691|NCT01308489|EXPERIMENTAL|Arm II (anterior and posterior spinal tumor resection)|Patients undergo anterior and posterior tumor resection on day 0.
62376692|NCT04198311|EXPERIMENTAL|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for five (5) weeks
62376693|NCT00118924|EXPERIMENTAL|1|One subcutaneous vaccination with a 10\^3 PFU dose of LGT(TP21)/DEN4 vaccine given in the deltoid region of either arm. A second booster vaccination will be given 6 months after the first vaccination.
62376694|NCT00118924|EXPERIMENTAL|2|One subcutaneous vaccination with a 10\^5 PFU dose of LGT(TP21)/DEN4 vaccine given in the deltoid region of either arm. A second booster vaccination will be given 6 months after the first vaccination. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
62376695|NCT00118924|PLACEBO_COMPARATOR|3|One subcutaneous vaccination with a placebo vaccine given in the deltoid region of either arm. A second placebo vaccination will be given 6 months after the first vaccination.
62376696|NCT01740765|EXPERIMENTAL|Eucaloric Feeding|Subjects will complete an initial eucaloric feeding study day. During this study day, subjects will receive 100% of their calorie requirements. 24-hour energy expenditure will be measured.
62752577|NCT04808947|ACTIVE_COMPARATOR|Local infiltration analgesia + ACB-iPACK block|"Patients in this group will receive LIA intraoperatively, as per institutional standard. The injected solution will be comprised of 100cc Ropiv 2%, + Ketorolac 30 mg + Epinephrine 25 ug.~Patients in this group will also receive preoperative nerve blocks under ultrasound guidance. These will include:~1. Adductor canal block with 0.5% Ropivacaine w/epi 20 mL~2. iPack block with 0.25% Ropivacaine w/epi 10 mL"
62752578|NCT02959827||Iodinated contrast agents|Children under age 4 in the Kaiser Permanente Northern California database, who had a diagnostic procedure with an iodinated contrast agent
62752579|NCT03362099|NO_INTERVENTION|Group Varenicline|Patients randomized to this group will collect polymorphisms at time zero and will receive varenicline for smoking cessation. The polymorphism result will only be known at the end of the protocol. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
62752580|NCT03362099|ACTIVE_COMPARATOR|Group Genetic|"The patients randomized to this arm will collect polymorphisms and could receive varenicline or bupropion or both depending on genetic polymorphisms for each one these drugs.~Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve."
62752581|NCT02313870|EXPERIMENTAL|A|Superpotent topical steroids/methotrexate
62752582|NCT02313870|OTHER|B|Superpotent topical steroids (clobetasol propionate)
62752583|NCT01174277||Collection of blood sample|Blood draw
62752584|NCT03069170|EXPERIMENTAL|Stem Cells|Intravenous administration of purified autologous bone marrow-derived stem cells.
62752585|NCT03069170|EXPERIMENTAL|Stem Cell Transplantation|Intrathecal administration of purified autolgous bone-marrow derived stem cells.
62752586|NCT01740479|ACTIVE_COMPARATOR|Complete Revascularization Strategy|"Complete Revascularization Strategy (Staged Non-Culprit Lesion PCI plus Optimal Medical Therapy): Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions.~All patients, regardless of randomized treatment allocation will receive optimal medical therapy consisting of risk factor modification and use of evidence-based therapies (including low dose acetylsalicylic acid (ASA) and ticagrelor)."
62752587|NCT01740479|NO_INTERVENTION|Optimal Medical Therapy Alone|"Culprit lesion only Revascularization Strategy (Optimal Medical Therapy Alone): No further revascularization of non-culprit lesions.~All patients, regardless of randomized treatment allocation will receive optimal medical therapy consisting of risk factor modification and use of evidence-based therapies (including low dose ASA and ticagrelor)."
62752588|NCT06411977|NO_INTERVENTION|Control group|Orthodontic patients with fixed appliances
62752589|NCT06411977|OTHER|Juice group|Orthodontic patients with fixed appliances with daily administration of vegetable juice up to 14 days
62752590|NCT01932320|EXPERIMENTAL|Part 1|Participants will receive single dose of all the 3 formulations of JNJ-40411813 (Formulation A: hard gelatin capsule filled with beads; Formulation B: immediate release tablet, and Formulation C: Nanosuspension formulation) without food in 3 periods (Period 1, Period 2, and Period 3). The sequences will be based on a computer-generated randomization schedule prepared by the sponsor before the study. Each period will be separated by a wash out period (no treatment) of at least 1 week.
62752591|NCT01932320|EXPERIMENTAL|Part 2|Participants will receive single dose of the selected solid dose formulation of JNJ-40411813 (Formulation A or Formulation B) from Part 1 without food and with food in 2 periods (Period 1 and Period 2). The sequences will be based on a computer generated randomization schedule prepared by the sponsor before the study. Each period will be separated by a wash out period of at least 1 week.
62752592|NCT01932320|EXPERIMENTAL|Part 3|Participants will receive single dose of the selected solid dose formulation of JNJ-40411813 (Formulation A or Formulation B) from Part 1 on two occasions (Day 1 and Day 10) without food along with ketoconazole from Day 6 to Day 14 with food.
62752593|NCT03321903||1: Intraoral Squamous Cell Carcinomas|Intraoral squamous cell carcinomas that are resected and receive adjuvant radiation therapy. These patients may receive a Carlo Erba Ink injection before surgical tumor resection, after tumor resection (in the postsurgical radiation field), or in both instances. Patients whose tumor is within 5 mm of the surface will have injections of India ink into the tumor itself and measurements made in the tumor prior to surgery. Patients whose tumor is deeper than 5 mm of the surface could participate only in the measurements of the postsurgical radiation field. EPR Oximetry measurements will be made in the tumor and/or, if applicable, over the course of radiation in the postsurgical radiation field as appropriate.
62752594|NCT03321903||2: Cutaneous Malignant Tumors|Patients with primary cutaneous malignant tumors (including but not limited to squamous cell carcinoma, basal cell carcinoma, or melanoma) whose tumor is within 5 mm of the surface and whose treatment plan includes surgical resection and/or postsurgical radiation therapy. These patients may receive a Carlo Erba Ink injection before surgical tumor resection, after tumor resection (in the postsurgical radiation field), in both the tumor and the postsurgical radiation field, or in the tumor prior to radiation therapy. EPR Oximetry measurements will be made in the tumor and/or, if applicable, over the course of radiation in the tumor or postsurgical radiation field as appropriate.
62752595|NCT03321903||3: Breast Cancers|Breast cancer patients whose treatment plan includes surgical resection followed by radiation therapy. All patients who receive a surgical resection will receive a Carlo Erba Ink injection in the radiation field after sufficient healing has occurred to the area to be injected, as determined in consultation with the treating physicians, and using topical anesthetic or local anesthetic, if the patient so desires. All patients in this cohort will be expected to agree to a minimum of one EPR Oximetry measurement in the planned radiation field prior to radiation and a minimum of one measurement made over the course of radiation therapy.
62376697|NCT01740765|EXPERIMENTAL|Underfeeding|Following the eucaloric feeding study day, subjects will undergo the underfeeding and overfeeding arms in random order. During the underfeeding study arm, subjects will receive 50% of their calorie requirements (as determined during the initial eucaloric study day) for 3 days. 24-hour energy expenditure will be measured.
62376698|NCT01740765|EXPERIMENTAL|Overfeeding|Following the eucaloric feeding study day, subjects will undergo the underfeeding and overfeeding arms in random order. During the overfeeding study arm, subjects will receive 150% of their calorie requirements (as determined during the initial eucaloric study day) for 3 days. 24-hour energy expenditure will be measured.
62376699|NCT01818128|ACTIVE_COMPARATOR|Neutral shape of bronchial tip|
62376700|NCT01818128|EXPERIMENTAL|Bent shape of bronchial tip|
62376701|NCT02336191||LDLT Recipients|Patients subjected to living donor liver transplantation
62376702|NCT03595982|EXPERIMENTAL|Procardia XL 30 mg|Procardia XL 30 mg XL Q 12h - When a patient's BP is persistently elevated after a dose of 30 mg of Procardia XL, the dose is increased to 60 mg Procardia XL divided in 2 doses of 30 mg given 12h apart.
62376703|NCT03595982|ACTIVE_COMPARATOR|Procardia XL 60 mg|Procardia XL 60 mg Q 24h - When a patient's BP is persistently elevated after a dose of 30 mg of Procardia XL, the dose is increased to 60 mg Procardia given once a day.
62376704|NCT03185091|OTHER|rapid ventricular pacing|Safety of rapid ventricular pacing during neurosurgical procedures
62376705|NCT06296043|EXPERIMENTAL|Progressive Muscle Relaxation Exercise Group|Application will be made on the day PMS symptoms begin and throughout the menstrual cycle.
62376706|NCT06296043|EXPERIMENTAL|Su-Jok Group|Application will be made on the day PMS symptoms begin and throughout the menstrual cycle.
62376707|NCT06296043|NO_INTERVENTION|Control Group|No application will be made to this group by the researcher.
62376708|NCT03474237||Non-functioning adrenal incidentaloma|patients who were diagnosed with non-functioning adrenal incidentaloma on computed tomography or magnetic resonance imaging
62376709|NCT03474237||Pheochromocytoma|patients who were diagnosed with pheochromocytoma biochemically or histologically
62376710|NCT03474237||Primary aldosteronism|patients who were diagnosed with primary aldosteronism by saline loading test
62376711|NCT03474237||Adrenal cushing syndrome|patients who were diagnosed with adrenal cushing syndrome by dexamethasone suppression test and 24 urine free cortisol test.
62376712|NCT03474237||Adrenocortical carcinoma|patients who were diagnosed with adrenocortical carcinoma by imaging study or histologic exam
62376713|NCT03942640|OTHER|perineural injection group|"perineural injection therapy group (subcutaneous prolotherapy) This group included 30 patients aged from 18 to 60 years~Buffered glucose preparation :~2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%.~Patients received 8 weekly injection sessions at sites of chronic constriction injurey of the following nerves :~Suprascapular nerve.."
62376714|NCT03942640|OTHER|deepprolotherapy group|Deep prolotherapy injection group The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine. The pathological area of the supraspinatous tendon was identified and graded using ultrasound pathology rating scale guided by ultrasonography (Simens Acuson p300 machine) Proper preparation with antiseptic solution of skin overlying the point of injection .
61986470|NCT00787085||Case|Patients hospitalized with a urine or blood culture positive for fungi
62752596|NCT03321903||4: Other tumors|Other tumors within 5 mm of the surface, whose planned treatment includes radiotherapy of the tumor and does not include a planned resection of the tumor. As these other qualifying malignancies are expected to occur only rarely, they will be grouped into a single cohort despite potential varied histology. These patients will receive a Carlo Erba Ink injection in their tumor prior to radiation therapy. All patients in this cohort will be expected to agree to a minimum of one EPR Oximetry measurement in the planned radiation field prior to radiation and a minimum of one measurement made over the course of radiation therapy.
62752597|NCT05999175|OTHER|Group 1 (20 subjects)|"using the delicate mint toothpaste Dentifricio gel tau-marin® Menta Delicata."
62376715|NCT03088332|EXPERIMENTAL|Endoscopic gastroplasty|Make a gastric tube similar to that obtained in surgical gastroplication however it will be created using intragastric endoscopic sutures.
62376716|NCT00693563|NO_INTERVENTION|Control Group|The Control Group will receive usual care following discharge from the inpatient rehabilitation unit.
62752598|NCT05999175|OTHER|Group 2 (12 subjects)|"using of the mint toothpaste Dentifricio gel tau-marin® Menta."
62752599|NCT05999175|OTHER|Group 3 (20 subjects)|"using the mint mouthwash Collutorio tau-marin® Menta."
62752600|NCT05999175|OTHER|Group 4 (20 subjects)|"using the delicate mint toothpaste Dentifricio gel tau-marin® Menta Delicata, mint mouthwash Collutorio tau-marin® Menta."
62752601|NCT05999175|OTHER|Group 5 (12 subjects)|continuing to use their routine oral hygiene products.
62752602|NCT02833753|EXPERIMENTAL|Dose Escalation|"Single arm dose finding for intraperitoneal Oxaliplatin. All patients will receive experimental treatment.~The first cohort of 3 patients will receive dose level 1. The second cohort of 3 patients will receive dose level 2. The Third cohort of 3 patients will receive dose level 3. The fourth cohort of 3 patients will receive dose level 2."
62752603|NCT05440006|EXPERIMENTAL|Fed+ Fasted|The first cycle with high-fat meal, the second cycle under fasting.
62752604|NCT05440006|EXPERIMENTAL|Fasted + Fed|The first cycle under fasting, the second cycle with high-fat meal.
62752605|NCT02509572|EXPERIMENTAL|Decision Support Arm|Patients randomized to the intervention will complete a sexual health screen (SHS). The results of the SHS will provide decision support for STI testing by risk stratifying patients with screening recommendations to the clinician based on risk.
62752606|NCT02509572|NO_INTERVENTION|Usual Care Arm|Patients randomized to the usual care arm will complete the sexual health screen (SHS). However these results and the STI testing decision support will not be shared with the clinician.
62752607|NCT03871101|ACTIVE_COMPARATOR|Scalpel|Soft tissue incision with scalpel in second- stage implant surgery.
62752608|NCT03871101|EXPERIMENTAL|Erbium laser|Soft tissue incision with 2780 nm Er,Cr:YSGG laser, at implant recovery settings (2.00 W power, 100 Hz H mode, 10% water and 10% air) in second-stage implant surgery.
62752609|NCT01106339||A|Patients with somatoform disorders due to DSM-IV
62752610|NCT03263858|EXPERIMENTAL|Cohort 1 and 2|
62752611|NCT00346502|EXPERIMENTAL|Ointment|Treatment will consist of four weeks of daily application of 20% BA ointment to the dysplastic nevi, after which it will be removed surgically and examined. A similar dysplastic nevi will be removed as a control. Four groups of patients will be enrolled. The first group will apply the ointment once a day, the second twice a day, the third three times a day, and the fourth four times a day.
62376717|NCT00693563|EXPERIMENTAL|Treatment Group|Scheduled Telephone Intervention
62376718|NCT06099678|EXPERIMENTAL|Elastic Band Training|This group will perform moderate intensity, whole-body elastic band training.
62752612|NCT00790166|ACTIVE_COMPARATOR|CPAP + ThermoSmart™ humidity|
62752613|NCT00790166|ACTIVE_COMPARATOR|CPAP + Conventional humidity|
62752614|NCT00790166|ACTIVE_COMPARATOR|CPAP + No added humidity|
61986471|NCT00787085||Control|Patients hospitalized with a urine culture negative for fungi
61986472|NCT06024044|NO_INTERVENTION|Control|The women patients in the control group who underwent hysterectomy were informed that mobilization training would be performed after a postoperative 2-day waiting period. Meanwhile, no intervention was made except for any routine nursing care.
62376719|NCT06099678|EXPERIMENTAL|Elastic Band Training with Maximal Mental Effort|This group will perform moderate intensity, whole-body elastic band training with maximal mental effort during muscle contraction.
62376720|NCT06099678|NO_INTERVENTION|Control|This group will not perform any training and maintain their regular level of physical activity.
62376721|NCT03148249|EXPERIMENTAL|interview with an ophthalmologist|Patients get an interview with an ophthalmologist
62376722|NCT03148249|EXPERIMENTAL|interview/treatment by a psychiatrist|patients get an interview and a possible treatment by a psychiatrist
62376723|NCT03092622|EXPERIMENTAL|exercise training|Outpatients treadmill interval training, 4x4 minutes with 3 minutes in between at lower intensity. 3 sessions weekly for 10 weeks to a total of 30 sessions.
62376724|NCT00638898|EXPERIMENTAL|Arm I|See Detailed Description
62752615|NCT06604845|EXPERIMENTAL|Group cognitive behavioural therapy|"Group CBT based on an adapted version of individual CBT for ADHD according to Safren's manual CBT for ADHD/Mastering Your Adult ADHD."
62752616|NCT06604845|ACTIVE_COMPARATOR|Activity group|The Activity group is a structured manualised group intervention designed by clinicians and researchers at Sahlgrenska University Hosptial.
62752617|NCT03673787|EXPERIMENTAL|Phase I|Increasing doses of ipatasertib in combination with a fixed dose of atezolizumab to establish the recommended phase II dose.
62376725|NCT03898752|EXPERIMENTAL|Lifestyle intervention|Diet, omega-3 fish oil (1g daily), CoQ10 (100 mg/day) and a normal Multi-vitamin, Smoking cessation, weight loss, exercise,
62752618|NCT03673787|EXPERIMENTAL|Phase II|The Phase II part of the study will evaluate the recommended phase II dose of ipatasertib identified in Phase I, in combination with atezolizumab, in six patient cohorts: patients with solid tumours who have hyperactivation of the PI3K pathway; patients with castrate-resistant prostate cancer with PTEN loss; patients with glioblastoma; patients with melanoma; patients solid tumour types refractory to immune-checkpoint inhibitors; patients with gynaecological cancers.
62752619|NCT03241771|EXPERIMENTAL|Naloxone Navigator 1.0|Participants randomized to the Naloxone Navigator 1.0 arm will receive a link to the web-based resource. They will also receive usual care from their health plan, pharmacy and physicians. As part of usual care, participants will have access to naloxone through standing orders (i.e., they can request it without a prescription under their usual pharmacy benefit).
62376726|NCT05315973|EXPERIMENTAL|Sensor group|
62376727|NCT01085695|EXPERIMENTAL|1|
62376728|NCT01085695|EXPERIMENTAL|2|
62752620|NCT03241771|NO_INTERVENTION|Usual Care|Participants in the usual care arm will receive usual care from their health plan, pharmacy and physicians. As part of usual care, participants will have access to naloxone through standing orders (i.e., they can request it without a prescription under their usual pharmacy benefit).
62376729|NCT01085695|EXPERIMENTAL|3|
62376730|NCT01085695|ACTIVE_COMPARATOR|4|
62376731|NCT03720106|OTHER|treatment arm|In this arm the GOAL therapy plan is used.
62376732|NCT00803296||Obese patients with type 2 diabetes|Patients with type 2 diabetes and BMI\>33
62376733|NCT00803296||Obese subjects with normal glucose tolerance|Subjects with normal glucose tolerance and BMI\>33
62376734|NCT00803296||Lean subjects with type 2 diabetes|Patients with type 2 diabetes and BM\<25
62376735|NCT00803296||Lean subjects with normal glucose tolerance|Subjects with normal glucose tolerance and BM\<25
62752621|NCT01566695|EXPERIMENTAL|Oral Azacitidine|Arm 1: Oral azacitidine tablets 300 mg daily (QD) + best supportive care (BSC) on days 1 through 21 of each 28-day treatment cycle.
62752622|NCT01566695|PLACEBO_COMPARATOR|Placebo|Arm 2: Identically matching placebo tablets plus best supportive care on days 1 to 21 of each 28-day treatment cycle.
62752623|NCT03392883|EXPERIMENTAL|Digital Health Assisted Mental Healthcare|This Digital Health Assisted Mental Healthcare intervention will be based on the novel mobile-based platform (Laddr® from Square2 Systems).
62376736|NCT05592145|OTHER|ViOptix T.Ox|ViOptix T.Ox machine is used to measure the oxygenation of composite tissue.
62376737|NCT04714554|EXPERIMENTAL|Part 1: Relugolix/E2/NETA Plus Erythromycin|"Treatment Period 1: Healthy premenopausal women will receive a relugolix/E2/NETA (40 mg/1 mg/0.5 mg) alone on Day 1.~Treatment Period 2: Healthy premenopausal women will receive erythromycin on Day 1 through 12 (500 mg, QID), with co-administration of a single dose of relugolix/E2/NETA (40 mg/1 mg/0.5 mg) with the morning dose of erythromycin on Day 8."
62376738|NCT04714554|EXPERIMENTAL|Part 2: Relugolix Plus Erythromycin|"Treatment Period 1: Male participants will receive a single 120-mg dose of relugolix alone on Day 1.~Treatment Period 2: Male participants will receive erythromycin on Days 1 through 12 (500 mg, QID), with co-administration of a single 120-mg dose of relugolix with the morning dose of erythromycin on Day 8."
62376739|NCT04481711|EXPERIMENTAL|Study group|Twenty-nine patients (female/male: 24/5) with grade 4 osteoarthritis were included in the study group. These patients underwent total knee arthroplasty
62376740|NCT04481711|NO_INTERVENTION|Control group|Twenty-two patients (female/male:13/9) with \<grade 4 osteoarthritis were included in the control group.
62376741|NCT06216769|ACTIVE_COMPARATOR|non-interrupted group|Anticoagulation is continued regardless of atrial fibrillation recurrence.
62376742|NCT06216769|EXPERIMENTAL|PIP anticoagulation group|Anticoagulation continuation will be determined based on the rhythm monitored by ILR. If atrial fibrillation persists more than 6 hours a day, anticoagulation should be started at that point on and continued for four weeks. Anticoagulation can be prescribed even in case of less-than-6-hour cumulative atrial fibrillation burden if the investigator decides that the anticoagulation is necessary.
62376743|NCT03079518|ACTIVE_COMPARATOR|Patients with HFREF & CKD|treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal
62376744|NCT03079518|ACTIVE_COMPARATOR|Patients with HFREF|treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal
62376745|NCT02811081|EXPERIMENTAL|Control|Passive deflation of residual carbon dioxide
62376746|NCT02811081|EXPERIMENTAL|Normal Saline Instillation|Instillation of isotonic normal saline in the sub-diaphragmatic region
62376747|NCT02811081|EXPERIMENTAL|Combined Intervention|Normal Saline Instillation + Pulmonary Recruitment
62752624|NCT03121677|EXPERIMENTAL|Nivolumab/Poly-ICLC/Vaccine/+/- Rituximab|"* All cycles are 4 weeks (wks), with nivolumab every 2 wks during Cycles 1-6 \& every 4 wks during Cycles 7-12 \& vaccine on Cycle 1 Days 1, 4, 8, 15; Cycle 2 Day 1; and then on Day 1 of Cycles 4, 6, 8, 10, 12~* After 2 cycles, restaging will be performed, \& patients with CR, PR, or SD will continue on nivolumab + vaccine. Patients with evidence of PD may initiate anti-CD20 mAb therapy (drug to be determined by the treating physician) weekly for 4 wks during Cycle 3, followed by a dose on Day 1 of every other cycle (Cycles 6, 8, 10, and 12).~* After 6 cycles, restaging will be performed again, and patients with CR, PR, or SD will continue nivolumab + vaccine. Patients with PD at that time point (but not treated with anti-CD20 mAb therapy thus far on this protocol) will initiate anti-CD20 mAb (drug to be determined by the treating physician) therapy weekly for 4 wks during Cycle 7, followed by a dose Day 1 of Cycles 10 \& 12 \& 2 additional doses 8 wks apart."
62752625|NCT03734653|EXPERIMENTAL|Square Wave Testosterone Therapy + SOC|All patients will receive transdermal testosterone. All patients will also receive standard of care enzalutamide. Patients will alternate between the two therapies.
62752626|NCT01032291|EXPERIMENTAL|lenalidomide plus cetuximab|Combination therapy of lenalidomide plus cetuximab
62752627|NCT01032291|EXPERIMENTAL|lenalidomide|Single agent therapy of lenalidomide
62376748|NCT04697108|OTHER|Proprioception Test (TRMOPL)|In the Familiarization stage (1), the TRMOPL was applied by means of a single evaluator with the aim of knowledge and understanding of the test. After five minutes, step (2) test started. In this step, the test was applied twice, by different evaluators, with an interval of five minutes between applications (inter-rater reliability). Ten minutes after the end of the tests, step (3) retest (intra-rater reliability) was started, following the same procedures as in step 2. The order of the evaluators was randomized through a draw in Excel, the order of randomization of the steps (2) and (3) was the same in order not to influence intra-rater reliability.
62376749|NCT06325644|EXPERIMENTAL|Ketogenic Diet|The KD will follow general principles the investigators have described with the aim to achieve blood ketones \>0.5 mM, which will require most participants to consume \<50 g/day carbohydrate and \~1.5 g/kg reference weight protein. Fat will comprise the remaining calories with an emphasis on monounsaturated and saturated sources from whole foods.
62376750|NCT04051489||Mobile App|Individuals with symptomatic knee osteoarthritis
62376751|NCT05119790|EXPERIMENTAL|Cohort A|
62376752|NCT05547594|EXPERIMENTAL|Prehabilitation|Arm undergoing multimodal prehabilitation (physical activity, nutritional education and anxiety management) during the weeks leading up to surgery
62376753|NCT05547594|NO_INTERVENTION|Standard of care|Arm receiving standard of care (no prehabilitation)
62376754|NCT06053281|EXPERIMENTAL|Vitamin D|DRE patients with proved vitamin D deficiency (Serum vitamin D level \<30ng/ml). intervention: Daily Cholecalciferol 1000 IU in 24 weeks.
62376755|NCT06053281|PLACEBO_COMPARATOR|Placebo|DRE patients with proved vitamin D deficiency (Serum vitamin D level \<30ng/ml). Interventions: Daily Placebo oral (Manufactured to mimic Cholecalciferol) in 24 weeks.
62752628|NCT04151628|EXPERIMENTAL|Coronary Lithotripsy System|All subjects will receive lithotripsy treatment from the Shockwave Medical Coronary IVL System
62752629|NCT03429673||Patients with surgeries|Pathologically diagnosed elderly early Chinese patients with non-small cell lung cancer who received lobectomy or segment/wedge dissection
62376756|NCT04501965|ACTIVE_COMPARATOR|Hydroxychloroquine/Azythromycin|Patients received Hydroxychloroquine 200 mg tablet orally 3 times daily for 10 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days
62376757|NCT04501965|EXPERIMENTAL|Quinquina/Azythromycin|Patients receive 3.5g tea bags of Cinchona/Stevia powder orally at the rate of 3 tea bags per day for 10 days
62376758|NCT04501965|EXPERIMENTAL|4plants/Azythromycin|Participants received 4Plants powder in a 3.5g tea bag orally three times daily for 10 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days
62376759|NCT02672150|NO_INTERVENTION|Control|During the Baseline Control data is collected in all 36 sites at the agency, staff, and youth level on the 6 months prior to the interventions in Arms 2 \& 3 to document what practice was before the study.
62752630|NCT05660902|NO_INTERVENTION|Control Group|Patients in this group continued their routine medical treatment program without any treatment.
62752631|NCT05660902|EXPERIMENTAL|Intervention Group|Patients in this group continued their routine medical treatment program without any treatment. Moreover, ROM exercises were performed by the researcher and health personnel trained by the researcher 3 times a day for 2 weeks, approximately 30 minutes.
62752632|NCT05768438|EXPERIMENTAL|Mulligan with upper limb movement|"This study arm will receive following therapy~.) Mulligan with upper limb movement."
62376760|NCT02672150|ACTIVE_COMPARATOR|Core|"In the second phase (after baseline) all 36 sites receive a Core condition that includes five interventions: (1) JJ-TRIALS Orientation Meetings, (2) Needs Assessment, (3) Behavioral Health Training, (4) Site Feedback Report, (5) Goal Achievement Training, (6) Monthly Site Check-ins, and (7) Quarterly Reports. As part of Goal Achievement Training, sites receive assistance in using their Site Feedback Reports to select goals to meet their local needs. Sites are trained on using Data-Driven Decision Making (DDDM) to inform decisions (e.g., selecting a goal, monitoring progress) and enlisting DDDM templates and tools (developed as part of the project) to plan and implement proposed changes.~these principles to their improvement efforts during the implementation phase."
62752633|NCT05768438|EXPERIMENTAL|Mckenzie exercises with neural mobilizations|"This study arm will receive following therapy~.) McKenzie exercises with neural mobilizations"
62752634|NCT04398173||Group A (previous negative biopsy)|Men with clinical suspicion of PCa, previous negative prostate biopsy who underwent prostate MRI
62376761|NCT02672150|EXPERIMENTAL|Enhanced|While the core intervention and DDDM are expected to facilitate change, organizations may need additional support to apply these principles to their improvement efforts during the implementation phase. In the third phase (after Core), 1/2 of the sites are randomly assigned to an Enhanced condition that provides continuing support for the use of DDDM tools by adding research staff facilitation of DDDM over a 12-month period and formalized Local Change Teams (LCTs) featuring representation from the JJ agency and a local BH provider, with meetings facilitated by research staff).
62376762|NCT02404909||Patients with liver tumors candidate to hepatectomy|
62376763|NCT02814812|EXPERIMENTAL|pancreatic surgery|
62752635|NCT04398173||Group B (biopsy naive)|Men with clinical suspicion of PCa, no previous negative prostate biopsy who underwent prostate MRI
62752636|NCT02710123|EXPERIMENTAL|Aerobic Exercise|Participants will receive an exercise prescription based on their heart rate threshold (HRT) for symptom exacerbation during the Buffalo Concussion Treadmill Test (BCTT). The script will ask the participant to exercise one a day for 20 minutes at 80% of HRT. Participants will wear a smart watch to monitor their frequency, actual time and HR during exercise. Treatment will continue until participant is fully recovered from their concussion. Intervention: Sub-Threshold exercise prescription
62752637|NCT02710123|PLACEBO_COMPARATOR|Stretching Exercise|Participants will receive a prescription for stretching exercises that they will be asked to do daily. Participants will wear a smart watch to monitor their frequency, actual time and HR during exercise. Treatment will continue until participant is fully recovered from their concussion. Intervention: Structured stretching exercise prescription.
62752638|NCT06608667||Mild ischemia reperfusion injury group(MIRIG)|Suzuki's score of 0 to 2 group were divided into mild ischemia-reperfusion injury group. Subjects matching the characteristics of this group were screened according to inclusion and exclusion criteria, and preoperative and postoperative characteristics of the corresponding recipients and donors were collected and recorded for subsequent analysis.
62376764|NCT01960192|EXPERIMENTAL|FVD regimen|FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
62376765|NCT01960192|EXPERIMENTAL|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
62376766|NCT03628040|SHAM_COMPARATOR|Sham Block|Patient will receive a single shot of normal saline 20 mL injected at the erector spinae plane
62376767|NCT03628040|ACTIVE_COMPARATOR|Erector Spinae Block|Patient will receive a single shot of Ropivacaine Injection \[Naropin\] 0.5% 20 mL injected at the erector spinae plane
62376768|NCT02114918|EXPERIMENTAL|Attention Modification Program|Active computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief. AMP is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word.
62376769|NCT02114918|PLACEBO_COMPARATOR|Attention Control Condition|Control computer-based attention training task, which is not designed to modify biased attention patterns in anxious patients. ACC is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. In this case, the probe randomly replaces the neutral word or the threat word.
62376770|NCT05619432|EXPERIMENTAL|Group A: Clinic Setting|Participants will complete their virtual reality (VR) visual training program by visiting a local clinic and using the head-mounted display (HMD) provided. Participants will receive initial training on using the device and software and are expected to complete their 6-weeks of visual training independently at the clinic. Additional training and FAQ materials will be available on site for participants to use as reference.
62376771|NCT05619432|EXPERIMENTAL|Group B: Home Setting|Participants will complete their virtual reality (VR) visual training program from their own homes using a head-mounted display (HMD) that is on loan for the study. Participants will receive initial training on using the device and software at the clinic and will take home the HMD to complete their 6-weeks of visual training independently from home. Additional training and FAQ materials will be given to participants to use as reference.
62376772|NCT03881644|ACTIVE_COMPARATOR|PACAP38 + Imigran|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Imigran infusion (0.4 mg/min) for 10 mins"
62376773|NCT03881644|PLACEBO_COMPARATOR|PACAP38 + Isotonic Saline|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Isotonic saline for 10 mins (placebo)"
62376774|NCT00914095|ACTIVE_COMPARATOR|methylphenidate|methylphenidate 10 mg tablets (1 mg /kg /day) 3 time a day
62376775|NCT00914095|PLACEBO_COMPARATOR|placebo|tablets of placebo 3 time a day
62376776|NCT05711511|EXPERIMENTAL|coventional obturation technique|In conventional method, paper point will be used to coat the walls of the canal with sealer, Standardized Protaper F-3 master gutta-percha cone will slid to the working length and ISO No.25 finger spreader was applied under vertical loading.The first accessory cone will slid promptly to proper length with a light coating of sealer. Compaction and accessory cone insertion will be continued;each spreader insertion will be seen to be slightly less deep than former, as mirrored by shorter and shorter accessory cone insertion. Condensation continued until the spreader reached 2-3 mm into the canal. Heat will be applied with to the root filling at or below canal orifice level, and the filling will then compacted apically with the help of a cold plugger.
62556070|NCT01358214||Intended to be treated with a mesh|This arm of the study populations is defined by patients in whom a clinical anamnesis independent of the requirements of this study suggests that a sub-urethral sling operation is indicated. These patients will be asked to participate in the validation of the questionnaire on quality of life.
62556071|NCT01358214||Non-symptomatic Population|This arm of the study population is defined by women that show no symptoms of incontinence. They will be asked to participate in the validation of the questionnaire on quality of life.
62556072|NCT03925675|EXPERIMENTAL|Axumin (fluciclovine-F18) PET/CT scan|Axumin (fluciclovine-F18) PET/CT scan to evaluate possible glioma recurrence to help differentiate scar (fake recurrence) from true tumor recurrence
62556073|NCT03707210|EXPERIMENTAL|Intervention|The experimental group uses the VR program to training chemotherapy skill. Use VR software to make a training education program.
62556074|NCT03707210|NO_INTERVENTION|usual care|Chemotherapy training as usual care (for training chemotherapy skill).
62556075|NCT00477880|EXPERIMENTAL|Cetuximab|Cetuximab lV weekly at an initial loading dose of 400 ml/m2, followed by three weekly maintenance doses of 250 mg/m2. Four infusions of C225 will be defined as a course of therapy.
62556076|NCT03989492|EXPERIMENTAL|Autonomic responses to stressors|Protocol 1: mental math and handgrip exercise. Protocol 2: systemic stressors and end-organ receptor stimulation. Protocol 3: local heating.
62376777|NCT05711511|ACTIVE_COMPARATOR|Obtura II|The Obtura II system will be prepared ,sealer will be applied to canal wall . A 23G needle is selected and a stopper will place at 4-6 mm of the WL. The control unit of Obtura II will be on, and the display showed the required temperature of 185°C. The gun will be loaded with a fresh pellet of gutta- percha and plunger will be pushed forward.The needle will be then positioned in the canal so that it reached 3 to 5 mm of the apical preparation. 3-4 mm of the gutta-percha was passively injected without any apical pressure and will be compacted gently with a #11 endodontic plugger. Thus, the apical plug will be created in this manner. A segmental technique will be used in which 3 to 4 mm of gutta-percha will be sequentially injected and compacted. Increments will be added until gutta-percha reached top orifice level, and then compaction will be done with a cold plugger. Excess gutta-percha was severed at or below the orifice level.
62752639|NCT06608667||Severe ischemia reperfusion injury group(SIRIG)|Suzuki's score of 3 to 4 group were divided into severe ischemia-reperfusion injury group. Subjects matching the characteristics of this group were screened according to inclusion and exclusion criteria, and preoperative and postoperative characteristics of the corresponding recipients and donors were collected and recorded for subsequent analysis.
62376778|NCT05129111|ACTIVE_COMPARATOR|STIMULATOR OF THE SALIVARY EXCRETION BASED ON PHYSICAL VIBRATION|Measurement of salivary secretion at rest and stimulated conditions.
62376779|NCT05129111|PLACEBO_COMPARATOR|STIMULATOR OF THE SALIVARY EXCRETION PLACEBO|Measurement of salivary secretion at rest and stimulated conditions.
62376780|NCT04784546||Mild COVID-19 Infection Group|Mild cases present with acute symptoms of respiratory tract infection and gastrointestinal complaints.
62376781|NCT04784546||Moderate COVID-19 Infection Group|Moderate patients experience pneumonia, they don't have clinically aberrant hypoxemia(O2 saturation is more than 90%) but they have positive findings on chest computerized tomography (CT) scans.
62376782|NCT04784546||Severe COVID-19 Infection Group|Severe patients present with pneumonia, they have hypoxemia (O2 saturation is less than 90%) and have positive findings on chest computerized tomography (CT) scans.
62376783|NCT04989140|EXPERIMENTAL|IxaPD|Ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of every 28-day cycle , pomalidomide 25mg qd day 1\~21 of every 28-day cycle, Dexamethasone 40 mg (20 mg for patients \>75 years of age) was given on days 1, 8, 15, and 22 of every 28-day cycle.
62376784|NCT01462422|OTHER|Primary prevention|
62376785|NCT01462422|OTHER|Secondary Prevention|
62376786|NCT01254786|ACTIVE_COMPARATOR|CPAP2 - HFPPV group|the non-dependent lung will be ventilated with CPAP of 2 cm H2O for 30 min followed with HFPPV for min.
62376787|NCT01254786|ACTIVE_COMPARATOR|HFPPV-CPAP2 group|the non-dependent lung will be ventilated with HFPPV for 30 min followed with CPAP of 2 cm H2O for 30 min.
62376788|NCT02254304|EXPERIMENTAL|Rebif in Relapsing Multiple Sclerosis (RMS) Subjects|
62376789|NCT02254304|EXPERIMENTAL|Rebif in Clinically Isolated Syndromes (CIS) Subjects|
62376790|NCT04949308||Genetic diagnosis|Genetic: Genetic diagnosis No Intervention foreseen, but genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD and at least one other method confirming PCD-diagnosis is needed
62376791|NCT04048057|EXPERIMENTAL|Modarete Intensity Continous Training|
62376792|NCT04048057|EXPERIMENTAL|High Intensity Interval Training I|
62752640|NCT04260763|EXPERIMENTAL|Social Cognition Group|Social Cognition Group
62752641|NCT03158012|ACTIVE_COMPARATOR|Active treatment|
62752642|NCT03158012|PLACEBO_COMPARATOR|Placebo treatment|
62752643|NCT01360398|OTHER|Cohort|COPD male and female patients between 40 and 85 years of age, recruited among the patients of the Southampton General Hospital and referring practices.
62752644|NCT00985907|EXPERIMENTAL|Doxil® + Melphalan + Velcade (DMV)|
62376793|NCT04048057|EXPERIMENTAL|High Intensity Interval Training II|
62376794|NCT04807244|OTHER|Treatment of deep carious lesions: Randomized-controlled trail|Teeth with reversible pulpitis will be included accordingly to the inclusion criteria (see below). After randomization, teeth will be treated either with selective caries removal (indirect pulp capping) or partial pulpotomy pursuant to the below described clinical protocol. The intention of this study arm is to evaluate both therapies.
62376795|NCT04807244|OTHER|Treatment of deep carious lesions: Prospective non-controlled intervention trial|Teeth with reversible pulpitis according to the inclusion criteria (see below) will be included. Depending on the clinical situation, a partial or full pulpotomy will be conducted accordingly to the defined clinical protocols (see below). In this study arm, we want to evaluate 1) different times of pulpal bleeding before pulp capping and 2) partial versus full pulpotomy on the clinical outcome in teeth with irreversible pulpitis.
62556077|NCT04164290|ACTIVE_COMPARATOR|treatment group 1|Jiashen tablet, 0.47g, oral, once a day
62556078|NCT04164290|ACTIVE_COMPARATOR|treatment group 2|Jiashen tablet, 0.94g, oral, once a day
62752645|NCT02280902||Patient with immunologic and inflammatory diseases|Patient treated with corticosteroids, immunosuppressive drugs or biotherapy for immunologic and inflammatory diseases
62752646|NCT04700657||15 patients affected by ocular GVHD|
62752647|NCT04700657||15 age-matched normal volunteers.|
62752648|NCT04362371|EXPERIMENTAL|Ainara|"Ainara is a class II medical device, already marketed in several EU countries. The product is a mucoadhesive moisturising gel for vulvovaginal use, indicated for the relief of symptoms of vaginal atrophy and dryness, and related discomfort. In each packaging there is a tube containing the gel (sterile and viscous with about 87% water) and a syringe-like plastic applicator with cannula and plunger.~Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration)."
62752649|NCT04911907|EXPERIMENTAL|Squamous cell carcinoma of head and neck: Utidelone Injection|Cohort 1 Squamous cell carcinoma of head and neck. Participants will be treated with utidelone monotherapy
62752650|NCT04911907|EXPERIMENTAL|Esophageal cancer: Utidelone injection|Cohort 2 Esophageal cancer. Participants will be treated with utidelone monotherapy.
62752651|NCT04911907|EXPERIMENTAL|Stomach cancer: Utidelone injection|Cohort 3 Stomach cancer. Participants will be treated with utidelone monotherapy.
62752652|NCT04911907|EXPERIMENTAL|Pancreatic cancer: Utidelone Injection|Cohort4 Pancreatic cancer. Participants will be treated with Utidelone monotherapy.
62752653|NCT04911907|EXPERIMENTAL|Ovarian cancer: Utidelone Injection|Cohort5 Ovarian cancer. Participants will be treated with Utidelone monotherapy.
62752654|NCT04911907|EXPERIMENTAL|Cholangiocarcinoma: Utidelone|Cohort 6 Cholangiocarcinoma. Participants will be treated with Utidelone monotherapy
62752655|NCT04911907|EXPERIMENTAL|Other solid tumors: Utidelone Injection|Cohort 7 Other solid tumors. Participants will be treated with Utidelone monotherapy
62752656|NCT06605833||2- 10+ years|Patients on routine follow-up, at 2 to 10+ (inclusive) following the completion of immunotherapy treatment for melanoma. These will be looked at in groups of 2 - 4 years, 5 - 7 years and 8 - 10+ years.
62752657|NCT04752137|OTHER|ICG Dye and use of SPY-PHI Imaging|ICG will be administered in the pre-operative unit via IV injection at the time that they present to the pre-operative unit, which is approximately 4 hours before surgery. ICG Angiography (SPY PHI) will be performed to detect any residual signal
62376796|NCT02996240|EXPERIMENTAL|Omega-3 FFA|Patients will take 12 capsules daily with meals, divided twice daily (example, 6 with breakfast and 6 with dinner).
62376797|NCT01563952|ACTIVE_COMPARATOR|Non-IVUS guided endeavor-R group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
62376798|NCT01563952|EXPERIMENTAL|IVUS guided endeavor-R group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
62376799|NCT01563952|ACTIVE_COMPARATOR|Non-IVUS guided Nobori group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
62376800|NCT01563952|EXPERIMENTAL|IVUS guided Nobori group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
62752658|NCT04330833|ACTIVE_COMPARATOR|Enhanced Usual Care Parent Education|Parent(s) and patients receiving care from clinicians whose practice has been randomized to the enhanced usual care parent education group.
62376801|NCT02884193|EXPERIMENTAL|Brief Cooling (Quick Icing)|Group receiving the application of cold on the ventral side of the dominant forearm for 30 seconds, using the technique of ice beakers dynamically.
62376802|NCT02884193|ACTIVE_COMPARATOR|Prolonged Cold|"Group receiving the intervention of ice bag for a period of 5 and a half minutes from 1 minute, on the ventral side of the dominant forearm"
62376803|NCT02884193|SHAM_COMPARATOR|Control|"Group receives a placebo application through an ice bag empty. The bag will be applied from 1 minute to 6 and a half minutes, as the group of prolonged cold"
62376804|NCT05312099||Case group|Women who have entered early menopause (before the age of 40), have chronic systemic diseases (diabetes, heart disease, hypertension, thyroid, rheumatic disease, psychiatric disease history), and use psychiatric drugs were not included in the study.
62376805|NCT05312099||Control group|Women under the age of 45, over the age of 55 with chronic systemic diseases (diabetes, heart disease, hypertension, thyroid, rheumatic disease, psychiatric disease history) and using psychiatric drugs were not included in the study.
62376806|NCT02871791|EXPERIMENTAL|Palbociclib, Everolimus, Exemestane|"* Palbociclib will be administered orally, 100mg, once daily for 21 consecutive days followed by a 7-day rest (28-day cycle)~* Everolimus will be administered orally, 5mg, once daily on a 28 day schedule~* Exemestane will be administered orally, 25mg, once daily on a 28 day schedule"
62556079|NCT04164290|ACTIVE_COMPARATOR|treatment group 3|Jiashen tablet,1.88g, oral, once a day
62556080|NCT04164290|ACTIVE_COMPARATOR|treatment group 4|Jiashen tablet,2.82g, oral, once a day
62556081|NCT04164290|ACTIVE_COMPARATOR|treatment group 5|Jiashen tablet,3.76g, oral, once a day
62556082|NCT04164290|ACTIVE_COMPARATOR|treatment group 6|Jiashen tablet,4.23g, oral, once a day
62556083|NCT04164290|PLACEBO_COMPARATOR|control group 1|Jiashen placebo tablet,0.47g, oral, once a day
62752659|NCT04330833|EXPERIMENTAL|Novel Communication Intervention|Parent(s) and patients receiving care from clinicians whose practice has been randomized to the novel communication intervention group.
62752660|NCT00764387|EXPERIMENTAL|Arm 1|
62752661|NCT00764387|ACTIVE_COMPARATOR|Arm 2|
62752662|NCT00420615|EXPERIMENTAL|Patupilone and Omeprazole|patupiloe + omeprazole
62376807|NCT04050475|EXPERIMENTAL|PSY-FMD|Subjects randomized in the PSY-FMD group carried out the Functional Therapy protocol over 20 individual sessions, which were scheduled twice a week for the first two months and once a week for the last month (three months total). The treatment program was specifically manualized for treating depression with the aim to increase mood, self-esteem and quality of life. Furthermore, patients followed a Fasting Mimicking Diet (FMD) protocol consisting of 3 cycles of 5 days a month each: the first day of the diet provided 1090 kcal (10% protein, 56% fat, 34% carbohydrate), the days 2-5 were identical in the formulation and provided 725 kcal (9-10% protein, 44-56% fat, 34-47% carbohydrate). Between cycles of FMD the subjects stuck to a free diet. At the end of the treatment all patients were re-tested through the same assessment protocol and the same things was realized at the follow-up (three months later the end of the treatment).
62752663|NCT00420615|EXPERIMENTAL|patupilone + midalzolam|patupilone + midalzolam
62752664|NCT01581489||Early cord clamping (ECC)|Early cord clamping consisted of early (=\< 10 s) clamping of the umbilical cord at birth.
62752665|NCT01581489||Delayed cord clamping (DCC)|Delayed cord clamping consisted of delayed (\>= 180 s) clamping of the umbilical cord at birth.
62376808|NCT04050475|NO_INTERVENTION|PSY|Subjects randomized into the control group (PSY) completed the same Functional Therapy program without practicing any diet. Specifically, at the end of the nutritional consultation the nutritionist suggested them to keep a food diary without changing their habitual diet style.
61997501|NCT06368453|NO_INTERVENTION|Mock results interpretation study and Usability evaluation|"A subset of the enrolled subjects (500 subjects) will participate in the mock results interpretation study and usability evaluation. For the mock study, the subjects will be presented with 5 mock INSTI® HIV ST devices with different results, and the subject's interpretation of each device will be recorded. The percentage of subjects who interpreted the mock results correctly for each result type will be calculated.~For the INSTI® HIV ST usability evaluation, the subjects will be presented with a questionnaire. The overall results of the questionnaire will be used to determine the percentage of subjects who found the INSTI® HIV ST easy to use."
62376809|NCT04752631|EXPERIMENTAL|TNK-tPA|TNK-tPA (0.25mg/kg) given as a single bolus over 5-10 seconds immediately upon randomization.
62376810|NCT04752631|NO_INTERVENTION|Routine Therapy|Patients will be treated with standard of care in compliance with guidelines for acute stroke
62376811|NCT02253680|NO_INTERVENTION|Routine care|Wool and crepe bandage for 24 hours post-operatively
62376812|NCT02253680|EXPERIMENTAL|Compression bandage|Actico, inelastic, short-stretch compression bandage worn 24 hours post-operatively
62376813|NCT01578525|NO_INTERVENTION|standard care|Standard care (by German definition), traditional care by physician and nurse on the ward
62376814|NCT01578525|OTHER|Intensified standard care|Intensified standard care: traditional care by physician and nurse, additional pharmaceutical care by a pharmacist during hospitalization
62752666|NCT05750654|EXPERIMENTAL|Small Tube Group|
62752667|NCT05750654|ACTIVE_COMPARATOR|Standard Tube Group|
62556084|NCT04164290|PLACEBO_COMPARATOR|control group 2|Jiashen placebo tablet,0.94g, oral, once a day
62556085|NCT04164290|PLACEBO_COMPARATOR|control group 3|Jiashen placebo tablet,1.88g, oral, once a day
62752668|NCT04385238||Pregnant Women|Pregnant women who are 18 years of age or older.
62752669|NCT04385238||Post-partum women|Women who gave birth within the last 6 months who are 18 years of age or older.
62752670|NCT04384601|EXPERIMENTAL|SOX Chemotherapy|"Three preoperative and three postoperative cycles of SOX chemotherapy~A cycle consist of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily)~Repeated every 21st day"
62752671|NCT04384601|ACTIVE_COMPARATOR|FLOT Chemotherapy|"Four preoperative and four postoperative cycles of FLOT chemotherapy~A cycle consist of Day 1 5-fluorouracil(5-FU) 2600mg/M2 administered via intravenous peripherally inserted central venous catheter(PICC) for 24 hour Leucovorin 200mg/M2 intravenous Oxaliplatin 85mg/ M2 intravenous Docetaxel 50mg/M2 intravenous~Repeated every 15th day"
62556086|NCT04164290|PLACEBO_COMPARATOR|control group 4|Jiashen placebo tablet,2.82g, oral, once a day
62556087|NCT04164290|PLACEBO_COMPARATOR|control group 5|Jiashen placebo tablet,3.76g, oral, once a day
62376815|NCT04918069|EXPERIMENTAL|Capsaicin|2g of 0.075% topical capsaicin ointment applied four times daily (preferably to the abdomen) for the first five days of chemotherapy
62376816|NCT04918069|PLACEBO_COMPARATOR|Placebo|2g of topical placebo ointment applied four times daily (preferably to the abdomen) for the first five days of chemotherapy
62376817|NCT03612674|ACTIVE_COMPARATOR|Standard colonoscopy (S)|A standard colonoscopy will be performed.
62376818|NCT03612674|EXPERIMENTAL|AEV assisted colonoscopy (E)|Colonoscopy with ARC Endocuff Vision attached to the top of the scope will be performed.
62376819|NCT00590941|NO_INTERVENTION|R-CHOP|Patients receiving R-CHOP via standard of care which consists of cyclophosphamide 750 mg/m2 IV day 1 of each 21 day cycle, doxorubicin 50 mg/m2 IV day 1 of each 21 day cycle, vincristine 1.4 mg/m2 IV day 1 of each 21 day cycle, prednisone 100 mg PO days 1-5 of each 21 day cycle, and rituximab 375 mg/m2 IV day 1 of each 21 day cycle.
62752672|NCT03263923|EXPERIMENTAL|Arm 1: Cognitive behavioral skills training & 4 wks online journaling|"Cognitive behavioral skills' training and 4 weeks of online journaling.~Participants receive cognitive behavioral skills training by online video, then participants must complete a 28 day online journal reflecting on the cognitive skills they used to handle various situations."
62752673|NCT03263923|ACTIVE_COMPARATOR|Arm 2: Reflective journaling training & 4 wks online journaling|"Reflective journaling training and 4 weeks of online journaling.~Participants watch a reflective journaling video and complete a 28 day journal using a different set of prompts to reflect on their days and describe how they handled various situations."
62376820|NCT01138462|NO_INTERVENTION|Standard Precautions|control arm, standards precautions for all residents living in the nursing home of control arm, including MRSA carriers
62752674|NCT03788018|EXPERIMENTAL|Effect of IV lidocaine and dexmedetomidine on PONV|
62752675|NCT03788018|EXPERIMENTAL|Effect of IV saline on PONV|
62752676|NCT02439450|EXPERIMENTAL|Arm 5: Viagenpumatucel-L + Nivolumab CPI Naive|Patients naïve to checkpoint inhibitor (CPI) therapy will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/ 0.5 mL for 18 weeks and bi-weekly nivolumab infusions. After 18 weeks of treatment, patients will continue on monotherapy standard of care nivolumab until confirmed disease progression or unacceptable toxicity, whichever occurs first. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
62376821|NCT01138462|OTHER|Intervention|Intervention arm, standards precautions for all residents living in nursing homes of intervention arm, and topical decolonization for MRSA carriers, including environmental disinfection
62376822|NCT06074133||Indeterminate Pulmonary Nodules|A combined biomarker model (hs-CYFRA 21-1, radiomics, Mayo) score will be obtained to estimate potential clinical utility compared to the Mayo Model.
62556088|NCT04164290|PLACEBO_COMPARATOR|control group 6|Jiashen placebo tablet,4.23g, oral, once a day
62752677|NCT02439450|EXPERIMENTAL|Arm 6: Viagenpumatucel-L + pembrolizumab|HS-110 dosing to be initiated at/before the start of the 3rd maintenance treatment cycle, or within 19 weeks of front-line pembrolizumab monotherapy. Patients will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/0.5 mL for 13 weeks in combination with SOC pembrolizumab every 3 weeks. Following the 13-week priming period, HS-110 injections will be administered for boosting every 3 weeks in combination with SOC pembrolizumab until confirmed disease progression or unacceptable toxicity, whichever occurs first.
62752678|NCT02439450|EXPERIMENTAL|Arm 5: Viagenpumatucel-L + Nivolumab CPI Progressor|Patients with prior checkpoint inhibitor (CPI) therapy will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/ 0.5 mL for 18 weeks and bi-weekly nivolumab infusions. After 18 weeks of treatment, patients will continue on monotherapy standard of care nivolumab until confirmed disease progression or unacceptable toxicity, whichever occurs first. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
62752679|NCT02439450|EXPERIMENTAL|Arm 6: Viagenpumatucel-L + pembrolizumab + pemetrexed|HS-110 dosing to be initiated at/before the start of the 3rd maintenance treatment cycle, or within 19 weeks of front-line pembrolizumab monotherapy. Patients will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/0.5 mL for 13 weeks in combination with SOC pembrolizumab + pemetrexed every 3 weeks. Following the 13-week priming period, HS-110 injections will be administered for boosting every 3 weeks in combination with SOC pembrolizumab + pemetrexed until confirmed disease progression or unacceptable toxicity, whichever occurs first.
62752680|NCT05582850|EXPERIMENTAL|DT-9081|Capsule, 25 mg, 50 mg and 100 mg
62752681|NCT06606470|EXPERIMENTAL|Intervention|Full ABCs education program
62752682|NCT06606470|NO_INTERVENTION|Control|No ABCs education program
62752683|NCT05232968|EXPERIMENTAL|Elderly volunteers participating in the long-term exercise program|Elderly volunteers will be recruited from participants in the long-term exercise program (ongoing since 2017) at the Center of Physical Activity BMC SAS in Bratislava.
62752684|NCT05232968|NO_INTERVENTION|Elderly sedentary volunteers|Control population will be recruited from the sedentary elderly, who dropped out from the exercise program ≥2 years prior entering this study and do not exercise on regular basis.
62752685|NCT05232968|EXPERIMENTAL|Elderly volunteers participating in the short-term exercise program|Elderly volunteers will follow 4-month of aerobic-strength training intervention and exercise induced effects on mild cognitive impairment will be determined afterwards.
62752686|NCT03651856|EXPERIMENTAL|Atomoxetine|Atomoxetine 40mg daily for 2 weeks uptitration Atomoxetine 40mg BID for 4 weeks Atomoxetine 40mg daily for 1 week weaning off
62752687|NCT05051631|EXPERIMENTAL|Intervention plus 12 months maintenance|Clinics in this group will be in the control phase for 2 months, receive the 4 month intervention, and be in the maintenance phase for 12 months.
62752688|NCT05051631|EXPERIMENTAL|Intervention plus 10 months maintenance|Clinics in this group will be in the control phase for 4 months, receive the 4 month intervention, and be in the maintenance phase for 10 months.
62752689|NCT05051631|EXPERIMENTAL|Intervention plus 8 months maintenance|Clinics in this group will be in the control phase for 6 months, receive the 4 month intervention, and be in the maintenance phase for 8 months.
62752690|NCT05051631|EXPERIMENTAL|Intervention plus 6 months maintenance|Clinics in this group will be in the control phase for 8 months, receive the 4 month intervention, and be in the maintenance phase for 6 months.
62752691|NCT05051631|EXPERIMENTAL|Intervention plus 4 months maintenance|Clinics in this group will be in the control phase for 10 months, receive the 4 month intervention, and be in the maintenance phase for 4 months.
62752692|NCT00011414|EXPERIMENTAL|1|Intervention given with dose escalation of tariquidar
62752693|NCT04494347|EXPERIMENTAL|Treatment Group|This is not a randomized study. Patients who are clinically indicated for both procedures will be offered the option to enroll in this registry for a combined procedure. Otherwise, they will undergo TMVr and LAAO in two separate session as clinically indicated (standard of care).
62752694|NCT02789423|ACTIVE_COMPARATOR|Dycal|Intervention: drug: Dycal, Other names: Calcium Hydroxide. Intervention Description:DPC using Dycal for direct pulp exposure was performed in 30 primary molar teeth after proper case selection.Clinical and radiographic evaluation was done.One month post operative criteria evaluated were-Clinical criteria:Spontaneous pain,Defective restoration/Recurrent caries,Sinus formation,TOP,Soft tissue swelling \& Mobility. Radiographic criteria:Defective restoration/Recurrent caries,Periapical or furcal radiolucency,Pathological internal resorption,Replacement resorption,Intracanal calcification \& Physiological resorption.The follow-up was at 3 and 6 months.
62752695|NCT02789423|ACTIVE_COMPARATOR|Biodentine|Intervention: drug: Biodentine, Other names: Calcium Silicate. Intervention Description:DPC using Biodentine for direct pulp exposure was performed in 30 primary molar teeth after proper case selection.Clinical and radiographic evaluation was done.One month post operative criteria were-Clinical criteria:Spontaneous pain,Defective restoration/Recurrent caries,Sinus formation,TOP,Soft tissue swelling \& Mobility.Radiographic criteria:Defective restoration/Recurrent caries, Periapical or furcal radiolucency,Pathological internal resorption,Replacement resorption,Intracanal calcification \& Physiological resorption.The follow-up was at 3 and 6 months.
62752696|NCT05997095|ACTIVE_COMPARATOR|30Hz (low-intensity)|"Volunteers receive 30 mins of neuromuscular electrical stimulation at 30Hz with a contraction pattern of 1 second on and 1 second off"
62752697|NCT05997095|EXPERIMENTAL|100Hz (higher-intensity)|"Volunteers receive 30 mins of neuromuscular electrical stimulation at 100Hz with a contraction pattern of 1 second on and 1 second off"
62376823|NCT05597111||Blood DHA levels of patients with PCOS|The patients diagnosed as PCOS according to Rotterdam criteria will be the study group. The DHA leves in blood sample of the patients will be recorded
62376824|NCT05597111||BloodDHA levels of the control group|The patients without PCOS will be control group. The DHA leves in blood sample of the patients will be recorded
62376825|NCT03656146|ACTIVE_COMPARATOR|Tablet Screening|Food insecurity screening conducted via electronic tablet
62376826|NCT03656146|ACTIVE_COMPARATOR|Verbal Screening|Food insecurity screening conducted via verbal face-to-face interview
62376827|NCT00261378|ACTIVE_COMPARATOR|Transarterialchemoembolisation (TACE)|Conventional TACE with doxorubicin
62376828|NCT00261378|OTHER|DC Bead|DC Bead with doxorubicin
62752698|NCT05997095|EXPERIMENTAL|30Hz (low-intensity, 3:1)|"Volunteers receive 30 mins of neuromuscular electrical stimulation at 30Hz with a contraction pattern of 3 seconds on and 1 second off"
62752699|NCT05989087||Early-onset Alzheimer's disease|Patients were recruited from the outpatient memory clinics of the Department of Neurology, Dokuz Eylül University Hospital. The patient group was diagnosed by an expert neurologist, according to the National Institute on Aging-Alzheimer's Association diagnostic criteria for Alzheimer's disease
62752700|NCT05989087||Healthy controls|Age-and gender-matched healthy volunteers were recruited via advertisements and word-of-mouth.
62752701|NCT03496233|EXPERIMENTAL|All patients included|All patients included will be treated with Elbasvir/grazoprevir for 8 weeks
62752702|NCT05022199|EXPERIMENTAL|Study Arm: SPY fluorescent angiography|
62752703|NCT05022199|NO_INTERVENTION|Historic Control Arm: Urinary diversion without the use of SPY|This arm consists of 215 historic controls who have undergone urinary diversion at UVA from 2015-2020 without the use of SPY fluorescent angiography
62752704|NCT03155919|EXPERIMENTAL|TAUchoc|Treatment composed by taurine powder and chocolate milk
62752705|NCT03155919|PLACEBO_COMPARATOR|PLAchoc|Treatment composed by placebo (starch powder) and chocolate milk
62752706|NCT00849615|EXPERIMENTAL|FLOT|
62752707|NCT02324140||Minimized extracorporeal circulation|Patients with severe aortic valve stenosis undergoing surgical aortic valve replacement using the minimized extracorporeal circulation (MECC, group 1)
62752708|NCT02324140||Conventional extracorporeal circulation|Patients with severe aortic valve stenosis undergoing surgical aortic valve replacement using the conventional extracorporeal circulation (CECC, group 2)
62752709|NCT02324140||Transcatheter aortic valve implantation, transfemoral access|Patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation using the transfemoral access route
62752710|NCT02324140||Transcatheter aortic valve implantation, transapical access|Patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation using the transapical access route
62556089|NCT02467140|ACTIVE_COMPARATOR|Self-fixating mesh|During surgery, the Parietex ProGrib mesh will be used.
62556090|NCT02467140|ACTIVE_COMPARATOR|Tack fixation|During surgery, the mesh will be fixated with tacks.
62556091|NCT05473494|EXPERIMENTAL|training group|
62556092|NCT05473494|ACTIVE_COMPARATOR|control group|
62376829|NCT06348862|EXPERIMENTAL|Listening to Quran|Listening to Quran during MRI
62376830|NCT06348862|EXPERIMENTAL|Listening to Music|Listening to Music during MRI
62376831|NCT06348862|EXPERIMENTAL|Listening to Natural Sound|Listening to Natural Sound during MRI
62376832|NCT06348862|NO_INTERVENTION|Listening to nothing|Listening to nothing during MRI
62376833|NCT01632553||Cases|women who have experienced DVA
62556093|NCT04109586|EXPERIMENTAL|Personalized nutrition therapy|Dietitian led assessment and individual nutritional therapy during inpatient rehabilitation with follow-up the first year after injury
62556094|NCT04109586|NO_INTERVENTION|Standard treatment|Standard treatment includes dietitian-led group session on nutrition after SCI and patient visits / consultations on request from doctor.
62376834|NCT01632553||Controls|women who have not experienced DVA
62376835|NCT05815862|EXPERIMENTAL|AL2846 capsule|orally administer AL2846 capsules monotherapy, 28 days as a treatment cycle.
62556095|NCT04629378|EXPERIMENTAL|Meropenem and amoxicillin/clavulanate plus pyrazinamide|Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus pyrazinamide 20-30 mg/kg orally once daily. All study treatments will be administered for 14 consecutive days.
62556096|NCT04629378|EXPERIMENTAL|Meropenem and amoxicillin/clavulanate plus bedaquiline|Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus bedaquiline 400 mg orally once daily. All study treatments will be administered for 14 consecutive days.
62752711|NCT03204799||normal group|normal group (without diabetes diagnosis/treatment and in normoglycemia
62752712|NCT03204799||prediabetes|high risk, impaired fasting glucose, impaired glucose tolerance
62752713|NCT03204799||drug naive type 2 diabetes|type 2 diabetes, anti-hypoglycemic drug naive
62752714|NCT03204799||type 2 diabetes with metformin monotherapy|type 2 diabetes with metformin monotherapy
62752715|NCT03204799||type 2 diabetes with SGLT2 inhibitor monotherapy|type 2 diabetes with SGLT2 inhibitor monotherapy
62752716|NCT03204799||dyslipidemia with ezetimibe therapy|dyslipidemia with ezetimibe therapy
62752717|NCT06608810|OTHER|Comparison of efficacy in pectoral nerve block type II, thoracic paravertebral block, and general an|
62752718|NCT05770934|EXPERIMENTAL|home-based BFRE|"Patients in the home-based BFRE group will be carefully instructed in how to perform the exercise program with four weekly sessions for 12 weeks (48 training sessions within an 84-day period). Each session will consist of one lower-limb resistance training exercise: sit-to-stand from a \~43 cm high chair. The exercise will consist of four rounds interspaced by a 30-seconds rest pause. The first, second, and third round will consist of 30, 15, 15 repetitions, while the fourth round will be performed until volitional fatigue. The patients will be instructed to perform both the eccentric and concentric contractions at a steady 2-sec pace with, preferably, no time for relaxation in the transition from eccentric to concentric phase (i.e. the bottom is only kissing the chair before reversing the movement upwards). When a patient can perform more than 25 repetitions in the last round, they are encouraged to add external resistance corresponding to around 5 kg."
62752719|NCT05770934|NO_INTERVENTION|Control Group|Patients in the control group will performed the same tests 12 months after surgery and 15 months after surgery as the intervention home-based BFRE group.
62752720|NCT05614908||Patients with Achilles tendon rupture|Patients treated non-surgically at Aarhus University Hospital from 2022 to approximately 2028. Comparing an 8 week liberal regime wtih an 11 week restrictive regime.
62752721|NCT02701777|ACTIVE_COMPARATOR|STDP|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
62752722|NCT02701777|ACTIVE_COMPARATOR|STDP + Training|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time. Motor training will follow paired stimulation.
62556097|NCT04629378|ACTIVE_COMPARATOR|Rifafour standard of care treatment|Rifafour e275® administered orally once daily for 14 consecutive days. Rifafour e275® will be administered according to the South African National TB Treatment Guidelines. The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
62752723|NCT02701777|ACTIVE_COMPARATOR|Sham STDP + Training|Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times. Motor training will follow stimulation.
62752724|NCT02701777|OTHER|Multisite-STDP + Training|Prospective Single Cohort Multisite-Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time. Motor training will follow paired stimulation.
62752725|NCT01673815|EXPERIMENTAL|1st: R eye video. 2nd: L eye no video|The right eye will be examined first with video, followed by the left eye without video.
62752726|NCT01673815|EXPERIMENTAL|1st: R eye no video. 2nd: L eye video|The right eye will be examined without video, followed by the left eye with video.
62752727|NCT01673815|EXPERIMENTAL|1st: L eye video. 2nd: R eye no video|The left eye will be examined first with video, followed by the right eye without video.
62752728|NCT01673815|EXPERIMENTAL|1st: L eye no video. 2nd: R eye video|The left eye will be examined first without video, followed by the right eye with video.
62752729|NCT02388035|EXPERIMENTAL|SBP-group 1|Spontanous bacterial peritonitis
62752730|NCT02388035|EXPERIMENTAL|CNNA-group 2|Culture negative neutrocytic ascites
62752731|NCT02388035|EXPERIMENTAL|MNBA-group 3|monomicrobial non-neutrocytic ascites
62376836|NCT02520141|EXPERIMENTAL|Treatment (ramucirumab)|Patients receive ramucirumab IV over 60 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62376837|NCT02902692|EXPERIMENTAL|Brief Mindfulness|45 minute brief mindfulness intervention (lead by study investigator) on day 1 followed by 7 days of 30 minute mindfulness practice at home (without study investigator)
62376838|NCT04829864|EXPERIMENTAL|STEP|Participants will participate, online or in-person, to the 8-9 sessions of the program addressing the psychological experience of pregnancy and supporting reflective capacities in relation to trauma and motherhood.
62376839|NCT04829864|NO_INTERVENTION|Usual prenatal cares|Participants of the comparison group will receive usual prenatal cares (ex. prenatal classes)
62556098|NCT03338634||Children 6 to 10|Children must be between the ages of 6-10 years-old at the time they participate. All children will be physically healthy and without diagnosed learning disorders. A parent or legal guardian must be able to accompany the child.
62556099|NCT02653248|EXPERIMENTAL|Cohort 1|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 8Gy. Total Dose: 40Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
62752732|NCT02388035|NO_INTERVENTION|group 4|no evidence of ascitic fluid infection
62752733|NCT03440918|ACTIVE_COMPARATOR|Baseline Antimicrobial Stewardship|Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
62752734|NCT03440918|EXPERIMENTAL|Procalcitonin-Guided Antimicrobial Stewardship|In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
62752735|NCT04051385|ACTIVE_COMPARATOR|stage II grade B periodontitis|"GCF and serum samples were taken before and after treatment from stage II grade B periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
62752736|NCT04051385|ACTIVE_COMPARATOR|stage III grade B periodontitis|"GCF and serum samples were taken before and after treatment from stage III grade B periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
62752737|NCT04051385|ACTIVE_COMPARATOR|gingivitis|"GCF and serum samples were taken before and after treatment from gingivitis patients.~Intervention: Non- surgical periodontal treatment (Scaling and oral hygiene instructions)"
62752738|NCT04051385|PLACEBO_COMPARATOR|periodontally healthy|GCF and serum samples were taken at baseline from periodontally healthy individuals.
62376840|NCT02060903|ACTIVE_COMPARATOR|Abametapir Lotion 0.74% w/w|Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.
62376841|NCT02060903|PLACEBO_COMPARATOR|Vehicle Lotion|Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.
62376842|NCT03885674|EXPERIMENTAL|Reminder Interventions|Receive daily reminders from Kessler Foundation study personnel on when to take their medication.
62752739|NCT05573750|EXPERIMENTAL|Intervention|Singing groups with an instrument
62752740|NCT05573750|OTHER|Control (delayed intervention)|Delayed comparator
62752741|NCT03256903|EXPERIMENTAL|Methoxyflurane|Patients will be supplied with up to two inhalers containing 3 mL methoxyflurane. A member of the research team will train the patient to self-administer methoxyflurane
62752742|NCT03256903|ACTIVE_COMPARATOR|Standard of Care (SoC)|Patients will be treated following standard of care (SoC) of the hospital, for emergency relief of trauma and associated pain. Any kind of analgesia administered by any route will be valid. Only administration of one analgesic (or fixed combinations) at baseline will considered SoC. Other required analgesics will be considered rescue medication.
62376843|NCT03885674|NO_INTERVENTION|Standard Condition|This group will not receive reminders on when to take their medication from Kessler Foundation staff and will receive the usual and standard care.
62376844|NCT02080494|NO_INTERVENTION|Control|No tranexamic acid given
62376845|NCT02080494|EXPERIMENTAL|Tranexamic Acid|15 mg/kg preoperative IV dose followed by another 15 mg/kg IV dose three hours after the initial dose
62376846|NCT05223686|EXPERIMENTAL|Human CD19-CD22 Targeted T Cells Injection|Single administration：1.0×10\^6 CAR+T, 3.0×10\^6 CAR+T，6.0×10\^6 CAR+T
62376847|NCT05655416|OTHER|Lower limb varicose vein|
62376848|NCT05637541|EXPERIMENTAL|Low-dose group|Drug 1 is a vial of 130 tablets of the experimental drug, and drug 2 is a vial of 130 tablets of the placebo
62376849|NCT05637541|EXPERIMENTAL|High-dose group|Drug 1 and 2 are each a vial of 130 tablets of the experimental drug
62376850|NCT05637541|PLACEBO_COMPARATOR|Placebo group|Drug 1 and drug 2 are each a vial of 130 tablets of the placebo
62376851|NCT02300844|EXPERIMENTAL|NNC0174-0833 10 mg/mL|
62752743|NCT03394599|ACTIVE_COMPARATOR|TheraTrainer Only|The 30 clients (15 per site) will have the opportunity to engage in cycling on the TheraTrainer only for the duration of their participation at the Geriatric program. Their carers will also be recruited.
62376852|NCT02300844|PLACEBO_COMPARATOR|Placebo|
62376853|NCT00857116|ACTIVE_COMPARATOR|Albendazole|Albendazole 400mg per os once daily for three consecutive days
62376854|NCT00857116|PLACEBO_COMPARATOR|Placebo|Placebo 400mg per os for three consecutive days
62752744|NCT03394599|EXPERIMENTAL|TheraTrainer + Motiview|The 30 clients (15 per site) will have the opportunity to engage in cycling on the TheraTrainer with the addition of Motiview (engaging videos to watching while cycling). Their carers will also be recruited.
62376855|NCT00205374|ACTIVE_COMPARATOR|Cidofovir|"Cidofovir (Vistide) is a commercially available agent approved by the FDA for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). The drug is not FDA approved for the treatment of RRP at this time. However, recent case reports have been encouraging with regard to the effectiveness of the agent in the treatment of RRP. The FDA has granted this study a safe to proceed designation with IND 58,481."
62752745|NCT01045941|EXPERIMENTAL|Patients with distal pancreatic cancer|Patients with distal pancreatic cancer amenable to a laparoscopic distal pancreatectomy
62752746|NCT03511508|ACTIVE_COMPARATOR|ChroPreg|The participants in the intervention Group receive the midwife-coordinated, individualized and specialized intervention plus standard care
62376856|NCT00205374|PLACEBO_COMPARATOR|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
62376857|NCT02208505|EXPERIMENTAL|Dexmedetomidine|we administrate the single-dose dexmedetomidine (0.5mcg/kg) with low-dose remifentanil infusion(TCI 1 ng/ml).
62752747|NCT03511508|NO_INTERVENTION|Standard care alone|"Participants in the control group receive the standard care for pregnant women with chronic disease.~The standard care is given to the participants in the control group. The standard care for pregnant women with chronic disease include five routine visits at a non-specialized midwife and an individually scheduled number of visits with an obstetrician, depending on the type and severity of the chronic Medical disease and possible pregnancy complications.~The women in the control Group have the same amount of ultrasound examinations as do the women in the intervention Group.~Women in the control Group can attend auditorium antenatal classes at the hospital."
62752748|NCT00091130|EXPERIMENTAL|Arm I (SGN-00101)|Patients receive SGN-00101 vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.
62752749|NCT00091130|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.
62752750|NCT00792662|EXPERIMENTAL|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
62752751|NCT00792662|PLACEBO_COMPARATOR|Placebo|Standard inactive pill.
62752752|NCT04215939|EXPERIMENTAL|Cold environment participants with spinal cord injury|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
62752753|NCT04215939|EXPERIMENTAL|Thermoneutral environment participants with spinal cord injury|In a thermoneutral enviroment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
62376858|NCT02208505|ACTIVE_COMPARATOR|Remifentanil|we administrate the high-dose remifentanil infusion(TCI 2 ng/ml) alone.
62376859|NCT05700760|EXPERIMENTAL|ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns)|Evidence-based 5 session psychosocial intervention that has been found to prevent \~50% of postpartum depression among low-income, at risk women.
62556100|NCT02653248|EXPERIMENTAL|Cohort 2|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 9Gy. Total Dose: 45 Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
62752754|NCT04215939|EXPERIMENTAL|Warm environment participants with spinal cord injury|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
62752755|NCT04215939|ACTIVE_COMPARATOR|Cold environment healthy male participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
62752756|NCT04215939|ACTIVE_COMPARATOR|Thermoneutral environment healthy male participants|In a thermoneutral enviroment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
62752757|NCT04215939|ACTIVE_COMPARATOR|Warm environment healthy male participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
62752758|NCT04215939|ACTIVE_COMPARATOR|Cold environment healthy female participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
62556101|NCT02653248|EXPERIMENTAL|Cohort 3|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 10Gy. Total Dose: 50Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
62376860|NCT05700760|ACTIVE_COMPARATOR|Enhanced Care as Usual (CAU)|Usual care at the study site does not include postpartum depression prevention. Instead, HFHS clinics try to screen for PPD that has already occurred and refer women for mental health care. Screening for existing PPD at these clinics primarily relies on the EPDS (10+), Perinatal women who score 10+ on the EPDS are referred for mental health services. Services received depends on follow-up, severity, and the mental health wait list. Our study will exclude women meeting criteria for likely current major depressive episode at baseline and assist them in obtaining mental health care. Enhanced CAU consists of usual care + monitoring and emergency referral, as is required to fulfill ethical obligations to trial participants.
62376861|NCT01427127|EXPERIMENTAL|ramosetron|Patients received intravenous ramosetron 0.3 mg at the end of surgery and 24hr after surgery.
62376862|NCT01427127|PLACEBO_COMPARATOR|Normal saline|Patients received intravenous normal saline at end of surgery and 24hr after surgery.
62752759|NCT04215939|ACTIVE_COMPARATOR|Thermoneutral environment healthy female participants|In a thermoneutral enviroment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
62752760|NCT04215939|ACTIVE_COMPARATOR|Warm enviroment healthy fmale participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
62376863|NCT02371694|EXPERIMENTAL|Fat Test drink (50g)|This drink contains 50g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
62752761|NCT06326619||SYST|Systemic treatment only. Systemic treatment was defined as the application of chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis (definition for both groups)
62752762|NCT06326619||PTR+SYST|primary tumor resection and systemic treatment At least one of the following surgical procedures were performed: German procedure codes OPS 5-455.\*, 5-456.\*, 5-484.\*, 5-485.\*
62752763|NCT01559259|EXPERIMENTAL|Ibuprofen/acetaminophen (lower dose)|
62752764|NCT01559259|EXPERIMENTAL|Ibuprofen/acetaminophen (middle dose)|
62752765|NCT01559259|EXPERIMENTAL|Ibuprofen/acetaminophen (high dose)|
62752766|NCT01559259|ACTIVE_COMPARATOR|Ibuprofen|
62752767|NCT01559259|PLACEBO_COMPARATOR|Placebo|
62376864|NCT02371694|EXPERIMENTAL|Fat Test drink (38g)|This drink contains 38g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
62376865|NCT02371694|EXPERIMENTAL|Fat Test drink (25g)|This drink contains 25g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
62376866|NCT02371694|EXPERIMENTAL|Fat Test drink (13g)|This drink contains 13g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
62376867|NCT02371694|PLACEBO_COMPARATOR|Fat Test drink (3g)|This drink contains no sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
62376868|NCT02371694|ACTIVE_COMPARATOR|Carbohydrate Test drink|This drink contains 20g of glucose from de-gassed lucozade energy.
62376869|NCT05659940||Healthy people|Healthy participants whose age and gender are consistent with CNV patients
62376870|NCT05659940||CNV patients|Patients who are diagnosed ocular chemical injury coming to Zhongshan Eye Center, Sun Yat-sen University for medical care
62376871|NCT04212611|EXPERIMENTAL|Group L|Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% levobupivacaine (group L)
62376872|NCT04212611|EXPERIMENTAL|Group R|Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% ropivacaine (group R).
62752768|NCT05877027|ACTIVE_COMPARATOR|Intervention Group 1|The patients in the Exercise group will be treated with a structured exercise program. The exercises will be applied by the research physiotherapist for 6 weeks, 2 days a week. Each training session is planned to last approximately 30 minutes.
62752769|NCT05877027|ACTIVE_COMPARATOR|Intervention Group 2|The patients in the topical agent group were prescribed by the orthopedist. they will use the topical agent. Diclofenac in gel form was chosen as a topical agent in the light of the literature. In this context, patients in both groups will apply the topical agent around the knee joint 4 days a week, 2 times a day (every 12 hours) in the morning and evening for 6 weeks.
62376873|NCT05124067|EXPERIMENTAL|Group A (DEXA)|patients will receive dexamethasone (0.15 mg/kg IV; maximum 5 mg)
62376874|NCT05124067|EXPERIMENTAL|Group B (ONDAN)|patients will receive ondansetron (0.05 mg/kg IV; maximum 4 mg)
62752770|NCT05877027|ACTIVE_COMPARATOR|Intervention Group 3|The PRP procedure with the same characteristics will be used in the treatment of patients in the PRP group. The PRP application will be prepared by the orthopedics and traumatology specialist physician in the research team, using the kits provided within the scope of the project. In order to collect venous blood for the PRP production procedure, gamma sterile vacuum tubes and blood collection set in special kits without the risk of contamination will be used. A total of 3 doses will be administered to the patients, with a one-week interval between doses.
62376875|NCT05124067|EXPERIMENTAL|Group C (DEXMED)|Patients will receive dexmedetomidine (0.3 μg/kg)
62752771|NCT02662153||Long-term opioid-use cohort|Persons who have received 70 or more days of Schedule II opioid dispensed in a 90-day period, after at least 183 days with no opioid dispensing.
62376876|NCT05124067|PLACEBO_COMPARATOR|Group D (CONTROL)|patients will receive normal saline
62752772|NCT02662153||IR/SA to ER/LA Switchers|Persons who have switched to or added on an ER/LA product after stable use of an IR/SA opioid regimen.
62376877|NCT02802657|EXPERIMENTAL|Conbercept 0.5mg Treat-and-Extend regimen|"Monthly intravitreal injections of Conbercept 0.5mg in the core treatment period and Treat-and-Extend Regimen of the same dose guided by BCVA stabilization and optical coherence tomography (OCT) in the extension treatment period.~Intervention: Drug: Conbercept"
62376878|NCT02802657|ACTIVE_COMPARATOR|Conbercept 0.5mg Pro Re Nata|"Monthly intravitreal injections of Conbercept 0.5mg in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization in the extension treatment period.~Intervention: Drug: Conbercept"
62376879|NCT03537001||Penthrox|Administration of Penthrox at the beginning of the management of the traumatized adult patient
62376880|NCT01126281|EXPERIMENTAL|Floseal use|
62376881|NCT02950311|EXPERIMENTAL|Intranasal xylitol spray|Two sprays each nostril, twice a day.
62376882|NCT02950311|PLACEBO_COMPARATOR|Intranasal saline spray|Two sprays each nostril, twice a day.
62376883|NCT01018615|EXPERIMENTAL|low dose silymarin and low dose EGCG|
62376884|NCT01018615|EXPERIMENTAL|high dose silymarin and low dose EGCG|
62376885|NCT00781183|EXPERIMENTAL|pulmonary rehabilitation|patients that are enrolled in pulmonary rehabilitation
62376886|NCT03998995|EXPERIMENTAL|IVR rehabilitation game intervention|Clinical trial patients' use the IVR rehabilitation game for two 15 minute sessions during one physical therapy session with their usual practitioner, with support from the physiotherapist and the game expert on the team.
62376887|NCT05265585||Echocardiography group|
62752773|NCT02662153||IR/SA to IR/SA Switchers|Persons who have switched to or added on a new IR/SA opioid after stable use of a different IR/SA opioid regimen.
62752774|NCT05781061|EXPERIMENTAL|Asynchronous Screening|Participants will be screened for medication abortion eligibility using written or online materials and questionnaires, without a synchronous conversation between the prescribing clinician and the patient.
62752775|NCT02228226||MG-1treated group|MG-1treated group: Patients those who underwent arthroscopic Bankart repair for glenohumeral instability using MG-1
62752776|NCT03284333|EXPERIMENTAL|other|no arm
62752777|NCT00824551|EXPERIMENTAL|Hyperbaric Oxygen Therapy|2 HBOT treatments
62752778|NCT00824551|ACTIVE_COMPARATOR|2|Standard care and treatment
62752779|NCT02099344|ACTIVE_COMPARATOR|Artegraft|Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
62752780|NCT02099344|ACTIVE_COMPARATOR|Propaten|Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
62376888|NCT05000866|NO_INTERVENTION|CHTC as usual|Participants complete the standard Couples HIV Testing and Counseling session (CHTC).
62376889|NCT05000866|ACTIVE_COMPARATOR|CHTC and communications skills training video|Participants complete the standard Couples HIV Testing and Counseling session and also watch a communication skills training video together.
62376890|NCT05000866|ACTIVE_COMPARATOR|CHTC and substance use module|Participants complete the standard Couples HIV Testing and Counseling session and also complete a substance use module together.
62376891|NCT05000866|ACTIVE_COMPARATOR|CHTC, communications skills training and substance use module|Participants complete the standard Couples HIV Testing and Counseling session and watch a communication skills training video and complete a substance use module together.
62376892|NCT03733249|EXPERIMENTAL|Rimiducid and Rivogenlecleucel|"Rimiducid: to treat uncontrolled GVHD in patients who have received rivogenlecleucel Rimiducid will be given at 0.4 mg/kg weight (intravenous infusion)~No further rivogenlecleucel infusions are planned. Patients who received rivogenlecleucel in the BP-004 study will be evaluated for long-term safety and efficacy."
62752781|NCT02512601|EXPERIMENTAL|Sulodexide|Compression therapy + Sulodexide (two capsules of Sulodexide 15 mg twice daily).
62376893|NCT02074436|EXPERIMENTAL|Prophylactic EACA|Prophylactic EACA 1000 mg PO twice daily if platelets \< 20 x 10⁹/L
62376894|NCT02074436|ACTIVE_COMPARATOR|Platelet transfusion|Platelet transfusion if platelet count is \< 20 x 10⁹/L in the outpatient or \< 10 x 10⁹/L in the inpatient setting
62752782|NCT06445153|NO_INTERVENTION|Control phase|Control phase: in this phase, all study patients receive the standard therapy of the respective study center.
62376895|NCT04722692|EXPERIMENTAL|Delayed SLND (SPIO-first arm)|"All study participants have been injected interstitially with SPIO, 2ml, at the primary operation. Magnetic axillary signal is registered at the end of the procedure but the SLN is not removed. If invasive cancer is found in the specimen, reoperation for SLND with the addition of Tc +/- BD is performed.~At reoperation, SPIO is the primary detection tracer."
62556102|NCT00801567|EXPERIMENTAL|1|All subjects will receive the intervention (MRS scan).
62752783|NCT06445153|EXPERIMENTAL|Intervention phase|In this phase, the intervention with Digi-POD is made available as Clinical Decision Support System. The intervention consists of providing patients, relatives and caregivers with Digi-POD decision support for the prevention of delirium and treatment decisions for delirium in accordance with the recommendations from the guidelines in addition to the standard therapy of the respective study center.
62752784|NCT03785860|PLACEBO_COMPARATOR|Placebo|On the Placebo arm of the intervention, participants will consume a placebo powder.
62376896|NCT04722692|ACTIVE_COMPARATOR|Late SLND (RI-first arm)|"All study participants have been injected interstitially with SPIO, 2ml, at the primary operation. Magnetic axillary signal is registered at the end of the procedure but the SLN is not removed. If invasive cancer is found in the specimen, reoperation for SLND with the addition of Tc +/- BD is performed.~At reoperation, Tc is the primary detection tracer."
62376897|NCT01428414|ACTIVE_COMPARATOR|Trastuzumab+ Carboplatin+Paclitaxel|Neoadjuvant treatment regimen:Trastuzumab,Carboplatin,Paclitaxel
62376898|NCT01428414|ACTIVE_COMPARATOR|Trastuzumab+Epirubicin+Paclitaxel|Neoadjuvant treatment regimen:Trastuzumab,Epirubicin,Paclitaxel
62376899|NCT05616572|EXPERIMENTAL|Caregiver|After consent, the study visit will occur. The study visit will consist of a brief set of demographic questions and a pre-game play knowledge assessment and anxiety assessment, followed by completion of the OncoWhiz game. Immediately after utilizing OncoWhiz, the participant will complete a knowledge assessment and anxiety assessment, in addition to a satisfaction survey.
62376900|NCT00766181||1: Lifestyle|Observatonal
62556103|NCT05439681|EXPERIMENTAL|MCO - low flux - high flux - HDF|"Patients who are on hemodialysis will be treated with four different hemodialysis sessions:~* Treatment 1: MCO membrane~* Treatment 2: low flux membrane~* Treatment 3: high flux membrane~* Treatment 4: HDF treatment with high flux membrane The order of the treatment regimens with the different membranes will be randomized."
62376901|NCT00766181||2: Lifestyle|Observational
62376902|NCT04448340||Parkinson Disease Dementia|the PDD group comprised of 58 patients fulfilling the Criteria for probable PDD of the Movement Disorders Society
62376903|NCT04448340||Dementia with Lewy Bodies|the DLB group comprised of 40 patients, according to the recent revised criteria for probable DLB
62376904|NCT06084065|EXPERIMENTAL|Ring arm|
62376905|NCT02981173|ACTIVE_COMPARATOR|Psilocybin High Dose|
62376906|NCT02981173|ACTIVE_COMPARATOR|Psilocybin Low Dose|
62376907|NCT02981173|PLACEBO_COMPARATOR|Placebo|
62376908|NCT01579526|EXPERIMENTAL|FP01 Dose 1|Drug
62376909|NCT01579526|EXPERIMENTAL|FP01 Dose 2|Drug
62376910|NCT01579526|EXPERIMENTAL|FP01 Dose 3|Drug
62556104|NCT05439681|EXPERIMENTAL|low flux - high flux - MCO - HDF|
62752785|NCT03785860|ACTIVE_COMPARATOR|Dietary Fiber|On the Dietary Fiber arm of the intervention, participants will consume a fiber powder.
62752786|NCT00923975|OTHER|Intended Users of the Software|Young adults, parents/guardians of young people under age 18, and healthcare professionals who work with this population would be intended users of the data management program. The DIDGET World Reports software is used to upload blood glucose results from the DIDGET Blood Glucose Monitoring System so that intended users can identify patterns in their diabetes management.
62752787|NCT00935350|PLACEBO_COMPARATOR|1|Control White bread containing 50g available carbohydrate
62376911|NCT01579526|ACTIVE_COMPARATOR|Comparator|Drug
62376912|NCT02462811|EXPERIMENTAL|CL-108|CL-108 hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
62376913|NCT02462811|ACTIVE_COMPARATOR|Active Comparator: Norco|Commercial product containing hydrocodone 7.5 mg, acetaminophen 325 mg
62376914|NCT02462811|PLACEBO_COMPARATOR|Placebo|CL-108 formulation without API
62376915|NCT01203111|EXPERIMENTAL|Intensive insulin regimen|Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: + insulin glulisine if HbA1c ≥7% at week 12 (end of treatment period 1)
62376916|NCT01203111|EXPERIMENTAL|insulin regimen|Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: no change, if HbA1c \<7% at week 12 (end of treatment period 1)
62376917|NCT03305913|EXPERIMENTAL|Dose Level 1|TAS-102 25 mg/m2 BID (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)
62376918|NCT03305913|EXPERIMENTAL|Dose Level 2|TAS-102 35 mg/m2 BID (days 1-5 and 8-12), Regorafenib 120 mg daily (3 weeks on, 1 week off)
62376919|NCT03305913|EXPERIMENTAL|Dose Level 3|TAS-102 35 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 160 mg daily (3 weeks on, 1 week off)
62376920|NCT03305913|EXPERIMENTAL|Dose Level -1a|TAS-102 25 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 80 mg daily (3 weeks on, 1 week off)
62376921|NCT03305913|EXPERIMENTAL|Dose Level -1b|TAS-102 35 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 80 mg daily (3 weeks on, 1 week off)
62556105|NCT05439681|EXPERIMENTAL|high flux - HDF - low flux - MCO|
62752788|NCT00935350|PLACEBO_COMPARATOR|2|White bread and milk control
62752789|NCT00935350|PLACEBO_COMPARATOR|3|Granola control
62556106|NCT05439681|EXPERIMENTAL|HDF - MCO - high flux - low flux|
62752790|NCT00935350|PLACEBO_COMPARATOR|4|Cornflakes and milk control
62752791|NCT00935350|PLACEBO_COMPARATOR|5|White rice control
62752792|NCT00935350|PLACEBO_COMPARATOR|6|Fruit yogurt control
62752793|NCT00935350|PLACEBO_COMPARATOR|7|Turkey dinner control
62752794|NCT00935350|EXPERIMENTAL|8|Granola
62752795|NCT00935350|EXPERIMENTAL|9|Cornflakes and milk
62752796|NCT00935350|EXPERIMENTAL|10|White Rice
62752797|NCT00935350|EXPERIMENTAL|11|Fruit yogurt
62752798|NCT00935350|EXPERIMENTAL|12|Turkey dinner
62752799|NCT00935350|PLACEBO_COMPARATOR|13|White Bread
62752800|NCT00935350|PLACEBO_COMPARATOR|14|White bread
62752801|NCT00935350|EXPERIMENTAL|15|Granola
62752802|NCT02493257|EXPERIMENTAL|intranasal capsaicin|The capsaicin solution will be prepared by using the formula previously reported by Van Rijswijk et al; (0.1mmol/l) diluted in ethanol and 0.9% normal saline (19). Using the mucosal atomizer device (MAD), 0.8 milliliters (mL) will be delivered to each nasal cavity for a total of 24.4 ug per nasal cavity. 5 consecutive applications of capsaicin or placebo will be administered intranasally, with 1 hour between each application.
62752803|NCT02493257|PLACEBO_COMPARATOR|Vehicle solution|100 μL of 1% ethanol in 0.9% saline solution. 5 consecutive applications of capsaicin or placebo will be administered intranasally, with 1 hour between each application.
62752804|NCT04396769|EXPERIMENTAL|FLOW-PA|Participants received the physical activity component of FLOW five days a week during participants' 45-minute long physical education (PE) class period for six months. Intervention activities were designed to promote moderate-vigorous physical activity through circuit-based stations with both aerobic and strength exercises. Trained research staff partnered with PE teachers to facilitate lessons and undergraduate college students were trained to complete activities with participants.
62752805|NCT04396769|ACTIVE_COMPARATOR|PE class as usual|Participants had PE class as usual 5 days a week for 45 minutes.
62752806|NCT06012448|EXPERIMENTAL|Dupilumab|All patients will receive dupilumab.
62752807|NCT05764304|EXPERIMENTAL|Sinomenine|
62752808|NCT05764304|ACTIVE_COMPARATOR|Glucocorticoid|
62376922|NCT03305913|EXPERIMENTAL|Dose Level -2a|TAS-102 30 mg/m2 BID (or 35 mg/m2 a.m. and 25 mg/m2 p.m.), (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)
62752809|NCT00724269|ACTIVE_COMPARATOR|Opti Free RepliniSH|Opti Free RepliniSH
62752810|NCT00724269|ACTIVE_COMPARATOR|ReNu Multi-Plus|ReNu Multi-Plus
62376923|NCT02496390|PLACEBO_COMPARATOR|Autologous|"Patients will be randomized to receive a fecal transplant using their own microbes/Feces (autologous - 9 patients).~Dosage - approx 100ml fecal sample, one time, procedure duration \~1hr"
62376924|NCT02496390|ACTIVE_COMPARATOR|Allogenic|"Patients will be randomized to receive a fecal transplant of feces/microbiome from the healthy donor (allogeneic - 12 patients).~Dosage - approx 100ml fecal sample, one time, procedure duration \~1hr"
62376925|NCT01037140|ACTIVE_COMPARATOR|cholecalciferol|
62556107|NCT03807726|EXPERIMENTAL|Intervention Group|Both standard usual care and the integrated breastfeeding education program (IBEP) will be provided to the participants in the intervention group. The integrated interventions are consisted of 1) four sessions of simulation breastfeeding education to build up the participants' performance accomplishment and vicarious learning including breastfeeding knowledge, skill, and self-efficacy; 2) two sessions of breastfeeding mindfulness training to equip women and their partners with stress reduction skills for their emotional arousal during breastfeeding; 3) a series of postpartum professional support to offer verbal persuasion in enhancing their breastfeeding skills and levels of self-efficacy. The details of each education components are presented at the following section.
62752811|NCT03982706||MRI-US Fusion|patients undergoing MRI targeted prostate biopsy
62752812|NCT03982706||Focal|patients undergoing focal treatment for localized prostate cancer (HIFU, NanoKnife, Cryotherapy)
62752813|NCT05213104|EXPERIMENTAL|group 1 - Flecainide 150 mg 6 months|Flecainide 150 mg 6 months in addition to standard of care
62752814|NCT05213104|EXPERIMENTAL|group 2 - Flecainide 150 mg 3 months|Flecainide 150 mg 3 months in addition to standard of care
62752815|NCT05213104|NO_INTERVENTION|group 3 - no Flecainide|to receive no additional treatment (standard of care only).
62752816|NCT01989780|ACTIVE_COMPARATOR|Arm A|weekly paclitaxel + bevacizumab
62752817|NCT01989780|EXPERIMENTAL|Arm B|"endocrine therapy\* + bevacizumab then back to weekly paclitaxel + bevacizumab therapy~(\*Letrozole, Anastrozole, Exemestane, Fulvestrant, LHRH Analogs + Aromatase inhibitors.)"
62752818|NCT02172495||Symptoms of COPD|Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms
62752819|NCT04671784||Enlarged mediastinal or abdominal|Consecutive patients with enlarged mediastinal or abdominal detected by cross-sectional imaging and confirmed at EUS will be enrolled.
62752820|NCT01166958|ACTIVE_COMPARATOR|Daily teriparatide (Forteo)|
62376926|NCT01037140|PLACEBO_COMPARATOR|placebo|
62376927|NCT01950364|EXPERIMENTAL|Arm A: Brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
62376928|NCT01950364|EXPERIMENTAL|Arm B: Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
62376929|NCT01183104|EXPERIMENTAL|Sitagliptin|
62752821|NCT01166958|ACTIVE_COMPARATOR|Monthly cycles of teriparatide followed by raloxifene|
62752822|NCT02359357|PLACEBO_COMPARATOR|Placebo single dose|Placebo administered as a single dose
62752823|NCT02359357|EXPERIMENTAL|Single dose (Dose level 1)|FDL169 (Dose level 1) administered as a single dose
62752824|NCT02359357|EXPERIMENTAL|Single dose (Dose level 2)|FDL169 (Dose level 2) administered as a single dose
62752825|NCT02359357|EXPERIMENTAL|Single dose (Dose level 3)|FDL169 (Dose level 3) administered as a single dose
62752826|NCT02359357|EXPERIMENTAL|Single dose (Dose level 4)|FDL169 (Dose level 4) administered as a single dose
62752827|NCT02359357|EXPERIMENTAL|Single dose (Dose level 5)|FDL169 (Dose level 5) administered as a single dose
62752828|NCT02359357|EXPERIMENTAL|Single dose (Dose level 6)|FDL169 (Dose level 6) administered as a single dose
62376930|NCT01183104|ACTIVE_COMPARATOR|Glimepiride|
62376931|NCT02685449|PLACEBO_COMPARATOR|group A|"On the first study day, insulin bolus was not given before a standardized pure protein meal. On the second day, pre-breakfast insulin was given as a square-wave bolus before the same standardized pure protein meal.~The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
62556108|NCT03807726|NO_INTERVENTION|Control Group|The mother and her partner in the control group will receive the standard usual care provided at the study site. The study site hospital where follows the 10 steps of the Baby Friendly Hospital Initiative will provide breastfeeding care during prenatal check-up and postpartum care. The standard care protocols encompass elements such as prenatal breastfeeding consultation using breastfeeding pamphlets, and postpartum care like skin to skin contact, rooming- in, and breastfeeding consultation using pamphlets. The pregnant women need to register for childbirth class which contains only one breastfeeding class by themselves if needed. After delivery, the mothers are taught on breastfeeding knowledge and skills by the nurses at the postpartum ward or nursey.
62556109|NCT05066360|OTHER|participants with epilepsy|healthy, menstruating females between 12-18 ages
62556110|NCT05066360|OTHER|healthy participants|epileptic, menstruating females between 12-18 ages
62752829|NCT02359357|EXPERIMENTAL|Single dose (Dose level 7)|FDL169 (Dose level 7) administered as a single dose
62556111|NCT06344273|EXPERIMENTAL|experimental group|"Lower Extremity ROM exercise will be performed for 20 minutes each at the beginning of the hour until the end of each eye session, examination and session in the case visits. Piper's Fatigue Scale and Hemodialysis Comfort Scale, which are part of data collection, will be applied again at the end of the 1st and 2nd week after the sessions begin. The individual's life segments will be tracked and recorded at each session."
62752830|NCT02359357|EXPERIMENTAL|Single dose (Dose level 8)|FDL169 (Dose level 8) administered as a single dose
62752831|NCT02359357|EXPERIMENTAL|Additional single dose 1|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
62752832|NCT02359357|EXPERIMENTAL|Additional single dose 2|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
62752833|NCT02359357|EXPERIMENTAL|Additional single dose 3|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
62752834|NCT02359357|EXPERIMENTAL|Additional single dose 4|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
62752835|NCT02359357|EXPERIMENTAL|Food effect - fasted|Single dose of FDL169 in fasted conditions
62752836|NCT02359357|EXPERIMENTAL|Food effect - fed|Single dose of FDL169 in fed conditions
62752837|NCT02359357|PLACEBO_COMPARATOR|Placebo - multiple dose|Repeat doses of placebo
62752838|NCT02359357|EXPERIMENTAL|Multiple dose - Dose level 1|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
62752839|NCT02359357|EXPERIMENTAL|Multiple dose - Dose level 2|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
62752840|NCT02359357|EXPERIMENTAL|Multiple dose - Dose level 3|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
62752841|NCT02359357|EXPERIMENTAL|Multiple dose - Dose level 4|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
62752842|NCT02359357|EXPERIMENTAL|Multiple dose - additional dose level 1|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
62752843|NCT02359357|EXPERIMENTAL|Multiple dose - additional dose level 2|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
62752844|NCT06247111|PLACEBO_COMPARATOR|Usual Care|Participants receive usual care from providers to manage their blood pressure
62752845|NCT06247111|ACTIVE_COMPARATOR|Remote Blood Pressure Monitoring + Telehealth|Participants will undergo remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management
62752846|NCT06036160|EXPERIMENTAL|Integrated care|
62752847|NCT05024175||CAR T cells|"* Eligibility to participate on this study if enrolled on a DF/HCC IRB corresponding main study and received infusion of CAR T cells~* The research study procedures include evaluations and follow up visits: Timepoints of each evaluation and follow up visit- per protocol~* Medical History/Physical Exam~* Blood Test~* Assessment of Disease: CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans.~* Tumor biopsy.~* Data Collection~* Biobanking"
62752848|NCT01177774||Recent-onset tics that will persist|Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who, when reassessed at 1 year after the first tic began (i.e. 6-12 months after study enrollment) will turn out to meet criteria for a chronic tic disorder (including Tourette syndrome). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).
61997502|NCT03670810|EXPERIMENTAL|100 milligram (mg) Lasmiditan|Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
61997503|NCT03670810|EXPERIMENTAL|200 mg Lasmiditan|Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
62376932|NCT02685449|ACTIVE_COMPARATOR|group B|"On the first study day, pre-breakfast insulin was given as a square-wave bolus before a standardized pure protein meal. On the second day, insulin bolus was not given before the same standardized pure protein meal.~The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
62376933|NCT03032523|EXPERIMENTAL|Remote Monitoring CGM Group|Participants wear a CGM that is blinded at bedside (to participant and clinical staff) but remotely monitored by study staff. If a blood sugar less than 46 mg/dl occurs, the study staff receive a notification and ask the clinical staff to perform a confirmation standard of care glucose test.
62376934|NCT03032523|NO_INTERVENTION|Blinded CGM Group|Participants wear a blinded CGM during the study period. Values are blinded to study staff, participant, and clinical staff.
62376935|NCT02983851|EXPERIMENTAL|Noninvasive mechanical ventilation|Patients in this group will receive Noninvasive mechanical ventilation as the initial mechanical ventilation (MV) strategy, irrespective of whether Invasive mechanical ventilation is used later during the following treatment.
62376936|NCT02983851|ACTIVE_COMPARATOR|Invasive mechanical ventilation|Patients in this group will receive Invasive mechanical ventilation as the initial MV strategy, irrespective of whether Noninvasive mechanical ventilation is used later during the following treatment.
62376937|NCT06379672|EXPERIMENTAL|intervention group|Subjects were asked to remain in a standing position with their feet shoulder-width apart. The right hand was placed on the chest and the left hand on the abdomen. Inhale to make the abdomen bulge and exhale to make the abdomen sink (inhale through the nose and exhale through the mouth). This was done 2 times a day, once in the morning and once in the afternoon. Complete 3 sets of 8 breaths each. Each breath lasts 10 seconds (4 seconds inhaling and 6 seconds exhaling).
62376938|NCT02234024|EXPERIMENTAL|Supplementation of gangliosides|Supplementation of dairy-derived concentrated gangliosides
62376939|NCT05550857|ACTIVE_COMPARATOR|Myofascial release|"Group A:~This group will receive routine physiotherapy with myofascial release. This protocol will be given for 3 alternative days per week. Each session will be of 45 minutes. Data will be collected at baseline, at 2nd week and at 4th week."
62376940|NCT05550857|EXPERIMENTAL|eccentric resistance exercise|"Group B:~This group will receive routine physiotherapy and myofascial release with eccentric resistance exercise . This protocol will be given for 3 alternative days per week. Each session will be of 60 minutes. Data will be collected at baseline, at 2nd week and at 4th week."
62376941|NCT04176328|EXPERIMENTAL|Cystic Fibrosis patients treated with Teicoplanin|Hospitalized male and female patients aged ≥ 18 years, suffering of Cystic Fibrosis.
62376942|NCT05347563||Group A|group A: Patient \< 18 years old admitted to a continuous monitoring unit - resuscitation for acute respiratory failure regardless of the ventilation modality and benefiting from TIE monitoring
62376943|NCT05347563||Group B (reference)|Group B (reference): Patient under general anesthesia with mechanical ventilation without respiratory pathology.
62376944|NCT02825238|NO_INTERVENTION|Control|Control group, did not undergo intervention.
62376945|NCT02825238|EXPERIMENTAL|Exercise group|Experimental, exercise group, underwent intervention
62556112|NCT06344273|NO_INTERVENTION|Control Group|"During the implementation period of the study, routine nursing care service will be provided to the patients in the control group and no additional nursing intervention will be applied. Piper's Fatigue Scale and Hemodialysis Comfort Scale, which are part of data collection, will be applied again at the end of the 1st and 2nd week after the sessions begin. The individual's life segments will be tracked and recorded at each session."
62752849|NCT01177774||Recent-onset tics that will remit|Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who will no longer have tics when reassessed 1 year after the first tic began (6 to 12 months after study enrollment). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).
62752850|NCT01177774||Tic-free control subjects|Children with no current or past tic disorder of similar age, sex and handedness as the children in the recent-onset tics groups.
62376946|NCT01060527||IBS-D|
62376947|NCT01060527||IBS-C|
62376948|NCT01060527||Controll|
62556113|NCT05102929|EXPERIMENTAL|active, then sham Intermittent Theta Burst Stimulation (iTBS) over DLPFC|This arm will first receive active iTBS stimulation and then sham iTBS over the left dorsolateral prefrontal cortex (DLPFC).
62556114|NCT05102929|EXPERIMENTAL|sham, then active intermittent Theta Burst Stimulation (iTBS) over DLPFC|This arm will first receive sham iTBS (i.e., with the TMS coil in the placebo orientation) and then active iTBS stimulation over the left dorsolateral prefrontal cortex (DLPFC).
62752851|NCT01177774||Existing TS/CTD|Children with current tics whose first tics were more than 12 months ago (DSM-5 Tourette's Disorder or Persistent \[Chronic\] Motor or Phonic Tic Disorder), of similar age, sex and handedness as the children in the recent-onset tics groups.
62752852|NCT03640052|PLACEBO_COMPARATOR|Placebo|Placebo capsule 1 time before bedtime
62376949|NCT01655641|EXPERIMENTAL|Tranexamic acid arm|"Along with the standard of care (routine surgical care involved in preventing blood loss during surgery) this arm will receive drug Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV for non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"
62376950|NCT01655641|ACTIVE_COMPARATOR|Standard of care arm|Includes routine surgical care involved in preventing blood loss during and after surgery.
62376951|NCT05977374|EXPERIMENTAL|elliptical training group.|In this group, Ultrasound 1MHz, 1.5W/cm2 7 mins, knee isometrics, and open chain activities. static stretching of the lower limbs will be given 10 reps each and held for 10 secs. 5 mins of warm-up activity on elliptical training will be given prior to the treatment group. then 3 mins of training with a set pace of 120 strides/min will start, then after 7 weeks, the timings will be increased to 5 mins. The base check-up will be conducted during 7 weeks and at the end of 12 weeks.
62376952|NCT05977374|OTHER|Conventional treatment group|Static stretching of the lower limbs as mentioned above, Ultrasound 1MHz 1.5W/cm2 7min, knee isometrics, open chain activities, anterior-posterior Maitland knee mobilizations grade 1 and 2, and home care plan.
62376953|NCT03245294|ACTIVE_COMPARATOR|Lumbar ESI with paramedian approach|Lumbar ESI with paramedian approach
62376954|NCT03245294|ACTIVE_COMPARATOR|Lumbar ESI with midline approach|Lumbar ESI with midline approach
62376955|NCT06485661|OTHER|Duchenne patients subjected to captopril|
62376956|NCT01659489||women undergoing laproscopy fo rsuspected adnexal torsion|
62376957|NCT05719415|EXPERIMENTAL|Pre and post BPA|
62752853|NCT03640052|ACTIVE_COMPARATOR|LTM1201L|LTM1201L capsule 1 time before bedtime
62752854|NCT03640052|ACTIVE_COMPARATOR|LTM1201LN|LTM1201LN capsule 1 time before bedtime
62752855|NCT03640052|ACTIVE_COMPARATOR|LTM1201LB|LTM1201LB capsule 1 time before bedtime
62376958|NCT03619902|EXPERIMENTAL|Imsidolimab|Participants received imsidolimab 750 mg intravenously (IV) on Day 1 followed by administration of 3 doses of subcutaneous (SC) imsidolimab 100 mg on Days 29, 57, and 85.
62752856|NCT03640052|ACTIVE_COMPARATOR|LTM1201LD|LTM1201LD capsule 1 time before bedtime
62752857|NCT02839577|ACTIVE_COMPARATOR|High Volume injection (HVI) with corticosteroid|"* 10 mls 0.5% bupivacaine hydrochloride~* 20 mg of Depomedrol (40 mg/ml methylprednisolonacetat)~* 40 mls saline (NaCl)~HVI with corticosteroid is injected one time at baseline and compared to HVI without corticosteroid."
62752858|NCT02839577|ACTIVE_COMPARATOR|High Volume injection (HVI) without corticosteroid|"* 10 mls 0.5% bupivacaine hydrochloride~* 40 mls saline (NaCl)~HVI with corticosteroid is injected one time at baseline and compared to HVI with corticosteroid."
62556115|NCT06133361|EXPERIMENTAL|PRP group|PRP will be injected in the palatal mucosa of the upper anterior teeth to accelerate orthodontic tooth movement. Patients in this group will undergo en-masse retraction of their upper front teeth using the same technique as the control group.
62752859|NCT05339750|EXPERIMENTAL|Allergy Skin Patch Testing|On day 1, subjects will have a allergy skin patch test applied and a routine skin examination. On day 3, the patch test will be removed and documentation of the test sites using iPhone app. On day 5, the final assessment for allergic contact dermatitis will be conducted by a medical professional.
61997504|NCT03670810|PLACEBO_COMPARATOR|Control 1 Sequence|"Control 1:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
62752860|NCT06225739||Pregnant women|
62752861|NCT06225739||Health care providers|In-depth interviews (IDIs) and focus group discussions (FGDs) will be used to assess the user experience and the perceptions of pregnant women and health workers on the feasibility, usability, and acceptability of open-source mobile applications for tracking pregnancy outcomes
62752862|NCT01636505|ACTIVE_COMPARATOR|short protocol|gnrh agonist versus gnrh antagonist
62752863|NCT01636505|ACTIVE_COMPARATOR|long protocol|
62752864|NCT00355537|EXPERIMENTAL|Active|
62752865|NCT00355537|PLACEBO_COMPARATOR|Placebo|
62556116|NCT06133361|ACTIVE_COMPARATOR|Traditional retraction group|In this group, patients will undergo en-masse retraction of their upper front teeth using a frictionless method by using coil springs attached between the anterior portion of the dental arch (which is an anterior segment only) to the miniscrews placed between the upper second premolars and the upper first molars.
62556117|NCT03937505|EXPERIMENTAL|Dose-escalation|Dose-cohort escalation of single intravenous injection of IS-001 starting with 20 mg (n=8), escalating in 20 mg increments until optimal dose is determined.
62376959|NCT06166251|EXPERIMENTAL|MP-LOW (pre-motor practice (MP) low ıntensity aerobic exercise )|"On the experimental day, they participated in 60 golf puttings (acquisition practice) followed by a half-hour low-intensity treadmill run.~Retention levels were measured 1 and 7 days after the experimental day with 10 puttings each.~Sleep quality (richard campbell sleep questionnaire) and cognitive level (Paced auditory serial addition test) were evaluated in all participants."
62752866|NCT06606925|EXPERIMENTAL|Functional (fMRI) and anatomic MRI imaging a two timepoints during pilot virtual reality simulation|Initial anatomic imaging and fMRI with virtual reality flight simulator scan with repeat testing performed at approximately 2 months (+/- 1 month) after initial scan.
62376960|NCT06166251|EXPERIMENTAL|MP-MOD (pre-motor practice (MP) moderate ıntensity aerobic exercise )|"On the experimental day, they participated in 60 golf puttings (acquisition practice) followed by a half-hour moderate-intensity treadmill run.~Retention levels were measured 1 and 7 days after the experimental day with 10 puttings each.~Sleep quality (richard campbell sleep questionnaire) and cognitive level (Paced auditory serial addition test) were evaluated in all participants."
62752867|NCT06305936|EXPERIMENTAL|Intervention group|As part of the 4-week intervention in the feasibility study, the intervention group will receive 1) Educational materials (videos) 2) Participation in a cooking workshop with introduction to PBD meals, including recipes, and 3) Daily delivered PBD dinner meal during the four weeks.
62752868|NCT06305936|NO_INTERVENTION|Control group|The control group will be asked to maintain habitual diet and lifestyle. In addition, they will follow the same outcome assessments as the intervention group.
62752869|NCT03262025||Operated patients who survived|Patients who were discharged in index hospital admission after operative intervention
62752870|NCT03262025||Operated patients who expired|Patients who expired in index hospital admission after operative intervention
62752871|NCT03262025||Non-operated patients who survived|Patients who were discharged in index hospital admission after being managed conservatively
62752872|NCT03262025||Non-operated patients who expired|Patients who expired in index hospital admission after being managed conservatively
62752873|NCT01279629||Tazarotene 0.1%|
62376961|NCT06166251|EXPERIMENTAL|MOD-MP (post-motor practice (MP) moderate ıntensity aerobic exercise )|"On the experimental day, they participated in a half-hour moderate-intensity treadmill run followed by 60 golf puttings (acquisition practices).~Retention levels were measured 1 and 7 days after the experimental day with 10 puttings each.~Sleep quality (richard campbell sleep questionnaire) and cognitive level (Paced auditory serial addition test) were evaluated in all participants."
62376962|NCT06166251|EXPERIMENTAL|LOW-MP ((post-motor practice (MP) low ıntensity aerobic exercise )|"On the experimental day, they participated in a half-hour low-intensity treadmill run followed by 60 golf puttings (acquisition practices).~Retention levels were measured 1 and 7 days after the experimental day with 10 puttings each.~Sleep quality (richard campbell sleep questionnaire) and cognitive level (Paced auditory serial addition test) were evaluated in all participants."
62376963|NCT06166251|NO_INTERVENTION|Control|"On the experimental day, they completed 60 golf puttings (just acquisition practices- NO EXERCISE) Retention levels were measured 1 and 7 days after the experimental day with 10 puttings each.~Sleep quality (richard campbell sleep questionnaire) and cognitive level (Paced auditory serial addition test) were evaluated in all participants."
62752874|NCT01279629||Calcipotriol 0.005%|
62752875|NCT02019446|EXPERIMENTAL|Laser Treatment|Participants randomized to laser group will undergo laser treatment at baseline and be asked to return for 2 subsequent visits six weeks apart (at weeks 6 and 12) to undergo further laser treatment of the hallux. Each visit will last approximately 45 minutes. Laser energy (1064 nm Nd:YAG) will be delivered via an optical fibre (300 μm core/320 μm clad) secured in a hand piece. Laser energy will be delivered by maintaining the tip of the optical fibre 3 mm from the treatment area to achieve around 1-1.5 mm diameter spot size (25.5 J/cm2 fluence per pulse; 10-pulse pulse-train to each spot in 0.5 seconds). Multiple treatment spots will be delivered to cover the entire area of involvement.
62752876|NCT02019446|ACTIVE_COMPARATOR|Standard Treatment (control group)|Control group volunteers will be asked to dedicate the same amount of time to the project with the same number of visits. However, they will receive conventional terbinafine therapy instead of laser treatments. Therefore, each of the 3 treatment visits would last only about 20 minutes.
62752877|NCT04915989|EXPERIMENTAL|GX-19N|Dose A of GX-19N will be intramuscularly administered via Electroporator(EP) on day 1 and day 29. (Optional administration on day 57)
62752878|NCT05730543|EXPERIMENTAL|Volbella or Juvederm Ultra XC filler|Injection will not exceed a total of 4 cc of hyaluronic acid filler for combined treatment sessions (initial treatment + possible touch up treatment session).
62752879|NCT01978249|EXPERIMENTAL|Chemotherapy first without primary tumor resection|Patients will receive chemotherapy first without primary tumor resection.
62752880|NCT01978249|ACTIVE_COMPARATOR|Primary tumor resection followed by chemotherapy|Patients will receive primary tumor resection followed by chemotherapy.
62752881|NCT05969548|ACTIVE_COMPARATOR|active 1200-pulse cTBS group|active 1200-pulse cTBS combined with speech language therapy
62752882|NCT05969548|ACTIVE_COMPARATOR|active 2400-pulse cTBS group|active 2400-pulse cTBS combined with speech language therapy
62752883|NCT05969548|ACTIVE_COMPARATOR|active 3600-pulse cTBS group|active 3600-pulse cTBS combined with speech language therapy
62752884|NCT05969548|SHAM_COMPARATOR|sham 1200-pulse cTBS group|sham 1200-pulse cTBS combined with speech language therapy
62752885|NCT05969548|SHAM_COMPARATOR|sham 2400-pulse cTBS group|sham 2400-pulse cTBS combined with speech language therapy
62752886|NCT05969548|SHAM_COMPARATOR|sham 3600-pulse cTBS group|sham 3600-pulse cTBS combined with speech language therapy
62752887|NCT03380546|EXPERIMENTAL|acarbose|The women will receive acarbose with a progressive increase of dose according to post prandial glucose values and digestive tolerance, with a maximal dose of 3 x 100 mg /day
62752888|NCT03380546|ACTIVE_COMPARATOR|prandial insulin|The women will receive prandial insulin according to usual practice (routine care according to French recommendations): before each meal, with dose titration according to post prandial values.
62752889|NCT00874640||Group 1|
62752890|NCT05679544|EXPERIMENTAL|Subjects occupationally exposed to PAHs|
62752891|NCT01459653||Only 1 group|Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.
62752892|NCT01497990|EXPERIMENTAL|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
62752893|NCT01997957|EXPERIMENTAL|TACE+HAIC-OXA+S-1|
62752894|NCT01997957|NO_INTERVENTION|TACE+HAIC-OXA|
62376964|NCT04268706|EXPERIMENTAL|CD30 positive r/r classical Hodgkin Lymphoma|"Patients with relapsed or refractory classical Hodgkin Lymphoma who have failed 3 prior lines of treatment, which may include a prior autologous and/or allogeneic stem cell transplant.~Patients will be treated with autologous CD30.CAR-T cells."
62752895|NCT04821674|EXPERIMENTAL|Cohort A1: DS-5670a 10 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 10 µg.
62752896|NCT04821674|EXPERIMENTAL|Cohort A2: DS-5670a 30 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 30 µg.
62376965|NCT02871570|EXPERIMENTAL|Moderate Hepatic Impairment|A single dose of IV Rivipansel over 20 minutes
62376966|NCT02871570|EXPERIMENTAL|Normal Hepatic Function|A single dose of IV Rivipansel over 20 minutes
62376967|NCT02772991|EXPERIMENTAL|Cases|All patients will be submmited to troponin measurements and CCTA. If CCTA shows coronary stenosis ≥ 50%, patient will initiate the ACS treatment and be hospitalized to have coronary cineangiography. If CCTA shows lesions \< 50%, the patient will be discharged and monitored for 30 days. A second sampling of the troponin will be obtained from all patients three hours after the first collection in order to evaluate for an increase/decrease of troponin.
62752897|NCT04821674|EXPERIMENTAL|Cohort A3: DS-5670a 60 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 60 µg.
62752898|NCT04821674|EXPERIMENTAL|Cohort A4: DS-5670a 100 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 100 µg.
62752899|NCT04821674|PLACEBO_COMPARATOR|Cohort A: Placebo|Healthy adults participants will be randomized to receive a intramuscular injection of placebo.
62752900|NCT04821674|EXPERIMENTAL|Cohort B1: DS-5670a 10 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 10 µg.
62752901|NCT04821674|EXPERIMENTAL|Cohort B2: DS-5670a 30 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 30 µg.
62752902|NCT04821674|EXPERIMENTAL|Cohort B3: DS-5670a 60 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 60 µg.
62752903|NCT04821674|EXPERIMENTAL|Cohort B4: DS-5670a 100 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 100 µg.
62752904|NCT04821674|PLACEBO_COMPARATOR|Cohort B: Placebo|Healthy elderly participants will be randomized to receive a intramuscular injection of placebo.
62752905|NCT05848700|EXPERIMENTAL|SEP-363856|
62752906|NCT05848700|PLACEBO_COMPARATOR|Placebo|
62752907|NCT00123578|EXPERIMENTAL|Lorazepam|Lorazepam for the treatment of mild GHB withdrawal.
62752908|NCT00123578|ACTIVE_COMPARATOR|Pentobarbital|Pentobarbital for the treatment of mild GHB withdrawal.
62752909|NCT05142254|EXPERIMENTAL|Tadalafil and Hydroxyurea|Tadalafil 2.5-5 mg/day and Hydroxyurea 20 mg/kg/day
62752910|NCT05142254|PLACEBO_COMPARATOR|Placebo and Hydroxyurea|Placebo and Hydroxyurea 20 mg/kg/day
62752911|NCT05978388|EXPERIMENTAL|Analysis of coronary CT angiography and CAC scoring at the time of catheter ablation|Based on the results of the coronary CT angiography and CAC scoring in the intervention group, relevant anti-ischemic and multimodality treatment will be initiated according to clinical guidelines.
62752912|NCT05978388|NO_INTERVENTION|No analysis of coronary CT angiography and CAC scoring at the time of catheter ablation|Patients in the control group will follow the current standard of care prior to ablation.
62752913|NCT02242435|EXPERIMENTAL|Ampion 4ml dose|4 mL intra-articular injection of Ampion
62752914|NCT02242435|PLACEBO_COMPARATOR|Placebo Solution|4 mL placebo intra-articular injection
62752915|NCT03900858|EXPERIMENTAL|Isoniazid/ Rifapentine 3 times a week|Intervention：Isoniazid/ Rifapentine 3 times a week given by DOT oral Rifapentine (450mg) plus Isoniazid (400mg) for 12 doses
62752916|NCT03900858|NO_INTERVENTION|No Intervention|No preventive treatment Follow up without intervention. Have already done.
62752917|NCT06604897||Sacubitril/Valsartan Cohort|Adult patients with essential hypertension who were prescribed sacubitril/valsartan.
62376968|NCT03201744|EXPERIMENTAL|Moderate Neuromuscular Block|Train of four count of 1-2. All procedures will start with low-pressure insufflation (8 mm Hg). Surgeon assessment of the conditions will be serially performed during surgery on an established visual scale. If conditions are deemed less than adequate (score 1-2), insufflation pressure will incrementally increase up to 15 mm Hg. Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
62376969|NCT03201744|EXPERIMENTAL|Deep Neuromuscular Block|Post tetanic count of 1-2. All procedures will start with low-pressure insufflation (8 mm Hg). Surgeon assessment of the conditions will be serially performed during surgery on an established visual scale. If conditions are deemed less than adequate (score 1-2), insufflation pressure will incrementally increase up to 15 mm Hg. Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
62376970|NCT02159001|ACTIVE_COMPARATOR|ECT treatment right after recruitment|This group receives electroconvulsive therapy treatment right after they are recruited.
62376971|NCT02159001|PLACEBO_COMPARATOR|ECT after 4 weeks period.|This group receives electroconvulsive therapy treatment after 4 weeks waiting period.
62376972|NCT04034069|EXPERIMENTAL|cTBS + iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of priming iTBS protocol (cTBS followed by iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
62752918|NCT06604897||Conventional Drug-control Cohort|Adult patients with essential hypertension who were prescribed angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB).
62752919|NCT05552794||Good outcome|Good outcome was defined as cerebral performance category (CPC): 1-2
62752920|NCT05552794||Poor outcome|Poor outcome was defined as cerebral performance category (CPC): 3-5
62752921|NCT00570791||Effect of age on intraocular pressure|Correlation between age and IOP with GAT compared to other tonometers.
62752922|NCT00570791||Effect of CCT and IOP|Correlation between CCT and IOP among all tonometers
62752923|NCT06034951|OTHER|Patients well established on tube feeds will act as their own control|These patients will switch from current to new tube feed to assess acceptability and tolerance
62752924|NCT02783040|EXPERIMENTAL|single dose cocktail (Midazolam, Warfarin, Omeprazole)|
62752925|NCT02783040|EXPERIMENTAL|single dose Midazolam|
62752926|NCT02783040|EXPERIMENTAL|single dose Digoxin|
62752927|NCT02783040|EXPERIMENTAL|multiple dose BI 425809|
62752928|NCT01851486|ACTIVE_COMPARATOR|Clonidine+ Saline|Clonidine 0.15 mg and saline 0.15 mg/kg
62752929|NCT01851486|ACTIVE_COMPARATOR|Clonidine + Naloxone|Clonidine 0.15 mg and Naloxone 0.15 mg/kg
62752930|NCT01851486|ACTIVE_COMPARATOR|Placebo +Naloxone|Placebo 0.15 mg+ naloxone 0.15 mg/kg
62752931|NCT01851486|PLACEBO_COMPARATOR|Placebo +saline|Placebo 0.15 mg+ saline 0.15 mg/kg
62752932|NCT05818917|EXPERIMENTAL|40mg|FHND5071, 40mg, tablet, orally, once daily
62752933|NCT05818917|EXPERIMENTAL|80mg|FHND5071,80mg, tablet, orally, once daily
62752934|NCT05818917|EXPERIMENTAL|160mg|FHND5071, 160mg, tablet, orally, once daily
62752935|NCT05818917|EXPERIMENTAL|240mg|FHND5071, 240mg, tablet, orally, once daily
62752936|NCT05818917|EXPERIMENTAL|320mg|FHND5071, 320mg, tablet, orally, once daily
62752937|NCT05818917|EXPERIMENTAL|400mg|FHND5071, 400mg, tablet, orally, once daily
62752938|NCT02182661|EXPERIMENTAL|Ba253BINEB|
62752939|NCT04037631||Patients without clinically significant age-related cataract|
62752940|NCT01495130|EXPERIMENTAL|Diagnostic (TRUS)|Patients undergo TRUS during RALP.
62752941|NCT04603781|ACTIVE_COMPARATOR|CBD-Isolate 300 mg.|Nightly oral administration of 300 mg. of CBD-Isolate for 28 consecutive days
62752942|NCT04603781|ACTIVE_COMPARATOR|Full-Spectrum CBD Oil 300 mg.|Nightly oral administration of 300 mg. of Full Spectrum CBD Oil for 28 consecutive days
62556118|NCT03937505|EXPERIMENTAL|Optimal dose-characterization|Single intravenous injection of IS-001 at the optimal dose will be administered to subjects assigned to the treatment group. Safety control subjects will not receive any study drug but will undergo robotic surgery and all associated safety assessment clinical trial procedures.
62556119|NCT04545840||Study group|Zirconia Implants will be placed. More than one implant can be placed in the same patient, as long as the subject presents natural teeth adjacent to the implant site.
62752943|NCT04603781|ACTIVE_COMPARATOR|Broad-Spectrum CBD oil 300 mg.|Nightly oral administration of 300 mg. of Broad-Spectrum CBD Oil for 28 consecutive days
62556120|NCT00379392|EXPERIMENTAL|Mental Imagery and CIT|Mental Imagery and Constraint Induced Therapy
62556121|NCT00379392|ACTIVE_COMPARATOR|Mental Imagery only|Mental Imagery only
62556122|NCT03223350|EXPERIMENTAL|Capsaicin|0.1% capsaicin cream, one application
62556123|NCT03223350|PLACEBO_COMPARATOR|Placebo|Topical cream with no active drug
62556124|NCT06581315|EXPERIMENTAL|Arm A (Donafenib)|Participants will receive Donafenib treatment until disease recurrence or unacceptable toxicity or up to 1 years.
62556125|NCT06581315|NO_INTERVENTION|Arm B (active surveillance)|Active surveillance of participants.
62556126|NCT00548613|EXPERIMENTAL|A|Patients with documented acute myocardial infarction (heart attack) occurring within 4-24 hours after onset of symptoms
62556127|NCT00548613|EXPERIMENTAL|B|Candidates for coronary artery bypass grafting that suffered a myocardial infarction (heart attack) within the past 12 months
62556128|NCT01750190|EXPERIMENTAL|Roxadustat|Participants will receive roxadustat tablets orally 3 times a week (TIW). The initial dose will be according to the tiered weight-based approach, with starting roxadustat doses of 70 milligrams (mg) TIW to participants weighing \<70 kilograms (kg) and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 grams/deciliter (g/dL) and Hb increase from baseline (BL) of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 234.9 weeks.
62567567|NCT05339373|OTHER|Sequence RT|18 subjects assigned to the sequence RT will receive a single 100 mg dose of the test product Airtal ® (1 x 100 mg tablet), marked as R in the sequence, in Period 1 and a single 100 mg dose of thetest product Aceclofenac (1 x 100 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62752944|NCT04603781|PLACEBO_COMPARATOR|Placebo Oil|Nightly oral administration of 300 mg. of Placebo Oil for 28 consecutive days
62752945|NCT05210517|NO_INTERVENTION|No intervention|
62752946|NCT05210517|EXPERIMENTAL|Empagliflozin|Empagliflozin 25 mg once daily for one week
62752947|NCT05210517|EXPERIMENTAL|Benzbromarone|Benzbromarone 100 mg once daily for one week
62752948|NCT05210517|EXPERIMENTAL|Empagliflozin-Benzbromarone|Empagliflozin 25 mg once daily for one week combined with Benzbromarone 100 mg once daily for one week
62752949|NCT01666535|OTHER|Influenza vaccination Timing #1|Influenza vaccination administered on the same day as infliximab administration (Day 0 to 4).
62752950|NCT01666535|OTHER|Influenza vaccination Timing #2|Influenza vaccination administered at the mid-point between infliximab infusions (Day 21 to 28)
62567568|NCT06307535|EXPERIMENTAL|Meaning-Centered Psychotherapy for Caregivers|Meaning-Centered Psychotherapy for Caregivers/MCP-C
62752951|NCT03294239|EXPERIMENTAL|Group A (Transurethal group)|Patients will have trans urethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone disintegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.
62376973|NCT04034069|ACTIVE_COMPARATOR|Sham cTBS + iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of non-primed, standard iTBS (sham cTBS followed by iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
62376974|NCT04034069|SHAM_COMPARATOR|Sham cTBS + sham iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of sham stimulation (sham cTBS followed by sham iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
62376975|NCT06237608|EXPERIMENTAL|Intervention|Attend DBT-informed skills group intervention
62567569|NCT06307535|ACTIVE_COMPARATOR|Supportive Psychotherapy for Caregivers|Supportive Psychotherapy for Caregivers/SP-C standard of care
62567570|NCT02045069|EXPERIMENTAL|2 days Ivermectin|Ivermectin 200 - 400 µg/kg once daily for 2 days
62567571|NCT02045069|EXPERIMENTAL|3 days Ivermectin|Ivermectin 200-400 µg/kg once daily for 3 days
62752952|NCT03294239|EXPERIMENTAL|Group B (Percutaneous group)|Patients will have per cutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the mid line 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
62376976|NCT03968588|EXPERIMENTAL|reduced-dose tacrolimus + standard-dose MMF|Tacrolimus dose was individually adjusted with a target trough blood level of between 3ng/mL and 8ng/mL throughout the study period (6 months after transplantation). MMF started within 72 hours after transplantation and the dose of MMF was 1.5\~2.0g per day.
62376977|NCT03968588|ACTIVE_COMPARATOR|standard-dose tacrolimus + reduced-dose MMF|Control group, target trough blood level was between 5ng/mL and 15ng/mL throughout the study period. MMF dose was 0.5\~1g per day and MMF started within 72 hours after transplantation.
62376978|NCT02591251|ACTIVE_COMPARATOR|The povidone-iodine group|The patients will be subjected to povidone-iodine (Betadine7.5%, Phama Care) for vaginal cleaning before the laparoscopic surgery
62567572|NCT02045069|PLACEBO_COMPARATOR|Placebo|Placebo
62752953|NCT05151432|EXPERIMENTAL|Pulsed US + Exercise Group|Twenty subjects will receive PUT, plus an exercise program.
62752954|NCT05151432|EXPERIMENTAL|Pulsed Electromagnetic + Exercise Group|Twenty subjects will receive PEMF, plus an exercise program.
62376979|NCT02591251|ACTIVE_COMPARATOR|Normal saline group|The patients will be subjected to normal saline solution (Sod. Chloride 0.9%, Nile) for vaginal cleaning before the laparoscopic surgery.
62376980|NCT02411266|PLACEBO_COMPARATOR|control|Subjects in this group will undergo sham preconditioning. A blood pressure cuff will be placed around the leg and inflated just lightly to a pressure of 30mmHg, not enough to affect arterial circulation. This will be maintained for 10min followed by 5min of deflation. This will constitute one conditioning cycle. There will be 3 sham conditioning cycles per treatment session.
62376981|NCT02411266|ACTIVE_COMPARATOR|treatment group|Study personnel will place a blood pressure cuff around the subject's leg and use it to interrupt the circulation to the leg for 10 minutes followed by release of the blood pressure for 5 minutes. This will be repeated for a total of 3 times every 24 to 48 hours up to 14 days. The cuff will be inflated for 10 minutes and then deflated for 5 minutes. There will be 3 cycles of this. The cuff will be inflated to 200mmHg to induce ischemia, confirmed by palpation of pedal pulses.
62376982|NCT04527536||early-set BMJ group|Infants were admitted to our hospital at 4-7 days of age and were followed up to 28 days. Other pathological jaundice factors were excluded.Those who met the criteria were the early-onset BMJ group.
62376983|NCT04527536||late-onset BMJ group|Infants were admitted to our hospital after 7 days of age and were followed up to 28-42 days or until the jaundice disappeared. Other pathological jaundice factors were excluded..Those who met the criteria were late-onset BMJ
62376984|NCT04527536||healthy control|During the same period, the healthy newborns who were born in the obstetrics department of our hospital. These newborns were mainly breastfed or breastfed, and grew well. They were enrolled at 7-14 days of age and were followed up to 28-42 days without pathological jaundice.
62376985|NCT04668365|EXPERIMENTAL|Zanubrutinib Combined With Standard Chemotherapy|"A: For the first-line treatment:~Rituximab, 375mg/m2, Intravenous administration on day 0, combined with regimen：CHOP (Cyclophosphamide, Epirubicin, Vincristine and Prednisone): repeated every 3 weeks, up to 6 cycles.~Zanubrutinib, 160mg twice daily continuous oral administration from 2 to 6 cycles for patients with CD79A/CD79B genetic abnormality.~Zanubrutinib combined with Rituximab for the 7 cycle.~B: For R/R DBCLC:~Rituximab, 375mg/m2, Intravenous administration on day 0, combined with regimen: GemOx(Gemcitabine, Oxaliplatin)/ DHAP(Cisplatin, Cytarabine, Dexamethasone)/ ICE(Ifosfamide, Etoposide, Carboplatin)/ GDP(Gemcitabine, Cisplatin, Dexamethasone): repeated every 3 weeks, up to 5 cycles.~Zanubrutinib, 160mg twice daily continuous oral administration from 2 to 5 cycles for patients with CD79A/CD79B genetic abnormality.~Maintenance treatment: Zanubrutinib, 160mg twice daily continuous oral administration for 12 months."
62376986|NCT04589832|EXPERIMENTAL|Study Treatment Arm|Phase 1b will determine the MTD of PAC-1 in combination with entrectinib. Study treatment will include: PAC-1 will be taken orally on Days 1-21 and Entrectinib will be taken orally on Days 1-28 of each 28-day cycle. Treatment will continue until disease progression (based on RECIST 1.1 criteria), unacceptable toxicity, subject withdrawal of informed consent, or subject death either from progression of disease, the therapy itself, or from other causes.
62376987|NCT01006915|EXPERIMENTAL|Surgical decompression|Surgical decompression of the common peroneal, tibial, and deep peroneal nerves
62376988|NCT01006915|NO_INTERVENTION|Standard medical care|Standard diabetic care and medical care provided for diabetic sensorimotor polyneuropathy
62376989|NCT05830240|EXPERIMENTAL|R130 Treatment Group|Every 7-14 days,1-2 ml R130 （concentration of 1x10\^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral in patients with relapsed/refractory head and neck cancer
62376990|NCT05690711|EXPERIMENTAL|HRS8179|
62376991|NCT05690711|PLACEBO_COMPARATOR|Placebo|
62752955|NCT05151432|EXPERIMENTAL|Pulsed US + Pulsed Electromagnetic + Exercise Group|Twenty subjects will receive PUT, PEMF, plus an exercise program.
62752956|NCT05151432|EXPERIMENTAL|Sham + Exercise group|Twenty subjects will receive sham PEMF and sham PUT plus exercises program.
62752957|NCT04453085|EXPERIMENTAL|Dose level 1|2.0 mg/kg/week
62752958|NCT04453085|EXPERIMENTAL|Dose level 2|4.0 mg/kg/week
62567573|NCT00792051|ACTIVE_COMPARATOR|1|Influenza vaccine
62567574|NCT00792051|PLACEBO_COMPARATOR|2|
62752959|NCT02813655|EXPERIMENTAL|Experimental arm|Tetracosactide (Synacthène®)
62752960|NCT02813655|PLACEBO_COMPARATOR|Control arm|placebo saline (0.9% NaCl)
62752961|NCT04395638|EXPERIMENTAL|Weekly Vitamin D group|
62752962|NCT04395638|EXPERIMENTAL|Daily Vitamin D group|
62376992|NCT02892734|EXPERIMENTAL|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes Q2W and ipilimumab IV over 90 minutes Q6W in the absence of disease progression or unacceptable toxicity.
62376993|NCT06359886|EXPERIMENTAL|B-Lynch Transverse Compression Suture|Transverse B-Lynch suture will be performed to these patients as a method of controlling postpartum heamorrhage in placenta previa patients
62376994|NCT02396264|EXPERIMENTAL|Mediterranean Diet|The diet programme will be characterized by carbohydrates (60 %); proteins (20 %, half comprised of vegetable proteins); total fat (20 %; saturated fat \< 10 %). After calculating the patient's energy need, the amount of calories will be successively adjusted to mantain the same weight of the time of recruitment
62376995|NCT02396264|ACTIVE_COMPARATOR|normocaloric diet|50% carbohydrates, 30% total lipids and 20% proteins. After calculating the patient's energy need, the amount of calories will be successively adjusted to mantain the same weight of the time of recruitment
62376996|NCT01191138|OTHER|Infracolic Anastamosis|The gastrojejunal anastamosis is done in the infracolic compartment
62376997|NCT01191138|OTHER|Supracolic Anastamosis|The gastrojejunal anastamosis is done in the supracolic compartment
62376998|NCT03215745|EXPERIMENTAL|Delirium prevention program|Delirium prevention program involved a non-pharmacologic preventive interventions that will be focused in: Delirium prevention program includes individualized non-pharmacological interventions such as multisensory stimulation, cognitive stimulation, activate the functional and family involvement.
62567575|NCT05644054|EXPERIMENTAL|Treatment (THC) - session 1|Patients will attend two sessions in a crossover design, where they will receive one of the drugs in a randomized sequence at each session.
62752963|NCT05894720|EXPERIMENTAL|Thrower's Ten Exercise Group|"the athletes were subjected to Thrower's Ten exercise program under the supervision of the same physiotherapist 3 days a week for a period of 6 weeks in addition to the routine practice programs thereof. Each session started with a 10-minute warm-up program and ended with a 10-minute cool-down program. The warm-up program included low-intensity aerobic activities and short stretching exercises. Stretching exercises for anterior-posterior-inferior capsule, right and left trapezoid muscles, chintug as well as posterior-lateral neck and latissimus dorsi muscles were given. Following the exercises, the athletes were made to perform low-intensity jogging and static stretching exercises. All athletes, who were included in the study sample, continued attending their 2-hour routine pool practice on 4 days a week in addition to the Thrower's Ten exercises for 6 weeks."
62752964|NCT00457821|EXPERIMENTAL|Ivacaftor Group A|Subjects in Part 1 who first received 25 mg or 75 mg of ivacaftor every 12 hours (q12h) for 14 days, then crossed over to receive the alternate dose for another 14 days.
62752965|NCT00457821|EXPERIMENTAL|Ivacaftor Group B|Subjects in Part 1 who first received 75 mg or 150 mg of ivacaftor q12h for 14 days then crossed over to receive the alternate dose for another 14 days.
62752966|NCT00457821|EXPERIMENTAL|Ivacaftor Group C|Subjects in Part 2 who received 150 mg or 250 mg of ivacaftor q12h for 28 days.
62752967|NCT00457821|PLACEBO_COMPARATOR|Placebo|Subjects who received placebo in Part 1 and subjects who received placebo in Part 2.
62752968|NCT01375868|EXPERIMENTAL|Vaccine Silgard|vaccination with tetravalent antiviral vaccine, 3 doses
62752969|NCT05864521|ACTIVE_COMPARATOR|Active Beetroot Juice Supplement (aBRJ) then Placebo Beetroot Juice Supplement (pBRJ)|Subjects randomized to this arm of the study will have aBRJ administered during Visit 2 and then pBRJ administered during Visit 3.
62752970|NCT05864521|ACTIVE_COMPARATOR|Placebo Beetroot Juice Supplement (pBRJ) then Active Beetroot Juice Supplement (aBRJ)|Subjects randomized to this arm of the study will have pBRJ administered during Visit 2 and then aBRJ administered during Visit 3.
62752971|NCT01459640|ACTIVE_COMPARATOR|Hyaluronic acid|
62752972|NCT01459640|EXPERIMENTAL|Bone marrow mesenchymal stem cells|Autologous bone marrow-derived mesenchymal stem cells
62752973|NCT02196116|ACTIVE_COMPARATOR|Group 1|Controls
62752974|NCT02196116|EXPERIMENTAL|Group 2|Cognitively-impaired subjects without dementia and without memory
62752975|NCT02196116|EXPERIMENTAL|Group 3|Cognitively-impaired subjects without dementia and with memory
61997505|NCT03670810|PLACEBO_COMPARATOR|Control 2 Sequence|"Control 2:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
62376999|NCT03215745|NO_INTERVENTION|Control group|Usual care
62377000|NCT04145193|ACTIVE_COMPARATOR|Control Arm (mFOLFOX6)|Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
62377001|NCT04145193|EXPERIMENTAL|Durvalumab|Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)
62377002|NCT04145193|EXPERIMENTAL|Oleclumab|Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)
62377003|NCT04145193|EXPERIMENTAL|Monalizumab|Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)
62377004|NCT02243306|EXPERIMENTAL|Cohort 1|Subjects on continuous ambulatory peritoneal dialysis (CAPD) will receive 5 mg of GSK1278863 orally, once daily for 14 days.
62752976|NCT03065101|OTHER|Trigen Intertan|"* Unique integrated interlocking screw and trapezoidal nail shape~* Resistance to femoral head rotation and cut-out~* Active compression through linear motion without rotation~* Single subtrochanteric lag screw option for stable fractures below lesser trochanter~* Preloaded cannulated set screw converts construct to fixed angle device~* Small proximal diameter of the nail promotes preservation of the lateral wall of the greater trochanter and gluteus medius tendon~* Clothespin tip for stress modulation in femoral shaft~* Potential for improved patient mobility and recovery~Manufactured by Smith \& Nephew Inc., 1450 Brooks Road, Memphis, TN 38116, U.S.A.~Interventions:~Randomisation to either Trigen Intertan or Sliding Hip Screw, Post-Surgery Follow Up"
62752977|NCT03065101|OTHER|Sliding Hip Screw|"SHS is a generic term for a group of devices used for internal fixation of trochanteric hip fractures. Also known as Compression Hip Screw or Dynamic Hip Screw. All devices feature a lag screw inserted into the femoral neck and a side plate held in place by cortical screws inserted into the proximal femoral shaft.~Therapeutic effect is achieved by guided collapse, where the lag screw can slide in the barrel of the side plate which compresses the fracture as the patient begins to weight-bear.~Participating sites may use whichever brand of SHS is currently in use.~Interventions:~Randomisation to either Trigen Intertan or Sliding Hip Screw, Post-Surgery Follow Up"
62752978|NCT06605339|NO_INTERVENTION|Control|The child in the control group did not receive any additional intervention.
62752979|NCT06605339|EXPERIMENTAL|Virtual reality|In the study, Oculus Quest 2 256 GB All-In-One Vr Virtual Reality Glasses were used, and the Epic Roller Coasters train game, an application that would attract the attention of children, was determined by the researchers. The virtual reality application was started 2 minutes before the procedure and continued until the procedure was completed.
62752980|NCT02788773|EXPERIMENTAL|Arm A - Durvalumab plus Tremelimumab|Durvalumab-IV for 60 minutes day 1 every 4 weeks Tremelimumab-IV every 60 minutes day 1, cycles 1-4
62752981|NCT02788773|EXPERIMENTAL|Arm B - Durvalumab alone|Durvalumab-IV for 60 minutes day 1 every 4 weeks
62752982|NCT03006029|EXPERIMENTAL|TAB08( Theralizumab)|TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
62752983|NCT02763254|EXPERIMENTAL|baltaleucel-T|Treatment consist of up to 5 doses of 2x10E7 cells/m2 administered intravenously every 2 weeks.
62752984|NCT04407650|ACTIVE_COMPARATOR|Metformin|Oral 1000 mg BD
62752985|NCT04407650|EXPERIMENTAL|Ursodeoxycholic acid|Oral 500 mg BD
62752986|NCT02630940||Idiopathic pulmonary fibrosis sufferers|Male or female idiopathic pulmonary fibrosis (IPF) sufferers over the age of 40, with a confirmed diagnosis of IPF against international guidelines. Patients are devoid of significant other medical, surgical or psychiatric illnesses that may affect respiratory symptoms or disease progression.
61997506|NCT03670810|EXPERIMENTAL|100 mg Lasmiditan Maximum Extended Enrollment (MEE)|Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
62377005|NCT02243306|EXPERIMENTAL|Cohort 2|Subjects on automated peritoneal dialysis (APD) will receive 5 mg of GSK1278863 orally, once daily for 14 days
62752987|NCT00549900|EXPERIMENTAL|Cervarix Group|Subjects received 3 doses of GSK580299 vaccine (Cervarix™, HPV -16/18 L1 VLP AS04 vaccine) according to a 0, 1, 6-month schedule.
62752988|NCT00746239|ACTIVE_COMPARATOR|1|Subjects will be randomly assigned to receive either Ramelteon and Escitalopram OR Placebo and Escitalopram.
62752989|NCT00746239|PLACEBO_COMPARATOR|2|Subjects will be randomly assigned to receive either Ramelteon and Escitalopram OR Placebo and Escitalopram.
62752990|NCT04039711|OTHER|Genital infections|Women with vaginal/cervical sampling indications
62752991|NCT01803178|ACTIVE_COMPARATOR|Plant Sterols|Plant Sterols
62752992|NCT01803178|PLACEBO_COMPARATOR|Placebo Product|Placebo Product
62752993|NCT05106712|EXPERIMENTAL|Vitamin D3|Participants will be treated with oral vitamin D3 4000IU capsules per day for around 12 weeks
62377006|NCT03710291|EXPERIMENTAL|TRC101|
62752994|NCT05106712|ACTIVE_COMPARATOR|"Ovulation-inducing drug Clomiphene citrate"|"Participants will be treated with oral Clomiphene citrate using its respective Stair-step dosage protocol as follow: 50 mg, 100 mg, and 150 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively."
62752995|NCT05106712|ACTIVE_COMPARATOR|"Ovulation-inducing drug Letrozole"|"Participants will be treated with oral Letrozole using its respective Stair-step dosage protocol as follow: 5 mg, 5 mg, and 7.5 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively, respectively."
62752996|NCT05106712|PLACEBO_COMPARATOR|Placebo|PCOS-Vitamin D-deficient infertile women in the control (Placebo) group will be treated with equal amount of placebo tablets per day for the same duration.
62752997|NCT02264665||Sunitinib|
62752998|NCT02264665||Afinitor|
62752999|NCT02264665||other treatment (chémotherapy, SSA..)|
62753000|NCT04051710|EXPERIMENTAL|Group-I (Test)|One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Test) twice daily.
61997507|NCT03670810|EXPERIMENTAL|200 mg Lasmiditan MEE|Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
62377007|NCT03710291|PLACEBO_COMPARATOR|Placebo|
62377008|NCT04376736|NO_INTERVENTION|Control arm|Patients are reminded about their appointments
62377009|NCT04376736|EXPERIMENTAL|Intervention arm|Patients are offered a one-time home visit by providers in lieu of their upcoming in-person visit
62753001|NCT04051710|ACTIVE_COMPARATOR|Group-II (Reference)|One inhalation of QVAR® 40 mcg (Beclomethasone dipropionate HFA), Inhalation Aerosol twice daily.
62753002|NCT04051710|PLACEBO_COMPARATOR|Group-III (Placebo)|One inhalation of Placebo Inhalation Aerosol twice daily.
62753003|NCT01545882|EXPERIMENTAL|Degarelix|Degarelix treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
62753004|NCT03804021||Roll over|Subjects who received ADVM-043 in a parent study (ADVANCE; NCT02168686)
62753005|NCT01832623|EXPERIMENTAL|Exploration of Vitamin D roles|Various exams will be performed during two visits (the same day or within three months) in order to answer the objectives of the study.
62753006|NCT03392389|EXPERIMENTAL|mRNA-1653|
62753007|NCT03392389|PLACEBO_COMPARATOR|Placebo|
62753008|NCT05258214|EXPERIMENTAL|Mulligan Bent Leg Raise With Conventional Therapy|"This group will receive mulligan's bent leg raise with conventional therapy. In a mulligan bent leg lift, the practitioner stands on the side of the supine subject on the couch with minimal hamstring stability. The subject's flexed knee is placed over the therapist's shoulder, and the subject is instructed to force the therapist with his leg before relaxing.~At this moment, the therapist pushes subject's bent knee as high as possible on the same side as his (therapist's) shoulder. Mulligan's Bent Leg is performed three times.~The raises took 7 seconds to keep and 5 seconds to relax. And conventional therapy includes ultrasound, lumber strengthening, stretching exercises, stabilizing exercises for 30 minutes."
62753009|NCT05258214|EXPERIMENTAL|Mulligan Traction Straight Leg Raise With Conventional Therapy|"This group will receive mulligan's traction Straight Leg Raise with conventional therapy. Patients were placed in a supine position on a low couch or the floor and provided the Mulligan traction leg raise with knees bent..~Mulligan's Traction is repeated three times. Straight Leg Raise was kept for 7 seconds and then relaxed for 5 seconds. Three repetitions of the pain-free Straight Leg Raise traction is performed. And conventional therapy include ultrasound, lumber strengthening, stretching exercises, stabilizing exercises for 30 minutes."
62753010|NCT05258214|EXPERIMENTAL|Neural Mobilization With Conventional Therapy|"This group will receive neural mobilization with conventional therapy. Straight leg raise movements will be used to trigger sciatic nerve pain during neural mobilization exercises.~Based on the participant's responses and tolerance, several repetitions may be done.~The range of motion will be expanded as the symptom increases before the full Straight Leg Raise range is reached.~The position will be kept for a total of 5 minutes and 30 seconds. Repetition will be carried out. And conventional therapy include ultrasound, lumber strengthening, stretching exercises, stabilizing exercises for 30 minutes."
62753011|NCT05636384|EXPERIMENTAL|Intervention|Patients enrolled in the intervention cluster (institution) are given specialized home-based medical care based on a specialized home-based medical team approach.
62377010|NCT01966406|EXPERIMENTAL|No nasogastric tube insertion before pancreaticoduodenectomy|The patients receiving pancreaticoduodenectomy will not undergo NG tube insertion before operation
62377011|NCT01966406|ACTIVE_COMPARATOR|Pre-operative NG tube use|The patients receiving pancreaticoduodenectomy will undergo NG tube insertion before operation
62377012|NCT03930810||FIC1-deficiency and Bsep-deficiency|
62377013|NCT05560074|EXPERIMENTAL|Buzzy|Buzzy®: It is a 8x5x2.5 cm sized, noninvasive device used for pain control in adults and children, developed by the pediatrician Ammy Baxter, with a plastic battery and vibration motor. A cold ice pack is placed under Buzzy. It has a local cold application and vibration effect. It is placed 3\~5 cm above the injection site for 15\~30 sec before and during the procedure, making local cold application and vibrations. One should be sure about the definite contact of Buzzy® with the skin. The ice pack is kept in a deep freezer and placed in the device before the procedure. After the procedure is completed, the ice pack is wiped with 70% alcohol, and kept and chilled again in the deep freezer. http://www.buzzy4shots.com/)
62377014|NCT05560074|EXPERIMENTAL|DistractionCards|"DistrACTION® Cards consisted of visual cards of 5 cm × 8 cm, covered with various pictures and shapes. In this method, the children first carefully examine the cards. Then, the PhD-qualified nurse researcher asks some questions about those cards to be answered by the children, such as How many ladybugs are there in the picture? How many apes are there in the picture? or Can you see the comet? The distraction procedure via distraction cards begin just before the venous blood specimen collection and continue until the end of the blood specimen collection"
62753012|NCT05636384|NO_INTERVENTION|Control|"Patients enrolled in the control cluster (institution) are only given the educational materials.~Except for the home-based care intervention, usual care for advanced cancer patients was not restricted for these patients."
62377015|NCT05560074|NO_INTERVENTION|Control|Controll group: Venous blood will be taken as usual on the blood collection room without applying an intervention to the children in the Control group. Children will follow the standard blood draw procedure.
62377016|NCT05022706|EXPERIMENTAL|Adolescents living with HIV|"1. cART directly observed therapy (DOT) for participants at risk of or with a history of non-adherence~2. monthly home visits by trained health promoters~3. ongoing support in navigating the health system, including accompaniment to appointments and assistance enrolling in public health insurance~4. monthly peer support groups"
62377017|NCT02325089|EXPERIMENTAL|Mandibular advancement device|Mandibular advancement device titrated to reduce or eliminate snoring and sleep apnea
62753013|NCT05849441|EXPERIMENTAL|Online mindfulness intervention|Participants will have access to the intervention between pre-test and post-test assessments. The intervention, Aware Program, is an online mindfulness education program for adolescents with 22q11DS designed to enhance their coping skills and ability to manage stress and anxiety in healthy ways.
62753014|NCT05849441|NO_INTERVENTION|Wait-List Control|Participants will not have access to the online mindfulness intervention between the pre-test and post-test assessments. After completing the post-test questionnaires, participants in the wait-list control group will receive access to the online mindfulness intervention (Aware Program).
62753015|NCT00834470|EXPERIMENTAL|Atropine|Atropine 0.01mg/kg IV
62753016|NCT00834470|PLACEBO_COMPARATOR|Normal saline|Same volume of atropine
62753017|NCT02124057||Healthy female control|Age-matched healthy control women
62377018|NCT02325089|PLACEBO_COMPARATOR|Placebo|Oral appliance identical to the mandibular advancement device without mandibular advancement
62377019|NCT01145404|EXPERIMENTAL|Arm A: Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
62377020|NCT01145404|EXPERIMENTAL|Arm B|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
62377021|NCT02483351|EXPERIMENTAL|Liberal RBC Transfusion Strategy|
62377022|NCT02483351|ACTIVE_COMPARATOR|Restrictive RBC Transfusion Strategy|
62377023|NCT02094664|NO_INTERVENTION|Standard oxygen via nasal cannula|Standard therapy
62377024|NCT02094664|ACTIVE_COMPARATOR|Heated and humidified oxygen|Heated and humified oxygen
62377025|NCT04300842||Cancer patient|This project expects to enroll 60 cancer patients and their subjective-objective measurements on fatigue, stress, and total steps will be observed.
62377026|NCT04300842||Healthy population|This project expects to enroll 60 healthy population and their subjective-objective measurements on fatigue, stress, and total steps will be observed.
62377027|NCT01855867|OTHER|Stribild|Single dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg) taken for 28 days, within 72 hours of a possible sexual exposure to HIV
62377028|NCT06049251|EXPERIMENTAL|ELDOA exercises|ELDOA exercises
62377029|NCT06049251|ACTIVE_COMPARATOR|Lumbar SNAGS and motor control exercises|Lumbar SNAGS and motor control exercises
62377030|NCT01731275|EXPERIMENTAL|E6011|
62377031|NCT01731275|PLACEBO_COMPARATOR|E6011 Matching Placebo|
62753018|NCT02124057||Healthy male control|Age-matched healthy control men
62753019|NCT02124057||Other Motor Neuron Disease Patients|Male participants with other motor neuron disease
62753020|NCT02124057||SBMA Patients|Men with genetically confirmed SBMA
62753021|NCT02124057||SMBA|SBMA carrier women
62753022|NCT02518958|EXPERIMENTAL|RRx-001 + Nivolumab|Patients enrolled in this trial will receive study drug (RRx-001) on Day 1 as a single agent. Nivolumab (3 mg/kg) will be administered on Day 2 or Day 3 as a single agent.
62753023|NCT04401618||Class V RMGI Restorations|Resin-modified glass ionomer (RMGI - Fuji 2 LC) Class V restorations performed by by 3rd and 4th-year dental students in adult patients of Schulich dental clinic over the last three years will be evaluated using mirrors and probes.
62753024|NCT04401618||Class V Glass ionomer - GIC Restorations|Glass ionomer (GI - Fuji 9) Class V restorations performed by by 3rd and 4th-year dental students in adult patients of Schulich dental clinic over the last three years will be evaluated using mirrors and probes.
62753025|NCT01438801|EXPERIMENTAL|NutropinAq|
62753026|NCT01740089|EXPERIMENTAL|Algeron 1.5 μg/kg|Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg).
62377032|NCT06352502||Furmonertinib group|Patients treated with Furmonertinib
62377033|NCT03565926|ACTIVE_COMPARATOR|Manual Therapy|"Manual Therapy Protocol~1. Articulation technique L4-S1~2. Lumbar neuromuscular technique~3. Fascial technique of crossed hands~4. Posteroanterior mobilizations of the lumbar vertebrae"
62377034|NCT03565926|EXPERIMENTAL|Hypopressive exercises|Protocol of 5 Hypopressive Exercises
62567576|NCT05644054|PLACEBO_COMPARATOR|Placebo - session 2|Patients will attend two sessions in a crossover design, where they will receive one of the drugs in a randomized sequence at each session.
62753027|NCT01740089|EXPERIMENTAL|Algeron 2.0 μg/kg|Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg).
62753028|NCT01740089|ACTIVE_COMPARATOR|PegIntron|PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg).
62567577|NCT02547792|EXPERIMENTAL|VXA-BYW.10 (Low Dose) Oral Vaccine|Single administration of Influenza B (Low Dose) oral vaccine tablets
62567578|NCT02547792|EXPERIMENTAL|VXA-BYW.10 (High Dose) Oral Vaccine|Single administration of Influenza B (High Dose) oral vaccine tablets
62567579|NCT02547792|PLACEBO_COMPARATOR|Placebo Tablets|Matching placebo dose (size and number of tablets) to low dose vaccine (part 1) and high dose (part 2)
62567580|NCT00003909|EXPERIMENTAL|Arm I|Approximately 2-5 hours before radiotherapy, patients receive motexafin gadolinium IV over 5 minutes. Patients undergo radiotherapy 5 days a week for 6 weeks.
62567581|NCT05689346|EXPERIMENTAL|study group|study group will receive high tone power therapy
62567582|NCT05689346|ACTIVE_COMPARATOR|control group|children in the contol group will recieve traditional treatment for improving balance.
62567583|NCT02461966|OTHER|Hepatocellular carcinoma (HCC)|Estimation of serum aflatoxin level in 40 patients with hepatocellular carcinoma (HCC)
62567584|NCT02461966|OTHER|20 cirrhotic patients|Estimation of serum aflatoxin level in 20 patients with liver cirrhosis
62567585|NCT02461966|OTHER|Control group|Estimation of serum aflatoxin level in 15 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study
62567586|NCT05813873|EXPERIMENTAL|Triflow|Use of Triflow device and exercise regime
62567587|NCT05813873|ACTIVE_COMPARATOR|Control|Only exercise regime
62567588|NCT05666635|EXPERIMENTAL|Experimental：LTC004|Monotherapy, dose escalation
62567589|NCT02059135|ACTIVE_COMPARATOR|Recombinant Human Antithrombin (ATryn)|ATryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
62567590|NCT02059135|PLACEBO_COMPARATOR|Normal Saline 0.9%|Placebo (Normal Saline 0.9%, matched for volume of active treatment) consisting of a loading dose over 15 minutes followed by continuous infusion.
62567591|NCT03972748|EXPERIMENTAL|Itraconazole|Oral Itraconazole capsules, 200 mg
62567592|NCT04720456|EXPERIMENTAL|SHAPE with Sonazoid|Up to 60 children (6-21 years of age) with a diagnosis of chronic liver disease, including some who will have portal hypertension who are followed at The Children's Hospital of Philadelphia (CHOP) will be enrolled in this arm. A SHAPE measurement using the ultrasound contrast agent Sonazoid® (perfluorobutane microbubbles) will be performed during a single visit. A dose of three vials with 16 μL each of microbubbles will be prepared. An infusion of the ultrasound contrast agent at the rate of 0.18 mL/kg/hour will be co-infused with an infusion of saline at the rate of 120 mL/hour resulting in an effective dosage of 1.44 μL microbubbles/kg/hour as per the FDA approved IND through an IV line in a peripheral vein. The total duration of contrast agent infusion is expected to range from 4 to 8 minutes, which includes a 2 min calibration period followed by 2-6 minutes of SHAPE acquisition (i.e., ultrasound imaging).
61997508|NCT03670810|PLACEBO_COMPARATOR|Control 1 Sequence MEE|"Control 1:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
62753029|NCT06332664|EXPERIMENTAL|Early Nutrition Intervention|For patients meeting the inclusion criteria and randomly assigned to the intervention group, the investigators will assess their nutritional status monthly. During the home-based period between chemotherapy cycles, the investigators will conduct follow-up and provide care using a mobile application (APP). In the event of new nutritional risks emerging in patients, timely recommendations for medical consultation will be made, and nutritional plans will be formulated accordingly.
62753030|NCT06332664|NO_INTERVENTION|standard care|Patients randomly assigned to the standard treatment group will receive standard care for cancer patients and will not be scheduled for interdisciplinary supportive therapy assessment unless requested by the patient, the primary oncologist, or their family.
62753031|NCT06026345||Treatment Arm|Patients enrolled and treated with the Affera Platform
62377035|NCT05570136|EXPERIMENTAL|Treatment|Participants in the treatment group will receive the 12-week STEP by a trained interventionist. In the first four weeks, the interventionist will focus on building participants' selfefficacy and health literacy and help participants learn the STEP exercise and principles. In the following four weeks, the interventionist will help the older adults to be more independent in prescribing exercise activities for themselves. In the last four weeks, participants will be fulling knowledgeable and independent on functional exercising; the interventionist will allocate community resources for long-term maintenance. After program completion, trained raters will administer at post-tests. There will also be a 3-month and 6-month follow-up evaluation after program completion.
62753032|NCT05721937||Exposed to CIBINQO during pregnancy|Received at least one dose of CIBINQO at any time during pregnancy or prior to pregnancy (within 1 day prior to the date of conception).
62753033|NCT05721937||Unexposed to CIBINQO during pregnancy|Diagnosed with moderate-to-severe atopic dermatitis, but not exposed to CIBINQO during pregnancy.
62377036|NCT05570136|SHAM_COMPARATOR|Control|Participants in the control group will receive weekly health newsletters and will not get any suggestions or encouragement to do exercise from the research team. A staff member will call the control group participants weekly to document any new exercise programs from usual community services. At this stage, participants will not be excluded from the study if they join an exercise program, but we will document what kind of exercise they are conducting. Trained raters will administer at post-tests and two follow-ups.
62377037|NCT04193605|ACTIVE_COMPARATOR|Mindfulness Based Stress Reduction|MBSR sessions received by the treatment group will include an orientation, approximately 8 intervention sessions, and an exit interview.
62377038|NCT04193605|NO_INTERVENTION|Standard of Care|The control condition will continue receiving usual care or standard of care.
62377039|NCT01736930|ACTIVE_COMPARATOR|Predictive pump suspension algorithm|The study laptop will be running actively during the night and suspending the patient's pump if the algorithm predicts hypoglycemia based on the patient's continuous glucose sensor trend.
62377040|NCT01736930|NO_INTERVENTION|Standard of Care|The control algorithm will run passively and not recommend suspensions or resumption to the patient's pump.
62753034|NCT03447314|EXPERIMENTAL|Part 1a: 50ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 50 nanogram (ng) intravenously (IV) on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with GSK3174998 24 milligram (mg) administered at 3-week intervals (Q3W) via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
62753035|NCT03447314|EXPERIMENTAL|Part 1a: 100ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
62753036|NCT03447314|EXPERIMENTAL|Part 1a: 150ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
62753037|NCT03447314|EXPERIMENTAL|Part 1a: 200ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
62753038|NCT03447314|EXPERIMENTAL|Part 1a: 250ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
62753039|NCT03447314|EXPERIMENTAL|Part 1b: 50ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 50 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
62753040|NCT03447314|EXPERIMENTAL|Part 1b: 100ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
62753041|NCT03447314|EXPERIMENTAL|Part 1b: 150ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
62753042|NCT03447314|EXPERIMENTAL|Part 1b: 200ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
62753043|NCT03447314|EXPERIMENTAL|Part 1b: 250ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
62753044|NCT03447314|EXPERIMENTAL|Part 1c: 50ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 50 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
62753045|NCT03447314|EXPERIMENTAL|Part 1c: 100ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
62753046|NCT03447314|EXPERIMENTAL|Part 1c: 150ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
62753047|NCT03447314|EXPERIMENTAL|Part 1c: 200ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
62753048|NCT03447314|EXPERIMENTAL|Part 1c: 250ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
62753049|NCT03447314|EXPERIMENTAL|Part 2a: GSK1795091 + 24 mg GSK3174998|Participants will be administered GSK1795091 at a dose identified in Part 1 along with GSK3174998 24 mg.
62753050|NCT03447314|EXPERIMENTAL|Part 2b: GSK1795091 + 80 mg GSK3359609|Participants will be administered GSK1795091 at a dose identified in Part 1 along with GSK3359609 80 mg.
62753051|NCT03447314|EXPERIMENTAL|Part 2c: GSK1795091 + 200 mg Pembrolizumab|Participants will be administered GSK1795091 at a dose identified in Part 1 along with pembrolizumab 200 mg.
62377041|NCT01241890||Children with Cystic Fibrosis, care as usual|Treatment according to the Dutch Central Guidance Committee (CBO) guidelines for CF. Assessments: home monitoring, symptoms, lung function, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
62377042|NCT02458742|EXPERIMENTAL|Morphine|0.5%Bupivacaine 2 ml with morphine 50 mcg for spinal anesthesia
62377043|NCT02458742|PLACEBO_COMPARATOR|Placebo|0.5%Bupivacaine 2 ml for spinal anesthesia
62753052|NCT02916888||Care provided by general pediatrician|Standard of care management of atopic dermatitis by general pediatrician. This includes an initial visit with a 2-week follow-up.
62753053|NCT02916888||Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by pediatric dermatologist. This includes an initial visit with a 2-week follow-up.
62753054|NCT02797093||HIV suppressed individuals|HIV suppressed individuals on chronic ART, suboptimal adherence and exposure, measured through TFV-DP in DBS.
62753055|NCT05235958|EXPERIMENTAL|Training intervention|8 weeks of non-linear periodized aerobic exercise; 3 sessions per week; 1 hour per session; standardized warm-up; individual training intensity according to cardiorespiratory fitness level
62377044|NCT02184390|EXPERIMENTAL|tutorial|Parents who receive access to the tutorial immediately
62377045|NCT02184390|NO_INTERVENTION|wait list control|Parents who are assessed at the same time points as the intervention arm, but do no receive access to the tutorial
62753056|NCT05235958|SHAM_COMPARATOR|Control Intervention|Recommendation to continue with current lifestyle (especially physical activity habits) during the following 8 weeks. At the final assessment after 8 weeks, individualized exercise recommendations according to established standard procedures in exercise medicine and offer to attend the standard medical follow-up in our outpatient clinics subsequent to study termination
62753057|NCT00856089|EXPERIMENTAL|Retapamulin|
62377046|NCT02758106|ACTIVE_COMPARATOR|HFCW oscillation|"HFCWO was performed using a Vest Airway Clearance System Model 105 (Hill-Rom, St. Paul, Minnesota). HFCWO was applied to each subject at a frequency of 10-12 Hz and a pulse pressure setting of 1-2 selected for 15 minutes. The patients receiving HFCWO were placed in a semi-upright sitting position. Following HFCWO, suction was performed immediately via an endotracheal tube.~Changes to the initial ventilator settings during HFCWO were recorded before and at 5, 10 and 15 minutes. The variables included peak airway pressure, positive-end expiratory pressure, respiratory rate, fraction of inspired oxygen, inspiratory time, and sensitivity settings. Following HFCWO, suction was performed immediately via an endotracheal tube."
62753058|NCT03754582|EXPERIMENTAL|Perampanel|Participants with POS with or without secondarily generalized seizures or PGTC seizures will receive perampanel 8 to 12 milligram (mg), tablets, orally, once daily for 28 days (Day -28 to Day -1) in Pretreatment Phase and followed by 8 to 12 mg dose of perampanel as intravenous infusion for 30 minutes, once daily from Day 1 to Day 4 in Treatment Phase, and then again 8 to 12 mg, tablets, orally, once daily from Day 5 to Day 11 in Follow-up Phase as an adjunctive therapy, along with 1 to a maximum of 3 marketed concomitant antiepileptic drugs (AEDs).
62753059|NCT02108717|EXPERIMENTAL|Group I|"The raters in this group one firstly reviewed the CT scans numbered from one to 60 using LCD monitor and after mandatory rests of 20 minutes, reviewed the remaining CT examinations numbered from 61 to 120 using iPhone with TeamViewer at their first visit.~They visited twice with an interval of four weeks and reviewed the CT scans using revered devices at each session."
62753060|NCT02108717|EXPERIMENTAL|Group II|"The raters in this group II firstly reviewed the CT scans numbered from one to 60 using iPhone with TeamViewer and 61 to 120 with the LCD monitor.~They visited twice with an interval of four weeks and reviewed the CT scans using revered devices at each session."
62753061|NCT02291757|ACTIVE_COMPARATOR|NEM brand eggshell membrane|Subjects will be given enough treatment capsules or placebo capsules for 30-days after initial assessment, covering both the 7- and 30-day follow-up visits.
62753062|NCT02291757|PLACEBO_COMPARATOR|Placebo|Subjects will be given enough treatment capsules or placebo capsules for 30-days after initial assessment, covering both the 7- and 30-day follow-up visits. At the 30-day evaluation, patients in the placebo group will cross over to the treatment group for the remainder of the study and all patients will be given a 60-day supply of treatment capsules covering the 90-day follow-up visit.
62753063|NCT06605755|EXPERIMENTAL|Intervention group|Intervention group: 1 dose of DTaP-IPV/Hib Pentavalent Vaccine at 2, 4 and 6 months of age, and 1 dose of enhanced vaccine at 18 months of age.
62753064|NCT06605755|ACTIVE_COMPARATOR|Control group|Control group: 1 dose of DTaP-IPV/Hib Pentavalent Vaccine at 2, 3 and 4 months of age, and 1 dose of enhanced vaccine at 18 months of age.
62753065|NCT03895086|EXPERIMENTAL|Specific Physical Activity|Specific patient care in telephone coaching of fibromyalgia patients.
62753066|NCT03895086|OTHER|Classic Physical Activity|Classic patient care in common group of multipathological patients.
62377047|NCT02758106|PLACEBO_COMPARATOR|placebo intervention|the patients undergoing CCPT received cup-hand percussion with the hands positioned 3 inches from the chest, striking the chest with a waving movement while they were placed in right and left decubitus positions for 5-10 minutes each. Following CCPT, suction was performed immediately via an endotracheal tube.
62753067|NCT00096148|EXPERIMENTAL|Arm I (idarubicin, cytarabine)|"Arm I: Patients receive idarubicin IV over 1 hour on days 1-3 and cytarabine IV continuously over 24 hours on days 1-4.~Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.~Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24 hours on days 1-4."
62753068|NCT00096148|EXPERIMENTAL|Arm II (idarubicin, cytarabine, bevacizumab)|"Patients receive idarubicin and cytarabine as in arm I. Patients also receive bevacizumab\* IV over 30-90 minutes on day 1. Patients who do not achieve complete remission (CR) after the first induction course may receive a second induction course approximately 28 days\* later. Patients who do not achieve CR after 2 courses are removed from the study.~NOTE: \*Patients in arm II receive bevacizumab, independently of chemotherapy administration schedule, once every 21 days for 1 year from CR date.~Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.~Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24 hours on days 1-4."
62753069|NCT04272866|ACTIVE_COMPARATOR|Group 1|Teeth in this group will be sealed with clinpro sealant
62753070|NCT04272866|EXPERIMENTAL|Group2|Teeth in this group will be sealed with embrace wetbond sealant
62753071|NCT04272866|EXPERIMENTAL|Group3|Teeth in this group will be sealed with triage sealant
62753072|NCT03832114|EXPERIMENTAL|Cohort A - no kidney transplant|C3G patients who have not received a kidney transplant and have reduced C3 blood levels.
62753073|NCT03832114|EXPERIMENTAL|Cohort B - kidney transplant|C3G patients who have received a kidney transplant and have C3G recurrence.
62377048|NCT05002036|ACTIVE_COMPARATOR|HA-GB|eyedrop containing hyaluronic acid and gingko biloba (Trium eyedrops, Sooft srl)
62377049|NCT05002036|NO_INTERVENTION|No treatment|no treatment for iatrogenic dry-eye
62377050|NCT06364306|EXPERIMENTAL|Robotically-assisted ventral hernia repair (RVHR)|
62753074|NCT02578680|EXPERIMENTAL|Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed|Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m\^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m\^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m\^2 IV Q3W until progression. (Participants who receive pembrolizumab 200 mg IV Q3W for up to 2 years but experience disease progression, will be eligible to receive a second course of pembrolizumab monotherapy 200 mg IV Q3W, at the investigator's discretion, for up to 1 additional year.)
62753075|NCT02578680|ACTIVE_COMPARATOR|Control|Participants receive saline placebo IV PLUS pemetrexed 500 mg/m\^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m\^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m\^2 IV Q3W until progression. (Effective 23-Dec-2019, participants will discontinue saline placebo. If documented progression occurs, participants may be able to receive pembrolizumab monotherapy Q3W for the remainder of the study.)
62377051|NCT06364306|ACTIVE_COMPARATOR|Open ventral hernia repair (OVHR)|
62377052|NCT05705687|OTHER|Favorable-BEP group|"Favorable decline of tumor markers~3 subsequent cycles of protocol BEP every 3 weeks~* Cisplatin 20 mg/m2/day IV x 5 days (D1 to D5),~* Etoposide 100 mg/m2/day IV x 5 days (D1 to D5)~* Bleomycin 30 mg/day IV or IM D1, D8, and D15."
62377053|NCT05705687|OTHER|Unfavorable-dose-dense group|"Unfavorable decline of tumor markers, testicular or peritoneal primary tumor~2 cycles every 3 weeks of :~* Paclitaxel 175 mg/m2 IV over 3 hours on Day 1,~* Cisplatin 20 mg/m2/day IV x 5 days (D1 to D5),~* Etoposide 100 mg/m2/day IV x 5 days (D1 to D5)~* Bleomycin 30 mg/day IV or IM D1, D8, and D15.~* Oxaliplatin 130 mg/m2 IV over 3 hours, given on Day 10,~* G-CSF 263 microg/day SC, to be started one day after chemotherapy and stopped one day before the next scheduled chemotherapy cycle (D6-7, D9, D11-14, D16-20).~Then, 2 cycles every 3 weeks of :~* Cisplatin 100 mg/m2 IV over 2 hours on Day 1,~* Bleomycin 25 mg/day, by continuous IV infusion over 24 hours for 5 days from Day 10 to Day 14,~* Ifosfamide 2 g/m2 IV over 3 hours on Days 10, 12, and 14,~* Mesna 500 mg/m2 IV at time-points 0, 3, 7 and 11 hours on the days when ifosfamide is administered (mesna could also be given orally),~* G-CSF 263 microg/day SC on Days 2 to 9 and Days 16 to 20."
62377054|NCT05705687|EXPERIMENTAL|Unfavorable-phase II group|"Unfavorable decline of tumor markers, mediastinal primary tumor, proposal to the patient to enter the phase II part. If patient refusal or ineligible for phase II group, the patient will enter the Unfavorable-dose-dense group.~1 additional cycle of~* Paclitaxel 250 mg/m² on Day 1 over the day,~* Ifosfamide 1,5 mg/m²,~* Mesna 500 mg/m2 IV at time-points 0, 3, 7 and 11 hours on the days when ifosfamide is administered (mesna could also be given orally),~* Cisplatin 25 mg/m² from Day 1 to Day 5,~* Collection of HSC.~Then~* if no metastases are detectable and the resection is technically feasible : early surgery whenever possible, followed by 2 additional cycles of TIP chemotherapy every 3 weeks~* if surgery is not possible or in case of metastatic disease : HDCT (including 3 cycles of the CE regimen (carboplatin AUC 8, using the Calvert formula, from Day 1 to Day 3 and etoposide 400 mg/m² from Day 1 to Day 3)) plus HSC support, followed by surgery of residual deposits."
62377055|NCT05111184|OTHER|Internvention group|
62377056|NCT04993430|EXPERIMENTAL|Group A|HRS8807 monotherapy dose escalation
62753076|NCT05105750|ACTIVE_COMPARATOR|aspirin 100 mg/d therapy|
62753077|NCT05105750|EXPERIMENTAL|indobufen 200 mg bid therapy|
62377057|NCT04993430|EXPERIMENTAL|Group B|HRS8807 monotherapy dose expansion
62377058|NCT04993430|EXPERIMENTAL|Group C|HRS8807 in combination with SHR6390 dose escalation
62377059|NCT04993430|EXPERIMENTAL|Group D|HRS8807 in combination with SHR6390 dose expansion
62377060|NCT02378610||Observation in High-stressed|Saliva and fecal samples will be collected from High-stressed persons
62377061|NCT02378610||Observation in Low-stressed|Saliva and fecal samples will be collected from Low-stressed persons
62377062|NCT03453346|EXPERIMENTAL|Noncirrhotic and cirrhotic GT-2|Generic sofosbuvir tablet 400 mg once daily plus weight-adjusted ribavirin tablet (1000 mg for \<75 kg, and 1200 mg for \>=75 kg) twice daily with meal, orally given, for 12 successive weeks
62753078|NCT03962257|NO_INTERVENTION|Conventional|This group will have standard of care infertility counseling and consent processes.
62753079|NCT03962257|EXPERIMENTAL|Engaged MD|This group will have standard of care infertility counseling and access to online teaching modules and the ability to sign consents online.
62377063|NCT03745391|ACTIVE_COMPARATOR|MULTIMODAL MAGNETIC RESONANCE (MR)|Diagnostic test: Multimodal Neuroimaging Test: MR The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization be assigned to Multimodal MR, will be directedly transferred to MR. It will be performed a multimodal MR taking into account that after discard an intracerebral haemorrhage and confirm an ischemic lesion if the patient fulfill criteria to receive intravenous alteplase, the test will be paused just to administer the treatment and immediately put again into the machine to complete the MR images. With all the information vascular neurologist will be decide if it is necessary administer endovascular treatment.
62377064|NCT03745391|ACTIVE_COMPARATOR|MULTIMODAL COMPUTED TOMOGRAPHY (CT)|Diagnostic test: Multimodal Neuroimaging Test: CT The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization is assigned to Multimodal CT, will be directedly transferred to CT. If the patient fulfill criteria to receive intravenous alteplase after discard an intracerebral haemorrhage the CT will be paused to administer the treatment and immediately will continue with the test. At the end of the test the vascular neurologist will decide if it is necessary administer endovascular treatment.
62377065|NCT03489538||RYGB Patients|Laparoscopic long limb roux-en-Y gastric bypass group. All consecutive patients eligible for bariatric surgery.
62377066|NCT04124952||Panoptix|Patients bilaterally implanted with the Panoptix intraocular lens.
62377067|NCT05807191|EXPERIMENTAL|Intervention Group|Kangaroo care was applied for 65 minutes to premature infants by their mothers based on the kangaroo care guide.
62377068|NCT05807191|NO_INTERVENTION|Control Group|Kangaroo care was routinely administered by the nurse for 65 minutes without using a kangaroo care guide.
62377069|NCT03239769|ACTIVE_COMPARATOR|conventional access group (CA)|A 4- to 5-cm incision was created, subplatysmal flaps were raised, and the strap muscles were mobilized. Then, the superior pole of the thyroid gland was exposed and the gland was delivered through the surgical incision, and the thyroid isthmus was divided. Finally, CLND was performed. The strap muscles were re-approximated with No.1 silk suture. The full-thickness skin was closed with interrupted monofilament.
62377070|NCT03239769|EXPERIMENTAL|aesthetic principles access group (APA)|The key difference focused on the disposal incision using aesthetic principles, which are depicted below. The incision was protected by Vaseline ointment. Excessive skin traction was avoided to prevent the injury on the skin edge. Bleeding was stanched with a low-power bipolar coagulation device. The surgical field does not have to be pulled in every direction to show the full operation field. The cervical linea alba was closed by continuous sutures with 3-0 absorbable Vicryl sutures. Interrupted sutures of 4-0 Vicryl were used to re-approximate the subcutaneous tissues. The epidermis was fixed with 3M steri-strip elastic skin closures rather than skin sutures.
62377071|NCT03239769|EXPERIMENTAL|minimally invasive access group (MIA)|With the MIA approach, a shorter incision of between 3 and 4 cm was created. The procedure used the Harmonic scalpel as an auxiliary device. First, the isthmus was divided. Second, the lower pole of the thyroid was dissected from the adipose tissue, and the inferior thyroid vessels were divided close to the thyroid gland for mobilization. The RLN and parathyroid glands were carefully dissected. Third, the superior pole of the thyroid gland was disconnected. Finally, CLND was performed. The closure procedure for the incision was similar to that for APA.
62377072|NCT05458492|EXPERIMENTAL|Sirolimus Arm|"Sirolimus, tablets 2 mg/day with dose adjustment of 1 to 3 mg/day for residual concentrations between 4 and 10 ng/mL~1 dose daily for 16 weeks"
62377073|NCT02833610|EXPERIMENTAL|Denosumab Injection|Patients will be administered Denosumab Q4W at a pre-determine dose for 12 cycles. Denosumab Q4W is administered by subcutaneous injection.
62377074|NCT00995215|EXPERIMENTAL|Spinal Cord Stimulation|The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.
62377075|NCT03755167|EXPERIMENTAL|IPL344|IV IPL344 administered once a day
62753080|NCT02775487||COPD and air quality|Persons enrolled in the study will have been diagnosed with Stage III or IV COPD and samples of air taken from their home environment.
62753081|NCT02804698|EXPERIMENTAL|Meta Salud Diabetes-Intervention|"1. Attend the thirteen weekly educational classes and physical activity group (prior physician approval) that are part of the Meta Salud Diabetes program.~2. Allow the research staff to collect your cholesterol, glucose, A1c, triglyceride levels, as well as your blood pressure, height, weight, and waist and hip circumference.~3. Respond to a survey about your nutrition and physical activity habits on three separate occasions (at the start of the 13-week program, just after you finish the program, and nine months after you finish the program).~4. You may also be invited to participate in a follow-up interview, where you will be asked about your experience during and after the Meta Salud Diabetes program."
62377076|NCT05455645|EXPERIMENTAL|Targeted intrinsic foot muscles exercise regimen|4 targeted intrinsic foot exercise will be performed at least 5 times per week, once in the laboratory, and four times at home. The participants will be followed up weekly at the laboratory visit. The real-time ultrasound imaging of intrinsic foot muscles will be used as guided visual biofeedback to instruct all participants to execute all exercise movement in a correct manner. If the participant misses a session, he/she is expected to replace the lost session within the same week.
62377077|NCT05455645|NO_INTERVENTION|Control|continue normal physical activity,
62377078|NCT04812665||Qualitative sub-study (SS1)|One group of caregivers (n = 10) will engage with the mHealth solution during 1 month. Subsequently, an individual semi-structured interview with each of the participants will proceed to gather user experience qualitative information.
62377079|NCT04812665||Quantitative sub-study (SS2)|A different group of caregivers (n = 55) will engage with the mHealth solution during 3 months. As elaborated in the following sections, a quantitative approach will be adopted to assess different emotional, behavioral and growth parameters before and after engaging with the mHealth solution (pre-post design).
62377080|NCT03990922|EXPERIMENTAL|CTPVB with ropivocaine|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with morphine
62377081|NCT03990922|PLACEBO_COMPARATOR|CTPVB with saline|Continuous Paravertebral block with saline and Patient-controlled analgesia with morphine
62377082|NCT01086267|EXPERIMENTAL|BMS-908662 (A1)|Phase 1
62377083|NCT01086267|EXPERIMENTAL|Cetuximab (A1)|Phase 1
62377084|NCT01086267|EXPERIMENTAL|BMS-908662 (B1)|Phase 2
62377085|NCT01086267|EXPERIMENTAL|BMS-908662 + Cetuximab (B2)|Phase 2
62377086|NCT00865358|EXPERIMENTAL|Yoga Group|A standardized hatha yoga protocol delivered in 12 weekly classes.
62377087|NCT00865358|NO_INTERVENTION|Usual care|Participants continue to receive their usual medical care for their back pain
62377088|NCT01985204|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62377089|NCT01985204|EXPERIMENTAL|Intervention|Iodine tablet
62377090|NCT02132416|ACTIVE_COMPARATOR|Surgical management|Operative fixation of unstable thoracic cage injuries and chest wall deformity. Thoracic Epidural anaesthesia will be offered. Paracetamol, Opioids and NSAID will be used as pain medication.
62377091|NCT02132416|ACTIVE_COMPARATOR|Conservative management|Conservative management of unstable thoracic cage injuries and chest wall deformity. Thoracic epidural anaesthesia will be offered. Paracetamol, Opioids and NSAID will be used as pain medication.
62377092|NCT00561067|ACTIVE_COMPARATOR|1|Methylprednisolone
62377093|NCT00561067|EXPERIMENTAL|2|Erythropoietin
62377094|NCT00952588|EXPERIMENTAL|AZD1152 1200 mg|AZD1152 1200 mg, iv, 7 day infusion monotherapy
62377095|NCT00952588|ACTIVE_COMPARATOR|LDAC 20 mg|LDAC 20 mg, sc, bd, 10 days (400mg per cycle)
62377096|NCT02176005|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
62377097|NCT02176005|EXPERIMENTAL|moxifloxacin + DAV132|Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
62377098|NCT02176005|EXPERIMENTAL|DAV132|DAV132 oral, 7.5g x3/day for 7 days
62377099|NCT02176005|PLACEBO_COMPARATOR|Negative control|Negative control: 7.5g x3/day for 7 days
62377100|NCT06279052|EXPERIMENTAL|Phone interview|"Patients will then be contacted by the investigator to arrange a telephone appointment date.~On the day of the telephone appointment, the psychiatry intern will call the patient to conduct the interview which will last between 30 and 60 minutes.~At the end of the telephone interview, the patient's participation in the research will end."
62377101|NCT05060081|EXPERIMENTAL|Pilates exercise program group|Pilates exercise program group will perform five exercises.
62377102|NCT05060081|ACTIVE_COMPARATOR|Traditional plank exercise program group|Traditional plank exercise program group will perform five exercises.
62377103|NCT03117699|EXPERIMENTAL|Hemiplegic subjects|"Testing of a new device for seated-standing passages after undergoing medical evaluation included Fugl Meyer scale, Berg scale and Bergego scale.~Phase 1 :~* 3 seated-standing passages with a handle equipped with 6 force captors~* 3 seated-standing passages with the device"
62377104|NCT03117699|EXPERIMENTAL|Healthy volunteers|"Testing of a new device for seated-standing passages .~Phase 1 :~* 3 seated-standing passages without help~* 3 seated-standing passages with a handle equipped with 6 force captors~* 3 seated-standing passages with the device"
62377105|NCT04653727||Online survey with 3.000 participants using mobile website technology|
61997509|NCT03670810|PLACEBO_COMPARATOR|Control 2 Sequence MEE|"Control 2:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 4.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
62377106|NCT00490126||Laparoscopic Surgery Database|
62377107|NCT00846027|EXPERIMENTAL|Bevacizumab + paclitaxel + gemcitabine|Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m\^2 IV, and gemcitabine 2000 mg/m\^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
62377108|NCT00112554|EXPERIMENTAL|Induction therapy arm I|Patients receive cytarabine IV continuously on days 1-3 and VNP40101M IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
62377109|NCT00112554|ACTIVE_COMPARATOR|Induction therapy arm II|Patients receive cytarabine as in arm I and placebo IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
62377110|NCT01661231|EXPERIMENTAL|Investigational Stents|Device: Astron/Pulsar-18 Stents Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease.
62556129|NCT01750190|PLACEBO_COMPARATOR|Placebo|Participants will receive roxadustat-matching placebo tablets orally TIW. The initial dose will be according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing \<70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 208.1 weeks.
62556130|NCT04435912|NO_INTERVENTION|PS alone group|Patients received only Protamine Sulfate for reversal of Heparin
62753082|NCT02804698|NO_INTERVENTION|Meta Salud Diabetes-Comparison Group|"1. Allow the research staff to collect your cholesterol, glucose, A1c, triglyceride levels, as well as your blood pressure, height, weight, and waist and hip circumference.~2. Respond to a survey about your nutrition and physical activity habits on three separate occasions (you will answer the first survey as soon as you finish reading and agree to participate by signing this form, the second survey will be three months from now, and the third survey will be 12 months from now)."
62753083|NCT02049827|EXPERIMENTAL|Renal transplant|
62753084|NCT03703817||tofacitinib citrate users|patients who have been using tofacitinib citrate for 6 months or more and less than 2 year in RA patients
62753085|NCT03703817||adalimumab users|patients who have been using adalimumab for 6 months or more and less than 2 year in RA patients
62753086|NCT06606860|EXPERIMENTAL|Arm 1|Treatment with a single dose of 20 mg/kg oxantel pamoate followed by administration of two daily doses placebo
62377111|NCT05465668|EXPERIMENTAL|Intervention: DWP16001 Drug A|1 tablet, Oral, once daily single dose
62377112|NCT05465668|EXPERIMENTAL|Intervention: DWP16001 Drug C|1 tablet, Oral, once daily single dose
62377113|NCT05790967|EXPERIMENTAL|Education Group|
62377114|NCT05790967|NO_INTERVENTION|CONTROL|
62377115|NCT01875874|EXPERIMENTAL|ELAD plus standard of care|Continuous ELAD treatment for a minimum of 3 days to a maximum of 10 days in addition to a standard of care for subjects with acute liver failure.
62377116|NCT04626570|EXPERIMENTAL|Cognitive and Behavioural Therapy plus Management as usual|12 sessions of CBT during 18 weeks AND management of obesity with nutritional and dietary treatment as usual
62377117|NCT04626570|NO_INTERVENTION|Management as usual|management of obesity with nutritional and dietary treatment as usual
62377118|NCT06327568||Case patients|Histological-confirmed high-grade anal intraepithelial neoplasia (AIN2+ and 3+) and invasive cancer; patients with macroscopic anal lesion.
61997510|NCT03670810|EXPERIMENTAL|Open Label Extension|Participants initially received 100 mg Lasmiditan at the first OLE visit, with flexible dosing (50, 100, or 200 mg) thereafter to optimize efficacy and tolerability.
62377119|NCT06327568||Control patients|Histological-confirmed low-grade anal intraepithelial neoplasia (AIN1), and subjects at high-risk for anal cancers, including: Immunocompromised subjects (patients with HIV infection, or taking immunosuppressive drugs, or post-organ transplantation); Men who have sex with men (MSM); Women aged at least 40 years with a history of CIN2+ and/or vulvar cancer; Subjects affected by anal and/or peri-anal localizations of Crohn's disease.
62377120|NCT06185686||Brain tumor patients receiving proton radiation therapy|Patients between 8 and 21 years old (inclusive) with a newly diagnosed primary brain tumor that will be treated with proton radiation therapy
62556131|NCT04435912|EXPERIMENTAL|PS and HC group|Patients received Hydrocortisone pre-treatment then Protamine Sulfate for the reversal of Heparine
62753087|NCT06606860|EXPERIMENTAL|Arm 2|Treatment with three daily dose of 20 mg/kg oxantel pamoate
62377121|NCT03756142||Multiple sclerosis patients|Analysis of orthostatic posture, initiation of walking and walking in MS patients with an EDSS between 0 and 4 (included) by a motion analysis system
62377122|NCT03756142||Healthy volunteers|Analysis of orthostatic posture, initiation of walking and walking in a group of healthy volunteers
62377123|NCT04315298|EXPERIMENTAL|Sarilumab 200mg IV (P2)|Phase 2
62377124|NCT04315298|EXPERIMENTAL|Sarilumab 200mg IV (P3:C1)|Phase 3: Cohort 1
62377125|NCT04315298|EXPERIMENTAL|Sarilumab 400mg IV (P2)|Phase 2
62377126|NCT04315298|EXPERIMENTAL|Sarilumab 400mg IV (P3:C1)|Phase 3: Cohort 1
62377127|NCT04315298|EXPERIMENTAL|Sarilumab 800mg IV (P3:C2)|Phase 3: Cohort 2
62556132|NCT04552353|EXPERIMENTAL|Vaway Lyo-Injection|Voriconazole, 200 mg/vial
62753088|NCT06606860|PLACEBO_COMPARATOR|Arm 3|Treatment with three daily doses of placebo
62753089|NCT02150057|NO_INTERVENTION|Control Group|This group receives no experimental bracing intervention in the study.
62753090|NCT02150057|ACTIVE_COMPARATOR|Experimental Group|This group will receive the Breg Fusion Osteoarthritis Knee Unloading Brace to wear for a determined amount of time per study protocol for the treatment of osteoarthritis pain.
62556133|NCT04552353|ACTIVE_COMPARATOR|Vfend Lyo-Injection|Voriconazole, 200 mg/vial
62377128|NCT04315298|EXPERIMENTAL|Sarilumab 800mg IV (P3: C3)|Phase 3: Cohort 3
62556134|NCT00661193|ACTIVE_COMPARATOR|Arm I|Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62556135|NCT00661193|ACTIVE_COMPARATOR|Arm II|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for 4 courses. Beginning in course 5 and for all subsequent courses, patients receive oral erlotinib hydrochloride alone on days 1-21. Courses with erlotinib hydrochloride repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62556136|NCT05869201|EXPERIMENTAL|Flu-M Quadro with preservative|150 volunteers were vaccinated with the Flu-M Quadro Inactivated Split Influenza Vaccine with a preservative
62556137|NCT05869201|EXPERIMENTAL|Flu-M Quadro without preservative|150 volunteers were vaccinated with the Flu-M Quadro Inactivated Split Influenza Vaccine without a preservative
62556138|NCT05869201|ACTIVE_COMPARATOR|Ultrix® Quadri|150 volunteers were vaccinated with Ultrix® Quadri Vaccine
62377129|NCT01426009|EXPERIMENTAL|EP-101 via nebulizer (eFlow®) 25 ug|EP-101 via nebulizer (eFlow®)
62377130|NCT01426009|ACTIVE_COMPARATOR|Tiotropium bromide via (Spiriva® Handihaler®)|Tiotropium bromide via (Spiriva® Handihaler®)
62377131|NCT01426009|ACTIVE_COMPARATOR|Ipratropium bromide Inhalation Solution|Ipratropium bromide Inhalation Solution via Handihaler® DPI
62377132|NCT01426009|PLACEBO_COMPARATOR|Placebo EP-101|Placebo
62377133|NCT01426009|EXPERIMENTAL|EP-101 via nebulizer (eFlow®) 50 ug|EP-101 via nebulizer (eFlow®)
62377134|NCT01426009|EXPERIMENTAL|EP-101 via nebulizer (eFlow®) 100 ug|EP-101 via nebulizer (eFlow®)
62377135|NCT01426009|EXPERIMENTAL|EP-101 via nebulizer (eFlow®) 200 ug|EP-101 via nebulizer (eFlow®)
62377136|NCT01732133|EXPERIMENTAL|Measurement of arterial pressure|
62377137|NCT02022592|EXPERIMENTAL|Lormetazepam|The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Sedalam®).
62377138|NCT02022592|ACTIVE_COMPARATOR|Midazolam|The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Midazolam-ratiopharm®, Midazolam-hameln®).
62377139|NCT02355925|EXPERIMENTAL|uhCG|The patients who receive Intrauterine injection of 500 IU of uhCG (0.5ml) before embryo transfer
62377140|NCT02355925|PLACEBO_COMPARATOR|Placebo|The patients who underwent Intrauterine injection of placebo (normal saline 0.5 ml) before embryo transfer
62377141|NCT02355925|OTHER|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
62377142|NCT06232187|EXPERIMENTAL|Feedback Group 1 (FG1)|"Participatns in FG1 will receive basic black box AI support, with simple explanation like standard plane, non standard plane or off plane."
62377143|NCT06232187|EXPERIMENTAL|Feedback Group 2 (FG2)|Participants in FG2 will receive explainable AI support, with more elaborate description of the anatomical structures and segmentation of the anatomy.
62377144|NCT06232187|NO_INTERVENTION|Control group (CG)|Participants in the CG will have a standard plane poster to help guide them to the EFW ultrasound standard plane images.
62377145|NCT03190681|EXPERIMENTAL|methylphenidate|
62377146|NCT03190681|PLACEBO_COMPARATOR|inactive pill|
62377147|NCT04476108|EXPERIMENTAL|750 Mg-500 mg LY3016859|Participants received LY3016859 every 2 weeks with 750 mg as starting dose followed by 500 mg intravenous (IV) infusion for a total of 4 doses.
62377148|NCT04476108|PLACEBO_COMPARATOR|Placebo|Participants received LY3016859 every 2 weeks with 750 mg as starting dose followed by 500 mg IV infusion for a total of 4 doses.
62556139|NCT00477048|OTHER|1|Replace Indinavir with SQV in patients with indinavir toxicity
62753091|NCT00664560|EXPERIMENTAL|ARM 1 PN 400 (VIMOVO)|PN400: 500 mg naproxen/20 mg esomeprazole
62753092|NCT00664560|ACTIVE_COMPARATOR|Arm 2 (celebrex)|Celecoxib 200 mg
62753093|NCT00664560|PLACEBO_COMPARATOR|Arm 3 (placebo)|sugar pill
62377149|NCT02845284|NO_INTERVENTION|Routine Care|Group education/counseling from Antenatal clinic midwives, routine PMTCT, HIV C\&T and family planning C\&T services on request.
62377150|NCT02845284|EXPERIMENTAL|Routine Care plus group support|Routine Care plus enhanced group support
62377151|NCT02845284|EXPERIMENTAL|Routine Care plus individual support|Routine Care plus enhanced individual support
62377152|NCT04690556|ACTIVE_COMPARATOR|Lucentis (ranibizumab)|Intravitreal injection
62377153|NCT04690556|EXPERIMENTAL|LUBT010 (proposed ranibizumab biosimilar)|Intravitreal injection
62377154|NCT04893395|EXPERIMENTAL|Pharmacogenomic Screening|Eligible patients who verbally consent to participate will receive two pharmacogenomics telehealth visits.
62377155|NCT02935907|EXPERIMENTAL|APG-115|APG-115 to be explored sequentially during accelerated dose escalation. This will continue until either the occurrence in Cycle 1 of one DLT or two Grade 2 toxicities (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events \[NCI CTCAE\] version 4.0) that are related or possibly related to APG-115. When either of these criteria is fulfilled, dose escalation will be converted to a standard 3+3 escalation scheme,
62377156|NCT02368730||desmopressin|Treatment according to standard clinical practice.
62556140|NCT02342301|EXPERIMENTAL|Standing Desk|Will use standing desk for 3 months
62556141|NCT02342301|ACTIVE_COMPARATOR|Traditional Desk|Will use traditional desk for 3 months
62556142|NCT04716647|EXPERIMENTAL|Ayurveda Intervention|Ashwagandha, Giloy and Tulsi were given in tablet form for oral administration.
62753094|NCT05948228|EXPERIMENTAL|Application of bioactive gel on teeth in patients assigned for orthodontic treatment|Application of bioactive gel on labial/buccal surfaces of teeth is done according to manufacturer instructions using microbrush followed by light curing
62753095|NCT05948228|ACTIVE_COMPARATOR|Application of Fluoride on teeth in patients assigned for orthodontic treatment|Application of fluoride gel will be done using a gel loaded tray held in the mouth for 4 minutes .After removal of tray ,patients must spit out the residual gel. The use of suction is a must to avoid the problem of over ingestion
62753096|NCT06606691||Nocturnal polygraphy study participants|This project aims to study approximately 263 individuals from different age groups and genders who are suspected of having sleep-related breathing disorders. The participants will be those referred for a nocturnal polygraphy study at the Sleep-Related Breathing Disorders and Home Ventilation Unit. During the polygraph test, participants will also wear the Xiaomi Mi Smart Band 8 wearable device to compare its accuracy in measuring sleep parameters, oxygen saturation, and heart rate against the polygraphy results.
62753097|NCT04802239|ACTIVE_COMPARATOR|calm waking group|calm waking state group
62753098|NCT04802239|EXPERIMENTAL|hypnosis session|hypnosis session group
62753099|NCT00856206|PLACEBO_COMPARATOR|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
62753100|NCT00856206|EXPERIMENTAL|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
62556143|NCT04163965|OTHER|Patients having a pacemaker|Patients having a pacemaker will sit down on a seat bearing capacitive ECG electrodes during their routine heart checkup at the cardiology. Simultaneously standard routine ECG measurements will take place.
62556144|NCT01961050|EXPERIMENTAL|Intervention|Dual-Focused Brief Physician Intervention (DFBPI)
62556145|NCT01961050|OTHER|Standard care|Services as usual including standard OB/GYN clinic visits; no experimental intervention is provided.
62556146|NCT06581497||ICIs|ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines.
62556147|NCT06581497||MWA+ICIs|ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines. All patients, except for those enrolled in ICIs, should also undergo MWA treatment.
62556148|NCT04113577||geriatric inpatients with neurocognitive disorder|usability assessment after 30 minutes to test the app
62556149|NCT04113577||unformal cargivers|usability assessment after 30 minutes to test the app with their relatives
62556150|NCT04113577||health professionals|usablity assessment after the enrollement of all patients and unformal caregivers
62556151|NCT05579028||Study|Patients of the group received supplemental nutritional support with Nutridrink ONS 200 ml, 2 bottles (400 ml) daily for 28 days from the date of inclusion. In a hospital setting, additional nutritional support will be added to the patient's standard hospital diet. After being discharged from the hospital, the patient will receive at his disposal the required amount of Nutridrink ONS 200 ml in amount of 400 ml per day and will take it in addition to his usual and habitual diet. The Nutridrink ONS 200 ml is recommended to be taken between main meals.
62753101|NCT01057225|EXPERIMENTAL|Arm I|Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28.
62753102|NCT02583230|EXPERIMENTAL|MedLink|For 8 weeks, the patient who is newly prescribed antidepressant medication will receive a mobile phone app (and a phone if they do not have a compatible Android phone) and a GSM enable pill bottle in order to provide and receive feedback regarding medication adherence.
62753103|NCT01371253|EXPERIMENTAL|Nintendo Wii traning|Balance training
62753104|NCT01371253|PLACEBO_COMPARATOR|EVA-soles|
62753105|NCT01686763||subarachnoid hemorrhage disease|subarachnoid hemorrhage patients
62753106|NCT05714618||Cases (Ischemic stroke): Left and right middle cerebral artery ischemic stroke|Patients presenting with acute onset focal neurological deficits and DWI-MRI evidence of an acute brain infarct of the left or right middle cerebral artery ischemic stroke.
62753107|NCT05714618||Controls (TIA): Patients with acute focal neurological symptoms without brain infarct on MRI.|Patients presenting with acute onset focal neurological deficits presumed to be of vascular origin, WITHOUT DWI-MRI evidence of an acute brain infarct.
62753108|NCT01713504|EXPERIMENTAL|Hypereosinophilic syndrome unexplained|
62753109|NCT01713504|ACTIVE_COMPARATOR|Hypereosinophilic syndrome explained|
62753110|NCT01713504|SHAM_COMPARATOR|Normal rate of eosinophilic|
62753111|NCT00551915|EXPERIMENTAL|AR51 (12, 10)|Participants were vaccinated with 0.5 ml of AR51 (12,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
62556152|NCT05579028||Control|Patients of the group received a standard hospital diet, and upon discharge from the hospital - their usual habitual diet.
62753112|NCT00551915|EXPERIMENTAL|PR51 (3, 10)|Participants were vaccinated with 0.5 ml of PR51 (3,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
62753113|NCT00551915|EXPERIMENTAL|PR51 (6, 10)|Participants were vaccinated with 0.5 ml of PR51 (6,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
62753114|NCT00551915|ACTIVE_COMPARATOR|PENTACEL™ + RECOMBIVAX HB™|Participants were vaccinated with 0.5 ml each of PENTACEL™ + RECOMBIVAX HB™ via intramuscular injection as a primary series at 2, 4, and 6 months of age, and with 0.5 ml PENTACEL™ as a booster at 12 to 14 months of age.
62377157|NCT02139280|ACTIVE_COMPARATOR|Arm 2: Cyclophosphamide 3 gms/m(2)|Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 3 gms/m(2).
62377158|NCT02139280|EXPERIMENTAL|Arm 1: 1.5 gms/m(2) Cyclophosphamide|Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 1.5 gms/m(2).
62377159|NCT00003992|EXPERIMENTAL|Arm I|Patients receive paclitaxel IV over 3 hours immediately followed by trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Paclitaxel repeats every 3 weeks for 4 courses and trastuzumab (Herceptin) repeats weekly for 10 courses. At 3 weeks following paclitaxel and trastuzumab (Herceptin), patients receive doxorubicin IV and cyclophosphamide IV over 1 hour every 3 weeks for 4 courses. Following chemotherapy, estrogen receptor (ER) positive and/or progesterone receptor (PR) positive patients receive oral tamoxifen twice daily for 5 years.
62377160|NCT00003992|EXPERIMENTAL|Arm II|Patients receive same therapy as in Arm I, except for additional trastuzumab (Herceptin) IV weekly beginning within 3 weeks following completion of chemotherapy and local therapy and continuing for 1 year. ER and/or PR positive patients receive tamoxifen as in Arm I but may be concurrent with trastuzumab (Herceptin). Following completion of doxorubicin and cyclophosphamide, post lumpectomy and post mastectomy patients may receive local radiotherapy daily for 5-6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62377161|NCT04142840|EXPERIMENTAL|Dexmedetomidine Group|"General anesthesia will be maintained by sevoflurane and remifentanil. End-tidal carbon dioxide will be controlled between 35 mmHg to 40 mmHg.Mean blood pressure(MAP) will be administrated between 80% and 120% of the baseline.Heart rate is going to be maintained between 50-100 beats per minute.~In consultation with the surgeons and 5 minutes prior to the departure of the operating room,all the anesthesia agents are discontinued and the patient will be transferred to the post-anaesthesia care unit.And reversal agents are given to antagonize the residual muscular relaxant.Once emergence agitation occurs,the patient assigned to the dexmedetomidine group will be infused with a single dose of 0.7ug/kg dexmedetomidine."
62377162|NCT04142840|ACTIVE_COMPARATOR|Propofol Group|"General anesthesia will be maintained by sevoflurane and remifentanil. End-tidal carbon dioxide will be controlled between 35 mmHg to 40 mmHg.Mean blood pressure(MAP) will be administrated between 80% and 120% of the baseline.Heart rate is going to be maintained between 50-100 beats per minute.~In consultation with the surgeons and 5 minutes prior to the departure of the operating room,all the anesthesia agents are discontinued and the patient will be transferred to the post-anaesthesia care unit.And reversal agents are given to antagonize the residual muscular relaxant.Once emergence agitation occurs,the patient assigned to the propofol group will be infused with a single dose of 0.5mg/kg propofol."
62377163|NCT05099718|EXPERIMENTAL|Hyaluronic acid|Application 3-times per day for 7 days.
62377164|NCT05099718|PLACEBO_COMPARATOR|Saline solution|Application 3-times per day for 7 days.
62377165|NCT01071941|EXPERIMENTAL|Group 1|The first subjects will receive a single infusion of rRp450. Subsequent subjects will receive rRp450 as four doses administered every 1-2 weeks.
62377166|NCT04135391|EXPERIMENTAL|Pre- and Post- exercise training effects|All recruited subjects received aerobic exercise training (HIIT or MICT). VO2peak, cardiac output (CO), bilateral frontal cortex blood volume (∆\[THb\]), oxyhemoglobin (∆\[O2Hb\]) and deoxyhemoglobin (∆\[HHb\]), ventilation efficiency, serum brain-derived neurotrophic factor (BDNF) levels, cognitive and life quality questionnaire, percentage of neuroblastic cell bearing neurites (% neurites), and cell fluorescent staining were examined before and after interventions.
62377167|NCT01832844|ACTIVE_COMPARATOR|"Group  with scan prior to infiltration "|
62377168|NCT01832844|PLACEBO_COMPARATOR|"Group  without scan "|"Patients will have a dummy lumber spine evaluation in order to put patients in blind conditions"
62377169|NCT03003013|ACTIVE_COMPARATOR|Biphasic Bone Graft With Autologous Platelet-rich Fibrin|Patients will undergo complete removal of the cystic cavity with the application of SYMBIOS biphasic bone graft material in combination with PRF in the cystic cavity
62556153|NCT02263963|EXPERIMENTAL|TAP Block Experal|Patient who randomized to this arm, will be blinded, TAP block will be performed under ultrasound guidance, where 20-30 ml of Exparel will be injected in transversus abdominis plane, bilaterally.
62556154|NCT02263963|NO_INTERVENTION|No TAP Block|
62556155|NCT00767403|EXPERIMENTAL|1|
62556156|NCT00767403|ACTIVE_COMPARATOR|2|
61997511|NCT06212102|EXPERIMENTAL|Progestin primed ovarian stimulation group|"HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.~In subsequent cycle, frozen embryo transfer was done"
62556157|NCT00767403|ACTIVE_COMPARATOR|3|
62556158|NCT05080296||All patients underwent DaTSCAN SPECT scans|
62753115|NCT05503771|EXPERIMENTAL|Intervention Group: ISA-MI|"The ISA-MI study condition involves, in addition to the standard of care described for the SOC group, a clinician training activity related to using the ISA (Infant Sleep Assessment) tool. Clinicians assigned to the ISA-MI Group will view a 20-30-minute recorded video training session on infant safe sleep (including its epidemiology, risk factors and recommendations), use of the ISA tool, and use of motivational interviewing-inspired (MI) communication skills to respond to ISA parent responses. The ISA tool builds on the 2022 AAP infant sleep recommendations and will be implemented at the 2-month WBV.~Parents/patients of physicians in the ISA-MI study condition will also be given several infant safe sleep related products that facilitate compliance with safe sleep recommendations, namely, a portable crib, a sleep sack and a pacifier."
62753116|NCT05503771|OTHER|Control Group: Standard of Care (SOC)|The SOC study condition consists of WBVs that follow the usual practice of American Academy of Pediatrics (AAP) Bright Futures Health Supervision Guidelines and includes age- and developmentally based anticipatory guidance. As part of their training, pediatric residents receive formal teaching on core aspects of providing primary care to infants, including the AAP recommendations on safe sleep. This includes the recommended ABCS: babies should sleep Alone (no objects or people), on their Back (supine), in a Crib (or safe alternative including portable crib or bassinet), and in a Smoke-free environment.
62753117|NCT01838265||AS: Active Surveillance Alone|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
62753118|NCT01838265||MRI-AS: MRI+ Active Surveillance|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
62377170|NCT03003013|ACTIVE_COMPARATOR|Biphasic Bone Graft Material only|Patients will undergo complete removal of the cystic cavity with the application of SYMBIOS biphasic bone graft material without PRF in the cystic cavity
62753119|NCT04329390||anticoagulant|Subjects of both sexes, aged 18 years or older, requiring the prescription of, or already on oral anticoagulant treatment, will be eligible for the study, irrespective of the index event, of the intended treatment duration, and the type of drug used.
62753120|NCT02294838|EXPERIMENTAL|MRI with parotid gland stimulation|All participants will have MRI imaging of the parotid gland with IV Gadovist pre and post parotid stimulation with lemon juice. 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered. Approximately three minutes after scan commencement, the salivary glands will be stimulated by orally administering a small portion (≈5 ml) of Citric acid.
62753121|NCT04137588||Group A|antiangiogenesis 7.5mg/Kg q3w+pemetrexed 500mg/m2 q3w+ platinum 75mg/m2 q3w
62753122|NCT04137588||Group B|immune checkpoint inhibitors 200mg q3w+pemetrexed 500mg/m2 q3w+platinum 75mg/m2 q3w
62556159|NCT03411161|EXPERIMENTAL|Combination therapy (S81694 + paclitaxel) phase I|Phase I: Single arm, non-randomized study in metastatic breast cancer patients. S81694 given intravenously every two weeks at different doses on D1 and D15 last for 28 days. The participants will also receive paclitaxel intravenously on D1, D8 and D15 last for 28 days.
62753123|NCT04137588||Group C|antiangiogenesis 7.5mg/Kg q3w+immune checkpoint inhibitors 200mg q3w+pemetrexed 500mg/m2 q3w+platinum 75mg/m2 q3w
62556160|NCT03411161|ACTIVE_COMPARATOR|paclitaxel phase II|"Phase II: Randomised phase II part , two-arm, in untreated metastatic triple negative breast cancer patients.~Paclitaxel given intravenously on D1, D8, and D15 at 80 mg/m² during a 28-day cycle."
62556161|NCT03411161|EXPERIMENTAL|Combination therapy (S81694 + paclitaxel) phase II|"Phase II: Randomised phase II part , two-arm, in untreated metastatic triple negative breast cancer patients.~S 81694 given intravenously on D1 and D15 at recommended phase 2 dose (RP2D). Paclitaxel given intravenously on D1, D8, and D15 during a 28-day cycle."
62556162|NCT00826969|ACTIVE_COMPARATOR|1|Ciclesonide 320µg
62753124|NCT01474772|EXPERIMENTAL|Pregabain|
62753125|NCT01474772|PLACEBO_COMPARATOR|Placebo|
62377171|NCT03333434|OTHER|AFO - Ankle_7 group|AFO is active comparator, ANKLE7 is the experimental treatment
62556163|NCT00826969|PLACEBO_COMPARATOR|2|Placebo
62377172|NCT03333434|OTHER|Ankle-7 - AFO group|AFO is active comparator, ANKLE7 is the experimental treatment
62377173|NCT06139445|EXPERIMENTAL|Study Group|
62556164|NCT02194361|EXPERIMENTAL|Anthocyan capsules|
62556165|NCT02194361|PLACEBO_COMPARATOR|Placebo|
62556166|NCT05973968||surufatinib|Surufatinib 300mg QD, po, every 4 weeks as a course of treatment, continuous administration until PD, death or intolerable toxicity
62556167|NCT02435524|EXPERIMENTAL|A&T Intervention Communes|
62556168|NCT02435524|NO_INTERVENTION|Control Communes|
62556169|NCT04501406|ACTIVE_COMPARATOR|Pioglitazone|Two arm, randomized, double-blind, placebo-controlled, 72 week treatment study receiving pioglitazone 15mg/day.
62377174|NCT06139445|PLACEBO_COMPARATOR|Plasebo Group|
62377175|NCT02986165|PLACEBO_COMPARATOR|Placebo control|100 g of flavoured water
62556170|NCT04501406|PLACEBO_COMPARATOR|Placebo|Two arm, randomized, double-blind, placebo-controlled, 72 week treatment study receiving placebo.
62753126|NCT05801757|ACTIVE_COMPARATOR|Propofol group|propofol 2-3mg/kg/h
62753127|NCT05801757|EXPERIMENTAL|R1 group|remimazolam 0.5mg/kg/h
62753128|NCT05801757|EXPERIMENTAL|R2 group|remimazolam 0.75mg/kg/h
62753129|NCT03201042||1a:Lyme patients- Erythema Migrans(EM)rash present|Patients with newly diagnosed Lyme disease based on the presence of a physician-documented EM rash. PCR, serology and Tcell based assay.
62556171|NCT01569295|EXPERIMENTAL|Idelalisib+bendamustine+rituximab|Participants will receive idelalisib plus bendamustine and rituximab
62556172|NCT01569295|PLACEBO_COMPARATOR|Placebo to match idelalisib+bendamustine+rituximab|Participants will receive placebo to match idelalisib plus bendamustine and rituximab
62753130|NCT03201042||1b:Lyme patients no typical EM|Patients documented symptoms of early Lyme disease, without a typical EM rash present, and the physician's intention to treat for Lyme disease. PCR, serology and Tcell based assay
62753131|NCT03201042||Cohort 2: healthy controls|Patients drawn from Lyme disease non-endemic areas and subjects with known exposure to Lyme disease will be excluded. PCR, serology and Tcell based assay.
62753132|NCT02728544|EXPERIMENTAL|Prader Willi syndrome|16 (8 males) PWS adolescents and young adults
62753133|NCT02728544|ACTIVE_COMPARATOR|Obese controls|16 - sex, age, and BMI-matched controls
62753134|NCT03401567|EXPERIMENTAL|Exercise group|Elbow bending exercises with blood flow restriction will be performed to the exercise group.
62753135|NCT03401567|NO_INTERVENTION|Control group|Control group will continue daily activities and a brochure on strengthening exercises and protection from injuries.
62753136|NCT04401930||Free-living elderly|"Free-living elderly over the age of 65 living in Metropolitan Area of Milan, in apparent good health conditions.~Male and Female"
62556173|NCT02288312|EXPERIMENTAL|BIA 2-093 800 mg fasting|Tablets 800 mg. Administration:Oral.
62556174|NCT02288312|EXPERIMENTAL|BIA 2-093 800 mg fed|Tablets 800 mg. Administration:Oral.
62753137|NCT04696367||Patients with acute intra-abdominal pathology|Patients admitted to hospital with acute intra-abdominal pathology
62753138|NCT03360890|EXPERIMENTAL|Cohort 1: salivary gland tumors without SOC treatment option|All patients will receive pembrolizumab and docetaxel. First pembrolizumab and docetaxel will be given together. After which patients will receive pembrolizumab alone until disease progression or up to 35 cycles (about 2 years).
61997512|NCT06212102|ACTIVE_COMPARATOR|GnRH antagonist group|"HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.~In subsequent cycle, frozen embryo transfer was done"
62556175|NCT02288312|EXPERIMENTAL|BIA 2-093 400 mg|Tablets 2 x 400 mg. Administration:Oral.
62556176|NCT02738710|EXPERIMENTAL|transumbilical wound|transumbilical incision
62556177|NCT02738710|ACTIVE_COMPARATOR|infra umbilical wound|infra umbilical incision
62556178|NCT01315431|EXPERIMENTAL|Tesetaxel-capecitabine|
62556179|NCT02203929||Phakic eyes|Phakic eyes will be monitored with 4 preoperative optical coherence tomography scans as these patients will undergo phacoemulsification and intraocular lens implantation prior to their macular hole surgery
62753139|NCT03360890|EXPERIMENTAL|Cohort 2: 'aggressive' thyroid cancer without SOC treatment op|All patients will receive pembrolizumab and docetaxel. First pembrolizumab and docetaxel will be given together. After which patients will receive pembrolizumab alone until disease progression or up to 35 cycles (about 2 years).
62753140|NCT06379958|ACTIVE_COMPARATOR|Part 1: Itraconazole 200mg|
62753141|NCT06379958|ACTIVE_COMPARATOR|Part 2: Phenytoin 100mg|
62753142|NCT06379958|ACTIVE_COMPARATOR|Part 3: Simvastatin 40mg|
62753143|NCT06379958|ACTIVE_COMPARATOR|Part 4: Upadacitinib 15 mg|
62556180|NCT02203929||Pseudophakic eyes|Phakic eyes will be monitored with 2 preoperative optical coherence tomography scans as there is no surgical intervention prior to the macular hole treatment.
62753144|NCT02135029|EXPERIMENTAL|Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)
61997513|NCT00302003|EXPERIMENTAL|Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim|Treatment consists of 3 cycles of Doxorubicin hydrochloride IV (25 mg/m2) days 1 \& 2, Vincristine sulfate IV (1.4 mg/m2 \[max 2.8 mg\]) Days 1 \& 8, Prednisone orally (40 mg/m2) Days 1-7, Cyclophosphamide IV (600 mg/m2) Days 1 \& 2, Filgrastim by mouth or IV (5 micrograms/kg/dose) 24 hours after Cyclophosphamide complete. See detailed description for remainder of therapy.
62556181|NCT06194968||Experimental: Urokinase|
62556182|NCT06194968||Active Comparator: Alteplase|
62753145|NCT02135029|ACTIVE_COMPARATOR|Atorvastatin|
62753146|NCT02135029|PLACEBO_COMPARATOR|Placebo|
62753147|NCT02106624|EXPERIMENTAL|High Nitrogen|In this arm, daily nitrogen supply is as much as 2.5-3.0 g per kilogram (lean mass weight)
62753148|NCT02106624|ACTIVE_COMPARATOR|conventional nitrogen|In this arm, daily nitrogen supply is 1.2-1.5g per kilogram (lean mass weight) as recommended by ESPEN guideline
62753149|NCT04835909|EXPERIMENTAL|Behavioral: modern board and card games|Participants will play modern board and card games in groups at medical center 2 times per week for at least 1 hour over a period of 16 weeks.
62753150|NCT04835909|ACTIVE_COMPARATOR|Behavioral: paper and pencil tasks|Participants will do cognitive paper and pencil tasks in groups at medical center 2 times per week for at least 1 hour over a period of 16 weeks.
62753151|NCT04835909|NO_INTERVENTION|Wait-list|Participants will be in a wait-list over a period of 16 weeks. Then, they received the board and card games' or paper and pencil tasks' intervention.
62753152|NCT06355609|EXPERIMENTAL|Treatment Group|A Phase II, Single-Arm Study Evaluating the 1st Line Efficacy and Safety of Sunvozertinib plus Anlotinib in EGFR-Sensitive Mutations Combined with Co-Mutations Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
62753153|NCT04449146|EXPERIMENTAL|shoulder localizer ultrasound|The localizer ultrasound of the shoulder is performed on an unclothed patient (at the shoulders) and comes to locate bony landmarks using the ultrasound probe as a Transcutaneous localizer. The Protocol plans to acquire different landmarks on the scapula: lower angle, coracoid, scapula spine and bilateral acromioclavicular joint (definition of the coronal plan). These acquisitions are carried out by the probe connected to a Tablet (Microsoft surface Pro 3) which allows to locate the probe and by extension of the probe the location of the points selected by ultrasound.
62556183|NCT05898724|EXPERIMENTAL|Blank group|Blank group: include six orthodontic patients, which have a surgical procedure to install two orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed orthodontic titanium miniscrews.
62556184|NCT05898724|EXPERIMENTAL|Silver hydroxyapatite group:|Silver hydroxyapatite group: include six orthodontic patients, which have a surgical procedure to install two silver hydroxyapatite nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed silver hydroxyapatite nano-coated orthodontic titanium miniscrews.
62556185|NCT05898724|EXPERIMENTAL|Zinc oxide group|Zinc oxide group: include six orthodontic patients, which have a surgical procedure to install two zinc oxide nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed zinc oxide nano-coated orthodontic titanium miniscrews.
62556186|NCT00495807|NO_INTERVENTION|1|No Words was delivered during the PCA management
62556187|NCT00495807|ACTIVE_COMPARATOR|2|Positive words was delivered as a positive control group during the therapy of the pain with PCA
62556188|NCT00495807|ACTIVE_COMPARATOR|3|Partially negative words was delivered during the PCA pain management
62556189|NCT00495807|ACTIVE_COMPARATOR|4|Totally negative words was delivered during the PCA pain management
62556190|NCT05857150||Lean Group|Participants with body mass index 20-25 kg/m\^2 will complete an outpatient study visit (body composition, blood draw, treadmill test, strength test) and an inpatient visit (muscle biopsies, fat biopsies, indirect calorimetry, exercise test).
62556191|NCT05857150||Obese Group|Participants with body mass index 30-45 kg/m\^2 will complete an outpatient study visit (body composition, blood draw, treadmill test, strength test) and an inpatient visit (muscle biopsies, fat biopsies, indirect calorimetry, exercise test).
62556192|NCT01366118|EXPERIMENTAL|TT tailored Ch plus IMRT|
62556193|NCT00593515|EXPERIMENTAL|1|Family CBT
62753154|NCT04159987|EXPERIMENTAL|Spinal muscular atrophy patient|
62753155|NCT01824329|ACTIVE_COMPARATOR|Prostate capsule sparing cystectomy Group|Prostate capsule sparing cystectomy involves removing the entire bladder.
62753156|NCT01824329|ACTIVE_COMPARATOR|Nerve sparing cystectomy Group|Nerve sparing cystectomy involves removal of the whole bladder and the entire prostate.
62753157|NCT00756795|EXPERIMENTAL|Attention Control|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Patient will be taught how to keep the Activity diary to record walking and physical activities.~Structured Interview will be conducted at baseline and post-intervention. All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis"
62753158|NCT05058612|EXPERIMENTAL|Midodrine|Midodrine 10 mg PO/NG q8h
62753159|NCT05058612|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose PO/NG q8h
61997514|NCT03799484|OTHER|Topical Anesthesia|2.5% Lidocaine/2.5% Prilocaine Cream will be applied to one side of the forehead and Petrolatum Ointment to the other prior to administration of Botulinum Toxin Type A Injection
62556194|NCT00593515|ACTIVE_COMPARATOR|2|Child-focused CBT
62753160|NCT03555981|EXPERIMENTAL|Early KMC|Continuous kangaroo mother care started within 24h of hospital admission, aiming for minimum 18h/day and until hospital discharge with encouragement of KMC at home
62753161|NCT03555981|ACTIVE_COMPARATOR|Standard care|Standard care under radiant heater or incubator until clinical stability criteria are met then intermittent or continuous Kangaroo mother care started at \>24h of hospital admission until hospital discharge with encouragement of KMC at home
61997515|NCT03799484|OTHER|Petrolatum|Petrolatum Ointment will be applied to one side of the forehead and 2.5% Lidocaine/2.5% Prilocaine Cream to the other side prior to administration of Botulinum Toxin Type A Injection
62753162|NCT06578416||Children who stutter|Preschool children who stutter aged 3 to 6-years
62753163|NCT06578416||Children who do not stutter|Preschool children who do not stutter aged 4 to 6-years
62753164|NCT01313845|ACTIVE_COMPARATOR|amantadine|administration of intravenous amantadine sulfate 200mg/500ml/bottle 1 bottle infusion over 3 hours, twice a day for consecutive 5 days
62753165|NCT01313845|PLACEBO_COMPARATOR|placebo|administration of 0.9% sodium chloride 500ml/bottle 1 bottle infusion over 3 hours twice a day for consecutive 5 days
62753166|NCT04348565|EXPERIMENTAL|Diabetes Care Programme|People with Type 2 Diabetes Mellitus of private general practitioner (GP) with solo-practice who receive the intervention (Diabetes Care Programme) in addition to usual medical care at the GP
62753167|NCT04348565|NO_INTERVENTION|Standard Usual Care|People with Type 2 Diabetes Mellitus of private general practitioner (GP) with solo-practice who only receive the usual medical care at the GP
62753168|NCT05138263||Young normal controls|"* age : 20 \~ 54~* without dementia, MCI, or other major neurological/psychiatric illness"
62753169|NCT05138263||Elderly normal controls|"* age : 55 \~ 90~* without dementia, MCI, or other major neurological/psychiatric illness"
62753170|NCT05138263||MCI (Mild cognitive impairment)|"* age : 55 \~ 90~* without major neurological/psychiatric illness~* concern regarding a change in cognition, lower performance in any cognitive domain that is greater than would be expected for the subject's age and educational background and preservation of independence in functional abilities"
62753171|NCT05138263||AD (Alzheimer's diseases)|"* age: 55 \~ 90~* National Institute of Aging and the Alzheimer's Association (NIA-AA) Probable AD dementia(Alzheimer's diseases)"
62753172|NCT02633254|EXPERIMENTAL|Single arm|Treatment group Magentic Resonance guided High Intensity Focused Ultrasound will be employed on uterine fibroids
62753173|NCT04288453|EXPERIMENTAL|Community-based activity program|Engagement in 8-week community-based activity program
62377176|NCT02986165|EXPERIMENTAL|Low dose pomace extract|1 g pomace extract powder
62753174|NCT04392141|EXPERIMENTAL|Standard Treatment|Patients diagnosed with COVID-19 which receive the standard treatment national guideline
62753175|NCT04392141|EXPERIMENTAL|Colchicine and Herbal Phenolic Monoterpene Fractions|Patients diagnosed with COVID-19 which receive the standard treatment national guideline plus Colchicine and Herbal Phenolic Monoterpene Fractions
62753176|NCT00075946|ACTIVE_COMPARATOR|Arm A: Rituximab Retreatment|Patients receive rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months.
62753177|NCT00075946|EXPERIMENTAL|Arm B: Rituximab Scheduled|Patients receive a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity.
62753178|NCT03506451|OTHER|Single arm non-therapeutic interventional study|All subjects who enroll on study will be asked to complete questionnaires at baseline before treatment starts; the questionnaires are repeated at one month, three and six months after radiation therapy has been completed. the demographics questionnaire is completed at baseline only; the FACT-HN is completed at all four time points.
62753179|NCT06479265||Older Adults|Healthy, adult age 65-75.
62377177|NCT02986165|EXPERIMENTAL|High dose pomace extract|2.5 g pomace extract powder
62377178|NCT02633917|EXPERIMENTAL|Motor control exercises|One group should perform motor control exercises
62377179|NCT02633917|ACTIVE_COMPARATOR|Standard exercises|the other group should perform standard physiotherapy exercises
62377180|NCT03698214||isolated traumatic brain injury|Adult patients having isolated traumatic brain injury with a head abbreviated injury scale (AIS) ≥ 3 and without severe injury to other regions (other AIS ≤ 1) were included. The patients were grouped and analyzed according to reversed shock index \< 1 or reversed shock index ≥ 1.
62377181|NCT00636506|EXPERIMENTAL|AMS 700 IPP 2005 Implant Group|Male subjects 21 years of age and older who are implanted with an AMS 700 IPP with MS (Momentary Squeeze) pump for erectile dysfunction.
62753180|NCT06479265||Younger Adults|Healthy, young adult age 18-29.
62753181|NCT04656041|EXPERIMENTAL|FOLFOX/ nal-IRI|"Treatment will be administered on an outpatient basis.~* FOLFOX with nal-IRI for eight two-week cycles (16 weeks total)~* Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks~* Surgery"
62753182|NCT03664791||Vanguard Rocc knee implant|Patient in need for a total knee arthroplasty and who met the inclusion/ exclusion criteria and received the Vanguard Rocc implant
62377182|NCT02400840|EXPERIMENTAL|Heart graft rejection|Assessment of cardiac allograft recipient with rejection by Cardiac MRI with gadobenic acid intravenous injection 0.2 ml/kg one time
62377183|NCT02400840|ACTIVE_COMPARATOR|No rejection|Assessment of cardiac allograft recipient without any rejection by Cardiac MRI with gadobenic acid intravenous injection 0.2 ml/kg one time
62377184|NCT05728424|ACTIVE_COMPARATOR|2 weeks vonoprazan containing triple regimen|"For two weeks:~Vonaprazan: 20 mg twice daily Amoxicillin: 1gm twice daily Levofloxacin: 500 mg once daily"
62556195|NCT02947360|EXPERIMENTAL|FOVUS|All eligible and consenting patients will receive a focused vascular ultrasound examination of the carotid arteries
62753183|NCT06602583||A study arm 1|baseline comparative arm of patients having already undergone angiography and fitting the inclusion criteria. The radiation exposure of this group would be collected from database of already done studies in the months prior to the initiation of the study (so as to prevent observer bias which may happen once the interventional cardiologist knows his inclusion in study, and may use a shorter or longer cine runs, thus influencing the outcomes). This would best represent the real-world data set, according to the routinely followed standard dose/ older low dose protocol.
62753184|NCT06602583||A study arm 2|a comparative arm where the patients being once eligible for the study; would undergo angiography using the new low dose protocol. A total of 5 to 8 different views (orthogonal) would be taken (2 for RCA and 4 to 6 for LAD/LCX)
62753185|NCT06444555|EXPERIMENTAL|Balanced Energy Protein Supplement|Fortified lipid-based nutrient supplement
62753186|NCT06444555|ACTIVE_COMPARATOR|Multiple Micronutrient Supplement|The United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP).
62753187|NCT05308472|PLACEBO_COMPARATOR|Placebo|
62753188|NCT05308472|EXPERIMENTAL|DISC-1459 oral dose level 1|
62753189|NCT05308472|EXPERIMENTAL|DISC-1459 oral dose level 2|
62753190|NCT05308472|EXPERIMENTAL|Open-Label Extension (optional)|
62753191|NCT00973544||control|drains would be removed when daily discharge will be below 20 cc for 2 consecutive days
62753192|NCT00973544||study|drains will be removed on post operative day (POD) 10
62753193|NCT00758264|EXPERIMENTAL|Group A|Meningococcal vaccine GSK134612 co-administered with pneumococcal vaccine GSK1024850A.
62753194|NCT00758264|ACTIVE_COMPARATOR|Group B|Pneumococcal vaccine GSK1024850A followed one month later by meningococcal vaccine GSK134612.
62753195|NCT00758264|ACTIVE_COMPARATOR|Group C|Meningococcal vaccine GSK134612 followed one month later by pneumococcal vaccine GSK1024850A.
62753196|NCT06605729|EXPERIMENTAL|e-learning|"The aim of the educational module intervention is to enhance the knowledge, attitudes, beliefs and behavior of HCPs about physical activity as a part of the management of chronic pain. The content of is based on most recent scientific knowledge and guidelines about the management of chronic pain and physical activity and on behavioral change. Four themes are presented: chronic pain, physical activity and chronic pain, specific populations and behavior change.~Each subpart can be studied separately. Having separated chapters will be easier for participants to navigate the content, to follow along and to be able to integrate the knowledge in their daily practice. The module will be available online through Teachable™ and will contain a mixture of video and additional written material. Completing the complete module will take approximately 2 hours."
62753197|NCT06606340||Eteplirsen|
62377185|NCT05728424|PLACEBO_COMPARATOR|1 week vonoprazan containing triple regimen|"For One week:~Vonaprazan: 20 mg twice daily Amoxicillin: 1gm twice daily Levofloxacin: 500 mg once daily~For the second week:~Placebo"
62556196|NCT04181619|EXPERIMENTAL|Coffeeberry beverage|300 mg Coffeeberry extract in 300 ml beverage
62556197|NCT04181619|PLACEBO_COMPARATOR|Color and flavor matched beverage|0 mg Coffeeberry extract in 300 ml flavor and color-matched beverage
62556198|NCT01977495|ACTIVE_COMPARATOR|Opt-in Enrollment|Opt-in enrollment: patient will be sent a recruitment letter, in which they must call the study team to take part in the study. During that call, the study team will schedule the participant for an intake visit.
62753198|NCT06606340||Golodirsen|
62753199|NCT06606340||Casimersen|
62753200|NCT01697163||Iressa|Lung cancer patients with EGFR mutation
62753201|NCT02511483|PLACEBO_COMPARATOR|IV-PCA morphine + Placebo PO|"Pain control after surgery will be performed through IV-PCA morphine. Placebo will be administered with the same schedule of Propranolol in the experimental arm.~Parallel evaluation of Quantitative Sensory Testing (QST), Psychometric assessment and COMT-haplotypes will be included along the trial."
62753202|NCT02511483|EXPERIMENTAL|IV-PCA morphine + Propranolol PO|"The morning of the surgery a dose of Propranolol 20 mg PO will be administered. After surgery pain control will be performed with IV-PCA morphine; in addition a second dose of Propranolol 20 mg PO will be administered .~During the first and second postoperative day Propranolol 30 mg PO (BID) will be administered. Parallel assessment of Quantitative Sensory Testing (QST), Psychometric assessment and COMT-haplotypes will be included along the trial."
62753203|NCT04975126|EXPERIMENTAL|CatInfo tool + Face-to-face discussion with physician|audio-visual presentation (CatInfo tool) before face-to-face informed-consent discussion with the physician
62753204|NCT04975126|NO_INTERVENTION|Face-to-face discussion with physician only|face-to-face informed-consent discussion with the physician only
62753205|NCT06587282|EXPERIMENTAL|PDA treatment|PDA treated with Bloom Micro Occluder System
62753206|NCT04088084|EXPERIMENTAL|standard of care+palmitoylethanolamide|PEA was supplemented for 3 months to the standard of care (SOC, topical IOP lowering med)
62753207|NCT04088084|NO_INTERVENTION|standard of care|patients were only on topical IOP lowering therapy (SOC)
62753208|NCT02370004|EXPERIMENTAL|Resistive Flexibility and Strength Training|Each subject will undergo Resistive Flexibility and Strength Training (RFST) with a trained practitioner.
62753209|NCT01364883|EXPERIMENTAL|Group 1|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16
62753210|NCT01364883|EXPERIMENTAL|Group 2|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24
62753211|NCT01364883|EXPERIMENTAL|Group 3|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, MVA ME-TRAP boost W8, MVA ME-TRAP boost W12
62753212|NCT01364883|EXPERIMENTAL|Group 4|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24
62753213|NCT01364883|EXPERIMENTAL|Group 5|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16
62753214|NCT01364883|EXPERIMENTAL|Group 6|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W12
62753215|NCT01364883|EXPERIMENTAL|Group 7|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
62753216|NCT03751358|EXPERIMENTAL|Unilateral Erector spinae plane block|Thoracic unilateral Erector spinae plane block performed on the volunteer and analyse of the spread of local anesthetic by magnetic resonance imaging
62753217|NCT06238141|EXPERIMENTAL|intervention group|
62377186|NCT06378606|ACTIVE_COMPARATOR|group A|"(Therapy group) It will include subjects that will receive computer based cognitive therapy sessions training.~omega 3 supplement ."
62753218|NCT06238141|SHAM_COMPARATOR|control group|
62753219|NCT05384418|EXPERIMENTAL|patients undergoing transcatheter aortic valve implantation|patients undergoing transcatheter aortic valve implantation for aortic stenosis
62753220|NCT02437305|EXPERIMENTAL|ABCDEs of Melanoma Skin Cancer|"A modified melanoma educational intervention that uses the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation but also incorporates the nomenclature melanoma skin cancer; indicates that melanoma is relevant for everyone regardless of race and ethnicity; includes images of melanoma on ethnic skin; informs people of the likelihood of melanoma developing in acral, subungual and mucosal surfaces; and provides guidance on self-skin examinations."
62753221|NCT02437305|ACTIVE_COMPARATOR|ABCDEs of Melanoma|"A conventional melanoma educational intervention using the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation."
62377187|NCT06378606|EXPERIMENTAL|Group B|"(Smartphone group) It will include subjects that will receive home program training by using their smartphones cognitive applications .~omega 3 supplement ."
62753222|NCT06152835||Breastfeeding Italian women|Italian women, aged 20-40 years who breastfeed children born at full term
62753223|NCT03523793|EXPERIMENTAL|Physical Therapists - CPG|Cross-sectional stepped wedge design with 16 physical therapy clinics (including approximately 40 physical therapists) being allocated to one of 4 sequences that differ in CPG implementation time (each sequence consisting of 4 clinics). This proposed study will be conducted over 68 weeks, with the initial 12 weeks serving as a baseline washout phase (before any clinic has received training), then 4 clinics crossing over from standard care (control) to CPG and decision support tool implementation (intervention) approximately every 8 weeks until week 44 when all 4 sequences (16 clinics) have completed training.
62753224|NCT03523793|ACTIVE_COMPARATOR|Physical Therapists - Control|This proposed study will be conducted over 68 weeks, with the initial 12 weeks serving as a baseline washout phase (before any clinic has received training), then 4 clinics crossing over from standard care (control) to CPG and decision support tool implementation (intervention) approximately every 8 weeks until week 44 when all 4 sequences (16 clinics) have completed training.
62753225|NCT06424158|EXPERIMENTAL|Massage Therapy Group|Participants in the massage therapy group are treated by a certified pediatric massage therapist for at least two 30- minute massage therapy sessions performed on postoperative days two and four or five. Participants will continue to receive standard of care, including any pain medications as needed.
62377188|NCT06378606|PLACEBO_COMPARATOR|group c|It won't receive interventions. only omega 3 supplement
62556199|NCT01977495|ACTIVE_COMPARATOR|Opt-out enrollment|Opt-out enrollment: patient will be sent a letter communicating to them that they have been enrolled into a research program at their doctor's office. After 10 days, the study team will contact the opt-out participants to schedule an intake visit.
62556200|NCT00153179|ACTIVE_COMPARATOR|1|Acipimox treatment for 7 days
62753226|NCT06424158|NO_INTERVENTION|Control Group|Participants in control group will continue to receive the normal standard of care as usual for their recovery and will be monitored by hospital staff in obtaining the same data points recorded clinically for post-op days 2 and 4/5; however, no therapeutic intervention will occur.
62753227|NCT03193086||Alemtuzumab treated MS patients|Those with Multiple Sclerosis that have commenced therapy with alemtuzumab (60 mg infusion over the course of 5 days) and completed treatment with alemtuzumab (additional 36 mg infusion during the course of 3 days, 12 months later).
62753228|NCT02045381||MRI group|Patient receives one research MRI prior to radiation treatment.
62753229|NCT03548506|ACTIVE_COMPARATOR|STN_O|Omnidirectional Deep Brain Stimulation of STN
62377189|NCT05182294|ACTIVE_COMPARATOR|Conventional symmetric nasal cannula|The patient's breathing pattern will be assessed by inductive plethysmography while using the cannula and receive HFNT for 2 hours during the first session. Patients will then be randomized to use of the conventional symmetric nasal cannula or the new asymmetric nasal cannula. At the end of the first session questionnaire data will be collected and ABGs will be repeated followed by a 30-minute rest period without any device. Patients will then crossover to receive HFNT via the other cannula type for another 2 hours during the second session. Inductive plethysmography will again be worn and ABGs will be obtained, and questionnaires will again be administered
62377190|NCT05182294|ACTIVE_COMPARATOR|AIRVO 2; new asymmetric nasal cannula|The patient's breathing pattern will be assessed by inductive plethysmography while using the cannula and receive HFNT for 2 hours during the first session. Patients will then be randomized to use of the conventional symmetric nasal cannula or the new asymmetric nasal cannula. At the end of the first session questionnaire data will be collected and ABGs will be repeated followed by a 30-minute rest period without any device. Patients will then crossover to receive HFNT via the other cannula type for another 2 hours during the second session. Inductive plethysmography will again be worn and ABGs will be obtained, and questionnaires will again be administered
62377191|NCT05064943||Total Knee Replacement|Patients who have undergone total knee replacement
62556201|NCT00153179|PLACEBO_COMPARATOR|2|placebo treatment for 7 days
62556202|NCT01101815|ACTIVE_COMPARATOR|Oral Naltrexone + ART|Naltrexone (oral). 50 mg maintenance daily for 48 weeks, plus group drug counseling manual driven, N= 100
62556203|NCT01101815|ACTIVE_COMPARATOR|Naltrexone Implant + ART|Naltrexone Implant + ART. Monthly maintenance for 48 Weeks plus, group drug counseling manual driven, N=100
62753230|NCT03548506|EXPERIMENTAL|STN_D|Directional Deep Brain Stimulation of STN
62753231|NCT04562402|ACTIVE_COMPARATOR|Phacoemulsification with endoscopic cyclophotocoagulation|Cataract extraction via phacoemulsification along with endoscopic cyclophotocoagulation of the ciliary body.
62753232|NCT04562402|ACTIVE_COMPARATOR|Phacoemulsification alone|Cataract extraction via phacoemulsification.
62753233|NCT00693823|ACTIVE_COMPARATOR|1|Femoral-popliteal surgical bypass with prosthetic graft
62753234|NCT00693823|ACTIVE_COMPARATOR|2|Interventional angioplasty and placement of an ePTFE covered stent graft within the femoral-popliteal artery as an endoluminal bypass percutaneously
62753235|NCT03569748|EXPERIMENTAL|IQOS|HEAT NOT BURN REDUCED RISK PRODUCT
62753236|NCT03569748|ACTIVE_COMPARATOR|E-CIG|ELECTRONIC CIGARETTE REDUCED RISK PRODUCT
62753237|NCT03407495|EXPERIMENTAL|single arm: IOP injection (MPB-1523)|single group treatment
62753238|NCT04506216|EXPERIMENTAL|cohort|adult patients with type 1 diabetes and insulin pump treatment . Duration of participation: 30 minutes
62753239|NCT03985410|EXPERIMENTAL|Treatment Sequence ABC|Participants will receive a single 3-hour intravenous (IV) infusion of 4 grams (g) of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 milligrams (mg) open-label moxifloxacin given at the end of the infusion (Treatment C). There will be 7 ± 2 days washout between treatments.
62753240|NCT03985410|EXPERIMENTAL|Treatment Sequence ACB|Participants will receive a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B). There will be 7 ± 2 days washout between treatments.
62753241|NCT03985410|EXPERIMENTAL|Treatment Sequence BAC|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C). There will be 7 ± 2 days washout between treatments.
62377192|NCT01836549|EXPERIMENTAL|Treatment (imetelstat sodium)|"Molecular Biology Phase: Patients will receive one infusion of imetelstat prior to surgery. Surgery will take place 12-24 hours after the infusion of imetelstat. Patients will continue to receive therapy on the same schedule as the Phase II patients starting 14-21 days after surgery.~Phase II: Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
62377193|NCT03185169|OTHER|Replens and coconut oil|Commercially available Replens applied via prefilled applicator into the vagina and coconut oil applied at the vaginal introitus and vulva. Both are to be administered by the patient 2 times per week, interval between dosing to be approximately 2 days. Patients will be encouraged to apply Preseed, coconut oil, or patient's personal lubricant of choice into the vagina prior to sexual activity.
62377194|NCT00921908||epidural catheter|subfascial placement of a triple-orifice epidural catheter
62377195|NCT00921908||multiholed catheter|subfascial placement of a multi-orifice 15 cm catheter
62377196|NCT02098629|ACTIVE_COMPARATOR|Milrinone+Esmolol|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
62377197|NCT02098629|PLACEBO_COMPARATOR|Saline infusion|Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion.
62377198|NCT03260062|EXPERIMENTAL|PEARLS|Participants in this arm will receive 10 1-hour weekly sessions of the PEARLS intervention
62377199|NCT03260062|ACTIVE_COMPARATOR|Control|Participants in this arm will receive 10 1-hour weekly sessions of the standard of care LSL Speech Therapy
62377200|NCT05723276|EXPERIMENTAL|Study arm|Psilocybin with therapeutic support
62377201|NCT00883792|EXPERIMENTAL|Colonoscopy screening|One-time colonoscopy is the screening tool used in this trial. All individuals in the screening group will be offered a full colonoscopy. At colonoscopy, all detected CRC precursor lesions will be removed, whenever possible.
62377202|NCT00883792|NO_INTERVENTION|Control|"The control group will not be offered any screening or intervention within the trial, but follow usual care in the participating countries. Individuals assigned to the control group will not be informed about their status as controls in the trial. This approach facilitates a truly population-based study, which will be used to estimate the effect of the screening intervention in the general population, mimicking national CRC screening programs.~All ethics committees at the participating centres have approved the study protocol before recruiting individuals to the trial. In Sweden, the national ethics committee particularly reviewed the non-information of the control group and found it ethically acceptable."
62377203|NCT05202184||Percutaneous thermal ablation of small HCC|Percutaneous thermal ablation of small HCC
62377204|NCT00374062|EXPERIMENTAL|I|relaxation tape 1
62377205|NCT00374062|EXPERIMENTAL|II|relaxation tape 2
62377206|NCT00374062|PLACEBO_COMPARATOR|III|relaxation tape 3
62753242|NCT03985410|EXPERIMENTAL|Treatment Sequence BCA|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A). There will be 7 ± 2 days washout between treatments.
62753243|NCT03985410|EXPERIMENTAL|Treatment Sequence CAB|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B). There will be 7 ± 2 days washout between treatments.
62753244|NCT03985410|EXPERIMENTAL|Treatment Sequence CBA|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A). There will be 7 ± 2 days washout between treatments.
62753245|NCT01760330|ACTIVE_COMPARATOR|IV acetaminophen|IV acetaminophen administered q 4 hrs. for a total of 24 hrs.
62753246|NCT01760330|PLACEBO_COMPARATOR|Placebo|Normal saline administered IV every 4 hrs. for a total of 24 hrs.
62753247|NCT01730833|EXPERIMENTAL|Treatment (pertuzumab, trastuzumab, nab-paclitaxel)|Patients receive pertuzumab IV over 30-60 minutes on day 1, trastuzumab IV over 30-90 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62753248|NCT03786302|EXPERIMENTAL|TAMP bioglass|Tailored amorphous multiporous bioglass (TAMP-BG) of 70% SiO2 / 30% CaO was prepared according to Wang et al. (2011, 2013) in the tissue engineering lab, Faculty of Dentistry, Alexandria University as follows: Scaffolds were grounded to 180- to 300-μm particle size and sterilized at 180°C for 2 hours. The resulting powder was mixed with distilled water to obtain a putty like consistency that was carried to the pulp chamber and condensed lightly on the pulp stumps.
62753249|NCT03786302|ACTIVE_COMPARATOR|Biodentine ™|Biodentine ™ (BD) pre-dosed capsule were gently tapped on a hard surface to diffuse the powder. Five drops of the liquid from the single dose dispenser were poured into the capsule and mixed for 30 seconds at 4,200 rpm in an amalgamator according to manufacturer's instructions to obtain putty- like consistency. (Powder-liquid system). It was then be carried to the pulp chamber and condensed lightly on the pulp stumps. Final restoration was applied after 12 minutes, allowing Biodentine ™ to set.
62753250|NCT04600076|EXPERIMENTAL|BabyCenter site and the community group|
62753251|NCT05723835|EXPERIMENTAL|Somapacitan|Participants will receive Somapacitan for 26-week main phase followed by 130-week extension phase.
62753252|NCT03465462|ACTIVE_COMPARATOR|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
62753253|NCT03465462|ACTIVE_COMPARATOR|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
62753254|NCT03465462|ACTIVE_COMPARATOR|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
62753255|NCT06608979|EXPERIMENTAL|Screening/Referral and Prevention|Participants will receive a brief PTSD screening, warm handoff to trauma-focused resources if screening positive, and two session peer support specialist-delivered educational program on interpersonal violence prevention.
62753256|NCT03145792|EXPERIMENTAL|Seeking Safety|Behavioral therapy for trauma and addiction.
62753257|NCT03145792|ACTIVE_COMPARATOR|CBT for Pathological Gambling|Behavioral therapy for gambling problems.
62753258|NCT02330302|ACTIVE_COMPARATOR|Femoral nerve block|Procedure: Ultrasound-guided femoral nerve block Drug: Ropivacaine 0.5% 30mls
62753259|NCT02330302|ACTIVE_COMPARATOR|Fascia Iliaca block|Procedure: Ultrasound-guided suprainguinal approach to fascia iliaca block Drug: Ropivacaine 0.5% 30mls
62753260|NCT05787093||pediatric patients accessing for constipation with rectal diameter >3 cm|
62377207|NCT04409990|OTHER|Shear Wave Elastography|SWE value measurement will be added during the ERUS examination.
62377208|NCT01209117|EXPERIMENTAL|Periods 1 - 4|Subjects will be randomized in a cross over fashion to receive the GSK2248761 WBM capsule formulation or one of three WBM tablet formulations in one of four sequences.
62377209|NCT01209117|EXPERIMENTAL|Period 5|Subjects in Part B will receive a formulation of GSK2248761 200mg WBM Tablet chosen from Periods 1 - 4 in part A in the fed state (moderate fat meal).
62377210|NCT02039089|EXPERIMENTAL|1|Part A: dose escalation of E2006 in Japanese subjects from 2.5 mg (1 x 2.5-mg tablet) up to 10 mg (1 x 10-mg tablet) then to 25 mg (2 x 10-mg tablet, 1 x 5-mg tablet).
62377211|NCT02039089|EXPERIMENTAL|2|Part B: E2006 10 mg for White subjects that will be group matched to the Japanese subjects in the 10 mg period in Part A.
62377212|NCT02039089|PLACEBO_COMPARATOR|3|E2006-matched placebo tablets
62377213|NCT01550770|EXPERIMENTAL|proprofol|
62377214|NCT03362216|EXPERIMENTAL|experimental group|Treated with Compound Methyl Salicylate Liniment group
62377215|NCT03362216|ACTIVE_COMPARATOR|Control group|Treated with Diclofenac Sodium Liniment group
62753261|NCT05787093||pediatric patients accessing for constipation with rectal diameter <3 cm|
62753262|NCT01874275|EXPERIMENTAL|VECTTOR|nerve stimulator treatment twice daily for duration of study - 365 days
62753263|NCT01874275|PLACEBO_COMPARATOR|Device - sham|placebo treatment - no electrical stimulation treatment twice daily for duration of study, 180 days - if VECTTOR arm experiencing improvement, subjects in Device-Sham arm will be crossed over into the VECTTOR group and followed for an additional 180 days, for a total study involvement (duration) of 365 days\>
62377216|NCT01989936|PLACEBO_COMPARATOR|Placebo|
62753264|NCT02938078|EXPERIMENTAL|Treatment Eye|One eye will be treated with Avenova; the other eye will not be treated. The investigator is masked as to which eye is receiving Avenova product.
62753265|NCT02938078|NO_INTERVENTION|Non-Treatment Eye|One eye will be treated with Avenova; the other eye will not will be treated. The investigator is masked as to which eye is receiving Avenova product.
62753266|NCT06608329|EXPERIMENTAL|Cohort 1|Period 1: Subjects received HDM1002 table (200 mg×1）in fasted state; Period 2: Subjects received HDM1002 tables (100 mg×2）in fasted state; Period 3: Subjects received HDM1002 table (200 mg×1）in fed state.
62753267|NCT06608329|EXPERIMENTAL|Cohort 2|Period 1: Subjects received HDM1002 tables (100 mg×2）in fasted state; Period 2: Subjects received HDM1002 table (200 mg×1）in fed state; Period 3: Subjects received HDM1002 table (200 mg×1）in fasted state.
62753268|NCT06608329|EXPERIMENTAL|Cohort 3|Period 1: Subjects received HDM1002 table (200 mg×1）in fed state; Period 2: Subjects received HDM1002 table (200 mg×1）in fasted state; Period 3: Subjects received HDM1002 tables (100 mg×2）in fasted state.
62377217|NCT01989936|EXPERIMENTAL|Eletriptan 40 mg|
62377218|NCT01989936|EXPERIMENTAL|Eletriptan 80 mg|
62377219|NCT06219876|ACTIVE_COMPARATOR|Control|wrist splints of an appropriate size in a neutral position for at least 8 hours at night for 3 months
62377220|NCT06219876|ACTIVE_COMPARATOR|Low Level Laser Treatment|"* wrist splints of an appropriate size in a neutral position for at least 8 hours at night for 3 months~* received an additional LLLT"
62753269|NCT02090049|EXPERIMENTAL|Puravita Breakfast|Puravita Breakfast is a high protein and high fiber soft bread that contains 22% fruit (figs, apricots, raisins and prunes), a selection of cereals: wheat, oat and spelt and no added sugar.
62753270|NCT02090049|PLACEBO_COMPARATOR|Control breakfast|White bread (85g) with jam (10g) and margarine (2g) adjusted for energy, fat, and sugar levels and for energy density.
62753271|NCT04092907|EXPERIMENTAL|HBM9036 0.25% Ophthalmic Solution|HBM9036, Ophthalmic Solution, twice a day, in the morning and evening
62377221|NCT06219876|ACTIVE_COMPARATOR|High Intensity Laser Treatment|"* wrist splints of an appropriate size in a neutral position for at least 8 hours at night for 3 months~* received an additional HILT"
62377222|NCT02573012|EXPERIMENTAL|Tocilizumab+prednisone (constant dose)|Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) or matching placebo orally for 24 weeks.
62753272|NCT04092907|PLACEBO_COMPARATOR|Placebo Ophthalmic Solution|placebo, Ophthalmic Solution, twice a day, in the morning and evening
62753273|NCT02893865|EXPERIMENTAL|Experimental|Continuous positive airway pressure Patients will receive continuous positive airway pressure during three months
62377223|NCT02573012|EXPERIMENTAL|Tocilizumab+prednisone (tapering dose)|Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) with 1 mg decrements every 4 weeks or matching placebo orally for 24 weeks.
62377224|NCT04853264|EXPERIMENTAL|Experimental: intervention group|Ultrasound-guided peripheral venipuncture performed by a registered nurse with expertise in vascular access.
62377225|NCT04853264|ACTIVE_COMPARATOR|Control group|Conventional peripheral venipuncture performed by a registered nurse.
62377226|NCT04043416|EXPERIMENTAL|System + Fall Prevention First, then Fall Prevention|"Participants in this arm will be invited to use the jDome BikeAround system for up to 30 minute sessions up to 3 times a week during the first 6 week campaign. During this campaign the participants will also participant in the standard fall prevention program. Following the 6 week washout period, the participants in this arm will just participate in the Fall Prevention program alone.~Fall Prevention Program focuses on reducing the incidence of residents' falls and mitigating risks of falls through a resident focused, team approach which ensures that a resident's environment and social, physical, cognitive and emotional strengths are supported. This is an interdisciplinary program involving nursing and program staff, physician/pharmacist, dietician, physiotherapist, housekeeping staff and the resident/POA. They communicate regarding their planned interventions and evaluation of resident progress and outcomes in falls prevention through documentation."
62377227|NCT04043416|EXPERIMENTAL|Fall Prevention first, then System +Fall Prevention|"Participants in this arm will participate in the Fall Prevention program alone during the first 6 week campaign. Following the 6 week washout period the participants will be invited to use the jDome BikeAround system for up to 30 minute sessions up to 3 times a week during the second 6 week campaign. During this campaign the participants will also participant in the standard fall prevention program~Fall Prevention Program focuses on reducing the incidence of residents' falls and mitigating risks of falls through a resident focused, team approach which ensures that a resident's environment and social, physical, cognitive and emotional strengths are supported. This is an interdisciplinary program involving nursing and program staff, physician/pharmacist, dietician, physiotherapist, housekeeping staff and the resident/POA. They communicate regarding their planned interventions and evaluation of resident progress and outcomes in falls prevention through documentation."
62377228|NCT01627041|EXPERIMENTAL|Arm I (daunorubicin hydrochloride, cytarabine)|Patients receive induction chemotherapy comprising daunorubicin hydrochloride IV daily on days 1-3 and cytarabine IV continuously on days 1-7 in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR after the first induction-chemotherapy course receive a second identical induction course.
62377229|NCT01627041|EXPERIMENTAL|Arm II (decitabine, daunorubicin hydrochloride, cytarabine)|Patients receive decitabine IV over 1 hour on days -5 to -1. Patients then receive induction chemotherapy as in arm I in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR after the first induction-chemotherapy course receive a second identical induction course.
62377230|NCT02033252|EXPERIMENTAL|Acupuncture|A series of acupuncture sessions within four weeks from the baseline with concurrent conventional medications for asthma
62377231|NCT02033252|NO_INTERVENTION|Waiting|Participants who will be allocated to waitlist will receive no acupuncture treatments throughout the 4 weeks while receiving other conventional managements for asthma. After 4 weeks, if participants choose to try the acupuncture treatment, the active acupuncture treatment will be provided for 4 weeks (3 sessions/week).
62556204|NCT02692443||SVR Survivors|Through the SVR and SVR II studies vital status has been followed annually for the entire SVR cohort. As of June 2014 352 subjects are alive, 18 of whom have undergone cardiac transplantation, and 18 have undergone biventricular conversion leaving 334 transplant-free survivors with single ventricle physiology. Each patient enrolled to this ancillary study from the parent SVR study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to the already scheduled parent study follow-up procedures.
62556205|NCT02692443||Healthy Controls|In addition to the SVR survivors, investigators plan to enroll 100 age- and gender-matched healthy controls. Healthy controls enrolled for participation in this ancillary study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to completing the Neurodevelopmental Testing Battery that is already part of the parent SVR study and completed by SVR Survivors as part of their SVR follow-up appointments.
62556206|NCT06437015|EXPERIMENTAL|Constraint-Induced Movement Therapy|
62556207|NCT06437015|ACTIVE_COMPARATOR|Mirror Therapy|
62556208|NCT02618759|EXPERIMENTAL|DSXS1505|To evaluate the therapeutic efficacy and safety of DSXS topical spray, 0.15%.
62753274|NCT02893865|SHAM_COMPARATOR|Sham Comparator|Sham-continuous positive airway pressure Patients will receive sham-continuous positive airway pressure during 3 months
62753275|NCT04363255|EXPERIMENTAL|Maintenance group|After 4-6 cycles of EP/EC chemotherapy regiment, maintenance therapy with toripalimab and anlotinib was followed and continued until disease progression.
62753276|NCT00728208|EXPERIMENTAL|GSK372475|Drug
62753277|NCT02524015|OTHER|Control|Standard Physical Therapy
62753278|NCT02524015|EXPERIMENTAL|Intervention|Novel Physical Therapy
62377232|NCT05431335|EXPERIMENTAL|Structured exercise program|The structured exercise program will be applied for 12 weeks, 2 days a week, for 45 minutes by a physiotherapist.
62377233|NCT05431335|OTHER|Aerobic exercise program|The aerobic exercise program will be applied for 12 weeks, 2 days a week, for 45 minutes by a physiotherapist.
62377234|NCT02050828|EXPERIMENTAL|AKB-9778 15 mg BID monotherapy|Subcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus monthly sham intravitreal injection for 3 months.
62377235|NCT02050828|EXPERIMENTAL|AKB-9778 15 mg BID + ranibizumab 0.3 mg|Subcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
62377236|NCT02050828|ACTIVE_COMPARATOR|ranibizumab 0.3 mg monotherapy|Placebo subcutaneous injection (BID) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
62377237|NCT04225936|EXPERIMENTAL|Group A: Mild Hepatic Impairment|Part 1
62377238|NCT04225936|EXPERIMENTAL|Group B: Moderate Hepatic Impairment|Part 1
62377239|NCT04225936|EXPERIMENTAL|Group C: Severe Hepatic Impairment|Part 2
62377240|NCT04225936|EXPERIMENTAL|Group D: Normal Hepatic function (control group)|Part 1
62377241|NCT04225936|EXPERIMENTAL|Group E: Normal Hepatic Function (optional, control group)|Part 2
62377242|NCT04469556|ACTIVE_COMPARATOR|Modified Folfirinox|"Modified FOLFIRINOX (Folinic acid/Leucovorin, 5-Fluouracil, Irinotecan, Oxaliplatin) administered intravenously.~Given that both regimens are standard of care, study treatment will be administered as per standard of care at each institution including a maintenance therapy approach which is encouraged in both arms. Dose modifications, anti-emetics, supportive medications, and use of growth factors should follow institutional guidelines."
62377243|NCT04469556|ACTIVE_COMPARATOR|Gemcitabine/nab-Paclitaxel|"Gemcitabine/nab-Paclitaxel administered intravenously.~Given that both regimens are standard of care, study treatment will be administered as per standard of care at each institution including a maintenance therapy approach which is encouraged in both arms. Dose modifications, anti-emetics, supportive medications, and use of growth factors should follow institutional guidelines."
62377244|NCT04290767|OTHER|Sonovue|ICU patients with acute shock status (septic or non-septic) who are eligible for enhanced-contrast brain ultrasound with sulphur hexafluoride microbubbles contrast (Sonovue, BRACCO, Milan, Italy) examination.
62377245|NCT03884556|EXPERIMENTAL|Arm 1, Single Agent|TTX-030
62377246|NCT03884556|EXPERIMENTAL|Arm 2, Anti-PD-1 Combination|TTX-030 plus pembrolizumab
62377247|NCT03884556|EXPERIMENTAL|Arm 4, Chemotherapy Combination|TTX-030 plus gemcitabine plus nab-paclitaxel
62377248|NCT01345825|EXPERIMENTAL|resistance training|
62556209|NCT02618759|PLACEBO_COMPARATOR|Placebo|Eligible patients will be randomized in a 1:1 ratio to Test or Placebo product.
62377249|NCT04068220|OTHER|Intraoperative FVEPs monitoring|adult patients admitted to TOH - Civic Campus, for chiasmal or pre-chiasmal lesions undergoing a first time minimally invasive endoscopic skull base surgery.
62377250|NCT01362049|ACTIVE_COMPARATOR|'Eligible' Subject Group - STAB|"Subjects between the ages of 21-55 years with low back pain \>12 months who are eligible for Treatment-Based Classification (TBC) stabilization exercises based on current criteria:~1. straight leg raise \> 90 degrees~2. aberrant trunk movement with trunk forward flexion~3. positive prone instability test AND/OR~4. passive lumbar mobility testing that is judged to be hypermobile at any level."
62377251|NCT01362049|ACTIVE_COMPARATOR|'Ineligible' Subject Group - STAB|Subjects between the ages of 21-55 years with low back pain \>12 months who are not eligible for the TBC-based stabilization exercises based on current criteria
62377252|NCT01362049|ACTIVE_COMPARATOR|'Eligible' Subject Group - MSI|"Subjects between the ages of 21-55 years with low back pain \>12 months who are eligible for Treatment-Based Classification (TBC) stabilization exercises based on current criteria:~1. straight leg raise \> 90 degrees~2. aberrant trunk movement with trunk forward flexion~3. positive prone instability test AND/OR~4. passive lumbar mobility testing that is judged to be hypermobile at any level."
62377253|NCT01362049|ACTIVE_COMPARATOR|'Ineligible' Subject Group -MSI|Subjects between the ages of 21-55 years with low back pain \>12 months who are not eligible for the TBC-based stabilization exercises based on current criteria
62377254|NCT04207944|EXPERIMENTAL|Sulindac|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Patients will continue drug for 3 years during follow-up.
62753279|NCT05093907|EXPERIMENTAL|BEY1107 + Capecitabine|Administer BEY1107 in combination with Capecitabine, 3-weeks as 1 cycle.
62377255|NCT04207944|PLACEBO_COMPARATOR|Placebo|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus placebo. Patients will continue placebo for 3 years during follow-up.
62377256|NCT00717951|EXPERIMENTAL|A|"Arm A is docetaxol+capecitabine chemotherapy"
62377257|NCT00717951|EXPERIMENTAL|B|"Arm B is docetaxol+cisplatin chemotherapy"
62377258|NCT04348136|EXPERIMENTAL|JR-141|
62377259|NCT03422744|EXPERIMENTAL|patient with peripheral lung lesion|"Patient presenting a peripheral lung lesion seen at Ct-scan but invisible at simple endoscopy.~Intervention : trans bronchial biopsy guided by echo-endoscopic miniprobes.~Intervention: If first intervention doesn't give a diagnosis we get cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control"
62377260|NCT04444323|EXPERIMENTAL|3D Telemedicine|Single arm. All patient seen face-to-face and then with 3D telemedicine.
62377261|NCT02397772|ACTIVE_COMPARATOR|Annual school-based deworming|Pre-school and school children (typically 2-14 years) will receive albendazole treatment from trained school teachers, as part of the ongoing national school-based deworming programme.
62377262|NCT02397772|EXPERIMENTAL|Annual community-based deworming|Standard school-based deworming supplemented by annual community-based deworming (2-99 years). All household members who are not enrolled in school will receive albendazole treatment from trained community health workers.
62377263|NCT02397772|EXPERIMENTAL|Biannual|Biannual school- and community-based deworming (2-99 years). All household members who are not enrolled in school will receive albendazole treatment from trained community health workers
62377264|NCT01965028|EXPERIMENTAL|Transcranial random noise stimulation (tRNS)|High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
62377265|NCT03378973|EXPERIMENTAL|High dose dexmedetomidine|Patients will receive dexmedetomidine 0.5 mcg/kg/hr plus propofol 50 mcg/kg/min
62377266|NCT03378973|ACTIVE_COMPARATOR|Low dose dexmedetomidine|Patients will receive dexmedetomidine 1.0 mcg/kg/hr plus propofol 25 mcg/kg/min
62377267|NCT05917392|ACTIVE_COMPARATOR|Supplementation-standard|Supplementation with Kimchi 50 gram daily for two months
62377268|NCT05917392|EXPERIMENTAL|Supplementation with probiotic|Supplementation with Kimchi plus LGG 50 gram daily for two months
62377269|NCT05917392|EXPERIMENTAL|Supplementation with polyphenol|Supplementation with Kimchi plus polyphenol 50 gram daily for two months
62377270|NCT04600427|EXPERIMENTAL|Epidural anesthesia|The patient will be positioned appropriately and the T11-12 (if not accessible we will accept 1-2 spaces above or below) interspace landmarked using established ultrasound guidance techniques. The patient's back will be prepped and draped in a sterile fashion. An epidural catheter will be inserted into the T11-12 interspace with a midline or paramedian approach using a 17G Tuohy needle. Plain preservative free bupivicaine 0.25% will be the local anesthetic used. After a 2-3 mL test dose to rule out intrathecal catheter positioning, a loading dose of 5-8 mL will be administered over 5-10 minutes to further rule out intravascular positioning of the catheter. Successful epidural placement will be defined by catheter insertion and confirmed by sensory blockade assessed by ice or pin prick testing. When correct positioning is confirmed, a continuous infusion of 3 mL per hour of bupivacaine 0.25% plain solution will begin.
62377271|NCT02308553|EXPERIMENTAL|Nintedanib + Paclitaxel|Nintedanib (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses
62753280|NCT00839449|EXPERIMENTAL|A|Patients in the group A are orally administered eicosapentaenoic acid ethyl ester.
62377272|NCT02308553|PLACEBO_COMPARATOR|Nintedanib-Placebo + Paclitaxel|Placebo (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses
62377273|NCT01616641||rheumatoid arthritis group|75 patients with rheumatoid arthritis
62377274|NCT01616641||control group|75 healthy women
62377275|NCT00975442|EXPERIMENTAL|Eccentric training|
62377276|NCT00975442|PLACEBO_COMPARATOR|Forearm band|
62377277|NCT04305665||HIV-1 positive persons|
62377278|NCT05103501|EXPERIMENTAL|experimental arm|PF regimen (cis-platinum of 75mg/m2/d, d1; 5-fluorouracil of 600mg/m2d1-4) combined with PD-1 inhibitors（pembrolizumab，200mg d1） every 3 weeks for 4 cycles followed by PD-1 inhibitors（pembrolizumab，200mg d1）every 3 weeks up to 2 years in a standard manner.
62377279|NCT03130465||Aripiprazole Once Monthly (AOM)|Schizophrenia patients who initiated maintenance treatment with AOM during a schizophrenia-related hospitalisation or during the first three months after this hospitalisation.
62556210|NCT04068493|EXPERIMENTAL|Dissonance-based obesity intervention|Participants in this arm will receive Enhanced Project Health.
62753281|NCT00839449|NO_INTERVENTION|B|Patients in the group B (control) are not administered eicosapentaenoic acid ethyl ester.
62753282|NCT06606795|NO_INTERVENTION|Control group|20 people will be included in the control group. A total of two measurements will be taken, one at the beginning and one at the end of the study. Respiratory muscle strength, respiratory function, and cervical and thoracic joint range of motion will be evaluated in the measurements. The control group will continue their normal weightlifting training throughout the study.
62753283|NCT06606795|EXPERIMENTAL|Spinal Manipulation Group|20 people will be included in the Spinal Manipulation Therapy (SMT) group. This group will continue their normal weightlifting training during the study and in addition to the weightlifting training, they will receive a total of three sessions of cervical and thoracic manipulation therapy once a week for three weeks. A total of two measurements will be taken at the beginning and end of the study. Respiratory muscle strength, respiratory function and cervical and thoracic joint range of motion will be evaluated in the measurements.
62753284|NCT01015235|PLACEBO_COMPARATOR|Arm 1: Placebo|Placebo
62753285|NCT01015235|ACTIVE_COMPARATOR|A2: KAI-1678|Test Drug
62753286|NCT01015235|ACTIVE_COMPARATOR|A3: Ketorolac|Active Comparator
62753287|NCT03280303||non-interventional study|This prospective, observational study will be conducted according to each site's routine clinical practice.
62753288|NCT05897840|EXPERIMENTAL|Continuous measurement of central venous oxygen saturation|"The measurement of SvcO2 is performed by spectrophotometry which is a quantitative measurement of wavelength transmission.~For this, a fiber optic probe, CeVOX probe, is used."
62753289|NCT03049267|EXPERIMENTAL|Apremilast|N=15
62753290|NCT03049267|PLACEBO_COMPARATOR|Placebo Oral Tablet|N=5
62753291|NCT04188418|EXPERIMENTAL|Group I (shuttle walk test, FBT)|Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive FBT sublingually daily on days 6-19.
62753292|NCT04188418|EXPERIMENTAL|Group II (shuttle walk test, morphine)|Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive morphine PO daily on days 6-19.
62753293|NCT04188418|ACTIVE_COMPARATOR|Group III (shuttle walk test, placebo)|Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive placebo (sublingually or PO) daily on days 6-19.
62753294|NCT00063895|EXPERIMENTAL|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62753295|NCT01986309|ACTIVE_COMPARATOR|Group L|Group L Lidocaine load dose 1.5 mg / kg over 5 minutes, followed by continuous infusion of 2 mg / kg / h, which is maintained until the end of surgical procedure
62753296|NCT01986309|PLACEBO_COMPARATOR|Group P|Normal saline solution administered under the same regimen
62377280|NCT03130465||Daily oral atypical AP|Schizophrenia patients who initiated maintenance treatment with any daily oral atypical AP during a schizophrenia-related hospitalisation or during the first three months after this hospitalisation.
62753297|NCT00683917|EXPERIMENTAL|Proellex 25 mg|Proellex 25 mg
62377281|NCT01620437|EXPERIMENTAL|Formulation A|
62753298|NCT00683917|EXPERIMENTAL|Proellex 50 mg|Proellex 50 mg
61986473|NCT06024044|EXPERIMENTAL|Mobilization Training|"A face-to-face Patient Information Form was applied to the training group in the first interview before the hysterectomy operation. The participants in the training group were given hysterectomy postoperative mobilization training by the researcher (B.K) using presentation and verbal information technique. A Post-Operative Follow-up Chart was given to the participants to fill in the 1st and 2nd postoperative days. The training group participants were followed up by the researcher on the 0th and 1st days after the operation in line with the mobilization training they received. The Post-Operative Follow-up Chart questioning the patients' mobilization times, distances, bowel functions and pain scores was filled in by the researcher in detail by face-to-face interview method. Mobilization time (minutes) and distance (meters) were evaluated by the patients and their relatives, and recorded on the chart, using the stopwatch and pedometer on the personal mobile phones of the patients."
61986474|NCT01039233|EXPERIMENTAL|Bicalutamide 50 mg Tablet|
61986475|NCT01039233|ACTIVE_COMPARATOR|Casodex® 50 mg Tablet|
62377282|NCT01620437|EXPERIMENTAL|Formulation B|
62377283|NCT04904991|EXPERIMENTAL|Qigong group|Participants in the Qigong group were given a structured program about Chan-Chung qigong for 3 months which was a modified form of the manual of Chan-Chuang qigong (Yeh et al., 2006), to tailor to patients with cognitive impairment. The Chan-Chuang qigong program included warmup prior to qigong practice, preparation for qigong practice . The movements should be repeated and maintained for 10 minutes per time, 3 time a day .
62753299|NCT00683917|ACTIVE_COMPARATOR|Lupron|Lupron Depot
62753300|NCT02051153|EXPERIMENTAL|Placebo|"Placebo: study participants received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.~Other Names: Placebo."
62753301|NCT02051153|EXPERIMENTAL|Modafinil|"Study participants received, in a double blind fashion, either a single dose (200 mg) of modafinil or a placebo pill identical to the drug.~Other Names:~Provigil"
62753302|NCT04554966|EXPERIMENTAL|Part A: ABBV-382 Dose A|Participants will receive intravenous (IV) ABBV-382 dose A on Day 1.
62753303|NCT04554966|EXPERIMENTAL|Part A: ABBV-382 Dose B|Participants will receive intravenous (IV) ABBV-382 dose B on Day 1.
62753304|NCT04554966|EXPERIMENTAL|Part B: Intravenous Cohort: ABBV-382 Dose A|Participants will receive intravenous (IV) ABBV-382 dose A on Days 1, 29 and 57.
62753305|NCT04554966|PLACEBO_COMPARATOR|Part B: Intravenous Cohort: Placebo for ABBV-382 Dose A|Participants will receive intravenous (IV) placebo for ABBV-382 dose A on Days 1, 29 and 57.
62753306|NCT04554966|EXPERIMENTAL|Part B: Intravenous Cohort: ABBV-382 Dose B|Participants will receive intravenous (IV) ABBV-382 dose B on Days 1, 29 and 57.
62753307|NCT04554966|PLACEBO_COMPARATOR|Part B: Intravenous Cohort: Placebo for ABBV-382 Dose B|Participants will receive intravenous (IV) placebo for ABBV-382 dose B on Days 1, 29 and 57.
62753308|NCT04554966|EXPERIMENTAL|Part B: Subcutaneous Cohort: ABBV-382|Participants will receive subcutaneous (SC) ABBV-382 dose C on Days 1, 29 and 57.
62753309|NCT06589791||Health care professionals|Cardiologists and nephrologists in China
62753310|NCT06445764|OTHER|e-learning|
62753311|NCT06445764|OTHER|Virtual reality training|
62753312|NCT06089213|EXPERIMENTAL|Interactive services|"Otago exercises performed in real-time or synchronous mode of digital health care. It consists of direct communication between physiotherapist and the patient."
62753313|NCT06089213|ACTIVE_COMPARATOR|Remote telemonitoring|Otago exercises performed remotely, using technologies such as messaging apps. It consists of indirect communication between physiotherapist and the patient.
62753314|NCT06608199|EXPERIMENTAL|PCV13-DT/TT(Pneuminvac)|250 infants will be administered with Minhai's PCV13-DT/TT(Pneuminvac)
62753315|NCT06608199|ACTIVE_COMPARATOR|PCV13(Prenenar13)|250 infants will be administered with Prenenar13
62753316|NCT01478802|ACTIVE_COMPARATOR|CMV Arm|Patients with moderate-to-severe Acute Respiratory Distress Syndrome treated solely with lung protective, low volume high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description section.
62753317|NCT01478802|EXPERIMENTAL|HFO-RMs Arm|Patients with moderte-to-severe Acute Respiratory Distress Syndrome treated initially with a 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO)-Recruitment Maneuvers (RMs), and then with lung protective CMV interspersed to additional HFO-RMs sessions (if required according to study protocol). The protocolized use of HFO-RMs may extend until day 10 post-randomization, according to pre-specified oxygenation criteria. Full details are provided in the Detailed Description Section.
62753318|NCT06609070|EXPERIMENTAL|Drug: CHG0521 Oral Coating|LSCC subjects who are not suitable for surgery after evaluation, or have surgical indications, do not agree to surgical treatment, or patients with recurrence and metastasis after surgery no longer have surgery.
62753319|NCT02817113|EXPERIMENTAL|NC-6004, Cetuximab and 5-FU|Cetuximab will be administered before the start of chemotherapy at a loading dose of 400 mg/m2 given, followed by a subsequent weekly doses of 250 mg/m2; NC-6004 will be administered on Day 1 every 3 weeks, and 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
62753320|NCT04899440|EXPERIMENTAL|Test Regimen|Oral Irrigator + Manual toothbrush + toothpaste Subjects will brush their teeth twice daily and will use the oral irrigator once in the evening daily
62753321|NCT04899440|SHAM_COMPARATOR|Control Regimen|Manual toothbrush + toothpaste Subjects will brush their teeth twice daily
62753322|NCT05491941|ACTIVE_COMPARATOR|Hour-1 Bundle|If the patient meets 2+ SIRS and chief complaint criteria, a second BPA may be triggered, which displays to the provider. The second alert identifies patients who progress to organ failure based on lab results, or who have a recorded instance of hypotension. When this alert appears, an automatic counter will begin and serve as our Sepsis Time Zero. The provider will receive sepsis order sets and guided to the Sepsis Navigator. The navigator will allow them to review relevant patient data, reference sepsis guidelines, and keep tabs on a live-updating sepsis checklist to ensure they complete each element in order and on time. Following identification in the ED, both study arms will receive the same bundle (see below). The only difference will be the timing: For the Hour-1 bundle, all interventions in the bundle must be initiated within 1 hour.
62753323|NCT05491941|ACTIVE_COMPARATOR|3-Hour Bundle|If the patient meets 2+ SIRS and chief complaint criteria, a second BPA may be triggered, which displays to the provider. The second alert identifies patients who progress to organ failure based on lab results, or who have a recorded instance of hypotension. When this alert appears, an automatic counter will begin and serve as our Sepsis Time Zero. The provider will receive sepsis order sets and guided to the Sepsis Navigator. The navigator will allow them to review relevant patient data, reference sepsis guidelines, and keep tabs on a live-updating sepsis checklist to ensure they complete each element in order and on time. Following identification in the ED, both study arms will receive the same bundle (see below). The only difference will be the timing: For the 3-hour bundle, all elements must be completed by 3 hours.
62753324|NCT03579472|EXPERIMENTAL|Treatment (bintrafusp alfa, eribulin mesylate)|Patients receive bintrafusp alfa IV over 50-80 minutes on days 1, 15, and 29, and eribulin mesylate IV over 2-5 minutes on days 1, 8, 22, and 29. Treatment repeats every 42 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
62377284|NCT04904991|NO_INTERVENTION|Control group|those in the control group received usual care for cognitive impairment during the same study period.
62377285|NCT02064829|ACTIVE_COMPARATOR|Reference Drug - Nab-paclitaxel|260 mg/m2 administered intravenously over 30 minutes on Day 1
62753325|NCT05843903|EXPERIMENTAL|#BabyLetsMove|There are four digital components to the intervention including Fitbit activity tracker, interactive self-monitoring and tailored feedback text messages, tailored skills training text messages and materials, and peer health coaching.
62377286|NCT02064829|EXPERIMENTAL|Test Drug - IG-001|260 mg/m2 administered intravenously over 30 minutes on Day 1
62377287|NCT02261402|EXPERIMENTAL|Medisinstart|Patients in this arm will receive the service; Medisinstart
62556211|NCT04068493|NO_INTERVENTION|Assessment Only|Participants in this arm will only complete the baseline assessment and 2 month assessment. They will not receive Enhanced Project Health.
62753326|NCT06605742|EXPERIMENTAL|Experimental Group|A Support and Counseling Program Based on the Roy Adaptation Model and a training booklet were prepared for women diagnosed with MGS. During the study, 5 counseling sessions were held for 4 months (16 weeks).
62753327|NCT06605742|EXPERIMENTAL|Control Grup|Women in the control group received routine care from the hospital. They filled out the scales at the first and last interviews. At the first interview, women in the control group were given an educational booklet.
62753328|NCT01693874|EXPERIMENTAL|Mindfulness Based Stress Reduction|All participants in this arm receive Mindfulness Based Stress Reduction (MBSR).
62753329|NCT01693874|ACTIVE_COMPARATOR|control|All participants in this arm receive an attention control
62753330|NCT05175768|ACTIVE_COMPARATOR|Nicotinamide Mononucleotide|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
62753331|NCT05175768|ACTIVE_COMPARATOR|Nicotinamide Mononucleotide with L-Leucine|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
62753332|NCT05175768|PLACEBO_COMPARATOR|Placebo|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
62753333|NCT04521998|EXPERIMENTAL|electroacupuncture|The needles remained in situ for 30 minutes, during which time the acupuncturist returned to stimulate the needles once to re-elicit the de qi sensation. Participants have 2 sessions per week, with total 5 weeks and 10 sessions. The body points included LI4, LI11, SP6 and ST36. The individual specific points protocol are as follows: GB20, TE5, SP10, GB34, LV3, ba xie, ba fen, Ashi). The acupuncture protocol consists of the body points and some of the individual specific points depending on subjects' condition.
62753334|NCT04521998|EXPERIMENTAL|Transcutaneous electrical nerve stimulation|The protocol consisted of first swabbing all points with alcohol, then pads of TENS were sticked on the proper location of acupoints included LI4, LI11, SP6 and ST36. Electrical output of one channel was administered to the surface of body via a combination of two pads. LI4 and LI11, ST36 and SP6 are combination of acupoints, respectively. Participants had 2 sessions per week, with total 5 weeks and 10 sessions. Each session lasted 30 minutes.
62753335|NCT02181361||hirudin plus aspirin|14 days after stroke onset, patients in the hirudin plus aspirin group received natural hirudin 0.75g, three times a day and aspirin 100mg, once daily.
62377288|NCT02261402|NO_INTERVENTION|Current Practice|Patients in this arm will receive the current pharmacy practice of advice and guidance with their new medicine. This involves dispensing the medicine and briefly providing information regarding its use and potential side-effects.
62753336|NCT02181361||Warfarin|14 days after stroke onset, patients in warfarin group were given an initial dose of 1.25mg of warfarin,once daily. 3 days later, INR of patients was checked every three days and the dose of warfarin was adjusted until reach the target range of 2 to 3. Since then INR monitoring was performed at 1, 2, 3, 6, 9, 12 months after stroke onset, targeting an INR between 2 and 3 and the dose of warfarin was adjusted accordingly.
62753337|NCT03764631||subjects with Type 2 Diabetes mellitus|
62753338|NCT02632279|EXPERIMENTAL|TRP depleted|TRP depleted protein drink
62753339|NCT02632279|PLACEBO_COMPARATOR|Placebo|Balanced protein drink (+1.21g of TRP)
62556212|NCT06581757||Residual, surplus serum samples|The study will utilise residual, surplus serum samples with a minimum volume of 300µl that have already been taken as part of the patient's routine care. The patients have already been consented for investigation of SAH and the leftover sample would otherwise be discarded by the laboratory.
62556213|NCT02872376||Anemic|Anemic patients
62753340|NCT04613765||Non-migrants|"53 non-migrant patients will be enrolled. Non-migrants will be defined as the group of native-born persons with a Belgian nationality or with a foreign nationality but with both parents native-born."
62753341|NCT04613765||Migrants|"60 migrant patients will be enrolled. This group will include both First Generation (FG) migrants defined as the group of foreign-born persons and Second Generation (SG) migrants defined as people native-born but with either a foreign nationality or with one or both parents foreign-born."
62753342|NCT01838330|EXPERIMENTAL|Chronic Kidney Disease Stage 3-4|Study participants with stage 3 or 4 CKD will receive 15 grams/day of soluble fiber psyllium for the first week, followed by 30 grams/day of a soluble fiber psyllium for 4 months.
62753343|NCT01838330|NO_INTERVENTION|Chronic Kidney Disease Stage 1-2|Study participants with stage 1 or 2 CKD will not receive study treatment
62753344|NCT05227560|EXPERIMENTAL|Emotional Freedom Technique group|"Personal characteristics questionnaire, State Anxiety Scale (SQS) and Stress Coping Styles Scale (SST) were applied to the intervention group at the pre-test stage. Subjective discomfort level scale (ERDS) was also applied to the intervention group before EFT was applied. After four sessions of EFT, DKO, SBO, ORDS were applied to the intervention group again in the post-test phase."
62753345|NCT05227560|NO_INTERVENTION|Control|Participants in the control group received no intervention throughout the study.
62753346|NCT05156840||Telehealth|Patients/Caregivers who received a telehealth follow-up visit from a pediatric hospitalist following hospital discharge.
62556214|NCT03982992|EXPERIMENTAL|DLI-TARGET|"14d screening period: methotrexate, cytarabine, dexamethasone infusion i.th.~Cycle 1 (all patients): d1-28: blinatumomab continuous infusion i.v., d4: allogeneic donor lymphocyte single infusion i.v., d29: methotrexate, cytarabine, dexamethasone infusion i.th.~Cycle 2 (only patients with toxicity ≤ grade 2 CTCAE in cycle 1): d43-d70: blinatumomab continuous infusion i.v., d46: allogeneic donor lymphocyte single infusion i.v., d71: methotrexate, cytarabine, dexamethasone infusion i.th."
62753347|NCT05156840||Usual Care|Patients/Caregivers who did not receive a telehealth follow-up visit from a pediatric hospitalist following hospital discharge.
62753348|NCT05791409|EXPERIMENTAL|Arm A|6 cycles epcoritamab + 26 cycles venetoclax
62753349|NCT05791409|EXPERIMENTAL|Arm B|12 cycles epcoritamab + 26 cycles venetoclax
62377289|NCT01376908|EXPERIMENTAL|Kuvan® + Phe-restricted diet|Subjects will be treated with Kuvan® tablets once daily along with Phe-restricted diet therapy.
62377290|NCT01376908|OTHER|Phe-restricted diet alone|Subjects will follow a Phe-restricted diet alone.
62377291|NCT04838340|ACTIVE_COMPARATOR|Standart care|Standart care group will leave in the hospital's usual care and no intervention will be applied.
62556215|NCT05954390|ACTIVE_COMPARATOR|Active Therapy|The active comparator intervention is a solution containing undenatured beta-glucans
62753350|NCT05331209|ACTIVE_COMPARATOR|Acupuncture only|Acupuncture treatments will take place at a frequency of once per week, with each session lasting between 30 to 45 minutes. At each session patients will be re-assessed by the study acupuncturist, with acupuncture points individualized in accordance with the principles of traditional Chinese medicine. At the same time, acupuncturists will include a set group of acupuncture points which have been used in the research of hot flashes: HT-6, Kid-3, Liv-3, SP-6.
62556216|NCT05954390|PLACEBO_COMPARATOR|Placebo|The placebo comparator intervention is the same solution used in the active comparator intervention except it does not contain any beta-glucans
62377292|NCT04838340|EXPERIMENTAL|Hypnobirthing group|Hypnobirthig training intervention will be applied to the Hypnobirthing group for 4 weeks and 3 hours a week and usual care will be provided by healthcare professionals.
62556217|NCT06487741|EXPERIMENTAL|Intervention|The intervention group receives a home-based rehabilitation program consisting of six weeks of daily static stretching exercises (six minutes a day).
62753351|NCT05331209|ACTIVE_COMPARATOR|Acupuncture-Acupressure|Patients randomly allocated to the acupuncture-acupressure arm of the study will first be treated by the study acupuncturist in accordance with the protocol described in the Acupuncture arm of the study. At the end of the first session, patients in this group will be taught by the study acupuncturist to self-treat at home with acupressure, on the acupressure points PC-7, ST-36, SP-9. Self-acupressure sessions will last between 3-5 minutes each, and will take place 3-4 times each day. At subsequent acupuncture treatments patients will receive reinforcement and guidance to ensure the fidelity of the self-acupuncture treatments
62753352|NCT01498575|EXPERIMENTAL|Teen Driving Plan|Access to web-based driving intervention
62556218|NCT06487741|NO_INTERVENTION|Control|The control group receives usual care, and no change in treatment is made. Participants will be encouraged to maintain their daily routine but refrain from changing the current pharmacological treatment or initiating new physical exercise practices during the study.
62556219|NCT00257400|EXPERIMENTAL|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy
62753353|NCT01498575|NO_INTERVENTION|Usual practice|Use of typical supervised practice driving resources
62753354|NCT05781334|ACTIVE_COMPARATOR|Virtual Consult Intervention|The intervention will consist of a quality improvement (QI)-based virtual consult designed by a multi-disciplinary team that will aim to address provider-level, patient-level, and system-level barriers to cardio-renal-metabolic disease medications.
62753355|NCT05781334|NO_INTERVENTION|Usual Care|Usual care
62753356|NCT06607575|OTHER|Control group|Newborns who will be subjected to routine practices during heel blood collection procedure and who will not be subjected to warming and vibration will constitute the control group.
62753357|NCT06607575|EXPERIMENTAL|Experimental group (warming)|Newborns who will be subjected to warming application during the heel blood collection procedure will constitute the 1st experimental group.
61986476|NCT04927390|EXPERIMENTAL|Mycophenolate Mofetil (MMF) Arm|Participants will receive mycophenolate mofetil (MMF) for up to 96 weeks, in addition to their background Standard of Care medication for systemic sclerosis related symptoms. They will receive 500mg twice daily over the first 4 weeks following their randomisation, and if tolerated the dose will be increased to a target dose of 1g twice daily starting from week 5 until their Final visit.
62556220|NCT00257400|ACTIVE_COMPARATOR|Individual Psychotherapy|Individual Psychotherapy
62556221|NCT05973799|EXPERIMENTAL|Fasting|Subjects will remain fasted prior to insulin-induced hypoglycemia.
62753358|NCT06607575|EXPERIMENTAL|Experimental group (vibration)|Newborns who will be subjected to vibration during the heel blood collection procedure will constitute the 2nd experimental group.
62753359|NCT06607575|EXPERIMENTAL|Experimental group (warming and vibration)|Newborns who will be subjected to both warming and vibration during the heel blood collection procedure will constitute the 3rd experimental group.
62753360|NCT00082706|EXPERIMENTAL|5-FU, Leucovorin, Gemcitabine + Cisplatin|5-FU continuous infusion over Days 1 - 5; Leucovorin once a day as a short infusion on Days 1 - 5; Cisplatin infusion over a few hours (usually 2-4 hours) once a day on Days 1 - 5; Gemcitabine infusion over 30 minutes on Days 1 \& 5 only.
62753361|NCT05802576||Vitamin K|The vitamin K oral anticoagulant will be used on 25 patients.
62753362|NCT05802576||Apixaban|The apixaban oral anticoagulant will be used on 25 patients.
62753363|NCT05802576||Rivaroxaban|The rivaroxaban oral anticoagulant will be used on 25 patients.
61986477|NCT04927390|NO_INTERVENTION|Control Arm|Standard of Care (no immunosuppression) for systemic sclerosis related symptoms.
62377293|NCT04369586|EXPERIMENTAL|meplazumab dose 1|0.06mg/kg for single dose
62556222|NCT05973799|EXPERIMENTAL|Feeding|Subjects will eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
62556223|NCT02064296|NO_INTERVENTION|Controls|Healthy pain free controls will be recruited for comparison with fibromyalgia patients.
62556224|NCT02064296|ACTIVE_COMPARATOR|Non-Traditional Acupuncture|40 fibromyalgia patients will be randomized to non-traditional laser acupuncture (Vita Laser 650, Lhasa OMS). They will receive 2 treatments per week for 4 weeks.
62556225|NCT02064296|ACTIVE_COMPARATOR|Traditional Acupuncture|40 fibromyalgia patients will be randomized to receive electro acupuncture (AS Super 4 digital needle stimulator, Harmony Medical Co) . They will receive 2 treatments per week for 4 weeks.
62753364|NCT05802576||Dabigatran|The dabigatran oral anticoagulant will be used on 25 patients.
62753365|NCT05135195|EXPERIMENTAL|First Set of Experiments|The anticipated number of participants is 336. All participants have healthy vision.
62753366|NCT05135195|EXPERIMENTAL|Second Set of Experiments|The anticipated number of participants is 100. Of these, 80 participants have healthy vision, and 20 have glaucoma.
62753367|NCT04527991|EXPERIMENTAL|Sacituzumab Govitecan-hziy|Participants will receive 10 mg/kg of sacituzumab govitecan-hziy intravenously on Day 1 and Day 8 of 21-day cycles.
62556226|NCT03098160|EXPERIMENTAL|Evofosfamide plus Ipilimumab|Ipilimumab to be administered at same dose. Evofosfamide dose to be determined during duration of trial
62556227|NCT05404685|EXPERIMENTAL|Transperitoneal RAPN with AirSeal system set to 7mmH.|Patient with Low Pressure Robotic Assisted Partial Nephrectomy at 7mm Hg
62556228|NCT05404685|ACTIVE_COMPARATOR|transperitoneal RAPN with AirSeal system set to standard insufflation pressure (12mmHg)|Control arm : Patient with standard insufflation pressure of 12 mm Hg
62556229|NCT06571773||CTR group|This group include the patients with the usage of CTR
62556230|NCT06571773||control group|This group include the patients without the usage of CTR
62556231|NCT04459039|EXPERIMENTAL|Fluid restriction|Within 12 h of surgery, the experimental group received 1000 mL 0.9% sterile saline intravenously.
62753368|NCT04527991|ACTIVE_COMPARATOR|Treatment of Physician's Choice|Participants will have the choice of receiving paclitaxel, docetaxel, or vinflunine at standard of care (SOC) doses of 175, 75, and 320 mg/m\^2 respectively, every 3 weeks on Day 1 of 21-day cycles.
62753369|NCT04640493|EXPERIMENTAL|SGLT2-SDB|Patients with newly diagnosed SDB will be given dapagliflozin (standard dosage, 10mg)
62556232|NCT04459039|PLACEBO_COMPARATOR|Non-fluid restriction|Within 12 h of surgery, the control group received 250 mL 0.9% sterile saline intravenously
62556233|NCT06582914||Pateints with a germline variant in a mismatch repair gene|Individuals with germline genetic testing results showing a pathogenic, likely pathogenic or variant of uncertain significance in MLH1, MSH2, MSH6, PMS2 or EPCAM.
62753370|NCT00534118|EXPERIMENTAL|Infusion|Patients receive up to four donor lymphocyte infusions at least 1 month apart in the absence of disease progression, unacceptable toxicity, or uncontrolled graft-versus-host disease
62753371|NCT01346046||Those with Type 2 diabetes|270 subjects with Type 2 diabetes
62753372|NCT01346046||Non diabetic|30 healthy subjects
62753373|NCT01762956|EXPERIMENTAL|Training group (TG)|The group of patients undergoing radiotherapy and submitted to pelvic floor muscles training.
62753374|NCT01762956|NO_INTERVENTION|Control group(CG)|The group of patients undergoing radiotherapy only.
62753375|NCT04526353|EXPERIMENTAL|Oxybutynin during 9 months.|0.1mg / kg 2x / day from inclusion and for 9 months.
62753376|NCT04526353|NO_INTERVENTION|No oxybutynin|No treatment affecting bladder function
62753377|NCT02748434|OTHER|Lipohypertrophy|Participants inject their insulin into the abdomen into areas of lipohypertrophy that were identified by ultrasound in Phase 1 of the study.
62753378|NCT02748434|OTHER|Normal Subcutaneous Tissue|Participants inject their insulin into the abdomen into areas with normal subcutaneous tissue.
62753379|NCT04365543|EXPERIMENTAL|UP-C/A for Misophonia|The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) are manualized treatments for treating emotional disorders in youth. We have modified the UP-C/A to meet the needs for youth with misophonia.
62753380|NCT04365543|EXPERIMENTAL|Psychoeducation and Relaxation Therapy|Psychoeducation and Relaxation Therapy (PRT) is a treatment that educates the child on misophonia and provides training in relaxation skills and tools for calming panic, anxiety and anger feelings.
62753381|NCT01159171|EXPERIMENTAL|1|
62556234|NCT04816643|EXPERIMENTAL|Low/Mid-Dose, ≥5 to <12 Years|Low/Mid-Dose (10mcg), 2 doses 21 days apart
62377294|NCT04369586|EXPERIMENTAL|meplazumab dose 2|0.12mg/kg for single dose
62377295|NCT04369586|EXPERIMENTAL|meplazumab dose 3|0.2mg/kg for single dose
62377296|NCT04369586|EXPERIMENTAL|meplazumab dose 4|0.3mg/kg for single dose
62377297|NCT04369586|EXPERIMENTAL|meplazumab dose 5|0.42mg/kg for single dose
62377298|NCT04369586|EXPERIMENTAL|meplazumab dose 6|0.56mg/kg for single dose
62377299|NCT04369586|EXPERIMENTAL|meplazumab multiple dose|0.3mg/kg for double doses, 1 dose/week
62377300|NCT04317794||All Participants|Participants who were prescribed with nusinersen sodium injection in Korea according to local marketing authorization.
62556235|NCT04816643|EXPERIMENTAL|Mid-Dose, ≥5 to <12 Years|Mid-Dose, (20mcg), 2 doses 21 days apart
62377301|NCT00255606|EXPERIMENTAL|Arm I|Patients receive docetaxel IV over 1 hour on days 1 and 15 and oral prednisone once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62377302|NCT00255606|EXPERIMENTAL|Arm II|Patients receive docetaxel IV over 1 hour on day 1 and prednisone once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62377303|NCT01623089||severe asthma|
62377304|NCT03731169|ACTIVE_COMPARATOR|TDM Only|This is the standard of care trial arm. Patients receive voriconazole dosages according to the product monograph. After day 4, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
62377305|NCT03731169|EXPERIMENTAL|Genotyping + TDM|After ascertaining CYP2C19 genetic status, the participants will be categorized as having either the ultra-rapid metabolizer (URM), extensive metabolizer (EM), heterozygous extensive metabolizer (HEM) or poor metabolizer (PM) phenotype. They will receive an experimental dosage regimen based on their phenotype. receive the following dosing regimen until TDM is conducted on day 4. After day 4, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
62377306|NCT05499689|ACTIVE_COMPARATOR|GON block group|30 patients who underwent greater occipital nerve block
62377307|NCT05499689|ACTIVE_COMPARATOR|Transcutaneous pulsed RF group|30 patients who underwent greater occipital nerve pulsed radiofrequency
62377308|NCT04139629|OTHER|antibody positive (CAT+)|patients found positive for one of the assayed antichlamydial antibodies
62377309|NCT04139629|OTHER|antibody negative (CAT-)|women with negative antichlamydia antibody test
61986478|NCT05442164||Before-group|Patients undergoing major emergency surgery before a supportive network is established
62377310|NCT03059511|ACTIVE_COMPARATOR|intravenous|single iv application of nalbuphine 0.05mg/kg
62377311|NCT03059511|ACTIVE_COMPARATOR|intranasal|single intranasal application of nalbuphine 0.1mg/kg in infants.
62377312|NCT01981096|EXPERIMENTAL|Fibromyalgia Integrative Training|8 week (16 sessions) combined intervention with cognitive-behavioral therapy and neuromuscular training
62377313|NCT01981096|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|8 week (16 session) cognitive-behavioral therapy treatment.
62377314|NCT05847556|EXPERIMENTAL|Monitoring of ototoxicity|Video game hearing tests will be used to determine if they can effectively monitor changes in hearing function over time remotely.
62377315|NCT05847556|NO_INTERVENTION|Tablet-based audiometry validation|Further validation of tablet-based audiometry compared to formal sound-booth audiometry.
62377316|NCT05847556|EXPERIMENTAL|Audio-training - intervention arm|Audio-training with video game hearing tests will be used to determine if it can improve spatial hearing perception.
62377317|NCT05847556|NO_INTERVENTION|Audio-training - control arm|No audio-training but video game hearing tests will be used as a comparator arm to identify if audio-training can improve spatial hearing perception.
62377318|NCT01352936||Experimental Group|
62377319|NCT01352936||Control Group|
62556236|NCT04816643|EXPERIMENTAL|High-Dose, ≥5 to <12 Years|High-Dose (30mcg), 2 doses 21 days apart
62556237|NCT04816643|EXPERIMENTAL|Low/Mid-Dose, ≥2 to < 5 Years|Low/Mid-Dose (10mcg), 2 doses 21 days apart
62377320|NCT01646346|EXPERIMENTAL|4D Conformal Image-Guided Partial Breast RT|This is a single arm trial designed to look at the results in women treated with partial breast irradiation twice daily for 5 days.
62556238|NCT04816643|EXPERIMENTAL|Mid-Dose, ≥2 to <5 Years|Mid-Dose, (20mcg), 2 doses 21 days apart
62556239|NCT04816643|EXPERIMENTAL|High-Dose, ≥2 to <5 Years|High-Dose, (30mcg), 2 doses 21 days apart
62556240|NCT04816643|EXPERIMENTAL|Low/Mid-Dose, ≥6 Months to <2 Years|Low/Mid-Dose, (10mcg), 2 doses 21 days apart
62556241|NCT04816643|EXPERIMENTAL|Mid-Dose, ≥6 Months to <2 Years|Mid-Dose, (20mcg), 2 doses 21 days apart
62556242|NCT04816643|EXPERIMENTAL|High-Dose, ≥6 Months to <2 Years|High-Dose, (30mcg), 2 doses 21 days apart
62556243|NCT04816643|PLACEBO_COMPARATOR|Placebo, ≥6 Months to <2 Years|
62753382|NCT00624819|EXPERIMENTAL|Synflorix + Infanrix + Havrix and/or Varilrix Group|This group consisted of subjects primed with Synflorix vaccine in the 10PN-PD-DIT-001 (1105553) and 007 (107046) studies. In 105553 study, subjects had been primed with 3 doses of Synflorix vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In 107046 study, subjects had received a booster dose of Synflorix vaccine at 12-18 months of age co-administered with Infanrix hexa vaccine. In this study, in the Year 4 (111347 study), subjects received at Month 48 (4 years post Dose 1 in study 105553) one additional dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix) and/or against varicella (a single dose of Varilrix).
62556244|NCT04816643|PLACEBO_COMPARATOR|Placebo, ≥2 to <5 Years|
62556245|NCT04816643|PLACEBO_COMPARATOR|Placebo, ≥5 to <12 Years|
62753383|NCT00624819|ACTIVE_COMPARATOR|Prevenar + Infanrix + Havrix and/or Varilrix Group|This group consisted of subjects vaccinated with Prevenar vaccine in the 10PN-PD-DIT-001 (105553) and 007 (107046) studies. In 105553 study, subjects had been primed with 3 doses of Prevenar vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In 107046 study, subjects had received a booster dose at 12-18 months of age of Prevenar vaccine co-administered with Infanrix hexa vaccine. In this study, in the Year 4 111347 study, subjects had received at Month 48 (4 years post Dose 1 in study 105553) one dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix and/or against varicella (a single dose of Varilrix).
62556246|NCT04816643|EXPERIMENTAL|Low-Dose, ≥6 Months to <2 Years|Low-Dose (3mcg), 2 doses 21 doses apart
62556247|NCT04816643|EXPERIMENTAL|Low-Dose, ≥2 to <5 Years|Low-Dose (3mcg), 2 doses 21 days apart
62556248|NCT04816643|EXPERIMENTAL|High-Dose, 12 to <16 Years (Troponin I Testing)|High-Dose (30mcg), 3 doses
62556249|NCT04816643|EXPERIMENTAL|Low/Mid-Dose, ≥5 to <12 Years (Troponin I Testing)|Low/Mid-Dose (10mcg), 3 doses
62556250|NCT04816643|EXPERIMENTAL|Placebo, ≥5 to <12 Years (Troponin I Testing)|
62556251|NCT04816643|EXPERIMENTAL|Low-Dose, ≥6 Months to <2 Years (3-dose regimen)|Low-Dose (3mcg), 3 doses
62556252|NCT04816643|EXPERIMENTAL|Low-Dose, ≥2 to <5 Years (3-dose regimen)|Low-Dose (3mcg), 3 doses
62556253|NCT04816643|PLACEBO_COMPARATOR|Placebo, ≥6 Months to <2 Years (3-dose regimen)|
62556254|NCT04816643|PLACEBO_COMPARATOR|Placebo, ≥2 to <5 Years (3-dose regimen)|
62556255|NCT03861624|EXPERIMENTAL|Intramedullary nailing|Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures via Intramedullary nailing with standard SIGN nail.
62556256|NCT03861624|ACTIVE_COMPARATOR|External Fixation|Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures External Fixation with uniplanar Dispofix external fixator.
62753384|NCT00624819|EXPERIMENTAL|Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix|This group consisted of subjects vaccinated with Prevenar and Synflorix vaccines in the 10PN-PD-DIT-001 (105553) and 10PN-PD-DIT-007 (107046) studies. In 105553 study, subjects had been primed with 3 doses Prevenar vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In the 107046 study, subjects had received at 12-18 months of age a booster dose of Synflorix vaccine co-administered with Infanrix hexa vaccine. In this study, in the Year 4 (111347 study), subjects had received at Month 48 (4 years post Dose 1 in study 105553) one additional dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix and/or against varicella (a single dose of Varilrix).
62377321|NCT01949792|ACTIVE_COMPARATOR|270 microg/kg rFVIIa|Each subject will receive one single injection of 270 microg/kg and three injections of 90 microg/kg rFVIIa (one injection every 3 hours) in a randomised order. The two administration days will be separated by a wash-out period of at least 48 hours
62753385|NCT00624819|EXPERIMENTAL|Unprimed Group|"This group consisted of subjects between, and including, 64-68 months of age at the time of additional vaccination (primed subjects) or dose 1 (unprimed subjects), and for whom the investigator believed that their parents/guardians could and would comply with the requirements of the protocol. Subjects were not previously vaccinated with any pneumococcal vaccine and received 2 doses of Synflorix vaccine at 64-68 and 66-70 months of age (at Day 0 and Month 2).~The Unprimed Group was added only in Year 4 of the study."
62753386|NCT05687812|EXPERIMENTAL|Diabetic group|After 10-12 h fasting, an OGTT test with 75 g glucose was performed on the participants, showing no glucose metabolism disorder. Another independent day was chosen as the test day, and the participants were asked to no-restrict carbohydrates and not make any changes in their diet in the days before the test. Volunteers were fed 100g of white bread containing only 250 ml of water and 50g of carbohydrate (CH) for breakfast (after 12 hours of fasting). After 1 week, the same participants were fed 250 ml of water and 100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH). During the test, venous and capillary blood samples were taken at 0, 30, 60, 90, and 120 minutes.
62377322|NCT01949792|ACTIVE_COMPARATOR|3x90 microg/kg rFVIIa|Each subject will receive one single injection of 270 microg/kg and three injections of 90 microg/kg rFVIIa (one injection every 3 hours) in a randomised order. The two administration days will be separated by a wash-out period of at least 48 hours
62556257|NCT05612581|EXPERIMENTAL|STRIVE: Cohort 1a (VIR-3434 + TDF)|Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks total
62556258|NCT05612581|EXPERIMENTAL|STRIVE: Cohort 2a (VIR-3434 + TDF)|Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks total
62556259|NCT05612581|EXPERIMENTAL|STRIVE: Cohort 3a (VIR-3434 + TDF)|Participants will receive combination therapy with VIR-3434 + TDF for 36 or 40 weeks total
62556260|NCT05612581|EXPERIMENTAL|STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)|Participants will receive combination therapy with VIR-3434 + VIR-2218 + TDF for 20 or 44 weeks total
62556261|NCT05612581|EXPERIMENTAL|STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)|Participants will receive combination therapy with VIR-3434 + VIR-2218 +TDF + PEG-IFNα for 48 weeks total
62377323|NCT04830176|ACTIVE_COMPARATOR|moringa|First phase of subjects were given dentifrice for brushing
62377324|NCT04830176|ACTIVE_COMPARATOR|miswak|second phase of subjects were given dentifrice for brushing
62377325|NCT01711606||unselected Fragile-X patients|
62377326|NCT03180294|EXPERIMENTAL|Bupropion 150 mg|One Bupropion 150 mg XL capsule by mouth (PO) in a.m. daily for one week; one Bupropion 150 mg XL capsule and one placebo capsule daily for 8 weeks; one placebo capsule daily for one 1 week (titration off).
62377327|NCT03180294|EXPERIMENTAL|Bupropion 300 mg|One Bupropion 150 mg XL capsule PO in a.m. daily for one week; two Bupropion 150 mg XL capsules PO in a.m. daily for 8 weeks (300 mg target dose); one Bupropion 150 mg XL capsule PO in a.m. daily for 1 week (titration off)
62556262|NCT05612581|EXPERIMENTAL|THRIVE: Cohort 1b (VIR-3434 + TDF)|Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks
62556263|NCT05612581|EXPERIMENTAL|THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)|Participants will receive combination therapy with VIR-3434 + VIR-2218 + TDF for 44 weeks total
62556264|NCT05271656|EXPERIMENTAL|C-Scan System|All study participants will undergo the C-Scan System procedure, followed by a standard of care optical colonoscopy
62556265|NCT05366452|EXPERIMENTAL|IMPELLA CP GROUP|patients will receive IMPELLA CP before PCI on top of conventional therapy based on the same protocol as the control group and emergent culprit PCI
62753387|NCT05687812|EXPERIMENTAL|Non-diabetic obese group|After 10-12 h fasting, an OGTT test with 75 g glucose was performed on the participants, showing no glucose metabolism disorder. Another independent day was chosen as the test day, and the participants were asked to no-restrict carbohydrates and not make any changes in their diet in the days before the test. Volunteers were fed 100g of white bread containing only 250 ml of water and 50g of carbohydrate (CH) for breakfast (after 12 hours of fasting). After 1 week, the same participants were fed 250 ml of water and 100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH). During the test, venous and capillary blood samples were taken at 0, 30, 60, 90, and 120 minutes.
62377328|NCT03180294|PLACEBO_COMPARATOR|Placebo|One placebo capsule PO in a.m. daily for 1 week; two placebo capsules PO in a.m. daily for 8 weeks; one placebo capsule PO in a.m. daily for 1 week (titration off)
62377329|NCT04493489|PLACEBO_COMPARATOR|BCG|After TURBT, the first year: once a week for 6 times, from the 7th week, once every 2 weeks, and 3 times. Administer once a month starting from the 13th week and continue to give 10 times. Second and third years: once a month, 12 times a year.
62753388|NCT05687812|EXPERIMENTAL|Non-diabetic and non-obese healthy group|After 10-12 h fasting, an OGTT test with 75 g glucose was performed on the participants, showing no glucose metabolism disorder. Another independent day was chosen as the test day, and the participants were asked to no-restrict carbohydrates and not make any changes in their diet in the days before the test. Volunteers were fed 100g of white bread containing only 250 ml of water and 50g of carbohydrate (CH) for breakfast (after 12 hours of fasting). After 1 week, the same participants were fed 250 ml of water and 100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH). During the test, venous and capillary blood samples were taken at 0, 30, 60, 90, and 120 minutes.
62556266|NCT05366452|ACTIVE_COMPARATOR|CONTROL GROUP|patients will receive IV inotropes associated or not with vasopressors according to the attached protocol and based on the current guidelines (annex 1) (2, 4) in addition to emergent culprit lesion PCI
62753389|NCT04807972|EXPERIMENTAL|Phase 1b Dose Escalation|Participants will receive escalating doses of ABBV-927 in combination with modified FOLFIRINOX (mFFX) and Budigalimab.
62753390|NCT04807972|EXPERIMENTAL|Phase 2 Cohort A|Participants will receive modified FOLFIRINOX on Day 1 and Day 15 of each 28 day cycle.
62377330|NCT04493489|EXPERIMENTAL|Propranolol plus BCG|After TURBT administered for 2 consecutive years, oral propranolol, starting dose 10mg, tid, then 20mg, tid,lastly increased to 40mg, bid. After the last BCG infusion, propranolol was gradually reduced, in the order of 20 mg, tid to 10 mg, tid.
62377331|NCT04800484|EXPERIMENTAL|Arm 1:|Testing Order: Clinical AFO, Tall Soft, Tall Firm, Short Soft, Short Firm, NoAFO
62377332|NCT04800484|EXPERIMENTAL|Arm 2:|Testing Order: Clinical AFO, Tall Soft, Tall Firm, Short Firm, Short Soft, NoAFO
62377333|NCT04800484|EXPERIMENTAL|Arm 3:|Testing Order: Clinical AFO, Tall Soft, Short Soft, Tall Firm, Short Firm, NoAFO
62377334|NCT04800484|EXPERIMENTAL|Arm 4:|Testing Order: Clinical AFO, Tall Soft, Short Soft, Short Firm, Tall Firm, NoAFO
62556267|NCT02207205|OTHER|Catheter vs venipuncture blood samples|Evaluation of whether there is any difference in results of whole blood clotting time in blood samples drawn from an indwelling catheter versus direct venipuncture
62753391|NCT04807972|EXPERIMENTAL|Phase 2 Cohort B|Participants will receive modified FOLFIRINOX (Day 1 and Day 15) + ABBV-927 in each 28 day cycle.
62377335|NCT04800484|EXPERIMENTAL|Arm 5:|Testing Order: Clinical AFO, Tall Soft, Short Firm, Tall Firm, Short Soft, NoAFO
62377336|NCT04800484|EXPERIMENTAL|Arm 6:|Testing Order: Clinical AFO, Tall Soft, Short Firm, Short Soft, Tall Firm, NoAFO
62377337|NCT04800484|EXPERIMENTAL|Arm 7:|Testing Order: Clinical AFO, Tall Firm, Tall Soft, Short Soft, Short Firm, NoAFO
62377338|NCT04800484|EXPERIMENTAL|Arm 8:|Testing Order: Clinical AFO, Tall Firm, Tall Soft, Short Firm, Short Soft, NoAFO
62377339|NCT04800484|EXPERIMENTAL|Arm 9:|Testing Order: Clinical AFO, Tall Firm, Short Soft, Tall Soft, Short Firm, NoAFO
62556268|NCT03817190|EXPERIMENTAL|2g Oral DS107|2g DS107 (4 DS107 capsules) administered once-daily for 16 weeks
62556269|NCT03817190|PLACEBO_COMPARATOR|Placebo|Placebo (4 placebo capsules) orally administered once-daily for 16 weeks
62556270|NCT06333418|EXPERIMENTAL|Virtual Reality Glasses|Before the colonoscopy procedure, 360-degree VR video scenes will be watched to patients 30 minutes using VR head device.
62556271|NCT06333418|EXPERIMENTAL|Glass waterfall|Before the colonoscopy procedure, patients will watch and listen 30 minutes a portative glass waterfall
62753392|NCT04807972|EXPERIMENTAL|Phase 2 Cohort C Expansion|Participants will receive modified FOLFIRINOX (Day 1 and Day 15) + ABBV 927 and Budigalimab as Intravenous (IV) Infusion in each 28 day cycle.
62753393|NCT02526524|EXPERIMENTAL|600 mg Met DR qAM|600 mg metformin delayed-release once daily in the morning
62377340|NCT04800484|EXPERIMENTAL|Arm 10:|Testing Order: Clinical AFO, Tall Firm, Short Soft, Short Firm, Tall Soft, NoAFO
62377341|NCT04800484|EXPERIMENTAL|Arm 11:|Testing Order: Clinical AFO, Tall Firm, Short Firm, Tall Soft, Short Soft, NoAFO
62556272|NCT06333418|NO_INTERVENTION|control group|Patients of the control group, will not receive any intervention except for applied routine hospital colonoscopy procedures
62556273|NCT03305250|ACTIVE_COMPARATOR|Interventional Arm|Using an Implantable Loop Recorder fo continuous rhythm monitoring and home follow-up. This will be combined with standard care procedure, which will include annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
62753394|NCT02526524|EXPERIMENTAL|900 mg Met DR qAM|900 mg metformin delayed-release once daily in the morning
62556274|NCT03305250|NO_INTERVENTION|Standard of Care Arm|The standard of care with annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
61986479|NCT05442164||After-group|Patients undergoing major emergency surgery after a supportive network is established
62377342|NCT04800484|EXPERIMENTAL|Arm 12:|Testing Order: Clinical AFO, Tall Firm, Short Firm, Short Soft, Tall Soft, NoAFO
62556275|NCT05782777|EXPERIMENTAL|Combination therapy group|Ezetimibe/high-intensity statin combination therapy
62556276|NCT05782777|ACTIVE_COMPARATOR|Statin monotherapy group|High-intensity statin monotherapy
62556277|NCT01200069|PLACEBO_COMPARATOR|Sugar water|500 milliliters of intravenous ringers lactate administered over 30 minutes prior to ECT for treatments 1,2 and 3
62556278|NCT01200069|ACTIVE_COMPARATOR|Ibuprofen|300mg/8milliliters of intravenous ibuprofen/caldolor over 30 min in 500mL of ringers lactate to be administered prior to ECT for treatments # 1, 2 and 3
62556279|NCT01259479|EXPERIMENTAL|1|Dose escalation, continuous treatment without DLTs
62556280|NCT03225417|EXPERIMENTAL|Experimental group|"Phase I: Ixazomib + Tacrolimus + Sirolimus. Ixazomib doses in this study is 3 to 4 mg of ixazomib on day +1, +8 and +15. Tacrolimus at a dose of 0.02 mg/kg/day and then 0.06 mg/kg/day. Sirolimus at a dose of 6 mg on day -5 and then 4 mg per day.~Phase II: Ixazomib+ any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.~Starting Dose of Ixazomib according to phase I."
62556281|NCT03225417|OTHER|Control group|Any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
62556282|NCT05053633||Combined spinal epidural anesthesia|The assessments are conducted in conscious patients under the procedure of Combined spinal epidural anesthesia.
62753395|NCT02526524|EXPERIMENTAL|1200 mg Met DR qAM|1200 mg metformin delayed-release once daily in the morning
62753396|NCT02526524|EXPERIMENTAL|1500 mg Met DR qAM|1500 mg metformin delayed-release once daily in the morning
62753397|NCT02526524|PLACEBO_COMPARATOR|Placebo-1|placebo match for 600 and 1200 mg Met DR qAM treatment groups
62753398|NCT02526524|PLACEBO_COMPARATOR|Placebo-2|placebo match for 900 and 1500 mg Met DR qAM treatment groups
62753399|NCT02526524|ACTIVE_COMPARATOR|2000 mg Met IR|1000 mg metformin immediate-release twice daily
62753400|NCT01656343||Belatacept treated kidney-only transplant recipients|
62753401|NCT01656343||CNI treated kidney-only transplant recipients|
62753402|NCT04132830||HIV-Exposed Uninfected Dyads|Mothers who had HIV during pregnancy and their HIV-negative young adult offspring
62753403|NCT04132830||HIV-Unexposed Uninfected Dyads|Mothers and young adults without HIV
62377343|NCT04800484|EXPERIMENTAL|Arm 13:|Testing Order: Clinical AFO, Short Soft, Tall Soft, Short Firm, Tall Firm, NoAFO
62377344|NCT04800484|EXPERIMENTAL|Arm 14:|Testing Order: Clinical AFO, Short Soft, Tall Soft, Tall Firm, Short Firm, NoAFO
62753404|NCT00202709|EXPERIMENTAL|Thought Field Therapy (TFT)|Treatment with TFT, first one hour, then 1/2 hour.
62753405|NCT00202709|NO_INTERVENTION|Wait list control|
62753406|NCT02123238|OTHER|Control|standard of care positioning (0 degree)
62753407|NCT02123238|OTHER|30 degree|30 degree bed positioning
62753408|NCT02123238|OTHER|60 degree|60 degree bed positioning
62753409|NCT06300125||Cryoablation|Percutaneous Cryoablation of Breast Cancer
62753410|NCT03326557|ACTIVE_COMPARATOR|Membrane sweeping|Membrane sweeping involves the insertion of a digit past the internal cervical os followed by three circumferential passes of the digit causing separation of the membranes from the lower uterine segment. When the cervix is closed, a massage of the cervical surface for 15 to 30 seconds will be performed instead. Membrane sweeping will be undertaken twice a day at 8 to 10 hours apart.
62753411|NCT03326557|ACTIVE_COMPARATOR|Transcervical Foley catheter insertion|Transcervical Foley catheter No. 18 F will be inserted under aseptic technique into the endocervical canal surpassed beyond the internal os. The balloon will be inflated with 60 ml of sterile water and the catheter is plastered to patient's thigh with gentle traction. The catheter will be checked for its position and the traction at 6 hours interval. If it were expelled spontaneously, it would not be re-inserted. Otherwise, the catheter will be removed after 24 hours.
62753412|NCT04007237|EXPERIMENTAL|Selsun Shampoo (SeS2 shampoo)|Subject were given the SeS2 1.8% shampoo for 2 weeks. They should use it everyday, 10ml each time for 10 minutes. Evaluation was weekly and note for side effects and compliance
62753413|NCT04007237|ACTIVE_COMPARATOR|Ketoconazole shampoo|Subject were given the Ketoconazole 2% shampoo for 2 weeks. They should use it everyday, 10ml each time for 10 minutes. Evaluation was weekly and note for side effects and compliance
61986480|NCT04935112|EXPERIMENTAL|Group 1 Treatment A (sitravatinib only)|Period 1: A single oral dose of 100 mg sitravatinib on Day 1
61986481|NCT04935112|EXPERIMENTAL|Group 1 Treatment B (sitravatinib and pantoprazole)|Period 2: Oral pantoprazole once daily for 7 days (Days 1 to 7) and a single oral dose of 100 mg sitravatinib on Day 7
62377345|NCT04800484|EXPERIMENTAL|Arm 15:|Testing Order: Clinical AFO, Short Soft, Tall Firm, Short Firm, Tall Soft, NoAFO
62377346|NCT04800484|EXPERIMENTAL|Arm 16:|Testing Order: Clinical AFO, Short Soft, Tall Firm, Tall Soft, Short Firm, NoAFO
62556283|NCT04893473||Group 1|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed immediately after surgery.~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for carbon dioxide."
62556284|NCT04893473||Group 2|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed 72 hours after surgery.~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for carbon dioxide."
62377347|NCT04800484|EXPERIMENTAL|Arm 17:|Testing Order: Clinical AFO, Short Soft, Short Firm, Tall Soft, Tall Firm, NoAFO
62377348|NCT04800484|EXPERIMENTAL|Arm 18:|Testing Order: Clinical AFO, Short Soft, Short Firm, Tall Firm, Tall Soft, NoAFO
62377349|NCT04800484|EXPERIMENTAL|Arm 19:|Testing Order: Clinical AFO, Short Firm, Tall Soft, Tall Firm, Short Soft, NoAFO
62753414|NCT06110897|EXPERIMENTAL|High Dose Resistance Exercise Training|Participants will complete a 16-week, twice/week progressive program beginning at a moderate intensity. Each session will last \~60 minutes and begin and end with a 5-minute warm-up/cool-down. Training will begin with standard familiarization sessions to introduce participants to the machines, teach correct lifting techniques, and ensure participant safety and comfort with each exercise machine. Participants will perform 3 sets of 8-12 repetitions on 9 different machines (i.e., leg press, hamstring curl, quadriceps extension, chest press, lat pulldown, shoulder press, biceps curl, triceps extension) and one body weight/free-weight abdominal exercise. Workload will begin at 60% of estimated 1-RM and will systematically and progressively increase during the intervention.
62377350|NCT04800484|EXPERIMENTAL|Arm 20:|Testing Order: Clinical AFO, Short Firm, Tall Soft, Short Soft, Tall Firm, NoAFO
62377351|NCT04800484|EXPERIMENTAL|Arm 21:|Testing Order: Clinical AFO, Short Firm, Tall Firm, Short Soft, Tall Soft, NoAFO
62377352|NCT04800484|EXPERIMENTAL|Arm 22:|Testing Order: Clinical AFO, Short Firm, Tall Firm, Tall Soft, Short Soft, NoAFO
62377353|NCT04800484|EXPERIMENTAL|Arm 23:|Testing Order: Clinical AFO, Short Firm, Short Soft, Tall Firm, Tall Soft, NoAFO
62377354|NCT04800484|EXPERIMENTAL|Arm 24:|Testing Order: Clinical AFO, Short Firm, Short Soft, Tall Soft, Tall Firm, NoAFO
62377355|NCT03426644|ACTIVE_COMPARATOR|Group A|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target.
62377356|NCT03426644|EXPERIMENTAL|Group B|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group B.
62753415|NCT06110897|ACTIVE_COMPARATOR|Low Dose Resistance Exercise Training|Participants will complete a 16-week, twice/week progressive program beginning at a low intensity. Each session will last \~60 minutes and begin and end with a 5-minute warm-up/cool-down. Training will begin with standard familiarization sessions to introduce participants to the machines, teach correct lifting techniques, and ensure participant safety and comfort with each exercise machine. Participants will perform 3 sets of 8-12 repetitions on 9 different machines (i.e., leg press, hamstring curl, quadriceps extension, chest press, lat pulldown, shoulder press, biceps curl, triceps extension) and one body weight/free-weight abdominal exercise. Workload will begin at 30% of estimated 1-RM and will systematically and progressively increase during the intervention.
62377357|NCT03426644|EXPERIMENTAL|Group C|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target.In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group C.
62377358|NCT03426644|EXPERIMENTAL|Group D|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group D.
62377359|NCT00562536|EXPERIMENTAL|A 1|Delayed umbilical cord clamping 30-45 seconds.
62377360|NCT00562536|NO_INTERVENTION|A 2|Immediate umbilibcal cord clamping
62377361|NCT01913015|EXPERIMENTAL|Arm I (abiraterone acetate, low then high fat breakfast)|Patients receive standard dose abiraterone acetate PO QD (held on days 2, 3, 9, and 10), and low-dose abiraterone acetate PO QD on days 3 and 10. Patients eat a low fat breakfast on day 3 and a high fat breakfast on day 10.
62377362|NCT01913015|EXPERIMENTAL|Arm II (abiraterone acetate, high then low fat breakfast)|Patients receive abiraterone acetate as in Arm I. Patients eat a high fat breakfast on day 3, and a low fat breakfast on day 10.
62377363|NCT02416765|ACTIVE_COMPARATOR|Sensor-augmented pump therapy|Patients will use conventional pump therapy and freely implement their usual basal rate and CHO-matching full prandial bolus to regulate glucose levels.
62753416|NCT01748526|EXPERIMENTAL|Treatment A|Each volunteer will receive a single 200 mg dose of canagliflozin (JNJ-28431754) on Day 1.
62753417|NCT01748526|EXPERIMENTAL|Treatment B|Each volunteer will receive a single 300 mg dose of canagliflozin (JNJ-28431754) on Day 1.
62753418|NCT03539289|OTHER|MUFA Diet|Monounsaturated Fatty Acids Diet
62753419|NCT03539289|OTHER|SFA Diet|Saturated Fatty Acids Diet
62753420|NCT04239222|EXPERIMENTAL|Revo-M to Proflex XC|Transtibial amputees randomized to start with Revo-M and cross over to Proflex XC
62753421|NCT04239222|EXPERIMENTAL|Proflex XC to Revo-M|Transtibial amputees randomized to start with Proflex XC and cross over to Revo-M
62753422|NCT04239222|EXPERIMENTAL|Revo-M to Taleo|Transfemoral amputees randomized to start with Revo-M and cross over to Taleo
62753423|NCT04239222|EXPERIMENTAL|Taleo to Revo-M|Transfemoral amputees randomized to start with Taleo and cross over to Revo-M
62377364|NCT02416765|ACTIVE_COMPARATOR|Single-hormone CLS with full boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
62377365|NCT02416765|ACTIVE_COMPARATOR|Single-hormone CLS with partial boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. A pre-meal partial prandial bolus will be given 10 minutes before the meal. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.
62377366|NCT02416765|ACTIVE_COMPARATOR|Dual-hormone CLS with full boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
62377367|NCT02416765|ACTIVE_COMPARATOR|Dual-hormone CLS with partial boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. A pre-meal partial prandial bolus will be given 10 minutes before the meal. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.
62753424|NCT04819438|EXPERIMENTAL|Riluzole orodispersible film (Test)|The subjects will be treated with one orodispersible film containing 50 mg of riluzole in two out of the four study periods according to the randomisation sequence
62753425|NCT04819438|ACTIVE_COMPARATOR|Rilutek® (Reference)|The subjects will be treated with one film-coated table containing 50 mg of riluzole in two out of the four study periods according to the randomisation sequence
62753426|NCT01426984|EXPERIMENTAL|BPD adults|adults with Borderline Personality Disorder (BPD)
62753427|NCT02478840|EXPERIMENTAL|Lamazym|1 mg Lamazym/kg Body weight
62753428|NCT04101539|ACTIVE_COMPARATOR|Standard Ablation (PVI)|Patients in this arm will receive standard ablation for atrial fibrillation (wide-area circumferential ablation to achieve pulmonary vein isolation \[PVI\]).
62753429|NCT04101539|EXPERIMENTAL|OPTIMA Ablation|Patients in this arm will receive standard PVI ablation and supplemental ablation of reentrant driver sites identified by OPTIMA analysis as sites likely supportive of persistent atrial fibrillation.
62753430|NCT05186103||HS-ASD|high-severity ASD
62556285|NCT04748484|OTHER|KCC active or inactive|The medical device KCC will be active, or inactive. Randomization will define when and how long time the medical device will be active, and when and how long time the medical device will be inactive. The patient won't know if the medical device is active or not. The battery charge indicator will work the same whether the device is operating or not.
62556286|NCT05635591|EXPERIMENTAL|KSD-101|
62556287|NCT02007525|EXPERIMENTAL|Yoga intervention|
62556288|NCT02007525|NO_INTERVENTION|Wait list control|
62753431|NCT05186103||LS-ASD|low-severity ASD
62753432|NCT05186103||control|typical development
62753433|NCT04913987|EXPERIMENTAL|Total knee|Standard care
62753434|NCT04913987|EXPERIMENTAL|Partial knee|Intervention using relatively new partial knee.
62753435|NCT01225965|EXPERIMENTAL|EIL05, Inhalation|
62377368|NCT03378128|EXPERIMENTAL|diagnostic laparoscopic assessment after neoadjuvant chemo|All patients will undergo a diagnostic laparoscopic assessment of disease following neoadjuvant chemotherapy
62377369|NCT03356795|EXPERIMENTAL|Cervical cancer-specific CAR-T cells|Peripheral blood mononuclear cells (PBMCs) of patients who have GD2, PSMA, Muc1 or Mesothelin positive cervical cancer will be obtained through apheresis, and T cells will be activated and modified to cervical cancer-specific CAR-T cells.
62377370|NCT05272306|ACTIVE_COMPARATOR|Sedation and Analgesia|A standardized sedation and analgesia will be administered by an experienced anesthesiologist. After administration of lidocaine and atropine sulfate, and also preoxygenation (100% 4 L/min oxygen for 3 minutes), patients will be induced with propofol and fentanyl via intravenous route at doses calculated according to ideal body weight. Anesthesia was maintained with propofol infusion. Repetitive intravenous boluses of propofol will be administered, if required. Patients will be received oxygen (100%, 3 L/min) through a nasal cannula during sedation and analgesia.
62377371|NCT05272306|ACTIVE_COMPARATOR|Gastro-laryngeal Tube|After administration of lidocaine and atropine sulfate, and also preoxygenation (100% 4 L/min oxygen for 3 min), patients will be induced with propofol and fentanyl. After induction of anesthesia, supraglottic airway device named Gastro-laryngeal Tube (GLT) will be inserted. Patients will be ventilated mechanically with a tidal volume of 6-8 mL/kg based on ideal body weight and a frequency of 12-14 breaths/min after inserting the GLT. Repetitive intravenous boluses of propofol will be administered, if required.
62377372|NCT01626755|EXPERIMENTAL|Nerve block|"Optimized intravenous pain treatment during surgery and for 7 days postoperatively.~Definition: strong opioid patient-controlled analgesia, non-opioids, ketamine intravenously.~Sciatic nerve block: infusion of local anesthetic."
62377373|NCT01626755|ACTIVE_COMPARATOR|Control|"Optimized intravenous pain treatment during surgery and for 7 days postoperatively.~Definition: strong opioid patient-controlled analgesia, non-opioids, ketamine intravenously.~Sciatic nerve block: saline infusion."
62377374|NCT00885729|EXPERIMENTAL|Stem cells|Cartilage defect are treated surgical either with chondrocytes or stem cells
62377375|NCT00885729|ACTIVE_COMPARATOR|Rehabilitation|Active rehabilitation program
62377376|NCT04012762|ACTIVE_COMPARATOR|Moderate-intensity group|WBVT application was 2-4 mm for vibration amplitude value and 25 Hz for training frequency in moderate-intensity group.
62556289|NCT02009722|ACTIVE_COMPARATOR|Intrathecal hydromorphone|Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
62753436|NCT01225965|PLACEBO_COMPARATOR|Placebo, 0,9% NaCl|
62753437|NCT03608137|EXPERIMENTAL|Cannabis users|Subjects of this group have to meet the DSM-5 criteria for schizophrenia and smoke cannabis at least two days per week for every week of the past month. They have to exhibit negative urine screen for any substance except benzodiazepines and cannabis.
62753438|NCT03608137|ACTIVE_COMPARATOR|Non- cannabis users (control group)|Subjects of this group have to meet the DSM-5 criteria for schizophrenia and have to report no cannabis use over the previous month, and exhibit negative urine screen for any substance except benzodiazepines.
62753439|NCT06399185|PLACEBO_COMPARATOR|Placebo group|20 ml of normal saline is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
62753440|NCT06399185|EXPERIMENTAL|Dexmedetomidine group|Dexmedetomidine 0.5 μg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
62753441|NCT06399185|EXPERIMENTAL|Esketamine group|Esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
62753442|NCT06399185|EXPERIMENTAL|Dexmedetomidine-esketamine group|Dexmedetomidine 0.5 μg/kg and esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
61986482|NCT04935112|EXPERIMENTAL|Group 2 Treatment C (sitravatinib only)|Period 1: A single oral dose of 100 mg sitravatinib on Day 1
62753443|NCT01778335|NO_INTERVENTION|Control|Control arm subjects will receive best medical care.
62753444|NCT01778335|EXPERIMENTAL|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
62377377|NCT04012762|ACTIVE_COMPARATOR|Vigorous-intensity group|WBVT application was 2-4 mm for vibration amplitude value and 40 Hz for training frequency in vigorous-intensity group.
62556290|NCT02009722|ACTIVE_COMPARATOR|Intrathecal morphine|Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
62556291|NCT00573378|EXPERIMENTAL|PEG-IFN-a2b|
62753445|NCT01897753||Small For Gestational Age (SGA) Children|SGA children under growth hormone treatment for more than 36 months.
62753446|NCT05627531|NO_INTERVENTION|Blank composition book with encouragement to write|The comparison group will receive a blank composition book with encouragement to write.
62753447|NCT05627531|EXPERIMENTAL|Narrative Medicine|The intervention group will receive a blank composition book with daily writing prompts developed during at least one in-person session with the Narrative Medicine Coordinator to discuss their writing and their writing process.
62377378|NCT00881686|EXPERIMENTAL|adenosine|Adenosine will be administered intravenously before surgery
62377379|NCT02331316|EXPERIMENTAL|Daily extra water intake 2L|"Timing of daily extra water intake~intervention-A: extra water intake: 8 8oz glasses of water a day (2L) - 2 first thing in the morning before breakfast, 2 before midday or midday meal, 2 before afternoon meal and 2 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
62556292|NCT00511732|EXPERIMENTAL|Technosphere Insulin|
62753448|NCT01813721||Group 1|All patients enrolled
61986483|NCT04935112|EXPERIMENTAL|Group 2 Treatment D (sitravatinib and famotidine)|Period 2: A single oral dose of 100 mg sitravatinib followed by a single oral dose of famotidine 40 mg approximately 2 hours after sitravatinib dose on Day 1
61986484|NCT05048810|EXPERIMENTAL|68Ga-DOTA-NT-20.3|Subjects will undergo PET imaging using 68Ga-DOTA-NT-20.3.
62556293|NCT00511732|PLACEBO_COMPARATOR|Technosphere Inhalation Powder|
62556294|NCT03552510|ACTIVE_COMPARATOR|Initial OPAMM|"At the start of the study, infants will receive mother's milk (to the maximum of 0.2 ml) to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding), and the remaining amount will be given by regular gavage feeding for 24 hours.~Then, infants will receive regular gavage feeding only for the next 24 hours."
62753449|NCT01626118|EXPERIMENTAL|Indomethacin 40 mg TID|
62753450|NCT01626118|EXPERIMENTAL|Indomethacin 40 mg BID|
62753451|NCT01626118|PLACEBO_COMPARATOR|Placebo|
62753452|NCT01626118|EXPERIMENTAL|Indomethacin 20 mg TID|
62753453|NCT06503328||Healthy Controls|Healthy subjects without present or past history of headache according to ICHD-III criteria.
62753454|NCT06503328||Episodic Cluster Headache|"Patients with a diagnosis of 3.1.1 Episodic Cluster Headache, according to ICHD-III criteria."
62753455|NCT06503328||Chronic Cluster Headache|"Patients with a diagnosis of 3.1.2 Chronic Cluster Headache, according to ICHD-III criteria."
62556295|NCT03552510|ACTIVE_COMPARATOR|Initial Gavage|"At the start of the study, infants will receive regular gavage feeding only for 24 hours.~Then, infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding), and the remaining amount will be given by regular gavage feeding for the next 24 hours."
62753456|NCT02944357|EXPERIMENTAL|Treatment (gemcitabine hydrochloride, cisplatin, AGS-003-BLD)|"NEOADJUVANT PHASE: Patients receive gemcitabine hydrochloride IV on days 1 and 8, AGS-003-BLD ID on day 1, and cisplatin IV on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive AGS-003-BLD ID on day 1. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo cystectomy during course 8.~ADJUVANT PHASE: Patients continue AGS-003-BLD ID on day 1 of course 9. Treatment repeats every 12 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity."
62753457|NCT05143723|EXPERIMENTAL|agonist group|Patients of the first group received GNRH-a for LPS at a dose of 0.2 mg, subdermally, daily from the second day after TVOP till 8 weeks of pregnancy.
62753458|NCT05143723|ACTIVE_COMPARATOR|group of progesterone and estradiol|The second group of patients received progesterone as LPS at a dosage of 30 mg per day, per os, and estradiol at a dosage of 3 mg per day, transdermally starting from the second day after TVOP till 8 weeks of pregnancy
62753459|NCT06089460|EXPERIMENTAL|Beef|Individuals will be asked to consume beef as their only source of protein and follow an individualized meal plan for 4 weeks. Thereafter, they will be instructed to continue beef consumption with any other foods desired for 4 weeks.
62753460|NCT06089460|EXPERIMENTAL|Meat analogue|Individuals will be asked to consume a commercial meat analogue product as their only source of protein and follow an individualized meal plan for 4 weeks. Thereafter, they will be instructed to continue the meat analogue consumption with any other foods desired for 4 weeks.
62753461|NCT06089460|EXPERIMENTAL|Beans/legumes|Individuals will be asked to consume beans/legumes as their only source of protein and follow an individualized meal plan for 4 weeks. Thereafter, they will be instructed to continue the bean/legume consumption with any other foods desired for 4 weeks.
62753462|NCT06254703||Patients receiving CKRT|"1. Adults (≥ 18 years of age)~2. Admitted to ICU~3. Plan to initiate CKRT by clinician's judgement"
62753463|NCT02430948|ACTIVE_COMPARATOR|Standard Support Outreach|Providers receive standard written screening recommendations and do not receive academic detailing (educational outreach)
62753464|NCT02430948|EXPERIMENTAL|Standard materials and academic detailing|Providers receive standard written screening recommendations and receive academic detailing (educational outreach)
62753465|NCT02430948|EXPERIMENTAL|Color-coded materials and no academic detailing|Providers receive color-coded written screening recommendations and do not receive academic detailing (educational outreach)
62753466|NCT02430948|EXPERIMENTAL|Color-coded materials and academic detailing|Providers receive color-coded written screening recommendations and receive academic detailing (educational outreach)
62753467|NCT02093429|EXPERIMENTAL|INCB047986 4 mg|Participants will receive INCB047986 4 mg once daily for at least 16 weeks.
62753468|NCT02093429|EXPERIMENTAL|INCB047986 6 mg|Participants will receive INCB047986 6 mg once daily for at least 16 weeks.
62556296|NCT05464979|EXPERIMENTAL|Esketamine intubation group|Esketamine at 0.5-1.0 mg/kg BW and rocuronium bromide at 0.6 mg/kg BW was given intravenously for induction intubation. After the intubation was completed, esketamine was continuously pumped at 0.3-1.5 mg/kg/h to maintain sedation. The Richmond Agitation Sedation Scale (RASS) was used to assess the sedation of patients every 1 hour and maintains a RASS score of -2 to 0.
62556297|NCT05464979|PLACEBO_COMPARATOR|Conventional intubation group|Midazolam at 0.1mg/kg BW, fentanyl at 1ug/kg BW, rocuronium bromide at 0.6mg/kg BW was given intravenously for induction intubation; After the intubation was completed, sufentanil at 0.1 μg/kg/h was administered for analgesia, and remazolam tosylate at an initial dose of 0.075 mg/kg/h was administered for sedation, and the dose of remazolam tosylate was adjusted according to the RASS score. The RASS score was assessed every 1 h and maintained at -2 to 0.
62753469|NCT02093429|EXPERIMENTAL|INCB047986 10 mg|Participants will receive INCB047986 10 mg once daily for at least 16 weeks.
62753470|NCT02088619|EXPERIMENTAL|Quality of Life Therapy (QOLT)|Positive emotion-focused cognitive behavioral psychotherapy
62753471|NCT02088619|ACTIVE_COMPARATOR|Heart Healthy Education (HHE)|Heart healthy education program
62377380|NCT02331316|EXPERIMENTAL|Daily extra water intake 1L|"Timing of daily extra water intake~Intervention-A: 4 8oz glasses of water a day (1L) - 1 first thing in the morning before breakfast, 1 before midday or midday meal, 1 before afternoon meal and 1 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
62377381|NCT02331316|EXPERIMENTAL|Daily extra water intake 500ml|"Timing of daily extra water intake~Intervention-A: 2 8oz glasses of water a day (500ml) - each half an hour before a meals.~Intervention-B: Drink extra water at anytime over 24 hours"
62377382|NCT02331316|EXPERIMENTAL|Daily extra water intake 120ml|"Timing of daily extra water intake~Intervention-A: 1/2 a glass of water on waking (120ml). If you forget to drink your water first thing, do not drink it later in the day, just skip this day and drink ½ a glass the next day on waking.~Intervention-B: Drink extra water at anytime over 24 hours"
62753472|NCT06607146|PLACEBO_COMPARATOR|Control Group|
62753473|NCT06607146|EXPERIMENTAL|Experimental Group|
62753474|NCT06052826|EXPERIMENTAL|Arm I (PT, cognitive education, nutrition education)|Patients undergo GA before lymphodepleting chemotherapy and recommendations based on assessment results communicated to treating physicians. Patients receive PT and delirium prevention education prior to lymphodepletion, at least once before CAR-T therapy, at least 2 times a week while inpatient, and at least once every other week outpatient up to day 30. Additionally, patients receive personalized nutritional guidance from a registered dietician prior to lymphodepletion, prior to CAR-T therapy and at least once a week up to day 30.
62753475|NCT06052826|ACTIVE_COMPARATOR|Arm II (standard of care)|Patients undergo GA and receive standard of care throughout study.
61986485|NCT01474876||Ankylosing Spondylitis|Participants with a diagnosis of ankylosing spondylitis
61986486|NCT01474876||Psoriatic Arthritis|Participants with a diagnosis of psoriatic arthritis
62753476|NCT02944864|EXPERIMENTAL|TQ-B3395|TQ-B3395 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62753477|NCT01591421|EXPERIMENTAL|BKM120 and Panitumumab|BKM120 will be given either daily starting day 1 cycle 1or 5 out of 7 days every week, depending on when patient is enrolled on the study, in combination with panitumumab given intravenously every two weeks starting day 1 cycle 1.
62753478|NCT04989205||HAP - group|The target group was individuals who engaged in regular or daily cannabis use, and who were motivated to quit cannabis. The formal inclusion criteria was a Severity of Dependence Scale (SDS) score ≥4 and being ≥16 years old. Exclusion criteria was polydrug use where cannabis was not the predominating substance of use and psychiatric comorbidity that was perceived as too severe to handle at the community-based centers .
62753479|NCT03513887||Group/Cohorts|we will prospectively collect patients with liver cirrhosis who fulfill all inclusion criterias and will be treated in the Department of Gastroenterology of the Second Affiliated Hospital of Xi'an Jiaotong University.
62753480|NCT02654431||Breast Cancer patients|Breast cancer patients
62753481|NCT02654431||women with breast cancer|women with breast cancer
62753482|NCT02654431||Cancer patients|Cancer patients
62753483|NCT05853107|EXPERIMENTAL|Implant AuTNA I|This is a single arm study where the status and performance of the implanted eye prior to the surgery serves as the comparator.
61986487|NCT02171260|EXPERIMENTAL|Eribulin Mesylate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle. A cycle of therapy is considered to be 21 days. The starting dose for eribulin mesylate will be at 1.1 milligram per square meter (mg/m\^2) (Dose Level 1), which is approximately 80% of the adult MTD, and will be escalated up to no more than 2.2 mg/m\^2.
61986488|NCT01424254|EXPERIMENTAL|Video-Capsule Endoscopy|VCE will be performed in the early morning following 200 mg of simethicone and 250 - 500 mg of erythromycin (as per physician's prescription), ingestion also in the absence of contra-indications
62753484|NCT05155852||Post-delivery preeclampsia patients|Women admitted to the high-risk unit(s) with elevated blood pressure and neurological symptoms, such as headache, after delivery.
61986489|NCT01424254|EXPERIMENTAL|Push Enterosopy|
62753485|NCT06384274|EXPERIMENTAL|Emotional Freedom Technique Group|"When the patient, who was determined to be in the emotional liberation group, was admitted to the unit, the patient's consent was first obtained; In the first 10 minutes, the patient will fill out the Patient Introduction Form, State Anxiety Scale, Subjective Disturbance Unit Scale and Vital Signs Form in the Unit.~Emotional liberation technique will be applied and then the subjective disturbance unit score will be recorded. Then the patient will fill out the State Anxiety Scale and Vital Signs Forms and the patient will be informed about the treatment. He will then be taken into treatment. When the patient leaves the treatment, the process will be completed by filling out the State Anxiety Scale, Subjective Disturbance Unit Scale and Vital Signs Form again within 10 minutes."
62753486|NCT06384274|EXPERIMENTAL|Virtual Reality Glasses Group|"Consent was first obtained for admission differences to the patient unit, which was noted to have virtual reality limits; Patient Introduction Form, State Anxiety Scale, Subjective Disturbance Unit Scale and Vital Tests Form will be filled in the unit.~Then the virtual reality of life will be explained and glasses will be purchased. Forest/beach/sea video images can be watched in virtual reality. The video is planned to last approximately 10 minutes. The application is planned to take 20-25 minutes. Before the session, the State Anxiety Scale, SUBJECTIVE DISORDER UNIT SCALE and Vital Tests Form will be filled in again, the patient will be informed and then the treatment will be administered.~Once the treatment is completed, the patient will take a third measurement within 10 minutes and the State Anxiety Scale, Subjective Disturbance Unit Scale and Life Parameters Form will be filled out again."
62753487|NCT06384274|NO_INTERVENTION|Control Group|When the patient determined to be in the control group is admitted to the unit, patient consent was obtained within the first 10 minutes and the Patient Introduction Form, State Anxiety Scale, Subjective Disturbance Unit Scale and Vital Signs Form will be filled in the unit. The patient will be prepared for the treatment, will be given special clothing for the treatment, and will be given standard training for the treatment. Then, the second measurement will be taken just before the patient enters the session. There will be at least 20 minutes between the second measurement and the first measurement. The State Anxiety Scale, Subjective Disturbance Unit Scale and Vital Signs Form will be filled out again. After the treatment process is completed, the patient will be measured for the third time and the process will be completed by filling out the State Anxiety Scale, Subjective Disturbance Unit Scale and Vital Signs Form again.
62753488|NCT03240315||COPD subjects|Subjects with GOLD stage I-IV COPD
62753489|NCT05043519|EXPERIMENTAL|FAM-NP41 Fluorescence Imaging|The patients will be injected with FAM-NP41 preoperatively, and fluorescence imaging of cranial nerves will be evaluated after the craniotomy.
62753490|NCT01373684|EXPERIMENTAL|Peginterferon alfa-2a add on|All patients are all currently being treated with long-term NA treatment. PEG-IFN will be given in a dose of 180 μg per week s.c. for a total duration of 48 weeks starting at week 0.
62753491|NCT01373684|ACTIVE_COMPARATOR|Nucleoside analogue|All patients are all currently being treated with long-term Nucleos(t)ide analogue treatment and will continue using this medication during the duration of the study.
62753492|NCT05491369|ACTIVE_COMPARATOR|Application users|Participants will use application for self-management.
62753493|NCT05491369|NO_INTERVENTION|Control group|Participants will be in the waiting list which don't use the app.
62753494|NCT06277986||Gastric cancer patients with non-cachexia|
62753495|NCT06277986||Gastric cancer patients with cachexia|
62753496|NCT03698045|EXPERIMENTAL|PRO-143 Ophthalmic Solution|PRO-143 Ophthalmic Solution applied four times per day (c/6 hours) during 10 days.
61986490|NCT03754894|EXPERIMENTAL|goup 1(with readymade plastic stent )|Will include 10 patients where combined full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement covered by ready-made plastic stent.
61986491|NCT03754894|EXPERIMENTAL|group 2 (control)|Will include 10 patients where combined full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement then suturing the flap in place.
61986492|NCT00208962|ACTIVE_COMPARATOR|1|
61986493|NCT02297828|EXPERIMENTAL|Boussignac CPAP|"Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).~Arterial blood samples to measure PaO2 and PaO2/FiO2 ratio are collected before surgery and at 1, 2 and 24 hours after extubation. Spirometry is performed at the same intervals measuring FEV1 and FVC."
62377383|NCT05972122|PLACEBO_COMPARATOR|Group S = SPSIPB group|A high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The procedure will be performed with the patient in the lateral decubitus position. After the scapula is shifted slightly laterally, the US probe is placed sagittal at the upper corner of the spina scapula, and the serratus posterior superior muscle is visualized with the third rib. The in-plane technique will be used. The block needle will be advanced in the craniocaudal direction to enter between the serratus posterior superior and the third rib. The block location will be confirmed by injecting 5 ml of saline between the rib and the muscle. After the block location is confirmed, 30 ml of 0.25% concentration bupivacaine will be used.
62377384|NCT05972122|OTHER|Group C = Control group|The intercostal infiltration with 30 ml of 0.25% concentration of bupivacaine will be performed by the surgical team.
62753497|NCT04773782|EXPERIMENTAL|avapritinib|Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.
62753498|NCT02090803||Graft of autologous hematopoietic stem cells|
62556298|NCT04428034|EXPERIMENTAL|Learning Skills Together Intervention|Participants in the Learning Skills Together program will begin their participation with a one-on-one phone call with an interventionist, who will ensure the participant is prepared to to attend the group sessions (e.g., familiar with videoconference technology) and will help the participant to set individual goals. The caregiver participant will then attend 4, group-based sessions lasting approximately 1.5 hours each, to learn about common complex care tasks managed by family caregivers to someone with mid-stage Alzheimer's disease, such as managing behavioral symptoms of dementia, incontinence, nutrition, transferring, medication management, and more. Sessions will integrate interactive activities, such as videos, case studies, and discussions. Approximately four weeks later, caregivers will be asked to attend a group reflection session to discuss application of what was learned and progress in meeting individual goals.
62377385|NCT03052634|EXPERIMENTAL|RC48-ADC 1.5 mg/kg (HER2 Positive)|
62377386|NCT03052634|EXPERIMENTAL|RC48-ADC 2.0 mg/kg (HER2 Positive)|
62556299|NCT03153163|EXPERIMENTAL|Trastuzumab Emtansine|Participants with HER2-positive LA/MBC who received prior trastuzumab and taxane therapy will receive trastuzumab emtansine.
62556300|NCT00673439|EXPERIMENTAL|Fondaparinux|daily subcutaneous injection of fondaparinux (7.5-10 mg)
62556301|NCT04903431|ACTIVE_COMPARATOR|Clinician-administered Crisis Response Plan|Clinicians will administer the Crisis Response Plan to 75 military veterans.
62556302|NCT04903431|EXPERIMENTAL|Self-administered Crisis Response Plan|Participants will complete a self-guided version of the Crisis Response plan online.
62556303|NCT05217576|OTHER|Comparison|"Comparison study:~The participants (at least 300) will be tested once with each of the 3 devices. First, a measurement with the NBM-200 will be performed according to the user manual. The best finger to use, in order of preference: 1) right thumb 2) left thumb 3) right index 4) left index.~The POC capillary test will follow the NBM-200 test, and the venous test will be performed last. A venous blood sample will be obtained from all participants in the comparison study, even if a subject is designated to donate and is deferred from donation because of low hemoglobin."
62556304|NCT05217576|OTHER|Precision A & B|"Precision study:~1. At least 12 subjects will be tested 6 consecutive times with the NBM-200, on either the right or left thumb, and then 6 times with the capillary device (with a separate finger-prick for each test).~2. At least 3 males and 3 females at 2 study sites (total of 12), preferably with hemoglobin levels close to the cutoff levels of 12.5 g/dL for females and 13 g/dL for males. Each subject will be tested on each of their right and left thumbs and indices (4 fingers) using at least two operators and two NBM-200 instruments on each finger.~A laboratory test with venous blood is not required for participants in the precision study."
62556305|NCT00946738|ACTIVE_COMPARATOR|physical therapy|
62753499|NCT06037941|EXPERIMENTAL|E-Nose Technology|Patients undergo a breathprinting test (E-Nose) at baseline and at the first three standard of care follow-ups, as scheduled by their treating physician, that involve a CT of the Chest and/or PET/CT. The E-Nose testing will be administered by trained staff. Staff will use proper personal protective equipment during collections. Subjects will undergo E-Nose testing in a presurgical or interventional radiology suite. Subjects must consent to no smoking, no tooth brushing, and no food or drinks starting on midnight of the day of the E-Nose test. If fasting from midnight until the E-Nose test is not feasible, subjects may consent to fasting for 2 hours prior to each E-Nose test. Subjects opting to fast for 2 hours before each E-Nose test can only have still, non-carbonated water and non-aromatic foods or foods that do not develop aromatic compounds, such as low salt simple crackers, starting at midnight on the day of the E-Nose test until 2 hours before the collection.
62753500|NCT04075968||group 1|exercise group; 6 weeks, twice a week, 30 minutes physical group exercises and 30 minutes general cognitive function exercises will be applied as groups.
62753501|NCT04075968||group 2|control group; patients will be given physical and cognitive home exercise program individually.
62377387|NCT03052634|EXPERIMENTAL|RC48-ADC 2.5 mg/kg (HER2 Positive)|
62377388|NCT03052634|EXPERIMENTAL|RC48-ADC 2.0 mg/kg (HER2 Low Expression)|
62556306|NCT00946738|NO_INTERVENTION|control|
62377389|NCT02550860|ACTIVE_COMPARATOR|soybean oil (SO)-based IVFE (Medialipide)|
62377390|NCT02550860|ACTIVE_COMPARATOR|fish oil (FO)-containing IVFE (Lipidem)|fish oil (FO)-containing IVFE (Lipidem)
62377391|NCT04098016|EXPERIMENTAL|Intervention|Participants will receive: 1) tailored behavior change goals, 2) self-monitoring with tailored feedback, and 3) skills training.
62377392|NCT03613168|EXPERIMENTAL|Trastuzumab plus Gem/Cis|Gemcitabine 1,000 mg/m2 Day 1 and Day 8, every 3 weeks Cisplatin 25 mg/m2 Day 1 and Day 8, every 3 weeks Trastuzumab, every 3 weeks, 8 mg/kg at first cycle then, 6 mg/kg
62377393|NCT03463213|EXPERIMENTAL|SHE Tribe|SHE Tribe is a social network-based peer-facilitated intervention to promote adoption of health behaviors
62377394|NCT03166228|ACTIVE_COMPARATOR|normal saline0.9%|0.9% saline distension media is used as long as diathermy is not in use
62377395|NCT03166228|PLACEBO_COMPARATOR|1.5% GLYCINE|1.5% GLYCINE DURING OPERATIVE HYSTEROSCOPY as long as diathermy is in use
62377396|NCT03227692|EXPERIMENTAL|Persona with iASSIST Knee|Having total knee arthroplasty (Persona Knee System) surgery with the use of a navigation system iASSIST Knee.
62377397|NCT03227692|ACTIVE_COMPARATOR|Persona without iASSIST Knee|Having total knee arthroplasty surgery (Persona Knee System) with the use of conventional surgical instruments, and without a navigation system iASSIST Knee.
62377398|NCT06177223|EXPERIMENTAL|Treatment Group|Cognitive Behavioral Therapy based sessions would be conducted with women victims of domestic violence in shelter homes
62377399|NCT06177223|NO_INTERVENTION|Waitlist Control Group|no intervention would be given to the participants
62377400|NCT01722214|EXPERIMENTAL|Group Adalimumab|A total of 53 patients with moderate to severe psoriasis will randomized in the adalimumab group. At Day 0 patients will receive adalimumab. It will be administered sub-cutaneously as described in the Canadian product monograph (80mg followed by 40mg at Week 1 and 40mg every other week). At Week 16, all patients will received two injections of placebo. As of Week 17, patients randomized to the adalimumab group will receive 40 mg adalimumab every other week until Week 51.
62556307|NCT04966871|EXPERIMENTAL|Group A (PfSPZ Vaccine; PfSPZ Challenge 7G8)|"14 volunteers will receive 3 doses of 9 x 10\^5 PfSPZ Vaccine on days 1, 8, 29.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 14 by DVI injection."
62556308|NCT04966871|EXPERIMENTAL|Group B (PfSPZ Vaccine; PfSPZ Challenge 7G8)|"14 volunteers will receive 9 x 10\^5 PfSPZ Vaccine on days 1, 8, 29.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 42 by DVI injection."
62753502|NCT04644978||Trainees and specialists in child and adult psychiatry|"The responder must be a practising specialist or trainee in psychiatry or child and adolescent psychiatry in the participating European countries on the basis of his / her own declaration. Responders could provide their consent by choosing I agree on the website, after reading the information leaflet and the informed consent form."
62753503|NCT03271073|EXPERIMENTAL|Apatinib plus S1|patients with advanced gastric cancer enrolled after failure of first-line systemic chemotherapy will be given Apatinib plus S1 till progressive disease,death or non-tolerable toxicity
62753504|NCT04854967|EXPERIMENTAL|De-implementation Intervention|"The oxygen de-implementation intervention will consist of: 1) an order to rescind the patient's home oxygen 2) an unlearning component targeting provider and patient education and 3) a substitution component that introduces alternative evidence-based therapies to treat dyspnea (e.g. teach-to-goal inhaler teaching and pursed lip breathing)."
62753505|NCT04854967|NO_INTERVENTION|Usual Care|The patient receives usual care from their assigned clinical provider.
62753506|NCT01946672|EXPERIMENTAL|isotopic intraoperative detection|Lower-limb drainage isotopic intraoperative detection
61986494|NCT02297828|ACTIVE_COMPARATOR|Ventury face mask|"Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).~Arterial blood samples to measure PaO2 and PaO2/FiO2 ratio are collected before surgery and at 1, 2 and 24 hours after extubation. Spirometry is performed at the same intervals measuring FEV1 and FVC."
62377401|NCT01722214|PLACEBO_COMPARATOR|Placebo Group|A total of 53 patients with moderate to severe psoriasis will be randomized in the placebo group. At Day 0 these patients will receive the placebo. It will be administered sub-cutaneously as described in the Canadian product monograph of adalimumab. At Week 16, all these patients will received two injections of adalimumab. As of Week 17, patients randomized to the placebo group will receive 40 mg adalimumab every other week until Week 67.
62377402|NCT02993783|EXPERIMENTAL|Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once on Days 1, 15, 43, 71 and 99.
62377403|NCT02993783|EXPERIMENTAL|Vedolizumab 600 mg|Vedolizumab 600 mg, IV infusion, once on Days 1, 15, 43, 71 and 99.
62377404|NCT00166244|ACTIVE_COMPARATOR|Fixed Dose|1 g MMF twice-daily (bid) for adults or 600 mg/m2 bid for paediatric patients. Treatment to be given orally unless it is not possible, in which case it is administered via intravenous (iv) infusion.
62377405|NCT00166244|ACTIVE_COMPARATOR|Concentration Controlled|1 g MMF bid for adults or 600 mg/m2 bid for paediatric patients. Thereafter, MMF doses will be adjusted to MPA AUC0-12 between 30-60mg.h/L based on 3-point abbreviated AUCs (taken at timepoints: 0, 30 min and 120 min always in fasted patients, except for pediatric patients on concomitant tacrolimus) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine MPA levels in plasma.
62377406|NCT04277052|EXPERIMENTAL|Group 1|Muscle disorders
62377407|NCT04277052|EXPERIMENTAL|Group 2|Disc displacements
62556309|NCT04966871|EXPERIMENTAL|Group C (PfSPZ Vaccine; PfSPZ Challenge 7G8)|"14 volunteers will receive 9 x 10\^5 PfSPZ Vaccine on days 1, 8, 29.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 70 by DVI injection."
62556310|NCT04966871|PLACEBO_COMPARATOR|Group A controls (Saline; PfSPZ Challenge 7G8)|"4 volunteers will receive Normal Saline (NS) as placebo on days 1, 8, 29.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 14 by DVI injection."
62753507|NCT06011798|ACTIVE_COMPARATOR|Anti-VEGF control arm|Prior to randomization, participants will receive 3 IVT injections of aflibercept over 4-week intervals. Upon randomization, participants will receive 2 mg aflibercept (50 μl of 40 μg/μl solution) IVT on Day 1, Weeks 8, and 16. A sham procedure will also be administered on Day 1.
62753508|NCT06011798|EXPERIMENTAL|foselutoclax arm|Prior to randomization, participants will receive 3 IVT injections of aflibercept over 4-week intervals. Upon randomization, participants will receive 10 μg foselutoclax (50 μl of 0.2 μg/μl solution) IVT on Day 1 and Weeks 8 and 16. 2 mg aflibercept (50 μl of 40 μg/μl solution) will also be administered on Day 1.
62753509|NCT01691885|EXPERIMENTAL|A/B|Placebo followed by Fluticasone Furoate Vilanterol Combination
62753510|NCT01691885|PLACEBO_COMPARATOR|B/A|Fluticasone Furoate Vilanterol Combination followed by Placebo
62753511|NCT00932620|ACTIVE_COMPARATOR|Simvastatin 40 mg|All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily
62753512|NCT00932620|ACTIVE_COMPARATOR|Simvastatin 10 mg plus ezetimibe 10 mg|All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily
62753513|NCT03473106|EXPERIMENTAL|Surgical Side|Surgical side requiring the use of a pneumatic tourniquet.
62753514|NCT03473106|NO_INTERVENTION|Non Surgical Side|Contralateral side (Control Thigh).
62753515|NCT04050696|EXPERIMENTAL|Treatment (with PT run-in)|Treatment group, to receive BQ treatment with PT, after stability established in 4 week PT run-in period
62753516|NCT04359290|EXPERIMENTAL|Ruxolitinib treatment|Ruxolitinib will be administered p.o. or by gavage feeding for max 28 days
62753517|NCT03659149|EXPERIMENTAL|Group 1|Period 1: Test drug 1(CKD-333 formulation I) Period 2: Test drug 2(CKD-333 formulation II) Period 3: Reference drug(CKD-330 + D086)
62753518|NCT03659149|EXPERIMENTAL|Group 2|Period 1: Test drug 1(CKD-333 formulation I) Period 2: Reference drug(CKD-330 + D086) Period 3: Test drug 2(CKD-333 formulation II)
62753519|NCT03659149|EXPERIMENTAL|Group 3|Period 1: Test drug 2(CKD-333 formulation II) Period 2: Reference drug(CKD-330 + D086) Period 3: Test drug 1(CKD-333 formulation I)
62753520|NCT03659149|EXPERIMENTAL|Group 4|Period 1: Test drug 2(CKD-333 formulation II) Period 2: Test drug 1(CKD-333 formulation I) Period 3: Reference drug(CKD-330 + D086)
62753521|NCT03659149|EXPERIMENTAL|Group 5|Period 1: Reference drug(CKD-330 + D086) Period 2: Test drug 1(CKD-333 formulation I) Period 3: Test drug 2(CKD-333 formulation II)
62753522|NCT03659149|EXPERIMENTAL|Group 6|Period 1: Reference drug(CKD-330 + D086) Period 2: Test durg 2(CKD-333 formulation II) Period 3: Test drug 1(CKD-333 formulation I)
62377408|NCT04277052|EXPERIMENTAL|Group 3|Other common joint disorders
62377409|NCT04277052|EXPERIMENTAL|Group 4|Mix type
62753523|NCT05536492|NO_INTERVENTION|G1-Control group|normal socket healing after extraction without intervention
62753524|NCT05536492|EXPERIMENTAL|G2|SOCKET AUGMENTATION WITH A-PRF ALONE
62753525|NCT05536492|EXPERIMENTAL|G3|SOCKET AUGMENTATION WITH A-PRF + ALLOGRAFT
62753526|NCT05289193|EXPERIMENTAL|Participants with Stage III Melanoma|All participants will have cytologically or histologically confirmed stage IIIB, IIIC, IIID melanoma that can be surgically removed.
62753527|NCT03867786|EXPERIMENTAL|Exercise Condition|Participants will undergo a 40 minute exercise protocol
62753528|NCT03867786|ACTIVE_COMPARATOR|Video Control Condition|Participants will view a 40 minute nature video
62377410|NCT04277052|EXPERIMENTAL|Group 5|Healthy individuals
62377411|NCT01935674|EXPERIMENTAL|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
62753529|NCT06344052|EXPERIMENTAL|Arm 1|vismodegib, with 3 cycles SP-002
62753530|NCT06344052|EXPERIMENTAL|Arm 2|vismodegib, with 1 cycles SP-002
62753531|NCT06344052|PLACEBO_COMPARATOR|Arm 3|vismodegib monotherapy
61986495|NCT00909779|EXPERIMENTAL|Arformoterol 15 mcg twice daily|Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.
61986496|NCT00909779|PLACEBO_COMPARATOR|Placebo twice daily|Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.
61986497|NCT04197414||Prostate cancer|Patients diagnosed as prostate cancer and have undergone prostatectomy
62377412|NCT01935674|EXPERIMENTAL|Continue ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
62377413|NCT03623204||Patients with bariatric surgery for obesity|
62753532|NCT06225895|PLACEBO_COMPARATOR|control group|patients will receive general anesthesia
62753533|NCT06225895|ACTIVE_COMPARATOR|E group|patients will receive Erector spinae plane block
62753534|NCT06225895|ACTIVE_COMPARATOR|R group|patients will receive rhomboid intercostal nerve block
62753535|NCT02118766|EXPERIMENTAL|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
62753536|NCT02118766|PLACEBO_COMPARATOR|Matching vehicle control|Matching vehicle control, applied twice daily for up to 28 days
62753537|NCT01242410|NO_INTERVENTION|Expectant Management|
62753538|NCT01242410|EXPERIMENTAL|Placement of cervical pessary since 23 weeks until 37 weeks|
62753539|NCT01432145|EXPERIMENTAL|6MP/MTX|6-Mercaptopurine 55mg/m2 per day, and methotrexate 15mg/m2 per week
62753540|NCT04965974|EXPERIMENTAL|1 blue light blocking filter group|digital blue light blocking filter is installed laptops and mobile phones of 80 individual using digital devices more than 4 hours. asked them to use the filter continuously while using digital devices.
62753541|NCT04965974|EXPERIMENTAL|2 non filter users|Effect of time duration of digital screen on the dry eyes is checked.
62753542|NCT01842035|EXPERIMENTAL|Regadenoson|"Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.~--------------------------------------------------------------------------------"
62753543|NCT00996294|EXPERIMENTAL|surgery|patients will be submitted to biliopancreatic diversion or gastric bypass
62377414|NCT04576273||Non-parasitic|
62377415|NCT04576273||Parasitic|
62377416|NCT06357429|EXPERIMENTAL|cold application|The first group consists of the experimental group in which cold application is planned to be applied to the hand LI4 point after surgical intervention
62753544|NCT02567682|EXPERIMENTAL|Fixed sequence, 2-periods|An open-label, fixed sequence, 2-period drug interaction study Period 1 Treatment A: Single dose of drug cocktail on Day 1 Period 2 Treatment B: GBT440 on Days 1 through 3 and Treatment C: Single dose of drug cocktail on Day 4 and GBT440 on Days 4 through 7
62377417|NCT06357429|EXPERIMENTAL|Control|The control group in which routine interventions in the clinic are applied.
62377418|NCT01671605||CKD not on dialysis|Patients with CKD not on dialysis (CKD III-IV)
62753545|NCT01888133|EXPERIMENTAL|Group Walk First|Participants attend a weekly walking group session from weeks 1-6 and are not required to attend from weeks 7-12.
62753546|NCT01888133|EXPERIMENTAL|Individual Walk First|Participants are not required to attend a weekly group walking sessions from weeks 1-6 and attend a weekly walking group session from weeks 7-12.
62377419|NCT01671605||Controls|Controls with normal kidney function (Control)
62377420|NCT01017549|OTHER|Treatment|This is a single arm study where all patients are treated with FDA cleared electronic brachytherapy treatment.
62753547|NCT04484649|EXPERIMENTAL|Intervention|Sleeping Healthy/Living Healthy
62753548|NCT04484649|ACTIVE_COMPARATOR|Control|Attention Control
62753549|NCT06446063||Treated group|
62753550|NCT06446063||Control group|
62753551|NCT01588262|OTHER|Stressmanagement counselling|
62753552|NCT01588262|NO_INTERVENTION|Control|
62753553|NCT02479165|ACTIVE_COMPARATOR|Opioid group|"If randomized to the opiod group, the patient was given the following regimen for 1 week, upon return from the intensive care unit, after surgery.~Tbl. Oxycodone (slow-release) 10mg, Twice daily for 1 week Tbl. Paracetamol 1000mg, Four times daily for 1 week Tbl.oxycodone 5mg Max 4 times daily, as needed, until discharge. Inj, oxycodone 2.5 mg, Max 4 times daily, as needed, until discharge Tbl. Magnesia 1g, Twice daily, for 1 week Sol. Sodiumpicosulfate 7.5mg/ml 10 drops daily, for 1 week"
62753554|NCT02479165|ACTIVE_COMPARATOR|Ibuprofene group|"If randomized to the ibuprofen group, the patient was given the following regimen for 1 week, upon return from the intensive care unit, after surgery.~Tbl. Ibuprofen (slow-release) 800mg, Twice daily, for 1 week Tbl. Paracetamol 1000mg, Four times daily, for 1 week Tbl.oxycodone 5mg Max 4 times daily, as needed. Until discharge. Inj, oxycodone 2.5 mg Max 4 times daily, as needed. Until discharge. Tbl. Lanzoprazole 40 mg, Once daily, for 1 week Tbl. Magnesia 1g, Twice daily, for 1 week Sol. Sodiumpicosulfate 7.5mg/ml, 10 drops daily, for 1 week"
62753555|NCT03840304|EXPERIMENTAL|Yoga Group|Participants in the intervention group engaged in a 8-week yoga program delivered at their place of work (IT companies). Sessions were group-based, prescribed three sessions per week during break time (30-mins).
61986498|NCT04197414||Renal cell cancer|Patients diagnosed as renal cell cancer and have undergone partial or radical nephrectomy
61986499|NCT04197414||Bladder cancer|Patients diagnosed as bladder cancer and have undergone radical or partial cystectomy
61986500|NCT04197414||Ureter cancer|Patients diagnosed as ureter cancer and have undergone nephroureterectomy or ureterectomy
62377421|NCT03271411|EXPERIMENTAL|Eye movement desensitization and reprocessing (EMDR) arm|
62377422|NCT03271411|EXPERIMENTAL|Progressive counting (PC) arm|
62556311|NCT04966871|PLACEBO_COMPARATOR|Group B controls (Saline; PfSPZ Challenge 7G8)|"4 volunteers will receive Normal Saline (NS) as placebo on days 1, 8, 29.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 42 by DVI injection."
62556312|NCT04966871|PLACEBO_COMPARATOR|Group C controls (Saline; PfSPZ Challenge 7G8)|"4 volunteers will receive Normal Saline (NS) as placebo on days 1, 8, 29.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 70 by DVI injection."
62753556|NCT03840304|NO_INTERVENTION|Wait-list Group|Participants in Wait-List control were not given any intervention. 8-weeks, group followed usual break time.
62753557|NCT06605183|OTHER|One hour per week of community walking for 6 months|Participants will participate in one, 60-minute group walk using Nordic poles at a local community park. Participants will be assessed before and after the 6-month program.
62377423|NCT04037059||Spinal Deformity Patients|For patients with disabling spinal deformities, long segment fusions have been shown to improve the health related quality of life (HRQOL). A consequence of spine fusion however is elimination of range of motion especially in the lumbar spine. Even in patients who report overall improvement in pain related domains, difficulty with some ADL's in this patient group has been well documented in previous studies. Complaints such as inability to dress independently, bathing of lower halves of their body, driving a motor vehicle, getting in and out of a chair/bed and performing perineal hygiene care following toileting have been reported.
62377424|NCT01718015||Patients with diabetic polyneuropathy|
62556313|NCT03660995|EXPERIMENTAL|SLI children|
62556314|NCT03660995|ACTIVE_COMPARATOR|Control children|
62556315|NCT00136227|EXPERIMENTAL|Lifestyle counseling|Behavioral: small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention
62556316|NCT01552161||Patients with negative coronarography.|Subjects who underwent coronary angiography and were classified as having no critical lesions in coronary arteries (a lesion of up to 50% of artery lumen is accepted as non-critical).
62556317|NCT01552161||Patients with positive coronarography|Subjects who underwent coronary angiography and were classified as having critical lesions in coronary arteries (over 50% narrowing of artery lumen).
62556318|NCT04656600|EXPERIMENTAL|Cerezyme® / Imiglucerase|Cerezyme® (imiglucerase for injection) is administered by intravenous infusion, 60 U/kg once every 2 weeks.
62556319|NCT02603588|EXPERIMENTAL|active acupuncture|intervention: subjects in the active acupuncture group received active sphenopalatine ganglion acupuncture
62556320|NCT02603588|SHAM_COMPARATOR|sham acupuncture|intervention: subjects in the sham acupuncture group received sham sphenopalatine ganglion acupuncture
62556321|NCT04150172|OTHER|Sequence A (RT)|"\[Sequence A (RT) \& Sequence B (TR)\] to receive the Investigational Product (IP) by the sequence in each period:~* Rebamipide IR 100 mg (R): Take one tablet each at 9 am, 3 pm and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours.~* Rebamipide SR 150 mg (T): Take one tablet each at 9 am and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours."
62556322|NCT04150172|OTHER|Sequence B (TR)|"\[Sequence A (RT) \& Sequence B (TR)\] to receive the Investigational Product (IP) by the sequence in each period:~* Rebamipide IR 100 mg (R): Take one tablet each at 9 am, 3 pm and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours.~* Rebamipide SR 150 mg (T): Take one tablet each at 9 am and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours."
62556323|NCT06263933|SHAM_COMPARATOR|Control group|Patients are followed in routine care.
62556324|NCT06263933|EXPERIMENTAL|DIPEM group|Patients have 5 session of mutual assistance with a mediator psychologist, during five days, with 1 session per day. Each session lasts 1h30, with 45 min for atelier, 15 min for pause and 30 min about collective discussion.
62556325|NCT00925704|ACTIVE_COMPARATOR|Calcitriol|
62556326|NCT00925704|EXPERIMENTAL|Lanthanum carbonate + calcitriol|
62556327|NCT00925704|EXPERIMENTAL|Sevelamer carbonate + calcitriol|
62753558|NCT03005301|EXPERIMENTAL|Experimental group|Selected acupoints will be stimulated by the new intelligent electro-acupuncture instrument.
61986501|NCT06094647|EXPERIMENTAL|Altitudes Condition|Approximately 30 individuals whose loved ones are experiencing FEP and receiving services from two of the five FEP clinics (OASIS and SHORE) will be recruited to participate in a digital platform, Altitudes, for 6 months as part of an adjunct service to the clinic's services. Participants will have access to and encouraged to use the educational and therapeutic content as well as the moderated online community network during their time engaging with the platform. They will be asked to complete a battery of measures at baseline, 3-months, and 6 months.
62377425|NCT01718015||Patients with diabetes without peripheral nerve disorder|
62377426|NCT01718015||Patients with polyneuropathies not due to diabetes|
62377427|NCT01718015||Patients not suffering from diabetes or nerve disease|Control subjects
62753559|NCT03005301|ACTIVE_COMPARATOR|Control group|Selected acupoints will be stimulated by the Hwato electroacupuncture instrument.
62377428|NCT01718015||Patients with unspecified nerve disease|
62377429|NCT06366854|ACTIVE_COMPARATOR|Intervention|Management consists of a strategy that targets capillary refill time and individualised haemodynamic parameters, using vasopressors, fluids as guided by fluid responsiveness tests and inotropic support as guided by echocardiography.
62377430|NCT06366854|ACTIVE_COMPARATOR|control group|Management guided by clinical team
62556328|NCT05577533|OTHER|O-Kidia battery|"A one-time visit will be performed in children aged 7 to 12 years old as follow :~Children will be playing on a series of games with a touch screen tablet while video, EEGs and digit trajectories data will be collected from this mobile device~1. Video recording of the participants during the tablet testing via the intrinsic camera - 30 min~2. Assessments - Paper and tablet psychometric tests will be used during the administrations, 1h45~3. Child health questionnaires - Questionnaires will be completed by children and parents during the visit, 20 min for each"
62556329|NCT06399835|EXPERIMENTAL|Enavogliflozin|Enavogliflozin 0.3 mg
62556330|NCT06399835|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone 15 mg
62556331|NCT02754050|EXPERIMENTAL|Polypectomy|When a 6-25mm polyp is identified the Tandem snare will be inserted through the colonoscope, remove and retrieve the polyp.
62556332|NCT01605851|OTHER|Closure, Foramen Ovale|Patients undergoing device closure of PFO
62556333|NCT02504528|EXPERIMENTAL|allergic asthma|asthma patients that sensitive to house dust mites.
62556334|NCT02504528|EXPERIMENTAL|normal controls|normal controls with or without sensitive to house dust mites.
62556335|NCT00985244|ACTIVE_COMPARATOR|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin
61986502|NCT06094647|NO_INTERVENTION|Treatment as Usual|Approximately 30 individuals whose loved ones are experiencing FEP and receiving services from three of the five FEP clinics (Encompass, Eagle, and AEGIS) will be recruited to participate in treatment as usual offered by their respective clinic. Participants will then be asked to complete the same battery of measures as the experimental group at baseline, 3-months, and 6 months.
62556336|NCT00985244|PLACEBO_COMPARATOR|Placebo|Subjects in this group will receive 3 times a week placebo
62556337|NCT04857489||Patients with Relapse Remitting Multiple Sclerosis|Blood sample
62556338|NCT04857489||Healthy Controls|Blood Sample
62556339|NCT01722630|NO_INTERVENTION|control|Patients received intravenously saline solution at 5 ml/Kg/h
61986503|NCT01734330|EXPERIMENTAL|Cognitive behavior therapy|Cognitive behavior therapy for 6 weeks associated to nicotine replacement for 12 weeks
62377431|NCT04394013|EXPERIMENTAL|Mindfulness Arm|The content of the approximately 20 minutes video is recorded in advance of the intervention by a certified teacher with teaching experience. The 20 minutes session consists of a series of body stretching exercises (around 17 different gentle and simple stretches from head to toe) with the incorporation of breathing technique (i.e. when to breathe in and breathe out). The whole body stretching exercise is performed with a sitting position, ideally on an exercise mat. As mentioned above, the participants are required to conduct the stretching exercise by following the guidance video for at least 5 days weekly for at least 2 weeks duration. The video will be uploaded onto a webpage which requires participants to log in and view the video. The webpage and video will be accessible through computers and mobile phones.
62377432|NCT04394013|ACTIVE_COMPARATOR|Non-mindfulness Arm|In this study, for control group, the participants are instructed with a similar video content as the intervention group, minus the incorporation of breathing technique, as breathing technique is hypothesised to be a key component of mindfulness.
62377433|NCT00688389||healthy|
62377434|NCT00688389||DF|
62377435|NCT00688389||DHF|
62377436|NCT01263470|PLACEBO_COMPARATOR|Placebo|
62377437|NCT01263470|EXPERIMENTAL|Alogliptin 6.25 mg QD|
62377438|NCT01263470|EXPERIMENTAL|Alogliptin 12.5 mg QD|
62377439|NCT01263470|EXPERIMENTAL|Alogliptin 25 mg QD|
62377440|NCT01263470|EXPERIMENTAL|Alogliptin 50 mg QD|
62377441|NCT01263470|ACTIVE_COMPARATOR|Voglibose 0.2 mg TID|
62377442|NCT03726749|EXPERIMENTAL|Tocilizumab and prednisone|"1. TCZ 162 mg administered by subcutaneous injection weekly for 52 weeks.~2. Prednisone taper over 8 weeks with a starting dose between 20 and 60 mg."
62556340|NCT01722630|EXPERIMENTAL|dopamine|Patients received intravenously saline solution at 5 ml/Kg/h and dopamine at 3 mcg/Kg/min
62556341|NCT01722630|NO_INTERVENTION|crystalloids|Patients received intravenously saline solution at 10 ml/Kg/h
61986504|NCT01734330|OTHER|Nicotine replacement|Nicotine replacement for 12 weeks
62377443|NCT04785144|EXPERIMENTAL|Arm 1A|50 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants who received two vaccinations of mRNA-1273 in DMID Protocol 20-0003 (NCT04283461). N=30.
62377444|NCT04785144|EXPERIMENTAL|Arm 1B|25 mcg of mRNA-1273 and 25 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants who received two vaccinations of mRNA-1273 in DMID Protocol 20-0003 (NCT04283461). N=30.
61986505|NCT00278954|OTHER|Gammaplex|Gammaplex
61986506|NCT06198556|EXPERIMENTAL|HRS-1167 with rifampicin|
62753560|NCT01741142|EXPERIMENTAL|ABT-436|Subject receiving ABT-436
61986507|NCT01086540|EXPERIMENTAL|Rituximab+PAH SOC|"Rituximab (1000 mg) will be administered as 2 intravenous infusions given 2 weeks apart.~Concurrent stable-dose Pulmonary Arterial Hypertension (PAH) medical therapy will be continued/managed as per standard of care (PAH SOC)."
62377445|NCT04785144|EXPERIMENTAL|Arm 2A|100 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29, and 50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 57 in COVID-19 naïve participants. N=15
62377446|NCT04785144|EXPERIMENTAL|Arm 2B|50 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29, and 50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 57 in COVID-19 naïve participants. N=15
62556342|NCT01384110|EXPERIMENTAL|Brown Seaweed Lemon Tea|Single administration of lemon tea containing 500 mg of brown seaweed powder and 50 g of sucrose
62556343|NCT01384110|PLACEBO_COMPARATOR|Placebo lemon tea|Single administration of placebo lemon tea containing 50 g of sucrose
62753561|NCT01741142|ACTIVE_COMPARATOR|Escitalopram|Subject receiving escitalopram.
62753562|NCT01741142|PLACEBO_COMPARATOR|Placebo|Subject receiving placebo
43796890|NCT03543124|ACTIVE_COMPARATOR|Water exchange (WE)|This group will have the air in the colon removed and replaced with water to guide the insertion of the colonoscope.
43796891|NCT03543124|EXPERIMENTAL|WE plus cap(WECAC)|The procedure of this group is similar with WE group, except a cap will be fitted onto the end of the colonoscope.
62753563|NCT03389555|EXPERIMENTAL|Vitamin C, Vitamin B1, Corticosteroids|"The combination of vitamin C, vitamin B1, hydrocortisone :~* Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days~* Vitamin B1 (thiamine) 100mg every 6 hours x 4-days~* Hydrocortisone 50mg every 6 hours x 4-days"
62753564|NCT03389555|PLACEBO_COMPARATOR|Placebo|Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components
62753565|NCT05438602|EXPERIMENTAL|Nirmatrelvir plus ritonavir for 5 days|Nirmatrelvir (2 tablets) plus ritonavir (1 capsule) will be given by mouth every 12 hours for 5 days followed by placebo for nirmatrelvir (2 tablets) plus placebo for ritonavir (1 capsule) every 12 hours for 10 days
62753566|NCT05438602|EXPERIMENTAL|Nirmatrelvir plus ritonavir for 10 days|Nirmatrelvir (2 tablets) plus ritonavir (1 capsule) will be given by mouth every 12 hours for 10 days followed by placebo for nirmatrelvir (2 tablets) plus placebo for ritonavir (1 capsule) every 12 hours for 5 days
62753567|NCT05438602|EXPERIMENTAL|Nirmatrelvir plus ritonavir for 15 days|Nirmatrelvir (2 tablets) plus ritonavir (1 capsule) will be given by mouth every 12 hours for 15 days.
62753568|NCT03504982|EXPERIMENTAL|Treatment 1|Treatment sequences: A\*-B-C-D
62753569|NCT03504982|EXPERIMENTAL|Treatment 2|Treatment sequences: D-A-B-C\*
62753570|NCT00909545|ACTIVE_COMPARATOR|Isradipine CR 5mg|Isradipine CR 5mg/day
62753571|NCT00909545|ACTIVE_COMPARATOR|Isradipine CR 10mg|Isradipine CR 10mg/day
62753572|NCT00909545|ACTIVE_COMPARATOR|Isradipine CR 20mg|Isradipine CR 20mg/day
62753573|NCT00909545|PLACEBO_COMPARATOR|Placebo|Placebo
62753574|NCT05641428|EXPERIMENTAL|Arm A (ARI-0001)|Infusion with Point of Care CAR T-cells
62753575|NCT05641428|ACTIVE_COMPARATOR|Arm B (Axi-cel)|Infusion with Standard of Care CAR T-cells
62753576|NCT06607094|EXPERIMENTAL|Optimized Water Vapor Thermal Therapy|The Rezum System is designed to treat patients with urinary symptoms associated with BPH.
62753577|NCT06121141|ACTIVE_COMPARATOR|Control|Full-strength lidocaine with epinephrine
62753578|NCT06121141|EXPERIMENTAL|Experimental|Dilute lidocaine with epinephrine
62753579|NCT01049165|ACTIVE_COMPARATOR|Arm 1 (BMS-813160 or placebo)|
62753580|NCT01049165|ACTIVE_COMPARATOR|Arm 2 (BMS-813160 or placebo)|
62753581|NCT01049165|ACTIVE_COMPARATOR|Arm 3 (BMS-813160 or placebo)|
62753582|NCT01049165|ACTIVE_COMPARATOR|Arm 4 (BMS-813160 or placebo)|
62753583|NCT01049165|ACTIVE_COMPARATOR|Arm 5 (BMS-813160 or placebo)|
62753584|NCT01049165|ACTIVE_COMPARATOR|Arm 6 (BMS-813160 or placebo)|
62753585|NCT01049165|ACTIVE_COMPARATOR|Arm 7 [14C] BMS-813160|
62753586|NCT01049165|ACTIVE_COMPARATOR|Arm 8 (BMS-813160 or placebo)|
62753587|NCT01049165|ACTIVE_COMPARATOR|Arm 9 (BMS-813160 or placebo)|
62753588|NCT05108025|EXPERIMENTAL|Study Treatment 1|DMT310 Powder mixed with Hydrogen Peroxide
62753589|NCT05108025|EXPERIMENTAL|Study Treatment 2|Placebo powder mixed with Hydrogen Peroxide
62753590|NCT04185649|EXPERIMENTAL|BAT8001 for injection|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with trastuzumab emtansine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
62753591|NCT04185649|ACTIVE_COMPARATOR|Control (lapatinib + capecitabine)|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with lapatinib plus capecitabine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
62753592|NCT02599649|EXPERIMENTAL|Low or Intermediate-1 MDS Group - Lirilumab|Lirilumab by vein over about 60 minutes 1 time each 28 day cycle.
62753593|NCT02599649|EXPERIMENTAL|Low or Intermediate-1 MDS Group - Nivolumab + Lirilumab|Nivolumab by vein over about 60 minutes every 2 weeks during Cycles 1-9. Lirilumab by vein over about 60 minutes 1 time each cycle. Cycle is 28 days.
62753594|NCT02599649|EXPERIMENTAL|High Risk MDS Group - Azacitidine + Lirilumab|Azacitidine by vein over about 60 minutes on Days 1-7 of each 28 day cycle. Lirilumab by vein over about 60 minutes on Day 7 of each 28 day cycle.
62556344|NCT02389179|ACTIVE_COMPARATOR|25 000 IU monthly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd). The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
62556345|NCT02389179|ACTIVE_COMPARATOR|50 000 IU monthly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd).The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
62556346|NCT02389179|ACTIVE_COMPARATOR|50 000 IU bi-weekly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd).The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
62556347|NCT01841684|EXPERIMENTAL|Anacetrapib|Participants receive anacetrapib 100 mg orally once daily for 12 weeks.
62556348|NCT01841684|PLACEBO_COMPARATOR|Placebo|Participants receive placebo orally once daily for 12 weeks.
62753595|NCT02599649|EXPERIMENTAL|High Risk MDS Group - Azacitidine + Lirilumab + Nivolumab|Azacitidine by vein over about 60 minutes on Days 1-7 of each 28 day cycle. Lirilumab by vein over about 60 minutes on Day 7 of each 28 day cycle. On Days 7 and 21 of Cycles 1-9 and then on Day 7 of Cycles 10 and beyond, Nivolumab by vein over about 60 minutes.
62556349|NCT02990429|EXPERIMENTAL|Forced Air warmer (bair hugger)|".~In groups: A = 45, receiving intraoperative forced air warming( bair hugger). The forced air was delivered at the high setting of 43ºC"
62556350|NCT02990429|EXPERIMENTAL|Intravenous Fluid Warmer(ranger warmer)|In groups:B =45, having intraoperative intravenous fluid via a fluid warmer patients received intravenous fluid via a fluid warmer after induction anesthesia. The device automatically heated fluid up to 41ºC as set point.
62556351|NCT00437567|ACTIVE_COMPARATOR|Prebiotics|Babies randomized to this arm will receive galacto-oligosaccharide supplements
61986508|NCT01086540|PLACEBO_COMPARATOR|Placebo + PAH SOC|"Placebo will be administered as 2 intravenous infusions given 2 weeks apart.~Concurrent stable-dose Pulmonary Arterial Hypertension (PAH) medical therapy will be continued/managed as per standard of care (PAH SOC)."
62556352|NCT00437567|PLACEBO_COMPARATOR|Placebo|Babies randomized to this arm will receive placebo
62556353|NCT05679050|EXPERIMENTAL|AG Regimen Followed by FOLFIRINOX Regimen|AG Regimen Followed by FOLFIRINOX Regimen
62556354|NCT06044142|EXPERIMENTAL|Group A: Oral Mucositis|Group A will be submitted to photodynamic therapy (Curcumin and red laser, λ450 nm) with 142 J/cm2, 100mW. The number of points will be calculated based on the size of lesion (1 laser shot per cm2 of lesion). The intervention will be repeated daily until cure of the oral mucositis was attained.
62753596|NCT01317537|EXPERIMENTAL|Received personal health record|received personal health record access
62753597|NCT01317537|NO_INTERVENTION|No personal health record|did not receive personal health record
62753598|NCT02001415|ACTIVE_COMPARATOR|Spectacles|Spectacles are the most common lens treatment to correct myopia. This arm is set to be as a control group for the other two arms. Myopia patients who enter in this group will wear a normal pair of glasses after the baseline examinations (axial length, refraction...).
62377447|NCT04785144|EXPERIMENTAL|Arm 2C|100 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
62556355|NCT06044142|PLACEBO_COMPARATOR|Group B: Oral Mucositis|Group B (control group) will be submitted to low level (LL) laser therapy (λ660 nm) with 1J energy per point at 100mW power output for 10 seconds on daily basis until the lesion is clinically cured. The light will be applied perpendicular to the lesion on a continuous mode. The number of points will be calculated similarly as mentioned for patients included in Group A.
62377448|NCT04785144|EXPERIMENTAL|Arm 2D|50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
62753599|NCT02001415|ACTIVE_COMPARATOR|Myovison|Myovision is a kind of specially designed, commercially available spectacle lenses that could control the peripheral refraction of myopia patients. Latest studies have changed the understanding of myopia--correcting both central and peripheral vision during lens treatment is indicating to be an effective way of slowing down eye growth. Patients who entered this group will wear a pair of Myovision after baseline examinations.
62556356|NCT01849237|ACTIVE_COMPARATOR|Standard therapy of septic shock|according to Surviving Sepsis Campaign 2012 Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
62556357|NCT01849237|EXPERIMENTAL|Mesenchymal stromal cells+ standard therapy of septic shock|"MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10\^9/l).~according to Surviving Sepsis Campaign 2012: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids"
62556358|NCT05895396||Liberty|The group implanted with Liberty 677MTY
62556359|NCT05895396||PanOptix|The group implanted with PanOptix
62556360|NCT00980694|EXPERIMENTAL|Ubiquinol|up to 600 mg per day, oral capsules for 8 weeks
62753600|NCT02001415|ACTIVE_COMPARATOR|Ortho-K|Orthokeratology has recently been reported as an effective way to control eye growth for myopia adolescents. Patents who enter this group will wear ortho-K lenses during sleep after baseline examinations.
62753601|NCT05275010|ACTIVE_COMPARATOR|Arm 1: PH FDC SC Using a Handheld Syringe|A single dose of PH FDC SC (600 mg pertuzumab/600 mg trastuzumab) will be administered by a healthcare professional subcutaneously (SC) into the participant's anterior thigh on Day 1, using a handheld syringe with hypodermic needle.
62753602|NCT05275010|EXPERIMENTAL|Arm 2: PH FDC SC Using the OBDS|A single dose of PH FDC SC (600 mg pertuzumab/600 mg trastuzumab) will be administered by a healthcare professional subcutaneously (SC) into the participant's anterior thigh on Day 1, using the on-body delivery system (OBDS).
62753603|NCT03894631|ACTIVE_COMPARATOR|Phaco/KDB|Eyes needing glaucoma and cataract extraction will receive combined KDB and phacoemulsification in one eye of a patient
62753604|NCT03894631|ACTIVE_COMPARATOR|Phaco/Trabectome|Contralateral eyes needing glaucoma and cataract extraction will receive combined Trabectome and phacoemulsification in contralateral eye of the same patient
62753605|NCT04588012|EXPERIMENTAL|Online self-help the OurRelationship.dk program|Couples in the intervention condition will receive the full OurRelationship program including the three modules, the Observe, the Understand, and the Respond module. The program takes 6-8 hours to complete the program after the randomization. The second coach call will take place after the Observe phase. The third coach call will take place after the Understand phase. The fourth coach call will take place after the Respond phase.
62753606|NCT04588012|ACTIVE_COMPARATOR|"Off line self-help the book Pas på Parforholdet"|"Couples in the active control group receive two copies of the book Pas på parforholdet, når kærligheden er kommet for at blive \[Take care of your relationship when love is here to stay\] by Mattias Stølen Due (2016). This book includes general research based knowledge on maintaining a healthy relationship as well as questions and exercises for couples to do on their own. To support couples in an activate self-help approach, a sheet with guidelines on using the book will help couples plan their reading and couple conversations. Regular questionnaires will be sent to couples in the control group (matched timely to the questionnaires received by the intervention group). As such, the active control condition will mirror the benefit that couples are likely to get from using well-chosen, solid literature with the addition of any benefit that the research participation (filling in questionnaire) will generate."
62753607|NCT01886690|EXPERIMENTAL|New Eye Drop Formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
62753608|NCT01886690|ACTIVE_COMPARATOR|REFRESH PLUS®|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
62753609|NCT03819556|ACTIVE_COMPARATOR|Active immunotherapy with milk protein|Daily dose fresh milk protein increased in 11 steps
62753610|NCT03819556|NO_INTERVENTION|Control|Diet free from milk protein
62753611|NCT06512051|EXPERIMENTAL|Treatment group A|SHR-A2102+Adebrelimab+Cisplatin/ Carboplatin
62753612|NCT06605105|EXPERIMENTAL|CYB003|Initial non-responders in CYB003-002 APPROACH or initial responders who later relapse will be eligible to receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. If a participant relapses again, the participant may receive an additional single 16mg of CYB003 (maximum of 3 16mg doses in CYB003-004 EXTEND). Participants will continue on their current antidepressants and receive psychological support throughout the study.
62753613|NCT02845622|EXPERIMENTAL|30g peeled hazelnuts cream|Every person in this group will receive a 30 g peeled hazelnuts cream as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
62753614|NCT02845622|EXPERIMENTAL|30g unpeeled hazelnuts cream|Every person in this group will receive a 30 g unpeeled hazelnuts cream as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
62753615|NCT02845622|EXPERIMENTAL|snack w/ 30g peeled hazelnuts|Every person in this group will receive a snack with 30 g peeled hazelnuts as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
62753616|NCT02845622|EXPERIMENTAL|snack w/ 2.5g cocoa powder|Every person in this group will receive a snack with 2.5 g cocoa powder as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
62753617|NCT02845622|EXPERIMENTAL|snack w/ 30g peeled hazelnuts+2.5g cocoa|Every person in this group will receive a snack with 30 g peeled hazelnuts and 2.5 g cocoa powder as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
62753618|NCT02845622|PLACEBO_COMPARATOR|empty snack|Every person in this group will receive an empty snack as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
62753619|NCT05718271|EXPERIMENTAL|Explicit instructions before + after extinction|
62753620|NCT05718271|EXPERIMENTAL|Explicit instructions before extinction|
62753621|NCT05718271|EXPERIMENTAL|Explicit instructions after extinction|
62753622|NCT05718271|NO_INTERVENTION|No explicit instructions|
61986509|NCT05825937||Elective Cardiac Surgery Patients|Patients having elective cardiac surgery, who have given written consent, will have the ClearSight device, along with the standard radial arterial line.
62556361|NCT03337061|EXPERIMENTAL|Experimental (Mindfulness)|This arm will receive mindfulness-based interventions through a mobile application
61986510|NCT05825937||Elective Neurointerventional Surgery Patients|Patients having elective neurointerventional surgery, who have given written consent, will have the ClearSight device, along with the standard radial arterial line.
62556362|NCT03337061|NO_INTERVENTION|Control (Sleep Advice)|This is the control arm that will receive usual care
62753623|NCT04246333|NO_INTERVENTION|Gastric Feeds|Patients in this arm will receive feeds via the standard route which is gastric feeds.
62753624|NCT04246333|EXPERIMENTAL|Duodenal Feeds|Patients in this arm will receive feeds via the experimental route which is duodenal feeds.
62753625|NCT00395291|EXPERIMENTAL|MK-0677 then Placebo|MK-0677 and Placebo - All subjects were given MK-0677 for a 30 +/- 7 days and then they were given a placebo for 30 +/- 7 days.
62753626|NCT00395291|EXPERIMENTAL|Placebo then MK-0677|MK-0677 and Placebo - All subjects were given Placebo for a 30 +/- 7 days and then they were given MK-0677 for 30 +/- 7 days.
61986511|NCT03226340|EXPERIMENTAL|S-amlodipine + Chlorthalidone|patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
62556363|NCT01231893|EXPERIMENTAL|olfactory ensheathing cell recipient|
62556364|NCT01231893|ACTIVE_COMPARATOR|control|
62556365|NCT03376919|EXPERIMENTAL|CLs++|CLs ++ gait training
62556366|NCT01055756|EXPERIMENTAL|Test (Cloratadd D)|Loratadine + Pseudoephedrine sulfate Test
62556367|NCT01055756|ACTIVE_COMPARATOR|Comparator (Claritin D)|Loratadine + Pseudoephedrine Comparator
62753627|NCT02663466||Recurrent Group|Patients with clinically confirmed recurrence of sacrococcygeal pilonidal sinus following Limberg flap surgery were eligible (recurrent group, RG). They were evaluated for erroneous off-midline closures as an exposure variable.
62753628|NCT02663466||Nonrecurrent Group|Patients who underwent same surgery from the January 2008 to July 2015 but have not had recurrence in the five-year follow-up period (non-recurrent group, NRG) were accepted eligible. They were evaluated for erroneous off-midline closures as an exposure variable.
62753629|NCT03676543|EXPERIMENTAL|Timed repetitive sensory stimulation|Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures
62753630|NCT06506032||Patients treated with NPWT with DSWI|Patients with deep sternal wound infection were enrolled in this study group.
62753631|NCT06506032||Patients without DSWI after cardiac surgery|Patients without deep sternal wound infection after cardiac surgery were enrolled in this study group.
62753632|NCT03515551|EXPERIMENTAL|Phase 1: Dose Escalation|Four fixed-dose, dose escalation cohorts (Cohorts 1 to 4) and 3 intrapatient dose escalation cohorts (Cohorts 5 to 7) to establish the MTD/RP2D of IMCnyeso.
62753633|NCT03515551|EXPERIMENTAL|Phase 2: Dose Expansion|Three planned cohorts treated at the RP2D to make a preliminary assessment of the anti-tumor activity of IMCnyeso. Phase 2 was not initiated and data were not collected.
62753634|NCT02312791||Palliative Patients|Inpatients evaluated for palliative radiation therapy.
62753635|NCT02925078|OTHER|<2 mm mucosa thickness|A Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) will be placed in subjects that have \<2 mm mucosa thickness.
62753636|NCT02925078|OTHER|≥2 mm mucosa thickness|A Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) will be placed in subjects that have ≥2 mm mucosa thickness.
62753637|NCT06607458|EXPERIMENTAL|Melphalan/HDS followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab|Melphalan/HDS is given as an infusion of Melphalan into the hepatic artery under general anesthesia. This treatment is administered twice, 8 weeks apart. Following 2 treatments with Melphalan/HDS, Trifluridine-tipiracil is given 35 mg/m2 up to a maximum of 80 mg per dose orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle; and intravenous (IV) bevacizumab 5 mg/kg body weight on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity
62753638|NCT06607458|ACTIVE_COMPARATOR|Trifluridine-tipiracil plus Bevacizumab Alone|Trifluridine-tipiracil plus Bevacizumab is the standard of care for patients with metastatic colorectal cancer. Trifluridine-tipiracil is given 35 mg/m2 up to a maximum of 80 mg per dose orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle; and intravenous (IV) bevacizumab 5 mg/kg body weight on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity
62753639|NCT06605352|EXPERIMENTAL|Pneumonia Panel|"The BIOFIRE®FILMARRAY® Pneumonia Panel is the only FDA approved mPCR test that can test 18bacteria (11 Gram negative, 4 Gram positive and 3 atypical), 7 antibiotic resistance markers, and 9 viruses in one test within 45 minutes.~Using rapid diagnostic test to improve the proportion of antibiotics change, including escalation, de-escalation, discontinuation, or addition of antimicrobial medications in 24 hours within sample collection."
62753640|NCT06605352|NO_INTERVENTION|Control group|Using current methods (empirical antibiotics) to treat patents with suspected bacterial infections.
62556368|NCT03119870|EXPERIMENTAL|1|Each subject will conduct 3 sessions, i.e. a training session, an anatomical MRI session and an EEG session. The first session will be to train the subject to carry out the different behavioral tasks that he will then have to perform during the session of EEG.
62556369|NCT00681343|EXPERIMENTAL|A|Thymoglobulin Induction
62556370|NCT00681343|EXPERIMENTAL|B|Campath-1H Induction
62556371|NCT00681343|EXPERIMENTAL|C|Daclizumab Induction
62556372|NCT05876806|EXPERIMENTAL|Dabrafenib + Trametinib|Subjects will receive Dabrafenib 150 mg twice daily orally plus Trametinib 2 mg once daily orally on a continuous basis. A treatment cycle is 28 days in duration. Subjects will continue treatment until an unacceptable toxicity, disease progression, or death occurs.
62753641|NCT01904643|EXPERIMENTAL|Treatment (lenalidomide, combination chemotherapy)|"LENALIDOMIDE PRIMING: Patients receive lenalidomide PO for 5 or 7 days.~RE-INDUCTION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-5. Patients failing to achieve blast count \< 5% at 21 days may receive a second course of induction therapy. Patients achieving complete remission proceed to lenalidomide priming.~LENALIDOMIDE PRIMING: Within 4-6 weeks, patients receive lenalidomide PO for 5 or 7 days and then proceed to consolidation therapy.~CONSOLIDATION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-4. Treatment repeats every 28-35 days for up to 2 courses in the absence of disease progression or unacceptable toxicity."
62753642|NCT01161550|EXPERIMENTAL|Arm 1|"GCSF 300 mcg SC Days 1-6~Cladribine 5 mg/m2 IV Days 2-6~Cytarabine 2 mg/m2 IV Days 2-6~ATRA 15 mg/m2 PO QD Days 7-20~Midostaurin 25 mg PO BID Days 7-20"
62753643|NCT01161550|EXPERIMENTAL|Arm 2|"GCSF 300 mcg SC Days 1-6~Cladribine 5 mg/m2 IV Days 2-6~Cytarabine 2 mg/m2 IV Days 2-6~ATRA 15 mg/m2 PO QD Days 7-20~Midostaurin 50 mg PO BID Days 7-20"
62753644|NCT05929118|EXPERIMENTAL|Aquatic Rehabilitation|Each group performed 70-90 minutes per session for a total of 6 interventions, all of which included warm-up activities, mobility training, strength training, functional exercise, and finishing activities. Each training was conducted 1-2 days apart, 2-3 times per week, and the training was completed within 2-3 weeks.
62753645|NCT05929118|EXPERIMENTAL|Land-based Rehabilitation|Each group performed 70-90 minutes per session for a total of 6 interventions, all of which included warm-up activities, mobility training, strength training, functional exercise, and finishing activities. Each training was conducted 1-2 days apart, 2-3 times per week, and the training was completed within 2-3 weeks.
62753646|NCT02103725|EXPERIMENTAL|pimecrolimus 10 mg/g cream|Active drug
62753647|NCT02103725|PLACEBO_COMPARATOR|Vehicle cream|Placebo drug
62753648|NCT03062553|EXPERIMENTAL|MCT + Neuromodulation (MCT-N)|"Participants (n=50) randomly assigned to the MCT-N condition will undergo transcranial alternating current stimulation (tACS) prior to participation in MCT.~Neuromodulation involving tACS will target increasing the power of the alpha band at dorsomedial prefrontal regions, and this is expected to also decrease the power of the beta band in ventro-medial regions. This will be confirmed by EEG recordings and source estimation during a task.~The Metacognitive Training (MCT) group intervention will consist of an 8-module cycle occurring twice a week for 4 weeks, for a total of 8 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects."
62753649|NCT03062553|EXPERIMENTAL|Sham/MCT group (MCT- S)|"Participants (n=50) randomly assigned to the Sham/MCT (MCT-S) condition will undergo the application of random patterns of low-grade currents to the same brain region as the neuromodulation condition prior to participation in MCT.~MCT is a four week program with eight one-hour sessions. MCT can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of an 8-module cycles occurring twice a week for 4 weeks, for a total of 8 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects."
62753650|NCT03062553|EXPERIMENTAL|Neuromodulation/Treatment as Usual TAU-N|"Participants (n=50) randomly assigned to the Neuromodulation/TAU (TAU - N) condition will undergo transcranial alternating current stimulation (tACS) prior to being placed on the TAU waitlist.~Neuromodulation involving tACS will target increasing the power of the alpha band at dorsomedial prefrontal regions, and this is expected to also decrease the power of the beta band in ventro-medial regions. This will be confirmed by EEG recordings and source estimation during a task.~TAU is a four week waitlist control group."
62753651|NCT04369118|EXPERIMENTAL|Conventional follow-up+chest wall restriction belt|Patients in this group benefit from conventional post-operative follow-up and wear the selective chest wall restriction belt in parallel. Patients in this group benefit from conventional post-operative follow-up . From Day 1 to Month 1
62753652|NCT04369118|ACTIVE_COMPARATOR|conventional postoperative follow-up|Patients in this group benefit from conventional post-operative follow-up . From Day 1 to Month 1
62753653|NCT04872348||Eyes receiving OMNI intervention after medication washout|
62753654|NCT04872348||Eyes receiving OMNI intervention without medication washout|
62753655|NCT01118169||Veterans|
62753656|NCT06490068|EXPERIMENTAL|LTC004+Toripalimab|Eligible subjects will receive LTC004 on day 1 of Week 1 and day 1 of week 3. Beginning at week 5, all subjects will receive LTC004 in combination with Toripalimab.
62753657|NCT03334851|EXPERIMENTAL|Part A, Cohort 1|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration
62753658|NCT03334851|EXPERIMENTAL|Part A, Cohort 2|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
62753659|NCT03334851|EXPERIMENTAL|Part A, Cohort 3|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
62753660|NCT03334851|EXPERIMENTAL|Part A, Cohort 4|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
62753661|NCT03334851|EXPERIMENTAL|Part A, Cohort 5|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
62753662|NCT03334851|EXPERIMENTAL|Part A, Cohort 6|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
62753663|NCT03334851|EXPERIMENTAL|Part A, Cohort 7|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
62753664|NCT03334851|EXPERIMENTAL|Part A, Cohort 8|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
62753665|NCT03334851|EXPERIMENTAL|Part B, Cohort 1|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous administration.
62753666|NCT03334851|EXPERIMENTAL|Part B, Cohort 2|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
62753667|NCT03334851|EXPERIMENTAL|Part B, Cohort 3|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
62753668|NCT03334851|EXPERIMENTAL|Part B, Cohort 4|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
62753669|NCT03334851|EXPERIMENTAL|Part B, Cohort 5|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
62753670|NCT03334851|EXPERIMENTAL|Part B, cohort 6|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
62753671|NCT01456195|PLACEBO_COMPARATOR|Placebo|Fasiglifam placebo-matching tablets, orally, once daily for up to 24 weeks.
62753672|NCT01456195|EXPERIMENTAL|Fasiglifam 25 mg|Fasiglifam 25 mg, tablets, orally, once daily for up to 24 weeks.
62753673|NCT01456195|EXPERIMENTAL|Fasiglifam 50 mg|Fasiglifam 50 mg, tablets, orally, once daily for up to 24 weeks.
62753674|NCT02737553|ACTIVE_COMPARATOR|enclosed morcellation|"In this group, after extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9.~doi: 10.1097/AOG.0000000000000823.)."
61986512|NCT03226340|ACTIVE_COMPARATOR|S-amlodipine + Telmisartan|patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
61986513|NCT01057420|OTHER|Inhalation of 80% Oxygen|Inhalation of 80% Oxygen by nonrebreathing reservoir face masks for 4 hours
61986514|NCT02591355|EXPERIMENTAL|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma injection
61986515|NCT02591355|PLACEBO_COMPARATOR|Saline|Saline solution injection
61986516|NCT04466540|EXPERIMENTAL|Hydroxychloroquine (HCQ)|HCQ group participants will receive a dose of 400mg twice daily (BID) in the first day, and a dose of 400 mg once daily (OD) from the second day of treatment, in a total of 7 days.
62556373|NCT06261424|NO_INTERVENTION|Control group|The control group will receive their usual care and will be asked to continue their usual activities and exercises for the whole project duration. Only one clinical guide exists for ataxia interventions and no specific guidelines for physiotherapy and occupational therapy interventions are specified in this guide in terms of frequency, duration and type of interventions that are effective with this population. Patients generally have an annual follow-up with a doctor or a clinical nurse at a Neuromuscular Diseases Clinic. Patients are then referred if needed for follow-up with the physiotherapist and occupational therapist. Typically, patients are referred to physiotherapy for mobility-related needs such as the introduction of a walking aid, orthotic and sometimes teaching an exercise program. In occupational therapy, patients are referred for needs such as the introduction of technical aids, home adaptation or the introduction of a wheelchair.
62556374|NCT06261424|EXPERIMENTAL|Intervention group|The intervention group will follow a 12-week rehabilitation program, 3 times a week (two sessions in a therapy room and one session of aquatherapy).
62556375|NCT01602068|EXPERIMENTAL|Dexamethasone Phosphate Ophthalmic|Dexamethasone Phosphate Ophthalmic: (40 mg/mL) solution delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)
62556376|NCT01602068|PLACEBO_COMPARATOR|100 mM Sodium Citrate Buffer|Placebo (100 mM sodium citrate buffer solution) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)
62753675|NCT02737553|ACTIVE_COMPARATOR|vaginal morcellation|In this group, after extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
62377449|NCT04785144|EXPERIMENTAL|Arm 2E|100 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1, and 100 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 29 in COVID-19 naïve participants. N=20
62753676|NCT05504265|OTHER|Postoperative NSAIDs|
62753677|NCT05504265|EXPERIMENTAL|Preemptive analgesia followed by Postoperative NSAIDs|
62753678|NCT05504265|EXPERIMENTAL|Postoperative patient-controlled analgesia pump|
62753679|NCT06608628|EXPERIMENTAL|Experimental group|Patient safety will play the escape room game.
62753680|NCT06608628|ACTIVE_COMPARATOR|Control Group|"The control group will receive traditional training.~."
62753681|NCT04919226|EXPERIMENTAL|Peptide Receptor Radionuclide Therapy (PRRT) Arm|
62753682|NCT04919226|ACTIVE_COMPARATOR|CAPTEM(Capecitabine-Temozolomide), Everolimus, FOLFOX(Folinic acid + Fluorouracil + Oxaliplatin)|
62753683|NCT01452230|EXPERIMENTAL|Supervised physical activity|
62753684|NCT01452230|NO_INTERVENTION|Usual care|
62753685|NCT00802191||Control Group|Participants with no movement disorders.
62753686|NCT00802191||Movement Disorders Participants|Participants have a movement disorder
62753687|NCT06605014||SOMADC-AC Cohort|"1. Asymptomatic adult volunteers~2. Patients admitted with TIA~3. Patients admitted with acute ischemic stroke"
62753688|NCT06142396|EXPERIMENTAL|Dara-CyBorD|Induction treatment with daratumumab-hyaluronidase (dara SC) in combination with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for four cycles of 28 days, followed by restaging with repeat PET-CT, bone marrow evaluation, and myeloma serological testing.
62753689|NCT06053801||Xolair|Chinese adolescents with Chronic Spontaneous Urticaria (CSU) inadequately controlled with H1 antihistamines
62753690|NCT06334081|EXPERIMENTAL|Group A dental implant placement by undersized drilling technique.|8 dental implants placed in the healed alveolar posterior maxillary ridge using undersized drilling technique
62753691|NCT06334081|EXPERIMENTAL|Group B dental implant placement by single drilling technique|8 dental implants placed in the healed alveolar posterior maxillary ridge using singledrilling technique
62753692|NCT05908526|EXPERIMENTAL|Treatment|Participants will start on 10mg suvorexant, po, qhs, including instructions on dosage, expectations, and potential side effects, for two nights. Following this low-dose run-in period, individuals in the treatment condition will be increased to 20mg for a 14-day active treatment period (i.e.,16 nights taking a pill). Other assessments include self-report research questionnaires and cognitive testing (completed at baseline and post-treatment), as well as EMA surveys, daily sleep diaries, and actigraphy.
62753693|NCT05908526|PLACEBO_COMPARATOR|Placebo|Participants in the control condition will take placebo (no drug) pill form, po, qhs, including instructions on dosage, expectations, and potential side effects for (16 nights taking a pill). Other assessments include self-report research questionnaires and cognitive testing, daily sleep diaries, and actigraphy.
62753694|NCT01076062|NO_INTERVENTION|Expectant management (EM) arm|Standard of care: routine clinic appointments until they deliver, fetal heart rate and contraction monitoring during their 41st week if not delivered. Also if they have not gone into labor the subjects will be scheduled for an induction by 42 weeks.
62753695|NCT01076062|EXPERIMENTAL|Induction of Labor (IOL) arm|Elective induction of labor at 39 weeks.
62753696|NCT06140381|ACTIVE_COMPARATOR|CTG|In conventional therapy, the treatment plan is determined based on medical opinion. After admission, each patient undergoes several multidisciplinary assessments aimed at objectively determining the care based on their needs. In this group, patients received only conventional rehabilitation. This will carry out in the same manner as a regular practice of the clinic. 3 sessions per week
62556377|NCT02367976|EXPERIMENTAL|rhprouk|rhprouk to be administrated in 60 minutes.
62556378|NCT02367976|NO_INTERVENTION|controlled|The controlled arm patients will be administrated in 90 minutes after randomized.
62556379|NCT04006002||Endoscopic Sleeve Gastrectomy|This group includes all patient who undergo Endoscopic Sleeve Gastrectomy for weight loss
62556380|NCT04006002||Laproscopic Sleeve Gastrectomy|This group includes all patient who undergo Laproscopic Sleeve Gastrectomy for weight loss
62556381|NCT00544635|EXPERIMENTAL|A|scars will be treated with light
62556382|NCT00544635|PLACEBO_COMPARATOR|B|no intervention
61986517|NCT04466540|PLACEBO_COMPARATOR|Placebo|The placebo group will follow the same regimen of administration
61986518|NCT04119856|OTHER|Intervention group|"Affiliation with outgoing lung team~* Instructions and teaching by the outgoing lung team.~* Needs-based consultation at Dept. of Respiratory Diseases and Allergy.~* Contact to the outgoing lung team in case of exacerbation of COPD."
62556383|NCT00838526|EXPERIMENTAL|1|
62556384|NCT00838526|ACTIVE_COMPARATOR|2|
62556385|NCT03293537|EXPERIMENTAL|Patients with dementia|The subject will be informed of the procedure and their task before the sensors are attached. Electrodermal activity (EDA) and heart rate (HR) will be continuously monitored while the subject views the image sequence on a PC monitor. EDA will be measured using electrodes attached to the middle (D3) and ring finger (D4). Heart rate will be measured using an infrared pulseoximeter attached to one of the free digits of the hand. A pulseoximeter is a non-invasive sensor, using tissue absorption of infrared light to determine blood-oxygen saturation (SaO2). EDA and HR will be recorded concurrently using commercial software. Data analysis will involve both commercial and in-house software.
62556386|NCT06345911|EXPERIMENTAL|Experimental group|The animal characters were shown to the child before the bloodletting procedure. The child was asked to choose one of them and the one chosen by the child was attached to the vacutainer.
62753697|NCT06140381|EXPERIMENTAL|ETG|In the absence of a standardized eccentric isokinetic training protocol established for hemiparetic subjects on the plantar flexor muscles, the protocol designed for this study drew inspiration from the one established by Clark and Patten. (2013) and by Harris-Love et al. (2017).This protocol allows the introduction of an eccentric stimulus for individuals who are new to this type of training and progressively advances their program to include workload levels sufficiently to stimulate muscle plasticity optimally, thereby inducing skeletal muscle adaptations. 3 sessions per week
62753698|NCT03042377|ACTIVE_COMPARATOR|Single-Visit Retreatment|Root canal retreatment were performed according to the guidelines for single-visit endodontic treatments.
62377450|NCT04785144|EXPERIMENTAL|Arm 2F|50 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1, and 50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 29 in COVID-19 naïve participants. N=20
62377451|NCT04785144|EXPERIMENTAL|Arm 2G|50 mcg of mRNA-1273 and 50 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
62377452|NCT04785144|EXPERIMENTAL|Arm 2H|25 mcg of mRNA-1273 and 25 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
62377453|NCT01269489||general population|a representative sample from general Slovenian population
62377454|NCT02393612|EXPERIMENTAL|DP-R202|Patients administrate DP-R202 (Sarpogrelate 300mg) once a day for 12 weeks
62377455|NCT02393612|ACTIVE_COMPARATOR|Anplag tab|Patients administrate Anplag tab (Sarpogrelate 100mg) 3 times a day for 12 weeks
62377456|NCT02280109|ACTIVE_COMPARATOR|Tenofovir Gel|Women will receive a single dose of tenofovir gel (1%;equivalent to 40 mg in 4ml's of gel) to determine the pharmacokinetics of tenofovir in the blood, cervical tissue, and cervicovaginal fluid.
62377457|NCT02280109|ACTIVE_COMPARATOR|Tenofovir Film|Women will receive a single dose of tenofovir film (1.3%;40 mg) to determine the pharmacokinetics of tenofovir in the blood, cervical tissue, and cervicovaginal fluid.
62377458|NCT04210232|EXPERIMENTAL|TECNIS® TORIC II Intraocular Lens (IOL)|Subjects will be implanted with the TECNIS Toric II IOL in one or both eyes qualified for study inclusion
62377459|NCT01680146|ACTIVE_COMPARATOR|PRO|Subjects will ingest 20 g of intrinsically labeled casein dissolved in water
62377460|NCT01680146|EXPERIMENTAL|PRO+FAT|Subjects will ingest 20 g of intrinsically labeled casein plus 26.7 g of anhydrous milk fat dissolved in water
61986519|NCT04119856|NO_INTERVENTION|Control group|"The usual practice~* Scheduled consultations at Dept. of Respiratory Diseases and Allergy.~* Contact to GP/doctor on call in case of exacerbation of COPD."
62556387|NCT06345911|NO_INTERVENTION|Control group|The child was subjected to routine bloodletting intervention with the vacutainer.
62556388|NCT06048952|ACTIVE_COMPARATOR|Music Therapy|30 Minutes before evaluate PONV at 2nd,4th,6th,12th,24th hours
61986520|NCT04371679||Endotracheal intubation and ventilation|Patients admitted at ICU that are intubated and ventilated
61986521|NCT04371679||Non-Invasive Ventilation|Patients admitted at ICU who are non-invasively ventilated
61986522|NCT00778011|ACTIVE_COMPARATOR|1|
61986523|NCT00778011|ACTIVE_COMPARATOR|2|
61986524|NCT00778011|ACTIVE_COMPARATOR|3|
62556389|NCT06048952|NO_INTERVENTION|No Intervention|No intervention performed PONV evaluated at 2nd,4th,6th,12th,24th hours
62556390|NCT01268462|EXPERIMENTAL|Heliox + PEP (Group 1)|
62556391|NCT01268462|EXPERIMENTAL|Oxygen+PEP(Group 2)|
62556392|NCT01268462|EXPERIMENTAL|Heliox ( Group 3)|
62556393|NCT01268462|ACTIVE_COMPARATOR|Oxygen (Group 4)|
62753699|NCT03042377|ACTIVE_COMPARATOR|"Multiple-Visit-Calcium Hydroxide"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
62753700|NCT03042377|ACTIVE_COMPARATOR|"Multiple-Visit-Corticosteroid Paste"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
62753701|NCT03042377|ACTIVE_COMPARATOR|"Multiple-Visit-Antibiotic Paste"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
62753702|NCT02319161||Group I|Group I: the patients with systolic blood pressure above to 150 mmHg following tourniquet inflation and in which bolus dose of calcium channel blocker 10 mg was administered by intravenous route.
62753703|NCT02319161||Group II|Group II: the patients with systolic blood pressure above to 150 mmHg following tourniquet inflation and in which bolus dose of beta blocker 0.5mg/kg was administered by intravenous route
62753704|NCT03691818|EXPERIMENTAL|Low-dose test drug group|X0002 Spray 1 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
62753705|NCT03691818|ACTIVE_COMPARATOR|Low-dose active drug control group|Ibuprofen Tablet 400 mg/time, 3 times /day; X0002 Placebo Spray 1 Spray/time/Knee, 2 times/day.
62753706|NCT03691818|PLACEBO_COMPARATOR|Low-dose placebo control group|Placebo Spray 1 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times/day.
62753707|NCT03691818|EXPERIMENTAL|Medium-dose test drug group|X0002 Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
62753708|NCT03691818|ACTIVE_COMPARATOR|Medium-dose active drug control group|X0002 Placebo Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Tablet 400 mg/time, 3 times /day.
62753709|NCT03691818|PLACEBO_COMPARATOR|Medium-dose placebo control group|X0002 Placebo Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
62753710|NCT03691818|EXPERIMENTAL|High-dose test drug group|X0002 Spray 4 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
62753711|NCT03691818|ACTIVE_COMPARATOR|High-dose active drug control group|X0002 Placebo Spray 4 Spray/time/Knee, 2 times/day; Ibuprofen Tablet 400 mg/time, 3 times /day.
62753712|NCT03691818|PLACEBO_COMPARATOR|High-dose placebo control group|X0002 Placebo Spray 4 Spray/time/Knee, 2 times/day; Placebo Tablet 400 mg/time, 3 times /day.
62753713|NCT01552616|EXPERIMENTAL|Activation Treatment|
62753714|NCT01552616|NO_INTERVENTION|Usual Care|This arm will not receive any study-motivated intervention. Subjects will receive usual care, but will participate in outcomes assessments.
62753715|NCT03206632|EXPERIMENTAL|BI 690517 dose group 1|
62753716|NCT03206632|EXPERIMENTAL|BI 690517 dose group 2|
62753717|NCT03206632|EXPERIMENTAL|BI 690517 dose group 3|
62753718|NCT03206632|PLACEBO_COMPARATOR|Placebo|Matching placebo for each dose group
62753719|NCT03130387|OTHER|Office hysteroscopy|Examinatin with Office hysteroscope for women with abnormal uterine bleeding who had a history of previous cesarean section
62753720|NCT03650101||Hydrocephalus group|"Inclusion criteria:~1. Age less than six months~2. Symptomatic hydrocephalus characterized by abnormal rate of head growth, full anterior fontanel, ventriculomegaly~3. A parent or a guardian qualified by Ugandan law to give informed consent~4. Patients from Eastern, Central and Northern districts of Uganda, and in geographic proximity to CURE hospital will be eligible~Exclusion criteria:~1. Age greater than six months~2. No evidence of progressive hydrocephalus~3. Patients outside of the districts specified in the inclusion criteria"
62753721|NCT03650101||Control group|"Inclusion criteria:~1. Born at GA ≥ 37 weeks~2. Age less than six months at the time of enrollment~3. No known medical conditions~4. With a parent or a guardian qualified by Ugandan law to give informed consent~5. Parents live in one of the villages in the Mbale or Budaka District, in geographic proximity to CCHU.~Exclusion criteria:~1. Born at GA \< 37 weeks~2. Age greater than six months~3. Evidence of one or more medical conditions~4. Living outside of the districts specified in the inclusion criteria."
62753722|NCT01062841|ACTIVE_COMPARATOR|Intervention: Targeted Infection Control|Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
62753723|NCT01062841|NO_INTERVENTION|Control|Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.
62753724|NCT05088083|EXPERIMENTAL|DCB Treatment Group|Subjects treated with DCB
62753725|NCT04084548|EXPERIMENTAL|Lidocaine and placebo|Lidocaine and placebo
62753726|NCT04084548|EXPERIMENTAL|Ketamine and placebo|Ketamine and placebo
62753727|NCT04084548|EXPERIMENTAL|Lidocaine and ketamine|Lidocaine and ketamine
62753728|NCT04084548|PLACEBO_COMPARATOR|Placebo and placebo|Placebo and placebo
62753729|NCT01478230|EXPERIMENTAL|N1/3-I5|5 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits
62753730|NCT01478230|ACTIVE_COMPARATOR|NX-I10|10 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits.
62753731|NCT05774054|ACTIVE_COMPARATOR|A|patients received (30ml /kg) ringer's lactate solution after first presentation then norepinephrine was added when persistent mean arterial pressure (MAP)\> 65 mmHg despite adequate fluid resuscitation
62753732|NCT05774054|ACTIVE_COMPARATOR|B|patients received ( 30ml /kg) ringer's lactate solution after first presentation combined with norepinephrine infusion (0.05 mic/kg/min)
62753733|NCT01789138|EXPERIMENTAL|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention: see 'Interventions' for more details.
62753734|NCT01789138|NO_INTERVENTION|Adherence counseling, standard of care|Standard of care: Antiretroviral therapy adherence is discussed with patient (study participant) according to usual practice in the medical institution no special protocol followed.
62753735|NCT04679857|EXPERIMENTAL|UC|Total Knee Arthroplasty with an ultracongruent insert
62753736|NCT04679857|ACTIVE_COMPARATOR|PS|Total Knee Arthroplasty with posterior stabilized design
62753737|NCT01926418|NO_INTERVENTION|Control|The control group receives the TPB questionnaires but receives no intervention
62753738|NCT01926418|EXPERIMENTAL|Implementation intentions|Participants are asked to specify when, where and how they will use condoms in the future. They will be sent weekly email reminders of their implementation intentions.
62753739|NCT01926418|EXPERIMENTAL|Planning task|Participants will be asked to practice the Tower of Hanoi task four times per week for ten to fifteen minutes.
62753740|NCT03885232|EXPERIMENTAL|PIVOT with MI|Clinics with providers trained in the Presumptively Initiating Vaccines and Optimizing Talk with Motivational Interviewing intervention (PIVOT with MI)
62753741|NCT03885232|ACTIVE_COMPARATOR|Control|Control-Care as usual
62753742|NCT05709067|EXPERIMENTAL|Probiotic Arm|
62753743|NCT05709067|PLACEBO_COMPARATOR|Control|
62753744|NCT04125238|EXPERIMENTAL|Episodic Future Thinking (EFT)|Participants will generate positive future events they are looking forward to at five time points in the future (1 day, 1 week, 1 month, 3 months, 1 year, 5 years, and 25 years). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions.
62753745|NCT04125238|SHAM_COMPARATOR|Control Episodic Thinking (CET)|Participants will generate positive recent past events that have happened to them at five time points in the recent past (last night from 7pm-10pm, yesterday between 4pm-7pm, yesterday between 1pm-4pm, yesterday from 10am-12pm, yesterday between 7am-10am, the night before last between 7pm-10pm, and evening before last between 4pm-7pm). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions.
62753746|NCT02871713|ACTIVE_COMPARATOR|Intrathecal morphine|Intrathecal morphine 100 mcg
62753747|NCT02871713|EXPERIMENTAL|Quadratus lumborum block|Bilateral QLB with 20 ml of 0.5% ropivacaine per side (maximum total dose 3 mg/kg)
62753748|NCT02871713|EXPERIMENTAL|Intrathecal morphine + Quadratus lumborum block|Bilateral QLB with 20 ml of 0.5% ropivacaine per side (maximum total dose 3 mg/kg) + Intrathecal morphine 100 mcg
62753749|NCT04201366||Sample 1|All participants fulfilling the inclusion criteria.
62753750|NCT04201366||Sample 2|Participants fulfilling the inclusion criteria and reports no neck/shoulder pain at baseline.
62753751|NCT04986046|ACTIVE_COMPARATOR|Fruit and vegetable prescription|Fruit and vegetable incentive program
62753752|NCT04986046|EXPERIMENTAL|Fruit and vegetable prescription + Home Plate Lite|Fruit and vegetable incentive program + asynchronous, electronic resources delivered over six weeks
62753753|NCT04986046|EXPERIMENTAL|Fruit and vegetable prescription + Virtual Home Plate|Fruit and vegetable incentive program + 45-minute, virtual, small-group classes twice weekly for six weeks
62753754|NCT05385081|OTHER|genomic profiling|"After informed consent a PET/CT scan is performed to determine disease spread and the best location for core needle biopsi. Genomic profiling is performed using Next Generation Sequencing, NGS, genpanel analysis by Oncomine Comprehensive vs 3 The result of NGS is discussed at weekly local and national tumor board meeting to decide a possible targeted treatment offer based on genomic profiling or a possibly treatment offer in a clinical trial.~Timelines in the course of investigation will be calculated using date of informed consent, PET/CT scan, biopsy, tumor board and date of start of next treatment, progression and death.~If the genomic profiling results in a targeted treatment offer the Growth Modulation Index is calculated from progressions-free survival on recent and current treatment. Treatment given without an actionable target is likewise evaluated for efficacy."
62753755|NCT05184101|EXPERIMENTAL|Nebulised heparin|Participants assigned to 'nebulised heparin' will receive nebulised heparin in addition to the standard care required as determined by the treating team.
62753756|NCT05184101|NO_INTERVENTION|Standard care|Participants assigned to 'standard care' will receive the standard care required as determined by the treating team and will not be treated with nebulised heparin.
62753757|NCT04753658||Pediatric Neuroblastoma Patients Treated with Lorlatinib|
62753758|NCT03085628|EXPERIMENTAL|Oxytocin|Oxytoxin nasal spray
62753759|NCT03085628|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray
62753760|NCT01988532||Adult PWH|
62753761|NCT05247970|EXPERIMENTAL|Part 1: S-309309|Participants will receive S-309309 at specific timepoints in a fasted state.
62753762|NCT05247970|EXPERIMENTAL|Part 2: S-309309 and Midazolam|Participants will receive S-309309 and Midazolam at specific timepoints fed state.
62753763|NCT05247970|PLACEBO_COMPARATOR|Part 1 and 2: Placebo|Participants will receive a matching placebo to S-309309 at specific timepoints in either a fed or fasted state.
62753764|NCT05467761|EXPERIMENTAL|Oral and IV psilocybin|Psilocybin with psychological support: Psilocybin will be administered in the form of capsules, taken orally with water, at one visit. Psilocybin will be administered through IV at the other visit.
62753765|NCT06604793|EXPERIMENTAL|Creatine Bolus|(Serving 1: 5 grams of creatine monohydrate + 3 grams of placebo in the morning; Serving 2: 8 grams of placebo in the evening) for 21 days.
62753766|NCT06604793|EXPERIMENTAL|Creatine Intermittent|(Serving 1: 2.5 grams of creatine monohydrate + 5.5 grams of placebo in the morning; Serving 2: 2.5 grams of creatine monohydrate + 5.5 grams of placebo in the evening) for 21 days.
62753767|NCT06604793|PLACEBO_COMPARATOR|Placebo|(Servings 1: 8 grams of placebo in the morning; Serving 2: 8 grams of placebo in the evening) for 21 days.
62753768|NCT04796103|ACTIVE_COMPARATOR|Dextrose Prolotherapy Group|Patients diagnosed with chondromalacia patella
62753769|NCT04796103|PLACEBO_COMPARATOR|Serum Physiological Group|Patients diagnosed with chondromalacia patella
62753770|NCT02388490|EXPERIMENTAL|Brentuximab vedotin|Brentuximab vedotin is an antibody-drug conjugate (ADC) composed of the anti-CD30 chimeric immunoglobulin G1 (IgG1) monoclonal antibody cAC10 and the potent antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker. cAC10 binds to the CD30 antigen, which has a very low expression on normal cells but is found on some tumor cells.
62377461|NCT05727631|EXPERIMENTAL|gentle human touch|In the study, after the mother in the experimental group was dressed in a clean apron, she was allowed to wash and disinfect her hands. When the temperature of the mother's hand was measured with a non-contact thermometer, it was allowed to warm it under a radiant heater until it reached 34 ºC. The mother, who was informed about the method before, was allowed to place the palm of one hand on the baby's crown, with her fingertips touching the eyebrow line. She placed her other hand on her lower abdomen, encircling the baby's waist and hips. It has been provided to perform sensitive touch operation without pressure and massage. The mother started the gentle touch method 5 minutes before the blood draw, and continued to do the touching during the blood draw and 5 minutes after the blood draw was finished.
62377462|NCT05727631|NO_INTERVENTION|Control group|"The standard procedure of the clinic was applied to preterm infants in the control group. In the standard procedure of the clinic, the mother was with her baby in the blood collection room and did not perform any procedure.~IN ALL BABIES IN THE CONTROL AND EXPERIMENTAL GROUP., Before the procedure, 5 minutes after the procedure and 20 minutes after the procedure, the mother filled out the STAI-I form. The NIPS scale to measure the infant's pain was scored by two independent observers before, during, and five minutes after the procedure. KTA, SPO2 values of the baby were recorded before, during and five minutes after the procedure. The baby's crying time was started when the crying started, and stopped when the crying stopped."
62377463|NCT03109444||Hip Ultrasound of Newborn infants|Newborns born at CRMC (term newborns and pre-mature newborns over 32 weeks gestational age). This will include newborns cared for in the neonatal intensive care unit (NICU) over 32 weeks gestational age, and newborns cared for on the normal labor and delivery floor. the newborn will receive an ultrasound of their hips while in the hospital (done by a trained sonographer). This will happen in the patient's room with the LAR present. An ultrasound of the hip takes approximately 15 minutes and is non-invasive, non-painful and does not utilize any ionizing radiation. Newborns will be scheduled to return once a week until the newborn's hips reach criteria for normal hip morphology or the newborn reaches 6 weeks of corrected age.
62377464|NCT04261218|EXPERIMENTAL|Group 1 - Dose Finding|The first 3 patients enrolled in Group 1 will receive tomivosertib at a dose of 100 mg orally twice daily (BID), under fasting conditions, and will be assessed for dose limiting toxicities (DLTs) during this 'run-in' period. They will also receive the first cycle of tomivosertib IN COMBINATION with weekly paclitaxel in the 'post run-in' period. Depending on the occurrence/absence of DLTs, this first group of 3 patients may need to be expanded (up to 9 patients) or the trial may proceed to start enrollment in Group 2 (detailed in the arm below).
62377465|NCT04261218|EXPERIMENTAL|Group 2 - Dose Expansion|It is anticipated that Group 2 patients will receive tomivosertib at a dose of 100 mg orally twice daily (BID) during the 'run-in' period, which is taken in combination with weekly paclitaxel (according to market label) during the 'post run-in' period.
62377466|NCT03307213|EXPERIMENTAL|BioFreedom™CoCr|Patients with CAD will receive the BioFreedom™CoCr stent if randomised to this arm.
62377467|NCT03307213|ACTIVE_COMPARATOR|BioFreedom™ SS|Patients with CAD will receive the BioFreedom™SS stent if randomised to this arm.
62377468|NCT02324413|ACTIVE_COMPARATOR|clonidine|Clonidine intravenous 1 or 2 micrograms / kg
62377469|NCT02324413|PLACEBO_COMPARATOR|Placebo|
62377470|NCT04241536|OTHER|No arm|This is an epidemiologic study. No arms are considered.
61986525|NCT03966755|EXPERIMENTAL|UFA dietary recommendations|Dietary intervention aimed at increasing UFA consumption.
61986526|NCT03966755|NO_INTERVENTION|Standard dietary recommendations|Standard of care dietary recommendations as currently performed in the clinic (2015-2020 United States Department of Agriculture (USDA) Dietary Guidelines for Americans)
62377471|NCT03303872||AF-pacemaker registry|
62377472|NCT04844567|EXPERIMENTAL|COVVR_A|Participants in the COVVR_A arm complete the synchronous block first, followed by the asynchronous block.
62377473|NCT04844567|EXPERIMENTAL|COVVR_B|Participants in the COVVR_B arm complete the asynchronous block first, followed by the synchronous block.
62377474|NCT02237144|EXPERIMENTAL|Cash transfer|1500 taka ($18.75) per household distributed monthly
62377475|NCT02237144|EXPERIMENTAL|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
62377476|NCT02237144|EXPERIMENTAL|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
62377477|NCT02237144|EXPERIMENTAL|Cash transfer + BCC|1500 taka ($18.75) per household distributed monthly Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
62377478|NCT02237144|EXPERIMENTAL|Food transfer + BCC|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
62377479|NCT04945304||Magnetic bariatric surgery|Bariatric procedure performed in a human using magnetic assistance in the steps of the surgery
62377480|NCT01012037|EXPERIMENTAL|linagliptin low dose|linagliptin low dose twice daily
62377481|NCT01012037|PLACEBO_COMPARATOR|placebo|placebo matching linagliptin
62377482|NCT01012037|EXPERIMENTAL|linagliptin medium dose|linagliptin medium dose once daily
62753771|NCT04677400|EXPERIMENTAL|Experimental Group|Participants in the Experimental group start the MBA intervention immediately (Time 0; T0).
62377483|NCT03686462|EXPERIMENTAL|Virtual reality-based interactive treadmill training|In this group, the subjects will receive virtual reality (VR)-based interactive treadmill training. During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
62377484|NCT03686462|SHAM_COMPARATOR|Treadmill training without VR-based interaction|The subjects in this group will receive the treadmill gait training. Virtual reality environment will be provided during the gait training but no feedback and interaction will be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of treadmill-based training.
62753772|NCT04677400|ACTIVE_COMPARATOR|Waiting-list group|Participants in the waiting-list group start the MBA intervention at Time 1 (T1; 15 days after the Experimental group).
62753773|NCT03817320|EXPERIMENTAL|Ixazomib Dose Level 1 (Stratum A)|Patients will be treated on ixazomib at 1.6 mg/m\^2/day on Days 1, 4, 8, and 11. Vincristine IV at 1.5 mg/m\^2 on Days 1, 8, 15 and 22. Pegaspargase IV/IM at 2500 IU/m\^2 on Days 2 and 15, Doxorubicin at 60 mg/m\^2 on Days 1, Dexamethasone IV/PO at 10 mg/m\^2 continuous starting on Day 1 thru Day 14, and IT chemotherapy dependent on patient's CNS status at time of enrollment. This arm is the starting Dose Level for patients being enrolled.
62753774|NCT03817320|EXPERIMENTAL|Ixazomib Dose Level 2 (Stratum A)|Patients will be treated on ixazomib at 2.0 mg/m\^2/day on Days 1, 4, 8, and 11. Vincristine IV at 1.5 mg/m\^2 on Days 1, 8, 15 and 22. Pegaspargase IV/IM at 2500 IU/m\^2 on Days 2 and 15, Doxorubicin at 60 mg/m\^2 on Days 1, Dexamethasone IV/PO at 10 mg/m\^2 continuous starting on Day 1 thru Day 14, and IT chemotherapy dependent on patient's CNS status at time of enrollment. Patients will be treated at this arm Dose Level once patient accrual at Dose Level 1 has been completed and dose escalation is allowed as defined by the 3+3 design.
62753775|NCT03817320|EXPERIMENTAL|Ixazomib Dose Level -1 (Stratum A)|Patients will be treated on ixazomib at 1.2 mg/m\^2/day on Days 1, 4, 8, and 11. Vincristine IV at 1.5 mg/m\^2 on Days 1, 8, 15 and 22. Pegaspargase IV/IM at 2500 IU/m\^2 on Days 2 and 15, Doxorubicin at 60 mg/m\^2 on Days 1, Dexamethasone IV/PO at 10 mg/m\^2 continuous starting on Day 1 thru Day 14, and IT chemotherapy dependent on patient's CNS status at time of enrollment. This arm Dose Level -1 is needed only if de-escalation from Dose Level 1 is required.
62753776|NCT03817320|EXPERIMENTAL|Ixazomib Dose Level 1 (Stratum B)|Patients will be treated on ixazomib at 1.6 mg/m\^2/day on Days 1, 4, 8, and 11. Vincristine IV at 1.5 mg/m\^2 on Days 1, 8, 15 and 22. Pegaspargase IV/IM at 2500 IU/m\^2 on Days 2 and 15, Doxorubicin at 60 mg/m\^2 on Days 1, Dexamethasone IV/PO at 10 mg/m\^2 continuous starting on Day 1 thru Day 14, and IT chemotherapy dependent on patient's CNS status at time of enrollment. Leucovorin PO/IV at 5 mg/m\^2/dose X 2 doses given 24 and 30 hours after IT Methotrexate or Triple IT will also be given on this arm. This arm is only for patients with Down syndrome (Stratum B).
62753777|NCT05027126|ACTIVE_COMPARATOR|Group A: Dexketoprofen (Stadium®)|Reference Drug Pharmaceutical Form: Tablets Dosage: 25 mg Administration way: oral
62753778|NCT05027126|EXPERIMENTAL|Group B: Fixed dose Dexketoprofen-Vitamin B Complex|Fixed dose combination: Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin, Thiamine,and Pyridoxine. Administration way: oral
62753779|NCT02982317||Study group|All patients recruited will undergo the same protocol. An anesthesiologist will perform manual palpation of the patients lumbar spine and identification of the intervertebral spaces from L1-S1. A member of the UBC Department of Engineering will perform the US scanning and level identification using the novel US technology. In addition, freehand US will be used by two practitioners to determine the participant's lumbar level locations as per gold standard.
62377485|NCT00733473|ACTIVE_COMPARATOR|1 Budesonide|This arm consist 50 children with recurrent wheezing who are hospitalized for wheezing epizode. They received 1 mg nebulized budesonide 2 times a day upto 5 days
62377486|NCT00733473|PLACEBO_COMPARATOR|2 Placebo saline|This arm consist 50 children with recurrent wheezing who are hospitalized for wheezing epizode. They received 2ml of nebulized saline 2 times a day upto 5 days
62377487|NCT00964769|EXPERIMENTAL|Pneumococcal polysaccharide vaccine|The immunogenic response to the pneumococcal polysaccharide vaccine was compared between children, adults and elderly.
62377488|NCT06283303|EXPERIMENTAL|Combination therapy with T3011 hepatic artery infusion , Regorafenib and Toripalimab|The study was divided into two dose groups, T3011 3×10\^8 plaque forming unit(PFU)/time (HAI) and T3011 1×10\^9 PFU/time (HAI), with a 3+3 dose escalation design. After the completion of the lead-in period, the patient entered the combination therapy period（combination therapy with T3011 hepatic artery infusion , Regorafenib and Toripalimab）,and the dosage of T3011 was determined according to the safety observation results of the lead-in period, the dose of toripalimab was 80mg intravenously, and regorafenib was 80mg orally once a day.
62753780|NCT04446130|EXPERIMENTAL|Decitabine combined with HAAG Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed T-ALL/LBL and T/M-MPAL patients.
62753781|NCT04872933|OTHER|Non-Waitlist|Patient will attend a total of 3 virtual assessments whilst in the study: at baseline, at 12 weeks then at 6 months. The online intervention will commence straight after completing the baseline visit.
62753782|NCT04872933|OTHER|Waitlist|Patient will be complete assessments at baseline and 12 weeks but will only start the online intervention after the 12-week assessment.
62753783|NCT04778163|EXPERIMENTAL|Humor group 1|"Group 1 - experimental - will participate in a humor group with a one-hour group session per week for 6 weeks."
62753784|NCT04778163|NO_INTERVENTION|Control group 2|"Group 2 - the control group - will follow an usual treatment regimen for 6 weeks. At the end of the Humor Group of group 1, the 2 groups of patients will undergo a second series of tests identical to those of the pregroup. The paired patients should be randomly assigned. The control group will do the Humor Group after 6 weeks."
62753785|NCT05946785|PLACEBO_COMPARATOR|local lactated Ringer's perfusion|lactated Ringer's is perfused through the microdialysis fiber to serve as the vehicle control
62753786|NCT05946785|EXPERIMENTAL|local ascorbate perfusion|local ascorbate is perfused through the microdialysis fiber to serve as the antioxidant experimental treatment
62753787|NCT05946785|EXPERIMENTAL|local L-NAME perfusion|local L-NAME is perfused through the microdialysis fiber to inhibit nitric oxide synthase
62753788|NCT02545114|OTHER|Tolvaptan|Intervention arm. Open label, no control group
62753789|NCT02136680|ACTIVE_COMPARATOR|Patients at Intervention Site|Staff receives CASA Education
62753790|NCT02136680|NO_INTERVENTION|Patients at CONTROL site|Staff does not receive CASA Education
62753791|NCT01010568|EXPERIMENTAL|Ofatumumab and Bendamustine|Ofatumumab and Bendamustine
62753792|NCT05566431|ACTIVE_COMPARATOR|ICP monitoring based Protocol|Arm one will use a consensus-developed management protocol for paediatric severe traumatic brain injury based on recommendations from the Brain Trauma Foundation Guidelines, which uses invasive intracranial pressure monitoring
62753793|NCT05566431|ACTIVE_COMPARATOR|No ICP Monitoring Protocol CREVICE|Arm two will use the Consensus-Revised Imaging and Clinical Examination (CREVICE) management protocol for paediatric severe traumatic brain injury based on imaging and clinical examination in the absence of invasive intracranial pressure monitoring
62753794|NCT04861467|EXPERIMENTAL|Experimental: Camrelizumab|camrelizumab as maintenance therapy after Chemoradiation(evaluation results：PR/SD)
62753795|NCT04861467|NO_INTERVENTION|observation|observation after Chemoradiation
62753796|NCT04861467|EXPERIMENTAL|Exploration：Camrelizumab|camrelizumab for maintenance after chemoradiation( evaluation results：CR)
62753797|NCT00845260|EXPERIMENTAL|Internet CBT|Internet-based cognitive behavior therapy (CBT).
62753798|NCT00845260|EXPERIMENTAL|Group CBT|Group cognitive behavior therapy (CBT).
62753799|NCT04510948|EXPERIMENTAL|Intervention (Implementing Patient Priorities Care)|Patient Priorities Care requires the elicitation and documentation of patient health outcome goals and care preferences and the alignment of clinical care with health goals and healthcare preferences (collectively referred to as health priorities). Participants will be contacted by a trained priorities facilitator in-person or over the phone to elicit their health priorities. This information will be documented in the PPC- GOALS AND PREFERENCES form in the EHR and shared with the clinicians who will then use the Patient Priorities Care approach with patients to inform and guide treatment decisions.
62753800|NCT04510948|NO_INTERVENTION|Usual Care (Not implementing PPC)|Patients will receive routine clinical care.
62753801|NCT06035393|EXPERIMENTAL|Treatment group A|Drug1 dose 1+Drug 3
62753802|NCT06035393|EXPERIMENTAL|Treatment group B|Drug1 dose 2+Drug 2+Drug 3
62753803|NCT06035393|EXPERIMENTAL|Treatment group C|Drug1 dose 3+Drug 2+Drug 3
62753804|NCT06035393|OTHER|Treatment group D|Drug 2+Drug 4
62753805|NCT05868005|EXPERIMENTAL|Primary care centres with the ISMiHealth software tool.|Primary care centres implementing the screening programme through the ISMiHealth software (tool-based arm).
62753806|NCT05868005|NO_INTERVENTION|Primary care centres that follow current routine care.|Primary care centres that follow the current practices in routine care (non tool-based arm).
62753807|NCT02514694|ACTIVE_COMPARATOR|LEO 32731|Active
62753808|NCT02514694|PLACEBO_COMPARATOR|Placebo|Placebo
62753809|NCT04871893|OTHER|Treatment with the blood-gas exchanger multiECCO2R for CO2 removal|Treatment of patients suffering from hypercapnia due to acute lung failure and acute kidney injury (AKI). Patients will be treated up to 72 hours with CVVHD/HDF with a standard multiFiltrate blood line kit (multiFiltrate or multiFiltrate Pro). In order to perform an ECCO2R procedure during CVVHD/HDF treatment, the blood-gas exchanger multiECCO2R is inserted in a specifically designed blood line kit downstream of the hemodialyzer.
62377489|NCT04337528|EXPERIMENTAL|Thrust Group|Participant will receive the thrust technique manipulation of the affected sacroiliac joint.
62753810|NCT04155346|EXPERIMENTAL|Facility-based prehabilitation (FBP)|"Exercise~* Three supervised exercise training sessions of aerobic and resistance exercises. Includes high-intensity interval aerobic training and whole-body resistance exercises (60 min/session)~* Specific exercises will also be prescribed to prepare regional and/or compensatory tissues for surgery~* Exercise session will be supervised by a Registered Kinesiologist/Exercise Physiologist~Nutrition~* Participants will receive an individualized nutrition assessment and counselling within the first week of prehabilitation and again in the week prior to surgery~* All sessions will conducted by a Registered Dietitian (60 min/session)~* Participants will also receive 20g of protein supplementation daily~Stress management and behavioural support~* Participants will be scheduled for a psychoeducation session within the first week of prehabilitation and again in the week prior to surgery~* All sessions will conducted by a psychologist (60 min/session)"
62753811|NCT04155346|EXPERIMENTAL|Home-based prehabilitation (HBP)|"Exercise~* Three unsupervised, home-based exercise training sessions of aerobic and resistance exercises. Includes continuous moderate-intensity aerobic training and whole-body resistance exercises (60 min/session)~* Specific exercises will also be prescribed to prepare regional and/or compensatory tissues for surgery~* Exercise session will be supervised by a Registered Kinesiologist/Exercise Physiologist~Nutrition~* Participants will receive an individualized nutrition assessment and counselling within the first week of prehabilitation and again in the week prior to surgery~* All sessions will conducted by a Registered Dietitian (60 min/session)~* Participants will also receive 20g of protein supplementation daily~Stress management and behavioural support~* Participants will be scheduled for a psychoeducation session within the first week of prehabilitation and again in the week prior to surgery~* All sessions will conducted by a psychologist (60 min/session)"
62753812|NCT04155346|NO_INTERVENTION|Usual Care|- This group will receive no additional intervention from the routine care.
62753813|NCT03905369|EXPERIMENTAL|Decision aid, SDM booster and deliberation training|In the first arm, patients have COMBO, consisting of the decision aid, the SDM-booster, and the values deliberation training for physicians
62753814|NCT03905369|ACTIVE_COMPARATOR|Deliberation training|In the second arm, patients have the values deliberation training for physicians alone.
62753815|NCT00000273|EXPERIMENTAL|Opiates|Opiate-dependent individuals who were currently not seeking treatment for their drug use, completed the 6-week protocol.
62753816|NCT00785421|EXPERIMENTAL|A|"Patients with KPS \> 80% and normal kidney function receive GFFC + LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.).~Pts with KPS \< 80 % and increased creatinin plasma levels (\>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) + Enoxaparin 1mg/kg daily s.c.~After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) + Enoxaparin 40mg/d s.c."
62753817|NCT00785421|ACTIVE_COMPARATOR|B|"Patients with KPS \> 80% and normal kidney function receive GFFC - LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w - Enoxaparin 1mg/kg daily s.c.).~Pts with KPS \< 80 % and increased creatinin plasma levels (\>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) - Enoxaparin 1mg/kg daily s.c.~After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) - Enoxaparin 40mg/d s.c."
62377490|NCT04337528|ACTIVE_COMPARATOR|Muscle-energy group|Participant will receive the muscle-energy technique manipulation of the affected sacroiliac joint.
62377491|NCT04337528|PLACEBO_COMPARATOR|Placebo Group|Participant will receive a placebo manipulation of the affected sacroiliac joint.
62377492|NCT01802294|EXPERIMENTAL|Parenting Program|12-week group-based parenting program (Sinovuyo Caring Family Programme) delivered in weekly sessions. Program is manualized.
62377493|NCT01802294|NO_INTERVENTION|Wait-list control|Wait-list control group. Program delivered 3 months after posttest.
62377494|NCT02649075|ACTIVE_COMPARATOR|SBI 10 g BID|Serum-derived Bovine Immunoglobulin / Protein Isolate (SBI) 10.0 grams twice per day
62377495|NCT02649075|PLACEBO_COMPARATOR|Placebo BID|Placebo w/control protein
62377496|NCT02251028|ACTIVE_COMPARATOR|Group A|Group A receives value-based cognitive behavior therapy after randomization.
62377497|NCT02251028|ACTIVE_COMPARATOR|Group B|Group B receives value-based cognitive behavior therapy after 3 months.
62377498|NCT00791011|EXPERIMENTAL|Cohort 4|AMG 655 (intermediate dose) with Vorinostat
62377499|NCT00791011|EXPERIMENTAL|Cohort 1|AMG 655 (low dose) with Bortezomib
62377500|NCT00791011|EXPERIMENTAL|Cohort 2|AMG 655 (low dose) with vorinostat
62377501|NCT00791011|EXPERIMENTAL|Cohort 5|AMG 655 (high dose) with Bortezomib
62377502|NCT00791011|EXPERIMENTAL|Cohort 6|AMG 655 (high dose) with Vorinostat
62377503|NCT00791011|EXPERIMENTAL|Cohort 7|Part 2 - Mantle Cell Lymphoma subjects only: AMG 655 at dose TBD with Bortezomib
62377504|NCT00791011|EXPERIMENTAL|Cohort 3|AMG 655 (intermediate dose) with Bortezomib
62377505|NCT02597686|EXPERIMENTAL|SD-PB training|
62377506|NCT02045225|EXPERIMENTAL|Cognitive behavioural therapy|Reduction of social anxiety \& substance use in gay/bi men
62377507|NCT02045979|EXPERIMENTAL|BI 695501|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
62753818|NCT05275543|EXPERIMENTAL|Physical and Occupational Therapy with Paro Robot|10-30 minute semi-structured, prescriptive therapy sessions with Paro robot focused on the categories of 1) speech; 2) balance and endurance; 3) memory; 4) self-esteem; 5) fine motor; 6) sensory stimulation
62377508|NCT02045979|ACTIVE_COMPARATOR|adalimumab-EU source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-EU source
62377509|NCT02045979|ACTIVE_COMPARATOR|adalimumab-US source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-US source
62377510|NCT03887325|ACTIVE_COMPARATOR|Maxipost|
62753819|NCT05275543|NO_INTERVENTION|Physical and Occupational Therapy without Paro Robot|10-30 minute semi-structured, prescriptive therapy sessions without Paro robot focused on the categories of 1) speech; 2) balance and endurance; 3) memory; 4) self-esteem; 5) fine motor; 6) sensory stimulation
62753820|NCT05275543|EXPERIMENTAL|Parents/Guardians of Hospitalized Children who use Paro Robot|"Parents/guardians of hospitalized children who are assigned to the following arm Physical and Occupational Therapy with Paro Robot"
62753821|NCT05275543|NO_INTERVENTION|Parents/Guardians of Hospitalized Children who do not use Paro Robot|"Parents/guardians of hospitalized children who are assigned to the following arm Physical and Occupational Therapy with out Paro Robot"
62753822|NCT02068846|ACTIVE_COMPARATOR|Ciprofloxacin|Active treatment twice daily for 28 days
62753823|NCT02068846|PLACEBO_COMPARATOR|Placebo|Placebo treatment twice daily for 28 days
62753824|NCT06511739|EXPERIMENTAL|SYHX1901-A|Participants in this group will receive dose A of SYHX1901 orally once daily (QD) for 52 weeks
62753825|NCT06511739|EXPERIMENTAL|SYHX1901-B|Participants in this group will receive dose B of SYHX1901 orally QD for 52 weeks
62753826|NCT06511739|EXPERIMENTAL|SYHX1901-C|articipants in this group will receive dose C of SYHX1901 orally QD for 52 weeks
62377511|NCT03887325|PLACEBO_COMPARATOR|Saline|
62377512|NCT01215786|OTHER|AGN-207281 ophthalmic solution|AGN-207281 0.1% ophthalmic solution on Days 1-7 and AGN-207281 0.3% ophthalmic solution on Days 8-14
62377513|NCT01215786|ACTIVE_COMPARATOR|Timolol ophthalmic solution 0.5%|timolol ophthalmic solution 0.5%
62377514|NCT01215786|PLACEBO_COMPARATOR|Placebo|AGN-207281 vehicle ophthalmic solution (Placebo)
62377515|NCT05320224|OTHER|Patient-Oriented Music Intervention (POMI) followed by No Music - Sequence AB|Patient participants will first receive 20-30 minutes of the patient-oriented music intervention (POMI) first, followed by no music, with a minimal washout period of four hours
62753827|NCT06511739|PLACEBO_COMPARATOR|Placebo followed by dose C of SYHX1901|Participants in this group will receive placebo orally QD for 24 weeks followed by dose C of SYHX1901 orally QD for 28 weeks.
62753828|NCT02055261|OTHER|OFF PPN DBS-ON PPN DBS|Patients randomly allocated to the order OFF Low frequency DBS of the pedunculopontine nucleus then ON Low frequency DBS of the pedunculopontine nucleus
62753829|NCT02055261|OTHER|ON PPN DBS - OFF PPN DBS|Patients randomly allocated to the order ON Low frequency DBS of the pedunculopontine nucleus then OFF Low frequency DBS of the pedunculopontine nucleus
62753830|NCT02952963|EXPERIMENTAL|Chenodeoxycholic Acid|Chenodeoxycholic Acid (1250 mg) dissolved in 200 ml water. Here after 50 ml clean water.
62753831|NCT02952963|EXPERIMENTAL|Chenodeoxycholic Acid and Colesevelam|Chenodeoxycholic Acid (1250 mg) and Colesevelam (3,75 g) dissolved in 200 ml water. Here after 50 ml clean water.
62753832|NCT04660292|EXPERIMENTAL|Study Group|The study group was treated with Maitland mobilization and manipulation techniques including postero-anterior Maitland mobilization for C1-C2, Maitland lateral PA glide for C3-C6 and Maitland thrust manipulation for cervico-thoracic junction. Frequency of mobilization was 2 days a week for 4 weeks. While intensity of mobilization was grade 3 and 4 based on the Maitland concept.13 Time of oscillations was 2 or 3 oscillations in a second for 1 to 2 minutes.
62753833|NCT04660292|ACTIVE_COMPARATOR|Control Group|While placebo treatment with conventional physiotherapy (active exercises-10 repetitions in all direction in pain free range, isometrics 5-10 seconds brief but maximum contraction each held for 5-16 seconds for flexors, extensors, side flexors and rotators)14 without gliding, oscillations and thrust were recommended for the control group.The placebo group was treated with baseline treatment including TENS 10 minutes and moist hot packs in sitting position for 15 minutes on cervical region in with head resting on table with a pillow.
62377516|NCT05320224|OTHER|No Music followed by Patient-Oriented Music Intervention (POMI) - Sequence BA|Patient participants will first receive no music first, followed by 20-30 minutes of the patient-oriented music intervention (POMI), with a minimal washout period of four hours
62377517|NCT05307081||1|
62377518|NCT03607994|ACTIVE_COMPARATOR|HIRREM-SOP (BCC|Acoustic stimulation linked to brainwave activity and continued current care.
62377519|NCT03607994|OTHER|nonspecific acoustic stimulation (NCC)|Continued current care and acoustic stimulation that is not linked to brainwave activity.
62377520|NCT00269620|EXPERIMENTAL|2|OrthoEvra
62377521|NCT00269620|EXPERIMENTAL|1|NuvaRing
62377522|NCT02292888|ACTIVE_COMPARATOR|patients with LVEF >40%|Correlation between hemodynamic variable : SV and echocardiographic variable : Doppler VTI will be compared before and after Passive Leg Raising (PLR) test.
62377523|NCT02292888|ACTIVE_COMPARATOR|patients with LVEF < or equal to 40%|Correlation between hemodynamic variable : SV and echocardiographic variable : Doppler VTI will be compared before and after Passive Leg Raising (PLR) test.
62377524|NCT03059524||patients with multiple organ failure|
62377525|NCT03059524||patients without multiple organ failure|
62377526|NCT03059524||normal subjects|
62377527|NCT05924503||Transcranial Doppler|Serial daily TCD during the ICU stay involving bilateral Middle cerebral artery (MCA) insonation
62377528|NCT06048913|EXPERIMENTAL|Nimotuzumab combined with concurrent chemoradiotherapy|Treatment options Nimotuzumab （400mg plus normal saline 250ml intravenous infusion for not less than 60 minutes. Starting from week 1 of radiotherapy, 1 dose of the same dose each time for a total of 6 doses）combined with chemoradiotherapy (Oral chemotherapy with the tigio regimen is given on days 1 to 2 of radiotherapy, with the drug dose calculated based on body surface area, and the oral tigio course from Monday to Friday is synchronized with radiation therapy) for the treatment of locally advanced elderly esophageal cancer patients, in which the tigio regimen with good clinical tolerability was selected for chemotherapy to evaluate the short-term efficacy and toxic side effects
62377529|NCT03371303||diabetology|
62377530|NCT03371303||cardiology|
62377531|NCT03371303||rheumatology|
62377532|NCT03371303||geriatrics|
62377533|NCT04177186|EXPERIMENTAL|strength training group|ST group only strength training will be provided.
62377534|NCT04177186|EXPERIMENTAL|strength training with botulinum toxin|BT-ST group, strength training will be provided after the administering Botulinum toxin into the muscle belly guided under Ultra sound imaging.
62377535|NCT03500536|NO_INTERVENTION|Waitlist Control|8 weeks of treatment as usual followed by 8 weeks of IntelliCare treatment.
62377536|NCT03500536|EXPERIMENTAL|Experimental|8 weeks of IntelliCare treatment followed by 8 weeks of treatment as usual.
62377537|NCT02148601|EXPERIMENTAL|Fecal Microbiota Transplantation|Fecal microbiota transplantation from healthy donors will be infused by colonoscopy
62377538|NCT02148601|ACTIVE_COMPARATOR|Standard Antibiotic Therapy|Standard antibiotic therapy according to European Guidelines (vancomycin and metronidazole) will be administered to the patients
62377539|NCT03351062|ACTIVE_COMPARATOR|Tamoxifen treatment group|Patients in this group will receive tamoxifen treatment.
62377540|NCT03351062|ACTIVE_COMPARATOR|Toremifene treatment group|Patients in this group will receive Toremifene treatment.
62377541|NCT04205474|ACTIVE_COMPARATOR|VSRR with tricuspid aortic valve|Patients with a tricuspid valve that previously underwent a valve sparing root procedure for aortic root aneurysm
62377542|NCT04205474|ACTIVE_COMPARATOR|VSRR with bicuspid aortic valve|Patients with a bicuspid valve that previously underwent a valve sparing root procedure for aortic root aneurysm
62377543|NCT01960764|EXPERIMENTAL|Pre-Treatment|Prior to receiving the transplant, this arm will be washed with an antimicrobial regimen
62377544|NCT01960764|PLACEBO_COMPARATOR|Control|This arm will still be transplanted with the autologous microbiome transplant cream, however it will not be pre-treated with an antimicrobial regimen
62753834|NCT04767178||Ibuprofen group|Infants that received oral ibuprofen were categorized into the ibuprofen group
62377545|NCT03797794|EXPERIMENTAL|PESF-treatment|The group undergoing the pulsating electrostatic field intervention
62377546|NCT03797794|SHAM_COMPARATOR|Placebo-treatment|The group undergoing the SHAM Pulsating Electrostatic Field
62377547|NCT01921959||Partners of intervention women|Partners of women randomized to intervention
62377548|NCT01921959||Partners of no intervention women|Partners of women randomized to control
62377549|NCT01142791|OTHER|ExAblate treatment|
62377550|NCT01902654||Knee osteoarthritis|Patients over 50 years who presented to an outpatient rheumatology for 1 year and who had knee osteoarthritis.
62377551|NCT01902654||Hand osteoarthritis|Patients over 50 years who presented to an outpatient rheumatology for 1 year and who had hand osteoarthritis.
62377552|NCT01902654||Soft tissue disease|All patients over 50 years who presented during the same period of time of other cohorts, to an outpatient rheumatology and who had soft tissue disease with no other rheumatic condition.
62753835|NCT04767178||Paracetamol group|Infants that received oral paracetamol were categorized into the paracetamol group
62753836|NCT04961541|EXPERIMENTAL|Group A - ICC Vaccine Formulation|2 doses of Formulation 1. 1 dose each on Days 0 and Day 56.
62753837|NCT04961541|EXPERIMENTAL|Group B -ICC Vaccine Formulation|2 doses of Formulation 2. 1 dose each on Days 0 and Day 56.
62753838|NCT04961541|EXPERIMENTAL|Group C - ICC Vaccine Formulation|2 doses of Formulation 1. 1 dose each on Days 0 and Day 56.
62753839|NCT04961541|EXPERIMENTAL|Group D - ICC Vaccine Formulation|2 doses of Formulation 3. 1 dose each on Days 0 and Day 56.
62753840|NCT04961541|EXPERIMENTAL|Group E - ICC Vaccine Formulation|2 doses of Formulation 4. 1 dose each on Days 0 and Day 56.
62753841|NCT04961541|EXPERIMENTAL|Group F- ICC Vaccine Formulation|2 doses of Formulation 5. 1 dose each on Days 0 and Day 56.
62753842|NCT04961541|EXPERIMENTAL|Group G- ICC Vaccine Formulation|2 doses of Formulation 6. 1 dose each on Days 0 and Day 56.
62753843|NCT04961541|EXPERIMENTAL|Group H- ICC Vaccine Formulation|2 doses of Formulation 7. 1 dose each on Days 0 and Day 56.
62753844|NCT04961541|EXPERIMENTAL|Group I- ICC Vaccine Formulation|2 doses of Formulation 8. 1 dose each on Days 0 and Day 56.
62753845|NCT04961541|EXPERIMENTAL|Group J -ICC Vaccine Formulation|2 doses of Formulation 9. 1 dose each on Days 0 and Day 56.
62753846|NCT04961541|EXPERIMENTAL|Group K - ICC Vaccine Formulation|2 doses of Formulation 10. 1 dose each on Days 0 and Day 56.
62377553|NCT03990051|EXPERIMENTAL|Pro-ocular™|Pro-ocular™ 1% topical gel applied dermally to forehead twice daily, morning and before bedtime.
62753847|NCT04961541|EXPERIMENTAL|Group L - ICC Vaccine Formulation|2 doses of Formulation 11. 1 dose each on Days 0 and Day 56.
62753848|NCT04961541|EXPERIMENTAL|Group M -ICC Vaccine Formulation|2 doses of Formulation 12. 1 dose each on Days 0 and Day 56.
62753849|NCT04961541|EXPERIMENTAL|Group N- ICC Vaccine Formulation|2 doses of Formulation 7. 1 dose each on Days 0 and Day 56.
62377554|NCT03990051|PLACEBO_COMPARATOR|Placebo|Vehicle topical gel without active ingredient applied dermally to forehead twice daily, morning and before bedtime.
62377555|NCT02230787|ACTIVE_COMPARATOR|Recession coverage without Emdogain|
62377556|NCT02230787|EXPERIMENTAL|Recession coverage with Emdogain|
62377557|NCT04582162|EXPERIMENTAL|Unsplinted implants|
62377558|NCT04582162|ACTIVE_COMPARATOR|Splinted implants|
62377559|NCT04585113||People with hand OA awaiting surgery|Patients with hand OA awaiting hand surgery of a joint with OA will be considered eligible. All IP joints in the hands are eligible (thus both IP, PIP and DIP) if in- and exclusion criteria are fulfilled.
62377560|NCT02098915|EXPERIMENTAL|intravenous metoclopramide|the experimental arm will receive intravenous metoclopramide
62377561|NCT02098915|PLACEBO_COMPARATOR|control arm|the control arm will receive placebo
62753850|NCT04961541|EXPERIMENTAL|Group O - qNIV with Matrix-M1 adjuvant|2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70.
62753851|NCT04961541|EXPERIMENTAL|Group P- SARS-CoV-2 rS with Matrix-M1 adjuvant|2 doses of Formulation 14. 1 dose each on Days 0 and Day 56.
62753852|NCT02198482|ACTIVE_COMPARATOR|Daunorubicin, Cytarabine (DA)|"DA~Induction I:~* Daunorubicin 60 mg/m² i.v., d 1-3~* Cytarabine 100 mg/m² cont. i.v., d 1-7~Induction II:~* Daunorubicin 50 mg/m² i.v. d 1-3~* Cytarabine 100 mg/m² cont. i.v., d 1-5~Consolidation therapy:~Patients with genetic favourable risk and those patients not eligible for allogeneic HSCT due to comorbidities, high HCT-CI or patient wish will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine (MiDAC).~* Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 1. Elderly patients (\>60 yrs): 8 mg/m2 by i.v. infusion on day 1.~* Intermediate-dose cytarabine:~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 1-3 Elderly patients (\>60 yrs): 1000 mg/m2 q12h on days 1-3 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with MiDAC may be given prior to alloHSCT."
62377562|NCT05751252|EXPERIMENTAL|0.0625 mg|Test the efficacy of Ganirelix administered subcutaneously at single-dose regimen of 0.0625 mg in 10 women with PCOS, in rectifying LH pulse frequency and LH amplitude
62377563|NCT05751252|EXPERIMENTAL|0.025 mg|Test the efficacy of Ganirelix administered subcutaneously at single-dose regimen of 0.025 mg in 10 women with PCOS, in rectifying LH pulse frequency and LH amplitude.
62377564|NCT01579162|EXPERIMENTAL|Healthy Controls|Healthy controls will be recruited to have approximately equal numbers of men and women. Controls will be of healthy weight as defined by a BMI 18-25 and without liver disease or risk factors for liver disease.
62377565|NCT01579162|EXPERIMENTAL|chronic HCV patients with F0-F2 fibrosis|
62377566|NCT01579162|EXPERIMENTAL|chronic HCV patients with F3-F4 fibrosis|
62377567|NCT01579162|EXPERIMENTAL|NASH patients with F0-F2 fibrosis|
62377568|NCT01579162|EXPERIMENTAL|NASH patients with F3-F4 fibrosis|
62377569|NCT02531919|EXPERIMENTAL|Sodium Bicarbonate|Dose concentration of 0.5 g/kg/day
62377570|NCT00720720|ACTIVE_COMPARATOR|1|plant sterol enriched margarine
62377571|NCT00720720|PLACEBO_COMPARATOR|2|placebo margarine
62377572|NCT02233894||Chronic obstructive pulmonary disease patients|
62377573|NCT01646736|PLACEBO_COMPARATOR|GC+CYC|Patients were treated with Glucocorticosteroid and Cyclophosphamide.
62377574|NCT01646736|EXPERIMENTAL|GC+T2|Patients were treated with Glucocorticosteroid and oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).
62377575|NCT05535790|EXPERIMENTAL|Intervention group|Exposure to 24-hour LED naturalistic lighting
62377576|NCT05535790|SHAM_COMPARATOR|Control group|Exposure to standard/traditional lighting setting with fluorescent tubes
62377577|NCT01859884|EXPERIMENTAL|Inform Me: web-based education tool|Intervention will receive the standard of care, the Inform Me intervention, a post-test evaluation, and 1 week recall test.
62377578|NCT01859884|NO_INTERVENTION|Control Standard of Care|This group receives standard of care with a post test.
62377579|NCT04368741|EXPERIMENTAL|Experimental group|SANZ®KINGWILL
62377580|NCT04368741|OTHER|Control group|GLUCERNA SR®
62377581|NCT03686527||Echocardiography|
62556394|NCT02983786||Non-Invasive Monitoring|"One non-invasive optode patch will be placed adjacent to the area of invasive monitoring and the second patch will be placed contralaterally. (12 hrs. daily is chosen primarily for budgetary reasons). The information for the non-invasive technology will be compared to the invasive technology.~ICG (Indocyanine Green) will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable)."
62377582|NCT03686527||MRI Fibrosis|
62377583|NCT05601765|ACTIVE_COMPARATOR|Standard communication pathways after discharge|"Patients who need contact within 72 hours of discharge are advised to call the bed section, from where they were discharged. Telephone counseling can be provided by the nurses available at the time of calling (e.g., questions for medical treatment, precautions after surgery etc.).~* If deemed relevant, the patient may be asked to appear in person at the ward (e.g., for the examination of wounds).~* If more serious conditions are suspected, a doctor or emergency department will be contacted by the nurse for assessment, triage and possibly readmission.~Patients who need contact after 72 hours of discharge are advised to call the outpatient clinic, if they have planned attendances here, or alternatively their own general practitioner or home care nurse.~Standard communication pathways between healthcare professionals across sectors are electronic correspondences and telephone inquiries."
62377584|NCT05601765|EXPERIMENTAL|Digital team-based communication after discharge|"Patients will be given access to digital communication with their healthcare team across sectors who are involved in their treatment and care after hospital discharge (eDialogue). They will be set up in a messenger-like tool on the day of discharge, and relevant healthcare professionals will be connected. Individually, the patients will define who they would like to involve, and consent is given digitally. The minimum participants for each patient will be the patient and/or their closest relative, the orthopaedic surgeon, a nurse from the outpatient clinic and a secretary. Patients will have access to eDialogue for 60 days after discharge, and the response rate is set to be 24 hours on weekdays. On weekends and public holidays, patients are informed that they cannot expect a response. If the primary healthcare professional is registered to be on vacation or other absence, substitutes within the respective health professional groups will be included."
62377585|NCT02590406|ACTIVE_COMPARATOR|Beach chair (BC) and ZEEP|Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
62377586|NCT02590406|EXPERIMENTAL|Reverse Trendelenburg and NIPPV|"Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface"
62377587|NCT02931955||Venom Group|"The investigators plan to include 15 patients with insect venom allergy and will collect blood at four time points and stool at three time points during the first week of immunotherapy.~The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients."
62556395|NCT05537207|EXPERIMENTAL|study group|low level laser therapy (LLLT) on the acupuncture points.in addition to non-steroidal anti-inflammatory drugs
62556396|NCT05537207|EXPERIMENTAL|control group|All women will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as will be described by their gynecologist.
62753853|NCT02198482|EXPERIMENTAL|Volasertib, Daunorubicin, Cytarabine|"VDA~Induction I~* Volasertib i.v., d1~* Daunorubicin 60 mg/m² i.v., d 2-4~* Cytarabine 100 mg/m² cont. i.v., d 2-8 Induction II~* Volasertib i.v., d1~* Daunorubicin 50 mg/m² i.v. d 2-4~* Cytarabine 100 mg/m² cont. i.v., d 2-6~Consolidation therapy:~Patients with genetic favourable risk and those patients not eligible for allogeneic HSCT will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine in combination with Volasertib (V-MiDAC).~* Volasertib i.v., d1~* Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 2. Elderly patients (\>60 yrs): 8 mg/m2 by i.v. on day 2.~* Intermediate-dose cytarabine:~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 2-4 Elderly patients (\>60 yrs): 1000 mg/m2 q12h on days 2-4 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with V-MiDAC may be given prior to alloHSCT."
62377588|NCT02931955||Pollen Group|"The investigators plan to include 15 patients with pollen allergy and will collect blood at five time points and stool at three time points during the first three months of immunotherapy.~The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients."
62377589|NCT02931955||Control Group|"The investigators plan to include 10 control persons without a clinical history of allergies. Blood and stool samples will be collected at seven/four times respectively.~The patients will receive usual standard of care and no intervention."
62377590|NCT01646255|EXPERIMENTAL|Rotigotine|Rotigotine, daily doses, treatment group
62377591|NCT01646255|PLACEBO_COMPARATOR|Placebo|Placebo, daily doses, placebo group
62556397|NCT02824055|PLACEBO_COMPARATOR|Placebo first; then RO5545965 15 mg; then RO5545965 5mg|Participants will receive placebo matched to RO5545965 capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 5 mg capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
62753854|NCT02198482|EXPERIMENTAL|Daunorubicin, Cytarabine, Volasertib|"DAV~Induction I~* Volasertib i.v., d7~* Daunorubicin 60 mg/m² i.v., d 1-3~* Cytarabine 100 mg/m² i.v., d 1-7 Induction II~* Volasertib i.v., d5~* Daunorubicin 50 mg/m² i.v. d 1-3~* Cytarabine 100 mg/m² cont. i.v., d 1-5~Consolidation therapy:~Patients with genetic fav. risk and those patients not eligible for alloHSCT will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine in combination with Volasertib (MiDAC-V).~* Volasertib i.v., d4~* Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 1. Elderly patients (\>60 yrs): 8 mg/m2 by i.v. on day 1.~* Intermediate-dose cytarabine:~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 1-3 Elderly patients (\>60 yrs): 1000 mg/m2 q12h on days 1-3 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with MiDAC-V may be given prior to alloHSCT."
62753855|NCT06079060|EXPERIMENTAL|Synthetic Nitrile Condom (61mm)|61mm width synthetic Nitrile condoms
62753856|NCT06079060|ACTIVE_COMPARATOR|Control Latex Condom|61mm width Natural Rubber Latex condoms
62753857|NCT04284735|OTHER|Controls|Patients with RA and without ILD
62753858|NCT04284735|OTHER|Cases|Patients with RA and ILD
62753859|NCT05371080|OTHER|LTFU Group|Participants who received at least one dose of the HZ/su vaccine in the ZOSTER-006/022 primary studies and are followed for long-term vaccine efficacy and safety in the current ZOSTER-101 study.
62753860|NCT05371080|OTHER|1-Additional Dose Group|Participants who received two doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and one additional dose of the HZ/su vaccine in the ZOSTER-049 study and are followed for persistence of immunogenicity and safety in the current ZOSTER-101 study.
62753861|NCT05371080|OTHER|Revaccination Group|Participants who received two doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and two additional doses of the HZ/su vaccine in the ZOSTER-049 study and are followed for persistence of immunogenicity and safety in the current ZOSTER-101 study.
62753862|NCT05371080|OTHER|Control Group|Participants who received two doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and no additional doses of the HZ/su vaccine in the ZOSTER-049 study, but who served as a control for the two groups that received 1 or 2 additional doses of HZ/su (1-Additional Dose and Revaccination groups). In the current ZOSTER-101 study, this Control group is used in the evaluation of the long-term vaccine efficacy, safety and as a control for persistence of immunogenicity to additional doses administered in ZOSTER-049 study.
62753863|NCT05842954|EXPERIMENTAL|KLU156|KLU156 once daily (QD) for 3 days under fed conditions (light meal).
62753864|NCT05842954|ACTIVE_COMPARATOR|Coartem|Coartem twice a day (BID) for 3 days under fed conditions.
62753865|NCT01389154|EXPERIMENTAL|Patients recommended for a lung biopsy.|Patients with a positive diagnosis of a peripheral, less than 3.0 centimeter lung lesion, recommended for bronchoscopic biopsy are eligible to be consented into the study.
62753866|NCT02913430|ACTIVE_COMPARATOR|Arm A|fulvestrant administered 500mg IM Q28 days plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
62753867|NCT02913430|ACTIVE_COMPARATOR|Arm B|Tamoxifen is administered orally, at a dose of20mg PO Qdaily plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
62753868|NCT02073838|EXPERIMENTAL|Ribavirin, vismodegib, decitabine|Decitabine 20mg/m2 IV QD days -7 to -3 for cycle 1. Ribavirin 1400mg BID and vismodegib 150mg QD starting on day 1. On subsequent cycles, decitabine will be administered on days 1 to 5.
62753869|NCT02073838|EXPERIMENTAL|Ribavirin, vismodegib|Ribavirin 1400mg BID, vismodegib 150mg QD
62753870|NCT05418283|ACTIVE_COMPARATOR|Exercise|12-week aerobic exercise program will be applied (3/week)
62753871|NCT05418283|NO_INTERVENTION|Control|No intervention will be applied.
62753872|NCT04407637||neck pain patients|Patients with acute non-specific neck pain were consecutively recruited from a private manual physiotherapy center as sample of convenience. Inclusion criteria were acute (\<3months) non-specific neck pain with a neck disability index (NDI) \> 8% and a Numerical Pain Rating Scale (NPRS) \>3 . Patients were excluded if they reported any of the following: a history of neck surgery, dizziness caused by neck or head movements and cervical radiculopathy diagnosed by a physician.
62753873|NCT04407637||healthy|Healthy control participants were included if they reported a NDI \< 8% and a NPRS =0. They were excluded if they reported neck pain during the last year, radiating symptoms in the shoulder or arm regions, or headache. Participants with a history of neck trauma or in treatment for spinal disorders or reporting pain during the manual assessment were excluded as well.
62377592|NCT01250392|OTHER|Control Arm|The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment.
62377593|NCT01250392|EXPERIMENTAL|Active Choice Only Arm|The active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
62556398|NCT02824055|PLACEBO_COMPARATOR|Placebo first; then RO5545965 5 mg; then RO5545965 15 mg|Participants will receive placebo matched to RO5545965 capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 5 mg capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
62556399|NCT02824055|EXPERIMENTAL|RO5545965 15 mg first; then Placebo; then RO5545965 5 mg|Participants will receive RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 1 to 3 in first intervention period; then placebo matched to RO5545965 capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 5 mg capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
62556400|NCT02824055|EXPERIMENTAL|RO5545965 15 mg first; then RO5545965 5 mg; then Placebo|Participants will receive RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 5 mg capsules orally daily from Weeks 6 to 8 in second intervention period; followed by placebo matched to RO5545965 capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
62556401|NCT02824055|EXPERIMENTAL|RO5545965 5 mg first; then Placebo; then RO5545965 15 mg|Participants will receive RO5545965 5 mg capsules orally daily from Weeks 1 to 3 in first intervention period; then placebo matched to RO5545965 capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
62556402|NCT02824055|EXPERIMENTAL|RO5545965 5 mg first; then RO5545965 15 mg; then Placebo|Participants will receive RO5545965 5 mg capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 6 to 8 in second intervention period; followed by placebo matched to RO5545965 capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
62556403|NCT05186389||"Control Group"|"15 non-obese participants considered metabolically-healthy : control group"
62556404|NCT05186389||Obese group (Ob)|"15 severely obese participants, candidates for bariatric surgery, but without T2D: obese group (Ob)"
62556405|NCT05186389||Obese and Type 2 Diabetes group (ObD)|"15 participants who are both severely obese, candidates for bariatric surgergy and diagnosed with T2D: obese and diabetic group (ObD)."
62556406|NCT02104570|OTHER|Control|In this session, participants will be evaluated before and after a muscle fatigue protocol, with no intervention.
62556407|NCT02104570|EXPERIMENTAL|Kinesio taping with tension|A kinesio taping technique for the deltoid muscle will be applied before fatigue protocol and removed after in the end of the evaluation session. Subjects will be evaluated before taping, after taping and after the fatigue protocol.
62556408|NCT02104570|SHAM_COMPARATOR|Kinesio taping without tension|A kinesio taping technique will be applied on the deltoid muscle without tension (tension is considered to be the therapeutic effect) before fatigue protocol and removed after in the end of the evaluation session. Subjects will be evaluated before taping, after taping and after the fatigue protocol.
62377594|NCT00589602|EXPERIMENTAL|T-Cell Depletion Transplant|"Our protocol is designed to attempt to improve the current results of matched unrelated donor (MUD) allo bone marrow transplant (BMT) and will be a major step towards the introduction and refinement of graft engineering. Our approach will address in a rational fashion all major technical and clinical aspects of MUD allo BMT.~Peripheral blood lymphocyte therapy; cyclophosphamide, tacrolimus, peripheral blood stem cell transplantation; total-body irradiation; 'allogeneic hematopoietic stem cell transplantation'"
62377595|NCT05682326|EXPERIMENTAL|Daprodustat|All participants will receive daprodustat for up to 52 weeks.
62377596|NCT00718991|EXPERIMENTAL|1|CLI patients receiving excimer laser recanalisation for the treatment of long infrapopliteal lesions
62377597|NCT06375694|ACTIVE_COMPARATOR|Probiotic|Participants will take the commercially available oral probiotic (Herbiotics Oral + Ent Probiotic) twice a day for 7 days as instructed by the manufacturer. This entails one lozenge twice a day taken by mouth and slowly chewed or allowed to melt in the mouth.
62377598|NCT06375694|PLACEBO_COMPARATOR|Placebo|Participants will take the commercially available Honest Placebo Pills by Zeebo twice a day for 7 days. This entails one tablet twice a day taken by mouth and slowly chewed or allowed to melt in the mouth.
62377599|NCT05574712|EXPERIMENTAL|Open-Label Treatment Group|Participants will be treated with neoadjuvant therapy for a total of 3 months (12 weeks) prior to prostatectomy. Therapy will consist of leuprolide acetate, abiraterone acetate, and belzutifan.
62377600|NCT03232502|NO_INTERVENTION|Control|
62377601|NCT03232502|EXPERIMENTAL|Intervention|
62377602|NCT04619381||African Americans with Coronary Artery Disease|African Americans with Coronary Artery Disease and currently taking clopidogrel
62377603|NCT03095157|PLACEBO_COMPARATOR|Placebo|
62377604|NCT03095157|EXPERIMENTAL|Treatment|
62377605|NCT00408785|EXPERIMENTAL|A|Injection
62377606|NCT00408785|PLACEBO_COMPARATOR|B|Injection
62377607|NCT04454840|EXPERIMENTAL|Biological+Riluzole|Plasma from healthy young people treatment + Riluzole
62377608|NCT04454840|ACTIVE_COMPARATOR|Riluzole|Riluzole
62377609|NCT01680562||skin cancer|Skin cancer patients with scheduled tumor excision and subsequent histopathological analysis of the tumor.
62377610|NCT03526692|EXPERIMENTAL|Sensorimotor/delta NF training group|"Three interventions will be administered:~* An electroencephalography recording (EEG) for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.~* The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.~* The third intervention is the neurofeedback training sensorimotor/delta ratio that will be recorded at channel Cz according to the International 10-20 system."
62377611|NCT03526692|EXPERIMENTAL|Beta1/theta NF training group|"Three interventions will be administered:~* An electroencephalography recording (EEG) for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.~* The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.~* The third intervention is the neurofeedback training Beta1/theta ratio that will be recorded at channel Fz according to the International 10-20 system."
62377612|NCT03526692|NO_INTERVENTION|Control group|"Three interventions will be administered:~* An electroencephalography recording for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.~* The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.~* The psychopedagogical care : Each session will be organized using the same video material than for the NF training sessions."
62377613|NCT02658149|EXPERIMENTAL|Psoas Compartment Block|After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
62377614|NCT02658149|ACTIVE_COMPARATOR|Periarticular Local Anesthetic|"An anesthetic cocktail of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues."
62377615|NCT03978286|EXPERIMENTAL|Vortioxetine therapy|patients who gave informed consent and met the inclusion criteria were attended by a psychiatrist. The pharmacological management were randomly assigned: these group of patients received vortioxetine (10 mg/day) for 8 weeks, in addition, the patients maintained their anti-diabetic treatment (oral hypoglycemic or insulin)
62377616|NCT03978286|EXPERIMENTAL|Sertraline therapy|patients who gave informed consent and met the inclusion criteria were attended by a psychiatrist. The pharmacological management were randomly assigned: these group of patients received sertraline (75 mg / day) for 8 weeks, in addition, the patients maintained their anti-diabetic treatment (oral hypoglycemic or insulin)
62377617|NCT02482415|EXPERIMENTAL|Intervention|Family caregivers were invited to meet in a group for 2 hours once a week for 3 weeks. Each meeting had a specific topic presented by a health care professional of the palliative care team (physician, nurse and social worker). The meetings addressed multi-dimensional issues in dialogue with the participants. A nurse acted as group leader and participated in all meetings. The intervention included both supportive and educational components. Each meeting began with a presentation based on a specific topic (palliative care, practical care and emotional reactions). This was followed by reflection and conversation, and finally a relaxation exercise
62377618|NCT02482415|NO_INTERVENTION|Control|
62377619|NCT04252391|ACTIVE_COMPARATOR|Standard care|Standard care will consist of standard physical therapy care which may include the following: cervical or thoracic manipulation or mobilization, muscle stretching, muscle strengthening, dry needling with or without electrical trigger point dry needling, soft tissue release and prescribed therapeutic exercises .
62753874|NCT05103176|EXPERIMENTAL|To PPC, with concurrent task|This arm will receive intermittent theta bust stimulation to the PPC site while subjects perform a grasp task
62753875|NCT05103176|EXPERIMENTAL|To PPC, without a concurrent task|This arm will receive intermittent theta bust stimulation to the PPC site without a concurrent task
62753876|NCT05103176|EXPERIMENTAL|To vertex, with concurrent task|This arm will receive intermittent theta bust stimulation to the vertex site (control condition) while subjects perform a grasp task
62753877|NCT00218816|EXPERIMENTAL|1|
62753878|NCT00218816|OTHER|2|
62753879|NCT01391572|EXPERIMENTAL|A|After esophagectomy, patients in Arm A will receive Large field radiation (tumor bed + ENI (elective nodal irradiation)) + Sequential chemotherapy
62753880|NCT01391572|ACTIVE_COMPARATOR|B|After esophagectomy, patients in Arm B will receive small field radiation (tumor bed only) + Sequential chemotherapy
62753881|NCT06135636|NO_INTERVENTION|Usual Care|No up-front education, routine counseling as per their primary provider's standard practice, and written education on cocooning and recommendation for partner Tdap vaccination provided upon completion of the postpartum survey
62753882|NCT06135636|EXPERIMENTAL|Upfront Education Only|Direct verbal and written education at the time of enrollment on cocooning and recommendation for partner Tdap vaccination prior to delivery
62753883|NCT06135636|EXPERIMENTAL|Upfront Education and Vaccination Administration:|Direct verbal and written education at the time of enrollment on cocooning and recommendation for partner Tdap vaccination prior to delivery plus the option to receive Tdap at their convenience at the WIH obstetric care clinic.
62377620|NCT04252391|ACTIVE_COMPARATOR|standard care with perineural electrical dry needling.|This arm will consist of standard care with perineural electrical dry needling, using a high frequency stimulation placed near the nerve, differing from addressing muscular trigger points. For example, a dry needle placed in the semispinalis capitus muscle along the greater occipital nerve pathway, stimulated at 80 Hz.
62377621|NCT01755390|EXPERIMENTAL|Cabazitaxel|"IV escalation part:~XRP6258 administered as a 1-hour IV infusion on Days 1, 8, 15 and 22 of each 5-week cycle until evidence of disease progression, unacceptable toxicity or patient's withdrawal.~Oral bioavailability part:~XRP6258 administered at the dose of 8.4 mg/m² as an oral administration on Day 1 Cycle 1 and as a weekly 1-hour i.v. infusion at the subsequent weeks of treatment. Patients receiving oral administration at Day 1, Cycle 1 are to fast for 12 hours before and 4 hours after administration."
62753884|NCT04488159|EXPERIMENTAL|Immunoscore stratification|"* Immunoscore low (I-Low; I0-1): 3 months CAPOX (oxaliplatin 130 mg/m2 IV over 2 h and capecitabine 1000 mg/m2 PO twice daily (days 1-14). 21-day treatment cycle.). Concomitantly, standardised physical excise (stair walking excise twice a week for 12 weeks), which will be monitored by an electronic sports device.~* Immunoscore intermediate-high (I-IntHi; I2-3): 6 months FOLFOX (oxaliplatin 85 mg/m2 IV (on day 1) and folinic acid 200 mg/m2 IV over 2 h, followed by a bolus of fluorouracil 400 mg/m2 IV over 2-4 min, followed by fluorouracil 600 mg/m2 IV over 22 h (for 2 consecutive days). 14-day treatment cycle.)~* Immunoscore high (I high; I4): no adjuvant treatment."
62753885|NCT04488159|ACTIVE_COMPARATOR|TNM stratification|"* TNM-based low-risk (pT1, pT2 or pT3 and pN1): 3 months CAPOX (oxaliplatin 130 mg/m2 IV over 2 h and capecitabine 1000 mg/m2 PO twice daily (days 1-14). 21-day treatment cycle.)~* TNM-based high-risk (pT4 and/or pN2): 6 months FOLFOX (oxaliplatin 85 mg/m2 IV (on day 1) and folinic acid 200 mg/m2 IV over 2 h, followed by a bolus of fluorouracil 400 mg/m2 IV over 2-4 min, followed by fluorouracil 600 mg/m2 IV over 22 h (for 2 consecutive days). 14-day treatment cycle.)"
62753886|NCT01904916|OTHER|Histological biopsy procedure|This is a diagnostic multicenter study combining histological biopsy of tumor material with DNA sequencing using Ion Torrent®, Next Generation Sequencing (NGS) platform. The study aims improve stratification of cancer patients by obtaining fresh tumor biopsies for next-generation sequencing for participation in clinical trials.
62753887|NCT03690492|EXPERIMENTAL|The Box 2.0|Patients will be given a Box, in which they will find a thermometer, blood pressure monitor, activity tracker, weight scale, blood oxygen saturation monitor, a single lead ECG device and a four lead ECG device. Also, they will be followed-up by use of two webcam consultations instead of a normal outpatient clinic visit.
62753888|NCT03690492|NO_INTERVENTION|Controls|Patients will not receive a Box. They will be followed up by standard care, returning to the outpatient clinic at the same frequency and timing as The Box 2.0 arm.
62753889|NCT00814697|EXPERIMENTAL|Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Coil Stimulation (rTMS) treatment in Alzheimer's disease. The Magstim Rapid2 stimulator with a peak magnetic field of 0.5-3.5 Tesla at 100% output was used over the right and left dorsolateral prefrontal cortex. Patients received 4 sessions of rTMS over 2 weeks, lasting approximately 30 minutes, 2 consecutive days a week for 2 weeks.
62753890|NCT02408003|EXPERIMENTAL|Levosimendan|"1. st dose: 12 µg/kg iv bolus for 10 min followed by 0,1 µg/kg/min for 20 min.~2. nd dose: 12 µg/kg iv bolus for 10 min followed by 0,2 µg/kg/min for 20 min."
62753891|NCT02408003|EXPERIMENTAL|Milrinone|"1. st dose: 48 µg/kg iv bolus for 10 min followed by 0,4 µg/kg/min for 20 min.~2. nd dose: 48 µg/kg iv bolus for 10 min followed by 0,8 µg/kg/min for 20 min."
62377622|NCT02738294|EXPERIMENTAL|Suspected EGC group|Participants with suspected EGC from white light endoscopy were enrolled.The endoscopist first used white light endoscopy to identify suspected gastric lesions and assessed lesions carefully with magnifying view, non-magnifying NBI view and ME-NBI view in sequence. After assessing suspected EGC in ME-NBI view, ME-NBI targeted biopsy was performed where abnormal phenomenon was identified in ME-NBI view.
62377623|NCT05402111|EXPERIMENTAL|SEP-363856|
62753892|NCT06607887|EXPERIMENTAL|IV antibiotic|
62753893|NCT06607887|ACTIVE_COMPARATOR|Oral Antibiotic|
62753894|NCT01790178|EXPERIMENTAL|Ultrasound Guided Biopsy|Ultrasound guided biopsy will be used in all patients.
62753895|NCT01790178|NO_INTERVENTION|Non-Ultrasound Guided Group|The control group will have non-ultrasound guided biopsies performed, which is the current standard of care.
62753896|NCT01118104|OTHER|Pulmonary vocational rehabilitation|
62753897|NCT04257175|EXPERIMENTAL|Cyclophosphamide, Flodarabine,CAR-T cells|"The appropriate participants will undergo lymhopheresis to collect lymphocytes from PBMC peripheral blood. CAR T CD19 cells will be produced. The participants will receive cyclophosphamide 300 mg / m² and flodarabine 30 mg / m² lymphodeplition intravenously daily for 3 days.~The CAR-T CD19 cells will be given on the 5 to 7 day post lymphodeplition ."
62753898|NCT01602783|EXPERIMENTAL|11C Acetate Imaging|11C acetate imaging
62753899|NCT02795507|EXPERIMENTAL|Device with feedback & exercises|"Training using Rehabit-Tec System - patient's hand will be positioned in this specialized motion control apparatus which allows movement of the non involved hand while receiving visual feedback of a virtual hand in the paretic side and a passive movement of the paretic hand + followed by 30 minutes of exercises (conventional sensorimotor active and passive exercises of the upper limb).~5 days per week for 3 weeks, 1 hour per day."
62753900|NCT02795507|ACTIVE_COMPARATOR|Device without feedback & exercises|"Training using Rehabit-Tec System - patient's hand will be positioned in a specialized motion control apparatus which allows movement of the non involved hand but without receiving visual feedback of a virtual hand in the paretic side and a passive movement of the paretic hand + followed by 30 minutes of exercises (conventional sensorimotor active and passive exercises of the upper limb).~5 days per week for 3 weeks, 1 hour per day."
62753901|NCT03848208|EXPERIMENTAL|Cohort 1: Cytisine 6.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62377624|NCT05402111|ACTIVE_COMPARATOR|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|
62377625|NCT05841277|EXPERIMENTAL|LY3819469 (Control)|LY3819469 administered subcutaneously (SC) to participants with normal renal function
62377626|NCT05841277|EXPERIMENTAL|LY3819469 (Severe Renal Impairment)|LY3819469 administered SC to participants with severe renal impairment
62377627|NCT05841277|EXPERIMENTAL|LY3819469 (End-Stage Renal Disease)|LY3819469 administered SC to participants with end-stage renal disease (ESRD)
62377628|NCT01438216||VUmc IC|Due to multicentre, 2 groups of patient in 1 cohort
62377629|NCT01438216||UMCN IC|Due to multicentre, 2 groups of patient in 1 cohort
62377630|NCT03662789|ACTIVE_COMPARATOR|Iron isomaltoside 1000|"The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment)."
61986527|NCT00822458|EXPERIMENTAL|Arm I|"Patients receive oral hedgehog antagonist GDC-0449 once daily on days 1 and 4-28 in course 1 and on days 1-28 in all subsequent courses. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.~Blood samples are collected periodically for pharmacokinetic studies. Archival tumor tissue samples are collected and analyzed for the expression of genes that activate the SHH (e.g., Gli1, Gli2, SFRP1, ATOH1, and PTCH2) or WNT (e.g., DKK2 and DKK4) cell signal pathways by in situ hybridization and reverse transcriptase real time-PCR."
61986528|NCT01758185|PLACEBO_COMPARATOR|recombinant hepatitis b vaccine|0.5ml intramuscular
61986529|NCT01758185|EXPERIMENTAL|Aleph influenza vaccine|0.5ml intramuscular
61986530|NCT01902342|EXPERIMENTAL|CES1 gene variant group|Oseltamivir 75 mg 1 cap
62377631|NCT03662789|PLACEBO_COMPARATOR|Placebo|Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%
61986531|NCT01902342|EXPERIMENTAL|CES1 gene wild type group|Oseltamivir 75 mg 1 cap
61986532|NCT02479256|EXPERIMENTAL|Clomiphene citrate + placebo|Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily), and one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
61986533|NCT02479256|EXPERIMENTAL|Tamoxifen + placebo|Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily), and one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
61986534|NCT05397054|EXPERIMENTAL|Investigator|Education, Reformulation, Environmental change, Used salt meter
62377632|NCT04118673|NO_INTERVENTION|Control (Standard Care)|Standard care during consultations. Advice and guidance offered by clinicians verbally and sometimes the addition of leaflets or a referral.
62377633|NCT04118673|EXPERIMENTAL|Intervention (Standard Care plus Lifestyle prescription - LRx)|Standard care during consultations with the addition of a physical lifestyle prescription. Advice and guidance will be offered by clinicians verbally, whilst being supported with a lifestyle prescription and a possible referral if required.
62377634|NCT05371795|ACTIVE_COMPARATOR|Lancets|
62377635|NCT05371795|EXPERIMENTAL|Comfort Marker 2.0|
62377636|NCT02949414|EXPERIMENTAL|Tracheal Replacement|Each patient will receive surgery to implant the cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells and all follow-up procedures.
62753902|NCT03848208|PLACEBO_COMPARATOR|Cohort 1: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62753903|NCT03848208|EXPERIMENTAL|Cohort 2: Cytisine 9.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62377637|NCT00684463|EXPERIMENTAL|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent
62377638|NCT01960452||Primary insomnia|
62377639|NCT01960452||Healthy sleeping controls|
61986535|NCT05397054|ACTIVE_COMPARATOR|Control|standard treatment with standard education
61986536|NCT00715325|EXPERIMENTAL|A|
61986537|NCT05368740||median IPI group|IPI score level was between 5-7
61986538|NCT05368740||high IPI group|IPI score level was between 8-10
62377640|NCT00146224|ACTIVE_COMPARATOR|Epoetin alfa RB|
62377641|NCT00146224|EXPERIMENTAL|Epoetin alfa DT|
62377642|NCT01830322|EXPERIMENTAL|CPI-613 Alone|This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing \[MTD\]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
62377643|NCT01830322|ACTIVE_COMPARATOR|Any non-gemcitabine chemotherapies or best supportive care|This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. This arm includes any best-practice standard-of-care chemotherapies deemed appropriate by the clinical investigators, including the option for supportive care, following good clinical practice.
62377644|NCT01830322|EXPERIMENTAL|Gemcitabine + CPI-613 in combination|This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. When gemcitabine and CPI-613 are administered in combination, gemcitabine will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. CPI-613 will be infused twice a week, administered on Days 1 and 4 for 3 consecutive weeks, followed by a week-of-rest, the same as gemcitabine. The dose of CPI-613 will be 710 mg/m2 infused IV over 2-hours (this is approximate maximum tolerated dosing \[MTD\] found from Phase I studies in combination with gemcitabine). To note, the dose of CPI-613 may be increased from 710 mg/m2 if ongoing Phase I trial data shows that the MTD of CPI-613 is higher than 710 mg/m2 CPI-613, diluted with D5W.
62377645|NCT01830322|EXPERIMENTAL|Gemcitabine alone or in combination with therapeutic agent(s)|This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. Gemcitabine, or Gemcitabine-based, chemotherapy will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. This arm includes any best-practice standard-of-care Gemcitabine-based chemotherapies deemed appropriate by the clinical investigators following good clinical practice.
62753904|NCT03848208|PLACEBO_COMPARATOR|Cohort 2: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62753905|NCT03848208|EXPERIMENTAL|Cohort 3: Cytisine 12.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62753906|NCT03848208|PLACEBO_COMPARATOR|Cohort 3: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62753907|NCT03848208|EXPERIMENTAL|Cohort 4: Cytisine 15.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62753908|NCT03848208|PLACEBO_COMPARATOR|Cohort 4: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62753909|NCT03848208|EXPERIMENTAL|Cohort 5: Cytisine 18.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62753910|NCT03848208|PLACEBO_COMPARATOR|Cohort 5: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62377646|NCT02576093|EXPERIMENTAL|0.1% WOL071-007|Formulation containing 0.1% WOL071-007 for topical application
62377647|NCT02576093|EXPERIMENTAL|0.3% WOL071-007|Formulation containing 0.3% WOL071-007 for topical application
62377648|NCT02576093|EXPERIMENTAL|1.0% WOL071-007|Formulation containing 1.0% WOL071-007 for topical application
62377649|NCT02576093|PLACEBO_COMPARATOR|WOL071-007 Placebo|Formulation containing Placebo of WOL071-007 for topical application
62377650|NCT00877227|EXPERIMENTAL|folinic acid|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns
62377651|NCT00877227|NO_INTERVENTION|2|control subjects admitted at the Neonatal Intensive Care Unit (NICU)
62753911|NCT03848208|EXPERIMENTAL|Cohort 6: Cytisine 21.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62753912|NCT03848208|PLACEBO_COMPARATOR|Cohort 6: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62753913|NCT03848208|EXPERIMENTAL|Cohort 7: Cytisine 24.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62753914|NCT03848208|PLACEBO_COMPARATOR|Cohort 7: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62753915|NCT03848208|EXPERIMENTAL|Cohort 8: Cytisine 27.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62753916|NCT03848208|PLACEBO_COMPARATOR|Cohort 8: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
61986539|NCT02990208|EXPERIMENTAL|VR exposure + diaphragmatic breathing|Virtual Reality Exposure Therapy + Diaphragmatic breathing
62377652|NCT00175838|ACTIVE_COMPARATOR|Intermediate risk group|Intermediate risk patients are randomised to a either a group receiving Aspirin only, or a group receiving both Hydroxyurea and Aspirin.
62377653|NCT00175838|ACTIVE_COMPARATOR|Low risk group|Patients are given Aspirin only with observation.
62377654|NCT00997607|EXPERIMENTAL|Ebola vaccine only|Participants will receive only the Ebola vaccine or a placebo injection.
62753917|NCT03848208|EXPERIMENTAL|Cohort 9: Cytisine 30.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62753918|NCT03848208|PLACEBO_COMPARATOR|Cohort 9: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
62753919|NCT05606536|EXPERIMENTAL|10 % hemodilution|"Recumbent surgery:~* infusion rate in first 20 minutes: 15 ml/kg/h~* infusion rate after 20 minutes: 2,6 ml/kg/h~Laparoscopic surgery:~* infusion rate in first 20 minutes: 16 ml/kg/h~* infusion rate after 20 minutes: 0,8 ml/kg/h"
62753920|NCT05606536|EXPERIMENTAL|20 % hemodilution|"Recumbent surgery:~* infusion rate in first 20 minutes: 26 ml/kg/h~* infusion rate after 20 minutes: 3,4 ml/kg/h~Laparoscopic surgery:~* infusion rate in first 20 minutes: 28 ml/kg/h~* infusion rate after 20 minutes: 1,6 ml/kg/h"
61986540|NCT02990208|ACTIVE_COMPARATOR|VR exposure|Virtual Reality Exposure Therapy
61986541|NCT04733365|EXPERIMENTAL|Training group|Patients admitted due to decompensated heart failure who will perform the training protocol - ERIC protocol
61986542|NCT04733365|NO_INTERVENTION|Control group|Patients admitted due to decompensated heart failure who will perform the standard rehabilitation nursing care for this type of patients
62377655|NCT00997607|EXPERIMENTAL|Marburg vaccine only|Participants will receive only the Marburg vaccine or a placebo injection.
62377656|NCT00997607|EXPERIMENTAL|Ebola and Marburg vaccine|Participants will receive both the Ebola and Marburg vaccines, one in each arm or placebo injections.
62377657|NCT04742140|ACTIVE_COMPARATOR|group I|each patient injected 0.5ml in each TrPs of saline by the same operator
62377658|NCT04742140|EXPERIMENTAL|group II|each patient injected 0.5ml in each TrPs of magnesium sulphate by the same operator
62377659|NCT05789706|EXPERIMENTAL|Intervention Arm|Patients will have Dayamed Arthur a novel intelligent medication adherence platform installed on their smartphone and configured with their pharmacy data providing accurate prompts and reminders to patients to take medications as directed In addition to the prompts patient all auditable information will be relayed to their PACT CPS through a provider dashboard allowing for timely and directed clinical intervention. Dayamed Arthur will provide automated alerts to the patients care team in specific scenarios.
62556409|NCT02350465|EXPERIMENTAL|Eccentric Exercise|Supervised strengthening exercise using eccentric muscle actions.
62753921|NCT05606536|EXPERIMENTAL|30 % hemodilution|"Recumbent surgery:~* infusion rate in first 20 minutes: 38 ml/kg/h~* infusion rate after 20 minutes: 5,1 ml/kg/h~Laparoscopic surgery:~* infusion rate in first 20 minutes: 44 ml/kg/h~* infusion rate after 20 minutes: 2,4 ml/kg/h"
62753922|NCT05606536|NO_INTERVENTION|Standart care|Infusion rate based upon the standard care.
62753923|NCT02944227|EXPERIMENTAL|Lucentis|Lucentis fixed treatment
62753924|NCT01505673|ACTIVE_COMPARATOR|Liraglutide|
62753925|NCT01505673|PLACEBO_COMPARATOR|Saline injection|
62753926|NCT01266356||Experimental Group|
62753927|NCT01266356||Control Group|
62753928|NCT05341895|OTHER|kinesiotape|Kinesiotape applied to the paraspinal muscles
62753929|NCT05341895|NO_INTERVENTION|Placebo|No intervention
62753930|NCT05704907|OTHER|gallblader ultrasound|
62753931|NCT04105738||Difficult airways|Documented history of difficult airways.
62753932|NCT04105738||Control (Not difficult airways)|Age matched with normal airways to be used as controls
62753933|NCT04748068|EXPERIMENTAL|Glidesheath Slender|The transradial procedure will be performed using the 7-Fr glidesheath slender (studied sheath)
62753934|NCT04748068|ACTIVE_COMPARATOR|Standard sheath|The transradial procedure will be performed using the standard 7- French radial sheath (comparator sheath)
62753935|NCT02373956|EXPERIMENTAL|MELECTIS G|"In addition to usual care as described for the other arm, patients randomized to this arm will have MELECTIS G added to their wound dressing according to the manufacturer's instructions.~Intervention: Usual care Intervention: MELECTIS G"
62377660|NCT05789706|NO_INTERVENTION|Standard of Care Arm|Study subjects will be counseled on medication adherence and strategies to remember how to take their medications correctly. Study subjects will then be followed as clinically indicated by their clinical care team.
62377661|NCT05793372||patients with Alzheimer's Disease|Patients with Alzheimer's disease
62377662|NCT01590446|PLACEBO_COMPARATOR|Placebo|
62556410|NCT02350465|ACTIVE_COMPARATOR|Concentric Exercise|Supervised strengthening exercise using concentric muscle actions.
62556411|NCT02383017|EXPERIMENTAL|Shroom Tech Sport|Shroom Tech Sport is a multi-ingredient performance supplement taken, in pill form, prior to work outs to enhance workout performance.
62753936|NCT02373956|ACTIVE_COMPARATOR|Usual care|"Patients randomized to this are will receive usual care according the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).~Intervention: Usual care"
62753937|NCT06608901|EXPERIMENTAL|REGN7544|
62753938|NCT06608901|PLACEBO_COMPARATOR|Placebo (PB)|
62753939|NCT03243214|ACTIVE_COMPARATOR|PD-MCI, TMS|The patient is treated with TMS stimulation according to protocol with an active coil.
61986543|NCT01894165|EXPERIMENTAL|ALXN1101|Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.
61986544|NCT01894165|PLACEBO_COMPARATOR|Placebo|Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.
62556412|NCT02383017|PLACEBO_COMPARATOR|Placebo|The placebo is a calorie matched sugar pill that will be taken in the same fashion as the STS pill.
62753940|NCT03243214|SHAM_COMPARATOR|PD-MCI, Sham-TMS|The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil.
62753941|NCT03424369||Eustachian tube unobstructed|
62753942|NCT03424369||Eustachian tube dysfunction|
61986545|NCT00939913|PLACEBO_COMPARATOR|intravenous N-acetlycysteine|"intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)as compared to placebo~Acetadote provided by Cumberland Pharmaceuticals Inc."
61986546|NCT00939913|PLACEBO_COMPARATOR|Placebo|Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
61986547|NCT03041246|EXPERIMENTAL|Study group - Treatment with PFFM|Manual treatment for the pelvic floor will be provided in two sessions two weeks apart as long as guidance towards exercise for strengthening of the pelvic floor
61986548|NCT03041246|NO_INTERVENTION|Control group -|Guidance towards exercise for strengthening of the pelvic floor with no other interventional treatment.
62377663|NCT01590446|ACTIVE_COMPARATOR|BMN 111|
62556413|NCT01689051|ACTIVE_COMPARATOR|Healthy subjects|
62753943|NCT02068690|EXPERIMENTAL|BI 425809 single rising dose|BI 425809 powder for oral solution (PfOS) in single rising doses
62753944|NCT02068690|EXPERIMENTAL|BI 425809 Crossover|Bioavailability of BI 425809 PfOS
62753945|NCT03617263|EXPERIMENTAL|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium once daily in the morning before breakfast
62753946|NCT03617263|PLACEBO_COMPARATOR|Placebo|Placebo tablet once daily in the morning before breakfast
62753947|NCT05550038|EXPERIMENTAL|compression ultrasound|All patients receive a 3-point compression ultrasound followed within 72 hours by a whole-leg ultrasound with Doppler performed by a vascular physician.
62377664|NCT05500391|EXPERIMENTAL|Experimental|Telesurveillance by a nurse
62377665|NCT05500391|OTHER|Control|On-site surveillance by a hospital physician
62556414|NCT01689051|ACTIVE_COMPARATOR|Patients with type 2 diabetes|
62556415|NCT04565574|EXPERIMENTAL|Part A: E7090 35 mg (Fasted + Fed + Fed)|Participants will receive E7090 35 milligram (mg) tablet, orally on Day 1 of Treatment Period 1 in fasted state, followed by E7090 35 mg tablet, orally on Day 1 of Treatment Period 2 in fed state (high-fat meal). A wash out period of 5 days will be maintained between Treatment Periods 1 and 2. Further participant will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 3 in fed state (low-fat meal).
62556416|NCT04565574|EXPERIMENTAL|Part A: E7090 35 mg (Fed + Fasted + Fed)|Participants will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 1 in fed state (high-fat meal), followed by E7090 35 mg tablet, orally on Day 1 of Treatment Period 2 in fasted state. A wash out period of 5 days will be maintained between Treatment Periods 1 and 2. Further participant will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 3 in fed state (low-fat meal).
62556417|NCT04565574|EXPERIMENTAL|Part B: E7090 35 mg + Rabeprazole 20 mg|Participants will receive E7090 35 mg tablet, orally on Day 1 in fasted state, followed by a wash out period of 5 days, further followed by rabeprazole 20 mg tablets, orally, once daily on Days 7 to 10, and then followed by E7090 35 mg tablet and rabeprazole 20 mg tablets, orally on Day 11 in fasted state.
62556418|NCT04565574|EXPERIMENTAL|Part C: E7090 35 mg + Rifampin 600 mg|Participants will receive E7090 35 mg tablet, orally on Day 1 in fasted state, followed by a wash out period of 5 days, further followed by rifampin 600 mg capsules, orally, once daily on Days 7 to 12, then followed by E7090 35 mg tablet and rifampin 600 mg capsules, orally on Day 13 in fasted state, and then by rifampin 600 mg capsules, orally, once daily on Days 14 to 18.
62753948|NCT06303648|EXPERIMENTAL|Cohort 1|50 mg x 1 dose
62753949|NCT06303648|EXPERIMENTAL|Cohort 2|100 mg x 1 dose
62753950|NCT06303648|EXPERIMENTAL|Cohort 3|150 mg x 1 dose
62753951|NCT06303648|EXPERIMENTAL|Cohort 4|200 mg x 1 dose
62753952|NCT05694338||Major surgery for gastrointestinal cancer|Patients with gastrointestinal cancer who are scheduled for major surgery
62753953|NCT03305419|EXPERIMENTAL|Subjects receiving treatment sequence ABC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence ABC in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
62753954|NCT03305419|EXPERIMENTAL|Subjects receiving treatment sequence ABP in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence ABP in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and P= Placebo. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
62377666|NCT05989815|EXPERIMENTAL|PBMT post muscle damage protocol (PBMT-post)|"Group submitted to pre-exercise Sham (placebo) photobiomodulation therapy (PBMT), and post-exercise active PBMT.~PBMT will be administered using the Joovv Elite System, which has 6 panels of red Light-Emiting Diodes (LEDs) (660±10nm) and 74 panels of infrared LEDs (850±10nm), totaling 900 LEDs covering an area of 12,193 cm². Athletes will stand 20 cm in front of the device, wearing only swim shorts to expose their thigh muscles and other body areas to the light. The total irradiation time will be 20 minutes, with 10 minutes (600 seconds) of irradiation for the anterior region and another 10 minutes (600 seconds) for the posterior region. The active PBMT dose applied in each region (anterior or posterior) will be 48.97 J/cm², with an irradiance of 81.62 mW/cm²."
62377667|NCT05989815|EXPERIMENTAL|PBMT pre (PBMT-pre)|"Group submitted to pre-exercise active photobiomodulation therapy (PBMT), and post-exercise Sham (placebo) PBMT.~PBMT will be administered using the Joovv Elite System, which has 6 panels of red Light-Emiting Diodes (LEDs) (660±10nm) and 74 panels of infrared LEDs (850±10nm), totaling 900 LEDs covering an area of 12,193 cm². Athletes will stand 20 cm in front of the device, wearing only swim shorts to expose their thigh muscles and other body areas to the light. The total irradiation time will be 20 minutes, with 10 minutes (600 seconds) of irradiation for the anterior region and another 10 minutes (600 seconds) for the posterior region. The active PBMT dose applied in each region (anterior or posterior) will be 48.97 J/cm², with an irradiance of 81.62 mW/cm²."
62377668|NCT05989815|SHAM_COMPARATOR|PBMT placebo (PBMT-sham)|"Group submitted to pre-exercise and post-exercise photobiomodulation therapy (PBMT) Sham (placebo).~PBMT will be administered using the Joovv Elite System, which has 6 panels of red Light-Emiting Diodes(LEDs) (660±10nm) and 74 panels of infrared LEDs (850±10nm), totaling 900 LEDs covering an area of 12,193 cm². Athletes will stand 20 cm in front of the device, wearing only swim shorts to expose their thigh muscles and other body areas to the light. The total irradiation time will be 20 minutes, with 10 minutes (600 seconds) of irradiation for the anterior region and another 10 minutes (600 seconds) for the posterior region. The Sham PBMT dose applied in each region (anterior or posterior) will be 0 J/cm², with an irradiance of 0 mW/cm²."
62377669|NCT00354484|EXPERIMENTAL|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
62377670|NCT00354484|ACTIVE_COMPARATOR|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
62377671|NCT05914233|EXPERIMENTAL|Single|Stimulation of the ultrasound retinal stimulation Device
62377672|NCT00758004|OTHER|Reference|Commercial 80 mg atorvastatin tablet
62377673|NCT00758004|OTHER|Test|Pediatric appropriate atorvastatin 40mg formulation
62377674|NCT00112840|EXPERIMENTAL|CCI-779 and bevacizumab|Patients receive CCI-779 IV on days 1, 8, 15, and 22 and bevacizumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of CCI-779 and bevacizumab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Phase II patients receive CCI-779 and bevacizumab as in phase I at the MTD determined in phase I. After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years after study entry.
62377675|NCT01008436|ACTIVE_COMPARATOR|Control|Traditional best-practice surgical hemostasis
62377676|NCT01008436|EXPERIMENTAL|Omni-stat Celox|Administration of 6 gr of Omni-stat Celox intraoperatively at the time of Hemostasis
62377677|NCT03932591|EXPERIMENTAL|intervention|Inhibitory kinesio taping method will be used for intervention group. Y shaped, 34-40 cm length, 5 cm width, skin color kinesio tape will be applied on spastic gastrocsoleus muscle. The base of Y shaped tape will be strapped on calcaneus ( no stretch for first 5 cm) and the both legs of Y shaped tape will be strapped on gastrocnemius muscle medial and lateral head with 15% stretch.
62377678|NCT03932591|SHAM_COMPARATOR|Control|Sham kinesio tape will be used for controlled group. 2,5 cm width, 5 cm length, skin color 2 pieces kinesio tape will be applied on medial and lateral head of gastrocnemius muscle without stretch. 5 cm length, 5 cm width, skin color 1 piece kinesio tape will be applied on achilles tendon without stretch.
62377679|NCT02639754|EXPERIMENTAL|Social Network Leader Endorsement|Leaders of social networks randomized to this arm will be trained to endorse frequent HIV testing, compliance with medical guidelines, and effective ways to communicate these concepts to social network members.
62377680|NCT02639754|ACTIVE_COMPARATOR|Routine Counseling|Members of social networks randomized to this arm will receive HIV counseling at baseline sessions.
62377681|NCT05413356|EXPERIMENTAL|treatment group|Ruxolitinib twice daily treatment, combined with steroids 1mg/kg/day for two weeks, and tampering 0.25 mg/kg/day every week
62377682|NCT02618512|EXPERIMENTAL|SBC-103|Patients were administered 1 mg/kg by IV infusion once every other week (qow) for at least 12 weeks. After evaluation of 12-week safety, tolerability, and pharmacodynamic data in individual patients, the dose was increased to 3 mg/kg qow. Infusions were to be at least 10 days apart and were administered every 14 days ±5 days.
62377683|NCT04361721||Chronic migraine patients|Three monthly administration of erenumab 70 mg subcutaneously.
62377684|NCT04471532|EXPERIMENTAL|Behavior change intervention|A 3-month behavior change intervention i.e. one initial, face-to-face, physical activity counselling and two telephone-assisted counselling.
62377685|NCT04471532|NO_INTERVENTION|Control|No attention
62377686|NCT01723124|EXPERIMENTAL|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
62377687|NCT02558972|PLACEBO_COMPARATOR|Northera-single dose|Study #1 -Does single large dose (600mg) of Northera improve upright hemodynamics and orthostatic intolerance in POTS and VVS
62556419|NCT03303235|EXPERIMENTAL|IV Methergine|"IV methylergonovine group~-IM 0.9% NaCl (1 ml)) + IV methylergonovine (2 mcg/ml) infusion (100 ml)"
61986549|NCT01097018|ACTIVE_COMPARATOR|Perifosine + Capecitabine|Perifosine 1 tablet daily + Capecitabine BID days 1 - 14 every 21 days
62753955|NCT03305419|EXPERIMENTAL|Subjects receiving treatment sequence APC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence APC in Part A; A= GSK2982772 120 mg TID, P= Placebo and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
62377688|NCT02558972|PLACEBO_COMPARATOR|Northera- chronic administration|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day.
62377689|NCT04955574|EXPERIMENTAL|Probiotic + Antibiotic Placebo|
62377690|NCT04955574|EXPERIMENTAL|Probiotic + Antibiotic|
62377691|NCT04955574|PLACEBO_COMPARATOR|Probiotic Placebo + Antibiotic Placebo|
62377692|NCT05393661||Patients undergoing inpatient rehabilitation poststroke|Inpatient rehabilitation poststroke
62377693|NCT01469637|EXPERIMENTAL|Sulfamethoxazole + MMX placebo|
62377694|NCT01469637|EXPERIMENTAL|Sulfamethoxazole + MMX Mesalazine/mesalamine|
62753956|NCT03305419|EXPERIMENTAL|Subjects receiving treatment sequence PBC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence PBC in Part A; P= Placebo, B= GSK2982772 240 mg TID and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
62753957|NCT03305419|EXPERIMENTAL|Subjects receiving GSK2982772 120 mg TID in cohort 2 : Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
62377695|NCT02937090||Polycystic Ovary Syndrome|"Premenopausal women between 18-40 years of age.~Diagnosed with PCOS using Rotterdam criteria (meet 2 of the 3):~1. chronic oligo- or amenorrhea (irregular periods during more than a year in combination with a cycle length longer than 35 days);~2. total or free T levels above the reference interval and/or excessive facial hair, acne;~3. transvaginal ultrasound with polycystic ovaries.~Exclusion of common medical disorders (normal thyroid function tests and serum prolactin and exclusion of 21-hydroxylase deficiency)."
62377696|NCT02937090||Control|Women matched for age and BMI.
62377697|NCT05257915||Perampanel|Epilepsy patients who had failed clinical treatment with 1-3 anti-epileptic drugs (AEDs) with the optimal dose and course of treatment and needed perampanel additional treatment.
62377698|NCT03979495|NO_INTERVENTION|Standard of care|standard of care
62377699|NCT03979495|ACTIVE_COMPARATOR|IT platform|Access to an IT platform for visit-based reminders about overdue abnormal cancer screening test results
62377700|NCT03979495|ACTIVE_COMPARATOR|IT platform with reminders|Access to an IT platform that will deliver both visit based and between visit reminders about abnormal cancer screening test results.
62377701|NCT03979495|ACTIVE_COMPARATOR|IT platform and patient navigation|the IT platform available in Arm 3 and navigation to help with scheduling and to address social barriers to care.
62377702|NCT04334044|EXPERIMENTAL|Ruxolitinib|Ruxolitinib 5 mg BID since the beginning of dyspnea or increment of work of breathing with pneumonia changes in chest CT-scan
62377703|NCT02513355|EXPERIMENTAL|NP(Changchun marina+cisplatin)+Endostar|Patients in this group will be given conventional chemotherapy medicine,NP plan (Changchun marina+cisplatin)recommended by treatment guidelines for Advanced non small cell lung cancer. Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles;Changchun marina;25mg/m2,d1 and d8,cisplatin 80mg/m2,d1, q21d×4
62377704|NCT02513355|EXPERIMENTAL|TP(Taxol+cisplatin or parapl) +Endostar|"Patients in this group will be given conventional chemotherapy medicine,TP(Taxol+cisplatin)recommended by treatment guidelines for Advanced non small cell lung cancer.~Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles; Taxol;135-175mg/m2,d1,cisplatin or parapl 75mg/m2,d1,q21d×4."
61986550|NCT01097018|PLACEBO_COMPARATOR|Placebo + Capecitabine|Placebo 1 tablet daily + Capecitabine BID days 1 - 14 every 21 days
61986551|NCT03207932||ultrasound|CVC insertion using ultrasound
62377705|NCT00537810|EXPERIMENTAL|Sibutramine|Sibutramine 15 mg daily
62377706|NCT00537810|PLACEBO_COMPARATOR|Placebo|Placebo Daily
62377707|NCT00537810|EXPERIMENTAL|Placebo/CBTsh|Placebo and Self-help CBT Placebo daily, Cognitive behavioral self-help manual for binge eating
62377708|NCT00537810|EXPERIMENTAL|Sibutramine/CBTsh|Sibutramine and Self-help CBT 15 mg daily Cognitive behavioral treatment manual for binge eating
62377709|NCT01945190|EXPERIMENTAL|True before sham electroacupuncture|Crossover design, individuals randomized to receive either true or sham acupuncture in first study day, and on the second study day whichever intervention was not administered on the first study day.
62377710|NCT01945190|EXPERIMENTAL|Sham before true electroacupuncture|Crossover design, individuals randomized to receive either true or sham acupuncture in first study day, and on the second study day whichever intervention was not administered on the first study day.
62377711|NCT02894294||Intervention district|implementation of the seasonal malaria chemoprevention
62377712|NCT02894294||Control district|no implementation of the seasonal malaria chemoprevention
62377713|NCT04770259|NO_INTERVENTION|Control|The control group will have a nursing evaluation and then follow the surgeon's instructions in the current standard way until de surgery day. In that day the RN will be evaluate again these group. Then, this group will be followed within the hospital and the first, second and third month after discharge.
62556420|NCT03303235|ACTIVE_COMPARATOR|Conventional|"IM methylergonovine group~-200 mcg IM methylergonovine (1 ml) + IV 0.9% NaCl infusion (100 ml)"
62556421|NCT05870384|EXPERIMENTAL|Psychotherapy|Group psychotherapy will be applied to a single intervention group.
62556422|NCT04294407||Stroke group|20 to 65 years old patients, with the clinical diagnosis of stroke (Mini-mental state examination (MMSE) score of ≥25)
62556423|NCT04294407||Healthy group|20 to 65 years old healthy subjects, without the clinical diagnosis of stroke
61986552|NCT03207932||landmark technique|CVC insertion using landmark technique
61986553|NCT03030573|OTHER|Device: Round ligament and the bile duct|The investigators describe the safety and efficacy of the reconstruction of the bile duct with the Round ligament.
62556424|NCT02193919||cohort 1 placebo + UVB|cohort 1 placebo + UVB
62556425|NCT02193919||South Beach Diet + UVB|South Beach DIet + UVB
62556426|NCT02193919||Ornish Diet + UVB|Ornish Diet + UVB
62753958|NCT03305419|EXPERIMENTAL|Subjects receiving GSK2982772 120 mg TID in cohort 3 : Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
62753959|NCT03305419|EXPERIMENTAL|Subjects receiving GSK2982772 240 mg TID in cohort 4: Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 240 mg TID for 14 days in Part B.
62753960|NCT03305419|EXPERIMENTAL|Subjects receiving GSK2982772 360 mg BID in cohort 5: Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 360 mg BID for 14 days in Part B.
62753961|NCT03305419|PLACEBO_COMPARATOR|Subjects receiving placebo in cohort 2 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
62753962|NCT03305419|PLACEBO_COMPARATOR|Subjects receiving placebo in cohort 3 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
62753963|NCT03305419|PLACEBO_COMPARATOR|Subjects receiving placebo in cohort 4 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
62753964|NCT03305419|PLACEBO_COMPARATOR|Subjects receiving placebo in cohort 5: Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
62753965|NCT02358031|EXPERIMENTAL|Pembrolizumab Monotherapy (Pembro Mono)|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for up to 35 cycles (up to \~2 years).
62753966|NCT02358031|EXPERIMENTAL|Pembrolizumab + Chemotherapy (Pembro Combo)|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 35 cycles (up to \~2 years); plus cisplatin 100 mg/m\^2 IV or carboplatin at a target area under the curve of 5 (AUC 5) IV, per Investigator's choice, on Day 1 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]); plus 5-FU 1000 mg/m\^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
62753967|NCT02358031|ACTIVE_COMPARATOR|Cetuximab + Chemotherapy (Control)|Participants receive cetuximab on Day 1 at a dose of 400 mg/m\^2 IV, and then 250 mg/m\^2 IV on Day 1 of each subsequent week until disease progression or unacceptable toxicity; plus cisplatin 100 mg/m\^2 IV or carboplatin AUC 5 IV (Investigator's choice) on Day 1 of each 3-week cycle (6 cycle maximum \[up to \~4 months\] for platinum-based therapy); plus 5-FU 1000 mg/m\^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
62753968|NCT03088748||Smith & Nephew Journey II PCR TKA|Subjects implanted with a Smith \& Nephew Journey II posterior cruciate retaining total knee arthroplasty
62753969|NCT03088748||Smith & Nephew Journey II BCR TKA|Subjects implanted with a Smith \& Nephew Journey II posterior bi-cruciate retaining total knee arthroplasty
62753970|NCT04319380|ACTIVE_COMPARATOR|SMC with SP+AQ|Administration of tetanus/diphtheria toxoids vaccine followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1 and 2.
62753971|NCT04319380|ACTIVE_COMPARATOR|RTS,S/AS01|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1 and 2.
62753972|NCT04319380|ACTIVE_COMPARATOR|RTS,S/AS01 plus SMC with SP+AQ|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1 and 2.
62753973|NCT03259503|EXPERIMENTAL|Treatment (olaparib, high-dose chemotherapy, transplant)|Patients receive olaparib PO BID on days -11 to -3, vorinostat PO on days -10 to -3, gemcitabine IV over 4.5 hours on days -9 and -4, busulfan IV over 3 hours on day -9 to -6, melphalan IV over 30 minutes on days -4 and -3, and undergo peripheral blood stem cell transplant IV over 30-60 minutes on day 0. Patients with CD20+ tumors also receive rituximab IV over 3-6 hours on day -10.
62753974|NCT06390540|EXPERIMENTAL|Exercise Group|"In the study, women will perform breathing and relaxation exercises for 8 weeks.~In the first phase of the intervention, women will be given home exercise program training. The training will be held face to face at the Family Health Center. The day and time will be determined according to the women's preference. Afterwards, women will be informed about the exercise program and the exercise program will be shared in writing.~In the second phase of the intervention, a total of four exercise videos will be sent to women every two weeks on Sunday.Exercise videos will be sent to women through social networks such as WhatsApp, Instagram, Facebook and Twitter.~Women's exercise routines will be recorded by researchers by calling the women and monitoring whether they do the exercises through self-report."
62753975|NCT06390540|NO_INTERVENTION|Control Group|No intervention will be made to women in the control group. When necessary, women's questions will be answered via phone. At the end of the study, breathing and relaxation exercise training will be given to the control group. Trainings will be held face to face at the Family Health Center. The training program will be planned taking into account the demands of women.
62753976|NCT03349645|EXPERIMENTAL|AMPION™ 4 mL dose|4 mL intra-articular injection of AMPION™
62753977|NCT00532025|EXPERIMENTAL|1|Sorafenib treatment
62753978|NCT02463747|EXPERIMENTAL|Prolonged Infusion of antibiotics|"Prolonged (4 hours) Infusion of antibiotics.~Intervention:~Primary care would be one of three options:~1. Piperacillin/tazobactam : 4.5gr, TID, I.V.~   Or~2. Fortum (Ceftazidim): 2.0gr, TID, I.V. - for penicillin-sensitive patients.~   Or~3. Meropenem: 1.0gr, TID, I.V.~Supplementation of Vancomycin will be at the discretion of the treating physician."
62753979|NCT02463747|ACTIVE_COMPARATOR|Fixed time infusion of antibiotics|"Fixed time (half and hour) infusion of antibiotics.~Intervention:~Primary care would be one of three options:~1. Piperacillin/tazobactam : 4.5gr, TID, I.V.~   Or~2. Fortum (Ceftazidim): 2.0gr, TID, I.V. - for penicillin-sensitive patients.~   Or~3. Meropenem: 1.0gr, TID, I.V.~Supplementation of Vancomycin will be at the discretion of the treating physician/"
62753980|NCT05469243||psychedelics|50 non active military participants not under the care of Dr. Gupta will be recruited through word of mouth and advertising to self-identify as having used psychedelic medicine for non recreational purposes (Appendix B recruitment letter). In addition to demographic information, they will be asked to complete the PGIC and anxiety, mood, pain and disability subscales, PEG, HADS and DI, provide information on their past medical history, nature/indications for use, and adverse events. This data will be collected once per participant and they will be able to speak with a research associate if further clarification if necessary at anytime.
62753981|NCT04979897||Intensive care unit stay during high bed occupancy in the COVID-19 pandemic|Adult patients (≥18 years old) who are mechanically ventilated for at least 48 hours in one of the participating ICUs during a high bed occupancy in the pandemic
62753982|NCT04979897||Intensive care unit stay during low bed occupancy in the COVID-19 pandemic|Adult patients (≥18 years old) who are mechanically ventilated for at least 48 hours in one of the participating ICUs during a low bed occupancy in the pandemic
61986554|NCT01763437|NO_INTERVENTION|Observation|30 patients will be randomized to observation alone. These patients will return 4 weeks (+/- 2 weeks) after their initial visit for lesion measurement and photographs.
61986555|NCT01763437|EXPERIMENTAL|Tetracycline|30 patients will be randomized to treatment with an intralesional injection of 0.05 mL of 2% tetracycline solution. These subjects will return 4 weeks (+/- 2 weeks) after treatment for lesion measurement and photographs.
61986556|NCT04634864|ACTIVE_COMPARATOR|Anodal tDCS|40 minutes of 2mA intensity direct current stimulation
61986557|NCT04634864|SHAM_COMPARATOR|sham tDCS|40 minutes of 0mA intensity. the session starts with a ramp up to 2mA, but machine is switched off after 2 minutes of stimulation.
61986558|NCT04777162|EXPERIMENTAL|tislelizumab+anlotinib|patients will be administrate with dual drugs, tislelizumab plus anlotinib.
61986559|NCT03760120|ACTIVE_COMPARATOR|PEP standard|
62753983|NCT01018134|EXPERIMENTAL|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered once daily to affected area
62753984|NCT01018134|EXPERIMENTAL|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered twice daily to affected area
62753985|NCT01018134|EXPERIMENTAL|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered once daily to affected area
62753986|NCT01018134|EXPERIMENTAL|Desoximetasone 0.25% twice daily|Desoximetasone topical spray 0.25% administered twice daily to affected area
62753987|NCT01018134|PLACEBO_COMPARATOR|Vehicle once daily|Vehicle administered to affected areas once daily
62753988|NCT01018134|PLACEBO_COMPARATOR|Vehicle twice daily|Vehicle administered to affected areas twice daily
62753989|NCT05891886|EXPERIMENTAL|Supplemental oxygen delivered by facemask|"Patients with acute PE will be randomized to breathing supplemental oxygen by non-rebreather face mask first.~Subjects will alternate treatments (supplemental oxygen or room air) every 30 minutes for 90 minutes (e.g. T=30, T=60, T=90) and then will maintain their treatment (oxygen or room air) for a total of 180 minutes."
62377714|NCT04770259|EXPERIMENTAL|Intervention|The intervention group will have a nursing evaluation and then will attend an evaluation by geriatarics team, kinesiology and nutrition, where a plan of physical cardiovascular, nutritional and metabolic prehabilitation is delivered. On the day of surgery, the RN will evaluate this group again. Then, this group will be followed within the hospital and the first, second and third month after discharge.
62377715|NCT02540655|EXPERIMENTAL|Stemchymal®|Infusion of Stemchymal®
62377716|NCT02540655|PLACEBO_COMPARATOR|Vehicle|Infusion of excipients
62377717|NCT05993585|EXPERIMENTAL|CRT Group|CRT group: We will include patients with symptomatic heart failure (LV ejection fraction \<35% on TTE, NYHA II-IV) and an RV pacing percentage of \>40%, thus meeting ESC Criteria for CRT upgrade.
62377718|NCT05993585|ACTIVE_COMPARATOR|Control Group|Control group: patients with an existing dual chamber pacemaker and with preserved ejection fraction
62377719|NCT03231592|EXPERIMENTAL|CSA Group|This group will receive CSA Shares (a selection of fresh fruits and vegetables from a local farm) each week for 24 weeks over the summer of 2017 and 2018. The CSA does not operate over the winter.
62377720|NCT03231592|ACTIVE_COMPARATOR|Enhanced Usual Care Group|This group will receive a handout about healthy eating, in addition to routine care in their primary care practice.
62377721|NCT05411263|EXPERIMENTAL|Patients with advanced heart failure undergoing clinically indicated right heart catheterisation|Patients with advanced heart failure undergoing right heart catheterisation as clinically indicated, irrespectively of their ejection fraction.
62377722|NCT01886092|ACTIVE_COMPARATOR|Active rTMS1|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex
62377723|NCT01886092|ACTIVE_COMPARATOR|Active rTMS2|Temporal low frequency repetitive transcranial magnetic stimulation of left primary auditory cortex
62377724|NCT01886092|ACTIVE_COMPARATOR|Active rTMS3|Frontal low frequency repetitive transcranial magnetic stimulation of left dorsolateral prefrontal cortex
61986560|NCT03760120|SHAM_COMPARATOR|PEP sham|
62753990|NCT05891886|ACTIVE_COMPARATOR|Room air delivered by facemask|"Patients with acute PE will be randomized to breathing room air by non-rebreather face mask first.~Subjects will alternate treatments (supplemental oxygen or room air) every 30 minutes for 90 minutes (e.g. T=30, T=60, T=90) and then will maintain their treatment (oxygen or room air) for a total of 180 minutes."
62753991|NCT04098237|EXPERIMENTAL|Standard of care treatment with Pancreaze (pancrelipase)|Pancrelipase capsules; 84,000 IU lipase units per main meal and 42,000 IU lipase units per snack; for 24 weeks
62753992|NCT03272828|ACTIVE_COMPARATOR|Parallel sided implant Group|A Parallel sided titanium dental implant will be placed in the edentulous mandible.
62753993|NCT03272828|ACTIVE_COMPARATOR|Tapered shaped implant Group|A tapered shaped titanium dental implant will be placed in the edentulous mandible.
62753994|NCT04911400|EXPERIMENTAL|Upper-lower clear plastic retainers + Class III elastics|Upper-lower clear plastic retainers + Class III elastics
62753995|NCT04911400|ACTIVE_COMPARATOR|Upper-lower clear plastic retainers|Upper-lower clear plastic retainers
62753996|NCT05345067|EXPERIMENTAL|Experimental: Laughter yoga session parts-1|Deep breathing exercises (5 minutes)
62753997|NCT05345067|EXPERIMENTAL|Experimental: Laughter yoga session parts-2|Warm-up exercises (10 minutes)
62753998|NCT05345067|EXPERIMENTAL|Experimental: Laughter yoga session parts-3|Childish games (10 minutes)
62753999|NCT05345067|EXPERIMENTAL|Experimental: Laughter yoga session parts-4|Laughter exercises (15 minutes)
62754000|NCT02927925|EXPERIMENTAL|Daratumumab|Participants will receive daratumumab 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion once weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks thereafter until study drug discontinuation due to progressive disease (PD), consent withdrawal or unacceptable toxicity.
62556427|NCT01729273|EXPERIMENTAL|Diet and Exercise Intervention|"Tests will include EndoPAT analysis to assess endothelial function, applanation tonometry to assess arterial stiffness, carotid artery imaging to assess the wall thickness of the carotid arteries, exercise testing to assess the physical exercise capacity of these children and blood work to evaluate the lipid profile and inflammation status (CRP).~The Home Exercise Program will be 3 days a week for 12 weeks and participants will connect with the trainer to perform 45-60 minutes of a combination of strength training and aerobic activity via Skype. The Dietary Approaches to Stop Hypertension(DASH) eating pattern will be prescribed to all participants in the treatment group and specific strategies to achieve goals will be discussed weekly by the participant over the phone."
62556428|NCT01532401|EXPERIMENTAL|chlorure de sodium|
62556429|NCT01532401|PLACEBO_COMPARATOR|Methylcellulose|
62556430|NCT03205319|EXPERIMENTAL|Intervention arm / e-learning|Patients will receive e-learning instead of upper GI endoscopy.
62556431|NCT03205319|NO_INTERVENTION|Control arm / upper GI endoscopy|Patients will receive the upper GI endoscopy, i.e. standard of care
62754001|NCT01071200|EXPERIMENTAL|A|Subjects treated with r-hFSH and r-hLH (2:1 ratio of r-hFSH:r-hLH)
62754002|NCT01071200|ACTIVE_COMPARATOR|B|Subjects treated with r-hFSH alone
62754003|NCT05757856|EXPERIMENTAL|Regimen 10 (Reclined)|NDX-3315 or NDX-3324 delivered via oral syringe at \~ 1.5 mL per minute while sitting reclined.
62754004|NCT05708638|ACTIVE_COMPARATOR|Patients who were assigned to have manual anesthesia induction group with propofol|Patients who were assigned to have a manual anesthesia induction group, propofol was administered 2-3 mg/kg in 1-2 minutes to achieve a level of hypnosis measured by bispectral index ( BIS ) of 35-60.
62377725|NCT01886092|SHAM_COMPARATOR|Sham Condition|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex
62377726|NCT06399068|EXPERIMENTAL|Reference-Test|
62377727|NCT06399068|EXPERIMENTAL|Test- Reference|
62556432|NCT05172115|EXPERIMENTAL|Conventional catheter-directed thrombolysis (CDT)|Conventional catheter-directed thrombolysis (CDT) will be the interventional arm. CDT will be administered using fixed-dose of 24 mg tissue plasminogen activator infusion over 24 hours (0.5 mg/h per catheter if bilateral or 1 mg/h per unilateral catheter) with 500 unit per hour of infusion of unfractionated heparin during the thrombolytic therapy. The therapeutic dose of heparin will immediately be substituted the CDT after termination, and twice-daily subcutaneous enoxaparin (1mg/kg) for the first 48 hours after the thrombolytic therapy will be administered. Direct oral anticoagulation will be in ones with no clinical deterioration.
62556433|NCT05172115|ACTIVE_COMPARATOR|Anticoagulation-only therapy|The anticoagulation-only therapy will be the assigned treatment in the control arm. Control patients will receive subcutaneous enoxaparin (twice-daily, 1mg/kg) in the first 48hours of enrollment. Direct oral anticoagulation will be in ones with no clinical deterioration.
62754005|NCT05708638|ACTIVE_COMPARATOR|Patients who were assigned to have target controlled infusions ( TCI) induction with propofol|Patients who were assigned to have TCI induction had the target effect site concentration (Ce) of propofol (Ce) set at 3 μg ml-1 using the Schneider model and subsequently modified to achieve and maintain a level of hypnosis measured by BIS of 35-55
62754006|NCT01937858||Normal renal function|
62754007|NCT01937858||Stage 2 and 4 and 5 chronic kidney disease|
62754008|NCT01937858||End stage renal disease on hemodialysis|
62754009|NCT05923294|EXPERIMENTAL|De-epithelialized gingival unit graft|In this split-mouth randomized controlled trial, the coin toss method will determine test and control groups. In both groups, connective tissue graft with a trapezoidal flap design will be applied to the recession area. To obtain the connective tissue graft, the gingival unit graft will be de-epithelialized in the test group.
62754010|NCT05923294|EXPERIMENTAL|De-epithelialized free gingival graft|In this split-mouth randomized controlled trial, the coin toss method will determine test and control groups. In both groups, connective tissue graft with a trapezoidal flap design will be applied to the recession area. To obtain the connective tissue graft, the traditional free gingival graft will be de-epithelialized in the control group.
62754011|NCT06607367|EXPERIMENTAL|Ruxolitinib and Eltrombopag|Ruxolitinib at a dose of 10mg BD and Eltrombopag at a dose of 50mg Dose adjustments may be required based on lack of efficacy, or thrombocytopenia may occur as per the study protocol .
62754012|NCT01244633|EXPERIMENTAL|Ecopipam|Active treatment
62754013|NCT01480414|EXPERIMENTAL|4times injection|the patients with ischemic lower limb ulcer who underwent 4times stem cell injection.
62754014|NCT01480414|EXPERIMENTAL|one injection|Patients with peripheral artery disease underwent cell transplantation just one time.
62754015|NCT00938821||Caudal Block|Review of charts of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B).
62754016|NCT03381482||Controls|Group 1: the 4ml of CSF collected in the surgery context will be kept for the study, and 6x5ml of blood will be added to the usual samples.
62754017|NCT03381482||Asymptomatic cases with high risk to develop AD|Group 2: 10ml of CSF and 6x5ml of blood will be collected
62754018|NCT03381482||Cases with isolated cognitive complaint|Group 3: 10ml of CSF and 6x5ml of blood will be collected
62754019|NCT03381482||Prodromal AD|Group 4: 10ml of CSF and 6x5ml of blood will be collected
62754020|NCT03381482||Mild to moderate probable AD-type dementia|Group 5: 10ml of CSF and 6x5ml of blood will be collected
62754021|NCT00711347|ACTIVE_COMPARATOR|DisCoVisc|Alcon's DisCoVisc Ophthalmic Viscosurgical Device (OVD) used at time of cataract surgery
62754022|NCT00711347|ACTIVE_COMPARATOR|Healon5|Abbott Medical Optic's (AMO) Healon5 Ophthalmic Viscosurgical Device (OVD) used at time of cataract surgery
62754023|NCT02307097|EXPERIMENTAL|CBB|
62754024|NCT02307097|EXPERIMENTAL|CBT|
62754025|NCT02307097|ACTIVE_COMPARATOR|WAIT|
62754026|NCT06232148||Robotic ventral hernia repairs|
62754027|NCT06232148||Open ventral hernia repairs|
62377728|NCT00865995||1|patients undergoing elective procedures with intubation and no known respiratory pathology
62377729|NCT00865995||2|patients with tracheostomy
62754028|NCT06232148||Laparoscopic ventral hernia repairs|
62754029|NCT01110837|ACTIVE_COMPARATOR|Allergen|
62754030|NCT01110837|PLACEBO_COMPARATOR|Placebo|
62754031|NCT03626272|ACTIVE_COMPARATOR|8-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 8 months.
62754032|NCT03626272|ACTIVE_COMPARATOR|4-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 4 months.
62754033|NCT03626272|ACTIVE_COMPARATOR|2-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 2 months.
62754034|NCT03568552|EXPERIMENTAL|Patient Decision Aid|Participating clinics (and their patients) will be randomly selected to implement the intervention, at which time their patients will receive Patient Decision Aid for Medication Assisted Treatment for opioid use disorder.
62754035|NCT03568552|NO_INTERVENTION|Prior to intervention|All participating clinics will start with a baseline period without the intervention. The clinics and their patients will remain in the no intervention condition until randomly selected to crossover to receive the intervention.
62754036|NCT04998539|EXPERIMENTAL|Upright wheelchair forward and occupant upright|Participant will push an upright wheelchair forward over a 5 m soft surface with the wheelchair occupant in the upright body position. The participant will perform the task once.
61986561|NCT00463749|ACTIVE_COMPARATOR|1|High-dose N-Acetylcystein during percutaneous coronary intervention and for 2 days post intervention 2 x/day
61986562|NCT00463749|PLACEBO_COMPARATOR|2|Placebo (NaCl)
61986563|NCT03695510|EXPERIMENTAL|Study arm|afatinib + pembrolizumab
61986564|NCT01075698|ACTIVE_COMPARATOR|Non-ARB group|
62377730|NCT00865995||3|patients with chronic lung disease or respiratory symptoms undergoing bronchoscopy
62377731|NCT03701061|EXPERIMENTAL|Participants that received AS03 Adjuvant|Subjects that participated in HIPCVAX-010 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine with AS03 Adjuvant study are included in the study. Subjects will receive a single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent).
62377732|NCT03701061|ACTIVE_COMPARATOR|Participants that did not receive AS03 Adjuvant|Subjects that participated in HIPCVAX-010 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine without AS03 Adjuvant study are included in the study. Subjects will receive a single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent).
62377733|NCT02432911|EXPERIMENTAL|CAG regimen|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
62556434|NCT04304989|EXPERIMENTAL|Intervention|This group of participants will receive a video-based mHealth program which includes two main elements: 1) nurse case management supported by a social service team, 2) individual-specific video messages covering self-care topics delivered via smartphone
62556435|NCT04304989|OTHER|Control|The participants in this group will receive usual care
62556436|NCT00366795|EXPERIMENTAL|Satavaptan|
62556437|NCT00366795|PLACEBO_COMPARATOR|Placebo|
62556438|NCT01043692|EXPERIMENTAL|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
62556439|NCT06358768||Gynecologists|ObGyn specialists
62556440|NCT06358768||Midwives|Midwives registered
62556441|NCT06358768||Anesthesiologists|Anesthesiologists specialists
62556442|NCT06358768||Surgical theatre nurse|nurse
62556443|NCT06358768||Sanitary support personnel|SSP regularly working in labour ward
62556444|NCT02245516|ACTIVE_COMPARATOR|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% Ophthalmic Suspension dosed QID for 4 weeks in subjects with Retinal Vein Occlusion or Diabetic Macular Edema
61986565|NCT01075698|ACTIVE_COMPARATOR|ARB group|
61986566|NCT04404855|OTHER|Intervention Group (NGS + Antibiotic Recommendation)|Next Generation Sequencing results along with Infectious Disease Pharmacist will be shared with clinical provider to determine appropriate standard of care antibiotic treatment at time of standard of care urology stone procedure. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
62556445|NCT02245516|ACTIVE_COMPARATOR|KPI-121 1.0% Ophthalmic Suspension|KPI-121 1.0% Ophthalmic Suspension dosed QID for 4 weeks in subjects with Retinal Vein Occlusion or Diabetic Macular Edema
62754037|NCT04998539|EXPERIMENTAL|Upright wheelchair backward and occupant upright|Participant will pull an upright wheelchair backwards over a 5 m soft surface with the wheelchair occupant in the upright body position. The participant will perform the task once.
61986567|NCT04404855|OTHER|Control Group|NGS results will not be shared with the clinical provider at time of standard of care urology stone procedure. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
61986568|NCT03697668|EXPERIMENTAL|imatinib-Dihydroartemisinin-piperaquine|triple combination
62556446|NCT03982290|ACTIVE_COMPARATOR|Lactobacillus plantarum PS128 (PS128)|Subjects will receive oral Lactobacillus plantarum PS128 capsules, 2 capsules per day, for 16 weeks.
62556447|NCT03982290|PLACEBO_COMPARATOR|Placebo|Subjects will receive oral placebo capsules, 2 capsules per day, for the first 8 weeks. The following 8 weeks, subjects will receive oral Lactobacillus plantarum PS128 capsules, 2 capsules per day, for 8 weeks.
62556448|NCT03982290|NO_INTERVENTION|Normal Control|Normal control group are enrolled by invitation from the age and gender matched healthy children.
62556449|NCT04513301|ACTIVE_COMPARATOR|Sintilimab alone|Sintilimab (200 mg q3w ×2cycle)
62556450|NCT04513301|EXPERIMENTAL|Sintilimab+Radiotherapy|Sintilimab (200 mg q3w ×2cycle)+RT 50-60Gy/25-30f
62556451|NCT04840303|EXPERIMENTAL|Hub user group|This group receives community-based mental wellness youth hub services for young people to enhance personal strengths and overall mental well-being.
62754038|NCT04998539|EXPERIMENTAL|Wheelie wheelchair forward and occupant upright|Participant will push a wheelchair using the wheelie technique forward over a 5 m soft surface with the wheelchair occupant in the upright body position.The participant will perform the task once.
62754039|NCT04998539|EXPERIMENTAL|Wheelie wheelchair backward and occupant upright|Participant will pull a wheelchair using the wheelie technique backwards over a 5 m soft surface with the wheelchair occupant in the upright body position.The participant will perform the task once.
62754040|NCT02240823|EXPERIMENTAL|adipose derived stem cells|
62754041|NCT05974657|PLACEBO_COMPARATOR|Placebo group|Composition: 400mg maltodextrin (excipient)； Capsule total weight: 400mg； Primary conditioning: HPMC Capsules (Hydroxypropyl Methylcellulose)； Secondary conditioning：Cardboard case Secondary packaging content：14 capsules / blister, 1 blisters per case Dosage regimen: Take one capsule daily before meals； Storage：Store in a cool, dry place without exposure to the sun.
62754042|NCT05974657|ACTIVE_COMPARATOR|Probiotic group|Composition: 20mg (2x109 UFC/ capsule) Lactobacillus acidophilus LA85 (active principle) and 380mg maltodextrin (excipient)； Capsule total weight: 400mg； Primary conditioning: HPMC Capsules (Hydroxypropyl Methylcellulose)； Secondary conditioning：Cardboard case Secondary packaging content：14 capsules / blister, 1 blisters per case Dosage regimen: Take one capsule daily before meals； Storage：Store in a cool, dry place without exposure to the sun.
62754043|NCT06009887|EXPERIMENTAL|Experimental: İntervention Group|Motivational interviewing is a counseling approach that pays special attention to the language of change, adopts a collaborative, goal-oriented communication style and aims to strengthen personal motivation and commitment to this change, revealing and discovering the reasons for the change in one's own, in an atmosphere of acceptance and empathy.
62377734|NCT02432911|ACTIVE_COMPARATOR|Low dose cytarabine|cytarabine 20mg bid for 10 days.
62377735|NCT04224909||Patients with Sudden Sensorineural Hearing Loss|
61986569|NCT03697668|ACTIVE_COMPARATOR|Dihydroartemisinin-piperaquine|standard of care
61986570|NCT02441933|ACTIVE_COMPARATOR|control group|
61986571|NCT02441933|EXPERIMENTAL|carboplatin group|
61986572|NCT01855633|EXPERIMENTAL|Tradtional Theta burst stimulation (TBS) rTMS|Participants will receive continuous theta burst stimulation (cTBS) rTMS to contralesional hemisphere based on a previous study (Huang et al., 2005)
62377736|NCT03248960|EXPERIMENTAL|iTreat Flu A+B Test and ellume.lab Flu A+B Test|"Upper respiratory tract samples from participants will be tested with:~iTreat Flu A+B Test; ellume.lab Flu A+B Test; Reverse Transcriptase Polymerase Chain Reaction (RT-PCR); and viral culture."
62377737|NCT02604628|NO_INTERVENTION|Control|Patients will be treated as standard of care.
62377738|NCT02604628|EXPERIMENTAL|Antibiotic Stewardship Intervention|Patients will be treated as standard of care. The Antibiotic Stewardship Intervention will be targeted at the physicians treating the community-acquired pneumonia patients. The purpose of the intervention is to increase prescription concordance with the national guideline for community-acquired pneumonia.
61986573|NCT01855633|ACTIVE_COMPARATOR|Modified TBS rTMS|Participants will receive modified cTBS rTMS to contralesional hemisphere based on a previous study (Nyffeler et al., 2006)
62377739|NCT04216511||Case-Lung Cancer|Patients with definite lung cancer diagnosis
62754044|NCT06009887|NO_INTERVENTION|No Intervention: Control Group|No interventions were made for those in the control group other than routine hospital practices.
62754045|NCT00961246|ACTIVE_COMPARATOR|general health information group|participants received general health information
62754046|NCT00961246|EXPERIMENTAL|individually-tailored intervention|participants received individually-tailored intervention
62754047|NCT02877654|EXPERIMENTAL|Irritable Bowel Syndrome|
62754048|NCT03876015||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
62754049|NCT05497050|EXPERIMENTAL|Experimental group|Family education
62754050|NCT05497050|NO_INTERVENTION|Control group|No training will be given.
62377740|NCT04216511||Control|Either patients with benign pulmonary nodule, or healthy individuals without pulmonary nodule but with risk factors to develop lung cancer matched to lung cancer group
62754051|NCT01610440|EXPERIMENTAL|Intervention Group|Participants will be given rehabilitation therapy plus human umbilical cord mesenchymal stem cells transplantation with one year follow-up
62377741|NCT01110486|EXPERIMENTAL|Monotherapy, once daily|
62377742|NCT01110486|EXPERIMENTAL|Combination with carboplatin|
62377743|NCT01110486|EXPERIMENTAL|Combination with docetaxel|
62754052|NCT05413265|OTHER|Phases 1 and 2|Phase 1 participants will help inform the cultural adaptation of the study design and materials. Phase 2 will enroll 10 dyads (20 individuals) of AN/AI people who smoke and a family member. Dyad participants will help beta-test the feasibility and acceptability of the financial incentives intervention.
62377744|NCT01110486|EXPERIMENTAL|Monotherapy, twice daily|
62377745|NCT01110486|EXPERIMENTAL|IV Monotherapy, once daily|
62377746|NCT01247012|ACTIVE_COMPARATOR|Lipid minimization|
62377747|NCT01247012|EXPERIMENTAL|Omegaven|
62377748|NCT06396689|ACTIVE_COMPARATOR|"Preterm-born infants assigned to synbiotics (PRE-SYN)"|
62377749|NCT06396689|PLACEBO_COMPARATOR|"Preterm-born infants to placebo (PRE-PLC)"|
62377750|NCT06396689|ACTIVE_COMPARATOR|"Term-born infants to synbiotics (TER-SYN)"|
62377751|NCT06396689|PLACEBO_COMPARATOR|"Term-born infants to placebo (TER-PLC)"|
62377752|NCT02966106|ACTIVE_COMPARATOR|Right prefrontal low frequency rTMS.|Right prefrontal low frequency rTMS (1Hz). A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
62377753|NCT02966106|PLACEBO_COMPARATOR|Sham-rTMS|Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
62556452|NCT04840303|NO_INTERVENTION|non-hub user active control group|This group does not receive the community-based mental wellness youth hub services but other generic youth services in the community.
62377754|NCT04330456|EXPERIMENTAL|SaE treatment|"This group will receive combined treatment of soft tissue sarcoma that include 3 steps:~1. step - preoperative stereotactic radiation therapy in hypofractionation mode (5 fractions 5 Gy each)~2. step - operation~3. step - postoperative conformal radiation therapy in normofractionation mode (25 fractions 2 Gy each)"
62377755|NCT03083470|EXPERIMENTAL|SOR007 0.15%|SOR007 Ointment 0.15% applied to the face twice daily for 28 days
62377756|NCT03083470|EXPERIMENTAL|SOR007 0.3%|SOR007 Ointment 0.3% applied to the face twice daily for 28 days
62377757|NCT03083470|EXPERIMENTAL|SOR007 1.0%|SOR007 Ointment 1.0% applied to the face twice daily for 28 days
62377758|NCT03083470|EXPERIMENTAL|SOR007|SOR007 Ointment 2.0% applied to the face twice daily for 28 days
62377759|NCT03083470|SHAM_COMPARATOR|Ointment Vehicle|SOR007 Ointment vehicle applied to the face twice daily for 28 days
62377760|NCT05834179|EXPERIMENTAL|cold endotracheal tube (ETT)|Patients who were intubated with an ETT which kept in the fridge.
62377761|NCT05834179|NO_INTERVENTION|Endotracheal tube (ETT) in the normal temperature|Patients who were intubated with an ETT which kept in the operation room.
62556453|NCT04840303|NO_INTERVENTION|non-hub user community control group|This group does not receive any youth services in the community.
62754053|NCT05482178|EXPERIMENTAL|Resistance exercise training plus hypocaloric diet|The participants received a caloric restriction of 20% of total energy estimated with Mifflin formula plus a structured, planned, and controlled resistance exercise program by a personal trained. The participant received the exercise program instructions every week and they performed by the own, and record the heart rate of each session on a paper format. All the appointment were once a month by trained nutritionists, and all the participants received a nutritional recommendation for the obesity management and a balanced food plan.
62754054|NCT05482178|ACTIVE_COMPARATOR|Hypocaloric diet|The participants received a caloric restriction of 20% of total energy estimated with Mifflin formula. All the appointment were once a month by trained nutritionists, and all the subjects received a nutritional recommendation for the obesity management and a balanced food plan.
62754055|NCT01209455|NO_INTERVENTION|Saline|Volunteers will receive an incremental rising dose infusion of IA NAC (6 doses) together with a co-infusion of normal saline to determine a dose response curve for arterial vasodilatation in the forearm.
62754056|NCT01209455|ACTIVE_COMPARATOR|Histamine antagonists|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of histamine antagonists (H1 and H2 antagonists) to determine vasodilatation in response to NAC in the presence of histamine antagonists.
62754057|NCT01209455|ACTIVE_COMPARATOR|Low dose paracetamol|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of low dose paracetamol to determine whether the vasodilatory response to NAC is inhibited.
62754058|NCT01209455|ACTIVE_COMPARATOR|High dose paracetamol|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of higher dose paracetamol to determine whether the vasodilatory response to NAC is inhibited.
62754059|NCT02076399|EXPERIMENTAL|Fostamatinib Disodium|Subjects begin with Fostamatinib Disodium tablet 100 mg PO bid and increase to 150 mg big after week 4 based on platelet count and tolerability.
62754060|NCT02076399|OTHER|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
62556454|NCT03958929|EXPERIMENTAL|Education group|Subjects will be asked to watch a 5-10 min education film two times (pre-op one day and post-op one day).
62556455|NCT03958929|NO_INTERVENTION|Control group|Standard patient procedure that includes a pre-operative discussion with an ophthalmologist about glaucoma surgery, during which the surgeon gains the patient's informed consent. Subjects will not be asked to watch education film..
62754061|NCT04909892|EXPERIMENTAL|COVI-MSC 1 vial|Subjects will receive intravenous infusions of COVI-MSC (one vial, \~18.5 million cells) on Day 0, Day 2, and Day 4.
62754062|NCT04909892|EXPERIMENTAL|COVI-MSC 2 vials|Subjects will receive intravenous infusions of COVI-MSC (two vials, \~37 million cells) on Day 0, Day 2, and Day 4.
62754063|NCT00976378|EXPERIMENTAL|0.05 mg/kg NOX-A12|
62754064|NCT00976378|EXPERIMENTAL|0.15 mg/kg NOX-A12|
62754065|NCT00976378|EXPERIMENTAL|0.45 mg/kg NOX-A12|
62377762|NCT02034539|EXPERIMENTAL|VADOplex treatment|best medical treatment in combination with intermittent pneumatic foot compression by the VADOplex system for 4 - 6 hours/day until total wound closure of the target lesion is achieved with a maximum treatment of 24 weeks
62556456|NCT03923140|EXPERIMENTAL|Tranilast|5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
62556457|NCT03709043|EXPERIMENTAL|Kudzu|Standardized kudzu
62556458|NCT03709043|PLACEBO_COMPARATOR|Control|Placebo
62556459|NCT01486225|OTHER|Innothera's brand Stokings|Innothera's branded grip-top silicone band stokingc
62556460|NCT01486225|OTHER|Other than Innothera's brand|
62556461|NCT04993001|ACTIVE_COMPARATOR|Emergence from general anesthesia with an open lung extubation strategy|
62556462|NCT04993001|PLACEBO_COMPARATOR|Emergence from general anesthesia with a conventional extubation strategy|
62754066|NCT00976378|EXPERIMENTAL|1.35 mg/kg NOX-A12|
62754067|NCT00976378|EXPERIMENTAL|2.7 mg/kg NOX-A12|
62754068|NCT00976378|EXPERIMENTAL|5.4 mg/kg NOX-A12|
62754069|NCT00976378|EXPERIMENTAL|10.8 mg/kg NOX-A12|
62754070|NCT00976378|EXPERIMENTAL|5.4 mg/kg NOX-A12 plus apheresis|
62754071|NCT02818348|EXPERIMENTAL|DRV cohort|Darunavir/Cobicistat 800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
62754072|NCT02818348|EXPERIMENTAL|ETR cohort|Etravirine 400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
62754073|NCT02279719|EXPERIMENTAL|BBI608 and Sorafenib|
62754074|NCT02279719|EXPERIMENTAL|BBI503 and Sorafenib|
62754075|NCT02279719|ACTIVE_COMPARATOR|Sorafenib|
62754076|NCT01552785||Healthy adults|
62754077|NCT04449393|EXPERIMENTAL|Emdogain® FL|Non-surgical periodontal therapy in terms of scaling and root planing will be applied at sites with remaining periodontal pockets at reevaluation. EDTA gel will be applied for 2 minutes in the respective pockets, followed by rinsing with saline, drying and application of Emdogain® FL.
62754078|NCT04449393|PLACEBO_COMPARATOR|Control group|Non-surgical periodontal therapy in terms of scaling and root planing will be applied at sites with remaining periodontal pockets at reevaluation, followed by rinsing with saline.
62754079|NCT00777400|EXPERIMENTAL|1|Efalizumab will be started on Day 0 until the end of the study at Week 24. At the end of the first week, after efalizumab is started, cyclosporine or tacrolimus will be decreased by 50% and at 2 weeks the dose of cyclosporine or tacrolimus will be completely discontinued. At 12 weeks Cellcept or myfortic will be discontinued and the patient will be converted to sirolimus for the remainder of the study.
62754080|NCT04432493|EXPERIMENTAL|Active TMS - OUD|Participants in the opioid used disorder group (OUD) in the active condition will receive repetitive TMS (rTMS), delivered at 110% of participants' resting motor threshold at 10 Hz continuously over the predefined DLFPC target for a total of 2000 pulses
62754081|NCT04432493|PLACEBO_COMPARATOR|Sham TMS - OUD|Identical parameters will be applied to the opioid used disorder (OUD) SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation
62754082|NCT04432493|ACTIVE_COMPARATOR|Active TMS - HC|Healthy Control (HC) participants in the active condition will receive repetitive TMS (rTMS), delivered at 110% of participants' resting motor threshold at 10 Hz continuously over the predefined DLFPC target for a total of 2000 pulses
62754083|NCT04432493|SHAM_COMPARATOR|Sham TMS - HC|Identical parameters will be applied to the healthy control (HC) SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation
62754084|NCT00100230|EXPERIMENTAL|1.|Oral Docosahexaenoic acid, dosage based on body weight
62754085|NCT00100230|PLACEBO_COMPARATOR|2|corn/soy oil placebo; oil not containing DHA...dosage based on body weight
62754086|NCT02386891|EXPERIMENTAL|Cold|The cold treatment was 18-20°C (64.5-68°F), which is at the lower end of the thermalneutral zone in healthy adults.
62377763|NCT02034539|NO_INTERVENTION|conservative treatment|best medical treatment of the target lesion alone
62377764|NCT06326164|ACTIVE_COMPARATOR|Group A|Control group.
62377765|NCT06326164|ACTIVE_COMPARATOR|Group B|Experimental group.
62377766|NCT05320640|EXPERIMENTAL|Experimental arm|"Drug: Chidamide10mg/day, day1-4; 20mg/day, day8, 11, 15, 18. Drug: Decitabine10mg/day, day1-5. Drug: Immune Checkpoint Inhibitors（anti-PD1/PD-L1/CTLA4 antibodies）. Physicians will decide which ICIs will be used during treatment.~Every 3 weeks."
62556463|NCT02601014|EXPERIMENTAL|Nivolumab and ipilimumab|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 60 minutes every 2 weeks for 36 weeks in the absence of disease progression or unacceptable toxicity.
62754087|NCT02386891|EXPERIMENTAL|Warm|The warm treatment was 25-27°C (77-80.6°F), which is above the range of the thermalneutral zone.
62754088|NCT01089023|EXPERIMENTAL|1|
62754089|NCT04397913||Treatment(paracetamol or ibuprofen)|Paracetamol and ibuprofen are administered at standard dose for children with PDA.
62754090|NCT04465435||SUN-participants|"University students enrolled in a selected university in Stockholm, studying on a full-time educational program with at least one academic year left before graduation.~There is no intervention. The exposures are repeated measures, 5 times (every three months), using web-based self-report questionnaires during one academic year. Also weekley SMS are used to measure depression, anxiety and pain intensity."
62377767|NCT00242944|ACTIVE_COMPARATOR|1|Pitavastatin
62377768|NCT00242944|ACTIVE_COMPARATOR|2|Atorvastatin
62377769|NCT02660060|EXPERIMENTAL|Pramipexole Dexa Medica|Each tablet contains 0.25 mg pramipexole dihydrochloride monohydrate. An oral single dose of the tablet was administered at the first day of each treatment period.
62377770|NCT02660060|ACTIVE_COMPARATOR|Pramipexole Boehringer Ingelheim Pharma|Each tablet contains 0.25 mg pramipexole dihydrochloride monohydrate. An oral single dose of the tablet was administered at the first day of each treatment period.
62377771|NCT02791477|OTHER|Attune FB PS|Attune FB PS knee arthroplasty
62754091|NCT05824039|EXPERIMENTAL|Experimental 1: low dose group|Tea infusion which contain 5 mg of flavonoids, (low dose of flavonoids treatment quantification) oral administration , once daily.
62754092|NCT05824039|EXPERIMENTAL|Experimental 2 : high dose group|Tea infusion which contain 20 mg of flavonoids, ( high dose of flavonoids Treatment quantification) oral administration , once daily .
62754093|NCT01808391||Clinical Follow-up Cohort|The clinical FU cohort comprises among patients who underwent clinical FU at 9, 12, and 24 months after index PCI those who arbitrarily underwent angiographic FU at 22 months (±60 days) after index PCI and those who did not undergo angiographic follow-up at all during the entire study period.
62754094|NCT01808391||Routine Angiographic Follow-up Cohort|The routine angiographic FU cohort comprises patients who underwent clinical FU at 9, 12, and 24 months after index PCI those who undergo angiographic FU at 10 months (±60 days) after index PCI.
62754095|NCT04071067||Emergency Clinical County Hospital Group|
62754096|NCT04071067||Municipal Clinical Hospital Group|
62754097|NCT02044601|EXPERIMENTAL|Chemoradiation + Onartuzumab|"Participants with wild-type EGFR mutation to be randomized, and may receive this regimen.~Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle. Paclitaxel 45 mg/m2 by vein once a week throughout radiation for 7 weeks. Carboplatin AUC 2 by vein once a week throughout radiation for 7 weeks. Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.~Phase II: Same regimen as in Phase I, but starting dose of Onartuzumab is maximum tolerated dose from Phase I."
62754098|NCT02044601|EXPERIMENTAL|Chemoradiation + Erlotinib + Onartuzumab|"Participants with EGFR mutation to receive this regimen. Participants with wild-type EGFR mutation to be randomized, and may receive this regimen.~Phase I: Erlotinib 150 mg by mouth every day throughout radiation, except for chemotherapy day. Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle. Paclitaxel 45 mg/m2 by vein once a week throughout radiation for 7 weeks. Carboplatin AUC 2 by vein once a week throughout radiation for 7 weeks. Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.~Phase II: Same regimen as in Phase I, but starting dose of Onartuzumab is maximum tolerated dose from Phase I."
62754099|NCT04355897|EXPERIMENTAL|Convalescent COVID 19 Plasma|Subjects will receive and intravenous infusion of 500 mls of Convalescent COVID 19 Plasma.
62754100|NCT05451173|EXPERIMENTAL|Cohort A|SBRT to be delivered with concurrent and adjuvant anti-PD-(L)1 immune checkpoint inhibitor.
62754101|NCT05451173|EXPERIMENTAL|Cohort B|Hypo-fractionated radiotherapy to be delivered with concurrent and adjuvant anti-PD-(L)1 immune checkpoint inhibitor.
62754102|NCT01672658|EXPERIMENTAL|Sensory Kinectics Balance System|Subjects will be randomized in to one of two groups. The group that will receive training on the SKBS device along with traditional vestibular and balance training.
62754103|NCT01672658|ACTIVE_COMPARATOR|Traditional Vestibular Rehabilitation|Traditional vestibular rehabilitation will include VOT exercises that will work toward increasing the gain of the system as well as walking, balance re-training, and functional mobility.
62377772|NCT05575024||Septic AKI|Patients with septic acute kidney injury requiring continuous renal replacement therapy
62754104|NCT06194955|ACTIVE_COMPARATOR|GIPR variant carriers|Inidividuals with GIPR variants: Determination of the incretin effect, and the insulinotropic actions of GIP and GLP-1 infusions during hyperglycemic clamp.
62754105|NCT06194955|PLACEBO_COMPARATOR|GIPR variant carrier controls|Healthy matched individuals: Determination of incretin effect, and the insulinotropic actions of GIP and GLP-1 infusions during hyperglycemic clamp.
62754106|NCT06194955|ACTIVE_COMPARATOR|GLP-1R variant carrier|Individuals with GLP-1R variants: Determination of incretin effect, and the insulinotropic actions of GIP and GLP-1 infusions during hyperglycemic clamp
62754107|NCT06194955|PLACEBO_COMPARATOR|GLP-1R variant carrier controls|Healthy matched individuals: Determination of incretin effect, and the insulinotropic actions of to GIP and GLP-1 infusions during hyperglycemic clamp.
62754108|NCT06194955|ACTIVE_COMPARATOR|GLP-2R variant carrier|Individuals with GLP-2R variants: Determination of bone resorption marker levels (CTX) and response to GLP-2 infusions during fasting blood glucose levels
62377773|NCT06041230|ACTIVE_COMPARATOR|Ultrasound guided ozone injection therapy|
62754109|NCT06194955|PLACEBO_COMPARATOR|GLP-2R variant carrier control|Healthy matched individuals: Determination of bone resorption marker levels (CTX) and response to GLP-2 infusions during fasting blood glucose levels
62754110|NCT06607393||Exposed|Patients initiating pemetrexed, cisplatin or carboplatin, and pembrolizumab as first-line treatment for metastatic NSCLC
62754111|NCT06607393||Comparator|Patients initiating pemetrexed and cisplatin or carboplatin as first-line treatment for metastatic NSCLC
62377774|NCT06041230|ACTIVE_COMPARATOR|Extracorporeal shock wave therapy|
62377775|NCT02319564|ACTIVE_COMPARATOR|beclomethasone|"beclomethasone dipropionate 250mcg per puff per puff (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
62377776|NCT02319564|ACTIVE_COMPARATOR|beclomethasone and salbutamol|"beclomethasone diprionate 250mcg and salbutamol 100mcg per puff (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
62377777|NCT02319564|PLACEBO_COMPARATOR|Placebo|"placebo (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
62377778|NCT05174351|EXPERIMENTAL|HFpEF patients|HFpEF patient who are currently taking beta blockers
62377779|NCT01300000|ACTIVE_COMPARATOR|Human Milk|ad lib
62377780|NCT01300000|ACTIVE_COMPARATOR|Milk based standard infant formula|ad lib
62377781|NCT01300000|EXPERIMENTAL|Milk based investigational infant formula|ad lib
62377782|NCT02582151|SHAM_COMPARATOR|Sham tibial nerve stimulation|Use of peripheral nerve stimulator in a location that will not actively stimulate the tibial nerve.
62377783|NCT02582151|ACTIVE_COMPARATOR|Tibial nerve stimulation|Transcutaneous peripheral nerve stimulator in a location that will actively stimulate the tibial nerve.
62377784|NCT01213849|EXPERIMENTAL|200/100 mcg fluticasone furoate/vilanterol|4 inhalations of 50/25 mcg fluticasone furoate/vilanterol
62377785|NCT01213849|EXPERIMENTAL|400/100 mcg fluticasone furoate/vilanterol|4 inhalations of 100/25 mcg fluticasone furoate/vilanterol
62754112|NCT01901523|EXPERIMENTAL|Provision of information|Reporting of discrepancy to journal
62377786|NCT01213849|EXPERIMENTAL|800/100 mcg fluticasone furoate/vilanterol|4 inhalations of 200/25 mcg fluticasone furoate/vilanterol
62377787|NCT02542566|ACTIVE_COMPARATOR|early weight bearing|early weight bearing and accelerated physiotherapy rehabilitation
62377788|NCT02542566|ACTIVE_COMPARATOR|protected weight bearing|protected weight bearing and conservative physiotherapy rehabilitation.
62377789|NCT03607292|EXPERIMENTAL|Group A|Anterior sciatic nerve block
62377790|NCT03607292|EXPERIMENTAL|Group P|Posterior sciatic nerve block
62377791|NCT01768702|SHAM_COMPARATOR|Control|Sham, no injection
62377792|NCT01768702|EXPERIMENTAL|C3BS-CQR-1 Treated|Injection of C3BS-CQR-1
62377793|NCT04272372||Group 1|Complete Decongestive Therapy
62377794|NCT04272372||Group 2|Complete Decongestive Therapy + PO Ketoprofen + Local ketoprofen gel
62377795|NCT04272372||Group 3|Complete Decongestive Therapy + Local Ketoprofen gel
62377796|NCT01807494|ACTIVE_COMPARATOR|Posterior approach|Subjects in this group will total hip replacement performed with a posterior surgical approach and total hip replacement components.
62377797|NCT01807494|ACTIVE_COMPARATOR|Anterior Approach|Subjects in this group will have total hip replacement performed with a direct anterior surgical approach and total hip replacement components.
62377798|NCT04331808|EXPERIMENTAL|TOCILIZUMAB|Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.
62377799|NCT04331808|NO_INTERVENTION|Standard of care|
62377800|NCT02239562|EXPERIMENTAL|SAD sPIF 0.1|single ascending dose (SAD) 3 patients with normal liver function tests (LFTs) and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: Single subcutaneous (SQ) dose 0.1 mg/kg sPIF or Placebo Day 1
62377801|NCT02239562|EXPERIMENTAL|SAD sPIF 0.5|single ascending dose (SAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: single SQ dose 0.5 mg/kg sPIF or Placebo Day 1
62377802|NCT02239562|EXPERIMENTAL|SAD sPIF 1.0|single ascending dose (SAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: Cohort 3: single SQ dose 1.0 mg/kg sPIF or Placebo Day 1
62754113|NCT00167596|EXPERIMENTAL|1|Early goal directed therapy based on StO2 evaluation
62754114|NCT00167596|ACTIVE_COMPARATOR|2|Early goal directed therapy
62556464|NCT02601014|EXPERIMENTAL|Enzalutamide plus Nivolumab and Ipilimumab|Patients will continue on standard of care enzalutamide, with the addition of nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 60 minutes every 2 weeks for 36 weeks in the absence of disease progression or unacceptable toxicity.
62754115|NCT06606457|EXPERIMENTAL|PACE CF Intervention|Participants will complete an baseline series of questionnaires, and then meet with the psychologist on their cystic fibrosis care team for 3 weekly meetings to complete the PACE CF program and learn mind-body strategies for pain management. Following completion of the program, they will complete a second assessment that includes another set of questionnaires and a brief qualitative interview to provide feedback about the program.
62754116|NCT03502967|EXPERIMENTAL|Hyperpolarized [1-13C] Pyruvate|Injection with hyperpolarized \[1-13C\] Pyruvate during MRI.
62377803|NCT02239562|EXPERIMENTAL|MAD sPIF 0.1|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ (one time) 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 0.1 mg/kg sPIF or Placebo Days 1-5
62377804|NCT02239562|EXPERIMENTAL|MAD sPIF 0.5|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 0.5 mg/kg sPIF or Placebo Days 1-5
62377805|NCT02239562|EXPERIMENTAL|MAD sPIF 1.0|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 1.0 mg/kg sPIF or Placebo Days 1-5
62377806|NCT02868801|PLACEBO_COMPARATOR|Placebo|placebo, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
62377807|NCT02868801|EXPERIMENTAL|Pregabalin SR tablet 165mg/day|1pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
62377808|NCT02868801|EXPERIMENTAL|Pregabalin SR tablet 330mg/day|1pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
62754117|NCT03502967|EXPERIMENTAL|Hyperpolarized [2-13C] Pyruvate|Injection with hyperpolarized \[2-13C\] Pyruvate during MRI.
62377809|NCT02868801|EXPERIMENTAL|Pregabalin SR tablet 660mg/day|2pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
62377810|NCT05637567|EXPERIMENTAL|Treatment Arm|100 mg acetylsalicylic acid per os once daily, starting 1-4 weeks before surgery until 6 months after surgery
62377811|NCT05637567|PLACEBO_COMPARATOR|Control Arm|Identically looking placebo pill, starting 1-4 weeks before surgery until 6 months after surgery
62377812|NCT06049706|EXPERIMENTAL|Active Priming (TMSr)|"To apply intervention, it will be used Repetitive Transcranial Magnetic Stimulation Model MagPro R20 (MagVenture Brazil, country Brazil) and the butterfly coil MCF-B70 (MagVenture Brazil, country Brazil).~Each session will last around 20 minutes, and it will be used a 1 Hz frequency, 1200 pulses/day, with 100% of Motor Threshold, once a day, 5 days a week, for two consecutive weeks.~Active Priming group participants will be previously stimulated for 10 minutes (20 trains of 5 seconds with intertrain interval of 25 seconds), with 6Hz frequency over Supplementary Motor Area, receiving 80% of Motor Threshold, with a total of 600 stimulations."
62556465|NCT03051672|EXPERIMENTAL|Pembrolizumab With Radiation|"pembrolizumab : 200 mg intravenously 2 to 7 days prior to radiotherapy (RT) and on day 1 of repeating 21-day cycles. Treatment up to 35 cycles.~Palliative radiation: a total dose of 20 Gy in 5 fractions"
62556466|NCT05111327|EXPERIMENTAL|Intervention|Students in the interventional groups will receive structured simulation guideline
62556467|NCT05111327|NO_INTERVENTION|Control|Students in the control groups will receive standard treatment.
62556468|NCT00543881|EXPERIMENTAL|1|Interventional group
62556469|NCT00543881|ACTIVE_COMPARATOR|2|Usual care group
62556470|NCT04083547||HIPEC group|All patients undergoing HIPEC will asked to join this prospective study.
62556471|NCT06033131|ACTIVE_COMPARATOR|Metformin ER|Metformin ER oral tablet 500 mg three times daily and increased to one gram (two tablets) three times daily as tolerated.
62556472|NCT06033131|PLACEBO_COMPARATOR|Placebo|1 placebo tablet three times daily and increased to 2 placebo tablets three times daily as tolerated.
62556473|NCT05204706|ACTIVE_COMPARATOR|Intervention arm|Women who meet study inclusion criteria and consent to study participation will be randomised using sealed envelope randomisation and online database for clinical trials to one of two groups in a 1:1 ratio.
62556474|NCT05204706|NO_INTERVENTION|Control arm|Women allocated to the control arm will receive standard care and no digital intervention. This includes self-monitoring blood glucose and lifestyle advice (diet, physical activity, optimal body weight) by a multidisciplinary team.
62556475|NCT01025089|EXPERIMENTAL|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|This is a multicenter, open-label phase II trial of neoadjuvant chemotherapy and concurrent cetuximab in patients with clinical Masaoka stage II-IVA thymoma or thymic carcinoma.. Patients will initially receive weekly cetuximab for 4 weeks to assess tumor response to cetuximab alone. Patients will then undergo weekly cetuximab along with concurrent CAP for 4 cycles. At the completion of this regimen, patients will undergo surgical resection and the specimen will be evaluated for CPR.
62556476|NCT01722578|EXPERIMENTAL|L-ornithine L-aspartate|L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
62556477|NCT01722578|PLACEBO_COMPARATOR|Placebo (sterile water)|Placebo (sterile water, 6 ampuoles of 10 ml each) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
62556478|NCT05778461|EXPERIMENTAL|L-ornithine L-Aspartate|LOLA will be administered via continuous intravenous infusion at a dosage of 0.75g/kg/day for 72h (maximum 30g/day). High volume plasma exchange (2x plasma volume) will be started at least 8 hours after initiation of LOLA, and will be completed within 4-5 hours depending on the volume of exchange. Three consecutive cycles of HVPE will be performed, starting at 8h, 32h and 56h respectively.
62556479|NCT05778461|PLACEBO_COMPARATOR|Placebo|Placebo will be administered via continuous infusion for 72h, along with HVPE (2x plasma volume) starting at 8h, 32h and 56h respectively.
62556480|NCT01001650|EXPERIMENTAL|Group 1|4 doses of 7,500 PfSPZ/immunization.
62556481|NCT01001650|EXPERIMENTAL|Group 2|4 doses of 30,000 PfSPZ/immunization
62556482|NCT01001650|EXPERIMENTAL|Group 3|4 doses of 135,000 PfSPZ/immunization
62556483|NCT01001650|EXPERIMENTAL|Group 4|4 or 6 doses of 135,000 PfSPZ/immunization.
62556484|NCT03165812|EXPERIMENTAL|SADJB-SG group|Patients in this group will undergo bariatric surgery. There are two parts to this procedure. One is the restrictive type of weight loss surgery, which reduces the stomach size. The other type prevents the body from absorbing fats and sugar properly, as the small intestine will be attached to the small stomach, bypassing most of the stomach and upper part of the small intestine. This surgery will be performed using a minimally invasive technique known as laparoscopic keyhole surgery.
62556485|NCT03165812|EXPERIMENTAL|IMT group|Patients in this group will be subjected to strict adherence to diet, optimisation of diabetic medications and close monitoring of blood glucose and HbA1c.
62556486|NCT01452516|OTHER|nanOss Bioactive Bone void filler|Lumbar fusion using interbody cages with autograft in conjunction with instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
62754118|NCT04070326|EXPERIMENTAL|Lanadelumab 150 mg: Age 2 to <6 Years|Participants aged 2 to \<6 years received lanadelumab subcutaneous (SC) injection at a dose of 150 milligrams (mg) for every 4 weeks (q4wks) over 52-week Treatment Period (26-week Treatment Period A and 26-week Treatment Period B).
62556487|NCT02399137|EXPERIMENTAL|Arm A (Experimental Arm)|MM-141 in combination with nab-paclitaxel and gemcitabine
62556488|NCT02399137|ACTIVE_COMPARATOR|Arm B (Comparator Arm)|Placebo in combination with nab-paclitaxel and gemcitabine
62556489|NCT02399137|NO_INTERVENTION|Observational Group|
62556490|NCT05392868|EXPERIMENTAL|SDF|38% silver diamine fluoride solution
62556491|NCT05392868|ACTIVE_COMPARATOR|KNO3|5% potassium nitrate solution
62556492|NCT00618371|EXPERIMENTAL|Raltegravir intensification|Patients will be administered raltegravir 400 mg orally twice daily in addition to antiretroviral therapy
62556493|NCT02885545|EXPERIMENTAL|Left atrial appendage occlusion|Patients receiving the Watchman device will have it placed via a percutaneous trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance. Patients will be anticoagulated for at least 45 days after the procedure.
62556494|NCT02885545|ACTIVE_COMPARATOR|Continuation of prescribed anticoagulant|Patients continuing medical therapy will continue to take their previously prescribed oral anticoagulation (vitamin K antagonist, apixiban or rivaroxaban) for the duration of the study unless a medical reason to alter therapy occurs.
62556495|NCT06392529||Voriconazole Group|
62556496|NCT06392529||Clotriamazole group|
62556497|NCT05265338|EXPERIMENTAL|Group A|In the fasting state, KC1036 po only once (60mg QD) and after 7 days，in the high fat diet state，KC1036 po only once (60mg QD).
62556498|NCT05265338|EXPERIMENTAL|Group B|In the high fat diet state, KC1036 po only once (60mg QD) and after 7 days, in the fasting state, KC1036 po only once (60mg QD).
62377813|NCT06049706|SHAM_COMPARATOR|Sham Priming|Sham Priming group participants will receive a placebo stimulation for ten minutes, with the same parameters and target area as the active group, they will hear the equipament noise and might feel any sensation in the scalp, but there won't be effective stimulation.
62377814|NCT00698139|ACTIVE_COMPARATOR|Intervention first, then control|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~On the first encounter, patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.~On the second encounter, patients will come to clinic in the morning for baseline measurements.Subsequently, they will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. The rest of the protocol will be as described for the first encounter."
62556499|NCT03431714|EXPERIMENTAL|single arm|Artesunate amodiaquine tablets containing 25/67.5 mg, 50/135mg and 100/270 mg base of artesunate-amodiaquine were administered according to body weight Dihrdroartemisinin piperaquine tablets containing 160/20mg and 320/40mg base of piperaquine dihydroartemisinin were administered according to body weight
62556500|NCT05593484|OTHER|Standard Referral|
62556501|NCT05593484|OTHER|Specialty Telemedicine Access for Referrals (STAR)|
62556502|NCT01380561|EXPERIMENTAL|Single Arm Study|asimadoline
62556503|NCT03052751|EXPERIMENTAL|Dosage Regimen 1|Subjects randomized in dosage regimen 1 will receive 3 doses of UCB7655 (dose 1) in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).
62556504|NCT03052751|EXPERIMENTAL|Dosage Regimen 2|Subjects randomized in dosage regimen 2 will receive 3 doses of placebo in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).
62556505|NCT05729737||Pancreatic ductal adenocarcinoma|"Patients who planned to receive first-line chemotherapy for pathologically diagnosed PDAC were recruited.~Intervention:Diagnostic test:Contrast-enhanced ultrasound"
62556506|NCT03989882|EXPERIMENTAL|Wheat germ|Wheat germ energy balls containing 30 g of wheat germ, peanut butter, and honey to form 2 energy balls that is approximately 200 kcal. Two energy balls will be consumed daily for 30 days.
62556507|NCT03989882|PLACEBO_COMPARATOR|Control|Control energy ball containing 30 g of cornmeal, peanut butter, and honey to form 2 energy balls that is approximately 200 kcal. Two energy balls will be consumed daily for 30 days.
62556508|NCT00218387|EXPERIMENTAL|200mg Modafinil|200mg Modafinil
62556509|NCT00218387|EXPERIMENTAL|400mg Modafinil|400mg Modafinil
62556510|NCT00218387|PLACEBO_COMPARATOR|Matching Placebo|Matching Placebo
62556511|NCT00317629|ACTIVE_COMPARATOR|1|
62556512|NCT00317629|EXPERIMENTAL|2|
62556513|NCT00127114|EXPERIMENTAL|Amantadine|
62556514|NCT00127114|PLACEBO_COMPARATOR|Placebo|
62556515|NCT03196063|ACTIVE_COMPARATOR|Eccentric|"Patients allocated in this group will perform three sets of 15 unipodal squats with the affected limb on an inclined plane. The patient will be instructed to perform only the eccentric phase of the exercise, keeping the torso erect and flexing the knee up to 90 degrees. The return to the initial position will be performed with the unaffected leg. To increase exercise load, the patient will carry a bag with washers. This protocol will last eight weeks, with 24 face-to-face sessions.~Both groups will also receive a protocol with complementary isotonic exercises, focusing on the strengthening of gluteus maximus, gluteus medius, hamstrings and calves."
62556516|NCT03196063|EXPERIMENTAL|Modified protocol|"Patients allocated in this group will receive treatment based on a protocol published in a clinical practice guide, with modifications to make the protocol more pragmatic. Thus, the use of mechanotherapy devices will be replaced by free weight exercises, so that the protocol can be performed in environments that do not offer this type of machinery. This protocol is composed of four exercise stages, being the first three stages performed in the presence of the physiotherapist, and will last eight weeks with approximately 24 face-to-face sessions.~Both groups will receive a protocol with complementary isotonic exercises, focusing on the strengthening of gluteus maximus, gluteus medius, hamstrings and calves."
62556517|NCT01597310|EXPERIMENTAL|Warfarin|25 mg Warfarin, Treatment Period 1 \& Treatment Period 2
62556518|NCT01597310|EXPERIMENTAL|Dexpramipexole|150 mg BID Treatment Period 2
62556519|NCT03212235|EXPERIMENTAL|Hypofractionated radiation therapy|"Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week.~After a 30-days break, adjuvant temozolomide days 1-5 every 28 days for 6 cycles."
62556520|NCT04864067|EXPERIMENTAL|Short Course Radiotherapy and Consolidation Chemotherapy|This arm will receive short course radiotherapy (5x5 Gy) during 1 week. Between 7 to 14 days after radiotherapy, patient will receive 9 cycles of FOLFOX. CapeOX may be given as alternative for FOLFOX.
62556521|NCT00877591|EXPERIMENTAL|1|Buprenorphine + Fosamprenavir/Ritonavir
62556522|NCT00877591|ACTIVE_COMPARATOR|2|Control Fosamprenavir/Ritonavir
62556523|NCT00877591|EXPERIMENTAL|3|Buprenorphine + Darunavir/Ritonavir
62556524|NCT00877591|ACTIVE_COMPARATOR|4|Control Darunavir/Ritonavir
62556525|NCT00877591|EXPERIMENTAL|5|Buprenorphine + Rifampin
62556526|NCT00877591|EXPERIMENTAL|6|Buprenorphine + Rifabutin
62754119|NCT04070326|EXPERIMENTAL|Lanadelumab 150 mg: Age 6 to <12 Years|Participants aged 6 to \<12 years received lanadelumab SC injection at a dose of 150 mg for every 2 weeks (q2wks) over 52-week Treatment Period (26-week Treatment Period A and 26-week Treatment Period B). Participants could switch to a dosing regimen of 150 mg q4wks in Treatment Period B at the investigator's discretion and sponsor's medical monitor approval, if they were well controlled (e.g., attack free) for 26 weeks with lanadelumab treatment in this study.Participants aged 6 to \<12 years received lanadelumab SC injection at a dose of 150 mg for every 2 weeks (q2wks) over 52-week Treatment Period (26-week Treatment Period A and 26-week Treatment Period B). Participants could switch to a dosing regimen of 150 mg q4wks in Treatment Period B at the investigator's discretion and sponsor's medical monitor approval, if they were well controlled (e.g., attack free) for 26 weeks with lanadelumab treatment in this study.
62754120|NCT01613989|ACTIVE_COMPARATOR|Treatment 1|Reference group, installation of hip prothesis following standard procedure
62754121|NCT01613989|ACTIVE_COMPARATOR|Treatment 2|:treatment group,installation of hip prosthesis with assistance by computer based on imaging EOS
62754122|NCT05192629|ACTIVE_COMPARATOR|Group Midazolam|"Administration of oral midazolam (0.25 mg/kg) as premedication before propofol-based sedation.~The patient receives an oral premedication containing 0.125mL/kg of midazolam (which corresponds to a dosage of 0.25mg/kg of Ozalin® 2mg/ml, with a maximum of 20 mg). He/she also receives an intranasal spray containing matching placebo of dexmedetomidine (NaCl 0.9%). The volume administered corresponds to 0.02 mL/kg (which corresponds to a dosage of 2 mcg/kg of pure dexmedetomidine 100 mcg/mL in group D)."
62754123|NCT05192629|EXPERIMENTAL|Group Dexmedetomidine|"Administration of intranasal dexmedetomidine as premedication before propofol-based sedation.~The patient receives an intranasal premedication containing 2 mcg/kg of dexmedetomidine. He/she also receives an oral solution containing matching placebo of midazolam (flavored-water prepared by the pharmacy). The volume administered corresponds to 0.125 mL/kg (which corresponds to a dosage of 0.25mg/kg of Ozalin® 2mg/mL, with a maximum of 20 mg or 10mL)."
62754124|NCT05988294|EXPERIMENTAL|Group A (Pilates Group)|Participants will receive Pilates exercises for 60 minutes followed by conventional physical therapy program for 45 minutes, 3 days/ week for 12 weeks.
62377815|NCT00698139|ACTIVE_COMPARATOR|Control first, then intervention|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~On the first encounter, patients will come to clinic in the morning for baseline measurements.Subsequently, the control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.~On the second encounter, patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The rest of the protocol will be as described for the first encounter."
62754125|NCT05988294|OTHER|Group B (Control Group)|Participants will receive conventional physical therapy program (diaphragmatic deep breathing exercises, bronchial hygiene techniques, assisted cough, stretching exercises and ROM exercises for both upper and lower limbs) for 45 minutes, 3 days/ week for 12 weeks.
62754126|NCT02754141|EXPERIMENTAL|Arm A-Monotherapy|BMS-986179, dose as specified
62754127|NCT02754141|EXPERIMENTAL|Arm B- Combination Therapy|BMS-986179 + nivolumab, dose as specified
62754128|NCT02754141|EXPERIMENTAL|Arm C-Combination Therapy|BMS-986179 + rHuPH20, dose as specified
62754129|NCT01960127|EXPERIMENTAL|Aerobic Exercise|Supervised aerobic training 3 times per week for 8 weeks (30-60 minute sessions)
62754130|NCT01960127|PLACEBO_COMPARATOR|Usual Care Group|These patients will continue with their normal daily activity ad will not be provided with supervised aerobic exercise training during the study period.
62754131|NCT04083261||High daily dose users|Total Cannabinoid Daily Dose greater than 50 mg
62754132|NCT04083261||Control|"Users that represent the median dose between high daily dose users and low daily dose users taking between 11-21 mg"
62754133|NCT04083261||Low daily dose users|Total Cannabinoid Daily Dose less than 10 mg
62754134|NCT00610441|EXPERIMENTAL|MK-8777 FD→PBO|Participants receive a fixed dose (FD) of MK-8777 100 mg twice each day (BID) for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive a fixed dose of placebo (PBO) BID for 3 weeks (Treatment Period 2).
62754135|NCT00610441|EXPERIMENTAL|PBO→MK-8777 FD|Participants receive a fixed dose of placebo BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive a fixed dose of MK-8777 100 mg BID for 3 weeks (Treatment Period 2).
62754136|NCT00610441|EXPERIMENTAL|MK-8777 RD→PBO|Participants receive rising doses (RD) of MK-8777 100-300 mg BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive rising doses of placebo BID for 3 weeks (Treatment Period 2).
62754137|NCT00610441|PLACEBO_COMPARATOR|PBO→MK-8777 RD|Participants receive rising doses of placebo BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive rising doses of MK-8777 100-300 mg BID for 3 weeks (Treatment Period 2).
62754138|NCT03648489|ACTIVE_COMPARATOR|Arm 1: Weekly paclitaxel alone|Paclitaxel, concentrate for solution for infusion 80mg per metre squared on day 1, 8 and 15 of a 28 day cycle. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria
62377816|NCT00698139|ACTIVE_COMPARATOR|Intervention Only|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour."
62377817|NCT01020994|EXPERIMENTAL|LAS41003|
62556527|NCT03238651|EXPERIMENTAL|Dose Escalation Part Schedule A: TAK-659 60 mg in Cohort 1|TAK-659, tablet, orally, once daily, in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 60 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema . If 60 mg, once daily is safe and tolerable, then the dose will be escalated to 80 mg, once daily and subsequently in 20 mg increments until MTD and/or RP2D is determined. Based on emerging safety, tolerability, PK data, a lower dose will be permitted.
62377818|NCT01020994|ACTIVE_COMPARATOR|LAS189962|
62377819|NCT01020994|ACTIVE_COMPARATOR|LAS189961|
62377820|NCT01968915|EXPERIMENTAL|LCL161|Dose escalation part: Eligible patients will start to receive oral LCL161 once a week and will receive weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour, in combination with LCL161 from cycle 2. Dose expansion part: Eligible patients will receive oral LCL161 at the maximum tolerated dose and/or recommended dose in combination with weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour from cycle 1.
62377821|NCT03398174|EXPERIMENTAL|Motor Control Exercise Plus Patient Education|"Participants will receive a total of 12 sessions (2 sessions per week) of exercise program consisting of motor control training and group patient education session once a week (6 sessions) all over 6-weeks.~The motor control training will be aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~The patient education program will be aiming to provide non-threatening information to enable patients to better understand their pain, change any unhelpful beliefs about LBP, and integrate self-management and active coping strategies that deals with fear avoidance behavior and catastrophic thought.~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
62377822|NCT03398174|EXPERIMENTAL|Motor Control Exercise|"Participants will receive the same motor control exercise program described in the patient education and motor control exercise group.~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
62377823|NCT03398174|EXPERIMENTAL|Patient Education|"Participants will receive the same patient education program described in the motor control exercise plus patient education group.~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
62377824|NCT00364611|EXPERIMENTAL|Docetaxel and Bevacizumab|Stratum 1: HER2 Negative participants with metastatic breast cancer treated with DB (docetaxel and bevacizumab) intravenously (IV) every 3 weeks (q3w) until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met
62377825|NCT00364611|EXPERIMENTAL|Docetaxel, Bevacizumab and Trastuzumab|Stratum 2: HER2 Positive participants with metastatic breast cancer treated with DBT (docetaxel, bevacizumab, and trastuzumab) IV q3w until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met
62377826|NCT01592942|EXPERIMENTAL|glue fixation|Optilene™ mesh 60 g/m2 (B. Braun), fixation Histoacryl™ cyanoacrylate glue (price 14+37 euros)
62377827|NCT01592942|ACTIVE_COMPARATOR|self-gripping|ProGrip™ mesh 60 g/m2 (Covidien, USA) (price 113 euros)
62377828|NCT01592942|ACTIVE_COMPARATOR|suture fixation|Ultrapro™ mesh 28 g/m2 (Ethicon, USA) (price 45 euros) fixated by non-absorbable sutures
62377829|NCT04316780||Nintedanib until 0 day - 2 days before transplant|Nintedanib taken until 0 - 2 days before receiving transplant
62377830|NCT04316780||Nintedanib until 3 days - 28 days before transplant|Nintedanib taken until 3-28 days before receiving transplant
62377831|NCT04316780||Nintedanib until > 28 days before transplant|Nintedanib taken until more than 28 days before receiving transplant
62377832|NCT04316780||Pirfenidone until 0 day - 1 day before transplant|Pirfenidone taken until 0 - 1 day before receiving transplant
62377833|NCT04316780||Pirfenidone until 2 days - 28 days before transplant|Pirfenidone taken until 2-28 day before receiving transplant
61986574|NCT01855633|SHAM_COMPARATOR|Sham rTMS|Participants will receive sham cTBS rTMS to contralesional hemisphere.
62754139|NCT03648489|EXPERIMENTAL|Arm 2: Weekly paclitaxel plus TAK228|"Paclitaxel, concentrate for solution for infusion 80mg per metre squared on day 1, 8 and 15 of a 28 day cycle. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria~TAK228, oral capsule 4mg on days 2-4, 9-11, 16-18 and 23-25 of a 28 day cycle i.e. in concurrence with paclitaxel. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria"
62754140|NCT06216899|EXPERIMENTAL|Smoothie|In the smoothie arm, you will be provided instructions, a blender, and food components to prepare the smoothie at home.
62754141|NCT06216899|ACTIVE_COMPARATOR|Formula|In the formula arm, you will be given conventional formula as per the direction of the gastroenterology team along with our dieticians.
62754142|NCT03089944|EXPERIMENTAL|Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks|Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
62754143|NCT03349424|EXPERIMENTAL|Stilamin group|Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin in addition to postoperative conventional treatment.
62754144|NCT03349424|NO_INTERVENTION|Control group|Patients in the control group will receive the postoperative conventional treatment, without addition of any new medicines.
62754145|NCT04287569|EXPERIMENTAL|video recording of endoscopy|Record of sequences of video-endoscopy and the reflectance of light through fibroscopy
62754146|NCT02388594|EXPERIMENTAL|ZFN Modified CD4+ T Cell|ZFN Modified CD4+ T Cell
62754147|NCT02388594|EXPERIMENTAL|ZFN Modified CD4+ T Cell with Cyclophosphamide|ZFN Modified CD4+ T Cell with Cyclophosphamide
62754148|NCT05577377|EXPERIMENTAL|OM intervention|
62754149|NCT01865006||Ligasure LF1212|
62754150|NCT01865006||Ultracision|
62754151|NCT01865006||Conventional|
62754152|NCT06036615|EXPERIMENTAL|Group A|Exercise Group, 6- month combined aerobic, strengthening, mobility- flexibility exercise intervention, 3- month de-training period
62754153|NCT06036615|NO_INTERVENTION|Group B|Control Group, 10- month normal physical activity, without participating in organized sports activities, no intervention
62754154|NCT05186701|EXPERIMENTAL|Kinesio taping and Conventional Physical Therapy|Standardized therapeutic kinesio taping (I shaped with 50-100% tension for 72 hours on both shoulders) along with Conventional Physical Therapy including Thermotherapy, myofacial release, exercise therapy (active isolated unilateral stretching of pectoralis minor muscle and strengthening of shoulder retractors).
62754155|NCT05186701|ACTIVE_COMPARATOR|Conventional Physical Therapy|Thermotherapy, myofacial release, exercise therapy (active isolated unilateral stretching of pectoralis minor muscle and strengthening of shoulder retractors).
62754156|NCT03356418|EXPERIMENTAL|WBV exercise group|Subjects will perform an isometric semi-squat exercise associated with the vibratory platform. The exercise will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will be connected at the beginning of each series, set at a vibration frequency of 40 Hertz (Hz) and peak-to-peak amplitude of 4 millimeters (mm) resulting in a peak acceleration of 128 ms2 (12.8 g). This should provide the equivalent of 3600 vertical vibrations, totaling 14400 vibrations per training session
62377834|NCT04316780||Pirfenidone until > 28 days before transplant|Pirfenidone taken more than 28 days before receiving transplant
62754157|NCT03356418|SHAM_COMPARATOR|Sham WBV exercise group|Subjects will perform an isometric semi-squat exercise associated with the vibratory platform. The exercise will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
62754158|NCT03078790|EXPERIMENTAL|meditation module|The patients in this arm will be offered the meditation/deep breathing module in the pre-operative area.
62754159|NCT04583254|EXPERIMENTAL|Arm 1 EBRT+High-dose (HDR) Brachytherapy Experimental|
62377835|NCT01087229|EXPERIMENTAL|equimolar oxygen-nitrous oxide mixture|"equimolar oxygen-nitrous oxide mixture~Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture."
61986575|NCT00780325|EXPERIMENTAL|1|CG100649, single oral dose of 2 mg
62377836|NCT01087229|PLACEBO_COMPARATOR|Placebo|Patients randomized to this arm will have the placebo.
62754160|NCT04583254|ACTIVE_COMPARATOR|Arm 2 EBRT+High-dose (HDR) Brachytherapy Standard of Care|
61986576|NCT00780325|EXPERIMENTAL|2|CG100649, single oral dose of 8 mg
61986577|NCT00780325|ACTIVE_COMPARATOR|3|Celecoxib, single oral dose of 200 mg
61986578|NCT00780325|ACTIVE_COMPARATOR|4|Naproxen, single oral dose of 500 mg
62377837|NCT04591704||Diabetic groups|COVID-19 patients with diabetes mellitus
62377838|NCT04591704||Control groups|COVID-19 patients without diabetes mellitus
62377839|NCT06108440|EXPERIMENTAL|action observation training group|Patients in Group A will receive action observation training with conventional treatment.
62377840|NCT06108440|ACTIVE_COMPARATOR|motor imagery training group|Patients in Group B will receive motor imagery with conventional treatment.
62377841|NCT05255497|EXPERIMENTAL|Biodex Balance Group|This group performed exercises using the biodex balance system
62377842|NCT05255497|NO_INTERVENTION|Control Group|This group was informed about diabetes self-management.
62754161|NCT06105736|EXPERIMENTAL|Parents|In this 22-week almost completely remote study, following a 5-week control phase, parents will receive intensive treatment twice per week for 5 weeks followed by a one-time, 1-on-1 counseling session with an RT psychologist (week 11). Then, parents will use skill practice and application in the home environment for 10 weeks. Following this, a final interview is conducted (week 22).
62754162|NCT06105736|EXPERIMENTAL|Children|In this 22-week almost completely remote study, following a 5-week control phase, children will receive intensive group treatment, twice a week for 5 weeks delivered remotely. During the children's sessions, they will use child structured videos, the PlayPosit curriculum and learning rewards. The following assessments will be completed by the parents, regarding their children, at each phase; EDI, ABC-2, FS, BRIEF-2, CRS, PSI-4SF and CGI-I. Following the completion of group treatment, there will be a one-time, 1-on-1 counseling session with an RT psychologist.
62754163|NCT05327634||Deprescribing|Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units
62754164|NCT00799045|EXPERIMENTAL|Aspirin + clopidogrel|Aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
62754165|NCT00799045|ACTIVE_COMPARATOR|Aspirin|Aspirin (80 mg/day) for 3 months following ASD closure.
62754166|NCT05401812|NO_INTERVENTION|Control|Standard care without glucocorticoid therapy.
62754167|NCT05401812|EXPERIMENTAL|Low dose and long treatment duration|Methylprednisolone equivalent dose 0.5 mg/kg/day for 5 days, followed by 0.25 mg/kg/day for 5 days.
62754168|NCT05401812|EXPERIMENTAL|Low dose and short treatment duration|Methylprednisolone equivalent dose 0.5 mg/kg/day for 4 days,, followed by 0.25 mg/kg/day for 3 days.
62754169|NCT05401812|EXPERIMENTAL|Moderate dose and long treatment duration|Methylprednisolone equivalent dose 1 mg/kg/day for 5 days, followed by 0.5 mg/kg/day for 5 days.
62754170|NCT05401812|EXPERIMENTAL|Moderate dose and short treatment duration|Methylprednisolone equivalent dose 1 mg/kg/day for 4 days, followed by 0.5 mg/kg/day for 3 days.
62754171|NCT06464744|PLACEBO_COMPARATOR|Placebo stimulation|Patients will receive stimulation from a placebo coil that only delivers skin tingling but no active brain stimulation.
62754172|NCT06464744|ACTIVE_COMPARATOR|Active stimulation|Patients will receive active brain stimulation from a magnetic figure-of-eight-coil.
62754173|NCT04775927|EXPERIMENTAL|education group|marriage preparation training
62754174|NCT04775927|NO_INTERVENTION|control group|No intervention
62754175|NCT05102097|EXPERIMENTAL|Experimental Group|Treadmill walk: i- warm up ( 5 minutes ) II- Main exercise (30 minutes) III- cool down (5 minutes) IV- Standard of care (10minutes)
62754176|NCT05102097|ACTIVE_COMPARATOR|Control group|Standard of care (10 minutes)
62754177|NCT04083313|ACTIVE_COMPARATOR|Endoloop|Patients in which appendiceal stump was ligated using Endoloop
62754178|NCT04083313|ACTIVE_COMPARATOR|Endostapler|Patients in which appendiceal stump was ligated using Endostapler
62754179|NCT04083313|ACTIVE_COMPARATOR|Endoclip|Patients in which appendiceal stump was ligated using Endoclip
62754180|NCT05069714|EXPERIMENTAL|MTX 1 week hold|Patients who will hold MTX for 1 week after an influenza vaccine.
62754181|NCT05069714|ACTIVE_COMPARATOR|MTX 2 week hold|Patients who will hold MTX for 2 weeks after an influenza vaccine.
62754182|NCT04463199|EXPERIMENTAL|Experimental|Experimental group received craniocervical flexion training for 4 weeks and postural advice
62754183|NCT04463199|NO_INTERVENTION|Control Group|Control group received only postural advice
62754184|NCT02649023||A: Patients with deep venous thrombosis|"All patients will be screened for deep venous thrombosis on postoperative day 3. Patients with a positive finding will be grouped in arm A"
62754185|NCT02649023||B: Patients without deep venous thrombosis|"All patients will be screened for deep venous thrombosis on postoperative day 3. Patients with a negative finding will be grouped in arm B"
62754186|NCT02502227|ACTIVE_COMPARATOR|Mindfulness Training|Mindfulness training intervention consisting of eight weekly 2.5 hour group sessions, a day-long retreat in the sixth week, and daily home mindfulness meditation
62754187|NCT02502227|ACTIVE_COMPARATOR|Mindful Attention Only Training|Mindful attention only training intervention consisting of eight weekly 2.5 hour group sessions, a day-long retreat in the sixth week, and daily home mindfulness meditation
62754188|NCT02502227|NO_INTERVENTION|No Treatment Control Condition|No treatment participants will be informed that their participation is important and that they are requested to not seek out similar treatments during this waiting period.
62754189|NCT02842515||Patients requiring dental avulsion|Patients requiring dental avulsion
62754190|NCT03133598||1|patients with intracranial aneurysms who underwent endovascular or miro-neurosurgical treatment
62754191|NCT02076360|EXPERIMENTAL|Preop Video|This arm will watch an instructional video in addition to their normal preoperative visit with the physician.
62754192|NCT02076360|NO_INTERVENTION|No video|This arm will receive only the normal preoperative visit with the physician without the additional video
62754193|NCT03371407||Parkinsonian patient under dopaminergic medication|
62754194|NCT03371407||Parkinsonian patient without dopaminergic medication|
62754195|NCT03371407||Control participants|
62754196|NCT01152905||Air/TIVA group|The patients received during the anesthesia a mixture of air with 30% oxygen All patients received total intravenous anesthesia (TIVA) using target controlled infusion of propofol and remifentanil.
62754197|NCT01152905||Nitrous oxide/TIVA group|The patients received nitrous oxide with 30% oxygen.All patients received total intravenous anesthesia (TIVA) using target controlled infusion of propofol and remifentanil.
62754198|NCT02024269|EXPERIMENTAL|Adipose Stem Cells|
62754199|NCT01543672|EXPERIMENTAL|SBRT group A|escalate MLD in medically inoperable patients with tumors larger than 5 cm in diameter (primary or solitary metastases)
62754200|NCT01543672|EXPERIMENTAL|SBRT group B|Escalate the MLD in patients with ≥ 2 lung metastases
62754201|NCT05569057|EXPERIMENTAL|SIM1811-03 Monotherapy|All participants receive SIM1811-03 alone
62754202|NCT02640625|EXPERIMENTAL|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
62754203|NCT01884558|EXPERIMENTAL|isavuconazole and metformin|Metformin single dose on days 1 and 8. Isavuconazole three times a day (TID) on Days 4 and 5 followed by isavuconazole once daily (QD) on Days 6-9.
62754204|NCT05966428|ACTIVE_COMPARATOR|Control Group|Conventional Exercises
62754205|NCT05966428|EXPERIMENTAL|Intervention Group|Conventional Exercises + Sensory Integration Therapy
62754206|NCT05340387|EXPERIMENTAL|Balance Resistance Aerobic Cognitive Exercises (BRACE)|BRACE include combination of exercises including, Balance, Resistance, Aerobic, Cognition Exercises.
62754207|NCT05340387|ACTIVE_COMPARATOR|Otago's Exercises|Otago's protocol is combination of warm up, strengthening, balance and flexibility exercises.
62754208|NCT02175862||Trauma patients before PS-HEMS|"The before period was between december 1 2009 to april 30 2010 (five months)."
62754209|NCT02175862||Traume patients after PS-HEMS|"The after period was between may 1 2010 to april 30 2011 (12 months)."
62754210|NCT01338480|EXPERIMENTAL|video|Participants in the intervention group watched an educational video illustrating informed consent information
62754211|NCT01338480|NO_INTERVENTION|control|Participants in the control group read an informed consent document.
62754212|NCT01018472|EXPERIMENTAL|Bifidobacterium infantis|
62754213|NCT01018472|PLACEBO_COMPARATOR|Placebo|
62754214|NCT03659773|EXPERIMENTAL|hematopoietic stem cell transplant (HSCT)|immune biomarkers to evaluate vaccine response in HSCT recipients
62754215|NCT03155334|OTHER|Prevalence of CCSVI in MS|Subjects with prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases - PIS User Testing
62754216|NCT03155334|OTHER|BVD Exploited Against MS|Subjects suffering from Brain venous drainage exploited against Multiple Sclerosis - PIS User Testing
62754217|NCT01094314|ACTIVE_COMPARATOR|sequential medium|
62754218|NCT01094314|ACTIVE_COMPARATOR|single medium|
62754219|NCT00831610|OTHER|STUDY|"1. Female healthy volunteers (25 to 55 years old) with normal weight.~2. Morbid Obese women waiting for bariatric surgery.~3. Post-bariatric female patients, 25 to 55 years old, MORE than 12 months of weight stability, pendular abdominal wall, clinical conditions to anchor-line abdominoplasty without flap undermining. Skin Evaluation before the abdominoplasty.~4. Group 3, submitted to anchor-line abdominoplasty without flap undermining."
62754220|NCT00831610|OTHER|CONTROL|Group 3: Post-bariatric female patients, 25 to 55 years old, LESS than 12 months of weight stability, pendular abdominal wall, clinical conditions to anchor-line abdominoplasty without flap undermining. Who will be submitted to abdominoplasty after the study period.
62754221|NCT02210689|EXPERIMENTAL|test product|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.)
62754222|NCT02210689|ACTIVE_COMPARATOR|reference product|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of Clindesse® (clindamycin phosphate vaginal cream 2% ) (Ther-Rx™)
62754223|NCT02210689|PLACEBO_COMPARATOR|placebo|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing vehicle of the test product (Watson Laboratories, Inc.)
62754224|NCT02210312||elective non-cardiac surgery and non-neurosurgical procedures|300 Patients aged 60 years and older undergoing elective non-cardiac surgery and non-neurosurgical procedures in general anaesthesia or combined general/regional anaesthesia with a duration of operation of 120 minutes or longer. 80 age-, gender- and education-matched healthy controls.
62754225|NCT01296633|EXPERIMENTAL|Medtable|The Medtable is a patient education tool used for collaborative planning. The Medtable focuses patients on how to take their medication and prompts them to anchor this task to familiar routines. The tool serves as an external workspace that helps provider and patient jointly visualize how to integrate constraints from medications (e.g., which can be taken together; dose spacing) and patients' routine (e.g., typical meal times) in order to create an optimal daily schedule. The completed Medtable shows providers how patients are thinking about taking their medications, allowing them to clear up any confusion. It encourages teach-back and teach-to-goal strategies recommended for patients with low health literacy. Completing the Medtable helps patients implement as well as create plans by encouraging them to think about when and where they will actually take their medication. It also provides a template developed with their providers that could help patients load pill organizers at home.
62754226|NCT01296633|ACTIVE_COMPARATOR|Usual care|Patients in the usual care condition at both research sites will receive the medication counseling and communication that is standard of care at these sites. This includes a medication reconciliation process, where patients are given a card with list of medications that is periodically checked. This provides an opportunity for providers to correct patient knowledge of their medications, and is similar to the process of creating a list for the Medtable. However, the Medtable also encourages patients and providers to collaborate in order to organize this list in terms of the patient's routine to create a patient-specific, concrete plan for taking the medications.
62754227|NCT02252185|EXPERIMENTAL|China made spine fusion system|patents in this arm will be implanted with Johnson\&Johnson Medical Suzhou made Spine Fusion System.
62754228|NCT02252185|ACTIVE_COMPARATOR|Imported spine fusion system|patents in this arm will be implanted with Imported EXPEDIUM screws and OPAL cage .
62754229|NCT03661788|EXPERIMENTAL|First placebo, than atomoxetin|Patients receive a placebo in the first of the two 14-day treatment intervals and atomoxetin in the second 14-day treatment intervals. Between the treatment intervals there is a wash-out phase of two weeks. The order of treatment is randomized.
62754230|NCT03661788|EXPERIMENTAL|First atomoxetin, than placebo|Patients receive atomoxetin in the first of the two 14-day treatment intervals and a placebo in the second 14-day treatment interval. Between the treatment intervals there is a wash-out phase of two weeks. The order of treatment is randomized.
62754231|NCT02226562|EXPERIMENTAL|Potassium nitrate and sodium fluoride|3.0% weight by weight (w/w) potassium nitrate mouthwash with 0.02% sodium fluoride
62754232|NCT02226562|OTHER|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate (SMFP)
61986579|NCT00780325|ACTIVE_COMPARATOR|5|Acetazolamide, single oral dose of 250 mg
61986580|NCT00780325|PLACEBO_COMPARATOR|6|Placebo, single oral administration
62754233|NCT02901002||Patient|Patients suffering from CRPS of the lower limb Patients with sensory testing in the two hand and neuropsychological evaluation
62754234|NCT02901002||Control|Healthy controls match by age, gender, Body Mass Index Healthy volunteers with sensory testing in the two hand and neuropsychological evaluation
62754235|NCT00338832|EXPERIMENTAL|1|Participants will receive the Physically Ready for Invigorating Movement Every Day program
62754236|NCT00338832|ACTIVE_COMPARATOR|2|Participants will receive the Program for Activity, Leisure Skills, and Socialization
62754237|NCT03645694|EXPERIMENTAL|SSA|Individuals with memory concerns in the experimental arm received the prototype facial recognition technology, which included a smartphone and smartwatch. The smartphone was equipped with facial recognition software application; the smartwatch communicated information with the smartphone. Persons with memory concerns and their family care partners were given a demonstration on how to utilize the technology.
62754238|NCT03645694|NO_INTERVENTION|Control|Control participants did not receive the technology; at the conclusion of follow-up, all controls were offered the technology to use.
62754239|NCT05865405|EXPERIMENTAL|Arm 1: 12 month MS CATCH tool intervention|Participants in arm 1 will receive 12 months of use of the MS CATCH tool. This will include in-visit interventions and monthly questionnaires.
62754240|NCT05865405|OTHER|"Arm 2: 6 month usual care, 6 month MS CATCH tool intervention"|"Participants in arm 2 will receive 6 months usual care followed by 6 months of MS CATCH tool intervention. These first 6 months will be used to assess the definition of usual care."
62754241|NCT06429163|PLACEBO_COMPARATOR|Standart analgesia|Standard variant of postoperative analgesia (systemic administration - intravenous, intramuscular, oral - non-steroidal anti-inflammatory drugs, paracetamol, opioid analgesics).
62754242|NCT06429163|ACTIVE_COMPARATOR|Pre-incisional infiltration|Prophylactic pre-incisional infiltration of the anterior abdominal wall + standard variant of postoperative analgesia
62754243|NCT06429163|ACTIVE_COMPARATOR|Presacral blockade|Prophylactic pre-incisional infiltration of the anterior abdominal wall + presacral blockade + standard variant of postoperative analgesia
61986581|NCT00415909|EXPERIMENTAL|TALL-104 + IM|TALL-104 cells and imatinib mesylate (IM) therapy
61986582|NCT01912144|OTHER|coffee|Coffee beverage
61986583|NCT00930566|EXPERIMENTAL|Extracorporal Photopheresis|
62377843|NCT04509297|EXPERIMENTAL|High protein milk|Experimental: High protein milk consumption This arm involved High protein milk whole consumption concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
62754244|NCT05346965|EXPERIMENTAL|Musical training programme|Participants in the experimental group received a weekly 1-hour musical training lesson for 6 months delivered by professionally qualified musicians. The participants will be assigned a particular musical instrument to learn, and this is based on their interests as well as their capabilities (i.e., fine motor skills), The training will begin at the lowest level (hitting simple notes) and end at the highest level (able to play an entire song).
62754245|NCT05346965|ACTIVE_COMPARATOR|Wait-list control group|To ensure equity of access to potentially effective intervention (i.e. musical training programme), participants in the wait-list control group will receive the same musical training programme as participants in the intervention group after the completion of all assessments.
62754246|NCT02994953|EXPERIMENTAL|Part A Cohort 1: M9241 4 mcg/kg + Avelumab 10 mg/kg|Participants received M9241 at a dose of 4 micrograms per kilogram (mcg/kg) a subcutaneous (SC) injection at time (up to -20 minutes) relative to the start of Avelumab infusion (time 0), once every 4 weeks, on Day 1 in combination with Avelumab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion every 2 weeks on Day 1 and 15 during each cycle (Each cycle=28 days) until any criterion for treatment discontinuation were met.
62754247|NCT02994953|EXPERIMENTAL|Part A Cohort 2: M9241 8 mcg/kg + Avelumab 10 mg/kg|Participants received M9241 at a dose of 8 mcg/kg SC injection at time (up to -20 minutes) relative to the start of avelumab infusion (time 0), once every 4 weeks, on Day 1 in combination with Avelumab 10 mg/kg IV infusion every 2 weeks on Day 1 and 15 of each cycle (Each cycle=28 days) until any criterion for treatment discontinuation were met.
62754248|NCT02994953|EXPERIMENTAL|Part A Cohort 3: M9241 12 mcg/kg + Avelumab 10 mg/kg|Participants received M9241 at a dose of 12 mcg/kg SC injection at time (up to -20 minutes) relative to the start of avelumab infusion (time 0), once every 4 weeks, on Day 1 in combination with Avelumab 10 mg/kg IV infusion every 2 weeks on Day 1 and 15 of each cycle (Each cycle=28 days) until any criterion for treatment discontinuation were met.
62754249|NCT02994953|EXPERIMENTAL|Part A Cohort 4: M9241 16.8 mcg/kg +Avelumab 10 mg/kg|Participants received M9241 at a dose of 16.8 mcg/kg SC injection at time (up to -20 minutes) relative to the start of avelumab infusion (time 0), once every 4 weeks, on Day 1 in combination with Avelumab 10 mg/kg IV infusion every 2 weeks on Day 1 and 15 of each cycle (Each cycle=28 days) until any criterion for treatment discontinuation were met.
62754250|NCT02994953|EXPERIMENTAL|Part A Cohort 5: M9241 16.8 mcg/kg + Avelumab 800 mg|Participants received M9241 at a dose of 16.8 mcg/kg SC injection at time (up to -20 minutes) relative to the start of avelumab infusion (time 0), once every 4 weeks, on Day 1 in combination with Avelumab 800 milligrams (mg) IV infusion once weekly for the first 12 weeks, then 800 mg once every 2 weeks of each cycle (Each cycle=28 days) until any criterion for treatment discontinuation were met.
62754251|NCT02994953|EXPERIMENTAL|Part B Cohort 1: UC Cohort Stage 1 combination therapy|Participants in the expansion cohorts received M9241 at dose of 16.8 mcg/kg SC injection at time (up to -20 minutes) relative to the start of avelumab infusion (time 0), once every 4 weeks on Day 1 in combination with Avelumab 800 mg IV infusion once weekly for the first 12 weeks, then 800 mg once every 2 weeks of each cycle (Each cycle=28 days) determined as the RP2D in the escalation part of the study.
62754252|NCT01430923|EXPERIMENTAL|Refrigeration free Latanoprost|Latanoprost refrigeration free formulation as per randomization schedule.
62754253|NCT01430923|ACTIVE_COMPARATOR|latanoprost 2-8˚ C|latanoprost stored at 2-8˚ C
62754254|NCT03352453|EXPERIMENTAL|Rapastinel 450mg|Rapastinel 450 milligram (mg) weekly intravenous (IV) injections.
62754255|NCT03352453|PLACEBO_COMPARATOR|Placebo|Placebo-matching rapastinel weekly IV injections.
62754256|NCT06176872||Cardiac Computed Tomography Angiography|Patients with acute ischemic stroke who receive cardiac computed tomography angiography as part of the routine diagnostic work-up of acute ischemic stroke.
62754257|NCT06176872||Retrospective matched cohort|A retrospective matched cohort of patients with acute ischemic stroke who did not receive cardiac computed tomography angiography.
62754258|NCT02282800||Case group|Case group include patients with generalized AgP were the tissue samples taken to analyse the number of vitamin D receptor present.
62754259|NCT02282800||Control group|Ethnically matched, systemically and periodontally healthy individuals were included in control group were also gingival tissue taken for analysis of number of receptors present in nucleus and cytoplasm
62754260|NCT01990430|EXPERIMENTAL|Exercise Intervention|"The exercise program was designed and conducted by a qualified exercise physiologist with oncologic training. The exercise program consisted in a twice weekly supervised training program developed in a social framework. The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation.~The nutrition program consisted of three theoretical and practice classes, where specific terms of nutrition and diet were explained. Teachers did not promote avoiding any group of aliments and a Mediterranean diet was encouraged to be followed."
62754261|NCT01990430|NO_INTERVENTION|Control|Patients will be asked to maintain their usual life style, without special changes
62754262|NCT06606743|EXPERIMENTAL|High-Intensity Interval Training|Participants in this group will receive high-intensity interval training 2 times per week for 10 consecutive weeks.
62754263|NCT06606743|ACTIVE_COMPARATOR|High-Velocity Circuit Resistance Training|Participants in this group will receive high-velocity circuit resistance training 2 times per week for 10 consecutive weeks.
62754264|NCT01295008||Patients with the classic form|
62754265|NCT01295008||Fabry disease and healthy controls|
62754266|NCT03752190|EXPERIMENTAL|Intravenous and intramuscular administration|Subjects will receive intravenous and intramuscular ACTH on different days
62754267|NCT02303080|PLACEBO_COMPARATOR|Control (WPM 0)|400 mL beverage with 85.0% maltodextrine, 15.0% fat and 0% of whey protein micelles Product given once after 1 hour of monitoring for baseline
62556528|NCT03238651|EXPERIMENTAL|Dose Escalation Part Schedule B: TAK-659 80 mg in Cohort 1|TAK-659, tablet, orally, once daily as 7 days on and 7 days off treatment (dosing on 7 days followed by 7 days of rest) in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 80 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. An alternative intermittent regimen may be evaluated if deemed necessary per the emerging data.
62556529|NCT03238651|EXPERIMENTAL|Expansion Part: TAK-659 MTD/RP2D|TAK-659, tablet, orally, once daily, in a 28-day treatment cycle until disease progression or unacceptable toxicity in participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who are relapsed and/or refractory. Dose and dosing schedule for this part will be MTD/RP2D determined from results of dose escalation part.
62754268|NCT02303080|ACTIVE_COMPARATOR|WPM 30|400 mL beverage with 43.7% of maltodextrine, 15.2 % fat and 41.1% (30 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
62754269|NCT02303080|ACTIVE_COMPARATOR|WPM 50|400 mL beverage with 16.3% of maltodextrine, 15.2 % fat and 68.5% (50 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
62754270|NCT02303080|ACTIVE_COMPARATOR|MC 50|400 mL beverage with 16.7% of maltodextrine, 15.0 % fat and 68.2% (50 g) of whey protein micelles 50 g of micellar casein Product given once after 1 hour of monitoring for baseline
62754271|NCT04611425|EXPERIMENTAL|Remimazolam|"Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours.~The dose of Remimazolam will be adapted according to our ICU protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale)"
62754272|NCT00622089|EXPERIMENTAL|1|150mg DIO-902 + 10mg Atorvastatin
62754273|NCT00622089|EXPERIMENTAL|2.|300mg DIO-902 + 10mg Atorvastatin
62754274|NCT00622089|EXPERIMENTAL|3|450mg DIO-902 + 10mg Atorvastatin
62754275|NCT05791695||Study Patients|Patients ≥ 18 years who have received one or more injections of aflibercept during the study period
62754276|NCT06537128|ACTIVE_COMPARATOR|LUNA-Adolescent|Dyads in the Learning to Understand and Navigate Anxiety-Adolescent (LUNA-Adolescent) group will receive internet-based cognitive behavioral therapy (LUNA-Adolescent), which includes 12 weekly treatment modules, 6 bi-weekly, 30-minutes telehealth visits, and email check-ins.
62754277|NCT06537128|PLACEBO_COMPARATOR|Treatment as Usual|Dyads in the standard-care cognitive behavioral therapy (CBT) group will receive 12 weekly sessions of transdiagnostic CBT for anxiety in autistic youth.
62754278|NCT01096537||Young workers|"Exposed young workers graduated in sectors at risk of occupational asthma (bakery, pastry-making or hairdressing)~Non-exposed young workers graduated in sectors without specific occupational exposure as the sale or the food sectors."
62754279|NCT01804582|EXPERIMENTAL|Family Navigator Consultation|"This group of parents will be contacted by a Family Navigator to assist them in accessing psychosocial resources based on their child and family needs. Components of this intervention are the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
62556530|NCT01204567|ACTIVE_COMPARATOR|Training follow-up after discharge|Aerobic training Home-program
62556531|NCT02226211|EXPERIMENTAL|air-Q group|
62556532|NCT02226211|EXPERIMENTAL|aura-i group|
62556533|NCT02102113|OTHER|No Family History of Psychosis (FHN)|Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions.
62556534|NCT02102113|EXPERIMENTAL|Family History of Psychosis (FHP)|Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions.
62556535|NCT03897283|EXPERIMENTAL|Anlotinib + TQB2450|TQB2450 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
62754280|NCT01804582|NO_INTERVENTION|Usual Care|No specific study intervention is provided to this group of parents. This control group will received the usual care that they have been receiving from their child's providers.
62754281|NCT05747482|OTHER|Omentectomy|Omentectomy during cancer gastric surgery
62754282|NCT05747482|OTHER|Omental preservation|Preserval omentation during cancer gastric surgery
62754283|NCT05148442|EXPERIMENTAL|IBI322|
62754284|NCT01866423|EXPERIMENTAL|Treatment (orteronel)|Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62754285|NCT00762567|EXPERIMENTAL|1|phenylephrine
62754286|NCT03051984|EXPERIMENTAL|NMES|Neuromuscular electrical stimulation (NMES) will be administered for 5 weeks post-TKA in the quadriceps of the surgical leg. Treatment will occur 5 days per week, twice daily for 45 minutes on each occasion.
62754287|NCT03051984|NO_INTERVENTION|Control|No intervention will be administered during the 5 weeks post-TKA in the surgical leg.
62754288|NCT04200768|OTHER|Standard|Standard of care
62754289|NCT06321198|EXPERIMENTAL|iMSC injection|Low dose injection once a week; Low dose injection twice a week; High dose injection once a week; High dose injection twice a week;
62754290|NCT06428565|EXPERIMENTAL|Low-level laser therapy (LLLT) or cold laser therapy|uses low-level lasers or light-emitting diodes to stimulate cellular function and improve healing. Physiotherapy, sports medicine, and rehabilitation use it as a non-invasive, painless complement or adjuvant therapy
62754291|NCT03618628|EXPERIMENTAL|People using a CFO|People who are currently wearing a carbon fiber off loading orthosis (CFO) will have a new CFO fabricated for them based on the results of our finite element (FE) model. We will then test both CFOs ability to reduce peak plantar compared to barefoot and the peak plantarflexor power of both braces.
62754292|NCT02299570|ACTIVE_COMPARATOR|Group A|Two enemas of RBX2660 (microbiota suspension) administered 7 days apart
62754293|NCT02299570|PLACEBO_COMPARATOR|Group B|Two enemas of placebo administered 7 days apart
62754294|NCT02299570|ACTIVE_COMPARATOR|Group C|1 enema of RBX2660 (microbiota suspension) and 1 enema of placebo administered 7 days apart
62754295|NCT06491290||Study cohort|
62754296|NCT04788797|ACTIVE_COMPARATOR|Prolyl Endopeptidase|Patients blinded-receive active AN-PEP at a dose of 2 capsules/breakfast, lunch and dinner during 8 weeks (study arm)
62754297|NCT04788797|PLACEBO_COMPARATOR|Placebo|Patients blinded-receive 2 capsules of a placebo (specially designed and prepared for the study) at breakfast, lunch and dinner during 8 weeks (Placebo arm).
62754298|NCT01571908|EXPERIMENTAL|Magnesium perfusion - Rocuronium|60 mg/kg of magnesium perfusion over 15 minutes before Anaesthesia. After Anaesthesia induction 0.6 mg/kg of Rocuronium intravenously
62754299|NCT01571908|ACTIVE_COMPARATOR|Placebo perfusion - Succinylcholine|1ml/kg of saline (placebo) over 15 minutes before Anaesthesia. After Anaesthesia induction 1 mg/kg of Succinylcholine intravenously
62754300|NCT03328169|ACTIVE_COMPARATOR|CBT-I|Cognitive Behavioral Therapy for Insomnia
62754301|NCT03328169|EXPERIMENTAL|Mindfulness|Mindfulness-Based Therapy
62754302|NCT03454269|ACTIVE_COMPARATOR|PD patients with visual hallucinations (PD-VH)|PD patients without hallucinations or illusions
62754303|NCT03454269|ACTIVE_COMPARATOR|Patients with illusions (PD-I)|PD patients with Illusions and without hallucinations
62754304|NCT03454269|ACTIVE_COMPARATOR|Patients without visual hallucinations or illusions (PD-nVHI))|PD patients without Illusions and with hallucinations
62754305|NCT03891004|EXPERIMENTAL|Tissue Adhesives Only|For the tissue adhesive, we will use Dermabond, which was FDA approved for skin closure in 1998. We will record the length of time of each closure method for comparison, and have patients follow-up at two, six and 12 weeks. At the 12 week visit we will score the appearance of the incision.
62754306|NCT03891004|ACTIVE_COMPARATOR|Subcuticular Suture Closure Method Only|For the suture arm we will only close the subcuticular layer. We will record the length of time of each closure method for comparison, and have patients follow-up at two, six and 12 weeks. At the 12 week visit we will score the appearance of the incision.
62754307|NCT05714072|EXPERIMENTAL|Ruxolitinib plus Abemaciclib|"This will be a phase 1 study with a traditional 3+3 design of combination ruxolitinib (at fixed doses of 10mg BID or 15mg BID) and abemaciclib. There are 3 planned dose levels of abemaciclib: 50, 100 and 150 mg. Cycles will be 4 weeks (28 days) long and DLT window will consist of first cycle."
62754308|NCT00280800|ACTIVE_COMPARATOR|1|constant CPAP
62754309|NCT00280800|EXPERIMENTAL|2|automatic CPAP
62377844|NCT04509297|PLACEBO_COMPARATOR|Placebo|This arm involved consumption of a maltodextrin drink with a 9% solution with a vanilla flavor concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime. drink r
62754310|NCT01539343|EXPERIMENTAL|Antimicrobial Lock Solution|Participants receive the HEAL antimicrobial solution for 2 hours once daily for a minimum of 5 consecutive days. Participants also receive the lock therapy once weekly for two additional weeks. Principle ingredients include minocycline, calcium disodium ethylenediaminetetraacetate (CaEDTA) and ethanol.
62754311|NCT01903551|EXPERIMENTAL|Loco-regional catheter|A suprafascial catheter will be positioned at the end of cardiac intervention during the thoracotomy closure. The catheter will be connected to a elastomeric pump, which delivers the analgesic drug (ropivacaine).
62754312|NCT01903551|NO_INTERVENTION|Intravenous analgesia|At the end of the cardiac intervention each patient will receive intravenous analgesia with morphine at 0.8 mg/h.
62754313|NCT00591968|NO_INTERVENTION|1|The control group will receive traditional ultrasound consults (i.e. travel to nearest tertiary center for intraabdominal sonographic evaluation and return with radiologist's report).
62377845|NCT05424744|EXPERIMENTAL|Telemedicine Management of Hypertension|using home blood pressure monitoring
62377846|NCT00697255|EXPERIMENTAL|corifollitropin alfa + recFSH|Eligible participants will receive a subcutaneous (SC) injection of corifollitropin alfa (Stage 1a: 15mcg, Stage Ib/II: 30 mcg) the first, second, or third day after onset of a progestagen-induced withdrawal bleeding. If the follicle growth is insufficient, the participant will receive a second or third dose of corifollitropin alfa (Stage 1a: 15 mcg, Stage Ib/II: 20 mcg). As soon as the largest follicle reaches a size of ≥12 mm, the participant will start daily SC injections with FSH (Stage 1A: 50 IU, Stage II: 75 IU) the same day. A bolus injection of hCG (5000 IU) will be administered if at least one follicle is ≥18 mm and in total no more than two follicles ≥15 mm are observed.
62377847|NCT00697255|EXPERIMENTAL|corifollitropin alfa + hCG|Eligible participants will receive a SC injection of corifollitropin alfa (Stage Ia:15 mcg, Stage Ib/II: 30 mcg) the first, second or third day after onset of a progestagen-induced withdrawal bleeding. If the follicle growth is insufficient the participant will receive a second or third dose of corifollitropin alfa (Stage IA: 15 mcg, stage Ib/II: 20 mcg). As soon as the largest follicle reaches a size of ≥12 mm the participant will start daily SC injections with hCG (Stage Ib/II: 200 IU) the same day. A bolus injection of hCG (5000 IU) will be administered if at least one follicle is ≥18 mm and in total no more than two follicles ≥15 mm are observed.
62377848|NCT02217449||HD|Prediction of histology
62377849|NCT02217449||Virtual Chromoendoscopy|Prediction of histology
62377850|NCT02809846|ACTIVE_COMPARATOR|Quell Device|Quell is a class II medical device with FDA 510(k) clearance for the symptomatic relief and management of chronic intractable pain, without a prescription. It operates by using an electrical stimulator to activate peripheral sensory nerves and trigger analgesia.
62377851|NCT02809846|SHAM_COMPARATOR|Sham Quell Device|Identical to Active Comparator, but provides sub-therapeutic electronic stimulation.
62377852|NCT01749865|EXPERIMENTAL|A, CIK|Biological/Vaccine: Cytokine-Induced Killer Cells
62377853|NCT01749865|NO_INTERVENTION|B, CONTROL|Regular follow up with no intervention
62377854|NCT02954952|OTHER|Standard of care (baseline)|Subjects will receive the Sedline sensor. The anesthesiologist will be blinded to the PSI Rev 1.X score and the raw EEG data from the Masimo device. Anesthesia management will be in accordance with standard of care protocols and procedures.
62377855|NCT02954952|EXPERIMENTAL|PSI Rev 1.X|The anesthesiologist will be monitoring subjects using an old version of PSI (Rev 1.X).
62377856|NCT02954952|EXPERIMENTAL|PSI Rev 2.X|The anesthesiologist will be monitoring subjects using a new version of PSI (Rev 2.X).
62377857|NCT01914991|ACTIVE_COMPARATOR|Control group|Conventional treatment: The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
62377858|NCT01914991|EXPERIMENTAL|Experimental group|dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
62377859|NCT05007301||Standard of care|Patients who are receiving the geko device as part of standard of care for wound management
62377860|NCT01481714|ACTIVE_COMPARATOR|Sodium Picosulphate preparation the day before|"Preparation the day before of the procedure using sodium picosulphate:~* A sachet mixed with 250 mL of water at 18:00 pm~* A sachet mixed with 250 mL of water at 21:00 pm~* A minimum of 4 litres of fluid were recommended throughout the preparation"
62754314|NCT00591968|EXPERIMENTAL|2|The experimental group will receive the teleultrasound service. Participants are randomly assigned to this group. All patients will receive a traditional clinical work-up. An ultrasound examination will be offered if, based on initial clinical evaluation by an attending physician, the patient is found to have symptoms consistent with any the following abnormalities: ascites, blunt abdominal trauma, cholelithiasis, cholecystitis, cholangitis, pancreatitis, hydronephrosis, abdominal aortic aneurysm, hepatitis, portal hypertension, urolithiasis, abnormal uterine bleeding, ovarian mass or torsion.
62754315|NCT05154136|EXPERIMENTAL|Etrumadenant then Etrumadenant + Itraconazole|"Participants will receive the Treatment A (etrumadenant) followed by Treatment B (etrumadenant + itraconazole).~A washout period of 5 days will be maintained between the two treatments."
62754316|NCT06266949||Patients|Participants will undergo a visual acuity test. Next they will perform the SONDA test 2 times at one visit and once more in a later visit Participants will fill in a questionnaire
62377861|NCT01481714|EXPERIMENTAL|Split-dose sodium picosulphate preparation|"The day before the procedure:~- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~* A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~* A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am."
62556536|NCT03642197|EXPERIMENTAL|Support Figure Attended (SFA)|Using simple randomization patients (female or male) not in romantic relationships will be randomized into support figure attended (SFA) and SFA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Support figures in the SFA arm will be requested to attend the four pre-surgery classes with the patient and the three clinical visits. The intervention is support figure attendance. Assessments will be completed by patients and support figures at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
62556537|NCT03642197|NO_INTERVENTION|SFA - Treatment as Usual (SFA-TAU)|Using simple randomization patients (female or male) not in romantic relationships will be randomized into support figure attended (SFA) and SFA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Support figures in the SFA-TU arm will not be requested to attend the four pre-surgery classes with the patient and the three clinical visits- patients will attend alone. Assessments will be completed by patients and support figures at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
62556538|NCT03642197|EXPERIMENTAL|Partner Attended (PA)|Using simple randomization female patients in cohabiting romantic relationships for at least 6 months will be randomized into partner attended (PA) and PA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Partners in the PA arm will be requested to attend the four pre-surgery classes with the patient and the three clinical visits. The intervention is partner attendance. Assessments will be completed by patients and partners at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
62556539|NCT03642197|NO_INTERVENTION|PA - Treatment as Usual (PA-TAU)|Using simple randomization female patients in cohabiting romantic relationships for at least 6 months will be randomized into partner attended (PA) and PA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Partners in the PA-TU arm will not be requested to attend the four pre-surgery classes with the patient and the three clinical visits- patients will attend alone. Assessments will be completed by patients and partners at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
62556540|NCT02561429|EXPERIMENTAL|SPT of histamine|SPT of histamine concentration 1, 5 and 10 mg/ml
62556541|NCT01257178|EXPERIMENTAL|Normal hepatic function|6mg, oral, once on day 1
62556542|NCT01257178|EXPERIMENTAL|Mild hepatic impairment|6 mg, oral, once on day 1
62556543|NCT01257178|EXPERIMENTAL|Moderate hepatic impairment|6 mg, oral, once on day 1
62556544|NCT01257178|EXPERIMENTAL|Severe hepatic impairment|6 mg, oral, once on day 1
62556545|NCT04468685|EXPERIMENTAL|Ondansetron|Ondansetron intraperitoneal in the gall bladder bed
62556546|NCT04468685|PLACEBO_COMPARATOR|Saline|Normal saline intraperitoneal in the gall bladder bed
62754317|NCT06266949||Healthy controls|Participants will perform the SONDA test 2 times
62754318|NCT00165750|EXPERIMENTAL|1|
62754319|NCT02430896||ADHD group|Children and adolescents who met the Diagnostic and Statistical Manual IV Text Revision (DSM-IV-TR) diagnostic criteria for ADHD and needed pharmacotherapy. Subjects will be taking Methylphenidate or Atomoxetine for 52 weeks.
62754320|NCT02430896||Normal control group|Children and adolescents will be recruited by advertisement, and will be assigned to normal group if they do not meet the Diagnostic and Statistical Manual IV Text Revision (DSM-IV-TR) diagnostic criteria for ADHD .
62754321|NCT03488888|SHAM_COMPARATOR|Normal Saline|"General Anesthesia + Bilateral Pectoral injection of Normal Saline 0,9%~1. Ultrasound-guided visualization of Pectoralis major and pectoralis minor muscles~2. Injection of 10 mL normal saline 0,9% between muscles lateral to the thoracoacromial artery.~3. Visualization of Pectoralis menor and Serratil Muscles~3- Injection of 20 mL of normal saline 0,9% between Pectoralis minor and serratil muscles 4-Visualize the hydrodissection performed by the solution"
62377862|NCT06305169||Referrals to endoscopy via the 2 week wait cancer pathway for all indications other than dysphagia|This group will have their serum biomarkers measured by gastropanel a commercially available blood test, along with full blood count and complete a questionnaire.
62377863|NCT00730249|ACTIVE_COMPARATOR|1|
62556547|NCT05881824|NO_INTERVENTION|standard care group (SCG)|The SCG received oral healthy lifestyle advice and counseling on physical activity and sleep habits
62556548|NCT05881824|ACTIVE_COMPARATOR|Mediterranean diet group (MDG)|The MDG was additionally subjected to a 6-month behavioral intervention aiming at weight loss and increasing adherence to the Mediterranean diet.
62556549|NCT03998267|ACTIVE_COMPARATOR|Intervention arm|"For the subjects using the app (intervention group): The mobile app team shall do the following:~* Educate/train patients on app usage~* Patients will be subscribed to the app and their profile on the app will be created~* Subjects will log in their blood sugar readings and communicate with the mobile app team (educators and physician) via the app~* Additionally patients will be placed on a diet and lifestyle plan as agreed upon by the patient and health care provider team, best suited towards the patient's needs~* Throughout the study, patient will receive notifications and advice on how to follow diet and lifestyle changes~* Throughout the study; patient interaction and app usage will be tracked~* Patients will additionally be interviewed by the research team together with Droobi to capture app experience at 3 months and 6 months"
62754322|NCT03488888|EXPERIMENTAL|Bupivacaine|"General Anesthesia + Bilateral Pectoral injection of 30 mL of 0.25% Bupivacaine~1. Ultrasound-guided visualization of Pectoralis major and pectoralis minor muscles~2. Injection of 10 mL of local anesthetic between muscles lateral to the thoracoacromial artery.~3. Visualization of Pectoralis minor and Serratil Muscles~3- Injection of 20 mL of local anesthestic between Pectoralis minor and Serratil muscles 4-Visualize the hydrodissection performed by the solution"
62754323|NCT03664674|EXPERIMENTAL|OTO-104|
62754324|NCT03664674|PLACEBO_COMPARATOR|placebo|
62754325|NCT03080545|EXPERIMENTAL|Open Label Enstilar|open label
62754326|NCT05888909||Type 2 diabetic nephropathy|The cohort will be divided into 2 or 3 groups according the pathological results of patients,and at least 3 groups according to clinical features such as renal function and proteinuria.
62754327|NCT06022081|OTHER|Diagnostic modalities comparison|All participants belong to a single arm. A chest X-ray (CXR) and lung ultrasound (LUS) in a predetermined order (CXR followed by LUS), will be performed sequentially for pneumothorax (PNX) detection after chest/mediastinal tube removal. There is no control group or randomization.
62754328|NCT00822705|ACTIVE_COMPARATOR|ORAL GLP-1, TABLET|
62754329|NCT00822705|ACTIVE_COMPARATOR|Oral PYY3-36|
62754330|NCT00822705|ACTIVE_COMPARATOR|Oral GLP-1 plus oral PYY3-36|
62754331|NCT00822705|PLACEBO_COMPARATOR|4|
62754332|NCT03604874|ACTIVE_COMPARATOR|low dose oxytocin|patients will receive intravenous infusion of 5 Units of oxytocin/500 mL lactated ringer solution. Starting rate will be 2 mU/min, incrementally increase by 2 mU/min every 30 minutes until achievement of adequate uterine contractions.
62754333|NCT03604874|EXPERIMENTAL|high dose oxytocin|patients will receive intravenous infusion of 5 Units of oxytocin/500 mL lactated ringer solution. Starting rate will be 4 mU/min, incrementally increase by 4 mU/min every 30 minutes until achievement of adequate uterine contractions
62754334|NCT02956044|ACTIVE_COMPARATOR|Group 1: Bexagliflozin alone|
62754335|NCT02956044|ACTIVE_COMPARATOR|Group 1: Metformin alone|
62754336|NCT02956044|ACTIVE_COMPARATOR|Group 1: Bexagliflozin + Metformin|
62754337|NCT02956044|ACTIVE_COMPARATOR|Group 2: Bexagliflozin alone|
62377864|NCT00730249|PLACEBO_COMPARATOR|2|
62377865|NCT03138798|EXPERIMENTAL|Laboraide TM dental support device|Receive Laboraide
62377866|NCT03138798|NO_INTERVENTION|Control Group|Patients will give consent in the first stage of labor. Subsequently, randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group B will not receive a Laboraide TM dental support device. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment.
62377867|NCT05801016|OTHER|Anorexia nervosa|Female anorexia nervosa patients
62377868|NCT05801016|OTHER|Healthy controls|Healthy female control participants
62754338|NCT02956044|ACTIVE_COMPARATOR|Group 2: Glimepiride alone|
62754339|NCT02956044|ACTIVE_COMPARATOR|Group 2: Bexagliflozin + Glimepiride|
62754340|NCT02956044|ACTIVE_COMPARATOR|Group 3: Bexagliflozin alone|
62754341|NCT02956044|ACTIVE_COMPARATOR|Group 3: Sitagliptin alone|
62754342|NCT02956044|ACTIVE_COMPARATOR|Group 3: Bexagliflozin + Sitagliptin|
62754343|NCT05751889|EXPERIMENTAL|Serious Game Intervention|Provided with a single session serious game intervention regarding HCV and safe sexual practice.
62754344|NCT05751889|ACTIVE_COMPARATOR|Traditional Health Education|Provided with a single session of traditional online healthcare education regarding HCV and safe sexual practice.
62754345|NCT04006990|EXPERIMENTAL|Intervention|Subjects are given recliner chairs and education on the dangers of bedrest
62754346|NCT04006990|NO_INTERVENTION|Control|Subjects are treated with standard care
62377869|NCT06257615|EXPERIMENTAL|Education provided via TeleNursing|Nursing intervention consists of 3 online video calls with educational content to the intervention group (1st, 2nd and 3rd weeks after discharge), 3 audio phone calls (4th, 5th and 6th weeks after discharge) and an educational booklet.
62377870|NCT06257615|NO_INTERVENTION|Control|No intervention was made
62754347|NCT05941338|EXPERIMENTAL|Arm 1|Drug:Tirelizumab , Carboplatin,albumin-bound paclitaxel Patients receive Tirelizumab IV on day 1, albumin-bound paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2cycles in the absence of disease progression or unacceptable toxicity. Then surgery.
62754348|NCT00278902|EXPERIMENTAL|ARRY-334543|
62754349|NCT05980364|EXPERIMENTAL|Experimental group|
62754350|NCT05980364|NO_INTERVENTION|Control group|
62754351|NCT03651518|EXPERIMENTAL|Kineret|
62754352|NCT03651518|EXPERIMENTAL|Humira|
62754353|NCT03651518|EXPERIMENTAL|Stelara|
62754354|NCT03651518|EXPERIMENTAL|Cosentyx|
62754355|NCT03651518|EXPERIMENTAL|Roactemra|
62754356|NCT03651518|EXPERIMENTAL|Rituximab|
62754357|NCT04509518|EXPERIMENTAL|Study group|Participants in the study group received exercise therapy program plus additional TENS therapy
62754358|NCT04509518|OTHER|Control group|Participants in the study group received exercise therapy program plus sham TENS
62754359|NCT03521232|EXPERIMENTAL|150 mg/60 ml|Niclosamide enemas 150 mg/60 ml given twice daily for 6 weeks
62754360|NCT03521232|EXPERIMENTAL|450 mg/60 ml|Niclosamide enemas 450 mg/60 ml given twice daily for 6 weeks
62754361|NCT03354884|EXPERIMENTAL|Cabozantinib|All subjects will receive open label Cabozantinib 60 mg orally once daily
62754362|NCT03080233||Pakistani adult|"Men and women aged 18 years or above,presenting with neurological deficit consistent with stroke in the Emergency Department at Aga Khan University Hospital~Consenting to participate in the study"
62754363|NCT04315688||Tresiba®|Patients with type 2 diabetes
62754364|NCT04660058||chronic gastritis|patients with chronic non-atrophic gastritis and chronic atrophic gastritis according to histopathological results
62754365|NCT04660058||precancerous lesion|patients with gastric intestinal metaplasia and intraepithelial neoplasia according to histopathological results
62754366|NCT04660058||gastric cancer|patients with gastric cancer according to histopathological results
62377871|NCT02952430||Frail|"Patients over 65 year old having emergency laparotomy with a Frailty score (Modified Rockwood score) of greater than or equal to five.~This group will then be observed after intervention to review outcomes."
62377872|NCT02952430||Not frail|"Patients over 65 year old having emergency laparotomy with a Frailty score (Modified Rockwood score) of less than five.~This group will then be observed after intervention to review outcomes."
62377873|NCT00435929|EXPERIMENTAL|1|
62377874|NCT00435929|EXPERIMENTAL|2|
62377875|NCT01635244|ACTIVE_COMPARATOR|Freestyle|Aortic valve replacement will be performed with a Freestyle stentless aortic bioprosthesis (Medtronic Cardiovascular; Minneapolis, MN).
62377876|NCT01635244|ACTIVE_COMPARATOR|Magna Ease|Aortic valve replacement will be performed with a Magna Ease aortic bioprosthesis (Edwards Lifesciences; Irvine, CA).
62377877|NCT01635244|ACTIVE_COMPARATOR|Trifecta|Aortic valve replacement will be performed with a Trifecta aortic bioprosthesis (St. Jude Medical; St. Paul, MN).
62377878|NCT06147180||Minimally invasive esophageal cancer resection group|Surgical Procedures: minimally invasive esophagectomy
62377879|NCT06147180||Open esophageal cancer resection group|Surgical Procedures: open esophagectomy
62754367|NCT03204409||Symptomatic adults|adult patients (\>18 years) presenting with febrile or rash illness of short duration (\<72h)
62754368|NCT05479344|EXPERIMENTAL|Contextual Behavioural Intervention Based on Meaning and Connection|The current intervention involves the identification of strengths (the first week, 90 minutes of intervention), the perception of the meaning in life (the second week, 90 minutes of intervention), the learning of strategies to develop plan (the third week, 90 minutes of intervention), and the understanding of emotion regulation strategies (the fourth week, 90 minutes of intervention).
62377880|NCT02749552|EXPERIMENTAL|Acceptance and Commitment Therapy|ACT intervention
62377881|NCT03289494|ACTIVE_COMPARATOR|Diet A|Balanced diet high in Slowly Digestible Starch
62754369|NCT05479344|OTHER|Waiting list group|The waiting list group will receive the same intervention at the end of the 3-month follow-up test.
62754370|NCT05432388|EXPERIMENTAL|remibrutinib low dose|remibrutinib oral tablet
62754371|NCT05432388|EXPERIMENTAL|remibrutinib medium dose|remibrutinib oral tablet
62556550|NCT03998267|PLACEBO_COMPARATOR|Standard of care arm|"For the subjects not using the app (the standard of care group):~* At time 0, will be seen by the dietician and diabetes educators at HGH endocrine clinics as part of standards of care~* The educators contact number and diabetes hotline number will be provided to the patients~  o The diabetes hotline number #16099 is a new service provided to diabetes patients at the national diabetes center to help communicate with the diabetes educators with questions relating to their diabetes management, medication adjustment such as dose titrations etc.~* Appointments thereafter with the educator and/or dietician will be decided and scheduled according to the individual patient needs, with a minimum visit every 3 months during the study period"
61986584|NCT05220579|EXPERIMENTAL|"Exposure to TOR device"|"Patients undergo standard therapy + exposure to the TOR device~Modes of patients' treatment with the TOR device:~The exposure is carried out for at least 5 (five) days in a row for at least 4 hours daily in the 15 + 15 mode (15 minutes exposure + 15 minutes break).~Standard therapy was prescribed in accordance with the recommended treatment regimens presented in the guidelines of the the Ministry of Health of Russia Prevention, diagnosis and treatment of coronavirus infection (COVID-19) No. 9 dated 26.10. 2020)."
62377882|NCT03289494|PLACEBO_COMPARATOR|Diet B|Balanced diet low in Slowly Digestible Starch
62377883|NCT04443205||no macrosomy|pregnant women whose child is not macrosomal
62754372|NCT05432388|EXPERIMENTAL|remibrutinib high dose|remibrutinib oral tablet
62754373|NCT05432388|EXPERIMENTAL|placebo 3 week / remibrutinib low dose 1 week|placebo oral tablet/ remibrutinib oral tablet
62754374|NCT05432388|PLACEBO_COMPARATOR|placebo|oral tablet
62754375|NCT02181101|EXPERIMENTAL|AA-BA|FEC-DocGemzar adjuvant chemotherapy; zoledronic acid i.v. 5 years
62754376|NCT02181101|EXPERIMENTAL|AB-BA|FEC-Doc adjuvant chemotherapy; zoledronic acid i.v. 5 years
62754377|NCT02181101|EXPERIMENTAL|AA-BB|FEC-DocGemzar adjuvant chemotherapy; zoledronic acid i.v. 2 years
62754378|NCT02181101|ACTIVE_COMPARATOR|AB-BB|FEC-Doc adjuvant chemotherapy; zoledronic acid i.v. 2 years
62754379|NCT06333522|EXPERIMENTAL|Losartan cohort|Patients will initiate Losartan treatment 2 weeks pre-operatively and will continue until 4 weeks post-operatively. Range of motion will be measured as part of standard of care at the time of enrollment and at post-op office visits 2-4 weeks, 4-8 weeks and 8-20 weeks post-operatively.
62754380|NCT06333522|NO_INTERVENTION|Control cohort|No additional steps in management are required for the control arm of the study. Range of motion will be measured as part of standard of care at the time of enrollment and at post-op office visits 2-4 weeks, 4-8 weeks and 8-20 weeks post-operatively.
62377884|NCT04443205||screened macrosomy|pregnant women whose child is macrosomal and have been screened g using ultrasound during the third trimester of pregnancy
62754381|NCT01823783|OTHER|DMD infant|Muscle biopsy
62754382|NCT01823783|OTHER|Control infant|Muscle biopsy (during lower limb operation surgery for pure orthopedic causes)
62754383|NCT04676841||Hemiarthroplasty|Hip fracture patients operated with hemiarthroplasty
62754384|NCT00161577|OTHER|A|Group A = Ketorolac
62754385|NCT00161577|PLACEBO_COMPARATOR|B|
62754386|NCT06095882|EXPERIMENTAL|acupuncture|
62754387|NCT06095882|NO_INTERVENTION|observe|
62754388|NCT05797038||TAC group in remission|The patients with idiopathic membranous nephropathy were divided into two groups, the remission group and the non-remission group after the application of tacrolimus. The renal pathological sections of the two groups were observed by microhyperspectral imaging system, and the differences in the spectra of the two groups were analyzed.
62754389|NCT05797038||TAC group without remission|The patients with idiopathic membranous nephropathy were divided into two groups, the remission group and the non-remission group after the application of tacrolimus. The renal pathological sections of the two groups were observed by microhyperspectral imaging system, and the differences in the spectra of the two groups were analyzed.
62754390|NCT03003221|ACTIVE_COMPARATOR|AIR-P Dental Toolkit|Families will be provided with the Autism Intervention Research Network on Physical Health (AIR-P) Dental Toolkit.
62754391|NCT03003221|EXPERIMENTAL|Parent Training|Families randomized to the Parent Training condition will be provided with the AIR-P Dental Toolkit and a 10-week behavioral parent-training intervention with additional booster sessions.
62377885|NCT04443205||no screened macrosomy|pregnant women whose child is macrosomal and havenot been screened g using ultrasound during the third trimester of pregnancy
62377886|NCT01582191|EXPERIMENTAL|Treatment (vandetanib, everolimus)|Patients receive vandetanib PO QD and everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62377887|NCT02980263|EXPERIMENTAL|Kawasaki patients|
62377888|NCT03035058|EXPERIMENTAL|Vedolizumab IV 300 mg Q4W|Vedolizumab 300 mg, intravenous (IV), once at Day 1 and Week 2; followed by vedolizumab 300 mg, IV, once every 4 weeks (Q4W) starting from Week 6 to Week 102.
62754392|NCT02624063|EXPERIMENTAL|Daclatasvir + Sofosbuvir|Daclatasvir 60 mg tablet + Sofosbuvir 400 mg tablet oral dosing once daily for 12 weeks
62754393|NCT02624063|EXPERIMENTAL|Simeprevir + Sofosbuvir|Simeprevir 150 mg tablet + Sofosbuvir 400 mg tablet oral dosing once daily for 12 weeks
62754394|NCT03937648|EXPERIMENTAL|COL-144 50mg|
62754395|NCT03937648|EXPERIMENTAL|COL-144 100mg|
62754396|NCT03937648|EXPERIMENTAL|COL-144 200mg|
62754397|NCT03937648|EXPERIMENTAL|COL-144 400mg|
62754398|NCT03937648|PLACEBO_COMPARATOR|Placebo|
62754399|NCT03440723|ACTIVE_COMPARATOR|Standard Dilation Exam|Participants receive two standard digital cervical dilation examinations conducted by two different physicians.
62754400|NCT03440723|EXPERIMENTAL|Dilation Exam with DilaCheck|Participants receive two cervical dilation examinations using DilaCheck devices conducted by two different physicians.
62754401|NCT02576535|EXPERIMENTAL|Fractionated stereotactic radiosurgery|The radiation dose will be delivered by the standard, FDA approved Leksell gamma unit (Gamma knife; Elekta Instruments, Atlanta, GA). Treatment dose and volume will be determined using the Gamma Plan software provided with the unit (Elekta Instruments, Atlanta, GA).
62754402|NCT06281665|PLACEBO_COMPARATOR|Placebo Group|Similar appearing placebo pill daily for 6 months will be given to subjects.
62754403|NCT06281665|EXPERIMENTAL|Intervention Group|Low-dose \[81 mg\] aspirin pill daily for 6 months will be given to subjects
62754404|NCT02760771||with BAV|patients undergoing transfemoral trans-catheter aortic valve implantations (TF-TAVI) with predilation of the aortic valve
62556551|NCT01738347|EXPERIMENTAL|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
62556552|NCT02897024|ACTIVE_COMPARATOR|Usual weekly|Usual weekly physical therapy is 1 hours of therapy one day per week for 40 weeks.
62556553|NCT02897024|EXPERIMENTAL|High intensity periodic|High intensity periodic physical therapy is 2 hours of therapy 5 days a week for 2 weeks, followed by an 18 week break, followed by another bout of high intensity therapy for 2 hours of therapy every weekday for two 10-consecutive-weekdays, followed by another 18 week break from therapy.
62754405|NCT02760771||without BAV|patients undergoing transfemoral trans-catheter aortic valve implantations (TF-TAVI) without predilation of the aortic valve
62556554|NCT03765450||Single Group Study|Patients with Acute Severe Ulcerative Colitis who are either a) biologic-naïve or b) biologic-experienced without a known history of anti-infliximab antibodies requiring infliximab infusion therapy as a part of standard of care.
62556555|NCT04132973|EXPERIMENTAL|Compassion guided self-help|Participants will engage in a six-week online compassion-based self-help programme with email guidance from the researcher.
62377889|NCT03035058|EXPERIMENTAL|Vedolizumab IV 300 mg Q8W + Placebo|Vedolizumab 300 mg, IV, once at Day 1 and Week 2; followed by vedolizumab 300 mg, IV, once every 8 weeks (Q8W) starting from Week 6 to Week 102 (and placebo, IV, Q8W starting from Week 10 to Week 98.
62556556|NCT02125500|EXPERIMENTAL|Sofosbuvir/Ledipasvir|"Non-cirrhotic patients will receive SOF/LDV Fixed Dose Combination (FDC) for 12 weeks.~Cirrhotic patients will receive SOF/LDV Fixed Dose Combination (FDC) for 24 weeks."
62377890|NCT03035058|PLACEBO_COMPARATOR|Placebo|Vedolizumab placebo-matching, IV, at Day 1 and Week 2; followed by Vedolizumab placebo-matching, IV, Q4W starting from Week 6 to Week 102.
62377891|NCT01389076|EXPERIMENTAL|Treatment arm|Low dose methotrexate and Bexxar
62377892|NCT05910983|EXPERIMENTAL|Patients receiving Bipolar enucleation of the prostate surgery only|50 patients diagnosed with benign prostatic hyperplasia and overactive bladder and referred for Bipolar enucleation of the prostate to treat their urinary symptoms. No Botox injections will be given.
62556557|NCT01385189|EXPERIMENTAL|Cohort 1|10 μg Na-GST-1/Alhydrogel vs. 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
62556558|NCT01385189|EXPERIMENTAL|Cohort 2|30 μg Na-GST-1/Alhydrogel vs. 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
62556559|NCT01385189|EXPERIMENTAL|Cohort 3|30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
62377893|NCT05910983|EXPERIMENTAL|Patients receiving Bipolar enucleation of the prostate surgery + Intravesical Botox Injections|50 patients diagnosed with benign prostatic hyperplasia and overactive bladder and referred for Bipolar enucleation of the prostate to treat their urinary symptoms. Botox injections will be given during the surgery.
62377894|NCT00846911||Group 1|
62377895|NCT05435092||Patients scheduled for primary TKA|Adult Patients diagnosed with osteoarthritis of the knee and who are scheduled for a primary total knee arthroplasty
62377896|NCT02112149|EXPERIMENTAL|LIVESTRONG Program|Participants randomized to the LIVESTRONG exercise program will attend a 12-week LIVESTRONG Program at one of the participating YMCA's in the greater Boston area or CT. We will have monthly teleconferences to discuss the study, recruitment, and the exercise program. Lastly, throughout the 12-week program, participants will record their attendance at the LIVESTRONG program as well as any exercise done outside of the program. We will provide them with a Physical Activity Log book to record their exercise.
62377897|NCT02112149|NO_INTERVENTION|Wait-List Control|Baseline data will be collected from all study participants before randomization. If a participant is randomized to wait-list control, then he/she will be told that he/she will start the LIVESTRONG program after three months and after he/she returns to Yale or DFCI to complete the 3-month clinic visit.
62377898|NCT02508506|EXPERIMENTAL|ALKS 5461|Sublingual tablet
62556560|NCT01385189|EXPERIMENTAL|Cohort 4|100 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
62556561|NCT01385189|EXPERIMENTAL|Cohort 5|100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
62556562|NCT04937881|EXPERIMENTAL|TAF arm|Fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF) delivered under direct observation for 8 weeks during pregnancy and 8 weeks in postpartum period
62556563|NCT04937881|ACTIVE_COMPARATOR|TDF arm|Fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF) delivered under direct observation for 8 weeks during pregnancy and 8 weeks in postpartum period
62556564|NCT04146103|EXPERIMENTAL|Experimental arm|Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally, for 3 months.
62556565|NCT04070261||User|
62556566|NCT06582277|EXPERIMENTAL|OVX836 - 180μg dose level|180 µg dose of an adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus.
62754406|NCT01242306|PLACEBO_COMPARATOR|BMS arm|bare metal stent arm
62754407|NCT01242306|ACTIVE_COMPARATOR|SES arm|sirolimus eluting stent arm
62754408|NCT00801034|PLACEBO_COMPARATOR|1|Calcium tablets
62754409|NCT00801034|ACTIVE_COMPARATOR|2|Potassium tablets
62754410|NCT01413620|EXPERIMENTAL|Vitamin E Treated|
62754411|NCT01413620|NO_INTERVENTION|Untreated|
62377899|NCT03330106|EXPERIMENTAL|Part A: Pevonedistat 25 mg/m^2 + Pevonedistat 50 mg/m^2|Pevonedistat 25 mg/m\^2, infusion, intravenously, once on Day 1 of Cycle 1, followed by pevonedistat 50 mg/m\^2, infusion, intravenously, once on Day 8 of Cycle 1.
62377900|NCT03330106|EXPERIMENTAL|Part A: Pevonedistat 50 mg/m^2 + Pevonedistat 25 mg/m^2|Pevonedistat 50 mg/m\^2, infusion, intravenously, once on Day 1 of Cycle 1, followed by pevonedistat 25 mg/m\^2, infusion, intravenously, once on Day 8 of Cycle 1.
62377901|NCT03330106|EXPERIMENTAL|Part B: Pevonedistat|Pevonedistat 25 mg/m\^2 in combination with docetaxel 75 mg/m\^2 or pevonedistat 20 mg/m\^2 in combination with carboplatin plus paclitaxel 175 mg/m\^2, infusion, intravenously, once on Day 1 in each 21-day treatment cycle followed by pevonedistat 25 mg/m\^2 or 20 mg/m\^2 infusion, intravenously, once on Days 3 and 5 in each 21-day treatment cycle for up to 12 cycles or symptomatic deterioration or PD, treatment is discontinued for another reason, or until the study is stopped. The combination and dose of pevonedistat will be based on investigator discretion.
62377902|NCT05412693|EXPERIMENTAL|Functional orthosis|Use of a functional orthosis device (AirCast Air-Stirrup) for 6 weeks. Weightbearing as tolerated will be allowed in both groups immediately after application of the cast or orthosis.
62377903|NCT05412693|ACTIVE_COMPARATOR|Cast immobilization|Use of a below-the-knee cast circular cast (3M scotch cast) for 6 weeks.
62377904|NCT05863806|EXPERIMENTAL|Mulligan Mobilzation|"MWM technique was carrying out in flexion, abduction, external and internal rotation directions. For this technique, participants were seated on a stretcher, and the physical therapist is standing opposite of the upper extremity that is treated. The internal hand of the physical therapist stabilizes participants' shoulder girdle and, with the thenar eminence of the other hand, performed a glide of the humeral head (this direction is the most suitable for treating such shoulder limitations).~Participants were asked to flex the affected shoulder until the pain started while the physical therapist sustained the gliding force to the humeral head. The single session of MWM technique was last around 20 minutes, in 3 sets of 10 repetitions with a rest interval of 30 seconds between each sets."
62377905|NCT05863806|ACTIVE_COMPARATOR|Trasverse Friction Massage|Transverse Friction Massage technique: Patients in the group B were receiving soft tissue massage (deep friction) is made to bend his/ her elbow to 90o and put forearm behind his/ her back, then lean back in half lying position. Thus arm is fixed in adduction and medial rotation. It was given in transverse direction for 10 - 12 minutes. Transverse friction massage was given twice a week with the gap of days for the first 3 week and then the repetition is increased to 3 to 4 times a week for the rest of duration.
62377906|NCT06193837||Group 1|Having prophylactic antibiotic in laparoscopic cholecystectomy
62377907|NCT06193837||Group 2|Not having prophylactic antibiotics in laparoscopic cholecystectomy
62377908|NCT03445962||Down Syndrome (DS)|Assessment of OSAS predictive factors in Down Syndrome without or without OSAS
62377909|NCT04474366|SHAM_COMPARATOR|Saline|Control group will receive an injection of 20ml of saline between the pectoralis minor and serratus anterior muscles bilaterally and 10ml of saline between the pectoralis minor and pectoralis major muscles bilaterally.
62377910|NCT04474366|EXPERIMENTAL|Ropivacaine|Intervention group will receive an injection of 20ml of 0.2% Ropivacaine between the pectoralis minor and serratus anterior muscles bilaterally and 10ml of 0.2% Ropivacaine between the pectoralis minor and pectoralis major muscles bilaterally (Not to exceed 225mg or 3.5mg/kg).
62377911|NCT03030157|EXPERIMENTAL|Long-term Intravesical Instillation of pirarubicin(THP)|A single instillation of pirarubicin (THP) plus one year long-term intravesical instillation after nephroureterectomy was performed. The ﬁrst instillation was initiated within 72-168 hours after surgery, followed by four times weekly and 11 times monthly (16 times in total in one year time) . Every time, THP 30 mg in 30 mL of normal saline was delivered into the bladder through a catheter and was retained for 30 minutes.
62377912|NCT03030157|ACTIVE_COMPARATOR|Single Intravesical Instillation of pirarubicin|A single intravesical instillation of THP after nephroureterectomy was performed. This instillation was initiated within 72-168 hours after surgery . THP 30 mg in 30 mL of normal saline was delivered into the bladder through a catheter and was retained for 30 minutes.
62377913|NCT01430364|ACTIVE_COMPARATOR|BIOSS implantation|
62377914|NCT00692393|ACTIVE_COMPARATOR|1|Surgery : Hartmann intervention
61986585|NCT05220579|NO_INTERVENTION|Control|"Patients received standard therapy~Standard therapy was prescribed in accordance with the recommended treatment regimens presented in the guidelines of the the Ministry of Health of Russia Prevention, diagnosis and treatment of coronavirus infection (COVID-19) No. 9 dated 26.10. 2020)."
62377915|NCT00692393|EXPERIMENTAL|2|Surgery : primary resection with anastomosis with protective stoma
62377916|NCT05270265|EXPERIMENTAL|Group 1 (low dose)|8-10 volunteers receiving three doses of 10 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56 via intramuscular injection (IM) in the deltoid region of the arm
62377917|NCT05270265|EXPERIMENTAL|Group 2 (standard dose)|8-10 volunteers receiving three doses of 50 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56 via intramuscular injection (IM) in the deltoid region of the arm
62377918|NCT05270265|EXPERIMENTAL|Group 3 (fractional dose)|8-10 volunteers receiving two doses of 50 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0 and 28, followed by one dose of 10 µg Pvs25-IMX313 in 50 µg Matrix-M1 on day 56 via intramuscular injection (IM) in the deltoid region of the arm
61986586|NCT05220579|PLACEBO_COMPARATOR|"Placebo (exposure to switched off TOR device)"|"Patients undergo standard therapy + a switched off TOR device was installed in the wards~Standard therapy was prescribed in accordance with the recommended treatment regimens presented in the guidelines of the the Ministry of Health of Russia Prevention, diagnosis and treatment of coronavirus infection (COVID-19) No. 9 dated 26.10. 2020)."
61986587|NCT05919303||Patient presenting with obstructive jaundice referred for CT evaluation|
62377919|NCT00948714|EXPERIMENTAL|Case|
62377920|NCT00948714|ACTIVE_COMPARATOR|Control|
62556567|NCT06582277|EXPERIMENTAL|OVX836 - 480μg dose level|480 µg dose of an adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus.
61986588|NCT01571258|NO_INTERVENTION|Control|
61986589|NCT01571258|EXPERIMENTAL|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
61986590|NCT01416727|EXPERIMENTAL|OSkER|"Observed SKills in the Emergency Room - workplace-based supervision."
61986591|NCT01416727|EXPERIMENTAL|EPIC|"Emergency Psychiatry Immersion Course - simulation-based training."
61986592|NCT05759442|ACTIVE_COMPARATOR|Metformin|Tablet Metformin HCl 500 mg per oral twice daily for 12 weeks
62754412|NCT06597266|EXPERIMENTAL|Experimental (evidence-generated socket) then Active Comparator (control socket)|Participants are first fitted with an evidence-generated prosthetic check socket (experimental), and then fitted with a prosthetist-led prosthetic check socket (active comparator)
62377921|NCT05848752|EXPERIMENTAL|Environmental Feature Experiment|
62754413|NCT06597266|EXPERIMENTAL|Active Comparator (control socket) then Experimental (evidence-generated socket)|Participants are first fitted with a prosthetist-led prosthetic check socket (active comparator), and then fitted with an evidence-generated prosthetic check socket (experimental)
62754414|NCT00350272|EXPERIMENTAL|Elvucitabine, Efavirenz, Tenofovir|"Elvucitabine (blinded) 10 milligrams (mg)/day in combination with open-label efavirenz 600 mg daily and open-label tenofovir 300 mg daily, all administered orally, over 12 weeks. Eligible participants continued with an additional 84 weeks of open-label treatment (through Week 96).~Participants who experienced at least a 2 log10 decrease in HIV-1 RNA from Baseline or who had an HIV-1 RNA level of less than 400 copies/ mL at Week 10 and had not experienced any Grade 3 or 4 hematological toxicity as of the Week 10 measurement were considered eligible for an additional 84 weeks of open-label treatment after Week 12."
62754415|NCT00350272|ACTIVE_COMPARATOR|Lamivudine, Efavirenz, Tenofovir|"Lamivudine (blinded) 300 mg daily in combination with open-label efavirenz 600 mg daily and open-label tenofovir 300 mg daily, all administered orally, over 12 weeks. Eligible participants continued with an additional 84 weeks of open-label treatment (through Week 96).~Participants who experienced at least a 2 log10 decrease in HIV-1 RNA from Baseline or who had an HIV-1 RNA level of less than 400 copies/mL at Week 10 and had not experienced any Grade 3 or 4 hematological toxicity as of the Week 10 measurement were considered eligible for an additional 84 weeks of open-label treatment after Week 12."
62754416|NCT01534507||Healthy Volunteer 1 (Group 1)|For study 1 : Up to 5 healthy volunteers for the initial pilot study and further 21 healthy volunteers for the main study 1
62754417|NCT01534507||Group 2 for study 2|Patients with diarrhoea due to irritable bowel syndrome
62754418|NCT01534507||Group 3 for study 2|Patients with constipation due to irritable bowel syndrome
62754419|NCT01534507||Group 4 for study 2|Patients with mixed bowel habit due to irritable bowel syndrome
62556568|NCT06020118|EXPERIMENTAL|Group i|Simultaneous Vaccination (Influenza vaccine and mRNA COVID booster) at Visit 1
62754420|NCT01534507||Group 5 for study 2: Healthy volunteer 2|Healthy participants to act as control
62754421|NCT06487507|EXPERIMENTAL|Low Fat Diet Group|Participants in this group will receive a low fat Mediterranean diet for 2 weeks.
62754422|NCT06487507|EXPERIMENTAL|Lower Carbohydrate Mediterranean Diet Group|Participants in this group will receive a lower carbohydrate Mediterranean diet for 2 weeks.
62754423|NCT01084980|EXPERIMENTAL|Tacrolimus|
62754424|NCT00411827|ACTIVE_COMPARATOR|1|PRK
62754425|NCT00411827|ACTIVE_COMPARATOR|2|LASIK
61986593|NCT05759442|ACTIVE_COMPARATOR|Apple cider vinegar|Apple Cider Vinegar 15ml per day diluted in 200 ml of water for 12 weeks
62377922|NCT04214106||Thiamine group|group 1: ICU patients who did not receive IV thiamine
62377923|NCT04214106||Non-thiamine group|group 2: ICU patients who received IV thiamine,100-500 mg/day for at least one day
62377924|NCT05600556|ACTIVE_COMPARATOR|Cohort I (standard imaging)|Patients receive 2D image review using standard computer screen on study. Patients undergo MRI and CT imaging at screening and on study
62556569|NCT06020118|EXPERIMENTAL|Group ii|Sequential vaccination with Influenza vaccination at Visit 1 and mRNA COVID booster at Visit 2
62377925|NCT05600556|EXPERIMENTAL|Cohort II (virtual reality)|Patients receive image review using virtual reality stimulation on study. Patients also view MRI treatment room using virtual reality stimulation. Patients undergo MRI and CT imaging at screening and on study
62377926|NCT02382952|EXPERIMENTAL|Differential Dissector|For patients in the study device group, blunt dissection will be performed with the Differential Dissector whenever the surgeon believes its use is appropriate.
62377927|NCT02382952|ACTIVE_COMPARATOR|Standard Dissection Method|For patients in the control group, blunt dissection will be performed by standard method.
62377928|NCT01355224|NO_INTERVENTION|No risk feedback|No obesity risk information given (control)
62377929|NCT01355224|EXPERIMENTAL|Genetic risk feedback|Only personal genetic risk information provided
62377930|NCT01355224|EXPERIMENTAL|Lifestyle risk feedback|Only personal lifestyle risk information provided
62377931|NCT01355224|EXPERIMENTAL|Both genetic or lifestyle risk feedback|Personal genetic and lifestyle information provided
62377932|NCT03357328|ACTIVE_COMPARATOR|Therapy light room|This group (4 NH units, about 35 patients) will receive light therapy administered via LED technology. The light will vary in intensity and colour temperature throughout the day. Ceiling-mounted LED-lights are installed in the living rooms of participating nursing home units. Between 07:00 and 10:00 light of 400 lux at eye level, with 4000 K, will be provided. Between 10:00 and 15:00 the light will comprise 1000 lux at eye level, with 6000 K. From 15:00 to 18:00 the light will comprise 400 lux at eye level and 4000 K. When light is on from 18:00 to 07:00, standard light (about 100 lux at eye level, 3000K) will be administered.
62377933|NCT03357328|PLACEBO_COMPARATOR|Standard light|"This group (4 NH units, about 35 patients) will receive standard light (100 lux at eye level, 3000K). The light will be administered between 07:00 and 18:00; and the same when light is on between 18:00 to 07:00. This represents the placebo light intervention, which at the same time ensures a constant standard light condition in all control units."
62377934|NCT00949949|EXPERIMENTAL|Cohort I (everolimus and gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and everolimus PO once daily or 3 times weekly.
62377935|NCT00949949|EXPERIMENTAL|Cohort II (everolimus, gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 1 hour on days 1 and 8 and everolimus PO once daily or 3 times weekly.
62377936|NCT00949949|EXPERIMENTAL|Cohort III (MTD)|Patients receive treatment as in cohort II.
62377937|NCT01654406|ACTIVE_COMPARATOR|Control|Pulsed dye laser (V-beam)
62377938|NCT01654406|EXPERIMENTAL|Experimental group|Fractional CO2 laser(eCO2)and pulsed dye laser (V-beam)
62377939|NCT02178592|EXPERIMENTAL|Dolutegravir|Twice-daily DTG 50 mg plus dual NRTI during RIF-containing TB treatment (isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions or acceptable alternative RIF-containing regimens) and for 2 weeks following discontinuation of TB treatment, then once-daily DTG 50 mg with the same NRTI through Week 52
62377940|NCT02178592|ACTIVE_COMPARATOR|Efavirenz|Once-daily EFV 600 mg plus dual NRTI through Week 52 along with TB treatment including isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions.
62377941|NCT05857215|EXPERIMENTAL|A- amilo-5MER solution for subcutaneous administration or matching placebo- 10 mg|Amilo-5MER solution for subcutaneous administration or matching placebo at a dose of 10 mg
62556570|NCT06020118|EXPERIMENTAL|Group iii|Sequential vaccination with mRNA COVID booster at Visit 1 and Influenza vaccination at Visit 2
62556571|NCT03826342|EXPERIMENTAL|Health Check-up for Expectant Moms|Theory-driven and derived from empirical support
62377942|NCT05857215|EXPERIMENTAL|B- amilo-5MER solution for subcutaneous administration or matching placebo- 30 mg|Amilo-5MER solution for subcutaneous administration or matching placebo at a dose of 30 mg
62556572|NCT03826342|ACTIVE_COMPARATOR|Time, attention, and information-matched control|Well-validated
62556573|NCT02251483|OTHER|SBI|Group 1: SBI (N=30) - one packet daily
62556574|NCT02251483|PLACEBO_COMPARATOR|Placebo|Group 2: Placebo (N=30) - one packet daily
62556575|NCT02115607|EXPERIMENTAL|Definity infusion|Infusion of Definity (Perflutren Lipid Microspheres)
62754426|NCT06453330|EXPERIMENTAL|An intervention group receiving standard placement of single implants with H-PRF|H-PRF preparation protocol involves taking a sample of venous blood from patients using a butterfly needle to collect up to 8-9ml tubes of blood. After the first tube is collected, it would immediately be placed in a horizontal centrifuge machine, balanced out with 3 tubes of water, to ensure the centrifuge is properly balanced. A set rpm and time will be chosen, and the centrifuge will run until the time is complete. The H-PRF clots would then be ready and taken out of the tubes to separate them from the red blood cells.
62556576|NCT00725920|EXPERIMENTAL|Topiramate|patients receiving the active drug: topiramate
62556577|NCT00725920|PLACEBO_COMPARATOR|Placebo Control group|patients received pills content placebo, that were identical to the pills content active drug
62754427|NCT06453330|NO_INTERVENTION|A control group receiving standard placement of single implants without H-PRF|this group will have standard implant placement without H-PRF
62754428|NCT02981407|ACTIVE_COMPARATOR|Liberal Transfusion Strategy|Red blood cell transfusion - One unit of packed red cells is transfused following randomization followed by enough red blood cell units to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days.
62754429|NCT02981407|ACTIVE_COMPARATOR|Restrictive Transfusion Strategy|Permitted to receive a red blood cell transfusion if the blood count is below 8 g/dL and the physician believes it is in the patient's best interest. A transfusion will be strongly recommended if the blood count drops to less than 7 g/dL. If the patient has symptoms of angina (e.g., chest discomfort described as pressure or heaviness) that do not go away with medication, a blood transfusion will be ordered regardless of the blood count.
61986594|NCT02195076||Breast Cancer patients|
62556578|NCT05647577||Inflammatory arthritis patients|Patients with an confirmed diagnosis of rheumatoid arthritis or axial spondyloarthritis.
62556579|NCT05647577||Participants from the general population|Patients with inflammatory arthritis will be compared to community-dwelling individuals from the 4th and 5th examination round from the Copenhagen City Heart Study (ClinicalTrials.gov identifier NCT02993172, I-Suite no. 03741, National Committee on Health Research Ethics approval HEH-2015-045).
62556580|NCT02499848|EXPERIMENTAL|Intraprostatic administration|PRX302
62754430|NCT06606041|ACTIVE_COMPARATOR|Group 1|
61986595|NCT02195076||Lung cancer patients|
61986596|NCT02195076||Healthy controls|
61986597|NCT01665456||Cases (women with complications)|Cases are women aged 15-49 years who delivered within 12 months prior to data collection and had experienced obstetric complication(s) that either necessitated treatment or hospitalization in order to prevent the likelihood of death of the mother.
62377943|NCT05857215|EXPERIMENTAL|C- amilo-5MER solution for subcutaneous administration or matching placebo- 90 mg|Amilo-5MER solution for subcutaneous administration or matching placebo at a dose of 90 mg
62556581|NCT02654054|PLACEBO_COMPARATOR|Placebo|Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/NETA) once daily (QD)
62556582|NCT02654054|EXPERIMENTAL|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
62556583|NCT02654054|EXPERIMENTAL|Elagolix + E2/NETA|Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
62556584|NCT06549946|EXPERIMENTAL|Phase Ia|In Phase Ia, subjects will receive Ixovex-1 intratumourally.
62377944|NCT05857215|EXPERIMENTAL|D- amilo-5MER solution for subcutaneous administration or matching placebo- 180 mg|Amilo-5MER solution for subcutaneous administration or matching placebo at a dose of 180 mg
62377945|NCT05857215|EXPERIMENTAL|E- amilo-5MER solution for subcutaneous administration or matching placebo- 360mg|Amilo-5MER solution for subcutaneous administration or matching placebo at a dose of 360 mg
62754431|NCT06606041|ACTIVE_COMPARATOR|Group 2|
62754432|NCT06606041|ACTIVE_COMPARATOR|Group 3|
62377946|NCT05385172||18-65 years old women|
62377947|NCT03427528|EXPERIMENTAL|FAB Pilot Study (Father/Male Participants)|"Fathers (male partners) received Fathers and Babies (FAB). FAB is a 12-session intervention with content that mirrors content found in MB, but was father-centric.~The initial FAB session was delivered in person or by phone by the home visitor working with the mother, and lasted 30 min on average. Subsequent sessions were delivered, in-person, via text message with embedded links to online content, or a mix of both in-person and text messages, depending on the preference and availability of the father. Fathers received three to six text messages per FAB session."
62377948|NCT03427528|EXPERIMENTAL|MB 1-on-1 Plus TEXT (Mother/Female Participants)|Home visiting clients received the Mothers and Babies with -Text Messages intervention in person during regular scheduled home visits (i.e., MB 1-on-1 plus MB-TXT) while her partner received Fathers and Babies in parallel. MB 1-on-1 is 12-sessions and is a postpartum depression preventive intervention. MB includes an introductory module followed by three cognitive-behavioral therapy modules: (1) pleasant activities, (2) thoughts, and (3) contact with others. After each in person session home visiting clients receive three messages to reinforce skill practice and remind them about their personal projects.
62377949|NCT05715840|EXPERIMENTAL|safety run-in Stage(single arm) and Phase 3: SG001+Platinum-based chemotherapy±Bevacizumab|SG001 360 mg, Intravenous infusion, D1, Q3W, up to approximately 2 years ; paclitaxel 175 mg/m\^2, Intravenous infusion, D1, Q3W, up to 6 cycles; cisplatin 50 mg/m\^2 or carboplatin(AUC=5) , Intravenous infusion, D1, Q3W, up to 6 cycles; with or without bevacizumab 15 mg/kg, Intravenous infusion, D1, Q3W, up to approximately 2 years All treatments will be administered until disease progression or toxicity
62377950|NCT05715840|PLACEBO_COMPARATOR|Phase 3: Placebo+Platinum-based chemotherapy±Bevacizumab|Placebo, Intravenous infusion, D1, Q3W, up to approximately 2 years ; paclitaxel 175 mg/m\^2, Intravenous infusion, D1, Q3W, up to 6 cycles; cisplatin 50 mg/m\^2 or carboplatin(AUC=5) , Intravenous infusion, D1, Q3W, up to 6 cycles; with or without bevacizumab 15 mg/kg, Intravenous infusion, D1, Q3W, up to approximately 2 years All treatments will be administered until disease progression or toxicity
62377951|NCT01549028|EXPERIMENTAL|Mobile-based PR program.|Home based mobile PR program for 3 months.
62377952|NCT03140046|EXPERIMENTAL|Corneal Topography|we will do Corneal Topography for every patient before doing photorefractive keratectomy (PRK) and also after it , to measure the change in the quality of vision and measure the change in the quality of vision
62377953|NCT02890940|EXPERIMENTAL|Pet Therapy|
62377954|NCT05634837|EXPERIMENTAL|Decision Support System counseling|In the Intervention group (CDSS group), women receive a personalised daily dietary plan based on the Mediterranean diet and according to participant's needs, habits and preferences.
62377955|NCT05634837|OTHER|Standard nutritional counseling|Participants of the Control group did not have access to CDSS and only received general lifestyle guidelines.
62377956|NCT01860131|ACTIVE_COMPARATOR|Weight Wise Community Modules: Workshops|Groups workshops (10 in total) designed to improve weight management skills and enhance self-efficacy, delivered over 3 months, prior to entering a multidisciplinary bariatric care.
62377957|NCT01860131|ACTIVE_COMPARATOR|Weight Wise Community Modules: Online|Online modules (13 in total) designed to improve weight management skills and enhance self-efficacy, delivered over 3 months, prior to entering a multidisciplinary bariatric care.
62754433|NCT02978963|EXPERIMENTAL|Cognitive Behavioral Therapy|All participants will receive cognitive behavioral therapy for excessive worry. Focus in treatment will be on reducing participants' intolerance uncertainty through in vivo and imaginary exposure to uncertainty inducing situations and thoughts. Treatment will also contain psycho education about anxiety and worry, as well as planning for maintenance of treatment gains. Parents of the participants will receive support and education about worry through an internet-delivered program.
61986598|NCT01665456||Control (women who did not experience any complications)|Controls are women aged 15-49 years who delivered within 12 months prior to data collection. They did not have or develop any of the complications which cases experienced or suffered from.Although controls did not have complications, they were individually matched on the basis of age and location. The idea was to compare how many cases were exposed versus how many controls were exposed.
62377958|NCT01860131|NO_INTERVENTION|Educational Written Materials|"Educational pamphlets about healthy living and tips on self-management strategies.~Delivered by mail 3 months prior to entering a multidisciplinary bariatric care.~This is minimal intervention and considered the control arm."
62377959|NCT05849740|EXPERIMENTAL|Treatment arm|Daratumumab and corticosteroid treatment
62377960|NCT02306148|PLACEBO_COMPARATOR|Control Group|Group will practice 15 seconds isometric lower limb stretching protocol and must continue practicing running as usual.
62377961|NCT02306148|EXPERIMENTAL|Foot and ankle strengthening|Group will be trained during 2 months by a physiotherapist for foot and ankle strengthening and must continue to exercise at home with a training software supervision. Must continue practicing running as usual.
62377962|NCT00715949||Mild Traumatic Brain Injury (MTBI) admits|admitted pediatric patients with mild traumatic brain injury (concussion)
62377963|NCT04490499|EXPERIMENTAL|HBVAXPRO™|Healthy children vaccinated approximately 8-9 years previously with a 2- or 3-dose infant series and toddler dose of Vaxelis® who will receive a single dose of Hepatitis B vaccine challenge (HBVAXPRO™).
62377964|NCT02554201|EXPERIMENTAL|Electrical pudendal nerve stimulation|Electrical pudendal nerve stimulation At a frequency of 2.0 Hz and a moderate intensity (25\~35 mA); 60 minutes three times a week for a total of four weeks
62754434|NCT00962169|EXPERIMENTAL|Quality improvement program|
62754435|NCT00962169|EXPERIMENTAL|Electronic patient device (EPD)|
62754436|NCT04547907|EXPERIMENTAL|nab-PHP|Nab-paclitaxel + trastuzumab+ patuzumab
62754437|NCT04547907|ACTIVE_COMPARATOR|TCbHP|Docetaxel + carboplatin + trastuzumab + patuzumab
62754438|NCT06606561|EXPERIMENTAL|Group 1 (Open Label)|"A total of eight subjects will be treated to assess safety prior to enrolling Group 2. We propose to assess the safety of 8 subjects in Group 1 at seven-day intervals. Each subject in Group 1 will be staggered by 5 days after receiving the dose of NANOVAE.~Dose - 2 mL of NANOVAE on day 0 containing 1.0 x 1011 to 9.0 x 1011 particles/ml. Product will be administered directly without any dilution."
62754439|NCT06606561|EXPERIMENTAL|Group 2 (Randomized, double blinded placebo control)|"Total of sixteen subjects will be randomized to either receive two doses of NANOVAE via intraarticular injections or receive two doses of a placebo.~Dose - 2 mL of NANOVAE or placebo on day 0 and day 15, containing 1 x 1011 particles/ml. The ratio is 1:1 for a total of 16 subjects in the Group 2. Product will be administered directly without any dilution."
62754440|NCT00223977|EXPERIMENTAL|Sodium ferric gluconate complex 125 mg|125 mg sodium ferric gluconate weekly x 8 weeks
62754441|NCT00223977|EXPERIMENTAL|Sodium ferric gluconate complex 250 mg|250 mg sodium ferric gluconate complex weekly x 4 weeks
62754442|NCT00223977|ACTIVE_COMPARATOR|Oral iron|325 mg ferrous sulfate three times daily x 8 weeks
62754443|NCT01212497|EXPERIMENTAL|Mindfulness meditation coaching|Assess effectiveness of using a virtual computer coach to train mindfulness meditation
62754444|NCT04997109|EXPERIMENTAL|APPLES-tele first, then PCA|Participants receiving the APPLES-tele intervention for 6 weeks followed by the PCA intervention for 6 weeks.
62754445|NCT04997109|EXPERIMENTAL|PCA first, then APPLES-tele|Participants receiving the PCA intervention for 6 weeks followed by the APPLES-tele intervention for 6 weeks.
62754446|NCT04997109|ACTIVE_COMPARATOR|Standard of Care Control Arm|Participants receiving the standard of care for 6 weeks.
62754447|NCT05056220|ACTIVE_COMPARATOR|High expected effect: Human Albumin 20% + Standard Medical Treatment|Participants stratified to a high expected effect of human albumin and randomized to active treatment with 20% Human Albumin infusions.
62754448|NCT05056220|PLACEBO_COMPARATOR|High expected effect: Saline (NaCl 0.9%) + Standard Medical Treatment|Participants stratified to a high expected effect of human albumin and randomized to placebo treatment with 0.9% NaCl (saline) infusions.
62754449|NCT05056220|ACTIVE_COMPARATOR|Low expected effect: Human Albumin 20% + Standard Medical Treatment|Participants stratified to a low expected effect of human albumin and randomized to active treatment with 20% Human Albumin infusions.
62754450|NCT05056220|PLACEBO_COMPARATOR|Low expected effect: Saline (NaCl 0.9%) + Standard Medical Treatment|Participants stratified to a low expected effect of human albumin and randomized to placebo treatment with 0.9% NaCl (saline) infusions.
62754451|NCT00537732|ACTIVE_COMPARATOR|control group|3 tablets, only 20 mg omeprazole, genotype independent
62754452|NCT00537732|ACTIVE_COMPARATOR|intervention group|20 vs. 60 mg daily, genotype dependent
62754453|NCT04194736|EXPERIMENTAL|Children|Minor patients hospitalized in pediatric intensive care unit having a percutaneous central venous catheter.
62754454|NCT02563860|EXPERIMENTAL|Open label|"Treatment with Lovastatin, dose escalating trial according to the following schedule:~10 mg daily for 8 week 20 mg daily for 8 weeks 40 mg daily for 16 weeks."
62754455|NCT01360372|ACTIVE_COMPARATOR|Methylnaltrexone|
62754456|NCT01360372|PLACEBO_COMPARATOR|saline placebo injection|
62754457|NCT01259076||Group 1|Participants who are eligible for and have opted to undergo gastric bypass surgery
62754458|NCT01259076||Group 2|Participants who are eligible for but decided not to undergo gastric bypass surgery.
62754459|NCT05851872|ACTIVE_COMPARATOR|Fasting group|Participant will be asked to fast at least 6 hours prior to the procedure
62754460|NCT05851872|EXPERIMENTAL|Non-Fasting group|Participants will be allowed to eat and drink up to 1 hour prior to the procedure.
62377965|NCT02554201|ACTIVE_COMPARATOR|Transvaginal electrical stimulation|At a current intensity of \< 60 mA (as high as possible to get a contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-min periods of stimulation); 30 min three times a week for a total of four weeks.
62377966|NCT02258191|ACTIVE_COMPARATOR|NIV treatment with telemonitoring|telemonitoring is used to manage NIV treatment
62377967|NCT02258191|SHAM_COMPARATOR|NIV treatment with sham telemonitoring|sham telemonitoring (data not used for NIV management)
62556585|NCT06549946|EXPERIMENTAL|Phase Ib|In Phase Ib, subjects will receive combination therapy with Ixovex-1 intratumourally and Pembrolizumab at the standard dose.
62754461|NCT00744978|EXPERIMENTAL|Varenicline|
62754462|NCT00744978|PLACEBO_COMPARATOR|Placebo|
62754463|NCT02202512|EXPERIMENTAL|BI 1060469 low dose|Low-Dose,Tablet,oral administration with 240 ml water,over 10 days
62754464|NCT02202512|EXPERIMENTAL|BI 1060469 high dose|High-Dose,Tablets,oral administration with 240 ml water, over 10 days
62754465|NCT02202512|ACTIVE_COMPARATOR|Cimetidine|
62754466|NCT02202512|ACTIVE_COMPARATOR|Naproxen|
62754467|NCT02202512|EXPERIMENTAL|BI 1021958|High-Dose,Tablets,oral administration with 240 ml water, over 10 days
62754468|NCT04170530|EXPERIMENTAL|mFOLFOXIRI|patients received FOLFOXIRI alone for 6 cycles before surgery.
62754469|NCT02943824|EXPERIMENTAL|Machine Learning Planning|Patients will be pre-operatively planned using a machine-learning computer program. An expert radiation oncologist will evaluate the plan prior to implantation. The prescription dose is 145 Gy for monotherapy LDR brachytherapy.
62754470|NCT02943824|ACTIVE_COMPARATOR|Radiation Therapist Planning|Patients will be pre-operatively planned manually by an expert radiation therapist (\> 60 cases planned). An expert radiation oncologist will evaluate the plan prior to implantation.The prescription dose is 145 Gy for monotherapy LDR brachytherapy.
62754471|NCT01502878|ACTIVE_COMPARATOR|Nut challenge|Double-blind placebo controlled oral challenge 5-50-200-1000 mg peanut or hazelnut protein, or placebo administered with 30 min intervals and 2 hour-follow-up after the last dose.
62754472|NCT01502878|PLACEBO_COMPARATOR|Nut challenge: Placebo|See intervention
62754473|NCT01502878|EXPERIMENTAL|Nut oral desensitization|Patients who have moderate to severe immediate allergic reaction at peanut challenge and who enter the oral desensitization program receive peanut protein daily, from 0,1 mg to 800 mg peanut protein, maintenance dose 800 mg.
61986599|NCT05473273||Natural Cycle Protocol|"Ultrasound monitoring to monitor follicular and endometrial growth. Serial measurements of serum Lutenizing Hormone (LH), estradiol (E2), and progesterone (P4) to identify ovulation.~Minimal endometrial thickness of 7 mm is required. No progesterone supplementation. Embryo transfer (ET) will be scheduled 5 days after the day of ovulation (120 hours of P4 exposure).~Blood samples will be drawn to measure PIBF, IL-17, IFγ, IL-10, IL-4 and TGF-ß1 on day of ovulation (P4 rise), on the day before ET, on the day of ET and 3 and 10 days later, between 9 and 12 am.~A blood test to measure beta human chorionic gonadotropin (ß-hCG) will be performed 3 and 10 days after ET and at 5 weeks +/- 3 days in case of pregnancy, between 9 and 12 am.~In case of pregnancy, a blood test to measure PIBF, IL-17, IFγ, IL-10, IL-4 and TGF-ß1 will be performed at 5 weeks +/- 3 days between 9 and 12 am.."
62754474|NCT05749003|EXPERIMENTAL|sensorimotor training program group|participants will receive Sensorimotor training exercise plus conventional physical therapy program of exercise.
62754475|NCT05749003|OTHER|Control group|participants will receive conventional physical therapy program of exercise.
62754476|NCT01598883|OTHER|ACT after initial heparin bolus less than 450|If a patients activated clotting time (ACT) is less than 450 after the bolus dose of heparin (350U/kg) they will be randomized to one of two interventions.
62556586|NCT06549946|EXPERIMENTAL|Phase II|In Phase II, subjects will receive combination therapy with Ixovex-1 intratumourally and Pembrolizumab at the standard dose.
62754477|NCT01598883|ACTIVE_COMPARATOR|ACT after first intervention less than 450|
62754478|NCT02998905|EXPERIMENTAL|NOAC|Apixaban or dabigatran or edoxaban or rivaroxaban
62754479|NCT02998905|ACTIVE_COMPARATOR|Acetylsalicylic Acid|Acetylsalicylic acid
62754480|NCT02183337|EXPERIMENTAL|BI 1356|"Treatment sequence AB_C or C_AB~* Treatment A: 5 days BI 1356 until steady state followed by~* Treatment B: combined treatment of BI 1356 with pioglitazone for 7 days~* Treatment C: 7 days of treatment with Pioglitazone alone"
62754481|NCT02183337|ACTIVE_COMPARATOR|Pioglitazone|"Treatment sequence AB_C or C_AB~* Treatment A: 5 days BI 1356 until steady state followed by~* Treatment B: combined treatment of BI 1356 with pioglitazone for 7 days~* Treatment C: 7 days of treatment with Pioglitazone alone"
62754482|NCT01613352|EXPERIMENTAL|Day surgery group|Patients who underwent breast conserving surgery and sentinel node biopsy only and were randomized to ambulatory surgery group.
62754483|NCT01613352|ACTIVE_COMPARATOR|In-Patient group|Patients who underwent breast conserving surgery and sentinel node biopsy only and were randomized to in-patient group.
62754484|NCT02630420|EXPERIMENTAL|cetuximab and savolitinib|Following assessment in Part 1 of dose-limiting toxicity and maximum tolerated dose, this drug combination will be administered in Part 2 of the study to assess safety, tolerability, response rate, and progression-free survival.
62754485|NCT03342573|EXPERIMENTAL|Single Arm|Patients with a biopsy proven diagnosis of PRP
62754486|NCT04609358|EXPERIMENTAL|Intervention group|The patients' nutrition were supported according the the algorithm of the enteral nutrition.
62754487|NCT04609358|NO_INTERVENTION|Control group|The patients' nutrition were supported according the prescription of the physicians and dietician in our hospital.
62754488|NCT05290454|EXPERIMENTAL|mNGS-guided treatment group|In mNGS-guided treatment group, participants undergo mNGS, using appropriate lower respiratory tract (LRT) specimen, and conventional microbiological diagnostic tests. LRT specimen, such as endotracheal aspiration (ETA), bronchoalveolar lavage fluid (BALF), or protected specimen brush (PSB), will be obtained within 24 hours after the participants entering the ICU. Conventional microbiology diagnostic techniques will be also applied using appropriate LRT specimens and other necessary specimens (such as blood, pleural fluid, urine, et al.). Clinicians alter or confirm the definitive treatment based on mNGS results, as well as results from conventional microbiology diagnostic techniques.
62754489|NCT05290454|NO_INTERVENTION|Conventional treatment group|In conventional treatment group, participants undergo conventional microbiological tests using appropriate LRT specimen, and other necessary specimens (such as blood, pleural fluid, urine, et al.). LRT specimen, such as endotracheal aspiration (ETA), bronchoalveolar lavage fluid (BALF), or protected specimen brush (PSB), will be obtained within 24 hours after the participants entering the ICU. Based on results of conventional microbiology diagnostic techniques, clinicians alter or confirm the definitive treatment of participants.
62754490|NCT02101801|OTHER|freshwater|receives vegetables from freshwater farms
62754491|NCT02101801|ACTIVE_COMPARATOR|recycled wastewater|receives vegetables from farms using recycled wastewater irrigation
62754492|NCT04859985|EXPERIMENTAL|SELUTION SLR DEB|Device: SELUTION SLR DEB. For patients randomized to the DEB strategy, all target lesions should be treated with DEB after appropriate lesion preparation, but provisional DES implantation is acceptable if the angiographic result is considered insufficient either after lesion preparation of after DEB treatment (poor flow, dissection type C or higher, residual stenosis \> 30%). For bifurcation lesions, when both main and side- branch are considered to require treatment, a DEB should be used for both.
62556587|NCT03530683|EXPERIMENTAL|maplirpacept (PF-07901801) Monotherapy|"In the phase 1a dose- escalation part for single-agent maplirpacept (PF-07901801), participants with Relapsing or Refractory (R/R) lymphoma will be enrolled in sequential dose cohorts to receive maplirpacept (PF-07901801) QW to characterize safety, tolerability, and PK; to determine the Maximum Tolerated Dose (MTD) or P1b Starting Dose (a dose lower than or equal to the single-agent MTD), and to gain preliminary evidence of antitumor activity.~In addition, participants with R/R Lymphoma may also be enrolled in a cohort to receive maplirpacept (PF-07901801) Q2W and a cohort to receive maplirpacept (PF-07901801) Q3W to characterize safety, tolerability, and PK; to determine the MTD; and to gain preliminary evidence of antitumor activity."
62556588|NCT03530683|EXPERIMENTAL|Cohort A: maplirpacept (PF-07901801) + Azacitidine|"Cohort A1: participants with newly diagnosed TP53-mutated Acute Myelocytic Leukemia (AML) will be treated with maplirpacept (PF-07901801) QW + azacitidine.~Cohort A2: participants with newly diagnosed TP53-mutated AML will be treated with maplirpacept (PF-07901801) QW + azacitidine."
62377968|NCT05057884|EXPERIMENTAL|Breathing training|The respiratory pattern modulation training is performed at home for 12 weeks twice daily for 15 min per session and consists of three components: 1) education on abnormal ventilation in heart failure, the effect of ventilation on PaCO2 and the autonomous nervous system, and chemoreceptor sensitivity; 2) 1-3 sessions of guided and monitored face-to-face training with slow nasal abdominal breathing and intermittent apnoea supported by the Healer vest (L.I.F.E., Milan, Italy) measuring electrocardiogram (ECG), and chest excursions at the level of the xiphoid, thoracic manubrium, and abdomen; 3) independent home-based apnoea training supported by hand-outs, videos and weekly phone calls to monitor progress and adherence, answer questions and encourage further progression with duration of breath-hold.
62377969|NCT05057884|NO_INTERVENTION|Control|The control group receives standard of care. They perform the study measurements before and after the intervention period of 12 weeks. They are offered to perform the breathing training after study completion.
62377970|NCT03643276|ACTIVE_COMPARATOR|pB: early (non-)HR-standard/MR-standard|"Induction (5 wks): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT methotrexate (MTX)~Consolidation (6 w/4 w): Consolidation extended (control arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-mercaptopurine (6-MP), IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 wks): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 wks): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 years after initial diagnosis): 6-MP, MTX \[without preceding blinatumomab (control arm of randomization R-MR)\]~Erwinase is given in case of allergy to pegaspargase."
62556589|NCT03530683|EXPERIMENTAL|Cohort B: maplirpacept (PF-07901801) + Azacitidine and Venetoclax|"Cohort B1: elderly or unfit participants with newly diagnosed TP53-wildtype AML will be treated with maplirpacept (PF-07901801) QW + azacitidine and venetoclax~Cohort B2: elderly or unfit participants with newly diagnosed TP53-wildtype AML will be treated with maplirpacept (PF-07901801) QW + azacitidine and venetoclax."
62377971|NCT03643276|EXPERIMENTAL|pB: early HR-exp./MR-standard|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)~Extra-compartment phase (8 wks): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 wks): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX \[without preceding blinatumomab (control arm of randomization R-MR)\]~Erwinase is given in case of allergy to pegaspargase."
62377972|NCT03643276|EXPERIMENTAL|pB: early (non)HR-standard/MR-exp.|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
62377973|NCT03643276|EXPERIMENTAL|pB: early HR-exp./MR-exp.|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX,IT MTX~Reinduction (6 weeks): Protocol II with dexamethasone, vincristine, doxorubicin, PEG-L-asparaginase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)~Maintenance phase (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
62556590|NCT03530683|EXPERIMENTAL|Cohort D1 and D2: maplirpacept (PF-07901801) + an anti-CD20 targeting agent|"Cohort D1: participants with Relapsing or Recurrent (R/R) CD20+ Diffuse Large B Cell Lymphoma (DLBCL) will be treated with maplirpacept (PF-07901801) QW, then an increased dose Q3W + an anti-CD20 targeting agent.~Cohort D2: participants with R/R CD20+ DLBCL will be treated with maplirpacept (PF-07901801) dosed QW for 4 weeks, then an increased dose Q3W + an anti-CD20 targeting agent."
62556591|NCT03530683|EXPERIMENTAL|Cohort E1 and E2: single agent maplirpacept (PF-07901801)|"Cohort E1: participants with Relapsing or Recurrent (R/R) Multiple Myeloma (MM) will be treated with single agent maplirpacept (PF-07901801) QW.~Cohort E2: participants with R/R MM will be treated with single agent maplirpacept (PF-07901801) increased dose QW."
62556592|NCT03530683|EXPERIMENTAL|Cohort F1, F2 and F3: maplirpacept (PF-07901801) + isatuximab, carfilzomib and dexamethasone|"Cohort F1: participants with Relapsing or Recurrent (R/R) Multiple Myeloma (MM) will be treated with increasing doses of maplirpacept (PF-07901801) + isatuximab, carfilzomib and dexamethasone.~Cohort F2: participants with R/R MM will be treated with maplirpacept (PF-07901801) QW + isatuximab, carfilzomib and dexamethasone.~Cohort F3: participants with R/R MM will be treated with maplirpacept (PF-07901801) increased dose QW + isatuximab, carfilzomib and dexamethasone."
62754493|NCT04859985|OTHER|DES|Device: Drug Eluting Stent. For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.
61986600|NCT05473273||Hormone Replacement Therapy Protocol|"Ultrasound monitoring of endometrial growth and exclude growing follicle~Oral Estradiol Valerate (Progyluton) 4 mg on cycle day 2 at 7 pm for 2 days. On 3rd day, increase dose to 6 mg. The dose may be increased based on endometrial thickness.~Once endometrial thickness is at least 7 mm and trilaminar, after 10-15 days of Estradiol Valerate administration, start Endometrin 100 mg at 1 pm and 9 pm. From 2nd day onwards increase to 3 times daily. Continue Progyluton \& Endometrin until 12 weeks of pregnancy~ET on the 5th full day of Endometrin administration~Blood test to measure PIBF, IL-17, IFγ, IL-4, IL-10 and TGF-ß1 on the 1st day of Endometrin supplementation (before 1st administration), on the 4th day of Endometrin administration, on the day of ET and 3 and10 days after, 4 to 7 hours after the morning administration.~Blood test to measure beta human chorionic gonadotropin (ß-hCG) will be performed 3 and 10 days after ET and at 5 weeks +/- 3 days if pregnancy."
62377974|NCT03643276|ACTIVE_COMPARATOR|pB: early (non-)HR-standard/HR-standard|"Induction (5 w): as in other pB arms~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT methotrexate, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX~Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide~Reinduction (3x4 w): Protocol III given 3 times with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX~Erwinase is given in case pegaspargase allergy. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)."
62754494|NCT02376101|ACTIVE_COMPARATOR|Standard ETT size|Their tracheas will be intubated with an appropriately sized ETT using the standard formula. The cuff will be inflated to achieve a seal by the air-leak test when holding CPAP of 20 cmH2O and the intracuff pressure will be measured using a manometer.
62556593|NCT03530683|EXPERIMENTAL|Cohort C1, C2 and C3: maplirpacept (PF-07901801) + Carfilzomib and Dexamethasone|"Cohort C1: participants with Relapsing or Refractory (R/R) Multiple Myeloma (MM) will be treated with maplirpacept (PF-07901801) QW~+ carfilzomib and dexamethasone.~Cohort C2: participants with R/R MM will be treated with maplirpacept (PF-07901801) QW + carfilzomib and dexamethasone.~Cohort C3: participants with R/R MM will be treated with maplirpacept (PF-07901801) Q2W + carfilzomib and dexamethasone."
62754495|NCT02376101|EXPERIMENTAL|ETT one size smaller|Their tracheas will be intubated with an ETT that is one size smaller (instead of a 5.0 ETT, we would use a 4.0 ETT). The cuff will be inflated to achieve a seal by the air-leak test when holding CPAP of 20 cmH2O and the intracuff pressure will be measured using a manometer.
61986601|NCT02862197||study group|hemodialysis treated patients as described in the inclusion of the study
62754496|NCT02471274|EXPERIMENTAL|Group 1|healthy control subjects with normal hepatic function
62754497|NCT02471274|EXPERIMENTAL|Group 2|subjects with mild hepatic impairment
62754498|NCT02471274|EXPERIMENTAL|Group 3|subjects with moderate hepatic impairment
62754499|NCT02471274|EXPERIMENTAL|Group 4|subjects with severe hepatic impairment
61986602|NCT02615730|EXPERIMENTAL|Paclitaxel & GSK2636771|Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily) in combination with a fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)
61986603|NCT02861703|EXPERIMENTAL|Online lifestyle intervention|"A weekly psychosocial intervention (Online Lifestyle Intervention) delivered in an online group format, to promote positive changes in physical (eating habits, physical activity) and mental health (body image, self-esteem, self-efficacy)."
62377975|NCT03643276|EXPERIMENTAL|pB: early HR-exp./HR-standard|"Induction (5 w): as in other pB arms~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)~Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide~Reinduction (3x4 w): as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
62377976|NCT03643276|EXPERIMENTAL|pB: early (non-)HR-standard/HR-exp.|"Induction (5 w): as in other pB arms~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX~Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)~Reinduction (3x4 weeks): as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX~Erwinase is given in case of pegaspargase allergy. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
62556594|NCT02556801|PLACEBO_COMPARATOR|SUBLIVAC FIX Phleum Prat. 0 AUN/ml|42 subjects received placebo (SUBLIVAC FIX Phleum Pratense 0 AUN/ml) sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
62556595|NCT02556801|EXPERIMENTAL|SUBLIVAC FIX Phleum Prat. 10,000 AUN/ml|42 subjects received SUBLIVAC FIX Phleum Pratense 10,000 AUN/ml) sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
62754500|NCT00805714||Acute myocardial infarction|AMI patients who are in need to be treated by statins
62754501|NCT01846663|EXPERIMENTAL|Rifaximin|Rifaximin, oral, 550 mg BID, 6 months of treatment
62377977|NCT03643276|EXPERIMENTAL|pB: early HR-exp./HR-exp.|"Induction (5 w): as in other pB arms~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)~Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)~Reinduction (3x4 weeks): as in arm pB: early (non-)HR-standard/HR-standard Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
62377978|NCT03643276|OTHER|pB: early non-HR/SR|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (4 w): Consolidation short with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
62377979|NCT03643276|ACTIVE_COMPARATOR|T: early non-SR-standard/(non-)HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or Protocol IA-CPM with prednisolone instead of dexamethasone and additional CPM~Consolidation (4 w): Protocol IB regular (control arm in randomization. R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~non-HR extra-compartment phase and reinduction: as in arm pB: early non-HR/SR~HR intensified consolidation and reinduction: as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
62556596|NCT02556801|EXPERIMENTAL|SUBLIVAC FIX Phleum Prat. 40,000 AUN/ml|40 subjects received SUBLIVAC FIX Phleum Pratense 40,000 AUN/ml sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
62556597|NCT02556801|EXPERIMENTAL|SUBLIVAC FIX Phleum Prat. 80,000 AUN/ml|40 subjects received SUBLIVAC FIX Phleum Pratense 80,000 AUN/ml sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
62556598|NCT01651117|NO_INTERVENTION|Usual Care|Enrolled in two different time frames. No interventions will be provided to this arm. They will complete planned surveys, and blood draws (baseline, 6 months, and 12 months).
62754502|NCT01846663|PLACEBO_COMPARATOR|Placebo|Placebo, oral, 0 mg BID, 6 months of treatment
62754503|NCT04942340|ACTIVE_COMPARATOR|Phase 1: Atipamezole & caffeine's in a 1:1 ratio|Is this arm, subjects will be randomized to IV administration of Atipamezole \& caffeine's in a 1:1 ratio
61986604|NCT02419742|EXPERIMENTAL|Trastuzumab|Participants will receive trastuzumab as a part of either AC-TH or TCH treatment regimen. The choice of the regimen will be based on investigator's discretion referring the local prescribing document of trastuzumab. AC-TH consists of doxorubicin and cyclophosphamide followed by either paclitaxel or docetaxel. TCH consists of docetaxel and carboplatin. Trastuzumab will be common in both treatment regimens and could be administered weekly or every 3 weeks, as per investigator discretion. Each cycle will be of 3 weeks.
62556599|NCT01651117|EXPERIMENTAL|Peer Mentoring|Participants in this arm will be mentored for 6 months by a veteran who was once in poor control but is now in good control. They will then be further randomized to either becoming a mentor for 6 months or having no other additional active intervention. All participants in this arm will be evaluated in person at baseline, 6 months, 12 months, and 18 months.
62754504|NCT04942340|PLACEBO_COMPARATOR|Phase 1: Precedex & Saline in a 1:1 ratio|Is this arm, subjects will be randomized to receive IV administration of Precedex \& Saline in a 1:1 ratio
62754505|NCT06552481|EXPERIMENTAL|NP-PWD application|Patients randomized to NP-PWD arm will have the NP-PWD device applied to their wound.
62754506|NCT06552481|ACTIVE_COMPARATOR|Standard of Care Wound VAC application|Patients randomized to the standard of care arm will have the standard wound vac device applied to their wound.
62754507|NCT06159205|EXPERIMENTAL|Group 1: SE Group|SE: standard exercises During the follow-up period, only the interventions included in the standard exercise program were applied to the SE Group.
62754508|NCT06159205|EXPERIMENTAL|Group 2: SE + CSE Group|CSE: core stability exercises During the follow-up period interventions included in both the standard and core stability program were applied to the SE + CSE group.
61986605|NCT00727753||Ranibizumab|
61986606|NCT00727753||Bevacizumab|
61986607|NCT00727753||Dry AMD|
61986608|NCT02136576|ACTIVE_COMPARATOR|Sensodyne|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
61986609|NCT02136576|ACTIVE_COMPARATOR|Crest Cavity Protection & MI Paste Plus|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
61986610|NCT02136576|ACTIVE_COMPARATOR|Clinpro 5000|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
62754509|NCT02879591|EXPERIMENTAL|Patients with schizophrenia|Patients with schizophrenia
62754510|NCT02879591|PLACEBO_COMPARATOR|Healthy volunteers|Healthy volunteers
61986611|NCT01393340|PLACEBO_COMPARATOR|Placebo|
61986612|NCT01393340|ACTIVE_COMPARATOR|Omalizumab|
61986613|NCT04026477|EXPERIMENTAL|Immediate Universal Trauma-Informed Care and Cultural Humility Training|Universal Trauma-Informed Care and Cultural Humility Training. After video and workshop training, staff will have ability to recognize trauma and racism and its impact on school procedures, practices, and children themselves. Staff will be able to apply core principles of cultural humility. Staff will examine their own cultural identity and how it influences their interactions and relationships with students of diverse cultural backgrounds (Principle 1). Staff will learn ways that privilege and oppression relate to their cultural identity and identify ways to flatten power hierarchies between themselves and students, including handling misbehavior from a trauma-informed, culturally humble perspective (Principle 2). Staff will problem-solve ways for their schools to be accountable for equitable discipline practices (Principle 3).
61986614|NCT04026477|ACTIVE_COMPARATOR|Waitlist Universal Trauma-Informed Care and Cultural Humility Training|All staff from waitlisted schools will receive Universal Trauma-Informed Care and Cultural Humility Training at the end of the waitlist period.
61986615|NCT00849160|EXPERIMENTAL|Darunavir/r|
61986616|NCT04448405||Patients followed by the CRIAVS|Patients followed by the CRIAVS (resource center for workers working with authors of sexual violence) in CHU Motpellier from June to October 2020
61986617|NCT01163708|ACTIVE_COMPARATOR|Navigation alone|Navigation system alone vs Prophecy technique with Navigation system validation
61986618|NCT01163708|EXPERIMENTAL|Prophecy and Navigation validation|
61986619|NCT01914185|NO_INTERVENTION|Comparison Schools|Regular health promotion activities
61986620|NCT01914185|EXPERIMENTAL|Comprehensive School Health (CSH)|Full time School Health Facilitator present in each school on a day-to-day basis for 3.5 years responsible for facilitating implementation of Comprehensive School Health
61986621|NCT06135155|EXPERIMENTAL|PEG-rhGH with new preparation|
62754511|NCT04780880||Youth football players|Young footballers aged 10-16 training and playing for a Polish football club.
62754512|NCT05901363|EXPERIMENTAL|Endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy|endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy
62754513|NCT05901363|ACTIVE_COMPARATOR|laparoscopic common bile duct exploration and laparoscopic cholecystectomy|
62754514|NCT03407053|ACTIVE_COMPARATOR|Ultra-processed diet then unprocessed diet|Participants assigned to this arm will consume ultra-processed diet for two weeks followed by unprocessed diet for two weeks
62754515|NCT03407053|ACTIVE_COMPARATOR|Unprocessed diet then ultra-processed diet|Participants assigned to this arm will consume unprocessed diet for two weeks followed by ultra-processed diet for two weeks
62377980|NCT03643276|EXPERIMENTAL|T: early non-SR-exp/(non-)HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or Protocol IA-CPM with prednisolone instead of dexamethasone and additional CPM~Consolidation (6 w): Protocol IB long (experimental arm in randomization R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~non-HR extra-compartment phase and reinduction: as in arm pB: early non-HR/SR~HR intensified consolidation and reinduction: as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
62377981|NCT03643276|OTHER|T: early SR/non-HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (4 w): Protocol IB regular with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
62377982|NCT00909194|EXPERIMENTAL|Intervention|Educational Seminar on Juvenile Primary Fibromyalgia Syndrome and CD-guided total body relaxation technique
62377983|NCT00909194|NO_INTERVENTION|Control|Control Arm consisted of an educational seminar on skin care
62377984|NCT05136209|EXPERIMENTAL|PCCC procedure without A-vit|Procedure/Surgery: PCCC procedure without A-vit ACCC + I / A + PCCC or ACCC + I / A +PCCC + IOL
62377985|NCT05136209|ACTIVE_COMPARATOR|PCCC+A-Vit procedure|Procedure/Surgery: PCCC+A-Vit procedure ACCC + I / A + PCCC + A-vit or ACCC + I / A +PCCC + IOL + A-vit
62377986|NCT00476515|EXPERIMENTAL|Rituximab|this study has only one arm as treatment group.
62377987|NCT01108224|EXPERIMENTAL|Psychosocial support|
62377988|NCT01108224|NO_INTERVENTION|Control group|
62377989|NCT04686929|EXPERIMENTAL|Cohort 1|The participants in Cohort 1 will receive abatacept s.c
62377990|NCT04891510|ACTIVE_COMPARATOR|REVOLVE Advanced Adipose System|Participants will receive the REVOLVE Advanced Adipose System technique during breast reconstruction.
62377991|NCT04891510|ACTIVE_COMPARATOR|LipoGrafter|Participants will receive the LipoGrafter technique during breast reconstruction.
62377992|NCT04891510|ACTIVE_COMPARATOR|Viality|Participants will receive the Viality technique during breast reconstruction.
61986622|NCT06135155|EXPERIMENTAL|PEG-rhGH with present preparation|
62377993|NCT05617248|EXPERIMENTAL|Experimental: Self-efficacy training (App)|This group will receive a digital one week self-efficacy training with three training sessions per day and EMA (10 per day).
62377994|NCT05617248|NO_INTERVENTION|Control|This group will receive EMA questionnaires for one week (10 per day).
62377995|NCT03608462|SHAM_COMPARATOR|rTMS targeting the right DLPFC|60 patients will be randomly allocated into this group,half of them will receive iTBS on the right DLPFC,while the other half will receive sham stimulation.
62377996|NCT03608462|SHAM_COMPARATOR|rTMS targeting the left LPC|60 patients will be randomly allocated into this group,half of them will receive iTBS on left LPC,while the other half will receive sham stimulation.
62377997|NCT03608462|NO_INTERVENTION|Observation group|To investigate the abnormalities of hippocampal neurogenesis in patients with early schizophrenia(n=30) compared to healthy controls(n=30)
62377998|NCT00362297|ACTIVE_COMPARATOR|Standard dose|
62377999|NCT00362297|EXPERIMENTAL|High-dose|
62378000|NCT03837301|EXPERIMENTAL|NESS-EFTR|Non-exposure Simple Suturing Endoscopic Full-Thickness Resection (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation (basin dissection)
62378001|NCT04533360||Community Cohort 1|1000 Participants from the community will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 1.
62378002|NCT04533360||Community Cohort 2|1000 Participants from the community will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 2.
62378003|NCT04533360||Healthcare Provider Cohort 1|500 hospital employees will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 1.
62378004|NCT04533360||Healthcare Provider Cohort 2|500 hospital employees will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 2.
62378005|NCT02106845|EXPERIMENTAL|P-gp probe substrate(digoxin)+regorafenib|
62378006|NCT02106845|EXPERIMENTAL|Group B: BCRP probe substrate (rosuvastatin) + regorafenib|
62378007|NCT03527836|ACTIVE_COMPARATOR|Lidocaine|Lidocaine brachial plexus block 0.4 ml/kg of 0.66% solution
62378008|NCT03527836|ACTIVE_COMPARATOR|Bupivacaine|Bupivacaine brachial plexus block 0.4 ml/kg of 0.33% solution
62378009|NCT03527836|ACTIVE_COMPARATOR|Mixture|Mixture brachial plexus block 0.4 ml/kg of 0.33% bupivacaine and 0.33% lidocaine solution
62378010|NCT00879788|EXPERIMENTAL|1|Ramipril capsules 10 mg (containing Ramipril 10 mg)of of OHM Laboratories Inc., USA (a subsidiary of Ranbaxy Pharmaceuticals Inc), USA
62378011|NCT00879788|ACTIVE_COMPARATOR|2|ALTACE® capsule 10 mg (containing Ramipril 10 mg)of King Pharmaceuticals Inc., Bristol, TN 37620, USA
62378012|NCT04296721|EXPERIMENTAL|Intensive weight-loss program|The life style change program will consist of two stages. The first will consist of a 3-month period of intensive diet and progressive exercise with biweekly consultations with a nutritionist (in groups or individually). The second stage will last for 9 months, until completion, with a diet that is progressively higher in calories, with more intense exercise, under the supervision of a community nurse and an individual nutritional consultation at 9 months.
62378013|NCT04296721|ACTIVE_COMPARATOR|Standard dietary recommendations|Patients will be followed according to the usual recommendations: A written diet (designed by a hospital nutritionist) and an exercise plan, depending on the patient's age and activity level, without any other type of evaluation or visit Visits in the Sleep Disorders Unit will be scheduled at 3 and 12 months
62378014|NCT01332851|EXPERIMENTAL|Promoting First Relationships (PFR)|"PFR is a strengths-based 10 week in-home parenting intervention based on attachment theory. Each week has a theme for discussion, an activity, and time for joining - checking in with the parent, listening to their concerns and establishing a positive, supportive relationship. The sessions include handouts which focus on the content area covered that day and applying a topic to their relationship with their child. The provider also videotapes playtime between parent and child. On alternate weeks, the provider watches the video with the parent, reflecting on both the parent's and the child's needs. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent identify her own feelings and needs around parenting."
62556600|NCT01651117|EXPERIMENTAL|Peer Mentoring FFM (from former mentee)|Participants in this arm will be mentored by the former mentee for 6 months and will be followed in person for an additional 6 months after the completion of the active intervention.
62754516|NCT04765423|EXPERIMENTAL|NaF PET/CT scan and F-18 fluciclovine PET/CT|"Visit 1: Participant receives a whole body \[F-18\] NaF PET/CT (diagnostic study)~Visit 2: Participant receives a whole body \[F-18\] fluciclovine PET/CT within 3 weeks of Visit 1"
61986623|NCT00746993|EXPERIMENTAL|1|Structured contraceptive counseling and routine care.
62378015|NCT01332851|ACTIVE_COMPARATOR|Resource & Referral|This condition consists of 1) Resource and Referral assistance provided over the phone, and 2) Local Services Resource Packet. The participant receives a phone call from a Resource and Referral Specialist to conduct a needs assessment to identify the particular needs or concerns of the family (such as housing needs, mental health, tangible goods). If a need is identified, the Referral and Referral Specialist will provide the family with local information regarding the stated need. The R\&R provider makes two follow-up check in calls with the families. In addition, families can call the Research and Referral Specialist if additional needs arise. The resource packet includes information organized by type of need or resource. These packets are updated regularly as services change over time.
62378016|NCT04661891|EXPERIMENTAL|Healthy Participants|The investigators will look at muscle activity of healthy participants from eight lower limb muscles during functional tasks (e.g. single-joint movement, walking, squatting, cycling).
62754517|NCT05023473|ACTIVE_COMPARATOR|PENG block+ morhine|the participants will receive PENG block before being attached to morphine PCA
62378017|NCT04661891|EXPERIMENTAL|Clinical Participants|The investigators will look at muscle activity of participants post-stroke from eight lower limb muscles during functional tasks (e.g. single-joint movement, walking, squatting, cycling).
62378018|NCT01960179|EXPERIMENTAL|lixisenatide|lixisenatide monotherapy by group (Group 1: 52-week treatment; Group 2: 24-week treatment)
62556601|NCT05477836|EXPERIMENTAL|Experimental group|Microwave-based colonoscopy
62556602|NCT04820426||Rheumatoid Arthritis patients|Rheumatoid arthritis patients will be evaluated in terms of the presence of neuropathic pain and its effect on the quality of life, at their admission.
62556603|NCT06531278|EXPERIMENTAL|first-line treatment of pancreatic cancer liver metastasis efficacy and safety|Adebelimab combined with irinotecan liposomal injection, oxaliplatin, Fluorouracil and calcium folinate
62556604|NCT01288716|PLACEBO_COMPARATOR|Placebo|
62556605|NCT01288716|ACTIVE_COMPARATOR|Arbaclofen|
62754518|NCT05023473|ACTIVE_COMPARATOR|MORPHINE|The participants will be given morphine PCA without PENG block
61986624|NCT00746993|NO_INTERVENTION|2|Routine care.
61986625|NCT02563678|ACTIVE_COMPARATOR|Diabetics with active, chronic infection|Adult patients with diabetes mellitus and current antibiotic use for active infection will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
61986626|NCT02563678|ACTIVE_COMPARATOR|No diabetes or infection|Adult patients without diabetes and not using antibiotics will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
62378019|NCT05564715|ACTIVE_COMPARATOR|Phase 1: Active Treatment|Participants will receive 10 sessions of active stimulation (1 mA anodal HD-tDCS targeting preSMA/dACC for 20 min) across 2 weeks. Word retrieval and other cognitive tasks will be completed at baseline, immediate follow-up after session 10, and a 2-month follow-up
61986627|NCT02563678|ACTIVE_COMPARATOR|Critically ill patients with infection|Adult patients with acute, life-threatening infection for which hyperbaric oxygen is clinically indicated will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
61986628|NCT02563678|ACTIVE_COMPARATOR|Carbon monoxide patients|Adult patients with acute carbon monoxide poisoning will have blood drawn before and after their first clinical hyperbaric oxygen treatment.
62378020|NCT05564715|SHAM_COMPARATOR|Phase 1: Sham Treatment|Participants will receive 10 sessions of sham stimulation across 2 weeks. Word retrieval and other cognitive tasks will be completed at baseline, immediate follow-up after session 10, and a 2-month follow-up
62378021|NCT05564715|ACTIVE_COMPARATOR|Phase 2: Active Treatment|For Phase 2, participants randomized into the sham group will have the opportunity to return after 2 months from completing Phase 1. They will receive the active treatment while being unblinded to their treatment condition. Following 10 active treatment sessions, word retrieval and other cognitive tasks will again be completed immediately following the last HD-tDCS session and then a 2-month follow-up.
62378022|NCT03663972|ACTIVE_COMPARATOR|Motoric Arm|Children will participate in an intervention based on traditional articulation approaches to speech therapy.
62378023|NCT03663972|ACTIVE_COMPARATOR|Phonologic Arm|Children will receive intervention that targets the conceptual representation of sounds.
62378024|NCT00984152|ACTIVE_COMPARATOR|1|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
62378025|NCT00984152|ACTIVE_COMPARATOR|2|TDF/FTC + Efavirenz (Atripla) Once-Daily
62378026|NCT02640924|EXPERIMENTAL|Proton radiotherapy|Proton radiotherapy will be totally 66 cobalt gray equivalent (CGE) in 10 fractions and delivered once daily, 5 fractions per week, over 2 weeks for HCC more than 1 cm away from the alimentary tract.
62556606|NCT00147459|ACTIVE_COMPARATOR|booster|no antibody and boosted
62754519|NCT03804567|EXPERIMENTAL|Oldpain2go®|This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs (chronic pain) that are troubling them.
62754520|NCT03804567|ACTIVE_COMPARATOR|Routine low back pain management|Normal accepted physiotherapy treatment for persistent low back pain.
62754521|NCT00905762|EXPERIMENTAL|Besifloxacin|Besifloxacin one drop instilled into study eye.
62754522|NCT00905762|ACTIVE_COMPARATOR|Gatifloxacin|Gatifloxacin one drop instilled into study eye.
62754523|NCT00905762|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin one drop instilled into study eye.
62754524|NCT01241344|ACTIVE_COMPARATOR|Brincidofovir|"* Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~* Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
62754525|NCT01241344|PLACEBO_COMPARATOR|Placebo|"* Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~* Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
62754526|NCT06430957||Group lowSTOP-B|Study group including patients in the low-risk group in the assessment to be made with STOP-BANG questionnaire.
62754527|NCT06430957||Group intermediateSTOP-B|Study group including patients in the medium-risk group in the assessment to be made with STOP-BANG questionnaire.
62754528|NCT06430957||Group highSTOP-B|Study group including patients in the high-risk group in the assessment to be made with STOP-BANG questionnaire.
62754529|NCT06430957||Group noneASA|The study group that includes patients who are not at risk for OSA in the evaluation with the criteria recommended by the ASA.
62754530|NCT06430957||Group mildASA|Study group including patients in the mild-risk group for OSA in the evaluation with the criteria recommended by the ASA.
62754531|NCT06430957||Group moderateASA|Study group including patients in the moderate-risk group for OSA in the evaluation with the criteria recommended by the ASA.
62754532|NCT06430957||Group severeASA|Study group including patients in the severe-risk group for OSA in the evaluation with the criteria recommended by the ASA.
62754533|NCT03920293|EXPERIMENTAL|Ravulizumab|Participants will receive ravulizumab for the duration of the study.
62754534|NCT03920293|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo during the 26-week randomized-controlled period of the study, after which they will enter the open-label extension period of the study and receive ravulizumab.
62754535|NCT06358781|NO_INTERVENTION|Group A (WG wheat flour intake= 0 g)|An acute randomized controlled trial was performed and the total study group is randomly divided into four groups: the amounts of WG wheat flour for group A were 0 g.
62754536|NCT06358781|EXPERIMENTAL|Group B (WG wheat flour intake= 25 g)|An acute randomized controlled trial was performed and the total study group is randomly divided into four groups: the amounts of WG wheat flour for group B were 25 g.
62754537|NCT06358781|EXPERIMENTAL|Group C (WG wheat flour intake= 50 g)|An acute randomized controlled trial was performed and the total study group is randomly divided into four groups: the amounts of WG wheat flour for group C were 50 g.
62754538|NCT06358781|EXPERIMENTAL|Group D (WG wheat flour intake= 100 g)|An acute randomized controlled trial was performed and the total study group is randomly divided into four groups: the amounts of WG wheat flour for group D were 100 g.
62754539|NCT00712569||1|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information.
62754540|NCT00712569||2|Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information.
62754541|NCT00712569||3|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it.
62754542|NCT02974335||Primary Care Providers (PCPs)|Key stakeholders including: informatics/Epic leaders, medical providers, and patients from the two health systems that will be involved in the study, as well as national health information technology leaders from other large health systems.
62378027|NCT02640924|EXPERIMENTAL|Radiofrequency Ablation|Multiple-electrode radiofrequency with switch-controller system (ME-SWC RFA) can create a large coagulation necrosis volume and successful treat HCC sized more than 3 cm, extending to 8.5 cm. ME-SWC RFA system uses up to 3 electrodes parallel insertion to inside of the tumors with an equilateral triangular confirmation before initiation of ablation. The distances between electrodes are about 1.5-2 cm, estimated by ultrasound measuring. The switching machine is set on the auto-mode, and all electrodes work alternately and switching each other automatically after impendence surge.
62556607|NCT01276860|OTHER|Psychomotor Vigilance Testing|The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
62556608|NCT04975711|EXPERIMENTAL|Test drug(HIP2105) or Reference drug(RLD2104) Sequence 1|Period 1: RLD2104 Period 2: HIP2105
62556609|NCT04975711|EXPERIMENTAL|Test drug(HIP2105) or Reference drug(RLD2104) Sequence 2|Period 1: HIP2105 Period 2: RLD2104
62556610|NCT05751707|EXPERIMENTAL|NIV+/-HFNC (non invasive ventilation +/- high flow nasal cannulae) & HFCWO|Patient with acute or acute on chronic respiratory failure is treated with non invasive ventilation (with or without high flow nasal cannulae oxygen) AND High Frequency Chest Wall Oscillations
62556611|NCT05751707|NO_INTERVENTION|NIV+/-HFNC and no HFCWO|Patient with acute or acute on chronic respiratory failure is treated with non invasive ventilation (with or without high flow nasal cannulae oxygen) AND NO High Frequency Chest Wall Oscillations
62556612|NCT05751707|EXPERIMENTAL|HFNC & HFCWO|Patient with acute or acute on chronic respiratory failure is treated with high flow nasal cannulae oxygen AND High Frequency Chest Wall Oscillations
62556613|NCT05751707|NO_INTERVENTION|HFNC and no HFCWO|Patient with acute or acute on chronic respiratory failure is treated with high flow nasal cannulae oxygen AND High Frequency Chest Wall Oscillations
62556614|NCT03505970|EXPERIMENTAL|Sodium bicarbonate|0.3 g∙kg-1body mass of sodium bicarbonate
62556615|NCT03505970|PLACEBO_COMPARATOR|Placebo|Individuals will ingest 0.3 g/kg maltodextrin before undergoing exercise
62754543|NCT02974335||Medical Assistants (MAs) + Registered Nurses (RNs)|Key stakeholders including: informatics/Epic leaders, medical providers, and patients from the two health systems that will be involved in the study, as well as national health information technology leaders from other large health systems.
62754544|NCT02974335||Patients|Key stakeholders including: informatics/Epic leaders, medical providers, and patients from the two health systems that will be involved in the study, as well as national health information technology leaders from other large health systems.
61986629|NCT02563678|ACTIVE_COMPARATOR|Glucose tolerance test|Diabetic patients co-enrolled in a hyperbaric oxygen and glucose control study will have blood drawn before and after their glucose tolerance test and their first clinical hyperbaric oxygen treatment.
62556616|NCT04951869|EXPERIMENTAL|Protescal group|Caesarean-section was done in the usual manner. The transverse suprapubic skin incision was made and abdominal layers opened as usual. After delivering the baby, uterine muscle is closed in two layers with braided absorbable suture, polyglactin 910 (Vicryl no 1). After hemostasis secure, 1 mL Protescal gel was applied at the uterine suture site in Protescal group. Peritoneal layer closed using braided absorbable suture, polyglactin 910 (Vicryl no 1). Rectus sheath was sutured using braided absorbable suture, polyglactin 910 (Vicryl no 1). Subcutaneous tissue closed interruptedly using braided absorbable suture, polyglactin 910 (Vicryl no 1). Protescal gel (0.5 mL) was applied over the subcutaneous tissue prior to skin closure in Protescal group. The skin was then closed with the subcuticular method using braided absorbable suture, polyglactin 910 (Vicryl 3-0).
62754545|NCT03456791||endometrial carcinoma( cases)|42 patients with abnormal uterine bleeding and diagnosed endometrial cancer at prior endometrial biopsy, underwent staging laparotomy will be subjected to withdrawal of blood sample for measurement of human epididymis protein 4
62754546|NCT03456791||benign diseases(control)|42 patients with abnormal uterine bleeding and diagnosed benign endometrial pathology by endometrial biopsy will be subjected to withdrawal of blood sample for measurement of human epididymis protein 4
62754547|NCT00837824|EXPERIMENTAL|Fabrazyme 1mg/kg every 2 weeks|Fabrazyme 1.0 mg/kg every 2 weeks
62754548|NCT00837824|EXPERIMENTAL|Fabrazyme 3mg/kg every 2 weeks|Fabrazyme 3.0 mg/kg every 2 weeks
62754549|NCT05363293|EXPERIMENTAL|Multiple Ascending Doses of AL001 vs. Placebo - Cohort 1|"Participants will be randomized to receive AL001. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort.~A total of 9 cohorts will receive 5 different dose levels of AL001 in multiple ascending doses under fasted conditions up to tolerability/safety limits.~Cohort 1 will include 8 AD subjects. In this cohort, 6 active and 2 placebo AD subjects (as per randomization code) will receive the following treatment or placebo:~• Cohort 1: 60% of 450 mg lithium carbonate equivalent of AL001 (1890 mg AL001 daily ×14 days, given as 3 × 210 mg AL001 capsules TID)"
62754550|NCT05363293|EXPERIMENTAL|Multiple Ascending Doses of AL001 vs. Placebo - Cohort 2|"The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.~Cohort 2 will be sub-divided into 2 cohorts: Cohort 2a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 2b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:~• Cohort 2a and 2b: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily × 14 days, given as 5 × 210 mg AL001 capsules TID)."
61986630|NCT02563678|EXPERIMENTAL|Brain injury research subjects|Research subjects co-enrolled in a study examining hyperbaric oxygen for post-concussive symptoms will have blood drawn before and after their first and fourth hyperbaric chamber sessions.
62378028|NCT02010931||primary|subjects who are 18 years or older, who have minimal residual disease detected by PCR at a level of 1/10-3 or higher, who are free form allogeneic stem cell transplantation until hematological relapse or until 18 months after minimal residual disease detection (whichever comes first)
62556617|NCT04951869|NO_INTERVENTION|Control group|Caesarean-section was done in the usual manner. The transverse suprapubic skin incision was made and abdominal layers opened as usual. After delivering the baby, uterine muscle is closed in two layers with braided absorbable suture, polyglactin 910 (Vicryl no 1). After hemostasis secure, No Protescal gel was applied at the uterine suture site in this Control group. Peritoneal layer closed using braided absorbable suture, polyglactin 910 (Vicryl no 1). Rectus sheath was sutured using braided absorbable suture, polyglactin 910 (Vicryl no 1). Subcutaneous tissue closed interruptedly using braided absorbable suture, polyglactin 910 (Vicryl no 1). No application of Protescal gel (0.5 mL) over the subcutaneous tissue prior to skin closure in this Control group. The skin was then closed with the subcuticular method using braided absorbable suture, polyglactin 910 (Vicryl 3-0).
62556618|NCT06280339|EXPERIMENTAL|Avoidance group|Avoidance Strategy: This strategy focuses on teaching individuals how to modify their immediate environments to make it easier to control food cravings. Examples include redesigning your home to remove tempting foods or limiting access to craved foods. It also covers tips on making grocery lists and communicating health goals within your social circle. Additionally, it includes a toolkit for situations where controlling the immediate environment may be challenging, such as at parties or social gatherings Both strategies include educational materials explaining the definition of food cravings, factors that contribute to food cravings, and the distinction between hunger and cravings.
62556619|NCT06280339|EXPERIMENTAL|Inclusion group|"Inclusion Strategy: This strategy teaches individuals how to modify their eating habits by paying attention to the portion size of craved foods and incorporating them into well-balanced meals, avoiding eating between meals. It also includes a toolkit for situations where individuals may struggle to include craved foods in their balanced meals.~Both strategies include educational materials explaining the definition of food cravings, factors that contribute to food cravings, and the distinction between hunger and cravings."
62556620|NCT00392691|EXPERIMENTAL|Zevalin, Rituximab, Melphalan|
62754551|NCT05363293|EXPERIMENTAL|Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3|"The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.~Cohort 3 will be sub-divided into 2 cohorts: Cohort 3a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 3b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:~• Cohort 3a and 3b: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily × 14 days, given as 7 × 210 mg AL001 capsules TID)"
62754552|NCT05363293|EXPERIMENTAL|Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4|"The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.~Cohort 4 will be sub-divided into 2 cohorts: Cohort 4a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 4b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:~• Cohort 4a and 4b: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily × 14 days, given as 8 × 210 mg AL001 capsules TID)"
62754553|NCT05363293|EXPERIMENTAL|Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5|"The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.~Cohort 5 will be sub-divided into 2 cohorts: Cohort 5a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 5b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:~• Cohort 5a and 5b: 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily × 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 × 210 mg AL001 capsules TID)"
62754554|NCT01470690|ACTIVE_COMPARATOR|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5 (BOC alone)
62754555|NCT01470690|ACTIVE_COMPARATOR|omeprazole|Omeprazole 40 mg QD for 5 consecutive days (OME alone)
62754556|NCT01470690|EXPERIMENTAL|boceprevir+omeprazole|Omeprazole 40 mg QD for 5 consecutive days combined with boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5 (BOC+OME)
62754557|NCT01039831||Patients with Parkinson's Disease|Consecutive patient sampling
62754558|NCT05797532|ACTIVE_COMPARATOR|breastfeeding|The mother was allowed to sit comfortably in the patient's room, the pulse oximeter probe was attached to the left foot of the newborn, and the newborn, who was placed on the mother's lap, was breastfeeding for 5 minutes before the heel lance, and breastfeeding was continued during the procedure.
62754559|NCT05797532|ACTIVE_COMPARATOR|skin to skin contact|The newborn's clothes were removed so that only the diaper and baby hat were left, and a pulse oximeter probe was attached to his left foot. The newborn was placed on the mother's bare chest between her two breasts, facing the mother's face, with her head up, in the prone position, covered with a baby blanket, and skin-to-skin contact was made between the mother and the newborn for at least 5 minutes before starting the heel lance procedure.
62754560|NCT05797532|ACTIVE_COMPARATOR|swaddling and holding|A pulse oximeter probe was attached to the newborn's left foot, and the legs were in flexion and abduction position, wrapped with a square cloth blanket and placed on his mother's lap. It was ensured that the newborn was held in the mother's lap with his head up and feet down for 5 minutes before heel lance.
62754561|NCT06446752|EXPERIMENTAL|Bexsero|Meningococcal Serogroup B vaccine rMenB+OMV NZ (Bexsero) administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).
62754562|NCT06446752|PLACEBO_COMPARATOR|Placebo|Normal saline (placebo) administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).
62754563|NCT06608446|EXPERIMENTAL|Telerehabilitation|"In the days following surgery, intervention group will receive a structured rehabilitation session by a physiotherapist. In this session, two booklets will be provided to the patients, with the aim of informing and educating, regarding the most frequent complications after breast cancer surgery and how to avoid their possible onset through the demonstration of exercises to be carried out at home, self-massage techniques of the scar, behaviors and lifestyle to be adopted immediately after surgery.~This group will carry out, starting from 10 days post-surgery, a home tele-rehabilitation intervention from Monday to Friday via the TeleHab device (Vald Performance) until 2 months after surgery.~Exercises for ROM recovery and strength recovery will be carried out three days a week and only exercises for ROM recovery will be carried out two days a week."
61986631|NCT02563678|EXPERIMENTAL|Hyperbaric chamber inside attendants|Hyperbaric chamber inside attendants will have their blood drawn before, mid-session, and after their chamber exposure during their regular duty day. The hyperbaric chamber exposure will include hyperbaric air and hyperbaric oxygen components (hyperbaric air/oxygen).
62378029|NCT02010567|EXPERIMENTAL|CLRX101 MTD/RP2D|During Phase Ib, we will evaluate the safety and determine the MTD/RP2D of CRLX101 + capecitabine (Cape) and radiation therapy (XRT) in patients with rectal cancer using the traditional 3+3 dose escalation design. Adverse events (AEs) will be evaluated via the CTCAE version 4.0. Patients in Phase Ib will also be followed for pathological response if they have resectable disease.
62556621|NCT06582069|EXPERIMENTAL|bleaching with 2% kiwi extract.|"The fresh pulpy kiwi will be bought 200 gm of kiwi fruits were cleaned, cut into round shapes and blended with 15 mL of distilled water in a blender to obtain about 50 mL of kiwi concentrate.~This concentrate will be filtered and then transferred into a cooling centrifuge to be processed at 2000 rpm for about 20 minutes at a temperature of 40°C.~The extract thus collected will be stored at 4°C till further use."
62556622|NCT06582069|EXPERIMENTAL|bleaching using 2,350 ppm ozone gas.|"A 2,350 ppm ozone concentration at a 615 cc per minute flow rate will be supplied by a well-known ozone producing machine.~The ppm of ozone supplied will be verified via an ozone detection device, and the ozone flow rate will be verified by a flow meter directly before the start of the experiment.~Ozone gas will be distributed to the tooth surfaces through special trays to assure a perfect seal to prevent any ozone leakage and to be safely employed to humans"
62556623|NCT06582069|EXPERIMENTAL|bleaching with 2% kiwi extract followed By 2,350 ppm ozone gas.|"The fresh pulpy kiwi will be bought 200 gm of kiwi fruits were cleaned, cut into round shapes and blended with 15 mL of distilled water in a blender to obtain about 50 mL of kiwi concentrate.~This concentrate will be filtered and then transferred into a cooling centrifuge to be processed at 2000 rpm for about 20 minutes at a temperature of 40°C.~The extract thus collected will be stored at 4°C till further use. A 2,350 ppm ozone concentration at a 615 cc per minute flow rate will be supplied by a well-known ozone producing machine.~The ppm of ozone supplied will be verified via an ozone detection device, and the ozone flow rate will be verified by a flow meter directly before the start of the experiment.~Ozone gas will be distributed to the tooth surfaces through special trays to assure a perfect seal to prevent any ozone leakage and to be safely employed to humans."
62556624|NCT06582069|EXPERIMENTAL|bleaching with 38% hydrogen peroxide.|Application of 38% H2O2 gel for 20 minutes. Then, the H2O2 gel will be removed, and teeth will be sprayed for 10 seconds with water from a 3-in-1 syringe
62556625|NCT00956423|EXPERIMENTAL|moderate-intensity exercise training|
62556626|NCT00956423|ACTIVE_COMPARATOR|low-intensity stretching|
62556627|NCT04748107|NO_INTERVENTION|Provider preference: Control group|Provider will prescribe blood pressure medication based on his professional expertise.
62556628|NCT04748107|EXPERIMENTAL|ICG directed therapy group|ICG directed therapy will be used to determine which blood pressure medication is received.
62556629|NCT04507464|EXPERIMENTAL|Ecological Momentary Intervention|Participants will receive real time physical activity notifications via a wearable activity tracker and smartphone application.
62556630|NCT04507464|NO_INTERVENTION|Physical Activity Guidelines|Participants will be sent general guidelines for disruption of sedentary time.
62556631|NCT04420845|OTHER|Intervention|
62556632|NCT06042543|EXPERIMENTAL|Screening|The EASTER project aims to further develop and validate two new technologies for cervical cancer screening and diagnosis: (i) screening for human papillomavirus (HPV) in urine with spectroscopy, and (ii) diagnosis with artificial intelligence-assisted technology from the Neo Sense Vector Company (NSV), a private company. The project will recruit 3200 women and screen them for HPV.
62556633|NCT01726829|EXPERIMENTAL|MD-Logic Artificial Pancreas (MDLAP) system|four consecutive outpatients overnight sessions at home under closed loop MD-Logic Artificial Pancreas (MDLAP) system
62556634|NCT01726829|ACTIVE_COMPARATOR|Standard treatment with sensor augmented pump therapy|four consecutive outpatients overnight sessions at home under standard treatment with sensor augmented pump therapy
62556635|NCT02792517|EXPERIMENTAL|Erenumab + Estrogen/Progestin Contraceptive|"Participants received a combination oral contraceptive for 3 28-day cycles during the study.~A single 140 mg dose of erenumab was administered subcutaneously to the abdomen on day 10 of cycle 3 by a healthcare provider."
62556636|NCT04186312|EXPERIMENTAL|Immediate Treatment|Cognitive-Behavioral Treatment program known as ACCESS
62556637|NCT04186312|OTHER|Delayed Treatment|Allowed to receive treatment as usual during study, then received ACCESS after delay of two-semesters
62754564|NCT06608446|ACTIVE_COMPARATOR|Standard care|Standard care consists of the usual treatment according to current clinical practice, no structured physiotherapeutic interventions will be carried out which generally consists of the delivery of two booklets, with the aim of informing and educating, regarding the most frequent complications after breast cancer surgery and how to avoid its possible onset through the demonstration of exercises to be carried out at home, self-massage techniques for the scar, behaviors and lifestyle to be adopted immediately after surgery.
62754565|NCT03960580|ACTIVE_COMPARATOR|OPN-375 186 μg BID|OPN-375 186 μg BID x 24 Weeks
61986632|NCT02563678|ACTIVE_COMPARATOR|Volunteers, hyperbaric oxygen|Healthy adult volunteers will have blood drawn before and after a single hyperbaric chamber session.
61986633|NCT02563678|EXPERIMENTAL|Volunteers, normobaric pressure|Healthy volunteers will have their blood drawn before and after breathing 100% oxygen at atmospheric pressure (normobaric oxygen) for 120 minutes.
62378030|NCT02010567|EXPERIMENTAL|Chemoradiotherapy + Surgery|In Phase II, CRLX101 will be administered at the RP2D in combination with capecitabine and radiation in patients with locally advanced rectal cancer for a total of 5-6 weeks, depending on the total radiation dose. A total of 3 doses of CRLX101 will be administered every other week. Surgery will take place at least 6 weeks after the completion of chemoradiotherapy.
62378031|NCT03631849|EXPERIMENTAL|Patients with peri-implantitis|
62378032|NCT03631849|ACTIVE_COMPARATOR|Patients without peri-implantitis|
62556638|NCT02604095|EXPERIMENTAL|Melatonin|Take one table at bedtime.
62754566|NCT03960580|ACTIVE_COMPARATOR|OPN-375 372 μg BID|OPN-375 372 μg BID x 24 Weeks
61986634|NCT04727229|EXPERIMENTAL|Bupivacaine Hydrochloride|Injection of Bupivacaine Hydrochloride 0.5% near the stellate ganglion.
61986635|NCT04727229|PLACEBO_COMPARATOR|Normal Saline Solution|Injection of Normal Saline near the stellate ganglion
62378033|NCT03429166|EXPERIMENTAL|STAIR stands for Skills Training in Affective and Interpersonal Regulation|STAIR stands for Skills Training in Affective and Interpersonal Regulation a non-trauma-focused treatment
62378034|NCT03429166|ACTIVE_COMPARATOR|Present Centered Therapy|PCT , a non-trauma-focused treatment
62378035|NCT00397449|EXPERIMENTAL|1, 2, 3|
62378036|NCT01970735|EXPERIMENTAL|FSHD patient|
62378037|NCT02141529|ACTIVE_COMPARATOR|Unipolar PRF|Unipolar pulsed radiofrequency thermocoagulation, intraarticularly in knee joint, 42oC of temperature during ten minutes
62378038|NCT02141529|EXPERIMENTAL|Bipolar PRF|Bipolar pulsed radiofrequency thermocoagulation, intraarticularly in knee joint, 42oC of temperature during ten minutes
62378039|NCT00926562|EXPERIMENTAL|Iopromide|Drug: Ultravist 370 mgl/ml, injection of intra-artery during cardiac interventional operation
62378040|NCT00926562|ACTIVE_COMPARATOR|Iodixanol|Drug: Visipaque 320 mgl/ml, injection of intra-artery
62754567|NCT03960580|PLACEBO_COMPARATOR|Placebo|Matching Placebo BID x 24 Weeks
62754568|NCT03096093|EXPERIMENTAL|Immunotherapy - pancreatic cancer|Intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with pancreatic or haematological cancer. Treatment will run concurrently with standard chemotherapy.
62754569|NCT03096093|EXPERIMENTAL|Immunotherapy - other late stage cancers|Intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with other late stage cancers, not receiving any other standard treatment.
62754570|NCT02456636|ACTIVE_COMPARATOR|Fee-for-Service Model (FFS, In clinic individual visits)|Participants will receive individual counseling from their physician or other healthcare professional during regular clinic visits.
62754571|NCT02456636|ACTIVE_COMPARATOR|Patient Centered Medical Home (PCMH, In clinic group visits)|Participants will take part in group weight-management counseling during in-person group visits; later sessions may be conducted via group telephone calls if the group prefers.
62378041|NCT05594667|EXPERIMENTAL|PEX010|25mg of PEX010 (one-time administration)
62378042|NCT00381706|EXPERIMENTAL|Arm A (ECF + cetuximab)|Patients receive cetuximab 400 mg/m\^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m\^2 IV over 60 minutes thereafter. Patients receive cetuximab IV on days 1, 8 and 15. Patients receive epirubicin 50 mg/m\^2 IV after cetuximab on day 1 followed by cisplatin 60 mg/m\^2 IV over 60 minutes. On days 1-21, patients receive 5-fluorouracil 200 mg/m\^2/day continuous IV infusion. Treatment repeats every 21 days in the absence of disease progression and unacceptable toxicity.
62378043|NCT00381706|EXPERIMENTAL|Arm B (IC + cetuximab)|Patients receive cetuximab 400 mg/m\^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m\^2 IV over 60 minutes thereafter. Patients receive cetuximab on days 1, 8 and 15. Patients receive cisplatin 30 mg/m\^2 IV over 30 minutes on days 1 and 8 after cetuximab. Patients also receive irinotecan 65 mg/m\^2 IV over 90 minutes on days 1 and 8 after receiving cisplatin.Treatment repeats every 21 days in the absence of disease progression and unacceptable toxicity.
62378044|NCT00381706|EXPERIMENTAL|ARM C (FOLFOX + cetuximab)|Patients receive cetuximab 400 mg/m\^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m\^2 IV over 60 minutes thereafter. Patients receive cetuximab on days 1 and 8. On Day 1, patients also receive oxaliplatin 85 mg/m\^2 IV over 120 minutes and leucovorin 400 mg/m\^2 IV over 120 minutes either concurrently with oxaliplatin via a separate infusion line or post oxaliplatin administration. Following leucovorin, patients will receive 5-fluorouracil 400 mg/m\^2 IV bolus injection, then 5-fluorouracil 2400 mg/m\^2 IV infusion over 46-48 hours. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
62378045|NCT02094196||Controls, highrisk for AD|Community-based ad-hoc participants, high risk for alcohol dependence, matched to inpatients by sociodemographics
62378046|NCT02094196||Controls, low risk for AD|Community-based ad-hoc participants, low risk for alcohol dependence, matched to inpatients by sociodemographics
62378047|NCT02094196||Alcohol detoxification|Inpatients with alcohol dependence from local psychiatric hospital wards (18-65 years old)
62754572|NCT02456636|ACTIVE_COMPARATOR|Disease Management (DM, Phone group visits)|Participants will take part in group weight-management counseling by telephone.
62754573|NCT01275612|EXPERIMENTAL|Cell therapy|
62754574|NCT04137653|EXPERIMENTAL|nab-Paclitaxel group|749 patients will be assigned into nab-Paclitaxel group.
62754575|NCT04137653|ACTIVE_COMPARATOR|paclitaxel group|749 patients will be assigned into paclitaxel group
62754576|NCT01007929|EXPERIMENTAL|1|14C-AZD1236
62754577|NCT01844011|EXPERIMENTAL|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart.
62754578|NCT01844011|NO_INTERVENTION|Education only|All women enrolled in the trial will receive a paper-based kick count chart, will be educated in the use of the kick count chart, and will be instructed to keep track of their fetal movements on a daily basis.
62754579|NCT00834990|EXPERIMENTAL|1|
62378048|NCT06246864|EXPERIMENTAL|Hydrocolloid dressing group|The premature baby's Oragastric tube will be fixed using a hydrocollaid dressing. Orogastric fixation will not be changed for 24 days. After 24 hours, the fixed patch will be removed using a silicone-based spray remover.
62378049|NCT06246864|ACTIVE_COMPARATOR|Hypoallergenic Flexible Patch group|Oragastric tube of premature baby Hypoallergenic Flexible Patch will be detected using . Orogastric fixation will not be changed for 24 days. After 24 hours, the fixed patch will be removed using a silicone-based spray remover.
62378050|NCT02310724||TODAY cohort|All subjects randomized to the TODAY clinical trial are eligible to participate in T2P2. The study performs long-term observation only and administers no treatment, care, or management.
62378051|NCT00088595|EXPERIMENTAL|Pasireotide|
62378052|NCT05275127||Q-SRP|Evaluation of changes of gingival crevicular fluid miRNA
62378053|NCT05275127||FM-SRP|Evaluation of changes of gingival crevicular fluid miRNA
62378054|NCT05124600|EXPERIMENTAL|SavvyHealth|Participants will use the new app, SavvyHealth, for 21 days.
62378055|NCT05124600|NO_INTERVENTION|Waiting list|Participants will be on the waiting list.
62378056|NCT05061758|EXPERIMENTAL|Four injections of 250µg LY3056480|"The treatment will be given transtympanically over the course of 2-7 weeks, according to dosing regimens below.~* Group 1 - Regimen 1. Day 1, Day 4, Day 8, Day 11~* Group 2 - Regimen 2. Weekly~* Group 3 - Regimen 3. Every two weeks"
62754580|NCT00834990|ACTIVE_COMPARATOR|2|
61986636|NCT05049070|EXPERIMENTAL|GoEyes|GoEyes Self administered refraction test + Standard of care refraction test
61986637|NCT00369512|EXPERIMENTAL|Erlotinib|Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
62378057|NCT05061758|PLACEBO_COMPARATOR|Four injections of placebo|"The treatment will be given transtympanically over the course of 2-7 weeks, according to dosing regimens below.~* Group 1 - Regimen 1. Day 1, Day 4, Day 8, Day 11~* Group 2 - Regimen 2. Weekly~* Group 3 - Regimen 3. Every two weeks"
62378058|NCT02901106|EXPERIMENTAL|Patient with recurring-remitting MS|
62378059|NCT02545049|EXPERIMENTAL|BAY94-8862|Finerenone tablet
62378060|NCT02545049|PLACEBO_COMPARATOR|Placebo|Matching placebo
62378061|NCT00424099|EXPERIMENTAL|Group 1: Methylphenidate + NTI|Methylphenidate 5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days + Nursing Telephone Intervention (NTI). NTI calls from study nurse 3 times weekly to ask about side effects and other symptoms.
62378062|NCT00424099|PLACEBO_COMPARATOR|Group 2: Placebo + NTI|Placebo capsule orally as needed for 14 days + NTI, calls from study nurse 3 times weekly to ask about side effects and other symptoms.
62378063|NCT00424099|EXPERIMENTAL|Group 3: Methylphenidate + Non NTI|Methylphenidate 5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days + Non NTI, calls from research staff 3 times weekly.
62378064|NCT00424099|EXPERIMENTAL|Group 4: Placebo + Non NTI|Placebo capsules as needed with Non NTI, calls from research staff 3 times weekly.
62378065|NCT06037265|OTHER|Total Sample Size|The total sample size will be up to 40 subjects that complete the full intended implant durations of either 7 days (n=up to 10) or60 days (n=up to 30). Group 1 patients will be enrolled first and at least 5 patients will complete the 7-day implant duration before Group 2 patients begin enrollment. Group 1 and Group 2 subjects can be screened in parallel. Group 2 enrollment will start immediately after at least 5 subjects in Group 1 have successfully completed the 7-day implantation period. Study subjects will have the PortIO device implanted by a qualified physician (Table 5) and then undergo prescribed, standard of care infusion regimen as determined by their treating physician over either the 7-day or the 60-day period. After the intended implant duration and use during the implant period, the device will then be removed and the subject will be followed for safety at 30 days after explant.
62556639|NCT02570802|OTHER|ultrasound of peripheral nerves|Ultrasonographic examination
62754581|NCT06605443||Large/giant congenital melanocytic nevi|Patients over 18 years of age with a large/giant congenital melanocytic nevi with an estimated size of 20 cm or more.
62378066|NCT05392101|EXPERIMENTAL|Patient group: 360mg deferasirox|Patient group receiving treatment
62378067|NCT01849328||Breast Cancer|
62378068|NCT01849328||Healthy|
62378069|NCT05898854|EXPERIMENTAL|Gastric or gastro-esophageal junctioncancer|Patients with biopsy verified gastric or gastro-esophageal junction cancer undergo FAPI PET/CT in addition to conventional imaging
62378070|NCT04239573|EXPERIMENTAL|Arm I (low intensity surveillance)|Patients undergo MRI or CT at the beginning of the trial and again in 1 year. Following the first year, patients with no abnormalities repeat MRI or CT every 2 years. Patients with positive imaging features on MRI and CT at 1 or 2 years and with negative EUS, repeat MRI or CT in 1 year. Patients with negative imaging repeat MRI or CT in 2 years.
62556640|NCT03727789|EXPERIMENTAL|Treatment (CBL0137)|Patients receive FACT complex-targeting curaxin CBL0137 IA over 15 minutes.
62754582|NCT06605443||Melanoma|Patients of either sex over 18 years old with histopathological confirmed melanoma. We will include patients with stage II, III or IV according to the American Joint Committee on Cancer (AJCC) staging.
62754583|NCT05839340|EXPERIMENTAL|Neurally Adjusted Ventilatory Assist|Infants will first be ventilated with NAVA for four hours. Following this, they will undergo a 20-minute stabilisation period prior to ventilating with assist control ventilation (ACV).
62754584|NCT05839340|EXPERIMENTAL|Assist Control Ventilation (ACV)|Infants will first be ventilated with ACV for four hours. Following this, they will undergo a 20-minute stabilisation period prior to ventilating with non-invasive neurally adjusted ventilatory assist.
62754585|NCT02791191|EXPERIMENTAL|Dose 1 LY3202626|3 mg LY3202626 given orally once daily for 52 weeks.
62754586|NCT02791191|EXPERIMENTAL|Dose 2 LY3202626|12 mg LY3202626 given orally once daily for 52 weeks.
62754587|NCT02791191|EXPERIMENTAL|Placebo|Placebo given orally once daily for 52 weeks.
62754588|NCT06287593|OTHER|group A|For patients with negative ctDNA after 3 weeks of neoadjuvant TKI treatment, radical resection surgery will be performed after continuing TKI treatment for 9-12 weeks.
62754589|NCT06287593|OTHER|group B|For patients with positive ctDNA after 3 weeks of neoadjuvant TKI treatment, radical resection surgery will be performed after continuing TKI treatment for 9-12 weeks.
62754590|NCT06287593|OTHER|group C|For patients with positive ctDNA after 3 weeks of neoadjuvant TKI treatment, radical resection surgery will be performed after 3 cycles of TKI plus chemotherapy.
62754591|NCT06287593|OTHER|group D|For patients with positive ctDNA after 3 weeks of neoadjuvant TKI treatment, radical resection surgery will be performed after 3 cycles of sequential neoadjuvant PD-1 blockades plus chemotherapy.
62754592|NCT06118541|EXPERIMENTAL|Vestibular Rehabilitation therapy|"The experimental group received a vestibular rehabilitation exercise program, The assessment tools used in this study included the Chinese version of the Dizziness Handicap Inventory (DHI), Dizziness Visual Analog Scale (DVAS), 16-item Post-Concussion Symptom Checklist (PCSC), Beck Anxiety Inventory (BAI), Traumatic Brain Injury Quality of Life (TBI-QOL) questionnaire, and a standing balance test. Measurements were taken at baseline and at weeks 2, 4, 8, and 12 post-intervention"
62754593|NCT06118541|EXPERIMENTAL|standard care|Monitor the patient's consciousness and limb muscle strength, give drugs according to the time point of administration, and educate the importance of early getting out of bed
62754594|NCT05699993|OTHER|IBI351+ itraconazole|Enrolled subjects were treated with IBI351 on an empty stomach on Day 1. Itraconazole was administered orally once daily after a standardized meal from Day 3 to Day 6. IBI351 and itraconazole were administered simultaneously on an empty stomach on Day 7. On Day 8, itraconazole was orally administered once after a standard meal.
62378071|NCT04239573|EXPERIMENTAL|Arm II (high intensity surveillance)|Patients undergo MRI or CT. Patients with 1-2 cm cyst undergo MRI or CT every 6 months for 1 year, then every 12 months for 2 years, and then every 24 months thereafter. Patients with 2-3 cm cyst undergo EUS within 6 months, and if EUS is negative, patients repeat MRI or CT in 1 year. If second EUS is negative, patients undergo alternate MRI or CT and EUS every 12 months. Patients with cyst \> 3 cm undergo EUS within 6 months, and if EUS is negative, patients undergo alternate MRI or CT with EUS every 3-6 months.
62378072|NCT04809649|EXPERIMENTAL|SUBA-itraconazole|Drug: SUBA-itraconazole Dosage Form: 65 mg capsules Dosage: 260 mg/day Frequency: 130 mg twice daily (BID) Duration: Up to 180 days
62378073|NCT00394277|EXPERIMENTAL|PEG-IFN 180 µg + Ribavirin 1200 mg|
62378074|NCT00394277|EXPERIMENTAL|PEG-IFN 180 µg + Ribavirin 1400/1600 mg|
62378075|NCT00394277|EXPERIMENTAL|PEG-IFN 360/180 µg + Ribavirin 1200 mg|
62378076|NCT00394277|EXPERIMENTAL|PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg|
62378077|NCT03685643|EXPERIMENTAL|Intervention - Dating application topic|The intervention will consist of four short videos with points of discussion, a scenario game, and a risk assessment tool regarding dating application usage.
62556641|NCT02566889|EXPERIMENTAL|Dose Escalation Group|Participants must have completed: a) recommended infliximab induction dosing regimen of 5 milligram (mg)/kilogram (kg) at Weeks 0, 2, and 6, followed by at least 1 maintenance doses of 5 mg/kg every 8 weeks (q8wk); or b) induction regimen with doses \>6 mg/kg and have received at least 2 maintenance doses of 5 mg/kg q8wk with clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose; or c) maintenance doses \>6 mg/kg within past 6 months and at least 2 maintenance doses of 5 mg/kg q8wk with clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose; d) must have lost clinical response, after first or subsequent q8wk maintenance dose of infliximab 5 mg/kg for participants who have completed the recommended infliximab induction dosing regimen or, after most recent (second or later) q8wk maintenance dose of infliximab 5 mg/kg for participants with an induction regimen with doses \>6 mg/kg or with previous maintenance doses \>6 mg/kg.
62556642|NCT02566889|EXPERIMENTAL|Reference Group|Participants must have completed: a) the recommended infliximab induction dosing regimen of 5 mg/kg at Weeks 0, 2, and 6, and have maintained a stable clinical response to infliximab after at least 1 maintenance doses of 5 mg/kg q8wk; or b) an induction regimen with doses \>6 mg/kg and have received at least 2 maintenance doses of 5 mg/kg q8wk and have maintained clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose 5 mg/kg maintenance dose; or c) maintenance doses \>6 mg/kg within the past 6 months and at least 2 maintenance doses of 5 mg/kg q8wk and have maintained a clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose 5 mg/kg maintenance dose.
62556643|NCT00825760|OTHER|1|Single treatment
62556644|NCT00825760|OTHER|2|12 treatments, once weekly
62556645|NCT02790437|EXPERIMENTAL|Treatment IdeS|IdeS intravenous infusion
62556646|NCT05706103|EXPERIMENTAL|Specific skilled motor training|13 weeks of treatment, with 18 supervised treatment sessions in combination with an individualized home-exercise program. This group will first receive low-load training (i.e. at 25-30% of the individual's repetition maximum, sessions 1-9) followed by high-load training (i.e. at 40-60% of the individual's one repetition maximum, sessions 10-18).
62556647|NCT05706103|ACTIVE_COMPARATOR|General extension training|13 weeks of treatment, with 18 supervised treatment sessions in combination with an individualized home-exercise program. This group will first receive low-load training (i.e. at 25-30% of the individual's repetition maximum, sessions 1-9) followed by high-load training (i.e. at 40-60% of the individual's one repetition maximum, sessions 10-18).
62754595|NCT05699993|OTHER|IBI351+ dextromethorphan|Enrolled subjects were orally administered dextromethorphan on an empty stomach on Day 1. IBI351 and dextromethorphan were orally administered simultaneously on an empty stomach on Day 3, followed by IBI351 12 hours later.
62378078|NCT03685643|PLACEBO_COMPARATOR|Control - Health and exercise topic|The control will consist of four short videos with discussion points and an interaction game regarding exercise and healthy living tips.
62378079|NCT04921969|EXPERIMENTAL|Ruxolitinib (1.5% Cream)|Study drug will be administered twice daiily.
62378080|NCT04921969|EXPERIMENTAL|Ruxolitinib (0.75% cream)|Study drug will be administered twice daily.
62378081|NCT04921969|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle cream will be administered twice daily.
62378082|NCT00646191|ACTIVE_COMPARATOR|A|
62378083|NCT00646191|ACTIVE_COMPARATOR|B|
62378084|NCT00646191|ACTIVE_COMPARATOR|C|
62378085|NCT02822924|OTHER|Prostate artery embolization treatment|Prostatic artery embolization (PAE) as a new treatment technology is a potentially promising, minimally invasive alternative procedure for BPH, which has been shown to be safe and effective in both animal models and clinical trials.
62378086|NCT03644173|EXPERIMENTAL|Study arm - PREP Intervention|Participants receiving the coaching intervention
62378087|NCT05773716|EXPERIMENTAL|Electroacupuncture plus pelvic floor muscle training|Participants in this arm will receive pelvic floor muscle training using unified standards, and electroacupuncture therapy for 6 weeks.
62378088|NCT05773716|SHAM_COMPARATOR|Sham electroacupuncture plus pelvic floor muscle training|Participants in this arm will receive pelvic floor muscle training using the same approach as that in experimental group, and sham electroacupuncture for 6 weeks.
62378089|NCT05703490||Cognitive Impaired Group|older adults (age 50 years and older) with either clinical diagnosis of cognitive impairment or determined to have cognitive impairment based on Montreal Cognitive Assessment (MoCA) Test, score of 26 or lower
62378090|NCT05703490||Cognitive Intact Group|Older adults age matched with Cognitive Impaired Group with MoCA score of greater than 26
62378091|NCT05299216|EXPERIMENTAL|Group A|Group A will receive Manual Diaphragm Technique in addition to Conventional Physical Therapy. Treatment will be provided for a total of four weeks, thrice a week.
62378092|NCT05299216|ACTIVE_COMPARATOR|Group B|Group B will receive Conventional Physical Therapy and Sham Diaphragm Technique. Conventional Physical Therapy group comprises electrotherapeutic treatment and exercise plan. Treatment will be provided for a total of four weeks, thrice a week.
62378093|NCT01785914||1|
62556648|NCT03241992|EXPERIMENTAL|MyChart Intervention|Subjects in the control arm will be enrolled in MyChart during the consent process and receive MyChart Disease Specific targeted IBD information and reminders as well as mood questionnaires. At week 2 subjects will receive reminders to get vaccinated with another reminder sent at 3 months. At month 1, subjects will receive the Promis Adult Short Form questionnaires for depression and anxiety through MyChart. If a subject is identified as having mild, moderate or a severe mood disorder a message will be sent to their gastroenterologist with a recommendation to discuss the results with the patient and to consider a referral to mental health services. Subjects will also receive educational information about IBD every 6 weeks along with reminders to take their medications.
62556649|NCT03241992|NO_INTERVENTION|Usual Care|Subjects in the control arm will be enrolled in MyChart during the consent process if they are not previously enrolled. Enrollment in MyChart will provide them with access to their medical record and the ability to send or receive messages with their gastroenterologist or any other providers they see at our institution. For patients with IBD it is standard practice to discuss medication adherence, vaccinations, and their mood at each appointment. Subjects will receive generic, non-IBD related messages through MyChart.
62556650|NCT01695616|PLACEBO_COMPARATOR|Placebo|Patients enrolled in this arm will take a tablet twice a day
62556651|NCT01695616|ACTIVE_COMPARATOR|Passiflora incarnata and isoflavona combination|Patients enrolled in this arm will take a tablet twice a day
62556652|NCT04366492|OTHER|persons in prison|
62556653|NCT05289037|EXPERIMENTAL|Arm 01|mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; \> / = 65 years (\~45% in \> / = 65 years) N=100
62378094|NCT00428285|EXPERIMENTAL|Single Arm|
62378095|NCT00536094|EXPERIMENTAL|1|Participants will receive cognitive behavioral therapy for anxiety that includes exposure
62378096|NCT00536094|ACTIVE_COMPARATOR|2|Participants will receive treatment as usual as delivered by school-based clinicians
62378097|NCT04837690||UEMR|
62378098|NCT05143736||Modeling cohort|The population enrolled at the intensive care unit of Zhujiang Hospital of Southern Medical University in Guangdong Province, China will be used as a modeling cohort.For the patients in this cohort, the nasal and fecal specimens and related clinical information will collected to construct the prediction model.
62378099|NCT05143736||validation cohort|The population enrolled at the intensive care unit of Dongguan People's Hospital in Guangdong Province, China will be used as a validation cohort.
62378100|NCT03678506|EXPERIMENTAL|Positive D-Dimer|At the first positive D-dimer results (during anticoagulation or after its temporary withdrawal) the patients are invited to assume Eliquis (apixaban) 2.5 mg twice daily, and continue this therapy for the following 18 months.
62556654|NCT05289037|EXPERIMENTAL|Arm 02|0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; \> / = 65 years (\~45% in \> / = 65 years) N=100
62556655|NCT05289037|EXPERIMENTAL|Arm 03|0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; \> / = 65 years (\~45% in \> / = 65 years) N=100
62378101|NCT03678506|NO_INTERVENTION|Negative D-Dimer|Patients with persistently negative results at the four serial D-dimer measurements, stay definitively without anticoagulation and discouraged to resume any antithrombotic drug for secondary VTE prevention.
62378102|NCT03483012|EXPERIMENTAL|Atezolizumab + Stereotactic radiosurgery (SRS)|"* Atezolizumab administered intravenously once every 3 weeks~* Stereotactic radiosurgery (SRS) begin within 14 days after brain MRI obtained"
62378103|NCT04367649|EXPERIMENTAL|Hall technique|
62378104|NCT04367649|ACTIVE_COMPARATOR|Atraumatic restorative treatment|
62378105|NCT04367649|SHAM_COMPARATOR|Conventional restorative treatment|
62378106|NCT02599324|EXPERIMENTAL|Cohort 1: Renal Cell Carcinoma (RCC)|"Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of everolimus to determine the recommended phase 2 dose (RP2D) of ibrutinib. (The RP2D was determined for each cohort separately.)~Phase 2: Participants receive ibrutinib at the RP2D determined in phase 1b in combination with everolimus."
62378107|NCT02599324|EXPERIMENTAL|Cohort 2: Urothelial Carcinoma (UC)|"Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of paclitaxel to determine the RP2D of ibrutinib. (The RP2D was determined for each cohort separately.)~Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b in combination with paclitaxel."
62378108|NCT02599324|EXPERIMENTAL|Cohort 3: Gastric Adenocarcinoma (GA or GC)|"Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of docetaxel to determine the RP2D of ibrutinib. (The RP2D was determined for each cohort separately.)~Phase 2: Participants receive docetaxel at the RP2D determined in Phase 1b in combination with docetaxel."
62378109|NCT02599324|EXPERIMENTAL|Cohort 4: Colorectal Adenocarcinoma (CRC)|"Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of cetuximab to determine RP2D of ibrutinib. (The RP2D was determined for each cohort separately.)~Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b in combination with cetuximab."
62378110|NCT02599324|EXPERIMENTAL|Cohort 5: Urothelial Carcinoma (UC) Ibrutinib|"Phase 1b: Participants receive ibrutinib at various dose levels to determine the RP2D of ibrutinib.(The RP2D was determined for each cohort separately.)~Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b."
62378111|NCT02599324|EXPERIMENTAL|Cohort 6: Urothelial Carcinoma (UC) With Pembrolizumab|"Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of pembrolizumab to determine the RP2D of ibrutinib. (The RP2D was determined for each cohort separately.)~Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b in combination with pembrolizumab."
62378112|NCT04647695|EXPERIMENTAL|IFN-beta 1b and remdesivir|a 5-day course of subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
62378113|NCT04647695|ACTIVE_COMPARATOR|Remdesivir|a 5-day course of IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
62378114|NCT06194721|EXPERIMENTAL|Cryotherapy|
62378115|NCT06194721|ACTIVE_COMPARATOR|Room temperature|
62378116|NCT03704090|ACTIVE_COMPARATOR|Control|Standard non-pharmacological intervention during 5 days after surgery.
62378117|NCT03704090|EXPERIMENTAL|Treatment|Occupational therapy intervention twice a day plus standard non-pharmacological prevention intervention during 5 days after surgery.
62378118|NCT02468804|EXPERIMENTAL|Parkinson's Disease Subjects, (rTMS)|The PD subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
62378119|NCT02468804|EXPERIMENTAL|Control Subjects (rTMS)|The control subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
62378120|NCT02468804|SHAM_COMPARATOR|Parkinson's Disease Subjects, (sTMS)|The PD subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
62754596|NCT05059821|EXPERIMENTAL|Experimental Personalized Cancer Vaccine|Patients with recurrent HCC after surgical resection and refractory to available line of treatment will receive Personalized peptide based vaccine with autologous heat shock protein 70 and autologous activated monocytes
62754597|NCT04376047|EXPERIMENTAL|Reverse Trendelenburg position group|Obese critically ill patients who are positioned in reverse Trendelenburg position
62754598|NCT04376047|ACTIVE_COMPARATOR|Semi-recumbent position group|Obese critically ill patients who are positioned in semi-recumbent position which is the routine ICU position
62378121|NCT02468804|SHAM_COMPARATOR|Control Subjects (sTMS)|The control subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
62378122|NCT01641341|PLACEBO_COMPARATOR|Placebo capsule|Placebo capsule (sugar pill with no active medication)
62378123|NCT01641341|ACTIVE_COMPARATOR|Active treatment|"Active treatment will consist of the following interventions:~1. Bowel Dysbiosis - probiotics Bifidobacterium infantis,~2. Maldigestion/Malabsorption - Pancrelipase~3. Parasitic infection/presence - Nitazoxanide"
62754599|NCT03496350|EXPERIMENTAL|Internet CBT|Internet-based cognitive behavioural therapy in Arabic with therapeutic guidance through email.
62754600|NCT03496350|NO_INTERVENTION|Wait-list|Wait-list control
62754601|NCT04418011|ACTIVE_COMPARATOR|Active 10 Hz rTMS|Active treatment will be targeted to an intensity that is 120% of the resting motor threshold. Stimulation will be delivered at 10 Hz according to conventional FDA-approved parameters (4 s on and 26 s off; 3000 pulses per session; total duration 37.5 mins) .
62754602|NCT04418011|ACTIVE_COMPARATOR|Active iTBS|Active iTBS will be targeted to an intensity that is 120% of the resting motor threshold. Stimulation will be delivered in triplet 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 9 seconds.
62754603|NCT04418011|SHAM_COMPARATOR|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters as either 10 Hz rTMS or iTBS.~For both active and sham stimulation, TMS coil positioning for each individual will be optimized by combining participant fMRI data, meta-analytic functional analysis, electric field modelling, and real-time neuronavigation."
62754604|NCT05357989|EXPERIMENTAL|10 mg buntanetap/posiphen|Buntanetap/posiphen 10 mg oral capsule with daily administration for a period of 6 months
62754605|NCT05357989|EXPERIMENTAL|20 mg buntanetap/posiphen|Buntanetap/posiphen 20 mg oral capsule with daily administration for a period of 6 months
62754606|NCT05357989|PLACEBO_COMPARATOR|Placebo|Placebo oral capsule with daily administration for a period of 6 months
62754607|NCT06607068||GIObDM - Older women with obesity and type 2 diabetes mellitus|Obesity will be assessed using the Body Mass Index (BMI), with older women being considered obese if they have a BMI above 30 km/m² (OPAS, 2002)
62754608|NCT06607068||GIOb - Older women with obesity and without type 2 diabetes mellitus|Obesity will be assessed using the Body Mass Index (BMI), with elderly women being considered obese if they have a BMI above 30 km/m² (OPAS, 2002)
62754609|NCT06607068||GIDM - Older women without obesity and with type 2 diabetes mellitus|The groups with DM2 will include elderly women who have already been medically diagnosed with DM2 , have been using a hypoglycemic/antidiabetic medication for at least 6 months and have fasting blood glucose ≥ 126mg/dL and/or HbA1c ≥ 6.5% in a blood test in the last 6 months.
62754610|NCT06607068||GIEut - Eutrophic older women|For the group of eutrophic older women, they must have a BMI ≥ 23 and ≤ 28 kg/m² (OPAS, 2002). The medications used by all participants will be surveyed, as well as their dosages and daily consumption.
62378124|NCT05557240|EXPERIMENTAL|NeoPep Vaccine1and 2 plus polyICLC concurrent to TMZ|
62378125|NCT02875366|PLACEBO_COMPARATOR|Placebo|Placebo matched to LUM/IVA fixed-dose combination tablet orally every 12 hours (q12h) for 24 weeks.
62556656|NCT05289037|EXPERIMENTAL|Arm 04|0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; \> / = 65 years (\~45% in \> / = 65 years) N=100
62556657|NCT05289037|EXPERIMENTAL|Arm 05|0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; \> / = 65 years (\~45% in \> / = 65 years) N=100
62556658|NCT05289037|EXPERIMENTAL|Arm 06|0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; \> / = 65 years (\~45% in \> / = 65 years) N=100
62556659|NCT05289037|EXPERIMENTAL|Arm 07|500 mcg/mL of BNT162b2 (Wildtype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; \> / = 65 years (\~45% in \> / = 65 years) N=50
62556660|NCT05289037|EXPERIMENTAL|Arm 08|500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; \> / = 65 years (\~45% in \> / = 65 years) N=50
62556661|NCT05289037|EXPERIMENTAL|Arm 09|500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; \> / = 65 years (\~45% in \> / = 65 years) N=50
62556662|NCT05289037|EXPERIMENTAL|Arm 10|500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; \> / = 65 years (\~45% in \> / = 65 years) N=50
62556663|NCT05289037|EXPERIMENTAL|Arm 11|500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; \> / = 65 years (\~45% in \> / = 65 years) N=50
62556664|NCT05289037|EXPERIMENTAL|Arm 12|500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; \> / = 65 years (\~45% in \> / = 65 years) N=50
62556665|NCT05289037|EXPERIMENTAL|Arm 13|500 mcg/mL CoV2 preS dTM-AS03 \[D614\] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; \> / = 65 years (\~45% in \> / = 65 years) N=50
62378126|NCT02875366|EXPERIMENTAL|LUM/IVA|LUM 400 milligram (mg)/IVA 250 mg fixed-dose combination tablet orally q12h for 24 weeks.
62378127|NCT00906932||Trachview videoscope, direct laryngoscopy|Each subject served as their own control - the Trachview videoscope and direct laryngoscopy was performed on by all subjects in a sequential fashion.
62556666|NCT05289037|EXPERIMENTAL|Arm 14|500 mcg/mL CoV2 preS dTM-AS03 \[B.1.351\] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; \> / = 65 years (\~45% in \> / = 65 years) N=50
62556667|NCT05289037|EXPERIMENTAL|Arm 15|500 mcg/mL CoV2 preS dTM-AS03 \[D614 + B.1.351\] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; \> / = 65 years (\~45% in \> / = 65 years) N=50
62556668|NCT05289037|EXPERIMENTAL|Arm 16|100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years; ( 45% in \> / = 49 years) N=100
62378128|NCT00906932||See above|See above
62556669|NCT05289037|EXPERIMENTAL|Arm 17|100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years; ( 45% in \> / = 49 years) N=100
62556670|NCT03499639|OTHER|patients with HCV and ESKD|Ombitasvir / Paritaprevir / Ritonavir/Ribavirin Oral Tablet
62556671|NCT02519374|PLACEBO_COMPARATOR|Placebo|Placebo
62378129|NCT04387591|EXPERIMENTAL|Fu's subcutaneous needling(FSN)|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
62378130|NCT04387591|ACTIVE_COMPARATOR|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in the total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
62556672|NCT02519374|ACTIVE_COMPARATOR|PROMITOR® dose 1|Investigational product dose 1
62556673|NCT02519374|ACTIVE_COMPARATOR|PROMITOR® dose 2|Investigational product dose 2
62556674|NCT02519374|ACTIVE_COMPARATOR|PROMITOR® dose 3|Investigational product dose 3
62556675|NCT00729937|EXPERIMENTAL|TMP/SMX vs. Placebo|Subjects with an acute uncomplicated cutaneous abscess will be randomized to receive either Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day) or 4 placebo pills (twice per day).
62754611|NCT03402971||healthy pregnant+healthy fetus|healthy pregnant women with suspected healthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
62754612|NCT03402971||non healthy pregnant|non healthy women with suspected healthy or unhealthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
62754613|NCT03402971||non healthy fetus|healthy or non healthy pregnant women with suspected non healthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
62754614|NCT01122342|EXPERIMENTAL|Vaginal Testosterone|Daily application of vaginal testosterone for 28 days.
62754615|NCT02222584||IBD group|patients with with inflammatory bowel disease who are visiting the out-patient clinic of severance hospital from July 2014 to February 2015
62556676|NCT00729937|EXPERIMENTAL|TMP/SMX vs. Clindamycin|Subjects with an acute uncomplicated wound infection will be randomized to receive Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day, with alternating 1 identical placebo pill, twice per day) or clindamycin (300 mg, four times per day, with 3 placebo pills on alternating doses).
62754616|NCT00760461|OTHER|Domperidone|
62754617|NCT04189653||General Ward Inpatients 2017-2018|ALL General Ward Inpatients on our Gastro-Enterology Surgery ward and Internal Medicine ward in the period august 1st 2017-august 31st 2018.
62754618|NCT04189653||General Ward Inpatients 2018-2019|ALL General Ward Inpatients on our Gastro-Enterology Surgery ward and Internal Medicine ward in the period august 1st 2018-august 31st 2019.
62754619|NCT01956630|EXPERIMENTAL|Genetically modified DCs plus CIK cells|Patients received four subcutaneous injections of 2-5×10e7 cells of DCs at the groin, axilla, and neck respectively on days 7, 9, 11, and 13 and i.v. infusions of 2-15×10e9 CIK on days 11 and 13 per cycle. The cycle was repeated until Wilms' tumor 1(WT1) turned negative by polymerase chain reaction(PCR) or graft-versus-host disease(GVHD) appeared.
62754620|NCT01956630|ACTIVE_COMPARATOR|Donor leukocyte infusions (DLI)|Patients received DLI at a dose of 2×10e7/kg, 5×10e7/kg and 1×10e8/kg cluster of differentiation 3(CD3)+ cells at months 1, 2 and 3 respectively unless GVHD appeared.
62754621|NCT02645851|EXPERIMENTAL|"PLR-induced SV changes based strategy"|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Stroke Volume (SV) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if SV changes ≥10%, or no administration otherwise. Measurement of beat-to-beat stroke volume by intraarterial pulse contour analysis using the PiCCO system (Pulsion, Germany) will be used to assess stroke volume changes. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
61986638|NCT05525156|EXPERIMENTAL|Aspirin arm|In addition to their antiretroviral regimen, participants self administer blister packaged enteric coated tablet of 75 mg aspirin (Cardisprin 75, Cosmos, Nairobi, Kenya) for 24 weeks at a dose of one tablet per day at evening times swallowed wholly with a glass of clean drinking water, preferably after a meal. All adults initiating antiretroviral therapy are prescribed the default combination of tenofovir (TDF) +lamivudine (3TC)+dolutegravir (DTG). Those with contraindications are alternatively prescribed abacavir+3TC+DTG or TDF +3TC+efavirenz and in special situations zidovudine+3TC+DTG
61986639|NCT05525156|PLACEBO_COMPARATOR|Placebo arm|In addition to their antiretroviral regimen, participants self administer blister packaged placebo (Cardisprin 75, Cosmos, Nairobi, Kenya) for 24 weeks at a dose of one tablet per day at evening times swallowed wholly with a glass of clean drinking water, preferably after a meal. The placebo has colour, shape and size similar to aspirin
61986640|NCT01429272|PLACEBO_COMPARATOR|Placebo & Placebo|Placebo for minocycline \& placebo for aspirin
61986641|NCT01429272|ACTIVE_COMPARATOR|minocycline & aspirin|Minocycline 100mg PO BID for 6 weeks \& Aspirin 81 mg PO BID for 6 weeks
61986642|NCT03795311|EXPERIMENTAL|Administration of chemotherapy molecules|"The treatment period is divided into 15-day periods.~Schema of the administration to the treatments which will proceed in the same way with each cycle:~Bevacizumab (5 mg/kg; during 30 min) + Oxaliplatine (85 mg/m2, during 2 hours) + Acide folinique (400 mg/m2) or Levofolinate de calcium (200 mg/m2) AND Irinotecan (during 2 hours) + 5-fluorouracile (2400 mg/m2 ; 46 hours) + Irinotecan (1 hour)"
61986643|NCT00335972|ACTIVE_COMPARATOR|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
62754622|NCT02645851|EXPERIMENTAL|"PLR-induced PP changes based strategy"|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Pulse Pressure (PP) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if PP changes ≥10%, or no administration otherwise. We will perform measurement of intraarterial blood pressure using vascular pressure transducers (Edwards Life Science, USA). Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
62754623|NCT02645851|OTHER|Usual Care|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the fluid bolus will be administered without measurement of any predictive index of fluid responsiveness. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
62378131|NCT01609491|ACTIVE_COMPARATOR|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) will be used in the syringes
62378132|NCT01609491|ACTIVE_COMPARATOR|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
62754624|NCT03697499|EXPERIMENTAL|fish oil and acute ozone exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
62378133|NCT01353066|ACTIVE_COMPARATOR|Intensive Medical Treatment|
62378134|NCT01353066|EXPERIMENTAL|Intensive medical treatment (IMM)+RYGBP|
62378135|NCT04262557|EXPERIMENTAL|Sunrise+PSG|PSG and Sunrise® will be set at the patient's home by IC@dom. The first night, the patient will be equipped by both PSG and Sunrise® and only by the Sunrise® for the two following nights.
62754625|NCT03697499|SHAM_COMPARATOR|fish oil and shame exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
62754626|NCT03697499|PLACEBO_COMPARATOR|soy oil and acute ozone exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
62754627|NCT03697499|OTHER|soy oil and shame exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
62754628|NCT03860012|EXPERIMENTAL|Folic Acid 800 mcg once weekly|Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
62754629|NCT01310400|EXPERIMENTAL|Inflexal 0.5 mL|
62754630|NCT01310400|EXPERIMENTAL|Inflexal 0.25 mL|
61986644|NCT00335972|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
61986645|NCT01782807|NO_INTERVENTION|Hysterectomy|Hysterectomy without oophorectomy or salpingectomy
61986646|NCT01782807|EXPERIMENTAL|Hysterctomy with salpingectomy or fimbriectomy|Salpingectomy or Fimbriectomy
62754631|NCT01310400|EXPERIMENTAL|Agrippal 0.25 mL|
62754632|NCT03641248|EXPERIMENTAL|Enteric coated Devil's Claw|H. procumbens 100 mg in enteric coated capsules
62754633|NCT03641248|ACTIVE_COMPARATOR|Non-enteric coated Devil's Claw|H. procumbens 100 mg in non-enteric coated capsules
62754634|NCT01937793|ACTIVE_COMPARATOR|effortful swallowing exercise|Subjects in the arm are asked to do the effortful swallowing exercise at home for 8 weeks. The training frequency is to exercise 3-4 days/week, 3 times/day, 10 repetitions per time. Besides the at home exercise, each subject is scheduled to meet the investigator at the hospital at weekly basis to discuss and review his/her exercise practice.
61986647|NCT02784990||Patient|
61986648|NCT05629832|EXPERIMENTAL|PTP group|
62378136|NCT05823428|ACTIVE_COMPARATOR|Rotator cuff debridement + acromioplasty|Group A was formed by performing rotator cuff debridement + acromioplasty in 18 patients.
62378137|NCT05823428|ACTIVE_COMPARATOR|Augmentation with subacromial bursa + acromioplasty|Group B was formed by performing augmentation with subacromial bursa + acromioplasty in 22 patients.
62754635|NCT01937793|ACTIVE_COMPARATOR|Mendelsohn swallowing exercise|Subjects in the arm are asked to do the Mendelsohn swallowing exercise at home for 8 weeks. The training frequency is to exercise 3-4 days/week, 3 times/day, 10 repetitions per time. Besides the at home exercise, each subject is scheduled to meet the investigator at the hospital at weekly basis to discuss and review his/her exercise practice.
62754636|NCT05061654|EXPERIMENTAL|Treatment arm|Eligible patients will be started on empiric ceftolozane-tazobactam in addition to standard care.
62754637|NCT02616497|ACTIVE_COMPARATOR|Aspirin|100mg/day
62754638|NCT02616497|ACTIVE_COMPARATOR|Triflusal|300mg twice or 600mg once daily
62754639|NCT02904005|OTHER|Depressed patients|Depressed patients with a recent suicide attempt or without any personal history of suicide attempt
62754640|NCT05467332||CRITICALLY ILL PATIENTS|CRITICALLY ILL PATIENTS AFTER INVASIVE MECHANICAL VENTILATION READY TO BE EXTUBATED.
62754641|NCT03627559||Pancreaticoduodenectomy patients|All patients undergoing pancreaticoduodenectomy receive a microdialysis catheter before skin closure and will be monitored postoperatively for lactate, pyruvate, glucose and glycerol in the microdialysate at certain timepoints
62754642|NCT05452369|EXPERIMENTAL|rhomboid intercostal plane block|as in intervention description
62754643|NCT05452369|EXPERIMENTAL|Erector spinae plane block|As in intervention description
62754644|NCT00958464||1|MRI protocol on 2 separate occasions
62754645|NCT02227173|EXPERIMENTAL|Single-Sequence, A B C|"Treatment A:~Single oral dose of montelukast, flurbiprofen, and digoxin on Day 1~Treatment B:~BMS-986020 orally twice daily (BID) on Day 8 through Day 10~Treatment C:~BMS-986020 orally BID, single oral dose of montelukast, flurbiprofen, and digoxin on Day 11; BMS-986020 BID on Day 12 through Day 17"
62754646|NCT02813668|EXPERIMENTAL|Lifestyle Intervention Training Program|Participants at risk for developing diabetes or with unmedicated diabetes will participate in a lifestyle intervention training program. Individuals in the training program, as well as un-enrolled workers at the study sites, will be exposed to positive changes at the worksite to promote increased physical activity and healthier diets.
62754647|NCT00945061|EXPERIMENTAL|Intraoperative radiation therapy|Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.
62754648|NCT00945061|EXPERIMENTAL|Intracavitary balloon brachytherapy|Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.
62754649|NCT00468676|ACTIVE_COMPARATOR|B|Treatment as usual
62754650|NCT00468676|EXPERIMENTAL|A|Case management intervention
62754651|NCT02298179|EXPERIMENTAL|RSV F 45 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine \[45 μg\], with no adjuvant.
62754652|NCT02298179|EXPERIMENTAL|RSV F 45 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine \[45 μg\], with aluminum hydroxide adjuvant.
62754653|NCT02298179|EXPERIMENTAL|RSV F 45 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine \[45 μg\], with MF59 adjuvant.
62754654|NCT02298179|PLACEBO_COMPARATOR|Placebo 1 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine \[45 μg\], Cohort 2: middle dosage of RSV F subunit vaccine \[90 μg\], and Cohort 3: high dosage of RSV F subunit vaccine \[135 μg\]). This placebo group belongs to Cohort 1.
62754655|NCT02298179|EXPERIMENTAL|RSV F 90 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine \[90 μg\], with no adjuvant.
62754656|NCT02298179|EXPERIMENTAL|RSV F 90 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine \[90 μg\], with aluminum hydroxide adjuvant.
62754657|NCT02298179|EXPERIMENTAL|RSV F 90 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine \[90 μg\], with MF59 adjuvant.
62754658|NCT02298179|PLACEBO_COMPARATOR|Placebo 2 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine \[45 μg\], Cohort 2: middle dosage of RSV F subunit vaccine \[90 μg\], and Cohort 3: high dosage of RSV F subunit vaccine \[135 μg\]). This placebo group belongs to Cohort 2.
62754659|NCT02298179|EXPERIMENTAL|RSV F 135 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine \[135 μg\], with no adjuvant.
62754660|NCT02298179|EXPERIMENTAL|RSV F 135 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine \[135 μg\], with aluminum hydroxide adjuvant.
62754661|NCT02298179|EXPERIMENTAL|RSV F 135 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine \[135 μg\], with MF59 adjuvant.
62754662|NCT02298179|PLACEBO_COMPARATOR|Placebo 3 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine \[45 μg\], Cohort 2: middle dosage of RSV F subunit vaccine \[90 μg\], and Cohort 3: high dosage of RSV F subunit vaccine \[135 μg\]). This placebo group belongs to Cohort 3.
62754663|NCT00923416||Prostate Cancer|
62754664|NCT06232460|EXPERIMENTAL|H80|5g, 10g and 20g dose escalation
62754665|NCT00560248||I|Patients presenting to the Emergency Department with chest pain suspected to be of cardiac origin.
61986649|NCT05629832|NO_INTERVENTION|Control group|
61986650|NCT03025542|EXPERIMENTAL|Treatment Arm 1|Subjects randomized in this arm will receive a combination of Bimekizumab and Placebo injections.
62754666|NCT03164317|ACTIVE_COMPARATOR|Intervention|Trained NCC together with electronic decision support system
62754667|NCT03164317|OTHER|Control|No trained NCC and electronic decision support system
62754668|NCT00002849|EXPERIMENTAL|induction and maintenance|dexamethasone induction followed by alpha interferon maintenance
62378138|NCT03581565|ACTIVE_COMPARATOR|Technique I|"Loading of a zinc polycarboxylate (with the requirements of ISO 9917) cement to fulfill the crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): placement of mixture into crown using a heidemann Spatula Setting Time (intraoral): 2-8 minutes"
62754669|NCT02337530|ACTIVE_COMPARATOR|Arm A|"Selumetinib: 75mg/ bid PO given on days 2-19 Pemetrexed: 500mg/m\^2 \& Cisplatin or Carboplatin\*: AUC6: 75mg/m\^2 given on day 1 Schedule = q 21 days~\*Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
61986651|NCT03025542|EXPERIMENTAL|Treatment Arm 2|Subjects randomized in this arm will receive Bimekizumab injections.
61986652|NCT04804397|EXPERIMENTAL|Sucrose|Sucrose: 1l sucrose sweetened soft drink per day for 8 weeks (1650 KJ, 97g carbohydrate per day) as 4 25cl drinks
62378139|NCT03581565|ACTIVE_COMPARATOR|Technique II|"Loading of a zinc polycarboxylate (with the requirements of ISO 9917) to fill the coronal half of the crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): placement of mixture into crown using a heidemann Spatula Setting Time (intraoral): 2-8 minutes"
62378140|NCT03581565|ACTIVE_COMPARATOR|Technique III|"Application of a zinc polycarboxylate (with the requirements of ISO 9917) to the axial walls of internal surface of crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): application of mixture into crown using a bonding applicator tip Setting Time (intraoral): 2-8 minutes"
62378141|NCT02807194|EXPERIMENTAL|general anesthesia|'lumbar disc herniation'
62378142|NCT02807194|EXPERIMENTAL|spinal anesthesia|'lumbar disc herniation'
62754670|NCT02337530|ACTIVE_COMPARATOR|Arm B|"Selumetinib: 75mg/ bid PO given on days 1-21 (continuous) Pemetrexed: 500mg/m\^2 \& Cisplatin\*: 75mg/m\^2 or carboplatin AUC 6 given on day 1 Schedule = q 21 days~\*\*Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
62754671|NCT02337530|ACTIVE_COMPARATOR|Arm C|"Selumetinib: NOT GIVEN Pemetrexed: 500mg/m\^2 \& Cisplatin\*: 75mg/m\^2 or carboplatin AUC6 given on day 1 Schedule = q 21 days~\*Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
62754672|NCT04537299|EXPERIMENTAL|Treatment Group|Subjects will receive treatment drug (Fisetin)
62754673|NCT04537299|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive placebo
62754674|NCT01599780||Full-Term Children|≥37 weeks gestation; 18 months old at the start of the study
61986653|NCT04804397|PLACEBO_COMPARATOR|Aspartame|Aspartame: 1l aspartame sweetened soft drink per day for 8 weeks as 4 25cl drinks
62378143|NCT01742039||b-blocker|
62378144|NCT01742039||amiodarone|
62378145|NCT01742039||atrial pacing|
62378146|NCT01742039||amiodarone plus atrial pacing|
62378147|NCT01742663|EXPERIMENTAL|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.)
62378148|NCT01742663|ACTIVE_COMPARATOR|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)
62378149|NCT01742663|PLACEBO_COMPARATOR|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.)
62378150|NCT00218569|EXPERIMENTAL|1|Naltrexone
62378151|NCT00218569|EXPERIMENTAL|2|Placebo
62378152|NCT03013426|EXPERIMENTAL|NVX-508|Administration of 1, 2 or 4 doses of NVX-508 at three dose levels; 0.05ml/kg. 0.1ml/kg and 0.17ml/kg in a 3 + 3 design.
62378153|NCT00608894|EXPERIMENTAL|LCP-Tacro|LCP-Tacro tablets(1,2,and 5mg tacrolimus)+ prednisone tablets(5mg)
62378154|NCT00608894|ACTIVE_COMPARATOR|Azathioprine|Azathioprine tablets(50mg)+ prednisone tablets(5mg)
62378155|NCT05714852|EXPERIMENTAL|Intervention|
62754675|NCT01599780||Preterm Children|\<33 weeks gestation; 18 months old at the start of the study
62754676|NCT02854488||Women Exposed to Yervoy (ipilimumab) During Pregnancy|Women Exposed to Yervoy (ipilimumab) During Pregnancy and the Children from These Pregnancies
62754677|NCT02062892|EXPERIMENTAL|Everolimus / Tacrolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
61986654|NCT05298748|OTHER|Ambient noise followed by Womb sound|At 34 weeks corrected age, preterm infants (29-33 weeks gestational age at birth), who are off respiratory support \>1.5 lpm, will be exposed to alternating 6-hour periods of a recording of ambient noise followed by commercially available womb sounds over a 24-hour period for a combined total of 12 hours of womb sounds and 12 hours of ambient noise.
62378156|NCT05714852|NO_INTERVENTION|Control|
62378157|NCT02105168|EXPERIMENTAL|Experimental arm|Blood sample Tumorous biopsy Healthy material sample
62378158|NCT02463331|ACTIVE_COMPARATOR|chloroquine plus prednisone|Chloroquine diphosphate 250mg/day associated to prednisone in variable doses
62378159|NCT02463331|EXPERIMENTAL|azathioprine plus prednisone|azathioprine in variable doses (50-150mg/day) associated to prednisone in variable doses
62378160|NCT04614194|EXPERIMENTAL|Arm A: Abemaciclib + Letrozole|Patient will take twice daily abemaciclib and daily letrozole (Arm A) for 2 weeks prior to your planned standard treatment for breast cancer. In addition to tests and procedures that are part of your standard care, you will have a biopsy and blood draw for study purposes prior to starting study treatment.
62378161|NCT04614194|EXPERIMENTAL|Arm B: Letrozole|Patient will take daily letrozole only (Arm B) according to treatment arm for 2 weeks prior to your planned standard treatment for breast cancer. In addition to tests and procedures that are part of your standard care, you will have a biopsy and blood draw for study purposes prior to starting study treatment.
62754678|NCT02062892|ACTIVE_COMPARATOR|Sirolimus / Tacrolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
62754679|NCT00524953|EXPERIMENTAL|I|10 patients after allogeneic BMT (non T-depleted).
62754680|NCT04195438|OTHER|Intervention Arm|CO and ABG Testing Arm
62754681|NCT03756363|EXPERIMENTAL|Non-solvent|Non-solvent use of a rotary retreatment system
62754682|NCT03756363|EXPERIMENTAL|Solvent|Solvent use in combination with a rotary retreatment system
61986655|NCT05298748|OTHER|Womb sound recordings followed by ambient noise|At 34 weeks corrected age, preterm infants (29-33 weeks gestational age at birth), who are off respiratory support \>1.5 lpm, will be exposed to alternating 6-hour periods of a recording of commercially available womb sounds followed by ambient noise over a 24-hour period for a combined total of 12 hours of womb sounds and 12 hours of ambient noise.
61986656|NCT01113632|EXPERIMENTAL|Ofatumumab 1000mg|Ofatumumab 300mg IV Day 1 followed by ofatumumab 1000mg weekly for a total of 8 weeks
61986657|NCT01113632|EXPERIMENTAL|Ofatumumab 2000mg|Ofatumumab 300mg IV Day 1 followed by ofatumumab 2000mg weekly for a total of 8 weeks
62754683|NCT00342173||Women in Costa Rica|Examining the natural history of HPV and cervical neoplasia in Costa Rican women.
62754684|NCT01688921|EXPERIMENTAL|STRATIS Needle-Free|Patients assigned to this arm will receive AFLURIA vaccine administered using the Stratis needle-free injection device.
62754685|NCT01688921|ACTIVE_COMPARATOR|Needle-Syringe|Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
62754686|NCT03913832|EXPERIMENTAL|sirolimus drug coated balloon (SCB)|Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB)
62754687|NCT03913832|ACTIVE_COMPARATOR|paclitaxel releasing coronary balloon catheter.|SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter
62754688|NCT06345794|EXPERIMENTAL|LY4100511 (DC-853) + Itraconazole|Single oral doses of LY4100511 (DC-853) with single and multiple doses of Itraconazole administered orally.
61986658|NCT03400319||Thoracic Aortic Aneurysm|Patients with Thoracic Aortic Aneurysm: Women: at the level of the sinus of valsalva ≥39mm, or ascending aorta ≥42mm. Men: at the level of the sinus of valsalva ≥44mm, or ascending aorta ≥46mm.
61986659|NCT03400319||No Thoracic Aortic Aneurysm|Patients without Thoracic Aortic Aneurysm: Women: at the level of the sinus of valsalva \<39mm, or ascending aorta \<42mm. Men: at the level of the sinus of valsalva \<44mm, or ascending aorta \<46mm.
62754689|NCT06345794|EXPERIMENTAL|LY4100511 (DC-853) + Fluconazole|Single oral doses of LY4100511 (DC-853) with single and multiple doses of fluconazole administered orally.
61986660|NCT03068247|EXPERIMENTAL|Interventional|10 weeks of duloxetine beginning at 30 mg per day for week 1, then 60 mg / day thereafter.
61986661|NCT03068247|PLACEBO_COMPARATOR|Placebo|10 weeks of placebo once daily for 1 week, then twice daily therafter.
62754690|NCT06345794|EXPERIMENTAL|LY4100511 (DC-853) + Carbamazepine|Single oral doses of LY4100511 (DC-853) with single and multiple doses of Carbamazepine administered orally.
61986662|NCT00908726|EXPERIMENTAL|Microemulsion propofol|
61986663|NCT00908726|ACTIVE_COMPARATOR|Lipid emulsion propofol|
61986664|NCT02826460||Liver Transplant Recipients|
61986665|NCT02701647|EXPERIMENTAL|25Hz-TT|Participants will receive 4s train of 25-Hz rTMS pulses with 50s inter-train interval, with an intensity of 80% resting motor threshold (RMT). Participant will receive a total of 600 rTMS pulses in 6 minutes for each hemisphere and a total of 1200 pulses followed by 30 minutes of treadmill training.
61986666|NCT02701647|EXPERIMENTAL|1Hz-TT|Participants will receive a total of 600 1-Hz rTMS pulses in 10 minutes for each hemisphere and a total of 1200 pulses ,with an intensity of 80% RMT, followed by 30 minutes of treadmill training.
61986667|NCT02701647|SHAM_COMPARATOR|Sham-TT|Sham rTMS will be applied over the same site as for real rTMS, however, with the cable of the coil disconnected. Another figure-of-eight coil using the same stimulation parameters (intensity, time, and frequency) as per 25Hz-TT group will be placed posterior to the subject's neck with the handle pointing backward to produce the same clicking sound effect. Sham rTMS will be followed by 30 minutes of treadmill training.
61986668|NCT02982967|OTHER|Physical Activity|Single-arm study with recreational physical activity intervention by 10 weeks (Duration: 60 minutes; Intensity: 65%-85% heart rate reserve; Frequency: 4 sessions/week).
62754691|NCT06605937||Grup 1|The children undergoing adenoidectomy and/or adenotonsillectomy whose parents will apply eustachian milking maneuver in the post-operative period.
62754692|NCT06605937||Grup 2|The children undergoing adenoidectomy and/or adenotonsillectomy whose parents will not apply eustachian milking maneuvers in the post-operative period.
62754693|NCT01367223|EXPERIMENTAL|solution of amino acids with glutamine|Group 1 as the experimental group who will be administered a solution of amino acids supplemented with glutamine
62754694|NCT01367223|OTHER|amino acids solution without glutamine|Group 2:control group will be administered a solution of amino acids (Aminoven Infant® or Vamin®) not supplemented with glutamine
62754695|NCT02204605|NO_INTERVENTION|Control|Visits are not videotaped
62754696|NCT02204605|EXPERIMENTAL|Videoed Patients|Patients will have their visit videotaped.
62754697|NCT03652857|EXPERIMENTAL|Apatinib Combined With Vinorelbine|Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer
62378162|NCT04420065|ACTIVE_COMPARATOR|Classical biventricular pacing|Commercially available LV-pacing capable CRT devices and quadripolar leads will be implanted. Right ventricular (RV) and right atrial (RA) leads will be placed according to standard practice. The LV lead will also be placed according to standard practice, targeting to a lateral, posterolateral, or anterolateral branch of the coronary sinus (CS). Interventricular delay programmed will be determined based on stroke volume maximization, and will be used as a criterion for BVP optimization. Atrioventricular delay optimization shall be automatically performed by the device.
61986669|NCT02158390|EXPERIMENTAL|Jasper-EMT with words and AAC|"Jasper-EMT with words and AAC~A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months."
61986670|NCT02158390|NO_INTERVENTION|Community treatment as usual|Children access educational and speech-language interventions available to them through schools and community resources.
62378163|NCT04420065|EXPERIMENTAL|Preferential left ventricular pacing|In G2 patients, an algorithm for preferential left ventricular pacing will be activated. Following selection of the dipole maximizing stroke volume during simultaneous LV-RV pacing, subsequent V-V delay optimization shall be delegated to the algorithm. Based on previous studies, a subgroup analysis of G2 will be performed, comparing those receiving ≥50% with those receiving \<50% preferential LV pacing evaluated over the total duration of the study (12 months).
62378164|NCT04507516||Water-only Fasting Cohort|Obese/overweight, non-diabetic patients undergoing elective water-only fasting treatment.
62378165|NCT02640430|ACTIVE_COMPARATOR|standard treatment|"Control group will be made of 20 COPD patients with severe and very severe airflow obstruction, mucus hypersecretion and reduced cough efficiency referred to standard pulmonary rehabilitation after acute exacerbation.~Control group will b treated with PEP-bottle over 10 daily sessions (20 minutes twice a day). Patients are asked to breath against a positive expiratory pressure determined by a column of water in a bottle (PEP Bolltle). PEP is one of the validated treatment used in the clearance of bronchial secretions in COPD patients.~All patients will receive regular treatment with inhaled bronchodilators and inhaled steroids according to current guidelines for their disease stage. Each patient will sign an informed consent form."
62378166|NCT02640430|EXPERIMENTAL|Free Aspire|"Experimental group will be made of 20 COPD patients with severe and very severe airflow obstruction , mucus hypersecretion , and reduced cough efficiency referred to standard pulmonary rehabilitation after acute exacerbation.~Patients are asked to use FREE ASPIRE Free Aspire is an electro-medical device which removes bronchopulmonary secretions noninvasively, without using a suction catheter and without generating airway pressure, positive or negative.~All patients will receive regular treatment with inhaled bronchodilators and inhaled steroids according to current guidelines for their disease stage. Each patient will sign an informed consent form."
62378167|NCT05063760|EXPERIMENTAL|TGCT patients - exercise|TGCT survivors, men, 25-55 yrs old, 3 and more years after successful treatment of TGCT, with the capacity to undergo aerobic-strength intervention assessed by cardiologist
62378168|NCT05063760|NO_INTERVENTION|TGCT patients - nonexercising controls|TGCT survivors, men, 25-55 yrs old, 3 and more years after successful treatment of TGCT, with the capacity to undergo aerobic-strength intervention assessed by cardiologist
62378169|NCT03564210|ACTIVE_COMPARATOR|Screen time permitted|Concussion sufferers permitted screen time for first 48 hours of recovery
62378170|NCT03564210|ACTIVE_COMPARATOR|Screen time abstain|Concussion sufferers asked to abstain from screen time for first 48 hours of recovery
62378171|NCT04605068|ACTIVE_COMPARATOR|Transverse preputial island flap (Duckett's technique)|72 patients (Group I) with penoscrotal hypospadias with chordee
62378172|NCT04605068|ACTIVE_COMPARATOR|Double-faced preputial flap (DFPF)|72 patients (Group II) with penoscrotal hypospadias with chordee
62378173|NCT04959786|EXPERIMENTAL|INTERVENTION ARM|
62378174|NCT04959786|NO_INTERVENTION|standard of care|
62378175|NCT04957745|EXPERIMENTAL|Visual confusion|Participants viewed peripheral targets in three different visual confusion conditions (three interventions): binocular visual confusion (unilateral opaque target), unilateral monocular visual confusion (unilateral see-through target), and bilateral monocular visual confusion (bilateral see-through target). Each intervention was presented twice in a randomized order, resulting in a total of six trials. During each trial, a peripheral target was presented in front of a forward-moving background for one minute. Participants were instructed to hold down the controller button while the target was visible and release it when a third or more of the target disappeared. After each trial, participants could take a brief break before the next trial in a different visual confusion condition was presented in a randomized order.
62378176|NCT01628458|EXPERIMENTAL|radiofrequency ablation|
62378177|NCT03896087|EXPERIMENTAL|clinical performance of the HCV DBS assay|The study will be conducted in different geographical regions and populations and is designed to meet requirements of the for assays (medical devices) used for the qualitative and quantitative detection of Hepatitis C RNA.
62378178|NCT03896087|ACTIVE_COMPARATOR|comparison PQ marked reference assay arm|Plasma specimens from the participants will be tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities.
62378179|NCT04139603|ACTIVE_COMPARATOR|Lumbopelvic kinesio taping (LPKT)|Two I-shaped kinesio tapes in 40 cm length will be applied bilaterally, beginning from 5 cm below the spina iliaca posterior superiors (SIPSs) to the level of the 12th costae, in maximum trunk flexion position, on the paravertebral muscles, by inhibition technique of muscle correction techniques. The tapes will be placed with no tension at 5 cm of both ends, and with 15-25% tension in between. In addition, an extra I-shaped tape will be placed perpendicullar to these tapes with the ligament correction technique, while the pregnant women are in the vertical upright position, at the level of the sacroiliac joints, starting with a tensile strength of 75-100% from the middle, and then with no tension at two ends.
62378180|NCT04139603|EXPERIMENTAL|Abdominal supported lumbopelvic kinesio taping (ALPKT)|An abdominal support tape will be added to the LPKT. In order to reduce the tension of the uterus ligaments, and to help perception of the normal elasticity of the target tissues, ligament technique will be used. The middle part of an I-shaped tape will be placed to the midpoint of the lower abdomen, and then will be progressed laterally and above with 50% tension.
62754698|NCT01868620|EXPERIMENTAL|Iontophoretic CXL|The iontophoretic CXL involves a constant current source and two electrodes. The main electrode is a circular cup, with a surrounding annular suction ring to affix the device on the cornea during the procedure. The electrode itself is a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with riboflavin solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated by a UVA light for 3mW/cm2 during 30 minutes.
62754699|NCT01868620|ACTIVE_COMPARATOR|Standard CXL|In the standard CXL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes.
62754700|NCT01076101||Sisters who have a diagnosis of SLE|Sisters who have a diagnosis of SLE
62378181|NCT04139603|PLACEBO_COMPARATOR|Placebo taping|A Micropore™ surgical plaster of the same color with KT will be applied with no tension, as described in the LPKT technique.
62754701|NCT01076101||Unaffected Sisters|Sisters of SLE patients who do not have a diagnosis of SLE
62754702|NCT03248193|EXPERIMENTAL|Healthy subjects|To assess safety and tolerability of scalp and limb hypothermia, as well as to determine the optimal temperature and pressure to be used. Establishing the occurrence or lack of core hypothermia will be studied.
62754703|NCT03248193|EXPERIMENTAL|Cancer subjects|Once the optimal temperature and pressure of scalp and limb hypothermia is established in healthy patients, a group of cancer patients will undergo concomitant scalp and limb hypothermia over multiple cycles of chemotherapy to establish safety and tolerability of repeated therapy.
62754704|NCT06056440|EXPERIMENTAL|VR group|The VR intervention program for the experimental group will be carried through the Oculus Quest 2 device (which consists of VR glasses and different accessories) will be used, in conjunction with software specifically designed for physical rehabilitation of upper and lower limbs: Dynamics VR. This VR intervention will be performed in addition to the patient's usual treatment program.
62556677|NCT00729937|EXPERIMENTAL|Cephalexin and TMP/SMX vs. Cephalexin|Subjects with acute uncomplicated cellulitis will be randomized to receive cephalexin (500 mg, four times per day) and Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day) or cephalexin (500 mg, four times per day) and placebo (4 pills, twice per day).
62556678|NCT00749905|EXPERIMENTAL|1|Low fiber diet for 5 days prior to procedure
62754705|NCT06056440|OTHER|Control group|
62556679|NCT00749905|ACTIVE_COMPARATOR|2|regular diet
61986671|NCT06449313|EXPERIMENTAL|Cemiplimab plus chemotherapy|cemiplimab given with standard of care chemotherapy for 4 treatments/cycles before surgery and then every 3 weeks for 1 year after surgery.
62754706|NCT04171180|ACTIVE_COMPARATOR|Controlled group|Controlled group: budesonide/formoterol(SYM) 160/4.5ug 1 inhalation bid\* 3 months (n=250).
62754707|NCT04171180|EXPERIMENTAL|Study group|Study group: SYM 160/4.5ug 2 inhalation bid\* 3 months (n=250).
61986672|NCT01330511||Bilateral Hydronephrosis Grade I-II|Patients with Bilateral Hydronephrosis Grade I-II
62556680|NCT01669291|ACTIVE_COMPARATOR|Bravelle & Menopur Agonist Long Protocol|Patients will use an LH agonist (Lupron) starting on day 18 of the oral contraceptive pill (OCP), 5 units b.i.d. followed by 5 units q.d. beginning on day one of stimulation medications. The 5 units q.d. dose will continue until the day of hCG administration.Patients will administer Bravelle and Menopur for ovarian stimulation.
62754708|NCT00940095|EXPERIMENTAL|Clazosentan 5 mg/h|Continuous intravenous infusion of clazosentan (5 mg/h) started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
62754709|NCT00940095|EXPERIMENTAL|Clazosentan 15 mg/h|Continuous intravenous infusion of clazosentan (15 mg/h) started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
62754710|NCT00940095|PLACEBO_COMPARATOR|Placebo|Continuous intravenous infusion of placebo matching clazosentan started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
62754711|NCT05105841|EXPERIMENTAL|Venetoclax + Obinutuzumab (V+G)|Participants will receive venetoclax + obinutuzumab for twelve 28-day cycles.
62754712|NCT05105841|EXPERIMENTAL|Venetoclax + Ibrutinib (V+I)|Participants will receive venetoclax + ibrutinib for fifteen 28-day cycles.
62378182|NCT05237414|EXPERIMENTAL|Binge Drinkers with Combined Intervention (active CT + active tDCS)|Subjects will perform a variation of the TNTA task (Anderson \& Green, 2001; López-Caneda et al., 2019) to enhance the suppression of alcohol-related memories. The Learning phase will be composed of 2 blocks of 12-image pairs (as there is no a baseline block), and in the TNT phase, all the stimuli to be inhibited will be alcohol-related images. After the Learning Phase, active neuromodulation will be performed using tDCS. Twenty minutes of 2 mA direct current will be applied on the scalp using a saline-soaked pair of 35 cm2 surface sponge electrodes, through an Eldith DC Stimulator Plus (Neuroconn, Germany). To stimulate the right DLPFC, the anodal electrode will be placed over F4 according to the 10-20 international system for EEG electrode placement. The cathode electrode will be over the contralateral supraorbital area. The current fade in for 15 seconds, is constant at 2 mA for 20 minutes, and then fade out for 15 seconds.
62378183|NCT05237414|EXPERIMENTAL|Binge Drinkers with Cognitive Intervention (active CT + sham tDCS)|Subjects perform the variation of the TNTA task for active CT. After the Learning Phase, sham neuromodulation is performed using the same montage of the active tDCS. However, the electric current fade in during 15 seconds until reaching 2 mA, then is constant at 2 mA for 15 seconds and fade out for 15 seconds. There is no current for the rest of the time.
62378184|NCT05237414|SHAM_COMPARATOR|Binge Drinkers with Control Intervention (sham CT + sham tDCS)|"Subjects will perform a variation of the TNTA task, where the Learning phase also have only two blocks of 12-image pairs. However, in this case the TNT phase is replaced by a Forced-Choice Reaction Time (FCRT) task, during which the participants only must categorize alcoholic and non-alcoholic images answering to the question What type of beverage was there in the image? (answer: Alcoholic drink or Non-alcoholic drink); thus, they do not have to inhibit the memories related to the alcoholic images. During this phase, sham neuromodulation will be performed using the same montage of the active tDCS. The electric current fade in during 15 seconds until reaching 2 mA, then is constant at 2 mA for 15 seconds and fade out for 15 seconds, while a sham memory inhibition CT is performed."
62378185|NCT05237414|NO_INTERVENTION|Non/Low-Drinkers|No intervention.
62378186|NCT04249791|EXPERIMENTAL|Uterus Transplantation|Patients undergo transplantation of the uterus from live donor.
62378187|NCT01808040|EXPERIMENTAL|1|"Tak700 (orteronel) dose escalation schedule:~* 1a 200 mg PO BID TAK700~* 1b 200mg PO BID TAK + glucocorticoid~  1a 300mg PO BID TAK700 starting dose~  1b 300 mg po BID + glucocorticoid 2a 400mg PO BID TAK700 2b 400 mg po BID + glucocorticoid"
62556681|NCT01669291|ACTIVE_COMPARATOR|Bravelle & Menopur Antagonist Protocol|Patients will complete standard dose of oral contraceptive pill (OCP) and will then administer GnRH antagonist (ganirelix acetate or cetrorelix acetate) 0.25 mg q.d. during the stimulation phase when the lead follicle size reaches 12mm. The antagonist will continue until the day of hCG administration. Patients will administer Bravelle and Menopur for ovarian stimulation.
62556682|NCT05031585|EXPERIMENTAL|Intervention Group|Nasal lubricant spray
62556683|NCT05031585|PLACEBO_COMPARATOR|Placebo|Placebo spray
62556684|NCT04499469|EXPERIMENTAL|Spreader Graft|Placement and attachment with 5.0 polydioxanone (PDS) suture 2 grafts in the middle third of the nose
62378188|NCT04995731||Women with pre or peri-menopausal abnormal uterine bleeding or post menopausal bleeding|Eligible women presenting to Women's Health hospital with pre or peri-menopausal AUB or PMB will be prospectively enrolled after obtaining their informed consent. AUB will be deﬁned by symptoms of heavy menstrual bleeding, inter-menstrual bleeding, meno-metrorrhagia, irregular menses, or other AUB among women aged ≥40 years who are not in menopause. Peri-menopausal bleeding will be defined as vaginal bleeding after 6 months of menopause after the age of 40 years. Postmenopausal status will be defined as the absence of menstruation for at least 12 months after the age of 40 years, where any pathological condition of amenorrhea is excluded.
62378189|NCT05116111|EXPERIMENTAL|SYHA1402 1000 mg plus placebo 500 mg|Eligible patients will be randomly assigned to receive SYHA1402 1000 mg and placebo 500 mg twice daily for 16 weeks of treatment after a placebo introduction period.
62378190|NCT05116111|EXPERIMENTAL|SYHA1402 1500 mg|Eligible patients will be randomly assigned to receive SYHA1402 1500 mg twice daily for 16 weeks of treatment after a placebo introduction period.
62556685|NCT04499469|NO_INTERVENTION|Without Spreader Graft|No engraftment in the middle third
62556686|NCT02378129|EXPERIMENTAL|Clinpro XT (3M ESPE, Minnesota, USA)|Resin-modified glass ionomer cement
62556687|NCT02378129|ACTIVE_COMPARATOR|Vidrion R (SS White, Gloucester, UK)|Conventional glass ionomer cement
62754713|NCT01069588||Calaxo|Received Calaxo screw
62754714|NCT01069588||Milagro|Received a Milagro screw
62556688|NCT04057729|EXPERIMENTAL|Arm 1 （IMP4297 100mg, Fasted-Fed）|Period 1: Fasted control → Period 2: Fed control
62556689|NCT04057729|EXPERIMENTAL|Arm 2（IMP4297 100mg, Fed- Fasted）|Period 1: Fed control → Period 2: Fasted control
62556690|NCT05590364|EXPERIMENTAL|Profhilo® Body treatment group|"1.5 ml per hand injected by a blunt tip microcannula (25G or 22G, preferably 22G), with fanning technique through a single entry point performing 5 passages and injecting 0,3 ml per passage.~Day 0: Information and consent form provided. Clinical photography, Clinical assessment, Instrumental assessment, First treatment of Profhilo® (refer to study protocol).~Day 30 (1 month after day 0): Clinical photography, Clinical assessment, Instrumental assessment, Second treatment of Profhilo® (refer to study protocol), Self-evaluation questionnaire.~Day 120 (4 months after day 0): Clinical photography, Clinical assessment, Instrumental assessment, NO treatment, Self-evaluation questionnaire."
62556691|NCT02274883|EXPERIMENTAL|Enriched Protein Fractions|This group is given Infant formula with enriched protein fractions.
62556692|NCT02274883|ACTIVE_COMPARATOR|Protein Fractions|This group is given Infant formula with protein fractions.
62556693|NCT04540419|EXPERIMENTAL|Ad5-nCoV single dose|375 subjects, Ad5-nCoV containing 5E10 vp, single dose
62556694|NCT04540419|PLACEBO_COMPARATOR|Placebo single dose|125 subjects, Placebo containing 0 vp, single dose
62754715|NCT06264817|ACTIVE_COMPARATOR|Control group : compressive bandaging|"Control group : compressive bandaging:~* Intensive phase (3 weeks): compressive bandaging (day and night-time) according to the usual practice~* Maintenance phase (5 weeks): usual compression sleeve during the day + Self bandages at night"
62754716|NCT06264817|EXPERIMENTAL|Intervention group: MOBIDERM Autofit Armsleeve|"Intervention group: MOBIDERM Autofit Armsleeve~* Intensive phase (3 weeks): MOBIDERM Autofit Armsleeve (day and night-time)~* Maintenance phase (5 weeks): usual compression sleeve during the day + MOBIDERM Autofit Armsleeve at night"
62378191|NCT05116111|PLACEBO_COMPARATOR|Placebo 1500 mg|Eligible patients will be randomly assigned to receive placebo 1500 mg twice daily for 16 weeks of treatment after a placebo introduction period.
62556695|NCT05469464|EXPERIMENTAL|Orismilast modified release tablets 20 mg BID|Oral, twice daily morning and evening
62556696|NCT05469464|EXPERIMENTAL|Orismilast modified release tablets 30 mg BID|Oral, twice daily morning and evening
62556697|NCT05469464|EXPERIMENTAL|Orismilast modified release tablets 40 mg BID|Oral, twice daily morning and evening
62556698|NCT05469464|PLACEBO_COMPARATOR|Placebo tablets BID|Oral, twice daily morning and evening
62556699|NCT03452943|EXPERIMENTAL|TEV-50717|TEV-50717 tablets twice daily (BID) up to 48 milligrams (mg)/day orally for a total of 12 weeks
62556700|NCT03452943|PLACEBO_COMPARATOR|Placebo|Placebo matched to TEV-50717 BID for a total of 12 weeks
62556701|NCT03987789|ACTIVE_COMPARATOR|Low PEEP group|Patients will receive a PEEP level ≤5 cmH2O without recruitment maneuvers
62556702|NCT03987789|EXPERIMENTAL|Driving-pressure-guided group|Patients will receive PEEP levels individually set at the highest possible value (up to 15 cmH2O) providing a driving pressure (airway plateau pressure minus PEEP) lower than 13 cmH2O, in addition to recruitment maneuvers
62556703|NCT03397030|EXPERIMENTAL|Home-Based Exercise Program|Participants will complete a prescribed home-based exercise program and will follow up with research staff at the UT Health San Antonio School of Nursing.
62556704|NCT03397030|NO_INTERVENTION|Waitlist-Control Group|Participants assigned to this group will be asked to maintain normal activity and visit the UT Health San Antonio School of Nursing for research appointments.
62378192|NCT04786639||Surgical Fixation Group|Open reduction with deltopectoral incision and humeral osteosynthesis with anatomic plates and screws will be performed for surgical fixation.
62556705|NCT05938114|EXPERIMENTAL|Group A (Bonalive®)|The test bone substitute is Bonalive®, bioactive glass S53P4, which contains SiO2, Na2O, CaO, and P2O5 (granule size 0.5-0.8mm). Bonalive® is osteoconductive, meaning that it has the ability of promoting bone growth across the granules and the grafting area and slowly replace it with new bone over time. Bonalive® is osteostimulative and has antibacterial properties
62378193|NCT04786639||Non-Operative Group|Non-surgical treatment will be performed with sling immobilization.
62378194|NCT04428762|EXPERIMENTAL|I-Port use arm|
62556706|NCT05938114|ACTIVE_COMPARATOR|Group B ( Bio-Oss®)|The comparator is Bio-Oss®, deproteinized bovine bone granules (granule size 0.25- 1mm). Bio-Oss® is osteoconductive, which means it acts as a scaffold only for new bone to grow.
62556707|NCT04959526|EXPERIMENTAL|Respiratory Function Testing|All subjects will receive standard respiratory function testing and ultrasound-based elastography measurements across various behaviors and conditions
62556708|NCT01173120|EXPERIMENTAL|Abatacept Combination Product (ACP)|Participants from the long-term period of study NCT00559585 who enrolled in the ACP substudy switched to administration of subcutaneous (SC) abatacept via the ACP for the duration of the substudy. Abatacept was administered SC using the ACP by the participant or caregiver on Substudy Day 1 and at weekly intervals thereafter. The ACP was a pre-filled liquid product device delivering 125 mg abatacept/device (125 mg/mL).
62556709|NCT05465837||Non covid Tracheostomy Patients|Adult patients (\>18 years) who underwent tracheostomy without having the covid-19 infection
62556710|NCT05465837||Covid-19 Tracheostomy Patients|Adult patients (\>18 years) who underwent tracheostomy had the covid-19 infection
62556711|NCT03295955|ACTIVE_COMPARATOR|Postop antibiotics group|Prescribe Amoxicillin Clavulanate
62556712|NCT03295955|NO_INTERVENTION|No postop antibiotics|Do not prescribe Amoxicillin Clavulanate
62556713|NCT05191004|EXPERIMENTAL|Phase 1b Dose Escalation|"NUV-422 will be administered orally at escalating dose levels in combination with fulvestrant until the recommended Phase 2 combination dose (RP2cD) is determined.~500 mg fulvestrant will be administered IM on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter."
62556714|NCT05191004|EXPERIMENTAL|Phase 2 NUV-422 + fulvestrant|"NUV-422 will be administered orally at the RP2cD in combination with fulvestrant.~500 mg fulvestrant will be administered IM on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter."
62556715|NCT05191004|EXPERIMENTAL|Phase 2 NUV-422 monotherapy|NUV-422 will be administered orally at the RP2cD.
62556716|NCT05191004|EXPERIMENTAL|Phase 2 fulvestrant monotherapy|500 mg fulvestrant will be administered IM on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter.
62556717|NCT00828165|EXPERIMENTAL|ARRY-300|
62556718|NCT00828165|PLACEBO_COMPARATOR|Placebo|Placebo
62556719|NCT05791396|EXPERIMENTAL|Donor FMT|Patients enrolled in this arm will receive donor FMT
62378195|NCT04428762|NO_INTERVENTION|Regular injection arm|
62556720|NCT05791396|PLACEBO_COMPARATOR|Placebo FMT|Patients enrolled in this arm will receive placebo FMT (that will be made of water)
62556721|NCT04767399|EXPERIMENTAL|Single visit|root canal treatment will be done in one visit
62556722|NCT04767399|EXPERIMENTAL|multiple visit|root canal treatment will be done in multiple visit
62556723|NCT03668678|EXPERIMENTAL|iGrow Readers Curriculum|The iGrow Readers nutrition and physical activity curriculum was implemented in early-childhood classrooms assigned to the IGrow Readers intervention group.
62556724|NCT03668678|NO_INTERVENTION|Standard Curriculum|The standard curriculum was provided within early-childhood classrooms assigned to the control group.
62556725|NCT03410056|PLACEBO_COMPARATOR|Phase 1b: Placebo|Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A \[less frequent\] or schedule B \[more frequent\]).
62556726|NCT03410056|EXPERIMENTAL|Phase 1b: Efavaleukin alfa Cohort 1|A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.
62378196|NCT03324867|EXPERIMENTAL|Intranasal Insulin 40 IU|40 IU of Humulin-R via nose Before surgery and everyday after surgery up to POD 7
62378197|NCT03324867|PLACEBO_COMPARATOR|Intranasal Normal Saline|Normal Saline via nose Before surgery and everyday after surgery up to POD 7
62378198|NCT03431623|EXPERIMENTAL|CKD-11101(Darbepoetin alfa)|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
62378199|NCT03431623|ACTIVE_COMPARATOR|NESP(Darbepoetin alfa)|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
62556727|NCT03410056|EXPERIMENTAL|Phase 1b: Efavaleukin alfa Cohort 2|A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.
62556728|NCT03410056|EXPERIMENTAL|Phase 1b: Efavaleukin alfa Cohort 3|A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.
62556729|NCT03410056|EXPERIMENTAL|Phase 1b: Efavaleukin alfa Cohort 4|A medium/high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.
62556730|NCT03410056|PLACEBO_COMPARATOR|Phase 2a: Placebo|Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.
62556731|NCT03410056|EXPERIMENTAL|Phase 2a: Efavaleukin alfa|Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.
62556732|NCT00738387|EXPERIMENTAL|ASA404 + docetaxel|"1800 mg/m2 of ASA404 intravenous (IV) on day 1 of each 21 day cycle~75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days"
62556733|NCT00738387|PLACEBO_COMPARATOR|Placebo + docetaxel|"Placebo i.v. on day 1 of each 21 day cycle~75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days"
62556734|NCT01666665|ACTIVE_COMPARATOR|metformin|Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
62556735|NCT01666665|PLACEBO_COMPARATOR|Sugar pill|sugar pill up to 3 times per day for 12 months
62556736|NCT02317003|EXPERIMENTAL|Intervention PPIL|Intervention delivered by the family doctor and based on structured information delivery according to cognitive and behavioural theories, a personalised written physical activity prescription in number of steps per day, a pedometer, and a pedometer logbook similar to diabetes logbooks.
62556737|NCT02317003|ACTIVE_COMPARATOR|Control OR|Oral recommendation of physical exercise delivered by the family doctor.
62556738|NCT04825392|EXPERIMENTAL|HX008|
62556739|NCT04184427|ACTIVE_COMPARATOR|Group I|6 mm height of power arm
62556740|NCT04184427|EXPERIMENTAL|Group II|3 mm height of power arm
62556741|NCT04184427|EXPERIMENTAL|Group III|9 mm height of power arm
62556742|NCT05024747|EXPERIMENTAL|Test Product|Participants will receive a single NicoDerm CQ patch (GSK Dungarvan) placed topically under fasted conditions to the upper part of the back for a total duration of 24 hours.
62556743|NCT05024747|ACTIVE_COMPARATOR|Reference Product|Participants will receive a single NicoDerm CQ patch (Alza) placed topically under fasted conditions to the upper part of the back for a total duration of 24 hours.
62556744|NCT05680584|ACTIVE_COMPARATOR|Melatonin|Preoperative oral melatonin 0.1mg/ kg in 10ml apple juice one hour before induction of anesthesia
62556745|NCT05680584|ACTIVE_COMPARATOR|Hydroxyzine|Preoperative oral hydroxyzine 1mg/ kg in 10ml apple juice one hour before induction of anesthesia
62556746|NCT05680584|PLACEBO_COMPARATOR|placebo|10ml apple juice one hour before induction of anesthesia
62556747|NCT01868906|OTHER|Arm-A: 18F-FMISO-PET without SCS|One 18F-FMISO-PET study for assessment of tumor hypoxia before radiotherapy and Temozolomide, without spinal cord stimulation.
62556748|NCT01868906|OTHER|Arm-B: 18F-FMISO-PET without/with SCS|"Two 18F-FMISO-PET studies for assessment of tumor hypoxia before radiotherapy and Temozolomide: one without and one with spinal cord stimulation"
62556749|NCT06453499||physical therapy|core stability exercise
62556750|NCT01122225||Septic shock|
62556751|NCT01479231|EXPERIMENTAL|dexlansoprazole|
61986673|NCT01330511||Bil. Hydronephrosis Grade III-IV, Other|Patient with Bilateral Hydronephrosis Grade III-IV and others with any hydronephrosis and distended bladder or MCKD
62378200|NCT01406366||Group 1|Group 1: 16 programs / 148 residents
62378201|NCT01406366||Group 2|Group 2: 16 programs / 142 residents
62378202|NCT00417391|EXPERIMENTAL|1 mg RR110|1 mg RR110
62378203|NCT00417391|EXPERIMENTAL|4 mg RR110|4 mg RR110
62754717|NCT02231411|ACTIVE_COMPARATOR|Ventilation during DCC (V-DCC)|Measuring the volume of placental transfusion with ventilation (CPAP 5 cm H2O between inflations) in infants born by C/S or VG using, as an initial surrogate marker, Hematocrits at 12 hours of life (HOL)
62754718|NCT02231411|ACTIVE_COMPARATOR|DCC plus dry and stimulate|Measuring the volume of placental transfusions with delayed cord clamping alone (DCC) in infants born by C/S or VD using, as an initial surrogate marker, Hematocrits at 12 hours of life (HOL)
62754719|NCT06513650||Drug deprescring and drug addition|"This multicentre, prospective, observational, pragmatic study on long-term therapy of hypotensive syncope consists of two distinct twin substudies to be undergone in parallel:~1. the Drug-deprescribing substudy wants to assess a strategy aimed to increase BP by deprescribing of hypotensive drugs in hypertensive patients affected by drug-related syncope, and;~2. the Drug-addition substudy wants to assess a therapeutic strategy aimed at increasing BP with fludrocortisone in syncopal patients with drug-unrelated permanent or intermittent hypotension."
62754720|NCT01727648|EXPERIMENTAL|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
62378204|NCT04021706|ACTIVE_COMPARATOR|anamorelin|one 100 mg tablet daily, taken one hour before breakfast
62378205|NCT04021706|PLACEBO_COMPARATOR|microcrystaline cellulose|one identical appearing tablet daily, taken one hour before breakfast
62378206|NCT04976309|EXPERIMENTAL|Placebo + saline|Placebo, 0.9% normal saline, single dose intravenous infusion over 30 minutes
62378207|NCT04976309|EXPERIMENTAL|Placebo + VIP and PACAP|Placebo, 0.9% normal saline, single dose intravenous infusion over 30 minutes
62754721|NCT01727648|EXPERIMENTAL|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
62754722|NCT01727648|EXPERIMENTAL|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
62378208|NCT04976309|EXPERIMENTAL|Lu AG09222 + VIP and PACAP|Lu AG09222, single dose intravenous infusion over 30 minutes
62378209|NCT00403390|EXPERIMENTAL|Brand name levothyroxine (Synthroid)|Dose previously demonstrated to normalize thyroid function given daily for 2 months
62378210|NCT00403390|ACTIVE_COMPARATOR|Generic formulation of Levothyroxine|Dosage previously determined to normalize thyroid function given daily for 2 months
62378211|NCT03887975|ACTIVE_COMPARATOR|Percentage of force in monoplane occlusion|Different occlusal scheme evaluation using tscan
62378212|NCT03887975|ACTIVE_COMPARATOR|Percentage of force in lingualized occlusion|Different occlusal scheme evaluation using tscan
62378213|NCT00648544|EXPERIMENTAL|1|
62378214|NCT00648544|ACTIVE_COMPARATOR|2|
62378215|NCT02813434|EXPERIMENTAL|Florbetapir|
62378216|NCT00933387|EXPERIMENTAL|open label|an open-labelled, single-arm
62556752|NCT06198816||DVT patients|
62556753|NCT01968772|OTHER|Transdermal Magnesium Chloride|This is a clear, odorless liquid that dries rapidly on the skin and leaves no oily residue. Its ingredients are water, magnesium chloride, and a proprietary blend of less than two-tenths of 1% trace minerals (Boron, Selenium, and Manganese).
62556754|NCT00270244|ACTIVE_COMPARATOR|1|Participants will receive treatment as usual
62556755|NCT00270244|EXPERIMENTAL|2|Participants will receive group interpersonal psychotherapy for depressed adolescents
62556756|NCT03106675|EXPERIMENTAL|HIFU-treatment|"* Pre-treatment imaging~* Pre-treatment questionnaires and laboratory blood samples~* Intervention (Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T)~* Follow-up (imaging, questionnaires, laboratory)~* Follow-up pain medication usage"
62556757|NCT03106675|ACTIVE_COMPARATOR|Radiation therapy|"* Pre-treatment imaging~* Pre-treatment questionnaires and laboratory blood samples~* Intervention (Varian Truebeam Radiotherapy System)~* Follow-up (imaging, questionnaires, laboratory)~* Follow-up pain medication usage"
62556758|NCT06341816|ACTIVE_COMPARATOR|Conventional|In the conventional group, heart failure treatment will be managed according to classical physical examination (e.g. peripheral edema, rales) and laboratory methods (pro-BNP). e.g. fluid restriction, diuretic therapy, etc.
62556759|NCT06341816|ACTIVE_COMPARATOR|VEXUS|In the vexus group, heart failure treatment will be given in a way that will reduce the vexus score. e.g. fluid restriction, diuretic therapy, etc.
62556760|NCT00662649|EXPERIMENTAL|Fingolimod 1.25 mg|Patients continued the same dose to which they had been randomized in the Core study (CFTY720D2301/NCT00289978), fingolimod 1.25 mg/day, in this Extension study.
62556761|NCT00662649|EXPERIMENTAL|Fingolimod 0.5 mg|Patients continued the same dose to which they had been randomized in the Core study, fingolimod 0.5 mg/day, in this Extension study.
62378217|NCT02355665|EXPERIMENTAL|Nicotine|Nicotine Spray
62378218|NCT02355665|PLACEBO_COMPARATOR|Placebo|Placebo to match Nicotine spray
62378219|NCT04095962|EXPERIMENTAL|Experimental Group|Training protocol will be held for 6 months, twice per week/ 60 min per sessions.
62378220|NCT04095962|NO_INTERVENTION|Control Group|Participants in the control group will receive monthly sessions regarding physical activity and health related topics as a complement to standard care. No specific exercise intervention will be conducted for this group.
62378221|NCT01393665|PLACEBO_COMPARATOR|Placebo|
62378222|NCT01393665|EXPERIMENTAL|PENNEL capsule|1cap or 2cap T.I.D
62378223|NCT03113799|OTHER|Single Arm study|Single Arm study In this study, the subject will act as their own control. On Day 1 of the two day study, the subject will be observed while treated on their standard EVD. On Day 2, the subject will be treated with the Smart External Drain (SED).
62378224|NCT01662986|ACTIVE_COMPARATOR|18 mcg tiotropium bromide|Patient to receive one tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
62378225|NCT01662986|PLACEBO_COMPARATOR|placebo|Patient to receive one placebo inhalation powder capsule daily (in the morning) via HandiHaler
62378226|NCT04825106|ACTIVE_COMPARATOR|Expected|Anaphylactic shock occurs after the injection of a drug known to cause allergic reactions
62556762|NCT00662649|EXPERIMENTAL|Placebo-fingolimod|Patients randomized to placebo in the Core study were re randomized to fingolimod (either 0.5 or 1.25 mg/day) in this Extension study.
62556763|NCT00662649|EXPERIMENTAL|Placebo-fingolimod 1.25 mg|Patients randomized to placebo in the Core study were re randomized to fingolimod 1.25 mg/day in this Extension study.
62378227|NCT04825106|ACTIVE_COMPARATOR|Unexpected, no distractor|Anaphylactic shock occurs unexpectedly, but their is no medical distractor
62556764|NCT00662649|EXPERIMENTAL|Placebo-fingolimod 0.5 mg|Patients randomized to placebo in the Core study were re randomized to fingolimod 0.5 mg/day in this Extension study.
62556765|NCT04038580|SHAM_COMPARATOR|Prescribed Laminated Socket|In this arm, participants will wear their clinically prescribed laminated socket. This period is approximately 2 weeks.
62754723|NCT01727648|ACTIVE_COMPARATOR|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
62378228|NCT04825106|ACTIVE_COMPARATOR|Unexpected, with distractor|Anaphylactic shock occurs unexpectedly. Scenario is set up such, that a tension pneumothorax may be a likely explanation
62378229|NCT03746340||Anesthetic|Sevoflurane Group Propofol Group
62378230|NCT01110928||Norditropin®|
62378231|NCT02717429|EXPERIMENTAL|Mindfulness Meditation Training (MMT)|Participants will attend four weekly group mindfulness meditation sessions of a 2-hour duration. The classes are a mixture of experiential practices, discussions surrounding the experiences, and didactics on mindfulness. In addition to the time spent in session, participants will be asked to complete 40 minutes of daily homework, which includes further practice of in-session meditative exercises and brief readings.
62378232|NCT02717429|ACTIVE_COMPARATOR|Computerized Cognitive Training|The active control group will be in the form of a cognitive training course where the participants will meet for the same amount of time as the MMT group. Homework will be reading and engaging in cognitive video game exercises for the same duration, around 40 minutes daily, as the MMT group.
62378233|NCT02717429|NO_INTERVENTION|Wait-List Control Group|This group will be used to compare the effects of the two active comparison groups and will not receive any intervention for the four week period.
62378234|NCT04913792||ZXR00|The ZXR00 group included 30 patients bilaterally implanted with the Tecnis Symfony IOL (Abbott Medical Optics, Inc.)
62378235|NCT02664740|EXPERIMENTAL|Phage therapy|"Patients randomized to this arm will have phage therapy.~Intervention: Topical anti-Staphylococcus bacteriophage therapy"
62378236|NCT02664740|PLACEBO_COMPARATOR|Placebo|"Patients randomized to this arm will have placebo therapy anologous to that of the experimental arm.~Intervention: Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy"
62378237|NCT01416506||Group 1|
62378238|NCT05790902|EXPERIMENTAL|Silodosin Group|The patients used Silodosin for ureteric calculi
62378239|NCT05790902|EXPERIMENTAL|Tamsulosin Group|The patients used Tamsulosin for ureteric calculi
62378240|NCT06258265|EXPERIMENTAL|Cohort 1, Therapeutic Dose Cohort: TAK-279 + TAK-279 Placebo + Moxifloxacin Placebo|Participants will receive TAK-279 Dose 1 and matching placebo, capsules, once daily (QD) on Days 1 to 7 with moxifloxacin matching placebo, capsule, once on Days 1 and 8.
62378241|NCT06258265|EXPERIMENTAL|Cohort 2, Supratherapeutic Dose Cohort: TAK-279 + Moxifloxacin Placebo|Participants will receive TAK-279 Dose 2, capsules, QD on Days 1 to 7 with moxifloxacin matching placebo, capsule once on Days 1 and 8.
62378242|NCT06258265|EXPERIMENTAL|Cohort 3A, Control Cohort: Moxifloxacin + TAK-279 Placebo + Moxifloxacin Placebo|Participants will receive moxifloxacin Dose 3, over-encapsulated tablet on Day 1 with TAK-279 matching placebo, QD on Days 1 to 7 and moxifloxacin placebo, capsule, once on Day 8.
62378243|NCT06258265|EXPERIMENTAL|Cohort 3B, Control Cohort: TAK-279 Placebo + Moxifloxacin Placebo + Moxifloxacin|Participants will receive moxifloxacin matching placebo, capsule on Day 1 with TAK-279 matching placebo, QD on Days 1 to 7 and moxifloxacin Dose 3, over-encapsulated tablet, once on Day 8.
62378244|NCT04503473|EXPERIMENTAL|High Intensity Stepping Training|The primary goal will be to perform continuous stepping while maintaining HR within 70-85% maximum predicted HR (if patients are deconditioned, PTs will gradually increase intensity to desired levels as tolerated). We will also record Ratings of Perceived Exertion (RPE) every 3-5 minutes, with goals of 15-18. Sessions will be divided into \~10 minute increments (\~25% of sessions) between speed-dependent treadmill training (described above for treadmill stepping), skill-dependent treadmill training, overground training, and stair climbing.
62378245|NCT04503473|ACTIVE_COMPARATOR|Conventional Therapy|Participants provided conventional therapy will perform various standardized exercise tasks during 40 minutes of 1 hr sessions. The type of therapeutic activities is based on published normative data of typical activities performed during clinical physical therapy sessions with focus on strengthening activities (25% of session); balance activities (25%); locomotor activities (25%), and combined stretching exercises (10-15%) and transfers (10-15%). Intensity of activities will be targeted at 30-40% of their HR reserve in attempts to maintain consistent intensities between training groups.
62378246|NCT05091073|EXPERIMENTAL|Fed group|Fed dosing conditions
62378247|NCT05091073|EXPERIMENTAL|Fasting group|Fasting dosing conditions
61986674|NCT01330511||Unilateral Hydronephrosis Grade I-II|Patients with Unilateral Hydronephrosis Grades I-II
61986675|NCT01330511||Unilateral Hydronephrosis Grade III-IV|Patients with Unilateral Hydronephrosis Grade III-IV
61986676|NCT05445765|EXPERIMENTAL|anti-CD33 CAR T cells|Dose escalation phase: anti-CD33 CAR T cells will be transduced with a lentiviral vector to express anti-CD33 CARs
62556766|NCT04038580|EXPERIMENTAL|Adjustable Sockets|In this condition, participants will be fitted with 3 different adjustable transfemoral sockets by a certified prosthetist. The order in which the sockets are fitted are randomized and the participant will spend approximately 4 weeks in each socket.
62556767|NCT02474277|OTHER|30 sec chair stand test|all patients in this Group receives a diagnostic test for functional impairment
62556768|NCT03520257|EXPERIMENTAL|Apatinib Plus Radiotherapy|
62556769|NCT03520257|OTHER|Apatinib|
62556770|NCT05177679|EXPERIMENTAL|Active Supplement|The active supplementation group participants will be asked to consume a daily carotenoid supplement for 9 months.
62556771|NCT05177679|PLACEBO_COMPARATOR|Placebo Control|The placebo control group participants will be asked to consume a placebo supplement for 9 months.
62556772|NCT03659214||Treated group|Patients with proven CF (sweat-test \> 60 mEq, 2 DF508 CF causing mutations, 12 to 20 years, and treated with ORKAMBI)
62556773|NCT03659214||Control group|Patients not carrying 2 DF508 CF causing mutations, not treated with ORKAMBI, and not carrying the G551D, G178R, S549N, S549R, G551S, G1244E,S1251N, S1255P or G1349D mutation or treated with Kalydeco
62556774|NCT04386382|EXPERIMENTAL|ridge splitting flapless technique using interchangeable guide|"Fabrication of interchangeable surgical guide stent:~* Optical scanning of the dental casts was done using Ceramill map 400~* The treatment plan and the surgical stent were designed using Mimics Innovation Suite 19 ™ software~* Series of creating and designing special 3D virtual guide slits and boxes that can accommodate and precisely fit the tools used for the ridge splitting technique."
62556775|NCT01371188||Controls|Healthy male volunteers, non-smokers, 20-40yo, living in the city of Mendonça, São Paulo-Brazil.
62556776|NCT01371188||Sugarcane Workers|Healthy male volunteers, non-smokers, 20-40yo, sugarcane workers, living in the city of Mendonça, São Paulo-Brazil.
62556777|NCT03334513||ROP group|children with retinopathy of prematurity received either bevacizumab or ranibizumab
62556778|NCT03231111|NO_INTERVENTION|traditional group|
62556779|NCT03231111|EXPERIMENTAL|Multimedia group|
62556780|NCT02834325||exit|HFNC with no need for mechanical ventilation
62754724|NCT03866538|NO_INTERVENTION|Continued Budesonide|Patients in this arm continue budesonide at the dose they were taking at the time of enrollment in the trial
62378248|NCT05091073|ACTIVE_COMPARATOR|Reference group|Reference dosing conditions
62378249|NCT02782364||Faecal Incontinence: fast-fill measurement first|Observational study where patients with faecal incontinence undergo two AAR measurements; one with the original step-wise technique and the second with the newer fast-fill technique. A further standard manometry measurement will be taken. 18 patients will undergo fast-fill measurement first.
62378250|NCT02782364||Faecal Incontinence: step-wise measurement first.|Observational study where patients with faecal incontinence undergo two AAR measurements; one with the original step-wise technique and the second with the newer fast-fill technique. A further standard manometry measurement will be taken. 18 patients will have step-wise measurement first.
62378251|NCT04849260|EXPERIMENTAL|Pexa-Vec combined with ZKAB001|"The combined treatment group is divided into two dose groups. The principle of 3+3 is adopted to determine RP2D, and RP2D will be used in subsequent patients in this cohort."
62556781|NCT02834325||failure|HFNC with need for mechanical ventilation
62556782|NCT00768248|ACTIVE_COMPARATOR|Active|3-7 days of perineural local anesthetic infusion
62556783|NCT00768248|PLACEBO_COMPARATOR|Placebo|3-7 days of perineural normal saline infusion
62556784|NCT02352701||Noltec®,ChongkundangAmoxicillin®,Cravit®|Noltec tab 10mg, Chongkundang Amoxicillin Cap 500mg 2caps and Cravit tab 500mg by oral, twice a day for 10 days
62556785|NCT02816983||SBRT for oligometastatic prostate cancer|
62378252|NCT04849260|ACTIVE_COMPARATOR|ZKAB001 monotherapy|ZKAB001 monotherapy.
62378253|NCT01389895|ACTIVE_COMPARATOR|AMG 557|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99.
62378254|NCT01389895|PLACEBO_COMPARATOR|AMG 557 Placebo|All will receive placebo on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99.
62378255|NCT05206682|EXPERIMENTAL|Vaginal Repair with Leuprorelin|CSD patients were treated with vaginal repair of CSD in combination with Leuprorelin . In the group of Vaginal Repair With Leuprorelin, the patients will get 3 times of Leuprorelin per 4 weeks perioperation. The detailed procedure of Vaginal Repair has been described in our previous study.
62378256|NCT05206682|NO_INTERVENTION|Vaginal Repair without Leuprorelin|The detailed procedure of Vaginal Repair has been described in our previous study.
62378257|NCT03752840|EXPERIMENTAL|Screening|
62378258|NCT03752840|ACTIVE_COMPARATOR|Case detection|
62556786|NCT05574439|ACTIVE_COMPARATOR|Non-responders: TCOC+ semaglutide|Semaglutide: 2.4 mg/week SC, concentration: 3.0 mg/ml) in combination with TCOC treatment (i.e. diet/weight consultations).
62556787|NCT05574439|PLACEBO_COMPARATOR|Non-responders: TCOC+ placebo|Placebo: 2.4 mg/week SC in combination with TCOC treatment (i.e. diet/weight consultations).
62556788|NCT05574439|ACTIVE_COMPARATOR|Insufficient responders: TCOC+ semaglutide|Semaglutide: 2.4 mg/week SC, concentration: 3.0 mg/ml) in combination with TCOC treatment (i.e. diet/weight consultations).
61986677|NCT04706195|EXPERIMENTAL|Person-centred care|PCC in the form of a combined eHealth and structured telephone support combined with an eHealth support on top of usual care
62556789|NCT05574439|PLACEBO_COMPARATOR|Insufficient responders: TCOC+ placebo|Placebo: 2.4mg/week SC in combination with TCOC treatment (i.e. diet/weight consultations).
62556790|NCT05574439|NO_INTERVENTION|Excellent Responders and Population-based reference group|No intervention.
62556791|NCT05544474||Expert surgeon on radical right colectomy|Expert surgeon on radical right colectomy com pricing corresponding author/senior author from paper included in a preliminary systematic review on this topic Sica GS, Vinci D, Siragusa L, Sensi B, Guida AM, Bellato V, García-Granero Á, Pellino G. Definition and reporting of lymphadenectomy and complete mesocolic excision for radical right colectomy: a systematic review. Surg Endosc. 2022 Sep 12. doi: 10.1007/s00464-022-09548-5.
62556792|NCT03412331|ACTIVE_COMPARATOR|Control Group|NPT including scaling and root planing was applied to 12 subjects with ultrasonic and hand instruments until the operator feels that root surface is clean, hard and smooth.
62754725|NCT03866538|EXPERIMENTAL|Withdrawal of Budesonide|Patients are weaned off of budesonide over 2 weeks and continued off of the medication for the duration of the trial
62556793|NCT03412331|EXPERIMENTAL|Test Group|Following NPT, toluidine blue O mediated PDT was performed with a LED source (625-635 nm wavelength) (FotoSan®, CMS Dental, Denmark) to 12 subjects. The dye (0.1 mg/ml) was applied with a canula into the periodontal pockets. After 3 minutes, the subjects rinsed their mouths with sterile saline solution for removal of excessive dye. Then, the applicator of photosensitizer was inserted until the bottom of the periodontal pocket and photoinactivation was performed in 6 sites per tooth for 10 seconds of each sites with a total of 60 seconds per tooth.
62556794|NCT00524940|EXPERIMENTAL|Study Group|
62556795|NCT04801992||MINI WELL Ready (SIFI SpA, Italy)|Extended depth of focus intraocular lens implantation
62556796|NCT04001036|EXPERIMENTAL|Experimental peritoneal dialysis solution IPX15|Patients will receive treatment with the experimental solution for nocturnal (long-dwell) exchange. For daily (short-dwell) exchanges, all patients will continue the 1 to 3 bags of glucose peritoneal dialysis solution as for their pre-randomization prescription.
62556797|NCT04001036|EXPERIMENTAL|Experimental peritoneal dialysis solution IPX07|Patients will receive 1 to 3 daily (short-dwell) exchanges with the experimental solution (the number of exchanges will be based on their pre-randomization prescription). All patients will receive icodextrin for nocturnal (long-dwell) exchange.
62556798|NCT06409273|EXPERIMENTAL|Intervention|Hybrid course : asynchronous online interactive course (2h30, 45%) followed by face-to-face socio constructivist teaching (3h00, 55%)
62556799|NCT06409273|ACTIVE_COMPARATOR|Control|Face-to-face socio constructivist teaching (100%) (5h30)
62556800|NCT05582070|EXPERIMENTAL|actigraphy|Patient with nasal obstruction
62556801|NCT04967573|EXPERIMENTAL|Prophylactic Anticoagulation|Rivaroxaban 10 mg od for 3 months
62556802|NCT04967573|ACTIVE_COMPARATOR|Therapeutic Anticoagulation|Rivaroxaban 20 mg od for 3 months
62556803|NCT00657189|EXPERIMENTAL|1|MEDI-545
62556804|NCT00657189|EXPERIMENTAL|2|MEDI-545
62556805|NCT00657189|EXPERIMENTAL|3|MEDI-545
62754726|NCT05778084|OTHER|Heart failure patients with reduced and mildly reduced ejection fraction|"* One paired test group described as Heart Failure patients with reduced and mildly reduced ejection fraction are indicated for Empagliflozin.~* Blood samples will be collected as a baseline before Empagliflozin administration to test for N-terminal Pro-B-type Natriuretic Peptide,~* Followed by administration of empagliflozin for 6 months.~* Then retest the N-terminal Pro-B-type Natriuretic Peptide after 6 months."
62754727|NCT00890994||Suspected breast cancer|
61986678|NCT04706195|NO_INTERVENTION|Usual care|Regular evidence-based treatment and care as outlined in treatment guidelines and followed as usual at their local primary care center
62378259|NCT00394654|EXPERIMENTAL|MEDI528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
62378260|NCT00394654|PLACEBO_COMPARATOR|PLACEBO|Placebo administered as a single intravenous infusion
62378261|NCT00442611|EXPERIMENTAL|Abatacept|Abatacept (dosed based upon weight) administered intravenously (IV) on days 1, 15, 30 and monthly thereafter for a total of 7 doses.
62378262|NCT00442611|PLACEBO_COMPARATOR|IV fluid|Placebo to match abatacept (IV fluid) administered on days 1, 15, 30 and monthly thereafter for a total of 7 doses.
62378263|NCT01252992||1:paradoxical reaction negative (RP-)|control group with tuberculosis but without paradoxical reaction
62378264|NCT01252992||1:paradoxical reaction negative (RP+)|group with tuberculosis and paradoxical reaction
62378265|NCT03501381|ACTIVE_COMPARATOR|High Dose Interleukin 2|HD IL-2 600,000 IU/kg Every 8 hours on Days 1-5 and Days 15-19
62378266|NCT03501381|EXPERIMENTAL|High Dose Interleukin 2 plus Entinostat|HD IL-2 600,000 IU/kg Every 8 hours on Days 1-5 and Days 15-19 plus Entinostat 5 mg orally every 2 weeks starting Day -14
62378267|NCT00716040|EXPERIMENTAL|Intervention|The intervention group will be submitted to four social-psychological individual sessions with a pre-trained health professional.
62378268|NCT00716040|OTHER|Control|The control group will be submitted to the usual care of the health service.
62378269|NCT02894892|ACTIVE_COMPARATOR|(A)Bismuth|(A)Bismuth (120mg/tab) 1 dose prior 1 hr before endoscopy
62378270|NCT02894892|ACTIVE_COMPARATOR|(B)Bismuth|(B)Bismuth (120mg/tab) 1 dose in the morning and endoscopy in the afternoon
62378271|NCT02894892|ACTIVE_COMPARATOR|(C)Bismuth|(C)Bismuth (120mg/tab) q.i.d. and endoscopy the next day
62378272|NCT02894892|ACTIVE_COMPARATOR|(D)Esomeprazole and Bismuth|(D)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) 1 dose prior 1 hr before endoscopy
62556806|NCT00657189|EXPERIMENTAL|4|MEDI-545
62556807|NCT00657189|PLACEBO_COMPARATOR|5|Placebo
62556808|NCT03524170|EXPERIMENTAL|Treatment (M7824, radiation therapy)|Patients receive M7824 IV over 1 hour every 14 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Beginning within 3 days after second dose of M7824, patients undergo radiation therapy QD for 5-10 days depending on the site of disease in the absence of disease progression or unacceptable toxicity.
62556809|NCT00560391|EXPERIMENTAL|Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 70 mg QD, lenalidomide, 15 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
62556810|NCT00560391|EXPERIMENTAL|Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 70 mg QD, lenalidomide, 20 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
62556811|NCT00560391|EXPERIMENTAL|Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 100 mg QD, lenalidomide, 20 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
62378273|NCT02894892|ACTIVE_COMPARATOR|(E)Esomeprazole and Bismuth|(E)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) 1 dose in the morning and endoscopy in the afternoon
61986679|NCT04781673|ACTIVE_COMPARATOR|Ketamine|"Infusion initiation: 0.1 mg/kg/hr Max: 0.3 mg/kg/hr Recommended titration: 0.1 mg/kg/hr\* as needed every 4 hours based on pain scores ≥5 and physician order~Dosing will be based on patient actual body weight (ABW) recorded as dosing weight on time of hospital admission."
62378274|NCT02894892|ACTIVE_COMPARATOR|(F)Esomeprazole and Bismuth|(F)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) q.i.d. and endoscopy the next day
62556812|NCT00560391|EXPERIMENTAL|Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 100 mg QD, lenalidomide, 25 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
62556813|NCT00560391|EXPERIMENTAL|Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, lenalidomide, and dexamethasone in varying doses in 28-day cycles.
62556814|NCT00423878|EXPERIMENTAL|1|Participants will switch to aripiprazole with a cross-titration from the current antipsychotic over 3-4 weeks. Allowed final dosage range for aripiprazole was 5-30 mg/day
62556815|NCT00423878|ACTIVE_COMPARATOR|2|Participants will continue with their current antipsychotic treatment, either olanzapine 5-20 mg/day, quetiapine 200-1200 mg/day, or risperidone 1-16 mg/day.
62556816|NCT02575833|PLACEBO_COMPARATOR|Placebo|Participants received a single dose of placebo administered by intravenous infusion on day 1.
62556817|NCT02575833|EXPERIMENTAL|Erenumab|Participants received a single dose of erenumab 140 mg administered by intravenous infusion on day 1.
62556818|NCT04107324|OTHER|PVE (Portal vein embolisation)|Standard of care when FLR is small.
62556819|NCT04107324|EXPERIMENTAL|ARAPS (Portal vein embolisation and associating RFA)|Experimental arm with PVE combined with RFA to induce accelerated liver hypertrophy.
62556820|NCT05649761|EXPERIMENTAL|QL1604 injection|Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.
62556821|NCT00318890|EXPERIMENTAL|Docetaxel + cisplatin followed by radiation|Docetaxel with cisplatin is given for three cycles, followed by concomitant therapy with weekly docetaxel for 4 weeks. Radiation therapy is given 5 days each week on Days 64-106 with a concomitant boost in the last 2 weeks of treatment. Amifostine is given as an injection on a daily basis during radiotherapy.
62556822|NCT01471743|EXPERIMENTAL|Impact Advance Recovery (R)|3 supplements per day for 5 days pre-operatively
62556823|NCT01471743|ACTIVE_COMPARATOR|Standard Supplement|3 supplement per day for 5 days pre-operatively
62556824|NCT03864419|EXPERIMENTAL|Cohort I (pediatric BL)|Patients receive cyclophosphamide IV and vincristine IV on day 1, and prednisone IV or PO on days 1-7 in the absence of disease progression or unacceptable toxicity. Patients then receive rituximab IV or rituximab hyaluronidase SC, cyclophosphamide IV, vincristine IV, and methotrexate IV on day 1. Cycles repeat every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
62556825|NCT03864419|EXPERIMENTAL|Cohort II (DLBCL)|Patients receive rituximab IV or rituximab and hyaluronidase human SC, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1, and prednisone PO on days 1-5 of cycle 1. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
62556826|NCT03864419|EXPERIMENTAL|Cohort III (Adult BL)|Patients receive rituximab IV or rituximab and hyaluronidase human SC in day 1, etoposide IV, doxorubicin IV, and vincristine IV on days 1-4. Patients also receive cyclophosphamide IV on day 5 and prednisone PO on days 1-5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
62556827|NCT03864419|EXPERIMENTAL|Cohort IV (MCD)|Patients receive rituximab IV or rituximab and hyaluronidase human SC on days 1, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.
62556828|NCT06132061|EXPERIMENTAL|Intervention group for universal prevention|Level 1 intervention (universal prevention) group
62556829|NCT06132061|EXPERIMENTAL|Intervention group for selective prevention|Level 2 intervention(selective prevention) group
62556830|NCT06132061|EXPERIMENTAL|Intervention group for targeted prevention|Level 3 intervention(targeted prevention) group
62754728|NCT04673370|EXPERIMENTAL|Ba Duan Jin Group|Ba Duan Jin plus health education. Participants take part in 16-week program. The health education is conducted as the Health Education Group. Besides, the participants attended two 90-minute sessions of group-based Ba Duan Jin training per week and practiced at least three 30-minute Ba Duan Jin sessions at home per day.
62378275|NCT02894892|OTHER|(G)Control|(G)These patients underwent endoscopy due to abdominal discomfort or other symptoms and did not have cancers in the digestive tract after series of workup.
62556831|NCT06132061|OTHER|Control group|
62556832|NCT06227039|NO_INTERVENTION|No treatment|This arm will be the current standard of care
62556833|NCT06227039|EXPERIMENTAL|Vibroacoustic|This arm will use the vibroacoustic device to provide a mechanical stimulus to the patient as treatment to reduce pain and anxiety. Augmented reality glasses will be worn but will be turned off.
62556834|NCT06227039|EXPERIMENTAL|Augmented Reality|This arm will use the augmented reality game to provide a visual stimulus to the patient as treatment to reduce pain and anxiety. Vibroacoustic device will be worn but will be turned off.
62182471|NCT04274062||peri partum integrated nursing care of placenta previa|"* Part (1) personal data:~* Part (2) baseline and characteristics of the patients participants:~* Tool II- An observation checklist: This tool is develop by researcher according to guideline of Royal College of Obstetricians and Gynaecologists, 2018), and divide into three main parts: preoperative, intraoperative and postoperative.~* Part (1) pre-operative: includes assessment of :~* patients general condition~* investigation~* reserved blood~* Hemoglobin level~* Impact of hysterectomy option. -9-~Part (2) Intra-operative:~Includes assessment of :-~* Investigation~* Vital signs~* Hypothermia~* Blood loss~* I.V fluid~* Blood gases~* Fetal condition and APGAR score.~* Part (3) Post-operative: Includes:~* maternal complication~* fetal complication~* psychological satisfaction"
62378276|NCT03894202||Ultra-early aneurysm treatment|Ultra-early aneurysm treatment is defined as definitive cerebral aneurysm treatment such as coiling or clipping within the initial twenty-four hours.
62378277|NCT03894202||Non-ultra-early aneurysm treatment|Non-ultra-early aneurysm treatment is defined as definitive cerebral aneurysm treatment such as coiling or clipping after the initial twenty-four hours.
62378278|NCT03748875|EXPERIMENTAL|Intervention group|an 8-session mindfulness-based relapse prevention program
62556835|NCT06227039|EXPERIMENTAL|Combination vibroacoustic and augmented reality|This arm will use both the augmented reality game and vibroacoustic device to provide a visual stimulus to the patient as treatment to reduce pain and anxiety.
62556836|NCT00606632|OTHER|124-Iodine-cG250 (124I-cG250)|Single arm study, comparing 124I cG250 PET/CT and CT. Each patient underwent a PET/CT and CT scan days (+/-2days) after receipt of 124I cG250.
62556837|NCT03544723|EXPERIMENTAL|Ad-p53 with anti-PD-1/anti-PD-L1 100% of patients|Up to 40 patients, all patients treated with intra-tumoral Ad-p53 (dose determined by tumor size) in combination with IV physician's choice of approved immune checkpoint inhibitor
62556838|NCT01288079|EXPERIMENTAL|1|TC-5214, 1 mg BID
62556839|NCT01288079|EXPERIMENTAL|2|TC-5214, 4 mg BID
62556840|NCT01288079|ACTIVE_COMPARATOR|3|Duloxetine 60 mg Q Day
62754729|NCT04673370|ACTIVE_COMPARATOR|Health Education Group|Health education. Participants take part in 16-week program. The health education includes work, rest, diet and other basic programs according to the different conditions of participants.
62754730|NCT01904149|EXPERIMENTAL|DKP/TRAM followed by DKP/TRAM|Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
62754731|NCT01904149|ACTIVE_COMPARATOR|DKP followed by DKP|Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
62378279|NCT03748875|NO_INTERVENTION|Control group|treatment as usual
62378280|NCT04615429|EXPERIMENTAL|Mesenchymal Stromal cells|Approximately 1x10E6 MSC/kg
62378281|NCT04615429|PLACEBO_COMPARATOR|Control group|Solution identical to experimental treatment, without the MSC
62378282|NCT04341025|OTHER|Single Arm|Patients are compared to themselves before and after the treatment.
62556841|NCT01288079|PLACEBO_COMPARATOR|4|Placebo
62556842|NCT04610905|NO_INTERVENTION|Control group|This group will be asked to maintain their daily routine.
62556843|NCT04610905|EXPERIMENTAL|Reducing sedentary behavior|This group needs to download an app on their computer and their smartphone. This app will give a notification every 30 minutes to walk during 2 minutes during working hours.
62556844|NCT04610905|EXPERIMENTAL|Increase physical activity|This group will be asked to be more physically active. They need to be active during 150min/week. Additionnaly they need to be active in periods of at least 10 minutes.
62556845|NCT02245009||Pacemaker patients|Patients with pacemaker, presenting for cardioversion.
62556846|NCT02245009||ICD patients|Patients with ICD, presenting for cardioversion.
62754732|NCT01904149|ACTIVE_COMPARATOR|TRAM followed by TRAM|Tramadol-single dose followed by Tramadol-multiple doses
62754733|NCT01904149|OTHER|Placebo followed by DKP/TRAM|Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
62754734|NCT01904149|OTHER|Placebo followed by DKP|Placebo single dose followed by Dexketoprofen-multiple doses
62556847|NCT02245009||CRT patients|Patients with CRT device, presenting for cardioversion.
62556848|NCT01366131|EXPERIMENTAL|A|
62556849|NCT01366131|EXPERIMENTAL|B|
62556850|NCT03878927|EXPERIMENTAL|Cohort A|"CPX-351 : Daunorubicin 44mg/m\^2 and cytarabine 100mg/m\^2/day on Days 1,3 and 5 (90 minute IV infusion)~Gemtuzumab ozogamicin: 3mg/m\^2/day on Day 1 (2 hour IV infusion)"
62754735|NCT01904149|OTHER|Placebo followed by TRAM|Placebo single dose followed by Tramadol-multiple doses
62556851|NCT03878927|EXPERIMENTAL|Cohort B|"CPX-351: Daunorubicin 44mg/m\^2 and cytarabine 100mg/m\^2 on Days 1, 3 and 5 (90 minute IV infusion)~Gemtuzumab ozogamicin: 3mg/m\^2 on Days 1, 4 (2 hour IV infusion)"
62556852|NCT03878927|EXPERIMENTAL|Cohort C|"CPX-351: Daunorubicin 44mg/m\^2 and cytarabine 100mg/m\^2 on Days 1, 3, and 5 (90 minute IV infusion)~Gemtuzumab ozogamicin: 3mg/m\^2 on Days 1, 4 and 7 (2 hour IV infusion)"
62556853|NCT03385317|EXPERIMENTAL|Mindfulness|
62754736|NCT05098938|EXPERIMENTAL|Acyclovir 50mg buccal/topical tablet treatment group|
62754737|NCT05098938|PLACEBO_COMPARATOR|Matching placebo group|
62754738|NCT06099418|EXPERIMENTAL|VB10.16 + placebo|"9 mg VB10.16 via i.m. needle free injections in the deltoid muscles and quadricep or gluteus muscle.~Placebo will be given via IV infusions."
62754739|NCT06099418|EXPERIMENTAL|VB10.16 + atezolizumab|"9 mg VB10.16 via i.m. needle free injections in the deltoid muscles and quadricep or gluteus muscle.~Atezolizumab will be given via IV infusions."
62754740|NCT05280106|EXPERIMENTAL|Pre-dilution online hemodiafiltration|The study was conducted for a 28-week period in two phases: For the first 12 weeks, all of the patients were subjected to CD with pre-dilution oL-HDF.After enrollment, all patients began a 2-week run-in period with conventional dialysis fluid containing acetate and the lowest dose of unfractionated heparin. The investigator titrated the heparin dose by reducing the dose step by step, 25% in each step, until the final minimal dose was achieved. The experimental study consisted of 3 phases, 4 weeks in each phase, and the phases were separated by 1-week washout periods. The second phase will run after finishing the first phase with the same protocol but with post-dilution online HDF.There will be 2 weeks washout period before starting this phase
62754741|NCT03106844|EXPERIMENTAL|Treatment|All patients in this study will receive Fecal Microbiota Tranplantation
62754742|NCT00420940|EXPERIMENTAL|90 Hz whole-body vibration|20-minute daily whole-body vibration at 90 Hz and 0.3g
62754743|NCT00420940|EXPERIMENTAL|30 Hz whole-body vibration|20-minute daily whole-body vibration at 90 Hz and 0.3g
62754744|NCT00420940|NO_INTERVENTION|control|control group (receiving no vibration)
62754745|NCT05788588|EXPERIMENTAL|HR19006|
62754746|NCT05788588|ACTIVE_COMPARATOR|All-in-one parenteral nutrition|
62754747|NCT03575117|EXPERIMENTAL|NCI HYT--GA + CSM--Be Well|"Participants who view the Common Sense Model (CSM) Be Well text and image communication will be invited to receive two sets of daily text messages: (1) one text message and one image per day and (2) National Cancer Institute (NCI) HealthyYouTXT-Get Active (HYT-GA) program that is delivered 2-5 times daily for 6 weeks. After baseline and at timepoint 2, participants will view a slide presentation with imagery and text related to colorectal cancer risk and sedentary lifestyle. The same messages will be delivered as a drip campaign alongside the NCI HYT-GA text messaging program."
62556854|NCT03026491||Children with chewing dysfunction|Descriptive characteristics including age, height, weight, transition time to additional food, meal time, number of meals, initial teething time, and number of teeth, were noted. The presence of open mouth, open bite, high palate, gag reflex, and oral hygiene were scored as absent or present as an observational oral motor assessment. Chewing evaluation was performed and scored with the Karaduman Chewing Performance Scale (KCPS). The International Dysphagia Diet Standardisation Initiative (IDDSI) was used to determine the tolerated food texture of children.
62556855|NCT03026491||Children without chewing dysfunction|Descriptive characteristics including age, height, weight, transition time to additional food, meal time, number of meals, initial teething time, and number of teeth, were noted. The presence of open mouth, open bite, high palate, gag reflex, and oral hygiene were scored as absent or present as an observational oral motor assessment. Chewing evaluation was performed and scored with the Karaduman Chewing Performance Scale (KCPS). The International Dysphagia Diet Standardisation Initiative (IDDSI) was used to determine the tolerated food texture of children.
62556856|NCT05430646|EXPERIMENTAL|CMUS group|Balloon dilatation and CMUS insertion were performed in this group.
62556857|NCT05430646|ACTIVE_COMPARATOR|Tandem DJ stent group|Balloon dilatation and Tandem DJ stent insertion were performed in this group.
62556858|NCT04507399|EXPERIMENTAL|Protein Beverage|Whey Protein Beverage
62556859|NCT04507399|EXPERIMENTAL|Control Beverage|Whey Permeate Beverage
62556860|NCT04831814|EXPERIMENTAL|Near Focus NBI|Use of the Near Focus NBI to make optical diagnosis
62556861|NCT04831814|ACTIVE_COMPARATOR|Standard Focus NBI|Use of the Standard Focus NBI to make optical diagnosis
62556862|NCT01184495|EXPERIMENTAL|Epoetin Bio-Manguinhos|
62556863|NCT01184495|ACTIVE_COMPARATOR|EPO-BioSimilar|Subcutaneous administration of EPO-BioSimilar
62754748|NCT03575117|OTHER|NCI HYT--GA + ACS usual messages|Adapted American Cancer Society (ACS) informational messages about colorectal cancer risk and lifestyle will be invited to receive one set of daily text messages, NCI HealthyYouTXT-Get Active (HYT-GA) program that is delivered 2-5 times daily for 6 weeks. After baseline and at timepoint 2, participants will view an informational slide presentation that is based on adapted language from American Cancer Guidelines related to cancer prevention and physical activity (https://www.cancer.org/healthy/eat-healthy-get-active/acs-guidelines-nutrition-physical-activity-cancer-prevention.html).
62754749|NCT04850976|EXPERIMENTAL|Self-Assembled Modified Macintosh Videolaryngoscope (SAM-VL) group|The self-assembled modified Macintosh videolaryngoscope (SAM-VL) used in this study was constructed from a portable video camera with Wi-fi connection (Wi-fi Endoscope Video Camera model YPC99) attached to a no. 4 Macintosh Laryngoscope blade (Riester® no.7040). The video signal is transmitted to an Android-based mobile phone (Android version 7.0). The portable 2 megapixels video camera is 8 mm in diameter with 8 Light Emitting Diode (LED) lights for adjustable lighting level and 3 meters cable length. Video resolution output is 640x480 pixels (VGA) and 1280x720 pixels (HD). The camera has 70º visual angle with focus length of 4- 6cm and is water-resistant. The camera was taped to the Macintosh blade at a distance of 5 cm from the distal end of the blade, using transparent waterproof Leukofix® tape.
62556864|NCT03295227|EXPERIMENTAL|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62556865|NCT00810147|ACTIVE_COMPARATOR|A1|
62556866|NCT00810147|ACTIVE_COMPARATOR|A2|
62556867|NCT00810147|ACTIVE_COMPARATOR|A3|
62556868|NCT00810147|ACTIVE_COMPARATOR|A4|
62556869|NCT00810147|PLACEBO_COMPARATOR|A5|
62754750|NCT04850976|ACTIVE_COMPARATOR|McGrath MAC® videolaryngoscope (McGrath) group|The McGrath MAC® videolaryngoscope used in this study was equipped with disposable blade no.4
62754751|NCT05041595||Sick Cohort|Borreliosis Subjects - All comers expressing signs and symtoms consistent with suspicion of acute Borreliosis and under medical examination for Lyme disease Borreliosis subjects with an Erythema Migrans Rash (subgroup)
62754752|NCT05041595||Apparently Healthy|Apparently healthy subjects living in an area non-endemic for Lyme disease Apparently healthy subjects living in an area endemic for Lyme disease
62754753|NCT04203069|PLACEBO_COMPARATOR|Control group : Day-time compression sleeve|Control group : Patients will wear the Day-time compression sleeve : THUASNE lymphatrex (± mitten) during 90 days.
62754754|NCT04203069|EXPERIMENTAL|Day-time compression sleeve and Night-time MOBIDERM Autofit|Intervention group : Patients will wear the Day-time compression sleeve : THUASNE lymphatrex (± mitten) + night-time Auto-Adjustable MOBIDERM® Autofit Armsleeve device with the possibility to wear an additional MOBIDERM® glove if a patient has a finger edema during 90 days.
62754755|NCT06241001|EXPERIMENTAL|Eccentric streching|Group A will receive eccentric stretching for ankle sprain
62754756|NCT06241001|ACTIVE_COMPARATOR|IASTM|Group B will only receive IASTM.
62754757|NCT01701479|EXPERIMENTAL|Experimental arm|"Subcutaneous aldesleukin (IL-2) will be given at a dose of 6 x 106 IU/m2/day in two 5 day blocks (days 1-5 and 8-12).~A continuous infusion of ch14.18/CHO is started on day 8. The duration of the infusion is dependent on the assigned infusion schedule. The duration will range from 10 to 21 days. Three dose levels will be considered with respect to daily dose (7 mg/m2, 10 mg/m2, 15 mg/m2), which relates to total doses of 100 mg/m2,150 mg/m2 and 210 mg/m2.~Patients will receive isotretinoin (13-cis-RA) 160 mg/m²/day divided into two equal doses given orally twice a day for 14 days after the completion of the ch14.18/CHO infusion. The starting day is dependent on the duration of ch14.18/CHO infusion and may be either day 19, 23, 24 or 30."
62754758|NCT01701479|ACTIVE_COMPARATOR|Comparator arm|"A continuous infusion of ch14.18/CHO is started on day 8. The duration of the infusion is dependent on the assigned infusion schedule. The duration will range from 10 to 21 days. Three dose levels will be considered with respect to daily dose (7 mg/m2, 10 mg/m2, 15 mg/m2), which relates to total doses of 100 mg/m2,150 mg/m2 and 210 mg/m2.~Patients will receive isotretinoin (13-cis-RA) 160 mg/m²/day divided into two equal doses given orally twice a day for 14 days after the completion of the ch14.18/CHO infusion. The starting day is dependent on the duration of ch14.18/CHO infusion and may be either day 19, 23, 24 or 30."
62754759|NCT00442520||2|colorectal cancer patients
62754760|NCT00442520||3|head and neck cancer patients
62754761|NCT00442520||1|lung cancer patients
62754762|NCT03142555|EXPERIMENTAL|Health talk plus intensive social media intervention|"Subjects in this group will receive:~1. General health talk;~2. Phone follow-up/counselling service (15 - 30 minutes);~3. Social media (intensive reminders);~4. Regular personalized what's app interaction ( up to 2 months duration)"
62754763|NCT03142555|PLACEBO_COMPARATOR|Health talk plus less intensive social media intervention|"Subjects in this group will receive:~1. General health talk;~2. Phone follow-up/counselling service (15 - 30 mintues);~3. Social media ( less intensive reminders)"
62754764|NCT04171791|EXPERIMENTAL|ABT-199 (Venetoclax)|Patients with Cutaneous T Cell Lymphoma (CTCL) will receive ABT-199 (Venetoclax).
62754765|NCT05019612||single-group/one cohort|Women with endometriosis, having the clinical indication for laparoscopic endometriosis excision
62754766|NCT02609230|EXPERIMENTAL|A|For the first arm (A), dose escalation will use the following single patient dose-escalation cohorts based on 'Design 4' proposed by Simon and colleagues: 125, 250, and 500 mg. every 3 weeks.
62754767|NCT02609230|EXPERIMENTAL|B|Following completion of Arm A dose escalation, subsequent cohorts will be tested in a minimum of 3 patients, the Arm B dose cohort will consist of dose levels administered every week (planned dosing of 250, 375, 500 and 625 mg).
62754768|NCT00969761|EXPERIMENTAL|A. BI 6727-cisplatin|patient to receive 3-weekly infusion escalating dose of BI 6727 combined to cisplatin
62754769|NCT00969761|EXPERIMENTAL|B. BI 6727-carboplatin|patient to receive 3-weekly infusion escalating dose of BI 6727 combined to carboplatin
62754770|NCT04449952|EXPERIMENTAL|AFEO-Containing Mouth Rinse|Participants with Diabetes (Type 1 and 2) will be randomized to receive AFEO-containing mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 milliliter (mL) of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.
61986680|NCT04781673|ACTIVE_COMPARATOR|Lidocaine|"Infusion initiation: 1 mg/kg/hr Max: 2 mg/kg/hr Recommended titration:0.25 mg/kg/hr\* as needed every 4 hours based on pain scores ≥5 and physician order~Dosing will be based on patient actual body weight (ABW) recorded as dosing weight on time of hospital admission."
62556870|NCT05175235|EXPERIMENTAL|CURATE.AI|"Participants will undergo two treatment periods: selection period and CURATE.AI modulation period. During the selection period, baseline ctDNA measurements and CT scans will be performed. Subsequently, participants will receive Standard of Care (SOC) doses of nivolumab/pembrolizumab and have their ctDNA measured at the end of the third cycle together with other SOC monitoring.~After the first ctDNA measurement and CT scan, selected patients who responded to treatment through both ctDNA and CT scan may continue into the CURATE.AI modulation period. Non-responders will receive SOC doses of nivolumab/pembrolizumab for 2 cycles before having their ctDNA measured and CT scan at the end of the 2 cycles. Subsequent responders through both ctDNA and CT scans may then continue into the CURATE.AI modulation period.~Only the dose of nivolumab/pembrolizumab will be modulated with CURATE.AI, based on measurements of the response marker (ctDNA)."
62556871|NCT02554071|EXPERIMENTAL|Pharmacist - Smoking Cessation Support'|Active Comparator Arm Receive smoking assessment Initial Smoking Cessation Counselling Smoking Cessation Prescription/Non-Prescription Product as required Follow-up Counselling
62556872|NCT03588091|EXPERIMENTAL|arm1|Pyrotinib Plus trastuzumab and docetaxel
62556873|NCT03588091|PLACEBO_COMPARATOR|arm2|placebo plus trastuzumab and docetaxel
62556874|NCT04835974|EXPERIMENTAL|diabetic patients with reflow phenomenon|All Assiut University heart Hospital patients ,and who meet the listed inclusion and exclusion criteria will be eligible for the study. Patients' charts will be retrieved based on their intervention procedures. The charts will be reviewed and eligible patients will be filtered. The needed variables will be entered into our data base for later data analysis.
62556875|NCT04952181|EXPERIMENTAL|optical biometry|
62556876|NCT04952181|EXPERIMENTAL|ultrasonic biometry|
62556877|NCT03333993|EXPERIMENTAL|Intervention Group|Patients in this group will be submitted to 10 sessions of Mat Pilates exercises, performed twice a week, lasting 60 minutes, for a period of 5 weeks (from the beginning to the end of radiotherapy). The program will consist of group sessions of up to 4 patients, supervised by a specialized physiotherapist. In addition, they will be guided to follow with the home exercises, according to the institutional routine.
62556878|NCT03333993|ACTIVE_COMPARATOR|Control Group|Patients assigned to this group will not participate in the Mat Pilates exercises and will be instructed to maintain the home exercises for upper limbs, guided by physiotherapists in the postoperative period, according to the institutional routine.
62556879|NCT02120196|EXPERIMENTAL|rifaximin|Arm 1: 109 patients will be treated with 1200 mg of rifaximin daily for 6 months.
62556880|NCT02120196|ACTIVE_COMPARATOR|norfloxacin|Arm 2: 109 patients will be treated with 400 mg of norfloxacin daily for 6 months.
62556881|NCT02262455|EXPERIMENTAL|STM 434|
62556882|NCT02262455|EXPERIMENTAL|STM 434 and Liposomal Doxorubicin|
62556883|NCT03751501|EXPERIMENTAL|Experimental Group|Indocyanine green-Guided Targeted Laser photocoagulation combines routine procedures, that are, the detection of macro-aneurysms by ICG angiography, laser photocoagulation and optional post-laser verification of the effectiveness of the photothrombosis by OCT. Indocyanine green-Guided Targeted Laser photocoagulation is administered in combination with anti VEGF treatment
61986681|NCT05546931|EXPERIMENTAL|Intervention|A smartphone-based, interactive coaching application designed to enhance adherence to home-based blood pressure monitoring, provided guidance on blood pressure management, patient-facing education, and assistance with modifying behaviors associated with poor blood pressure control; connected to a wireless blood pressure cuff for accurate blood pressure measurement and automated storage on a digital platform. All participants in the experimental arm receive a smartphone for the 6-month intervention duration and the home-based blood pressure cuff.
62182472|NCT04274062||peri partum regular care of placenta previa|Routine nursing care of all cases of placenta previa (preoperative, intraoperative and postoperative)..
62556884|NCT03751501|SHAM_COMPARATOR|Control Group|Sham laser is administered at randomization visit and repeated if needed 3 month later in combination with anti VEGF treatment
62556885|NCT05211648|EXPERIMENTAL|Patients with Aktiia bracelet|This is a prospective open-label single arm study. Study participants will wear the Aktiia bracelet for 6 months and will continue in parallel the procedures of the Remote Hypertension Program.
62556886|NCT02040805|EXPERIMENTAL|Group Cognitive-Behavioral Therapy|Sixteen sessions of group therapy facilitated by a psychologist.
62556887|NCT02040805|EXPERIMENTAL|Peer Facilitated Support Group|Fifteen sessions of peer-facilitated group support.
62556888|NCT00969111|EXPERIMENTAL|Postop Non-High Risk|Proton to 66.6 CGE
62556889|NCT00969111|EXPERIMENTAL|Postop High Risk|IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE
62556890|NCT00969111|EXPERIMENTAL|Salvage Non-High Risk|Proton to 70.2 CGE
62556891|NCT00969111|EXPERIMENTAL|Salvage High Risk|IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE
62556892|NCT05483790|EXPERIMENTAL|multidomain intervention|The interventions were conducted for 6-week training phase and 6-week maintenance phase. Including cognitive training, physical exercise, healthy lifestyle education, and computerized interaction training. The multimodal intervention program included the in-person training course (90-minute, once per week for 6 weeks), computerized interaction training (30-minute, 3 times per week for 6 weeks), and homework (30-minute, every day for 12 weeks).
62754771|NCT04449952|EXPERIMENTAL|Listerine Cool Mint Mouth Rinse (Marketed product)|Participants with Diabetes (Type 1 and 2) will be randomized to receive Listerine cool mint mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 mL of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.
62754772|NCT04449952|EXPERIMENTAL|5 Percent (%) Hydroalcohol Mouth Rinse|Participants with Diabetes (Type 1 and 2) will be randomized to receive 5% Hydroalcohol mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 mL of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.
62754773|NCT04965948|EXPERIMENTAL|Active group|Snack enriched with camelina sativa oil
62754774|NCT04965948|PLACEBO_COMPARATOR|Placebo group|Snack no enriched with camelina sativa oil
62754775|NCT01654159|PLACEBO_COMPARATOR|Monofocal|"Monofocal IOL Implant~Manufacturers of IOLs used as monofocal comparator are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
62754776|NCT01654159|EXPERIMENTAL|Multifocal|"Multifocal IOL~Manufacturers of multifocal IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
62754777|NCT01654159|EXPERIMENTAL|Toric|"Toric IOL~Manufacturers of toric IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
62556893|NCT05483790|NO_INTERVENTION|the control|Throughout the 6-week training phase and 6-week maintenance period, the control group only received 30-minute health education through booklets, home visits, or phone calls once every week.
62556894|NCT01116063|EXPERIMENTAL|Single arm open label|All patients will receive the study drugs and will be evaluated
62556895|NCT02257281|EXPERIMENTAL|Active Therapeutic Ultrasound|The three inflammatory forearm spots on the same side induce by the experimentally skin model(1%, 0.5%, 0% SLS) treat with active therapeutic ultrasound .
62556896|NCT02257281|PLACEBO_COMPARATOR|Non-active Therapeutic Ultrasound|The contralateral three inflammatory forearm spots induce by the experimentally skin model(1%, 0.5%, 0% SLS) treat with non-active therapeutic ultrasound .
62556897|NCT04586673|EXPERIMENTAL|ChAdOx1.tHIVconsv1 low dose|3 participants will receive one dose of ChAdOx1.tHIVconsv1 at 5 x 10\^9 vp
62556898|NCT04586673|EXPERIMENTAL|ChADOx1.tHIVconsv1 higher dose|10 participants will receive one dose of ChAdOx1.tHIVconsv1 at 5 x 10\^10 vp and one dose each of MVA.tHIVconsv3 at 1 x 10\^8 pfu and MVA.tHIVconsv4 at 0.9 x 10\^8 pfu.
62556899|NCT03639779|EXPERIMENTAL|Sodium thiosulfate|50 ml vials of sodium thiosulfate (250mg/ml) will be used for treatment.
62556900|NCT03639779|PLACEBO_COMPARATOR|Saline solution|30 ml vials of sodium chloride 0.9% will be used for the control treatment.
62556901|NCT02147041|EXPERIMENTAL|EGCG(Epigallocatechin Gallate)|EGCG(Epigallocatechin Gallate)(500 mg, three times a day, 12 weeks)
62556902|NCT02147041|PLACEBO_COMPARATOR|placebo|cellulose (500mg, three times a day, 12 weeks)
62754778|NCT04284124|ACTIVE_COMPARATOR|Erector Spinae block|Done unilaterally with the patient in the prone position about 20 min before induction of general anesthesia. Skin is prepared by 10% povidone iodine. An ultrasound machine with a large bandwidth, multifrequency convex probe (1-8 MHz) will be used for block performance. A 22G, 50-mm, at the T4 level of the spine using an in-plane approach. Probe is placed 2-3 cm laterally to the spine using a sagittal approach. Once the erector spinae muscle and the transverse processes is identified, the needle will be inserted deep into the muscle. The needle will be directed from a cranial to a caudal direction. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of local anesthetic, 20 ml of 0.25% bupivacaine will be administered for block performance. Distribution of local anesthetic will be observed in both cranial and caudal directions.
62556903|NCT05475314|EXPERIMENTAL|ReFerm(R); fermented oat gruel|ReFerm® is manufactured by the fermentation of an oat gruel with L. plantarum 299v. The product is tested for pH and colony-forming units (CFU) of Enterobacteriaceae, yeasts/moulds, and L. plantarum 299v. The pH must be \< 4.0, the CFU of Enterobacteriaceae and yeasts/moulds must be \< 100/mL, and the CFU for L. plantarum 299v must be \> 10E+08 immediately after completion of fermentation. The energy content of 100 mL ReFerm® is 58 kcal (240 kJ), from 1.6 g protein, 9.8 g carbohydrate, and 0.9 g fat. Each ReFerm® package contained 250 ml
62556904|NCT05475314|PLACEBO_COMPARATOR|Thick-it(R); thickened water|Thick-it ® mildly thick, Kent Precision Foods Group, Inc.; commercially available) was chosen as a placebo to mimic the viscosity. This product contains artesian mineral water and ≤ 2% xanthan gum, calcium chloride, malic acid, potassium benzoate, potassium sorbate (to preserve freshness), sodium hexametaphosphate, and disodium EDTA. The energy content of 237 mL Thick-it ® (one package) was 5 kcal (21 kJ) from 0 g protein, 1 g carbohydrate, and 0 g fat
62556905|NCT05334030|EXPERIMENTAL|Stroke|
62556906|NCT05334030|EXPERIMENTAL|Healthy|
62556907|NCT05325827|EXPERIMENTAL|Group A: H-FICB under ultrasound guidance before general anesthesia|Group A was subjected to a high fascia iliaca compartment block under ultrasound guidance before general anesthesia.
62556908|NCT05325827|NO_INTERVENTION|Group B: FBC combined with SBC under ultrasound guidance before general anesthesia|Group B was subjected to a femoral nerve block combined with a sciatic nerve block under ultrasound guidance before general anesthesia.
62556909|NCT03307226|EXPERIMENTAL|Youth Development Accounts (YDA)|"Youth Development Accounts (YDA)~* Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development~* Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)"
62754779|NCT04284124|ACTIVE_COMPARATOR|PECS type II block|Done unilaterally, patient is put in the supine position with ipsilateral arm abducted and externally rotated with elbow flexed 90 degrees. High frequency probe is put in the ipsilateral clavipectoral triangle between the clavicle medially and above and the shoulder joint laterally. The pectoralis major and minor and the plane between them are identified guided by pulsating thoracoacromial artery or its pectoral branch. Needle is advanced in plane targeting the space where the artery is located, 2ml of normal saline is injected to confirm the location. Then, 10 ml of bupivacaine 0.25% is injected. Probe is moved laterally and caudally towards the anterior axillary fold parallel to the deltopectoral groove till the serratus muscle slips appear underneath the pec minor attached to the underlying ribs. Targeting the plane between pec minor and serratus at the level of the third rib, 2 ml of normal saline is injected for confirmation of the needle tip then 20 ml of bupivacaine 0.25%.
62754780|NCT04125056|EXPERIMENTAL|test group|Hydronidone capsules (Specification: 30 mg / capsule）
62754781|NCT04125056|PLACEBO_COMPARATOR|Control group|Hydronidone capsules (Specification: 15 mg / capsule）
62754782|NCT04820257|EXPERIMENTAL|Home based exercise|Home based exercise with health coaching
62754783|NCT04820257|NO_INTERVENTION|Usual care|Usual care, waiting list
62754784|NCT05408507|EXPERIMENTAL|Older patients with advanced cancer|Patients over 60 years old with advanced, incurable cancer.
62754785|NCT06420219||Observational|Patients undergo photography, blood sample collection, tissue collection and have their medical records reviewed on study.
62378283|NCT02239029|ACTIVE_COMPARATOR|Platelet rich plasma|"Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.~Patients with bilaetral knee osteoarthritis randomized receive on dose of PRP in one knee and placebo with normal saline in the other side."
62556910|NCT03307226|EXPERIMENTAL|YDA + Multiple Family Groups (MFG)|"YDA + Multiple Family Groups (MFG)~* Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development~* Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs)~* Multiple Family Groups sessions focused on strengthening family relationships and mental health"
62754786|NCT04532593|EXPERIMENTAL|Stem cell group|
62754787|NCT04532593|PLACEBO_COMPARATOR|Control|
62754788|NCT01862471|EXPERIMENTAL|DVT prophylaxis|"Neuromuscular electrical stimulation using a custom-built, two-channel stimulator (Duo-STIM (stimulator), Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation was applied every 20 seconds over a period of 5 minutes.~Intermittent pneumatic compression using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 1 second duration over a period of 5 minutes."
62754789|NCT05352698||Non-Cardiac Surgery Patient|Our study population will be comprised of any patient undergoing non-cardiac surgery who meets standard of care criteria for BNP testing. This includes patients who are a) \>65 years old, b) revised cardiac risk index (RCRI) ≥1 or c) \>45 years old with significant cardiovascular disease (coronary artery disease, peripheral arterial disease, cerebral vascular disease, congestive heart failure, obstructive intracardiac disease such as severe aortic stenosis, severe mitral stenosis or severe hypertrophic obstructive cardiomyopathy)
62754790|NCT05282576|ACTIVE_COMPARATOR|Experimental Group|We applied neurophysiological facilitation techniques in addition to conventional rehabilitation.
62556911|NCT03307226|NO_INTERVENTION|Usual Care|Usual Care consisting of curricula delivered at secondary schools in Uganda including Life Planning Skills, and Adolescent Sexual Reproductive Health
62378284|NCT02239029|PLACEBO_COMPARATOR|normal saline|Normal saline was injected into the other side of knee as the control group.
62378285|NCT01982669||Different degree of spicy food intake|
62378286|NCT01172561|ACTIVE_COMPARATOR|Usual Care Group|All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
62754791|NCT05282576|OTHER|Control Group|Critical ill patients was applied their conventional physiotherapy
62754792|NCT03537742|EXPERIMENTAL|alirocumab|alirocumab 150mg subcutaneous every other week for one year following start of study drug
62754793|NCT03537742|PLACEBO_COMPARATOR|placebo|placebo to match alirocumab every other week for one year following start of study drug
62754794|NCT01323270|EXPERIMENTAL|rLP2086|rLP2086 and Repevax
62556912|NCT01687894||Vasopressins & propofol|Administer vasopressin 0.05 or 0.07 IU/kg before sitting position during propofol anesthesia.
62378287|NCT01172561|EXPERIMENTAL|Lay Health Advisor Intervention|The Lay Health Advisor education intervention - The intervention consisted of an intensive, reinforced, one on one, interactive ed. program (an initial meeting, then 2 calls and a series of 4 postcards mailed at regular intervals and a 2nd visit. Woman were enrolled for about 12 to 14 months.
62556913|NCT01687894||Placebo & propofol|Administer saline 10 ml (placebo) 2 min before beach chair position during propofol anesthesia
62556914|NCT01687894||Vasopressins & sevoflurane|Administer vasopressin 0.05 or 0.07 IU/kg 2 min before beach chair position during sevoflurane anesthesia
62754795|NCT01323270|PLACEBO_COMPARATOR|Saline and Repevax|Saline and Repevax
62754796|NCT05151640||Nintedanib treatment group|
62754797|NCT01819129|EXPERIMENTAL|Faster-acting insulin aspart (FIAsp)|Meal time faster-acting insulin aspart is given in combination with once daily insulin glargine and metformin in a basal-bolus regimen. Insulin glargine and metformin treatment are open labelled background medication.
62754798|NCT01819129|ACTIVE_COMPARATOR|Insulin aspart|Meal time insulin aspart is given in combination with once daily insulin glargine and metformin in a basal-bolus regimen. Insulin glargine and metformin treatment are open labelled background medication.
62754799|NCT03511625|EXPERIMENTAL|Acthar|80 units of Acthar Injectable Product will be injected subcutaneously daily for three days, followed by twice weekly for four weeks.
62556915|NCT01687894||Placebo & sevoflurane|Placebo (saline 10 ml) for vasopressin is administered 2 min before beach chair position during sevoflurane anesthesia
62556916|NCT01526655|ACTIVE_COMPARATOR|Abdominal total hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision
62556917|NCT01526655|ACTIVE_COMPARATOR|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
62754800|NCT03511625|ACTIVE_COMPARATOR|Depo Medrol|40 milligrams of Depo Medrol will be injected intramuscularly one time
62754801|NCT05186831|EXPERIMENTAL|Text-based monitoring|Patients will be asked to take their BP two times daily and text their BP to the study phone number twice a day for 14 days.
62754802|NCT05186831|ACTIVE_COMPARATOR|Online patient portal|Patients will be asked to take their BP two times daily. They will be given instructions on how to upload BP readings to the online patient portal and will be asked to upload all BP readings. This represents enhanced standard of care.
62754803|NCT06127264|NO_INTERVENTION|NoCDO|Participants will complete study activities without wearing a CDO
62754804|NCT06127264|EXPERIMENTAL|SSCT|Participants will complete study activities while wearing a CDO fastened to their self-selected proximal cuff tightness
62754805|NCT06127264|EXPERIMENTAL|Loose|Participants will complete study activities while wearing a CDO fastened to a loose proximal cuff tightness
62378288|NCT05452187||Patients with IBD and chronic HCV infection treated with DAAs and/or interferon.|Cohort patients with IBD and chronic HCV infection treated with DAAs and/or interferon collected from the ENEIDA database.
62378289|NCT01784211|EXPERIMENTAL|LY2605541 (Part A)|0.5 units per kilogram (U/kg) LY2605541 subcutaneously (SC) once daily for 15 days. Part A involved 3 clamp procedures on Days 8, 11, and 14. Participants remained on their regular physician-prescribed mealtime insulin.
62754806|NCT06127264|EXPERIMENTAL|Moderate|Participants will complete study activities while wearing a CDO fastened to a moderate proximal cuff tightness
62378290|NCT01784211|ACTIVE_COMPARATOR|Glargine (Part A)|0.5 U/kg insulin glargine SC once daily for 15 days. Part A involved 3 clamp procedures on Days 8, 11, and 14. Participants remained on their regular physician-prescribed mealtime insulin.
62378291|NCT01784211|EXPERIMENTAL|First LY2605541 + Exercise,Then LY2605541 Alone (Part B)|0.5 U/kg LY2605541 SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 17 (no exercise on Day 20).Participants remained on their regular physician-prescribed mealtime insulin.
62378292|NCT01784211|EXPERIMENTAL|First LY2605541 Alone, Then LY2605541 + Exercise (Part B)|0.5 U/kg LY2605541 SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 20 (no exercise on Day 17). Participants remained on their regular physician-prescribed mealtime insulin.
62378293|NCT01784211|ACTIVE_COMPARATOR|First Glargine + Exercise, Then Glargine Alone (Part B)|0.5 U/kg insulin glargine SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 17 (no exercise on Day 20). Participants remained on their regular physician-prescribed mealtime insulin.
62378294|NCT01784211|ACTIVE_COMPARATOR|First Glargine Alone, Then Glargine + Exercise (Part B)|0.5 U/kg insulin glargine SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 20 (no exercise on Day 17).
62378295|NCT02701569|EXPERIMENTAL|Rebound exercise|Repeated jumping on a mini trampoline was performed with feet slightly apart
62754807|NCT06127264|EXPERIMENTAL|Tight|Participants will complete study activities while wearing a CDO fastened to a tight proximal cuff tightness
62378296|NCT02701569|NO_INTERVENTION|Control|No exercise was administered but participants continued with routine medical care
62754808|NCT01165788||autologous BMT recipients|Lymphoma patients who received an autologous BMT as adults
62754809|NCT06219837|ACTIVE_COMPARATOR|bupivacaine group|the patient in this arm will receive 20 ml of 0.25% bupivacaine injection by ultrasound guided transversalis fascia block for inguinal herniorraphy
61986682|NCT05546931|ACTIVE_COMPARATOR|Enhanced usual care|WebMD, a smartphone-based tool for learning about blood pressure and other health conditions. Enhanced usual care participants receive a wireless blood pressure cuff for accurate blood pressure measurement and automated storage on a digital platform. All participants in the experimental arm receive a smartphone for the 6-month intervention duration and the home-based blood pressure cuff.
62378297|NCT04089228|EXPERIMENTAL|Kinesiotape Group and INIT|Kinesiotaping and Integrated Neuromuscular Inhibition Technique (KT + INIT )
62378298|NCT04089228|ACTIVE_COMPARATOR|INIT Group|Integrated Neuromuscular Inhibition Technique (INIT)
61986683|NCT00376909|EXPERIMENTAL|Intervention|Series of telephone support calls from a trained prevention care manager
61986684|NCT00376909|NO_INTERVENTION|Usual Care|Usual care
61986685|NCT03571581|EXPERIMENTAL|Mindfulness Training (MT)|Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
61986686|NCT00895258|EXPERIMENTAL|IPS-CT|Participants will receive individual placement and support (IPS) plus cognitive training (CT).
62378299|NCT03739060|ACTIVE_COMPARATOR|Active TENS group|Conventional transcutaneous electric nerve stimulation
62378300|NCT03739060|PLACEBO_COMPARATOR|Placebo TENS group|0 amperes transcutaneous electric nerve stimulation
62378301|NCT03607461|EXPERIMENTAL|Smartphone App Users|Smartphone App Users will receive important information and prescriptive exercise via a smartphone app upon returning home from the hospital following total knee arthroplasty
62378302|NCT03607461|ACTIVE_COMPARATOR|Home Health Users|Home Health Users will have already undergone traditional home health physical therapy and/or skilled nursing for the purpose of comparing outcomes
62378303|NCT02087241|EXPERIMENTAL|AZD1775 + carboplatin + pemetrexed|Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.
62754810|NCT06219837|PLACEBO_COMPARATOR|20 ml of 0.9% normal saline solution|he patient in this arm will receive 20 ml of 0.9% normal saline solution by ultrasound guided transversalis fascia block for inguinal herniorraphy
62754811|NCT01253057||Experimental Group|
62754812|NCT01253057||Control Group|
62754813|NCT04108845|EXPERIMENTAL|experimental group|Received Vaccine: 15-valent pneumococcal Conjugate Vaccine, 0.5 ml/dose
62754814|NCT06357871||Test cohort|To establish the score
62754815|NCT06357871||Validation cohort|To validate the score
62754816|NCT04347473|EXPERIMENTAL|Ilumya|Ilumya 100mg subcutaneous at weeks 0, 4 and 16.
62754817|NCT04009200||circumcision|"Modified Yale Preoperative Anxiety Scores (m-YPAS), Visual Analogue Scale Anxiety (VAS-anxiety) will be evaluated when patients are taken to the preoperative waiting room.~After awakening, patients will be taken to the postoperative wake-up room where Pediatric Anesthesia Recovery Delirium Scores (PAED), Recovery Agitation 5-point Scores (EA), FLACC scores will be evaluated every 5 minutes and mean arterial pressure, pulse, SPO2 values will be recorded. Duration of stay in recovery unit will be recorded"
62754818|NCT04009200||inguinal hernia|"Modified Yale Preoperative Anxiety Scores (m-YPAS), Visual Analogue Scale Anxiety (VAS-anxiety) will be evaluated when patients are taken to the preoperative waiting room.~After awakening, patients will be taken to the postoperative wake-up room where Pediatric Anesthesia Recovery Delirium Scores (PAED), Recovery Agitation 5-point Scores (EA), FLACC scores will be evaluated every 5 minutes and mean arterial pressure, pulse, SPO2 values will be recorded. Duration of stay in recovery unit will be recorded"
62754819|NCT01238770|EXPERIMENTAL|Cyclophosphamid + Pazopanib|Cyclophosphamid + Pazopanib
61986687|NCT00895258|ACTIVE_COMPARATOR|IPS-ES|Participants will receive individual placement and support (IPS) plus enhanced support (ES).
62556918|NCT05980845|ACTIVE_COMPARATOR|Assigned Interventions|It was explained to the patients in the nature sounds group that nature sounds would be played for 30 minutes in three HD sessions for one week, starting from the beginning of the session. Afterwards, the patients were informed about the usage of the Mp3 player and in-ear headphones, they were demonstrated that they could adjust the volume to the level they desired, and it was stated that they should not detach the headphones until the 30-minute recording was over. The patients listened to nature sounds for 30 minutes in three HD sessions for one week under the supervision of the researcher.
62556919|NCT05980845|NO_INTERVENTION|Control Group|"Patients in the control group were not intervened by the researcher during the HD sessions. Before the first HD session started, the Descriptive Characteristics Form and Trait Anxiety Scale were performed by the researcher while the patients were in the waiting room. Then, in every three HD sessions for one week, when the patients went to their beds, their vital signs were measured and recorded on the Vital Signs Monitoring Form and the State Anxiety Scale was administered just before the HD treatment session was started. Then, the vital signs of the patients were measured and recorded on the Vital Signs Monitoring Form at the 30th minute, 1st, 2nd, 3rd hour of the HD session and immediately after the end of the HD session. At the same time, the State Anxiety Scale was performed again immediately after the end of the HD session. The patient was then transferred out of the unit."
62556920|NCT05560490|EXPERIMENTAL|FibroFix Cartilage P Implant + Drill set|Participants that have been implanted with FibroFix Cartilage P Implant using the FibroFix Drill Set
62556921|NCT02588963|EXPERIMENTAL|Experimental Group 1|Children whose caregivers were subjected to a health education session
62556922|NCT02588963|EXPERIMENTAL|Experimental Group 2|Children who were subjected to nasal clearance protocol
62556923|NCT02588963|EXPERIMENTAL|Experimental Group 3|Children whose caregivers were subjected to health education session and who were subjected to respiratory physiotherapy protocol
62556924|NCT02588963|PLACEBO_COMPARATOR|Control Group|Children who were not subjected to respiratory physiotherapy protocol for nasal clearance and whose parents were not subjected to health education session
62556925|NCT04941820|EXPERIMENTAL|Clinical pharmacist intervention + usual care arm|Patients in the clinical pharmacist intervention + usual care arm received the clinical pharmacist intervention as well as usual care provided by the surgical team
62556926|NCT04941820|NO_INTERVENTION|Usual care arm (Control arm)|Patients in the control arm received usual care by the surgical team without a coordinated contribution from the clinical pharmacist
62556927|NCT01276041|EXPERIMENTAL|pertuzumab in combination with trastuzumab and paclitaxel|This is a phase II study of pertuzumab in combination with trastuzumab and paclitaxel for the treatment of patients with Stage IV HER2 (+) breast cancer.
62556928|NCT04021888|EXPERIMENTAL|Exercise Group|
62556929|NCT04021888|ACTIVE_COMPARATOR|Control|
62556930|NCT01963741|EXPERIMENTAL|leukotriene D4|Nasal provocation test was induced by leukotriene D4 with a stepwisely concentration method (4 mcg/ml, 8 mcg/ml, 16 mcg/ml).
62556931|NCT01963741|EXPERIMENTAL|histamine|Nasal provocation test was induced by histamine with a stepwisely concentration method (0.4 mg/ml, 0.8 mg/ml, 1.6 mg/ml, 3.2mg/ml).
62556932|NCT03766516||Cohort|"1. Any patient planning to administer BrentuximabVedotin to treat the target disease.~2. Any patient administering BrentuximabVedotin to treat the target disease.~3. Any patient tracing BrentuximabVedotin after treating the target disease.~4. Any patient administering another salvage option for cancer as the target disease has relapsed after terminating treatment using BrentuximabVedotin."
62556933|NCT01305668||Emphysema phenotype|
62556934|NCT01305668||No-Emphysema phenotype|
62556935|NCT01995513|EXPERIMENTAL|Enzalutamide & Abiraterone/prednisone|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily
62556936|NCT01995513|ACTIVE_COMPARATOR|Enzalutamide placebo & Abiraterone/prednisone|Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily.
62556937|NCT02404805|EXPERIMENTAL|Sequence 1a|Sequence 1,2,3: simeprevir only, then dolutegravir only, then both simeprevir and dolutegravir.
62754820|NCT06450379||13-valent pneumococcal conjugate vaccine (PCV13): 3+0 group|Children less than 3 years having received 1 dose of (PCV13) at 6, 10 and 14 weeks of age
62754821|NCT06450379||13-valent pneumococcal conjugate vaccine (PCV13): 2+1 booster group|Children less than 3 years having received 1 dose of (PCV13) at 6 and 14 weeks of age and a booster at 9 months of age
62754822|NCT06450379||RTS,S/AS01 Vaccine-exposed|Children less than 3 years having received RTS,S/AS01 vaccine
62754823|NCT06450379||RTS,S/AS01 Vaccine-non exposed|Children less than 3 years having not received RTS,S/AS01 vaccine
62754824|NCT02310854|ACTIVE_COMPARATOR|ACL Reconstruction|Primary reconstructive surgery of ACL with hamstring autograft (All-inside, Arthrex, Napels, Florida, USA)
62556938|NCT02404805|EXPERIMENTAL|Sequence 1b|Sequence 1,3,2: simeprevir only, then both simeprevir and dolutegravir, then dolutegravir only.
62556939|NCT02404805|EXPERIMENTAL|Sequence 2a|Sequence 2,1,3: dolutegravir only, then simeprevir only, then both simeprevir and dolutegravir.
62556940|NCT02404805|EXPERIMENTAL|Sequence 2b|Sequence 2,3,1: dolutegravir only, then both simeprevir and dolutegravir, then simeprevir only.
62556941|NCT02404805|EXPERIMENTAL|Sequence 3a|Sequence 3,1,2: both simeprevir and dolutegravir, then simeprevir only, then dolutegravir only.
62556942|NCT02404805|EXPERIMENTAL|Sequence 3b|Sequence 3,2,1: Both simeprevir and dolutegravir, then dolutegravir only, then simeprevir only.
62378304|NCT02087241|EXPERIMENTAL|Placebo + carboplatin + pemetrexed|Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.
62378305|NCT02804685|NO_INTERVENTION|Control|It consists on only a regular training performance
62556943|NCT05536063|EXPERIMENTAL|group A|bilateral ESPB with 0.5 ml/kg of 0.25% bupivacaine (limited to a maximum dose of 20 ml) for each side
62754825|NCT02310854|EXPERIMENTAL|ACL Repair|Primary augmented suture of ACL using Dynamic Intraligament Stabilization (DIS; Mathys Medical Bettlach, Switzerland)
62754826|NCT03024333||Healthy subjects|"Healthy subjects are:~1. Between 19-60 years old~2. Able to sign the informed consent after the whole study is explained to them~3. Self-reporting no history of swallowing disorders, neurological deficits and/or cancer of the mouth, neck or brain, or head or neck surgery~4. Able to sit upright with or without back support of chair~5. No other diseases affect swallowing function"
62556944|NCT05536063|EXPERIMENTAL|Group B|bilateral ESPB with 0.5 ml/kg of 0.25% bupivacaine (limited to a maximum dose of 20 ml) + dexamethasone 0.1 mg/kg for each side
62556945|NCT05536063|NO_INTERVENTION|Group C|control group will receive the standard analgesic regimen only
61986688|NCT02629341|ACTIVE_COMPARATOR|Functional yogurt powder|This arm will receive one daily serving of the functional yogurt which is enriched in Calcium, D, K, C vitamins, Zn, Mg, L-leucin and the Lactobacillus plantarum 3547 probiotic
61986689|NCT02629341|PLACEBO_COMPARATOR|Control yogurt powder|This arm will receive one daily serving of the control yogurt which consists of a regular yogurt not enriched
62556946|NCT01609868|ACTIVE_COMPARATOR|control|infants in this arm will receive the current treatment that is standard of care for these infants, powder protein modular to achieve 4 gm/kg/day
62556947|NCT01609868|EXPERIMENTAL|experimental|this group will receive a liquid protein modular that recently became commercially avaliable, to achieve the same protein of 4 grm/kg/day as the powder comparision group
62556948|NCT01725035||Fatty liver|
62754827|NCT01121627|EXPERIMENTAL|Computerized cognitive training|A 12 week computerized cognitive training
62754828|NCT03760757|EXPERIMENTAL|PCSO-524® (no krill oil)|Four total capsules per day (2 in the morning; 2 at night) for 29 days. Amounts per day equal to 800 mg olive oil, 400 mg lipid extract (\~58 mg EPA and 44 mg DHA) and 1.8 mg vitamin E (d-alpha-tocopherol).
62754829|NCT03760757|EXPERIMENTAL|ESPO-572® (75% PCSO-524®, 25% krill oil)|Four total capsules per day (2 in the morning; 2 at night) for 29 days. ESPO-572®, a 75/25% PCSO-24®/Krill oil blend. Each capsule of the ESPO-572® contains green lipped mussel oil, krill oil, olive oil and vitamin E.
62556949|NCT01725035||Non Fatty liver|
62556950|NCT04583735|OTHER|TEPEZZA|Participants received intravenous infusion of 10 milligrams per kilogram (mg/kg) teprotumumab at first infusion and then 20 mg/kg once every 3 weeks (Q3W) for next 7 infusions during the double masked treatment period. Proptosis non-responders who completed the double-masked treatment period had opted to receive 10 mg/kg teprotumumab at first infusion and then 20 mg/kg Q3W for next 7 infusions during open label treatment period.
62378306|NCT02804685|EXPERIMENTAL|Experimental|It consists on performing the protocol which includes 6 strength, agility and balance exercises together with the regular training. The exercise program has to be performed twice a week during 6 weeks
62378307|NCT04844450|EXPERIMENTAL|Single Ascending Dose (SAD)|Participants in cohorts 1-5 and cohorts 3a-5a will receive subcutaneous (SC) injection of single dose (Part A) of JNJ-75220795 or matching placebo.
62378308|NCT04844450|EXPERIMENTAL|Multiple Ascending Dose (MAD)|Participants in cohorts 6-8 will receive SC injection of 2 doses (Part B) of JNJ-75220795 or matching placebo. Participants in cohorts 9-11 will receive SC injection of 4 doses (Part C) of JNJ-75220795 or matching placebo.
62754830|NCT04332939|EXPERIMENTAL|Exercise + real tDCS|"Intervention will last 8 weeks where participants will be trained at a rate of 3 workouts per week.~For the first week, participants will receive 5 daily sessions of anodal tDCS (2 mA, 20 min)."
62378309|NCT02912741|EXPERIMENTAL|Vanish xt Extended Contact Varnish|Vanish xt Extended Contact Varnish is a resin modified glass ionomer cement and fluoride varnish used to treat white spot lesions to be more resistant to early caries progression.
62754831|NCT04332939|SHAM_COMPARATOR|Exercise + Sham tDCS|"Intervention will last 8 weeks where participants will be trained at a rate of 3 workouts per week.~For the first week, participants will receive 5 daily sessions of sham tDCS."
62378310|NCT02912741|ACTIVE_COMPARATOR|Resin infiltration|Resin infiltration is a low viscous resin infiltrates into small pores of white spot lesions to block entrance of bacteria into dentinal tubules of the tooth and more resistant to early caries progression.
62378311|NCT03249480|EXPERIMENTAL|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
62378312|NCT03656536|EXPERIMENTAL|Pemigatinib|
62378313|NCT03656536|ACTIVE_COMPARATOR|Gemcitabine + Cisplatin|Participants who experience disease progression while receiving gemcitabine + cisplatin or during the follow-up period and before starting a new anticancer therapy will be eligible to cross over and receive pemigatinib.
62378314|NCT03042494|PLACEBO_COMPARATOR|Control|Isocaloric food without the test prebiotic.
62378315|NCT03042494|EXPERIMENTAL|Prebiotic|Prebiotic consumed as one daily serving of 7 g in Group 1 and consumed as one daily serving of 2.5-3 g in Group 2.
62378316|NCT03639688|PLACEBO_COMPARATOR|Left-sided threading|Patients intubated with fiberoptic bronchoscope by threading the tube on the left labial commissure
62378317|NCT03639688|ACTIVE_COMPARATOR|Right-sided threading|Patients intubated with fiberoptic bronchoscope by threading the tube on the right labial commissure
62378318|NCT05791773||Group rTKA (robotic total knee arthroplasty)|the robot assisted total knee arthroplasty
62378319|NCT05791773||Group cTKA (conventional total knee arthroplasty)|the conventional jig-based total knee arthroplasty
62378320|NCT04688827|EXPERIMENTAL|training group 1: low-intensity resistance training|
62378321|NCT04688827|EXPERIMENTAL|training group 2: moderate-intensity resistance training|
62378322|NCT03140033|ACTIVE_COMPARATOR|Misoprostol oral tablets|79 women will recieve 400 micrograms of misoprostol ( misotac) sublingually and 20 IU of oxytocin at cord clamping
62378323|NCT03140033|PLACEBO_COMPARATOR|Ranitidine oral tablets|79 women will recieve ranitidine oral tablets sublingually and 20 IU of oxytocin at cord clamping
62754832|NCT02801721|ACTIVE_COMPARATOR|Stimulation|Stimulation group received psycho social stimulation. In the stimulation there were anemic and non anemic children. All anemic children received iron(syrup) supplementation.
62754833|NCT02801721|NO_INTERVENTION|No stimulation|No stimulation group did not receive any stimulation. In the no stimulation group there were anemic and non anemic children. All anemic children received iron (syrup) supplementation
62754834|NCT04538235||Bi-block (Serratus and erector spinae block) group|"The Bi-block consisted in performing an ESP block followed by a SAP block on the side ipsilateral to the thoracic surgery. For the ESP block, 40 ml of Ropivacaine 2mg/ml were injected under the erector spinae muscle plane, at the level of the 4th thoracic vertebra. For the SAP block, 40 ml of Ropivacaine 2 mg/ml were injected under the serratus anterior muscle plane. The cumulative dose of Ropivacaine did not exceed 3 mg/kg.~Regional anesthesia was performed before surgery."
62754835|NCT04538235||Thoracic Epidural Analgesia (TEA) group|"The thoracic epidural was performed according to a standardized protocol, with a Tuohy needle via the median puncture technique, at the level of T4-T5 intervertebral space. After a test dose of 2 to 3 ml of Lidocaine, 5 to 10 ml of a mixture of Ropivacaine 2 mg/ml and Sufentanil 0.5 µg / mL were injected. Epidural continuous administration was performed with the same mixture of anesthetic connected to a CADD Solis ™ pump set according to a PCEA protocol adapted to the patient's weight (continuous flow rate from 3 to 6 ml/h, self-administered bolus dose from 3 to 5 ml, refractory period 30 min).~Regional anesthesia was performed before surgery."
62754836|NCT05637489|EXPERIMENTAL|Treatment|Patients receive PING administered by RN
62754837|NCT05637489|NO_INTERVENTION|Control|Usual care
62754838|NCT03818347|EXPERIMENTAL|oxyhydrogen generator (AMS-H-03)|Model: AMS-H-03 Rated gas output (L) : 3L/min, concentration of hydrogen and the oxygen was 66.6% and 33.3%, respectively In this group, the patients will inhale hydrogen and oxygen with oxyhydrogen generator. The check indexes are questionnaire of sleep, diet and exercise, CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62754839|NCT03818347|PLACEBO_COMPARATOR|Control|In this group, the patients will inhale normal air with analogue machine. The check indexes are questionnaire of sleep, diet and exercise, CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62754840|NCT04269577|EXPERIMENTAL|SSP training - early PD|Practice of the Swipe Slide Pattern task alone for a group of patients with early Parkinson's disease (PD)
62754841|NCT04269577|EXPERIMENTAL|SSP training - mid PD|Practice of the Swipe Slide Pattern task alone for a group of patients with mid-stage Parkinson's disease (PD)
62754842|NCT04269577|EXPERIMENTAL|SSP training - HC|Practice of the Swipe Slide Pattern task alone for a group of healthy age-matched controls (HC)
62754843|NCT03893240|OTHER|Participants with Late Onset Pompe disease|This is a multi-center, low-interventional study with a retrospective component in participants with LOPD. During a single study visit, assessments including but not limited to, liver health, neutralizing antibodies to SPK-3006 capsid and GAA, anti-GAA binding antibodies, GAA activity and GAA antigen levels will be performed. Additional information will be collected to provide retrospective evaluations relating to muscle and liver inflammation and/or injury. Historic data relating to Pompe disease will be collected from medical records. The retrospective and laboratory data collected may assist in providing baseline information for a future investigational gene therapy study.
62378324|NCT05474924|EXPERIMENTAL|Budesonide Intrapolyp injection|"patients are to receive Endoscopic Intrapolyp steroid injection weekly for 5 weeks, using the following technique, where 2 nasal packs soaked in xylometazoline hydrochloride 0.1%  Otrivin adult nasal drops applied one pack in each nostril for 5 minutes before injection, then using the 0° nasal endoscopy patients receive intrapolyp budesonide injection by 0.5 mg/ml budesonide respules commercially available as Pulmicort ampules 1 ml for each nostril using 1 cc 28 gauge needle sterile syringe, where injections carefully distributed amongst visible polyps avoiding visible vessels, No local anesthesia will be used before injections, patients come back to the clinic weekly to complete a series of 5 injections."
62556951|NCT04583735|PLACEBO_COMPARATOR|Placebo|Participants received teprotumumab matching placebo by intravenous infusion, Q3W for 8 infusions during the double masked treatment period. Proptosis non-responders who completed the double-masked treatment period had opted to receive 10 mg/kg teprotumumab at first infusion and then 20 mg/kg Q3W for next 7 infusions during open label treatment period.
62754844|NCT01686750|EXPERIMENTAL|Integrated care centers|"Integrated care centers will provide HIV prevention and treatment services to high risk populations of IDU or MSM in an accepting and supportive environment.~* HIV voluntary counseling and testing \& staging~* Risk reduction services including free condoms, needle and syringe exchange, opiate substitution therapy~* Substance abuse counseling~* Sexually transmitted infection screening and treatment~* Access to free antiretroviral therapy and adherence support~* Peer community outreach"
62754845|NCT01686750|NO_INTERVENTION|Standard services|In Standard Services sites, HIV testing, prevention, and treatment services will be available through standard venues. Government centers typically provide most HIV testing services and are the only source for free antiretroviral therapy. Non-governmental organizations typically provide prevention and risk reduction services.
62754846|NCT00645528|EXPERIMENTAL|Insulin Education Class Participants|Participation in an insulin educational class at week 0 and again at week 2
62754847|NCT04595682|EXPERIMENTAL|Study Participants|Participants in this group will track their menstrual cycle, provide daily saliva samples, and undergo two rounds of alcohol sensitivity testing (with both placebo and alcohol).
62754848|NCT03654170|EXPERIMENTAL|All Subjects|BI 425809 mixed with \[C14\] BI 425809
62754849|NCT03904953|EXPERIMENTAL|Study group|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
62754850|NCT03904953|ACTIVE_COMPARATOR|Control group|Stretching of erector spine, hip flexors, hamstring muscles and gastro-soleus muscles; back-strengthening of cervical, thoracic and lumbar spine and posture exercises will be taught to the patients in the first session and the patients will be requested to repeat the exercises three times a week for 8 weeks individually at home.
62182473|NCT03310671||CASES|"Cases:~* Age ≥ 65 years at the time of cardiac ultrasound~* Genetically diagnosed HFH or in a first-degree relative~* History of hypercholesterolemia with LDLc levels\> 220 mg / dL without lipid-lowering treatment"
62556952|NCT03612921|ACTIVE_COMPARATOR|oral group|the patients will receive oral amantadine sulfate using the dose 100 mg 90 minute prior to the surgery and infusion of100cm I.V saline
62556953|NCT03612921|ACTIVE_COMPARATOR|I.V group|the patients will receive 100 mg I.V amantadine sulfate infusion over 60minute prior to the surgery and placebo tablet 90 minute prior to the surgery
62556954|NCT03612921|PLACEBO_COMPARATOR|control group (group C)|the patients will receive placebo tablet 90 minute prior to the surgery and infusion of 100cm I.V saline over 60minute prior to the surgery
62556955|NCT04352101|EXPERIMENTAL|Bupropion|Participants randomized to take bupropion for 8 weeks.
62556956|NCT04352101|ACTIVE_COMPARATOR|Escitalopram|Participants randomized to take escitalopram for 8 weeks.
62556957|NCT06291896|OTHER|Single Arm|"All participants perform:~conventional breast examination path (i.e., screening mammogram, integrated with other radiological/histological output when deemed necessary by the responsible Investigator in each site) AND MammoWave exam."
62754851|NCT02887040|EXPERIMENTAL|Radiation|Study subjects receive a single daily radiation fraction of 180cGy, 5 days a week for 6 weeks overall, to a total radiation dose of 5400cGy.
62754852|NCT02887040|EXPERIMENTAL|Antineoplaston therapy + Radiation|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for 104 weeks. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Study subjects also receive a single daily radiation fraction of 180cGy, 5 days a week for 6 weeks overall, to a total radiation dose of 5400cGy.
62754853|NCT02323204|EXPERIMENTAL|Psychological First Aid|Link for Injured Kids, a form of psychological first aid
62754854|NCT02323204|ACTIVE_COMPARATOR|Trauma Education|"Educational materials, So you've been in an accident provided to parents."
62754855|NCT04746482||exposure group|subjects in this group are single visit
62754856|NCT06021158|ACTIVE_COMPARATOR|AID-count|
62754857|NCT06021158|EXPERIMENTAL|AID-estimate|
62556958|NCT02635412|PLACEBO_COMPARATOR|Scheduled delivery at 34 weeks|Scheduled delivery at 34 weeks (range 33 weeks 5 days to 34 weeks 3 days)
62754858|NCT06021158|EXPERIMENTAL|AID-detect|
62754859|NCT04991727||PEEP|The patient was admitted to the operating room, and routine ECG monitoring was performed. The patient was placed in supine position, and ultrasound lung examination was performed. The images of the patient were saved and the score of lung ventilation area was recorded. The induction of general anesthesia was started, and endotracheal intubation was performed after 3min of preoxygenation (100% O2) to establish a safe and effective artificial airway.Mechanical ventilation was performed after endotracheal intubation, and a second time was performed immediately after endotracheal intubation was completed.Pulmonary ultrasound was performed. The PEEPgroup was given the first RM (pulmonary retraction) with pressure maintained at 40cmH2O for 30s, followed by a 7cmH2O PEEP to maintain mechanical ventilation, and the RMS was repeated every 30 minutes until the end of surgery
62754860|NCT04991727||ZEEP|"The patient was admitted to the operating room, and routine ECG monitoring was performed. The patient was placed in supine position, and ultrasound lung examination was performed. The images of the patient were saved and the score of lung ventilation area was recorded. The induction of general anesthesia was started, and endotracheal intubation was performed after 3min of preoxygenation (100% O2) to establish a safe and effective artificial airway. Mechanical ventilation was performed after endotracheal intubation, and a second time was performed immediately after endotracheal intubation was completed~On pulmonary ultrasound, patients in the ZEEP group maintained normal mechanical ventilation throughout the operation without PEEP or RMS"
62754861|NCT00717522|EXPERIMENTAL|Pomalidomide|7 mg pomalidomide taken orally once daily (QD) on days 1 through 21 of each 28-day cycle
62556959|NCT02635412|ACTIVE_COMPARATOR|Scheduled delivery at 36 weeks|Scheduled delivery at 36 weeks (range 35 weeks 5 days to 36 weeks 3 days)
62556960|NCT06430593||low-flow anesthesia|0,5 lt/min
62556961|NCT06430593||normal flow anesthesia|\>1 lt/min
62754862|NCT05867836|ACTIVE_COMPARATOR|IFA-90|Iron and folic acid (IFA) for 90 days
62754863|NCT05867836|EXPERIMENTAL|MMS-90|Multiple micronutrient supplementation (MMS) for 90 days with 2 distributions of MMS supplements (2 x 90 pill bottles; distributed at different ANC visits)
62754864|NCT05867836|EXPERIMENTAL|MMS-180|Multiple micronutrient supplementation (MMS) for 180 days but with 1 distribution of MMS supplements (1 x 180 pill bottle)
62754865|NCT03344549|EXPERIMENTAL|Teleconsultation|In the patients of the experimental group, the nutritional intervention is carried out through teleconsultation with the free technological tool chosen (the patients from home and the nutritionist from the remote clinic).
62378325|NCT05474924|ACTIVE_COMPARATOR|budesonide wash|"patients will be instructed to perform budesonide nasal wash, through a 250 ml squeeze bottle filled with saline, 0.5 mg/ml budesonide Pulmicort ampule added to the solution and half the amount used for each nostril, patients gurgle with antiseptic solution to minimize the risk of oral candidiasis, patients carry out the wash twice daily for one month duration"
62378326|NCT05474924|ACTIVE_COMPARATOR|Oral steroid|patients receive oral prednisolone 1 mg/kg/d tapering it by 5 mg/day for 2 weeks, patients will be prescribed omeprazole 20mg protective against gastrointestinal effects of steroid
62378327|NCT04128072|EXPERIMENTAL|Mogamulizumab + Total Skin Electron Beam Therapy (TSEB)|"Treatment with mogamulizumab will be continued until disease progression or the occurrence of another withdrawal criterion as specified in the protocol.~TSEB will start 28 days after mogamulizumab cycle 2 day 1 at a dose of 12 Gy in 8 fractions over two weeks (4 fractions per week)."
62378328|NCT01661725|EXPERIMENTAL|Group ACYW135 Meningococcal Polysaccharide Vaccine|0.5ml/ vial
62378329|NCT02005211|EXPERIMENTAL|AZD3293|AZD3293 will be administered as single dose of an oral solution in Part 1 and single and multiple doses of an oral solution in Part 2. The ascending doses are planned to be 15, 50 and 150 mg for young subjects in Part 1 and 15 and 50 mg for elderly subjects in Part 2. Before proceeding to next dose level, safety, tolerability and pharmacokinetic data from the previous cohort(s) will be evaluated by a Safety Review Committee. Part 2 will start after confirming safety and tolerability in Part 1.
62378330|NCT02005211|PLACEBO_COMPARATOR|Placebo|Placebo given (2 subjects in each cohort)
62378331|NCT01481428|ACTIVE_COMPARATOR|Attention Control|
62378332|NCT01481428|EXPERIMENTAL|Computer-facilitated HIV intervention|
62378333|NCT02445352|ACTIVE_COMPARATOR|Rosuvastatin 5mg & Placebo & Placebo|Once a day, administration of rosuvastatin 5mg and two types of placebo for 20 weeks
62378334|NCT02445352|EXPERIMENTAL|DP-R207 5/10mg & Placebo & Placebo|Once a day, administration of DP-R207 5/10mg and two types of placebo for 20 weeks
62378335|NCT02445352|ACTIVE_COMPARATOR|Rosuvastatin 10mg & Placebo & Placebo|Once a day, administration of rosuvastatin 10mg and two types of placebo for 20 weeks
62378336|NCT02445352|EXPERIMENTAL|DP-R207 10/10mg & Placebo & Placebo|Once a day, administration of DP-R207 10/10mg and two types of placebo for 20 weeks
62378337|NCT02445352|ACTIVE_COMPARATOR|Rosuvastatin 20mg & Placebo & Placebo|Once a day, administration of rosuvastatin 20mg and two types of placebo for 20 weeks
62378338|NCT02445352|EXPERIMENTAL|DP-R207 20/10mg & Placebo & Placebo|Once a day, administration of DP-R207 20/10mg and two types of placebo for 20 weeks
62378339|NCT04691011|OTHER|Muscle|
62378340|NCT04691011|OTHER|Spinal cord|
62378341|NCT04691011|OTHER|Brain|
62556962|NCT02386137|EXPERIMENTAL|Patient|Woman aged more than 18 years having one or two symptomatic fibroid with size \< 15cm.
62556963|NCT04419753|ACTIVE_COMPARATOR|No Attention Focus Walking Group (NAFWG)|In each training session, the NAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway without attention focus instruction (20 minutes) and cool down (5 minutes).
62378342|NCT04837781|EXPERIMENTAL|Normal vitamin D|Include patients with normal vitamin D level (above 30ng/ml). Vitamin D level will be measured at the beginning of treatment if there is deficiency then the patient refer to specialized physician to be supplied with vitamin D supplement to optimized the level to normal then start orthodontic treatment
62556964|NCT04419753|EXPERIMENTAL|External Attention Focus Walking Group (EAFWG)|In each training session, the EAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway with external attention focus instructions (20 minutes) and cool down (5 minutes).
62754866|NCT03344549|OTHER|Face-to-face consultation|In the patients of the other group, the nutritional intervention is offered through face-to-face consultations carried out by the nutritionist of the nutrition service of the institution.
62754867|NCT05970133|EXPERIMENTAL|Laparoscopic surgery|The patients in this group will undergo laparoscopic surgery.
61986690|NCT03198741|ACTIVE_COMPARATOR|Aspirin+clopidogrel|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),continue aspirin + clopidogrel (12-month DAPT group).The treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
62378343|NCT04837781|EXPERIMENTAL|Vitamin D deficiency|Include patients with unknown vitamin D level until time of canine retraction where we measure level if deficiency exist (below 30ng/ml) then the patient will be referred to specialized physician to be supplied with vitamin D supplement.
62556965|NCT04419753|EXPERIMENTAL|Internal Attention Focus Walking Group (IAFWG)|In each training session, the IAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway with internal attention focus instructions (20 minutes) and cool down (5 minutes).
62754868|NCT05970133|ACTIVE_COMPARATOR|Robotic surgery|The patients in this group will undergo robotic surgery.
62754869|NCT00916058|EXPERIMENTAL|Dose Level 1|Dose Level 1; Bendamustine 30 mg/m\^2 total, Melphalan 200 mg/m\^2 total (140 mg/m\^2 total for patients with Creatinine Clearance \<70 ml/min)
62754870|NCT00916058|EXPERIMENTAL|Dose Level 2|Dose Level 2; Bendamustine 60 mg/m\^2 total, Melphalan 200 mg/m\^2 total (140 mg/m\^2 total for patients with Creatinine Clearance \<70 ml/min)
62754871|NCT00916058|EXPERIMENTAL|Dose Level 3|Dose Level 3; Bendamustine 90 mg/m\^2 total, Melphalan 200 mg/m\^2 total (140 mg/m\^2 total for patients with Creatinine Clearance \<70 ml/min)
62754872|NCT00916058|EXPERIMENTAL|Dose Level 4|Dose Level 4; Bendamustine 120 mg/m\^2 total, Melphalan 200 mg/m\^2 total (140 mg/m\^2 total for patients with Creatinine Clearance \<70 ml/min)
62754873|NCT00916058|EXPERIMENTAL|Dose Level 5|Dose Level 5; Bendamustine 150 mg/m\^2 total, Melphalan 200 mg/m\^2 total (140 mg/m\^2 total for patients with Creatinine Clearance \<70 ml/min)
62754874|NCT00916058|EXPERIMENTAL|Dose Level 6|Dose Level 6; Bendamustine 225 mg/m\^2 total, Melphalan 200 mg/m\^2 total (140 mg/m\^2 total for patients with Creatinine Clearance \<70 ml/min)
62378344|NCT04837781|EXPERIMENTAL|Control|includes patients with unknown vitamin D level until the completion of canine retraction where we measure level. If deficiency exists (below 30ng/ml) then we will refer the patient to specialized physician to be supplied with vitamin D supplement
62378345|NCT03011424|EXPERIMENTAL|Early Postoperative Extracorporal Liver Support Therapy (ELS)|Early Postoperative Extracorporal Liver Support Therapy (ELS) by using the Molecular Adsorbent Recirculating System (MARS)
61986691|NCT03198741|EXPERIMENTAL|Aspirin|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),receive aspirin + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
62378346|NCT05489718|EXPERIMENTAL|treated with different doses of single intravitreal inmection of IBI324|
62378347|NCT05489718|EXPERIMENTAL|treated with different doses of multiple intravitreal inmection of IBI324|
62556966|NCT02258711|EXPERIMENTAL|SIMPLe 2.0 plus Treatment as Usual (TAU)|Psychoeducative and self-monitoring smart-phone application plus treatment as usual which includes pharmacological and psychological treatment.
62754875|NCT00916058|EXPERIMENTAL|Phase 2|Bendamustine 225 mg/m\^2 total, Melphalan 200 mg/m\^2 total (140 mg/m\^2 total for patients with Creatinine Clearance \<70 ml/min)
62378348|NCT03869489|EXPERIMENTAL|Anodal left dorsolateral prefrontal cortex tDCS stimulation|
62378349|NCT03869489|EXPERIMENTAL|Anodal right dorsolateral prefrontal cortex tDCS stimulation|
62378350|NCT03869489|SHAM_COMPARATOR|Sham tDCS stimulation|
62378351|NCT02274311|EXPERIMENTAL|Clomiphene citrate|Patients receiving clomiphene citrate
62556967|NCT02258711|NO_INTERVENTION|Treatment as usual (TAU)|Treatment as usual which includes pharmacological and psychological treatment.
62556968|NCT01640249|PLACEBO_COMPARATOR|Placebo|Participants received placebo capsule orally with approximately 200 to 300 milliliter (mL) of room temperature water in the morning.
62556969|NCT01640249|EXPERIMENTAL|LY3006072|Participants received LY3006072 capsules starting at 1 milligram (mg) and escalating doses of 3 mg, 10 mg, 20 mg and 40 mg.
62556970|NCT02806882|EXPERIMENTAL|Ceftaroline fosamil|600mg 1 hour intravenous infusion ZINFORO
62556971|NCT05588700|ACTIVE_COMPARATOR|Control group|
62754876|NCT06302140|EXPERIMENTAL|Part A: [14C]-Nanatinostat|
62754877|NCT06302140|EXPERIMENTAL|Part B (Treatment A): Nanatinostat (free base) tablets in combination with Valganciclovir|Patients will be randomized into 2 treatment sequences (AB and BA) in Periods 1 and 2. Each treatment period is 24 hours.
62754878|NCT06302140|EXPERIMENTAL|Part B (Treatment B): Nanatinostat mesylate tablets in combination with Valganciclovir|Patients will be randomized into 2 treatment sequences (AB and BA) in Periods 1 and 2. Each treatment period is 24 hours.
62754879|NCT06302140|EXPERIMENTAL|Part C: Single-agent Nanatinostat (free base) tablets|
62754880|NCT05440669|EXPERIMENTAL|White Noise|white noise will reduce pain and stress
62754881|NCT05440669|NO_INTERVENTION|control|white noise will not reduce pain and stress
62754882|NCT02114125|NO_INTERVENTION|Usual Care Group:|Usual care consists of standard institutionalized services provided by physicians, nurses, and support staff (e.g., nurse assistants, social workers) in long-term care facilities.
62754883|NCT02114125|EXPERIMENTAL|High-intensity physical activity (5PA)|The intervention conducts the group-based physical activity, 5 days per- week for 8 weeks.
62754884|NCT02114125|EXPERIMENTAL|Low-intensity PA and CT(3PA+2CT)|The intervention conducts 3 days per-week physical activity and 2 days per-week cognitive training for 8 weeks.
62754885|NCT02114125|EXPERIMENTAL|High-intensity PA and CT (5PA+5CT)|The intervention conducts the individual-based, multi-domains cognitive training, 5days per- week and group-based physical activity, 5 days per- week and for 8 weeks.
62754886|NCT02114125|EXPERIMENTAL|Low-intensity cognitive training (2CT)|The intervention conducts the individual-based, multi-domains cognitive training, 2 days per- week for 8 weeks.
62754887|NCT02114125|EXPERIMENTAL|High-intensity cognitive training (5CT)|The intervention conducts the individual-based, multi-domains cognitive training, 5 days per- week for 8 weeks.
62754888|NCT02667223|EXPERIMENTAL|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
62754889|NCT02667223|ACTIVE_COMPARATOR|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered subcutaneously to healthy volunteers
62754890|NCT02667223|EXPERIMENTAL|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
62754891|NCT02667223|EXPERIMENTAL|Cohort 5: bococizumab 450 mg + rHUPH20|bococizumab 450 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
62754892|NCT02667223|EXPERIMENTAL|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg co-mixed with rHuPH20 and administered subcutaneously to subjects with hypercholesterolemia receiving a statin
62754893|NCT04213703||Patients with Epidermolysis Bullosa|Patients who have been diagnosed with Epidermolysis Bullosa
62754894|NCT01054937|EXPERIMENTAL|4SC-203|
62754895|NCT01054937|PLACEBO_COMPARATOR|Placebo|
62754896|NCT05313321||Primary total hip arthroplasty receiving the Insignia Stem|Patients undergoing primary total hip arthroplasty that will likely receive the Insignia Stem and associated Stryker Acetabular Component.
62754897|NCT02165956|EXPERIMENTAL|New Infant Cereal|The amount of cereal administered will be free and from 6 to 12 months of age.
62556972|NCT05588700|EXPERIMENTAL|Intervention group|
62754898|NCT02165956|ACTIVE_COMPARATOR|Standard Infant Cereal|The amount of cereal administered will be free and from 6 to 12 months of age.
62754899|NCT05292209|EXPERIMENTAL|Active|Riluzole 50mg BID
62754900|NCT05292209|PLACEBO_COMPARATOR|Control|Placebo Matching Double-Dummy Pills
62754901|NCT04349748|EXPERIMENTAL|Group 1|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the second observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
62754902|NCT04349748|EXPERIMENTAL|Group 2|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the third observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
62754903|NCT04349748|EXPERIMENTAL|Group 3|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the fourth observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
62754904|NCT04349748|EXPERIMENTAL|Group 4|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the fifth observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
62754905|NCT06157541|EXPERIMENTAL|Part 1|"Patients with recurrent disease. Interventions:~* allogeneic CMV-specific T cells (cell suspension for infusion), dose cohorts: 2 × 10\^7 cells, 4 × 10\^7 cells, 8 × 10\^7 cells; 4 infusions; administered weekly~* pembrolizumab 400 mg (solution for injection); 18 infusions; administered every 6 weeks"
61986692|NCT03198741|EXPERIMENTAL|Clopidogrel|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),receive clopidogrel + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
61986693|NCT02081144|NO_INTERVENTION|Control Condition|Control or Standard Care condition. No intervention will be provided.
62556973|NCT01109446|EXPERIMENTAL|Platelet Rich Plasma|
62556974|NCT01109446|SHAM_COMPARATOR|Isotonoic Saline Solution|
62556975|NCT01109446|ACTIVE_COMPARATOR|Steroid (Triamcinolonacetonid)|
62754906|NCT06157541|EXPERIMENTAL|Part 2 Group A|"Patients with recurrent disease. Interventions:~* allogeneic CMV-specific T cells (cell suspension for infusion), maximum-tolerated dose identified in phase I; 4 infusions; administered weekly~* pembrolizumab 400 mg (solution for injection); 18 infusions; administered every 6 weeks"
62754907|NCT06157541|EXPERIMENTAL|Part 2 Group B|"Patients with newly diagnosed disease. Interventions:~* allogeneic CMV-specific T cells (cell suspension for infusion), maximum-tolerated dose identified in phase I; 4 infusions; administered weekly~* pembrolizumab 400 mg (solution for injection); 18 infusions; administered every 6 weeks"
62754908|NCT04837989|EXPERIMENTAL|Diabetes Body Project|Participants randomized to the experimental condition will receive virtual Diabetes Body Project groups immediately.
62754909|NCT04837989|ACTIVE_COMPARATOR|Educational|Participants randomized to the control condition will receive an education brochure and will be offered the Diabetes Body Project after 6 months.
62556976|NCT00218933|ACTIVE_COMPARATOR|moderate exercise training|
62556977|NCT00218933|EXPERIMENTAL|high intensity exercise training|
62754910|NCT06289192|EXPERIMENTAL|Smoking Cessation Intervention|Participants will receive a virtual counselor intervention for smoking cessation, be offered the opportunity to utilize nicotine replacement therapies, participate in shared decision-making around lung cancer screening, and be supported by a community health worker. Participants will be followed for a total of 3 months. Assessments will be conducted at baseline, 1 month, and 3 months.
62754911|NCT05959629|EXPERIMENTAL|Waterlase Express™, BIOLASE®|Root canals will be instrumented up to size 30/0.04 taper using Er,Cr:YSGG laser (Waterlase Express™, BIOLASE®), followed by standard of care (NaOCl).
62754912|NCT05959629|ACTIVE_COMPARATOR|Sodium Hypochlorite|Root canals will be instrumented up to size 30/0.04 taper using standard of care (NaOCl).
62754913|NCT00864669|EXPERIMENTAL|A|Metformin HCl 500 mg tablets, single dose
62556978|NCT00218933|NO_INTERVENTION|controls|
62754914|NCT00864669|ACTIVE_COMPARATOR|B|CLUCOPHAGE® XR 500 mg tablets, single dose
62754915|NCT04248920|EXPERIMENTAL|Intervention Group|Intervention Group. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO). As part of the C2C program, participants will be contacted 6 months later for a supplementary consultation over the telephone and to answer any questions. Epilepsy is unique among chronic, episodic disorders in that PWE lose their ability to make choices during a seizure and depend to a greater degree on the decisions of others including family, friends and colleagues. For this reason, we encourage the PWE to invite their support network to attend the patient education sessions.
62754916|NCT04248920|OTHER|Waitlist Control Group|Waitlist Control Group. The control group continues TAU and will be followed up 12 months after randomization. The control group will receive C2C after the 12-month follow-up.
62754917|NCT04184414|EXPERIMENTAL|CART cells|dosage：Once dose，1.0\*10\^6cells/kg CART cells Administration mode:Intravenous infusion
62754918|NCT05037448|OTHER|Telehealth|Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
62754919|NCT01956136|EXPERIMENTAL|Arm 1|The patients receive 10 weeks of Music-based Neurological Rehabilitation (MBNR) and Standard Care (SC) followed by 10 weeks of SC only.
62754920|NCT01956136|EXPERIMENTAL|Arm 2|The patients receive 10 weeks of Standard Care (SC) only followed by 10 weeks of Music-based Neurological Rehabilitation (MBNR) and SC.
62754921|NCT05287529|EXPERIMENTAL|8-Week Yoga Class|Randomized to immediately begin an 8-week Yoga Class via Telehealth
62754922|NCT05287529|ACTIVE_COMPARATOR|Waitlisted for 8-Week Yoga Class|Randomized to start an 8-week Yoga Class via Telehealth 8-weeks from the start of the study.
62754923|NCT03885570||Groups/Cohorts|"1) Patients undergoing mitral valve replacement surgery;2) Age 18-75 years old;3) 48h preoperative biochemical indicators, blood general indicators, coagulation indicators are complete."
61986694|NCT02081144|EXPERIMENTAL|Texting + NRT Condition|Enrollment in NCI's Smokefree TXT Program 4 weeks of Nicotine Replacement Patches 4 weeks of Nicotine Replacement Gum Faxed Referral CT Smokers Quitline
62754924|NCT02826434|EXPERIMENTAL|PVX-410 and Durvalumab|"Each patient will receive 6 PVX-410 vaccine injections and 2 infusions of Durvalumab.~* The injection of PVX-410 will be co-administered with Hiltonol every 2 weeks for 6 injections.~* The infusion of Durvalumab will be given on the day of the 4th and 6th PVX-410 injection, for a total of 2 infusions."
62754925|NCT06075329|EXPERIMENTAL|Contemplative Practice|Maitribodh Sambodh (MSD) is a unique form of contemplative practice which combines breath watch, mantra or vibrational sound chant, focused meditation followed by loving kindness or a gratitude exercise at the end.
62754926|NCT06075329|OTHER|Waitlist Control|The arm will eventually get the intervention.
62754927|NCT05950061|EXPERIMENTAL|Sertraline|Sertraline
62754928|NCT05950061|EXPERIMENTAL|Escitalopram|Escitalopram
62556979|NCT03161379|EXPERIMENTAL|CY, Nivolumab, GVAX, and SBRT|CY, Nivolumab, GVAX, and SBRT
62754929|NCT03645525|EXPERIMENTAL|Mesenchymal stem cell|Human Umbilical Cord-derived Mesenchymal stem cell in the saline
62754930|NCT03645525|PLACEBO_COMPARATOR|placebo|saline without mesenchymal stem cell
62754931|NCT03982264|ACTIVE_COMPARATOR|ESD group|In ESD group, enrolled patients will receive the treatment modality of ESD to remove the rectal NET
62754932|NCT03982264|EXPERIMENTAL|EMR-C group|In EMR-C group, enrolled patients will receive the treatment modality of EMR-C to remove the rectal NET
62754933|NCT06607042|EXPERIMENTAL|Intervention Group|This group receives treatment
61986695|NCT06181890||control group|"Infertile women who will be included in the control group will be interviewed twice in total. Pretest data will be obtained by applying the Personal Information Form, Infertility Impact Scale, Infertility Self-Efficacy Scale - Short Form and Coping with Infertility Stress Scale in the first interview. Four weeks after obtaining the pre-test data, post-test data will be obtained by applying the Infertility Impact Scale, Infertility Self-Efficacy Scale - Short Form and Coping with Infertility Stress Scale."
62378352|NCT04808492|EXPERIMENTAL|CureWave High Intensity Laser|The participant will lie prone and the HILT will be administered in two preliminary test locations. In order to evaluate any possible adverse reactions, the initial treatment location will be delivered at a decreased intensity at two separate locations above the target treatment areas. The Power for these two locations will be at a half dose (22 W) for one minute each. The initial, half dose treatment area is indicated by the Blue circles in the image below. Upon conclusion of the initial test treatments (at half dose), the skin with be evaluated for excessive redness or any other changes in skin appearance. Also, the participant will be asked about any discomfort. Should no unanticipated changes in skin appearance occur and the participant reports no discomfort, the treatment will be administered. The process of applying the laser at half dosage will occur prior to each treatment.
62754934|NCT06607042|NO_INTERVENTION|Waitlist Control-group|This group consists of individuals randomized to the waitlist condition
62754935|NCT02179736|EXPERIMENTAL|Active treatment|
62754936|NCT05888961|ACTIVE_COMPARATOR|Control subjects|
62754937|NCT05888961|EXPERIMENTAL|Subjects with an isolated cognitive complaint|
62754938|NCT05888961|EXPERIMENTAL|Subjects with minor neurocognitive disorders|
62754939|NCT05888961|EXPERIMENTAL|Subjects with major neurocognitive disorders of the mild to moderate Alzheimer's disease type|
62754940|NCT02094742|OTHER|all-commers|All patients will undergo a biopsy of their metastatic lesion and have a blood sample taken for molecular screening purposes. No drugs are administered or other interventions are performed.
62754941|NCT01620502|ACTIVE_COMPARATOR|EPA 3.5 g/day|
62754942|NCT01620502|PLACEBO_COMPARATOR|Placebo capsules|oleic oil
62754943|NCT01620502|EXPERIMENTAL|DHA 1.75 g/day|DHA 1.75 g/day
62754944|NCT01140568|EXPERIMENTAL|nilotinib|Patients will take nilotinib twice daily at the standard dose of 400mg taken by mouth twice a day until disease progression or development of unacceptable side effects.
62754945|NCT06505018|EXPERIMENTAL|Telemonitoring group|"Standard of care with digital telemonitoring Cureety TechCare. The telemonitoring will comprise weekly adverse event (AE) evaluations and their analyses by the Cureety TechCare."
62754946|NCT06505018|NO_INTERVENTION|Standard-of-care group|
62754947|NCT04659928|EXPERIMENTAL|High volume evacuation (HVE) suction only and hydrogen peroxide|
62754948|NCT04659928|EXPERIMENTAL|HVE suction and extraoral vacuum aspirator (EVA) and hydrogen peroxide|
62754949|NCT04659928|EXPERIMENTAL|HVE suction and external evacuation device (EED) and hydrogen peroxide|
62754950|NCT02708849|EXPERIMENTAL|Ketamine plus lamotrigine|
62754951|NCT02708849|PLACEBO_COMPARATOR|ketamine plus placebo|
62754952|NCT02269176|EXPERIMENTAL|Telmisartan|Low dose of telmisartan, uptitrated to high dose in case no sufficient effect is observered
62754953|NCT02269176|ACTIVE_COMPARATOR|Losartan|Low dose of losartan, uptitrated to high dose in case no sufficient effect is observered
62754954|NCT04446260|EXPERIMENTAL|Part 1 Dose escalation|
62754955|NCT04446260|EXPERIMENTAL|Part 2 PK expansion|
62754956|NCT04446260|EXPERIMENTAL|Part 3 Indication expansion|
62754957|NCT06220591|ACTIVE_COMPARATOR|Superior trunk group|"The patient will undergo selective supraclavicular nerve block, then will undergo block of superior trunk The fifth \& sixth cervical nerve roots of the brachial plexus on the side of the affected clavicle."
62754958|NCT06220591|ACTIVE_COMPARATOR|Clavipectoral fascial plane group|The patient will undergo selective supraclavicular nerve block, then will undergo clavipectoral fascial plane block on the lateral and medial ends of the affected clavicle.
62754959|NCT06600763|EXPERIMENTAL|Ice pack|Ice pack application group: An ice pack kept in the refrigerator and having a temperature of -10 degrees Celsius will be wrapped in sterile gauze and applied to the drain area of the pediatric patient who is decided to end the surgical drain indication. The temperature of the area where the ice pack is applied will be measured at one minute intervals, and when the relevant area reaches a temperature of 13.6 0C, the physician will be informed and the drain removal procedure will be initiated. The child will be asked to mark the degree of pain felt before, during and after the procedure.
62754960|NCT06600763|EXPERIMENTAL|warm gel|Warm gel pad application group: Gel pads kept at room temperature will be applied to the drain area of the pediatric patient whose surgical drain indication is decided to end, in a sheath designed to wrap around the drain. After waiting for 10 minutes in the application area, the drainage system will be removed by the physician.
62754961|NCT06600763|NO_INTERVENTION|Control|Control group: The integrated drainage system will be withdrawn by the physician. The child will not receive any non-pharmacologic intervention before, during or after the procedure.
62754962|NCT01551290|PLACEBO_COMPARATOR|Group I: Placebo|Participants in Group I receive placebo
62754963|NCT01551290|EXPERIMENTAL|Group II: Infliximab|Participants in Group II receive 5 mg/kg infliximab
62754964|NCT01949623||RP patients|Retinitis Pigmentosa patients
62754965|NCT01949623||Controls|Patients who will be undergoing surgery for macular hole, epiretinal membrane, or vitreomacular traction, patients who have a retinal detachment , patients with neovascular age related macular degeneration and patients with diabetic retinopathy.
62754966|NCT00145418|EXPERIMENTAL|1|Oxaliplatin + Docetaxel as first line therapy of Stage IV or IIIB unresectable non-small cell lung cancer. The primary objective of the trial is to determine the response rate by RECIST criteria to the combination of oxaliplatin and docetaxel in patients with previously untreated NSCLC.
62754967|NCT05993780|OTHER|ARDS patient|14 patients with ARDS were included in the study. It was planned as a single group.
62754968|NCT05362591|EXPERIMENTAL|resin bonded bridge with no preparation|resin bonded bridge without enamel preparation
62754969|NCT05362591|ACTIVE_COMPARATOR|resin bonded bridge with minimal preparation|resin bonded bridge with minimal preparation on tooth enamel
62556980|NCT06511765|EXPERIMENTAL|Intravenous injection of Ropivacaine combined with Dexamethasone + usual treatment|The experimental treatment consists in one single interlaminal injection of 2x20ml Ropivacaine (0.375%) distributed over the L4-L5 (Lumbar vertebrae 4 and 5) and L5-S1 (Lumbar vertebrae 5 and sacrum 1) levels on both sides, combined with 2x4ml Dexamethasone soluble (i.e. 2x1ml). This dose and method of administration are those required for locoregional anesthesia.
62754970|NCT02379026|EXPERIMENTAL|Exercise & Protein Drink/Diet|High-protein (1.2-1.5 g protein per kg bodyweight; a milk-based protein drink will provide 50 g protein/day) energy-restricted (500 kcal deficit) diet and a multimodal exercise program (balance, flexibility, aerobic, resistance) 3 times/week, each lasting 1 hour. 1 tablet of Vitamin D3 (25 micrograms) x three days/week. Total duration 16 weeks.
62754971|NCT02379026|ACTIVE_COMPARATOR|Exercise|A multimodal exercise program (balance, flexibility, aerobic, resistance) will take place 3 times/week, each one lasting 1 hour. Participants in this group will follow their habitual diet. 1 tablet of Vitamin D3 (25 micrograms) x three days/week. Total duration 16 weeks.
61986696|NCT06181890||intervention group|"Before starting motivational interviews with infertile women in the intervention group, pre-test data will be obtained by applying the Personal Information Form, Infertility Impact Scale, Infertility Self-Efficacy Scale - Short Form and Coping with Infertility Stress Scale. A total of 4 sessions of motivational interviews will be held for infertile women, 1 session per week for four weeks. At the end of four weeks, post-test data will be obtained by applying the Infertility Impact Scale, Infertility Self-Efficacy Scale - Short Form and Coping with Infertility Stress Scale."
62556981|NCT06511765|PLACEBO_COMPARATOR|Intravenous injection of Placebo (sodium chloride 0.9%) + usual treatment|The placebo treatment consists in one single interlaminal injection of 2x20ml sodium chloride 0.9% distributed over the L4-L5 and L5-S1 levels on both sides.
62556982|NCT02454933|EXPERIMENTAL|MEDI4736 & AZD9291 Combination|10mg/kg q2w (IV) infusion \& once daily tablet 80 mg
62556983|NCT02454933|EXPERIMENTAL|AZD9291 Monotherapy|Once daily tablet 80 mg
62556984|NCT04936737|EXPERIMENTAL|Beta-alanine supplementation and high intensity exercise|Individuals will participate in a high-intensity exercise and will be supplemented with beta-alanine. This protocol will be conducted for six non-consecutive days.
62556985|NCT04936737|EXPERIMENTAL|Beta-alanine supplementation only|In this protocol, the individuals will be supplemented with beta-alanine without the exercise protocol for six non-consecutive days.
62556986|NCT00713037|EXPERIMENTAL|(18F)-FMISO/CT|The study utilizes PET/CT scanning with (18F)-FMISO/CT in addition to standard used CT and MRI. Patients enrolled in this trial completed 2 PET/CT investigations, the first before proton radiation therapy and the second at a dose of approximately 30 Gy (24-36 Gy).
62556987|NCT04632225|ACTIVE_COMPARATOR|Engensis|64 mg Engensis per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
62556988|NCT04632225|PLACEBO_COMPARATOR|Placebo|32 mL of Placebo per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
62556989|NCT00929461|OTHER|Omega-3 group|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
62556990|NCT00929461|OTHER|Omega 3 + Omega 6 group|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter.
62754972|NCT05130216||Total Knee Arthroplasty|Patients who have undergone total knee arthroplasty post one-year.
62556991|NCT01197911|EXPERIMENTAL|Mild impairment|
62556992|NCT01197911|EXPERIMENTAL|Moderate impairment|
62556993|NCT01197911|EXPERIMENTAL|Normal HF|
62556994|NCT01313065|EXPERIMENTAL|VX15/2503|VX15/2503 monoclonal antibody at a concentration of 0.3 mg/kg - 20 mg/kg to be administered intravenously on a weekly dosing cycle.
62754973|NCT00727142|ACTIVE_COMPARATOR|open shunt|functioning shunt
62754974|NCT00727142|ACTIVE_COMPARATOR|closed shunt|NON FUNCTIONING SHUNT
62754975|NCT04015037|EXPERIMENTAL|Group A|The participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion
62754976|NCT04015037|EXPERIMENTAL|Group B|The participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion
62754977|NCT02557958|EXPERIMENTAL|Azithromycin|Azithromycin 250mg daily, single daily use for 8 weeks
62754978|NCT02557958|PLACEBO_COMPARATOR|Placebo|Placebo daily for 8 weeks
62754979|NCT06484257|ACTIVE_COMPARATOR|Myopia|
62754980|NCT06484257|OTHER|Hypermetropia|
62754981|NCT01069302|ACTIVE_COMPARATOR|High loading and high maintenance|Clopidogrel loading 600mg and maintenance 150mg for 7days
62754982|NCT01069302|ACTIVE_COMPARATOR|High loading and low maintenance|Clopidogrel loading 600mg and maintenance 75mg for 7days
62378353|NCT04808492|PLACEBO_COMPARATOR|Control|The participant will lie prone and the Placebo HILT will be administered is the same capacity as the treatment group however no Laser treatment will be administered. Upon conclusion of the placebo treatment, the skin with be evaluated for excessive redness or any other changes in skin appearance. Also, the participant will be asked about any discomfort.
62378354|NCT01830829|EXPERIMENTAL|Jaylyn|Jalyn: dutasteride 0.5 mg/day and tamsulosin 0.4 mg/day combination tablet
62378355|NCT01830829|PLACEBO_COMPARATOR|Placebo|Placebo
62754983|NCT01069302|ACTIVE_COMPARATOR|Low loading and high maintenance|Clopidogrel loading 300mg and maintenance 150mg for 7days
62378356|NCT03630185|EXPERIMENTAL|Custom-manufactured compression hosiery (Isobar)|The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
62754984|NCT01069302|ACTIVE_COMPARATOR|Low loading and low maintenance|Clopidogrel loading 300mg and maintenance 75mg for 7days
62754985|NCT00435162|EXPERIMENTAL|Low Dose|
62754986|NCT00435162|EXPERIMENTAL|Medium Dose|
62754987|NCT00435162|EXPERIMENTAL|High Dose|
62754988|NCT06599567|ACTIVE_COMPARATOR|Traditional therapy|Cold - Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises
62754989|NCT06599567|ACTIVE_COMPARATOR|Graded motor imagery|Cold-Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises, graded motor imagery training (body right-left discrimination exercise, imagining the movement and exercising the opposite limb in front of the mirror).
62754990|NCT06599567|ACTIVE_COMPARATOR|Nintendo Wİİ|Cold - Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises, games involving your relevant shoulder such as boxing and bowling on the Nintendo Wii game console.
62754991|NCT06475209|EXPERIMENTAL|Adebrelimab combined with Apatinib|Evaluation of the Efficacy and Safety of Adebrelimab in Combination with Apatinib in Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Each treatment cycle spans 3 weeks. Sequential medication administration begins on the first day of each cycle: Adebrelimab is administered at a dosage of 1200mg on day 1, every 3 weeks, while Apatinib is given orally at a dosage of 250mg daily from day 1 to day 14, every 3 weeks, with a one-week hiatus following two weeks of continuous intake. Administration timing allows for a window of ±5 days. Subjects are required to undergo comprehensive assessments, including vital signs monitoring, anthropometric measurements, physical examinations, laboratory analyses, and performance status evaluations, to assess treatment tolerability for continuation.
62754992|NCT02899221|EXPERIMENTAL|Treatment (high dose rate brachytherapy, hyperthermia)|Patients undergo high dose rate brachytherapy for 15-30 minutes. Immediately after radiation therapy (no longer than 90 minutes), patients undergo interstitial hyperthermia treatment for up to 60 minutes.
62754993|NCT01054040|NO_INTERVENTION|Standard nutrition cardiac care|Patients will receive standard care of group nutrition counselling and individual counselling if requested
62754994|NCT01550341|ACTIVE_COMPARATOR|Buprenorphine|
62182474|NCT03310671||Controls|"* Genetically Similar~* Siblings of the normocholesterolemic case, defined by LDLc \<190 mg / dl without lipid-lowering treatment.~* In the absence of available siblings, first cousins may be included.~* In the presence of several siblings available, the same sex will be included,~* Environmentally similar~* Stable partner of the case with cohabitation\> 25 years"
62182475|NCT00043186|PLACEBO_COMPARATOR|Placebo|Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.
62182476|NCT00043186|EXPERIMENTAL|Denosumab 6 mg every 3 months|Participants received denosumab 6 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
62182477|NCT00043186|EXPERIMENTAL|Denosumab 14 mg every 3 months|Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
62182478|NCT00043186|EXPERIMENTAL|Denosumab 30 mg every 3 months|Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.
62556995|NCT01348048|EXPERIMENTAL|Specialised palliative care (SPC) group|Patients continue with their standard treatment (typically they receive treatment in one or more hospitals departments and from their GP). In addition, they are offered a consultation in the SPC out-patient clinic (or at home if the patient cannot attend the hospital) as soon as possible and no more than one week after randomization. If possible, each patient will have at least two contacts to the SPC in the trial period.
62754995|NCT01550341|PLACEBO_COMPARATOR|Placebo|
62754996|NCT00278369|EXPERIMENTAL|A|6 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course
62754997|NCT00278369|EXPERIMENTAL|B|9 mcg/kg Denileukin Diftitox administered IV/daily on days -4 to -2 of standard interleukin 2 dose course
62754998|NCT00278369|EXPERIMENTAL|C|9 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course
62754999|NCT01968291|EXPERIMENTAL|Teach-back|Patients are prompted to state back in their own words their comprehension of the information given to them at discharge.
62755000|NCT01968291|NO_INTERVENTION|Standard Discharge Instructions|Patient receives usual discharge instructions as administered by the nurse assigned to the patient.
62378357|NCT03630185|ACTIVE_COMPARATOR|Off-the-rack stockings (Sigvaris)|Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
62378358|NCT00854984|EXPERIMENTAL|Self-help CBT|A nurse supported self-help CBT intervention in addition to usual care.
62556996|NCT01348048|NO_INTERVENTION|Standard care group|Patients continue with their standard treatment. They are instructed to contact either their GP or their hospital department if they feel that additional treatment or care is needed.
62556997|NCT06407739|EXPERIMENTAL|Three-Phase Physical Therapy Intervention|This group will be given the three-phase physical therapy intervention and each phase prolong for period of one month
62556998|NCT03854760|EXPERIMENTAL|anesthesiologist with limited experiment|Anesthesiologists with limited experiment of bronchoscopy.
62556999|NCT05016739|EXPERIMENTAL|CADISS System|
62557000|NCT03013816|EXPERIMENTAL|Testimonial Messaging|This video features four personal testimonials with strong emotional appeal, including an adolescent kidney transplant recipient, a pediatric liver transplant recipient, a young adult kidney transplant candidate, and an adolescent whose twin brother was a deceased organ donor. There are minimal facts about transplantation or donation.
62557001|NCT03013816|EXPERIMENTAL|Informational Messaging|This video mirrors common educational campaigns and included segments of HRSA's animated video, Organ Donation and Transplantation: How Does it Work? The IM video presents facts about donation, including the current supply-demand problem in transplantation, common reasons for/against donor designation, donation myths, and the importance of communicating with parents about donation. Information about how to register as a donor is also included. The video contains no personal testimonials.
62755001|NCT06261736|EXPERIMENTAL|Antibiotic Group|Those randomized to this group will receive a one-time dose of an oral antibiotic prior to the urethral bulking procedure. The antibiotic will be based on the participants' allergies, medical history, and current medication list.
62755002|NCT06261736|OTHER|No antibiotic group|Those randomized to this group will not receive an antibiotic prior to the urethral bulking procedure.
62755003|NCT04086368|ACTIVE_COMPARATOR|The Synthes Pediatric LCP Plate System|Open osteotomy and osteofixation with the pediatric LCP hip plate
62755004|NCT04086368|EXPERIMENTAL|The adolescent Lateral Femoral Nail|Percutaneous osteotomy and intramedullary nailing
62755005|NCT06159881|EXPERIMENTAL|Personalized cross linking|Participants were treated with personalized energy cross linking according to their thinnest point corneal pachymetry
62755006|NCT01618383|OTHER|Colonic biopsies|Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy
62755007|NCT01713361|EXPERIMENTAL|ISIS-FXIRx Dose 2|Group B: ISIS-FXIRx Dose #2
62755008|NCT01713361|EXPERIMENTAL|ISIS-FXIRx Dose 3|Group C: ISIS-FXIRx Dose #3
62755009|NCT01713361|ACTIVE_COMPARATOR|Enoxaparin|Enoxaparin (40mg)
62755010|NCT02193035|EXPERIMENTAL|Single group|Patients with severe aortic stenosis treated with transcatheter aortic valve replacement (TAVR). Microparticle levels will be measured before and after TAVR.
62755011|NCT06110715|SHAM_COMPARATOR|control group|participants with depressive disorder
62755012|NCT06110715|EXPERIMENTAL|Active group|participants with depressive disorder
62755013|NCT05783076|EXPERIMENTAL|stereotactic body radiation therapy plus vNKT cells|"Stereotactic body radiatuon therapy is performed by Cyberknife, an image-guided frameless stereotactic robotic radiosurgery system (Accuray Corporation, Sunnyvale CA). Prescription doses ranged from 35-40Gy/5f.~Allogeneic peripherial blood monocytes (PBMC) are collected from healthy individuals. vNKT cells are isolated from PBMC and then expanded. Quality tests shoud be performed before isolated cells become cell therapy products. After quality control, vNKT cells should be transfused into patients within 24 hours. Adoptive cell therapy is initiated 2-3 weeks after SBRT. Cell therapy is performed twice a month with the interval of 24-48 hours within 6 months after SBRT. The number of vNKT cells transfused once is 1.5×10\^8/Kg±15%. While cell therapy is performed once a months 6 months after SBRT. Cell therapy will be delivered for one year or until disease progression if it occurs within one year."
62755014|NCT05392855|EXPERIMENTAL|Symptom driven|Symptom driven performance of airway clearance regimen
62755015|NCT05392855|ACTIVE_COMPARATOR|Continuous|Continuous performance of baseline daily airway clearance regimen
62755016|NCT06608004||patient|ALS patients referred to the ALS Reference Centre at Dijon University Hospital and Lyon University Hospital
62755017|NCT03638531|EXPERIMENTAL|Anodal tDCS|Anodal tDCS will be applied in nine experimental sessions over a 2-week period.
62755018|NCT03638531|SHAM_COMPARATOR|SHAM tDCS|SHAM tDCS will be applied in nine experimental sessions over a 2-week period.
62755019|NCT04265508||Low MELD score|MELD score of 6 - 11
62755020|NCT04265508||High MELD score|MELD score of ≥ 17
62755021|NCT01689714|EXPERIMENTAL|Tc 99m EC20|Patients received 2 intravenous (IV) injections: 1 mg of folic acid (to reduce the uptake of FolateScan in normal tissues), followed 1 to 3 minutes later by 0.1 mg of EC20 labeled with 15 to 25 mCi of technetium-99m (99mTc) over 30 seconds in a total injection volume of 1 to 2 mL.2 Each injection was given as a slow IV push via a free-flowing indwelling IV catheter in an upper extremity vein (i.e., in the antecubital fossa).
62755022|NCT06204692|OTHER|Computer Guided Dental Implant Surgery.|Computer Guided Dental Implant Surgery
62755023|NCT01690559||Group 1|Patient treated with Ciproxan without dilution treatment in daily clinical practice
62755024|NCT05496452|EXPERIMENTAL|Beta-lactoglobulin|Daily supplementation over 12 day period. A nutritional supplement.
62755025|NCT05496452|PLACEBO_COMPARATOR|Carbohydrate|Daily supplementation over 12 day period. Energy matched control.
62755026|NCT03855631||Kabuki syndrome/ unaffected parents|Intervention on primary cultured cells from 4 patients with KS and sex match parents
62378359|NCT00854984|NO_INTERVENTION|Usual care|
62378360|NCT01922518|ACTIVE_COMPARATOR|Septal pacing group|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
62378361|NCT01922518|ACTIVE_COMPARATOR|Apex pacing group|Put RV lead around the apex
62755027|NCT03232814|EXPERIMENTAL|Group-based walking|Participants will engage in one supervised outdoor group-based walking session per week for the 8 week program.
62755028|NCT02249299|ACTIVE_COMPARATOR|Sativex Oromucosal Spray|Participants will titrate onto Sativex during the first two weeks of the study, carried out according to a standardised dosing schedule. After 2 weeks the clinician and participant will decide on the optimal dose for the remainder of the 4 week trial
62378362|NCT02845115|OTHER|control|standard care : usual technique for implanting
62378363|NCT02845115|EXPERIMENTAL|laser velocimetry|optimized implantation of laser velocimetry
62378364|NCT02828644|ACTIVE_COMPARATOR|EVO Multitasking|EVO Multitasking is a digital intervention that requires subjects to navigate a character through a game-like space, while collecting objects, in a fixed period of time. The intervention was administered to the subjects during the parent study (Akili-001R)
62378365|NCT02828644|ACTIVE_COMPARATOR|EVO Words|EVO Words is a digital intervention that requires subjects to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time. The intervention was administered to the subjects during the parent study (Akili-001R)
62378366|NCT00994890|EXPERIMENTAL|Tanezumab 2.5 mg|
62755029|NCT02249299|PLACEBO_COMPARATOR|Placebo|Participants will titrate onto the placebo during the first two weeks of the study, carried out according to a standardised dosing schedule. After 2 weeks the clinician and participant will decide on the optimal dose for the remainder of the 4 week trial
62755030|NCT03826836|NO_INTERVENTION|Control Group|Treatment as usual (i.e. best medical treatment).
62378367|NCT00994890|EXPERIMENTAL|Tanezumab 5 mg|
62378368|NCT00994890|EXPERIMENTAL|Tanezumab 10 mg|
62378369|NCT04154111|EXPERIMENTAL|Real TBS to the mPFC|Thirty sessions of real Theta Burst Stimulation (TBS) will be delivered to the left medial prefrontal cortex (mPFC)
62378370|NCT04154111|SHAM_COMPARATOR|Sham TBS to the mPFC|Thirty sessions of sham Theta Burst Stimulation (TBS) will be delivered to the left medial prefrontal cortex (mPFC)
62378371|NCT04154111|EXPERIMENTAL|Real TBS to the dlPFC|Thirty sessions of real Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)
62378372|NCT04154111|SHAM_COMPARATOR|Sham TBS to the dlPFC|Thirty sessions of sham Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)
62378373|NCT03309293|OTHER|controls|biological samples bank
62755031|NCT03826836|EXPERIMENTAL|Mindfulness-based stress reduction|Treatment as usual (i.e. best medical treatment) in combination with an eight-week mindfulness-based stress reduction programme.
62755032|NCT01546025|PLACEBO_COMPARATOR|Relaxation training|
62378374|NCT03309293|EXPERIMENTAL|cases|
62378375|NCT04456803|EXPERIMENTAL|Ferric citrate tablet|Ferric citrate arm will receive ferric citrate tablets three times a day with each meal.
62378376|NCT04456803|ACTIVE_COMPARATOR|Sevelamer carbonate tablet|Sevelamer carbonate arm will receive sevelamer carbonate tablets three times a day with each meal.
62755033|NCT01546025|ACTIVE_COMPARATOR|Brief Motivational Counseling|
62755034|NCT04293510||group study 1|children and adolescents who diagnosed as lupus patients
62755035|NCT04293510||group study 2|age and sex matched healthy children free from any infection with no family history of immunological diseases
62755036|NCT06306651|EXPERIMENTAL|High flow nasal cannula therapy group|Patients who will be randomized to high flow nasal cannula therapy. High flow nasal oxygen cannula will be applied at a flow of 20 L/min at FiO2 of 0.4 at a temperature of 36oC.
62755037|NCT06306651|ACTIVE_COMPARATOR|Conventional oxygen therapy group|Patients who will be randomized to simple oxygen mask therapy. The simple face mask will be applied in a rate range between 6-10 L/min.
62755038|NCT06162195|EXPERIMENTAL|The H1 Implant|Cementless, ceramic-on-ceramic hip resurfacing arthroplasty (HRA) device.
62755039|NCT06162195|ACTIVE_COMPARATOR|Cementless total hip replacement|Cementless ceramic-on-poly or ceramic-on-ceramic total hip replacement
62755040|NCT06437626|EXPERIMENTAL|Mexidol®|Participants received Mexidol® IV 500 mg 2 times a day for 10 days, then Mexidol® FORTE 250 orally 250 mg 1 tablet 3 times a day for 60 days
62755041|NCT06437626|PLACEBO_COMPARATOR|Placebo|Participants received Mexidol Placebo matching Mexidol® IV 500 mg 2 times a day for 10 days, then Mexidol® FORTE 250 orally 250 mg 1 tablet 3 times a day for 60 days
62755042|NCT02444546|EXPERIMENTAL|Treatment (sargramostim, wild-type reovirus)|Patients receive sargramostim SC daily on days 1 and 2 and wild-type reovirus IV over 60 minutes on days 3-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
62755043|NCT05410847|EXPERIMENTAL|Experimental|"Camrelizumab: 200mg，iv，30min, q3w, 4 cycles. Nab-Paclitaxel: intraperitoneal nab-paclitaxel 80 mg/m2 and intravenous nab-paclitaxel 180 mg/m2 on days 1, q3w, 4 cycles.~S-1：According to the body surface area, BSA \<1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA \>1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week, q3w, 4 cycles.~For patients who were operable, the original regimen was continued for 4 cycles of adjuvant treatment after operation, followed by maintenance of carrelizumab monotherapy to 1 year.~Inoperable patients were selected for follow-up treatment according to guidelines recommended by the investigator."
62755044|NCT04580758|ACTIVE_COMPARATOR|Fractional laser with PRP fluid|Fractional CO2 laser then the PRP is injected afterwards
62755045|NCT04580758|ACTIVE_COMPARATOR|Fractional laser with PRP gel|Fractional CO2 laser then the PRP gel is injected afterwards
62755046|NCT06041711|ACTIVE_COMPARATOR|General anesthesia group|Patients allocated to the general anesthesia group will be subjected to general anesthesia with induction with propofol and will sevoflurane (inhalational agent) used for maintenance. End of the procedure all patients will be extubated and awakened in the operating room. İntravenous morphine patient-controlled analgesia will be used in the postoperative period.
62755047|NCT06041711|ACTIVE_COMPARATOR|Regional anesthesia group|Patients allocated to the regional anesthesia group will be subjected to combined spinal-epidural anesthesia with heavy bupivacaine or spinal anesthesia with PENG(pericapsular nerve group) block with bupivacaine. If lumbar combined spinal epidural anesthesia is applied epidural patient-controlled analgesia will be used in the postoperative period. If spinal anesthesia and PENG block is applied, intravenous morphine patient-controlled analgesia will be used in the postoperative period.
62755048|NCT05545995||TIME LAPSE|Women who proceed to embryo transfer after time lapse assisted embryo selection.
62755049|NCT05545995||NI-PGT-A|Women who proceed to embryo transfer after non-invasive PGT-A assisted embryo selection.
62755050|NCT00248118|ACTIVE_COMPARATOR|Active medication|300mg bupropion HCL
62182479|NCT00043186|EXPERIMENTAL|Denosumab 14 mg every 6 months|Participants received denosumab 14 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
62378377|NCT03934515||Group A - etCO2|"At the end of the anaesthesia , as usual, the secretions are aspirated with a suction tube of 18 Fr of caliber (diameter 6 mm). When the tube is inserted into the endotracheal tube, before proceeding with the aspiration of the secretions, a capnometer is attached to its outer end, measuring the etCO2 value for 10-15 seconds. At the end of the measurement, authors proceed with the aspiration of the secretions as usual.~Authors then proceed with the laying of a NGT according to local protocols. Also in this case, once the NGT has been inserted, the etCO2 is measured at the end of the probe for 10-15 seconds. At the end of the measurement, the capnometer can be detached, as a standard procedure, and the NGT can be used as usual.~At the end of the procedure, therefore, for each patient, two values of etCO2 are acquired which will allow to obtain two populations of values of the etCO2: the values recorded at the endotracheal level and the one recorded at the oesophageal level."
62557002|NCT03013816|EXPERIMENTAL|Blended Messaging|This video features four personal testimonials with strong emotional appeal, including an adolescent kidney transplant recipient, a pediatric liver transplant recipient, a young adult kidney transplant candidate, and an adolescent whose twin brother was a deceased organ donor. There are minimal facts about transplantation or donation.
62557003|NCT01284010||Group 1|Diagnostic, complete remission, and germ-line specimens are analyzed for DNA profiling and gene resequencing by the Affymetrix SNP6.0 microarray platform, PCR, and fluorescence in situ hybridization (FISH). Frequency of genetic alterations are performed by the Agilent 2100 Bioanalyzer. Results are then compared with the data already generated from pediatric patients.
62557004|NCT00470535|EXPERIMENTAL|Arm 1 - Oral Erlotinib hydrochloride|Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity
62557005|NCT04754841|EXPERIMENTAL|SURVIVAL AND FUNCTIONALITY INVITRO IN CRYOPRESERVED PLATELETS|Platelet concentrates will be administered 3 alternatives of cryopreservative solution: 5% dimethylsulfoxide (solution 1), 5% dimethylsulfoxide plus 160 mg of 5% dextrose (solution 2) and 5% dimethylsulfoxide plus 2% albumine (solution 3 ). They will then be frozen at -80 ° C and their survival and functionality will be subsequently evaluated in vitro.
62557006|NCT02060812|EXPERIMENTAL|Group I, SSNB & ANB|21 patients were randomly allocated into group I, and received suprascapular nerve block (SSNB) and axillary nerve block (ANB) both with 10mL ropivacaine.
62557007|NCT02060812|PLACEBO_COMPARATOR|Group II, SSNB alone|The other 21 patients were allocated into group II, and received suprascapular nerve block (SSNB) with 10mL ropivacaine and axillary nerve block (ANB) with placebo (10mL normal saline).
62557008|NCT04470583||Mild/moderate COVID-19 affected pregnant and postnatal women|Pregnant and postnatal women who contracted COVID-19 and recovered without the need for ventilation will be classified as mild to moderate. Participants will be aged between 18-50 years old.
62557009|NCT04470583||Severe/Critical COVID-19 affected pregnant and postnatal women|"Pregnant and postnatal women who are admitted to hospital after contracting COVID-19 and received ventilatory support before recovering will be classified as severe to critical. Participants will be aged between 18-50 years old.~These participants will be identified from Intensive Treatment Unit (ITU), and standard COVID-19 wards."
62557010|NCT04470583||Mild/moderate COVID-19 affected non-pregnant participants|Both male and non-pregnant female participants who contracted COVID-19 and recovered without the need for ventilation will be classified as mild to moderate. Participants will be aged between 18-60 years old.
62755051|NCT00248118|PLACEBO_COMPARATOR|Placebo|Placebo pill
62755052|NCT05683678||Cohort 1|"Participants who started selumetinib and discontinued selumetinib before enrollment (the discontinued cohort)."
62755053|NCT05683678||Cohort 2|"Participants who started selumetinib before enrollment and are continuing to receive selumetinib at the time of enrollment (the continuing cohort)."
62755054|NCT05683678||Cohort 3|"Participants who started selumetinib on the day of enrollment or intend to initiate selumetinib within 3 months after enrollment (the initiating cohort)."
62755055|NCT01921374|EXPERIMENTAL|sleep parameters|To assess the sleep parameters.
62755056|NCT01921374|OTHER|cardiovascular parameters|To assess the cardiovascular profile of control mothers and caregivers-mothers.
62755057|NCT01921374|EXPERIMENTAL|imflammatory and immunological profile|To assess the inflammatory profile of caregivers-mothers and control mothers
62755058|NCT01921374|EXPERIMENTAL|hormonal profile|To assess the hormonal profile of caregivers-mothers and control mothers.
62755059|NCT01921374|EXPERIMENTAL|metabolic profile|To assess the health profile of caregivers-mothers and control mothers.
62755060|NCT01524003|EXPERIMENTAL|Cryotherapy after VIA triage|Women who test HPV positive will be randomized to the experimental arm or the standard of care arm. In the Experimental arm VIA will be done to determine acceptability for cryotherapy \[R/O high-grade CIN too large for cryotherapy (usually 3-4 quadrant disease) or cancer\]. All acceptable patients will have an ECC done and then immediate cryotherapy.
62755061|NCT01524003|ACTIVE_COMPARATOR|Colposcopy and biopsy|Standard of care. Women testing positive for HPV will be randomized to the experimental arm (immediate cryotherapy) or the Standard of care arm, for colposcopy, biopsy, and leep based on the pathology results.
62755062|NCT05105282|ACTIVE_COMPARATOR|Deep Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
62755063|NCT05105282|ACTIVE_COMPARATOR|Superficial Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
62755064|NCT01698450|OTHER|Focused Ultrasound for Movement Disorders|
62755065|NCT01240525|OTHER|CD4 DLI|Patients will receive trial product manipulated CD4 DLI post transplant as trial treatment.
62755066|NCT01240525|OTHER|No DLI|Patients will receive no DLI post transplant as trial treatment.
62755067|NCT05484531||CLEAR|Adult subjects suffering from myopia AND/OR astigmatism treated with CLEAR.
62182480|NCT00043186|EXPERIMENTAL|Denosumab 60 mg every 6 months|Participants received denosumab 60 mg SC every 6 months until Month 42.
62755068|NCT00596154|EXPERIMENTAL|1|Rituximab, methotrexate (MTX), procarbazine and vincristine (R-MPV). The peripheral blood stem cell (PBSC) harvest procedure will be performed at the discretion of the hematology attending (usually after the 1st or 2nd cycle of R-MPV)and high dose chemotherapy Busulfan, Thiotepa, and Cyclophosphamide. Patients will be off study at the time of death. All patients will be followed for survival every 6 months throughout their lifetime. Survival status may be obtained by phone call, clinical visit or medical records (e.g. physician notes/laboratory results of clinic or hospital visit.
62755069|NCT03691844|EXPERIMENTAL|AMZ001 + Placebo|on the target knee
62755070|NCT03691844|EXPERIMENTAL|AMZ001|on the target knee
62755071|NCT03691844|PLACEBO_COMPARATOR|Placebo|on the target knee
62755072|NCT03691844|ACTIVE_COMPARATOR|Comparator|Diclofenac gel on the target knee
62755073|NCT01213186|EXPERIMENTAL|Drug: high dose of MSC treatment|Participants will receive high dose of MSC from Day 0 through the Week 48 study visit. Participants will then be followed until the Week 48 study visit.
62755074|NCT01213186|EXPERIMENTAL|low dose of MSC treatment|Participants will receive a low dose of MSC treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks.
62755075|NCT01213186|PLACEBO_COMPARATOR|low dose of MSC|Participants will receive a saline placebo treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks.
62755076|NCT05872997|EXPERIMENTAL|Mobilization With Movement|Mobilization With Movement
62755077|NCT05160519|EXPERIMENTAL|Experimental|30 participants will be irradiated with Class IV laser therapy over the left parasternal area to examine the effectiveness of Class IV laser.
62755078|NCT05160519|SHAM_COMPARATOR|Sham Controlled|30 participants will subject to irradiation but the equipment will be kept off.
62755079|NCT05124509||Three doses of BNT162b2 vaccine|Solid organ transplant patients who received three doses of BNT162b2
62755080|NCT05124509||Two doses of Coronavac and one of BNT162b2 vaccine|Solid organ transplant patients who received two doses of CoronaVac and one dose of BNT162b2
62755081|NCT02007057|ACTIVE_COMPARATOR|Interscalene nerve block|"Interscalene block is performed preoperatively with ultrasound guidance and neurostimulation 0.8 milliampere. The block is performed using in-plane approach with a needle of 50 mm for a neurostimulation. During the injection, it is verified that the diffusion extends to the anterior and posterior space. If the posterior distribution is limited, the needle is remobilized to obtain an overall diffusion: a bolus of 20 mL of ropivacaine 0.75% is made by the anesthetist. The effectiveness of the nerve block is checked before the start of surgery."
62755082|NCT02007057|EXPERIMENTAL|Suprascapular nerve block|The suprascapular block is performed at the end of surgery when the incisions are closed but before the removal of the surgical drapes. The material used is a compound of a 10 cc syringe sterile equipment, a green intramuscular needle (14 gauge) and a bulb 10 cc of 0.75% Ropivacaine. The injection of 10 cc is realized by the technical princeps
62755083|NCT00801489|EXPERIMENTAL|Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)|See Detailed Description
62755084|NCT01727115|ACTIVE_COMPARATOR|NUTRAMIGEN®|"Subjects are orally fed ad libitum (following guidelines printed on the labels).~Subjects will receive the Nutramigen® formula for a 4 week period~Then depending of the result of the challenge test we have the following possibilities:~* If the test is positive: The children continue the formula Nutramigen®~* If the test is negative: A Follow up formula is given~  * (Nan pro2) if child \> 6 months~ * (Nan pro1) if child \< 6 months"
62755085|NCT01727115|EXPERIMENTAL|ALTHERA®|"Subjects are orally fed ad libitum (following guidelines printed on the labels).~Subjects will receive the Althera® formula for a 4 week period~Then depending of the result of the challenge test we have the following possibilities:~* If the test is positive: The children continue the formula Althera®~* If the test is negative: A Follow up formula is given~  * (Nan pro2) if child \> 6 months~ * (Nan pro1) if child \< 6 months"
62755086|NCT04812093||Medical Tool|Spectroscopic otoscope
62755087|NCT04531358|ACTIVE_COMPARATOR|Callergin|One puff (140 microliter) into each nostril
62755088|NCT04531358|ACTIVE_COMPARATOR|Alpin Alpensalz|One puff (140 microliter) into each nostril
62755089|NCT04531358|EXPERIMENTAL|no treatment|Patients do not receive a treatment
62755090|NCT06301724|EXPERIMENTAL|Stellate ganglion block|the patients were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)
62755091|NCT06301724|PLACEBO_COMPARATOR|Injection|the patients were provided with injection, which was with the same procedure of stellate ganglion block but no drugs.
62755092|NCT05955924|EXPERIMENTAL|Nicotinamide|Intervention Drug : Nicotinamide
62755093|NCT05955924|PLACEBO_COMPARATOR|Placebo|Intervention: Placebo Oral Capsule
62755094|NCT01398332||Aortic pathologies|Indication for aortic endovascular stent graft repair
62755095|NCT01643850|EXPERIMENTAL|MCS110|Participants will receive a single dose of 10mg/kg on day 1 administered by regular infusion.
62755096|NCT01643850|PLACEBO_COMPARATOR|Placebo|Part A: single-dose placebo to match MCS110 (10 mg/kg, 1 h i.v. infusion) Part B: single dose placebo to match MCS110 (10 mg/kg, 1 h i.v. infusion administered i.v. at Day 1, followed by 6 doses of placebo to match MCS110 (10 mg/kg)
62755097|NCT01643850|EXPERIMENTAL|MCS110 3 mg/kg|Part C: MCS110 3 mg/kg (i.v. infusion)
62755098|NCT01643850|EXPERIMENTAL|MCS110 5 mg/kg|Part C: MCS110 5 mg/kg (i.v. infusion)
62755099|NCT01643850|EXPERIMENTAL|MCS110 10 mg/kg|Part C: MCS110 10 mg/kg (i.v. infusion)
62755100|NCT01643850|EXPERIMENTAL|MCS110 3 mg/kg & MCS110 10mg/kg|Part C: MCS110 3 mg/kg (i.v. infusion) \& MCS110 10 mg/kg (i.v. infusion)
62755101|NCT01643850|EXPERIMENTAL|MCS110 5 mg/kg & MCS110 10mg/kg|Part C: MCS110 5 mg/kg (i.v. infusion) \& MCS110 10 mg/kg (i.v. infusion)
62755102|NCT06353256|EXPERIMENTAL|Usual Care|Usual postpartum care
62755103|NCT06353256|EXPERIMENTAL|Usual care and community health worker intervention|Usual postpartum care and community health worker visits and support
62755104|NCT03387995||Anterior communicating artery aneurysm|Contains 5 subgroups: LVIS stent, Solitire stent, Enterprise stent, Neuroform stent and flow diveter stent.
62755105|NCT03387995||Middle cerebral artery aneurysm|Contains 5 subgroups: LVIS stent, Solitire stent, Enterprise stent, Neuroform stent and flow diveter stent.
62557011|NCT04470583||Severe/Critical COVID-19 affected non-pregnant participants|Both male and non-pregnant female participants who are admitted to hospital after contracting COVID-19 and received ventilatory support before recovering will be classified as severe to critical. Participants will be aged between 18-60 years old. These participants will be identified from Intensive Treatment Unit (ITU), and standard COVID-19 wards.
62378378|NCT03934515||Group B - pH|"At the end of the anaesthesia , once the NGT is inserted, the pH is measured by aspirating the gastric contents and measuring on specific litmus paper the pH values, both at a distance of 25 cm from the mouth (oesophageal site) and at a distance of 40 cm (gastric site).~At the end of the procedure, for each patient two values of pH are acquired which will allow to obtain two pH value populations: a value at oesophageal level and a value at the gastric level."
62378379|NCT06227416|NO_INTERVENTION|Ex-vivo samples from already excised SCC and BCC areas from mohs surgery|
62755106|NCT03387995||Posterior communicating artery aneurysm|Contains 5 subgroups: LVIS stent, Solitire stent, Enterprise stent, Neuroform stent and flow diveter stent.
62755107|NCT03387995||Internal carotid artery aneurysm|Contains 5 subgroups: LVIS stent, Solitire stent, Enterprise stent, Neuroform stent and flow diveter stent.
62755108|NCT03387995||Vertebrobasilar system aneurysms|Contains 5 subgroups: LVIS stent, Solitire stent, Enterprise stent, Neuroform stent and flow diveter stent.
62557012|NCT04521894||Primary PCa without metastases Group|Participants who are suspected of prostate cancer due to elevated PSA or clinical symptoms but have not received any treatment and eventually confirmed prostate cancer after surgery or biopsies.
62755109|NCT04424992||Covid19 infection related patients|The patients enrolled in the study are all patients with clinical and microbiological diagnosis of COVID-19 infection hospitalized since February 23, 2020 at San Gerardo Hospital (ASST-Monza).
62182481|NCT00043186|EXPERIMENTAL|Denosumab 100 mg every 6 months|Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
62378380|NCT06227416|EXPERIMENTAL|Ex-vivo samples from punch biopsy from patients with AKs|
62378381|NCT05441436||Allogeneic hematopoietic stem cell transplantation|Patients in waiting list for and after allogeneic hematopoietic stem cell transplantation.
62755110|NCT06555302|EXPERIMENTAL|Cognitive Rehabilitation + Occupational Therapy (Telerehabilitation)|"A trained OT will deliver the 8-week stroke telerehabilitation program. There will be 13 total sessions with 2 sessions/week for the first 5 weeks and 1 session/week for the last 3 weeks. The cognitive rehabilitation and OT components will be titrated as follows:~* Sessions 1-4 will focus on cognitive rehab.~* Sessions 5-10 will review/provide additional cognitive rehab and deliver OT.~* Sessions 11-13 may briefly review cognitive rehab but focus primarily on OT."
62755111|NCT00725348|EXPERIMENTAL|A|R115866
62755112|NCT01169415|EXPERIMENTAL|Protracted (30 days), Dexamethasone|Participants will receive a protracted course (30 days) of dexamethasone after surgery.
62755113|NCT01169415|EXPERIMENTAL|Abbreviated (14 days), dexamethasone|Participants will receive an abbreviated (14 days) course of dexamethasone after surgery.
62755114|NCT06605963|EXPERIMENTAL|PPV-06|PPV-06 10 μg + Montanide™ ISA 51 VG in subcutaneous administration
62755115|NCT06605963|PLACEBO_COMPARATOR|Placebo|
62755116|NCT04393467|EXPERIMENTAL|real tSMS|tSMS will be delivered by a magnet applied to M1, bilaterally (120 min daily, for 6 months). Magnet will be kept in position by a plastic helmet.
62755117|NCT04393467|SHAM_COMPARATOR|sham tSMS|A non-magnetic steel cylinder, with same size, weight and appearance of the magnet, will be used for sham stimulation.
62557013|NCT04521894||Primary PCa with metastases Group|Participants who are suspected of prostate cancer due to elevated PSA or clinical symptoms but have not received any treatment and eventually confirmed prostate cancer after surgery or biopsies. And the 18F-PSMA-PET/CT scan confirmed metastases.
62557014|NCT04521894||Oligometastatic PCa group|"Oligometastaticis a subgroup of metastatic patients with a limited number of secondary lesions (threshold ranging from 3 to 5) in one or few organs."
62557015|NCT04521894||Biochemical recurrence Group|Proven biochemical recurrence after radical therapy (PSA \>0.2 ng/mL after radical prostatectomy, PSA ≥2 ng/mL above the nadir after external-beam radiotherapy) or persisting PSA after radical treatment with rising PSA values.
62557016|NCT04521894||Control Group|Prostate cancer benign prostatic hypertrophy or normal prostate.
62557017|NCT03597295|EXPERIMENTAL|Retifanlimab 500 mg|Retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).
62557018|NCT04404660|EXPERIMENTAL|AUTO1|
62557019|NCT01759602|EXPERIMENTAL|C1-esterase inhibitor (Cinryze)|This is a phase 1b open-label, interventional proof-of-concept study in patients with neuromyelitis optica (NMO) in which all subjects will receive 3 daily infusions of 2000 Units of intravenous CINRYZE at the onset of an NMO exacerbation in addition to standard of care high-dose steroids, plus an additional 2 infusions of 1000 Units of intravenous CINRYZE during a second treatment phase with plasma exchange, if necessary.
62557020|NCT04331613|EXPERIMENTAL|CAStem|A dose-escalation with 3 cohorts with 3 patients/cohort who receive doses of 3, 5 or 10 million cells/kg. If there is no safety concerns for each cohort, the dose will be escalated from lower dose to next higher dose.
62557021|NCT01034878|EXPERIMENTAL|Sunitinib|50 mg once daily 6 weeks cycle 4 weeks on and 2 weeks off
61986697|NCT02293655|PLACEBO_COMPARATOR|MPH Discontinuation|"1. Double-blind (DB) placebo-controlled 4-week methylphenidate (MPH) titration trial. Pts will receive 3 active dosages of MPH (children \<25kg: 18mg, 27mg, 36mg; children \>25kg: 18mg, 36mg, 54mg for) as well as 1 random week of placebo, given qAM. Pts will begin on the lowest dose (or a randomized placebo week) and proceed through all dose conditions in an incremental fashion.~2. DB 4-week MPH maintenance phase. The clinician, parent, and teacher ratings of behavior and side effects from the titration trial weeks will be graphed. Two doctors will blindly review the graphs and judge which week was the optimal dose week. Pts will then receive their optimal dose of MPH (qAM) for 4 weeks.~3. DB 4-week MPH Discontinuation Phase. Pts in this arm will receive placebo (qAM)."
62182482|NCT00043186|EXPERIMENTAL|Denosumab 210 mg every 6 months|Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.
62182483|NCT00043186|ACTIVE_COMPARATOR|Alendronate 70 mg|Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.
62378382|NCT05441436||Solid organ transplantation|Patients in waiting list for and after solid organ transplantation.
62557022|NCT05842993|EXPERIMENTAL|Hydrogen inhalation|Patients receive hydrogen inhalation.
62557023|NCT05842993|PLACEBO_COMPARATOR|Placebo|Patients receive placebo.
62557024|NCT00652340|EXPERIMENTAL|A|
62557025|NCT00652340|PLACEBO_COMPARATOR|B|
62557026|NCT04527887|ACTIVE_COMPARATOR|Dextenza (IDI) (Sustained Release Dexamethasone, (0.4 mg)|intracanalicular dexamethasone insert
62557027|NCT04527887|PLACEBO_COMPARATOR|ProLong™ collagen plugs|collagen plug
62557028|NCT00512122|EXPERIMENTAL|EN only|Withholding PN during the first week of ICU stay
62557029|NCT00512122|ACTIVE_COMPARATOR|EN plus early PN|Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E Parenteral nutrition targeted at covering calculated needs together with the enteral nutrition intake that is achieved
62557030|NCT01317628|OTHER|Lifestyle counseling|Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.
62557031|NCT03952182|ACTIVE_COMPARATOR|Spinal Orthosis (LSO, TLSO, etc)|Patient's in this arm will be given an orthosis for the treatment of their injury (TLSO for thoracic or upper lumbar injury, LSO for lumbar injury)
62557032|NCT03952182|EXPERIMENTAL|No Spinal Orthosis|the patient's in this arm will not be given an orthotic. They will be given a bending restriction and otherwise remain activities as tolerated.
62557033|NCT00124748|EXPERIMENTAL|Imatinib 400 mg|Oral dose of 400mg Imatinib once daily. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted, reduced, or escalated based on guidelines defined in protocol.
61986698|NCT02293655|ACTIVE_COMPARATOR|Sustained MPH|"1. Double-blind (DB) placebo-controlled 4-week methylphenidate (MPH) titration trial. Pts will receive 3 active dosages of MPH (children \<25kg: 18mg, 27mg, 36mg; children \>25kg: 18mg, 36mg, 54mg for) as well as 1 random week of placebo, given qAM. Pts will begin on the lowest dose (or a randomized placebo week) and proceed through all dose conditions in an incremental fashion.~2. DB 4-week MPH maintenance phase. The clinician, parent, and teacher ratings of behavior and side effects from the titration trial weeks will be graphed. Two doctors will blindly review the graphs and judge which week was the optimal dose week. Pts will then receive their optimal dose of MPH (qAM) for 4 weeks.~3. DB 4-week MPH Discontinuation Phase. Pts in this arm will continue their optimal MPH dose (qAM)."
62378383|NCT01935167|EXPERIMENTAL|A Group|DW1029M 600mg for 24 weeks
62755118|NCT06345950|EXPERIMENTAL|Liposomal Glutathione|"Each participant receives their treatment i.e., Liposomal Glutathione hard gel capsules at a total dose of 500 mg glutathione. Treatments are consumed with a glass of water (approx. 125mL), followed by a standardized breakfast (diet-controlled condition). Capillary whole blood samples are collected at different time points up to 24 hours post-dose.~A washout period of at least 14 days between each treatment is used."
62755119|NCT06345950|EXPERIMENTAL|Standard Glutathione|"Each participant receives their treatment i.e., Standard Glutathione hard gel capsules at a total dose of 500 mg glutathione. Treatments are consumed with a glass of water (approx. 125mL), followed by a standardized breakfast (diet-controlled condition). Capillary whole blood samples are collected at different time points up to 24 hours post-dose.~A washout period of at least 14 days between each treatment is used."
62755120|NCT06345950|EXPERIMENTAL|New Micellar Glutathione (Lipomicel)|"Each participant receives their treatment i.e., LipoMicel Glutathione soft gel capsules at a total dose of 600 mg glutathione. Treatments are consumed with a glass of water (approx. 125mL), followed by a standardized breakfast (diet-controlled condition). Capillary whole blood samples are collected at different time points up to 24 hours post-dose.~A washout period of at least 14 days between each treatment is used."
62755121|NCT05480436|EXPERIMENTAL|Experimental Group|"Total of 400 participants received one dose of BBIBP-Corv and IIV4 on Day 0, and received one dose of BBIBP-Corv and PPV23 on Day 28. Blood sampling was performed on Day 0, Day 28 and Day 56 for humoral immunity assessment.~30 of the 400 participants were selected to collect three blood samples on Day 0, Day 42 and Day 56 for cellular immune assessment."
62755122|NCT05480436|ACTIVE_COMPARATOR|Control Group 1|"Total of 400 participants received two doses of BBIBP-Corv on Day 0 and Day 28. Blood sampling was performed on Day 0, Day 28 and Day 56 for humoral immunity assessment.~30 of the 400 participants were selected to collect three blood samples on Day 0, Day 42 and Day 56 for cellular immune assessment."
62755123|NCT05480436|ACTIVE_COMPARATOR|Control Group 2|Total of 400 participants received one dose IIV4 on Day 0 and received one dose PPV23 on Day 28. Blood sampling was performed on Day 0, Day 28 and Day 56 for humoral immunity assessment.
62755124|NCT00635739|ACTIVE_COMPARATOR|A, 1|
62755125|NCT00635739|PLACEBO_COMPARATOR|A, 2|
62755126|NCT05250076|ACTIVE_COMPARATOR|Intervention Group|"The beige Kinesio Tape (Prim Tape®) will be applied, from distal to proximal, 5cm wide, cut in I and with tension below 50%. The Kinesio Tape will be placed along the entire path of the median nerve, from the wrist to the armpit. The participants will remain in the supine position on a treatment table (Posturarte® Olympic), without inclination (Posturarte® Olympic). To clean the participant's skin, cotton (MASMI®) will be passed with ethyl alcohol (Fergus®). Scissor (Maped®) will be used to cut the Kinesio Tape."
62755127|NCT05250076|NO_INTERVENTION|Control Group|The participants will remain at rest in a supine position on a treatment table (Posturarte® Olympic) without inclination for 5 minutes.
62378384|NCT01935167|EXPERIMENTAL|B Group|DW1029M 1200mg for 24 weeks
62755128|NCT05421442||Abatacept Group|Participants with established rheumatoid arthritis (RA) or psoriatic arthritis (PsA) and receiving abatacept
62755129|NCT05421442||Non-targeted Disease Modifying Anti-rheumatic Drug (DMARD) Group|Participants with established RA or PsA and not previously treated with any targeted disease modifying anti-rheumatic drugs (DMARDs) and who start treatment with a non-targeted DMARD
62755130|NCT05421442||Targeted DMARD Group|Participants with established RA or PsA and previously treated without abatacept who start treatment with targeted DMARDs
62755131|NCT00616382|EXPERIMENTAL|Stepwise Indo|Stepwise escalating doses of indomethacin, until ductal closure or maximum of 1 mg/kg/dose.
62755132|NCT00616382|EXPERIMENTAL|PTX|Combined administration of indomethacin and pentoxifylline, an inhibitor of TNF alpha
61986699|NCT02109614|EXPERIMENTAL|Extended release Niacin|Taking 1500-2000mg niacin daily
62378385|NCT01935167|PLACEBO_COMPARATOR|C Group|Placebo for 24 weeks
62378386|NCT01603615|EXPERIMENTAL|BOTOX®|Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study.
62378387|NCT03849014|ACTIVE_COMPARATOR|Dynamic Hip Screw|Dynamic Hip Screw is used for internal fixation of fractures of the certain types of hip fractures. The implant assembly consisting of a lag screw, a side plate, and cortical screws that fix the side plate to the proximal femoral shaft.
62378388|NCT03849014|ACTIVE_COMPARATOR|Proximal Femoral Nail|The Proximal Femoral Nail offers osteosynthesis for the several types of hip fractures. It consists of an anatomically curved nail, double neck screw, and two locking screws for distal end.
62378389|NCT05056272||PCOS GROUP|
62755133|NCT01420874|EXPERIMENTAL|FOLFOX6 & EGFRBi armed ATC Infusions|"FOLFOX6: IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, \& in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.~EGFRBi armed ATC Infusions: Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion"
62755134|NCT04610489|OTHER|Study Population|All subjects will undergo bilateral mid-turbinate swabs for COVID Antigen (Quidel Sofia SARS Antigen Fluorescent Immunoassay (FIA)) as well as bilateral rt-PCR testing (Quest SARS-CoV-2 rRT-PCR).
62755135|NCT01297361|OTHER|Plasma Vitamin B12 and Folic acid levels|Blood sample was drawn
62755136|NCT03193723|ACTIVE_COMPARATOR|Group A|US guided five step field block will be performed
62755137|NCT03193723|ACTIVE_COMPARATOR|Group B|Spinal anesthesia will be administered in sitting position
62755138|NCT06394895||Subject-recipient (high incidence /low incidence group)|
62755139|NCT06394895||Subject-donor|
62755140|NCT04631289||metformin/non-metformin group|"Preadmission metformin exposure was defined as a record of metformin usage in Medications on admission in MIMIC-III.~Metformin group included non-AKI type 2 diabetes patients with preadmission metformin exposure.~Non-metformin group included non-AKI type 2 diabetes patients without preadmission metformin exposure."
62755141|NCT04590313|ACTIVE_COMPARATOR|Arthrodesis|MTPJ I Arthrodesis
62755142|NCT04590313|NO_INTERVENTION|Watchful waiting|No intervention, patient information leaflet
62755143|NCT00774839||Newly diagnosed stage II-III colon cancer 65 years or older|Medicare-eligible (≥ or = to 65 years) patients diagnosed with stage II - III colon cancer, are at least 4 months into chemotherapy and up to 7 months post-chemotherapy.
61986700|NCT02109614|PLACEBO_COMPARATOR|No Naicin|Placebo Comparator arm will be taking 1500mg of placebo daily
62378390|NCT05056272||Non PCOS group|
62378391|NCT03781154|EXPERIMENTAL|Group-based exercise|Virtually-delivered supervised exercise sessions will take place twice per week for approximately one hour, and include aerobic, muscular strength and endurance, balance, and flexibility components.
62378392|NCT03781154|NO_INTERVENTION|Control Group|A physical activity education control group
62378393|NCT03700931|EXPERIMENTAL|Eating recall condition|Participants receive a questionnaire asking them to write down what they ate the day before at breakfast, between breakfasts and lunch, at lunch, between lunch and dinner, at dinner, and after dinner, reporting for each episode the foods and drinks consumed, place, time of the day and people present (10).
62378394|NCT03700931|ACTIVE_COMPARATOR|Non-eating recall condition|Participants receive a questionnaire asking them to write down their school, homework (assignment), study, or work-related activities, two at morning, two at afternoon and two at night, of the day before reporting the name of each activity, place, time of the day and people present.
62378395|NCT03529734|EXPERIMENTAL|12 min running group|This group will perform a 12 min high intensity running with the goal to cover maximal possible distance.
62378396|NCT03529734|EXPERIMENTAL|Local strengthening exercise group|This group will perform local strengthening exercises (curl-ups, left side trunk flexion, trunk extension, right side trunk flexion). Each participant will have to perform three sets of each exercise with the maximal possible number of repetitions with a slow tempo (1s concentric phase and 2 s eccentric phase). Between sets, minimal rest (15 s) will be administered.
62378397|NCT00965744|EXPERIMENTAL|Vessel sealing system LigaSure (VS group)|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
62378398|NCT00965744|NO_INTERVENTION|Conventional hand-tied method (CH group)|Patients in CH group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the conventional hand-tied method.
62557034|NCT00124748|EXPERIMENTAL|imatinib 800 mg|Patients randomized to receive 800 mg Imatinib were to receive 400 mg twice daily (b.i.d.) oral administration, in the morning and the evening. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted or reduced based on guidelines defined in protocol.
62557035|NCT00533286|PLACEBO_COMPARATOR|A|placebo (2 tablets daily)
62755144|NCT04038892|ACTIVE_COMPARATOR|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 7 days a week for 8 weeks. After the training given by the physiotherapist, all exercise sessions will be performed at home.
61986701|NCT00809003||Sjogren's group|
61986702|NCT00809003||Dry eye|
61986703|NCT00809003||Normals|
61986704|NCT05023226|PLACEBO_COMPARATOR|LPVS group|The general ventilator setting.
61986705|NCT05023226|EXPERIMENTAL|LPVS + RM group|Recruitment maneuver.
62755145|NCT04038892|EXPERIMENTAL|Nintendo Wii Fit Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive Nintendo Wii Fit based exercise training for 40 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised by physiotherapist in a clinic per week.
62755146|NCT04038892|EXPERIMENTAL|BreathingLabs Breathing Games Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive BreathingLabs Breathing Games based exercise training for 40 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised by physiotherapist in a clinic per week.
62755147|NCT02445677|EXPERIMENTAL|Active TENS|Receiving active transcutaneous electrical nerve stimulation (TENS) treatments during the rehabilitation sessions (only the first half of the rehabilitation period, i.e. 4 to 6 weeks.
62755148|NCT02445677|PLACEBO_COMPARATOR|Simulated TENS|Receiving simulated transcutaneous electrical nerve stimulation (TENS) treatments during the rehabilitation sessions (only the first half of the rehabilitation period, i.e. 4 to 6 weeks.
62755149|NCT05417269|EXPERIMENTAL|Cohort 1 - Phase I (IMCY-0141 Dose 1)|The first dose (Cohort 1) will consist of the administration of 150 μg of peptide (IMCY-0141) in two separate injections of 75 μg each (500μl each).
62755150|NCT05417269|EXPERIMENTAL|Cohort 2 - Phase I (IMCY-0141 Dose 2)|The second dose (Cohort 2) will consist of the administration of 450 μg of peptide (IMCY-0141) in two separate injections of 225 μg each (500μl each).
62755151|NCT05417269|EXPERIMENTAL|Cohort 3 - Phase I (IMCY-0141 Dose 3)|The third dose (Cohort 3) will consist of the administration of 1350 μg of peptide (IMCY-0141) in two separate injections of 675 μg each (500μL each).
62755152|NCT05417269|EXPERIMENTAL|Group 1 - Phase II (IMCY-0141 Dose 1)|Administration of IMCY-0141, 150 μg combined with alum adjuvant.
62755153|NCT05417269|EXPERIMENTAL|Group 2 - Phase II (IMCY-0141 Dose 2)|Administration of IMCY-0141, 450 μg combined with alum adjuvant.
62755154|NCT05417269|EXPERIMENTAL|Group 3 - Phase II (IMCY-0141 Dose 3)|Administration of IMCY-0141, 1350 μg combined with alum adjuvant.
62755155|NCT05417269|PLACEBO_COMPARATOR|Group 4 (Placebo Group) - Phase II|Administration of placebo combined with alum adjuvant.
62755156|NCT05417269|ACTIVE_COMPARATOR|Group 5 (Active Control Group) - Phase II|Parallel, Open-Label, Active Control Group Oral administration of Dimethyl Fumarate (DMF) given according to its SmPC for the whole duration of the study.
62755157|NCT01812200|ACTIVE_COMPARATOR|Dabigatran, Ticagrelor, ASA|Dabigatran 150mg td Ticagrelor 90 mg td ASA 100 mg od for 5 days
62755158|NCT01812200|ACTIVE_COMPARATOR|Rivaroxaban, Ticagrelor, ASA|Rivaroxaban 20 mg od Ticagrelor 90 mg td ASA 100 mg od for 5 days
62755159|NCT01812200|ACTIVE_COMPARATOR|Phenprocoumon, Ticagrelor, ASA|Phenprocoumon X mg to reach an INR of 2-3 on day 5 of triple therapy Ticagrelor 90 mg td ASA 100 mg od for 5 days
62755160|NCT06127043|EXPERIMENTAL|Rosnilimab SC Dose 1|This arm will receive High dose Rosnilimab SC
62755161|NCT06127043|EXPERIMENTAL|Rosnilimab SC Dose 2|This arm will receive low dose Rosnilimab SC
62755162|NCT06127043|PLACEBO_COMPARATOR|Placebo|This arm will receive Placebo SC
62755163|NCT04795167||FlowTriever Arm|FlowTriever Arm subjects are defined as those subjects where FlowTriever is used as the Primary Treatment for pulmonary embolism.
62755164|NCT04795167||Context Arm|Subjects with high-risk pulmonary embolism who are treated with non-FlowTriever therapies.
62755165|NCT04795167||Prior Therapy Arm|Subjects presenting with low/intermediate-risk PE who received advanced therapy but subsequently progressed to high-risk PE in the same hospital setting/admission.
62755166|NCT03800342|EXPERIMENTAL|Healthy|Healthy individuals will participate in two separate days of cardiopulmonary exercise testing (CPET) (separated by a minimum of two, maximum of 7 days apart) prior to starting the aerobic exercise training program (AET). Individuals will then complete a 4-5 week (4x/week x 17 sessions) continuous, high-intensity AET. Each training session will consist of cycling for 3-5 minutes to warm-up, 45 minutes at 70% of heart rate reserve (HRR-determined from pre-training CPET), and 5-10 minutes to cool down. Following the AET, individuals will repeat the two separate days of CPET performed pre-training.
62378399|NCT03506113|ACTIVE_COMPARATOR|Gram stain-guided therapy group|The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics. The results of the Gram stains are categorised as Gram-positive cocci (GPC) chains, GPC clusters, Gram-positive bacilli (GPB), Gram-negative rods (GNR), or a combination of these. A non-pseudomonal beta-lactam antibiotic is selected when the Gram stain of the endotracheal aspirate shows only GPC chains and/or GPB. An anti-MRSA agent is selected when the Gram stain results show GPC clusters without GNR. An anti-pseudomonal agent is selected when the Gram stain results show GNR without GPC clusters. The combination of an anti-pseudomonal agent and an anti-MRSA agent is selected when the Gram stain results show both GPC clusters and GNR.
62378400|NCT03506113|ACTIVE_COMPARATOR|Guidelines-based therapy group|Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to the Infectious Disease Society of America and the American Thoracic Society (IDSA/ATS) guidelines because 47.7% of S. aureus isolates are MRSA in Japanese ICUs
62378401|NCT00312728|EXPERIMENTAL|bevacizumab|
62378402|NCT01774227|EXPERIMENTAL|The pops-titration group|"The titration method uses power that is titrated according to the audible pop."
62378403|NCT01774227|EXPERIMENTAL|The slow-coagulation group|The slow-coagulation group utilize the low-energy using the Gaasterland's slow-coagulation technique
62378404|NCT02516306|EXPERIMENTAL|EV06 Ophthalmic Solution|EV06 Ophthalmic Solution: Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.
62378405|NCT02516306|PLACEBO_COMPARATOR|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution (EV06 vehicle): Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.
62378406|NCT01913652|EXPERIMENTAL|Cabazitaxel|"INN: Cabazitaxel Cabazitaxel will be administered at a dose of 25 mg/m² by intravenous infusion, over 1 hour, on day 1 of each 21 day cycle.~Treatment should be administered until disease progression, unacceptable toxicity or patient's refusal."
62378407|NCT00935467|OTHER|Saxagliptin|
62557036|NCT00533286|EXPERIMENTAL|B|diazepam (2 x 5 mg)
62755167|NCT01596881||Multiple Sclerosis Patients|Physician-confirmed diagnosis of multiple sclerosis. Any subtype is acceptable. For example, relapsing-remitting, secondary progressive, primary progressive
62755168|NCT01596881||Healthy Normal Subjects|Volunteers with healthy eyes.
62755169|NCT06184464||prostate patient|use of Leupreline
62755170|NCT01065194|EXPERIMENTAL|Levosimendan|Chronic stable heart failure
62755171|NCT01065194|PLACEBO_COMPARATOR|Placebo|Chronic Stable Heart Failure
62755172|NCT06553716|ACTIVE_COMPARATOR|Rotator cuff space approach (GroupA)|In the Rotator cuff interval recess group,we injected 20 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into into the Rotator cuff interval/anterior capsule.
62755173|NCT06553716|EXPERIMENTAL|Rotator cuff space approach combined with posterior glenohumeral recess approach (GroupB)|In the Rotator cuff interval and posterior glenohumeral recess group,we injected 10 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the Rotator cuff interval/anterior capsule and 10 mL mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the posterior glenohumeral.
62755174|NCT02116647|EXPERIMENTAL|Psychoanalytic therapy|manualized psychoanalytic psychotherapy
62755175|NCT02116647|NO_INTERVENTION|Control Group|Standard care
62755176|NCT05923736|OTHER|Case group : digital osteoarthritis|
62378408|NCT05939219|EXPERIMENTAL|3-month-old group|"Randomly inoculate 4 batches of 15-valent pneumococcal conjugate vaccine. Immunization program and dosage: Basic immunization at 0, 1, and 2 months, booster immunization at 12-15 months of age, a total of 4 doses administered.~Dosage form: water injection type"
62557037|NCT06281366||Control|Pregnant women with a positive first-trimester screening for preeclampsia (high risk) and no pregnancy complications (preeclampsia, fetal death, preterm birth, PPROM, low birthweight).
62755177|NCT05923736|OTHER|Control group : lumbago, osteoporosis|
62378409|NCT05939219|EXPERIMENTAL|7-11 month old experimental group|"The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1.~Immunization program and dosage: Basic immunization for 0 and 2 months program; Strengthen one dose after 12 months of age; A total of 3 doses were administered.~Dosage form: water injection type"
62378410|NCT05939219|ACTIVE_COMPARATOR|7-11 month old control group|"The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1.~Immunization program and dosage: Basic immunization for 0 and 2 months program; Strengthen one dose after 12 months of age; A total of 3 doses were administered.~Dosage form: water injection type"
62378411|NCT05939219|EXPERIMENTAL|12-23 months old experimental group|"The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1.~Immunization program and dosage: Immunize 2 doses using the 0 and 2 month program, with a total of 2 doses administered.~Dosage form: water injection type"
62378412|NCT05939219|ACTIVE_COMPARATOR|12-23 months old control group|"The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1.~Immunization program and dosage: Immunize 2 doses using the 0 and 2 month program, with a total of 2 doses administered.~Dosage form: water injection type"
62557038|NCT06281366||Cases|Pregnant women with a positive first-trimester screening for preeclampsia (high risk) and any of the following pregnancy complications: preeclampsia, fetal death, preterm birth, PPROM, low birthweight.
62557039|NCT04342819|EXPERIMENTAL|SGLT2i|Empagliflozin 25 mg per oral once daily
62557040|NCT02926066|EXPERIMENTAL|AAV2-hAADC|"Dosage form: Aqueous solution Dose(s): 2.37x10\^11 vg/case(High dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect~Dosage form: Aqueous solution Dose(s): 1.81x10\^11 vg/case(Standard dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect"
62557041|NCT04040036|EXPERIMENTAL|VR-Rollercoaster|The children in the VR groups were told to watch the video by wearing virtual glasses during the blood draw. By wearing the VR headsets in the VR-Rollercoaster Group, individuals feel as if they are getting on and riding a rollercoaster. The rollercoaster speeds up and slows down.
62557042|NCT04040036|EXPERIMENTAL|VR-Ocean Rift|The children in the VR groups were told to watch the video by wearing virtual glasses during the blood draw. By wearing the VR headsets in the VR-Ocean Rift Group, individuals can take an underwater tour with 12 different marine animals with slow music.
62557043|NCT04040036|NO_INTERVENTION|Control|They would be monitored during the procedure if their informed consent was received. Control group children did not receive any distraction techniques.
62557044|NCT04230928|PLACEBO_COMPARATOR|Standard GLB Control|Individuals will receive the standard Diabetes Prevention Program-Group Lifestyle Balance (GLB) program as outlined by the American Diabetes Association. This program will be taught at the Baylor Scott \& White Health and Wellness Center by trained research staff.
62557045|NCT04230928|EXPERIMENTAL|VLC-GLB Intervention|Individuals will receive a version of the DPP-GLB program in which 4 of the 12 modules will teach a very low carbohydrate diet instead of the standard. All other components of the DPP-GLB will follow the standard. This program will be taught at the Baylor Scott \& White Health and Wellness Center by trained research staff.
62557046|NCT04852029|ACTIVE_COMPARATOR|Control Group|to remain on current dose of low dose hCG
62557047|NCT04852029|EXPERIMENTAL|Intervention Group|increased dose of low dose hCG prescribed
62557048|NCT05582798|ACTIVE_COMPARATOR|Alpha1-Proteinase Inhibitor 180mg/kg|Alpha1-Proteinase Inhibitor 180mg/kg, intravenous infusion, 50mg/ml
62557049|NCT05582798|ACTIVE_COMPARATOR|Alpha1-Proteinase Inhibitor 120mg/kg|Alpha1-Proteinase Inhibitor 180mg/kg, intravenous infusion, 50mg/ml
62557050|NCT05582798|PLACEBO_COMPARATOR|Placebo 1|Sodium chloride 0.9% volume to match that of Alpha1-Proteinase Inhibitor 180mg/kg, intravenous infusion.
62755178|NCT01301521|EXPERIMENTAL|Cinnulin PF|Will take (by mouth) 2 gelatin capsules that contains 1 gram (2-500 mg capsules) water-soluble cinnamon extract (Cinnulin PF) once a day for 1 year plus 1 year of follow-up plus standard of care aggressive lifestyle therapy.
62755179|NCT01301521|PLACEBO_COMPARATOR|Placebo|Will take (by mouth) 2 placebo capsules (gelatin capsule filled with wheat bran) once a day for 1 year plus 1 year of follow-up plus standard of care aggressive lifestyle therapy.
62755180|NCT00536874|EXPERIMENTAL|Gemcitabine And Oxaliplatin|A Phase II Study of Neoadjuvant Gemcitabine And Oxaliplatin In Patients With Potentially Resectable Previously Untreated Pancreatic Adenocarcinoma
62755181|NCT04131205||Minimal Hepatic Encephalopathy|Patients with hyperammonemia and minimal hepatic encephalopathy
62755182|NCT04131205||Control|Healthy controls
62755183|NCT00867087|EXPERIMENTAL|Rituximab 375 mg/m^2 + Inotuzumab Ozogamicin 1.8 mg/m^2|Inotuzumab ozogamicin, in combination with rituximab, will be administered to patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma prior to an autologous stem cell transplant (aSCT).
62755184|NCT02908646|EXPERIMENTAL|microcoil|patients who plan for microcoil localization
62755185|NCT02908646|PLACEBO_COMPARATOR|hookwire|patients who plan for hookwire localization
62755186|NCT01513603|EXPERIMENTAL|CLAG-M|
62755187|NCT05176197|EXPERIMENTAL|Almond Group|Participants will consume almonds every day for 16 weeks, but will not be allowed to consume any other nuts or nut products.
62755188|NCT05176197|EXPERIMENTAL|Control Group|Participants will consume pretzels every day for 16 weeks, but will not be allowed to consume any other nuts or nut products.
62755189|NCT02818374|EXPERIMENTAL|Disabled People with behavioral trouble|
62755190|NCT06014931|EXPERIMENTAL|Telemedicine ICU Recovery Clinic|scheduled telemedicine study visits 3 weeks and 3 months after hospital discharge or return-to-home if discharged to another facility
62755191|NCT06014931|NO_INTERVENTION|Standard Recovery Conditions (i.e., Control)|Control group participants will proceed with follow-up as determined by the discharging hospital team and directed to use the provided PICS guide to connect with commonly used resources.
61986706|NCT03040466|ACTIVE_COMPARATOR|reusable fiberoptic ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using reusable fiberoptic flexible ureteroscope (URF-P6, Olympus). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
62755192|NCT05507879||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood samples at time of therapy initiation. Patients who develop cardiac toxicity may undergo additional collection of blood samples. Patients' medical records are also reviewed.
62755193|NCT01056003||all patients admitting endoscopy for EGD|
62755194|NCT04942015|EXPERIMENTAL|Honghuaruyi Wan|Honghuaruyi Wan will be used in this arm. Patients should start taking medicine with warm water on the first day of menstruation. For patients with VAS score \< 7 points, 1g / time, twice a day; for patients with VAS score ≥ 7 points and pain is hard to bear, 2g / time, twice a day. According to the above usage and dosage, take 3 menstrual cycles continuously, and observe 3 menstrual cycles after stopping the drug.
62755195|NCT04942015|PLACEBO_COMPARATOR|Placebo|Placebo of Honghuaruyi Wan will be used in this arm. Patients should start taking medicine with warm water on the first day of menstruation. For patients with VAS score \< 7 points, 1g / time, twice a day; for patients with VAS score ≥ 7 points and pain is hard to bear, 2g / time, twice a day. According to the above usage and dosage, take 3 menstrual cycles continuously, and observe 3 menstrual cycles after stopping the drug.
62755196|NCT00960037|EXPERIMENTAL|Vitamin D|Vitamin D3 supplementation based on baseline 25(OH)D level
62755197|NCT00960037|PLACEBO_COMPARATOR|Placebo|
62755198|NCT00107315|EXPERIMENTAL|Arm 1|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral capecitabine twice daily on days 1-7
62755199|NCT03839485|ACTIVE_COMPARATOR|Pasta Guedes-Pinto|Endodontic treatment using Guedes-Pinto Paste
62755200|NCT03839485|EXPERIMENTAL|Pasta Guedes-Pinto without antibiotic|Endodontic using Guedes-Pinto paste without antibiotic
62557051|NCT05582798|PLACEBO_COMPARATOR|Placebo 2|Sodium chloride 0.9% volume to match that of Alpha1-Proteinase Inhibitor 120mg/kg, intravenous infusion.
62755201|NCT03660228|EXPERIMENTAL|Peri-Transfusion QOL Assessment|"* Participants will be given a study packet containing a paper copy of the QUALMS~* Study participants will fill out the survey on the day before their first/next pRBC transfusion.~* Study participants will receive a second paper copy of the QUALMS, along with a stamped envelope addressed to the appropriate site~* The second assessment will be scored and compared with the first, and both the patient and provider will be sent a report with the results"
62755202|NCT06602180|EXPERIMENTAL|Exprimental group A|Thirty-one patients will receive: Scapular PNF technique, (TAPA) technique for the affected shoulder region plus conventional physiotherapy program in a form of (CDT).
62755203|NCT06602180|EXPERIMENTAL|Experimental: group B|Thirty-one patients will receive Scapular PNF technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT))
62755204|NCT06602180|EXPERIMENTAL|Experimental: group C:|Thirty-one patients will receive Activity-Oriented Antiedema Proprioceptive Therapy (TAPA) technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT)
61986707|NCT03040466|EXPERIMENTAL|disposable digital ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using disposable digital flexible ureteroscope (LithoVue, Boston Scientific). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
61986708|NCT03727412|ACTIVE_COMPARATOR|Naproxen Group|patients with an abdominal aortic aneurysm undergoing endovascular epair and taking preoperatively naproxen (Naprosyn, tab 500 mg twice/day for 4 days)
62378413|NCT05939219|EXPERIMENTAL|2-5 year old experimental group|"The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1.~Immunization program and dosage: 1 dose administered. Dosage form: water injection type"
62378414|NCT05939219|ACTIVE_COMPARATOR|2-5 year old control group|"The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1.~Immunization program and dosage: 1 dose administered. Dosage form: water injection type"
62755205|NCT00031655|EXPERIMENTAL|Treatment (nonmyeloablative allogeneic PBSCT)|"NONMYELOALATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0. Patients with minimal residual disease may receive donor lymphocyte infusion IV.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO very 8 hours on days 0 to 40 with taper to day 96."
62755206|NCT01472783|EXPERIMENTAL|Veliparib|
62755207|NCT04460924||MSM HIV-uninfected and ART naïve|Men who have sex with men without HIV infection, not receiving ART
62755208|NCT04460924||MSM HIV-infected starting ART|Men who have sex with men with HIV infection, starting ART
62755209|NCT04460924||MSM HIV-infected on ART with >500 CD4 Tcells|Men who have sex with men with HIV infection, on ART and with \>500 CD4 T cells/uL
62755210|NCT04460924||MSM HIV-infected on ART with <350 CD4 Tcells|Men who have sex with men with HIV infection, on ART and with \<350 CD4 T cells/uL
62755211|NCT04460924||MSM HIV negative patients starting PEP with INST|Men who have sex with men without HIV infection, starting post-exposure prophylaxis with raltegravir
62755212|NCT02723006|EXPERIMENTAL|TAK-580 + nivolumab|TAK-580 orally, once weekly along with nivolumab, intravenous, every 2 weeks.
62755213|NCT02723006|EXPERIMENTAL|TAK-202 (plozalizumab) + nivolumab|TAK-202 (plozalizumab) 2 milligram (mg), intravenous, once in Week 1, 3, 5, 9, and every 4 weeks thereafter with nivolumab infusion, intravenous, every 2 weeks.
62755214|NCT02723006|EXPERIMENTAL|vedolizumab + nivolumab + ipilimumab|Vedolizumab intravenous, once in Week 1, 3, 5, and 13 along with nivolumab infusion, intravenous, once in Week 1, 4, 7, 10, and 13 and every 2 weeks thereafter, along with ipilimumab intravenous, once in Week 1, 4, 7, and 10.
62755215|NCT01336530|EXPERIMENTAL|Tepilta®|
62755216|NCT01336530|ACTIVE_COMPARATOR|Oxetacaine|
62755217|NCT01336530|ACTIVE_COMPARATOR|Antacids|
62755218|NCT01336530|PLACEBO_COMPARATOR|Placebo|
62755219|NCT00539383|EXPERIMENTAL|1|
62378415|NCT05677828||Antagonist - SMART|Women who have had a SMART IVF stimulation cycle with Letrozole after a failed antagonist IVF stimulation cycle between 2010 and 2020.
62378416|NCT05677828||Antagonist - Antagonist|Women who have had an antagonist stimulation IVF cycle after a previously failed antagonist IVF stimulation cycle between 2010 and 2020.
62378417|NCT03523715|EXPERIMENTAL|Prunes|The study group will be instructed to consume 4 oz of prunes as well as docusate sodium twice daily for 3 days after surgery.
62378418|NCT03523715|PLACEBO_COMPARATOR|Control|The placebo group will be instructed to take docusate sodium twice daily for 3 days after surgery.
62378419|NCT04144933|EXPERIMENTAL|Opioid-free General Anesthesia (OFA)|Opioid-free preoperative medications, Opioid-free pre-intubation medications, Opioid-free maintenance medication, postoperative nausea and vomiting prophylaxis.
62378420|NCT04144933|ACTIVE_COMPARATOR|Traditional Opioid-containing General Anesthesia (TOA)|Opioid-sparing preoperative medications, Opioid-containing pre-intubation medications, Opioid-containing maintenance medications, postoperative nausea and vomiting prophylaxis.
62378421|NCT06269406|EXPERIMENTAL|Intervention Group ibuprofen 400 and Curcumin|
62378422|NCT06269406|EXPERIMENTAL|Intervention Group ibuprofen 200 and Curcumin|
62378423|NCT06269406|PLACEBO_COMPARATOR|Intervention Group ibuprofen 400 and placebo|
62557052|NCT02465905|ACTIVE_COMPARATOR|Raw milk|For raw milk immunotherapy (RMI), fixed dose of raw milk was daily administered at home, determined using tolerated threshold dose during the DBPCFC. Augmentation was made every 5 weeks in the allergy clinic.
62378424|NCT00083616|EXPERIMENTAL|Panitumumab|Participants received panitumumab 6 mg/kg once every 2 weeks weeks administered by intravenous (IV) infusion until progressive disease, inability to tolerate the investigational product, or discontinuation of treatment for other reasons.
62557053|NCT02465905|ACTIVE_COMPARATOR|Heated milk|For heated milk immunotherapy (HMI), families were asked to weekly increase the daily dose of milk at home using industrial preparations. Milk included in the preparation was less and less heated among time. Passage from heated-milk to half-heated milk and then raw milk was performed in the allergy clinic.
62557054|NCT00408512|ACTIVE_COMPARATOR|Thiazides|Thiazidic diuretic
62557055|NCT00408512|ACTIVE_COMPARATOR|Non Tiazidic|Non tiazidic diuretic treatment: Any other therapy can be considered in this arm: example: CCB, BB, ACEi, ARB
62557056|NCT02071225|EXPERIMENTAL|Obinutuzmab + Bendamustine|Participants will receive obinutuzumab and bendamustine in 28-days cycles for a maximum of 6 cycles
62557057|NCT00858494|EXPERIMENTAL|homeopathic cold remedy|
62557058|NCT05624918|EXPERIMENTAL|Investigational Group|"Nab-paclitaxel + gemcitabine + NovoTTF-200T(P) for 3 cycles (28 day cycles)~Participants who have stable disease or better after the first 3 cycles of treatment will undergo pancreatectomy within 8 weeks of receiving treatment. If the surgery yields R0 or R1 then patient will receive another 3 cycles of treatment regimen (within 8 weeks of surgery).~Those who do not undergo surgery will still be included in the evaluable patients for the objectives"
62557059|NCT04553159|EXPERIMENTAL|Adipose Derived Stem Cell(ADSC) arm|"Participants allocated to this arm will have tumescent liposuction performed on them to obtain lipoaspirate. The lipoaspirate will then be processed to obtain the stromal vascular fraction. This Adipose derived stromal vascular fraction which contains stem cells will then be infiltrated into the keloid tissue as a single dose infiltration.~This will be harvested and infiltrated as the whole cell pellet (stromal vascular fraction) comprising of an estimate total of 9 million ADSCs (range: 8.4-9.72; SD ± 6.6)."
62557060|NCT04553159|ACTIVE_COMPARATOR|Triamcinolone Acetanoide (TAC) arm|Participants in this arm will receive a single dose Triamcinolone acetanoide infiltration into the keloid. This will be a single dose infiltration of 40mg/cubic centimetres of keloids.
62557061|NCT02094300|EXPERIMENTAL|Endovascular|
62557062|NCT06306300|NO_INTERVENTION|Study I|Study I is a population-based cross-sectional screening study (n=30,000 individuals) using rapid tests to determine the prevalence of HCV infection in people attending a Basic Health Care Unit.
62378425|NCT04602299|EXPERIMENTAL|Set the minimum time of gastroscopy|
62378426|NCT04602299|NO_INTERVENTION|Observe the procedure time of gastroscopy|
62378427|NCT03323086|EXPERIMENTAL|Brief Intervention (BI) with Technology Extender|Participants assigned to BI condition will receive a face to face session lasting 45-60 minutes delivered by a health coach. Following the session, participants will be given access to a study website and receive texts-of-the day on study topics.
62378428|NCT03323086|OTHER|Brochure|Participants assigned to the Brochure condition will receive materials prepared by the Centers for Disease Control and Prevention on the study topics.
62378429|NCT04251377|EXPERIMENTAL|Single-stage surgery + DAC® + topical antibiotics|Experimental group is composed of single-stage procedure associated to the use of biofilm inhibitor (Defensive Antibacterial Coating® DAC®) and topical antibiotics=new strategy
62378430|NCT04251377|NO_INTERVENTION|control group : two-stage surgery|Control group is composed of two-stage procedure without biofilm inhibitor (standard protocol)
62755220|NCT06059872|EXPERIMENTAL|Chronic Stroke with lower limb disability|The investigators will enroll 55 Veterans with chronic subcortical stroke in the 12-week HIIT intervention, with the expectation that 48 participants (85%) will complete the entire program. In our experience, 65% of participants will respond to the HIIT intervention, resulting in an estimated 31 responders and 17 resistors. Each chronic subcortical stroke participant will be asked to participate in the HIIT study protocol. Classification of resistor or responder: A responder to the 12-week HIIT intervention will be defined as a participant who increases their walking speed to greater than 0.6 m/s. A resistor to the intervention will be defined as a participant who does not increase their walking speed to greater than 0.6 m/s.
62755221|NCT05423340|EXPERIMENTAL|Use Own Brand of Flavored Product|Participants will use their current flavor of e cigarettes for 90 days
62755222|NCT05423340|EXPERIMENTAL|Use Provided Tobacco Flavor|Participants will use a new assigned flavor for 90 days
62755223|NCT05423340|ACTIVE_COMPARATOR|"Vaping Abstinence - use Tobacco Free Nicotine Pouches"|Participants will be asked to stop vaping for 90 days and instead only use the provided 'tobacco free' nicotine pouches.
62755224|NCT02002936|EXPERIMENTAL|SyB C-1101|
62755225|NCT06344910||Patients with HFrEF|
62378431|NCT01693289|EXPERIMENTAL|Metformin plus letrozole|metformin :850mg tablets twice daily for 6 months letrozole :5mg tablets twice daily form day 3to7 of cycle
61986709|NCT03727412|PLACEBO_COMPARATOR|Control group|patients with an abdominal aortic aneurysm undergoing endovascular epair and taking placebo
61986710|NCT03099876||7 days treament group|7 days of triple therapy (Ilaprazole 10mg, Clarithromycin 500mg Amoxicillin 1000mg B.I.D)
61986711|NCT03099876||10 days treatment group|10 days of triple therapy (Ilaprazole 10mg, Clarithromycin 500mg Amoxicillin 1000mg B.I.D)
61986712|NCT02716558|EXPERIMENTAL|Moisture tolerant resin sealant|Moisture resistant sealant (wet bond sealant)
61986713|NCT02716558|ACTIVE_COMPARATOR|ART sealant|Glass inomer based sealant
62378432|NCT01693289|EXPERIMENTAL|ovarian drilling|bilateral diathermy ovarian drilling, four drills each ovary
62378433|NCT04916106|EXPERIMENTAL|One parameter TEA group for 4 weeks|Choose two acupoints,give 25Hz electrical stimulation for 4 weeks.
62378434|NCT04916106|EXPERIMENTAL|Another parameter TEA group for 4 weeks|Choose two acupoints,give 100 Hz electrical stimulation for 4weeks.
62755226|NCT03041675|EXPERIMENTAL|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
62755227|NCT03041675|SHAM_COMPARATOR|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
62755228|NCT02928029|EXPERIMENTAL|Phase1, arm1: 33 kBq/kg Radium-223 dichloride+SOC|Phase 1: Radium-223 dichloride; 33 kiloBecquerel (kBq)/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC (standard of care) bortezomib/ dexamethasone.
62755229|NCT02928029|EXPERIMENTAL|Phase1, arm2: 55 kBq/kg Radium-223 dichloride+SOC|Phase 1: Radium-223 dichloride; 55 kBq/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/ dexamethasone.
62755230|NCT02928029|PLACEBO_COMPARATOR|Phase2, arm1: Placebo+SOC|Phase 2: Matching placebo (isotonic saline) every 6 weeks for a total of 6 doses plus SOC bortezomib/dexamethasone.
62755231|NCT02928029|EXPERIMENTAL|Phase2, arm2: Radium-223 dichloride+SOC|Phase 2: Phase 1b-selected dose of radium-223 dichloride every 6 weeks for 6 doses plus SOC bortezomib/dexamethasone
62755232|NCT05081349|EXPERIMENTAL|Hydra+L-Carnitine|Hydroxycarbamide+ L-Carnitine+supportive treatment
62557063|NCT06306300|NO_INTERVENTION|Substudy I|The sub-study associated with Study I is a cross-sectional study to assess the usability of a self-test for the detection of HCV antibodies in oral fluid (n=1,500 participants included in Study I).
62378435|NCT04916106|EXPERIMENTAL|Sham-TEA group for 2 weeks, and the random TEA for the next 2 weeks.|Choose two non-acupoints，give 25Hz and 100Hz electroacupuncture stimulation respectively for the first 2 weeks. Then give supplement TEA treatment as described above for the next 2 weeks.
62378436|NCT05412160|EXPERIMENTAL|ARM A - BioArginine receivers|Patients will be randomized to receive BioArginine C™ twice daily on top of usual chronic inhaled therapy
62378437|NCT05412160|PLACEBO_COMPARATOR|ARM B - placebo receivers|Patients will be randomized to receive placebo twice daily on top of usual chronic inhaled therapy
62378438|NCT05683158||chronic stroke|The subject consisted of the physician's confirmation of chronic hemiplegia onset ≥ 6 months Mini-mental state examination≥25 Biceps ≤2, Triceps≤2 Ability to Sit on a chair alone FMA upper extremity score ≥ 21points, FMA upper extremity score ≤ 66 points The symptom is mild or moderate level (MAS≤2) and can sit alone. The subject reaches to target by affected arm in 3 directions(medial_45, forward_90 and lateral_135 degrees)
62378439|NCT05683158||Healthy|"Matching aged people, not having neurological system or orthopedic disease on Upper extremity.~The subject reaches to target by non-dominant arm in 3 directions(medial_45, forward_90 and lateral_135 degrees)"
62378440|NCT06375811|ACTIVE_COMPARATOR|Pre-IVF Treatment with 60 day course of oral GnRH antagonist|For those who agree to be randomized, subjects will be randomized to elagolix 200mg BID. The medication will be taken orally and subjects will be counseled to take the medication at the same time each day. This arm will also include participants who do not want to be randomized while choose elagolix.
62755233|NCT05081349|ACTIVE_COMPARATOR|Hydra only|Hydroxycarbamide+ supportive treatment
62755234|NCT05081349|ACTIVE_COMPARATOR|L-Carnitine only|L-Carnitine+ supportive treatment
62755235|NCT05081349|NO_INTERVENTION|Supportive measures|Supportive only
62755236|NCT00607113|EXPERIMENTAL|Avastin|Cycle 1 (First 3 weeks of study) - Avastin 15 mg/kg intravenous (IV)
62755237|NCT00607113|EXPERIMENTAL|Avastin + RAD001|Cycle 2: Avastin 15 mg/kg intravenous (IV) every 3 weeks + RAD001 10 mg orally daily for 3 weeks
62755238|NCT00607113|EXPERIMENTAL|RAD001|Cycle 1 (First 3 weeks of study)- RAD001 10 mg orally daily for 21 Days
62755239|NCT03985982|EXPERIMENTAL|Botulinum toxin A|Botulinum Toxin A will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m injections) into glabellar area.
62755240|NCT03985982|PLACEBO_COMPARATOR|Placebo|Placebo will be administered in double blind fashion in cycle 1 divided in five 0.1 mL injections into the glabellar area.
62755241|NCT06338514|ACTIVE_COMPARATOR|Dry needling group (study group)|Real dry needling into the muscle under ultrasound guidance.
62755242|NCT06338514|SHAM_COMPARATOR|Sham dry needling group (control group)|Sham dry needling into the subcutaneous fatty tissue under ultrasound guidance.
62755243|NCT06606431|EXPERIMENTAL|Participant Group|"The intervention is multilevel and is based on bringing together two population groups in the community with complementary needs:~1. People over 16 years of age isolated at home due to mobility problems or chronic mental illness.~2. Volunteers from the neighborhood, especially people with interested in improving their emotional well-being.~REBEC will conduct a first individual interview to confirm that the volunteers are emotionally and vitally stable at the time of the intervention.~A personalized relational dynamic of help will be set up in each case (one-to-one interaction, relational level). This interaction can consist of listening at home or going with the person on the street to bring them closer to the different proposals for community social activities.~The group of social isolation and/or unwanted loneliness will also receive support from the community team, to provide a personalized response to the physical, health, social or psychological needs detected by the v"
62755244|NCT06606431|NO_INTERVENTION|Control Group|In-waiting list for intervention in future rounds; habitual care
62755245|NCT05894538|EXPERIMENTAL|Arm D - Ivermectin 600|"Ivermectin - 7-mg tablets~Participant will be instructed to take a pre-specified number of tablets for 6 consecutive days based on their weight for a daily dose of approximately 400-600 µg/kg."
62755246|NCT05894538|PLACEBO_COMPARATOR|Arm D - Placebo|"Placebo - appearance and size matched to active study drug.~Participant will be instructed to take a pre-specified number of tablets for 6 consecutive days based on their weight, matched to active study drug dosing."
62755247|NCT05916625|EXPERIMENTAL|Pet scan with the specific radioligand [11C]SB207145|"The following examen are added by the study :~neuropsychologic consultation PET scan MRI biological sample Questionnaires"
62755248|NCT01842165|OTHER|177Lu-octreotate therapy|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
62755249|NCT00921414|ACTIVE_COMPARATOR|1|observation : 3 years maintenance period with assesments and surveillance every 2 months
62755250|NCT00921414|EXPERIMENTAL|2|maintenance period infusions of Rituximab 375 mg/m2/2 months and assessement and surveillance
62755251|NCT00746265|ACTIVE_COMPARATOR|SBT|Standard behavioral treatment based on the LEARN manual.
62755252|NCT00746265|ACTIVE_COMPARATOR|ABT|Acceptance-based group that is based on the behavioral interventions contained in LEARN manual
62755253|NCT02913001|EXPERIMENTAL|Low Glycemic Load Diet|Participants received a diet education to follow a low glycemic load diet and received some low glycemic load staple foods.
61986714|NCT03163888||Navigation TKR group|TKR performed under computer navigation without violating distal femur bone marrow.
61986715|NCT03163888||Conventional TKR group|TKR performed under conventional distal femur cutting juts with violation of distal femur bone marrow.
62755254|NCT02913001|ACTIVE_COMPARATOR|Usual Eating Plan|Participants received a diet education to continue with their usual diet.
62755255|NCT00803257|EXPERIMENTAL|1|Lumbrical splint and lumbrical stretches
62755256|NCT00803257|ACTIVE_COMPARATOR|2|Lumbrical Splint and regular exercises
62755257|NCT00803257|ACTIVE_COMPARATOR|3|Regular splint and lumbrical exercises
62755258|NCT00803257|ACTIVE_COMPARATOR|4|Regular splint and regular exercises
62755259|NCT06605326|EXPERIMENTAL|Subcutaneous Treprostinil Group|Patients in this group received subcutaneous treprostinil, starting at a dose of 1.25 to 4 ng/kg/min and gradually titrated according to patient response. The target dose was over 20 ng/kg/min after 3 months of treatment. All patients were referred for lung transplantation during or after treprostinil treatment.
62755260|NCT05056688|EXPERIMENTAL|Application of training set to experimental group|Testicular Model BSE/TSE Training Set
62755261|NCT05056688|NO_INTERVENTION|Control Group|
62755262|NCT00416663|EXPERIMENTAL|single arm|open label,single arm,intervention is Angiogenic Cell Precusors(ACPs)
62755263|NCT06604416||Backward walking exercise group|Healthy subjects aged 18-25 years were included in the study. Cognitive and physical function assessments were performed face-to-face by a physiotherapist before and after backward walking exercise. In addition, assessments during the exercise were performed by the same physiotherapist. Assessments were made immediately before and immediately after the walking exercise. All assessments were supervised by the physiotherapist.
62755264|NCT06604416||Forward walking exercise group|Healthy subjects aged 18-25 years were included in the study. Cognitive and physical function assessments were performed face-to-face by a physiotherapist before and after forward walking exercise. In addition, assessments during the exercise were performed by the same physiotherapist. Assessments were made immediately before and immediately after the walking exercise. All assessments were supervised by the physiotherapist.
62557064|NCT06306300|ACTIVE_COMPARATOR|Study II - Specialist|"HCV standard-of-care treatment; control arm. Participants randomized for the Standard-of-Care HCV treatment arm will be referred for the usual treatment of hepatitis C by specialists (hepatologists and/or infectious disease specialists) at a tertiary center \[INI/FIOCRUZ or Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ)\]. Participants will be treated with the pan-genotypic therapeutic regimen single-pill daily, at a fixed dose and duration: sofosbuvir/velpatasvir 400/100 mg (Epclusa, Gilead Sciences, USA) 1 tablet orally per day for 12 weeks."
62557065|NCT06306300|ACTIVE_COMPARATOR|Study II - Non Specialist|"Decentralized hepatitis C treatment (DS HCV treatment; experimental arm).Participants randomized for the Decentralized-and-Simplified HCV treatment (DS HCV treatment) arm will be referred for simplified treatment of chronic hepatitis C at the Primary Health Care unit where participants were included in Study I and are registered for care. The treatment will be conducted by a non-specialist physician (general practitioner or family doctor) after training provided by a specialist (hepatologist) on the treatment of patients with hepatitis C using DAAs. Participants will be treated with a pan-genotypic therapeutic regimen, a fixed-dose, single-pill daily: sofosbuvir/velpatasvir 400/100 mg (Epclusa, Gilead Sciences, USA), 1 tablet orally per day for 12 weeks."
62755265|NCT06604416||Control group|Participants did not perform any walking exercise. Cognitive and physical function assessments were performed before and after the assessment tests, with 30 minutes of rest in between.
62557066|NCT05881395||Women with epidural analgesia experiencing pain during labor|Patients reporting pain will have their sensory block checked using ice and pinprick tests, prior to, and following and epidural top-up.
62182484|NCT00604188|EXPERIMENTAL|Direct Suboxone Induction|Participants received 8 mg of Suboxone and placebo Subutex on Day 1, 16 mg of Suboxone and placebo Subutex on Day 2, and all participants received open label Suboxone from Day 3 to Day 28. Suboxone dosage may be titrated from Day 4 to Day 28 up to 24 mg per day.
62378441|NCT06375811|OTHER|Pre-IVF Treatment with 60 day course of Placebo or SOC IVF|For those who agree to be randomized, subjects will be randomized to placebo, BID. The medication will be taken orally and subjects will be counseled to take the medication at the same time each day. This arm will also include participants who want to continue their ongoing or planned IVF and follow standard of care (SOC) (SOC IVF) if the participants do not want to delay the IVF procedure.
62378442|NCT05664828|EXPERIMENTAL|Single dose (i.v.) SN132D|SN132D is a nanoparticle solution at 20 µmol Mn/kg dosage, administrated via intravenous infusion.
62378443|NCT01051856|ACTIVE_COMPARATOR|SEAMGUARD with bioabsorbable staple|In this arm pancreatic transection will be executed using an endoscopic linear stapling device. The individual staple depth can be chosen by the operating surgeon. Bioabsorbable Mesh sleeves specifically manufactured for the chosen staple depth and cartridge length will be placed over the stapler before firing.
62378444|NCT01051856|ACTIVE_COMPARATOR|TissueLink with radiofrequency ablation|After pancreatic transection, with any method chosen by the operating surgeon, the pancreatic remnant will be treated with TissueLink alone for an ablation depth (thickness) of approximately 7 mm using electrosurgical generator settings of 100 W and a saline drip rate of 1-2 drops per second.
62378445|NCT02227901|EXPERIMENTAL|Treatment (tipifarnib, EBRT, temozolomide)|"TIPIFARNIB: Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~CONCURRENT CHEMOTHERAPY DURING RADIATION THERAPY: Within 5-9 days after starting tipifarnib, patients undergo EBRT daily and receive temozolomide PO daily for 6 weeks.~POST-RADIATION CHEMOTHERAPY: Beginning at week 10 post-radiation therapy, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for 1 year or 12 complete courses in the absence of disease progression or unacceptable toxicity."
62378446|NCT03904862|EXPERIMENTAL|Phase I - Skeletally-immature|Skeletally-immature children with refractory or recurrent medulloblastoma of the SHH group
62557067|NCT02283723|EXPERIMENTAL|Patient Group 1|This patient group will begin receiving the Health TAPESTRY intervention from time zero.
62557068|NCT02283723|ACTIVE_COMPARATOR|Patient Group 2|Using a step-wedge approach, this patient group will receive the intervention after a six month waiting period where they will be used as a comparable group. In the first six months, they will receive usual care.
62557069|NCT01354405||Lanreotide|
62755266|NCT05785637||Initiation a non-invasive ventilation at night|Neuromuscular patients with chronic respiratory failure who initiate a non-invasive ventilation at night.
62755267|NCT04677660|EXPERIMENTAL|TAK-919|TAK-919 0.5 mL, intramuscular injection in the upper arm
62755268|NCT04677660|PLACEBO_COMPARATOR|Placebo|TAK-919 Matching Placebo, intramuscular injection in the upper arm
61986716|NCT04139707|EXPERIMENTAL|Caring4Dementia Group|The experimental group will receive Careing4Dementia downloadable on their smartphone or tablet. Caring4Dementia will tell and show caregivers of a person living with dementia how to 1) manage difficult behaviors, 2) deal with refusal, 3) deal with tensions and 4) manage work-life demands. The app is self-administered and self-paced and contains surveys referring to the outcome measurements tools used in the study. The intervention will be for 30 days without any restriction or limitation in terms of timing, location or frequency of use.
62378447|NCT03904862|EXPERIMENTAL|Phase II - Skeletally-mature|Skeletally-mature subjects with refractory or recurrent medulloblastoma of the SHH group
62557070|NCT05586555|OTHER|Control group (normal hearing in regards of age)|Normal hearing participants according to pure tone hearing levels defined for age and tested frequency (audiometry ISO 7029 and Wang \& Puel, 2020 recommendations for hearing loss at the tested frequencies). Total of 32 subjects in this arm.
62755269|NCT01696344||Cohort 1|No additional ablation after AF termination(PVAI only)
62755270|NCT01696344||Cohort 2|Additional ablation of extra-PV triggers before and after isoproterenol-challenge after AF termination (PVAI + ablation of extra-PV triggers)
62755271|NCT00037817|EXPERIMENTAL|1|Dose escalation cohort
62755272|NCT00037817|EXPERIMENTAL|2|Molecular response cohort
62755273|NCT00037817|EXPERIMENTAL|3|Celecoxib combination cohort at MTD
62755274|NCT02383420|EXPERIMENTAL|Predicate & Invest-GOS|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
62378448|NCT03904862|EXPERIMENTAL|Surgical|Subjects who are eligible for the Phase I or Phase II arm of the trial and are candidates for surgery, may be enrolled in the surgical arm prior to initiation of the Phase I or Phase II treatment.
62378449|NCT00362440|EXPERIMENTAL|Leptin|Leptin replacement therapy
62378450|NCT00362440|PLACEBO_COMPARATOR|Pioglitazone or metformin|Diabetes treatment therapy
62755275|NCT02383420|EXPERIMENTAL|Predicate & Invest-CsI|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
62755276|NCT02383420|EXPERIMENTAL|Predicate & Invest.-Cadavers GOS & CsI|Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
62755277|NCT00851578|EXPERIMENTAL|WATCHMAN|non-valvular atrial fibrillation patients contraindicated to warfarin
62378451|NCT03224832|EXPERIMENTAL|group 1|group 1 will be Pancreatoduodenectomy With Mesopancreas. Artery-first Approach
62755278|NCT05061108|EXPERIMENTAL|Intervention|Randomized selection of recruited participants that will receive intervention
62755279|NCT05061108|NO_INTERVENTION|Control|Randomized selection of recruited participants that will not receive intervention
62755280|NCT04857437|EXPERIMENTAL|Part 1|Single, Escalating Doses of PF-07202954 or Placebo (Cohorts 1 and 2)
62755281|NCT04857437|EXPERIMENTAL|Part 2|Repeated, Escalating Doses of PF-07202954 or placebo from Day 1 to Day 14, inclusive (Cohorts 3, 4, 5, 6 7, and optional Cohort 8)
61986717|NCT04139707|ACTIVE_COMPARATOR|White Paper Group|The White Paper group will receive a white paper on the principles of communicating efficiently with persons living with dementia.
62755282|NCT04857437|EXPERIMENTAL|Part 3|Single dose of PF-07202954 with a high-fat/high-caloric meal and a single dose following an overnight fast of ≥10 hours
62755283|NCT04016558|EXPERIMENTAL|StreamLine|Diabetes education, behavioral management
62755284|NCT04016558|EXPERIMENTAL|TunedIn|Diabetes distress reduction, emotion regulation techniques.
62755285|NCT04016558|EXPERIMENTAL|FixIt|Unified program combining diabetes education, behavioral management, diabetes distress reduction, and emotion regulation techniques.
62755286|NCT06606236|NO_INTERVENTION|Control group|The teeth were not exposed to dental bleaching agents (healthy pulps with normal/basal NPY values). n=10
62755287|NCT06606236|EXPERIMENTAL|Pola Office system group|Application of Pola office n=10
62755288|NCT06606236|EXPERIMENTAL|Opalescent Boost system group|Application of Opalescent Boost n=10
62755289|NCT06606236|EXPERIMENTAL|Zoom system group|Application of Zoom! n=10
62755290|NCT01761318|ACTIVE_COMPARATOR|Liraglutide|"Liraglutide: Solution for subcutaneous injection 6 mg/ml; Flexpen 3 ml.~Dose: s.c. 0,6 mg (0,1 mL) once daily. After 1 week, the dose will be increased to 1,2 mg (0,2 mL) once daily. If tolerated, after 1 week, dose will be increased to 1.8 mg (0,3 mL) once daily. In case of a hypoglycaemic episode, the dosage of oral blood glucose lowering medicaments will be adjusted first. If hypoglycaemia persists, Liraglutide / Liraglutide placebo will be adjusted on the basis of clinical parameters.~Duration: 26 weeks"
62755291|NCT01761318|PLACEBO_COMPARATOR|Liraglutide-placebo|"Liraglutide placebo: Solution for injection; Flexpen 3 ml.~Dosage: same as Liraglutide~Duration: 26 weeks"
62755292|NCT04805203|OTHER|blood samples|4 blood samples per patient maximum (at diagnosis of covid19, during intensive care if applicable, at revecory of covid 19 and 6 months after recovery.
62755293|NCT00043108|EXPERIMENTAL|Treatment|Thoracic RT (50.4 Gy/1.8 Gy Fx) Paclitaxel (50mg/m2/weekly X 6) Carboplatin (AUC 2/weekly X 6)
62755294|NCT03040414|ACTIVE_COMPARATOR|PID Algorithm|Participants will receive insulin delivered by the Medtronic Minimed 670G 3.0 HCL system using a PID algorithm..
62755295|NCT03040414|EXPERIMENTAL|PID + Fuzzy Logic Algorithm|Participants will receive insulin delivered by the Medtronic advanced hybrid closed loop system (Minimed 670G 4.0 AHCL) with Guardian Sensor (3) continuous glucose monitoring sensor.
62755296|NCT02011620|ACTIVE_COMPARATOR|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
61986718|NCT04139707|NO_INTERVENTION|Control Goup|The control group will not receive any intervention.
61986719|NCT02555033|EXPERIMENTAL|M-RT|Machine-based resistance training. Exercising 'traditional' machine-based resistance training.
61986720|NCT02555033|EXPERIMENTAL|M-IRT|Machine-based instability resistance training; a similar training program with exercise-machines, but with additional unstable devices placed between participant and exercise-machine or floor respectively.
61986721|NCT02555033|EXPERIMENTAL|F-IRT|Free weight instability resistance training; conducted free-weight resistance training on unstable devices using dumbbells instead of exercise-machines.
61986722|NCT01010308|EXPERIMENTAL|Intervention Group:|"The patients in this study are infants aged 1 month to 1 year of age with head and neck hemangiomas currently causing /or with impending function loss (e.g. vision, airway obstruction, feeding, etc), or hemangiomas currently causing/or with potential for facial disfigurement~Infants aged 1 month to 1 year of age with head and neck hemangiomas that received treatment with systemic propranolol in the past 2 years as a control group"
62378452|NCT03224832|EXPERIMENTAL|group2|group2 will be Pancreatoduodenectomy With Mesopancreas Dissection. Standard Approach
62755297|NCT02011620|NO_INTERVENTION|Standard care|Standard care - no intervention with nitrates
62755298|NCT03411200|EXPERIMENTAL|Intervention group (n=50)|Participants in the intervention group will receive usual care and the multimodal and exercise-based intervention.
62755299|NCT03411200|NO_INTERVENTION|Control group (n=50)|Participants in the control group will receive usual care.
62755300|NCT06439888|EXPERIMENTAL|Part I : Stereotactic Body Radiation Therapy + All-trans retinoic acid|"Part I will allow to evaluate the safety of pan-metastases directed SBRT combined with ATRA in N=6 patients.~* SBRT to all lesions more than 1.5cm, on Monday up to Friday, over a maximum of 2 weeks,~* ATRA 150 mg/m2/day given orally for 3 days every 3 weeks for a maximum of 4 cycles (about 3 months), starting on the same day as SBRT."
62755301|NCT06439888|EXPERIMENTAL|Part II : Stereotactic Body Radiation Therapy + All-trans retinoic acid|"Part II will allow to evaluate the lympho-protective efficacy of ATRA upon radiation-induced lymphopenia. The experimental arm consists in :~* SBRT to all lesions more than 1.5cm, on Monday up to Friday, over a maximum of 2 weeks,~* ATRA 150 mg/m2/day given orally for 3 days every 3 weeks for a maximum of 4 cycles (about 3 months), starting on the same day as SBRT."
62755302|NCT06439888|PLACEBO_COMPARATOR|Part II : Stereotactic Body Radiation Therapy alone|"Part II will allow to evaluate the lympho-protective efficacy of ATRA upon radiation-induced lymphopenia. The control arm consists in :~- SBRT to all lesions more than 1.5cm, on Monday up to Friday, over a maximum of 2 weeks"
62755303|NCT03091985|EXPERIMENTAL|Group A|"Drainage of the lactating breast using:~PersonalFit - Breast shield \& Brownie - Breast shield~Breast shields are each to be used for 15 min pumping with the symphony breastpump"
62755304|NCT03091985|EXPERIMENTAL|Group B|"Drainage of the lactating breast using:~Brownie - Breast shield \& PersonalFit - Breast shield~Breast shields are each to be used for 15 min pumping with the symphony breastpump"
62755305|NCT03644914|EXPERIMENTAL|Intervention Group (Reading Program)|First graders who will receive the 10-week reading program (a total of 20 hours), twice weekly in 1-hour sessions, and will continue to receive typical classroom reading instruction.
62755306|NCT03644914|NO_INTERVENTION|Control Group|First graders who will not take part in the reading program but will continue to receive typical classroom reading instruction.
62755307|NCT01690546|EXPERIMENTAL|BUP/VLNXT to VIVITROL|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
62755308|NCT02933073|EXPERIMENTAL|OncoImmunome/Vaccine Phase|Women with Stage III/IV Ovarian Cancer who have received the standard of care treatment (surgical debulking and chemotherapy) for their cancer and are now in clinical remission will be given the experimental drug (vaccine) called OncoImmunome, which has been produced specifically for each participant.
62755309|NCT05139381||Treated with Mepolizumab|
62755310|NCT02417116|PLACEBO_COMPARATOR|Control|Minims Saline (Preservative Free) lubricant eye drops - daily for 90 days
62755311|NCT02417116|ACTIVE_COMPARATOR|Hypromellose - standard treatment|Tear Supplement: Hypromellose 0.3% eye drops - daily for 90 days
62755312|NCT02417116|ACTIVE_COMPARATOR|Combination treatment|Tear Supplement 2: Hylo-Forte 0.2% Sodium Hyaluronate eye drops, Omega 3 nutrition supplement: Omega-3 tablets, Eye bag: TranquilEyes Moist Heat Lid Compresses - Daily for 90 days;
62755313|NCT01418131|ACTIVE_COMPARATOR|Rectal tacrolimus|Active medications - Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml 3mls will be applied rectally twice a day
62755314|NCT01418131|PLACEBO_COMPARATOR|Rectal Placebo|Placebo 3ml applied rectally twice a day. Identical to Interventional agent expect for the lack of tacrolimus
61986723|NCT01010308|NO_INTERVENTION|Historical control group|Ten infants (1-12 months of age) treated with propranolol will be identified from a Dermatology Database. Patients will be considered as controls if they were treated with propranolol before 1 year of age and had digital photography documentation of their hemangioma.
62378453|NCT01227252|EXPERIMENTAL|LY2886721|
62378454|NCT01227252|PLACEBO_COMPARATOR|Placebo|
62755315|NCT04889768|EXPERIMENTAL|Experimental: HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery|"1. surgical exploration, if PCI\<20, then we perform this study.~2. HIPEC: Taxol (Paclitaxel Injection) 75 mg/m2, d1, d3 within 72 hours after surgical exploration; oral chemotherapy:S-1: 80mg/m2, twice daily for d1-d14, and then suspend for one week; Intravenous drip anti-PD-1 antibody Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~3. Chemotherapy and PD-1 treatment (4 cycles) : Taxol 150mg/m2,d1; S-1: 80-120mg/m2, twice daily for two weeks, and then suspend for one week; Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~4. Surgery: Secondary surgical exploration: if PCI less than 20, then assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases ). For inoperable patients, continue to use this program for treatment.~5. After the surgery, HIPEC for two cycles, anti-PD-1 antibody Camrelizumab (SHR-1210) for 4 cycles, and PS chemotherapy for 4 cycles."
62755316|NCT02992951|EXPERIMENTAL|DACC-Coated Post-Operative Dressing|DACC-Coated Post-Operative Dressing
62755317|NCT02992951|NO_INTERVENTION|Non-DACC coated Occlusive Post-operative Film Dressing|Non-DACC coated Occlusive Post-operative Film Dressing
62755318|NCT04975737|EXPERIMENTAL|Vaccine Group|3590 volunteers who will receive 1 dose (0.5 ml) of the vaccine GamTBvac administered twice with an 8-week interval between administrations.
62755319|NCT04975737|PLACEBO_COMPARATOR|Placebo group|3590 volunteers who will receive 1 dose (0.5 ml) of the placebo administered subcutaneously twice with an 8-week interval between administrations.
62755320|NCT05496686|EXPERIMENTAL|225Ac-MTI-201 4.7 microCi|Cohort 1: Participants were administered a single dose of 4.7 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
62755321|NCT05496686|EXPERIMENTAL|225Ac-MTI-201 9.5 microCi|Cohort 2: Participants were administered a single dose of 9.5 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
62755322|NCT05496686|EXPERIMENTAL|225Ac-MTI-201 19 microCi|Cohort 3: Participants were administered a single dose of 19 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
62755323|NCT05496686|EXPERIMENTAL|225Ac-MTI-201 38 microCi|Cohort 4: Participants were administered a single dose of 38 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
62755324|NCT05496686|EXPERIMENTAL|225Ac-MTI-201 76 microCi|Cohort 5: Participants were administered a single dose of 76 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
62755325|NCT05496686|EXPERIMENTAL|225Ac-MTI-201 152 microCi|Cohort 6: Participants were administered a single dose of 152 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
62755326|NCT05496686|EXPERIMENTAL|225Ac-MTI-201 254 microCi|Cohort 7: Participants were administered a single dose of 254 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
62755327|NCT05496686|EXPERIMENTAL|225Ac-MTI-201 424 microCi|Cohort 8: Participants were administered a single dose of 424 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
62755328|NCT05496686|EXPERIMENTAL|225Ac-MTI-201 564 microCi|Cohort 9: Participants were administered a single dose of 564 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
62755329|NCT05496686|EXPERIMENTAL|225Ac-MTI-201 750 microCi|Cohort 10: Participants were administered a single dose of 750 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
62755330|NCT05496686|EXPERIMENTAL|225Ac-MTI-201 998 microCi|Cohort 11: Participants were administered a single dose of 998 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
62755331|NCT05496686|EXPERIMENTAL|225Ac-MTI-201 1327 microCi|Cohort 12: Participants were administered a single dose of 1327 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
62755332|NCT04503668|ACTIVE_COMPARATOR|Nk1-RA|Nk1-RA will be given on day 1 of each 3-week chemotherapy cycle, for up to 6 cycles.
62755333|NCT04503668|EXPERIMENTAL|Olanzapine|Olanzapine will be given on days 1-4 of each 3-week chemotherapy cycle, for up to 6 cycles.
62755334|NCT03820453|EXPERIMENTAL|Active group|One tablet per day in the morning through oral administration of a dietary supplement containing Tribulus terrestris as the main active ingredient. During three months with the possibility to extend for another three months.
62755335|NCT03820453|PLACEBO_COMPARATOR|Control group|One tablet per day in the morning through oral administration of Placebo. During three months.
62755336|NCT00873379|ACTIVE_COMPARATOR|melatonin|.5 mg (one half of a 1 mg tablet of GNC rapid dissolving Melatonin, natural product number (NPN) 80001380)
62755337|NCT00873379|PLACEBO_COMPARATOR|placebo|half a white placebo tablet
61986724|NCT01010308|NO_INTERVENTION|Angiogenesis marker control group|The angiogenesis marker control group will consist of 6 -10 patients seen in the Dermatology clinic for conditions other than IH and not receiving corticosteroids or beta blockers.
61986725|NCT01510379|ACTIVE_COMPARATOR|Reletex|Reletex plus scheduled IV ondansetron 4 mg q 6 hours for a total of 4 doses. Breakthrough nausea will be treated using IV promethazine 25 mg q 6 hours prn during the hospital stay and in elixir at the same dose and frequency after discharge.
62755338|NCT03626636|ACTIVE_COMPARATOR|Active Group|Treatment Group 1: 25 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be injected intravitreally with 1.0mg of Luminate®
62755339|NCT03626636|PLACEBO_COMPARATOR|Placebo Group|Treatment Group 2: 15 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be treated with a sham injection
62755340|NCT00011362|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone
62378455|NCT04237610||Bipolar disorder type I|
62378456|NCT04237610||Bipolar disorder type II|
62755341|NCT00011362|PLACEBO_COMPARATOR|Placebo|Saline
62755342|NCT04757688|EXPERIMENTAL|Cardiac radioablation (CRA)|CRA delivered via linear accelerator (stereotactic body radiotherapy) to the suspected arrhythmogenic substrate to a dose of 25 Gy in 1 fraction.
62755343|NCT00693017|ACTIVE_COMPARATOR|Zonisamide|
62755344|NCT00693017|PLACEBO_COMPARATOR|Placebo|
62755345|NCT01817673|EXPERIMENTAL|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
62755346|NCT01817673|PLACEBO_COMPARATOR|placebo (dextrose)|20 g/d for 5 d followed by 5 g/d throughout the trial
62755347|NCT03634566|ACTIVE_COMPARATOR|NAC group|Group NC received NAC 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
62378457|NCT04237610||healthy controls|
62755348|NCT03634566|PLACEBO_COMPARATOR|Control group|Group C (Control group) will receive ringer acetate continuous infusion at same rate for 2 days.
62755349|NCT01023087||Treatment|Patients with sepsis treated with polymyxin E (colistin)
62378458|NCT01997892||Chronic Kidney Disease (CKD)|Participants with CKD on dialysis and treated with PEG epoetin beta for a minimum of 14 weeks immediately prior to being switched to darbepoetin alfa.
62378459|NCT03388554|ACTIVE_COMPARATOR|Active tDCS|Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). The anode was placed with the middle of the electrode over a point midway between F3 and FP1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The cathode was located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients in the active tDCS group were maintained on their antipsychotic medications throughout the study period.
62378460|NCT03388554|SHAM_COMPARATOR|Sham tDCS|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham tDCS group were maintained on their antipsychotic medications throughout the study period.
62378461|NCT03037333|OTHER|fluoroscopy|
62557071|NCT05586555|EXPERIMENTAL|CI group (cochlear implanted subjects)|"Cochlear implanted subjects with bilateral, severe-to-profound sensorineural hearing loss, with at least one Oticon Medical cochlear implant system .~Up to 40 subjects in this arm:~* 20 subjects will perform experiment 1 \& 2~* 20 subjects will perform experiment 3~  * The subjects of the experiment 3 ore either those taken part to experiment 1 and 2, or subjects who only take port to the experiment 3"
62557072|NCT01864707|EXPERIMENTAL|usual care + acupuncture|standardized acupuncture treatment in addition to usual care
62378462|NCT03037333|OTHER|ECG/ECHO|
62378463|NCT02728310|ACTIVE_COMPARATOR|Levobupivacaine infusion|1500 mg of Levobupivacaine by an infusion rate of 10 ml/h for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected.
62378464|NCT02728310|PLACEBO_COMPARATOR|Saline infusion|300 ml of Saline (for Levobupivacaine as placebo) by an infusion rate of 10 ml/h for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected.
62378465|NCT04177394||MitraClip G4 System|Percutaneous mitral valve repair using the MitraClip G4 system
62378466|NCT03760302||Patient given analgesics or hypnotics|All patients treated with any kind of analgesics or hypnotics are analyzed and compared.
62378467|NCT05115006||Cohort 1|Participants diagnosed with stage II and stage III melanoma who have undergone surgery
62378468|NCT02765854|EXPERIMENTAL|Arm B (ixazomib and dexamethasone)|MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A.
62378469|NCT02765854|EXPERIMENTAL|Arm C (ixazomib, dexamethasone, lenalidomide)|MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21.
62378470|NCT02765854|ACTIVE_COMPARATOR|Arm A (ixazomib and dexamethasone)|UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone.
62378471|NCT05983679||Adults|
62378472|NCT04857606|EXPERIMENTAL|AMG 609|Up to 7 cohorts ranging by various dose levels.
62378473|NCT04857606|EXPERIMENTAL|Placebo|Participants will receive the matching placebo.
62557073|NCT01864707|EXPERIMENTAL|usual care+mbsr|mindfulness based stress reduction in addition to usual care not recruiting anymore
62557074|NCT01864707|ACTIVE_COMPARATOR|usual care|usual care without additional treatment
62557075|NCT05292027|EXPERIMENTAL|low-dose radiotherapy group|Neoadjuvant chemotherapy combined with low-dose radiotherapy sequential concurrent chemoradiotherapy
62557076|NCT05292027|NO_INTERVENTION|control group|Neoadjuvant chemotherapy sequential concurrent chemoradiotherapy
62557077|NCT00638508|ACTIVE_COMPARATOR|Ketorolac|Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
62557078|NCT00638508|EXPERIMENTAL|Ketorolac with Ropivacaine|Patients will receive Ketorolac 5 mg and Ropivacaine 0.5% (Group 2) via an infusion catheter at the incision site
62755350|NCT01023087||Control|Patients with sepsis treated with other, non-nephrotoxic antibiotic medication
62755351|NCT04350671|EXPERIMENTAL|Interferon-β 1a|Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine
62755352|NCT04350671|ACTIVE_COMPARATOR|Control|Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine
62755353|NCT03048266||MEN1 Patients Who Have Developed Aggressive PNETs-Cases|
62755354|NCT03048266||MEN1 Patients Who Have Developed Non-Aggressive PNETs-Controls|
62755355|NCT05266183|EXPERIMENTAL|Simultaneous Variety, Small Portion|3 different foods served in a small portion.
62755356|NCT05266183|EXPERIMENTAL|Simultaneous Variety, Large Portion|3 different foods served in a large portion.
62755357|NCT05266183|EXPERIMENTAL|Single-Food, Small Portion|1 food served in a small portion.
62755358|NCT05266183|EXPERIMENTAL|Single-Food, Large Portion|1 food served in a large portion.
62755359|NCT04906720|NO_INTERVENTION|Standard of care|Usual standard of care post atrial fibrillation ablation.
62755360|NCT04906720|EXPERIMENTAL|Colchicine|0.6mg colchicine oral twice daily for 7 days.
62755361|NCT00765882|EXPERIMENTAL|1|Linaclotide 290 micrograms
62557079|NCT05674825|EXPERIMENTAL|Group 1: Targeted agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 1 subjects will comprise treatment naïve subjects with localized disease and (i) are eligible for neoadjuvant treatment, (ii) have unresectable disease, or (iii) are medically unfit for surgical resection.
62557080|NCT05674825|EXPERIMENTAL|Group 1: Standard of care agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 1 subjects will comprise treatment naïve subjects with localized disease and (i) are eligible for neoadjuvant treatment, (ii) have unresectable disease, or (iii) are medically unfit for surgical resection.
62557081|NCT05674825|EXPERIMENTAL|Group 2: Targeted agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 2 will comprise treatment naïve subjects with metastatic disease.
62755362|NCT00765882|EXPERIMENTAL|2|Linaclotide 145 micrograms
62755363|NCT00765882|PLACEBO_COMPARATOR|3|Matching placebo
62755364|NCT02759107|EXPERIMENTAL|Tirzepatide (Part A)|Participants received escalating single doses of either 0.25 milligram (mg) or 0.5mg or 1mg, or 2.5mg or 5mg or 8mg Tirzepatide by subcutaneous injection.
61986726|NCT01510379|OTHER|Control|Scheduled IV ondansetron 4 mg q 6 hours for a total of 4 doses. Breakthrough nausea will be treated using IV promethazine 25 mg q 6 hours prn during the hospital stay and in elixir at the same dose and frequency after discharge.
61986727|NCT02598427|EXPERIMENTAL|Intrathecal Pertuzumab and Trastuzumab|"Four cohorts will enroll in a dose escalation of pertuzumab and a consistent dose of trastuzumab. The cohorts will be assigned as follows:~Cohort: Intrathecal Dose:~1. 10mg pertuzumab, 80mg trastuzumab~2. 20mg pertuzumab, 80mg trastuzumab~3. 40mg pertuzumab, 80mg trastuzumab~4. 80mg pertuzumab, 80mg trastuzumab"
62378474|NCT03923829|EXPERIMENTAL|Zinc administration with scaling and root planing|systemic administration of Zinc cap of 50 mg elemental zinc as zinc sulphate, once a day for 12 weeks in addition to scaling and root planing
62378475|NCT03923829|ACTIVE_COMPARATOR|scaling and root planing|scaling and root planing
62755365|NCT02759107|PLACEBO_COMPARATOR|Placebo (Part A)|Participants received single dose of placebo by subcutaneous injection.
62755366|NCT02759107|EXPERIMENTAL|Tirzepatide (Part B)|Participants received fixed doses of either 0.5mg or 1.5mg or 4.5mg Tirzepatide once weekly for four weeks or titrated doses of 5mg, 5mg, 8mg and 10mg Tirzepatide once weekly for four weeks by subcutaneous injection.
62755367|NCT02759107|PLACEBO_COMPARATOR|Placebo (Part B)|Participants received placebo once weekly for four weeks by subcutaneous injection.
62755368|NCT02759107|ACTIVE_COMPARATOR|Dulaglutide (Part B)|Participants received 1.5mg Dulaglutide once weekly for four weeks by subcutaneous injection.
62755369|NCT02759107|EXPERIMENTAL|Tirzepatide (Part C)|Participants received fixed doses of either 0.5mg or 5mg Tirzepatide once weekly for four weeks or titrated doses of 5mg,5mg,10mg,10mg or 5mg,5mg,10mg,15mg Tirzepatide once weekly for four weeks by subcutaneous injection
62378476|NCT01610414|EXPERIMENTAL|GSK1437173A Group|Subjects received 2 doses of the candidate HZ vaccine GSK 1437173A, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
62378477|NCT01610414|PLACEBO_COMPARATOR|Placebo Group|Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
62378478|NCT00908050|PLACEBO_COMPARATOR|Placebo|Placebo arm
62378479|NCT00908050|ACTIVE_COMPARATOR|botulinum toxin type A|Active arm
62378480|NCT02655263|NO_INTERVENTION|Control|12 hours of fasting
62378481|NCT02655263|EXPERIMENTAL|GH infusion|12 hours of fasting
62378482|NCT02655263|EXPERIMENTAL|GH and ketone bodies infusion|12 hours of fasting
62557082|NCT05674825|EXPERIMENTAL|Group 2: Standard of care agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 2 will comprise treatment naïve subjects with metastatic disease.
62557083|NCT05674825|EXPERIMENTAL|Group 3: Targeted agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 3 will comprise subjects with metastatic or unresectable disease who have received at least one prior systemic therapy, whether matched or unmatched.
62557084|NCT05674825|EXPERIMENTAL|Group 3: Standard of care agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 3 will comprise subjects with metastatic or unresectable disease who have received at least one prior systemic therapy, whether matched or unmatched.
62755370|NCT02759107|PLACEBO_COMPARATOR|Placebo (Part C)|Participants received placebo once weekly for four weeks by subcutaneous injection.
62755371|NCT00297895|ACTIVE_COMPARATOR|Ultrasound observation + delayed CLND if recurrence detected|
62755372|NCT00297895|ACTIVE_COMPARATOR|CLND|
62755373|NCT03553498|EXPERIMENTAL|IV hydromorphone and IV acetaminophen|"1000 mg IV acetaminophen administered over 5-10 minutes~1 mg hydromorphone administered over 5-10 minutes"
62755374|NCT03553498|PLACEBO_COMPARATOR|IV hydromorphone and placebo|"100 ml IV normal saline administered over 5-10 minutes~1 mg hydromorphone administered over 5-10 minutes"
62755375|NCT02357693|EXPERIMENTAL|aprepitant|aprepitant 80 mg one hour before surgery
62755376|NCT02357693|PLACEBO_COMPARATOR|placebo|oral placebo one hour before surgery
62755377|NCT06178536|EXPERIMENTAL|Rex implant machined transcortical portion|Implants in these group will have a machined portion at the neck of the implant
62755378|NCT06178536|ACTIVE_COMPARATOR|Rex implant roughened transcortical portion|Rex implants with a rough surface until the neck of the implant
62755379|NCT00068224||Ciliopathy|Children and adults who carry a clinical diagnosis of a known ciliopathy and those patients who have typical features suggestive of a cliopathy but not fulfilling the diagnostic criteria.
62755380|NCT02840643|EXPERIMENTAL|Constraint Therapy and Bimanual Therapy|Children in this arm will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Hand Therapy (constraint therapy), followed by 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Bimanual Hand Therapy (bimanual therapy). During constraint therapy, children will wear a mitt over their less-impaired hand and actively use their more-impaired hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements. During bimanual therapy, children will actively use both hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements.
62755381|NCT02840643|EXPERIMENTAL|Bimanual Therapy and Constraint Therapy|Children in this arm will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Bimanual Hand Therapy (bimanual therapy), followed by 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Hand Therapy (constraint therapy). During bimanual therapy, children will actively use both hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements. During constraint therapy, children will wear a mitt over their less-impaired hand and actively use their more-impaired hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements.
62755382|NCT01780714|ACTIVE_COMPARATOR|Conventional cigarettes (CC)|Smokers are continuing to smoke exclusively their usual own brand of CC, for 5 days, ad libitum, under highly controlled conditions
62755383|NCT01780714|EXPERIMENTAL|Tobacco Heating System 2.1 (THS 2.1)|Smokers are switching to the exclusive and ad-libitum use of THS 2.1 for 5 days, under highly controlled conditions
62378483|NCT02696590|EXPERIMENTAL|MS patients injectable Vitamin D3|MS patients who received injectable form of Vitamin D3, received 600.000 IU Intramuscular vitamin D3 injection, in two weeks; 300.000 IU at the study entry and 300.000 IU in second week
62378484|NCT02696590|EXPERIMENTAL|MS patients orally Vitamin D3|received the same total dose of 600 000 IU D3 in two weeks, in the form of twelve pearls, each containing 50 000 IU D3 as follows: the first pearl was delivered at study entry, followed by one pearl each day for another 11 Days.
62378485|NCT02696590|ACTIVE_COMPARATOR|Healthy groups Injectable Vitamin D3|who received injectable form of Vitamin D3, received 600.000 IU Intramuscular vitamin D3 injection, in two weeks; 300.000 IU at the study entry and 300.000 IU in second week
62378486|NCT02696590|ACTIVE_COMPARATOR|Healthy groups Vitamin D3 orally|received the same total dose of 600 000 IU D3 in two weeks, in the form of twelve pearls, each containing 50 000 IU D3 as follows: the first pearl was delivered at study entry, followed by one pearl each day for another 11 Days.
61986728|NCT02558257||Palliative Care Survey|Initial consultation visit followed by phone survey within 1 week +/- 4 days of initial consultation.
61986729|NCT01970839|OTHER|Tourniquet, pain, nerve injury, sensory nerve function|
62755384|NCT05209451|ACTIVE_COMPARATOR|Control Condition - No additional study intervention|Subjects will receive a 12-week, digital, evidence-based behavioral health program for smoking cessation delivered through the patient portal and a written guide on existing digital access resources along with any other necessary material.
62755385|NCT05209451|EXPERIMENTAL|Loaner Digital Device|Subjects will receive a 12-week, digital, evidence-based behavioral health program for smoking cessation delivered through the patient portal and a written guide on existing digital access resources along with any other necessary material. Participants in this group will also receive a loaned Bluetooth enabled iPad with data plan coverage for the study duration.
62755386|NCT05209451|EXPERIMENTAL|Loaner Digital Device + Coaching Support|Subjects will receive a 12-week, digital, evidence-based behavioral health program for smoking cessation delivered through the patient portal and a written guide on existing digital access resources along with any other necessary material. Participants in this group will also receive a loaned Bluetooth enabled iPad with data plan coverage for the study duration plus up to six coaching call, 15-20 minutes in duration.
62755387|NCT01223885|EXPERIMENTAL|Camel's milk, Cow's milk allergy|
62755388|NCT01309048|EXPERIMENTAL|Patients with painful bone metastasis|Patients with bone metastasis causing pain
62755389|NCT02180880|EXPERIMENTAL|Pregabalin and Oxcarbazpepine|Pregabalin and Oxcarbazepine
62755390|NCT00101816|EXPERIMENTAL|1|
62755391|NCT02995083|ACTIVE_COMPARATOR|Knee injection with corticosteroids|Using clinically accepted methods, subjects will undergo a palpation guided injection of corticosteroids into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
62755392|NCT02995083|PLACEBO_COMPARATOR|Knee injection with saline|Using clinically accepted methods, subjects will undergo a palpation guided injection of saline into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
62755393|NCT02995083|SHAM_COMPARATOR|Knee injection with air|Using clinically accepted methods, subjects will undergo a palpation guided injection of air into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
62755394|NCT05785715|EXPERIMENTAL|NX-13 250mg|Subjects will take study drug by ingesting three tablets per day, recommended at the same time daily for consistency. Subjects in a NX-13 group will receive either 250 mg or 750 mg of NX-13 in 3 tablets and subjects in the placebo group will receive matching placebo.
62755395|NCT05785715|EXPERIMENTAL|NX-13 750mg|Subjects will take study drug by ingesting three tablets per day, recommended at the same time daily for consistency. Subjects in a NX-13 group will receive either 250 mg or 750 mg of NX-13 in 3 tablets and subjects in the placebo group will receive matching placebo.
62755396|NCT05785715|PLACEBO_COMPARATOR|NX-13 Placebo|Subjects will take study drug by ingesting three tablets per day, recommended at the same time daily for consistency. Subjects in a NX-13 group will receive either 250 mg or 750 mg of NX-13 in 3 tablets and subjects in the placebo group will receive matching placebo.
62755397|NCT04361604||250 Patients co infected HIV and SRAS-CoV2|Cohort of Patient co infected HIV AND SRAS-CoV2
62755398|NCT04361604||20 patients infected HIV without COVID-19|Group of 20 comparative patients PLWHIV without COVID-19. This group will realise only the interview of the research.
62755399|NCT00881764||Exposed Cohort|Children who had inguinal hernia surgery and general anesthesia before 36 months of age (n=500). These children should be ages 8 yr, 0 mo to 15 yr, 0 mo at the time of the study period.
62755400|NCT00881764||Unexposed Cohort|Children who are siblings of the exposed children (inguinal hernia surgery and general anesthesia) and differ in age from the exposed children by less than 36 months and have no history of surgery or exposure to volatile and intravenous anesthetics or sedatives including barbiturates, benzodiazepines and chloral hydrate less than 36 months of age. These children should also be ages 8 yr, 0 mo to 15 yr, 0 mo at the time of the study period.
62755401|NCT05599451|ACTIVE_COMPARATOR|THS Blade device|Subjects randomized to this arm participated in 5 days of ad libitum use, in confinement, of the THS Blade device (using regular THS blade tobacco sticks) between 06:30 AM and 11:00 PM.
62755402|NCT05599451|ACTIVE_COMPARATOR|THS Induction Mono device|Subjects randomized to this arm participated in 5 days of ad libitum use, in confinement, of the THS Induction Mono device (using regular THS induction tobacco sticks) between 06:30 AM and 11:00 PM.
62755403|NCT05599451|ACTIVE_COMPARATOR|THS Induction Mid device|Subjects randomized to this arm participated in 5 days of ad libitum use, in confinement, of the THS Induction Mid device (using regular THS induction tobacco sticks) between 06:30 AM and 11:00 PM.
62755404|NCT05599451|ACTIVE_COMPARATOR|Cigarette|"Subjects randomized to this arm participated in 5 days of ad libitum use, in confinement, of the subject's preferred brand of regular (non-mentholated) cigarette between 06:30 AM and 11:00 PM.~(Every subject brought a sufficient number of unopened, single-brand packs of CIG for the entire confinement period.)"
62755405|NCT03217370|OTHER|all haematologists|"There will be only one arm: the haematologists will all be included in the interventional phase.~Interventions are: 1) rewriting guidelines to order blood components; 2) to show the last hemoglobin value on the orders for erytrocytes and the last platelet count on the orders dor thrombocytes and 3)implementation of a clinical decision support system in the electronic rodering of blood components to stimulate restrictive blood transfusion."
62755406|NCT04134117|EXPERIMENTAL|Tisagenlecleucel|"Study procedures include screening for eligibility and study treatment including, leukapheresis, evaluations, and follow up visits.~- Tisagenlecleucel will be administered intravenously as a one-time rapid infusion predetermined dose following lymphodepleting chemotherapy."
62755407|NCT01370837|EXPERIMENTAL|Healthy controls|
62378487|NCT04992000|EXPERIMENTAL|4-free app + PHN intervention|"The intervention group was received initial education, 4-free apps, and followed by PHN interventions.~Education, app, and PHN intervention"
62557085|NCT04720053|EXPERIMENTAL|Wearable brain sensing wellness device headband system|Subject diagnosed with fibromyalgia at Mayo Clinic GIM Fibromyalgia Clinic will receive a wearable brain sensing wellness device headband system, and will be given a demonstration of the mindfulness sessions, with detailed instructions on how to begin each session.
62755408|NCT01370837|EXPERIMENTAL|Diabetes|Patients with diabetes mellitus without polyneuropathy.
62755409|NCT01370837|EXPERIMENTAL|Polyneuropathy|Patients with diabetes and polyneuropathy.
62755410|NCT03970096|EXPERIMENTAL|Arm A1 (TBI, TnD)|Patients undergo TBI BID on days -10 to -7, and receive thiotepa IV over 3 hours on days -6 and -5, fludarabine IV over 30 to 60 minutes on days -6 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
62755411|NCT03970096|EXPERIMENTAL|Arm A2 (busulfan, TnD)|Patients receive fludarabine IV over 30 to 60 minutes on days -6 to -2, busulfan IV over 180 minutes on days -5 to -2, and undergo TBI BID on day -1. Patients also receive tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
62378488|NCT04992000|EXPERIMENTAL|4-free app alone|The apps alone group received the initial education and the 4-free Apps.
62755412|NCT03970096|EXPERIMENTAL|Arm C1 (TBI, PTCy, tacrolimus)|Patients undergo TBI BID on days -4 to -2 or -3 to -1, and receive PBSC IV on day 0. Patients also receive cyclophosphamide IV over 1 to 2 hours on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
62557086|NCT06272565||CON(Non diabetes control group)|Non diabetes patients undergoing phacoemulsification surgery
61986730|NCT01940809|EXPERIMENTAL|Arm A1 (ipilimumab, dabrafenib, trametinib)|Patients receive dabrafenib PO BID and trametinib PO QD for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
62182485|NCT00604188|ACTIVE_COMPARATOR|Subutex-to-Suboxone Induction|Participants received 8 mg Subutex and placebo Suboxone on Day 1, 16 mg Subutex and placebo Suboxone on Day 2, and all participants received open label Suboxone from Day 3 to Day 28. Suboxone dosage may be titrated from Day 4 to Day 28 up to 24 mg per day.
62378489|NCT04992000|NO_INTERVENTION|education|Standard care group received just the initial education.
62378490|NCT01078779|EXPERIMENTAL|Chloroquine|
62378491|NCT01078779|PLACEBO_COMPARATOR|Placebo|
62378492|NCT01276392||Heparin|10 Patients undergoing continuous renal replacement therapy using heparin for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
62378493|NCT01276392||CiCa|10 Patients undergoing continuous renal replacement therapy using citrate for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
62557087|NCT06272565||NDR(Non diabetes retinopathy diabetes patients)|Non DR diabetes patients undergoing phacoemulsification surgery
62557088|NCT06272565||NPDR (non proliferative diabetes retinopathy)|DR patients with no sign of any neovascularization suggested by fluorescein sodium angiography and receiving intravitreal injection surgery
62755413|NCT03970096|EXPERIMENTAL|Arm C2 (busulfan, PTCy, tacrolimus)|Patients receive fludarabine IV over 30 to 60 minutes on days -5 to -2, busulfan IV over 180 minutes on days -5 to -2, PBSC IV on day 0, cyclophosphamide IV over 1 to 2 hours on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
62755414|NCT03970096|EXPERIMENTAL|Arm D1 (TBI, tacrolimus, methotrexate) [DISCONTINUED NOVEMBER 2021]|Patients undergo TBI BID on days -6 to -4, and receive cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
62378494|NCT06239649||TKA with radiofrequency ablation genicular nerve block|TKA with radiofrequency ablation genicular nerve block
62378495|NCT06239649||TKA without nerve block|TKA without radiofrequency ablation genicular nerve block
62378496|NCT04752228|EXPERIMENTAL|ACE Screen|"At the initial visit, the Philadelphia ACE Survey, a validated ACE questionnaire, will be administered by a research coordinator. A Lifestyle Assessment package will also be provided for self-completion, featuring General Demographics, Cardiovascular and Medication History, Health Behaviours, the Short Form (36) Health Survey, the Patient Health Questionnaire-9, the General Anxiety Disorder-7 questionnaire, the Seattle Angina Questionnaire-7, and the modified Perceived Need for Card Questionnaire. Patients who test positive for ACE will receive a 3-page printed ACE Resource Pack.~At 3 months, the Lifestyle Assessment will be administered again.~At 6 months, the Philadelphia ACE survey, Lifestyle Assessment, as well as a scale assessing their comfort level in being screened for ACE, disclosing their ACE status to their clinicians, and their confidence level in their clinicians' ability to help them manage their ACEs will be administered."
62755415|NCT03970096|EXPERIMENTAL|Arm D2 (busulfan, tacrolimus, methotrexate) [DISCONTINUED NOVEMBER 2021]|Patients receive busulfan IV over 180 minutes on days -8 to -5, cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
62755416|NCT06608836|EXPERIMENTAL|Group 1|An ice massage will be applied to the quadrices muscle for a duration of 3 minutes.
62557089|NCT06272565||PDR (proliferative diabetes retinopathy)|DR patients with neovascularization suggested by fluorescein sodium angiography and receiving intravitreal injection surgery
62755417|NCT06608836|EXPERIMENTAL|Group 2|A cold spray application will be performed to the quadrices muscle.
62755418|NCT01429428|PLACEBO_COMPARATOR|Stockings side one|This side of the compression stockings is just the fabric (placebo).
62755419|NCT01429428|ACTIVE_COMPARATOR|Stocking side two|This side of compression stocking emits far-IR radiation.
62755420|NCT05785533|EXPERIMENTAL|Smartphone App|The mobile app will allow recording of study outcomes (pain using the vNRS and functional outcomes using the ASKp) and house an interactive educational component to provide daily reminders on pharmacological (ibuprofen and acetaminophen) and non-pharmacological (ice, elevation, and range of motion exercises) for pain management and when to return to activity. The app will collect pain scores using the verbal Numeric Rating Scale (vNRS) and functional outcomes using the Activities Scale for Kids (ASKp) scores on days 3, 5, 7, 10, 12, and 14. The ASKp will be completed by the child with assistance from the caregiver.
62557090|NCT02505737|EXPERIMENTAL|TH-CBT|The treatment works by teaching people with PD (PWP) the coping skills needed to manage their emotional reactions to the numerous challenges posed by the disease. Specifically, the treatment targets maladaptive thought patterns (e.g., I have no control; I am helpless) and behaviors (e.g., social isolation, lack of exercise, poor sleep habits, excessive worry), and critically, provides caregivers with the tools needed to encourage the PWPs' practice of their newly acquired coping skills. Treatment is administered over the phone and no travel is required.
62557091|NCT02505737|OTHER|Enhanced Usual Care|All participants will continue to receive their routine medical treatment under the supervision of their personal doctors (e.g., neurologists, psychiatrists, primary care physicians, therapists) while participating in the study. This routine treatment (e.g., usual care) will be further enhanced with the provision of written educational materials for effective coping with PD, the close clinical monitoring of depressive symptoms by study staff, and the provision of counseling resources in the local community.
62755421|NCT05785533|ACTIVE_COMPARATOR|Standard of Care|The standard of care group will be asked to read the paper-based discharge instructions in the ED, outlining pharmacological and non-pharmacological pain management and return to activity identical to the information contained in the mobile app. They will download onto their smartphone device a Data Collection App that will only allow them to record the following study outcome measures: daily use of ice, analgesia, range of motion exercises, elevation, and pain using the vNRS and ASKp scores on days 3, 5, 7, 10, 12, and 14. The ASKp will be completed by the child with assistance from the caregiver.
62755422|NCT04373499|EXPERIMENTAL|Virtual Teach-to-Goal (V-TTG)|"The RA will show the patient how to use the tablet to access the education module and be available for questions about the technology / tablet but not about the content. Within the module, the child will:~* answer questions about how to use the inhaler as part of a pre-video assessment.~* watch a video about how to correctly use a Metered Dose Inhaler (MDI) and spacer.~* answer questions on the tablet to assess how well they understand how to use the inhaler.~If a child answers any questions incorrectly, they will watch the video again and have another chance to answer the incorrect questions. The child will receive instruction by video one or multiple times (up to 3 times), depending on how much they understand after each round of instruction, as demonstrated by their responses to questions."
62755423|NCT04373499|ACTIVE_COMPARATOR|Brief Intervention (BI)|The RA will give the patient a handout about inhaler technique and read the steps to the child.
62755424|NCT02152059|EXPERIMENTAL|BIBF1120|BIBF1120 200 mg twice daily continuously
62755425|NCT04774900||Standardised|The procedures will be observed with standardized equipment placement.
62755426|NCT04774900||Modified|The procedures will be observed with modified equipment placement - placement according to older methodology or custom.
62755427|NCT03892083|ACTIVE_COMPARATOR|Anodal tDCS (M1)|tDCS applied over primary motor cortex. Dose: 1mA, 20 minutes
62755428|NCT03892083|EXPERIMENTAL|Anodal Cerebellar tDCS|tDCS applied over the cerebellum. Dose: 1mA, 20 minutes
61986731|NCT01940809|EXPERIMENTAL|Arm A2 (dabrafenib, trametinib, nivolumab, ipilimumab)|Patients receive dabrafenib PO BID and trametinib PO QD for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
62755429|NCT03892083|EXPERIMENTAL|Cathodal Cerebellar tDCS|tDCS applied over the cerebellum. Dose: 1mA, 20 minutes
62755430|NCT03892083|SHAM_COMPARATOR|Sham tDCS|tDCS applied over the cerebellum Dose: 1mA, 20 minutes (30s ON)
62755431|NCT01381003|EXPERIMENTAL|pCCLchimGp91s lentiviral vector transduced CD34+ cells|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
62755432|NCT05297279|ACTIVE_COMPARATOR|Active/Intervention Treatment Arm|Participants will receive weekly food voucher (with a specified amount) for home delivery of omega-3 rich food (with a minimum of 4 grams of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) in the weekly food order) and personalized dietary coaching. Participant will also receive a single 1-hour one-on-one session (dietary motivational coaching) by a dietary coach to guide participants to consume at least 500 mg of EPA+DHA daily at the beginning of the study, followed by weekly 30-minute calls during the 12-week intervention study period.
61986732|NCT01940809|EXPERIMENTAL|Arm B1 (ipilimumab, trametinib)|Patients receive trametinib PO QD for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
62182486|NCT04555005|OTHER|Mindfulness based intervention|Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak
62755433|NCT05297279|PLACEBO_COMPARATOR|Control Treatment Arm|Participants will receive a voucher of weekly food voucher (with a specified amount) for home delivery. Participants in the control arm will also receive a single one-on-one session by a trained research staff member at the beginning of the study, which will be followed by weekly 30-minute calls with the participant during the 12-week intervention study period. The trained research staff member will assist with the online ordering of foods and will provide calls centered on general publicly available, guideline-based dietary recommendations without tailoring or personalization (no dietary coaching). This group will not receive guidance specifically about omega-3 fatty acids.
62755434|NCT03663127|EXPERIMENTAL|Beauty Drink|"Subjects receive two bottles Beauty Drink per day for 8 weeks of a stage."
62755435|NCT03663127|PLACEBO_COMPARATOR|Placebo|Subjects receive two bottles placebo per day for 8 weeks of a stage.
62755436|NCT04161963||Phaco|tandard ultrasound phacoemulsification cataract surgery
62755437|NCT04161963||FLACS|femtolaser assisted cataract surgery
62755438|NCT04161963||phaco+MIGS|combined phacoemulsification cataract surgery plus micro invasive glaucoma surgery
62755439|NCT02781025||Oligometastatic Disease|Patients with oligometastatic cancer, defined as biopsy proven disease involving at least one organ other than the primary tumor organ. Regional lymph node metastases are not considered metastatic.
62755440|NCT05654987||pregnat women|refugee internal or external pregnant women from Ukraine
62755441|NCT05654987||Post partum women|refugee internal or external women during postpartum period (one year after give birth) from Ukranie
62755442|NCT06276881|EXPERIMENTAL|Healthy Controls|
62755443|NCT05628506|EXPERIMENTAL|intervention group|
62755444|NCT05628506|NO_INTERVENTION|control group|
62755445|NCT02027467|EXPERIMENTAL|StemAlive®|Stem Alive® includes ingredients like green tea, ashwagandha. Dose: 3 capsules twice daily to be taken orally for 14 days.
62755446|NCT02027467|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules (for StemAlive®) containing polyethylene glycol, rice powder and magnesium stearate. Dose: 3 capsules twice daily to be taken orally for 14 days.
62755447|NCT04213781|OTHER|Usual care|Sedation according to Dixon's up-and-down method.
62755448|NCT04213781|EXPERIMENTAL|Audiovisual distraction|Audiovisual distraction using HappyMed Video Glasses during procedure. Sedation according to Dixon's up-and-down method.
62755449|NCT06604975|EXPERIMENTAL|NDI-PP- CDI groups|Copeptin represents a new biomarker, direct mirror of AVP release with remarkable characteristics (stable, rapid determination, small blood volume). Copeptin has become a diagnostic tool in adult PPS and eliminated WDT in the diagnostic process. In children, basal copeptin values help for NDI and to exclude CDI (basal copeptin threshold \> 30 and \>3.53 pmol/l (Se 100%, Sp 87.4%), respectively). Below 3.53 pmol/l, basal copeptin performance was inadequate to discriminate PP and CDI, highlighting the relevance of the stimulated copeptin study to improve this strategy.
62755450|NCT02858531||patients < 24 months or 60 years with bronchiolitis or ARF|ARF = Acute Renal Failure
62755451|NCT03029195|EXPERIMENTAL|Study group|Nasoalveolar molding therapy for cleft lip and palate infants
62755452|NCT03029195|NO_INTERVENTION|Control group|No nasoalveolar molding therapy for cleft lip and palate infants
62755453|NCT03029195|NO_INTERVENTION|Age matched Norms|Normal (non-cleft) age matched infants
62755454|NCT05763615|EXPERIMENTAL|Patients|Children aged 1 to 5 benefiting from a 3T MRI at the Necker Enfants-Malades hospital as part of the initial assessment of a tumor or cervico-facial malformation and at the first postoperative follow-up MRI if indicated for the care during a period of 12 months.
62755455|NCT05763615|EXPERIMENTAL|Control patients|Children aged 1 to 5 benefiting from a 3T MRI at the Necker Enfants-Malades hospital as part of the initial assessment of an ENT pathology other than that of the patient group.
61986733|NCT01940809|EXPERIMENTAL|Arm B2 (trametinib, nivolumab, ipilimumab)|Patients receive trametinib PO QD for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
62755456|NCT03258281|ACTIVE_COMPARATOR|evolocumab 420mg|75 subjects on optimal statin therapy undergoing elective PCI will receive evolocumab 420mg.
62755457|NCT03258281|PLACEBO_COMPARATOR|placebo|75 subjects on optimal statin therapy undergoing elective PCI will receive placebo
62755458|NCT03745443|EXPERIMENTAL|Intervention group|Intervention: increase and decrease positive end-expiratory pressure. PEEP titration: 20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11 ventilation was maintained on PEEP 11 for 2 minutes.Then, PEEP was reduced by 2 for every 5 breaths to 5.Total time to titrate was 5 minutes.
62755459|NCT03745443|NO_INTERVENTION|Control|Ventilation with PEEP 3 during anesthesia and surgery
61986734|NCT01940809|EXPERIMENTAL|Arm C1 (ipilimumab, dabrafenib)|Patients receive dabrafenib PO BID for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
62182487|NCT02615678|EXPERIMENTAL|Acupuncture|Acupuncture including scalp needling will be applied to selected points based on literature
62755460|NCT01430507|EXPERIMENTAL|Medium Dose|Medium Dose Revamilast
62755461|NCT01430507|EXPERIMENTAL|High Dose|High Dose Revamilast
62755462|NCT01430507|PLACEBO_COMPARATOR|Placebo|Matching Placebo in Triple Dummy Format
62755463|NCT01430507|EXPERIMENTAL|Low dose|Low dose Revamilast
62755464|NCT06606626|PLACEBO_COMPARATOR|8h Sleep (at home)|Participants sleep 8h at home
62755465|NCT06606626|EXPERIMENTAL|8h Sleep (Laboratory)|Participants sleep 8h in the lab
62557092|NCT06404957|EXPERIMENTAL|Mindfulness-based Applied|Patients in the experimental group were determined, 6-week, 90-minute-a-week mindfulness-based nursing interventions were taught, and group applications were made before the intervention and after; pre-test and post-test questionnaires were applied.
62755466|NCT06606626|EXPERIMENTAL|4h Sleep (Laboratory)|Participants sleep 4h in the laboratory
62755467|NCT06606626|EXPERIMENTAL|0h Sleep (Laboratory)|Participants sleep 0h in the laboratory
62755468|NCT03315104|EXPERIMENTAL|FLU-IGIV High Dose|"Participants will receive a single infusion of high dose of FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive standard of care (SOC) antiviral treatment for flu. Administered intravenously at a dose of 450 mL of 65 g/mL FLU-IGIV diluted to 500 mL with normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.~FLU-IGIV: Single dose, sterile liquid formulation for IV administration."
62755469|NCT03315104|EXPERIMENTAL|FLU-IGIV Low Dose|"Participants will receive a single infusion of low dose of FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive SOC antiviral treatment for flu. Administered intravenously at a dose of 225 mL of 65 g/mL FLU-IGIV diluted to 500 mL with normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.~FLU-IGIV: Single dose, sterile liquid formulation for IV administration."
62755470|NCT03315104|PLACEBO_COMPARATOR|FLU-IGIV Placebo|"Participants will receive a single infusion of placebo for FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive SOC antiviral treatment for flu. Administered IV as 500 mL of normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.~Placebo for FLU-IGIV: Single dose, normal saline solution for IV administration."
62755471|NCT01289340||Polymem (R)|superficial burns treated with Polymem wound dressing until complete wound healing
62755472|NCT01289340||Biaten IBU|burns treated with Biaten IBU until complete wound healing.
62755473|NCT01289340||Hartmen dressing|burns treated with hartman or saline wet dressing until wound healing
62755474|NCT03666507||Brain stem associated tumors|Brain stem associated tumors
62755475|NCT03666507||Tumors without brain stem assocation|Tumors without brain stem assocation
61986735|NCT01940809|EXPERIMENTAL|Arm C2 (dabrafenib, nivolumab, ipilimumab)|Patients receive dabrafenib PO BID for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
61986736|NCT01940809|EXPERIMENTAL|Arm D1 (ipilimumab)|Patients receive ipilimumab IV over 90 minutes Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
62557093|NCT06404957|ACTIVE_COMPARATOR|Control groups|No intervention was made in the control group. At the start of the intervention step of the study and after six weeks, pre-test and post-test questionnaires were applied to control groups.
62557094|NCT02321111|ACTIVE_COMPARATOR|D5W (5% Dextrose in water) + Saline|IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours plus Saline infusion at a rate of 30 mL/hour
62755476|NCT06490653|ACTIVE_COMPARATOR|Tranexamic acid|Patients will be asked to clean their nose with tap water as part of the routine treatment before the administration. After then, Tranexamic acid (500mg/5 ml) will be sprayed through the bleeding side nostril and then external pressure will be applied to the nose for 10 minutes.
62755477|NCT06490653|EXPERIMENTAL|Blood Stopper (Ankaferd)|Patients will be asked to clean their noses with tap water as part of the routine treatment before the administration. After then, 5 ml of Ankaferd® will be sprayed through the bleeding side nostril and external nasal pressure will be performed for 10 minutes.
62755478|NCT01820403|EXPERIMENTAL|portion size small|400 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
62755479|NCT01820403|EXPERIMENTAL|portion size medium|800 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
62557095|NCT02321111|ACTIVE_COMPARATOR|D5W (5% Dextrose in water) + Intralipid|IV Administration of 5% Dextrose in water /D5W (vehicle) 12 mg plus Intralipid infusion at a rate of 30 ml/hour
62557096|NCT02321111|ACTIVE_COMPARATOR|Eritoran + Intralipid|IV administration of Eritoran 12 mg every 12 hours plus Intralipid infusion at a rate of 30 ml/hour
62557097|NCT02449278|EXPERIMENTAL|ISRT group|"Six cycles Chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals) .~Consolidation involved-site radiotherapy (ISRT) following in patient with complete or partial response beginning 1 month after last cycle of chemotherapy."
62755480|NCT01820403|EXPERIMENTAL|portion size large|1600 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
62755481|NCT01820403|NO_INTERVENTION|control|no box lunch provided to participants.
62755482|NCT04963114|EXPERIMENTAL|Art therapy|art therapy in the form of a one-hour guided tour of art works followed by a two-hour guided creative painting workshop on specific themes such as beauty and wonder and colors and emotions
62755483|NCT00521599|EXPERIMENTAL|MF DPI 2 x 100 mcg BID|2 inhalations of mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks
62755484|NCT00521599|EXPERIMENTAL|MF DPI 1 x 200 mcg BID|1 inhalation of mometasone furoate dry powder inhaler (MF DPI) 200 mcg plus 2 inhalations of placebo matching MF DPI 100 mcg twice daily (BID) for 8 weeks
62755485|NCT00521599|PLACEBO_COMPARATOR|Placebo|2 inhalations of placebo matching mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks
62755486|NCT05456568|EXPERIMENTAL|All participants|All participants will use IPC daily at home for 12 weeks alongside usual and standard care
62755487|NCT02943356|EXPERIMENTAL|Tadalafil|Patients will be treated with Tadalafil for 8 weeks.
62755488|NCT06513377|EXPERIMENTAL|People post-stroke|The intervention includes a stress test that induces progressive feelings of fatigue.
62755489|NCT06513377|EXPERIMENTAL|Older adults with sarcopenia|The intervention includes a stress test that induces progressive feelings of fatigue.
62755490|NCT06513377|EXPERIMENTAL|Healthy individuals|The intervention includes a stress test that induces progressive feelings of fatigue.
62755491|NCT04839978|EXPERIMENTAL|Preventive Intervention|Students in schools assigned to the preventive intervention study condition will take part in the Connect school-based prevention program and the community-level Communities Mobilizing for Change and Action (CMCA) intervention.
62755492|NCT04839978|NO_INTERVENTION|Delayed Intervention Control Group|Students in schools assigned to the control group will not receive the Connect and CMCA interventions. Schools in the control group will receive usual school and community prevention and be offered the trial's programs after this three-year study ends.
62755493|NCT04429659||Group 1, patients with amblyopia and partially refractive ET|children with both amblyopia and partially refractive accommodative esotropia
62755494|NCT04429659||Group 2, patients with refractive ET|children with refractive esotropia
62755495|NCT02627287|EXPERIMENTAL|DV3316 pen-injector|
62378497|NCT04752228|OTHER|Lifestyle Assessment|"At the initial visit, no Philadelphia ACE Survey will be administered. The Lifestyle Assessment packaged will be provided for self-completion, featuring General Demographics, Cardiovascular and Medication History, Health Behaviours, the Short Form (36) Health Survey, the Patient Health Questionnaire-9, the General Anxiety Disorder-7 questionnaire, the Seattle Angina Questionnaire-7, and the modified Perceived Need for Card Questionnaire.~At 3 months, the Lifestyle Assessment will be administered again.~At 6 months, the Philadelphia ACE survey, Lifestyle Assessment, as well as a scale assessing their comfort level in being screened for ACE, disclosing their ACE status to their clinicians, and their confidence level in their clinicians' ability to help them manage their ACEs will be administered."
62557098|NCT02449278|ACTIVE_COMPARATOR|IFRT group|"Six cycles Chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-field radiotherapy (IFRT) following in patient with complete or partial response beginning 1 month after last cycle of chemotherapy."
62557099|NCT00690911|EXPERIMENTAL|1|open label adalimumab 40mg
62755496|NCT02627287|ACTIVE_COMPARATOR|FlexPen®|
62755497|NCT01791881|ACTIVE_COMPARATOR|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®)
62755498|NCT01791881|EXPERIMENTAL|Botulinum toxin type A(Hugeltox)|Botulinum toxin type A(Hugeltox)
61986737|NCT01940809|EXPERIMENTAL|Arm D2 (nivolumab, ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses
61986738|NCT04487873||Bronchiectasis|Having been diagnosed with non-cystic fibrosis bronchiectasis
62378498|NCT04741867|EXPERIMENTAL|receiving health education|
62557100|NCT02548832|EXPERIMENTAL|Berberine|Berberine 500 mg with breakfast, meal, and dinner.
61986739|NCT04487873||Healthy individuals|Healthy individuals without chronic disease
61986740|NCT03837561|EXPERIMENTAL|Cunox|Cunox (botulinum toxin type A), 0.1 mL injected into each of 5 sites once.
61986741|NCT03837561|ACTIVE_COMPARATOR|Botox|Botox (botulinum toxin type A), 0.1 mL injected into each of 5 sites once.
62557101|NCT02548832|EXPERIMENTAL|Bezafibrate|Bezafibrate 200 mg on breakfast and dinner.
62557102|NCT02548832|EXPERIMENTAL|Berberine plus Bezafibrate|Berberine 500 mg with breakfast, meal, and dinner, and bezafibrate 200 mg only on breakfast and dinner.
62755499|NCT01757561||Propofol-Abnormal|patients with preoperative SjvO2\<55%,using the TIVA technology with propofol,
62755500|NCT01757561||Propofol-Normal|patients with preoperative SjvO2≥55%,using the TIVA technology with propofol,
62755501|NCT01757561||Sevoflurane-Abnormal|patients with preoperative SjvO2\<55%,using the VIMA technology with sevoflurane,
62755502|NCT01757561||Sevoflurane-Normal|patients with preoperative SjvO2≥55%,using the VIMA technology with sevoflurane,
62755503|NCT02186054|OTHER|Imaging- MRI examinations|Liver MRI imaging will be performed on 50 patients.
62755504|NCT00286195|NO_INTERVENTION|I|Consecutive patients, open label
62182488|NCT01940783|OTHER|Intervention|All participants in the study will receive one pre-operative MRI, prior to cochlear implantation, and two cone-beam computed tomography scans, after cochlear implantation
62378499|NCT04741867|EXPERIMENTAL|Level of compliance|
62378500|NCT04741867|EXPERIMENTAL|Coping with stress|
62755505|NCT05908071|EXPERIMENTAL|SHEN26|Participants will receive SHEN26 400mg twice daily for 5 days.
62755506|NCT05908071|PLACEBO_COMPARATOR|SHEN26 placebo|Participants will receive SHEN26 placebo twice daily for 5 days.
62755507|NCT01546441|EXPERIMENTAL|interprofessional assessment|patients receive an interprofessional assessment in a team environment
62755508|NCT01546441|ACTIVE_COMPARATOR|usual care|Usual care in family practice
62755509|NCT03533907||treated|The women included were patients of the Humanitas Fertility Center; they all had a diagnosis of infertility and were trying to become pregnant. They received ≥1 month of therapy with UA 5 mg/day
62755510|NCT03222830|EXPERIMENTAL|RIF group|"According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle ."
62755511|NCT06024850||multiligamentar knee reconstruction|"Any patient who benefits of a multiligamentar knee reconstruction at hospital of Saint-Etienne will be included.~Datas collected by medical record."
62755512|NCT03036345|EXPERIMENTAL|Surgery patients|Patients receiving shoulder surgery in the Beach Chair Position, and monitored by both INVOS and FORE-SIGHT monitors.
62755513|NCT04753554|ACTIVE_COMPARATOR|Conventional group|The patient group that whose oxygenation will be managed by blood gas analysis.
62755514|NCT04753554|EXPERIMENTAL|ORI group|The patient group that whose oxygenation will be managed by ORI values
62755515|NCT04139577|EXPERIMENTAL|Fecal Microbiota Transplant (FMT) FOR HIGH-RISK ACUTE GVHD|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~this research study for up to 6 months. You may receive up to 2 cycles of the study treatment.~- Fecal Microbiota Transplant ( FMT)- Oral Study Drug, predetermined dosage and timings, up to 2 cycles.~* One cycle of treatment consists of one induction week of FMT followed by three weeks of maintenance FMT.~* The maintenance weeks happen for 3 weeks after the induction week.~* All doses will be administered in the clinic.~* A second cycle of treatment as deemed appropriate"
62755516|NCT02919280||No treatment|This is an observational study. No intervention / treatment involved.
62755517|NCT03494517||Preeclampsia|"Women aged 18-45 years~1. Confirmed pregnancy \> 30 weeks of gestation~2. Singleton or multiple pregnancies~3. Admission in maternity of the Women's hospital with clinically suspected signs of severe preeclampsia:~   * Systolic blood pressure \>140 mmHg or diastolic pressure \> 90 mmHg and~  * Proteinuria \> 0.3 grams in a 24-hour urine or protein:creatinine ratio \>0.3 or~  * Signs of end-organ dysfunction (platelet count \< 100'000G/l, serum creatinine \>110 mg/l, or doubling of the serum creatinine, elevated serum transaminases to twice normal concentration)"
62755518|NCT06608706|EXPERIMENTAL|Trauma-focused therapy: EMDR for psychosis and treatment as usual (TAU)|Patients randomized to receive max. 26 sessions of EMDR for psychosis.
62755519|NCT06608706|NO_INTERVENTION|Treatment as usual (TAU) and waiting list (WL)|Patients randomized to continue with treatment as usual (TAU) for 6 months as a waiting list (WL) control group. TAU consists of an individual combination of treatments for SSDs in line with Norwegian national guideline (e.g. medication, cognitive therapy, work training, music therapy).
62755520|NCT02924714|OTHER|Discontinuation of imatinib|Patients treated with imatinib longer than 5 years for oligo-metastatic GIST (≤ 3 metastases) and who have no longer detectable GIST lesions on CT/MRI imaging following complete surgical resection (R0/R1-resection) or RFA of the metastases are assigned to discontinue imatinib.
62755521|NCT02793596|EXPERIMENTAL|Obstetrical patients|Obstetrical patients requiring epidural analgesia for delivery
62755522|NCT04960384|PLACEBO_COMPARATOR|Placebo|
62755523|NCT04960384|EXPERIMENTAL|Human Fibroblast Growth Factor-2 (FGF-2)|
62755524|NCT00230282|EXPERIMENTAL|Fludarabine, cytoxan, then alemtuzumab|Fludarabine and cyclophosphamide days 1 to 3 for six 28-day cycles. Minimal residual disease positive responders continued on-treatment to receive alemtuzumab 30 mg weekly. MRD negative responders were observed.
62755525|NCT05979636|EXPERIMENTAL|Test group|
62755526|NCT05979636|ACTIVE_COMPARATOR|Control group|
62755527|NCT02083705|EXPERIMENTAL|SI+CC|"Chest compression will be superimposed by sustained inflations during CPR:~CC+SI group Infants randomized in the SI group requiring CC, would receive CC at a rate of 90/min during an SI with a duration of 20sec (CC+SI). After 20 sec the SI will be interrupted for 1 sec and the next SI will be started for another 20sec13. Throughout this time CC is continued until ROSC. Every 45 sec (approximately 2 SIs) the clinical team would assess for changes in heart rate. CC+SI was continued until ROSC."
62755528|NCT02083705|ACTIVE_COMPARATOR|3:1 CPR|"CPR using 3:1 C:V ratio:~3:1 C:V group Infants randomized into the 3:1 group requiring CC, would received CC using the current 3:1 C:V ratio recommend in the neonatal resuscitation guidelines16. Every 45 sec the clinical team would assess heart rate. 3:1 C:V CPR was continued until ROSC."
62755529|NCT04174989|EXPERIMENTAL|Plasminogen-Depleted Plasma Infusion|Patients presenting with acute upper gastrointestinal hemorrhage (AUGIH) and due to undergo a plasma transfusion, will be randomized to receive a one-time infusion (up to 8 hours) of up to two 250 mL units of PDP. In case of transfusions needing more than two units, the third unit and above will consist in regular plasma regardless of treatment group. Patients will be continuously monitored for 8 hours following the transfusion, and will be assessed between 8-12 hours after plasma transfusion or the following morning (the earlier of the two options), between 24-48 hours after plasma transfusion or at discharge (the earlier of the two options) and after 30±3 days after transfusion.
62755530|NCT04174989|OTHER|Fresh-Frozen Plasma Infusion|Patients presenting with acute upper gastrointestinal hemorrhage (AUGIH) and due to undergo a plasma transfusion, will be randomized to receive a one-time infusion (up to 8 hours) of up to two 250 mL units of FFP. In case of transfusions needing more than two units, the third unit and above will consist in regular plasma regardless of treatment group. Patients will be continuously monitored for 8 hours following the transfusion, and will be assessed between 8-12 hours after plasma transfusion or the following morning (the earlier of the two options), between 24-48 hours after plasma transfusion or at discharge (the earlier of the two options) and after 30±3 days after transfusion.
62755531|NCT00854217|PLACEBO_COMPARATOR|placebo, hemodilution|
62755532|NCT03826173|EXPERIMENTAL|Positive Psychology|On a weekly basis, participants will engage in group-based intervention sessions that focus on personal strengths and the value of positive emotions and cognitions. Participants will receive daily text-messages addressing the content introduced during group sessions.
62755533|NCT03826173|ACTIVE_COMPARATOR|Physical Activity Promotion|On a weekly basis, participants will engage in group-based intervention sessions that focus on the standard physical activity promotion components of the PPPA condition. Participants will receive daily text-messages addressing the content introduced during group sessions.
62755534|NCT06225648|EXPERIMENTAL|Threonine in Adults > 60|Threonine: all subjects will receive up to 7 threonine test levels, in random order.
62755535|NCT03594916|EXPERIMENTAL|Active tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). Active stimulation consists of 2 mA current applied continuously for 20 minutes.
62755536|NCT03594916|SHAM_COMPARATOR|Sham tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). The 2 mA current will be applied for 30 seconds at the beginning of the session.
62378501|NCT04400669|EXPERIMENTAL|Mechanical Bowel Preparation|Patients will have only clear liquids after a normal breakfast and lunch on the day before surgery and subsequently fasten for 7-9 hours prior to surgery. Patients will ingest first dose of 45 ml oral sodium phosphate (NaP) enema (BT ORAL SOLUSYON 45 ML®, Yenisehir Lab. Tic. San. Ltd. Sti, Turkey) at 4 p.m. and a second dose at 8 p.m. in the evening before the scheduled surgery.
61986742|NCT02515955|EXPERIMENTAL|Cohort 1|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
62755537|NCT03304054|EXPERIMENTAL|amifamapridine phosphate tablets|
62755538|NCT03304054|PLACEBO_COMPARATOR|placebo tablets|
62755539|NCT01921218|EXPERIMENTAL|Treatment|Belatacept (Nulojix) IV
62557103|NCT01117896|EXPERIMENTAL|Adult vs Pedi manikin CC quality|"The primary objective is to determine whether chest compression deterioration occurs at the same rate in pediatric and adult manikins. The primary endpoint will be the difference in mean number of effective compressions per minute in each manikin at times 1, 2, 5 and 10 minutes.~Another objective is to identify the correlation between the anaerobic threshold and the deterioration of compressions in each manikin. The endpoint will be the difference between mean time to ineffective compressions (defined as 10 consecutive compressions that fail to meet AHA guidelines for depth and rate) and mean time to anaerobic threshold in each manikin."
62378502|NCT04400669|ACTIVE_COMPARATOR|Low fibre diet|Patients will be given detailed instructions about the pre-operative diet (total daily Fibre intake inferior to 10 g) to be used for 3 days prior to surgery.
62557104|NCT01117896|EXPERIMENTAL|Stepstool use|A third main objective is to determine the effect of the stepstool use on the quality of chest compressions and metabolic demand. The endpoint will be the difference between mean time to ineffective compressions (defined as 10 consecutive compressions that fail to meet AHA guidelines for depth and rate) and mean time to anaerobic threshold in each experimental group.
62557105|NCT02166255|EXPERIMENTAL|Treatment (APN401)|Patients receive autologous siRNA-transfected peripheral blood mononuclear cells APN401 IV over 30 minutes.
62557106|NCT01126242|EXPERIMENTAL|tape|Group I will be treated with non-elastic adhesive tape around the affected ankle, applied by the 'van Unen-technique'. This technique is an alternative for the 'Coumans- technique'. The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity. Taping is a treatment that involves no loss of time, requires no crutches and is not attended with any ultimate impairment of function.
62557107|NCT01126242|ACTIVE_COMPARATOR|Lace-up brace|The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
62557108|NCT01126242|ACTIVE_COMPARATOR|Semi rigid brace|A semi-rigid brace, the M-step® from Medi®, will be applied. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
62557109|NCT02346656||Treated subjects|All subjects recruited and treated with the Axium neurostimulator
62557110|NCT04970615||Two-dimensional images|Patients who receive pre-operativeinformation while the two-dimensional MR images are being shown to them by the neurosurgeon.
62557111|NCT04970615||Three-dimensional printed model|Patients who receive pre-operative information while the three-dimensional printed models are being shown to them by the neurosurgeon.
62557112|NCT05580250|EXPERIMENTAL|Part A: Single Dose LY3526318|LY3526318 administered orally in three study periods.
62557113|NCT05580250|PLACEBO_COMPARATOR|Part A: Single Dose Placebo|Placebo administered orally in three study periods.
62755540|NCT01921218|ACTIVE_COMPARATOR|Control|Calcineurin inhibitor based therapy (cyclosporine or tacrolimus)
62755541|NCT03798730|EXPERIMENTAL|Solid Model|"1. Cake~   -Control Vanilla Cake and Protein Fortified Vanilla Cake~2. Biscuit -Control Lemon Biscuit and Protein Fortified Lemon Biscuit"
62755542|NCT03798730|EXPERIMENTAL|Liquid Model|"Whey Protein Beverages~* Native sample (protein unheated)~* Denatured whey protein (protein heated to denature)"
62755543|NCT02878525|EXPERIMENTAL|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
61986743|NCT02515955|EXPERIMENTAL|Cohort 2|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
62755544|NCT02878525|ACTIVE_COMPARATOR|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
62755545|NCT05501431||Progressive Supranuclear Palsy (PSP)|Participants with possible or probable PSP, wearing the Verily Study Watch for 1 year.
62755546|NCT05501431||Healthy Controls (HC)|Participants without a neurological condition, age and gender matched to the PSP cohort, , wearing the Verily Study Watch for 1 year.
62755547|NCT01882049|EXPERIMENTAL|Treatment|Use of Realize gastric band (Ethicon) in adolescents for weight reduction
62755548|NCT01352741|EXPERIMENTAL|Tapentadol Prolonged Release|Tapentadol Prolonged Release (100 - 500 mg per day) Oral administration twice daily
62182489|NCT04347785||Neurologic deficit|All consecutive patients from a tertiary referral center who underwent CEA for carotid artery stenosis who presented alterations in the neurologic examination after ICA clamping during CEA area selected
62378503|NCT04400669|ACTIVE_COMPARATOR|MBP plus low fibre diet|This group will receive both mechanical bowel preparation and 3-days low fibre diet.
62557114|NCT05580250|EXPERIMENTAL|Part B: Multiple Dose LY3526318|LY3526318 administered orally.
62557115|NCT05580250|PLACEBO_COMPARATOR|Part B: Multiple Dose Placebo|Placebo administered orally.
62378504|NCT04400669|NO_INTERVENTION|Control|Control subjects will receive no instructions about the pre-operative diet (free diet).
62378505|NCT02617199|EXPERIMENTAL|Epidural anesthesia|Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
62378506|NCT02617199|ACTIVE_COMPARATOR|intravenous analgesia|ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
62378507|NCT01910142|ACTIVE_COMPARATOR|calcium supplement with vitamin K|Milk product supplying about 420 mg Ca and 7.5 μg vitamin D3 and 100 μg vitamin K. Additional 200 mg calcium in the form of carbonate
62378508|NCT01910142|PLACEBO_COMPARATOR|calcium supplement without vitamin K|Milk product supplying about 420 mg Ca and 7.5 μg vitamin D3. no vitamin K. Additional 200 mg calcium in the form of carbonate
62378509|NCT03491254||Group A/exposure group|Huaier Granule \& biliary drainage
62378510|NCT03491254||Group B/non-exposure group|biliary drainage.
62378511|NCT05546957|EXPERIMENTAL|Arm 1: Aspirin QD|Randomized 1:1:1
62378512|NCT05546957|EXPERIMENTAL|Arm 2: Aspirin QD + rivaroxaban BID|Randomized 1:1:1
62378513|NCT05546957|EXPERIMENTAL|Arm 3: Aspirin QD + rivaroxaban QD|Randomized 1:1:1
62378514|NCT03262285||phacoemulsification|patients undergoing phacoemulsification surgery for senile cataract
62378515|NCT03262285||extracapsular cataract extraction|patients undergoing extracapsular cataract extraction surgery for senile cataract
62378516|NCT04019197|EXPERIMENTAL|Participants with HIV and lipohypertrophy: semaglutide arm|Participants with HIV/lipohypertrophy will receive semaglutide 0.25 mg x4 weeks, then semaglutide 0.5 mg x4 weeks, then semaglutide 1.0 mg x24 weeks, then no drug x24 weeks.
62378517|NCT04019197|PLACEBO_COMPARATOR|Participants with HIV and lipohypertrophy: placebo arm|Participants with HIV/Lipohypertrophy will receive placebo x32 weeks, then no placebo for 24 weeks.
62378518|NCT01087073|EXPERIMENTAL|Patient Activation|Patient knowledge in diabetes self-management behaviors and clinical measures (HbA1c, LDL, HDL, BMI, BP) are tracked at baseline, 10-weeks (post-program), 3 months (post-program) and 6 months (post-program).
62378519|NCT01087073|EXPERIMENTAL|Provider Training Evaluation|Pre-post surveys are conducted at each training session to assess overall satisfaction with the curriculum, knowledge of SDM, and understanding of techniques to promote its use in the healthcare setting.
62378520|NCT01087073|EXPERIMENTAL|Quality Improvement Evaluation|We measure quality improvement efforts through biannual staff experience surveys and one-on-one provider and clinic staff interviews.
62378521|NCT01087073|EXPERIMENTAL|Community Outreach Evaluation|"Pre-post surveys will be disseminated at nutrition tours (Save-A-Lot, Walgreens, 61st Street Farmers Market) to assess change in knowledge of healthy eating behaviors and proper nutrition. Surveys will also assess participant satisfaction of the tours.~Interviews will also be performed with community stakeholders to assess the costs/benefits of the collaboration and overall feedback on involvement."
62378522|NCT01087073|NO_INTERVENTION|Global Evaluation of the Intervention|A chart review will be performed in order to evaluate our intervention to improve diabetes processes of care and clinical outcomes among our target population. Chart abstractions will be performed on medical records obtained from our six intervention clinics. In addition, chart abstractions from two University of Illinois at Chicago clinics and three FQHCs located on the West Side of Chicago will serve as control data.100 charts will be randomly selected from each clinic per year of the intervention. The chart review will contain charts from adult diabetes patients over a seven year period that matches the duration of the Improving Diabetes project.
62378523|NCT01250899|NO_INTERVENTION|Vitamin D Sufficient|HIV-infected men and women with HIV-1 viral load \<200 copies/mL on stable ART and 25(OH)D level ≥30ng/mL receive no intervention.
62378524|NCT01250899|EXPERIMENTAL|Vitamin D Insufficient|HIV-infected men and women with HIV-1 viral load \<200 copies /mL on stable ART and 25(OH)D level \<30ng/mL receive 50,000 IU twice weekly for 5 weeks followed by 2000 IU daily to complete 12 weeks.
62755549|NCT01352741|ACTIVE_COMPARATOR|Tapentadol Prolonged Release with Pregabalin|Tapentadol Prolonged Release (100 - 300 mg per day) with Pregabalin (150 - 300 mg per day) Both administered orally twice a day.
62755550|NCT03362788||VKA|"Patients receiving VKA as anticoagulant treatment plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.~Treatment will be at operator's discretion or, post discharge, at prescribing physician's discretion."
62755551|NCT03362788||NOAC|"Patients receiving a NOAC as anticoagulant treatment plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.~Treatment will be at operator's discretion or, post discharge, at prescribing physician's discretion."
62378525|NCT04825704|ACTIVE_COMPARATOR|Bupivacaine|Topical administration of bupivacaine via gauze swab in the tonsillar fossae after removal of throat tonsils.
62378526|NCT04825704|PLACEBO_COMPARATOR|Sodium chloride|Topical administration of 0,9% sodium chloride via gauze swab in the tonsillar fossae after removal of throat tonsils.
62378527|NCT01774838|EXPERIMENTAL|Prasugrel|3 months treatment with 10 mg prasugrel
62378528|NCT01774838|ACTIVE_COMPARATOR|Clopidogrel|3 months treatment with clopidogrel 75 mg
62557116|NCT05580250|EXPERIMENTAL|Part C: Iohexol + Simvastatin + Metformin + LY3526318|Iohexol administered intravenously (IV) and simvastatin, metformin, and LY3526318 administered orally.
62557117|NCT02502032|EXPERIMENTAL|Cisatracurium 0.005 mg/kg|The group received pretreatment of cisatracurium 0.005 mg/kg.
62557118|NCT02502032|EXPERIMENTAL|Cisatracurium 0.01 mg/kg|The group received pretreatment of cisatracurium 0.01 mg/kg.
62557119|NCT02502032|EXPERIMENTAL|Cisatracurium 0.02 mg/kg|The group received pretreatment of cisatracurium 0.02 mg/kg.
62557120|NCT03623503||first group|Observational study of 25 newborn with a likely EOS
62557121|NCT03623503||second group|Observational study of v33 newborn with a possible EOS
62557122|NCT03500198|EXPERIMENTAL|Investigational Device: Next Generation TECNIS IOL|Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL
62557123|NCT03500198|ACTIVE_COMPARATOR|Control Device: TECNIS Monofocal IOL|Control Monofocal Intraocular Lens: TECNIS Monofocal IOL
62378529|NCT00506740|ACTIVE_COMPARATOR|Electrocautery|Elesurgical instruments are used to cut and coagulate tissue using alternatig electric current focusing intense heat at the surgical site. In electrosurgery, the patient is included in the circuit and current enters the patient's body.
62378530|NCT03109535|ACTIVE_COMPARATOR|Fitbit-only Group|Participants received a Fitbit Zip activity monitor to wear daily for 10 weeks.
62378531|NCT03109535|EXPERIMENTAL|Fitbit + MapTrek Group|Participants received a Fitbit Zip activity monitor to wear daily for 10 weeks. Participants also received access to an mHealth game called MapTrek for 10 weeks. MapTrek places users in weekly walking races and sends automated text messages to participants on a daily basis. Messages include a link to the online game as well as motivational messages designed to increase physical activity.
61986744|NCT02515955|EXPERIMENTAL|Cohort 3|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
62378532|NCT01172704|ACTIVE_COMPARATOR|Care as Usual|Participants randomized to CAU receive the standard care given to patients of the Boston Medical Center who are interested in learning more about HIV/AIDS. Included in this care would be referrals for HIV counseling and testing.
62378533|NCT01172704|EXPERIMENTAL|Skills Building - Motivational Interviewing|Participants randomized to SB-MI will receive three individual sessions and a booster. Content of the sessions are as follows; Session 1: Risk Behavior Feedback \& Building Motivation; Session 2: Building Motivation \& Skill Selection and Practice; Session 3: Developing Change Plan \& Skill Practice and Booster Session(s): Review Change Plan Implementation, Maintaining Motivation \& Skill Practice.
62755552|NCT01854892|EXPERIMENTAL|Manipulation|Spinal manipulation
62378534|NCT04520295||HER2 positive cohort|
62378535|NCT03944551|EXPERIMENTAL|Bubble CPAP|
62557124|NCT03963193|EXPERIMENTAL|Etoposide plus Cisplatin|Etoposide 100mg/m\^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m\^2 ivggt on days 1, 2, 3, repeated every 21 days. When the investigator believes that the participant is not suitable for continued medication or the evaluation is progressive disease (PD) according to the RECIST 1.1 standard, the medication is over.
62755553|NCT01854892|EXPERIMENTAL|Mobilization|Spinal mobilization
62755554|NCT01854892|EXPERIMENTAL|Laser Therapy|Cold laser therapy
62755555|NCT03112525||Patient under Rivaroxaban|
62755556|NCT03112525||Patient under Apixaban|
62755557|NCT00866047|EXPERIMENTAL|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion
62378536|NCT03944551|OTHER|Standard Therapy|
62378537|NCT05956990|EXPERIMENTAL|multidimensional rehabilitation group|The intervention is based on the behavior change wheel and includes dietary intervention, exercise intervention, psychological support, and behavior management. Through various methods such as training, education, and motivation, the patient's ability, opportunities, and motivation will be increased, thereby promoting healthy behavior.
62378538|NCT05956990|NO_INTERVENTION|Control group|The patients will receive the conventional clinical guidance according to The First Affiliated Hospital of Xiamen University, including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence.
62378539|NCT05933993||Mothers, following an elective cesarean sections|The cohort in this study consists of Danish mothers, undergoing an elective cesarean section in one og the three participating hospitals.
62378540|NCT02413086|EXPERIMENTAL|Early-stage amputation+external herbs chitosan|Individuals with DFU were given early-stage amputation and wound was given herbs chitosan after amputation.
62378541|NCT02413086|EXPERIMENTAL|Early-stage amputation+traditional gauze|Individuals with DFU were given early-stage amputation and wound was given traditional gauze after amputation.
62378542|NCT02413086|EXPERIMENTAL|Amputation+external herbs chitosan|Individuals with DFU were given amputation and wound was given herbs chitosan after amputation.
62557125|NCT03963193|EXPERIMENTAL|Irinotecan plus Cisplatin|Irinotecan 65 mg/m\^2 ivggt on days 1, 8, Cisplatin 30 mg/m\^2 ivggt on days 1, 8, repeated every 21 days. When the investigator believes that the participant is not suitable for continued medication or the evaluation is progressive disease (PD) according to the RECIST 1.1 standard, the medication is over.
62755558|NCT05452954|OTHER|Brief behavioral parent training|A newly developed, easily applicable, individually tailored first-line behavioral training for parents of children (4-12 years) with behavioral problems and (symptoms of) ADHD, that will be provided in an early stage, before other treatments have been applied.
62755559|NCT01571284|EXPERIMENTAL|Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)|Aflibercept 4 mg/kg IV infusion over 60 minutes followed by Irinotecan 180 mg/m\^2 IV infusion over 90 minutes and Leucovorin 400 mg/m\^2 IV infusion over 120 minutes at the same time followed by 5-Fluorouracil (5-FU) 400 mg/m\^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m\^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until disease progression (DP), unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.
62755560|NCT02830347||Amoxicillin|No randomization is performed. Patients who are prescribed antibiotics by the clinician performing the tooth extraction ( based on case complexity and intra operative judgement) are recruited into this group.The principal investigator is not involved in the decision to prescribe antibiotics or not.
62755561|NCT02830347||No Amoxicillin|Patients who do not receive antibiotics after extractions are recruited into this group.
61986745|NCT02515955|EXPERIMENTAL|Cohort 4|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
62755562|NCT01869361|PLACEBO_COMPARATOR|Placebo|The patient will be given a loading dose of 50mg placebo by mouth followed by 25mg by mouth every six hours for a total of eight doses over 48 hours.
62755563|NCT01869361|ACTIVE_COMPARATOR|Indomethacin|The patient will be given a loading dose of 50mg indomethacin by mouth followed by 25mg by mouth every six hours for a total of eight doses over 48 hours.
62378543|NCT02413086|EXPERIMENTAL|Amputation+traditional gauze|Individuals with DFU were given amputation and wound was given traditional gauze after amputation.
62378544|NCT02959736||National Rehabilitation Hospital Dublin|Music Therapy (MATADOC)
62557126|NCT05092789|EXPERIMENTAL|Kinesio taping group|"Participants in this group will receive treatment through standardized therapeutic Kinesio taping along with conventional therapy.~Tape will be water proof, porous, adhesive,with width of 5cm and thickness of 0.5 mm."
62378545|NCT02959736||Spectrum|Music Therapy (MATADOC)
62378546|NCT02959736||Royal Hospital for Neuro-disability London|Music Therapy (MATADOC)
62378547|NCT06059274|EXPERIMENTAL|Topical serum|An investigational topical serum containing hyaluronic acid, vitamin B5, madecassoside and La Roche-Posay Thermal Spring Water
62378548|NCT00597857|PLACEBO_COMPARATOR|1|receipt of a placebo pill for 16 days
62378549|NCT00597857|ACTIVE_COMPARATOR|2|oral pill of hydrocortisone (ranging from 20mg - 2.5mg) taken for 10 days with a taper for 6 days (based on Pitman et al, 2002).
62378550|NCT01841164|EXPERIMENTAL|Montelukast|5 to 7 days of treatment with montelukast 10 mg 2 tablets bid. Efficacy of treatment is evaluated on airway responsiveness to inhaled leukotriene E4.
62378551|NCT01841164|PLACEBO_COMPARATOR|Sugar pill|Placebo for montelukast 5-7 days 2 tablets bid. Efficacy of treatment is evaluated on airway responsiveness to inhaled leukotriene E4.
62378552|NCT04481724|EXPERIMENTAL|gamma-linolenic acid (GLA) supplementation|Sonova GLA safflower oil (840 mg GLA per day)
62378553|NCT04481724|PLACEBO_COMPARATOR|placebo control|1500 mg 'light' olive oil per day
62378554|NCT03390127|EXPERIMENTAL|Group P|After LMA Supreme™ insertion, PEEP of 7 cmH2O would apply during general anesthesia with mechanical ventilation.
62378555|NCT03390127|NO_INTERVENTION|Group Z|After LMA Supreme™ insertion, PEEP would not apply during general anesthesia with mechanical ventilation.
62378556|NCT03617471|EXPERIMENTAL|Paracetamol oral tablets 1g tid|Patients received paracetamol one gram three times daily. Venopuncture for PK profiling
62378557|NCT03617471|EXPERIMENTAL|Paracetamol oral granules 1g tid|Patients received paracetamol one gram three times daily. Venopuncture for PK profiling
62378558|NCT05614700|ACTIVE_COMPARATOR|High dose-rate brachytherapy|Two HDR-BT treatment schedules, either a single fraction 19Gy treatment or 27Gy in 2 fractions approximately 2 weeks apart will be used to be decided by treating centre.
62378559|NCT05614700|EXPERIMENTAL|Ultra-hypofractionated external beam radiotherapy|Patients will receive 5 fractions of 7.25Gy per fraction which will be delivered alternate days over no more than 2 weeks to provide a total dose of 36.25Gy.
62378560|NCT01159886|ACTIVE_COMPARATOR|left lateral|After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus position. Then terminal ileal intubation will be attempted.
62378561|NCT01159886|ACTIVE_COMPARATOR|supine|After confirmation of cecal intubation, patient will undergo randomization to the supine position. Then terminal ileal intubation will be attempted.
62378562|NCT02735044|EXPERIMENTAL|HOE901-U300|HOE901-U300 (Insulin glargine 300 Units/milliliter \[U/mL\]) Subcutaneous(SC) injection once daily for 12 months.
62378563|NCT02735044|ACTIVE_COMPARATOR|Lantus|Lantus (Insulin glargine 100 U/mL) SC injection once daily for 12 months.
62557127|NCT05092789|EXPERIMENTAL|Cervical thrust manipulation group|"Participants in this group will receive treatment via cervical thrust manipulation along with conventional therapy.~Manipulation will be directed on mid cervical spine."
62557128|NCT05092789|ACTIVE_COMPARATOR|Conventional therapy group|.Participants of this group will receive only conventional therapy which will include: Hot pack for 10 minutes Stretching Exercises
62557129|NCT05243160|NO_INTERVENTION|control|Treatment as usual
62557130|NCT05243160|EXPERIMENTAL|Intervention|Intervention group will be exposed to a medication review by a clinical pharmacologist
62557131|NCT03997630|EXPERIMENTAL|Interventional group|Interventional group: All patients included in this group will receive a continuous heated and humidified high-flow (30 to 60 l/min) oxygenation with a nasal cannula for 48 hours. Initially, flow rate will be started at 50 l/min with a FiO2 at 50%. According to the protocol, flow rate and FiO2 will be titrated on SpO2 and respiratory tolerance. Weaning and failure of high-flow oxygenation are described in detail in the study protocol.
61986746|NCT02515955|EXPERIMENTAL|Cohort 5|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
62378564|NCT02460094|EXPERIMENTAL|Panel 1: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
62378565|NCT02460094|EXPERIMENTAL|Panel 2: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
62378566|NCT02460094|EXPERIMENTAL|Panel 3: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
62378567|NCT02460094|EXPERIMENTAL|Panel 4: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
62378568|NCT04409691|ACTIVE_COMPARATOR|prednison group|
62378569|NCT04409691|EXPERIMENTAL|prednison+sirolimus group|
62378570|NCT01607749|EXPERIMENTAL|Educational Program|"Students in the intervention schools learn the educational program Asthma, Sport and Health in three sessions during a period of 6 weeks. The content of the educational program has been published elsewhere."
62378571|NCT01607749|NO_INTERVENTION|Asthma information for teachers|Information about asthma the Ministry of Education to all schools in the community.
62378572|NCT03621124||Brown Adipose Tissue Positive patients|Patients with known malignancy and incidental finding of positron emission tomography/ computerized tomography (PET/CT) scans positive for brown adipose tissue (BAT). After obtaining informed consent and all initial screening visit procedures, patients will participate in two four-hour recording sessions in the whole room indirect calorimeter to assess resting energy expenditure, and patient's thermal (comfort) response to the temperature of the room.
62557132|NCT03997630|ACTIVE_COMPARATOR|Control group|Control group: All patients included in this group will receive a low flow oxygenation (flow rate \< 15 l/min) with nasal cannula (flow rate ≤ 6 l/min) or non-rebreathing mask (flow rate ≥ 7 l/min).
62378573|NCT03621124||Brown Adipose Tissue Negative Patients|Patients with known malignancy and no evidence of brown adipose tissue BAT activity positron emission tomography/ computerized tomography (PET/CT) scans to be matched to group 1 for primary tumor and stage, sex, age (±5 years), BMI (±3 Kg/m2). After obtaining informed consent and all initial screening visit procedures, patients will participate in two four-hour recording sessions in the whole room indirect calorimeter to assess resting energy expenditure, and patient's thermal (comfort) response to the temperature of the room.
62378574|NCT02092506|ACTIVE_COMPARATOR|triple therapy|10 day triple therapy (PPI, amoxicillin 1g, clarithromycin 500mg twice daily)
62557133|NCT02728700|EXPERIMENTAL|Treatment (sirolimus, HSCT, MMF)|Patients receive sirolimus PO starting on day -3, 3 times a week during hospitalization and then once a week for up to 6 months. Patients undergo HSCT on day 0. Patients also receive mycophenolate mofetil IV or PO TID on days 1-180. Treatment continues in the absence of disease progression or unacceptable toxicity.
62755564|NCT04093765|EXPERIMENTAL|Sustained high incidence villages|Villages classified as high incidence, low probability of elimination (P. falciparum cumulative incidence \>84 cases/1000/year, in spite of \>1 year of functioning malaria post) will be eligible to be included in group 1. Villages in this group will be addressed by MSAT waves of 10-15 villages. Interventions will consist of 1 Ultrasensitive Rapid Diagnostic Test (URDT) and antimalarials drugs.
62755565|NCT04093765|EXPERIMENTAL|Seasonal focal transmission villages/locations|"This group will follow the NMCP case/and foci investigation guidelines, but use URDT instead of standard RDT for screening. MSAT group 2 locations will be cluster of houses, villages or clusters of villages selected based on the results of case or foci/outbreak investigation. Interventions will consist of 1 Ultrasensitive Rapid Diagnostic Test (URDT) and antimalarials drugs.~* Village inclusion after case investigation~* Village inclusion after outbreak investigation"
62755566|NCT02409004|EXPERIMENTAL|Ataluren|Ataluren 1375 mg powder for oral suspension administered once daily on Days 1 and 11 Rifampin 300 mg capsules administered twice daily on Day 3 to Day 12
62182490|NCT04347785||control|The control patients are submitted to the same procedure but with no neurologic alterations, are consecutively selected. a 1 to 1 ratio is used
62378575|NCT02092506|ACTIVE_COMPARATOR|Concomitant therapy|10-day concomitant therapy (PPI, amoxicillin 1g, clarithromycin 500mg, metronidazole 400mg twice daily).
62378576|NCT02092506|ACTIVE_COMPARATOR|sequential therapy|10-day sequential therapy (PPI and amoxicillin 1 g twice daily x 5 days followed by PPI, clarithromycin 500mg, metronidazole 400mg twice daily x 5days)
62557134|NCT03474666|ACTIVE_COMPARATOR|Strict Glycemic Control Group|Intravenous insulin as described by Keegan and Cols. 2010.
62557135|NCT03474666|ACTIVE_COMPARATOR|Standard Glycemic Control Group|Subcutaneous insulin as instititional protocol.
62755567|NCT05868863||osteoporotic fractures or neoplastic lesions of the bony pelvis|"Patient aged 80 and over suffering from osteoporotic fractures or neoplastic lesions of the bony pelvis treated by percutaneous cementoplasty with or without screw fixation at university hospital center of Saint-Etienne between January 1st 2012 and February 28th 2023 will be included.~Analysis datas of medical record."
62755568|NCT05379062|EXPERIMENTAL|Active Singing Group|Active singing in a group
62755569|NCT05379062|EXPERIMENTAL|Receptive Music Group|Receptive music/auditive group
62755570|NCT05379062|NO_INTERVENTION|Control Group|Treatment as usual
62755571|NCT01548313||Pregnant women from Ljubljana region|Women at 3rd trimester of pregnancy living in the Ljubljana region.
62557136|NCT03233893|EXPERIMENTAL|light activated calcium silicate|Apply light activated calcium silicate in deep occlusal caries lesions and taking the base line image for the first group after restoring the cavity with composite restoration and taking the follow up x-ray image after one year to measure the calcific bridge formation.
62557137|NCT03233893|ACTIVE_COMPARATOR|light activated calcium hydroxide|Apply the light activated calcium hydroxide in deep occlusal carious lesions and taking the base line image for the second group after restoring with composite restoration and taking the follow up x-ray image after one year to measure the calcific bridge formation.
62557138|NCT00599365|EXPERIMENTAL|Pharmacy Care arm|"The pharmacist:~* will take all the patient's medication bottles, and give medication boxes filled with medications in the order the patient should take them in.~* will need to obtain a complete list of medications.~* will teach the patient about the medications.~* will provide a medication schedule, and other papers about the medications.~* will count the pills in the medication boxes.~* will review all the medications with the patient and answer any question.~* will check to see if the medication is working for the patient.~* will work with the patient's kidney doctor to adjust medications if needed.~* will give the medication boxes filled with medications to take home."
62557139|NCT00599365|NO_INTERVENTION|Control|"The pharmacist:~* will obtain a complete list of medications.~* will count the pills in the patients' medication bottles.~* will inform patients to take their medications from these bottles."
62557140|NCT01634841|ACTIVE_COMPARATOR|Walnut group|This group will have their habitual diet supplemented with 30 to 45g (1 to 1.5 oz) of walnuts daily.
62557141|NCT01634841|ACTIVE_COMPARATOR|Control group|This group will eat their habitual diet and refrain from eating walnuts.
62557142|NCT02941471|EXPERIMENTAL|Interferential Stimulation|Medical Device: Interferential stimulation. Stimulation parameters: 4 KHz of carrier stimulation, beat frequency between 80-160Hz, amplitude upto 33mA. Delivered via two 100mm x 50mm adhesive pads placed on the anterior abdominal wall
62557143|NCT02941471|ACTIVE_COMPARATOR|Standard electrical stimulation|Medical Device: Standard electrical stimulation. Parameters set to provide continuous electrical stimulation at a pulse width of 210µs and a frequency of 14Hz and an amplitude upto 33mA.
62557144|NCT02001987|EXPERIMENTAL|Tocilizumab|Participants will receive tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection once a week administered as monotherapy or in combination with methotrexate or other csDMARDs (at investigator's discretion) for 24 weeks. Participants who complete the core study period will be allowed to enter a long-term-extension (LTE) period to continue study treatment for up to a maximum of another 52 weeks or until the commercial availability of SC tocilizumab, whichever occurs first.
62557145|NCT04750889||RFID tags localization|
62557146|NCT04750889||Wire localization|
62557147|NCT05969535|EXPERIMENTAL|intervention group|This group will consist of 35 primiparous pregnant women. The training program, prepared in line with travelbe's human-human relations model, will continue for a total of 4 weeks, 2 days a week.
62557148|NCT05969535|NO_INTERVENTION|control group|This group will consist of 35 primiparous pregnant women. No training program will be given to this group and routine pregnant follow-up will continue.
62755572|NCT01548313||Pregnant women from Izola region|Women at 3rd trimester of pregnancy living in the Izola region.
62755573|NCT01548313||Pregnant women from Murska Sobota region|Women at 3rd trimester of pregnancy living in the Murska Sobota region.
62755574|NCT05617053||DAART|Popliteal artery lesion treated by directional atherectomy with anti-restenotic therapy for the treatment of popliteal atherosclerotic lesions.
62755575|NCT05617053||ATP/Supera stenting|Angioplasty and Supera stent implantation for the treatment of popliteal atherosclerotic lesions.
62755576|NCT02413736|EXPERIMENTAL|Imatinib|Imatinib 400 mg/day for 24 months.
62755577|NCT02413736|NO_INTERVENTION|No imatinib|No further imatinib.
62755578|NCT04994782|NO_INTERVENTION|Usual care recipients|Participant dyads in this group will receive usual care (standard clinical education materials)
62755579|NCT04994782|EXPERIMENTAL|Usual care plus GAME-EOL intervention|Participant dyads in this group will receive usual care (standard clinical education materials) plus the GAME-EOL intervention.
62755580|NCT01900821||Women|All women having mammograms
62755581|NCT01409083|EXPERIMENTAL|intravenous bicarbonate|Diluted sodium bicarbonate will be injected to s new IV catheter expecting a rise in end-tidal CO2
62755582|NCT01409083|PLACEBO_COMPARATOR|control|equal volume of normal saline will be randomely injected
62755583|NCT03419377|EXPERIMENTAL|Standard care and sexological counseling|Standard care including gynecological examination and 6-8 sexological consultations.
62557149|NCT01400542||OSAS +|Patient with obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography
62557150|NCT01400542||OSAS -|Patient without obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography
62755584|NCT03419377|NO_INTERVENTION|Standard care|Standard care including gynecological examination.
62755585|NCT00820482|ACTIVE_COMPARATOR|Group A|Group A: 75 UI/day of Hp-hMG (Menopur®, Ferring, Copenhaghen, Dinamarca)
62755586|NCT00820482|EXPERIMENTAL|Group B|75UI/day of rFSH (Gonal®, Serono, Ginebra, Suiza) + 75UI/day of rLH (Luveris®, Serono, Ginebra, Suiza)
62755587|NCT00896363|ACTIVE_COMPARATOR|Active|Parallel Group - High Dose Arm, Low Dose Arm
62755588|NCT00896363|PLACEBO_COMPARATOR|Placebo|Parallel Group
62755589|NCT06605001|EXPERIMENTAL|Delay of Gratification - Treat|Reward presented is a sweet treat.
62755590|NCT06605001|EXPERIMENTAL|Delay of Gratification - Gift|Reward presented is a wrapped gift.
62755591|NCT01442506||Barrett|
62755592|NCT05684757|ACTIVE_COMPARATOR|Dietary Advice: Sweet Taste|Participants will be asked to reduce their free sugar intakes to less than 5% TEI. To aid with this, they will be asked to reduce their intakes of foods and drinks high in free sugars, and replace these with foods low in sugars, that remain high in sweet taste, eg. fruit, low-calorie sweetened foods and drinks. The intervention will be provided to participants in written form, in an opaque sealed envelope.
61986747|NCT02515955|EXPERIMENTAL|Cohort 6|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
61986748|NCT02515955|EXPERIMENTAL|Cohort 7|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
62557151|NCT05134311|EXPERIMENTAL|3D-US|These subjects will have a 3D rendering of their vascular testing shown to them.
62557152|NCT05134311|NO_INTERVENTION|Standard US|These subjects will be shown a hand drawn sketch of the results of the vascular testing.
62755593|NCT05684757|ACTIVE_COMPARATOR|Dietary Advice: Taste|Participants will be asked to reduce their free sugar intakes to less than 5% TEI. To aid with this, they will be asked to reduce their intakes of foods and drinks high in free sugars, and replace these with foods low in sugars, that remain high in taste, eg. nuts, foods and drinks flavoured with herbs and spices. The intervention will be provided to participants in written form, in an opaque sealed envelope.
62755594|NCT05684757|ACTIVE_COMPARATOR|Dietary Advice: No taste|Participants will be asked to reduce their free sugar intakes to less than 5% TEI. To aid with this, they will be asked to reduce their intakes of foods and drinks high in free sugars, and replace these with foods low in sugars, that are low in taste, eg. foods and drinks that are plain-flavoured, wholegrains. The intervention will be provided to participants in written form, in an opaque sealed envelope.
62755595|NCT04862949||Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab
62755596|NCT01126658||All subjects act as their own contral|
62755597|NCT00648674|EXPERIMENTAL|1|Apligraf
62755598|NCT04881929|EXPERIMENTAL|KN026 + Docetaxel|KN026 30 mg/kg IV + Docetaxel 75/m2 every 3 weeks for four cycles
62755599|NCT05034315|EXPERIMENTAL|Whole egg consumption|
62755600|NCT05034315|NO_INTERVENTION|No egg control|
62755601|NCT03600766|ACTIVE_COMPARATOR|Mirabegron|oral mirabegron 50 gm plus tamsulosin 0.4 mg once daily for 8 weeks
62755602|NCT03600766|ACTIVE_COMPARATOR|Placebo|oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
62755603|NCT05740605|EXPERIMENTAL|HABIT-ILE therapy at home without a HABIT-ILE follow-up at home|2 weeks of HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) therapy at home followed by 9 weeks of usual care
62755604|NCT05740605|EXPERIMENTAL|HABIT-ILE therapy at home with a HABIT-ILE follow-up at home|2 weeks of HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) therapy at home followed by 9 weeks of HABIT-ILE follow-up at home
62755605|NCT05740605|ACTIVE_COMPARATOR|Classic HABIT-ILE therapy without follow-up HABIT-ILE at home|2 weeks of classic HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) therapy on site followed by 9 weeks of usual care
62755606|NCT05740605|ACTIVE_COMPARATOR|Classic HABIT-ILE therapy with follow-up HABIT-ILE at home|2 weeks of classic HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) therapy on site followed by 9 weeks of HABIT-ILE follow-up at home
62755607|NCT00446472|EXPERIMENTAL|1|Randomized to Regranex gel
62755608|NCT00446472|ACTIVE_COMPARATOR|2|Placebo hydrogel will be used for a total of 16 weeks
62182491|NCT01113671|PLACEBO_COMPARATOR|Placebo|
62557153|NCT03711097|NO_INTERVENTION|Control|Upper left or right central and lateral incisor
62557154|NCT03711097|EXPERIMENTAL|Varnish Intervention|Upper central and lateral incisor contralateral to control upper central and lateral incisor
62557155|NCT05397080|EXPERIMENTAL|TAU + multicomponent treatment VIRTUAL FIBROWALK|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
62755609|NCT01779869|EXPERIMENTAL|Single group assignment - imaging|All patients will undergo PET-MR myocardial perfusion imaging during rapid intravenous administration of 0.4 mg regadenoson.
62755610|NCT02274272|PLACEBO_COMPARATOR|Placebo Capsules|
62755611|NCT02274272|EXPERIMENTAL|ADR-1|Lactobacillus reuteri GMNL-89
62755612|NCT02274272|EXPERIMENTAL|GMNL-263|Lactobacillus reuteri GMNL-263
62755613|NCT01327053|EXPERIMENTAL|LDE225 200 mg|The study was double blinded and enrolled at least 50 evaluable patients in the 200 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.
62755614|NCT01327053|EXPERIMENTAL|LDE225 800 mg|The study was double blinded and enrolled at least 100 evaluable patients in the 800 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.
62755615|NCT06080646||MDD (Major Depressive Disorder) Group|Individuals (ages 18-70 years) who meet DSM-5 criteria for MDD, as assessed using the Structured Clinical Interview for DSM-5 (SCID-5), with Stable psychiatric medication regime for \> 1 month will be recruited for participation in EEG and fMRI sessions in this observational study.
62755616|NCT06080646||Unaffected Comparison Group|50 unaffected comparison participants will be matched as a group to the age, race, educational level, handedness, and parental socio-economic status of the MDD patient group will be recruited for participation in EEG and fMRI testing sessions identical to those administered to the patients
62755617|NCT02562508|EXPERIMENTAL|9-17y (0,1,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
62755618|NCT02562508|EXPERIMENTAL|9-14y (0,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
62557156|NCT05397080|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
62557157|NCT05397080|ACTIVE_COMPARATOR|TAU + multicomponent treatment VIRTUAL + 4 face-to-face sessions|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training. In this arm a 4 face-to-face session will be added to solve doubts and emphasize the most important points of therapy
62755619|NCT02562508|EXPERIMENTAL|18-26y (0,1,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
62755620|NCT06225024|ACTIVE_COMPARATOR|BoNT-A|BoNT-A was injected into the affected gastrocnemius muscle under ultrasonography guidance at doses recommended by standard guidelines and appropriate for the patient (50 IU to the medial head, 25 IU to the lateral head). In addition, conventional physical therapy exercises (stretching exercises, range of motion (ROM) exercises, neurophysiologic exercises, and gait exercises) were applied to the patients five days a week for four weeks.
62755621|NCT06225024|EXPERIMENTAL|BoNT-A and ESWT|In addition to the treatments (BoNT-A injection and exercise) in Group 1, one week after the injection, a total of 4 sessions (2 days a week) of ESWT (1000 impulses with an energy density of 0.1 mj/mm2, pressure of 2 bar, and frequency of 4 Hz) were applied to the medial and lateral heads of the gastrocnemius muscle.
62755622|NCT02418208||Test retest- 2 visits|Eligible participants will arrive for 2 testing visits a week apart and an optional third visit within 6-12 months.
62755623|NCT02418208||Single Visit|Eligible participants will arrive for a single testing visit
62755624|NCT01384331|ACTIVE_COMPARATOR|Group 1 Marvelon ,placebo|"7 days daily intake of oral capsule containing Marvelon ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules containing starch for 21 day treatment Cycle"
62755625|NCT01384331|ACTIVE_COMPARATOR|Marvelon|"* 21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~* for one cycle of 21 days"
61986749|NCT02515955|EXPERIMENTAL|Cohort 8|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
62182492|NCT01113671|EXPERIMENTAL|d-alpha-tocopheryl acetate|
62378577|NCT02628366|EXPERIMENTAL|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention arm will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
62755626|NCT01384331|ACTIVE_COMPARATOR|NuvaRing|21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days Treatment will be for 21 days
62755627|NCT01384331|PLACEBO_COMPARATOR|Starch capsule|21 days daily oral placebo capsules Treatment will be for one 21 day cycle
62755628|NCT06608342|EXPERIMENTAL|Autologous hematopoietic stem cell transplantation combined with CD19-CART|
62755629|NCT05785741|EXPERIMENTAL|DB-1310 Dose Level 1|Enrolled Subjects will receive a single-dose of DB-1310 at Dose Level 1 on Day 1 of each cycle Q3W
61986750|NCT04318509|EXPERIMENTAL|PKU GMPOWER|(casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years
61986751|NCT04720729|EXPERIMENTAL|Single arm|Patients with HER2-negative metastatic breast cancer, starting a second line of chemotherapy
61986752|NCT05797493||ES-SCLC|ES-SCLC receiving upfront chemo-immunotherapy
62378578|NCT02628366|NO_INTERVENTION|Fixed Dialysate Temperature at 36.5°C|Dialysis centres in the control group will provide usual care, which is standard dialysis using a fixed dialysate temperature of 36.5°C
62378579|NCT01742182|NO_INTERVENTION|Control|
62378580|NCT01742182|NO_INTERVENTION|PD patients without sleep problems|
62378581|NCT01742182|ACTIVE_COMPARATOR|PD patients with sleep problems|light exposure
62378582|NCT01742182|PLACEBO_COMPARATOR|PD patients with sleep problem|light exposure
62378583|NCT02289118||Diagnostic Imaging|\[18F\]T807 imaging tracer.
62378584|NCT00443534|EXPERIMENTAL|1|
62378585|NCT00098865|EXPERIMENTAL|Thalidomide and Temozolomide|"Thalidomide:~Oral thalidomide on days 1-28 of a 28 day cycle initiated at 3 mg/kg and increased to maximum dose of 24 mg/kg or 1000 mg as tolerated.~Temozolomide:~Oral temozolomide on days 1-5 of 28 day cycle given at 200 mg/m2 or 150 mg/m2 for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal radiation.~Patients were treated for 6 cycles unless disease progression or excessive toxicity. Treatment could continue beyond 6 cycles if absent disease progression"
62378586|NCT05972577|EXPERIMENTAL|Supportive care (GO!)|Patients undergo personalized GO! plan consisting of study visits over 50 minutes at baseline and 6 months after first visit or at the time of hospital admission for bone marrow transplant and over 25 minutes at 3 and 12 months after transplant. Patients complete questionnaires once a month for up to 6 months and wear an accelerometer for up to 6 months.
62378587|NCT05431972|EXPERIMENTAL|Cardea SOLO|for 7 day holter monitor (patch type)
62378588|NCT05431972|ACTIVE_COMPARATOR|12 Lead EKG|(traditional EKG for under 2 minutes)
62378589|NCT03208504|EXPERIMENTAL|Treatment|All subjects in treatment arm will be implanted with the Single Branch Nexus™ Aortic Arch Stent graft System.
62378590|NCT03254849|EXPERIMENTAL|empagliflozin 25 mg|Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 1: 25 mg/d empagliflozin + hydrochlorothiazide placebo
62378591|NCT03254849|EXPERIMENTAL|hydrochlorothiazide 25 mg|Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 2: 25 mg/d hydrochlorothiazide + empagliflozin placebo
61986753|NCT00777647|EXPERIMENTAL|Sugar-sweetened soft drink|54g sugar/L, 180kJ/100mL
62557158|NCT02986529|ACTIVE_COMPARATOR|GV-971 150mg/capsule|900mg, oral
62557159|NCT02986529|EXPERIMENTAL|GV-971 300mg/capsule|900mg, oral
62755630|NCT05785741|EXPERIMENTAL|DB-1310 Dose Level 2|Enrolled Subjects will receive a single-dose of DB-1310 at Dose Level 2 on Day 1 of each cycle Q3W
62755631|NCT05785741|EXPERIMENTAL|DB-1310 Dose Level 3|Enrolled Subjects will receive a single-dose of DB-1310 at Dose Level 3 on Day 1 of each cycle Q3W
62755632|NCT05785741|EXPERIMENTAL|DB-1310 Dose Level 4|Enrolled Subjects will receive a single-dose of DB-1310 at Dose Level 4 on Day 1 of each cycle Q3W
62755633|NCT05785741|EXPERIMENTAL|DB-1310 Dose Level 5|Enrolled Subjects will receive a single-dose of DB-1310 at Dose Level 5 on Day 1 of each cycle Q3W
62755634|NCT05785741|EXPERIMENTAL|DB-1310 Dose Expansion 1|Enrolled Subjects with advanced/unresectable, or metastatic adenocarcinoma NSCLC with EGFR activating mutation who have progressed on or after standard systemic treatments will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
62755635|NCT05785741|EXPERIMENTAL|DB-1310 Dose Expansion 2|Enrolled Subjects with advanced/unresectable, or metastatic NSCLC without EGFR activating mutation who have progressed on or after standard systemic treatments will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
62378592|NCT02158000|ACTIVE_COMPARATOR|Group A|In group A , 100 women with excessive endometrial fluid by transvaginal ultrasound during ICSI cycles are allocated to receive one tab / 8 hs of Diosmin ( 500mg) beginning from the day of ovum retrieval and for 3 days (till the day of embro trasfer) in addition to aspiration of the fluid by an IUI catheter.
62755636|NCT05785741|EXPERIMENTAL|DB-1310 Dose Expansion 3|Enrolled Subjects with advanced/unresectable, or metastatic CRPC who have progressed on or after standard systemic treatments will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
61986754|NCT00777647|EXPERIMENTAL|Aspartame-sweetened soft drink|1.5kJ/100mL
61986755|NCT00777647|ACTIVE_COMPARATOR|Semi-skimmed milk|202kJ/100mL
62378593|NCT02158000|NO_INTERVENTION|Group B|In group B (control group) 100 women with excessive endometrial fluid by transvaginal ultrasound during ICSI cycles, no thing will be done
62378594|NCT01524809|EXPERIMENTAL|Treatment period 1|
62755637|NCT05785741|EXPERIMENTAL|DB-1310 Dose Expansion 4|Enrolled Subjects with advanced/unresectable, or metastatic HNSCC who have progressed on or after standard systemic treatments will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
62755638|NCT05785741|EXPERIMENTAL|DB-1310 Dose Expansion 5|Enrolled Subjects with advanced/unresectable, or metastatic BC with HER2-positive (IHC3+, or IHC2+ and ISH+) who have progressed on or after HER2 targeted systemic treatments will receive a single-dose of DB-1310 on a selected dose level Day 1 of each cycle Q3W in combination with trastuzumab deruxtecan.
62755639|NCT05785741|EXPERIMENTAL|DB-1310 Dose Expansion 6|Enrolled Subject with other advanced/unresectable, or metastatic solid tumors who have progressed on or after standard systemic treatment, or for which no standard systemic treatment is available will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
62557160|NCT02986529|EXPERIMENTAL|GV-971 450mg/capsule|900mg, oral
62557161|NCT02986529|PLACEBO_COMPARATOR|Placebo|Oral
62557162|NCT05436795|EXPERIMENTAL|Interventional Arm|In the interventional arm, we will offer a self-administered supervised COVID-19 testing strategy with an investigational device - Abbott's Panbio COVID-19 Antigen Self-test. The self-test process will be facilitated by the COVIDSmart CARE! digital App and platform. Suspected COVID-19 patients will be triaged into one of three action plans: a) clinical care pathways, b) prevention (home quarantine, isolation) pathways, or c) social distancing.
62755640|NCT05785741|EXPERIMENTAL|DB-1310 Dose Expansion 7|Enrolled subjects with advanced/unresectable, or metastatic non-squamous NSCLC with EGFR exon 19 deletion or L858R mutation who haven't received any treatment in locally advanced, or metastatic disease will receive a single-dose of DB-1310 on a selected dose level Day 1 of each cycle Q3W in combination with Osimertinib.
62755641|NCT05785741|EXPERIMENTAL|DB-1310 Dose Expansion 8|Enrolled subjects with NSCLC with EGFR who will receive DB-1310 on a selected dose level in combination with Osimertinib
62755642|NCT05785741|EXPERIMENTAL|DB-1310 Dose Expansion 9|Enrolled subjects with NSCLC with KRAS mutation who will receive DB-1310 on a selected dose level (RP2D)
62755643|NCT05785741|EXPERIMENTAL|DB-1310 Dose Expansion 10|Enrolled subjects with ESCC who will receive DB-1310 on a selected dose level (RP2D)
62755644|NCT05785741|EXPERIMENTAL|DB-1310 Dose Expansion 11|Enrolled subjects with BTC who will receive DB-1310 on a selected dose level (RP2D)
62378595|NCT01524809|EXPERIMENTAL|Treatment period 2|
62378596|NCT03844061|EXPERIMENTAL|MMF + Rituximab + Belimumab|Two infusions of 1000 mg of Rituximab, two weeks apart, weekly subcutaneous injections of 200 mg of Belimumab, and background MMF, 1000 -1500 mg twice daily for 48 weeks.
62755645|NCT05785741|EXPERIMENTAL|DB-1310 Dose Level 6|Enrolled subjects with HER2 positive BC who will receive DB-1310 on a selected dose level in combination with Trastuzumab
62755646|NCT05785741|EXPERIMENTAL|DB-1310 Dose Level 7|Enrolled subjects with HER2 positive BC who will receive DB-1310 on a selected dose level in combination with Trastuzumab
61986756|NCT00777647|PLACEBO_COMPARATOR|Water|0kJ/100mL
61986757|NCT00559520|ACTIVE_COMPARATOR|Impact|"patient receiving 3 drinks Impact a day during 5 days before surgery"
62378597|NCT03844061|PLACEBO_COMPARATOR|MMF + Placebo + Placebo|Two placebo infusions of normal saline, two weeks apart, weekly saline placebo subcutaneous injections, and background MMF, 1000 -1500 mg twice daily for 48 weeks.
62755647|NCT05785741|EXPERIMENTAL|DB-1310 Dose Level 8|Enrolled subjects with HER2 positive BC who will receive DB-1310 on a selected dose level in combination with Trastuzumab
62378598|NCT02916628|EXPERIMENTAL|Group 1|auricular acupressure + group counseling
62557163|NCT05436795|NO_INTERVENTION|Conventional Arm|"Participants presenting to test for SARS-CoV-2 will be staged on their self-reported severity of symptoms (mild, moderate, severe) and tested with rapid antigen tests, followed by RT-PCR testing. Suspected COVID-19 patients will be triaged into one of three action plans: a) clinical care pathways, b) prevention (home quarantine, isolation) pathways, or c) social distancing.~Conventional arm is the standard of care arm."
62557164|NCT01050530|EXPERIMENTAL|OPC-41061|
62755648|NCT05785741|EXPERIMENTAL|DB-1310 Dose Level 9|Enrolled subjects with NSCLC subjects with EGFR Ex19del or L858R, G719X, S768I, L861Q alone or in combination with other EGFRm who will receive DB-1310 on a selected dose level in combination with Osimertinib
62755649|NCT05785741|EXPERIMENTAL|DB-1310 Dose Level 10|Enrolled subjects with NSCLC subjects with EGFR Ex19del or L858R, G719X, S768I, L861Q alone or in combination with other EGFRm who will receive DB-1310 on a selected dose level in combination with Osimertinib
62755650|NCT05785741|EXPERIMENTAL|DB-1310 Dose Level 11|Enrolled subjects with NSCLC subjects with EGFR Ex19del or L858R, G719X, S768I, L861Q alone or in combination with other EGFRm who will receive DB-1310 on a selected dose level in combination with Osimertinib
62755651|NCT01080768|EXPERIMENTAL|Aliskiren/amlodipine + Placebo to amlodipine|"During the first week of active treatment, patients were instructed to take one tablet of aliskiren/amlodipine 150/5 mg and one capsule of placebo to amlodipine daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 2 tablets of aliskiren/amlodipine 150/5 mg/day and 1 capsule of placebo to amlodipine.~The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."
62557165|NCT01050530|PLACEBO_COMPARATOR|Placebo|
62557166|NCT05117216|EXPERIMENTAL|Parental Vigilant Care|3 sessions of group parental training
62557167|NCT05117216|ACTIVE_COMPARATOR|Technological Parental Monitoring|The installation of filtering devices on adolescents' mobile phones and setting them for reducing time use and prohibiting inappropriate content
62557168|NCT05117216|ACTIVE_COMPARATOR|PVC + TPM|combining both group parental training and installation of filtering devices
62557169|NCT05117216|NO_INTERVENTION|Control|Control group that did not receive any intervention
61986758|NCT00559520|EXPERIMENTAL|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
62557170|NCT05469672|ACTIVE_COMPARATOR|low-level laser therapy|LLLT will be performed 3 times a week for a period of 3 weeks
62557171|NCT05469672|ACTIVE_COMPARATOR|high-intensity laser therapy|HILT will be performed 3 times a week for a period of 3 weeks
62557172|NCT03565900|EXPERIMENTAL|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1, Day 30 and Day 60 and a single 0.5 mL IM injection of PNEUMOVAX™23 at 12 months after HSCT. Participants will have received HSCT 90 to 180 days prior to Day 1. Those who develop chronic graft-versus-host-disease (GVHD) during the first year after HSCT will receive V114 instead of PNEUMOVAX™23 as their fourth dose.
62378599|NCT02916628|PLACEBO_COMPARATOR|Group 2|placebo acupressure + group counseling
62378600|NCT02916628|NO_INTERVENTION|Group 3|self-help smoking cessation
62378601|NCT02916628|NO_INTERVENTION|Group 4|Non-smokers
62378602|NCT05894486|EXPERIMENTAL|Lutetium[177Lu] Oxodotreotide Injection|"Treatment consisted of a cumulative administered radioactivity of 29.6 Giga Becquerel (GBq) (800 mCi) Lutetium\[177Lu\] Oxodotreotide Injection: Four administrations of 7.4 GBq (200 mCi).~Concomitant amino acids were given with each administration for kidney protection.~Lutetium\[177Lu\] Oxodotreotide Injection was administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.~In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections were allowed."
62378603|NCT01713907|EXPERIMENTAL|Ulthera® treatment|All enrolled subjects will receive one full face and neck Ulthera® treatment.
62378604|NCT05598840|EXPERIMENTAL|APP group|Four months before surgery, the C4T APP, in addition to standard protocol, will be provided to all the patients randomized in the APP group.
61986759|NCT03696810|OTHER|• Laboratory tests|• Laboratory tests (HbA1C levels and lipids)
62378605|NCT05598840|ACTIVE_COMPARATOR|Normal VLCD (Very Low Calory Diet) group|Normal preoperative standard protocol will be provided to all the patients randomized in the normal group.
62378606|NCT02563886|EXPERIMENTAL|EAMT, then standard care|Electrically Assisted Movement Therapy precedes usual and customary care.
62378607|NCT02563886|ACTIVE_COMPARATOR|Standard care, then EAMT|Usual and customary care precedes Electrically Assisted Movement Therapy.
62378608|NCT03795545|ACTIVE_COMPARATOR|Ultraslow shock wave lithotripsy (SWL)|"SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes.~The rest of the session at 22kv (full power)."
62378609|NCT03795545|ACTIVE_COMPARATOR|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
62378610|NCT00836953|EXPERIMENTAL|Study Group|Participants received 2 doses of Fluzone® vaccine
62378611|NCT05391412|EXPERIMENTAL|Fibrinogen group|The fibrinogen concentrate (20-30mg/kg, max 2g) will be administered in 100ml (Aqua pro injection) intravenously to the patient.
62378612|NCT05391412|NO_INTERVENTION|Control group|Patients in the control group will not receive any additional medication than standard of care.
62378613|NCT03080441|EXPERIMENTAL|Phase 1 Group 1|pressure stockings worn during dialysis treatment
62378614|NCT03080441|EXPERIMENTAL|Phase 1 Group 2|Midodrine before dialysis treatment
62378615|NCT03080441|EXPERIMENTAL|Phase 1 Group 3|pressure stocking and Midodrine
62378616|NCT00533780|EXPERIMENTAL|MRI high resolution 3D diffusion|Total duration is about 8 minutes.
62378617|NCT05340816|EXPERIMENTAL|Manual Lymphatic Drainage|5 days, 30 minutes, Manual Lymphatic Drainage
62378618|NCT05340816|EXPERIMENTAL|Transcutaneous Electrical Nerve Stimulation|5 days, 20 minutes, Transcutaneous Electrical Nerve Stimulation
62378619|NCT05340816|NO_INTERVENTION|Control|no any intervention
62378620|NCT04949633|EXPERIMENTAL|Induction of labor|women randomized in the experimental group will be admitted to the labor ward to undergo induction of labor with intra-veinous oxytocin and early amniotomy. Oxytocin will be administered according to the French guidelines for induction of labor. Maximum oxytocin used should not exceed 10 UI.
62378621|NCT04949633|ACTIVE_COMPARATOR|Second cervical ripening|"women randomized in the control group will undergo a second cervical ripening lasting a maximum of 24 hours with either:~* Vaginal slow releasing system of dinoprostone PROPESS® which is inserted in the vagina, against the cervix and left in place during 24 hours.~* Oral misoprostol (ANGUSTA®) 25 µg every 2 hours, 8 times (maximum dosage should not exceed 200µg). Tablets will be given one at the time by midwives.~* Vaginal gel of dinoprostone (2 mg PROSTINE®) every 6 hours, maximum dose of 6 mg.~The choice of the cervical ripening agent will depend of the local protocol of the participating maternity unit. The choice between ANGUSTA®, PROPESS® and PROSTINE® will be made by investigators of each participating unit at the beginning of the trial.~At the end of the second cervical ripening procedure women not in labor will be transferred to the labor ward for induction of labor with oxytocin."
62378622|NCT04170855|OTHER|Furosemide Injection|"Patients with diuretic resistance:~The presence of diuretic resistance, defined as having clinical signs of fluid overload despite diuretic therapy (this information is routinely collected at each clinical visit). Fluid overload is defined as the presence of at least two of the following clinical features:~* Peripheral or sacral oedema~* Jugular venous distension ≥ 7 cm~* Radiographic pulmonary oedema or pleural effusion~* Enlarged liver or ascites~* Pulmonary rales, paroxysmal nocturnal dyspnoea, or orthopnoea~* Point of Care UltraSound (POCUS) evidence of congestion. Inferior Vena Cava diameter \>2.5 cm and/or failure to collapse at least 50% with sharp inspiration"
61986760|NCT01367158|EXPERIMENTAL|3ABCWY|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of the same in current study
62755652|NCT01080768|ACTIVE_COMPARATOR|Amlodipine + Placebo to aliskiren/amlodipine|"During the first week of active treatment, patients were instructed to take one capsule of amlodipine 5 mg and one tablet of placebo to aliskiren/amlodipine 150/5 mg daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 1 capsule of amlodipine 10 mg/day and 2 tablets of placebo to aliskiren/amlodipine 150/5 mg/day.~The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."
62755653|NCT00534287|ACTIVE_COMPARATOR|MeroMono|Monotherapy with meropenem
62755654|NCT00534287|ACTIVE_COMPARATOR|MeroMoxi|Combination therapy with meropenem + moxifloxacin
62378623|NCT05375656|ACTIVE_COMPARATOR|Traditional Inuit Diet|"The traditional Inuit diet will consist of local foods, being primarily of animal origin, e.g. fish, marine mammals, caribou, and lamb. The diet will be supplemented with eggs, potatoes, and berries, and/or other foods low in starch and with no sucrose content. The diet will therefore have a high content of fat and protein, a low content of carbohydrate and no content of sucrose.~The participants will receive foods that will cover at least 100% of their energy requitement. Each participant will throw a dice in order to randomize the order of which the participants receive the two intervention diets."
62557173|NCT03565900|ACTIVE_COMPARATOR|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1, Day 30 and Day 60 and a single 0.5 mL IM injection of PNEUMOVAX™23 at 12 months after HSCT. Participants will have received HSCT 90 to 180 days prior to Day 1. Those who develop chronic GVHD during the first year after HSCT will receive Prevnar 13™ instead of PNEUMOVAX™23 as their fourth dose.
62557174|NCT01762800|EXPERIMENTAL|fluticasone propionate/salmeterol|Randomised treatment at Visit 2
62557175|NCT01762800|EXPERIMENTAL|tiotropium bromide|Randomised treatment at Visit 2
62557176|NCT03685916|OTHER|Control|50 grams carbohydrate in the form of rice, 200 milliliters of plain water and 20 grams of garden peas.
62557177|NCT03685916|EXPERIMENTAL|Cumin Rice|50 grams carbohydrate in the form of rice with cumin, 200 milliliters of plain water and 20 grams of garden peas.
62557178|NCT03685916|EXPERIMENTAL|Cumin Drink|50 grams carbohydrate in the form of rice, 200 milliliters of cumin extract in solution and 20 grams of garden peas.
62557179|NCT03685916|EXPERIMENTAL|Cornsilk Rice (Low dose)|50 grams carbohydrate in the form of rice with cornsilk extract (low dose), 200 milliliters of plain water and 20 grams of garden peas.
62557180|NCT03685916|EXPERIMENTAL|Cornsilk Rice (High dose)|50 grams carbohydrate in the form of rice with cornsilk extract (high dose), 200 milliliters of plain water and 20 grams of garden peas.
62557181|NCT03685916|EXPERIMENTAL|Cornsilk Drink (Low dose)|50 grams carbohydrate in the form of rice, 200 milliliters of cornsilk extract (low dose) in solution and 20 grams of garden peas.
62557182|NCT03685916|EXPERIMENTAL|Cornsilk Drink (High dose)|50 grams carbohydrate in the form of rice, 200 milliliters of cornsilk extract (high dose) in solution and 20 grams of garden peas.
62557183|NCT03685916|EXPERIMENTAL|Tamarind Rice|50 grams carbohydrate in the form of rice with Tamarind, 200 milliliters of plain water and 20 grams of garden peas.
62557184|NCT03685916|EXPERIMENTAL|Tamarind Drink|50 grams carbohydrate in the form of rice, 200 milliliters of Tamarind extract in solution and 20 grams of garden peas.
62557185|NCT02969044|EXPERIMENTAL|PF-06651600|Study Drug
62557186|NCT02969044|PLACEBO_COMPARATOR|Placebo|Placebo
62557187|NCT02737241|ACTIVE_COMPARATOR|LP-HoLEP|Low power Holmium laser enucleation of the prostate
62557188|NCT02737241|ACTIVE_COMPARATOR|HP-HoLEP|High power Holmium laser enucleation of the prostate
62557189|NCT00664079||1|Patients who are receiving vasoactive medications and/or are mechanically ventilated.
62755655|NCT06609018|EXPERIMENTAL|Test Lenses, Then Control Lenses|Participants will wear the Test Lenses in both eyes for one week and then cross over to the Control Lenses in both eyes for one week.
62557190|NCT01817296|EXPERIMENTAL|Single arm|
62557191|NCT03854903|EXPERIMENTAL|Dose Level A1|"* Palbociclib: 75mg daily for 21 days of each 28 day cycle~* Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle~* Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
62557192|NCT03854903|EXPERIMENTAL|Dose Level A2|"* Palbociclib: 75mg daily for the first 21 days of each 28 day cycle~* Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle"
61986761|NCT01367158|EXPERIMENTAL|2ABCWY|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of Tdap in current study
62557193|NCT03854903|EXPERIMENTAL|Dose Level B1|"* Palbociclib: 100mg daily for 21 days of each 28 day cycle~* Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle~* Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
62557194|NCT03854903|EXPERIMENTAL|Dose Level B2|"* Palbociclib: 100mg daily for 21 days of each 28 day cycle~* Bosutinib: 500mg on days 1-5 of each week of the 28 day cycle~* Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
62557195|NCT02301169|ACTIVE_COMPARATOR|T4P1001|
62557196|NCT02301169|SHAM_COMPARATOR|Placebo|
62557197|NCT04682392|ACTIVE_COMPARATOR|Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction Group|This group will use Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction for rehab.
62755656|NCT06609018|EXPERIMENTAL|Control Lenses, Then Test Lenses|Participants will wear the Control Lenses in both eyes for one week and then cross over to the Test Lenses in both eyes for one week.
62755657|NCT04853693|EXPERIMENTAL|Mom´s Supporting Mom (MSM)|A preventive intervention that involves psychoeducation and peer techniques described in study detailed description.
62557198|NCT04682392|ACTIVE_COMPARATOR|Non Delfi PTS Personalized Tourniquet System for Blood Flow Restriction Group|Standard post operative ACL rehab without Blood flow restriction
62755658|NCT04853693|ACTIVE_COMPARATOR|Enhanced Treatment as Usual|Referral to treatment in the community and monitoring
62378624|NCT05375656|EXPERIMENTAL|Western Carbohydrate-Rich Diet|"The Western diet will have high amounts of grain products, e.g. bread, pasta, rice, as well as fruits and vegetables and some foods with a high sucrose content, e.g. cake and sweet snacks and/or drinks, and cereal products with added sucrose. The diet will have a low amount of meat. Hence, the diet will be high in carbohydrates, starch, and some sucrose and have a lower content of protein and fat.~The participants will receive foods that will cover at least 100% of their energy requitement. Each participant will throw a dice in order to randomize the order of which the participants receive the two intervention diets."
62755659|NCT00825058|EXPERIMENTAL|1|
62755660|NCT00825058|PLACEBO_COMPARATOR|2|
62755661|NCT00825058|ACTIVE_COMPARATOR|3|
62755662|NCT02345668|EXPERIMENTAL|Transdiagnostic Internet-based Treatment|Intervention group that carries out the Emotion Regulation Protocol and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages)
62755663|NCT02345668|EXPERIMENTAL|Treatment as Usual|Intervention group that receives psychological and/or pharmacological treatment from a clinician of the mental health unit.
62755664|NCT02229214|EXPERIMENTAL|VI-0521 (Qsymia)|"* Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)~* Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)~* Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)~* Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)"
62378625|NCT03485404|EXPERIMENTAL|VB12+FA|Patients will receive oral supplementation of 0.5mg methylcobalamin, 3/day and 5 mg folic acid, 1/day for 7 days before non-cardiac surgery.
62378626|NCT03485404|PLACEBO_COMPARATOR|Placebo|Patients with receive oral tablets of placebo for folic acid 1/d and placebo for methylcobalamin 3/d, which look exactly like the interventional drugs as oral supplementation for 7 days before non-cardiac surgery.
62378627|NCT03485404|OTHER|Non-surgical controls|Age and sex-matched community elderly people are included for two sessions of NPB test evaluation for calculation of POCD incidence as normal control to in Z value calculation of POCd incidence to rule out learning effect.
62557199|NCT00648778|EXPERIMENTAL|1|Loxapine Succinate Capsules 25 mg
62557200|NCT00648778|ACTIVE_COMPARATOR|2|Loxitane® Capsules 25 mg
62557201|NCT02780258|EXPERIMENTAL|Restylane Silk Treated Hand|The dorsal aspect of one hand will be injected with Restylane Silk.
62755665|NCT02229214|PLACEBO_COMPARATOR|Sugar pill|Days 1-28: Placebo
62755666|NCT00452036||Minor head injury|patients with minor head injury
62755667|NCT00452036||minor head injury|patients with minor head injury
62755668|NCT01080066||Non-Interventional Study|
62378628|NCT02411877|ACTIVE_COMPARATOR|Normothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using the Trevo Pro Retriever (Stryker), after which normothermia will attempt to keep core body temp between 38 and 36.5 degrees centigrade.
62755669|NCT04860895|OTHER|Nasopharyngeal swabs|Nasopharyngeal swabs samples of volunteers who is referred with suspicion of Covid19.
62755670|NCT02509039|EXPERIMENTAL|CC-122|CC-122 is administered orally, on a 5 continuous days out of 7 days per week intermittent dosing schedule.
62755671|NCT02845479|EXPERIMENTAL|Integrative Care Intervention|Broad-based, multi-agent integrative care program delivered by naturopathic doctors (ND) in conjunction with standard surgical and oncologic care.
62755672|NCT01806025||Cystic Fibrosis Patients|Patients with Cystic Fibrosis with two known severe (class I and class II) mutations
62755673|NCT00629746|EXPERIMENTAL|NIM (Nerve Integrity Monitor)|
62755674|NCT04503161|EXPERIMENTAL|Hydrogel recipient|
61986762|NCT01367158|EXPERIMENTAL|3ABx2CWY|two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of the same in current study
62755675|NCT04730778||CIN|"STEMI patients who develop CIN contrast induced nephropathy within 1 week from primary PCI."
62755676|NCT04730778||Control|STEMI patients who do not meet criteria of CIN through 1 week post primary PCI
62755677|NCT01434394|EXPERIMENTAL|Neo-adjuvant Erbitux-based chemotherapy|Neo-adjuvant Erbitus-based chemotherapy before surgery: Erbitus, Docetaxel, Cisplatin.
61986763|NCT01367158|EXPERIMENTAL|2ABx2CWY|two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of Tdap in current study
61986764|NCT01367158|EXPERIMENTAL|3ABCWY+OMV|Two doses Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus outer membrane vesicles (OMV) in previous study and one dose of the same in current study
62557202|NCT02780258|NO_INTERVENTION|Control Hand|The dorsal aspect of the hand that is not treated will be used for baseline comparison.
62557203|NCT01870778|EXPERIMENTAL|Serelaxin (RLX030)|Participants received continuous intravenous infusion of serelaxin 30 ug/kg/day for 48 hours.
62557204|NCT01870778|PLACEBO_COMPARATOR|Placebo|Participants received continuous intravenous infusion of matching placebo to serelaxin for 48 hours.
62557205|NCT01417637|ACTIVE_COMPARATOR|low level laser|"In this group, the 890 nm diode laser (Ga As) Mustang 2000+, Russia) with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the painful muscles.~Laser therapy for both the treatment and placebo groups will be applied on all painful muscles three times a week for four weeks."
62557206|NCT01417637|PLACEBO_COMPARATOR|Placebo|In Group 2 (placebo) the low power laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
62557207|NCT04343846||group A|low birth weight children
62557208|NCT04343846||group B|normal birth weight children
62557209|NCT02566681|EXPERIMENTAL|MSC construct for Osteonecrosis|Patients with definite diagnosis of osteonecrosis of the jaw by clinical and radiological examination of any etiology will receive a construct made of Bone Marrow Stem Cell + Tricalcium Phosphate + Demineralized Bone Matrix (MSC+TP+DBM).
62755678|NCT01434394|NO_INTERVENTION|Surgery and radiotherapy|Surgery and post-operative radiotherapy.
62755679|NCT06537297|EXPERIMENTAL|Intrathecal Pemetrexed with double Furmonertinib plus bevacizumab|
62755680|NCT04508751|OTHER|Healthy Pregnancy|"Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.~Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded."
62755681|NCT04508751|OTHER|Pregnant Mothers with gestational diabetes|"Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.~Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded."
62755682|NCT04508751|OTHER|Pregnant Mothers with infants diagnosed with IUGR|"Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.~Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded."
62755683|NCT01284478|OTHER|Dexamethasone Implant|Patients will be treated with the Ozurdex (Dexamethasone Implant)
62755684|NCT05144880|EXPERIMENTAL|electroacupuncture with 2Hz group|
62755685|NCT05144880|EXPERIMENTAL|electroacupuncture with 100Hz group|
61986765|NCT01367158|EXPERIMENTAL|2ABCWY+OMV|Two doses Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus outer membrane vesicles (OMV) in previous study and one dose of Tdap in current study
62755686|NCT02240368||Group 1|Children age between 1 month to 12 months
62755687|NCT02240368||Group 2|Children age between 13 months and 36 months
62755688|NCT02240368||Group 3|Children age between 37 months to 144 months
62755689|NCT05815836||Acute Ischemic Stroke|504 patients admitted to a specialized stroke service because of an acute ischemic stroke. The circulating proteome and metabolome as well as specific molecular targets of interest (i.e. NfL) will be assessed upon admission (day 1), the next morning (day 2), day 3, day 7 (or day of discharge if earlier), and day 90. Routinely collected clinical data including from neuroimaging will be collected throughout hospitalization. Clinical follow-up will be performed at 3 months.
62755690|NCT05815836||Acute Intracerebral hemorrhage|130 patients admitted to a specialized stroke service because of an acute intracerebral hemorrhage. The circulating proteome and metabolome as well as specific molecular targets of interest (i.e. NfL) will be assessed upon admission (day 1). Routinely collected clinical data including from neuroimaging will be collected throughout hospitalization.
62755691|NCT05815836||Stroke Mimics|51 patients admitted to the emergency department because of acute stroke-like symptoms caused by epileptic seizures, migraine attacks, or other stroke-mimicking diseases. The circulating proteome and metabolome as well as specific molecular targets of interest (i.e. NfL) will be assessed upon admission (day 1), the next morning (day 2), day 3, day 7, and day 90. Routinely collected clinical data including from neuroimaging will be collected throughout hospitalization.
62755692|NCT05815836||Healthy subjects|102 subjects without acute neurological symptoms. The circulating proteome and metabolome as well as specific molecular targets of interest (i.e. NfL) will be assessed.
62755693|NCT05199376|EXPERIMENTAL|Percutaneous cryotherapy|Cryoablation of the tumor
62755694|NCT04618042|EXPERIMENTAL|FX06|
62755695|NCT04618042|PLACEBO_COMPARATOR|Placebo|
62755696|NCT02516293|EXPERIMENTAL|Intervention group|"* Physical exercise intervention~* Nutritional counseling~* Pharmaceutical counseling"
62755697|NCT02789670||MS patients|MS patient group is composed by 20 Individuals with inflammatory brain lesions seen in MRI (Radiologically Isolated syndrome) 20 patients with only one clinically isolated syndrome (CIS) 20 patients with relapsed remittent Multiple sclerosis (RRMS) 20 patients with primary progressive Multiple Sclerosis (PPMS)
62755698|NCT02789670||Control group patients|"Control patient cohort is composed by 20 patients suffering from inflammatory neurological disease other than MS Devic syndrome, Neurosarcoidosis, Neurobehcet... (autoimmune disease control group with neurological disease) 20 patients with systemic sclerosis (autoimmune disease control group) without neurological disease)~40 healthy subjects"
62755699|NCT02029716|PLACEBO_COMPARATOR|Part A|RTA 408 lotion 0.5%, 1%, and 3% and lotion vehicle applied to skin twice daily for 14 days
62755700|NCT02029716|EXPERIMENTAL|Part B|Up to 3% RTA 408 lotion applied to skin twice daily for 14 days (% concentration to be determined, based on results from Part A, \~100 cm2 surface area)
62755701|NCT02029716|EXPERIMENTAL|Part C|3% RTA 408 lotion applied to skin twice daily for 28 days (\~500 cm2 surface area)
62755702|NCT02157441|EXPERIMENTAL|all patients|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
62755703|NCT01563120|ACTIVE_COMPARATOR|metformin|metformin up to 2550mg per day
62755704|NCT01563120|ACTIVE_COMPARATOR|glybenclamide|glybenclamide up to 20mg per day.
62755705|NCT04690907|EXPERIMENTAL|Intervention group|Dietary intervention: Written material on healthy diet during pregnancy, 2 virtual dietary counseling sessions given by a dietician. Otherwise basic care and counseling at maternity care clinics.
62755706|NCT04690907|NO_INTERVENTION|Control group|Written material on healthy diet during pregnancy, otherwise basic care and counseling at maternity care clinics.
62755707|NCT04338724|EXPERIMENTAL|CS1002|
62557210|NCT05787626|EXPERIMENTAL|Interventional group|The intervention consists of the application of a myofascial technique in the diaphragmatic region, one hand of the therapist will be placed on the hemidiaphragm to be treated and the other hand on the same side but on the dorsal part of the patient on the costal edge of the last ribs.
62557211|NCT05787626|SHAM_COMPARATOR|Control group|In the subjects of the control group, the hands will be placed in the same position but without any therapeutic intention, applying the minimum possible pressure.
62557212|NCT06458465|NO_INTERVENTION|No Intervention: Patients receiving no intervention|Group one will not receive add-on therapy; they will receive standard care only.
62755708|NCT00742365||A|Participants will be given a 1-hour lab test of bright light treatment, then the bright light treatment for 6 weeks.
62755709|NCT00742365||B|Participants will be given a 1-hour treatment of the red light placebo, then the bright light treatment for 6 weeks.
62557213|NCT06458465|ACTIVE_COMPARATOR|Active Comparator: Patients receiving curcumin|Group two will receive curcumin as an add-on therapy on daily basis
62557214|NCT06458465|ACTIVE_COMPARATOR|Active Comparator: Patients receiving pentoxiphylline|Group three will receive pentoxiphylline as an add-on therapy on daily basis
62557215|NCT01311687|EXPERIMENTAL|Pomalidomide + Low-Dose Dexamethasone|Participants received 4 mg pomalidomide administered by mouth on Days 1 to 21 of each 28-day treatment cycle and 40 mg dexamethasone (or 20 mg for participants \> 75 years of age) administered by mouth once per day on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression.
62755710|NCT00198861||Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors
62755711|NCT01799239|EXPERIMENTAL|First Test product; then SenSura|"The subject in this arm first test the Test product The test product is a newly developed ostomy appliance with a new top film. Due to company confidentiality the product is not described in further details.~After cross-over the subject test SenSura which is CE-marked and commerical available."
62755712|NCT01799239|ACTIVE_COMPARATOR|First SenSura, Then Test product|"The subject in this arm first test SenSura which is CE-marked and commerical available.~After cross-over the subject test the Test product The test product is a newly developed ostomy appliance with a new top film. Due to company confidentiality the product is not described in further details."
62557216|NCT01311687|ACTIVE_COMPARATOR|High-Dose Dexamethasone|Participants received 40 mg dexamethasone (or 20 mg for participants \> 75 years of age) administered by mouth once per day on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day treatment cycle until disease progression.
62755713|NCT03163693|EXPERIMENTAL|Group dexmedetomidine|20 eligible patients are received 0.5ug/kg dexmedetomidine intravenously 15 minutes before surgery
62755714|NCT03163693|PLACEBO_COMPARATOR|Group control|20 eligible patients are received equal volumes normal saline intravenously 15 minutes before surgery
62755715|NCT02538562||Study Population|Available tumor samples from patients with gastric or gastroesophageal junction cancer will be analyzed. No study visits or interventions are planned.
62755716|NCT04875507|ACTIVE_COMPARATOR|Positive psychology|The experimental group(n=60), who will receive a 1.5-hour workshop covering positive psychology techniques delivered by a qualified research assistant, in groups of less than 5 people.
61986766|NCT01367158|EXPERIMENTAL|3ABCWYqOMV|Two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of outer membrane vesicles (qOMV) in previous study and one dose of the same in current study
62755717|NCT04875507|NO_INTERVENTION|Control|The control group will receive no intervention.
62557217|NCT02163512||Non-refractory ascites|
62557218|NCT02163512||Refractory ascites|
62755718|NCT03054350|EXPERIMENTAL|Vadadustat, Dose 1|Daily oral dose
62755719|NCT03054350|EXPERIMENTAL|Vadadustat, Dose 2|Daily oral dose
61986767|NCT01367158|EXPERIMENTAL|2ABCWYqOMV|Two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of outer membrane vesicles (qOMV) in previous study and one dose of Tdap in current study
62557219|NCT05735483|EXPERIMENTAL|Lebrikizumab|"Participants will receive Lebrikizumab administered subcutaneously (SC).~Placebo will be administered to maintain the blind of parent study J2T-MC-KGBI."
62557220|NCT05735483|EXPERIMENTAL|Lebrikizumab - Optional Extension Period (OEP)|During the OEP, participants will be assigned to dose and treatment group based on participant weight and response achieved at treatment week-52.
62557221|NCT01852760||UC in Remission|Patients with UC in remission
62557222|NCT01852760||UC Mild Disease|Patients with mild UC disease activity based on partial Mayo Score
62557223|NCT01852760||UC Moderate to severe|Patients with ulcerative colitis with moderate to severe disease activity based on partial Mayo score
62755720|NCT03054350|EXPERIMENTAL|Vadadustat, Dose 3|Daily oral dose
62755721|NCT03054350|PLACEBO_COMPARATOR|Placebo|Daily oral dose
62755722|NCT04801368|EXPERIMENTAL|Receiving Ropivacaine|Patients receiving Ropivacaine.
62755723|NCT04801368|EXPERIMENTAL|Receiving Liposomal Bupivacaine|Patients receiving Liposomal Bupivacaine.
62755724|NCT01132898||cross-sectional TBI|Participants with a mild, moderate, or severe Traumatic Brain Injury enrolled within 5 years from injury. Seen at only one visit.
62755725|NCT01132898||HV|Healthy Volunteer with no history of TBI
62755726|NCT01132898||Prospective TBI|Participants with a mild, moderate, or severe Traumatic Brain Injury enrolled within 1 year from injury.
62557224|NCT06578390|EXPERIMENTAL|Experimental|Patients will wear the device during their polysomnographic recording
62557225|NCT05751213|EXPERIMENTAL|knack technique.|pelvic floor muscle exercises with knack technique.
62755727|NCT01132898||Remote Select Exposure Samples|Participants who are unable to travel to the NIH Clinical Center to participate can remote consent, answer questionnaires remotely, and have biospecimens sent to our lab for analysis.
62755728|NCT01132898||Select Exposure Group|US government associated personnel experiencing TBI-like symptoms arising after possible exposure to a non-natural energy source
62755729|NCT01132898||Select Exposure Matched Unaffected|a longitudinal control group comprised of unaffected volunteers matched to the Select Exposure group
62755730|NCT04267731|PLACEBO_COMPARATOR|Placebo|Cellulose 0.75g per day
62755731|NCT04267731|EXPERIMENTAL|Low dose|0.25g VMK223 per day
62755732|NCT04267731|EXPERIMENTAL|Middle dose|0.5g VMK223 per day
62755733|NCT04267731|EXPERIMENTAL|High dose|0.75g VMK223 per day
62755734|NCT05008731|EXPERIMENTAL|Group 1|botulinum toxin: 100 units (0.5ml) in 1 injection
62755735|NCT05008731|PLACEBO_COMPARATOR|Group 2|Placebo: 0.5 ml in 1 injection
62755736|NCT01129037|OTHER|Goal directed fluid management|
62755737|NCT03633630|EXPERIMENTAL|Amla (Emblica Officinalis)|1000 mg dose per day. Two capsules of 500 mg, one in the morning before breakfast and the other before dinner during 90 days.
62755738|NCT03633630|PLACEBO_COMPARATOR|Placebo|1000 mg dose per day. Two capsules of 500 mg, one in the morning before breakfast and the other before dinner during 90 days
62755739|NCT06040203|EXPERIMENTAL|Leukocyte-rich Platelet rich plasma (LR-PRP)|This group of patients will be treated with single injection of autologous leukocyte rich platelet rich plasma.At the 6-month follow-up visit, the patient will be informed about the treatment received.
62755740|NCT06040203|EXPERIMENTAL|Leukocyte-poor Platelet rich plasma (LP-PRP)|This group of patients will be treated withsSingle injection of autologous leukocyte poor platelet rich plasma.At the 6-month follow-up visit, the patient will be informed about the treatment received.
62755741|NCT06040203|PLACEBO_COMPARATOR|Saline solution|This group of patients will be treated with single intra-articular injection of saline solution (placebo). At the 6-month follow-up visit, patients will be informed about the treatment received. Patients of this group can cross-over to the treatment arm after 6 months following a dedicated randomization list.
62755742|NCT04124458|ACTIVE_COMPARATOR|Pulsed Radiofrequency Ablation|In radiofrequency ablation arm, sensory brunch of occipital nerve will be burn with max allowable temperature: 42 degrees Celsius, real temperature: 41 degrees Celsius, power=65 volts, two cycles of 180 second.
62755743|NCT04124458|ACTIVE_COMPARATOR|Bilateral Occipital Nerve Block|In this arm all steps are the same as other arm, except the generator will not be on and patient will have pain relief by injecting numbing medications beside the sensory nerves.
62755744|NCT06516614|EXPERIMENTAL|Sleep-Promoting Intervention|Individualized sleep-promoting program for adolescents with type 1 diabetes
62755745|NCT06516614|ACTIVE_COMPARATOR|Enhanced Usual Care|Educational Materials
62755746|NCT00975104|EXPERIMENTAL|AMG 745 0.3 mg/kg|0.3 mg/kg AMG 745
61986768|NCT01367158|ACTIVE_COMPARATOR|3B|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine in previous study and one dose of the same in current study
62557226|NCT05751213|ACTIVE_COMPARATOR|pelvic floor muscle exercises|pelvic floor muscle exercises
62755747|NCT00975104|EXPERIMENTAL|AMG 745 1.0 mg/kg|1.0 mg/kg, AMG 745
61986769|NCT01367158|ACTIVE_COMPARATOR|2B|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine in previous study and one dose of Tdap in current study
62755748|NCT00975104|PLACEBO_COMPARATOR|Placebo|Placebo
62755749|NCT00975104|EXPERIMENTAL|AMG 745 3.0 mg/kg|3.0 mg/kg, AMG 745
62755750|NCT04582435|EXPERIMENTAL|Insulin icodec|Participants will receive individualised weekly doses of insulin icodec
62755751|NCT04962841||Frail older adults treated with nutraceuticals and drugs|
62755752|NCT04962841||Frail older adults not treated with nutraceuticals and drugs|
62755753|NCT00771732|EXPERIMENTAL|1|Light therapy
62755754|NCT00771732|SHAM_COMPARATOR|2|"6 minute session given with machine off"
61986770|NCT01367158|ACTIVE_COMPARATOR|1ACWY|One dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine followed by one dose of placebo and one dose of Tdap in current study
62557227|NCT00262028|EXPERIMENTAL|MenACWY-CRM (2-10 years)|Subjects received one dose of investigational MenACWY-CRM conjugate vaccine
62557228|NCT00262028|EXPERIMENTAL|MenACWY-CRM (12-23 months)|Subjects received one dose of investigational MenACWY-CRM conjugate vaccine
62557229|NCT00262028|ACTIVE_COMPARATOR|MenACWY-PS (2-10 years)|Subjects received one dose of licensed comparator MenACWY polysaccharide (MenACWY-PS) vaccine
62557230|NCT00262028|EXPERIMENTAL|MenACWY-CRM+PnC (12-15 months)|Subjects received one dose of MenACWY-CRM vaccine alone or concomitantly with PnC
62557231|NCT00262028|EXPERIMENTAL|MenACWY-CRM+DTaP (16-23 months)|Subjects received one dose of MenACWY-CRM vaccine alone or concomitantly with DTaP
62557232|NCT04275154||CAR-T patients|Relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) or acute lymphoblastic leukemia (ALL) with intent to undergo commercially available CAR-T cell therapy
62755755|NCT01460355|ACTIVE_COMPARATOR|Botulinum toxin plus surgery|Intraoperative injection of 5U (0.1 ml) of Botulinum Toxin will be given to the recessed muscle during surgery
62755756|NCT01460355|PLACEBO_COMPARATOR|Saline solution plus surgery|Saline solution (0,1 ml)will be given to the recessed muscle during surgery procedure
62755757|NCT01527513|EXPERIMENTAL|Eslicarbazepine acetate (BIA 2-093)|
62755758|NCT01527513|PLACEBO_COMPARATOR|Placebo|
62755759|NCT02502669|ACTIVE_COMPARATOR|Finasteride 23.5 mg tablets group|Finasteride 23.5mg tablets and large placebo tablets once per week
62755760|NCT02502669|ACTIVE_COMPARATOR|Finasteride 33.5 mg tablets group|Finasteride 33.5 mg tablets and small placebo tablets once per week
62755761|NCT02502669|PLACEBO_COMPARATOR|Placebo group|Large and small placebo tablets once per week
62755762|NCT03293433||Patient with lung cancer|Patient with pulmonary nodule showed in scanner (defined as a rounded picture higher than 5 mm and less than 30 mm in the lung parenchyma) presenting at one of the 3 participant services and meeting the inclusion criteria and exclusion. A blood punction will be performed in order to extract micro RNA.
62755763|NCT00649766|ACTIVE_COMPARATOR|1|tailored print messages to encourage eye examination behavior
62557233|NCT01019434|OTHER|Temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
62557234|NCT01019434|EXPERIMENTAL|Temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
62557235|NCT04708613||Former Professional Football Players|Former professional football players who played in at least 3 professional seasons, with at least 3 games each season.
62557236|NCT04708613||Control Groups|Friends and brothers of the Former Professional Football Player group.
62557237|NCT06492395|EXPERIMENTAL|Len+DEB-TACE+HAIC|Patients will receive the combination treatment of Len+DEB-TACE+HAIC.
62557238|NCT06492395|ACTIVE_COMPARATOR|Len+DEB-TACE|Patients will receive the combination treatment of Len+DEB-TACE.
62557239|NCT06513338|EXPERIMENTAL|eculizumab|C5 monoclonal treatment plus standard treatment
62557240|NCT00097448|OTHER|1|Nineteen days of oral prednisone
62755764|NCT00649766|ACTIVE_COMPARATOR|2|targeted print messages to encourage eye examination behavior
62755765|NCT04416529|EXPERIMENTAL|Intervention (tele-MBCT) group|"Tele-MBCT was an 8-week program delivered to participants online via a videoconferencing program called Zoom by a tele-MBCT instructor. Tele-MBCT was delivered in three, 8-week rounds. Each round consisted of 8 weekly, 2-hour group sessions with 4-6 participants on Wednesdays from 2:00 to 4:00 pm. Participants were trained in mindfulness concepts and techniques including mindful eating, body scan, sitting meditation, breathing awareness, mindful walking and mindful movements. Participants were given a mindfulness a book called The Mindful Way Workbook and a practice log. The book was a guide for their daily practice at home and the practice log was a simple log for self-recording daily practices (number of minutes of daily MBCT practice) and a note pad for recording the reasons/obstacles for not practicing."
62755766|NCT04416529|NO_INTERVENTION|Control Group|Participants in the control group continued their usual caregiving activities.
62557241|NCT00097448|EXPERIMENTAL|2|Four doses of methylprednisolone sodium succinate delivered by injection to the middle ear over 2 weeks
62557242|NCT05611983|ACTIVE_COMPARATOR|Observation fo touch|
62557243|NCT05611983|ACTIVE_COMPARATOR|Observation of pictures|
62557244|NCT05611983|ACTIVE_COMPARATOR|Imagery of touch|
62557245|NCT05611983|ACTIVE_COMPARATOR|Mirror therapy|
62557246|NCT05802628|EXPERIMENTAL|Investigational group|
62557247|NCT03901313|EXPERIMENTAL|Sequence ABC|Healthy volunteers will receive Treatments A, then B, and then C, with a 6-day washout between treatments, during a stay at the clinic of 20 days
62557248|NCT03901313|EXPERIMENTAL|Sequence ACB|Healthy volunteers will receive Treatments A, then C, and then B, with a 6-day washout between treatments, during a stay at the clinic of 20 days
62557249|NCT03901313|EXPERIMENTAL|Sequence BAC|Healthy volunteers will receive Treatments B, then A, and then C, with a 6-day washout between treatments, during a stay at the clinic of 20 days
62557250|NCT03901313|EXPERIMENTAL|Sequence BCA|Healthy volunteers will receive Treatments B, then C, and then A, with a 6-day washout between treatments, during a stay at the clinic of 20 days
62557251|NCT03901313|EXPERIMENTAL|Sequence CAB|Healthy volunteers will receive Treatments C, then A, and then B, with a 6-day washout between treatments, during a stay at the clinic of 20 days
62557252|NCT03901313|EXPERIMENTAL|Sequence CBA|Healthy volunteers will receive Treatments C, then B, and then A, with a 6-day washout between treatments, during a stay at the clinic of 20 days
62557253|NCT01339403||HIV infected|No study specific intervention, non-interventional trial
62557254|NCT01339403||HIV-uninfected|No study specific intervention, non-interventional trial
62557255|NCT04783402|EXPERIMENTAL|e-OTCAT|The experimental group will receive the e-OTCAT program that consists of a 12-week videoconference-based occupational therapy intervention at the same time women with breast cancer receive chemotherapy.
62755767|NCT06606782||Elective Surgery Patients|This cohort includes adult patients undergoing elective surgery who were assessed for residual gastric content using ultrasound and a preoperative questionnaire. All patients adhered to standard preoperative fasting guidelines prior to the assessment.
62755768|NCT00756184|ACTIVE_COMPARATOR|A|Intervention will consist of intensive teaching on the nature of glaucoma, value of IOP control, need to adhere to medical therapy and counseling on the proper use of travoprost eye drops.
62378629|NCT02411877|EXPERIMENTAL|Mild hypothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using the Trevo Pro Retriever (Stryker). Subjects will also have a catheter placed in the femoral vein (Zoll Thermogard XP technology with the Quattro catheter) and temperature brought to 33 degrees centigrade as quickly as possible. They will stay in mild hypothermia for 12 hours, and then be rewarmed very slowly.
62378630|NCT00572065|EXPERIMENTAL|All Patients|Arsenic trioxide \[TrisenoxTM Injection\], will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12.
62378631|NCT02450240||Depression and Anxiety Disorders|"350 subjects who screen positive for anxiety or depressive symptoms on the Patient Health Questionnaire (PHQ-9) ≥ 10 and/or Overall Anxiety Severity and Impairment Scale (OASIS) ≥ 8.~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
62378632|NCT02450240||Eating Disorders|"350 subjects who screen positive for problems related to eating behavior on the Eating Disorder Screen (SCOFF), score ≥ 2.~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
62378633|NCT02450240||Substance Use Disorders|"350 subjects who screen positive for problems related to substance use on the Drug Abuse Screening Test (DAST-10), score \> 2.~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
62378634|NCT02450240||Healthy Controls|"150 subjects who do not screen positive for anxiety and depression symptoms or problems related to eating behavior and/or substance use.~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
62378635|NCT01030757|EXPERIMENTAL|Tomotherapy|Intervention: Stereotactic Body Radiation Therapy using Tomotherapy. Tomotherapy treatment: A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the PTV.
62378636|NCT05840393|EXPERIMENTAL|Intervention Group: Discharge training based on the Roy adaptation model|Oncologic palliative care patients and caregivers in this group will receive discharge training based on the Roy adaptation model.
62378637|NCT05840393|NO_INTERVENTION|Control Group: Standard discharge training|Oncologic palliative care patients and caregivers in this group will not receive any training other than the discharge training routinely applied in the clinic.
62378638|NCT01576887|PLACEBO_COMPARATOR|Placebo|
62378639|NCT01576887|EXPERIMENTAL|Bardoxolone Methyl|
62378640|NCT00597129|EXPERIMENTAL|Multi Dose levels|different doses of 90YhPAM4 will be given only once.
62378641|NCT06450782|EXPERIMENTAL|PIR Group|Participants in the PIR Group will apply one session of post-isometric relaxation technique.
62378642|NCT06450782|EXPERIMENTAL|MR Grup|Participants in the MR Group will apply one session of myofascial release technique.
62378643|NCT06450782|NO_INTERVENTION|Control Group|No intervention will be made to the participants in the Control Group.
62378644|NCT01814228|EXPERIMENTAL|right atrium ganglionated plexi transcatheter ablation|right atrium ganglionated plexi transcatheter ablation
62755769|NCT00756184|PLACEBO_COMPARATOR|B|"Intervention with travoprost therapy and TDA monitoring. Patients of this arm will also be prescribed travoprost and will be followed up in a standard clinical fashion. This group will receive a comparable amount of personal physician attention, but will not be given adherence, or glaucoma education and will not be told that their adherence will be monitored. Their attention placebo intervention will discuss the importance and techniques of good eye health (sunglasses, vitamins, cataract development, etc but no details, or discussion of either glaucoma or adherence) will insure that the study results are not a result of a change in physician attention to a patient, per se, rather than adherence training."
62755770|NCT04427995||Oen Angle Glaucoma|• Patients aged 30-95 with primary or pigmentary / pseudoexfolliative / juvenile / normal pressure open angle glaucoma or combined mechanism glaucoma with IOP of 10-40 mmHg on maximum tolerated medical therapy who are either progressing, above IOP target, or poorly adherent or tolerant to medical therapy. Phakic or pseudophakic eyes and previous laser trabeculoplasty will be included.
62755771|NCT04923646|EXPERIMENTAL|Active|Primer
62755772|NCT04923646|NO_INTERVENTION|Control|No Primer
62755773|NCT02966093|EXPERIMENTAL|Lenvatinib|In the randomization phase, participants will receive lenvatinib until disease progression. Participants who discontinue due to confirmed disease progression will enter Extension Phase. Participants who discontinue without confirmed disease progression will be followed for tumor assessment until confirmed disease progression or initiation of anticancer therapy, at which time the participants will enter Follow-up period of Extension Phase.
62378645|NCT03687931|EXPERIMENTAL|Arm 1|Dexamethasone suspension dose level 1
62378646|NCT03687931|EXPERIMENTAL|Arm 2|Dexamethasone suspension dose level 2
62378647|NCT06054594|EXPERIMENTAL|Metabolically healthy obesity (MHO)|Healthy/normal metabolic profile
62755774|NCT02966093|EXPERIMENTAL|Placebo|In the randomization phase, participants will receive lenvatinib matched placebo until disease progression. Participants who discontinue due to confirmed disease progression will enter Extension Phase. Participants who discontinue without confirmed disease progression will be followed for tumor assessment until confirmed disease progression or initiation of anticancer therapy, at which time the participants will enter Follow-up period of Extension Phase.
62755775|NCT05045742||Training|A subset of patients that are used to train the machine learning algorithm.
62755776|NCT05045742||Validation|"A subset of patients that are held back and used to validate the algorithm's accuracy."
62755777|NCT00613925|ACTIVE_COMPARATOR|Pipelle Group|Women were randomized to have an endometrial biopsy collected using Pipelle de Cornier instrument.
62755778|NCT00613925|ACTIVE_COMPARATOR|Explora group|Women were randomized to have an endometrial biopsy collected using Explora curette instrument.
62755779|NCT06478797|ACTIVE_COMPARATOR|Control group|Sepsis will be treated with a standardized therapy protocol, where participants will receive fluids for resuscitation. Specifically, they will receive 40-60 ml/kg of fluids before the initiation of inotropes
62755780|NCT06478797|EXPERIMENTAL|Intervention group|Sepsis will be treated with early inotropes, where participants will receive adrenaline after the first bolus of 20 ml/kg
62755781|NCT03796143|EXPERIMENTAL|ACT self-help book condition|Participants in this condition will be asked to read The Mindfulness and Acceptance Workbook for Depression by Strosahl and Robinson (2008), a self-help book based on acceptance and commitment therapy.
62755782|NCT03796143|ACTIVE_COMPARATOR|CBT self-help book condition|Participants in this condition will be asked to read Cognitive Behavioral Workbook for Depression by Knaus (2006), a self-help book based on acceptance and commitment therapy.
62755783|NCT03796143|OTHER|Choice of two self-help books|Participants in this condition will have the option of receiving either the self-help book by Strosahl and Robinson (2008) or the book by Knaus (2006).
62755784|NCT04844203||Patients with unsteadiness|Patients with unsteadiness referred for an ENMG
62755785|NCT03115853|EXPERIMENTAL|HCTZ plus Aliskiren then HCTZ and Placebo|"HCTZ 25 mg plus Aliskiren 150mg for 2weeks. Aliskiren is increased to 300mg for 4 week if 150mg was tolerated.~Then HCTZ 25 mg po plus Placebo"
62378648|NCT06054594|EXPERIMENTAL|Metabolically unhealthy obesity (MUHO)|Abnormal metabolic profile
62557256|NCT04783402|OTHER|Control Group|At the beginning of chemotherapy, the participants allocated to the control group will only receive an educational handbook containing information about most frequent side-effects of cancer and cancer treatments, plus standard care for these patients.
62557257|NCT03207984|ACTIVE_COMPARATOR|Control SCTG|Root coverage surgery with subepithelial connective tissue graft to an extensive treat multiple gingival recessions in aesthetic areas
61986771|NCT06093412||unilateral epidural anesthesia (UEA) group|Patients were divided into two groups based on the type of anesthesia they received; a UEA group (n = 42) and a combined spinal epidural anesthesia (CSEA) group (n = 64).
62182493|NCT01367444|EXPERIMENTAL|SAR422459 (Dose 1)|Starting dose of SAR422459 given through subretinal injection
62378649|NCT01511549|EXPERIMENTAL|Dose 1|SAR113945 low dose
62378650|NCT01511549|EXPERIMENTAL|Dose 2|SAR113945 medium dose
62557258|NCT03207984|EXPERIMENTAL|Test CM|Root coverage surgery with Mucograft® collagen matrix to treat an extensive multiple gingival recessions in aesthetic areas
62378651|NCT01511549|EXPERIMENTAL|Dose 3|SAR113945 high dose
62378652|NCT01511549|PLACEBO_COMPARATOR|Placebo|Placebo
62378653|NCT01701349|ACTIVE_COMPARATOR|Fosbretabulin + paclitaxel + carboplatin|"Six 21 day cycles of:~Fosbretabulin (60 mg/m2) IV on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC 6) IV on Day 2"
62557259|NCT00999986|NO_INTERVENTION|placebo|
62557260|NCT00999986|ACTIVE_COMPARATOR|cyclophosphamide|
62557261|NCT03389503|ACTIVE_COMPARATOR|Right radial approach|Right radial approach for coronary angiography and coronary intervention
62557262|NCT03389503|ACTIVE_COMPARATOR|Left radial approach|Left radial approach for coronary angiography and coronary intervention
62557263|NCT02839772|ACTIVE_COMPARATOR|Current skin care regimen|Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 6 litres of water with added sodium hypochlorite (0.0125%), air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
62755786|NCT03115853|EXPERIMENTAL|HCTZ and Placebo, then HCTZ and Aliskiren|"HCTZ 25 mg po plus Placebo.~Then HCTZ 25 mg plus Aliskiren 150mg for 2weeks. Aliskiren is increased to 300mg for 4 week if 150mg was tolerated."
62755787|NCT01108432|EXPERIMENTAL|Electronic Referrals|Dental practices randomized to the experimental group will have options on how to refer patients to the tobacco cessation website.
62755788|NCT01108432|NO_INTERVENTION|Routine Referral|Dental practices in this arm will refer patients to the Decide2Quit website by using an information prescription.
62755789|NCT02427568|PLACEBO_COMPARATOR|Placebo with therapy|Inactive placebo administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by (optional) inactive placebo supplemental dose.
62755790|NCT02427568|ACTIVE_COMPARATOR|MDMA-assisted therapy (125 mg)|125 mg 3,4-methylenedioxymethamphetamine (MDMA) administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by a (optional) supplemental dose of 62.5 mg MDMA.
62755791|NCT03989427|EXPERIMENTAL|Brushing First and Flossing Later (BF)|The participants in BF group were asked to use modified bass method of tooth brushing first using Colgate® tooth brush (the amount of Colgate® tooth paste used is half-length of the toothbrush's head) and then floss with Colgate® dental floss using Spool method for a 2-week period. This is followed by a one week wash out period wherein they will practice oral hygiene according to their habitual method. After this cross over is done in which participants will change the sequence to FB wherein they will floss first and brush later.
62755792|NCT03989427|EXPERIMENTAL|Flossing First and Brushing Later (FB)|The participants in FB group were asked to floss first with Colgate® dental floss using Spool method and then modified bass method of tooth brushing first using Colgate® tooth brush (the amount of Colgate® tooth paste used is half-length of the toothbrush's head) for a 2-week period. This is followed by a one week wash out period wherein they will practice oral hygiene according to their habitual method. After this cross over is done in which participants will change the sequence to BF wherein they will brush first and floss later.
62755793|NCT04844658|EXPERIMENTAL|standard treatment + NASAFYTOL®|"Minimum 25 patients will receive NASAFYTOL® as a supportive supplementation to standard treatment of hospitalized patients infected with COVID-19.~For each patient, 8 capsules of NASAFYTOL® taken orally per day (4 capsules in the morning and 4 capsules in the evening before meal ,with a full glass of water. ) in support of the standard COVID-19 treatment in force in the hospital from the day after the randomization (day1) and during the period of hospitalization and maximum for 14 days"
62755794|NCT04844658|ACTIVE_COMPARATOR|standard treatment + FULTIUM® - D3 800|"Minimum 25 patients will receive vitamin D , FULTIUM® - D3 800 as a supportive supplementation to standard treatment of hospitalized patients infected with COVID-19.~For each patient,1 capsule of Vitamin D taken orally per day (1 capsule in the morning) in support of the standard COVID-19 treatment in force in the hospital from the day after the randomization (day1) and for the duration of the hospitalization and maximum for 14 days"
62755795|NCT01636388|EXPERIMENTAL|Allogeneic Stem Cell Transplantation|Reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP specific cytotoxic T-lymphocyte (CTL) infusions in EBV positive patients with poor risk Hodgkin Lymphoma.
62755796|NCT03362931|EXPERIMENTAL|XEN45 Glaucoma Treatment System (hereafter referred to as XEN)|XEN45 unilaterally implanted in the study eye
62755797|NCT06218381|EXPERIMENTAL|Image Exposure Arm|This within-subjects design study will have all participants view three types of exposure during fMRI scanning: VBE to combat images, VBE to masked everyday scenes (control), and conscious visible exposure to the same images (control).
62378654|NCT01701349|PLACEBO_COMPARATOR|Placebo + paclitaxel + carboplatin|"Six 21-day cycles of:~Placebo (formulated and packages to match fosbretabulin)on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC6) IV on Day 2"
62378655|NCT04559867|ACTIVE_COMPARATOR|Needle Knife Fistulotomy|The study doctor will gain access to the bile ducts using the cutting technique called a needle knife fistulotomy. When using this technique, the study doctor makes a cut directly into the bile duct.
62378656|NCT04559867|ACTIVE_COMPARATOR|Sphincterotomy|The study doctor will gain access to the bile ducts using the cutting technique called a sphincterotomy. Using this method, a heated metal wire cuts the opening to the bile duct after a wire has been passed into it.
62378657|NCT03389867|EXPERIMENTAL|Male Sexual Health Formulation|Kaempferia parviflora extract 100mg daily
62378658|NCT02680366|EXPERIMENTAL|collagen/ABMNC scaffold|collagen/ABMNC scaffold covered on Foley catheter balloon inserted after hysteroscopic adhesiolysis
62378659|NCT02680366|ACTIVE_COMPARATOR|Foley catheter balloon|Foley catheter balloon inserted after hysteroscopic adhesiolysis
62378660|NCT02627196|EXPERIMENTAL|Device and Medical Management|Subjects will be implanted with the BAROSTIM NEO System and receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association \[AHA\] / American College of Cardiology \[ACC\] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
62755798|NCT06489795|EXPERIMENTAL|Experimental intervention: Laparoscopic or robot-assisted radical/simple hysterectomy|In the experimental arm, patients with early-stage cervical cancer will be treated by using laparoscopic or robot-assisted radical/simple hysterectomy.
62755799|NCT06489795|OTHER|Control intervention: Abdominal radical/simple hysterectomy|In the control arm, abdominal radical/simple hysterectomy (ARH) will be used as standard therapy.
62755800|NCT02683486|EXPERIMENTAL|Activities of daily living on iO2t|Patients will complete simulated activities of daily living on intelligent oxygen therapy (an auto-titrating oxygen system)
62378661|NCT02627196|ACTIVE_COMPARATOR|Medical Management|Subjects will receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association \[AHA\] / American College of Cardiology \[ACC\] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
62755801|NCT02683486|ACTIVE_COMPARATOR|Activities of daily living on LTOT|Patients will complete activities of daily living on their usual long-term oxygen therapy.
62755802|NCT05172453||Nationwide hospital-based cohort|HBV-infected mother-infant pairs have been followed from registry to post vaccination serological test (PVST) in hospitals nationwide.
62378662|NCT03215849|SHAM_COMPARATOR|Routine Medical Therapy|Routine Medical Therapy
62378663|NCT03215849|EXPERIMENTAL|Routine Medical Therapy + LVP|Routine Medical Therapy + LVP
62378664|NCT03215849|EXPERIMENTAL|Routine Medical Therapy + BiVP|Routine Medical Therapy + BiVP
62378665|NCT05749276|EXPERIMENTAL|Darzalex|"DARZALEX®~Dose level 1 : 1800 mg Day 1 Dose level 2 : 1800 mg Day 1 and 8 (+/- 2 days) Dose level 3 : 1800 mg à Day 1, 8 (+/- 2 days) and D15 (+/- 2 days)"
62378666|NCT00840385|EXPERIMENTAL|A|
62378667|NCT03315702||control／mechanical ventilation|venous blood samples collected from patients twice，relatively before mechanical ventilation and 3rd hour after mechanical ventilation
62378668|NCT04511091||Vats Group|patients underwent planned VATS lobectomy for NSCLC from the Italian VATS Group Database (a validated, risk-adjusted, prospective, outcomes-based program with 50 participating hospitals in Italy) were included in the analysis.
62378669|NCT01860794|OTHER|Mesencephalic Neuronal Precursor Cells|
62378670|NCT02672306|EXPERIMENTAL|UCMSCs|Subjects with Alzheimer's Disease Intervention: UCMSCs
62378671|NCT02672306|PLACEBO_COMPARATOR|Placebo|Subjects with Alzheimer's Disease Intervention: Placebo (normal saline)
62378672|NCT05518994|EXPERIMENTAL|Cohort 1|Subjects with ctDNA-level-relapse Astrocytoma before clinical relapse, determined according to the dynamics of TISF ctDNA.
62378673|NCT05518994|EXPERIMENTAL|Cohort 2|Subjects with clinical-relapse Astrocytoma, determined according to the response assessment in neuro-oncology (RANO) criteria for gliomas.
62378674|NCT05518994|NO_INTERVENTION|Cohort 3|Subjects without ctDNA-level-relapse and clinical-relapse Astrocytoma.
62755803|NCT05172453||Community-based cohort|HBV-infected mother-infant pairs have been followed from registry to post vaccination serological test (PVST) in Bao' an district, Shenzhen
61986772|NCT06093412||combined lumbar and epidural anesthesia (CSEA) group|Patients were divided into two groups based on the type of anesthesia they received; a UEA group (n = 42) and a combined spinal epidural anesthesia (CSEA) group (n = 64).
62755804|NCT03484832|EXPERIMENTAL|Spray group|Using Walter Ritter Ethyl Chloride Spray and placebo cream
62755805|NCT03484832|EXPERIMENTAL|EMLA group|Using EMLA cream and placebo spray
62378675|NCT02302586|ACTIVE_COMPARATOR|Patient Controlled Analgesia (IV PCA)|Postoperative intravenous (IV) morphine PCA is being used for acute pain control: Basal infusion: 0.3 mg/kg/h Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
62378676|NCT02302586|ACTIVE_COMPARATOR|Thoracic Paravertebral Block (TPVB)|Preoperative thoracic paravertebral block (TPVB) at 4 levels from T4 to T8 is being performed and total of 20 mL Bupivacaine 0.5% is deposited (5 mL per level by using landmark technique)
62378677|NCT06397157|EXPERIMENTAL|Virtual Reality+Motor Imagery+Routine physical therapy|Participants in Group A will receive Virtual Reality (VR) and Motor Imagery (MI) training with Routine physical therapy for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
62378678|NCT06397157|ACTIVE_COMPARATOR|Virtual Reality+Routine physical therapy|Participants in Group A will receive Virtual Reality (VR) training with Routine physical therapy for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
62378679|NCT06397157|ACTIVE_COMPARATOR|Motor Imagery+ Routine physical therapy|Participants in Group A will receive Motor Imagery(MR) training with Routine physical therapy for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
62378680|NCT06142162||control|healthy children
62378681|NCT06142162||sepsis-1|children with sepsis on the 1 day
62378682|NCT06142162||sepsis-7|children with sepsis on the 7 day
61986773|NCT03350854|NO_INTERVENTION|The non-intervention control group|In the non-intervention control group, providers are blind to the patient's preferred decision making role.
62182494|NCT01367444|EXPERIMENTAL|SAR422459 (Dose 2)|Escalating dose of SAR422459 given through subretinal injection
62378683|NCT06142162||severe bacterial infection|children with severe bacterial infection
62378684|NCT06142162||severe viral infection|children with severe viral infection
62378685|NCT02203916|EXPERIMENTAL|Azilsartan Medoxomil 40 mg|Azilsartan medoxomil 40 mg, tablets, orally, once daily for 6 weeks.
62378686|NCT02203916|EXPERIMENTAL|Azilsartan Medoxomil 80 mg|Azilsartan medoxomil 80 mg, tablets, orally, once daily for 6 weeks.
62378687|NCT02203916|PLACEBO_COMPARATOR|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for 6 weeks.
62378688|NCT03192384||Before intervention|Data from clusters before educational programme intervention implemented.
62378689|NCT03192384||After intervention|Data from clusters after educational programme intervention implemented
62378690|NCT01445002|EXPERIMENTAL|BM32 low dose|3 subcutaneous injections of 10 micrograms in a time span of 8 weeks
62755806|NCT03484832|PLACEBO_COMPARATOR|Placebo group|Using placebo cream and placebo spray
62755807|NCT01294943||Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
62755808|NCT00442832|EXPERIMENTAL|TD-1792|
62755809|NCT00442832|ACTIVE_COMPARATOR|Vancomycin|
62755810|NCT00462735|EXPERIMENTAL|Advanced Head and Neck Cancer|Patients with stage IVA and IVB or high-risk stage III squamous cell carcinomas of the head and neck
62755811|NCT04854031||Cochlear Implant Recipients|30 participants who lost their hearing and received one or two cochlear implants as adults will participate in this study. We will include unilaterally and bilaterally implanted individuals listening with their everyday hearing configuration. Individuals with residual acoustic hearing better than 60 A-weighted decibels at any audiometric frequency will be excluded. Participants will range in age between 19 and 80 years old, although most are expected to be within 50 - 75 years of age.
62755812|NCT02764723|ACTIVE_COMPARATOR|Hyperbaric bupivacaine|12.5 mg of 0.5% hyperbaric bupivacaine
62755813|NCT02764723|EXPERIMENTAL|Isobaric ropivacaine|15 mg of 0.5% isobaric ropivacaine
62755814|NCT05268393|EXPERIMENTAL|BREATHE-T1D|BREATHE-T1D is a 6-week group mindfulness program adapted specifically for teens with type 1 diabetes.
62755815|NCT05268393|PLACEBO_COMPARATOR|BREATHE-T1D Health Education|The health education placebo comparator is a 6-week group diabetes-specific education program designed to be informational but not supportive.
62755816|NCT01396265|EXPERIMENTAL|Afatinib alone (Reference)|Tablet, Oral administration with 240 mL of water
62755817|NCT01396265|EXPERIMENTAL|Rifampicin + Afatinib (Test)|Tablet, Oral administration with 240 mL of water
62755818|NCT05813652||RIPPLE-C cohort|This is a retrospective closed cohort study using a single-arm, pre-post design. Therefore, we will be selecting patients from the CPCSSN database to create our single-arm cohort. Patients included in this cohort will be 18 years of age or older, and will have had at least one contact with their primary care clinic between the dates of March 13, 2018 and March 13, 2020.
62378691|NCT01445002|EXPERIMENTAL|BM32 medium dose|3 subcutaneous injections of 20 micrograms in a time span of 8 weeks
62378692|NCT01445002|EXPERIMENTAL|BM32 high dose|3 subcutaneous injections of BM32 over a time span of 8 weeks
62378693|NCT01445002|PLACEBO_COMPARATOR|Placebo|3 subcutaneous injections over a time span of 8 weeks
62755819|NCT01819987|ACTIVE_COMPARATOR|Mailing information|Participants in the mailing information group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
62378694|NCT02286752|ACTIVE_COMPARATOR|neostigmine|
62378695|NCT02286752|ACTIVE_COMPARATOR|sugammadex|
62755820|NCT01819987|EXPERIMENTAL|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
62755821|NCT04120857|NO_INTERVENTION|Educational Control Group|Education provided for optional use
62755822|NCT04120857|EXPERIMENTAL|Gentle Stretching and Education|Gentle Stretching for 60 minutes twice weekly
62755823|NCT03158623|EXPERIMENTAL|Platelet Rich Plasma|30cc of PRP was administered at closure of wound
62755824|NCT03158623|EXPERIMENTAL|Cellerate (Activated Collegen)|1gm of Cellerate was administered at closure of wound
62755825|NCT06050668|EXPERIMENTAL|Essential Amino Acid Supplementation|Subjects randomized to intervention arm of this study will receive essential amino acid (EAA)-based oral nutrition supplementation in addition to standard of care postoperative nutrition. Subjects will take 1 scoop (26.7g) of supplement twice daily for 4 weeks after injury. Supplementation will begin within 72 hours of surgical fixation. The EAA-based supplement used in this clinical trial is MEND™ Repair and Recover®.
62378696|NCT02569645|EXPERIMENTAL|Single Arm - Rosuvastatin|This is a single arm, of Rosuvastatin (Crestor®) 40 mg orally daily starting 2 weeks prior to the initiation of radiation at week 1 and stopped 4 weeks after the completion of radiation at the start of week 12 or 13, depending on whether 25 or 30 fractions of radiotherapy are given.
62378697|NCT06500234|EXPERIMENTAL|megestrol acetate-olanzapine|Megestrol acetate 160 mg, oral, everyday Olanzapine 2.5 mg, oral everyday
62378698|NCT06500234|PLACEBO_COMPARATOR|control|Starch powder 50 mg, oral, everyday,
62378699|NCT00571051|EXPERIMENTAL|1|MBSR 8 week course
62378700|NCT00571051|NO_INTERVENTION|2|8 weeks of natural history
62378701|NCT05538585|EXPERIMENTAL|Part 1: Navocaftor with food|Participants will receive navocaftor administered with food
62378702|NCT05538585|EXPERIMENTAL|Part 1: Navocaftor without food|Participants will receive navocaftor administered without food
62755826|NCT06050668|NO_INTERVENTION|Standard of Care Postoperative Nutrition|Subjects randomized to the control arm of this study will receive no intervention. They will receive standard of care postoperative nutrition.
62755827|NCT00348907|ACTIVE_COMPARATOR|1|immediate thermal cure (1st year)
62755828|NCT00348907|SHAM_COMPARATOR|2|late thermal cure (2 years)
62755829|NCT02178813|EXPERIMENTAL|Administration of minocycline|"All patients in the study will receive minocycline periprocedurally with the following schedule:~* Day prior to procedure: 800mg p.o., 700mg p.o.~* Day of procedure: 600mg i.v., 500mg p.o.~* Day after procedure: 400mg p.o., 400mg p.o."
62755830|NCT03442257|EXPERIMENTAL|SMS group|Participants in the intervention group will receive four semi-personalized messages per week in addition to their usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
62755831|NCT03442257|NO_INTERVENTION|Control|The control group will receive usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
62755832|NCT03831880|OTHER|Daily to Weekly|Genotropin to somatrogon
62755833|NCT03831880|OTHER|Weekly to Daily|somatrogon to Genotropin
62755834|NCT04518852|EXPERIMENTAL|Treatment group|The participants will receive the combined treatment of local therapy (TACE, oxaliplatin and epirubicin), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)
62755835|NCT05170750|EXPERIMENTAL|Mechanical foot stimulation evaluation|"We have a 2 factors' interaction (vision and foot) with several levels.~* foot: 4 levels =3 foams and a Control (CT) condition)~* vision: 2 levels (open/close) A test will consist of maintaining a standing position on a stabilometric platform for 30s in a given condition. 3 trials are performed for each condition (combination of different levels) Between each trial: the subject is asked to self evaluate his stability. We evaluate the plantar discrimination with a discrimination disk. 5 foot zones are tested.~3/5 subjects from PIMOUSS1 are asked to be in PIMOUSS2. We have the interaction of 2 factors. foot: 2 levels (insole/CT) vision : 2 levels (open/close) A trial is the combination of the different levels while walking. It is repeated 5 times per condition.~The participant will perform this task under several experimental conditions presented in a randomized order:~* Trajectory: (straight ahead/90° turns)~* Visual: (close/open)~* Mechanical stimuli (CT/insole)"
62755836|NCT00773786|EXPERIMENTAL|Arformoterol|Arformoterol twice daily for 1 week via nebulizer
62755837|NCT00773786|PLACEBO_COMPARATOR|Placebo|Placebo twice daily for 1 week
62755838|NCT06601959||Adolescent female students|Adolescent female students from elementary to secondary schools in the Ikwuano Local Government Area of Abia State, Nigeria
62755839|NCT02256267|EXPERIMENTAL|LY2835219|Single oral dose of LY2835219
62755840|NCT02256267|EXPERIMENTAL|LY2835219 + Rifampin|Single oral dose of LY2835219 with rifampin orally, once daily for 14 days
62755841|NCT06608108||Group 1|Non-interventional studies
62755842|NCT06608394||Preoperative exercise habits group|Moderate-intensity aerobic exercise or strength training was performed at least 3 times per week for 6 months before surgery.
62755843|NCT06608394||No exercise habit before operation group|There was no regular exercise habit for 6 months before surgery
62755844|NCT06608394||The exercise habit group was maintained after operation|Moderate-intensity aerobic exercise was continued at least three times per week after surgery
62755845|NCT06608394||The exercise habit was not maintained after operation|Did not maintain a regular exercise habit after surgery
62755846|NCT01228604|EXPERIMENTAL|Methylphenidate|
62755847|NCT00687752||1|hydramnios
62755848|NCT00687752||2|normal
62755849|NCT03122353|EXPERIMENTAL|Calcipotriene Hydrate and Betamethasone|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
62755850|NCT03122353|ACTIVE_COMPARATOR|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
62755851|NCT03122353|PLACEBO_COMPARATOR|Placebo|Topical suspension without active ingredient
62378703|NCT05538585|EXPERIMENTAL|Part 2: Galicaftor with food|Participants will receive galicaftor administered with food
62378704|NCT05538585|EXPERIMENTAL|Part 2: Galicaftor without food|Participants will receive galicaftor administered without food
62378705|NCT00671515|EXPERIMENTAL|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
62378706|NCT02089178|EXPERIMENTAL|intravenous|the total intravenous anesthesia group
62378707|NCT02089178|ACTIVE_COMPARATOR|inhalation|the inhalation anesthesia group
62755852|NCT00585546|EXPERIMENTAL|LVAD and Clenbuterol|
62755853|NCT03032614|EXPERIMENTAL|Combination of Carboplatin, Eribulin, and Veliparib|Eribulin will be administered intravenously (IV) on days 1 and 8 of each cycle at a dose of 1.1 mg/m2 over a 2-5 minute time period; on cycle day 1. Carboplatin will be administered intravenously at a dose of AUC 5 on day 1 of each cycle, over 30 min, immediately following eribulin infusion, per institutional guidelines. Veliparib will be given at 120 mg bid (two times a day), on days 2-12 for the first cycle of the safety run-in period and thereafter at 240 mg bid.
62755854|NCT06391281|NO_INTERVENTION|Control|routine care
62755855|NCT06391281|EXPERIMENTAL|Education|The patient receiving hemodialysis treatment will be given fistula self-care training in 2 sessions. An educational booklet will be provided after the training.
62755856|NCT04392908||Patients|Pediatric patients from 12 to 17 with cancer diagnosis only taken by Meyer Children's Hospital prior consent. Knowledge of fluent Italian language is required
62755857|NCT04392908||Parents|Parents of pediatric patients prior consent. Knowledge of fluent Italian language is required
62378708|NCT01657253|EXPERIMENTAL|PRO-148|"PRO-148 containing: xanthan gum and sulphate chondroitin, ophthalmic solution~doses: 1 drop in each eye, quarter in day"
62378709|NCT01657253|ACTIVE_COMPARATOR|Systane®|"Systane containing: polyethylene glycol 400 0.4%, propylene glycol 0.3% and hydroxypropyl guar~doses: 1 drop in each eye, quarter in day"
62378710|NCT00103779|EXPERIMENTAL|1|
62378711|NCT02840552|EXPERIMENTAL|FCH-PET/CT|18F-Fluoromethylcholine (18F-FCH) PET/CT
62378712|NCT00425191|EXPERIMENTAL|1|
62378713|NCT00425191|EXPERIMENTAL|2|
62378714|NCT00425191|EXPERIMENTAL|3|
62378715|NCT01440829|EXPERIMENTAL|LOLA group|Intervention: LOLA (30g per day) for a week.
62378716|NCT01440829|NO_INTERVENTION|Control group|Patients will not be treated with LOLA.
62182495|NCT01367444|EXPERIMENTAL|SAR422459 (Dose 3)|Maximum tolerated dose (MTD) of SAR422459 given through subretinal injection
62378717|NCT03001765|OTHER|Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac|Intensive monitoring strategy of discharging from the Emergency Department with an external 30 day cardiac monitoring system. A negative 30 day external monitor report will be followed by an implantable cardiac monitor.
62378718|NCT04225806|EXPERIMENTAL|Investigational|Subjects will be treated with the investigational device and followed per protocol.
62378719|NCT02367859|EXPERIMENTAL|Treatment (dabrafenib)|Patients receive dabrafenib PO BID every 12 hours plus trametinib daily PO for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients whose disease is judged to be not amenable to resection will continue dabrafenib and trametinib indefinitely as long as there has not been tumor progression.
62378720|NCT04919694|EXPERIMENTAL|combination of orbital compression and strabismus surgery|orbital compression and strabismus surgery are performed at the same time
62755858|NCT04392908||Medical Staff|Medical staff including doctor, psychologist and nurse
62755859|NCT06605976|EXPERIMENTAL|DAX CoPilot Group|Participants in this arm were given a DAX CoPilot license and asked to use it for clinical documentation in the EHR.
62755860|NCT06605976|NO_INTERVENTION|Control group|Participants in this arm were not given a DAX CoPilot license and were asked to use standard methods for clinical documentation in the EHR.
62755861|NCT02055534|EXPERIMENTAL|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the Amyloidosis Center
62378721|NCT04919694|ACTIVE_COMPARATOR|perform strabismus surgery after orbital compression|Firstly, perform orbital compression, after about 3 to 6 months ,strabismus surgery is done.
62378722|NCT04764838|EXPERIMENTAL|Intervantion|Pregnant Yoga
62378723|NCT04764838|NO_INTERVENTION|Control|The clinic will receive routine care
62378724|NCT02429089|EXPERIMENTAL|Group I|The patients will receive the same molecules (cetuximab and LEE011) but this phase I study will determine the DLTs by dose escalation of LEE011 (400 mg and 600mg).
62378725|NCT05297292|ACTIVE_COMPARATOR|Lucentis-0.5mg（Q4w）|It is administered once every 4 weeks for 48 weeks. Intravitreal injection was used, and the dose was 0.5mg.
62557264|NCT02839772|EXPERIMENTAL|Current skin regimen plus 2% glycerine|Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 1 litre of water with added sodium hypochlorite (0.0125%) and 2% glycerine, air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
62755862|NCT02055534|OTHER|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the Amyloidosis Center
62755863|NCT06556238|EXPERIMENTAL|Nicotine Metabolite Ratio|Subjects identified as cigarette smokers wishing to quit will receive the Nicotine Metabolite Ratio (NMR) test in a primary care setting and the results of the NMR will be used to inform medication recommendations for tobacco cessation.
62755864|NCT06111066||vitamin D deficiency|The umbilical cord blood 25(OH)D levels: \<30nmol/L
62755865|NCT06111066||vitamin D insufficiency|The umbilical cord blood 25(OH)D levels: 30\~50nmol/L
62755866|NCT06111066||vitamin D sufficiency|The umbilical cord blood 25(OH)D levels: \>50\~250nmol/L
62755867|NCT03789032|EXPERIMENTAL|Rabeprazole and Vadadustat|Subjects will receive vadadustat 300 mg on day 1, rabeprazole 20 mg every 12 hours on days 2 through 5 and vadadustat 300 mg and rabeprazole on day 6
62755868|NCT06306664|EXPERIMENTAL|Group A|the patients will receive green filter of bioptron light therapy and conventional treatment((ice application+ exercise program)) for jumper knee three times a week for four weeks.
62755869|NCT06306664|EXPERIMENTAL|Group B|the patients will receive yellow filter of bioptron light therapy and conventional treatment for jumper knee three times a week for four weeks.
62755870|NCT06306664|PLACEBO_COMPARATOR|Control group|the patients will receive conventional treatment (ice application+ exercise program) for jumper knee three times a week for four weeks.
62755871|NCT04393688|EXPERIMENTAL|Experimental: Tri-wire Peripheral Balloon Dilatation Catheter|Percutaneous transluminal angiography (PTA) will be performed using the Tri-wire Peripheral Balloon Dilatation Catheter. Interventions: Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter; Procedure: Percutaneous Transluminal Angiography.
62755872|NCT04393688|ACTIVE_COMPARATOR|Active Comparator: OHICHO Ⅱ PTA Balloon Catheter.|Percutaneous transluminal angiography (PTA) will be performed using OHICHO Ⅱ PTA Balloon Catheter, a commercially available high-pressure PTA balloon. Multiple balloons, inflations and/or prolonged inflation may be used. Interventions: Device: OHICHO Ⅱ PTA Balloon Catheter. Procedure: Percutaneous Transluminal Angiography.
62755873|NCT03670329|EXPERIMENTAL|URGO2875|Dressing
62755874|NCT05256342|ACTIVE_COMPARATOR|Duloxetine|Eight weeks treatment, one pill a day. Week 1st - 30 mg a day. Weeks 2nd - 8th - 60 mg a day.
62378726|NCT05297292|EXPERIMENTAL|MW02-1.0mg（Q4w）|It is administered once every 4 weeks for 48 weeks. Intravitreal injection was used, and the dose was 1.0mg.
62378727|NCT05297292|EXPERIMENTAL|MW02-1.5mg（Q4w）|It is administered once every 4 weeks for 48 weeks. Intravitreal injection was used, and the dose was 1.5mg.
62378728|NCT05297292|EXPERIMENTAL|MW02（Q8w）|It is administered once every 4 weeks for 3 consecutive times, and then once every 8 weeks for 48 weeks.
62378729|NCT04545931|EXPERIMENTAL|Posterior tibial nerve stimulation|First arm will undergo posterior tibial nerve stimulation ( one session per week for 12 weeks )
62378730|NCT04545931|EXPERIMENTAL|Desmopressin|Second arm will receive medical treatment (desmopressin 0.2 mg . single evening dose ) for 12 weeks
62378731|NCT04530318|EXPERIMENTAL|TolDec|Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded
62378732|NCT04530318|PLACEBO_COMPARATOR|Placebo|Placebo of dendritic cells
62557265|NCT02394470|OTHER|Acute heart failure HF,Chronic HF,Advanced chronic HF|patient admitted to the hospital for acute heart failure (de-novo or exacerbation of chronic heart failure), for Chronic HF and for Advanced chronic heart failure
62557266|NCT02924831|EXPERIMENTAL|Moxibustion group|drug:moxa Moxibustion was to stimulate acupoints of Guanyuan(RN4)and the Zusanli(ST36) with burned moxa.
62755875|NCT05256342|ACTIVE_COMPARATOR|Etoricoxib|Eight weeks treatment. 60 mg daily pill ; from the second week adding omeprazol 20 mg daily
62378733|NCT04818112|EXPERIMENTAL|Behavioral ATVV intervention|A multi-sensory behavioral intervention that includes auditory, tactile, visual and vestibular (ATVV) stimulation contingent upon infant cues.
62378734|NCT04818112|ACTIVE_COMPARATOR|Attention control|An attention control group that receives education on safe infant care and the same amount of attention as the intervention group.
62378735|NCT04574791|NO_INTERVENTION|Multimodal Pain Regimen|current standard of care post-operative pain regimen in the hospital, which comprises of standing doses of oral acetaminophen 975 mg three times a day, gabapentin 300 mg two times a day, and intravenous ketorolac 30 mg three times a day for patients \<65 years and 15 mg IV Q8h for patients who are \>65 years, supplemented with PRN oxycodone and tramadol.
62755876|NCT04419740|EXPERIMENTAL|Mindfulness based psychological intervention|"Patients allocated to the intervention group will receive an email with a link to a video and a pdf document. The video and the pdf document will introduce them to the principles and the practice of mindfulness. They will also receive an access code to an e-tool valid for 1 month. On this e-tool the patient will have access to short guided meditations both general and specific to infertility. They will be instructed to follow the découverte (discovery) program of 8 meditations of 10 minutes and then the program désir de parentalité (wish to become a parent) of 13 minutes 15 meditations of 13 minutes each. Patients will be given access to all other meditations programs of PetitBambou and instructed to meditate with the program for at least 10-15 minutes on a daily basis."
62755877|NCT04419740|NO_INTERVENTION|Standard care|The control group will have no additional intervention and will receive standard care in the institution. Women in all 3 study sites have access to counselling/psychological support with a trained professional before treatment initiation. During that consultation coping and stress reduction strategies are discussed.
62378736|NCT04574791|EXPERIMENTAL|Multimodal Pain Regimen + Tizanidine|current standard of care post-operative pain regimen in the hospital, which comprises of standing doses of oral acetaminophen 975 mg three times a day, gabapentin 300 mg two times a day, and intravenous ketorolac 30 mg three times a day for patients \<65 years and 15 mg IV Q8h for patients who are \>65 years, supplemented with PRN oxycodone and tramadol supplemented with standing doses of oral tizanidine in the hospital and for 14 days after discharge
62378737|NCT03001791|EXPERIMENTAL|Er:YAG laser|Excisional biopsy of fibrous hyperplasia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.
62378738|NCT03001791|EXPERIMENTAL|CO2 laser|Excisional biopsy of fibrous hyperplasia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.
62755878|NCT01065051|EXPERIMENTAL|Riociguat (Adempas, BAY63-2521)|Participants received a single oral dose of 1 mg riociguat.
62755879|NCT01065051|PLACEBO_COMPARATOR|Placebo|Participants received a single oral dose of 1 mg placebo.
62755880|NCT02671539|EXPERIMENTAL|open label injection of rAAV2.REP1|This is an open label, single arm interventional trial with subretinal injection of rAAV2.REP1 and fellow eye comparison
62755881|NCT05834465||Group 1|After using a non-contact tonometer to measure, the intraocular pressure is reduced by 0-10mmHg.
62755882|NCT05834465||Group 2|After using a non-contact tonometer to measure, the intraocular pressure is reduced by 10-20mmHg.
62755883|NCT05834465||Group 3|After using a non-contact tonometer to measure, the intraocular pressure is reduced over 20mmHg.
62755884|NCT05568914|EXPERIMENTAL|Assessments|"In this single-arm trial, each participant undergoes the following measurements/assessments:~Physical: Body weight (before and after dialysis), length Biophysical: NRS2002, GLIM, Bio-electrical Impedance Analysis Metabolic: Indirect Calorimetry Nutritional: dietary anamnesis, 3-days nutritional diary"
62755885|NCT02460783|EXPERIMENTAL|5-2 CR|Healthy living diet for 5 days/week; Calorie Restriction (480 Kcal in the form of a shake) for 2 days/week.
62755886|NCT02460783|ACTIVE_COMPARATOR|Healthy Living Diet|Healthy living diet for 7 days/week
62755887|NCT06463704||Observational cohort for potential study volunteers|This is a general screening protocol to develop a registry of potential volunteers for our clinical trials. There is no intervention to be administered.
62755888|NCT05427539|EXPERIMENTAL|TEST/CONTROL|Eligible subjects that are habitual contact lens wearers will be randomized into the (test/control) sequence and wear two different study lens designs (test and control designs) one at a time bilaterally over 2 wear periods.
62755889|NCT05427539|EXPERIMENTAL|CONTROL/TEST|Eligible subjects that are habitual contact lens wearers will be randomized into the (control/test) sequence and wear two different study lens designs (test and control designs) one at a time bilaterally over 2 wear periods.
62755890|NCT01900106|EXPERIMENTAL|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
62755891|NCT01900106|ACTIVE_COMPARATOR|ABC/3TC + DRV/r|abacavir/lamivudine + darunavir/ritonavir
62755892|NCT02666456||Cross-sectional cohort|Patients with chronic peripheral neuropathic pain
62755893|NCT02666456||Longitudinal cohort|Painless patients before and after potential chronic neuropathic pain-inducing interventions (chemotherapy, Operation)
62755894|NCT00504855|ACTIVE_COMPARATOR|Gortex (Waterproof) Cast Padding|Randomized application of one of two cast padding materials
62755895|NCT00504855|ACTIVE_COMPARATOR|Cotton/Cotton-Poly Cast Padding|Randomized application of one of two cast padding materials
62755896|NCT01218100|EXPERIMENTAL|1|Combination group - starting dose level nebivolol 5mg and lisinopril 10mg
62755897|NCT01218100|ACTIVE_COMPARATOR|2|Nebivolol monotherapy group - starting dose level nebivolol 5mg
62755898|NCT01218100|ACTIVE_COMPARATOR|3|Lisinopril monotherapy group - starting dose level lisinopril 10mg
62755899|NCT01218100|PLACEBO_COMPARATOR|4|Placebo group - starting dose is placebo
62755900|NCT05596617|NO_INTERVENTION|Standard of Care|Standard of care management of severe Covid-19 patients
62755901|NCT05596617|EXPERIMENTAL|Oral bedtime melatonin|Standard of care with oral bedtime melatonin
62755902|NCT02141490|EXPERIMENTAL|Ferumoxytol + Magnetic Resonance Imaging (MRI)|Ferumoxytol +MRI
62755903|NCT02073032||Head -Neck cancer patients, no intervention|
62755904|NCT01810068|SHAM_COMPARATOR|Placebo|patients who are undergoing diagnostic cystoscopy
62755905|NCT01810068|ACTIVE_COMPARATOR|HOLEP|Holmium laser enucleation of the prostate
62378739|NCT03001791|EXPERIMENTAL|Scalpel|Excisional biopsy of fibrous hyperplasia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
62378740|NCT05486689|EXPERIMENTAL|Standard Program|Pulmonary Rehabilitation
62378741|NCT02837549|EXPERIMENTAL|Occupational therapy treatment|"Participants will undergo the following as appropriate:~1. Thermal Modalities Hot packs, focused on areas with limitations Paraffin, focused on digital limitations~2. Application of the Physiotouch (a low-intensity negative pressure device)~3. Passive Range of Motion~4. Active Range of Motion~5. Functional Activities"
62378742|NCT03201133||Patellofemoral pain syndrome with changes in proximal factors|
62557267|NCT02924831|EXPERIMENTAL|Acupuncture group|material: stainless steel needle In acupuncture treatment, needles were applied to acupoints of Guanyuan(RN4)and Zusanli(ST36),with manipulations to get Deqi sensation.
62557268|NCT02924831|PLACEBO_COMPARATOR|Placebo group|material: stainless steel needle Needles were applied to acupoints of Guanyuan(RN4)and Zusanli(ST36),but without any manipulations and Deqi sensation.
62378743|NCT03201133||Patellofemoral pain syndrome with changes in local factors|
62378744|NCT03201133||Patellofemoral pain syndrome with changes in distal factors|
62378745|NCT03769857|EXPERIMENTAL|NEM® + BIOCURC®|"NEM® + BIOCURC®~NEM, 500 mg, #0 capsule, once daily orally for 2 weeks PLUS BIOCURC, 350 mg, #10 oval softgel, once daily orally for 2 weeks"
62378746|NCT03769857|PLACEBO_COMPARATOR|Placebo|Placebo, 500 mg, #0 capsule, once daily orally for 2 weeks PLUS Placebo, 350 mg, #10 oval softgel, once daily orally for 2 weeks
62378747|NCT03708484|ACTIVE_COMPARATOR|Aerobic Interval Training|Aerobic Interval Training is active comparator
62557269|NCT02924831|EXPERIMENTAL|Zusanli（ST36)-acupuncture group|material: stainless steel needle Stimulating acupoints of Zusanli(ST36) with acupuncture.
62557270|NCT02924831|EXPERIMENTAL|Guanyuan(RN4)-acupuncture group|material: stainless steel needle. Stimulating acupoint of Guanyuan(RN4) with acupuncture.
62755906|NCT01810068|ACTIVE_COMPARATOR|monopolar TURP|Monopolar transurethral resection of the prostate
62755907|NCT01810068|ACTIVE_COMPARATOR|Bipolar TURP|Bipolar transurethral resection of the prostate
62755908|NCT02085096|EXPERIMENTAL|Problem-Solving Therapy|A problem-solving therapy training program will be provided to the spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
62755909|NCT02085096|PLACEBO_COMPARATOR|Standard Supportive Care|Participants who are randomized to this arm will be encouraged to use whatever supporting care is recommended to them by their health provider.
62755910|NCT02868034|EXPERIMENTAL|SMT Only|Patients receive 2 sessions on SMT during week 1, no additional treatment.
62755911|NCT02868034|EXPERIMENTAL|SMT extended|2 sessions of SMT in week 1 and 6 additional sessions of SMT during weeks 2-4.
62182496|NCT01176305||Danish Women 15 to 49 years old.|Free of previous VTE and current use of oral contraceptives.
62378748|NCT03708484|EXPERIMENTAL|Aerobic + Resistive Interval Training|Aerobic + Resistive Interval Training is experimental
62378749|NCT06461195|EXPERIMENTAL|Regular respiratory physiotherapy while being monitored|Patients receive their standard respiratory physiotherapy, but in the mean time they are monitored with a stethoscope, spirometer and a wearable to measure physiological parameters.
62378750|NCT05516264|OTHER|Dog visits first|Participants receive the three dogs visits first and then, after a break, receive the three control visits
62378751|NCT05516264|OTHER|Control visits first|Participants receive the three control visits first and then, after a break, receive the three dog visits
62378752|NCT04290000||hematological malignancies|hematological malignancies treated with CAR-T Cells
62378753|NCT06339281|EXPERIMENTAL|Apatinib mesylate combined with chemotherapy (Capecitabine/vinorelbine)|
62378754|NCT06339281|ACTIVE_COMPARATOR|Apatinib mesylate combined with endocrine|
62378755|NCT02390362|EXPERIMENTAL|Rituximab|Rituximab 375 mg/m2 will be administered intravenously on Study weeks 1 \& 3.
62378756|NCT02390362|ACTIVE_COMPARATOR|Mycophenolate Mofetil (MMF)|Mycophenolate Mofetil will be continued in the patients in the MMF arm at a standard oral dose of 600 mg/m2 PO, BID starting on Study week 1 and continuing for 12 months
62378757|NCT00675844|EXPERIMENTAL|Elvucitabine|Participants currently receiving elvucitabine will continue elvucitabine as part of their antiretroviral therapy (ART) regimen for an additional 48 months.
62378758|NCT03303625|EXPERIMENTAL|Cohort 0: Adults (Ad26.RSV.preF)|Participants aged greater than or equal to (\>=) 18 to lesser than or equal to (\<=) 50 years will receive vector Ad26.RSV.preF at 1\*10\^11 viral particles (vp) via intramuscular (IM) route (Group 1) on Day 1 and 29.
62378759|NCT03303625|PLACEBO_COMPARATOR|Cohort 0: Adults (Placebo)|Participants aged \>= 18 to \<= 50 years will receive placebo via IM route (Group 2) on Day 1 and 29.
62378760|NCT03303625|EXPERIMENTAL|Cohort 1: RSV seropositive Toddlers (Ad26.RSV.preF)|RSV seropositive participants aged \>=12 to \<=24 months will receive Ad26.RSV.preF at 5\*10\^10 vp via IM route (Group 3) on Day 1 and 29.
62378761|NCT03303625|PLACEBO_COMPARATOR|Cohort 1: RSV seropositive Toddlers (Placebo)|RSV seropositive participants aged \>= 12 to \<= 24 months will receive placebo via IM route (Group 4) on Day 1 and 29.
62378762|NCT01034709||Symptomatic|Subjects with a confirmed CMV viremia by the site's CMV-LDT as well as CMV symptoms
62755912|NCT02868034|EXPERIMENTAL|SMT with Activation Exercises|2 sessions of SMT during week 1 and 6 additional sessions of lumbar multifidus activating exercises during weeks 2-4.
62755913|NCT02868034|EXPERIMENTAL|SMT with Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of spinal mobilizing exercises during weeks 2-4.
62755914|NCT02868034|EXPERIMENTAL|SMT with Mobilizing and Activation Exercises|2 sessions of SMT during week 1; 6 sessions of lumbar multifidus activating exercises and spinal mobilizing exercises during weeks 2-4.
62755915|NCT02868034|EXPERIMENTAL|SMT extended with Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of SMT and spinal mobilizing exercises during weeks 2-4.
62755916|NCT02868034|EXPERIMENTAL|SMT extended with Activation Exercises|2 sessions of SMT during week 1; 6 sessions of SMT and lumbar multifidus activating exercises during weeks 2-4.
62755917|NCT02868034|EXPERIMENTAL|SMT extended with Activation and Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of SMT, multifidus activating and spinal mobilizing exercises during weeks 2-4.
62378763|NCT01034709||Asymptomatic|Subjects who must have been serologically positive for CMV IgG prior to transplantation and do not have any CMV symptoms
62378764|NCT00780676|EXPERIMENTAL|Dasatinib sensitivity signature|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
62378765|NCT00780676|EXPERIMENTAL|SRC pathway activity signature|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
62378766|NCT00780676|EXPERIMENTAL|Dasatinib target index|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
62378767|NCT00780676|EXPERIMENTAL|Selumetinib pathway predictor|Participants predicted to respond to selumetinib/AZD6244 by predictive gene signature (either MEK pathway activity predictor positive or MEK pathway predictor negative) receive selumetinib 75 mg by mouth twice daily (BID).
62378768|NCT05272540||Day case surgery|Adult patients who are operated on as outpatients in day surgery. Treatment and care follow clinical routine. Weighing on a scales measuring bioelectrical impedance data before and after the surgery is added.
62755918|NCT02810301|EXPERIMENTAL|Treatment (Probiotic ES1)|Capsules containing 1 billion CFU of B. longum ES1 per capsule. One capsule taken before and after consuming 2 slices of bread for 7 days.
62755919|NCT02810301|PLACEBO_COMPARATOR|Placebo|Capsules not containing the active ingredient B. longum ES1. One capsule taken before and after consuming 2 slices of bread for 7 days.
62755920|NCT00937404|EXPERIMENTAL|IPV Group|Healthy male or female subjects between, and including, 60 and 90 days of age at the time of the first vaccination, receive 3 doses of Poliorix at 2 (Study Day 0, Visit 1), 3 (Study Month 1, Visit 2) and 4 (Study Month 2, Visit 3) months of age, administered intramuscularly into the upper right side of the thigh.
62755921|NCT02098369|OTHER|Usual care|Written education material (basic)
62378769|NCT05272540||In patient surgery|Adult patients who are operated on as inpatients in hospital care. Treatment and care follow clinical routine. Weighing on a scales measuring bioelectrical impedance data before the surgery and every morning during hospital stay is added.
62378770|NCT04671745||Expérimental|patient receiving care with interactive music
62378771|NCT04671745||Control|patient receiving care without interactive music
62378772|NCT05794672|EXPERIMENTAL|Part A|"Part A1: Each subject in three of the single inhaled dose cohorts will receive a single inhaled dose A, B, or C elarekibep and placebo in the fourth cohort.~Part A2: Each subject will receive a single Intravenous (IV) dose D elarekibep in one cohort."
62378773|NCT05794672|EXPERIMENTAL|Part B|Each subject will receive multiple inhaled doses C elarekibep or placebo twice daily (BID) for 6 days in the first cohort and a single inhaled dose on Day 7 in the second cohort.
62755922|NCT02098369|EXPERIMENTAL|Proactive|Written education material (basic) Additional education material PELICAN-Proactive \[In addition to the usual care, participants will receive educational material and a proactive telephone peer coaching program (coaches call participants)\]
62755923|NCT02098369|EXPERIMENTAL|Reactive|Written education material (basic) Additional education material PELICAN-Reactive \[In addition to the usual care, participants will receive educational material and a reactive telephone peer coaching program (participants call coaches)\]
62755924|NCT00991328|ACTIVE_COMPARATOR|Cerebral Desaturation, i.e; SctO2 < 60 % for 5 minutes|Once the cerebral desaturation is established, the study personnel will attempt to optimize the level of oxygen within the brain of the study patients.
62755925|NCT00991328|NO_INTERVENTION|Patients with SctO2 less than 60 %.|The study patients will not get any intervention in this arm if the Sct02 falls below 60%
62755926|NCT03908372|EXPERIMENTAL|Induction chemotherapy(IC)+IMRT|Induction chemotherapy for two cycles, the patients with complete response will receive 60 Gy to the gross target volume of nasopharynx, partial response 64 Gy, and the absence of response will receive concurrent chemoradiotherapy as the same as CCRT arm
62378774|NCT01962116|PLACEBO_COMPARATOR|Heparin lock|
62378775|NCT01962116|EXPERIMENTAL|Citrate lock|
62557271|NCT05081401||Individualized 9-12 month all-oral regimen|Treatment regimen is individually designed in this trial by responsible physicians at study sites based on radiological, clinical, bacteriological as well as drug sensitivity test results. RIF resistance was confirmed with phenotypic or molecular drug sensitivity test. Drug resistance to FQs, SLIDs, INH and Eto was evaluated by GeneXpert MTB/XDR. PZA resistance was confirmed by whole genome sequencing. Candidate anti-TB drugs are BDQ, LZD, FQs, Cs, Cfz, Z, Dlm and INH.
62557272|NCT06582303|EXPERIMENTAL|Experimental Group: Virtual reality intervention plus conventional physical therapy|The experimental group initially got VR intervention by playing all four easy-level games twice for three minutes each during the first and second weeks. This group again underwent VR intervention, playing all four same games with a difficulty level of twice 5 min duration for the third, fourth, fifth, and sixth weeks. The experimental group had an intervention of 24 sessions, lasting 4 days/week for a total of 6 weeks. During the first two weeks, patients received 24 minutes of VR hand games and 24 minutes of therapy sessions per day and for the next four weeks, this group received 40 minutes of VR hand games and 40 minutes of conventional therapy session per day. This group received conventional physical therapy that consists of range of motion, stretching, resistance, and strengthening exercises. At follow-up of two weeks this group only received conventional physical therapy.
62557273|NCT06582303|ACTIVE_COMPARATOR|Control Group: Conventional physical therapy|The control group received conventional physical therapy, which consists of range of motion, stretching, resistance, and strengthening exercises. The CPT group had a conventional intervention of 24 sessions, lasting 4 days per week for a total of 6 weeks. The CPT group was given 48 minutes of conventional physical therapy sessions per day for weeks 1 and 2, followed by 80 minutes of conventional physical therapy sessions per day for the next 4 weeks. At a follow-up of two weeks, this group also received conventional physical therapy.
62557274|NCT06342453|ACTIVE_COMPARATOR|Phase I (focus group)|Patients participate in focus groups to develop CrA intervention on study.
62557275|NCT06342453|EXPERIMENTAL|Phase II arm I (CrA)|Patients participate in CrA interventions comprising drawing, painting, and making sculptures with a trained artist for 30 minutes once a week for 4 sessions over 12 weeks.
62557276|NCT06342453|ACTIVE_COMPARATOR|Phase II arm II (watch videos)|Patients passively watch videos for 30 minutes once a week for 4 sessions over 12 weeks.
62557277|NCT02670616|EXPERIMENTAL|ibrutinib in combination with r-CHOP|Ibrutinib560 mg daily on day 1-21 per each cycle ,Rituximab375 mg/m2, Cyclophosphamide750 mg/m2, doxorubicin 50 mg/m2, vincristine1.4 mg/m2 on day 1; Prednisolone 100mg per day on day 1-5 ,cycle length: 21 days ,Six cycles of treatment
62557278|NCT02218138|EXPERIMENTAL|Learning 2 BREATHE|Learning 2 BREATHE, Mindfulness-based group program
62378776|NCT00832065||Patients With Sleep Apnea and Low Testosterone|Adult male patients between 18-70 years of age with nely diagnosed OSAS documented by all night polysomnography(PSG)
62378777|NCT01624974|EXPERIMENTAL|MK-1029/Placebo|Participants received 4 weeks treatment with MK-1029 150 mg once daily (QD) + ML 10 mg QD in Period III and Placebo QD + ML 10 mg QD in Period V. Period IV was a 4-week wash-out period during which participants received single-blind Placebo QD and open-label ML 10 mg QD.
62755927|NCT03908372|ACTIVE_COMPARATOR|Concurrent chemoradiotherapy(CCRT)|cisplatin 100mg/m2 IV on d1 of each 21 days for two cycles at least and 70 Gy radiotherapy
62755928|NCT03638869|PLACEBO_COMPARATOR|Arm 1|100 mL Ocean Spray® Diet Cranberry Juice
61986774|NCT03350854|EXPERIMENTAL|The intervention group|The provider will be informed of the patient preference in treatment decision making (preferred role) and have a discussion about this with the patient in the intervention group.
62557279|NCT02218138|EXPERIMENTAL|Colorado Blues|Colorado Blues, Cognitive-behavioral depression prevention group
62557280|NCT03024502|EXPERIMENTAL|EPP-AF Gel 1%|Group of patients that will be treated with EPP-AF mucoadhesive gel 1%, during 7 day, 1x/day.
62755929|NCT03638869|EXPERIMENTAL|Arm 2|REL-1017 25 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
62755930|NCT03638869|EXPERIMENTAL|Arm 3|REL-1017 50 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
62755931|NCT03638869|EXPERIMENTAL|Arm 4|REL-1017 75 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
62755932|NCT04540458|OTHER|3D printed model|Mother or Mother/Father is given 3D printed model of fetus' face
62755933|NCT04540458|OTHER|Placebo|Mother or Mother/Father is given printed picture of 3D ultrasound of fetus
62755934|NCT01686659|EXPERIMENTAL|SpHb Arm|These are the patients whose primary anesthesiologists have been allocated to treat them while having access to data from a continuous noninvasive hemoglobin monitoring device
61986775|NCT02117999|EXPERIMENTAL|Cross-linking with iontophoresis|Transepithelial cross-linking by using iontophoresis to administer riboflavin into the corneal stroma
61986776|NCT02117999|ACTIVE_COMPARATOR|Standard corneal cross-linking|Standard corneal cross-linking includes de-epithelialization and stromal soaking by applying drops of riboflavin
61986777|NCT06275282|EXPERIMENTAL|Regenerative Peripheral Nerve Interface (RPNI)|Participants will have regenerative peripheral nerve interfaces (RPNIs) created on nerves in their residual thighs. During either the same surgery or a separate surgery, electrodes will be implanted into these RPNIs.
62557281|NCT03024502|EXPERIMENTAL|Clotrimazole cream|Group of patients that will be treated with clotrimazole cream, during 7 day, 1x/day.
62557282|NCT03024502|EXPERIMENTAL|EPP-AF Gel 2%|Group of patients that will be treated with EPP-AF mucoadhesive gel 2%, during 7 day, 1x/day.
62557283|NCT00711243|EXPERIMENTAL|Cohort 1a|Docetaxel 25 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
62557284|NCT00711243|EXPERIMENTAL|Cohort 2a|Docetaxel 30 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
62557285|NCT00711243|EXPERIMENTAL|Cohort 3a|Docetaxel 40 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
62557286|NCT00711243|EXPERIMENTAL|Cohort 4a|Docetaxel 50 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
61986778|NCT03864640||Colorectal cancer|Patients with colorectal cancer
62378778|NCT01624974|EXPERIMENTAL|Placebo/MK-1029|Participants received 4 weeks treatment with Placebo QD + ML 10 mg QD in Period III and MK-1029 150 mg QD + ML 10 mg QD in Period V. Period IV was a 4-week wash-out period during which participants received single-blind Placebo QD and open-label ML 10 mg QD.
62378779|NCT05885373|EXPERIMENTAL|SIM01|2 sachets daily for 3 months
62378780|NCT02079311|EXPERIMENTAL|Active self-warming blanket|Active warming with BARRIER® EasyWarm active self-warming blanket during the perioperative phase
62378781|NCT02079311|ACTIVE_COMPARATOR|Forced air warming device|Active warming with forced air warming (FAW) during the intraoperative phase.
62378782|NCT03085212|EXPERIMENTAL|Online stress management program|Participants will receive free access to Stress Free Now, which is an online stress management program developed by the Cleveland Clinic that uses mindfulness and cognitive-behavior therapy to help individuals learn to manage their stress.
62378783|NCT03085212|ACTIVE_COMPARATOR|Wait list control|Participants in this arm will receive free access to the Stress Free Now program at the end of the study.
62378784|NCT01914510|EXPERIMENTAL|ENMD-2076|ENMD-2067 will be taken orally at a dose of 275 mg, once a day, everyday. Patients with a body surface area of less than 1.65 m2 will receive a starting dose of 250 mg, once a day, everyday.
62378785|NCT00422968|ACTIVE_COMPARATOR|coronary artery bypass graft|coronary artery bypass graft
62378786|NCT00422968|EXPERIMENTAL|percutaneous coronary intervention|Using silorimus eluting stent
62378787|NCT05283785||( group 1)|End to End sutures
62378788|NCT05283785||( group 2 )|End to Side sutures
62378789|NCT03170089|ACTIVE_COMPARATOR|Intervention|Professional tooth cleaning (scaling) Oral Health educational program
62557287|NCT00711243|EXPERIMENTAL|Cohort 5a|Docetaxel 60 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
62557288|NCT01525329|EXPERIMENTAL|Solid Organ Transplant with AKs|Patients who have undergone kidney or liver transplant within 2 years and have at least 4 premalignant skin lesions on the face, ears, scalp, forearms and/or dorsal hands. Patients will serve as their own control, and one side of the body will be randomized to either 5-FU plus PDT, and the other will receive PDT alone.
62557289|NCT01525329|ACTIVE_COMPARATOR|Actinic Keratoses|Patients with at least 4 actinic keratoses on the face, ears, scalp, forearms and/or dorsal hands. Patients will serve as their own control, and one side of the body will be randomized to either 5-FU plus PDT, and the other will receive PDT alone.
62755935|NCT01686659|NO_INTERVENTION|Control Arm|These are the patients whose primary anesthesiologists have been allocated to treat them without having access to data from a continuous noninvasive hemoglobin monitoring device
62378790|NCT03170089|NO_INTERVENTION|Control|NO program or scaling done
62557290|NCT02257710||Orsiro|All subjects requiring coronary revascularization with Drug Eluting Stents (DES)
62557291|NCT01644656|EXPERIMENTAL|acoustic radiation force impulse (ARFI)|Imaging of liver and spleen using modified ultrasound
62557292|NCT05056116|EXPERIMENTAL|Biliary Tract Cancer|Surufatinib 250mg/Toripalimab 240mg
62755936|NCT01795326||Germany|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
62378791|NCT05015062|EXPERIMENTAL|Mobile-based intervention with standardized incentive|Participants will receive biweekly messages containing HIV-related educational modules from village doctors who will receive standardized compensation for performing the work.
62378792|NCT05015062|EXPERIMENTAL|Mobile-based intervention with performance-based incentive|Participants will receive biweekly messages containing HIV-related educational modules from village doctors who will receive performance-based compensation for performing the work.
62378793|NCT05015062|NO_INTERVENTION|Control without intervention|Participants will not receive the mobile-based intervention
62378794|NCT03153124|EXPERIMENTAL|Respiratory muscle training|- three months of intradialytic training of a physical therapy protocol with PowerBreath.
62378795|NCT03153124|NO_INTERVENTION|Control|No intervention
62378796|NCT01786499|OTHER|Relaxation Response Training|
62378797|NCT01365715|EXPERIMENTAL|Preoperative embolization|32 patients with spinal metastasis/metastases will undergo arteriography and receive transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
62378798|NCT01365715|ACTIVE_COMPARATOR|Control group|32 patients with spinal metastasis/metastases will undergo arteriography of spinal metastasis/metastases without receiving transcatheter arterial embolization prior to surgery.
62378799|NCT01560754|EXPERIMENTAL|Transdermal nicotine patch|Subjects will apply a combination of 7 or 14 mg nicotine transdermal patches until reaching their highest well tolerated dose of 7 to 28 mg/day.
62378800|NCT01560754|PLACEBO_COMPARATOR|Transdermal placebo patch|Subjects will apply a combination of 7 or 14 mg placebo transdermal patches until reaching their highest well tolerated dose.
62378801|NCT00717561|EXPERIMENTAL|Arm 1|
62378802|NCT00717561|ACTIVE_COMPARATOR|Arm 2|
62378803|NCT02194192|EXPERIMENTAL|Group E|Ephedrine 10 mg in Normal Saline 10 ml
62378804|NCT02194192|ACTIVE_COMPARATOR|Group O|Ondansetron 8 mg in Normal saline 10 ml
62378805|NCT02194192|PLACEBO_COMPARATOR|Group P|Normal saline 10 ml
62378806|NCT03493373|EXPERIMENTAL|Exercise and nervous system mobilization|This group will receive neural mobilization and therapeutic exercise: two sessions of 60 minutes during 8 weeks.
62378807|NCT03493373|EXPERIMENTAL|Exercise|This group will receive therapeutic exercise: two sessions of 60 minutes during 8 weeks.
62378808|NCT06410794|EXPERIMENTAL|Comparing VR training and ABM training|The objective of this study is to investigate whether VR and ABM training increases work ability, work-related self-efficacy, attention and reduces symptoms of depression and anxiety and consequently change an attentional bias from negative to positive stimuli. We will compare patients receiving work-related interventions + VR, work-related interventions + ABM training and work-related interventions only. We will also investigate whether positive changes in attentional bias are associated with increased work participation. Self-reported work ability, self-efficacy, depression, anxiety and objective computerised cognitive and emotional testing will be assessed at baseline (start rehabilitation/treatment) and at posttest (end rehabilitation/treatment).
62378809|NCT06410794|NO_INTERVENTION|Patients' experiences with the usage of VR.|The objective of this part is to investigate the experiences in using VR. R\&D personell will make individual interviews with five patients at each of the three clinics involved in piloting VR. The aim of the interviews will be to capture how the patients experienced the VR activity, the demands of the VR activity, how VR has influenced different aspects of health and whether VR has influenced the abilities to return to work.
62378810|NCT05727527|ACTIVE_COMPARATOR|Study group|Will initially receive the infiltration injection after applying a candy flavor first, followed by sterile water in the next visit
62378811|NCT05727527|ACTIVE_COMPARATOR|Control group|Will initially receive the infiltration injection after applying sterile water first, followed by candy flavor in the next visit
61986779|NCT05870033||Men group|Muscle activity amongst men with KOA
61986780|NCT05870033||Women group|Muscle activity amongst women with KOA
62378812|NCT03381703|EXPERIMENTAL|Part 1|Investigate the absorption, metabolism, and excretion of YH12852
62378813|NCT03381703|EXPERIMENTAL|Part 2|Investigate the absolute bioavailability of YH12852
62378814|NCT02035410|ACTIVE_COMPARATOR|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
62378815|NCT02035410|NO_INTERVENTION|Control group|No intervention group
62378816|NCT01213342|EXPERIMENTAL|Treatment Group|This group will receive Omega-3 EFA supplements for 8 weeks. They will take 4 capsules/day.
62378817|NCT01213342|PLACEBO_COMPARATOR|Placebo Group|This group will receive placebo supplements for 8 weeks. They will take 4 capsules a day.
62378818|NCT01241318|EXPERIMENTAL|Chlorhexidine cord care|Mothers located in health facility catchment areas assigned to this arm will apply Chlorhexidine gluconate (4%) to their infants daily until three days after the cord completely separates. Bottles of chlorhexidine is provided to women during antenatal care.
62378819|NCT01241318|ACTIVE_COMPARATOR|Dry cord care|Mothers in health facility catchment areas assigned to this arm will use dry cord care - keeping their babies' umbilical stumps clean and dry - as per normal routine standard of care and in accordance with Zambia Ministry of Health policy.
62378820|NCT00060567|OTHER|1|Active combination of E7070 and irinotecan.
62378821|NCT00060567|OTHER|2|Active combination of E7070 and irinotecan.
62378822|NCT00060567|OTHER|3|Active combination of E7070 and irinotecan.
62378823|NCT05076552|EXPERIMENTAL|Phase 1a: Dose Escalation|In Phase 1a, participants will receive TACH101 in a 48 hour lead in period followed by repeated dosing at different dosing regimens in each 28 day cycle.
62557293|NCT02303912|OTHER|Open label dose escalation|"Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days.~Dose escalation will be done using 3+3 dose escalation design"
62557294|NCT01318317|EXPERIMENTAL|Treatment (cellular adoptive immunotherapy following PBSCT)|Patients receive standard salvage chemotherapy per standard practice and undergo standard mobilization for stem cell collection with G-CSF and/or plerixafor. Some patients may also receive rituximab IV within 4 weeks of transplant. Patients receive standard myeloablative conditioning followed by autologous PBSCT. Patients then undergo infusion of ex vivo expanded autologous TCM-enriched CD8+ T cells expressing CD19-specific CAR on day 2 or 3 after transplant.
62557295|NCT05677035|EXPERIMENTAL|Pharmacokinetic evaluation|LINO-1713 (Estetrol 15mg/Drospirenone 3mg)
62557296|NCT05677035|EXPERIMENTAL|Pharmacodynamic evaluation|LINO-1713 (Estetrol 15mg/Drospirenone 3mg)
62557297|NCT00054457|EXPERIMENTAL|docetaxel + capecitabine|"Patients receive docetaxel IV over 1 hour on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, at each tumor measurement, and at the end of treatment.~Patients are followed every 3 months until disease progression and then every 6 months until 3 years from registration."
62557298|NCT06583187|NO_INTERVENTION|Control Group|Routine clinical care will be applied to the control group. No action will be taken.
62557299|NCT06583187|EXPERIMENTAL|Experimental Group|Before circumcision, the child will be coloring mandala pictures of the pediatric clinic.
62557300|NCT04844112|EXPERIMENTAL|Experimental arm|"patients undergo routine conventional feasibility planning ultrasound, and clinical decision of RFA feasibility is made based on conventional planning ultrasound.~Then additional planning ultrasound using automatic CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging."
62557301|NCT03438838|ACTIVE_COMPARATOR|Laparoscopic Heller's Myotomy (LHM)alone|A minimum 10 patients undergo Laparoscopic Heller's myotomy alone
62557302|NCT03438838|ACTIVE_COMPARATOR|LHM with Anterior Fundoplication|A Minimum 10 patients undergo Laparoscopic Heller's myotomy along with fundoplication
62557303|NCT04053621|EXPERIMENTAL|Experimental group|"Metformin at patient´s tolerated oral dose (maximum of 2550 mg per day) and thiamine pyrophosphate (weekly dose of 1 gram administered by IV: 25 ml of thiamine pyrophosphate + 250 ml saline solution at a 60-80 drops/minute rate).~Total duration of 12 weeks."
62557304|NCT04053621|PLACEBO_COMPARATOR|Placebo group|"Metformin at patient´s tolerated oral dose (maximum of 2550 mg per day) and weekly administration of 275 ml of saline solution at a 60-80 drops/minute rate).~Total duration of 12 weeks."
62557305|NCT02731716|EXPERIMENTAL|New Payment Model|Providers in the first arm will no longer be paid based upon FFS, but on the new payment model. Providers will receive a PMPM payment for attributed members, a quality incentive payment based upon attainment of sixteen quality metrics, and a possible bonus payment for savings in total cost of care at the provider organization level.
62557306|NCT02731716|EXPERIMENTAL|Social Comparisons|Providers will no longer be paid based upon FFS, but on the new payment model. Providers will receive a PMPM payment for attributed members, a quality incentive payment based upon attainment of sixteen quality metrics, and a possible bonus payment for savings in total cost of care at the provider organization level. Providers will also receive weekly emails that will show comparisons of their own performance against their peers within the same provider organization on specific quality measures and total cost of care.
62557307|NCT02731716|EXPERIMENTAL|A1c Member/Provider Incentive|Providers will no longer be paid based upon FFS, but on the new payment model, which includes a PMPM payment for attributed members, a quality incentive payment based upon attainment of quality metrics, and a possible bonus payment for savings in total cost of care. Providers will also receive weekly emails that will show comparisons of their own performance against their peers within the same provider organization on specific quality measures and total cost of care. There is also a shared incentive between the member and the provider. The member incentive will be a payment made to diabetic patients with an A1C of greater than or equal to 9% who experience a reduction of at least 0.5%. Each participating member and PCP can receive up to $75 per quarter for A1C reduction.
62557308|NCT01618448|EXPERIMENTAL|Placebo|Placebo once daily
62557309|NCT01618448|EXPERIMENTAL|Tolvaptan|Tolvaptan 15mg once daily
62378824|NCT05076552|EXPERIMENTAL|Phase 1b: Dose Expansion|"In Phase 1b, participants will receive TACH101 at the RP2D identified in Phase 1a. Two cohorts of participants will be enrolled:~* Participants with gastrointestinal cancers.~* Participants with high microsatellite instability (MSI-H) metastatic colorectal cancer (CRC)."
62378825|NCT02531633|EXPERIMENTAL|Part A: Sirukumab, Dose 1+prednisone (6-month taper)|Subjects will receive blinded sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
62378826|NCT02531633|EXPERIMENTAL|Part A: Sirukumab, Dose 1+prednisone (3-month taper)|Subjects will receive blinded sirukumab 100 mg SC q2w for 52 weeks plus a pre-specified maximum of 3-month oral prednisone taper regimen.
62378827|NCT02531633|EXPERIMENTAL|Part A: Sirukumab, Dose 2+prednisone (6-month taper)|Subjects will receive blinded sirukumab 50 mg SC every 4 weeks (q4w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
62378828|NCT02531633|PLACEBO_COMPARATOR|Part A:Placebo to match sirutkumab+prednisone (6-month taper)|Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
62378829|NCT02531633|PLACEBO_COMPARATOR|Part A:Placebo to match sirukumab+prednisone (12-month taper)|Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 12-month oral prednisone taper regimen.
62557310|NCT04127773||NEX group|oro gastric tube placement using NEX insertion length predictor
62557311|NCT04127773||NEMU group|oro gastric tube placement using NEMU insertion length predictor
62557312|NCT01854476|EXPERIMENTAL|Tranexamic acid|pad-gauze with tranexamic acid (Hemostopan™)
62557313|NCT01854476|PLACEBO_COMPARATOR|Pad gauze|Pad gauze with no tranexamic acid
62557314|NCT00982657|EXPERIMENTAL|Cohort 1|CVX-060 + sunitinib
62557315|NCT00982657|EXPERIMENTAL|Cohort 2|CVX-060 + sunitinib
62755937|NCT01795326||United Kingdom|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
62378830|NCT02531633|EXPERIMENTAL|Part B:Open-label sirukumab 100 mg SC (if applicable)|Subjects completing Part A will receive open label 100 mg SC q2w for a maximum of 52 weeks based on remission status and disease activity at the primary 52-week endpoint or prednisone tapering status of subject during Part A. Methotrexate will be provided to subjects, alone or in addition to sirukumab treatment during Part B, based on the discretion of the investigator.
62378831|NCT01631006|SHAM_COMPARATOR|Low CPAP pressure|Patients are submmited to a CPAP with low pressure for 20 minutes
62378832|NCT01631006|ACTIVE_COMPARATOR|High CPAP pressure|Patients are submmited to a high pressure of CPAP for 20 minutes
62378833|NCT00898950|EXPERIMENTAL|Aspirin low dose|Effects of using aspirin 75 mgs/day for 2 weeks.
62378834|NCT00898950|EXPERIMENTAL|Aspirin medium dose|Effects of using aspirin 300 mgs/day
62378835|NCT00898950|EXPERIMENTAL|aspirin high dose|aspirin 900mgs QID orally for 2 weeks
62378836|NCT00898950|PLACEBO_COMPARATOR|placebo|
62378837|NCT05193890||Epilepsy only|Epilepsy only patients who underwent our gene panel and the Clinical exome Solution
62378838|NCT05193890||Intelectual Disability only|Intelectual Disability only patients who underwent our gene panel and the Clinical exome Solution
62378839|NCT05193890||Epilepsy and Intelectual Disability|Intelectual Disability and Epilepsy patients who underwent our gene panel and the Clinical exome Solution
62378840|NCT06390293|EXPERIMENTAL|Group guided WET-R|
62378841|NCT06390293|OTHER|Waiting-List (WL) condition|
62557316|NCT00982657|EXPERIMENTAL|Cohort 3|CVX-060 + sunitinib
62557317|NCT00982657|EXPERIMENTAL|Expanded cohort|CVX-060 + sunitinib
62557318|NCT00982657|EXPERIMENTAL|Phase II - Arm A|CVX-060 + sunitinib
62755938|NCT01795326||Spain|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
61986781|NCT00415233|EXPERIMENTAL|1.1Gbq with rhTSH|Patients receive 1.1GBq dose of radioactive iodine and rhTSH
61986782|NCT00415233|EXPERIMENTAL|3.2 GBq with rhTSH|Patients receive 3.2GBq dose of radioactive idodine and rhTSH
61986783|NCT00415233|EXPERIMENTAL|1.1GBq without rhTSH|Patients only receive 1.1GBq dose of radioactive iodine and no rhTSH
62378842|NCT04139421|ACTIVE_COMPARATOR|Urban Green Space group|This group of participants would experience a 3-hour Shinrin-Yoku session in urban green space.
62557319|NCT00982657|ACTIVE_COMPARATOR|Phase II - Arm B|sunitinib alone
62557320|NCT03280810|EXPERIMENTAL|Movement group|patients with schizophrenia (experimental group) have psycho-corporal training once a week, during 1 hour and a half for a period of two months
62557321|NCT03280810|NO_INTERVENTION|Control group|No intervervention : patients with schizophrenia (comparator group) who don't have psycho-corporal training
62378843|NCT04139421|EXPERIMENTAL|Rural Green Space group|This group of participants would experience a 3-hour Shinrin-Yoku session in rural green space.
62378844|NCT01864629|OTHER|Contraception after preterm birth|Intervention name: Focused contraception counseling This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
62378845|NCT01864629|NO_INTERVENTION|Control Group|Participants will receive the standard postpartum contraception counseling that is received by all patients who deliver at our institution.
62378846|NCT06257394|EXPERIMENTAL|[Arm A, Dasatinib(Sprycel) Arm]|"▪ Arm A : Philadelphia chromosome-positive : Induction (Except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.)~* Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~  1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → DI #1 → IM #2 → DI #2 → Maintenance~ 2. If MRD or qPCR positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~* M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT~  1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~ 2. If MRD or qPCR positive after the post-reinduction : Consolidation #3 using Blinatumomab~     * In Arm A, except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib."
62557322|NCT01428596|EXPERIMENTAL|Arm I|Lower dose HIVAX vaccine
62557323|NCT01428596|PLACEBO_COMPARATOR|Arm II|lower dose, placebo control
62557324|NCT01428596|EXPERIMENTAL|Arm III|Higher dose HIVAX vaccine
62557325|NCT01197352|EXPERIMENTAL|Text message queries with feedback|Weekly prompted queries about drinking behavior with personalized feedback.
62557326|NCT01197352|ACTIVE_COMPARATOR|Text message queries|Weekly prompted queries about drinking behavior
62557327|NCT01197352|NO_INTERVENTION|Control|Weekly text reminders to complete final (12 week) instruments
62557328|NCT02817737||CT|Measured with computed tomography
62557329|NCT02817737||plain Radiography|Measured with plain Radiography
62755939|NCT01795326||Hungary|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
62755940|NCT01795326||Netherlands|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
62755941|NCT01795326||Sweden|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
62755942|NCT01795326||Romania|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
62755943|NCT01795326||Italy|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
62755944|NCT04937335||Non-hemorrhage group|Patients recognized as craniopharyngioma pathologically without tumoral hemorrhage observed during the operation
62755945|NCT04937335||Hemorrhage group|Patients recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation
62755946|NCT01641146|EXPERIMENTAL|Enhanced Sexual Health Intervention for Men|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
62755947|NCT01641146|ACTIVE_COMPARATOR|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
62755948|NCT01665430|EXPERIMENTAL|Tocilizumab|Participants will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenous infusion every 4 weeks up to 104 weeks.
62755949|NCT00992381|EXPERIMENTAL|1|PN400
62755950|NCT00992381|ACTIVE_COMPARATOR|2|Naproxen
62378847|NCT06257394|EXPERIMENTAL|[Arm B, Non-Dasatinib(Sprycel) Arm]|"▪ Arm B : Other VHR ALL except Philadelphia chromosome-positive : Induction~* Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~  1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → Allogeneic HSCT~ 2. If MRD positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~* M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT~  1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~ 2. If MRD positive after the post-reinduction : Consolidation #3 using Blinatumomab"
62378848|NCT01114594||PKD|Patients with Autosomal Dominant Polycystic Kidney Disease
62378849|NCT01114594||non-PKD CKD|Patients with non-Polycystic Chronic Kidney Disease
62378850|NCT03996525|EXPERIMENTAL|Electrical Stimulation|"Electrical Stimulation~The patient will receive active electrical stimulation."
62557330|NCT05422001|EXPERIMENTAL|Intervention, low-dose ketamine|Two 1 ml syringes with Esketamine (5 mg/ml) will be prepared and study drug will be administered as intravenous bolus dose, 0,1 mg/kg. The study drug will be administered after an intravenous morphine dose.
62755951|NCT04768959|NO_INTERVENTION|No Intervention: TAU + waiting list|This control group is a waiting list group. Participants received treatment as usual (TAU). Once the RCT is finished, participants have the chance to participate in the intervention group.
62755952|NCT04768959|EXPERIMENTAL|Experimental: TAU + Feliz-Mente Intervention|Feliz-Mente (third generation psychotherapy):The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
62755953|NCT05153811|EXPERIMENTAL|Non-Contingent Condition|Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, encouragement to reduce drinking but payment not based on drinking.
62755954|NCT05153811|EXPERIMENTAL|mHealth and CM|Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, weekly CM based on wrist biosensor readings. Participants will also interact with a mobile health application to facilitate drinking reduction.
62755955|NCT05153811|EXPERIMENTAL|CM|Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, weekly CM based on wrist biosensor readings
62378851|NCT03996525|PLACEBO_COMPARATOR|Sham Treatment|"No Electrical Stimulation~The patient will receive sham electrical stimulation."
62378852|NCT00835757||1|Diabetic peripheral neuropathy
62378853|NCT00835757||2|Healthy controls
62378854|NCT02079506|EXPERIMENTAL|Treatment A|
62378855|NCT02079506|EXPERIMENTAL|Treatment B|
62557331|NCT05422001|PLACEBO_COMPARATOR|Placebo|Two 1 ml syringes with saline will be prepared and study drug will be administered as intravenous dose, same volume as if Esketamine. The placebo drug will be administered after an intravenous morphine dose.
62557332|NCT04969146|EXPERIMENTAL|Modified Cognitive Behavioral Therapy Intervention Dyadic|The patient and caregiver in the dyadic intervention will have 5 sessions of Modified CBTi. The patient and caregiver will complete the assessment at 3- and 6 months follow up.
62557333|NCT04969146|EXPERIMENTAL|Modified Cognitive Behavioral Therapy Intervention Patient Only|The patient in the patient only intervention arm will receive 5 sessions of Modified CBTi. The patient and caregiver will complete the assessment at 3- and 6 months follow up
62755956|NCT03100539|EXPERIMENTAL|Therapist treated massage (TT-M)|Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.
62755957|NCT03100539|NO_INTERVENTION|Wait list control (WL-C)|Participants in the waitlist control will be instructed to continue their medical care as normal and to not begin any massage treatment during the 6 months of the study. At the competition of the final 6 month outcome, participants in the control arm will be eligible to attend a caregiver training session and receive a complementary massage session from a TOMCATT study therapist.
62557334|NCT01475799|EXPERIMENTAL|Percutaneous Aortic Valve 18F System|Evaluation of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the Treatment of Patients with Severe Aortic Stenosis.
62755958|NCT03100539|EXPERIMENTAL|Care ally assisted massage (CA-M)|CA-M consisted of in-person training for veteran/care-ally dyads to learn a standardized 30-minue massage routine, instructional DVD, and printed treatment manual. Participants were to complete three care ally-assisted massage sessions weekly for 12-weeks.
62755959|NCT00787930||Manic Subject with DWM Hyperintensities >2|Subjects with acute mania who were treated with naturalistic protocol (starting with valproic acid) who had a BOYKO DWM Hyperintensity rating \>2 and a YMRS \<15 at week 3.
62755960|NCT00787930||Manic Subjects with DWM Hyperintensities <3|Subjects with acute mania who were treated with naturalistic protocol (starting with valproic acid)who had a BOYKO DWM Hyperintensity rating \<3 and a YMRS \<15 at week 3.
62755961|NCT04794647|EXPERIMENTAL|cervical mobilization|'Rotation mobilization' was applied to the symptomatic segment / segments after the detailed evaluation (symptom localization tests, cervical region safety tests, joint play tests, pain provocation/alleviation tests) in accordance with the Kaltenborn-Evjenth system in cervical region. Five series of 45-s mobilizations were performed with 15 s of rest. Each patient received 6 treatment sessions over a period of 3 week.
62755962|NCT04794647|PLACEBO_COMPARATOR|placebo mobilization|Placebo mobilization was applied to the cervical region in the same position and the same grip with the mobilization group. The physiotherapist put her hand on a randomly selected faset without any pushing or pulling, The duration of placebo mobilization was the same as the duration of the other group. Each patient received 6 treatment sessions over a period of 3 week.
62755963|NCT04569136|EXPERIMENTAL|Intervention group|"* Educating the patient about mastitis and self-management strategies~* Treating with therapeutic ultrasound~* Administering and teaching breast massage"
62755964|NCT04569136|SHAM_COMPARATOR|Sham group|"* Educating the patient about mastitis and self-management strategies~* Receiving sham ultrasound~* Administering and teaching breast massage"
62755965|NCT04569136|OTHER|Usual care group|Receiving usual obstetric care, which may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff
62755966|NCT05486000|EXPERIMENTAL|treatment group|This group contains patients with chronic left heart failure who are undergoing intervention in the atrial shunt implant system
62755967|NCT06389734|EXPERIMENTAL|Intervention group|The intervention group will receive combining manual soft tissue release and exercise training.
62755968|NCT06389734|ACTIVE_COMPARATOR|Control group|The control group will receive combining myofascial release and exercise training.
62755969|NCT01449110|PLACEBO_COMPARATOR|Placebo in PP|Placebo arm in primary cardiovascular prevention (PP)
62755970|NCT01449110|PLACEBO_COMPARATOR|Placebo in SP|Placebo arm in secondary cardiovascular prevention (SP)
62755971|NCT01449110|ACTIVE_COMPARATOR|Grape extract in PP|Grape extract obtained without resveratrol in primary cardiovascular prevention
61986784|NCT00415233|EXPERIMENTAL|3.2GBq without rhTSH|Patients only receive 3.2GBq dose of radioactive iodine and no rhTSH
62557335|NCT01154231||Nonacog Alfa (Genetical Recombination)|
62557336|NCT00980252|EXPERIMENTAL|CBT|UK-based intervention
62557337|NCT02164045|EXPERIMENTAL|BMS-663068- Fasted|BMS-663068 tablet twice a day by mouth on specified days
62557338|NCT02164045|EXPERIMENTAL|BMS-663068- Fed|BMS-663068 tablet twice a day by mouth on specified days
62557339|NCT02070250|EXPERIMENTAL|From Cancer to Health (C2H-D)|Individuals participating in the From Cancer to Health (C2H-D) Stress Management Psychological Intervention
62755972|NCT01449110|ACTIVE_COMPARATOR|Grape extract in SP|Grape extract without resveratrol in secondary cardiovascular prevention
62557340|NCT05234801||DARCO™ Headed Cannulated Screw|Patients who received a device from the DARCO™ Headed Cannulated Screw family of devices during routine lower limb surgery.
62557341|NCT05234801||ORTHOLOC™ 3Di Recon-Midfoot/Flatfoot System|Patients who received a device from the ORTHOLOC™ 3Di Recon-Midfoot/Flatfoot System family of devices during routine lower limb surgery.
62755973|NCT01449110|EXPERIMENTAL|Resveratrol-enriched grape extract in PP|Resveratrol-enriched grape extract (Stilvid) in primary cardiovascular prevention
62755974|NCT01449110|EXPERIMENTAL|Resveratrol-enriched grape extract in SP|Resveratrol-enriched grape extract (Stilvid) in secondary cardiovascular prevention
62557342|NCT05234801||ORTHOLOCTM 3Di 2 Foot Reconstruction System: CROSSCHECK™ Module|Patients who received a device from the ORTHOLOCTM 3Di 2 Foot Reconstruction System: CROSSCHECK™ Module family of devices during routine lower limb surgery.
62557343|NCT02690038|EXPERIMENTAL|Intervention Arm 1: Treatment|"Baseline Ig \< 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks).~Baseline Ig \> or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks)."
62755975|NCT05027490|EXPERIMENTAL|patients receiving CANUT support (guide + dietary interviews)|"Patients included in this arm will have following interventions :~* CANUT support : patients will receive the CANUT guide (food guide) to help them deal with eating disorders encountered during their chemotherapy treatment ; the CANUT support includes calls from a dietician between chemotherapy cycles for support and advice.~* anthropometric measures~* Prehension strength measurement~* food quality of life questionnaire (Qualité de Vie Alimentaire QVA)~* Quality of Life Questionnaire Core 30 (QLQ C30)~* Scratch \& Snif Test~* Taste Strip Test~* Nutrition interview~* 24 H feed back questionnaire~* condiment questionnaire~* tobacco questionnaire"
62755976|NCT05027490|ACTIVE_COMPARATOR|patients not receiving canut support (guide + dietary interviews)|"Patients included in this arm will have following interventions :~* anthropometric measures~* Prehension strength measurement~* food quality of life questionnaire (Qualité de Vie Alimentaire QVA)~* Quality of Life Questionnaire Core 30 (QLQ C30)~* Scratch \& Snif Test~* Taste Strip Test~* Nutrition interview~* 24 H feed back questionnaire~* condiment questionnaire~* tobacco questionnaire"
62755977|NCT00338273|ACTIVE_COMPARATOR|A1|
62755978|NCT00338273|PLACEBO_COMPARATOR|A2|
62755979|NCT02370641|ACTIVE_COMPARATOR|urolithin excretors|The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
62755980|NCT02370641|ACTIVE_COMPARATOR|non excretors|The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
62755981|NCT01714518||ILD diagnosis|Patients subjected to Cryobiopsy and/or VATS for diagnosis of interstitial lung disease
62755982|NCT00888329|EXPERIMENTAL|Aprepitant|40 mg aprepitant
62755983|NCT00888329|PLACEBO_COMPARATOR|Placebo|Placebo
62755984|NCT03100812|EXPERIMENTAL|Group A|
62755985|NCT03100812|EXPERIMENTAL|Group B|
62755986|NCT04450628|NO_INTERVENTION|Surgeon blinded|"During blinded cases no adjustment will be made to the surgical procedure based on EndoFLIP results, as the operating surgeon will not be informed of the measured values.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
62755987|NCT04450628|EXPERIMENTAL|Surgeon unblinded|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
62755988|NCT02082223|EXPERIMENTAL|Preoperative Rehabilitation|"Patient \& caregiver input regarding 'single biggest concern right now' (modified BEACON buttons) will be elicited. Information gathered by the study team which includes a trained nursing coach and the patient/caregiver will together develop an individualized 'toolbox' of possible interventions to improve preoperative quality of life.~Candidate interventions include, but not limited to: Participation in SMART program, caregiver participation in Caregivers study protocol MC1295 (IRB 13-002943), nutritional recommendations (deficiencies, immuno-nutrition), low impact resistance training/tai chi, referral to financial or counseling services, establishment of information sources \& plans for concerns not frequently covered in clinical practice such as sleeplessness, spiritual assistance."
62755989|NCT06087263|EXPERIMENTAL|Regorafenib|
62755990|NCT04862234|EXPERIMENTAL|Continuous Glucose Monitoring|Aim 1 participants will have a continuous glucose monitor (CGM) placed preoperatively and will wear the CGM throughout hospitalization.
62755991|NCT04862234|EXPERIMENTAL|Dulaglutide|Aim 2 participants randomized to receive dulaglutide within 72 hours prior to a planned surgery.
62755992|NCT04862234|PLACEBO_COMPARATOR|Placebo|Aim 2 participants randomized to receive a placebo to match dulaglutide within 72 hours prior to a planned surgery.
62755993|NCT02671149|EXPERIMENTAL|Drink water|Participants will receive two 150ml drinks of water during the dehydration protocol
62755994|NCT02671149|NO_INTERVENTION|Drink nothing|Participants will drink nothing during the dehydration protocol
62755995|NCT06607055||Interventional - blood collection|HLA-DR dosage, at the time of inclusion and once a week then
62755996|NCT03455868||Sleeve gastrectomy diabetes|70 Men and women with or without type 2 diabetes and obesity undergoing sleeve gastrectomy
62755997|NCT03455868||Control without obesity or diabetes|30 Men and women who are overweight (without obesity) and without diabetes
62378856|NCT00407420|EXPERIMENTAL|Mandometer|Active intervention - one meal eaten per day off Mandometer
62755998|NCT01920997||No drug intervention|The objective of this study is to investigate the expression of NEI network and urine metabolomics of healthy women with normal menstrual cycles.
62755999|NCT01128348|EXPERIMENTAL|patient advocate|"Patient advocate works with patient before, during, and after a visit to asthma doctor.~Patient receives video of asthma education materials"
62756000|NCT01128348|ACTIVE_COMPARATOR|asthma education|Patient receives video of asthma education materials
62756001|NCT04270058||Cohort 1|Cohort 1 will be pregnant patients who have been exposed to at least 1 dose of TEGSEDI within 25 weeks prior to conception or during pregnancy.
62756002|NCT04270058||Cohort 2|Cohort 2 will be pregnant patients who have hATTR-PN, who were not exposed to TEGSEDI or have not received TEGSEDI within the previous 25 weeks prior to conception.
62756003|NCT01466660|EXPERIMENTAL|afatinib|afatinib once daily.
62557344|NCT02690038|ACTIVE_COMPARATOR|Intervention Arm 2: Control|"Baseline Ig \< 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks).~Baseline Ig \> or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks)."
62557345|NCT04996628|EXPERIMENTAL|Pancreatic Quantitative Sensory Testing (P-QST)|Definite Chronic Pancreatitis patients undergoing decompressive invasive treatments (endoscopic therapy or surgery) to relieve main pancreatic duct obstruction due to stones and/or stricture for management of pain will undergo P-QST prior to clinically-indicated invasive treatment.
62557346|NCT00209040|EXPERIMENTAL|1|Subjects with posttraumatic stress disorder
62557347|NCT00209040|ACTIVE_COMPARATOR|2|Healthy controls
62557348|NCT00209040|ACTIVE_COMPARATOR|3|Combat controls
62557349|NCT05778201|EXPERIMENTAL|Baby Drink group|1 package/ day for 1 month
62557350|NCT05377463|EXPERIMENTAL|Condition 1: Component 1|1) Peer-Support for Medication-Assisted Treatment
62557351|NCT05377463|EXPERIMENTAL|Condition 2: Component 2|2) Behavioral Activation Therapy
62557352|NCT05377463|EXPERIMENTAL|Condition 3: Components 1 and 2|"Participants assigned to a combination of:~1. Peer-Support for Medication-Assisted Treatment~2. Behavioral Activation Therap"
62557353|NCT05377463|EXPERIMENTAL|Condition 4: No Components|Participants not assigned to any of the 2 components. They are placed on a wait list and will receive components after the primary data collection period.
62557354|NCT05630911||High Reinvestor Group (HRG)|"Participants will be invited to complete a series of standing balance trials. The trials will involve participants standing in three different positions on a foam surface (i.e., Airex balance pad elite with a dimension of 16.1 width x 19.7 length x 2.4 height, or equivalent).The three different standing positions will be: wide-base standing on foam (WBF), narrow-base standing on foam (NBF), and tandem standing on foam (TAF) (i.e., low-level of task difficulty, moderate-level of task difficulty, and high-level of task difficulty, respectively). For each standing position, participants will be required to perform two consecutive standing balance trials, with a 1-minute rest break in between."
62557355|NCT05630911||Low Reinvestor Group (LRG)|"Participants will be invited to complete a series of standing balance trials. The trials will involve participants standing in three different positions on a foam surface (i.e., Airex balance pad elite with a dimension of 16.1 width x 19.7 length x 2.4 height, or equivalent).The three different standing positions will be: wide-base standing on foam (WBF), narrow-base standing on foam (NBF), and tandem standing on foam (TAF) (i.e., low-level of task difficulty, moderate-level of task difficulty, and high-level of task difficulty, respectively). For each standing position, participants will be required to perform two consecutive standing balance trials, with a 1-minute rest break in between."
62557356|NCT01607450|OTHER|Saline|12 hour saline (control) infusion prior to PET study
62557357|NCT01607450|EXPERIMENTAL|GLP-1 Low dose|GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study
62557358|NCT01607450|EXPERIMENTAL|GLP-1 Mid-Range Dose|GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study
62756004|NCT01466660|ACTIVE_COMPARATOR|gefitinib|gefitinib once daily
62756005|NCT02279849|EXPERIMENTAL|Communications|These 6 stores received the communications intervention. Communications materials were developed for each program phase; 1) Healthier Drinks, 2) Healthier Essentials, and 3) Healthier Snacks. Each phase's materials included posters, recipe cards, educational handouts, shelf talkers, price tags, door signs, educational displays, and promotional giveaways (i.e., drink tumblers, re-usable shopping bags) to encourage healthy food purchasing and consumption. Stores receiving the communications intervention also received either a small refrigerator or freezer to help provide the environmental supports needed to stock perishable fruits and vegetables.
62756006|NCT02279849|NO_INTERVENTION|Control|These 6 stores received no intervention.
62557359|NCT01607450|EXPERIMENTAL|GLP-1 High Dose|GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study
62756007|NCT02279849|EXPERIMENTAL|Pricing|These 6 stores received a pricing intervention. 10-30% with discounts for specific foods contingent on price elasticity of demand, initial wholesale price, and projected store-level sales. Items were given the minimum discount needed to increase store supply and consumer demand. For example, brand name frozen vegetables were discounted 30% at the wholesaler, in order to provide the storeowner with enough incentive to stock the item. The % discount passed from the storeowner to the consumer was ultimately a decision made by the storeowner, but was suggested to be at least 50% in order to increase consumer demand. Discounts were automatically applied at wholesaler registers to stores receiving the pricing intervention.
62756008|NCT02279849|EXPERIMENTAL|Combined (Communications & Pricing)|These 6 stores received communications materials as well as pricing incentives as intervention (see Communications \& Pricing Arms Descriptions).
62756009|NCT04671758||AR TAVI|The population consists in patients with severe symptomatic AR on native aortic valve who are candidates for surgical aortic valve replacement but who are deemed inoperable by the heart team due to technical issues (i.e., porcelain aorta, previous coronary artery bypass grafting,...), extreme left ventricular dysfunction or comorbidities (liver cirrhosis, severe chronic obstructive pulmonary disease...).
62756010|NCT04913597||Recombinant human thrombopoietin (rh-TPO) group|Patients who fail previous steroids and avatrombopag and then switch to Rh-TPO will be enrolled. The reason for switch will be recorded. Patients will be given rh-TPO 300 U/kg once daily for 14 days as initial treatment. After initial treatment, maintenance therapy were performance. At initial therapy, rhTPO will be suspended when platelet counts ≥100×10\^9 / L. During maintenance therapy, patients with platelet counts \>150×10\^9 / L will suspend treatment until platelet counts drop to ≤150×10\^9 / L. Dosing interval will be prolonged when platelet count is ≥100×10\^9 / L to ≤150×10\^9 / L. Dose modification is not required when platelet count is ≥30×10\^9 / L to \<100×10\^9 / L. The efficacy, safety, and patient/physician preference will be assessed.
62756011|NCT04913597||Avatrombopag group|Patients who fail previous steroids and rh-TPO and then switch to avatrombopag will be enrolled. The reason for switch will be recorded. Patients will be given avatrombopag 20mg once daily as initiate treatment, and adjust the dosage according to the count of platelets. The maximum dose of avatrombopag is 40mg daily.Avatrombopag will be terminated any time the platelet counts increased above 250×10\^9/L. Dose adjustment of avatrombopag will be allowed to maintain platelet counts between 30×10\^9/L and 150×10\^9/L. The efficacy, safety, and patient/physician preference will be assessed.
62756012|NCT03259048||pediatric group|pediatric group from age of one day to eighteen years.
62756013|NCT01389531|OTHER|Stents|All recruited patients will be receiving a stent during a rigid bronchoscopy procedure.
62756014|NCT03602313|ACTIVE_COMPARATOR|Traditional Gait Training|The Traditional Gait Training group will receive gait training as presently performed without additional modalities.
62756015|NCT03602313|EXPERIMENTAL|Body Weight Support Training|The Body Weight Support group will received body weight support gait training in lieu of traditional gait training.
61986785|NCT03189615|EXPERIMENTAL|Patients with mild hepatic impairment (Group1)|
62378857|NCT00407420|ACTIVE_COMPARATOR|Control|Nutritional and activity advice alone
62378858|NCT02705547|EXPERIMENTAL|Rosuvastatin (Crestor)|This is an open-label study of Rosuvastatin (Crestor) in patients with FRDA. Study subjects will receive 10 mg of Rosuvastatin daily for 3 months.
62378859|NCT01809704||Normal|Normal results from clinical exam and free of ocular pathology.
62378860|NCT01809704||Glaucoma|Clinical exam results consistent with glaucoma and visual field defects consistent with glaucoma.
62378861|NCT01809704||Retina|Clinical exam results consistent with retina pathology
62378862|NCT00601653|ACTIVE_COMPARATOR|1|Cognitive behavioral therapy plus general nutrition counseling
62756016|NCT00741494|NO_INTERVENTION|1|HBA score over 65% control
62756017|NCT00741494|NO_INTERVENTION|2|HBA score over 65%, non-participant (to even out the participation between patients with low HBA scores and those with high HBA scores)
62378863|NCT00601653|EXPERIMENTAL|2|Cognitive behavioral therapy plus low energy density diet counseling
62378864|NCT03996655|EXPERIMENTAL|Group S|Sugammadex for reversal of steroidal neuromuscular blockers, intravenous injection ,2mg/kg
62378865|NCT03996655|ACTIVE_COMPARATOR|Group N|Reversal of neuromuscular blockers, iv injection, 0.05 mg/kg
62378866|NCT02946008|EXPERIMENTAL|SBRT|Stereotactic Body Radiation Therapy (SBRT) will be delivered over 5 treatment sessions for approximately 1.5 weeks total.
62378867|NCT01948791|EXPERIMENTAL|ENA713|Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks.
62756018|NCT00741494|ACTIVE_COMPARATOR|3|HBA score over 65%. PICSI dish is used to select the sperm for ICSI.
62756019|NCT00741494|EXPERIMENTAL|4|HBA score less than 65%. PICSI dish used to select sperm for ICSI.
62756020|NCT00741494|NO_INTERVENTION|5|HBA Score less than 65%. Control
62756021|NCT03745183|EXPERIMENTAL|Senna alata leaf decoction|The participants were instructed to take a bath once a day using a syndet bar and to towel dry their skin before applying the akapulko decoction. Fresh decoction was prepared by the patients every day. After a bath, the patient applied the fresh cooled decoction by hand on the whole body especially on the affected areas and left it to dry. Approximately one glassful (350ml) of akapulko decoction should be consumed for one whole body application. The total duration of daily application should be 4 weeks (28 days +3) until the next outcome assessment.The patients were given illustrated, laminated instructional materials and a tabulated checklist of instructions on how to prepare and apply the decoction which served as a monitoring sheet of each patient.
62756022|NCT04911244|EXPERIMENTAL|VAP group|patients confirmed diagnosis of VAP with bronchoalveolar lavage
62756023|NCT04911244|EXPERIMENTAL|Non VAP group|patients confirmed not VAP with bronchoalveolar lavage
62756024|NCT02635139|EXPERIMENTAL|Breakfast Skipping|Effect of breakfast skipping on metabolism
62756025|NCT02635139|EXPERIMENTAL|Dinner Skipping|Effect of dinner skipping on metabolism
62756026|NCT03289832|ACTIVE_COMPARATOR|Crucera-SGS®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a non-cruciferous diet and to ingest daily for 10 days, Crucera-SGS® as a source of glucoraphanin which is converted to sulforaphane; 9 capsules (450 mg or 1.03 mmol GR) per day.~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third days of chromometer readings, 2 biopsies will be taken from the upper buttocks for a total of 8 skin-punch biopsies per individual."
62756027|NCT03289832|ACTIVE_COMPARATOR|Meriva 500-SF®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a non-cruciferous diet and to ingest daily for 10 days, Meriva 500-SF® as a source of curcumin; 2 capsules (1000 mg or 2.72 mmol total curcuminoids) per day.~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third day of chromometer readings, 2 biopsies will be taken from the upper buttocks, for a total of 8 skin-punch biopsies per individual."
62756028|NCT03289832|ACTIVE_COMPARATOR|Crucera-SGS® and Meriva 500-SF®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a cruciferous vegetable-free diet and to ingest daily for 10 days, Crucera-SGS® as a source of glucoraphanin which is converted to sulforaphane; 9 capsules (450 mg or 1.03 mmol GR) and Meriva 500-SF® as a source of curcumin; 2 capsules (1000 mg or 2.72 mmol total curcuminoids) per day.~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third day of chromometer readings, 2 biopsies will be taken from the upper buttocks for a total of 8 skin-punch biopsies per individual."
62756029|NCT03824275|EXPERIMENTAL|18F- DCFPyL PET/CT|Upon enrollment, subjects will undergo standard of care imaging (defined as a CT or MRI of the chest, abdomen, and pelvis, and 99mTc bone scans) if not obtained within 45 days of enrollment. Subjects will have standard of care laboratory evaluations including complete blood count (CBC), serum chemistries, hepatic panel, lactate dehydrogenase (LDH), and PSA. Liquid biopsies for circulating tumor DNA (ctDNA) and exosome analysis will occur at the same time. Subjects will then undergo 18F- DCFPyL PET/CT.
62756030|NCT04755166|EXPERIMENTAL|100:0|100 % bone substitute, 0% autogenous bone
62756031|NCT04755166|EXPERIMENTAL|90:10|90% bone substitute, 10% autogenous bone
62756032|NCT02032693|EXPERIMENTAL|Everycell™|Patient will take 1 tablet two times daily of Everycell™ (double-blind) for the 4-week treatment period.
62756033|NCT02032693|PLACEBO_COMPARATOR|Placebo|Patient will take 1 tablet two times daily of the placebo (double-blind) for the 4-week treatment period.
62756034|NCT06487312||Age ≥ 18 years old, regardless of gender, who need ultrasound examination; 3) Voluntarily participat|
62378868|NCT01657149|EXPERIMENTAL|Research Group|receive lymphatic massage and individual physiotherapy
62378869|NCT01657149|ACTIVE_COMPARATOR|Control group|receive individual physiotherapy only
62378870|NCT03652090||cystic fibrosis patients|Cystic fibrosis patients carrying to 2 CFTR mutations undergoing cell sampling
62378871|NCT03652090||healthy heterozygotes|healthy heterozygotes carrying 1 CFTR mutations undergoing cell sampling
62378872|NCT03652090||healthy control|subject with no evidence of any symptoms compatible with Cystic Fibrosis undergoing cell sampling
62756035|NCT01913665|ACTIVE_COMPARATOR|B.Lactis|children with functional constipation
62756036|NCT01913665|ACTIVE_COMPARATOR|Inulin|children with functional constipation
62756037|NCT01913665|ACTIVE_COMPARATOR|B.Lactis+ınulin|children with functional constipation
62756038|NCT01913665|PLACEBO_COMPARATOR|plasebo|children with functional constipation
62756039|NCT04573426||Overweight/Obese+Drug+Stigma|40 participants with overweight or obesity will consume 1,000mg of acetaminophen in a liquid vehicle briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
62756040|NCT04573426||Overweight/Obese+Drug+Control|40 participants with overweight or obesity will consume 1,000mg of acetaminophen in a liquid vehicle briefly following the start of the appointment. After one hour, they will read a short control vignette meant to have no impact on their emotional state.
62756041|NCT04573426||Overweight/Obese+Placebo+Stigma|40 participants with overweight or obesity will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
62756042|NCT04573426||Overweight/Obese+Placebo+Control|40 participants with overweight or obesity will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short control vignette meant to have no impact on their emotional state.
62756043|NCT04573426||Normal Weight+Placebo+Stigma|40 participants with normal weight will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
62756044|NCT00716430|ACTIVE_COMPARATOR|QI|Quality Improvement Centres
62756045|NCT00716430|NO_INTERVENTION|Non-QI|No Quality Improvement Programme
62756046|NCT03897296|EXPERIMENTAL|healthy subjects examined with water-perfused catheter|healthy subjects - subjects without signs of functional and organic anorectal pathology
62557360|NCT02582229|EXPERIMENTAL|Interventionnal|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
62557361|NCT00613808|NO_INTERVENTION|A - Standard of Care (control)|Standard of care - dressings and sustained compression only for the two week screening period and then for 20 weeks thereafter
62756047|NCT04149223|NO_INTERVENTION|Control|Current practice at baseline, routine cirrhosis care.
62756048|NCT04149223|EXPERIMENTAL|Intervention|Use of a standardized cirrhosis order set.
62756049|NCT04149223|ACTIVE_COMPARATOR|Intervention + EMR|Use of a standardized cirrhosis order set embedded within an electronic medical record.
62378873|NCT05858437|EXPERIMENTAL|PA Intervention|The group which receives the PA as a dietary food supplement. A single capsule contains 500mg of sodiumpropionate, which is taken twice daily for 28 days.
62756050|NCT06284993|EXPERIMENTAL|The more frequent acupuncture treatment group (Group M)|The more frequent acupuncture treatment group (Group M)
62378874|NCT05858437|PLACEBO_COMPARATOR|Placebo Intervention|The control-group receives a placebo instead of propionate. The placebo contains maltodextrin and the same amount of sodium chloride as compared to the PA intervention. The placebo is taken twice per day for 28 days.
62378875|NCT05967728|EXPERIMENTAL|Remote Ischemic Conditioning (RIC)|"For the CSVD patients, each RIC session consists of 4 cycles of inflating a blood-pressure cuff around an upper arm to reduce blood flow to that limb for approximately 5 minutes, after which it is deflated for around 5 minutes to restore normal blood flow. The procedure will use the RIC auto-control device with a cuff that inflates to a pressure of up to 200 mmHg. The patients will use the device once daily for a total of 60 days.~For the MSU patients in the non-randomized component of the study, the device cuff will inflate around a limb to reduce blood flow for approximately 5 minutes, after which it will deflate for around 5 minutes to restore normal blood flow. This cycle will repeat (for a maximum of 6 cycles) until the patient is transferred to the hospital for further management."
62378876|NCT05967728|SHAM_COMPARATOR|Sham RIC|For the CSVD patients randomized to sham, each RIC session consists of 4 cycles of inflating a blood-pressure cuff around an upper arm to 30mmHg for approximately 5 minutes, after which it is deflated for around 5 minutes. The procedure will use the same RIC device as the treatment arm, just randomized to run the sham protocol. The patients will use the device once daily for a total of 30 days. After 30 days, they will cross over to true RIC as described above, once daily for the remaining 30 days, accomplished by remote reprogramming of their device protocols.
62378877|NCT00405275|ACTIVE_COMPARATOR|Arm 1|Etanercept and Methotrexate. Participants also received placebo hydroxychloroquine and sulfasalazine
62378878|NCT00405275|ACTIVE_COMPARATOR|Arm 2|Hydroxychloroquine, sulfasalazine and methotrexate. Participants also received placebo etanercept.
62378879|NCT05353218|ACTIVE_COMPARATOR|Group intermediate cervical plexus block (GI)|Patients anesthetized with intermediate cervical plexus block.
62378880|NCT05353218|ACTIVE_COMPARATOR|Group deep cervical plexus block (GD)|Patients anesthetized with deep cervical plexus block.
62378881|NCT03042728|ACTIVE_COMPARATOR|Dog interaction|Dog interaction will be received by patients in addition to usual care of fibromyalgia.
62378882|NCT03042728|ACTIVE_COMPARATOR|Human Interaction|Human interaction will be received by patients in addition to usual care of fibromyalgia.
62378883|NCT00366444|EXPERIMENTAL|1|
62378884|NCT00366444|PLACEBO_COMPARATOR|2|
62557362|NCT00613808|ACTIVE_COMPARATOR|B Same treatment for 6 weeks, 200ppm NO gas|Subjects were treated by topical application of 200ppm Nitric Oxide gas delivered to the wound area for 8 hours per day for 6 weeks
62557363|NCT01012336|EXPERIMENTAL|Aprepitant|
62557364|NCT02058069|EXPERIMENTAL|Robotic Assisted Total Knee Arthroplasty|
62557365|NCT00149461|EXPERIMENTAL|Written Asthma Action Plan Group|Participants randomized to the written asthma action plan group received an asthma action plan form along with asthma education from their specialist physician.
62756051|NCT06284993|EXPERIMENTAL|The less frequent acupuncture treatment group (Group L)|The less frequent acupuncture treatment group (Group L)
62756052|NCT06086860|EXPERIMENTAL|Mulligan mobilization with dry needling.|Participants in this group will receive Mulligan mobilization with dry needling.
62756053|NCT06086860|ACTIVE_COMPARATOR|Mulligan mobilization without dry needling.|Participants in this group will receive Mulligan mobilization without dry needling.
62756054|NCT02836782||Naive patients|Patients who begin their first antiretroviral regimen. Blood sample withdrawal
62557366|NCT00149461|NO_INTERVENTION|No Written Instructions Group|Participants randomized to the usual care group received no written instructions other than prescriptions from their specialist physician.
62756055|NCT02836782||Experienced patients|"Patients with a history of antiretroviral treatment, switching to a new regimen.~Blood sample withdrawal"
62756056|NCT02976480|ACTIVE_COMPARATOR|Irrigation|The subjects randomized to this group will have their simple lacerations irrigated with a normal saline solution.
62378885|NCT03918213|EXPERIMENTAL|healthy subjects examined with solid-state catheter|healthy subjects - subjects without signs of functional and organic anorectal pathology
62756057|NCT02976480|EXPERIMENTAL|No Irrigation|The subjects randomized to this group will not have their simple lacerations directly irrigated with a normal saline solution.
62557367|NCT03831711|EXPERIMENTAL|Diagnostic (68-Ga RM2, PET/MRI)|Patients receive 68-Ga RM2 IV and after 45 minutes undergo PET/MRI over 30-60 minutes.
62557368|NCT06511921|ACTIVE_COMPARATOR|post operative Crohn's patients|
62557369|NCT06511921|SHAM_COMPARATOR|post operative Cronn's patients|
62756058|NCT01245881|EXPERIMENTAL|Treatment group|Broad-spectrum UV block plus non-ablative 1,550-nm fractional treatment
62557370|NCT01146171|EXPERIMENTAL|BMS-844203 (CT-322)|
62557371|NCT03348878|OTHER|cohort of uncontrolled hypertensive patients|
62557372|NCT04009759|ACTIVE_COMPARATOR|Morphine|"Morphine group (M) (n=80), where patients will be treated with i.v. injection of Morphine 2 mg/ml - 5 ml - 10 mg Epidural. The treatment will be given during CPR as soon as possible."
62756059|NCT01245881|ACTIVE_COMPARATOR|Control group|
62756060|NCT02286934|EXPERIMENTAL|Carvedilol|"* Day 1 to 3 : Carvedilol 12.5 mg qd~* Day 4 to 8 : Carvedilol 25 mg qd~* Day 9 to 11 : Carvedilol 12.5 mg qd~Isoproterenol Sensitivity Test~* Day 0, 1.5h post-dose Injection of isoproterenol 4 times (0.25, 0.5, 1, 2 ug/mL), time interval of 10 minutes.~* Day 1, 8, 1.5h post-dose Injection of isoproterenol 4 times (5, 10, 20, 40 ug/mL), time interval of 10 minutes.~Measure change of heart rates after 1, 2, 3 minutes post injection of isoproterenol."
62378886|NCT01304927|ACTIVE_COMPARATOR|Cholecalciferol + calcium|Group of intervention: Each man will receive 300,000 IU (7500 ug) Cholecalciferol (VD3) orally once after blood and semen sampling and performed DXA scan. Thereafter they will receive VD tablets of 1,400 IU (35 ug) + 500 mg calcium daily for 3 months. At 3 months a clinical control and blood sampling will be performed, followed by continued daily intake of 1400 IU VD3 + 500 mg calcium. At end of treatment at five months after inclusion the men deliver two semen samples, have a blood sample drawn and a DEXA scan performed.
62378887|NCT01304927|PLACEBO_COMPARATOR|placebo|Group receiving placebo: Each man will receive placebo oral mixture once after blood- and semen sampling and performed DXA scan. Thereafter they will receive placebo tablets daily for 3 months. At 3 months a clinical control and blood sampling will be performed, followed by continued daily intake of placebo. At end of treatment at five months after inclusion the men deliver two semen samples, have a blood sample drawn and a DEXA scan performed.
62378888|NCT03088410|EXPERIMENTAL|Nevirapine|150 HIV-Exposed Uninfected (HEU) infants on Nevirapine (NVP) Prophylaxis
62378889|NCT03088410|ACTIVE_COMPARATOR|Zidovudine|150 HIV-Exposed Uninfected (HEU) infants on Zidovudine (AZT) Prophylaxis
62378890|NCT03088410|NO_INTERVENTION|HIV- unexposed Uninfected (HUU) Infants|150 HIV- unexposed Uninfected (HUU) Infants
62378891|NCT05220293|EXPERIMENTAL|Betamethasone Dipropionate Nasal Cream 0.0644% Treatment|Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).
62378892|NCT04844970|EXPERIMENTAL|Anamorelin|Patients randomized to anamorelin HCL will take it daily for 24 weeks starting 3-5 days prior to chemotherapy
62378893|NCT04844970|PLACEBO_COMPARATOR|Placebo|Patients randomized to placebo will take it daily for 24 weeks starting 3-5 days prior to chemotherapy
62557373|NCT04009759|ACTIVE_COMPARATOR|Ketamine|"Ketamine (K) group (n=80), where patients will be treated with i.v. injection of S-Ketamine 10 mg/ml - 5 ml - 50 mg Ketamin Abcur. The treatment will be given during CPR as soon as possible."
62557374|NCT04009759|PLACEBO_COMPARATOR|Saline|"Control group (n=80), where patients will be treated with i.v. 5 ml of NaCl 0,9% B. Braun. The treatment will be given during CPR as soon as possible."
61986786|NCT03189615|EXPERIMENTAL|Patients with moderate hepatic impairment (Group 2)|
61986787|NCT03189615|EXPERIMENTAL|Healthy subjects (Group 3)|
61986788|NCT03640585|EXPERIMENTAL|Music therapy|Children listened to Classical music disc for 45 minutes.Children treated by neurodevelopmental therapy while listening to this music.A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients.
61986789|NCT03640585|PLACEBO_COMPARATOR|Control|Only the neurodevelopmental therapy was applied in the control group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
62378894|NCT01881724|NO_INTERVENTION|Usual Care|
62378895|NCT01881724|EXPERIMENTAL|sleep education program|
62378896|NCT01289028|EXPERIMENTAL|Nilotinib|nilotinib 400 mg twice daily (bid).
62378897|NCT05846542|EXPERIMENTAL|Video-game based therapy group|The video-game based therapy group will receive a conventional physiotherapy and video-game based therapy, two days a week for a total of 8 weeks (15 minutes conventional physiotherapy session+30 minutes video-game based therapy).
62378898|NCT05846542|ACTIVE_COMPARATOR|Conventional physiotherapy group|The conventional physiotherapy group individuals will be given a conventional physiotherapy two days per week for a total of 8 weeks (conventional physiotherapy session will last 45 minutes).
62378899|NCT01282190|EXPERIMENTAL|Motivational interview|
62378900|NCT00252499|PLACEBO_COMPARATOR|Placebo Arm|matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd
62378901|NCT00252499|EXPERIMENTAL|Rosiglitazone Arm|rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd
62378902|NCT00252499|EXPERIMENTAL|Fenofibrate Arm|micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid
62378903|NCT01731600|EXPERIMENTAL|N8-GP|
62378904|NCT00962416|ACTIVE_COMPARATOR|1|Biolimus eluting Stent (Biomatrix)
62378905|NCT00962416|ACTIVE_COMPARATOR|2|Bare metal stent (Gazelle)
62378906|NCT03551704|ACTIVE_COMPARATOR|CBT + EFT|"The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices."
62378907|NCT03551704|EXPERIMENTAL|CBT + EFT + CM|This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on biochemical verification. The schedule will incorporate an increasing magnitude of reinforcement.
62557375|NCT00413101|EXPERIMENTAL|1|
62557376|NCT02477644|EXPERIMENTAL|Olaparib|Tablets per os 300 mg
62557377|NCT02477644|PLACEBO_COMPARATOR|Placebo|Tablets per os 300 mg
62756061|NCT00497328|OTHER|N-acetylcysteine Group (NAC)|"N-acetylcysteine Group (NAC)~Intravenous infusion 154mEq/L of sodium chloride (0.9% normal saline) at a rate of 1mL/kg/hour from 12 hours before till 6 hours after cardiac catheterization Oral NAC 1200mg dissolve in 250ml of water twice a day the day before to the day after the procedure (total 6 doses)"
62378908|NCT02586116|ACTIVE_COMPARATOR|nanOss|nanOss Cervical IBF System with nanOss BA Bone Void Filler
62557378|NCT01834625||Florbetapir +ve NPH patients|Florbetapir +ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months
62557379|NCT01834625||Florbetapir -ve patients|Florbetapir -ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months
62756062|NCT00497328|OTHER|Sodium Bicarbonate Group (SOB)|"Sodium Bicarbonate Group (SOB)~Intravenous infusion154meq/L sodium bicarbonate in 5% dextrose in water at a rate of 3 mL/kg/hour for 1 hour immediately before radiocontrast injection. For patients weighing more than 110 kg, the initial fluid bolus and drip will be limited to those doses administered to a patient weighing 110 kg.~Intravenous infusion154meq/L sodium bicarbonate in 5% dextrose in water at a rate of 1 mL/kg/hour during the contrast exposure and for 6 hours after the procedure"
62756063|NCT00497328|OTHER|Combination Group (COM: NAC and SOB)|"Combination Group (COM: NAC and SOB)~Intravenous infusion of 154 meq/l sodium bicarbonate at a rate of 3ml/kg/hour for 1 hour before cardiac catheterization and 1 ml/kg/hour till 6 hours after procedure Oral NAC 1200mg dissolve in 250ml of water twice a day the day before to the day after the procedure (total 6 doses). All patients will be monitored regularly for pulmonary congestion and hemodynamics compromise hourly after PCI for 6 hours and every 4 hour thereafter for 24 hours."
62756064|NCT03500172|ACTIVE_COMPARATOR|DTP, Continue DTP if Responsive|"DTP:~* Standard of care (SoC), minus clinic referrals for antiretroviral therapy (ART) treatment initiation and management.~* Nurse initiated and managed ART within the community on mobile van at sites served by the mobile van which already provides SoC services~Continues with DTP intervention if virally suppressed at 6 months."
62756065|NCT03500172|ACTIVE_COMPARATOR|DTP, Standard of Care (SoC) if Responsive|"DTP:~* Standard of care, minus clinic referrals for ART treatment initiation and management.~* Nurse initiated and managed ART within the community on mobile van at sites served by the mobile van which already provides SoC services~SoC:~* HIV counseling and testing (HTC)~* Sexually transmitted infection (STI) screening and treatment~* Tuberculosis (TB) screening and referral~* Health education through peer educators and peer supported follow-up related to linkages to care~* Referrals to Department of Health (DoH) primary healthcare clinics or TB HIV Care (THC) drop-in center for ART treatment initiation and management~Returns to SoC if virally suppressed at 6 months."
62756066|NCT03500172|ACTIVE_COMPARATOR|DTP, Continue DTP if Non-Responsive|"DTP:~* Standard of care, minus clinic referrals for ART treatment initiation and management.~* Nurse initiated and managed ART within the community on mobile van at sites served by the mobile van which already provides SoC services~Continues with DTP intervention if not virally suppressed at 6 months."
62756067|NCT03500172|ACTIVE_COMPARATOR|DTP, DTP+ICM if Non-Responsive|"DTP:~* Standard of care, minus clinic referrals for ART treatment initiation and management.~* Nurse initiated and managed ART within the community on mobile van at sites served by the mobile van which already provides SoC services~ICM:~* Standard of Care~* Assignment of peer case manager~* Face-to-face meeting to tailor ICM approach to FSW preference~* Self-efficacy building in face-to-face sessions and bi-weekly text messages~* Relational support through monthly calls, face-to-face meetings every three months, and additional support through female sex worker (FSW) initiated interaction~Receives both interventions at 6 months if non-virally suppressed."
62756068|NCT03500172|ACTIVE_COMPARATOR|ICM, Continue ICM if Responsive|"ICM:~* Standard of Care~* Assignment of peer case manager~* Face-to-face meeting to tailor ICM approach to FSW preference~* Self-efficacy building in face-to-face sessions and bi-weekly text messages~* Relational support through monthly calls, face-to-face meetings every three months, and additional support through FSW initiated interaction~Continues with ICM intervention at 6 months if virally suppressed."
62756069|NCT03500172|ACTIVE_COMPARATOR|ICM, SoC if Responsive|"ICM:~* Standard of Care~* Assignment of peer case manager~* Face-to-face meeting to tailor ICM approach to FSW preference~* Self-efficacy building in face-to-face sessions and bi-weekly text messages~* Relational support through monthly calls, face-to-face meetings every three months, and additional support through FSW initiated interaction~SoC:~* HIV counseling and testing (HTC)~* STI screening and treatment~* TB screening and referral~* Health education through peer educators and peer supported follow-up related to linkages to care~* Referrals to DOH primary healthcare clinics or THC drop-in center for ART treatment initiation and management~Returns to SoC if virally suppressed at 6 months."
61986790|NCT05966324|EXPERIMENTAL|Cohort 1|Oral tablet dose of baxdrostat 1 mg or placebo, administered as a single dose (Day 1) and multiple doses (once daily \[QD\] for 5 days, Days 6 - 10) to Japanese subjects
62378909|NCT02586116|ACTIVE_COMPARATOR|C-Plus|C-Plus PEEK IBF Device with autograft
62378910|NCT06423404|EXPERIMENTAL|Experimental Group: Active Break group|The Experimental Group, receiving a 12-week program of video-guided active breaks with curricular content in the school classroom
62378911|NCT06423404|OTHER|Control group: waiting list group|The Control Group, receiving the same intervention as the experimental group after the final data collection. During the time of the intervention, the waiting list group will receive the usual classes.
62378912|NCT03844529|EXPERIMENTAL|Sunmax FULLSGEN with Lidocaine|A subject would only receive single injection treatment(day 1) using Sunmax FULLSGEN , and there would be 6 follow-up visits at 4th, 12th, 24th, 36th and 52nd week after injection treatment.
62378913|NCT03844529|ACTIVE_COMPARATOR|Sumax FACIALGAIN collagen Implant with Lidocaine|A subject would only receive single injection treatment(day 1) using Sumax FACIALGAIN collagen Implant with Lidocaine, and there would be 6 follow-up visits at 4th, 12th, 24th, 36th and 52nd week after injection treatment.
62378914|NCT01832051|EXPERIMENTAL|HER2-PET|Injection of 89Zr-trastuzumab followed by PET scan
62378915|NCT03626389||Patients receiving physiotherapy in primary care|Physiotherapy, without predetermined selection of specific modalities
62378916|NCT05120375|EXPERIMENTAL|A/ Accelerated titration|1mg of BAT6021
62378917|NCT05120375|EXPERIMENTAL|B/ Accelerated titration|3mg of BAT6021
62378918|NCT05120375|EXPERIMENTAL|C/ Accelerated titration|10mg of BAT6021
62378919|NCT05120375|EXPERIMENTAL|"D/standard 3 + 3"|30mg of BAT6021
62378920|NCT05120375|EXPERIMENTAL|"E/standard 3 + 3"|100mg of BAT6021
62557380|NCT04435873||Mail Survey Participants|Approximately 1200 home patients will receive mail surveys. Of these, one thousand and twenty (1,020) patients will be asked to complete the survey once. One hundred and eighty (180) patients will be asked to complete the survey twice.
62557381|NCT04435873||Telephone Survey Participants|Three hundred (300) home patients will be surveyed by phone. Of those, one hundred and twenty will be asked to complete the survey once. One hundred and eighty patients will be asked to complete the phone surveys on two separate occasions.
61986791|NCT05966324|EXPERIMENTAL|Cohort 2|Oral tablet dose of baxdrostat 3 mg or placebo, administered as a single dose (Day 1) and multiple doses (QD for 5 days, Days 6 - 10) to Japanese subjects
61986792|NCT05966324|EXPERIMENTAL|Cohort 3|Oral tablet dose of baxdrostat 3 mg or placebo, administered as a single dose (Day 1) and multiple doses (QD for 5 days, Days 6 - 10) to Caucasian subjects
62378921|NCT05120375|EXPERIMENTAL|"F/standard 3 + 3"|300mg of BAT6021
62378922|NCT05120375|EXPERIMENTAL|"G/standard 3 + 3"|600mg of BAT6021
62378923|NCT05120375|EXPERIMENTAL|"H/standard 3 + 3"|900mg of BAT6021
62378924|NCT03083964|ACTIVE_COMPARATOR|Usual Care|Usual care involves a lifestyle coaching intervention delivered in primary care sites.
62378925|NCT03083964|EXPERIMENTAL|Priming|Priming involves usual care plus just in time reminder messages related to mindful eating and physical activity.
62378926|NCT05707195|EXPERIMENTAL|Experimental:children hospitalized in pediatric intensive care unit|All parents of children aged 0 to 18 who have been hospitalized in the pediatric intensive care unit over a period of 24 months will be offered the study.
62378927|NCT05661838||non-PPCs group|Patients without PPCs (Pleural effusion, Pulmonary atelectasis, Pulmonary infection)
62378928|NCT05661838||PPCs group|Patients with PPCs (Pleural effusion, Pulmonary atelectasis, Pulmonary infection)
62378929|NCT05759949|EXPERIMENTAL|RLY-5836 Single Agent Arm|RLY-5836 single agent arm for participants with unresectable or metastatic solid tumors
62378930|NCT05759949|EXPERIMENTAL|RLY-5836 + Fulvestrant Arm|RLY-5836 + fulvestrant combination arm for participants with HR+, HER2- locally advanced or metastatic breast cancer
62378931|NCT05759949|EXPERIMENTAL|RLY-5836 + Palbociclib + Fulvestrant Arm|RLY-5836 + palbociclib + fulvestrant triple combination arm for participants with HR+, HER2- locally advanced or metastatic breast cancer
62378932|NCT05759949|EXPERIMENTAL|RLY-5836 + Ribociclib + Fulvestrant Arm|RLY-5836 + ribociclib + fulvestrant triple combination arm for participants with HR+, HER2- locally advanced or metastatic breast cancer
62378933|NCT05759949|EXPERIMENTAL|RLY-5836 + Abemaciclib + Fulvestrant Arm|RLY-5836 + abemaciclib + fulvestrant triple combination arm for participants with HR+, HER2- locally advanced or metastatic breast cancer
62557382|NCT00548678|EXPERIMENTAL|A|intravenous diclofenac sodium
62378934|NCT05684367|EXPERIMENTAL|Center-Based Walking Exercise|Subjects will be randomly assigned to receive a center-based walking exercise intervention 3 days per week for the duration of the study.
62756070|NCT03500172|ACTIVE_COMPARATOR|ICM, Continue ICM if Non-Responsive|"ICM:~* Standard of Care~* Assignment of peer case manager~* Face-to-face meeting to tailor ICM approach to FSW preference~* Self-efficacy building in face-to-face sessions and bi-weekly text messages~* Relational support through monthly calls, face-to-face meetings every three months, and additional support through FSW initiated interaction~Continues with ICM intervention at 6 months if non-virally suppressed."
62756071|NCT03500172|ACTIVE_COMPARATOR|ICM, ICM+DTP if Non-Responsive|"ICM:~* Standard of Care~* Assignment of peer case manager~* Face-to-face meeting to tailor ICM approach to FSW preference~* Self-efficacy building in face-to-face sessions and bi-weekly text messages~* Relational support through monthly calls, face-to-face meetings every three months, and additional support through FSW initiated interaction~DTP:~* Standard of care, minus clinic referrals for ART treatment initiation and management.~* Nurse initiated and managed ART within the community on mobile van at sites served by the mobile van which already provides SoC services~Receives both interventions at 6 months if non-virally suppressed."
62756072|NCT03500172|NO_INTERVENTION|Standard of Care (SoC)|"Standard of Care (SoC):~* HIV counseling and testing (HTC)~* Sexually transmitted infection (STI) screening and treatment~* Tuberculosis (TB) screening and referral~* Health education through peer educators and peer supported follow-up related to linkages to care~* Referrals to Department of Health (DoH) primary healthcare clinics or TB HIV Care (THC) drop-in center for ART treatment initiation and management"
62756073|NCT04524559|PLACEBO_COMPARATOR|conventional physical therapy training|received 90 minutes conventional physical therapy training focused on regaining typical movement, prohibiting abnormal muscle tone, promoting postural reactions and enhancing postural mechanisms.
62756074|NCT04524559|EXPERIMENTAL|oral stimulation|received 30 minutes of oral motor training five days week. The training included oral stimulation (facilitation) conducted before the child's actual meal time. The designed protocol comprised modified perioral and intraoral maneuvers based on Fucile's protocol
62756075|NCT04449939|EXPERIMENTAL|Group 1|Single dose of KY1005 by i.v. infusion
62756076|NCT04449939|EXPERIMENTAL|Group 2|Single lower dose KY1005 by s.c. injection
62756077|NCT04449939|EXPERIMENTAL|Group 3|Single higher dose KY1005 by s.c. injections
62756078|NCT05108090|OTHER|Procedure/Surgery|Mohs micrographic surgery followed by sentinel lymph node biopsy
62378935|NCT05684367|EXPERIMENTAL|Home-Based Walking Exercise|Subjects will be randomly assigned to walk for exercise in their community five days/week.
62557383|NCT00548678|ACTIVE_COMPARATOR|B|intravenous ketorolac
62557384|NCT00548678|ACTIVE_COMPARATOR|C|oral diclofenac (Cataflam)
62557385|NCT00548678|ACTIVE_COMPARATOR|D|oral aspirin
62378936|NCT04458311|EXPERIMENTAL|Phase I|Increasing doses of tildrakizumab in combination with a fixed dose of abiraterone to establish the recommended phase II dose in patients with metastatic castration resistant prostate cancer..
62557386|NCT00857155|NO_INTERVENTION|Aspirin only|Continue aspirin until surgery
62557387|NCT00857155|OTHER|Clopidogrel and Aspirin|
62557388|NCT01157793|EXPERIMENTAL|Group 1|
62557389|NCT01157793|EXPERIMENTAL|Group 2|
62557390|NCT01008605|EXPERIMENTAL|Caverject Impulse|representative users
62557391|NCT04826367|EXPERIMENTAL|Exercise Group (EG)|"The participants in the EG will perform relaxation exercises in groups of up to 8 people, 3 days a week for 6 weeks via WhatsApp (© 2020 WhatsApp, Inc.) or Zoom (© 2012-2020 Zoom Video Communications, Inc.) applications. Relaxation exercises will be performed with the Progressive Relaxation Exercises (PRE) technique defined by Jacobson et al.\[11\] Tele-rehabilitation sessions will last approximately 40 minutes of each, accompanied by a physiotherapist who has 8 years of experience in the field of oncological rehabilitation."
62557392|NCT04826367|NO_INTERVENTION|Control Group (CG)|Participants in this group will have a brochure with simple exercises (relaxation exercises involving the upper and lower extremities) in sitting and lying positions. They will be advised to be as active as possible at home and to take mild walks at home. Any supervised exercise program will not apply to participants in the CG. If the participants apply any regular exercise program within 6 weeks, the participants in this group will be excluded from the study.
62557393|NCT02306993||Healthy volunteers without SCT|Includes Healthy African American female volunteer between the ages of 18 and 45 years without sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
62557394|NCT02306993||Healthy volunteers with SCT|Includes Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
62378937|NCT04458311|EXPERIMENTAL|Phase II|The Phase II part of the study will evaluate the recommended phase II dose identified in Phase I of the study in patients with metastatic castration resistant prostate cancer.
62756079|NCT01710943|EXPERIMENTAL|Web-based Cognitive Behavioral Treatment|"Participants who are randomly assigned to the treatment condition will receive the same standard care as those in the control condition and they will also receive access to the web-based CBT intervention. Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial."
62756080|NCT01710943|NO_INTERVENTION|Treatment as Usual|TAU consists of the usual Veterans Integrated Service Network 2 (VISN) primary care services. As we have described, all of the participants will be recruited from patients presenting for treatment typically for physical complaints in primary care clinics in VA's VISN 2 (Upstate NY). VISN 2 officially practices a co-located, collaborative care model of integrated (behavioral health and physical health) in its primary care clinics. This integrated model has been implemented widely in both VA and non-VA primary care clinics in the United States .
62378938|NCT00586833||1|No CHF/HTN Never diagnosed with CHF and undergoing current treatment for HTN
62378939|NCT00586833||2|CHF with HFpEF HFpEF Cases will be recruited from the community. Subjects will be largely drawn from an existing Mayo database examining all incident cases of HF in Olmsted County.
62378940|NCT00586833||3 Healthy normal adults|No identifiable cardiac issues at time of exercise.
62378941|NCT03870789||Retrospective|The Investigators will examine data from 1-year prior to paramedic implementation of the Hamilton Early Warning Score tool.
62557395|NCT02306993||Volunteers with SCD|Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell disease. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell disease affects bone.
62756081|NCT01467115|EXPERIMENTAL|Treatment|Treatment with induction chemotherapy followed by radiation and cetuximab.
62756082|NCT02031081|EXPERIMENTAL|Treatment Period 1|A randomized assignment of prucalopride or placebo for a period of 28 days, crossover design
62557396|NCT03981172||Non-obese/HED|Non-obese women given 60 gram portions of high energy density snack foods to consume daily for two weeks.
62756083|NCT02031081|EXPERIMENTAL|Treatment Period 2|A randomized assignment of either prucalopride or placebo for a period of 28 days, crossover design. Subjects who received active drug in Treatment Arm 1 will receive placebo and vice versa.
62756084|NCT00272948|EXPERIMENTAL|Prophylaxis Arm|
62756085|NCT00272948|ACTIVE_COMPARATOR|Control Arm|
62378942|NCT03870789||Prospective|The Investigators will examine data from 1-year after paramedic implementation of the Hamilton Early Warning Score tool.
62378943|NCT00806611|EXPERIMENTAL|50% Ethanol|Operating surgeon injects 20 ml of 50% ethanol on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
62378944|NCT00806611|PLACEBO_COMPARATOR|Placebo|Operating surgeon injects 20 ml of saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
62378945|NCT03441516|EXPERIMENTAL|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400mg bid + Donepezil 10mg qd for 24 weeks
62378946|NCT03441516|ACTIVE_COMPARATOR|Aripezil® Tab.|Donepezil 10mg qd for 24 weeks
62378947|NCT02505009|EXPERIMENTAL|entecavir pretreated vaccine arm|Arm A,case group: 75 cases will be enrolled to receive Engerix-B injection and compared with histological non-vaccine treated controls
62557397|NCT03981172||Non-Obese/LED|Non-obese participants that were given 60 gram portions of low energy density foods to consume daily for two weeks.
62756086|NCT06275984|OTHER|Online training|Participants will perform an online training in CPR-AED
62378948|NCT02505009|EXPERIMENTAL|tenofovir pretreated vaccine arm|Arm B case group: A total of 50 patients will be randomized into case (vaccine) and control group according to age, gender, pretreatment HBV DNA level.
62378949|NCT02505009|ACTIVE_COMPARATOR|Entecavir pretreated control arm|Arm A control group: Age, gender and pretreatment DNA matched histological controls
62557398|NCT03981172||Obese/LED|Obese participants that were given 60 gram portions of low energy density snack foods to consume daily for two weeks.
62756087|NCT02705014|EXPERIMENTAL|treatment group|patients were administered with pulsatile gonadotropin-releasing hormone (GnRH )therapy for 12 months at an interval of 90 minutes.The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L.
62756088|NCT02272751|EXPERIMENTAL|Exercise Intervention|"Subjects allocated to the Exercise arm will aim to undertake a personal prescribed home exercise programme for half an hour three times a week.~Exercises will be progressed at 6 weeks as subjects progress. All exercise sessions will be documented in the logbooks provided.~Outcome measures will be assessed at baseline, mid-way (6 weeks) and at the end of intervention (12 weeks)."
62756089|NCT02272751|EXPERIMENTAL|Relaxation Intervention|"Subjects allocated to the Relaxation arm will aim to undertake a guided relaxation programme on a CD for half an hour three times a week.~All relaxation sessions will be documented in the logbooks provided. Outcome measures will be assessed at baseline, mid-way (6 weeks) and at the end of intervention (12 weeks)."
62378950|NCT02505009|ACTIVE_COMPARATOR|tenofovir pretreated control arm|Arm B control group: A total of 50 patients will be randomized into case (vaccine) and control group according to age, gender, pretreatment HBV DNA level.
62378951|NCT03742271|EXPERIMENTAL|senofilcon A|Subjects that are habitual spectacle wearers that have never worn contact lenses and have had an eye exam and an updated spectacle prescription in the last 6 months will be enrolled and fitted into the senofilcon A TEST Lens for a total period of 4 weeks.
62756090|NCT01574898|ACTIVE_COMPARATOR|Niquitin® Fresh Mint 4 mg|
61986793|NCT05966324|EXPERIMENTAL|Cohort 4|Oral tablet dose of baxdrostat 10 mg or placebo, administered as a single dose (Day 1) and multiple doses (QD for 5 days, Days 6 - 10) to Japanese subjects
61986794|NCT02250443|EXPERIMENTAL|BYM338|BYM338 Group
61986795|NCT04518254|EXPERIMENTAL|Tyrosine - Test|4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine No stress exposure
62378952|NCT02363673|EXPERIMENTAL|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy in aqua distilla according to their symptoms and characteristic manifestations of their disorder. Although different individualised remedies may be dispensed, each remedy will be homoeopathic. Remedies will be dispensed in aqua distilla. Each individualised homoeopathic remedy will have an individualised dosage, frequency and duration based on the laws of individualised homoeopathic prescribing.
62557399|NCT03981172||Obese/HED|Obese participants that were given 60 gram portions of high energy density snack foods to consume daily for two weeks.
62557400|NCT02039193|EXPERIMENTAL|adherence priming|"To investigate various types of how to conduct a standardized CBT-protocol, all therapists are tutored in peer dyads (tandem peer tutoring). Immediate before sessions 1 to 5, the therapists are required to contact the tandem-partner face-to-face or via self-phone to deliberate the forthcoming session by a 5 to 10 minute brief communication (primings; comparable to Flückiger \& Grosse-Holtforth, 2008).~Adherence priming: Immediately before sessions 1 to 5, therapists have a five-minute conversation about how to implement the disorderspecific interventions that are described in the treatment protocol. These communications are focused on therapists' understanding of patients GAD and the related comorbidities and how these issues can be addressed in the prescriptive treatment protocol."
62756091|NCT01574898|ACTIVE_COMPARATOR|V0118 - B mg|
62756092|NCT01574898|EXPERIMENTAL|V0474 - C mg|
62756093|NCT01574898|EXPERIMENTAL|V0474 - B mg|
62756094|NCT01574898|EXPERIMENTAL|V0474 - A mg|
62756095|NCT03509493||Patients without structural heart disease|
62756096|NCT03509493||Patients with structural heart disease|
61986796|NCT04518254|EXPERIMENTAL|Tyrosine - Stress|4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine Stress exposure
62557401|NCT02039193|EXPERIMENTAL|resource priming|Resource priming: Immediately before sessions 1 to 5, therapists have a five-minute conversation about how to implement strengths-based micro-interventions in the forthcoming session. Strengths-based micro-interventions addresses therapists explicit focus on patients' preexisting strengths and abilities, subtle changes and improvements during therapy (potential recources) as well as motivational preparedness, readiness and goals (motivational resources; Grawe, 2006; Flückiger, et al., 2010).
62756097|NCT03509493||Patients with high risk parameters for AF development|
62756098|NCT03509493||Patients post-cryptogenic stroke|
62756099|NCT03509493||Patients post-cardioversion therapy|
62756100|NCT03509493||Patients post-ablation therapy|
62756101|NCT03202355|EXPERIMENTAL|Group 1 (Control)|Subjects assigned to this group receive fixed appliance orthodontic treatment only
62756102|NCT03202355|EXPERIMENTAL|Group 2 (OP1)|Subjects assigned to this group receive fixed appliance orthodontic treatment in conjunction with receiving daily OrthoPulse™ treatments.
62756103|NCT03517930|EXPERIMENTAL|Test treatment|Healthy adult subjects under fasted conditions
62756104|NCT03517930|ACTIVE_COMPARATOR|Reference treatment|Healthy adult subjects under fasted conditions
62756105|NCT05685563||sweep rowers|Each subject was assessed using DIERS formetic 4D and DIERS pedoscan devices. Additionally, participants in each group were assessed by FAIR test, Cluster of Laslett, trigger point palpation of the m. piriformis and Visual analogue scale.
62756106|NCT05685563||scull rowers|Each subject was assessed using DIERS formetic 4D and DIERS pedoscan devices. Additionally, participants in each group were assessed by FAIR test, Cluster of Laslett, trigger point palpation of the m. piriformis and Visual analogue scale.
62756107|NCT05685563||control non-rowers|Each subject was assessed using DIERS formetic 4D and DIERS pedoscan devices. Additionally, participants in each group were assessed by FAIR test, Cluster of Laslett, trigger point palpation of the m. piriformis and Visual analogue scale.
62756108|NCT05411523||Observational (spinal cord stimulation, questionnaires)|Patients receiving spinal cord stimulation therapy complete questionnaires over 30 minutes at baseline and at 3, 6, and 12 months.
62756109|NCT04060381||Fetuses of normal weight women|Fetuses of normal pregnancies of normal weight mothers are included from gestational week 37
62756110|NCT04060381||Fetuses of severely obese women|Fetuses of normal pregnancies of severly obese mothers are included from gestational week 37
62756111|NCT04060381||New-borns in need of blood transfusion|Neonates mainly receive blood due to blood loss, often because of repeated blood sampling
62378953|NCT03164746|ACTIVE_COMPARATOR|DRY group|Dry sheet therapeutic body wraps will be conducted through twice-a-week sessions for a 3-month duration. Sessions take place in the same quiet room and they usually last 45 minutes each up to 1 hour depending on the patient's response. During sessions, the patient wearied a bathing suit. Sessions were conducted under the supervision of an occupational therapist and involved at least two members of the patient's care team.
62557402|NCT02039193|EXPERIMENTAL|supportive resource priming|Supportive resource priming: The supportive resource priming condition has the very same protocol as the resource priming condition (5 brief tandem peer tutorings). The only difference in the procedure is that the therapists are allowed to integrate a helpful significant person of the patients (such as the partners or the best friends) around session 1 and 7 to encourage and support the patient to realize their treatment plans (active integration of interpersonal resources). However, the integration of a significant other person does not touch the CBT-treatment protocol.
61986797|NCT04518254|EXPERIMENTAL|Placebo - Test|4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo No stress exposure
61986798|NCT04518254|EXPERIMENTAL|Placebo - Stress|4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo Stress exposure
61986799|NCT01327300|ACTIVE_COMPARATOR|Mesalamine|This group received the drug Mesalamine for 12 weeks then a wash out for 3 weeks prior to crossing over to the placebo arm.
62378954|NCT03164746|EXPERIMENTAL|WET Group|Wet sheet therapeutic body wraps will be conducted through twice-a-week sessions for a 3-month duration. Sessions take place in the same quiet room and they usually last 45 minutes each up to 1 hour depending on the patient's response. During sessions, the patient wearied a bathing suit. Sessions were conducted under the supervision of an occupational therapist and involved at least two members of the patient's care team.
62756112|NCT04060381||New-borns in need for closure of the arterial duct|Neonates mainly receive medication (Ibuprofen) because of symptoms like apnea, due to their patent arterial duct.
62756113|NCT03833271|ACTIVE_COMPARATOR|TNF-alpha inhibitor|
61986800|NCT01327300|PLACEBO_COMPARATOR|Placebo|This group will receive the Placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
61986801|NCT05245708|EXPERIMENTAL|oxytocin|a single dose of 24 international units (IU) of OT will be administered with 3 puffs of treatment to each nostril.
61986802|NCT05245708|EXPERIMENTAL|placebo|a single dose of 24 international units (IU) of placebo will be administered with 3 puffs of treatment to each nostril.
61986803|NCT00930579|EXPERIMENTAL|Metformin|Women with newly diagnosed early invasive breast cancer will receive Metformin
62378955|NCT04003415|EXPERIMENTAL|Investigational Device Arm|Once consented for the study, participants will undergo testing with the investigational device for a one hour period. Testing will entail the participant wearing an EKG monitor, a respiratory rate monitor, a pulse oximeter, and being positioned next to the investigational device. The investigational device is contactless and captures chest movement of participants which allows it to estimate real time heart rate and respiratory rate. Additional data collected with the EKG monitor, respiratory rate monitor, and the pulse oximeter will be used to validate the vital sign data collected by the investigational device. After data collection is complete, participant involvement will then be over. Participants will have the option to return on a later date for additional testing (up to a maximum of three sessions total), within the six month window of the study. Participants will continue their standard of care therapies for their respiratory condition.
62378956|NCT01804413|ACTIVE_COMPARATOR|Pegvisomant-glucagon test|To compare the combined pegvisomant with the glucagon test to the insulin tolerance test and the glucagon test in diagnosing adult growth hormone and cortisol insufficiency.
62378957|NCT01804413|ACTIVE_COMPARATOR|Insulin tolerance test|To compare the combined pegvisomant with the glucagon test to the insulin tolerance test and the glucagon test in diagnosing adult growth hormone and cortisol insufficiency.
62557403|NCT00460603|ACTIVE_COMPARATOR|B|bevacizumab 5 mg/kg every 2 weeks + FOLFOX
62756114|NCT03833271|ACTIVE_COMPARATOR|Methotrexate|
62756115|NCT03833271|ACTIVE_COMPARATOR|Healthy|
62756116|NCT04046354|EXPERIMENTAL|Group A|The group will use microwave ablation equipment to treat benign thyroid nodules.
62756117|NCT04046354|ACTIVE_COMPARATOR|Group B|The group will use radiofrequency ablation equipment to treat benign thyroid nodules.
62756118|NCT05621759|EXPERIMENTAL|Reduced-Dose Post-Transplant Cyclophosphamide, Abatacept, and Short-Duration Tacrolimus|"Participants to receive:~* Cyclophosphamide 25 mg/kg IV over 1 hour on Day 3 and Day 4 following transplant~* Abatacept 10 mg/kg IV on Day 5, Day 14, Day 28, and Day 56 following transplant~* Tacrolimus 0.02 mg/kg IV by continuous infusion, starting on Day 5 following transplant. May switch to oral administration when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Tacrolimus treatment is continued until Day 60 and then tapered over a period of 4 weeks in the absence of GvHD."
62756119|NCT00359333|EXPERIMENTAL|Single Group|
62756120|NCT04796688|EXPERIMENTAL|Fludarabine + Cyclophosphamide + AT19 cells|Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (300 mg/kg) on days -5, -4, and -3, followed by the infusions of AT19 cells on day 0-2. The study will be divided into three groups: B-ALL, B-CLL, and B-cell lymphoma. Doses of 0.5×10\^7, 1.0×10\^7, and 2.0×10\^7 CAR+ T cells (with an allowance of ±20%) will be tested in each group in the 3+3 dose-escalation study. Each dose group has 3 patients. If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.The maximum dose could be extended.
62756121|NCT03075722|EXPERIMENTAL|Saturn nasal mask|Participants to use nasal mask in-home for 7 ± 3 days
62756122|NCT00408096|ACTIVE_COMPARATOR|1|The Copeland uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact area used as a treatment for shoulder osteoarthritis
62756123|NCT00408096|ACTIVE_COMPARATOR|2|The Global Cap uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact area used as a treatment for shoulder osteoarthritis
62756124|NCT03088631|ACTIVE_COMPARATOR|Metformin group|
62756125|NCT03088631|PLACEBO_COMPARATOR|Placebo group|
62756126|NCT03619928|EXPERIMENTAL|Dry needling|Procedure in which a thin needle is used to penetrate the skin, subcutaneous tissues and muscle with the intention of mechanically stimulating the tissue without the use of an anesthetic. The physiological mechanism supporting the effects of dry needling remains to be clarified. It has been suggested that the needle works according to the pain gate control theory, indicating that one type of sensory input could be inhibited in the Central nervous system by another input
62756127|NCT03619928|ACTIVE_COMPARATOR|Massotherapy|Among the therapeutic approaches for DOMS is massage therapy. Several authors have examined the effects of DOMS massage and indirect markers of muscle damage, such as impaired muscle function, edema and muscle changes in blood proteins.
62756128|NCT02637427|EXPERIMENTAL|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg, range 10-20 cc/Kg, to a maximum of 5 units)
62756129|NCT02637427|NO_INTERVENTION|No transfusion|No transfusions prior to the procedure
62756130|NCT03062618|EXPERIMENTAL|Part A: Single Dose|Two escalating sequences of single oral doses of PRCL-02, in 3 periods, starting at 4 milligrams (mg)
62756131|NCT03062618|PLACEBO_COMPARATOR|Part A: Single Dose (Placebo)|Two escalating sequences of matching placebo oral tablets, in 3 periods
62756132|NCT03062618|EXPERIMENTAL|Part B: Multiple Dose|Multiple oral doses of PRCL-02 for 28 days, at up to 3 dose levels
62756133|NCT03062618|PLACEBO_COMPARATOR|Part B: Multiple Dose (Placebo)|Multiple oral doses of placebo for 28 days, at matching dose levels
62756134|NCT03062618|EXPERIMENTAL|Part C: Multiple Dose|Multiple oral doses of PRCL-02 for 28 days, at up to 3 dose levels
62756135|NCT03062618|PLACEBO_COMPARATOR|Part C: Multiple Dose (Placebo)|Multiple oral doses of placebo for 28 days, at matching dose levels
61986804|NCT00668044|EXPERIMENTAL|Arm 1|
61986805|NCT00668044|EXPERIMENTAL|Arm 2|
61986806|NCT05045560||antenatal diagnosis of anorectal malformation|Groupe 1 : antenatal diagnosis of anorectal malformation
61986807|NCT05045560||postnatal diagnosis of anorectal malfiormation with associated anomalies on antenatal ultrasound|Groupe 2 : postnatal diagnosis of anorectal malfiormation with associated anomalies on antenatal ultrasound
62557404|NCT00460603|EXPERIMENTAL|C|AG-013726 5 mg bid+ bevacizumab 2 mg/kg every 2 weeks + FOLFOX
62557405|NCT00460603|EXPERIMENTAL|A|AG-013736 5 mg bid starting dose + FOLFOX
62756136|NCT00731653|EXPERIMENTAL|1|BCI-024 and BCI-049
62756137|NCT05181774||Bleeding|After one-year follow-up, AF patients with anticoagulation-related bleeding complications were enrolled in this group.
62756138|NCT05181774||Non-bleeding|After one-year follow-up, AF patients without anticoagulation-related bleeding complications were enrolled in this group.
62756139|NCT00132795|EXPERIMENTAL|1 Therapeutic Phone System|patients assigned to this condition will have unlimited access to the therapeutic telephone system for 4 months.
62756140|NCT00132795|ACTIVE_COMPARATOR|2 Standard care|Standard post-CBT care (i.e., no formal relapse prevention or professional treatment).
62756141|NCT01665079|EXPERIMENTAL|Propofol|14 obese patients(IMC\>35 kg m-2) scheduled for laparoscopic bariatric surgery
62756142|NCT01567501|EXPERIMENTAL|Levocetirizine Dihydrochloride tablets 5 mg|Levocetirizine dihydrochloride Tablets, 5 mg of M/s Ipca Laboratories Limited, India
62756143|NCT01567501|ACTIVE_COMPARATOR|Xyzal|XYZAL (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA
62756144|NCT06607848|EXPERIMENTAL|Acunex Vario AN6V|Patients will receive the Acunex IOL during cataract surgery
62756145|NCT06607848|EXPERIMENTAL|PureSee|Patients will receive the PureSee IOL during cataract surgery
62756146|NCT01453946|OTHER|Entocort|Study Medication
62756147|NCT05326581||PATIENTS|patients benefiting from an MRI examination as part of their care
62756148|NCT05326581||VOLUNTEERS|healthy volunteers among staff.
62756149|NCT03926000|ACTIVE_COMPARATOR|Pregabalin (PG)|Patients will receive 150 mg pregabalin one hour before the procedure.
62756150|NCT03926000|PLACEBO_COMPARATOR|Control placebo (C)|Patients will receive placebo tablet one hour before surgery.
62756151|NCT04527874|EXPERIMENTAL|Intervention|Clusters in the intervention arm receive the VITAL intervention (see intervention)
62756152|NCT04527874|NO_INTERVENTION|Control|Clusters in the control arm continue standard of care.
62756153|NCT06519123|EXPERIMENTAL|Study population - Clinicians and Patients|Clinicians will audio record 4 patient encounters on two separate days each (240 encounters).
62756154|NCT04951271|EXPERIMENTAL|Intervention (SFA) group|solution-focused approach intervention was applied for 7 weeks
62756155|NCT04951271|NO_INTERVENTION|Control (no intervention) group|No intervention was made.
62756156|NCT01028716|EXPERIMENTAL|Treatment (nonmyeloablative HCT, TBI)|Patients receive fludarabine IV over 30-60 minutes daily on days -6 through -2 and cyclophosphamide IV over 1-2 hours on days -6, -5, and 3-4. Patients undergo total-body irradiation on day -1. Patients undergo donor peripheral blood stem cell transplant on day 0. Patients then receive tacrolimus IV once daily or PO BID on days 5-180 (may be continued if active GvHD is present), mycophenolate mofetil IV or PO TID on days 5-35 (may be continued if GvHD present), and filgrastim IV beginning on day 5 until the ANC is \>= 1,000/mm\^3 for three consecutive days.
62756157|NCT03414255|EXPERIMENTAL|Micronized DHACM|1mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM)
62756158|NCT03414255|PLACEBO_COMPARATOR|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
62756159|NCT03297489|EXPERIMENTAL|Diagnostic (intravital microscopy)|Patients receive fluorescein sodium injection IV. Patients also undergo observation of primary and metastatic tumors via microscopy over 15-20 minutes during the course of standard of care surgery.
61986808|NCT05045560||postnatal diagnosis of anorectal malformation with anormal antenatal ultrasound|Groupe 3 : postnatal diagnosis of anorectal malformation with anormal antenatal ultrasound
62756160|NCT01719029|EXPERIMENTAL|Conventional Diet|Low carbohydrate/higher fat diet: 40% carbohydrate, 45% fat, 15% protein
62756161|NCT01719029|EXPERIMENTAL|Complex Carbohydrate Diet|High complex carbohydrate/lower fat diet: 60% complex carbohydrate, 25% fat, 15% protein
62756162|NCT03995680|EXPERIMENTAL|Chewable tablet of mebendazole|"* 3-5 year olds allocated to the swallowable tablet arm will be given the crushed tablet on a spoon mixed with a small amount of clean water;~* 6-12 year olds allocated to the swallowable tablet arm will be given the whole tablet to swallow with a glass of clean water;"
62756163|NCT03995680|ACTIVE_COMPARATOR|Swallowable tablet of mebendazole|"* 3-5 year olds allocated to the chewable tablet arm will be encouraged to chew the tablet and swallow it without water; if they cannot chew it then a small amount of water will be added to the tablet in a spoon;~* 6-12 year olds allocated to the chewable tablet arm will be encouraged to chew the tablet and then swallow it without water."
62756164|NCT04463628||Questionnaire and/or interview|An online questionnaire to assess the quantitative aspect of the impact of lockdown on all areas of the cystic fibrosis patient's health, be it physical, mental or social (using quality of life assessment in particular and interviews in the human and social sciences).
62756165|NCT04674501||Thoracic irradiation|A cohort of cancer patients who receive thoracic irradiation. Patients with any type of malignancy, such as lung cancer, breast cancer, esophageal cancer, or thymoma, are eligible as long as the patients undergo thoracic irradiation.
62756166|NCT01567202|EXPERIMENTAL|Arm DC|In this arm, the patients will receive DC vaccination in addition to the standard therapy, including Surgery, Chemotherapy, and Radiotherapy.
62756167|NCT01567202|PLACEBO_COMPARATOR|Arm Placebo|In this arm, the patients will receive blank placebo instead of the DC vaccination in addition to the standard therapy.
62756168|NCT06363890||Adult Australian travelers|1200 Healthy Australian adult tourists traveling to Southeast Asia.
62756169|NCT05347927||Test group|will receive water resistante padding and a cast
62756170|NCT05347927||Control group|will receive traditional non-water resistante padding and cast
62756171|NCT01216358||Arm 1: Combined contraceptive|Initiating an estrogen/progesterone contraceptive
62756172|NCT01216358||Arm 2: Progesterone only contraceptive|Initiating a progesterone-only contraceptive
62378958|NCT02270190|OTHER|tenesmus patients|Percutaneous Tibial Nerve Stimulation (PTNS) will be applied to all patients in the study
62378959|NCT02826083|EXPERIMENTAL|XXS|
62378960|NCT02826083|PLACEBO_COMPARATOR|Placebo|
62378961|NCT04303247|EXPERIMENTAL|CD19+CD22 targeted CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage.~dosage: the number of anti CD19+CD22 CAR T cells~-1(if needed) 1×10\^5/KG~1. 3×10\^5 /KG~2. 6×10\^5 /KG~3. 1×10\^6/KG~Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion."
62756173|NCT01216358||Arm 3 (control): Non-hormonal contraceptive|Initiating or using non-hormonal contraception or not using contraception
62756174|NCT05472545|EXPERIMENTAL|Neurofeedback Group|Mothers of adolescent participants will view real-time fMRI neurofeedback representing activity in their daughter's anterior insula during an emotion discussion task. Activity will be presented as a colored bar of moving height, and mothers will be instructed to attempt to downregulate the activity through what they say to their daughter.
62756175|NCT05472545|NO_INTERVENTION|Control Group|The paradigm for the control condition will be identical to that of the experimental condition except that no neurofeedback will be presented. Participants in the control group will be told that we would like to see if the mother can regulate her daughter's brain activity through supportive statements.
62378962|NCT03775473|OTHER|progastrin|anyone who will participate in colon screening at the Princess Grace Hospital in Monaco and who has signed the informed consent document
62756176|NCT02233738|EXPERIMENTAL|Group Motivational Interviewing (GMI)|Group Motivational Interviewing (GMI) participants will receive four structured, back-to-back, 90-min sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
62756177|NCT02233738|ACTIVE_COMPARATOR|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to Group Motivational Interviewing (GMI) (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
62756178|NCT01211353|EXPERIMENTAL|Personalized Drinking Feedback|Personalized feedback on drinking behaviors
62756179|NCT01211353|ACTIVE_COMPARATOR|Education-Only|Educational information about alcohol
62182497|NCT01798862|EXPERIMENTAL|Endometrial injury by hysteroscopy or pipelle sapling|Endometrial Sampling by pipelle or hysteroscopy performed once between 6th to 10th day in the cycle prior to the fresh IVF/ ICSI cycle.
62756180|NCT04627181|EXPERIMENTAL|FCM + placebo|"1. Ferric carboxymaltose: Single dose, 500 mg~2. Placebo: Single dose"
62756181|NCT04627181|EXPERIMENTAL|B12 + placebo|"1. Hydroxycobalamine: Single dose, 1000 mcg~2. Placebo: Single dose"
62756182|NCT04627181|EXPERIMENTAL|FCM +B12|"1. Ferric carboxymaltose: Single dose, 500 mg~2. Hydroxycobalamine: Single dose, 1000 mcg"
62756183|NCT04627181|PLACEBO_COMPARATOR|Placebo + placebo|"1. Placebo: Single dose~2. Placebo: Single dose"
62756184|NCT05652231||School children (control group)|parented school children (control group)
62756185|NCT05652231||Non-Governmental orphanage children (exposed group 1)|
62756186|NCT05652231||Governmental orphanage children (exposed group 2)|
62756187|NCT02928003|EXPERIMENTAL|Lung Surgery|
62378963|NCT03172013||Cirrhotic ascitic patients with SBP,|Cirrhotic ascitic patients with SBP,
62378964|NCT03172013||cirrhotic ascitic patients without SBP,|cirrhotic ascitic patients without SBP,
62378965|NCT03172013||Healthy volunteers|Healthy individuals
62378966|NCT02180191||Obesity|27 obese individuals (20 men and 7 women with mean BMI: 39.98±5.56 kg/m2)
62378967|NCT02180191||Diabetes|26 patients with newly diagnosed type 2 diabetes (18 men and 8 women with mean BMI: 28.63±5.08 kg/m2)
62378968|NCT02180191||Control|Healthy control subjects (22 men and 6 women with mean BMI: 23.02±1.70 kg/m2)
62378969|NCT02689141|EXPERIMENTAL|Bendamustine + Ofatumumab + Ibrutinib|Bendamustine: 70mg/m² i.v. Ofatumumab: 1000 mg i.v. Ibrutinib: 420 mg po
62756188|NCT06474091||Observational|Patients undergo collection of blood samples and have their medical records reviewed on study. Patients also undergo collection of archived tissue samples on study.
62756189|NCT06083324||General cancer patients|All patients undergoing treatment for cancer on an exercise regimen
62756190|NCT06083324||Head and neck cancer patients|All patients undergoing treatment for head and neck cancer on an exercise regime
62756191|NCT06083324||Colorectal cancer patients|All patients undergoing treatment for colorectal cancer on an exercise regime
62378970|NCT04874350|EXPERIMENTAL|LPCN 1148|Oral LPCN 1148 capsules, administered as BID.
61986809|NCT00363779|EXPERIMENTAL|LGL Patients administered cyclosporine|Large Granular Lymphocyte Leukemia (LGL) is a low grade non-Hodgkins lymphoma characterized by tissue invasion of the marrow, spleen, and liver. Cyclosporine 5-10 mg/kg/day was administered as an oral preparation given every 12 hours. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml.
62756192|NCT06083324||Pancreatic cancer patients|All patients undergoing treatment for pancreatic cancer on an exercise regime
62756193|NCT06083324||Metastatic breast cancer patients|All patients undergoing treatment for metastatic breast cancer on an exercise regime
62756194|NCT02485652|EXPERIMENTAL|HM61713|HM61713 800 mg (2 x 400 mg tablets) once daily (QD)
62756195|NCT00659100|EXPERIMENTAL|A|
62756196|NCT06086444|PLACEBO_COMPARATOR|Placebo|Normal saline for intravenous administration.
62378971|NCT04874350|PLACEBO_COMPARATOR|Placebo|Oral matching placebo capsules, administered as BID.
62557406|NCT02851784|ACTIVE_COMPARATOR|MWA only|The HCC patients will be treated only by MWA.No adoptive immunotherapy will be used.
62756197|NCT06086444|ACTIVE_COMPARATOR|Tranexamic acid|Tranexamic Acid for intravenous administration.
62756198|NCT05391425||premenopausal|Premenopausal patients, presented in Arnavutkoy State Hospital Gynecology Clinic with lower urinary tract symptoms that will be treated with Solifenacin (Vesicare 5mg).
62756199|NCT05391425||postmenopausal|Postmenopausal patients, presented in Arnavutkoy State Hospital Gynecology Clinic with lower urinary tract symptoms that will be treated with Solifenacin (Vesicare 5mg).
62756200|NCT06296160|EXPERIMENTAL|Interventional Arm|"Based on the Ultrasound result, Dry Weight Modification:~Duration: 2 months. Number of visits: 5 visits.~A- Intervention Phase (Dry weight modification)= \[Day-1 and Day-15\]~B- Observational Phase (No Dry weight modification on Day 30, Day 45, and Day 60)."
62756201|NCT06296160|NO_INTERVENTION|Control Arm|"* Includes patients who will receive usual ambulatory and at-discharge care.~* No dry-weight modification (The study investigators will not modify the dry weight).~* All subjects in the Control group will be under follow-up close observation for two months \[5 visits\].~* The participant will follow the standard of care practice (Dry Weight evaluation according to clinical judgment by the assigned physician and biological data.~Study procedures:~1. Obtain a lung ultrasound after the midweek dialysis session.~2. The 8-zone lung ultrasound method calculates the number of B-line scores.~3. Check the Blood Pressure 3 times/day on non-Dialysis days.~4. Check the ambulatory blood pressure for 48 hours (Baseline on Day 1 and Follow-up on Day 60)."
61986810|NCT04476979|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)
62756202|NCT05124587||Patients with confirmed COVID-19 in the hospital setting|
62378972|NCT05692206||according to the neck disability index, mildly and moderately affected|
62378973|NCT05692206||According to the neck disability index, severely affected and very severely affected|
62378974|NCT03128606|EXPERIMENTAL|GLPG3067 single dose|Single dose of GLPG3067 oral suspension at up to 6 dose levels in ascending order.
62378975|NCT03128606|PLACEBO_COMPARATOR|Placebo single dose|Single dose of Placebo oral suspension.
62378976|NCT03128606|EXPERIMENTAL|GLPG3067 oral suspension fed 1|Single dose 1 of GLPG3067 oral suspension after a standardized breakfast.
62378977|NCT03128606|EXPERIMENTAL|GLPG3067 oral tablet fed 1|Single dose 1 of GLPG3067 oral tablet after a standardized breakfast.
62378978|NCT03128606|EXPERIMENTAL|GLPG3067 oral tablet fasted 1|Single dose 1 of GLPG3067 oral tablet after an overnight fast.
62557407|NCT02851784|EXPERIMENTAL|MWA combined with immunotherapy|The HCC patients will be treated firstly by MWA, and then treated by courses of adoptive immunotherapy.
62378979|NCT03128606|EXPERIMENTAL|GLPG3067 oral tablet fed 2|Single dose 2 of GLPG3067 oral tablet after a standardized breakfast.
62378980|NCT03128606|EXPERIMENTAL|GLPG3067 oral tablet fed 2 high-fat high-calorie|Single dose 2 of GLPG3067 oral tablet after a high-fat high-calorie breakfast
62378981|NCT03128606|EXPERIMENTAL|GLPG3067 multiple dose|Multiple doses of GLPG3067 oral suspension at up to 5 dose levels in ascending order.
62378982|NCT03128606|PLACEBO_COMPARATOR|Placebo multiple dose|Multiple doses of Placebo oral suspension.
62557408|NCT04632576|EXPERIMENTAL|transcutaneous electrical acupoint stimulation|transcutaneous electrical acupoint stimulation is one of the many forms of acupuncture, and is a distinctive part of Chinese medicine that has been practiced in China for thousands of years. It is employed by placing electrodes on acupoint and electrical stimulation is given after anesthetic induction to the end of the surgery.
62557409|NCT04632576|NO_INTERVENTION|Control|"Electrodes are placed on same acupoints as the experimental group, and will receive the optimal intensity test before the anesthesia induction, but no electrical stimulation is given during the operation."
62557410|NCT04004481||Adult patients undergoing major open abdominal surgery|Observational study. In the patients undergoing major open abdominal surgery for cancer tramadol will be used for postoperative analgesia. In the postoperative period parent compound and metabolites of tramadol will be measured. Postoperative analgesia and adverse effects will be registered and compared between CYP2D6 phenotypes observed.
62557411|NCT02762929|EXPERIMENTAL|HTX-011A: 200 mg|HTX-011A (bupivacaine/meloxicam), 200 mg/6 mg via injection.
62557412|NCT02762929|EXPERIMENTAL|HTX-011B: 30 mg|HTX 011B (bupivacaine/meloxicam), 30 mg/0.9 mg via injection.
62557413|NCT02762929|EXPERIMENTAL|HTX-011B : 60 mg|HTX-011B (bupivacaine/meloxicam) 60 mg/1.8 mg via injection or instillation.
62557414|NCT02762929|EXPERIMENTAL|HTX-011B: 120 mg|HTX- 011B (bupivacaine/meloxicam), 120 mg/3.6 mg via injection or instillation.
62557415|NCT02762929|EXPERIMENTAL|HTX-011B: 200 mg|HTX- 011B (bupivacaine/meloxicam), 200 mg/6 mg via injection.
62557416|NCT02762929|ACTIVE_COMPARATOR|Bupivacaine HCI|Bupivacaine HCI, 50 mg via injection.
62557417|NCT02762929|ACTIVE_COMPARATOR|Saline Placebo|Saline placebo via injection.
62557418|NCT02762929|EXPERIMENTAL|HTX-002, 60 mg|HTX- 002, 60 mg via injection.
62557419|NCT02762929|EXPERIMENTAL|HTX-002, 120 mg|HTX-002, 120 mg via injection.
62557420|NCT02762929|EXPERIMENTAL|HTX-002, 200 mg|HTX-002, 200 mg via injection.
62557421|NCT02762929|EXPERIMENTAL|HTX-009|HTX-009, 3.6 mg via injection.
62557422|NCT01506869||Type 2 diabetes|
62557423|NCT01506869||Prediabetes|
62557424|NCT01506869||Normal glucose regulation|
62557425|NCT06295276|EXPERIMENTAL|Intervention|a six-week muscle training program with 5 exercises 3 times a week as video-guided exercises for homework alone and the same exercises once a week guided by Zoom. The program lasts 6 weeks
62557426|NCT06295276|OTHER|Waiting list/control intervention/delayed teletherapy intervention|After the 6 weeks, participants are offered the opportunity to take part in the intervention program (see above)
62378983|NCT03128606|EXPERIMENTAL|GLPG3067/GLPG2222 multiple dose|Multiple doses of GLPG3067 oral suspension combined with GLPG2222 oral tablet up to 2 dose levels in ascending order.
62557427|NCT04095039|EXPERIMENTAL|Hi Arm|Patients to allow blood serum phosphate levels to rise to 6.5 mg/dl or above
62557428|NCT04095039|NO_INTERVENTION|Lo Arm|Patients to titrate blood serum phosphate levels to the standard \<5.5mg/dl
62557429|NCT04544774||Allergic rhinitis patients|Patients with persistent or intermittent allergic rhinitis complaints, confirmed by skin prick tests and/or immunocap for specific IgEs, that start with AIT treatment.
61986811|NCT04476979|EXPERIMENTAL|Dexamethasone + Tocilizumab|"Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)~+Tocilizumab 8mg/kg D1 and if no response (No decrease of oxygen requirement) a second fixed dose of 400mg wil be administered at D3"
62378984|NCT03128606|PLACEBO_COMPARATOR|GLPG3067/GLPG2222 Placebo multiple dose|Multiple doses of GLPG3067 matching placebo oral suspension combined with GLPG2222 matching placebo oral tablet.
62378985|NCT03128606|EXPERIMENTAL|GLPG3067/GLPG2222/GLPG2737 multiple dose|Multiple doses of GLPG3067 oral tablet combined with GLPG2222 oral tablet and GLPG2737 oral capsule at up to 2 dose levels in ascending order.
62756203|NCT05648864|EXPERIMENTAL|Viamigo intervention|All eligible and consenting dyads will be asked to participate in the Viamigo intervention (mobile application), consisting of three main components: (1) a face-to-face technology training session of 60 minutes, (2) a 3-month period of using the Viamigo intervention with support phone calls of approximately 5 minutes by the coordinating investigator once every two weeks, and (3) an evaluation phone call of 5-10 minutes.
62756204|NCT01269359||radiation|
62378986|NCT03128606|PLACEBO_COMPARATOR|GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose|Multiple doses of GLPG3067 matching placebo oral tablet combined with GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule.
62378987|NCT06454565|EXPERIMENTAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises|All classes are conducted offline and are implemented by professional Health Qigong instructors.
62378988|NCT06454565|EXPERIMENTAL|Locked exercise|All classes are held offline with professional instructors.
62378989|NCT06454565|EXPERIMENTAL|Multiplayer open exercise|All classes are held offline with professional instructors.
62378990|NCT06454565|EXPERIMENTAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises combined with locked exercise|All classes are held offline with professional instructors.
62557430|NCT01237119|EXPERIMENTAL|Liraglutide|A once-daily glucagon-like peptide 1 (GLP-1) analogue. Currently has regulation approval for use in type 2 diabetics (ref: guidelines)
62557431|NCT01237119|PLACEBO_COMPARATOR|Placebo|Liraglutide-Placebo manufactured by Novo Nordisk.
62378991|NCT06454565|EXPERIMENTAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises combined with open exercise|All classes are held offline with professional instructors.
62557432|NCT00235755|PLACEBO_COMPARATOR|Placebo|
62557433|NCT00235755|EXPERIMENTAL|Retigabine 600 mg|
62557434|NCT00235755|EXPERIMENTAL|Retigabine 900 mg|
62756205|NCT02084680|NO_INTERVENTION|Control|Control group standard care
62756206|NCT02084680|EXPERIMENTAL|Community Health Workers|individual prenatal education
62378992|NCT06454565|NO_INTERVENTION|Control group|Disseminating knowledge about the dangers of drugs
62557435|NCT03290378|ACTIVE_COMPARATOR|AVE-901 50 mg|
62557436|NCT03290378|ACTIVE_COMPARATOR|AVE-901 25 mg|
62378993|NCT02249351|EXPERIMENTAL|Talsaclidine|
62557437|NCT03290378|PLACEBO_COMPARATOR|Placebo|
62378994|NCT02249351|PLACEBO_COMPARATOR|Placebo|
62378995|NCT04754906||young neurotypical subjects|people from 18 to 40 years old
62378996|NCT04754906||elderly neurotypical subjects|people over 55 years of age
62378997|NCT04754906||Elderly subjects with mild cognitive impairment|people over 55 years of age, with a diagnosis of mild cognitive impairment
62378998|NCT00414973|EXPERIMENTAL|A|
62378999|NCT00414973|ACTIVE_COMPARATOR|B|
62379000|NCT01341925|PLACEBO_COMPARATOR|Placebo Supplement and No PEP|Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
62557438|NCT01159405|EXPERIMENTAL|99mTc-GP|99mTc-GP with SPECT/CT imaging \& whole body scan.
62557439|NCT04968613|EXPERIMENTAL|Madopar monotherapy group|Patients in this group received Madopar monotherapy
62557440|NCT04968613|ACTIVE_COMPARATOR|senfrol monotherapy group|Patients in this group were treated with senfrol (D2 receptor agonist) alone
62557441|NCT04968613|PLACEBO_COMPARATOR|placebo group|Patients in this group were treated with selegiline alone
62756207|NCT03741023|OTHER|Trauma Patients|"During Hospitalization:~Patients routinely have blood drawn at time of admission and every 12 hours following admission up until 2 weeks post-admission or until discharge. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (2 blue-top tubes) per time point during their normal course of care for this study, for a total of 72.8 mL of blood drawn per week. In addition to the routine blood draws, a finger stick may also be obtained the same day. Approximately 3 drops of blood (100μL maximum) will be removed by the finger stick.. Finger sticks will not be collected in the pediatric population.~Follow-Up Visits Any complications resulting from traumatic injury will be documented at these routine care visits. These complications will be documented if they occur within 2 years of injury."
62379001|NCT01341925|EXPERIMENTAL|Omega-3 and PEP|"Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
62557442|NCT05678660||Long Group|Older adults individuals with longstanding HIV, stable and on antiretroviral therapy for at least 7 years
62756208|NCT03741023|OTHER|Invasive Elective Surgery Patients|"During Hospitalization:~Patients routinely have blood drawn pre-, intra- and post-operatively. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (for patients 7 years of age or older) or 2mL of blood drawn (for patients under the age of 7 years old) immediately prior to surgery, every 30 minutes intraoperatively, every 6 hours for 3 days post-operatively, and every 12 hours from 3 days post-operative until discharge. Total blood volume drawn within one week will not exceed 150mL for patients ≥7 years of age and 55mL for patients \<7 years of age (\~3% total blood volume).~Follow-Up Visits Any complications resulting from surgery will be documented at these routine care visits. These complications will be documented if they occur within 2 years of surgery."
62756209|NCT03741023|OTHER|Healthy Volunteers|Blood will be taken from healthy, non-pregnant adults who weigh at least 110 pounds by research staff trained in venipuncture at a one-time study visit.
62756210|NCT03397888|EXPERIMENTAL|Cohort 1|Mild Impairment, Child-Pugh Category A
62756211|NCT03397888|EXPERIMENTAL|Cohort 2|Moderate Impairment, Child-Pugh Category B
62756212|NCT03397888|EXPERIMENTAL|Cohort 3|Essentially Healthy man or woman without liver disease matched to Cohorts 1 \& 2 for age, sex and weight.
62756213|NCT01485900|EXPERIMENTAL|Cohort 1|Dose 1: 20 days 3-step uptitration with doses A, B, and C of SAR407899 vs. placebo
62756214|NCT01485900|EXPERIMENTAL|Cohort 2|Dose 2: 20 days 3-step uptitration with doses B, C and D of SAR407899 vs. placebo
62756215|NCT03770728|PLACEBO_COMPARATOR|Placebo|Participants received placebo (matched to Efpeglenatide) subcutaneous (SC) injection once weekly up to Week 30 on top of metformin alone or in combination with SU.
62756216|NCT03770728|EXPERIMENTAL|Efpeglenatide 2 mg|Participants received Efpeglenatide 2 milligrams (mg) SC injection once weekly up to Week 30 on top of metformin alone or in combination with SU.
62756217|NCT03770728|EXPERIMENTAL|Efpeglenatide 4 mg|Participants received Efpeglenatide 4 mg SC injection once weekly up to Week 30 on top of metformin alone or in combination with SU. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg and was maintained at the 4 mg dose through-out the treatment duration, up to Week 30.
62756218|NCT03770728|EXPERIMENTAL|Efpeglenatide 6 mg|Participants received Efpeglenatide 6 mg SC injection once weekly up to Week 30 on top of metformin alone or in combination with SU. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg until Week 3 and later up-titrated to 6 mg and was maintained at the 6 mg dose through-out the treatment duration, up to Week 30.
62756219|NCT06413420||Cohort 1: Solriamfetol-exposed participants with narcolepsy or OSA|Pregnant women with a diagnosis of narcolepsy or OSA
62756220|NCT06413420||Cohort 2: Unexposed participants with narcolepsy or OSA|Pregnant women with a diagnosis of narcolepsy or OSA
62756221|NCT06413420||Cohort 3: Other-exposed participants with narcolepsy or OSA|Pregnant women with a diagnosis of narcolepsy or OSA
62756222|NCT06413420||Cohort 4: Solriamfetol-exposed participants without narcolepsy or OSA|Pregnant women without a diagnosis of narcolepsy or OSA
62756223|NCT06413420||Cohort 5: Other-exposed participants without narcolepsy or OSA|Pregnant women without a diagnosis of narcolepsy or OSA
62756224|NCT01888731|EXPERIMENTAL|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
62756225|NCT01888731|ACTIVE_COMPARATOR|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 50 mg of GlaxoSmithKline Research Triangle Park, NC
62756226|NCT02209402|NO_INTERVENTION|Usual Care|
62756227|NCT02209402|EXPERIMENTAL|Exercise Training|
62756228|NCT01204229|EXPERIMENTAL|MCID|
62756229|NCT01204229|EXPERIMENTAL|BMI|
62756230|NCT03122821|EXPERIMENTAL|Group 1|Real Trans-cranial direct stimulation + Mental Imagery
62756231|NCT03122821|ACTIVE_COMPARATOR|Group 2|Sham Trans-cranial direct stimulation + Mental imagery
62756232|NCT05783921|EXPERIMENTAL|TQB2618 injection +Penpulimab injection+Chemotherapy (Paclitaxel+Cisplatin or Carboplatin)|TQB2618 injection combined with Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin, 21 days as a treatment cycle. After 4\~6 cycles, TQB2618 injection combined with Penpulimab injection, 21 days as a treatment cycle.
62756233|NCT05783921|ACTIVE_COMPARATOR|Penpulimab injection + Chemotherapy (Paclitaxel+Cisplatin or Carboplatin)|Penpulimab injection combined with Paclitaxel, Cisplatin or Carboplatin, 21 days as a treatment cycle. After 4\~6 cycles, Penpulimab injection, 21 days as a treatment cycle.
62756234|NCT05814198||FGR|In the group with FGR, we will calculate the HALP score with the complete blood count and albumin values.
62379002|NCT01341925|EXPERIMENTAL|Omega-3 and No PEP|Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
62756235|NCT05814198||SGA|In the group with SGA, we will calculate the HALP score with the complete blood count and albumin values.
62756236|NCT04940897|EXPERIMENTAL|Intervention|Usual care plus ketone meter and fluid therapy for identified high risk DKA patients
62756237|NCT05868733|EXPERIMENTAL|Cohort 1A|Healthy Adults, 18-70yrs
62756238|NCT05868733|EXPERIMENTAL|Cohort 2A|HIV-infected Adults, 18-50yrs
62756239|NCT05868733|EXPERIMENTAL|Cohort 3A|Adolescents, 12 17yrs
62756240|NCT05868733|EXPERIMENTAL|Cohort 4A|Children, 6-11yrs
62756241|NCT05868733|EXPERIMENTAL|Cohort 5A|Children, 18mos-5yrs
62756242|NCT05868733|EXPERIMENTAL|Cohort 1B|Healthy Adults, 18-70yrs
62756243|NCT05868733|EXPERIMENTAL|Cohort 2B|HIV-infected Adults,18-50yrs
62756244|NCT05868733|EXPERIMENTAL|Cohort 3B|Adolescents, 12 17yrs
62379003|NCT01341925|EXPERIMENTAL|Placebo Supplement and PEP|"Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
62379004|NCT01467024||EIA Negative|Blood donor specimens that tested non-reactive by previously licensed HTLV screening assay.
62379005|NCT01467024||EIA Repeat Reactive|Blood donor specimens that tested repeat reactive by previously licensed HTLV screening assay, but are unconfirmed.
62379006|NCT01467024||Known Positive|Blood donor specimens that tested repeat reactive with a licensed HTLV screening assay and have been confirmed through additional, unlicensed supplemental testing.
62379007|NCT02471586|ACTIVE_COMPARATOR|Coronary PCI guided by IVUS|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with IVUS guidance according to local standard practice. IVUS imaging is required pre and post stent implantation.~At the end of the procedure, a final IVUS imaging run must be performed.~After the final IVUS run, a blinded OCT imaging run shall be performed to document final stent dimensions and results."
62557443|NCT05678660||Short Group|Older adults living with HIV, on stable antiretroviral treatment for at least 1 but not more than 2 years,
62557444|NCT01189162|EXPERIMENTAL|NIMV- nasal respiratory support|Infants with RDS will be treateg with nasal intermittent mandatory ventilation
62756245|NCT05868733|EXPERIMENTAL|Cohort 4B|Children, 6-11yrs
62379008|NCT02471586|ACTIVE_COMPARATOR|Coronary PCI guided by OCT|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with OCT guidance according to the algorithm described in the protocol. OCT imaging is required pre and post stent implantation.~At the end of the procedure, a final OCT imaging run must be performed."
62379009|NCT02471586|ACTIVE_COMPARATOR|Coronary PCI guided by Angiography|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with angiography guidance according to local standard practice.~At the end of the procedure, a blinded OCT shall be performed to document final stent dimensions and results."
62379010|NCT02612792|ACTIVE_COMPARATOR|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
62557445|NCT01189162|EXPERIMENTAL|HFNC- nasal respiratory support with HFNC|Infants with RDS will be treated with nasal respiratory support with high flow nasal canulla
62557446|NCT06583044||Dentistry clinical student diagnosed with bruxism|This group includes dental clinical students diagnosed with bruxism.
62557447|NCT06583044||Dentistry clinical student without bruxism diagnosis|This group includes dental clinical students diagnosed without bruxism.
62557448|NCT05911334|EXPERIMENTAL|Restorative Occupational Approaches for Disordered Eating (ROADE)|Novel Outpatient Occupational Therapy Intervention using chronic illness management strategies, yoga, meditation for disordered eating. 8-weeks with 2 visits per week each lasting 1 hour.
62756246|NCT05868733|EXPERIMENTAL|Cohort 5B|Children, 18mos-5yrs
62756247|NCT03310008|EXPERIMENTAL|Dose level 1 (escalation|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
62756248|NCT03310008|EXPERIMENTAL|Dose level 2 (escalation)|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
62756249|NCT03310008|EXPERIMENTAL|Dose level 3 (escalation)|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
62756250|NCT03310008|EXPERIMENTAL|Recommended dose level (expansion)|The dose expansion arm will use the maximum tolerated dose.
62756251|NCT06356779|EXPERIMENTAL|Local ablative therapy|"Discussion at multidisciplinary team conferences Lesion-specific treatment plan with allocation to~* surgical metastasectomy~* stereotactic radiotherapy~* thermal ablation~* electroporation"
62756252|NCT03351686|EXPERIMENTAL|tranexamic acid group|
62756253|NCT03351686|NO_INTERVENTION|non tranexamic (control) group|
62756254|NCT01371149|NO_INTERVENTION|Physician led ventilator set up|Patients will be set up on non-invasive ventilation as per the current gold standard physician led approach
62557449|NCT03440840|EXPERIMENTAL|Computer Training with active tDCS|Participants randomized to this arm will receive computer-based cognitive training using a car racing game with active transcranial direct current stimulation (tDCS).
62557450|NCT03440840|ACTIVE_COMPARATOR|Computer Training with sham tDCS|Participants randomized to this arm will receive computer-based cognitive training using a car racing game with sham transcranial direct current stimulation (tDCS).
62379011|NCT02612792|ACTIVE_COMPARATOR|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
62557451|NCT03440840|PLACEBO_COMPARATOR|Computer Training with or without tDCS|Participants in this arm will watch educational videos as a comparator to computer training with the car racing game (watching educational videos).
62557452|NCT00323375|EXPERIMENTAL|AQ-13 (Investigational 4-Aminoquinoline)|Arm: Experimental: AQ-13 AQ-13 capsules with 350 mg AQ-13 base per capsule. Two capsules orally on days 1 and 2, one capsule orally on day 3.
62557453|NCT00323375|ACTIVE_COMPARATOR|CQ (Chloroquine)|Arm: Active Comparator: CQ CQ Capsules with 300 mg CQ base per capsule per capsule. Two capsules orally on days 1 and 2, one capsule orally on day 3.
62557454|NCT01820598|OTHER|m-NMES first|Multisite electrostimulator first (Visit 1) and conventional electrostimulator then (Visit 2)
62557455|NCT01820598|OTHER|c-NMES first|Conventional electrostimulator first (Visit 1) and multisite electrostimulator then (Visit 2)
62756255|NCT01371149|EXPERIMENTAL|parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
62379012|NCT02612792|ACTIVE_COMPARATOR|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin for treating furcation defect
62379013|NCT00381784|EXPERIMENTAL|Community PROMISE|Community PROMISE is a community level HIV/STD prevention program that relies on role model stories and peer advocates from the community. Sites will adapt PROMISE for local use remaining faithful to the core elements.
62379014|NCT00381784|EXPERIMENTAL|Mpowerment|MPowerment is a community level HIV/STD prevention program that relies on peer advocates from the community to lead outreach activities including discussion groups (Mgroups), venue-based outreach, social events and a publicity campaign. Sites will adapt MPowerment for local use remaining faithful to the core elements.
62379015|NCT06014476||Experimental Group|Caregivers of patients with disorders of consciousness, including Coma, Unresponsive Wakefulness Syndrome (UWS), and Minimally Consciousness State (MCS). And caregivers of patients emerge from the minimally conscious state (EMCS)
62379016|NCT06014476||Control group|caregivers of patients with other disease
62557456|NCT01738295|ACTIVE_COMPARATOR|Donepezil|Donepezil administration. In this group Donepezil (Aricept pill, 5 mg) will be orally administrated 3h before each experiment (1 week intervals)
62557457|NCT01738295|PLACEBO_COMPARATOR|Lactose pill|Placebo administration. In this group, placebo (lactose pill) will be orally administrated 3h before each experiments (1 week intervals)
62557458|NCT03119402|EXPERIMENTAL|RRT + active tDCS|Rhythmic Reading Training, administered for 5 hours over 10 days consecutive (30-minute training sessions per day) + simultaneous 20 minutes of active tDCS (1.5 mA, 5x5cm anodal electrode on left parieto-temporal regions and 5x5cm cathodal electrode on right parieto-temporal regions).
62756256|NCT02686151|ACTIVE_COMPARATOR|letrozole|2.5mg/tablet(Jiangsu Hengrui Medicine Co., Ltd. products), orally taken 5mg once a day for 5 days
62756257|NCT02686151|OTHER|Polygeline Injection|500ml and 0.9% Sodium Chloride Injection (250ml) with dexamethasone 1mg intravenous injection，once a day for 2 days
62756258|NCT06026371|EXPERIMENTAL|Group I (fecal microbiota transplant)|Patients receive fecal microbiota capsules PO QD for 7 days
62379017|NCT02110550|NO_INTERVENTION|IPS.emmax crown|
62379018|NCT02110550|EXPERIMENTAL|IPS.emmax endocrown|Patients with excessively undermined and endodontically treated molars will receive the IPS.emmax endocrown as the restoration of choice.
62379019|NCT00840528|EXPERIMENTAL|Ozone exposure|Exposure to ozone at 0.4ppm
62379020|NCT04366089|ACTIVE_COMPARATOR|Standard of care|Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), plus hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
62557459|NCT03119402|SHAM_COMPARATOR|RRT + sham tDCS|Rhythmic Reading Training, administered for 5 hours over 10 days consecutive (30-minute training sessions per day) + simultaneous 20 minutes of sham tDCS (with the same active tDCS setup, current applied for 30 seconds,
62557460|NCT02319317|EXPERIMENTAL|Risky driving prevention|Web-based behavioral intervention to promote teen driver attention to the roadway, addressing mobile technology and passengers.
62557461|NCT02319317|EXPERIMENTAL|Control group|Web-based behavioral intervention for healthy lifestyles.
62557462|NCT01657838|EXPERIMENTAL|Arm 1: isavuconazole only|Single dose of isavuconazole on Day 1
62557463|NCT01657838|EXPERIMENTAL|Arm 2: isavuconazole + ketoconazole|Single dose of isavuconazole on Day 4 and ketoconazole twice daily (BID) for 24 days
62557464|NCT05431894|EXPERIMENTAL|Intervention Arm|Group received support from Laguna Coaches
62557465|NCT05431894|NO_INTERVENTION|Control Arm|Group received no support from Laguna Coaches
62557466|NCT06190392|EXPERIMENTAL|Modified simplified diagnostic strategy MODS|
62557467|NCT00857571|EXPERIMENTAL|Suspension|PF-02413873 suspension
62557468|NCT00857571|EXPERIMENTAL|Tablet|PF-02413873 Phase 2 Tablets
62557469|NCT05937412|ACTIVE_COMPARATOR|alcohol group|70% isopropyl alcohol will be topically applied and spread uniformly on a prespecified area of at least 3 cm x 3cm on the dorsum of the hand. A skin swab will be obtained from the selected skin area just before and 20 seconds after topical application of alcohol and honey.
62557470|NCT05937412|ACTIVE_COMPARATOR|honey group|honey will be topically applied and spread uniformly on a prespecified area of at least 3 cm x 3cm on the dorsum of the hand. A skin swab will be obtained from the selected skin area just before and 20 seconds after topical application of alcohol and honey.
62557471|NCT01874028|EXPERIMENTAL|Trientine dihydrochloride|
62557472|NCT04418557||Pregnant women without COVID-19 Infection|Women who are tested for COVID-19 at the time of admission for labor and delivery and test negative
62557473|NCT04418557||Pregnant women with a history of COVID-19 infection|Women who are tested for COVID-19 at any point during their pregnancy, including at the time of admission for labor and delivery, and test positive
62557474|NCT04418557||Pregnant women vaccinated for COVID-19|Women who are vaccinated against COVID-19 at any point during their pregnancy
62557475|NCT05268991||AGE Participants|Participants aged 65 and older with diagnosis of solid tumor malignancy or lymphoma and planned to start a new chemotherapy regimen in the outpatient setting
62756259|NCT06026371|PLACEBO_COMPARATOR|Group II (Placebo)|Patients receive placebo PO QD for 7 days
62756260|NCT03279913|EXPERIMENTAL|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
62379021|NCT04366089|EXPERIMENTAL|Oxygen-ozone and probiotic|"Oxygen-ozone therapy, probiotic supplementation plus standard of care~Oxygen-ozone therapy: systemic autohemotherapy (twice a day).~Probiotic supplementation: SivoMixx 200 billion (six sachets twice a day)."
62379022|NCT05651269|EXPERIMENTAL|Milciclib plus gemcitabine|"Name: milciclib Dose: 150 mg/day Mode of administration: oral~Combination product:~Name: gemcitabine Dose: 1000 mg/m2 Mode of administration: intravenous"
62379023|NCT05686629|EXPERIMENTAL|Jaktinib 100mg BID|Jaktinib hydrochloride tablets, 2 x 50mg dosage, BID
62379024|NCT05686629|PLACEBO_COMPARATOR|Placebo|2 x Placebo tablets, BID
62379025|NCT00850629|PLACEBO_COMPARATOR|placebo|Placebo
62379026|NCT00850629|EXPERIMENTAL|lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
62379027|NCT00631969|EXPERIMENTAL|Vardenafil ODT (STAXYN, BAY38-9456)|Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
62379028|NCT00631969|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
62379029|NCT05012709|EXPERIMENTAL|intervention group|The intervention group received six 30-minute MST sessions. During MST session, participants can choose their preferred sensory stimuli such as essential oil diffuses, music and so on.
62379030|NCT05012709|NO_INTERVENTION|control group|The TAU group received usual routine care.
62379031|NCT05631730|EXPERIMENTAL|Flecainide and Metoprolol|"Participants will receive flecainide 50 mg twice daily (BID), with a dosage target of 100 mg BID. The maximum daily dose of flecainide will not exceed 300 mg. The first dose of flecainide will be initiated in-hospital with a 12-lead electrocardiogram (ECG) taken after 3 hours. If the ECG is considered normal after flecainide treatment, the participant will continue with 50 mg BID from the next day. Participants will receive a dosage of Metoprolol taking into consideration prior beta-blocker use and concomitant medications. The maximum daily dose of metoprolol will not exceed 200 mg. Within the run-in period, the dosage of both Flecainide and Metoprolol will be increased to the maximum tolerable dose.~The Study Team can change the immediate-release formulation of Flecainide to controlled release at the same daily dose of flecainide. Whether metoprolol sustained release will be dosed once daily (QD) or BID, will be up to the investigator and patient preference."
62379032|NCT05631730|ACTIVE_COMPARATOR|Metoprolol Alone|Participants will receive a dosage of Metoprolol taking into consideration prior beta-blocker use and concomitant medications. Within the run-in period, the dosage will be increased to the maximum tolerable dose. Whether metoprolol sustained release will be dosed QD or BID, will be up to the investigator and patient preference. The maximum daily dose of metoprolol will not exceed 200 mg.
62379033|NCT01592110|EXPERIMENTAL|Cohort 1|25 mg of risperidone-SABER administered as a SC injection of 0.25 mL (100 mg/mL concentration) in the abdominal region
62379034|NCT01592110|EXPERIMENTAL|Cohort 2|50 mg of ZX003 (risperidone-SABER-DosePro) administered as 0.5 mL (100 mg/mL concentration) via the DosePro Needle-free Delivery System in the abdominal region
62557476|NCT05952102|EXPERIMENTAL|52 children with community acquired pneumonia will receive Nigella sativa oil capsules|52 children with community-acquired pneumonia will receive Nigella sativa oil in capsules at a dose of 40 mg/kg/day (8), as an adjunct therapy to the usual pneumonia treatment till the recovery of the disease.
62379035|NCT01592110|EXPERIMENTAL|Cohort 3|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL (100 mg/mL concentration) in the abdominal region
62379036|NCT01592110|EXPERIMENTAL|Cohort 4|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL (100 mg/mL concentration) in the abdominal region
62379037|NCT03675685|EXPERIMENTAL|CCH (Collagenase clostridium histolyticum)|
62557477|NCT05952102|NO_INTERVENTION|52 children|52 children with community-acquired pneumonia with the usual pneumonia treatment as a control group
62557478|NCT06472297|EXPERIMENTAL|Unmasked CGM feedback|The CGM system is used by the participant according to manufacturer instructions for the condition interval in their normal living environment.
62557479|NCT05302986|EXPERIMENTAL|Surgery with intravenous injection of tranexamic acid|The dose will be 0.1 mg / kg (= 10 mg/kg) and diluted in a 100 mL infusion bag of sodium chloride. The product will have to be administered as a slow infusion over 10 minutes.
62557480|NCT05302986|PLACEBO_COMPARATOR|Surgery with intravenous injection of Placebo (0.9% sodium chloride)|A 100 mL infusion bag of sodium chloride will be administered as a slow infusion over 10 minutes.
62756261|NCT02720601|EXPERIMENTAL|Irinotecan & Capecitabine|"Irinotecan at 120 mg/m2 intravenously every three weeks + Capecitabine at 1500 mg/m2/day orally twice per day for a total of 14 days.~The treatment cycle is once every 21 days."
62756262|NCT03430505|ACTIVE_COMPARATOR|Bilevel|Bilevel 10 minutes after bronchoprovocation with saline solution 4.5%. IPAP 12 and EPAP 8
62756263|NCT03430505|ACTIVE_COMPARATOR|Albuterol|400micrograms after bronchoprovocation with saline solution 4.5%.
62756264|NCT00994734|NO_INTERVENTION|clinic administration of mifepristone|
62557481|NCT04453319|EXPERIMENTAL|Application of the device (PICO)|PICO® is a disposable, single-use pump without a canister that generates an effective, non-adjustable, negative pressure of -80 mmHg and that can be used for up to 7 days.(-1113) It incorporates leak detection and low battery indicators and is connected to a 4-layer absorbent dressing that primarily removes wound exudates through evaporative loss. The mechanism of action has been postulated to occur because of the combined effects of a reduction in the frequency of dressing changes, a reduction in stress concentration in the tissue surrounding the incision, and an enhancement in the appositional strength of the incision line, thus reducing dead space and minimizing the risk of wound contamination.(14) PICO® has also been demonstrated to enhance lymphatic clearance and decrease the risk of hematomas or seromas
62557482|NCT04453319|NO_INTERVENTION|Conventional Dressing of the femoral wound|Conventional Dressing of the femoral wound
62557483|NCT01606826||Asthmatics|Subjects with active asthma.
62557484|NCT01606826||Healthy Controls|Subjects without any known pulmonary disease.
62557485|NCT02397512|EXPERIMENTAL|Lactulose group|Subjects will ingest 50g of lactulose once
62756265|NCT00994734|EXPERIMENTAL|home administration of mifepristone|
62756266|NCT02267330||Standard of care, Exposure recording|Patient will undergo fracture surgery as per standard of care, and will have radiation exposure recording.
62756267|NCT06209515||Patients with neurodegenerative disease|Patient diagnosed with neurodegenerative disease (ICD-10 diagnosis code) between 2010-2021
62756268|NCT06209515||Matched controls|Age, gender, and place of residency matched for those of a patient that was alive at the end of the year of the diagnosis
62756269|NCT01215617|EXPERIMENTAL|Aerobic Interval Training|Patients randomized to training will meet for supervised aerobic interval training three times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate
62756270|NCT01215617|OTHER|Control|Patients will receive standard medical treatment at the University Hospital lung department.
62756271|NCT02240849|EXPERIMENTAL|Functional pillow|cervical pillow, designed functionally to decrease neck pain and help to ensure the right support of the cervical curve, was applied to patients' posterior neck area.
62756272|NCT02240849|PLACEBO_COMPARATOR|General pillow|Applicants Randomly allocated to this group were issued by placebo-general pillow. There is not any specific intervention for their neck discomfort except for that.
62756273|NCT03724981|EXPERIMENTAL|Dulaglutide Pen|Injection of commercial dulaglutide pen on a practice pad.
62756274|NCT03724981|EXPERIMENTAL|Semaglutide Pen|Injection of commercial semaglutide pen on a practice pad.
62557486|NCT02397512|PLACEBO_COMPARATOR|Control group|Subjects will ingest 50g of sucrose once
62557487|NCT03484702|EXPERIMENTAL|Administration of JCAR017|
62557488|NCT03348540|EXPERIMENTAL|Attention Control Training|"* 6 sessions in the clinic lasting approximately 10 minutes each.~* Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
62756275|NCT01119833|EXPERIMENTAL|GMI-1070|
62557489|NCT03348540|PLACEBO_COMPARATOR|Comparison Task|"6 sessions in the clinic of a presumably inactive neutral-neutral stimuli intervention lasting approximately 10 minutes each.~• Each session will consist of 128 presentations of pairs of faces, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
62557490|NCT06582238||Egyptian Dentists|Dentists (at various levels of education and years of practice) practicing in Egypt
62557491|NCT06582238||Nigerian Dentists|Dentists (at various levels of education and years of practice) practicing in Nigeria
62557492|NCT04208152|ACTIVE_COMPARATOR|anle138b|Dosage: 50 mg and higher Dosage form: capsule Frequency: once daily Duration: One day for SAD and seven days for MAD
62756276|NCT01119833|PLACEBO_COMPARATOR|Placebo|
62756277|NCT01135914|EXPERIMENTAL|Combination Therapy|Participants received ranibizumab intravitreal injection and laser photocoagulation treatments
62756278|NCT01135914|EXPERIMENTAL|Ranibizumab Monotherapy|Participants received ranibizumab intravitreal injection therapy only
62756279|NCT01135914|ACTIVE_COMPARATOR|Laser Monotherapy|Participants received Laser photocoagulation therapy only
62756280|NCT05374577||Patients with a suspected diagnosis of post/long-COVID-19|Patients with a suspected post-COVID-19 syndrome or a long-COVID-19 syndrome at least 3 months after severe acute respiratory syndrome coronavirus(CoV) type 2 (SARS-CoV-2) infection (symptomatic or asymptomatic)
62557493|NCT04208152|PLACEBO_COMPARATOR|placebo|Matching placebo Dosage form: capsule Frequency: once daily Duration: One day for SAD and seven days for MAD
62756281|NCT05374577||Patients without post/long-COVID-19 Syndrome|Patients at least 3 months after a SARS-CoV-2 infection (symptomatic or asymptomatic) without post/long-COVID-19.
62756282|NCT00780637|EXPERIMENTAL|Bradykinin|Patients receive 0, 10, 20, and 40 ng/min/100cc forearm volume of intrabrachial bradykinin, for 5 minutes at each dose. Forearm blood flow will be measured by strain gauge plethysmography, blood samples will be obtained to measure t-PA, PAI-1 at each dose. FMD and Radial artery tonometry will also be performed under resting conditions.
62756283|NCT03727087||Melanoma|Subjects with clinically confirmed melanoma or high suspicion of a primary malignancy of melanoma based on skin exam or imaging and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
62756284|NCT06099470|EXPERIMENTAL|Real-time synchronized telerehabilitation program (STP).|Subjects in this group will have face to face real-time video tele-habilitation sessions twice a week using Zoom
62756285|NCT06099470|EXPERIMENTAL|Pre-recording non-synchronized telerehabilitation program (NSTP)|Subjects in this group will receive their therapeutic exercises through instructional videos sent via Email or WhatsAPP.
62756286|NCT06099470|OTHER|Home non-supervised control group (HCG)|Minimum intervention which is a PDF file containing the same exercises with no follow ups.
61986812|NCT03518385||Patients with intracavitary fluid|to evaluate the correlation between the presence of intracavitary fluid during hormonal stimulation for IVF depending on the position of C-section-scar and the presence of an isthmocele, this group patients will have intracavitary fluid.
62756287|NCT03134365|EXPERIMENTAL|Mixed meal|
61986813|NCT03518385||Patients without intracavitary fluid|to evaluate the correlation between the presence of intracavitary fluid during hormonal stimulation for IVF depending on the position of C-section-scar and the presence of an isthmocele, in this group patients will not have intracavitary fluid.
61986814|NCT01433510|EXPERIMENTAL|Grazax Tablets 75000 SQT|Timothy Extract
62557494|NCT00071110|EXPERIMENTAL|1|Electroacupuncture (EA).
62557495|NCT00071110|PLACEBO_COMPARATOR|2|Sham
62557496|NCT00276484|ACTIVE_COMPARATOR|1|Atorvastatin 80 mg
62557497|NCT00276484|EXPERIMENTAL|2|Atorvastatin 40 mg + ezetimibe 10 mg
62379038|NCT00727350|EXPERIMENTAL|1|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
62557498|NCT01614873|ACTIVE_COMPARATOR|Pressure Support Ventilator|"Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden).~During pressure support the inspiratory muscles are assisted by a constant inspiratory pressure adjusted by the prescriptor and applied to the airway by either an invasive or a non invasive interface. Then the subject initiate the inspiratory effort and a constant pressure is delivered to the airway in order to assist inspiration. Three levels of pressure will be tested (5 cmH2O, 8 cmH2O and 12 cmH2O)"
62557499|NCT01614873|EXPERIMENTAL|NAVA|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with trigger adjusted on diaphragmatic electromyogram. Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). During NAVA the inspiratory muscles are assisted by a pressure which is proportional to this electrical activity. Then the subject initiate the inspiratory effort and a pressure proportional to the integrated EMG activity is delivered to the airway in order to assist inspiration. The adjustment of the level of NAVA (expressed in cmH2O/microvolt) will be adjusted in order to obtain a peak pressure similar to pressure support (5 cmH2O, 8 cmH2O and 12 cmH2O)
62557500|NCT05344495|ACTIVE_COMPARATOR|hyalse group|ultrasonographic median nerve hydrodissection by hyalase and bupivacaine 0.5%
62557501|NCT05344495|ACTIVE_COMPARATOR|midazolam group|ultrasonographic median nerve hydrodissection by midazolam and bupivacaine 0.5%
62557502|NCT01848925|EXPERIMENTAL|SANGUINATE™|PEG-bHb-CO
62557503|NCT01848925|ACTIVE_COMPARATOR|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
62557504|NCT03499067|EXPERIMENTAL|Test lens|Subjects wearing the test contact lens either as first or second pair during the cross-over study.
62557505|NCT03499067|ACTIVE_COMPARATOR|Control lens|Subjects wearing the control contact lens either as first or second pair during the cross-over study.
62557506|NCT04925843||Patients undergoing liver transplant for end-stage liver disease|The investigators propose to conduct a retrospective cohort study to explore the association between fibrinogen concentration and intraoperative bleeding in patients who underwent a liver transplant between July 2008 and January 2021.
62557507|NCT00652054|EXPERIMENTAL|1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks.
62557508|NCT06283537|EXPERIMENTAL|Online episiotomy group|30 students will be assigned to the online education group with a random sampling model. To this group; Online episiotomy simulation training will be provided.
62756288|NCT03134365|ACTIVE_COMPARATOR|Combined meal|
61986815|NCT01981447|ACTIVE_COMPARATOR|Group A|IV Lacosamide administered (intravenously) over 30 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1 mg/ kg and 2.9 mg/kg over 30 minutes.
62379039|NCT02202161|EXPERIMENTAL|GSK2330672 10 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 10 mg BID for 14 days.
62557509|NCT06283537|EXPERIMENTAL|Face to face training group|30 students will be assigned to the face-to-face education group with a random sampling model. This group will be given face-to-face episiotomy simulation training in the school environment, which is traditionally applied to the face-to-face training group..
62557510|NCT04913558|ACTIVE_COMPARATOR|Traditional Treatment Arm|This group will consist of thirty employed lactating women suffering from stress and fatigue. This group will receive the same lifestyle modification advice that will be given to the aerobic exercise group during the six weeks of the program period.
62557511|NCT04913558|EXPERIMENTAL|Aerobic exercise group|This group will consist of thirty employed lactating women suffering from stress and fatigue. These women will perform aerobic exercise for 30 minutes for each session, 5 times per week, for 6 weeks in the form of treadmill training (60- 70% of HR max) and do some modifications of their routine by following lifestyle modification advice given to them during the 6 weeks of the program period.
61986816|NCT01981447|ACTIVE_COMPARATOR|Group B|IV Lacosamide to be administered (intravenously) over 15 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1mg/kg, 2,4 mg/kg
62557512|NCT05129774|EXPERIMENTAL|radical surgery with PALND|
61986817|NCT00657007|PLACEBO_COMPARATOR|Placebo|IV infusion over 2 hours
61986818|NCT00657007|EXPERIMENTAL|Belimumab 1 mg/kg|1 mg/kg IV infused over 2 hours
61986819|NCT00657007|EXPERIMENTAL|Belimumab 4 mg/kg|4 mg/kg IV infused over 2 hours
62557513|NCT05129774|ACTIVE_COMPARATOR|radical surgery without PALND|
62557514|NCT05079048|ACTIVE_COMPARATOR|conventional retentive element|The conventional group received implant-supported mandibular overdentures retained by metal housings and nylon retentive elements,
62557515|NCT05079048|EXPERIMENTAL|PEEK retentive element|PEEK group received implant-supported mandibular overdentures retained by PEEK housings ,
62557516|NCT01793493|EXPERIMENTAL|Cognitive stimulation|
62756289|NCT05132998|EXPERIMENTAL|Cardiac Rehabilitation Program (CRP) Group|"1. Baseline consultation with physiatrist specialized in CRP - addressing CVRF control, comorbidities and disabilities; case-by-case discussion with a cardiologist specialized in CR will be undertaken, for tailoring exercise prescription. Nutritional individualized plan addressing dietary goals. Psychological management addressing psychosocial outcomes and motivation for healthy lifestyle habits~2. Multidisciplinary team educational meeting: periodic group sessions with health education purposes~3. Exercise intervention - 2 times/week sessions at CR facilities, supervised by a physiatrist, conducted by physiotherapist. Heart rate (HR) continuously monitored during each session by remote electrocardiographic monitoring or HR monitor. Exercise intensity estimated according to CR guidelines, determined after CV risk stratification, using CPET results."
62756290|NCT05132998|ACTIVE_COMPARATOR|Community Exercise Group|"a) Besides standard medical and supportive care, psychological and nutritional individual support will be offered on demand, in hospital setting, according to the attending physician standard clinical assessment and usual care.~Exercise intervention - Performed at a community-based facility, comprising 2 sessions/week, prescribed according to current physical activity guidelines for cancer survivors. Exercise intervention will be conducted by an exercise physiologist, internationally certified in exercise for cancer patients"
62756291|NCT05502159|ACTIVE_COMPARATOR|Group M-TAPA = M-TAPA group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 0,5 mg/kg meperidin will be performed for rescue analgesia.
62756292|NCT05502159|ACTIVE_COMPARATOR|Group EOB = EOB group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 0,5 mg/kg meperidin will be performed for rescue analgesia.
62756293|NCT04094142|EXPERIMENTAL|Treatment arm|"Acalabrutinib is provided as hard gelatin capsules for oral administration. Acalabrutinib 100 mg will be administered approximately every 12 hours from day 1 to day 28 Rituximab is provided as single-use vials for intravenous administration only. Rituximab 375 mg/m2 will be administered on day 1.~Lenalidomide is provided as opaque hard capsules for oral administration. Lenalidomide 20 mg will be administered once daily from day 1 to day 21"
62756294|NCT01567592|EXPERIMENTAL|Active Shockwave Therapy|Treatment group. Patients in this group receive actual shockwave therapy.
62756295|NCT01961960|EXPERIMENTAL|ASP7374 group|
62379040|NCT02202161|EXPERIMENTAL|GSK2330672 20 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 20 mg BID for 14 days.
62379041|NCT02202161|EXPERIMENTAL|GSK2330672 30 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 30 mg BID for 14 days.
62379042|NCT02202161|EXPERIMENTAL|GSK2330672 90 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 90 mg BID for 14 days.
62379043|NCT02202161|PLACEBO_COMPARATOR|GSK2330672-matched placebo|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by matching placebo (of GSK2330672) BID for 14 days.
62379044|NCT02202161|ACTIVE_COMPARATOR|Sitagliptin 50 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by Sitagliptin 50 mg BID for 14 days. In this study, sitagliptin 50 mg BID will be provided as open-label (unblinded) study treatment.
62379045|NCT01378494||HIV+|HIV+ patients that entered the 1917 Clinic at UAB as naive to ART
62379046|NCT04678349|EXPERIMENTAL|PHGG|Patient who met inclusion criteria and consented during intervention period will be assigned as PHGG group. Surgical medical officer will obtain consent from eligible subject. After consented, subjects will be assessed weight and PG-SGA during admission. They will be given 4 scoops (40g) PHGG, which provide 160kcal, 0.24g protein, 30.4g soluble fibre, 40g carbohydrate and 0g sugar once allowed orally. Staff nurse in charged will monitor compliance of subject on the PHGG. Daily stoma output \& consistency will be recorded and daily energy protein intake will be assessed by dietitian in charged. Renal profile will be taken daily as routine procedure for patients with ileostomy.
62379047|NCT04678349|OTHER|CG|Historical records of patients with ileostomy under conventional care from January 2016 to June 2019 (before started on PHGG) will be assessed and traced retrospectively from the medical system. Data will be recorded in data collection sheet.
62379048|NCT01711944|EXPERIMENTAL|Online PSST|An online version of Problem-Solving Skills Training (PSST) will be compared to standard (face-to-face) PSST
62379049|NCT01711944|ACTIVE_COMPARATOR|Face-to-Face PSST|This is an 8-session face-to-face Problem-Solving Skills Training intervention
62379050|NCT02022644|EXPERIMENTAL|Group 1 - 20 mg|Tumor diameter: 1 cm, Tumor volume: \~0.5cm3, Infusion Volume: 2-3 ml, Irinotecan conc.: 20 mg/ml, Infusion time: 6-24 hours, no more than 48
62379051|NCT02022644|EXPERIMENTAL|Group 2 - 40 mg|Tumor diameter: 2 cm,Tumor volume: \~4.1cm3, Infusion Volume: 3-4 ml, Irinotecan conc.: 40 mg/ml, Infusion Time: 6-24 hours, no more than 48
62379052|NCT02022644|EXPERIMENTAL|Group 3 - 140 mg|Tumor diameter: 3 cm, Tumor volume: \~14cm3, Infusion Volume: 6-7 ml, Irinotecan conc.: 140 mg/ml, Infusion Time: 6-24 hours, no more than 48
62379053|NCT02022644|EXPERIMENTAL|Group 4 - 340 mg|Tumor diameter: 4 cm, Tumor volume: \~34cm3, Infusion Volume: ≤17 ml, Irinotecan conc.: 340 mg/ml, Infusion Time: 6-24 hours, no more than 48
62379054|NCT02022644|EXPERIMENTAL|Group 5 - 40 mg|Tumor diameter: 1 cm, Tumor volume: \~0.5cm3, Infusion Volume: 2-3 ml, Irinotecan conc.: 40 mg/ml, Infusion Time: 6-24 hours, no more than 48
62379055|NCT02022644|EXPERIMENTAL|Group 6 - 80 mg|Tumor diameter: 2 cm, Tumor volume: \~4.1cm3, Infusion Volume: 3-4 ml, Irinotecan conc.: 80 mg/ml, Infusion Time: 6-24 hours, no more than 48
62379056|NCT02022644|EXPERIMENTAL|Group 7 - 280 mg|Tumor diameter: 3 cm, Tumor volume: \~14cm3, Infusion Volume: 6-7 ml, Irinotecan conc.: 280 mg/ml, Infusion Time: 6-24 hours, no more than 48
62756296|NCT01946464||undergoing surgery with general anesthesia|pts: edentulous, bearded, obstructive sleep apnea, Mallampati Class III or IV
62557517|NCT01793493|ACTIVE_COMPARATOR|Sanitary education|
62557518|NCT04385017|OTHER|DNA from monocytes|It will consist in the collection of 2 additional tubes at their blood draw. For DNA analysis, informed consent will be collected in writing
62557519|NCT02537561|EXPERIMENTAL|Arm 1: Cisplatin, Gemcitabine, Talazoparib Solid Tumors|"* Dose levels of the drugs will be dependent on which dose level the participants is enrolled.~* Cisplatin will be infused as a 30 minute intravenous piggyback (IVPB) on Day 1 of each 21 day cycle.~* Gemcitabine will be infused as a 30 minute IVPB on Days 1 and 8 of each 21 day cycle. On day 1, gemcitabine will be given before cisplatin.~* Talazoparib will be started with cycle 2. It is an oral drug which will be administered on an outpatient basis daily.~* Cisplatin and gemcitabine will be given for a total of 6 cycles.~* Talazoparib may be continued as a single agent maintenance therapy."
61986820|NCT00657007|EXPERIMENTAL|Beimumab 10 mg/kg|10 mg/kg IV infused over 2 hours
61986821|NCT00657007|EXPERIMENTAL|Belimumab 20 mg/kg|20 mg/kg IV infused over 2 hours
61986822|NCT03305328|EXPERIMENTAL|Active|Participants within the Active condition receive 30 minutes of alpha-frequency Transcranial Alternating Current Stimulation (tACS) stimulation for four consecutive days. Participants are stimulated at their baseline peak alpha frequency, or the frequency at which they exhibit maximal power within the 8 to 12 Hz range. Stimulation was administered over occipitoparietal sites, where tACS current models showed maximal effect over the dorsal extrastriate.
62756297|NCT01946464||Mallampati I and II|Control group Mallampati I visualization of tonsils, uvula and soft palate Mallampati II visualization of hard and soft palate, and upper portion of tonsils and uvula.
62756298|NCT04536922|EXPERIMENTAL|iTCR + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCR-Transduced PBL + high- or low-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeks following cell infusion
62756299|NCT00998855||Adolescents|Post pubertal, sedentary lean and obese Hispanic adolescents
62379057|NCT02022644|EXPERIMENTAL|Group 8 - 680 mg|Tumor diameter: 4 cm, Tumor volume: \~34cm3, Infusion Volume: ≤17 ml, Irinotecan conc.: 680 mg/ml, Infusion Time: 6-24 hours, no more than 48
62379058|NCT01265173|ACTIVE_COMPARATOR|Cefotaxime|iv 2G q 8hrs for general, dose titration if needed (eg.CKD)
62379059|NCT01265173|EXPERIMENTAL|Ceftriaxone|iv 2G q 24hrs
62379060|NCT01265173|EXPERIMENTAL|Ciprofloxacine|iv 400mg q 12hrs for general, dose titration if needed (eg.CKD)
62379061|NCT00764322|EXPERIMENTAL|Tamoxifen 20|One arm, containing the ultra-rapid and extensive metabolizer genotypes, continues treatment with tamoxifen at 20mg.
62379062|NCT00764322|ACTIVE_COMPARATOR|Tamoxifen 40|This arm, containing the intermediate and poor metabolizer genotypes, receives escalated treatment with tamoxifen at 40mg.
62379063|NCT01084811||chronic rhinosinusitis with nasal polyps|
62379064|NCT01084811||chronic rhinosinusitis without nasal polyps|
62379065|NCT01084811||Control group|
62379066|NCT02402049|ACTIVE_COMPARATOR|1: Natrum muriaticum 30C|Natrum muriaticum 30C
62379067|NCT02402049|ACTIVE_COMPARATOR|2: Lachesis 30C|Lachesis 30C
62557520|NCT02537561|EXPERIMENTAL|Arm 2: Cisplatin, Gemcitabine, Talazoparib NSCLC|"* Dose levels of the drugs will depend on what the MTD is in the dose escalation portion of the study~* Cisplatin will be infused as a 30 minute intravenous piggyback (IVPB) on Day 1 of each 21 day cycle.~* Gemcitabine will be infused as a 30 minute IVPB on Days 1 and 8 of each 21 day cycle. On day 1, gemcitabine will be given before cisplatin.~* Talazoparib will be started with cycle 2. It is an oral drug which will be administered on an outpatient basis daily.~* Cisplatin and gemcitabine will be given for a total of 6 cycles.~* Talazoparib may be continued as a single agent maintenance therapy."
62557521|NCT01167478|EXPERIMENTAL|Caffeine|
62756300|NCT05807776|EXPERIMENTAL|tislelizumab|Received tislelizumab for 2 cycles, 200mg, iv, d1,Q3W. Patients achieved PR or reduced SD were enrolled in arm 1 and accepted surgery. After surgery, patients in arm 1 would receive tislelizumab as adjuvant therapy for 3-6 months.
62379068|NCT02402049|ACTIVE_COMPARATOR|3: Sepia 30C|Sepia 30C
62379069|NCT02402049|ACTIVE_COMPARATOR|4: Nux vomica 30C|Nux vomica 30C
62756301|NCT05807776|EXPERIMENTAL|tislelizumab+lenvatinib|"Received tislelizumab for 2 cycles, 200mg, iv, d1,Q3W. Patients achieved PD or increased SD were enrolled in arm 2 and continued to accept treatment with tislelizumab and lenvatinib for 2 cycles.~After 2 cycles, patients would receive surgery according to their physical conditions.~After surgery, patients in arm 2 would receive tislelizumab and lenvatinib as adjuvant therapy for 3-6 months."
62756302|NCT05145361|EXPERIMENTAL|B001 injection|Subjects randomized to this arm will receive B001 twice, at day 1 and day 15, up to the end of the study.
62379070|NCT02402049|ACTIVE_COMPARATOR|5: Pulsatilla 30C|Pulsatilla 30C
62379071|NCT02402049|ACTIVE_COMPARATOR|6 Folliculinum 30C|Folliculinum 30C
62379072|NCT02402049|PLACEBO_COMPARATOR|1: Placebo Natrum muriaticum|Placebo Natrum muriaticum
62379073|NCT02402049|PLACEBO_COMPARATOR|2: Placebo Lachesis|Placebo Lachesis
62379074|NCT02402049|PLACEBO_COMPARATOR|3: Placebo Sepia|Placebo Sepia
62379075|NCT02402049|PLACEBO_COMPARATOR|4: Placebo Nux vomica|Placebo Nux vomica
62379076|NCT02402049|PLACEBO_COMPARATOR|5: Placebo pulsatilla|Placebo pulsatilla
62756303|NCT05145361|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive Placebo twice, at day 1 and day 15, up to the end of the study.
62756304|NCT05366491|ACTIVE_COMPARATOR|bronchial asthma patients|patients diagnosed with bronchial asthma
62756305|NCT05366491|ACTIVE_COMPARATOR|healthy controls|healthy subjects with age and sex matched to bronchial asthma patients
62756306|NCT02949986|EXPERIMENTAL|Tablet-based Fall Prevention|The exercise program will be self-administered via a tablet-based version of the fall prevention program and the exercises performed in the home.
62756307|NCT04693104|EXPERIMENTAL|PVA Hydrogel|PVA Hydrogel (Rottapharm Biotech, Monza): 2 mL prefilled syringe for intra-articular injection
62756308|NCT04693104|ACTIVE_COMPARATOR|Synvisc-One®|Synvisc-One® (Genzyme Corporation, Ridegield, New Jersey, USA): 6 mL prefilled syringe for intra-articular injection
62756309|NCT06420362|EXPERIMENTAL|Blood Flow Restriction Training Group|While the basketball players continue their current basketball training; The 90-minute BFR program will be applied 3 sessions a week for 3 weeks. In the BFR program, biceps curls, triceps curls, shoulder presses, shoulder abduction exercises and sport-specific routine training will be applied. Exercises: 30% of 1 maximum repetition with resistance and 60% of arterial occlusion pressure restricted; Based on previous studies in the literature, the first set will be performed with 30 repetitions and the other three sets with 15 repetitions, a total of 4 sets and a 30-second rest between sets. There will be a 10-minute warm-up exercise before each BFR training and a 10-minute cool-down exercise at the end of the training.
62756310|NCT06420362|NO_INTERVENTION|Routine Training|Initial evaluations will be made for all participants. Then, they will continue their routine basketball training programs for 3 weeks.
62756311|NCT05415592||DePuy Synthes Radial Head Replacement System|Participants will undergo a radial head replacement or partial replacement of the elbow joint with the DePuy Synthes Radial Head Replacement System.
62756312|NCT03135444|EXPERIMENTAL|Provider Field Test|15 providers will be given an initial version of the PSA TOOL, over a 4 week period, they will be able to provide feedback on the tool. This will be used to revise the screening decision aid. Informal interviews with providers will also be conducted by a member of the study team to obtain feedback about ease of use and usefulness of the tool.
62756313|NCT03135444|EXPERIMENTAL|Patient test of revised PSA TOOL|150 patients will be asked to use the revised PSA TOOL. Pre- and Post-tests will be given to see if the tool changed the knowledge that patients have an option to be screened for prostate cancer and of specific factors to be considered in the screening decision. Informal interviews with patients who are exposed to the tool will also be conducted by a member of the study team to obtain feedback on issues addressed by the survey questions.
62756314|NCT03482284|EXPERIMENTAL|Monosaccharide 1|Participants receive standardized meals with a defined amount of monosaccharide 1.
62756315|NCT03482284|EXPERIMENTAL|Monosaccharide 2|Participants receive standardized meals with a defined amount of monosaccharide 2.
62756316|NCT00874406|EXPERIMENTAL|1|transhepatic arterial chemotherapy (TAC) were given 7 days before liver metastasis resection. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
62756317|NCT00874406|ACTIVE_COMPARATOR|2|Liver metastasis resection was done without TAC. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
62756318|NCT01082510|ACTIVE_COMPARATOR|BCG maintenance therapy|
62756319|NCT01082510|EXPERIMENTAL|UFT maintenance therapy|
62756320|NCT01161095|EXPERIMENTAL|Immediate|LNG-IUS insertion within the timeframe of delivery of the placenta to 72 hours postpartum
62756321|NCT01161095|ACTIVE_COMPARATOR|Interval|LNG-IUS insertion after 6 weeks postpartum
62756322|NCT01696617|EXPERIMENTAL|Aripiprazole 8-week group|Adjunctive aripiprazole 8-week treatment
62756323|NCT01696617|ACTIVE_COMPARATOR|Aripiprazole 6-week group|Adjunctive aripiprazole 6-week treatment
62756324|NCT00712530|EXPERIMENTAL|1|"Single low-dose DermaVir immunization~* 0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir~* Administered topically with DermaPrep under two skin patches (0.4 mL/patch)"
62756325|NCT00712530|EXPERIMENTAL|2|"Single medium-dose DermaVir immunization~* 0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir~* Administered topically with DermaPrep under four skin patches (0.8 mL/patch)"
62756326|NCT00712530|EXPERIMENTAL|3|"Single high-dose DermaVir immunization~* 0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir~* Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)"
62756327|NCT04355533|EXPERIMENTAL|Hospitalized children or consulting at hospital|
62756328|NCT04355533|EXPERIMENTAL|Parents of one included child|
61986823|NCT03305328|SHAM_COMPARATOR|Sham Control|Participants within the Sham condition receive 30 minutes of sham Transcranial Alternating Current Stimulation for four consecutive days, during which no current was passed. To control for awareness of the Sham stimulation, all Sham control participants receive a brief, 10 second pulse of random noise stimulation at the beginning and end of the 30 minutes.
62756329|NCT04355533|EXPERIMENTAL|Children with potential COVID disease during the first wave|
62756330|NCT04355533|EXPERIMENTAL|Children SARS-coV2 positive|
62756331|NCT04355533|EXPERIMENTAL|Person living under the same roof as children included in the study|
62756332|NCT04623268||Adult offspring|Adult female and male offspring to AAA patients 45-80 years of age at inclusion Children to detected AAA patients. Found in the Multigeneration registry
62756333|NCT04623268||Control group|Matched women and men, without parents with AAA. Matched in the Swedish Multigeneration registry
62756334|NCT03411252|EXPERIMENTAL|Mirabegron|Patients will receive 50 mg of oral Mirabegron daily for 4 weeks and then switch to placebo by mouth daily for an additional 4 weeks.
62756335|NCT03411252|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo by mouth daily for 4 weeks and then switch to oral Mirabegron 50 mg daily for an additional 4 weeks.
62756336|NCT01480609|ACTIVE_COMPARATOR|Dose-Dialysis|Subjects will be dosed with study drug followed by a scheduled dialysis session
62756337|NCT01480609|ACTIVE_COMPARATOR|Dialysis-Dose|Subjects will be dosed following the completion of their scheduled dialysis session
62756338|NCT03581539|ACTIVE_COMPARATOR|Group #1|Transverses Abdominis Plane (TAP) block
62756339|NCT03581539|ACTIVE_COMPARATOR|Group #2|Quadratus Lumborum (QL) block
62756340|NCT03581539|ACTIVE_COMPARATOR|Group #3|Surgeon Infiltration using Exparel
62756341|NCT05067920||Asymptomatic patients|60 patients without COVID-19 symptoms related at the time of diagnosis.
62756342|NCT05067920||Symptomatic patients|60 patients with COVID-19 symptoms related at the time of diagnosis.
62756343|NCT02497378|EXPERIMENTAL|JNJ-54767414 (Daratumumab) +Bortezomib+Dexamethasone|Participants will be administered JNJ-54767414 (daratumumab) intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, then on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks), First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles. Bortezomib at a dose of 1.3 milligram per meter square (mg/m\^2) subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle for 8 treatment cycles and Dexamethasone orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles.
62756344|NCT01967017|EXPERIMENTAL|Lidocaine|Paracervical block using 15 mL of 1 % lidocaine
62756345|NCT01967017|PLACEBO_COMPARATOR|Placebo|paracervical block using 15 mL of bacteriostatic saline
62756346|NCT01842932|EXPERIMENTAL|Phloroglucin & Placebo|Phloroglucin 20ml before examination \& Placebo 1ml before examination
62756347|NCT01842932|EXPERIMENTAL|Cimetropium bromide & Placebo|Cimetropium bromide 1ml before examination \& Placebo 20ml before examination
62756348|NCT05190029|EXPERIMENTAL|Complete sample|Group of 120 children evaluated by craniosacral therapy for cranial blocks and primitive reflexes.
62756349|NCT05363761|EXPERIMENTAL|Ablation Treatment|Neurotronic Infusion Catheter Treatment
62756350|NCT01385111|ACTIVE_COMPARATOR|Arm A|EBUS centered
62756351|NCT01385111|EXPERIMENTAL|Arm B|EUS centered
62756352|NCT04782245|EXPERIMENTAL|Treatment group Daplagliflozin|
62756353|NCT04782245|PLACEBO_COMPARATOR|Control group|
62756354|NCT03198455|EXPERIMENTAL|Andosan|The Agaricus blazei Murill-based mushroom extract, Andosan™, is given as one dosage 60 ml/day orally for 2 months. The intervention solution is given for 1 month's consumption at a time in a neutral plastic container
62756355|NCT03198455|PLACEBO_COMPARATOR|Placebo|The placebo is drinking water with brownish food coloring, given as one dosage 60 ml/day orally for 2 months. The placebo solution is given for 1 month's consumption at a time in a neutral plastic container (same as for intervention/experimental solution).
62756356|NCT06066905|EXPERIMENTAL|chidamide and azacitidine|
62756357|NCT06216782||Non-small cell lung cancer patients receiving neoadjuvant therapy|Patients diagnosed with non-small cell lung cancer who received neoadjuvant therapy.
62756358|NCT06216782||Small cell lung cancer patients receiving neoadjuvant therapy|Patients diagnosed with small cell lung cancer who received neoadjuvant therapy.
62756359|NCT00657839|EXPERIMENTAL|Arm 1|
62756360|NCT00657839|PLACEBO_COMPARATOR|Arm 2|
62756361|NCT03333122||Breast Conserving Therapy|Patient who undergo breast conserving therapy or breast conserving therapy with oncoplastic therapies will complete the BREAST-Q Lumpectomy survey module.
62756362|NCT03333122||Mastectomy|Patients who undergo mastectomy will complete the BREAST-Q Mastectomy survey module.
62756363|NCT03333122||Mastectomy with Reconstruction|Patient who undergo breast reconstruction will complete the BREAST-Q Reconstruction survey module. This group will be further subdivided based on implant or autologous tissue reconstruction.
62756364|NCT05693740|ACTIVE_COMPARATOR|group 1|Patients in this group will undergo pulsed light accelerated crosslinking (pl-ACXL)
62379077|NCT02402049|PLACEBO_COMPARATOR|6: Placebo Folliculinum|Placebo Folliculinum
62379078|NCT02857205|OTHER|Fecal samples|High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
62379079|NCT03926780|ACTIVE_COMPARATOR|Warfarin|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin by the regular starting dose with follow up of the INR to target (2-3)
62379080|NCT03926780|EXPERIMENTAL|Rivaroxaban|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban in a dose of 20 mg per day
62557522|NCT03158103|EXPERIMENTAL|MEK162 in combination with Pexidartinib|Pexidartinib will be administered orally by the patients on a twice daily basis throughout the treatment cycle. Pexidartinib is available in 200mg tablets. MEK162 wiIl be administered orally on a twice daily basis throughout the treatment cycle. MEK162 is available in 15mg tablets. In this phase I study all patients will have a 2-week lead in of pexidartinib therapy alone. Thereafter, pexidartinib will be administered in combination with MEK162 on a consecutive daily basis. A treatment cycle consists of 28 days. In the dose escalation portion the dose of pexidartinib and MEK 162 will depend on the dose level cohort onto which the patient is enrolled.
61986824|NCT04700358||Patients with Cystic Fibrosis|Patients with pulmonary Cystic Fibrosis with or without bacterial colonization
61986825|NCT04700358||Control group|Healthy age- and sex-matched controls including healthy individuals and patients with acute or chronic bacterial infections
61986826|NCT01012622|EXPERIMENTAL|OROS Methylphenidate Hydrochloride|
61986827|NCT04283162|EXPERIMENTAL|conventional treatment plus calcium dobesilate|maintain lifestyle habits and the usual treatment, plus the use of calcium dobesilate (500 mg, orally, 3 times per day) for 12 months
62379081|NCT02520102|EXPERIMENTAL|sargramostim|Sargramostim is administered daily until the absolute neutrophil count (ANC) equals or exceeds 1500/mm\^3 for 3 consecutive measurements or up to 42 days post-induction chemotherapy.
62379082|NCT06471088||All Participants|This study will be conducted on subjects who were administered with Dovprela Tablets as part of their usual treatment in accordance with their local labelling. Clinical data obtained through observation will be collected from the time of the first dose of Dovprela tablet to 26 weeks of treatment and up to 6 months after the end of treatment.
62379083|NCT04536350|EXPERIMENTAL|Aviptadil Treatment|Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
62379084|NCT04536350|PLACEBO_COMPARATOR|Placebo Treatment|Participants in the control group will receive an Inhalation of 0.9% NaCl solution three times a day for 10 days
62756365|NCT05693740|ACTIVE_COMPARATOR|group 2|Patients in this group will undergo continuous-light accelerated crosslinking (cl-ACXL)
62379085|NCT03883295|EXPERIMENTAL|Control|root canal treatment will be initiated
62379086|NCT03883295|EXPERIMENTAL|NeoMTA Plus|vital pulp treatment using neomta plus will be used.
62379087|NCT02506907||Atherosclerotic|Patients with atherosclerotic intracranial stenosis
62557523|NCT04766177|EXPERIMENTAL|bumetanide group|Bumetanide a dose of 0.5 mg twice per day
62557524|NCT04766177|PLACEBO_COMPARATOR|Placebo|Placebo twice daily
62557525|NCT02042352||pH test|VpH test gloves
62756366|NCT03610581|EXPERIMENTAL|Regimen 1: Single Ad26.HPV16 or Ad26.HPV18 and MVA.HPV16/18|Participants will receive a dose of adenovirus serotype 26 (Ad26)-human papillomavirus (HPV)16 or HPV18 (Ad26.HPV16 or Ad26.HPV18) as prime immunization and a dose of Modified Vaccinia Ankara (MVA)-HPV16/18 (MVA.HPV16/18) as boost immunization.
61986828|NCT04283162|ACTIVE_COMPARATOR|conventional treatment group|maintain lifestyle habits and the usual treatment for 12 months
61986829|NCT00641407|EXPERIMENTAL|1|
61986830|NCT00641407|ACTIVE_COMPARATOR|2|
61986831|NCT02488655|EXPERIMENTAL|Echopulse|Echopulse HIFU
61986832|NCT02098577||PD patients cross-over treatment|30 PD patients (according to Gelb et al) in Hoen\&Yahr stage 3, underwent cross-over treatment with the ability to walk without any assistance with mini-mental state examination score \>26.
62379088|NCT01785940|EXPERIMENTAL|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
62379089|NCT03371394||median 1|
62379090|NCT03371394||median 2|
62557526|NCT04977804|ACTIVE_COMPARATOR|Eccentric only training|This is the experimental control; where this group will be used as the standard active comparison condition.
62557527|NCT04977804|EXPERIMENTAL|Eccentric plus blood-flow restriction|This is the experimental condition involving the eccentric resistance training with blood flow restriction.
62756367|NCT03610581|EXPERIMENTAL|Regimen 2: Double Ad26.HPV16 or Ad26.HPV18 and MVA.HPV16/18|Participants will receive a double dose of Ad26.HPV16 or Ad26.HPV18 as prime immunization and a dose of MVA.HPV16/18 as boost immunization.
62756368|NCT03610581|EXPERIMENTAL|Regimen 3: Ad26.HPV16/Ad26.HPV18 mix and MVA.HPV16/18|Participants will receive a mix of Ad26.HPV16/Ad26.HPV18 as prime immunization and a dose of MVA.HPV16/18 as boost immunization.
62756369|NCT03610581|PLACEBO_COMPARATOR|Control: Placebo|Participants will receive matched placebo as prime and boost immunizations.
62756370|NCT05967546||Experimental Group|ECG data and clinical data from this group of arrhythmia patients will be used to build a deep learning model.
62756371|NCT03153644||Patients|Women with chronic medical conditions
62756372|NCT03153644||Primary Care Providers and Medical Staff|"Primary care providers can include doctors and advanced practice professionals, including midwives, nurse practitioners, and physician assistants.~Medical staff can include social workers, nurses, medical assistants, and administrative staff"
62756373|NCT03153644||Primary Practice|Primary care practices (family medicine, internal medicine, medicine-pediatric, or any combination of these) that at a practice-level already provide contraceptive counseling and services to reproductive-age women
62756374|NCT03858335|EXPERIMENTAL|Constraint-induced movement therapy|Children in constraint-induced movement therapy (CIMT) group will wear forearm splint on the unaffected arm 24 hours for 3 weeks, and receive 15 mCIMT sessions(30-hour dosage)
62756375|NCT03858335|NO_INTERVENTION|Control|Children in control group will receive only traditional rehab therapies without wearing splint
62756376|NCT03182023||ECMO mode|ECMO mode includes Venovenous- ECMO and Venoarterial- ECMO
62756377|NCT00062023|ACTIVE_COMPARATOR|Arm I Sulindac|Oral sulindac twice daily.
61986833|NCT02098577||PD patients stabilometric platform|30 PD patients (according to Gelb et al) in Hoen\&Yahr stage 3, underwent stabilometric platform treatment, with the ability to walk without any assistance with mini-mental state examination score \>26.
61986834|NCT01867827|EXPERIMENTAL|Neurofeedback and Physical Exercise|This group will undergo neurofeedback intervention in the fMRI scanner in weeks 1,5 and 12. They will also undergo physical exercise training on WiiFit device once a week after the first month till the end of the study at 12 weeks.
62557528|NCT04322448||Cubital Tunnel Syndrome Patients|Cubital Tunnel Syndrome patients. Patients will undergo standard of care exams and surgery. During surgery, the surgeon will apply the mechanomyography (MMG) to the targeted nerve immediately prior and post decompression. Subjects will be followed until they are 6 months postop.
62557529|NCT04322448||Peroneal Nerve Decompression Patients|Patients with compressive peroneal nerve neuropathy and will undergo a Peroneal Nerve Decompression (PND). Patients will undergo standard of care exams and surgery. During surgery, the surgeon will apply the mechanomyography (MMG) to the targeted nerve immediately prior and post decompression. Subjects will be followed until they are 6 months postop.
62557530|NCT02771873|NO_INTERVENTION|Usual care|Screening for CVD risk factors plus one time education regarding management of risk factors will be provided to all family members.
62557531|NCT02771873|EXPERIMENTAL|Life style Intervention and care coordination|Integrated cardiovascular disease risk management.
62756378|NCT00062023|ACTIVE_COMPARATOR|Arm II Aspirin|Oral aspirin once daily.
62756379|NCT00062023|ACTIVE_COMPARATOR|Arm III Ursodiol|Oral ursodiol three times daily.
62756380|NCT00062023|PLACEBO_COMPARATOR|Arm IV: Sulindac Placebo|Oral sulindac placebo twice daily.
62756381|NCT02031835|OTHER|BWSTT (3 days a week for maximum of 20 minutes session)|BWSTT (20 minutes of treadmill training (velocity (≥0.1km/h) and body weight support (≤40% of patients weight) according to patients capability and comfort
62756382|NCT04652375|EXPERIMENTAL|Albumin Solution|Participants will receive Albumin solution for fluid resuscitation post-surgery.
62756383|NCT04652375|EXPERIMENTAL|Lactated Ringer's Solution|Participants will receive lactated Ringer's for fluid resuscitation post-surgery
62756384|NCT02350387|EXPERIMENTAL|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
62756385|NCT02350387|EXPERIMENTAL|Low Intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
62756386|NCT02682589|ACTIVE_COMPARATOR|Open surgery|Patients undergo open CME. A standard midline incision carefully protected is made through the abdominal wall and the abdominal cavity is explored. A colectomy with CME is performed with the removal of the afflicted colon and its accessory lymphovascular supply at their origins by resecting the colon and mesocolon in an intact envelope of visceral peritoneum and mesenteric fascia.
62756387|NCT02682589|EXPERIMENTAL|Laparoscopic surgery|Patients undergo laparoscopic CME. A small infraumbilical incision is made through the abdominal skin and the abdominal cavity is insufflated with carbon dioxide to allow access and visualization. The abdominal cavity is explored. A colectomy with CME is performed using laparoscopic-assisted techniques. A 6-8cm midline auxiliary incision is made for specimen extraction and anastomosis.
62756388|NCT05293444|OTHER|Overnight fasting|overnight fasting(minimum 6 hrs) for control group.
62756389|NCT05293444|EXPERIMENTAL|Maltodextrin|"Route: Oral Dose:~* 400 ml at 10PM night before surgery(12.5g/100ml)~* 200 ml in the morning at 6 AM (12.5g/100ml) on the day of surgery."
62756390|NCT02029183|EXPERIMENTAL|bi-level positive airway pressure|bi-level positive airway pressure for 6 hour per night，total 7 days
62756391|NCT01101971|EXPERIMENTAL|first year medical students|
62756392|NCT04715789|EXPERIMENTAL|physical therapy intervention|"1. core stability exercises:~   1. Multifidus exercises~  2. Frontal \& Side Plank exercise~  3. Pelvic floor exercises~  4. abdominal exercises~2. Strengthening exercises~   1. Bridging~  2. straight leg raise~  3. gluteus medius strength~  4. gluteus maximus strengthening for about 20 min to 30 min to strength back and proximal hip control muscles"
61986835|NCT01867827|ACTIVE_COMPARATOR|Physical Exercise|This group will undergo Physical Exercise intervention on the WiiFit device 3 times a week in the first month and once a week after the first month till the end of the study at 12 weeks.
62379091|NCT05243940|ACTIVE_COMPARATOR|dexmedetomidine-ketamine-lidocaine (DKL) group|combination of dexmedetomidine-ketamine-lidocaine in one syringe
62379092|NCT05243940|ACTIVE_COMPARATOR|remifentanil (control) group|remifentanil infusion (TCI Minto protocol)
62379093|NCT03260673||the diabetic group|patients with type 2 diabetes scheduled to undergo cataract surgery
62379094|NCT03260673||the control group|patients without diabetes scheduled to undergo cataract surgery
62379095|NCT01035216|EXPERIMENTAL|GNKG168|The starting dose will be 0.25 mg/kg. If the dose is tolerable, subsequent cohorts will be enrolled and treated with 0.5, 0.75, 1.0 and 1.5 mg/kg. If 0.25 mg/kg proves to be intolerable, the dose will be reduced to 0.15 mg/kg.
62379096|NCT01693562|EXPERIMENTAL|Escalation Cohort (MEDI4736 0.1 mg/kg Q2W)|Participants will receive intravenous (IV) infusion of MEDI4736 (durvalumab) 0.1 mg/kg every 2 weeks (Q2W) in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62379097|NCT01693562|EXPERIMENTAL|Escalation Cohort (MEDI4736 0.3 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 0.3 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62379098|NCT01693562|EXPERIMENTAL|Escalation Cohort (MEDI4736 1 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 1 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62756393|NCT04715789|EXPERIMENTAL|graded exposure and graded activity in addition to phycal therapy intervention|"1. Graded exposure:This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity~2. Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities for about 10 min before physical therapy program (strengthening)"
62379099|NCT01693562|EXPERIMENTAL|Escalation Cohort (MEDI4736 3 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 3 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62379100|NCT01693562|EXPERIMENTAL|Escalation Cohort (MEDI4736 10 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62379101|NCT01693562|EXPERIMENTAL|Escalation Cohort (MEDI4736 15 mg/kg Q3W)|Participants will receive IV infusion of MEDI4736 15 mg/kg every 3 weeks (Q3W) in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62379102|NCT01693562|EXPERIMENTAL|Exploration Durvalumab 20 mg/kg (Q4W)|Participants will receive IV infusion of MEDI4736 20 mg/kg every 4 weeks (Q4W) in the dose-exploration phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62557532|NCT03021681|OTHER|COPD group(self control)|Prior treatment:20 stable COPD patients were enrolled,estimated the respiratory function and serum index Intervention:autologous bronchial basal cell transplantation After treatment:Estimate the change of respiratory function and serum index in third days , first months, third months, sixth months and first years of the follow-up after treatment respectively
62756394|NCT01529580|EXPERIMENTAL|1 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 1 week before your child begins active treatment with their interventionist.
62756395|NCT01529580|EXPERIMENTAL|2 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 2 weeks before your child begins active treatment with their interventionist.
62379103|NCT01693562|EXPERIMENTAL|Expansion SCCHN Cohort (MEDI4736 10 mg/kg Q2W)|Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62379104|NCT01693562|EXPERIMENTAL|Expansion Non-SCCHN Cohort HPV positive (MEDI4736 10 mg/kg Q2W)|Participants with non-SCCHN human papilloma virus positive (Non-SCCHN HPV+) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62379105|NCT01693562|EXPERIMENTAL|Expansion NSCLC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with non-small-cell lung cancer (NSCLC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62379106|NCT01693562|EXPERIMENTAL|Expansion HCC Total Cohort (MEDI4736 10 mg/kg Q2W)|Participants with hepatocellular carcinoma (HCC Total) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62379107|NCT01693562|EXPERIMENTAL|Expansion ACM Cohort (MEDI4736 10 mg/kg Q2W)|Participants with advance cutaneous melanoma (ACM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62379108|NCT01693562|EXPERIMENTAL|Expansion UM Cohort (MEDI4736 10 mg/kg Q2W)|Participants with uveal melanoma (UM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62379109|NCT01693562|EXPERIMENTAL|Expansion GEC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with gastroesophageal cancer (GEC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62557533|NCT01582035|EXPERIMENTAL|Panel 1|TMC647055 in combination with TVR for 10 days. Immediately followed by the extension phase: TVR at a dose of 750 mg every 8 hours for 12 weeks in combination with Peg IFN and RBV followed by either 12 or 36 weeks of PegIFN -RBV treatment alone.
62557534|NCT01582035|EXPERIMENTAL|Panel 2|TMC647055 in combination with TVR for 10 or 14 days. Immediately followed by the extension phase: TVR at a dose of 750 mg every 8 hours for 12 weeks in combination with Peg IFN and RBV followed by either 12 or 36 weeks of PegIFN -RBV treatment alone.
62557535|NCT05335824|EXPERIMENTAL|The platelet-rich plasma (PRP) group:|The patients in this group received PRP injections immediately before the canine retraction, and after 8 weeks of the onset of retraction
62557536|NCT05335824|EXPERIMENTAL|The injectable platelet-rich fibrin (I-PRF) group|The patients in this group received I-PRF injections immediately before the canine retraction, and after 8 weeks of the onset of retraction
62756396|NCT01529580|EXPERIMENTAL|3 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 3 weeks before your child begins active treatment with their interventionist.
62756397|NCT01212211|EXPERIMENTAL|change in drug therapy|Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
62756398|NCT01212211|NO_INTERVENTION|reference|drug treatment of ten patients will remain unchanged during the three months of inclusion
62756399|NCT06223256|EXPERIMENTAL|NBL-028|Patients will be treated with NBL-028 at starting dose of 0.01 mg/kg in dose escalation stage. In dose expansion stage, patients will be treated with NBL-028 at the recommended dose or multiple doses (if necessary) determined in the dose escalation stage.
62756400|NCT04080479|EXPERIMENTAL|Bolus enteral feeding|"The patients randomized into this study arm will receive bolus enteral feeding. The study subjects will undergo the following interventions:~* Quadriceps Muscle Layer Fitness measurement~* Muscle Strength measurement~* Acute Physiology and Chronic Health Evaluation~* Sequential Organ Failure Assessment~* Nutritional Risk Screening~* Energy and Protein Intake"
62756401|NCT04080479|EXPERIMENTAL|Continuous enteral feeding|"The patients randomized into this study arm will receive bolus enteral feeding.~The study subjects will undergo the following interventions:~* Quadriceps Muscle Layer Fitness measurement~* Muscle Strength measurement~* Acute Physiology and Chronic Health Evaluation~* Sequential Organ Failure Assessment~* Nutritional Risk Screening~* Energy and Protein Intake"
62756402|NCT04814368|EXPERIMENTAL|LNA043|Placebo to canakinumab + LNA043
62756403|NCT04814368|PLACEBO_COMPARATOR|Placebo|Placebo to canakinumab
62756404|NCT04814368|EXPERIMENTAL|canakinumab + LNA043|canakinumab + LNA043
62756405|NCT04814368|EXPERIMENTAL|canakinumab|canakinumab
62756406|NCT05519501|EXPERIMENTAL|SyntrFuge System|Adipose tissue microsized via the SyntrFuge System
62756407|NCT05519501|OTHER|Standard of Care|Offloading
62756408|NCT03387943|EXPERIMENTAL|PLD plus Cisplatin|liposomal doxorubicin(PLD) 35 mg/m2,iv,d1, plus cisplatin 75 mg/m2,drip,d1-3, once every 21days, for 6 cycles, to progression or intolerance.
62756409|NCT00882596|EXPERIMENTAL|1|Contura accelerated partial breast irradiation. Following a lumpectomy, a Contura balloon catheter is placed in the lumpectomy cavity. Later that morning, accelerated partial breast irradiation begins.
62379110|NCT01693562|EXPERIMENTAL|Expansion TNBC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with triple-negative breast cancer (TNBC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62756410|NCT04217967|ACTIVE_COMPARATOR|Lenalidomide group|lenalidomide 25mg qod d1\~21 days, rest 7 days
62557537|NCT05335824|ACTIVE_COMPARATOR|The control group|The patients in this group did not receive any injections
62557538|NCT04982289|EXPERIMENTAL|ALXN1830 Dosing Arm 1|Participants will receive ALXN1830. Treatment will be received for 16 weeks followed by an Observation Period (no treatment) for 8 weeks.
62557539|NCT04982289|EXPERIMENTAL|ALXN1830 Dosing Arm 2|Participants will receive ALXN1830. Treatment will be received for 16 weeks followed by an Observation Period (no treatment) for 8 weeks.
62557540|NCT04982289|EXPERIMENTAL|ALXN1830 Dosing Arm 3|Participants will receive placebo for 8 weeks, then ALXN1830 for 8 weeks, followed by an Observation Period (no treatment) for 8 weeks.
62557541|NCT04707573|EXPERIMENTAL|CKD, Stage 3|Participants with Stage 3 Chronic Kidney Disease (CKD) (Estimated Glomerular Filtration Rate \[eGFR\] 30 - 59 milliliters \[mL\]/minute) received a single 500 milligram (mg) oral dose of Vadadustat after fasting for at least 4 hours.
62557542|NCT04707573|EXPERIMENTAL|CKD, Stage 4|Participants with Stage 4 CKD (eGFR \<30 mL/minute and not yet on dialysis) received a single 500 mg oral dose of Vadadustat after fasting for at least 4 hours.
62557543|NCT01718197||Mild-to-Moderate Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
62557544|NCT01718197||Severe Asthma|"Major Criteria: (1 required)~1. Treatment with oral corticosteroids for at least 6 of the previous 12 months~2. Treatment with high-dose inhaled corticosteroids (ICS) for at least 10 of the previous 12 months~Minor Criteria: (2 required)~1. Daily treatment with an asthma controller medication in addition to ICS, or~2. Asthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis, or~3. Persistent airway obstruction with baseline FEV1 \<80% predicted, or~4. ≥ 1 urgent visits for asthma in the previous 12 months, or~5. ≥ 3 systemic corticosteroid bursts in the previous 12 months, or~6. Prompt deterioration with a reduction in oral or inhaled corticosteroid dose, or~7. A near-fatal asthma event (i.e., intubation) in the past"
62557545|NCT01718197||Healthy Controls|Those without asthma or other chronic lung disease.
62379111|NCT01693562|EXPERIMENTAL|Expansion PAC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with pancreatic adenocarcinoma (PAC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62557546|NCT01869868||Depression, ECT|
62557547|NCT05418101|EXPERIMENTAL|Part A Cohort 1: Dose level 1|Participants will be randomized to SAD dose of VIS171 (or placebo).
62557548|NCT05418101|EXPERIMENTAL|Part A Cohort 2: Dose level 2|Participants will be randomized to SAD dose of VIS171 (or placebo).
62756411|NCT04217967|ACTIVE_COMPARATOR|Ixazomib group|ixazomib 4mg orally, once a week, 3 times a month
62756412|NCT04217967|EXPERIMENTAL|Combination group|ixazomib 4mg orally, once a week, 3 times a month lenalidomide 25mg qod d1\~21 days, rest 7 days use in combination
62756413|NCT06082024||delirium|Patients present with delirium within 7 days after general anesthesia
62756414|NCT06082024||non delirium|The patient did not develop delirium for 7 days after general anesthesia
62756415|NCT00391677|EXPERIMENTAL|1|Participants will receive social skills training with attention shaping procedures
62756416|NCT00391677|ACTIVE_COMPARATOR|2|Participants will receive social skills training without attention shaping procedures
62756417|NCT06607432|ACTIVE_COMPARATOR|Active tIS 0.30 V/m and Sham|Group 1 with 10 participants to receive a dose of 0.30 V/m and sham. The order of the intervention will be randomized.
62756418|NCT06607432|ACTIVE_COMPARATOR|Active tIS 0.35 V/m and Sham|Group 2 with 10 participants to receive a dose of 0.35 V/m and sham. The order of the intervention will be randomized.
62557549|NCT05418101|EXPERIMENTAL|Part A Cohort 3: Dose level 3|Participants will be randomized to SAD dose of VIS171 (or placebo).
62557550|NCT05418101|EXPERIMENTAL|Part A Cohort 4: Dose level 4|Participants will be randomized to SAD dose of VIS171 (or placebo).
62557551|NCT05418101|EXPERIMENTAL|Part A Cohort 5: Dose level 5|Participants will be randomized to SAD dose of VIS171 (or placebo).
62557552|NCT05418101|EXPERIMENTAL|Part B Cohort 1: Dose level to be determined from SAD Cohort(s) data|Participants will be randomized to MAD dose of VIS171.
62557553|NCT05418101|EXPERIMENTAL|Part B Cohort 2: Dose level to be determined from SAD Cohort(s) data|Participants will be randomized to MAD dose of VIS171.
62557554|NCT05418101|EXPERIMENTAL|Part B Cohort 3: Dose level and regimen to be determined from prior MAD and SAD Cohort(s)|Participants will be randomized to MAD dose of VIS171.
62557555|NCT00399061|ACTIVE_COMPARATOR|1|Systane
62557556|NCT00399061|ACTIVE_COMPARATOR|2|Optive
62557557|NCT00399061|PLACEBO_COMPARATOR|3|Restasis
62557558|NCT06158893|EXPERIMENTAL|salbutamol|children will receive 0.15 milligram per kilogram of salbutamol diluted with normal saline to a total volume of 4 ml by inhalation 20 minutes preoperatively
62557559|NCT06158893|ACTIVE_COMPARATOR|budesonide|children will receive 0.5 milligram per kilogram of budesonide diluted with normal saline to a total volume of 4 ml by inhalation 20 minutes preoperatively
62557560|NCT06158893|PLACEBO_COMPARATOR|normal saline|children will receive 0.4 ml of normal saline 0.9 by inhalation 20 minutes preoperatively
62557561|NCT03108131|EXPERIMENTAL|Treatment (cobimetinib, atezolizumab)|Participants receive cobimetinib PO QD on days 1-21 and atezolizumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62557562|NCT00758524|EXPERIMENTAL|Core Period: LCI699 0.25 mg QD|Participants received LCI699 0.25 mg capsules, orally, once daily (QD), with or without food for up to 8 weeks.
62557563|NCT00758524|EXPERIMENTAL|Core Period: LCI699 0.5 mg QD|Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.
62557564|NCT00758524|EXPERIMENTAL|Core Period: LCI699 1.0 mg QD|Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.
62557565|NCT00758524|EXPERIMENTAL|Core Period: LCI699 0.5 mg BID|Participants received LCI699 0.5 mg capsules, orally, twice daily (BID), with or without food for up to 8 weeks.
62557566|NCT00758524|ACTIVE_COMPARATOR|Core Period: Eplerenone 50 mg BID|Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.
62557567|NCT00758524|PLACEBO_COMPARATOR|Core Period: Placebo|Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.
62756419|NCT06607432|ACTIVE_COMPARATOR|Active tIS 0.40 V/m and Sham|Group 3 with 10 participants to receive a dose of 0.40 V/m and sham. The order of the intervention will be randomized.
62756420|NCT06468527|OTHER|Diponecaftor/Placebo|Diponecaftor once daily for 8 weeks followed by placebo once daily for 8 weeks. In between both periods there will be a washout period to minimize a possible carryover effect.
62756421|NCT06468527|OTHER|Placebo/Diponecaftor|Placebo once daily for 8 weeks followed by diponecaftor once daily for 8 weeks. In between both periods there will be a washout period to minimize a possible carryover effect.
62557568|NCT00758524|EXPERIMENTAL|Withdrawal Period: LCI699 0.25 mg QD|Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
62379112|NCT01693562|EXPERIMENTAL|Expansion UC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with urothelial carcinoma (UC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62379113|NCT01693562|EXPERIMENTAL|Expansion GBM Cohort (MEDI4736 10 mg/kg Q2W)|Participants with glioblastoma multiforme (GBM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose- expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62756422|NCT05826691||Patients required prostate surgery for LUTS|Patients with LUTS attributable to bladder outlet obstruction because BPH
62756423|NCT00006046|EXPERIMENTAL|Hu3S193 10 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
62379114|NCT01693562|EXPERIMENTAL|Expansion OC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with ovarian cancer (OC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62379115|NCT01693562|EXPERIMENTAL|Expansion STS Cohort (MEDI4736 10 mg/kg Q2W)|Participants with soft- tissue sarcoma (STS) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62756424|NCT00006046|EXPERIMENTAL|Hu3S193 25 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
61986836|NCT04867265|ACTIVE_COMPARATOR|Professional Adult Medium Skin CPR-AED Training Manikin with CPR Monitor (Prestan)|medical students trained BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
62756425|NCT00006046|EXPERIMENTAL|Hu3S193 50 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
62756426|NCT00006046|EXPERIMENTAL|Hu3S193 100 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
62756427|NCT00006046|EXPERIMENTAL|Hu3S193 200 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
62756428|NCT04231058|EXPERIMENTAL|Transcutaneous Electrical Nerve Stimulation (TENS)|15 experimental subjects treated withTENS and Pulmonary Rehabilitation
62557569|NCT00758524|PLACEBO_COMPARATOR|Withdrawal Period: LCI699 0.25 mg QD Placebo|Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
62756429|NCT04231058|NO_INTERVENTION|Rehabilitation|15 experimental subjects treated with Pulmonary Rehabilitation only
62756430|NCT05249881|OTHER|semaglutide|semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and long-term weight management. Semaglutide acts like human glucagon-like peptide-1 in that it increases insulin secretion, thereby increasing sugar metabolism
62756431|NCT00003136|EXPERIMENTAL|Arm A|Cyclophosphamide (40mg/kg/day on days -6, -5 and -4), Carboplatin (1600, 1700 or 1800 mg/m2 on days -6, -5, -4 and -3), Amifostine (910 mg/m2 on days -6, -5, -4 and -3), Peripheral blood stem cell transplantation (day 0), G-CSF (beginning day 4)
62379116|NCT01693562|EXPERIMENTAL|Expansion SCLC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with small-cell lung cancer (SCLC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62379117|NCT01693562|EXPERIMENTAL|Expansion MSI-high Cancer Cohort (MEDI4736 10 mg/kg Q2W)|Participants with microsatellite instability (MSI)-high cancer will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62379118|NCT01693562|EXPERIMENTAL|Expansion NPC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with nasopharyngeal carcinoma (NPC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose- expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62379119|NCT02869451|EXPERIMENTAL|Treatment|Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months.
62557570|NCT00758524|EXPERIMENTAL|Withdrawal Period: LCI699 0.5 mg QD|Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
62756432|NCT02362230|EXPERIMENTAL|Icotinib|Icotinib 125 mg BID
62557571|NCT00758524|PLACEBO_COMPARATOR|Withdrawal Period: LCI699 0.5 mg QD Placebo|Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
62557572|NCT00758524|EXPERIMENTAL|Withdrawal Period: LCI699 1.0 mg QD|Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
62756433|NCT04650412|EXPERIMENTAL|Intervention|Bundle of comorbidities care
62756434|NCT04650412|NO_INTERVENTION|Control|Standard care
62756435|NCT03525184|PLACEBO_COMPARATOR|Normal sleep|A normal sleep condition and the placebo treatment (0.9 g protein/kg body weight/day + placebo beverage; NS)
62756436|NCT03525184|PLACEBO_COMPARATOR|72-h Sleep restriction with placebo beverage|Sleep restriction (72-h with 2-h of sleep per night) and the placebo treatment (0.9 g protein/kg body weight/day + placebo beverage; SR),
62756437|NCT03525184|EXPERIMENTAL|72-h Sleep restriction with multi-nutrient beverage|Sleep restriction (72-h with 2-h of sleep per night) and the experimental treatment (1.5 g protein/kg body weight/day + multi-nutrient beverage; SR+).
62756438|NCT00493636|ACTIVE_COMPARATOR|A (Sorafenib + Gemcitabine or Capecitabine)|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)
62756439|NCT00493636|PLACEBO_COMPARATOR|B (Placebo + Gemcitabine or Capecitabine)|Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)
62756440|NCT02590822|NO_INTERVENTION|Standard Care|The Standard Care group will be contacted weekly (where possible) to reinforce cognitive behavioural adaptations and encourage compliance to diet and exercise. They will be provided with standard lifestyle advice according to NICE guidance.
62756441|NCT02590822|EXPERIMENTAL|Total Dietary Replacement|"Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.~The TDR will be undertaken alongside health behaviour coaching and relapse prevention contact \& current medications will need to be adjusted initially and throughout the study."
62756442|NCT02590822|EXPERIMENTAL|Supervised Exercise|"The exercise group will attend thrice weekly 60minute supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. An initial assessment of cardiorespiratory fitness will be performed (VO2 max) to allow design of a tailored exercise programme.~Current medication will need to be adjusted initially and throughout the study."
62379120|NCT02050672|ACTIVE_COMPARATOR|untreated|Semen was prepared with routinely used media
62379121|NCT02050672|EXPERIMENTAL|myo-inositol|"routinely used semen preparation media have been enriched with myo-inositol 2mg/ml.~in particular the stock solution was prepared in order to add 15microliters per ml of medium"
62379122|NCT02898792|EXPERIMENTAL|targeted infusion of remifentanil untreated OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
62379123|NCT02898792|EXPERIMENTAL|targeted infusion of remifentanil CPAP treated OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
62379124|NCT02898792|EXPERIMENTAL|targeted infusion of remifentanil No OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
62379125|NCT03754842|PLACEBO_COMPARATOR|Placebo|
62379126|NCT03754842|EXPERIMENTAL|Nicotinamide Riboside + Pterostilbene|
62379127|NCT04002206|EXPERIMENTAL|Muscle Energy Technique|Post isometric relaxation technique was used in experimental group
62379128|NCT04002206|ACTIVE_COMPARATOR|Static Stretch|Static stretching was given in control group
62379129|NCT02814591||Cohort 1: Controls|40 volunteers free from bone disease. No family histroy of osteogenesis imperfecta (OI). No history of non-accidental fracture. No history of osteoarthritis (OA) or clinical manifestations of disease. No clinical features of OI, OA or osteoporosis (OP). Normal haemoatology and biochemical blood screen. Controls will be gender and age matched (within five years) to the disease cohort patients. Children and adults both required.
62379130|NCT02814591||Cohort 2: Patients with ostegenesis imperfecta (OI).|40 patients with OI. Patients must have been clinically diagnosed with OI. Participants will be identified form the Royal National Orthopaedic Hospital, Metabolic Unit database. Bone mineral density (BMD) confirmed with DXA.
62379131|NCT02814591||Cohort 3: Patients with osteoarthritis (OA)|40 patients with OA. Patients must have been clinically diagnosed with OA. Participants will be identified from the Royal National Orthopaedic Hospital, Metabolic Unit database.
62379132|NCT02814591||Cohort 4: Patients with osteoporosis (OI)|40 patients with OI receiving treatment with bisphosphonates. Patients must have been clinically diagnosed with OI and bisphosphonates prescribed as a course of treatment. 20 Adults and 20 Children. Where possible participants will be identified from the Royal National Orthopaedic Hospital (RNOH), Metabolic Unit Database; if not from the RNOH then diagnosis will be otherwise confirmed.
62379133|NCT02814591||Cohort 5: Patients with osteoporosis (OP) (2 treatment groups)|Patients must have been clinically diagnosed with OP. The first group will have been prescribed with bisphosphonate anti-resorptive treatment; the second with anabolic agents. Where possible participants will be identified from the Royal National Orthopaedic Hospital (RNOH), Metabolic Unit Database; if not from the RNOH then diagnosis will be otherwise confirmed. Bone mineral density (BMD) will be confirmed with DXA. Where possible measurements will be acquired prior to the start of treatment and then up to 4 follow up visits at flexible time points to allow scheduling to coincide with hospital appointments. Minimum time between vistis should be 2 months.
62756443|NCT05536089||ctDNA positive|Postoperative ctDNA positive
62756444|NCT05536089||ctDNA negative|Postoperative ctDNA negative
62756445|NCT00075387|EXPERIMENTAL|Arm I (combination chemotherapy)|"Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA over 10 minutes.~Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
62756446|NCT00075387|EXPERIMENTAL|Arm II (combination chemotherapy, sodium thiosulfate)|"Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA as in Arm I. Patients also receive sodium thiosulfate IV over 15 minutes 4 and 8 hours later.~Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
62756447|NCT01498627||Case Group|Subjects in this group are incident cases (i.e. newly diagnosed subjects) reported as having occurred in the previous twelve months before the recruitment consultation.
61986837|NCT04867265|ACTIVE_COMPARATOR|Resusci Anne QCPR AED (Laerdal)|medical students trained BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
61986838|NCT04867265|ACTIVE_COMPARATOR|Resusci Baby QCPR (Laerdal)|medical students trained BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
62756448|NCT01498627||Control Group|Subjects selected from the pool of potential referents reported by physicians in general practice, who meet the same general inclusion and exclusion criteria as the cases.
61986839|NCT06294418|EXPERIMENTAL|Low grade glioma|Patients with postoperative low grade glioma will undergo one FCI scan.
61986840|NCT00755131|EXPERIMENTAL|Training Group|Postinfarction patients undergo 6-month exercise-based Cardiac Rehabilitation Program
62557573|NCT00758524|PLACEBO_COMPARATOR|Withdrawal Period: LCI699 1.0 mg QD Placebo|Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
62557574|NCT00758524|EXPERIMENTAL|Withdrawal Period: LCI699 0.5 mg BID|Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
62756449|NCT04014140||Patients with multi-vessel coronary artery disease (MVCAD)|iFR measurements will be taken pre-operatively during the invasive coronary angiography.
62756450|NCT01819558|EXPERIMENTAL|immune therapy|6 administration every 2 weeks of intra-muscular 200 micrograms of protein recwt1-A10+AS01B at week 1, 3, 5, 7, 9 and 11.
62756451|NCT05870917|EXPERIMENTAL|VRD-based regimen Combined CART-ASCT-CART2|"VRD：Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22 in a 28-day cycle. Autologous BCMA-directed CAR-T cells, Double infusion intravenously at a target dose of (2-4)±20％ x 10\^6 anti-BCMA CAR+T cells/kg respectively.~Participants will receive VRD-based induction, first CAR-T infusion, VR consolidation, ASCT followed by the second CAR-T infusion, and R maintenance."
62756452|NCT05164601||AMI Patients Cohort|
62756453|NCT06279104||real-world study (RWS)-Chemotherapy|
62756454|NCT06279104||RWS-ICI|
62756455|NCT06606587|EXPERIMENTAL|Group Experimental: Application of Comfort-in Jet Injection Method|Application of Comfort-in Jet Injection Method Comfort-in jet injection method was used for palatal anesthesia of the permanent 1st molar. Using a silicone flat cap, it was placed 5 mm below the palatal gingival margin, close to the free gingiva, and with a steep angle. 0.3 ml of anesthetic solution was administered by pressing the jet injection system button. 1 mL Articaine Hydrochloride (Ultracaine D-S forte, Hoechst, Canada) containing 1/100,000 epinephrine was used as a local anesthetic agent in the injections. 31 patients were included in this group and the procedure was performed. After waiting for 2 minutes, the anesthetized area was probed with the help of a probe (probing gingiva) to check whether the anesthesia had taken effect. Afterwards, buccal infiltration anesthesia was performed with the help of a traditional dental injector and tooth extraction was performed.
62756456|NCT06606587|OTHER|Group Control: Application of Traditional Dental Injection Method|Application of Traditional Dental Injection Method Palatal injection; It was applied 5-10 mm below the palatal gingival margin\*, on the attached gum, and with a 45-degree needle angle. After needle entry, 0.2-0.3 mL of anesthetic solution was stored when bone contact was removed (3-5 mm). 1 mL Articaine Hydrochloride (Ultracaine D-S forte, Hoechst, Canada) containing 1/100,000 epinephrine and a 27 G dental needle were used as local anesthetic agents for injections. 25 patients were included in this group and the procedure was performed. After waiting for 5 minutes, the anesthetized area was probed with the help of a probe (probing gingiva) to check whether the anesthesia had taken effect. Afterwards, buccal infiltration anesthesia was performed with the help of a traditional dental injector and tooth extraction was performed.
62756457|NCT03158272|EXPERIMENTAL|Monotherapy|Cabiralizumab administered as a single agent intravenous formulation
62756458|NCT03158272|EXPERIMENTAL|Combination Therapy|Cabiralizumab will be administered in combination with Nivolumab as an intravenous formulation
62756459|NCT01151735|ACTIVE_COMPARATOR|C-1-esterase inhibitor 1000 units|1000 units of C-1-esterase inhibitor given at time of prodromal symptoms
62756460|NCT01151735|ACTIVE_COMPARATOR|1500 units of C-1-esterase inhibitor|treatment with 1500 units of C-1-esterase inhibitor IV at the time of prodromal symptoms to decrease risk of exacerbation of HAE
62756461|NCT01151735|PLACEBO_COMPARATOR|placebo injection|placebo injection given for prodromal symptoms as double blinded therapy
62756462|NCT02367391|EXPERIMENTAL|Motivational Text Messages|
62756463|NCT02367391|SHAM_COMPARATOR|Control|
62756464|NCT06037785|EXPERIMENTAL|SPSM intervention|Heart rate self monitoring Online shock management modules
62756465|NCT06037785|NO_INTERVENTION|usual care|standard observation and post-ICD shock care at each clinic that includes ICD interrogations monitored in-person or via home monitor
62756466|NCT05752227||benign lung lesions|Patient who were diagnosed with peripheral lung lesions including consolidation, atelectasis, or cavitation
62756467|NCT05752227||malignant lung lesions|patients diagnosed with malignant lung lesions
62756468|NCT01738932||Patients|women with histologically verified endometriosis
62756469|NCT01738932||Controls|Healthy Danish blood donors
62756470|NCT03510468|EXPERIMENTAL|Pharmacokinetic study in healthy volunteers|Healthy volunteers received Tenofovir alafenamide (TAF) 25 mg once daily for 14 days followed by TAF 25 mg once daily and Rifapentine (RPT) dosed by weight in 150-mg tablet increments (maximum oral dose of 900 mg) 750 or 900 mg (depending on weight) and Isoniazid (INH+ pyridoxine), 15 mg/kg (up to 900 mg) once weekly from days 15-31.
62756471|NCT02636244|EXPERIMENTAL|SHAPE Gel|1% SHAPE Gel applied twice daily for 12 weeks.
62756472|NCT05899595|EXPERIMENTAL|Personalized training group with the fatigue status (PERSO)|The PERSO group will perform similar exercises as the RECO group but the training load will be adapted by changing the intensity (with the same volume as RECO) depending on the fatigue scores of the week. The aerobic fatigue score will set the load for the aerobic exercises and the muscle fatigue score for the resistance exercises.
62756473|NCT05899595|ACTIVE_COMPARATOR|Traditional training group following the recommendations (RECO)|The RECO group will perform aerobic and resistance exercises to reach the recommendations for patients with chronic pathologies, with a moderate intensity and an increasing volume.
62756474|NCT06539858||Interventional group|This group will receive massage once a week for 4 weeks.
62756475|NCT06539858||non-intervention group|No intervention will be made to this group
62756476|NCT04216368|EXPERIMENTAL|experimental group|
62756477|NCT04216368|OTHER|controlled group|
62756478|NCT04698785|EXPERIMENTAL|Regorafenib and best supportive care|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by regorafenib and best supportive care followed by a 7-day period of rest.~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
62756479|NCT00182780|EXPERIMENTAL|Arm I - American ginseng (low dose)|"Patients receive oral American ginseng twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study.~Quality of life is assessed at baseline, every 2 weeks during treatment, and at the end of treatment.~PROJECTED ACCRUAL: A total of 280 patients (70 per treatment arm) will be accrued for this study within 35 months."
62756480|NCT00182780|EXPERIMENTAL|Arm II - American ginseng (mid-dose)|"Patients receive oral American ginseng at the mid-dose twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
62379134|NCT02814591||Cohort 6: Patients with rickets and osteomalacia|10-15 participants with rickets and 10-15 participants with osteomalacia. Patients must have been clinically diagnosed with rickets/osteomalacia. Blood tests for 25-hydroxyvitamin D should be less than or equal to 25 nmol/L. Once participants are on treatment further measurements will be made 6 months afterwards. Participants for rickets and osteomalacia groups will be recruited to give a total of 10 complete sets of data per group.
62557575|NCT00758524|PLACEBO_COMPARATOR|Withdrawal Period: LCI699 0.5 mg BID Placebo|Participants received LCI699 matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
62557576|NCT00758524|ACTIVE_COMPARATOR|Withdrawal Period: Eplerenone 50 mg BID|Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
62557577|NCT00758524|PLACEBO_COMPARATOR|Withdrawal Period: Eplerenone 50 mg BID Placebo|Participants received eplerenone matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
62557578|NCT00758524|PLACEBO_COMPARATOR|Withdrawal Period: Placebo|Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 1 week (Week 8 to Week 9).
62557579|NCT03221647||Controls|Intestinal biopsies from controls, affected by gastroesophageal reflux,
62557580|NCT03221647||GCD CD (Gluten Containing Diet CD)|Intestinal biopsies from GFD patients had with negative serology (anti-tTg antibodies between 0 and 1.5 U/ml and EMA negative) and normal biopsy (Marsh T0-1).
62756481|NCT00182780|EXPERIMENTAL|Arm III - American ginseng (high-dose)|"Patients receive oral American ginseng at the high dose twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
62756482|NCT00182780|OTHER|Arm IV - Placebo|"Patients receive oral placebo twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
62379135|NCT02814591||Cohort 7: 5 patients with suspected bone infection.|Participants will have been diagnosed at RNOH with a suspected bone infection. Participants will be scanned around the localised area of suspected infection. Participants may have 1 or 2 vists; the latter to take place after all infection has cleared up. This is not subject to a fixed time frame.
62557581|NCT03221647||GFD CD (Gluten Free Diet CD)|Intestinal biopsies from GCD-CD patients with villous atrophy (Marsh T3a-c) had positive serology (anti-tTg antibodies \>30 U/ml and EMA positive) ).
62557582|NCT05356871||Healthy participants|Healthy men and women within the age of 18 and 75 yrs.
62557583|NCT03810716|EXPERIMENTAL|Interactive Platform|Tha participants in this group will see the interactive platform and answer a survey before and after the intervention. Their clinical health records will be checked one month ago.
62557584|NCT03810716|NO_INTERVENTION|Control|The participants in this group will answer the survey. Their clinical health records will be checked one month ago.
62557585|NCT02336945||Type 2 diabetes|Subjects with type 2 diabetes who meet one of the therapy conditions
62557586|NCT04215887||Sleep unit|Children admitted to sleep unit for sleep study
62557587|NCT04215887||School|Healthy children in school
62756483|NCT05884112|EXPERIMENTAL|Narcolepsy (type1 +type 2) with depression|Stimulate with Double 70mm Alpha Coil figure of 8 stimulator (8-shaped stimulator) (Magstim Company, UK, high frequency magnetic stimulator with force power booster), each treatment will give subjects 1800 pulses, including 60 TBS Section stimulation, each section has 2 seconds of stimulation (30 pulses) and 8 seconds of interval, a total stimulation time of 10 minutes.
62557588|NCT04215887||Emergency department|Children seen in triage in emergency department at SCH
62557589|NCT04215887||General practice|Adults or children attending general practice
62557590|NCT04215887||Ambulance|Adults or children in rapid response vehicle
62557591|NCT05372354|EXPERIMENTAL|Part 1 Arm A: Dose Finding|
62557592|NCT05372354|EXPERIMENTAL|Part 1 Arm B: Dose Finding|
62557593|NCT05372354|EXPERIMENTAL|Part 1 Arm C: Dose Finding|
62557594|NCT05372354|ACTIVE_COMPARATOR|Part 2 Arm D: Dose Expansion|
62557595|NCT05372354|EXPERIMENTAL|Part 2 Arm E: Dose Expansion|
62557596|NCT05372354|EXPERIMENTAL|Part 2 Arm F: Dose Expansion|
62557597|NCT05372354|EXPERIMENTAL|Part 2 Arm G: Dose Expansion|
62557598|NCT01875146|ACTIVE_COMPARATOR|4x4 min HIT|Conventional 4x4 min high-intensity interval training
62557599|NCT01875146|EXPERIMENTAL|4x4 min HIT + WBV (18 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 18 Hz during the active rest
62557600|NCT01875146|EXPERIMENTAL|4x4 min HIT + WBV (30 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 30 Hz during the active rest
62557601|NCT01875146|ACTIVE_COMPARATOR|whole-body vibration at 30 Hz|4x3 min whole-body vibration at 30 Hz
62557602|NCT06074393|EXPERIMENTAL|Care partners of patients with advanced Parkinsonian Syndromes|Care partners of patients with advanced Parkinsonian Syndromes will participate in a tailored support group
62557603|NCT04261062||Subject|Patients in surgical intensive unit
61986841|NCT00755131|NO_INTERVENTION|Control Group|Postinfarction patients NOT undergoing 6-months exercise-based Cardiac Rehabilitation program
62379136|NCT02890511|EXPERIMENTAL|DHP107(Oral paclitaxel)|"* Phase I (determining MTD) The patients diagnosed with either advanced or metastatic solid cancers were enrolled. The administered dose was escalated in a step-wise manner by an increment of 2 x 50 mg/m2 at each dose level. Three patients were treated for toxicity evaluation for each dose level.~* Phase IIa (efficacy evaluation) The safety and efficacy of the corresponding dose was investigated more closely by increasing the patient number to 6 or more patients in the dose tentatively determined as recommended dose for phase IIa clinical trial."
62379137|NCT03523806|EXPERIMENTAL|Solution-Focused Coaching Group|Half of the participants (n=15) will be assigned a coach and receive coaching 8 times for up to 1 hour over 6 months. The first session will take place in the home and subsequent session will take place online using an online meeting tool.
62379138|NCT03523806|NO_INTERVENTION|Control Group|Half of the participants (n=15) will not be receiving coaching
62379139|NCT01926652|EXPERIMENTAL|candesartan|Single administration : candesartan cilexetil 32mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd
62379140|NCT01926652|EXPERIMENTAL|amlodipine|Single administration : amlodipine 10mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd
62379141|NCT04932694|EXPERIMENTAL|Study group|Core stabilization exercises will be conducted for 8 weeks, 3 sessions per day at home, and exercises will be supervised remotly.
62379142|NCT04932694|NO_INTERVENTION|Control group|No exercise will be given to the participants in the control group
62557604|NCT02892331|NO_INTERVENTION|Control|This group does not change physical activity during the intervention period, but will receive exercise training after the study is complete
62557605|NCT02892331|EXPERIMENTAL|MOD-INT|The Moderate intensity exercise training (MOD-INT) group will exercise at a moderate aerobic exercise intensity for 24 weeks
62557606|NCT02892331|EXPERIMENTAL|HIGH-INT|High Intensity exercise training (HI-INT) group will exercise at a high aerobic intensity for 24 weeks
62557607|NCT02213159|ACTIVE_COMPARATOR|Dexmedetomidine|prior to anticipated end of surgery bolus of 1 microgram/kg Dexmedetomidine intravenously over 10 minutes followed by 0.5 micrograms/kilogram/hour intravenous infusion until removal of laparoscopes
62557608|NCT02213159|ACTIVE_COMPARATOR|Morphine|prior to anticipated completion of surgery morphine 0.08 mg/kilogram intravenous bolus over 10 minutes followed by a saline infusion until removal of the laparoscopes
62557609|NCT02487914|ACTIVE_COMPARATOR|lidocaine iontophoresis using interferential current|the threshold of pressure, tactile,and pain thresholds were evaluated after the iontophoresis of Lidocaine using interferential current.
62557610|NCT02487914|ACTIVE_COMPARATOR|interferential current|the threshold of pressure, tactile,and pain thresholds were evaluated after the application of interferential current.
62557611|NCT02487914|ACTIVE_COMPARATOR|lidocaine|the threshold of pressure, tactile,and pain thresholds were evaluated after the application of topical Lidocaine.
62557612|NCT04631354|EXPERIMENTAL|Sequence A|Participants will receive a single dose of two radio-labelled 6 mg S-770108 capsules (total 12 mg per dose), by oral inhalation using a S-770108 inhaler at a target peak inspiratory flow rate (PIFR) of 15 L/minute on Day 1 of Period 1 followed by a single dose of two radio-labelled 6 mg S-770108 capsules by oral inhalation at a target PIFR of 30 L/minute on Day 1 of Period 2. There will be a 5 to 13 day washout period between the two treatment periods.
62557613|NCT04631354|EXPERIMENTAL|Sequence B|Participants will receive a single dose of two radio-labelled 6 mg S-770108 capsules (total 12 mg per dose), by oral inhalation using a S- 770108 inhaler at a target PIFR of 30 L/minute on Day 1 of Period 1 followed by a single dose of two radio-labelled 6 mg S-770108 capsules by oral inhalation at a target PIFR of 15 L/minute on Day 1 of Period 2. There will be a 5 to 13 day washout period between the two treatment periods.
62557614|NCT02232984||All study patients|All study patients will be implanted with a Boston Scientific (BSC) quadripolar Cardiac Resynchronization Therapy (CRT-D) and a currently approved quadripolar left ventricular lead. At the pre-discharge visit, multiple vectors will be tested in order to assess their respective performance.
62557615|NCT06216275|EXPERIMENTAL|Intervention Arm|Participants receiving the integrated approach of Snoezelen therapy, aromatherapy, and the use of personal items.
62557616|NCT06216275|NO_INTERVENTION|Control Arm|Participants receiving standard care practices for dementia and agitation without the integrated approach.
62756484|NCT05884112|SHAM_COMPARATOR|Narcolepsy with depression|Sham-control
62756485|NCT03176472|EXPERIMENTAL|ricolinostat|Ricolinostat 120 mg, taken once daily (QD) by mouth; each dose in 12 mL liquid formulation (10 mg ricolinostat per mL)
62756486|NCT03176472|PLACEBO_COMPARATOR|placebo|Placebo, 12 mL of liquid formulation with no active ingredient (i.e., ricolinostat), taken once daily (QD) by mouth
62756487|NCT02704923|ACTIVE_COMPARATOR|Atropine|
62756488|NCT02704923|PLACEBO_COMPARATOR|Placebo|
62756489|NCT04253899|ACTIVE_COMPARATOR|Standard pediatric group:|patients ≤17 yo with acute perforated appendicitis and interval appendectomy (n=25)
62756490|NCT04253899|EXPERIMENTAL|Experimental pediatric group:|patients ≤17 yo with acute perforated appendicitis abscess and observation (n=25)
62756491|NCT04253899|ACTIVE_COMPARATOR|Standard adult group:|patients ≥18 yo with acute perforated appendicitis and interval appendectomy (n=25)
62756492|NCT04253899|EXPERIMENTAL|Experimental adult group:|Patients ≥18 yo with acute perforated appendicitis and observation (n=25)
62756493|NCT05859373|EXPERIMENTAL|TQB3728 tablets+chemoradiation, sequential maintenance with TQB2450 injection|TQB3728 tablets combined with sequential or concurrent chemoradiation, 21 days as a treatment cycle. After 4\~6 cycles, sequential maintenance therapy of TQB2450 injection.
62756494|NCT05859373|EXPERIMENTAL|TQB3728 tablets+chemoradiation, sequential maintenance with TQB3728 tablets and TQB2450 injection|TQB3728 tablets combined with sequential or concurrent chemoradiation, 21 days as a treatment cycle. After 4\~6 cycles, sequential maintenance with TQB3728 tablets and TQB2450 injection for 4 cycles. Then sequential maintenance with TQB2450 injection monotherapy；
62756495|NCT05859373|ACTIVE_COMPARATOR|Sequential or concurrent chemoradiation, sequential maintenance with TQB2450 injection.|Sequential or concurrent chemoradiation, 21 days as a treatment cycle. After 4\~6 cycles, sequential maintenance with TQB2450 injection；
62756496|NCT05910034|EXPERIMENTAL|Trilaciclib+Envafolimab+Docetaxel|Trilaciclib:240mg/m2 IV d1,within 4h before chemotherapy; Envafolimab:300mg SC d1,Q3W; Docetaxel:75mg/m2 IV d1, Q3W
62756497|NCT05910034|EXPERIMENTAL|Envafolimab+Docetaxel|Envafolimab:300mg SC d1,Q3W; Docetaxel:75mg/m2 IV d1, Q3W
62756498|NCT05910034|EXPERIMENTAL|Docetaxel|Docetaxel: 75mg/m2 IV d1, Q3W
62756499|NCT03289221|EXPERIMENTAL|Experimental Group|Thirty (30) consecutive patients indicated for treatment of prostate cancer with HIFU (FocalOneR, Edap TMS, France) will be selected to the manometry study before the treatment together with the application of specific questionnaires (Cleveland Clinic Incontinence Score-CCIS, Fecal Incontinence Quality of Life Score-FIQLS, and Rome IV for functional constipation. This evaluaton will be conducted again after the treatment.
62756500|NCT00902018|EXPERIMENTAL|eltrombopag|10 ITP patients were treated with daily oral eltrombopag 75mg for 2 weeks and complete testing was done at weekly intervals 3 times they then were allowed to receive long-term eltrombopag
62756501|NCT00902018|EXPERIMENTAL|romiplostim|3 of the patients who received eltrombopag were also treated with romiplostim 10 micrograms/kg weekly for 2 weeks with the same complete testing done at weekly intervals three times after a washout period \> 1 month they then resumed long-term eltrombopag
62756502|NCT00902018|SHAM_COMPARATOR|healthy controls|no intervention single blood draw with complete studies
62557617|NCT02287922|EXPERIMENTAL|ALX-0061 150 mg q4w|ALX-0061 150 mg every 4 weeks from baseline through Week 12 + placebo every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
62379143|NCT02330471|EXPERIMENTAL|Spray|cervical coagulation using a superficial electrical coagulation mode, ie spray coagulation
62379144|NCT02330471|ACTIVE_COMPARATOR|Forced|cervical coagulation using a deep tissue electrical coagulation mode, ie forced coagulation
62557618|NCT02287922|EXPERIMENTAL|ALX-0061 150 mg q2w|ALX-0061 150 mg every 2 weeks from baseline through Week 12 + placebo every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
62557619|NCT02287922|EXPERIMENTAL|ALX-0061 225 mg q2w|ALX-0061 225 mg every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
62756503|NCT03068416|EXPERIMENTAL|CAR T cells|Autologous 3rd generation CD19-targeting CAR T cells
62756504|NCT06208189|EXPERIMENTAL|high-effort session|Participants will perform sets with as many repetitions they can each set.
62756505|NCT06208189|EXPERIMENTAL|low-effort session|Participants will perform sets with half of the anticipated number of repetitions of the high-effort session.
62756506|NCT06208189|SHAM_COMPARATOR|Control session|The control session all procedures will be identical to the high-effort session.
62756507|NCT03054805|EXPERIMENTAL|Magnesium oxide and MIYAIRI-BM|"Magnesium oxide 125 mg twice per day for children with weight \< 15 kg, 250 mg twice per day for weight \<15-30 kg, and 500 mg twice per day for weight \> 30 kg for 12 weeks.~MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight \< 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight \> 30 kg for 12 weeks."
62756508|NCT03054805|ACTIVE_COMPARATOR|Magnesium oxide|MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight \< 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight \> 30 kg for 12 weeks.
62756509|NCT03054805|NO_INTERVENTION|Healthy Children|Healthy Children
62756510|NCT00574665|EXPERIMENTAL|1|
62756511|NCT02337283|EXPERIMENTAL|BI 425809 very low dose - part I|Part I only - very low dose tablet, oral administration with 240 ml water, over 14 days
62756512|NCT02337283|PLACEBO_COMPARATOR|Placebo - part I|Part I only - placebo tablet, oral administration with 240ml water, over 14 days
62756513|NCT02337283|EXPERIMENTAL|BI 425809 low dose - part I|Part I - low dose tablet, oral administration with 240 ml water, over 14 days
62756514|NCT02337283|EXPERIMENTAL|BI 425809 medium dose - part I|Part I only - medium dose tablet, oral administration with 240 ml water, over 14 days
62379145|NCT05788562||Experimental group|Incorporate blood gas analysis indicators in D1-D7, after birth,1 week before and on the day of onset of early complications
62379146|NCT05788562||Control group|Incorporate blood gas analysis indicators in D1-D7,D14,D28after birth and the day of diacharge
62756515|NCT02337283|EXPERIMENTAL|BI 425809 high dose -part I|Part I only - high dose tablet, oral administration with 240 ml water, over 14 days
62756516|NCT02337283|EXPERIMENTAL|BI 425809 low dose - part II|Part II - one low dose tablet on day 1 of visit 2 and 2a
62756517|NCT02337283|EXPERIMENTAL|BI 425809 very high dose -part I|Part I only - very high dose tablet, oral administration with 240 ml water, over 14 days
62756518|NCT00800319|EXPERIMENTAL|RDC-0313, 5mg|5 mg of RDC-0313; single dose
62756519|NCT00800319|EXPERIMENTAL|RDC-0313, 15 mg|15 mg RDC-0313; single dose
62756520|NCT00800319|EXPERIMENTAL|RDC-0313, 25mg|25 mg RDC-0313; single dose
62756521|NCT00800319|EXPERIMENTAL|RDC-0313, 50 mg|50 mg RDC-0313; single dose
62379147|NCT03899389||Acute Coronary Syndrome (ACS)|Patients with STEMI or NSTEMI infarction, who were admitted to the hospital with chest pain.
62379148|NCT03899389||Stable Angina (SA)|Patients with stable angina who were scheduled for conventional coronary angiography.
62379149|NCT03899389||Control Group (CON)|Healthy control group responding by age and gender to examined groups.
62557620|NCT02287922|ACTIVE_COMPARATOR|TCZ 162 mg q1w or q2w|Open-label TCZ. Injections were to be performed q1w or q2w depending on the approved label per region (last injection was administered at Week 10 or Week 11, depending on the dose regimen).
62756522|NCT00800319|EXPERIMENTAL|RDC-0313, 75 mg|75 mg RDC-0313; single dose
62756523|NCT00800319|PLACEBO_COMPARATOR|Placebo|volume-match placebo; single dose
62379150|NCT05006651|NO_INTERVENTION|Laryngoscope|Intubation with traditional laryngoscope
62379151|NCT05006651|ACTIVE_COMPARATOR|McGrath MAC|Intubation with video laryngoscope
62379152|NCT05006651|ACTIVE_COMPARATOR|Trachway|Intubation with video stylet
62379153|NCT03165682||Group 1|Twenty-five patients with Systemic Lupus Erythematosus with prominent fatigue symptoms ( inclusion criterion: FSS of at least 4)
62557621|NCT04272892|EXPERIMENTAL|Digital CBT-I|6 weeks digital (online) cognitive behavioural therapy for insomnia
62756524|NCT06605261|EXPERIMENTAL|Yoga (intervention) Group|A yoga program will be conducted with 64 women undergoing endocrine therapy, experiencing joint pain or vasomotor symptoms, who are randomly assigned to the intervention group. The program will be delivered online via a digital platform for 4 weeks, 60 minutes per session, 4 days a week, with an instructor. An introductory session will provide information on yoga philosophy and program details. Each session will start with breathing exercises (pranayama), followed by yoga postures (asanas), and end with meditation. Participants will receive a yoga guide and necessary equipment (yoga mats, blocks) before starting. The FACT-ES Endocrine Symptoms Subscale will be re-administered in the second week. After each session, participants will report any adverse effects via digital communication. One month after the program, participants will be asked if they continued yoga at home, and reasons for discontinuation will be recorded.
62756525|NCT06605261|NO_INTERVENTION|Control Group|No intervention will be applied to individuals in this group, and they will continue with the routine exercises recommended by their physicians. After their data is collected as part of the control group, they will be invited by the researcher to participate in the online yoga sessions conducted with the intervention group.
62756526|NCT05192018|EXPERIMENTAL|Group A|This group will have their ileostomy reversed after 3 weeks from the index operation. All procedures were performed by the same senior surgeons. The duration of the operation was noted and the ease of reversal of stoma and closure of abdominal wall were assessed on ascale of 0-10 (0 = difficult, 10 = easy) by the operating surgeons.
62756527|NCT05192018|ACTIVE_COMPARATOR|Group B|This group will be discharged home after the primary colorectal surgery with a defunctioning ileostomy and brought back after an interval of 3 months ,or after completion of their adjuvant therapy, for reversal. All procedures were performed by the same senior surgeons. The duration of the operation was noted and the ease of reversal of stoma and closure of abdominal wall were assessed on ascale of 0-10 (0 = difficult, 10 = easy) by the operating surgeons.
62379154|NCT03165682||Group 2|Twenty-five patients with Systemic Lupus Erythematosus without subjectively enhanced fatiguability
62379155|NCT03165682||Group 3|Twenty-five age, sex and educationally matched controls among the health worker.
62379156|NCT02995811||Observational Cohort|"* On Days 1, 3, 7 and 10 of ICU admission, patients will undergo ultrasound assessment of the diaphragm, transverse and rectus abdominis, quadriceps rectus femoris, and tibialis anterior muscles. Imaging all four muscles together requires approximately 1 hour.~* Physical activity monitoring: On Days 1-10 of ICU admission patients will wear an activity monitor. These devices use several inertial motion sensors to track the movement and acceleration of the limbs in horizontal and vertical directions.~* Patients will also undergo daily assessment of global peripheral skeletal muscle strength assessed by the Medical Research Council Sum-score and global function measured by the Chelsea Critical Care Physical Assessment Scale"
62557622|NCT04272892|ACTIVE_COMPARATOR|Sleep hygiene information|Leaflet of sleep hygiene information
62756528|NCT03009708|EXPERIMENTAL|Allograft patients|Allograft patients followed at the Institut de Cancérologie Lucien Neuwirth perform blood samples during their post graft follow up in the usual practice, weekly. With the present study, two more blood tubes will be collected with the weekly blood samples.
62379157|NCT06456411||Group A (fNIRS)|Participants undergo fNIRS for over 15 minutes.
62379158|NCT06456411||Group B (fNIRS, VR)|Patients undergo fNIRS for over 15 minutes followed by a relaxation period using VR for over 15 minutes.
62379159|NCT06456411||Group C (fNIRS)|Patients undergo fNIRS for over 15 minutes.
62379160|NCT00646347|EXPERIMENTAL|A|Conventional stroke upper limb rehabilitation is given
62379161|NCT00646347|ACTIVE_COMPARATOR|B|Neuro Hand Orthosis Program is given
62557623|NCT02118805||Patients with ALS|No intervention is used in this study. The health of muscle is monitored over time.
62756529|NCT01598753|ACTIVE_COMPARATOR|Tramadol|
62756530|NCT01598753|PLACEBO_COMPARATOR|Placebo|
62379162|NCT05907005|EXPERIMENTAL|Intervention Group|Receive iCBT-based EMI with message content, delivery frequency and timing personalised to participants' preferences.
62379163|NCT05907005|NO_INTERVENTION|Control Group|Receive general mental health information through instant message.
62379164|NCT05789940|EXPERIMENTAL|Arm A: Hysteroscopy|Patients randomized to the hysteroscopy arm will receive misoprostol antibiotic prophylaxis to dilate the cervix before surgery, and anti-adhesion barrier gels will be used, according to routine procedures at each center. In case of intrauterine retention complicated by endometritis, antibiotic treatment for 48 hours (penicillin, metronidazole, fluoroquinolones or a combination of these antibiotics) will be administered according to the standard practice of each center. Evacuated retention product will be sent for pathological examination. Rh-negative women will receive prophylaxis to prevent Rh alloimmunization.
62379165|NCT05789940|EXPERIMENTAL|Arm B: Aspiration|Patients randomized to the aspiration arm will receive misoprostol antibiotic prophylaxis to dilate the cervix before surgery and anti-adhesion barrier gels will be used, according to routine procedures at each center. In case of intrauterine retention complicated by endometritis, antibiotic treatment for 48 hours (penicillin, metronidazole, fluoroquinolones or a combination of these antibiotics) will be administered according to the standard practice of each center. Evacuated retention product will be sent for pathological examination. Rh-negative women will receive prophylaxis to prevent Rh alloimmunization.
62379166|NCT03640715|OTHER|group A|Group A: no vulnerability according to expert with no indication of any PASS marker care
62379167|NCT03640715|OTHER|group B|Group B: probable vulnerability according to the expert with indication of at least one PASS marker care
62379168|NCT03640715|OTHER|group c|Group C: high vulnerability according to the expert with indication of at least two care markers PASS
62379169|NCT04029649|EXPERIMENTAL|Beta-1,3/1,6-D-Glucan Ganoderma lucidum|This group received capsule contains 180 mg Beta-1,3/1,6-D-Glucan from mycelium extract of Ganoderma lucidum with dose 3x1 capsule a day for 90 days
62557624|NCT02118805||Patients with Myasthenia Gravis|No intervention is used in this study. The health of muscle is monitored over time.
62557625|NCT02118805||Patients with Muscle Disease|No intervention is used in this study. The health of muscle is monitored over time.
62557626|NCT02118805||Patients with Stroke|No intervention is used in this study. The health of muscle is monitored over time.
62557627|NCT02118805||Patients with Parkinson's Disease|No intervention is used in this study. The health of muscle is monitored over time.
62557628|NCT02118805||Healthy Volunteers|No intervention is used in this study. The health of muscle is monitored over time.
62756531|NCT01598753|ACTIVE_COMPARATOR|Cognitive Behavior Therapy for FM|
62756532|NCT01598753|SHAM_COMPARATOR|Health Education|
62756533|NCT05517369|EXPERIMENTAL|Hybrid-ESD+|All participants receive resection of non-pedunculated colorectal polyp between 2 and 3 cm using the Hybrid-ESD+ method.
62756534|NCT03469830|EXPERIMENTAL|SSCP & SPMS|"The smart scar care pad (SCCP):~The SCCP is a newly invented insert material that can maximise treatment outcomes via enhanced compression and occlusion. The wearing regime for SCCP is 4 hours a day for the first day, with 2-hour increments added every other day until the total wearing time reached 23 hours. SSCP was cleaned twice a day for hygienic reasons.~The smart pressure monitored suit(SPMS):~The SPMS is a type of custom-made pressure garment. SPMS was used 23 hours a day and only removed when showering."
62756535|NCT03469830|ACTIVE_COMPARATOR|SPMS|"The smart pressure monitored suit(SPMS):~The SPMS is a type of custom-made pressure garment. SPMS was used 23 hours a day and only removed when showering."
62756536|NCT06608043||Intervention Group|This intervention group consists of multi-component modules developed to help individuals with breast cancer adopt a healthy lifestyle and improve their quality of life. The sessions are based on the 'Do Live Well' model, Kolb's Experiential Learning Theory, and CBT-based problem-solving skills.
62756537|NCT06608043||Control Group|Patients in the control group will continue conventional medical treatments, occupational therapy and physiotherapy sessions.
62756538|NCT04486482|OTHER|KB109 + Self Supportive Care (SSC)|
62756539|NCT04486482|OTHER|Self Supportive Care (SSC) Alone|
62756540|NCT06067048|EXPERIMENTAL|Treatment arm|Zanubrutinib, 320 mg per day (four 80 mg capsules)
62756541|NCT01173029||Resistant Arterial Hypertension|Subjects with systemic arterial hypertension in whom arterial pressure control was not achieved (24hr ambulatory pressure monitoring: mean 24hr systolic pressure \>/=130 mmHg or mean 24hr diastolic pressure \>/=80mmHg) by non-investigation specialized hypertensive unit care, in spite of appropriate drug treatment regimen with three or more anti-hypertensive drugs including a diuretic. Anti-hypertensive drug treatment was non-investigational and was prescribed at discretion of the physician who performed primary evaluation.
62756542|NCT01173029||Pseudo-resistant Arterial Hypertension|Subjects with systemic arterial hypertension in whom arterial pressure control was achieved (24hr ambulatory pressure monitoring: mean 24hr systolic pressure \<130 mmHg and mean 24hr diastolic pressure \<80mmHg) by non-investigation specialized hypertensive unit care, with appropriate drug treatment regimen with three or more anti-hypertensive drugs including a diuretic. Anti-hypertensive drug treatment was non-investigational and was prescribed at discretion of the physician who performed primary evaluation.
62756543|NCT00587236||1|Patients with chronic ulcerative colitis and concurrent primary sclerosing cholangitis.
62557629|NCT01709825|PLACEBO_COMPARATOR|Sugar Pill|Sugar Pill will be taken as a capsule once daily for 6 weeks.
62379170|NCT04029649|PLACEBO_COMPARATOR|Placebo|This group received empty capsule with dose 3x1 capsule a day for 90 days
62756544|NCT00587236||2|Patients with chronic ulcerative colitis and known dysplasia or cancer.
62756545|NCT05325216|EXPERIMENTAL|POPRC group|pelvic-organ preserving radical cystectomy with orthotopic ileal neobladder
62756546|NCT05325216|ACTIVE_COMPARATOR|SRC group|standard radical cystectomy with orthotopic ileal neobladder
62756547|NCT04644744|EXPERIMENTAL|Hypothermic oxygenated perfusion (HOPE)|Application of end-ischemic Hypothermic machine perfusion (HOPE) for a minimum of 2 hours (until hepatectomy)
62756548|NCT04644744|EXPERIMENTAL|Normothermic machine perfusion (NMP)|Application of end-ischemic normothermic machine perfusion (NMP) for a minimum of 4 hours (up to 24 hours)
62379171|NCT01308853|OTHER|Macrolane|Open label
62379172|NCT03316755|NO_INTERVENTION|without pamphlet|a group not exposed to pamphlet
62379173|NCT03316755|EXPERIMENTAL|With pamphlets|a group exposed to pamphlet
62379174|NCT01009333|EXPERIMENTAL|Low InterStim rate setting at 5.2 Hz|
62379175|NCT01009333|EXPERIMENTAL|Medium InterStim rate setting at 14 Hz|
62557630|NCT01709825|EXPERIMENTAL|Probiotic- Bifidobacterium bifidum|Bifidobacterium bifidum (Supplement A) will be taken as a capsule once daily for 6 weeks.
62557631|NCT01709825|EXPERIMENTAL|Probiotic- Lactobacillus helveticus|Lactobacillus helveticus (Supplement B) will be taken as a capsule once daily for 6 weeks.
62557632|NCT01709825|EXPERIMENTAL|Probiotic- Bifidobacterium longum ss. Infantis R0033|Bifidobacterium longum ss. Infantis R0033 (Supplement C)will be taken as a capsule once daily for 6 weeks.
62379176|NCT01009333|EXPERIMENTAL|High InterStim rate setting at 25 Hz|
62379177|NCT03856749|EXPERIMENTAL|Treatment|The wheelchair user and caregiver will be trained together on wheelchair skills using remote technology (Zoom for healthcare and/or Facetime).
62379178|NCT03856749|NO_INTERVENTION|Control|The wheelchair user and caregiver will receive the same self-study materials provided to the Treatment arm. Usual care, which may include wheelchair skills training for both wheelchair users and caregivers( but which often does not do so to an adequate extent) by wheelchair user's clinical therapist.
62379179|NCT03330548|ACTIVE_COMPARATOR|TeleMOVE!|Veterans randomized to the control arm will participate in TeleMOVE!, an arm of the Management of Overweight Veterans (MOVE!) program. TeleMOVE! is telehealth treatment program within the VA designed to improve the lives of Veterans by assisting with weight management and health promotion. This program includes daily interaction with in-home messaging technologies and clinician contact as needed
62756549|NCT04644744|ACTIVE_COMPARATOR|Conventional cold storage (CCS)|Conventional cold storage
62756550|NCT04243018|EXPERIMENTAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Intervention to improve well-being and reduce the negative effects of shame and self-stigma in a population of adults experiencing homelessness.This will involve participating in two sessions, lasting two and a half hours each, over a period of two weeks. Well-being will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition participants will be provided with an acceptance and commitment training workbook. The workbook will foster core processes of the ACT model through psycho-education, daily exercises, tips and tools.
62756551|NCT04243018|ACTIVE_COMPARATOR|Peer Support Group|This peer support group will involve discussing themes around experiencing homelessness, shame and stigma and will be facilitated by an experienced peer support group leader.This will involve participating in two sessions, lasting two hours each, over a period of two weeks.
62756552|NCT00453115|EXPERIMENTAL|study arm|GemOx
62756553|NCT00246025|EXPERIMENTAL|Dabigatran etexilate 110 mg|Dabigatran etexilate 110 mg capsule, once a day, oral administration
62756554|NCT00246025|EXPERIMENTAL|Dabigatran etexilate 150 mg|Dabigatran etexilate 150 mg capsule, once a day, oral administration
62756555|NCT00246025|EXPERIMENTAL|Dabigatran etexilate 220 mg|Dabigatran etexilate 110 mg capsule, 2capsules, once a day, oral administration
62756556|NCT00246025|PLACEBO_COMPARATOR|Placebo|matching placebo capsule, once a day, oral administration
62379180|NCT03330548|EXPERIMENTAL|Culinary Rx|Veterans randomized to the experimental arm will participate in Culinary Rx. Culinary Rx is an online instructional cooking and nutrition course that healthcare professionals can prescribe to patients who need to transition away from a Standard American Diet to a more health-supportive, whole foods, plant-based lifestyle. In partnership with The Plantrician Project, this course will focus on teaching the foundational cooking skills needed for long-term behavioral change, coupled with lifestyle education around nutrition and resources that will help users successfully face the many challenges inherent to dietary change.
62557633|NCT06368011|EXPERIMENTAL|experimental group:relatives of schizophrenia patients|The population of the study consisted of the relatives of schizophrenia patients who were registered and actively attending the Ministry of Health Dr. Nafiz Körez Sincan State Hospital Community Mental Health Center.The sample size of the study was calculated at 95% confidence level according to the independent t test using 'G. Power-3.1.9.7' before the study was started.As a result of the analysis, the minimum sample size was calculated as 32, with 16 in the experimental group and 16 in the control group.
62557634|NCT06368011|NO_INTERVENTION|control group:relatives of schizophrenia patients|
62557635|NCT04558229|NO_INTERVENTION|Standard of Care Clinician Counseling|
62557636|NCT04558229|EXPERIMENTAL|Additional Standardized Counseling|
62557637|NCT00443690|PLACEBO_COMPARATOR|2|placebo control
62557638|NCT00443690|EXPERIMENTAL|1|KW-3902IV
62557639|NCT01151124|EXPERIMENTAL|CTX0E03 DP|human neural stem cell product, once only injection, increasing doses
62557640|NCT01030419|EXPERIMENTAL|FlexToBa physical activity DVD|Participants in this arm will receive a physical activity program delivered by DVD that focuses on exercises targeting flexibility, toning and balance. These exercises will be progressive in nature throughout the six months and will also focus on modifications for all ability levels. Participants will be provided with three DVDs including: an Introduction to physical activity, Sessions 1-3, and Sessions 4-6, which they will be asked to watch and participate in over the course of six months.
62557641|NCT01030419|PLACEBO_COMPARATOR|Usual care-Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 12-month follow-up testing.
62756557|NCT03596073|EXPERIMENTAL|Topical Calcipotriene Ointment|-Topical Calcipotriene Ointment will be administered by the participants to their upper extremities twice a day for the period between core biopsy and surgical removal of their breast lesion
62756558|NCT03596073|PLACEBO_COMPARATOR|Topical Vaseline|-Topical Vaseline will be administered by the participants to their upper extremities twice a day for the period between core biopsy and surgical removal of their breast lesion
62756559|NCT06606067|EXPERIMENTAL|Duloxetine|Participants received Duloxetine 30 mg / 24 h 2 weeks before surgery and 1 week after surgery
62379181|NCT02003430||≥65 years old|20 patients greater than or equal to 65 years of age
62379182|NCT02003430||<65 years old|20 patients less than 65 years of age
62379183|NCT03525821|EXPERIMENTAL|intranasal administration of ketamine|intranasal adminstration of ketamine combined with nitrous oxide befor reduction of fracture
62557642|NCT03524443||Patient suffering from anorexia/bulimia|Each patient will receive standard care: multidisciplinary and corresponding to the HAS recommendations for anorexia nervosa and bulimia nervosa associated with semimonthly or weeklies sessions of art therapy treatment, using all types of art, realized by trained professional, in Toulouse. Each patient will be her own control before art therapy Female patients with anorexia nervosa or bulimia according to DSM-5 criteria, patient will be above 16 years-old
62557643|NCT04333316|OTHER|large head group|study the postoperative patient's satisfaction
62557644|NCT04333316|OTHER|dual mobility group|study the postoperative patient's satisfaction
62557645|NCT04854161|EXPERIMENTAL|Compassion and Empathic Attunement to Affect|Empathic Attunement to Affect is based on Emotion-Focused Therapy. Compassion training program is based on Compassion Cultivation Training, CCT
62557646|NCT04854161|ACTIVE_COMPARATOR|Focusing and Empathic Attunement to Affect|Empathic Attunement to Affect is based on Emotion-Focused Therapy. Focusing training program is based on Focusing-Oriented Therapy
62557647|NCT01795963|PLACEBO_COMPARATOR|Placebo Control|Participants in the control condition will view a presentation that teaches inert information about anxiety, depression, and relationships such as definitions, prevalence rates, common problems associated with these conditions and available forms of treatment. This presentation was used initially in Cuckrowicz \& Joiner (2007) and has since been shown to be effective as a placebo in two previous ePREP studies (Braithwaite \& Fincham, 2007; Braithwaite \& Fincham, 2008). This presentation is identical to the ePREP intervention in its set up, the only difference being, there is no information included in this presentation that teaches specific skills or strategies for improving relationships, depression or anxiety.
62557648|NCT01795963|ACTIVE_COMPARATOR|ePREP|The ePREP intervention teaches individuals how to recognize and combat dynamic risk factors that lead to relationship distress.
62756560|NCT06606067|PLACEBO_COMPARATOR|Placebo|Participants received Placebo / 24 h 2 weeks before surgery and 1 week after surgery
62756561|NCT05976503|EXPERIMENTAL|Tunodafil Hydrochloride plus alcohol|Participants received 100 mg Tunodafil Hydrochloride Tablets plus 0.5 g/kg alcohol.
62756562|NCT05976503|EXPERIMENTAL|Placebo plus alcohol|Participants received placebo plus 0.5 g/kg alcohol.
62557649|NCT04251104|EXPERIMENTAL|Level of personal relevance of images|This is an exploratory randomized controlled study to compare the effectiveness of three types of autobiographical stimuli, classified according to their level of personal relevance (high, medium and low), in the induction of positive emotions resulting from the retrieval of specific positive autobiographical memories. To this end, the investigators will use three types of images, classified according to their personal relevance: a) personal autobiographical photographs (high personal relevance); b) images of locations related to the participants' lives (medium personal relevance); and c) images from the Internation Affective Picture System (IAPS; low personal relevance).
62557650|NCT04251104|OTHER|Age (young and older adults comparison)|To analyse any age-related differences in the effectiveness of the use of the three types of images to regulate emotion, the investigators will compare the efficacy of the three categories of pictures (high, medium and low relevance) in inducing positive mood states in a group of young adults (age range: 18-35 years) and a group of older adults (65 years or over).
62756563|NCT05976503|EXPERIMENTAL|Tunodafil Hydrochloride|Participants received 100mg Tunodafil Hydrochloride Tablets.
62756564|NCT06606730|OTHER|Control|Administration of pembrolizumab for 6 months
61986842|NCT01992861||Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)|Patients undergo radiation therapy and receive chemotherapy per standard of care. Patients undergo DCE MRI, DW MRI, and MR spectroscopy at baseline, 2-2.5 weeks, 4-5 weeks, and 1 month following radiation therapy completion, and FDG PET/CT at baseline, 2-2.5 weeks, and 4-5 weeks.
62379184|NCT06212505||Adults patients with severe hemophilia A (FVIII<2%)|"Adults patients with severe hemophilia A (FVIII\<2%) who are:~* on prophylaxis with FVIII concentrates after a washout period of 48h for SHL FVIII molecules and at least 4 days for EHL FVIII~* or receive on demand FVIII treatment without any FVIII treatment since 48h for SHL FVIII molecules and since 4 days for EHL FVIII"
62379185|NCT04545086|EXPERIMENTAL|VBE Group|Video Based Education was given before undergoing MRI procedure and Anxiety was assessed within 20 minutes of Intervention. Assessment of Experience, Co-operation and Opinion regarding intervention was done.
62379186|NCT04545086|EXPERIMENTAL|MT Group|Music Therapy was given before undergoing MRI procedure and Anxiety was assessed within 20 minutes of Intervention. Assessment of Experience, Co-operation and Opinion regarding intervention was done.
62379187|NCT04545086|NO_INTERVENTION|Control Group|Routine Information was given before undergoing MRI procedure and Anxiety was assessed within 20 minutes of Intervention. Assessment of Experience, Co-operation was done.
62379188|NCT05407376|ACTIVE_COMPARATOR|Intervention- High Dose|Participation will last approximately 6 months. Participants enrolled in the high-dose intervention arm will receive a weekly produce delivery directly to their home in addition to the completion of 3 questionnaires and collection of the HbA1c at the end of study.
62379189|NCT05407376|ACTIVE_COMPARATOR|Intervention-Low Dose|Participation will last approximately 6 months. Participants enrolled in the low-dose intervention arm will receive a weekly produce delivery directly to their home in addition to the completion of 3 questionnaires and collection of the HbA1c at the end of study. The amount of produce provided in this arm will be lower per month per household size than the high dose arm.
62379190|NCT05407376|NO_INTERVENTION|Usual Care|Participation will last approximately 6 months. Participants enrolled in the Usual Care arm will complete 3 questionnaires and collection of the HbA1c at the end of study.
62379191|NCT04399304||Simultaneous|One-stage bilateral high tibial osteotomy
62379192|NCT04399304||Staged|Two-stage bilateral high tibial osteotomy
62379193|NCT01893879|EXPERIMENTAL|(RS)2-(3-benzoylphenyl)-propionic acid|"Patients receive study drug PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.~Laboratory biomarker analysis will be performed."
62379194|NCT01893879|PLACEBO_COMPARATOR|placebo for study drug|"Patients receive placebo PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.~Laboratory biomarker analysis will be performed."
62379195|NCT06202677|EXPERIMENTAL|Experimental: Intervention group: Obsessive Compulsive Disorder Program|Participants will complete an 8-day self-guided programme on obsessive compulsive disorder delivered via a mobile phone application with daily exercises guided by cognitive-behavioural and exposure and response prevention principles.
62379196|NCT06202677|ACTIVE_COMPARATOR|Control group|Participants will complete an 8-day self-guided programme on cooperation delivered via a mobile phone application with daily exercises that differ from the intervention group in terms of content but are comparable in terms of duration.
62379197|NCT01077310|ACTIVE_COMPARATOR|Intramuscular naltrexone|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
62379198|NCT01077310|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail.
62379199|NCT03742687|EXPERIMENTAL|A:Large target volume|The target volume for radiotherapy treatment volume is considered too large for a standard treatment of 66Gy in 33 fractions, considering the expected normal tissue toxicity with a standard treatment plan. Heterogeneously Hypofractionated Radiotherapy plan ( 24 fractions )
62379200|NCT03742687|EXPERIMENTAL|B:Fragile patient|The patient is too fragile for standard long-course radiotherapy with 66 Gy. Heterogeneously Hypofractionated Radiotherapy plan ( 24 fractions )
62379201|NCT04726566||Arthroscopic stabilization|Patient will have an anatomical surgery of chronic lateral ankle instability under arthroscopy
62379202|NCT00486148|NO_INTERVENTION|"group S"|Breast milk
61986843|NCT05125328|EXPERIMENTAL|neurosurgery with fixation|
61986844|NCT06104358|EXPERIMENTAL|Active Treatment HU6|Subjects who are randomized to active study drug will receive 450mg of HU6 for 14 day and then 600mg of HU6 for 168 days. N = 24
62379203|NCT00486148|NO_INTERVENTION|"group A"|Control Infant formula
62379204|NCT00486148|EXPERIMENTAL|"group B"|Infant formula supplemented with 0.4 g/100 ml of oligosaccharides
62379205|NCT04863118|EXPERIMENTAL|Strength training protocol performed in shallow water and dry land|Parkinson Disease and healthy individuals
62756565|NCT06606730|EXPERIMENTAL|Deescalation|Patients will be followed up according to standard practice for 4 years
62379206|NCT04863118|EXPERIMENTAL|High-intensity training protocol performed in shallow and deep water|Parkinson Disease and healthy individuals
62379207|NCT03593005|EXPERIMENTAL|Order A|The participants will be tested in the following order: Zurich (Low altitude: 470m above sea level) and consecutively High Altitude (Säntis; 2500m above sea Level)
62379208|NCT03593005|EXPERIMENTAL|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
62379209|NCT00648973|EXPERIMENTAL|1|Diphenhydramine 50 mg
62379210|NCT00648973|EXPERIMENTAL|2|Diphenhydramine 25 mg
62379211|NCT00648973|ACTIVE_COMPARATOR|3|Pseudoephedrine 120 mg
62557651|NCT06411964|EXPERIMENTAL|GOS|Galactooligosaccharide (GOS) is a prebiotic supplement. Taken once daily for the duration for the intervention
62557652|NCT06411964|PLACEBO_COMPARATOR|Placebo|Maltodextrin placebo taken once daily for the duration of the intervention
62557653|NCT05293119|EXPERIMENTAL|Tofacitinib|In this group, study participants will be treated with per oral tofacitinib citrate (5 mg/twice daily)
62557654|NCT05293119|ACTIVE_COMPARATOR|Topical corticosteroid|In this group, patients will apply topical Mometasone furoate 0.1% once daily
62379212|NCT03858855|EXPERIMENTAL|Group I (bergamot essential oil)|Patients inhale 7 drops of bergamot essential oil using an essential oil administration bottle TID (morning, midday, and evening) for up to 7 days. Patients also use a journal to document symptoms, time of inhalation, and medication use TID for up to 7 days.
62379213|NCT03858855|EXPERIMENTAL|Group II (chamomile essential oil)|Patients inhale 7 drops of chamomile essential oil and complete journal as in group I.
62379214|NCT03858855|EXPERIMENTAL|Group III (ginger essential oil)|Patients inhale 7 drops of ginger essential oil and complete journal as in group I.
62379215|NCT03858855|ACTIVE_COMPARATOR|Group IV (almond essential oil)|Patients inhale 7 drops of almond essential oil and complete journal as in group I.
62379216|NCT03211104|EXPERIMENTAL|curcumin|"Curcumin extracted from curcuma longa linn.~* formulation : curcumin powder 240mg/capsule~* general name : Diferuloylmethane~Taking curcumin 3 times a day(1,440mg/day) for 6 months at the first off treatment in patients with prostate cancer receiving intermittent androgen deprivation therapy"
62379217|NCT03211104|PLACEBO_COMPARATOR|control|The control group Take a placebo containing lactose and vitamin B2. Reddish brown capsules with the same shape as curcumin.
62379218|NCT01894685|EXPERIMENTAL|Mesalazine|Mesalazine, 3 grams once daily for six months
62557655|NCT01573585|ACTIVE_COMPARATOR|Usual care|The usual care will consist of strength training, endurance, range of motion, patient education, weight shifting in standing and gait re-training.
62756566|NCT03104972|EXPERIMENTAL|tDCS - placebo|tDCS-placebo (sham) group to receive either transcranial direct stimulation (tDCS) or matching placebo (sham( during 5 following days (one session each day). After a one week break, there will be a crossover between the control group and the sham group: those we received tDCS in the 1st week will get sham, while those who received sham in the 1st week will received tDCS at the 3rd week.
62756567|NCT03104972|EXPERIMENTAL|tRNS - placebo|trans cranial random stimulation (tRNS)-sham group, who will receive the same type of intervention with the same intervals as above but with tRNS instead of tDCS.
62379219|NCT01894685|PLACEBO_COMPARATOR|Placebo|Placebo, 3 grams, once daily for six months
62379220|NCT01220596|EXPERIMENTAL|Sequential therapy|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
62379221|NCT01220596|ACTIVE_COMPARATOR|Peginterferon alfa-2a monotherapy|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
62379222|NCT06065241|EXPERIMENTAL|Experimental Group|Participants in this arm will receive a herbal capsule formulation, called LLP-01, consisting of 2 capsules taken once daily without food for 60 days. The capsules contain extracts from naturally occurring plant species, including Withania somnifera, Rosmarinus officinalis, Curcuma longa, Cotinus coggygria, Panax ginseng, Cordyceps militaris, Camellia sinensis, Cotinus coggygria, and Piper nigrum.
62379223|NCT06065241|PLACEBO_COMPARATOR|Placebo Group|Participants in this arm will receive Placebo capsules, which are visually identical to the capsules in the Experimental Group. These placebo capsules are filled with rice flour and a minor amount of Curcuma longa powder and should be taken in the same manner as the Experimental Group, with 2 capsules taken once daily without food for 60 days.
62379224|NCT00772889|EXPERIMENTAL|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.
62557656|NCT01573585|EXPERIMENTAL|FAST protocol|The Fast muscle activation and stepping training will be the Experimental arm of this trial. This program will be exercises emphasizing speed of movement.
62557657|NCT03022084|EXPERIMENTAL|Desyncra|This group will use the sound-therapy device, Desyncra™ for Tinnitus Therapy System.
62557658|NCT03022084|OTHER|Cognitive Behavioral Therapy|Standard of Care
62557659|NCT02392481||Healthy subjects|
62557660|NCT02392481||Mild asthma|
62557661|NCT02392481||Moderate asthma|
62557662|NCT02392481||Severe asthma|
62557663|NCT04759196|ACTIVE_COMPARATOR|NESIS - Levetiracetam|"Participant with a score NESIS of 4 or more (increased risk of having cortical depression).~Levetiracetam is an anti-epileptic drug known to be inefficient in other condition with cortical depression. It will be use as an active comparator."
62756568|NCT03104972|EXPERIMENTAL|tDCS-tRNS|tDCS-tRNS group. Here the same intervention as above will be provided with the same intervals, but real tDCS and real tRNS will be provided in a counterbalanced fashion. This would allow to compare the different treatment in a within-subject design, as well as to compare the effect of those to sham stimulation in the first two groups in a between-subject design.
62756569|NCT04199364|EXPERIMENTAL|Low FiO2 threshold|A fraction of inspired oxygen (FiO2) of 25% to have an oxygen saturation (SpO2) of 90-92%.
62756570|NCT04199364|EXPERIMENTAL|Medium FiO2 threshold|A fraction of inspired oxygen (FiO2) of 35% to have an oxygen saturation (SpO2) of 90-92%.
62756571|NCT01632228|EXPERIMENTAL|Onartuzumab + Bevacizumab|All participants will receive onartuzumab intravenous (IV) infusion followed by bevacizumab IV infusion every 3 weeks.
61986845|NCT06104358|PLACEBO_COMPARATOR|Placebo|Placebo Comparator is non-active study drug. N = 24
61986846|NCT01907477|OTHER|neutropenic patients|
62379225|NCT00772889|ACTIVE_COMPARATOR|Fluarix elderly Group|Subjects aged ≥66 years received one dose of Fluarix vaccine.
62756572|NCT01632228|ACTIVE_COMPARATOR|Placebo + Bevacizumab|All participants will receive placebo matched with onartuzumab followed by bevacizumab IV infusion every 3 weeks.
62379226|NCT00772889|ACTIVE_COMPARATOR|Fluarix young Group|Subjects aged 19-43 years received one dose of Fluarix vaccine.
62379227|NCT03601091|ACTIVE_COMPARATOR|PR|PRECEDEX 200 mcg 2 ml,0,3 mcg/kg/h, intravenous continue infusion, 4 hours.
62379228|NCT03601091|ACTIVE_COMPARATOR|DO|DORMICUM 5MG/5 ML, 0,1 mg/kh/h, intravenous continue infusion for 4 hours
62379229|NCT02492542|EXPERIMENTAL|Electric Stimulation Treatment|Patients in the intervention group were treated with electric stimulation based on the routine clinical nursing.
62379230|NCT02492542|NO_INTERVENTION|control group|patients in this group only received routine clinical nursing without electric stimulation
62379231|NCT04347434|EXPERIMENTAL|Atorvastatin 80 mg|"Treatment with atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy.~If there is no achievement of the target level of LDL-C, ≤1.5 mmol / L after 5-6 weeks from the AMI onset, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day."
62379232|NCT04347434|ACTIVE_COMPARATOR|Atorvastatin-Ezetimibe|In the absence of reaching the target level of LDL-C of ≤1.4 mmol / L and a decrease in the indicator by ≥50% after 5-6 weeks from the onset of AMI, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
62379233|NCT04451486|EXPERIMENTAL|Treatment dose 1|1x10\*5 CD61-Lin- cells /0.25mL DPBS
62379234|NCT04451486|EXPERIMENTAL|Treatment dose 2|1x10\*6 CD61-Lin- cells /0.25mL DPBS
62379235|NCT04451486|EXPERIMENTAL|Treatment dose 3|1x10\*7 CD61-Lin- cells /0.25mL DPBS
62756573|NCT00966849|EXPERIMENTAL|Conditional Cash Transfer|Vulnerable households in this arm will receive conditional cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
62756574|NCT00966849|EXPERIMENTAL|Unconditional Cash Transfer|Vulnerable households in this arm will receive unconditional cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
62756575|NCT00966849|OTHER|Control|Vulnerable households in this arm will not receive cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
62756576|NCT00324428|EXPERIMENTAL|Transcranial Magnetic Stimulation (TMS)|This arm provides active 1Hz repetitive TMS (rTMS) applied to SII
62756577|NCT00324428|SHAM_COMPARATOR|Transcranial Magnetic Stimulation Sham|This arm provides sham 1Hz repetitive TMS (rTMS) applied to SII
62756578|NCT00593853|ACTIVE_COMPARATOR|1|
62379236|NCT02084394||no intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the concommittent ultrasound of the temporal artery. Deemed interventional by JHUIRB but no actual intervention done to subject.
62379237|NCT01864304||Williams Syndrome|Children and adults with Williams Syndrome
62379238|NCT01864304||Control Group|Controls will be recruited in 2 ways: 1) a gender matched and age- and BMI-similar control for each WS patient, and, 2) sibling controls when available
62379239|NCT02839655|EXPERIMENTAL|Da Vinci Xi|
62379240|NCT01751269|EXPERIMENTAL|Ascending Single and Multiple dose of RPX7009|Ascending Single and Multiple dose of RPX7009
62756579|NCT00593853|PLACEBO_COMPARATOR|2|
61986847|NCT02950077|EXPERIMENTAL|All subjects|Individuals who are under the care of the Yale Liver Center with a diagnosis of autoimmune hepatitis
61986848|NCT03365817|EXPERIMENTAL|Taper off|Decrease of opioid daily dose until discontinuation for up to six months.
61986849|NCT03365817|ACTIVE_COMPARATOR|Control Group|No changes on opioids and adjuvant medication for up to six months.
61986850|NCT05886296|EXPERIMENTAL|pre-surgical information session for people who must undergo shoulder rotator cuff surgery|implementation of an information session for people who have to undergo rotator cuff surgery of the shoulder on the post-operative evolution
61986851|NCT05886296|NO_INTERVENTION|Usual care|Participants will undergo usual care
61986852|NCT01888146|EXPERIMENTAL|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
62379241|NCT01751269|PLACEBO_COMPARATOR|Normal Saline|Ascending Single and multiple dose of normal saline.
62379242|NCT03137173|EXPERIMENTAL|ceftobiprole medocaril|Patients treated with ceftobiprole medocaril 500 mg q8h (with dose adjustment for renal impairment).
62379243|NCT03137173|ACTIVE_COMPARATOR|vancomycin+aztreonam|Patients treated with vancomycin 1000 mg (or 15 mg/kg) q12h plus aztreonam 1000 mg q12h (both with dose adjustment for renal impairment).
62756580|NCT00858260||hemodialysis patients|Adult patients undergoing maintenance dialysis since at leat three months
62756581|NCT03830853||Successful CTO PCI achieved|Patients will have successful CTO PCI (chronic total occlusion percutaneous coronary intervention) followed by physiological and intracoronary imaging. These measurements will be repeated at a 3 month follow up angiogram procedure.
62756582|NCT04277117|OTHER|Waitlisted control|"Phase 1 (6 months, months 1-6):~* Educational materials on healthy eating for diabetes~* No meal delivery~Phase 2 (6 months, months 7-12): Standard MOWCTX home meal delivery: 5 meals a week, delivered daily 2 to 4X a week"
62756583|NCT04277117|EXPERIMENTAL|"Daily Warm MTM in-person delivery"|"Phase 1 (6 months, months 1-6):~* Educational materials on healthy eating for diabetes~* 10 medically-tailored meals (MTM) per week, delivered 3-5x per week Mon-Fri~* Each delivery day, 1 hot and 1 frozen + snack delivered to the participant's home by trained volunteers and/or paid delivery drivers who provide human interaction. Depending on the participant's availability (3-5 days/week), more frozen meals will be given one day to account for a total of 10 meals every week.~Phase 2 (6 months, months 7-12): Standard MOWCTX home meal delivery: 5 meals a week, delivered daily 2 to 4X a week"
62379244|NCT06410729||Benign mesenteric lymph node enlargement (BLNE)|Lymph nodes with a diameter \> 8 mm on preoperative imaging without metastasis on postoperative pathology were termed benign mesenteric lymph node enlargement.
62379245|NCT06410729||Non-benign mesenteric lymph node enlargement (NBLNE)|Lymph nodes with a diameter \< 8 mm on preoperative imaging without metastasis on postoperative pathology were termed non-benign mesenteric lymph node enlargement.
62756584|NCT04277117|EXPERIMENTAL|"Weekly Frozen MTM drop shipment"|"Phase 1 (6 months, months 1-6):~* Educational materials on healthy eating for diabetes~* 10 medically-tailored meals (MTM) delivered once a week~* Each week all meals are frozen.~* Meals are shipped to the participant's home with no human interaction~Phase 2 (6 months, months 7-12): Standard MOWCTX home meal delivery: 5 meals a week, delivered daily 2 to 4X a week."
62756585|NCT04206475|EXPERIMENTAL|IM-FTP|rehabilitated over 1-month through IM-FTP, including physio-kinesis/occupational, speech, and neuropsychology treatments
62557664|NCT04759196|EXPERIMENTAL|NESIS - Topiramate|"Participant with a score NESIS of 4 or more (increased risk of having cortical depression).~Topiramate is an anti-epileptic drug known to be efficient in other condition with cortical depression. The investigators want to test his efficacy in chronic subdural hematoma with probable cortical depression."
62557665|NCT04759196|ACTIVE_COMPARATOR|Non NESIS - Levetiracetam|"Participant with a score NESIS of 3 or less (increased risk of having epileptic discharges).~Levetiracetam is an anti-epileptic drug known to be inefficient in other condition with cortical depression. It will be use as an active comparator.~Levetiracetam should be as efficient as Topiramate in a group a participant with epileptic discharges."
62557666|NCT04759196|EXPERIMENTAL|Non-NESIS - Topiramate|"Participant with a score NESIS of 3 or less (increased risk of having epileptic discharges).~Topiramate is an anti-epileptic drug known to be efficient in other condition with cortical depression. The investigators want to test his efficacy in chronic subdural hematoma with probable cortical depression.~Topiramate should be as efficient as Levetiracetam in a group a participant with epileptic discharges."
62557667|NCT03252405|ACTIVE_COMPARATOR|mask ventilation|induction is made with mask ventilation
62557668|NCT03252405|EXPERIMENTAL|intravenous induction|induction is made with intravenous cannulation
62557669|NCT03408639|EXPERIMENTAL|CinnaPoietin®|"The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.~In addition to main intervention, Nephrovit tablet/day and vitamine B12 100 mcg/month will be prescribed for patients."
62557670|NCT03408639|ACTIVE_COMPARATOR|Eprex®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response. In addition to main intervention, Nephrovit tablet/day and vitamine B12 100 mcg/month will be prescribed for patients.
62557671|NCT02047474|EXPERIMENTAL|Treatment (mFOLFIRINOX)|"NEOADJUVANT THERAPY: Patients receive mFOLFIRINOX comprising oxaliplatin IV over 2 hours, levoleucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously for 46 hours on day 1. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Beginning 3-8 weeks after completion of neoadjuvant therapy patients undergo surgical resection.~ADJUVANT THERARPY: Beginning within 12 weeks after surgery, patients receive mFOLFIRINOX as in neoadjuvant therapy. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
62756586|NCT04206475|ACTIVE_COMPARATOR|standard rehabilitation|physio-kinesis, occupational, speech, and neuropsychology treatments
62756587|NCT06404372|EXPERIMENTAL|Demetech Barbed PDO Suture|Subjects who meet Inclusion/Exclusion criteria will receive treatment with Demetech Barbed PDO Sutures. Fifty-seven subjects will be treated. In addition, up to 2 run-in subjects may be treated with Demetech Barbed PDO Sutures by the investigator to allow the investigator to become familiar with Demetech Barbed PDO Suture characteristics. This run-in cohort will be required to meet all study inclusion/exclusion criteria and will be followed in the same manner as the non-run-in cohort.
62756588|NCT06603064|EXPERIMENTAL|Active then Sham|In this arm, participants will first undergo active theta burst stimulation (cTBS) at the first visit and then undergo sham cTBS in the second visit.
62756589|NCT06603064|EXPERIMENTAL|Sham then Active|In this arm, participants will first undergo sham theta burst stimulation (cTBS) at the first visit and then undergo active cTBS in the second visit.
61986853|NCT01888146|NO_INTERVENTION|Treatment as usual|Patients in this arm will receive care as usual and utilize services as they currently exist in the health plan system.
62379246|NCT06410729||Metastatic mesenteric lymph node enlargement (MLNE)|Lymph nodes with a diameter \> 8 mm on preoperative imaging with metastasis on postoperative pathology were termed metastatic mesenteric lymph node enlargement .
61986854|NCT03575312|EXPERIMENTAL|Enrofloxacin|enrofloxacin by dermal route, by inhalation, oral adminstration
61986855|NCT00629837|EXPERIMENTAL|Arm 1|
61986856|NCT00629837|EXPERIMENTAL|Arm 2|
61986857|NCT00629837|ACTIVE_COMPARATOR|Arm 3|
61986858|NCT00629837|ACTIVE_COMPARATOR|Arm 4|
62756590|NCT06065319||All Comers to Cardiac Rehabilitation|Any participant that is enrolled in cardiac rehabilitation is eligible for this study.
62379247|NCT04437329|EXPERIMENTAL|DNF-N|"1. Induction chemotherapy:~   three cycles of intravenous docetaxel 60 mg/m² on day 1, intravenous nedaplatin 60 mg/m² on day 1, and continuous intravenous fluorouracil 600 mg/m² per day from day 1 to day 5, every 3 weeks~2. Concurrent chemoradiotherapy:~   three cycles of 100 mg/m² nedaplatin every 3 weeks, concurrently with intensity-modulated radiotherapy~3. Radiotherapy: radical intense modulated radiation therapy"
62379248|NCT04437329|ACTIVE_COMPARATOR|DPF-P|"1. Induction chemotherapy:~   three cycles of intravenous docetaxel 60 mg/m² on day 1, intravenous cisplatin 60 mg/m² on day 1, and continuous intravenous fluorouracil 600 mg/m² per day from day 1 to day 5, every 3 weeks~2. Concurrent chemoradiotherapy:~   three cycles of 100 mg/m² cisplatin every 3 weeks, concurrently with intensity-modulated radiotherapy~3. Radiotherapy: radical intense modulated radiation therapy"
62379249|NCT02607865|EXPERIMENTAL|Semaglutide 3 mg|
62379250|NCT02607865|EXPERIMENTAL|Semaglutide 7 mg|
62379251|NCT02607865|EXPERIMENTAL|Semaglutide 14 mg|
62379252|NCT02607865|ACTIVE_COMPARATOR|Sitagliptin 100 mg|
62379253|NCT01310192|EXPERIMENTAL|1|Investigational Imaging Device
62557672|NCT03182933|EXPERIMENTAL|Liposomal bupivacaine group|20ml 1.33% liposomal bupivacaine administered in adductor canal (a type of peripheral nerve block)
62557673|NCT03182933|ACTIVE_COMPARATOR|Standard bupivacaine group|20ml 0.5% standard bupivacaine in adductor canal (a type of peripheral nerve block)
62557674|NCT02276456|EXPERIMENTAL|early follow-up|Follow-up within 7 days after discharge from hospital after having an MI. This will be the early-follow-up or experimental arm.
62557675|NCT02276456|NO_INTERVENTION|standard follow-up|Follow-up appointment within 14-18 days after discharge from hospital after having an MI
62557676|NCT02084225||Course participants|Physicians, nurses and orthopedic officers who staff the emergency intake and orthopedic procedure area of HEAL hospital, Goma DRC, Black Lion Hospital, Addis Ababa and Kindu General Hospital in Kindu DRC. These participants recorded their nerve block intervention over one year for pain management and assessed patient pain level after 10 cc lidocaine.
62557677|NCT02002221|EXPERIMENTAL|Vildagliptin (LAF237)|Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study
62557678|NCT02002221|PLACEBO_COMPARATOR|Placebo|In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study
62557679|NCT01506388|EXPERIMENTAL|folye catheter plus vaginal IMN|intracervical foley catheter plus vaginal IMN
62756591|NCT00559468|EXPERIMENTAL|Sugammadex + Sevoflurane|After receiving sevoflurane and the last dose of rocuronium, at the reappearance of first twitch (T1; 3-10% starting amplitude), a dose of 4.0 mg/kg sugammadex was administered.
62379254|NCT02499172|EXPERIMENTAL|Cohort 1|Cohort 1: Women who were pregnant and received at least one dose of ShancholTM during the mass OCV vaccination campaign.
62379255|NCT02499172|NO_INTERVENTION|Cohort 2|Cohort 2: Women who received at least one dose and who became pregnant after the mass vaccination campaign; hence their fetuses were not exposed to the vaccine.
62379256|NCT02499172|NO_INTERVENTION|Cohort 3|Cohort 3: Women who were pregnant in Chikwawa District at the time of the vaccination campaign in Nsanje District, but who did not receive the vaccine during the campaign.
62557680|NCT01506388|ACTIVE_COMPARATOR|Misoprostol vaginally|intravaginal misoprostol
62557681|NCT03573622|EXPERIMENTAL|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
62557682|NCT03573622|ACTIVE_COMPARATOR|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
62756592|NCT00559468|EXPERIMENTAL|Sugammadex + Propofol|After receiving propofol and the last dose of rocuronium, at the reappearance of first twitch (T1; 3-10% starting amplitude), a dose of 4.0 mg/kg sugammadex was administered.
62756593|NCT03794206|EXPERIMENTAL|Treatment Arm|Single-arm of subjects who receive treatment with Vesair Balloon
62379257|NCT02499172|NO_INTERVENTION|Cohort 4|Cohort 4: Women who become pregnant in Chikwawa District after the vaccination campaign in Nsanje District, and who did not receive the vaccine during the campaign.
62379258|NCT01695928|ACTIVE_COMPARATOR|Extracorporeal shockwave therapy (ESWT)|Active treatment
62379259|NCT01695928|PLACEBO_COMPARATOR|ESWT Placebo|No extracoporeal shockwave therapy
62379260|NCT01369667|ACTIVE_COMPARATOR|vitamin D|Capsule, one taken daily
62379261|NCT01369667|PLACEBO_COMPARATOR|Placebo|Capsule, one taken daily
62379262|NCT04607291|EXPERIMENTAL|Health services research (Witness CARES services) Intervention|Patients who are not prepared for a colonoscopy or stool test receive educational materials, messages, and videos electronically or by mail with information about colorectal screening and are followed up by phone within 2 weeks. Patients desiring colonoscopy, receive navigators assistance with obtaining the screening (e.g.,determining gastrointestinal doctor, scheduling appointment, prep materials and process, transportation, escort). Patients desiring a stool test, receive navigators assistance by facilitating fecal tests.
62557683|NCT06582576||Responders|"Individuals who have a gastric pacemaker for treating gastroparesis and have experienced a substantial or full symptomatic improvement after the implantation."
62379263|NCT04050891|NO_INTERVENTION|group GA (general anesthesia)|"After pre-oxygenation general anesthesia was induced using 2mg/kg propofol, 1μg/kg of fentanyl. After loss of consciousness 0.5 mg/kg of atracurium was injected. The endotracheal tube (ETT) was placed and inflated. The patient was mechanically ventilated to adjust end tidal CO2 between 35 and 40mmHg, anesthesia was maintained using 1.2 % isoflurane diluted in 3L of 50 % oxygen mixed with air. Increments of fentanyl (0.5 μg/kg ) and atracurium 10 mg were used whenever required and the hemodynamic values were maintained within 20% of the basal values.~At the end of surgery, residual muscle relaxant was reversed with 50µg/kg neostigmine and 0.02 mg/kg atropine."
62379264|NCT04050891|ACTIVE_COMPARATOR|group RA (regional anesthesia)|received combined supraclavicular and interscalene block.The mixture of anesthetic suolution was prepared by 20 ml isobaric bupivacaine 0.5% plus 10ml lidocaine 2% plus 10ml normal saline, total volume was 40ml which is devided into 25ml for suraclavicular block and 15ml for intersalene block
62379265|NCT01173328|EXPERIMENTAL|Pursed-lip Breathing|
62379266|NCT04022304|EXPERIMENTAL|Sequence: Humulin® N- Biocon Insulin N-Humulin® N|"Period 1: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
62379267|NCT04022304|EXPERIMENTAL|Sequence: Biocon Insulin N- Humulin® N- Humulin® N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Humulin® N(100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
62379268|NCT04022304|EXPERIMENTAL|Sequence: Humulin® N- Humulin® N-Biocon Insulin N|"Period 1: 0.4 IU/kg of Humulin® N(100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
62379269|NCT04022304|EXPERIMENTAL|Sequence: Biocon Insulin N- Humulin® N- Biocon Insulin N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
62379270|NCT04022304|EXPERIMENTAL|Sequence: Humulin® N-Biocon Insulin N- Biocon Insulin N|"Period 1: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
62379271|NCT04022304|EXPERIMENTAL|Sequence: Biocon Insulin N- Biocon Insulin N-Humulin® N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
62379272|NCT02169466|EXPERIMENTAL|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
62379273|NCT02169466|EXPERIMENTAL|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
62379274|NCT02169466|EXPERIMENTAL|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
62379275|NCT02169466|EXPERIMENTAL|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
62379276|NCT03999333|EXPERIMENTAL|Virtual Reality|Every participant is provided with a VR headset
62379277|NCT01865136|OTHER|Medical Post Abortion Care by Midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
62379278|NCT01865136|NO_INTERVENTION|Medical Post Abortion Care by physician|Women with incomplete abortion is diagnosed and treated with misoprostol by physician
62557684|NCT06582576||Non-responders|"Individuals who have a gastric pacemaker for treating gastroparesis and answered have experienced some or none symptomatic improvement after the implantation."
62557685|NCT04389229|EXPERIMENTAL|UTIL-01|Single dose autologous unmodified tumour infiltrating lymphocytes
62557686|NCT04389229|EXPERIMENTAL|CoTIL-01|Single dose autologous gene modified tumour infiltrating lymphocytes
62557687|NCT06329739||Experimental group|Parkinson's Disease patients with genetic mutation
62557688|NCT06329739||Control group|Parkinson's Disease patients without genetic mutation
62379279|NCT03908866|EXPERIMENTAL|PICC(Peripherally inserted central catheter)|Patients randomly assigned to receive a peripherally inserted central catheter(PICC).
62557689|NCT04367779||A : High Grade Sarcoma|Pediatric and adult patients with High Grade Sarcoma treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
62379280|NCT03908866|ACTIVE_COMPARATOR|CVC(Central venous catheter )|Patients randomly assigned to receive a centrally inserted central venous catheter(CVC).
62379281|NCT06446830|EXPERIMENTAL|vitamin B|"oral vitamin B complex tablets preoperative and continue post-operative for 2 days One tablet oral once daily for 1- 2 days according to the length of stay; the tablet is a vitamin (B1, B6, B9, and B12).~Oral daily vitamin B concentration; Tablet is composed of ; B1= 250mg, B6= 150 mg, B12= 0,250 mg, B9= 0.5mgm, B2 15 mg standard analgesic ladder will be implemented in the form of; Paracetamol 1gram (2 tablets) / 8hr for 48 hours, Ketorolac 30 mg / 12 hour for 48 hours. Any pain will be treated appropriately with nalbuphine till the patient is comforted, and the total dose will be documented.~the routine ladder of paracetamol and ketorolac will be modified according to organ functions and the presence of any contraindication for usage"
62379282|NCT06446830|ACTIVE_COMPARATOR|standard|"patients will receive a preoperative; Oral placebo tablet (once/day) Post-operative and continue post-operative for 2 days; One placebo capsule oral once daily for 2 days. standard analgesic ladder will be implemented in the form of; Paracetamol 1 gram (2 tablets) / 8hr for 48 hours. Ketorolac / 12 hours for 48 hours. Any pain will be treated appropriately with nalbuphine till the patient is comforted, and the total dose will be documented.~the routine ladder of paracetamol and ketorolac will be modified according to organ functions and the presence of any contraindication for usage"
62379283|NCT01263405||Normal|normal volunteers without sarcoma
62379284|NCT01263405||Sarcoma|Sarcoma
62557690|NCT04367779||B : Brain tumors|Pediatric and adult patients with Brain Tumors treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
62756594|NCT00387413|EXPERIMENTAL|Treatment Arm A1|In treatment Arm A1 Period 1 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. In treatment Arm A1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2.
62557691|NCT04367779||C : Meningioma|Pediatric and adult patients with Meningioma treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
62557692|NCT00495391|ACTIVE_COMPARATOR|1|Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if \<75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
62756595|NCT00387413|EXPERIMENTAL|Treatment Arm A2|In treatment Arm A2 Period 1 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. In treatment Arm A2 Period 2 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. There will be a washout of approximately one week between periods 1 and 2.
62379285|NCT01118884|EXPERIMENTAL|sedation|20 healthy uncooperative children aged 36-96 months were examined in a cross-over study design , each patient served as his/her own control. Each patient was assigned randomly to received 1 of 2 drug regimens for initial sedation session and the other regimen administered at second session which was one week later.
62379286|NCT03108742|EXPERIMENTAL|dermal stapler|
62379287|NCT03108742|ACTIVE_COMPARATOR|classic intradermal suture|
62379288|NCT05375838|EXPERIMENTAL|mRNA-1273 Plus Placebo|Participants will receive 2 intramuscular (IM) injections, one in each arm, of mRNA-1273 plus placebo at the specified dose level on Day 1.
62379289|NCT05375838|EXPERIMENTAL|mRNA-1010 Plus Placebo|Participants will receive 2 IM injections, one in each arm, of mRNA-1010 plus placebo at the specified dose level on Day 1.
62379290|NCT05375838|EXPERIMENTAL|mRNA-1010 Plus mRNA-1273|Participants will receive 2 IM injections, one in each arm, of mRNA-1010 plus mRNA-1273 at the specified dose level on Day 1.
62379291|NCT05375838|EXPERIMENTAL|Dose A: mRNA-1073 Plus Placebo|Participants will receive 2 IM injections, one in each arm, of mRNA-1073 plus placebo at the specified dose level on Day 1.
62557693|NCT00495391|PLACEBO_COMPARATOR|2|Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if \<75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
62557694|NCT05800886|EXPERIMENTAL|Tea Group|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of tea within 15 minutes. Patients were supported by the investigator for early mobilization from the 4th hour after surgery.
62379292|NCT05375838|EXPERIMENTAL|Dose B: mRNA-1073 Plus Placebo|Participants will receive 2 IM injections, one in each arm, of mRNA-1073 plus placebo at the specified dose level on Day 1.
62756596|NCT00387413|EXPERIMENTAL|Treatment Arm B1|In treatment Arm B1 Period 1 subject will receive 30 milligram (mg) Duloxetine plus GSK189254 Placebo in Week 1, in Week 2 60 mg Duloxetine plus GSK189254 Placebo and in Week 3 30 mg Duloxetine plus GSK189254 Placebo. In treatment Arm B1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2.
62756597|NCT00387413|EXPERIMENTAL|Treatment Arm B2|In treatment Arm B2 Period 1 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. In treatment Arm B2 Period 2 subject will receive 30 milligram (mg) Duloxetine plus GSK189254 Placebo in Week 1, in Week 2 60 mg Duloxetine plus GSK189254 Placebo and in Week 3 30 mg Duloxetine plus GSK189254 Placebo. There will be a washout of approximately one week between periods 1 and 2.
62756598|NCT04666831|EXPERIMENTAL|AMI and CBT Intervention|Participants will receive four weekly sessions of individual therapy (60 minutes) with a graduate student therapist over videoconferencing technology or telephone. The intervention combines Adapted Motivational Interviewing (AMI) and Cognitive Behavioural Therapy (CBT) techniques for food addiction. Participants will complete questionnaires at baseline, postintervention or 1-month postbaseline, and 2- and 4-months postbaseline.
62379293|NCT05375838|EXPERIMENTAL|Dose C: mRNA-1073 Plus Placebo|Participants will receive 2 IM injections, one in each arm, of mRNA-1073 plus placebo at the specified dose level on Day 1.
62379294|NCT03407027|EXPERIMENTAL|Quadratus triamcinolone|Quadratus lumborum muscle and fascia infiltration with 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
62379295|NCT03407027|EXPERIMENTAL|Gluteus triamcinolone|Gluteus maximus and fascia infiltration with 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
62379296|NCT03407027|ACTIVE_COMPARATOR|Quadratus without triamcinolone|Quadratus lumborum muscle and fascia infiltration with 10ml of levobupivacaine 0,25%.
62379297|NCT02710422|EXPERIMENTAL|Arm 1 - Amniotic Membrane Placement|Participants who receive the human amniotic membrane placement after robotic assisted radical prostatectomy (RARP). Participants will also undergo PSA measurement and complete the EPIC 26 and Sexual History Inventory for Men (SHIM) psychosocial questionnaires at protocol-defined intervals.
62379298|NCT02710422|OTHER|Arm 2 - No Amniotic Membrane Placement|Participants who do not receive human amniotic membrane placement after robotic assisted radical prostatectomy (RARP). Participants will also undergo PSA measurement and complete the EPIC 26 and Sexual History Inventory for Men (SHIM) psychosocial questionnaires at protocol-defined intervals.
62379299|NCT04782492|EXPERIMENTAL|Y-composite graft|The saphenous vein is anastomosed to the middle portion of the left internal thoracic artery as Y-composite fashion. Then, left anterior descending artery, if targeted, is bypassed with left internal thoracic artery. Other native coronary arterial targets are bypassed with saphenous vein graft.
62379300|NCT04782492|ACTIVE_COMPARATOR|aortocoronary conduit|The saphenous vein is anastomosed to the ascending aorta as aortocoronary fashion. Then, left anterior descending artery, if targeted, is bypassed with left internal thoracic artery. Other native coronary arterial targets are bypassed with saphenous vein graft.
62379301|NCT02019992||sepsis|sepsis defined as suspected infection and systemic inflammatory response
62379302|NCT02019992||severe sepsis|sepsis with organ dysfunction or septic shock defined as sepsis plus hypotension
62379303|NCT02019992||control group|control defined as non-infected patients without systemic inflammatory response.
62379304|NCT04321590|EXPERIMENTAL|3 g 35% beta-glucan|Supplement containing 3 g of 35% oat beta-glucan
62379305|NCT04321590|EXPERIMENTAL|5 g 35% beta-glucan|Supplement containing 5 g of 35% oat beta-glucan
62379306|NCT04321590|EXPERIMENTAL|3 g 70% beta-glucan|Supplement containing 3 g of 70% oat beta-glucan
62557695|NCT05800886|EXPERIMENTAL|Coffee Group|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of coffee within 15 minutes. Patients were supported by the investigator for early mobilization from the 4th hour after surgery.
62557696|NCT05800886|EXPERIMENTAL|Warm Water Group|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of warm water within 15 minutes. Patients were supported by the investigator for early mobilization from the 4th hour after surgery.
62557697|NCT05800886|ACTIVE_COMPARATOR|Control Group|The first mobilization and oral intake of the patients in the control group started at the 8th hour. Control group didn't receive any intervention. Participants received usual care from health professionals.
62756599|NCT04666831|NO_INTERVENTION|Waitlist Control|Participants will complete questionnaires at baseline, 1-month postbaseline, and 2- and 4-months postbaseline (at timepoints comparable to the intervention arm). They will not receive any intervention during this time. Following the 3-month waitlist, they will cross over into the same procedure as the intervention arm.
62756600|NCT00076336|EXPERIMENTAL|Telbivudine 600 mg|Participants received Telbivudine 600 mg and a matching lamivudine placebo orally once a day for up to 104 weeks. Participants were followed-up for 16 weeks post-treatment.
62756601|NCT00076336|ACTIVE_COMPARATOR|Lamivudine 100 mg|Lamivudine 100 mg and a Telbivudine matching placebo orally once a day for up to 104 weeks. Participants were followed-up for 16 weeks post-treatment.
62756602|NCT02163720||Yondelis®-Caelyx®-relapse ovarian cancer|Yondelis®-Caelyx®-relapse ovarian cancer
62756603|NCT01238835|EXPERIMENTAL|TAVR-TA|Transcatheter valve replacement with transapical access
62756604|NCT05710211|EXPERIMENTAL|CLONEMF cohort|
62756605|NCT03396679||CASPAR criteria agreement|PsA patients fulfilling CASPAR criteria in remission as determined by physician with patient and physician's global assessment of disease activity in agreement compare to Ultrasound examination
62756606|NCT03396679||CASPAR criteria disagreement|PsA patients fulfilling CASPAR criteria in remission as determined by physician with patient and physician's global assessment of disease activity in disagreement compare to Ultrasound examination
62756607|NCT04346108|EXPERIMENTAL|Epoch 1: IGIV 200-600 mg/kg|Participants received 200 to 600 mg/kg of Immunoglobulin Intravenous (IGIV) infusion for every 3 or 4 weeks for up to 13 weeks.
62756608|NCT04346108|EXPERIMENTAL|Epoch 2: IGSC (20%) 50-200 mg/kg|Participants who entered to Epoch 2 from Epoch 1 received 50-200 mg/kg of Immune Globulin Subcutaneous (Human) 20% infusion once a week up to approximately 24 weeks after Epoch 1.
62756609|NCT04346108|EXPERIMENTAL|Epoch 3: IGSC (20%) 100-400 mg/kg|Participants who entered to Epoch 3 from Epoch 1 received 100-400 mg/kg of Immune Globulin Subcutaneous (Human) 20% infusion biweekly up to approximately 12 weeks after Epoch 2.
62756610|NCT03436875||Healthy|Healthy people either with (FH+) or without (FH-) a family history of diabetes or Alzheimer's Disease.
62756611|NCT03436875||unhealthy|People type 2 diabetes or Alzheimer's Disease that have either: a family history of that disease (FH+) or no family history of T2D or Alzheimer's for two generations (FH-).
62756612|NCT03865667||Primary Total Hip Arthroplasty|Single-arm, single-center, prospective follow-up study with consecutively enrolled newly or previously implanted subjects with the PROFEMUR® Preserve Femoral Stem(s) and CoCr (cobalt-chromium) Modular Neck combined with other Wright Medical Technologies (WMT) or MPO (MicroPort) THA (Total Hip Arthroplasty) components including acetabular shells, acetabular liners and femoral heads.
62756613|NCT05357664|EXPERIMENTAL|Total Hip Arthroplasty|Pinnacle acetabular shells used with PINNACLE DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
62756614|NCT05357664|EXPERIMENTAL|Revision Total Hip Arthroplasty|Pinnacle acetabular shells used with Pinnacle DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
62756615|NCT02139735|EXPERIMENTAL|Ultrasound|3 MHz (Mega Hertz) ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ (Temporomandibular joint) and masseter muscles bilaterally
62756616|NCT02139735|EXPERIMENTAL|Ultrasound associated with stretchting|"3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally.~Active stretching of the masseter muscles with mouth opening and closed lips"
62756617|NCT02139735|EXPERIMENTAL|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
62756618|NCT04713904|EXPERIMENTAL|Clormadinone Ethinyl estradiol Test Product|
62557698|NCT02476019|EXPERIMENTAL|ISIS-FGFR4RX|ISIS-FGFR4RX administered subcutaneously
62756619|NCT04713904|ACTIVE_COMPARATOR|Clormadinone Ethinyl estradiol Reference Product|
62756620|NCT01229072|EXPERIMENTAL|1|Heparin Blausiegel
62756621|NCT01229072|ACTIVE_COMPARATOR|2|Liquemine
62756622|NCT03292419|OTHER|Topography guided LASI|
62756623|NCT04709016||male or transgender patients|of sexual orientation MSM (men having sex with men) or bi-sexual, consultant in sexual health centers
62756624|NCT03150576|ACTIVE_COMPARATOR|Control|4 cycles of: Paclitaxel 80mg/m2 Day 1, 8 \& 15, every 3 weeks, Carboplatin area under the curve (AUC) 5 Day 1, every 3 weeks
62756625|NCT03150576|EXPERIMENTAL|Research 1|4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 \& 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day -2 to Day 10 every 3 weeks
62756626|NCT03150576|EXPERIMENTAL|Research 2|4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 \& 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day 3 to Day 14 every 3 weeks
62379307|NCT04321590|EXPERIMENTAL|5 g 70% beta-glucan|Supplement containing 5 g of 70% oat beta-glucan
62379308|NCT03928509||Estrie CIUSSS|Subjects from the Estrie's Integrated Health and Social Services Centre
62379309|NCT03928509||Saguenay-Lac-Saint-Jean CIUSSS|Subjects from the Saguenay-Lac-Saint-Jean's Integrated Health and Social Services Centres
62557699|NCT02476019|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously
62557700|NCT06577805||grafts with a single artery (GSA)|recipients of grafts with a single artery undergoing living donor robotic-assisted kidney transplantation
62379310|NCT00653692||Observational|Poly drug dependent women
62379311|NCT04719533|EXPERIMENTAL|Pre-marked episiotomy location|Women in this group will undergo pre-marking of episiotomy location
62557701|NCT06577805||grafts with multiple single arteries (GMA)|recipients of grafts with multiple renal arteries undergoing living donor robotic-assisted kidney transplantation
62756627|NCT05055258|EXPERIMENTAL|300 mg KVD824|300 mg KVD824 twice a day for 12 weeks
62379312|NCT04719533|NO_INTERVENTION|No pre-marked episiotomy location|Women in this group will not undergo pre-marking of episiotomy location
62379313|NCT00172003|EXPERIMENTAL|Zoledronic acid|Zoledronic acid, dosage according to calculated creatinine clearance, administered as a 15 minute infusion every 3 weeks for 12 months. Study infusion visits should occur not earlier than the scheduled visit and no later than 3 days after the scheduled visit. The dose of zoledronic acid in patients with baseline creatinine clearance \> 60 mL/min was recommended to be 4 mg infused over no less than 15 minutes.
62379314|NCT01406730|EXPERIMENTAL|exercise|16 weeks of running exercise
62379315|NCT01406730|NO_INTERVENTION|control|
62379316|NCT04787835|EXPERIMENTAL|Forearm Nerve Block|Patients will receive a nerve block of the radial, median, and ulnar nerves at the level of the forearm using 1% lidocaine with epinephrine. The lidocaine will be injected subcutaneously, using a total dose of less than 7mg per kilogram.
62379317|NCT04787835|ACTIVE_COMPARATOR|Local Anesthetic Infiltration|Patients will receive local anesthetic infiltration, using 1% lidocaine with epinephrine, to the fracture site and surrounding tissue. No nerve blocks will be performed. The lidocaine will be injected subcutaneously, using a total dose of less than 7mg per kilogram.
62379318|NCT04882124|EXPERIMENTAL|CSJ117 8mg|Intervention: Drug: CSJ117
62379319|NCT04882124|EXPERIMENTAL|CSJ117 4mg|Intervention: Drug: CSJ117
62379320|NCT04882124|PLACEBO_COMPARATOR|CSJ117 Placebo|Intervention: Drug: Placebo
62379321|NCT05656131|EXPERIMENTAL|fluzoparib|Fluzoparib: 150 mg twice daily (morning and evening) for 21 consecutive days as a cycle until disease progression or intolerance.
62379322|NCT05656131|EXPERIMENTAL|fluzoparib+Camrelizumab|"Fluzoparib: 150 mg twice daily (morning and evening) for 21 consecutive days as a cycle until disease progression or intolerance.~Camrelizumab: 200 mg IV drip over approximately 30 minutes (no less than 20 minutes and no more than 60 minutes) on Day 1 of each 3-week treatment cycle until disease progression or intolerance."
62379323|NCT06317415|EXPERIMENTAL|Intervention group|
62379324|NCT06317415|PLACEBO_COMPARATOR|control group|
62379325|NCT03228836|EXPERIMENTAL|Sintilimab (IBI308)|
62379326|NCT02526537||Gefitinib|Stage IB NSCLC Patients with high risk factors and EGFR gene sensitive mutation who can not tolerate or decline chemotherapy and choose Gefitinib for postoperative therapy (Gefitinib 250 mg daily for 2 years).
62379327|NCT02526537||Non-specific treatment|Stage IB NSCLC Patients with high risk factors and EGFR gene sensitive mutation who can not tolerate or decline chemotherapy and choose Non-specific treatment.(Chinese herbal medicine and nonspecific immunomodulators as adjuvant anti-cancer treatment for 2 years).
62379328|NCT01807676|ACTIVE_COMPARATOR|ET View Double Lumen Tube|Patients assigned to the thisgroup will be intubated using the VivaSight-DL.
62379329|NCT01807676|ACTIVE_COMPARATOR|conventional Double Lumen Tube|Patients assigned to the first group will be intubated using conventional DLT (Bronchocath, left sided; Rüsch, Kernen, Germany).
62379330|NCT05744830|EXPERIMENTAL|Overdenture|Each patient in this group will receive a single implant overdenture.
62379331|NCT05744830|EXPERIMENTAL|Complete Denture|Each patient in this group will receive a removable complete denture without implants.
62379332|NCT00517725|ACTIVE_COMPARATOR|Carvedilol|
62379333|NCT00517725|ACTIVE_COMPARATOR|Bisoprolol|
62379334|NCT00517725|ACTIVE_COMPARATOR|Nebivolol|
62379335|NCT06161233|EXPERIMENTAL|CAPABLE cohort|Group that receives the CAPABLE mobile application and a smartwatch during treatment
62379336|NCT01521351||carotid thermal heterogeneity|Patients that have carotid thermal heterogeneity detected by MR
62379337|NCT01521351||no carotid thermal heterogeneity|Patients that DONT have carotid thermal heterogeneity detected by MR
62379338|NCT01521351||carotid artery disease|Patients with detected carotid artery disease by ultrasound
62756628|NCT05055258|EXPERIMENTAL|600 mg KVD824|Two 300 mg KVD824 tablets twice a day for 12 weeks
62756629|NCT05055258|EXPERIMENTAL|900 mg KVD824|Three 300 mg KVD824 tablets twice a day for 12 weeks
62756630|NCT05055258|PLACEBO_COMPARATOR|Placebo to KVD824|One, two or three placebo tablets to be taken twice a day for 12 weeks
62379339|NCT01521351||no carotid artery disease|Patients with no carotid artery disease detected by ultrasound
62557702|NCT03379337|EXPERIMENTAL|Dental imaging|4 incisors and 4 canine teeth of subjects were imaged with the experimental and the commercial device.
62756631|NCT01327274|EXPERIMENTAL|Treatment Arm|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI \> 3.5) will undergo the interventional treatment arm by having outpatient surgery and the Magnetic MIni-Mover Magnimplant procedure is performed during which the magnetic implant is surgically placed. After 2 years of treatment with the implanted magnet and brace treatment, the Magnetic Mini-Mover Magnimplant will be explanted. After surgery and recovery, all subjects will be fitted for an orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo 3MP treatment for 18-24 months, enough to attempt to improve their PSI (\< 3.25).
62379340|NCT03229876|EXPERIMENTAL|CD19-UCART|All patients will be treated with 1 injection of CD19-UCART. Three escalating dose-levels (1.0-2.0x10\^6/kgBW, 2.5-5.0x10\^6/kgBW, 5.5-10.0x10\^6/kgBW) of CD19-UCART will be evaluated using a 3+3 design. Each CD19-UCART injection will be administered at Day 0.
62756632|NCT06190938||The relation between diabetes, its neurological and optical complications with hearing loss|
62557703|NCT04582032|ACTIVE_COMPARATOR|Dexketoprofen group,|IV cannulation was performed on hand dorsum or brachial and canulation place was recorded. Patients allocated in dexketoprofen group were administered intravenous dexketoprofen (50 mg/2ml) and 0,3 mg/kg midazolam 10 minutes prior to general anesthesia induction
62756633|NCT05024929||Prospective Cohort|Patients with differentiated thyroid cancer for whom oncogene-specific targeted therapy is planned from commercial supply or as part of a separate therapeutic trial
62756634|NCT05024929||Data Sharing Cohort|Patients with differentiated thyroid cancer enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing
62756635|NCT01389401||reflux laryngitis group pre-treatment|adults with clinical suspicion of Reflux Laryngitis confirmed by 24-hour double probe esophageal monitoring who have not made use of any treatment in the past 15 days.
62756636|NCT01389401||study group - post treatment|adults with reflux laryngitis after 16 weeks of treatment with proton pump inhibitor (omeprazole 40 mg twice a day)and dietary/lifestyle changes that present improvement in symptoms and video laryngoscopic signs of chronic laryngitis
62756637|NCT01389401||control group|healthy controls paired by gender and age that do not present symptoms and videolaryngoscopic signs suggestive of reflux laryngitis
62756638|NCT03159689|EXPERIMENTAL|Mixed Tree Nuts|a hypo caloric weight loss dietary plan with mixed tree nuts
62756639|NCT03159689|ACTIVE_COMPARATOR|Pretzels|a hypo caloric weight loss dietary plan with pretzels
62756640|NCT02129478|EXPERIMENTAL|Olanzapine|
62756641|NCT00387374|EXPERIMENTAL|Stratum I (radiotherapy, bevacizumab, chemotherapy)|Patients undergo prophylactic radiotherapy on days 1-5 and 8-12. Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 15. Patients also receive paclitaxel IV over 3 hours or carboplatin IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 36 (course 2).
62756642|NCT00387374|EXPERIMENTAL|Stratum II (radiotherapy, chemotherapy, bevacizumab)|Patients undergo prophylactic radiotherapy and receive paclitaxel and carboplatin as in stratum I. Patients also receive bevacizumab IV over 30-90 minutes on day 15 (course 1). In both strata, treatment with paclitaxel, carboplatin, and bevacizumab repeats every 21 days for 5-6 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response or stable disease may continue to receive single-agent bevacizumab every 21 days in the absence of disease progression or unacceptable toxicity.
62756643|NCT05618730|EXPERIMENTAL|EXP-TC punctal plug together with artificial tears|EXP-TC: A punctal plug as a delivery system for Tacrolimus. EXP-TC has 3 different sizes (Small, Medium and Big for Wide EXP-TC)
62756644|NCT05618730|ACTIVE_COMPARATOR|Artificial tears|Preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories)
62756645|NCT02390414||Gets HSCT|Patients with higher-risk myelodysplastic syndrome (MDS) aged 60-75 who are fit for HSCT and actually undergo HSCT.
62756646|NCT02390414||No HSCT|Patients with higher-risk myelodysplastic syndrome (MDS) aged 60-75 who are fit for HSCT but do not undergo HSCT.
62756647|NCT04607941||Cases|Subjects diagnosed as positive for SARS-CoV-2 infection
62756648|NCT04607941||Close Subjects|"Subjects living within the same household as cases:~* close cases if tested positive for SARS-CoV-2 following contact tracing recommendations~* close controls if tested negative for SARS-CoV-2 following contact tracing recommendations"
62756649|NCT04607941||Control Subjects|Controls selected within the population to allow for an age, gender and location of residence-matched analysis with cases
62379341|NCT05819424|EXPERIMENTAL|Placebo intervention first and Active intervention one week later|Participants will be consuming a placebo on a clinic day at least one week prior to a clinic day where they will consume the active intervention.
62379342|NCT05819424|EXPERIMENTAL|Active intervention first and Placebo intervention one week later|Participants will be consuming active intervention on a clinic day at least 1 week prior to a clinic day where they will consume the placebo.
62756650|NCT00929773|ACTIVE_COMPARATOR|Erchonia PL2000 Laser|Low level laser light energy comprised of 1 milliWatts (mW) of red light (635 nm).
62756651|NCT00929773|PLACEBO_COMPARATOR|Placebo laser|inactive light
62756652|NCT02502604|EXPERIMENTAL|Goal Management Training|Participants in this arm of the study will attend GMT sessions, which will be administered weekly over a nine-week period following a script with accompanying slides and participant workbooks.
62756653|NCT02502604|NO_INTERVENTION|Wait List Control|Participants in this category will be placed on a wait-list to receive goal management training following completion of their study participation.
62756654|NCT06242639||metal-ceramic FPD|
62756655|NCT04214483||Diagnosis of Acne|Patients who have been diagnosed with acne, subdivided into the various types.
62756656|NCT04707989|EXPERIMENTAL|Ketone-Promoting Food Ingredient 1|Novel ketone-promoting food ingredient (#1) administered in a beverage once daily for 28 days.
62379343|NCT03611946|EXPERIMENTAL|rZIKV/D4Δ30-713 (10^3)|Participants will receive a single dose of rZIKV/D4Δ30-713 at study entry (Day 0).
62379344|NCT03611946|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
62379345|NCT03611946|EXPERIMENTAL|rZIKV/D4Δ30-713 (10^4)|Participants will receive a single dose of rZIKV/D4Δ30-713 or placebo at study entry (Day 0).
62379346|NCT04022590|EXPERIMENTAL|E-clothes|The participants with E-clothes do aerobic training at home
62379347|NCT04022590|ACTIVE_COMPARATOR|Home exercise|The participants with healthy consultation do aerobic training at home.
62379348|NCT02347202|EXPERIMENTAL|Online counseling via Zoom teleconferencing|Each participant will be assigned a random number which is linked to group assignment. The numbers will be assigned consecutively to participants as they enroll. All caregivers in the treatment group will receive 6 counseling sessions in 4 months, using teleconferencing. The first session will be an individual session. The caregiver will be asked to select family members to participate in the next 4 sessions. The 4 family sessions will be followed by another individual session with the spouse/partner caregiver. The counselor will send the primary caregiver an email to be forwarded to family members with instructions on how to access the TTDC training on using the teleconferencing technology. All caregivers in the control group will be able to call the counselor for resource information and support.
62379349|NCT02347202|OTHER|Telephone support as needed|All caregivers in the control group will be able to call the counselor for resource information and support as needed.
62379350|NCT05604911||Kidney transplant patients|
62379351|NCT01633775||Ahmed glaucoma implant|
62379352|NCT01633775||Trabeculectomy with mitomycin C (MMC)|
62379353|NCT03422757|EXPERIMENTAL|adaptive DBS|adaptive Deep Brain Stimulation, by AlphaDBSvext.
62379354|NCT03422757|ACTIVE_COMPARATOR|conventional DBS|conventional Deep Brain Stimulation, by AlphaDBSvext.
62379355|NCT00805649|EXPERIMENTAL|1|eyes with predominately classic lesions
62379356|NCT00805649|EXPERIMENTAL|2|eyes with occult lesions
62379357|NCT02258841|EXPERIMENTAL|Personalized online Safety Decision Aid|Setting priorities for safety; Danger Assessment; Personalized Action Plan
62379358|NCT02258841|ACTIVE_COMPARATOR|General Online Risk/Safety Information|General Risk and Safety Information; Basic Emergency Safety Plan
62379359|NCT03721549|EXPERIMENTAL|Moderate Dose Inoculum|Moderate dose of Norwalk GI.1 Virus, 3.6x10\^5 genome copies
62379360|NCT03721549|EXPERIMENTAL|Higher Dose Inoculum|Higher dose of Norwalk GI.1 Virus, 1x10\^6 genome copies
62379361|NCT05613192|ACTIVE_COMPARATOR|Placebo|Group 1: patients receive the standard conventional therapy in addition to placebo for 4 months.
62379362|NCT05613192|EXPERIMENTAL|Cholecalciferol|Group 2: patients receive the standard conventional therapy in addition to a single oral dose of cholecalciferol 300,000 IU followed by oral cholecalciferol 800 IU daily for 4 months.
62379363|NCT04011137|NO_INTERVENTION|Control|No exercise - 30-min of rest
62379364|NCT04011137|EXPERIMENTAL|High-intensity interval training|8 x 60 s intervals at 70% peak power output (intersperesed with 60 s recovery intervals at 10% peak power output)
62756657|NCT04707989|PLACEBO_COMPARATOR|Ketone Free Placebo|Beverage matched for appearance, volume, taste and texture to experimental arm (ketone promoting food ingredient #1) that does NOT contain a ketone ingredient. Consumed once daily for 28 days.
62379365|NCT04011137|EXPERIMENTAL|Moderate-intensity continous training|25 min at 45% peak power output
62379366|NCT02847000|EXPERIMENTAL|Decitabine + Tetrahydrouridine|Tetrahydrouridine (THU) is supplied as 250 mg/capsule, Decitabine (Dec) as 5 mg/capsule.
62379367|NCT02565576|ACTIVE_COMPARATOR|CFZ533|CFZ533
62379368|NCT02565576|PLACEBO_COMPARATOR|Placebo|Placebo
62379369|NCT01158885|EXPERIMENTAL|Single Arm|"A maximum of two courses of the following regimen will be administered.~* Clofarabine: 20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.~* Cytarabine intravenous: 1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.~* Methotrexate: to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age.~* Intrathecal (IT) cytarabine: is optional for acute myelogenous leukemia (AML) patients."
62379370|NCT03194672|EXPERIMENTAL|Intervention Condition|"This experimental condition has three major components:~1. Individual sessions: Roughly 12 90-minute sessions over 3 months Prenatal sessions covering contraceptive options, including long-acting reversible contraception. Prenatal and postnatal sessions will also cover (a) financial benefits of smoking cessation; (b)financial literacy/budgeting skills based upon selected components of the Money Matters curriculum; (c) establishing concrete steps to reach educational/career goals; (d) healthy eating habits; and (e) importance of HPV vaccinations and getting a medical home.~2. Transportation assistance for medical home appointments.~3. Electronic Prompts/Reminders to Encourage Completion of Goals."
62379371|NCT03194672|NO_INTERVENTION|Treatment as Usual Control Condition|"The comparison group will be a Usual Care control group. The control group will have access to standard medical and behavior health services as part of routine care. Prior to randomization, each enrolled participant will receive a listing of contact information for organizations offering this routine care.~The only interaction the HAT providers will have with control group participants is to have periodic and brief phone conversations in which updated changes in contact information will be collected. The HAT providers will also obtain updated changes in contact information for HAT intervention group participants."
62379372|NCT03151772|EXPERIMENTAL|Disulfiram|Disulfiram 200 mg twice daily and copper 2,5 mg once daily. For bioavailability purpose only, treatment is withdrawn postoperatively
62379373|NCT03151772|EXPERIMENTAL|Metformin|Metformin 850 mg x 3 daily. For bioavailability purpose only, treatment is withdrawn postoperatively
62557704|NCT04582032|OTHER|Saline group|IV cannulation was performed on hand dorsum or brachial and canulation place was recorded. Patients allocated in control group were administered intravenous 2 ml of saline and 0,3 mg/kg midazolam 10 minutes prior to general anesthesia induction
62756658|NCT04707989|ACTIVE_COMPARATOR|Ketone-Promoting Food Ingredient 2|Previously characterized ketone-promoting food ingredient (#2) administered in a beverage once daily for 28 days.
62756659|NCT03350139||Patients treated with gamma knife radiosurgery|Collection of non-genetic, chronobiological, therapeutic and co-morbidities
62756660|NCT02144506|EXPERIMENTAL|T&E|"Home-based exercises program T\&E.This exercise program proposes 50 exercises with a booklet, cards and an electronic tablet. The participants choose their exercises on the basis of a rating scale of perception of exercise difficulty."
62557705|NCT04191811||Depression Internet-delivered CBT|12 weeks of guided internet-delivered CBT for depression.
62557706|NCT04191811||Insomnia Internet-delivered CBT|12 weeks of guided internet-delivered CBT for insomnia.
62557707|NCT04191811||Social Anxiety Internet-delivered CBT|12 weeks of guided internet-delivered CBT for social anxiety.
62756661|NCT02144506|ACTIVE_COMPARATOR|OTAGO|"Programm OTAGO is a home-based exercises program."
62557708|NCT01061593|EXPERIMENTAL|ATT+Immunoxel|TB patients with DS-TB, MDR-TB, XDR-TB or TB-HIV on standard ATT + Immunoxel honey lozenge once per day day
62756662|NCT01504633|EXPERIMENTAL|DHA+EPA Group|DHA/EPA capsule (100mg DHA + 20mg) and placebo syrup per day
62756663|NCT01504633|EXPERIMENTAL|Fe Group|Placebo capsule and Fe syrup (16mg elemental iron) per day
62756664|NCT01504633|EXPERIMENTAL|DHA/EPA+Fe Group|DHA/EPA capsule (100mg DHA + 20mg) and Fe syrup (16mg elemental iron) per day
62756665|NCT01504633|EXPERIMENTAL|Placebo Group|Placebo capsule and placebo syrup
62756666|NCT00445848|EXPERIMENTAL|Erlotinib and Bevacizumab|
62756667|NCT02608775|EXPERIMENTAL|Metrodoloris Medical System|Application of a skin electrode
62756668|NCT02608775|ACTIVE_COMPARATOR|Aisys® care station, Acertys|SPI calculated from photoplethysmography
62756669|NCT01867840||arthritis|
62756670|NCT04882644|EXPERIMENTAL|Aerobic Exercise Intervention Group|The subjects receive an intensive aerobic exercise for 3 months and a health education content for 12 months.
62756671|NCT04882644|NO_INTERVENTION|Control Group|The subjects do not change their physical activity routine and receive a health education content for 12 months.
62756672|NCT03197428|EXPERIMENTAL|PRP group|15 patients will receive platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
62756673|NCT03197428|PLACEBO_COMPARATOR|Control group|15 patients will receive whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
62756674|NCT02111135|EXPERIMENTAL|Group 1|b-OPV, m-IPV HD and m-OPV2
62557709|NCT01061593|PLACEBO_COMPARATOR|ATT+Placebo|TB patients with DS-TB, MDR-TB, XDR-TB or TB-HIV on standard ATT + Placebo lozenge made of corn syrup once/day
62557710|NCT02423200|EXPERIMENTAL|VX-745 dose level 1|Active Group 1: VX-745 dose level 1 twice daily
62557711|NCT02423200|EXPERIMENTAL|VX-745 dose level 2|Active Group 1: VX-745 dose level 2 twice daily
62557712|NCT05563454|EXPERIMENTAL|Dose step 1|Each participant will receive an single dose (SD) of dose 1 of BAY2395840 or matching placebo.
62557713|NCT05563454|EXPERIMENTAL|Dose step 2|Each participant will receive an single dose (SD) of dose 2 of BAY2395840 or matching placebo.
62756675|NCT02111135|ACTIVE_COMPARATOR|Group 2|b-OPV, t-IPV and m-OPV2
62756676|NCT06607250||Bladder cancer patients|
62557714|NCT05563454|EXPERIMENTAL|Dose step 3|Each participant will receive an single dose (SD) of dose 3 of BAY2395840 or matching placebo.
62557715|NCT05563454|EXPERIMENTAL|Dose step 4|Each participant will receive multiple doses (MDs) of dose 3 of BAY2395840 or matching placebo.
62557716|NCT02791737|EXPERIMENTAL|Supportive care (otago exercise programme)|Patients attend 8 physical therapy visits twice monthly for 4 months or until transplant. Patients also undergo an individualized exercise program at home for 6 months. The program comprises 3 main components: walking over 30 minutes twice a week, strengthening and balance retraining exercise over 30 minutes three times a week.
62756677|NCT02088073|EXPERIMENTAL|Sodium zirconium cyclosilicate 10 g three times daily|Sodium zirconium cyclosilicate 10 g three times daily for 48 hours (acute phase)
62756678|NCT02088073|PLACEBO_COMPARATOR|Placebo once daily|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days.
62756679|NCT02088073|EXPERIMENTAL|Sodium zirconium cyclosilicate 5 g once daily|Sodium zirconium cyclosilicate (ZS) 5 g once daily for 28 days (maintenance phase)
62756680|NCT02088073|EXPERIMENTAL|Sodium zirconium cyclosilicate 10 g once daily|Sodium zirconium cyclosilicate (ZS) 10 g once daily for 28 days (maintenance phase)
62756681|NCT02088073|EXPERIMENTAL|Sodium zirconium cyclosilicate 15 g once daily|Sodium zirconium cyclosilicate (ZS) 15 g once daily for 28 days (maintenance phase)
62756682|NCT04058808|EXPERIMENTAL|Participants with Atrial Fibrillation attending the clinic.|
62756683|NCT04538274|EXPERIMENTAL|Patient researcher intervention|Intervention conducted by trained patient researchers to restart CPAP in addition to usual care
62756684|NCT04538274|NO_INTERVENTION|Usual care|Usual care
62756685|NCT06605235|EXPERIMENTAL|Lignocaine|patients received 20 ml of 1% lignocaine (Xyloaid-lignocaine HCl injection) infiltrated in the gall bladder bed after removal of the gall bladder, along with 10 ml of 1% lignocaine infiltration at the port sites at the end of the procedure
62756686|NCT06605235|EXPERIMENTAL|Bupivacaine|Subjects received 20 ml of 0.25% bupivacaine (Bupicain-Bupivacaine HCl injection) infiltration in gall bladder bed, along with 10 ml of 0.25% bupivacaine at port sites
62756687|NCT06605235|EXPERIMENTAL|Lignocaine + Bupivacaine|patients received 10 ml of 1% lignocaine along with 10 ml of 0.25% bupivacaine infiltrated in gall bladder bed, and then 5 ml of 1% lignocaine along with 5 ml of 0.25% bupivacaine at the port sites
62756688|NCT03580642|EXPERIMENTAL|eHealth Technologies|eHealth Technologies is a messure of diferent paramenters of the patient; heart rate, blood pressure, weight, thermometer, daily activity.
62756689|NCT03580642|NO_INTERVENTION|Control|Habitual treatment.
62756690|NCT05925283|PLACEBO_COMPARATOR|midazolam|Patients were assigned to receive oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
62756691|NCT05925283|EXPERIMENTAL|esketamine|Patients were assigned to receive intranasal esketamine 1mg/kg approximately 30-40 minutes before surgery using a computer-generated random number table.
62756692|NCT05925283|EXPERIMENTAL|midazolam and esketamine|Patients were assigned to receive intranasal esketamine 0.6mg/kg and oral midazolam 0.3mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
62756693|NCT00996281|EXPERIMENTAL|Azilsartan Medoxomil and Chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily for up to 52 weeks.~For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of azilsartan medoxomil 80 mg and chlorthalidone 25 mg."
62756694|NCT00996281|ACTIVE_COMPARATOR|Olmesartan Medoxomil and Hydrochlorothiazide QD|"Participants in the United States:~Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg.~Participants in Europe:~Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 20 mg and hydrochlorothiazide 25 mg."
62756695|NCT05084560|EXPERIMENTAL|AWZ1066S|"AWZ1066S~Part A Cohort A1- 100mg single dose Cohort A2- 200mg single dose Cohort A3- 400mg single dose Cohort A4- 800mg fasted single dose and 800mg fed single dose Cohort A5- 1200mg single dose Cohort A6- 1600mg single dose~The doses for part B will be selected following review of data from Part A. Cohort B1- AWZ1066S once daily for 7 days Cohort B2- AWZ1066S once daily for 7 days Cohort B3- AWZ1066S once daily for 7 days Cohort B4- AWZ1066S once daily for 7 days"
62756696|NCT05084560|PLACEBO_COMPARATOR|Placebo|"Placebo~Cohort A1- equivalent placebo single dose Cohort A2- equivalent placebo single dose Cohort A3- equivalent placebo single dose Cohort A4- equivalent placebo fasted single dose and equivalent placebo fed single dose Cohort A5- equivalent placebo single dose Cohort A6- equivalent placebo single dose~The doses for part B will be selected following review of data from Part A. Cohort B1- equivalent placebo once daily for 7 days Cohort B2- equivalent placebo once daily for 7 days Cohort B3- equivalent placebo once daily for 7 days Cohort B4- equivalent placebo once daily for 7 days"
62756697|NCT04657380|ACTIVE_COMPARATOR|Usual case management practices|The first-episode psychosis services participating in the study offer case-management, which will correspond to the treatment as usual in the control group. All the centers are part of the National Transition Network (https://idpsy.org/reseau-transition/centres/). Involvement in this network ensures homogeneity of the usual practices which correspond to the internationally standards. Care delivery is based on intensive treatment during the critical period of psychosis, relying on a wide network of caring and non-caregiving professionals, working together with a view to the successful recovery of the patient. The patient and his or her family are at the center of care and receive proposals for psychoeducation and support throughout the different phases of the illness. This is concomitant with a regular evaluation of patients in order to update the care offer according to their clinical needs.
62557717|NCT01509339|EXPERIMENTAL|Vancomycin for Inhalation|250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
62557718|NCT04467502|EXPERIMENTAL|CBT with VRET|
62557719|NCT04467502|ACTIVE_COMPARATOR|CBT with imaginal ET|
62557720|NCT04271228|EXPERIMENTAL|DreaMed Advisor Pro|Using the DreaMed Advisor Pro as an advisory tool for Health Care Professionals during routine clinical use
62557721|NCT01549717|EXPERIMENTAL|Elective cardiac surgery patients|Patients undergoing elective cardiac surgery
62557722|NCT01722708|EXPERIMENTAL|clindamycin|
62557723|NCT01722708|EXPERIMENTAL|metronidazole|
62379374|NCT01644812|ACTIVE_COMPARATOR|Aerobic exercise|The exercise intervention is a 12-week program involving 150 minutes of moderate intensity exercise (65-69% of participant's age-predicted \[220-age\] maximum heart rate) each week. Participants will complete one 50-minute supervised treadmill exercise session in the laboratory and 100 minutes of exercise on their own. These exercises may include walking, jogging, biking, or other forms of aerobic exercise. The at-home exercise regimen will be individualized for each participant.
62557724|NCT06211101|EXPERIMENTAL|Experimental: Intervention Group|Nurses were trained on the kangaroo care guide. Online training was given to neonatal nurses on the kangaroo care guide created by the researcher in line with the literature.
62557725|NCT06211101|NO_INTERVENTION|No Intervention: Control Group|Nurses weren't trained on the kangaroo care guide.
62557726|NCT03738046|EXPERIMENTAL|Pilot Treatment Arm|Group therapy will occur once weekly (60-90-minute sessions) at the HOPE TEAM offices for 24 weeks. The group sessions with consist of 4 skill modules, each of which last 6 sessions. Three of these--the Cognitive, Social Skills, and Problem-Solving Modules-will be modules taken from Cognitive and Behavioral Social Skills Training (CBSST; Granholm McQuaid, \& Holden, 2016) and modified for use with CHR adolescents. The fourth module-Stress Coping-will be adapted for this sample from an established group CBT treatment for psychosis (Lecomte, Leclerc, \& Wykes, 2016).
62557727|NCT05576090|EXPERIMENTAL|Mindfulness Meditation|Half of the subjects will be randomly assigned to participate in the Mindfulness Meditation intervention. This class will meet once a week, for two hours, over the course of six weeks.
62557728|NCT05576090|ACTIVE_COMPARATOR|Sleep Education|Half of the subjects will be randomly assigned to participate in the Sleep Education intervention. This class will meet once a week, for two hours, over the course of six weeks.
62557729|NCT04091516|OTHER|Low-fat plant-based diet|For 12 weeks, participants will follow a diet comprised of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. Except for light refreshments and tastings at the group sessions, no meals will be provided. Participants will handle their own food preparation and purchases, with guidance from the education team, with no restriction on energy intake.
62756698|NCT04657380|EXPERIMENTAL|Mobile case-management application|"The intervention tested will be a mobile application used during consultations involving the patient and the case manager to define care objectives. The mobile application to be evaluated will result from the process of a co-design phase based on the iterative user-centered design approach, involving representatives of carers, patients and caregivers. These stakeholders will define the content and form of the smartphone application during co-building workshops.~The main purpose of the final application will be to assist in the definition of patients' goals using an approach rooted in recovery theory, with the monitoring of goal achievement in three phases : 1) defining priorities for the patients, through a recovery oriented discussion with the patient and the case manager 2) Setting the concrete objectives and list concrete actions tho achieve them 3) evaluating the achievements."
62756699|NCT00612014|PLACEBO_COMPARATOR|1|
62756700|NCT00612014|EXPERIMENTAL|2|40 micrograms/kg
62756701|NCT00612014|EXPERIMENTAL|3|80 micrograms/kg
62756702|NCT00612014|EXPERIMENTAL|4|160 micrograms/kg
62756703|NCT00612014|EXPERIMENTAL|5|320 microgram/kg
62756704|NCT00612014|EXPERIMENTAL|6|600 microgram/kg
62756705|NCT02046850|EXPERIMENTAL|selumetinib 75mg.|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule
62756706|NCT02046850|OTHER|rifampicin 600mg.|Volunteers will receive rifampicin 600mg administered by mouth, as a capsule
62756707|NCT02046850|EXPERIMENTAL|selumetinib 75mg and rifampicin 600mg|Volunteers will receive selumetinib 75mg and rifampicin 600mg, by mouth, as a capsule
62756708|NCT04384445|EXPERIMENTAL|Zofin Plus Standard Care|Participants in this group will receive standard of care plus Zofin on day 0, day 4 and day 8.
62756709|NCT04384445|PLACEBO_COMPARATOR|Placebo Plus Standard Care|Participants in this group will receive standard of care plus placebo (Saline) on day 0, day 4 and day 8.
62756710|NCT06299982|EXPERIMENTAL|608 160 mg W0+80 mg Q2W|Participants will receive starting dose of 160 milligrams (mg) 608 at week 0 followed by 80mg 608 once every two weeks (Q2W) by subcutaneous injection for 12 weeks.
62756711|NCT06299982|EXPERIMENTAL|608 160 mg Q4W|Participants will receive 160 milligrams 608 once every four weeks (Q4W) by subcutaneous injection for 12 weeks.
62756712|NCT01919047||Betanis group|Patients receiving Betanis for Overactive Bladder
62756713|NCT06607562|EXPERIMENTAL|Probiotics group|10B CFU/Sachet/Day BC99 before meals; Storage: Store in cool and dry place without sun exposure.
62756714|NCT06607562|PLACEBO_COMPARATOR|Placebo|Maltodextrin one Sachet/Day before meals; Storage: Store in cool and dry place without sun exposure.
62557730|NCT04173507|EXPERIMENTAL|Treatment (talazoparib, avelumab)|Patients receive talazoparib PO daily and avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62756715|NCT00929188|EXPERIMENTAL|001|JNJ-42160443 Type=1 unit=mg number=10 form=solution for injection route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
62756716|NCT00929188|PLACEBO_COMPARATOR|002|Placebo Form=solution for injection route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
62756717|NCT00068250|EXPERIMENTAL|Phase I: Temozolomide 100 mg|Rituximab, methotrexate, temozolomide 100 mg/m\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\^2.
62756718|NCT00068250|EXPERIMENTAL|Phase I: Temozolomide 150 mg|Rituximab, methotrexate, temozolomide 150 mg/m\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\^2.
62756719|NCT00068250|EXPERIMENTAL|Phase I: Temozolomide 200 mg|Rituximab, methotrexate, temozolomide 200 mg/m\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\^2.
62756720|NCT00068250|EXPERIMENTAL|Phase II: Temozolomide 100 mg|Rituximab, methotrexate, temozolomide 100 mg/m\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\^2.
62756721|NCT05013918||Hospitalized people in Nursing Home|
62557731|NCT02930044|EXPERIMENTAL|Early glargine dose|Subcutaneous insulin glargine will be administered within two hours of starting the IV insulin infusion.
62557732|NCT02930044|PLACEBO_COMPARATOR|Standard therapy|Retrospective arm that received standard insulin therapy for treatment of DKA
62557733|NCT00443729|EXPERIMENTAL|1|Raltegravir \& Placebo
62557734|NCT00443729|ACTIVE_COMPARATOR|2|Lopinavir (+) Ritonavir \& Placebo
62756722|NCT04059523|EXPERIMENTAL|S6G5T-3|topical cream
62756723|NCT04059523|ACTIVE_COMPARATOR|Retin-A® 0.1% Cream|topical cream
62756724|NCT03094650|EXPERIMENTAL|MindMotion PRO|The training sessions consist of virtual reality based rehabilitation exercises using the MindMotion PRO device.
62756725|NCT01766492||male (age > 18 y/o) with prostate cancer|Men received Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer
62756726|NCT04288258|EXPERIMENTAL|Treatment|Health and Wellness Program
62756727|NCT05643183|EXPERIMENTAL|Patients receiving Astmakompas|30 patients from two hospital sites (AMC and MST)
62756728|NCT01185964|EXPERIMENTAL|Phase 1b: Olaratumab + doxorubicin|"All cycles are 21 days.~Cycles 1-8: Olaratumab 15 mg/kg on days 1+8, and doxorubicin 75 mg/m2 on day 1~All subsequent cycles until progression: Olaratumab 15 mg/kg on days 1+8"
62756729|NCT01185964|EXPERIMENTAL|Phase 2: Olaratumab and doxorubicin|"All cycles are 21 days.~Cycles 1-8: Olaratumab 15 mg/kg on days 1+8, and doxorubicin 75 mg/m2 on day 1~All subsequent cycles until progression: Olaratumab 15 mg/kg on days 1+8"
62756730|NCT01185964|ACTIVE_COMPARATOR|Phase 2: Doxorubicin: Optional Olaratumab After Progression|"All cycles are 21 days.~Cycles 1-8: doxorubicin 75 mg/m2 on day 1 until disease progression.~At disease progression: optional Olaratumab 15 mg/kg on days 1+8 until further progression."
62756731|NCT01048294|ACTIVE_COMPARATOR|Standard Light Treatment|30 min of Standard bright light treatment (color 5000K)
62756732|NCT01048294|EXPERIMENTAL|Blue enriched Light treatment 20 min|20 minutes of Blue enriched light treatment (color 17000K)
62756733|NCT01048294|EXPERIMENTAL|Blue enriched light treatment 30 min|30 minutes of Blue enriched light treatment (color 17000K)
62756734|NCT02089464|ACTIVE_COMPARATOR|NBS-rTMS + task-oriented rehabilitation|NBS-guided rTMS + task-oriented rehabilitation
62756735|NCT02089464|SHAM_COMPARATOR|Sham rTMS + task-oriented rehabilitation|Sham rTMS + task-oriented rehabilitation
62756736|NCT04839471|EXPERIMENTAL|BI-754091 plus afatinib|BI-754091 plus afatinib
62756737|NCT00342277||Pregnant Women|Consecutive pregnant women admitted with either: Preterm labor/delivery/PROM. Termdelivery without labor/spontaneous labor /chorioamnionitis/failed labor leading to c-section
62756738|NCT06606353||Dyad|people with neurocognitive disorders and their carers with an intelligent digital health companion
62756739|NCT02147223|ACTIVE_COMPARATOR|Flavanol rich product A|250 mg flavanols
62756740|NCT02147223|ACTIVE_COMPARATOR|Flavanol rich product B|500 mg flavanols
62756741|NCT02147223|ACTIVE_COMPARATOR|Flavanol rich product C|750 mg flavanols
62756742|NCT02147223|PLACEBO_COMPARATOR|Flavanol free product|flavanol free
62756743|NCT01394224|EXPERIMENTAL|Levetiracetam IV Infusion (1500 mg)|
62756744|NCT01394224|EXPERIMENTAL|Levetiracetam tablets (1500 mg)|
62756745|NCT03964246|EXPERIMENTAL|Compassion Meditation (CM) intervention group|10-week group intervention consisting of compassion meditation training.
62756746|NCT03964246|ACTIVE_COMPARATOR|Psychoeducational healthy aging group|10-week group focused on review and discussion of psychoeducational videos related to healthy aging topics
62756747|NCT04686760|EXPERIMENTAL|Nitroglycerin solution|
62756748|NCT04686760|NO_INTERVENTION|standard solution|
62756749|NCT01037049|NO_INTERVENTION|Group 1|Patients who have surgery at 6 weeks after radiotherapy/chemoradiotherapy
62756750|NCT01037049|EXPERIMENTAL|Group 2|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy
62756751|NCT03490422|EXPERIMENTAL|Pulpotomy|Pulpotomy is performed in carious-exposed pulp in mature permanent teeth
62756752|NCT06489704|EXPERIMENTAL|Assessments at 3200 m and 760 m, respectively|Participants will have a echocardiography near their resident altitude at 3200 m and after relocation to 760 m after 1 and 7 days
62756753|NCT01967823|EXPERIMENTAL|1/Cyclophosphamide & Fludarabine + Anti-ESO murine TCR transduced PBL + HD Aldesleukin|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + anti-ESO murine T-cell receptor (TCR) transduced PBL + high-dose (HD) aldesleukin
62756754|NCT04126265|NO_INTERVENTION|Routine colonoscopy group|The patient underwent routine colonoscopy.
62756755|NCT04126265|EXPERIMENTAL|Artificial intelligence assisted colonoscopy group|The real-time automatic polyp detection system was used to assist the endoscopist.
62756756|NCT03257163|EXPERIMENTAL|Treatment (pembrolizumab, capecitabine, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks, patients undergo surgery. Beginning up to 56 days after surgery, patients receive pembrolizumab IV over 30 minutes on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks of resting, patients continue to receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 11 courses in the absence of disease progression or unacceptable toxicity. Beginning course 4, patients undergo radiation therapy over 15-30 minutes on days 1-5 for up to 5 weeks.
62756757|NCT00832130|EXPERIMENTAL|Manual Mini System|Treatment with experimental Manual Mini System
62756758|NCT00832130|ACTIVE_COMPARATOR|Warm Compress Therapy|Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase
62756759|NCT01860157|SHAM_COMPARATOR|Sham H1 Coil|deep rTMS sham treatment
62557735|NCT04133857|ACTIVE_COMPARATOR|Group A|undergo HIIT first then SSMIT protocol
62756760|NCT01860157|ACTIVE_COMPARATOR|Active H1|deep rTMS active treatment
62756761|NCT01778049|EXPERIMENTAL|Empagliflozin 10 mg dose|Empagliflozin open label treatment period
62756762|NCT01778049|EXPERIMENTAL|Placebo add on 10 mg dose|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo add on run-in
62557736|NCT04133857|ACTIVE_COMPARATOR|Group B|undergo SSMIT first then HIIT protocol
62756763|NCT01778049|EXPERIMENTAL|Empagliflozin/Linagliptin 25/5 mg Dose|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
62756764|NCT01778049|EXPERIMENTAL|Empagliflozin/Linagliptin 10/5 mg Dose.|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
62756765|NCT01778049|EXPERIMENTAL|Empagliflozin/Linagliptin 10/5 mg Dose|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
62756766|NCT01778049|EXPERIMENTAL|Empagliflozin 25 mg dose|Empagliflozin open label treatment period
62756767|NCT01778049|EXPERIMENTAL|Empagliflozin/Linagliptin 25/5 mg Dose.|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
62756768|NCT01778049|EXPERIMENTAL|Placebo add on 25 mg dose|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo add on run-in
62756769|NCT01981863|EXPERIMENTAL|Epsilonaminocaproic acid|One arm: Epsilonaminocaproic acid 10 gr IV, followed by 1 gr/hr infusion Second arm: placebo
62756770|NCT01981863|PLACEBO_COMPARATOR|Placebo, Antifibrinolytic activity|Placebo: same IV volume as experimental arm
62756771|NCT06378749|EXPERIMENTAL|PreCharge Intervention Pilot|After completing the baseline assessment, all pilot participants will have access to the PreCharge pilot program for 30 days. At the end of the 30 day pilot, they will be directed to the follow-up assessment.
62756772|NCT02366117|EXPERIMENTAL|Training|"Data collected during the first pahse of the study will be presented and discussed in a specialist focus group, which will work with the study team as advisors and trainers, to decide on the type of training to be developed.~This training intervention will be applied to the facilities presenting half the patient sample size."
62756773|NCT02366117|NO_INTERVENTION|No Training|Facilities representing half the sample size will not be trained as in the Experimental Arm and continue their standard of care for these patients.
62756774|NCT04773561|EXPERIMENTAL|multifetal pregnancy in the 3rd trimester|Corneal tomography, optical coherence tomography and optical coherence tomography angiography were performed in the 3rd trimester, 30-36 weeks of gestational age.
62756775|NCT04773561|ACTIVE_COMPARATOR|singleton pregnancy in the 3rd trimester|Corneal tomography, optical coherence tomography and optical coherence tomography angiography were performed in the 3rd trimester, 30-36 weeks of gestational age.
62756776|NCT04773561|ACTIVE_COMPARATOR|age-stratified healthy non-pregnant women|Corneal tomography, optical coherence tomography and optical coherence tomography angiography were performed.
62557737|NCT01236469||Retrospective Patients|Pediatric (21 years of age or younger) patients who received a CryoValve SG Aortic Valve distributed during the 2000 to 2003 period as an aortic valve replacement.
62756777|NCT04118036|EXPERIMENTAL|Surgery Arm|"In the surgical arm participants who require reoperation and have evidence of CDKN2A/B or C loss and intact RB from a prior tumor sample will receive~* Pembrolizumab-prior to surgery, at predetermined dose and time point~* Abemaciclib: every 12 hours from the day of pembrolizumab infusion to the morning of surgery~* Post surgery Participants with receive~  * Abemaciclib, twice daily oral at specified dose for 21 day cycle~ * Pembrolizumab intravenous once in 21 day cycle (3 weeks)"
62756778|NCT04118036|EXPERIMENTAL|Non Surgery Arm|"The treatment arm will be comprised of participants not requiring surgery.~- Participants will receive treatment with~* Abemaciclib, twice daily oral at specified dose for 21 day cycle~* Pembrolizumab intravenous once in 21 day cycle (3 weeks)"
62756779|NCT00983515|ACTIVE_COMPARATOR|Colchicine alone|-baseline colchicine pharmacokinetics
62756780|NCT00983515|EXPERIMENTAL|Colchicine with Ritonavir|-colchicine pharmacokinetics in presence of steady-state ritonavir
62379375|NCT01644812|SHAM_COMPARATOR|stretching|The exercise intervention is a 12-week program involving 150 minutes of stretching each week (one 50-minute stretching session in the laboratory and 100 minutes of stretching at home). Participants in the stretching condition will work with a facilitator to create a stretching regimen for 100 minutes of home stretching throughout the week. The facilitator will provide a list of potential stretches with descriptions on how to perform them.
62756781|NCT04259788|EXPERIMENTAL|Intervention|The intervention group will receive in-person dietary counseling from a registered dietitian to help participants consume a diet that is consistent the AHEI dietary guidelines. Participants in this arm will be asked to consume this diet for a 12-week period and discontinue any vitamin or supplement intake during this time. During the first 4 weeks 2 meals and 1 snack/day will be shipped to the participant. During the last 8 weeks of the intervention, the study will provide the participants with a 14-day meal plan (3 meals and 2 snacks) that adheres to the AHEI maximum score criteria to help facilitate adherence to the diet.
62379376|NCT01511692|EXPERIMENTAL|Lira --> placebo|
62379377|NCT01511692|PLACEBO_COMPARATOR|Placebo --> glim|
62379378|NCT01511692|ACTIVE_COMPARATOR|Glim --> lira|
62557738|NCT01926405|OTHER|Subjects with narcolepsy or with idiopathic hypersomnia|
62756782|NCT04259788|NO_INTERVENTION|Control|Participants in this arm will not receive the dietary intervention.
62379379|NCT01700595|EXPERIMENTAL|new technical intervention|''new technical intervention'' represents the surgical procedure which is applied for the patients assigned to this group because of their certain characteristics. Namely, pediatric patients with broad axillary, anterior chest wall, mammary and neck scars are treated with this surgical approach.
62379380|NCT02380703|EXPERIMENTAL|Aggression Prevention Training (APT)|APT will use active learning tools, including didactics, role-playing, and multimedia (eg, books and DVDs) to educate and provide skill training for the caregiver. The 6-8 modules in the intervention will include 4 core modules that address 4 main aggression risk factors: a) recognizing pain, b) treating pain, c) increasing pleasant activities, and d) improving patient-caregiver communication. Caregivers can select 2 to 3 additional elective sessions; elective selection is guided by the needs of the dyad to further enhance skills related to these core topics. Sessions will take place in the patient's home.
62557739|NCT01926405|OTHER|Control patients with no sleeping disorder|
62557740|NCT02883816|EXPERIMENTAL|cystic fibrosis|assessment of lung function in newborns screened for cystic fibrosis
62756783|NCT03292939|OTHER|vaginal progestrone group|cohort of patients who received 400mg vaginal progestrone .
62756784|NCT05949515||Minneapolis Heart Institute|
62756785|NCT05949515||The Feinstein Institutes for Medical Research|
62756786|NCT05949515||NCH Baker Downtown Hospital|
62756787|NCT05949515||OhioHealth Research Institute|
62756788|NCT05949515||Baptist Health Baptist Hospital|
62756789|NCT05949515||St. Mary's Medical Center|
62756790|NCT05949515||Corewell Health William Beaumont University Hospital - Research Institute|
62756791|NCT05949515||University of Chicago Medicine|
62379381|NCT02380703|PLACEBO_COMPARATOR|Enhanced Usual Primary Care (EU-PC)|EU-PC provides the patient and caregiver educational materials on pain, notifies the primary care provider of the PWD's level of pain and depression, and provides 8 weekly supportive telephone calls to caregivers.
62756792|NCT06353399|EXPERIMENTAL|Intra-marrow penetrations|Twelve test patients will receive guided bone regeneration therapy with the use of intra-marrow penetrations prior to bone graft placement.
62756793|NCT06353399|ACTIVE_COMPARATOR|No Intra-marrow penetrations|Twelve test patients will receive guided bone regeneration therapy without the use of intra-marrow penetrations prior to bone graft placement.
62756794|NCT01203436|EXPERIMENTAL|Supplemental Oxygen|Supplemental oxygen to achieve a pulse oximetry target range of 96% to 99%.
62557741|NCT03281174||EV71 vaccine group|The group which received two doses EV71 vaccine (400U/0.5ml) on day 0,28 in phase III clinical trial.
62756795|NCT01203436|ACTIVE_COMPARATOR|Conventional Oxygen|Conventional oxygenation at a pulse oximetry target of 89% to 94%.
62756796|NCT03385707||CGM and Microbiota|Participants will wear a Dexcom continuous glucose monitor (CGM) and activity monitor for two weeks. They will not be aware of sensor glucose values. A stool sample will be collected. The investigators will evaluate relationships between patterns of postprandial glycemia, recorded by CGM, food intake, and microbiome composition.
62756797|NCT02779907||Study Population|Children aged 4-6 years resident in Chikwawa District.
62756798|NCT06605911|EXPERIMENTAL|Topical triamcinolone acetonide|Group I
62756799|NCT06605911|EXPERIMENTAL|Topical curcumin|Group II
62756800|NCT06605911|ACTIVE_COMPARATOR|Topical triamcinolone acetonide combiend with topical curcumin|Group III
62756801|NCT02003066|EXPERIMENTAL|Standard|
62756802|NCT02003066|ACTIVE_COMPARATOR|Conservative|
62756803|NCT06408675||group 1 with a Cobb angle of ≤10°|cervical lordosis cobb angele ≤10°
62557742|NCT03281174||Placebo group|The group which received two doses placebo (0U/0.5ml) on day 0,28 in phase III clinical trial.
62756804|NCT06408675||group 2 with an angle greater than >10°|cervical lordosis cobb angele \>10°
62557743|NCT01036854|EXPERIMENTAL|Regime 1|Regime 1 will be orally administered once daily in the morning over 6 consecutive days.
62557744|NCT01036854|ACTIVE_COMPARATOR|Regime 2|Regime 2 will be orally administered twice daily at 12 hours interval (morning and evening) over 6 consecutive days
62756805|NCT01069861|EXPERIMENTAL|one|
62756806|NCT03457506|OTHER|Patients undergo a digital PET/CT|Single arm prospective study of paired PET scans. Patients who are referred to the nuclear medicine department to undergo a PET scan, will undergo a PET/CT scan on the conventional scanner as well as the digital PET/CT scanner.
62756807|NCT02676336|ACTIVE_COMPARATOR|Violet™ Iodine|3mg molecular iodine (I2) daily
62756808|NCT02676336|PLACEBO_COMPARATOR|Placebo|3mg placebo daily
62756809|NCT02676336|ACTIVE_COMPARATOR|Cross-over|Subjects on placebo will be offered 3 months of active post-treatment
62756810|NCT04571268||Healthy validation subjects|Healthy subjects who meet the inclusion criteria and participate in data collection for the purpose of developing and validating the biomechanical models used to track scapular motion
62756811|NCT04571268||Healthy comparison subjects|Healthy subjects who meet the inclusion criteria and participate in data collection for comparison of shoulder motion and muscle activation patterns with RCT subjects
62756812|NCT04571268||RCT subjects|Subjects who have sustained a major rotator cuff tear
62756813|NCT01187368|EXPERIMENTAL|Evaheart LVAS (EVA2)|The objective of the study is to evaluate the safety and effectiveness of the EVA2 by demonstrating non-inferiority to commercially approved LVADs when used for the treatment of refractory NYHA Class III with dyspnea upon mild physical activity or Class IV heart failure.
62756814|NCT01187368|ACTIVE_COMPARATOR|HeartMate 3 (HM3)|The objective of the study is to evaluate the safety and effectiveness of the EVA2 by demonstrating non-inferiority to commercially approved LVADs when used for the treatment of refractory NYHA Class III with dyspnea upon mild physical activity or Class IV heart failure.
62756815|NCT00607711|EXPERIMENTAL|Single arm|
62756816|NCT03087942|EXPERIMENTAL|Group 1|ESRD patients
62756817|NCT03087942|EXPERIMENTAL|Group 2|healthy volunteers
62756818|NCT03087942|EXPERIMENTAL|Group 3|severe and moderate renal impaired patients
62756819|NCT03087942|EXPERIMENTAL|Group 4|mild renal impaired patients
62756820|NCT05664295||insomnia patients|Jenkins Sleep Disorders scale skor \>1 and Epworth Sleepiness scale skor \>9
62756821|NCT05664295||noninsomniacs|Jenkins Sleep Disorders scale skor \<2 and Epworth Sleepiness scale skor \<10
61986859|NCT03543592|OTHER|3 dimensional power Doppler|100 women suffering post-menopausal bleeding (occurred after at least 12 months of amenorrhea) will be included in the study and 3 dimensional ultrasonography and Doppler will be done for them
61986860|NCT05658679||patients with pancreatic cancer|Patients with pancreatic tumors diagnosed clinically or pathologically
61986861|NCT05658679||Participants without pancreatic cancer|Participants who judged the pancreas to be completely healthy through medical examination
62379382|NCT03030794|ACTIVE_COMPARATOR|Repetitive TMS|Subjects will receive the repetitive transcranial magnetic stimulation study procedure.
62756822|NCT06462534|EXPERIMENTAL|Band-Frail Intervention|Individuals 65 years or older living with T2D and frailty will participate in elastic band resistance training and diabetes education sessions.
62756823|NCT06139562|EXPERIMENTAL|Time-Restricted Feeding (TRF)|Time-restricted feeding program from sunrise to sunset
62756824|NCT06139562|ACTIVE_COMPARATOR|Extended-Time Feeding (ETF)|Extended-time feeding program that allows them to eat at any time of the day
62756825|NCT04830904|EXPERIMENTAL|Use of lycra garments|the subjects are assessed with and without wearing the device
62756826|NCT00309699|PLACEBO_COMPARATOR|003|Placebo Daily for 3 weeks
62756827|NCT00309699|ACTIVE_COMPARATOR|002|Quetiapine 400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
62756828|NCT00309699|EXPERIMENTAL|001|Paliperidone ER 3 to 12 mg daily, flexibly dosed, for 12 weeks
62756829|NCT03037099|EXPERIMENTAL|Enhanced GI Concept Education|This group will receive enhanced GI concept nutrition education including GI values of foods, low GI recipes, menus, and application through websites with chat rooms, online videos and print materials. These will be reinforced through email, text messaging/phone calls, and postal mail.
62379383|NCT03030794|PLACEBO_COMPARATOR|No (blocked) repetitive TMS|Subjects will not receive the repetitive transcranial magnetic stimulation study procedure by blocking the stimulation between the coil and the head, but the audiovisual conditions will be mimicked.
62756830|NCT03037099|NO_INTERVENTION|Usual Care|Usual care group will receive only standard printed copies of Canada Food Guide and Canadian Diabetes Association GI resources.
62756831|NCT06608797|EXPERIMENTAL|Training|Computer based cognitive training delivered remotely via Zoom Health
62756832|NCT06608797|SHAM_COMPARATOR|sham comparator|The sham comparator group will receive sham memory exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 placebo control sessions).
62379384|NCT02316379|EXPERIMENTAL|Hyperpolarized 129 Xenon|Administration of up to 1 liter doses of Hyperpolarized Xenon gas during MRI to optimize acquisition of images for adults vs. proton MR imaging. These scans, utilizing volunteers for calibration, may be utilized through this study to optimize the scan details.
62379385|NCT05544110|EXPERIMENTAL|Active stimulation group|Participants receive active transcranial magnetic stimulation.
62379386|NCT05544110|SHAM_COMPARATOR|Sham stimulation group|Participants receive sham transcranial magnetic stimulation.
62379387|NCT05357924|ACTIVE_COMPARATOR|robotic-assisted laparoscopy|The robotic-assisted resection of endometriosis will be performed using the da Vinci Surgical System Si (Intuitive Surgical) using up to five ports as needed. An umbilical port was placed for the laparoscope (10/12 mm), a 5-mm port for the assistant, and two to three ports (5/8 mm) for the robotic arms.
62756833|NCT00838825|NO_INTERVENTION|traditional|The traditional arm is composed of primary care physicians who continue the health care delivery model existing for the 5 years prior to the study. The traditional includes the physician, a pool of resources including random assignment of diabetic educators and includes the entire panel of patients assigned to the PCP.
62756834|NCT00838825|EXPERIMENTAL|care management|The care management group is composed of primary care physicians who have been assigned a specific physician extender, the care manager, and an additional medical assistant and form a care manager team working together with registry support, team meetings and instruction in self-management and includes the entire panel of patients assigned to the PCP.
62756835|NCT01711229|ACTIVE_COMPARATOR|Group I: IV acetaminophen|Group I will receive 1 gram IV acetaminophen 15 minutes prior to going to the operating room for arthroscopic rotator cuff repair
62756836|NCT01711229|ACTIVE_COMPARATOR|group 2|Group 2 will receive 1.5grams of oral acetaminophen immediately prior to proceeding to the operation groom for arthroscopic rotator cuff surgery
62756837|NCT03989050||Melanoma patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for melanoma
62756838|NCT03989050||Non-small cell lung cancer (NSCLC) patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for NSCLC
62756839|NCT03989050||other malignancy patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for other malignancy
61986862|NCT06462651|EXPERIMENTAL|L. reuteri|Dietary Supplement: L. reuteri
61986863|NCT06462651|PLACEBO_COMPARATOR|Placebo|
61986864|NCT05601856||Alzheimer's Patient|"patients with AD whose clinical dementia rating (CDR) is \> 1 Age 65-90 with none of the criteria below:~1. Familial Alzheimer's Disease (AD)~2. Severe cardiovascular disease~3. Severe respiratory system disease~4. Severe liver disease~5. Severe kidney disease~6. Severe central nervous system diseases~7. Having a lifespan of fewer than 3 months~8. History of psychiatric illness~9. Major neurological diseases other than AD~10. Current use of corticosteroids, antibiotics, or bowel motility modification agents~11. Any history of Alcoholism or illicit drug dependence~12. Previous inclusion in this study~13. Difficulty with follow-up or poor compliance~14. Severe hearing impairment~15. Severe vision impairment"
62756840|NCT04302701|EXPERIMENTAL|Dichoptic arm|Dichoptic visual training will be performed with the patient wearing his spectacles using the computer game included in Vivid Vision (Vivid Vision, San Francisco, USA) which will be run in the Oculus Rift OC CV1 virtual reality head mounted display (Oculus VR, Menlo Park, California, USA). Each subject will have 20 treatment sessions, divided into 1 hour-sessions performed twice a week for 10 weeks. Each session will be 60 minutes. Adherence to the treatment regimen will be assessed by the number of hours spent in training at the end of 5th week.
62756841|NCT04302701|ACTIVE_COMPARATOR|Patching|Patients in the control group will be instructed to continue wearing spectacles if required. Patients will be prescribed two continuous hours of daily patching with at least one hour of near activities during patching. Adhesive skin patches will be provided by the study. The parent/patient will be instructed to spend at least one of the hours of patching time each day performing eye-hand coordination activities at near. Adherence to the treatment protocol will be assessed by having the parent call / send a message to an investigator at the start and end of the occlusion sessions completed each day, thus making the most as accurate as possible assessment of the patient's adherence to the prescribed treatment
62756842|NCT03354481|EXPERIMENTAL|Behavioral recording of arithmetic and associated information|The experiment will contain several behavioral tasks in which solving time and correct answer will be recorded. The main one will be a computerized task on arithmetic facts. There will also be three additional tasks as described below.
62557745|NCT01036854|ACTIVE_COMPARATOR|Regime 3|Regime 3 will be orally administered three times daily at 8 hour intervals (morning, afternoon, evening) over 6 consecutive days.
62756843|NCT02069730|EXPERIMENTAL|Unmatched Treatment (Selinexor)|"Selinexor, 30mg/m2, by mouth, twice weekly, every 28 day cycles.~If patients have a druggable aberration but there is no access to the relevant agent, then patients will receive selinexor"
62557746|NCT01036854|EXPERIMENTAL|Regime 4|Regime 4- Day 1- a single dose will be given. Day 2- one placebo capsule; Day 3- a single dose will be given . Day 4 \& 5- two placebo capsules on each day; Day 6- a single does will be given.
62756844|NCT02069730|EXPERIMENTAL|Matched Therapy|"EGFR or HER2 Inhibitor,FGFR Inhibitor,C-KIT Inhibitor, Anti-androgen ,NOTCH Inhibitor,MEK or PI3K Inhibitor .~If the matched therapy is given through a clinical trial, the dosing schedule will be determined by that particular trial protocol. For matched treatments administered outside of a clinical trial, the dosing schedule will be the recommended dose by the expertise of the treating investigator."
62756845|NCT00686322|OTHER|1|Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
62557747|NCT04650204|EXPERIMENTAL|Arm A (perampanel)|Patients receive perampanel PO QD for 40 weeks in the absence of disease progression or unacceptable toxicity.
62557748|NCT04650204|ACTIVE_COMPARATOR|Arm B (ASD)|Patients receive ASD per standard of care for 40 weeks in the absence of disease progression or unacceptable toxicity.
62557749|NCT01216735|ACTIVE_COMPARATOR|smokers, Fluticasone first, then Placebo|The current smokers will be given a 3-week treatment course of inhaled fluticasone (220 ug fluticasone twice a day administered as a MDI) . The subjects and the investigators will be blinded to the random choice of inhaler.
62756846|NCT02072135|EXPERIMENTAL|Exparel|Exparel 266mg
62379388|NCT05357924|ACTIVE_COMPARATOR|conventional laparoscopy|Laparoscopic-assisted cystectomy of endometrioma will be performed using up to four 5-mm ports, including an umbilical port and additional ports as dictated by each individual surgery.
62379389|NCT03158155||Patients with vitamin D deficiency|1. children with vitamin D deficiency with age group from 2-5 years old
62557750|NCT01216735|PLACEBO_COMPARATOR|smokers Placebo first, then Fluticasone|The current smokers will be given a 3-week treatment course of inhaled placebo MDI. The subjects and the investigators will be blinded to the random choice of inhaler.
62557751|NCT01216735|NO_INTERVENTION|health non-smokers|The healthy non-smokers will have only visit 1 and no intervention.
62557752|NCT03895814|EXPERIMENTAL|Multi-baseline Step Training|"Participants will be assessed before and after a 2-week baseline period, and again before and after a 2 week protective step training period. Participants will also be assessed 2 months later at a follow-up visit."
62756847|NCT02593422|EXPERIMENTAL|Expressive Writing|Writing about ovarian cancer: Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
61986865|NCT05601856||Spousal Caregiver to Alzheimer's Patient|"Spousal Caregiver to Alzheimer's Patient group, Age 65-90 with none of the criteria below:~1. Familial Alzheimer's Disease (AD)~2. Severe cardiovascular disease~3. Severe respiratory system disease~4. Severe liver disease~5. Severe kidney disease~6. Severe central nervous system diseases~7. Having a lifespan of fewer than 3 months~8. History of psychiatric illness~9. Major neurological diseases other than AD~10. Current use of corticosteroids, antibiotics, or bowel motility modification agents~11. Any history of Alcoholism or illicit drug dependence~12. Previous inclusion in this study~13. Difficulty with follow-up or poor compliance~14. Severe hearing impairment~15. Severe vision impairment"
62379390|NCT01081951|EXPERIMENTAL|1|"Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose recommended by Investigator.~Full dose: 300 mg twice daily (bid) or Reduced doses: 200 mg twice daily (bid) or 100 mg twice daily (bid).~The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions."
62557753|NCT05784883||Consecutive patients ≥60-year-old presenting to the echocardiography clinic|
62756848|NCT02593422|ACTIVE_COMPARATOR|Fact Writing (Control)|Writing about ovarian cancer: Participants will be asked to write about the facts of their experience with ovarian cancer
62756849|NCT05039671|EXPERIMENTAL|Measurement-based care|Clinicians will receive a 3-hour interactive MBC training followed by six months of post-training consultation. Training and consultation will include how to collect, score, and use student- and parent-reported progress measures with students and families to inform collaborative progress monitoring and treatment decisions.
62756850|NCT05735366|EXPERIMENTAL|Q3W Dose Escalation part|Patients will receive SAIL66 as tri-weekly IV infusions at escalated doses.
62756851|NCT05735366|EXPERIMENTAL|Expansion part|Patients will receive SAIL66 as a IV infusion at the recommended dose.
62379391|NCT01081951|ACTIVE_COMPARATOR|2|paclitaxel iv and carboplatin iv
62379392|NCT01911884|OTHER|Patients with a Rokitansky Syndrome|Patients with a Rokitansky Syndrome
62756852|NCT05735366|EXPERIMENTAL|QW Dose Escalation part|Patients will receive SAIL66 as a weekly IV infusion at escalated doses.
62756853|NCT06167005||One anastomosis gastric bypass|
62756854|NCT06167005||Roux en y gastric bypass|
62756855|NCT06167005||Sleeve gastrectomy|
62756856|NCT06167005||Adjustable gastric band|
62756857|NCT05028517|EXPERIMENTAL|FMF Connect Intervention + Coaching|Participants receive the FMF Connect mobile health app plus text-based coaching to support continued use of the app and individualized goal setting.
62756858|NCT05028517|EXPERIMENTAL|FMF Connect Intervention (no coaching)|Participants receive the FMF Connect mobile health app. They do not receive coaching.
62756859|NCT05028517|NO_INTERVENTION|Waitlist comparison group|Participants receive the FMF Connect mobile health app at the conclusion of the study.
62756860|NCT03217084|ACTIVE_COMPARATOR|MI varnish GC|MI Varnish is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDEN Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish . Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue.
62756861|NCT03217084|ACTIVE_COMPARATOR|White Varnish 3M|"White Varnish is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. White Varnish an innovative tri-calcium phosphate.~Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish . Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue."
62756862|NCT01846195|SHAM_COMPARATOR|no blood draw|CM 1500 with no blood draw
62756863|NCT01846195|ACTIVE_COMPARATOR|blood draw|CM 1500 with blood draw
62756864|NCT03692494|EXPERIMENTAL|Unilateral vocal fold paralysis standard of care voice therapy|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques.
62756865|NCT03692494|EXPERIMENTAL|Unilateral paralysis standard of care voice therapy plus EMST|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques. EMST consists of blowing into respiratory device at a measure threshold pressure. As strength improves threshold resistance will be increased.
62756866|NCT03692494|EXPERIMENTAL|Parkinson's disease standard of care voice therapy plus EMST|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques. EMST consists of blowing into respiratory device at a measure threshold pressure. As strength improves threshold resistance will be increased.
62756867|NCT02504112||X-Ray PSI Group|Male or female patients, over 18 years old and with indication of total knee arthroplasty
62379393|NCT02177604|EXPERIMENTAL|Wingate HIT|7 days of high-fat overfeeding (50% excess calories) in conjunction 3 supervised sessions of Wingate High-intensity Interval Training.
62379394|NCT02177604|EXPERIMENTAL|Modified HIT|7 days of high-fat overfeeding (50% excess calories) in conjunction with 3 supervised sessions of Modified High-Intensity Interval Training
62379395|NCT02177604|ACTIVE_COMPARATOR|No Exercise Control|7 days of high-fat overfeeding (50% excess calories) with no supervised exercise
62379396|NCT00772980|EXPERIMENTAL|1|Drug: Neramexa mesylate Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
62379397|NCT00772980|PLACEBO_COMPARATOR|2|Drug: Placebo Double-blind treatment period of 17 weeks placebo
62557754|NCT02749617|EXPERIMENTAL|apixaban|apixaban 2.5 mg PO BID
62557755|NCT01202045||systemic sclerosis patients|Every patient will have a rest echocardiography, a stress echocardiography, a right heart catheterization, a blood specimen, and a pulmonary function test.
62756868|NCT05922072|ACTIVE_COMPARATOR|Long NPO group|6,4 and 2 hours NPO for solids/ formula milk, breast milk and clear fluid respectively
62756869|NCT05922072|EXPERIMENTAL|Short NPO group|6,4 and 1-hour NPO for solids/ formula milk, breast milk and clear fluid respectively
62756870|NCT05409859||Participants|Children patients of 5 years and younger who received manual therapies by a chiropractor in private practice.
62756871|NCT02396771|EXPERIMENTAL|Massage|Women allocated to the uterine massage group will be provided with 2 minutes of trans-abdominal uterine massage starting promptly after placental delivery.
62756872|NCT02396771|EXPERIMENTAL|Compression|Women allocated to the uterine compression group will be provided with 2 minutes of sustained trans-abdominal uterine compression starting promptly after placental delivery.
62756873|NCT04529369|EXPERIMENTAL|Prominent middle lobe BPH satisfactory channel after MLO PVP|
62756874|NCT04529369|ACTIVE_COMPARATOR|Prominent middle lobe BPH unsatisfactory channel after MLO PVP|
62756875|NCT02438956|PLACEBO_COMPARATOR|Crystalline Cellulose|looks like and is given in the same way as the experimental treatment but contains no active ingredient
62379398|NCT04211649|EXPERIMENTAL|3 days of antibiotherapy|The patient viewed for the first time at the hospital and suspected of leptospirosis received a probabilistic antibiotherapy
62379399|NCT04211649|NO_INTERVENTION|7 days of antibiotherapy (Amoxycilline or Doxycycline)|When the leptospirosis is confirmed ( PCR Leptospirosis positive) the pobabilistic antibiotherapy is switched to a prophylactic antibiotherapy with Amoxicillin or Doxycycline.
62379400|NCT05503966|EXPERIMENTAL|Positive ABM|The ABM intervention will be initiated two weeks after antidepressant treatment started (baseline) and continues with two daily sessions for two weeks.
62756876|NCT02438956|EXPERIMENTAL|Glutathione supplement|500 mg/day Setria glutathione supplement
62756877|NCT00596245|EXPERIMENTAL|1|MT 400, naproxen sodium 550mg
62756878|NCT05362227|OTHER|High-Volume|Patients in the group were instructed to take 4 L of solution on the day before the colonoscopy
62756879|NCT05362227|OTHER|Low-Volume|Patients in the group were instructed to take 2 L of solution on the day before the colonoscopy
62756880|NCT04003480|EXPERIMENTAL|FRAME|Vein graft to be treated with FRAME
62756881|NCT00964340|PLACEBO_COMPARATOR|Placebo|The Placebo treatment group will be administered eight placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
62756882|NCT00964340|ACTIVE_COMPARATOR|0.5g SRT2104|The 0.5g SRT2104 treatment group will be administered 2 SRT2104 capsules with 6 matching placebo capsules, for a total of 8 capsules per day. 0.5g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
62756883|NCT00964340|ACTIVE_COMPARATOR|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered 8 SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
62756884|NCT03655327||stroke patients|stroke patients with upper limb paresis
62756885|NCT03655327||healthy control group|healthy participants with no motor disability of the upper limb
62756886|NCT00974688|ACTIVE_COMPARATOR|Group 1|
62756887|NCT00974688|ACTIVE_COMPARATOR|Group 2|
62756888|NCT03281330||persons with Multiple Sclerosis|
61986866|NCT05601856||Healthy adult control|"Age-matched to Spousal Caregiver to Alzheimer's Patient group Age 65-90 with none of the criteria below:~1. Familial Alzheimer's Disease (AD)~2. Severe cardiovascular disease~3. Severe respiratory system disease~4. Severe liver disease~5. Severe kidney disease~6. Severe central nervous system diseases~7. Having a lifespan of fewer than 3 months~8. History of psychiatric illness~9. Major neurological diseases other than AD~10. Current use of corticosteroids, antibiotics, or bowel motility modification agents~11. Any history of Alcoholism or illicit drug dependence~12. Previous inclusion in this study~13. Difficulty with follow-up or poor compliance~14. Severe hearing impairment~15. Severe vision impairment"
62756889|NCT03281330||Healthy controls|
62756890|NCT06093178||Residents of Athy, Co. Kildare|Anyone who lives, works or plays in Athy and the surrounding 5 Km who is over 18 years is invited to take part.
62756891|NCT00597363|EXPERIMENTAL|1|Neptune PAD utilization to accelerate closure of the vascular access site
62756892|NCT00597363|ACTIVE_COMPARATOR|2|manual compression for closure of the vascular access site
62756893|NCT02728960|EXPERIMENTAL|Traumatic Brain Injury|Documented history of Traumatic Brain Injury
62756894|NCT02728960|ACTIVE_COMPARATOR|Normal Controls|No prior history of concussion, TBI, blast exposure, stroke, or other major neurological disorder
62756895|NCT02728960|ACTIVE_COMPARATOR|Sequence Development Volunteers|
62756896|NCT04443517|EXPERIMENTAL|Maintenance-Alpha Optimization / Wake from Propofol|During the first randomization, participants randomized to intraoperative oscillatory EEG alpha optimization will receive individualized titration of anesthetic gas and opioid. During the second randomization, participants randomized to conversion to a propofol infusion for emergence from anesthesia will received an infusion of propofol 400mg/h and simultaneous reduction of desflurane concentration during the final 10-20 minutes of surgery.
62756897|NCT04443517|ACTIVE_COMPARATOR|Maintenance-Alpha Optimization / Wake from Volatile|During the first randomization, participants randomized to intraoperative oscillatory EEG alpha optimization will receive real-time monitoring of alpha recordings and individualized titration of desflurane and opioid. During the second randomization, participants randomized to standard emergence from volatile anesthesia will be woken up per standard practice.
62756898|NCT04443517|ACTIVE_COMPARATOR|Maintenance-Routine Care / Wake from Propofol|During the first randomization, participants randomized to standard of care will receive anesthesia per usual care with quantitative processed EEG index values and EEG wave forms. During the second randomization, participants randomized to conversion to a propofol infusion for emergence from anesthesia will received an infusion of propofol 400mg/h and simultaneous reduction of desflurane concentration during the final 10-20 minutes of surgery.
62756899|NCT04443517|NO_INTERVENTION|Maintenance-Routine Care / Wake from Volatile|During the first randomization, participants randomized to standard of care will receive anesthesia per usual care with quantitative processed EEG index values and EEG wave forms. During the second randomization, participants randomized to standard emergence from volatile anesthesia will be woken up per standard practice.
62756900|NCT03838991|EXPERIMENTAL|Monostotic fibrous dysplasia|Patients with monostotic Fibrous dysplasia.
62756901|NCT03838991|EXPERIMENTAL|Polyostotic fibrous dysplasia|Patients with polyostotic Fibrous dysplasia.
62756902|NCT03838991|ACTIVE_COMPARATOR|Controls|Control patients having a scheduled surgery for osteoarthritis.
62557756|NCT05378035||DOAC Recipients|"We shall recruit the DOAC recipients that meet the following inclusion criteria:~1. Chinese NVAF patients on apixaban, dabigatran, edoxaban, or rivaroxaban for 6 months or more.~2. Patients aged 18-80 years old.~3. Patients who are able to provide an informed consent.~4. Patients who are indicated for elective medical procedures that require interruption of DOAC for 48 hours, such as colonoscopy, pleural biopsy, cardiac catheterization, digital subtraction angiograph, etc."
62557757|NCT05881837|EXPERIMENTAL|Treatment group A|HRS9531 injection
62557758|NCT05881837|EXPERIMENTAL|Treatment group B|HRS9531 injection
62756903|NCT05473351||Thirst|Patients undergoing invasive mechanical ventilation for at least 24 hours in one of the participating centers
62756904|NCT04304170|EXPERIMENTAL|Verum group|The dietary supplement under study was composed of fructo-oligosaccharides - FOS: 4.95 gr / sachet and Bifidobacterium animalis lactis: VES002 (LMG P-28149): 5 billion / sachet. They came in the form of sachets of powder to be diluted in a glass of water. Doses were 2 sachets per day for the first 5 days and then 1 sachet per day for the next 25 days.
61986867|NCT03948256|ACTIVE_COMPARATOR|Control intervention|Prompt closure, based on best available scientific data
61986868|NCT03948256|EXPERIMENTAL|Experimental intervention|Gradual weaning, based on best available scientific data
61986869|NCT00136305|EXPERIMENTAL|Pictorial Asthma Action Plan|
61986870|NCT00136305|ACTIVE_COMPARATOR|Written Asthma Action Plan|
61986871|NCT04977076|ACTIVE_COMPARATOR|Interrupted NOAC use (group 1)|Patients in group 1 will receive standard care. Therefore, DOAC use will be interrupted at least 24 hours in advance of ICA or PCI. Based on the renal clearance, last DOAC intake may be extended to 48 hours prior to the procedure \[Table 2\]. After the procedure, patients will continue using their DOAC as usual.
62557759|NCT05881837|EXPERIMENTAL|Treatment group C|HRS9531 injection
62756905|NCT04304170|PLACEBO_COMPARATOR|Placebo group|The comparative product was a placebo that looked strictly identical to the verum and contained only excipients (60% maltodextrin / 40% sucrose).They came in the form of sachets of powder to be diluted in a glass of water. Doses were 2 sachets per day for the first 5 days and then 1 sachet per day for the next 25 days.
62756906|NCT05130606|EXPERIMENTAL|Video Arm|"Culturally Targeted Narrative Video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor. Participants in the video arm will be asked to watch an 18-minute video that the research team developed and tested previously about HBOC and genetic services. The video is recorded with Spanish audio and is available with English subtitles."
62756907|NCT05130606|ACTIVE_COMPARATOR|Fact Sheet Arm|Participants in the Fact Sheet arm will receive a Fact sheet about HBOC and genetic services and will be asked to read it in their own time. The Fact Sheet is available in English and Spanish.
62557760|NCT05881837|EXPERIMENTAL|Treatment group D|HRS9531 injection
62557761|NCT05881837|PLACEBO_COMPARATOR|Treatment group E|HRS9531 injection Placebo
62557762|NCT05881837|PLACEBO_COMPARATOR|Treatment group F|HRS9531 injection Placebo
62557763|NCT05881837|PLACEBO_COMPARATOR|Treatment group G|HRS9531 injection Placebo
62557764|NCT05881837|PLACEBO_COMPARATOR|Treatment group H|HRS9531 injection Placebo
62557765|NCT02036619||pregnant women without known diabetes|
62557766|NCT01199146|EXPERIMENTAL|Abiraterone acetate|
62557767|NCT01002924|EXPERIMENTAL|All Participants|All participants invited to enroll on study will receive EC145 (vintafolide) 2.5 mg by intravenous bolus on Monday, Wednesday, and Friday of Weeks 1 and 3 in each 4-week cycle.
62557768|NCT01127256|EXPERIMENTAL|1|
62557769|NCT01127256|ACTIVE_COMPARATOR|2|
62379401|NCT05503966|ACTIVE_COMPARATOR|No ABM|This group will in addition to TAU complete the schedule of intermediate assessments as in the ABM group, but no ABM , thus controlling for the aspects of the ABM group that are additional to TAU (increased engagement in cognitive activity and repeated assessment over time), but not including the training component itself (SSRI Active comparison group).
62379402|NCT05503966|NO_INTERVENTION|TAU|Patients allocated to this group will be assessed at baseline and at the primary end-point as well after 12 weeks and 6 months follow-up. They will not complete any instruments during the intervention period to prevent the effect of some cognitive activity and provide a more ecologically valid version of TAU as it happens in primary care.
62379403|NCT04652102|EXPERIMENTAL|Randomized Observer-blinded Phase 2b: CVnCoV vaccine|Participants will be vaccinated with CVnCoV 12 µg vaccine on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
62557770|NCT05482217|EXPERIMENTAL|Intervention group|This group was exposed to psychoeducational and problem-solving sessions for five weeks.
62557771|NCT05482217|NO_INTERVENTION|The control group|No intervention was given: only the regular clinic advice for five weeks or treatment as usual.
62557772|NCT04880486|SHAM_COMPARATOR|Control group|usually care with extra health education on upper limb exercise
62557773|NCT04880486|EXPERIMENTAL|Exercise group|usually care with extra supervision upper limb exercise with VR
62557774|NCT03124277|EXPERIMENTAL|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
62756908|NCT01922063|EXPERIMENTAL|Physiotherapy Intervention|20 treatment sessions of a comprehensive physiotherapy program, 12 weeks' duration, with custom tailored instructions by the supervising physician; physicians discussed the course of therapy with the physiotherapist 1x/week. Patients had been treated by physiotherapist according to written prescriptions. Duration of treatment 30 min/ session. Patients were encouraged to practice regular home exercise.
62756909|NCT01922063|SHAM_COMPARATOR|Sham neck massage|"received twenty sessions sham neck massage of 30 minutes' duration each with the patients lying in supine position on a massage bed and the head of the patient resting on the therapist's knees"
62756910|NCT01922063|NO_INTERVENTION|No therapy|"no further therapy, patients were asked to wait and see for the first three months after operation, and no particular treatment was planned"
62756911|NCT01749592|EXPERIMENTAL|Cochlear Implant|Surgical Implantation of a Cochlear Implant
62756912|NCT05712304|NO_INTERVENTION|conventional examination|For patients in the CE group, the colonoscope was withdrawn directly from the splenic flexure to the rectum, and polyps that were found were removed
62756913|NCT05712304|EXPERIMENTAL|second examination|For patients in the SE group, the colonoscope was reinserted into the cecum, additional polyps were removed from the proximal colon during the third withdrawall(third pass), and the remainder of the colon from splenic flexure to rectum was examined in a standard manner
62756914|NCT03668054|EXPERIMENTAL|Bevacizumab (Lumiere®)|Dosage form: intravitreal single dose vial. Dosage: 0.05ml (1.25 mg) Frequency: monthly injections (up to 6 doses)
62756915|NCT04303143||Primary|Primary
62756916|NCT04244864|ACTIVE_COMPARATOR|Treatment as usual (TAU)|8-12 months of treatment
62756917|NCT04244864|EXPERIMENTAL|Cross-sectoral social intervention|8-12 months of treatment
62756918|NCT04579302|EXPERIMENTAL|serratus anterior block|serratus anterior block with 20 ml bupivacaine
62756919|NCT04579302|EXPERIMENTAL|erector spinae block|erector spinae block with 20 ml bupivacaine
62756920|NCT04579302|SHAM_COMPARATOR|control group|sham block with 20 ml saline
62756921|NCT02546440|EXPERIMENTAL|treatment arm|patients are treated with dimethylfumarate over 24 weeks. Dosage will be escalated weekly from 30 mg/d to 720 mg/d over 9 weeks. The dose escalation scheme is the same as approved for psoriasis treatment in Germany
62756922|NCT05530044|EXPERIMENTAL|vaccine|Promotes COVID-19 vaccine uptake
62756923|NCT05530044|ACTIVE_COMPARATOR|climate change|Promotes climate change activism
62756924|NCT03385265|EXPERIMENTAL|DIPPer Academy|Parents randomized to this group will participate in the DIPPer Academy curriculum.
62756925|NCT03385265|ACTIVE_COMPARATOR|Standard of Care Control|Parents randomized to this group will receive care as usual from their child's diabetes provider
62756926|NCT02115750|ACTIVE_COMPARATOR|Enbrel (etanercept)|Enbrel 50mg weekly times 24 weeks.
62756927|NCT02115750|EXPERIMENTAL|CHS-0214|CHS-0214 50mg weekly times 24 weeks.
62756928|NCT03589391|EXPERIMENTAL|Procedures with the use of device for LOR monitoring|Patients enrolled suffered from chronic back pain and underwent epidural infiltration. The device is used.
62379404|NCT04652102|PLACEBO_COMPARATOR|Randomized Observer-blinded Phase 2b: Placebo|Participants will be administered the matching placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
62557775|NCT03124277|OTHER|Control group|Best local diet
62379405|NCT04652102|EXPERIMENTAL|Randomized Observer-blinded Phase 3: CVnCoV vaccine|Participants will be vaccinated with CVnCoV 12 µg vaccine on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
62379406|NCT04652102|PLACEBO_COMPARATOR|Randomized Observer-blinded Phase 3: Placebo|Participants will be administered the matching placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
62379407|NCT04652102|EXPERIMENTAL|Open-label Phase|"After unblinding, the trial will shift from a randomized observer-blinded to an open-label design, and the following cohorts will be defined:~Cohort A: participants who received at least 1 dose of CVnCoV in the randomized observer-blinded phases and choose to receive an authorized/licensed vaccine for preventing COVID-19 (AV) as standard of care through their national vaccination program.~Cohort B: participants who received at least 1 dose of CVnCoV in the randomized observer-blinded phases and choose to remain in the trial without receiving any AV.~Participants on the placebo arm will be withdrawn."
62557776|NCT03996902|EXPERIMENTAL|Tailored intervention|Brief Motivational Smoking Intervention
62379408|NCT02506972|OTHER|30g oats|Classic Quick Quaker Oats
62557777|NCT03996902|EXPERIMENTAL|Control|Intervention consistent with standard clinical practice (Control)
62557778|NCT02046811|EXPERIMENTAL|Patient activation and education|Patient activation and education (PAE)
62756929|NCT03589391|NO_INTERVENTION|Procedures without the use of device for LOR monitoring|Patients enrolled suffered from chronic back pain and underwent epidural infiltration
62756930|NCT01463930|EXPERIMENTAL|Audiovisual videodisc and medical verbal information|
62756931|NCT01463930|ACTIVE_COMPARATOR|Medical verbal information|
62756932|NCT02889679|EXPERIMENTAL|Underwater resection|All eligible lesion identified in a patient will be resected by the underwater technique. Excluded lesions will be resected by standard polypectomy.
62756933|NCT02889679|ACTIVE_COMPARATOR|Conventional resection|All eligible lesion identified in a patient will be resected by the conventional (gas distended colon) resection techniques. Excluded lesions will be resected by standard polypectomy.
62756934|NCT03817333||ACOS smoking history >20 pack-years|Subjects with asthma-COPD overlap syndrome
62756935|NCT03817333||IRAO smoking history <5 pack-years|Subjects with an incomplete reversibility of airway obstruction
62379409|NCT02506972|OTHER|30g oats plus 9g sugar|Classic Quick Quaker Oats
62379410|NCT02506972|OTHER|40g oats|Classic Quick Quaker Oats
62379411|NCT02506972|OTHER|60g oats|Classic Quick Quaker Oats
62379412|NCT02506972|OTHER|22g cream of rice cereal|Cream of Rice Cereal, B\&G Foods, Inc.
62379413|NCT02506972|OTHER|29g cream of rice cereal|Cream of Rice Cereal, B\&G Foods, Inc.
62379414|NCT02506972|OTHER|33g cream of rice cereal|Cream of Rice Cereal, B\&G Foods, Inc.
62379415|NCT02506972|OTHER|44g cream of rice cereal|Cream of Rice Cereal, B\&G Foods, Inc.
62379416|NCT00494195|EXPERIMENTAL|1|The first cohort will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml. The anatomical midline point of the muscle will be identified on the skin and two to six vector injections will be distributed in the direction of an X. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
62557779|NCT02046811|EXPERIMENTAL|PAE plus physician activation|PAE plus physician activation (PAE + MD)
62557780|NCT02046811|EXPERIMENTAL|PAE, MD, plus teledermoscopy|PAE physician activation, plus teledermoscopy (PAE +MD +TD)
62379417|NCT00494195|EXPERIMENTAL|2|The second cohort will receive the same dose of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
62379418|NCT02710110|EXPERIMENTAL|Active Respiratory Trainer|Participants enrolled in this arm will be given the PowerLung trainer. The adjustable spring allows for discrete and calibrated changes to the valve, which in turn blocks air until sufficient inspiratory or expiratory pressure is applied by an individual. In addition, the Micro Mouth Pressure Meter, Pulmonary Function testing, videofluoroscopic swallowing study (VFSS), Swallowing Quality of Life Questionnaire (SWAL-QOL), Iowa Oral Pressure Instrument (IOPI), and capsaicin for use in the reflexive cough test.
62557781|NCT04273308|EXPERIMENTAL|whole-body vibration training|a 12-week whole-body vibration training that conducted 3 times per week, with 5-min continuous vibration at 12-Hz frequency and 3-mm amplitude each time.
62557782|NCT01156545|EXPERIMENTAL|Treatment arm|BIBW 2992 plus simvastatin arm
62557783|NCT01156545|ACTIVE_COMPARATOR|control arm|BIBW 2992 arm
62557784|NCT05027308|EXPERIMENTAL|Teduglutide 0.05 milligram per kilogram (mg/kg)|Participants will receive teduglutide 0.05 milligram per kilogram \[mg/kg\] (0.025 mg/kg for participants with moderate or greater renal impairment) subcutaneous \[SC\] injection once daily in a 28-week treatment cycle consisting of a 24-week treatment period followed by a 4-week no treatment follow-up period for a maximum of 3 cycles.
62557785|NCT01342081|EXPERIMENTAL|1|DE-111 ophthalmic solution
62557786|NCT01342081|ACTIVE_COMPARATOR|2|Tafluprost ophthalmic solution 0.0015%
62557787|NCT01342081|ACTIVE_COMPARATOR|3|Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
62557788|NCT00615199|EXPERIMENTAL|1mg BD|
62557789|NCT00615199|EXPERIMENTAL|5mg BD|
62557790|NCT00615199|EXPERIMENTAL|15mg BD|
62557791|NCT00615199|PLACEBO_COMPARATOR|Placebo BID|
62557792|NCT06067165|EXPERIMENTAL|POET feeling|POET will include six guided digital treatment modules for the youth, and six modules for the parents administered over the course of six weeks.
62557793|NCT06067165|ACTIVE_COMPARATOR|Supportive treatment|The active control will be supportive treatment. It includes six guided digital treatment modules for the youth, and six modules for the parents administered over the course of six weeks.
62557794|NCT05409586||no recurrence|Patients who recovered after IGM treatment and had no signs of relapse
62756936|NCT03264105|EXPERIMENTAL|NovaPro™ Flow|NovaPro™ Flow Flowable Composite, Nanova Biomaterials company, USA
62756937|NCT03264105|ACTIVE_COMPARATOR|Conventional resin-based flowable composite|Filtek™Supreme Ultra Flowable Restorative, 3M ESPE company, USA
62756938|NCT00989521|PLACEBO_COMPARATOR|placebo|normal saline for inhalation
62756939|NCT00989521|ACTIVE_COMPARATOR|PUR003|PUR003 for inhalation
62756940|NCT01905488||Group N|patients who didn't show internal jugula vein valve incompetency (IJVVI)
62756941|NCT01905488||Group PT|patients who showed IJVVI after pneumoperitoneum or Trendelenburg position
62756942|NCT01905488||Group S|patients who showed IJVVI in supine position
62756943|NCT06105216|EXPERIMENTAL|Intervention Group|
62756944|NCT06105216|NO_INTERVENTION|Control Group|
62557795|NCT05409586||recurrence|Patients whose symptoms reappear 3 months after IGM treatment
62557796|NCT04238819|EXPERIMENTAL|Dose Escalation: Abemaciclib + Irinotecan + Temozolomide|Abemaciclib given orally, irinotecan given intravenously (IV) and temozolomide given orally.
62557797|NCT04238819|EXPERIMENTAL|Dose Expansion: Abemaciclib + Irinotecan + Temozolomide|Abemaciclib given orally, irinotecan given IV and temozolomide given orally.
62557798|NCT04238819|EXPERIMENTAL|Dose Escalation: Abemaciclib + Temozolomide|Abemaciclib and temozolomide given orally.
62557799|NCT04238819|EXPERIMENTAL|Dose Expansion: Abemaciclib + Temozolomide|Abemaciclib and temozolomide given orally.
62756945|NCT02460913|EXPERIMENTAL|Acupuncture|patients received a 20 to 30 minutes session of acupuncture
62756946|NCT02460913|ACTIVE_COMPARATOR|IV Morphine|patients received an intravenous titration of morphine every 5 minutes.
62756947|NCT04111016||Participants able to access the intervention|These group sessions will be delivered by government health workers, and include behavioral recommendations about responsive stimulation, nutrition, water, sanitation and hygiene, lead poisoning prevention, and maternal mental health. Pregnancy groups and caregiver-child groups will be held separately, and mothers and caregivers who attend sessions will receive simple toys and books to use during some of the intervention sessions, which they will be permitted to take home with them. In addition, mothers and caregivers who attend intervention sessions will receive 30 sachets containing 1 gm multiple micronutrient powder (MNP) per month. Beginning as soon as pregnancy is confirmed, health workers will facilitate pregnant women in receiving the Iron and Folic acid supplements already provided by the Government of Bangladesh and will continue the supplementation up to three months post-partum period.
62756948|NCT00481715|EXPERIMENTAL|1|Web-based weight loss program
62756949|NCT00481715|EXPERIMENTAL|2|Cash incentive weight loss program
62756950|NCT00481715|EXPERIMENTAL|3|Web-based program plus the cash incentive program
62557800|NCT04238819|EXPERIMENTAL|Part C Stage 1: Abemaciclib in Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide|Abemaciclib given orally, dinutuximab given IV, granulocyte macrophage colony-stimulating factor (GM-CSF) given subcutaneously (subQ), irinotecan given IV and temozolomide given orally or IV.
62557801|NCT04238819|EXPERIMENTAL|Part C Stage 2: Abemaciclib in Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide|Abemaciclib given orally, dinutuximab given IV, GM-CSF given subQ, irinotecan given IV and temozolomide given orally or IV.
62557802|NCT06284369|EXPERIMENTAL|Loss-framed message|Loss-framed message. This 54-second video advertisement employs a loss-framed message, highlighting the detrimental costs associated with continued smoking, including the severe negative health impacts such as increased vulnerability to complications from COVID-19 and the likelihood of ICU hospitalization. The main focus of the ad is a well-known young male Mongolian singer, who serves as the central figure conveying the message.
62557803|NCT06284369|EXPERIMENTAL|Gain-framed message|Gain-framed message. In this 59-second video advertisement, the emphasis is on highlighting the gains associated with quitting smoking. The narrative follows a female protagonist who, one year after quitting, meets with her physician. The physician highlights the client's improved lung X-ray and blood test results compared to the previous year, offering congratulations on the decision and celebrating the positive health outcome. Encouraged by this progress, the client is motivated to continue making positive lifestyle choices.
62557804|NCT01224405|ACTIVE_COMPARATOR|Treatment arm|ten docetaxel cycles + maintenance androgen deprivation.
62557805|NCT01224405|EXPERIMENTAL|suspension arm|Ten Docetaxel cycles + stop androgen deprivation therapy
62557806|NCT01224405|EXPERIMENTAL|intermittent arm|Intermittent Docetaxel
62557807|NCT01224405|ACTIVE_COMPARATOR|Continuous arm|Continuous Docetaxel
62557808|NCT02610751||Smoking|No interventions were applied to this group. Measurements of female fetal testosterone, maternal cotinine and testosterone levels, newborn anogenital distance, second digit to fourth digit (2D:4D) finger length ratio, newborn length and birth weight are collected.
62557809|NCT02610751||Non-smoking|No interventions were applied to this group. Measurements of female fetal testosterone, maternal cotinine and testosterone levels, newborn anogenital distance, second digit to fourth digit (2D:4D) finger length ratio, newborn length and birth weight are collected.
62557810|NCT02212314|EXPERIMENTAL|Response Inhibition Training|Treatment group will receive immediate treatment after pre-test.
62557811|NCT02212314|NO_INTERVENTION|Waitlist Crossover|Waitlist group will not receive intervention while treatment group is active, but waitlist group will be offered treatment after post-test is completed.
62756951|NCT00481715|NO_INTERVENTION|4|No intervention
62756952|NCT01704729|OTHER|group2|Cycloplegic subjective refraction by an experienced optometrist or ophthalmologist
62756953|NCT01704729|OTHER|group3|"Cycloplegic subjective refraction by a vision technician trained in the Zhongshan Ophthalmic Center's Rural Refractionist Program"
62756954|NCT01704729|OTHER|group4|Cycloplegic subjective refraction by an experienced optometrist or ophthalmologist
62756955|NCT01704729|OTHER|group1|Non-cycloplegic self-refraction using First Generation, Child-Specific fluid-filled adjustable spectacles and updated self-refraction protocol
62756956|NCT05220280|NO_INTERVENTION|Local standard of care|
62756957|NCT05220280|EXPERIMENTAL|Imatinib + local standard of care|
62557812|NCT04820738|EXPERIMENTAL|Experimental group|Sensorimotor training exercises include wall slides , core exercises (Planks, leg raises, crunches, bridging) balance exercises (single leg side lift, leg lift with dumble, balance on stability ball) on unstable surface for 50-60 min (3 sets of 10 rep) of exercises and gait training (different patterns of walking).
62756958|NCT05220280|EXPERIMENTAL|Infliximab + local standard of care|
62756959|NCT00328653|EXPERIMENTAL|NOVA22007 0.05%|four times daily
62756960|NCT00328653|EXPERIMENTAL|NOVA22007 0.1%|four times daily
62756961|NCT00328653|SHAM_COMPARATOR|Vehicle|administered four times daily
62756962|NCT05941520|EXPERIMENTAL|Group 1 (acolbifene)|Patients receive acolbifene PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo 3D mammography and collection of blood samples during screening and at the end of acolbifene treatment. In addition, patients undergo RPFNA during screening and during day 1-10 of their menstrual cycle, or if not menstruating, at the convenience of the patient and study staff.
62756963|NCT05941520|ACTIVE_COMPARATOR|Group 2 (tamoxifen)|Patients receive tamoxifen PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo 3D mammography and collection of blood samples during screening and at the end of tamoxifen treatment. In addition, patients undergo RPFNA during screening and day 1-10 of their menstrual cycle, or if not menstruating, at the convenience of the patient and study staff.
62756964|NCT05608525|EXPERIMENTAL|Anodal tDCS stimulation to the ipsilesional M1|"Participant will receive 1 mA anodal tDCS stimulation to the ipsilesional M1 of cortical representation of the affected upper limb.~Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training."
62756965|NCT05608525|EXPERIMENTAL|Anodal tDCS to the contralesional premotor cortex|Participant will receive 1mA anodal tDCS to the contralesional premotor cortex. Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training.
62756966|NCT05608525|SHAM_COMPARATOR|Sham tDCS|"Participant will receive sham tDCS stimulation with anode placed over the scalp area corresponding to ipsilesional M1.~Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training."
62756967|NCT04289077||Patients with histopathological proven DTF|
62756968|NCT05889442|EXPERIMENTAL|Levcromakalim|
62756969|NCT05889442|PLACEBO_COMPARATOR|Placebo|
62756970|NCT03114124|ACTIVE_COMPARATOR|Bipolar Ablation Catheter|Subjects will be randomized by random computer programming to receive standard ablation catheter for their procedure.
62756971|NCT03114124|EXPERIMENTAL|MIFI Ablation Catheter|Subjects will be randomized by random computer programming to receive an ablation with MIFI technology. MIFI Catheter contains tightly spaced multielectrode pattern
62756972|NCT04152551|EXPERIMENTAL|Adult Treatment Arm|Intervention treatment arm. Adults (18+ years) with type 1 OI. Must have at least mild hearing loss. Will receive Risedronate (35mg, 0-2x/week as clinically indicated) for duration of study. Changes in hearing, quality of life, and bone density will be monitored.
62557813|NCT04820738|ACTIVE_COMPARATOR|Control group|Cut back on high-fat foods. Drink plenty of water Use sugar and salt in moderation. Eat fruits and vegetables Get enough calcium Pump up your iron. Get enough fiber
62379419|NCT02710110|SHAM_COMPARATOR|Sham Trainer|Participants enrolled in this arm will be given the PowerLung trainer; however, the adjustable spring allows for discrete and calibrated changes to the valve and these will not have any resistance. In addition, the Micro Mouth Pressure Meter, Pulmonary Function testing, videofluoroscopic swallowing study (VFSS), Swallowing Quality of Life Questionnaire (SWAL-QOL), Iowa Oral Pressure Instrument (IOPI), and capsaicin for use in the reflexive cough test.
62379420|NCT02557867|EXPERIMENTAL|Obese|Body composition measurement before surgery using Dual energy X-ray absorptiometry. Dexmedetomidine infusion during surgery. Venous blood sampling for dexmedetomidine plasmatic levels during and after surgery. Liver blood flow indirect non-invasive assessment after surgery using indocyanine. Liver biopsy during surgery.
62379421|NCT02557867|EXPERIMENTAL|Non-obese|Body composition measurement before surgery using Dual energy X-ray absorptiometry. Dexmedetomidine infusion during surgery. Venous blood sampling for dexmedetomidine plasmatic levels during and after surgery. Liver blood flow indirect non-invasive assessment after surgery using indocyanine. Liver biopsy during surgery.
62379422|NCT01004874|EXPERIMENTAL|Bevacizumab, XRT, Temozolomide, Topotecan|Patients are treated with standard radiation therapy and daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation. Following completion of radiation therapy, patients have a MRI and, if there is no evidence of disease progression, patients receive 12 cycles of Avastin, temozolomide, and topotecan. Beginning a minimum of 14 days after the last radiation treatment, the Avastin is dosed at 10 mg/kg every other week; temozolomide is given at 150 mg/m2 daily the first 5 days in combination with topotecan on days 2 through 6 at 1.5 mg/ m2 for patient not taking EIAEDs and 2.0 mg/ m2 for patients taking EIAEDs on days 2-6 of each 28-day.
62379423|NCT00320619|EXPERIMENTAL|1|Participants will receive either EACA.
62379424|NCT00320619|PLACEBO_COMPARATOR|2|Participants will receive placebo.
62756973|NCT04152551|NO_INTERVENTION|Child (Bisphosphonate Arm)|Observational (no investigational intervention) arm. Children (6-17 years) with any type of OI who are already receiving bisphosphonate treatment as standard of care treatment for orthopedic symptoms. Changes in hearing, quality of life, and bone density will be observed for the duration of the study.
62756974|NCT04152551|NO_INTERVENTION|Child (Control Arm)|Observational arm. Children (6-17 years) with any type of OI who are not receiving bisphosphonate treatment. Changes in hearing, quality of life, and bone density will be observed for the duration of the study.
62379425|NCT05686876|EXPERIMENTAL|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
62557814|NCT04196283|EXPERIMENTAL|Arm 1: ABBV-368 + Tilsotolimod|Participants will be administered ABBV-368 and Tilsotolimod at various timepoints as described in the protocol.
62557815|NCT04196283|EXPERIMENTAL|Arm 2: ABBV-368 + Tilsotolimod + Nab-paclitaxel|Participants will be administered ABBV-368, Tilsotolimod and Nab-paclitaxel at various timepoints as described in the protocol.
62756975|NCT04152551|NO_INTERVENTION|Adult Control Arm|Observational arm. Adults (18+ years) with type 1 OI. Changes in hearing, quality of life, and bone density will be monitored.
62756976|NCT02508740|EXPERIMENTAL|normal renal function|Healthy subjects with normal renal function (Stage 1, \>90 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
62756977|NCT02508740|EXPERIMENTAL|mild renal impairment|Patients with mild renal impairment (Stage 2, 60-89 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
62756978|NCT02508740|EXPERIMENTAL|moderate renal impairment|Patients with moderate renal impairment (Stage 3, 30-59 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
62756979|NCT02508740|EXPERIMENTAL|severe renal impairment|Patients with severe renal impairment (Stage 4, \<30 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
62756980|NCT02508740|EXPERIMENTAL|End Stage Renal Disease (ESRD)|Patients with End Stage Renal Disease (ESRD) receiving dialysis for at least 3 months preceding the initial dose in this study (Stage 5) will participate in 2 treatment periods and will receive a single oral dose of 0.25 mg bevenopran at 3 hours after completion of the last hemodialysis session of the week in Period 1 and a single oral dose of 0.25 mg bevenopran at 3 hours before initiation of the last hemodialysis session of the week in Period 2
62557816|NCT04196283|EXPERIMENTAL|Arm 3: ABBV-368 + Tilsotolimod + Nab-paclitaxel + ABBV-181|Participants will be administered ABBV-368, Tilsotolimod, Nab-paclitaxel and ABBV-181 at various timepoints as described in the protocol.
62557817|NCT00505063|OTHER|A|Immunization Schedule patients \<7 years.
62557818|NCT00505063|OTHER|B|Immunization Schedule patients \> or = to 7 years and \<11 years of age
62557819|NCT00505063|OTHER|C|Immunization Schedule patients \> or = to 11 years of age
62557820|NCT02565745|EXPERIMENTAL|Skin Dressing|Hydrocolloid dressings applied during hospitalization
62557821|NCT02565745|ACTIVE_COMPARATOR|Moisturizing cream|Use of moisturizing cream, as part of conventional skin care
62557822|NCT03885843|EXPERIMENTAL|RDN Group|renal nerve stimulation, mapping and denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator after renal angiography.
62557823|NCT03885843|SHAM_COMPARATOR|Sham Group|renal artery angiography group, without any renal nerve stimulation, mapping or denervation
62557824|NCT03401463|ACTIVE_COMPARATOR|once a day|Cuff pressure checks once a day.
62557825|NCT03401463|ACTIVE_COMPARATOR|three times a day|Cuff pressure checks three times a day
62557826|NCT04143373|EXPERIMENTAL|Warm saline|this site was irrigated during impacted mandibular third molar surgery, with normal saline of 37 ± 1 ° C as for the experimental side.
62756981|NCT00871117|EXPERIMENTAL|Kinrix + M-M-R II + Varivax|Subjects received at Day 0 one dose of Kinrix, intramuscularly in the deltoid region of the left upper arm, co-administered with one dose of M-M-R II and Varivax each, subcutaneously in the deltoid of the right upper and lower arm, respectively.
62756982|NCT00871117|ACTIVE_COMPARATOR|Kinrix + M-M-R II -> Varivax|Subjects received at Day 0 one dose of Kinrix, intramuscularly in the deltoid region of the left upper arm, co-administered with one dose of M-M-R II, subcutaneously in the deltoid of the right upper arm. At Day 30 they received one dose of Varivax subcutaneously in the deltoid region of the right upper arm.
62756983|NCT01090388||1|Participants voluntarily completed a telephone interview using a questionnaire compiled using validated, patient-centered measures of cancer outcomes and psychosocial status.
62379426|NCT02313506|ACTIVE_COMPARATOR|Immediate Intervention Group|Education session, Fitbit Flex, and remote coaching by a PT. These three components of the intervention will be delivered to the participants in Month 1. At the end of the education session, the PT will help participants set personal activity goals. In Month 1, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute weekly phone calls and progressively modify their activities. In Month 2, they will continue using the Fitbit and have access to a PT via email as needed, but no weekly phone calls.
62379427|NCT02313506|PLACEBO_COMPARATOR|Delayed Intervention Group|Same intervention with a 1 month delay: The full intervention will be initiated in Month 2 with a brief education session, use of Fitbit Flex, and counselling by a physiotherapist. The trial will conclude at the end of Month 2.
62379428|NCT04139772|ACTIVE_COMPARATOR|Docetaxel|Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.
62756984|NCT06245057|EXPERIMENTAL|Maternity care home model (MCHM)|Office based prenatal care integrated with comprehensive social services within the maternity care home model.
62756985|NCT06245057|NO_INTERVENTION|Usual care arm|Office based prenatal care with individually outsourced social service referrals.
62756986|NCT02477735||Study group|Infants with COME who will be referred for TTI will undergo actigraphy for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
62756987|NCT02477735||Healthy infants|Healthy infants that were recruited from the community well-baby clinics.
62756988|NCT03249935|EXPERIMENTAL|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
62756989|NCT05973981|ACTIVE_COMPARATOR|Status Quo Packages|Cigarette packages appear as they normally do - no standardization
62756990|NCT05973981|EXPERIMENTAL|Partial standardization|Cigarette packages appear with half of the package using a standardized color
62379429|NCT04139772|EXPERIMENTAL|Abiraterone or Enzalutamide|"Patient will receive Abiraterone or Enzalutamide based on previous treatment.~Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.~Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment."
62379430|NCT04572724|EXPERIMENTAL|Sacubitril/Valsartan treatment group|"Sacubitril/Valsartan will be administered step by step with a titrated dose. When patients switching to Sacubitril/Valsartan from RAS inhibitor, a washout period of at least 36 hours is required to decrease the risk of angioedema.~All subjects can have a beta-blocker, CCB, and/or alpha-blockers to control BP. Dialysis treatment: patients normally complete hemodialysis or peritoneal dialysis, need to ensure adequate dialysis requirements, no obvious overload, patients achieve dry weight after dialysis."
62379431|NCT04572724|ACTIVE_COMPARATOR|RAS inhibitor treatment group|RAS inhibitor group allows the use of a monodose of any ACEi or ARB. All subjects can have a beta-blocker, CCB, and/or alpha-blockers to control BP. Dialysis treatment: patients normally complete hemodialysis or peritoneal dialysis, need to ensure adequate dialysis requirements, no obvious overload, patients achieve dry weight after dialysis.
62379432|NCT03165799|EXPERIMENTAL|Mindfulness Education|"Participants viewed an informational video titled, All it Takes is 10 Mindful Minutes by mindfulness expert, Andy Puddicombe. Following the video, a guided discussion was provided that focused on how the principles of mindfulness can be used to influence a physician's state of mental presence, allowing for moments of clarity, insight, and reflection, and potentially enhance provider and patient safety."
62379433|NCT03165799|NO_INTERVENTION|No Intervention|Participants did not receive mindfulness education.
62379434|NCT01119924|ACTIVE_COMPARATOR|Mirtazapine|Mirtazapine 15mg/day or placebo once a day on the fist week, then 30 mg/day or placebo once a day, and then for 7 consecutive weeks
62379435|NCT01119924|PLACEBO_COMPARATOR|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
62557827|NCT04143373|NO_INTERVENTION|Room temperature saline|this site was irrigated during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C as for the control side.
62756991|NCT05973981|EXPERIMENTAL|Full standardization|Cigarette packages appear with all of the packages fully standardized (by color and font)
62756992|NCT02242981|EXPERIMENTAL|LY2623091|Single oral dose of LY2623091
62756993|NCT04591548||Endometriosis|All patients had laparoscopy due to infertility (and endometriosis). All women had BMI in normal range and regular menstrual cycle (21-35 days). Partner's semen analysis was normal in all cases. The investigators excluded patients with hormonal therapy in the last year, irregular menstrual cycle, smokers and patients with autoimmune diseases, malignant or suspected malignant diseases, previous pelvic inflammatory disease, leiomyoma uteri or polycystic ovaries. None of the patients had previous pelvic surgery.
62756994|NCT04591548||Primary infertility|All patients had laparoscopy due to infertility (and endometriosis). All women had BMI in normal range and regular menstrual cycle (21-35 days). Partner's semen analysis was normal in all cases. The investigators excluded patients with hormonal therapy in the last year, irregular menstrual cycle, smokers and patients with autoimmune diseases, malignant or suspected malignant diseases, previous pelvic inflammatory disease, leiomyoma uteri or polycystic ovaries. None of the patients had previous pelvic surgery.
62379436|NCT01311973||Renal Function Group #1|Creatinine clearance \> 90 mL/min
62756995|NCT03425721||All Participants|
62756996|NCT05239455||Healthy adult participants|Performance criteria will be evaluated in healthy adult participants, who receive radiolabeled, autologous infusions of LR-RBC components after being stored for 42 days at 1-6°C.
62756997|NCT03449693|EXPERIMENTAL|Magnesium Oxide Supplement|Magnesium Oxide 250 mg tablet, daily for 30 days.
62756998|NCT03449693|NO_INTERVENTION|No Supplement|No Intervention
61986872|NCT04977076|EXPERIMENTAL|Uninterrupted NOAC use (group 2)|In group 2, all patients will continue to use their specific DOAC as usual. This means that no adjustments of DOAC use will be made before and after ICA or PCI. After the procedure patients will continue to use DOAC from the next planned dose.
62379437|NCT01311973||Renal Function Group #2|Creatinine clearance 60-69 mL/min
62379438|NCT01311973||Renal Function Group #3|Creatinine clearance 50-59 mL/min
62379439|NCT01311973||Renal Function Group #4|Creatinine clearance 40-49 mL/min
62379440|NCT01311973||Renal Function Group #5|Creatinine clearance 30-39 mL/min
62379441|NCT01311973||Renal Function Group #6|Creatinine clearance 20-29 mL/min
62379442|NCT01311973||Renal Function Group #7|Creatinine clearance \< 20 mL/min (not on dialysis)
62379443|NCT01922466|EXPERIMENTAL|Bee Venom Acupuncture|
62379444|NCT01922466|EXPERIMENTAL|Loxoprofen|
62379445|NCT01922466|EXPERIMENTAL|EWCT : Bee Venom Acupucture and Loxoprofen|
62379446|NCT04715659||COPD patients|
62379447|NCT01573611|EXPERIMENTAL|Grape Powder|
62379448|NCT01573611|PLACEBO_COMPARATOR|Placebo Powder|
62379449|NCT00779818|EXPERIMENTAL|Group 1|Treatment by electrical acupuncture
62379450|NCT00779818|EXPERIMENTAL|Group 2|Treatment by laser
62756999|NCT03835884|EXPERIMENTAL|AR-13503 Implant 10.6 Dose|Single dose of AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
62757000|NCT03835884|EXPERIMENTAL|AR-13503 Implant 21.2 Dose|Single dose of AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
62757001|NCT03835884|EXPERIMENTAL|AR-13503 Implant 42.4 Dose|Single dose of AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
62757002|NCT03835884|EXPERIMENTAL|AR-13503 Implant 63.6 Dose|Dose of AR-13503 Implant 63.6 Dose (63.6 µg) administered into a single eye of up to 5 subjects (DME) who will be followed for 24 weeks. Subjects may qualify to receive an additional dose at Week 12.
62557828|NCT02860546|EXPERIMENTAL|TAS-102 + Nivolumab|Participants received a dose of 35 milligrams per meter square (mg/m\^2) of TAS-102 tablets orally twice per day (BID) within 1 hour after completion of morning and evening meals, in 4-week cycle. In each 4-week cycle, TAS-102 was administered for 2 weeks, as 5 days a week with 2 days rest, followed by a 14-day rest. Also participants received 3 milligrams per kilogram per dose (mg/kg/dose) Nivolumab intravenous (I.V) infusion over 60 minutes every 14 days (on Day 1 and Day 15 of each 4-week cycle).
62557829|NCT02951754|EXPERIMENTAL|IR-MPH|Immediate-release methylphenidate (IR-MPH) 10 mg two or three times daily with doses increasing weekly until symptom control
62557830|NCT06452017|EXPERIMENTAL|telerehabilitation exercise group|this group will receive a structured telerehabilitation exercise protocol of low to moderate intensity warm up ,aerobic ,resistance and cool down exercises for 3 times a week progressively increased for 8 weeks in addition to routine medical care for GDM.
62557831|NCT06452017|ACTIVE_COMPARATOR|routine medical care|The control group will receive routine medical care including oral medication,diet and regular walk.
62557832|NCT05553821|ACTIVE_COMPARATOR|Manual pressure group|A sand bag weighing 3.5-4 kg is applied to the CAG area of this group of patients.
62557833|NCT05553821|EXPERIMENTAL|Cold pressure group|A cold sand bag weighing 3.5-4 kg is applied to the CAG area of this group of patients.
62757003|NCT06608992|EXPERIMENTAL|using SURGICEL® Powder|The SURGICEL® Powder will be sprayed in areas such as the posterior joint capsule, medial gap, lateral gap, suprapatellar pouch, and infrapatellar fat pad. After the SURGICEL® Powder fully react and change color, any unreacted SURGICEL® Powder will be appropriately washed using an irrigation gun.
62757004|NCT06608992|NO_INTERVENTION|not using SURGICEL® Powder|The SURGICEL® Powder will not be used during the surgery.
62757005|NCT02970006|EXPERIMENTAL|neurovisual stimulation|Participants in this study will be adults who have already undergone implantation of SCS for the treatment of their pain conditions. The study involves no further treatment or intervention. Subjects will be approached for participation in this study during their routine postoperative clinical visit to the Center for Neuromodulation at the Ohio State University (OSU).All eligible patients will undergo a one-day visit for the virtual reality and full body illusion intervention. This research will also investigate leg embodiment and leg analgesic effects during SCS integrated with different patterns of virtual leg illumination.
62757006|NCT05234424|ACTIVE_COMPARATOR|THRIVE 40 L/min|40 L/min with 100% oxygen for 10 minutes.
62757007|NCT05234424|EXPERIMENTAL|THRIVE 100 L/min|100 L/min with 100% oxygen for 10 minutes.
62557834|NCT03618251||ischemic stroke|all patients with a suspicion of ischemic stroke
62557835|NCT00381979|EXPERIMENTAL|1|set
62557836|NCT03665740|EXPERIMENTAL|Resveratrol|Doses of resveratrol at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the resveratrol, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment.
62757008|NCT02241057|EXPERIMENTAL|Temperature|Evaluate the temperature profile of the air activated 3-cell patch during 8 hours of wear
62757009|NCT02241057|EXPERIMENTAL|Adhesion|Evaluate the adhesion with and without the presence of a temperature probe
62757010|NCT05540769|EXPERIMENTAL|case group|
62757011|NCT01335750|EXPERIMENTAL|Multipurpose Solution #1|B\&L Renu Fresh Multipurpose Solution
62757012|NCT01335750|EXPERIMENTAL|Multipurpose Solution #2|OptiFree Replenish Multipurpose Solution
62757013|NCT01335750|EXPERIMENTAL|Multipurpose Solution #3|Ciba ClearCare Multipurpose Solution
62757014|NCT01335750|ACTIVE_COMPARATOR|Multipurpose Solution #4|Saline Solution
62757015|NCT00539513|EXPERIMENTAL|N-Acetylcysteine|Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose titrated to 3000 mg within the first week, in addition to the medication regimen they are on at enrollment
62757016|NCT00539513|PLACEBO_COMPARATOR|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
62757017|NCT06223789|EXPERIMENTAL|Volt PFA Catheter Sensor Enabled (SE)|
62757018|NCT03591614|EXPERIMENTAL|Dendritic cell DKK1 vaccine|5-10x106 DKK1 loaded dendritic cells. Three doses will be given two weeks apart, followed by 11 months of observations.
62757019|NCT02844335|EXPERIMENTAL|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
62557837|NCT03665740|PLACEBO_COMPARATOR|Placebo|Doses of placebo at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the placebo, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment
62757020|NCT02844335|ACTIVE_COMPARATOR|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
62757021|NCT05670548||Abnormal postpartum glucose metabolism|GDM with positive OGTT results at 6-12 weeks postpartum
62379451|NCT05012514|NO_INTERVENTION|Control- Without intervention|The participants have the right side of the abdomen as a control without inversion
62379452|NCT05012514|ACTIVE_COMPARATOR|LLLT- With intervention|The participants received the LED PBMT treatment with associated red and infrared wavelengths sequentially on the left side of the abdomen
62557838|NCT03606785|ACTIVE_COMPARATOR|tranexamic acid group|
62557839|NCT03606785|PLACEBO_COMPARATOR|placebo group|
62557840|NCT00485264|EXPERIMENTAL|Cohort I|"Participants between the ages of 12 and 18 years; receiving raltegravir poloxamer film coated tablet:~Stage I starting dose: Weight based dose of \~6 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: 400-mg tablet taken orally twice daily."
62557841|NCT00485264|EXPERIMENTAL|Cohort IIA|"Participants between the ages of 6 and 11 years, receiving raltegravir poloxamer film coated tablet:~Stage I starting dose: Weight based dose of \~8 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants \< 25 kg were switched to a weight-based dose of the chewable tablet."
62557842|NCT00485264|EXPERIMENTAL|Cohort IIB|"Participants between the ages of 6 and 11 years; receiving raltegravir chewable tablet:~Stage I starting dose: Weight based dose of \~8 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: Weight based dose of \~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily."
62557843|NCT00485264|EXPERIMENTAL|Cohort III|"Participants between the ages of 2 and 5 years; receiving raltegravir chewable tablet:~Stage I starting dose: Weight based dose of \~6 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: Weight based dose of \~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily."
62557844|NCT00485264|EXPERIMENTAL|Cohort IV|"Participants between the ages of 6 and 23 months; receiving raltegravir oral granules for suspension (20 mg/mL):~Stage I starting dose: Weight based dose of \~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data."
62557845|NCT00485264|EXPERIMENTAL|Cohort V|"Participants between the ages of 4 weeks and 5 months; receiving raltegravir oral granules for suspension (20 mg/mL):~Stage I starting dose: Weight based dose of \~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data."
62557846|NCT01130532|ACTIVE_COMPARATOR|2.5 milligram (mg) titrated to 5 mg Tadalafil|2.5 mg for 4 weeks, followed by 5 mg for 8 weeks with option to continue treatment at 5 mg for an additional 4 weeks
62557847|NCT01130532|ACTIVE_COMPARATOR|5 mg Tadalafil|5.0 mg for 12 weeks with option to continue treatment for additional 4 weeks
62557848|NCT01130532|PLACEBO_COMPARATOR|Placebo|for 12 weeks
62557849|NCT03015246|PLACEBO_COMPARATOR|Extended-Release Morphine + placebo stressor|Participants will be maintained on extended-release morphine (dose tailored to the individual, based on pre-experimental opioid use amount), in three divided daily doses. The placebo stressor will be administered on one day.
62557850|NCT03015246|EXPERIMENTAL|Buprenorphine/Naloxone low dose + placebo stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 1.4/0.36 mg/day. The placebo stressor will be administered on one day.
62757022|NCT05670548||Control|GDM with negative OGTT results at 6-12 weeks postpartum
62757023|NCT05291975|ACTIVE_COMPARATOR|Erchonia® EVRL™|The Erchonia® EVRL™ is made up of (1) 635 nanometers red laser diode and (1) 405 nanometers violet laser diode mounted in a portable handheld device.
62757024|NCT05291975|PLACEBO_COMPARATOR|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® EVRL™ but does not emit any therapeutic light.
62757025|NCT02125903|ACTIVE_COMPARATOR|Continuous Adductor Canal Block (CACB)|"Continuous Adductor Canal block performed with:~loading dose 0,375% Ropivacaine 15ml (56,25mg) start infusion 0,2% Ropivacaine 6ml/h~Procedure: Femoral Nerve Block. Adductor Canal Block Drug: Ropivacaine"
62757026|NCT02125903|ACTIVE_COMPARATOR|Continuous Femoral Nerve Block (CFNB)|"Continuous Femoral Nerve Block performed with:~loading dose 0,375% Ropivacaine 15ml (56,25mg) start infusion 0,2% Ropivacaine 6ml/h~Procedure: Femoral Nerve Block. Adductor Canal Block Drug: Ropivacaine"
62379453|NCT01715376||Integrative Chinese and western medicine|Integrative Chinese and western medicine group treat with western medical therapy for CHD refering to the 'Chronic stable angina pectoris diagnosis and treatment guide'which is published by Chinese society of Cardiology, Chinese Medical Association in March, 2007, including the anti-ischemia treatment(nitric acid ester,β-blocker,calcium antagonist,ACEI), anti platelet therapy(aspirin and/or clopidogrel) and other statins.TCM should be confirmed by the physicians, according to the syndrome differentiation and the treat plan recommended in this study.
62757027|NCT02120521||Sepsis group|Sixty patients are critically ill with evidence of sepsis during ICU stay (sepsis group) and sixty patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of sTREM-1 and MNDA will be monitored.
62757028|NCT02120521||SIRS group|Sixty patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of sTREM-1 and MNDA will be monitored.
62379454|NCT01715376||Western medicine|western medical therapy for CHD can refer to the 'Chronic stable angina pectoris diagnosis and treatment guide'which is published by Chinese society of Cardiology, Chinese Medical Association in March, 2007, including the anti-ischemia treatment(nitric acid ester,β-blocker,calcium antagonist,ACEI), anti platelet therapy(aspirin and/or clopidogrel) and other statins.
62757029|NCT02521233|EXPERIMENTAL|Test 1: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 12,5 mg) a day, in the morning.
62757030|NCT02521233|EXPERIMENTAL|Test 2: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 25 mg) a day, in the morning.
62757031|NCT02521233|ACTIVE_COMPARATOR|Comparator: losartan+hydrochlorothiazide (Hyzaar®)|he patients will take 1 tablet (Losartan 50 mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
62757032|NCT04909359||Crohn's disease (CD)|People with CD recently receiving vedolizumab as standard of care will be followed up to 5 years.
62757033|NCT04909359||Ulcerative colitis (UC)|People with UC recently receiving vedolizumab as standard of care will be followed up to 5 years.
62757034|NCT01129882|EXPERIMENTAL|Aripiprazole IM depot|Active treatment of monthly doses of aripiprazole IM depot (300 mg or 400 mg)
62379455|NCT05705960|EXPERIMENTAL|Chestnut|
62379456|NCT04322266|EXPERIMENTAL|Sequence 1 (Reference-Test)|Period1: HCP1306+HGP0904+HGP0608, Period 2: HCP1701
62379457|NCT04322266|EXPERIMENTAL|Sequence 2 (Test-Reference)|Period1: HCP1701, Period 2: HCP1306+HGP0904+HGP0608
62379458|NCT01132768|ACTIVE_COMPARATOR|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily.
62379459|NCT01132768|EXPERIMENTAL|Olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily.
62379460|NCT05327244|EXPERIMENTAL|Intervention|All CAI participants will complete the same intervention and will walk 6, 1-mile paths in the real wold (ie: around campus) with vibration feedback within 2 weeks of baseline assessment. A study team member will accompany each participant during each training.
62757035|NCT02208453|EXPERIMENTAL|InSpace implantation|InSpace device implantation
62757036|NCT00589056|EXPERIMENTAL|Single arm|Nelfinavir
62757037|NCT03099941|EXPERIMENTAL|Biofeedback group|The biofeedback application which helps patient to understand neutral position and how to maintain it in exercises that are prescribed by the physical therapist
62757038|NCT03099941|ACTIVE_COMPARATOR|Physical therapist feedback group|In physical therapist feedback group feedback applied by oral and tactile stimulation of physical therapist to helps patient to understand neutral position and how to maintain it in exercises that are prescribed
62757039|NCT06019247|NO_INTERVENTION|Usual Services.|Generally, providers of rehabilitation Usual Care for PSMI at CAISAME-EP include 2 full-time psychologists, 2 full-time social workers, a half-time occupational therapist, and a half-time psychiatrist. This team, however, also provides services to clients with other mental conditions (e.g., substance use). As a result, the Usual Care services are of lower intensity than IPS and omit most of the key ingredients of the intervention. Moreover, it does not follow a standardized manual/protocol. The Usual Care team also offers other services such as psychiatric medication, individual and group psychotherapy, and psychoeducation for clients and relatives.
62379461|NCT05327244|NO_INTERVENTION|Healthy Control|Posttest data from CAI participants will be compared to de-identified healthy control data collected as part of a previous study. Healthy control participants completed a single research session to collect walking biomechanics using the same methods as this project. They received no further follow up or intervention and the inclusion/ exclusion criteria for this group match those of the chronic ankle instability cohort.
62379462|NCT03114670|EXPERIMENTAL|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|Patients will receive a full dose CART infusion at day 0.
62379463|NCT01856179|EXPERIMENTAL|Echium oil young|"BMI\<25,~age 20-30"
62379464|NCT01856179|EXPERIMENTAL|Echium oil older|age 40-70 BMI \<25
62379465|NCT01856179|EXPERIMENTAL|Echium oil older, overweight|age 40-70 BMI \>25
62379466|NCT05414669|EXPERIMENTAL|Interventional group|Allopurinol 300 mg was administered orally for a total of 3 days, starting from the day before ESWL
62379467|NCT05414669|PLACEBO_COMPARATOR|Control Group|Placebo was administered orally for a total of 3 days, starting from the day before ESWL
62379468|NCT00992485|EXPERIMENTAL|autologous adipose derived stem cell|
62379469|NCT00652522|ACTIVE_COMPARATOR|A|Best Medical Treatment, ICD/CRT implant
62379470|NCT00652522|EXPERIMENTAL|B|AF Ablation, ICD/CRT implant
62379471|NCT01984294|EXPERIMENTAL|LDV/SOF+RBV|Participants will receive LDV/SOF plus RBV for 8 weeks.
62379472|NCT01984294|EXPERIMENTAL|LDV/SOF + GS-9669 250 mg|Participants will receive LDV/SOF plus GS-9669 250 mg for 8 weeks.
62379473|NCT01984294|EXPERIMENTAL|LDV/SOF + GS-9669 500 mg|Participants will receive LDV/SOF plus GS-9669 500 mg (2 x 250 mg) for 8 weeks.
62379474|NCT03637166|EXPERIMENTAL|Order A|"The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)"
62379475|NCT03637166|EXPERIMENTAL|Order B|"The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level)."
62379476|NCT03016832|EXPERIMENTAL|Huangkui|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing; HuangKui Capsule 2.5g/tid, oral dosing
62379477|NCT03016832|ACTIVE_COMPARATOR|controlled|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing; HuangKui Capsule 2.5g/tid, oral dosing irbesartan tablets 150mg /qd, oral dosing; Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
62379478|NCT03016832|OTHER|combined treatment|irbesartan tablets 150mg /qd, oral dosing HuangKui Capsule 2.5g/tid, oral dosing.
61986873|NCT05836064|EXPERIMENTAL|GastroBot-assisted bowel preparation group (GB-group)|Adult patients with no surgical high-risk comorbidities and colonoscopy indications for screening, surveillance, or diagnosis who are undergoing a colonoscopy. GastroBot assisted with the polyethylene glycol bowel preparation: patients will receive the instructions through the WhatsApp application, being guided by the software bot with multiple and personalized alternative instructions according to results.
61986874|NCT05836064|EXPERIMENTAL|Conventional-assisted bowel preparation group (C-group).|Adult patients with no surgical high-risk comorbidities and colonoscopy indications for screening, surveillance, or diagnosis who are undergoing a colonoscopy. The patients received bowel polyethylene glycol bowel preparation instructions in writing without prior personalized advice.
62379479|NCT02495584|EXPERIMENTAL|Treatment 1|500ml fortified milk (10µg vitamin D3) +1 supplement capsule (10µg vitamin D3) daily for 24 weeks
62379480|NCT02495584|EXPERIMENTAL|Treatment 2|500ml fortified milk (10µg vitamin D3) +1 supplement capsule (placebo) daily for 24 weeks
62379481|NCT02495584|EXPERIMENTAL|Treatment 3|500ml unfortified milk (placebo) +1 supplement capsule (10µg vitamin D3) daily for 24 weeks
62379482|NCT02495584|PLACEBO_COMPARATOR|Treatment 4|500ml unfortified milk (placebo) +1 supplement capsule (placebo) daily for 24 weeks
62379483|NCT00959829|PLACEBO_COMPARATOR|silence|"The control group listened silence and was evaluated the same things."
62379484|NCT03681873|EXPERIMENTAL|Study Group|Patients will receive both the clinically indicated and extremely low dose exams
62379485|NCT01738594|EXPERIMENTAL|Arm A (carfilzomib)|Patients receive carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16.
62379486|NCT01738594|EXPERIMENTAL|Arm B (carfilzomib, romidepsin)|Patients receive carfilzomib as in Arm A and romidepsin IV over 4 hours on days 1, 8, and 15.
62379487|NCT03245840|EXPERIMENTAL|Budesonide Oral Suspension|Participants received 10 milliliters (mL) of budesonide oral suspension at a concentration of 0.2 milligram per milliliter (mg/mL), twice daily, for up to 4 years 5 months.
62379488|NCT02020213|OTHER|Posaconazole, salvage|Posaconazole, per oral , 400 mg, bid , 8 weeks.
62379489|NCT03474939|ACTIVE_COMPARATOR|MIDAZOLAM|Patients receive midazolam 7,5mg night before and 60 minutes prior to surgery as part of preanesthetic medication
62379490|NCT03474939|PLACEBO_COMPARATOR|PLACEBO|Patients receive 1000mg Glucose tablets night before and 60 minutes prior to surgery during premedication
62379491|NCT02783651||No treatment 1|It is planned to have 20-30 sites participating on the trial for chart review of approximately 200-235 patients initiating treatment for Philadelphia chromosome-negative (Ph-) Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) between January 2013 and March 2019.
62379492|NCT02783651||No Treatment 2|Initial record abstraction will occur at study site with subsequent reviews occurring at the site every 3 months thereafter until study conclusion on March 2020.
62379493|NCT03174392|EXPERIMENTAL|Resistance based training study:|Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
62379494|NCT03174392|ACTIVE_COMPARATOR|Speed based training study:|Each training session will begin by determining the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
62379495|NCT00338806|EXPERIMENTAL|Interpersonal Psychotherapy-Prevention|Participants will receive interpersonal psychotherapy for prevention with adolescents
62379496|NCT00338806|ACTIVE_COMPARATOR|Educational and Clinical Monitoring|Participants will receive educational clinical monitoring
62757040|NCT06019247|EXPERIMENTAL|Adapted IPS|The IPS program adaptation process, will be conducted with 2 teams of providers, each consisting of an employment specialist, a case manager: psychologist, social worker and a psychiatrist, who will work in coordination to provide IPS services (each specialist will have between 15 and 20 clients). The IPS team will consist of providers and will be trained by the Research Adaptation Team in consultation and supervised. Weekly case-oriented supervision with a trained IPS supervisor, biweekly telephone contact, and telephone consultations as needed will help the IPS teams maintain high fidelity IPS. Following randomization, individuals assigned to receive IPS will be assigned to an IPS treatment team and will be introduced directly to their assigned case managers. Case management and IPS staff will be in close proximity to facilitate both IPS staff attendance at case management team meetings and the ongoing interaction necessary for efficient IPS implementation.
62379497|NCT02625363|EXPERIMENTAL|Glucose Ref - Std|250 ml glucose solution with 50 gram available carbohydrate per serving, used as reference
62757041|NCT01338610|EXPERIMENTAL|ESBA105|ESBA105 ophthalmic solution, 1 drop in each eye 3 times per day for 4 weeks
62379498|NCT02625363|EXPERIMENTAL|Glucose Ref and 450 ml water|250 ml glucose solution with 50 gram available carbohydrate per serving. Sample was consumed with additional water intake @150 ml at 45, 75, and 105 minutes after meal consumption
62379499|NCT02625363|EXPERIMENTAL|White Bread with 250 ml water|White bread with 50 gram available carbohydrate was consumed with 250 ml water immediately after meal consumption
62379500|NCT02625363|EXPERIMENTAL|White Bread and 700 ml water|White bread with 50 gram available carbohydrate was consumed with 250 ml water immediately after meal consumption. Moreover, subjects given additional water intake @150 ml at 45, 75, and 105 minutes after meal consumption
62379501|NCT02625363|EXPERIMENTAL|White Bread with 125 ml water (twice)|Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes
62757042|NCT01338610|PLACEBO_COMPARATOR|Vehicle|ESBA105 vehicle, 1 drop in each eye 3 times per day for 4 weeks
61986875|NCT01577147|OTHER|sample collection|Ovulation prediction products provided to aid conception
62379502|NCT05162300|EXPERIMENTAL|Group A|"Subjects will be given the same-day combination of VI Peel (Procedure) and Botox Cosmetic (Botulinum Toxin) (Drug). Botox will be administered via intramuscular injection via package insert to Glabella, Forehead and Crows Feet. Dosage will follow package insert guidelines.~The two interventions will be administered once at the start of the study, subsequent study visits will focus on assessment and evaluation."
62757043|NCT04904796|EXPERIMENTAL|Constraint-induced Movement Therapy With Home-based Hand-arm Bimanual Intensive Therapy|Children in experimental group will receive 2-hour clinic-based CIMT sessions, 5 days/week for 3 weeks (30 hours), and 2-hour home-based HABIT sessions, 3 days/week for 5 weeks (30 hours).
62379503|NCT04340089||observation group|the patients can go to squatting on the toilet at any time as they want to after taking the capsule
62379504|NCT04340089||control group|The patients can move freely
62379505|NCT04952116|OTHER|Eyelid reconstruction|Direct eyelid closure will be done in small defects after periocular defects with or without canthyolysis , Larger defects will be reconstructed with anterior and posterior lamella reconstruction using grafts and flaps
62757044|NCT04904796|ACTIVE_COMPARATOR|Constraint-induced Movement Therapy only|Children in experimental group will receive 2-hour clinic-based CIMT sessions, 5 days/week for 3 weeks (30 hours).
62757045|NCT01382121|EXPERIMENTAL|Peer modeling|Participants watch a video geared to increase confidence in ability to preform fitness test. Male participants will watch a video of a male adolescent completing the fitness test and talking about coping mechanisms used to preform to the best of his ability. Female participants will watch a video of a female adolescent completing the fitness test and talking about coping mechanisms used to preform to the best of her ability.
62757046|NCT01382121|ACTIVE_COMPARATOR|Control|Participants watch a video unrelated to the fitness test and self-efficacy. The video depicts healthy food and nutrition options.
61986876|NCT01207531||Survival Group|
62379506|NCT01085942||Asymptomatic rotator cuff tear|Subjects identified with an asymptomatic rotator cuff tear
61986877|NCT01207531||Death group|
61986878|NCT01329094||Patients with severe mental illness|In-patients and out-patients with severe mental illness attending treatment at Aarhus University Hospital, Risskov.
61986879|NCT01329094||Healthy controls|Healthy controls recruited from staff members at Aarhus University Hospital, Risskov
62379507|NCT01234337|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006) + Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
62557851|NCT03015246|EXPERIMENTAL|Buprenorphine/Naloxone moderate dose + placebo stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 4.2/1.08 mg/day. The placebo stressor will be administered on one day.
61986880|NCT02984033||Head and Neck patients|Patients affected by squamous cell carcinoma of head and neck (oral cavity, larynx, pharynx and hypopharynx) with no metastasis
61986881|NCT02392962|EXPERIMENTAL|Experimental I|This group performed static stretching
61986882|NCT02392962|ACTIVE_COMPARATOR|Experimental II|This group performed dynamic stretching
61986883|NCT00457509|EXPERIMENTAL|Group 1|Dose 1 with Adjuvant
61986884|NCT00457509|EXPERIMENTAL|Group 2|Dose 2 with adjuvant
61986885|NCT00457509|EXPERIMENTAL|Group 3|Dose 3 with adjuvant
62757047|NCT04095663|ACTIVE_COMPARATOR|Partial Colectomy|Elective segmental colectomy for diverticular disease involves removal of the segment of colon (most commonly sigmoid and/or left colon) where there has been disease identified by computed tomography imaging or colonoscopy. Elective colectomy usually removes the affected colon along with adjacent segments that have diverticula, with a primary anastomosis performed to reestablish bowel continuity. Most surgeons now perform the procedure using a laparoscopic approach, when possible, and sometimes use a temporary, protective stoma if the re-connection is considered high-risk. The technique for laparoscopic resection is not specified by the protocol (allows for any number of laparoscopic port sites, all incision types, hand-assistance and robotic) with details of the technique recorded. If randomized to elective colectomy, patients will be encouraged to undergo the procedure within 6 weeks of assignment.
62757048|NCT04095663|ACTIVE_COMPARATOR|Medical Management|"Medical management for diverticular disease has been used for over 30 years and includes a set of interventions, all components of which have been the subject of small, but often positive trials. All patients randomized to medical management or who select it as their treatment in the observational cohort will view a video (provided in English and Spanish) that explains each element of the medical management toolbox: diet and exercise recommendations, fiber supplementation (e.g., augmenting dietary fiber or over the counter fiber supplements), with mesalazine tablets or suppositories, probiotics and rifamycin. In consultation with their physician, they will be recommended to a regimen of diet and exercise and fiber supplementation. Clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise."
62757049|NCT00928278|EXPERIMENTAL|Treatment A - PF-04764793|PF-04764793 using inhaler A
62757050|NCT00928278|ACTIVE_COMPARATOR|Treatment B - PF-04764793|PF-04764793 using inhaler B
62379508|NCT01234337|PLACEBO_COMPARATOR|Placebo + Capecitabine|Capecitabine was administered orally at a dose of 1,000 mg/m\^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
62757051|NCT00928278|EXPERIMENTAL|Treatment C - PF-04764793|PF-04764793 using inhaler A
62757052|NCT00928278|ACTIVE_COMPARATOR|Treatment D - PF-04764793|PF-04764793 using inhaler B
62757053|NCT02753621|EXPERIMENTAL|Singing Intervention|Twelve weekly group singing classes lasting 60-90 minutes under the direction of a professional choir director and a social worker with a music background.
62757054|NCT02753621|ACTIVE_COMPARATOR|Discussion/Support Group Intervention|Twelve weekly 60-90 minute discussion groups led by a facilitator trained in discussion group facilitation; occurring at the same time and in the same location (next door) as experimental intervention (group singing).
62757055|NCT02280824|EXPERIMENTAL|A|Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access
62757056|NCT04920721||Allergic|suspected of immediate hypersensitivity reaction to platinum salts with positiv skin tests
62757057|NCT04920721||Non allergic|suspected of immediate hypersensitivity reaction to platinum salts with negativ skin tests
62757058|NCT04553653|NO_INTERVENTION|Baseline|Data on diagnosis and care of patients presenting with acute severe hypertension will be collected at baseline (prior to the implementation of a checklist)
62757059|NCT04553653|EXPERIMENTAL|Intervention arm|The intervention arm will be enrolled after the checklist implementation.
62757060|NCT03172091|EXPERIMENTAL|Acute rejection|Pulmonary transplant patients with acute rejection
62757061|NCT03172091|OTHER|Control group|Pulmonary transplant patients without acute rejection
62757062|NCT02670707|EXPERIMENTAL|"Cytarabine (experimental) arm"|On this arm, patients will receive single therapy with cytarabine.
62379509|NCT03648502|EXPERIMENTAL|dementia (D-HI)|hearing impaired dementia
62379510|NCT03648502|OTHER|Mild cognitive impairment (MCI-HI)|MCI with hearing loss
62379511|NCT03648502|ACTIVE_COMPARATOR|normal (N-HI)|normal cognition with hearing loss
62379512|NCT04276831|ACTIVE_COMPARATOR|Laryngoscope McCoy|Patients will be intubated using laryngoscope McCoy
62757063|NCT02670707|ACTIVE_COMPARATOR|"Vinblastine/prednisone (standard) arm"|On this arm, patients will receive standard-of-care therapy with vinblastine and prednisone.
62757064|NCT01245738||Participants|Participants admitted to participating tertiary cardiac care centers who experienced a first coronary event.
62757065|NCT05517070||Hemophilia Group|Hemophilia adult patients
62757066|NCT05517070||Control Group|Healthy adult subjects
62757067|NCT01395121|EXPERIMENTAL|nilotinib|nilotinib 400mgs oral tablets
62757068|NCT02838901|EXPERIMENTAL|Beet It Beetroot Juice|70 cc (3.8 millimoles nitrate) Beet It organic beetroot juice once a day for 30 days. Vitamin C 500 mg (tablets) will be given along with each dose of the juice.
62757069|NCT02838901|PLACEBO_COMPARATOR|Beet It Beetroot Juice Placebo|70 cc Beet It organic beetroot juice (placebo) once a day for 30 days. The placebo beet juice is identical in appearance and taste with nitrate removed. Vitamin C 500 mg (tablets) will be given along with each dose of the juice.Beet It Placebo Beetroot juice.
62757070|NCT04621214||Group-A|Group A were performing their duties on visual triage
62757071|NCT04621214||Group-B|Group A were performing their duties on Audio-visual triage
62757072|NCT05945134|EXPERIMENTAL|Visual and auditory feedback STS training group|The interactive interface of visual and auditory feedback system was designed using LabVIEW and integrated force plates for training. Signals from the pressure detectors of the seat and two force plates on the floor will be converted to the indication of the body weight distribution (indicated by the size of the two circles of both legs, larger circle represented the more weight beard on the leg) and the movement path of the overall center of pressure (indicated by a mobile solid dot).
62757073|NCT05945134|ACTIVE_COMPARATOR|Conventional STS training group|Only verbal and visual cues which were commonly used by the therapist.
62757074|NCT01133275|EXPERIMENTAL|Lenalidomide and Prednisone Therapy|All participants received lenalidomide and prednisone therapy for 6 cycles (24 weeks). Each cycle is 28 days (4 weeks).
62757075|NCT01230515||Caregiver|Family members will be asked to complete a demographic survey, an assessment of the patient's current pain, and a series of questionnaires including: Caregiver Pain Medicine Questionnaire, the Stressful Caregiving Adult Reactions To Experiences of Dying Scale, and the Caregivers' Self Efficacy in Pain Management Questionnaire. Upon completion of the questionnaires, patients and caregivers will be interviewed separately.
62757076|NCT01230515||Hospice staff|Hospice staff will be asked to complete the Pain Knowledge and Attitudes survey. They will also complete the Technology Acceptance Model (TAM) questionnaire to assess the perceived utility of an opioid titration order sheet to help manage pain control. A demographic survey will also be completed.
62757077|NCT01230515||Referring physician|Referring physicians will be asked to complete the Pain Knowledge and Attitudes survey as well as the TAM questionnaire and Demographic Survey.
62757078|NCT01230515||Patient|Demographic information includes education, marital status, number in household, and employment status will be obtained from patient. Clinical data will be obtained from the patient's medical records. Information to be obtained will include information about the type of cancer, stage of disease, time since diagnosis, current treatment for cancer, type of pain, time since onset of pain, and time of first opioid prescription. The patient will also take a pain assessment survey.
62757079|NCT00673023|EXPERIMENTAL|1|
62757080|NCT00673023|EXPERIMENTAL|2|
62757081|NCT00673023|EXPERIMENTAL|3|
62757082|NCT03426475|NO_INTERVENTION|Control Group|Care of nursing home residents as usual.
62379513|NCT04276831|ACTIVE_COMPARATOR|Laryngoscope Macintosh|Patients will be intubated using laryngoscope Macintosh
62379514|NCT03757299|EXPERIMENTAL|Self HPV|
62757083|NCT03426475|EXPERIMENTAL|Interventional Group|Implementation of interprof ACT measures to improve collaboration and communication between general practitioners and nursing staff. Measures are selected and adapted by nursing home management / nurses, GPs and residents' relatives or representatives.
62757084|NCT00267605|EXPERIMENTAL|Treatment|FHPADHD 50% randomized to receive Strongest Families (formerly Family Help Program): behavioural distance intervention
62757085|NCT00267605|ACTIVE_COMPARATOR|Control|ADHD Standard Care 50% randomized to receive standard/usual care for ADHD
62757086|NCT02128815|EXPERIMENTAL|Coaching|diabetes health coaching + usual diabetes self-management education
62757087|NCT02128815|NO_INTERVENTION|Usual Care|Usual care or self-management education
62757088|NCT03887260|ACTIVE_COMPARATOR|GA group|Patients will receive general anaesthesia for nephrectomy/NSS procedures via lumbotomy. Analgesia will be provided by titration of fentanyl during surgery. An intravenous patient controlled morphine pump will be used postoperatively.
62757089|NCT03887260|EXPERIMENTAL|ESP group|Patients will receive general anaesthesia with ESP block for nephrectomy/NSS procedures via lumbotomy. Catheter will be inserted in the erector spinae plane on the side of surgery. Postoperatively patients will get continuous infusion of 0,125% Bupivacaine+Adrenaline to the catheter for 24h and PCA morphine pump intravenously.
62757090|NCT06239246||2000 hospitalized patients|hospitalized patients with heart diseases
61986886|NCT00457509|EXPERIMENTAL|Group 4|Dose 4 with adjuvant
62379515|NCT02499640|NO_INTERVENTION|GC|Control group - CG (n = 20), which suffered no recuperative technique
62757091|NCT06239246||10000 community population|
62757092|NCT00504504|EXPERIMENTAL|Rituximab + ABVD Chemotherapy|Rituximab 375 mg/m\^2 by vein (IV) over 3 to 8 hours weekly for 6 weeks in a row. ABVD Chemo: Adriamycin 25 mg/m\^2 IV, Bleomycin 10 U/m\^2 IV, Vinblastine 6 mg/m\^2 IV, DTIC 375 mg/m\^2 IV. Each but Rituximab over 3 hours every other week for a total of 12 treatments.
62757093|NCT03023254|OTHER|hydrotherapy group|"Subjects included in the hydrotherapy group will undergo a 3-week Avène hydrotherapy in addition to their usual psoriasis and/or pruritus management (treatments and/or skin care products)."
62757094|NCT03023254|NO_INTERVENTION|Control group|"Subjects included in the control group will not undergo the hydrotherapy and will keep following their usual psoriasis and/or pruritus management (treatments and/or skin care products)."
62379516|NCT02499640|EXPERIMENTAL|G1|G1 (n = 20) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 9±1 degrees Celsius
62379517|NCT02499640|EXPERIMENTAL|G2|G2 (n = 20) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 14±1 degrees Celsius
62379518|NCT02499640|EXPERIMENTAL|G3|G3 (n = 20) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 9±1 degrees Celsius
62379519|NCT02499640|EXPERIMENTAL|G4|G4 (n = 20) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 14±1 degrees Celsius
62379520|NCT02621008|EXPERIMENTAL|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
62757095|NCT00712621|OTHER|I|"OUTLINE: This is a randomized, multicenter study. Patients are selected according to age ( 25 to 49 vs 50 to 85), time since initial completion of therapy (3 to 18 months), and are separated in two groups.~Arm I: Quality of life is assessed at baseline and at 3 and 6 months."
62757096|NCT00712621|OTHER|II|"OUTLINE: This is a randomized, multicenter study. Patients are selected according to age ( 25 to 49 vs 50 to 85), time since initial completion of therapy (3 to 18 months), and are separated in two groups.~Arm II: Quality of life is assessed at baseline and at 3 and 6 months."
62379521|NCT03436524||Training cohort|Cohort of chronic lymphocytic leukemia patients at Binet A stage for the development of the risk stratification model
62557852|NCT03015246|EXPERIMENTAL|Buprenorphine/Naloxone high dose + placebo stressor|Participants will be maintained on Buprenorphine-Naloxone (Zubsolv™) sublingual tablet doses of 12.8/3.16 mg/day. The placebo stressor will be administered on one day.
61986887|NCT00457509|ACTIVE_COMPARATOR|Group 5|Control
62379522|NCT03436524||Validation cohorts|Cohorts of chronic lymphocytic leukemia patients at Binet A stage for the validation of the risk stratification model
62379523|NCT04754724|EXPERIMENTAL|GIMate|Individuals with suspected lactose intolerance who start with GIMate use first
62757097|NCT06605521||Subclavian lymph node dissection+radiotherapy group|Subclavian lymph node dissection+radiotherapy
62757098|NCT06605521||Simple clavicular region radiotherapy group|Simple clavicular region radiotherapy
61986888|NCT00878709|EXPERIMENTAL|Neratinib|240 mg orally daily for one year
61986889|NCT00878709|PLACEBO_COMPARATOR|Placebo|orally daily for one year
62379524|NCT04754724|ACTIVE_COMPARATOR|H2 Check|Individuals with suspected lactose intolerance who start with H2 Check use first
62379525|NCT03507270|OTHER|FABP group|Coronary angiography and PCI (according to indications).
62379526|NCT01402375|EXPERIMENTAL|Hydrocodone (first trial)|Hydrocodone 5mg / Acetaminophen 500mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
62379527|NCT01402375|ACTIVE_COMPARATOR|Codeine (first trial)|Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
62557853|NCT03015246|EXPERIMENTAL|Extended-Release Morphine + active stressor|Participants will be maintained on extended-release morphine (dose tailored to the individual, based on pre-experimental opioid use amount), in three divided daily doses. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
62757099|NCT01666639|ACTIVE_COMPARATOR|Control Group|
62757100|NCT01666639|EXPERIMENTAL|Intervention Group|
62757101|NCT06189703|ACTIVE_COMPARATOR|Group A: Treatment Arm|The same device placement will be used for sham as in the active arm.
62757102|NCT06189703|SHAM_COMPARATOR|Group B: Sham-Control Arm|The same device placement will be used for sham as in the active arm.
62757103|NCT03880448|EXPERIMENTAL|Metronidazole + periodontal surgery|Periodontal surgery + Metronidazole (metronidazole 500mg/8h/7days)
62757104|NCT03880448|PLACEBO_COMPARATOR|Placebo + periodontal surgery|Periodontal surgery + Placebo (cornstarch 500mg/8h/7days)
62379528|NCT01402375|EXPERIMENTAL|Oxycodone (for second trial)|Oxycodone 5mg / Acetaminophen 325mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
62557854|NCT03015246|EXPERIMENTAL|Buprenorphine/Naloxone low dose + active stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 1.4/0.36 mg/day. The placebo stressor will be administered on one day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
62379529|NCT01402375|ACTIVE_COMPARATOR|Codeine (for second trial)|Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
62379530|NCT01402375|EXPERIMENTAL|Oxycodone (third trial)|Oxycodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
62379531|NCT01402375|ACTIVE_COMPARATOR|Hydrocodone (third trial)|Hydrocodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
62379532|NCT03202667|ACTIVE_COMPARATOR|Empagliflozin|Treatment with empagliflozin 25mg tablets once daily for 28 days
62557855|NCT03015246|EXPERIMENTAL|Buprenorphine/Naloxone moderate dose + active stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 4.2/1.08 mg/day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
62557856|NCT03015246|EXPERIMENTAL|Buprenorphine/Naloxone high dose + active stressor|Participants will be maintained on Buprenorphine-Naloxone (Zubsolv™) sublingual tablet doses of 12.8/3.16 mg/day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
62557857|NCT00631215|EXPERIMENTAL|1|Healthy Adults
62757105|NCT05285475|EXPERIMENTAL|Group A|"The exercise protocol for this group will be abdominals, pelvic stretching and kegels exercises (PFM) for three days/week lasting about 30 minutes with approximately 1600-1800ml (8-10 glasses) intake of water for 8 weeks (two consecutive menstrual cycles)~Exercises include:~Piriformis stretching (5 repetitions×20 seconds) Adductor stretching (5 repetitions×20 seconds) Sit-ups (10 repetitions×3 sets) Bridging (10 repetitions×3 sets) Kegels exercises (10 repetions×3 sets) Pelvic elevation (10 repetitions×3 sets) Pelvic rotation (10 repetitions×3 sets) Cobra pose (5 repetitions×20 seconds)"
62757106|NCT05285475|NO_INTERVENTION|Group B|The participants in this group will be asked neither to do any exercise nor to change their daily basis routine.
62757107|NCT05318612|OTHER|Control group (biopsy group)|Standard of care: biopsy + adjuvant treatment
62757108|NCT05318612|EXPERIMENTAL|Intervention group (LITT group)|Biopsy + LITT + adjuvant treatment
62757109|NCT05579249|EXPERIMENTAL|Semaglutide|Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management.
62757110|NCT05579249|ACTIVE_COMPARATOR|Other anti-obesity medication|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
62757111|NCT05816642|ACTIVE_COMPARATOR|Single targeted therapy|sunitinib or pazopanib
62757112|NCT05816642|EXPERIMENTAL|targeted therapy combined with immunotherapy|Programmed death-ligand 1 Inhibitor combined with axitinib
62757113|NCT00856141|EXPERIMENTAL|1. High fluidic parameters|Bottle height varied from 90-110cms, fixed aspiration flow rate 40cc/min, vacuum upto 650mmHg depending on the grade of cataract
62379533|NCT03202667|PLACEBO_COMPARATOR|Placebo|Treatment with Placebo tablets once daily for 28 days
62379534|NCT03577444||Dysphagia patients|Patients who had been diagnosed with neurogenic dysphagia related to either stroke or traumatic brain injury at two university affiliated hospitals
62379535|NCT02132169|EXPERIMENTAL|AC-170 0.24%|
62757114|NCT00856141|ACTIVE_COMPARATOR|2. Low fluidic parameters|Bottle height varied from 70-90cms, fixed aspiration flow rate of 25cc/min, vacuum upto 400mmHg, depending on the grade of cataract
62379536|NCT02132169|PLACEBO_COMPARATOR|AC-170 0%|
62379537|NCT05757466|EXPERIMENTAL|Main arm|"Patients receive 6 cycles of prolgolimab monotherapy with subsequent assessment of response by PET/CT using Lugano and LYRIC criteria. Patients with complete response continue prolgolimab therapy for up to 24 cycles. Patients are switched to combination therapy with prolgolimab and chemotherapy (bendamustine) if the complete response is not achieved after 6 cycles of therapy or in case of relapse during prolgolimab monotherapy.~Patients without complete response after 6 cycles of prolgolimab monotherapy or with relapse during monotherapy will receive 3 cycles of combination therapy with prolgolimab and bendamustine every 28 days. Collection of hematopoietic stem cells is performed at any stage of combination therapy. Response evaluation after 3 cycles of combination therapy is performed by PET/CT using Lugano and LYRIC criteria. Autologous stem cell transplantation is conducted in patients who achieve complete or partial response."
62379538|NCT01876134||Elective cardiac surgery|
62379539|NCT05509556||patients with calcaneal spur on the lateral radiograph of the foot|The group in which talocalcaneal angle measurement was performed in patients with calcaneal spurs on the lateral radiograph of the foot.
62379540|NCT05509556||patients without calcaneal spur on lateral radiograph of the foot|The group in which talocalcaneal angle measurement was performed in patients without calcaneal spur on the lateral radiograph of the foot.
62379541|NCT03810261|EXPERIMENTAL|Oil-based vitamin D group|Oil-based vitamin D, 1000 IU/day for 8 weeks
62379542|NCT03810261|EXPERIMENTAL|Water-based vitamin D group|Water-based vitamin D, 1000 IU/day for 8 weeks
62379543|NCT03810261|EXPERIMENTAL|Vitamin D capsules group|Vitamin D capsules with starch-adsorbed vitamin D (powder), 1000 IU/day for 8 weeks
62379544|NCT03810261|NO_INTERVENTION|Control group|This group will receive no intervention.
62379545|NCT05823389|EXPERIMENTAL|Flapless Emdogain (FEMD) group|Re-instrumentation with flapless emdogain application
62757115|NCT05699252|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT) condition|Participants randomized to this arm will be taught about the role of cognitions (particularly pain catastrophizing), pain beliefs (including perceived control), and maladaptive or unhelpful coping behaviors in chronic pain. This technique will help participants: (1) identify and change or restructure unhelpful or negative thinking about pain; (2) utilize positive coping strategies including positive coping self-statements; relaxation techniques; behavioral activation (including setting goals for activation), activity pacing and scheduling; and (3) cope with pain flare-ups.
62379546|NCT05823389|ACTIVE_COMPARATOR|Placebo group|Re-instrumentation without flapless emdogain application
62557858|NCT04165746|EXPERIMENTAL|Enhanced Institutional Care|"Caregivers at institutions will participate in a caregiving training, called Video Feedback Intervention to Promote Positive Parenting (VIPP). During VIPP a trained interventionist meets with a caregiver and child in the home environment.~The VIPP Interventionist will meet with caregivers and children for 5, 2-hours sessions over 6-8 weeks to discuss recordings of children and their caregivers. As described above, the sessions will focus on creating a positive atmosphere by reinforcing positive interactions."
62557859|NCT04165746|EXPERIMENTAL|Enhanced Foster Care|"Foster parents will be recruited, consented to background checks, and trained in Portuguese. Hired foster parents will supported and monitored by project social workers and psychologists from local Foster Care programs. Foster parents will received frequent visits from the social workers, with visits occurring weekly for several months after placement of the child, then biweekly and later monthly. Project social workers will consult weekly with US staff experienced in dealing with young children in foster care.~Additionally, foster parents will participate in the VIPP caregiving training, in the same format as that described in the Enhanced Institutional Care Arm: the VIPP Interventionist will meet with caregivers and children for 5, 2-hours sessions over 6-8 weeks to discuss recordings of children and their caregivers. As described above, the sessions will focus on creating a positive atmosphere by reinforcing positive interactions."
62557860|NCT02530502|EXPERIMENTAL|Treatment (RT, temozolomide, pembrolizumab)|"RT PORTION: Patients undergo focal RT over 42 days, and receive concurrent temozolomide PO QD on days 1-42 and pembrolizumab IV over 30 minutes on days 1, 22, and 43.~POST-RT: After completion of RT, patients receive temozolomide PO QD on days 1-5 and 29-34 of course 1 and days 1-5 and 29-33 of subsequent courses, and pembrolizumab IV over 30 minutes on days 1, 22, and 43. Treatment repeats every 9 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, patients deriving benefit may continue to receive pembrolizumab for an additional 12 months."
62557861|NCT04239755|ACTIVE_COMPARATOR|Doxycycline|Group (1) 25 patients that receive doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 days.
62557862|NCT04239755|PLACEBO_COMPARATOR|Placebo|group (2) will be 25 patients will receive placebo in addition to the standard treatment.
62557863|NCT05411757|EXPERIMENTAL|IBR900 cell injection|IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab
62557864|NCT04347720||Indomethacin Arm|Intravenous indomethacin at 0.1-0.3 mg/kg IV every 12-24h for a total of 3 doses as choice of initial pharmacotherapy.
62557865|NCT04347720||Standard dose ibuprofen Arm|Standard dose ibuprofen \[Oral/intravenous\] at 10 mg/kg followed by 2 doses of 5mg/kg at 24 h intervals irrespective of postnatal age as choice of initial pharmacotherapy.
62757116|NCT05699252|EXPERIMENTAL|Hypnotic Cognitive Therapy (HYP-CT) condition|Participants randomized to this arm will be taught about the role of hypnosis to reduce pain, increase comfort and well-being, and to instill and reinforce healthy, adaptive cognitions. This technique will help participants to use their ability to enter a state of focused attention to then increase their acceptance of new adaptive ideas about pain provided both by (1) clinicians during sessions and on audio recordings, as well as (2) the participants themselves during self-hypnosis practice.
62757117|NCT05699252|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy (MBCT) condition|Participants randomized to this arm will be taught about the role of MBCT in training the mind to respond more adaptively to pain. This technique will help participants: (1) apply the skills they learn not only to pain but also to the problems pain causes for them, including sleep disturbance, depressed mood, stress, and other problems; (2) build on their strengths and their innate ability to focus their attention at will, and to use this ability to mindfully perceive experience in a non-judgmental, non-reactive way; and (3) notice their moment-to-moment experience and to shift their relationship to this experience. With enhanced mindful awareness comes the opportunity to then mindfully choose how to respond to the pain in a way that reduces stress and is most helpful or adaptive.
62757118|NCT05699252|NO_INTERVENTION|Usual Care (UC) Control Group condition|In the Usual Care condition, participants will not participate in a study treatment, but rather they will continue with their usual care for chronic pain and will complete the seven study assessment sets. At the end of the study, after the final 6-month follow-up assessment period, participants will be given the opportunity to receive any one of the three treatments that they would like as part of an open label phase of the study UNLESS participants have developed new problems that would make them ineligible.
62757119|NCT03336372|EXPERIMENTAL|Picato topical gel|
62757120|NCT02695823|EXPERIMENTAL|Patients undergoing liver transplantation|
62757121|NCT04899375|EXPERIMENTAL|One group taking part in 2 separate conditions|Subjects will be randomly assigned to either group A or B. Session 1 will serve to familiarize all participants with the battery of tests including the 100 mm VAS, Short-form Mcgill Pain Questionnaire (SF-MPQ), Likert perception scale adapted from Kiefer et al. (2017), algometry, manual muscle testing, assessed via hand-held dynamometer (HHD), and grip strength assessed via hydraulic hand dynamometer; subjects will also be instructed in the AROM protocol. Familiarization will be conducted a minimum of 24 hours prior to the first condition. There will be a minimum washout period of 1 week to reduce both order and carry-over effects. Only the principal investigator will be abreast to the order of intervention, sufficiently blinding the raters. Prior to each trial, participants will be instructed to refrain from resistance training for a minimum of 48 hours and to abstain from the use of stimulants or analgesic medication for a minimum of 6 hours prior to reporting to the lab.
62379547|NCT02679430|OTHER|Prostate Arterial Embolization|"Intervention: Patients will undergo prostatic artery embolization.~The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms."
62757122|NCT04744389|EXPERIMENTAL|Hypothermic Machine Perfusion|uDCD and cDCD after Normothermic Regional Perfusion matching the inclusion criteria, ECD matching the inclusion criteria, uDCD and cDCD exceeding the inclusion criteria.
62379548|NCT00065351|EXPERIMENTAL|1|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
62379549|NCT04990999|EXPERIMENTAL|Vestibular Root Extraction|
62379550|NCT04990999|ACTIVE_COMPARATOR|Atraumatic extractions using periotomes followed by conventional forceps|
62379551|NCT05348564|EXPERIMENTAL|Direct contact|Study team contact of family members
62379552|NCT05348564|NO_INTERVENTION|Indirect contact|Proband initiated contact of family members
62379553|NCT00519571|EXPERIMENTAL|1|
62379554|NCT02839512|EXPERIMENTAL|Jejunal to Ileal Diversion|All subjects who receive jejunal to ileal diversion endoscopic procedure
62379555|NCT02854501||Uncomplicated pregnancies|women who did not develop any of the complications
62379556|NCT02854501||Preeclampsia|pregnant women who developed preeclampsia
62379557|NCT02854501||Isolated IUGR|participants were those who had IUGR
62379558|NCT02854501||Any complication|participants who developed other complications (abruptio placentae, stillbirth, or preterm labor).
62379559|NCT00474539|EXPERIMENTAL|1|
62379560|NCT00474539|ACTIVE_COMPARATOR|2|
62379561|NCT06439342|EXPERIMENTAL|Maribavir|Participants will receive maribavir 400 milligrams (mg), tablets, orally twice a day (BID) for up to 8 weeks.
62557866|NCT04347720||Adjustable dose ibuprofen Arm|Adjustable dose ibuprofen \[Oral/intravenous\] as choice of initial pharmacotherapy. The dose of ibuprofen will be 10 mg/kg followed by 2 doses of 5 mg/kg at 24 h intervals if treated within the first 7 days after birth. Higher doses of ibuprofen up to 20 mg/kg followed by 2 doses of 10 mg/kg at 24 h intervals if treated after the postnatal age cut-off for lower dose as per the local center policy
62757123|NCT04744389|EXPERIMENTAL|Normothermic Machine Perfusion|uDCD and cDCD after Normothermic Regional Perfusion matching the inclusion criteria, ECD matching the inclusion criteria, uDCD and cDCD exceeding the inclusion criteria.
62379562|NCT02417129|EXPERIMENTAL|BI 695500|375 mg/m2; One intravenous infusion once a week for 4 weeks
62379563|NCT02417129|ACTIVE_COMPARATOR|Rituximab (US reference product)|375 mg/m2; One intravenous infusion once a week for 4 weeks
62379564|NCT01097434|ACTIVE_COMPARATOR|Arm 1|Biodegradable polymer limus-eluting stents
62757124|NCT05533463|EXPERIMENTAL|HRS-4642|"In Dose Escalation:~HRS-4642 will be injected QW. Six dose levels are preset.~In Dose Expansion:~1 to 2 dose cohorts will be selected for dose expansion stage.~In Indication Expansion:~Enrollment into the dose expansion cohorts may be from any eligible solid tumor type."
62379565|NCT01097434|ACTIVE_COMPARATOR|Arm 2|Permanent polymer limus-eluting stent
62379566|NCT02150291|ACTIVE_COMPARATOR|Group A|one capsule of 5 mg of Folic acid twice daily and a tablet of Neurobion three times per day during hepatitis C treatment
62379567|NCT02150291|ACTIVE_COMPARATOR|Group B|Patients will receive one capsule of 5 mg of Folic acid twice daily during hepatitis C treatment
62757125|NCT06204861|EXPERIMENTAL|Capacitive and Resistive Electric Transfer Therapy Group|Participants underwent 30 minutes of treatment per session, three times per week for four weeks during the experiment.
62757126|NCT06204861|EXPERIMENTAL|Balance Training Group|Participants underwent 30 minutes of training per session, three times per week for four weeks during the experiment.
62757127|NCT06204861|EXPERIMENTAL|Balance Training Combined with Capacitive and Resistive Electric Transfer Therapy Group|Participants underwent 30 minutes of training and treatment per session, three times per week for four weeks during the experiment.
62757128|NCT03887520|OTHER|Cardiovascular disease|Patients with established Cardiovascular disease
62757129|NCT01571128|EXPERIMENTAL|Male-Specific Intervention Package|Gender-specific interventions targeted specifically for boys offered in an integrated services delivery modality. Cross-Sectional Arm.
62757130|NCT01571128|EXPERIMENTAL|Female-Specific Intervention Package|Gender-specific interventions targeted specifically for girls offered in an integrated services delivery modality. Cross-Sectional Arm.
62379568|NCT02150291|ACTIVE_COMPARATOR|Group C|Patients will receive a tablet of Neurobion three times per day during hepatitis C treatment
62379569|NCT02150291|PLACEBO_COMPARATOR|Group D|Patients will receive matching placebo capsule to take during hepatitis C treatment
62757131|NCT01571128|NO_INTERVENTION|HIV Positive Cohort (Males and Females)|Behavioral data on HIV positive youth. Longitudinal Arm.
62757132|NCT01571128|EXPERIMENTAL|Pre-Exposure Prophylaxis (Females)|PrEP adherence and feasibility. Longitudinal Arm.
62757133|NCT01571128|EXPERIMENTAL|Cash Transfer Cohort (Females)|School attendance, behavioral data, and feasibility. Longitudinal Arm
62757134|NCT00579241|EXPERIMENTAL|1 Transcranial imaging using Doppler Ultrasound|Transcranial imaging using Doppler ultrasound
62757135|NCT02614807|EXPERIMENTAL|Intervention|All recruited patients will receive a standard endorsement of lower fluid intake (\<1.5 Litres/day) by a hypertension nurse and physician and an additional treatment consisting of a bottle (237 ml) of Nepro (a low sodium, low potassium content protein supplement) a day (supply for 4 weeks will be provided).
62757136|NCT00383734|EXPERIMENTAL|1|newfill
62757137|NCT00383734|EXPERIMENTAL|2|Eutrophill
62757138|NCT05526144|PLACEBO_COMPARATOR|Placebo group|Placebo group will receive placebo tablets
62757139|NCT05526144|ACTIVE_COMPARATOR|Study group|Study group will receive Synthroid (Levothyroxine) 25, 50, or 75 mcg daily
62757140|NCT02134665||severe acute pancreatitis|patients who received vancomycin therapy and whose serum vancomycin level was monitored, and who also had diagnosed as severe acute pancreatitis.
62757141|NCT02134665||Pneumonia|patients who received vancomycin therapy and whose serum vancomycin level was monitored, and who also had diagnosed as pneumonia.
62757142|NCT04943458||Cardiac surgery group|
62757143|NCT04943458||Glaucoma group|
62757144|NCT04943458||Control group|
62757145|NCT01672099|ACTIVE_COMPARATOR|nutrient enriched dairy|Yoghurt product which contains vitamin K2 and extra dairy nutrients; all in a concentration of 15% of the recommended allowed daily intake (RDI)
62757146|NCT01672099|PLACEBO_COMPARATOR|Basic dairy|2 basic yoghurt products
62757147|NCT00824083||1|sarcoma survivors
62757148|NCT00824083||2|healthy subjects
62757149|NCT02059551|EXPERIMENTAL|Intervention|"In case of positive D-dimer testing or in patients with a high clinical probability of PE, these patients have MRI protocol combined with venous ultrasonography of the legs. MRI includes 2 different sequences: Unenhanced steady-state-free precession sequences (SSFP) sequences and angiography sequences. (please see \\\\\\intervention section\\\\\\ for more details). MRI readings will be performed centrally by two independent readers blinded to the results of diagnostic reference standard. Venous ultrasonography of the legs will be interpreted locally."
62757150|NCT02281487|ACTIVE_COMPARATOR|Hysterectomy|standard hysterectomy
62379570|NCT03212209|EXPERIMENTAL|CPAP C- Flex-Plus by Philips Respironics|Four consecutive weeks with CPAP C- FLEX PLUS treatment. After these 4 weeks, patients will undergo full PSG with CPAP FLEX- PLUS. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
62557867|NCT04347720||Acetaminophen Arm|Acetaminophen \[Oral/intravenous\] at 15mg/kg every 6h for 3-7 days as choice of initial pharmacotherapy.
62557868|NCT04347720||Control group|Infants \<29 weeks GA with echocardiography-confirmed PDA but never received any pharmacotherapy
62557869|NCT04347720||Reference group|Infants \<29 weeks GA who were never diagnosed with PDA
62757151|NCT02281487|EXPERIMENTAL|Hysterectomy plus tubectomy|Hysterectomy plus tubectomy
62757152|NCT05173688|EXPERIMENTAL|Low maintenance dose propofol group|The low maintenance dose propofol group was maintained at 4-6 mg/kg/h
62757153|NCT05173688|EXPERIMENTAL|High maintenance dose propofol group|The high maintenance dose propofol group was maintained at 8-12 mg/kg/h
62757154|NCT04160247|ACTIVE_COMPARATOR|Angulated screw-retained crown|Restorations are connected to the implants by angulated screw channel system
62757155|NCT04160247|PLACEBO_COMPARATOR|Cemented crown|Restorations are cemented onto the implant abutment
62757156|NCT06606665||elderly with bronchiectasis ( EXPERİMENTAL GROUP )|"elderly with bronchiectasis~Interventions:~Other: Participants will have to sign an informed consent form before the evaluation.~Demographic information; It will be evaluated with a demographic information evaluation form.~Other: Cognitive skills; It will be evaluated with the Montreal Cognitive Assessment Scale.~Other: Reaction time; It will be evaluated with the 12-Red Square Test on the App-coo test application via tablet.~Other: Quality of life assessment; It will be evaluated with the Nottingham Health Profile.~Other: Lower extremity muscle strength assessment; It will be evaluated with a 30-second sit-and-stand test.~Other: Hand grip strength measurement test; It will be evaluated with a dynamometer.~Other: Pulmonary function assessment; It will be evaluated by spirometry. Other: Balance assessment will be done with the Wii Fit Balance Board."
62757157|NCT06606665||healthy controls (CONTROL GROUP)|"Age-matched healthy volunteers~Interventions:~Other: Participants will have to sign an informed consent form before the evaluation.~Demographic information; It will be evaluated with a demographic information evaluation form.~Other: Cognitive skills; It will be evaluated with the Montreal Cognitive Assessment Scale.~Other: Reaction time; It will be evaluated with the 12-Red Square Test on the App-coo test application via tablet.~Other: Quality of life assessment; It will be evaluated with the Nottingham Health Profile.~Other: Lower extremity muscle strength assessment; It will be evaluated with a 30-second sit-and-stand test.~Other: Hand grip strength measurement test; It will be evaluated with a dynamometer.~Other: Pulmonary function assessment; It will be evaluated by spirometry. Other: Balance assessment will be done with the Wii Fit Balance Board."
62757158|NCT00953680|ACTIVE_COMPARATOR|losartan /HCTZ combination tablet|single dose losartan 100 mg/HCTZ 12.5 mg combination tablet
62757159|NCT00953680|ACTIVE_COMPARATOR|losartan tablet + HCTZ capsule|Single dose losartan 100 mg tablet + HCTZ 12.5 mg capsule
62757160|NCT02177643|ACTIVE_COMPARATOR|Diacerein|Diacerein 50 mg immediate release capsule, once daily for the starting 28 days and Diacerein 50 mg immediate release capsule twice a day for the remains of the study.
62757161|NCT02177643|PLACEBO_COMPARATOR|Placebo|Placebo capsules once a day for the starting 28 days and two times daily for the remainder of the study.
62757162|NCT01605227|EXPERIMENTAL|cabozantinib|Subjects randomized to the cabozantinib arm will also receive placebo-matched prednisone capsules.
62757163|NCT01605227|ACTIVE_COMPARATOR|prednisone|Subjects randomized to the prednisone arm will also receive placebo-matched cabozantinib.
62757164|NCT01280539|EXPERIMENTAL|TENS|Transcutaneous electrical nerve stimulation will be applied on the impaired hand
62757165|NCT01280539|SHAM_COMPARATOR|Sham TENS|Sham TENS will be applied to the impaired hand
62757166|NCT02112682|ACTIVE_COMPARATOR|Completion axillary treatment|Completion axillary treatment according to the Dutch breast cancer guideline
62757167|NCT02112682|NO_INTERVENTION|No completion axillary treatment|
62757168|NCT03094078|ACTIVE_COMPARATOR|News with Spin|News items reporting results of pre-clinical studies with spin
62757169|NCT03094078|EXPERIMENTAL|News without spin|News items reporting results of pre-clinical studies without spin
62757170|NCT00951522|EXPERIMENTAL|1|GS-9411 2.4 mg
62757171|NCT00951522|EXPERIMENTAL|2|GS-9411 4.8 mg
62757172|NCT00951522|EXPERIMENTAL|3|GS-9411 7.2 mg
62757173|NCT00951522|EXPERIMENTAL|4|GS-9411 9.6 mg
62757174|NCT00951522|PLACEBO_COMPARATOR|5|Placebo
62757175|NCT02707081|PLACEBO_COMPARATOR|Placebo control group|Saline was given both intraperitoneally and intravenously during caesarean section
62757176|NCT02707081|ACTIVE_COMPARATOR|Intraperitoneal instillation group|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure with intravenous normal saline in a volume equivalent to that used in intravenous lidocaine group as placebo to ensure blinding.
62757177|NCT02707081|ACTIVE_COMPARATOR|Intravenous injection group|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery and 100 ml of saline intraperitoneally as placebo to ensure blinding
62757178|NCT05734521||Pregnant women exposed to avalglucosidase alfa|Pregnant women with a confirmed diagnosis of Pompe disease and avalglucosidase alfa exposure during the pregnancy and/or lactation
62757179|NCT05734521||Infants born to mother/father exposed to avalglucosidase alfa|Infants born to mother/father with a confirmed diagnosis of Pompe disease and exposed to avalglucosidase alfa
62757180|NCT05384535|EXPERIMENTAL|Bi-parametric Screening MRI|Bi-parametric MRI to be administered to High Risk males
62757181|NCT04704427|EXPERIMENTAL|Rehabilitative BCI training|The experimental group will receive brain computer interface-based lower limb function training (BCI-LLT), 30 minutes/time, 5 times/week, with a 4-week training period.. The training using the lower limb orthosis targeted the patient's ability to walk.
62757182|NCT04704427|ACTIVE_COMPARATOR|Traditional physical therapy protocol|The control group will only receive traditional physical therapy protocol. The traditional physical therapy protocol of lower limb conducted with the same treatment frequency, intensity and duration of treatment, including muscle strength training, balance training and walking training, etc.
62379571|NCT03212209|EXPERIMENTAL|CPAP with Sensawake by Fisher and Paykel|Four consecutive weeks with CPAP Sensawake treatment. After these 4 weeks, patients will undergo full PSG with the same CPAP modality. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
62379572|NCT03212209|ACTIVE_COMPARATOR|CPAP fixed pressure|Four consecutive weeks with CPAP fixed pressure treatment. After these 4 weeks, patients will undergo full PSG with the same CPAP modality. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
62379573|NCT03170635|OTHER|6 week Refreshing Recess program|Education and coaching for recess supervisors to learn about how to promote positive social interaction and active play with all students during recess. Provision of play activities for students during recess that foster active play, teamwork, and inclusion of students with disabilities and/or social challenges.
62379574|NCT02615561|EXPERIMENTAL|Phase 1 (Cure phase)|Efficacy and safety of the medical device Bepanthen Itch Relief Cream in children´s mild AD (responders will enter study phase 2)
62557870|NCT04403724|ACTIVE_COMPARATOR|premixed injection|will receive an intrathecal injection of 2.4 ml hyperbaric bupivacaine 0.5%, 20 µg fentanyl, and 100 µg preservative-free morphine mixed together.
62557871|NCT04403724|ACTIVE_COMPARATOR|sequential injections|will receive an intrathecal injection of 2,4 ml hyperbaric bupivacaine 0.5% followed immediately by the opioid mixture by two separate syringes.
62557872|NCT05447104|ACTIVE_COMPARATOR|ADA Clinically-Tested Reference Sugar-Free Gum|Peppermint flavored sugar-free chewing gum (1 piece = 2.2 grams)
62379575|NCT02615561|EXPERIMENTAL|Phase 2 (Care phase) / Arm 1|Efficacy and safety of the new cosmetic Bepanthen test product in maintaining healthy skin in the remission phase after cure of children´s mild AD
62379576|NCT02615561|ACTIVE_COMPARATOR|Phase 2 (Care phase) / Arm 2|Efficacy and safety of Stelatopia (cosmetic comparator) in maintaining healthy skin in the remission phase after cure of children´s mild AD
62757183|NCT05270902|ACTIVE_COMPARATOR|Adsorber Group|"Surgery with CPB will be performed according to institutional standards, depending on indications and surgical preferences.~For the intervention group (adsorber-group), the CytoSorb adsorber will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 300-400 ml.min-1."
62757184|NCT05270902|NO_INTERVENTION|Control|The control group (no-adsorber group) will be treated similarly, but no filter circuit will be installed.
62757185|NCT03693963|OTHER|Single Arm, treated with Serranator|Subjects treated with Serrantor
62757186|NCT01400295||coronary angiography|The investigators reviewed all consecutive patients who were undergoing coronary angiography
62757187|NCT02436668|ACTIVE_COMPARATOR|Ibrutinib|"Ibrutinib daily in combination with:~Nab-paclitaxel and gemcitabine"
62757188|NCT02436668|PLACEBO_COMPARATOR|Placebo|"Placebo daily in combination with:~Nab-paclitaxel and gemcitabine"
62757189|NCT05137457|EXPERIMENTAL|"Delivering Online ZZZ's with Empirical support (DOZE) app"|"The mobile Cognitive Behavioral Therapy for insomnia (CBTi) will be offered using the Delivering Online ZZZ's with Empirical support (DOZE) app. Patients assigned to the intervention group will be given the DOZE app which is an integrated smart phone app and web based self-management program for adolescents and young adults with sleep problems. The intervention will be delivered on restricted password-protected application. Participants will be encouraged to log onto the sleep dairy once a day over 10-weeks to complete sleep diary, develop and track their goals, and receive sleep health education tailored sleep health interventions. After 10-weeks, participants will complete questionnaires on sleep health, pain, and Health Related Quality of Life (HQRL). The use of actigraphy will be optional in view of the COVID19 pandemic."
62757190|NCT05137457|ACTIVE_COMPARATOR|Sleep Diary Only Attention Control|"The control group will receive the control version of the DOZE app where the patients will be able to access the sleep diary only, without the CBTi intervention. Participants will simply use the app to input entries into their sleep diary as an attention control over a 10-week period.~After the 10-week intervention period, participants will again complete a battery of questionnaires on sleep health, pain, and HRQL. The use of actigraphy will be optional in view of the COVID19 pandemic."
62757191|NCT00810485|EXPERIMENTAL|ADX10059 50 mg|twice-daily
62757192|NCT00810485|EXPERIMENTAL|ADX10059 100 mg|twice-daily
62757193|NCT00810485|EXPERIMENTAL|ADX10059 150 mg|twice-daily
61986890|NCT03830554|EXPERIMENTAL|intervention group|product name: organic Atlas cedar wood essential oil (Cedrus Atlantica): the intervention group smell 2 drops of organic Atlas cedar wood essential oil (applied on cotton ball) for a period of five consecutive nights (at least 8 hours each night).
61986891|NCT03830554|NO_INTERVENTION|control group|participants of this group received no intervention.
61986892|NCT05918679|EXPERIMENTAL|Healthy Adults group 1|
61986893|NCT05918679|EXPERIMENTAL|Healthy Adults group 2|
61986894|NCT05918679|EXPERIMENTAL|Healthy Adults group 3|
61986895|NCT05918679|EXPERIMENTAL|Healthy Adults group 4|
61986896|NCT05918679|EXPERIMENTAL|Healthy Adults group 5|
62379577|NCT02352428|EXPERIMENTAL|Skin Cancer Screening Training|Recruited family physicians and dermatologists in Calgary, Canada, take part in a 5.5-hour face-to-face skin cancer screening training program. Screening for skin cancer will be conducted by trained physicians according to instructions they received in the training program.
62757194|NCT00810485|PLACEBO_COMPARATOR|ADX10059 Matching Placebo|twice-daily
62757195|NCT02145104|EXPERIMENTAL|Arm A|cilinidpine 10mg + valsartan 160mg
62757196|NCT02145104|EXPERIMENTAL|Arm B|cilnidipine 5mg + valsartan 160mg
62757197|NCT02145104|ACTIVE_COMPARATOR|Arm C|valsartan 160mg
62757198|NCT01287221|ACTIVE_COMPARATOR|Rifampicin|Subjects randomized to this arm will receive 300 mg Rifampicin two times a day for 12 months.
62757199|NCT01287221|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive placebo capsules twice daily for 12 months. The capsules will contain riboflavin (vitamin B2).
62757200|NCT00642174|EXPERIMENTAL|Prasugrel|Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.
62757201|NCT00642174|ACTIVE_COMPARATOR|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.
62757202|NCT05777122|EXPERIMENTAL|group A|lignocaine gel every 8 hours
62757203|NCT05777122|EXPERIMENTAL|group B|chewing gum every 8 hours 5-10 mins chew
62757204|NCT00571246|EXPERIMENTAL|Topiramate|Participants will be randomized to topiramate (250mg)
62757205|NCT00571246|EXPERIMENTAL|Lamotrigine|Participants will be randomized to lamotrigine (250mg)
62757206|NCT00571246|PLACEBO_COMPARATOR|Placebo|Participants will be randomized placebo
62757207|NCT02198599|EXPERIMENTAL|Mobility-enhancing-nursing intervention|A 30 day mobility enhancing-nursing intervention for patients with Multiple Scerosis and stroke to expand kinaesthetic competence in order to increase compensation of limitations, improve functionality, and quality of life
62757208|NCT02198599|NO_INTERVENTION|Standard usual rehabilitation care|Participants in the control group will receive usual care, which is based on the principles of rehabilitation nursing. Based on patients functional ability (EBI data) the nursing process is used to determine objectives and interventions. The main focus is on providing a therapeutic environment and supporting and advancing abilities to perform the Activities of Daily Living, support mobility and kinesthetic perception.
62757209|NCT06180681|ACTIVE_COMPARATOR|Standard Collaborative Life Skills Program Implementation|CLS is a school-delivered intervention coordinating three empirically-supported approaches: teacher consultation and a daily behavior report card, behavioral parent training and child skills training. The three components are integrated over a 10-12 week period to improve symptoms and functional impairment among youth with ADHD.
62757210|NCT06180681|EXPERIMENTAL|Team-Enhanced Collaborative Life Skills Program Implementation|We will integrate three team-based implementation strategies to enhance team effectiveness in CLS, including Team Charters, Team Communication Training via Student Handoff Protocols, and Team Performance Monitoring. These interventions have been shown to improve cognitive (e.g., shared mental models) and affective ((e.g., trust, collective efficacy) team-based emergent states and enhance team-based processes, such as communication and coordination.
62757211|NCT03085888||Prospective Cohort|This is a prospectively enrolling cohort study with a pre-specified molecular analysis plan. A stratified case-cohort design will be employed to select cancer cases and non-cancer subjects who will be assayed. All cases of cancer (breast and non-breast cancer) will be selected. A random subset of the overall study cohort will also be selected.
62757212|NCT01286987|EXPERIMENTAL|Talazoparib|
62757213|NCT03552536|EXPERIMENTAL|A: MK-8583 100mg|After fasting, a single oral dose of 100 mg MK-8583 in capsule form.
62557873|NCT05447104|EXPERIMENTAL|Marketed Gum: Sugar-free gum|Orbit White, peppermint flavored sugar-free chewing gum Mars Wrigley Confectionary US, LLC (1 piece = 2.0 grams)
62557874|NCT02901938|EXPERIMENTAL|cemented femoral stem group|The patients with avascular necrosis of the femoral head complicated by osteoporotic femoral neck fracture will be randomly assigned to undergo implantation of cemented femoral stem.
62557875|NCT02901938|EXPERIMENTAL|cannulated compression screws group|The patients with avascular necrosis of the femoral head complicated by osteoporotic femoral neck fracture will be randomly assigned to undergo percutaneous internal fixation with cannulated compression screws.
62557876|NCT03329339|NO_INTERVENTION|2 L PEG with ascorbic acid group|
62557877|NCT03329339|EXPERIMENTAL|1 L PEG with ascorbic acid with PLD|
62557878|NCT05445102|EXPERIMENTAL|autogenous demineralized dentin graft as bone substitute in treatment of intrabony defect|
62557879|NCT02902224|PLACEBO_COMPARATOR|PLACEBO|Single intragastric instillation of 300ml tap water via nasogastric tube
62557880|NCT02902224|ACTIVE_COMPARATOR|GLUCOSE|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
62557881|NCT02902224|ACTIVE_COMPARATOR|FRUCTOSE|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
62557882|NCT04594681|PLACEBO_COMPARATOR|Placebo|
62557883|NCT04594681|EXPERIMENTAL|KHK4951|
62557884|NCT03256604||Fresh left-over sputum|All fresh sputum samples that were sent to the Department of Microbiology between November 1 2015 and January 30 2016 under the standard requirements for sputum cultures at the accredited (ISO 17025 and 15189 beginning in 1993) laboratory were kept cold (4-8 ͦC) after analysis by microscope and cultures until it was collected and coded by the study nurse in the evening (left-over samples).
62557885|NCT00967330|EXPERIMENTAL|1|
62557886|NCT00967330|ACTIVE_COMPARATOR|2|
62557887|NCT02387840|EXPERIMENTAL|NF1-associated Optic Pathway Glioma (OPG)|Patients with neurofibromatosis type 1 (NF1) associated OPG will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
62557888|NCT02387840|EXPERIMENTAL|NF1 without brain tumor|Patients with NF1 without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
62557889|NCT02387840|EXPERIMENTAL|Without NF1 and with brain tumor exposed to therapy|Patients without NF1 and with low grade gliomas exposed to therapy will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
62557890|NCT02387840|EXPERIMENTAL|Without NF1 and with untreated low grade brain tumors|Patients without NF1 and with untreated low grade gliomas will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
62757214|NCT03552536|EXPERIMENTAL|B: MK-8583 ≤ 150 mg|After fasting, a single oral dose of ≤ 150 mg MK-8583 in capsule form, with the dose based on the results from earlier treatments
61986897|NCT01733407|PLACEBO_COMPARATOR|Sugar pill|Placebo arm
62557891|NCT02387840|EXPERIMENTAL|Without NF1 and without brain tumors|Patients without NF1 and without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
62557892|NCT02387840|EXPERIMENTAL|Brain tumors of assorted pathology|Patients with brain tumors of assorted pathologies will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
62557893|NCT05850325|OTHER|Group 1: Elbow Flexed at 90 Degrees|subjects will be instructed to exercise the forearm with the elbow positioned by their side, in 90° of flexion.
62757215|NCT03552536|EXPERIMENTAL|C: MK-8583 ≤ 150 mg|After fasting, a single oral dose of ≤ 150 mg MK-8583 in capsule form, with the dose based on the results from earlier treatments
62757216|NCT03760159||Group RESPIRATORY SIMUL (Study A)|In 46 healthy subjects, a computer program will generate random instructions of periods of normal breathing, voluntary end-expiratory breathing cessation periods (as surrogate of central apnoea) and Muller's manœuvre (as surrogate of obstructive apnoea). Meanwhile, the KCG will record the parameters of biological interest. ECG, heart rate, beat to beat non-invasive blood pressure (Finometer), ventilation, end-tidal CO2 (AD instruments), O2 saturation (Nellcor), cardiac output (CO) (Philips) will also be recorded.
62557894|NCT05850325|EXPERIMENTAL|Group 2: Elbow Fully Flexed|subjects will be instructed to exercise the forearm with their elbow fully flexed to achieve supination and the elbow extended to achieve pronation.
62557895|NCT04521881|ACTIVE_COMPARATOR|Active|A single dose of Tranexamic acid 500mg given by intramuscular injection
62757217|NCT03760159||Group SDB (Study B)|In patients suspected of sleep apnoea and admitted to the sleep unit of the Erasme hospital to perform sleep test as required by their medical condition, the investigators will simultaneously record KCG and PSG and qualitatively compare the data (Bland-Altman plots).
62757218|NCT03760159||Group nCPAP (Study C)|In patients with a diagnosis of sleep apnea, the investigators will determine if KCG is capable to reliably assess the efficacy of the nCPAP therapy in comparison to simultaneous PSG recording. Ongoing adjustment in the CPAP therapy pressure during the night, and its effect on cardiovascular haemodynamic assessed by the KCG, will be taken into account as well.
62757219|NCT03760159||Group UNSELECTED (Study D)|After validation of the three previous steps, the investigators plan to extend the recordings on 100 unselected consecutive patients, without recruitment restrictions, which will undergo PSG recordings because of complains of sleep apnoea.
62757220|NCT03918226|OTHER|Exploratory Laparotomy|Exploratory Laparotomy of patients presenting acute abdomen and whose diagnosis later on confirmed on histopathology to be tuberculosis
62757221|NCT06185842|EXPERIMENTAL|Intervention group|breathing exercise, walking exercise and vaccination counseling
62757222|NCT06185842|NO_INTERVENTION|Control group|
62757223|NCT04709484|EXPERIMENTAL|USG-guided steroid injection group|In the USG-guided group, steroid injection will be made to the area where the fascia is thickened under USG guidance. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
62757224|NCT04709484|EXPERIMENTAL|Palpation-guided steroid injection group|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus bone and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
62757225|NCT02002104||EPCs|No proliferation and no differentiation on the ePTFEs
62757226|NCT02002104||Modified ePTFE|EPCs adherence, proliferation and differentiation on the ePTFEs.
62757227|NCT04852042|EXPERIMENTAL|mHealth Group|12 month text messaging program about diet and physical activity behavioral goals
62757228|NCT04852042|EXPERIMENTAL|mHealth+Community Health Worker (CHW) support|same as mHealth group + monthly behavioral phone counseling by a CHW
62757229|NCT04852042|NO_INTERVENTION|Control group|Assessments only
62757230|NCT01555359||Patients undergoing stem cell collection|
62379578|NCT02352428|NO_INTERVENTION|No Skin Cancer Screening Training|Recruited family physicians and dermatologists in Edmonton, Canada, WILL BE TRAINED AFTER THE SCREENING PHASE, i.e. during the screening phase non-trained physicians will carry out skin cancer screenings according to standard medical practice.
62757231|NCT05256420|EXPERIMENTAL|Kinesiotape|Application of a kinesiotape bandage on the knee.
62757232|NCT05256420|SHAM_COMPARATOR|Sham Bandage|Application of a sham bandage on the knee.
62757233|NCT04052438||Patients with recurrent abortion.|More than three idiopathic involuntary miscarriages.
62757234|NCT04052438||Patients with implantation failure.|More than three IVF abortions with good quality embryos or more than two abortions in oocyte donation cycles.
62379579|NCT05646160|EXPERIMENTAL|chronic migraine (CM)|CM is diagnosed after a patient has experienced a tension or migraine headache for at least 15 days in a month for at least 3 months, when not less than 8 days is characterized by the symptoms typical of migraine diagnosis.
62757235|NCT04862897||Patient-controlled admissions|Patients who have been granted access to patient-controlled admissions and agreed to its use with inpatient care and outpatient care
62757236|NCT01367704|ACTIVE_COMPARATOR|Control School|Control schools (where the coaches do not receive the Coaching Boys into Men (CBIM) training until following academic year 'wait list control')
62757237|NCT01367704|EXPERIMENTAL|Intervention School|Intervention schools (where coaches receive the CBIM training at start of sports season)
62757238|NCT06363578|EXPERIMENTAL|Group dexmedetomidine 0.5|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg diluted in saline.
62757239|NCT06363578|EXPERIMENTAL|Group dexmedetomidine1|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 1 μg/kg diluted in saline.
62757240|NCT03739645|EXPERIMENTAL|Eye position and tense arousal over time a metrics for sustained attention in conditioned fear.|After conditioning the conditioned stimulus induces autonomic metrics like skin conductance and cognitive ratings like expectancy of the unconditioned stimulus after conditioning. Activity across blocks in the conditioning stage demonstrates that the skin conductance can produce a progressive decrease in skin conductance over the conditioning stage of our fear conditioning protocol. The decline is not apparently related to habituation or changes in the skin conducting electrodes or recording system. It does correspond to the decrease in performance of a visual fixation task which is part of the fear conditioning during the conditioning stage; and to an increase in the unpleasant psychologic activation termed tense arousal over the same stage. If both these changes are found he then we may conclude that sustained task related attention is produced during fear conditioning
62757241|NCT02036164|ACTIVE_COMPARATOR|Concurrent chemoradiation|"Radiation: Radiation Therapy~* External beam pelvic radiotherapy (45-50.4 Gy in 1.8 Gy fractions) delivered by Linear accelerator machine~* Vaginal brachytherapy for 4-5 fractions~Chemotherapy: Cisplatin~- Cisplatin 40 mg/m2 i.v., q wk, 6 cycles during radiotherapy"
62757242|NCT02036164|EXPERIMENTAL|Concurretn chemoradiation plus adjuvant chemotherapy|"Radiation: Radiation Therapy~* External beam pelvic radiotherapy (45-50.4 Gy in 1.8 Gy fractions) delivered by Linear accelerator machine~* Vaginal brachytherapy for 4-5 fractions~Chemotherapy: Cisplatin, paclitaxel, carboplatin~* Cisplatin 40 mg/m2 i.v., q wk, 6 cycles during radiotherapy~* Paclitaxel 175 mg/m2 i.v. q 4 wks, 3 cycles starting 4 week after completion of CCRT~* Carboplatin AUC 5 i.v. q 4 wks, 3 cycles given together with paclitaxel"
62379580|NCT05646160|EXPERIMENTAL|episodic migraine with aura (EMa)|EMa, known as classical migraine, is characterized by an attack of pain lasting several or tens of minutes, during which the appearance of unilateral visual and sensory symptoms from the central nervous system, usually associated with pain and migraine symptoms.
62757243|NCT03180437|ACTIVE_COMPARATOR|Group A|In this group, the patients will receive IRE surgery to control the local tumor under CT .
62757244|NCT03180437|EXPERIMENTAL|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and IRE surgery
62557896|NCT04521881|PLACEBO_COMPARATOR|Placebo|One Injection of the placebo which is 10 mL Sodium Chloride (0.9%)
62757245|NCT00858897|EXPERIMENTAL|Normoglycemia|80-140 mg/dL
62757246|NCT00858897|EXPERIMENTAL|Hyperglycemia|200-250 mg/dL
62757247|NCT00612742|EXPERIMENTAL|testosterone gel|1% testosterone transdermal gel
62757248|NCT00612742|PLACEBO_COMPARATOR|placebo gel|placebo transdermal gel
62757249|NCT03095027|OTHER|FID122819, then stenfilcon A|FID122819 contact lenses worn first, followed by stenfilcon A contact lenses, as randomized. Each product worn in both eyes in a daily disposable mode for at least 8 hours per day, 5 days per week, for 1 week
62757250|NCT03095027|OTHER|Stenfilcon A, then FID122819|Stenfilcon A contact lenses worn first, followed by FID122819 contact lenses, as randomized. Each product worn in both eyes in a daily disposable mode for at least 8 hours per day, 5 days per week, for 1 week
62757251|NCT03711929|EXPERIMENTAL|Test Arm: DE-109 Injectable Solution|Intravitreal injection of DE-109 440 µg in the study eye(s) every 2 months (Day 1, Month 2, and Month 4).
62757252|NCT03711929|SHAM_COMPARATOR|Control Arm: Sham Procedure|Sham procedure administered to the study eye(s) every 2 months (Day 1, Month 2, and Month 4). The sham procedure mimics an intravitreal injection without penetrating the eye.
62757253|NCT03711929|OTHER|Dummy Arm: DE-109 Injectable Solution|Dummy Arm: Intravitreal injection of DE-109 at an undisclosed, fixed dose (within the range of 44 µg to 880 µg) in the study eye(s) every 2 months (Day 1, Month 2, and Month 4).
62757254|NCT03711929|EXPERIMENTAL|Open-label:DE-109 Injectable Solution|Subjects completing the Month 6 pre-dose evaluations (the final evaluations in the double-masked period) began the open-label period of the study, in which all subjects received intravitreal injection of DE-109 440 μg in the study eye(s) every 2 months for an additional 6 months of dosing.
62757255|NCT00842439|EXPERIMENTAL|Cognitive Behavioral Intervention (CBI)|Participants will meet with an interventionist once a week for 12 weeks. They will discuss the child's behavior, will learn coping skills and how to deal with other people.
62757256|NCT00842439|EXPERIMENTAL|Nutritional Supplements (NUT)|Participants will be asked to take omega-3 supplements, multivitamin tablets, and calcium tablets every day for 12 weeks.
62757257|NCT00842439|EXPERIMENTAL|CBI + NUT|Participants will receive both the cognitive behavioral intervention and the nutritional supplements.
62757258|NCT00842439|NO_INTERVENTION|No intervention|Participants will not be asked to come for sessions or any other intervention. They will receive a list of the types of help that are available if they are interested in following up on their own.
62757259|NCT03995056|NO_INTERVENTION|Control-group|Subjects diagnosed with NAFLD and a sedentary lifestyle will have no changes in their habits and diets.
62379581|NCT05646160|EXPERIMENTAL|episodic migraine without aura (EMb)|EMb is diagnosed after at least 5 attacks per month, characterized by a one-sided, pulsating headache of moderate or severe intensity, which increases with physical activity, sometimes with vomiting, and sensitivity to light and sound. This episode of migraine must last from 4 to 72 hours.
62379582|NCT06038968|EXPERIMENTAL|Methotrexate group|methotrexate group will receive 40 mg of MTX in 500 ml of irrigation fluid during vitrectomy and 250 ug intra-silicone oil injection at the end of vitrectomy
62379583|NCT06038968|PLACEBO_COMPARATOR|Control group|control group will not receive MTX in irrigation fluid during vitrectomy nor intra-silicone at the end of vitrectomy
62379584|NCT05362825||Un-resectable synchronous liver limited metastasis colorectal cancer|Un-resectable synchronous liver limited metastasis colorectal cancer patients undergoing neo-adjuvant chemotherapy FOLFOXIRI regimen, up to 12 cycles.
62379585|NCT00536640|EXPERIMENTAL|Arm A (Erlotinib, Bevacizumab)|
62379586|NCT00536640|ACTIVE_COMPARATOR|Arm B (Gemcitabine, Cisplatin, Bevacizumab)|
62379587|NCT03377452|EXPERIMENTAL|Acceptance and the Behavioral Changes to Treat Sleep Apnea (ABC-SA)|Six session manual-based program using acceptance-and commitment therapy (ACT) framework, behavior change strategies and sleep apnea/PAP education. Sessions delivered in individual format, either in-person or via telehealth.
62379588|NCT03377452|ACTIVE_COMPARATOR|Non-directive sleep apnea education control|Six session sleep apnea and PAP education program. Sessions delivered in individual format, either in-person or via telehealth.
62379589|NCT05257668|ACTIVE_COMPARATOR|Group 1|High intensity interval training
62379590|NCT05257668|ACTIVE_COMPARATOR|Group 2|Moderate intensity training
62379591|NCT05257668|NO_INTERVENTION|Group 3|Control
62379592|NCT02638753|ACTIVE_COMPARATOR|Education|Patients will receive 4 sessions (1 hour each) of education on pain neurophysiology.
62379593|NCT02638753|EXPERIMENTAL|Education combined with hypnosis|Patients will receive 4 sessions (1 hour each) of education on pain neurophysiology combined with hypnosis.
62379594|NCT04099030||Opioid shortage|Patients undergoing laparoscopic cholecystectomy during time of Fentanyl drug shortage
62379595|NCT04099030||Normal Opioid supply (no shortage)|Patients undergoing laparoscopic cholecystectomy during time of normal Fentanyl drug supply
62379596|NCT00861302|EXPERIMENTAL|Treatment group|This is the only group in the study. It consists of patients with chronic musculoskeletal pain who are receiving the treatment program
62379597|NCT00850135|OTHER|Continuous Glucose Monitor in pregnancy|The Seven Continuous Glucose Monitoring System: Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
62379598|NCT05335785|ACTIVE_COMPARATOR|5 session lazer therapy|30 patients will be included to 5 session lazer therapy group. They will take totally 5 sessions of high-intensity laser every other day.
62379599|NCT05335785|ACTIVE_COMPARATOR|10 session lazer therapy|30 patients will be included to 10 session lazer therapy group. They will take totally 10 sessions of high-intensity laser every other day.
62379600|NCT05335785|OTHER|control group|30 patients will be included to control group. They will take only exercise program three times in a week.
62379601|NCT04272996|OTHER|surgery alone|craniotomy for SDH evacuation
62757260|NCT03995056|EXPERIMENTAL|Exercise-group|This group with diagnosed NAFLD patients will perform a high-intensity aerobic interval exercise training without changing their diets.
62757261|NCT02588703|EXPERIMENTAL|Cognitive Behavioral Therapy|9-session 2-hour group cognitive behavioral therapy
62757262|NCT02588703|ACTIVE_COMPARATOR|Usual Care|9-session 2-hour group counseling
62757263|NCT00085254|EXPERIMENTAL|Arm 1 (Safety Run In)|"INITIATION COURSE: Patients receive cilengitide IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Doses of cilengitide: 500mg, 1000mg and 2000mg~Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
62379602|NCT04272996|ACTIVE_COMPARATOR|Surgery plus embolization|surgery for evacuation of SDH followed by embolization of middle meningeal vessel
62379603|NCT00740194|EXPERIMENTAL|1|Aromatase inhibition
62379604|NCT00740194|ACTIVE_COMPARATOR|2|Estradiol
62757264|NCT00085254|EXPERIMENTAL|Phase II (Arm1-500mg)|"INITIATION COURSE: Patients receive cilengitide (500mg) IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV (500mg) on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~cilengitide, Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
62757265|NCT00085254|EXPERIMENTAL|Phase II (Arm 2 -2000mg)|"INITIATION COURSE: Patients receive cilengitide (2000mg) IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV (2000mg) on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~cilengitide,Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
62757266|NCT01992614|EXPERIMENTAL|Cohort 1|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
62757267|NCT01992614|EXPERIMENTAL|Cohort 2|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
62757268|NCT01992614|EXPERIMENTAL|Cohort 3|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
62757269|NCT05340634|ACTIVE_COMPARATOR|Oral Contraceptive|Drospirenone 4 mg once a day for 6 months
62757270|NCT05340634|EXPERIMENTAL|Oral Contraceptive + Food supplement Metionac|Drospirenone 4 mg once a day and Metionac twice daily (200 mg S-adenosylmethionine, 100 mg N-acetylcisteine, 75 mg alpha lipoid acid and 0,65 Vitamin B6) for 6 months
62757271|NCT05340634|OTHER|Food supplement MetioNac|Metionac twice daily (200 mg S-adenosylmethionine, 100 mg N-acetylcisteine, 75 mg alpha lipoid acid and 0,65 Vitamin B6) for 6 months
62757272|NCT02100163|EXPERIMENTAL|Virtual Reality Hypnosis|The patient receives VRH daily.
62757273|NCT02100163|EXPERIMENTAL|Audio Hypnosis|The patient receives Audio Hypnosis daily.
62757274|NCT02100163|EXPERIMENTAL|Standard Treatment|The patient receives the standard treatment. This is a control group and there are no interventions.
62757275|NCT05523596|EXPERIMENTAL|Dose Level 1|ICM20
62379605|NCT03990324|NO_INTERVENTION|Control group|The control group did not received intervention and sat on a table for approximately 5 minutes
62757276|NCT05523596|EXPERIMENTAL|Dose Level 2|ICM20 and benznidazole ascending dose 2
62757277|NCT05523596|EXPERIMENTAL|Dose Level 3|ICM20 and benznidazole ascending dose 3
62757278|NCT05523596|EXPERIMENTAL|Dose Level 4|ICM20 and benznidazole ascending dose 4
62757279|NCT02295215|NO_INTERVENTION|Sedentary Group|The patients will not do exercise training
62757280|NCT02295215|EXPERIMENTAL|Trained Group|The patients will do exercise training for sixteen weeks.
61986898|NCT01733407|ACTIVE_COMPARATOR|L-serine|amino acid supplementation with L-serine
61986899|NCT04087187|EXPERIMENTAL|Arm1: AZD5718 Dose A + AZD5718 Dose B + AZD5718 Dose C|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment A: AZD5718 Dose A, Treatment B: AZD5718 Dose B, Treatment C: AZD5718 Dose C, with a minimum washout period of 4 days between each dose administration."
62379606|NCT03990324|EXPERIMENTAL|Stretching group|The stretching group received a standardized manual stretching protocol
62379607|NCT00002494|EXPERIMENTAL|Combination therapy|Patients receive combination therapy as described in the study description. All patients must complete at least the first 3 courses of chemotherapy. Courses 2 and 3 each repeat 3 times in the absence of disease progression or unacceptable toxicity. On days 134-139, patients who have had prior bone marrow involvement receive cranial radiation therapy. Patients who achieve less than a complete response and who have an HLA-matched sibling should undergo allogeneic bone marrow transplant on protocol CLB-9113. Patients are followed monthly for 6 months, every 2 months for 18 months, every 6 months for 2 years, and thereafter for survival.
62757281|NCT01633203||locally advanced gastric cancer|Patients with resectable, locally advanced cT3-4 and/or N+ gastric carcinoma treated with 3 perioperative epirubicin cisplatin capecitabine polychemotherapy
62757282|NCT04860934|ACTIVE_COMPARATOR|Physical therapy|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks
62757283|NCT04860934|EXPERIMENTAL|Physical therapy + Dual Task Training Program|Each child in this group will perform one-hour session consist of two tasks (cognitive and balance task) in addition to the selected physical therapy program as control group three times weekly for 8 successive weeks.
62757284|NCT00694096|EXPERIMENTAL|1|
62757285|NCT03224650||Surgical|Patients treated surgically for spinal metastases
62757286|NCT03224650||Non-operative|Patients treated non-operatively for spinal metastases
62757287|NCT03224650||Expectant|Patients receiving no treatment for spinal metastases
62757288|NCT00795548|EXPERIMENTAL|5-Azacitidine|5-Azacitidine in addition to standard donor lymphocyte infusions.
62757289|NCT04610892|EXPERIMENTAL|MEDI6570 Low dose|Monthly Subcutaneous administration.
61986900|NCT04087187|EXPERIMENTAL|Arm2: AZD5718 Dose A + AZD5718 Dose C + AZD5718 Dose B|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment A: AZD5718 Dose A, Treatment C: AZD5718 Dose C, Treatment B: AZD5718 Dose B, with a minimum washout period of 4 days between each dose administration."
61986901|NCT04087187|EXPERIMENTAL|Arm3: AZD5718 Dose B + AZD5718 Dose A + AZD5718 Dose C|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment B: AZD5718 Dose B, Treatment A: AZD5718 Dose A, Treatment C: AZD5718 Dose C, with a minimum washout period of 4 days between each dose administration."
61986902|NCT04087187|EXPERIMENTAL|Arm4: AZD5718 Dose B + AZD5718 Dose C + AZD5718 Dose A|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment B: AZD5718 Dose B, Treatment C: AZD5718 Dose C, Treatment A: AZD5718 Dose A, with a minimum washout period of 4 days between each dose administration."
62757290|NCT04610892|EXPERIMENTAL|MEDI6570 Medium dose|Monthly Subcutaneous administration.
61986903|NCT04087187|EXPERIMENTAL|Arm5: AZD5718 Dose C + AZD5718 Dose A + AZD5718 Dose B|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment C: AZD5718 Dose C, Treatment A: AZD5718 Dose A, Treatment B: AZD5718 Dose B, with a minimum washout period of 4 days between each dose administration."
62757291|NCT04610892|EXPERIMENTAL|MEDI6570 High dose|Monthly Subcutaneous administration.
62757292|NCT04610892|PLACEBO_COMPARATOR|Placebo Low dose|Monthly Subcutaneous administration.
62757293|NCT04610892|PLACEBO_COMPARATOR|Placebo Medium dose|Monthly Subcutaneous administration
62757294|NCT04610892|PLACEBO_COMPARATOR|Placebo High dose|Monthly Subcutaneous administration
62379608|NCT06028178||Experimental group|The experimental group will recruit 300 participants undergoing blood culture, droplet digital PCR and transcriptome analysis.
62757295|NCT05082428||Patients treated with Tofacitinib|Patients treated with tofacitinib for ulcerative colitis in Finland.
62757296|NCT02070393|EXPERIMENTAL|Radiation Treatment using Protons|14 -24 Radiation Treatments (typically 1.5 - 1.8 cobalt-Gray equivalent per fraction for 14-24 treatments).
61986904|NCT04087187|EXPERIMENTAL|Arm6: AZD5718 Dose C + AZD5718 Dose B + AZD5718 Dose A|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment C: AZD5718 Dose C, Treatment B: AZD5718 Dose B, Treatment A: AZD5718 Dose A, with a minimum washout period of 4 days between each dose administration."
62379609|NCT06028178||Control group|The control group will recruit 60 participants undergoing blood culture only.
62379610|NCT00806494|EXPERIMENTAL|Treatment Arm|Fesoterodine 4mg, escalating to 8mg as required
62379611|NCT02150304||intravenous aminophylline|intravenous aminophylline use during spinal anesthesia
62757297|NCT03065842|EXPERIMENTAL|Abortion- and contraceptive-use stigma reduction program|Four sessions (à 120 min), every week in 1 month.
62757298|NCT03065842|ACTIVE_COMPARATOR|Usual standards|Usual standards
62757299|NCT05265884|EXPERIMENTAL|Group A (Kinesio taping group)(Experimental group):|This group includes 30 patients who will receive Kinesiotaping, in additional to traditional treatment (ROM exercises, stretching exercises, and Deep friction message) 3 times per week for one month.
62757300|NCT05265884|ACTIVE_COMPARATOR|Group B (control group)|This group includes 30 patients who will receive traditional treatment only (ROM exercises, stretching exercises, and Deep friction message) 3 times per week for 1 month.
62557897|NCT02665793|EXPERIMENTAL|DBPCFC to peanut cookie, then single-dose DBPCFC x 2|"Patients will undergo 3 sets of double-blind, placebo-controlled food challenge (DBPCFC):~1. DBPCFC to incremental doses of peanut (or placebo) baked into a cookie biscuit~2. DBPCFC to a single dose of peanut (or placebo) equivalent to 1 dosing interval below that to which that patient reacted at the baseline DBPCFC to gain entry to the study, on two separate occasions"
62757301|NCT00665756|ACTIVE_COMPARATOR|1|second trabeculectomy
62757302|NCT00665756|ACTIVE_COMPARATOR|2|Ahmed silicone drainage device implantation
62379612|NCT02150304||no intravenous aminophylline|no use of intravenous aminophylline during spinal anesthesia
62379613|NCT02149628|ACTIVE_COMPARATOR|desflurane|use desflurane as a primary anesthetics during anesthesia guided by bispectral index (BIS)
62379614|NCT02149628|EXPERIMENTAL|propofol|propofol infusion with target-controlled infusion(TCI) device guided by BIS
62557898|NCT02665793|EXPERIMENTAL|Single dose DBPCFC x 2, then DBPCFC to peanut cookie|"Patients will undergo 3 sets of double-blind, placebo-controlled food challenge (DBPCFC):~1. DBPCFC to a single dose of peanut (or placebo) equivalent to 1 dosing interval below that to which that patient reacted at the baseline DBPCFC to gain entry to the study, on two separate occasions~2. DBPCFC to incremental doses of peanut (or placebo) baked into a cookie biscuit"
62557899|NCT04082897|EXPERIMENTAL|Combination of Obinutuzumab, Atezolizumab and Venetoclax|"Obinutuzumab will be administered iv from cycle 1 to cycle 8 :~* cycle1: 100 mg iv (day 1) and 900 mg iv (day 2) 1000mg iv (day 8 and day 15)~* Cycle 2-8: 1000 mg iv on day 1~Atezolizumab will be administered iv at 1.200 mg fixed dose from C1 to C18:~* Cycles 1: day 2~* Cycle 2-18: day 1~Venetoclax will start from day 15 of cycle 1 on a weekly ramp-up basis:~week 1: 20 mg (from day 15 cycle 1) week 2: 50 mg (from day 1 to day 7 cycle 2) week 3: 100 mg (from day 8 to day 14 cycle 2) week 4 200 mg (from day 15 to day 21 cycle 2) week 5: 400 mg (from day 1 cycle 3) venetoclax will be thereafter continued until day 21 of cycle 35"
62557900|NCT01434095|ACTIVE_COMPARATOR|half-dose PDT(photodynamic therapy)|The study include single arm; treated group, and no control group was included.
62557901|NCT04747470|EXPERIMENTAL|Part 1: Cohort 1: GS-3583 675 μg|Participants with advanced solid tumors will receive GS-3583 675 μg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for up to 13 cycles (up to 52 weeks) or until the participant met study treatment discontinuation criteria.
62557902|NCT04747470|EXPERIMENTAL|Part 1: Cohort 2: GS-3583 2000 μg|Participants with advanced solid tumors will receive GS-3583 2000 μg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for up to 13 cycles (up to 52 weeks) or until the participant met study treatment discontinuation criteria.
62557903|NCT04747470|EXPERIMENTAL|Part 1: Cohort 3: GS-3583 6000 μg|Participants with advanced solid tumors will receive GS-3583 6000 μg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for up to 13 cycles (up to 52 weeks) or until the participant met study treatment discontinuation criteria.
62757303|NCT00060814|EXPERIMENTAL|Combined Pharmacotherapy and Counseling|300 mg Bupropion/4mg Nicotine Gum/Motivational Interviewing
62757304|NCT00183378|ACTIVE_COMPARATOR|1|Routine medical care with education: therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support.
62757305|NCT00183378|ACTIVE_COMPARATOR|2|Walking: the therapist introduces a walking program and assists the caregiver in establishing a daily walking routine of 30 minutes for the study participant.
62757306|NCT00183378|ACTIVE_COMPARATOR|3|Light exposure: the therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
62757307|NCT00183378|ACTIVE_COMPARATOR|4|Combination: the therapist provides education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
62379615|NCT02299128|SHAM_COMPARATOR|Minimally Therapeutic Treatment|Non-differential, prescriptive protocol of physical therapy treatment with minimal to no therapeutic benefit.
62379616|NCT02299128|EXPERIMENTAL|Skilled Treatment|Differential treatment based on the results from the assessment. Physical Therapy treatment in this arm will be pragmatically designed and modified by the treating therapist. Treatments will include manual therapy to the cervical spine, neuromotor retraining (position sense and movement sense), habituation and adaptation exercises.
62379617|NCT05905601|EXPERIMENTAL|NORTH|"Participants in the experimental arm will be provided access to the Full NORTH smartphone application designed to support young adults at risk for psychosis. They will also have access to the research team by phone for technical troubleshooting and support as necessary."
62379618|NCT05905601|EXPERIMENTAL|"NORTH Lite"|"Participants in the control arm will be provided access to the NORTH Lite smartphone application designed to support young adults at risk for psychosis. They will also have access to the research team by phone for technical troubleshooting and support as necessary."
62379619|NCT02712008|EXPERIMENTAL|REGN910-3 (3 mg: 2 mg)|Participants were administered intravitreal injection of REGN910-3 (3 milligram (mg):2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.
62379620|NCT02712008|EXPERIMENTAL|REGN910-3 (6 mg:2 mg)|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to week 12.
62379621|NCT02712008|ACTIVE_COMPARATOR|Aflibercept 2 mg|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12.
62757308|NCT01833260|EXPERIMENTAL|With music|Pulmonary rehabilitation with music in the room
62757309|NCT01833260|NO_INTERVENTION|Without music|
62757310|NCT03497546|EXPERIMENTAL|Exercise|Usual care PLUS concurrent (aerobic and strength) supervised exercise program of 16 weeks (3 sessions/week, 60 min/session, progressively increasing in volume and intensity). The program will be conducted by certified Exercise Science professionals.
62557904|NCT04747470|EXPERIMENTAL|Part 1: Cohort 4: GS-3583 12000 μg|Participants with advanced solid tumors will receive GS-3583 12000 μg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for up to 13 cycles (up to 52 weeks) or until the participant met study treatment discontinuation criteria.
62557905|NCT04747470|EXPERIMENTAL|Part 1: Cohort 5: GS-3583 20000 μg|Participants with advanced solid tumors will receive GS-3583 20000 μg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for up to 13 cycles (up to 52 weeks) or until the participant met study treatment discontinuation criteria.
62757311|NCT03497546|NO_INTERVENTION|Control|Usual care routinely delivered after bariatric surgery, based on national (Spanish) and international recommendations, focused on nutritional status monitoring and diet/physical activity counseling.
62757312|NCT04710641|EXPERIMENTAL|MTL-CEBPA in combination with sorafenib|Intravenous infusion of MTL-CEBPA 130mg/m2 given once every 3 weeks. Oral sorafenib 400mg twice a day will commence C1D8.
62557906|NCT04747470|EXPERIMENTAL|Part 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer Therapy|Participants with head and neck squamous cell carcinoma (HNSCC) will receive GS-3583 at a dose determined in Part 1 on Day 1 of every 21-day cycles for up to 8 cycles + ZIM 360 mg, on Day 1 of each 21-day cycle up to 105 weeks + cisplatin 100 mg/m\^2 of BSA on Day 1 of each 21-day cycle up to 6 cycles + carboplatin area under the curve 5 mg/mL/min on Day 1 of each 28- day cycle up to 6 cycles + 5-5-flourouracil (5-FU) 1000 mg/m\^2 of BSA/day on Days 1 to 4 of 21-day cycle up to 6 cycles.
62757313|NCT04710641|ACTIVE_COMPARATOR|Sorafenib alone|Oral sorafenib 400mg twice a day commencing Day1
62379622|NCT02712008|EXPERIMENTAL|REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at Week 16 and Q8 through Week 32.
62557907|NCT04747470|EXPERIMENTAL|Part 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer Therapy|Participants with non-small cell lung cancer (NSCLC) will receive GS-3583 at a dose determined in Part 1 on Day 1 of every 21-day cycles for up to 8 cycles + docetaxel 75 mg/m\^2 on Day 1 of each 21-day cycle until 1 or more criteria for discontinuation are met.
62557908|NCT04747470|EXPERIMENTAL|Part 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer Therapy|Participants with HNSCC will receive GS-3583 at a dose determined in Part 1 on Day 1 of every 21-day cycles for up to 8 cycles + ZIM 360 mg, on Day 1 of each 21-day cycle up to 105 weeks + cisplatin 100 mg/m\^2 of BSA on Day 1 of each 21-day cycle up to 6 cycles + carboplatin area under the curve 5 mg/mL/min on Day 1 of each 21-day cycle up to 6 cycles + 5-FU 1000 mg/m\^2 of BSA/day on Days 1 to 4 of 21-day cycle up to 6 cycles.
62757314|NCT00355342|EXPERIMENTAL|Salmeterol 50 mcg BID|Participants randomized to this arm received salmeterol 50 microgram (mcg), formulated with lactose via the DISKUS™ inhaler one inhalation twice daily (BID) one inhalation in the morning and one inhalation in the evening for 156 Weeks. Each DISKUS contained 60 doses of study medication. Participant were provided with albuterol/salbutamol as relief medication. DISCUS is registered trademark product of GlaxoSmithKline.
62757315|NCT00355342|EXPERIMENTAL|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Participants randomized to this arm received Fluticasone propionate/salmeterol combination product 250/50 mcg, formulated with lactose via the DISKUS inhaler one inhalation BID, one inhalation in the morning and one inhalation in the evening for 156 Weeks. Each DISKUS contained 60 doses of study medication. Participant were provided with albuterol/salbutamol as relief medication.
62757316|NCT06607861|ACTIVE_COMPARATOR|Control group|nebulization of 4 mL 0.9% saline plus conventional management ( consisted of bed rest in the supine position, good hydration with continuous infusion of 30 mL/kg/day lactated Ringer solution, 1 g paracetamol plus 130 mg caffeine every 6 h. Diclofenac sodium suppository (100 mg) was given twice daily for 5 days as routine post-operative pain management
62379623|NCT02712008|EXPERIMENTAL|REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at Week 20 and Q12 through Week 32.
62757317|NCT06607861|ACTIVE_COMPARATOR|Dex. group|nebulization of 1 µg/kg dexmedetomidine diluted in 4 mL 0.9% saline twice daily ( fixed times 9 a.m, and 9 p.m) plus conventional management ( consisted of bed rest in the supine position, good hydration with continuous infusion of 30 mL/kg/day lactated Ringer solution, 1 g paracetamol plus 130 mg caffeine every 6 h. Diclofenac sodium suppository (100 mg) was given twice daily for 5 days as routine post-operative pain management
62557909|NCT04747470|EXPERIMENTAL|Part 2: Randomized Expansion Cohort A: Combination Anticancer Therapy|Participants with HNSCC will receive ZIM 360 mg, on Day 1 of each 21-day cycle up to 105 weeks + cisplatin 100 mg/m\^2 of BSA on Day 1 of each 21-day cycle up to 6 cycles + carboplatin area under th e curve 5 mg/mL/min on Day 1 of each 21-day cycle up to 6 cycles + 5-FU 1000 mg/m\^2 of BSA/day on Days 1 to 4 of 21-day cycle up to 6 cycles.
62557910|NCT04747470|EXPERIMENTAL|Part 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer Therapy|Participants with NSCLC will receive GS-3583 at a dose determined in Part 1 on Day 1 of every 21-day cycles for up to 8 cycles + docetaxel 75 mg/m\^2 on Day 1 of each 21-day cycle until 1 or more criteria for discontinuation are met.
62757318|NCT06607861|ACTIVE_COMPARATOR|Lidocaine group|bilateral nebulization (60 mg) using a mucosal atomization device twice daily plus conventional management ( consisted of bed rest in the supine position, good hydration with continuous infusion of 30 mL/kg/day lactated Ringer solution, 1 g paracetamol plus 130 mg caffeine every 6 h. Diclofenac sodium suppository (100 mg) was given twice daily for 5 days as routine post-operative pain management
62757319|NCT02969590|NO_INTERVENTION|No Intervention: Spontaneous Cycle (1 month)|In order to qualify for the intervention phase, subjects needed to demonstrate favorable mucus at ovulation (Insler score of greater than or equal to 10 within 24h of an LH surge) and progesterone level in the luteal phase consistent with ovulation (a single P4 of greater than or equal to 3ng/ ml between days 18-35 of menstrual cycle).
62757320|NCT02969590|ACTIVE_COMPARATOR|NET Arm - Norethindrone (4 months)|"This arm will receive Norethindrone (NET) first then experience estradiol withdrawal (E2WD).~On the day prior to each admission, we instructed subjects to apply three fresh estradiol (E2) patches (0.3mg/day) to achieve mid-cycle level E2 effects.~On the day of the first and third admission, subjects were randomized to the experimental condition, either: (1) oral progestin administration (e.g., a single dose of 0.35mg norethindrone) with continuation of the E2 patches; or (2) estradiol withdrawal (e.g., removal of the patches). Subject then received the converse intervention for admissions two and four.~Subjects resumed treatment with the 0.1mg E2 patch until their next scheduled inpatient assessment. We required a minimum of five days at this level before repeating the dose escalation and the next evaluation."
62379624|NCT02712008|EXPERIMENTAL|Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week16 and Q8 through Week 32.
62757321|NCT02969590|ACTIVE_COMPARATOR|E2WD Arm - Estradiol (4 months)|"This arm will experience estradiol withdrawal (E2WD) first and then receive Norethindrone (NET).~On the day prior to each admission, we instructed subjects to apply three fresh estradiol (E2) patches (0.3mg/day) to achieve mid-cycle level E2 effects.~On the day of the first and third admission, subjects were randomized to the experimental condition, either: (1) oral progestin administration (e.g., a single dose of 0.35mg norethindrone) with continuation of the E2 patches ; or (2) estradiol withdrawal (e.g., removal of the patches). Subject then received the converse intervention for admissions two and four.~Subjects resumed treatment with the 0.1mg E2 patch until their next scheduled inpatient assessment. We required a minimum of five days at this level before repeating the dose escalation and the next evaluation."
62379625|NCT02712008|EXPERIMENTAL|Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week 20 and Q12 through Week 32.
62379626|NCT02712008|EXPERIMENTAL|Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at week 16 and Q8 through week 32.
62557911|NCT04747470|EXPERIMENTAL|Part 2: Randomized Expansion Cohort B: Combination Anticancer Therapy|Participants with NSCLC will receive docetaxel 75 mg/m\^2 on Day 1 of each 21-day cycle until 1 or more criteria for discontinuation are met.
62557912|NCT02060305|EXPERIMENTAL|Bevacizumab|Bevacizumab intra-articular injection; dose 20mg\~40mg every 28 days for 4 times
62557913|NCT03231163|PLACEBO_COMPARATOR|No Music|
62557914|NCT03231163|EXPERIMENTAL|Relaxing Classical Music|
62757322|NCT01638052|NO_INTERVENTION|0.25% Bupivacaine|This is our standard of care concentration
62757323|NCT01638052|EXPERIMENTAL|0.25% Bupivacaine + Clonidine|These are not two separate drugs, but a mixture of Bupivacaine and Clonidine.
62757324|NCT03018470||Control cohort|Patient with COPD and home NIV admitted for planned respiratory review and without any sign of exacerbation
62379627|NCT02261246|EXPERIMENTAL|Immediate treatment|This arm receives spinal manipulation treatment shortly after enrollment
62379628|NCT02261246|EXPERIMENTAL|Delayed treatment|This arm receives spinal manipulation treatment approximately 4 weeks after enrollment
62379629|NCT02261246|NO_INTERVENTION|Healthy control (no low back pain)|In this arm, healthy controls are tested at baseline.
62379630|NCT01812395|ACTIVE_COMPARATOR|Ultrasonic Dissector Thyroidectomy|Thyroidectomy using harmonic focus (r) device
62379631|NCT01812395|ACTIVE_COMPARATOR|Classic thyroidectomy|Patients having conventional thyroidectomy
62379632|NCT04058795|EXPERIMENTAL|Cancer Distress Coach (CaDC)|Participants in this group will get the mHealth CaDC app, which will give them tools based on cognitive behavioral therapy principles to manage their stress.
62379633|NCT04058795|EXPERIMENTAL|CaDC and mCoaching|Participants in this group will get both the CaDC app and weekly clinician support.
62379634|NCT04058795|EXPERIMENTAL|mCBT|Participants in this group will get 8-sessions with a therapist to receive cognitive behavioral therapy (CBT).
62379635|NCT04058795|NO_INTERVENTION|Control|Participants in this group can use mental health services commonly available to all cancer patients at their local medical facility but will not receive access to the CaDC app.
62379636|NCT02819583|EXPERIMENTAL|PCAR-019|Enrolled patients will receive PCAR-019 with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
62379637|NCT00423267|EXPERIMENTAL|Posaconazole|Eligible subjects will be stratified at Baseline by disease site (skeletal, lung, or soft tissue) and by immune status (immunocompromised or non-immunocompromised) and will then be randomly assigned to receive Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months.
62379638|NCT00423267|ACTIVE_COMPARATOR|Fluconazole|Eligible subjects will be stratified at Baseline by disease site (skeletal, lung, or soft tissue) and by immune status (immunocompromised or non-immunocompromised) and will then be randomly assigned to receive Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months. Fluconazole treatment or placebo only occurred during Period A.
62379639|NCT03484052|OTHER|Jugular ultrasound|
62379640|NCT02404038|ACTIVE_COMPARATOR|Arm A: Injectable|This arm will receive Nur-Isterate administered as an intramuscular injection administered bi-monthly (every 8 weeks).
62379641|NCT02404038|ACTIVE_COMPARATOR|Arm B: Intra-vaginal|This arm will receive the Nuvaring a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days.
62379642|NCT02404038|ACTIVE_COMPARATOR|Arm C: Oral|This arm will receive Triphasil a daily oral contraceptive of 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle
62379643|NCT05131035|EXPERIMENTAL|Speeded Cognitive Training|Participants in this condition will complete 40 hours of Cognitive Remediation with a mid-point assessment (20 hours/5 weeks) to determine the impact of speeded cognitive training tasks on cognition and social function.
62379644|NCT05131035|ACTIVE_COMPARATOR|Non-Speeded Cognitive Training|Participants in this condition will complete 40 hours of Cognitive Remediation with a mid-point assessment (20 hours/5 weeks) to determine the impact of non-speeded cognitive training tasks on cognition and social function.
62757325|NCT03018470||Exacerbation cohort|Patient with COPD and home NIV admitted for acute exacerbation of COPD
62757326|NCT03018470||Outpatient exacerbation|Patient with COPD and home NIV admitted for planned respiratory review and with signs of acute exacerbation of COPD but not requiring inpatient management
62757327|NCT03159364|EXPERIMENTAL|Infusion of pathogen-specific CTLs|Repetitive CTL infusions to treat microbial infections
62379645|NCT00684073|EXPERIMENTAL|Subutex®/Suboxone®|Subutex® for first two days of study followed by Suboxone® for last 3 days of study
62557915|NCT03231163|EXPERIMENTAL|Self-Selected Relaxing Music|
62557916|NCT03460002|EXPERIMENTAL|Measles vaccine|In intervention villages children will be weighed and receive standard measles vaccine in one dose if they are between 9-59 months old.
62557917|NCT03460002|EXPERIMENTAL|Oral polio vaccine|In intervention villages children will be weighed and receive standard oral polio vaccine in one or two doses if they are between 0-8 months old.
62757328|NCT04370990|ACTIVE_COMPARATOR|Active|Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation
62757329|NCT04370990|NO_INTERVENTION|controle|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously
62757330|NCT03150069||Morquio A / Biological Mothers|Women with Morquio A who have biological children
62757331|NCT03150069||Morquio A / No Biological Children|Women with Morquio A who do not have biological children (both adoptive mothers and non-mothers)
62757332|NCT03150069||Morquio B / Biological Mothers|Women with Morquio B who have biological children
62757333|NCT03150069||Morquio B / No Biological Children|Women with Morquio B who do not have biological children (both adoptive mothers and non-mothers)
62757334|NCT01219036|OTHER|Non-adherent|
62757335|NCT01219036|OTHER|Adherent|
62757336|NCT04604912||Peanut-allergic patients' group|The aim is to include 30 patients with peanut allergy. Those patients will undergo diagnostic food challenges (incremental doses) while blood will be samples before, during and after the testing. The patients will receive standard of care during and after the challenge. Allergic symptoms will be treated according to established guidelines.
62757337|NCT04604912||Control group|The aim is to include 20 control participants, 10 peanut-tolerant and 10 fish-tolerant individuals. Those participants will undergo diagnostic food challenges (incremental or single doses) while blood will be samples before, during and after the testing. Same safety measures will be applied for food challenges of control individuals, as for the allergic patients.
62757338|NCT05489627|EXPERIMENTAL|Main arm of the study|"Medial knee instabilities will be addressed in this arm. Due to the fact that isolated injury of medial stabilizers of the knees is very rare, included will be patients with D concomitant ACL QTB reconstruction and MCL reconstruction. Any accompanying intraarticular injuries such as meniscal lesions will be addressed as well.~17 patients will be included in this arm - this number was calculated and rounded up as a mean of number patients from studies of Alm et al. 2021 (17 patients in ACLR+MCLR group), Lee et al. 2020 (10 patients in ACLR+MCLR group), Kitamura et al. 2013 (16 patients in ACLR+MCLR group), LaPrade et al. 2012 (8 patients in ACLR+MCLR group), Lind et al. 2009 (34 patients in ACLR+MCLR group) and Kim et al. 2008 (12 patients in ACLR+MCLR group). All above referenced studies apart from the study of LaPrade et al. were retrospective."
62757339|NCT02865889||Uterine oncologic Indications for surgery|
62757340|NCT04306289|ACTIVE_COMPARATOR|Real tDCS|The participant will receive anodal tDCS for 20 min at an intensity of 2 mA while seated comfortably and quietly in a room. The intensity will start at 0 mA and will be incrementally increased to 2mA over the initial 30 seconds. At the 19:30 minute time point, the current will gradually be reduced from 2 mA to 0 mA.
61986905|NCT04800211|NO_INTERVENTION|Control|Continue smoking under ad libitum use of subjects' own brand of conventional lit-end cigarettes, without use of any other type of tobacco/nicotine containing product, for the entire duration of study participation.
62757341|NCT04306289|SHAM_COMPARATOR|Sham tDCS|Identical to the real tDCS, except the participants will only receive the initial 30 seconds of ramp-up, after which the current will be set to 0 for the remainder of the 20 minutes.
62757342|NCT06606704|EXPERIMENTAL|Creatine Bolus 5|
62757343|NCT06606704|EXPERIMENTAL|Creatine Bolus 3|
62757344|NCT06606704|EXPERIMENTAL|Creatine Intermittent 5|
61986906|NCT04800211|EXPERIMENTAL|Test 1|"Exclusive ad libitum use of test e-Vapor Product NuMark LLC, MarkTen® XL Bold CLASSIC\* without use of any other type of tobacco/nicotine containing product, for the entire duration of study participation.~\*Product no longer sold commercially"
61986907|NCT04800211|EXPERIMENTAL|Test 2|"Exclusive ad libitum use of test e-Vapor Product Nu Mark LLC, MarkTen® XL Bold MENTHOL\* without use of any other type of tobacco/nicotine containing product, for the entire duration of study participation.~\*Product no longer sold commercially"
61986908|NCT04267991||Tacrolimus|Patients were treated with 0.03 % tacrolimus ointment twice daily for 6 months.
62379646|NCT04121052|EXPERIMENTAL|Treatment Sequence 1|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62557918|NCT03460002|NO_INTERVENTION|Weighing-MV|In control villages children aged 9-59 months acting as controls to the MV-intervention arm will be weighed only.
62757345|NCT06606704|PLACEBO_COMPARATOR|Placebo|
62757346|NCT04397809||Acute Pulmonary Exacerbation (APE)|Those subjects presenting with APE will be treated with at least two pathogen specific I.V. antibiotics, as dictated by their treating physician and compliant with standard guidelines for care of an APE.
62757347|NCT04397809||Baseline Health|Those subjects presenting at baseline health will be identified by their treating physician as such and will not be starting on any treatments for APE.
62757348|NCT01497509|EXPERIMENTAL|Patients electing to receive intrapartum epidural analgesia|
62757349|NCT01497509|NO_INTERVENTION|Patients electing not to receive epidural analgesia|
62757350|NCT05773261|ACTIVE_COMPARATOR|MobilLINK TrabecuLINK cup|"The investigational device in this study is the newly developed MobilLINK TrabecuLINK cup. It will in this study be combined with a uncemented LCU stem.~The MobilLINK TrabecuLINK cups are made from Tilastan, a Ti6A4V alloy. The MobileLINK press-fit shells are hemispheric and polar flattened. An equatorial press-fit is built into the shells for primary stability after cementless implantation. All shells have a polar hole, which is used to connect an impactor handle for implantation of the shell. This polar hole can be closed with a polar screw. The MobileLINK TrabecuLINK shells have a 3D printed trabecular surface structure with a pore size of 610 to 820 μm and a porosity of 70 %."
61986909|NCT04267991||Phototherapeutic Keratectomy|Patients underwent transepithelial PTK for subepithelial infiltrates.
61986910|NCT04267991||Control|patients received only artificial tears eyedrop
61986911|NCT03873389||Ocrelizumab|All participants enrolled in the study. All participants will be receiving the treatment of interest (Ocrelizumab)
61986912|NCT03625245|PLACEBO_COMPARATOR|Control Yogurt|Control yogurt
61986913|NCT03625245|EXPERIMENTAL|Yogurt Variety 1|Experimental Yogurt 1: Dextrin, wheat bran, whole oatmeal
62379647|NCT04121052|EXPERIMENTAL|Treatment Sequence 2|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62557919|NCT03460002|NO_INTERVENTION|Weighing-OPV|In control villages children aged 0-8 months acting as controls to the OPV-intervention arm will be weighed only.
62557920|NCT01891864|EXPERIMENTAL|GP2015 Etanercept|Solution for subcutaneous injection in pre-filled syringe. The drug is administered in a dose of 50 mg twice weekly for the first 12 weeks and 50 mg once weekly thereafter
62379648|NCT04121052|EXPERIMENTAL|Treatment Sequence 3|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62757351|NCT05773261|ACTIVE_COMPARATOR|Pinnacle Gription Series 100 cup|"For the control group a Pinnacle Gription cup series 100 with a apex hole eliminator will be used together with a neutral cross-linked polyethylene (XLPE) Marathon liner (DePuy Synthes by Johnson \& Johnson, Norderstedt, Germany). The Pinnacle Gription cup is a hemispherical, single-geometry, titanium press-fit cup with a solid body. The outer surface consists of a porous coating with 300 μm sintered titanium beads coated with an extra layer of irregularly shaped pure titanium pieces. In cases where no initial stability can be reached when using the Pinnacle 100 series, the Pinnacle Gription sector cup with additional bone screws will be used. The cross-linked Marathon insert is made of 1050 GUR resin, irradiated with 50 kGy, remelted and plasma sterilized.~The Pinnacle Gription cup will be implanted together with a Corail stem (DePuy Synthes)."
62379649|NCT04121052|EXPERIMENTAL|Treatment Sequence 4|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62379650|NCT04121052|EXPERIMENTAL|Treatment Sequence 5|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62379651|NCT04121052|EXPERIMENTAL|Treatment Sequence 6|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62379652|NCT04121052|EXPERIMENTAL|Treatment Sequence 7|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62757352|NCT04720274|EXPERIMENTAL|Participants with Hip Pain or Injuries|
62757353|NCT04720274|ACTIVE_COMPARATOR|Healthy Participants|
62757354|NCT03692351|ACTIVE_COMPARATOR|Cup with screw holes|Uncemented Trilogy cup (Zimmer, Warzaw, IN, US), screw fixation (2 or 3 screws)
62757355|NCT03692351|EXPERIMENTAL|Cup without screw holes|Uncemented Trilogy cup (Zimmer, Warzaw, IN, US) without screw holes, press-fit fixation
62757356|NCT00789581|EXPERIMENTAL|Doxorubicin/cyclophosphamide, ixabepilone|Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by ixabepilone at 40 mg/m2 given for 4 cycles of 21 days each.
62557921|NCT01891864|ACTIVE_COMPARATOR|Enbrel ® Etanercept|Solution for subcutaneous injection in pre-filled syringe. The drug is administered in a dose of 50 mg twice weekly for the first 12 weeks and 50 mg once weekly thereafter
62557922|NCT01235754|PLACEBO_COMPARATOR|placebo gel|placebo transdermal gel
62557923|NCT01235754|EXPERIMENTAL|testosterone gel|transdermal testosterone gel
62557924|NCT02548156|OTHER|Test dentifrice|1.5g (± 0.05g) of Test dentifrice followed by 10mL of de-ionised water rinse, then 10 mL orange juice rinse
62557925|NCT02548156|OTHER|Reference dentifrice|1.5g (± 0.05g) of Reference dentifrice followed by 10mL of de-ionised water rinse, then 10 mL water rinse
62557926|NCT02548156|OTHER|Comparator dentifrice|1.5g (± 0.05g) of Comparator dentifrice followed by 10mL of de-ionised water rinse, then 10 mL orange juice rinse
62557927|NCT00293787|EXPERIMENTAL|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5% in both eyes each morning at 8 a.m. and Timolol vehicle in both eyes each evening at 8 p.m. for 3 months
62557928|NCT00293787|ACTIVE_COMPARATOR|Xalatan + Timolol 0.5%|Timolol 0.5% in both eyes each morning at 8 a.m. and Xalatan in both eyes each evening at 8 p.m. for 3 months
62757357|NCT00789581|ACTIVE_COMPARATOR|Doxorubicin/cyclophosphamide, paclitaxel|Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by paclitaxel at 80 mg/m2 weekly for 12 weeks.
62757358|NCT06599840|OTHER|Intervention group|CBT-based parent intervention consisting of 7 group sessions.
62757359|NCT04378829||ambulatory follow-up|
62757360|NCT04378829||hospital follow-up|
62757361|NCT04378829||intensive care unit follow-up|
62757362|NCT05517213|EXPERIMENTAL|Etoposide|Etoposide1.2g/m2(Pump continuously for 24h)+G-CSF10ug/kg.
62757363|NCT05517213|EXPERIMENTAL|Cyclophosphamide|Cyclophosphamide 3.0g/m2+Grh-CSF10ug/kg.
62757364|NCT04988282|ACTIVE_COMPARATOR|Steroid|"Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks; followed by a gradual reduction of 25% every 2 weeks.~Total Duration:12-16 weeks"
62757365|NCT04988282|OTHER|control|standard symptom-relief therapy (since there is no current standard therapy for post-COVID Interstitial Lung Disease, patients in this arm will be commenced symptom-relief therapies including bronchodilators, inhaled corticosteroids, non-steroid anti-inflammatories, cough relievers, and long-term oxygen if the patient has respiratory failure)
62757366|NCT00681694||MRBT|MRI-assisted brachytherapy, the experimental arm
62757367|NCT00681694||USBT1|Standard ultrasound-guided brachytherapy performed by group 1 (control arm 1)
62757368|NCT00681694||USBT2|Standard ultrasound-guided brachytherapy performed by group 2 (control group 2)
62757369|NCT03245736|EXPERIMENTAL|Tisotumab Vedotin|All patients will be administered tisotumab vedotin (HuMax-TF-ADC) in 21 day treatment cycles.
62757370|NCT04685707|EXPERIMENTAL|HFFS, then Control|Participants first performed the HFFS (increased hip flexion) exercise session. After a washout period of at least 24h, they then performed the Control (walking/running) exercise session.
62757371|NCT04685707|EXPERIMENTAL|Control, then HFFS|Participants first performed the Control (walking/running) exercise session. After a washout period of at least 24h, they then performed the HFFS (increased hip flexion) exercise session.
62757372|NCT06069141|ACTIVE_COMPARATOR|single-dose BPG plus doxycycline|single-dose benzathine penicillin G (2.4 MU intramuscularly once) plus doxycycline (100 mg orally twice daily for 7 days)
62757373|NCT06069141|PLACEBO_COMPARATOR|single-dose BPG|single-dose benzathine penicillin G (2.4 MU intramuscularly once)
62757374|NCT06214052|EXPERIMENTAL|VH4524184|Participants will receive VH4524184.
62757375|NCT06214052|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo matching VH4524184.
62757376|NCT04006210|EXPERIMENTAL|ND0612 Group|ND0612 continuous SC infusion + Active IR-LD/CD (grey capsules) + Placebo IR-LD/CD (white capsules). Randomized DBDD Maintenance Treatment for 12 weeks.
62757377|NCT04006210|ACTIVE_COMPARATOR|IR-LD/CD Group|Placebo for ND0612 continuous SC infusion + Placebo IR-LD/CD (grey capsules) + Active IR-LD/CD (white capsules). Randomized DBDD Maintenance Treatment for 12 weeks.
62757378|NCT04006210|OTHER|Oral IR-LD/CD Adjustment|Active IR-LD/CD (white capsules). Open-label Treatment in Run-in 1 for 4-6 weeks.
62757379|NCT04006210|OTHER|ND0612 Conversion|ND0612 continuous SC infusion + Active IR-LD/CD (grey capsules). Open-label Treatment in Run-in 2 for 4-6 weeks.
62757380|NCT04006210|OTHER|Open-Label Extension|ND0612 continuous SC infusion + Standard of care LD/dopa-decarboxylase inhibitor. Open-label Treatment in Extension for up to 54 months.
62757381|NCT03344107|ACTIVE_COMPARATOR|Vortek double-J stent|Vortek double-J stent after RIRS.
62757382|NCT03344107|ACTIVE_COMPARATOR|Polaris Loop stent|Polaris Loop ureteral stent after RIRS.
62757383|NCT02403635|OTHER|Midazolam + ASP2151|400 mg ASP2151 followed by 7.5 mg midazolam
62757384|NCT04326244||Snoring obesity patient|Constitution in Chinese Medicine Questionnaire, physical examination, blood test and genetic test are provided to subjects. The blood test includes High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin; the DNA test includes FTO、MC4R、BDNF、PPARG、ADRB3、UCP1. Epworth Sleepiness Scale, laryngoscope and polysomnography are also performed in the patients enrolled
62757385|NCT06224660|EXPERIMENTAL|Low Dose|SRD-001
62757386|NCT06224660|EXPERIMENTAL|High Dose|SRD-001
62757387|NCT06224660|NO_INTERVENTION|Control|No-Intervention Control
62757388|NCT05683574|EXPERIMENTAL|etoricoxib 90 mg + cyclobenzaprine 15 mg|Investigational group: FDC of etoricoxib 90 mg + cyclobenzaprine 15 mg from Eurofarma Laboratórios SA
62757389|NCT05683574|ACTIVE_COMPARATOR|etoricoxib 90 mg|Comparator group: etoricoxib 90 mg (Arcoxia®)
62757390|NCT05683574|ACTIVE_COMPARATOR|cyclobenzaprine hydrochloride 15 mg|Comparator group: cyclobenzaprine hydrochloride 15 mg (XL - Mitrul®)
62757391|NCT04209114|EXPERIMENTAL|Arm A: Combination Therapy|Neoadjuvant (pre-surgical treatment) nivolumab + bempeg, followed by radical cystectomy (RC), followed by adjuvant (post-surgical treatment) nivolumab + bempeg
62757392|NCT04209114|EXPERIMENTAL|Arm B: Monotherapy|Neoadjuvant nivolumab, followed by RC, followed by adjuvant nivolumab
62757393|NCT04209114|OTHER|Arm C: Standard-of-care|RC alone, without neoadjuvant or adjuvant therapy
62757394|NCT02387801|EXPERIMENTAL|Ixekizumab Dosing Q2W|160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q2W) every 2 weeks through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44.
62757395|NCT02387801|EXPERIMENTAL|Ixekizumab Dosing Q4W|160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q4W) every 4 weeks through week 44.
62757396|NCT03894969|EXPERIMENTAL|Sh_NTHi-Mcat_1 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.
62757397|NCT03894969|EXPERIMENTAL|Sh_NTHi-Mcat_3 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.
62379653|NCT04121052|EXPERIMENTAL|Treatment Sequence 8|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62379654|NCT04121052|EXPERIMENTAL|Treatment Sequence 9|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62379655|NCT04121052|EXPERIMENTAL|Treatment Sequence 10|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62557929|NCT01715961|OTHER|anthropometric measurement|"The muscle area assessed by CT scan imaging at a lumbar vertebral landmark (L3) at the time of diagnosis, at the end of treatment, at 12 and 18 months~* anthropometric measures (weight, height, BMI, brachial and calf circumference) and MNA (mini nutritional assessment)~* albuminemia, transthyretin, orosomucoid, CRP~* functional test to attest the muscular strength: hand grip test, unipodal test, up and go test~* hematological and non-hematological chemotherapy toxicities of cycle 1 and cycle 2~* OS and PFS at 18 and 24 months~* GCB and ABC phenotypes determined by immunohistochemistry and transcriptome analysis"
62557930|NCT02365987|EXPERIMENTAL|Interesterified|Interesterified blend of palm kernal and plam stearin. 50g fat.
62557931|NCT02365987|ACTIVE_COMPARATOR|Un-interesterified|Un-interesterified blend of palm kernal and plam stearin. 50g fat.
62557932|NCT01523652||Nadroparin/control (phase 1)|patients affected by benign pelvic gynaecologic diseases were enrolled and treated with nadroparin for prophylactic anticoagulation; patients untreated with nadroparin were as control group.
62557933|NCT01523652||Nadroparin (phase 2)|patients were enrolled among women planning gynaecological pelvic surgery and treated for 4 weeks with nadroparin for prophylactic anticoagulation. All these patients underwent laparotomy;
62557934|NCT04897854|ACTIVE_COMPARATOR|Immediate treatment|The treatment schedule will be direct (start within 3 weeks of bate of diagnosis) FOLFIRINOX or nab paclitaxel in combination with gemcitabine per investigator's choice. Dosage and frequency of administration will be according to local protocol.
62557935|NCT04897854|ACTIVE_COMPARATOR|Delayed treatment|"The treatment schedule will be delayed treatment (based on symptoms) with FOLFIRINOX or nab paclitaxel in combination with gemcitabine per investigator's choice. Dosage and frequency of administration will be according to local protocol.~Chemotherapy will start as soon as one of the following criteria is met:~* Decline in performance status to ECOG \< 1 or Karnofsky \< 80%~* Weight loss more than 5% of the total body weight from the time of study entry~* Persistent nausea requiring medication~* Pain requiring regular narcotic analgesics~* Development of clinically significant third-space fluid collections~* Liver function deterioration in the presence of progressive liver metastases"
62557936|NCT05148221|EXPERIMENTAL|A three-week tailored, virtual exercise intervention.|A three-week tailored, virtual exercise intervention.
62557937|NCT01071915|EXPERIMENTAL|Degarelix 240/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenace of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
62557938|NCT02904772|OTHER|alipogene tiparvovec with IS|Patients in the Immuno+ group will receive an immunosuppressant regimen to be initiated three days prior to alipogene tiparvovec administration. The regimen is to be continued for 12 weeks: Cyclosporins (3 mg/kg/day) and mycophenolate mofetil (2 x 1 g/day). Patients will receive IV bolus of 1mg/kg of methyl Prednisolone half an hour prior to IMP administration.
62757398|NCT03894969|EXPERIMENTAL|Sh_NTHi-Mcat_6 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.
61986914|NCT03625245|EXPERIMENTAL|Yogurt Variety 2|Experimental Yogurt 2: Pea protein, oatmeal
62379656|NCT04121052|EXPERIMENTAL|Treatment Sequence 11|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
61986915|NCT05862532|EXPERIMENTAL|Welsh Herbal tea with Senna|Welsh Herbal tea with green tea and Senna
61986916|NCT05862532|EXPERIMENTAL|Welsh Herbal tea with rhubarb root|Welsh Herbal tea with green tea and rhubarb root
61986917|NCT05862532|ACTIVE_COMPARATOR|Green tea|Dartmoor green tea
61986918|NCT02092662||Stroke|Stroke patients at the subacute phase
61986919|NCT02092662||Healthy controls|healthy age-matched voluntiers
62757399|NCT03894969|ACTIVE_COMPARATOR|NTHi-Mcat Group|Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.
62757400|NCT03894969|EXPERIMENTAL|Shingrix-Only Group|Subjects belonging to this group were originally randomized to either Sh_NTHi-Mcat_1 Group, Sh_NTHi-Mcat_3 Group or Sh_NTHi-Mcat_6 Group, they received at least 1, maximum 2 doses of GSK Biologicals Shingrix vaccine at Day 1 and Day 61, but didnt receive any dose of NTHI Mcat investigational vaccine. Only safety data were collected for these subjects.
62757401|NCT00922155|NO_INTERVENTION|EBUS|After the PPLs been localized by endobronchial ultrasound(EBUS), patients in the EBUS group received transbronchial biopsy and bronchial washing at the bronchus located by EBUS.
62757402|NCT00922155|ACTIVE_COMPARATOR|EBUS-GS|After PPLs been localized by EBUS, the EBUS and guide sheath were then inserted to localize the lesion again. Transbronchial biopsy and brushing were done through the guide sheath after the probe been removed.
62757403|NCT04243902|EXPERIMENTAL|1 - standard manual valve (without leg-bag)|"The valve will initially be tested in 8 participants who currently use a standard manual valve (without leg-bag).~This first group will include a safety cohort of participants (n=4). All safety data will be reviewed from the initial 4 participants before further participants can undergo the study investigation."
62757404|NCT04243902|EXPERIMENTAL|2 - drainage bag with free drainage|The valve will then be tested with participants (n=8) who currently use a drainage bag with free drainage.
62757405|NCT05553977||Consecutive patients for outpatient colonoscopy|The researchers will offer to participate in the study to patients scheduled for a colonoscopy who meet all the inclusion criteria and none of the exclusion criteria
62757406|NCT01154283|ACTIVE_COMPARATOR|Bi-level, standard, NIPPV|Standard NIPPV with both an inspiratory and expiratory positive airway pressure.
62757407|NCT01154283|EXPERIMENTAL|IPAP-only, NIPPV|NIPPV with only inspiratory positive airway pressure, no expiratory positive airway pressure
62757408|NCT05866484||TESA-ICSI|Compare ICSI outcomes with high Sperm DNA fragmentation undergoing TESA (testicular sperm extraction)
62757409|NCT05866484||Zymot-ICSI|Compare ICSI outcomes with high Sperm DNA fragmentation using microfluidic sperm separation device (Zymot)
62757410|NCT02241876|PLACEBO_COMPARATOR|Placebo|The patients will be treated with placebo as follows: 15 mL (0 mg of drug), once a day, during 7 days in each cycle (2 days before chemotherapy with cisplatin, on the day of chemotherapy and more 4 days after chemotherapy).
62757411|NCT02241876|EXPERIMENTAL|N-Acetylcysteine|The patients will be treated with n-acetylcysteine as follows: 15 mL (600mg of drug), once a day, during 7 days in each cycle (2 days before chemotherapy with cisplatin, on the day of chemotherapy and more 4 days after chemotherapy).
62757412|NCT03350893|PLACEBO_COMPARATOR|Control Group|Emulsion base without probiotics
61986920|NCT05295927|EXPERIMENTAL|Group A: EPI-7386 + Abiraterone Acetate Plus Prednisone (AAP)|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive EPI-7386 + AAP to determine the recommended phase 2 dose (RP2D) dose of EPI-7386 in combination with AAP in dose finding portion of the study. In dose expansion portion of the study, participants will receive EPI-7386 RP2D in combination with AAP.
62757413|NCT03350893|EXPERIMENTAL|Active Group|Emulsion base with probiotics
62757414|NCT03274427|EXPERIMENTAL|One-drug Regimes|Basic drugs therapy of HCC by TACE.
62757415|NCT03274427|EXPERIMENTAL|Two-Drug Regimens|Basic drugs therapy of HCC by TACE; Arginine hydrochloride
62757416|NCT03274427|EXPERIMENTAL|Three-Drug Regimens|Basic drugs therapy of HCC by TACE; Arginine hydrochloride;Trimetazidine hydrochloride
62757417|NCT03707951|EXPERIMENTAL|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 8 weeks; administered orally
62757418|NCT03707951|PLACEBO_COMPARATOR|Placebo|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 8 weeks; administered orally
62757419|NCT01926808||Vitamin D supplementation|
62757420|NCT03365141|EXPERIMENTAL|Experimental group|"All lesions will treated with NBUVB or excimer laser weekly and application of topical tacrolimus ointment twice daily for a total of 12-week period.~Intervention: Intralesional injection of triamcinolone acetonide (0.4mg/cc) will be performed weekly."
62757421|NCT03365141|ACTIVE_COMPARATOR|Control group|All lesions will treated with NBUVB or excimer laser weekly and application of topical tacrolimus ointment twice daily for a total of 12-week period.
62757422|NCT03833089|NO_INTERVENTION|Control|ICD recipients in optimal Medical treatment as per guidelines according to their comorbidity
62757423|NCT03833089|EXPERIMENTAL|Targeted serum potassium levels|ICD recipients recipients in optimal Medical treatment as per guidelines according to their comorbidity. In addition to guideline recommended treatment, this cohort will be treated to increase serum potassium levels to 4.5-5.0 mEq/L.
62757424|NCT04283565|NO_INTERVENTION|Strategy 1: Usual practice|No systematic screening of asymptomatic AOMI and routine management of FRCV.
62757425|NCT04283565|EXPERIMENTAL|Strategy 2: Motivationnal interviewing|No systematic screening of asymptomatic AOMI and management of CVRF by a motivationnal interviewing.
62557939|NCT02904772|OTHER|alipogene tiparvovec without IS|Patients in the Immuno- group will not receive an immunosuppressant regimen during 12 weeks. Patients will receive IV bolus of 1mg/kg of methyl Prednisolone half an hour prior to IMP administration.
62557940|NCT00842673|EXPERIMENTAL|1|30 mg ST101
62557941|NCT00842673|EXPERIMENTAL|2|90 mg ST101
62757426|NCT04283565|EXPERIMENTAL|Strategy 3: Systematic screening of AOMI by BPI measurement|Systematic screening of AOMI by BPI measurement and routine management of FRCV.
62757427|NCT04283565|EXPERIMENTAL|Strategy 4: Both strategies|Systematic screening of AOMI by BPI measurement and management of CVRF by a motivationnal interviewing.
62757428|NCT02549222||Control Cohort|During the Control cohort period patients will have study data collected following transfusion with only conventional PCs for up to 21 days of transfusion support, as clinically indicated in a manner that is consistent with the local standard of care.
62757429|NCT02549222||INTERCEPT Cohort|During the INTERCEPT phase, patients will receive only INTERCEPT PCs and will have study data collected following transfusion for up to 21 days of transfusion support, as clinically indicated in a manner that is consistent with the local standard of care.
62757430|NCT00505037|EXPERIMENTAL|ASP1585 dose #1|
62757431|NCT00505037|EXPERIMENTAL|ASP1585 dose #2|
62757432|NCT00505037|EXPERIMENTAL|ASP1585 dose #3|
62757433|NCT00505037|PLACEBO_COMPARATOR|Placebo|
62379657|NCT04121052|EXPERIMENTAL|Treatment Sequence 12|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions ( low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62557942|NCT00842673|EXPERIMENTAL|3|180 mg ST101
62557943|NCT00842673|PLACEBO_COMPARATOR|4|Placebo
62557944|NCT03123744|EXPERIMENTAL|Palbociclib 125 mg|Palbociclib is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study measurements will be obtained at baseline and about every 8 weeks thereafter. Subjects will continue study drug until disease progression or unacceptable toxicity.
62557945|NCT05767658|EXPERIMENTAL|Safe Sleep|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for infant safe sleep and b) an online community and social network of other pregnant WIC clients and new parents
62557946|NCT05767658|EXPERIMENTAL|Breastfeeding|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for breastfeeding and b) an online community and social network of other pregnant WIC clients and new parents
62557947|NCT05767658|EXPERIMENTAL|Safe Sleep and Breastfeeding|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for infant safe sleep and breastfeeding, and b) an online community and social network of other pregnant WIC clients and new parents
62557948|NCT05767658|ACTIVE_COMPARATOR|Early Brain Development and Parent -Child Relationships|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for early brain development and parent-child interactions (control intervention) and b) an online community and social network of other pregnant WIC clients and new parents.
62557949|NCT02664181|EXPERIMENTAL|Oral THU/decitabine + Nivolumab|Oral THU \~10 mg/kg, followed by oral decitabine \~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days. This drug combination is administered with Nivolumab 3mg/kg IV Q2 weeks until progression
62557950|NCT02664181|ACTIVE_COMPARATOR|Nivolumab|Nivolumab 3mg/kg IV Q2 weeks until progression; This is the standard of care for patients with NSCLC who have progressed on prior chemotherapy.
62557951|NCT01495650|EXPERIMENTAL|Intervention arm|
62557952|NCT01495650|NO_INTERVENTION|Control arm|Routine practice
62557953|NCT02154867|EXPERIMENTAL|Fecal transplantation|Fecal transplantation of freshly prepared feces from healthy donor. Application by colonoscope in proximal half of colon.
62557954|NCT02154867|PLACEBO_COMPARATOR|Placebo fecal transplantation|Sham transplant subject's own feces. Application by colonoscope in proximal part of colon.
62557955|NCT02968576|ACTIVE_COMPARATOR|Truvada|Naked form Truvada (drug)
62557956|NCT02968576|EXPERIMENTAL|PSS-Truvada|Proteus Sensor System (PSS) (device) encapsulated Truvada (drug)
62557957|NCT01437293|EXPERIMENTAL|Experimental|L-dopa / carbidopa / entacapone (LCE)
61986921|NCT05295927|EXPERIMENTAL|Group B: EPI-3786 + Apalutamide|Participants with mCRPC will receive EPI-7386 + apalutamide to determine RP2D dose of EPI-7386 in combination with apalutamide in dose finding portion of the study. In dose expansion portion of the study, participants will receive EPI-7386 RP2D in combination with apalutamide.
62557958|NCT06401135|EXPERIMENTAL|Control group|"Group 1 will receive inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 10% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 10% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
62557959|NCT06401135|EXPERIMENTAL|Low intensity inspiratory muscle training group|"Group 2 will receive inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
62557960|NCT06401135|EXPERIMENTAL|High intensity inspiratory muscle training group|"Group 3 will receive inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 60% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 60% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
62757434|NCT00505037|ACTIVE_COMPARATOR|Sevelamer hydrochloride|
62757435|NCT03378427|EXPERIMENTAL|Tedizolid Phosphate 200 MG [Sivextro]|All included patients will receive prolonged (\>= 6 weeks) tedizolid treatment given orally.
61986922|NCT04167007|ACTIVE_COMPARATOR|Group I|Gemcitabine at 1000 mg/m²
61986923|NCT04167007|ACTIVE_COMPARATOR|Group II|Oxaliplatin at 85 mg/m² ; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) and 5-FU 2400 mg/m²
61986924|NCT02540460|EXPERIMENTAL|LCB01-0371 800mg|LCB01-0371 800mg
61986925|NCT02540460|EXPERIMENTAL|LCB01-0371 800mg BID|LCB01-0371 800mg BID
62757436|NCT05460598|ACTIVE_COMPARATOR|interventional group: beddings with cooling effects|"Cooling beddings: linen made of the Outlast Technology https://www.outlast.com/en/. This product is made of 100 % lyocell and utilizes phase change materials based on natural wax. When this phase change material melts, heat is extracted from the environment and stored in microcapsules called thermocules. When the body cools down, these thermocules harden again release the heat from the linen. This might help to balances the body temperature and prevent warmth-aggravated itch.~- The mattress is made of polyurethane foam and designed as a cool gel topper to be placed onto the standard hospital mattress. Heat is also absorbed and stored into this topper. This topper is covered with an Obatex cover. It protects the cool gel topper from moisture and organic liquids and is made of polyamide fabric."
62757437|NCT05460598|PLACEBO_COMPARATOR|control group: commonly used bedding|
62757438|NCT01952665|ACTIVE_COMPARATOR|comfilcon A|Daily wear soft contact lens comfilcon A
62757439|NCT01952665|ACTIVE_COMPARATOR|lotrafilcon B|Daily wear soft contact lens lotrafilcon B
62757440|NCT03855813|OTHER|Test-retest reliability|Patients with knee osteoarthritis will perform the 30 seconds chair stand test as a self test twice at home to evaluate intra rater reliability. Same patients will be tested with the same performance test by a physical therapist to evaluate the inter rater reliability.
62757441|NCT04043754|EXPERIMENTAL|PRF treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers , the PRF membrane cut into small pieces and mixed with the ABG will be placed within the IBDs until they will be completely filled. Then the other two PRF membranes in each patient will be adapted over the grafted defect Finally horizontal mattress and interrupted sutures will be carried out.
62557961|NCT01869933|EXPERIMENTAL|1% OC-10X|Subjects selected to Cohort I will receive active 1% OC-10X in OD (Oculus Dexter - right eye) and placebo (vehicle) in OS (Oculus Sinister - left eye) in the Period 1 dosing. On Study Day 1 the subjects will have a drop instilled in each eye by personnel at study hours 0, 3, 6 and 9, and be evaluated frequently throughout the day. Subjects will be examined on Study Day 2 (24 hours after first dose). On Study Day 3 (48 hours after the first dose), these subjects will commence Period 2 dosing, with the active (OD) or placebo (OS). Dosing will continue q.i.d. for an additional 13 days.
62557962|NCT01869933|EXPERIMENTAL|2% OC-10X|Subjects selected to Cohort II will receive active 2% OC-10X in OD (Oculus Dexter - right eye) and placebo (vehicle) in OS (Oculus Sinister - left eye) in the Period 1 dosing. On Study Day 1 the subjects will have a drop instilled in each eye by personnel at study hours 0, 3, 6 and 9, and be evaluated frequently throughout the day. Subjects will be examined on Study Day 2 (24 hours after first dose). On Study Day 3 (48 hours after the first dose), these subjects will commence Period 2 dosing, with the active (OD) or placebo (OS). Dosing will continue q.i.d. for an additional 13 days.
62557963|NCT05111782|EXPERIMENTAL|Treatment Group|The treatment group will consist of persons with low back pain. This group will be further divided into groups for each decade.
62557964|NCT05111782|NO_INTERVENTION|Healthy Control Group|The control group will consist of healthy controls. This group will be further divided into groups for each decade.
62557965|NCT02254980|EXPERIMENTAL|Vitamin-E group|Vitamin-E diffused polyethylene
62757442|NCT04043754|ACTIVE_COMPARATOR|GTR treated patients|"Periodontal surgery with MEMBRANE is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers ; then, ABG will be applied alternatively with MEMBRANE into the IBD according to the sandwich technique until the IBD will be completely filled. Finally the flap will be repositioned and sutures completed by interrupted sutures."
62757443|NCT05068063|EXPERIMENTAL|Femoral Triangle + IPACK block|Patients randomized to receive a combination of femoral triangle block and active IPACK block
62757444|NCT05068063|ACTIVE_COMPARATOR|Femoral Triangle block|Patients randomized to receive a combination of femoral triangle block and sham IPACK block
62757445|NCT05533203|EXPERIMENTAL|Prodencel Treated for mCRPC|"Cohort 1: Each subject would receive Prodencel treatment at a dose of 5×10\^6 cells every two weeks for a total of 3 doses.~Cohort 2: Each subject would receive Prodencel treatment at a dose of 10×10\^6 cells every two weeks for a total of 3 doses.~Cohort 3: Each subject would receive Prodencel treatment at a dose of 15×10\^6 cells every two weeks for a total of 3 doses.~Cohort 4: The safe and effective dose from cohort 1-3 is recommended for booster immunization of cohort 4. Subjects will receive additional Prodencel treatment every 4 weeks, until disease progression or intolerance after the 3 doses of immune induction, to evaluate the safety and tolerability of the booster immunization."
62757446|NCT01689623|EXPERIMENTAL|Panel I|Each participant will be administered a single oral 40-mg atorvastatin dose on Day 1 and Day 13. The participants will receive TMC435 once daily dose of 150 mg from Day 4 until Day 15.
62757447|NCT01689623|EXPERIMENTAL|Panel II|Each participant will be administered a single oral 40-mg simvastatin dose on Day 1 and Day 13. The participants will receive TMC435 once daily dose of 150 mg from Day 4 until Day 15.
62557966|NCT02254980|ACTIVE_COMPARATOR|Control group|Standard polyethylene
62557967|NCT02535403|EXPERIMENTAL|ICBT|14 weeks of internet-based cognitive behavioral therapy with therapist support
62557968|NCT02535403|NO_INTERVENTION|Wait-list|14 weeks wait-list control
62557969|NCT00741000|EXPERIMENTAL|Experimental|Cervical low force mobilization procedure.
62557970|NCT02955212|PLACEBO_COMPARATOR|Placebo / Upadacitinib 15 mg|Participants randomized to receive placebo once daily for 12 weeks in Period 1 followed by upadacitinib 15 mg once daily for up to 52 weeks in Period 2.
62557971|NCT02955212|EXPERIMENTAL|Upadacitinib 15 mg|Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1 and up to an additional 52 weeks in Period 2.
62557972|NCT01705795|ACTIVE_COMPARATOR|Mepolizumab|Mepolizumab 750 mg four times one month apart.
61986926|NCT02540460|EXPERIMENTAL|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
61986927|NCT02540460|PLACEBO_COMPARATOR|Placebo|LCB01-0371 800mg, LCB01-0371 800mg BID, LCB01-0371 1200mg BID
62757448|NCT00743028|EXPERIMENTAL|1|
62757449|NCT00743028|EXPERIMENTAL|2|
62757450|NCT00743028|EXPERIMENTAL|3|
62757451|NCT00743028|EXPERIMENTAL|4|
62757452|NCT00743028|EXPERIMENTAL|5|
62757453|NCT00743028|EXPERIMENTAL|6|
62757454|NCT05179603|EXPERIMENTAL|Cohort A: (sub study 01) classic Hodgkin lymphoma (cHL)|SAR444245 and pembrolizumab administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
62757455|NCT05179603|EXPERIMENTAL|Cohort C1: (sub study 03) diffuse large B Cell lymphoma (DLBCL)|SAR444245 administered every 2 weeks on Day 1 of each cycle (14 days per cycle) for up to 52 cycles.
62757456|NCT02683070|EXPERIMENTAL|The PNB group|Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) will be performed after the completion of surgery before extubation.
62757457|NCT02683070|ACTIVE_COMPARATOR|The TRAM group|Intravenous tramadol of 1.5mg/kg will be administrated after the completion of surgery before extubation.
62757458|NCT02275390|EXPERIMENTAL|Nurse-led Psycho-education [SPBB: Self-learning program]|"The Nurse-led Psychoeducation Program is comprised of eight 2-hour sessions held at every two weeks (over 4 months). The program consists of five themes: (a) orientation and engaging and understanding of mental health/illness, its related behaviors and community support resources; (b) working collaboratively and empowering and minimizing resistance and challenges using motivational interviewing approach; (c) effective interpersonal and communication skills; (d) strategies in coping with mental illness, sleep hygiene and allaying anxiety; and (e) self-review and evaluation and establishing a realistic plan for future.~\[Note: The participants in the SPBB will complete the self-help and problem-solving manual (5 modules) for caregivers of people with psychotic disorders over 20 weeks, together with an orientation, understanding about psychosis and its care and 4 review sessions.\]"
62757459|NCT02275390|ACTIVE_COMPARATOR|Usual Psychiatric Outpatient Care|"Routine psychiatric outpatient care provided by two psychiatric outpatient clinics under study~\[Note: for SPBB trial, routine psychiatric outpatient care provided by two psychiatric outpatient clinics under study\]"
62757460|NCT06045182|ACTIVE_COMPARATOR|Group A (Maitland mobalizations )|Patients in this group will receive Maitland mobilizations along with hot pack and TENS for pain and disability. A total of 3 sessions would be conducted over a period of 1 week.
62757461|NCT06045182|EXPERIMENTAL|Group B (Maitland Moblizations along with piriformis stretch)|Patients will receive Maitland mobilizations along with hot pack and TENs and additional stretch of piriformis muscle is given. A total of 3 sessions would be conducted over a period of 1 week.
62757462|NCT06512896|OTHER|The safety and tolerability of intraluminal injection of FOLactis|Evaluate the safety and tolerability of intraluminal injection of FOLactis combined with systemic anti-tumor therapy in patients with advanced solid tumors accompanied by malignant pleural and peritoneal effusion, determine the optimal dose, and explore preliminary efficacy
62757463|NCT00849706||Study group|Medical staff personal, doctors and nurses, working night shifts.
62757464|NCT03777917|EXPERIMENTAL|Belotero Balance®|
62757465|NCT03777917|NO_INTERVENTION|No treatment|
62557973|NCT01705795|PLACEBO_COMPARATOR|Placebo|Placebo (saline) four times one month apart
62757466|NCT01952444|EXPERIMENTAL|Group 1 ETI-204 and Ciprofloxacin|Participants will receive a single IV dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1, immediately followed by an IV dose of ciprofloxacin 400 mg infused over 60 minutes, followed by oral doses of ciprofloxacin (750 mg every 12 hours) from Day 2 to Day 8 and a final dose on the morning of Day 9.
62757467|NCT01952444|OTHER|Group 2 ETI-204 Alone|Participants will receive a single IV dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1.
62757468|NCT03403231|ACTIVE_COMPARATOR|Arm 1: Stock messages only|Participants will only receive the stock messages that encourage following recommended behaviors for reducing the risk for developing diabetes.
62757469|NCT03403231|EXPERIMENTAL|Arm 2: Urgency frame message strategy|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the urgency frame message strategy.
62757470|NCT03403231|EXPERIMENTAL|Arm 3: Social norm message strategy|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the social norm messaging strategy.
62757471|NCT03403231|EXPERIMENTAL|Arm 4: Urgency frame and social norm strategies|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the urgency frame and social norm messaging strategies.
62757472|NCT03403231|EXPERIMENTAL|Arm 5: Implementation Intentions and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the implementation intentions and urgency frame messaging strategies.
62757473|NCT03403231|EXPERIMENTAL|Arm 6: Implementation Intentions and Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the implementation intentions and social norm messaging strategies.
62757474|NCT03403231|EXPERIMENTAL|Arm 7: Implementation Intentions, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the implementation intentions, urgency frame, and social norm messaging strategies.
62757475|NCT03403231|EXPERIMENTAL|Arm 8: Implementation Intentions|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the implementation intentions messaging strategy.
62757476|NCT03403231|EXPERIMENTAL|Arm 9: Preference Checklists and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the preference checklists and urgency frame messaging strategies.
62757477|NCT03403231|EXPERIMENTAL|Arm 10: Preference Checklists and Social Norms|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the preference checklists and social norm messaging strategies.
62757478|NCT03403231|EXPERIMENTAL|Arm 11: Preference Checklists, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the preference checklists, urgency frame, and social norm messaging strategies.
62757479|NCT03403231|EXPERIMENTAL|Arm 12: Preference Checklists|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the preference checklists messaging strategy.
62757480|NCT03403231|EXPERIMENTAL|Arm 13: Tailored Aspirations and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the tailored aspirations and urgency frame messaging strategies.
62757481|NCT03403231|EXPERIMENTAL|Arm 14: Tailored Aspirations and Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the tailored aspirations and social norm messaging strategies.
62757482|NCT03403231|EXPERIMENTAL|Arm 15: Tailored Aspirations, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the tailored aspirations, urgency frame, and social norm messaging strategies.
62757483|NCT03403231|EXPERIMENTAL|Arm 16: Tailored Aspirations|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the tailored aspirations messaging strategy.
62757484|NCT03885765||Test group|The first 60 patients recruited.
62757485|NCT03885765||Validation group|The last 100 patients recruited.
62757486|NCT04897919|EXPERIMENTAL|dihydroartemisinin-piperaquine|"First dose will be given supervised. The rest will be provided and the parents should take it at home.~Dihydroartemisinin-piperaquine dosing as recommended by manufacturer"
62757487|NCT04897919|ACTIVE_COMPARATOR|artemether-lumefantrine|"First dose will be given supervised. The rest will be provided and the patients should take it at home.~Artemether-lumefantrine dosing as recommended by manufacturer"
62757488|NCT02159222|EXPERIMENTAL|Additional physical therapy|
62757489|NCT00881153|EXPERIMENTAL|1|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)
62757490|NCT00881153|ACTIVE_COMPARATOR|2|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)
62557974|NCT00927589|EXPERIMENTAL|1|
62557975|NCT04809532|EXPERIMENTAL|Group A|Transverse abdominis plane (TAP ) block via 20ml 0.25% bupvicaine on both sides of midline will be given at end of surgery
62557976|NCT04809532|NO_INTERVENTION|Group B|At the end of surgery, no additional intervention will be done.
62557977|NCT02144714|EXPERIMENTAL|SB5|SB5, single dose of 40 mg via subcutaneous injection (study drug)
62557978|NCT02144714|ACTIVE_COMPARATOR|EU sourced Humira®|EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
62557979|NCT02144714|ACTIVE_COMPARATOR|US sourced Humira®|US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
62757491|NCT01537146|ACTIVE_COMPARATOR|Femoral Block|
62757492|NCT01537146|ACTIVE_COMPARATOR|Local Infiltration Anagesia|
62757493|NCT02470143||Bike application arm|The bike application arm contains cardiac patients that will be instructed to use the cycling application during a one month period.
62757494|NCT03978962||Study population|Patients subjects to a Guided Tissue Regeneration or Guided Bone Regeneration procedure
62757495|NCT03220581|ACTIVE_COMPARATOR|Referral for care|Referral for mental health issues and family support services
62757496|NCT03220581|EXPERIMENTAL|Behavioral therapy|8-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors
62757497|NCT06380439|EXPERIMENTAL|wrist ankle acupuncture|wrist ankle acupuncture using 0.25 x 25mm filiform needle on lower 1, lower 4, lower 5 area ipsilateral to the surgical side, then covered with 5cm long micropore, retention for 4 hours
62757498|NCT06380439|SHAM_COMPARATOR|sham wrist ankle acupuncture|0.25 x 25mm filiform needle pricked and placed on the surface of the skin on lower 1, lower 4, lower 5 area ipsilateral to the surgical side, covered with 5cm long micropore, retention for 4 hours
62757499|NCT04368091||All-comers, real-world registry|Subjects requiring infrainguinal revascularization with the Xtreme Touch - Neo (Magic Touch PTA)
62757500|NCT04479475|EXPERIMENTAL|Supportive care through social support persons|MMT participants will attend seven sessions over the course of six weeks to build social support systems and make progress toward drinking and drug use goals. Social support persons identified by participating MMT clients will jointly attend up to five sessions over the course of six weeks.
62757501|NCT03003078|OTHER|OncoSil™ plus SOC Chemotherapy|OncoSil™ implanted with concurrent Standard of care Chemotherapy - either FOLFIRINOX or gemcitabine + Abraxane.
62757502|NCT06456229|NO_INTERVENTION|Arm 1|Control arm with no nutritional supplementation
62757503|NCT06456229|ACTIVE_COMPARATOR|Arm 2|Control arm with nutritional supplementation but without probiotics
62757504|NCT06456229|EXPERIMENTAL|Arm 3|Nutritional supplementation with probiotics
62757505|NCT03128268|EXPERIMENTAL|All Enrollees|"Intervention: Diagnostic test~All enrollees will receive a 4D MRI as a research intervention using imaging software for 4 dimensional images for Cardiac MRI"
62757506|NCT04072679|EXPERIMENTAL|Sintilimab+IBI305|Sintilimab: 200mg (D1, q3w） IBI305: 7.5mg/kg or 15mg/kg (D1, q3w）
62757507|NCT03694392||Flublok Recipients|Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine.
62757508|NCT03694392||SD-IIV Recipients|Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV).
62757509|NCT01338077|EXPERIMENTAL|Sodium alginate|Oral suspension, 50 mg/ml
62757510|NCT01338077|ACTIVE_COMPARATOR|Omeprazole|20 mg/cap
62757511|NCT04140955|EXPERIMENTAL|Tapering plan and telephone counselling|Patients receive an individually customized tapering plan at discharge and telephone counselling 5-7 days after discharge.
61986928|NCT01837992|ACTIVE_COMPARATOR|Standard dose|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, and will be administered the standard recommended primaquine dose of 0.25mg/kg for 14 consecutive days.
61986929|NCT01837992|ACTIVE_COMPARATOR|High dose|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, and will be administered a primaquine dose of 0.5mg/kg/day for 14 consecutive days.
62757512|NCT04140955|NO_INTERVENTION|Control group|Patients receive standard care and treatment, i.e. no tapering plan or telephone counselling.
62757513|NCT05126264|EXPERIMENTAL|Modified dosage|Ibuprofen pill at morning and afternoon; Placebo at night
62757514|NCT05126264|ACTIVE_COMPARATOR|Normal dosage|Ibuprofen three times a day: morning, afternoon and night
62757515|NCT01759563|OTHER|single arm study|
62757516|NCT01113489|EXPERIMENTAL|beclomethasone dipropionate suspension for nebulization|
62757517|NCT01113489|PLACEBO_COMPARATOR|placebo|
62757518|NCT04165187|EXPERIMENTAL|BAT+Home exercise program|The patients in this group will participate in BAT for 3 days a week for 6 weeks in addition to home exercise program.
62757519|NCT04165187|ACTIVE_COMPARATOR|Home exercise program|The patients in the control group will perform home exercise program, two times a day, 7 days a week for 6 weeks.
62757520|NCT02255565|EXPERIMENTAL|Very Low Dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a very low dose level for 6 weeks.
62757521|NCT02255565|EXPERIMENTAL|Low Dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a low dose level for 6 weeks.
62757522|NCT02255565|EXPERIMENTAL|Moderate dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a moderate dose level for 6 weeks.
62757523|NCT03614416|EXPERIMENTAL|EOXY device and Gold standard oximter and SaO2 measures|Heart rate and SPO2 measures provided from EOXY device Heart rate measures provided from gold standard oximeter. SaO2 measures provided from blood sampling There is only one arm: all subjects have simultaneously three interventions (as required in the European standard ISO 80601-2-61), to qualify a pulse oximeter
62757524|NCT06237920|EXPERIMENTAL|Nivolumab|1 cycle of intravenous nivolumab on day 1 and 1 cycle of intraveous nivolumab on day 29. Total administration frequency is twice.
62757525|NCT06237920|EXPERIMENTAL|Nivolumab and relatlimab|1 cycle of intravenous nivolumab and relatlimab on day 1 and 1 cycle of intraveous nivolumab and relatlimab on day 29. Total administration frequency is twice.
62757526|NCT05746650|EXPERIMENTAL|1) Electrical stimulation + growth hormone|One bout of electrical stimulation with 200 eccentric contractions. This is followed by daily injections with somatropin (33.3 ug/kg in the first week, 50 ug/kg in the second week) for two weeks.
62757527|NCT05746650|EXPERIMENTAL|2) Electrical stimulation|One bout of electrical stimulation with 200 eccentric contractions
61986930|NCT01837992|OTHER|Control|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, but will not receive primaquine until the time of confirmed recurrent parasitaemia or completion of 3 months follow up.
62757528|NCT05746650|ACTIVE_COMPARATOR|3) Growth hormone|Daily injections with somatropin (33.3 ug/kg in the first week, 50 ug/kg in the second week) for two weeks.
62757529|NCT05746650|PLACEBO_COMPARATOR|4) Control|No intervention
62757530|NCT06320249|EXPERIMENTAL|The high-frequency manipulation group|In the high-frequency manipulation group, patients will undergo rotation-traction manipulation three times weekly. A total of 12 treatments for four weeks.
62757531|NCT06320249|EXPERIMENTAL|The low-frequency manipulation group|In the low-frequency manipulation group, patients will undergo rotation-traction manipulation once time weekly. A total of 4 treatments for four weeks.
61986931|NCT02034955|EXPERIMENTAL|Post-Operative adaptive radiotherapy|All Patients enrolled in this study will have additional scans (Cone-Beam CT, MRI) daily during their treatment. This extra imaging will help us see any changes that might have occurred during radiation treatment and update the treatment plan to include these changes before patient treatment is continued.
62379658|NCT04121052|EXPERIMENTAL|Treatment Sequence 13|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62379659|NCT04121052|EXPERIMENTAL|Treatment Sequence 14|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62757532|NCT06320249|ACTIVE_COMPARATOR|The cervical traction group|The cervical traction group will be subjected to cervical traction three times a week. A total of 12 treatments for four weeks.
62757533|NCT06306690||1. Patients with rhodopsin mutation (RHO)|Following a clinical diagnosis, patients undergo genetic testing. Patients with rhodopsin mutation (RHO) a mutation are categorised into subgroup 1.
62757534|NCT06306690||2. Patients with pre-mRNA factor 8 (PRPF8) mutation|Following a clinical diagnosis, patients undergo genetic testing. Patients with pre-mRNA factor 8 (PRPF8) mutation are categorised into subgroup 2.
62557980|NCT02015728|EXPERIMENTAL|Regimen B|"Depending on tumor biology testing, subjects assigned to Regimen B will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Everolimus 3 mg/m2/dose daily PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
62557981|NCT02015728|EXPERIMENTAL|Regimen C|"Depending on tumor biology testing, subjects assigned to Regimen C will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Erlotinib 85 mg/m2/dose daily PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
62557982|NCT02015728|EXPERIMENTAL|Regimen D|"Depending on tumor biology testing, subjects assigned to Regimen D will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Dasatinib 60 mg/m2/dose BID PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
62557983|NCT02015728|EXPERIMENTAL|Regimen A|"Depending on tumor biology testing, subjects assigned to Regimen A will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Sorafenib 150 mg/m2/dose BID PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
62557984|NCT02668575|NO_INTERVENTION|Usual Care|Patients randomized to the control arm of this study will continue to receive the standard of high-quality CF care provided to all patients at the UPMC CF Center.
62757535|NCT06306690||3.Patients a cone-specific phosphodiesterase, i.e. PDE6B, mutation|Following a clinical diagnosis, patients undergo genetic testing. Patients with a cone-specific phosphodiesterase, i.e. PDE6B, mutation are categorised into subgroup 3.
62757536|NCT06306690||4. Patients with Chromosome 2-Open (C2orf71) mutation|Following a clinical diagnosis, patients undergo genetic testing. Patients with Chromosome 2-Open (C2orf71) mutation are categorised into subgroup 4.
62757537|NCT06306690||5. Patients with Guanylate Cyclase (GUCY2D) mutation|Following a clinical diagnosis, patients undergo genetic testing. Patients with Guanylate Cyclase (GUCY2D) mutation are categorised into subgroup 5.
62757538|NCT06306690||6. Patients with RP- specific nuclear receptor (Nr2E3) mutation|Following a clinical diagnosis, patients undergo genetic testing. Patients with RP- specific nuclear receptor (Nr2E3) mutation are categorised into subgroup 6.
62757539|NCT02185157|EXPERIMENTAL|Experimental: Dual Task exercises|Dual-task training, includes 18 sessions model of cognitive and 12 motor dual-task exercises model, were administered in groups of four participants in a comfortable environment, without distraction effects. The 50-minute sessions included 30 minutes of motor dual-task exercises, and then, the participants were divided into pairs. The first pair performed free walks during 10 minutes at their maximal speeds, while the other received individual cognitive dual-task training for the same time, and these activities will be exchanged, so that all pairs could walk and receive cognitive training.
62757540|NCT02185157|OTHER|Control intervention: Aerobic training|The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
62757541|NCT05011214|ACTIVE_COMPARATOR|group S|patients were anesthetized by face mask with 5 vol% sevoflurane with total 5 L/min-1 fresh gas flow. Anaesthesia was maintained by continuously using 3-4% sevoflurane.
62757542|NCT05011214|EXPERIMENTAL|group E|patients received 0.5mg/kg IV esketamine at first, after surgical field disinfection, another 0.25mg/kg IV esketamine was administered. Then 1mg/kg propofol was administered every 5 minutes after intubation.
62757543|NCT04763486|EXPERIMENTAL|Prophylactic antibiotic treatment|Will be given Cefamezin antibiotic within 6 hours of delivery
62757544|NCT04763486|NO_INTERVENTION|No intervention|Will not get antibiotic prophylactics
62757545|NCT05423938|EXPERIMENTAL|Bi1 diacare hp-hc|During 6 days, patients received 2 ONS of a specific formula for diabetes, high energy (300 kcal/unit) and high protein (20%), with fiber, EPA\&DHA, EVOO and a specific mix of low glycemic index of carbohydrate
62757546|NCT05423938|ACTIVE_COMPARATOR|Control|During 6 days, patients received 2 ONS of a standar formula, high energy (300 kcal/unit) and high protein (20%), without fiber, without EPA\&DHA, without EVOO and without a specific mix of low glycemic index of carbohydrate
62557985|NCT02668575|EXPERIMENTAL|Supportive Care Intervention|Patients randomized to the intervention arm will receive a protocolized supportive care intervention from a palliative care nurse practitioner.
62557986|NCT00610129|EXPERIMENTAL|1|MK-0646
62557987|NCT03690050|EXPERIMENTAL|Diode Subthreshold Micropulse Laser|"DSML is a relatively new laser technology aimed at minimising damage (tissue-sparing) to choroid and retina but maintaining treatment efficacy by its selective effect on the retinal pigment epithelium (RPE). It is performed using laser that, instead of delivering a continuous-wave laser beam, as the standard laser, it provides very small, repetitive, low energy pulses of laser separated by a brief rest period. This rest period allows the tissue to cool down between laser pulses avoiding the increased tissue heat that would be produced by continuous laser and allowing the use of lower laser energy power to achieve an effect. The reduced heat produced in the tissue and the reduced energy power required for the treatment may reduce side effects."
62757547|NCT05302206|EXPERIMENTAL|patients with ileostomy without type 2 diabetes|colonic glucose or saline infusion via ileostomy
62757548|NCT05302206|EXPERIMENTAL|patients with ileostomy with type 2 diabetes|colonic glucose or saline infusion via ileostomy
61986932|NCT03375021|EXPERIMENTAL|Sequence 1 PL|Eligible subjects were randomized to Sequence 1 PL in which they received placebo (P) followed by crossover to CX717 200 mg low dose (L) of active treatment
62757549|NCT01276444|ACTIVE_COMPARATOR|Pulmonary artery catheter (PAC)|PAC was used to guide hemodynamic therapy after combined valve repair
62757550|NCT01276444|ACTIVE_COMPARATOR|COMPLEX|An combination of transpulmonary thermodilution and continuous monitoring of central venous saturation was used to guide hemodynamic therapy after combined valve repair surgery.
62757551|NCT04183855|EXPERIMENTAL|control|no supplement will be provided on the day of the experiment
62757552|NCT04183855|EXPERIMENTAL|Generation UCAN|carbohydrates - protein (Generation UCAN supplement, 250ml, 10% solution)
62757553|NCT04183855|EXPERIMENTAL|Mirexus PhytoSpherix|carbohydrates alone (Mirexus PhytoSpherix, 250ml, 10% solution)
62757554|NCT04086797|EXPERIMENTAL|IQP-AE-103|2 capsules after 3 main meals per day (total 1980 mg)
62757555|NCT04086797|PLACEBO_COMPARATOR|Placebo|2 capsules after 3 main meals per day
62757556|NCT00853125|EXPERIMENTAL|Sunitinib plus Irradiated Allogeneic Lymphocytes|
62757557|NCT00671372|EXPERIMENTAL|Cohorts 1-5|
62757558|NCT00671372|EXPERIMENTAL|Cohorts 6, 6A, 7, 7A|
62757559|NCT04410666|EXPERIMENTAL|GREEN TEA MOUTH WASH|an infusion at 13%, with 13 g of green tea (commercially divided) in 100 ml of saline solution, at a temperature of approximately 90 ° C.
62379660|NCT04121052|EXPERIMENTAL|Treatment Sequence 15|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62557988|NCT03690050|ACTIVE_COMPARATOR|Standard threshold laser (532 nm laser)|Green-yellow argon laser photocoagulation at threshold levels has been used for many years as the standard laser for the treatment of many retinal disorders including DMO. The ETDRS demonstrated the efficacy of laser in preventing visual loss in patients with DMO.
62557989|NCT02696291|EXPERIMENTAL|Cohort 1 - 30 mg|Subjects receiving UV-4B 30 mg oral solution or placebo
62757560|NCT04410666|PLACEBO_COMPARATOR|Placebo|distilled water, in sterile glass containers.
62757561|NCT05737420|EXPERIMENTAL|Interventional video call|All patients suspected of stroke in a prehospital setting are examined according to a prehospital stroke score. The emergency services personnel then contact the on-call neurologist and a live video stream is initiated. The on-call neurologist then examines the patient via the video-call.
62757562|NCT05737420|NO_INTERVENTION|Control with standard care|All patients suspected of stroke in a prehospital setting are examined according to a prehospital stroke score. The emergency services personnel then contact the on-call neurologist by telephone. .
62557990|NCT02696291|EXPERIMENTAL|Cohort 2 - 75 mg|Subjects receiving UV-4B 75 mg oral solution or placebo
62557991|NCT02696291|EXPERIMENTAL|Cohort 3 - 150 mg|Subjects receiving UV-4B 150 mg oral solution or placebo
62557992|NCT02696291|EXPERIMENTAL|Cohort 4 - X mg (dose to be determined)|Subjects receiving UV-4B X mg (dose to be determined) oral solution or placebo
62557993|NCT02696291|EXPERIMENTAL|Cohort 5 - Y mg (dose to be determined)|Subjects receiving UV-4B Y mg (dose to be determined) oral solution or placebo
62557994|NCT02909686|EXPERIMENTAL|Boswellia Serrata|400-800mg in capsule form by mouth every day
62557995|NCT02909686|EXPERIMENTAL|Curcumin|1000-2000mg in capsule form by mouth every day
62557996|NCT02909686|EXPERIMENTAL|Epimedium|1000-2000mg in capsule form by mouth every day
62557997|NCT02909686|EXPERIMENTAL|Fisetin|200-800mg in capsule form by mouth every day
62557998|NCT02909686|EXPERIMENTAL|Luteolin|200-400mg in capsule form by mouth every day
62557999|NCT02909686|EXPERIMENTAL|Nettle|435-1305mg in capsule form by mouth every day
62757563|NCT01878110|EXPERIMENTAL|COMB|
62757564|NCT03080883|EXPERIMENTAL|Group I (lower dose apixaban)|Patients receive lower dose apixaban PO BID for 365 days.
62757565|NCT03080883|EXPERIMENTAL|Group II (higher dose apixaban)|Patients receive higher dose apixaban PO BID for 365 days.
62757566|NCT05842863|EXPERIMENTAL|Dialectical Behavior Therapy + Cognitive Behavioral Therapy for Insomnia|
62757567|NCT05842863|ACTIVE_COMPARATOR|Dialectical Behavior Therapy Only|
62757568|NCT01878669|PLACEBO_COMPARATOR|saline|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
62757569|NCT01878669|EXPERIMENTAL|n-acetyl cysteine|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
62757570|NCT04976218|EXPERIMENTAL|Experimental arm|Enrolled patients in this arm will be administered TGFβR-KO CAR-EGFR T Cells in 3+3 based escalation manner.
62757571|NCT01067482||Glaucoma patients|
62757572|NCT01067482||Glaucoma suspect group|
62757573|NCT01067482||Normal population|
62757574|NCT02465749|EXPERIMENTAL|Continuous Oxygen|Continuous oxygen intake and routine drug treatment .
62757575|NCT02465749|EXPERIMENTAL|Blue Light Deprivation|Wearing blue light-absorbing sunglasses at daily time and routine drug treatment
62757576|NCT02465749|EXPERIMENTAL|Continuous Oxygen Therapy Combined With Blue Light Deprivation|Continuous oxygen intake , Wearing blue light-absorbing sunglasses at daily time and routine drug treatment
62757577|NCT02465749|OTHER|control|Routine drug treatment
62558000|NCT02909686|EXPERIMENTAL|Pycnogenol|200-400mg in capsule form by mouth every day
62757578|NCT06021093||Medical Hypnosis|Study intervention: The hypnotherapy will include 2 individual hypnotherapy sessions plus daily listening to these recorded sessions and to (3 or 4) standardized hypnosis recordings. The individual sessions will be provided by CF and ET, both certified hypnotherapists and health care professionals (respectively nurse and physician). Preferably, these sessions take place during a planned admission for chemotherapy. If preferred by the patient, this can also take place at the hypnotherapist's office. If preferred by the patient, this can also take place at the venue of the hypnotherapist. A large part of the first session will be devoted to answering participants' questions and giving information about hypnosis, followed by exercises as an introduction to hypnosis. The goal of these exercises is to enable participants to increase their awareness and abilities in accessing mental imagery and hypnosis. At the end of the session, information will be provided about the home-based practice.
62757579|NCT00477269|EXPERIMENTAL|STI571|STI571
62757580|NCT00477269|PLACEBO_COMPARATOR|Placebo|Placebo
62757581|NCT00477269|EXPERIMENTAL|All Patients|Open label extension
62757582|NCT02337972|EXPERIMENTAL|Diabetic patients|Patients with Diabetes Mellitus and macular edema who were determined by their treating physician to require at least 3 serial injections with an anti-Vascular epithelial growth factor (VEGF). Prior to each injection a use of povidone-iodine 4% drops will be performed to clean the conjunctival sac
62757583|NCT05281536|EXPERIMENTAL|Postural Changes from 45° to 10° in supine decubitus|Postural changes from 45° to 10° in supine decubitus Three times of 60 minutes each step before (45°, baseline) - during (10°, intervention) - after (45°, control)
62757584|NCT02897531|ACTIVE_COMPARATOR|ES anastomosis|Stapled end-to-side anastomosis
62757585|NCT02897531|ACTIVE_COMPARATOR|SS anastomosis|Stapled side-to-side anastomosis
62757586|NCT01850472||Healthy controls|Individuals with no psychiatric diagnosis as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment. There is no intervention administered in this study.
62757587|NCT06101602|EXPERIMENTAL|With Floss Band|"Floss band made of natural rubber, black in color and 4 in width will be wrapped around the thigh, starting from the distally to superiorly with an overlap of 50%. Perform exercises:~• Multi-directional leg swing"
62757588|NCT06101602|ACTIVE_COMPARATOR|Without floss Band|"Perform exercises without floss band.~• Multi-directional leg swing"
62757589|NCT05764668|EXPERIMENTAL|Zihua Wenfei Zhisou Granule|Patients in experimental treatment arm were given Zihua Wenfei Zhisou Granule (15 g/bag, one bag at a time, three times/day ). All treatment lasted for 14 days and no other antitussive/decongestant or bronchodilators are given to any patients.
62757590|NCT05764668|PLACEBO_COMPARATOR|Zihua Wenfei Zhisou Granule-matched placebo|"Patients in placebo treatment arm were given Zihua Wenfei Zhisou Granule-matched placebo (15 g/bag, one bag at a time, three times/day ). All treatment lasted for 14 days and no other antitussive/decongestant or bronchodilators are given to any patients.~Placebo does not contain active pharmaceutical ingredients, and its main ingredients are lactose, beta-cyclodextrin, stevioside, and caramel."
62757591|NCT04077866|ACTIVE_COMPARATOR|Temozolomide alone|Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.
62757592|NCT04077866|EXPERIMENTAL|Temozolomide + B7-H3 CAR-T|"Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.~The B7-H3 CAR-T will be administrated via intratumoral or Intracerebroventricular injection through an Ommaya catheter in between Temozolomide cycles. Temozolomide treatment in the cycles of B7-H3 CAR-T treatment will be stopped."
62757593|NCT03473964||Treatment|The study intervention is the observation of study subjects who have received H.P. Acthar® Gel (adrenocorticotrophic hormone), 40 units twice weekly injections in patients who have sarcoid uveitis and to assess it's effectiveness by measuring changes the degree of aqueous and vitreous inflammatory cells present, the degree of aqueous flare, and changes in visual acuity, macular thickness, intraocular pressure and quality of life measures assessed by using the National Eye Institute Visual Function Questionnaires (VFQ-25)
62757594|NCT02252549|ACTIVE_COMPARATOR|A|SPIES+WLI assisted TURB
62757595|NCT02252549|ACTIVE_COMPARATOR|B|WLI assisted TURB
62757596|NCT02860624|EXPERIMENTAL|10 mg ilaprazole|
62757597|NCT02860624|ACTIVE_COMPARATOR|40 mg esomeprazole|
62757598|NCT02430493||ticagrelor|Chinese subjects aged over 18, diagnosed as ACS and treated with ticagrelor at least one tablet
62558001|NCT02909686|EXPERIMENTAL|Reishi Mushroom|1600-3200mg in capsule form by mouth every day
62558002|NCT02909686|EXPERIMENTAL|Resveratrol|200-600mg in capsule form by mouth every day
62558003|NCT02909686|PLACEBO_COMPARATOR|Placebo|in capsule form by mouth every day
62757599|NCT04676308||AI arm|Standard colonoscopy with Artificial Intelligence-GI GeniusTM
62757600|NCT04676308||Cuff arm|Endo-cuff Vision aided colonoscopy with Artificial Intelligence -GI GeniusTM
62558004|NCT04207658|EXPERIMENTAL|Valsalva's Pushing|The gravitas are informed about spontaneous pushing at the active phase of dilatation (6cm) in second stage of labour and they are encouraged for spontaneous pushing just at the onset of pushing. At the expulsion phase (baby's head is visible in vulva), they are encouraged to perform the Valsalva's manoeuvre that they have practised in routines of delivery; When contractions start, breathe twice normally. Take a deep breath and hold. Compress the air with the help of diaphragm and abdominal muscles. Push strongly and long (for 10-15 sec). Breathe out and take another deep breath, hold it and push as strongly as possible for another 10-15 seconds. Stop pushing when contractions are mild. Breathe 2-3 times in normal style. Relax and have a rest until the next contraction.
62757601|NCT06154941|EXPERIMENTAL|Giomer based Varnish|
62757602|NCT06154941|ACTIVE_COMPARATOR|CPP-ACP based varnish|
62757603|NCT03795207|EXPERIMENTAL|Arm SBRT + DURVALUMAB|"Radiation (SBRT) + Immunotherapy treatment (Durvalumab)~64 patients will be enrolled in this arm~Durvalumab, will be started one month prior to SBRT and then given for a total of 12 months.~Patient will receive one injection per months (1500 mg/cycle)~SBRT will be started one month after Durvalumab and patients will receive 3 fractions of radiation"
62757604|NCT03795207|ACTIVE_COMPARATOR|Arm SBRT|"Radiation (SBRT)~32 patients will be enrolled in this arm~Patients will receive only 3 fractions of radiation"
62558005|NCT04207658|NO_INTERVENTION|control|Practices on Spontaneous Pushing Group The gravitas are informed about spontaneous pushing at the active phase of dilatation (6cm) in second stage of labour and they are encouraged for spontaneous pushing just at the onset of pushing. Just after feeling the push, the gravitas are requested perform pushing as follows; Breathe normally until participants feel the push when contractions start, pull back muscles surrounding the uterus while breathing. Start pushing gradually and breathe out smoothly by minimizing lips. Push between breaths for 5-6 seconds while pushing downwards by breathing out. Breathe normally when contractions weaken.
62558006|NCT00567008|EXPERIMENTAL|1|Varenicline (Chantix)
62558007|NCT00567008|PLACEBO_COMPARATOR|2|Placebo
62558008|NCT02120638|ACTIVE_COMPARATOR|Pyrazinamide Sensitive Comparator|"Pyrazinamide containing regimen: Regimen B1 - 6ZAmkLfxClrPto\\6ZlfxClrPto~* Six months of chemotherapy with Pyrazinamide,Amikacin,Levofloxacin,Clarithromycin,plus Prothionamide,followed by~* Six months of Pyrazinamide,Levofloxacin,Clarithromycin,plus Prothionamide"
62757605|NCT05826730|ACTIVE_COMPARATOR|Exercise|Eccentric muscle training for neck muscles
62757606|NCT05826730|NO_INTERVENTION|Control|Home exercise program for neck muscles
62757607|NCT02020876||Practicing urologic surgeons|Performing at least 60 radical prostate surgeries annually
62757608|NCT02261129|EXPERIMENTAL|Telmisartan, film-coated tablet|one tablet of telmisartan
62757609|NCT02261129|ACTIVE_COMPARATOR|Telmisartan, conventional tablet|Two tablets of telmisartan
62379661|NCT04121052|EXPERIMENTAL|Treatment Sequence 16|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62379662|NCT05467033|EXPERIMENTAL|Experimental|0,3ug/kg in 100ml 0,9% NaCl managed as intravenous infusion;
62379663|NCT05467033|PLACEBO_COMPARATOR|Placebo comparator|0,9% NaCl managed as intravenous infusion;
62757610|NCT00330044|EXPERIMENTAL|Drug|Carboplatin and Pemetrexed
62757611|NCT00970814|ACTIVE_COMPARATOR|Levetiracetam XR|Group received Levetiracetam
62757612|NCT00970814|PLACEBO_COMPARATOR|Sugar Pill|Placebo
62757613|NCT04900337|EXPERIMENTAL|AMOR 18 Powder & Inhalation|"AMOR_inhaled Double Pack- Each kit contains two tubes that after mixing result with 1.14 % ACC in 10 ml suspension.~AMOR_powder- ACC in a dry powder (up to 2000mg Calcium/day sublingually)."
62757614|NCT04900337|PLACEBO_COMPARATOR|Placebo|"Placebo_Inhaled Double Pack - Each kit contains two tubes of saline at different volumes (similar to investigational product) after mixing the results remains saline at a final volume of 10ml.~Placebo_Powder: Each sachet contains powder at the same particle size and weight as the powder of the investigational product."
62757615|NCT00668018|EXPERIMENTAL|Arm 1|
62379664|NCT05246228||Patient with cSCC addressed to adjuvant radiotherapy as per clinical practice|The aim of the study is to evaluate patient's outcome according to the post-radiation lymphocytes count and to the changes induced in the immune cell population by a loco-regional treatment as radiotherapy. The way to objectivate these results is to collect some blood samples and analyze them.
62757616|NCT06535022|EXPERIMENTAL|Interventional group: Cyclic enteral nutrition with ketogenic nighttime fasting|Interventional group: Cyclic enteral daytime nutrition (12 hours) with ketogenic nighttime fasting (12 hours) with supplementation of exogenous ketones (ß-hydroxybutyrate) in the Intensive Care Setting.
62757617|NCT06535022|NO_INTERVENTION|Control group: Conventional continuous enteral nutrition|Continuous (24 hours) enteral nutrition in the Intensive Care Setting.
62757618|NCT00159913|EXPERIMENTAL|Sildenafil Low dose|
62757619|NCT00159913|EXPERIMENTAL|Sildenafil Medium dose|
62757620|NCT00159913|EXPERIMENTAL|Sildenafil High dose|
62757621|NCT00159913|PLACEBO_COMPARATOR|Placebo|
62757622|NCT03433820|EXPERIMENTAL|randomized repeated biopsy|"The study will entail 1 cohort with a randomized repeated biopsy collection time. Three skin punch biopsies (3 mm) of the lower back will be taken from each volunteer on day 0. One biopsy sample taken on day 0 will serve as a baseline measurement for the repeated samples regarding the histology, immunohistochemistry, and RNA sequencing (RNA-seq) or real-time reverse transcription polymerase chain reaction (qRT-PCR) assessments.~Repeated biopsies of the same location as on day 0 will be taken on day 7, 14 or 21 (biopsy lesion and day randomized), and day 28, 42 or 56 (biopsy lesion and day randomized) for all subjects. The observation biopsy (biopsy lesion randomized) will serve as primary biopsy and followed for all measurements."
62757623|NCT02014480|EXPERIMENTAL|Umeclidinium|All subjects will receive UMEC in the dose of 62.5 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
62757624|NCT02014480|EXPERIMENTAL|Vilanterol|All subjects will receive VI in the dose of 25 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
62757625|NCT02014480|EXPERIMENTAL|Umeclidinium/Vilanterol|All subjects will receive UMEC/VI in the dose of 62.5/25 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
62757626|NCT04026269|EXPERIMENTAL|MOAP treatment|Chlormethine Hydrochloride Injection 10mg d1,8 iv Vindesine Sulfate for Injection 4mg d1,8 iv Doxorubicin Hydrochloride Injection 25mg/m2 d1,8 iv Prednisone Acetate Tablets 1-1.5mg/kg/d d1-10 po 28 days/Cycle
62757627|NCT04832906|ACTIVE_COMPARATOR|"Group A Ulipristal Acetate (UA) - Fibristal group (n=35)"|Patients within this group received oral Ulipristal Acetate (Fibristal ©) 5 mg / day starting from the first day of menstrual bleeding, and for 3 months (period of the study).
62757628|NCT04832906|ACTIVE_COMPARATOR|"Group B Uterine artery embolization (UAE) group (n=35)"|Patients within this group underwent bilateral selective uterine artery embolization, during which polyvinyl alcohol (PVA) particles was administered via a catheter followed by capping with a plug of gelatin sponge. The end point for embolization is to have a static column of contrast in the uterine artery, with only a stump filling when the internal iliac artery was injected. The gelatin sponge cap was thought to both complete the occlusion of the uterine artery and to prevent PVA particles from being drawn out of the uterine artery by the Venturi effect, which would result in non-target embolization.
62757629|NCT02370537|EXPERIMENTAL|Sequence AB|A single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 7.
62757630|NCT02370537|EXPERIMENTAL|Sequence BA|A single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 7.
62757631|NCT02811913|OTHER|High frequency rTMS|Each subject is provided with three different brain stimulation interventions in a single arm, single session crossover design study. One of the sessions was 5 Hz rTMS
62757632|NCT02811913|OTHER|Low frequency rTMS|Each subject is provided with three different brain stimulation interventions in a single arm, single session crossover design study. One of the sessions was 1 Hz rTMS
62757633|NCT02811913|OTHER|Sham rTMS|Each subject is provided with three different brain stimulation interventions in a single arm, single session crossover design study. One of the sessions was sham rTMS
62379665|NCT03139773|EXPERIMENTAL|Normal Weight|Received control breakfast beverage and breakfast beverage supplemented with omega-3 fatty acids.
62379666|NCT03139773|EXPERIMENTAL|Overweight/Obese|Received control breakfast beverage and breakfast beverage supplemented with omega-3 fatty acids.
62379667|NCT00930501||Cancer patients|women 5-45 yr olf pre and post chemotherapy
62379668|NCT04387695|EXPERIMENTAL|SBRT + TACE + Sorafenib|SBRT sequential TACE combined with Sorafenib
62757634|NCT01058512|EXPERIMENTAL|Single|single-arm study
62757635|NCT03672682||DLBCL with chemoresistance|15 patients with DLBCL with chemoresistance or relapsed less than 2 years after completion of first-line therapy
62757636|NCT03672682||DLBCL with chemosensitivity|15 patients with DLBCL with chemosensitivity without relapse within 2 years following the end of first-line therapy.
62757637|NCT03672682||Healthy patients|15 healthy patients
62379669|NCT04387695|ACTIVE_COMPARATOR|Sorafenib|Sorafenib 800 mg/day orally
62757638|NCT01437098|EXPERIMENTAL|MDT-2111 CoreValve TAVI|Transcatheter Aortic Valve Implantation (TAVI) with MDT-2111 CoreValve system. Access sites for the implant include: Iliofemoral, Subclavian and Direct Aortic.
62757639|NCT02743780|EXPERIMENTAL|MGV354|Part 3: MGV354 ophthalmic suspension, 1 drop in both eyes once per day for 7 days
62757640|NCT02743780|PLACEBO_COMPARATOR|Placebo|Part 3: MGV354 placebo, 1 drop in both eyes once per day for 7 days
62757641|NCT00644618|ACTIVE_COMPARATOR|A|
62757642|NCT00644618|EXPERIMENTAL|B|
62757643|NCT04509245|EXPERIMENTAL|Effects of a digitally assisted lifestyle intervention|Testing the effects of a low-calorie diet in connection with app-based digital education and behavioral change program on glucose metabolism and disease management.
62757644|NCT00723866|EXPERIMENTAL|1|BtxA+mCIMT (combination group)
62757645|NCT00723866|PLACEBO_COMPARATOR|2|BtxA+ conventional rehabilitation (control group)
62757646|NCT01187004||Acute Lung Injury (ALI)|patients who might develop acute lung injury (ALI) after cardiac surgery with cardiopulmonary by pass
62757647|NCT04254159|EXPERIMENTAL|Neuromuscular Electrical Stimulation Group|Asthma Education Aerobic Exercise Quadriceps Strengthening by superimposed NMES
62757648|NCT04254159|ACTIVE_COMPARATOR|Control Group|Asthma Education Aerobic Exercise Quadriceps Strengthening
61986933|NCT03375021|EXPERIMENTAL|Sequence 2 PH|Eligible subjects were randomized to Sequence 2 PH in which they received placebo (P) followed by crossover to CX717 800 mg High dose (H) of active treatment
62379670|NCT01096615|ACTIVE_COMPARATOR|Tested product: Lactobacillus paracasei LP-33|Each patient will be randomly assigned to either tested product or comparative product (placebo) in accordance with a randomisation table
62379671|NCT01096615|PLACEBO_COMPARATOR|Comparative product : placebo|Each patient will be randomly assigned to either tested product or comparative product (placebo) in accordance with a randomisation table .
62379672|NCT00879593|EXPERIMENTAL|PtcCO2|
62379673|NCT00703781|EXPERIMENTAL|Bromfenac|Bromfenac Ophthalmic Solution 0.09%, Dosed 1 Drop Daily
62379674|NCT00703781|PLACEBO_COMPARATOR|Placebo|Placebo, Dosed 1 Drop Daily
62379675|NCT06371326|EXPERIMENTAL|ZT002 Injection|Participants will be randomized to receive ZT002 injection in 1of 2 dose cohorts.
62757649|NCT00304018|EXPERIMENTAL|cord blood transplant|
62757650|NCT06078111|EXPERIMENTAL|Prism 10|participants perform rehabilitation activities while wearing 10° visual field deviation prismatic goggles
62757651|NCT06078111|ACTIVE_COMPARATOR|Neutral Prism|participants perform rehabilitation activities while wearing neutral (no deviation) visual field deviation prismatic goggles
62757652|NCT02785458|NO_INTERVENTION|Usual Care|Subjects will receive the current standard of care.
62757653|NCT02785458|EXPERIMENTAL|EMC2 Strategy|Subjects will receive the EMC2 Strategy. See description of strategy below.
62757654|NCT05397587|EXPERIMENTAL|Experimental Group aged 6~23 months|Up to 146 subjects aged 6\~23 months and have received EV71 vaccine developed by Sinovac Biotech Co., Ltd will be collected blood samples at 36 months after full immunization and at the age of 72 months.
62757655|NCT05397587|EXPERIMENTAL|Experimental Group aged 24~35 months|Up to 128 subjects aged 24\~35 months and have received EV71 vaccine developed by Sinovac Biotech Co., Ltd will be collected blood samples at 36 months after full immunization .
61986934|NCT03375021|EXPERIMENTAL|Sequence 3 LP|Eligible subjects were randomized to Sequence 3 LP in which they received CX717 200 mg Low dose (L) of active treatment followed by crossover to placebo (P)
62757656|NCT05397587|EXPERIMENTAL|Experimental Group aged 36~71 months|100 subjects aged 36\~71 months and have received EV71 vaccine developed by Sinovac Biotech Co., Ltd will be collected blood samples at 36 months after full immunization .
61986935|NCT03375021|EXPERIMENTAL|Sequence 4 HP|Eligible subjects were randomized to Sequence 2 PH in which they received CX717 800 mg High dose (H) of active treatment followed by crossover to placebo (P)
61986936|NCT03724409|EXPERIMENTAL|Cohort 1|Subject will be administered 2.96 gigabecquerels of \[90\]Y-DOTATOC intra-aterially to the liver
61986937|NCT03724409|EXPERIMENTAL|Cohort 2|Subject will be administered 3.33 gigabecquerels of \[90\]Y-DOTATOC intra-aterially to the liver
61986938|NCT03724409|EXPERIMENTAL|Cohort 3|Subject will be administered 3.7 gigabecquerels of \[90\]Y-DOTATOC intra-aterially to the liver
61986939|NCT03724409|EXPERIMENTAL|Cohort 4|Subject will be administered 4.17 gigabecquerels of \[90\]Y-DOTATOC intra-aterially to the liver
61986940|NCT03724409|EXPERIMENTAL|Cohort 5|Subject will be administered 4.44 gigabecquerels of \[90\]Y-DOTATOC intra-aterially to the liver
61986941|NCT03724409|EXPERIMENTAL|Cohort 6|Subject will be administered 5.18 gigabecquerels of \[90\]Y-DOTATOC intra-aterially to the liver
61986942|NCT06418503|SHAM_COMPARATOR|Balance Training|Completing a Tetris (block stacking) computer game while attached to an EMG device by electrodes and leads.
61986943|NCT06418503|EXPERIMENTAL|EMG-Biofeedback Training|Completing an EMG-biofeedback block stacking game using the electrodes to detect muscle signals which are controlling the movements of the blocks.
61986944|NCT00983151|EXPERIMENTAL|Active|
61986945|NCT00983151|PLACEBO_COMPARATOR|Placebo|
61986946|NCT02190812|EXPERIMENTAL|Forearm supporter|This study measured the effect of proper forearm supporter to alleviate pain and improve the wrist and grip strength in the subjects with tennis elbow.
61986947|NCT02190812|EXPERIMENTAL|Grip ball|In this study a portable grip ball training system is developed. This study use the grip ball to train the wrist muscle. It's expected to reduce the risk of injury of the elderly in their daily lives.
61986948|NCT05256667|OTHER|Root canal treatment in single visit - RCT-SV|Group 1- RCT-SV: Endodontic treatment in a single visit using chemomechanical preparation (rotary NiTi instruments, 5.25% NaOCl, 17% EDTA) and passive ultrasonic irrigation (PUI), followed by obturation (gutta-percha and epoxy resin-based sealer) and final restoration (composite resin).
61986949|NCT05256667|OTHER|Root canal treatment in two visits with intracanal dressing - RCT-TVWD|Group 2- RCT-TVWD: Endodontic treatment in two visits using chemomechanical preparation (rotary NiTi instruments, 5.25% NaOCl, 17% EDTA) and passive ultrasonic irrigation (PUI), followed by intracanal dressing (calcium hydroxide powder, CPMC, glycerine) and temporary restoration (glass ionomer cement) for 7 days. After 7 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation (gutta-percha and epoxy resin-based sealer) and final restoration (composite resin).
62379676|NCT06371326|PLACEBO_COMPARATOR|ZT002 Placebo|Participants will be randomized to receive same volume Placebo in 1 of 2 dose cohorts.
62558009|NCT02120638|EXPERIMENTAL|Pyrazinamide Resistant Comparator|"Regimen without Pyrazinamide: Regimen B2 - 6HAmkLfxClrPto\\18HlfxClrPto~* Six months of chemotherapy with Isoniazid,Amikacin,Levofloxacin,Clarithromycin,plus Prothionamide,followed by~* Eighteen months of Isoniazid,Levofloxacin,Clarithromycin,plus Prothionamide"
62757657|NCT05397587|ACTIVE_COMPARATOR|Control Group aged 36~71 months|100 subjects aged 36\~71 months and have received EV71 vaccine developed by Institute of Medical Biology,Chinese Academy of Medical Sciences will be collected blood samples at 36 months after full immunization .
62757658|NCT06184412||Control group without periodontal disease|Women without periodontal disease neither PCOS
62757659|NCT06184412||PCOS group with or without periodontal disease|Women with PCOS with or without periodontal disease
62757660|NCT05585229|EXPERIMENTAL|Psilocybin-assisted Psychotherapy|Participants will undergo a single-arm, 8-week therapeutic intervention using natural standardized psilocybin-assisted psychotherapy as a treatment for opioid tapering in chronic pain patients. Specifically, they will undergo one or two standardized natural psilocybin (PEX010) dosing sessions; 25mg at week 3 and 37.5mg at week 7.
61986950|NCT05256667|OTHER|Root canal treatment in two visits without intracanal dressing - RCT-TVWOD|Group 3- RCT-TVWOD: Endodontic treatment in two visits using chemomechanical preparation (rotary NiTi instruments, 5.25% NaOCl, 17% EDTA) and passive ultrasonic irrigation (PUI), followed by temporary restoration (glass ionomer cement) for 2 days, without intracanal dressing. After 2 days, an identical chemomechanical preparation on visit 2 will be performed performed, followed by obturation (gutta-percha and epoxy resin-based sealer) and final restoration (composite resin).
61986951|NCT02628795|EXPERIMENTAL|PRT + FM|Progressive resistance training + functional mobility training 3 d/wk x 16 wk
61986952|NCT02628795|ACTIVE_COMPARATOR|Usual Care|Post-surgical usual care including physical therapy
61986953|NCT05533931|EXPERIMENTAL|Resistive Breathing Training group|The patients performed two sessions each of 15 minutes session of resistive breathing for four days a week for six weeks using an inspiratory resistive device. Ask patient to take long slow inspirations while breathing through the resistive device
62757661|NCT04706273||GORE® VIABAHN® Endoprosthesis|Participants with symptomatic peripheral arterial disease in superficial femoral artery lesions.
62757662|NCT03023826|EXPERIMENTAL|LY3202626 (R-Fasting)|Single oral dose of LY3202626 (R) capsule under fasting conditions.
61986954|NCT05533931|ACTIVE_COMPARATOR|inspiratory hold technique|With the patient in a comfortable position such as side lying or reclined, the therapist may assist the patient by placing both hands on abdominal area to provide proprioceptive feedback. Then in a relaxed tone of voice therapist instructs the patient to sniff quickly through the nose three times with slow, relaxed exhalations
61986955|NCT02065960|EXPERIMENTAL|Stereotactic body radiotherapy (SBRT)|Radiotherapy with SBRT to a dose of 40 Gy in 5 fractions delivered every other day over a period of 10-12 days, followed by breast conserving surgery.
62379677|NCT02350192|EXPERIMENTAL|e-health educational intervention (eHEI)|Participants in the intervention group received usual care and additional individualized educational intervention administered by a trained nurse who was experienced in cardiac nursing. The exercise prescription had been set as walking exercise for 30 minutes per day for 5 days per week. The exercise dosage might be modified with physician's order to suit the individual's physical condition and agreed goals if necessary. The 30- minutes educational intervention was conducted in a private room of the clinic. The content covered general information related to coronary heart disease and benefit of performing exercise, the e-health educational intervention (eHEI) link demonstration and re-demonstration. In addition, one telephone follow-up was conducted at week 2 to facilitate the usage of the e-HEI link.
62757663|NCT03023826|EXPERIMENTAL|LY3202626 (T1-Fasting)|Single oral dose of LY3202626 (T1) tablet under fasting conditions.
62757664|NCT03023826|EXPERIMENTAL|LY3202626 (T1-Fed)|Single oral dose of LY3202626 (T1) following a high fat breakfast.
62757665|NCT03800589|ACTIVE_COMPARATOR|phaco and Ex-Press|patients with co-existing cataract and glaucoma, qualified to the combined glaucoma surgery according to the protocol which were randomized to phacoemulsification with implantation of the Ex-Press
61986956|NCT00860912|EXPERIMENTAL|Intervention: Collagen matrix|Cystocele repair: Veritas reinforcing material implanted for reinforcement of cystocele repair with collagen matrix
61986957|NCT00860912|OTHER|Native tissue repair|Intervention: Cystocele repair performed: No reinforcing material used and routine performance of a cystocele repair using native tissues.
61986958|NCT04748315|EXPERIMENTAL|SEMT(1:1)|Participants in this arm will perform an a speed endurance maintenance training consisted of work to rest ratio 1:1.
61986959|NCT04748315|EXPERIMENTAL|SEMPT(1:3)|Participants in this arm will perform an a speed endurance maintenance training consisted of work to rest ratio 1:3.
62757666|NCT03800589|ACTIVE_COMPARATOR|deep sclerectomy, phaco and Ex-press|patients with co-existing cataract and glaucoma, qualified to the combined glaucoma surgery according to the protocol which were randomized to deep sclerectomy, phacoemulsification, ExPress implantation
62757667|NCT00824005|PLACEBO_COMPARATOR|Placebo Injections|Participants will receive placebo injections.
61986960|NCT04748315|NO_INTERVENTION|Control|Participants in this arm will receive no intervention
61986961|NCT04103762|EXPERIMENTAL|indocyanine green|During the surgery, intraoperative cholangiography using indocyanine green will be performed
61986962|NCT04103762|ACTIVE_COMPARATOR|standard cpo|"During the surgery, intraoperative cholangiography using a contrast product gold standard will be performed"
61986963|NCT04215380|EXPERIMENTAL|Intervention Group|This arm will receive 100% natural Gum Arabic provided in a powder form as 30-grams-dose for 12 weeks
61986964|NCT04215380|PLACEBO_COMPARATOR|Control group|This group will be provided with pectin powder provided as two-gram-dose fo
61986965|NCT00545155||Geriatric EMS Patients|Cohort for reliability and concurrent validity testing.
62757668|NCT00824005|EXPERIMENTAL|Active Stem Cell Injections|Participants will receive active stem cell injections.
62757669|NCT04067037|EXPERIMENTAL|Camrelizumab Combined With AVD regimen|Camrelizumab 200mg, Intravenous administration on day 1 and day 15 combined with regimen：AVD (Epirubicin, Vincristine and Dacarbazine): repeated every 4 weeks, up to 6 cycles.
62757670|NCT04829474||Women consulting for spouse abuse|The study focuses on women consulting a doctor as part of spouse abuse, whatever the context (at the request of the police or not) or their motivation (medical or social).
61986966|NCT02157142|EXPERIMENTAL|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
61986967|NCT04930354|EXPERIMENTAL|Single arm|Single arm dose escalation study; ECP1014 oral capsule of10mg, 20mg, 40mg, 80mg and 160mg given once daily for 28 days
62757671|NCT04283942|EXPERIMENTAL|Intermittent Calorie Restriction (ICR)|Participants in ICR group were instructed to ensure 2 successive days of fasting-mimicking and 5 days of recovery per week. On fasting-mimicking days, the participants were instructed to consume approximately 500 kcal/day and they were provided with plant-based meal replacement (ZhenBaiNian nutrition bar, Beijing Wanlaikang Nutrition and Health Food Science and Technology Research Institute Co., Ltd, China) to improve adherence and ensured adequate intake of micronutrients. In the rest 5 days of recovery per week, participants were allowed to consume their usual diet.
62757672|NCT04283942|OTHER|Control (Continuous calorie restriction, CCR)|Participants in control group were instructed to consume the prescribed calories (25 kcal / kg × \[height (cm) - 100\] kg) every day by eating conventional food without time restriction.
62757673|NCT03733028|EXPERIMENTAL|Mobile Intervention for Reducing Anger (MIRA)|Participants in this arm will be provided with a device that has the MIRA application (app) and asked to use the app for a period of 4 weeks.
62757674|NCT03733028|ACTIVE_COMPARATOR|Mindfulness Intervention|Participants in this arm will be provided with a device that has the Mindfulness application (app) and asked to use the app for a period of 4 weeks.
62757675|NCT01086319||Patients exposed to saxagliptin|
62757676|NCT01086319||Patients exposed to oral antidiabetic drugs (not saxagliptin)|
62757677|NCT00481312|ACTIVE_COMPARATOR|1|Dexmedetomidine
61986968|NCT03274531|EXPERIMENTAL|Interventional Arm|Immediate referral of hypertensive patients to the attending physician based on automated office blood pressure measurements
62757678|NCT00481312|ACTIVE_COMPARATOR|2|Midazolam
62757679|NCT05131776|EXPERIMENTAL|EUS-guided oncosil injection|All patients will receive OncoSilTM during the 4th week of the first chemotherapy cycle.
62757680|NCT02989051|EXPERIMENTAL|Restrictive fluid treatment|Restrictive fluid regimen
62757681|NCT02989051|ACTIVE_COMPARATOR|Liberal fluid treatment|This is seen as current standard clinical treatment, wherein patients will receive a more liberal fluid regimen.
62757682|NCT00902421|ACTIVE_COMPARATOR|Antimuscarinics|
62757683|NCT00902421|EXPERIMENTAL|Selective serotonin reuptake inhibitors|Selective serotonin reuptake inhibitor
62757684|NCT02612701|EXPERIMENTAL|Cigarettes|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking two standard cigarettes
62757685|NCT02612701|EXPERIMENTAL|E-cigarettes (nicotine free e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking nicotine free e-cigarette liquid.
62757686|NCT02612701|EXPERIMENTAL|E-cigarettes (low nicotine e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking low concentration(4-6 mg/mL) e-cigarette liquid.
62757687|NCT02612701|EXPERIMENTAL|E-cigarettes (high nicotine e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking high concentration (18-24 mg/mL) e-cigarette liquid.
61986969|NCT03274531|NO_INTERVENTION|Observational Arm|Repeated automated office blood pressure measurements and referral of hypertensive patients to the attending physician after completion of the trial
62757688|NCT03282110|EXPERIMENTAL|ta-VNS & Electro-acupuncture|"1. Device:ta-VNS(transcutaneous vagus nerve stimulation):2 times per day,5 consecutive days per week for two months~2. Other:Electro-acupuncture:3 times per week, once every other day for two months"
62757689|NCT03282110|ACTIVE_COMPARATOR|Citalopram|citalopram for oral administration; 10mg for the first 1-3 days, 20mg for the following 4-7 days；40mg for the left days within two months
62757690|NCT05208086||Patients|"Cycle1 day1: collection of 24h urine and an urine sample from miction the day of the visit.~Cycle 2 day1:collection of 24h urine and an urine sample from miction the day of the visit Cycle 4 day 1: collection of 24h urine and an urine sample from miction the day of the visit."
62757691|NCT06461052|NO_INTERVENTION|Control|
62757692|NCT06461052|EXPERIMENTAL|Intervention|patient information via a video explaining the procedure, followed by a15-minute music therapy session of your choice in the OR waiting room.
62757693|NCT04360512|EXPERIMENTAL|One session|One session of talus posteriorization
62757694|NCT04360512|EXPERIMENTAL|Two sessions|Two sessions of talus posteriorization
62757695|NCT04360512|EXPERIMENTAL|Three sessions|Three sessions of talus posteriorization
62757696|NCT04360512|EXPERIMENTAL|Four sessions|Four sessions of talus posteriorization
62757697|NCT06309251||Patients requiring KD|Pediatric patients with any disease which require a ketogenic diet (KD), i.e. metabolic or genetic disorder or neurological (congenital and acquired) diseases
62757698|NCT01261130|EXPERIMENTAL|Part I-A: 10μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation A
61986970|NCT01523548|EXPERIMENTAL|Carbon Monoxide|Inhaled Carbon Monoxide therapy administered over 16 weeks
61986971|NCT02028351||Normal|No Intervention
61986972|NCT02028351||Cataract|No intervention
61986973|NCT02028351||Maculopathy|No Intervention
61986974|NCT02541747|ACTIVE_COMPARATOR|massage|massage for 30 min, once a week for 4 weeks
61986975|NCT02541747|NO_INTERVENTION|control|Rest as control
61986976|NCT05492565||Men who have sex with men|Men who have sex with men at substantial risk for HIV infection due to high-risk sexual habits
61986977|NCT05492565||Transgender women|Transgender women at substantial risk for HIV infection due to high-risk sexual habits
61986978|NCT05492565||Sex workers|Sex workers at substantial risk for HIV infection due to high-risk sexual habits
61986979|NCT05492565||HIV-uninfected people at substantial risk for HIV infection (other)|All HIV-uninfected people at substantial risk for HIV infection due to any other reason, including having an HIV-positive life partnerwith an HIV-positive life partner
62757699|NCT01261130|EXPERIMENTAL|Part I-B: 30μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation B
62757700|NCT01261130|EXPERIMENTAL|Part I-C: 100μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation C
61986980|NCT01557296|PLACEBO_COMPARATOR|Diabetic diet|Control group. Subjects with Insulin Treated Diabetes Mellitus and Gastroparesis. Diet: Food of large particle size during 20 weeks.
61986981|NCT01557296|ACTIVE_COMPARATOR|Diet food in small particle size|Intervention group: Subjects with Insulin Treated Diabetes and Gastroparesis. Intervention Diet: Food of small particle size during 20 weeks.
61986982|NCT05566210|ACTIVE_COMPARATOR|Acupuncture group|Acupuncture was performed 2-3 times a week for 30 minutes each time for 3 months, starting from the 5th day of menstruation (spontaneous menstruation or drug withdrawal hemorrhaging menstruation)
61986983|NCT05566210|PLACEBO_COMPARATOR|Sham acupuncture group|Sham acupuncture was performed 2-3 times a week for 30 minutes each time for 3 months, starting from the 5th day of menstruation (spontaneous menstruation or drug withdrawal hemorrhaging menstruation)
61986984|NCT04159233|OTHER|Adapted 'Brief Behavioral Therapy for Insomnia' (BBTI)|All participants will receive the same intervention in this pilot study.
61986985|NCT02574130|EXPERIMENTAL|Nebulized amikacin|Amikacin 400 mg nebulized every 12 hours plus intravenous antibiotic(s) for 10 days
61986986|NCT02574130|PLACEBO_COMPARATOR|placebo|nebulized placebo every 12 hours plus intravenous antibiotic(s)for 10 days.
61986987|NCT03071458||Patients with HCC|The cohort is composed of patients with HCC with available tumor and non tumor samples collected retrospectively. These patients have HCC of different stages (localized and advanced stages) It is an observational retrospective study.
61986988|NCT01893554|EXPERIMENTAL|Group 1: RSV vaccine|Healthy RSV-seropositive children ages 12 to 59 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
61986989|NCT01893554|PLACEBO_COMPARATOR|Group 1: Placebo|Healthy RSV-seropositive children ages 12 to 59 months will receive one dose of the placebo administered as nose drops at study entry.
62757701|NCT01261130|EXPERIMENTAL|Part I-D: 10μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation D
62757702|NCT01261130|EXPERIMENTAL|Part I-E: 30μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation E
62757703|NCT01261130|EXPERIMENTAL|Part I-F: 100μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation F
62757704|NCT01261130|EXPERIMENTAL|Part II-A: 10μgNaGST1/Alhydrogel|Part II (endemic area), Formulation A
62757705|NCT01261130|EXPERIMENTAL|Part II-B: 30μgNaGST1/Alhydrogel|Part II (endemic area), Formulation B
62757706|NCT01261130|EXPERIMENTAL|Part II-C: 100μgNaGST1/Alhydrogel|Part II (endemic), Formulation C
62757707|NCT01261130|EXPERIMENTAL|Part II-D: 10μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation D
62757708|NCT01261130|EXPERIMENTAL|Part II-E: 30μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation E
62757709|NCT01261130|EXPERIMENTAL|Part II-F: 100μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation F
62757710|NCT01261130|ACTIVE_COMPARATOR|Part II-G: Butang® hepatitis B vaccine|Part II (endemic), HepB comparator
62757711|NCT06455111|EXPERIMENTAL|Keenoa|Participants randomized to this arm will document a 3-day dietary assessment using Keenoa.
62757712|NCT06455111|ACTIVE_COMPARATOR|ASA24|Participants randomized to this arm will document a 3-day dietary assessment using the web-based Automatic Self-Administered 24-Hour (ASA24) Dietary Assessment Tool.
62757713|NCT06607822|EXPERIMENTAL|Patient-centered assistant system|Participants engaged in the outpatient clinic visit procedure with a patient-centered assistant system based on Large-Language Model (LLM) for 10 minutes.
62757714|NCT06607822|NO_INTERVENTION|Control group|Participants engaged in the outpatient clinic visit procedure without the support of patient-centered assistant system based on Large-Language Model (LLM) or any similar artificial intelligence assistance for 10 minutes.
62757715|NCT03028480||Subjects with Bronchial asthma|Subjects with a refractory asthma whose symptoms are inadequately controlled despite receiving standard asthma medications will be enrolled
62757716|NCT04220112|EXPERIMENTAL|Real Time Functional MRI (rt-fMRI)|Real-time fMRI (rt-fMRI) neurofeedback (focused on amygdala down-regulation) intervention
62757717|NCT04220112|SHAM_COMPARATOR|Sham|Sham-controlled group
62757718|NCT04522154|OTHER|MR-TTE|Patient receiving cardiac magnet resonance imaging and echocardiography
62757719|NCT02763475|EXPERIMENTAL|Natural Killer (NK) Cells + Chemotherapy|Starting on day -6, 60mg/Kg cyclophosphamide by vein will be administrated. Day -5 to -1 fludarabine administrated by vein at 25 mg/m2. 24-48 hours after chemotherapy completion, NK cell infusion will be injected (day 0). On day 7 a second NK cell infusion will be administrated. First infusion consist of 5x10\^7/kg NK CD3-CD56+ NK cells. The second NK cell infusion will include up to 5x10\^8 CD3-CD56+ cells if no treatment related toxicity occurred. Subcutaneous IL-2 (1x10\^6 UI/m2) three times a week for two weeks will be administrated after first NK infusion.
62757720|NCT03630198|ACTIVE_COMPARATOR|Corticosteroid with lidocaine|This arm will include an injection mixture of corticosteroid and lidocaine
62757721|NCT03630198|EXPERIMENTAL|Corticosteroid with normal saline|This arm will include a mixture of corticosteroid and normal saline. The purpose of normal saline is to keep the volume and concentration similar when compared to the injections containing lidocaine.
62757722|NCT06276582|EXPERIMENTAL|Screening for neonatal jaundice with a mobile health device|Neonatal jaundice will be screened using the app Picterus JP and the results will be compared to the total serum bilirubin level from a blood test.
62757723|NCT02238314|EXPERIMENTAL|Tipranavir low dose|
62757724|NCT02238314|EXPERIMENTAL|Tipranavir high dose|
62757725|NCT00144924|EXPERIMENTAL|laparoscopic pyloromyotomy|
62757726|NCT00144924|ACTIVE_COMPARATOR|open pyloromyotomy|
62757727|NCT03294135|EXPERIMENTAL|Conventional Group|Participants who received primary vaccination in study V48P7 on Days 0, 28 (+10) and 300 (+21) (55 participants) and who received a booster vaccination in study V48P7E1 (NCT00387634) (55 participants). For these participants a second booster vaccination within six months after the annual blood draw was to be administered within the present study only in case their Neutralization Test (NT) titer resulted below 10.
62757728|NCT03294135|EXPERIMENTAL|Accelerated/Rapid Group|Participants who received primary vaccination in study V48P7 on Days 0, 7 (+3) and 21 (+7) (66 participants) and who received a booster vaccination either in study V48P7E1 (NCT00387634) (9 participants) or before enrolment in study V48P7E1 (NCT00387634) (40 participants). For these participants a second booster vaccination within six months after the annual blood draw was to be administered within the present study only in case their NT titer resulted below 10.
62379678|NCT02350192|NO_INTERVENTION|Control group|Control group received standard care only. The control group also received standard usual care comprising the doctor follow up with medication. During an individualized educational session conducted by a trained research assistant , a briefing on healthy life style and an an additional educational leaflet about coronary heart disease which is customarily given to patient with cardiovascular risks was given to the patient. In the control group, no e-health educational intervention has been provided to the patients of the control group.
62757729|NCT03294135|EXPERIMENTAL|Accelerated Conventional Group|Participants who received primary vaccination in study V48P7 on Days 0, 14 (+3) and 300 (+21) (133 participants) and who received a booster vaccination in study V48P7E1 (NCT00387634) (109 participants). For these participants a second booster vaccination within six months after the annual blood draw was to be administered within the present study only in case their NT titer resulted below 10.
62757730|NCT05176002|EXPERIMENTAL|Neoadjuvant Camrelizumab combined with radiotherapy group|
62757731|NCT02488213|ACTIVE_COMPARATOR|Usual Diet Guidance|The patients will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed in outpatient patients treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre.
61986990|NCT01893554|EXPERIMENTAL|Group 2: RSV vaccine|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
62757732|NCT02488213|EXPERIMENTAL|Nutritional Counseling|The patients will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material.
62757733|NCT03417362|OTHER|Animation|Animation describing process of early medical abortion, what to expect, how to take medicines. This is prior to consultation.
62757734|NCT03417362|NO_INTERVENTION|Standard|Standard of Care - no animation ,standard consultation only.
62757735|NCT05819021||SAINT® Stimulation|All participants will receive 10 treatments per day for 5 days (M-F) of SAINT® stimulation therapy.
62757736|NCT03404804|EXPERIMENTAL|Oral Challenge|Patients with low-risk symptoms of amoxicillin allergy who receive oral amoxicillin to delabel their respective allergy.
62757737|NCT05857033|EXPERIMENTAL|Direct local anesthesia with Buzzy|
62757738|NCT05857033|EXPERIMENTAL|Indirect local anesthesia with Buzzy|
62757739|NCT05857033|ACTIVE_COMPARATOR|Direct local anesthesia|
62757740|NCT05857033|ACTIVE_COMPARATOR|Indirect local anesthesia|
62757741|NCT03867565|NO_INTERVENTION|No nutritional diagnosis|Patients without nutritional diagnosis get SOC
62379679|NCT01339845|ACTIVE_COMPARATOR|Vaccine arm|Thirty clusters (approximately 80,000 people) will receive cholera vaccine alone
62757742|NCT03867565|EXPERIMENTAL|Nutritional diagnosis|Patients with nutritional diagnosis get nutritional intervention by dietitian.
62757743|NCT01817101|ACTIVE_COMPARATOR|Dietary Supplement capsule|One capsule at meals (3 each day) during 1 year with Omega-3 fatty acid supplementation
62757744|NCT01817101|PLACEBO_COMPARATOR|Empty gelatine capsule|One capsule at meals (3 each day during 1 year)
62757745|NCT01312389|EXPERIMENTAL|Phase 2: Arm A|10 patients will receive vaccine (OC-L, an autologous vaccine comprised of autologous oxidized tumor cell lysate, admixed with Montanide ISA 51 VG) injected by intradermal/subcutaneous injection in both groin regions.
62757746|NCT01312389|EXPERIMENTAL|Phase 2: Arm B|10 patients will receive vaccine (OC-L, an autologous vaccine comprised of autologous oxidized tumor cell lysate, admixed with Montanide ISA 51 VG) injected by intradermal/subcutaneous injection in both groin regions, administered in combination with intravenous Ampligen.
61986991|NCT01893554|PLACEBO_COMPARATOR|Group 2: Placebo|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the placebo administered as nose drops at study entry.
61986992|NCT01893554|EXPERIMENTAL|Group 3: RSV vaccine|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
62379680|NCT01339845|ACTIVE_COMPARATOR|Vaccine plus hygiene and safe water arm|Thirty clusters (approximately 80,000 people)will receive both cholera vaccine and behaviour change
62757747|NCT01312389|EXPERIMENTAL|Phase 1|3 patients will be enrolled receiving the vaccine (tumor lysate/Montanide) plus Ampligen using a 3+3 approach. If no DLTs in the first three subjects, we will move to phase II; if one 1/3 subject develops DLTs, we will enroll 3 additional subjects; if 2/6 subjects develop DLTs, we will discontinue the study. Following completion of run---in phase I (3 or 6 subjects), we will transition to Phase 2.
62757748|NCT03109808|EXPERIMENTAL|e-health strategy|Assigned intervention: e-health strategy
62757749|NCT03109808|ACTIVE_COMPARATOR|Traditional Oral Hygiene Education|Assigned intervention: traditional oral hygiene education
62757750|NCT00429117||Survey|Physician members of the International Gynecologic Oncologists Society or the Society of Gynecologic Oncologists.
62379681|NCT01339845|NO_INTERVENTION|Non-intervention arm|30 neighbourhoods(approximately 80,000 people) will continue their standard habits and practices
62757751|NCT02446418|EXPERIMENTAL|Fluticasone Furoate/Vilanterol|Subjects will receive FF/VI 92 micrograms (mcg)/22 mcg or FF/VI 184 mcg/22 mcg as decided by the investigator QD via ELLIPTA DPI for 24 weeks.
62757752|NCT02446418|ACTIVE_COMPARATOR|FP/S OR BUD/F|Subjects will receive FP/S (250 mcg/50 mcg or 500 mcg/50mcg) twice daily via DISKUS or BUD /F (200 mcg/6mcg or 400 mcg/12mcg one or two inhalations) twice daily via TURBUHALER DPI as decided by the investigator for 24 weeks.
61986993|NCT01893554|PLACEBO_COMPARATOR|Group 3: Placebo|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the placebo administered as nose drops at study entry.
61986994|NCT01893554|EXPERIMENTAL|Group 4: RSV vaccine|Healthy infants between the ages 4 to 6 months who have not been screened for RSV serostatus will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
62379682|NCT05372289|EXPERIMENTAL|Supplemented patients|
62558010|NCT05328739|EXPERIMENTAL|Home care group|"The home care program included education, counseling and nursing care to determine and meet the self-care/dependant care needs of patients and caregivers at home after brain surgery.~At preoperative period (PRP) an average of 90-120 minutes of training was given to both the patient and the caregiver until the patient was discharged. At this stage, the training was carried out in order to prepare the patient and caregiver for the transition to home. At postoperative period (POP) two home visits were made within the first month following the discharge, planned for education, counseling and nursing care. The first home visit was made in the first week after discharge (10-18 days after surgery), and the second home visit was made 30-40 days after surgery. Then, in the home visits made once in the 2nd, 3rd and 4th months.No home visits were made between the 4th-month attempt and the 6th month, but telephone counseling was provided when necessary. Home visits ranged from 60 to 120 minutes."
62558011|NCT05328739|NO_INTERVENTION|Control group|The patient received routine care in the hospital until discharge. Three home visits were made to collect the data of patients and caregivers in the 1st and 3rd and 6th months of POP after discharge, but no intervention was made. The visits took about 30-45 minutes.
62558012|NCT02082015|EXPERIMENTAL|true coil|Use the true coil / Low frequency rTMS / Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp
62558013|NCT02082015|SHAM_COMPARATOR|sham coil|Use the sham coil / Low frequency rTMS / Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: vertical to scalp
62757753|NCT04533542||Arm I (3 video or telephone conferences)|Participants attend up to 3 video or telephone conferences over 2 hours each with a minimum of 24 hours and maximum of 1 week between sessions. Participants take a fixed number of puffs on 3 randomly assigned conditions (combinations of carrier and nicotine concentrations).
62757754|NCT04533542||Arm II (2 video or telephone conferences)|Participants attend up to 2 video or telephone conferences over 2 hours each with a minimum of 24 hours and maximum of 1 week between sessions. Participants take a fixed number of puffs on a nicotine-free condition and 3 randomly assigned conditions (combinations of carrier concentration and nicotine form).
62757755|NCT03546166|EXPERIMENTAL|TREATMENT|
62757756|NCT06440889|EXPERIMENTAL|Varicose Vein Group|Ebene Bio-Ray Knee Guard Wear the test product in the daytime for about 1-2 hours. Then, proceed to gradually lengthen the duration of wear to 4-6 and 6-8 hours.
62757757|NCT06440889|OTHER|Healthy Group|Ebene Bio-Ray Knee Guard Wear the test product in the daytime for about 1-2 hours. Then, proceed to gradually lengthen the duration of wear to 4-6 and 6-8 hours.
62757758|NCT02377570|EXPERIMENTAL|THERANOVA 400 dialyzer prototype AA|THERANOVA 400 dialyzer prototype AA in hemodialysis treatment
62757759|NCT02377570|EXPERIMENTAL|THERANOVA 400 dialyzer prototype BB|THERANOVA 400 dialyzer prototype BB in hemodialysis treatment
62379683|NCT05372289|NO_INTERVENTION|Standard of care|
62379684|NCT02640989|EXPERIMENTAL|Group 1|"* Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~* Seasonal trivalent influenza vaccine, Anflu®"
62379685|NCT02640989|EXPERIMENTAL|Group 2|"* Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~* Seasonal trivalent influenza vaccine, VAXIGRIP"
62379686|NCT02640989|ACTIVE_COMPARATOR|Group 3|"* Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~* Seasonal trivalent influenza vaccine, Fluarix"
62379687|NCT02591511|EXPERIMENTAL|health-education app|Smart phone and pad is a stroke-related health education app intervention group
62379688|NCT02591511|ACTIVE_COMPARATOR|health education manuals|stroke-related health education manual control group
62379689|NCT05890131|EXPERIMENTAL|Digital letter|The experimental group will receive a digital letter with information on the newly approved heart failure therapy option, SGLT-2 inhibitors. The letter will also invite recipients to be evaluated by a heart failure specialist for potential initiation of the therapy.
62379690|NCT05890131|NO_INTERVENTION|Control|The control group will not be sent the digital letter and will therefore receive usual follow-up and care in the public healthcare system.
62379691|NCT03773016|EXPERIMENTAL|Art apps - Group 1 (A-B)|Cross-over use of two different visual art apps on touchscreen tablets (App A and App B)
62379692|NCT03773016|EXPERIMENTAL|Art apps - Group 2 (B-A)|Cross-over use of two different visual art apps on touchscreen tablets (App B and App A)
62757760|NCT02377570|EXPERIMENTAL|THERANOVA 400 dialyzer prototype CC|THERANOVA 400 dialyzer prototype CC in hemodialysis treatment
62757761|NCT02377570|ACTIVE_COMPARATOR|FX CorDiax 80 dialyzer|FX CorDiax 80 dialyzer in hemodialysis treatment
62757762|NCT04165655|EXPERIMENTAL|Keep Achieving (KA) group|Participants in the experimental group will take part in a 10-week group based activity programme. The activity programme will consist of 1, 50 minute session each week for the duration of 10-weeks. The activity sessions will include semi-structures free play sessions, sport specific sessions facilitated by local sports teams and swimming sessions.
62757763|NCT04165655|NO_INTERVENTION|Waitlist control group|Participants in this group will not receive the 10-week group based activity intervention throughout the duration of this study. Participants will be able to participate in the 10-week activity intervention once this research has ended.
62757764|NCT05535738|EXPERIMENTAL|Baseline Contact Allergen|Individuals who will have allergic contact dermatitis induced via squaric acid dibutyl ester (SADBE) and/or known patch test allergens followed by skin and blood sampling. There is a protocol to sensitize individuals to SADBE if they have not previously been exposed to SADBE.
62379693|NCT03508973|EXPERIMENTAL|Sculptra|Sculptra, an injectable implant containing microparticles of ply-L-lactic acid, carboxymethylcellulose, non-pyrogenic mannitol and sterile water, will be injected into the decolletage.
62379694|NCT04833049|EXPERIMENTAL|TAK-994 Dose 1 + [14C]TAK-994 Dose 2 + [14C]TAK-994 Dose 3|TAK-994 Dose 1, tablet, orally, on Day 1, followed by \[14C\]TAK-994 Dose 2, infusion, intravenously, on Day 1 of Part A, followed by a washout period of at least 8 days, further followed by \[14C\]TAK-994 Dose 3, suspension, orally, on Day 1 of Part B.
62379695|NCT02346799|EXPERIMENTAL|Control|Participants in the control group will not receive any additional treatment, apart from receiving daily emails 15 minutes before the start of their self-reported workout window. This is to control for reminder effects that may be present in the other treatment conditions. Participants in this condition will also receive a lump payment upon completion of an exit survey at the end of the intervention to equalize overall compensation.
62379696|NCT02346799|EXPERIMENTAL|Flexible Incentive|Participants in the flexible incentive condition will be paid $3 or $7 for each workout they complete during the treatment period (with a limit of one incentivized workout per day, and twelve incentivized workouts during the four-week treatment period). These participants will receive daily emails 15 minutes before the start of their self-reported workout window, but they can work out anytime of the day and still receive their incentive payment.
62379697|NCT02346799|EXPERIMENTAL|Routine Incentive|Participants assigned to the routine incentive condition will receive the same treatment as those in the flexible incentive condition except that, in order to receive their incentive payment, they must begin their workout within their two-hour workout window. For instance, if an employee chooses a 2pm to 4pm workout window, she will receive a reminder to exercise at 1:45 pm and must swipe into the gym between 2pm and 4pm in order to receive the $3 or $7 incentive payment.
62757765|NCT05535738|EXPERIMENTAL|Contact Allergen with Immunomodulator Pre-Treatment|Individuals from Arm 1 (Baseline Contact Allergen) who have been exposed to SADBE and/or known patch test allergens followed by skin and blood sampling. These individuals will be pre-treated via administration of a single dose of 1 biologic from the following list: dupilumab, adalimumab, ustekinumab, guselkumab, canakinumab, sarilumab; or a single application of 1 topical steroid from the following list: betamethasone valerate, triamcinolone acetonide, fluticasone propionate. Allergic contact dermatitis will then be induced and the skin sampled.
62757766|NCT02839902|EXPERIMENTAL|TAK-085 4g|A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule is orally administered immediately after meal twice a daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.
62757767|NCT02839902|EXPERIMENTAL|Control Group|Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.
62757768|NCT06300723|EXPERIMENTAL|BRL-101|Autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the BCL11A gene. Subjects will receive a single infusion of BRL-101.
62757769|NCT05610631||Pulmonary arterial hypertension|Pulmonary arterial hypertension
62757770|NCT05610631||PH due to left heart diseases|PH due to left heart diseases
62757771|NCT05610631||PH due to lung disease and/or hypoxia|PH due to lung disease and/or hypoxia
62757772|NCT05610631||Chronic thromboembolic PH|Chronic thromboembolic PH
62757773|NCT05610631||Miscellaneous PH|Miscellaneous PH
62757774|NCT06151951|EXPERIMENTAL|Group A|Movement control training of Neck flexor muscles with Pressure Biofeedback along with baseline treatment
62757775|NCT06151951|EXPERIMENTAL|Group B|Movement control training of Neck flexor muscles with Visual Biofeedback along with baseline treatment
62757776|NCT05571007|EXPERIMENTAL|True acupressure|Using three true acupoints. Acupoints: Yongquan (K1), Sayingjiao (SP6), Zusanli (ST36). Patient Position: Lying or sitting position. Time: first 2 hours of HD.
61986995|NCT01893554|PLACEBO_COMPARATOR|Group 4: Placebo|Healthy infants between the ages 4 to 6 months who have not been screened for RSV serostatus will receive one dose of the placebo administered as nose drops at study entry.
62757777|NCT05571007|SHAM_COMPARATOR|Sham acupressure|Using three sham acupoints. Acupoints: Sham acupoints are located on 1 cun from the true acupoint. Patient Position: Lying or sitting position. Time: first 2 hours of HD.
62757778|NCT01982006|ACTIVE_COMPARATOR|Phaco|Cataract surgery by phacoemulsification
62757779|NCT01982006|EXPERIMENTAL|Femto|Corneal incision, anterior capsulorhexis and lens fragmentation by femtosecond laser
62757780|NCT01283399||Rituximab + Methotrexate|All participants with active refractory RA who were eligible to receive treatment with methotrexate and rituximab in the Investigators' opinion as per the routine clinical practice following inadequate response to a single cycle of anti-TNF therapy.
62757781|NCT01461629||heart failure|left systolic heart failure (EF \</= 40%)
62757782|NCT02094027|EXPERIMENTAL|Guided Self Help|Guided Self Help intervention to reduce binge eating
62757783|NCT02094027|PLACEBO_COMPARATOR|Treatment As Usual|No intervention for binge eating (treatment as usual in the form of bariatric surgery)
62379698|NCT02346799|EXPERIMENTAL|Social Routine Incentive|Participants assigned to this condition will have an identical experience to those in the routine incentive except that both partners who sign up for the study will be required to coordinate and select a common workout window. Thus, both partners will receive their daily reminders at the same time (and will be incentivized for working out at the same time). The incentive payment, however, will not be linked to whether or not a participant's partner completes a workout - only to the participant's own exercise decision.
62379699|NCT02346799|NO_INTERVENTION|Holdout Control|If experimental enrollment exceeds target, exercise data will be collected for these additional participants, but they will receive no intervention of any kind.
62757784|NCT04264650|NO_INTERVENTION|Control group|Standard care
62757785|NCT04264650|EXPERIMENTAL|One active intervention group|provided with COOL Passport, a mobile healthcare application
62757786|NCT04264650|EXPERIMENTAL|The other active intervention group|provided with access to the Health Promotion Cloud system and use of game-based interactive platforms along with COOL Passport
62757787|NCT03503292|EXPERIMENTAL|CYP2D6 rapid metabolizer|Participants with CYP2D6 rapid metabolizer status will received granisetron for for post operative nausea and vomiting prophylaxis and treatment
62757788|NCT03503292|EXPERIMENTAL|CYP2D6 normal metabolizer|Participants with CYP2D6 poor or normal metabolizer status will received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment
62757789|NCT02429713|EXPERIMENTAL|Short-duration tourniquet group|The tourniquet was inflated immediately before cement application and deflated after its hardening
62757790|NCT02429713|ACTIVE_COMPARATOR|Long-duration tourniquet group|The tourniquet was inflated immediately before incision and deflated after the hardening of the cement
62757791|NCT05616819|ACTIVE_COMPARATOR|Treatment Order A|Active light condition for 2 weeks, a 2-week washout period, and 2 weeks of placebo light treatment.
62757792|NCT05616819|PLACEBO_COMPARATOR|Treatment Order B|Placebo light treatment for 2 weeks, a 2-week washout period, and 2 weeks of active light treatment.
62757793|NCT02855723|ACTIVE_COMPARATOR|GS strategy|sentinel node biopsy
62757794|NCT02855723|OTHER|Classic strategy|systematic lymphadenectomy
62757795|NCT06127355|EXPERIMENTAL|Ursodeoxycholic Acid|500 mg of ursodeoxycholic acid (UDCA)
62757796|NCT06127355|PLACEBO_COMPARATOR|Control|500 mg of Placebo
62757797|NCT03773133|EXPERIMENTAL|Treatment|i.v. administrations of up to three radioactivity levels of Satoreotide tetraxetan.
62757798|NCT01034371|EXPERIMENTAL|One-stop hybrid revasularization|
62757799|NCT01034371|ACTIVE_COMPARATOR|Off-pump coronary artery bypass|
62757800|NCT01390779|EXPERIMENTAL|SENSIMED Triggerfish|All subjects enrolled in the trial were housed in a sleep laboratory for 24 hours, during which they underwent SENSIMED Triggerfish recording on one randomly selected eye.
62757801|NCT02404922|EXPERIMENTAL|CTP-730 Low Dose or Matching Placebo|Capsule, once daily.
62757802|NCT02404922|EXPERIMENTAL|CTP-730 Mid Dose or Matching Placebo|Capsule, once daily
62757803|NCT02404922|EXPERIMENTAL|CTP-730 High Dose or Matching Placebo|Capsule, once daily.
62757804|NCT02435680|EXPERIMENTAL|Arm 1: MCS110+carboplatin+gemcitabine|MCS110+carboplatin+gemcitabine
62757805|NCT02435680|ACTIVE_COMPARATOR|Arm 2: carboplatin+gemcitabine|carboplatin+gemcitabine
62757806|NCT04332471|ACTIVE_COMPARATOR|Control|Patients in the control group will be treated using the home therapy protocol only.
62757807|NCT04332471|ACTIVE_COMPARATOR|Radial shockwave therapy|Patients will receive 4 sessions of radial shockwave therapy.
62757808|NCT04332471|ACTIVE_COMPARATOR|Focused shockwave therapy|Patients will receive 4 sessions of focused shockwave therapy.
62757809|NCT00591149|EXPERIMENTAL|1|"Patients will be treated with oxaliplatin 130 MG/M2 IV over 2 hours on day 1 and docetaxel 60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle. Cycles of treatment will be repeated every 3 weeks for a total of 4 cycles or until disease progression or intolerable toxicity.~Patients who were treated with 4 cycles of oxaliplatin and docetaxel and had a response or stable disease will be treated with cetuximab at 400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks, or until disease progression or intolerable toxicity."
62757810|NCT01655043|EXPERIMENTAL|coronary artery disease patients|Patients with suspected coronary artery disease prospectively recruited for myocardial perfusion MRI. All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar, Lantheus) at both stress and rest. Stress to be induced using 5 ml intravenous (IV) regadenoson (Lexiscan, Astellas US LLC), and the effects of regadenoson were reversed with 50 mg IV aminophylline following the completion of stress imaging.
62757811|NCT03355560|EXPERIMENTAL|Nivolumab|Nivolumab starting 4-11 weeks after surgery for 6 doses.
62558014|NCT05252299|EXPERIMENTAL|Refresher Training Group|"This study will use telemedicine to facilitate an innovative use of rolling refresher training (RRT), a technique used in medical education to provide hands-on interactive training at regular intervals with the goal of improving psychomotor skills required for high stakes procedures such as cardiopulmonary resuscitation. This study seeks to interrogate our hypothesis that providing instruction on CSS use to caretakers via telemedicine every 3 months during the first year of an infant's life is feasible and acceptable to caregivers."
62379700|NCT01066637|EXPERIMENTAL|Dosimetry Group|To determine its potential for use in humans, we measured 18F-NOS myocardial activity in patients after orthotopic heart transplantation (OHT) (3 women and 9 men) and normal healthy volunteers (2 women and 2 men), and correlated it with pathologic allograft rejection, tissue iNOS levels, and calculated human radiation dosimetry.
62379701|NCT01066637|EXPERIMENTAL|Kinetic Analysis Group|Measurement of myocardial levels of enzyme nitric oxide synthase(iNOS) using PET and 18F-NOS in post heart transplant patients (5 women and 5 men) undergoing endomyocardial biopsy as part of their normal post-transplant evaluation. Kinetic data of the tracer will be compared with the heart tissue measurements of iNOS measured by immunohistochemistry.
62558015|NCT05252299|NO_INTERVENTION|Traditional Group|They leave the hospital without the additional training and under hospital's normal discharge plan
62757812|NCT04662073|EXPERIMENTAL|Camostat|Participants are randomized to receive camostat for 10 days.
62757813|NCT04662073|PLACEBO_COMPARATOR|Matching Placebo|Participants are randomized to receive placebo to match camostat for 10 days.
62757814|NCT00263640|PLACEBO_COMPARATOR|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Children received lifestyle counselling.
62757815|NCT00263640|EXPERIMENTAL|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
62757816|NCT04972227|EXPERIMENTAL|CY6463|CY6463 once-daily (QD) for 14 days
62379702|NCT03755362|ACTIVE_COMPARATOR|Standard treatment (control)|Dental evaluation and dental prophylaxis at baseline, 3, 6, and 9 months and standard oral hygiene instruction.
62558016|NCT04000139|ACTIVE_COMPARATOR|Standardized anthocyanin rich extract|3 doses of 2x 500mg in capsules daily
62757817|NCT04972227|PLACEBO_COMPARATOR|Placebo|placebo QD for 14 days
61986996|NCT04429893|EXPERIMENTAL|Group BM|The patients will receive 20 ml of 0.5% bupivacaine plus 150 mg magnesium sulphate in 0.9% normal saline with a total volume of 25 ml.
61986997|NCT04429893|ACTIVE_COMPARATOR|Group B|The patients will receive 20 ml of 0.5% bupivacaine plus 5 ml 0.9% normal saline with total volume 25 ml
62757818|NCT00517439|EXPERIMENTAL|Group 1|Group 1 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1000 po bid) plus PEGASYS (180 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
62757819|NCT00517439|EXPERIMENTAL|Group 2|Group 2 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (500 mg po bid) plus PEGASYS (180 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
62757820|NCT00517439|EXPERIMENTAL|Group 3|Group 3 will receive HCV polymerase inhibitor pro-drug 500mg po bid plus PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd for 24 weeks; after 24 weeks, those achieving a rapid virological response (RVR) will stop all medication, and non-RVR patients will remain on triple combination for an additional 24 weeks.
62757821|NCT00517439|EXPERIMENTAL|Group 4|Group 4 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1500 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
62757822|NCT00517439|EXPERIMENTAL|Group 5|Group 5 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1000 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
62757823|NCT00517439|EXPERIMENTAL|Group 6|Group 6 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (500 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
62757824|NCT00517439|ACTIVE_COMPARATOR|Group 7|Standard of care (SOC)
61986998|NCT01594996||Seroquel XR group|
62757825|NCT05615194|PLACEBO_COMPARATOR|Placebo|Normal saline in volume equivalent of dexmedetomidine dose according to patient weight ; Administered via infusion pump (Smith Medical Medfusion® 4000 Syringe Infusion Pump) so that the full dose is delivered over 10 minutes during induction of general anesthesia
62379703|NCT03755362|EXPERIMENTAL|Intensive Treatment|Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to \<20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
62757826|NCT05615194|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine 0.6 mcg/kg (adjusted body weight) ; Administered via infusion pump (Smith Medical Medfusion® 4000 Syringe Infusion Pump) so that the full dose is delivered over 10 minutes during induction of general anesthesia
62757827|NCT01102543||Premature babies < 28 GA|
62757828|NCT01102543||Premature babies > 28 & < 32 weeks GA|
62757829|NCT04833153|EXPERIMENTAL|PFP intervention|PFP 10 week continuing education intervention
62757830|NCT04833153|NO_INTERVENTION|Control arm|Usual care
62757831|NCT05492799|EXPERIMENTAL|single arm|AX 250 300 mg - open label
62757832|NCT06176495|NO_INTERVENTION|Control Group|Patients with Diabetes and Family Member Caregivers who will receive no text messages over the designated period of the designated
62757833|NCT06176495|OTHER|Intervention Group|Patients with Diabetes and Family Member Caregivers who will receive Educational Text Messages via WhatsApp over the designated period of the intervention
62757834|NCT02226315||Multiple gestations|Women with a multiple gestation who were evaluated with the MaterniT21 PLUS LDT and have passed their Estimated Date of Delivery (EDD).
62757835|NCT02100020|EXPERIMENTAL|Direct Referral to Physical Activity|The REF group will be referred to a centre-based community exercise program in their respective community (either the MacWheelers or Revved Up) by a clinical neurologist where they will be prescribed exercise based on the PAGs for adults with MS, and according to their individual capabilities.
62757836|NCT02100020|NO_INTERVENTION|Control|The CON group will be provided with a print copy of the PAGs and a link to an online resource for physical activity information.
62379704|NCT04168515||Patient|
62757837|NCT04947878|NO_INTERVENTION|Standard care|will not review a prompt list before their visit.
62757838|NCT04947878|EXPERIMENTAL|Prompt list|The patients in the intervention group will review a prompt list before their visit.
62757839|NCT05665673||Study Group|Sociodemographic information about the stroke patients included in the study will be obtained and some physical tests will be performed.
62379705|NCT04168515||Caregiver|
62379706|NCT04168515||Healthcare provider|
62379707|NCT03544385|EXPERIMENTAL|Treatment Group|
62379708|NCT03544385|PLACEBO_COMPARATOR|Placebo Group|
62379709|NCT05431231||psychiatric ward|Adults consenting to treatment, who are admitted in the psychiatric ward at the Sheba Medical Health Center, whose first hospitalization has been up to five years before their current referral.
62558017|NCT04000139|PLACEBO_COMPARATOR|Placebo|3 doses of 2x 500mg in capsules daily
62757840|NCT03114436||Consented deceased organ donors|Includes neurological determination of death (DND) and by circulatory determination of death (DCD).
62757841|NCT02621177|EXPERIMENTAL|NBP607|Trivalent Inactivated Cell Culture-derived Influenza Vaccine
62757842|NCT02621177|ACTIVE_COMPARATOR|Agrippal S1|Trivalent Inactivated Egg-derived Influenza Vaccine
62757843|NCT00495521|EXPERIMENTAL|Active|4-Aminosalicylic acid extended release granules (as volume equivalent of active product), 50 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 50 mg/kg orally two times daily for 2 weeks
62757844|NCT00495521|PLACEBO_COMPARATOR|Placebo|Placebo granules identical in appearance to the active arm (as volume equivalent of active product), 0 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 0 mg/kg orally two times daily for 2 weeks
62757845|NCT06351098|EXPERIMENTAL|Nap|Children are nap promoted
62757846|NCT02596373|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks
62757847|NCT02596373|ACTIVE_COMPARATOR|Mitoxantrone Hydrochloride Injection|Mitoxantrone Hydrochloride Injection 14 mg/m2 will be infused intravenously once over 30 minutes in 150 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks
62757848|NCT03251859|ACTIVE_COMPARATOR|Standard ticagrelor maintenance dose|Ticagrelor 90 mg twice daily for the first 45 days after myocardial infarction treated with percutaneous coronary intervention.
62757849|NCT03251859|EXPERIMENTAL|Reduced ticagrelor maintenance dose|Ticagrelor 90 mg twice daily for the first 30 days after myocardial infarction treated with percutaneous coronary intervention, then reduction of the maintenance dose to ticagrelor 60 mg twice daily for the next 15 days.
62757850|NCT01389349|EXPERIMENTAL|Acupuncture|
61986999|NCT02159755|EXPERIMENTAL|Treatment (ibrutinib, palbociclib)|Patients receive ibrutinib PO QD on days 1-28 and palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61987000|NCT04622839|EXPERIMENTAL|Group 1|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
61987001|NCT04622839|EXPERIMENTAL|Group 2|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
62379710|NCT05431231||Online hospitalization|adults consenting to treatment in their homes, who are found in an acute state that requires hospitalization, whose first hospitalization has been up to five years before their current referral. All the therapeutic treatments, assessment and follow-up meetings that are included in the service are provided online.
62757851|NCT01389349|SHAM_COMPARATOR|Sham Control|
62757852|NCT02880514|EXPERIMENTAL|PROPEL Mini Sinus Implant|Placement of the Propel Mini Sinus Implant in one frontal sinus ostia (FSO) assigned to the treatment group following in-office balloon dilation
62757853|NCT02880514|ACTIVE_COMPARATOR|Balloon Sinus Dilation Alone|In-office balloon dilation of the contralateral frontal sinus ostia (FSO) without implant placement
62379711|NCT05431231||Soteria|adults consenting to treatment in a house in the community, who are found in an acute state that requires hospitalization, whose first hospitalization has been up to five years before their current referral.
62379712|NCT02056249||Healthy, lean subjects|Volunteers without anemia (hematocrit), diabetes (A1c), use of illicit drugs and antidepressants, or any other major health issues.
62379713|NCT02685839|ACTIVE_COMPARATOR|Traditional rehabilitation|"Each subject will do traditional rehabilitation work two times per week and one hour at a time~, lasting 24 weeks."
62757854|NCT02426190|ACTIVE_COMPARATOR|Arm 1|Patients in Arm 1 receive standard of care rehabilitation protocol using a recumbent or Nu-step bike during warm-up, followed by individualized therapeutic exercise, and cool-down protocols. The warm-up phase in the study refers to therapeutic exercise. The therapeutic exercise aims to condition and prepare patients for subsequent functional or therapeutic activities. The active comparator (Arm 1) is to ask participants to use modalities, such as a recumbent bike or a Nu-step bike during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
62757855|NCT02426190|EXPERIMENTAL|Arm 2|Patients in Arm 2 will use an anti-gravity treadmill (AlterG) during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
62757856|NCT02426190|EXPERIMENTAL|Arm 3|Patients in Arm 3 will use a recumbent or Nu-step bike along with the PENS neuromuscular stimulation modality during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
62757857|NCT02426190|EXPERIMENTAL|Arm 4|Patients in Arm 4 will use both an anti-gravity treadmill (AlterG) and the PENS neuromuscular stimulation modality during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
62757858|NCT03035773|EXPERIMENTAL|ARM A; Care Plan Only|SCP document delivered to the patient \& Primary Care Provider
62757859|NCT03035773|EXPERIMENTAL|ARM B; Care Plan During Visit|SCP document provided to the patient in an in-person survivorship visit and copy sent to PCP
62757860|NCT03035773|EXPERIMENTAL|ARM C; Care Plan During Visit + Additional Visit|SCP document provided to the patient in an in-person survivorship visit with an additional follow-up visit and copy of the document sent to PCP
62757861|NCT06136286|NO_INTERVENTION|Control|Standard of care postoperative rehabilitation. Subject will undergo standard rehab following surgery without BFR.
62757862|NCT06136286|EXPERIMENTAL|Intervention - Blood Flow Restriction Therapy (BFR)|Subjects will undergo standard postoperative rehabilitation that incorporates BFR during certain exercises.
62558018|NCT02744872|ACTIVE_COMPARATOR|Felodipine|Tablet Felodipin 10 mg x 1 daily
62757863|NCT04511117|ACTIVE_COMPARATOR|Control Group|ProTaper Next rotary system and iRoot SP sealer will be used for root canal treatment, followed by composite restorations.
62757864|NCT04511117|EXPERIMENTAL|Endocrown Group|ProTaper Next rotary system and iRoot SP sealer will be used for root canal treatment, followed by endocrown restorations.
62558019|NCT02744872|PLACEBO_COMPARATOR|Placebo|Identical placebo once daily
62558020|NCT00870844|EXPERIMENTAL|Lu AA24493 (CEPO): 0.5 mcg/kg|
62558021|NCT00870844|EXPERIMENTAL|Lu AA24493 (CEPO): 5.0 mcg/kg|
62558022|NCT00870844|EXPERIMENTAL|Lu AA24493 (CEPO): 50.0 mcg/kg|
62558023|NCT00870844|PLACEBO_COMPARATOR|Placebo|
62757865|NCT02695368|EXPERIMENTAL|Exposed patients: Plasma-filter on|"Those operated with Novaerus NV800 on for at least 2 Days prior to index surgery. This Group will also in the analysis be sub-grouped according to measurements prior to study start into:~* regular operating theater~* ultra-Clean operating theaters"
62757866|NCT02695368|EXPERIMENTAL|Unexposed patients: Plasma-filter off|Those with Novaerus NV800 off for at least 2 Days prior to index surgery
62558024|NCT01296087|EXPERIMENTAL|TC-6987|
62558025|NCT01296087|PLACEBO_COMPARATOR|Placebo|
62757867|NCT02695368|EXPERIMENTAL|Mixed patients: Plasma-filter on or off|Those receiving multiple surgeries in different theaters with Novaerus NV800 on or off status will belong to a mixed Group.
62757868|NCT01741532|EXPERIMENTAL|Deferiprone|Deferiprone 80 mg/mL oral solution
62757869|NCT01741532|PLACEBO_COMPARATOR|Placebo|Matching placebo solution
62757870|NCT00826358|EXPERIMENTAL|A|ABT-143 capsules 5/45mg
62757871|NCT00826358|ACTIVE_COMPARATOR|B|ABT-335 45mg and rosuvastatin 5mg
62558026|NCT03606616||ACOSOG Z0011 no further ALND arm|patients meeting the criteria for ACOSOG Z0011 trial inclusion：histologically confirmed invasive breast cancer;clinical T1/T2;breast conserving surgery；1 or 2 positive sentinel lymph nodes; Whole-breast RT planned; no preoperative chemotherapy
61987002|NCT04622839|EXPERIMENTAL|Group 3|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
61987003|NCT02487238|EXPERIMENTAL|Fecal Microbiota Enema|Live, healthy, human donor stool prepared as fecal enemas. Fecal enemas are prepared and collected by Rebiotix(®) (RBX2660), using extensively screened donor stool. Enemas will be administered on site at one of the participating trial sites by trained study investigators. Enemas are given: 2x per week for 6 weeks (total = 12 enemas over 6 weeks). Patients will be masked to enema contents.
61987004|NCT02487238|PLACEBO_COMPARATOR|Normal Saline Enema|Normal saline enemas will be administered on site at one of the participating trial sites by trained study investigators. Enemas are given: 2x per week for 6 weeks (total = 12 enemas over 6 weeks). Patients will be masked to enema contents.
61987005|NCT01885546|OTHER|Enhanced meter feature usability|Home diabetes monitoring by patient using provided blood glucose monitoring system.
62757872|NCT05482815|EXPERIMENTAL|Voice Prosthesis|Subjects receive a Voice prosthesis using the Provox Puncture Set, then undergo an articulation training program (3 weeks). The voice prosthesis is replaced after 3 months and 6 months.
62757873|NCT00509743|EXPERIMENTAL|A|Low dose Diclofenac
62757874|NCT00509743|EXPERIMENTAL|B|High dose Diclofenac
62757875|NCT05679167|ACTIVE_COMPARATOR|Supervised digital training: core stability|The patients will be identified at the primary health center and after fulfilling the inclusion criteria and all baseline examination are completed the patients will be randomized. In group 1 the patients will attend supervised digital training with focus on core stability
62757876|NCT05679167|ACTIVE_COMPARATOR|Supervised digital training: aerobic exercise|The patients will be identified at the primary health center and after fulfilling the inclusion criteria and all baseline examination are completed the patients will be randomized. In group 2 the patients will attend supervised digital training with focus on aerobic exercise
62757877|NCT05679167|ACTIVE_COMPARATOR|Non-supervised daily physical activity|The patients will be identified at the primary health center and after fulfilling the inclusion criteria and all baseline examination are completed the patients will be randomized. In group 3 will start a daily physical activity program, with regular support from a physiotherapist.
62757878|NCT01107600|EXPERIMENTAL|Nobel Active®|Immediate implant and socket preservation
62757879|NCT05685732|EXPERIMENTAL|Cohort 1: SDX/d-MPH in 4-5 year old|13.1 mg/2.6 mg SDX/d-MPH, 26.1 mg/5.2 mg SDX/d-MPH, 39.2 mg/7.8 mg SDX/d-MPH
62757880|NCT05685732|PLACEBO_COMPARATOR|Cohort 1: Placebo in 4-5 year old|matching placebo
62757881|NCT05685732|EXPERIMENTAL|Cohort 2: SDX/d-MPH in 6-12 year old|26.1 mg/5.2 mg SDX/d-MPH, 39.2 mg/7.8 mg SDX/d-MPH, 52.3 mg/10.4 mg SDX/d-MPH
62757882|NCT05685732|PLACEBO_COMPARATOR|Cohort 2: Placebo in 6-12 year old|matching placebo
62379714|NCT02685839|EXPERIMENTAL|Power rehabilitation|Each subject will do Power rehabilitation work with motion tracking and biofeedback recording two times per week and one hour at a time, lasting 24 weeks.
62379715|NCT04882826|OTHER|Sequence TR|22 subjects assigned to the sequence TR will receive a single 100 mg dose of the test product Sildenafil (1 x 100 mg tablet), marked as T in the sequence, in Period 1 and a single 100 mg dose of the reference product Viagra® (1 x 100 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62757883|NCT05273216||Observational Study (no different study arms)|Prospective, longitudinal, multicenter, observational study to investigate hemodynamic changes (by TCD and perfusion MRI) and blood biomarkers as predictors of reperfusion injury / intracranial hemorrhage after stroke thrombectomy of the anterior cerebral circulation
62757884|NCT03076086|EXPERIMENTAL|induced sputum procedure|Biomarker assessment (concentration of PiP3 and phosphoproteins in sputum samples) baseline and reproducibility twice in a 3 week interval of the different donors.
62757885|NCT00913991|EXPERIMENTAL|Stress Management #1|8 weeks of individual stress management training sessions
62757886|NCT00913991|ACTIVE_COMPARATOR|Stress Management #2|8 weeks of individual stress management training sessions
62757887|NCT01452139|EXPERIMENTAL|At-Risk Genetics Arm: Prasugrel|Treatment of STEMI patients carrying at least 1 at-risk genetic variant with prasugrel 10mg daily for 1 month.
62558027|NCT00839358|ACTIVE_COMPARATOR|Albumin plus midodrine|Albumin 40 g every 15 days during 1 year or until liver transplantation. Midodrine 5mg/8h. It can be increased according the value of mean arterial pressure. If there is no increase (defined as at least 10mmHGin MAP)midodrine can be increased at a dose of 10mg/8h. This treatment will be given during 1 year or until liver transplantation.
62757888|NCT01452139|ACTIVE_COMPARATOR|At-Risk Genetics Arm: Clopidogrel|Treatment of STEMI patients carrying at least 1 at-risk genetic variant with clopidogrel 150mg daily for 1 week followed by 75mg daily.
62757889|NCT01452139|ACTIVE_COMPARATOR|Low Risk Genetics Arm: Clopidogrel|Treatment of STEMI patients with no at-risk genetic variants with clopidogrel 75mg daily.
62757890|NCT06465303|EXPERIMENTAL|RTP-026|
62757891|NCT06465303|EXPERIMENTAL|Placebo|
62757892|NCT00823992|PLACEBO_COMPARATOR|placebo|
62757893|NCT00823992|EXPERIMENTAL|taspoglutide|
62757894|NCT05462990|EXPERIMENTAL|QUC398|QUC398 150 mg/mL, solution for s.c. injection (1 mL). 2 injections will be applied per dose to complete the 300 mg
62757895|NCT05462990|PLACEBO_COMPARATOR|Placebo|Placebo 0 mg/mL, solution for s.c. injection (1 mL). 2 injections will be applied per dose to ensure blinding
62379716|NCT04882826|OTHER|Sequence RT|22 subjects assigned to the sequence RT will receive a single 100 mg dose of the reference product Viagra® (1 x 100 mg tablet), marked as R in the sequence, in Period 1 and a single 100 mg dose of the test product Sildenafil (1 x 100 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62379717|NCT03515265|EXPERIMENTAL|Fiber resin composite|Fiber reinforced resin composite restoration used as dentin substitute covered by conventional resin composite
62558028|NCT00839358|PLACEBO_COMPARATOR|salin solution plus pills|Placebo of albumin in the same schedule thats in arm 1; placebo of midodrine in the same schedule thats in arm 1.
62558029|NCT05268562|ACTIVE_COMPARATOR|Anesthesia induction with Ketamine|Subjects will receive Ketamine to begin anesthesia for their cardiac surgery.
62558030|NCT05268562|ACTIVE_COMPARATOR|Anesthesia induction with Propofol|Subjects will receive Propofol to begin anesthesia for their cardiac surgery.
62558031|NCT03228888|EXPERIMENTAL|Artificial Sounds|"Participants were provided headphones and a portable MP3 device which played a metronome tick at specified rhythm calculated as follows: a) if a patient's cadence was below the normality, the BPM of the stimulus was set at a value of 10% higher than one's own cadence; b) if a patient's cadence was below, but close to normality (less than 10% difference), the BPM of the stimulus was set at normality values; c) if a patient's cadence was above the normality, the BPM of the stimulus was set at a value equal to one's own cadence.~Participants performed daily 30 minutes of walking assisted by the rhythmic acoustic stimuli."
62757896|NCT01650220||Veterans with a history of PTSD|
62757897|NCT01650220||Veterans without a history of PTSD|
62757898|NCT06608784||Patients with epilepsy|Patients with epilepsy who experienced a recent generalized tonic-clonic seizure
62757899|NCT06608784||Patients with first seizure|Patients who experienced a recent generalized tonic-clonic seizure without any previous history
62757900|NCT06608784||Normal population|Participants without history of seizure or epilepsy
62757901|NCT05498233|OTHER|RT-sequence|Group 1 (14 volunteers, RT sequence) will take 2 tablets of Diclectin in Period 1 and 2 tablets of Doxylamine + Pyridoxine in Period 2
62757902|NCT05498233|OTHER|TR-sequence|Group 2 (14 volunteers, sequence TR) will take 2 tablets of Doxylamine + Pyridoxine in Period 1 and 2 tablets of Diclectin in Period 2.
62757903|NCT03834506|EXPERIMENTAL|Pembrolizumab+Docetaxel|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to a maximum of 35 cycles (approximately 2 years) PLUS docetaxel 75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle (Q3W) for a maximum of 10 cycles (approximately 7 months). Participants also concomitantly receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours, and 1 hour prior to docetaxel administration and prednisone 5 mg by oral tablets twice daily during each 21-day docetaxel cycle.
62757904|NCT03834506|PLACEBO_COMPARATOR|Placebo+Docetaxel|Participants receive placebo by IV infusion on Day 1 of each 21-day cycle (Q3W) for up to a maximum of 35 cycles (approximately 2 years) PLUS docetaxel 75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle (Q3W) for a maximum of 10 cycles (approximately 7 months). Participants also concomitantly receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours, and 1 hour prior to docetaxel administration and prednisone 5 mg by oral tablets twice daily during each 21-day docetaxel cycle.
62379718|NCT03515265|ACTIVE_COMPARATOR|Microhybrid resin composite|Microhybrid resin composite restoration with lower strength compared to Fiber reinforced resin composite restoration
62379719|NCT03062644|EXPERIMENTAL|MR308 100 mg bid|Tramadol/Celecoxib)
62558032|NCT03228888|EXPERIMENTAL|Ecological Sounds|"Participants were provided headphones and a portable MP3 device which played an ecological rhythmic sound obtained by actual footsteps of human at specified rhythm calculated as follows: a) if a patient's cadence was below the normality, the BPM of the stimulus was set at a value of 10% higher than one's own cadence; b) if a patient's cadence was below, but close to normality (less than 10% difference), the BPM of the stimulus was set at normality values; c) if a patient's cadence was above the normality, the BPM of the stimulus was set at a value equal to one's own cadence.~Participants performed daily 30 minutes of walking assisted by the rhythmic acoustic stimuli."
62757905|NCT01510184|EXPERIMENTAL|Zevalin|Participants received rituximab 250 milligram per meter square (mg/m\^2) by intravenous infusion on Day 1. If required by the governing regulatory agency, rituximab was to be followed 4 hours later by In-111-Zevalin 5.0 millicurie (mCi) on Day 1. And on Days 7-9: participants received rituximab 250 mg/m\^2 by intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 millicurie/kilogram (mCi/kg) 10-minute intravenous push (0.3 mCi/kg in participants with a platelet count in 100,000/ microliter \[μL\] to 149,000/μL).
61987006|NCT06268561||OZURDEX patients|Patients treated by Dr Garcin and Pr Thuret CHU of Saint Etienne in the context of post-OZURDEX endophthalmitis
62757906|NCT01510184|NO_INTERVENTION|Observation|Participants who were randomized in this arm group did not receive any anti-lymphoma therapy unless they had a relapse of their disease.
62757907|NCT03998748|EXPERIMENTAL|Experimental|This group of participants will receive the feedback that they have a genetic vulnerability to depression.
61987007|NCT06328153|EXPERIMENTAL|FSN group|Fu's subcutaneous needling (FSN) is a new type of acupuncture. Patients in the FSN Group only received FSN treatment, without other interventions such as oral drugs or topical drugs.
62379720|NCT03062644|EXPERIMENTAL|MR308 150 mg bid|Tramadol/Celecoxib
62379721|NCT03062644|EXPERIMENTAL|MR308 200 mg bid|Tramadol/Celecoxib
62379722|NCT03062644|ACTIVE_COMPARATOR|Tramadol 100 mg qid|Tramadol
62558033|NCT03782168||Placental Abruption|Mother-infant dyads with suspected or confirmed diagnosis of placental abruption
62558034|NCT03782168||Phenotypically-matched controlled group|Healthy mother-infant dyads admitted for delivery
62379723|NCT03062644|ACTIVE_COMPARATOR|Celecoxib 100 mg bid|Celecoxib
62379724|NCT03062644|PLACEBO_COMPARATOR|Placebo|Placebo
62379725|NCT04510844|EXPERIMENTAL|Study Drug Group|Participants who will receive a shot of the Evolocumab at Visit 3 and self-administer the rest of the shots at visit 4-7.
62379726|NCT04510844|PLACEBO_COMPARATOR|Placebo group|Participants who will receive a Placebo shot at Visit 3 and self-administer the rest of the shots at visit 4-7.
62379727|NCT04061304|EXPERIMENTAL|Active rTMS (Anorexia Nervosa)|"Patients in this arm will receive 40 sessions of active rTMS. Every day, the first session of rTMS for both groups will be applied to the left DLPFC using intermittent Theta Burst Stimulation (iTBS).~For the second session each day the patients in the anorexia group will receive low-frequency treatment (1 Hz, 60 second cycles, 30 second inter-train interval, 20 trains, 1200 total pulses) at 120% of the resting motor threshold to the orbitofrontal cortex"
62379728|NCT04061304|EXPERIMENTAL|Active rTMS (Bulimia Nervosa)|"Patients in this arm will receive 40 sessions of active rTMS. Every day, the first session of rTMS for both groups will be applied to the left DLPFC using intermittent Theta Burst Stimulation (iTBS).~For the second session each day the patients in the bulimia group will receive high-frequency (10 Hz, 5 second cycles, 50 pulses, 25 second inter-train interval, 60 trains, 3000 total) at 120% of the resting motor threshold treatment to the left dorsomedial prefrontal cortex"
62757908|NCT03998748|ACTIVE_COMPARATOR|Control|This group of participants will receive the feedback that they do not have a genetic vulnerability to depression.
62558035|NCT01807403|EXPERIMENTAL|Deep brain stimulation of subthalamic nucleus|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.Stimulation of subthalamic nucleus
62379729|NCT04061304|SHAM_COMPARATOR|Sham rTMS (Anorexia Nervosa)|Patients in this arm will receive 40 sessions of sham rTMS. They will be set up the same as the active Anorexia Nervosa group however their will be no actual brain stimulation.
62558036|NCT01807403|EXPERIMENTAL|Deep brain stimulation of caudate nucleus|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker. Caudate nucleus stimulation
62558037|NCT01807403|EXPERIMENTAL|Deep brain stimulation of nucleus accumbens|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.Nucleus accumbens stimulation.
62757909|NCT05245630||Robotic arm assisted PET/CT guided biopsy|"In this group, participants were recruited for robotic-assisted PET/CT guided biopsy from the FDG avid lung lesions.~biopsies were done using an automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) to guide the needle for biopsy. It is a robotic arm with a four-ax guide arm and a planning console. Pre-interventional fused PET/CT images from Biograph mCT 16 scanner were sent via LAN cable to the device (MAXIO-EX) console."
62558038|NCT02932462|EXPERIMENTAL|DSXS 1535|DSXS 1535 topical product
62558039|NCT02932462|PLACEBO_COMPARATOR|Placebo|Vehicle
62558040|NCT00268450|EXPERIMENTAL|study intervention|Neo-adjuvant cisplatin, gemcitabine and bevacizumab followed by radical cystectomy. Patients without residual disease will enter follow up after surgery. Patients with residual disease will receive adjuvant therapy with bevacizumab and ciaplatin.
62558041|NCT01324778|EXPERIMENTAL|A|
62558042|NCT01324778|ACTIVE_COMPARATOR|B|
62558043|NCT06306248||MDD patients|"60 patients with a depressive episode in course of major depression (MDD) and treated with a chronobiological intervention including total sleep deprivation (TSD) + light therapy (LT).~Each subject will participate in the study for 6 months, will undergo MRI and clinical evaluation that will take overall about 2 hours at baseline (V0), after one week of chronobiological treatment and at 6 month follow-up."
62757910|NCT05245630||PET fused CT-Fluoroscopy guided biopsy|"In this group, participants were recruited for PET fused CT-Fluoroscopy guided biopsy from the FDG avid lung lesions.~A biopsy needle was placed to the target lesion on PET/CT under CT fluoroscopy"
62757911|NCT03286946|EXPERIMENTAL|Blunt-type block needle|block with Blunt-type block needle.
62757912|NCT03286946|ACTIVE_COMPARATOR|Sharp-type block needle|block with Sharp-type block needle.
62757913|NCT04422561|EXPERIMENTAL|Ivermectin group|Contacts who will receive prophylactic ivermectin
62757914|NCT04422561|NO_INTERVENTION|Control group|Contacts who will be only observed without prophylaxis
61987008|NCT06328153|ACTIVE_COMPARATOR|Drug Group|Celecoxib is a member of Nonsteroidal Antiinflammatory Drugs (NSAIDs) and the most commonly used treatment for knee osteoarthritis. Patients in the drug group received only oral celecoxib, no other oral or topical drugs, and no other physical therapies.
62379730|NCT04061304|SHAM_COMPARATOR|Sham rTMS (Bulimia Nervosa)|Patients in this arm will receive 40 sessions of sham rTMS. They will be set up the same as the active Bulimia Nervosa group however their will be no actual brain stimulation.
62379731|NCT03960593||Patients with cancer and / or hematological|The population of the study will be all patients over 70 years of age with oncogeriatric HDJ cancer prior to initiation of oncologic therapy such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or hormone therapy. new generation.
62379732|NCT04244773|EXPERIMENTAL|Intervention group: ENDS and smoking cessation|
62379733|NCT04244773|ACTIVE_COMPARATOR|Control group: Smoking cessation counseling|
62379734|NCT03928106|OTHER|intervention|pharmacist responsible for enrollment will administer the following interventions: identifying the medication discrepancies make the recommendations to correct these discrepancies contact the physician to resolve these discrepancies
62379735|NCT03928106|OTHER|control|pharmacists will identify medication discrepancies no recommendation will be written by pharmacists to solve these discrepancies
62379736|NCT01566981|EXPERIMENTAL|Diabetes with ICT support (E-diabetes)|The group of randomly selected patients with DM type II, who will get the software application and web- based support Intervention: Computerised support to the Diabetes type II patients
62379737|NCT01566981|NO_INTERVENTION|Diabetes without support|The group of randomly selected patients with DM type II, without software application and web-based support.
62379738|NCT02073227|EXPERIMENTAL|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 300 mg, and 4 tablets of metformin extended release (MET XR), 500 mg each, administered together under fed conditions.
62379739|NCT02073227|EXPERIMENTAL|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
62379740|NCT02073227|EXPERIMENTAL|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
62379741|NCT02729870||Oral Glucose Gel|This group will consist of participants ages 1 - 7. The subject who are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
62379742|NCT02729870||Oral Placebo Gel|The group will consist of participants ages 1 - 7. The subjects who are less than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3- 7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
62379743|NCT02824315|EXPERIMENTAL|AL-335+Simeprevir (SMV)+Odalasvir (ODV)|Participants will receive AL-335 800 milligram (mg) once daily from day 1-3; SMV 75 mg once daily from Day 4-13; loading dose of ODV 150 mg on Day 14, followed by ODV 50 mg once daily from Day 15 to 23; ODV 50 mg once daily + AL-335 800 mg once daily from day 24-26; ODV 50 mg once daily + SMV 75 mg once daily from Day 27-33 and ODV 50 mg once daily + SMV 75 mg once daily + AL-335 800 mg once daily from Day 34 to 36.
62757915|NCT04381325|EXPERIMENTAL|MSB0254 Injection|This experiment will start from 4mg/kg with a dose increase of 3+3, and is planned to be carried out in 5 dose groups, namely 4mg/kg, 8mg/kg (100% increase), 12mg/kg (50% increase), 16mg/kg (33% increase) and 20mg/kg (25% increase).MSB0254 injection was administered intravenously on day 1 and day 15 every 28 days.To collect pharmacokinetic blood samples after repeated administration, MSB0254 injection was not administered on day 1 of the third cycle (C3D1).The observation period of DLT was 28 days after the first administration. An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W).
62757916|NCT01205802|ACTIVE_COMPARATOR|PTFE group|MHV reconstruction with ringed Goretex
62757917|NCT01205802|PLACEBO_COMPARATOR|Homograft group|MHV reconstruction with homograft
62757918|NCT02498067|EXPERIMENTAL|Intervention|Participants will complete a 10-15 minute questionnaire . After completing the questionnaire, a research assistant (RA) will provide a brief orientation to the rPlan app and use the rPlan app for up to 15 minutes. After viewing rPlan, participants will be asked a series of questions regarding the app's usability, helpfulness, and content appropriateness (10 min). The participant will also be given an STI test.
62757919|NCT05331703|EXPERIMENTAL|group A|will receive a designed physical therapy program in addition to program of virtual reality
62757920|NCT05331703|EXPERIMENTAL|group B|will receive a designed physical therapy program in addition to program of mirror therapy.
62757921|NCT01512680|EXPERIMENTAL|Type 1 diabetes patient|Type 1 diabetes patient are included in this study to have an education to Functional Insulin Therapy (intervention)
62757922|NCT00167102|EXPERIMENTAL|Alefacept|
62757923|NCT00167102|PLACEBO_COMPARATOR|Placebo|
62757924|NCT03740542|ACTIVE_COMPARATOR|Esophagectomy with Pyloroplasty|Esophagectomy with Pyloroplasty
62757925|NCT03740542|EXPERIMENTAL|Esophagectomy without Pyloroplasty|Esophagectomy without Pyloroplasty
61987009|NCT06389747|ACTIVE_COMPARATOR|%80 BFR group|%80 intensity BFR technique will be applied to this group.
61987010|NCT06389747|ACTIVE_COMPARATOR|%20 BFR group|%20 intensity BFR technique will be applied to this group.
62757926|NCT04018560|EXPERIMENTAL|Intervention|
62757927|NCT04018560|NO_INTERVENTION|Usual care|
62757928|NCT04285307|EXPERIMENTAL|Study group|Study group
62757929|NCT03251040|OTHER|Fibrin sealant|Single arm pilot study
62757930|NCT00580164||1|Splint
62757931|NCT00580164||2|No Splint
62757932|NCT03532932||UC Participants|Participants diagnosed with moderate to severe UC from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in UC participants particularly on the use of available biological therapies.
62757933|NCT03532932||CD Participants|Participants diagnosed with moderate to severe CD from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in CD participants particularly on the use of available biological therapies.
62757934|NCT04412733|EXPERIMENTAL|Pulsed Ultrasound Group|Patients in pulsed ultrasound group received pulsed ultrasound treatment (frequency: 1000 kHz, intensity: 0.5w/cm2, on-off ratio: 1:2 ) 5-min daily session, 5 days per weeks, for a total of 15 sessions.
62757935|NCT04412733|SHAM_COMPARATOR|Sham Group|Control group received sham ultrasound with the same protocol.
61987011|NCT05793528||Those who had lumbar radicular pain|Patients with lumbar radicular pain identified by inclusion and exclusion criteria
62757936|NCT02363374|ACTIVE_COMPARATOR|Arm A: Chemotherapy -> Chemoradiotherapy|Induction chemotherapy followed by chemoradiotherapy before surgery
62757937|NCT02363374|EXPERIMENTAL|Arm B: Chemoradiotherapy -> Chemotherapy|Combined chemoradiotherapy followed by three cycles chemotherapy before surgery
61987012|NCT04879004|EXPERIMENTAL|Ropivacaine Group|ESPB performed with infusion of Ropivacaine 0,375% (20 ml at ech side)
61987013|NCT04879004|PLACEBO_COMPARATOR|Control Group|ESPB performed with infusion of N/S 0,9% (20 ml at each side)
61987014|NCT05636930||smart bracelet|Type and specification:FRA-B39
61987015|NCT01920919|EXPERIMENTAL|Dexamethasone 1 mg|Dexamethasone 1 mg per day, for 180 days
61987016|NCT01920919|PLACEBO_COMPARATOR|Placebo|Placebo tablet, for 180 days
62757938|NCT06247228|EXPERIMENTAL|Experimental group|Experimental group will receive the Click2Move intervention for one year, including a wearable (provided by the research group) and mobile phone application downloaded in the participants own mobile phone. Click2Move intervention comprises elements at three levels: environmental (activity tracking and app provision, reminders, cooperative challenges, and social chat), organisational level (organisational support and motivational messages), and at individual level (educational materials, self-monitoring, feedback provision, demonstration videos and a list of strategies).
61987017|NCT03045887|EXPERIMENTAL|Part A Cohort 1: Placebo- GSK2292767 (GSK) 200 µg-GSK 1000 µg|Subjects will receive an inhaled single dose of placebo in Period 1, GSK2292767 200 µg in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
61987018|NCT03045887|EXPERIMENTAL|Part A Cohort 1: GSK 50 µg-Placebo-GSK 1000 µg|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, placebo in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
61987019|NCT03045887|EXPERIMENTAL|Part A Cohort 1: GSK 50 µg- GSK 200 µg-Placebo|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, GSK2292767 200 µg in Period 2, and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.
62757939|NCT06247228|NO_INTERVENTION|Control group|Participants in the control arm will be asked to complete the same study measurements as those in the intervention arms, at the same time points. The control arm participants will not receive any device, nor will they have to download the mobile phone application. After the year of the intervention, they will be able to receive the intervention if they agree.
62558044|NCT06577818|EXPERIMENTAL|CC+SI (Chest compression during sustained inflation)|"CC+SI Group (Intervention group): Newborns randomized to CC+SI will receive CPR with a SI using a peak inflation pressure (PIP) of 30cmH2O while receiving CC. The PIP was chosen based on our animal studies and two previous clinical trials. CC will be performed at a rate of minimum 90/min. Each SI will be delivered for duration of 30sec with a 1 sec pause between the next SI for 30sec is started while CCs are continued. After 2x30sec CC+SI (total of 60sec), Heart rate (HR) will be assessed: A HR \<60/min means CC+SI is continued for another 60sec (2x30sec CC+SI), followed by another HR assessment. If HR \>60/min, CC are stopped (current standard of care). CC+SI will continued until ROSC."
62558045|NCT06577818|ACTIVE_COMPARATOR|3:1 C:V (3:1 Compression:Ventilation ratio)|"3:1 C:V Group (Control group - Standard of Care): Newborns randomized to 3:1 C:V will receive a CC rate of 90/min and 30 ventilations/min as per current resuscitation guidelines. The PIP used for the 30 inflations will also be 30cmH2O) as per current resuscitation guidelines. Every 60sec, a HR assessment as per neonatal guidelines will be performed to assess if HR is \<60/min - continue CC or \>60/min - stop CC (current standard of care). 3:1 C:V will be continued until ROSC."
62757940|NCT00359944|EXPERIMENTAL|AC-3933|AC-3933, 5mg twice daily
62757941|NCT00359944|EXPERIMENTAL|AC-3933, 20 mg twice daily|AC-3933, 20 mg twice daily
62757942|NCT00359944|PLACEBO_COMPARATOR|Placebo|Sugar Pill twice daily
62757943|NCT00445939|EXPERIMENTAL|Adalimumab 160 mg/80 mg|
62757944|NCT00445939|EXPERIMENTAL|Adalimumab 80 mg/40 mg|
62757945|NCT00445939|PLACEBO_COMPARATOR|Placebo|
62757946|NCT01167010|EXPERIMENTAL|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a day for 12 weeks.
62379744|NCT02996175|EXPERIMENTAL|SMART|"Treatment group targeting behavioral sleep problems for 5 weeks.~1. Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems~2. Information on healthy sleep hygiene, preventative techniques, and use of visual supports~3. Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking~4. Information on procedures for delayed sleep onset and problematic sleep associations~5. Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future"
62757947|NCT01167010|ACTIVE_COMPARATOR|Foraseq|Foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
62757948|NCT01167010|ACTIVE_COMPARATOR|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
62757949|NCT00873535|ACTIVE_COMPARATOR|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
62757950|NCT00873535|PLACEBO_COMPARATOR|Placebo|This group (N=40) will receive placebo in the same dosing regimen as for Varenicline. The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
62757951|NCT00750191|ACTIVE_COMPARATOR|Intradiscal Biacuplasty|"On the day of the procedure, patients were given midazolam for relaxation and, if needed, fentanyl IV during the procedure. For treatment subjects, two TransDiscal probes were positioned under fluoroscopic guidance in the posterior annulus of the intervertebral disc. The probes were attached to the Radiofrequency generator and Radiofrequency energy was delivered. Placement of the probes within the disc annulus was confirmed using oblique, lateral, and anterior-posterior fluoroscopic images.~Following completion of procedure the patient was transferred to recovery and monitored for 45 minutes then discharged home with instructions. It was expected that the patient limit their activities during the first week after the procedure."
62757952|NCT00750191|PLACEBO_COMPARATOR|Sham|"Sham procedures mimicked active treatment procedures, except that the probes were positioned just outside of the disc and no radiofrequency energy was delivered through the electrodes. Thus, sham patients were provided similar tactile, auditory and visual experiences as treatment patients, without receiving the active RF treatment.~Following completion of procedure the patient was transferred to recovery and monitored for 45 minutes then discharged home with instructions. It was expected that the patient limit their activities during the first week after the procedure.~The study will be unblinded at 6 months. If the patients in the IDB group show significant improvement compared to placebo they will be offered IDB."
62757953|NCT04139681|EXPERIMENTAL|A. Vogels Sore Throat Lozenges|Each patients receives 1 glass containing 20 A.Vogel Sore Throat lozenges at inclusion visit 1. They first suck under supervision in the study centre one Vogel Sore Throat lozenge and document every 15 minutes the pain 90 minutes. Patients will receive the rest of the bottle still containing 19 Vogel Sore Throat lozenges and have to take them for 4 days (5 lozenges per day, throughout the day) and record tonsillitis pain.
62757954|NCT06055465|EXPERIMENTAL|Sacituzumab Govitecan and Pembrolizumab|"* Neoadjuvant treatment with pembrolizumab and sacituzumab govitecan is given for a total for 4 cycles. Pembrolizumab is administered first on day 1 every cycle. Sacituzumab govitecan is administered second on day 1 and 8 every cycle. The next cycle should start a minimum 14 days after the Day 8 dose.~* Surgery is to be performed within 4-8 weeks after day 1 of last cycle of neoadjuvant pembrolizumab/SG.~* Postoperative radiotherapy is recommended for patients with R1/R2 resection.~* Maintenance treatment with pembrolizumab alone is given for a total for 13 cycles. This is to be started within 4-8 weeks after surgery or within 4 weeks after postoperative radiotherapy."
62558046|NCT04197804||Tourette group|20 subjects with Tourette Syndrome undergoing an evaluation to identify the IQ. Subsequently, 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) concerning the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration of about 3 minutes) concerning the linguistic field.
62757955|NCT01267331|EXPERIMENTAL|stem cells injection|Direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG
62757956|NCT01267331|PLACEBO_COMPARATOR|palcebo intramyocardial injection|Direct intramyocardial injection of placebo containing saline and 5% human serum albumin during CABG.
62757957|NCT00670891|EXPERIMENTAL|HBOT|HBOT
62757958|NCT02638207|EXPERIMENTAL|0.5 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
62757959|NCT02638207|EXPERIMENTAL|1.0 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (1.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
62757960|NCT02638207|EXPERIMENTAL|2.0 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (2.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
62757961|NCT01298102|EXPERIMENTAL|influenza vaccine|Pandemrix vaccine (Influenza A/H1N1 2009)to be injected to renal transplant patients, haemodialyzed patients, and controls
62757962|NCT05037487|PLACEBO_COMPARATOR|Placebo|Smoked placebo cannabis
62757963|NCT05037487|EXPERIMENTAL|20 mg CBD|Smoked cannabis with CBD
62757964|NCT05037487|EXPERIMENTAL|20 mg CBD + 20 mg THC|Smoked cannabis with CBD and THC
62757965|NCT05037487|EXPERIMENTAL|20 mg THC|Smoked cannabis with THC
62757966|NCT02834585||Ultrasound|Patients undergoing Ultrasound
62757967|NCT02834585||Magnetic Resonance Imaging|Patients undergoing Magnetic Resonance Imaging
62757968|NCT02887053|EXPERIMENTAL|All subjects|All subjects will have an MRI examination
62757969|NCT02818036|EXPERIMENTAL|naltrexone|single 50mg dose of naltrexone
62757970|NCT02818036|PLACEBO_COMPARATOR|sugar pill|single sugar pill
62757971|NCT04919460|OTHER|clinical observation combined with pathological biopsy|Clinical observation (including inspection and palpation) combined with pathological biopsy. That is, inspecting and palpating the oral cavity and neck of the screened object. If positive lesions are found, then further pathological biopsy will be performed.
62558047|NCT04197804||Control group|20 subjects without Tourette Syndrome subjected to an evaluation to identify the IQ. Subsequently 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) concerning the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration of about 3 minutes) concerning the linguistic field.
62757972|NCT04919460|EXPERIMENTAL|Clinical observation, in vivo staining combined with pathological biopsy|Clinical observation (including inspection and palpation), in vivo staining (reagent: toluidine blue) combined with pathological biopsy. That is, inspecting and palpating the oral cavity and neck of the screened object. At the same time, in vivo staining is performed on each participant. The reagent used for staining is toluidine blue. As long as the screening subjects found positive lesions or abnormal living body staining, pathological biopsy was performed.
62757973|NCT00793572|EXPERIMENTAL|Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy|See Detailed Description
62757974|NCT04145960||Lymph node metastasis|Axillary lymph node metastasis ≥ 4 Lymph nodes
62757975|NCT01994772|ACTIVE_COMPARATOR|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5 ° C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5 ° C for 24 hours.
61987020|NCT03045887|EXPERIMENTAL|Part A Cohort 1: GSK 50 µg-GSK 200 µg-GSK 1000 µg|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, GSK2292767 200 µg in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
62379745|NCT02996175|ACTIVE_COMPARATOR|WISE|Standard of care sleep treatment enhanced with psychoeducation. 1 Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome 2 Introduction to understanding and interpreting results from clinical evaluations 3 Introduction to educational planning, expectations, and transition planning 4 Introduction to lifespan development and advocacy and support services available 5 Feedback on current concerns and methods for obtaining services to manage concerns
62558048|NCT06583226|ACTIVE_COMPARATOR|gelatin sponge + cyanoacrylate + suspending sutures|After administration of local anesthesia (2% articaine hydrochloride with epinephrine 1:100,000), palatal thickness will be measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area. Epithelialized gingival graft will be harvested. After a rectangular-shaped initial incision, a graft with 1-1.5 mm thickness will be harvested approximately 1.5 to 3 mm away from the gingival margins of the upper teeth. The donor site will be closed with a gelatin sponge + cyanoacrylate + suspending sutures.
62558049|NCT06583226|ACTIVE_COMPARATOR|gelatin sponge + cyanoacrylate + suspending sutures + coconut oil|After local anesthesia (2% articaine hydrochloride with epinephrine 1:100,000) administration, palatal thickness will be measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area and the mean value will be recorded as palatal tissue thickness. The epithelialized gingival graft will be harvested using 15 knives. After a rectangular-shaped initial incision, a graft with 1-1.5 mm thickness will be harvested approximately 1.5 to 3 mm away from the gingival margins of the upper teeth. The donor site will be closed with a gelatin sponge, cyanoacrylate suspending sutures and coconut oil.
62379746|NCT02491528|EXPERIMENTAL|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
62379747|NCT02491528|ACTIVE_COMPARATOR|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
62567593|NCT04720456|ACTIVE_COMPARATOR|SHAPE with Lumason|Up to 60 children (6-21 years of age) with a diagnosis of chronic liver disease, including some who will have portal hypertension who are followed at CHOP will be enrolled in this arm. A SHAPE measurement using the ultrasound contrast agent LUMASON® (sulfur hexafluoride lipid-type A microspheres) will be performed during a single visit. Two doses of 0.03 mL/kg (or 2.4 mL maximum) as per package labeling will be prepared and mixed with saline at a 1:10 dilution in a 50 ml bag of saline. The diluted preparation of Lumason will be through an IV line in a peripheral vein up to 4 mL/min using an infusion setup. The total duration of contrast agent infusion is expected to range from 4 to 8 minutes, which includes a 2 min calibration period followed by 2-6 minutes of SHAPE acquisition (i.e., ultrasound imaging).
62757976|NCT01994772|PLACEBO_COMPARATOR|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5 ° C for 48 hours.
62757977|NCT04944368|EXPERIMENTAL|Vaccine candidate|
62757978|NCT04944368|PLACEBO_COMPARATOR|Saline placebo|
62757979|NCT02700789||Pregnant women|Women with a positive urinary pregnancy test following in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) treatment will be invited to attend for an additional transvaginal ultrasound scan at 33-34 days gestation. This will be conducted by a single investigator with experience in early pregnancy ultrasound using a Voluson E8 machine with a high frequency (5-9MHz and 9-12MHz) transvaginal probe and following standard operating procedures.
62757980|NCT02607241|ACTIVE_COMPARATOR|BRS|"OCT-guided BRS implantation: implantation of a bioresorbable scaffold (BRS) under OCT guidance.~Note: Absorb™ from Abbott Vascular has been used as BRS until this product became unavailable in April 2017. Currently the recruitment is stopped due to this issue, until the use of another BRS gets final approval."
62757981|NCT02607241|EXPERIMENTAL|DCB-only|FFR-guided DCB-only PCI: PCI using DCB (SeQuent Please™, B Braun Melsungen GmBH) without stent implantation und FFR guidance
62757982|NCT00266838|PLACEBO_COMPARATOR|Lacrystat|Lacrystat
62757983|NCT00266838|ACTIVE_COMPARATOR|Maxidex|Applying Maxidex
61987021|NCT03045887|EXPERIMENTAL|Part A Cohort 2: Placebo-GSK 500 µg-GSK 2000 µg|Subjects will receive an inhaled single dose of placebo in Period 1, GSK2292767 500 µg in Period 2, and GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
61987022|NCT03045887|EXPERIMENTAL|Part A Cohort 2: GSK 100 µg-Placebo- GSK 2000 µg|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, placebo in Period 2, and GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
62757984|NCT00096499|EXPERIMENTAL|Treatment (ispinesib)|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62757985|NCT05756114|ACTIVE_COMPARATOR|Psychoeducation Condition|Participants receive a weekly email with a Qualtrics survey link containing psychoeducational content.
62757986|NCT05756114|EXPERIMENTAL|Support Group Condition|Participants will attend six weekly online SMART Recovery meetings in groups of five to eight.
62757987|NCT04385641|EXPERIMENTAL|Dose-finding (Group A)|"In this study, the dose was explored according to the 3+3 mode, in which group A was divided into three dose groups: 1.5\*10＾9 group, 2\*10＾9 group and 3\*10＾9 group. If DLT occurs in one of the first three subjects in each dose group within four weeks after cell infusion, three subjects will continue to be included. If more than 1/6 cases of DLT appear in 6 subjects with 1.5\*10＾9 dose, the dose level and/or cell infusion frequency and method will be reduced after discussion between the investigator, the collaborator and DMC. If DLT did not occur in the first 3 subjects within 4 weeks after receiving 1.5\*10＾9 cell infusion，another three subjects were enrolled into the group received 2\*10＾9 cell infusion. DLT did not occur within 4 weeks after cell infusion, it will increase to 3\*10＾9 dose group. That is to say, the first three subjects were included for observation for 4 weeks in the 3\*10＾9 dose group, if DLT did not occur, there will be another 3 cases, reaching to 6 subjects."
62757988|NCT04385641|EXPERIMENTAL|Extended research (Group B)|If DLT≤1/6, the dose will not be increased. This dose will also be used as the treatment dose of group B. If DLT is more than 1/6 in the 3\*10＾9 dose group, three subjects will be added in 2\*10＾9 dose group. If DLT ≤1/6 in 4-week observation, the 2\*10＾9 will be the maximum tolerable dose, and will be used as the treatment dose of group B. The subjects in group A were enrolled first, after at least 4 weeks of observation for all subjects, six subjects will be included in group B.
62757989|NCT00221715|EXPERIMENTAL|1|bypass by autologous saphenous vein
62757990|NCT00221715|ACTIVE_COMPARATOR|2|bypass by dacron or PTFE Prosthesis
62757991|NCT04294316|OTHER|Sonovue group|ICU patients with successful resuscitation after out-hospital or in-hospital cardiorespiratory arrest who are eligible for enhanced-contrast brain ultrasound, extracranial echo-color duplex, and ocular ultrasound.
62757992|NCT05933642|ACTIVE_COMPARATOR|Treatment group|Intravenous (IV) infusion of (aminophylline 150mg and frusemide 120mg diluted to 50ml NS), IV load 10ml over 60 minutes, followed by IV infusion of 4 ml/hour
62757993|NCT05933642|ACTIVE_COMPARATOR|Control group|IV infusions of furosemide (120mg diluted to 50ml NS), IV load 10ml over 60 minutes, followed by IV infusion of 4 ml/hour
62757994|NCT06351319||training group|
62757995|NCT06351319||validation group|
62757996|NCT04960878|PLACEBO_COMPARATOR|Placebo|1.5 g maltodextrin in a sachet once daily for 8 weeks.
62757997|NCT04960878|EXPERIMENTAL|Synbiotic|1.5 g synbiotics supplement of Lactobacillus rhamnosus HN001 (1.5×10\^11 CFU) , Bifidobacterium lactis HN019 (7.5×10\^10 CFU), and 500mg fructooligosaccharides in a sachet once daily for 8 weeks.
62757998|NCT02962271||Psoriatic Arthritis|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
61987023|NCT03045887|EXPERIMENTAL|Part A Cohort 2: GSK 100 µg-GSK 500 µg-Placebo|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, GSK2292767 500 µg in Period 2 and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.
62757999|NCT02962271||Psoriasis|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
61987024|NCT03045887|EXPERIMENTAL|Part A Cohort 2: GSK 100 µg-GSK 500 µg-GSK 2000 µg|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, GSK2292767 500 µg in Period 2, GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
61987025|NCT03045887|EXPERIMENTAL|Part B: GSK|Subjects will receive inhaled repeat dose of GSK2292767 2000 µg once daily for 14 days.
61987026|NCT03045887|EXPERIMENTAL|Part B: Placebo|Subjects will receive inhaled repeat dose of placebo once daily for 14 days.
62567594|NCT04720456|EXPERIMENTAL|Longitudinal SHAPE|SHAPE will be used to monitor subjects identified in the initial examination as having portal hypertension for up to 18 months. These subjects will undergo laboratory testing every 6 months as a part of their clinical standard of care. During these times the SHAPE examination will also be repeated using the same ultrasound contrast agent and infusion methodologies (including dosages) as during the initial study.
62758000|NCT05074888|EXPERIMENTAL|Prospekta|Tablet for oral use. 1 tablet twice daily. The tablets are taken outside of meals (between meals or 15 minutes before eating or drinking), keep the tablets in the mouth, without swallowing, until completely dissolved.
61987027|NCT02994160|EXPERIMENTAL|Fast electrodes|Implant temporary Fast electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
61987028|NCT04242004|EXPERIMENTAL|DHA group|
62758001|NCT05074888|PLACEBO_COMPARATOR|Placebo|Tablet for oral use. Placebo using Prospekta scheme.
62758002|NCT04599868|ACTIVE_COMPARATOR|Low dose of magnesium sulfate group|patients will receive 4 g intravenous loading dose of magnesium sulfate on 150 ml saline over 20 minute period. Patients then will receive maintenance therapy with magnesium sulfate 1g / h
62758003|NCT04599868|ACTIVE_COMPARATOR|High dose of magnesium sulfate group|patients will receive 4 g intravenous loading dose of magnesium sulfate on 150 ml saline over 20 minute period. Patients then will receive maintenance therapy with magnesium sulfate 2g/h
62758004|NCT03467984|EXPERIMENTAL|LBVE|Infants will receive a 0.5mL intramuscular injection of LBVE at 6,10 and 14 weeks of age
62758005|NCT03467984|ACTIVE_COMPARATOR|Prevnar13|Infants will receive a 0.5mL intramuscular injection of Prevnar13 at 6,10 and 14 weeks of age
62758006|NCT04790513|EXPERIMENTAL|LIB003 (lerodalcibep)|300 mg SC Q4W
61987029|NCT04242004|PLACEBO_COMPARATOR|placebo group|
62758007|NCT04790513|ACTIVE_COMPARATOR|evolocumab|420 mg SC Q4W
62379748|NCT05663827|EXPERIMENTAL|Ruxolitinib add-on group|Once diagnosed with steroid-refractory GVHD, after discussion with family, as per their willing, Ruxolitinib will be administered as add-on therapy. Its dose depends on participants' age and body weight. Usually a dosage of 5mg once per day will be applied as initiation and titrated in accordance with clinical response.
62379749|NCT00866606|EXPERIMENTAL|Benefix|Subjects received on-demand treatments with BeneFIX over a 6-month (calendar day) period.
62379750|NCT01021293|EXPERIMENTAL|Poliorix Group|Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Poliorix™ (IPV) vaccine at 2, 3 and 4 months of age, administered intramuscularly into the anterolateral side of the right thigh.
62379751|NCT01021293|ACTIVE_COMPARATOR|Control Group|Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Oral Poliomyelitis Vaccine (OPV) at 2, 3 and 4 months of age, according to the vaccination policy recommended in China.
62379752|NCT04928521|ACTIVE_COMPARATOR|ESP block with 20 mL local anesthetic solution|An erector spinae plane block will be performed at the level of the 5th thoracic vertebrae with 20 mL of 0.25% bupivacaine solution under ultrasound guidance before the operation.
62379753|NCT04928521|ACTIVE_COMPARATOR|ESP block with 30 mL local anesthetic solution|An erector spinae plane block will be performed at the level of the 5th thoracic vertebrae with 30 mL of 0.25% bupivacaine solution under ultrasound guidance before the operation.
62379754|NCT05673382|EXPERIMENTAL|Treatment group|Eight weeks of individually tailored ICBT, were participants receives in total 8 modules out of 20 possible depending on their current problems and described situation with weekly support by a therapist.
62379755|NCT05673382|NO_INTERVENTION|Control group|The control group is a wait-list control condition. Participants are instructed to wait. After the treatment group has finished their treatment and post-treatment measures has been collected, the control group receive the same treatment as the treatment group got.
62379756|NCT00462488|ACTIVE_COMPARATOR|Treatment Schedule A -|"Induction Phase is a single intravesical dose of Vicinium at 30 mg in 40 mL PBS once per week for 6 weeks. If free of disease at 12 weeks after the first instillation, the subject enters Maintenance dosing in which 30 mg of Vicinium is administered once per week for 3 weeks followed by 9 weeks of no therapy.~If the subject had histologically confirmed disease that is stage \<T2, they repeat the Induction phase dosing. If the subject is free of disease, the subject enters the maintenance dosing phase of every 12 weeks (3 weeks of therapy followed by 9 weeks of no therapy until disease recurrence is confirmed by positive biopsy or up to a maximum of Week 51 (end-of-study \[EOS\])."
62379757|NCT00462488|ACTIVE_COMPARATOR|Treatment Schedule B|"Induction Phase is a single intravesical dose of Vicinium at 30 mg in 40 mL PBS once per week for 12 weeks followed by 1 week of no therapy.~If 13 weeks after the first instillation of Vicinium the subject is free of disease, they have a break from therapy before entering Maintenance dosing in which 30 mg of Vicinium is administered once weekly for 3 weeks followed by 9 weeks of no therapy. If the subject is free of disease, additional maintenance cycle(s) are repeated every 12 weeks (3 weeks of therapy followed by 9 weeks of no therapy until disease recurrence is confirmed by positive biopsy or up to a maximum of Week 57 (EOS)."
62379758|NCT01292850||Healthy Volunteers|15 healthy volunteers were recruited
62758008|NCT04790513|ACTIVE_COMPARATOR|alirocumab|300 mg SC Q4W
62379759|NCT01357720|EXPERIMENTAL|Quinvaxem|
62379760|NCT01357720|ACTIVE_COMPARATOR|Tritanrix Hib/HepB + Quinvaxem|
62758009|NCT02138474|EXPERIMENTAL|Lacticum acidum homaccord|Lacticum acidum homaccord 30 mL bottle of medicated sucrose pillules take 5 pillules of the medication in the morning and in the evening for 4 weeks
62558050|NCT04160650|EXPERIMENTAL|Educational nursing intervention|"Patients in experimental group receive standard care and one-hour educational session. Patients are provided knowledge of~* healthy diet~* malnutrition, its prevalence and consequences for patients with CRC undergoing CT~* side effects impairing nutrition intake during CT treatment.~* prevention and self-care methods of the side effects Teach-back is used to verify participants' understanding. Empowering effect is confirmed by using active listening and asking patients' individual side effects, self-care strategies and need of additional knowledge in the beginning of the session and supporting patients' self-care methods when they have been applicable and effective. Additional knowledge of each theme is offered. To reinforce the intervention effect patients receive after the first CT a self-monitoring diary including assessment of side effects prevalence and intensity (NRS 0-10) before and after the self-care strategies. They return diaries by the 5th cycle of CT."
62567595|NCT04082026|EXPERIMENTAL|Early Adolescent Skills for Emotions (EASE)|EASE has four core features: Seven group sessions for young adolescents and three for their caregivers; Delivered by non-specialists; Trans-diagnostic: addressing depression, anxiety, distress, and other problems as defined by the young people themselves; and Designed for young people and their caregivers in low- and middle-income countries living in communities affected by adversity.
62758010|NCT02138474|PLACEBO_COMPARATOR|Placebo|Unmedicated sucrose pillules, take 5 pillules twice daily for 4 weeks
62758011|NCT01616940|NO_INTERVENTION|Standard-of-care|Standard-of-care at 3 demonstration sites includes: HIV medical care, medical case management, and referral to substance abuse, mental health, and housing services.
62758012|NCT01616940|EXPERIMENTAL|Enhanced Peer Intervention|Provides emotional, informational, and instrumental peer support, in addition to Standard-of-Care.
62379761|NCT03723811|EXPERIMENTAL|1|SJP002 BID
62379762|NCT03723811|EXPERIMENTAL|2|SJP002 QID
62379763|NCT03723811|PLACEBO_COMPARATOR|Placebo 1|SJP002 Placebo 1
62379764|NCT03723811|PLACEBO_COMPARATOR|Placebo 2|SJP002 Placebo 2
62379765|NCT01057394|ACTIVE_COMPARATOR|Radiofrequency Ablation|PVI using RF ablation
62758013|NCT00642369|EXPERIMENTAL|quetiapine fumarate|quetiapine fumarate was administered 25mg on the 1st day,738±41mg/day on the 14th day, and 738±48mg/day on the 28th day.
62758014|NCT00642369|ACTIVE_COMPARATOR|haloperidol|haloperidol was administered 2mg on the 1st day,16±7mg/day on the 14th day, and 18±6mg/day on the 28th day.
62758015|NCT02059759|PLACEBO_COMPARATOR|Placebo|"Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).~Intervention: Placebo"
62758016|NCT02059759|EXPERIMENTAL|1.0 IL-2|"Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).~Intervention: 1.0 MIU IL-2 per day"
62758017|NCT02059759|EXPERIMENTAL|2.0 IL-2|"Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).~Intervention: 2.0 MIU IL-2 per day"
62758018|NCT00293709||Patients with Psoriatic Arthritis|
62758019|NCT03934970||Diabetic Neuropathy|Thirty Egyptian patients with type 2 diabetes mellitus complaining of symptoms suggestive of peripheral neuropathy including 12 males and 18 females with a mean of 50.90 ± 9.18.
62758020|NCT03934970||Healthy Control Subjects|Fifteen normal healthy Egyptian volunteers including10 males and 5 females with a mean age of 45.67±7.77 years.
62758021|NCT03162484|EXPERIMENTAL|Physical activity intervention group|"The intervention consisted in doing physical activities two to four times per week, each session last 60 minutes. The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.~Each session starts with a warm up. The main part of the session is divided into two sections. The first section includes different exercises to improve balance, mobility and coordination. The second section is comprised of communicative and cooperative games. The session finishes with a cool-down."
62758022|NCT03162484|NO_INTERVENTION|Control group|People in control group did not receive any physical activity program.
62758023|NCT01391598|ACTIVE_COMPARATOR|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
62758024|NCT01391598|PLACEBO_COMPARATOR|Saline|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
62758025|NCT01556776|EXPERIMENTAL|Lenalidomide|lenalidomide maintenance following firstline treatment with FCR, BR, FR, or FC(if Rituximab is contraindicated)
62758026|NCT01556776|PLACEBO_COMPARATOR|Placebo|placebo
61987030|NCT05804175||Post surgical (non-cardiac) PACU patients with anticipated overnight stay.|"In this study investigators will recruit patients that meet the following criteria:~* Inclusion Criteria:~  * ≥18 years old undergoing non-cardiac surgery~ * Post-operative patients admitted to the PACU and expected to stay in the hospital for at least overnight~ * Receiving supplemental oxygen via face mask in the PACU~ * On continuous SpO2 saturation monitoring~ * Receiving standard postoperative of care~* Exclusion Criteria:~  * Requirement for any form of postoperative invasive ventilatory support~ * Patients receiving only local or topical anesthesia~ * Day/outpatient surgery~ * Unable to cooperate with the application of the study device~ * Surgical/nursing/anesthesia staff suggest no study-related monitoring because of medical situation"
62379766|NCT01057394|EXPERIMENTAL|Visually Guided Ablation|PVI using visually guided ablation with an endoscopic ablation system
62758027|NCT00741195|EXPERIMENTAL|1|Docetaxel/Bevacizumab
62758028|NCT02443194|ACTIVE_COMPARATOR|Group # 1- ACTIVE|"Patients who underwent resection or biopsy of glioblastoma (newly diagnosed glioblastoma), will randomization ratio of 1: 1 by the pharmacist (by age, KPS, the degree of tumor resection) two research groups:~Group # 1: consisting of 50 patients who will be treated immediately after diagnosis, 30 mg Cymbalta duloxetine -morning for a week and then a dose exceeding 60 mg for 3 months."
62758029|NCT02443194|PLACEBO_COMPARATOR|Group # 2-PLACEBO|Group # 2 will include 50 patients treated immediately after diagnosis with placebo for 3 months
61987031|NCT00301210|EXPERIMENTAL|1|tramadol dose 1
61987032|NCT00301210|EXPERIMENTAL|2|tramadol dose 2
61987033|NCT01555268|EXPERIMENTAL|Arm A (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 22.
61987034|NCT01555268|EXPERIMENTAL|Arm B (trebananib, cytarabine)|Patients receive trebananib as in Arm A. Patients also receive cytarabine SC BID on days 1-14 of course 1 and days 1-7 of subsequent courses.
62758030|NCT06079073|EXPERIMENTAL|Application plus treatment module|"The following exercises are pre-recorded and presented in the treatment module:~Tongue~1. Tongue brushing~2. Tongue sliding~3. Tongue suction~4. Tongue down Soft palate~1. Elevate soft palate and uvula 2. Balloon blow Facial~1. Put your finger in the oral cavity against your cheek. Pull against your finger with the cheek muscles.~2. Air pump Exercise adherence is registered in a study application"
62758031|NCT06079073|NO_INTERVENTION|Application awaiting access to treatment module|Participants receiving a code not unlocking the treatment module will have full access to all other parts of the mobile app. After 90 days, during the outcome evaluation, all participants will receive a new code unlocking the treatment module in order to keep outcome evaluators blinded.
62758032|NCT01893372|EXPERIMENTAL|Eltrombopag|Eltrombopag 200 mg by mouth daily in a 28 day cycle.
62758033|NCT01893372|EXPERIMENTAL|Eltrombopag + Hypomethylating Agent (HMA)|"Eltrombopag in combination with continuation of hypomethylating agent in 28-day cycles. Eltrombopag 200 mg by mouth daily in a 28 day cycle.~The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study. Eltrombopag should be initiated at the start of the next HMA cycle whenever possible so the start date of both agents is consistent."
62758034|NCT05242666|OTHER|DCM1: MRI Spinal Cord|3T MR Imaging of the cervical spinal cord, before and at 3-6 months after surgery.
62758035|NCT05242666|OTHER|DCM2: MRI Brain and Spinal Cord|3T MR Imaging of the brain and cervical spinal cord, before and at 3-6 months after surgery. A subset will also be invited to undergo 7T MRI Brain and Spinal Cord Imaging.
62758036|NCT05242666|OTHER|DCM3: [11C]-PIB MR/PET Cervical Spinal Cord|\[11C\]PIB PET/MR Imaging of the cervical spinal cord, before and at 3-6 months after surgery.
62758037|NCT05242666|OTHER|Healthy Volunteer: MRI Brain and Spinal Cord|Age-Matched Healthy Controls will undergo MRI Brain and Spinal Cord. A subset will also be invited to undergo interval imaging at 3-6 months.
62758038|NCT04551001|EXPERIMENTAL|Cold forcep|Cold forcep polypectomy performed for polyps \<=3mm.
62758039|NCT04551001|EXPERIMENTAL|Cold snare|Cold forcep polypectomy performed for polyps \<=3mm.
62758040|NCT05179083|EXPERIMENTAL|High-impact Exercise|
62758041|NCT05179083|ACTIVE_COMPARATOR|Low-impact Exercise|
62758042|NCT01341691|PLACEBO_COMPARATOR|Placebo 20mg|
62758043|NCT01341691|ACTIVE_COMPARATOR|K2CG 60 mg extender|
62758044|NCT01341691|ACTIVE_COMPARATOR|K2CG 60 mg|
62758045|NCT01341691|ACTIVE_COMPARATOR|K2CG 20mg extender|
62758046|NCT01341691|ACTIVE_COMPARATOR|K2CG 20mg|
62758047|NCT01341691|PLACEBO_COMPARATOR|Placebo 60mg|
62758048|NCT05173610|EXPERIMENTAL|SBRT arm|Patients will be treated with stereotactic body radiotherapy (SBRT) for oligometastasis from hepatocellular carcinoma
62758049|NCT02117895|EXPERIMENTAL|Pancreatectomy & celiac plexus resection|Left celiac plexus resection will be performed besides standard distal pancreatectomy. Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
62758050|NCT02117895|ACTIVE_COMPARATOR|Pancreatectomy|Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
62758051|NCT01620164|OTHER|Parkinsonian patients OFF/ON|9 patients will be evaluated with psychophysical measurements of 3D perception, in OFF then ON conditions
62758052|NCT01620164|OTHER|healthy subjects|Healthy subjects will be evaluated with psychophysical measurements of 3D perception, without treatment
62758053|NCT01620164|OTHER|Parkinsonian patients ON/OFF|9 patients will be evaluated with psychophysical measurements of 3D perception, in ON and then OFF conditions
62758054|NCT03647111||Cohorts 1|
62758055|NCT02357862||Mitral Valve Annuloplasty|All eligible patients
62758056|NCT03225768|EXPERIMENTAL|Guided Training|
61987035|NCT00446407|EXPERIMENTAL|Collaborative Stepped Care|Screening, Antidepressants, Psychosocial interventions (psychoeducation, IPT, adherence management) by Health Counselor, support and supervision by Psychiatrist.
61987036|NCT00446407|ACTIVE_COMPARATOR|Enhanced Usual Care|
61987037|NCT01952756|ACTIVE_COMPARATOR|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
61987038|NCT01952756|PLACEBO_COMPARATOR|Dummy Placebo|One tablet twice per day for 12 weeks
61987039|NCT01344603||epidural|
61987040|NCT01344603||standard|
62758057|NCT03208114|EXPERIMENTAL|Group A|Receiving the written information of the name of a breast milk substitute on the infant's discharge documents
62758058|NCT03208114|NO_INTERVENTION|Group B|Not receiving the written information of the name of a breast milk substitute on the infant's discharge documents
62758059|NCT02344979||Group rHuTPO|Patients were treated with recombinant human thrombopoietin(rHuTPO)on d2,d4,d6,d9 of chemotherapy cycle.
62758060|NCT02344979||Group rHuIL-11|Patients were treated with recombinant human interleukin-11(rHuIL-11)on d9-d15 after chemotherapy.
62758061|NCT01975337|EXPERIMENTAL|End stage renal disease participants|End stage renal disease (ESRD) participants received a single 400 mg (2 x 200 mg capsules) oral dose of alisporivir with food at any time during the 2 hours after completion of hemodialysis on Day 1.
62558051|NCT04160650|NO_INTERVENTION|Standard care|"Patients in control group receive standard care, information of~* general CT induced side effects and their self-care; nausea, diarrhoea, obstipation and sores in the mouth, peripheral neuropathy symptoms, local venous irritation, heart symptoms, mucous and skin irritation~* side-effects' self-monitoring, fluid intake, medication dose changes, effect of CT~* weight control~* taste alteration~* cold sensitivity~* variable diet~* dietary supplements~* available dietitian services~They receive a self-monitoring diary, which includes only side effects and their intensity (NRS 0-10)."
61987041|NCT06390969||Survey respondent|All respiratory doctors who respond to the survey
61987042|NCT05582668||Cohort 1|Cohort 1: Older patients with overweight, obesity after bariatric surgery
61987043|NCT05582668||Cohort 2|Cohort 2: Older patients with overweight, obesity without bariatric surgery
62379767|NCT01349842|EXPERIMENTAL|Circulating Tumor Cells|Centralized determination of CTC by CellSearch® technology (Veridex), the only technology currently validated in clinical practice for the early evaluation of response to chemotherapy of breast cancers. This evaluation is performed by blood sampling comparing the CTC level before the first injection of each new line of chemotherapy. Chemotherapy can only be continued in the case of a positive CTC response. Discontinuation of chemotherapy can also be decided by the clinician on the basis of other clinical or radiological arguments.
62379768|NCT01349842|OTHER|Clinical and radiological criteria|Management of chemotherapy according to the usual clinical and radiological criteria adopted by the patient's attending physician.
62379769|NCT05096442|EXPERIMENTAL|Genoss® DCB|Paclitaxel Coated PTCA Balloon Catheter
62379770|NCT05096442|ACTIVE_COMPARATOR|SeQuent® Please NEO|Paclitaxel Coated PTCA Balloon Catheter
62379771|NCT01738568|EXPERIMENTAL|Exercise|Aerobic exercise
62379772|NCT01649752|EXPERIMENTAL|Differentiated stem cell therapy group|After ovum pick-up, MSC differentiated to endometrium is deposited in the uterine cavity.Embryo transfer will be done at day 5 at the blastocyst stage.
62379773|NCT01649752|EXPERIMENTAL|undifferentiated stem cell therapy group|Immediately postmenstrual undifferentiated MSC is deposited in the uterine cavity. Ovum pick-up will be done as usual.Embryo transfer will be done at day 5 at the blastocyst stage.
62379774|NCT01649752|NO_INTERVENTION|Control group|ovum pick-up as usual and embryo transfer at day 5 at the blastocyst stage.
62379775|NCT04973722|EXPERIMENTAL|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously
62379776|NCT04973722|ACTIVE_COMPARATOR|Prolia|60 mg/1 ml, once every 6 months administered subcutaneously
62379777|NCT05066802|EXPERIMENTAL|modified FOLFIRINOX|oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 42\~46h continuous infusion, every other week for 6 cycles (12 weeks).
62379778|NCT02934061|EXPERIMENTAL|Tizaspray®|Tizaspray® administered intranasally in patients with acute low back pain
62379779|NCT02934061|ACTIVE_COMPARATOR|Sirdalud®|Sirdalud® 2 mg tablets administered in patients with acute low back pain
62379780|NCT04729010|SHAM_COMPARATOR|Randomized Subjects receive a sham acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
62379781|NCT04729010|ACTIVE_COMPARATOR|Randomized Subjects receive a real acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
62379782|NCT02489656|EXPERIMENTAL|Coloplast Hydrocoated silicone JJ stent|Double loop ureteral stent endoscopic placement
62379783|NCT02489656|ACTIVE_COMPARATOR|Boston Percuflex Plus JJ stent|Double loop ureteral stent endoscopic placement
62379784|NCT03530189||Normoglycemic group|"The infant will enter this group if a single blood glucose concentration is between 2.1 and 2.5 mmol/l (38-45 mg/dL), or a single blood glucose concentration is between 8.6 - 10 mmol/l (155-180 mg/dL) with all other measures between 2.6 and 8.5 mmol/l (47-153 mg/dL).~To all premature infants intravenous 10% dextrose at 60-90 mL/kg/day will be started as soon as possible after birth."
62558052|NCT05977192|EXPERIMENTAL|Standard MI|
62558053|NCT05977192|EXPERIMENTAL|Intensive MI|
62558054|NCT05977192|EXPERIMENTAL|MOTIVACC|
62558055|NCT05045287|EXPERIMENTAL|hypofractionated radiation therapy|receive chest wall and nodal irradiation at a dose of 43.5 Gy in 15 fractions over 3 weeks
62558056|NCT00634946|EXPERIMENTAL|I|
62558057|NCT00634946|EXPERIMENTAL|II|
62558058|NCT00634946|EXPERIMENTAL|III|
62558059|NCT00634946|PLACEBO_COMPARATOR|IV|
62558060|NCT02026050|ACTIVE_COMPARATOR|intraarticular dexamethasone|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2 ml serum phsyologic and after surgery 2 ml 8 mg dexamethasone+ 8 ml serum phsyologic administration for intraarticular
61987044|NCT04843748|EXPERIMENTAL|single arm|single arm open label study
62758062|NCT01975337|ACTIVE_COMPARATOR|Matched healthy participants|Healthy participants (matched to those with end stage renal disease by sex, age, weight, and smoking status), received a single 400 mg (2 x 200 mg capsules) oral dose of alisporivir with food on Day 1.
62758063|NCT03622112|EXPERIMENTAL|AZD7594 Dose 1|The randomized subjects will receive AZD7594 55 μg/50 μg (nominal/delivered dose), oral inhalation via dry powder inhaler (DPI) once daily.
62758064|NCT03622112|EXPERIMENTAL|AZD7594 Dose 2|The randomized subjects will receive AZD7594 99 µg/90 µg, oral inhalation via DPI once daily.
62558061|NCT02026050|ACTIVE_COMPARATOR|interscalene dexamethasone|interscalene brachial plexus was preoperative performed 30 ml 0.5 % bupivacaine added 2 ml 8mg dexamethasone and after surgery 10 ml serum phsyologic administration for intraarticular
62758065|NCT03622112|EXPERIMENTAL|AZD7594 Dose 3|The randomized subjects will receive treatment with AZD7594 198 µg/180 µg, oral inhalation via DPI once daily.
62758066|NCT03622112|EXPERIMENTAL|AZD7594 Dose 4|The randomized subjects will receive treatment with AZD7594 396 µg/360 µg, oral inhalation via DPI once daily.
62758067|NCT03622112|EXPERIMENTAL|AZD7594 Dose 5|The randomized subjects will receive treatment with AZD7594 792 µg/720 µg, oral inhalation via DPI once daily.
62758068|NCT03622112|PLACEBO_COMPARATOR|Placebo|The randomized subjects will receive AZD7594 matching placebo oral inhalation via DPI once daily.
62758069|NCT03622112|ACTIVE_COMPARATOR|Fluticasone Furoate|The randomized subjects will receive treatment with fluticasone furoate (FF) oral inhalation via DPI, 100 µg per nominal dose, once daily (open-label).
62558062|NCT02026050|PLACEBO_COMPARATOR|serum phsyologic|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
62558063|NCT01530464|ACTIVE_COMPARATOR|Aminophylline|
62758070|NCT02594800|ACTIVE_COMPARATOR|standard dose|Drug: Rosuvastatin rosuvastatin 10 mg daily for 52 weeks.
61987045|NCT00511615||1|Patients with cervical cancer scheduled to be treated with the LEEP procedure.
61987046|NCT01420445|EXPERIMENTAL|YHD001 dose level 1|YHD001 dose level 1
61987047|NCT01420445|EXPERIMENTAL|YHD001 dose level 2|YHD001 dose level 2
61987048|NCT01420445|ACTIVE_COMPARATOR|Pelargonium sidoides extract|Pelargonium sidoides extract (Syrup)
61987049|NCT01420445|PLACEBO_COMPARATOR|Placebo|Placebo for YHD001 \& active comparator(syrup)
61987050|NCT01879774|OTHER|Patients with hyponatremia|Neuropsychological and motoric tests are conducted in patients with hyponatremia.
61987051|NCT01879774|OTHER|Patients with normal serum sodium|Neuropsychological and motoric tests are conducted in patients with normal serum sodium.
61987052|NCT01356797|ACTIVE_COMPARATOR|hyperbaric bupivacaine|
61987053|NCT01356797|EXPERIMENTAL|hypobaric levobupivacaine with fentanyl|
62558064|NCT01530464|ACTIVE_COMPARATOR|Ambrisentan|
62558065|NCT01530464|EXPERIMENTAL|Aminophylline and ambrisentan|Treatment 3: Aminophylline, 500 mg plus Ambrisentan, 5 mg
62558066|NCT03298204||Chemoradiotherapy|
62558067|NCT03298204||Chemoradiotherapy following chemotherapy|
62558068|NCT03298204||Chemoradiotherapy followed by chemotherapy|
62558069|NCT01403051|EXPERIMENTAL|Arm A: EFV/FTC/TDF plus vitamin D3 and calcium carbonate|Participants were administered FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), calcium carbonate and vitamin D3 4000 IU.
62758071|NCT02594800|EXPERIMENTAL|intensive dose|Drug: Rosuvastatin rosuvastatin 20 mg daily for 52 weeks.
62758072|NCT03029546||Glucose load|"50 subjects undergoing routine gestational diabetes screen with 50g glucose load.~5 subjects undergoing follow-up gestational diabetes screen with 100g glucose load."
62758073|NCT03029546||Control|50 subjects undergoing water ingestion with the same study measurements as the glucose load group at the same time intervals.
62758074|NCT05405491|EXPERIMENTAL|PCR group|
62758075|NCT05405491|SHAM_COMPARATOR|Control group|
62379785|NCT03530189||Group with impaired glucose|"The infant can be hypoglycemic, hyperglycemic or unstable. The infant will be hypoglycemic if blood glucose concentration is ≤2,5 mmol/l (45 mg/dL) on ≥2 measures \>1 hour apart, or any blood glucose concentration is≤2,0 mmol/l (36 mg/dL). Hypoglycemia will be treated with intravenous bolus of 10% dextrose.~The infant will be hyperglycemic if blood glucose concentration is ≥8,6 mmol/l (155 mg/dL) on ≥2 measures \>1 hour apart, or any blood glucose concentration ≥10,1 mmol/l (182 mg/dL). Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion.~The infant will be unstable if at least 1 blood glucose concentration is ≤2,5 mmol/l (45 mg/dL) and ≥1 blood glucose concentration is ≥8,6 mmol/l (155 mg/dL)."
62379786|NCT00958113||Autoimmune Thyroid Disease|Patients with Hashimoto's disease or Graves' disease
62558070|NCT01403051|EXPERIMENTAL|Arm B: EFV/FTC/TDF plus vitamin D placebo and calcium placebo|Participants were administered FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), a placebo for calcium carbonate, and a placebo for vitamin D3.
62758076|NCT00572611|EXPERIMENTAL|I|Single oral dose of 20 mg \[14C\]-bilastine
62758077|NCT01836796|ACTIVE_COMPARATOR|Lactobacillus Reuteri low|100 million Lactobacillus Reuteri once daily
62758078|NCT01836796|ACTIVE_COMPARATOR|Lactobacillus Reuteri High|10 billion Lactobacillus Reuteri once daily
62379787|NCT00958113||Unaffected Population|Population not known to be affected by Hashimoto's Disease or Graves' Disease
62558071|NCT03367819|EXPERIMENTAL|Phase 1: mCRPC/NSCLC|Isatuximab dose 1 and REGN2810 predefined dose
62758079|NCT01836796|PLACEBO_COMPARATOR|Placebo|
62758080|NCT06325293|ACTIVE_COMPARATOR|IMP arm|"Azithromycin Pfizer® powder for oral suspension:~1 daily dose for 5 days, 10mg/kg/day on day 1 and 5mg/kg/day on days 2-5"
62758081|NCT06325293|PLACEBO_COMPARATOR|Placebo arm|5 days of placebo
62558072|NCT03367819|EXPERIMENTAL|Cohort A-1: mCRPC, isatuximab and REGN2810 combination|Participants with mCRPC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
62758082|NCT01448824|EXPERIMENTAL|Part 1 (Cohort A): 100 mg, 1800 mg LY2484595, Placebo|"Period 1: Participants will receive either 100 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14 of Period 1.~Washout period lasting ≥14 days.~Period 2: Participants will receive either 1800 mg LY2484595 tablets or placebo tablets QD by mouth on Days 1 through 14 of Period 2."
62379788|NCT06425224|ACTIVE_COMPARATOR|Group 1: Tens therapy + dapoxetine placebo on demand.|"There will be 3 weekly therapy sessions for 12 continuous weeks, lasting 30 minutes each. 20 Hertz with a pulse width of 200 µsec will be administered in each session. The intensity will be applied to each patient depending on individual tolerance. TENT therapy will be performed as follows:~1. The active electrode is placed and adhered 3 - 5 cm above the internal malleolus and 1 cm behind the tibia.~The second reference electrode is attached to the calcaneus.~Continuous current, Frequency: 20 Hz Pulse width: 200 µsec, Time: 30 min. Intensity: to the patient's tolerance, gross motor perception to verify correct application, upon reaching it, increase the intensity to clearly sensory activation.~They will also receive dapoxetine placebo (capsules with only excipients without active ingredient) as needed, taken 3 to 4 hours before sexual intercourse during the 12 weeks of the intervention."
62758083|NCT01448824|EXPERIMENTAL|Part 1 (Cohort B): 300 mg LY2484595, Placebo|Participants will receive either 300 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
62379789|NCT06425224|ACTIVE_COMPARATOR|Group 2: Standard treatment (dapoxetine 30 mg as needed) + placebo therapy.|Patients in this group will receive dapoxetine 30 mg, taken 3 to 4 hours before sexual intercourse, for the 12 weeks of the study. In addition to the medication, patients will receive three weekly sessions of placebo therapy for twelve continuous weeks, lasting 30 minutes each. For this, the black electrode will be placed on the external malleolus and the red one 4 finger widths towards the head on the lateral edge of the tibia. 20 Hertz with a pulse width of 200 µsec will be administered in each session.
62558073|NCT03367819|EXPERIMENTAL|Cohort A-2: mCRPC, isatuximab monotherapy|Participants with mCRPC will be given isatuximab dose 2
62558074|NCT03367819|EXPERIMENTAL|Phase 2 Cohort B: NSCLC|Participants with NSCLC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
62558075|NCT03367819|EXPERIMENTAL|Possibly Phase 2 Cohort C: mCRPC|Isatuximab dose 3 will be given in combination with REGN2810 predefined dose or isatuximab dose 3 will be given as monotherapy in participants with mCRPC
62558076|NCT03367819|EXPERIMENTAL|Possibly Phase 2 Cohort D: NSCLC|Isatuximab dose 3 will be given in combination with REGN2810 predefined dose
62558077|NCT00001850||Children|with reproductive disorders
62558078|NCT00001850||Men|with reproductive disorders
62558079|NCT00001850||Woman|with reproductive disorders
62558080|NCT04931693|ACTIVE_COMPARATOR|control|conventional control group(C) (n=20) where20 children will receive IV paracetamol 20 mg / kg and atracurium top ups at a dose of 0.1mg/kg. every 30 minutes.
62558081|NCT04931693|ACTIVE_COMPARATOR|PECs|Pectoral nerves blocks group (P) (n=20) where 20 children will have PECs Block and atracurium top ups upon request.
62558082|NCT01467297|EXPERIMENTAL|ceftidoren|ceftidoren 200 mg bid for 5 days
62758084|NCT01448824|EXPERIMENTAL|Part 1 (Cohort C): 600 mg LY2484595, Placebo|Participants will receive either 600 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
62758085|NCT01448824|EXPERIMENTAL|Part 1 (Cohort D): 1200 mg LY2484595, Placebo|Participants will receive either 1200 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
62379790|NCT06425224|EXPERIMENTAL|Group 3: Tens therapy + standard treatment (dapoxetine 30 mg as needed).|"Tens therapy + standard treatment (dapoxetine 30 mg as needed).~Patients in this group will receive electrostimulation therapy of the posterior tibial nerve, 3 weekly therapy sessions for 12 continuous weeks, lasting 30 minutes each. 20 Hertz with a pulse width of 200 µsec will be administered in each session. The intensity will be applied to each patient depending on individual tolerance.~In addition to the therapy, patients in this group will receive dapoxetine as needed, taken 3 to 4 hours before sexual intercourse during the 12 weeks of the intervention."
62379791|NCT03431415|ACTIVE_COMPARATOR|Surgery|Patients that will undergo surgery (anatomical segmentectomy, lobectomy or bilobectomy) as primary lung cancer treatment
62379792|NCT03431415|ACTIVE_COMPARATOR|SBRT (Stereotactic Body Radiation Therapy)|Patients that will undergo SBRT as primary lung cancer treatment
62379793|NCT01572844|EXPERIMENTAL|Treatment lesion|Lesion A, target lesion, 2cm x 2cm (+/- 1cm) treated with 1 pass Fractionated Carbon Dioxide (FCO2) Laser followed by application of 4 ml of 5% topical sodium thiosulfate solution (STS), 8 to 10 treatments over 6 months.
62379794|NCT01572844|NO_INTERVENTION|No Treatment Lesion|Lesion B, similar area of calcinosis on the same patient, which did not receive treatment is evaluated.
62558083|NCT01467297|ACTIVE_COMPARATOR|levofloxacin|levofloxacin 500 mg once daily for 7 days
62379795|NCT02603939||Participants with Advanced Knee OA|People with advanced knee osteoarthritis requiring joint replacement surgery are being assessed for their pain responses before and after joint replacement surgery
62379796|NCT02603939||Participants with Early Knee OA|Participants with osteoarthritis with early disease who do not require joint replacement surgery are being assessed for pain
62379797|NCT01951326|ACTIVE_COMPARATOR|RHB-104|5 RHB-104 capsules administered orally BID
62379798|NCT01951326|PLACEBO_COMPARATOR|Placebo|5 placebo capsules administered orally BID
62379799|NCT02409628|EXPERIMENTAL|EktoTherix|One application of the EktoTherix scaffold to a fresh wound resulting from a full thickness excision of skin cancer.
62379800|NCT06032429|EXPERIMENTAL|Shared Medical Appointments|This strategy is conducted by groups of patients meeting over time for comprehensive care, usually involving a practitioner with prescribing privileges, for a defining chronic condition or health care state. Meanwhile, this model often use educational and/or self-management enhancement strategies, paired with medication management, in an effort to achieve improved disease outcomes.
62379801|NCT06032429|NO_INTERVENTION|Standard care|Routine health education without more advanced illustration
62379802|NCT02465541|EXPERIMENTAL|Arm I (gentle yoga and dietary counseling)|Participants undergo onsite gentle yoga once weekly over 45-60 minutes for 8 weeks and home-based gentle yoga for 6 weeks. Participants also undergo dietary counseling over 8 weeks.
62379803|NCT02465541|ACTIVE_COMPARATOR|Arm II (enhanced usual care)|Participants undergo enhanced usual care designed to educate on best practices for exercise, diet and lifestyle change once weekly for 14 weeks.
62379804|NCT01562379|NO_INTERVENTION|No food|A control in which mothers will receive nutrition education about continued breastfeeding and adequate complementary feeding throughout the period of 6-18 months of age.
62558084|NCT03139474|ACTIVE_COMPARATOR|agonist group|Triptorelin at a dose 1 milligram per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
62558085|NCT03139474|ACTIVE_COMPARATOR|antagonist group|•Multiple dose Gonadotrophin releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .
62558086|NCT00516659|ACTIVE_COMPARATOR|Group 1|Group 1 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 37.5µg LT
62558087|NCT00516659|PLACEBO_COMPARATOR|Group 2|Group 2 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 0µg LT (placebo patch containing no LT)
62558088|NCT03920514|ACTIVE_COMPARATOR|GROUP 1|IUI 24 hours after hCGadminstration
62379805|NCT01562379|ACTIVE_COMPARATOR|Plumpy Doz|In this control arm children will receive prepackaged, lipid-based Plumpy'Doz (Nutriset, Mulaunay, France) for daily consumption as a snack.
62379806|NCT01562379|EXPERIMENTAL|Wheat Soy Blend (WSB++)|Children will receive a WFP-developed Wheat-Soy Blend (WSB++) snack to be consumed daily.
62379807|NCT01562379|EXPERIMENTAL|Chickpea based complementary food supplement|Children will receive a Chickpea based complementary food supplement to be consumed daily.
62379808|NCT01562379|EXPERIMENTAL|Rice based complementary food supplement|Children will receive a locally developed rice based complementary food supplement.
62558089|NCT03920514|ACTIVE_COMPARATOR|GROUP 2|IUI 36 hours after hCG adminstration
62558090|NCT03920514|ACTIVE_COMPARATOR|GROUP 3|IUI 48 hours after hCG adminstration
62558091|NCT03920514|ACTIVE_COMPARATOR|GROUP 4|IUI at time of hCG adminstration
62558092|NCT02811965|NO_INTERVENTION|Control|Pressure mapping is performed without a heel offloading intervention applied.
62558093|NCT02811965|EXPERIMENTAL|Pillow Condition 1|Pressure mapping is performed with the Pillow condition 1 intervention applied to the heel.
62558094|NCT02811965|EXPERIMENTAL|Pillow Condition 2|Pressure mapping is performed with the Pillow condition 2 applied to the heel.
62758086|NCT01448824|EXPERIMENTAL|Part 2 (Cohort E): 100 mg LY2484595 ± 400 mg Ketoconazole|"Period 1: Participants will receive 100 milligrams (mg) LY2484595 tablet by mouth on Day 1 of Period 1.~Washout period lasting ≥14 days.~Period 2: Participants will receive 400 mg ketoconazole tablets once daily (QD) by mouth on Days 1 through 14 of Period 2. Participants will receive 100 mg LY2484595 tablet by mouth on Day 5 of Period 2."
62758087|NCT03060512|ACTIVE_COMPARATOR|Crossover Group 1|"Crossover Group Movantik to Polyethylene Glycol 3350~2-period, 2-treatment cross-over model: Subjects will be randomized to Movantik during Treatment period 1 (2 weeks), then crossed over to receive Polyethylene Glycol 3350 for Treatment period 2 (2 weeks) after 1 week washout."
62379809|NCT01023139|NO_INTERVENTION|Standard of care (SOC)|No intervention following phase 1 of the study is done during this 2nd phase. Participants will have their height and weights examined at 3 month and 6 month following end of phase 1. During these two visits, they will receive counseling from the physician regarding food choices and exercise maintenance.
62558095|NCT02811965|EXPERIMENTAL|Heel Foam Pillow|Pressure mapping is performed with the heel foam pillow device applied to the heel.
62558096|NCT02811965|EXPERIMENTAL|Offloading Device A|Pressure mapping is performed with Offloading Device A applied to the heel.
62558097|NCT02811965|EXPERIMENTAL|Offloading Device B|Pressure mapping is performed with Offloading Device B applied to the heel.
62558098|NCT02811965|EXPERIMENTAL|Offloading Device C|Pressure mapping is performed with Offloading Device C applied to the heel.
62558099|NCT02368964|EXPERIMENTAL|High dose hCG|The hCG group- will be triggered for final follicular maturation with high dose hCG (500 mcg)-38 hours prior to oocyte aspiration
62558100|NCT02368964|EXPERIMENTAL|Double trigger|Double trigger Group- will receive GnRH agonist (Decapeptyl 0.2mg) 40 hours prior to oocyte aspiration and hCG (250mcg) 34 hours prior to the oocyte aspiration
62379810|NCT01023139|EXPERIMENTAL|Continuing Behavioral Therapy (CoBT)|This arm follows the end of the phase 1 which incorporates behavioral therapy, nutrition counseling and pharmacotherapy with Sibutramine while medically supervised. Participants randomized to this arm no longer receive medication and will receive behavioral therapy once a month and then evaluated at 3 months and six months for weight loss maintenance.
62379811|NCT01660529|EXPERIMENTAL|hTERT/Survivin Multi-Peptide Vaccination|single-arm Phase I study for patients with metastatic breast cancer who have failed at least one regimen for metastatic disease
62379812|NCT02773511|OTHER|Bone healing|Bone healing in surgical or conservative treatment for children type 1 humeral condyle fracture
62379813|NCT02773511|OTHER|Fracture displacement|Fracture displacement in surgical or conservative treatment for children type 1 humeral condyle fracture
62379814|NCT05161624||Path planning model|
62379815|NCT05161624||Junior ablation specialists|
62379816|NCT05161624||Senior ablation specialists|
62379817|NCT03003429|EXPERIMENTAL|Heart rate monitor|The intervention consist in monitoring the heart rate variability during one night by using a heart rate monitor and a Polar RS800CX
62558101|NCT01299675||Chronic Performance|Subjects enrolled prior to or within 30 days post implant of SureScan pacing system. In office follow-up visits required every 6 months.
62558102|NCT01299675||Multiple MRI Scan Characterization|Subject enrolled into study at the time of MRI Scan indication. Subject followed per clinic standard of care.
62558103|NCT05334524|ACTIVE_COMPARATOR|kinesiotaping with combined chain exercises|"3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension.~Combined chain exercises will apply with 10 secs hold with 10 repetitions which will include quadriceps setting, SLR, full arc extension, cycling in the air, wall slides and step-up and step-down exercises."
62558104|NCT05334524|ACTIVE_COMPARATOR|kinesiotaping|"3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension."
62758088|NCT03060512|ACTIVE_COMPARATOR|Crossover Group 2|"Crossover group Polyethylene Glycol 3350 to Movantik~2-period, 2-treatment cross-over model: Subjects will be randomized to Polyethylene Glycol 3350 during Treatment period 1 (2 weeks), then crossed over to receive Movantik for Treatment period 2 (2 weeks) after 1 week washout."
62379818|NCT05746572|EXPERIMENTAL|Medicine Session|3,4-methylenedioxymethamphetamine (MDMA) in combination with massed exposure therapy for PTSD
62379819|NCT03187795|EXPERIMENTAL|Oxybutynin chloride IR then Mirabegron|Subjects randomized to this group will receive oxybutynin IR (5 mg three times daily) for 6 weeks. After the initial 6 weeks, subjects in this group will then be switched to an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily).
62379820|NCT03187795|EXPERIMENTAL|Mirabegron then Oxybutynin chloride IR|Subjects randomized to this group will receive an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily). After the initial 6 weeks, subjects in this group will then be switched to receive oxybutynin IR (5 mg three times daily) for 6 weeks
62758089|NCT02908685|EXPERIMENTAL|Part 1 Group A: Adolescents and Adults (Risdiplam)|Adolescent and adult participants aged 12-25 years will receive risdiplam for at least 12 weeks. Once the placebo-controlled period is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
62758090|NCT02908685|PLACEBO_COMPARATOR|Part 1 Group A: Adolescents and Adults (Placebo)|Adolescent and adult participants aged 12-25 years will receive placebo matching to risdiplam for at least 12 weeks. Once placebo-controlled period is completed, participants will be first switched to their cohort risdiplam dose. After the Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
62379821|NCT00945685|EXPERIMENTAL|Endymion study group|
62379822|NCT00742391|ACTIVE_COMPARATOR|1|PEP005 (ingenol mebutate) Gel
62758091|NCT02908685|PLACEBO_COMPARATOR|Part 1 Group B: Children (Placebo)|Children aged 2-11 years will receive placebo matching to risdiplam for at least 12 weeks. Once placebo-controlled period is completed, participants will be first switched to their cohort risdiplam dose. After the Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
62379823|NCT00742391|PLACEBO_COMPARATOR|2|Vehicle gel
62379824|NCT05141565||The Kunshan Elderly Health Study (KEHS)|Community-based observational cohort.
62758092|NCT02908685|EXPERIMENTAL|Part 1 Group B: Children (Risdiplam)|Children aged 2-11 years will receive risdiplam for at least 12 weeks. Once the placebo-controlled period is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
62758093|NCT02908685|PLACEBO_COMPARATOR|Part 2: Placebo|Participants aged 2-25 years will receive placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants will be switched to risdiplam (5 mg once daily for participants with a body weight (BW) \>/=20kg or 0.25 mg/kg for participants with a BW \<20) in a blinded manner and participants will continue with treatment until Month 24. After Month 24, participants will be offered the opportunity to enter the open-label phase.
62758094|NCT02908685|EXPERIMENTAL|Part 2: Risdiplam|Participants aged 2-25 years will receive risdiplam at the dose selected based on the results from Part 1 of the study (5 mg once daily for participants with a body weight (BW) \>/=20kg or 0.25 mg/kg for participants with a BW \<20 kg), for 24 months. After 24-month treatment, participants will be offered the opportunity to enter the open-label phase.
62379825|NCT00264511|EXPERIMENTAL|Hyperbaric oxygen treatment|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
62379826|NCT00264511|NO_INTERVENTION|No hyperbaric oxygenation|Patients randomised to this group will receive standard trauma care.
62379827|NCT04264182|EXPERIMENTAL|Ultra-conservative ICD programming|Single VF zone programming strategy with maximal detection extension to avoid ICD shock delivery with monitoring-only VT detection zones
62379828|NCT04264182|NO_INTERVENTION|Standard programming (physician discretion)|Usual care ICD programming, which is historically unchanged from ICD programming pre-LVAD
62379829|NCT06336876|EXPERIMENTAL|Survey Participant|The sample will be a convenience sample of hospital-registered nurses and para-professional nursing services staff (e.g., patient care technicians and specialty area technicians) who agree to participate in an online survey launched via the Survey Monkey® portal.
62379830|NCT06125626|EXPERIMENTAL|Probiotics|This arm will receive a daily sachet of Lacticaseibacillus rhamnosus LR04 + Streptococcus thermophilus FP4 + Bifidobacterium breve BR03
62379831|NCT06125626|PLACEBO_COMPARATOR|Placebo|This arm will receive a dose of placebo
62379832|NCT03479203|EXPERIMENTAL|Healthy, Non-Smokers|Non-nicotinized electronic cigarette aerosol (16 2-second long puffs)
62758095|NCT04604197|EXPERIMENTAL|Angiography and Clinical Follow up|After PCI. The patient is randomized to an angiographic follow-up at 6 months and a Clinical Follow to 36 months
62758096|NCT04604197|ACTIVE_COMPARATOR|Clinical Follow up|After PCI. The patient is randomized to a Clinical Follow to 36 months
62758097|NCT03742999|ACTIVE_COMPARATOR|group A|Group (A) physical therapy program for 60 minutes per session, three times a week for three consecutive months
62758098|NCT03742999|ACTIVE_COMPARATOR|group B|Group (B) E-Link Upper Limb Exerciser (augmented biofeedback training)for 60 minutes per session, three times a week for three consecutive months
62758099|NCT03742999|EXPERIMENTAL|group C|group (C) physical therapy program and E-Link Upper Limb Exerciser
62379833|NCT02912832|EXPERIMENTAL|TBDx|"All samples were tested with TBDx and compared with smear microscopy and Xpert MTB/RIF using solid and liquid culture as gold standard.~Operators were blinded to all other results for a sample upon data entry."
62379834|NCT02543801|ACTIVE_COMPARATOR|Hip Cohort Liposomal Bupivacaine|Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac
62379835|NCT02543801|ACTIVE_COMPARATOR|Hip Cohort Ropivacaine|Ropivacaine Clonidine Epinephrine Ketorolac
62379836|NCT02543801|ACTIVE_COMPARATOR|Knee Cohort Liposomal Bupivacaine|Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac
62558105|NCT03208686|OTHER|Intervention Group|A single-arm intervention comprised of discussion groups, text messages, and a cloud-based cellular glucometer.
61987054|NCT04859751|EXPERIMENTAL|VB4-845 Injection|"Induction - 30 mg of Vicinium in 50 mL of saline administered twice weekly (BIW) for 6 weeks followed by once weekly for 6 weeks, for a total of 12 weeks.~Maintenance - 30 mg of Vicinium in 50 mL of saline administered once weekly every other week for up to 104 weeks."
61987055|NCT03892460|EXPERIMENTAL|Treatment|Neuromuscular electrical stimulation
61987056|NCT03892460|NO_INTERVENTION|Control|No treatment control
62379837|NCT02543801|ACTIVE_COMPARATOR|Knee Cohort Ropivacaine|Ropivacaine Clonidine Epinephrine Ketorolac
62379838|NCT04045873|EXPERIMENTAL|ECMO plus IABP|
62379839|NCT04045873|EXPERIMENTAL|IABP|
62379840|NCT00440232|EXPERIMENTAL|Frovatriptan|5.0 mg of Frovatriptan given as single dose
62379841|NCT00440232|PLACEBO_COMPARATOR|placebo|
62379842|NCT01156012|EXPERIMENTAL|T2345|One drop of T2345
62379843|NCT01156012|ACTIVE_COMPARATOR|Prostaglandin|One drop
62379844|NCT04540614|EXPERIMENTAL|Intervention|70 participants receiving active comparator treatment plus experimental
62379845|NCT04540614|ACTIVE_COMPARATOR|Control|70 participants receiving active comparator treatment
62379846|NCT00550615|EXPERIMENTAL|Dasatinib Dose Escalation|Phase 1 employed a standard 3+3 dose-escalation design to assess safety, MTD and dose-limiting toxicity (DLT). Maximum Tolerated Dose (MTD) was defined as the next lowest dose level below where ≥ 2/3 or ≥ 3/6 patients experience dose limiting toxicities in cycle 1.
62379847|NCT00550615|EXPERIMENTAL|Dasatinib Maximum Tolerated Dose|Once the maximum tolerated dose is determined, an additional patients will be enrolled into the Phase II portion of this trial.
62379848|NCT01744340|EXPERIMENTAL|head and neck|Cetuximab, 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly there after Eribulin Mesylate 1.4mg/m2
61987057|NCT01196546|EXPERIMENTAL|Vildagliptin/metformin|
61987058|NCT02393833|ACTIVE_COMPARATOR|Induction chemotherapy|Approved induction CT regimen after randomization
61987059|NCT02393833|EXPERIMENTAL|Induction chemotherapy followed by CM maintenance|Approved induction chemotherapy followed by 12 months of CM maintenance
61987060|NCT00405873|EXPERIMENTAL|AMT2003|
61987061|NCT02595086|EXPERIMENTAL|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy(LPPG) with D1+ lymphadenectomy is performed (exclude lymph node station No. 5) in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy. Extra-corporeal gastro-gastrostomy should be performed
62379849|NCT01744340|EXPERIMENTAL|Colon- closed as of May 2014|"Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
62379850|NCT02442765|PLACEBO_COMPARATOR|Stage 1: Placebo|Participants received matching placebo orally twice daily (BID) for 6 weeks (Days 1-42) in Stage 1. Participants who completed Stage 1 were eligible to Participate in Stage 2.
62758100|NCT04380103|EXPERIMENTAL|XELOXIRI/Bevacizumab|drugs: Irinotecan, Oxaliplatin, Capecitabine, Bevacizumab bevacizumab 5mg/kg on day1, irinotecan 150mg/m2 or 165mg/m2 on day1, oxaliplatin 85mg/m2 on day1 and capecitabine 1000mg/m2 twice a day on day1-7, administered every 2 week for 12 cycles, after 12 cycles, administer bevacizumab 5mg/kg on day 1 and capecitabine 1000mg/m2 twice a day on day1-7 as maintenance therapy.
62379851|NCT02442765|EXPERIMENTAL|Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)|Participants received AVP-786-18 mg orally once daily (QD) in the morning and placebo orally QD in the evening for the first 7 days, followed by AVP-786-18 mg orally BID for the remaining 5 weeks (Days 8-42). Participants who completed Stage 1 were eligible to participate in Stage 2.
62379852|NCT02442765|EXPERIMENTAL|Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)|Participants received AVP-786-18 mg orally QD in the morning and placebo orally QD in the evening for the first 7 days, followed by AVP-786-18 mg orally BID for 2 weeks (Days 8-21). From Day 22, participants received AVP-786-28 mg orally BID for the remaining 3 weeks. Participants who completed Stage 1 were eligible to participate in Stage 2.
62379853|NCT02442765|PLACEBO_COMPARATOR|Stage 2: Placebo|Participants who received matching placebo orally BID for 6 consecutive weeks in Stage 1 were re-randomized in Stage 2 to receive the study drug or placebo from Day 43 to Day 85.
62379854|NCT02442765|EXPERIMENTAL|Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) to: Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)|Participants who received AVP-786-18 mg in Stage 1 continued to receive AVP-786-18 mg orally BID for the 6 weeks (Days 43-85) in Stage 2..
62558106|NCT04989543|OTHER|healthy population|"Interventions: vaginal swabs:~* Nugent scores,~* cytobacteriological examination (in particular to determine the Clue Cells)~* evaluation of the vaginal microbiota.~On receipt of the Nugent score results, the doctor will confirm whether or not the patient is included in one of the two arms under study:~* healthy population~* pathological population with bacterial vaginosis"
62758101|NCT03738501|EXPERIMENTAL|Chest physiotherapy with SET|Chest physiotherapy will be provided by a single physiotherapist not involved in outcomes assessment. Airway clearance technique will be Slow Expiratory Technique (SET). SET is a slow modulation of airflow in order to remove bronchial secretions within infants lungs. Experimental group will also benefit for standard medical and non-pharmacological care (e.g Standard Treatment)
62758102|NCT03738501|ACTIVE_COMPARATOR|Standard treatment|Medical treatment, health education for parents, rhinopharyngeal clearance using isotonic saline solution, advices.
61987062|NCT02595086|ACTIVE_COMPARATOR|Laparoscopic DG|"Laparoscopic distal gastrectomy(LDG) with D1+ lymphadenectomy in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.~Anastomosis method (extra-corporeal or intra-) and reconstruction type (Billroth I (gastroduodenostomy), Billroth II, or Roux-en Y gastrojejunostomy) are optional according to the surgeon's preference"
61987063|NCT02722850|EXPERIMENTAL|ALIVE - Physical Activity|PA CONDITION: The goal of the PA condition is to encourage participants to gradually increase moderate to vigorous PA to 150 minutes per week and to increase resistance training to a total of 15 minutes per day twice per week.
61987064|NCT02722850|EXPERIMENTAL|ALIVE - Dietary Modification|DIET CONDITION: The goal of the dietary condition includes increasing intake of fruit and vegetable to 5-servings per day. The program also encourages participants to increase the consumption of colorful fruits and vegetables. The fat goals consist of reducing saturated fats to \<10% of total kilocalories per day, trans fats to \<3 grams per day, and added sugar to \<50 grams per day.
62379855|NCT02442765|EXPERIMENTAL|Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)|Participants who received AVP-786-28 mg in Stage 1 continued to receive AVP-786-28 mg orally BID for 6 weeks (Days 43-85) in Stage 2
62379856|NCT02442765|EXPERIMENTAL|Experimental: Stage 1: Placebo to: Stage 2: AVP-786-18 d6-DM 18 mg/Q 4.9 mg|Participants who were placebo responders or non-responders in Stage 1 received AVP-786-18 for 1 week, orally, QD, followed by AVP-786-18 BID for 2 weeks; followed by AVP-786-28 BID for the last 3 weeks.
62379857|NCT02442765|EXPERIMENTAL|Stage 1: Placebo to: Stage 2: AVP-786-28 d6 DM 28 mg/Q 4.9 mg|Participants who were placebo responders or non-responders in Stage 1 received AVP-786-28 for 1 week, orally, QD, followed by AVP-786-28 BID for 2 weeks; followed by AVP-786-28 BID for the last 3 weeks.
62379858|NCT03393091||Incidence of possible anaphylaxis|Data will be collected on 1000 consecutive general anaesthetic procedures in Assiut University Hospitals. After each elective operating list the anaesthetist will be asked to complete a form in which they will document the number of patients receiving general anaesthesia on the list and the number of those patients who developed any of the following features: unexpected, unexplained hypotension; unexpected bronchospasm resistant to treatment; angioedema; urticaria; severe itching; widespread erythema
62379859|NCT04012294|EXPERIMENTAL|allopurinol|150 mg daily for a month then 300 mg daily for the rest of the study (5 months)
62558107|NCT04989543|OTHER|pathological population|"Interventions: vaginal swabs:~* Nugent scores,~* cytobacteriological examination (in particular to determine the Clue Cells)~* evaluation of the vaginal microbiota.~On receipt of the Nugent score results, the doctor will confirm whether or not the patient is included in one of the two arms under study:~* healthy population~* pathological population with bacterial vaginosis"
62558108|NCT03385889|EXPERIMENTAL|Cervical Spine Mobilization Group|Subjects with cervicogenic headache who will be assigned to cervical spine mobilization group and receive intervention directed to C1/2 of ipsilateral side of unilateral dominant headache.
62758103|NCT04374591|OTHER|Sodium Bicarbonate|Inhalation of Sodium Bicarbonate 8.4% via nebulizer
62758104|NCT04374591|PLACEBO_COMPARATOR|Control|placebo
62758105|NCT03770494|EXPERIMENTAL|LY3405105|LY3405105 administered orally.
62758106|NCT04683081||Foley catheter group|pregnant women who were applied Foley catheter for cervical ripening
62758107|NCT04683081||Cook balloon catheter group|pregnant women who were applied Cook balloon catheter for cervical ripening
62758108|NCT04683081||Modified double-balloon Foley catheter group|pregnant women who were applied modified double-balloon Foley catheter for cervical ripening
62758109|NCT02956759|EXPERIMENTAL|Early Intervention|pan-retinal photocoagulation laser treatment applied to the study eye within 2-4 weeks.
62758110|NCT02956759|ACTIVE_COMPARATOR|Standard Care|pan-retinal photocoagulation laser treatment deferred until the onset of any PDR.
61987065|NCT04199299||Persons who cannot communicate unequivocally|Persons with intellectual disability, childhood autism, and/or cerebral palsy who cannot communicate unequivocally and therefore cannot communicate their needs and wishes, e.g. whether they are uncomfortable, in pain, scared, angry, happy, pleased.
61987066|NCT01848756|EXPERIMENTAL|SNX-5422|Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle. Subjects will continue treatment on a 28-day cycle at the discretion of the principal investigator based on safety.
61987067|NCT04988347|EXPERIMENTAL|Spirulina|Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days
61987068|NCT04988347|PLACEBO_COMPARATOR|Placebo|Placebo in capsules, 1 capsule orally each 8 hours, for 60 days
61987069|NCT01946373|EXPERIMENTAL|Chemotherapy + T cells + IL-2|Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m\^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10\^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses.
61987070|NCT01946373|EXPERIMENTAL|Chemotherapy + T cells + IL-2 + DCV|Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m\^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10\^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses. After completion of the IL-2 treatment 3-5 doses of weekly intradermal vaccinations with up to 1.5 x 10\^7 Dendritic cells pulsed with autologous tumor lysate and NY-ESO-1 peptide.
61987071|NCT03797833|NO_INTERVENTION|Standard treatment|ECV according to standard practice.
61987072|NCT03797833|ACTIVE_COMPARATOR|Spinal anaesthesia|ECV after low dose spinal anaesthesia (Bupivacain 2,5 mg plus Sufentanil 5 micrograms (µg)
61987073|NCT05791045|ACTIVE_COMPARATOR|double lumen tube|In the DLT group, the lung on the side to be treated was distinguished from the ventilator and extinguished and single lung ventilation was performed with the other lung.
61987074|NCT05791045|ACTIVE_COMPARATOR|single lumen tube|In the SLT group, after thoracoscopic input, the anesthetist was in contact with the surgeon and his lung pressures were reduced manually until the lowest pressure, where the surgeon's vision was optimal.
61987075|NCT02494427|EXPERIMENTAL|1|CAD/CAM manufactured fixed unitary dental prostheses
61987076|NCT02494427|ACTIVE_COMPARATOR|2|Conventionally manufactured unitary dental prostheses
61987077|NCT00651755|EXPERIMENTAL|Aprepitant + CHOP/R-CHOP|Aprepitant 125 mg oral (PO) Day 1 of Cycle 1 followed by 80 mg PO Daily Days 2-3 with CHOP (steroid in CHOP) or R-CHOP plus Rituximab 375 mg/m\^2 intravenous Day 1. CHOP or R-CHOP chemotherapy: (1) bolus or 48-hour infusion CHOP \[cyclophosphamide 750 mg/m\^2 IV Day 1, doxorubicin 25 mg/m\^2/day IV given bolus or over 48 hours continuous infusion Days 1-2, vincristine 2 mg IV Day 1, prednisone PO 100 mg \* 5 days\]; or (2) Bolus or 48-hour infusion R-CHOP \[Rituximab 375 mg/m\^2 on Day 1 + CHOP as above\]. \[For patients receiving R-CHOP, CHOP may be administered starting on Day 2 at the discretion of the treating physician\]
61987078|NCT00651755|EXPERIMENTAL|Standard of Care (Control) + CHOP/R-CHOP|Anti-emetics, Ondansetron 8 mg daily for 2 days, plus steroids in CHOP or R-CHOP regimen.
61987079|NCT03754712|ACTIVE_COMPARATOR|Intervention Vitamin D3 along with SSRIs|One tablet of vitamin D3 (2000IU) per day for 8 weeks
62379860|NCT05757791|EXPERIMENTAL|Participants with Major Depressive Disorder (MDD)|Patients will receive empagliflozin 10mg daily for two weeks and then empagliflozin 25mg for four weeks, for a total treatment duration of 6 weeks. Patients will be instructed to take the medication each morning, daily, with or without food. The number of doses given may be increased to a small degree to allow for flexibility in the scheduling of follow-up visits.
62379861|NCT01730625|EXPERIMENTAL|ABMT + CBT|CBT and ABMT
62379862|NCT01730625|OTHER|CBT Alone|CBT alone (compare/control group)
62379863|NCT01730625|PLACEBO_COMPARATOR|ABMT placebo + CBT|ABMT placebo training and CBT
62379864|NCT04048876|EXPERIMENTAL|CC-90001 400 mg once daily (QD)|CC-90001 400 mg QD
62758111|NCT01258153|EXPERIMENTAL|Nepadutant Low Dose|
62758112|NCT01258153|EXPERIMENTAL|Nepadutant High Dose|
62758113|NCT01258153|PLACEBO_COMPARATOR|Placebo|
62758114|NCT05623254|OTHER|TAU + MINDF (Treatment-as -Usual + Mindfulness)|Treatment-as-usual combined with weekly mindfulness sessions delivered on-line for patients and caregivers (a specific platform for on-line sessions will be used)
62758115|NCT00523705|EXPERIMENTAL|escitalopram|Escitalopram 10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
62758116|NCT00523705|PLACEBO_COMPARATOR|placebo|Placebo tablets matched to drug.
62758117|NCT02241330|PLACEBO_COMPARATOR|Control|Control wheat used for meal, level of zinc is usual
62758118|NCT02241330|ACTIVE_COMPARATOR|fortification|Fortification Wheat is fortified before testmeal administration. Zinc level is comparable to WHO recommendation
62758119|NCT02241330|ACTIVE_COMPARATOR|Biofortified|Biofortification Biofortified wheat is used for testmeal administration. Zinc concentration is around 30% higher than control
62758120|NCT06605794|EXPERIMENTAL|Device-intervention Group|FreeFlow percutaneous atrial septal shunt
62758121|NCT01175200|ACTIVE_COMPARATOR|Prasugrel|
62758122|NCT01175200|ACTIVE_COMPARATOR|Clopidogrel|
62758123|NCT01175200|ACTIVE_COMPARATOR|Lansoprazole|proton pump inhibitor
62758124|NCT01175200|PLACEBO_COMPARATOR|Placebo|
62758125|NCT05238012|EXPERIMENTAL|Xuezhikang Capsule|Experimental drug: Xuezhikang Capsule, specification: 300mg / capsule.
62758126|NCT05238012|ACTIVE_COMPARATOR|Atorvastatin Calcium Tablets|Control drug: Atorvastatin Calcium Tablets, specification: 20mg / tablet.
62758127|NCT02125357|OTHER|A - Abiraterone Acetate|Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care, or until PSA progression then cross-over to Arm B.
62758128|NCT02125357|OTHER|B - Enzalutamide|160mg PO OD as per standard of care, or until PSA progression then cross-over to Arm A.
61987080|NCT03754712|NO_INTERVENTION|SSRIs|Patients treated with SSRIs
61987081|NCT00312091|EXPERIMENTAL|A, Stage 1|Tablet containing d4T, 3TC, and NVP taken orally twice daily for the first 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for the final 4 weeks
61987082|NCT00312091|EXPERIMENTAL|A, Stage 2|Tablet containing d4T, 3TC, and NVP taken orally twice daily for 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 4 weeks
61987083|NCT00312091|EXPERIMENTAL|B, Stage 1|Liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 2 weeks, then tablet containing d4T, 3TC, and NVP taken orally twice daily for 2 weeks
61987084|NCT00312091|EXPERIMENTAL|B, Stage 2|Liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 4 weeks, then tablet containing d4T, 3TC, and NVP taken orally twice daily for 4 weeks
61987085|NCT00849407||1|melanoma patients
62758129|NCT02131376|ACTIVE_COMPARATOR|Cortical renorrhaphy|Cortical renorrhaphy is performed after partial nephrectomy using a running barbed suture on MH (36mm) needle. Polymer locking clips are used to maintain tension. A base layer running stitch is performed prior to the cortical renorrhaphy.
61987086|NCT00849407||2|controls
61987087|NCT04693507|EXPERIMENTAL|Teverelix TFA 120 mg 6-weekly|Participants receive teverelix TFA loading dose on Day 0 (120 mg SC + 120 mg IM) and teverelix TFA maintenance doses of 120 mg SC at week 6 and 6-weekly thereafter up to week 24
61987088|NCT04693507|EXPERIMENTAL|Teverelix TFA 180 mg 6-weekly|Participants receive teverelix TFA loading dose on Day 0 (180 mg SC + 180 mg IM) and teverelix TFA maintenance doses of 180 mg SC at week 6 and 6-weekly thereafter up to week 24
61987089|NCT02680483||AF cohort|AF consecutive patients
61987090|NCT05103215|EXPERIMENTAL|lidocaine group|Patients in the lidocaine group receive an intravenous injection of 1.5 mg/kg Lidocaine HCl 2% at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
61987091|NCT05103215|PLACEBO_COMPARATOR|control group|Patients in control group receive the same volume of saline injection.
61987092|NCT01643993|EXPERIMENTAL|hCG at Time of Embryo Transfer|Patients will have hCG and media (for a total of 20 microliters) inserted during a mock embryo transfer immediately prior to actual embryo transfer.
61987093|NCT01643993|OTHER|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
61987094|NCT03410589||Single arm|
61987095|NCT02159924||Asymptomatic|
61987096|NCT03790839|EXPERIMENTAL|Sequential arm ABC|A: Sitagliptin 100 mg QD in the morning on Days 1-5; B: Sitagliptin 100 mg QD in the morning and dorzagliatin 75 mg BID (morning and evening) on Days 6-10, with only the morning dose on Day 10; C: Dorzagliatin 75 mg BID (morning and evening) on Days 11-15, with only the morning dose on Day 15.
61987097|NCT06490328|EXPERIMENTAL|DKF-MA102|Leuprorelin acetate
62379865|NCT04048876|EXPERIMENTAL|CC-90001 200 mg once daily|CC-90001 200 mg QD
62379866|NCT04048876|EXPERIMENTAL|CC-90001 100 mg once daily|CC-90001 100 mg QD
62758130|NCT02131376|EXPERIMENTAL|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
62758131|NCT01007123|EXPERIMENTAL|A3309 low dose|Administered once daily for the duration of the study
62758132|NCT01007123|EXPERIMENTAL|A3309 intermediate dose|Administered once daily for the duration of the study.
62758133|NCT01007123|EXPERIMENTAL|A3309 high dose|Administered once daily for the duration of the study
62758134|NCT01007123|PLACEBO_COMPARATOR|Placebo|Administered once daily for the duration of the study
62758135|NCT03094364|ACTIVE_COMPARATOR|Immediate Treatment|"Patients will receive an in-home consultation with an occupational/physical therapist in which they are educated about the intervention, the system is set up, and they are guided through use of the system. After initial contact, therapist support will be available via telephone to address specific difficulties with operating the system, as well as three additional home visits throughout the 3 week intervention.~The rehabilitation program requires use of the rehabilitation gaming system for 1.5 hours daily for 21 consecutive days (equivalent dosage to standard CI therapy), limb activation device worn for 90% of waking hours, and completion of the automated transfer package to facilitate real-world arm use (e.g., problem-solving modules, daily monitoring of arm use). After completing the intervention, the patient will receive additional consultation with the therapist to formulate goals for follow-up. Follow-up assessments will be conducted to assess long-term retention of motor gains."
62758136|NCT03094364|ACTIVE_COMPARATOR|Delayed Treatment|"Patients will receive an in-home consultation with an occupational/physical therapist in which they are educated about the intervention, the system is set up, and they are guided through use of the system. After initial contact, therapist support will be available via telephone to address specific difficulties with operating the system, as well as three additional home visits throughout the 3 week intervention.~The rehabilitation program requires use of the rehabilitation gaming system for 1.5 hours daily for 21 consecutive days (equivalent dosage to standard CI therapy), limb activation device worn for 90% of waking hours, and completion of the automated transfer package to facilitate real-world arm use (e.g., problem-solving modules, daily monitoring of arm use). After completing the intervention, the patient will receive additional consultation with the therapist to formulate goals for follow-up. Follow-up assessments will be conducted to assess long-term retention of motor gains."
62758137|NCT03615287||Group A|40 subjects undergoing Medical Treatment
62758138|NCT03615287||Group B|40 subjects undergoing Surgical Treatment
62758139|NCT03615287||Group C|40 control subjects
62558109|NCT03385889|EXPERIMENTAL|Cervical Spine Manipulation Group|Subjects with cervicogenic headache who will be assigned to cervical spine manipulation group and receive intervention directed to C1/2 of ipsilateral side of unilateral dominant headache.
61987098|NCT02796040|EXPERIMENTAL|patients with ICD (impulse control disorder)|More precisely, the main purpose is to demonstrate that fractional anisotropy (FA) (data obtained with DTI) in the ventral tegmental area (VTA) is different between patients with ICD and patients without ICD
61987099|NCT02796040|OTHER|patients without ICD (impulse control disorder)|More precisely, the main purpose is to demonstrate that fractional anisotropy (FA) (data obtained with DTI) in the ventral tegmental area (VTA) is different between patients with ICD and patients without ICD
61987100|NCT05584865|EXPERIMENTAL|Group I|
62558110|NCT03385889|NO_INTERVENTION|Control Group|No intervention. Subjects in this groups will wait for 5 minutes between pre- and post-testing of dependent variables.
62558111|NCT03759548||Breast Cancer|Breast Cancer's patients undergoing pharmacological treatments prior or after surgery.
62558112|NCT03759548||Colorectal Cancer|Colorectal Cancer's patients undergoing pharmacological treatments prior or after surgery.
62558113|NCT03903302|ACTIVE_COMPARATOR|CS 1 I SAD|Single dose pharmacokinetics of CS1 I
62758140|NCT01340937|EXPERIMENTAL|V419 Lot A|V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
61987101|NCT05584865|ACTIVE_COMPARATOR|Group II|
62379867|NCT04048876|PLACEBO_COMPARATOR|Placebo once daily|Placebo QD
62558114|NCT03903302|ACTIVE_COMPARATOR|CS 1 II SAD|Single dose pharmacokinetics of CS1 II
62558115|NCT03903302|ACTIVE_COMPARATOR|CS 1 III SAD|Single dose pharmacokinetics of CS1 III
62558116|NCT03903302|ACTIVE_COMPARATOR|CS 1 II MAD|Multiple dose pharmacokinetics of CS1 II
62558117|NCT06155201|EXPERIMENTAL|depression disorder|The depressive disorder group must complete four years of follow-up and intervention. Collect blood samples from more than 5,000 patients with depressive disorders.
62558118|NCT06155201|EXPERIMENTAL|anxiety disorder|The anxiety disorder group must complete four years of follow-up and intervention. Collect blood samples from more than 5,000 patients with depressive disorders.
62558119|NCT06155201|EXPERIMENTAL|autism spectrum disorder|The autism spectrum disorder group must complete four years of follow-up and intervention. Collect blood samples from more than 1,000 patients with depressive disorders.
61987102|NCT00690014|EXPERIMENTAL|A|
61987103|NCT02146547|ACTIVE_COMPARATOR|aripiprazole oral|the recommended starting dose for aripiprazole is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals.Aripiprazole is effective in a dose range of 10 to 30 mg/day.
62379868|NCT00819052|ACTIVE_COMPARATOR|NVP IR|200 mg orally twice a day (po BID)
62379869|NCT00819052|EXPERIMENTAL|NVP XR|400 mg orally once a day (po QD)
62379870|NCT03271944|OTHER|Single group 30 post menopause females.|
62558120|NCT06155201|EXPERIMENTAL|attention deficit hyperactivity disorder|The attention deficit hyperactivity disorder group must complete four years of follow-up and intervention. Collect blood samples from more than 1,000 patients with depressive disorders.
62558121|NCT05667090|EXPERIMENTAL|Vitamin D group|Oral supplementaiton of 2,304,000 IU vitamin D3 in 4 weeks
62558122|NCT05667090|PLACEBO_COMPARATOR|Placebo Group|Oral supplementaiton of placebo in 4 weeks
62558123|NCT04314453||T group|The degenerative lumbar spinal stenosis patients accepted the PELD with TESSYS procedure.
62758141|NCT01340937|EXPERIMENTAL|V419 Lot B|V419 (Lot B) 0.5 mL IM at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
62758142|NCT01340937|EXPERIMENTAL|V419 Lot C|V419 (Lot C) 0.5 mL IM at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
62558124|NCT04314453||U group|The degenerative lumbar spinal stenosis patients accepted the PELD with U route procedure.
62558125|NCT04756947||Pelvic injury|Paediatric patients (age ≤ 18 years) with a single pelvic bone fracture or pelvic ring injury, excluding pathological fractures.
61987104|NCT02146547|ACTIVE_COMPARATOR|Aripiprazole depot|"The recommended starting and maintenance dose of aripiprazole depot is 400 mg. Titration of the dose of this medicinal product is not required. It should be administered once monthly as a single injection (no sooner than 26 days after the previous injection).~After the first injection, treatment with 10 mg to 20 mg oral aripiprazole should be continued for 14 consecutive days to maintain therapeutic aripiprazole concentrations during initiation of therapy.~If there are adverse reactions with the 400 mg dosage, reduction of the dose to 300 mg once monthly should be considered."
62758143|NCT01340937|ACTIVE_COMPARATOR|Control|Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age
62758144|NCT00644904|EXPERIMENTAL|Treatment|Starting dose of 4,000 IU per day of Vitamin D3 titrating up to a dose of 40,000 IU per day of Vitamin D3 by month six. In the second six-month part of the trial, patients titrate back down to 4,000 IU per day of Vitamin D3 and then discontinue it completely at the end of the 12 month trial period.
62758145|NCT00644904|OTHER|Control|Patients are allowed to supplement with up to 4,000 IU per day of Vitamin D3 if desired.
62758146|NCT04766385|EXPERIMENTAL|KHK7791|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
62758147|NCT05799989||Surgical fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with surgical fixation
62758148|NCT05799989||Atraumatic fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with surgical fixation
62758149|NCT05448313|EXPERIMENTAL|Dyadic intervention|Veterans and their support person will participate in MOVE!
62758150|NCT05448313|ACTIVE_COMPARATOR|Veteran-only intervention|Veterans will participate in MOVE! alone
61987105|NCT02146547|ACTIVE_COMPARATOR|Paliperidone|The recommended dose of paliperidone for the treatment of schizophrenia is 6 mg once daily, administered in the morning. Initial dose titration is not required. Some patients may benefit from lower or higher doses within the recommended range of 3 mg to 12 mg once daily. Dosage adjustment, if indicated, should occur only after clinical reassessment. When dose increases are indicated, increments of 3 mg/day are recommended and generally should occur at intervals of more than 5 days.
61987106|NCT02146547|ACTIVE_COMPARATOR|Paliperidone palmitate|The first two administrations of paliperidone palmitate (150 mg at visit 3 and 100 mg one week later) need to be administered deep into the deltoid muscle in order to attain therapeutic concentrations rapidly. No oral supplementation with paliperidone is needed. Following the second dose, monthly maintenance doses can be administered in either the deltoid or gluteal muscle. The recommended monthly maintenance dose is 75 mg, although some patients may benefit from lower doses within the recommended range of 25 to 150 mg based on individual patient tolerability and/or efficacy.
62379871|NCT02743546|EXPERIMENTAL|Dose Optimization:Participant with Certain B-Cell Malignancies|Participants with certain B-cell malignancies (diffuse large B-cell lymphoma \[DLBCL\], mantle cell lymphoma \[MCL\], or follicular lymphoma \[FL\]) will receive rising doses of intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met. Dose escalation will continue until the recommended phase 2 dose or maximum tolerated dose is reached.
61987107|NCT01680718|EXPERIMENTAL|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
62558126|NCT04756947||Pelvic and acetabular injury|Paediatric patients (age ≤ 18 years) with a combined pelvic and acetabular injury or an isolated acetabular fracture, excluding pathological fractures.
62558127|NCT03358927|ACTIVE_COMPARATOR|Standard Group|Deferred fast-track care
62558128|NCT03358927|EXPERIMENTAL|Immediate Fast-Track Group|Immediate fast-track care
62558129|NCT02711202|ACTIVE_COMPARATOR|Sirolimus|Patients received two applications of anti-CD52 MabCampath (Alemtuzumab), a single dose of anti-TNF-α Remicade (Infliximab) monoclonal antibodies in the early posttransplant period. First 14 days patients received tacrolimus monotherapy, at post-operative day (POD) 14, they were randomized to sirolimus monotherapy.
62558130|NCT02711202|ACTIVE_COMPARATOR|Tacrolimus|Patients received two applications of anti-CD52 MabCampath (Alemtuzumab), a single dose of anti-TNF-α Remicade (Infliximab) monoclonal antibodies in the early posttransplant period. First 14 days patients received tacrolimus monotherapy, at POD 14, they were randomized to tacrolimus monotherapy.
62558131|NCT00677521|EXPERIMENTAL|1|
62558132|NCT04785872|EXPERIMENTAL|Intervention group|
62558133|NCT04785872|NO_INTERVENTION|Control group|
62558134|NCT06209580|EXPERIMENTAL|Arm 1|AMT-253 Dose Escalation
62758151|NCT04113174||SAIL databank|Anonymised records from around 5 million people in Wales, with linked primary care, ED attendance, hospital admissions, outpatient data, social care, Welsh Care Homes Dataset, and ONS mortality data. SAIL includes eFI summary scores and individual components.
62758152|NCT04113174||ResearchOne|Nationally representative, de-identified data from around 6 million primary care electronic health records on the TPP SystmOne clinical system. ResearchOne includes eFI summary scores and individual components.
62758153|NCT04113174||Leeds Data Model|Anonymised, linked primary, secondary, community and social care data from 810,000 patients across 108 practices in Leeds, including eFI summary scores and individual components.
62758154|NCT04113174||CARE75+|National prospective cohort study (n≈1,200) collecting detailed sociodemographic information, frailty measures (including eFI scores), simple instruments suitable for use in primary care (e.g. gait speed, timed-up-and-go test; activities of daily living; informal care; loneliness), and key outcomes at six, 12, 24 and 48 months. CARE75+ is a very rich dataset that provides a highly efficient method to investigate how simple instruments might augment eFI performance.
62758155|NCT01748474|EXPERIMENTAL|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
62758156|NCT01748474|PLACEBO_COMPARATOR|Sham room air|Room air will be applied similarly to oxygen
62758157|NCT03872830|EXPERIMENTAL|Experimental: group1|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:47.13mg Volume:2ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
62758158|NCT03872830|EXPERIMENTAL|Experimental: group2|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:94.25mg Volume:4ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
62758159|NCT03872830|EXPERIMENTAL|Experimental: group3|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:188.5mg Volume:8ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
62758160|NCT03872830|PLACEBO_COMPARATOR|Experimental: group4|Generic name:Placebo; Placebo:normal saline Dosage form:Injection Dosage:4ml/injection Volume:10ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the placebo.
62758161|NCT00383643|PLACEBO_COMPARATOR|Placebo|Eligible subjects randomized to this arm received placebo as gelatin capsule and a liquid capsule to fully maintain the blind.
62758162|NCT00383643|ACTIVE_COMPARATOR|Zolpidem tartrate|Eligible subjects randomized to this arm received zolpidem as gelatin capsule and a placebo liquid capsule to fully maintain the blind.
62758163|NCT00383643|ACTIVE_COMPARATOR|Sodium oxybate|Eligible subjects randomized to this arm received placebo as gelatin capsule and a sodium oxybate capsule to fully maintain the blind.
62758164|NCT05093543|EXPERIMENTAL|Intervention|"The experimental group is based on a telematic multidisciplinary approach for CnsLBP. Scheduled and periodic telematic sessions will be performed. The multidisciplinary approach (to be carried out by telematic means) consists of a biopsychosocial rehabilitation program for patients with CnsLBP that includes physical rehabilitation/physiotherapy and psychosocial group sessions (performed by psychologists, social workers), which will be offered as part of the integrated program.~Patients assigned to the experimental group will receive a Google Meet® link by email, so that they may join the weekly 2-hour group sessions (every Tuesday at 9 a.m.). Google Meet® is a free real-time meeting app by Google that does not require download, has no session time limit, and neither limits the number of users per session. Patients assigned to the experimental group will receive a single-use link by email to access each online group session."
62758165|NCT05093543|NO_INTERVENTION|Control|Explanation for choice of comparators {6b} The telematics multidisciplinary approach (experimental group) will be compared to Standard of Care (SoC) (control group). SoC consists of a patient's follow up according to the usual clinical practice. In Bellvitge University Hospital's setting, the treatment protocol for CnsLBP indicates physical rehabilitation/physiotherapy as the first treatment step, and Pain Clinic evaluation as a second step for those who did not improve. For patients who did not improve with the previous steps and that still demand a solution for their CnsLBP, a third step would be to refer the patient for surgical evaluation - a spine surgeon would, then, evaluate, alongside with the patient, whether a surgical approach would be appropriate for his/her case. If the surgery is ruled out by the spine surgeon, the patient may be referred, once more, to physical rehabilitation/physiotherapy and/or to the Pain Clinic, at the surgeon's discretion.
62758166|NCT00651495|EXPERIMENTAL|1|Participants receive a $50 financial incentive if they view at least 3 of 5 patient decision aids in a group screening.
62758167|NCT00651495|ACTIVE_COMPARATOR|2|No financial incentive for watching patient decision aids in group screenings
62758168|NCT01194843|EXPERIMENTAL|Ropivacaine|Ropivacaine administration by local per and post surgery infiltration
62758169|NCT01194843|ACTIVE_COMPARATOR|Physiological serum|Administration of physiological serum by local per and post surgery infiltration
62758170|NCT03777709|EXPERIMENTAL|Intervention|The FAITH! App intervention includes a 10-week core series of multimedia education modules with a LS7 focus and other features including interactive self-quizzes, self-monitoring (diet/physical activity), and social networking. Participants will follow a weekly schedule of each module concentrating on each LS7 component. Personalized messages will be delivered to each participant 3-4 times weekly over the intervention phase through the app dashboard, text message, or email. The sharing board will be moderated weekly to foster discussion on behavior change influences and participant successes/challenges to healthy lifestyle. Participants will maintain app access for the duration of the study.
61987108|NCT01680718|EXPERIMENTAL|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
61987109|NCT01680718|PLACEBO_COMPARATOR|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010). Participants will self-administer 5 puffs per nostril.
61987110|NCT02334007|EXPERIMENTAL|LMWH: Dalteparin|Consenting patients undergoing lung resection will receive standard postoperative thromboprophylaxis in hospital until the time of discharge. Subsequently, patients will be administered LMWH for duration of 30 days as outpatients.
62758171|NCT03777709|NO_INTERVENTION|Delayed Intervention/Control|"The delayed intervention group will not receive additional materials while under the control time point (intervention group within intervention/maintenance phases)."
62758172|NCT06489990|ACTIVE_COMPARATOR|intervention group|"the intervention is combination intervention strategy of  Comorbidity-Co-causes-Joint-prevention"
62758173|NCT06489990|PLACEBO_COMPARATOR|control group|receiving routine health education and mental health knowledge
62758174|NCT00502723|ACTIVE_COMPARATOR|2|Radical laparoscopy prostatectomy
62758175|NCT00502723|EXPERIMENTAL|1|Radical retropubic prostatectomy
62758176|NCT03695380|EXPERIMENTAL|Arm A: Cobimetinib - Niraparib|Stage 2 - Patients will receive cobimetinib PO QD on Days 1-21 (21/7 schedule) in combination with niraparib PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1, Cohort 1.
62758177|NCT03695380|EXPERIMENTAL|Arm B: Cobimetinib - Niraparib - Atezolizumab|Stage 2 - Patients will receive cobimetinib PO QD on Days 1-21 (21/7 schedule) in combination with niraparib QD on Days 1-28 at the established doses for the triplet regimen in Stage 1,Cohort 2 plus atezolizumab by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle.
62758178|NCT03695380|EXPERIMENTAL|Cohort 1 - Cobimetinib - Niraparib|"Stage 1 - Patients in Cohort 1 will be treated with cobimetinib plus niraparib.~Cobimetinib: Patients will receive a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle.~Niraparib: Patients will receive a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle."
62379872|NCT02743546|EXPERIMENTAL|Dose Expansion: Participants with DLBCL|Participants with DLBCL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
62379873|NCT02743546|EXPERIMENTAL|Dose Expansion: Participants with FL|Participants with FL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
62379874|NCT02743546|EXPERIMENTAL|Dose Expansion: Participants with MCL|Participants with MCL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
62379875|NCT02743546|EXPERIMENTAL|Dose Expansion: Participants with CLL|Participants with chronic lymphocytic leukemia (CLL) will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
62379876|NCT00869375|ACTIVE_COMPARATOR|CLEARWAY GROUP|Endovascular peripheral intervention - Percutaneous transluminal angioplasty with simultaneous in situ thrombolysis (local thrombolytic plus low pressure balloon angioplasty) with Clearway balloon
62379877|NCT00869375|ACTIVE_COMPARATOR|ANGIOJET GROUP|Endovascular peripheral intervention - Percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy with AngioJet Rheolytic Thrombectomy System
62758179|NCT03695380|EXPERIMENTAL|Cohort 2 - Cobimetinib - Niraparib - Atezolizumab|"Stage 1 - Patients in Cohort 2 will be treated with cobimetinib plus niraparib and atezolizumab.~Cobimetinib: Patients will receive a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle.~Niraparib: Patients will receive a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle.~Atezolizumab: Patients will also receive atezolizumab administered as an IV infusion at a fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle."
62758180|NCT02904122|OTHER|Teleconsultation|Teleconsultation using a specific camera SoproCare®6
62758181|NCT01960543|ACTIVE_COMPARATOR|Bupivacaine|"Intrathecal administration of bupivacaine 0.5%~Doses:~Bupivacaine 7 mg plus fentanyl 15 ug for patients shorter than 160 cm. Bupivacaine 9 mg plus fentanyl 15 ug for patients equal or taller than 160 cm or hip replacement."
62758182|NCT01960543|ACTIVE_COMPARATOR|Levobupivacaine|"Intrathecal administration of levobupivacaine 0.5%:~Doses:~Levobupivacaine 7 mg plus fentanyl 15 ug for patients shorter than 160 cm. Levobupivacaine 9 mg plus fentanyl 15 ug for patients equal or taller than 160 cm or hip replacement."
62379878|NCT04820946||various episodic mood disturbances patient group|A group of patients with various episodic mood disturbances was used as a clinical case control group.
62758183|NCT05114122|EXPERIMENTAL|Vonlay lithium disilicate ceramic restorations|Vonlay is a hybrid of an onlay with an extended buccal veneer surface for use in bicuspid regions where there is mostly enamel to bond to. The vonlay is less invasive, more readily repairable, less technique-sensitive to attain adequate bonding, and will leave sounder tooth structure remaining if further treatment is required in the future
62758184|NCT05114122|ACTIVE_COMPARATOR|Onlay lithium disilicate ceramic restorations|Onlays are used to restore large areas of decay and also used to replace old restorations, whether they are defective amalgam fillings, old cast-gold onlays, or fabricated from some other material
62758185|NCT01477463|EXPERIMENTAL|Arm A: Vitamin D|4,000 IU oral vitamin D3
62758186|NCT01477463|EXPERIMENTAL|Arm B: Placebo + Vitamin D|Placebo + 4000 IU oral Vitamin D3
62758187|NCT05082220|EXPERIMENTAL|10 ml ESPB group|ESPB group using 10 ml mixture of local anesthetics and contrast medium using ultrasound and fluoroscopy
62758188|NCT05082220|EXPERIMENTAL|20 ml ESPB group|ESPB group using 20 ml mixture of local anesthetics and contrast medium using ultrasound and fluoroscopy
62758189|NCT04372654|EXPERIMENTAL|Radial group|Use of Electroducer Sleeve on radial route
62758190|NCT04372654|EXPERIMENTAL|femoral group|Use of Electroducer Sleeve on femoral route
62758191|NCT01981200|EXPERIMENTAL|Resistance training in AECOPD|The patients conduct daily training during admission with weight cuff 3 set of 10 rep.
62758192|NCT01640418|EXPERIMENTAL|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
62758193|NCT01640418|NO_INTERVENTION|Standard Care|Standard Care
62758194|NCT01688947|EXPERIMENTAL|V116517 - 50 mg|V116517 50-mg tablets
62758195|NCT01688947|EXPERIMENTAL|V116517 - 30 mg|V116517 30-mg tablets
62758196|NCT01688947|ACTIVE_COMPARATOR|Pregabalin|Pregabalin capsules
62758197|NCT01688947|PLACEBO_COMPARATOR|Placebo|Placebo
62758198|NCT04061954|EXPERIMENTAL|Intervention group|"Families in the intervention group received:~1. Parents participate in a group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug and alcohol abuse, anger management, family planning, parenting skills, communication skills, and dealing with couples conflicts~2. Family visits to address topics as family cohesion, intra-familial communication and psychological basic need of children~3. Trauma-focused therapies~4. Parents receive training regarding agriculture and micro credit projects, and financial assistance~5. One child per family receives a social skill training group preparing them for returning to school~6. Access to schools and school material~7. If needed medical assistance is provided~8. If needed legal assistance is provided"
62758199|NCT04061954|NO_INTERVENTION|No intervention group|The control group was invited to participate in three interviews getting small amounts of money (\~2,5 €) as decompensation of their time.
62758200|NCT02961790|EXPERIMENTAL|Group I (low-dose oxybutynin chloride)|Patients receive lower dose oxybutynin chloride PO BID on days 8-49 in the absence of unacceptable toxicity.
62758201|NCT02961790|PLACEBO_COMPARATOR|Group II (low-dose placebo)|Patients receive lower dose placebo PO BID on days 8-49 in the absence of unacceptable toxicity.
62758202|NCT02961790|EXPERIMENTAL|Group III (high-dose oxybutynin chloride)|Patients receive lower dose oxybutynin chloride PO BID on days 8-14 and higher dose oxybutynin chloride on days 15-49 in the absence of unacceptable toxicity.
61987111|NCT02334007|PLACEBO_COMPARATOR|Placebo|After undergoing lung resection these patients will research standard post-op TE prophylaxis and upon discharge will be administered a placebo injection of subcutaneous saline for 30 days duration.
61987112|NCT03249311|EXPERIMENTAL|Levomilnacipran|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
61987113|NCT03249311|ACTIVE_COMPARATOR|Duloxetine (Cymbalta)|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
62379879|NCT04820946||Disruptive Mood Dysregulation Disorder (DMDD) patient group|DMDD patients referred to the hospital for suicidal behaviors between 2013 and 2018 in terms of diagnostic stability, psychiatric comorbidity, and psychosocial factors.
62758203|NCT02961790|PLACEBO_COMPARATOR|Group IV (high-dose placebo)|Patients receive lower dose placebo PO BID on days 8-14 and higher dose placebo on days 15-49 in the absence of unacceptable toxicity.
62758204|NCT02945553|EXPERIMENTAL|NMES|Neuromuscular electrical stimulation (NMES) group
62758205|NCT02945553|ACTIVE_COMPARATOR|Microstimulation|Microstimulation
62758206|NCT01384357||ultrasound,lymphadenopathy|
61987114|NCT03249311|PLACEBO_COMPARATOR|Levomilnacipran Placebo-matched capsules|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
62758207|NCT01070563||Usual|CT angiography is performed 6 hours after the clinical diagnosis of brain death.
62758208|NCT01070563||TCD|When the diagnosis of brain death is made, TCD is performed and then every 2 hours until the flow patterns compatible with brain death are found. Then a CT angiography is performed.
62758209|NCT06054516||Ischemic heart disease|
62758210|NCT01980277|EXPERIMENTAL|LY2780301 + paclitaxel|"The following dose-levels will be investigated:~* Continuous daily PO LY2780301 400 mg QD + weekly paclitaxel 70 mg/m²/week~* Continuous daily PO LY2780301 400 mg QD + weekly paclitaxel 80 mg/m²/week~* Continuous daily PO LY2780301 500 mg QD + weekly paclitaxel 80 mg/m²/week~A dose reduction could be explored:~- Continuous daily PO LY2780301 300 mg QD + weekly paclitaxel 70 mg/m²/week"
62758211|NCT06217523|NO_INTERVENTION|Control Group|Doctor-only care; receiving standard care without genetic information
62758212|NCT06217523|EXPERIMENTAL|Intervention Group|Pharmacist-guided care; dosing of statin medication based on genetic information
62758213|NCT06599983|EXPERIMENTAL|Test group|The test group attended the one day educational programme, Educational Storytelling, an Educational Program Against Child Abuse and Neglect.
62758214|NCT06599983|NO_INTERVENTION|Control group|The control group did not attend the one day educational programme, Educational Storytelling, an Educational Program Against Child Abuse and Neglect.
62758215|NCT02071420|EXPERIMENTAL|Experimental Group|This group will receive the seated active workstation intervention, the ergonomic intervention and the email intervention for 16 weeks.
62758216|NCT02071420|ACTIVE_COMPARATOR|Active Control|This group will receive the ergonomic intervention and email intervention only for 16 weeks. This group will not receive a seated active workstation.
62758217|NCT02536066|NO_INTERVENTION|Control|maintain usual physical activity patterns
62758218|NCT02536066|EXPERIMENTAL|Intervention|Addition of daily postprandial physical activity in addition to usual activity patterns
62758219|NCT00869245|EXPERIMENTAL|1|Cardiac MRI Protocol. Patients will be transferred to the observation unit and undergo a stress cardiac MRI evaluation.
61987115|NCT03628755|ACTIVE_COMPARATOR|Digital Manipulation|Digital manipulation of thyroid cartilage (DMT) Duration: Each child was given 15-20 minute session. Frequency: Twice in a week. Total 24 sessions were performed. The aim of DMT was to reduce the severity of stuttering and improve the fluency.
62379880|NCT04779476||Control Group|No dressing material will be used post dental extraction
62758220|NCT00869245|EXPERIMENTAL|2|Conventional care cardiac testing. Patients will be transferred to the observation unit and undergo cardiac testing as determined by their treating physician.
62758221|NCT06346366|ACTIVE_COMPARATOR|Open loop|The control arm (open loop) consists of standard treatment for diabetes with continuous subcutaneous insulin infusion or insulin injections for 3 months.
62758222|NCT06346366|EXPERIMENTAL|Closed loop|The intervention arm is 3 months closed loop control of blood glucose with the BIHAP. The BIHAP contains a self-learning algorithm which automatically maintains the glucose levels within target limits via subcutaneous administration of insulin (Humalog®) and glucagon. Patients complete a training period before the intervention period will start.
62758223|NCT01909882|OTHER|Family member's massage therapy|Family member's massage therapy
62758224|NCT03610503|EXPERIMENTAL|Music|Patients listen to music during EMG test
62758225|NCT03610503|NO_INTERVENTION|Control (Standard Care)|Patients do not listen to music during EMG test (ie. Standard of care)
62758226|NCT04938999|EXPERIMENTAL|MVgPA group|"The MVgPA group consists of 24 sessions conducted over 12 weeks for the study participants by the staff of residential care facilities.~The structured MVgPA group session (10 - 12 participants) will be conducted twice per week. The 75-min music-paced physical activities will be presented in the PowerPoint slideshow. The instructions for an upper limb exercise will be presented in a large number pad in the slideshow, and the participants will then be asked to follow the actions and directions presented on the slide."
62758227|NCT04938999|OTHER|Control group|residential care facilities will conduct their usual activities during the study period. A trained RA2 will record the activities conducted by the residential care facilities during the study period.
62758228|NCT02852395|EXPERIMENTAL|Part 1 Single Dose|Part 1 single daytime oral dose of JNJ-48816274 or placebo. Doses of JNJ-48816274 will start at 5 milligram (mg) and increase sequentially to a maximum dose of 250 mg.
62758229|NCT02852395|EXPERIMENTAL|Part 2 Crossover Sleep Study|Part 2 single nighttime oral dose of JNJ-48816274 or placebo administered during each of 3 or 4 crossover periods separated by 7-9 days. The doses of JNJ-48816274 will be selected based on data from Part 1 (not to exceed 250 mg).
61987116|NCT03628755|ACTIVE_COMPARATOR|fluency shaping Therapy|"Fluency Shaping Therapy Duration:Each child was given 30-minute session. Fluency Shaping Therapy (FST) Frequency: Twice in a week Total 24 sessions were performed.~The aim of DMT was to reduce the severity of stuttering and improve the fluency"
62558135|NCT06209580|EXPERIMENTAL|Arm 2|AMT-253 Dose Expansion
62558136|NCT05850611|EXPERIMENTAL|Methylene Blue|The first intervention group (group A) includes diabetic patients with chronic foot ulcers who, despite common treatments, will be undergone oral methylene blue intervention (70 mg in 200 ml of milk) for 4 weeks.
62558137|NCT05850611|EXPERIMENTAL|Milk (control)|Patients with non-healing Diabetic Foot Ulcers only will receive 200 ml of milk for 4 weeks.
62558138|NCT05850611|EXPERIMENTAL|Methylene Blue and Platelet-Rich Plasma-Fibrin Glue|Patients with non-healing Diabetic Foot Ulcers will treat with PRP-Fibrin-Glue plus oral methylene blue (70 mg in 200 ml of milk) for 4 weeks.
62558139|NCT05850611|EXPERIMENTAL|Milk and Platelet-Rich Plasma-Fibrin Glue (control)|Patients with non-healing Diabetic Foot Ulcers will be treated with PRP-Fibrin-Glue and 200 ml of milk for 4 weeks.
62558140|NCT01495299||cataract patients with glaucoma|
62558141|NCT06464484|EXPERIMENTAL|Experimental: cases|Consumed one probiotic for 30 days everyday with or without food. Dicoflor 60 probiotic supplements were provided that contained Lactobacillus rhamnosus GG (ATCC 53103) that contained 6x10\^9 colony forming units (cpu)) per capsule.
62558142|NCT06464484|NO_INTERVENTION|Controls|Had high stress levels but did not consume probiotics
62558143|NCT00096629|EXPERIMENTAL|human PSMA|Patients will receive a total of 6 vaccinations via the intramuscular route. Sites of injection should have intact lymphatic drainage. Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
62558144|NCT00096629|EXPERIMENTAL|mouse PSMA|Patients will receive a total of 6 vaccinations via the intramuscular route. Sites of injection should have intact lymphatic drainage. Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
62558145|NCT05823285|EXPERIMENTAL|QLS31903|0.01μg/kg-2.16 μg/kg QLS31903 for injection
62558146|NCT01215136|ACTIVE_COMPARATOR|Cohort 1|Single-agent everolimus (enrollment limited to patients with patients with creatinine clearance \< 60 ml/min AND Karnofsky performance status of 60-70%)
62558147|NCT01215136|ACTIVE_COMPARATOR|Cohort 2|Everolimus plus paclitaxel (enrollment limited to patients with creatinine clearance \< 60 ml/min OR Karnofsky performance status of 60-70%)
62558148|NCT06511843|ACTIVE_COMPARATOR|Pain Coping Information|A 4-minute audio recording about common pain coping techniques (e.g., ice, rest, medication, surgery).
62558149|NCT06511843|EXPERIMENTAL|Lyrical music|"A 4-minute audio recording of Leonard Cohen's song Hallelujah sung by Rufus Wainwright with choral accompaniment."
62558150|NCT06511843|EXPERIMENTAL|Instrumental Music|A 4-minute audio recording of instrumental, theta wave music.
62758230|NCT02852395|EXPERIMENTAL|Part 3 Repeated Dose (Optional)|Part 3 daytime oral dose of JNJ-48816274 or placebo administered once daily for 7 consecutive days. Doses will be determined based on data from Part 1, and may increase sequentially (not to exceed 250 mg/day).
62758231|NCT06607159|EXPERIMENTAL|Intervention|Group of children in whom the protocol is implemented (the whole class)
62758232|NCT06607159|NO_INTERVENTION|Control|Group of children in whom the protocol is not implemented (the whole class)
62379881|NCT04779476||Alveogyl Group|Alveogyl will be placed in the dental socket after extraction
62379882|NCT04779476||Cutanplast Group|Absorbable gelatin sponges contain will be placed in the dental socket after extraction
62758233|NCT01011803|EXPERIMENTAL|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were \[diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)\]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
62379883|NCT02425995|EXPERIMENTAL|Arthroscopic intercondylar and posteromedial portal|
62379884|NCT02070081|EXPERIMENTAL|Surgery|
62379885|NCT05278884|EXPERIMENTAL|ACLS and then VAST teaching intervention|For each hospital, the intervention will be to pair a 2-day technical resuscitation skills training adapted from the ACLS/AHA and a 3-day VAST course for a multidisciplinary team of 20 participants (i.e., nurses, doctors, non-physician anesthesia providers). Participants' resuscitation skills will be tested at 4 time points: immediately before the ACLS course, immediately after the ACLS course, immediately after the VAST Course, and at 4 months post training.
62379886|NCT03527290|EXPERIMENTAL|Time Restricted Eating|Participants will be instructed and counseled to incorporate a 12-hour Time Restricted Eating (TRE) regimen that begins upon waking and concludes within a 12-hour period (e.g. if wake at 6:30 AM then all caloric intake occurs between 6:30 AM and 6:30 PM). Water and non-caloric beverages (e.g. herbal tea) outside the period are encouraged as desired. There are no specific content or energy intake changes to the diet counseled or recommended as the focus of the counseling in this arm is timing of eating with innate circadian patterns and developing plans and approaches to follow this plan.
62758234|NCT02157792|EXPERIMENTAL|Part A|This part will be 3 + 3 dose escalation study of M6620 in combination with gemcitabine as well as gemcitabine and cisplatin in participants with advanced solid tumors.
62758235|NCT02157792|EXPERIMENTAL|Part B|This part will be 3 + 3 dose escalation study of M6620 in combination with cisplatin or cisplatin and etoposide in participants with advanced solid tumors.
62558151|NCT04709562|EXPERIMENTAL|High Velocity Nasal Insufflation (HVNI)|Patients randomly assigned to this arm will be placed on HVNI therapy with an appropriately fitted Vapotherm Prosoft HVNI nasal cannula. Physiologic and ventilation parameters will be recorded.
62758236|NCT02157792|EXPERIMENTAL|Part B2|This part will be 3 + 3 dose escalation study of M6620 in combination with irinotecan in participants with advanced solid tumors.
62758237|NCT02157792|EXPERIMENTAL|Part C1|This will be the expansion part of the study in which participants with advanced non-small cell lung cancer (NSCLC) will be administered M6620 in combination with gemcitabine.
62379887|NCT03527290|ACTIVE_COMPARATOR|Standard Cardiometabolic Health Diet|Participants will be instructed and counseled with standard clinical dietary guidance for improving cardiometabolic health, where the focus is on the content, specifically a dietary pattern that emphasizes vegetables, fruits, whole grains, legumes, nuts/seeds, low fat dairy, seafood, lean poultry and meat and avoidance of foods with high levels of sodium, added sugars, saturated fats, and trans fats. There is no prescription to reduce energy intake.
62379888|NCT00847691||Sarcoma|patients with biopsy or excision of sarcoma (suspected or diagnosed)
62379889|NCT01320527|EXPERIMENTAL|Nutriceutical formulation|Nutritional supplement
62379890|NCT01320527|PLACEBO_COMPARATOR|Placebo 1|
62379891|NCT01320527|PLACEBO_COMPARATOR|Placebo 2|
62379892|NCT00694434||1|Patients with 2 or more frozen blastocyst that scored GES 70 or better in the fresh cycle.
62379893|NCT00694434||2|Patients with 2 or more frozen blastocysts scoring GES \<70 in the fresh cycle.
62558152|NCT04709562|ACTIVE_COMPARATOR|Noninvasive Positive Pressure Ventilation (NIPPV)|Patients randomly assigned to this arm will be placed on NIPPV therapy with an appropriately fitted full face mask using a pressure support mechanical ventilator system. Physiologic and ventilation parameters will be recorded.
62558153|NCT06512753||Hydroxychloroquine (HCQ)|HCQ is administered orally at a dosage of 400 mg daily.
62558154|NCT06512753||Methotrexate (MTX)|MTX is given at a dose of 15 mg per week, orally or subcutaneously. Additionally, folate supplementation is administered concurrently as part of standard care, with folate 10 mg/week administered 24 hours after MTX intake.
62758238|NCT02157792|EXPERIMENTAL|Part C2|This will be the expansion part of the study in which participants with advanced triple negative breast cancer (TNBC) will be administered M6620 in combination with cisplatin.
62758239|NCT02157792|EXPERIMENTAL|Part C3|This will be the expansion part of the study in which participants with platinum-resistant advanced small cell lung cancer (SCLC) will be administered M6620 in combination with cisplatin or carboplatin.
62758240|NCT01158144|EXPERIMENTAL|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
62758241|NCT01158144|ACTIVE_COMPARATOR|Conctrol|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
62758242|NCT05929378|EXPERIMENTAL|3-point fixation group|Lightweight Mesh Fixation with 3-point Fixation. First fixation is in cooper ligament. Second fixation is in the back of rectus abdominis. Third fixation is in the later of tractus iliopubicus.
62758243|NCT05929378|ACTIVE_COMPARATOR|1-point fixation group|Lightweight Mesh Fixation with 1-point Fixation in the back of rectus abdominis.
62758244|NCT04864132||Subjects survived from COVID-19|The subjects who had confirmed COVID-19 infection aged between 18-30/years
62758245|NCT04864132||Subjects never had COVID-19|"The subjects aged between 18-30/years who have not been diagnosed with COVID-19 as of March 11of 2020 and who have not been in contact and risky according to the Life Fits Into Home application"
62758246|NCT02218073|EXPERIMENTAL|Treatment Sequence AB|Participants will receive 10 milligram (mg) JNJ-42756493 tablet orally on Day 1 of Period 1 and 100 microgram (mcg) of JNJ-61818549 as intravenous injection 2 hours after the intake of 10 mg JNJ-42756493 oral solution on Day 1 of Period 2.
62758247|NCT02218073|EXPERIMENTAL|Treatment Sequence BA|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection after the intake of 10 mg JNJ-42756493 oral solution on Day 1 of Period 1 and JNJ-42756493 10 mg tablet orally on Day 1 of Period 2.
62758248|NCT01730339|ACTIVE_COMPARATOR|Group 1|
62758249|NCT01730339|ACTIVE_COMPARATOR|Group 2|
62758250|NCT06327893||Aquatic rescue|Patients treated by the Danish EMS following an aquatic rescue performed by lay or professional rescuers are identified from the Danish PEMR using the Danish Drowning Formula (DDF) and extensive manual validation.
62758251|NCT01386541|ACTIVE_COMPARATOR|BYK324677|"* Dose group I: total daily dose 2 mg (1 mg BID or 2 mg SID)~* Dose group II: total daily dose 4 mg (2 mg BID or 4 mg SID)~* Dose group III: total daily dose 6 mg (3 mg BID or 6 mg SID)~In each dose group 12 subjects (8 subjects BYK324677, 4 subjects placebo) are planned.~Within each dose group, the subjects will be randomised to either BYK324677 or placebo at a ratio of 2:1.~Within each verum group, the subjects will be randomised to one of the 2 treatment sequences (BID/SID or SID/BID, ratio 1:1) and treated in a cross-over manner."
62758252|NCT01386541|PLACEBO_COMPARATOR|Placebo|
62758253|NCT00846040|EXPERIMENTAL|Obese RF then RC|Obese adult volunteers (BMI above 30 kg/m2) randomized to receive an 85% reduction of baseline dietary fat (RF) for 2 weeks. After a washout period of 2 weeks, they then received a 60% reduction of baseline dietary carbohydrate (RC) for 2 weeks
62379894|NCT03315676|ACTIVE_COMPARATOR|Oral Bonoprazan|Daily intake of Bonoprazan
62379895|NCT03315676|ACTIVE_COMPARATOR|Oral Esomeprazol|Daily intake of Esomeprazol
62379896|NCT02340936|EXPERIMENTAL|LR-ESHAP (lenalidomide 5 mg)|Intervention: lenalidome 5mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 5 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
62379897|NCT02340936|EXPERIMENTAL|LR-ESHAP (lenalidomide 10mg)|Intervention: lenalidome 10mg combined with R-ESHAP( 3 cycles of treatment every 21 days: lenalidomide 10 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
62379898|NCT02340936|EXPERIMENTAL|LR-ESHAP (lenalidomide 15mg)|Intervention: lenalidome 15mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 15 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
62558155|NCT05038878|EXPERIMENTAL|GnRH antagonist (Elagolix)|Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression
62379899|NCT02340936|EXPERIMENTAL|LR-ESHAP (lenalidomide 20mg)|Intervention: lenalidome 20mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 20 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
62558156|NCT02548169|ACTIVE_COMPARATOR|Group 1|Group 1 will consist of patients with resectable, borderline resectable or locally advanced pancreatic cancer. Group 1 will receive DC Vaccine + Standard of Care Chemotherapy.
62558157|NCT02548169|ACTIVE_COMPARATOR|Group 2|Group 2 will consist of patients with metastatic pancreatic cancer, newly diagnosed/untreated metastatic pancreatic cancer, or metastatic pancreatic cancer who have undergone prior neo-adjuvant therapy. Group 2 will receive DC Vaccine + Standard of Care Chemotherapy.
62758254|NCT00846040|EXPERIMENTAL|Obese RC then RF|Obese adult volunteers (BMI above 30 kg/m2) randomized to receive a 60% reduction of baseline dietary carbohydrate (RC) for 2 weeks. After a washout period of 2 weeks, they then received an 85% reduction of baseline dietary fat (RF) for 2 weeks.
62379900|NCT05031494|EXPERIMENTAL|YH003 with Toripalimab in subjects with unresectable /metastatic melanoma|YH003 in combination with Toripalimab in subjects with unresectable /metastatic melanoma after having failed PD-1/L1 +/- CTLA-4 treatment;
62558158|NCT06320184||Intervention cohort|LDCT screening volunteers enrolled in the BioMILD trial (clinicaltrial.gov NCT02247453) with solid and sub-solid baseline LDCT lung nodules, including baseline-identified cancer patients.
62558159|NCT06320184||Validation cohort|LDCT screening volunteers enrolled in the SMILE trial (clinicaltrial.gov NCT03654105) and in the RISP trial (clinicaltrial.gov NCT05766046).
62758255|NCT00846040|ACTIVE_COMPARATOR|Lean Control|Lean adult volunteers (BMI below 30kg/m2) placed on a weight-maintenance diet using a standard diet composition of 50% carbohydrate, 35% fat, and 15% protein on an out-patient basis
62758256|NCT01861925||Normal eye|Astigmatism smaller than 1.5 diopters
62758257|NCT01861925||Large regular astigmatism|Astigmatism of \> 1.5 diopters, regular astigmatism.
62758258|NCT01861925||Large irregular astigmatism|Astigmatism of \> 1.5 diopters, irregular astigmatism.
62758259|NCT01632813||CHD group|Seven-year-old children with CHD who were four years old when they participated in Paediatric ICU follow-up study (i.e. first follow-up time point) (Neurocognitive development of children four years after critical illness and treatment with tight glucose control, Clinical Trials # NCT00214916). The children of the CHD-group underwent cardiac surgery as infants (=\<1year).
62758260|NCT01632813||Control group|Seven-year-old healthy control children who were four years old when they participated in Paediatric ICU follow-up study (i.e. first follow-up time point) (Neurocognitive development of children four years after critical illness and treatment with tight glucose control, Clinical Trials # NCT00214916). These children have never undergone cardiac surgery.
62758261|NCT02699450|ACTIVE_COMPARATOR|Arm A: 0.3 mg Ranibizumab|Participants will receive 0.3 milligrams (mg) ranibizumab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
62758262|NCT02699450|EXPERIMENTAL|Arm B: 1.5 mg Faricimab|Participants will receive 1.5 mg faricimab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
62758263|NCT02699450|EXPERIMENTAL|Arm C: 6 mg Faricimab|Participants will receive 6 mg faricimab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
62758264|NCT01514240|EXPERIMENTAL|D9421-C|D9421-C 9 mg once daily
62758265|NCT01514240|ACTIVE_COMPARATOR|Mesalazine|Mesalazine 1 g three times a day
62379901|NCT05031494|EXPERIMENTAL|YH003 with Toripalimab in subjects with PDAC|YH003 in combination with Toripalimab in subjects with unresectable/ metastatic pancreatic ductal adenocarcinoma (PDAC) as 2nd line treatment;
62758266|NCT05539560|EXPERIMENTAL|Intervention group|Olfactory training twice a day with essential oils
62379902|NCT05031494|EXPERIMENTAL|YH003 with Toripalimab plus standard chemotherapy|YH003 in combination with Toripalimab plus standard chemotherapy (Nab-paclitaxel + Gemcitabine) in subjects with unresectable/metastatic PDAC as 1st line treatment;
62558160|NCT04929327|ACTIVE_COMPARATOR|Self-etch resin based sealant|Self-etch resin based sealant (prevent seal) without prior sandblasting.
62558161|NCT04929327|ACTIVE_COMPARATOR|Prior Sandblasting|Self-etch resin based sealant prevent seal) with prior sandblasting.
62558162|NCT04929327|ACTIVE_COMPARATOR|Total-etch resin based sealant|Total-etch resin based sealant (ultraseal XT) (Ultradent Pro. Inc., USA)
62558163|NCT02943980|EXPERIMENTAL|CMAC Videolaryngoscope|tracheal intubation using CMAC
62558164|NCT02943980|EXPERIMENTAL|Macintosh laryngoscope|tracheal intubation using Macintosh laryngoscope
62758267|NCT05539560|PLACEBO_COMPARATOR|Control group|Olfactory training twice a day with fragrance-free oils
62758268|NCT05429645|EXPERIMENTAL|3-dimensional guidance technique|3-dimensional (3D) guidance technique to position the heart probes in the setting up of a pace maker
62758269|NCT03386786|EXPERIMENTAL|Intervention (Health Partner)|The mobile health (mHealth) product, Health Partner for Knees and Hips (Health Partner), is a combination of a mobile application (app) and a web-based portal.
62758270|NCT03386786|OTHER|Control|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
62758271|NCT05344339|EXPERIMENTAL|Billroth-II modified|An opening will be made at jejunum 25 cm from Treitz's ligament. Another at greater curvature of the stomach right above transected line. A straight stapling device will be used to make isoperistaltic anastomosis at posterior wall of the stomach. After checking for bleeding, common entry hole will be closed using running suture and 3 -5 sutures to attach afferent loop to the remnant stomach
62758272|NCT05344339|ACTIVE_COMPARATOR|Roux-en-Y|Jejunum will be transected 25 to 30 cm from Treitz's ligament. Marginal vessels will be transected if needed to make sure the loop will reach the stomach without tension. Isoperistaltic gastrojejunostomy will be made at posterior wall of the stomach. After checking for bleeding, common entry hole will be closed using running suture. Jejunojejunal mesenteric defect and Petersen's defect will be closed.
62758273|NCT06385093|EXPERIMENTAL|Eldecalcitol|Participants receive oral eldecalcitol 0.75μg daily for 12 months
62758274|NCT06385093|ACTIVE_COMPARATOR|Alfacalcidol + calcium carbonate|Participants receive oral calcitriol 0.5μg daily and 1.5g calcium carbonate daily for 12 months
62758275|NCT01825278||Single group, obese surgical patients with monitoring strip|All eligible patients will have a monitoring strip prospectively applied to their right chest
62758276|NCT03373032|EXPERIMENTAL|Stiper - A|Stiper, breast cancer patients during chemotherapy cycles, once a week, during 10 weeks
62758277|NCT03373032|EXPERIMENTAL|Acupuncture - B|Acupuncture with needles, breast cancer patients during chemotherapy cycles, once a week, during 10 weeks
62758278|NCT03373032|EXPERIMENTAL|Exercise - C|Exercise, breast cancer patients during chemotherapy cycles, once a week, during 10 weeks
62758279|NCT03373032|EXPERIMENTAL|Follow Up - D|Selected patients from the 3 groups Stiper / Acupuncture / Exercise. One session with a Peridell Massager
62758280|NCT03373032|OTHER|Observation - S|Group patients who were unable to participate in the intervention group A / B and C. In this group, only the evaluation will be performed.
62758281|NCT04066686||Young|Participants recruited into one of two groups on age stratification. Young cohort defined as aged 18-65yrs old
62379903|NCT05260450|EXPERIMENTAL|Group A (Long-pulsed group)|Nail clippings allocated to group A received laser treatment with a 1064 nm Nd:YAG-laser. They received one treatment with laser settings: pulse duration 10 ms, spot size 3 mm, fluence 40-50 J/cm2, number of laser pulses 100 /cm2.
62758282|NCT04066686||Elderly|Participants recruited into one of two groups on age stratification. Elderly cohort defined as over 65yrs of age.
62758283|NCT04326725||Hydroxychloroquine|Subjects with prophylaxis
62758284|NCT03989973||Cirrhosis patients|Patients were diagnosed by liver biopsy, CT or ultrasound
62758285|NCT01556048|EXPERIMENTAL|IMMEDIATE START GROUP|Randomized to participate in Behavioral Activation for pathological grief starting at Week 1 of entry into the study
62379904|NCT05260450|ACTIVE_COMPARATOR|Group B (Short-pulsed group)|Nail clippings allocated to group B received laser treatment with a 1064 nm Nd:YAG-laser. They received one treatment with laser settings: pulse duration 0.3 ms, spot size 3 mm, fluence 40 J/cm2, number of laser pulses 100 /cm2.
62758286|NCT01556048|PLACEBO_COMPARATOR|DELAY START GROUP|Randomized to participate in Behavioral Activation for pathological grief starting at Week 12 of entry into the study
62758287|NCT00123097|EXPERIMENTAL|Chlorinated polyethylene elastomer first|Patient receives prosthetic made from CPE then the SOC, silicon.
62758288|NCT00123097|ACTIVE_COMPARATOR|Silicon first|Patient receives prosthetic made from the SOC, silicon, followed by the CPE,Chlorinated polyethylene elastomer.
62758289|NCT04270162|EXPERIMENTAL|New intervention protocol with inspirometer|Respiratory exercises without use of inspirometerwill be taken out 50% and 80% to have it as muscle strength training values for the respiratory muscles based on the contra-relax technique)
62758290|NCT04270162|ACTIVE_COMPARATOR|Protocol of use of inspirometer in a conventional way|This gonna be a experimental group 2 with conventional use of the conventional way.
62758291|NCT04270162|ACTIVE_COMPARATOR|Respiratory exercises without use of inspirometer|This group gonna be a control group with breathing exercises without the use of inspirometer.
62758292|NCT00168103|EXPERIMENTAL|C1-INH 10 U/kg bw|10 Units (U)/kg body weight (bw) dose
62758293|NCT00168103|EXPERIMENTAL|C1-INH 20 U/kg bw|20 U/kg bw dose
62758294|NCT00168103|PLACEBO_COMPARATOR|Placebo|
62758295|NCT04421872|EXPERIMENTAL|General anesthesia Group|
62758296|NCT04421872|NO_INTERVENTION|Healthy control group|
62758297|NCT01244581|EXPERIMENTAL|Amoxicillin-clavulanate|Oral amoxicillin-clavulanate 40 mg/kg/day divided in two daily doses for 7 days
62758298|NCT01244581|PLACEBO_COMPARATOR|Placebo|
62758299|NCT00402714|ACTIVE_COMPARATOR|1|Extracorporeal photopheresis, pentostatin and total body irradiation
62758300|NCT00402714|ACTIVE_COMPARATOR|2|Pentostatin and total body irradiation
62758301|NCT00196859|ACTIVE_COMPARATOR|A|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
62758302|NCT00196859|EXPERIMENTAL|B|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
62758303|NCT01839240|EXPERIMENTAL|Treatment (azacitidine, cytarabine, and mitoxantrone)|"INDUCTION: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5, cytarabine IV over 4 hours on days 6 and 10, and mitoxantrone hydrochloride IV over 60 minutes on days 6 and 10.~CONSOLIDATION: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients ineligible for allogeneic stem cell transplantation continue on to maintenance.~MAINTENANCE: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
62758304|NCT02736266|EXPERIMENTAL|Pembrolizumab (MK-3475)|Pembrolizumab (MK-3475) will be administered at the dose of 200mg, as a 30-minute intravenous infusion, every 3 weeks, for a total of 3 cycles prior to radical cystectomy.
62758305|NCT04811105|ACTIVE_COMPARATOR|steam ablation|The fistula tract which treated with steam ablation
62758306|NCT04811105|ACTIVE_COMPARATOR|control group|The fistula tract which do not take any treatment
62758307|NCT04442256|OTHER|Dupilumab|All patients will be administered subcutaneous doses of dupilumab in a monthly fashion. Observation period will be 30 minutes after injection
62758308|NCT04585711|OTHER|Optimal dosing|Obese children (≥ 2 year old) and adults with juvenile idiopathic arthritis (JIA) or Rheumatoid Arthritis (RA) who are starting etanercept as part of their routine medical care.
62758309|NCT04966728||suspected tear of the anterior superior labrum of the hip|One group consisted of patients with suspected tear of the anterior superior labrum of the hip.
62758310|NCT04966728||non-hip joint diseases|For non-hip joint reasons, come to the ultrasound department of our hospital to diagnose patients at the same time, and exclude other past and current hip diseases
62758311|NCT01924442||On-Pump|Cardiac bypass using Heart Lung Machine
62758312|NCT01924442||Off-Pump|Cardiac bypass surgery on beating heart
62758313|NCT05082350|EXPERIMENTAL|Healthy Group,|Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
62758314|NCT05082350|EXPERIMENTAL|Hypercholesterolemia|Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
61987117|NCT03628755|EXPERIMENTAL|combination Group|Combination Group (DMT+FST) Duration:Each subject was given 45-Minute session Frequency: Twice in a week Total 24 sessions were performed combination group was more significant option for reducing the severity of stuttering and improve fluency than practice the single DMT or FST
61987118|NCT00973739|EXPERIMENTAL|Lapatinib|"Lapatinib PO dosed according to age:~Children/adolescents (less than 18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO twice daily~Adults (18 years of age or older): 1,500 mg PO once daily~Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment."
62758315|NCT03483805|EXPERIMENTAL|Treatment|Protalsafe product, daily, 12 weeks
62758316|NCT03483805|PLACEBO_COMPARATOR|Placebo|Placebo product, daily, 12 weeks
62758317|NCT03704662|OTHER|Stereotactic Body Radiation Therapy|Patients undergo Stereotactic Body Radiation Therapy (25 to 35 Gy over five fractions)
61987119|NCT03057405||intra-operative CBCT|
61987120|NCT03057405||3D virtual planning + intra-operative navigation|
61987121|NCT03057405||3D virtual planning + intraoperative navigation + IO CBCT|
61987122|NCT05781295|EXPERIMENTAL|TauroLock™|The patient will be followed up to a maximum of 6 months after randomization after have a Taurlock™ injected each time catheter will be used.
62758318|NCT03704662|OTHER|Preoperative Fractionated Radiation Therapy and Chemotherapy|Concurrent chemotherapy with radiation treatment (50.4 Gy over 28 fractions).
62758319|NCT02253823|EXPERIMENTAL|TPV+RTV - low dose|
62758320|NCT02253823|EXPERIMENTAL|TPV+RTV - high dose|
61987123|NCT05781295|PLACEBO_COMPARATOR|Physiological serum (NaCl 0.9%)|The patient will be followed up to a maximum of 6 months after randomization after have a Physiological serum injected each time catheter will be used.
61987124|NCT06344754|EXPERIMENTAL|Gamified Family Planning Education|Family planning training will be provided to university students through gamification.
61987125|NCT01838993|ACTIVE_COMPARATOR|Lidocaine|Inhalation of lidocaine before intubation
61987126|NCT01838993|PLACEBO_COMPARATOR|Control|Normal saline inhalation before intubation
62758321|NCT03999138||Single Arm|
62758322|NCT02906215|EXPERIMENTAL|Care Coordination Intervention|The care coordination intervention will consist of a mobile application designed for treatment providers, an interagency communication protocol, and a series of cross-training in HIV and addiction issues.
62758323|NCT03426358|EXPERIMENTAL|Patients undergoing HSCT|LSM assessed by Elastographic Techniques
62758324|NCT00899717|EXPERIMENTAL|A|
62758325|NCT00899717|PLACEBO_COMPARATOR|B|
62758326|NCT04185974|EXPERIMENTAL|C12 irradiation|Evaluation of Safety and Toxicity of C12 ion reirradiation
62758327|NCT04185974|ACTIVE_COMPARATOR|Photon irradiation|Evaluation of Safety and Toxicity of photon re-irradiation
62758328|NCT01359761|EXPERIMENTAL|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Post Admission Cognitive Therapy Individual Sessions; Up to Two (2) Inpatient Booster Sessions; Up to Four (4) Telephone Booster Sessions Following Psychiatric Discharge; 12-Months Case Management
62758329|NCT01359761|NO_INTERVENTION|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services; 12-Months Case Management
62758330|NCT01944566|EXPERIMENTAL|heavy armpit odour|subjects with heavy armpit odour
62758331|NCT04636177|EXPERIMENTAL|Pain Rehabilitation Virtual Reality (PRVR)|Participants will complete VR in PT to engage participants in a series of immersive games customized to align with individual PT needs delivered over \~6-12 weeks or until clinician believes the patient is done with treatment. Patients in the PRVR arm will be given a structured HEP to practice prescribed exercises at home with integrated VR activities. PRVR participants will be allocated a VR headset for use in PT sessions and with HEP. VR will supplement treatment and be used in session (either in-person or telehealth) and at home as part of their prescribed treatment homework.
62758332|NCT03413098|EXPERIMENTAL|Trial nasal Continuous Positive Airway Pressure (CPAP) mask|Trial nasal CPAP mask
62758333|NCT03255213|EXPERIMENTAL|Late Onset Pompe Disease who have tongue weakness|
62758334|NCT02425605|EXPERIMENTAL|CCRT-sorafenib group|
62379905|NCT01594749|EXPERIMENTAL|Fosaprepitant Regimen|On Day 1, participants received fosaprepitant, 150 mg intravenous (IV) infusion, \~30 minutes prior to chemotherapy PLUS dexamethasone 12 mg, orally (PO) \~30 minutes prior to chemotherapy PLUS ondansetron 16 mg total dose: 8 mg PO \~30-60 minutes prior to chemotherapy, followed by 8 mg PO, 8 hours after first dose PLUS dexamethasone placebo, PO \~30 minutes prior to chemotherapy. On Days 2 and 3, participants received ondansetron placebo, PO every 12 hours. Rescue Therapy: For established cases of nausea or vomiting, medications may have been prescribed from these permitted choices: 5-HT3 antagonists (granisetron, dolasetron, tropisetron or ondansetron); phenothiazines (e.g. prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine); butyrophenones (e.g. haloperidol or droperidol); benzamides (e.g. metoclopramide or alizapride); benzodiazepines; corticosteroids; domperidone.
62379906|NCT01594749|ACTIVE_COMPARATOR|Control Regimen|On Day 1, participants received fosaprepitant placebo, 150 mL IV infusion, \~30 minutes prior to chemotherapy PLUS dexamethasone 20 mg, PO \~30 minutes prior to chemotherapy PLUS ondansetron 16 mg total dose: 8 mg PO \~30-60 minutes prior to chemotherapy; followed by 8 mg PO, 8 hours after the first dose. On Days 2-3, participants received ondansetron 8 mg, PO every 12 hours. Rescue Therapy: For established cases of nausea or vomiting, medications may have been prescribed from these permitted choices: 5-HT3 antagonists (granisetron, dolasetron, tropisetron or ondansetron); phenothiazines (e.g. prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine); butyrophenones (e.g. haloperidol or droperidol); benzamides (e.g. metoclopramide or alizapride); benzodiazepines; corticosteroids; domperidone.
62379907|NCT01951976|EXPERIMENTAL|Intervention Condition|"Questionnaires and yoga classes.~Group will attend a series of 90-minute yoga classes twice a week for 12 weeks."
62379908|NCT05696002||Advanced pelvic oncological resection|Complex resection
62379909|NCT03583502|EXPERIMENTAL|Supplemented|krill oil and fish oil supplement
62379910|NCT03583502|NO_INTERVENTION|Controls|The control group did not receive any supplementation.
62379911|NCT04101162|OTHER|liver biopsy|
62558165|NCT02691234|EXPERIMENTAL|Extracorporeal Shockwave Therapy and debridement|The treatment will be performed as an outpatient care procedure with no anesthesia. Patients will undergo wound debridement and cleansing before each treatment. The transducer device will be positioned against the lesion area and shockwaves will be delivered at a gradually increasing energy, with a maximum energy level of 0.09mJ/mm2
62558166|NCT02691234|ACTIVE_COMPARATOR|debridement and cleansing.|The standard treatment to the control group and the treatment group will be performed as an outpatient care procedure with no anesthesia. Patients will undergo wound debridement and cleansing. The physician will treat the patient in regard to his medical state: antibiotic medication if needed, dressing and off loading with Orthotic devices
62558167|NCT00879086|ACTIVE_COMPARATOR|Eribulin mesylate|
62558168|NCT00879086|ACTIVE_COMPARATOR|Ixabepilone|
62558169|NCT03367195|ACTIVE_COMPARATOR|Treatment 1|1 Omeprazole capsule 20 mg and 1 placebo caplet of DLBS2411, twice daily
62379912|NCT04101162|OTHER|ATI|
62379913|NCT01424267||1|
62379914|NCT05466240|ACTIVE_COMPARATOR|AT-752 750-mg TID for 5 days|Tablet; 750-mg, Three (3) times a day for 5-days
62379915|NCT05466240|ACTIVE_COMPARATOR|AT-752 Dose A for 5 days|Tablet; Dose A, for 5-days
62379916|NCT05466240|ACTIVE_COMPARATOR|AT-752 Dose B for 5 days|Tablet; Dose B, for 5-days
62379917|NCT01143844||Exposed females, ages 11-40|"* Prior exposure to alkylating agent chemotherapy and/or radiation therapy~* At least 1 year from completion of chemotherapy and/or radiation therapy~* Uterus and at least one ovary are present~* Not pregnant or breastfeeding in the past 3 months~* Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~* No medical condition (other than cancer) known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
62558170|NCT03367195|EXPERIMENTAL|Treatment II|1 DLBS2411 caplet 250 mg and 1 placebo capsule of Omeprazole, twice daily
62558171|NCT03860974|EXPERIMENTAL|Serratus Plane (single injection)|A single injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL on each side for bilateral surgery)
62558172|NCT03860974|ACTIVE_COMPARATOR|Paravertebral (single injection)|Single injection paravertebral blocks will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL each side for bilateral surgery)
62558173|NCT02969252|OTHER|Open label|Single and multiple dose, open label, pharmacokinetics and safety study
62558174|NCT03982511|EXPERIMENTAL|PCIT-Health|Participants assigned to the PCIT-Health arm will receive the intervention.
62558175|NCT03982511|NO_INTERVENTION|Wait list control|Participants in the wait list control will receive an invitation to participate in the intervention 10 months after baseline data collection.
62558176|NCT02500589|EXPERIMENTAL|Mood management enhancement|In the SMK-MM enhanced arm, behavioral mood management will be integrated into the evidence-based smoking cessation counseling.
62567596|NCT04082026|PLACEBO_COMPARATOR|Enhanced Treatment As Usual (ETAU)|The Enhanced Treatment as Usual (ETAU) consisted of a single psychoeducation individual session, jointly for eligible adolescents and their caregivers, that included information on: (i) the results of the screening; (ii) self-care strategies; and, (iii) seeking services from local health or community services offering psychosocial / mental health care support.
62758335|NCT06082596|EXPERIMENTAL|Monotherapy group 1(Dose escalation phase)|BEBT-908 for injection， dosage form ：Injection； specification: 25 mg , administration method: 10mg/m2，intravenous drip, firstly the subjects were given a single dose and observed for 6 days. At the end of the observation period, if the subjects were tolerant to a single dose and safe, they would receive the same dose for a cycle (21 days), giving the drug three times a week for 2 weeks and stopping the drug for 1 week. A total of 21 days is a cycle.
62379918|NCT01143844||Unexposed females, ages 40-50|"* Never exposed to chemotherapy or radiation therapy~* Regular menstrual cycle (every 21-35 days)~* Uterus and at least one ovary are present~* Not pregnant or breastfeeding in the past 3 months~* Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~* No medical condition known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
62379919|NCT01143844||Unexposed females, ages 11-35|"* Never exposed to chemotherapy or radiation therapy~* Regular menstrual cycle (every 21-35 days)~* Uterus and at least one ovary are present~* Not pregnant or breastfeeding in the past 3 months~* Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~* No medical condition known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
62379920|NCT04335357|PLACEBO_COMPARATOR|placebo|The appearance and fill of placebo syringes will be identical to the active comparator.
62758336|NCT06082596|EXPERIMENTAL|Monotherapy group 2(Dose escalation phase)|BEBT-908 for injection， dosage form ：Injection； specification: 25 mg , administration method: 15mg/m2，intravenous drip, firstly the subjects were given a single dose and observed for 6 days. At the end of the observation period, if the subjects were tolerant to a single dose and safe, they would receive the same dose for a cycle (21 days), giving the drug three times a week for 2 weeks and stopping the drug for 1 week. A total of 21 days is a cycle.
61987127|NCT03774433|EXPERIMENTAL|Laddr|All participants in the study will be invited to use Laddr, described in the intervention section.
62758337|NCT06082596|EXPERIMENTAL|Monotherapy group 3(Dose escalation phase)|BEBT-908 for injection， dosage form ：Injection； specification: 25 mg , administration method: 22.5mg/m2，intravenous drip, firstly the subjects were given a single dose and observed for 6 days. At the end of the observation period, if the subjects were tolerant to a single dose and safe, they would receive the same dose for a cycle (21 days), giving the drug three times a week for 2 weeks and stopping the drug for 1 week. A total of 21 days is a cycle.
62379921|NCT04335357|ACTIVE_COMPARATOR|TBR-760|TBR-760 is supplied as a ready-to-use solution in pre-filled syringes at a concentration of 5 mg/ml.
62758338|NCT06082596|EXPERIMENTAL|Monotherapy group 4(Dose escalation phase)|BEBT-908 for injection， dosage form ：Injection； specification: 25 mg , administration method: 33.75mg/m2，intravenous drip, firstly the subjects were given a single dose and observed for 6 days. At the end of the observation period, if the subjects were tolerant to a single dose and safe, they would receive the same dose for a cycle (21 days), giving the drug three times a week for 2 weeks and stopping the drug for 1 week. A total of 21 days is a cycle.
62758339|NCT06082596|EXPERIMENTAL|Monotherapy group 5(Dose escalation phase)|BEBT-908 for injection， dosage form ：Injection； specification: 25 mg , administration method: 45mg/m2，intravenous drip, firstly the subjects were given a single dose and observed for 6 days. At the end of the observation period, if the subjects were tolerant to a single dose and safe, they would receive the same dose for a cycle (21 days), giving the drug three times a week for 2 weeks and stopping the drug for 1 week. A total of 21 days is a cycle.
62758340|NCT06082596|EXPERIMENTAL|Monotherapy group 6（Dose expansion phase）|BEBT-908 for injection ，dosage form ：Injection ；specification: 25mg , administration method: 15mg/m2，intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week，21 days as cycle, until the disease progressed or withdrew.
62758341|NCT06082596|EXPERIMENTAL|Monotherapy group 7（Dose expansion phase）|BEBT-908 for injection ，dosage form ：Injection ；specification: 25mg , administration method: 22.5mg/m2，intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week，21 days as cycle, until the disease progressed or withdrew.
62758342|NCT01263392|ACTIVE_COMPARATOR|Polyvinyl Chloride Catheter|Re-use clean polyvinyl chloride catheters for intermittent catheterization of children with spina bifida.
62758343|NCT01263392|ACTIVE_COMPARATOR|Hydrophilic catheter|Use hydrophilic catheters (Speedicath) for intermittent catheterization of children with spina bifida.
62758344|NCT01215110|EXPERIMENTAL|TMC207 700/500/400|TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14
62758345|NCT01215110|EXPERIMENTAL|TMC207 500/400/300|TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.
62758346|NCT01215110|EXPERIMENTAL|TMC207 400/300/200|TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14
62758347|NCT01215110|EXPERIMENTAL|TMC207 200/100|TMC207- 200 mg Day 1 and 100 mg Days 2-14
62758348|NCT01215110|ACTIVE_COMPARATOR|Rifafour e-275 mg|Rifafour e-275 mg
62758349|NCT06327633|EXPERIMENTAL|Olfactory Training Group|The subjects repeatedly sniffed pleasant scents of rose, lemon, clove, eucalyptus, coffee and cinnamon twice a day, 5-min per time, with focus, until the completion of the study. Meanwhile, all patients will also continue on their existing dose and regimen of glucose- lowering schemes throughout the study. Visits at 3-week intervals will be performed to evaluate the blood glucose situation, assess the safety of intervention and confirm the compliance of participants.
62758350|NCT06327633|NO_INTERVENTION|Control Group|The subjects will maintain the original diet and lifestyle, and also continue on their existing dose and regimen of glucose- lowering schemes throughout the study. Visits at 3-week intervals will be performed to evaluate the blood glucose situation.
62758351|NCT05762861|NO_INTERVENTION|Usual follow up|Group 1: To keep follow-up in their usual family practice/ pulmonology consultations
62758352|NCT05762861|EXPERIMENTAL|Home telemonitoring|Group 2: To keep follow-up in their usual family practice/ pulmonology consultations and associate an interactive home telemonitoring system managed by the researchers.
62758353|NCT05518773||Nusinersen treated|Children and adults who are currently treated with nusinersen for at least 6 months prior to enrollment.
62379922|NCT04873895|EXPERIMENTAL|TACE+axitinib+HCQ|2 weeks of axitinib 5mg BID and hydroxychloroquine 600 mg BID followed by lobar or segmental trans arterial chemoembolization monthly until the entire tumor burden is treated, then continue axitinib/HCQ until progression or intolerable toxicity.
62379923|NCT01383551|EXPERIMENTAL|"Becoming Parents intervention"|"A Becoming Parents Programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
62379924|NCT01383551|NO_INTERVENTION|Usual prenatal education|Attend usual prenatal classes which will be provided by the midwives in the hospital.
62379925|NCT04828928|EXPERIMENTAL|proportion of patients with neuropathy|to prospectively study patients with a wild-type amyloid cardiopathy condition to identify and describe the associated neuropathy
62379926|NCT01814891|EXPERIMENTAL|Orange maize|"Children were fed orange maize and the intervention name was orange"
62758354|NCT05518773||Risdiplam treated|Children and adults who are currently treated with risdiplam for at least 6 months prior to enrollment.
62758355|NCT02360644|EXPERIMENTAL|Arm 1: Drug Metabolism and Transport|"The aim of Arm 1 is to determine the effect of vitamin D deficiency and repletion on xenobiotic clearance in vivo. The study will evaluate the in vivo function of targeted metabolism and transport pathways in 40 CKD and 18 healthy volunteer subjects (controls) under the influence of a vitamin D depleted state and repeated under a vitamin D replete state with cholecalciferol.~The function of two major phase I drug metabolizing enzymes (CYP2B6, CYP3A), and three transporters \[P-gp, MRP2, and MATE1/2K\] will be assessed by administering oral bupropion, midazolam, olmesartan, and fexofenadine."
62758356|NCT02360644|EXPERIMENTAL|Arm 2: Vitamin D Pharmacokinetics|The aim of Arm 2 is to determine the effect of CKD on the in vivo function of individual CYP450s responsible for vitamin D metabolism and their functional relevance on the pharmacokinetics of cholecalciferol. A total of 90 CKD subjects will be enrolled \[30 per group: group I (CKD stage 1/2), group II (CKD stage 3), and group III (CKD stage 4/5, pre-ESRD)\], as well as 30 healthy controls.
62758357|NCT00110071|EXPERIMENTAL|Treatment (chemoradioimmunotherapy)|Patients receive a dosimetric dose of iodine I 131 tositumomab IV over 40-60 minutes on day -24 followed by gamma camera imaging over the next 6 days. Patients then receive a therapeutic dose of iodine I 131 tositumomab via central line over 40-60 minutes on day -14. Patients also receive fludarabine phosphate IV QD on days -11 to -9 OR days -11 or -7. Patients undergo autologous or syngeneic peripheral blood stem cell transplantation on day 0.
62379927|NCT01814891|ACTIVE_COMPARATOR|Blue vitamin A group|Received vitamin A in the form of retinyl palmitate in oil at the estimated average requirment.
62379928|NCT01814891|PLACEBO_COMPARATOR|White|Received oil only at the same volume as the vitamin A group
62567597|NCT00623168|EXPERIMENTAL|Treatment Only|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with Ribavirin.
62379929|NCT06091202|ACTIVE_COMPARATOR|CORPs Intervention|"The CORPs Intervention is a nurse-led intervention.~A) An intake assessment with a Nurse Care Manager at the start of the study by phone or video to discuss the patient's pain experience, care options, and goals. Resources are provided and focus on non-medication options at the VA, and as appropriate, in the community.~B) 5 Check-in phone/video appointments with a Nurse Care Manager, scheduled to take place near 2-, 4-, 8-, 12-, and 16-weeks. These visits will provide further assistance with goal planning and care coordination for pain management.~C) Optional 6-week virtual group education class covering topics like complementary and integrative approaches to pain, sleep and pain, and the neurobiology of pain.~D) Patients in this arm can contact their nurse with questions for the full 12 months of participation."
62379930|NCT06091202|PLACEBO_COMPARATOR|Minimally Enhanced Usual Care (MEUC)|"The minimally enhanced usual care arm is a one-time education session.~A) One-time education session with a Nurse Care Manager by phone/video to review pain resources. These resources focus on non-medication options at the VA, and as appropriate, in the community."
62379931|NCT02678156||LYoplant ONlay|Primary objective of the study is the generation of clinical data in patients receiving Lyoplant® Onlay for dura repair to assess its safety.
62379932|NCT03734133|EXPERIMENTAL|Foot orthoses|Different foot orthoses
62379933|NCT03640104|EXPERIMENTAL|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
62379934|NCT03640104|OTHER|Nutrition Guidelines|Participants will receive general nutritional recommendations according to international standards
62379935|NCT02221570|ACTIVE_COMPARATOR|Baclofen|Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
62379936|NCT02221570|PLACEBO_COMPARATOR|Placebo|placebo of baclofen
62379937|NCT01265940|EXPERIMENTAL|Pazopanib + Vinflunine|
62379938|NCT06464887||Recurrent acute pancreatitis|
62379939|NCT06464887||Non-recurrent acute pancreatitis|
62379940|NCT05390034|EXPERIMENTAL|ART|Developed by Berking and Whitley (Berking \& Whitley, 2014), this transdiagnostic program aims to improve general emotion regulation skills, and more specifically by increasing participants' emotion regulation flexibility. ART targets several skills, such as acceptance, tolerance, non-judgmental awareness, self-support, analysis of the causes of emotions and emotional modification. This intervention consists of 9 sessions (2 hours each), each of which starts with the presentation of a vicious circle for psycho-education. This vicious circle is then transformed into a virtuous circle by introducing an emotion regulation skill. Participants are invited to reflect, discuss and practice this skill. Exercises are also recommended at home, with the help of audios and a written workbook made available. All the material was translated into French for the purpose of this research.
62379941|NCT05390034|ACTIVE_COMPARATOR|Relaxation|The relaxation group will be based mainly on the intervention developed by Dominique Servant (Relaxation and meditation, 2021), adapted for this research for the group format and divided into 9 modules (2 hours each). This intervention proposes an added psycho-education part similar to the dedicated session of the ART program, followed by the teaching of different relaxation techniques to the participants, who are invited to test them in session and then to practice them at home. This control group focuses on a specific component present in the ART group (relaxation), allowing us to assess the impact of the other components of the ART program and thus explore our flexibility hypothesis (requiring several emotion regulation skills). Note that the mindfulness meditation components were removed from the program for this study, as they were considered a second emotion regulation skill.
62567598|NCT02972905|PLACEBO_COMPARATOR|Session 1: Placebo|Subjects will receive a single dose inhalation of GSK2269557 matching placebo via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
62758358|NCT01012921|ACTIVE_COMPARATOR|Bio-Gide® membrane|Bio-Gide® membrane This is a biodegradable bilayer membrane for bone and tissue regeneration. It has a natural collagen structure and is of porcine origin
62758359|NCT01012921|EXPERIMENTAL|MembraGel|MembraGel The Straumann membrane is a synthetic degradable barrier membrane
62758360|NCT04867941|EXPERIMENTAL|Part1: Mild hepatic insufficiency|Participants with mild hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
62758361|NCT04867941|EXPERIMENTAL|Part 1: Moderate hepatic insufficiency|Participants with moderate hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
62758362|NCT04867941|EXPERIMENTAL|Part 1: Normal hepatic function|Participants with normal hepatic function will receive a single oral dose of 50 mgACP-196 (2 x 25 mg capsules) on Day 1 of the study.
62758363|NCT04867941|EXPERIMENTAL|Part 2: Severe hepatic insufficiency|Participants with sever hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
62379942|NCT04084873|EXPERIMENTAL|Experimental PBrE|Participants are exposed to several words of emotional contents (positive, and negative). The differences between these words will allow the regulation and counter regulation of emotional processes (Schwager y Rothermund, 2013). The words are related to clinical and personal characteristics of the patients and they will promote an emotional identification that improve the emotional regulation (Kashdan, Barret y McKnight, 2015).
62567599|NCT02972905|EXPERIMENTAL|Session 1: GSK2269557 200 mcg|Subjects will receive a single dose inhalation of GSK2269557 200 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
62758364|NCT03040869||CHD Patients|coronary angioplasty confirmed coronary heart disease.
62758365|NCT03040869||non-CHD patients|coronary angioplasty confirmed no coronary heart disease.
62758366|NCT05476432|EXPERIMENTAL|HAIC 1d|Oxaliplatin, leucovorin, and bolus fluorouracil were conducted equally in the both groups, while infusional fluorouracil 2400 mg/m² was given over 23 hours in the HAIC 1d group
62758367|NCT05476432|ACTIVE_COMPARATOR|HAIC 2d|Oxaliplatin, leucovorin, and bolus fluorouracil were conducted equally in the both groups, while infusional fluorouracil 2400 mg/m² was given over 46 hours in the HAIC 2d group
62758368|NCT00380029|EXPERIMENTAL|Erlotinib|erlotinib given before and after transurethral resection of a bladder tumor, TURBT
62758369|NCT03334279||non smokers|
62758370|NCT03334279||cigarette smokers|Cigarette smokers to be included in the study must be frequent smokers (at least 10 cigarettes a day) for a period not less than 5 years.
62758371|NCT03334279||simultaneous cigarette and cannabis smokers|frequent cigarette smokers (at least 10 cigarettes a day) and frequent cannabis smoker (at least 3 times/week) for not less than 5 years.
62758372|NCT01187446|EXPERIMENTAL|TSEBT & Vorinostat|"Total skin electron beam therapy (TSEBT) will be performed per institution guidelines.~Vorinostat will be administered at a dose of 400 mg/day, starting one day prior to the initiation of TSEBT. During TSEBT, vorinostat should be taken in the morning and preferably prior to TSEBT."
62758373|NCT01187446|ACTIVE_COMPARATOR|TSEBT only|"Total skin electron beam therapy (TSEBT) will be administered according to the Stanford 6-field technique or equivalent technique per institutional standards. Patients will receive a planned total skin dose of 12 grey (Gy) fractionated at 2 Gy/cycle (each cycle requiring 2 days of treatment); 4 days each week; for a total of 3 weeks. Supplements will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions (1-2 Gy fractions to a total dose of 12 Gy). Discrete tumors may receive additional boost treatment not to exceed 12 Gy."
62567600|NCT02972905|EXPERIMENTAL|Session 1: GSK2269557 500 mcg|Subjects will receive a single dose inhalation of GSK2269557 500 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
62758374|NCT04152330|OTHER|Comparison between intervention and control group|"The subjects will be randomized to two groups, intervention group (IG) and control group (CG). Each day GI Parents-Baby receives guidance for 6 weeks of stimulation activities and will be instructed to keep an online execution diary, directly with the researcher of videos and messages via cell phone. Parents is understood as a generalist nomenclature and will be considered a parent, mother or principal.~GC subjects receive standard guidance from the pediatric and pediatric cardiology clinic."
62758375|NCT01244789|ACTIVE_COMPARATOR|Observation|postoperative observation only
62758376|NCT01244789|EXPERIMENTAL|Combination chemotherapy|postoperative 6 courses of 3 weekly iv carboplatin-paclitaxel combination chemotherapy
62758377|NCT01533467|OTHER|Perineal device used|Use of the perineal device during delivery
62758378|NCT01533467|NO_INTERVENTION|No intervention|Controls, delivered as normal
62758379|NCT03975127|NO_INTERVENTION|Routine|women will routinely be invited to attend for cervical screening via the SCCRS application.
62758380|NCT03975127|EXPERIMENTAL|SMS|Women aged under 30 years will be identified to receive an SMS following cervical screening invitation using information from the CHI Broadcast
62758381|NCT00531297|EXPERIMENTAL|Treatment arm|endoscopic posterior mesorectal resection
62379943|NCT04084873|PLACEBO_COMPARATOR|Control PBrE|Participants are exposed to several neutral words. These words do not have any emotional content and there are no reasons to think that they have any effect over the emotional regulation.
62379944|NCT04084873|OTHER|Control|Participants do not receive the intervention.
62379945|NCT03043300||US Travelers to South or Southeast Asia|"Adult individuals who are planning a short term trip to South or Southeast Asia and meet all eligibility criteria will complete the questionnaires and/or provide stool specimens at the following time points:~1. No greater than 4 weeks prior to travel departure: Screening Criteria Review~2. One week prior to travel departure: Pre-Travel Questionnaire and Pre-Travel Stool Specimen Collection~3. Two weeks after return from travel: Short-Term Post-Travel Questionnaire and Short-Term Post-Travel Stool Specimen Collection~4. 14 weeks after return from travel: Long-Term Post-Travel Questionnaire and Long-Term Post-Travel Stool Specimen Collection"
62379946|NCT06030154|EXPERIMENTAL|Amplification of Positivity Therapy|AMP-A will involve 12, one-hour weekly therapy sessions completed one-on-one with a therapist. The sessions and between-session homework will focus on amplifying positive thoughts, emotions, and behaviors to address anxiety/depression and alcohol use.
62558177|NCT02500589|OTHER|Health education control|"In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with personal health care. Participants also will receive chronic-disease-specific self-management information."
62558178|NCT00508599|NO_INTERVENTION|1|Study 1 is the control arm in which participants continue with their normal activity.
62758382|NCT05207332|EXPERIMENTAL|Vegan product|
62758383|NCT05207332|ACTIVE_COMPARATOR|Control|
62758384|NCT06434155||Primary Open Angle Glaucoma|"1. Patients older than 18 years of age with primary open-angle glaucoma (POAG)~2. POAG diagnosed on the basis of IOP measurements more than 21 mmHg, Open angle on gonioscopy (Grade 3 or 4 on Schaffer grading system for angle width), glaucomatous visual field defects consistent with glaucomatous optic disc changes.~3. Eyes with baseline macular and ONH OCT images and ONH photographs of adequate quality and r performed within 6 months of each other were selected"
62758385|NCT05298995|EXPERIMENTAL|ARM A: MB/other embryonal tumor|After a lymphodepleting regimen, patients affected by relapsed/refractory MB/other embryonal tumor will receive 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells.
62758386|NCT05298995|EXPERIMENTAL|ARM B: Hemispheric HGG|After a lymphodepleting regimen, patients affected by relapsed/refractory hemispheric high grade glioma will receive 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells.
62758387|NCT05298995|EXPERIMENTAL|ARM C: Thalamic HGG, DMG, DIPG and other rare CNS tumors not included in Arm A and B|After a lymphodepleting regimen, patients affected by relapsed/refractory thalamic HGG, DMG, DIPG and other rare CNS tumors not included in Arm A and B will receive 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells.
62758388|NCT01767493|EXPERIMENTAL|[18F]Florbetapir PET imaging|\[18F\]Florbetapir and PET imaging
62758389|NCT02220023|EXPERIMENTAL|Nitric Oxide|40 ppm, one time administration, inhaled.
62758390|NCT04371822|ACTIVE_COMPARATOR|5 mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin \< 500 ng/ml will receive a single dose of 5 mg of Stannous Protoporphyrin and They will be exposed to sunlight one hours every day for 14 days
62758391|NCT04371822|ACTIVE_COMPARATOR|7mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin \< 500 ng/ml will receive a single dose of 7 mg of Stannous Protoporphyrin and They will be exposed to sunlight two hours every day for 14 days
62758392|NCT04371822|ACTIVE_COMPARATOR|9 mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin \< 500 ng/ml will receive a single dose of 9 mg of Stannous Protoporphyrin and They will be exposed to sunlight three hours every day for 14 days
62758393|NCT04371822|ACTIVE_COMPARATOR|5mg TPPS dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin \< 500 ng/ml will receive a single dose of 5 mg of sulfonatoporphyrin(TPPS), and They will be exposed to sunlight two hours every day for 14 days
62758394|NCT04371822|PLACEBO_COMPARATOR|placebo|No intervention
62758395|NCT00827281|EXPERIMENTAL|1|DCS-augmented CBT for smoking cessation
62758396|NCT00827281|PLACEBO_COMPARATOR|2|Placebo-augmented CBT for smoking cessation
62758397|NCT02526823|ACTIVE_COMPARATOR|R-CHOP/CHOPE or ABVD chemotherapy regimen|R-CHOP/CHOPE every 21 days or ABVD every 28 days for total 6 courses
62758398|NCT02526823|EXPERIMENTAL|R-CDOP/CDOPE or DBVD chemotherapy regimen|R-CDOP/CDOPE every 21 days or DBVD every 28 days for total 6 courses
62758399|NCT04726033|EXPERIMENTAL|Dose level 1 of 64Cu-TLX592|Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu
62758400|NCT04726033|EXPERIMENTAL|Dose level 2 of 64Cu-TLX592|Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu combined with 8mg of unlabelled TLX592 (mass dose of 10mg).
62758401|NCT04726033|EXPERIMENTAL|Dose level 3 of 64Cu-TLX592|Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu combined with 18mg of unlabelled TLX592 (mass dose of 20mg).
62758402|NCT04726033|EXPERIMENTAL|Confirmation of optimal 64Cu-TLX592 dose|"Based on the result of Groups 1-3, the optimal dose and imaging timepoints will be selected to treat 3 patients with higher tumour burden (≥10 metastatic sites and/or visceral disease as detected on a 68Ga-PSMA-11 or 18F-DCFPyl PSMA PET/CT scan).~Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu combined with 0, 8 or 18mg of unlabelled TLX592."
62758403|NCT03837665|EXPERIMENTAL|PRP Treatment|Participants receive platelet rich plasma treatment. Participants will be asked to make up to 5 trips to the clinic (one for eligibility, one for the PRP, three follow-up visits). Participation is expected to last up to about 6 weeks. After the second visit and application of PRP, patients will be monitored closely for any complications or concerns. This will include a follow up phone call 3-5 days after the initial application of PRP. Patients will also be followed closely in 2 week intervals or sooner should any problems or concerns arise.
62758404|NCT04690803|ACTIVE_COMPARATOR|treatment with forced-air cooling|comparing treatment with and without forced-air cooling in a comparative lower extremity model
62758405|NCT04690803|NO_INTERVENTION|treatment without forced-air cooling|comparing treatment without forced-air cooling in a comparative lower extremity model
62558179|NCT00508599|EXPERIMENTAL|2.|Study 2 consists of 48 hours of complete bed rest.
62758406|NCT02387125|EXPERIMENTAL|Part 1 Dose Escalation of CMB305|Patients with melanoma, NSCLC, ovarian cancer, or sarcoma will be enrolled. Patients will receive CMB305, a sequential regimen of LV305 and G305. Two cohorts are planned based on LV305 dose.
62758407|NCT02387125|EXPERIMENTAL|Part 2 Expansion of CMB305|Arm A will enroll up to 9 patients each with NSCLC or ovarian cancer, or up to 18 patients with the sarcoma subtypes, synovial sarcoma or MRCL. Arm B will enroll up to 9 additional patients with selected sarcoma subtypes to explore subcutaneous (SC) dosing of LV305 and G305 on the same schedule. Arm C will enroll up to 9 patients with synovial sarcoma or MRCL for treatment with CMB305 and with oral metronomic CPA. Arm D will enroll up to 9 patients with synovial sarcoma or MRCL at selected sites for treatment with CMB305 and IT G100. Arm E will enroll up to 6 patients with soft tissue sarcoma any subtype for treatment with a higher dose of CMB305 than previous arms.
62758408|NCT03836430|EXPERIMENTAL|Newborn Behavioral Observation|The Newborn Behavioral Observation-Family Wellness (NBO-FW) intervention is the experimental arm of this RCT. It consists of 3 NBOs - 2 during the birth hospitalization and the third at 6 weeks post-discharge as well as a journal with prompts for mothers to reflect on their infant's behavior and their own transition to motherhood. NBOs are clinical relationship-building tools used by trained clinicians/therapists to help parents understand their babies' unique language.
62758409|NCT03836430|NO_INTERVENTION|Usual care|This arm is the usual care arm. Of note, both arms receive 2 parenting books, one at hospital discharge and one at 6 weeks post-discharge.
62379947|NCT06030154|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|The CBT intervention will involve 12, one-hour weekly therapy sessions completed one-on-one with a therapist. The sessions and between-session homework will focus on monitoring of the relationship between thoughts, emotions, and alcohol use.
62379948|NCT06187051||Patient presenting a type 1A endoleak after EVAR treated by relining with FEVAR|
62379949|NCT06187051||Patient presenting a type 1A endoleak after EVAR treated by explantation of the EVAR|
62558180|NCT05950672|EXPERIMENTAL|CAT Intervention Group|The experimental group will take part in the CAT intervention (Table 1) after baseline assessments. All cat-training methods will be positive reinforcement based, using owner-approved food, toys and social reinforcers (e.g. petting).
62758410|NCT02913209||Multiple Sclerosis Fatigue (MSF) Cohort|Participants will complete study assessments over 4 visits to the DC VAMC. Disease severity will be assessed by the EDSS, and a cognitive battery will be completed. Peak torque assessment for the knee flexors and extensors will be performed on an isokinetic dynamometer (Biodex System 4). Muscle morphology measures of the rectus femoris will be obtained using diagnostic musculoskeletal ultrasound. The sonographic measures will include muscle thickness and echogenicity. Isokinetic and isoinertial mode fatigue measures for the knee extensors will be assessed on separate visits (at least 48 hours apart). Performance-based measures of function will include an assessment of patient mobility and the 25-foot walk test. Muscle power will be estimated by the timed sit to stand test. Subjective measures of fatigue and quality of life include the MSQoL, MFIS, and Neurology Quality of Life Adult Fatigue Bank (AFB).
62758411|NCT04493814||Cohort|All the patients with type 2 diabetes followed at Universitary Hospital of Nancy who had undergone a DEXA and a Fibroscan between 2014 and 2019.
62758412|NCT06277349|OTHER|Non toric multifocal IOL combined with corneal incisional surgery|Non-toric Multifocal IOL (Rayner) - Model M-Flex 630F - CE marked since 2006 (in routine use). Surgery is performed under topical anaesthesia. Preoperatively, the horizontal meridian will be marked in the sitting position with a blue marking pen or insulin syringe at the limbus. The temporal self sealing incision, injection of viscoelastic substance, capsulorhexis, phacoemulsification, irrigation/aspiration of cortical material and injection of viscoelastic substance into the capsular bag are performed as standard procedure. Corneal limbal relaxing incisions (LRI) according to the Donnenefeld nomogram will be performed combined with standard non-toric multifocal IOL.
62558181|NCT05950672|NO_INTERVENTION|CAT Control Group|Control participants will not participate in the CAT intervention. After the completion of the third assessment (end of proposal-related data collection), control participants will be offered the opportunity to participate in cat training classes.
62379950|NCT02608892|EXPERIMENTAL|Intervention|BSweet2Babies video
62379951|NCT02608892|NO_INTERVENTION|Control|Usual care
62379952|NCT01833793||Group 1|
62379953|NCT01027065|EXPERIMENTAL|Tritherapy: CYT107+ vaccine+ antiviral|
62379954|NCT01027065|EXPERIMENTAL|Bitherapy: CYT107 + antiviral|
62379955|NCT00731666|OTHER|Titan® IPP|Subjects implanted with Titan® IPP
62558182|NCT06156995|EXPERIMENTAL|Treatment group|Using 0.30mm × 75mm millineedle (produced by Suzhou Medical Equipment Factory, Huatuo brand) deeply punctures the Zhongliao acupoint to reach the sacral nerve. The acupuncture needle is connected using the MuhiStim Sensor nerve stimulator produced by Pajunk in Germany. Connect the positive pole to the left Zhongliao hole and the negative pole to the right Zhongliao hole. The frequency, current, and pulse width of sacral nerve electrical stimulation are 2 Hz, 5mA, and 0.1 ms, respectively.Electroacupuncture stimulates the sacral nerve for 30 minutes, once a day, five times a week. After the treatment, rest for two days before starting the next treatment. Five sessions are considered as one course of treatment, with a total of four courses for four consecutive weeks.
62558183|NCT06156995|ACTIVE_COMPARATOR|control group|Mosapride citrate tablets (produced by Lunan Beite Pharmaceutical Co., Ltd., with the national drug approval number H19990317), oral administration, 5mg once, three times a day, taken before meals. 5 days is one course of treatment, with 2 days of rest during the treatment period. The total treatment period is 4 weeks, with a total of 4 courses.
62558184|NCT04790903|EXPERIMENTAL|Venetoclax (Schedule A)|"Participants enrolled in dosing Schedule A will receive a total of six 21-day cycles of venetoclax treatment for 5 days in combination with Polatuzumab Vedotin + R-CHP (Rituximab, Cyclophosphamide, Doxorubicin and Prednisone) as described below:~Schedule A: Participants will self-administer Venetoclax orally (PO) once daily (QD) at a dose of 800 mg for 5 consecutive days as follows:~Cycle 1: 5 consecutive days of dosing on Days 4-8. Cycles 2-6: 5 consecutive days of dosing on Days 1-5."
62558185|NCT04790903|EXPERIMENTAL|Venetoclax (Schedule B)|"Participants enrolled in dosing Schedule B will receive a total of six 21-day cycles of venetoclax treatment for 10 days in combination with Polatuzumab Vedotin + R-CHP as described below:~Schedule B: Participants will self-administer Venetoclax orally (PO) once daily (QD) at a dose of 800 mg for 10 consecutive days as follows:~Cycle 1: 10 consecutive days of dosing on Days 4-10. Cycles 2-6: 10 consecutive days of dosing on Days 1-10."
62558186|NCT03928483|EXPERIMENTAL|Modified WW Food program|Participants will be assigned to a SmartPoints budget and number and types of ZeroPoint foods.
62558187|NCT03036826||Piperacillin/Tazobactam|Group of patients receiving Piperacillin/Tazobactam as antiinfective therapy
62558188|NCT03036826||Meropenem|Group of patients receiving Meropenem as antiinfective therapy
62379956|NCT04589117|EXPERIMENTAL|Expressive writing|"The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email.~The progression of writing exercises flows as follows:~* Week 1: Writing to expressive difficult emotions~* Week 2: Writing to cultivate compassion \& forgiveness~* Week 3: Writing to nurture positive emotions~* Week 4: Writing to invite insight, perspective, \& growth"
62379957|NCT02938611||The study population|Persons with stage \>=4 chronic kidney disease.
62379958|NCT01979328|EXPERIMENTAL|Study arm|geko neuromuscular electrostimulation
62758413|NCT06277349|OTHER|Toric multifocal IOL alone|Toric Multifocal IOL (Rayner) - Model M-Flex T 588 or 638 - CE marked since January 2007. Surgery is performed under topical anaesthesia. Preoperatively, the horizontal meridian will be marked in the sitting position with a blue marking pen or insulin syringe at the limbus. The temporal self sealing incision, injection of viscoelastic substance, capsulorhexis, phacoemulsification, irrigation/aspiration of cortical material and injection of viscoelastic substance into the capsular bag are performed as standard procedure. The multifocal toric IOL will be implanted.
62758414|NCT03267173|EXPERIMENTAL|CAR-T|A single dose of Chimeric antigen receptor T cells will be administered by vascular interventional mediated as one dose infusions. According to the patient's condition and weight, the intervention dose of aE7 CAR-T cells per kilogram of body weight was treated once.
62758415|NCT05975008|EXPERIMENTAL|RECLAIM intervention|Eight sessions of a brief mindfulness-based intervention that meets weekly in a virtual setting.
62758416|NCT05975008|NO_INTERVENTION|Psychoeducation materials only|We will use a psychoeducation-only control group. They will only receive psychoeducational materials (e.g., suggested readings, podcasts, blogs). These are the same materials that the intervention arm participants will receive.
62758417|NCT01867957|EXPERIMENTAL|Low-dose GC1109|
62758418|NCT01867957|PLACEBO_COMPARATOR|Low-dose Placebo|
62758419|NCT01867957|EXPERIMENTAL|High-dose GC1109|
62758420|NCT01867957|PLACEBO_COMPARATOR|High-dose Placebo|
62758421|NCT02931604|EXPERIMENTAL|Sinus irrigation|Sinus irrigation intervention
62758422|NCT06352593|EXPERIMENTAL|Group D (Dexmedetomidine)|Patients will be administered Dexmedetomidine 0.5 μg/kg for 10 min and then 0.4 μg/kg/h adjusted to 0.2-0.6 μg/kg/h.
61987128|NCT01813669|EXPERIMENTAL|Integrative Coping Group|"The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:~Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions"
62558189|NCT06551155||Healthy patients|Patients with available DXA results, at risk and in periodic follow-up and/or attending outpatient visits for preventive screening
62758423|NCT06352593|PLACEBO_COMPARATOR|Group C (placebo group)|Patients will receive normal saline (control group) .
62758424|NCT01483534|EXPERIMENTAL|Targeted Lung Denervation|Targeted Lung Denervation
62558190|NCT06551155||Osteopenic patients|Patients with available DXA results, enrolled during outpatient visits and/or emergency room and/or hospital admissions
62558191|NCT06551155||Non-fractured osteoporotic patients|Patients with available DXA results, enrolled during outpatient visits and/or emergency room and/or hospital admissions
62558192|NCT06551155||Fractured osteoporotic patients|Patients with available DXA results or prescribed as per clinical practice, enrolled during hospital admissions
62558193|NCT02943837|ACTIVE_COMPARATOR|EUS-FNA|Device: 22G FNA needle
62558194|NCT02943837|EXPERIMENTAL|EUS-FNB|Device: 20G FNB needle
62558195|NCT04683861|EXPERIMENTAL|Spinal cord stimulation therapy|Spinal cord stimulation at the thoracic levels ranging from T10 to T12.
62558196|NCT01541085||Darunavir/Ritonavir (DRV/r)|
62558197|NCT01541085||Efavirenz (EFV)|
62558198|NCT01366820|EXPERIMENTAL|NNZ-2566|20 mg/kg intravenous bolus infusion of NNZ-2566 over 10 minutes followed by a continuous intravenous infusion of 6 mg/kg/h (n=133) intravenous infusion of NNZ-2566 for a total of 72 consecutive hours.
62558199|NCT01366820|PLACEBO_COMPARATOR|Sodium Chloride (0.9%) for Injection|Intravenous bolus infusion of Sodium Chloride (0.9%) for Injection over 10 minutes followed by a continuous intravenous infusion of Sodium Chloride (0.9%) for Injection for a total of 72 consecutive hours.
62558200|NCT04512664|ACTIVE_COMPARATOR|short term group|cold treatment for 4 hours
62758425|NCT05296460|EXPERIMENTAL|dapsone gel and trichloroacetic acid|trichloroacetic acid peeling on right side of face and dapsone gel on left side
62758426|NCT02980146||"Group patients with colorectal cancer"|Major patients treated surgically for colorectal cancer at Nantes University Hospital or at the Institut de Cancerologie de l'Ouest and agreeing to participate in the study
62758427|NCT04413474||Study group|Unselected critically ill patients who met the inclusion criteria
62558201|NCT04512664|EXPERIMENTAL|long term group|cold treatment for 48 hours
62758428|NCT00828399|EXPERIMENTAL|Glutamine|
62758429|NCT00828399|PLACEBO_COMPARATOR|Whole protein|
62758430|NCT01977443|ACTIVE_COMPARATOR|APD-209 Eye drops|APD-209 Eye drops
62758431|NCT01977443|PLACEBO_COMPARATOR|APD-209 Placebo Eye drops|APD-209 Placebo Eye drops
62758432|NCT04150731|EXPERIMENTAL|Breast cancer and FES|Only one arm: All included are patients with disseminated breast cancer and all have an experimental FES-PET/CT done
62558202|NCT05391373|EXPERIMENTAL|Laughter Therapy Group|The women with breast cancer in the intervention group received two sessions of laughter therapy per week for eight weeks.Each laughter therapy session lasted 40 minutes.
62558203|NCT05391373|NO_INTERVENTION|Control group|The control group did not receive any intervention during the study period.
62758433|NCT06495840||Elderly patients|elderly patients undergo non-cardiac surgery (aged ≥ 65 years)
62758434|NCT02590562||RA patients treated with routine clinical practice|Describe in routine clinical practice the treatment patterns of usage of biological DMARDs in patients suffering from RA including frequency of monotherapy, biological DMARDs usage status (types, dosage), concomitant DMARDs usage information (type and dosage)
62758435|NCT00308893|EXPERIMENTAL|Escitalopram|Treatment response after 3 and 6 weeks
62758436|NCT01281098|ACTIVE_COMPARATOR|Panretinal Photocoagulation (PRP)|Group 1: Panretinal photocoagulation treatment (PRP) at week-0 that can be repeated every 6 weeks.
62758437|NCT01281098|EXPERIMENTAL|Pegaptanib + Panretinal Photocoagulation (PRP)|Group 2: Combination treatment of pegaptanib intravitreous injections at weeks 0, 6 and 12 that can be repeated every 6 weeks. Plus PRP after first injection (2 weeks +/- 1 week)and that can be repeated every 12 weeks.
62758438|NCT06148311|EXPERIMENTAL|Sublingual dexmedetomidine|Participants will be administered 120 micrograms sublingual film following start of an autonomic crisis. In case the crisis has not subsided after 2 hours, the patient will be instructed to take the second dose. The maximum amount for the study is two oral films within two hours for each episode but not more than 24 hours apart, one at the beginning of the crisis and if needed, one additional within two hours.
62758439|NCT06148311|PLACEBO_COMPARATOR|Matching Sublingual Placebo|Participants will be administered the matching placebo sublingual film following start of an autonomic crisis. In case the crisis has not subsided after 2 hours, the patient will be instructed to take the second dose. The maximum amount for the study is two oral films within two hours for each episode but not more than 24 hours apart, one at the beginning of the crisis and if needed, one additional within two hours.
62758440|NCT03446053|EXPERIMENTAL|N-Rephasin® SAL200|Forty subjects will be randomly assigned to receive either N-Rephasin® SAL200 injection or a placebo administered by a 60-min intravenous infusion. Within each group, 8 subjects (6 active and 2 placebo) will receive a single dose of 6 mg/kg, followed by multiple ascending dose of 3, 6, 9, and 12 mg/kg/day.
62758441|NCT03446053|PLACEBO_COMPARATOR|INT200-Placebo|Saline
62758442|NCT04401306|EXPERIMENTAL|Self-regulated simulation training|
62758443|NCT04401306|ACTIVE_COMPARATOR|Instructor-regulated simulation training|
62758444|NCT05878756|EXPERIMENTAL|Functional strength training|With conventional therapy,the ten tasks were STS, one leg standing, weight shifting(from one side of body to other), step-ups, lateral step-ups, squatting against wall, picking an object from standing position, walking forward, walking backward and kicking the ball preform from the patient 5 days per week for 4 weeks.
62758445|NCT05878756|ACTIVE_COMPARATOR|Conventional therapy|passive and active range of motion exercises,Stretching and strengthening exercise 5 days per week for 4 weeks.
62758446|NCT03849690|EXPERIMENTAL|TAK-906 25 mg; Esomeprazole 40 mg + TAK-906 25 mg|TAK-906 25 milligram (mg), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 4 days, further followed by esomeprazole 40 mg, capsule, orally, once daily on Days 1 to 5 along with TAK-906 25 mg, capsule, orally, once on Day 4 of Study Period 2.
62758447|NCT04424056|EXPERIMENTAL|Anakinra +/- Ruxolitinib|"Anakinra +/- Ruxolitinib~According to clinical stage (gradual strategy):~Stage 2b or 3 : Anakinra +/- ruxolitinib depending of evolution; Advanced stage 3 : Anakinra and Ruxolitinib"
62758448|NCT04424056|EXPERIMENTAL|Tocilizumab +/- Ruxolitinib|"Tocilizumab +/- Ruxolitinib~According to clinical stage (gradual strategy):~Stage 2b or 3 : Tocilizumab +/- ruxolitinib depending of evolution; Advanced stage 3: Tocilizumab +ruxolitinib"
62758449|NCT04424056|ACTIVE_COMPARATOR|Standard of care|Treatment with drugs or procedures in routine clinical practice
61987129|NCT01813669|NO_INTERVENTION|Waitlist Control|Participants in the waitlist condition will not receive any experimental intervention. They can continue any treatments as usual. The waitlist will be approximately 10-14 weeks in duration. At the end they will be offered the opportunity to participate in the intervention. If they elect to participate in the intervention, post-study data will also be collected from this group, approximately 13-weeks following the first group session.
61987130|NCT05459103|EXPERIMENTAL|Intervention group|Participants in the intervention group received a 12-week bidirectional remote interaction intervention.
62558204|NCT04902001|EXPERIMENTAL|Adolescents with obesity|Adolescents with obesity aged 12-16 years old
62558205|NCT01214655|EXPERIMENTAL|LY2523355 on Days 1, 2, and 3|Starting dose was 2 milligrams per meter squared (mg/m\^2) administered by a 1-hour intravenous (IV) infusion on Days 1, 2, and 3 of every 21-day Cycle.
62558206|NCT01214655|EXPERIMENTAL|LY2523355 on Days 1, 5, and 9|Starting dose was 8 milligrams per meter squared (mg/m\^2) administered by a 1-hour IV infusion over 1 hour on Days 1, 5, and 9 of every 21-day Cycle.
62558207|NCT01483443|EXPERIMENTAL|Oophrectomy group|Patient undergone oophrectomy along with primary tumor
62558208|NCT01483443|NO_INTERVENTION|without oophrectomy|Patient group without oophrectomy
62558209|NCT02068274||chronic pain|CO2 monitoring in chronic pain patients who treated with opioids.
62558210|NCT01916525|EXPERIMENTAL|Exercise based cardiac rehabilitation|Patients will receive written instructions and a referral to the exercise-based rehabilitation unit. The patient will be taught to use fitness room. Each session of training will be controlled by heart rate. Instruction will also be given for at-home training and filling in a training diary, and training will be scheduled at Verve once a week. On the first visit the patient will receive a device that measures physical activity during the study. Training will also be monitored from the training diary. Structured questionnaires will be used to check compliance and implementation of care will be determined from medication and other health-related habits once a month (during the first 6 months) and finally after 12 months.
62558211|NCT01916525|NO_INTERVENTION|Control|A conventional post-acute care group treated according to finnish guidelines.
62558212|NCT03348332|NO_INTERVENTION|Sedentary pregnant women|Pregnant women who do not exercise regularly during pregnancy
62558213|NCT03348332|EXPERIMENTAL|Exercise pregnant women|Pregnant women who participate in a supervised exercise program
62558214|NCT02392117||Insulin degludec|
62558215|NCT01772290|ACTIVE_COMPARATOR|A: Vismodegib|
62558216|NCT01772290|EXPERIMENTAL|B: Rabeprazole + Vismodegib|
62558217|NCT01772290|EXPERIMENTAL|C: Itraconazole + Vismodegib|
62758450|NCT02275117|EXPERIMENTAL|ALD403 Dose Level 1|ALD403 Dose Level 1 (IV)
62758451|NCT02275117|EXPERIMENTAL|ALD403 Dose Level 2|ALD403 Dose Level 2 (IV)
62758452|NCT02275117|EXPERIMENTAL|ALD403 Dose Level 3|ALD403 Dose Level 3 (IV)
62758453|NCT02275117|EXPERIMENTAL|ALD403 Dose Level 4|ALD403 Dose Level 4 (IV)
62758454|NCT02275117|PLACEBO_COMPARATOR|Placebo|Placebo (IV)
62758455|NCT02218086|EXPERIMENTAL|professionals|balancing on the slackline / wobbling board 3 times by 30 seconds balancing on the slackline with a fix visual anchor / moving visual anchor 3 times by 30 seconds
62379959|NCT01323933|EXPERIMENTAL|AB0024|"The starting dose for Part A will be 1 mg/kg. Subsequent doses of 3, 10, and 20 mg/kg are planned. Three to 6 patients will be enrolled using a 3 + 3 design. Doses of AB0024 will be administered on Days 1, 15, 29, and 43 to characterize the safety, tolerability, and PK.~The dose expansion phase of the study will begin upon completion of the dose escalation phase. Up to 20 patients will be enrolled into one or two cohorts of Part B. The first expansion cohort will be dosed up to the MTD defined as the highest dose level with an observed incidence of DLT in \<33% of patients enrolled from Part A."
62379960|NCT01425528|EXPERIMENTAL|Kuvan Cohort 1|This cohort will be enrolled first. Analysis will be done to determine the optimum dosing of Kuvan to normalize BH4 levels in the Cerebral Spinal Fluid. This cohort will begin at a dose of 20mg/kg/day.
62758456|NCT02218086|EXPERIMENTAL|beginners|balancing on the slackline / wobbling board 3 times by 30 seconds pre-training compared to post-training
62758457|NCT01991223|PLACEBO_COMPARATOR|Placebo group|NS infusion will be done during surgery.
62758458|NCT01991223|EXPERIMENTAL|Dex group|DEX infusion will be done during surgery.
62758459|NCT06339502|NO_INTERVENTION|Control group|With the students in the control group, a standard individual article review will be conducted under the supervision of the instructor.
62758460|NCT06339502|EXPERIMENTAL|Experimental group|The students in the experimental group will be divided into 7 main groups of 7 students according to their academic grade point average. In these groups, each member will be responsible for one of the 7 sections of the article. Those who take the same section in the groups will unite to form expert groups and specialize by working on this section. Students will then return to their main groups and analyze an experimental article. From the groups presenting their reviews, a winner will be selected.
62758461|NCT01239888|ACTIVE_COMPARATOR|Oxytocin|
62758462|NCT01239888|ACTIVE_COMPARATOR|Oxytocin and Tibolone|
62379961|NCT01425528|EXPERIMENTAL|Kuvan Cohort 2|Participants in cohort 2 will be enrolled after the analysis of cohort 1 data has taken place. Dosing for cohort 2 will be based on results obtained in cohort 1, but will plan on starting at 30 mg/kg/day.
62379962|NCT00542425|PLACEBO_COMPARATOR|Placebo|
62558218|NCT01772290|EXPERIMENTAL|D: Fluconazole + Vismodegib|
62558219|NCT03142737|EXPERIMENTAL|Red kidney bean intake|Subjects will consume 1/2 cup of cooked red kidney bean following diet normalization for 3 days.
62558220|NCT03142737|EXPERIMENTAL|Eggs intake|Subjects will consume 2 cooked large eggs following diet normalization for 3 days.
62558221|NCT03142737|EXPERIMENTAL|Peanut butter intake|Subjects will consume 2 tablespoons of peanut butter following diet normalization for 3 days.
62558222|NCT03142737|EXPERIMENTAL|Ground beef intake|Subjects will consume 2 ounces of 90% lean ground beef following diet normalization for 3 days.
62558223|NCT03142737|EXPERIMENTAL|Intact beef intake|Subjects will consume 2 ounces of intact beef following diet normalization for 3 days.
62558224|NCT04015973|NO_INTERVENTION|Group A: Control|Standard Care
62758463|NCT01239888|PLACEBO_COMPARATOR|Placebo|
62758464|NCT03938220||fluid responders|fluid responder if stroke volume increases by \> 10% after the fluid challenge
62758465|NCT03938220||fluid non responders|fluid responder if stroke volume increases by \<= 10% after the fluid challenge
62558225|NCT04015973|EXPERIMENTAL|Group B: High energy diet|High energy diet for 8-12 weeks pre-surgery
61987131|NCT05459103|EXPERIMENTAL|Control group|Participants in the control group received a 12-week unidirectional remote interaction intervention.
62558226|NCT01668745|EXPERIMENTAL|Early measles vaccine|The intervention is about to administer an early standard dose of Edmonston-Zagreb (EZ) measles vaccine in addition to the conventional dose. As such children will be randomised to receive either an early measles vaccine at 4 months after DTP3 or not. Thereafter both groups of children will receive the recommended EZ measles vaccine at 9 months of age according to WHO policy.
62558227|NCT01668745|NO_INTERVENTION|Control|
61987132|NCT05045144|EXPERIMENTAL|RSV lot1 Group|Participants randomized to the RSV lot1 Group received one dose of RSV MAT Lot 1 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.
62379963|NCT00542425|EXPERIMENTAL|BA058 20 µg|
62558228|NCT01849965|ACTIVE_COMPARATOR|DSC127|DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
62758466|NCT05857449|EXPERIMENTAL|Part A|Each subject receive the same dose(X1mg) of LPM3480392 in 15minutes in the first cycle, 5 minutes in the second cycle, and 2 minutes in the third cycle .
62758467|NCT05857449|EXPERIMENTAL|Part B|Each subject receive LPM3480392 X2mg in the first cycle and LPM3480392 X3mg in the second cycle .
62758468|NCT01000922|EXPERIMENTAL|Regular Human Insulin|Single injection
62758469|NCT01000922|EXPERIMENTAL|Lispro|Single injection
62758470|NCT01000922|EXPERIMENTAL|VIAject|Single injection
62758471|NCT01000922|EXPERIMENTAL|VIAject 50%|Single injection
62758472|NCT01000922|EXPERIMENTAL|VIAject/Insulin glargine|Single injection
62379964|NCT00542425|EXPERIMENTAL|BA058 40 µg|
62379965|NCT00542425|EXPERIMENTAL|BA058 80 µg|
62379966|NCT00542425|ACTIVE_COMPARATOR|teriparatide|
62558229|NCT01849965|PLACEBO_COMPARATOR|Vehicle gel|Vehicle gel comprising HEC with parabens
62758473|NCT01000922|EXPERIMENTAL|Insulin Glargine/VIAject|Single injection
62758474|NCT02205346||no treatment|no treatment
62758475|NCT04811443||Patients with solid tumors who have received myelosupressive therapy|
62758476|NCT04617418||subjects with refractory focal epilepsy with a seizure frequency|The investigators will include 100 subjects with refractory focal epilepsy with a seizure frequency of at least one per month, and ask them to keep a seizure diary and use the TapCounter app for three months.
62758477|NCT01900301|EXPERIMENTAL|Scopolamine .4mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
62758478|NCT01900301|PLACEBO_COMPARATOR|Intranasal placebo|Participants will be randomized to a placebo, administered via nasal drops, prior to each session of exposure therapy
62758479|NCT01900301|EXPERIMENTAL|Scopolamine .5mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
61987133|NCT05045144|EXPERIMENTAL|RSV lot2 Group|Participants randomized to the RSV lot2 Group received one dose of RSV MAT Lot 2 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.
62379967|NCT03840681|EXPERIMENTAL|Ridge augmentation by collagen membrane|"* Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* Flap will be done.~* bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed at defected area then covered at the defected area by a collagen membrane which will be stabilized by tacks.~* The site will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
62379968|NCT03840681|ACTIVE_COMPARATOR|augmentation by titanium reinforced PTFE|"* Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* Flap will be done.~* bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.~* The site will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
62379969|NCT03855618||1 case group|Consecutive 10 post-stroke patients in intensive rehabilitation treatment with an acute event occurring no later than 15 days from admission to the SOR Neurological Foundation don Gnocchi ONLUS IRCCS; age 18-90. It is required to sign an informed consent to the patient's participation in the study or if unable to sign, of the proxy.
62558230|NCT01849965|PLACEBO_COMPARATOR|Standard of Care gel|Aquasite gel, as standard of care gel
62558231|NCT00809562|EXPERIMENTAL|1|
62558232|NCT00809562|PLACEBO_COMPARATOR|2|
62558233|NCT03575208|EXPERIMENTAL|HBIG followed by Peginterferon alfa-2a|HBIg x 12 weeks followed by peginterferon alfa-2a 180mcg x 24 weeks
62558234|NCT03575208|ACTIVE_COMPARATOR|Peginterferon alfa-2a|Peginterferon alfa-2a 180mcg x 24 weeks
62758480|NCT01900301|EXPERIMENTAL|Scopolamine .6mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
62758481|NCT03578692||Surgery group|The protocol for patients assigned to surgery group was as follows. ASUC patients were admitted in, estimated their baseline situations and tested their blood and fecal indicators including PCT, IL-6 and FC on admission. All patients were treated according to the ECCO guideline 2012. Patients who showed bad response to medicine (glucocorticoid for 5 days and rescue therapy for 3 days) were recommended and classified in the surgery group. Their baseline manifestations were collected and compared with the medical group, to exploit the baseline indicators with great sensitive and specificity predicting the high risk for surgery.
62758482|NCT03578692||Medical group|The protocol for patients assigned to medical group was as follows. ASUC patients were admitted in, estimated their baseline situations and tested their blood and fecal indicators including PCT, IL-6 and FC on admission. All patients were treated according to the ECCO guideline 2012. Patients who showed response to medicine (glucocorticoid for 5 days or rescue therapy for 3 days) were classified in the medical group. Their baseline manifestations were collected and compared with the surgery group.
62758483|NCT02323841|EXPERIMENTAL|conservative treatment in cervix cancer|we performed conservative treatment cervix cancer patients with IB FIGO stage without pelvic involvement
62758484|NCT02479581|EXPERIMENTAL|ERAS group|Perioperative management follows the Enhanced Recovery after Surgery（ERAS） program
62558235|NCT03684850|ACTIVE_COMPARATOR|Exercise therapy group|(n = 40)
62558236|NCT03684850|EXPERIMENTAL|Knee brace and exercise group|(n = 40)
62558237|NCT03684850|EXPERIMENTAL|Footwear device group|(n = 40)
62558238|NCT03827889|EXPERIMENTAL|WMP of fluoride varnish|Whole mouth protocol group
62558239|NCT03827889|EXPERIMENTAL|TWLP of fluoride varnish|Tooth with lesion Protocol
62558240|NCT03827889|ACTIVE_COMPARATOR|DHP (educational intervention)|Diet and Hygiene guidance Protocol
62758485|NCT02479581|EXPERIMENTAL|Conventional control group|Perioperative management follows the conventional program
62758486|NCT01728077|EXPERIMENTAL|Brivaracetam|At Entry Visit (EV), subjects will start on the individualized Brivaracetam (BRV) dose that they had reached at the completion of the previous study. Dose adjustments of the Investigational Medicinal Product (IMP) are allowed at any time based on the clinical judgment of the investigator. The BRV dose can be increased or decreased in increments of 50 mg/day based on the individual subject's seizure control and/or tolerability; however, the BRV dose should not exceed 200 mg/day during the study and must always be administered as a symmetrical morning and evening dose. Upon completion or early discontinuation from this study, there will be a Down-Titration Period in steps of 50 mg/day on a weekly basis until 20 mg/day for 1 week is reached, followed by a Post-Treatment Period (between 2 and 4 weeks) during which the subject will not receive study drug. No down-Titration Period will be applicable if subjects are continued on BRV after they complete this study.
62758487|NCT05304143|EXPERIMENTAL|Virtual Reality intervention group|The exploration in the intervention group will be carried out with virtual reality glasses compatible with the magnetic resonance imaging equipment.
62758488|NCT05304143|ACTIVE_COMPARATOR|Conventional nurse support|The exploration in the control group will be carried out with the standard procedure for claustrophobic patients that includes close nursing support.
62758489|NCT02350049||Investigational|Cementless Medial Partial Knee
62758490|NCT02350049||Control|Cemented Medial Partial Knee
62758491|NCT01971463|EXPERIMENTAL|Normal Saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
62558241|NCT03274193|EXPERIMENTAL|Yoga|The yoga group will engage in the yoga training program which is 60 minutes per session, 2 times per week for 12 weeks.
62758492|NCT03078283|EXPERIMENTAL|Participants|Consumption of a given type of high-fiber snack food, with each individual functioning as her own control
61987134|NCT05045144|EXPERIMENTAL|RSV lot3 Group|Participants randomized to the RSV lot3 Group received one dose of RSV MAT Lot 3 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.
62758493|NCT04216940|EXPERIMENTAL|M-pro|
62379970|NCT04509635|EXPERIMENTAL|Arm A|Using treatment of cetuximab plus chemotherapy. Cetuximab: 500 mg/m2 IV over 2 hours, day 1, every 2 weeks. Chemotherapy: detailed regimen is determined by a multi-disciplinary team.
62379971|NCT04509635|ACTIVE_COMPARATOR|Arm B|Using treatment of chemotherapy alone. Chemotherapy: detailed regimen is determined by a multi-disciplinary team
62558242|NCT03274193|NO_INTERVENTION|Control|The control group will be asked not to participate in any exercise program during the course of the study.
62758494|NCT04216940|EXPERIMENTAL|Hyflex|
62558243|NCT05280392||People living with HIV|PLWH who were offered to participate in the EHVA T02/ANRS VRI07 clinical trial
62558244|NCT01328184|EXPERIMENTAL|Reference|multiple doses of Microgynon
62558245|NCT01328184|ACTIVE_COMPARATOR|Test|multiple doses of Microgynon + BI 10773
62558246|NCT03097627|EXPERIMENTAL|ICG Intervention|The intervention to be administered is intravenous indocyanine green for intra-thoracic lesion localization and use of a near infrared camera to detect the ICG. All study subjects will receive this same intervention; there is only one arm.
62558247|NCT05415163|EXPERIMENTAL|vascular photobiomodulation|Laser will be applied with the spot located in the radial artery of the participant's arm (right or left), and fixed to the wrist with a specific bracelet.
62379972|NCT02924766|EXPERIMENTAL|Niraparib + Apalutamide/[Abiraterone Acetate + Prednisone]|Participants will receive initial starting dose of Niraparib 200 milligram (mg) once daily in combination either with Apalutamide 240 mg (4\*60 mg) once daily or Abiraterone Acetate 1000 mg (4\*250 mg) plus 10 mg Prednisone (5 mg twice daily) for 28 days of cycle 1. Once a safe dose of niraparib is selected with each Andrgen Receptor (AR)-targeted therapy \[Apalutamide or Abiraterone Acetate plus Prednisone\], then an expansion phase (Part 2) will open to further explore safety and assess antitumor activity.
62379973|NCT05022693|EXPERIMENTAL|BIO89-100 30 mg, Open Lable, Single Dose|
62558248|NCT05415163|SHAM_COMPARATOR|photbiomodulation-sham|The device will be placed with the spot located in the radial artery of the participant's arm (right or left), and fixed to the wrist with a specific bracelet no laser apllied.
62558249|NCT03871543|OTHER|Part 1|All eligible subjects enrolled into Part 1 will be fit and dispensed with Test Lens 1
62558250|NCT03871543|OTHER|Part 2|All eligible subjects (based on CLDEQ responses) enrolled into Part 2 will be fit and dispensed with Test Lens 2 and will follow the same procedures as Part 1.
62558251|NCT05924724|EXPERIMENTAL|Usage Flash-Glucose Monitoring FGM|Participants in this arm will transition from routine care using SMBG to using FGM after one week. They will receive training on how to use the FGM device. The FGM will be used continuously from that point until delivery, throughout the entire pregnancy.
62558252|NCT05924724|NO_INTERVENTION|Usage Self-Monitoring Blood Glucose SMBG|Participants in this arm will remain in the routine care using SMBG. They will use it continuously from diagnosis until delivery, throughout the entire pregnancy.
62558253|NCT01088477||Breast cancer patients with acquired anti-hormonal resistance|
62758495|NCT02917213||StudyGroup|"A cohort of 92 patients with first ST elevation acute myocardial infarction (AMI), sinus rhythm, and LV ejection fraction \< 45% in the first 24-72 h after symptoms onset.~In the first 24 hours after enrollment a coagulation blood test, a Doppler echocardiogram exam, a Carotid duplex ultrasound exam, a Transcranial Doppler monitoring and a Reveal LINQ insertable cardiac monitoring system will be 1:1 randomly implanted.~A clinical examination (including neuropsiquiatric evaluation), a Doppler echocardiogram exam, a cardiac MRI and a brain MRI will be performed after a week and after 6 months after enrollment."
62758496|NCT04907149|EXPERIMENTAL|Absolute Bioavailability - Period 1|Participants will receive GLPG3970 under fasted conditions followed by an intravenous (i.v.) microtracer microdose of \[14C\]GLPG3970 on Day 1.
62758497|NCT04907149|EXPERIMENTAL|Mass Balance - Period 2|Participants will receive \[14C\]GLPG397 under fasted conditions on Day 1.
62758498|NCT04359732|OTHER|Hybrid PET/MRI|For the purposes of the study, in addition to standard imaging (EUS and CT scan), a fully integrated hybrid PET/MRI (PET/MRI) study with FDG will replace the Standard PET (pre-surgical evaluation) used for evaluating distant metastases and will be considered as the add-on procedure at three time points. The additional evaluation for patients is that during nCRT treatment.
62758499|NCT02115841|EXPERIMENTAL|E1|Experiment 1 will measure the cortical excitability change after TENS intervention.
62758500|NCT02115841|EXPERIMENTAL|E2|Experiment 2 will measures implicit sequential motor task performance and cortical hemodynamic response using near infrared spectroscopy (NIRS) during motor execution. Cortical excitability will also be measured contemporary
62758501|NCT02046174|EXPERIMENTAL|Macrobead Implantation Arm|patients who will undergo up to 4 implantations of RENCA macrobeads (no less than 3 months apart), at an amount of 8 RENCA macrobeads per kilogram of body weight
62758502|NCT02046174|NO_INTERVENTION|Best Supportive Care Arm|patients who will receive, or continue receiving, best supportive care, defined as management of symptoms aimed at maintaining or improving quality of life, but not including approved therapies targeting the patient's malignancy
62379974|NCT03833336|PLACEBO_COMPARATOR|Placebo|normal saline solution plus oral lactose capsules
62758503|NCT01752790|EXPERIMENTAL|Top-down|patients randomized on top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus azathioprine (2 mg/Kg per os/day). During maintaining phase, patients will receive subsequent infusions of infliximab (5 mg/kg every 8 weeks), starting 8 weeks after the end of the induction phase (week 14). At 12 motnhs patients will stop azathioprine and continue infliximab (5 mg/kg every 8 weeks)
62758504|NCT01752790|ACTIVE_COMPARATOR|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day). Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop).
62758505|NCT01933230|OTHER|Excel Cryo Cooling System Collar|An Excel Cryo Cooling System collar will be placed around the neck for a 2 hour neck cooling period. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level and pressure both in the head and in the blood.
62758506|NCT00954798|EXPERIMENTAL|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 vaccine formulation 1 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13.
62758507|NCT00954798|EXPERIMENTAL|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 vaccine formulation 2 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13.
62758508|NCT00954798|EXPERIMENTAL|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 vaccine formulation 3
62379975|NCT03833336|ACTIVE_COMPARATOR|Intravenous ferric carboxymaltose|Ferric carboxymaltose 500-1000 mg at 0,6,12,24 weeks ( adjusted by protocol)
62379976|NCT03833336|ACTIVE_COMPARATOR|Oral iron A: ferroglycine sulfate|oral capsules of ferroglycine sulfate iron until week 24
62379977|NCT03833336|ACTIVE_COMPARATOR|Oral iron B: sucrosomial iron|oral capsules of sucrosomial iron until week 24
61987135|NCT05045144|EXPERIMENTAL|RSV+Flu pooled Group|"Participants randomized in this group received one dose of RSVPreF3 vaccine (RSV MAT vaccine) from one of the three lots used (Lot 1, Lot 2 or Lot 3 of same formulation of RSVPreF3 vaccine) and one dose of the Flu D-QIV vaccine on Day 1, and were followed up until the end of the study (Day 181).~The participants in this group were considered for the immunogenicity and safety analyses of the RSV MAT and Flu D-QIV vaccines."
62379978|NCT01731197|EXPERIMENTAL|Test ISP-10|10 grams of the test ISP will be consumed as a dry-blended beverage
62379979|NCT01731197|EXPERIMENTAL|Test ISP-20|20 grams of the test ISP will be consumed as a dry-blended beverage
62379980|NCT01731197|ACTIVE_COMPARATOR|Control ISP-10|10 grams of the control ISP will be consumed as a dry-blended beverage
62558254|NCT01416519|EXPERIMENTAL|Group 1|After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
62567601|NCT02972905|EXPERIMENTAL|Session 1: GSK2269557 700 mcg|Subjects will receive a single dose inhalation of GSK2269557 700 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
62758509|NCT00511784||OrthoEvra(norelgestromin/ethinylestradiol contraceptive patch)|subjects in insurance claims database who used transdermal patch containing 6 milligrams norelgestromin and 0.75 milligram ethinyl estradiol worn for 1 week for 3 consecutive weeks; the fourth week was patch-free
62379981|NCT01731197|ACTIVE_COMPARATOR|Control ISP-20|20 grams of the control ISP will be consumed as a dry-blended beverage
62379982|NCT04890730||Southern Medical University of Nanfang Hospital|Southern Medical University of Nanfang Hospital
62379983|NCT04890730||Tongji Hospital Affiliated to Tongji University|Tongji Hospital Affiliated to Tongji University
62379984|NCT04890730||The Second Affiliated Hospital Of Nanchang University|The Second Affiliated Hospital Of Nanchang University
62379985|NCT00685828|ACTIVE_COMPARATOR|Arm I|Patients receive low-dose oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
62379986|NCT00685828|EXPERIMENTAL|Arm II|Patients receive high-dose oral imatinib mesylate twice daily in the absence of disease progression or unacceptable toxicity.
62379987|NCT01636739||Rota Group|Subjects will receive Rotarix® as per routine practice
62379988|NCT01052675||Pharmacodependance cases|Case report from one of the French CEIP for drug and substance problematic use, abuse or dependence except alcohol and tobacco.
62379989|NCT04723303|EXPERIMENTAL|Treatment Arm|A single IV infusion of ULSC's in patients with DM or PM
62379990|NCT03267576|EXPERIMENTAL|Treatment Sequence AB|Participants will receive metformin monotherapy at stable doses (greater than or equal to \[\>=\] 1500 milligram per day \[mg/day\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition. A washout period of at least 16 days (from Days 28 to 43) of metformin monotherapy will be maintained between each treatment period.
62379991|NCT03267576|EXPERIMENTAL|Treatment Sequence BA|Participants will receive treatment B from Day 0 to 27 (treatment Period 1), followed by treatment A from Day 44 to 71 (treatment period 2), under fasted condition. A washout period of at least 16 days (from days 28 to 43) of metformin monotherapy will be maintained between each treatment period.
62379992|NCT05408403|ACTIVE_COMPARATOR|Transversalis Fascia Plane Block|Transversalis Fascia Plane Block (TFPB) will be performed the patients in Group A after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively
62379993|NCT05408403|ACTIVE_COMPARATOR|Quadratus Lumborum Block|Anterior Quadratus Lumborum Block ( Anterior QLB) will be performed the patients in Group B after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively
62558255|NCT01416519|EXPERIMENTAL|Group 2|After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
62558256|NCT00835393|EXPERIMENTAL|1|
62379994|NCT04971759|EXPERIMENTAL|Group L|30 Patients will receive Levobupivacaine 5%
62379995|NCT04971759|EXPERIMENTAL|LD group|30 patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomidine.
62379996|NCT04971759|EXPERIMENTAL|LF group|30 patients will receive Levobupivacaine 5% + 1µg/kg fentanyl
62558257|NCT00835393|ACTIVE_COMPARATOR|2|
62558258|NCT01551771|EXPERIMENTAL|GW824575|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
62379997|NCT04802928|PLACEBO_COMPARATOR|A|Placebo tablets.
62758510|NCT00511784||levonorgestrel-containing oral contraceptives|subjects in insurance claims database who were first time users of triphasic levonorgestrel-containing oral contraceptives with 30 micrograms ethinyl estradiol taken for 21 consecutive days followed by no pill or an inert pill for 7 days
62379998|NCT04802928|EXPERIMENTAL|B|
62558259|NCT01551771|PLACEBO_COMPARATOR|GW824575 matched-placebo|Placebo
62558260|NCT01644682|EXPERIMENTAL|Arm-1|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive IWFPL intervention.
62558261|NCT01644682|EXPERIMENTAL|Arm-2|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive IDWL intervention.
62558262|NCT01644682|EXPERIMENTAL|Arm-3|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive ITN intervention.
62558263|NCT01644682|NO_INTERVENTION|Control|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will not receive any intervention, Control group
62558264|NCT04069819|PLACEBO_COMPARATOR|Control group|Escitalopram 20 mg tablet once daily for 6 week plus placebo tablet twice daily for 6 weeks
62558265|NCT04069819|EXPERIMENTAL|Cilostazol group|Escitalopram 20 mg tablet once daily for 6 week plus Cilostazol 50mg tablet twice daily for 6 weeks
62558266|NCT04908592|ACTIVE_COMPARATOR|D Group (50 patients)|
62558267|NCT04908592|PLACEBO_COMPARATOR|C Group (50 patients)|
61987136|NCT05045144|ACTIVE_COMPARATOR|Flu+Placebo Group|"Participants randomized in this group received one dose of Flu D-QIV vaccine co-administered with one dose of placebo at Day 1, and were followed up until the end of the study (Day 181).~This group was considered comparator for immunogenicity and safety analyses for RSV+ Flu Pooled group."
61987137|NCT01871116|EXPERIMENTAL|POWER-remote|Participants will start a weight loss program called POWER-remote for Breast Cancer Survivors. This program involves two main components: an online portion accessed on a computer through the internet and a telephone portion to help monitor progress.
62379999|NCT03140267|EXPERIMENTAL|Difficult to wean patients|Maximal Inspiratory Pressure and Peak Pressure from the inclusion day to the extubation day will be measure.
62558268|NCT01213966|EXPERIMENTAL|800 mg OZ439 po single dose|800 mg OZ439 po single dose
62558269|NCT01213966|EXPERIMENTAL|400 mg OZ439 p.o. single dose|400 mg OZ439 p.o. single dose
62758511|NCT05997849|ACTIVE_COMPARATOR|Monitoring and psychoeducation module|The participants in this group will have access only to the monitoring and psychoeducation module for 30 days. The monitoring module consists of a set of self-report measures, and the psychoeducation is delivered through videos.
62380000|NCT05230069||Patients post emergency evaluation|Interview of patients post notification of emergency system
62380001|NCT06231251|ACTIVE_COMPARATOR|control group|exposed to low caloric diet (15 calories/kilogram) and exercise
62380002|NCT06231251|ACTIVE_COMPARATOR|endoscopic band ligation|endoscopic reduction of ghrelin rich gastric mucosa with band ligation will be applied starting from the fundus till the mid body in 3-4 rows 1-2 cm apart for luminal reduction
62380003|NCT06231251|ACTIVE_COMPARATOR|endoscopic argon plasma coagulation|argon plasma mediated reduction of gastric mucosa rich in ghrelin receptors by appling argon to stomach mucosa from fundus to mid body
62558270|NCT01213966|EXPERIMENTAL|200mg OZ439 p.o. single dose|200mg OZ439 p.o. single dose
62558271|NCT01213966|EXPERIMENTAL|1200 mg OZ439 po single dose|1200 mg OZ439 po single dose
62380004|NCT05977569|EXPERIMENTAL|Prolonged Fasting|All participants are asked to act as their own control prior to being asked to undergo 3 days of fasting.
62380005|NCT06135506|EXPERIMENTAL|control group|conventional ridge splitting with conventional simultaneous implant placement.
62380006|NCT06135506|EXPERIMENTAL|study group|computer guided ridge splitting assisted by artificial intelligence with simultaneous computer guided implant placement.
62558272|NCT03487471|ACTIVE_COMPARATOR|Real-time elastography|98 patients with breast lesion will a receive breast ultrasound (real time elastography)
62558273|NCT03487471|ACTIVE_COMPARATOR|Shear Wave|98 patients with breast lesion will a receive breast ultrasound (shear wave elastography)
62558274|NCT05509387|EXPERIMENTAL|4mA Stimulation|
62558275|NCT05509387|ACTIVE_COMPARATOR|2mA Stimulation|
62558276|NCT05509387|SHAM_COMPARATOR|SHAM|
62558277|NCT03039114|EXPERIMENTAL|Parsaclisib + Hexal and Gazyvaro|
62558278|NCT01397357||suspected Myocardial Ischemia|Patient with diagnosis of suspected coronary artery disease (CAD) or recurrent ischemic symptoms assessed by under-effort angina symptoms and/or cardiac conventional stress test, and the presence of at least two risk factors.
62558279|NCT00980486||BMI <30|BMI \<30
62558280|NCT00980486||BMI 30-39|BMI 30-39
62558281|NCT00980486||BMI >40|BMI \>40
62758512|NCT05997849|EXPERIMENTAL|Mindfulness strategies module|Participants in this group will have access to the monitoring, psychoeducation and mindfulness strategies modules for 30 days. The mindfulness strategies module includes a set of mindfulness-based self-guided techniques for depression and anxiety symptoms. These techniques are delivered in three steps: Learning, Understanding and Practicing.
62758513|NCT05997849|EXPERIMENTAL|Behavioral activation strategies module|Participants in this group will have access to the monitoring, psychoeducation and mindfulness strategies modules for 30 days. The behavioral activation strategies module includes a set of behavioral activation self-guided techniques for depression and anxiety symptoms. These techniques are delivered in three steps: Learning, Understanding and Practicing.
62758514|NCT05997849|EXPERIMENTAL|Cognitive strategies module|Participants in this group will have access to the monitoring, psychoeducation and mindfulness strategies modules for 30 days. The mindfulness strategies module includes a set of cognitive-based self-guided techniques for depression and anxiety symptoms, derived from CBT guidelines. These techniques are delivered in three steps: Learning, Understanding and Practicing.
62758515|NCT04405544|OTHER|Main|patients with COVID-19 and Acute Encephalopathy
62758516|NCT04405544|OTHER|Control|patients with COVID-19 without Acute Encephalopathy
62758517|NCT05076760|EXPERIMENTAL|MEM-288 Intratumoral Injection|"Part 1 MEM-288 monotherapy: Patients with accessible, subcutaneous, or superficial lymph node lesion ≥ 1 cm3 that is palpable will receive intratumoral injection of MEM-288 once every 3 week (planned 2 doses, maximum 6 doses) at one of three dose cohort levels.~* Dose cohort level 1 (1 x 10\^10 viral particles)~* Dose cohort level 2 (3.3 x 10\^10 viral particles)~* Dose cohort level 3 (1 x 10\^11 viral particles)"
62758518|NCT05076760|EXPERIMENTAL|Dose combination of MEM-288 Intratumoral Injection plus anti-PD1 (Nivolumab) Intravenous Infusion|Part 2 MEM-288 plus nivolumab combination: Patients with accessible, subcutaneous, or superficial lymph node lesion ≥ 1 cm3 that is palpable will receive intratumoral injection of MEM-288 maximum total dose of 1x10\^11 viral particles once every 3 week (planned 2 doses, maximum 6 doses). MEM-288 may be injected in multiple lesions until the maximum injection dose (1x10\^11 viral particles) is reached (minimum dose per lesion of 1x10\^10 viral particles). Nivolumab 360 mg IV every 3 weeks.
62758519|NCT01488214|EXPERIMENTAL|Scleroderma patient|Evaluation of Scleroderma patient
62758520|NCT01488214|PLACEBO_COMPARATOR|Healthy subjects|Evaluation of healthy subjects
62758521|NCT00309140|EXPERIMENTAL|Enzastaurin|
62758522|NCT03946982|EXPERIMENTAL|Low thoracic patient controlled epidural analgesia|
61987138|NCT01871116|ACTIVE_COMPARATOR|Self-directed|"Participants will receive a pamphlet entitled Aim for a Healthy Weight, to help guide weight loss goals without access to the web-based POWER-remote system and coach support."
62558282|NCT06165276|EXPERIMENTAL|Group 1|Adults receiving Low Dose TetraMen-T with adjuvant
62758523|NCT03946982|ACTIVE_COMPARATOR|Lumbar epidural patient controlled epidural analgesia|
62758524|NCT03946982|ACTIVE_COMPARATOR|Low thoracic epidural morphine|
62558283|NCT06165276|EXPERIMENTAL|Group 2|Adults receiving High Dose TetraMen-T without adjuvant
62758525|NCT03946982|ACTIVE_COMPARATOR|Lumbar epidural morphine|
62758526|NCT01742910|OTHER|Tecnis ZCB00|eyes with implantation of Tecnis ZCB00
62558284|NCT06165276|EXPERIMENTAL|Group 3|Toddlers receiving Low Dose TetraMen-T with adjuvant
62558285|NCT06165276|EXPERIMENTAL|Group 4|Toddlers receiving High Dose TetraMen-T without adjuvant
62558286|NCT06165276|EXPERIMENTAL|Group 5|Infants receiving Low Dose TetraMen-T with adjuvant. Subjects were to receive a booster dose of the same formulation at age 13 months
62758527|NCT01742910|OTHER|Acrysof SA60AT|eyes with implantation of Acrysof SA60AT
62758528|NCT04812990||hepatitis c patients|50 patients will be recruited for study group from consecutive patients previously diagnosed by hepatitis C regardless of the etiology of the condition and regularly attending at Soad Kafay hospital. Participants with history of smoking and alcoholism that could affect their oral health status were excluded.
62758529|NCT04812990||clinically healthy patients|populations will be randomly recruited from the out-patient of dental diagnosis clinic in Misr University For science \& technology university to include total 50 clinically healthy participants, with no history of liver disease, or any other chronic debilitating illness, or habit of smoking or drinking, , as well as history of an intervention or condition that could affect the oral mucosa (e.g., history of radiotherapy and/or not receiving any medication that could affect oral health.
62758530|NCT03679078|EXPERIMENTAL|IDDSI nutritional supplement drink|Single arm designed, 28day on IDDSI nutritional supplement drink
62758531|NCT02577770|EXPERIMENTAL|200mg caffeine plus acupuncture|In healthy subjects
62758532|NCT02577770|EXPERIMENTAL|400mg caffeine plus acupuncture|In healthy subjects
62758533|NCT02577770|PLACEBO_COMPARATOR|Decaffeinated plus acupuncture|In healthy subjects
62758534|NCT05226364|EXPERIMENTAL|Rubber tourniquet|The blood sample is taken with a rubber tourniquet,
62758535|NCT05226364|EXPERIMENTAL|Fabric tourniquet|The blood sample is taken with a a fabric tourniquet
62758536|NCT05226364|EXPERIMENTAL|No tourniquet|The blood sample is taken without tourniquet
62758537|NCT00579046|EXPERIMENTAL|1|
62758538|NCT05132257||PM No-ROP|Premature without retinopathy of prematurity. Prematurity was defined as birth at \< 37 weeks gestation.
62380007|NCT05433064|EXPERIMENTAL|Epidural Stimulator|Subjects will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord. After 2 weeks recovery,patients will undergo a structured program of physical rehabilitation and electrical stimulation.
62758539|NCT05132257||Mild ROP|Prematurity with mild retinopathy of prematurity. ROP not needing treatment. Prematurity was defined as birth at \< 37 weeks gestation.
62758540|NCT05132257||Severe ROP|Prematurity with type 1 retinopathy of prematurity. Prematurity was defined as birth at \< 37 weeks gestation.
62758541|NCT05132257||Fullterm|Heathal fullterm.
62758542|NCT01996267|ACTIVE_COMPARATOR|FEC-T +Pertuzumab|Fluorouracil; 500 mg/m2; day 1 Epirubicine; 90 mg/m2; day 1 Cyclophosphamide; 500 mg/m2; day 1 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg) Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle is repeated every 21 days
62558287|NCT06165276|EXPERIMENTAL|Group 6|Infants receiving Low Dose TetraMen-T with adjuvant. Subjects were to receive a booster dose of the same formulation at age 13 months
62758543|NCT01996267|ACTIVE_COMPARATOR|PTC+Pertuzumab|Paclitaxel; 80 mg/m2; day 1,8 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1 Carboplatin; AUC=6; day 1 Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle repeated every 21 days
62758544|NCT05202665|EXPERIMENTAL|Flouride Varnish applications (non-invasive approaches)|ClinproTM White Varnish 22600 ppm, 3M ESPE was applied in line with the manufacturer's recommendation to non-cavitated proximal caries lesion.
62758545|NCT05202665|EXPERIMENTAL|Resin Infiltration (micro-invasive approaches)|ICON DMG was applied in line with the manufacturer's recommendation to non-cavitated proximal caries lesion.
62758546|NCT04837729|EXPERIMENTAL|Experimental (acupressure) group|Acupressure (complementary and integrative medicine method) Acupressure will be applied individually to the experimental group for 20-25 minutes three times a week for four weeks. Data collection forms will be applied 3 times in total, before the intervention, in the second and the fourth week.
62758547|NCT04837729|NO_INTERVENTION|Control group|No intervention will be made to women in the control group. However, data collection forms will be applied 3 times in total, before the intervention, in the second and the fourth week.
62758548|NCT01620515|NO_INTERVENTION|Active Surveillance|Subjects with low risk localized (T1c) prostate cancer who are being followed with active surveillance and not undergoing active treatment for prostate cancer.
62380008|NCT04050228|NO_INTERVENTION|Standard Neoadjuvant Chemotherapy Monitoring|"Patients who will be randomized to the control arm with Standard Neoadjuvant Chemotherapy Monitoring will receive Phase I chemotherapy consisting of anthracycline-based treatment followed by Phase II chemotherapy consisting of taxane-based treatment.~Patients will be imaged but no modifications to treatment will occur in this trial arm depending on response by quantitative ultrasound."
62558288|NCT06165276|EXPERIMENTAL|Group 7|Infants receiving High Dose TetraMen-T without adjuvant. Subjects were to receive a booster dose of the same formulation at age 13 months
62758549|NCT01620515|EXPERIMENTAL|NX-1207 2.5 mg|
62558289|NCT06165276|ACTIVE_COMPARATOR|Group 8|Infants receiving Menjugate ®. Subjects were to receive a booster dose of low-dose adjuvanted TetraMen-T at age 13 months. Routine vaccines were deferred.
62758550|NCT01620515|EXPERIMENTAL|NX-1207 15 mg|
62758551|NCT03592719|EXPERIMENTAL|MI-PrEP|"Participants in this arm will receive the manualized two-session intervention entitled Motivational Interviewing to Increase PrEP Uptake"
62758552|NCT03592719|ACTIVE_COMPARATOR|Enhanced Treatment as Usual (E-TAU)|Participants in this arm will receive two sessions which entail psychoeducation on PrEP.
62758553|NCT01549535|ACTIVE_COMPARATOR|Group A (study group)|Subjects in Group A (study group) will undergo a Standard view colonoscopy followed immediately by a PeerScope System™ extended view colonoscopy.
62758554|NCT01549535|ACTIVE_COMPARATOR|Group B (control group)|Group B (control group) will undergo a PeerScope System™ extended view colonoscopy followed immediately by a Standard view colonoscopy.
62758555|NCT00571636|ACTIVE_COMPARATOR|fentanyl|Patients assigned to this arm will receive continuous infusion of fentanyl + open label boluses of Fentanyl if necessary.
62758556|NCT00571636|PLACEBO_COMPARATOR|placebo|Patients assigned to this arm will receive continuous infusion of placebo+ open label boluses of Fentanyl if necessary.
62380009|NCT04050228|EXPERIMENTAL|Adaptive Chemotherapy Monitoring|"Patients who will be randomized to the experimental arm Adaptive Chemotherapy Monitoring and demonstrate Response (+) will continue until standard chemotherapy is completed. For patients who do not demonstrate response after 4 weeks of chemotherapy, an early switch to the second phase of chemotherapy could occur (Phase II/Taxane) At the discretion of the treating medical oncologist.~Patients will undergo Quantitative Ultrasound on the following time points: Pre-treatment, Weeks 1, 4, 8, 12 and Pre-Operatively. These QUS time points correspond to the following chemotherapy times."
62380010|NCT02972294|EXPERIMENTAL|TXA + IIM|The patients randomized to this arm will have iron isomaltoside 1000 and tranexamic acid
62758557|NCT01079013|EXPERIMENTAL|treosulfan|
62758558|NCT01510015|ACTIVE_COMPARATOR|Anti-psychotic medication|Participants are treated with psychological treatment both group and individually as well as medications according to their mental condition.
62758559|NCT01510015|ACTIVE_COMPARATOR|Counseling|Participants will receive individual and group therapy
62758560|NCT01693380|EXPERIMENTAL|Influenza vaccine|"Schoolchildren from 6 to 8 years received two intra-muscular doses of 0.5 ml of inactivated influenza vaccine, of the Southern Hemisphere, 2009.~Schoolchildren above 8 years received one intra-muscular dose of 0.5 ml of inactivated influenza vaccine, of the Southern Hemisphere, 2009."
62758561|NCT01693380|SHAM_COMPARATOR|Control vaccine|"Schoolchildren received one intra-muscular dose of 0.5 ml of Meningococcal C conjugate vaccine.~Schoolchildren under nine years of age received also one intra-muscular dose of 0.5 ml of varicella vaccine one month after the Meningococcal C vaccine."
62758562|NCT05387980||Patients receiving CIBINQO|Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
62380011|NCT02972294|EXPERIMENTAL|Placebo TXA + IIM|The patients randomized to this arm will have iron isomaltoside 1000 and Placebos tranexamic acid
62380012|NCT02972294|EXPERIMENTAL|TXA + Placebo IIM|The patients randomized to this arm will have Placebos iron isomaltoside 1000 and tranexamic acid
62758563|NCT05010330||healthy control|healthy people
62758564|NCT05010330||lung cancer|patients diagnosed with lung cancer
62758565|NCT04525924|EXPERIMENTAL|Bright light therapy|Bright light therapy (BLT) will be given via a lightbox device in the morning for 30 minutes after waking up. Duration of therapy will be 7 consecutive days.
62758566|NCT05728151|EXPERIMENTAL|For group A|Group A will be inducted as before in addition of giving a peribulbar block up to 5 ml ( according to the volume of the eye ) of Articaine 4 % with adrenaline 1/100000 mixed with 10IU of Hyaluronidase by a single injection technique: a 26/27 gauge needle will be inserted as far laterally as possible in the inferotemporal quadrant. Once the needle is under the globe, it will be directed along the orbital floor, passing the globe equator to a depth controlled by observing the needle/hub junction reaching the plane of the iris. After negative aspiration for blood, with the globe in primary gaze, and start injection and the injected volume will be guided by digital intraocular pressure.
62758567|NCT05728151|EXPERIMENTAL|Group L|General Anesthesia will be inducted as before in addition of giving a peribulbar block up to 5 ml ( according to the volume of the eye ) of Lidocaine 2%mixed with 10IU of Hyaluronidase by a single injection technique.
62380013|NCT02972294|EXPERIMENTAL|Placebo TXA + Placebo IIM|The patients randomized to this arm will have Placebos iron isomaltoside 1000 and Placebos tranexamic acid
62558290|NCT06455215|EXPERIMENTAL|Garden intervention|The gardens in the intervention group will receive an 8-week intervention that includes 1) educational materials, 2) healthy cooking demonstrations, food and transportation support and 3) garden social activities.
62758568|NCT05728151|EXPERIMENTAL|Group M|General Anesthesia will be inducted as before in addition of giving a peribulbar block up to 5 ml (according to the volume of the eye) of Mepivacaine 3% mixed with 10IU of Hyaluronidase by a single injection technique.
62758569|NCT05223881|EXPERIMENTAL|Cystic Fibrosis|Patients who are diagnosed with Cystic Fibrosis.
62380014|NCT06012266|ACTIVE_COMPARATOR|Group A: Dapagliflozin first, Empagliflozin second|"Patients randomized to Group A will start with Dapagliflozin on Visit 1 and take Dapagliflozin once daily up to the day before Visit 3.~On the day of Visit 3, they will switch to Empagliflozin once daily, to be continued up to the day preceding Visit 4."
62380015|NCT06012266|ACTIVE_COMPARATOR|Group B: Empagliflozin first, Dapagliflozin second|"Patients randomized to Group B will start with Empagliflozin on Visit 1 and take Empagliflozin once daily up to the day before Visit 3.~On the day of Visit 3, they will switch to Dapagliflozin once daily, to be continued up to the day preceding Visit 4."
62758570|NCT05223881|ACTIVE_COMPARATOR|Healthy Normal|Patients in this arm will be a sibling of patients who have been diagnosed with Cystic Fibrosis.
62758571|NCT01274780|EXPERIMENTAL|Darunavir / Ritonavir|
62758572|NCT01274780|EXPERIMENTAL|Atazanavir / Ritonavir|
62758573|NCT05006209|ACTIVE_COMPARATOR|One visit root canal treatment with CHX|The teeth were treated in one-visit (OV) root canal treatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation.
62758574|NCT05006209|ACTIVE_COMPARATOR|Two visit root canal treatment with CH|The teeth were treated in two visit (TV) root canal treatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
62758575|NCT05719506|SHAM_COMPARATOR|control group 1|control group (nebulized normal saline without drug: group C) .The drugs will be prepared in 0.9% normal saline to a final volume of 3ml. Nebulization will be performed using a wall nebulizer and wall oxygen source on 4 l/min . A Research nurse who will not participate in the evaluation of sedation administered the drugs to all children in nebulizer sessions ∼30 min before transfer to the OR.
62758576|NCT05719506|EXPERIMENTAL|dexmedetomidine group 2|"that receive nebulized dexmedetomidine (3 μg/kg; group D),The drugs will be prepared in 0.9% normal saline to a final volume of 3ml. Nebulization will be performed using a wall nebulizer and wall oxygen source on 4 l/min . A Research nurse who will not participate in the evaluation of sedation administered the drugs to all children in nebulizer sessions ∼30 min before transfer to the OR.~Patients will be assessed for sedation score then separated from their parents and the ease of separation will be recorded."
62758577|NCT05719506|EXPERIMENTAL|ketamine group 3|"nebulized ketamine (3mg/kg; group K) ,The drugs will be prepared in 0.9% normal saline to a final volume of 3ml. Nebulization will be performed using a wall nebulizer and wall oxygen source on 4 l/min . A Research nurse who will not participate in the evaluation of sedation administered the drugs to all children in nebulizer sessions ∼30 min before transfer to the OR.~Patients will be assessed for sedation score then separated from their parents and the ease of separation will be recorded."
62758578|NCT06349187||Doctors of various clinical specialties who are currently working in medical field|Participants over the age of 18, with higher medical education, capable
62758579|NCT02762955|EXPERIMENTAL|BCD-057 group|"BCD-057 group includes patients with moderate to severe plaque psoriasis, who will receive BCD-057 subcutaneously at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23. Patients will be invited for randomization at week 24 (in order to keep the double-blind design of the study), but it will have a formal character (assignment of a new randomization number and lot). From week 25 patients of this group will continue to receive BCD-057 at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.~BCD-057 is adalimumab biosimilar, monoclonal antibody to tumor necrosis factor alfa."
62758580|NCT02762955|ACTIVE_COMPARATOR|Humira® group|"Humira® group includes patients with moderate to severe plaque psoriasis, who will receive Humira® subcutaneously at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23. At week 24 participants will re-randomized (1:1) to treatment with Humira® or will transitioned to BCD-057. Patients will receive BCD-057 or Humira® at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.~BCD-057 is adalimumab biosimilar, monoclonal antibody to tumor necrosis factor alfa.~Humira® is original drug of adalimumab, monoclonal antibody to tumor necrosis factor alfa."
62758581|NCT03690739|ACTIVE_COMPARATOR|platinum-based chemotherapy|According to the investigator's discretion
62758582|NCT03690739|ACTIVE_COMPARATOR|PLD + Trabectedin|PLD 30 mg/m² + Trabectedin 1.1 mg/m² q21
62758583|NCT03946124|OTHER|Fesoterodine|Subjects (irrespective of preference) will receive a 90-day supply of open label fesoterodine 4 mg per day. Medication will start 1 week after the baseline visit. After 2 weeks of treatment, dose may be increased to 8 mg over the telephone based on symptom report. This dosing regimen is direct alignment with clinical care. Change of prescription to another anti-cholinergic may occur during the study period, if determined necessary by the physician.
62758584|NCT01025362|EXPERIMENTAL|Lactation counseling|"Intervention arm: The mother and child health centres will implement The Baby-Friendly Initiative to improve their lactation counseling.~Other Names: The Baby Friendly Community Health Service"
62758585|NCT01025362|ACTIVE_COMPARATOR|Standard care|The comparison group was mother and child health centres which continued offering standard care.
62758586|NCT02510365|EXPERIMENTAL|Functional collagen scaffold|Functional neural regeneration collagen scaffold transplantation.
62758587|NCT02845947|EXPERIMENTAL|Music Therapy|Music Therapy to be provided for pediatric patients undergoing extubation readiness trial
62758588|NCT02845947|NO_INTERVENTION|Control|Patients undergoing standard extubation readiness trial
62758589|NCT01257490|EXPERIMENTAL|Intensive counseling|4 sessions of intensive counseling plus bupropion
62758590|NCT01257490|ACTIVE_COMPARATOR|Brief Counseling|Brief physician advice to quit plus bupropion
62758591|NCT03872427|EXPERIMENTAL|Treatment (telaglenastat hydrochloride)|Patients receive telaglenastat hydrochloride PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, or PET/CT during screening and on study, and collection of blood samples during screening and on study.
62758592|NCT03798054|EXPERIMENTAL|Soliqua (insulin glargine/lixisenatide)|iGlarLixi (insulin glargine/lixisenatide) will be self-administered subcutaneously once daily in the morning on top of metformin for 24 weeks.
62758593|NCT03798054|ACTIVE_COMPARATOR|Lantus (insulin glargine)|Insulin glargine will be self-administered subcutaneously once daily at any time of the day on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.
62758594|NCT03798054|ACTIVE_COMPARATOR|Lyxumia (lixisenatide)|Lixisenatide will be self-administered subcutaneously once daily according to the locally approved label on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.
62758595|NCT01151605|EXPERIMENTAL|obese subjects|obese (BMI \>30Kg/m2) subjects infused with insulin dextrose or saline 1 week apart. Each infusion will continue for up to 14 hr
62758596|NCT01151605|ACTIVE_COMPARATOR|Normal weight subjects|Normal weight subjects infused with insulin dextrose or saline 1 week apart. Each infusion will continue for up to 14 hr
62380016|NCT04771936|NO_INTERVENTION|Control Group|The control group who shall be awaiting surgery and not receiving a regular physiotherapy exercise intervention
62380017|NCT04771936|ACTIVE_COMPARATOR|Conventional Exercise Group|The conventional exercise group shall be subject to a set of conventional exercises based on a program described by Deyle et al (2000).
62558291|NCT06455215|ACTIVE_COMPARATOR|Delayed intervention|The control group will be asked to abstain from intervention activities during the 8 week period. The control group will receive the delayed 8-week intervention one year after the intervention group.
62758597|NCT01151605|EXPERIMENTAL|obese type 2 diabetes subjects|obese (BMI \>30Kg/m2) subjects with type 2 diabetes infused with insulin dextrose or saline 1 week apart. Each infusion will continue for up to 14 hr
62758598|NCT05462002||plantar fasciitis group|Distance runners with plantar fasciitis
62758599|NCT05462002||asymptomatic control group|Distance runners without plantar fasciitis
62758600|NCT01252550|ACTIVE_COMPARATOR|Activia®|Activia® (125g/pot)
62758601|NCT01252550|PLACEBO_COMPARATOR|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
62758602|NCT05346991|EXPERIMENTAL|Intervention arm|Implementation of the Tobacco-Free Teachers, Tobacco Free Society program in government schools in Bihar, India
62758603|NCT05346991|NO_INTERVENTION|Control arm|Delayed intervention - control arm schools receive the program after all data collection is complete
62758604|NCT01143051|ACTIVE_COMPARATOR|Treatment C|Active comparator arm utilizing marketed Primatene Mist with CFC propellant at the labeled dose.
62758605|NCT01143051|EXPERIMENTAL|Treatment 1|T1 is HFA propelled epinephrine inhalation aerosol 125 mcg/inhalation
62758606|NCT01143051|EXPERIMENTAL|Treatment 2|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation
62758607|NCT03723174||Single Arm|baseline data will be calculated before the oral health educational program using gingival index and after 3 months from the intervention
62758608|NCT01410669|EXPERIMENTAL|Motivational Interviewing (MI)|
62758609|NCT02615860|EXPERIMENTAL|Topical 85% trichloroacetic acid (TCA)|AIN lesions are treated with trichloric acid
62380018|NCT04771936|EXPERIMENTAL|Conventional Exercise Group with added core exercises|This exercise group shall be subject to a set of conventional exercises based on a program described by Deyle et al (2000) and core exercises aimed at the activation of the core muscles as adapted from Imai et al (2010).
62380019|NCT03394196|EXPERIMENTAL|No HIV-2 resistance|
62758610|NCT02615860|ACTIVE_COMPARATOR|Surgical electrocautery (ECA)|AIN lesions are treated with electrocautery
62758611|NCT01221025|EXPERIMENTAL|parecoxib|Parecoxib, a water-soluble prodrug of valdecoxib, is a high-selective COX-2 inhibitor that is first available for intravenous administration.
62758612|NCT00118352|EXPERIMENTAL|Treatment (chemotherapy, TBI, transplant)|"NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive alemtuzumab IV over 6 hours once daily on days -6, -5, and -4 OR days -5 and -4 and fludarabine phosphate IV over 30 minutes on days -4, -3, and -2. Patients also undergo low-dose TBI on day 0.~ALLOGENEIC PBSCT: After completion of TBI, patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV every 12 hours on days -3 to 180 followed by a taper until day 365 in the absence of GVHD. Beginning 4-6 hours after completion of allogeneic PBSCT, patients receive mycophenolate mofetil PO every 8 hours on days 0 to 100 followed by a taper until day 156 in the absence of GVHD."
62758613|NCT06333743|EXPERIMENTAL|laser ablation treatment|Laser vaporization is performed using a carbon dioxide laser under colposcopy. All patients received 1% mepivacaine hydrochloride paracervix block. No general anesthesia was used. Before laser vaporization began, scaly columnar nodules were visible in all patients. The evaporation depth is 8-10mm, and the edge is 5mm from the abnormal discovery or transition area.
62758614|NCT06333743|ACTIVE_COMPARATOR|LEEP or conization treatment|The cervix was stained with iodine solution and the diseased lesion was visualized. LEEP or conization was performed to a depth of approximately 1.5 cm to resect disease in the cervical canal.
62558292|NCT04935541|ACTIVE_COMPARATOR|Dexmedetomidine infusion|Dexmedetomidine (Precedex, Meditera, USA) was administered at a loading dose of 1 µg/kg for 10 minutes before local anesthesia to be applied to the eye by the surgeon. During the surgical procedure, it was administered at a dose of 0.4 µg/kg/h-1 infusion.
62558293|NCT04935541|ACTIVE_COMPARATOR|Remifentanil infusion|Remifentanil (Ultiva, Glaxo SmithKline, Turkey) infusion was started at a dose of 0.05 µg/kg/min-1, 10 minutes before the start of the surgery as baseline infusion and continued at the same infusion dose throughout the surgical procedure.
62758615|NCT05059223|EXPERIMENTAL|AXS-12 (reboxetine)|Up to 5 weeks
62758616|NCT05059223|PLACEBO_COMPARATOR|Placebo|Up to 5 weeks
62380020|NCT03394196|EXPERIMENTAL|HIV-2 NRTI resistance only|
62380021|NCT03394196|EXPERIMENTAL|HIV-2 NRTI and PI resistance|
62380022|NCT05087563|EXPERIMENTAL|Neurolens|Our proprietary contoured prism lens design, commercially known as neurolens.
62380023|NCT05087563|PLACEBO_COMPARATOR|Control lens|A simple refractive error correction lens
62380024|NCT00536458|EXPERIMENTAL|radiotherapy|minichep + radiotherapy
62380025|NCT00536458|ACTIVE_COMPARATOR|B|MINI CHEP
62380026|NCT05825365|ACTIVE_COMPARATOR|Selumetinib|Participants will orally receive selumetinib twice daily (BID) (approximately every 12 hours) at a dose of 25 mg per square meter of body surface area (BSA) on a continuous dosing schedule (28-day per cycle with no rest periods between cycles) for a maximum of 36 cycles.
62758617|NCT06252896|EXPERIMENTAL|IASTM Group|Individuals were positioned on the stretcher so that the area to be applied was exposed. ADYDM to be applied to ensure comfortable movement of the instrument on the tissue before application baby oil was applied to cover the area. In order to increase the effectiveness of the application suggestions were made to the person to relax. Application ADYDM for each muscle group tool (Figure 3.4) for 5 minutes. The occurrence of allergic reactions on the skin the test was terminated.
62758618|NCT06252896|PLACEBO_COMPARATOR|Control Group|The control group was kept for 30 minutes without ADYDM application and then muscle strength assessment, flexibility assessment, agility assessment, balance assessment and finally aerobic capacity assessment were performed respectively.
62758619|NCT03415698|ACTIVE_COMPARATOR|Standard Medical Therapy|Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required)
62758620|NCT03415698|ACTIVE_COMPARATOR|G-CSF + Standard Medical Therapy|G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
62758621|NCT04697186|EXPERIMENTAL|berberine , amoxicillin and rabeprazole triple therapy|Berberine 300mg three time daily for 14days, amoxicillin 1000 mg and rabeprazole 10 mg by mouth, twice daily for 14 days.
62758622|NCT04697186|ACTIVE_COMPARATOR|Bismuth-containing Quadruple Therapy|amoxicillin 1000 mg，clarithromy 500mg，rabeprazole 10 mg, and Bismuth 220mg by mouth, twice daily for 14 days.
62758623|NCT03368716|EXPERIMENTAL|Acceptance-based Behavioral Treatment|Family acceptance-based behavioral treatment (ABBT) will be piloted with 16 child-caregiver pairs. At weeks 0 (pre-treatment), 9 (mid-treatment), and 18 (post-treatment), feedback regarding the feasibility and acceptability will be collected from participants through surveys and semi-structured group interviews to refine the family ABBT protocol.
62758624|NCT02448953|ACTIVE_COMPARATOR|negative lymph node|lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination
62758625|NCT02448953|ACTIVE_COMPARATOR|positive lymph node|lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination
62758626|NCT04815122||Carriers of the Met allele of the COMT Val158Met polymorphism|Women with obesity carriers of the Met allele of the COMT Val158Met polymorphism
62558294|NCT03701893|EXPERIMENTAL|Lactobacillus PS11610|Lactobacillus PS11610 for couples with genital dysbiosis and infertility. Each dose contains 1\*10E9 colony forming unit (CFU) of Lactobacillus PS11610.Two daily doses for her and one daily dose for him until pregnancy or end of study period (6 months).
62558295|NCT06424548|EXPERIMENTAL|Administration of Sarpogrelate|The intervention group will receive aspirin 100mg plus sarpogrelate 100mg
62558296|NCT06424548|OTHER|Traditional administration of Clopidogrel|The control group will receive aspirin 100mg plus clopidogrel 75mg
62558297|NCT03236467|EXPERIMENTAL|FM + PTSD|Individuals suffering from Fibromyalgia and PTSD
62558298|NCT03832686|EXPERIMENTAL|Virtual Coach App|Participants in the experimental arm (Group A) will receive a comprehensive swallowing rehabilitation app. This study seeks to determine if a mobile application may enhance adherence to swallowing therapy in patients undergoing radiation therapy for head and neck cancer. No devices - outside of the Smartphone already owned by the participant - will be used in this study. Similarly, no drugs, biological materials, or other substances will be used.
62558299|NCT03832686|NO_INTERVENTION|Standard of Care|The paper group (Group B) will be given paper exercise logs to fill out Participants will be educated regarding potential radiation-related side effects and trained in the same series of swallowing exercises by the SLP. The paper log treatment group will serve as a standard treatment group. As adherence is a primary goal of the target intervention, paper logging will be necessary to determine relative adherence while minimizing reporting bias.
62558300|NCT01981902||Dehydration|Non-Invasive Optical Spectroscopic monitoring method for dehydration
62558301|NCT04293874|EXPERIMENTAL|Low Omega-3LC group|Participants will consume a personalized meal plan for 2 weeks and consume an increased quantity of fish to 6 oz. wild salmon (1 steak, 6oz /steak)or 14.3 oz. (5.5 packs, 2.6 oz/pack) of chunk light tuna (1020 mg Omega-3LC/week) for 6 weeks.
62558302|NCT04293874|EXPERIMENTAL|High Omega-3LC group|Participants will consume a personalized meal plan for 2 weeks and consume an increased quantity of fish to 12 oz. wild salmon (2 steak,12 oz /steak)or 28.6 oz. (11 packs, 2.6 oz/pack) of chunk light tuna (2040 mg Omega-3LC/week) for 6 weeks.
62558303|NCT05630846|EXPERIMENTAL|MMRV(H)NS Group|Healthy children aged 4 to 6 years of age receive 1 dose of an investigational measles, mumps, and rubella (MMR) at release potency and varicella at high (V\[H\]NS) potency vaccine on Day 1.
62558304|NCT05630846|EXPERIMENTAL|MM(H)RVNS Group|Healthy children aged 4 to 6 years of age receive 1 dose of an investigational measles, rubella (MR), and varicella (VNS) at release potency and mumps at high (M\[H\]) potency vaccine on Day 1.
62558305|NCT05630846|EXPERIMENTAL|M(L)M(L)R(L)V(L)NS Group|Healthy children aged 4 to 6 years of age receive 1 dose of an investigational measles, mumps, rubella (MMR), and varicella (VNS), all at low (L) potency vaccine on Day 1.
62758627|NCT04815122||Non-carriers of the Met allele of the COMT Val158Met polymorphism|Women with obesity non-carriers of the Met allele of the COMT Val158Met polymorphism
62758628|NCT02573246|EXPERIMENTAL|Cognitive Restructuring+rTMS (left)|Participants in this arm will be administered the neuromodulation enhanced cognitive restructuring intervention over the left side of the brain and will partake in short term and long term follow up testing.
62758629|NCT02573246|SHAM_COMPARATOR|Cognitive Restructuring + sham rTMS|Participants in this arm will receive cognitive restructuring alone as an active intervention and will partake in short term and long term follow up testing.
62758630|NCT02573246|EXPERIMENTAL|Cognitive Restructuring+rTMS (right)|Participants in this arm will be administered the neuromodulation enhanced cognitive restructuring intervention over the right side of the brain and will partake in short term and long term follow up testing.
62758631|NCT02947854|EXPERIMENTAL|Photosensitizer and adjuvant|Run-in cohort for selection of fimaporfin starting dose in the main study. Single intradermal dosing of fimaporfin and adjuvant (Hiltonol \[poly-ICLC\]) followed by light application.
62758632|NCT02947854|EXPERIMENTAL|Photosensitizer, adjuvant and antigens|Main part: Intradermal dosing of fimaporfin, adjuvant (Hiltonol, poly-ICLC) and antigens (KLH and HPV E7) followed by light application.
62758633|NCT02947854|EXPERIMENTAL|Assessments of time between ID dosing and light|Optional part: Assessment of different time interval between intradermal dosing of fimaporfin, adjuvant/antigens and light application.
62758634|NCT06607237|EXPERIMENTAL|Investigational Product|
62558306|NCT05630846|ACTIVE_COMPARATOR|MMRV_Lot 1 and Lot 2 Pooled Group|Healthy children aged 4 to 6 years of age receive 1 dose of a marketed measles, mumps, rubella (MMR), and varicella (V) vaccine of Lot 1 or of 1 vaccine dose of a marketed MMRV vaccine of Lot 2 on Day 1.
62558307|NCT01197534|EXPERIMENTAL|Dosing Regimen A|Oral Treatment
62558308|NCT01197534|EXPERIMENTAL|Dosing Regimen B|Oral Treatment
62558309|NCT01197534|PLACEBO_COMPARATOR|Dosing Regimen C|Oral Treatment
62558310|NCT00962897||Surgical Bypass Group|Those patients that underwent bypass of blockage in the thigh with surgery.
62758635|NCT01007071|EXPERIMENTAL|Growth hormone|Subjects randomized to growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Dose adjustments based on serum insulin-like growth factor-1 (IGF-1) levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 standard deviation (SD) to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
62758636|NCT01007071|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo for 16 weeks. As noted above, placebo subjects will be initiated on a daily subcutaneous injection, with dose changes based on changes in active drug subjects.
62758637|NCT04847895||Lucentis|Patients administered Lucentis by prescription
62758638|NCT06269198|NO_INTERVENTION|Control arm|Blinded data collection by the WARD-CSS without vital signs and active alerts displayed to the ward staff
62558311|NCT00962897||Stent-graft group|Patients that underwent treatment of blockage in the thigh with balloon angioplasty and stent placement.
62558312|NCT03517410||Smart phone Use Experimental group|Patients with CLBP
62558313|NCT05244694|EXPERIMENTAL|Insulin|Participants will complete a 60 minute hyperinsulinemic-euglycemic infusion.
62558314|NCT01364012|EXPERIMENTAL|Bevacizumab + Paclitaxel/Carboplatin|Participants will receive bevacizumab on Day 1 of each 3-week cycle in combination with paclitaxel and carboplatin for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive bevacizumab on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
62380027|NCT05825365|PLACEBO_COMPARATOR|Placebo|Participants will orally receive placebo twice daily (BID) (approximately every12 hours) at a dose of 25 mg per square meter of body surface area (BSA) on a continuous dosing schedule (28-day per cycle with no rest periods between cycles) for a maximum of 36 cycles. Transfer to selumetinib on REiNS-defined PD.
62380028|NCT05238844|EXPERIMENTAL|ATI-2173 25mg, Vebicorvir 300mg and Tenofovir 300mg|Subjects randomized to active arm will receive active 25mg ATI-2173 + active Vebicorvir 300mg + active Tenofovir 300mg
62380029|NCT05238844|ACTIVE_COMPARATOR|Tenofovir Disoproxil Fumarate|Subjects randomized to placebo arm will receive placebo 25mg ATI-2173 + placebo Vebicorvir 300mg + active Tenofovir 300mg
62380030|NCT05297552|EXPERIMENTAL|RC48-ADC + JS001|Participants received 6 preoperative cycles of RC48-ADC PLUS JS001, followed by surgery, followed by up to 20 cycles of postoperative JS001.
62558315|NCT01364012|ACTIVE_COMPARATOR|Placebo + Paclitaxel/Carboplatin|Participants will receive bevacizumab matching placebo on Day 1 of each 3-week cycle in combination with paclitaxel and carboplatin for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive bevacizumab matching placebo on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
62558316|NCT00266279|EXPERIMENTAL|Treatment with Study Drugs|Treatment with combination of oxaliplatin and capecitabine using study dose and schedule.
62380031|NCT05673785|EXPERIMENTAL|Brentuximab Vedotin + CHP|Brentuximab vedotin 1.8 mg/kg, intravenous (IV) infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m\^2 and doxorubicin 50 mg/m\^2 IV, on Day 1 of each 21-day cycle, and prednisone 100 mg tablets, orally, on Days 1 through Day 5, for up to 8 cycles (6 months) or until progressive disease (PD), unacceptable toxicity, whichever occurs first.
62380032|NCT05624892|EXPERIMENTAL|Experimental Group|Application of mirror therapy to the experimental group with virtual reality application
62380033|NCT05624892|NO_INTERVENTION|Control Group|Application of classical mirror therapy to the control group
62380034|NCT06267040||women diagnosed with uncomplicated cystitis|women older than 18 years diagnosed with uncomplicated cystitis and treated accordingly
62558317|NCT05990829|EXPERIMENTAL|Ozurdex group|Standard 25-gauge pars plana vitrectomy (PPV) will be performed under retrobulbar anaesthesia using high-speed vitrectomy system. Clear all the vitreous hemorrhage and proliferative membrane during PPV operation, panretinal photocoagulation should be completed. The vitreous cavity will be filled with balanced salt solution. An injection of Ozurdex will be performed at the end of the surgery.
62758639|NCT06269198|EXPERIMENTAL|Intervention arm|Monitoring by the WARD-CSS including vital signs and active alerts relayed to the nurses' smartphones during hospitalization
62758640|NCT05607082|NO_INTERVENTION|Holdout control condition with no message|Participants will only receive the standard pharmacy messaging.
62380035|NCT06267040||control group|women older than 18 years presented for reasons unlikely to affect the lower urinary tract
62380036|NCT01171872||Unaffected|Individuals who do not have IBD
62758641|NCT05607082|EXPERIMENTAL|"Control condition with waiting for you message"|This control condition will use the text message that we've found to be the best performing in our last mega-study of vaccine text messages to recommend a COVID vaccination.
62758642|NCT05607082|EXPERIMENTAL|"Control condition with waiting for you message with a GIF"|This control condition will use the text message that we've found to be the best performing in our last mega-study of vaccine text messages and includes a GIF to recommend a COVID vaccination.
62380037|NCT01171872||Affected|Individuals who have IBD
62380038|NCT00710151||1|Subjects with PCNSL who have survived disease-free for 2 years or more. Treatments will vary depending upon site of enrollment and will include chemotherapy, blood brain barrier disruption (BBBD) with chemotherapy, radiation, and stem cell transplantation.
62380039|NCT01002040|ACTIVE_COMPARATOR|One Dose Influenza vaccine|Arepanrix H1N1 Influenza vaccine (one dose)
62380040|NCT01002040|ACTIVE_COMPARATOR|Two Doses Influenza vaccine|Arepanrix H1N1 Influenza vaccine (2 doses, 3 weeks apart)
62380041|NCT00396344|PLACEBO_COMPARATOR|1|Saline control
62380042|NCT00396344|EXPERIMENTAL|2|
62380043|NCT00396344|EXPERIMENTAL|3|
62380044|NCT02951585|EXPERIMENTAL|KARTILAGE CROSS|Kartilage® Cross (2.2 mL, 16 mg/g of hyaluronic acid)
62380045|NCT02951585|PLACEBO_COMPARATOR|Placebo|Saline solution (2.2-2.5 mL, NaCl 9 mg/g)
62380046|NCT02924987|OTHER|Aflibercept injection|Not applicable. There will be no randomization nor stratification to any to study arms or groups.
62380047|NCT06482138|OTHER|Control|Biopsy and cytobrush during a scheduled structural intervention in general anesthesia
62380048|NCT06482138|OTHER|Olfactory Dysfunction|Biopsy and cytobrush during consultation in local anesthesia
62380049|NCT01608139|EXPERIMENTAL|Curcumin + Sorafenib + Vorinostat|"Participant assigned to a dose level of the study drug combination based on when joined this study. Up to 9 dose levels of the study drug combination will be tested. Three (3) to 6 participants will be enrolled at each dose level of the study drug combination. During first cycle only, Curcumin initiated on Day 1, Vorinostat on Day 3 and Sorafenib on Day 5. Beginning with Cycle 1 Day 5, all agents administered continuously. Cycle of therapy is 28 days.~Starting dose of Curcumin: 4 grams by mouth per day on Day 1. Starting dose of Sorafenib: 200 mg by mouth daily beginning on Day 5. Starting dose of Vorinostat: 100 mg by mouth daily beginning on Day 3."
62380050|NCT03523403|EXPERIMENTAL|Acute phase - intervention|Participants will be asked to consume 3 whole apples and a high-fat meal (a mixture of commercially available whipping cream and milk, providing 1 g of fat per kg of body weight) within 30 minutes.
62380051|NCT03523403|NO_INTERVENTION|Acute phase - control|Participants will be asked to consume a high-fat meal (a mixture of commercially available whipping cream and milk, providing 1 g of fat per kg of body weight) within 30 minutes.
62380052|NCT03523403|EXPERIMENTAL|Chronic phase - intervention group|Participants will be asked to consume 3 whole apples per day for 6 weeks.
62380053|NCT03523403|NO_INTERVENTION|Chronic phase - control group|Participants will be asked to consume no apples per day for 6 weeks.
62380054|NCT04430036|EXPERIMENTAL|Cisplatin, Gemcitabine plus human monoclonal antibodies|The safety run-in of the study will first enroll three patients who will begin treatment with cisplatin and gemcitabine plus AGEN2034 and AGEN1884 as outlined in the treatment plan. These first 3 patients will be assessed for DLTs and there will be a pause in enrollment until all three complete the DLT period. If there are no DLTs in the first 3 patients, we will proceed to further accrual to stage I of phase II. If there is 1 DLT in the initial 3 patients, we will enroll 3 additional patients to the safety run-in. If \> 2 DLTs are experienced in the initial 3 patients, the study will be terminated, otherwise additional subjects will be enrolled into the phase ll first stage and reassessed after 2 cycles of therapy and proceed to planned surgery. If criteria are met to continue to the second stage of the Phase II portion of the study, additional patients will be enrolled for an anticipated total of 36 evaluable patients. Patients will be treated and endpoints evaluated.
62380055|NCT01809327|EXPERIMENTAL|Canagliflozin 100 mg|Participants will receive one 100 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.
62380056|NCT01809327|EXPERIMENTAL|Canagliflozin 300 mg|Participants will receive one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.
62380057|NCT01809327|EXPERIMENTAL|Metformin XR|Participants will receive metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.
62567602|NCT02972905|PLACEBO_COMPARATOR|Session 2: Placebo|Subjects will receive repeated doses of GSK2269557 matching Placebo once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
62758643|NCT05607082|EXPERIMENTAL|Planning message recommending same time/location as last vaccination|This condition will use a text message recommending the same time and location as the participant's last vaccination to get a COVID vaccination.
62758644|NCT05607082|EXPERIMENTAL|Message from local pharmacy team|This condition will use a text message from the participant's local pharmacist recommending a COVID vaccination.
62758645|NCT05607082|EXPERIMENTAL|Message including link to resources combating misinformation|This condition will use a text message including a link to to resources combating misinformation and then recommend a COVID vaccination.
62758646|NCT05607082|EXPERIMENTAL|Message including link to resources combating misinformation with a GIF|This condition will use a text message including a link to to resources combating misinformation and then recommend a COVID vaccination and will include a GIF.
62758647|NCT05607082|EXPERIMENTAL|Message offering free round trip ride to the pharmacy|This condition will use a text message offering a free round trip ride to the pharmacy to get a COVID vaccination.
62758648|NCT05607082|EXPERIMENTAL|Message communicating latest data on COVID transmission in patient's area|This condition will use a text message informing the participant of the latest data on COVID transmission in participant's area and recommend a COVID vaccination.
62758649|NCT05607082|EXPERIMENTAL|Message encouraging vaccination in preparation for the holidays|This condition will use a text message to encourage a COVID vaccination in preparation for the holidays.
62758650|NCT05607082|EXPERIMENTAL|Message conveying the CDC recommends vaccination|This condition will use a text message to encourage a COVID vaccination by conveying the CDC recommends vaccination.
62758651|NCT01457950|EXPERIMENTAL|Arm 1|denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind phase
62758652|NCT01457950|PLACEBO_COMPARATOR|Arm 2|placebo subcutaneous injection, single dose at the start of the 6-month double-blind phase
62758653|NCT01457950|EXPERIMENTAL|Arm 3|open-label phase follows the double-blind phase, denosumab 60mg subcutaneous injection, single dose at the start of the 6-month open-label phase
62758654|NCT04606589|NO_INTERVENTION|Standard-of-care|The standard-of-care arm will receive intermittent monitoring of pulse rate and blood oxygen saturation with a conventional pulse oximeter. Temperature and respiratory rate will also be monitored intermittently with a digital thermometer and manual counting of breaths respectively.
62758655|NCT04606589|EXPERIMENTAL|neoGuard vital signs monitor|The intervention group will receive continuous vital signs monitoring of pulse rate, blood oxygen saturation, temperature and respiratory rate with the neoGuard device.
62758656|NCT02632201|EXPERIMENTAL|PIK-HER2 cells|PIK-HER2 cells treatment will be performed every 3 weeks with a total of three periods.
62758657|NCT02632201|ACTIVE_COMPARATOR|DC-PMAT|DC-PMAT treatment will be performed every 3 weeks with a total of three periods.
62758658|NCT01201616|EXPERIMENTAL|High fat, low carbohydrate diet|Fats intake 55% , Protein 17% and carbohydrate 28% of total energy
62758659|NCT01201616|ACTIVE_COMPARATOR|Low fat, high carbohydrate diet|Fat intake 20%, Protein 17% and carbohydrate 63% of total energy intake
62558318|NCT05990829|ACTIVE_COMPARATOR|Aflibercept group|Standard 25-gauge pars plana vitrectomy (PPV) will be performed under retrobulbar anaesthesia using high-speed vitrectomy system. Clear all the vitreous hemorrhage and proliferative membrane during PPV operation, panretinal photocoagulation should be completed. The vitreous cavity will be filled with balanced salt solution. An injection of aflibercept will be performed at the end of the surgery.
62758660|NCT04412213||children of possitive family history of stuttering|
62758661|NCT04412213||children of negative family history of stuttering|
62758662|NCT04563728|ACTIVE_COMPARATOR|Camera Group|"1) The camera(s) will be a stationary device installed by the study technician on the ceiling of a common living area of the participant's home. The camera(s) will record video and audio data to be stored in our secure data base. The cameras will be purchased from YI Technology (see more details in Section 1.7). A sign will be placed outside the home to notify individuals regarding the potential recording, reading, NOTICE Audio and/or video surveillance may be in use on these premises. Highlighted video and audio data will be reviewed daily by the study technician. If there is evidence of abuse, exploitation, and neglect on these video and audio data, a report will be made to APS and the IRB."
62758663|NCT04563728|ACTIVE_COMPARATOR|Mock Camera Group|"2) The mock camera(s) will be a stationary device installed on the ceiling of a common living area of the participant's home. They will not record video or audio but will be installed with a sensor chip and a Wi-Fi connection, which will notify the study team if the device has been touched, tampered, altered, or disrupted power sources. After installing the device, the study technician and study coordinator will test the anti-tampering sensor to ensure potential future tampering will be detected. A sign will be placed outside the home to notify individuals regarding the potential recording, reading, NOTICE Audio and/or video surveillance may be in use on these premises. Daily check-ins to assess whether elder abuse may have been experienced by the participant will occur by phone or other preferred mode of communication. In the event of reported abuse, exploitation, and neglect, despite not being mandatory reporters, we will report to NJ APS and the IRB."
62380058|NCT01809327|EXPERIMENTAL|Canagliflozin 100 mg + Metformin XR|Participants will receive one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.
62380059|NCT01809327|EXPERIMENTAL|Canagliflozin 300 mg + Metformin XR|Participants will receive one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.
62380060|NCT05021666|EXPERIMENTAL|Group A1|PB-718 vs placebo
62380061|NCT05021666|EXPERIMENTAL|Group A2|PB-718 vs placebo
62380062|NCT05021666|EXPERIMENTAL|Group A3|PB-718 vs placebo
62380063|NCT05021666|EXPERIMENTAL|Group A4|PB-718 vs placebo
62380064|NCT05021666|EXPERIMENTAL|Group A5|PB-718 vs placebo
62380065|NCT05021666|EXPERIMENTAL|Group A6|PB-718 vs placebo
62380066|NCT05021666|EXPERIMENTAL|Group B1|PB-718 vs placebo
62558319|NCT04965805|EXPERIMENTAL|Cold plasma jet|The treatment scheme of the cold plasma jet will be applied in the following manner, quantity and frequency: Cold plasma is always applicated for 30 seconds/ cm\^2 wound size. Wounds will be treated three times in the first week, twice in the second week and once per week in the following observation period. In case of locally infected ulcers, treatment will be performed 1x per day during the first week and afterwards in the same manner as in non-infected ulcers. After application of cold plasma, the wound will be covered with Adaptic perforated gauze and a non-active dressing.
62558320|NCT04965805|ACTIVE_COMPARATOR|Best Practice wound dressings|Immediately after dressing removal, the wound will be cleaned with a physiological saline solution soaked swab. In case of locally infected wounds, an antiseptic will be used instead of the physiological saline solution. Subsequently, a wound phase-adapted primary dressing will be applied according to the experience of the practitioner and, if necessary, the wound will be covered with a secondary dressing according to the experience of the practitioner as well. In case of locally infected wounds, silver dressings can be applied. The dressing will be changed at least every 2nd day and on weekends every 3rd day; in case of locally infected wounds, dressings will be changed daily. Dressing changes beyond visits can also be performed by the general practitioner, a nursing service, or by the participant him- or herself.
62558321|NCT00608101|EXPERIMENTAL|1|Day 1 hyperinsulinemic euglycemic clamps with either 0.2 mg fludrocortisone, 0.75 mg Dexamethasone, or both given orally before each morning and afternoon clamp. Day 2 hyperinsulinemic hypoglycemic glucose clamp.
62558322|NCT00608101|EXPERIMENTAL|2|Fludrocortisone will be administered in doses of 0.05mg, 0.1mg and 0.2 mg form at the start of each clamp period on day 1. Dexamethasone will be administered orally in the doses of 0.18 mg, 0.375mg and 0.75mg doses. The combination of the 0.05mg fludrocortisone and 0.18mg dexamethasone and 0.1mg of fludrocortisone and 0.375 mg doses will be administered at the start of each day 1 clamp period. Day 2 90 minutes of moderate exercise.
62758664|NCT04563728|NO_INTERVENTION|Usual Care|Each participant will receive educational packages about elderly community-living.
62758665|NCT02435290||patients with malignant cancer receiving chemotherapy|five hundred patients suffering malignant cancer from eight wards ( breast , GIT ,gynecological , genitourinary , lung , head and neck, lymphoma and myeloma ,skin and melanoma) ,receiving various chemotherapy protocols .
62758666|NCT03584191||People with Obesity|General population - potential participants will be recruited using various and numerous general population as appropriate in each country.
62558323|NCT01873352|ACTIVE_COMPARATOR|CA+RD|Catheter ablation of atrial fibrillation plus renal sympathetic denervation
62558324|NCT01873352|ACTIVE_COMPARATOR|CA (control)|Catheter ablation of atrial fibrillation (control group)
62380067|NCT05021666|EXPERIMENTAL|Group B2|PB-718 vs placebo
62380068|NCT05021666|EXPERIMENTAL|Group B3|PB-718 vs placebo
62380069|NCT05021666|EXPERIMENTAL|Group B4|PB-718 vs placebo
62380070|NCT03756285|EXPERIMENTAL|AZD4831|AZD4831 tablets taken orally for for 90 days.
62380071|NCT03756285|PLACEBO_COMPARATOR|Placebo|Placebo tablets taken orally for 90 days.
62380072|NCT02460120|EXPERIMENTAL|Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System
62380073|NCT03453528|EXPERIMENTAL|68Ga-PSMA|68Ga-PSMA
62380074|NCT05344859|EXPERIMENTAL|Arm 1|Adaptive Rewards + Weekly automated coaching
62380075|NCT05344859|EXPERIMENTAL|Arm 2|Adaptive Rewards + Weekly human coaching
62380076|NCT05344859|EXPERIMENTAL|Arm 3|Fixed Reward + Weekly automated coaching
62380077|NCT05344859|EXPERIMENTAL|Arm 4|Fixed Reward + Weekly human coaching
62380078|NCT04191694|OTHER|Control|Patients will receive the standard dose of anti-emetic according to hospital practice (Ondansetron 4mg IV, intra-operatively)
62380079|NCT04191694|ACTIVE_COMPARATOR|Chewing Gum|Patients will receive the standard dose of anti-emetic according to hospital practice (Ondansetron 4mg IV, intra-operatively) they will also receive chewing in the recovery room and on the post-natal ward.
62380080|NCT05472051||Young girls housekeepers|Malian young girls migrating from rural areas towards Bamako to seek for a job as housekeepers. Include young girls aged at least 12 years.
62558325|NCT06352021|EXPERIMENTAL|kaleidoscope group|The children in the kaleidoscope group were shown the kaleidoscope by the researcher five minutes before the blood sampling, and they were encouraged to look at the kaleidoscope during the procedure and describe the patterns they saw.
62558326|NCT06352021|NO_INTERVENTION|control group|This group underwent routine blood sampling procedures and did not receive any intervention to reduce their pain.
62758667|NCT03584191||Health Care Professionals|Health Care Professionals include primary care physicians and specialists who treat patients with obesity.
62758668|NCT02593812|EXPERIMENTAL|"Training off medication"|"Participants will train on the postural stepping task before taking their first daily dose of standard Parkinson's medication (dopamine), i.e. while off dopamine replacement medication"
62380081|NCT05231928|EXPERIMENTAL|Argon Laser Iridoplasty|Argon Laser is applied to the anterior iris surface after pharmacological miosis and instillation of ocular surface anesthetic using YAG capsulotomy lens or Abraham Iridotomy lens as auxiliary lenses. Laser is applied at sites and with parameters that are tailored for each case according to exact iris configuration, iris colour and pupil diameter.
62758669|NCT02593812|OTHER|"Training on medication"|"Participants will train on the postural stepping task after taking their first daily dose of standard Parkinson's medication (dopamine), i.e. while on dopamine replacement medication"
62758670|NCT04492709|EXPERIMENTAL|Treatment|The subjects will receive oral midazolam solution of 2 mg as a single dose on 2 occasions, 6 days apart (Days 1 and 7). The first dose will be prior to dosing with oral AZD5718 tablet and the second dose after five administrations of AZD5718 under fasted conditions.
62758671|NCT02727556|EXPERIMENTAL|Functional dyspepsia patient|Visual stimuli of food and non-food images will be presented to patients. Non-food images include positive, neutral, negative emotional pictures.
62758672|NCT02727556|EXPERIMENTAL|Healthy|Visual stimuli of food and non-food images will be presented to participants. Non-food images include positive, neutral, negative emotional pictures.
62758673|NCT05079750|EXPERIMENTAL|Group 1: Low Dose|n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 5x10\^9 vp
62758674|NCT05079750|EXPERIMENTAL|Group 2: Mid Dose|n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 2.5x10\^10 vp Note: may be increased to n=9 following interim safety reviews
62758675|NCT05079750|EXPERIMENTAL|Group 3: High Dose|n=14 participants vaccinated with two doses of ChAdOx1 biEBOV 5x10\^10 vp, twelve weeks apart Note: will be decreased to n=11 if Group 2 is increased to n=9
62758676|NCT02442791|EXPERIMENTAL|GLP-1|"Half of the participants will receive the study drug, that will be given as follows:~250 mL isotonic sodium chloride added 1.5 mL of 20% Human Albumin added 25 microg Byetta (Lilly, Exenatide).~The study drug infusion is initiated as soon as possible at rate of 72ml/hour (0.12 μg/min) for 15 min (set volume at 18 ml), followed by 26ml/hour (0.043 μg/min) to be continued for 6 hours (set volume at 156 ml). This concludes the pharmacological intervention."
62758677|NCT02442791|PLACEBO_COMPARATOR|Placebo|"Half of the participants will receive placebo, that will be given as follows:~250 mL isotonic sodium chloride added 1.5 mL of 20% Human Albumin. The placebo infusion is administered exactly the same way as the study drug infusion."
62758678|NCT04927767|EXPERIMENTAL|Denture adhesives|Participants will be shown to apply the adhesive following the manufacturer's instructions. The denture is pressed firmly into place, then held firmly as the participant bites down to secure it. Participants will be instructed to apply the adhesive twice daily with an 8-hour interval.
62758679|NCT03594149|EXPERIMENTAL|antibacterial prophylaxis|Levofloxacin 500 mg/d p.o. during the first 3 cycles of azacytidine
62758680|NCT03594149|NO_INTERVENTION|control|No levofloxacin will be given.
62758681|NCT04371640|ACTIVE_COMPARATOR|Sirolimus|Sirolimus + standard medical care Day 1: 10mg Days 2-7: 5mg
62758682|NCT04371640|PLACEBO_COMPARATOR|Placebo|Placebo + standard medical care Day 1: 10mL Days 2-7: 5mL
62758683|NCT01420172||Post hematopoietic stem cell transplantation|Patients who were seen post hematopoietic stem cell transplantation between 01Jan2000 and 30Jun2011
62758684|NCT05602675|EXPERIMENTAL|LY3871801 + Methotrexate (Part 1)|LY3871801 administered orally in combination with methotrexate given orally.
62758685|NCT05602675|EXPERIMENTAL|LY3871801 + Repaglinide + Drug Cocktail (Part 2)|LY3871801 administered orally in combination with repaglinide given orally and drug cocktail which includes warfarin, dextromethorphan and midazolam administered orally.
62758686|NCT02057094|PLACEBO_COMPARATOR|Control|Dining facility recovery feeding only, no supplemental protein consumed (an isoenergetic, carbohydrate supplement will be consumed by those assigned to the Control group)
62758687|NCT02057094|ACTIVE_COMPARATOR|Protein|"Consume dining facility food with:~2, 20 g whey protein supplements daily (for \~27 days)~1, 40 g casein protein supplement daily (for \~27 days)"
62758688|NCT02057094|ACTIVE_COMPARATOR|High-Protein|"Consume dining facility food with:~2, 40 g whey protein supplements daily (\~27 days)~1, 50 g casein protein supplement daily (\~27 days)"
62758689|NCT03190265|EXPERIMENTAL|Arm A: CY, Nivolumab, Ipilimumab, GVAX, CRS-207|
62380082|NCT00542139|EXPERIMENTAL|1|
62380083|NCT00542139|ACTIVE_COMPARATOR|2|
62380084|NCT03823963|OTHER|Standard care|pressure ulcer prevention standard care
62380085|NCT03823963|EXPERIMENTAL|standard care + Mepilex® Border|pressure ulcer prevention standard care + Mepilex® Border applied on sacrum
62758690|NCT03190265|EXPERIMENTAL|Arm B: Nivolumab, Ipilimumab, CRS-207|
62758691|NCT01976897||The study population|"Only one group is included. See inclusion/exclusion criteria.~Intervention: Knee flexion measurement 1~Intervention: Knee flexion measurement 2~Intervention: Heel - interface pressure measurements"
62758692|NCT05211921|OTHER|Multi-Gyn ActiGel Plus|vaginal gel
62758693|NCT04126720|ACTIVE_COMPARATOR|vitamin E|topical Corticosteroid (Kenacort A Orabase: triamcinolone acetonide 0.1% 5 gram adhesive paste - Dermapharm) four times daily and Vitamin E capsule (Vitamin E 400: 400 mg vitamin E capsules - Pharopharmaceuticles) daily.
62758694|NCT04126720|PLACEBO_COMPARATOR|Placebo|topical Corticosteroid (Kenacort A Orabase: triamcinolone acetonide 0.1% 5 gram adhesive paste - Dermapharm) four times daily and placebo capsule daily
62758695|NCT05295823|NO_INTERVENTION|Healthcare provider performed standard PVR measurement using existing ultrasound technology|The Urologic healthcare provider will perform standard point-of-care PVR measurement on the participant (3 consecutive measurements during the same encounter) using existing ultrasound technology
62758696|NCT05295823|EXPERIMENTAL|Healthcare provider performed PVR measurement using Butterfly and bladder ultrasound images|The Urologic healthcare provider will perform PVR measurement on the participant (3 consecutive measurements during the same encounter) using the Butterfly and bladder ultrasound images
61987139|NCT03485820|EXPERIMENTAL|COMPASS|COMPASS is a complex intervention that combines 2 evidence-based treatment strategies at a new point of care (transition from inpatient rehabilitation). The objective of home visits by an occupational therapy (OT) practitioner is to remediate barriers in the home and community that influence daily activities and community participation. The treatment will include a set of 1 predischarge and four 75-minute postdischarge visits. The intervention is followed by 2 booster sessions.
62380086|NCT01235767|EXPERIMENTAL|ASF supplement pre-pregnancy to term|Supplement of animal-source foods rich in iron, zinc, vitamin A, and vitamin B12
62380087|NCT01235767|EXPERIMENTAL|ASF Supplement mid-gestation to term|Supplement of animal-source foods rich in iron, zinc, vitamin A, and vitamin B12
62380088|NCT01235767|NO_INTERVENTION|Routine prenatal care|Nutrition education and iron-folate supplements during pregnancy
62380089|NCT00231972|EXPERIMENTAL|Project Enhance|Participants will receive the risk reduction program, Project Enhance
62380090|NCT00231972|ACTIVE_COMPARATOR|Active Comparison Condition|Participants will receive standard prevention case management
62380091|NCT06189027|ACTIVE_COMPARATOR|MDMA Assisted Psychotherapy|A longitudinal course of psychotherapy with administration of MDMA on two occasions to assist with the psychotherapeutic process
62758697|NCT05295823|EXPERIMENTAL|Healthcare provider performed PVR measurement using Butterfly and abstract bladder images|The Urologic healthcare provider will perform PVR measurement on the participant (3 consecutive measurements during the same encounter) using the Butterfly and abstract bladder images
62758698|NCT05295823|EXPERIMENTAL|Self PVR measurement using Butterfly and bladder ultrasound images|The participant will perform self PVR measurement (3 consecutive measurements during the same encounter) using the Butterfly and bladder ultrasound images (prior to catheterization, if needed)
62758699|NCT05295823|EXPERIMENTAL|Self PVR measurement using Butterfly and abstract bladder images|The participant will perform self PVR measurement (3 consecutive measurements during the same encounter) using the Butterfly and abstract bladder images (prior to catheterization, if needed)
62380092|NCT06189027|PLACEBO_COMPARATOR|Placebo Assisted Psychotherapy|A longitudinal course of psychotherapy with administration of placebo on two occasions to assist with the psychotherapeutic process
62380093|NCT06022497|EXPERIMENTAL|Intervention Group|In the intervention group, Tidal Model-based emotion regulation nursing interventions were applied in addition to the routine treatment. Tidal Model-based emotion regulation nursing interventions were structured as eight sessions in total. Each individual in the intervention group participated in a session for a total of 8 weeks, one session per week. All interviews were conducted face to face.
62758700|NCT01480973|EXPERIMENTAL|MRI post lung SBRT|Feasibility of MRI to differentiate between benign and malignant changes seen after lung SBRT.
62758701|NCT06201793|ACTIVE_COMPARATOR|control group|control group (Mesalamine group, n =23) who will receive 1 g mesalamine three times daily for 6 months.
62758702|NCT06201793|ACTIVE_COMPARATOR|Minocycline group|minocycline group, n = 23) will receive 1 g mesalamine three times daily plus 100 mg minocycline orally twice daily for 6 months.
62758703|NCT00875056|EXPERIMENTAL|Follicular Lymphoma (FL)|Participants with relapsed/refractory FL received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol.
62758704|NCT00875056|EXPERIMENTAL|Indolent non-FL B-NHL or MCL|Participants with indolent non-follicular lymphoma (FL) B-cell non-Hodgkin's lymphoma (B-NHL), or with mantle cell Lymphoma (MCL) received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol.
62380094|NCT06022497|NO_INTERVENTION|Control Group|The control group received only routine treatment.
61987140|NCT03485820|SHAM_COMPARATOR|Education program|"An OT practitioner will deliver the program in accordance with Evidence-Based Educational Guidelines for Stroke Survivors after Discharge Home. Topic order is determined by participants. Four 75-minute sessions will be provided. Topics may include stroke symptoms, risk factors and preventing stroke recurrence, nutrition, managing emotions, sleep, pain. Written materials from the National Stroke Association and the American Stroke Association are provided."
62758705|NCT00875056|EXPERIMENTAL|Other Disease|Participants with disease other than relapsed/refractory follicular lymphoma (FL), non-FL B-cell non-Hodgkin's lymphoma (B-NHL), or mantle cell Lymphoma (MCL), as assessed by the Independent Central Pathological Committee, received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol. This group was created to include participants who enrolled, but whose later diagnoses by the Independent Central Pathological Committee excluded them from analysis in the FL and non-FL B-NHL/MCL groups because they had different disease than those prespecified in the protocol.
62758706|NCT02614040|ACTIVE_COMPARATOR|0.9% Saline|Patients in a month randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
62380095|NCT04815915|EXPERIMENTAL|Study Group|Graston tool was used to treat patients 3 times in a week according protocol for 6 weeks' treatment plan with extensions bised exercises protocol following pattern of APTA.
62380096|NCT05246644|EXPERIMENTAL|Intravenous Acetaminophen|subjects will receive IV acetaminophen and a placebo oral acetaminophen starting immediately after surgery and for 8 doses
62380097|NCT05246644|ACTIVE_COMPARATOR|Oral acetaminophen|subjects will receive a placebo for IV acetaminophen and active oral acetaminophen starting immediately after surgery and for 8 doses
62380098|NCT03323372|ACTIVE_COMPARATOR|control group|In group 1 (G1-control), the operator applied a desensitizing gel based on 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2% ®, FGM , Joinville, Santa Catarina, Brazil) with the aid of a custom silicone tray, which was made from a model obtained from the patient, with a vacuum plasticizer. A small layer of the gel was placed on the surface of the tray that was in contact with the vestibular face of the upper anterior teeth of the participants. The tray remained in position in the mouth for 10 minutes, according to the manufacturer's specifications.
62380099|NCT03323372|EXPERIMENTAL|experimental group|In group 2 (G2-intervention group), the operator applied a desensitizing gel containing 3% potassium nitrate and 0.25% sodium fluoride (Ultra EZ®, Ultradent Products Inc, South Jordan, UT, Estados Unidos) with the help of a tray in which the material is stored on the vestibular surfaces of the upper anterior teeth of the participants. The tray remained in position in the mouth for 15 minutes, according to the manufacturer's specifications.
62380100|NCT04360291||Healthy volunteers|Healthy volunteers
62758707|NCT02614040|ACTIVE_COMPARATOR|Physiologically-balanced|Patients in a month randomized to physiologically-balanced isotonic fluid will receive physiologically-balanced isotonic crystalloid (Plasma-Lyte© A or Lactated Ringer's) whenever isotonic intravenous fluid administration is ordered by the treating provider.
62380101|NCT04360291||Retinopathy pigment|Patients with retinopathy pigment
62758708|NCT01744678|EXPERIMENTAL|Access to experimental break room|"Subjects will visit the experimental break room 4 times per Orbit 1 shift:~* first, prior to the beginning of the work shift~* second, during an operationally feasible 20-min break during the 1st half of the work shift~* third, once during an operationally feasible 20-min break during the 2nd half of the work shift~* fourth, immediately after the end of the work shift~In the break room, subjects will be passively exposed to blue-wavelength enriched ceiling lights during all four visits for each work shift.~Also in the break room, subjects will perform 10-minutes of mild exercise during the first three visits to the break room during each work shift."
62380102|NCT05637294|OTHER|Sequence of three treatment periods in the following order: ABC|Splinting at night while sleeping for 6 weeks (period A), then no treatment for 6 weeks (period B), then splinting at day and night for 6 weeks (period C). Each treatment period will be separated by 3-week washout period.
62380103|NCT05637294|OTHER|Sequence of three treatment periods in the following order: ACB|Splinting at night while sleeping for 6 weeks (period A), then splinting at day and night for 6 weeks (period C), then no treatment for 6 weeks (period B). Each treatment period will be separated by 3-week washout period.
62380104|NCT05637294|OTHER|Sequence of three treatment periods in the following order: BAC|No treatment for 6 weeks (period B), then splinting at night while sleeping for 6 weeks (period A), then splinting at day and night for 6 weeks (period C). Each treatment period will be separated by 3-week washout period.
62380105|NCT05637294|OTHER|Sequence of three treatment periods in the following order: BCA|No treatment for 6 weeks (period B), then splinting at day and night for 6 weeks (period C), then splinting at night while sleeping for 6 weeks (period A). Each treatment period will be separated by 3-week washout period.
62380106|NCT05637294|OTHER|Sequence of three treatment periods in the following order: CAB|Splinting at day and night for 6 weeks (period C), then splinting at night while sleeping for 6 weeks (period A), then no treatment for 6 weeks (period B). Each treatment period will be separated by 3-week washout period.
62380107|NCT05637294|OTHER|Sequence of three interventions/treatments in the following order: CBA|Splinting at day and night for 6 weeks (period C), then no treatment for 6 weeks (period B), then splinting at night while sleeping for 6 weeks (period A). Each treatment period will be separated by 3-week washout period.
62380108|NCT05084820|EXPERIMENTAL|Action observation treatment|Action observation treatment
62380109|NCT05084820|ACTIVE_COMPARATOR|conventional treatment|conventional treatment
62380110|NCT04493229|EXPERIMENTAL|Oxytocin|Oxytocin IM injection will be given per randomization prior to first outpatient physical therapy session
62380111|NCT04493229|ACTIVE_COMPARATOR|Placebo|Placebo IM injection will be given per randomization prior to first outpatient physical therapy session
62380112|NCT03299621|EXPERIMENTAL|PLE (Phase Lag Entropy) monitoring|Investigators monitor the change of PLE value using the sensor of PLEM™ during propofol anesthesia.
62380113|NCT03299621|EXPERIMENTAL|Muscle relaxant injection|Investigators monitor the change for PLE value using the sensor of PLEM™ before and after the injection of muscle relaxant.
62380114|NCT04491331||Non-anesthetized volunteers|Hemodynamic parameters will be measured in supine position. Volunteers will be turned into prone position. After a five-minute stabilization phase will be monitored CI, MAP, heart rate (HR), stroke volume variation SVV, systemic vascular resistance index (SVRI) by non-invasive measurements using a ClearSight (Edwards) in two prone positions (lying on support system allowing a free abdomen and then lying flat without any device). Furthermore, the width of the inferior vena cava and vena jugularis interna, vena saphena and vena cephalica will be measured by ultrasound. The measurement will be performed in inspiration and in expiration phase.
62380115|NCT00942422|EXPERIMENTAL|defined green tea catechin extract / correlative analysis|Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62380116|NCT04296929|EXPERIMENTAL|Affected arm in lymphedema patients|Complex decongestive physiotherapy treatment will be applied to the arm (affected arm) that develops lymphedema after unilateral breast cancer treatment.
62380117|NCT04296929|NO_INTERVENTION|Unaffected arm in lymphedema patients|After unilateral breast cancer treatments, the non-lymphedema side in the upper extremities, is the unaffected arm. No treatments will be applied to the unaffected side.
62380118|NCT06039904|EXPERIMENTAL|Arm A|Arm A was first assigned to Treatment I of natural rubber knee support followed by Treatment II of sponge knee support
62380119|NCT06039904|EXPERIMENTAL|Arm B|Arm B was first assigned to Treatment II of sponge knee support followed by Treatment I of natural rubber knee support
62380120|NCT02442375|ACTIVE_COMPARATOR|standard dose prescription|"* FDG-PET-scan in treatment mask for radiotherapy planning~* Accelerated radiotherapy IMRT/VMAT with SIB (34 fraction in 5.5 weeks)"
62380121|NCT02442375|EXPERIMENTAL|FDG-PET guided gradient dose prescription|"* FDG-PET-scan in treatment mask for radiotherapy planning~* Accelerated radiotherapy IMRT/VMAT with SIB (34 fraction in 5.5 weeks)"
62380122|NCT05320211|EXPERIMENTAL|3D-printed hand orthoses|
62380123|NCT01040416||Bleeding marginal ulcer after RYGB|
62380124|NCT01571973|NO_INTERVENTION|control group|outpatients receiving usual care
62380125|NCT01571973|EXPERIMENTAL|intervention group|outpatients receiving pharmaceutical care or pharmacotherapeutic follow-up by 6 months
62558327|NCT03207776|OTHER|Control|Treatment of patients in the usual manner based on their diagnosis and resources available at that site (Usual Care).
62380126|NCT03795051|EXPERIMENTAL|Navigated TMS|Each participant will receive 30 sessions of 10 Hz or 20 Hz navigated transcranial magnetic stimulation over the left DLPFC.
62558328|NCT03207776|OTHER|Intervention|A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services (COPD Clinical Pathway).
62380127|NCT03511924|EXPERIMENTAL|Intradialytic resistance training|During the 12-week intradialytic training plan subjects will be performed 3 to 5 sets of 3 different lower extremities exercises, each set will consist of 12 up to 18 repetitions of a single exercise. Subjects will take 1 to 2 minutes rest between each set. The resistance training will be realized 3 times per week and will be performed during haemodialysis therapy.
62380128|NCT03511924|NO_INTERVENTION|Control programme|Control subjects will receive no intervention during the 12-weeks of the experiment. Through the 12-week control period, all participants will be instructed to maintain a standard treatment regimen and to maintain their customary dietary and physical activity patterns.
62380129|NCT04016506||Pancreas injury|children with Pancreas trauma
62380130|NCT00939341|EXPERIMENTAL|1|Symbicort Turbuhaler 160/4.5 µg delivered dose
62380131|NCT02354690|EXPERIMENTAL|A|7 days before tumor harvest, patients will begin taking vemurafenib until admission for lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine, followed by TIL infusion and interleukin-2.
62380132|NCT04697589|EXPERIMENTAL|SBRP 300 mg|300 mg standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
62380133|NCT04697589|EXPERIMENTAL|SBRP 600 mg|600 mg standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
62380134|NCT04697589|PLACEBO_COMPARATOR|Placebo|Colored maltodextrin
62380135|NCT01526967||New moldable user|Subjects presenting with peristomal lesions with a traditional barrier and for whom a ConvaTec Moldable Technology™ Skin Barrier is used as a replacement.
62558329|NCT02828293||GMK Sphere|Patients who underwent total knee replacement using GMK Sphere implants. Patients underwent surgery before the inclusion in the study.
62558330|NCT02828293||GMK PS Fixed Bearing|Patients who underwent total knee replacement using GMK PS Fixed Bearing implants. Patients underwent surgery before the inclusion in the study.
62758709|NCT04894643|OTHER|Preoperative, proton- radiotherapy combined with chemotherapy|Patients treated with three cycles of chemotherapy with Nab-PACLitaxel (Abraxane®) (125 mg/m² on day 1, 8, 15; powder for making a infusion solution) and Gemcitabine (1000 mg/m² on day 1, 8, 15; powder for making a infusion solution), followed by concomitant chemotherapy with capecitabine (1.660ml/m² on 5 days per week during the radiation therapy) and proton-therapy (with simultaneous integrated boost (SIB) 50.4 Gy Relative Biological Effectiveness (RBE) and 60.2 Gy (RBE) in 28 fractions of 1.8 Gy (RBE) and 2.15 Gy (RBE) 5 days per week), followed by re-evaluation and surgery
62758710|NCT02583100|EXPERIMENTAL|Intensive Feedback|Participants in this arm will receive intensive feedback on their complication rates, surgical technique, and peri-operative surgical management from peer surgeons participating in the study.
62758711|NCT02583100|ACTIVE_COMPARATOR|Routine Feedback|Participants in this arm will receive routine feedback on their complication rates.
62758712|NCT05086757|EXPERIMENTAL|Trauma Resilience and Recovery Program (TRRP)|Enrollment in TRRP which includes 3 major steps: (1) in-hospital education, brief risk reduction session, and tracking patients' emotional recovery via an automated text-messaging system, (2) conducting a 30-day screen via telephone to identify patients who are good candidates for psychological treatment, and (3) providing referral to formal mental health services, if needed.
62558331|NCT02828293||GMK UC Fixed Bearing|Patients who underwent total knee replacement using GMK UC Fixed Bearing implants. Patients underwent surgery before the inclusion in the study.
62380136|NCT01526967||New osomate|Subjects for whom a ConvaTec Moldable Technology™ Skin Barrier is used as the first long-term (within 7 days of ostomy surgery) system following surgery and have intact peristomal skin.
62558332|NCT01692626|EXPERIMENTAL|Pimecrolimus on Left vs. Placebo on Right|Patients will apply a thin layer of the Pimecrolimus cream twice daily for four weeks (unless rash worsens sooner) to one half of face at the same time the are started on cetuximab. Patients will be provided with a placebo cream to apply to the other side of their face. The study coordinator will instruct the patient regarding which side of the face to apply the investigational cream. This will be randomly assigned by the study coordinator based on a randomization list generated by the biostatistics core and will only be known to the study coordinator.
62558333|NCT01692626|EXPERIMENTAL|Pimecrolimus on Right vs. Placebo on Left|Patients will apply a thin layer of the Pimecrolimus cream twice daily for four weeks (unless rash worsens sooner) to one half of face at the same time the are started on cetuximab. Patients will be provided with a placebo cream to apply to the other side of their face. The study coordinator will instruct the patient regarding which side of the face to apply the investigational cream. This will be randomly assigned by the study coordinator based on a randomization list generated by the biostatistics core and will only be known to the study coordinator.
62758713|NCT05086757|ACTIVE_COMPARATOR|Enhanced Usual Care|Receive brief education about mental health after traumatic injury, educational materials about mental health recovery, and local referral information to assist treatment-seeking patients in seeking care
62758714|NCT04599270|EXPERIMENTAL|Intervention group|"Teenager encounter psychologist for conduct a Substance Use risk Personality Scale (SURPS) assessment to identify personality characteristics that represent a risk for the development of problematic substance use. Only adolescents with at-risk personality traits according to the SURPS will be randomized for further assessment.~If adolescent have not risk personality traits, the patient will go out of the study.~If adolescent have risk personality traits, other tests and scales will be performed to study the intensivity of dependance of substance use and the patient will be randomized.~If he is randomized in intervention group, the patient will follow PREVENTURE program (2 session of 90 min by videoconference), within 3 months after inclusion and will be contacted by phone by the psychologist at 1, 3, 6 and 12 month after sessions to answer the same tests and scales."
62380137|NCT01824524|EXPERIMENTAL|OROS Hydromorphone|
62380138|NCT04306770|ACTIVE_COMPARATOR|Intervention|OPTIMUM Programme
62380139|NCT04306770|NO_INTERVENTION|Control|Treatment as usual
62380140|NCT01377038|ACTIVE_COMPARATOR|Duloxetine|Phenotype assessment prior to and after treatement with duloxetine 20-30 mg oral daily for eight weeks.
62380141|NCT01377038|ACTIVE_COMPARATOR|Diclofenac|Phenotype assessment prior to and after treatment with topical diclofenac four times daily
62758715|NCT04599270|ACTIVE_COMPARATOR|Control group|"Teenager encounter psychologist for conduct a Substance Use risk Personality Scale (SURPS) assessment to identify personality characteristics that represent a risk for the development of problematic substance use. Only adolescents with at-risk personality traits according to the SURPS will be randomized for further assessment.~If adolescent have not risk personality traits, the patient will go out of the study.~If adolescent have risk personality traits, other tests and scales will be performed to study the severity of substance use disorders and the patient will be randomized.~If he is randomized in control group, the patient will follow routine care and will be contacted by phone by the psychologist at 1, 3, 6 and 12 month after inclusion to answer the same tests and scales."
62758716|NCT04912323|EXPERIMENTAL|MAGNITUDE® Scaffold|Subject with up to three study lesions treated by implanting a maximum of 3 R3 Vascular MAGNITUDE® Bioresorbable Drug-Eluting Scaffolds
62758717|NCT02956850|EXPERIMENTAL|Part I: SAD in Healthy Volunteers|Healthy volunteers will receive single dose of RO7020531 or matching placebo orally on Day 1 of each cohort. A planned dose-escalation sequence for SAD is 3 milligrams (mg), 10 mg, 20 mg, 40 mg, 60 mg, 100 mg, 140 mg, and 170 mg.
62380142|NCT02865681|ACTIVE_COMPARATOR|Conventional IVF|Conventional ovarian stimulation consist of ovarian stimulation with daily gonadotropins injections daily starting in the early follicular phase (cycle day 3). The final maturation of oocytes will be induced with the standard hCG trigger when at least two follicles reached 18 mm or greater. Oocyte retrieval will be performed by either local or general anesthesia depending on the ovarian response, i.e., the number of mature follicles. Retrieved oocytes will be fertilized by IVF/ICSI and subsequently cultured until the blastocyst stage. All blastocysts will be vitrified. A single thawed blastocyst will be transferred in a subsequent natural or artificially prepared cycle.
62380143|NCT02865681|EXPERIMENTAL|IVF protocol using nasal gonadotropins|Instead of injectable gonadotropins, nasal human menopausal gonadotropins (hMG; menopur) and oral clomiphene citrate and/or oral letrozole starting in the early follicular phase (cycle day 3). When at least two follicles reached 18 mm or greater, Synarel (Nafarelin) will be used instead of the injectable HCG trigger. Oocyte retrieval will be performed by either local or general anesthesia depending on the ovarian response, i.e., the number of mature follicles. Retrieved oocytes will be fertilized by IVF/ICSI and subsequently cultured until the blastocyst stage. All blastocysts will be vitrified. A single thawed blastocyst will be transferred in a subsequent natural or artificially prepared cycle.
62380144|NCT01104922|EXPERIMENTAL|Cetuximab and stereotactic radiosurgery|
62380145|NCT02884440|EXPERIMENTAL|TAP block ropivacaine|Bilateral ultrasound guided with 15 ml ropivacaine 5mg/ml on each side under general anesthesia at the end of the intervention
62380146|NCT02884440|PLACEBO_COMPARATOR|TAP block placebo|Bilateral ultrasound guided with 15 ml saline on each side under general anesthesia at the end of the intervention
62380147|NCT01149044|ACTIVE_COMPARATOR|Upfront Thrombectomy followed by PCI|Upfront manual aspiration thrombectomy followed by PCI
62558334|NCT05565989|ACTIVE_COMPARATOR|control (MI)|Motivational Interview
62558335|NCT05565989|EXPERIMENTAL|experimental (MI/MBM/II)|Motivational Interview + mindfulness-bases meditation practice + intention implementation
62558336|NCT04885309|ACTIVE_COMPARATOR|Obturator Nerve Block + Spinal Anaesthesia|Patients who underwent obturator nerve block with spinal anesthesia prior to TURBT
62758718|NCT02956850|EXPERIMENTAL|Part I: MAD in Healthy Volunteers|Healthy volunteers will receive RO7020531 (100 mg, 140 mg, and 170 mg as selected based on safety, pharmacokinetic (PK) and pharmacodynamic (PD) data of SAD cohorts) or matching placebo orally every other day (QOD) from Day 1 through to Day 13.
62758719|NCT02956850|EXPERIMENTAL|Part II: CHB Participants|CHB participants will receive RO7020531 (150 mg and 170 mg as selected based on safety, PK and PD data of MAD cohorts) or matching placebo orally QOD from Day 1 through to Day 41, unless in Cohort 4 in case of once a week (QW) dosing as dose modification.
62758720|NCT02034175|EXPERIMENTAL|SomnaPatch|SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.
62380148|NCT01149044|ACTIVE_COMPARATOR|PCI Alone|PCI without upfront manual aspiration thrombectomy
62380149|NCT05496855|ACTIVE_COMPARATOR|Conventional follow-up|Conventional follow-up strategy with blood tests and face-to-face visits at the hospital every 6 months
62380150|NCT05496855|EXPERIMENTAL|Remote monitoring|Monthly remote monitoring of patient-reported outcomes and triage of patients using an algorithm will guide healthcare providers in scheduling patients for a video consultation or face-to-face hospital visits.
62380151|NCT01586286|PLACEBO_COMPARATOR|Ointment Base|Patients in this arm will serve as the control and will undergo pelvic floor physical therapy and receive placebo (lanolin and mineral oil base).
62558337|NCT04885309|SHAM_COMPARATOR|Spinal Anaesthesia|Patients who underwent spinal anesthesia prior to TURBT
62558338|NCT03813173|ACTIVE_COMPARATOR|central cervical dissection|
62558339|NCT03813173|EXPERIMENTAL|non central cervical dissection|
62558340|NCT06581510|EXPERIMENTAL|Custom-Made Zirconia crowns|CAD/CAM zirconia crown customized for each patient
62758721|NCT02034175|ACTIVE_COMPARATOR|Polysomnography|Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
62758722|NCT04926207|EXPERIMENTAL|Physical Activity Breaks Intervention|Participants will sit continuously for 3 hours and interrupt their sitting by walking on a treadmill at a moderate intensity for 3 min.
62558341|NCT06581510|EXPERIMENTAL|3D Printed Resin Crowns|Printed resin crowns customized for each patient
62758723|NCT04926207|ACTIVE_COMPARATOR|Talking Breaks Control|Participants will sit continuously for 3 hours. They will interrupt solitary sitting activities (while remaining seated) by talking to a researcher for 3 min on pre-selected topics of general interest.
62380152|NCT01586286|ACTIVE_COMPARATOR|Nifedipine Ointment|Patients in this arm will undergo pelvic floor physical therapy, but will receive compounded vaginal nifedipine.
62380153|NCT00523172|ACTIVE_COMPARATOR|Group A|"1) Group A will receive 9 manipulative therapy treatments (adjustments) to one area: the hip with pre-manipulative static and post active-assisted stretch of tight hip muscles. After the last (or 9th) treatment these patients will receive general advice and recommendations on managing HOA and how to gently and safely increase general exercise.~• Based on a previous trial, Group A treatment appears superior than placebo. There will be a 3, 6 and 9 month follow up."
62380154|NCT00523172|ACTIVE_COMPARATOR|Group B|2) Group B will receive 9 treatments with manipulative therapy treatments (adjustments) to the entire kinetic chain (five areas): the lumbosacral, sacroiliac, hip, knee, ankle and foot joints with pre-manipulative static and post active-assisted stretch of tight hip muscles. There will be a 3, 6 and 9 month follow up.
62558342|NCT06581510|EXPERIMENTAL|Ready-Made Zirconia Crowns|Nuu smile ready made zirconia crown
62758724|NCT01773343|ACTIVE_COMPARATOR|CO2 laser at 1 month interval|CO2 laser treatment of mild to severe acne scars at 1 month interval
62758725|NCT01773343|ACTIVE_COMPARATOR|CO2 laser at 3 monrths interval|CO2 laser treatment of mild to severe acne scars at 3 month intervals
62758726|NCT01570153||ADHF patients|
62558343|NCT02655731|OTHER|Treatment|PVI with HeartLight
62380155|NCT00523172|OTHER|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
62380156|NCT03041493|EXPERIMENTAL|Electronic cigarettes (EC) smokers|
62380157|NCT03041493|EXPERIMENTAL|traditional cigarette (TC) smokers|
62380158|NCT03041493|ACTIVE_COMPARATOR|nonsmokers|
62558344|NCT02205463|EXPERIMENTAL|KD019|Patients with HER2+ metastatic or unresectable adenocarcinoma of the esophagus, gastroesophageal junction or stomach will receive trastuzumab and mFOLFOX-6 in combination with KD019 to evaluate the safety, toxicity and MTD of this regimen. There will be four dose cohorts for KD019. KD019 will be administered orally continuously daily on a 28 day cycle. Trastuzumab and mFOLFOX-6 will be administered as infusions every 2 weeks at standard doses without escalation. The sequence on the days when all agents are administered will be KD019 followed by trastuzumab and mFOLFOX-6.
62758727|NCT06200974||High dose rate prostate brachytherapy|"Radiation. High dose rate prostate brachytherapy is delivered under anesthesia in 2 procedures, 1-2 weeks apart.~HDR brachytherapy is also accomplished as an out-patient."
62758728|NCT05607498|EXPERIMENTAL|EMB-07-Patients with solid tumor|Patients with solid tumor will receive intravenous infusions of EMB-07 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is reached or all planned doses are administered.
62758729|NCT05607498|EXPERIMENTAL|EMB07-Patients with lymphoma|Patients with lymphoma will receive intravenous infusions of EMB-07 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is reached or all planned doses are administered.
62758730|NCT02574013|EXPERIMENTAL|sponge-assisted surgery group|Patients offered surgery with use of the retractor sponge
62758731|NCT02574013|NO_INTERVENTION|Control group|Patients receiving standard care, i.e. surgery in Trendelenburg position
62758732|NCT02154048|ACTIVE_COMPARATOR|ropivacaine + dexamethasone|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an IV preservative-free dexamethasone 8 mg injection.
62758733|NCT02154048|PLACEBO_COMPARATOR|ropivacaine + placebo|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an intravenous (IV) normal saline placebo injection.
62758734|NCT02154048|ACTIVE_COMPARATOR|ropivacaine + dexamethasone + placebo|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with both 1:400,000 epinephrine and preservative-free dexamethasone 8mg and an IV normal saline placebo injection.
62758735|NCT03404908|EXPERIMENTAL|TAP|Ultrasound-guided transversus abdominis plane block at the end of cesarean section
61987141|NCT00005831|EXPERIMENTAL|Treatment (trastuzumab, combination chemotherapy)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15; paclitaxel IV over 3 hours and carboplatin IV over 15 minutes on day 1; and gemcitabine IV over 30 minutes on days 1 and 8. Courses repeat every 3 weeks. Patients achieving a complete response (CR) receive 3 courses past CR. Patients achieving a partial response or stable disease continue on therapy until CR or disease progression or unacceptable toxicity.
62758736|NCT03404908|EXPERIMENTAL|QLB|Ultrasound-guided quadratus lumborum block at the end of cesarean section
62758737|NCT00889889|EXPERIMENTAL|1|
62758738|NCT00889889|PLACEBO_COMPARATOR|2|
62758739|NCT01063491|EXPERIMENTAL|Early graft angiography after coronary artery bypass surgery|Treatment of any bypass graft abnormalities that are discovered will be performed if needed
61987142|NCT03501758||Remission with treatment|Patients randomized to continue medical treatment with biologics
61987143|NCT03501758||Remission without treatment|Patients randomized to stop medical treatment with biologics
61987144|NCT06059911|EXPERIMENTAL|Multi-ingredient dietary supplement|20 g of a multi-ingredient dietary supplement. Composition: 200 mg caffeine, 3.3 g creatine monohydrate, 3.2 g β-alanine, 6 g citrulline malate and 5 g BCAA
62758740|NCT01063491|NO_INTERVENTION|No early angiography after coronary artery bypass surgery|
62758741|NCT00701298|ACTIVE_COMPARATOR|Group 1 (chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients whose disease is not responding after the first course may crossover to group 2.
62558345|NCT05785182||Open Fracture|High energy open fracture.
62558346|NCT05785182||Infected Fracture|Infected open or closed fracture.
62558347|NCT04362228|EXPERIMENTAL|Whole-body exercise|
62380159|NCT01913509|EXPERIMENTAL|Combined Therapy of FES and BAT|Patients with hemiplegic shoulder pain is applied functional electrical stimulation and bilateral arm training (FES-BAT) one hour daily, 3 days per week for 4 weeks and a total of 12 sessions to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected arm.
62380160|NCT01913509|ACTIVE_COMPARATOR|Conventional Rehabilitation|The stroke patients in CR group receive a structure protocol using electrical modality such as transcutaneous electrical nerve stimulation (TENS) and bilateral arm training (TENS-BAT) one hour daily, 3 days per week for 4 weeks and a total of 12 sessions.
62380161|NCT03620292|EXPERIMENTAL|Intraoperative NIR fluorescence imaging|"A non-randomized, non-blinded, prospective, single center pilot dose escalation study with bevacizumab-800CW for NIR fluorescence image guided surgery in hilar cholangiocarcinoma~* IV-administration of 10, 25 or 50 mg of the fluorescent tracer bevacizumab-800CW to a total of 15 patients with resectable hilar cholangiocarcinoma 3 days prior to surgery.~* Peroperative open air NIR fluorescence imaging~* Ex vivo endoscopic and histopathological NIR fluorescence imaging"
62380162|NCT04957810|NO_INTERVENTION|Patients who are given regular home functional exercises and discharged from the hospital|Discharge guidance using regular home function exercises, that is, existing regular missions and paper-based brochures
62380163|NCT04957810|ACTIVE_COMPARATOR|Patients who are guided by conventional discharge guidance and the optimized WeChat official account|Use regular discharge guidance and optimized WeChat public account guidance
62380164|NCT02125812|PLACEBO_COMPARATOR|scaling and root planing|scaling and root planing
62380165|NCT02125812|EXPERIMENTAL|scaling and systemic moxifloxacin|scaling and root planing combined with systemic moxifloxacin
62380166|NCT05956327|EXPERIMENTAL|Intervention Group|Aerobic endurance training on a bicycle ergometer
62380167|NCT05956327|ACTIVE_COMPARATOR|Control Group|Flexibility, strengthening and balance training
62380168|NCT02556346|EXPERIMENTAL|MT-3724 Phase 1 5 mcg/kg/dose|MT-3724 5 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
62380169|NCT02556346|EXPERIMENTAL|MT-3724 Phase 1 10 mcg/kg/dose|MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
62758742|NCT00701298|EXPERIMENTAL|Group 2 (chemotherapy and antineoplastic agent)|Patients receive decitabine as in group 1 and pegylated interferon alfa-2b subcutaneously on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62758743|NCT00266929||Surgical|Subjects receiving surgical treatment for Type II odontoid fracture per discretion of investigator (non-randomized allocation)
62380170|NCT02556346|EXPERIMENTAL|MT-3724 Phase 1 20 mcg/kg/dose|MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
62558348|NCT05575973|EXPERIMENTAL|mitoxantrone hydrochloride liposome|Patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) will receive sequentially mitoxantrone hydrochloride liposome in combination with rituximab and lenalidomide for up to 6 cycles (28 days per cycle).
62558349|NCT04113473|EXPERIMENTAL|Yoga Group|Experimental group received individualised yoga therapy twice a week for an hour for 12-weeks.
62758744|NCT00266929||Non-surgical|Subjects treated with non-operative treatment options
62758745|NCT06044805|EXPERIMENTAL|Therapeutic Efficacy of Chloroquine Plus Primaquine|"An invivo single arm trial. Chloroquine (tablet containing 150mg of base) - it was given on days 0 (10mg/kg), 1(10mg/kg) and 2 (5mg/kg). Total dose, 25 mg base/kg.~Primaquine - it was given once a day (0.25 mg/kg) for fourteen days, starting on day 0 of CQ treatment. Total dose, 3.5mg/kg.~The medications were administered under direct observation and the patient was monitored for vomiting for 60 minutes."
62380171|NCT02556346|EXPERIMENTAL|MT-3724 Phase 1 50 mcg/kg/dose|MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
62758746|NCT00297102|ACTIVE_COMPARATOR|Roflumilast|500 mcg, once daily, oral administration in the morning
62758747|NCT00297102|PLACEBO_COMPARATOR|Placebo|once daily
62758748|NCT01587638||Hypertensive users of Beta blocker|Patients aged ≥18 years and at least 1 diagnosis of hypertension (ICD-9-CM: 401.xx-405.xx) during this time frame in a US Managed care population
62758749|NCT03552211||Patients treated with biotin|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat
62758750|NCT03552211||Control patients|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat
62758751|NCT02081638|ACTIVE_COMPARATOR|Elite Controller|Elite controllers not on ART
62758752|NCT02081638|ACTIVE_COMPARATOR|Treated Progressors|HIV infected on ART
62758753|NCT04740840|EXPERIMENTAL|Levamlodipine group|Blood pressure lowering therapy with 2.5mg levamlodipine, plus metoprolol succinate
62758754|NCT04740840|SHAM_COMPARATOR|Amlodipine group|To receive 5mg amlodipine to lower blood pressure, plus metoprolol succinate
62758755|NCT04348019|EXPERIMENTAL|Time restricted feeding|Participants in the intervention arm of the study will consume food and beverages of their choice within one hour of waking and the feeding window will extend 6 hours. Beyond these hours, participants will observe a prolonged fast (i.e., an 18-h overnight fast).
62758756|NCT04348019|PLACEBO_COMPARATOR|Control|Participants in the control arm of the study will fast each night for 8 hours.
62558350|NCT04113473|NO_INTERVENTION|Control Group|Control group were given education session and continued on usual care for 12-weeks.
61987145|NCT06059911|PLACEBO_COMPARATOR|Placebo dietary supplement (97% maltodextrin)|20 g of isoenergetic placebo dietary supplement. Composition: 97% flavored maltodextrin, similar in color, flavor, taste and energy to the experimental multi-ingredient supplement
61987146|NCT02408939||Intervention|Patients resuscitated from in-hospital cardiac arrest and treated with stress-dose hydrocortisone for postresuscitation shock
62567603|NCT02972905|EXPERIMENTAL|Session 2: GSK2269557 200 mcg|Subjects will receive repeated doses of GSK2269577 200mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
62758757|NCT04388046|EXPERIMENTAL|skeletal class 2 malocclusion|10 patients treated with type IV Herbst appliance. The appliance was connected directly to the mandible by a bilateral reconstruction bone plates to provide a skeletal anchorage and avoid any mandibular teeth involvement
61987147|NCT02408939||Control|Patients resuscitated from in-hospital cardiac arrest and treated according to contemporary standards that did not include stress-dose steroids for postresuscitation shock
62567604|NCT02972905|EXPERIMENTAL|Session 2: GSK2269557 500 mcg|Subjects will receive repeated doses of GSK2269577 500mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
62758758|NCT05154617|OTHER|Standard surgical monitoring, along with the Flo Trac® system monitoring.|
62758759|NCT05388838|ACTIVE_COMPARATOR|Negative control|uveitis patients with a diagnosis other than ocular diagnosis other than ocular lymphoma and without cerebral lymphoma (15 patients),
62758760|NCT05388838|ACTIVE_COMPARATOR|Primary ocular Lymphoma without brain involvementand never treated|patients with primary ocular lymphoma without brain involvement and never treated (5 patients),
62758761|NCT05388838|ACTIVE_COMPARATOR|Primary ocular Lymphoma without brain involvement and treated|patients with primary ocular lymphoma without brain involvement, treated and considered in remission (5 patients),
62758762|NCT05388838|ACTIVE_COMPARATOR|Primary ocular Lymphoma without brain involvement in relapse|patients with primary ocular lymphoma without brain involvement, considered in relapse (5 patients),
62758763|NCT05388838|ACTIVE_COMPARATOR|Positive control|patients with cerebral lymphoma with or without ocular involvement and without uveitis (15 patients).
62758764|NCT05388838|ACTIVE_COMPARATOR|Patients without brain involvement and without uveitis|Patients presenting for cataract follow-up (pre- or post-operative), glaucoma, retinal detachment or epiretinal membrane, with no brain damage or uveitis (15 patients).
62758765|NCT02442453|ACTIVE_COMPARATOR|curcuma longa|"curenext gel containing curcuma longa i.e. turmeric has strong antioxidant and antiinflammatory properties.~Test group:Topical application twice daily for ten minutes after brushing for four weeks."
62758766|NCT02442453|PLACEBO_COMPARATOR|Placebo gel|Placebo gel consists of corbopol 934 polymer and triethonalamine. Control group:Topical application twice daily for ten minutes after brushing for four weeks.
62758767|NCT01493219||Epilepsy|Blood and urine sample collection, pre and post op
62758768|NCT01493219||Glioma|Blood and urine sample collection, pre and post op
62758769|NCT01943838|EXPERIMENTAL|SAR245408 polymorph E tablets|Escalating doses of SAR245408 polymorph E tablets, once daily dosing with morning meal every day for two 28-days cycles
62758770|NCT05324020|EXPERIMENTAL|E- Health medication adherence Intervention group|3 Month monitoring adherence and side-effect management using an eHealth intervention . Participants are in contact with there clinical care team which intervene in cases of non-adherence and/or side-effect reporting.
62758771|NCT01172730||Ultrasound scanning|
62758772|NCT05145855||Anosognosia-positive group|Patients will be included in the anosognosia-positive group if they achieved at least one positive anosognosia score before rehabilitation. The anosognosia score for HN will be calculated by subtracting the patient's self-evaluation score from the score assigned by the rehabilitation nurse using the parallel Catherine Bergego Scale.
62758773|NCT05145855||Anosognosia-negative group|Patients will be included in the anosognosia-negative group if they achieved zero or negative anosognosia score before rehabilitation.
62758774|NCT01537081|EXPERIMENTAL|Mucinex 2400 mg/day|The study is designed to meet regulatory requirement outside the US. The dosing regimen and assessments timepoints were dictated by IR GGE and do not match approved Mucinex labeling. Participants were instructed to take 2 Mucinex 600 mg tablets and 1 placebo tablet matching the 200 mg IR guaifenesin tablet by mouth, every 12 hours for 7 days. To ensure complete blinding, on Hours 6 and 18, this treatment group took 2 matching Mucinex placebo tablets combined with 1 IR guaifenesin placebo tablet.
62758775|NCT01537081|ACTIVE_COMPARATOR|Immediate-release Guaifenesin 800 mg/Day|The dosing regimen and assessments timepoints were dictated by immediate-release guaifenesin (IR GGE). Participants were instructed to take 1 immediate-release guaifenesin (IR GGE) 200 mg tablet and 2 matching Mucinex placebo tablets by mouth, every 6 hours for 7 days.
62758776|NCT01537081|PLACEBO_COMPARATOR|Placebo|Double dummy technique was employed requiring a large number of tablets and water to be consumed. Participants were instructed to take 2 matching Mucinex placebo tablets combined with 1 matching IR guaifenesin placebo tablet by mouth, every 6 hours for 7 days.
62758777|NCT00525629|EXPERIMENTAL|Walnut Diet|48 Grams of Walnuts Daily
62758778|NCT00525629|PLACEBO_COMPARATOR|Control Diet|Isocaloric Diet with No Walnuts
62758779|NCT05315427||Evaluation of the impact of music therapy on the pain of patients|One music therapy session
62758780|NCT04316078|EXPERIMENTAL|personalized engagement platform|Patients registered into personalized engagement platform (PEP) will receive personalized educational videos (PEV) according to disease, treatment protocol and side effects.
62758781|NCT04316078|NO_INTERVENTION|control group|The control group will not be registered to the PEP nor receive any PEVs.
62758782|NCT00941369|EXPERIMENTAL|1|Insulin glargine: Lantus® (100 U/ml) in TactiPen® re-usable pen
62758783|NCT00941369|ACTIVE_COMPARATOR|2|Neutral Protamine Hagedorn basal insulin: Insuman® Basal (100 I.U./ml) in TactiPen® re-usable pen
62758784|NCT01214304|PLACEBO_COMPARATOR|Lavender Scent|Patients will receive aromatherapy with a fake lavender scent (placebo) which will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure.
61987148|NCT01914406|OTHER|high intense interval training|Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
62380172|NCT02556346|EXPERIMENTAL|MT-3724 Phase 1b|MT-3724 IV for 6 doses over 12 days for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Phase 1 portion of the study)
62567605|NCT02972905|EXPERIMENTAL|Session 2: GSK2269557 700 mcg|Subjects will receive repeated doses of GSK2269577 700mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
62758785|NCT01214304|EXPERIMENTAL|Essential Lavender Oil|Patients will receive essential Lavender Oil which will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure.
62758786|NCT00777530|EXPERIMENTAL|1|
62758787|NCT06360081|EXPERIMENTAL|Zongertinib (manufacturer 1) test followed by zongertinib (manufacturer 2) reference treatment (T-R)|
62758788|NCT06360081|EXPERIMENTAL|Zongertinib (manufacturer 2) reference followed by zongertinib (manufacturer 1) test treatment (R-T)|
62758789|NCT01912157|PLACEBO_COMPARATOR|No Intervention|The control condition are 3 sessions writing about individual time-management (placebo).
62758790|NCT01912157|ACTIVE_COMPARATOR|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing).
62758791|NCT05877040|EXPERIMENTAL|Treated|
62758792|NCT06426368||Group I|HF with reduced ejection fraction (HFrEF, LVEF ≤ 40%)
62758793|NCT06426368||Group II|HF with mildly reduced ejection fraction (HFmrEF, LVEF 41-49%)
62758794|NCT06426368||Group III|HF with preserved ejection fraction (HFpEF, LVEF ≥ 50%)
62758795|NCT00066469|EXPERIMENTAL|Cyclophosphamide, prednisone, rituximab|Patients receive cyclophosphamide IV over 30-60 minutes on day 1 and oral prednisone or methylprednisolone IV twice daily on days 1-5. During courses 1 and 2 only, patients also receive rituximab IV over 2-5 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression, a new primary or secondary malignancy, or unrelated disease
62758796|NCT02184377||RLN+SLN paralysis|unilateral recurrent laryngeal and superior laryngeal nerve paralysis
62567606|NCT05465629|NO_INTERVENTION|Placebo|Participants who have gastrointestinal issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
62758797|NCT02184377||RLN paralysis|unilateral recurrent laryngeal nerve paralysis
62758798|NCT04092192|ACTIVE_COMPARATOR|Forceps|Subjects randomized to this cohort will have their IVC filter removed using a rigid forceps device that will be used to engage the filter apex directly and allow for the filter to be capture/removed.
62758799|NCT04092192|ACTIVE_COMPARATOR|Snare|Subjects randomized to this cohort will have their IVC filter removed using an endovascular snare (like a lasso) device that is designed to catch the hook of the filter and allow it to be captured.
62758800|NCT06162533||Vaccinated against SARS-CoV-2|"Individuals who received a SARS-CoV-2 vaccine but have no record of a previous SARS-CoV-2 infection.~Subgroups will be formed according to the number and type of vaccines against SARS-CoV-2."
62758801|NCT06162533||Previously SARS-CoV-2 infected|"Individuals who were previously infected with SARS-CoV-2 but have not received a SARS-CoV-2 vaccine.~Subgroups will be formed according to the number and time period of previous SARS-CoV-2 infections."
62758802|NCT06162533||Hybrid Immunity against SARS-CoV-2|"Individuals who received a SARS-CoV-2 vaccine and who were previously infected with SARS-CoV-2.~Subgroups will be formed according to the number and time period of previous SARS-CoV-2 infections, the number and type of vaccines against SARS-CoV-2, and according to whether the vaccination or the infection was the first immune conferring event."
62758803|NCT06162533||No immunity against SARS-CoV-2|Individuals who have not received a SARS-CoV-2 vaccine and were not previously infected with SARS-CoV-2.
62758804|NCT02169128||Patients and their significant others|Patients affected by necrotizing fasciitis and their significant others
62758805|NCT04408417|EXPERIMENTAL|Harnessing Sequence A|Participants will harness their child into the 2 different child safety seats in the following order: control, prototype, prototype, control.
62758806|NCT04408417|EXPERIMENTAL|Harnessing Sequence B|Participants will harness their child into the 2 different child safety seats in the following order: prototype, control, control, prototype.
62758807|NCT04408417|EXPERIMENTAL|Harnessing Sequence C|Participants will harness their child into the 2 different child safety seats in the following order: control, control, prototype, prototype.
62758808|NCT04408417|EXPERIMENTAL|Harnessing Sequence D|Participants will harness their child into the 2 different child safety seats in the following order: prototype, prototype, control, control.
62758809|NCT02775110|ACTIVE_COMPARATOR|Immediate Discontinuation Group|Patients will discontinue the natalizumab therapy at once and initiate another disease modifying therapy at 1 month following the last natalizumab infusion. The disease modifying therapy at 1 month following natalizumab discontinuation will be at the discretion of the neurologist and may differ among patients.
62758810|NCT02775110|EXPERIMENTAL|Taper-off Group|Patients will be administered two more natalizumab infusion, one at six weeks and the second at eight weeks (14 weeks from study entry), followed by six months natalizumab discontinuation. Another DMT will be initiated within two months after the last natalizumab infusion.
62758811|NCT00902993|EXPERIMENTAL|1|Part A single and multiple dose and part B fractionated dose
62758812|NCT00902993|PLACEBO_COMPARATOR|2|
62758813|NCT06254872|EXPERIMENTAL|Peer Mentors|Participants will be trained in how to be peer mentors to anonymous participants through a smartphone app. Participants will provide daily prompts to their mentees to encourage anonymous discussion in the group chat feature of the smartphone app. Participants will provide daily encouragement to their mentees to use features of the smartphone app to practice mindfulness skills.
62758814|NCT05671224|NO_INTERVENTION|Standard counseling|Standard induction of labor counseling
62758815|NCT05671224|EXPERIMENTAL|Visual aid counseling|Counseling on induction of labor with either a video or a handout
62758816|NCT05739695|EXPERIMENTAL|VBN|Virtual bronchoscopy
62758817|NCT05739695|EXPERIMENTAL|VBN+rEBUS|Combination of VBN and radial EBUS
62758818|NCT05739695|ACTIVE_COMPARATOR|rEBUS|Radial EBUS as a gold standard
62758819|NCT02648451|EXPERIMENTAL|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES Rome for a period of 9 days
62758820|NCT04820634|EXPERIMENTAL|VR-JIT|In this arm, participants would participate in simulated interviews utilizing a software program and virtual interviewer, once a week for 90 minutes.
62758821|NCT04820634|PLACEBO_COMPARATOR|Wonderworks|In this arm, participants would participate in a similar intervention, also once a week for 90 minutes. However, in this arm, the intervention would be in a virtual office environment completing office tasks.
62758822|NCT05978076||Every children with elevated serum lipase|Every children with elevated serum lipase after trauma during those years will be included.
62758823|NCT04274153|EXPERIMENTAL|Gardasil9|Two doses of the 9-valent HPV vaccine to be administered to participants at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
62758824|NCT03177811|ACTIVE_COMPARATOR|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
62758825|NCT03177811|PLACEBO_COMPARATOR|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
61987149|NCT01914406|ACTIVE_COMPARATOR|continuous moderate training|Continued exercise 45 min.
61987150|NCT02235142|EXPERIMENTAL|Localised prostat cancer and androgen deficiency|
62380173|NCT03198728|EXPERIMENTAL|SOV2012-F1-treated|200 patients treated with SOV2012-F1, starting dose of 600 mg - (400 mg with morning meal and 200 mg with evening meal). Dose titrated on Days 28 and 56 up to a maximum of 600 mg TU in the morning and 400 mg in the evening or down to 200 mg TU in the morning based on plasma T at Days 14 and 42.
62758826|NCT01173549|EXPERIMENTAL|001|no intervention Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
62758827|NCT01173549|EXPERIMENTAL|002|Canagliflozin/Placebo Placebo/Canagliflozin Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).
62758828|NCT00989638||Women at high risk for breast cancer|
62758829|NCT03789695|EXPERIMENTAL|Dabigatran etexilate|Dabigatran etexilate (Pradaxa) 110 mg b.i.d. or 150 mg b.i.d. according SmPC during 2 years
62758830|NCT03789695|ACTIVE_COMPARATOR|Warfarin|Warfarin under the control of INR once a month (target range 2.0 - 3.0) during 2 years
62758831|NCT05804630|ACTIVE_COMPARATOR|Experiment 1, arm 1: Articaine infiltration anesthesia|This arm aims to compare efficacy and safety of infiltration anesthesia of Articaine (Orabloc®) to block anesthesia of Lidocaine (Octocaine®). It would be a split-mouth study design. The patient in this arm would be randomly assigned to one anesthetic agent and technique at one side (left or right) of the wisdom tooth surgery first, and the other side (left or right) of wisdom tooth surgery would use the other anesthetic agent and technique accordingly.
62758832|NCT05804630|ACTIVE_COMPARATOR|Experiment 1, arm 2: Lidocaine block anesthesia|This arm aims to compare efficacy and safety of infiltration anesthesia of Articaine (Orabloc®) to block anesthesia of Lidocaine (Octocaine®). It would be a split-mouth study design. The patient in this arm would be randomly assigned to one anesthetic agent and technique at one side (left or right) of the wisdom tooth surgery first, and the other side (left or right) of wisdom tooth surgery would use the other anesthetic agent and technique accordingly.
62380174|NCT03198728|ACTIVE_COMPARATOR|Andro-Gel™ treated|100 patients treated with AndroGel, starting dose of 40.5 mg QD. Dose titrated according to approved label, using samples from Days 14 and 42 and dose adjustments on Days 28 and 56.
62758833|NCT05804630|ACTIVE_COMPARATOR|Experiment 2, arm 1: Lidocaine+1:100000 adrenaline block anesthesia|This arm aims to compare efficacy and safety of block anesthesia of Lidocaine containing different concentration of epinephrine (adrenaline), i.e. Octocaine® (Lidocaine+1:100000 adrenaline) vs. Xylestesin-A® (Lidocaine+1:80000 adrenaline). It would be a split-mouth study design. The patients in this arm would be randomly assigned to one anesthetic agent at one side (left or right) of the wisdom tooth surgery first, and the other side (left or right) of wisdom tooth surgery would use the other anesthetic agent accordingly.
62758834|NCT05804630|ACTIVE_COMPARATOR|Experiment 2, arm 2: Lidocaine+1:80000 adrenaline block anesthesia|This arm aims to compare efficacy and safety of block anesthesia of Lidocaine containing different concentration of epinephrine (adrenaline), i.e. Octocaine® (Lidocaine+1:100000 adrenaline) vs. Xylestesin-A® (Lidocaine+1:80000 adrenaline). It would be a split-mouth study design. The patients in this arm would be randomly assigned to one anesthetic agent at one side (left or right) of the wisdom tooth surgery first, and the other side (left or right) of wisdom tooth surgery would use the other anesthetic agent accordingly.
62758835|NCT04965961|EXPERIMENTAL|Recombinant human erythropoietin treatment|Participants receive intravenous injections of 9 International Units per kg bodyweight epoetin-β (NeoRecormon, Roche, Mannheim, Germany) three times per week for four weeks on non-consecutive days. Subjects receive tablets with 80mg iron (Tardyferon, Pierre Fabre Pharme GmbH, Freiburg, Germany) to ensure sufficient iron stores for the expected increase in erythropoeisis.
62758836|NCT04965961|PLACEBO_COMPARATOR|Control group|Participants receive intravenous injections of \~0,5 mL saline (NaCl 0,9%) three times per week for four weeks on non-consecutive days.
62758837|NCT04526145|EXPERIMENTAL|Stress and emotion Management for Black/African Americ|Four weekly sessions delivered in a group format via Zoom teleconference. The following topics are listed in the workbook: Planning Your Information Diet; My Spheres of Influence Worksheet; Practical Wisdom for Tolerating Uncertainty; Reducing Anxiety With Thought Challenging; Reducing Anxiety Through Distraction Activities; Starting a Planning Practice; Starting a Daily Gratitude Practice; Starting a Daily Breathing Practice; Improving the Quality of Your Social Connections; Developing a Regular Exercise Routine; and Creating Your Stress-Resilience Action Plan. Each session will begin with a 15-30 minute check in on what went well, challenges, and Coronavirus Anxiety workbook. The Coronavirus Anxiety Workbook topics are complementary and the sessions will tie together the themes of comprehensive stress and emotional management through blood pressure knowledge/self-monitoring, diet, interpersonal communication skills building, and sleep hygiene.
62758838|NCT04104685|EXPERIMENTAL|FCD105 Foam|FCD105 Foam
62758839|NCT04104685|ACTIVE_COMPARATOR|3% Minocycline Foam|3% Minocycline Foam
62758840|NCT04104685|ACTIVE_COMPARATOR|0.3% Adapalene Foam|0.3% Adapalene Foam
62758841|NCT04104685|PLACEBO_COMPARATOR|Vehicle Foam|Vehicle Foam
62758842|NCT02912130|NO_INTERVENTION|Control|No Intervention
62380175|NCT05719259||Enrolled population|"All patients meeting eligibility criteria (Adult patients, under a documented or expected time under mechanical ventilation of at least \>48h) and providing one of:~* Informed consent~* Hospital level consent~* Non-objection notice~* Waiver of consent"
61987151|NCT02229136|EXPERIMENTAL|Miracle Mouthwash plus Hydrocortisone|Miracle Mouthwash plus Hydrocortisone, swish and expectorate 10cc (10 mLs) 4 times per day, every day for 12 weeks.
62758843|NCT02912130|EXPERIMENTAL|Exercise|"1. Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise~2. Resistance Exercise i.e. 60 minutes per week of progressive resistance training"
62758844|NCT02912130|EXPERIMENTAL|Exercise+Nutrition|"1. Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise~2. Dietary Supplement i.e. Protein Supplementation 1.2-1.5g/kg/body weight per day"
62758845|NCT02912130|EXPERIMENTAL|Nutrition|Dietary Supplement: Protein Supplementation i.e. 1.2-1.5g/kg/body weight per day
62758846|NCT01863121||Cirrhotic Patients|Patients of cirrhosis
62758847|NCT01618617|EXPERIMENTAL|Probiotic, high dose|High dose Multistrain probiotic, 100 billion cfu/day
62758848|NCT01618617|EXPERIMENTAL|Probiotic, low dose|Low dose Multistrain probiotic, 15 billion cfu/day
62758849|NCT01618617|PLACEBO_COMPARATOR|Placebo|Placebo
62758850|NCT03452826|EXPERIMENTAL|Antibiotic therapy according to the result of mPCR|Combined use of a respiratory broad panel Multiplex polymerase chain reaction (mPCR) (performed on a lower respiratory tract sample : bronchoalveolar lavage fluid or tracheal aspirate, otherwise sputum) and procalcitonin.
62380176|NCT05719259||VAP population|Subset of the enrolled population fulfilling U.S. Food and Drug Administration (FDA) criteria for VAP diagnosis at any time during the follow up
62380177|NCT05719259||Microbiologically evaluable VAP population|Subset of the VAP population with a documented causative agent (bronchoalveolar lavage \[BAL\], endotracheal aspirate \[ETA\], blood sample, sputum, or pleural fluid) within 48 hours from VAP diagnosis
62558351|NCT06582875|EXPERIMENTAL|Semaglutide|To minimize the risk of gastrointestinal adverse events, a standard and proven dose-escalation regimen will be employed, starting at 0.25 mg once weekly semaglutide at randomization. Following 4 weeks of treatment with 0.25 mg, the dose will be escalated to 0.5 mg once weekly and maintained for another 4 weeks until finally escalating to the target dose of 1 mg once weekly semaglutide. Participants will remain on the 1 mg dose for 22 months until the end of treatment visit; however, dose reductions and extensions of dose escalation intervals will be allowed (e.g., if treatment with trial product is associated with unacceptable adverse events). The minimum tolerated dose to remain in the study is 0.50 mg/week. All dose changes will be recorded.
62758851|NCT03452826|NO_INTERVENTION|Antibiotic therapy at discretion of ICU physicians|Antibiotic therapy at discretion of ICU physicians
62758852|NCT01431937|ACTIVE_COMPARATOR|GSK2018682|Active Drug
62758853|NCT01431937|PLACEBO_COMPARATOR|Placebo Control|Placebo
62758854|NCT02969096|EXPERIMENTAL|Targeted Cryoablation Therapy|liver cancer patients received targeted cryoablation therapy.
62380178|NCT02994927|ACTIVE_COMPARATOR|Prednisone group|Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
62380179|NCT02994927|EXPERIMENTAL|Avacopan group|Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
62380180|NCT04978922|EXPERIMENTAL|TelEPOC with Machine Learning (ML)|"Hospital with an active telemonitoring programme of readmitted COPD patients (TelEPOC) after application of an artificial intelligence system (Machine Learning: ML).~\* TelEPOC: The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own."
62380181|NCT04978922|NO_INTERVENTION|TelEPOC without ML|Hospitals with an active telemonitoring programme of readmitted COPD patients (TelEPOC) without the application of an artificial intelligence system (Machine Learning: ML).
62758855|NCT03674099|EXPERIMENTAL|Imatinib|Imatinib will be administered orally one tablet (400mg) twice daily, 800mg per day for 14 consecutive days.
62758856|NCT03674099|ACTIVE_COMPARATOR|Methylprednisolone|Methylprednisolone will be administered once a day either in tablets; Medrol 1g per day or iv; Solumedrol 1000 mg per day, both for three consecutive days.
62567607|NCT05465629|ACTIVE_COMPARATOR|Viome's Precision Nutrition Program|Participants who have gastrointestinal issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
62758857|NCT03209232|EXPERIMENTAL|Accelerated induction|Patients in group 1 will receive an accelerated induction of infliximab at 0,1,3 weeks (5 mg/kg) and then at week 7,11,15.
61987152|NCT02229136|ACTIVE_COMPARATOR|Prednisolone|Prednisolone oral solution 15 mg/5 ml; swish and expectorate 10cc (10 mL) 4 times per day, every day for 12 weeks.
62758858|NCT03209232|ACTIVE_COMPARATOR|Per protocol|Patients in group 2 will receive a per protocol induction of infliximab at 0,2,6 weeks (5 mg/kg) and then at week 14.
61987153|NCT04361981||Cases|COVID-19 infection patients with a Deep Venous Disease event
61987154|NCT03796481||Cases|People with chronic spinal pain (i.e. chronic low back pain or chronic neck pain) with comorbid insomnia
61987155|NCT03796481||Controls|People with chronic spinal pain (i.e. chronic low back pain or chronic neck pain) without comorbid insomnia
61987156|NCT05972499|PLACEBO_COMPARATOR|Group A (control group)|"The children in this group will receive physical therapy exercises to improve gross motor function and functional performance for 30 minutes per session ,3 times per week for three successive months as the following:~Forward and sideways walking between parallel bars, as well as walking training with a stepper. Obstacles such as rolls and wedges are placed across the walking track during gait training in an open manner"
62758859|NCT00353431|ACTIVE_COMPARATOR|1|"Conventional insulin group:~In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician."
62758860|NCT00353431|EXPERIMENTAL|2|"Intensive insulin therapy algorithm:~The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake."
62758861|NCT01703117|EXPERIMENTAL|age matched cohort 50-95 years old|20-22 subjects between the ages of 50-95 will receive riluzole
62758862|NCT01703117|PLACEBO_COMPARATOR|24 subjects between 50-95 years old|20-22 subjects between 50-95 will receive placebo
62558352|NCT06582875|PLACEBO_COMPARATOR|Placebo|To minimize the risk of gastrointestinal adverse events, a standard and proven dose-escalation regimen will be employed, starting at 0.25 mg once weekly placebo at randomization. Following 4 weeks of treatment with 0.25 mg, the dose will be escalated to 0.5 mg once weekly and maintained for another 4 weeks until finally escalating to the target dose of 1 mg once weekly placebo. Participants will remain on the 1 mg dose for 22 months until the end of treatment visit; however, dose reductions and extensions of dose escalation intervals will be allowed (e.g., if treatment with trial product is associated with unacceptable adverse events). The minimum tolerated dose to remain in the study is 0.50 mg/week. All dose changes will be recorded.
62558353|NCT04662879|EXPERIMENTAL|Intervention Arm (Site)|"Two interventions are performed:~1. Have Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score calculated, and if Score is \>0,~2. Have abdominal imaging performed."
62558354|NCT04662879|NO_INTERVENTION|Observation Arm (Site)|Passive follow-up by electronic medical record for study endpoints of pancreatic cancer diagnosis.
62558355|NCT03443349|OTHER|Use of the medical Device: Vibwife One|"The medical device will be used according to its market authorization.~Because it will be used for the first time in pregnant women, the following three step application procedure has been determined:~* First five pregnant women use the device for 10 minutes. Each of them in a position and module proposed by the midwife with the agreement of the woman.~* Next 10 pregnant women use the device for 20 minutes. Again, position and module according to the decision of the midwife with the agreement of the woman.~* All the remaining pregnant women (35) use the device for 30 minutes. Position and module according to the decision of the midwife with the agreement of the woman.~During the intervention period, position and module might be changed once if required."
62758863|NCT04596332||Group A|Patients with the initial central venous pressure(CVP1) \<8 mm Hg
62758864|NCT04596332||Group B|Patients with 8≤CVP1≤12mm Hg
62558356|NCT03936205|NO_INTERVENTION|Control|
62558357|NCT03936205|EXPERIMENTAL|Dexmedetomidine|
62168154|NCT04765540|EXPERIMENTAL|T3: BAU + High Intensity Activities|"T1 plus an additional bundle of 'high-intensity' active interventions delivered for three weeks, including:~* Free soap and free facemasks provided to handwashing station users in regular giveaways at key times, along with encouragement to return to the station and to spread the word.~* A 'community message board' along with encouragement to make a mark on a scoreboard at the top of the board before/after use of the station to increase commitment and as an additional social cue. This will also visually show cumulative number of uses as a persistent cue of the social norm.~* General encouragement to use the stations, provided by the intervention delivery team while they are at the station. Intervention team members are equipped with a loudhailer to assist this.~* In addition, village handwashing station committees will be encouraged to try out their own ideas for encouraging more people to use the stations."
62558358|NCT05902286|EXPERIMENTAL|OSC+|The 25 participants assigned to the OSC+ condition will complete a five-week intervention for the Osc+ portion of the study using emWave software for biofeedback. There will be one 30-60 minute in-person HRVB session once a week completed at the University Parkway Center. In addition to the in-person session, the participant will complete four 20-minute homework sessions during the following week. The format of five weeks of one weekly session and four homework sessions is effective at helping participants learn and implement breathing and biofeedback skills. The five HRVB session will be based on the Lehrer and colleagues' protocol.
62758865|NCT04596332||Group C|Patients with CVP1\>12 mm Hg
62758866|NCT03564405|EXPERIMENTAL|UNI-DEB|
62758867|NCT05027334|EXPERIMENTAL|Interventional arm|Participants will be asked to use a designed mobile app to monitor their blood sugar levels
62758868|NCT01956045||Decision making|
62758869|NCT06102356||Cohort 1|Patients diagnosed with Psoriasis referred to the outpatient clinics of Dermatology and Venereology of FPG already treated with a systemic biologic drug for at least one year.
62758870|NCT04615975|EXPERIMENTAL|Intervention|Patients will receive 21 days of a very low carbohydrate mediterranean ketogenic diet with phytoextracts and 7 days of a low carbohydrate diet
62758871|NCT04881500|EXPERIMENTAL|Motivational interview|"Patients followed in the primary care network participating in the study and those followed in the addictology network of northern Finistère in the context of their pathology will be offered the opportunity to participate in the study.~If the patient was randomized to the intervention group, the patient will receive 2 individual sessions (motivational interview) by telephone within 1 month of inclusion. They will then be assessed at month 1, month 3 and month 6. These assessments will be done by telephone."
62758872|NCT04881500|ACTIVE_COMPARATOR|Routine Care|"Patients followed in the primary care network participating in the study and those followed in the addictology network of northern Finistère in the context of their pathology will be offered the opportunity to participate in the study.~If the patient has been randomized to the control group, the patient will be assessed at month 1, month 3 and month 6. These assessments will be done by telephone."
62758873|NCT04481802|EXPERIMENTAL|RadiaAce gel|RadiaAce Gel is a clear, non-oily Hydrogel wound dressing for the management of Radiation Dermatitis which provides optimal moist wound environment necessary to the healing process. RadiaAce gel contains Acemannan, a high molecular polysaccharide obtained from the inner gel of Aloe Vera leaves and it is considered the main functional component of Aloe vera (Sahu et al. 2013).
62758874|NCT04481802|ACTIVE_COMPARATOR|Biafine|one of the standard skin care in radiation oncology, this treatment was chosen as the comparator.
62758875|NCT04890587|EXPERIMENTAL|AL8326|"Part 1:(closed)Cohort 1 will initiate with AL8326 for single dose and multiple dose (28-Day cycles) . After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, several additional cohorts will be sequentially for the same 28-day cycles.~Part 2 :(open)Each subject will receive a dose from Part 1 of this study for continuous 28-Day cycles of therapy.~Part 3:(open)Cohort 3 will initiate with AL8326(bid), for 28-Day cycles . After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, two additional cohorts will be sequentially enrolled at decreased dose of AL8326 for the same 28-day cycles."
62558359|NCT05902286|SHAM_COMPARATOR|OSC-|"Similarly, for the Osc- procedures, the client will be required to complete a five-week intervention. Participants will be instructed that the purpose of this portion of the study is to decrease their breathing oscillations. A program was designed by Yoo and colleagues that gives feedback regarding a calmness score which reflects a better score (i.e., higher) when participants breathe in a pattern that elicits less variability (i.e., less oscillations). They will be asked to complete four 20-minute homework assignments at home and asked to come up with techniques to decrease their heart rate."
62558360|NCT05791097|EXPERIMENTAL|Arm A: Ociperlimab + tislelizumab + chemotherapy|Participants will receive ociperlimab in combination with tislelizumab and platinum-based doublet chemotherapy
62558361|NCT05791097|ACTIVE_COMPARATOR|Arm B: Placebo + pembrolizumab + chemotherapy|Participants will receive ociperlimab placebo in combination with pembrolizumab and platinum-based doublet chemotherapy
62558362|NCT05791097|PLACEBO_COMPARATOR|Arm C: Placebo + tislelizumab + chemotherapy|Participants will receive ociperlimab placebo in combination with tislelizumab and platinum-based doublet chemotherapy
62558363|NCT02852954||study group1|20 paraffin embedded blocks which was diagnosed endometrial cancer
62558364|NCT02852954||control group|20 paraffin embedded blocks of healthy women
62558365|NCT02852954||study group2|20 paraffin embedded blocks which was diagnosed endometrial hyperplasia
62558366|NCT05137392|EXPERIMENTAL|Test group|The test group will receive the novel regimen of oral hygiene instruction, including use of a commercially available intelligent toothbrush connected to the Chinese consumer version of an application and receiving targeted oral health message as well as use of interdental toothbrush
62168155|NCT04513535|EXPERIMENTAL|manual therapy combination 1|Cervical manipulation, Thoracic manipulation
62558367|NCT05137392|OTHER|Control group|The test group will receive the standard regimen of oral hygiene instruction, including use of a commercially available manual toothbrush and receiving a brochure for oral hygiene instruction as well as use of interdental toothbrush
62558368|NCT03566030||Tenofovir Disoproxil Fumarate 300 mg QD|Administered Tenofovir Disoproxil Fumarate 300 mg QD
62558369|NCT03566030||Tenofovir Alafenamide|Administered Tenofovir Alafenamide 25 mg QD
62558370|NCT06107569|EXPERIMENTAL|Promicrobioma|MIcrobiote tranplant
62558371|NCT06107569|ACTIVE_COMPARATOR|Antibiotic (metronidazole or vancomycin)|Antibiotic commonly used for treatment of CDI, including oral vancomycin or metronidazol)
62758876|NCT00119912|ACTIVE_COMPARATOR|A 1 Intervention arm Flex Sig|Randomised from the population registry, age 50-64 years and invited for Flexible Sigmoidoscopy (Flex Sig) screening. Half of invitees are additionally invited to provide a stool sample for fecal occult blood testing (Intervention arm A 2). They are drawn directly from the population registry without prior consent to be randomized - approved by Regional Ethics Committees of South-East Norway..
62758877|NCT00119912|NO_INTERVENTION|B Control arm|"No screening group randomised from population age 50-64 years. As for the active intervention arm, the control group was not informed about being randomized to 'no screening' since 'no screening' was the current usual care (and still is in 2015) in Norway - approved by Regional Ethics Committees of South-East Norway."
62758878|NCT00119912|ACTIVE_COMPARATOR|A 2 Intervention arm Flex Sig + iFOBT|Randomised from the population registry, age 50-64 years and invited for Flexible Sigmoidoscopy (Flex Sig) screening plus an immunochemical test for fecal occult blood (iFOBT). As for arms A 1 and B, they are drawn directly from the population registry without prior consent to be randomized.
62758879|NCT00867776|EXPERIMENTAL|AAHC Excercise Program Support Group|Participants taking part in the AAHC Exercise Program Support Group (the intervention).
62758880|NCT00914563|EXPERIMENTAL|LIDCO|The extensively burnt patients (age range 18-75 years) with second and the third degree burns, with TBSA above 15%, with or without inhalation injury will be included to the study. We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. We will use in the LIDCO group the continuous real-time hemodynamic monitoring through transpulmonal lithium dilution additionally. The monitor Lithium Dilution Cardiac Output (LIDCO) Plus permits, through analysis of the arterial blood pressure trace, to acquire items about CO, SVR and DO2. In fluid resuscitation, we will use a combination of the balanced crystalloids and synthetic colloids (of the middle molecular weight) in the ratio 2 ml/kg/% TBSA: 1 ml/kg/% TBSA.
62758881|NCT00914563|NO_INTERVENTION|Standard care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
62758882|NCT03144193|EXPERIMENTAL|Experimental|Topical anti-aging cosmetic cream (active)
62758883|NCT03144193|PLACEBO_COMPARATOR|Placebo|Basic formulation without active ingredients (vehicle)
62758884|NCT04688918|ACTIVE_COMPARATOR|Group A (Retrolamianar block(RLB))|Ultrasound-guided RLB with injection of 0.4ml/kglocal anesthestic (bupivacaine) 0.25%will be performed under strict aseptic precautions with ultrasound guidance with patient in the prone position.
62758885|NCT04688918|ACTIVE_COMPARATOR|Paravertebral group|Ultrasound-guided paravertebral injection of 0.4ml/kg saline 0.9% will be performed under strict aseptic precautions under ultrasound guidance with patient in the prone position.
62758886|NCT06046469|ACTIVE_COMPARATOR|CT group|this group of patient is doing CT abdomen and plevis with IV contrast then they undergo TURBT and compare the radiological staging to histopathological staging.
62758887|NCT06046469|ACTIVE_COMPARATOR|MRI group|this group of patient is doing MRI pelvis with contrast then they undergo TURBT and compare the radiological staging to histopathological staging.
62758888|NCT02434354|EXPERIMENTAL|neo-adjuvant/adjuvant pembrolizaumab 200 mg IV|All subjects will receive 1 cycle neo-adjuvant pembrolizumab 200mg IV followed by complete surgical resection followed by pembrolizumab Q3weeks for 1 year
62758889|NCT02761694|EXPERIMENTAL|Part 1: Vevorisertib 5 mg QD|Participants will receive vevorisertib 5 mg orally once a day (QD) until discontinuation or toxicity.
62758890|NCT02761694|EXPERIMENTAL|Part 1: Vevorisertib 10 mg QD|Participants will receive vevorisertib 10 mg orally QD until discontinuation or toxicity.
62758891|NCT02761694|EXPERIMENTAL|Part 1: Vevorisertib 20 mg QD|Participants will receive vevorisertib 20 mg orally QD until discontinuation or toxicity.
62758892|NCT02761694|EXPERIMENTAL|Part 1: Vevorisertib 25 mg QD|Participants will receive vevorisertib 25 mg orally QD until discontinuation or toxicity.
62558372|NCT03700762||pathologically results|finally proved by pathologically results
62558373|NCT03700762||evaluate by ultrasound gray-scale ratio|the results confirmed by the cut-off value of ultrasound gray-scale ratio
62558374|NCT01937221||mild cognitive impairment|
62558375|NCT01937221||mild to moderate cognitive impairment|
62558376|NCT01937221||normal or control group|
62558377|NCT00711295|EXPERIMENTAL|Cohort 1, Treatment Arm 1|"Stratum A (18-59 ys)/B(\>=60 ys): 120 healthy volunteers per stratum will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.~Among Stratum A volunteers, 60 will participate in antibody kinetics evaluation and 30 in cellular immunity evaluation.~Randomization to Treatment Arms 1 and 2 at 2:1 ratio. Subjects in Treatment Arm 1 will be included in the immunologic determination of lot-to-lot consistency."
62758893|NCT02761694|EXPERIMENTAL|Part 1: Vevorisertib 25 mg QOD|Participants will receive vevorisertib 25 mg orally every other day (QOD) until discontinuation or toxicity.
62758894|NCT02761694|EXPERIMENTAL|Part 1: Vevorisertib 50 mg QD|Participants will receive vevorisertib 50 mg orally QD until discontinuation or toxicity.
62758895|NCT02761694|EXPERIMENTAL|Part 1: Vevorisertib 75 mg QD|Participants will receive vevorisertib 75 mg orally QD until discontinuation or toxicity.
62758896|NCT02761694|EXPERIMENTAL|Part 1: Vevorisertib 100 mg QD|Participants will receive vevorisertib 100 mg orally QD until discontinuation or toxicity.
62758897|NCT02761694|EXPERIMENTAL|Part 2: Vevorisertib 50 mg QD plus Paclitaxel|Participants will receive vevorisertib 50 mg orally QD plus paclitaxel 80 mg/m\^2 via intravenous (IV) infusion on Days 1, 7, 15 followed by a week of rest of each 28-day cycle until discontinuation or toxicity.
62758898|NCT02761694|EXPERIMENTAL|Part 2: Vevorisertib 75 mg QD plus Paclitaxel|Participants will receive vevorisertib 75 mg orally QD plus paclitaxel 80 mg/m\^2 via IV infusion on Days 1, 7, and 15 followed by a week of rest of each 28-day cycle until discontinuation or toxicity.
62758899|NCT02761694|EXPERIMENTAL|Part 2: Vevorisertib 50 mg QD plus Fulvestrant|Participants will receive vevorisertib 50 mg orally QD plus fulvestrant 500 mg via intramuscular (IM) injection on Days 1 and 15 of Cycle 1, and Day 1 of each 28-day cycle thereafter until discontinuation or toxicity.
62168156|NCT04513535|EXPERIMENTAL|manual therapy combination 2|Cervical manipulation, glenohumeral mobilization
62168157|NCT04513535|EXPERIMENTAL|manual therapy combination 3|cervical manipulation, sleeper stretch
62168158|NCT04513535|EXPERIMENTAL|manual therapy combination 4|thoracic manipulation, glenohumeral mobilization
62168159|NCT04513535|EXPERIMENTAL|manual therapy combination 5|thoracic manipulation, sleeper stretch
62168160|NCT04513535|EXPERIMENTAL|manual therapy combination 6|glenohumeral mobilization, sleeper stretch
62380182|NCT00129376|EXPERIMENTAL|Doxorubicin+cyclophosphamide - Docetaxel|Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles. Later, docetaxel (36 mg/m2) was administered an intravenous infusion, weekly for six weeks followed by a 2-week resting period (8-week cycle).
62380183|NCT01116128|EXPERIMENTAL|D-MP|
62380184|NCT05010434|EXPERIMENTAL|Sintilimab and Bevacizumab Combined with Radiotherapy|
62380185|NCT03112499|ACTIVE_COMPARATOR|PCNL Group|Patients with renal calculi 10-30mm in maximal diameter in who percutaneous nephrolithotomy (PCNL) will be conducted
62380186|NCT03112499|ACTIVE_COMPARATOR|mini-PCNL Group|Patients with renal calculi 10-30mm in maximal diameter in who mini- percutaneous nephrolithotomy (mini-PCNL) will be conducted
62558378|NCT00711295|EXPERIMENTAL|Cohort 1, Treatment Arm 2|"Stratum A (18-59 ys)/B(\>=60 ys): 60 healthy volunteers per stratum will receive 2 vaccinations with 3.75 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.~Randomization to Treatment Arms 1 and 2 at 2:1 ratio."
62558379|NCT00711295|EXPERIMENTAL|Cohort 1, Treatment Arm 3|"Stratum A (18-59 ys): 2060 healthy volunteers will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in safety evaluation only.~Randomization within Treatment Arms 3 and 4 at 1:1:1 ratio per study site to receive one of three different lots of the H5N1 influenza vaccine."
62558380|NCT00711295|EXPERIMENTAL|Cohort 2, Treatment Arm 1|"300 immune compromised individuals 18 years or older will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21.~100 will participate in immunogenicity evaluation and 30 in cellular immunity evaluation."
62758900|NCT02761694|EXPERIMENTAL|Part 2: Vevorisertib 75 mg QD plus Fulvestrant|Participants will receive vevorisertib 75 mg orally QD plus fulvestrant 500 mg via IM injection on Days 1 and 15 of Cycle 1, and Day 1 of each 28-day cycle thereafter until discontinuation or toxicity.
62758901|NCT00463983|EXPERIMENTAL|octreotide|octreotide SR 30 mg intra muscularly every 4 weeks
62758902|NCT05166382|EXPERIMENTAL|Group 1: SomaSignal Informed Medical Management (CVDT2D test, informed)|Blood draw for cardiovascular CVDT2D test at baseline and 6 months (+/- 30 days). SomaSignal Test results will be sent to the providers and then shared with study participants. Participants' medical record will be reviewed, and they may be contacted within 30 days after baseline and 6-month visits to review changes in treatment strategy (nothing, add/remove medication, etc.) made at visit.
62758903|NCT05166382|PLACEBO_COMPARATOR|Group 2: Standard of Care (CVDT2D test, uninformed)|Similar to group 1 but SomaSignal CV test results will not be provided to participants until after the intervention period.
62758904|NCT02850263||Cohort 1 / Anti-VEGF treatment naïve patients|Anti-VEGF treatment of naïve patients (who have not received any previous anti-VEGF treatment) with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the United Kingdom.
62758905|NCT02850263||Cohort 2 / Anti-VEGF treatment non-naïve patients|Anti-VEGF treatment of non-naïve patients (who have received previous anti-VEGF treatment) with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the UK.
62758906|NCT02850263||Cohort 3 / Total study population|Anti-VEGF treatment naïve patients and anti-VEGF treatment non-naïve patients with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the UK.
62758907|NCT04128397|EXPERIMENTAL|traditional stimulation site continuous theta burst stimulation (cTBS)|arm: experimental: performing cTBS to tic patients for continuous 5 days ,3 times for a day (0 minute ,15 minute ,60 minute). The stimulation site include left supplementary motor area, right supplementary motor area, left primary motor area, right primary motor area , left superior parietal lobule, right superior parietal lobule. Determination of stimulation target is a common method of determination in previous studies. For example the vertex (Cz) was measured for each patient and the SMA defined at 15% of the distance between inion and nasion anterior to Cz on the sagittal midline.
62758908|NCT04128397|EXPERIMENTAL|precise stimulation site cTBS|arm: experimental: performing cTBS to tic patients for 5 days ,3 times for a day (0 minute ,15 minute ,60 minute). The stimulation site include left supplementary motor area, right supplementary motor area, left primary motor area, right primary motor area , left superior parietal lobule, right superior parietal lobule. The stimulation target is determined by the resting-state functional connectivity, which is robust functional connectivity with the GPi or Thalamus.
62758909|NCT02891681|EXPERIMENTAL|NIR/US (Neoadjuvant Chemotherapy Cohort)|"Patients will have the NIR/US baseline scan performed before their first treatment. The desirable schedule will be \>= 7 days after initial biopsy to avoid confounding effects from the biopsy related acute inflammatory response.~* In addition, patients will also have NIR/US performed at end of cycle 1, end of cycle 2, end of cycle 3, end of cycle 5 (only if treatment regimen changed), and prior to surgery.~* The number of NIR/US study visits may vary (5-6) depending on the patient's treatment regimen"
62758910|NCT02891681|EXPERIMENTAL|NIR/US (Neoadjuvant Endocrine Cohort)|"Patients will have the NIR/US baseline scan performed before their first treatment. The desirable schedule will be \>= 7 days after initial biopsy to avoid confounding effects from the biopsy related acute inflammatory response.~* In addition, patients will also have NIR/US performed at end of cycle 1, end of cycle 2, end of cycle 3, at time of treatment regimen change (only intended for those who have had a change in their regimen), and prior to surgery.~* The number of NIR/US study visits may vary (5-6) depending on the patient's treatment regimen"
62758911|NCT02823132||patients who develop a fungal infection|
62758912|NCT02823132||patients without fungal infection|
62758913|NCT02340182|EXPERIMENTAL|Antibiotics|"All volunteers will self-administer the following antibiotics for 7 consecutive days (concomitantly):~1. Vancomycin 250mg 3dd2;~2. Ciprofloxacin 500mg 2dd1;~3. Metronidazole 500mg 3dd1."
62558381|NCT00711295|EXPERIMENTAL|Cohort 3, Treatment Arm 1|300 chronically ill patients 18 years or older will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.
62380187|NCT03112499|ACTIVE_COMPARATOR|RIRS Group|Patients with renal calculi 10-30mm in maximal diameter in who retrograde intrarenal surgery (RIRS) will be conducted
62558382|NCT00711295|EXPERIMENTAL|Cohort 1, Treatment Arm 4|"Stratum A (18-59): 540 healthy volunteers will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity assessment.~Randomization within Treatment Arms 3 and 4 at 1:1:1 ratio per study site to receive one of three different lots of the H5N1 influenza vaccine.~Subjects in Treatment Arm 4 will be included in the immunologic determination of lot-to-lot consistency."
62558383|NCT00674739|EXPERIMENTAL|imiquimod cream|2.5% imiquimod cream applied daily to wart area for up to 8 weeks
62558384|NCT00674739|EXPERIMENTAL|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
62380188|NCT03223740|EXPERIMENTAL|Arm 1 pre-operative chemoradiation|Chemo1 x 2 followed by ChemRT followed by Surgery followed by Chemo2 x 2
62558385|NCT00674739|PLACEBO_COMPARATOR|placebo cream|placebo cream applied daily to wart areas for up to 8 weeks
62558386|NCT04282109|EXPERIMENTAL|Arm 1|NIVOTAX (nivolumab + paclitaxel, follow by maintenance with nivolumab)
62558387|NCT04282109|ACTIVE_COMPARATOR|Arm 2|ERBITAX (cetuximab + paclitaxel, follow by maintenance with cetuximab)
62558388|NCT00766740|ACTIVE_COMPARATOR|1|thrombectomy
62380189|NCT03223740|ACTIVE_COMPARATOR|Arm 2 post operative chemoradiation|Surgery followed by Chemo1 x 2 followed by ChemRT followed by Chemo2 x 2
62380190|NCT02881918||squamous cell carcinoma|Patients affected by Head \& Neck Squamous Cell Carcinoma. Blood sample at diagnosis, before any antitumor treatment
62558389|NCT00766740|ACTIVE_COMPARATOR|2|Standard PCI
62558390|NCT06582082|EXPERIMENTAL|pulmonary rehabilitation|The study group will receive pulmonary rehabilitation
62558391|NCT06582082|ACTIVE_COMPARATOR|lip breathing|the control group will stick to pursed lip breathing only
62558392|NCT03472781||Children with intraocular inflammation|All children diagnosed with intraocular inflammation at Singapore National Eye center from from January 1989 to January 2017.
62558393|NCT05637372||Study group|Patients without any disorders and diseases in age range ensuring full temporomandibular joint development.
61987157|NCT05972499|ACTIVE_COMPARATOR|Group B (study group)|"Task-oriented training with pretend play treatment:~Individual interviews will be conducted with subjects and their parents to find their favorite story and to set up a pretend play situation for each subject. The child will have his specific script, will be constructed from his favorite story. The physical therapist will use modeling, prompts, and encouragement to initiate pretend play. Actions and verbalization on the scripts will be constructed to describe the performance of activities based on task-oriented training which include:~Forward, sideways and backward walking. Walking through obstacle course. Walking up and down stairs. Walking up and down ramps. Running. Jumping. Each task will be given for 4 minutes and one minute rest. The child will be encouraged to complete the task and will be verbally cued during training. Tasks will be progressed according to each child's performance. These progressions included increasing the number of repetitions, and speed."
61987158|NCT00300950|ACTIVE_COMPARATOR|1|Gencitabine
62558394|NCT01909856|EXPERIMENTAL|Arm1|1st cycle Palonosetron, 2nd cycle Granisetron
62558395|NCT01909856|EXPERIMENTAL|Arm2|1st cycle Granisetron, 2nd cycle Palonosetron
62558396|NCT02246751|EXPERIMENTAL|Single subject design case series|Targeted Training for trunk control, 5-6 days a week for 9 months, minimum of 20 minutes per day.
62558397|NCT04768192||Pediatric patients with acquired brain injury|Subjects with a acquired brain injury occurred in the last 10 months prior the beginning of the treatment
62558398|NCT01739465|ACTIVE_COMPARATOR|Self expanding metallic stent （SEMS ）placement only|Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing
62558399|NCT01739465|EXPERIMENTAL|Endoscopic radiofrequency ablation plus SEMS|Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. The radiofrequency ablation (RFA) catheter (EMcision, London, United Kingdom) would be placed under fluoroscopic guidance across the biliary stricture. Radiofrequency energy will be delivered to the malignant site. After that,A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing
62558400|NCT01739465|EXPERIMENTAL|Photodynamic therapy plus SEMS|Photofrin is injected 3 days prior to laser activation of the agent.Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) will be carried out to determine the length and positon of the biliary malignant. Delivery Fiber used along with the laser system to activate the photosensitizing agent and induce tumor tissue necrosis. A self expanding metallic stent (SEMS) will be placed the site of biliary narrowing
62558401|NCT03557112|EXPERIMENTAL|the treatment group|TPF regimen induction chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy
62558402|NCT03557112|ACTIVE_COMPARATOR|the control group|TPF regimen induction chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
62558403|NCT04617457|EXPERIMENTAL|NAPOX chemotherapy|NAPOX chemotherapy in 14-day cycles with the four IMPs given intravenously in the following order: nal-irinotecan, oxaliplatin, folinic acid and 5-fluouracil.
61987159|NCT00300950|EXPERIMENTAL|2|Gemcitabine with GI-4000
62558404|NCT05204212|EXPERIMENTAL|Experimental intervention|Percutaneous closure of the LAA by use of the CE-mark approved LAA exclusion device Amplatzer Cardiac Plug or Amulet followed by dual antiplatelet therapy with aspirin 100mg od and clopidogrel 75 mg od for 3 months. In patients with excessive bleeding risk DAPT duration can be shortened according to the physicians' discretion to a minimum of 6 weeks. Oral anticoagulants are not prescribed in this group.
62558405|NCT05204212|NO_INTERVENTION|Control intervention|No catheter-based LAA closure. Treatment with best medical care (warfarin or NOAC therapy or other best medical care if (N)OAC therapy is contraindicated).
62558406|NCT04115319|EXPERIMENTAL|SEP363856|SEP363856 50mg, 75mg, 100mg, flexibly dosed once daily capsule
62758914|NCT04736680||Lost Virtual Visit|Pediatric patients who had scheduled an appointment for a virtual visit and missed.
62758915|NCT04736680||Attended Virtual Visit|Pediatric patients who had scheduled an appointment for a virtual visit and attended.
62758916|NCT01515475|ACTIVE_COMPARATOR|Glasses|Glasses are prescribed at enrollment and worn per protocol throughout the duration of the study.
62758917|NCT01515475|PLACEBO_COMPARATOR|Observation|Glasses will not be prescribed unless the patient has confirmation of one or more deterioration criteria as described in the protocol.
62758918|NCT02630017|EXPERIMENTAL|ADHD group|Adults with ADHD
62758919|NCT02630017|EXPERIMENTAL|non-ADHD group|Adults without ADHD
62758920|NCT03378089|EXPERIMENTAL|Music Therapy|Participants in the experimental group will be given choices about how to proceed with the session: active or passive, improvisation, re-creative or receptive songs, or receptive (relaxation). Three music therapy sessions will be completed, the first within 24 hours of admission, the second 24-96 hours of session 1, and the final session the day before stem cell infusion.
62758921|NCT03378089|ACTIVE_COMPARATOR|No Music Therapy|Participants randomized to the standard care group will be asked to rate the same symptoms as those in the experimental group. This will mark the beginning of a 45-minute control condition period during which the participants may fill the 45-minute time-period in whatever ways they choose.
62758922|NCT05744726|EXPERIMENTAL|A-PRF|Advance Platelet-Rich Fibrin
62558407|NCT04115319|ACTIVE_COMPARATOR|quetiapine XR|quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
62758923|NCT05744726|ACTIVE_COMPARATOR|Bone-wax|
62758924|NCT05744726|NO_INTERVENTION|Conventional Dental Extraction protocol|Control Group
62758925|NCT04363593|OTHER|prospective group COVID|New patients consulting for suspected or diagnosed COVID(+)
62758926|NCT04363593|OTHER|retrospective group COVID|Patients already diagnosed with COVID(+) or with a suspicion of unconfirmed COVID or at a date before the apparition of the COVID infection (April-March 2019)
62758927|NCT04363593|OTHER|Hospital staff|All hospital staff including those already diagnosed at COVID(+)
62758928|NCT00623662|ACTIVE_COMPARATOR|1|Glucose infusion.
62758929|NCT00623662|PLACEBO_COMPARATOR|2|Normal saline infusion.
62758930|NCT02217371|EXPERIMENTAL|ADHD patient|
62758931|NCT02217371|ACTIVE_COMPARATOR|Healthy volunteers|
62758932|NCT05466500|ACTIVE_COMPARATOR|Ultrasound guided axillary block with intravenous dexamethasone|The probe will be placed parallel to the anterior axillary fold at the axilla to identify the axillary artery and to identify the hyperechoic median, ulnar, and radial nerves in relation to the axillary artery. The musculocutaneous nerve which supplies the skin of the lateral side of the forearm had to be blocked also. It is found between the biceps brachii and coracobrachialis muscles .The needle is inserted in-plane from the anterior aspect and directed toward the posterior aspect of the axillary artery. All four nerves in the axillary region will be blocked and use of intravenous dexamethasone as an adjuvant to bupivacaine for Post-operative analgesia following sensory blockade of the axillary brachial plexus in paediatrics undergoing below elbow orthopaedic surgeries.
62758933|NCT05466500|PLACEBO_COMPARATOR|Ultrasound guided axillary block|The probe will be placed parallel to the anterior axillary fold at the axilla to identify the axillary artery and to identifythe hyperechoic median, ulnar, and radial nervesin relation to the axillary artery. The musculocutaneous nerve which supplies the skin of the lateral side of the forearm had to be blocked also. It is found between the biceps brachii and coracobrachialis muscles .The needle is inserted in-plane from the anterior aspect and directed toward the posterior aspect of the axillary artery. All four nerves in the axillary region will be blocked
62758934|NCT04963140|EXPERIMENTAL|Intervention|Intervention subjects will monitor their lung function daily by Forced Oscillation Technique (FOT) device. The embedded algorithm signals when an increased risk of exacerbation is detected and subjects shall modify their treatment based on the action plan prescribed by the study doctor at enrolment and used for the self-management of their asthma
61987160|NCT01741922|EXPERIMENTAL|ASA evening&placebo morning|Patients will receive acetylsalicylic acid (100 mg)in the evening and placebo in the morning.
61987161|NCT01741922|ACTIVE_COMPARATOR|ASA morning&placebo evening|Patients will receive acetylsalicylic acid (100 mg) in the morning and placebo in the evening
62168161|NCT02764788|EXPERIMENTAL|Specific auriculotherapy|Auriculotherapy on specific points with needles
62558408|NCT04505657|EXPERIMENTAL|Celecoxib plus lidocaine|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
62558409|NCT04505657|ACTIVE_COMPARATOR|Celecoxib|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure
62758935|NCT04963140|SHAM_COMPARATOR|Control|Control subjects will monitor their lung function daily by Forced Oscillation Technique (FOT) device. The embedded algorithm used in the intervention arm is disabled. Subjects will follow the action plan prescribed by the study doctor at enrolment for the self-management of their asthma
62758936|NCT02436408|EXPERIMENTAL|Vismodegib|150mg taken orally once daily
62758937|NCT02526082||Total, observational|Various cardiovascular risk groups described below
62758938|NCT02526082||High-risk intervention|Healthy but at high risk in 1974
62758939|NCT02526082||High-risk control|Healthy but at high risk in 1974
62758940|NCT02526082||Low-risk conrtol|Healthy and at low risk in 1974
62758941|NCT02526082||Sick control|Medications or clinical disease in 1974
62758942|NCT02526082||Refused|Refused or no response in 1974
62758943|NCT01094353|ACTIVE_COMPARATOR|Mini-sling|The minisling Ophira™ is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
62758944|NCT01094353|ACTIVE_COMPARATOR|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
62758945|NCT02822131|OTHER|low phosphate|low phosphate will be induced by low phosphate diet and additional treatment with oral phosphate binder sevelamer.
62758946|NCT02822131|OTHER|high phosphate|high phosphate diet will be induced by oral supplementation with sodium phosphate.
62758947|NCT05774184|ACTIVE_COMPARATOR|Barzolvolimab (CDX-0159)|300 mg subcutaneous administration every 4 weeks through week 24
62758948|NCT05774184|PLACEBO_COMPARATOR|Placebo then barzolvolimab (CDX-0159) 300mg|Matching placebo subcutaneous administration every 4 weeks through week 16, then 300mg subcutaneous administration every 4 weeks through week 24
62758949|NCT05981079|EXPERIMENTAL|Model-based dosing regimen|Drug: Piperacillin Sodium and Tazobactam Sodium for Injection. Dosing regimen: GA\<28 weeks: 30 mg/kg, Q8H; 28 weeks ≤GA\<34 weeks: 50 mg/kg，Q8H.
62758950|NCT05981079|ACTIVE_COMPARATOR|Empirical dosing regimen|Drug: Piperacillin Sodium and Tazobactam Sodium for Injection. Dosing regimen: 90 mg/kg，Q8H.
62758951|NCT00642148|ACTIVE_COMPARATOR|Seretide|
62758952|NCT00642148|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62758953|NCT00642148|EXPERIMENTAL|GW856553|
62758954|NCT04205851|EXPERIMENTAL|KIN-1901|Single or repeat (once weekly for 4 weeks) KIN-1901 subcutaneous injection
62758955|NCT04205851|PLACEBO_COMPARATOR|Placebo|Single or repeat (once weekly for 4 weeks) placebo subcutaneous injection
62758956|NCT02209948|EXPERIMENTAL|Temozolomide|Those patients will take 6 additional Temozolomide cycles
62758957|NCT02209948|NO_INTERVENTION|Without treatment|
62758958|NCT02635347|EXPERIMENTAL|Remote Ischemic Conditioning (RIC) group|Participants will receive RIC during transplant and the initial four post-transplant days. During transplant: first intervention after induction of anesthesia but before commencing surgery and the second at the conclusion of the procedure. After transplant: RIC applied daily during the first four consecutive postoperative days. Pneumatic tourniquet will be used to induce RIC
62168162|NCT02764788|SHAM_COMPARATOR|Non-specific auriculotherapy|Auriculotherapy on non-specific auriculotherapy points with needles
62758959|NCT04536948|EXPERIMENTAL|Group 1|Cooling gel application
62758960|NCT04536948|ACTIVE_COMPARATOR|Group 2|Cold pack was applied
62758961|NCT03622671|ACTIVE_COMPARATOR|Skeletonized LIMA|In patients in this arm the left internal mammary artery will be skeletonized without opening of the left pleural cavity during CABG.
62758962|NCT03622671|ACTIVE_COMPARATOR|Pedicled LIMA|In patients in this arm the left internal mammary artery will be harvested as a pedicled graft with wide opening of left pleural cavity.
62758963|NCT01945645|EXPERIMENTAL|Intervention|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
62758964|NCT06108648|EXPERIMENTAL|Lavender oil|"Lavender chest wrap:~Before the first application pour 10-15 ml of lavender essential oil 10% evenly on the cotton cloth. Put the soaked cotton in the plastic bag, close it and put it to heat in two heating pads (2-5 minutes) so that the oil is distributed on all the fabric. Place the cotton cloth around the patient's chest. Cover the cotton cloth with a woolen fabric that is 2 cm larger than the cotton cloth."
62758965|NCT06108648|ACTIVE_COMPARATOR|Control|Standard care: supportive measures according to national standards.
62758966|NCT02572232|EXPERIMENTAL|Combitube, Easytube, Laryngeal masks|Combitube, Easytube, Laryngeal mask airway are intubated in pediatric airway manikins by probands in randomized order.
62758967|NCT01068951|ACTIVE_COMPARATOR|Mesenchymal stem cells|Comparison of active treatment with autologous mesenchymal stem cells (in addition to standard treatment) to standard treatment of patients newly diagnosed with type 1 diabetes mellitus.
62758968|NCT01068951|NO_INTERVENTION|Control|
62758969|NCT01511328|EXPERIMENTAL|HPV testing|Women randomised to this arm get primary HPV testing
62758970|NCT01511328|NO_INTERVENTION|cytology|women included follow the standard procedure with primary cytology
62758971|NCT03641846|ACTIVE_COMPARATOR|LiST + 5mg Tadalafil Group|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks.
62758972|NCT03641846|PLACEBO_COMPARATOR|LiST+Placebo Group|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily placebo pill. Total treatment period = 4 weeks.
62758973|NCT01317186||Group I|Stage 2 Non-diabetic Chronic Kidney Disease
62758974|NCT01317186||Group II|Stage 3 Non-diabetic Chronic Kidney Disease
62758975|NCT01317186||Group III|Stage 4 Non-diabetic Chronic Kidney Disease
62758976|NCT01503606|ACTIVE_COMPARATOR|one-week treatment group|Cefazolin 1.0gm IVs q 12 hours plus clarithromycin 500mg po bid after randomization for one week
62758977|NCT01503606|ACTIVE_COMPARATOR|until-delivery treatment group|Cefazolin 1.0gm IVs q 12 hours plus clarithromycin 500mg po bid after randomization until delivery
62758978|NCT04736953|ACTIVE_COMPARATOR|Sirolimus|Sirolimus 1 to 2 mg bid
62758979|NCT04736953|PLACEBO_COMPARATOR|Placebo|Placebo 1 to 2 mg bid
62758980|NCT00592540|EXPERIMENTAL|Unrelated Donor BMT|
62758981|NCT02978105|EXPERIMENTAL|Experimental|self-conditioning techniques plus standard care
62758982|NCT02978105|ACTIVE_COMPARATOR|Control|Standard care: dietary recommendations, exercise recommendations, and behavioral recommendations
62758983|NCT00300482|ACTIVE_COMPARATOR|A|ABT-335 + 10 mg rosuvastatin
62758984|NCT00300482|ACTIVE_COMPARATOR|B|ABT-335 + 20 mg rosuvastatin
62758985|NCT00300482|PLACEBO_COMPARATOR|C|ABT-335 monotherapy
62758986|NCT00300482|PLACEBO_COMPARATOR|D|10 mg rosuvastatin monotherapy
62758987|NCT00300482|PLACEBO_COMPARATOR|E|20 mg rosuvastatin monotherapy
62758988|NCT00300482|PLACEBO_COMPARATOR|F|40 mg rosuvastatin monotherapy
62758989|NCT02794987||Classification group|Group of endoscopists that will use the previous classification to select the bile duct tissular lesion images detected by SpyGlass® choledoscopy as benign or malignant with the different subtypes
62758990|NCT02794987||No classification group|Group of endoscopists that will classified the bile duct tissular lesion images detected by SpyGlass® choledoscopy as benign or malignant with the different subtypes without using the classification.
62758991|NCT05516784|ACTIVE_COMPARATOR|Clopidogrel|The primary endpoint is the non-inferiority in platelet reactivity of clopidogrel versus ticagrelor among CYP2C19\*2 or \*3 allele carriers.
62758992|NCT05516784|EXPERIMENTAL|Ticagrelor|The primary endpoint is the non-inferiority in platelet reactivity of clopidogrel versus ticagrelor among CYP2C19 CYP2C19\*2 or \*3 allele carriers.
62758993|NCT00904618|EXPERIMENTAL|TVT-SECUR|This study arm consisted of 48 women operated from January 2007 to October 2008. All patients underwent the implantation of the TVT-SECUR for the treatment of stress urinary incontinence or stress predominant mixed urinary incontinence. The surgery was done under local anesthesia by one high-volume surgeon.
62758994|NCT03332719|ACTIVE_COMPARATOR|Enbrel®|Enbrel® 50 mg injectable solution in autoinjector SureClick® contains: 50 mg etanercept and excipients/Once a week Methotrexate 15 to 25 mg /Once a week
62758995|NCT03332719|EXPERIMENTAL|Enerceptan®.|Enerceptan®. Injectable Solution in prefilled syringes Source: GEMABIOTECH S. A. Formulation per unit: 1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg /Once a week
62558410|NCT04505657|ACTIVE_COMPARATOR|lidocaine|placebo to celecoxib administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
62558411|NCT06302673|EXPERIMENTAL|Laserpuncture|Laserpuncture : using RJ Laser with Nogier B wave setting, frequency 584 Hz, power 50 mW, wavelength 785 nm, and energy of 2 Joules at each acupuncture point ( PC6 Neiguan and CV12 Zhongwan)
62558412|NCT06302673|SHAM_COMPARATOR|Sham-Laserpuncture|Sham Laserpuncture: The laser is turned on but not activated at each acupuncture point ( PC6 Neiguan and CV12 Zhongwan)
62558413|NCT06483009|EXPERIMENTAL|Combination Therapy of Sintilimab and Chemotherapy with Cryoablation|
62558414|NCT01134250|EXPERIMENTAL|F16IL2 in combination with paclitaxel|
62558415|NCT02692859|EXPERIMENTAL|Vaccine(Chengdu Olymvax Biopharmaceuticals Inc.)|Hib conjugate vaccine
62558416|NCT02692859|ACTIVE_COMPARATOR|Vaccine (Walvax Biotechnology Co., LTD.)|Hib conjugate vaccine
62558417|NCT04365010|EXPERIMENTAL|Sodium Bicarbonate Ringer's Injection|"1. administration route and dosage：Intravenous infusion, 500\~1000 ml/time. The dosage can be increased or decreased according to the age, weight and symptoms.~2. rate: according to the the routine rate of fluid resuscitation of septic shock in the ICUs of Zhongda Hospital, School of Medicine, Southeast University."
62558418|NCT04365010|ACTIVE_COMPARATOR|0.9% Sodium Chloride Injection|"1. administration route and dosage：Intravenous infusion, 500\~1000 ml/time. The dosage can be increased or decreased according to the age, weight and symptoms.~2. rate: according to the the routine rate of fluid resuscitation of septic shock in the ICUs of Zhongda Hospital, School of Medicine, Southeast University."
62758996|NCT02929901|ACTIVE_COMPARATOR|caffeine and chlorogeinc acid|caffeine (200 mg) 1 capsule / day for 6 months plus chlorogenic acid (200 mg) 1 capsule / day for 6 months
62758997|NCT02929901|ACTIVE_COMPARATOR|caffeine|caffeine (200 mg) 1 capsule / day for 6 months plus placebo (200) mg 1 capsule / day for 6 months
62758998|NCT02929901|ACTIVE_COMPARATOR|chlorogenic acid|chlorogenic acid (200 mg) 1 capsule / day for 6 months plus placebo (200 mg) 1 capsule / day for 6 months
62758999|NCT02929901|PLACEBO_COMPARATOR|placebo|placebo (200 mg) 1 capsule / day for 6 months plus placebo (200 mg) 1 capsule / day for 6 months
62759000|NCT02119039|EXPERIMENTAL|RGTA OTR 4120 (CACICOL20)|
62558419|NCT05755880|NO_INTERVENTION|General anesthesia|
62558420|NCT05755880|ACTIVE_COMPARATOR|Dexamethason|
62558421|NCT00118157|EXPERIMENTAL|Treatment (lapatinib, tamoxifen)|Patients receive lapatinib ditosylate PO daily and tamoxifen citrate PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62558422|NCT03503604|EXPERIMENTAL|group 1|hPV19 mAb plus FOLFOX(5-Fluorouracil,Oxaliplatin,Leucovorin)
62558423|NCT03503604|EXPERIMENTAL|group 2|hPV19 mAb plus paclitaxel/carboplatin
62558424|NCT03503604|EXPERIMENTAL|group 3|hPV19 mAb plus gemcitabine/carboplatin
62558425|NCT03503604|EXPERIMENTAL|group 4|hPV19 mAb plus FOLFIRI(5-Fluorouracil,Irinotecan, Leucovorin)
62558426|NCT05840458||PENG Block|Patients will be submitted to PENG block intervention guiding by ultrasound.
62558427|NCT00017693|EXPERIMENTAL|0.75mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
61987162|NCT03337100|EXPERIMENTAL|Co-Dispensing|Early implementation of a naloxone co-dispensing pharmacy program. Pharmacies in the phase 1 (early) naloxone co-dispensing arm will be assigned to implement the pharmacy based naloxone co-dispensing program first relative to the phase 2 arm.
62558428|NCT00017693|EXPERIMENTAL|1.5mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
62558429|NCT00017693|EXPERIMENTAL|3.0mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
62567608|NCT05465629|ACTIVE_COMPARATOR|Viome's condition-based supplements|Participants who have gastrointestinal issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
62759001|NCT02119039|ACTIVE_COMPARATOR|Genteal HA|
62759002|NCT03694743|EXPERIMENTAL|2Shape rotary system|root canal preparation using 2Shape rotary system in mandibular molars with symptomatic pulpitis
62759003|NCT03694743|ACTIVE_COMPARATOR|Protaper Next rotary system|root canal preparation using Protaper Next rotary system comparing to 2Shape rotary system in mandibular molars with symptomatic pulpitis
62759004|NCT06103318|ACTIVE_COMPARATOR|ICOnnectat|"ICOnnecta't is a stepped-care digital intervention tailored to breast cancer patients' psychosocial needs. It consists of four levels:~1. rst level. Psychosocial Screening and Monitoring: Patients assess their emotional distress and symptoms; consultations with a health psychologist are scheduled if distress is high.~2. nd level. Campus (Psychoeducation and Health Education): Patients access educational resources covering medical information, emotional well-being, relationships, and healthy habits.~3. r level. Community Psychosocial Support: Patients engage in an online community to share experiences and concerns under supervision.~4. th level. Online Group Psychotherapy: Patients participate in online group psychotherapy sessions led by a psycho-oncology specialist."
62759005|NCT06103318|EXPERIMENTAL|ICOgnition|"ICOgnition enhances ICOnnecta't with a Cognitive Module, following the same stepped-structure and specifically addressing cognitive deficits in breast cancer patients. It includes:~1. rst level. Cognitive Screening and Monitoring: Patients complete monthly cognitive assessments and online objective cognitive tests. If scores indicate impairment, they advance to the next level.~2. nd level. Cognitive Psychoeducational Campus: Patients undergo psychoeducation focusing on cognitive impairment understanding, behavioural strategies to enhance cognitive functioning, and acceptance strategies through mindfulness and metaphors.~3. rd level. Online Cognitive Training: Individual 30-minute online cognitive training sessions are conducted twice a week for 12 weeks, targeting specific cognitive skills. Sessions are facilitated through the CogniFit program, integrated with the ICOnnecta't App."
62759006|NCT04175457|EXPERIMENTAL|e-cigarette inhalation with nicotine|inhalation of e-cigarette vapor with nicotine for 30 minutes.
62759007|NCT04175457|ACTIVE_COMPARATOR|e-cigarette inhalation without nicotine|inhalation of e-cigarette vapor without nicotine for 30 minutes.
62759008|NCT01540448|ACTIVE_COMPARATOR|No-3DCT|All patients were subjected to a CT scan with 3D mesenteric angiography but the surgeon was able to view the 3D reconstruction only after surgery.
62759009|NCT01540448|EXPERIMENTAL|3DCT|All patients were subjected to a CT scan with 3D mesenteric angiography and the surgeon was able to view 3D reconstruction before and during laparoscopic colorectal resection.
62759010|NCT02501720|ACTIVE_COMPARATOR|Tourniquet Group|Post burn flexion contractures will be released under tourniquet control
62759011|NCT02501720|EXPERIMENTAL|Tumescent technique group|Post burn flexion contractures will be released using Tumescent solution
62759012|NCT02719119|EXPERIMENTAL|monthly EVL|Elective band ligation was applied after premedication with hyoscine-N-butylbromide (20 mg intramuscularly). A multiband ligator and video endoscopes were utilized. Ligation was initiated at or slightly below the bleeding point. During each treatment session, each varix was ligated with one or two elastic bands. Variceal obliteration success was when all varices disappeared or residual varices were too small to be ligated further. Once esophageal varices were obliterated, surveillance endoscopy was performed every 3 months for 1 year and then every 6 months to check for recurrent varices. Patients in this group will underwent endoscopic variceal ligation monthly.
62759013|NCT02719119|EXPERIMENTAL|bi-weekly EVL|Elective band ligation was applied after premedication with hyoscine-N-butylbromide (20 mg intramuscularly). A multiband ligator and video endoscopes were utilized. Ligation was initiated at or slightly below the bleeding point. During each treatment session, each varix was ligated with one or two elastic bands. Variceal obliteration success was when all varices disappeared or residual varices were too small to be ligated further. Once esophageal varices were obliterated, surveillance endoscopy was performed every 3 months for 1 year and then every 6 months to check for recurrent varices. Patients in this group will underwent endoscopic variceal ligation bi-weekly.
62380191|NCT03089008|EXPERIMENTAL|Eccentric exercises|The patients were instructed to stand with straight legs on a small step, lift up on the toes, hereafter put the weight on the injured leg and slowly lower the heel as far as possible until they felt a maximal stretch of the calf muscles and/or the Achilles tendon. The exercises were repeated 15 times. Then the patients were told to repeat the exercises with semi-flexed knee. If possible the series should be repeated twice increasing to three times at each session. If pain decreased they should increase the load on the Achilles tendons by wearing a rug sack and increasing the weight of the rug sack by adding weights (5kg each). The patients were told that some pain was to be expected from the tendon during exercise, but that increasing daily pain or morning stiffness indicated that the exercises had been progressed too fast.
62380192|NCT03089008|OTHER|Control treatment, stretching exercises|The patients were instructed in standing stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee). The stretch was slowly increased and maintained for 30s. This stretch was to be repeated five times during each session. The patients were instructed that the stretching should be pain free, although a small degree of unpleasantness was allowed.
62380193|NCT00284258|EXPERIMENTAL|1|CPT-11 and TS-1
62380194|NCT00284258|ACTIVE_COMPARATOR|2|CPT-11, 5-FU and l-LV
62558430|NCT00017693|PLACEBO_COMPARATOR|Placebo for rsIL-4R|The placebo for recombinant human soluble IL-4 receptor (rsIL-4R) consisted of identically prepared excipient in the same volume (2.5 mL). To maintain blinding, medication was dispensed by an individual who was not responsible for patient care or assessment. Treatment assignment was blinded to all personnel involved in direct conduct or monitoring of the study.
62558431|NCT05158673|PLACEBO_COMPARATOR|Group A (Placebo)|The administration of two capsules of 500 mg orally of placebo (excipient q.s. starch capsule) 1 every 12 hours, for 12 weeks.
62759014|NCT03168243|EXPERIMENTAL|High Energy High Protein Tube Feed|As study is a single arm design, all patients will be in the intervention group. The will act as their own control by means of a 3 day baseline period. All patients in the study will receive the same intervention, the high energy high protein tube feed, in quantities specified by their dietitian based on their nutritional requirements.
62558432|NCT05158673|ACTIVE_COMPARATOR|Group B (Flavonoid)|Two capsules of 500 mg of the flavonoid supplement (whose total flavonoid content is 15 mg/capsule) orally every 12 hours for 12 weeks.
62168163|NCT02764788|PLACEBO_COMPARATOR|Seed auriculotherapy|Auriculotherapy on non-specific auriculotherapy points with seeds
62759015|NCT05097508|EXPERIMENTAL|Group A: Patients will receive Atracurium.|Baseline RE and SE will be recorded. Anesthesia will be induced by propofol (dose 2-3 mg/kg) and fentanyl as analgesia (dose 1-2 mg/kg). Tracheal intubation will be facilitated with atracurium (dose 0.5 mg/kg) after an acceleromyography count of 0. Anesthesia will be maintained with isoflurane in an air-O2 mixture (FiO2 0.6, 2 L/min). Mechanical ventilation will be maintained at a tidal volume of 5-7 ml/kg. Ventilator frequency will be adjusted for maintenance of an ETCO2 of 35-40 mmHg. After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Atracurium (dose 0.005-0.01 mg/kg/min) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery.
62558433|NCT05157412|EXPERIMENTAL|Steroids + Doxycycline|Systemic Prednisolone in decreasing doses (40 mg/d on days 1-7, 20 mg/d on days 8-14, and 10 mg/d on days 15-21) along with Doxycycline (200 mg as a loading dose on the 1st day, followed by 100 mg once daily one hour before meal as a maintenance dose) for 3 weeks.
62558434|NCT05157412|ACTIVE_COMPARATOR|Steroids Only|Systemic Prednisolone in decreasing doses (40 mg/d on days 1-7, 20 mg/d on days 8-14, and 10 mg/d on days 15-21) for 3 weeks.
62558435|NCT05098652|EXPERIMENTAL|Immediate Intervention|Complete baseline survey, complete 3 weeks of daily diaries and intermittent survey, receive 12 weeks of CurB-IT, then complete 3 rounds of 21-day daily diaries and intermittent surveys while receiving attention during the 12-week intervals between daily diaries.
62558436|NCT05098652|ACTIVE_COMPARATOR|Delayed intervention|Complete baseline survey, complete 3 weeks of daily diaries, receive 12 weeks of attention, complete 3 weeks of daily diaries and 1 intermittent survey, receive 12 weeks of CurB-IT, then complete 2 rounds of 21-day daily diaries and intermittent surveys while receiving attention during the 12-week intervals between daily diaries.
62558437|NCT03177525|EXPERIMENTAL|Social SUCCESS|
62558438|NCT03177525|OTHER|Wait List|
62558439|NCT00944060|EXPERIMENTAL|lifestyle intervention|Control group: usual WIC care
62558440|NCT04311294|ACTIVE_COMPARATOR|ANS-6637 Low Dose|200mg ANS-6637 (2 tablets)
62558441|NCT04311294|ACTIVE_COMPARATOR|ANS-6637 High Dose|600mg ANS-6637 (2 tablets)
62558442|NCT04311294|PLACEBO_COMPARATOR|Placebo|0mg matched placebo (2 tablets)
62558443|NCT00452244|EXPERIMENTAL|study arm|Iressa (gefitinib) + simvastatin
62558444|NCT00452244|ACTIVE_COMPARATOR|control arm|Iressa (gefitinib) only
62558445|NCT06060561||Observational|Patients undergo saliva sample collection and complete questionnaires on study. Patients' medical records are reviewed.
62558446|NCT06230445|EXPERIMENTAL|UHealth digital therapeutic group|The patients in this group will use UHealth application to monitor their symptoms and give medical advisement through digital methods.
62558447|NCT06230445|NO_INTERVENTION|Regular follow-up group|The patients in this group will use paper-based follow-up to monitor their symptoms and give medical advisement in outpatient clinic.
62558448|NCT02969382|EXPERIMENTAL|SEP-363856|SEP-363856 capsule (50 mg or 75 mg) once daily
62558449|NCT02969382|PLACEBO_COMPARATOR|Placebo|Placebo capsule once daily
62558450|NCT03365362|EXPERIMENTAL|Long-Term Varenicline|Participants will receive 24 weeks of varenicline at standard doses (0.5 mg/day for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily)
62558451|NCT03365362|ACTIVE_COMPARATOR|Short-Term Varenicline|Participants will receive 12 weeks of varenicline at standard doses (0.5 mg/day for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily), followed by matching placebo twice daily through week 24.
62558452|NCT03365362|EXPERIMENTAL|Directly Observed Therapy|Participants receiving directly observed therapy (DOT) will receive varenicline from opioid treatment program nurses at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.
62558453|NCT03365362|ACTIVE_COMPARATOR|Self Administered Therapy|Patients receiving varenicline self administered therapy (SAT) will self-administer all varenicline doses.
62558454|NCT03908450|ACTIVE_COMPARATOR|Control intervention|Predilatation of coronary de-novo stenosis followed by a SeQuent®Please or SeQuent®Please Neo balloon (paclitaxel 3.0 μg/mm²)
62558455|NCT03908450|EXPERIMENTAL|Experimental intervention|Predilatation of coronary de-novo stenosis followed by a sirolimus coated SeQuent®SCB balloon (sirolimus 4.0 μg/mm²)
62558456|NCT01499095|EXPERIMENTAL|HOE901-U300|
62558457|NCT01499095|ACTIVE_COMPARATOR|Lantus|
62558458|NCT05190445|EXPERIMENTAL|Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel|Patients aged 18 years or older with HER2-positive gastric or GEJ adenocarcinoma who have progressed on prior treatment with a regimen containing a platinum and fluoropyrimidine and a HER2-directed therapy such as trastuzumab and now are candidates for treatment with ramucirumab and paclitaxel
62558459|NCT05190445|EXPERIMENTAL|Cinrebafusp alfa (PRS-343) in combination with tucatinib|Patients aged 18 years or older with HER2 low (IHC 1+ or IHC 2+ without HER2/neu amplification) gastric or GEJ adenocarcinoma who have received at least one prior treatment regimen
62558460|NCT04254848|EXPERIMENTAL|completely edentulous patients with maxillary tori|20 completely edentulous patients with maxillary tori will be recruited for the study. The oral stereognosis will be evaluated by oral stereognostic test which employs manipulation and identification 6 different test pieces when placed in the patients mouth.
62759016|NCT05097508|EXPERIMENTAL|Group R: Patients will receive rocuronium.|Baseline RE and SE will be recorded. Anesthesia will be induced by propofol (dose 2-3 mg/kg) and fentanyl as analgesia (dose 1-2 mg/kg). Tracheal intubation will be facilitated with rocuronium (dose 0.6 mg/kg) after an acceleromyography count of 0. Anesthesia will be maintained with isoflurane in an air-O2 mixture (FiO2 0.6, 2 L/min). Mechanical ventilation will be maintained at a tidal volume of 5-7 ml/kg. Ventilator frequency will be adjusted for maintenance of an ETCO2 of 35-40 mmHg. After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Rocuronium (dose 0.01-0.012 mg/kg/min ) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery.
62759017|NCT00908648|NO_INTERVENTION|1|standard white light
62759018|NCT00908648|EXPERIMENTAL|2|Narrow Band Imaging
61987163|NCT03337100|NO_INTERVENTION|Usual Care|"Usual care/Phase 2 naloxone co-dispensing:~Pharmacies in the usual care/phase 2 naloxone co-dispensing arm will provide usual pharmacy services to patients receiving chronic opioid therapy (no naloxone co-dispensing). After 10 months, they may implement the pharmacy-based naloxone co-dispensing program."
62759019|NCT05036382||Experimental Group|A group that receives an incentive message one month after the start of the experiment
62759020|NCT05036382||Control Group|A group that does not receive an incentive message (for equity, incentive messages will be sent in the last month of the experiment)
62759021|NCT04720716|EXPERIMENTAL|Sintilimab combined with IBI310|
62759022|NCT04720716|ACTIVE_COMPARATOR|Sorafenib|
62558461|NCT04254848|ACTIVE_COMPARATOR|completely edentulous patients without maxillary tori|20 completely edentulous patients without maxillary tori will serve as control group for the study. The oral stereognosis will be evaluated by oral stereognostic test which employs manipulation and identification 6 different test pieces when placed in the patients mouth.
62558462|NCT04785547|EXPERIMENTAL|Blincyto|Blincyto is given over a 28-day cycle. Starting day for patients, who are MRD-positive before HSCT is between day +60 and day +100 and for patients, who become MRD-positive post HSCT it is between day +60 and day +360 post HSCT.
62759023|NCT02653495|EXPERIMENTAL|Influenza vaccine in metabolic syndrome|Influenza vaccine
62759024|NCT02653495|EXPERIMENTAL|Influenza vaccine in healthy controls|Influenza vaccine
62759025|NCT02963987|EXPERIMENTAL|100% Portion Size|100% Food and Beverage Portion Size
62759026|NCT02963987|EXPERIMENTAL|150% Portion Size|150% Food and Beverage Portion Size
62759027|NCT02851407|EXPERIMENTAL|Defibrotide|Defibrotide is administered intravenously at a dose of 25 mg/kg/day in addition to best supportive care on the day before the first day of the conditioning regimen and will continue (for those patients without a VOD diagnosis) for a recommended minimum of 21 days and end no later than Day +30 post HSCT
62759028|NCT02851407|OTHER|Best Supportive Care|Best supportive care alone (without the addition of defibrotide) according to institutional guidelines and patient need, is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner, or diagnosis of VOD, if applicable
62759029|NCT04218357|EXPERIMENTAL|Probenecid|2g probenecid, one pill by mouth once, for one day
61987164|NCT01154621|EXPERIMENTAL|1|Single dose of 750mg of intravenous AZD9742 in healthy elderly volunteers
61987165|NCT01154621|PLACEBO_COMPARATOR|2|Sterile 5% dextrose solution
62759030|NCT04218357|PLACEBO_COMPARATOR|matching placebo|Placebo, one pill by mouth once, for one day
62759031|NCT05753566|EXPERIMENTAL|Rezvilutamide +ADT+ SRT|Rezvilutamide along with ADT for 6 cycles (28 days for each cycle) in combination with salvage radiation therapy (SRT) according to standard of care
62759032|NCT05753566|EXPERIMENTAL|Rezvilutamide +ADT|Rezvilutamide along with ADT for 12 cycles (28 days for each cycle)
62380195|NCT05734703|EXPERIMENTAL|Standard Topical Daily Dose|Only one arm in the study. Subjects treated with the topical daily for 90 days. The comparison will be 'before' and 'after' treatment skin biopsy results.
62558463|NCT02764593|EXPERIMENTAL|Arm 1 (Nivolumab + Cisplatin)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. Cisplatin will be given weekly. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
62380196|NCT06095024||Linked to national data|"Patients will be randomly assigned to be asked to link personal data with national cancer data.~The outcome measure will be the proportion of completed questionnaires"
62759033|NCT02867618|EXPERIMENTAL|Carfilzomib + TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 and carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle.
61987166|NCT06203925||Primary Study|The study will be a cohort study. Adult SGM living in the metropolitan area of Rio de Janeiro who voluntary want to perform HCV testing ordered through a web-based platform will be eligible for this study. SGM will be defined by gay, bisexual and other cisgender MSM, TGW, transgender men, and gender nonbinary/diverse individuals.
61987167|NCT06203925||Ancillary Study|The study will be a cross-sectional study. Adult MSM or TGW attending a presential visit for PrEP (initiation or follow-up) at INI/FIOCRUZ will be eligible for this study.
62759034|NCT00171925|EXPERIMENTAL|Zoledronic acid (ZOL446)|Participants received intravenous infusion of Zoledronic acid every 4 weeks for 48 weeks, and calcium and Vitamin D daily.
62558464|NCT02764593|EXPERIMENTAL|Arm 2 (Nivolumab + High-dose Cisplatin)|Patients will receive Nivolumab via IV administration starting 14 days prior to IMRT, then Day 1 of IMRT and then every 21 days for 6 doses. Cisplatin will be given every 21 days for 3 doses. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
62558465|NCT02764593|EXPERIMENTAL|Arm 3 (Nivolumab + Cetuximab)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. Cetuximab will be given for 7 doses. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
62558466|NCT02764593|EXPERIMENTAL|Arm 4 (Nivolumab + IMRT)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
62759035|NCT00171925|NO_INTERVENTION|Control|No treatment with study medication.
62759036|NCT06366542|ACTIVE_COMPARATOR|Vestibular Rehabilitation Therapy (VRT)|Participants went through conventional VRT in addition to optokinetic exercise training. The VRT exercises were composed of gaze stabilization, head motion, and postural stability exercises with static and dynamic balance exercises. Ten repetitions of each VRT exercise were practiced in the same session for three sets. Moreover, participants were instructed to watch optokinetic stimulation videos. The optokinetic stimulation training was conducted using the following displays (a mobile and TV screen).
62759037|NCT06366542|EXPERIMENTAL|Virtual Reality|The same intervention program for the control group was implemented for participants in the experimental group, with the addition of using the VR split screen in Samsung Gear VR goggles in the last 4 sessions. Using the VR goggles, participants started watching the videos for 30 seconds to 1 minute in the sitting position in the first two sessions, followed by 1-2 minutes in the standing position for the last 2 sessions.
62759038|NCT04072367|OTHER|Active Treatment Group|NeVa Stent Retrievers
62759039|NCT04072367|OTHER|Control Device|Solitare Stent Retrievers
62759040|NCT05869422|PLACEBO_COMPARATOR|Placebo|placebo tablet containing no iron
61987168|NCT02475577|EXPERIMENTAL|Control|Control: Peripherals with HealthInterlink technology will record and transmit data, without intervention. Subject is able to view graphed data, bring the HealthInterlink tablet/smartphone to the physician's office and share data with family/other caregiver.
62759041|NCT05869422|EXPERIMENTAL|Low Dose Iron|low-dose tablet containing 6mg of iron
62558467|NCT06156397|ACTIVE_COMPARATOR|Standard Physiotherapy Exercise Group|The exercise protocol will transition from simple to difficult as a result of literature research, and a standard exercise program will be applied, each session lasting 45 minutes.
62558468|NCT06156397|ACTIVE_COMPARATOR|Telerehabilitation Based Supervised Exercise Group|Telerehabilitation exercise protocol exercises will last 45 minutes in total, transitioning from simple to difficult, and will be implemented with patients via Zoom.
62759042|NCT01255007|EXPERIMENTAL|Post chemotherapy group|The first group consists of patients with colorectal liver metastases who have had treatment with chemotherapy and are now awaiting surgery. This group would have had Multidetector Liver CT (MDCT) imaging prior to the chemotherapy, and will now undergo post chemotherapy MDCT as part of standard clinical care in addition to Gd-EOB-DTPA enhanced liver MRI and Diffusion Weighted MRI (DW-MRI). The MRI will be performed as an additional imaging investigation after obtaining informed consent.
62380197|NCT06095024||Linking to national data, early vs. late questions|"Subset of cohort 1: Patients will be randomly assigned to be asked the question about data linkage at the beginning vs. end of the questionnaire~The outcome measure will be the proportion answering yes in each arm"
62380198|NCT06095024||Different PROM Completion rate|"Patients will be randomised to two different PROM questionnaires~The outcome measure will be the completion rate of the two different questionnaires"
62558469|NCT06156397|ACTIVE_COMPARATOR|Mobile Application Supported Exercise Group|In the Mobile Application-Based exercise group, a virtual clinic will be created for the patients through the Becure application, and the patients will apply a gradual exercise program that will last approximately 45 minutes, determined by the physiotherapist, and the patients will be followed for 6 weeks through this application.
62558470|NCT06582290|EXPERIMENTAL|Autistic|"This will be participants who are waiting for an autism assessment in the Oxfordshire CAMHS Neurodevelopmental Conditions (NDC) pathway. The participant are will complete the OVAAT and an ADOS-2 assessment.~The participant will have a neurodevelopmental assessment using the ADOS-2 is an existing tool that we use to assess autism and a developmental history - this is the current standard assessment process. They will receive feedback from this appointment. The second appointment will be using the OVAAT. This assessment will be video and audio recorded (through Microsoft Teams) so that we can check whether another clinical researcher comes to the same conclusion as the person providing the OVAAT. We will only keep the recording until the 2nd researcher has watched and listened to the recording."
62759043|NCT01255007|EXPERIMENTAL|Pre and Post Chemotherapy Group|The second group consists of patients with colorectal liver metastases who are due to receive neoadjuvant chemotherapy. This group will be imaged prior to receiving and after receiving chemotherapy. This will all be done prior to surgical resection of their colorectal liver metastases.
62759044|NCT02518594|ACTIVE_COMPARATOR|Progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to \< 35 wks
62168164|NCT05359926|EXPERIMENTAL|Early Urethral Catheter Removal|Removal of the urethral catheter in the operating room at the conclusion of surgery
62380199|NCT06095024||Impact of additional PROMS on completion and satisfaction|"Patients will be randomised to either a standard PROM or additional, symptom directed questionnaire~The outcome measure will be the satisfaction rate of patients in each arm"
62380200|NCT02913885|ACTIVE_COMPARATOR|Group 2|curodont repair is a biomimetic regeneration scaffold for remineralization
62380201|NCT02913885|EXPERIMENTAL|Group 1|fluoride varnish inhibit progression of white spot lesion
62759045|NCT02518594|PLACEBO_COMPARATOR|Placebo|placebo softgel capsule, daily from randomization to \< 35 wks
62380202|NCT04711395||Cataract Surgery Group|
62380203|NCT04711395||Non-surgical group|
62380204|NCT01166776||Umbilical cord|To isolate Umbilical cord Wharton's jelly matrix to be used as a scaffold for tissue regenerative applications, including avascular necrosis.
62380205|NCT00813774|ACTIVE_COMPARATOR|Reference|Lyophilized formulation (reference)
62380206|NCT00813774|EXPERIMENTAL|Liquid|Liquid Formulation (test)
62380207|NCT00813774|EXPERIMENTAL|Pre-filled Syringe|Pre-filled syringe (test)
62759046|NCT02518594|ACTIVE_COMPARATOR|Arabin Pessary|placement management from randomization to \< 35 wks
62759047|NCT03589365|OTHER|Preterm group|young adults born preterm will performed an Magnetic resonance imaging (MRI)
62759048|NCT03589365|OTHER|control group|young adults born at term will performed an Magnetic resonance imaging (MRI)
62759049|NCT03294096|EXPERIMENTAL|experimental group|
62759050|NCT03294096|ACTIVE_COMPARATOR|control group|
62759051|NCT05122923|EXPERIMENTAL|Patients with Serious Game|
62759052|NCT05122923|NO_INTERVENTION|Patients without Serious Game|
61987169|NCT02475577|EXPERIMENTAL|Intervention 1|Intervention 1: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver.
61987170|NCT02475577|EXPERIMENTAL|Intervention 2|Intervention 2: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver, and a call will be placed by the nurse research assistant to study subject (on Blue alerts) or study subject's healthcare professional (on Red alerts). The physicians will have access to the subject's data on a web-based program.
62380208|NCT02394366|EXPERIMENTAL|Active|Original Healing Salve (Puremedy, Inc.) including 1x homeopathic dilutions of Calendula, Echinacea, and Sambucus extracts, plus extracts from pine and Balsam fir; acute effects only
62759053|NCT05761678||Transgender people|Whether they have transitioned or not, with or without reassignment surgery.
62759054|NCT00977938|PLACEBO_COMPARATOR|12m DAPT Study Arm|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
61987171|NCT01412021||Humira|Participants with juvenile idiopathic arthritis who received Humira (adalimumab).
61987172|NCT02128399||patients before and after intervetion|
61987173|NCT02937519|EXPERIMENTAL|Melodie group|Induction chrono-chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy
61987174|NCT02937519|OTHER|Routine-Chemotherapy|Induction routine-chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
61987175|NCT00453921|PLACEBO_COMPARATOR|1|Placebo Capsule and Placebo Memory and Attention Training (Placebo as both conditions)
61987176|NCT00453921|ACTIVE_COMPARATOR|2|Methylphenidate capsules and Memory and Attention Training (Active Med/Active therapy)
62759055|NCT00977938|ACTIVE_COMPARATOR|30m DAPT Study Arm|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine treatment in addition to aspirin.
61987177|NCT00453921|ACTIVE_COMPARATOR|3|Methylphenidate capsules and Placebo Memory and Attention Training (Active Med/Placebo therapy)
61987178|NCT00453921|ACTIVE_COMPARATOR|4|Placebo capsules and Memory and Attention Training (Placebo Med/Active therapy)
61987179|NCT03195114||Multimodality Imaging and Biomarkers|Post-TAVR patients who received commercial Medtronic Evolut-R or Evolut PRO bioprosthesis implant and found to have at least mild PVL on 1-month post-TAVR echocardiogram will undergo multimodality imaging and biomarkers evaluation at 1-month and 7-months post-TAVR.
61987180|NCT01236937|ACTIVE_COMPARATOR|Bellows-based breath hold biopsy|CT guided biopsy is preformed with the use a bellows-based breath
62380209|NCT02394366|PLACEBO_COMPARATOR|Control|Original Health Salve olive oil and beeswax base only without homeopathic or herbal extracts; acute effects only
62380210|NCT05761262||PATIENTS WITH SMA TYPE I|
62380211|NCT05761262||PATIENTS WITH SMA TYPE II|
62380212|NCT05761262||PATIENTS WITH SMA TYPE III|
62380213|NCT02276690|EXPERIMENTAL|Dosage of hepcidin|In order to assess iron deficiency, patients randomized in this arm will have dosage of hepcidin by mass spectrometry
62380214|NCT02276690|ACTIVE_COMPARATOR|Usual biomarker dosage|In order to assess iron deficiency, patients randomized in this arm will have usual biomarker dosages (ferritin and transferrin saturation)
62380215|NCT02784184||1 year follow-up group|1 year follow-up group including 6 measurements
62380216|NCT02784184||40 days diaper study subgroup|"Subgroup of the 1 year follow-up group including 15 girls undergoing daily measurement of urinary hormone excretion"
62380217|NCT00906555|NO_INTERVENTION|1|hemodialysis patients with baseline Kt/V between 1.2 and 1.7 (1.2 ≤ Kt/V \< 1.7)
62380218|NCT00906555|EXPERIMENTAL|2|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
62380219|NCT06094686||Ankylosing spondylitis group|Thirty patients with AS according to the modified New York criteria were included in this cross-sectional study.
62380220|NCT06094686||Healthy volunteers|Control group was consisted of 31 healthy volunteers
62380221|NCT04857840|EXPERIMENTAL|Arm A: Investigational Product /Period 1,2 and 3 if any (open label)|Firibastat 1000 mg tablets QD - 12 weeks
62380222|NCT04857840|PLACEBO_COMPARATOR|Arm B: Placebo/Period1 only|Placebo tablets QD 12 weeks in Period 1 only, followed by open label Period 2 and 3 if any.
62380223|NCT04735211||Children whom develop chronic postsurgical pain|Children whom had chronic pain at 3 moths after surgery
62380224|NCT04735211||Children whom not develop chronic postsurgical pain|Children whom not develop chronic pain at 3 moths after surgery
62380225|NCT01468844|EXPERIMENTAL|Minocycline|Participants injected with bevacizumab for three months followed by PRN dosing and 100mg minocycline twice daily for 24 months
62380226|NCT01468844|PLACEBO_COMPARATOR|Placebo|Participants injected with bevacizumab for three months followed by PRN dosing and placebo twice daily for 24 months
62380227|NCT04726436|EXPERIMENTAL|Dextrose 5%|100 mL/ hour of dextrose 5% were given starting 1 hour before operation and continue till approximately middle of surgery by communicating with surgeon to assess the timing and dosing of dextrose solution effect on PONV.
62380228|NCT04726436|EXPERIMENTAL|Dextrose 10%|100 mL/ hour of dextrose 10% were given starting 1 hour before operation and continue till approximately middle of surgery by communicating with surgeon
62380229|NCT04726436|PLACEBO_COMPARATOR|Saline placebo|100 mL/ hour of normal saline were given starting 1 hour before operation and continue till approximately middle of surgery by communicating with surgeon
62558471|NCT06582290|EXPERIMENTAL|Neurotypical|"These participants will be neurotypical young people recruited from the general population of Oxfordshire. They will only receive an OVAAT appointment.~The participants will first complete screening measures to assess their eligibility for the study. If they are still eligible, an OVAAT appointment will be arranged. This will be the same process as group 1. This assessment will be video and audio recorded (through Microsoft Teams) so that we can check whether another clinical researcher comes to the same conclusion as the person providing the OVAAT. We will only keep the recording until the 2nd researcher has watched and listened to the recording."
62558472|NCT03707626||LAD with collaterals with and without wellens sign|
62380230|NCT01738724|EXPERIMENTAL|Dienogest|Dienogest 2mg pills daily during 6 months
62380231|NCT01738724|EXPERIMENTAL|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
62380232|NCT01738724|ACTIVE_COMPARATOR|Desogestrel|Desogestrel 75mcg pills daily during six months
62380233|NCT02353806|EXPERIMENTAL|Pregnant women taking amlodipine|Women already taking amlodipine besylate 5 mg for treatment of chronic hypertension in pregnancy who plan to breastfeed postpartum will be assigned to the single experimental arm.
62558473|NCT03203317|EXPERIMENTAL|Insulin-stimulation|2 h insulin-clamp
62558474|NCT03203317|EXPERIMENTAL|Exercise|10 min of maximal exercise
62558475|NCT05908877||Overweight and Obese Children|Children diagnosed as overweight or obese, defined by the Centers for Disease Control and Prevention (CDC) as a BMI between the 85th and 95th percentile, or above the 95th percentile for the same age and sex, respectively.
62558476|NCT04459936|EXPERIMENTAL|Management by Rheumatologist|Treatment of modifiable risk factors for cardiovascular disease managed by the Rheumatologist according to national guideline.
62558477|NCT04459936|ACTIVE_COMPARATOR|Management by General Practitioner|Treatment of modifiable risk factors for cardiovascular disease managed by the General Practitioner according to national guideline.
62759056|NCT05908409|EXPERIMENTAL|Dose Escalation: IDP-121 0.015 Up to 0.70 mg/kg|"IDP-121 will be administered as a 4-hours i.v. infusion twice a week (3 weeks on, 1 week off) on days 1, 4, 8, 11, 15 and 18 in 28-day treatment (a Cycle) (Table 4). A minimum interval of 3 days and no more than 5 days between dosing is allowed.~Patients can receive IDP-121 until disease progression, unacceptable toxicity or any other discontinuation criteria are met, or for a maximum treatment period of 1 year, whichever occurs first. Patients at the RP2D may enter the expansion phase."
62759057|NCT05908409|EXPERIMENTAL|Expansion Phase: IDP-121 at RP2D|Additional 17 patients will be enrolled for treatment at the RP2D level to further study safety and evaluate efficacy. DP-121 will be administered as a 4-hours i.v. infusion twice a week (3 weeks on, 1 week off) on days 1, 4, 8, 11, 15 and 18 in 28-day treatment Patients can receive IDP-121 until disease progression, unacceptable toxicity or any other discontinuation criteria are met, or for a maximum treatment period of 1 year, whichever occurs first.
62759058|NCT04023357|EXPERIMENTAL|PEEK|"PEEKs (polyetheretherketones) are presented as alternative materials to metal and glass ceramics,1 Their elastic modulus comparable to those of cortical bone and dentin so the polymer could exhibit good stress distribution. Also they have high fracture resistance, and low abrasion to the antagonist enamel.~Yet clinical studies are needed to evaluate their clinical performance."
62759059|NCT04023357|ACTIVE_COMPARATOR|Emax|lithium disilicate glass-ceramic which is etchable and proved to have good success rate if used for Endocrowns
62759060|NCT04102553|EXPERIMENTAL|F-18-PSMA-1007|Patients will receive F-18-PSMA-1007 PET/CT first, followed by F-18-Fluorocholine PET/CT.
62759061|NCT04102553|ACTIVE_COMPARATOR|F-18-Fluorocholine|Patients will receive F-18-Fluorocholine PET/CT first, followed by F-18-PSMA-1007 PET/CT.
62759062|NCT05446792|ACTIVE_COMPARATOR|Pelvic floor muscle training (PFMT)|For the intervention of the PFMT group, which is non-invasive, a physical therapist experienced in this type of training will carry out the sessions, which will be individualized, in a specific room for care ocused on pelvic physiotherapy, with a stretcher, air conditioning and a lock on the door, for the patient to feel safe.
62759063|NCT05446792|EXPERIMENTAL|Pilates exercises (PE)|For the intervention of the PE group, in the first week the protocol will be used to familiarize the participants with the exercises, where the correct execution of the movements will be demonstrated and each principle of the method will be explained: concentration, centralization, precision, breathing, control and fluidity; and for familiarization with the correct voluntary contraction of the PFM. Participants in the PE group will be instructed and reminded to voluntarily contract the PFM during each repetition of the Pilates strengthening exercises. During the stretching exercises, the participant will be instructed not to perform the contraction. The springs will be changed according to the evolution of the participants, by replacing them with a spring of greater resistance. Basic equipment such as: Cadillac Trapezio, Combo Chair, Universal Reformer, Ladder Barrel and Wall Unit will be used.
62759064|NCT01605318|EXPERIMENTAL|Phase1: Dose-escalation Phase: Labetuzumab Govitecan (LG) Once Weekly Dosing|Participants will receive 8, 12 and 16 mg/dose of LG once weekly dosing until unacceptable toxicity, progressive disease or death whichever occurs first, for each 21-day cycle for up to up to 8 cycles, with a contingency to examine intermediate dose levels of 10 or 14 mg/kg, or if necessary to a lower dose level of 6 mg/kg.
62759065|NCT01605318|EXPERIMENTAL|Phase1: Dose-escalation Phase: LG Twice Weekly Dosing|Participants will receive 6 and 9 mg/kg per dose twice weekly dose of LG until unacceptable toxicity, progressive disease or death whichever occurs first, for each 21-day cycle for up to up to 8 cycles. A lower dose level of 4 mg/kg may be added if \> 1 out of 3 or 2 out of 6 participants are unable to tolerate all 4 doses without dose delay or reduction.
62759066|NCT01605318|EXPERIMENTAL|Phase 2: Dose-expansion Phase: LG Once or Twice Weekly Dosing|Participants will receive selected doses of LG once or twice weekly until unacceptable toxicity, progressive disease or death whichever occurs first, for each 21-day cycle for up to 8 cycles.
62759067|NCT00276094|EXPERIMENTAL|Ospemifene 30 mg/day and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of ospemifene 30 mg each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
62380234|NCT01970540|EXPERIMENTAL|lurbinectedin (PM01183) / doxorubicin|
62380235|NCT01873196|EXPERIMENTAL|Receive extra oil|This arm will receive enough oil to prepare the CSB they receive in the newly recommended proportion of 100g CSB: 30g oil. They will receive education and instructions on the new method of preparation.
62380236|NCT01873196|NO_INTERVENTION|Control-No extra oil received|This group will continue to receive only 1L of oil with their CSB has they already have been. They also will not receive any new education.
62380237|NCT01873196|EXPERIMENTAL|Receives behavior changed messages on CSB package|Group receiving CSB repackaged into 2kg packages with messages on package on how to prepare. Only in Phase II.
62380238|NCT01873196|NO_INTERVENTION|Control-No repackaged CSB|
62380239|NCT02411773|ACTIVE_COMPARATOR|Exercise Training plus Sodium Bicarbonate|Subjects with CKD will undergo exercise training on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each exercise session three times a week.
62558478|NCT01258140|ACTIVE_COMPARATOR|1|Patients examined with normal-dose Computed tomography pulmonary angiography
62558479|NCT01258140|ACTIVE_COMPARATOR|2|Patients examined with low-dose Computed tomography pulmonary angiography
62558480|NCT05491902||Early onset mild to moderate AD|Patients aged 50 to 69
62558481|NCT05491902||Late onset mild to moderate AD|Patients aged 70 and above
62558482|NCT05491902||Older Healthy Volunteer|Aged 50 to 69
62380240|NCT02411773|ACTIVE_COMPARATOR|Exercise Training plus Placebo|Subjects with CKD will undergo exercise training on a stationary bicycle,for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.
62380241|NCT02411773|ACTIVE_COMPARATOR|Control to Exercise (Stretching) plus Sodium Bicarbonate|Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each stretching session three times a week.
62558483|NCT05491902||Younger Healthy Volunteer|Aged 18 - 25
62558484|NCT05204667|EXPERIMENTAL|Methocarbamol 380 mg/paracetamol 300 mg (4 times/day)|Patients treated with two oral tablets of methocarbamol 380 mg/paracetamol 300 mg 4 times/day up to 7 days (i.e., every 6 hours±1 hour).
62558485|NCT05204667|ACTIVE_COMPARATOR|Methocarbamol 380 mg/paracetamol 300 mg (6 times/day)|Patients treated with two oral tablets of methocarbamol 380 mg/paracetamol 300 mg 6 times/day up to 7 days (i.e., every 4 hours±1 hour).
62558486|NCT05758870||Research Group|surgical stabilization of low rib fracures by internal fixation
62558487|NCT05758870||Controls Group|conservative treatment of low rib fractures
62558488|NCT04952961|EXPERIMENTAL|Single Arm Intervention|Participants will be shown how to perform vulval self-examination in a face-to-face intervention and provided with an information leaflet. They will be sent reminders to self-examine each month.
62558489|NCT04527510||Conventional-reading|
62558490|NCT04527510||Second-reading|
62558491|NCT04527510||Concurrent-reading|
62558492|NCT04527510||Tow-view-reading|
62558493|NCT04527510||Handheld US-screening|
62558494|NCT01298232|NO_INTERVENTION|EMAT-guided therapy|electromechanical activation time (EMAT, obtain by phonocardiogram, Audicor, USA)
62558495|NCT01298232|NO_INTERVENTION|Symptomatic-guided therapy|HF therapy guided by clinical symptoms
62558496|NCT01022840|PLACEBO_COMPARATOR|Placebo|Placebo as saline solution
62558497|NCT01022840|EXPERIMENTAL|Low dose|S-Ketamine
62558498|NCT01022840|ACTIVE_COMPARATOR|High dose|
62759068|NCT00276094|EXPERIMENTAL|Ospemifene 60 mg/day and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of ospemifene 60 mg each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
62759069|NCT00276094|PLACEBO_COMPARATOR|Placebo tablets and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of placebo each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
62759070|NCT04931290|EXPERIMENTAL|supracapsular delivery of plate of valve|ncision of the perilimbal superior temporal conjunctiva with separation of the conjunctiva from the Tenon's capsule till reaching the encapsulated valve plate. Incision of the capsule in a z pattern will be done then the plate is dissected from the tissues and delivered out of the capsule through the opening to the subconjunctival space.The mobility of AGV and its tube will be evaluated and refixation of the plate will be done if needed. The plate will be covered with ologen implant sizing 12mm width and 1 mm thickness. The conjunctiva will be closed by 10/0 nylon sutures.
62759071|NCT06008769|EXPERIMENTAL|12 Week Manualized Cognitive-Behavioral Therapy Intervention|Participants will receive a once-per-week, 12 week manualized cognitive-behavioral therapy intervention.
62759072|NCT06350487|EXPERIMENTAL|SGLT2 inhibitor group|SGLT2 inhibitor group will receive Enavogliflozin (0.3mg oral tablet once daily).
62759073|NCT06350487|NO_INTERVENTION|Control group|Control group will not receive any SGLT2 inhibitors during the study period.
62380242|NCT02411773|PLACEBO_COMPARATOR|Control to Exercise (Stretching) plus Placebo|Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.
62380243|NCT02411773|NO_INTERVENTION|Healthy Control|Healthy subjects without CKD will not receive any interventions.
62380244|NCT04885075|OTHER|Intravenous Diazepam|Intravenous diazepam (0.2mg/kg/dose) single dose stat
62380245|NCT04885075|OTHER|Intranasal Midazolam|Intranasal midazolam (0.2mg/kg/dose) single dose stat
62380246|NCT01925014|EXPERIMENTAL|Low-dose CT|Diagnostic CT with low-dose radiation
62380247|NCT01925014|ACTIVE_COMPARATOR|Standard-dose CT|Diagnostic CT with standard-dose radiation
62380248|NCT02048774|ACTIVE_COMPARATOR|High Social Position|The investigators will randomly assign a participant to a higher social position.
62380249|NCT02048774|EXPERIMENTAL|Low Social Position|The investigators will randomly assign a participant to a lower social position.
62380250|NCT02670187|EXPERIMENTAL|GLS-5300|GLS-5300 at 0.67 mg DNA/dose
62380251|NCT02670187|EXPERIMENTAL|GLS-5300 at 2 mg DNA/dose|GLS-5300 at 2 mg DNA/dose
62380252|NCT02670187|EXPERIMENTAL|GLS-5300 at 6 mg DNA/dose|GLS-5300 at 6 mg DNA/dose
62380253|NCT05292456||RA, SLE, and vasculitis patients who have just started glucocorticoid treatment|
62380254|NCT05292456||RA, SLE and vasculitis patients receiving glucocorticoid treatment for the last 2 years|
62380255|NCT04673630|EXPERIMENTAL|Tezepelumab|Tezepelumab subcutaneous injection
62380256|NCT02330640|EXPERIMENTAL|ticagrelor|90mg Bid for 30days after first dose
62380257|NCT02330640|ACTIVE_COMPARATOR|clopidogrel|75mg Qd for 30days first dose
62380258|NCT02330640|OTHER|asprin|100mg Qd all patients will be given asprin 100mg Qd within 24hours after CABG
62380259|NCT03944811|ACTIVE_COMPARATOR|Transcrestal sinus floor elevation using Summers technique|
62380260|NCT03944811|EXPERIMENTAL|Transcrestal sinus floor elevation using piezoelectric surgery|
62380261|NCT03432208|ACTIVE_COMPARATOR|ESOPHAGO-GASTRO-DUODENOSCOPY (EGD)|GI consult Procedure performed is EGD
62380262|NCT03432208|EXPERIMENTAL|ENDOSCOPIC ULTRASOUND (EUS)|GI consult Procedure performed is EUS
62380263|NCT04486404||Group 1|Online survery to healtcare personnel and other professionals in the front-line from Col, Bra and Ec.
62380264|NCT04486404||Group 2|Online survery to healtcare personnel and other professionals in the front-line from Col, Bra, Ch and Ec.
62759074|NCT01826955||Open gastrectomy|patient who undergoing open gastrectomy
62759075|NCT01826955||laparoscopic gastrectomy|patient who undergoing laparoscopic gastrectomy
62759076|NCT00058526|EXPERIMENTAL|Cohort 1|Six doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
62759077|NCT00058526|EXPERIMENTAL|Cohort 2|Six doses of dHER2 (100 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
62759078|NCT00058526|EXPERIMENTAL|Cohort 3|Six doses of dHER2 (500 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.
62759079|NCT00058526|EXPERIMENTAL|Cohort 4|Three doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 4, and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.
62759080|NCT02703870|ACTIVE_COMPARATOR|Verum tDCS|Verum group receiving complete treatment of tDCS
62759081|NCT02703870|SHAM_COMPARATOR|sham tDCS|Sham group receiving sham tDCS
62759082|NCT02703870|ACTIVE_COMPARATOR|real VRT|Real Vision Restoration Training
62759083|NCT04508465||OMEGA|Patients who have undergone major emergency abdominal surgery including the stomach, small or large bowel, or rectum for conditions such as perforation, ischemia, abdominal abscess, bleeding or obstruction.
62759084|NCT01443637||Coronary CT Angiography (CCTA)|Patients included in the CONFIRM Registry are those that have previously undergone clinically-indicated CCTA as part of their standard of care.
62759085|NCT02109523|EXPERIMENTAL|Intervention|Patients enrolled in the intervention arm will receive two educational sessions on the importance of medication and barriers to adherence
62759086|NCT02109523|ACTIVE_COMPARATOR|Usual Care|The usual care group received routine discharge counseling performed by the cardiologists and nurses.
62759087|NCT05958823|EXPERIMENTAL|Group S (Serratus anterior plane block)|The patient who underwent open heart surgery will be taken to the cardiovascular surgery intensive care unit after the surgical procedure. Necessary preparations will be made to perform serratus anterior plane block (SAP). After ensuring the hygiene of the anterior chest wall, it is advanced with an 8 cm long peripheral block needle under ultrasound guidance. SAP block is a local anesthetic injection procedure applied superficially or deeply to the serratus anterior muscle and specifically targeting the lateral cutaneous and muscular branches of the intercostal nerves. The long thoracic nerve and the thoracodorsal nerve are located in the fascial plane on the surface of the serratus anterior muscle and can be blocked. The serratus anterior block can be performed anywhere between the anterior and posterior axillary lines and the 2nd and 7th ribs.
62759088|NCT05958823|EXPERIMENTAL|Group P ( PECS I-II)|The patient who underwent open heart surgery will be taken to the postoperative intensive care unit. Preparation for the PECS block will be made, and after the anterior chest wall hygiene is ensured, an 8 cm long peripheral block needle will be advanced under ultrasound guidance. PECS II block is a combination of PECS I and subpectoral local anesthetic injection targeting the lateral cutaneous branches of the intercostal nerves, long thoracic and thoracodorsal nerves. To perform the PECS I block, the ultrasound probe is placed in the midclavicular line and in the parasagittal plane, and the pectoralis major-minor, axillary vessels and pleura are visualized. After identifying the second and third ribs by sliding the ultrasound probe caudally, the lower end will be rotated towards the axilla to make the probe parallel to the deltapectoral groove.
62759089|NCT01911312|EXPERIMENTAL|Intervention|
62759090|NCT01911312|ACTIVE_COMPARATOR|Body Temperature Control|Stimulation performed with body temperature control
62759091|NCT02980744|EXPERIMENTAL|STUFFS|Participants will undergo a sedentary behaviour intervention which includes breaking up prolonged sitting by standing and walking around for 5 minutes every half-hour, standing and walking during television commercial breaks, doing 2 sets of 10 sit-to-stand transitions three times per day, and going to the kitchen to grab some drink every hour. A wrist-worn Misfit activity monitor - a motivational tool that will track adherence to the intervention will be used throughout the intervention period (i.e. 8 weeks). This device which is commercially available provides activity feedback for the user in real time.
62759092|NCT00070252|EXPERIMENTAL|Treatment (tipifarnib, capecitabine, docetaxel)|"Phase Ib: Patients receive oral tipifarnib twice daily and oral capecitabine twice daily on days 1-14 and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Phase II: Patients receive oral tipifarnib twice daily for 6 days. Beginning at least 48 hours after completion of the initial dose of tipifarnib, patients receive treatment as in phase Ib for up to 6 courses at the MTD of capecitabine."
62759093|NCT03283098|PLACEBO_COMPARATOR|Placebo|Intravenous (IV) administration of placebo three times a week (TIW) for 4 weeks for a total of 12 doses. Participants were followed for an additional 4 weeks.
62759094|NCT03283098|EXPERIMENTAL|Etelcalcetide|5 mg intravenous (IV) dose of etelcalcetide three times a week (TIW) for 4 weeks for a total of 12 doses. Participants were followed for an additional 4 weeks.
62759095|NCT00976885||Subjects with normal health|
62759096|NCT00976885||Subjects with Stroke|
62759097|NCT03252093|EXPERIMENTAL|Angiotensin-(1-7)|Intervention: Drug: 200 mcg/kg/day injected subcutaneously once daily for 21 days
62759098|NCT03252093|PLACEBO_COMPARATOR|Placebo for Angiotensin-(1-7)|Intervention: Placebo for Angiotensin-(1-7) injected subcutaneously once daily for 21 days
62759099|NCT01309906|EXPERIMENTAL|Investigational lens|Bausch \& Lomb investigational silicone hydrogel lens
62759100|NCT01309906|ACTIVE_COMPARATOR|Air Optix Aqua lens|Ciba Vision Air Optix Aqua contact lens
62759101|NCT02228343|EXPERIMENTAL|Ayurveda|Ayurvedic therapy
62759102|NCT01065948|EXPERIMENTAL|Patients|
62380265|NCT04742764|ACTIVE_COMPARATOR|Group A|Patients randomized to standard medical therapy.
62759103|NCT01095653|EXPERIMENTAL|Group 1|
62759104|NCT01095653|EXPERIMENTAL|Group 2|
62759105|NCT01095653|EXPERIMENTAL|Group 3|
62759106|NCT04688541|ACTIVE_COMPARATOR|First standard Foley catheter than Optitip catheter|"Each participant is given the 2 trial catheters for successive periods of 4 weeks (+ up to 7 days) for each treatment period:~Study period 1 = Standard Foley catheter Study period 2 = Optitip catheter"
62759107|NCT04688541|ACTIVE_COMPARATOR|First Optitip catheter than standard Foley catheter|"Each participant is given the 2 trial catheters for successive periods of 4 weeks (+ up to 7 days) for each treatment period:~Study period 1 = Optitip catheter Study period 2 = Standard Foley catheter"
62759108|NCT02093988|EXPERIMENTAL|Topical and Intravenous TXA|
61987181|NCT01236937|NO_INTERVENTION|No Bellows-based breath hold.|CT guided biopsy is preformed without the use a bellows-based breath
62759109|NCT02093988|ACTIVE_COMPARATOR|Intravenous TXA only|
62759110|NCT02549352|EXPERIMENTAL|LEO 43204 gel|Treatment once daily for 3 days
62759111|NCT02549352|PLACEBO_COMPARATOR|Vehicle gel|Treatment once daily for 3 days
62759112|NCT04022681||Non-specific liver disease|Patients who were categorised as having a non-specific liver disease in the original BALLETS study.
62759113|NCT06180330|EXPERIMENTAL|Aquatic baby class|8 weeks program of aquatic exercises for infants
62759114|NCT06180330|NO_INTERVENTION|No intervention|No intervention
62759115|NCT04829305|EXPERIMENTAL|Low dose of SHR2285|The subjects will receive a single dose of SHR2285 (cohort 1).
62759116|NCT04829305|EXPERIMENTAL|Medium dose of SHR2285|The subjects will receive a single dose of SHR2285 (cohort 2).
62759117|NCT04829305|EXPERIMENTAL|High dose of SHR2285|The subjects will receive a single dose of SHR2285 (cohort 3).
62759118|NCT05111106||Non-Pathology Eyes|Cataract Surgery with implantation of Symfony IOL in eyes without pre-existing pathology..
62759119|NCT05111106||Glaucoma Eyes|Cataract Surgery with implantation of Symfony IOL with pre-existing glaucoma.
62759120|NCT05111106||Retinopathy Eyes|Cataract Surgery with implantation of Symfony IOL in eyes with pre-existing retinal pathology..
62759121|NCT06200922|EXPERIMENTAL|Synchronous Group|Will receive guidance and perform a real-time guided pelvic physiotherapy protocol through online physiotherapy by the physiotherapist.
62759122|NCT06200922|EXPERIMENTAL|Asynchronous Group|Will receive guidance and perform a pelvic physiotherapy protocol after the evaluation, without the real-time monitoring by the physical therapist
62759123|NCT06200922|ACTIVE_COMPARATOR|Face-to-face group|Will receive guidelines and will perform a pelvic physiotherapy protocol oriented in person by the physical therapist.
62759124|NCT03958591|EXPERIMENTAL|Intensive-de-escalation group with intelligent management|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin will be applied. Then the oral hypoglycemic therapies will be prescribed. Wearable devices and smart apps will be used to manage and follow-up patients.
62759125|NCT03958591|EXPERIMENTAL|Intensive-de-escalation group without intelligent management|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin will be applied. Then the oral hypoglycemic therapies will be prescribed. Traditional ways such as telephone contact will be used to follow-up patients.
62759126|NCT03958591|ACTIVE_COMPARATOR|Traditionally upgrading group|The combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks and thereafter the oral hypoglycemic therapies will be applied. Traditional ways will be used to follow-up patients.
62759127|NCT05785260||Group 1|All patients are assessed. The neuropsychologist assessed global cognitive status and disposition to Mindfulness. Engineered bands for multi-parameter heart rate monitoring were delivered.From the time of delivery, for 9 consecutive days the patient received a reminder via WhatsApp at the most convenient time slot. At this point, he would wear the supplied chest strap by wetting it appropriately so that it adhered perfectly to the skin. The heart rate App was accessed via Bluetooth and recorded the basal heart rate for about 10 minutes.Then the Mindfulness session was carried out. At the end of 9 days, the completed input tests plus the heart rate measurement were sent on day 10, except for the Mindfulness session, which was not scheduled. After two weeks, the measurement was repeated with the same procedure.
62759128|NCT05785260||Group 2|Patients in this group met the inclusion criteria and did not take any measurements. They underwent only the neuropsychological evaluation
62759129|NCT06052111|EXPERIMENTAL|Group F (fentanyl group)|Fentanyl (1 μg/kg) was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose followed by continuous infusion at a rate of (1μg/kg/hr) after intubation. It was stopped 10 minutes before the end of surgery.
62759130|NCT06052111|EXPERIMENTAL|Group D (dexmedetomidine group)|The patients were received a loading dose of dexmedetomidine (1 μg/kg) intravenously over 15 minutes before induction of anesthesia, followed by continuous infusion at a rate of (0.6 μg/ kg/ hr) after intubation and was stopped 10 minutes before the end of surgery.
62759131|NCT04159272|EXPERIMENTAL|Mindfulness Training|The MT programme adheres to a standardized protocol developed from MBSR (Kabat-Zinn, 1990) and MBCT (Segal et al., 2012) manuals and is adjusted to an adolescent population. Adjustments are based on our ample experience with mindfulness and adolescents in different contexts. Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience. This accepting attitude changes the person's relationship with the experience, being a detached and non-reactive orientation. Participants learn to recognize entanglement with one's thoughts and emotions and there is an increased understanding of one's spontaneous reactions. If adolescents adopt these skills, their negative emotions and cognitions will no longer be reinforced, creating the opportunity to deal with problematic thoughts and feelings.
61987182|NCT04287777|EXPERIMENTAL|Mupirocin gel|Topical administration of Mupirocin gel 20 mg/g BID for 7 days
62759132|NCT04159272|NO_INTERVENTION|Control|Participants follow their regular course curriculum.
62759133|NCT04983836|EXPERIMENTAL|Serratus Block|
62759134|NCT04983836|OTHER|Paravertebral Block|
62759135|NCT01465750||Ovarian Cancer|
62759136|NCT02282371|EXPERIMENTAL|Cetuximab + BYL719 + IMRT|Cetuximab loading dose, 400 mg/m2 intravenously (IV). IMRT, 1 fraction/day, up to total of approximately 70 Gy, over approximately 33 treatment days Cetuximab 250 mg/m2 weekly IV X 7 weeks Daily BYL719, according to dose escalation scheme followup clinic visits every 3 months for 2 years,every 6 months for the next 3 years, and annually thereafter.
62759137|NCT02295007|OTHER|text message|all families will receive text messages to which they can respond to report symptoms
62759138|NCT04926090|EXPERIMENTAL|Emotional Support Plan - Clinician Guided (ESP-C) + (Bi)Weekly Monitoring|This will involve brief assessment visits throughout the fall semester, without prompting to use the ESP-C. Visits will be weekly for the first 6 weeks and then biweekly for the remaining 9 weeks of the term.
62759139|NCT04926090|EXPERIMENTAL|Emotional Support Plan - Clinician Guided (ESP-C) + 4x Daily Monitoring|Participants in this arm will be prompted on their phones 4x/day, to report on activities, mood, suicidal ideation, distress level and ESP use since the last prompt. They will also participate in brief assessment visits conducted weekly for the first 6 weeks and then biweekly for the remaining 9 weeks of the term.
62380266|NCT04742764|ACTIVE_COMPARATOR|Group B|Patients randomized to cytokine removal therapy with Cytosorb, with the adsorber device changed in every 12 hours.
62759140|NCT04926090|EXPERIMENTAL|Emotional Support Plan - Self Guided (ESP-S) + 4x Daily Monitoring|Participants in this arm will be prompted on their phones 4x/day, to report on activities, mood, suicidal ideation, distress level and ESP use since the last prompt. They will be asked to complete questionnaires weekly for the first 6 weeks and then biweekly for the remaining 9 weeks of the term.
62759141|NCT00645879|EXPERIMENTAL|OKG, Glutamine, and Disodium Citrate|Ornithine Alpha Ketoglutarate for 4 weeks, followed by 2 week washout period. 4 weeks Glutamine, followed by 2 week washout period. 4 weeks Disodium Citrate, followed by 2 to 12 week washout period. Then continue an additional 30 weeks on Disodium Citrate (drug producing the best increment in plasma glutamine levels).
62759142|NCT00481325|EXPERIMENTAL|A1|
62759143|NCT00481325|ACTIVE_COMPARATOR|A2|
62759144|NCT00481325|PLACEBO_COMPARATOR|A3|
62759145|NCT02156817||Late Preterm Infants (LPT)|34 weeks and 0-6 days gestational age
62380267|NCT04742764|ACTIVE_COMPARATOR|Group C|Patients randomized to cytokine removal therapy with Cytosorb, with the adsorber device changed in every 24 hours.
62759146|NCT02156817||Moderate preterm infants (MPT)|32 weeks and 0-6 days gestational age
62759147|NCT04583202|PLACEBO_COMPARATOR|Placebo exposure|All patients undergo 2 placebo exposures
62759148|NCT04583202|EXPERIMENTAL|Birch Pollen Exposure|All patients undergo 4 allergen exposures
62759149|NCT00393302||1 & 2|"1. Retrospective chart review: HIV testing rates~2. Prospective cohort group: HIV testing rates"
62759150|NCT05403892||Participant|"The participants must be teenage basketball players (12-17 years old).~The exclusion criteria are:~* have suffered in the last 3 months of lower limb musculoskeletal disorders such as pain for more than 7 days (ankle distortion outcomes, leg/foot fractures, plantar heel pain, metatarsalgias, etc);~* athletes who have undergone surgery on their lower limb."
62759151|NCT01342965|EXPERIMENTAL|Erlotinib|Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity.
62759152|NCT01342965|ACTIVE_COMPARATOR|Chemotherapy|Participants received gemcitabine 1250 mg/m\^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m\^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first.
62759153|NCT03884192|EXPERIMENTAL|Sintilimab Arm|Sintilimab consolidation therapy
62759154|NCT03884192|NO_INTERVENTION|Observation Arm|Observation
61987183|NCT04287777|ACTIVE_COMPARATOR|Mupirocin ointment|Topical administration of Mupirocin ointment 20mg/g TID for 7 days.
61987184|NCT04287777|PLACEBO_COMPARATOR|Placebo|Topical administration of Placebo (ointment) TID for 7 days
62759155|NCT04316741|EXPERIMENTAL|Brief Intervention+Health Coaching|Brief intervention with social-media delivered health coaching
62759156|NCT04316741|NO_INTERVENTION|Control|Enhanced usual care brochure plus attention control with social media messaging
62759157|NCT03504813|EXPERIMENTAL|Urinary Incontinence|"The involuntary loss of urine through the urethra, objectively demonstrable and constituting for the person who suffers it a social and hygienic problem.~In this arm, participants will receive the following interventions: physical activities program, training of the pelvic floor and counseling about occupational performance"
62558499|NCT05744167|EXPERIMENTAL|Blood flow restriction training (BFRT)|Participants will engage in a supervised 12-week lower extremity resistance exercise program, 2 times per week. BFRT will be at an intensity of 40% of 1RM with an occlusive cuff placed at the proximal end of both lower extremities to restrict the return of blood flow. The cuff will be inflated to 50% of the limb occlusion pressure in the first week, which will be increased with 10% every week during the first 4 weeks to reach a maximum of 80% limb occlusion pressure on week 4 that will be kept for the remaining 9 weeks of the program. Each exercise will be performed for 4 sets of 12 repetitions with a 30-second rest period between sets and 3 minutes rest between exercises without occlusion.
62759158|NCT03504813|EXPERIMENTAL|Insomnia|"A condition characterized by an unsatisfactory amount or quality of sleep which persists for a considerable period. This disorder includes difficulties for the falling and/or staying asleep and early awakening in the final phase of sleep.~In this arm, participants will receive the following interventions: physical activities program, relaxation training and counseling about occupational performance."
62759159|NCT03504813|EXPERIMENTAL|Risk of falls|"Involuntary events that cause people to lose balance and find themselves on the ground or other firm surfaces. The factor of falls can be intrinsic (related to the person) or extrinsic (derived from the activity or environment of the individual).~In this arm, participants will receive the following interventions: physical activities program, and counseling about occupational performance"
62759160|NCT02796872|PLACEBO_COMPARATOR|mother's breast milk.|mother's breast milk.
62759161|NCT02796872|ACTIVE_COMPARATOR|other GOS|Commercial infant formula containing 4% w/w FOS:GOS (1:3)
62759162|NCT02796872|EXPERIMENTAL|B-GOS 3%|Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)
62759163|NCT02796872|EXPERIMENTAL|B-GOS 2%|Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)
62759164|NCT02306304|OTHER|Israeli Arab men|Single arm study. The arm includes all enrolled patients screened by duplex ultra sound for abdominal aortic aneurysms.
62759165|NCT05393414|EXPERIMENTAL|Opioid Sparing Multimodal Regimen|After surgery, the experimental group will receive a combination of ketorolac 30 mg intravenous (IV) every six hours for patients younger than 65 years old or ketorolac 15mg IV every six hours for those older than 65 years old; and acetaminophen 1 gram by mouth (PO) every six hours up to 72 hours
62759166|NCT05393414|EXPERIMENTAL|Opioid Based Multimodal Regimen|After surgery, the control group will receive a combination of morphine 0.1 mg/kg IV every six hours and oxycodone combined with acetaminophen (2.5 mg / 325 mg) two tabs PO every six hours up to 72 hours
62759167|NCT01810848|ACTIVE_COMPARATOR|Hylan G-F 20|Patients will receive a single injection of hylan G-F 20 6ml into affected knee. Injections will be performed under fluoroscopic guidance.
62759168|NCT01810848|SHAM_COMPARATOR|Control|Patients will receive a single sham puncture into the affected knee. Sham punctures will be identical to the treatment injections in all other respects, including duration, use of sterile drapes, sterile preparation, and dimming of the lights. This procedure will include a 22g needle stick through the skin without violating the joint capsule or performing arthrocentesis.
62759169|NCT05173428|EXPERIMENTAL|Interventional Gruop|Online motivational interviews based on the transtheoretic model with the intervention group will be held via zoom. Data collection forms will be applied to the intervention group at the first interview, at the 3rd month as an interim monitoring, and at the 6th month as the final monitoring.
62759170|NCT05173428|NO_INTERVENTION|Control Gruop|No intervention will be made to the control group, and data collection forms will be applied at the first interview and 6 months after the first interview.
62759171|NCT01945736||Cohort 1|\> or = 90 days to \< 2 years on enteral methadone. Dose schedule is per routine medical care.
61987185|NCT03344042|ACTIVE_COMPARATOR|Fentanyl|100mcg Fentanyl administered into epidural space during regular contractions before cervical dilation
62759172|NCT01945736||Cohort 2|2 years to \< 6 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age \> or = to 95 percentile.
62380268|NCT02650193|EXPERIMENTAL|HSP-130|"Cycle 0:~Regimen A: HSP 130, 3 mg, single SC injection in the deltoid region (n = 6) Regimen B: HSP 130, 6 mg, single SC injection in the deltoid region (n = 6)~Cycles 1-4:~Regimen B (n = 12): HSP 130, 6 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4.~Potential Regimen A (n = 12): 3 mg with background chemotherapy: Inclusion of this cohort will be based on assessment of comparability between Regimens A and B in Cycle 0 for ANC and CD34+ as defined above. If performed, this regimen will be HSP 130, 3 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4, as appropriate.~Conditional Regimen C (12 mg):This cohort will not be initiated until data from cycle 0 for 3 mg and 6 mg and Cycles 1-4 for 6 mg has been reviewed and analyzed."
62380269|NCT04106011||Patients with Neuropathic Pain|
62759173|NCT01945736||Cohort 3|6 years to \< 18 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age \> or = to 95 percentile.
62759174|NCT01663428|EXPERIMENTAL|Sup-ER Splint|Experimental group that will receive Sup-ER splint.
62759175|NCT01663428|ACTIVE_COMPARATOR|Control (Currently accepted treatment)|Control group that will receive the currently accepted treatment.
62380270|NCT00443365|NO_INTERVENTION|1|Coronary Artery Bypass Grafting with no Mitral Valve intervention
62759176|NCT01294462|EXPERIMENTAL|1|Ticagrelor (AZD6140)
62380271|NCT00443365|ACTIVE_COMPARATOR|2|Coronary Artery Bypass Grafting + Mitral Annuloplasty
62380272|NCT02358928|OTHER|Low calorie diet|Calorie-restricted diet is composed of 50% carbohydrate, 15-20% protein and 30-35% fat.
62759177|NCT01294462|ACTIVE_COMPARATOR|2|Clopidogrel
62759178|NCT01697462||Cohort|
62759179|NCT01346111||generation cohort|Included 5 hospitals from Buenos Aires, Argentina
62759180|NCT02729610|ACTIVE_COMPARATOR|DLT group|In this arm, patient will be intubated with a double lumen endotracheal tube
62759181|NCT02729610|EXPERIMENTAL|BB group|In this arm, patient will be intubated with an endobronchial blocker
62759182|NCT05732584|EXPERIMENTAL|structured family voice stimulation|Patients in this group were provided with structured family voice stimulation
62759183|NCT05732584|EXPERIMENTAL|unstructured family voice stimulation|Patients in this group were provided with unstructured family voice stimulation
62759184|NCT05732584|NO_INTERVENTION|Control group|Patients in this group will receive no specific voice stimulation
62759185|NCT03720665|ACTIVE_COMPARATOR|Caffeine group|"* 200mg caffeine tablet~* transcranial alternating current stimulation (140 Hz tACS) at 1 mA~* transcranial alternating current stimulation (140 Hz tACS) at 0.4 mA~* transcranial alternating current stimulation (140 Hz tACS) sham~* paired associative stimulation (PAS 25)"
61987186|NCT03344042|ACTIVE_COMPARATOR|Sufentanyl|10mcg sufentanyl administered into the epidural space during regular contractions before cervical dilation
61987187|NCT03344042|NO_INTERVENTION|Control|No epidural analgesia
62759186|NCT03720665|PLACEBO_COMPARATOR|Placebo group|"* Non-active tablet~* transcranial alternating current stimulation (140 Hz tACS) at 1 mA~* transcranial alternating current stimulation (140 Hz tACS) at 0.4 mA~* transcranial alternating current stimulation (140 Hz tACS) sham~* paired associative stimulation (PAS 25)"
62759187|NCT05630222|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 800 mg IV infusion over 20 min.
62759188|NCT05630222|ACTIVE_COMPARATOR|Morphine|Morphine Sulfate 0.1 mg/kg IV
62759189|NCT05630222|ACTIVE_COMPARATOR|Ibuprofen plus Acetaminophen|Ibuprofen 400 mg plus Acetaminophen 1000 mg IV infusion over 20 min.
62759190|NCT04615260|OTHER|Single arm subject is own control|Posterolateral fusion is bilateral, patients will receive the Nanobone graft on the right side of their spine and the local bone graft on their left side.
62759191|NCT02744612|EXPERIMENTAL|Arm I: Ibrutinib 420 mg PO QD + BV 1.8 mg/kg IV Q21 days|Patients receive ibrutinib 420 mg PO QD on days 1-21 and brentuximab vedotin 1.8 mg/kg IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62759192|NCT02744612|EXPERIMENTAL|Arm II: Ibrutinib 560 mg PO QD + BV 1.8 mg/kg IV Q21 days|Patients receive ibrutinib 560 mg PO QD on days 1-21 and brentuximab vedotin 1.8 mg/kg IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62380273|NCT02358928|OTHER|Low carbohydrate diet|Carbohydrate-restricted diet is composed of 20% carbohydrates, 35% protein and 45% fat.
62759193|NCT04962607||Study Group|"1. Asymptomatic primary molars with deep carious lesions scheduled for regular treatment.~2. Exposure of a vital pulp due to caries.~3. No clinical or radiographic evidence of pulp degeneration, such as spontaneous pain, excessive bleeding from the root canal, internal root resorption, inter-radicular and/or periapical bone destruction, swelling, or sinus tract.~4. The possibility of proper restoration of the teeth."
61987188|NCT05947201|EXPERIMENTAL|AK104+cisplatin+albumin paclitaxel+fluorouracil|AK104 (10 mg/kg d1), in combination with cisplatin (20 mg/m2 on d1-3) and albumin paclitaxel (100mg/m2 on d1,d8), fluorouracil (600 mg/m2 on d1-5) Q3W, intravenously
61987189|NCT05423028|ACTIVE_COMPARATOR|Dextrose|
61987190|NCT05423028|EXPERIMENTAL|Vitamin B12|
62380274|NCT01278810|EXPERIMENTAL|Icaritin|
61987191|NCT05423028|EXPERIMENTAL|Dextrose + Vitamin B12|
62380275|NCT03983304|EXPERIMENTAL|Muscle Toning|The treatments are designed to evaluate muscle toning, firming and strengthening in the abdomen and buttocks.
62380276|NCT05696613|EXPERIMENTAL|Phase 3a Cohort 1|3 mg SNP-ACTH Gel sc injection 3 times per week
62380277|NCT05696613|EXPERIMENTAL|Phase 3a Cohort 2|5 mg SNP-ACTH Gel sc injection 3 times per week
62380278|NCT05696613|EXPERIMENTAL|Phase 3b Cohort 1|Dose level to be confirmed once Phase 3a part is completed
62380279|NCT05696613|ACTIVE_COMPARATOR|Phase 3b Cohort 2|Rituximab arm: Patients randomized to the rituximab arm will receive 1 g IV infusion on T0 (after baseline measures are collected) and day 15. A second course of rituximab 1g IV infusion will be administered 6 months after the first rituximab infusion and an additional 1 g IV infusion 14 days following the first 6-month infusion.
62380280|NCT01172340|EXPERIMENTAL|Behavioral and support intervention|one individual counseling session with diet and exercise recommendations plus 16 weeks of group sessions, plus 8 weeks of phone followup
62380281|NCT01172340|PLACEBO_COMPARATOR|wait-listed control group|Controls receive individual counseling session and recommendations, mailed health information, and after post-test measures are offered an abbreviated group-based intervention
62380282|NCT06059521|EXPERIMENTAL|Software Refraction|Refraction is done by software with subjective refraction through a mobilerone.
62759194|NCT04962607||control group|"1. Asymptomatic primary molars with deep carious lesions scheduled for regular treatment.~2. Exposure of a vital pulp due to caries.~3. No clinical or radiographic evidence of pulp degeneration, such as spontaneous pain, excessive bleeding from the root canal, internal root resorption, inter-radicular and/or periapical bone destruction, swelling, or sinus tract.~4. The possibility of proper restoration of the teeth."
62759195|NCT00858598||Pro Osteon|All patients in this pilot study will receive pro osteon as a bone void filler and will be enrolled according to the same inclusion / exclusion criteria.
62759196|NCT02265419|EXPERIMENTAL|Cytosorb group|Extracorporeal treatment with the Cytosorb adsorber for 24 hours after heart surgical operation.
62759197|NCT06024837||Patients with Colo-rectal Cancer|Patients with Colo-rectal Cancer will be included.
62759198|NCT02174523|EXPERIMENTAL|40mg lurasidone|Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.
62759199|NCT02174523|PLACEBO_COMPARATOR|placebo|Single oral administration of 40 mg study drug placebo after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg placebo, once daily between Day 4 and Day 8.
62759200|NCT06213142|EXPERIMENTAL|CBToolkit|CBToolkit includes two SSI modules: (1) Mindful Awareness, with the goal of increasing awareness and tolerance of physical sensations and emotional experiences using mindfulness practices and tips and (2) Flexible Problem Solving, with the goal of promoting cognitive flexibility, applying problem-solving strategies in difficult scenarios, and learning to modify behavioral action tendencies.
62759201|NCT01649544|EXPERIMENTAL|EPICOR|"Cardiac ablation system EPICOR (CE n°0344).~* ablation device EpicorTM UltraCinchTM LP (Class III device)~* Positioning system and calibration EpicorTM LP (LP PASTM; device Class IIa)~* Cable connection EpicorTM LP (unsterile)~* Ablation Control System EpicorTM LP (Class IIb)"
62759202|NCT01649544|ACTIVE_COMPARATOR|Amiodarone|"Cordarone :~400 mg/d during the 2 first months 200 mg/d from 3th to 18th month"
62759203|NCT02654392|PLACEBO_COMPARATOR|placebo|This group will receive isoenergetic carbohydrate (corn syrup) supplement daily for 5 weeks
62759204|NCT02654392|OTHER|Polyunsaturated fatty acid group|This group will receive a plant essential fatty acid food supplement, Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, \& Pumpkin oils, containing a 2.5:1 omega-6 to omega-3 ratio (1.5 g per 70kg body mass plus an additional 0.5 g on exercise days)
62759205|NCT05023616|EXPERIMENTAL|Real-time home CPR training|Online real-time home CPR(cardiopulmonary resuscitation) training will be provided to participants
62759206|NCT05023616|ACTIVE_COMPARATOR|Conventional CPR training|Conventional CPR training will be provided to participants
62759207|NCT04253990|EXPERIMENTAL|Precut-EMR|"For treating of 10\~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.~In Precut-EMR, endoscopist submucosally inject with saline around a polyp. Subsequently, circumferential incision/precutting was made with the tip of the snare around 2 mm outside the tumor. After that, the snare was positioned in the cut groove and tightend, and the tumor was resected using electrical current."
62380283|NCT06059521|ACTIVE_COMPARATOR|Refraction by retinoscopy|Refraction is done objectively by retinoscopy.
62380284|NCT03894306||medication lock box + brief counseling|
62380285|NCT03894306||medication lock bag + brief counseling|
62380286|NCT03894306||brief counseling alone|
62380287|NCT00992615|EXPERIMENTAL|Arm 20 cores|
62380288|NCT00992615|ACTIVE_COMPARATOR|arm 12 cores|
62759208|NCT04253990|ACTIVE_COMPARATOR|Conventional EMR|"For treating of 10\~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.~Conventional EMR had been widely used technique. Endoscopist submucosally inject with saline around a polyp. After that, snare is positioned around a polyp, and polyp was resected using electrical current"
62759209|NCT02288962|EXPERIMENTAL|cabergoline|"Target dose for cabergoline is 2 mg/week.The medication is administered in the evening to minimize side effects. If intolerable side effects occur despite this, it may be necessary to treat with a lower dose than 2 mg per week.~Treatment scheme: 0.5 mg x 1 per week the first 2 weeks, then 0.5 mg x 2 per week the next 2 weeks, then 1 + 0.5 mg per week the next 2 weeks, then 1 mg x 2 per week (target dose) for the rest of the study"
62759210|NCT02288962|NO_INTERVENTION|observation|visits and controls as usual
62759211|NCT02761148||Control|
62759212|NCT02761148||White matter hyperintensity|
62759213|NCT00795041||1|10 women with indication for ART with ICSI or IVF
62759214|NCT04920591|EXPERIMENTAL|doll therapy (DT)|doll therapy (emathy dolls)
62759215|NCT04920591|NO_INTERVENTION|Standard treatment (ST)|standard clinical practice
62759216|NCT04202510|ACTIVE_COMPARATOR|iStent|iStent Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
62759217|NCT04202510|ACTIVE_COMPARATOR|iStent Inject|iStent Inject Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
62759218|NCT04202510|ACTIVE_COMPARATOR|Hydrus|Hydrus Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
62759219|NCT01997814|ACTIVE_COMPARATOR|Test Group|Patients in Test Group were given Herbal Immunomodulators (SeptilinTM) 2 tablets twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
62759220|NCT01997814|PLACEBO_COMPARATOR|Control Group|Patients in Control Group were given placebo drug 2 tablets twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
62759221|NCT01716338|ACTIVE_COMPARATOR|Glyburide|1.5 mg (lowest dose) by mouth every day with breakfast for 7 days
62759222|NCT01716338|PLACEBO_COMPARATOR|Sugar Pill (Capsule)|Matching placebo capsule by mouth every day with breakfast for 7 days
62759223|NCT05209308|EXPERIMENTAL|Cohort A|"Ven low dose + Rituximab + Zandelisib"
62380289|NCT03815955|EXPERIMENTAL|Non-Sedentary Behaviour Group|Participants in this arm will model the primary care team as they engage in minimal sedentary behaviour and replace sitting with standing and light, incidental movements.
62759224|NCT05209308|EXPERIMENTAL|Cohort B|"Ven standard dose + Rituximab + Zandelisib"
62759225|NCT02187523|EXPERIMENTAL|Telmisartan/HCTZ FDC|
61987192|NCT06431568||Intravenous Ondansetron for patients undergoing Cesarean section under spinal Anesthesia|Pregnant patients undergoing elective caesarean section with no co-morbidities will receive intravenous ondansetron
61987193|NCT04878523|PLACEBO_COMPARATOR|Placebo drink|
61987194|NCT04878523|EXPERIMENTAL|multi berries juice|
62759226|NCT02187523|ACTIVE_COMPARATOR|Telmisartan and HCTZ individual tablets|
62759227|NCT05445908|EXPERIMENTAL|SKB264+KL-A167（Part1，TNBC）|Participants received SKB264 followed by KL-A167
62759228|NCT05445908|EXPERIMENTAL|SKB264（Part2，TNBC）|Participants received SKB264
62759229|NCT05445908|EXPERIMENTAL|SKB264+KL-A167（Part2，TNBC）|Participants received SKB264 followed by KL-A167
62759230|NCT05445908|EXPERIMENTAL|SKB264（Part3，HR+/HER2- BC）|Participants received SKB264
62759231|NCT05445908|EXPERIMENTAL|SKB264+KL-A167（Part3，HR+/HER2- BC）|Participants received SKB264 followed by KL-A167
62759232|NCT02110888|EXPERIMENTAL|SCS + PNS|Mutlticolumn SCS lead + Monocolumn SCS lead
62759233|NCT02110888|ACTIVE_COMPARATOR|SCS|Mutlticolumn SCS lead
62759234|NCT00048815|ACTIVE_COMPARATOR|citalopram|Subjects in this arm received 20mg/day of citalopram taken orally for 12 weeks.
62759235|NCT00048815|EXPERIMENTAL|St. John's Wort|Subjects in this arm received 810 mg/day of St. John's Wort taken orally (in three tablets of 270mg each) for 12 weeks.
62759236|NCT00048815|PLACEBO_COMPARATOR|Placebo|Subjects in this arm received double-dummy (look-alike) placebo for 12 weeks.
62759237|NCT06607081|EXPERIMENTAL|Perioperative Pre ERAS group|
62759238|NCT06607081|NO_INTERVENTION|Control group|
62759239|NCT00569309|EXPERIMENTAL|Prevnar|The conjugate vaccine for Streptococcus pneumoniae will be administered during weeks 9, 17, and 25 after autologous HSCT - the study nurse will arrange for the vaccine to be administered at the specified time and the patient will be instructed to notify an investigator or study nurse of any side effects of vaccine administration. At the specified times, patients will fill out the quality-of-life assessment. All patients enrolled on this trial will have samples procured for all proposed laboratory correlative studies.
62759240|NCT05280327|EXPERIMENTAL|experimental group|virtual reality application
62759241|NCT05280327|NO_INTERVENTION|control group|standard care group
62759242|NCT01778374|EXPERIMENTAL|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
62759243|NCT01778374|EXPERIMENTAL|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
62759244|NCT00160199|EXPERIMENTAL|1|
62380290|NCT03815955|NO_INTERVENTION|Standard Care Control Group|Participants that are limited to standing, due to amputations, diabetic foot pain and ulcers, or sensory diabetic neuropathy, will follow standard care and attend the DIGMA in a seated position.
62380291|NCT04961125||colorectal polyposis|
62380292|NCT02171806|EXPERIMENTAL|BI 1744 CL multiple rising doses|
62380293|NCT02171806|PLACEBO_COMPARATOR|Placebo|
62558500|NCT05744167|EXPERIMENTAL|Muscle damaging resistance training (MDRT)|Participants will engage in a supervised 12-week lower extremity resistance exercise program, 2 times per week. MDRT will be at an intensity of 80% or 120% of 1RM. The first session will be at 120% 1RM and consist of eccentric-only exercises. The concentric phase of the movement will be supported completely by a coach. The eccentric phase of the movement will be accentuated by increasing the time under tension to six seconds. Each exercise will be performed for 4 sets of 4 repetitions with 2 minutes rest between sets and 3 minutes rest between exercises. The eccentric-only exercise session will be followed by 2 (after the first session) or 3 (after all other sessions) concentric-only exercise sessions at 80% of 1RM. Here, the eccentric phase of the movement will be supported completely by a coach. In the 12 week period, there will be a total of seven eccentric-only exercise sessions.
62558501|NCT05744167|NO_INTERVENTION|Control group|Control group will be asked to maintain their usual lifestyle.
62558502|NCT02105987|EXPERIMENTAL|ABC/DTG/3TC|Subject will take ABC 600 mg/DTG 50 mg/3TC 300 mg FDC once daily in the morning or the evening, at approximately the same time each day for 24 weeks. After Week 24, subjects will continue on this treatment arm for an additional 24 weeks.
62558503|NCT02105987|ACTIVE_COMPARATOR|Comparator|Subjects will continue on their current Combination antiretroviral therapy (cART) regimen for 24 weeks. At Week 24, subjects will switch to ABC/DTG/3TC FDC for an additional 24 weeks.
62558504|NCT01777503|EXPERIMENTAL|prasugrel|prasugrel 60 mg loading dose, followed by 5 mg once daily until the end of follow-up
62558505|NCT01777503|ACTIVE_COMPARATOR|clopidogrel|Clopidogrel 300 mg loading dose followed by 75 mg once day until the end of follow-up
62558506|NCT05192239|PLACEBO_COMPARATOR|Placebo|Delta-9-tetrahydrocannabinol (THC) free fruit snack gummy. One time, two gummies will be ingested prior to an exercise bout.
62558507|NCT05192239|ACTIVE_COMPARATOR|10 mg THC|Delta-9-tetrahydrocannabinol (THC) 5 milligrams (mg) in gummy form. One time, two gummies will be ingested prior to an exercise bout.
62558508|NCT05894707|EXPERIMENTAL|80 mg SCT650C or normal saline|Eight qualified participants will be randomized at a ratio of 6:2 to receive 80 mg SCT650C or normal saline on Day 1
62558509|NCT05894707|EXPERIMENTAL|160 mg SCT650C or normal saline|Eight qualified participants will be randomized at a ratio of 6:2 to receive 160 mg SCT650C or normal saline on Day 1
62558510|NCT05894707|EXPERIMENTAL|40 mg SCT650C or normal saline|Eight qualified participants will be randomized at a ratio of 6:2 to receive 40 mg SCT650C or normal saline on Day 1
62558511|NCT05894707|EXPERIMENTAL|20 mg SCT650C or normal saline|Eight qualified participants will be randomized at a ratio of 6:2 to receive 20mg SCT650C or normal saline on Day 1
62558512|NCT06058702|ACTIVE_COMPARATOR|Delta-9-THC|Active delta-9-THC (0.036 mg/kg) administered intravenously over 20 minutes.
62558513|NCT06058702|PLACEBO_COMPARATOR|Placebo|Control: small amount of alcohol administered intravenously (quarter teaspoon), with no delta-9-THC, over 20 minutes.
62759245|NCT00160199|ACTIVE_COMPARATOR|2|
62759246|NCT00872378|ACTIVE_COMPARATOR|Exenatide|Laparoscopic adjustable gastric banding group: twice daily exenatide therapy plus a standard diet and exercise program
62759247|NCT00872378|PLACEBO_COMPARATOR|Placebo|Laparoscopic adjustable gastric banding group: twice daily placebo therapy plus a standard diet and exercise program
62759248|NCT02390674|ACTIVE_COMPARATOR|Ciclosporin|Single intravenous administration of ciclosporin (2.5mg per kilogram body weight) immediately prior to reperfusion during primary percutaneous coronary intervention. Ciclosporin is dissolved in saline (maximum concentration 2.5mg per millilitre)
62759249|NCT02390674|PLACEBO_COMPARATOR|Saline|Single intravenous administration of placebo (saline) immediately prior to reperfusion during primary percutaneous coronary intervention
61987195|NCT03128814||Elite (pre)adolescent tennis players|
61987196|NCT03128814||Age- and gender-matched controls|
62168165|NCT05359926|ACTIVE_COMPARATOR|Delayed Urethral Catheter Removal|Removal of the urethral catheter in next morning after surgery
62380294|NCT02171806|EXPERIMENTAL|BI 1744 CL medium dose, females|
62380295|NCT03000764|EXPERIMENTAL|Biomarkers|
62380296|NCT01899729|EXPERIMENTAL|IMO-8400 Regimen 1|IMO 8400 at 0.075 mg/kq q wk x 12 wks
62380297|NCT01899729|EXPERIMENTAL|IMO-8400 Regimen 2|IMO-8400 at 0.15 mg/kg q wk x 12 wks
62558514|NCT01868802|EXPERIMENTAL|Ketamine treated|
62558515|NCT01868802|PLACEBO_COMPARATOR|Control, placebo treated|
62759250|NCT04507451|EXPERIMENTAL|Trained group|"Patients will benefit from usual respiratory physiotherapy (secretion clearance treatment and recruitment maneuvers), and muscle training. This program will be delivered 5 days a week.~Inspiratory muscle training (IMT): using a threshold IMT device with mouthpiece, 5 sets of 6 breaths, intensity is prescribed at 60% of maximal inspiratory pressure for the first set, and then increased to the highest tolerable intensity to allow completion of the 6th breath Expiratory muscle training (EMT): using a bottle filled with water, starting at 5cm and then increased to 8 cm gradually, 5 sets of 6 breaths~Training program starts after mechanical ventilation weaning, as soon as the patient is collaborative, and is continued until 1 month after ICU discharge"
62380298|NCT01899729|EXPERIMENTAL|IMO-8400 Regimen 3|IMO_8400 at 0.3 mg/kg q wk x 12 wks
62380299|NCT01899729|PLACEBO_COMPARATOR|Placebo|Saline (placebo) q wk x 12 wks
62558516|NCT01866826|EXPERIMENTAL|HIV Infected Subjects|Human immunodeficiency virus (HIV) infected subjects with viral suppression on antiretroviral (ART). Double-blinded/placebo controlled trial with cross-over design. Rifaximin
62759251|NCT04507451|PLACEBO_COMPARATOR|Untrained group|"Patients will benefit from usual respiratory physiotherapy (secretion clearance treatment and recruitment maneuvers), and muscle exercises that are not planned to train muscles. This program will be delivered 5 days a week.~Inspiratory exercises: fractionated inspiration, 5 sets of 6 breaths Expiratory exercises: using a bottle filled with water (1 cm)~Exercises program starts after mechanical ventilation weaning, as soon as the patient is collaborative, and is continued until 1 month after ICU discharge"
62759252|NCT01963013|EXPERIMENTAL|Non-returning catheter valve|Non-returning catheter valve (UnometerTM SafetiTM Plus) was used in experimental group only.
62759253|NCT01963013|ACTIVE_COMPARATOR|Conventional urine bag|Conventional urine bag hasn't the non-returning catheter valve.
62759254|NCT01453738|EXPERIMENTAL|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2-4ml Plasmalyte A followed by 2 ml of Hyaluronan
62759255|NCT01453738|PLACEBO_COMPARATOR|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte
62759256|NCT05462977|EXPERIMENTAL|Group exercise with beat-accented synchronous music stimulation|Participants will be asked to participate in a music-based group exercise program for 24 weeks (up to 6 days/week, 30 - 45 min/day), which is designed for older adults with functional limitations to safely exercise on a chair or in a supported standing posture for the improvement of aerobic capacity, upper and lower body strength, and balance control at a gradually increasing pace based on the tempo of the beat-accented synchronous music playlists.
62380300|NCT01899729|EXPERIMENTAL|IMO-8400 Regimen 4|IMO_8400 at 0.6 mg/kg q wk x 12 wks
62380301|NCT01355094|ACTIVE_COMPARATOR|"Stampede VAC"|"Calgary-home-made Stampede VAC system with only closed drain bulb suction"
62558517|NCT01866826|PLACEBO_COMPARATOR|HIV Infected Subjects Placebo|HIV infected subjects with viral suppression on ART. Double-blinded/placebo controlled trial with cross-over design. Placebo
62558518|NCT04751487|EXPERIMENTAL|Itepekimab Q2W in former smokers|Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for up to 52 weeks
62380302|NCT01355094|EXPERIMENTAL|KCI AbThera|commercial AbThera vacuum assisted abdominal closure at 125 mmHg suction
62380303|NCT05698160||coagulation dysfunction group|The critically ill patients in intensive care unit showed coagulation dysfunction after treated with tigecycline.
62759257|NCT06285747||Observational|Patients complete questionnaires and undergo chest wall and breast lymphedema measurements by clinical assessment and using the Delfin Moisture Meter D Compact and have their medical records reviewed on study.
62759258|NCT02510651|EXPERIMENTAL|ORSHFS|Melanocyte-keratinocyte suspension.
62759259|NCT03197974|OTHER|Mindfulness for Bipolar|Introduction to, and training in the skills of mindfulness, self-compassion, and values-oriented action, and how these can be applied to managing symptoms of bipolar disorder.
62380304|NCT05698160||non-coagulation dysfunction group|The critically ill patients in intensive care unit showed normal coagulation function after treated with tigecycline.
62380305|NCT03575780|EXPERIMENTAL|KX2-391 Ointment|KX2-391 ointment 1% will be administered once daily over 5 consecutive days
62380306|NCT01137006|EXPERIMENTAL|IMC-20D7S (1A-4A Cohorts)|Escalating doses up to 30 milligrams per kilogram (mg/kg) administered intravenously (i.v.) every 2 weeks; includes Cohorts 1A, 2A, 3A, and 4A.
62380307|NCT01137006|EXPERIMENTAL|IMC-20D7S (1B-3B Cohorts)|Escalating doses up to 30 mg/kg administered i.v. every 3 weeks; includes Cohorts 1B, 2B, and 3B.
62380308|NCT04030819|NO_INTERVENTION|control group|no intervention
62380309|NCT04030819|EXPERIMENTAL|experimental group|schema therapy
62558519|NCT04751487|EXPERIMENTAL|Itepekimab Q4W in former smokers|SC administration of Itepekimab every 4 weeks (Q4W) for up to 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP
62168166|NCT04390893|EXPERIMENTAL|ultrasound positioning group|
62558520|NCT04751487|PLACEBO_COMPARATOR|Placebo in former smokers|SC administration of matching placebo Q2W for up to 52 weeks
62558521|NCT04751487|EXPERIMENTAL|Itepekimab Q2W in current smokers|SC administration of Itepekimab every 2 weeks (Q2W) for 52 weeks
62759260|NCT03197974|OTHER|Psychoeducation for Bipolar|Information about bipolar disorder and the patient's role in managing the condition, including identifying triggers, and responding to early warning signs of episodes, and developing a healthy lifestyle
62759261|NCT04859244|EXPERIMENTAL|Part 1: GS-441524 (QD, 7 days)|750 mg GS-441524 administered QD for 7 days
62759262|NCT04859244|EXPERIMENTAL|Part 2: GS-441524 (TID, 3 days)|750 mg GS-441524 administered TID for 3 days
62759263|NCT04091984||Prospera Arm|There is no intervention in this study. Adult patients who have received a kidney allograft from a genetically different donor in the past 2 years including within 60 days and who have been selected by their healthcare provider to receive Prospera dd-cfDNA testing according to their regular interval testing schedule as part of their clinical care will have medical records pertaining to their kidney rejection status collected at each study visit.
62759264|NCT04091984||Control Arm|The control arm will consist of retrospective data review of cases where a renal allograft from a genetically different donor was performed. Data pertaining to to their kidney rejection status from a minimum of 3 time points per year post allograft (up to 5 years) or until renal allograft failure will be collected.
62759265|NCT02445937|NO_INTERVENTION|Control|The control group will receive usual care, in which the frequency and content of physician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
62759266|NCT02445937|EXPERIMENTAL|Behavioral: The PARTNER II Intervention|"The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists."
62759267|NCT05264441|OTHER|Asthma and COPD patients|There will be only 1 arm in this study. COPD and asthma patients will be in the same arm.
62759268|NCT03153072|OTHER|A child with supraventricular tachycardia|
62759269|NCT03009838|ACTIVE_COMPARATOR|letrozole|letrozole 2.5 mg oral tablets will be started daily from day 3 of the menses for 5 days in a dose of 5 mg/day
62759270|NCT03009838|ACTIVE_COMPARATOR|laparoscopic drilling|laparoscopy will be performed using three-puncture technique. Each ovary will be cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using a monopolar electrosurgical needle
62380310|NCT02983695|EXPERIMENTAL|treatment|all participants will be in this arm and will receive study drug 'Cannabidiol-Rich whole Plant Extract (TIL-TC150) to assess dosing and tolerability according to study protocol.TIL-TC150 Oil is the study product The active ingredients in TIL-TC150 Oil are THC and CBD, present in a 1:50 ratio. These active ingredients are derived from Cannabis sativa L. strains produced by Tilray, and suspended in a grape seed oil. This suspension is administered at a dose of 2mg/kg/day CBD divided BID and titrated up to a maximal dose of 16mg/kg/day CBD (or maximal tolerated).
62380311|NCT03595176|EXPERIMENTAL|Coronary Lithotripsy System|All subjects will receive lithotripsy treatment from the Shockwave Medical Coronary IVL System
62558522|NCT04751487|PLACEBO_COMPARATOR|Placebo in current smokers|SC administration of matching placebo Q2W for 52 weeks
62168167|NCT04390893|ACTIVE_COMPARATOR|leak test positioning group|
62380312|NCT06210165|EXPERIMENTAL|Sugammadex|IV Sugammadex 4mg/kg once after Train of Four ratio 0.7 to 0.9
62380313|NCT06210165|ACTIVE_COMPARATOR|Neostigmine and atropine|IV Neostigmine 40mcg/kg and IV Atropine 10mcg/kg once after Train of Four ratio 0.7 to 0.9
62380314|NCT00806533||HES 130 / 0.42|paediatric patients aged up to 12 years requiring non-emergency volume replacement therapy with HES 130/0.42
62759271|NCT04841759|EXPERIMENTAL|"Post COVID-19 fatigue at baseline yes"|SARS-CoV2 survivor who attends the exercise program and suffers from post-COVID-19 fatigue Syndrome according to the Post-Covid-19-Functional Scale (PCFS)
62759272|NCT04841759|ACTIVE_COMPARATOR|"Post COVID-19 fatigue at baseline no"|SARS-CoV2 survivor who attends the exercise program and doesn't suffer from post-COVID-19 fatigue Syndrome according to the Post-Covid-19-Functional Scale (PCFS)
62759273|NCT03780478|EXPERIMENTAL|SPG Block|Sphenopalatine ganglion block
62759274|NCT03780478|PLACEBO_COMPARATOR|Placebo Control|Saline injection
62759275|NCT01247532|EXPERIMENTAL|Waitlist|
62759276|NCT02750384|EXPERIMENTAL|50% SDD granules, fasting|50% spray dried dispersion granules, fasting
62759277|NCT02750384|ACTIVE_COMPARATOR|25% SDD powder for suspension, fasting|25% spray dried dispersion powder for suspension, fasting
62759278|NCT02750384|EXPERIMENTAL|50% SDD granules, fed|50% spray dried dispersion granules, fed
62759279|NCT05654688|EXPERIMENTAL|Graston|Graston technique and traditional physical treatment (control)
62759280|NCT05654688|EXPERIMENTAL|Muscle energy technique|Muscle energy technique and traditional physical treatment
62759281|NCT05654688|ACTIVE_COMPARATOR|Traditional physical therapy|Traditional physical therapy treatment as heat application
62759282|NCT00682136|ACTIVE_COMPARATOR|1|Open Laparotomy Arm: All patients enrolled in the study who are undergoing elective open laparotomy surgery.
62759283|NCT00682136|ACTIVE_COMPARATOR|2|Laparoscopic Arm: All patients enrolled in the study who are undergoing elective laparoscopic abdominal surgery.
62759284|NCT02356094||Cases|Patients with primary open angle glaucoma, randomly selected from the Glaucoma Outpatient Clinic to be submitted to Pentacam examination
62759285|NCT02356094||Controls|Control group of age and central corneal thickness matched healthy subjects, randomly selected from the General Ophthalmology Outpatient Clinic to be submitted to Pentacam examination
62759286|NCT03103672||Groupe I|Patients who will receive inhalation anesthesia
62759287|NCT03103672||Groupe 2|Patients who will receive total intravenous anesthesia
62759288|NCT01889134|EXPERIMENTAL|Alendronate|Sedron (alendronate) 70 mg taken orally once a week for 12 months
62759289|NCT01889134|ACTIVE_COMPARATOR|Parathyroidectomy|Selective parathyroidectomy
62759290|NCT01889134|NO_INTERVENTION|Control group|No intervention
62380315|NCT06184165|EXPERIMENTAL|N°1: PMI in PPC|"Progressive periodic catatonia (SSD phenotype) Premotor inhibition using personalized rTMS (40 sec continuous theta-burst on each of the 5 targets corresponding to hyper-perfused regions, i.e. functional biomarker, 120%).~N = 40."
62380316|NCT06184165|ACTIVE_COMPARATOR|N°2: PFA in PPC|"Progressive periodic catatonia (SSD phenotype) Classical left-prefrontal activation using intermittent theta-burst rTMS (72 trains, 120%).~N = 40."
62759291|NCT01766349||esophagus cancer patients|Respiratory muscle performance will be followed in patients with esophagus cancer during CCRT or RT treatments.
62759292|NCT04994873|EXPERIMENTAL|STEP: Positivity skill enhancement|This intervention includes the Enhanced TAU described below plus it entails 4 in-person sessions delivered during an inpatient psychiatric admission, followed by mood monitoring and skills messages delivered post-discharge via app, to promote the practice of increasing attention to positive affect and experiences as a means of reducing risk for suicidal behavior.
62759293|NCT04994873|ACTIVE_COMPARATOR|Enhanced TAU|his comparison intervention involves regular programming of the inpatient psychiatric unit, followed by safety plan and resources loaded onto an app that the participant has access to post-discharge.
62759294|NCT01895933|ACTIVE_COMPARATOR|Active / control|One side has been treated with SurgiShield
62759295|NCT01895933|NO_INTERVENTION|No intervention|One side has no intervention
62759296|NCT02740543|ACTIVE_COMPARATOR|Allergic Asthma (AA)|
62759297|NCT02740543|NO_INTERVENTION|Control|
62759298|NCT02193087|ACTIVE_COMPARATOR|Group A: TDV Liquid + Placebo|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Liquid Formulation 1, diluted 1:5 with vaccine diluent, subcutaneous injection on Day 1, and TDV Liquid Formulation placebo-matching solution, subcutaneous injection, once on Day 90 (Month 3).
62759299|NCT02193087|ACTIVE_COMPARATOR|Group B: TDV Liquid|TDV Liquid Formulation 1, diluted 1:5 with vaccine diluent, subcutaneous injection on Day 1 and Day 90 (Month 3).
62759300|NCT02193087|EXPERIMENTAL|Group C: TDV Liquid|TDV Liquid Formulation 2, subcutaneous injection on Day 1 and Day 90 (Month 3).
62380317|NCT06184165|ACTIVE_COMPARATOR|N°3: PMI in nPPC|"Other phenotype of SSD than PPC (nPPC) Premotor inhibition using personalized rTMS (40 sec continuous theta-burst on each of the 5 targets corresponding to most perfused premotor regions).~N = 40."
62759301|NCT02193087|EXPERIMENTAL|Group D: TDV Lyophilized|TDV Lyophilized Formulation reconstituted with water, subcutaneous injection on Day 1 and Day 90 (Month 3).
62759302|NCT04015583|EXPERIMENTAL|exergaming group|"The exergaming group (EXG) performed exercise using Exerheart® devices (D\&J Humancare, Busan, South Korea) composed of a running/jumping mat \[730(W) × 730(D) × 130(H)\] and a tablet PC on a stand (can be adjusted to any height between 70 and 155 cm) (Supplemental Figure 1A). Exerheart® is an exergaming developed for in-situ running along with the video game called Alchemist's Treasure (D\&J Humancare, Busan, South Korea). To play this game, the subject has to run or jump on a spot on the mat to move a virtual avatar on the screen of the tablet PC to the front, back, left, and right along with music. The subject can control the speed of avatar movement by running or jumping speed on the mat."
62759303|NCT04015583|ACTIVE_COMPARATOR|treadmill exercise group|The treadmill exercise group (TEG) performed exercise using commercial treadmills (MOTUS, Gyeonggi-do, South Korea). Each subject walked or ran on the treadmill at a comfortable speed.
62380318|NCT06184165|EXPERIMENTAL|N°4: PFA in nPPC|"Non-progressive periodic catatonia SSD phenotype Classical left-prefrontal activation (PFA) using intermittent theta-burst rTMS (72 trains, 120%).~N = 40."
62380319|NCT01110889|EXPERIMENTAL|AGO178C 0.5 mg /day|
62380320|NCT01110889|EXPERIMENTAL|AGO178C 1 mg / day|
62380321|NCT01110889|PLACEBO_COMPARATOR|Placebo|
62380322|NCT05277194|EXPERIMENTAL|KeepCalm App|The KeepCalm app is designed to help manage stress and prevent challenging behaviors in children with autism. The app uses physiological stress tracking, assessed using heart rate monitoring, to indicate when challenging behaviors are likely to occur. The app then recommends strategies to help prevent the onset of challenging behaviors. The app can also be used to track trends in triggers, behaviors, and strategies, and to communicate this information to parents and other members of a child's educational team.
62759304|NCT02249494|EXPERIMENTAL|Smartphone (mobile app) & telehealth|Participants will install and use a mobile application designed to provide nutritional recommendations for hypertensive patients. These recommendations will be based on the DASH diet guidelines appropriate to patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol. The call service will be offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can use this call center when they have questions about diagnosis and management of their patients.
62759305|NCT02249494|PLACEBO_COMPARATOR|nutritional counseling & telehealth|Physicians who are enrolled for this group will continue performing routine nutritional counseling in their clinical practice. The call service will be offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can use this call service when they have questions about diagnosis and management of their patients.
62380323|NCT05277194|NO_INTERVENTION|Waitlist Control|Individuals assigned to the waitlist control condition will gain access to the KeepCalm app following the study's completion. During the trial, they will not receive any intervention, but will complete baseline and post-intervention measures during the trial.
62380324|NCT00413777|EXPERIMENTAL|Tolvaptan 45/15 mg/day orally for up to 4 years|Participants received tolvaptan 45 mg orally in the morning and 15 mg orally 8 hours later for up to 4 years.
62380325|NCT00413777|EXPERIMENTAL|Tolvaptan 60/30 mg/day orally for up to 4 years|Participants received tolvaptan 60 mg orally in the morning and 30 mg orally 8 hours later for up to 4 years.
62558523|NCT04214834|ACTIVE_COMPARATOR|Rapid-wean|15% decrements from the stabilization dose of morphine/methadone
62558524|NCT04214834|ACTIVE_COMPARATOR|Slow-wean|10% decrements from the stabilization dose of morphine/methadone
62558525|NCT05929404||Patients on antithrombotic medications|Participants undergoing ERCP procedure taking antithrombotic medications (including antiplatelet and/or anticoagulant medications) at baseline.
62558526|NCT05929404||Non-antithrombotic users|Participants undergoing ERCP procedure not taking antithrombotic medications (including antiplatelet and/or anticoagulant medications) at baseline.
62380326|NCT04051944|EXPERIMENTAL|Rozanolixizumab|Subjects in this arm will receive predefined subcutaneous doses of rozanolixizumab at a specified frequency.
62759306|NCT05569538|EXPERIMENTAL|Cohort A (Patients refractory to, relapsed or intolerant of ruxolitinib):|"Bomedemstat : The starting dose of bomedemstat at Initial Treatment Period Cycle 1 Day 1 will be 0.4 mg/kg daily for all patients in Cohort A. The first up-titration is not permitted until Initial Treatment Period Cycle 2 Day 1; thereafter, the dose may be up-titrated no more frequently than every 4 weeks from the prior up- or down-titration (note: down-titrations may occur at any time (or the current dose maintained) in the best interest and safety of the patient), to a target platelet count range of 50-100 x 10\^9/L.~Ruxolitinib: Patients will continue their prior, stable dose of ruxolitinib. This same dose will be continued throughout the study unless dose modification is required because of toxicity."
62380327|NCT00131131|EXPERIMENTAL|Exercise|The intervention was an exercise program of moderate to vigorous intensity. The intervention started with 30-minute sessions three times per week, with the ultimate goal to have participants exercise four to five times per week for 45 to 60 minutes per session.
62380328|NCT00131131|NO_INTERVENTION|Control|Women in the control group did not attend instructional sessions with the exercise interventionist and did not receive the motivational mailings
62380329|NCT03399331|EXPERIMENTAL|group 1|Efficacy of Manuka honey on severity and pain of OM compared to placebo (standard care) and to assess which of the two interventions is more beneficial.
62380330|NCT03399331|EXPERIMENTAL|Group 2|Efficacy of olive oil on severity and pain of OM compared to placebo (standard care) and to assess which of the two interventions is more beneficial.
62380331|NCT03399331|PLACEBO_COMPARATOR|Group 3|The control group at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine
62380332|NCT04543565|EXPERIMENTAL|Trial group|subject in this group will receive Pradefovir mesylate tablet and the placebo of tenofovir disoproxil fumarate tablet, once daily for 96 weeks
62380333|NCT04543565|ACTIVE_COMPARATOR|Control group|subject in this group will receive tenofovir disoproxil fumarate tablet and the placebo of Pradefovir mesylate tablet, once daily for 96 weeks.
62380334|NCT05283122|EXPERIMENTAL|The Mostafa Maged technique to prevent and control post-partum bleeding in placenta previa cases|primigravida patients with placenta previa conditions and their ages between ( 18 - 30 ) years old
62380335|NCT02440828|EXPERIMENTAL|tobramycin inhalation|twice daily tobramycin inhalation (Bramitob) 300 mg and standard intravenous antibiotics treatment
62380336|NCT02440828|PLACEBO_COMPARATOR|Placebo|twice daily placebo inhalation and standard intravenous antibiotics treatment
62380337|NCT04815291|EXPERIMENTAL|Device|Receives SCOUT at biopsy
62558527|NCT02152137|EXPERIMENTAL|efatutazone dihydrochloride, paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 and efatutazone dihydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62558528|NCT05832632|EXPERIMENTAL|Headspace Basics Program|
62558529|NCT05832632|EXPERIMENTAL|Headspace Breathing Exercises|
61987197|NCT03857984|EXPERIMENTAL|Erythrocyte Fatty-Acid Status|Erythrocyte Fatty-Acid Status Profiling of HD patients are studied before and after a single HD using LC-MS / MS
62168168|NCT02569944|ACTIVE_COMPARATOR|perineal bag|Perineal bag was placed in infants to collect an urine sample.
62168169|NCT02569944|EXPERIMENTAL|Bladder stimulation|Bladder stimulation technique was used in infants of this arm to obtain an urine sample
62168170|NCT01190449|EXPERIMENTAL|Arm I|Patients receive high-dose ofatumumab IV over 2-8 hours on days 1, 8, 15, and 22 and then once monthly in months 3-9.
62380338|NCT02655315|ACTIVE_COMPARATOR|DEFERIPRONE|Half of participants will receive the deferiprone (DFP) to 15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
62380339|NCT02655315|PLACEBO_COMPARATOR|PLACEBO|Half of participants will receive the placebo twice daily morning and evening. The treatment lasts nine months.
62380340|NCT05229575|EXPERIMENTAL|Stereotactic Body Radiation Therapy (SBRT)|Patients undergo 5 fractions of image-guided stereotactic body radiation therapy to primary breast tumor over 2 weeks
62380341|NCT03295331||GINA-defined clinical diagnosis of Asthma|All patients with GINA-defined clinical diagnosis of Asthma seen at respiratory clinic from January to August 2016 with age 18 and above
62380342|NCT02093741||ADVATE - 2mL|
62380343|NCT02489877||Multiple Sclerosis|Patients diagnosed with Multiple Sclerosis
62380344|NCT02489877||without Multiple Sclerosis|Healthy individuals without neurological disease associated
62558530|NCT05832632|EXPERIMENTAL|Headspace Stress Program|
62558531|NCT05832632|ACTIVE_COMPARATOR|Active Control (Audiobook)|
62558532|NCT05832632|NO_INTERVENTION|Passive Control|
62759307|NCT05569538|EXPERIMENTAL|Cohort B (Cohort B will consist of 10 patients who are JAK inhibitor naïve):|"Bomedemstat: The starting dose of bomedemstat at Initial Treatment Period Cycle 1 Day 1 will be 0.4 mg/kg daily for all patients in Cohort B. The first up-titration is not permitted until Initial Treatment Period Cycle 2 Day 1; thereafter, the dose may be up-titrated no more frequently than every 4 weeks from the prior up- or down-titration (note: down-titrations may occur at any time (or the current dose maintained) in the best interest and safety of the patient), to a target platelet count range of 50-100 x 10\^9/L.~Ruxolitinib: Patients will start treatment with ruxolitinib at Initial Treatment Period Cycle 1 Day 1. The starting dose of ruxolitinib will be 10 mg BID. This same dose will be continued throughout the study unless dose modification is required because of toxicity."
62759308|NCT04671082|EXPERIMENTAL|Tolperisone 50 mg|Tolperisone 50 mg
62759309|NCT04671082|EXPERIMENTAL|Tolpersione 100 mg|Tolperisone 100 mg
62759310|NCT04671082|EXPERIMENTAL|Tolperisone 200 mg|Tolperisone 200 mg
62759311|NCT04671082|PLACEBO_COMPARATOR|Placebo|Placebo
62759312|NCT02085525|OTHER|Weekly NP Visits|100 HNC (Head and Neck Cancer) patients seen weekly in a Nurse Practitioner (NP) led symptom management clinic for supportive care.
62759313|NCT02085525|OTHER|Every Other Week NP Visits|100 HNC (Head and Neck Cancer) patients seen every other week in a Nurse Practitioner (NP) led symptom management clinic for supportive care.
62759314|NCT02418312|ACTIVE_COMPARATOR|histamine-2 receptor antagonist group|famotidine 40mg qd for 6 months.
62759315|NCT02418312|PLACEBO_COMPARATOR|placebo group|placebo for 6 months.
62759316|NCT02385916|EXPERIMENTAL|EstroSense®/MD|3 capsules per day during the study period
62759317|NCT02385916|PLACEBO_COMPARATOR|Placebo|3 capsules per day during the study period
62759318|NCT02362126||Patients undergoing EFTR|Patients with non-lifting adenomas, adnomas at difficult anaotomic locations , T1-carcinomas or submucosal colorectal tumors
62759319|NCT03032653|ACTIVE_COMPARATOR|Late WB|Intervention: Patients receive a plaster splint in the operating room. They are not permitted to WB or ROM on the affected limb at this stage. At the first follow-up appointment (two weeks post-op), the splint is removed and a removable pre-fabricated walking boot applied. At this stage the patient is permitted to WB as tolerated while wearing the boot, and to perform ROM exercises with the boot removed. At six weeks post-op, the boot is discontinued and full unrestricted and unprotected weightbearing and ROM is permitted.
62759320|NCT03032653|EXPERIMENTAL|Immediate unprotected WB and ROM|Patient do NOT receive a brace or splint of any kind. They are permitted to weightbear and range of motion as tolerated within the limitations of their own comfort. Use of ambulatory aids of any kind is permitted as needed without restrictions.
62759321|NCT05944562|EXPERIMENTAL|Dose De-Escalation Cohort: Tulmimetostat (CPI-0209)|Daily CPI-0209 by mouth for days 1-28 of each 28-day cycle. Dose will depend on dose level assignment of 300 mg daily, 250 mg daily, or 200 mg daily.
62759322|NCT05944562|EXPERIMENTAL|Dose Expansion Cohort: Tulmimetostat (CPI-0209)|Daily CPI-0209 by mouth for days 1-28 of each 28-day cycle. Dose will be the maximum-tolerated dose found during the dose de-escalation cohort.
62759323|NCT04382625|EXPERIMENTAL|Hydroxychloroquine (HCQ)|Initial dose: HCQ 400mg x 2 (800mg) then 200mg by mouth, three times per day (600mg/24hr period) starting 8 hours after the initial dose for a total of 14 doses over 5 days Plus Usual Care (See below for full description)
62558533|NCT04190992|EXPERIMENTAL|Application (APP) group|After completing the questionnaires at baseline, participants in the experimental group will be asked to receive a pamphlet and an E-based \& personalized breast reconstruction surgery decision aid at clinic.
62558534|NCT04190992|OTHER|Usual care group|After completing the questionnaires at baseline, participants in the control group will only receive a pamphlet as usual care
62759324|NCT04382625|NO_INTERVENTION|Usual Care|The care of hospitalized patients with covid-19 is evolving with hospital guidelines arising across the U.S. with several commonalities. Patients receive clinical assessment, chest x-ray, covid-19 testing, basic labs (WBC, CMP), and additional labs based on protocol or clinical judgment (ABG, CRP, LDH), antibiotics for possible bacterial pneumonia, acetaminophen for fever, supplemental O2, and consideration for mechanical ventilation. Early intubation over escalating noninvasive support. Low tidal volume ventilation and prone positioning are lung protective strategies used in critically ill covid-19 patients that are based on management of acute respiratory distress syndrome generally. Conservative fluid replacement is used to avoid worsening oxygenation.
62759325|NCT01920893|PLACEBO_COMPARATOR|Placebo|Placebo (for dupilumab), 2 subcutaneous injections on Day 1 as a loading dose followed by a single injection every week (QW) from Week 1 to 15 added to Mometasone furoate nasal spray (MFNS).
62380345|NCT02489877||with other neurological diseases|Patients diagnosed with the following diseases: Lateral Amniotrofic Sclerosis, Headache , Parkinson's disease, Dementia and Epilepsy.
62380346|NCT00639808|PLACEBO_COMPARATOR|1|
62380347|NCT00639808|EXPERIMENTAL|2|TZP-101
62759326|NCT01920893|EXPERIMENTAL|Dupilumab 300 mg QW|Dupilumab, 2 Subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection QW from Week 1 to 15 added to MFNS.
62380348|NCT00161720||All participants|Participants with severe congenital protein C deficiency who were treated under an emergency use IND.
62380349|NCT04062513|EXPERIMENTAL|Olfactive stimulation intervention with familiarization|Participants will receive the olfactive stimulation intervention with mothers' milk odor during a previous period of nine hours and during heel prick. Sucrose will be also administered during heel prick.
62380350|NCT04062513|EXPERIMENTAL|Olfactive stimulation intervention|Participants will receive the olfactive stimulation intervention with mothers' milk odor during heel prick only. Sucrose will be also administered during heel prick.
62380351|NCT04062513|OTHER|Standard care|In the control arm, participants will receive the standard care for pain which is sucrose administration.
62380352|NCT06378164|EXPERIMENTAL|Combined volitional and reactive step training|
62380353|NCT06378164|PLACEBO_COMPARATOR|Non-specific exercise group|
62380354|NCT01172054|EXPERIMENTAL|VAX128|Novel H1N1 Influenza vaccine
62380355|NCT01172054|PLACEBO_COMPARATOR|Placebo|one IM injection
62380356|NCT01635387|EXPERIMENTAL|Aliskiren|
62558535|NCT00439985|OTHER|Behavioral: Cognitive Behavior Therapy|
62759327|NCT04819230|EXPERIMENTAL|Bias Modification|Attention (ATT) and interpretation (ITT) bias training. Participants complete the ATT and ITT tasks twice per week for four weeks. The ATT trains attention toward neutral stimuli and away from negative stimuli. On trials with one neutral and one threat word, the probe will always follow the location of the neutral word. Therefore, there is a contingency between the valence of the word and the location of the probe. Participants will be asked to indicate which type of probe had appeared in each trial by pressing a corresponding button as rapidly and accurately as possible. The ITT trains participants to make benign (vs. threatening) interpretations of socially-ambiguous scenarios. For each trial, a word suggesting a socially threatening or benign interpretation is presented then replaced by a sentence describing a socially-ambiguous scenario. Participants indicate if they thought the word and sentence were related. Participants will receive corrective feedback after each trial.
62759328|NCT04819230|PLACEBO_COMPARATOR|Control Condition|"A combination of attention (ATT-C) and interpretation (ITT-C) control tasks~These tasks are identical to the experimental tasks (ATT and ITT) with the exceptions that:~ATT-C: It is designed to train attention toward neither neutral nor the threat stimuli. This will be achieved by having an equal number of probes follow the location of the threatening word and the neutral word.~ITT-C: It is not designed to train benign interpretations of ambiguous social scenarios. Thus, no feedback will be given during the inter-trial interval, rather participants will see a blank screen between trials.~Participants will complete both the ATT-C and ITT-C tasks twice per week for four weeks, totaling to eight experimental sessions."
62759329|NCT02133664|EXPERIMENTAL|lipoic acid and omega-3 fatty acids|lipoic acid and omega-3 fatty acids
62759330|NCT02133664|PLACEBO_COMPARATOR|placebo|placebo oil and placebo lipoic acid
62759331|NCT04909502|EXPERIMENTAL|EHP-101 Once a day (OD)|
62759332|NCT04909502|EXPERIMENTAL|EHP-101 Twice a day (BID)|
62380357|NCT01635387|PLACEBO_COMPARATOR|Placebo|
62759333|NCT01628614||POAG or OHT|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
62759334|NCT02726880|ACTIVE_COMPARATOR|Referral for care|
62759335|NCT02726880|EXPERIMENTAL|Behavioral therapy|
62759336|NCT05562362|EXPERIMENTAL|Fasted State|Sparsentan will be administered in 3-dose level in healthy subjects. Subjects will be randomized to 1 of 3 dose levels (200mg, 400mg and 800 mg) and will receive a single dose of sparsentan in the fasted state on Period 1, Day 1 (Study Day 1)
62759337|NCT05562362|EXPERIMENTAL|Fed State|Sparsentan will be administered in 3-dose level in healthy subjects. Subjects will have a single dose of sparsentan (200mg, 400mg and 800 mg) in the fed state (high-fat breakfast) on Period 2, Day 1 (Study Day 8)
62759338|NCT05562362|EXPERIMENTAL|Fed State - Multiple|Sparsentan will be administered in 3-dose level in healthy subjects. Subjects will have multiple doses of sparsentan (200mg, 400mg and 800 mg) in the fed state on Period 3, Days 1 to 14 (Study days 12 to 25)
62759339|NCT01887119|ACTIVE_COMPARATOR|Eplerenone|Eplerenone 50 mg 1dd during four weeks
62380358|NCT00245635|EXPERIMENTAL|Fluoxetine|Fixed/flexible dosing regimen of fluoxetine based on weight of subject and reaction to dosage, varying between 10mg and 80mg tablets once a day.
62168171|NCT01190449|EXPERIMENTAL|Arm II|Patients receive a lower dose of ofatumumab IV over 2-8 hours on days 1, 8, 15, and 22 and then once monthly in months 3-9.
62168172|NCT01263275|EXPERIMENTAL|Active tDCS|
62168173|NCT05066178|EXPERIMENTAL|CAS Treatment for MV ASD|Participants will receive CAS treatment, modified for minimally verbal children with autism
62380359|NCT00245635|PLACEBO_COMPARATOR|Placebo|Placebo tablets will be given 1/day for the duration of the study with a dosing schedule equivalent to that of the drug.
62380360|NCT04411225|EXPERIMENTAL|Cannabidiol Augmentation|The cannabidiol will be administered as an oral solution to be mixed in any fluid. The formulation is 100 mg/ml. It will be administered at 500 mg at bedtime X 1 week then 500 mg BID.
62380361|NCT04411225|PLACEBO_COMPARATOR|Placebo Augmentation|Placebo will appear identical to the cannabidiol solution
62558536|NCT01875978|ACTIVE_COMPARATOR|Phytosterols & placebo|Group A:daily 1.8g phytosterols powder for 4 weeks first;group B:placebo for 4 weeks first
62759340|NCT01887119|PLACEBO_COMPARATOR|Placebo|Eplerenone-matched placebo
62759341|NCT03250039|EXPERIMENTAL|Mass Balance|Cumulative recovery of radioactivity in urine and feces
62759342|NCT03250039|EXPERIMENTAL|Absolute Bioavailability|Oral absolute bioavailability
62759343|NCT05825924|ACTIVE_COMPARATOR|Study Arm A: Electronic Cigarettes (18mg/ml)|Participants randomized to study arm A will be provided a free e-cigarette and sufficient nicotine cartridges (18 mg/ml) supply to last till next in person visit. Participants will be instructed to use the device ad libitum one week before their quit day to familiarize themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the e-cigarette exclusively for the next 12 weeks. Smokers often take 10 to 15 puffs over the course of 5 to 8 minutes, repeating this pattern with each cigarette. On the other hand, users of EC may periodically use it throughout the day, and they may or may not take their puffs like those of traditional cigarettes
62759344|NCT05825924|ACTIVE_COMPARATOR|Study Arm B: 21 mg nicotine patches|Participants randomized to study arm B will be provided 21 mg nicotine patches supply to last till next in person visit. Participants will use the nicotine patch daily for one week before their quit day to familiarize themselves with its use. On their designated quit day they will stop smoking and use nicotine patches daily for the next 12 weeks. Usually a full-strength patch (15-22 mg of nicotine) daily for four weeks is suggested for use in majority of the smokers, followed by a lower strength patch (5-14 mg of nicotine) for an additional four weeks, depending on their body size and smoking habits
62759345|NCT03854292||Hysteroscopic tubal electrocoagulation|Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopic electrocoagulating roller ball
62759346|NCT03854292||Laparoscopic tubal disconnection|Coagulation of the mid isthmus region of the affected Fallopian tube, with the bipolar forceps. using direct current that was no greater than 25 Watts.
62759347|NCT01053559|OTHER|certolizumab pegol|Subjects will receive FDA approved Cimzia injections as indicated on the product label. Subjects will undergo 3 wireless capsule endoscopies, one at screening,Day 84 and Day 168 as well as monthly bloodwork.
62759348|NCT04963530|EXPERIMENTAL|Wear of antagonist teeth to monolithic zirconia restorations|Evaluate enamel wear antagonist to monolithic zirconia restorations monitoring the short and medium-term volume loss and assessing the factors that may influence this wear.
62759349|NCT04963530|EXPERIMENTAL|Wear of antagonist teeth to lithium disilicate restorations|Evaluate enamel wear antagonist to lithium disilicate restorations monitoring the short and medium-term volume loss and assessing the factors that may influence this wear.
62759350|NCT04963530|EXPERIMENTAL|Wear of antagonist teeth to metalceramic restorations|Evaluate enamel wear antagonist to metal ceramic restorations monitoring the short and medium-term volume loss and assessing the factors that may influence this wear.
62759351|NCT04963530|EXPERIMENTAL|Wear of natural enamel|Evaluate physiological enamel wear (control group) monitoring the short short and medium-term volume loss and assessing the factors that may influence this wear.
62759352|NCT05801055|EXPERIMENTAL|Arm 1|Arm which will be randomised to get the combination drink prior to the diagnostic endoscopy
62759353|NCT05801055|NO_INTERVENTION|Arm 2|Comparator arm where endoscopy will be done without any drink
62759354|NCT05433740|EXPERIMENTAL|Group I: Adjustable ligament|In the adjustable ligament method, binding tape with a button at one end and button holes along the band was wrapped around the outer end of the bite-block section of the device. The ends of the tape were then passed over the outer end of the bite block between two tubes and adjusted at or above the ear level (except neck veins), and fixed by inserting the button through the appropriate hole.
62759355|NCT05433740|NO_INTERVENTION|Group II: Adhesive tape|The laryngeal mask was fixed using the standard method using adhesive tape.
62759356|NCT03521713|EXPERIMENTAL|EPORON|"\<Part 1 Treatment Period\> Week 1 to Week 24 Initial Phase (Week 1 to Week 4) : 50 IU/kg of Erythropoietin Alpha, three times a week (3 x 50 IU/kg/week) No dose adjustments will be permitted during the first 4 weeks of the study. Maintenance Phase (Week 5 to Week 24) The dose will be adjusted to maintain Hb levels between 10 and 12 g/dL.~\<Part 2 Treatment Period\> : Week 25 to Week 52 The dose of Erythropoietin Alpha will be adjusted to maintain hemoglobin levels between 10 and 12 g/dL as subcutaneous administration in accordance with the given dosing algorithm. The further details are the same as those for maintenance phase of Part 1 Treatment Period."
62380362|NCT04102696|EXPERIMENTAL|The aromatherapy arm|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
62380363|NCT04102696|PLACEBO_COMPARATOR|The placebo arm|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
62759357|NCT03521713|ACTIVE_COMPARATOR|EPREX|"\<Part 1 Treatment Period\> Week 1 to Week 24 Initial Phase (Week 1 to Week 4) : 50 IU/kg of Erythropoietin Alpha, three times a week (3 x 50 IU/kg/week) No dose adjustments will be permitted during the first 4 weeks of the study. Maintenance Phase (Week 5 to Week 24) The dose will be adjusted to maintain Hb levels between 10 and 12 g/dL.~\<Part 2 Treatment Period\> : Week 25 to Week 52 The dose of Erythropoietin Alpha will be adjusted to maintain hemoglobin levels between 10 and 12 g/dL as subcutaneous administration in accordance with the given dosing algorithm. The further details are the same as those for maintenance phase of Part 1 Treatment Period."
62759358|NCT05058105|EXPERIMENTAL|FL058 500mg and Meropenem 1000mg|"FL058 500mg and Meropenem 1000mg (8 subjects);~FL058 Placebo and Meropenem 1000mg(2 subjects)"
62759359|NCT05058105|EXPERIMENTAL|FL058 1000mg and Meropenem 1000mg|"D1~FL058 1000mg(8 subjects) and FL058 Placebo(2 subjects);~D4~Meropenem 1000mg(8 subjects) and Meropenem Placebo(2 subjects);~D7\~ D15~FL058 1000mg and Meropenem 1000mg (8 subjects);~FL058 Placebo and Meropenem 1000mg(2 subjects)"
62759360|NCT05058105|EXPERIMENTAL|FL058 1000mg and Meropenem 2000mg (IV 120min)|"FL058 1000mg and Meropenem 2000mg (8 subjects);~FL058 Placebo and Meropenem 2000mg(2 subjects)"
62759361|NCT05058105|EXPERIMENTAL|FL058 1000mg and Meropenem 2000mg (IV 180min)|"FL058 1000mg and Meropenem 2000mg (8 subjects);~FL058 Placebo and Meropenem 2000mg(2 subjects)"
62759362|NCT05058105|EXPERIMENTAL|FL058 2000mg and Meropenem 2000mg|"FL058 2000mg and Meropenem 2000mg (8 subjects);~FL058 Placebo and Meropenem 2000mg(2 subjects)"
62759363|NCT00167180|ACTIVE_COMPARATOR|CML|Patients with Chronic Myelogenous Leukemia (CML) who have failed or refused Gleevec(TM) therapy and will receive Donor Lymphocyte Infusion.
62759364|NCT00167180|ACTIVE_COMPARATOR|Non-CML or CML that Relapsed after Donor Lymphocyte Infusion|Patients with non-CML or CML who have failed Donor Lymphocyte Infusion (DLI) and will receive induction chemotherapy plus DLI.
62759365|NCT02885870|EXPERIMENTAL|Patient|"Patient with :~* Spinal muscular atrophy (n=25)~* X-linked spinobulbar muscular atrophy (n=25)~* Amyotrophic lateral sclerosis (n=25)"
62759366|NCT02885870|EXPERIMENTAL|Healthy subject|Subject without any neurologic or spine affection Subject matched for sex and age with patient arm
62759367|NCT03455829|EXPERIMENTAL|Part 1: Cohort 1 G1T38 + Osimertinib|Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
62759368|NCT03455829|EXPERIMENTAL|Part 1: Cohort 2 G1T38 + Osimertinib|Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
62759369|NCT03455829|EXPERIMENTAL|Part 1: Cohort 3 G1T38 + Osimertinib|Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
62380364|NCT04979338|ACTIVE_COMPARATOR|Surgery-specific general anesthetic + ultrasound guided peripheral nerve block #1|"Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the pre-incision, intra-op, mid-surgery, end of surgery, or continuous time points:~* Bilateral spermatic cord block (0.5% bupivacaine, 10cc per spermatic cord)~* Local anesthetic (0.25% or 0.5% bupivacaine + 1:200K epinephrine)~* Bilateral ultrasound guided pudendal nerve block (20-40 cc of 0.25% bupivacaine + 1:200K epinephrine)~* Ultrasound guided Continuous Infraclavicular Brachial Plexus Block~* Ultrasound guided Continuous Femoral Nerve Block~* Pecs I \& II Block (0.25% bupivacaine: 15-30ml per side for Pecs I-III)"
62168174|NCT05455489||FUNCTIONAL MR|Patients with symptomatic severe secondary MR (3-4+, according to the multiparametric study algorithm), both ischemic or non-ischemic etiology, on optimal medical therapy
62380365|NCT04979338|ACTIVE_COMPARATOR|Surgery-specific general anesthetic + ultrasound guided peripheral nerve block #2|"Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the intra-op, post-op, or end of surgery time points:~* Bilateral ultrasound-guided Transversus Abdominis Plane Block (40-60cc of 0.25% bupivacaine with 1:200K epinephrine)~* Local anesthetic (0.25 or 0.5% bupivacaine + 1:200K epinephrine)"
62759370|NCT03455829|EXPERIMENTAL|Part 1: Cohort 4 G1T38 + Osimertinib|Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
62759371|NCT03455829|EXPERIMENTAL|Part 1: Cohort 5 G1T38 + Osimertinib|Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
62759372|NCT03790774|EXPERIMENTAL|Neurofeedback|Three times per week, for six weeks, participants will receive biofeedback about the quality of their electroencephalograms (EEG; neurofeedback) during a letter identification task.
61987198|NCT06455397|EXPERIMENTAL|The BEAM Program Group|All study participants will complete 12 weeks of the BEAM program. Each week of BEAM includes: (a) 15-20 minutes of therapeutic mental health and parenting video content, (b) exercises to practice key skills, (c) access to the online forum to cultivate social support through interaction with other parents and peer coaches, (d) individual check ins with peer coaches (i.e., trained and supervised staff with lived experience) via Zoom for Healthcare, phone, or direct messaging, and (e) a brief in-app survey for symptom monitoring to track progress. Participants will also be invited to virtual group drop-in sessions facilitated by peer coaches and be connected with a systems navigator who can support participants in accessing other community resources (e.g., childcare programs, legal aid, housing).
62380366|NCT04979338|ACTIVE_COMPARATOR|Surgery-specific general anesthetic + local anesthetic at incision site|"Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the mid-surgery or end of surgery time points:~* Bilateral spermatic cord block (0.5% bupivacaine, 10cc per spermatic cord)~* Local anesthetic (0.25 or 0.5% bupivacaine + 1:200K epinephrine)"
62759373|NCT06384326||Spanish parents|Spanish parents were recruited at the Department of Paediatric Dentistry of UIC between March 2023 and July 2023, accomplishing the second phase of the survey.
62380367|NCT01889615||Suspected ovarian cancer|dual time PET/CT
62380368|NCT05261594|OTHER|Panic disorder|Participants will be randomized to start with either the caffeine condition or placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).
62380369|NCT05261594|OTHER|Healthy controls|Participants will be randomized to start with either the caffeine condition or placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).
62380370|NCT06336694||peritoneal metastases|No intervention had been adminstered during treatment of patients.
62759374|NCT06384326||Italian parents|Italian parents were recruited at the Unit of Dental Care for Special Needs Patients and Paediatric Dentistry at the University of Bologna, Bologna, Italy, and the Unit of Paediatric Dentistry at the University of Pisa, Pisa, Italy between September 2020 and March 2022
61987199|NCT01997515|ACTIVE_COMPARATOR|Group K (Ketamine)|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
61987200|NCT01997515|PLACEBO_COMPARATOR|Group P (Placebo)|Group P (placebo) will receive the same amount of saline.
62380371|NCT06336694||without peritoneal metastases|No intervention had been adminstered during treatment of patients.
62567609|NCT03416205|EXPERIMENTAL|EST|EST is an operation using the Erbao electric knife and Three-cavity incision knife to make a large incision to the duodenal nipples，and the incision scope is the nipple mouth uplift length of 4/5. It has been used since 1974. The technique is intuitive and intact. However, EST cut too small to achieve the purpose of treatment and will affect the next step, and if the incision is too large it may be easier to occur gastrointestinal perforation and bleeding.The EST will also damage the anatomy of the Oddi sphincter structure,which causes bacterial reflux to the bile duct, the recurrence of CBD.Some surgeons prefer it because it's postoperative pancreatitis rate is lower and it may be easier to find the lesion position if bleeding or perforation occurs.
62759375|NCT04149860|EXPERIMENTAL|Part A: Lu AF87908 or Placebo|Participants in Cohorts A1 to A6 will receive a single dose of either Lu AF87908 or matching placebo at specific dose levels on Day 1.
62759376|NCT04149860|EXPERIMENTAL|Part B: Lu AF87908 or Placebo|Participants in Cohorts B1 to B3 will receive a single dose of either Lu AF87908 or matching placebo at specific dose levels on Day 1.
62759377|NCT04149860|EXPERIMENTAL|Part C: Lu AF87908 or Placebo|Participants in Cohorts C1 and C4 will receive a single dose of either Lu AF87908 or matching placebo at specific dose levels on Day 1.
62759378|NCT02581462|EXPERIMENTAL|FLOT alone|Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT
62759379|NCT02581462|EXPERIMENTAL|FLOT + Herceptin/Pertuzumab|Pre-operative therapy with FLOT + Herceptin/Pertuzumab followed by surgical resection followed by post-operative therapy with FLOT + Herceptin/Pertuzumab
62759380|NCT02739321|EXPERIMENTAL|Mattress Technology On then Off|"Intervention: Sound to Sleep System will be turned on for the first two weeks of the study allowing the participant sleeping atop the mattress to feel the vibrations synced to the audio input. Sound to sleep system will be turned on during this phase of the study. The sound to sleep system will sync an audio input with the vibrations of the mattress technology and allow the user to control the intensity of the vibration.~No intervention: The mattress technology will be turned off for the second two weeks of the study. During this time, there will be no intervention."
62759381|NCT02739321|EXPERIMENTAL|Mattress Technology Turned Off then On|"No intervention: For the first two weeks of the study, the mattress technology will not be turned off. There will be no intervention during this time.~Intervention: Sound to Sleep System will be turned on for the second two weeks of the study allowing the participant sleeping atop the mattress to feel the vibrations synced to the audio input. Sound to sleep system will be turned on during this phase of the study. The sound to sleep system will sync an audio input with the vibrations of the mattress technology and allow the user to control the intensity of the vibration."
62759382|NCT02441140|EXPERIMENTAL|Culdocentesis|"* Patients with known or highly likely ovarian cancer (i.e. highly elevated CA-125, ascites, pelvic mass) scheduled for cytoreductive surgery will be identified during preoperative consultation and offered participation in the study.~* During Surgery:~  * Blood Collection~ * Vaginal Swab~ * Chromopertubation~ * Culdocentesis~ * Tissue Collection"
62759383|NCT00545220|EXPERIMENTAL|1|PST
62759384|NCT00545220|SHAM_COMPARATOR|2|Attention Control
62759385|NCT04695002||Control group|Citizens in the control group participate in the existing course of vocational rehabilitation offered in the municipal employment department, without the use of MIRA app.
62759386|NCT04695002||MIRA group|Citizens in the MIRA group will participate in the existing course of vocational rehabilitation offered in the municipal department. In addition they will be introduced to MIRA at the beginning of the rehabilitation course, and use MIRA throughout the course of rehabilitation.
62759387|NCT01902888||Popliteal aneurysm|GORE® VIABAHN® Endoprosthesis used to treat popliteal aneurysm
62759388|NCT05214391|EXPERIMENTAL|Intervention ( zanubrutinib)|30 enrolled patients are picked up to take zanubrutinib at the indicated dose.
62759389|NCT03285087|EXPERIMENTAL|DEX 0.2 μg/kg/h|Patients will receive dexmedetomidine for sedation with initial maintenance dose rate of 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
62759390|NCT03504241|EXPERIMENTAL|MSCs 10^4 cells/kg+anti-rejection drugs|The first dosing cohort of 2 participants will receive 12 infusions of 10\^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg every 4-weeks.
62759391|NCT03504241|EXPERIMENTAL|MSCs 10^5 cells/kg+anti-rejection drugs|If the first 3 infusions of 10\^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10\^5 cells/kg every 4-weeks.
62759392|NCT01869413|EXPERIMENTAL|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours). For example, an 80 kg patient would receive 800 mg prior to incision and a 400 mg/hr infusion for the duration of surgery. For a 6 hour procedure, the total dose administered would be 3200 mg.
62380372|NCT02062099|EXPERIMENTAL|Memory complaint /MCI/ mild to moderate MA|Memory complaint (without cognitive decline): 12 patients/ Mild Cognitive Impairment: 12 patients/ Mild to moderate Alzheimer Disease: 12 patients
62380373|NCT01796106|EXPERIMENTAL|Resin infiltration|Enrolled proximal early caries lesions will be treated using the resin infiltrant Icon (DMG, Germany).
62759393|NCT01869413|PLACEBO_COMPARATOR|Placebo control|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
61987201|NCT00493584|EXPERIMENTAL|1|Primary PCI in patients with acute Non-STEMI
62380374|NCT01796106|ACTIVE_COMPARATOR|Fluoride varnish & Oral hygiene instruction|Oral hygiene instruction and topical fluoridation therapy (Duraphat Fluoride Varnish, Colgate, USA) will be provided.
62380375|NCT01392040||Patients in oral anticoagulant therapy|Patients taking oral anticoagulant therapy
62759394|NCT03035253|EXPERIMENTAL|OMP-305B83 combined with FOLFIRI or FOLFOX|
62759395|NCT00704561|ACTIVE_COMPARATOR|DES - Zotarolimus Drug eluting stents|Zotarolimus Drug eluting stents in overlap
62759396|NCT00704561|ACTIVE_COMPARATOR|BMS -Bare metal stent|Bare metal stent
62759397|NCT05516030|EXPERIMENTAL|HIFT for People with MRD|12-week, thrice weekly HIFT intervention for adults with MRD at a local facility that currently hosts HIFT for people with disability and, thus, is conducive to the training needs of individuals with MRD. We will provide financial support for 12-week membership costs, transportation, and participant compensation for completing pre- and post-intervention assessments. Baseline and post-intervention testing will include assessments of weight, body composition, flexibility, and strength, in addition to quality of life, sense of community, self-determination, sleep, and life satisfaction. Each participant will also have energy expenditure assessed during two, randomly selected HIFT sessions during the 12-wk intervention.
62759398|NCT04969965|EXPERIMENTAL|Aumolertinib|single dose oral 110mg of aumolertinib
62759399|NCT02798770||Stroke Center Basel|
62759400|NCT00074373||human beings|human beings of all sexes, ages, and health statuses
62759401|NCT01639287||Painless|"Painless synovitis group(called cold synovitis)"
62759402|NCT01639287||Painful|Painful synovitis group
62759403|NCT03624426|EXPERIMENTAL|Automated SSEP Monitored Group|SSEP monitored group: When a nerve alert is signaled by the automated SSEP device, the surgeon will be informed with the aim to reverse the signal changes. The possible surgical interventions include repositioning the operative arm into a more neutral position, avoidance of excessive traction, removal of retractors, and using a smaller implant to avoid over-correction/traction. The actual intervention will depend on the possible mechanism of nerve injury and treated accordingly.
62759404|NCT03624426|NO_INTERVENTION|Standard Group|The automated SSEP device will be connected and will be blinded to the surgeon. The screens of the automated SSEP device will be covered by an opaque plastic bag and the alarms will be turned off. No intervention is planned for this group.
62759405|NCT04677426|EXPERIMENTAL|Subjects with Progressive Interstitial Lung Disease|Assess the intra-visit reliability and sensitivity to progression of 129Xe MR imaging measurements using a standardized imaging protocol in subjects with IPF and cHP.
62759406|NCT06245239||group I|children aged \< 3years undergoing hypospadias repair surgery.
62759407|NCT03861572|EXPERIMENTAL|Isokinetic eccentric group|The isokinetic eccentric training will be carried out with the volunteers positioned seated on the dynamometer with the apparent axis of the ankle joint rotation aligned with the dynamometer's axis of rotation. Movement will be executed in the angular velocity of 30°·s-1. Ankle range of motion (ROM) will be standardized for all participants in 50º, which shall respect each individual's maximal dorsiflexion amplitude. The 50° eccentric training ROM will start from each subject's 80% of the maximal dorsiflexion. This procedure will be used to ensure that all subjects perform training on the same plantar flexor muscular length, which should promote the same level of muscular requirement among the participants. This methodology was recently used by GEREMIA and VAZ (2016) study.
62759408|NCT03861572|ACTIVE_COMPARATOR|Traditional eccentric training|Participants will be engaged in an intervention program consisting of 12 weeks of traditional eccentric training. The training will be carried out with the volunteers at gym in stand position. Concentric phase will be realized with both legs and the eccentric one only with one of them. Training progression will be the same from de isokinetic eccentric group. The same periodization from eccentric group will be used to permit us a posteriori comparison between groups. Training sessions will be performed at university gym, twice a week, with a minimum interval of 72 hours between sessions. Each training session will comprise the same specific warming protocol for the ankle joint from the eccentric training.
62380376|NCT04914806||Cases|Infants treated with iNO (from birth to 1-3 weeks of life) or sequential treatment with iNO and sildenafil (for 1 to 3 months).
62380377|NCT04914806||Controls|Infants matched to cases (gestational/postnatal age, gender, disease state) and no iNO treatment.
62380378|NCT02084472|ACTIVE_COMPARATOR|study 1: aqueous cream and baby oil|enrolled patients in this arm use either aqueous cream or baby oil as a soap substitute
62558537|NCT02721381|EXPERIMENTAL|Self-Directed Group|Participants assigned to the self-directed group will receive access to the secure, password-protected, ImPACT Online web-based program for four months. The web application contains 12, self-directed lessons, each of which takes approximately 75 minutes to complete. Participants will be encouraged to complete one lesson per week and to practice the intervention techniques with their child between each lesson. Each lesson consists of a Narrated Slideshow with embedded video clips, a Written Manual, a self-check quiz, short interactive exercises, a Homework Plan, and reflection questions. Participants in the self-directed group may contact project staff via phone or email for assistance with technology-related problems (e.g., difficulty with logins, problems playing video). However, they will receive no assistance or support in learning the intervention from project staff outside of the self-directed web-based program.
62759409|NCT00847665|ACTIVE_COMPARATOR|Turning every 4 hours|The four-hours repositioning group patients were turned every four hours following the next sequence: left side, back with a 30º elevation of the head end and the foot end of the bed, right side using the 30º tilt, back.
62759410|NCT00847665|EXPERIMENTAL|Turning every 2 hours|The two-hours repositioning group patients, were turned every two hours following the next sequence: left side, back with a 30º elevation of the head end and the foot end of the bed, right side using the 30º tilt, back.
62759411|NCT01113905||Radiation Only|
62759412|NCT01113905||Radiation and Chemotherapy|
62759413|NCT03846531|ACTIVE_COMPARATOR|Nano-Pulse Stimulation (NPS) Lesion|Three of four selected SK lesions receive Nano-Pulse Stimulation treatment.
62759414|NCT03846531|NO_INTERVENTION|Non-Treated Lesion|One of four SK lesions is randomized to not receiving Nano-Pulse Stimulation treatment.
62759415|NCT01971216|NO_INTERVENTION|Control|Breastfeeding mothers who are not randomised to relaxation intervention
62759416|NCT01971216|EXPERIMENTAL|Relaxation|Breastfeeding mothers randomised to use relaxation tape at 2 weeks post-partum
62759417|NCT01206283|ACTIVE_COMPARATOR|Cerebral perfusion pressure-targeted|15 comatose operated patients after aneurysmal subarachnoid haemorrhage and severe traumatic brain injury respectively were managed postoperatively using cerebral perfusion pressure-targeted therapy according to the American Associations of Neurological Surgeons. Results were categorised into different Glasgow Outcome Scores.
62759418|NCT01206283|ACTIVE_COMPARATOR|Intracranial pressure-targeted therapy|
62759419|NCT03112967|EXPERIMENTAL|OSS(Suprep)|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
62759420|NCT03112967|ACTIVE_COMPARATOR|4L PEG solution(Colyte)|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
62759421|NCT04942665|EXPERIMENTAL|Low Dose|Prior to surgery these patients will be given a ICG dose of 0.05 mg IV.
62380379|NCT02084472|ACTIVE_COMPARATOR|study 2: emulsifying ointment and cetomacrogol|patients in this study arm continue to use emulsifying ointment and cetomacrogol as a moisturiser, the current standard of care in our institution
62759422|NCT04942665|PLACEBO_COMPARATOR|Standard Dose|Prior to surgery these patients will be given the ICG standard dose of 2.5 mg IV.
62759423|NCT03060395|SHAM_COMPARATOR|A1/A2 milk|"Commercial conventional A1/A2 semi-skimmed fresh pasteurised cow milk. Progressive intake of intervention milk as follows:~* Days 1 and 2: 100 mL twice a day~* Days 3 and 4: 150 mL twice a day~* Days 5 and 6: 200 mL twice a day~* Days 7 to 14: 250 mL twice a day"
62759424|NCT03060395|ACTIVE_COMPARATOR|A2 milk|"Commercial A2 semi-skimmed fresh pasteurised cow milk.~Progressive intake of intervention milk as follows:~* Days 1 and 2: 100 mL twice a day~* Days 3 and 4: 150 mL twice a day~* Days 5 and 6: 200 mL twice a day~* Days 7 to 14: 250 mL twice a day"
62759425|NCT03410797|OTHER|Voice Disorder Requiring Voice Therapy|Individuals with a voice disorder such as muscle tension dysphonia (MTD), vocal fold atrophy or vocal fold lesions recommended for voice therapy as treatment.
62759426|NCT00496197|EXPERIMENTAL|1.|Subjects receive anidulafungin IV followed by oral therapy with fluconazole or voriconazole.
62759427|NCT03067493|EXPERIMENTAL|Neo-MASCT group|Patients in the treatment group will receive a total of 6 courses of Neo-MASCT treatment. The whole period of Neo-MASCT treatment for each patient will be up to 24 months.Three stratification factors are considered, i.e.tumor size (2.1-3.0cm, 3.1-5.0cm), tumor number (1, \>1) and type of surgery (RFA，hepatectomy).
62759428|NCT03067493|NO_INTERVENTION|Control group|Patients in the control group will be actively monitored during the trial period. Patients will receive assessment every 3 months in the first 3 years.
62380380|NCT04995666|EXPERIMENTAL|Hearing Aid|Participants will wear Phonak rechargeable Audeo hearing aids
62380381|NCT04202029|OTHER|pulseoxymetry arm|pulseoxymetry arm: standard monitoring: pulseoxymetry and non-invasive blood preassure monitoring
62759429|NCT04902404|EXPERIMENTAL|First Pathways Group|Parents in the First Pathways Game group will be instructed to log into the First Pathways website daily and play First Pathways games with their child. They will receive daily reminders for the first month after randomization but will not receive reminders for the second month.
62380382|NCT04202029|EXPERIMENTAL|thoracic impedance monitoring arm|thoracic impedance monitoring arm: standard monitoring and additionally thoracic impedance measurement)
62759430|NCT04902404|NO_INTERVENTION|Wait-list Control|Parents in the wait-list control group will receive access to the First Pathways game after completing their final two-month study assessment.
62380383|NCT02139176|ACTIVE_COMPARATOR|Patient referral|Women are given an invitation to give to a male partner inviting them to come to the clinic for important pregnancy information
62380384|NCT02139176|EXPERIMENTAL|contract referral|Same as control. However, if the male partner does not present, a community worker will trace the partner in the community.
62380385|NCT06360510||%5 dextrose group|
62380386|NCT06360510||betamethasone group|
62380387|NCT04653558||definite LNB|patients with definite early Lyme neuroborreliosis
62759431|NCT06416176|EXPERIMENTAL|Experimental group|Participants in the experimental group received an 8-week MBSR program by an MBSR instructor.
62759432|NCT06416176|NO_INTERVENTION|Control group|The patients in the control group continued to visit the society for their scheduled examinations and controls; no intervention was given to them. Furthermore, the control group received an invitation to participate in an identical MBSR program session following the study's conclusion.
62380388|NCT04653558||possible LNB|patients with possible early Lyme neuroborreliosis
62380389|NCT01007318|ACTIVE_COMPARATOR|Single port|Single port through the transumbilical incision was made by wound retractor combined with surgical glove and then 3 trocal was inserted to the finger part of the surgical glove. Laparoscopic instrument was working through the single port and resected appendix removed through it.
62380390|NCT01007318|ACTIVE_COMPARATOR|3 port|3 port laparoscopic appendectomy was done by conventional method
62380391|NCT00886587|EXPERIMENTAL|11054-010|F# 11054-010 Investigational Device
62380392|NCT00886587|ACTIVE_COMPARATOR|10495-053|F# 10495-053 Atopiclair
62380393|NCT04035473|ACTIVE_COMPARATOR|Sequence A (Oraxol, IV paclitaxel)|"The treatment sequences will be:~A Oraxol (paclitaxel + HM30181) on Days 1, 2, and 3 of Treatment Period 1 followed by IV paclitaxel on Day 1 of Treatment Period 2 B IV paclitaxel on Day 1 of Treatment Period 1 followed by Oraxol on Days 1, 2, and 3 of Treatment Period 2"
62380394|NCT04035473|ACTIVE_COMPARATOR|Sequence B (IV paclitaxel, Oraxol)|"The treatment sequences will be:~A IV paclitaxel on Day 1 of Treatment Period 1 followed by Oraxol on Days 1, 2, and 3 of Treatment Period 2 B Oraxol (paclitaxel + HM30181) on Days 1, 2, and 3 of Treatment Period 1 followed by IV paclitaxel on Day 1 of Treatment Period 2"
62380395|NCT03410602|PLACEBO_COMPARATOR|Supragingival and subgingival scaling|Supragingival and subgingival scaling group comprised of 15 orthodontic patients treated with routine full-mouth supragingival scaling and subgingival scaling only around all banded first molars. Parameters such as radiographic evidence of alveolar crestal bone level, gingival index, probing pocket depth and clinical attachment level around the banded first molars and full-mouth plaque index were recorded as a change from baseline to 12th month.
62380396|NCT03410602|ACTIVE_COMPARATOR|Subgingival irrigation|Subgingival irrigation group comprised of 15 orthodontic patients treated with full-mouth supragingival scaling and subgingival scaling only around all banded first molars followed by irrigation with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent. Parameters such as radiographic evidence of alveolar crestal bone level, gingival index, probing pocket depth and clinical attachment level around the banded first molars and full-mouth plaque index were recorded as a change from baseline to 12th month.
62380397|NCT01906814|EXPERIMENTAL|3 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for three cycles.
62567610|NCT03416205|EXPERIMENTAL|EPBD|EPBD is an operation using the Columnar expansion balloon to expand duodenal to achieve the purpose of using the basket and other instruments to take stone out. Balloon expansion may retain part of the sphincter not destroyed, and basically retain the normal physiological function of the nipple sphincter.Thus it may reduce the risk of recurrence of stones and bacterial reflux. However,the postoperative pancreatitis rate is high(4.8% -19.5% ), and nipple sphincter tear is uncontrollable in EPBD.If the digestive tract perforation or bleeding occur after EPBD,it is hard to accurately find the lesion position.Some surgeons prefer it for it's lower bleeding and perforation rate.
62759433|NCT05250050|EXPERIMENTAL|Genotypic resistance guided therapy|After Helicobacter pylori drug resistance mutation gene detection, according to genotypic antibiotic resistance pattern of each one, give esomeprazole 20mg bid and bismuth potassium citrate 0.6 g bid, combined two sensitive antibiotics of Amoxicillin, tetracycline,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.
62759434|NCT05250050|EXPERIMENTAL|Phenotypic resistance guided therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to phenotypic antibiotic resistance pattern of each one, give esomeprazole 20mg bid and bismuth potassium citrate 0.6 g bid, combined two sensitive antibiotics of Amoxicillin, tetracycline,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.
62759435|NCT05250050|ACTIVE_COMPARATOR|Empiric therapy|Esomeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid, and Amoxicillin 1.0 g bid (no penicillin allergy) OR tetracycline 0.5g qid (penicillin allergy) for 14 days
62759436|NCT04716075|EXPERIMENTAL|Acalabrutinib 2x100mg oral capsule +alloSCT|Acalabrutinib administered 2x100mg p.o. daily for 3-6 months before alloSCT +acalabrutinib administered 2x100mg p.o. daily for 9 months after alloSCT
62759437|NCT04007289|ACTIVE_COMPARATOR|APIXABAN|Apixaban, 1 pill of 2.5 mg per os twice a day (one in the morning and one in the evening) for 24 months.
62759438|NCT04007289|PLACEBO_COMPARATOR|PLACEBO|Placebo, 1 pill per os twice a day (one in the morning and one in the evening) for 24 months.
62380398|NCT01906814|ACTIVE_COMPARATOR|6 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for six cycles.
62380399|NCT04972890|PLACEBO_COMPARATOR|Control group|with 2cc saline/NaCl 0,9% solution once at baseline
61987202|NCT00493584|ACTIVE_COMPARATOR|2|Standard medical treatment and coronary angiography after 3 days in patients with Non-STEMI.
61987203|NCT00982475|ACTIVE_COMPARATOR|PVI with robotic navigation|
61987204|NCT00982475|PLACEBO_COMPARATOR|PVI manually|
62380400|NCT04972890|EXPERIMENTAL|Stem Cell Group|with umbilical cord stem cells 15x10\^6 cells in 2 cc saline/NaCl 0,9% solution once at baseline
62380401|NCT04525911||Symptomatic COVID-19 infection confirmed or probable|Patients and medical staff having symptomatic COVID-19 infection confirmed (by RT-PCR or ELISA serology) or probable (CT criteria)
62759439|NCT02862951||Term pregnancy (>37 weeks gestation)|Term pregnancy (\>37 weeks gestation)
62759440|NCT04447599|EXPERIMENTAL|Photographs|Photographs
62759441|NCT05544942|EXPERIMENTAL|GCWB1001|1 capsule once a day
62759442|NCT05544942|ACTIVE_COMPARATOR|Placebo|1 capsule once a day
62759443|NCT06363318|EXPERIMENTAL|Group A laparoscopic appendicectomy|In Group A (50 patients) laparoscopic appendicectomy was done
62759444|NCT06363318|ACTIVE_COMPARATOR|Group B open appendicectomy|In Group B(50 patients) open appendicectomy was done
62759445|NCT01488292|EXPERIMENTAL|RECAP social skills and reading program|
62759446|NCT01488292|NO_INTERVENTION|Control group (services as usual)|Control Group (services as usual)
62759447|NCT04298866|OTHER|Experimental arm|
62759448|NCT05662904|EXPERIMENTAL|Donor-derived CD33-deleted CD34+ HSC combined with Gemtuzumab-Ozogamicin (GO)|Patients will be transplanted with CD33-deleted CD34+ HSC derived from the initially matched family donor. Upon HSC engraftment, patients will be treated with escalating doses of the anti-CD33 antibodydrugconjugate Gemtuzumab-Ozogamicin (GO). A conditioning regimen containing GO (d-14, d-11, d-8), Fludarabine 30 mg/m2 (d-6 to d-3) and Melphalan 140mg/m2 (d-2) is used prior to transplantation.
62759449|NCT00600691|EXPERIMENTAL|1|5mg finasteride orally, daily for 2 weeks prior to prostate biopsy and one week following prostate biopsy.
62380402|NCT05439629|EXPERIMENTAL|Experimental group：BAT5906|Intravitreal injection; Dosage: 4.0 mg / eye / time, 50 μl; Duration of administration: every 4 weeks, administered to week 48, not administered at 52 weeks.
62759450|NCT03671707|EXPERIMENTAL|Intervention group|Brief AWARD advice + Nicotine replacement therapy sampling + Active referral
62759451|NCT03671707|ACTIVE_COMPARATOR|Control group|Very brief advice (VBA) + Leaflet
62759452|NCT03186391||Patients with suspected PAD|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
62759453|NCT02798991|EXPERIMENTAL|10 mg of GSK3179106 QD-Cohort 1|Eligible six subjects will receive 10 mg oral dose once daily for 14 days
62759454|NCT02798991|EXPERIMENTAL|50 mg of GSK3179106 QD-Cohort 2|Eligible six subjects will receive 50 mg oral dose once daily for 14 days
62759455|NCT02798991|EXPERIMENTAL|200 mg of GSK3179106 QD-Cohort 3|Eligible six subjects will receive 200 mg oral dose once daily for 14 days
61987205|NCT05067582|PLACEBO_COMPARATOR|Placebo Capsules|1 capsule twice daily
61987206|NCT05067582|EXPERIMENTAL|L1-79 200 mg or 300 mg Capsules|1 capsule twice daily
61987207|NCT03967392|ACTIVE_COMPARATOR|GROUP X(xylocaine)|20 ml bupivacaine 0.5% + 20 ml normal saline.
62380403|NCT05439629|ACTIVE_COMPARATOR|Control group：Lucentis®|Intravitreal injection; Dosage: 0.5 mg / eye / time, 50 μl; Duration of administration: every 4 weeks, administered to week 48, not administered at 52 weeks.
62380404|NCT05569356||Arrhythmogenic Right Ventricular Cardiomyopathy (Prospective)|
62380405|NCT05569356||Arrhythmogenic Right Ventricular Cardiomyopathy (Retrospective)|
62380406|NCT03155776||GUS_infants|Infants patient undergoing general anesthesia for abdominal surgery
62380407|NCT01097733||Pre-procedural cardiac CT|CRT patients will undergo pre-procedural cardiac CT to assess for dyssynchrony, scar, and coronary venous anatomy. The CT venogram will be randomize to pre-knowledge to implanting physician or blinded. The CT dyssynchrony and scar assessment will remain blinded to caregivers and patients.
62759456|NCT02798991|EXPERIMENTAL|400 mg of GSK3179106 QD-Cohort 4|Eligible six subjects will receive 400 mg oral dose once daily for 14 days
62759457|NCT02798991|EXPERIMENTAL|25 mg of GSK3179106 BID-Cohort 5|Eligible six subjects will receive 25 mg oral dose twice daily for 14 days
62759458|NCT02798991|EXPERIMENTAL|200 mg of GSK3179106 BID-Cohort 6|Eligible six subjects will receive 200 mg oral dose twice daily for 14 days
62759459|NCT02798991|PLACEBO_COMPARATOR|Matching placebo QD-Cohort 1, 2, 3, 4|Eligible two subjects, per cohort, will receive oral dose of matched placebo once daily for 14 days
62759460|NCT02798991|PLACEBO_COMPARATOR|Matching placebo BID-Cohort 5, 6|Eligible two subjects, per cohort, will receive oral dose of matched placebo twice daily for 14 days
62759461|NCT00823745|EXPERIMENTAL|1|\[14C\]-PF-00868554
62759462|NCT00695799||1|Anesthesia Providers at UMDNJ
62759463|NCT01603797|EXPERIMENTAL|Internet delivered ACT|Internet delivered acceptance and commitment therapy (ACT), 7 weeks treatment
62759464|NCT01603797|ACTIVE_COMPARATOR|Online discussion forum|Active wait-list condition. Were offered to participate in a moderated online discussion forum. After post-treatment assessment the control group were offered treatment.
62759465|NCT01361074|EXPERIMENTAL|In Vivo Exposure|
62759466|NCT01361074|EXPERIMENTAL|Augmented Reality Exposure|
62759467|NCT03351114|EXPERIMENTAL|Crisaborole 2% ointment|Crisaborole 2% ointment applied to affected skin twice per day.
62759468|NCT01471418|EXPERIMENTAL|Disease population|
62759469|NCT03738059|PLACEBO_COMPARATOR|group I (placebo)|will receive intravenous normal saline (NS)
61987208|NCT03967392|ACTIVE_COMPARATOR|GROUPX(Dxylocaine and dexamethasone)|20 ml bupivacaine 0.5% + 18 ml normal saline + 8 mg dexamethasone 2 ml
62567611|NCT03416205|EXPERIMENTAL|sEST+EPBD|sEST+EPBD is an operation combining EST and EPBD. Investigators use the Erbao electric knife and Three-cavity incision knife to make a small incision to the duodenal nipples, and the incision length is less than 5mm while the incision scope is less than the nipple mouth uplift length of 1/2. Then, Investigators match the appropriate Columnar expansion balloon according to the diameter of the common bile duct and gradually expand the duodenal nipples.This method allows the nipple sphincter to be cut in a small range, then the balloon can guide the direction of the nipple sphincter tearing after the expansion , so that the digestive tract bleeding, perforation may be smaller and more controllable. Besides,it may reduce postoperative pancreatitis rate and the recurrence rate of stones.
62759470|NCT03738059|EXPERIMENTAL|group II (Dex 0.5)|will receive intravenous Dex 0.5 mcg/kg
62759471|NCT03738059|EXPERIMENTAL|group III (Dex 0.25)|will receive intravenous Dex 0.25 mcg/kg
62759472|NCT03738059|EXPERIMENTAL|group IV (Dex 0.2)|will receive intravenous Dex 0.2 mcg/kg.
62759473|NCT00361699|ACTIVE_COMPARATOR|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
62759474|NCT00361699|NO_INTERVENTION|No intervention|Patient has no intervention.
62759475|NCT02537262|EXPERIMENTAL|carbohydrate group|
62759476|NCT02537262|PLACEBO_COMPARATOR|NPO(None Per Oral) group|
62759477|NCT03546504|EXPERIMENTAL|dental procedures modification and OT|Modifying dental environment and procedures to reduce sensory stimulation. Occupational therapy provides desensitization techniques around the dental visit and home oral hygiene and habit training for oral hygiene activities.
61987209|NCT05995158||Smokers ≥ 10 cigarettes/day|metagenomic testing of the subgingival plaque samples 16S rRNA metagenomic testing (sampling, extraction and sequencing of the oral microbiome in the samples)
62759478|NCT00839462|EXPERIMENTAL|Arm 1|
62759479|NCT00839462|ACTIVE_COMPARATOR|Arm 2|
62759480|NCT03132103|EXPERIMENTAL|Solar simulated radiation (SSR)|Solar simulated radiation (SSR)
61987210|NCT05995158||Smokers < 10 cigarettes/day|metagenomic testing of the subgingival plaque samples 16S rRNA metagenomic testing (sampling, extraction and sequencing of the oral microbiome in the samples)
61987211|NCT05995158||non-smokers|metagenomic testing of the subgingival plaque samples 16S rRNA metagenomic testing (sampling, extraction and sequencing of the oral microbiome in the samples)
62759481|NCT03132103|PLACEBO_COMPARATOR|Placebo SSR|Placebo SSR
62759482|NCT03132103|EXPERIMENTAL|Oral Vitamin D3|Oral Vitamin D3
62759483|NCT03132103|PLACEBO_COMPARATOR|Placebo Oral Vitamin D3|Placebo Oral Vitamin D3
62759484|NCT05920044|EXPERIMENTAL|Intervention Group:|Participants will receive an eight-week individualized balance and proprioception training program.
62759485|NCT05920044|ACTIVE_COMPARATOR|Control group|Participants will continue their usual care, including general strength and flexibility exercises.
62759486|NCT00106691|EXPERIMENTAL|20 mg Toremifene Citrate|The subject takes one dose by mouth of the 20mg Toremifine Citrate tablet once a day for the length of the trial (360 days).
62759487|NCT00106691|EXPERIMENTAL|Placebo|The subject takes a placebo tablet identical in appearance to the toremifene 20mg tablet, administered by mouth daily for 360 days
62759488|NCT03838016|EXPERIMENTAL|Treatment cohort with classic galactosemia|These children and their parents receive the Babble Boot Camp intervention and also participate in the close monitoring activities (progress reports that the speech-language pathologist generates during the online meeting with the family; monthly daylong audio recording; questionnaires that are sent out every three to six months; formal speech and language testing at ages 2 1/2, 3 1/2, and 4 1/2 years).
62759489|NCT03838016|EXPERIMENTAL|Treatment cohort with classic galactosemia, delayed start|The children in the control cohort enter the study when they are younger than 5 months old and participate in the close monitoring until they are 24 months old. They start getting the same treatment type and intensity as the treatment cohort but at a delayed age, when they turn 15 months.
62759490|NCT03838016|NO_INTERVENTION|Older control cohort with classic galactosemia|The children in the older control cohort are 6 months to 4 1/2 years old and provide standardized test results in the area of speech and language development at child ages 2 1/2, 3 1/2, and 4 1/2 years. They receive no treatment and no close monitoring. These families provide questionnaire information every three months until child age 24 months.
62380408|NCT00827112|EXPERIMENTAL|Arm A|maraviroc (Selzentry, Celsentri) 150 mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100mg QD Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, but expressing cosmetic concerns because of the jaundice or scleral icterus (associated with bilirubin elevations) and wish to discontinue atazanavir (Reyataz) in spite of reassurances by the investigator, will be permitted on a single occasion only to switch to another protease inhibitor either darunavir (Prezista)/ritonavir (Norvir)((800/100 mg) QD or lopinavir/ritonavir (Kaletra, Aluvia)(400/100mg) BID and remain in the study. If the investigator decides to switch to a protease inhibitor other than darunavir (Prezista)/ritonavir (Norvir) or lopinavir/ritonavir (Kaletra, Aluvia)(, then the subject must be discontinued from the study.
62558538|NCT02721381|EXPERIMENTAL|Therapist-Assisted Group|"Participants assigned to the therapist-assisted group will be given access to the ImPACT Online web-based program for four months and will be encouraged to work through the program at the same pace as the self-directed group. Participants will also receive 2, 30-minute remote coaching sessions per week (24 total sessions) via video conferencing software by a trained therapist to assist them in learning the intervention. The first coaching session of the week will involve the coach and participant and will be used to help clarify the content of the relevant lesson and help the participant apply the lesson content to their own child. The second coaching session of the week will involve the coach, participant, and child and will be used to provide the participant with live feedback on their use of the intervention techniques as they practice with their child."
62168175|NCT05455489||DEGENERATIVE MR|Patients with symptomatic severe primary MR (3-4+, according to the multiparametric study algorithm)
62168176|NCT05845099|ACTIVE_COMPARATOR|Polymethyl Methacrylate-Based Complete Removable Dentures.|The patient will be provided by a CRD to restore his missing teeth which will be manufactured by heat curing processing technique
62759491|NCT03838016|NO_INTERVENTION|Typical controls|These children are free of any medical or developmental diagnosis. They enter the study at ages 2 to 5 months and provide close monitoring data until they are 24 months old, then they receive standardized speech and language testing at ages 2 1/2, 3 1/2, and 4 1/2 years, just like the treatment cohort, but the typical controls receive no treatment under this study.
62759492|NCT01735708|PLACEBO_COMPARATOR|Health Education|Participants in the Health Education arm will receive 7 individual sessions, each of which will focus on a different health education topic.
62759493|NCT01735708|ACTIVE_COMPARATOR|HIVPASS Intervention|Participants in the HIVPASS intervention arm will receive 7 individual sessions with the study interventionist, the first of which is a collaborative meeting with the PCP. Sessions will focus on pain interference and depression management.
62759494|NCT04364607|ACTIVE_COMPARATOR|Neostigmine group|After cesarean delivery, women will receive 0.5 mg IM neostigmine
62759495|NCT04364607|PLACEBO_COMPARATOR|Placebo group|After cesarean delivery, women will receive IM NaCl 0.9% as a placebo
62759496|NCT03505489|EXPERIMENTAL|Mannitol challenge|Mannitol challenge performed per standard mannitol challenge procedure with deep inhalation technique
61987212|NCT00329407|ACTIVE_COMPARATOR|Topiramate Treatment|In this open label non-placebo controlled trial all subjects received topiramate, the active medication. Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM \& 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM \& 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM \& 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
62380409|NCT00827112|EXPERIMENTAL|Arm B|"emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD~Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, but expressing cosmetic concerns because of the jaundice or scleral icterus (associated with bilirubin elevations) and wish to discontinue atazanavir in spite of reassurances by the investigator, will be permitted on a single occasion only to switch to another protease inhibitor either darunavir/ritonavir (800/100 mg) QD or lopinavir/ritonavir (400/100mg) BID and remain in the study. If the investigator decides to switch to a protease inhibitor other than darunavir/ritonavir or lopinavir/ritonavir, then the subject must be discontinued from the study."
62380410|NCT03592134||Clinical settings|Infants with the choice of the non respiratory support and settings of the non respiratory support defined by clinical practice (nocturnal gas exchange, apneas, bradycardia, oxygen desaturation)
61987213|NCT01454570|EXPERIMENTAL|Powered Exoskeleton|persons with SCI trained to use a powered exoskeleton to ambulate overground
62380411|NCT03592134||Physiological settings|Infants with the choice of the non respiratory support and settings of the non respiratory support defined by the measurement of work of breathing
62759497|NCT03505489|EXPERIMENTAL|Mannitol challenge w/ TBI|Mannitol challenge performed per standard mannitol challenge procedure except with tidal breathing technique
62759498|NCT03505489|EXPERIMENTAL|Methacholine challenge w/ DI|Methacholine challenge performed per standard 2-minute tidal breathing challenge procedure except with deep inhalation technique
62759499|NCT03505489|EXPERIMENTAL|Methacholine challenge|Methacholine challenge performed per standard 2-minute tidal breathing challenge procedure (tidal breathing technique)
62759500|NCT00597831||A|All patients in the Rijnstate Hospital with an indication for unilateral ECT treatment and a major depression or psychotic depression according to DSM IV-TR criteria.
62759501|NCT02419131|EXPERIMENTAL|Behavioral Headache Therapy|A standard, manualized behavioral intervention for primary headache disorders
62759502|NCT02419131|EXPERIMENTAL|Cognitive Processing Therapy|A gold-standard treatment for PTSD, called Cognitive Processing Therapy
62759503|NCT02419131|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as usual, receiving standard care for PTHA
62759504|NCT06395402|EXPERIMENTAL|Dosimetry-based lutetium Lu 177 dotatate therapy|"Intravenous administration of lutetium Lu 177 dotatate once every 8 weeks for up to 4 total cycles.~Intended administered radioactivity:~Cycle 1: 200 millicuries (mCi) Cycles 2, 3, and 4: based upon dosimetry for radiation exposure to bone marrow (no more than 1 Gy per administration) and kidneys (maximum dose 28 Gy total). Not to exceed 400 millicuries (mCi) per cycle (1400 mCi maximum for all cycles)."
62380412|NCT02251366|NO_INTERVENTION|SOC Examination Based Cohort|Participants in this arm will receive standard of care (SOC) retinal examinations at each study visit.
62380413|NCT02251366|ACTIVE_COMPARATOR|Physician-Guided Diagnostic|Participants in this arm of the study will only receive the physical standard-of-care retinal examination at the 4-month and -month office visits, unless requested by the Physician-Investigator or study participant. At each standard study visit, the physician will use diagnostic imaging to determine if the participant will receive the anti-VEGF injection.
62380414|NCT00811395|PLACEBO_COMPARATOR|Placebo + IFN-β|Placebo (for teriflunomide) once daily concomitantly with interferon-β \[IFN-β\] for 24 additional weeks
62380415|NCT00811395|EXPERIMENTAL|Teriflunomide 7 mg + IFN-β|Teriflunomide 7 mg once daily concomitantly with interferon-β \[IFN-β\] for 24 additional weeks
62380416|NCT00811395|EXPERIMENTAL|Teriflunomide 14 mg + IFN-β|Teriflunomide 14 mg once daily concomitantly with interferon-β \[IFN-β\] for 24 additional weeks
62380417|NCT00811395|PLACEBO_COMPARATOR|Placebo + GA|Placebo (for teriflunomide) once daily concomitantly with glatiramer acetate \[GA\] for 24 additional weeks
62380418|NCT00811395|EXPERIMENTAL|Teriflunomide 7 mg + GA|Teriflunomide 7 mg once daily concomitantly with glatiramer acetate \[GA\] for 24 additional weeks
62380419|NCT00811395|EXPERIMENTAL|Teriflunomide 14 mg + GA|Teriflunomide 14 mg once daily concomitantly with glatiramer acetate \[GA\] for 24 additional weeks
62380420|NCT05466591|EXPERIMENTAL|Pre-hospital rule-out strategy|Patients undergo a point-of-care troponin T measurement. If troponin is low, an acute coronary syndrome is considered ruled-out and the care for the patient is transferred to the general practitioner. If troponin is elevated, the patient is immediately transported to the emergency department.
62380421|NCT05466591|NO_INTERVENTION|Emergency department rule-out strategy|According to standard care, the patients are immediately transported to the emergency department.
62380422|NCT01873599|EXPERIMENTAL|Intervention|Participants in the intervention condition will be asked to write for 15 minutes on three days each week to one of the seven positive affect writing prompts on www.stressvax.com. Subjects who do not complete a journal entry within 7 days will receive an email reminder, in case they have lost their password or have some technical problem accessing the site.
62380423|NCT01873599|NO_INTERVENTION|Control|As there is no clinical standard of care treatment for psychological distress, patients randomized into this condition will receive their usual care. At the end of three months, subjects in this condition will be given access to the positive affect journaling intervention.
62380424|NCT00327210|EXPERIMENTAL|BGATHome|Blood Glucose Awareness Training at Home Internet Intervention
62380425|NCT00327210|NO_INTERVENTION|Control|No intervention
62380426|NCT01132391|EXPERIMENTAL|1|Endoanal application
62380427|NCT01132391|EXPERIMENTAL|2|Perianal application
62380428|NCT01066611|ACTIVE_COMPARATOR|1|CAL-263
62380429|NCT01066611|PLACEBO_COMPARATOR|2|Placebo
62380430|NCT03681808|EXPERIMENTAL|Test|Soft Contact Lens
62380431|NCT03681808|ACTIVE_COMPARATOR|Control|Contact lens
62380432|NCT04831892|EXPERIMENTAL|Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal|Topical lotion containing isosorbide diesters and colloidal oatmeal to be applied to the entire body once daily.
62380433|NCT04831892|ACTIVE_COMPARATOR|Moisturizer containing colloidal oatmeal|Topical moisturizer with colloidal oatmeal to be applied to the entire body once daily
62380434|NCT06307210||age group 75-84|Inpatient rehabilitation included physiotherapy (30-60 min, 5 times/week), strength and endurance training (30-45 min, 3-5 times/week), occupational therapy (30 min, 2-3 times/week), and neuropsychological training (30 min, 2 times/week).
62380435|NCT06307210||age group 85-99|Inpatient rehabilitation included physiotherapy (30-60 min, 5 times/week), strength and endurance training (30-45 min, 3-5 times/week), occupational therapy (30 min, 2-3 times/week), and neuropsychological training (30 min, 2 times/week).
62759505|NCT06395402|ACTIVE_COMPARATOR|Standard lutetium Lu 177 dotatate|Intravenous administration of lutetium Lu 177 dotatate once every 8 weeks for up to 4 total cycles. Each cycle is intended to receive 200 millicuries of radioactivity for a total treatment of 800 millicuries.
62380436|NCT03097497|EXPERIMENTAL|Physiotherapy re-education program|Physiotherapy re-education program based on the pre-activation of the transverse abdominal muscle, performed with progressive difficulty and supervised at all times by an expert physiotherapist. The intervention will last 4 weeks, with two weekly sessions of 30-35 minutes each. Sessions will be held individually.
62380437|NCT03097497|ACTIVE_COMPARATOR|Conventional treatment by GP|"Will follow conventional treatment prescribed by the general practitioner in a primary care consultation. This conventional treatment is based on the clinical guidlines of the Institut Català de la Salut~http://www.gencat.cat/ics/professionals/guies/docs/guia_lumbalgies.pdf"
62380438|NCT04528693|EXPERIMENTAL|Intervention|40 women with insulin resistance aged 25-45, BMI 18,5-29,9 will perform, for a period of 3 months, 3 times a week, strength training, interspersed with bouts of endurance exercise carried out on circuit machines integrated with the Milon computer software.
62759506|NCT02668861|EXPERIMENTAL|Vitamin D+Budesonide Nasal Spray|Vitamin D 4000IU/day for 8 weeks + Budesonide Nasal Spray 128ug/d for 8 week
62759507|NCT02668861|PLACEBO_COMPARATOR|placebo+Budesonide Nasal Spray|Placebo for 8 weeks + Budesonide Nasal Spray128ug/d for 8 week
62759508|NCT03943550|EXPERIMENTAL|RO7049665|Participants will receive a subcutaneous (SC) dose of RO7049665 every 2 weeks for 4 doses.
62759509|NCT03943550|PLACEBO_COMPARATOR|Placebo|Participants will receive a SC dose of matching placebo every 2 weeks for 4 doses.
62759510|NCT02615405|EXPERIMENTAL|EPA|3.5 g/day in Studies 1 \& 2
62759511|NCT02615405|ACTIVE_COMPARATOR|DHA|1.75 g/day in Studies 1 \& 2
62759512|NCT02615405|PLACEBO_COMPARATOR|Placebo capsules|oleic oil in Study 1
62759513|NCT04906967|ACTIVE_COMPARATOR|modified sural flap|modified sural flap used to cover soft tissue defect around ankle
62759514|NCT04906967|ACTIVE_COMPARATOR|anterolateral thigh flap|anterolateral thigh flap used to cover soft tissue defect around ankle
62759515|NCT05138068|EXPERIMENTAL|MDMA-assisted psychotherapy|Two sessions of manualized MDMA-assisted psychotherapy with flexible dose of MDMA from 80 to 120 mg and optional supplemental dose 1.5 to 2 hours later. MDMA sessions are preceded by 3 non-drug preparatory psychotherapy sessions and followed by 3 integrative non-drug psychotherapy sessions.
62759516|NCT05138068|OTHER|Delayed treatment|Participants randomly assigned to the delayed treatment control condition will wait 16 weeks and then receive MDMA-assisted therapy protocol described in the experimental arm of the study.
62759517|NCT02466074|EXPERIMENTAL|Acetazolamide|Acetazolamide in oral daily divided dose administered for 6 consecutive months
62759518|NCT02466074|PLACEBO_COMPARATOR|Placebo|Placebo in oral daily divided dose administered for 6 consecutive months
62759519|NCT01724567|EXPERIMENTAL|Weight Loss|12 weeks of Low Calorie Diet to obtain a 10 - 15 % weight loss. Followed by 40 weeks on a weight maintenance diet and interval training 2 times a week.
62759520|NCT01724567|EXPERIMENTAL|Interval Training|12 weeks of interval training 3 times a week followed by 40 weeks of interval training 2 times a week.
62759521|NCT05425654|EXPERIMENTAL|RL-MPV + BBC/auto-HCT+ nivolumab|Rituximab, methotrexate (MTX), procarbazine, vincristine and lenalidomide (RL-MPV). The peripheral blood stem cell (PBSC) harvest procedure will be performed after 2nd cycle of RL-MPV. High dose chemotherapy Busulfan, Thiotepa, and Cyclophosphamide. 3 months after auto-HSCT, maintenance therapy with nivolumab 3 mg/kg is started for 6 months every 2 weeks
62759522|NCT00387738|EXPERIMENTAL|1|TOLAMBA™ dose-intense regimen
62759523|NCT00387738|EXPERIMENTAL|2|TOLAMBA™ lower-dose regimen
62759524|NCT00387738|PLACEBO_COMPARATOR|3|
62759525|NCT01229943|EXPERIMENTAL|Arm I (octreotide acetate and everolimus)|Patients receive 28-day cycles until progression or unacceptable toxicity consisting of: everolimus 10 mg PO QD on days 1-28 and octreotide acetate 20 mg IM on day 1.
62759526|NCT01229943|EXPERIMENTAL|Arm II (octreotide acetate, everolimus, and bevacizumab)|Patients receive 28-day cycles until progression or unacceptable toxicity consisting of: everolimus 10 mg PO QD on days 1-28, octreotide acetate 20 mg IM on day 1 and bevacizumab 10 mg/kg IV on days 1 and 15.
62759527|NCT05388773|EXPERIMENTAL|Arm S (Low Risk)|"Low risk patients are defined as T1-T2 AND 0 or 1 metastatic lymph nodes AND \<3 cm AND clear (≥3mm) margins AND no extracapsular extension (ECE) AND no perineural invasion AND no lymphovascular invasion.~Patients will undergo transoral surgical resection of the oropharyngeal tumor."
62759528|NCT05388773|EXPERIMENTAL|Arm RT (Intermediate Risk)|"Intermediate risk patients are defined as having any of the following features: One or more close (\<3mm) margins, OR minimal ≤1 mm ECE OR 1 or more metastatic lymph nodes \>3 cm in diameter OR 2-4 lymph nodes positive (≤ 6 cm in diameter), OR perineural invasion OR lymphovascular invasion~Patients will undergo transoral surgical resection of the oropharyngeal tumor. Following surgery, patients will receive low-dose IMRT five times a week for 3 weeks."
62759529|NCT05388773|EXPERIMENTAL|Arm CRT (High Risk)|"High risk patients are defined as having any of the following features: One or more positive margins OR \>1 mm ECE OR ≥ 5 metastatic lymph nodes.~Patients will undergo transoral surgical resection of the oropharyngeal tumor. Following surgery, patients will receive low-dose IMRT six times a week and a weekly chemotherapy infusion (cisplatin or carboplatin) during radiation therapy.~Patients will receive 2 Gy/fraction, 6 fractions per week with at least a 6-hour interfraction interval between each treatment:~* PTV-P50 or PTV-N50: 50 Gy in 25 fractions (2 Gy/fx)~* PTV-N45: 45 Gy in 25 fractions (1.8 Gy/fx) with simultaneous integrated boost to the PTV-P50 volume.~* PTV-P30 or PTV-N30: 30 Gy in 15 fractions (2 Gy/fx)"
62759530|NCT00763906|PLACEBO_COMPARATOR|1|Patients were assigned to norepinephrine infused at the clinician's discretion.
61987214|NCT03968302|EXPERIMENTAL|ARM A|The triple regimen, amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole 40 mg twice a day
62759531|NCT00763906|ACTIVE_COMPARATOR|2|Patients were assigned to norepinephrine infused under computerized fuzzy logic control.
62759532|NCT00041171|EXPERIMENTAL|Arm 1: placebo + docetaxel|"Patients receive oral placebo three times daily on days 1-14 and docetaxel IV over 1 hour on day 15.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
62759533|NCT00041171|EXPERIMENTAL|Arm 2: Hypericum perforatum + docetaxel|"Patients receive oral Hypericum perforatum three times daily on days 1-14 and docetaxel as in arm 1.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
62759534|NCT00041171|EXPERIMENTAL|Arm 3: Hypericum perforatum + docetaxel|"Patients receive docetaxel as in arm 1 and continue to receive their chronic regimen of Hypericum perforatum except on day 15.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
62759535|NCT00554398|EXPERIMENTAL|A|MK-0518 400mg twice a day
62759536|NCT00554398|NO_INTERVENTION|B|No intervention
61987215|NCT03968302|EXPERIMENTAL|ARM B|The quadruple regimen,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day, omeprazole 40 mg twice a day dose and colloidal bismuth subcitrate 240 mg twice daily
62759537|NCT01468610|ACTIVE_COMPARATOR|Workers with MDD|
62759538|NCT05985876|EXPERIMENTAL|KULEA-NET application|Participants using the KULEA-NET application in addition to the usual care
62759539|NCT05985876|EXPERIMENTAL|Control Group: Usual Care|Control participants will receive usual care i.e. standard obstetrical care at MWHC and Mamatoto Village and will receive the standard Babyscripts app only without the KULEA-NET tile.
62759540|NCT00681980|EXPERIMENTAL|A, 2, III|Patients with side effects to corticosteroids
62759541|NCT00681980|EXPERIMENTAL|B|patient with corticosteroids
62759542|NCT00681980|EXPERIMENTAL|3|Valproic acid and corticosteroids
62759543|NCT04079062|EXPERIMENTAL|ONO-4685 (PartA, D)|
62380439|NCT04528693|NO_INTERVENTION|Control|40 women with insulin resistance aged 25-45, BMI 18,5-29,9 will be asked to maintain their current level of physical activity and their diet for a period of 3 months.
62558539|NCT02721381|NO_INTERVENTION|Web-Based Information Control Group|Participants assigned to the web-based information control group will be given access the Resources page with links to the same ASD information websites, but will not receive access to other aspect of the ImPACT Online program. This condition will be used to control for participant maturation as well as the potentially confounding effect of having access to autism-related information via the internet.
62759544|NCT04079062|PLACEBO_COMPARATOR|Placebo (PartA, D)|
62759545|NCT04079062|EXPERIMENTAL|KLH+placebo (Part B)|
62759546|NCT04079062|EXPERIMENTAL|KLH+ONO-4685 (PartC)|
62380440|NCT01628718|ACTIVE_COMPARATOR|CPT-C|Cognitive Processing Therapy, cognitive version only (CPT-C) delivered in 12 60-minute one-on-one treatment sessions.
62380441|NCT01628718|EXPERIMENTAL|Adaptive Disclosure (AD)|Adaptive Disclosure delivered in eight 90-minute one-on-one treatment sessions.
62380442|NCT01204489|EXPERIMENTAL|Intensified dietary counseling|The dietary intervention consists of tailored dietary counseling, information leaflets and self-evaluation cards given to the families.
62759547|NCT04079062|EXPERIMENTAL|KLH+placebo (PartC)|
62759548|NCT02896036|EXPERIMENTAL|Veress needle entry with concomitant CO2|For the group of participants who will be randomized to concomitant CO2 insufflation; the Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle. If the opening pressure is less than or equal to 10 mmHg, the process of insufflation will be allowed to continue. In case of a higher opening pressure, the veress will be withdrawn and reinserted up to 3 times. A failed entry will be called if the peritoneal cavity cannot be insufflated after 3 attempts.
62759549|NCT02896036|ACTIVE_COMPARATOR|Veress needle entry with subsequent CO2|For the other group of participants who will be randomized to subsequent CO2 insufflation; the Veress needle will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by insertion of the Veress needle. The gas insufflation will be started and the opening pressure will be noted. If the opening pressure is less than or equal to 10 mmHg, the process of insufflation will be allowed to continue. In case of a higher opening pressure, the Veress needle will be withdrawn and reinserted up to 3 times. Each time the needle is to reinserted, the CO2 insufflator will be switched off until the location of the Veress needle is felt to be adequate.
62759550|NCT05081063|EXPERIMENTAL|Low Titer O+ Whole Blood|Low Titer O+ Whole blood provided to Level A trauma patients
62380443|NCT01204489|ACTIVE_COMPARATOR|Normal dietary counseling|Public health nurses continue their usual dietary counseling.
62759551|NCT05081063|ACTIVE_COMPARATOR|Component Therapy|Component Therapy of O+ pRBC and FFP dispatched to trauma bay for level A traumas
62759552|NCT00197145|EXPERIMENTAL|GW873140|
61987216|NCT03002012|EXPERIMENTAL|Sertraline|Fluconazole Standard of Care + Sertraline
61987217|NCT03002012|PLACEBO_COMPARATOR|Control|Fluconazole Standard of Care + Placebo Oral Tablet
61987218|NCT04349488|ACTIVE_COMPARATOR|Treatment|Anode placed over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
61987219|NCT04349488|PLACEBO_COMPARATOR|Placebo|Anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation, 5 days a week for 4 weeks
61987220|NCT05774587|ACTIVE_COMPARATOR|Active control|Participants will complete a 3-month cardiac rehabilitation programme supported by the onsite CR service
62380444|NCT04118140|EXPERIMENTAL|True SA (Somatic Acupressure ) group|Receiving true somatic acupressure+usual care
62380445|NCT04118140|SHAM_COMPARATOR|Sham SA group|Receiving sham somatic acupressure+usual care
62380446|NCT04118140|OTHER|Usual care group|Receiving usual care only (an education booklet regarding knowledge of BC and FSD symptom cluster management advice)
62558540|NCT03759392|EXPERIMENTAL|Omecamtiv Mecarbil|Omecamtiv mecarbil was administered as an oral modified-release tablet twice daily for up to 20 weeks. Participants randomized to this arm started at an omecamtiv mecarbil dose of 25 mg twice daily. The dose could be increased based on plasma concentrations at Weeks 2 and 6.
62759553|NCT02696499|EXPERIMENTAL|PA101B|
62759554|NCT02696499|PLACEBO_COMPARATOR|Placebo|
62759555|NCT05798481|EXPERIMENTAL|sodium nitrite and N-acetycysteine mixture|"sodium nitrite 2.5mg + N-acetylcysteine 50mg~Sodium nitrite 5 mg + N-acetylcysteine 50mg"
62759556|NCT02192762|EXPERIMENTAL|Withdrawal regulation training|Withdrawal coping skills
62759557|NCT02192762|ACTIVE_COMPARATOR|Relaxation training|Relaxation skills instruction
62759558|NCT00943475|ACTIVE_COMPARATOR|anaesthesia, circumcision|
62759559|NCT03089879|EXPERIMENTAL|Shigella Group|Healthy male and female subjects, aged 22 to 50 years, previously primed with 3 doses of the GVGH Shigella sonnei 1790GAHB vaccine in the H03_01TP parent study and who had undetectable antibody titers at baseline, received one intramuscular booster dose of the same vaccine in the current study, at Day 1.
62759560|NCT03089879|EXPERIMENTAL|Placebo Group|Healthy male and female subjects, aged 22 to 50 years, who previously received placebo in the H03_01TP parent study and who had undetectable antibodies at baseline, received one intramuscular GVGH Shigella sonnei 1790GAHB vaccine dose in the current study, at Day 1.
62759561|NCT03089879|EXPERIMENTAL|Naïve Group|Healthy male and female subjects, aged 22 to 50 years, who were not part of H03_01TP parent study, received one intramuscular GVGH Shigella sonnei 1790GAHB vaccine dose in the current study, at Day 1.
62759562|NCT05026892||moderate to severe|patients with known inflammatory rheumatism, auto-immune or auto-inflammatory diseases (as define in the inclusion criteria) with moderate to severe or severe form of covid-19
62759563|NCT05026892||begining to moderate|Patients with known inflammatory rheumatism, auto-immune or auto-inflammatory diseases (as define in the inclusion criteria) with begnin to moderate or moderate form of covid-19
62759564|NCT01986387|EXPERIMENTAL|Virtual Peer-to-Peer Support Mentoring|In addition to standard medical care, adolescents in the experimental group will receive the VP2P support program, a manualized peer-mentorship program that will provide modeling and reinforcement by peers (young adults with chronic pain aged 16-25 years who have learned to function successfully with their chronic pain to the mentored participants).
62759565|NCT01986387|NO_INTERVENTION|Waitlist Control|The control group will receive usual care but without the mentorship intervention. They will be offered the VP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
62759566|NCT04928573||Group I|"All participants previously randomized in Brazil for the phase III study RTXM83-AC-01-11 already completed, which was conducted to support the registration of the new biosimilar of rituximab (Vivaxxia) in different countries.~The RTXM83-AC-01-11 study compared the efficacy and safety between biosimilar rituximab (RTXM83) and the reference rituximab (Mabthera®), both associated with CHOP chemotherapy (RTXM83-CHOP and R-CHOP, respectively) and included participants of the research with a diagnosis of lymphoma other than large B cell (LDGCB) CD20 positive."
62759567|NCT01620151|NO_INTERVENTION|No extended neck|Patient will not undergo thyroid surgery with extended neck
62759568|NCT01620151|EXPERIMENTAL|Extended neck|Patients who undergoing thyroid surgeries are positioned with extended neck by using pillow under shoulder in order to facilitate neck exposure and make the surgery easier.
62759569|NCT03970174|EXPERIMENTAL|Intervention|Two of the 4 Medicine wards will have implemented the care transition module of Care Connector
62759570|NCT03970174|NO_INTERVENTION|Control|Remaining 2 of 4 Medicine wards will use all other aspects of Care Connector (except for care transition module)
62759571|NCT03000543|NO_INTERVENTION|Vitamin A pool size in infants without inflammatory condition|Assessing vitamin A (VA) pool size in infants without inflammatory condition using model based compartmental analysis from the fraction of oral dose-derived 13C10-VA and 13C4-VA in plasma over time.
62759572|NCT03000543|EXPERIMENTAL|Vitamin A pool size in infants with inflammatory condition|Assessing vitamin A (VA) pool size in infants without inflammatory condition using model based compartmental analysis from the fraction of oral dose-derived 13C10-VA and 13C4-VA in plasma over time.
62759573|NCT03141567||Outpatient|Individuals undergoing clinically indicated Right Heart Catheterization.
62759574|NCT03141567||Inpatient|Individuals undergoing clinically indicated Right Heart Catheterization.
62759575|NCT04477629|EXPERIMENTAL|Belatacept|Participants will receive Belatacept along with an upfront tacrolimus taper Participants will also receive mycophenolate mofetil and corticosteroids are part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice.
62380447|NCT06238349|OTHER|Control group|Conventional treatment: Neonates will be placed in an incubator (Ningbo David Medical Device Co., LTD, XHZ model) at 30℃ and relative humidity at 55%. Throughout the study, exclusive breastfeeding and professional care will be provided for the newborns. Newborns requiring phototherapy receive it in the following manner: Phototherapy eye masks (Foshan Forman Medical Technology Co., LTD., Yuesun Mechanical Equipment No. 20160015) and phototherapy diapers (Foshan Baojusheng Medical Equipment Co., LTD., GB/T33280) will be used to cover the eyes and perineum, respectively. Phototherapy was provided via LED blue light continuous irradiation with a wavelength of 425-475nm. All treated neonates will receive continuous phototherapy for 12 hours, then allowe to rest for 6-8 hours, then receive another 12 hours of continuous phototherapy. The decision to continue with further treatment depends on changes in the neonate's jaundice.
62558541|NCT03759392|PLACEBO_COMPARATOR|Placebo|Participants randomized this arm received placebo tablets (matching the appearance of the omecamtiv mecarbil tablets) twice daily for up to 20 weeks.
62558542|NCT05702983|EXPERIMENTAL|STSA-1002 subcutaneous injection: dose 1 (First cohort)|
62558543|NCT05702983|EXPERIMENTAL|STSA-1002 subcutaneous injection: dose 2 (Second cohort)|
62759576|NCT03148145|ACTIVE_COMPARATOR|Constant Steps Goal|Step Goal Delivery by Smartphone
62759577|NCT03148145|EXPERIMENTAL|Averaged Steps Goals and Random Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
62759578|NCT03148145|EXPERIMENTAL|Algorithm Steps Goal and Random Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
62759579|NCT03148145|EXPERIMENTAL|Algorithm Steps Goal and Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
62759580|NCT01050374|PLACEBO_COMPARATOR|1|albendazole + praziquantel
62759581|NCT01050374|ACTIVE_COMPARATOR|2|mebendazole + praziquantel
62759582|NCT03058666|EXPERIMENTAL|Aerosolized Calfactant|"1. NICU Patients with a clinical diagnosis of RDS~2. Inspired oxygen ≥21% to maintain adequate oxygen saturation~3. Not Intubated~4. Requiring Nasal continuous positive airway pressure"
62759583|NCT03058666|NO_INTERVENTION|Usual Care|There will be no protocol driven interventions in the usual care group.
62759584|NCT06072716|EXPERIMENTAL|interventional|chitosan loaded with miconazole nanoparticles gel
62759585|NCT06072716|EXPERIMENTAL|control|miconazole gel
62759586|NCT03825250|NO_INTERVENTION|Group A: Control|Standard of care
62558544|NCT04737941|EXPERIMENTAL|Immediate foam sclerotherapy|Immediate foam sclerotherapy group patients are treated with immediate (first-visit) foam sclerotherapy and truncal vein endothermal ablation is scheduled when anatomy is suitable. Compression therapy is started immediately.
62759587|NCT03825250|EXPERIMENTAL|Group B: Sodium Valproate Treatment|15 mg/kg for 1-2 weeks
62759588|NCT03825250|EXPERIMENTAL|Group C: Sodium Valproate Treatment|15 mg/kg for 4-6 weeks
62759589|NCT03825250|EXPERIMENTAL|Group D: Sodium Valproate Treatment|25 mg/kg for 4-6 weeks
62759590|NCT03024138||Repeat CT|
62759591|NCT03929289|EXPERIMENTAL|Social Facilitation|Cognitive tasks during the 2 functional Magnetic Resonance Imaging (fMRI) observed or not by a subject's known peer.
62759592|NCT00953524|EXPERIMENTAL|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1
62380448|NCT06238349|EXPERIMENTAL|Sunbathing group|The sunbathing group will receive all interventions prescribed for the control group and assign to sunbathing (placement in a bed next to a sunny window) after birth for one week according to the following plan: Every morning and afternoon neonates will sunbath for 0.5 to 1 hour to avoid excess sun exposure. Healthcare workers will guide and assist families in their preparations. The caregiver will place a black eye patch on the infants to protect the retina, and a cloth will be wrapped around the hands and feet to prevent scratching, but care will be taken that the wrap is not too tight to avoid circulation disorders. Baby boys will have their genitals covered to protect them from sun damage. After feeding, the newborn will be placed on a sunny platform with fully exposed skin and frequent position changes, while the glass of the window prevent injury from UV light exposure.
62380449|NCT06238349|EXPERIMENTAL|Bifidobacterium group|The newborns in the Bifidobacterium group will receive all interventions prescribed for the control group, and also be assigned to orally be given Bifidobacterium triple viable powder (Shanghai Xinyi Pharmaceutical Company, Peifeikang powder, 0.5 g/dose, 3 times/day. Bifidobacterium triple viable powder contains live bacteria of long Bifidobacterium at no less than 1.0 × 107 CFU/g, stored at 2.8℃ away from light) beginning within 24 hours after birth and continuing for 1 week. No sunbathing will be prescribed.
62558545|NCT04737941|ACTIVE_COMPARATOR|Scheduled treatment|Scheduled treatment group patients are treated with scheduled endovenous ablation including foam sclerotherapy and/or endothermal ablation depending on reflux anatomy. Compression therapy is started immediately.
62558546|NCT06058546|PLACEBO_COMPARATOR|Placebo group|Jiuweihuaban Pill placebo, 1 bag each time, p.o. , tid
62759593|NCT00953524|EXPERIMENTAL|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2
62759594|NCT00953524|EXPERIMENTAL|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Vaccine formulation 3
62759595|NCT00953524|PLACEBO_COMPARATOR|Placebo Group|Participants will receive a placebo vaccine
62759596|NCT03143673|EXPERIMENTAL|ACURATE TA™|Patient implanted with ACURATE TA™ Bioprosthesis
62759597|NCT02821377|EXPERIMENTAL|intravenous furosemide|intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge Intervention: drug: furosemide ; other name: lasix
62759598|NCT02821377|EXPERIMENTAL|intravenous hypertonic saline solutions|small volumes of hypertonic saline solutions (HSS) (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge Intervention: Hypertonic saline solutions (1.4-4.6%NaCl) Intervention other name: not specified
62759599|NCT02821377|ACTIVE_COMPARATOR|seriated paracentesis|no intervention Intervention: no drug only seriated paracentesis repeated paracentesis from the first day after admission until 3 days before discharge
62759600|NCT03213574|ACTIVE_COMPARATOR|Control Group|The control group will be administered intraoperative fluids throughout his or her surgery per the discretion of the anesthesiologist as is typical for this type of case. They will use an arterial line but without a FloTrac and therefore will have no data regarding the SVV.
62759601|NCT03213574|EXPERIMENTAL|Treatment Group|The treatment group will receive a FloTrac arterial line that will allow the anesthesiologist to administer intraoperative fluids based on the study algorithm.
62759602|NCT05060380|EXPERIMENTAL|Exercise training|The exercise training group will receive progressive muscle resistive exercise, 10 sets of exercises for 2 times per week for a total of 6 months.
62380450|NCT06238349|EXPERIMENTAL|Combination group|The combination group will receive all interventions of both the group sunbathing and the Bifidobacterium group as well as all interventions prescribed for the control group.
62380451|NCT03177473||CervicalStim PEMF group|all subjects will receive active CervicalStim bone growth stimulator
62380452|NCT02646891|PLACEBO_COMPARATOR|Adults: Placebo|Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.
62380453|NCT02646891|EXPERIMENTAL|Adults: 30 µg P2-VP8|Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
62380454|NCT02646891|EXPERIMENTAL|Adults: 90 µg P2-VP8|Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
62759603|NCT05060380|NO_INTERVENTION|Control|The control group will be asked to maintain their normal lifestyle and will be advised to continue their standard care of treatment.
62759604|NCT06606639|EXPERIMENTAL|Caffeine - Trial 1|
62759605|NCT06606639|EXPERIMENTAL|Caffeine - Trial 2|
62380455|NCT02646891|PLACEBO_COMPARATOR|Toddlers: Placebo|Toddlers received one intramuscular injection of placebo on Day 0.
62380456|NCT02646891|EXPERIMENTAL|Toddlers: 30 µg P2-VP8|Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.
62380457|NCT02646891|EXPERIMENTAL|Toddlers: 90 µg P2-VP8|Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.
62380458|NCT02646891|PLACEBO_COMPARATOR|Infants: Placebo|Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.
62380459|NCT02646891|EXPERIMENTAL|Infants: 15 µg P2-VP8|Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
62380460|NCT02646891|EXPERIMENTAL|Infants: 30 µg P2-VP8|Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
62558547|NCT06058546|EXPERIMENTAL|Low dose group|Jiuweihuaban Pill , 1 bag each time, p.o. , tid
62759606|NCT06606639|EXPERIMENTAL|Caffeine - Trial 3|
62759607|NCT06606639|PLACEBO_COMPARATOR|Placebo - Trial 1|
62759608|NCT06606639|PLACEBO_COMPARATOR|Placebo - Trial 2|
62759609|NCT00394602||Patients|Patients receiving chemoradiation for abdominal-pelvic tumors.
62759610|NCT00394602||Caregiver Controls|Healthy controls with no prior cancer diagnosis.
62759611|NCT00633789|EXPERIMENTAL|1|
62759612|NCT00633789|PLACEBO_COMPARATOR|2|
62380461|NCT02646891|EXPERIMENTAL|Infants: 90 µg P2-VP8|Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
62380462|NCT03661983|EXPERIMENTAL|Open Label Stabilization Phase: Aripiprazole|Participants began treatment with aripiprazole at a 2.0 mg/day dose, with the dose titrated to 5.0 mg/day after 2 days. Subsequent dose adjustments were based on the participant's weight to achieve optimum control of tics up to the maximum recommended doses based on the United States Labeling, up to Week 8 and then continued on the most stabilized dose up to minimum Week 14 or maximum Week 20. Participants who met stabilization criteria were randomized to Double-blind Randomization Phase.
62759613|NCT04021173|EXPERIMENTAL|Anfibatide|
62759614|NCT04021173|PLACEBO_COMPARATOR|Placebo|
62558548|NCT06058546|EXPERIMENTAL|High dose group|Jiuweihuaban Pill , 1 bag each time, p.o. , tid
62759615|NCT01449773|EXPERIMENTAL|n-3 PUFAs|
62759616|NCT01449773|PLACEBO_COMPARATOR|Corn and soybean oil pill|
62759617|NCT04835376|EXPERIMENTAL|Randomized Crossover: Percussion Palm Cup Safety and Usability - Cup 1|The standard percussor palm cups are made out of a soft vinyl material molded into shape. The outer diameter of the infant palm cup is 1-3/4 inches and there is a 1-inch diameter pocket inside this product similar to a suction cup.
62380463|NCT03661983|EXPERIMENTAL|Double Blind Phase: Aripiprazole Full Dose|Participants who met stabilization criteria and randomized to receive full dose of aripiprazole i.e. 5 mg or 10 mg for \<50 kg participants,and 10 mg or 20 mg for \>50 kg participants (2 tablets a day), based on stabilized dose in open-label stabilization phase, up to 12 weeks in Double-Blind Phase.
62759618|NCT04835376|EXPERIMENTAL|Randomized Crossover: Percussion Palm Cup Safety and Usability - Cup 2|This product was developed by MMRI personnel using a small custom 3D printed plastic handle and a 0.93-inch, single bellow, Buna-N rubber suction cup. The handle was made on the MMRI's 3D printer using ABS plastic and the suction cup was sourced from McMaster Carr (#5427A106). The handle is made up of three pieces; top, base and a pin that is designed to fix the top, base and suction cup to each other. There is a small hole through the pin which helps relieve some of the pressure that builds in the suction cup during use. It is not shown in the image to the right, but the handle will be coated in Plasti Dip for added user comfort.
62380464|NCT03661983|EXPERIMENTAL|Double Blind Phase: Aripiprazole Half Dose|Participants who met stabilization criteria and randomized to receive half dose of aripiprazole i.e. 2 mg or 5 mg for \<50 kg participants, and 5 mg or 10 mg for \>50 kg participants (2 tablets a day), based on stabilized dose in open-label stabilization phase, up to 12 weeks in Double-Blind Phase.
62759619|NCT04835376|EXPERIMENTAL|Randomized Crossover: Percussion Palm Cup Safety and Usability - Cup 3|This product was developed by MMRI personnel using a large custom 3D printed plastic handle and a 0.93-inch, single bellow, Buna-N rubber suction cup. The handle was made on the MMRI's 3D printer using ABS plastic and the suction cup was sourced from McMaster Carr (#5427A106). The handle is made up of three pieces; top, base and a pin that is designed to fix the top, base and suction cup to each other. There is a small hole through the pin which helps relieve some of the pressure that builds in the suction cup during use. It is not shown in the image to the right, but the handle will be coated in Plasti Dip for added user comfort.
62759620|NCT00898924||Group 1|Tissue samples were collected from patients on Day 1, Cycle 1. Whole blood and serum samples were collected on Day 1 (Cycle 1), Day 1 (Cycle 3), post-radiotherapy ZD1839 and at progression.
62380465|NCT03661983|PLACEBO_COMPARATOR|Double Blind Phase: Placebo|Participants who met randomization criteria and randomized to receive aripiprazole matching-placebo tablets, 2 daily, orally, up to 12 weeks in Double-Blind Phase.
62558549|NCT02197819|EXPERIMENTAL|External Rotation Brace|Shoulder placed in an external rotation brace for 4 weeks
62558550|NCT02197819|ACTIVE_COMPARATOR|Traditional Sling|Patient placed in traditional sling
62558551|NCT02142608|EXPERIMENTAL|BR55|All patients received BR55 as a single intravenous injection at the dose of 0.03 mL/kg...
62380466|NCT00439309|EXPERIMENTAL|VascuSeal|Consists of two liquids that when mixed together in situ rapidly cross-link to form a biocompatible absorbable sealant that is tissue adherent. These liquids are sprayed onto tissues using the Dual Liquid Applicator. The formed Sealant remains intact for approximately 2 to 7 days. During this period the Sealant undergoes hydrolysis where it is absorbed into the circulatory system and is excreted through the kidneys.
62759621|NCT01871155|EXPERIMENTAL|Nutri-jelly along with radiotherapy|Continuous intake: orally take 1-3 boxes / day for at least 3 days/ week during radiotherapy
62380467|NCT00439309|ACTIVE_COMPARATOR|GELFOAM/THROMBIN|GELFOAM/THROMBIN description - GELFOAM Sterile Compressed Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified porcine Skin Gelatin USP Granulates and Water for Injection, USP. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids. Although not necessary, GELFOAM can be used either with or without thrombin to obtain hemostasis.
62759622|NCT01871155|NO_INTERVENTION|Radiotherapy only|Receive either definitive (total of 30-35 fractions) or palliative ( total of 10 fractions) radiotherapy with no continuous intake of Nutri-Jelly
62759623|NCT05278702||hemodialysis|
62759624|NCT05278702||peritoneal dialysis|
62759625|NCT01357824||Patients admitted for elective surgery|The patient admitted for elective surgery can be included, and will both the case and control, as we intubate the same patient twice, with and without Sellick´s maneuver.
62759626|NCT00047619|EXPERIMENTAL|Pulsatile lavage group|pulsatile lavage therapy
62759627|NCT00047619|SHAM_COMPARATOR|Sham lavage group|sham pulsatile lavage
62759628|NCT00918268|EXPERIMENTAL|Influenza vaccine|
62759629|NCT02608580|OTHER|Patients with sicke cell disease|"Adult sickle cell disease patients will fill in a survey about the quality of their hospital care, in the transition period between the pediatric to an adult hospital care system.~Since filling in this survey is not part of the standard of care, this study has been defined as interventional."
62759630|NCT03497091||Enteral Tube fed children|Enteral Formula
62759631|NCT02181478|EXPERIMENTAL|Treatment (intra-osseous UCB with hMSC co-transplant)|"REDUCED INTENSITY CONDITIONING (RIC):~Flu/Cy/TBI: Patients receive cyclophosphamide IV over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total-body irradiation on day -1.~Flu/Mel: Patients receive fludarabine daily on days -5 to -2, a single dose of melphalan on day -2, and ATG on day -3 and day-2.~GVHD PROPHYLAXIS: Patients receive cyclosporine PO or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO BID on days -5 to 100.~TRANSPLANT: Patients undergo a co-transplantation of an intra-osseous umbilical cord blood transplantation and a mesenchymal stem cell transplantation on day 0."
62759632|NCT05594069|EXPERIMENTAL|Pre Group|intervention before and during radiotherapy
62558552|NCT06551597|EXPERIMENTAL|MT1 - The group receiving magnetotherapy to the head in addition to standard therapy|
62558553|NCT06551597|ACTIVE_COMPARATOR|MT2 - The group receiving magnetotherapy to the pelvis in addition to standard therapy|
62558554|NCT06551597|NO_INTERVENTION|Control group - The group receiving only standard therapy|
62558555|NCT02304471||Control|healthy subjects
62759633|NCT05594069|OTHER|Re Group|intervention during radiotherapy only
62759634|NCT01376479|EXPERIMENTAL|INV21 Low Dose|
62759635|NCT01376479|EXPERIMENTAL|INV21 High Dose|
62759636|NCT05768204|EXPERIMENTAL|Experimental group|Prednisolone, oral, 2 mg/kg.d (maximum dose 60 mg/day), two or three times a day , 5 days.
62759637|NCT05768204|PLACEBO_COMPARATOR|Placebo group|The same amount of placebo was taken orally as the trial for 5 days
62759638|NCT01545232|ACTIVE_COMPARATOR|1:1:1 Blood Transfusion Ratio|
62759639|NCT01545232|ACTIVE_COMPARATOR|1:1:2 Blood Transfusion Ratio|
62759640|NCT01479595|EXPERIMENTAL|QBX258|Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total.
62759641|NCT01479595|PLACEBO_COMPARATOR|Placebo|Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total.
62759642|NCT05675267||patient with chest pain|
62759643|NCT04262713|OTHER|Patients implanted with Meije duo stem size 1 or 2|"Among this arm, patients that meet criteria ( weight\>~60kg and / or a long neck / varus and / or a DEVANE score ≥ 4 ) will perform hip X ray"
62759644|NCT05945771|ACTIVE_COMPARATOR|Randomized double blind grape seed extract design|Grape seed extract
62759645|NCT05945771|PLACEBO_COMPARATOR|Control|Placebo (starch)
62759646|NCT05118984|ACTIVE_COMPARATOR|Azithromycin group|Azithromycin capsule (Zithromax, Pfizer) (250 mg / 12 hrs on empty stomach for 3 days).
62558556|NCT02304471||CKD|chronic kidney disease
62558557|NCT02304471||ESRD|end-stage renal disease
62558558|NCT05012046|EXPERIMENTAL|Orange juice|Treatment beverage
62558559|NCT05012046|EXPERIMENTAL|Orange flavoured drink|Treatment beverage
62380468|NCT00782756|EXPERIMENTAL|RT, with temozolomide and bevacizumab|This treatment regimen is novel in that it delivers the initial course of RT over 2 weeks instead of 6 weeks; also, the addition of bevacizumab during and after RT is a new approach.
62380469|NCT05709587|EXPERIMENTAL|Virtual Reality training group|Virtual Reality training group: Three virtual environments employed in this study,time constraints,terrain changes, and moving obstacles were set to increase the difficulty of the walking task.The participants had to complete a task three times to proceed to the next level.
62380470|NCT03838666|EXPERIMENTAL|Suspension of human autologous MSC 3P|Patients will receive perioperative hAMSC (1.5 ml) treatment in order to accelerate the healing of the surgically repaired rotator cuff and increase the mechanical properties of the tendon.
62380471|NCT04709406||obese patients|obese patients underwent bariatric surgery
61987221|NCT05774587|EXPERIMENTAL|mHealth technology assisted exercise counselling (mHealth)|Participants will complete a walking mHealth technology assisted exercise counselling intervention. All participants will have 4 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
62380472|NCT02160639|NO_INTERVENTION|usual care|usual care includes diabetes self management education
62380473|NCT02160639|ACTIVE_COMPARATOR|diabetes self management support|diabetes self management support in addition to usual care, which includes diabetes self management education
62380474|NCT00939146|OTHER|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
62380475|NCT00939146|OTHER|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
62380476|NCT04495322|EXPERIMENTAL|10 mg TG-1000|Eligible subjects will receive single oral dose of study drug (2 x 5-mg TG-1000 capsules)on Day 1 under fasted condition.
62380477|NCT04495322|EXPERIMENTAL|20 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (20 mg TG-1000 capsule or Placebo capsule) on Day 1 under fasted condition.
62380478|NCT04495322|EXPERIMENTAL|40 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (2 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
62380479|NCT04495322|EXPERIMENTAL|80 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (4 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
62380480|NCT04495322|EXPERIMENTAL|120 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (6 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
62380481|NCT04495322|EXPERIMENTAL|160 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (8 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
62380482|NCT04495322|EXPERIMENTAL|X mg TG-1000 (fasted)+wash-out+X mg TG-1000 (fed)|Based on the preliminary results, one optimal dose (X mg) of TG-1000 will be selected. Subject will receive a single oral dose of TG-1000 under fasted condition. After washout period, subject will receive a single oral dose of TG-1000 under fed condition.
61987222|NCT00734279|EXPERIMENTAL|1|Girls with Early Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
62380483|NCT04495322|EXPERIMENTAL|X mg TG-1000 (fed)+wash-out+X mg TG-1000 (fasted)|Based on the preliminary results, one optimal dose (X mg) of TG-1000 will be selected. Subject will receive a single oral dose of TG-1000 under fed condition. After washout period, subject will receive a single oral dose of TG-1000 under fasted condition.
62380484|NCT02967172|EXPERIMENTAL|Peri-incisional injection|"A single, 25 cc multimodal analgesic cocktail will be injected following completion of ankle fracture fixation/instrumentation while the patient remains under general anesthesia and prior to skin closure. The injection will be administered as such:~* 20 mL injected into the peri-incisional soft tissues in a circumferential fashion~* 5mL injected into the ankle joint This cocktail includes 200 mg of 0.8% ropivacaine, 0.6 mg of epinephrine, 5 mg of morphine sulfate, and sodium chloride solution. All infiltrations will be completed with a blunt trochar to minimize the risk of intravascular injection.~Interventions:~Drug: Ropivacaine Drug: Epinephrine Drug: Morphine Drug: 0.9% sodium chloride solution Following surgery, patients in the treatment and non-treatment groups will both be provided with the same intravenous (patient-controlled analgesia) and oral pain medications scheduled per needed."
62380485|NCT02967172|NO_INTERVENTION|Control|Ankle fracture fixation/instrumentation will be completed per the standard of care. No peri-incisional injection will be completed.
62380486|NCT06193161|EXPERIMENTAL|Therapist-guided internet delivered prolonged exposure|Therapist-supported internet delivered prolonged exposure comprising psychoeducation about PTSD, controlled breathing, imaginal exposure including processing, in vivo exposure and relapse prevention. The treatment will be delivered in a digital platform for eight weeks. Participants will have access to a therapist that will guide them through treatment in a text based format.
62558560|NCT05012046|EXPERIMENTAL|Water|Treatment beverage
61987223|NCT00734279|EXPERIMENTAL|2|Girls with Delayed Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
61987224|NCT00734279|EXPERIMENTAL|3|Boys with Early Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
62380487|NCT06193161|NO_INTERVENTION|Waiting list|Waiting list up for eight weeks and up until the 1-month follow up.
62380488|NCT01773616|EXPERIMENTAL|Rituximab|Rituximab, methyl prednisolone and mycophenolate mofetil
62380489|NCT01773616|ACTIVE_COMPARATOR|Oral prednisolone|Oral prednisolone, methyl prednisolone and mycophenolate mofetil
62380490|NCT02933411||Group A|Adolescent women with heavy menstrual bleeding and low von willebrand factor activity.
62558561|NCT03934346|OTHER|Zinc transport kinetics|Three different amounts of dietary zinc are used in the creation of a standard curve for determining zinc absorption kinetics: 4 mg, 7 mg, and 15 mg of zinc.
61987225|NCT00734279|EXPERIMENTAL|4|Boys with Delayed Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
62759647|NCT05118984|PLACEBO_COMPARATOR|Placebo group|placebo capsules (manufactured in pharmacy department with the same shape, color and consistency as Azithromycin capsule every 12hrs for 3 days). A single pharmacist will be responsible for manufacturing of placebo capsules and packing all medications into sterile boxes and labelling of them as 1 or 2.
61987226|NCT04475133|EXPERIMENTAL|Low-frequency and high-intensity|"The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve.~The parameters are continuous stimulation of low frequency (2 hz) and high intensity (slightly painful) during 16 minutes."
61987227|NCT04475133|EXPERIMENTAL|High-frequency and low-intensity|"The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve.~The parameters are high frequency (100 hz) and low intensity trains. There are 5 trains, 5 second active current and 55 second without current per train.~The current is off on the first 11 minutes and the next 5 minutes it will be on. The total time is 16 minutes."
61987228|NCT04475133|SHAM_COMPARATOR|Control group|The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve without current during 16 minutes.
61987229|NCT05422599|EXPERIMENTAL|Lemon balm|300mg Lemon balm and Maltodextrin
61987230|NCT05422599|PLACEBO_COMPARATOR|Placebo|Placebo
61987231|NCT04103632|EXPERIMENTAL|Young recreational athletes (12-18 years)|"Young recreational athletes (12-18 years) of different sport disciplines:~* Indoor sports~* Outdoor sports~* Swimming~* Winter sports"
61987232|NCT02954510|EXPERIMENTAL|Intervention|Single arm utilizing ferumoxytol
61987233|NCT00245206|EXPERIMENTAL|1: Risperdal|Participants randomized to this arm will be prescribed risperdal. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
61987234|NCT00245206|EXPERIMENTAL|3: Aripiprazole|Participants randomized to this arm will be prescribed aripiprazole. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
61987235|NCT00245206|EXPERIMENTAL|4: Olanzapine|Participants randomized to this arm will be prescribed olanzapine. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
61987236|NCT05325528|EXPERIMENTAL|study group|patients in this arm will be treated with Tislelizumab in Combination with Oxaliplatin and Tegafur
61987237|NCT04854811|PLACEBO_COMPARATOR|Placebo|Placebo oral capsule, once daily for 12 weeks
61987238|NCT04854811|EXPERIMENTAL|Roflumilast (100 microgram)|once daily for 12 weeks
61987239|NCT02938689|EXPERIMENTAL|Lumbar extension exercise|Exercise education based on Mckenzie lumbar extension exercise for 4 weeks
62380491|NCT05370560||Type 2 diabetes mellitus|In this case-control study, T2DM was diagnosed according to the diagnostic criteria recommended by the WHO in 1999. T2DM was confirmed when fasting plasma glucose (FPG) ≥ 7.0 mmol/L and/or 2-h post-glucose load (OGTT2h) ≥ 11.1 mmol/L.
62380492|NCT05370560||Impaired glucose regulation|In this case-control study, IGR was diagnosed according to the diagnostic criteria recommended by the WHO in 1999. IGR was defined as impaired fasting glucose (\[FPG\] ≥ 6.1 mmol/L and \< 7.0 mmol/L, and \[OGTT2h\] \< 7.8 mmol/L) and/or impaired glucose tolerance (FPG \< 7.0 mmol/L, and OGTT2h ≥ 7.8 mmol/L and \< 11.1 mmol/L).
62380493|NCT05370560||Control|Those with FPG \< 6.1 mmol/L and OGTT2h \< 7.8 mmol/L were considered controls.
62380494|NCT06237361|EXPERIMENTAL|traditional physical therapy programs|group that received traditional physical therapy programs (TPTP) alone
62380495|NCT06237361|EXPERIMENTAL|Pilates group|received both traditional physical therapy programs and Pilates exercises.
62380496|NCT01984359|OTHER|Single arm|Biosamples will be obtained at multiple time-points for all participants
62759648|NCT00769717|EXPERIMENTAL|Wellness-Centered|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
61987240|NCT02938689|ACTIVE_COMPARATOR|Lumbar flextion exercise|Exercise education based on Wilillams lumbar flexion exercise for 4 weeks
61987241|NCT01828047||Elective colorectal surgeries|Patients undergoing elective colorectal procedures with an Enhanced Recovery Program. Orthogonal polarization spectral (OPS) imaging will be used to measure sublingual microcirculation
62380497|NCT04072796||Case group|Case group reported urinary complaints
62380498|NCT04072796||Control group|Control group did not have any urinary complaints.
61987242|NCT01627054|EXPERIMENTAL|AT7519M|
61987243|NCT02834104|EXPERIMENTAL|Myocardial fibrosis|
61987244|NCT01067222|EXPERIMENTAL|BF2.649|
61987245|NCT01067222|ACTIVE_COMPARATOR|Modafinil|
61987246|NCT01067222|PLACEBO_COMPARATOR|Placebo|
62380499|NCT02016586|NO_INTERVENTION|Control Group|Subjects in the control group will continue to take the prenatal supplement primarily consisting of folic acid (400 mcg), elemental iron (60 mg) and will receive breastfeeding advice during prenatal visits.
62380500|NCT02016586|EXPERIMENTAL|Intervention|Lactation support in conjunction with a maternal nutritional supplement S348S0
62380501|NCT02532075|EXPERIMENTAL|Inspiratory Warm Up|(IWU). Two sets of 15 breaths
62168177|NCT05845099|EXPERIMENTAL|Photopolymerized Methacrylate- Based Complete Removable Dentures.|The patient will be provided by a CRD to restore his missing teeth which will be manufactured by 3D-printed (Digital Light Processing).
62168178|NCT05356195|EXPERIMENTAL|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive single infusion of CTX001 through central venous catheter.
61987247|NCT06044376|ACTIVE_COMPARATOR|Probiotic Group|"During the baseline period, all participants consumed milk formula without any addition of probiotics three servings per day for 14 days. One serving of milk formula consists of 36 gram that is diluted in 180 mL lukewarm water.~The participants in the probiotic group consumed milk formula added with triple Bifidobacterium strain containing Bifidobacterium longum BB536 (6.9 x 10\^7 CFU/serving), Bifidobacterium breve M16-V (6.9 x 10\^7 CFU/serving), Bifidobacterium longum subsp. infantis M-63 (6.9 x 10\^7 CFU/serving). The milk formula is consumed three servings per day for 90 days during the intervention period. One serving of milk formula consists of 36 gram that is diluted in 180 mL lukewarm water."
62380502|NCT02532075|EXPERIMENTAL|Expiratory Warm Up|(EWU). Two sets of 15 breaths
62380503|NCT02532075|EXPERIMENTAL|Combination Warm Up|(RWU). One set of 15 breaths inspiratory and one set of 15 breaths expiratory
62380504|NCT02532075|OTHER|Control Trial|No warm up
62380505|NCT00888316||Without Iron Overload|Patients entering study without pre-HSCT iron-overload. Iron overload will be defined as liver ion concentration (LIC above normal (\>1.8 mg/g) on R2 magnetic resonance imaging (MRI) of the liver.
62759649|NCT00769717|ACTIVE_COMPARATOR|Weight-Centered|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
62759650|NCT06524557||with chronic liver disease|patients with hepatitis B virus, hepatitis C virus and other chronic liver disease.
62759651|NCT06524557||without chronic liver disease|patients without hepatitis B virus, hepatitis C virus and other chronic liver disease.
62759652|NCT03781219|EXPERIMENTAL|HL-085 plus Vemurafenib|HL-085 will be administered as BID with specified dose. And the Vemurafenib will be taken as the instruction in the label ( 960 mg, BID)
62380506|NCT00888316||With Iron-Overload|Patients entering study with pre-HSCT iron-overload. Iron overload will be defined as liver ion concentration (LIC above normal (\>1.8 mg/g) on R2 magnetic resonance imaging (MRI) of the liver.
62380507|NCT01096966|EXPERIMENTAL|Bupivacaine TTS|
62380508|NCT01096966|PLACEBO_COMPARATOR|Placebo patch|
62380509|NCT06016595||singel|
62759653|NCT01658137|ACTIVE_COMPARATOR|Typical Western Diet|"The comparator dietary pattern (Typical Western Diet) approximates the inflammatory dietary pattern typically consumed by North Americans. It contains refined grains, processed foods, dairy fat, meats, sugar and high glycemic index foods, and few fruits, nuts, legumes, and vegetables. The fruits and vegetables are highly processed (e.g. juices) and lower in micronutrients than those in the intervention diet. The saturated fat content of this diet does not meet national guidelines for health. The polyunsaturated fat:saturated fat ratio is \~0.5 (low)."
62759654|NCT01658137|EXPERIMENTAL|Prudent Diet|"The experimental dietary pattern (Prudent Diet) is based on intakes of foods hypothesized to have beneficial effects on inflammation and long-term health. This dietary pattern includes micronutrient and macronutrient levels consistent with healthy eating in epidemiological studies and randomized controlled trials. The diet is constructed with low-fat dairy products, fish, chicken, and lean meats to minimize saturated fat and increase protein and calcium. The diet is rich in fruits, vegetables, whole grains, nuts, legumes, and seeds that are good sources of potassium, magnesium, and dietary fiber. This diet provides a 'favorable' macronutrient profile that is low in saturated fat, has a polyunsaturated/saturated fat ratio of \~1.0 (high), and low in high glycemic index carbohydrates."
62759655|NCT01463111|OTHER|Mood stabilizer|Participants diagnosed with Bipolar Disorder will receive standard of care open-label treatment with a mood stabilizer for six weeks.
62759656|NCT03344640|EXPERIMENTAL|secukinumab|AIN457 300 mg subcutaneously (s.c.) for 12 weeks
62759657|NCT03344640|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneously for 12 weeks
62759658|NCT05566457|EXPERIMENTAL|HGWD group|Patients in the HGWD group (n = 46) soaked and washed Immersion and Washing limbs with HGWD infusion packs, followed by smearing limbs with vitamin E and vitamin B12. The composition of HGWD infusion pack was: 60g Radix Astragali (Huangqi), 15g Ramulus Cinnamomi (Guizhi), 15g Paeonia lactiflora (Baishao), 15g Gentiana (Qinjiao), 6g Scorpio (Quan-Xie), 20g Rhizoma Zingiberis Recens (Shengjiang), 20 Jujubes (Dazao), 30g Geranium wilfordii (Laoguancao), 12g radix sileris (Fangfeng), 30g Spatholobus suberectus (Jixueteng), 15g Ligusticum (Chuanxiong), 15g Poria (Fuling), and 15g Radixcyathulae (Chuanniuxi). HGWD infusion pack was boiled in water and extraction was performed twice to obtain a total of 500 ml drug-containing water. The drug-containing water was maintained at 39 to 40℃ for soaking and washing limbs for 20min twice a day for consecutive 14 days
62759659|NCT05566457|PLACEBO_COMPARATOR|control group|Patients in the control group and the HGWD group used vitamin E milk and vitamin B12 to smear the limbs three times per day for 14 days.
62759660|NCT00549029||1,2|Group 1 for the patients with rhabdomyolysis Group 2 for the control without any myopathy
62759661|NCT00598078|EXPERIMENTAL|1|
62759662|NCT00598078|EXPERIMENTAL|2|
62759663|NCT00598078|PLACEBO_COMPARATOR|3|
62759664|NCT03239782|EXPERIMENTAL|Metabolically unhealthy|"Subjects classified as metabolically unhealthy (MONW) go on to participate in a calorie restriction intervention.~MONW subjects will participate in a supervised weight loss program to help ensure they are under a similar weekly energy deficit and achieve a 5 % weight loss at approximately the same time. Participants will be prescribed a reduced-calorie diet (\~500 kcal/d below their needs for weight maintenance), and will be instructed not to change their physical activity habits, in order to achieve a weekly weight loss of \~0.5 kg.~The macronutrient composition of the diet will be the same for all groups (55-60 % of energy from carbohydrate, 15-20 % from protein, and 20-30 % from fat); no vitamins or other nutritional supplements will be given."
62759665|NCT00545532|EXPERIMENTAL|Conventional dose|Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.
62759666|NCT00545532|EXPERIMENTAL|Double dose|Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.
62759667|NCT00900146|EXPERIMENTAL|Canakinumab 5 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 5 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose \>200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c \>7.5% were treated with a daily injection of insulin glargine as add-on therapy."
61987248|NCT06044376|PLACEBO_COMPARATOR|Placebo Group|During the research period (both baseline and intervention period), all participants consumed milk formula without any addition of probiotics three servings per day for 104 days. One serving of milk formula consists of 36 gram that is diluted in 180 mL lukewarm water.
62558562|NCT02978638|OTHER|Finetech Vocare Bladder System|This is a pilot study of the Finetech Vocare Bladder System to improve continence and voiding in human subjects with chronic spinal cord injury. Each subject will act as their own control, comparing function with the Finetech Vocare Bladder System in use and not in use.
61987249|NCT02637778|EXPERIMENTAL|Cardioprotective diet|The study participants receive defined personal nutrition counselling every two weeks and they get daily menu plans (with optimised nutrient profiles) over an entire period of 20 wks (follow-up 20 wks).
62759668|NCT00900146|EXPERIMENTAL|Canakinumab 15 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 15 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose \>200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c \>7.5% were treated with a daily injection of insulin glargine as add-on therapy."
62380510|NCT03593720||Hypospadias|Patients with hypospadias
62380511|NCT03593720||Control|Patients without hypospadias
62380512|NCT02018276|EXPERIMENTAL|The effect of perioperative lidocaine infusion|
62759669|NCT00900146|EXPERIMENTAL|Canakinumab 50 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 50 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose \>200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c \>7.5% were treated with a daily injection of insulin glargine as add-on therapy."
62759670|NCT00900146|EXPERIMENTAL|Canakinumab 150 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 150 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose \>200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c \>7.5% were treated with a daily injection of insulin glargine as add-on therapy."
62759671|NCT00900146|PLACEBO_COMPARATOR|Placebo + Metformin|In 4 month dose finding period as well as during intermediate period, patients received one injection of canakinumab matching placebo monthly and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations).
62759672|NCT01794741|ACTIVE_COMPARATOR|Dymista nasal spray|azelastine 137mcg per spray/fluticasone propionate 50mcg per spray one spray per nostril twice a day for three months
62759673|NCT01794741|ACTIVE_COMPARATOR|fluticasone propionate nasal spray|fluticasone propionate nasal spray 50mcg per spray per nostril twice a day
62759674|NCT05615987|ACTIVE_COMPARATOR|Classic injection|200iu/2ml OnabotulinumtoxinA in total to 2-4 points proximal to the gastrocnemius muscle
62759675|NCT05615987|EXPERIMENTAL|İnjection along the length of the muscle|A total of 200iu/2ml of onabotulinumtoxinA by spreading along the length of the gastrocnemius muscle
62380513|NCT02018276|ACTIVE_COMPARATOR|The effect of perioperative magnesium infusion|
62380514|NCT03588949|EXPERIMENTAL|Active Dietary Supplement|Dietary Supplement with L-carnitine (FertilHom)
62380515|NCT03588949|PLACEBO_COMPARATOR|Control Dietary Supplement|Dietary Supplement with 50% RDA of beta-carotene
62558563|NCT02440464|EXPERIMENTAL|Ixazomib Maintenance|Allogeneic HSCT and Fludarabine/Melphalan/Bortezomib conditioning followed by Ixazomib maintenance
62380516|NCT02745795|EXPERIMENTAL|MIG: Motivational Interview Group|Group submitted to three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
62380517|NCT02745795|SHAM_COMPARATOR|CIG: Conventional Intervention Group|Group submitted to three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
62380518|NCT01633372|EXPERIMENTAL|itacitinib 100 mg|itacitinib 100 mg twice a day
62380519|NCT01633372|EXPERIMENTAL|itacitinib 200 mg|itacitinib 200 mg twice a day
62380520|NCT01633372|EXPERIMENTAL|itacitinib 300 mg|itacitinib 300 mg once a day
62380521|NCT01633372|EXPERIMENTAL|itacitinib 400 mg|itacitinib 400 mg once a day
62380522|NCT01633372|EXPERIMENTAL|itacitinib 600 mg|itacitinib 600 mg once a day
62380523|NCT05232461|ACTIVE_COMPARATOR|PrimeC ER Fasted|Single dose PrimeC-ER (748 mg), administered following an overnight fast of at least 10 hours.
62380524|NCT05232461|ACTIVE_COMPARATOR|PrimeC ER Meal|Single dose PrimeC-ER (748 mg), administered at 30 minutes after the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours.
62759676|NCT03551977|EXPERIMENTAL|Intervention group|The intervention group will receive the iCanCope with Pain app with all five components: (I) symptom trackers for pain, sleep, mood, physical, and social function; (II) goal setting to improve pain and function; (III) coping toolbox of pain self-management strategies; (IV) social support; (V) age-appropriate pain education
62759677|NCT03551977|ACTIVE_COMPARATOR|Control group|The control group will receive the iCanCope with Pain control app with only the first self-registration component (I) symptom trackers for pain, sleep, mood, physical, and social function.
62759678|NCT03593135|EXPERIMENTAL|Intervention group|Intervention group taking their diet according to their original meal pattern only dietary guideline were given regarding high glycaemic and low glycaemic diet. Medical treatments continued (including tablet Tagipment 50mg/1000mg twice a day)(Metformin + Sitagliptin group). 15ml apple cider vinegar (American garden organic vinegar) (containing 5% acetic acid) mixed in 200ml water during meal at night time was prescribed.
62380525|NCT05232461|ACTIVE_COMPARATOR|Marketed ciprofloxacin and celecoxib|Single dose of 750 mg of ciprofloxacin 200 mg of celecoxib, co-administered following an overnight fast of at least 10 hours.
62759679|NCT03593135|PLACEBO_COMPARATOR|Comparison group|Control group also taking their diet according to their original meal pattern only dietary guideline were given regarding high glycaemic and low glycaemic diet. Medical treatment continued (including tablet Tagipmet 50mg/1000mg twice a day)( Metformin + Sitagliptin group). Flavor of apple cider vinegar used as placebo, mixed in 200ml plain water during meal at night time.
62380526|NCT03416972||Stage I-III NSCLC patients|Stage I/II NSCLC patients receiving standard stereotactic body radiation therapy and Stage III patients receiving Standard platinum-based chemoradiotherapy will receive PET/MRI, DCE-CT, ECG/EKG, and bloodwork before and six weeks post treatment.
62380527|NCT04951479|EXPERIMENTAL|Gel-Bead Embolization|
62380528|NCT00656799|EXPERIMENTAL|Sugammadex|IV single bolus dose of 4.0 mg/kg sugammadex
62380529|NCT00983242|ACTIVE_COMPARATOR|Colchicine alone|baseline colchicine pharmacokinetics
62759680|NCT01344538|EXPERIMENTAL|Ginger Root Extract|
62759681|NCT01344538|PLACEBO_COMPARATOR|Lactose Capsule|
62759682|NCT05254405|EXPERIMENTAL|Open-Label Infusion of Brexanolone|This is a single arm pilot study of open label brexanolone delivered intravenously over a continuous 60-hour period. Infusions will be administered in a certified healthcare setting in accordance with the Zulresso™ dosing, administration and safety guidelines.
62759683|NCT05700292|EXPERIMENTAL|High-intensity Interval Training|Training is based on 5 circuits, with intervals of 1 minute (high intensity) by 2 minutes (low intensity), with a total training time of 15 minutes (plus 5 more minutes of warm-up and 5 of cool-down exercises). The high intervals will be performed with the following exercises: squat, reverse lunge \& knee-up, reverse jump and walkout pushup, while the low intervals were performed jogging. The heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate of 85% to 95%. To monitor heart rate during training, a polar brand chest sensor, model H9, will be used.
62759684|NCT05700292|ACTIVE_COMPARATOR|Moderate-intensity continuous training|Continuous aerobic training (jogging). Also, the heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate from 60% to 75% and an increase in training time from 25 to 45 minutes (considering 5 minutes of warm-up and 5 of cool-down exercises). To monitor heart rate during training, a polar brand chest sensor, model H9, will be used as well.
62759685|NCT04806490||Chinese participants with Yin Deficiency Syndrome|"The participants with Yin Deficiency syndrome were included in this study. Chinese Medicine Experts evaluated the main symptoms of Yin Deficiency syndrome, diagnosed those participants.~And the participants were measured by the standard scale for syndrome differentiation of Yin Deficiency syndrome. The participants were followed up for 12 months to observe whether there were any manifestations of Yin Deficiency syndrome during the observation period."
62380530|NCT00983242|EXPERIMENTAL|Colchicine with Verapamil HCl ER|colchicine pharmacokinetics in presence of steady-state verapamil
62380531|NCT05839002||Training cohort|Training cohort will be used to find the best calculation and cut-off values for PTBS in ESCC after nCRT.
62380532|NCT05839002||Validation cohort|The study's conclusion will be verified in Zhongshan Hospital Xiamen branch.
62380533|NCT04062240||Additional BIS sensor|Many providers caring for cardiovascular surgical patients utilizes BIS monitoring to gauge depth of anesthesia. The current practice involves placement of the BIS sensor on the patient's forehead per the manufacturer's recommendation on arrival to the operating room. The intervention in this study will add an additional BIS sensor to the patient's forehead. After syncing the two monitors for time, and ensuring appropriate skin contact and signal quality of both sensors, BIS monitoring will commence. BIS readings will be available every 12 seconds during the duration of the study, yielding up to 240 points of comparison per enrolled patient.
62380534|NCT06010992|NO_INTERVENTION|Group 1|35 Patients with type 2 diabetes receiving treatment with metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors (such as vildagliptin).
62558564|NCT02440464|PLACEBO_COMPARATOR|Placebo|Allogeneic HSCT and Fludarabine/Melphalan/Bortezomib conditioning followed by placebo maintenance.
62759686|NCT04806490||Chinese participants without Yin Deficiency Syndrome|"The participants without Yin Deficiency syndrome were included in this study. Chinese Medicine Experts evaluated the main symptoms of Yin Deficiency syndrome, diagnosed those participants.~And the participants were measured by the standard scale for syndrome differentiation of Yin Deficiency syndrome. The participants were followed up for 12 months to observe whether there were any manifestations of Yin Deficiency syndrome during the observation period."
62759687|NCT03950687|ACTIVE_COMPARATOR|Control group A|intravenous administration, maintaining the same dose and frequency administrated in the sceening period, for 32 weeks
62759688|NCT03950687|EXPERIMENTAL|Experimental group B|intravenous administration, 0.5μg/kg, once a week, for 32 weeks
62759689|NCT03950687|EXPERIMENTAL|Experimental group C|"intravenous administration,~1μg/kg, once every two weeks, for 32 weeks"
61987250|NCT02637778|EXPERIMENTAL|Cardioprotective diet + 3 g EPA+DHA/d|"The study participants receive defined personal nutrition counselling every two weeks and they get daily menu plans (with optimised nutrient profiles) over an entire period of 20 wks (follow-up 20 wks).~Participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)."
62759690|NCT03263468|EXPERIMENTAL|Same sitting complete revascularization|After treatment of the IRA, subjects will undergo PCI of all suitable significant non-IRA lesions (≥70% by visual assessment or FFR\<0.80 in 50-70% lesions with vessel diameter \>2mm).
62759691|NCT03263468|ACTIVE_COMPARATOR|Staged non-IRA PCI|Only the IRA will be intervened upon during the index primary PCI procedure. Staging of the non-IRA lesions will be performed 48 hours to 45 days after the primary PCI procedure. All suitable non-IRA lesions (≥70% by visual assessment or FFR\<0.80 in 50-70% lesions with vessel diameter \>2mm) will be treated with PCI irrespective of whether there are clinical symptoms or evidence of ischemia.
62759692|NCT03445728|EXPERIMENTAL|Treatment arm|Patients were randomly assigned to two groups before emergent coronary angiography: those who received intravenous (iv.) nicorandil before and after (ivgtt.) reperfusion with PCI (nicorandil group);
62759693|NCT03445728|PLACEBO_COMPARATOR|Placebo arm|Patients were randomly assigned to two groups before emergent coronary angiography, those who received placebo before and after reperfusion with PCI.
62759694|NCT00301535|EXPERIMENTAL|1|
62759695|NCT00301535|NO_INTERVENTION|2|
62759696|NCT05764473|EXPERIMENTAL|A (Med/UCLP)|"Following the Mediterranean Diet for six weeks, then following the Ultimate Cholesterol Lowering Plan for six weeks.~Food diaries collected at baseline, week 2, week 4, week 6, week 8, week 10, week 12.~Cardiometabolic risk markers, menopause symptoms and physical activity collected at baseline, week 6, week 12."
62759697|NCT05764473|EXPERIMENTAL|B (ULCP/Med)|"Following the Ultimate Cholesterol Lowering Plan for six weeks, then following the Mediterranean Diet for six weeks.~Food diaries collected at baseline, week 2, week 4, week 6, week 8, week 10, week 12.~Cardiometabolic risk markers, menopause symptoms and physical activity collected at baseline, week 6, week 12."
61987251|NCT03727503|OTHER|group/cohort|operated patients from cardiac surgery. Once they arrived in the ICU, we will measure PPV with the capstesia and the PICCO device at baseline, and after a volume expansion of 500 ml of crystalloid.
61987252|NCT02382679|PLACEBO_COMPARATOR|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
61987253|NCT02382679|EXPERIMENTAL|Experimental: Vitamin Mixture|Vitamin coenzyme Q10, magnesium, riboflavin and omega-3-fatty acid combination.
61987254|NCT05885074|EXPERIMENTAL|Empagliflozin Arm|Investigator will enroll 12 obese participants who have intentionally lost greater than or equal to 5% of body weight through a non-pharmacological structured weight loss program based on diet and exercise within the last 6 months. The participants will take empagliflozin 25mg/day orally for 12 months.
62759698|NCT04027270|NO_INTERVENTION|Standard of Care|These individuals will receive standard of care for post operative recovery following a prostatectomy.
62759699|NCT04027270|EXPERIMENTAL|Physical Therapy|These individuals will receive post operative physical therapy in addition to standard of care for post operative recovery following a prostatectomy.
62759700|NCT05499338|EXPERIMENTAL|Experimental group|The experimental group received a lecture session explaining what stretching is, its advantages and the importance of stretching in injury prevention. The specific intervention programme was to be performed at least 3 days/week (after training) for 12 weeks. These were static, active stretches of the muscles of the lower back, psoas iliacus, quadriceps, adductors, gluteus, hamstrings, and sural triceps. For each muscle group, the stretch was held for 60 seconds, divided into 3 repetitions of 20 seconds. Between each repetition, we did not return to the initial position but sought a new barrier to the stretch which would provoke the sensations described above. The total time dedicated to stretching was approximately 15 minutes per session.
62759701|NCT05499338|NO_INTERVENTION|Control group|The control group performed the initial and final assessments and continued to perform their team's standard/habitual stretches. To record whether they performed the stretches prescribed by the club, the researchers went to the end of the training unknown sessions and recorded whether the players performed them or not.
62380535|NCT06010992|EXPERIMENTAL|Group 2|35 Patients with type 2 diabetes receiving nitazoxanide 500 mg orally twice daily in addition to metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors (such as vildagliptin).
62759702|NCT03719404|EXPERIMENTAL|sodium hypochlorite group|sodium hypochlorite and EDTA are used in endodontic retreatment cases
62759703|NCT03719404|EXPERIMENTAL|chlorhexidine group|chlorhexidine and citric acid are used in endodontic retreatment cases
62759704|NCT05477537|EXPERIMENTAL|Add-on group|Subjects with Anorexia Nervosa (AN) involved in a day hospital or an inpatient program following HAS guidelines for anorexia nervosa treatment (treatment as usual) who will receive in addition an adapted physical activity program (one lesson per week, during 8 weeks)
62759705|NCT05477537|ACTIVE_COMPARATOR|Treatment as usual group|Subjects with Anorexia Nervosa involved in a day hospital or an inpatient program following HAS guidelines for AN treatment (treatment as usual).
62759706|NCT01561755|EXPERIMENTAL|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
62759707|NCT01561755|PLACEBO_COMPARATOR|Placebo|Saline 2gr/kg over 2 days of saline
62380536|NCT03570528||Maxillary Retrusion|CT
62380537|NCT03570528||Healthy Patients|
62380538|NCT01320033|EXPERIMENTAL|CD2475/101 40 mg|Participants receive 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.
62759708|NCT05300685|ACTIVE_COMPARATOR|Group 1: Standard of care|"1. Prior to graft harvest - infiltration of 1% lidocaine with 1:100,000 epinephrine up to a maximum of 10 mL~2. Routine, standard graft site hemostasis with monopolar cautery~3. No suture closure of graft site~4. No further infiltration of local anesthetic in mouth"
62380539|NCT01320033|ACTIVE_COMPARATOR|Doxycycline 100 mg|Participants receive 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.
62558565|NCT05100056||HL Participants: BV Salvage Pre-ASCT|Participants diagnosed with HL who undergone or undergoing pre-ASCT BV salvage and continue with post-ASCT treatment will be observed prospectively over 24-month period after treatment cessation.
62558566|NCT05100056||HL Participants: BV Consolidation Treatment Post-ASCT|Participants diagnosed with HL who undergone or undergoing post-ASCT BV consolidation treatment will be observed prospectively over 24-month period after treatment cessation.
62759709|NCT05300685|EXPERIMENTAL|Group 2: Standard of care + Long acting local|"1. Prior to graft harvest - infiltration of 1% lidocaine with 1:100,000 epinephrine up to a maximum of 10 mL~2. Routine, standard graft site hemostasis with monopolar cautery~3. No suture closure of graft site~4. Up to a maximum of 10mL of 0.5% bupivacaine infiltration in the buccal graft site"
62759710|NCT05300685|EXPERIMENTAL|Group 3: Standard of care + Buccal block|"1. Prior to graft harvest - infiltration of 1% lidocaine with 1:100,000 epinephrine up to a maximum of 10 mL~2. Routine, standard graft site hemostasis with monopolar cautery~3. No suture closure of graft site~4. Up to a maximum of 10mL of 0.5% bupivacaine infiltration as a buccal block"
62558567|NCT01059656|EXPERIMENTAL|1:Pazopanib|Pazopanib 800mg/j
62759711|NCT01067599|ACTIVE_COMPARATOR|Low nicotine|Conventional smokeless tobacco product with 1) NNN plus NNK of \<2 μg/gram and nicotine levels of \>5 mg/g wet weight
62759712|NCT01067599|ACTIVE_COMPARATOR|Medium nicotine|Conventional smokeless tobacco product with ) NNN plus NNK of \<2 μg/gram and nicotine levels of 3-5 mg/g wet weight.
62759713|NCT01067599|ACTIVE_COMPARATOR|High nicotine|Conventional smokeless tobacco product with NNN plus NNK of \<2 μg/gram and nicotine levels of \<3 mg/g wet weight
62759714|NCT06605417||L/GCMN|Patients with congenital nevus with estimated size of 20 cm or more in adulthood (\> 18 years old)
62759715|NCT06605417||Melanoma|Patients affected with Spitz-type or conventional melanomas in patients under 30 years of age
62759716|NCT05940545|ACTIVE_COMPARATOR|Cohort 1|6 patients will be randomised to starting dose of favipiravir 1800 mg BD (day 1), then 800mg BD Day 2 to 10, or standard of care.
62759717|NCT05940545|ACTIVE_COMPARATOR|Cohort 2|6 patients will be randomised to starting dose of favipiravir 2600 mg BD (day 1), then 1200mg BD day 2 to 10, or standard of care.
62759718|NCT05940545|ACTIVE_COMPARATOR|Cohort 3|6 patients will be randomised to starting dose of favipiravir 1800 mg BD (day 1), then 800mg BD Day 2 to 10 plus Ribavirin, or standard of care.
62168179|NCT05965518|EXPERIMENTAL|High-Intensity Interval Training|
62380540|NCT01320033|PLACEBO_COMPARATOR|Placebo|Participants receive matching placebo tablet plus placebo capsule orally once daily for 16 weeks.
62380541|NCT01199692||Age|
62380542|NCT01199692||Gender|
62380543|NCT01199692||Ethnicity|
62380544|NCT01199692||Body Mass Distribution|
62380545|NCT01199692||Dietary Habits|
62380546|NCT01199692||Exercise Habits|
62380547|NCT01199692||Medication Requirements|
62380548|NCT01199692||Disease State Burden|
62380549|NCT02169726||Musculoskeletal injuries|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
62380550|NCT04780191|EXPERIMENTAL|Active MyoRegulator® treatment|Five consecutive days of 20 minutes active stimulation with MyoRegulator® device
62759719|NCT05940545|ACTIVE_COMPARATOR|Cohort 4|6 patients will be randomised to starting dose of favipiravir 2600mg BD (day 1), then 1200mg BD day 2 to 10 plus Ribavirin, or standard of care.
62759720|NCT05640206|EXPERIMENTAL|Test group|intra-articular i-PRF injection after arthrocentesis
62759721|NCT05640206|EXPERIMENTAL|Control group|only arthrocentesis
62759722|NCT04357509|EXPERIMENTAL|ScTIL210|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention, ScTIL210(Super circulating tumor infiltrating lymphocytes).
61987255|NCT05885074|PLACEBO_COMPARATOR|Placebo Arm|Investigator will enroll 12 obese participants who have intentionally lost greater than or equal to 5% of body weight through a non-pharmacological structured weight loss program based on diet and exercise within the last 6 months. The participants will take a placebo pill orally once a day for 12 months.
62759723|NCT03261856||small intetsinal bacterial overgrowth|Glucose breath test, 75 g glucose in 250 ml water. Breath samples collected at baseline and every 15 min for 2 hours
61987256|NCT02855437|ACTIVE_COMPARATOR|Interactive Voice Response|The interactive voice response system (IVR) is an automated telephone system that is used to contact study participants. At enrollment the study coordinator will explain how the IVR works, planned survey schedule, and that participant -initiated calls to IVR are allowed.
61987257|NCT02855437|ACTIVE_COMPARATOR|RheumPro Smartphone Application|RheumPro is a UAB developed smartphone application to capture patient reported outcomes. At enrollment the study coordinator will explain how RheumPro works, planned survey schedule, and that participant -initiated surveys in RheumPro are allowed.
61987258|NCT03905122||continous veno-venous hemodialysis|to measure the fluid changes by using bioreactance method in continous veno-venous hemodialysis group
61987259|NCT03905122||hemodialysis|to measure the fluid changes by using bioreactance method in hemodialysis group
61987260|NCT06460649|EXPERIMENTAL|Progressive relaxation techniques+Benson relaxation techniques|Participants in group A will receive progressive relaxation techniques along benson relaxation sessions will be conducted 3 times a week for 12 weeks . Total number of sessions will be 3
61987261|NCT06460649|ACTIVE_COMPARATOR|Progressive relaxation techniques|Participants in group B will receive progressive relaxation techniques only. Sessions will be conducted 3 times a week for 12 weeks.36 sessions over all
62380551|NCT04780191|SHAM_COMPARATOR|Sham MyoRegulator® treatment|Five consecutive days of 20 minutes sham stimulation with MyoRegulator® device
62380552|NCT01041885|EXPERIMENTAL|INSTRUCT|INSTRUCT scaffold implantation
62380553|NCT01112189|EXPERIMENTAL|Patients with stem cells|Patients that receive the stem cells treatment
61987262|NCT03725007|EXPERIMENTAL|Participants of age group 12 to <18 years receiving dose A|Participants of age group 12 to \<18 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
62380554|NCT01112189|ACTIVE_COMPARATOR|Compressed sleeve treatment|Patients that will receive the compressed sleeve treatment
62759724|NCT03261856||Fructose breath Test|Fructose breath test, 25 g fructose in 250 ml water. Breath samples collected at baseline and every 30 min for 3 hours
62380555|NCT06191991|EXPERIMENTAL|Atorvastatin with ALG-055009|Single dose PO administration of 40 mg atorvastatin (Day 1), then a washout period of at least 2 days, followed by PO QD administration of 0.9 mg ALG-055009 for 14 days (Days 3-16) and single dose PO administration of 40 mg atorvastatin (Day 15).
62380556|NCT06191991|EXPERIMENTAL|Rosuvastatin with ALG-055009 (optional)|Single dose PO administration of 10 mg rosuvastatin (Day 1), then a washout period of at least 4 days, followed by PO QD administration of 0.9 mg ALG-055009 for 11 days (Days 5-15) and single dose PO administration of 10 mg rosuvastatin (Day 11).
61987263|NCT03725007|EXPERIMENTAL|Participants of age group 12 to <18 years receiving dose B|Participants of age group 12 to \<18 years administered with upadacitinib dose B (weight dependent) as described in the protocol.
61987264|NCT03725007|EXPERIMENTAL|Participants of age group 6 to <12 years receiving dose A|Participants of age group 6 to \<12 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
61987265|NCT03725007|EXPERIMENTAL|Participants of age group 2 to <6 years receiving dose A|Participants of age group 2 to \<6 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
62168180|NCT05965518|ACTIVE_COMPARATOR|Continuous Moderate Exercise|
62380557|NCT00006463|EXPERIMENTAL|Therapy ECTEINASCIDIN 743 (1100 ug/m2 )|
62380558|NCT00006463|EXPERIMENTAL|ECTEINASCIDIN 743 (1300 ug/m2)|
62380559|NCT00783263|EXPERIMENTAL|Rosuvastatin 5 mg + Ezetimibe 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
62380560|NCT00783263|ACTIVE_COMPARATOR|Rosuvastatin 10 mg|Participants who received rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
62380561|NCT00783263|EXPERIMENTAL|Rosuvastatin 10 mg + Ezetimibe 10 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
62380562|NCT00783263|ACTIVE_COMPARATOR|Rosuvastatin 20 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
62380563|NCT03887286|EXPERIMENTAL|treatment group|All participants to receive standard transthoracic echocardiogram and hand held echocardiogram
62380564|NCT02332694|EXPERIMENTAL|High intensity whole-body infrared heating|The participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
62380565|NCT05882435|NO_INTERVENTION|Usual Organization|X-rays are done in the radiology department and the images are made available to emergency physicians without waiting for the radiologist's report, which is usually done on a delayed basis.
62759725|NCT03261856||Lactose Breath test|Lactose breath test, 25 g lactose in 250 ml water. Breath samples collected at baseline and every 30 min for 5 hours
62759726|NCT04272008|ACTIVE_COMPARATOR|Annovera (alone)|Annovera without tampon use
61987266|NCT03725007|EXPERIMENTAL|Participants of age group 2 to <18 years receiving dose A|Participants of age group 2 to \<18 years administered with upadacitinib dose A as described in the protocol.
61987267|NCT01984775|EXPERIMENTAL|GSK2894512 0.5%|Each subject will receive a topical application of GSK2894512 0.5% under semi-occlusive patch conditions once daily (OD) for 21 days.
61987268|NCT01984775|EXPERIMENTAL|GSK2894512 1%|Each subject will receive a topical application of GSK2894512 1% under semi- occlusive patch conditions OD for 21 days.
62380566|NCT05882435|OTHER|Organization with AI|X-rays are done in the radiology department and the images are made available to emergency physicians with the AI interpretation. X-rays flagged by IA as anormal or suspicious will be reviewed without delay by the radiologist, non-flagged X-rays will be reviewed by radiologists on a delayed basis.
62380567|NCT00971191|EXPERIMENTAL|treatment|Patients treated with brief exposure to PF-00299804 prior to surgical resection
62380568|NCT03698695|EXPERIMENTAL|THN201|THN201: Donepezil 5mg capsule and Mefloquine 10mg capsule once daily for 15 days
62380569|NCT03698695|ACTIVE_COMPARATOR|Donepezil|Donepezil 5mg capsule and Mefloquine placebo capsule once daily for 15 days
62759727|NCT04272008|ACTIVE_COMPARATOR|Annovera with tampon use|Annovera with tampon use
62380570|NCT03698695|PLACEBO_COMPARATOR|Placebo|Donepezil placebo capsule and Mefloquine placebo capsule once daily for 15 days
62380571|NCT04748250|EXPERIMENTAL|Acupuncture Group|This group will receive acupuncture therapy for 30 minutes, three times per week for six months using the internationally recognized standard acupuncture needle which is 3 cm long with diameter o.3 mm, pushing it with twisting movement to the required depth until the De Qi sensation will be obtained.
62380572|NCT04748250|EXPERIMENTAL|Soy Group|This group will receive soy products for six months which including: Soy milk: 100 millilitre of soy milk every day, every bottle of original soy milk contains 300 millilitre or Soy beans: 100 gram of cooked soy beans per day.
62380573|NCT04748250|EXPERIMENTAL|Acupuncture and Soy Group|Every patient in this group will receive acupuncture therapy sessions in abdominal acu-points as in group (A) for 30 minutes, three times per week for six months in addition to administration of soy products in the form of soy milk or soy beans daily in breakfast for three months as in group (B).
62759728|NCT06072092||Out-of-hospital cardiac arrest adult patients|All patients aged ≥18 years and in out-of-hospital cardiac arrest (OHCA) on arrival at the physician response unit (PRU) in Graz, Austria + surroundings.
62380574|NCT05963165|EXPERIMENTAL|Experimental group|Patients who will perform non-phonatory exercises in parallel with medical therapy for the first week
62380575|NCT05963165|NO_INTERVENTION|Control group|patients who will perform standard medical therapy only during the first week.
62759729|NCT04070196|OTHER|Leucocyte testing|The PD effluent will be sent to the laboratory for leucocyte testing for patients presented with suspected PD peritonitis.
62759730|NCT03943680|EXPERIMENTAL|PRGF|Post-extraction socket grafted with PRGF-Endoret
62759731|NCT03943680|ACTIVE_COMPARATOR|ABB|Post-extraction socket grafted with anorganic bovine bone (ABB)
62759732|NCT03171246|EXPERIMENTAL|CD-TREAT (Solid food-based intervention)|"Solid food-based dietary intervention replicating composition of exclusive enteral nutrition (EEN).~Daily for up to 12 weeks."
61987269|NCT01984775|EXPERIMENTAL|GSK2894512 2%|Each subject will receive a topical application of GSK2894512 2% under semi-occlusive patch conditions OD for 21 days.
61987270|NCT01984775|PLACEBO_COMPARATOR|Vehicle|Each subject will receive a topical application of Vehicle cream under semi-occlusive patch conditions OD for 21 days.
62380576|NCT01011764|ACTIVE_COMPARATOR|SKILLS group|The SKILLS intervention targets a specific set of social skills over 8 bi-weekly sessions. The intervention is delivered to a small group of children with autism at school during lunchtime. The content delivered to the group of young children with autism including lessons developed from a manual by Seattle Children's Hospital Research Foundation. Children are given weekly homework assignments to reinforce the topics discussed in the group sessions.
62759733|NCT02854124||Patients with stage Ib and II melanoma|Melanoma and peritumoral skin excision
62759734|NCT01256281|EXPERIMENTAL|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
62759735|NCT02312219||Low Dose Methotrexate|Subjects will take 1 mg folic acid once daily plus 5 mg methotrexate (MTX) . If clinically stable at the week 1 visit, the dose of MTX will be increased to 10 mg once weekly through week 12. For subjects who remain clinically stable on 10 mg MTX or placebo through the week 12 visit, the dose of MTX will be increased to 15 mg once weekly through week 24. If the subject does not meet the criteria for dose escalation at the week 1 or 12 study visit, then the subject will remain on his/her current dose until the next study visit at which time he/she will be re-evaluated for dose escalation.
61987271|NCT01984775|ACTIVE_COMPARATOR|Sodium lauryl sulfate 0.1%|Each subject will receive a topical application of 0.2 milliliter (mL) of Sodium lauryl sulfate under semi-occlusive patch conditions OD for 21 days. This will serve as a positive control.
61987272|NCT01984775|ACTIVE_COMPARATOR|Petrolatum|Each subject will receive a topical application of 0.2 mL of Petrolatum under semi-occlusive patch conditions OD for 21 days. This will serve as a negative control.
62168181|NCT01794650|OTHER|Meal composition|Changing the glycaemic index of the meals consumed after exercise and before sleep. (High GI - High GI, Low GI - Low GI, High GI - Low GI, Low GI - High GI).
62168182|NCT02578628|ACTIVE_COMPARATOR|Active|These subjects will continue to receive Patient Engagement services.
61987273|NCT03149107|EXPERIMENTAL|IPPI + NAC|"IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician \& rater).~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention. Double-blinded."
61987274|NCT03149107|EXPERIMENTAL|PSM + NAC|"PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician \& rater).~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention. Double-blinded."
61987275|NCT03149107|EXPERIMENTAL|IPPI + Placebo|"IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician \& rater).~Placebo will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM)."
61987276|NCT03149107|ACTIVE_COMPARATOR|PSM + Placebo|"PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician \& rater).~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Placebo will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM)."
61987277|NCT02467465|EXPERIMENTAL|Physical therapy modalities|Manual therapy techniques aimed to relaxed gastrocnemius and soleus muscles tone, movilizations, stretching and home exercises.
61987278|NCT02467465|EXPERIMENTAL|Invasive Physical therapy modalities|Manual therapy techniques aimed to relaxed gastrocnemius and soleus muscles tone, movilizations, stretching and home exercises. Previously, DN will be applied in gastrocnemius and soleus muscles.
61987279|NCT06327958||Group 1: McGRATH-MAC Videolaryngoscope,|Cormack-Lehane (C\&L) and percentage of glottic opening (POGO) scores in the airway management training of medical students.
61987280|NCT06327958||Group 2: C-MAC Videolaryngoscopy|Cormack-Lehane (C\&L) and percentage of glottic opening (POGO) scores in the airway management training of medical students.
61987281|NCT06327958||Group 3: Macintosh Laryngoscope.|Cormack-Lehane (C\&L) and percentage of glottic opening (POGO) scores in the airway management training of medical students.
62759736|NCT02312219||Placebo|Subjects will take 1 mg folic acid once daily plus placebo once weekly. If clinically stable at weeks 1 and 12, the number of placebo tablets will be increased in a manner matching those on the MTX.
62759737|NCT04401956|ACTIVE_COMPARATOR|Gluten free bread with added gluten|Bread will be eaten by the participants for 4 consecutive days.
62759738|NCT04401956|ACTIVE_COMPARATOR|Gluten free bread with added FODMAPs|Bread will be eaten by the participants for 4 consecutive days.
62759739|NCT04401956|EXPERIMENTAL|Traditional manufactured wheat bread|Bread will be eaten by the participants for 4 consecutive days.
61987282|NCT02051946|ACTIVE_COMPARATOR|Retroject device only|The first 5 patients enrolled will serve as controls and will have the device alone placed on the eye (without an injection of ethacrynic acid).
61987283|NCT02051946|EXPERIMENTAL|Retroject injection with ethacrynic acid injection|The next 3 patients, after the first 5 controls, will have the device placed on the eye with a subsequent injection of ethacrynic acid into the episcleral vein.
61987284|NCT02051946|EXPERIMENTAL|randomization to ethacrynic acid or balanced salt solution|The last 12 patients will all have the device placed on their eye. They will then be randomized in a 2:1 ratio to receive either an injection of ethacrynic acid or balanced salt solution.
61987285|NCT05084573|EXPERIMENTAL|Liposomal bupivacaine|Patients will receive a single bolus interscalene injection of 10mL 1.33% LB followed by placement of indwelling (sham) catheter in the interscalene region. Upon arrival in the recovery room, a nurse will connect the catheter to a fixed-rate portable elastometric pump (Easypump®, B Braun, Germany) filled with 300mL normal saline (NS) at a default fixed rate of infusion of 5mL/hr. The syringe, catheter, pump and clamp will be covered by opaque black bags to conceal the milky appearance of LB. The catheter will be removed on postoperative day 2.
61987286|NCT05084573|ACTIVE_COMPARATOR|Standard bupivacaine CISB|Patients will receive a single bolus interscalene injection of 10mL 0.25% SB followed by placement of indwelling (sham) catheter in the interscalene region. Upon arrival in the recovery room, a nurse will connect the catheter to a fixed-rate portable elastometric pump (Easypump®, B Braun, Germany) filled with 300mL 0.2% SB at a default fixed rate of infusion of 5mL/hr. The syringe, catheter, pump and clamp will be covered by opaque black bags to conceal the drug appearance. The catheter will be removed on postoperative day 2.
61987287|NCT01583335|EXPERIMENTAL|Improved lifestyle|
61987288|NCT01583335|NO_INTERVENTION|Control group|The control group was seen at baseline and follow-up, but not in between.
61987289|NCT01583335|NO_INTERVENTION|Shadow group|The shadow group was followed in registers exclusively
62168183|NCT02578628|NO_INTERVENTION|Control|These patients will have all Patient Engagement services discontinued.
62168184|NCT02917083|EXPERIMENTAL|CD30.CAR T Cells|Each patient will receive one infusion of CAR modified T cells.
62759740|NCT04401956|EXPERIMENTAL|Traditional manufactured spelt bread|Bread will be eaten by the participants for 4 consecutive days.
62759741|NCT04401956|EXPERIMENTAL|Conventional manufactured wheat bread|Bread will be eaten by the participants for 4 consecutive days.
62759742|NCT04401956|EXPERIMENTAL|Conventional manufactured spelt bread|Bread will be eaten by the participants for 4 consecutive days.
62759743|NCT06606392|OTHER|Group A|Group A 30 subjects will receive short foot exercise and stretching exercise gastrocnemius, soleus muscle and planter fascia stretch.
62759744|NCT06606392|EXPERIMENTAL|Group B|Group B will receive Biodex balance training and short foot exercise.
62759745|NCT06606288||Conduction system pacing|Medicare beneficiaries indicated for CRT implanted with a Medtronic dual-chamber transvenous pacemaker on or after the study start date with lead type and placement data indicating conduction system pacing.
62759746|NCT06606288||Bi-ventricular pacing|Medicare beneficiaries indicated for CRT implanted with a Medtronic bi-ventricular pacemaker (CRT-P) on or after the study start date with lead type and placement data not indicating conduction system pacing.
62759747|NCT05302856|EXPERIMENTAL|Presumably fertile male patients going through ART treatment|
62759748|NCT05302856|EXPERIMENTAL|Subfertile/infertile male patients with abnormal semen analysis|
62759749|NCT05302856|EXPERIMENTAL|Male patients suffering from unexplained infertility|
61987290|NCT02730572||Concerta to authorized generic (AG) formulation|Participants in the Truven Commercial Claims and Encounters (CCAE) database who enroll in the study will have a confirmed diagnosis of ADHD and continuously using Concerta for at least 60 days. Participants who will switch from Concerta to AG formulation will be observed.
61987291|NCT02730572||Concerta to equivalent generic (EG) formulation|Participants in the Truven Commercial Claims and Encounters (CCAE) database who enroll in the study will have a confirmed diagnosis of ADHD and continuously using Concerta for at least 60 days. Participants who will switch from Concerta to EG formulation will be observed.
61987292|NCT01990495|ACTIVE_COMPARATOR|Exercise vs. usual care|The study involves two arms randomized to exercise and usual care groups
61987293|NCT01990495|ACTIVE_COMPARATOR|Usual care|This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.
61987294|NCT02803151|EXPERIMENTAL|Stereotactic ablative radiotherapy|Image-guided stereotactic ablative radiotherapy
61987295|NCT03350360|EXPERIMENTAL|Attention Control Training Clinic|"Attention Control Training Clinic will consist of:~* 6 sessions in the clinic lasting approximately 10 minutes each.~* Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
61987296|NCT03350360|EXPERIMENTAL|Attention Control Training Web-delivery|"Attention Control Training Web-delivery will consist of:~* 6 sessions lasting approximately 10 minutes each logged into via the internet from the participants' home.~* Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard).~* Ideally participants will complete 2 sessions per week, allowing them to complete the trial in less than one month's time"
61987297|NCT03350360|PLACEBO_COMPARATOR|Comparison Task Clinic|"* 6 sessions in the clinic of a presumably inactive neutral-neutral stimuli intervention lasting approximately 10 minutes each.~* Each session will consist of 128 presentations of pairs of faces, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard).~(Note that those receiving this arm, are invited to repeat the attention control training web-delivery arm at the end of their participation)."
61987298|NCT01756495|EXPERIMENTAL|Losmapimod 7.5 mg|Each subject will receive losmapimod 7.5 mg BID orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
61987299|NCT01756495|EXPERIMENTAL|Losmapimod 20 mg|Each subject will receive losmapimod 20 mg QD orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
61987300|NCT01756495|ACTIVE_COMPARATOR|Moxifloxacin 400 mg|Each subject will receive moxifloxacin 400 mg orally on Day 5, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
61987301|NCT01756495|PLACEBO_COMPARATOR|Placebo|Each subject will receive losmapimod matched placebo and moxifloxacin placebo orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
61987302|NCT01568931|ACTIVE_COMPARATOR|Urokinase|Patients will be randomized to to receive local bolus of 200,000 units urokinase
62759750|NCT00320255|PLACEBO_COMPARATOR|Cohort 1: Placebo|Participants received placebo tablets once daily
61987303|NCT01568931|ACTIVE_COMPARATOR|Saline|Patients will be randomized to to receive local bolus of intracoronary saline
61987304|NCT01271088|EXPERIMENTAL|N-acetylcysteine|N-acetylcysteine: Experimental N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin
61987305|NCT01271088|NO_INTERVENTION|Control|Vancomycine and/or amikacin alone
62558568|NCT05027204|EXPERIMENTAL|Docetaxel combined with Nivolumab|"Phase Ib: The eligible patients with SCCHN will received Docetaxel for Injection (Albumin-bound) 75 mg/m\^2 or 100 mg/m\^2 sequentially in combination with Nivolumab 360 mg to evaluate safety and efficacy and explore RP2D.~Phase II: According to the RP2D determined in the phase Ib study, patients will be treated with Docetaxel for Injection (Albumin-bound) combined with Nivolumab until participants meet the criteria for termination or withdrawal criteria, for a maximum of 2 years."
62558569|NCT06451757|EXPERIMENTAL|Sonlicromanol (KH176)|Oral administration of 100 mg sonlicromanol (KH176) twice daily
62759751|NCT00320255|PLACEBO_COMPARATOR|Cohort 1: Apixaban, 5 mg|Participants received apixaban as tablet, 5 mg, once daily
61987306|NCT04022096|EXPERIMENTAL|Tegoprazan 25mg QD|Tegoprazan 25mg tablet, once daily, oral administration
61987307|NCT04022096|ACTIVE_COMPARATOR|Lansoprazole 15mg QD|Lansoprazole 15mg capsule, once daily, oral administration
61987308|NCT01042730|ACTIVE_COMPARATOR|Pitavastatin 1 mg daily|
61987309|NCT01042730|ACTIVE_COMPARATOR|Pitavastatin 4 mg daily|
61987310|NCT01337219|OTHER|Arm A|experimental treatment (Nebcinal/Aeroneb Idehaler pocket) - 6day-wash out period - standard treatment (Tobi/Pari LC Plus)
61987311|NCT01337219|OTHER|Arm B|standard treatment (Tobi/Pari LC Plus) - 6day-wash out period - experimental treatment (Nebcinal/Aeroneb Idehaler)
61987312|NCT00829374|EXPERIMENTAL|1|Dimebon, 5 mg orally three times daily
61987313|NCT00829374|EXPERIMENTAL|2|Dimebon, 20 mg orally three times daily
61987314|NCT00829374|PLACEBO_COMPARATOR|3|Placebo orally three times daily
62759752|NCT00320255|ACTIVE_COMPARATOR|Cohort 1: Apixaban, 10 mg|Participants received apixaban as tablet, 10 mg, once daily
62759753|NCT00320255|ACTIVE_COMPARATOR|Cohort 1: Apixaban, 20 mg|Participants received apixaban as tablet, 20 mg, once daily
62380577|NCT01011764|EXPERIMENTAL|ENGAGE group|The ENGAGE intervention targets two social domains, and two learning contexts. The two social domains are peer acceptance and social engagement with peers. The social group will be small and include children with ASD as well as their typical peers. There will be a greater number of typical peers included to model social behaviors and foster friendships. The typical peers will be selected based on results from the friendship survey and teacher nominations. The two learning contexts are direct instruction in a group social skills format during lunchtime and individualized embedded generalization activities in the school day.
62380578|NCT00514592||All|All patients enter the same group
62380579|NCT04599660||Low Risk GISTs|This cohort include patients affected by primary GIST at very-low and low risk of recurrence/progression, referred to participating Institutions between January 2000 and February 2020.
62380580|NCT00957723|OTHER|Triathlon® CR Total Knee System|Participants receive the Triathlon® CR Total Knee System
62380581|NCT05488327|EXPERIMENTAL|Intervention with lenalidomide|All subjects will be treated with lenalidomide 5mg/day.
62380582|NCT02297204|EXPERIMENTAL|aflibercept|"2mg, as needed, intravitreal administration. All subjects will be treated with intravitreal (IVT) aflibercept injections as needed in the presence of clinically relevant diabetic macular edema (CR-DME). If CR-DME is not present the subject will not receive an IVT aflibercept injection and will be observed.~If a subject has recurrent CR-DME they will receive an IVT aflibercept 2.0 mg injection and interval between visits will be reduced to 4 weeks.~At week 12 through end of study, all subjects will be evaluated for focal laser treatment."
62380583|NCT06127108|EXPERIMENTAL|Experimental: Nasal sampling/Testing (professional use)|Operator or delegated study staff will collect one anterior nasal swab sample from both nostrils. The collected anterior nasal swab will the tested with the Panbio™ COVID-19/Flu A\&B Panel by the operator at the study site in a near patient testing setting (e.g. GP center or hospital clinic). After the anterior nasal swab is collected, the operator or delegated study staff will collect one anterior nasal swab from both nostrils of the subject for RT-PCR testing. VTM samples will be shipped daily to the central lab for testing with the RT-PCR protocols for Flu A, Flu B and SARS-CoV-2.
62380584|NCT04367740||Serum Antibodies|Blood samples to be obtained assess for IgG antibodies against SARS-CoV2
62380585|NCT02610894|EXPERIMENTAL|mHealth application|Participants will be provided an iPad Mini tablet computer loaded with an mHealth application (PoCAH) to provide enhanced post-operative pain care management. The app will utilize algorithms tailored to the patient's needs and symptoms in an attempt to reduce poor outcomes related to post-operative pain management.
62380586|NCT02610894|ACTIVE_COMPARATOR|Control Group|Participants will be provided an iPad Mini tablet computer loaded with a PDF of the As usual standard discharge and care instructions for post-operative pain care management.
62380587|NCT04624581|EXPERIMENTAL|Patient with fibromyalgia syndrome|250 patients with fibromyalgia syndrome (according to American College of Rheumatology 2016) will realize explorations to characterize central sensitization: reflex nociceptive flexion threshold by electrophysiological measure and blood sampling for evaluate the distribution of gene polymorphism.
62380588|NCT04624581|SHAM_COMPARATOR|Healthy subjects|50 healthy matched volunteers (age, sex and menopausal status for women) will realize explorations to characterize central sensitization: reflex nociceptive flexion threshold by electrophysiological measure and blood sampling for evaluate distribution of gene polymorphism
62380589|NCT02653989|EXPERIMENTAL|MDV9300|
62380590|NCT04423224|ACTIVE_COMPARATOR|Control group|Control group Management of the hemodynamic status in the control group will be performed in the discretion of the attending anesthesiologist, with the aim of keeping mean arterial pressure (MAP) \> 65mmHg. The type and amount of delivered fluids, and vasoactive or inotropic drugs will be recorded.
62380591|NCT04423224|ACTIVE_COMPARATOR|GDFM|Goal-directed fluid management group (GDFM). . Baseline SV will be measured after the patients will be turned to left/right position \& before implementation of regional anesthesia. Fluid challenges of 250 ml will be repeated until SV fails to increase by 10%. At this point, preload is considered optimized and SV optimum is defined. SV trigger is defined as SV opt - 10%. N/S 250ml boluses will be administered when SV is below SV trigger. Inotropic drugs will be administered (dobutamine infusion at 0.2-10mcg/kg/min) if CO is below 3.5 L/min and vasopressors (phenylephrine bolus doses of 50-100mcg) if SV and CO are within the target range but MAP is below 65mmHg. Patients will be reassessed during the intraoperative period every 10 minutes . Except from the fluid boluses, all patients will be administered Ringer's lactate solution at an infusion rate of 2ml/kg/h.
62380592|NCT05707520||MPA|Immunosuppressant with enteric-coated mycophenolate sodium
62380593|NCT05707520||None MPA|Immunosuppressant without enteric-coated mycophenolate sodium
62380594|NCT05039411|EXPERIMENTAL|PF2020-CELL (UC-MSCs) - Allogeneic Human Umbilical Cord Mesenchymal Stem Cells|Two million cells per milliliter (2M/mL) with a total of 60 million PF2020-CELL (UC-MSCs) will be injected locally around the fistula tract, with a separation of 1 cm between injections. All patients to receive allogeneic PF2020-CELL (UC-MSCs) via intralesional injection for 5 consecutive visits, with a 4-week interval between the injections. If the patient is completely healed during any course of stem cell injections, subsequent stem cell treatments can be discontinued. However, patients will still be required to undergo regular follow-up examinations, including physical examinations and other medical tests, until the study is completed.
62380595|NCT02675582|PLACEBO_COMPARATOR|Control|Mix 1 flavored still beverage
62558570|NCT06451757|PLACEBO_COMPARATOR|Matching Placebo|Oral administration of 100 mg matching placebo twice daily
62558571|NCT05369754|EXPERIMENTAL|YBSW015 injection 180mg|
62558572|NCT05369754|EXPERIMENTAL|YBSW015 injection 450mg|
62558573|NCT05369754|EXPERIMENTAL|YBSW015 injection 900mg|
62168185|NCT01199445|EXPERIMENTAL|triple fortified extruded rice|
62759754|NCT00320255|PLACEBO_COMPARATOR|Cohort 2: Placebo|Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.
62759755|NCT00320255|ACTIVE_COMPARATOR|Cohort 2: Apixaban, 5 mg|Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.
62759756|NCT04237038|EXPERIMENTAL|laparoscopic Nissen fundoplication short gastric vessel divi|Randomized clinical trial conducted in forty patients submitted to short gastric vessel division (SGVD) forty patients without SGVD. Patients were evaluated with standarized questionnaires to measure the degree of satisfaction in relation to surgical procedure and to the quality of life.
62759757|NCT02709187|EXPERIMENTAL|RT group|combination dose of Candesartan and Rosuvastatin and DP-R208 in order
62759758|NCT02709187|EXPERIMENTAL|TR group|DP-R208 and combination dose of Candesartan and Rosuvastatin in order
62759759|NCT04875650|EXPERIMENTAL|Physics Forceps|
62759760|NCT04875650|OTHER|Conventional Forcep|
62759761|NCT03871452|ACTIVE_COMPARATOR|ABS in external bleeding|Drug Ankaferd Blood Stopper Bleeding control in 10 minutes with ABS
62759762|NCT03871452|ACTIVE_COMPARATOR|Repetition of ABS stopped bleeding|Repetition of ABS stopped bleeding
62759763|NCT05180318|PLACEBO_COMPARATOR|0.9% saline preadministration group|0.9% saline will be given intravenously 24-36 hours before operation and immediately after operation
62759764|NCT05180318|EXPERIMENTAL|Esketamine preadministration group|Esketamine (0.25 mg/kg) will be given intravenously 24-36 hours before surgery (infusion time: 40 min) and immediately after surgery (infusion time: 40 min).
62759765|NCT00990327|EXPERIMENTAL|Apadenoson|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson or the active comparator: adenosine.
62759766|NCT00990327|ACTIVE_COMPARATOR|Adenosine|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson or the active comparator: adenosine.
62759767|NCT06607926|ACTIVE_COMPARATOR|Control group|Neoadjuvant therapy with platinum-doublet chemotherapy plus tislelizumab for four cycles, followed by surgery and adjuvant therapy.
62759768|NCT06607926|EXPERIMENTAL|Experimental group|Neoadjuvant therapy with platinum-doublet chemotherapy plus tislelizumab and Tα1 for four cycles, followed by surgery and adjuvant therapy.
62759769|NCT03732365|EXPERIMENTAL|Investigational Group|Patients who are randomized to the investigational regimen will receive Ultrasonic Drug Delivery, which includes infusion of up to 2 grams of cefazolin in 100 mL saline followed by external ultrasound in addition to standard of care antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days as well as standard of care adjunct therapy.
62759770|NCT03732365|ACTIVE_COMPARATOR|Comparator Group|Patients who are randomized to the comparator regimen will receive antibiotic according to the antibiotic package insert instructions for standard of care for the particular gram-positive pathogen over a period of no more than 14 days as well as standard of care adjunct therapy.
62759771|NCT03856008|EXPERIMENTAL|Exercises focused on flexor muscles.|Flexor cervical stabilization exercises will be applied.
62759772|NCT03856008|EXPERIMENTAL|Exercises focused on extensor muscles.|Extensor cervical stabilization exercises will be applied.
62168186|NCT01199445|OTHER|regular meal|regular vitamin A meal
62380596|NCT02675582|EXPERIMENTAL|Herbal beverage 1|Mix 2 flavored still beverage with a botanical extract(1)
62380597|NCT02675582|EXPERIMENTAL|Herbal Beverage 2|Mix 3 flavored still beverage with a botanical extract(2)
62380598|NCT02675582|EXPERIMENTAL|Combined Herbal Beverage|Mix 4 flavored still beverage with 2 botanical extracts (1,2)
62558574|NCT05369754|EXPERIMENTAL|YBSW015 injection 1800mg|
62558575|NCT02983019||Therapy with interferons' inducers|Therapy according to routine practice (including Kagocel) Groups will be splitted during the final data analysis
62759773|NCT03856008|NO_INTERVENTION|Control.|No intervention will be applied.
62759774|NCT04442321|ACTIVE_COMPARATOR|PENS plus exercise group|Experimental: PENS plus exercise group 4-week intervention program with 1 weekly treatment session, one of percutaneous electrical stimulation. In addition, self-management loaded exercise, prescribed by the physical therapist but completed by the patient independently . It involved isometric exercises, eccentric exercise, eccentric-concentric with weight or resistive therapeutic band.
62759775|NCT04442321|SHAM_COMPARATOR|Sham PENS plus exercise group|Sham Comparator: Sham PENS plus exercise group 4-week intervention program with 1 weekly treatment session, one of percutaneous electrical stimulation. In addition, self-management loaded exercise, prescribed by the physical therapist but completed by the patient independently. It involved isometric exercises, eccentric exercise, eccentric-concentric with weight or resistive therapeutic band.
62759776|NCT02674282|EXPERIMENTAL|ACL-injured|ACL injured professional soccer players submitted to ACL reconstruction.
62759777|NCT02674282|NO_INTERVENTION|Control|Healthy professional soccer players
62759778|NCT05431920|EXPERIMENTAL|Experimental|Vitamin D3: single 50,000 IU loading dose + 4,000 IU daily dose for three months
62759779|NCT05431920|ACTIVE_COMPARATOR|Active control|Vitamin D3: 2,000 IU daily dose for three months
62759780|NCT04134130|OTHER|GnRH antagonist + FSH + testosterone|"At the start of the study: 240 mg of the gonadotropin releasing hormone antagonist Degarelix (Ferring GmbH, Wittland, Kiel, Germany) + recombinant FSH (Gonal-f, Merck Serrono S.A. Aubonne, Schweiz), 300 IU every second day for 5 weeks.~After 3 weeks: 1000 mg testosterone once."
62380599|NCT01948089|EXPERIMENTAL|Variable Structured Cognitive Exercise|This training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. Each participant will receive 30 minutes of cognitive exercise per day, 3 days a week for 10 weeks.
62759781|NCT04134130|OTHER|GnRH antagonist + testosterone|"At the start of the study: 240 mg of the gonadotropin releasing hormone antagonist Degarelix (Ferring GmbH, Wittland, Kiel, Germany).~After 3 weeks: 1000 mg testosterone (Nebido, Bayer AB, Solna, Sweden) once."
62380600|NCT01948089|EXPERIMENTAL|Constant Structured Cognitive Exercise|This training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. Each participant will receive 30 minutes of cognitive exercise per day, 3 days a week for 10 weeks.
62759782|NCT00590824|EXPERIMENTAL|A|Hu14.18-IL2 --\>Resection--\>Hu14.18-IL2
62759783|NCT00590824|EXPERIMENTAL|B|Resection --\>Hu14.18-IL2--\>Hu14.18-IL2
62759784|NCT02276118|EXPERIMENTAL|e.motion PS Pro group|the patients who receives total knee arthroplasty with the e.motion PS pro prosthesis
62759785|NCT02276118|ACTIVE_COMPARATOR|Genesis II group|the patients who receives total knee arthroplasty with the Genesis II prosthesis
62759786|NCT05622266|EXPERIMENTAL|Pulpotomy|The removal of a small portion of the vital coronal pulp as a means of preserving the remaining coronal and radicular pulp tissues.
62759787|NCT05622266|ACTIVE_COMPARATOR|Root Canal Therapy|The complete removal of the vital dental pulp. Any material or combination of materials placed inside a root canal for the purpose of obturating and sealing the canal space.
62759788|NCT04495556||Typical|Patients with typical symptom onset including: acute unilateral optic neuritis, double vision due to an internuclear ophthalmoplegia or sixth nerve palsy, facial sensory loss or trigeminal neuralgia in a young adult (\<40 years of age), cerebellar ataxia and nystagmus, partial myelopathy, sensory symptoms in a CNS (central nervous system) pattern, Lhermitte's symptom, asymmetric limb weakness, urge incontinence or erectile dysfunction, or other neurological presentation considered to be typical by the site investigator.
62759789|NCT04495556||Atypical|Patients with atypical onset including: bilateral optic neuritis or unilateral optic neuritis with a poor visual recovery, complete gaze palsy or fluctuating ophthalmoparesis, intractable nausea, vomiting, or hiccups, complete transverse myelopathy with bilateral motor and sensory involvement, encephalopathy, subacute cognitive decline, headache or meningismus, isolated fatigue or asthenia, constitutional symptoms, other clinical presentations considered atypical by the site investigator (examples include: vague or patchy sensory symptoms, pain, short lasting bilateral blurred vision, etc.), or absence of clinical symptoms with MRI features suggestive of MS.
62759790|NCT01985490|EXPERIMENTAL|epiretinal membrane|
62759791|NCT01766895||uremic patients|blood sampling of viral hepatitis in uremic patients
62759792|NCT02106247|EXPERIMENTAL|1 BI 1181181 low dose|tablet
62380601|NCT03309722||early stage|
62380602|NCT03309722||advanced|
62558576|NCT02983019||Therapy without interferons' inducers|Therapy according to routine practice Groups will be splitted during the final data analysis
62759793|NCT02106247|EXPERIMENTAL|BI 1181181 high dose|tablet
62759794|NCT02106247|EXPERIMENTAL|Placebo|tablet
62759795|NCT05985213||CSVD patients|The neuroimaging diagnosis will follow the Standards for Reporting Vascular Changes on Neuroimaging (STRIVE) criteria established by the neuroimaging experts in 2013. The interpretation and assessment will be conducted jointly by one experienced radiologist and one experienced neurologist.
62759796|NCT00628589|EXPERIMENTAL|Inhaled Loxapine 5 mg|Inhaled Loxapine 5 mg, may repeat x 1 or 2 after 2 hours
62759797|NCT00628589|EXPERIMENTAL|Inhaled Loxapine 10 mg|Inhaled Loxapine 10 mg, may repeat x 1 or 2 after 2 hours
62380603|NCT01041586|EXPERIMENTAL|BTVA|
62380604|NCT06482801|EXPERIMENTAL|IT injection of double ICI|Arm 1: intra-tumor injection of double ICIs only.
62380605|NCT06482801|EXPERIMENTAL|IT injection of double ICI and chemodrug|Arm 2: intra-tumor injection of double ICIs and a chemodrug.
62380606|NCT06482801|EXPERIMENTAL|IT injection of double ICI and chemodrug plus bevacizumab|Arm 3: intra-tumor injection of double ICIs, a chemodrug, and bevacizumab.
62380607|NCT01858337|EXPERIMENTAL|green beans group,|1 of the 2 vegetable groups. The infants were weaned only with vegetables. With green beans every other day and another vegetable on the days in between.
62759798|NCT00628589|PLACEBO_COMPARATOR|Inhaled placebo|Inhaled Loxapine placebo, may repeat x 1 or 2 after 2 hours
62759799|NCT03234556|ACTIVE_COMPARATOR|Arm I (SR-Bx)|Patients undergo SR-Bx. If SR-Bx doesn't reveal clinically significant cancer, then MRI will be done in 3 months, and if lesion is present (PIRADS ≥ 3) schedule for MRUS-Bx. If there is no lesion, then no biopsy. Schedule MRI in 12 months after the initial MRI.
62759800|NCT03234556|EXPERIMENTAL|Arm II (MRI, MRUS-Bx, SR-Bx)|"Patients undergo MRI. Must be scheduled at least one day before MRUS biopsy.~* If MRI shows no lesion present (PIRADS 1-2), then no MRUS-Bx. Schedule for SR-Bx only.~* If MRI shows lesion present (PIRADS ≥ 3), perform MRUS-Bx, which will be done first and followed immediately by SR-Bx."
62759801|NCT05708781|EXPERIMENTAL|CSE Group|in addition to Conventional treatment, core strengthening exercise were given
62759802|NCT05708781|EXPERIMENTAL|IDBE Group|in addition to Conventional treatment, intensive dynamic back exercise were given
62759803|NCT05708781|ACTIVE_COMPARATOR|Control Group|Conventional Treatment
62759804|NCT00934947|PLACEBO_COMPARATOR|Sugar pill|
62759805|NCT00934947|EXPERIMENTAL|Propranolol, Propanolol ER|
62168187|NCT00645099|EXPERIMENTAL|001|paliperidone ER 6-mg or 9-mg tablet once daily flexible dosing for 6 months
61987315|NCT03911895||patients with coronary artery diseas undergoing PCI|Effect of stent length on patients with coronary artery undergoing PCI
61987316|NCT02447133||Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Maestro device
61987317|NCT00428896|EXPERIMENTAL|1|ZD1839
61987318|NCT06074913|OTHER|Healthy group|After the healthy volunteers met the requirements through screening (i.e., demographic data recording,medical history taking, physical examination report review and recording on the day of enrollment), IRT was performed on the extremities, with 1 image automatically taken every 10 s for 1 min, and 6 images for each site.
61987319|NCT06074913|OTHER|Diabetic group|After screening to meet the inclusion criteria for this study, IRT was performed on the extremities, with 1 image automatically taken every 10s for 1 min, and 6 images for each site.
61987320|NCT06074913|OTHER|Diabetic peripheral neuropathy group|After screening to meet the inclusion criteria for this study, IRT was performed on the extremities, with 1 image automatically taken every 10s for 1 min, and 6 images for each site.
61987321|NCT06074913|EXPERIMENTAL|EA group|Subjects in this group received electroacupuncture along with the basic treatment at a frequency of 2 treatments per week for 6 weeks for a total of 12 interventions.
61987322|NCT06074913|OTHER|Waiting list group|The subjects in this group will receive only basal treatment with no additional therapies during the study period.
61987323|NCT03145168|EXPERIMENTAL|High Target Mean Arterial Pressure|
61987324|NCT03145168|ACTIVE_COMPARATOR|Low target Mean Arterial Pressure|
62380608|NCT01858337|EXPERIMENTAL|Artichoke group|1 of the 2 vegetable groups. The infants were weaned only with vegetables. With Artichoke every other day and another vegetable on the days in between
62558577|NCT03457181|ACTIVE_COMPARATOR|music group|in music group, patient was asked to choose one music genres from 5 different music genres according to his/her preference. Patient selected music was delivered by an iPhone 6 and Music app (Apple Inc., USA) through the iPhone's headphones.
62759806|NCT05731076|EXPERIMENTAL|Self-management support nutrition and exercise group|Educate how to plain regular exercise and eat enough protein diet with self-management support.
62759807|NCT05731076|NO_INTERVENTION|Routine health education group|Routine health education.
62759808|NCT03085511|EXPERIMENTAL|Egg Breakfast (EB)|"The EB will receive the following breakfast:~2 scrambled eggs, 120 mL skim milk, 2 slices of Mrs. Bairds® Extra Thin White Bread, 5 g of butter, and 18 g of Smuckers® Strawberry Jam."
61987325|NCT05259007|EXPERIMENTAL|Group 1|Group 1 propolis with lactic acid extract on top of the treatment given by doctor
61987326|NCT05259007|OTHER|Group 2|Grorup 2 Lactic acid extract on top of the treatment by the doctor
61987327|NCT05259007|PLACEBO_COMPARATOR|Group 3|Group 3 the treatment given by the doctor and placebo treatment
61987328|NCT01559896|EXPERIMENTAL|intervention and placebo|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
61987329|NCT01662908|EXPERIMENTAL|edoxaban tosylate|
62759809|NCT03085511|ACTIVE_COMPARATOR|Cereal Breakfast (CB)|"The CB will receive the following breakfast:~1.5 cups of Special K® Ready-to-Eat Original Cereal, 200 ml Silk® Original Soymilk, 1 slice of Nature's Own® Double Fiber Wheat Bread, 13 g of butter, and 10 g of Smuckers® Sugar-Free Strawberry Jam."
62759810|NCT05285124|EXPERIMENTAL|tDCS and melatonin intervention|In real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes. Participants were given a 3-mg fast-release oral dose of melatonin.
62380609|NCT01858337|ACTIVE_COMPARATOR|Apple group|1 of the 2 fruit groups. The infants were weaned only with fruits. With Apple every other day and other fruits on the days in between
62380610|NCT01858337|ACTIVE_COMPARATOR|Plums group|1 of the 2 fruit groups. The infants were weaned only with vegetables. With Plums every other day and other fruits on the days in between
62380611|NCT04313309|EXPERIMENTAL|Support Group|This is the only group in the study consisting of patients with chronic musculoskeletal pain who are receiving the Integrative Yoga Therapy Program
62380612|NCT06117072|EXPERIMENTAL|Dash diet group, salt free diet|This randomized controlled intervention study aimed to compare the effects of a Dietary Approaches to Stop Hypertension (DASH) diet and a salt-free diet on blood pressure in hypertension patients. Methods: This study was conducted with 60 patients with primary hypertension. One group (n=30) was given an individualized DASH diet, the other group was given a salt-free diet (n=30), and the participants were followed for two months.
62759811|NCT05285124|EXPERIMENTAL|tDCS intervention|In real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
62759812|NCT05285124|EXPERIMENTAL|Melatonin intervention|Participants were given a 3-mg fast-release oral dose of melatonin.
62759813|NCT05285124|PLACEBO_COMPARATOR|Control|Patients were treated with the placebo and sham-tDCS.
61987330|NCT01662908|ACTIVE_COMPARATOR|heparin/warfarin|
61987331|NCT00496756|OTHER|Sorafenib|"The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the table below, providing no dose limiting toxicity (Grade 3 or 4) is observed. If grade 3 or 4 toxicity is observed, delay and dose modification will occur as defined in protocol. Once dose level 3 is reached, the patient will remain at that dose as defined in following section.~Dose Level 1 Day 1-28 400 mg b.i.d. Dose Level 2 Day 29-56 600 mg b.i.d. Dose Level 3 Day 57- 800 mg b.i.d.~A treatment cycle will be 4 weeks.~Two 4-week cycles will be administered. At the completion of two cycles (week 8), restaging will occur. Patients will continue on therapy per study protocol."
62168188|NCT00645099|ACTIVE_COMPARATOR|002|olanzapine 10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
62168189|NCT01461161|EXPERIMENTAL|20 mg bardoxolone methyl|
61987332|NCT06316531|EXPERIMENTAL|Experimental Group|Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
61987333|NCT06316531|EXPERIMENTAL|Control group|Participants receive T-DM1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
61987334|NCT05578534||High CO2 gap (Pcv-aCO2 > 6 mmHg)|Patients had high PCO2 gaps before initial resuscitation
61987335|NCT05578534||Normal CO2 gap (Pcv-aCO2 ≤6 mmHg)|Patients had normal PCO2 gaps before initial resuscitation
61987336|NCT05578534||Responsive (15% increase in CI or stable MAP was achieved)|Patients who respond to initial resuscitation with 15% increase in CI
61987337|NCT05578534||Non-responsive (< 15% increase in CI or a stable MAP was not achieved)|Patients who do not respond to initial resuscitation with less than 15% increase in CI
61987338|NCT05578534||Survivors|Patients who survived after 28 days
61987339|NCT05578534||Non survivors|Patients who do not survive within 28 days
61987340|NCT01844609|EXPERIMENTAL|Self Study Journal Club|25 Chinese Medical Professionals that will be participating in Self Study Journal Club Meetings three times a week for one hour for 8 weeks with interactive questions and answers and discussion of the journal articles.
61987341|NCT01844609|EXPERIMENTAL|Intensive Journal Club|25 Chinese Medical Professionals that will be participating Face to Face Journal Club Meetings three times a week for one hour for 8 weeks along with a native English speaking mentor.
61987342|NCT01001507|EXPERIMENTAL|Integrated HIV/FP services|Family planning services are integrated into HIV care and treatment services at this facility.
61987343|NCT01001507|NO_INTERVENTION|Standard (non-integrated), referral-based, services|Patients from the HIV care and treatment clinic will be referred for family planning services, and will not receive FP services by the HIV care provider
62380613|NCT05989152|EXPERIMENTAL|Definite prosthetic valve endocarditis|adult patients with a valvular prosthesis presenting a definite infective endocarditis (IE) according to the ESC classification in force, not operated on in the acute phase (before the PET scan at the end of treatment) and presenting a pathological FDG uptake on the prosthetic valve at the start of curative antibiotic treatment.
61987344|NCT05931679|ACTIVE_COMPARATOR|Interactive VR|a virtual classroom - learners wearing VR headsets in the safety of their home are immersed in a computer-generated simulation centre. Through their avatars, they can interact from a first-person perspective with their environment, colleagues and instructors. The virtual patient has been in a car accident and the learners, by interacting with the virtual trauma bay environment, must work together to perform a primary trauma survey and resuscitate the patient. The interactive VR environment provides the team with real time information (e.g. oxygen saturation levels, heart rate) in a realistic environment that includes the uncertainty, noise, and time pressures of a real case.
61987345|NCT05931679|ACTIVE_COMPARATOR|360 degree video|An immersive environment based on high-definition 360o video obtained from our simulation centre. Single learners, wearing a VR headset, find themselves in the resuscitation room, at the foot of the bed, leading a trauma team through the assessment and resuscitation of a patient in a virtual choose-your-own-adventure scenario. At several key points in the videos, learners are presented with interactive decision points, and their choices determine how the rest of the video unfolds.
61987346|NCT05931679|ACTIVE_COMPARATOR|Theatre-based education|Traditional theatre-based simulation sessions require the physical presence of interdisciplinary groups of learners caring for a physical mannequin-based patient, where social distancing is challenging.
61987347|NCT04637542|EXPERIMENTAL|Control Group (Traditional)|"Application in the Control Group: After the theoretical lesson, the control group was taken to the Anatomy Laboratory. The laboratory consists of three application rooms, one control room and one analysis room. The Anatomy of the Organs Forming the Genital System was explained using an anatomical model of the genital system organs by a researcher responsible for the human anatomy course. Students were given time until the end of the lesson to work on the models. During this time, their questions were answered. At the end, all of the students were given a State Inventory by the researcher and asked to fill it in. Students were then asked to use textbooks and atlases to study for the Knowledge Test (post-test) which took place three days later."
62168190|NCT01461161|EXPERIMENTAL|60 mg bardoxolone methyl|
62168191|NCT01461161|EXPERIMENTAL|80 mg bardoxolone methyl|
62380614|NCT04328181|EXPERIMENTAL|SPCCT and standard DECT|Comparative intra-patients (each patient will have both types of scanner imaging done), clinical superiority study, evaluating the imaging performances (e.g. image quality and radiation dose) of SPCCT and standard DECT for several body regions/anatomical structures.
62380615|NCT00779116|ACTIVE_COMPARATOR|RediTab/Zyrtec|Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
62380616|NCT00779116|ACTIVE_COMPARATOR|Zyrtec/RediTab|Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.
62380617|NCT02444689|EXPERIMENTAL|Electronic Media Application|Participants will receive an age-appropriate behavioral intervention designed to promote weight loss, improved diet quality, and exercise.
62380618|NCT02444689|ACTIVE_COMPARATOR|Control|Participants will receive standard of care education and feedback on how to implement a heart healthy lifestyle to promote weight loss, improved diet quality and exercise.
62380619|NCT00439699|EXPERIMENTAL|Memantine|Tremor reduction
62380620|NCT04489602||Intervention|Each patient complete ObsQoR-10F questionnaire 3 times (before delivery, on Day 1, on Day 2)
62380621|NCT06247475||Medical professionals|Attending physicians of National Taiwan University Hospital
62380622|NCT06247475||Healthcare-related professionals|Medical Radiation Technologist of National Taiwan University Hospital
62380623|NCT06247475||Medical students|Medical students of National Taiwan University College of Medicine who have passed the first stage of Taiwan Medical Licencing Exam.
62380624|NCT06247475||General public|Volunteers from Taiwan Emergency Medical Technician Association
62380625|NCT00807989|ACTIVE_COMPARATOR|Carbamazepine|Carbamazepine
61987348|NCT04637542|EXPERIMENTAL|Experimental Group (Mobile)|"Application in Experimental Group: After the theoretical lesson, students in the experimental group were taken to an empty classroom. The mobile application was installed on the smartphones of the students in the experimental group by the researchers and they were told not to share it with anyone until the end of the study. At the end of the study, the mobile application was also installed on the phones of the students in the control group due to ethical sensitivity. Anatomy of Organs Forming the Genital System was explained on the mobile application containing the genital system organs. The students were allowed to ask questions and the questions were answered. Afterwards, all students in the experimental group were given a State Inventory by the researcher and asked to fill it in. Students were then asked to study using the genitalsystem.apk mobile application until the Knowledge Test (post-test) which took place three days later."
61987349|NCT04684381|EXPERIMENTAL|L-glutamine|Pharmacokinetic characteristics of L-glutamine
62759814|NCT03082573|ACTIVE_COMPARATOR|Group A|"Will be receiving the same background medications and H.P. Acthar gel 40 units twice weekly for 12 weeks.~Patients in group A, can be cross over to group B on week 13 if disease is uncontrolled for continuation until week 24. If their disease is under control then they will continue with the same dosage until week 24.~If the disease is under control, then tapering the steroid dosage can be attempted at the principal investigation's discretion."
61987350|NCT03796780|ACTIVE_COMPARATOR|Extra-Virgin Olive Oil|Daily consumption of 25 mL Extra-Virgin Olive Oil for 6 weeks
62759815|NCT03082573|ACTIVE_COMPARATOR|Group B|"Will be receiving the same background medications and H.P. Acthar gel 80 units twice weekly for 12 weeks.~if the disease is not under control, will continue with same dosage until week 24. If the disease is under control, will be given the option to reduce the dosage to 40 units twice weekly only if patient is suffering from H.P. Acthar gel related adverse effects.~If the disease is under control, then tapering the steroid dosage can be attempted at the principal investigation's discretion."
62380626|NCT00807989|EXPERIMENTAL|Lamotrigine/Valproate|Lamotrigine and Valproate combination therapy
62380627|NCT05454709|EXPERIMENTAL|Dasiglucagon|Dasiglucagon 1mg/ml solution for subcutaneous injection. Size and frequency of dosing will be determined by the AP algorithm. Duration: 3 days.
62380628|NCT05454709|ACTIVE_COMPARATOR|GlucaGen|Glucagon 1mg/ml solution for subcutaneous injection. Size and frequency of dosing will be determined by the AP algorithm. Duration: 3 days.
62380629|NCT05314699|EXPERIMENTAL|resistance-aerobic exercise group, RA|Participants conduct 5-min warm up, 13-min resistance exercise, 12-min aerobic exercise, and 5-min cool down.
62380630|NCT05314699|EXPERIMENTAL|aerobic-resistance exercise group, AR|Participants conduct 5-min warm up, 12-min aerobic exercise, 13-min resistance exercise, and 5-min cool down.
62380631|NCT05314699|NO_INTERVENTION|reading control group, RC|Participants conduct reading for 35 minutes.
62380632|NCT00005533||Coronary Heart Disease Patients|
62380633|NCT01196091|EXPERIMENTAL|LY2127399 every 2 weeks|Administered SC
62380634|NCT01196091|EXPERIMENTAL|LY2127399 every 4 wks|During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
62380635|NCT01196091|PLACEBO_COMPARATOR|Placebo|Administered SC
62380636|NCT00934726||1 group, schizophrenia patients|Patients with schizophrenia according to ICD-10(diagnostic and statistical manual of mental disorders)
62380637|NCT02978911|EXPERIMENTAL|Skull base tumors|Patients who presented a skull base tumor that requires a surgical removal
62380638|NCT05786976|EXPERIMENTAL|Lotion BNO 3732 for topical care|
62380639|NCT05786976|ACTIVE_COMPARATOR|Body Lotion Benchmark product for topical care|
62380640|NCT03362658||Patients|ALS patients (as well as patients with other related disorders such PLS, PMA, and ALS-FTD) will be recruited from ALS clinics under the direction of neurologists who are participating in this study. ALS patients should meet research criteria for suspected, possible, probable, probable laboratory supported, or definite ALS.
61987351|NCT03796780|PLACEBO_COMPARATOR|Refined Olive Oil|Daily consumption of 25 mL Refined Olive Oil for 6 weeks
61987352|NCT05812521|EXPERIMENTAL|Paravertebral block with methylene blue|With the patient sitting, the patient will receive paravertebral block at T4-T5 level before general anesthesia induction
61987353|NCT05812521|ACTIVE_COMPARATOR|Thoracic Epidural Anesthesia|With the patient sitting, the patient will receive thoracic epidural anesthesia at T4-T8 level before general anesthesia induction
62380641|NCT03362658||Controls|Healthy controls who are age and gender matched to patients.
62380642|NCT03642327|ACTIVE_COMPARATOR|Independent online training (IND)|IND refers to practitioners Independently doing the online training.
62380643|NCT03642327|EXPERIMENTAL|Maintenance of Certification (MOC)|MOC involves a guided learning experience, approved by the American Board of Pediatrics and the American Board of Family Medicine for Maintenance of Certification credits. This involves a Quality Improvement project with 3 waves of data collection to assess and improve implementation while participating in 4 monthly webinars led by Dr. Dubowitz.
62380644|NCT02293265|OTHER|Non-drug interventional group|All enrolled participants will provide a blood sample, spirometry , and feedback on their severe asthma symptoms via questionnaires, and health related quality of life and burden of illness through response to self-administered questionnaires. No investigational product will be administered to participants.
61987354|NCT02316067|EXPERIMENTAL|Rehabilitation|Eight weeks of rehabilitation (CHORDATA® Method)
61987355|NCT02316067|NO_INTERVENTION|Control|Participants maintained their daily-life activities routine during the same eight weeks period and were tested before and after this control period.
61987356|NCT02395900|ACTIVE_COMPARATOR|Flaxseed|30 grams Flaxseed powder
62380645|NCT05791669|EXPERIMENTAL|38% silver diamine fluoride|
62380646|NCT05791669|ACTIVE_COMPARATOR|5% sodium fluoride varnish|
62380647|NCT05248100|EXPERIMENTAL|Conditional Cash Transfer|Eligible and consenting participants living in an intervention health facility catchment area will receive the same standard of care HIV tracing and clinical services as control participants, plus the opportunity to receive a one-time incentive of 22,500 Tanzanian Shillings (TSH) (\~$10), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment.
62380648|NCT05248100|NO_INTERVENTION|Control|Eligible and consenting participants living in a control health facility catchment area will receive the standard of care HIV tracing and clinical services.
62380649|NCT03653286|EXPERIMENTAL|NMES and Run|NMES and run
62380650|NCT03653286|OTHER|Only Run|Only Run
62380651|NCT06376812|EXPERIMENTAL|Physical activity intervention|Multi-level intervention to increase physical activity
62380652|NCT01637792|EXPERIMENTAL|Three 2-liter exchanges group|A group of randomly assigned patients undergoing three 2-liter exchanges daily CAPD.
62759816|NCT04358705|EXPERIMENTAL|Young Cigarillo User (YCU) Sample|"Aim 1: Online survey. 392 participants from the full YCU sample~Supplemental Aim 1: A sample of 196 heterosexual females from the Aim 1 survey will be compared to the SGM females~Aim 2: 150 participants from Columbus, Ohio, and surrounding areas will be recruited for an Eye Tracking Activity to capture visual attention to cigarillo packaging. Visual attention will be examined in 3 conditions: 1) flavored product images, 2) unflavored product images, and 3) a mixture of flavored and unflavored product images.~Aim 3: (162 participants from Aim 1 survey). Consists of the Online Electronic Tobacco Marketplace (ETM) and the aim 3 survey components:~* Demographic screener questions~* Tobacco product withdrawal scale~* ETM~* Quality Assurance Question~* Tobacco product withdrawal scale~* Survey (nicotine dependence \& flavor preferences)~A sample of 88 from the 162 Aim 3 participants will be compared with 88 SGM participants from supplemental Aim 1."
61987357|NCT02395900|PLACEBO_COMPARATOR|control|dietary and exercise recommendation
62380653|NCT01637792|ACTIVE_COMPARATOR|Four 2-liter exchanges group|A group of randomly assigned patients undergoing four 2-liter exchanges daily CAPD.
62380654|NCT04749368|EXPERIMENTAL|Cohort A|Participants will receive BRII-835 (VIR-2218) for 32 weeks
62380655|NCT04749368|EXPERIMENTAL|Cohort B|Participants will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with IFN-α up to Week 40
62380656|NCT04749368|EXPERIMENTAL|Cohort C|Participant will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) up to Week 40
61987358|NCT02601742|ACTIVE_COMPARATOR|Zinc group|Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
61987359|NCT02601742|PLACEBO_COMPARATOR|Placebo group|Pedialyte oral electrolyte solution, 330 ml per day for 7 days
61987360|NCT03891420|EXPERIMENTAL|Galidesivir|Galidesivir IV infusion
61987361|NCT03891420|PLACEBO_COMPARATOR|Placebo|Placebo IV infusion
61987362|NCT02101047|EXPERIMENTAL|phenylephrine 50mcg bolus|Phenylephrine 50 mcg bolus dosing with continuous placebo infusion
62380657|NCT00816894|EXPERIMENTAL|D-serine arm|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes.
61987363|NCT02101047|EXPERIMENTAL|Phenylephrine 100 mcg bolus|Phenylephrine 100 mcg bolus dosing wtih continuous placebo infusion.
61987364|NCT02101047|EXPERIMENTAL|Phenylephrine continuous infusion 100mcg/min|Continuous phenylephrine infusion of 100 mcg/min with placebo bolus dosing.
61987365|NCT02968303|EXPERIMENTAL|Induction treatment|Induction vemurafenib and cobimetinib (6 weeks) directly followed by ipilimumab and nivolumab
61987366|NCT02968303|NO_INTERVENTION|No induction treatment|Upfront ipilimumab and nivolumab without induction by vemurafenib and cobimetinib
61987367|NCT02183831||Capsular tension ring non insertion group|The patients who had same cataract surgery procedure without CTR insertion
61987368|NCT02183831||Capsular tension ring insertion group|The patients who underwent capsular tension ring insertion just before IOL implantation during cataract surgery
61987369|NCT03563417|ACTIVE_COMPARATOR|PCI|
61987370|NCT03563417|OTHER|OMT|
62759817|NCT04358705|EXPERIMENTAL|Sexual and Gender Minority (SGM) Female Cigarillo Users|"Supplemental Aim 1: An online convenience sample of 196 SGM females will complete the Aim 1 online survey and will be compared to sample of 196 heterosexual females from the YCU sample~Supplemental Aim 3: (88 SGM females who participated in the Supplemental Aim 1 survey). Consists of the ETM and the aim 3 survey components in the following order:~* Demographic screener questions~* Tobacco product withdrawal scale~* ETM~* Quality Assurance Question~* Tobacco product withdrawal scale~* Survey (nicotine dependence \& flavor preferences)"
61987371|NCT01069146|EXPERIMENTAL|Mild therapeutic hypothermia|Sepsis treatment according to standard guidelines plus mild therapeutic hypothermia
61987372|NCT01069146|NO_INTERVENTION|Control|Sepsis treatment according to standard guidelines
61987373|NCT00632450||1|
62380658|NCT00816894|ACTIVE_COMPARATOR|Olanzapine arm|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
62380659|NCT03702166|OTHER|Interventional CPT|This study will examine the effectiveness of Cognitive Processing Therapy (CPT) for the alleviation of PTSD and tinnitus-related distress among individuals with co-morbid PTSD and tinnitus.
62380660|NCT00508820|EXPERIMENTAL|1|Romiplostim
62759818|NCT04358705|OTHER|Cognitive interview|Separate population of participants (n=29) who were a mix of cigarillo users, dual e-cigarette and cigarillo users, e-cigarette users, and non-users. The cognitive interviews informed the Aim 1 survey
62380661|NCT02309372|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT)|Those assigned to the CBT arm will undergo therapy with the Beating the Blues (BtB) computerized intervention.
62380662|NCT02309372|NO_INTERVENTION|Usual Care|No specific depression care will be provided through this study for those assigned to this arm. However, the participant's caregiver may choose to provide depression treatment outside of this trial.
62759819|NCT03002818||HCV Genotype 1 Participants|Participants receiving paritaprevir/ritonavir/ombitasvir with dasabuvir (Viekirax®/Exviera®, 3D regimen)
61987374|NCT03051321|EXPERIMENTAL|Wellness toileting system|Subjects given SchwabCare Wellness Toileting system
61987375|NCT00984243|EXPERIMENTAL|Photodynamic Therapy|PHOTODYNAMIC THERAPY (PDT)
61987376|NCT03424174|EXPERIMENTAL|Coated Total Knee Arthroplasty|Implantation coated Total Knee Arthroplasty
61987377|NCT03424174|ACTIVE_COMPARATOR|Standard Total Knee Arthroplasty|Implantation Standard Total Knee Arthroplasty
61987378|NCT00819338|ACTIVE_COMPARATOR|polyunsaturated|5g per day of polyunsaturated fatty acids (3.5g EPA and DHA).
61987379|NCT00819338|PLACEBO_COMPARATOR|monounsaturated|5g a day of oleic enriched sunflower oil
61987380|NCT04833621|ACTIVE_COMPARATOR|NMES GROUP|NMES TREATMENT AND PHYSICAL TREATMENT
61987381|NCT04833621|ACTIVE_COMPARATOR|CONTROL GROUP|JUST PHYSICAL TREATMENT
61987382|NCT01771432|ACTIVE_COMPARATOR|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics.
61987383|NCT01771432|OTHER|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
61987384|NCT04467879|EXPERIMENTAL|"Zona Plus - Active - Normal Grip"|Using the Zona Plus Device, the patient will perform a twelve-minute isometric handgrip therapy session at approximately the same time each day . After an initial handgrip strength assessment (the session calibration), a two-minute isometric routine is performed four times, two sessions per hand, with a one-minute non-grip, or rest session between each isometric routine.
61987385|NCT04467879|SHAM_COMPARATOR|"Control Device - Sham - Weaker Grip"|Using the Zona Sham Control Device the patient will perform a twelve-minute isometric handgrip therapy session at approximately the same time each day. After an initial handgrip strength assessment (the calibration), a two-minute isometric routine is performed four times, two sessions per hand, with a one-minute non-grip, or rest session between each isometric routine.
61987386|NCT01635959||Patients with Gastrointestinal Trackt Symptoms|
61987387|NCT01037387|ACTIVE_COMPARATOR|Control|Conventional treatment for COPD
61987388|NCT01037387|EXPERIMENTAL|NIMV group|NIMV: Conventional treatment plus noninvasive mechanical ventilation
61987389|NCT00256698|ACTIVE_COMPARATOR|1|Anastrozole
61987390|NCT00256698|EXPERIMENTAL|2|Anastrozole + Fulvestrant
62380663|NCT04297124|EXPERIMENTAL|[14C]-CC-90009|A single IV dose of 0.6 mg \[14C\]-CC-90009 containing approximately 2 µCi of radioactivity will be administered on Day 1 under fasted conditions.
62759820|NCT03351556|NO_INTERVENTION|Comparison Arm|Participants in the comparison group will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS.
62759821|NCT03351556|EXPERIMENTAL|Active Intervention 1|Participants will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month (\~$4.50) for up to 6 months conditional on visit attendance.
62759822|NCT03351556|EXPERIMENTAL|Active Intervention 2|Participants will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month (\~$10.00) for up to 6 months conditional on visit attendance.
62759823|NCT03160469|EXPERIMENTAL|Elipse capsule insertion group|All patient who inserted elipse capsule in single clinic
62759824|NCT02142283|EXPERIMENTAL|Trevo Thrombectomy Procedure|Trevo Thrombectomy Procedure and Medical Management
62759825|NCT02142283|ACTIVE_COMPARATOR|Medical Management|Medical Management
61987391|NCT00471848|EXPERIMENTAL|Treatment Arm|Antithymocyte globulin with cyclosporin in first line treatment of patients with acquired severe aplastic anaemia and patients with non-severe aplastic anaemia who are transfusion dependent
61987392|NCT04174287|EXPERIMENTAL|F-18-AV45|F-18-AV45 imaging
61987393|NCT01977170|EXPERIMENTAL|Hib/PRP-T vaccine|"One dose, correspond to 0.5 ml, composed of:~PRP-T 10ug NaCl 0.85%~Frequency: 1 injection"
61987394|NCT03257553|EXPERIMENTAL|intervention arm|do fecal calprotectin, doppler and ultrasound for each patient
62380664|NCT02371980|EXPERIMENTAL|Open-label: Vortioxetine 10 mg|Vortioxetine 10 mg, capsules, orally, once, daily (QD) up to 8 weeks. Participants who achieved response (defined as a ≥50% reduction in Montgomery Asberg Depression Rating Scale (MADRS) total score from Baseline) continued to receive vortioxetine 10 mg, capsules, orally, QD for up to Week 16 (stabilization period) in the Open-label Period.
61987395|NCT02258100||Paper|Patients receiving care documented via paper anesthesia record.
61987396|NCT02258100||AIMS|Patients receiving care documented via electronic anesthesia record.
62558578|NCT03457181|ACTIVE_COMPARATOR|operating room noise group|in operating room noise group, operating room noise was delivered by an iPhone and Microphone App (Free version, Von Bruno). This application allows the iPhone to be used as a live microphone.
61987397|NCT03717480|EXPERIMENTAL|TCR α/β Reagent System|"* The stem cell apheresis product will be depleted of TCRαβ T cells by negative selection using the automated CliniMACS® Plus device.~* CD34+ stem cell counts will be obtained before and after processing with the Miltenyi ClinicMACs device"
61987398|NCT02512432|OTHER|Keratoconus|
62759826|NCT00803348|ACTIVE_COMPARATOR|1|Initial Bolus dose of 0.2% ropivicaine followed by 0.2% ropivicaine infusion until day 2 post-op
62759827|NCT00803348|EXPERIMENTAL|2|Initial Bolus dose of 0.2% ropivicaine followed by 0.1% ropivicaine infusion until day 2 post-op
61987399|NCT03747965|EXPERIMENTAL|Mesothelin-directed CAR-T cells infusion|"Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation."
62380665|NCT02371980|PLACEBO_COMPARATOR|Double-blind: Placebo|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine placebo-matching capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
62759828|NCT00803348|PLACEBO_COMPARATOR|3|Initial Bolus dose of 0.375% ropivicaine followed by saline infusion until day 2 post-op
62759829|NCT03117608|EXPERIMENTAL|AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE (aMAT)|injection of aMAT obtained with Lipogems® technology.
62759830|NCT03117608|ACTIVE_COMPARATOR|platelet-rich plasma (PRP)|single injection of platelet-rich plasma
62759831|NCT04664530|PLACEBO_COMPARATOR|Control group|
62759832|NCT04664530|EXPERIMENTAL|Treatment group|
62759833|NCT03386747|EXPERIMENTAL|Home Visiting Group|Intervention: Home visits to improve parenting behaviors
62759834|NCT03386747|EXPERIMENTAL|Center based parenting group|Intervention: Center based parenting groups
62759835|NCT03386747|NO_INTERVENTION|control group|The rest of pregnant women and their children who will not receive the intervention
62759836|NCT01024582|EXPERIMENTAL|accelerated partial breast irradiation|pre-operative radiation of the in situ tumor in the breast
62759837|NCT03340896|ACTIVE_COMPARATOR|TPF followed by radiotherapy|"Induction chemotherapy by Docetaxel 75 mg/m² day 1,cisplatin 75 mg/m² day 1 and 5 fluorouracil 750mg/m²(day 1 to day 5) 3 cycles day1, day 22, day 43 followed (for responders or stable disease patients) by radiotherapy~Radiotherapy ;70 gray fractionization: 2Gy/day, 5days/week, for 7 weeks."
62759838|NCT03340896|EXPERIMENTAL|Cisplatin and radiotherapy|"Drug and radiation • Cisplatin: 100 mg / m² administered IV at J1, J22 and J43 of radiotherapy~. Radiotherapy 70 gray fractionization: 2Gy/day, 5days/week, for 7 weeks."
62759839|NCT04299919||Recurrence|All hepatocellular carcinoma (HCC) patients have been regularly monitored for recurrence via contrast CT or contrast-enhanced MRI after minimally invasive treatment or hepatectomy. The recurrence status included new intrahepatic lesions and/or extrahepatic metastasis.
61987400|NCT03853447||Diagnostic imaging|"The progression of fibrosis will be assessed based on diagnostic imaging of thre subgroups including~Patients with chronic pancreatitis (CP; N=50) of any aetiology, except gallstones, based on MANNHEIM.~Patients with their first attack of acute pancreatitis (AP; N=50) of any aetiology except gallstones using the revised Atlanta criteria for AP.~Patients with recurrent AP (RAP; N=50) except gallstones, defined as two or more cases of AP as diagnosed by the revised Atlanta Criteria."
61987401|NCT04142021||patients with 3-vessel disease with or without left main|Patients with 3-vessel disease with or without left main involvement referred to CABG treatment based on coronary angiography.
61987402|NCT00497172|EXPERIMENTAL|1|drug-eluting stent
61987403|NCT00497172|ACTIVE_COMPARATOR|2|bare-metal stent
62380666|NCT02371980|EXPERIMENTAL|Double-blind: Vortioxetine 5 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 5 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
61987404|NCT05551494||Endometriosis group|Cases will include women aged 18-45 with a surgical diagnosis of endometriosis in the previous 24 months or with a current nonsurgical diagnosis of endometriosis who report having lived in the past ten years in the Lombardy area. At study entry, we will collect urinary sample.
61987405|NCT05551494||Control group|Control group are women aged 18-45 attending our outpatient clinic for periodical gynaecological care, contraception, or cervical cancer screening programme, and without a previous clinical or surgical diagnosis of endometriosis who report having lived in the past ten years in the Lombardy area. At study entry, we will collect urinary sample.
61987406|NCT00678119|EXPERIMENTAL|1: AGS-003+sunitinib|Single arm study AGS-003 plus sunitinib
61987407|NCT02129985|EXPERIMENTAL|Exenatide|patients were all received a short-term intensive insulin therapy,then randomised to Exenatide group(10 ug two times a day for three months)
61987408|NCT02129985|ACTIVE_COMPARATOR|Metformin|patients were all received a short-term intensive insulin therapy,then randomised to metformin group(850mg two times a day for three months)
62380667|NCT02371980|EXPERIMENTAL|Double-blind: Vortioxetine 10 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 10 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
62380668|NCT02371980|PLACEBO_COMPARATOR|Double-blind: Vortioxetine 20 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 20 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
61987409|NCT05174039|EXPERIMENTAL|Oral miglustat|The proposed dosing regimen is daily oral miglustat (MTD, up to 200 mg TID)
61987410|NCT01038024|EXPERIMENTAL|Antioxidant Supplements|
61987411|NCT00325754|ACTIVE_COMPARATOR|E-Cylinder|22-lb E-cylinder towed on a cart
62380669|NCT00498706|EXPERIMENTAL|Telephone-administered CBT|Participants will receive telephone-administered cognitive behavioral therapy.
62380670|NCT00498706|ACTIVE_COMPARATOR|Face-to-face CBT|Participants will receive face-to-face cognitive behavioral therapy.
62380671|NCT04744766|ACTIVE_COMPARATOR|Hadfield technique group|central/mammary duct excision is done by the ordinary method described by Hadfield
62380672|NCT04744766|ACTIVE_COMPARATOR|Al Masad technique group|same procedure with de-epithelization of the upper pararaeolar area
62380673|NCT00875966|EXPERIMENTAL|1|Azithromycin for oral suspension 200mg/5mL
62380674|NCT00875966|ACTIVE_COMPARATOR|2|Zithromax (azithromycin for oral suspension) 200mg/5mL
61987412|NCT00325754|ACTIVE_COMPARATOR|Lightweight Cylinder|3.6-lb lightweight cylinder that can be carried
61987413|NCT06171776|ACTIVE_COMPARATOR|fuji XI|chemically cured glass ionomer
61987414|NCT06171776|EXPERIMENTAL|RetroMTA|cacium silicat cement
61987415|NCT06171776|EXPERIMENTAL|Theracal LC|resin based calcium silicate cement
61987416|NCT02380664|NO_INTERVENTION|Swimmers|Swimmers that continue their normal swimming activity
61987417|NCT02380664|EXPERIMENTAL|WBV swimmers|Swimmers that perform a whole-body vibration training
61987418|NCT02380664|EXPERIMENTAL|Plyometric swimmers|Swimmers that perform a plyometric training
61987419|NCT02380664|NO_INTERVENTION|Sedentary controls|Controls that do not perform swimming or other physical activities
61987420|NCT05272904|ACTIVE_COMPARATOR|Conventional closure method|Following mastectomy, skin is closed using subcutaneous sutures followed by intracutaneous running suture. Depending on the surgeons discretion a vacuum closed suction drain was placed beneath the skin flaps.
61987421|NCT05272904|EXPERIMENTAL|Quilting|The implemented intervention is the quilting suture technique. The subcutaneous tissue is sutured to the pectoralis muscle placing multiple rows of running sutures. The suture starts at either end of the scar, running back and forth, creating rows of quilting stiches. The rows are placed transversely from the cranial to the caudal end of the wound with 2-3 cm between them, totalling some three to ﬁve rows for the cranial ﬂap. The caudal ﬂap is quilted with 2-3 rows in a caudal to cranial fashion. A subcutaneous suture followed by a intracutaneous running suture is used to close the skin. No wound drain is placed.
61987422|NCT03134560|ACTIVE_COMPARATOR|With vein display instrument|Vein cannulation was done after the vein display instrument displays the veins using infrared
61987423|NCT03134560|NO_INTERVENTION|Without vein display instrument|vein cannulation was done without any vein display instrument
61987424|NCT05448651|EXPERIMENTAL|Active substance 1|UPB-101 Cohort 1
62380675|NCT02278159||Peritoneal dialysis only|Patient on PD modality 90 days after renal replacement therapy initiation and not transferred to HHD
62380676|NCT02278159||Home hemodialysis only|Patient on HHD 90 days after renal replacement therapy initiation and not transferred to PD
62380677|NCT02278159||PD and HHD|Patient on PD 90 days after RRT initiation and transferred to HHD less than 90 days after PD failure
62380678|NCT02278159||HHD and PD|Patient on HHD after RRT initiation and transferred to PD less than 90 days after HHD failure
62380679|NCT01521637|EXPERIMENTAL|NMES|The 'NMES' arm will be treated with NMES.
62380680|NCT01521637|SHAM_COMPARATOR|No NMES|The 'No NMES' arm of the experiment will be sham-treated with NMES. The device will be installed, but not used.
62380681|NCT01308528|EXPERIMENTAL|Sodium enoxaparin|Endocris - 40 mg/0,4mL
62380682|NCT01308528|EXPERIMENTAL|sodium enoxaparin Clexane|Clexane - 40 mg/ 0,4mL
62380683|NCT01318291|PLACEBO_COMPARATOR|Control|
61987425|NCT05448651|EXPERIMENTAL|Active substance 2|UPB-101 Cohort 2
62380684|NCT01318291|EXPERIMENTAL|CCRI Group|
62380685|NCT01584427|ACTIVE_COMPARATOR|Healthy Carbohydrate Diet|4 weeks of intervention with a diet rich in Arabinoxylans and Resistent Starch.
62380686|NCT01584427|PLACEBO_COMPARATOR|Western Style Diet|4 weeks of intervention with a diet with low content of Resistent Starch and Arabinoxylans
62759840|NCT04299919||Non-recurrence|All hepatocellular carcinoma (HCC) patients have been regularly monitored for recurrence via contrast CT or contrast-enhanced MRI after minimally invasive treatment or hepatectomy. The recurrence status included new intrahepatic lesions and/or extrahepatic metastasis.
61987426|NCT05448651|EXPERIMENTAL|Active substance 3|UPB-101 Cohort 3
61987427|NCT05448651|EXPERIMENTAL|Active Substance 4|UPB-101 Cohort 4
62380687|NCT00728572|EXPERIMENTAL|Experimental|Participant will receive a brief exam, a Basic Technique apex contact adjustment and Surface EMG.
62380688|NCT00728572|SHAM_COMPARATOR|Sham|Participants will receive a sham Basic Technique adjustment (an adjacent contact not indicated by examination)and surface EMG.
62380689|NCT01609673|NO_INTERVENTION|Control|"35 patients using Cyclosporin or Tacrolimus (C0=100-200/5-10ng/mL)+ Myfortic® 1440mg/dia + Steroids.~Medications will be administered orally, twice a day"
62380690|NCT01609673|ACTIVE_COMPARATOR|Intervention|"35 randomized Patients Converted to Certican® (Everolimus C0=6-10 ng/mL) + Myfortic® 1440mg/day + Steroids.~On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
62380691|NCT04681573|OTHER|Single ARM|Only one arm
62380692|NCT00369564|EXPERIMENTAL|Arm I Glutamic Acid|Patients receive oral glutamic acid 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).
62759841|NCT05661305||Control|Healthy Egyptian individuals to provide the first of its kind resource on human genetic variation in Egyptians, which is essential for understanding the significance of detected variations in patients with inherited cardiovascular disease and their families.
61987428|NCT03134027||Subjects from which PDXs have been generated.|Subjects will be identified from which PDXs have been generated from an already approved IRB protocol.
61987429|NCT03134027||Subjects without an existing PDX|Subjects with prostate cancer amenable to a tumor biopsy.
61987430|NCT02068222|EXPERIMENTAL|ABT-450/r and ABT-530 plus RBV|ABT-450/r (150 mg/100 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
61987431|NCT02323230|EXPERIMENTAL|DPX-Survivac + low dose cyclophosphamide|
61987432|NCT01103687|EXPERIMENTAL|Ad26.ENVA.01 (rAd26)|Participants will receive the Ad26.ENVA.01 (rAd26) vaccine at baseline.
61987433|NCT01103687|PLACEBO_COMPARATOR|Placebo Vaccine|Participants will receive the placebo vaccine at baseline.
61987434|NCT05118451|EXPERIMENTAL|3d reconstruction visualization model to guide preoperative planning and surgery|All patients in this study were operated by the medical team whose main members were the medical team leader, and all patients underwent anatomic hepatectomy. The main points of anatomic hepatectomy are summarized as follows :(1) determine and mark the boundary of liver segment according to ischemia line or staining. (2) The postoperative liver section should fully expose the iconic veins and vessels. (3) The initial part of Glisson's pedicle of the target liver segment was severed. Tissue was taken from the surgical margins of all patients and sent to frozen sections for examination. Routine pathological examinations were performed on all resected liver after surgery. Postoperative patients were treated with relevant perioperative symptomatic treatment, and blood routine examination, liver function and coagulation function were detected on the 1st, 3rd and 5th day after surgery.
62759842|NCT05661305||Cases|Egyptian patients and their family members diagnosed with different types hereditary cardiomyopathies.
62759843|NCT06507501|EXPERIMENTAL|Blood Flow Restriction Exercise Training (BFRT)|"Exercises will be performed under the supervision of a researcher physiotherapist, at low intensity and progressively, under blood flow restriction for 6 weeks, 2 days a week, for a total of 12 exercise sessions. The 1 MT method will be used to determine the amount of resistance in strengthening exercises.~Blood flow restriction will be made by wearing a pneumatic tourniquet from the proximal thigh, within a safe pressure range specific to each individual.~Blood flow restriction United States Food and Drug Administration Using the (FDA) approved H+Cuff device, it will be applied for 20 minutes, with a 1-minute break between exercises. The cuff pressure will be maintained during the rest period, and after the application, individuals will rest for 15 minutes to ensure reperfusion and other exercises will continue."
62380693|NCT00369564|PLACEBO_COMPARATOR|Arm II Placebo|Patients receive oral placebo 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).
62380694|NCT04101227|EXPERIMENTAL|Treatment Arm|AD04 (ondansetron)
62380695|NCT04101227|PLACEBO_COMPARATOR|Placebo Arm|Matching Placebo
62168192|NCT02867332|EXPERIMENTAL|Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10\^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
62380696|NCT01693666|EXPERIMENTAL|Lifestyle intervention group|The LIFE program emphasizes improved nutritional quality, moderate physical activity, and weight maintenance (±10 lb) in obese pregnant women using a contingency management (CM) approach to reinforce behavior change. Participants will meet with the study dietitian and exercise physiologist every 2-4 weeks to develop and maintain individualized nutrition and physical activity plans, reinforced by CM. When the subject meets with the interventionists at their regular appointments, they will review the diet and exercise requirements, and provide vouchers earned as reinforcement from the previous study period. Diet requirements include at least 5 days of food logs each week. Exercise requirements include objective verification of up to 5 exercise sessions per week (as prescribed).
62380697|NCT01693666|NO_INTERVENTION|Routine care group|Participants in the Routine Care (RC) control group will receive no additional intervention beyond standard of care.
62380698|NCT00645229|EXPERIMENTAL|Arm A|
62380699|NCT00040911|EXPERIMENTAL|Arm I (alternative medicine procedure)|Patients undergo electroacupuncture therapy to specific acupuncture points on the arms and legs over 25 minutes twice daily on days 1 and 2 and then once daily on days 3-7 during week 1 of chemotherapy course 1 (9 acupuncture treatments total).
62380700|NCT00040911|SHAM_COMPARATOR|Arm II (alternative medicine procedure)|Patients undergo electroacupuncture therapy to sham points on the arms and legs as in arm I.
62380701|NCT04837768|ACTIVE_COMPARATOR|Serum Progesterone Levels >9.2 ng/ml|These patients will receive only twice-daily vaginal progesterone supplementation following embryo transfer
62759844|NCT06507501|EXPERIMENTAL|Conventional Exercise Training|Participants who will be included in the conventional exercise group will apply the same exercise program as the participants in the blood flow-restricted exercise group, without blood flow restriction, for 6 weeks, 2 days a week, in a total of 12 sessions, at medium-high intensity.
62759845|NCT03001700|EXPERIMENTAL|Treatment|Subjects will be treated with the Serranator™ Alto PTA Serration Balloon Catheter device
62759846|NCT04202146|EXPERIMENTAL|Contingency Management + Motivational Interviewing|Participants will complete a seven-day combined CM with two sessions of brief Motivation Interviewing (MI) followed by standardized individual drug counseling.
62759847|NCT01355263|EXPERIMENTAL|iron tablet, vitamin a capsule|children in Group I received a 200,000 IU vitamin A capsule just one time initially; Group II received ferrous sulfate (element Fe 1-2 mg/kg•day) once a day for 6 months;.
62759848|NCT03192033|OTHER|Arterial closure device used is Proglide® (Abbott)|
62759849|NCT03192033|OTHER|Arterial closure device used is Femoseal® (Terumo)|
62380702|NCT04837768|ACTIVE_COMPARATOR|Serum Progesterone Levels <9.2 ng/ml|These patients will receive twice-weekly intramuscular progesterone supplementation in addition to the twice-daily vaginal supplementation following embryo transfer
62380703|NCT04652349|EXPERIMENTAL|HGP1910|
62759850|NCT01228994|ACTIVE_COMPARATOR|Baclofen 30 mg/day|Baclofen medication
62759851|NCT01228994|PLACEBO_COMPARATOR|Placebo pill|placebo pill
62759852|NCT01228994|ACTIVE_COMPARATOR|Baclofen 60 mg/day|Baclofen medication high dose
62759853|NCT01996592||cesarean section deliveries|those subjects having an elective cesarean section will complete an informed consent form, complete the preoperative questionnaire, and then be contacted for 60 days postoperatively
62759854|NCT02590601|ACTIVE_COMPARATOR|Bromocriptine + Guideline-driven medical therapy|"In addition to heart failure treatment described above, patients will be administered bromocriptine 2.5 mg orally twice daily for 14 days, followed by 2.5 mg orally daily for 42 days.~Although not a study procedure, we recommend anticoagulation with prophylactic doses of subcutaneous low-molecular weight heparin during the whole duration of bromocriptine therapy."
62759855|NCT02590601|OTHER|Guideline-driven medical therapy|New onset PPCM will be managed according to the principles of guideline-driven medical therapy for new-onset heart failure as per the position statement for treatment of PPCM published by the European Society of Cardiology (ESC) and the Canadian Cardiovascular Society (CCS) update on heart failure and pregnancy . The choices and administration of GDMT will be left at the discretion of the treating physician
62759856|NCT00000262|PLACEBO_COMPARATOR|Placebo +/- 30% Nitrous oxide|
62759857|NCT00000262|ACTIVE_COMPARATOR|Sevoflurane 0.2% +/- 30% Nitrous oxide|
62759858|NCT00000262|ACTIVE_COMPARATOR|Sevoflurane 0.4% +/- 30% Nitrous oxide|
62380704|NCT04652349|EXPERIMENTAL|HCP1903|
62380705|NCT04652349|ACTIVE_COMPARATOR|HGP1909|
62759859|NCT01022515||patients with pheochromocytoma|Patients with pheochromocytoma / paraganglioma are being followed as recommended according to international standards. No intervention is expected except regular measurement of plasma CgA (as usual) and EM66 (research purpose) levels.
62759860|NCT01022515||Patients with essential hypertension|Patients with essential hypertension will be selected as controls. EM66 and CgA plasma levels will be assessed in these patients after having excluded the presence of a pheochromocytoma / paraganglioma with normal urinary metanephrines / normetanephrines excretion levels.
62759861|NCT04790825|EXPERIMENTAL|Intensive periodontal treatment|Adjunctive full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing after the administration of local anesthesia.
62759862|NCT04790825|ACTIVE_COMPARATOR|Community-based periodontal care|Standard cycle of supragingival mechanical scaling and polishing.
62759863|NCT01709942|EXPERIMENTAL|degarelix group|group of patients treated with long acting GnRH antagonist
62759864|NCT01709942|ACTIVE_COMPARATOR|Cetrorelix 0.25mg|patients treated with gonadotropin and Cetrorelix ina flexible GnRH antagonist protocol
62380706|NCT04652349|ACTIVE_COMPARATOR|HGP1911|
62759865|NCT05016167|OTHER|Control group (replacement every 24 hours)|The monitoring electrodes were not replaced for 24 hours, the electrodes were removed at the end of 24 hours (the protocol currently used in the institution) in control group.
62759866|NCT05016167|EXPERIMENTAL|Experimental Group (replacement every 12 hours)|In the experimental group, the monitoring electrodes were replacement every 12 hours within 24 hours.
62759867|NCT05499793|EXPERIMENTAL|Treatment group (Ginger)|"All the participants were given Zingiber Officinale powder (500 mg) capsules twice daily for twelve weeks.~Zingiber Officinale capsules were purchased from Pure Mountain Botanicals, 1712 Pioneer Ave # 1139 Cheyenne Wyoming 82001 (USA)"
62759868|NCT05499793|PLACEBO_COMPARATOR|Control group (Placebo)|All the participants were given starch powder (50 mg) capsules twice daily for twelve weeks.
62759869|NCT04105439||control|healthy subjects who do not have the disease
62759870|NCT04105439||patients with Behçet's disease|subjects who do have the disease ( Behçet's disease )
62759871|NCT02470754|ACTIVE_COMPARATOR|EC Block1/TC Block 2|Participants will be randomized into one of two groups. In this group, participants will be assigned to Electronic Cigarettes only for Study Block #1, then crossover to Tobacco Cigarettes only for Study Block #2.
62759872|NCT02470754|ACTIVE_COMPARATOR|TC Block 1/EC Block 2|Participants will be randomized into one of two groups. In this group, participants will be assigned to Tobacco Cigarettes only for Study Block #1, then crossover to Electronic Cigarettes only for Study Block #2.
62759873|NCT05110469|EXPERIMENTAL|Group M|IV Magnesium sulphate 30 mg/kg in 100 ml NaCl 0.9%
62759874|NCT05110469|EXPERIMENTAL|Group P|IV Meperidine 0.5 mg/kg in 100 ml NaCl 0.9%
62558579|NCT04305743|EXPERIMENTAL|5 Injections|Participant's bladder is backfilled with 50 mL of 1% lidocaine for 15 minutes, then drained prior to procedure start. Dose of 100 units onabotulinumtoxin A with dilution to 100 Units/10 mL with preservative-free 0.9% Sodium Chloride Injection is prepared. Cystoscopy is performed. The 23 gauge Laborie InjeTAK needle is inserted 3 mm into the detrusor. 5 injections of 2 mL each (total volume of 10 mL) in a single procedure is performed 1 cm apart in the bladder body. For the final injection, approximately 1 mL of sterile normal saline should be injected such that the remaining onabotulinumtoxin A in the needle is delivered to the bladder.
62759875|NCT04920006|NO_INTERVENTION|Aim 1: Focus Groups|A series of three sequential focus groups will be used to gather ADRD caregiver feedback about EnACT intervention techniques, including frequency, duration, delivery, feasibility, acceptability, and relevance of the intervention. Between focus groups, we will refine and edit the EnACT intervention in an iterative process. Intervention scenarios and activities will be chosen and refined as part of Aim 1 in preparation for testing feasibility and acceptability.
62759876|NCT04920006|EXPERIMENTAL|Aims 2 & 3: Intervention|A Stage 1b pilot study will be conducted to test the feasibility and acceptability (Aim 2) of the EnACT intervention and potential mechanisms of change over time and their subsequent impact on proximal and distal outcomes (Aim 3). This arm will use a randomized waitlist control design.
62759877|NCT06337474|EXPERIMENTAL|anti-CD19 CAR NK cells|
62759878|NCT06519461|EXPERIMENTAL|family-centered teaching model group|The family-centered teaching group provided knowledge and skills of family-centered services for interns in internship
62759879|NCT06519461|NO_INTERVENTION|conventional family approach group|The conventional family approach provided interns to interact with children in internships.
62759880|NCT01133626|PLACEBO_COMPARATOR|Placebo|Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
62759881|NCT01133626|EXPERIMENTAL|BDP HFA 320 µg/day|Participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning for 6 weeks (42 days). During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
62759882|NCT01133626|ACTIVE_COMPARATOR|Prednisone|Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a 10/mg a day prednisone capsule.
62759883|NCT05577832|EXPERIMENTAL|Experimental|3 different injection techniques in Single Group design, 1 ml intramuscular injection of dodex amp 1 ml will be applied to the deltoid muscle, one technique per week, for 1 weeks(3 day). The effects of the three techniques on pain, satisfaction with hematoma, comfort and fear of injection will be compared.
62759884|NCT06178016|EXPERIMENTAL|Experimental Group|Participants in this group will have the Bystander Intervention Program for Dating Violence. The aim of this program, which will be prepared taking into account the needs of the country and institutions, is to provide knowledge and skills to safely intervene in dating violence. The program will be implemented at a convenient time for the experimental group of students within the 2023-2024 Spring semester academic calendar, taking into account the 1st-grade course schedule of Istanbul University-Cerrahpaşa Florence Nightingale Faculty of Nursing.
62759885|NCT06178016|NO_INTERVENTION|Control Group|The control group will not participate in the Bystander Intervention Program for Dating Violence, an interview consisting of one session is planned considering for the placebo effect. The control group students will be given a single 60-minute information session on dating violence and the students will be expected to fill out the scales to be filled out within the scope of the research at the pre-test and post-test times. At the end of the study, the Bystander Intervention Program for Dating Violence will be carried out with the voluntary participants in the control group, taking into account the ethics.
62759886|NCT01882010|SHAM_COMPARATOR|Controls|Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
62759887|NCT01882010|PLACEBO_COMPARATOR|PD Patients placebo|PD patients that receive placebo, have blood draw, physical exam and UPDRS part III assessment, MEG, Motion analysis.
62759888|NCT01882010|EXPERIMENTAL|PD Patients sargramostim|PD patients that receive Leukine, have blood draw, physical exam and UPDRS part III assessment, MEG, Motion analysis.
62759889|NCT03811847|EXPERIMENTAL|Sequence 1:MPH, PBO, MPH, PBO, PBO, MPH|"Over the 16-week study, each participant moved through four, 4-week treatment periods: a Placebo (PBO) lead-in, acclimation period followed by three, crossover Methylphenidate (MPH) vs PBO blocks. Each block consisted of treatment with MPH for two-weeks and treatment with PBO for two-weeks; each block order will be randomly assigned. In this group, participants first received Methylphenidate (MPH) for 2 weeks, then placebo for 2 weeks, then MPH for 2 weeks, then Placebo for 2 weeks, then Placebo for 2 weeks, then MPH for 2 weeks."
62759890|NCT03811847|EXPERIMENTAL|Sequence 2:MPH, PBO, PBO, MPH, MPH, PBO|"Over the 16-week study, each participant moved through four, 4-week treatment periods: a Placebo (PBO) lead-in, acclimation period followed by three, crossover Methylphenidate (MPH) vs PBO blocks. Each block consisted of treatment with MPH for two-weeks and treatment with PBO for two-weeks; each block order will be randomly assigned. In this group, participants first received Methylphenidate (MPH) for 2 weeks, then placebo for 2 weeks, then PBO for 2 weeks, then MPH for 2 weeks, then MPH for 2 weeks, then PBO for 2 weeks."
62380707|NCT02734472||Hanzhong cohort|A total of 4623 adolescents aged 6-15 years old in Hanzhong rural areas were recruited in 1987.During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
62380708|NCT02734472||Mei county cohort|A total of 675 individuals from 126 families were recruited in this family-based dietary intervention study. A community-based BP screening was conducted among adults aged 18-60 years in the study villages. The probands who had a mean systolic BP (SBP) between 130-160 mmHg and/or a diastolic BP (DBP) between 85-100 mmHg and no use of antihypertensive medications and their parents, siblings, spouses, and offspring were recruited in this study. During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
62380709|NCT02177942|EXPERIMENTAL|Test beverage powder|30 grams of cereal beverage powder with protein and added micronutrients will be made up to 100 mL drink using luke warm water. Subjects will be administered two doses of the drink (100 mL each) everyday
62380710|NCT02177942|ACTIVE_COMPARATOR|Control beverage powder|30 grams of cereal beverage powder with low protein and no added micronutrients will be made up to 100 mL using luke warm water. Subjects will be administered two doses of the drink (100 mL each) everyday
62380711|NCT02295254||Research group|The study contain only one group: travelers who intended to travel to tropical destinations. The participants will give a feces sample before and after the travel.
62380712|NCT04052594|EXPERIMENTAL|LY3475766 - IV|LY3475766 administered intravenously (IV) to participants with dyslipidemia
62380713|NCT04052594|PLACEBO_COMPARATOR|Placebo - IV|Placebo administered IV to participants with dyslipidemia
62380714|NCT04052594|EXPERIMENTAL|LY3475766 - SC|LY3475766 administered subcutaneously (SC) to participants with dyslipidemia
62380715|NCT04052594|PLACEBO_COMPARATOR|Placebo - SC|Placebo administered SC to participants with dyslipidemia
62380716|NCT04091451|EXPERIMENTAL|HZ/su Group|Subjects randomized to the HZ/su group will receive 2 doses of HZ/su vaccine at visit day 1 and visit month 2 and will be followed up until the study end.
62380717|NCT04091451|PLACEBO_COMPARATOR|Placebo Group|Subjects randomized to Placebo group will receive placebo at visit day 1 and visit month 2 and will be followed up until the study end.
62380718|NCT04838587||6750 Children <3 years ( 5 sites)|A total of 6750 children from the will be identified from the respective health facility catchment area during the Census stage of the study. Each of the 5 health facilities will identify 1350 children under 3 years of age in their respective catchment area. During the Surveillance stage, the participants will be enrolled into the study if and when they present with diarrhoea at the Health facility.
62380719|NCT04585633||Low Risk|no complication develop within 30 days after the operation and high GOS value
62380720|NCT04585633||High Risk|"complication or complications develop within 30 days after the operation and low GOS value~Complications:~* Moderate to severe intracerebral hemorrhage confirmed in a brain CT scan (Midline shift in brain imaging ≥ 3 mm),~* İntracranial hypertension requiring post op surgical drainage,~* Status epilepticus or seizures,~* The need for tracheal intubation or use of mechanical ventilation after surgery,~* Decrease in GKS,~* Unmanageable agitation that requires restriction or sedation,~* Need for respiratory failure and oxygen therapy,~* Unexpected serious motor deficit~* Died"
62380721|NCT05074160||OLP Registry primary analysis population|Adult primary liver transplant recipients who are transplanted with an OCS perfused DBD or DCD donor liver according to the approved indication and matching eligibility criteria
62380722|NCT04310267|ACTIVE_COMPARATOR|classic occlusal level, low point of force application|the point of force application for maxillary protraction is at the level of the occlusal plane.
62380723|NCT04310267|ACTIVE_COMPARATOR|Nasal level, Medium point of force application|the point of force application for maxillary protraction is at 20 mm from the occlusal plane (Nasal floor).
62380724|NCT04310267|ACTIVE_COMPARATOR|Infrorbital level, High level|the point of force application for maxillary protraction is at the level of the infraorbital foramen
62380725|NCT02773849|EXPERIMENTAL|ADSTILADRIN|Intravesical administration of ADSTILADRIN into the bladder
62380726|NCT05762224|EXPERIMENTAL|Effect of kinesio taping on upper limb lymphedema|Kinesio taping was applied 2 times a week for 3 weeks to the KT group. KT improves fluid movement by widening the distance between connective tissues like skin and fascia,fascia and muscles and skin and muscles.
62380727|NCT05762224|ACTIVE_COMPARATOR|Effect of pressure garments on upper limb lymphedema|PG group received pressure garments ( 20-60 mmHg)for at least 15 to 18 hours per day for 3 weeks.
62759891|NCT03811847|EXPERIMENTAL|Sequence 3:MPH, PBO, PBO, MPH, PBO, MPH|"Over the 16-week study, each participant moved through four, 4-week treatment periods: a Placebo (PBO) lead-in, acclimation period followed by three, crossover Methylphenidate (MPH) vs PBO blocks. Each block consisted of treatment with MPH for two-weeks and treatment with PBO for two-weeks; each block order will be randomly assigned. In this group, participants first received Methylphenidate (MPH) for 2 weeks, then placebo for 2 weeks, then MPH for 2 weeks, then Placebo for 2 weeks, then Placebo for 2 weeks, then MPH for 2 weeks."
62759892|NCT03811847|EXPERIMENTAL|Sequence 4:PBO, MPH, MPH, PBO, MPH, PBO|"Over the 16-week study, each participant moved through four, 4-week treatment periods: a Placebo (PBO) lead-in, acclimation period followed by three, crossover Methylphenidate (MPH) vs PBO blocks. Each block consisted of treatment with MPH for two-weeks and treatment with PBO for two-weeks; each block order will be randomly assigned. In this group, participants first received PBO for 2 weeks, then MPH for 2 weeks, then MPH for 2 weeks, then Placebo for 2 weeks, then MPH for 2 weeks, then PBO for 2 weeks."
62759893|NCT03811847|EXPERIMENTAL|Sequence 5: PBO, MPH, MPH, PBO, PBO, MPH|"Over the 16-week study, each participant moved through four, 4-week treatment periods: a Placebo (PBO) lead-in, acclimation period followed by three, crossover Methylphenidate (MPH) vs PBO blocks. Each block consisted of treatment with MPH for two-weeks and treatment with PBO for two-weeks; each block order will be randomly assigned. In this group, participants first received PBO for 2 weeks, then MPH for 2 weeks, then MPH for 2 weeks, then Placebo for 2 weeks, then Placebo for 2 weeks, then MPH for 2 weeks."
62759894|NCT03811847|EXPERIMENTAL|Sequence 6: PBO, MPH, PBO, MPH, MPH, PBO|"Over the 16-week study, each participant moved through four, 4-week treatment periods: a Placebo (PBO) lead-in, acclimation period followed by three, crossover Methylphenidate (MPH) vs PBO blocks. Each block consisted of treatment with MPH for two-weeks and treatment with PBO for two-weeks; each block order will be randomly assigned. In this group, participants first received PBO for 2 weeks, then MPH for 2 weeks, then PBO for 2 weeks, then MPH for 2 weeks, then MPH for 2 weeks, then PBO for 2 weeks."
62759895|NCT04348045|EXPERIMENTAL|ARM A - olaparib|Olaparib tablets at 300 mg orally twice daily until PD (RECIST 1.1) or unacceptable toxicity.
62759896|NCT04348045|EXPERIMENTAL|ARM B - durvalumab plus selumetinib|"Durvalumab plus selumetinib until PD (RECIST 1.1 and/or iRECIST), unacceptable toxicity, withdrawal of consent, or death.~Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle,~Selumetinib administered as 75 mg twice daily dose for 21 days on and 7 days off (a 28-day cycle)."
62759897|NCT04348045|ACTIVE_COMPARATOR|ARM C - FOLFIRI|FOLFIRI FOLFIRI (irinotecan 180 mg/m2 IV on day 1, folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2 every 2 weeks) until PD (RECIST 1.1) unacceptable toxicity, withdrawal of consent, or death.
62759898|NCT06367907|EXPERIMENTAL|ST-EF, schema therapy - emotion focused|9-weeks treatment protocol based on emotion focused interventions, such as chair dialogs, imagery rescripting or role play
62759899|NCT06367907|ACTIVE_COMPARATOR|ST-AC, schema therapy - active control|9-weeks treatment protocol based on cognitive interventions, e.g. psychoeducation, socratic dialog, pro/contra discussions etc. but no experiential techniques
62759900|NCT04947631|EXPERIMENTAL|DKF-313|Dutasteride 0.5mg + Tadalafil 5mg
62759901|NCT04947631|ACTIVE_COMPARATOR|Dutasteride|Dutasteride 0.5mg
62759902|NCT04947631|ACTIVE_COMPARATOR|Tadalafil|Tadalafil 5mg
62759903|NCT00100295|EXPERIMENTAL|A|Herbal treatment
62759904|NCT00100295|PLACEBO_COMPARATOR|B|
62759905|NCT06107439|OTHER|sampling and clinical data collection|Participant blood and urine are sampled for inflammatory signal analysis
62759906|NCT05976022|EXPERIMENTAL|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
62759907|NCT01540409|EXPERIMENTAL|AVI-4658 (Eteplirsen)|Multiple-Dose Extension Study
62759908|NCT00715364|EXPERIMENTAL|1|
62759909|NCT00715364|PLACEBO_COMPARATOR|2|
62759910|NCT04612660|EXPERIMENTAL|Specific Education and Dynamic Group|"1. Motivational group education specifically focused on cervical cancer prevention;~2. Dynamic group interaction and role play discussion sessions on the benefits of Self-Sample collection HPV testing and procedures;~3. Engaging community bilingual physicians in cervical cancer screening and referral;~4. Patient navigation assistance."
62759911|NCT04612660|ACTIVE_COMPARATOR|General Health Education|Comparison group participants received general health education focusing on healthy lifestyle, and prevention of disease through routine health examinations.
62759912|NCT00906139|ACTIVE_COMPARATOR|Propofol|To receive propofol (0.5 mg/kg up to 400 mg) and fentanyl (0.05 mg);
62759913|NCT00906139|ACTIVE_COMPARATOR|Midazolam|To receive midazolam (0.1 mg/kg) and fentanyl (0.05 mg).
62182498|NCT01798862|ACTIVE_COMPARATOR|COH for IVF without hysteroscopy or pipelle sampling|Procedure: COH for IVF Both GnRH agonists (long, starting at day 2 or 21) with triptorelin acetate 0.1 mg (Gonapeptyl daily) and antagonists with ganirelix 0.25mg (Orgalutran) or cetrorelix 0.25mg (Cetrotide) protocols will be used; for ovarian stimulation both recombinant FSH ( Puregon) and human menopausal gonadotrophin ( Menopur) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the Hcg triggering and for luteal phase support 600 mg progesterone tablets ( Utrogestan) will be applied.
62380728|NCT01271049|PLACEBO_COMPARATOR|Control Food Product|Consumption of placebo food product
62380729|NCT01271049|EXPERIMENTAL|Novel Food Product|Consumption of novel food product
62380730|NCT05675124|EXPERIMENTAL|Needlescopic laparoscopic adrenalectomy|Needlescopic laparoscopic surgery refers to the use of instruments with a diameter of less than or equal to 3 mm for laparoscopic surgery.
62759914|NCT04535713|EXPERIMENTAL|Single arm|A total of 260 patients will receive gemcitabine 600 mg/m2 (maximum dose: 1000 mg) on D1 and D8, doxorubicin 18 mg/m2 on D1 and D8 (maximum dose: 32 mg), docetaxel 25 mg/m2 on D1 and D8 (maximum dose: 42 mg), on Days 1 and 8. After the first cycle, nivolumab 240 mg IV will be added on Day 1 of each cycle (see product information; www.accessdata.fda.gov). Treatment cycles are given every 3 weeks. Patients in this study may continue treatment until significant disease progression or unacceptable toxicity occurs up to one year of therapy. Patients who withdraw or do not complete the first 2 treatment cycles and first follow up CT scan/MRI will be replaced.
62759915|NCT02073357|EXPERIMENTAL|Light general anaesthesia (BIS = 50)|Light general anaesthesia
62759916|NCT02073357|EXPERIMENTAL|deep general anaesthesia (BIS = 35)|deep general anaesthesia
62759917|NCT02691403|SHAM_COMPARATOR|Placebo QL block|30 ml single shot QL block with saline 0.9%
62759918|NCT02691403|ACTIVE_COMPARATOR|Active QL block|30 ml single shot QL block with 0.25% levo-bupivacaine
62759919|NCT03831945|ACTIVE_COMPARATOR|Single infusion of VRC01 and 10-1074|Single infusion of 40 mg/kg VRC-HIVMAB060-00-AB (VRC01) in 100 mL of saline and 30 mg/kg of 10-1074 in 250 mL of saline when viral load is \>/= 200 copies/mL in HIV-infected individuals undergoing antiretroviral treatment interruption.
62380731|NCT05675124|ACTIVE_COMPARATOR|conventional laparoscopic adrenalectomy|a 12 mm camera port ,and two additional (left anterior axillary line and left midclavicular line; for left tumors) or three additional(right anterior axillary line, right midclavicular line, and subxiphoid; for right tumors) 5 mm working ports along the ipsilateral subcostal were created regionally.
62380732|NCT06246162|EXPERIMENTAL|Lipo-MIT combination regimen group|"Initial diagnosis induction treatment regimen Lipo-MIT +VD (VMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Bortezomib: 1.3mg/m2 d1, 4, 8, 11, subcutaneous injection; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of VMD regimen induction therapy are performed.~Reinduction therapy regimen after relapse Lipo-MIT + PD (PMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Pomalidomide: 4 mg/d d1-d21, orally; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of PMD regimen induction therapy are performed."
62380733|NCT02620631|PLACEBO_COMPARATOR|Placebo|Subjects receive intrathecal injection of saline at time of spinal anesthesia
62380734|NCT02620631|EXPERIMENTAL|Morphine|Subjects receive intrathecal injection of morphine sulfate 0.2mg at time of spinal anesthesia
62759920|NCT03831945|PLACEBO_COMPARATOR|Single infusion of Normal Saline|Single infusion of 100 mL and 250 mL of normal saline when viral load is \>/= 200 copies/mL in HIV-infected individuals undergoing antiretroviral treatment interruption.
62759921|NCT00004142|EXPERIMENTAL|Radiofrequency Ablation + HAI of Floxuridine/5-FU|Radiofrequency Ablation Combined With Post-Ablation Hepatic Arterial Infusion (HAI) of Floxuridine Alternating With 5-Fluorouracil (5-FU)
62759922|NCT05725460|EXPERIMENTAL|dextrose 5%|10 mls of dextrose under ultrasound to separate the median nerve from adjacent structures
62759923|NCT05725460|ACTIVE_COMPARATOR|steroid|10 mls of steroid used to separate the median nerve from adjacent structures
62759924|NCT00159575|EXPERIMENTAL|M: Metformin P: Placebo|
62759925|NCT01269385|EXPERIMENTAL|Arm I|Patients receive PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31; alemtuzumab subcutaneously on days 3, 4, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; and rituximab IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity.
62759926|NCT04075422||Prospective cohort|64 patients treated with Bezlotoxumab
62759927|NCT04075422||Retrospective Cohort (Control)|All the first episodes diagnosed in each participating sites during the previous year that meet the inclusion criteria
62759928|NCT02428621|EXPERIMENTAL|Twicare® appliance|Group treated with the Twicare® appliance. This appliance is a removable mandibular propulsive adjustable preformed medical device. It is made out of soft and stiff thermoplastics. Its two gutters are linked to each other according to different antero-posterior positions. It is EC marked since 2011.
62759929|NCT02428621|ACTIVE_COMPARATOR|Removable Herbst appliance|Group treated with the removable Herbst appliance. This appliance is a medical device measured made composed of telescopic metallic hinges and resin gutters made-to-measure based on dental impression.
61987435|NCT05118451|NO_INTERVENTION|Based on high-quality thin slice CT images to guide preoperative planning and surgery.|All patients in this study were operated by the medical team whose main members were the medical team leader, and all patients underwent anatomic hepatectomy. The main points of anatomic hepatectomy are summarized as follows :(1) determine and mark the boundary of liver segment according to ischemia line or staining. (2) The postoperative liver section should fully expose the iconic veins and vessels. (3) The initial part of Glisson's pedicle of the target liver segment was severed. Tissue was taken from the surgical margins of all patients and sent to frozen sections for examination. Routine pathological examinations were performed on all resected liver after surgery. Postoperative patients were treated with relevant perioperative symptomatic treatment, and blood routine examination, liver function and coagulation function were detected on the 1st, 3rd and 5th day after surgery.
61987436|NCT03147365|NO_INTERVENTION|Control group|Twenty five children who will not receive any physical therapy treatment.
62380735|NCT04726124|EXPERIMENTAL|treatment group|Microwave Ablation Therapeutic Apparatus. Patients with primary lower extremity varicose veins were treated with endovenous microwave therapy using Microwave Ablation Therapy Apparatus. Ultrasound examination and questionnaire survey（AVVQ and VCSS) were performed at 1 week, 3 months, 6 months,12 months after treatment,drug use and adverse events were recorded to assess complications and target lesion closure rate.
62380736|NCT04726124|EXPERIMENTAL|control group|Semiconductor Laser Treatment Apparatus. Patients with primary lower extremity varicose veins were treated with endovenous laser treatment using Semiconductor Laser Treatment Apparatus. Ultrasound examination and questionnaire survey（AVVQ and VCSS) were performed at 1 week, 3 months, 6 months, 12 months after treatment,drug use and adverse events were recorded to assess complications and target lesion closure rate.
62380737|NCT01842191|EXPERIMENTAL|Fish oil|
62380738|NCT01842191|PLACEBO_COMPARATOR|Placebo|
62380739|NCT02364999|EXPERIMENTAL|Bevacizumab-Pfizer|Bevacizumab-Pfizer plus paclitaxel and carboplatin
62567612|NCT05496647|EXPERIMENTAL|Virtual Reality (VR)|Virtual Reality Application (VR) VR group patients will be shown VR videos that include landscapes such as nature and the sea, giving people a feeling of comfort and peace, and making them feel like they are inside. During the surgical procedure, VR videos will be watched for an average of 20 minutes with X-brand VR glasses. In the research, similar studies will be examined and 360o VR video, which is a licensed product with atmospheric music background, containing relaxing nature images and nature sounds will be used.
61987437|NCT03147365|EXPERIMENTAL|Study group A|Twenty five children who will receive physical therapy treatment which include aerobic exercises.
61987438|NCT03147365|EXPERIMENTAL|Study group B|Twenty five children who will receive physical therapy treatment which include modified strength training program.
62182499|NCT04901845||Patients applying to Primary Healthcare Consultation|Consequent patients applying to the Primary healthcare to consult for any reason during 2 week period
62380740|NCT02364999|ACTIVE_COMPARATOR|Bevacizumab-EU|Bevacizumab-EU plus paclitaxel and carboplatin
62380741|NCT00218283|EXPERIMENTAL|1 - Nicotine Lozenge|Use of nicotine lozenge plus behavioral counseling to help reduce tobacco use prior to quit date.
62380742|NCT00218283|PLACEBO_COMPARATOR|2 Behavioral counseling|Use of behavioral counseling alone to help reduce tobacco use prior to quit date.
62380743|NCT01843933|NO_INTERVENTION|Standard monitoring and blinded to capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion will be used to collect and record data but staff will be blinded to the monitor output.
62380744|NCT01843933|ACTIVE_COMPARATOR|Capnography|Capnography will be added to standard monitoring practices. A portable capnography monitor (Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion) will be used to collect and record data.
62380745|NCT02615808|EXPERIMENTAL|Oxygen saturation data visualization|During intervention periods staff in both units will have access to the data visualization tool in the electronic health record.
62380746|NCT02615808|NO_INTERVENTION|Control|During control periods, the staff will not have access to the data visualization and will continue to use standard of care electronic health record and monitor data to understand oxygen status and trends.
62380747|NCT04793243|EXPERIMENTAL|Intervention group|Formed by 22 patients that received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
62380748|NCT04793243|NO_INTERVENTION|Control group|Formed by 20 patients that did not receive supplementation
62759930|NCT02428621|NO_INTERVENTION|Untreated|Children will not wear any interceptive activator. They will have a routine follow-up with their orthodontist waiting for the placing of a fixed appliance.
62759931|NCT01524432|EXPERIMENTAL|Drug loaded microcapsules socks|Study medication
62759932|NCT01524432|PLACEBO_COMPARATOR|No drug loaded microcapsules socks|Placebo medication
62759933|NCT03008902||Non-patients|Non-patients, who have not had vertebral fractures or hyperkyphosis, and have not been seen at BIDMC, will be recruited from the community as described in section B3C and B6 below. The non-patient group will consist of 16 healthy adults ages 18-40.
62380749|NCT01815866||CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
62759934|NCT03008902||Patients|Patients, who have been seen at BIDMC for vertebral fractures or hyperkyphosis, will be identified by review of medical records as described in B3C and B6 below. The patient group will consist of 32 adults ages 75 and older who have previously been diagnosed with a thoracic vertebral fracture at BIDMC.
62759935|NCT04699812|OTHER|COHORT 1|This will include subjects with no known history of AF
62759936|NCT04699812|OTHER|COHORT 2|This will include subjects with no known history of aF, but with history of frequent premature atrial contractions (PACs), frequent premature ventricular contractions (PVCs), supraventricular tachycardia (SVT), or non-sustained ventricular tachycardia (NSVT)
62759937|NCT04699812|OTHER|COHORT 3|This will include subjects with known history of paroxysmal, persistent, or chronic AF
62759938|NCT04699812|OTHER|COHORT 4|Will include subjects with permanent AF
62759939|NCT01223898|EXPERIMENTAL|Nilotinib|
62759940|NCT00686842|EXPERIMENTAL|VEGF Inhibitor PTC299|Single arm study - all subjects received PTC299
62759941|NCT06160856||Normal intra-abdominal pressure|
62759942|NCT06160856||Elevated intra-abdominal pressure|
62759943|NCT05332249||Lumbar|Patients undergo lumbar spinal surgery for degenerative lumbar spinal disease.
62759944|NCT05332249||Cervical|Patients undergo cervical spinal surgery for degenerative cervical spinal disease.
62759945|NCT01929720|EXPERIMENTAL|Arm I (CBT for worry, uncertainty & insomnia)|Patients wear a wrist actigraph and complete a sleep diary and worry record daily in weeks 1 and 5. Patients participate in a Behavioral Intervention (cognitive-behavioral therapy) in which they receive education on the components of anxiety (physical cognitive, and behavioral) and practice relaxation techniques and behavioral sleep strategies in weeks 2-5.
62759946|NCT01929720|ACTIVE_COMPARATOR|Arm II (wait-list control)|Patients wear a wrist actigraph and complete a sleep diary and worry record daily in weeks 1 and 5. This is a wait-list comparison, so after six weeks, patients in the control group complete the behavioral (cognitive-behavioral therapy)intervention for worry, uncertainty, and insomnia.
62759947|NCT02061397|EXPERIMENTAL|simvastatin treatment arm|Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
62759948|NCT00681564|EXPERIMENTAL|One-Stage Full-Mouth Disinfection|Scaling and root planing, four quadrants in one session Tongue brushing with a 1% chlorhexidine gel (1 minute) Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes) Subgingival chlorhexidine (1%) irrigation in all pockets Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention Basic oral hygiene instructions Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)
62759949|NCT00681564|ACTIVE_COMPARATOR|Periodontal care|Basic oral hygiene instructions Supragingival plaque removal
62759950|NCT01778322||Index Embolization Cohort|WEB Aneurysm Embolization System
62759951|NCT02408354|ACTIVE_COMPARATOR|Triheptanoin|"Triheptanoin/ Placebo Randomized to receive active Triheptanoin first for 12 weeks. At cross-over, participants will receive placebo for 12 weeks.~Each drug will be dispensed successively. A one-month wash out period is planned for 4 weeks between triheptanoine and placebo phases."
62380750|NCT03561844|ACTIVE_COMPARATOR|aromatherapy-scent|
62380751|NCT03561844|ACTIVE_COMPARATOR|aromatherapy-touch|
62380752|NCT03561844|NO_INTERVENTION|waiting-list control|
62759952|NCT02408354|PLACEBO_COMPARATOR|Placebo|"Placebo / Triheptanoin Randomized to receive active Placebo first for 12 weeks. At cross-over, participants will receive Triheptanoin for 12 weeks.~Each drug will be dispensed successively. A one-month wash out period is planned for 4 weeks between placebo and triheptanoin phases."
62759953|NCT03927313|ACTIVE_COMPARATOR|Standard of care anti-tubercular therapy|Standard of care anti-TB treatment. (10 mg/kg oral rifampicin, 5 mg/kg oral isoniazid, 15 mg/kg oral ethambutol and 25 mg/kg oral pyrazinamide daily for 2 months as fixed dose combination tablets (followed by 10 mg/kg oral rifampicin and 5 mg/kg isoniazid daily for 4-7 months in routine care after study completed)).
62759954|NCT03927313|EXPERIMENTAL|Intensified anti-tubercular therapy|"Standard of care anti-TB therapy as described in Arm 1,~Plus additional 25 mg/kg rifampicin (total dose rifampicin 35 mg/kg orally for the first 56 days of treatment) and linezolid ( 1,200 mg orally daily for first 28 days reduced to 600 mg daily for next 28 days)."
62380753|NCT03087110|EXPERIMENTAL|Cord blood infusion|Matched sibling donor cord blood cell infusion
62380754|NCT00735072|EXPERIMENTAL|Maraviroc|Maraviroc (dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).
62759955|NCT03927313|EXPERIMENTAL|Intensified anti-tubercular therapy plus aspirin|"Standard of care anti-TB therapy as described in Arm 1,~Plus additional 25 mg/kg rifampicin (total dose rifampicin 35 mg/kg orally for the first 56 days of treatment) and linezolid ( 1,200 mg orally daily for first 28 days reduced to 600 mg daily for next 28 days),~Plus aspirin (1000mg orally daily for the first 56 days of Tuberculous Meningitis treatment)"
62759956|NCT05281770||Erenumab|Patients will be treated with this drug within standard of care treatment
62759957|NCT05281770||Galcanezumab|Patients will be treated with this drug within standard of care treatment
62759958|NCT05281770||Fremanezumab|Patients will be treated with this drug within standard of care treatment
62759959|NCT03345654||New Hearing Aid Users fit with standard-of-care|Adults (18+) with hearing loss and newly fit with hearing aids
62759960|NCT00938977|ACTIVE_COMPARATOR|CPAP|Response to treatment before/after treatment in patients with OSAS and SOH
62759961|NCT00938977|ACTIVE_COMPARATOR|Bilevel support ventilation|Before and after effect of Bilevel support ventilation in patients with SOH without OSA
62759962|NCT00413829|OTHER|1|
62759963|NCT04592172|EXPERIMENTAL|Bedtime Routine Education|50 families will be randomly assigned to receive the bedtime routine intervention, 3 Cs for Bedtime ZZZs delivered by research assistants at the 12-month and 15-month well-child visits, in additional to receiving usual clinical care. The intervention will take approximately 30-45 minutes to implement at each study visit. Research assistants will be trained and supervised by board-certified Behavioral Sleep Medicine providers. This intervention focuses on developing an individualized bedtime routine, including such activities as a bath, teeth-brushing, reading stories, singing songs, and cuddling, based on parent's preferences. Families will receive appropriate materials for their bedtime routine, including a CuddleBright kit, bedtime books, toothbrush/toothpaste, and the created bedtime chart to take home.
62759964|NCT04592172|NO_INTERVENTION|Control group|50 families will be randomly assigned to control group (usual care).
62759965|NCT02775331|EXPERIMENTAL|Units using Titania1 software|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
62759966|NCT02775331|EXPERIMENTAL|Units using Titania2 software|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
62759967|NCT02775331|NO_INTERVENTION|Units using Titania3 software|Employees working in shift planning units (clusters) where a standard shift planning software (Titania3) without interactive shift rostering or guidance for health-supporting shift ergonomics is used by shift planners.
62759968|NCT02562209|EXPERIMENTAL|PACER diet|High Protein Atkin's Complete (Lacto) VEgetaRian Diet (PACER Diet) to be followed for 8 weeks.
62759969|NCT02562209|ACTIVE_COMPARATOR|Standard weight reducing diet|This group was prescribed Standard weight reducing diet to be followed for 8 weeks.
62759970|NCT05947279|EXPERIMENTAL|Posterior parietal cortex group|Posterior parietal cortex group, which will receive the stimulation to their left posterior parietal cortex
62759971|NCT05947279|EXPERIMENTAL|Cerebellum group|Cerebellum group, which will receive stimulation to their right cerebellum,
62759972|NCT05947279|SHAM_COMPARATOR|Sham group|Sham group, which will have the electrode cap placed on their head but receive no stimulation
62759973|NCT02262078|PLACEBO_COMPARATOR|Placebo (Saline)|Participants receive normal saline, administered by inhalation over 10-15 minutes, using a nebulizer
62759974|NCT02262078|EXPERIMENTAL|Sodium Nitrite|Participants receive Sodium Nitrite inhalation solution, administered by inhalation over 10-15 minutes, using a nebulizer
62759975|NCT02937857|ACTIVE_COMPARATOR|Standard treatment only|Standard treatment only such as antiasthmatic, expectorant and antipyretic
62759976|NCT02937857|EXPERIMENTAL|Standard treatment+Xiyanping injection|Standard Treatment such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection intravenous administration of 0.2-0.4mL/kg/day ,QD for 5 days.
62759977|NCT01962987|EXPERIMENTAL|Diclofenac Sodium 3% gel - Test|The diclofenac sodium 3% test gel is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Test Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
62380755|NCT00735072|PLACEBO_COMPARATOR|Placebo|Placebo (dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).
62380756|NCT04775485|EXPERIMENTAL|Arm #1|Pediatric patients with low-grade glioma treated with DAY101 (Registrational Arm)
62380757|NCT04775485|EXPERIMENTAL|Arm #2|Expanded access arm of pediatric patients with low-grade glioma treated with DAY101
62380758|NCT04775485|EXPERIMENTAL|Arm #3|Pediatric patients with advanced solid tumors treated with DAY101
62380759|NCT03082768|EXPERIMENTAL|[18F]MNI-968|To evaluate \[18F\]MNI-968 (aka PF-06730110) as a D1 receptor targeted radiopharmaceutical
62759978|NCT01962987|ACTIVE_COMPARATOR|Diclofenac Sodium 3% gel - Reference|The Reference diclofenac sodium 3% gel (Solaraze®) is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Reference (Solaraze®) Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
62759979|NCT01962987|PLACEBO_COMPARATOR|Placebo gel|The placebo gel (contains no active ingredient) is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough placebo gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
62759980|NCT02529748|EXPERIMENTAL|Participants for Surface Skin Sampling|Adult volunteers with healthy, intact skin will have surface skin wipe samples collected following contact with the approved test substances to measure the quantitative transfer of the test substances to and from the skin surface.
62759981|NCT03026478|EXPERIMENTAL|Betamethasone dipropionate 0.05%|topical Betamethasone dipropionate 0.05% in orabase with clotrimazole 1% in oral lichen planus two times a day for one month
62182500|NCT04901845||Patients applying to Specialized Healthcare Consultation|Consequent patients applying to the Specialized healthcare to consult for any reason during 2 week period
62380760|NCT01553695|ACTIVE_COMPARATOR|general population|
62380761|NCT01553695|EXPERIMENTAL|ADHD Patient|
62380762|NCT01281722||healthy adults|healthy adults with the age among 20 to 95 years old
62380763|NCT01281722||melanoma cases|the people who are diagnosed melanoma in NTU hospital
62380764|NCT01235494|EXPERIMENTAL|polarised 3 helium|inhaled gas
62380765|NCT04525287||Severe COVID-19|Patients who have one of the following conditions during treatment: 1. Respiratory distress, RR≥30 beats/min; 2. In resting state, mean oxygen saturation≤93%; 3. Arterial oxygen partial pressure ( PaO2)/Inhalation Oxygen Concentration (FiO2) ≤300mmHg (1mmHg=0.133kPa); 4. Respiratory failure occurs and mechanical ventilation is required; 5. Shock occurs; 6. ICU monitoring and treatment is required for combined other organ failure.
62380766|NCT04525287||Mild COVID-19|The patient only showed symptoms such as fever and respiratory tract in general, and no severe symptoms occurred during the visit and follow-up.
62380767|NCT03166189|EXPERIMENTAL|bone marrow-derived MSC and HRT|endometrial injection of autologous cell product of MSC with hormonal replacement therapy before frozen/thawed ET
62380768|NCT03166189|ACTIVE_COMPARATOR|hormonal replacement therapy|standard endometrial preparation for frozen/thawed ET
62380769|NCT03004833|EXPERIMENTAL|Arm A|4 Cycles of Nivolumab plus AVD followed by IF-RT (30 Gy)
62380770|NCT03004833|EXPERIMENTAL|Arm B|4 Cycles of Nivolumab, followed by 2 cycles of Nivolumab plus AVD, followed by 2 Cycles of AVD followed by IF-RT (30 Gy)
62380771|NCT00702741|EXPERIMENTAL|A|Chondrogen (low dose)
62380772|NCT00702741|EXPERIMENTAL|B|Chondrogen (high dose)
62380773|NCT00702741|PLACEBO_COMPARATOR|C|Hyaluronan
62380774|NCT00676806|EXPERIMENTAL|Myeloablative conditioning|Umbilical cord blood for hematopoietic rescue following myeloablative conditioning
62380775|NCT00676806|EXPERIMENTAL|Reduced intensity conditioning|Umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
62759982|NCT03026478|ACTIVE_COMPARATOR|Clobetasol propionate 0.05%|Topical Clobetasol propionate 0.05% in orabase with clotrimazole 1% in oral lichen planus patients two times a day for a month
62759983|NCT00320749|EXPERIMENTAL|capecitabine, docetaxel, gemcitabine|Dose escalation study of mGTX using three dose levels (DL1-3). Patients received docetaxel on days 1 and 8, gemcitabine on days 8 and 15, and capcitabine on days 8 through 21. Gemcitabine fixed dose at 750 mg/m2 over 75 min, capecitabine twice daily and escalated from 500 to 650 mg/m2 at DL2 and docetaxel increased from 30 to 36 mg/m2 at DL3.
62759984|NCT05637697||Ambulatory|
62759985|NCT05637697||Limited Ambulation|
62759986|NCT05361499|EXPERIMENTAL|Streptococcus pneumoniae 6B (Sp_6B) inoculated|
62380776|NCT01664585|EXPERIMENTAL|Training group|"The rationale and means for the exercise program are to~1. Motivate and teach participants for postural and motor control and strengthening exercises~2. Monitor and motivate to continue exercise training, and to increase their physical activity~Training is organised six times as a 60-min session during six months: two individually supervised sessions, and four following training sessions will be accomplished in groups of 10 participants guided by an experienced physical therapist. Three weekly similar home training sessions are recommended for participants. Information on amount of exercise sessions per week and repetitions of each exercise will be collected via exercise diary. To perform home training, a DVD and/or booklet will be provided to participants in the training group."
62759987|NCT02958202|EXPERIMENTAL|BMN 044 IV 6 mg/kg|Weekly intravenous (IV) dosing with 6 mg/kg
62380777|NCT01664585|SHAM_COMPARATOR|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0), and the participants in this group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
62380778|NCT04819711|ACTIVE_COMPARATOR|Intervention|Thinking Healthy group intervention integrated into antenatal pregnancy school classes
62380779|NCT04819711|NO_INTERVENTION|Control|Participants randomized to the control arm will not be offered the THP intervention but will attend the 5 sessions of the routine group antenatal pregnancy school classes. The class provides education about pregnancy, birth and new-born care and offers support to women. The women will also be able to access all usual care and support offered by the participating hospitals
62380780|NCT02655211|ACTIVE_COMPARATOR|CO2-CO2-Med|Participants will receive two blocks of CO2 laser treatment, followed by one block of usual care.
62380781|NCT02655211|ACTIVE_COMPARATOR|Med-CO2-CO2|Participants will receive one block of usual care, followed by two blocks of CO2 laser therapy.
62380782|NCT02655211|ACTIVE_COMPARATOR|CO2-Med-CO2|Participants will receive one block of CO2 laser therapy, one block of usual care, and finally one more block of CO2 laser therapy.
62380783|NCT02655211|ACTIVE_COMPARATOR|PDL-PDL-MED|Participants will receive two blocks of PDL laser therapy, followed by one block of usual care.
62380784|NCT02655211|ACTIVE_COMPARATOR|Med-PDL-PDL|Participants will receive one block of usual care, followed by two blocks of PDL laser therapy.
62759988|NCT02958202|EXPERIMENTAL|BMN 044 IV 9 mg/kg|Weekly intravenous (IV) dosing with 9 mg/kg
62759989|NCT02958202|EXPERIMENTAL|BMN 044 SC 6 mg/kg|Weekly subcutaneous (SC) dosing with 6 mg/kg
62759990|NCT01579825|EXPERIMENTAL|Buffer|
62759991|NCT01579825|NO_INTERVENTION|Control|
62759992|NCT06508307|EXPERIMENTAL|Part 1: Dose Escalation|"The study consists of a total of six dose groups, with the lowest dose group being 3×10\^6 and the highest dose reaching 1×10\^9 PFU. In case the maximum dose of 1×10\^9 PFU fails to achieve the Maximum Tolerated Dose (MTD), the Safety Monitoring Committee (SMC) will convene to discuss whether to designate it as Maximum Feasible Dose (MFD) or consider escalating further based on current safety and preliminary efficacy data. However, any escalation beyond that of similar drugs' Phase I clinical trials, such as JX-594:NCT00629759 and JX-929:NCT00574977, where the highest administered dose was 3×10\^9 PFU, shall be avoided. This precaution ensures adherence to established safety protocols.~A single dose of GC001 will be administered up to 4mL (The injection volume is based on the length of the lesion)."
62759993|NCT04612543|ACTIVE_COMPARATOR|Genial Posterior Composite with Polyethylene fiber|The enamel and dentin were conditioned with bonding procedure.After bonding procedures, remaining tooth composite resin walls were created and cured for 20 s. Prepared ribbond fiber pieces, 2-mm-wide approximately 12mm-long, (Ribbond Thinner, Higher, Modulus - Ribbond Inc,Seattle) were wetted with an unfilled resin for 2 minutes at a non-light environment. The inner surfaces of the prepared class I cavity were lined with flowable resin. After removing the excess resin, pre-wetted polyethylene fiber was condensed circumferentially and embedded with a hand instrument into the bed of unpolymerized flowable composite and then polymerized for 20 seconds with Light Emitting Diodes. After curing for 20 s, composite resin was applied to the rest of the cavity incrementally, each increment was cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
62380785|NCT02655211|ACTIVE_COMPARATOR|PDL-Med-PDL|Participants will receive one block of PDL laser therapy, followed by one block of usual care, followed by one block of PDL laser therapy.
62380786|NCT02655211|ACTIVE_COMPARATOR|PDL-CO2-Med|Participants will receive one block of PDL laser therapy, followed by one block of CO2 laser therapy, followed by one block of usual care.
62380787|NCT02655211|ACTIVE_COMPARATOR|CO2-PDL-Med|Participants will receive one block of CO2 laser therapy, followed by one block of PDL laser therapy, followed by one block of usual care.
62380788|NCT02655211|ACTIVE_COMPARATOR|Med-PDL-CO2|Participants will receive one block of usual care, followed by one block of PDL laser therapy, followed by one block of CO2 laser therapy.
62759994|NCT04612543|ACTIVE_COMPARATOR|Genial Posterior Composite|The enamel and dentin were conditioned with bonding procedure using an applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Genial Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments
62759995|NCT02710435||Arm 1 - Prospective|"Includes eligible subjects in the prospective arm who undergo baseline testing followed by the Reducer System implant procedure~Arm 1 has been closed to enrollment-March 2023"
62380789|NCT02655211|ACTIVE_COMPARATOR|Med-CO2-PDL|Participants will receive one block of usual care, followed by one block of CO2 laser therapy, followed by one block of PDL laser therapy.
62380790|NCT02655211|ACTIVE_COMPARATOR|PDL-Med-CO2|Participants will receive one block of PDL laser therapy, followed by one block of usual care, followed by one block of CO2 laser therapy.
62380791|NCT02655211|ACTIVE_COMPARATOR|CO2-Med-PDL|Participants will receive one block of CO2 laser therapy, followed by one block of usual care, followed by one block of PDL laser therapy.
62380792|NCT03277651||liver fibrosis|liver biopsy proved
62380793|NCT03277651||portal hypertension|hepatic venous pressure gradient (HVPG) proved
62380794|NCT03432585||Family Support Grant applicants|Participants include applicants for the Family Support Grants that will be provided for the American Society for Nutrition annual meeting who are willing to complete the applicant survey.
62380795|NCT02630381|EXPERIMENTAL|Shock wave arm|Unfocused extracorporeal shock wave therapy will be applied on the distal radius on one site when the patient is receiving general anaesthesia for surgery on the lower extremity or spine.
62380796|NCT02630381|NO_INTERVENTION|Contra-lateral arm|The distal radius and/or wrist that did not receive UESWT will not be treated
62380797|NCT06460935|EXPERIMENTAL|Experimental: PLISSIT Group|Nursing students in this group will be given online sexual health training. The training will last for 5 weeks. The training is 20 hours in total. During the training, students will learn the PLISSIT model and evaluate cases involving using this model. Questionnaire will be applied before the training after the training
62380798|NCT06460935|NO_INTERVENTION|No Intervention: Control group|Nursing students in this group will not be subjected to any application and will continue their routine nursing lessons. The questionnaire will be administered to the control group before the training given to the experimental group after the training.
62380799|NCT04762550||Patients undergoing Liver Transplantation|This is a prospective observational study that intends to offer participation to all patients undergoing liver transplantation at Toronto General Hospital. Parameters that will be measured include Thrombin generation, viscoelastic testing utilizing ROTEM, and conventional laboratory testing (INR, aPTT and Fibrinogen level) at five time points: (a) Prior to cross-clamp application; (b) within the first 30 minutes of venous cross clamp removal; (c) after 30 minutes of reperfusion; (d) On arrival in the intensive care unit (ICU) or post-anesthesia recovery unit; and (5) 12 hours post-operatively.
62380800|NCT00003958|EXPERIMENTAL|Arm I|Vincristine sulfate IV once a wk on wks 0-12, 15, 18-24, 27, 30-36, and 39. Dactinomycin IV once a wk on wks 0, 3, 6, 9, 12, 21, 24, 27, 30, 33, 36, and 39. Cyclophosphamide IV once a wk on wks 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, and 39. After 12 weeks of chemotherapy, depending on tumor shrinkage, pts may undergo surgery. After recovery from therapeutic conventional surgery, patients receive radiation therapy once a day, 5 days a wk, during wks 12-18. For pt receiving radiotherapy during wks 0-6, dactinomycin is omitted during wks 3 and 6 and during wks 15 and 18. For patients receiving radiotherapy during wks 12-18, dactinomycin is omitted during wks 15 and 18. Patients with adequate response at wk 24 continue chemotherapy during wks 24-39. All pts receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously beginning 24 hours after completion of each course of chemotherapy and continuing 1 year, until hematopoietic recovery.
62380801|NCT00003958|EXPERIMENTAL|Arm II|"Patients receive treatment as in arm I, except dactinomycin is replaced with topotecan hydrochloride IV over 15-30 minutes daily for 5 days during weeks 3, 9, 21, 27, 33, and 39.~All patients receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously beginning 24 hours after completion of each course of chemotherapy and continuing 1 year, until hematopoietic recovery."
62380802|NCT02466906|EXPERIMENTAL|rhGM-CSF group|rhGM-CSF was injected subcutaneously perioperation.
62380803|NCT02466906|PLACEBO_COMPARATOR|placebo group|Placebo was injected subcutaneously perioperation.
62380804|NCT03110757|EXPERIMENTAL|Group A|10mcg Sm-TSP-2/Alhydrogel® (n=8)
62380805|NCT03110757|EXPERIMENTAL|Group B|10mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
62380806|NCT03110757|EXPERIMENTAL|Group D|30mcg Sm-TSP-2/Alhydrogel® (n=8)
62380807|NCT03110757|EXPERIMENTAL|Group E|30mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
62380808|NCT03110757|EXPERIMENTAL|Group G|100mcg Sm-TSP-2/Alhydrogel® (n=8)
62380809|NCT03110757|EXPERIMENTAL|Group H|100mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
62380810|NCT03110757|ACTIVE_COMPARATOR|Pooled Active Comparator Group|Euvax B Hepatitis B vaccine (n=12)
62759996|NCT02710435||Arm 2 - COSIRA|Includes subjects who were previously enrolled and treated with the Reducer System during the COSIRA study and agree to participate in this long term follow up study
62380811|NCT03441399|EXPERIMENTAL|Escalating Incentives|Participants assigned to the escalating financial incentives will receive an increasing financial incentive for taking their antidepressant medication for the initial 6 weeks of treatment.
62380812|NCT03441399|EXPERIMENTAL|De-escalating Incentives|Participants assigned to the de-escalating financial incentives will receive a decreasing financial incentive for taking their antidepressant medication for the initial 6 weeks of treatment.
62380813|NCT03441399|NO_INTERVENTION|Control|Participants in this condition will receive usual care.
62380814|NCT03345849|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo once daily for 12 weeks in Part 1. Clinical non-responders will receive 45 mg upadacitinib once daily for 12 weeks in Part 2.
62380815|NCT03345849|EXPERIMENTAL|Upadacitinib|Participants will receive 45 mg upadacitinib once daily for 12 weeks in Part 1. Clinical non-responders will receive 30 mg upadacitinib once daily for 12 weeks in Part 2.
62380816|NCT01810289|EXPERIMENTAL|MJAP Clinics Intervention|START intervention. This is a stepped wedge design so each clinic will experience both conditions.
62380817|NCT01810289|NO_INTERVENTION|MJAP Clinics Pre-Intervention|Standard of care. This is a stepped wedge design so each clinic will experience both conditions.
62380818|NCT06115512|EXPERIMENTAL|AGA111|AGA111 in autologous blood coagulum (ABC) is locally delivered at the intervertebral space.
62380819|NCT06115512|PLACEBO_COMPARATOR|Placebo|Placebo in ABC is locally delivered at the intervertebral space.
62380820|NCT04888195||Questionnaire|This study aims to examine the cancer patient's symptom clusters and their changes over chemotherapy among pediatric patients with blood cancer in Hong Kong
62380821|NCT02438670|NO_INTERVENTION|Open-Loop Care|The subjects Open-Loop Care for the 24-hour period prior to each study sessions assessed for time in the target range 70-180 mg/dL, and frequency of hypoglycemia and hyperglycemia as assessed by CGM.
62380822|NCT02438670|EXPERIMENTAL|PID algorithm with HMS|"Subjects will be treated with closed-loop care for 27.5h using a proportional-integral-derivative (PID) control algorithm, incorporating a personalized model of glucose-insulin dynamics.~The health monitoring system (HMS) predicts impending hypoglycemia, and will be used in both experimental arms as an important safety feature of the device."
62380823|NCT02438670|EXPERIMENTAL|MPC algorithm with HMS|"Subjects will be treated with closed-loop care for 27.5h using a model predictive control (MPC) control algorithm with HMS, using the identical model as in the first experimental arm.~The health monitoring system (HMS) predicts impending hypoglycemia, and will be used in both experimental arms as an important safety feature of the device."
62380824|NCT00605228|EXPERIMENTAL|1|
62380825|NCT00605228|ACTIVE_COMPARATOR|2|
62380826|NCT02085486|EXPERIMENTAL|Ultrasound-assisted puncture|Ultrasound-assisted puncture by the nursing staff of patients with difficult AV-shunts.
62380827|NCT02085486|OTHER|Standard|Classical method wtih inspection and palpation
62380828|NCT05071391||Obese|Obese patients undergoing Roux-en-Y gastric bypass
62380829|NCT03160872||Women who undergo donor sperm insemination|Non infertile women who undergo donor sperm insemination cycle
62380830|NCT06053086|EXPERIMENTAL|Cohort A : Experimental group|In cohort A, for patients with high and undetermined risk of fibrosis (bf+), an adaptive BC RT (ETHOS) will be delivered.
62380831|NCT06053086|ACTIVE_COMPARATOR|Cohort B : Control group|In cohort B, for patients with low risk of fibrosis (bf-), an IMRT will be delivered.
62380832|NCT02006394|EXPERIMENTAL|Active Diet|Reduced glycemic index bread products, fish oil capsules, and polyphenol capsules.
62380833|NCT02006394|PLACEBO_COMPARATOR|Placebo Diet|Market variety bread products, corn oil capsules, and corn starch capsules.
62380834|NCT03089749||Control|Participants with no history of Traumatic Brain Injury, Traumatic Spinal Cord Injury or Intracranial Neoplasm. A single draw of 5 mL of blood will be obtained as well as demographic information and a brief medical history to act as comparison data to the other groups.
62380835|NCT03089749||Traumatic Brain Injury (TBI)|"Patients with Acute Severe TBI (post-resuscitation GCS of 8 or less). Participants will have blood draws at the time points identified below:~* At 24h from the time of CNS insult~* At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~* At 3, 6, and 12 months from the time of CNS insult~* Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained from the participant. Demographic data will be collected, including:~* Age~* Sex~* History of prior CNS insult~* Clinical indicators of severity including baseline, post-resuscitation Glasgow Coma Scale (GCS) scores for brain injury patients~* Radiographic indicators of severity including volume of intracranial hemorrhage, effacement of basal cisterns, amount of midline shift as well as Marshall and Rotterdam CT head scores for TBI.~* Outcome data including discharge, 3-, 6-, and 12-month extended Glasgow Outcome Scale (GOS) scores"
62380836|NCT03089749||Spinal Cord Injury (SCI)|"Patients with acute spinal cord injury (SCI) (post-resuscitation ASIA score of C, B or A). Participants will have blood draws at the time points identified below:~* At 24h from the time of CNS insult~* At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~* At 3, 6, and 12 months from the time of CNS insult~* Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:~* Age~* Sex~* History of prior CNS insult~* Clinical indicators of severity including baseline post-resuscitation American Spinal Injury Association (ASIA) score and ASIA impairment scale (AIS) grade for patients with spinal cord injury (SCI)~* Radiographic indicators of severity including the degree of cord compression, area of cord signal change and the SFGH MRI scale will be employed.~* Outcome data including discharge, 3-, 6-, and 12-month ASIA scores for SCI patients"
62558580|NCT04305743|ACTIVE_COMPARATOR|20 Injections|Participant's bladder is backfilled with 50 mL of 1% lidocaine for 15 minutes, then drained prior to procedure start. Dose of 100 units onabotulinumtoxin A with dilution to 100 Units/10 mL with preservative-free 0.9% Sodium Chloride Injection is prepared. Cystoscopy is performed. The 23 gauge Laborie InjeTAK needle is inserted 3 mm into the detrusor. 20 injections of 0.5 mL each (total volume of 10 mL) in a single procedure is performed 1 cm apart in the bladder body. For the final injection, approximately 1 mL of sterile normal saline should be injected such that the remaining onabotulinumtoxin A in the needle is delivered to the bladder.
62558581|NCT05725239|EXPERIMENTAL|Vagus Nerve Stimulation (VNS) only|
62182501|NCT05336513|OTHER|Diet Control|"Diet Control (DC): nutritional education and adherence monitoring. DC will be based on the Portuguese Nova Roda dos Alimentos following the principles of the Mediterranean diet."
62558582|NCT05725239|EXPERIMENTAL|Transcranial Magnetic Stimulation (TMS) only|
62380837|NCT03089749||Intracranial Neoplasm|"Patients undergoing resection of intra-axial brain tumors (commonly gliomas such as glioblastoma multiforme, astrocytomas and oligodendrogliomas). All participants will have blood draws at the time points identified below:~* At 24h from the time of CNS insult~* At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~* At 3, 6, and 12 months from the time of CNS insult~* Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:~* Age~* Sex~* History of prior CNS insult~* Clinical indicators of severity including baseline, Karnofsky and Modified Rankin performance status scores for oncology patients.~* Radiographic indicators of severity including the pre- and postoperative tumor volumes that will be quantitated.~* Outcome data including discharge, 3-, 6-, and 12-month Karnofsky and Modified Rankin scores for oncology patients."
62380838|NCT03391375|EXPERIMENTAL|DNA-Protein|Co-administration of DNA-HIV-PT123 and AIDSVAX B/E at week 0, 4 and 24
62759997|NCT02710435||Arm 3 - CE Mark|"Includes subjects who received a Reducer System under CE Mark (unrelated to the COSIRA study), and agree to participate in this long term follow up study~Arm 3 has been closed to enrollment-June 2017"
62759998|NCT06258486|EXPERIMENTAL|ICG Injection|This patient will undergo ICG injection into the lymph nodes in order to see if there are any leaks.
62759999|NCT06258486|PLACEBO_COMPARATOR|ICG non-injection|This patient will not have ICG injection. the lymphadenectomy is considered complete at this point.
62760000|NCT01666119|EXPERIMENTAL|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone)will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
62760001|NCT02764528|NO_INTERVENTION|Control|Women will receive standard antenatal care but will not receive any additional handwashing promotion, soap, or handwashing device during their enrollment. At the end of data collection, handwashing with soap will be recommended to participants in the control arm and their families.
62760002|NCT02764528|EXPERIMENTAL|Clinic|Handwashing promotion from healthcare workers at antenatal care clinic.
62760003|NCT02764528|EXPERIMENTAL|Clinic + home|Handwashing promotion from healthcare workers at antenatal care clinic and from community health volunteers at home visits.
62760004|NCT02764528|EXPERIMENTAL|Clinic + home + handwashing device|Handwashing promotion from healthcare workers at antenatal care clinic and from community health volunteers at home visits with provision of one handwashing device.
62760005|NCT01901965|EXPERIMENTAL|NMES|neuromuscular electrical stimulation (NMES) of the quadriceps muscle with Kneehab
62380839|NCT03481296|ACTIVE_COMPARATOR|Advanced Control|The advanced control group receives a set of standard materials regarding colorectal cancer screening.
62380840|NCT03481296|EXPERIMENTAL|Culturally Adapted Decision Support Navigation Intervention|The culturally adapted decision support navigation intervention group receives everything advanced group receives as well as decision support and navigation contacts.
62380841|NCT05626465||Abusive Head Trauma (AHT)|
62380842|NCT05626465||Accidental traumatic brain injury|
62380843|NCT05626465||Cranioplasty|
62380844|NCT05626465||Infant malaise without AHT|
62558583|NCT05725239|EXPERIMENTAL|Synchronized VNS and TMS|
62558584|NCT03327844|ACTIVE_COMPARATOR|RET using bi-Antibiotics|Interventions: Bi-antibiotics (Ciprofloxacin and Metronidazole) placed into the root canal during first treatment stage (disinfection stage)
62760006|NCT01901965|EXPERIMENTAL|eccentric training|unilateral eccentric resistance exercises
62380845|NCT04648995|OTHER|High energy|Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
62380846|NCT04648995|OTHER|Low energy|Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ
62558585|NCT03327844|ACTIVE_COMPARATOR|RET using non-setting Calcium Hydroxide|Interventions: non-setting calcium hydroxide placed into the root canal during first treatment stage (disinfection stage)
62760007|NCT01901965|SHAM_COMPARATOR|sham NMES|neuromuscular electrical stimulation of the quadriceps muscle with intensity which causes no visible contraction or displacement of the leg (activation below motor threshold)
62760008|NCT03209076|EXPERIMENTAL|Robotic|Robotic low anterior resection
62760009|NCT03209076|ACTIVE_COMPARATOR|Laparoscopic|Laparoscopic low anterior resection
62760010|NCT03809091||Bronchiectasis|The patient with bronchiectasis who has no apparent bronchiectasis-causing etiology will be enrolled. The patient's family who has no bronchiectasis will be also enrolled to identify the patient-specific variants.
62760011|NCT02088502|ACTIVE_COMPARATOR|N-acetylcysteine|Patients in the N-acetylcysteine group receive 600 mg non-effervescent N-acetylcysteine tablet plus placebo twice daily from 24 hours before to 48 hours after administration of contrast material.
62760012|NCT02088502|ACTIVE_COMPARATOR|Theophylline|Patients in the Theophylline group receive 200 mg Theophylline slow-release tablet plus placebo twice daily from 24 hours before to 48 hours after administration of contrast material.
62760013|NCT02088502|ACTIVE_COMPARATOR|Theophylline plus N-acetylcysteine|Patients in the Theophylline plus N-acetylcysteine group receive Theophylline slow-release 200 mg tablet plus non-effervescent N-acetylcysteine 600 mg tablet twice daily from 24 hours before to 48 hours after administration of contrast material.
62760014|NCT00868530|EXPERIMENTAL|Xyntha|This trial was an open-label and included assessments of safety, clinical efficacy, and Factor VIII (FVIII) recovery in Chinese subjects with hemophilia A. Subjects received on-demand treatments with Xyntha over a 6-month (calendar day) period.
62558586|NCT02611908|EXPERIMENTAL|ibrutinib +obinutuzumab|
62380847|NCT01327924||Norditropin NordiFlex® users|
62380848|NCT01881906|OTHER|Control - usual care|"The patients randomized to the control group received no training but are offered the chance to participate in the supervised training after they have completed their antineoplastic treatment, at least after twelve weeks. Patients in early 2nd line treatment (switch maintenance) will be offered training after 12 weeks, although they have not completed chemotherapy."
62558587|NCT03674736|EXPERIMENTAL|Methionine bioavailability in Rice|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 7 times. You could be expected to participate in up to 7 different sets of experiments which will take 8 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or Rice which will be provided by the investigators
62760015|NCT03649529|EXPERIMENTAL|GPA-TriMAR-T|Patients' autologous T cells will be isolated and transduced by GPA-TriMAR lentivirus to generate the GPA-TriMAR-T cells, and these cells will then be infused back into the patient for intervention.
62760016|NCT01887821|ACTIVE_COMPARATOR|Chloroquine|25mg base/kg for 3 days
62760017|NCT01887821|ACTIVE_COMPARATOR|Dihydroartemisinin/Piperaquine|Dihydroartemisinin 40 mg + piperaquine phosphate 320 mg per tablet; once daily for three days, doses depend on weight
62760018|NCT03366103|EXPERIMENTAL|Treatment (navitoclax, vistusertib)|Patients receive navitoclax PO QD and vistusertib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62760019|NCT05139199|EXPERIMENTAL|Auricular Point Acupressure|A 1-month regimen of auricular point acupressure, comprising usual-care of approximately 15-20 point pressing each time,3 times a day, seven times peer week.
62760020|NCT05139199|NO_INTERVENTION|usual-care group|These participants follows the standard Chemotherapy follow-up consisting of counseling by nurses and doctors.
62760021|NCT01020162|ACTIVE_COMPARATOR|Non-surgical|TENS, amitriptyline, gabapentin.
62760022|NCT01020162|ACTIVE_COMPARATOR|Surgical intervention|Resection of the ilioinguinal nerve
62760023|NCT05214989|EXPERIMENTAL|Tailored intervention|Tailored intervention designed to address individual barriers to cardiac rehabilitation participation
62760024|NCT03165123|PLACEBO_COMPARATOR|placebo group|The patients will receive oral placebo tablet, one hour before induction of anesthesia and 5 mg Intra-venous dexamethasone within 1-2 minutes after the umbilical cord is clamped.
62760025|NCT03165123|ACTIVE_COMPARATOR|Azithromycin group|The patients will receive 250 mg oral Azithromycin tablet, one hour before induction of anesthesia and 5 mg Intra-venous dexamethasone within 1-2 minutes after the umbilical cord is clamped.
62760026|NCT06352528|EXPERIMENTAL|Group 1: Moderate Hepatic Impairment|
62760027|NCT06352528|EXPERIMENTAL|Group 2: Severe Hepatic Impairment|
62760028|NCT06352528|EXPERIMENTAL|Group 3: Normal Hepatic Function|
62760029|NCT02362945|EXPERIMENTAL|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl (sodium chloride)0.9% solution IV). ( the oxytocin is the routine practice in our department).
62760030|NCT02362945|NO_INTERVENTION|Control:|Treatment with oxytocin after fetal extraction (10 units in 100ml NaCl 0.9% solution IV). as commonly given for Post-Partum Hemorrhage (PPH) at our obstetrical ward.Active Comparator: (this is the routine practice in our department).
62760031|NCT05102617|EXPERIMENTAL|Group A: Split-Face Device Only Treatment|Subjects will receive a split face treatment with the PicoSure Pro and/or PicoSure devices using different device settings on each half of the face.
62760032|NCT05102617|EXPERIMENTAL|Group B: Split-Face Treatment with Cosmeceuticals|Subjects will receive a full face treatment with the PicoSure Pro or PicoSure device and will use topical cosmeceuticals on only half of their face.
62380849|NCT01881906|OTHER|Exercise + usual care|The supervised exercise training is carried out in groups of 12-16 patients and each session has a duration of 1.5 hours. The training comprised warm up exercises, strength and fitness training as well as stretching. Warm up exercises consisted of 10 minutes of light, stationery cycling, adjusted to 60-90% of the patient's maximum HR. The practical aim of strength training was to complete 3 series of 5-8 sets, with 70-90% of 1RM. Cardiovascular training was carried out as interval training on stationery bikes. Intensity was equivalent to 85-95% of each patient's maximum HR and lasted approximately 10-15 minutes. After the training session, 5-10 minutes were dedicated to stretching the large muscle groups in order to increase agility. Following each training session, progressive relaxation of 15-20 minutes was performed.
62380850|NCT02616328||Participants with confirmed rheumatoid arthritis|
62760033|NCT05102617|EXPERIMENTAL|Group C: Device Only Treatment|Subjects will receive treatments with the PicoSure Pro or PicoSure device on multiple areas of the body such as the face, décolletage, back, legs, arms, and hands.
62760034|NCT03514680|NO_INTERVENTION|Period I|-Consented patients will complete electronic versions of the PRO-CTCAE CIPN severity and interference items, 0 - 10 worst CIPN pain numerical rating scale, and QLQ-CIPN20 via tablet prior to their clinician visit at the outpatient oncology center at three consecutive clinic visits: baseline, visit 2, visit 3.
62760035|NCT03514680|EXPERIMENTAL|Period II|"* Consented patients will complete the same battery of assessments from the usual care period at the baseline, visit 2, and visit 3 time points.~* Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm"
62760036|NCT05244460|EXPERIMENTAL|Intervention|Patients who receive droperidol 2.5mg intravenous once and diphenhydramine 25mg intravenous once
62760037|NCT03250078||FAMILIAL PANCREATIC CANCER and/or GENE MUTATION|An inherited genetic syndrome associated with Pancreatic Cancer and/or with a strong family history of Pancreatic Cancer.
62760038|NCT04420962||Microbial Keratitis|Presence of a bacteria or fungal keratitis with ≥ 2mm stromal infiltrate
62760039|NCT04420962||Viral or Inflammatory Keratitis|Non-infectious inflammatory, Viral, Acanthamoeba, or other forms of keratitis
62760040|NCT02017288||Cancer|Participants diagnosed with incident oral cancer
62760041|NCT02017288||Control|Participants without oral lesions or cancers matched to oral cancer/precursor participants on age, gender, smoking/betel nut habits
62760042|NCT02017288||Precursor|Participants clinically diagnosed with oral lesions
62760043|NCT03649373||ED Patients|We retrospectively reviewed patient charts of all patients admitted for shoulder dislocation at the ED at Copenhagen University Hospital Hvidovre between January 1st 2014 and December 31st 2014. A total of 151 patients' charts were reviewed.
62760044|NCT00511433|EXPERIMENTAL|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
62760045|NCT00511433|ACTIVE_COMPARATOR|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
62760046|NCT06606418|ACTIVE_COMPARATOR|Acupuncture group|The patients in this group received acupuncture treatment.
62760047|NCT06606418|SHAM_COMPARATOR|Sham acupuncture group|The patients in this group received sham acupuncture treatment.
62380851|NCT01430598|ACTIVE_COMPARATOR|A|Subacromial decompression before repair of a complete rotator cuff tear.
62380852|NCT01430598|ACTIVE_COMPARATOR|B|Subacromial decompression after repair of a complete rotator cuff repair.
62380853|NCT04297176|EXPERIMENTAL|Traditional monitoring method|Patients are dosed using two timed vancomycin serum concentrations
62380854|NCT04297176|ACTIVE_COMPARATOR|One concentration method|Patients are dosed based on one timed vancomycin serum level
62380855|NCT02453828|EXPERIMENTAL|Checklist|after non-cardiac surgery, patients will have current standard-of-care anesthesia handover during anesthesia transitions in care with an additional, electronically pre-populated checklist displayed on the anesthesia record keeping system
62380856|NCT02453828|ACTIVE_COMPARATOR|Standard of Care|after non-cardiac surgery, patients will have current standard-of-care anesthesia handover during anesthesia transitions in care
62380857|NCT05027711|EXPERIMENTAL|A|Magnetic Resonance-guided Stereotactic Body Radiotherapy (MRgSBRT), if a biologically effective dose (BED) of ≥ 100 Gy is achievable using an ITV
62380858|NCT05027711|EXPERIMENTAL|B|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT), if a biologically effective dose (BED) of ≥ 100 Gy is achievable using an ITV
62760048|NCT00815191|ACTIVE_COMPARATOR|Vital Heat|Vital HEAT (vH2) Temperature Management System
62760049|NCT00815191|ACTIVE_COMPARATOR|Forced air|Forced-air warming
62760050|NCT04580277|EXPERIMENTAL|Chronic pouchitis|This arm will include subjects with chronic pouchitis and will receive tofactinib 10 mg twice daily for 8 weeks
62760051|NCT05639101|OTHER|Intervention group|Clinicians will use a Clinical decision support system to better manage their patients. Asthmatic patients will use a smartphone app for their self management.
62760052|NCT05639101|NO_INTERVENTION|Control|Asthmatic patients that will not be subject to any intervention
62760053|NCT00182767|EXPERIMENTAL|Treatment (ixabepilone and doxorubicin)|Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1.
62760054|NCT06155734||Retrospective intervention cohort|
62760055|NCT02273635|EXPERIMENTAL|andrographolides|Coated tablets containing 140 mg andrographolides twice a day orally administered for a period of 24 months.
62760056|NCT02273635|PLACEBO_COMPARATOR|sugar tablets|Coated tablets containing 140 mgs excipients twice a day orally administered for a period of 24 months.
62760057|NCT02542891|EXPERIMENTAL|Blended CBT|"Internet based blended depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with smart phone components. The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, and (4) relapse prevention. These will be delivered over 16 sessions (8 online and 8 face-to-face), once a week. The online platform is called Moodbuster.~The trial will not interfere with regular medication treatment, and patient's care will be monitored throughout the study."
62760058|NCT02542891|ACTIVE_COMPARATOR|Treament as Usual (TAU)|"In order to increase the comparability between the two arms, we defined TAU as a traditional face to face CBT of 16 sessions. These sessions will be administered over a course of 16 weeks.~The trial will not interfere with regular medication treatment, and patient's care will be monitored throughout the study."
62760059|NCT00438854|EXPERIMENTAL|Dasatinib treatment|All patients were treated with dasatinib pills by mouth as treatment.
62760060|NCT05184465|EXPERIMENTAL|Bupivacaine|"Spinal anesthesia was administered to the patients for anesthetic support of the surgical intervention.Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table.Spinal anesthesia was performed with 3 ml of 0.5% bupivacaine. Then the patient was placed on his back.Surgery was allowed to start after 40 minutes if the upper level of the sensory block reached the Th10 segment."
62760061|NCT05184465|EXPERIMENTAL|Levobupivacaine|"Spinal anesthesia was administered to the patients for anesthetic support of the surgical intervention.Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table.Spinal anesthesia was performed with 3 ml of 0.5% Levobupivacaine. Then the patient was placed on his back.Surgery was allowed to start after 40 minutes if the upper level of the sensory block reached the Th10 segment."
62760062|NCT05184465|EXPERIMENTAL|Hyperbaric bupivacaine|"Spinal anesthesia was administered to the patients for anesthetic support of the surgical intervention.Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table.Spinal anesthesia was performed with 3 ml of 0.5% Hyperbaric bupivacaine. Then the patient was placed on his back.Surgery was allowed to start after 40 minutes if the upper level of the sensory block reached the Th10 segment."
62760063|NCT02658747||Cohort Docetaxel|Participants initiated on docetaxel for the treatment of relapsed non-small cell lung cancer (NSCLC)
62760064|NCT01898949|EXPERIMENTAL|Cold Exposure|
62760065|NCT05379114|EXPERIMENTAL|INVESTIGATIONAL DEVICE|new medical device for the treatment of head lice infestation: Paranix ®
62760066|NCT05379114|ACTIVE_COMPARATOR|COMPARATOR DEVICE|dimethicone based head lice treatment (medical device class 1) already in market in europe: Pouxit ®
62760067|NCT06246019||Early Blood-based biomarkers Arm|The results of the blood-based biomarkers will be communicated to the managing neurologist at visit 1 (at 3 months from baseline visit).
62380859|NCT05027711|EXPERIMENTAL|C|Magnetic Resonance-guided Stereotactic Body Radiotherapy (MRgSBRT). If a BED of ≥ 100 Gy cannot be achieved using an ITV concept (e.g. due to OAR constraints), patients will be treated in arm C using MRgSBRT with the highest achievable dose as deemed appropriate by the treating radiation oncologist
62380860|NCT00858949||Post surgery monitored group|Outpatients undergoing elective surgery with anesthesia that is expected to last one hour and to require significant postoperative opioids
62380861|NCT05155540|ACTIVE_COMPARATOR|Direct mechanical thrombectomy|Direct mechanical thrombectomy performed within 4.5 of stroke onset without giving intravenous recombinant tissue plasminogen activator.
62380862|NCT05155540|ACTIVE_COMPARATOR|Bridging therapy|Mechanical thrombectomy performed within 4.5 of stroke onset after giving intravenous recombinant tissue plasminogen activator at a dose of 0.9 mg/Kg
62380863|NCT02161224|EXPERIMENTAL|1: FG-4592 in subjects with moderate hepatic impairment|
62380864|NCT02161224|EXPERIMENTAL|2: FG-4592 in healthy subjects|
62558588|NCT03674736|EXPERIMENTAL|Lysine bioavailability in Chickpeas|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 7 times. You could be expected to participate in up to 7 different sets of experiments which will take 8 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or Chickpeas which will be provided by the investigators
62760068|NCT06246019||Late Blood-based biomarkers Arm|The results of the blood-based biomarkers will be communicated to the managing neurologist at visit 2 (at 9 months from baseline visit).
62760069|NCT04932330||ICU-acquired weakness group|Patients receiving extracorporeal membrane oxygenation support who had a Medical Research Council (MRC) sum score \< 48 out of a maximal score of 60 when discharged.
62760070|NCT04932330||no ICU-acquired weakness group|Patients receiving extracorporeal membrane oxygenation support who had a Medical Research Council (MRC) sum score ≥ 48 out of a maximal score of 60 when discharged.
62760071|NCT02238340|EXPERIMENTAL|Extended-release oxycodone 10mgr|Extended-release oxycodone 10 mgrs , started 12 hours before orthopaedic surgery
62760072|NCT02238340|EXPERIMENTAL|Extended-release oxycodone 20 mgr|Extended-release oxycodone 20 mgr , started 12 hours before orthopaedic surgery
62760073|NCT04394273||Long- Term Exercise Group|They will exercise one an hour, two days a week, from the 16th week of pregnancy to the 32nd week (16 weeks).In this session, clinical pilates exercises are used as the basic exercise model and this exercise model is applied as a mixed exercise model in the form of posture and body mechanics training, lower-upper extremity strength training, pelvic floor muscle training and breathing exercises. Exercises can be started from the mat level and advanced in a modified manner with theraband and pilates ball.
62760074|NCT04394273||Short-Term Exercise Group|They will exercise half an hour, two days a week, from the 16th week of pregnancy to the 32nd week (16 weeks).n this session, clinical pilates exercises are used as the basic exercise model and this exercise model is applied as a mixed exercise model in the form of posture and body mechanics training, lower-upper extremity strength training, pelvic floor muscle training and breathing exercises. Exercises can be started from the mat level and advanced in a modified manner with theraband and pilates ball.
62760075|NCT04394273||Home Program|Pregnant women who choose the home program group are told to continue their home program until the 32nd week, which includes posture and body mechanics training, increase their physical activity levels and be as active as possible and take daily walks.
62760076|NCT06198101|ACTIVE_COMPARATOR|myofascial release technique|This group receive Myofascial Release Technique
62760077|NCT06198101|EXPERIMENTAL|Myofascial Release Technique along with segmental massage vibrator|this group receive Myofascial Release Technique along with segmental massage vibrator
62760078|NCT04029389|EXPERIMENTAL|Recalcitrant Plantar Fasciitis/Conservational|After ESWT therapy patients suffer from extreme pain will recieve only conservational therapy (26 patients)
62760079|NCT04029389|EXPERIMENTAL|Recalcitrant Plantar Fasciitis/Local|After ESWT therapy patients suffer from extreme pain will receive local steroid injections
62760080|NCT04029389|EXPERIMENTAL|Recalcitrant Plantar Fasciitis/Tibial nerve|After ESWT therapy patients suffer from extreme pain will receive tibial nerve block
62760081|NCT05190601||Group 1|Enuresis nocturna with children
62760082|NCT00358332|EXPERIMENTAL|Group 1: FMP2.1/AS02A 10 mcg dose or rabies vaccine.|20 children will be randomized to receive either the 10 mcg dose of FMP2.1/AS02A (n=15) or rabies vaccine (n=5) on study days 0, 30 +/- 7, and 60 +/- 7.
62760083|NCT00358332|EXPERIMENTAL|Group 2: FMP2.1/AS02A 25 mcg dose or rabies vaccine.|40 children will be randomized to receive either the 25 mcg dose of FMP2.1/AS02A (n=30) or rabies vaccine (n=10) on study days 0, 30 +/- 7, and 60 +/- 7.
62760084|NCT00358332|EXPERIMENTAL|Group 3: FMP2.1/AS02A 50 mcg dose or rabies vaccine.|40 children will be randomized to receive either the 50 mcg dose of FMP2.1/AS02A (n=30) or rabies vaccine (n=10) on study days 0, 30 +/- 7, and 60 +/- 7.
62760085|NCT01544413|EXPERIMENTAL|Laparoscopic sentinel lymph node biopsy|This is a single armed study. After endoscopic marking using Tc99m HSA and indocyanine green fluid, Laparoscopic sentinel lymph node biopsy was performed and evalute at backtable.
62760086|NCT05630651|EXPERIMENTAL|ZS801|Single intravenous (i.v.) infusion of ZS801 Intervention: Gene Therapy / Gene Transfer
62760087|NCT00042432|EXPERIMENTAL|cinacalcet (AMG 073)|
62760088|NCT00042432|PLACEBO_COMPARATOR|Placebo|
62760089|NCT04699292||Cohort A|MLS patients managed by surgery only
62760090|NCT04699292||Cohort B|MLS patients receiving preoperative RT to a dose of 36 Gy (equivalent) followed by surgery
62760091|NCT04699292||Cohort C|MLS patients receiving preoperative RT to a dose of 50 Gy (equivalent) followed by surgery
62760092|NCT04699292||Cohort D|MLS patients receiving surgery followed by postoperative RT to a dose of 50-66 Gy (equivalent)
62760093|NCT04699292||Cohort E|MLS patients with oligometastatic and/or oligoprogressive disease receiving definitive RT to a dose of 36Gy (equivalent)
62760094|NCT01777555|EXPERIMENTAL|CVT-301|CVT-301 at Dose Level 1 for 1st 14 days of treatment then increased to Dose level 2 for last 14 days of treatment.
62760095|NCT01777555|PLACEBO_COMPARATOR|Inhaled Placebo|Subjects randomized to receive placebo in a 1:1 randomization scheme
62760096|NCT00672087||A|Chronic prostatitis/chronic pelvic pain syndrome patients
62760097|NCT00672087||B|Painful bladder syndrome/interstitial cystitis patients
62760098|NCT00672087||C|Asymptomatic controls
62760099|NCT04225091|PLACEBO_COMPARATOR|Placebo drink|
62760100|NCT04225091|EXPERIMENTAL|Triple up® Collagen Drink|
62760101|NCT01073540|EXPERIMENTAL|Arm 1|
62760102|NCT01073540|ACTIVE_COMPARATOR|Arm 2|
62760103|NCT03211793|EXPERIMENTAL|MSC injections|Intramuscular injection of mesenchymal stromal cells (50 million allogeneic MSCs in 0.9% NaCl and 10% human serum albumin).
62760104|NCT03211793|PLACEBO_COMPARATOR|Placebo injections|Intramuscular injection of placebo (NaCl 0.9% + 10% human serum albumin)
62760105|NCT04197063|EXPERIMENTAL|Current SSB restaurant portions purchase refill|Offered a menu with current SSB restaurant portion sizes with the option to purchase refills
62760106|NCT04197063|EXPERIMENTAL|Current SSB restaurant portions free refill|Offered a menu with current SSB restaurant portion sizes plus free beverage refills
62760107|NCT04197063|EXPERIMENTAL|</= 16 oz. SSB portions with the option to purchase refills|Offered a menu with \</= 16 oz. SSB portion sizes with the option to purchase refills
62760108|NCT04197063|EXPERIMENTAL|</= 16 oz. SSB portions plus free refills|Offered a menu with \</= 16 oz. SSB portion sizes plus free refills
62760109|NCT05562180|EXPERIMENTAL|Intervention arm|These participants will use the app to customize their weekly meal plan and grocery delivery
62760110|NCT05562180|NO_INTERVENTION|comparison|These participants will not receive a weekly meal plan and will not get grocery delivery
62760111|NCT01234805|EXPERIMENTAL|Supportive care (yoga therapy)|Patients participate in yoga classes comprising postures, deep relaxation, breathing practices, and meditation twice weekly for 75 minutes during weeks 1-6. Patients then practice yoga at home twice weekly for 45 minutes during weeks 7-12.
62760112|NCT04711941|EXPERIMENTAL|ToM training|ToM training was composed of six lessons two times a week. Through several types of stimuli, the trainer worked together with the participant to comprehend and hypothesize interpretations of the emotions and social interactions, providing discussion occasions to enhance the attribution of mental states and emotions. Every lesson had a duration of 45/60 minutes in order to avoid excessive fatigue in the participant.
62760113|NCT04711941|ACTIVE_COMPARATOR|Non mentalistic training|ToM training was composed of six lessons two times a week. Through several types of stimuli, the trainer worked together with the participant to provide a historical and descriptive overview of cinema movies, TV news, documentaries, newspapers, and advertising. Every lesson had a duration of 45/60 minutes in order to avoid excessive fatigue in the participant.
62760114|NCT01296074|EXPERIMENTAL|Corticosteroid|Methylprednisolone will be given during cardiopulmonary bypass.
62760115|NCT05820698|EXPERIMENTAL|The Mediterranean style diet|Participants in the Mediterranean style diet arm (n = 12) will receive dietary advice to follow a Mediterranean style diet by the Research Nutritionist.
62760116|NCT05820698|EXPERIMENTAL|The Mediterranean style diet with time-restricted eating|Participants in the Mediterranean style diet with time-restricted eating arm (n = 12) will receive dietary advice to follow a Mediterranean style diet combined with time-restricted eating by the Research Nutritionist.
62760117|NCT05820698|ACTIVE_COMPARATOR|The UK diet with time-restricted eating|Participants in the UK diet with time-restricted eating arm (n = 12) will receive dietary advice to follow a UK diet combined with time-restricted eating by the Research Nutritionist.
62760118|NCT02868450|EXPERIMENTAL|Patients with HLA-DQB1 06 and/or HLA-DRB 13|
62760119|NCT06065605||Fabry patients without clinical evidence of nephropathy|No deterioration of kidney function.
62760120|NCT06065605||Fabry patients with clinical evidence of nephropathy|Deterioration of kidney function.
62760121|NCT06065605||Naïve Fabry patients|These patients have no received treatment.
62380865|NCT01702402|EXPERIMENTAL|Intervention Arm|Intervention activities will include behaviour change communications on healthy timing and spacing of pregnancy, couples counselling, social networking and expansion of contraceptive options for postpartum women, including provision of oral contraceptive pills and condoms in the home.
62380866|NCT01702402|OTHER|Comparison|A comparison area received standard government health services.
62760122|NCT06065605||Healthy controls|Not diagnosed with Fabry disease.
62760123|NCT03212417|OTHER|Interventional trial without phases-supportive care.|This is a feasibility pilot study project assessing the presence of compassion fatigue in clinical research nurses (cohort 1) and bone marrow transplant nurses (cohort 2). A survey will be completed by participants prior to and after an educational presentation. The intervention includes the risk factors, signs and symptoms, and interventions on compassion fatigue. The survey will be completed prior to the education, immediately following the education, one month following the education and two months following the education. A final survey will be implemented for the cohort 2 only. The objective of this concluding analysis is to gather data relative to CF and coping mechanisms.
62760124|NCT01660737||PASCALLERG® tablets in patients with hay fever|Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.
62760125|NCT01996163||Male|
62760126|NCT01996163||Female|
62760127|NCT02120170|ACTIVE_COMPARATOR|Hemoclipping during colon polypectomy for all lesion|The enrolled patients of group 1 will be performed hemoclipping for all polypectomy lesion irrespective of the presence of immediate bleeding.
62760128|NCT02120170|NO_INTERVENTION|No hemoclipping if there were no bleeding during polypectomy|The patients of group 2 will be performed hemoclipping only for the immediate bleeding during colon polypectomy
62760129|NCT04389112|EXPERIMENTAL|Patients with actinic keratoses|
62760130|NCT04389112|EXPERIMENTAL|patients with squamous cell carcinoma in situ|
62760131|NCT04389112|EXPERIMENTAL|patients with squamous cell carcinomas|
62380867|NCT01228435|EXPERIMENTAL|ALK-inhibitor naive|No prior exposure to ALK-inhibitor
62380868|NCT01228435|EXPERIMENTAL|ALK-inhibitor pre-treated|Prior exposure to ALK inhibitor
62760132|NCT04389112|EXPERIMENTAL|patient with invasive metastates|
62760133|NCT03184610||OCT-scanning|Patients with Keratoconus are scanned with an OCT-Prototype
62760134|NCT03184610||OCT-scanning for volunteers|Volunteers with healthy eyes are scanned with an OCT-Prototype
62760135|NCT01125969|ACTIVE_COMPARATOR|Control|
62760136|NCT01125969|EXPERIMENTAL|Incentive|
62760137|NCT01125969|EXPERIMENTAL|Peer Mentoring|
62380869|NCT05998603|EXPERIMENTAL|High protein intake supplementation|A 60g daily dose of whey protein supplementation
62760138|NCT01125969|EXPERIMENTAL|Incentives and Peer Mentoring|
62558589|NCT03674736|EXPERIMENTAL|Methionine bioavailability in Wheat|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 7 times. You could be expected to participate in up to 7 different sets of experiments which will take 8 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or Wheat bread which will be provided by the investigators
62760139|NCT01777542|ACTIVE_COMPARATOR|Treatment Period 1|One half of subjects will be randomly assigned to receive Recombinant Human Insulin Growth Factor 1 (rhIGF-1) , and the other half of subjects will be randomly assigned to receive placebo.
62760140|NCT01777542|PLACEBO_COMPARATOR|Treatment Period 2|Subjects that initially received Recombinant Human Insulin Growth Factor 1 (rhIGF-1) will now receive placebo, and subjects that initially received placebo will now receive Recombinant Human Insulin Growth Factor 1 (rhIGF-1).
62760141|NCT05622435|EXPERIMENTAL|T10070|
62760142|NCT03726515|EXPERIMENTAL|CART-EGFRvIII + Pembrolizumab|
62760143|NCT02378194|PLACEBO_COMPARATOR|Placebo group|
62760144|NCT02378194|EXPERIMENTAL|HD-003 (800mg/day)|
62380870|NCT05998603|EXPERIMENTAL|Moderate protein intake supplementation|A 20g dose of whey protein supplementation
62760145|NCT02378194|EXPERIMENTAL|HD-003 (1600mg/day)|
62760146|NCT02594098|EXPERIMENTAL|Secukinumab|Secukinumab (300 mg) via subcutaneous injection using 2 prefilled syringes
62760147|NCT02594098|PLACEBO_COMPARATOR|Placebo|Placebo via subcutaneous injection using 2 prefilled syringes
62760148|NCT01657136|ACTIVE_COMPARATOR|Ivabradine|Ivabradine will be initiated at a dose of 5 mg twice daily. Dosage should be augmented up to 7.5 mg twice daily in case of symptoms persistence and/or HR \> 85 bpm at rest ECG and eventually lowered up to 2.5 mg twice daily in the presence of side effects (phosphenes, diplopia and symptomatic bradycardia).
62760149|NCT01657136|ACTIVE_COMPARATOR|Beta blocker (Bisoprololo)|Bisoprololo will be initiated at a single dose of 5 mg daily. Dosage should be augmented up to 10 mg single dose daily in case of symptoms persistence and/or HR \> 85 bpm at rest ECG and eventually lowered up to 2,5 mg single dose daily in the presence of side effects (symptomatic bradycardia, hypotension).
62760150|NCT01564095|EXPERIMENTAL|Tacrolimus + HTK|Ex vivo Tacrolimus Rinse (20 ng/ml solved in 1000 ml HTK) of marginal liver grafts prior to implantation
62760151|NCT01564095|PLACEBO_COMPARATOR|HTK|Ex vivo Rinse (1000 ml HTK) of marginal liver grafts prior to implantation
62760152|NCT01156389|ACTIVE_COMPARATOR|Arm A Ritonavir plus Pyramax|7 days of ritonavir followed by 3 days of ritonavir plus Pyramax followed by 7 days of ritonavir followed by a 33 day follow-up period (40 days since last Pyramax dosing) and a study completion evaluation.
62182502|NCT05336513|EXPERIMENTAL|Diet Anti-inflammatory|Diet Anti-inflammatory (DAI): nutritional education and adherence monitoring. The DAI dietary intervention will be based on combining individual food items described as potential anti-inflammatory mitigators.
62182503|NCT03864341|EXPERIMENTAL|Homelessness Prevention Services|
62380871|NCT05998603|PLACEBO_COMPARATOR|Carbohydrate placebo|An isocaloic maltodextrin carbohydrate placebo
62380872|NCT05998603|OTHER|Control group, no supplementation|Control group, not taking any supplementation, only completing basic training activities
62380873|NCT04549675|EXPERIMENTAL|Arm 1 Sun Safe Partners Online Intervention|Web-based intervention called Sun Safe Partners Online. Website developed by the study team. Participants received individual username and password to login.
62380874|NCT04549675|ACTIVE_COMPARATOR|Generic Online Sun Safety Information intervention|Publicly online available skin cancer and sun protection information emailed to participants in 4 seperate email links.
62760153|NCT01156389|ACTIVE_COMPARATOR|Arm B Pyramax|3 day treatment course of Pyramax, followed by a follow up period of 40 days since last Pyramax dosing and a study completion evaluation.
62760154|NCT00023686|EXPERIMENTAL|surgery|"Patients undergo radical prostatectomy.~Patients are followed every 6 months for 5 years and then annually thereafter."
62760155|NCT00023686|EXPERIMENTAL|radiation|"Patients undergo brachytherapy with implanted iodine I 125 or palladium Pd 103 seeds.~Patients are followed every 6 months for 5 years and then annually thereafter."
62760156|NCT05489653|EXPERIMENTAL|mixed music group|If assigned to the mixed music group, in order to synchronize active daytime music and passive music at bedtime, active daytime music will require patients to perform physical music activities once a week and watch a recorded music intervention video three times a week during the study period (The content is the same as the physical music activities) and follow the activities, and the intervention content before going to bed is the same as the intervention content of the pure passive music group.
62760157|NCT05489653|ACTIVE_COMPARATOR|pure passive music group|If assigned to the pure passive music group, they are required to listen to soft and low-pitched music at about 60 beats per minute 30 minutes before bed every day for four weeks.
62760158|NCT05489653|NO_INTERVENTION|conventional treatment|Conventional treatment group maintained their original lifestyle and were post-tested with the assistance of a single-blind study evaluator.
62760159|NCT04617886|EXPERIMENTAL|Sadness condition|
62760160|NCT04617886|EXPERIMENTAL|Happiness condition|
62760161|NCT05290987|EXPERIMENTAL|Advanced Water S-100 ionized nasal spray|2 sprays in each nostril, 6 times a day during 8 days
62760162|NCT05290987|PLACEBO_COMPARATOR|Nasal spray with purified water|2 sprays in each nostril, 6 times a day during 8 days
62182504|NCT05674292|EXPERIMENTAL|Erchonia Violet Zerona Z6|405nm violet laser light therapy.
62380875|NCT03659695|EXPERIMENTAL|Grape Powder|69 g/d freeze dried grape powder
62380876|NCT03659695|PLACEBO_COMPARATOR|Placebo powder|69 g/d placebo powder matched for taste and appearance
62380877|NCT04123340|EXPERIMENTAL|Additional intraprocedural CT-scan|Additional intraprocedural CT-scan
62760163|NCT05401045|EXPERIMENTAL|observation group|"1. Exercise plan: Each session of the self-designed METexercises were divided into 8 components. There are 4 sets and 8-repetitions per component, taking approximately 4 minutes to complete and consuming approximately 18 calories. Patients were instructed to exercise once in the morning and once in the evening.Metabolic equivalent intensity: The intensity of exercise was expressed as metabolic equivalents (METs).~2. Exercise training: Members of the fatigue management team in the ward taught the patients to perform MET exercises using videos.The fatigue management team members confirmed that the patient could perform the exercise independently and correctly."
62760164|NCT05401045|NO_INTERVENTION|control group|Participants received routine exercise health education that included information pertaining to CRF (causes of CRF, clinical manifestations, related factors, the necessity and importance of fatigue prevention, and measures to improve CRF, etc.) and exercise (3-5 times per week, regardless of the type of exercise). The patients were also informed about the precautions for exercise.
62380878|NCT00670813|EXPERIMENTAL|Modafinil (Vigil)|"Modafinil Arm: during the 40 h sleep deprivation period (morning until evening next day) the depressed patient receives 200 mg of Modafinil each at 12:00, 24:00 and again at 12:00 o' clock"
62558590|NCT03674736|EXPERIMENTAL|Lysine bioavailability in Lentils|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 7 times. You could be expected to participate in up to 7 different sets of experiments which will take 8 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or Lentils which will be provided by the investigators
62380879|NCT00670813|PLACEBO_COMPARATOR|Placebo|"Placebo Arm: during the 40 h sleep deprivation period (morning until evening next day) the depressed patient receives Placebo at 12:00, 24:00 and again at 12:00 o' clock"
62380880|NCT00545740|EXPERIMENTAL|SPD476 (1.2 g)|
62380881|NCT00545740|EXPERIMENTAL|SPD476 (2.4 g)|
62558591|NCT05933954|OTHER|Healthy volunteers 5G-FR2 exposed vs sham-exposed skin|A 5G source, only exposing a small skin-area, will be placed on each arm of the participants. Only one of the two sources will emit waves (controlled by a computer). One arm will be exposed to 20W/m2 (a dose rate inferior to the recommended maximum for EMW exposure in Switzerland), the other not (sham-exposed). The exposure time is 20 min.
62760165|NCT03784846|EXPERIMENTAL|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, cognitive behavioral therapy (CBT), and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
62760166|NCT03784846|ACTIVE_COMPARATOR|Stress Management Education|SME was designed as an active control condition for other mindfulness-based intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
62760167|NCT03784846|NO_INTERVENTION|No Intervention Control|No contact control condition (other than baseline, post, and follow-up assessments)
62760168|NCT02210481||GLUC-MAC-COHORT|post vitrectomy for retinal detachment or epimacular membrane patients
62760169|NCT04526873|NO_INTERVENTION|Control|No intervention control group
62760170|NCT04526873|EXPERIMENTAL|Postcard: non-telehealth, photo|This group receives a postcard that does not include telehealth information and features a stock photo
62760171|NCT04526873|EXPERIMENTAL|Postcard: non-telehealth, salience/humorous cartoon|This group receives a postcard that does not include telehealth information and features a humorous cartoon as well as examples of serious health risks that the visit could help prevent (stroke and heart attack)
62760172|NCT04526873|EXPERIMENTAL|Postcard: telehealth, photo|This group receives a postcard that does includes telehealth information and features a stock photo
62760173|NCT04526873|EXPERIMENTAL|Postcard: telehealth, salience/humorous cartoon|This group receives a postcard that includes telehealth information and features a humorous cartoon as well as examples of serious health risks that the visit could help prevent (stroke and heart attack)
62760174|NCT04526873|EXPERIMENTAL|Phone call|This group receives a phone call
62760175|NCT02699008|ACTIVE_COMPARATOR|HPR-Ticagrelor row|ACS patients aftergoing PCI treated with clopidogrel and aspirin were included. in the 3-5th day after prescription of clopidogrel, platelet function were tested simultaneously by three methods: Light transmittance aggregometry（LTA）, Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA\>50%;MAADP\>47mm;CTP2Y\<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
62760176|NCT02699008|ACTIVE_COMPARATOR|HPR-Clopidogrel row|Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA\>50%;MAADP\>47mm;CTP2Y\<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
62760177|NCT02699008|ACTIVE_COMPARATOR|unHPR row|Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA\>50%;MAADP\>47mm;CTP2Y\<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
62760178|NCT02650128|EXPERIMENTAL|Lithoplasty System|Shockwave Coronary Rx Lithoplasty® System is a lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic de novo coronary arteries prior to stent placement
62760179|NCT06300918|EXPERIMENTAL|Injecting anti-VEGF drugs 3 days before operation|Injecting Conbercept into vitreous cavity 3 days before performing vitrectomy.
62760180|NCT06300918|EXPERIMENTAL|Injecting anti-VEGF drugs 7 days before operation|Injecting Conbercept into vitreous cavity 7 days before performing vitrectomy.
62760181|NCT06300918|EXPERIMENTAL|Injecting anti-VEGF drugs 14 days before operation|Injecting Conbercept into vitreous cavity 14 days before performing vitrectomy.
62760182|NCT01710527|OTHER|Metformin 500mg|Cross over, two treatment, two period, two sequence, cross over, single dose
62380882|NCT00545740|EXPERIMENTAL|SPD476 (4.8 g)|
62380883|NCT00545740|PLACEBO_COMPARATOR|Placebo|
62760183|NCT01710527|OTHER|Glucophage 500mg|Cross over, two treatment, two period, two sequence, sigle dose
62760184|NCT01873729|EXPERIMENTAL|Naltrexone|Naltrexone
62760185|NCT01892761||TCL/MMF Group|
62760186|NCT01892761||CyA/MMF Group|
62760187|NCT00869050|EXPERIMENTAL|Capecitabine and Temozolomide|Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg and Temozolomide 150-200 mg/m2/day (PO divided BID).
62760188|NCT05767580||alzehimer demantia geriatric|It is a group of individuals over the age of 65, diagnosed with Alzheimer's dementia, able to walk independently, have no communication problems, and volunteer to participate in the research.
62760189|NCT05767580||healty geriatric|This is a group of healthy geriatric individuals over the age of 65 who have not been diagnosed with Alzheimer's dementia, can walk independently, have no communication problems, and volunteered to participate in the study.
62760190|NCT00611468|EXPERIMENTAL|Intravenous Topotecan and Oral Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
62760191|NCT04341545|EXPERIMENTAL|Letrozole|Participants will be given letrozole 10mg daily for one week after standard medical management for tubal ectopic pregnancy by methotrexate injection. Subsequently they will receive the standard management for medical management of tubal ectopic prengnacies.
62760192|NCT04341545|PLACEBO_COMPARATOR|Placebo|Participants will be given identical looking placebo for one week and receive the same standard management for medical management of tubal ectopic pregnancies.
62558592|NCT05933954|OTHER|Patients with dermatoporosis 5G-FR2 exposed vs sham-exposed skin|A 5G source, only exposing a small skin-area, will be placed on each arm of the participants. Only one of the two sources will emit waves (controlled by a computer). One arm will be exposed to 20W/m2 (a dose rate inferior to the recommended maximum for EMW exposure in Switzerland), the other not (sham-exposed). The exposure time is 20 min.
62558593|NCT05933954|OTHER|Patients with atopic dermatitis 5G-FR2 exposed vs sham-exposed skin|A 5G source, only exposing a small skin-area, will be placed on each arm of the participants. Only one of the two sources will emit waves (controlled by a computer). One arm will be exposed to 20W/m2 (a dose rate inferior to the recommended maximum for EMW exposure in Switzerland), the other not (sham-exposed). The exposure time is 20 min.
62558594|NCT05933954|OTHER|Skin-cancer prone patients 5G-FR2 exposed vs sham-exposed skin|A 5G source, only exposing a small skin-area, will be placed on each arm of the participants. Only one of the two sources will emit waves (controlled by a computer). One arm will be exposed to 20W/m2 (a dose rate inferior to the recommended maximum for EMW exposure in Switzerland), the other not (sham-exposed). The exposure time is 20 min.
62558595|NCT06014060|EXPERIMENTAL|24 Months DAPT|Dual antiplatelet therapy consisting of aspirin and clopidogrel will be continued for 12 months after randomisation.
62558596|NCT06014060|ACTIVE_COMPARATOR|12 Months DAPT|Dual antiplatelet therapy will be discontinued and patients will receive aspirin monotherapy for 12 months after randomisation.
62558597|NCT01330303|ACTIVE_COMPARATOR|tamsulosin - Reference|Reference drug administration followed by Test drug administration
62558598|NCT01330303|ACTIVE_COMPARATOR|tamsulosin - Test|Test drug administration followed by Reference drug administration
62182505|NCT05957809|EXPERIMENTAL|1. Structured exercise group|This group will receive structured exercise training with 60-75 minute sessions per day, 2 days a week, for 8 weeks.
62760193|NCT05713903|EXPERIMENTAL|Laparoscopic right colectomy|In laparoscopic right colectomy subgroup, the patient will be placed in a lithotomy position. Entrance in the peritoneal cavity will be completed via the open Hasson method. Overall, 4 ports will be used: 10mm at the umbilicus for optical entry, 12mm in the left midclavicular line below the umbilicus as the main working port, 5mm at the McBurney point, and 5mm between the umbilicus and the xiphoid process. Dissection of the peritoneal fold, under the terminal ileum, will be performed based on the medial to lateral approach. Similar to the open approach, the ileocolic vessels, as well as the right branches of the middle colic will be ligated at their origin for cecal and proximal ascending tumors. For hepatic flexure cancers, the medial colic vessels will be ligated. The ileocolic anastomosis will be completed either intracorporeally or extracorporeally, using staples or sutures.
62760194|NCT05713903|ACTIVE_COMPARATOR|Open right colectomy|In the open right colectomy group, the operation will start with a midline incision and dissection based on the lateral to medial approach. The lateral peritoneal fold along Toldt's line will be incised and the ascending colon will be mobilized from the retroperitoneum according to the embryological dissection planes. Dissection will continue until the anterior surface of the superior mesenteric vessels at the third duodenal part. Ileocolic and right colic vessels will be ligated at their origins. For hepatic flexure tumors, the middle colic vessels will be also ligated at their origin. The ileocolic anastomosis will be performed using an automatic stapler. The anastomosis will be completed either with staples or sutures.
62760195|NCT05445206|EXPERIMENTAL|Health Adult|The target population is healthy adult volunteers who do not have preexisting heart or lung conditions or illness. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders.
62760196|NCT02066506|SHAM_COMPARATOR|asymptomatic group|patients with systemic right ventricle who are asymptomatic,
62760197|NCT02066506|SHAM_COMPARATOR|symptomatic group|symptomatic group : patients with systemic right ventricle and heart failure signs and/or decrease exercise performance
62760198|NCT02066506|SHAM_COMPARATOR|control|healthy subject matched with patients of asymptomatic group
62760199|NCT01046604|NO_INTERVENTION|No treatment|This is the group of patients that will not undergo any treatment with Lovaza prior to mitral valve repair surgery. This is the 'control' group.
62760200|NCT01046604|ACTIVE_COMPARATOR|Lovaza treated|This arm will be the group of patients that will be treated with Lovaza prior to undergoing mitral valve repair surgery.
62760201|NCT03971604|EXPERIMENTAL|group 1|treated with VA
62380884|NCT00578396|ACTIVE_COMPARATOR|Dose Level 1|1 lb/day fresh red grapes
62558599|NCT04762667|EXPERIMENTAL|Patients will undergo reverse shoulder arthroplasty with patient-specific instrumentation.|The patients underwent preoperative planning. A 3D model was made based on CT. The optimal position of the components of the endoprosthesis has been calculated. patient-specific instrumentation were created for each scapula and humerus using 3D modeling software. Individual guides use during operation for exact position of the components of the endoprosthesis.
62760202|NCT03971604|EXPERIMENTAL|group 2|treated with VE
62760203|NCT03971604|EXPERIMENTAL|group 3|treated with VA+VE
62760204|NCT03971604|NO_INTERVENTION|group 4|No intervention
62760205|NCT02954419||IgA nephropathy group|Eligible biopsy-proven primary IgA nephropathy patients.
62760206|NCT05981937||Indocyanine Green|Indocyanine green infusion in left-side colorectal surgery (elective segmentary colic resection)
62760207|NCT05981937||non-Indocyanine Green|No infusion of Indocyanine green in left-side colorectal surgery (elective segmentary colic resection )
62760208|NCT01371643|ACTIVE_COMPARATOR|Medical treatment by Octreotide LAR|Medical therapy with Octreotide LAR 30 mg/month for 3 months preceding surgery
62760209|NCT01371643|ACTIVE_COMPARATOR|Surgical debulking followed by Octreotide LAR|Surgical debulking of pituitary tumor followed by Octreotide LAR if not surgically cured
62182506|NCT05957809|NO_INTERVENTION|2. Control group|This group will be assessed at the beginning, 8. and 24. weeks.
62380885|NCT00578396|ACTIVE_COMPARATOR|Dose Level 2|2/3 lb/day fresh red grapes
62760210|NCT03829943||Vitamin D deficiency|The study group will be males discovered to have Vitamin D deficiency.
62380886|NCT00578396|ACTIVE_COMPARATOR|Dose Level 3|1/3 lb/day fresh red grapes
62380887|NCT05131659|EXPERIMENTAL|Executive function group therapy|
62380888|NCT01400204||MDMA|poly drug users that used MDMA at New Years Eve
62380889|NCT01400204||Other Drugs|poly drug users that used drugs at New Years Eve, but not MDMA
62380890|NCT01400204||Alcohol|poly drug users that used no drugs at New Years Eve, but did consume alcohol
62760211|NCT03829943||Control group|The control group will be males with normal Vitamin D status
62760212|NCT03142724|EXPERIMENTAL|[18F]MNI-968|To assess the safety and tolerability and to determine the radiation dosimetry of \[18F\]MNI-968.
62760213|NCT05544175|EXPERIMENTAL|NEUROMOdulation pain therapy in combination with intensive physiotherapy|"Neuromodulation therapy (low-voltage electrical stimulation of the posterior roots of the spinal cord) by electrodes inserted epidurally from a laminotomy in the lumbosacral region.~Intensive, four hour per day, individual physiotherapy (soft techniques, methods based on neurophysiology, so-called neuroproprioceptive facilitation, inhibition (Vojta's reflex method, Motor programs activating therapy, Proprioceptive neuromuscular stimulation, Bobath concept) will be combined with methods of acquiring motor skills (individualized therapy using the knowledge of sensorimotor learning) will take minimally one month."
62380891|NCT04395521|EXPERIMENTAL|Facebook group arm|Access to a diabetic foot self-management support program via a Facebook group platform for three months plus the standard care.
62760214|NCT01175642|EXPERIMENTAL|Cognitive remediation|Cognitive remediation
62760215|NCT01175642|ACTIVE_COMPARATOR|Functional Adaptive Skills Training|Functional and social skills group treatment
62760216|NCT01175642|ACTIVE_COMPARATOR|Combined Treatment|Combined cognitive remediation and functional adaptive skills training
62760217|NCT02153346|OTHER|Arm 1|Intervention 1 \& 2 are associated with Arm 1. All patients enrolled in the study will possibly receive both the valuation of lost productivity and work productivity and activity impairment questionnaires, which are outside of the patient's usual care.
62760218|NCT05063188|ACTIVE_COMPARATOR|Control group|
62760219|NCT05063188|EXPERIMENTAL|Intervention group|
62760220|NCT03598205|EXPERIMENTAL|DIABEC plus intravitreal dexamethazone|Intervention:Curmin formulation (DIABEC) plus dexamethazone intravitreal injection. Oral curcumin formulation (DIABEC 2 tablets/die) in combination with Dexamethazone (0,7 mg) intravitral injection for diabetic macular edema treatment
62380892|NCT04395521|NO_INTERVENTION|Standard care arm|Carry on with the routine diabetes care offered to the participants in their health facilities.
62760221|NCT03598205|NO_INTERVENTION|dexamethazone intravitreal injection|Intervention: dexamethazone intravitreal injection (0,7 mg) in PRN for diabetic macular edema treatment monotherapy.
62380893|NCT03568513|EXPERIMENTAL|Treatment|Patients in the treatment arm with weight between 35 kg to 50 kg will receive 50 mg capsule of curcumin twice a day (maximum dose 2.8 mg/kg/day, which is within the GRAS approved dose) and those over 50 kg in weight will receive three curcumin capsules a day (maximum dose 3 mg/kg/day, within GRAS recommended dose). Study duration will be 8 weeks.
62760222|NCT00503334|EXPERIMENTAL|preOP booster|
62760223|NCT00503334|PLACEBO_COMPARATOR|preOP booster placebo|
62760224|NCT00367744|ACTIVE_COMPARATOR|Rosigitazone arm|Rosiglitazone active 4 mg BID
62760225|NCT00367744|PLACEBO_COMPARATOR|Placebo arm|Matching Placebo BID
62760226|NCT03359057|EXPERIMENTAL|Estradiol + levonorgestrel + folic acid|Coated tablet of the test product - ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days.
62760227|NCT03359057|PLACEBO_COMPARATOR|Folic acid|Coated tablet of placebo coated tablet containing folic acid 0.4 mg only on the last 7 days of the cycle.
62760228|NCT03164083|EXPERIMENTAL|mesenchymal stem cell|Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection
62760229|NCT03164083|EXPERIMENTAL|placebo|The patients who are in control group and underwent placebo injection
62760230|NCT06521775|EXPERIMENTAL|Diagnostic (Ga-68 PSMA-11, PET/CT)|Patients receive Ga-68 PSMA-11 IV and then undergo PET/CT 50-70 minutes after injection at baseline and approximately 12-20 weeks during investigational therapy.
62760231|NCT04416607|EXPERIMENTAL|corifollitropin alpha|Ovarian stimulation protocol is performed with a single dose of 100 μg (\<60 kg) or 150 μg (≥60 kg) of corifollitropin alpha (Elonva, Schering-Plough, Brazil), plus gonadotropin-releasing hormone antagonist co-treatment (Ganirelix 25 mcg/day, Orgalutran, Schering-Plough, Brazil) in a flexible protocol (at least 1 follicle \>14 mm or 3 or more follicles \>12 mm).
62760232|NCT04416607|ACTIVE_COMPARATOR|menotropin|150-300 IU/day HMG (menotropin, Menopur, Ferring, Brazil) is administered, starting on cycle day 3, according to age, AMH level and AFC, plus gonadotropin-releasing hormone antagonist co-treatment (Ganirelix 25 mcg/day, Orgalutran, Schering-Plough, Brazil) in a flexible protocol (at least 1 follicle \>14 mm or 3 or more follicles \>12 mm).
62760233|NCT00546260|PLACEBO_COMPARATOR|1|Placebo for each Dose cohort: 10, 20, 40, and 60 mg
62760234|NCT00546260|EXPERIMENTAL|2|Experimental drug for each Dose cohort: 10, 20, 40, and 60 mg
62760235|NCT03221790|EXPERIMENTAL|Low and High FODMAP Diets in IBS|"This study will be comprised of the following four time periods: baseline, run-in, low FODMAP diet, and high FODMAP diet. Participants will undergo baseline assessment with questionnaires on demographics, IBS symptoms (IBS symptom severity scoring questionnaire), diet, and psychological parameters. Baseline mucosal colonic biopsies will be obtained, and metabolome analysis from urine samples. These will be repeated 3 other times during each of the above time periods. Low FODMAP Diet followed by a High FODMAP Diet"
62760236|NCT05385445|EXPERIMENTAL|Audit and Feedback Group 1|"The intervention Group 1 received the standard feedback report with a one-page summary of the CWC recommendations of interest. Group 1 did not receive any data specific to their prescribing."
62760237|NCT05385445|EXPERIMENTAL|Audit and Feedback Group 2|"Intervention Group 2 received the standard feedback report, CWC recommendation summary and practice-specific data related to their prescribing rates for the CWC recommendations of interest, compared to rates for other providers at their clinic, in their health region and in the province."
62760238|NCT05385445|NO_INTERVENTION|Control|The control group received the standard feedback report with no information related to CWC.
62760239|NCT05596487|EXPERIMENTAL|experimental: repetitive standardized patient simulation|In the study, an end-of-life care nursing education program was applied to all students. In the second stage, the standard patient-based practice was performed once with the control group nursing students and twice with the intervention group students.
62380894|NCT03568513|PLACEBO_COMPARATOR|Placebo|Patients in the placebo arm will receive a capsule which has similar size, shape and color of the curcumin capsule. The placebo capsule will contain inert food powder. Study duration will be 8 weeks.
62760240|NCT05596487|NO_INTERVENTION|control grup|
62760241|NCT02966795|EXPERIMENTAL|Glecaprevir/Pibrentasvir for 8 Weeks|Non-cirrhotic participants with hepatitis C virus genotype 5 or 6 received oral glecaprevir/pibrentasir (300 mg/120 mg) once daily with food for 8 weeks, according to label.
62760242|NCT02966795|EXPERIMENTAL|Glecaprevir/Pibrentasvir for 12 Weeks|Participants with hepatitis C virus genotype 5 or 6 and compensated cirrhosis received oral glecaprevir/pibrentasir (300 mg/120 mg) once daily with food for 12 weeks, according to label.
62380895|NCT00590031|EXPERIMENTAL|1|External Beam Radiation Therapy, Cisplatin, Irinotecan
62380896|NCT02541994|OTHER|Ultrasound Testing|Single arm with all patients getting measurements of axial length and central corneal thickness.
62380897|NCT06182215||Prospective observational cohorts|patients undergoing elective major abdominal surgery (estimated operation time over 2 hours)
62380898|NCT04473495||video|patients who enjoyed an educational video
62380899|NCT04473495||control|patients who didn't enjoy any educational video
62380900|NCT04234399||Group|All patients receiving SOC imaging and Axumin PET scans.
62380901|NCT04799340|EXPERIMENTAL|holistic face training + repetition lag training|
62380902|NCT04799340|NO_INTERVENTION|waitlist control|
62380903|NCT01888965|EXPERIMENTAL|Dovitinib|Dovitinib 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years
62380904|NCT03194256|ACTIVE_COMPARATOR|Normal Nicotine Content Cigarettes|Spectrum Research Cigarettes: 15.8 mg nicotine/g tobacco, 9 mg of tar
62380905|NCT03194256|EXPERIMENTAL|Very Low Nicotine Content Cigarettes|Spectrum Research Cigarettes: 0.4 mg nicotine/g tobacco, 9 mg of tar
62760243|NCT00600041|EXPERIMENTAL|A|Pantoprazole IV
62760244|NCT00600041|PLACEBO_COMPARATOR|B|NaCl 0.9% IV
62380906|NCT06369584|EXPERIMENTAL|prone position during ECMO in pediatric ARDS|Procedure: Prone positioning The process of prone positioning requires 5-6 people, with one person acting as the commander responsible for directing and monitoring the implementation of prone positioning. The process of monitoring includes ECMO flow and vital signs. The second person is in charge of the patient's head, including endotracheal intubation, ventilator lines, and jugular ECMO cannula. The third person is responsible for femoral ECMO cannula and central venous line. The fourth to sixth individuals are responsible for rotating the patient's torso towards the side without an ECMO tube. Before initiating prone ventilation, pressure ulcer protection patches should be placed to protect areas under pressure. During ECMO support period, each patient needs to undergo at least four sessions of prone ventilation. Each session should last between 16 to 24 hours.
62380907|NCT06369584|NO_INTERVENTION|supine position during ECMO in pediatric ARDS|Procedure: Supine position Patients assigned to supine will remain in a semi-recumbent position.
62380908|NCT04543656|EXPERIMENTAL|AI-Based Lifestyle Recommendations Group|Participants in this group receive AI-based, personalized lifestyle recommendations based on analysis of their activity tracker and blood pressure data.
62380909|NCT04543656|ACTIVE_COMPARATOR|Control Group|Participants in this group do not receive the lifestyle recommendations, but are provided with an identical activity tracker and blood pressure monitor.
62558600|NCT04762667|OTHER|Patients will undergo conventional reverse shoulder arthroplasty.|This group of patients was examined according to the standard method, Rg and CT of the shoulder joint were performed. According to the study, the sizes of the endoprosthesis were selected. Installation of the components of the endoprosthesis during the operation was carried out using standard (included in the set) guides. Orientation was performed according to the anatomical landmarks of the glenoid and the neck of the humerus, without taking into account the individual characteristics of the bones.
62760245|NCT01146652|EXPERIMENTAL|Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)|Participants who completed any of initial studies:Part A or B of EFC11072, ACT11575, EFC10832 or SFY13370 were enrolled in LTS11210 and received sarilumab 150 milligrams (mg) subcutaneously (SC) once weekly (qw). Dose could be reduced to 150 mg every 2 weeks (q2w) due to neutropenia, thrombocytopenia or increase in liver enzymes (alanine aminotransferase \[ALT\]). After dose regimens selection for Phase 3 studies (150 mg q2w and 200 mg q2w), participants already receiving 150 mg qw were switched to sarilumab 200 mg q2w. Treatment duration per participant was at least 264 weeks from first study drug administration in LTS11210. Participants continued to be treated beyond 264 weeks until sarilumab was commercially available in their respective countries or until 2020, at the latest (maximum duration: 523 weeks). Participants who were already taking concomitant non-biologic DMARDs in initial study continued stable dose of one or combination of conventional synthetic DMARDs they were taking.
62380910|NCT04678193||COVID19 PCR positive test and negative or high risk asymptomatic|Patient population COVID-19 infection risk assessment real time epidemiology with 27000 subjects
62380911|NCT04678193||COVID19 PCR positive test Stage 1 infection|Patient population of PCR positive COVID-19 Stage 1 infection in registry targeted for ECL-19 treatment for reduced hospitalization with 2700 subjects (10% ECL-19 and 20% Placebo)
62380912|NCT03411356|ACTIVE_COMPARATOR|Daily Caloric Restriction (DCR)|Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.
61987439|NCT03139149|ACTIVE_COMPARATOR|Early surgery|After exclusion of indications for an emergency operation, conservative treatment is performed up to 12 hours from the moment of admission. Each patient receive blood test, blood lactate investigation, blood biochemistry, X-ray of the abdomen, ultrasound and CT on the admission. Each patient receive water-soluble contrast in 3 h after admission. In case of of clinical and radiologic signs of obstruction in 12 h after admission, surgery is performed. On the first stage of surgical treatment laparoscopic adhesiolysis is performed. If it is impossible to eliminate the cause of obstruction by laparoscopic technique laparotomy is performed.
62380913|NCT03411356|EXPERIMENTAL|Intermittent Fasting (IMF)|Participants in this group will focus on modified intermittent fasting as their dietary weight loss strategy.
62380914|NCT04271202|OTHER|Treatment|Effects of galacenezumab (emgality) treatment (injectable 240 mg initial dose followed by 120 mg treatments 1 and 2 month later) on brain functioning.
62380915|NCT04098029|EXPERIMENTAL|Group 1 Low HLA compatibility|The patients in the first group will receive two CBU of low-level HLA matched infusions within a 6-month interval. The low-level match is 3 or less HLA compatibility degree by A, B, DRB1 loci.
62182507|NCT01836198|EXPERIMENTAL|LY2409021 Only (Part A, Cohort 1)|Part A, Period 1. Participants will receive a single 20-milligram (mg) oral dose of LY2409021 on Day 1.
62380916|NCT04098029|EXPERIMENTAL|Group 2 High HLA compatibility|The patients in the second group will receive two CBU of high-level HLA matched infusions within a 6-month interval. The high-level match is 4 or more HLA compatibility degree by A, B, DRB1 loci.
62380917|NCT04098029|OTHER|Standard therapy|Patients with standard therapy as a control group
62380918|NCT03261739|EXPERIMENTAL|RYI- 018|The doses of RYI-018 to be evaluated in sequential cohorts will be 0.6 mg/kg, 1.2 mg/kg, and 2.5 mg/kg.
62380919|NCT03261739|PLACEBO_COMPARATOR|Placebo|vehicle control
62380920|NCT05970146|EXPERIMENTAL|Ultrasound guided Stellate ganglion block|The procedure is going to be the anterior paratracheal approach on the cervical sympathetic chain
62380921|NCT05970146|EXPERIMENTAL|unilateral cervical epidural|The patient is placed in prone position, with stabilization of the forehead on a padded support
62380922|NCT05761405|ACTIVE_COMPARATOR|Ceftriaxone (CRO)|Ceftriaxone infusion. Ceftriaxone is a beta-lactam antibiotic that is the standard-of-care antibiotic for prophylaxis of asymptomatic bacteriuria in Switzerland. The choice of 2000 mg delivered intravenously reflects the general practice.
62760246|NCT01146652|EXPERIMENTAL|Sarilumab monotherapy|Participants who completed study EFC13752 were enrolled in LTS11210 and received sarilumab 200 mg q2w. Dose could be reduced to 150 mg q2w due to neutropenia, thrombocytopenia or increase in liver enzymes (ALT). Treatment duration per participant was at least 264 weeks from first study drug administration in LTS11210. Participants continued to be treated beyond 264 weeks until sarilumab was commercially available in their respective countries or until 2020, at the latest (maximum duration: 523 weeks).
62760247|NCT03952117|ACTIVE_COMPARATOR|Active tDCs|Active tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator. The cathode will be positioned facing the primary motor cortex area and the anode over the contralateral supraorbital area.
62760248|NCT03952117|SHAM_COMPARATOR|Sham tDCS|Sham stimulation will be delivered to the motor cortex using a sham tDCS device that delivers a direct current for 10 seconds at the beginning and end of tDCS to provide sensory experiences similar to active stimulation.
62760249|NCT02568098|EXPERIMENTAL|TMEC-14-022 (OxTREC 39-14)|Subjects had previously taken drug CQ and PQ
62760250|NCT02568098|EXPERIMENTAL|TMEC 12-004 (OxTREC 58-11)|Subjects had previously taken drug PQ and DHA-PQP
62760251|NCT02568098|EXPERIMENTAL|New subject|"Subjects who not previously participated in study TMEC 12-004 (OxTREC ref. 58-11) and study TMEC 14-022 (OxTREC ref. 39-14)."
62760252|NCT04104074|EXPERIMENTAL|Radiotherapy Plus Sintilimab|HCC Patients will be received radiotherapy and concurrent Sintilimab (PD-1 inhibitor)treatment.
62760253|NCT04789161||double kissing crush stenting|patients with true bifurcation lesion undergoing double kissing crush stenting
62760254|NCT04789161||double kissing culotte stenting|patients with true bifurcation lesion undergoing double kissing culotte stenting
62760255|NCT05703620|EXPERIMENTAL|Chronic Kidney Disease|Renal Denervation
62760256|NCT05703620|EXPERIMENTAL|Heart Failure|Renal Denervation
62760257|NCT05703620|EXPERIMENTAL|End stage renal disease|Renal Denervation
62760258|NCT01218451|EXPERIMENTAL|Group 1|Single dose of NeisVac-C vaccine at 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
62760259|NCT01218451|EXPERIMENTAL|Group 2|Single dose of NeisVac-C vaccine at 6 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
62380923|NCT05761405|ACTIVE_COMPARATOR|Aminoglycoside (AMK)|Amikacin infusion Amikacin is an aminoglycoside routinely used in Australia (e.g. amikacin, gentamicin) as the standard of care for antibiotic prophylaxis for endourological treatments. It is also used globally for fever in neutropenia in hematological patients. Due to their relatively limited use, aminoglycosides have low resistance rates amongst Enterobacteriaceae. A single dose of 1000mg will be used intravenously
62760260|NCT01218451|ACTIVE_COMPARATOR|Group 3|Two doses of NeisVac-C vaccine at 2 and 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
62760261|NCT03353922|EXPERIMENTAL|Tolperisone HCl 150 mg|150 mg tolperisone tablets or cyclobenzaprine 10 mg oral tablet administered by mouth every 8 hours for 3 days
62760262|NCT03353922|PLACEBO_COMPARATOR|Placebo Oral Tablet|sugar pills administered by mouth every 8 hours for 3 days
62760263|NCT03353922|ACTIVE_COMPARATOR|Cyclobenzaprine 10 mg oral tablet|10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days
62760264|NCT02926092||Arm 1|Observation of progression of disease over time.
62760265|NCT02148432|EXPERIMENTAL|dexmedetomidine 0.5 mcg/kg/hr|
62760266|NCT02148432|ACTIVE_COMPARATOR|dexmedetomidine 1.0 mcg/kg/hr|
62760267|NCT00701636|EXPERIMENTAL|Cases|The first 15 subjects enrolled will receive the intervention drug daptomycin as surgical antibiotic prophylaxis.
61987440|NCT03139149|ACTIVE_COMPARATOR|Late surgery|After exclusion of indications for an emergency operation, conservative treatment is performed up to 48 hours from the moment of admission. Each patient receive blood test, blood lactate investigation, blood biochemistry, X-ray of the abdomen, ultrasound and CT on the admission. Each patient receive water-soluble contrast 3 h after admission. In case of present of obstruction and absence of contrast in colon in 36 h after intake (48 h after admission) a surgery is perform. On the first stage of surgical treatment laparoscopic adhesiolysis is performed. If it is impossible to eliminate the cause of obstruction by laparoscopic technique laparotomy is performed.
62760268|NCT00701636|NO_INTERVENTION|Controls|15 subjects will be enrolled in the standard of care antibiotic group to serve as the controls. Controls will receive no experimental medications or treatments. The purpose of enrolling control patients was to serve as a reference group for intervention patients. Specifically cases and controls will be compared for changes in commonly collected hematologic parameters, creatinine, and CPK. Additionally, parameters collected during anesthesia will be compared. Controls will be matched to the intervention group by age (+/- 10 years), gender, and ethnicity.
62760269|NCT01544452|OTHER|Total preoperative MR evaluation|Total diagnostic evaluation with MRI of the liver, abdomen, colonography and rectum in one session combined with CT thorax
62760270|NCT01544452|OTHER|Standard diagnostic evaluation|Standard preoperative diagnostic evaluation for patients with rectal cancer, incl. CT thorax, abdomen and MRI of the rectum and colonoscopy
62760271|NCT01180816|EXPERIMENTAL|Temozolomide (Temodar)|
62760272|NCT05606419|EXPERIMENTAL|CDED + PEN|Crohn's Disease Exclusion Diet (CDED)+Partial Enteral Nutrition (PEN): Patients will follow the first phase diet (CDED+50%PEN) for 6 weeks and will continue with CDED phase 2 + 25%PEN for another 6 weeks. Total duration: 12 weeks.
62760273|NCT05606419|ACTIVE_COMPARATOR|Usual Nutritional Care + PEN|Partial Enteral Nutrition (PEN) + usual nutritional care: Patients will be given PEN plus the usual advice for a healthy dietary pattern. PEN will cover the 50% of total energy requirements for the first 6 weeks. During the second 6 weeks, PEN will cover the 25% of the total energy requirements.Total duration: 12 weeks
62760274|NCT05606419|ACTIVE_COMPARATOR|CDED + Dairy|Crohn's Disease Exclusion Diet (CDED) + dairy products: Patients will follow the first phase diet CDED + 50% of their energy requirements covered by dairy products for 6 week and then will continue with the CDED phase 2 diet + 25% dairy products.
62380924|NCT05761405|EXPERIMENTAL|AminoglycosideLD + Mannitol (AMK1/2 + MAN)|Amikacin + Mannitol combination The addition of Mannitol enhances bactericidal effect of amikacin in E.coli and K.pneumoniae in animal models and allows for a decrease of amikacin dosing. A single dose of 500mg (low dose or LD - decrease by 50%) systemic amikacin will be used intravenously in combination with 5 grams mannitol delivered intravenously.
62380925|NCT00142818|EXPERIMENTAL|Naltrexone plus modafinil|Nal + Mod
62380926|NCT00142818|EXPERIMENTAL|Naltrexone|Nal
62380927|NCT00142818|EXPERIMENTAL|Modafinil|Mod
62380928|NCT00142818|PLACEBO_COMPARATOR|Placebo|Placebo
62380929|NCT02176434|EXPERIMENTAL|Tolerance|Combined kidney and hematopoietic stem cell transplantation from the same donor.
62380930|NCT05704140||catheter based dialysis|All patients receiving catheter based dialysis in Vienna as of November 2022
62380931|NCT00403689|EXPERIMENTAL|x|capsules containing beta glycan
62380932|NCT00403689|PLACEBO_COMPARATOR|y|capsules containing placebo (waxy maize starch)
62380933|NCT02583828|ACTIVE_COMPARATOR|Cyclophosphamide alone|Patients who were resistant to letrozole will be randomized to receive cyclophosphamide alone or letrozole plus cyclophosphamide. Patients in this arm will receive cyclophosphamide 50 mg daily.
62760275|NCT03093974|EXPERIMENTAL|CMS (Colimesthate sodium)|Inhaled colistimethate sodium twice daily. The active pharmaceutical ingredient consisting of pure CMS one million international units (MIU) / 80 mg of CMS / 33 mg colistin base activity (CBA) was provided as a powder for nebuliser solution in 10R International Organization for Standardization (ISO) glass vials.
62760276|NCT03093974|PLACEBO_COMPARATOR|Placebo|Saline solution inhaled twice daily, provided and administered at the same way of the IMP.
62380934|NCT02583828|EXPERIMENTAL|Cyclophosphamide plus letrozole for resistant patients|Patients who were resistant to letrozole will be randomized to receive cyclophosphamide alone or letrozole plus cyclophosphamide. Patients in the this will receive cyclophosphamide 50 mg daily plus letrozole 2.5 mg daily.
62380935|NCT02583828|EXPERIMENTAL|Cyclophosphamide plus letrozole for treat-naive patients|Patients who haven't received letrozole hormonotherapy will be randomized to receive letrozole plus cyclophosphamide or letrozole alone. Patients in this arm will receive cyclophosphamide 50 mg daily plus letrozole 2.5 mg daily.
62380936|NCT02583828|ACTIVE_COMPARATOR|letrozole alone|Patients who haven't received letrozole hormonotherapy will be randomized to receive letrozole plus cyclophosphamide or letrozole alone. Patients in this arm will receive letrozole 2.5 mg daily.
62380937|NCT05920109|EXPERIMENTAL|experimental group|Patients in the experimental group will have a continuous Erector Spinae Plane Block within the first 6 hours post-admission, with a continuous 1ml/h infusion of Ropivacaine (2mg/ml) associated with a 25 ml bolus every 6h.
62380938|NCT05920109|NO_INTERVENTION|control group|Patients in the control group will receive intravenous multimodal analgesia in the trauma bay. Thoracic epidural analgesia or continuous paravertebral block or serratus plane block will be performed within the first 12 hours post-admission if the pain is not controlled according to our national guidelines.
62380939|NCT01252576||women with and without sexual dysfunction|women with and without female sexual dysfunction
62380940|NCT05839899|ACTIVE_COMPARATOR|Mifepristone plus Single dose misoprostol|Participant will take mifepristone, then one dose of misoprostol at home to pass the pregnancy (current routine abortion care).
62380941|NCT05839899|EXPERIMENTAL|Mifepristone plus two doses misoprostol|Participant will take mifepristone, then at home will take two doses of misoprostol 4 hours apart to pass the pregnancy.
62380942|NCT00474552|EXPERIMENTAL|1|Experimental-Placebo Comparator
62380943|NCT05512195|EXPERIMENTAL|New delineation approach （NDA）group|use a new method for clinical target volume delineation by referencing the nerve fiber bundles
62380944|NCT01521260|PLACEBO_COMPARATOR|Placebo group|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
62380945|NCT01521260|ACTIVE_COMPARATOR|Chlorhexidine group|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
62380946|NCT02424890|ACTIVE_COMPARATOR|Repetitive Sim Group|9 simulation sessions
62380947|NCT02424890|ACTIVE_COMPARATOR|Control Group|3 simulation sessions
62380948|NCT04009252|EXPERIMENTAL|Intervention Group|3D model to be printed and used as teaching tool to discuss injury with patient as well as its associated long-term outcomes and potential complications. The operative plan will also be reviewed with the patient using the model as well as post-operative course (ie rehabilitation)
62380949|NCT04009252|NO_INTERVENTION|Control Group|The CT image will be shown to the patients along with teaching
62380950|NCT05364658|EXPERIMENTAL|Juvene IOL|Eyes that have been implanted with the LensGen Juvene IOL
62760277|NCT02488291|EXPERIMENTAL|0.5 sufentanil|0.5µg/ml sufentanil, 0.1% ropivacaine for 6ml/h
62760278|NCT02488291|EXPERIMENTAL|0.25 sufentanil|0.25µg/ml sufentanil, 0.1% ropivacaine for 6ml/h
62760279|NCT05128162|EXPERIMENTAL|Open Label Oral Psilocybin|This is an open-label study, and participants who meet the inclusion and exclusion criteria will be eligible and invited to enroll. Enrolled participants are planned to receive 2 doses of psilocybin: a 15 mg dose followed 2 weeks later by a 25 mg dose. The total planned duration of the study for an individual participant from screening to last follow-up is approximately 8 months.
62760280|NCT00413920|EXPERIMENTAL|Without Steroids|Patients received Enteric-coated Mycophenolate Sodium (EC-MPS), administered orally 2 times a day for 6 months. Patients also received cyclosporine and a dose of methylprednisolone immediately after transplantation, but did not subsequently receive oral corticosteroids for the remainder of the study.
62760281|NCT00413920|ACTIVE_COMPARATOR|With Steroids|Patients received Enteric-coated Mycophenolate Sodium (EC-MPS), administered orally 2 times a day for 6 months. Patients also received cyclosporine and a dose of methylprednisolone immediately after transplantation, and subsequently continued to receive daily oral prednisone.
62760282|NCT03400657||fully implemented to the MDT decision|group of patients fully implemented to the MDT decision
62760283|NCT03400657||not completly implemented to the MDT-decision|group of patients not completly implemented to the MDT decision
62760284|NCT03400657||not implemented to the MDT decision|group of patients not implemented to the MDT decision
62760285|NCT04965922|EXPERIMENTAL|Multimodal intervention at inclusion|Multimodal intervention will be proposed to Multiple system atrophy patients and their caregivers.
62760286|NCT04965922|OTHER|Multimodal intervention at 6 month|Multimodal intervention will be proposed to Multiple system atrophy patients and their caregivers.
62760287|NCT04143217|EXPERIMENTAL|Open-Label Treatment|SPN-812 Open-Label Treatment 200mg to 600mg SPN-812 once daily for up to 156 weeks
62760288|NCT02474537|EXPERIMENTAL|Normal hepatic function|Subjects with normal hepatic function
62760289|NCT02474537|EXPERIMENTAL|Mild hepatic impairment|Subjects with mild hepatic impairment
62760290|NCT02474537|EXPERIMENTAL|Moderate hepatic impairment|Subjects with moderate hepatic impairment
62760291|NCT02474537|EXPERIMENTAL|Severe hepatic impairment|Subjects with severe hepatic impairment
62380951|NCT06048068|EXPERIMENTAL|Informational Intervention Arm|Participants in this arm will receive access to the informational intervention program, via a website link that they will access through their own person phone/tablet/computer.
62380952|NCT06048068|NO_INTERVENTION|Control Arm|Participants in this arm will receive usual care and no access to the informational intervention program.
62380953|NCT06135766|EXPERIMENTAL|A Lust for Life programme group|A Lust for Life programme will be delivered to participants by their class teachers in ten weekly sessions.
62380954|NCT06135766|OTHER|Waiting list control group|Participants will receive curriculum as usual from their class teacher, and placed on a 12-week waiting list for the programme.
62380955|NCT00438191||1|Subjects who wear the splint whenever the feel the need.
62760292|NCT01691014||adalimumab|
62760293|NCT01691014||Etanercept|
62760294|NCT01691014||infliximab|
62760295|NCT01691014||Certolizumab|
62760296|NCT00043823|EXPERIMENTAL|Avastin + Tarceva|Combination Therapy (Avastin + Tarceva) = Avastin IV Day 1 of each 21-day cycle + oral Tarceva daily.
61987441|NCT02301273|ACTIVE_COMPARATOR|Usual Physiotherapy|Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
62380956|NCT00438191||2|Subjects who wear the splint whenever possible.
62380957|NCT02875782|EXPERIMENTAL|DM intervention|Subjects will receive a patient-centered motivational intervention with two components: (1) the stage-matched smoking cessation intervention and (2) the relationship between smoking and diabetic complications. All subjects will receive a self-help cessation manual with DM components and take the exhaled carbon monoxide test. The total counseling process will take about 20 minutes. Three consecutive (3-, 6- and 12-month) follow ups will be conducted. Also, the counselor will further the progress of their action plan and barriers encountered in the behavioral change process as well as engage them in the process, enhance their self-efficacy, and identify individual barriers and facilitators.
62760297|NCT03508193|EXPERIMENTAL|Intervention|Whole-foods based smoothie as nutritional therapy
62760298|NCT04346979|EXPERIMENTAL|Study Group|Telerehabilitation based yoga and mindfulness training will be given to the study group.
62760299|NCT04346979|EXPERIMENTAL|Control Group|Yoga and mindfulness training will be provided by sending a video recording to the control group.
62760300|NCT05482581||Questionnaires assessed adolescents and young adults|①14-35 years old; ②Being able to read and communicate in Chinese.
62760301|NCT00340600||DES Exposed|DES-exposed mothers, daughters and sons, and identified subjects
62760302|NCT00340600||DES Unexposed|DES-unexposed mothers, daughters and sons, and identified subjects
62760303|NCT03535662|EXPERIMENTAL|Orvepitant|Orvepitant single 20mg dose
62760304|NCT03535662|EXPERIMENTAL|Orvepitant and itraconazole|Orvepitant single 20mg dose in combination with repeat dose itraconazole
62760305|NCT02737644||CHD birth cohort|Cases are identified as those whose newborns screened and confirmed with CHD during the follow-up and four age- and delivery-hospital matched controls are selected for each case from the rest of the cohort.
62760306|NCT06034067|EXPERIMENTAL|Osseodensification (test) group|Implant site preparation will be completed using osseodensification technique where tapered multifluted burs (Densah Burs; Versah, MI, USA) will be used as per manufacturer's instructions.
62760307|NCT06034067|ACTIVE_COMPARATOR|Standard (control) group|Implant site preparation will be completed using conventional drilling protocol technique where standardized drills provided by Straumann (Straumann®, Institute Straumann AG, Basel, Switzerland)) will be used as per manufacturer's instructions.
62760308|NCT01684644|EXPERIMENTAL|New Forest Parenting Programme|The New Forest Parenting Programme is a parent training programme specifically developed to treat ADHD in preschool children. The programme is delivered as an 8 week intervention for individual parents and their child.
62760309|NCT01684644|OTHER|Treatment as Usual|Treatment as usual for preschool ADHD consists of psychoeducation groups for parents.
62760310|NCT01155466|EXPERIMENTAL|Preladenant 2 mg|Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks
62760311|NCT01155466|EXPERIMENTAL|Preladenant 5 mg|Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks
62760312|NCT01155466|EXPERIMENTAL|Preladenant 10 mg|Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks
62760313|NCT01155466|PLACEBO_COMPARATOR|Placebo|Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks
62760314|NCT01155466|ACTIVE_COMPARATOR|Rasagiline 1 mg|Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks
62760315|NCT05004038|ACTIVE_COMPARATOR|Early Group|We will conduct a randomized, double-blind trial using a stepped-wedge design and involving a total of 60 patients with stable treated HIV and suppressed viral load who will all receive the BCG vaccine during the course of the study. Patients will be divided into two groups of equal size (early and late groups regarding administration of the BCG verum). The trial will be placebo-controlled and double-blind. Patients in the early group will receive the BCG verum at the beginning of Treatment Phase 1, and then the placebo at the beginning of Treatment Phase 2.
62760316|NCT05004038|ACTIVE_COMPARATOR|Late Group|Patients in the late group will receive placebo at the beginning of Treatment Phase 1 and then the BCG verum at the beginning of Treatment Phase 2.
62760317|NCT02092051|EXPERIMENTAL|Continuous glucose monitoring|Continuous glucose monitoring with DexCom G4 platina during 6 months
62760318|NCT02092051|NO_INTERVENTION|Conventional therapy|Conventional therapy during 6 months using only SMBG for glucose monitoring
62760319|NCT06482320||Study Group|Adults aged between 22 and 70 years and owners of smartwatch capable of EKG recording referred at the ER, Cardiology ward or Cardiology Clinic for palpitation are eligible according to the inclusion criteria.
62760320|NCT04140201|ACTIVE_COMPARATOR|Receive oral hypoglycemic +omega 3|Eicosapentanoic acid + standard treatment
62760321|NCT04140201|ACTIVE_COMPARATOR|Receive oral hypoglycemic +statin|Simvastatin + standard treatment
62760322|NCT04140201|ACTIVE_COMPARATOR|Receive oral hypoglycemic +fibrate|Fenofibrate +standard treatment
62760323|NCT04140201|NO_INTERVENTION|Receive oral hypoglycemic only|Standard treatment only
62760324|NCT04594265|EXPERIMENTAL|Ketone Monoester|Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US) 0.5 g/kg (max 50 g)
62760325|NCT04594265|PLACEBO_COMPARATOR|Placebo Treatment|Maltodextrin-based placebo (Science In Sport, UK) in isocaloric dose to the experimental arm.
62760326|NCT04594265|ACTIVE_COMPARATOR|Ketone Monoester in presence of low-dose insulin clamp|Same as experimental arm, but in the presence of a low-dose insulin clamp to suppress free fatty acid metabolism
62760327|NCT02049190|EXPERIMENTAL|onapristone 10 mg BID|onapristone 10 mg BID extended-release tablets
62760328|NCT02049190|EXPERIMENTAL|onapristone 20 mg BID|onapristone 20 mg BID extended-release tablets
62760329|NCT02049190|EXPERIMENTAL|onapristone 30 mg BID|onapristone 30 mg BID extended-release tablets
62760330|NCT02049190|EXPERIMENTAL|onapristone 40 mg BID|onapristone 40 mg BID extended-release tablets
62760331|NCT02049190|EXPERIMENTAL|onapristone 50 mg BID|onapristone 50 mg BID extended-release
62760332|NCT02049190|EXPERIMENTAL|onapristone 30 mg BID + abiraterone 1000 mg|Expansion cohort: onapristone 30 mg BID + abiraterone 1000 mg
62760333|NCT02049190|EXPERIMENTAL|onapristone 50 mg BID + abiraterone 1000 mg|Expansion cohort: onapristone 50 mg BID + abiraterone 1000 mg
62760334|NCT02049190|EXPERIMENTAL|Expansion cohort: onapristone 50 mg BID|Expansion cohort: onapristone 50 mg BID
62760335|NCT05133713||Catheter directed thrombectomy|
62760336|NCT05133713||Systemic anticoagulation|
62760337|NCT02426775|NO_INTERVENTION|Methylmalonic Acidemia Control Arm|patients with Methylmalonic Acidemia will receive standard therapy only (protein restricted diet, L-carnitine, metronidazole and vitamin B12)
62380958|NCT02875782|PLACEBO_COMPARATOR|Control group|Subjects will receive usual care provided at the DM clinic. All subjects will receive a self-help cessation manual and take the exhaled carbon monoxide test. Counselor will give follow-up calls to the patients to assess their smoking status and other health-related lifestyle practices. Three consecutive (3-, 6- and 12-month) follow ups will be conducted with all participants. The total counseling process will take about 20 minutes.
62380959|NCT00315640|EXPERIMENTAL|Anecortave Acetate 3 mg Depot|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
62760338|NCT02426775|EXPERIMENTAL|Methylmalonic Acidemia Active arm|patients with Methylmalonic Acidemia will receive Carglumic Acid in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12)
62760339|NCT02426775|NO_INTERVENTION|Propionic Acidemia Control Arm|patients with Propionic Acidemia will receive standard therapy only (protein restricted diet, L-carnitine, metronidazole and biotin)
62760340|NCT02426775|EXPERIMENTAL|Propionic Acidemia Active arm|patients with Propionic Acidemia will receive Carglumic Acid in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and biotin)
62760341|NCT04297189|EXPERIMENTAL|Coaching Intervention|Single arm pilot study of coaching intervention
62760342|NCT05617300|EXPERIMENTAL|MBDC course|8 week MBDC Course including 8 weekly 2 hour classes and a retreat (4 hours). Individual classes will be held virtually via web-based video calls.
62760343|NCT01115335|ACTIVE_COMPARATOR|Gomco|NMC performed using a Gomco clamp
62760344|NCT01115335|ACTIVE_COMPARATOR|Mogen clamp|NMC performed using a Mogen clamp
62760345|NCT01115335|ACTIVE_COMPARATOR|Plastibell|NMC performed using a Plastibell device
62760346|NCT01669421|EXPERIMENTAL|Alpha-1 Antitrypsin (human) standard dose baseline|Alpha-1 Antitrypsin (human) 60 mg per kg per week for 4 weeks. Study week 4
62760347|NCT01669421|EXPERIMENTAL|Alpha-1 Antitrypsin (human) Double dose|Alpha-1 Antitrypsin (human) 120 mg/kg per week for 4 weeks. Study week 8
62760348|NCT01669421|EXPERIMENTAL|Alpha-1 Antitrypsin (human) standard dose|4 weeks on A1PI at 60 mg/kg per week after the other 2 phases. Collected@ study week 12
62760349|NCT01053013|EXPERIMENTAL|Macrobead Implantation|patients will undergo up to 4 implantations of RENCA macrobeads (no less than 3 months apart), at an amount of 8 RENCA macrobeads per kilogram of body weight
62182508|NCT01836198|EXPERIMENTAL|LY2409021+Gemfibrozil (Part A, Cohort 1)|Part A, Period 2. Participants will receive a morning (AM) and evening (PM) oral dose of 600 mg gemfibrozil on Days 1-20 and an AM oral dose only of 600 mg gemfibrozil on Day 21. Participants will also receive a single 20-mg oral dose of LY2409021 on Day 4.
62380960|NCT00315640|EXPERIMENTAL|Anecortave Acetate 15 mg Depot|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
62380961|NCT00315640|EXPERIMENTAL|Anecortave Acetate 30 mg Depot|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
62380962|NCT00315640|OTHER|Anecortave Acetate Vehicle|
62380963|NCT02020564|EXPERIMENTAL|Treatment Group|Computerized exercised will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
62760350|NCT04192968||Patients|Children implanted cochlear since 3 years in uni or bilateral and followed in the pediatric otolaryngology department of Necker-Enfants Malades Hospital.
62760351|NCT04192968||Patients with disappointing language development or poor cortical responses|Children having participated in the main ImplantHear3 study and who present with disappointing language development or poor cortical responses.
62760352|NCT06536205|EXPERIMENTAL|experimental group|An 8-week training based on acceptance and commitment therapy will be applied to this group.
62760353|NCT06536205|NO_INTERVENTION|control group|There will be no intervention in this group. Only relevant forms will be filled out.
62760354|NCT01084278|EXPERIMENTAL|Healthy|Healthy participants with normal renal function (Creatinine Clearance \[CrCl\] ≥90 mL/min) received one colchicine 0.6 mg tablet on study day 1.
62760355|NCT01084278|EXPERIMENTAL|Mild renal impairment|Participants with mild renal impairment (estimated Glomerular Filtration Rate \[eGFR\] 60 to 89 mL/min) received one colchicine 0.6 mg tablet on study day 1.
62380964|NCT02020564|PLACEBO_COMPARATOR|Placebo control group|Computerized exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
62760356|NCT01084278|EXPERIMENTAL|Moderate renal impairment|Participants with moderate renal impairment (CrCl/eGFR 30 to 59 mL/min) received one colchicine 0.6 mg tablet on study day 1.
62760357|NCT01084278|EXPERIMENTAL|Severe renal impairment|Participants with severe renal impairment (eGFR 15 to 29 mL/min) received one colchicine 0.6 mg tablet on study day 1.
62760358|NCT01084278|EXPERIMENTAL|End stage renal disease (ESRD)|Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on study day 1 immediately following dialysis. After a 14-day washout, participants received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.
62760359|NCT05879367|EXPERIMENTAL|Eflornithine Dose Level 1 + Temozolomide|
62760360|NCT05879367|EXPERIMENTAL|Eflornithine Dose Level 2 + Temozolomide|
62760361|NCT05879367|EXPERIMENTAL|Eflornithine Dose Level -1 + Temozolomide|
62760362|NCT03663530|EXPERIMENTAL|Circadian misalignment|Meals in this condition will be delayed by 4 hours relative to the circadian alignment condition. Food intake during this period will be from 1 PM to 11 PM.
62558601|NCT03334929|EXPERIMENTAL|Virtual Reality intervention|Participants will be wearing Virtual Reality headset called Oculus gear equipped with Samsung galaxy S7 during the trigger point injections. The VR app chosen is called Relax VR - Rest, Relaxation \& Meditation, which will provide a calm beach scene with waves and soothing musics.
62558602|NCT03334929|NO_INTERVENTION|control|Participants in this group will receive trigger point injections without any intervention. The trigger point injections will be performed in daily manner.
62760363|NCT03663530|ACTIVE_COMPARATOR|Circadian alignment|Meals in this condition will be aligned to the sleep episode. Food intake during this period will be from 9 AM to 7 PM.
62760364|NCT05553964|EXPERIMENTAL|Study Groups|"Positives: Symptomatic vs. Asymptomatic Negatives: Symptomatic vs. Asymptomatic~Each broken down by age groups:~2-14 years old 15-24 years old 25-64 years old 65+ years old"
62182509|NCT01836198|EXPERIMENTAL|LY2409021 Only (Part A, Cohort 2)|Part A, Period 1. Participants will receive a single 20-mg oral dose of LY2409021 on Day 1.
62380965|NCT04377399|ACTIVE_COMPARATOR|high dose|vitamin D (40,000 IU weekly) for 24 weeks
62380966|NCT04377399|ACTIVE_COMPARATOR|Low dose|vitamin D (5,000 IU weekly) for 24 weeks
62760365|NCT04451824|EXPERIMENTAL|Intervention with Routine Use of Red Light|Routine Use of red light (635nm) for 30 minutes on patients is to be observed in relation to its effect(s) in achieving circumferential reduction of the thighs, hips and waist of the patient, and a contour reduction of any protrusion of fat.
62380967|NCT02140762|EXPERIMENTAL|MenABCWY|Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months
62760366|NCT03797118|EXPERIMENTAL|FFRct|Patients will receive cCTA, ICA, FFRct, and FFRinv per protocol.
62760367|NCT05961969||Patients undergoing robotic Transabdominal Top-down Intersphincteric Resection|Patients undergoing robotic Transabdominal Top-down Intersphincteric Resection with Double-stapling Coloanal Anastomosis
62760368|NCT05985278|EXPERIMENTAL|[ Lu-177]-Catalase|Participants received \[ Lu-177\]-Catalase intratumoral injection
62760369|NCT02124512|EXPERIMENTAL|Arm 1 Rifaximin SSD|Subjects randomized to this arm of the study will receive 80 mg per day Rifaximin SSD
62380968|NCT02140762|ACTIVE_COMPARATOR|Placebo/MenACWY|Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months
62380969|NCT05869526|ACTIVE_COMPARATOR|Fish oil|Fish oil 4 g/day
62760370|NCT02124512|PLACEBO_COMPARATOR|Arm 2 Placebo|Placebo
62760371|NCT02501317|EXPERIMENTAL|Active Perineal Rehabilitation protocol|"study group that will be treated with Active Perineal Rehabilitation protocol"
62760372|NCT02501317|ACTIVE_COMPARATOR|Kari Bo protocol|control group will be treated with the protocol already widely used
62760373|NCT05873179||Role-playing for learning the clinical interview|
62760374|NCT06508268||Persons with Mild Cognitive Impairment due to AD|
62760375|NCT06508268||Persons with mild AD|
62760376|NCT06508268||Persons with moderate AD|
62760377|NCT06508268||Persons without cognitive impairment, age-matched with persons with MCI due to AD and AD|
62760378|NCT02580383||Group none|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.~When both needles were positioned inadequately for a facet joint."
62760379|NCT02580383||Group partial|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.~when one of the needles for a facet joint medial branch was placed inadequately."
62760380|NCT02580383||Group complete|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.~When all needles were placed adequately.'"
62760381|NCT04710407|EXPERIMENTAL|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will receive a total of five doses of TBPM-PI-HBr 600 mg orally every 8 hours.
62760382|NCT01628367|EXPERIMENTAL|Membrane|Test (membrane): Extraction and immediate implant placement will be performed. The gaps between the implant and socket walls will be filled with a bone graft material. Sites in the test group will receive a high-density PTFE (d-PTFE) membrane over the socket.
62760383|NCT01628367|ACTIVE_COMPARATOR|Collagen plug|Control (collagen plug): Extraction and immediate implant placement will be performed. The gaps between the implant and socket walls will be filled with a bone graft material. Sites in the control group will receive a collagen wound dressing over the socket.
62760384|NCT01011933|EXPERIMENTAL|Treatment (selumetinib)|Patients receive selumetinib PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Blood and archived tumor tissue samples are collected for biomarker studies.
62760385|NCT05693142|EXPERIMENTAL|RGX-202 Dose 1|A single IV infusion of RGX-202 at a dose of 1×10\^14 GC/kg body weight
62760386|NCT05693142|EXPERIMENTAL|RGX-202 Dose 2|A single IV infusion of RGX-202 at a dose of 2x10\^14 GC/kg body weight
62760387|NCT02352636|ACTIVE_COMPARATOR|Treatment arm 1|"Subjects will receive magnetotherapy (MAT). The magnetic pellets will contain an average of \~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm. The experimental object will be applied to the reactive region of each of the six selected acupoints as detected by an acupoint detector. The justifications for selecting these acupoints are described below. To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation prior to the application of MAT. Subjects will be asked to wear a pair of laser protective goggles to blind them during therapy administration."
62760388|NCT02352636|ACTIVE_COMPARATOR|Treatment arm 2|Subjects will receive laser auriculotherapy (LAT). A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use12, 26. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear. Laser protective goggles will be provided to the subjects and the researchers for eye protection. Similarly, a plaster without magnetic pellets that mimics MAT treatment will be applied on these six acupoints after LAT.
62760389|NCT02352636|EXPERIMENTAL|Treatment arm 3|Subjects will receive a combined approach using MAT and LAT. LAT will be administered prior to the application of MAT on the selected auricular points, which would be implemented similar to the procedures in treatment arm 1 and 2.
62380970|NCT05869526|ACTIVE_COMPARATOR|Krill oil|Krill oil 4g/day
62380971|NCT05869526|PLACEBO_COMPARATOR|Placebo|Vegetable oil 4g/day
62380972|NCT03416036|EXPERIMENTAL|Arm 1: TV003 + rDEN2Δ30-7169|Participants will receive a single dose of TV003 at study entry (Day 0) and rDEN2Δ30-7169 on Day 28.
62760390|NCT02352636|PLACEBO_COMPARATOR|Placebo arm|"Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment."
62760391|NCT00989235|ACTIVE_COMPARATOR|Abatacept (10 mg/Kg)|
62558603|NCT02783495|EXPERIMENTAL|Device: iPad|Patients with brain tumors receive an iPad with the ReMind app. The patients will use the app to train neurocognitive and compensatory skills for 3 hours per week over the course of 12 weeks (36 hours in total)
62380973|NCT03416036|EXPERIMENTAL|Arm 2: TV003 + rDEN3Δ30|Participants will receive a single dose of TV003 at study entry (Day 0) and rDEN3Δ30 on Day 28.
62380974|NCT03416036|PLACEBO_COMPARATOR|Arm 3: Placebo + rDEN2Δ30-7169|Participants will receive placebo at study entry (Day 0) and rDEN2Δ30-7169 on Day 28.
62380975|NCT03416036|PLACEBO_COMPARATOR|Arm 4: Placebo + rDEN3Δ30|Participants will receive placebo at study entry (Day 0) and rDEN3Δ30 on Day 28.
62380976|NCT03511729||A single exposure to general anesthesia|Participants who have surgery under general anesthesia (without anesthesia/surgery before)
62760392|NCT00989235|ACTIVE_COMPARATOR|Abatacept (5 mg/Kg)|
62760393|NCT02801279|EXPERIMENTAL|Kinect-based bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
62760394|NCT02801279|EXPERIMENTAL|Conventional bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
62760395|NCT02291848|EXPERIMENTAL|Group A|Patients receiving TAA-specific CTLs as therapy for Myeloma
62760396|NCT02291848|EXPERIMENTAL|Group B|Patients receiving TAA-Specific CTLs as adjunctive therapy following autologous or syngeneic transplant for myeloma
62760397|NCT02291848|EXPERIMENTAL|Group C|Patients with high risk MGUS or smoldering myeloma receiving a fixed dose TAA-Specific CTLs
62760398|NCT01437527|EXPERIMENTAL|Interventional arm|Body image therapy with Anamorphic Micro software
62760399|NCT01437527|ACTIVE_COMPARATOR|control arm|Body image therapy as usual
62760400|NCT02947165|EXPERIMENTAL|NIS793|
62760401|NCT02947165|EXPERIMENTAL|NIS793 + PDR001|
62760402|NCT01804712|EXPERIMENTAL|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
62760403|NCT00594542|EXPERIMENTAL|0.5% lidocaine group|Group that receives 0.5% lidocaine with 1:200,000 epinephrine
62760404|NCT00594542|EXPERIMENTAL|1.0% lidocaine group|Group that receives 1.0% lidocaine with 1:100,000 epinephrine
62760405|NCT06131944|EXPERIMENTAL|Rested & Ready to Learn|All participants will receive the four-week Rested \& Ready to Learn sleep promotion program which includes text messaging to parents, home activities for parents and children to complete together, and brief classroom lessons.
62760406|NCT00723346|EXPERIMENTAL|1|
62760407|NCT00723346|EXPERIMENTAL|2|
62760408|NCT00723346|EXPERIMENTAL|3|
62760409|NCT00723346|ACTIVE_COMPARATOR|4|
62760410|NCT00457977|ACTIVE_COMPARATOR|Pneumovax (PPSV23)|pneumococcal capsular polysaccharide vaccine (PPSV23) (Pneumovax)
62760411|NCT00457977|ACTIVE_COMPARATOR|Prevnar (PCV7)|diphtheria protein-conjugated vaccine (PCV7) (Prevnar) 1.0 mL dose
62760412|NCT03094286|EXPERIMENTAL|Arm 1|Durvalumab (MEDI4736) monotherapy at the recommended dose of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients
62760413|NCT00031746|ACTIVE_COMPARATOR|soy protein + isoflavones|
62760414|NCT00031746|ACTIVE_COMPARATOR|casein proteins|
62760415|NCT01822535|NO_INTERVENTION|No Drug: Tetraplegia|"Tetraplegia: Lesion level T1 and above, American Spinal Injury Association (ASIA) impairment levels A and B, ages 18-68 years.~Exposure of up to 2 hours in a cool room."
62760416|NCT01822535|NO_INTERVENTION|No Drug: AB Controls|AB Controls: Matched for age and gender to subjects with tetraplegia. Exposure of up to 2 hours in a cool room.
62760417|NCT01822535|EXPERIMENTAL|Drug (midodrine): Tetraplegia|Persons with tetraplegia who completed Visit 1 (no drug). Participants are administered midodrine hydrochloride (10 mg tablet) by a physician before exposure of up to 2 hours in a cool room. (Visit 2)
62760418|NCT00670176|EXPERIMENTAL|I|
62760419|NCT04031274||TAVI no MR|Patients undergoing TAVI with MR up to moderate following the procedure
62380977|NCT03511729||Multiple exposures to general anesthesia|Participants who have surgery under general anesthesia (had anesthesia/surgery before)
62380978|NCT03085342|EXPERIMENTAL|Liver MRI|Liver MRI including noncontrast (precontrast) flow measurement, DCE, DWI using multiple b-values, MRE and MR fat quantification.
62380979|NCT06459856|EXPERIMENTAL|Balloon Blowing, Percussion|intervention will be given as blowing 10-15 balloons per day for 6 days. 05.minutes active cycle of breathing technique as baseline 10 minute to blowing 15 balloons 10 minutes percussion 25 minutes session
62760420|NCT04031274||TAVI + MR no further intervention|Patients undergoing TAVI with MR more than moderate following the procedure, no further mitral valve intervention
62760421|NCT04031274||TAVI + MR undergoing TMVR/r|Patients undergoing TAVI with MR more than moderate following the procedure, underwent transcatheter mitral valve intervention
62760422|NCT05347940|EXPERIMENTAL|Study group (A)|Study group (A):15 patient received traditional physical therapy program in addition to motor imagery in form of mirror therapy.
62760423|NCT05347940|EXPERIMENTAL|Study group (B)|Study group (B):15 patient received traditional physical therapy program only.
62760424|NCT06276218|EXPERIMENTAL|self-adjustable clavicular brace|
62760425|NCT06276218|ACTIVE_COMPARATOR|standard clavicular brace|
62760426|NCT03395301|EXPERIMENTAL|tubal occlusion|Fiber coils were inserted into the interstitial part of fallopian tubes, and IVF-ET was taken out in the following.
62760427|NCT03833570|EXPERIMENTAL|Melatonin therapy|"Rapid Release Capsules Melatonin, 10 mg in combination with the symptomatic treatment~Symptomatic treatment which included:~* Miconaz oral gel~* BBC oral spray~* Oracure gel~* Alkamisr sachets~Melatonin capsules dose: Two tablets,30 minutes before sleeping once daily for six weeks~Symptomatic treatment dose: Three times a day for six weeks"
62760428|NCT03833570|ACTIVE_COMPARATOR|Conventional therapy|"Conventional therapy (symptomatic treatment) which included:~* Miconaz oral gel~* BBC oral spray~* Oracure gel~* Alkamisr sachets~Dose: Three times a day for six weeks"
62380980|NCT06459856|ACTIVE_COMPARATOR|Perccussion|intervention Will be given as Buteyko breathing techniques for 3 weeks. 15 Minutes ACBT with rest interval 10 minutes percussion 25 minutes session
62380981|NCT05178511|EXPERIMENTAL|hydrochloric acid ensartinib|Ensatinib 225mg daily, QD, until progression or intolerance
62380982|NCT04631757|EXPERIMENTAL|Camrelizumab plus Chemoradiotherapy|Patients with initial unresectable proximal gastric or gastroesophageal junction (GEJ) adenocarcinoma will receive camrelizumab 200mg q3w, SOX regimen (oxaliplatin 130mg/m2, d1, Q3w + S-1 40-60mg bid, d1-d14, Q3w), and intensity modulated radiotherapy for tumors and high-risk lymphatic drainage areas (45Gy/25d). Resectable patients after conversion therapy will receive D2 resection.
62380983|NCT04073472|EXPERIMENTAL|mesenchymal stem cells (MSCs)|Direct injection of 75 million allogeneic bone marrow derived mesenchymal stem cells (MSC) into ileal pouch fistula at baseline and possibly again after 3 months if not completely healed.
62558604|NCT06573931|EXPERIMENTAL|Lumbar Erector Spinae Plane Block|Patients will receive lumbar erector spinae plane block at the end of surgery.
62760429|NCT02496845|EXPERIMENTAL|Group A|Topical treatment and PK. Administration of VL#FIA3-30 (dual administration of MH30-01 \& IS045-01)
62760430|NCT02496845|EXPERIMENTAL|Groups B, C, D|Dual topical biweekly administration and intraurethral. Triple topical weekly administration. Multiple topical administration. Administration of VL#FIA3-30 (dual administration of MH30-01 \& IS045-01)
62760431|NCT02491034|OTHER|Intervention|Depression Education Intervention
62760432|NCT04643639|EXPERIMENTAL|Active|
62380984|NCT06039540||Modified Drug Therapy Group|Patient in this group will undergo a one-year course of medication, including Captopril(tablet, 0.3mg/kg, tid), Metoprolol(tablet, 0.2mg/kg, bid), Spironolactone(tablet, 2-4mg/kg, bid), Torsemide(tablet, 0.2-0.5mg/ mg, bid), and Potassium Citrate(powder, 0.06g/kg, tid).e Traditional Drug Therapy Group
62558605|NCT06573931|EXPERIMENTAL|Fascia Iliaca Block|Patients will receive fascia iliaca block at the end of surgery.
62380985|NCT06039540||Traditional Drug Therapy Group|Patient in this group will undergo a one-year course of medication, including Torsemide(tablet, 0.2-0.5mg/mg, bid) and Potassium Citrate(powder, 0.06g/kg, tid).
62558606|NCT06573931|EXPERIMENTAL|Lumbar Plexus Block|Patients will receive lumbar plexus block at the end of surgery.
62558607|NCT00107627|ACTIVE_COMPARATOR|1|Skin staples;
62558608|NCT00107627|ACTIVE_COMPARATOR|2|Monocryl subcuticular sutures.
62760433|NCT04643639|NO_INTERVENTION|Control|
62760434|NCT05853055|EXPERIMENTAL|Post-COVID-19 (respiratory training and monitoring)|Post-COVID-19 patients allocated to this arm get an additional respiratory training added to their conventional rehabilitation program. Patients will train twice daily for the length of their rehabilitation stay. An incentive spirometer (Voldyne 5000 R, Sherwood Medical, St. Louis, USA) will be used to complete training sessions of 15 mins each.
62760435|NCT05853055|NO_INTERVENTION|Post-COVID-19 (control and monitoring)|Patients receive the same therapeutical interventions as the Post-COVID19 respiratory training arm excluding respiratory training.
62760436|NCT01165320|EXPERIMENTAL|Participants with Esophageal Candidiasis|Candida infection is strongly suspected based on clinical symptoms and the participant's clinical course, white moss (plaque) is observed on the esophageal mucosa, and therapy via intravenous infusion is judged to be suitable for the present episode of esophageal candidiasis. MK-0991 therapy as a single loading dose of 70 mg/m\^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m\^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 7 and 28 days, respectively.
62760437|NCT01165320|EXPERIMENTAL|Participants with Invasive Candidiasis|Candida infection is strongly suspected based on the presence of refractory fever not responding to an antibiotic agent, or clinical symptoms at the site of disease, or the participant's clinical course. In addition, at least 1 of the following criteria must be met: 1) Candida infection is strongly suspected based on radiographic imaging findings and positive serological test for fungus, 2) yeast is observed by direct microscopy or histopathological test of tissue biopsied from the site of disease, or 3) Candida species are observed by culture test of specimens sampled from the site of disease. MK-0991 therapy as a single loading dose of 70 mg/m\^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m\^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 14 and 56 days, respectively.
62760438|NCT01165320|EXPERIMENTAL|Participants with Aspergillosis|Aspergillus infection is strongly suspected based on clinical symptoms and the participant's clinical course, and characteristic radiographic imaging findings are observed. In addition, at least 1 of the following criteria must be met: 1) risk factors predisposing to an Aspergillus infection, 2) positive serological test for Aspergillus, 3) acute-branching mold with separated hyphae are observed by direct microscopy or histopathological test, or 4) Aspergillus species are observed by culture test. MK-0991 therapy as a single loading dose of 70 mg/m\^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m\^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 14 and 84 days, respectively.
62760439|NCT03859518||patients with Vitiligo|
62760440|NCT03859518||control|
62760441|NCT04224272|EXPERIMENTAL|ZW25 (zanidatamab) + palbociclib + fulvestrant|ZW25 (zanidatamab) plus palbociclib, fulvestrant
62380986|NCT02294370||subjects at the early stages of diabetes|Subjects at the early stages of diabetes, individuals with impaired glucose tolerance (IGT, 2h plasma glucose during oral glucose tolerance test \>7.8-11.1 mmol/l (n=50) or with type 2 diabetes (fasting plasma glucose \> 7.0 mmol/l and/or 2h plasma glucose \> 11.1 mmol/l on two occasions, or both criteria fulfilled in same oral glucose tolerance test while not pregnant, n=50) with short duration (\<3 years)
62380987|NCT03000413|EXPERIMENTAL|Ketamine|Intravenous ketamine infusion: bolus 2mg per kg and continuous infusion (2mg/kg/h)
62380988|NCT03000413|ACTIVE_COMPARATOR|Fentanyl|Fentanyl: bolus infusion 1μg per kg and continuous infusion (1μg/kg/h)
62380989|NCT05571852|EXPERIMENTAL|Computerized Cognitive Training|Participants will be asked to complete short sessions of around 10 minutes each consisting of a variety of games designed to train the five cognitive skills (attention, memory, coordination, reasoning and perception). Each training session include two games selected among a pool of 12 different games. Participants will be asked to complete a training lasting for 8 weeks in which they could access the training platform as frequently as they wanted.
62380990|NCT05487092|EXPERIMENTAL|Letrozole|They will be given letrozole 2.5mg daily on top of combined oral contraceptive (COC) pills (Microgynon 30, which contains 30mcg ethinyloestradiol and 150 mcg levonorgestrel) orally for 6 months after laparoscopic ovarian cystectomy, followed by COC pills alone subsequently as routine
62380991|NCT05487092|PLACEBO_COMPARATOR|Standard treatment|They will be given placebo tablets (which will be identical to letrozole) on top of COC pills (Microgynon 30, which contains 30mcg ethinyloestradiol and 150 mcg levonorgestrel) orally for 6 months after laparoscopic ovarian cystectomy, followed by COC pills alone subsequently
62760442|NCT05135858|EXPERIMENTAL|CPG2|6 infusions of glucarpidase
62760443|NCT00541099|EXPERIMENTAL|Avastin & Docetaxel|Avastin 10.0 mg/kg on days 1 and 15; Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel; Docetaxel 35 mg/m2 on day 1, 8, 15
62380992|NCT01845766|EXPERIMENTAL|rehabilitation arm|daily standardized exercise rehabilitation during the admission period, and daily standardized self exercise after discharge
62380993|NCT01845766|NO_INTERVENTION|control arm|
62380994|NCT05119998|EXPERIMENTAL|IBI325 and sintilimab combination does-escalation|
62380995|NCT05119998|EXPERIMENTAL|IBI325 monotherapy does-escalation|
62380996|NCT02282774|EXPERIMENTAL|SB|receive subtenon block of 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture
62380997|NCT02282774|SHAM_COMPARATOR|C|receive subtenon block of 4mL saline
62380998|NCT04460391|EXPERIMENTAL|experimental group|Early standing training and routine rehabilitation
62380999|NCT04460391|ACTIVE_COMPARATOR|control group|Conventional rehabilitation，Muscle training and breathing training
62381000|NCT02858596|EXPERIMENTAL|Semi-solid feed group|Given semi-solid feed protocol
62381001|NCT02858596|PLACEBO_COMPARATOR|Liquid feed group|Given liquid feed protocol
62381002|NCT01211366|ACTIVE_COMPARATOR|Conventional Transfusion|Infants will receive PRBCs, crystalloid, and colloid for hemodynamic instability per the usual routine at the discretion of the attending intensive care physician
62381003|NCT01211366|EXPERIMENTAL|Cell Saver|Infants will receive washed cell-saver RBCs for hemodynamic instability in the first 24 hours post-operative period as long as Hgb is \< 13 gm/dL and cell-saver is available.
62381004|NCT00696540|EXPERIMENTAL|1|Salbutamol is diluted in hypertonic (3%) saline.
62381005|NCT00696540|ACTIVE_COMPARATOR|2|Salbutamol is diluted in normal (0.9%) saline.
62381006|NCT05376241||Women age 39-49 in the United States|The group is women age 39-49 in the United States who receive a decision aid intervention. The intervention is a breast cancer screening decision aid with information about screening guidelines, breast cancer mortality reduction, false positives, overdiagnosis, and a personal breast cancer risk estimate.
62381007|NCT03106857|PLACEBO_COMPARATOR|Group A|Physical activity, a low caloric diet, and the routine standard care for constipation
62381008|NCT03106857|NO_INTERVENTION|Group B|No intervention
62760444|NCT05910125|EXPERIMENTAL|DAPT group|Receiving dual antiplatelet therapy immediately after randomization (Oral aspirin 100mg+clopidogrel 300mg, Day 1). Participants who show no evidence of intracranial hemorrhage on skull CT 24 hours after randomization will receive oral aspirin 100mg/d (Day 2-90) and clopidogrel 75mg/d (Day 2-21), while those with intracranial hemorrhage on skull CT will not receive any antiplatelet drugs.
62381009|NCT05528159||Robotic and Laparoscopic Urologic Surgery Group|Patients scheduled for robotic/laparoscopic urologic surgeries that will be performed under supine and trendelenburg position
62381010|NCT02417935|EXPERIMENTAL|Duloxetine|20 milligrams (mg) duloxetine orally once a day (QD) for one week and then 40 mg duloxetine orally QD for 3 weeks. Duloxetine dosage may be increased up to 60 mg QD at week 4 or week 8. Placebo will be given with duloxetine for blinding. Dosage will be tapered down during the final week of the study.
62381011|NCT02417935|ACTIVE_COMPARATOR|Pregabalin|150 mg pregabalin orally twice a day (BID) for 1 week and then 300 mg pregabalin orally BID for 3 weeks. Pregabalin dosage may be increased up to 450 mg BID at week 4 or 8, and increased up to 600 mg BID at week 8. Placebo will be given with pregabalin for blinding. Dosage will be tapered down during the final week of the study.
62381012|NCT02352181|PLACEBO_COMPARATOR|S group|S Group: will be transfused patients according to standard management based on conventional coagulation profile of the laboratory
62381013|NCT02352181|EXPERIMENTAL|R group|The R group will consist of patients transfused according to an algorithm based on the data of the coagulation ROTEM analysis.
62760445|NCT05910125|ACTIVE_COMPARATOR|IVT group|Receiving intravenous thrombolysis immediately after randomization (Intravenous alteplase, 0.9mg/kg, a maximum dosage of 90mg). Participants who show no evidence of intracranial hemorrhage on skull CT 24 hours after randomization will receive oral aspirin 100mg/d (Day 2-90), while those with intracranial hemorrhage on skull CT will not receive any antiplatelet drugs.
62760446|NCT01363180||Control|
62760447|NCT01363180||Trauma-exposed without PTSD|
62760448|NCT01363180||Trauma-exposed with PTSD|
62760449|NCT05999526|EXPERIMENTAL|Reconnection to mechanical ventilation for 1 hour|As soon as the success of the spontaneous breathing trial is confirmed, the participant will be kept on the mechanical ventilator for 1 hour using the previous ventilatory parameters and, afterwards, extubated.
62381014|NCT05168189||Ivabradine Group|patients with chronic coronary syndrome using Ivabradine for heart rate control or as anti-anginal treatment.
62760450|NCT05999526|ACTIVE_COMPARATOR|Direct extubation|The participant will be extubated immediately after the spontaneous breathing trial.
62760451|NCT04414124|OTHER|KB109 + Self Supportive Care (SSC)|
62760452|NCT04414124|OTHER|Self Supportive Care (SSC) Alone|
62760453|NCT01300819|PLACEBO_COMPARATOR|Placebo|
62760454|NCT01300819|EXPERIMENTAL|Rotigotine|
62760455|NCT02421913|ACTIVE_COMPARATOR|S(+)-ketamine group (SG)|Five minutes before surgery, patients in the SG group received an intravenous continuous infusion containing 0.3 mg.kg-1.h-1 of S(+)-ketamine
62760456|NCT02421913|PLACEBO_COMPARATOR|placebo group (PG)|PG received the same dose of saline.
62760457|NCT06061289|NO_INTERVENTION|Education and healthy diet|The healthy diet education session included a PowerPoint presentation on healthy dietary guidelines and sample recipes of healthy meals.
62381015|NCT05168189||Non-Ivabradine Group|patients with chronic coronary syndrome NOT using Ivabradine for heart rate control or as anti-anginal treatment.
62381016|NCT02946268|EXPERIMENTAL|Volume of bolus|Ropivacaine 0.2% volume increased or decreased by 1ml based on previous patient experience. If pain greater than or equal to 5/10 in the previous patient, the current patient will receive an increase in volume of bolus by 1ml. If pain is less than 5/10 in the previous patient the current patient will receive a decrease in volume by 1ml.
62558609|NCT00107627|ACTIVE_COMPARATOR|3|Caprosyn subcuticular sutures.
62760458|NCT06061289|EXPERIMENTAL|Detox|The guided component of the detoxification program included an additional PowerPoint presentation with the information about the investigational product, directions, and dosing information for its consumption.
62760459|NCT05210868|EXPERIMENTAL|CM355|"1. Dose Escalation Phase CM355~2. Dose Expansion Phase CM355"
62760460|NCT05226091|EXPERIMENTAL|Intervention arm|GP practices randomised to the intervention will receive a mail and email about the result of the PLEASANT study and advising them to implement the study findings.
62760461|NCT05226091|NO_INTERVENTION|Usual care arm|GP practices randomised to control will not receive either mail or email and they will continue with usual care.
62760462|NCT00579995|ACTIVE_COMPARATOR|N-Acetylcysteine|Oral N-Acetylcysteine 600 mg
62760463|NCT00579995|ACTIVE_COMPARATOR|Sodium Bicarbonate|Sodium bicarbonate 3 milliliter per kilogram per hour (3 mL/kg/hr) infused at 1 mL/kg/hr for 6 hours post-procedure
62381017|NCT02946268|EXPERIMENTAL|Rate of delivery of bolus|Ropivacaine 0.2% rate increased or decreased by 50ml/hr based on previous patient experience. If pain greater than or equal to 5/10 in the previous patient at 30 minutes, the current patient will receive an increase in rate of bolus by 50ml/hr. If the pain is less than 5/10 the rate will be decreased by 50ml/hr.
62760464|NCT04896203||Group 1|Ulcerative Colitis or Crohn's Disease patients, in remission according to inclusion criteria
62381018|NCT02946268|EXPERIMENTAL|Interval between bolus|Ropivacaine 0.2% interval increased or decreased by 1 hour based on previous patient experience. If the previous patient received pain score of 2/10 at 2 hours then the current patient will have an interval of three hours. If the pain is greater than 2/10, the interval will be shortened by 1 hour.
62381019|NCT00911144|EXPERIMENTAL|Synflorix Group|Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.
62760465|NCT04896203||Group 2|Ulcerative Colitis or Crohn's Disease patients, with activity defined by the inclusion criteria
62760466|NCT01376570|EXPERIMENTAL|Contingency Management arm|The Contingency Management arm will receive the abstinence-reinforcing contingency management intervention.
62760467|NCT01376570|ACTIVE_COMPARATOR|Control arm|The Control arm will receive the performance feedback intervention.
62760468|NCT01763320|EXPERIMENTAL|Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
62760469|NCT01763320|ACTIVE_COMPARATOR|medical group|all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
62760470|NCT05545202|OTHER|A: Pentaisomaltose 16 %|Pentaisomaltose 40 % sterile solution; 40 mL will be transferred to a total volume of 100 mL, so the final concentration is 16 %.
62760471|NCT05545202|ACTIVE_COMPARATOR|B: DMSO 10 %|"Comparator:~DMSO 99.9 % sterile solution; 10 mL will be transferred to a total volume of 100 mL, so the final concentration is 10 %."
62760472|NCT02130336|EXPERIMENTAL|Aerobic interval training|"Frequency: Exercise 3 times a week. Twice under supervision and home exercise once a week.~Duration: Totally 40 minutes in one session. Intensity: 10-minute warm-up and 5-minute cool-down at 40% maximal heart rate (HRmax), participants and exercise 4-minute high-intensity training at 85-90% HRmax and 4 times separated by 3-minute active recovery at 70% HRmax.~Type: Using treadmill while under supervision."
62760473|NCT02130336|EXPERIMENTAL|Continuous moderate-intensity exercise|"Frequency: 5 times a week. Twice under supervision and home exercise 3 times a week.~Duration: Totally 45 minutes per session. Intensity: 10-minute warm-up at 40% maximal heart rate (HRmax), 30-minute moderate intensity exercise at 50-70% HRmax and 5-minute cool-down at 40% HRmax Type: Using treadmill under supervision."
62760474|NCT02130336|NO_INTERVENTION|Control group|Subjects in control group will receive general exercise knowledge and counseling.
62760475|NCT05863923|EXPERIMENTAL|Intervention|The M2Q2-HIV intervention includes 3 functions: 1) Extended CHW services, 2) M2Q2 computer-tailored peer messaging, and 3) texting facilitation to quitline use and the quitline intervention. Our goals are to promote the use of an underused, available, government-funded resource for public health (quitline) and NRT that the quitline provides, thus promoting smoking cessation among PLWH.
61987442|NCT02301273|EXPERIMENTAL|Enhanced Physiotherapy|Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (\>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
62381020|NCT00911144|ACTIVE_COMPARATOR|Prevenar Group|Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.
62381021|NCT01568983|PLACEBO_COMPARATOR|Control|"12 weeks intake of 0.5 liter/day placebo juice containing sugar, aromas and salt corresponding to the berry juices in the other groups.~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
62381022|NCT01568983|ACTIVE_COMPARATOR|Mana-juice|"12 weeks intake of 0.5 liter/day of a commercially available berry juice (Mana blue) rich in polyphenols (grape, cherries, bilberries and aronia).~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
62760476|NCT05863923|ACTIVE_COMPARATOR|Comparison|"Comparison smokers will receive five brief risk of smoking texts as minimal texting intervention, to enhance blinding to knowledge of randomization group."
62760477|NCT03693313|EXPERIMENTAL|CrossFit KAMP Group 1|14 weeks of CrossFit Kids exercise program
62760478|NCT03693313|ACTIVE_COMPARATOR|CrossFit KAMP Wait-list Group|Waitlist group that waits 14 weeks while group 1 does exercise program. After first 14 weeks will then participate in 14 weeks of CrossFit Kids exercise program
62760479|NCT01170598|EXPERIMENTAL|Exercise|
62760480|NCT01134406|EXPERIMENTAL|Hydros Joint Therapy|Experimental viscosupplement.
62760481|NCT01134406|EXPERIMENTAL|Hydros-TA Joint Therapy|Experimental viscosupplement.
62760482|NCT01134406|ACTIVE_COMPARATOR|Synvisc-One|Commercial control.
62760483|NCT04128982||Videolaryngoscopy|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
62760484|NCT04690920|NO_INTERVENTION|Control|
62760485|NCT04690920|EXPERIMENTAL|Tocilizumab|
62760486|NCT04690920|EXPERIMENTAL|Remdesivir|
62760487|NCT04690920|ACTIVE_COMPARATOR|Standard Treatment|
62760488|NCT06455410|EXPERIMENTAL|GP combined with adebrelimab neoadjuvant therapy+CCRT|Adebrelimab (1200mg) to be administered on Day 1 of the Lead-in Phase (-14 days to the start of the neoadjuvant chemoimmunotherapy phase). Patients receive neoadjuvant therapy with gemcitabine (1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) and adebrelimab (given 1200mg on day 1) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1, D22, D43 of RT).
62760489|NCT06455410|ACTIVE_COMPARATOR|GP neoadjuvant therapy+CCRT|Patients receive neoadjuvant therapy with gemcitabine (1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1, D22, D43 of RT).
62760490|NCT00973882|EXPERIMENTAL|Carboplatin-Etoposide|
62760491|NCT06105086|EXPERIMENTAL|medical doctors and clinical laboratory managers|Semi-structured interviews
62760492|NCT04465877|EXPERIMENTAL|JTT-662 5 mg|JTT-662 5 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
62760493|NCT04465877|EXPERIMENTAL|JTT-662 10 mg|JTT-662 10 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
62760494|NCT04465877|EXPERIMENTAL|JTT-662 20 mg|JTT-662 20 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
62760495|NCT04465877|PLACEBO_COMPARATOR|Placebo|Placebo orally once daily from Day -1 to Day 28
62760496|NCT05173415|EXPERIMENTAL|Sirius Pintution Group|Patients who are randomized for the Pintution Clip will receive a preoperative ultrasound-guided marking in the axillary lymph nodes that indicate for surgical removal. Surgical procedure is standardized with a handheld probe leading intraoperatively to the marked lymph node and its excision. Successful detection, time of the procedure (beginning of localization intervention to completed lymph node excision), and intra- and postoperative complication rate will be measured. Intra- and postoperative complications are adverse events during the surgery or within 48 hours after the surgery.
62760497|NCT05173415|ACTIVE_COMPARATOR|HydroMARK(C) Clip Group|Patients who are randomized for the standard clip will receive a preoperative ultrasound-guided marking with HydroMark® Clip in the axillary lymph node that indicate for surgical removal. Surgical procedure is standardized with intraoperative ultrasound-guided wire-localization of the clip and lymph node excision. Successful detection, time of the procedure (beginning of localization intervention to completed lymph node excision), and intra- and postoperative complication rate will be measured. Intra- and postoperative complications are adverse events during the surgery or within 48 hours after the surgery.
62760498|NCT01852825|EXPERIMENTAL|NAC + MK-8237 (Part 2)|Nasal Allergen Challenge (NAC) treatment consisting of 1800 Biological Units (BU) of HDM extract on Days -14, 56 and 84; starting on Day 1 a single tablet of MK-8237 with 12 Development Units (DUs), administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
62760499|NCT01852825|PLACEBO_COMPARATOR|NAC + Placebo (Part 2)|NAC treatment consisting of 1800 BU of HDM extract on Days -14, 56 and 84; starting on Day 1 a single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
62760500|NCT01852825|EXPERIMENTAL|NAC (Part 1)|Nasal Allergen Challenge (NAC) consisting of 100 µl fixed volume of 10,000 biological units (BU) of HDM extract delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1
62760501|NCT06437886|EXPERIMENTAL|pecto-intercostal fascial block and rectus sheath block-based opioid-sparing anesthesia|
62760502|NCT06437886|NO_INTERVENTION|high-dose opiod traditional anesthesia|
62760503|NCT00504790|EXPERIMENTAL|GSK923295|anti-mitotic compound under study
62760504|NCT00933244|OTHER|High Dose Vitamin D3|"Loading Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take daily for 15 days and placebo gel-caps (white) to take daily for 15 days.~Maintenance Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take two times a month for 350 days and placebo gel-caps (white) to take daily for 350 days."
62558610|NCT03715920|ACTIVE_COMPARATOR|High Voltage Pulsed Galvanic Current|HVPG current is a new form of neuromuscular electrical stimulation.The total output voltage of the device ranged from 0 to 500 volts and the current intensity was increased until the sensible contraction of the applied muscle was achieved without causing too much sense of discomfort
62760505|NCT00933244|OTHER|Low Dose Vitamin D3|"Loading Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 15 days plus placebo gel-caps (yellow) to take daily for 15 days.~Maintenance Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 350 days plus placebo gel-caps (yellow) to take two times a month for 350 days."
61987443|NCT04356690|EXPERIMENTAL|Cohort 1 - Etoposide|Participants that are on ventilation Etoposide 150 mg/m2 daily days 1 and 4
62760506|NCT00933244|PLACEBO_COMPARATOR|Placebo|"Loading Dose: Placebo gel-caps (yellow) to take daily for 15 days plus placebo gel-caps (white) to take daily for 15 days.~Maintenance Dose: Placebo gel-caps (yellow) to take two times a month for 350 days plus placebo gel-caps (white) to take daily for 350 days."
62760507|NCT04863248|EXPERIMENTAL|trilaciclib + docetaxel|Patients will receive trilaciclib administered IV prior to docetaxel administered IV on Day 1 of each 21-day cycle.
62760508|NCT04863248|PLACEBO_COMPARATOR|placebo + docetaxel|Patients will receive placebo administered IV prior to docetaxel administered IV on Day 1 of each 21-day cycle.
62760509|NCT04580745|EXPERIMENTAL|MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057."
62760510|NCT04580745|EXPERIMENTAL|Placebo for MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo."
62760511|NCT04808206||Obese patients eligible for laparoscopic bariatric surgery|
62760512|NCT03209648|EXPERIMENTAL|Debio 1450|In Treatment Period 1, participants will receive single oral dose of Debio 1450 40 mg on Day 1. In Treatment Period 2, participants will receive itraconazole 200 mg, twice daily (BID) orally, on Day 1, followed by itraconazole 200 mg once daily (QD), on Days 2 to 4, and then single oral dose of Debio 1450 40 mg and itraconazole 200 mg on Day 5, followed by a single oral dose of itraconazole 200 mg on Days 6 and 7.
62760513|NCT02836873|ACTIVE_COMPARATOR|Bexagliflozin tablets, 20 mg|Each subject will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study.
62760514|NCT02836873|PLACEBO_COMPARATOR|Placebo tablets|Each subject will receive a placebo (inactive) tablet once daily for the duration of the study.
62760515|NCT02649192|ACTIVE_COMPARATOR|Influenza Virus Vaccine Plus Vitamins A and D|Participants receive influenza virus vaccine and Vitamins A and D supplement on Day 0 and Day 28.
62760516|NCT02649192|PLACEBO_COMPARATOR|Influenza Virus Vaccine Plus Placebo|Participants receive influenza virus vaccine and matched placebo on Day 0 and Day 28.
62760517|NCT04598126|ACTIVE_COMPARATOR|Traditional physical therapy|Traditional physical therapy
62760518|NCT04598126|EXPERIMENTAL|patient education manual +traditional physical therapy|Patient education manual +traditional physical therapy
62760519|NCT04588155||Chronic Low-Back Pain|Subjects diagnosed with Chronic Low-Back Pain in rehabilitation program: functional assessment (with temporal and kinematic analysis) and clinical assessment.
62760520|NCT04588155||Healthy|Healthy subjects: functional assessment (with temporal and kinematic analysis)
62760521|NCT06120595|OTHER|Standard of care|Patients will receive standard follow-up according to national guidelines developed by the Norwegian Breast cancer group (NBCG).
62760522|NCT06120595|EXPERIMENTAL|Standard of care + REBECCA-assisted intervention|Patients will, in addition to receiving standard follow-up every 6 months, also receive REBECCA-assisted follow-up at frequencies when the REBECCA-system indicate this. The patients will receive a REBECCA smartwatch that they will wear for 12 months. They will also have to install a REBECCA patient app on their mobile and a REBECCA plug-in on their computer for objective RWD collection related to their QoL and lifestyle over the next 12 months. The REBECCA system detects signs of deterioration in patients' QoL during the study period, the intervention will include changes in medication given, dietary advice, referral to a psychologist/psychiatrist and/or personal training with a physiotherapist at 'Pusterommet' (SUH) who will create a personalized training programme, e.g. 2-4 sessions per week.
62760523|NCT03783104|EXPERIMENTAL|250μg of vitamin B12 supplementation|Group 1 (Intervention) will receive 250μg of vitamin B12 supplementation delivered daily to the mother from 12 weeks gestation up to 6 months post-partum.
62760524|NCT03783104|ACTIVE_COMPARATOR|50μg of vitamin B12 supplementation|Group 2 (Control) will receive 50μg of vitamin B12 supplementation delivered daily to the mother from 12 weeks gestation up to 6 months post-partum.
61987444|NCT04356690|NO_INTERVENTION|Cohort 1 - Control|Standard of care therapy in participants that are on ventilation
62760525|NCT02845778|EXPERIMENTAL|melatonin niosomes oral gel 2.5 mg|apply onto oral mucosa as single use
62760526|NCT02845778|EXPERIMENTAL|melatonin niosomes oral gel 5 mg|apply onto oral mucosa as single use
62760527|NCT02845778|EXPERIMENTAL|melatonin niosomes oral gel 10 mg|apply onto oral mucosa as single use
62760528|NCT05528900|EXPERIMENTAL|FPEIS children|
61987445|NCT00885755|EXPERIMENTAL|1|
62760529|NCT04175925|EXPERIMENTAL|Part A: BMS-986322|
62760530|NCT04175925|EXPERIMENTAL|Part B: BMS-986322 Placebo|
62760531|NCT04175925|EXPERIMENTAL|Part C: BMS-986322 with famotidine|
62760532|NCT01369082||CIT Islet Transplantation Recipients|"Subjects who received an islet-cell transplant for Type 1 Diabetes (T1D) while enrolled in one of the Clinical Islet Transplantation (CIT) parent studies and continue to have islet graft function. All subjects will continue immunosuppressive medications under CIT08. Detailed follow-up evaluations including but not limited to islet function will occur on an annual basis.~The immunosuppressive medications (e.g., tacrolimus, sirolimus, cyclosporine, mycophenolate mofetil \[MMF\], mycophenolic sodium) in this study are obtained by prescription unless provided by the study through the drug distributor. Generic brands are allowed, when available. Antibacterial, antifungal, and antiviral prophylaxis, insulin therapy, and other standard therapies will be provided per site-specific practices."
62760533|NCT02118597||Triple Combination Therapy|Participants who demonstrated genotype 1 chronic hepatitis C infection and had a history of unsuccessful treatment with pegylated interferon (peginterferon) alfa + ribavirin, and who were subjected to receive a triple combination therapy with simeprevir or boceprevir plus peginterferon alfa-2a and ribavirin were observed.
61987446|NCT05311696||Residential Cohort|Those completing the program in a residential context
61987447|NCT05311696||Online Cohort|Those completing the program online
61987448|NCT01861548||Children (up to 24 months after birth)|Investigators include into the study children delivered from women observed starting from between 8-12 weeks of single pregnancy, not assisted with reproductive technology, and not expected to be finished as spontaneous abor-tion. All women with the serious chronic diseases specified in study protocol such as diabetes, hypertension, nephrop-athy, epilepsy and cancer are excluded from the study. The same refers to suspicion of serious child malformations known to exist at the inclusion into the study.
61987449|NCT03090854||Alzheimer disease patients|
62381023|NCT01568983|ACTIVE_COMPARATOR|Optijuice|"12 weeks intake of 0.5 liter/day of berry juice rich in polyphenols (grape, cherries, blueberry and aronia) and added extract from press cake of black currant.~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
62760534|NCT02977845|EXPERIMENTAL|Primary aim|The primary aim of this study is to assess the effect of Qigong on managing dyspnea, fatigue, and anxiety (as a cluster) in lung cancer patients.
62760535|NCT02977845|EXPERIMENTAL|Secondary aim|The secondary aim of this study is exploring the effect of Qigong on cough which is another common symptom linked with dyspnea, fatigue, and anxiety as a cluster, and QOL in lung cancer patients.
62760536|NCT03342040|EXPERIMENTAL|TAP block|Patients undergoing laparoscopic ventral hernia repair with TAP block with 0.2% ropivacaine under ultrasound guidance
62760537|NCT03342040|ACTIVE_COMPARATOR|No TAP block|Patients undergoing laparoscopic ventral hernia repair without TAP block
62760538|NCT04391595|EXPERIMENTAL|Arm 1|400 mg of LY3214996 QD for 6 doses and 100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. On Day 6, participants will receive Abemaciclib + LY3214996 dose 7 to 9 hours prior to craniotomy for tumor resection.
62760539|NCT00917072|EXPERIMENTAL|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
62760540|NCT00917072|EXPERIMENTAL|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center.
62760541|NCT00917072|PLACEBO_COMPARATOR|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
62760542|NCT04848714|EXPERIMENTAL|Group A: ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab´)2]|ANAWIDOW \[antivenin latrodectus (black widow) equine immune F(ab´)2\] lyophilized powder for solution 10 mL
62760543|NCT02921828||Multiple myeloma patients who received Pomalyst|Among relapsed or refractory multiple myeloma patients, all patients who received Pomalyst will be targeted in this surveillance.
62760544|NCT04437719|EXPERIMENTAL|Obvio-19 App|"If the patient is willing to participate to the trial, his given oral, free, informed and express consent will be collected and traced in his medical file. After enrollment, patients will be sent an invitation via email to download the Obvio-19 mobile app. After downloading the Obvio-19 app, patients will receive instructions as to how they may communicate with the study investigator. Communication may occur through the chat function of the app or live telephone conversations.~Patients must log into the Obvio-19 app daily to complete the questionnaires. The Obvio-19 system is designed to identify responses that indicate the participant is at an increased risk for serious illness or exhibiting serious symptoms, such as coughing up blood. Such patients will be notified by the app of this status and prompted to seek medical attention."
62760545|NCT04626089|EXPERIMENTAL|Metformin glycinate|620 mg bid (PO) plus standard treatment for 14 days
62760546|NCT04626089|PLACEBO_COMPARATOR|Placebo|Placebo tablets bid (PO) plus standard treatment for 14 days
62760547|NCT00303446|ACTIVE_COMPARATOR|Dutasteride|Dutasteride 0.5 mg/day
62760548|NCT00303446|PLACEBO_COMPARATOR|Placebo|Matched placebo
62558611|NCT03715920|PLACEBO_COMPARATOR|Russian Current|"Russian currents are a high frequency current of 2500 Hz and reduce the resistance of the skin and it would penetrate deeper and reach deeper motor nerves.Russian movement, a protocol developed by Kots, also known as Russian Technique, was used in the literature. There were 10 muscle contractions per treatment session in this protocol. Each contraction lasted for 10 seconds and a resting time of 50 seconds were given for the next contraction (transition: rest ratio was 1/5)."
62760549|NCT02372552|EXPERIMENTAL|CROMA|Microwave coagulation of small blood vessels
62760550|NCT02047201|EXPERIMENTAL|Experimental|Induction chemotherapy (Docetaxel, Cisplatin and Fluorouracil) following radiochemotherapy (IMRT using PET/CT images after IC for treatment planning + cisplatin iv 40 mg/m2 weekly).
62760551|NCT03234439|EXPERIMENTAL|myStrength Intervention|The myStrength intervention arm will be encouraged to utilize the chronic pain offering consisting of 6 modules. Each module has 5 activities and can take on average 5-15 minutes to complete. Study participants assigned to the myStrength intervention will have one week to complete each module. In addition to completing the required chronic pain modules, study participants in the myStrength intervention arm will have the option to also select other areas of interest and complete corresponding activities at their own pace. myStrength utilization will be recorded and analyzed.
62760552|NCT03234439|NO_INTERVENTION|Waitlist Control|The waitlist control group will gain access to the myStrength platform 60 days following the start of the study.
62760553|NCT04053751|EXPERIMENTAL|closed suctioning system|Closed suctioning system will be compared with open suctioning system
62381024|NCT03855358|EXPERIMENTAL|TQB2450 Injection and Anlotinib Hydrochioride Capsules|
62381025|NCT05580107|EXPERIMENTAL|Dose|"Five patients will be included into the 24 mg dose level. In case of dose limiting toxicity (DLT) in at least one patient, 5 additional patients will be enrolled in the 24 mg dose level.~If the treatment is well tolerated, i.e. no DLT is encountered, the dose of MDPK67b is escalated to 48 mg on a second cohort of 5 patients. In case of DLT in at least one patient at the 48 mg dose level, the 24 mg dose level of MDPK67b is expanded from 5 to 10 patients, or declared the maximum tolerated dose (MTD) if already expanded to 10 patients."
62381026|NCT05768568|ACTIVE_COMPARATOR|Group I|Manual Toothbrush.
62760554|NCT04053751|NO_INTERVENTION|open suctioning system|The patient will be monitored with closed system for one day and open aspiration system on the other day.
62760555|NCT00354107|EXPERIMENTAL|Treatment (monoclonal antibody therapy, chemotherapy)|"Patients receive monoclonal antibody SGN-30 IV alone on day 1 in weeks 1-8. Beginning in week 5, patients receive ICE chemotherapy comprising ifosfamide IV over 2 hours on days 1-3, carboplatin IV over 1 hour on day 1, and etoposide IV over 1 hour on days 1-3. Treatment with ICE repeats every 3 weeks for 6 courses\*\* in the absence of unacceptable toxicity. Patients also receive intrathecal therapy comprising methotrexate, cytarabine, and hydrocortisone once on day 29 (week 5).~Cohorts of 3-6 patients receive a pre-determined dose of monoclonal antibody SGN-30 with possible dose de-escalation to 1 dose level below in the event of ≥ 2 of 6 patients experience dose-limiting toxicity (DLT). The dose at which ≤ 1 of 6 patients experience DLT will be used in a phase II study."
62760556|NCT01839019|PLACEBO_COMPARATOR|Placebo|Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.
62760557|NCT01839019|EXPERIMENTAL|ODM-102|Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.
62760558|NCT05837949|EXPERIMENTAL|MS FIT: Falls Insight Track|Participants in this arm will receive 12 months use of MS FIT mobile tool intervention
62760559|NCT02750865|NO_INTERVENTION|Control Usual Care|In this arm the subject receives usual care and just completes the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment.
62760560|NCT02750865|EXPERIMENTAL|Embodied Conversational Agent (ECA)|In this arm the subject is trained how to use a tablet device which they take home for the duration of the study. These subjects complete the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment.
62760561|NCT03876691||Do not resuscitate|Patients who are suggested to family about a do-not-resuscitate order treatment by physicians.
62760562|NCT04589351|ACTIVE_COMPARATOR|Ezetimibe|One treatment period of 16 weeks with1 capsule of ezetimibe 10mg per day, as add-on to standard care.
62760563|NCT04589351|PLACEBO_COMPARATOR|Placebo|One treatment period of 16 weeks with 1 capsule of matching placebo per day, as add-on to standard care.
62760564|NCT03327376||Characteristic and regularity of CRT|The patients who have a central venous catheterization conduct the daily ultrasound-screening for CVC-related Thrombosis (DUCT).
62760565|NCT00979368|ACTIVE_COMPARATOR|BMS-816336 or placebo (Panel 1)|
62760566|NCT00979368|ACTIVE_COMPARATOR|BMS-816336 or placebo (Panel 2)|
62760567|NCT00979368|ACTIVE_COMPARATOR|BMS-816336 or placebo (Panel 3)|
62760568|NCT00979368|ACTIVE_COMPARATOR|BMS-816336 or placebo (Panel 4)|
62760569|NCT00979368|ACTIVE_COMPARATOR|BMS-816336 or placebo (Panel 5)|
62760570|NCT00440856|NO_INTERVENTION|Control|
62760571|NCT00440856|EXPERIMENTAL|experimental|Participants are given their disc fragments following their operation
62381027|NCT05768568|ACTIVE_COMPARATOR|Group II|Powered Toothbrush
62760572|NCT03352583|ACTIVE_COMPARATOR|Day|Group receives casein protein during the day (greater than 6 hours before bed).
62760573|NCT03352583|EXPERIMENTAL|Night|Group receives casein protein immediately before going to bed.
62760574|NCT06496438|ACTIVE_COMPARATOR|Psychobiotics|"Patients operated on for gastrointestinal cancer and currently undergoing chemotherapy will be randomized to receive a probiotic regime therapy with four psychobiotics \[one sachet twice daily for a month\]."
62381028|NCT02394028|EXPERIMENTAL|Induction Phase - Cohort 1 (Exploratory): Etrolizumab 210 mg|Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one subcutaneous (SC) injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
62381029|NCT02394028|EXPERIMENTAL|Induction Phase - Cohort 1 (Exploratory): Etrolizumab 105 mg|Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
62760575|NCT06496438|PLACEBO_COMPARATOR|Placebo|Patients operated on for gastrointestinal cancer and currently undergoing chemotherapy will be randomized to receive placebo sachets which will be identical to the probiotic regime.
62760576|NCT02523768|EXPERIMENTAL|ATG-F|The ATG-Fresenius® is administered by slow infusion over four hours after antihistamine (2 bulbs Polaramine® IV) and intravenous methylprednisolone (minimum 30mg); it is started on day 0 prior to surgery at doses of 4 mg / kg, and then continued to day 1, day 2 to 4mg / kg, then day 3, day 4 at the dose of 3 mg / kg
62760577|NCT02523768|ACTIVE_COMPARATOR|Simulect|The anti CD25 (basiliximab, Simulect®) is administered intravenously before surgery of renal transplantation (Day 0 and Day + 4 (1 ampoule of 20 mg x 2 times).
62381030|NCT02394028|PLACEBO_COMPARATOR|Induction Phase - Cohort 1 (Exploratory): Placebo|Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.
62760578|NCT06594796|EXPERIMENTAL|Combined lifestyle intervention with LBP care|A combined lifestyle intervention (GLI) integrated into standard care for LBP according to clinical guidelines of the Dutch physiotherapy (KNGF) and delivered by GLI certified physio/exercise therapists. A GLI aims to increase physical activity, improve diet and sleep, change health behavior, and are effective in reducing weight amongst overweight and obese adults. The intervention is tailored to the patient's lifestyle risk and clinical LBP factors using shared decision-making. Patients define their own treatment goals and remain in charge of the treatment procedures. The intervention has a duration of two years of which the first six months focus on behavioral change, the latter 18 months focus on maintenance of newly set behaviors. Participants are guided using group and individual sessions where evidence-based behavioral change techniques will be employed such as motivational interviewing, self-monitoring and action and coping planning.
62760579|NCT06594796|NO_INTERVENTION|Usual care|Usual care as prescribed by the medical specialist. This can vary from a watchful waiting strategy to referral to physiotherapy, exercise therapy, or general practitioner care according to the Dutch physiotherapy (KNGF) and general practice (NHG) guidelines for LBP; e.g. education, exercise therapy and pain medication. It may also involve re-entry to the hospital after failed treatment in primary care.
62760580|NCT01678352|EXPERIMENTAL|Cohort 1|Patients must have undergone surgery or biopsy alone (no postoperative radiation or chemotherapy) and have a baseline MRI scan (within 4 weeks of the first vaccine) that shows stable disease or regression (no progression from the initial surgery/biopsy).
62760581|NCT01678352|EXPERIMENTAL|Cohort 2|Patients received surgery or biopsy and radiation therapy (RT) (including fractionated external beam radiation therapy and/or stereotactic radiosurgery), which was completed ≥ 6 months prior to enrollment, and have a baseline MRI scan within 4 weeks prior to the first vaccine that shows stable disease or regression.
62760582|NCT01678352|EXPERIMENTAL|Cohort 3|Patients with recurrent WHO grade 2 glioma may have received prior external beam radiotherapy and/or chemotherapy. Patients with stable WHO grade 2 glioma must have had prior chemotherapy (at least one cycle of Temozolomide or PCV-based chemotherapy). With regard to the prior therapy in Cohort 3, patients may have had treatment for no more than 2 prior relapses. Relapse is defined as progression following initial therapy (i.e. radiation +/- chemo if that was used as initial therapy) or observation of stable disease. The intent therefore is that patients may have had 3 prior therapies (initial therapy and treatment for 2 relapses). If the patient had a surgical resection for relapsed disease, and no anti-cancer therapy was instituted for up to 12 weeks, and the patient undergoes another surgical resection, this is considered as 1 relapse.
62760583|NCT00966719|ACTIVE_COMPARATOR|Lactation Consultant|"In hospital meeting with lactation consultant~1 to 3 follow up visits at weekly intervals with lactation consultant"
62760584|NCT00966719|NO_INTERVENTION|current treatment for jaundice|Babies will receive current standard of care for jaundice (IV fluids and phototherapy)
62760585|NCT00739180|OTHER|Control|Standard care control
62760586|NCT00739180|ACTIVE_COMPARATOR|Aerobic Exercise|
62760587|NCT00739180|ACTIVE_COMPARATOR|Resistance Exercise|
62760588|NCT03739957|EXPERIMENTAL|BPCO Media Kit|The kit is composed of a Bluetooth pulse oximeter and an APP for Android system downloadable from Google Play and installed on the Android smartphone of the patient from version 4.1 on.
62760589|NCT05945056|EXPERIMENTAL|Electrotherapy with Frog Leg Exercise Intervention|Experimental group received Frog leg technique along with transcutaneous electrical nerve stimulation for 10 sessions of duration half hour each on regular basis.
62760590|NCT05945056|ACTIVE_COMPARATOR|Standard Exercise Therapy with Electrotherapy|Control group received standard exercise therapy treatment along with transcutaneous electrical nerve stimulation for 10 sessions of duration half hour each on regular basis.
62760591|NCT04418336|ACTIVE_COMPARATOR|Endoscopic Pilonidal sinus treatment (EPSIT)|Endoscopic Pilonidal sinus treatment (EPSIT)
62760592|NCT04418336|ACTIVE_COMPARATOR|Sinus Laser Closure (SiLaC)|Sinus Laser Closure (SiLaC)
62760593|NCT04418336|ACTIVE_COMPARATOR|lay open technique|lay open technique
62760594|NCT01016314|EXPERIMENTAL|Aspen Spinous Process System|Subjects randomized to the Aspen study arm will have the Aspen device implanted as supplemental posterior fixation only and according to the manufacturer's recommendations.
62760595|NCT01016314|ACTIVE_COMPARATOR|Pedicle Screw Fixation|Subjects randomized to the pedicle screw group will have the pedicle screws implanted according to the standard procedures and practices at that institution. The procedure may be performed according to surgeon preference, including a traditional open, minimally invasive or percutaneous approach. Only pedicle screws cleared by FDA for this indication will be used in this study.
61987450|NCT03989245||Target arm: UCC (Cognitive Behavioural Unit)|Patients receiving care in Cognitive Behavioural Unit (UCC )
62381031|NCT02394028|EXPERIMENTAL|Induction Phase - Cohort 2 (Open-Label): Etrolizumab 210 mg|"Cohort 2 is enrolling participants after Cohort 1 and is considered a feeder cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking for the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12."
62381032|NCT02394028|EXPERIMENTAL|Induction Phase - Cohort 2 (Open-Label): Etrolizumab 105 mg|"Cohort 2 is enrolling participants after Cohort 1 and is considered a feeder cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12."
62381033|NCT02394028|EXPERIMENTAL|Induction Phase - Cohort 3 (Pivotal): Etrolizumab 210 mg|Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
62381034|NCT02394028|EXPERIMENTAL|Induction Phase - Cohort 3 (Pivotal): Etrolizumab 105 mg|Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
62381035|NCT02394028|PLACEBO_COMPARATOR|Induction Phase - Cohort 3 (Pivotal): Placebo|Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.
62381036|NCT02394028|PLACEBO_COMPARATOR|Maintenance Phase - Placebo Responders: Placebo|Participants who received placebo during the Induction Phase (from Cohorts 1 and 3) and achieved a CDAI-70 response at Week 14 will undergo a sham randomization into the Maintenance Phase. Placebo responders from induction will receive blinded maintenance treatment with an SC injection of placebo once every 4 weeks (q4w) from Week 16 to Week 64.
62381037|NCT02394028|PLACEBO_COMPARATOR|Maintenance Phase - Etrolizumab Responders: Placebo|Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64.
62381038|NCT02394028|EXPERIMENTAL|Maintenance Phase - Etrolizumab Responders: Etrolizumab 105 mg|Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of etrolizumab (105 mg) q4w from Week 16 to Week 64.
62381039|NCT05659459|EXPERIMENTAL|KIN001|75mg pamapimod oral tablet 5mg pioglitazone oral tablet twice daily for 14 days
62381040|NCT05659459|PLACEBO_COMPARATOR|Placebo|75mg pamapimod-placebo oral tablet 5mg pioglitazone-placebo oral tablet twice daily for 14 days
62381041|NCT05761236|ACTIVE_COMPARATOR|Training group|In the first 2 weeks, sessions were held with all patients once a week. In these two sessions, the basic information of scoliosis were explained to both groups. Postural corrections were explained to the patients, including the basic elements of clinical pilates.It was stated that they should breathe towards the concave side of the major curve (weak breathing zone) during exercises and postural corrections.In the Pilates-based exercise program, sessions are planned as 10 minutes of warm-up, 10 minutes of cool-down and 40 minutes of scoliosis-specific pilates-based exercises for approximately 1 hour. Total number of exercises is 12 for one session. After a 2-week joint training week, the training group switched to hybrid type telerehabilitation and continued their exercise sessions with a physiotherapist 3 days a week via synchronous video conferences (Zoom Application) and by themselves at home on the rest of the week.
62381042|NCT05761236|ACTIVE_COMPARATOR|Control group|In the first 2 weeks, sessions were held with all patients once a week. In these two sessions, the basic information of scoliosis were explained to both groups. Postural corrections were explained to the patients, including the basic elements of clinical pilates. It was stated that they should breathe towards the concave side of the major curve (weak breathing zone) during exercises and postural corrections.In the Pilates-based exercise program, sessions are planned as 10 minutes of warm-up, 10 minutes of cool-down and 40 minutes of scoliosis-specific pilates-based exercises for approximately 1 hour. Total number of exercises is 12 for one session.The patients in the control group continued the exercise program every day of the week for 12 weeks. Exercise lists were sent to the patients in the form of electronic booklets via an electronic communication application every week, and their continuity with the exercise program was checked with the diaries they were asked to fill in.
62760596|NCT02116114|EXPERIMENTAL|Aquatic exercises|"* 3 times a week~* heating~* aerobic training~* slowdown"
62381043|NCT04588376|EXPERIMENTAL|Clinician-level and clinic-level monthly feedback|Group of 22 clinics to receive clinician-level and clinic-level monthly feedback on appropriate antibiotic use for three acute respiratory tract infections
62381044|NCT04588376|ACTIVE_COMPARATOR|Clinic-level only monthly feedback|Group of 17 clinics to receive clinic-level only monthly feedback on appropriate antibiotic use for three acute respiratory tract infections
62381045|NCT04319861|EXPERIMENTAL|Anal fistula plug|The anal fistula plug procedure was performed as followings. A fistula probe was used to identify fistula tracts, and internal and external openings. Gentle mechanical debridement was performed with a blunt curette to remove the necrotic tissue with care not to enlarge the track, then hydrogen peroxide and sterile saline were used to repeatedly to irrigate the fistula. The anal fistutla plug was filled into the fistula, and sutured with a figure-of-eight 2-to-0 Vicryl suture to ensure the plug was fixed in the internal opening of the fistula, avoiding the anal fistula plug being extruded. Trimming the plug at the external fistula and the external opening was left open to ensure adequate drainage.
62381046|NCT00517634|EXPERIMENTAL|Sequence 1: FP, SFC, Placebo|Fluticasone Propionate (FP) 100 micrograms (mcg) twice daily (BID) in the first treatment period: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID in the second treatment period: Placebo in the third treatment period
62381047|NCT00517634|EXPERIMENTAL|Sequence 2: Placebo, SFC, FP|Placebo in the first treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
62381048|NCT00517634|EXPERIMENTAL|Sequence 3: SFC, FP, Placebo|Salmeterol/Fluticasone Propionate 50/100 Combination mcg BID in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Placebo in the third treatment period
62381049|NCT00517634|EXPERIMENTAL|Sequence 4: SFC, Placebo, FP|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the first treatment period: Placebo in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
62381050|NCT00517634|EXPERIMENTAL|Sequence 5: FP, Placebo, SFC|Fluticasone Propionate 100 mcg BID in the first treatment period: Placebo in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
62381051|NCT00517634|EXPERIMENTAL|Sequence 6: Placebo, FP, SFC|Placebo in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
62760597|NCT02116114|NO_INTERVENTION|control group|The control group participated in the study only to usual care , conventional medical treatment orientation about the disease , methods of energy conservation and evaluation.
62760598|NCT05295147|EXPERIMENTAL|Palmar Grasp Reflex Stimulation|
62760599|NCT05295147|NO_INTERVENTION|Control Group|
62381052|NCT06259591|EXPERIMENTAL|Pedometer follow-up and coaching|Pedometer follow-up plus text message coaching Monday/ Wednesday/ Friday
62381053|NCT06259591|ACTIVE_COMPARATOR|Pedometer follow up|Pedometer follow-up from day 8- 30 after surgery
62381054|NCT02407236|PLACEBO_COMPARATOR|Induction Study - Placebo Intravenous (IV)|Participants will be randomized to receive single dose of placebo as Intravenous (IV: into the vein) infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study, but will not be randomized.
62381055|NCT02407236|EXPERIMENTAL|Induction Study - Ustekinumab 130 milligram (mg) IV|Participants will be randomized to receive single dose of ustekinumab 130 mg as IV infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study and will be randomized.
62381056|NCT02407236|EXPERIMENTAL|Induction Study - Ustekinumab 6 mg/kg IV|Participants will be randomized to receive ustekinumab approximating 6 mg/kg of body weight, as intravenous infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study and will be randomized.
62381057|NCT02407236|OTHER|Induction Study- Placebo- Nonresponsders at Week 8|Participants without clinical response to placebo at Week 8 will receive a single IV infusion of ustekinumab approximating 6mg/kg along with matching subcutaneous (SC) placebo (to maintain the blind). Participants in clinical response at Week 16 will be eligible to enter Maintenance study and will be randomized.
62760600|NCT05581095|ACTIVE_COMPARATOR|Mindful Eating Self-Help Book Only|"Participants will be invited to read about and practice a variety of mindful eating-related strategies over the course of 10 weeks based on Dr. Michelle May \& Dr. Kari Anderson's self-help book entitled, Eat What You Love, Love What You Eat for Binge Eating. Participants will also be asked to complete a weekly electronic log describing their experiences with the weekly mindfulness-based practices."
62760601|NCT05581095|EXPERIMENTAL|Mindful Eating Self-Help Book + Smartphone App|"Participants will be invited to read about and practice a variety of mindful eating-related strategies over the course of 10 weeks based on Dr. Michelle May \& Dr. Kari Anderson's self-help book entitled, Eat What You Love, Love What You Eat for Binge Eating. In addition, participants will be asked to use the companion Am I Hungry? Mindful Eating Virtual Coach smartphone application three times daily. Participants will also be asked to complete a weekly electronic log describing their experiences with the weekly mindfulness-based practices."
62760602|NCT02016937||group g|general anesthesia, n: 21
62760603|NCT02016937||group S|spinal anesthesia, n: 21
62760604|NCT02016937||group E|epidural anesthesia, n: 21
62760605|NCT02016937||group V|vaginal birth, without anesthesia, n: 21
62760606|NCT03283969|PLACEBO_COMPARATOR|Control Powder|Isocaloric powder
62381058|NCT02407236|OTHER|Induction study-Ustekinumab Nonresponders at Week 8|Participants without clinical response to ustekinumab (130 mg or 6 mg/kg \[IV\]) at Week 8 will receive a single dose of ustekinumab 90 mg subcutaneously along with matching placebo intravenously (to maintain the blind). Participants in clinical response at Week 16 (that is, delayed responders) will be eligible to enter Maintenance study, but will not be randomized.
62381059|NCT02407236|PLACEBO_COMPARATOR|Maintenance Study - Placebo Subcutaneous (SC)|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44.
61987451|NCT03989245||Control arm: SSR (Geriatric Follow-up and Rehabilitation Unit)|Patients receiving care in Geriatric Follow-up and Rehabilitation Care Unit (SSR)
62381060|NCT02407236|EXPERIMENTAL|Maintenance Study - Ustekinumab 90mg SC every 12 weeks|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive ustekinumab 90 mg subcutaneously every 12 weeks, beginning Week 0 of Maintenance study through Week 44.
62381061|NCT02407236|EXPERIMENTAL|Maintenance Study - Ustekinumab 90mg SC every 8 weeks (q8w)|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive ustekinumab 90 mg subcutaneously every 8 weeks, beginning Week 0 of Maintenance study through Week 44.
62381062|NCT02407236|OTHER|Maintenance Study - Placebo IV - Responder - Placebo SC|Participants in clinical response to Induction treatment with IV Placebo will receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44. Participants are not randomized.
62381063|NCT02407236|OTHER|Maintenance Study-Delayed Responder-Ustekinumab 90mg SC q8w|Participants without clinical response to induction treatment ustekinumab (130 mg or 6 mg/kg \[IV\]) at Week 8 but in clinical response at Week 16 after receiving Induction Ustekinumab at week 8 (delayed responders) will receive ustekinumab 90 mg subcutaneously every 8 weeks, beginning Week 0 of Maintenance study through Week 44. Participants are not randomized.
62760607|NCT03283969|EXPERIMENTAL|Freeze Dried Strawberry Powder|Contains freeze dried strawberries
62760608|NCT04774471||Women with breast lesions|Women with an identified breast lesion have a non-invasive non-contrast MRI scan prior to biopsy.
62760609|NCT01958021|EXPERIMENTAL|LEE011 + letrozole|LEE011 (Ribociclib) oral (3 weeks on/ 1 week off) in combination with oral once daily letrozole. 600mg LEE011 QD + 2.5 mg letrozole QD
62760610|NCT01958021|PLACEBO_COMPARATOR|Placebo + letrozole|Matching ribociclib placebo was the control drug and was administered orally once daily.
62760611|NCT03843944|EXPERIMENTAL|Safinamide|Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
62760612|NCT01410292|EXPERIMENTAL|meal D|low fiber and low GI
62760613|NCT01410292|EXPERIMENTAL|meal C|low Fiber and High GI
62760614|NCT01410292|EXPERIMENTAL|meal B|high Fiber and low GI
62760615|NCT01410292|EXPERIMENTAL|meal A|high fiber and high GI meal
62760616|NCT00987896|EXPERIMENTAL|Megachannel Application|Colonoscopy with loaded Megachannel is performed
61987452|NCT01328860|EXPERIMENTAL|Biologic; Stem Cells|
61987453|NCT06008509|EXPERIMENTAL|Gastric Echography|All the patients that entry to the study are going to recieve gastric echography to determine the level of gastric emptying before the induction of anesthesia.
61987454|NCT03756298|EXPERIMENTAL|Combination|Atezolizumab + capecitabine combination arm
61987455|NCT03756298|ACTIVE_COMPARATOR|Control|Capecitabine alone arm
61987456|NCT03371992|OTHER|Lung Cancer Patients|Lung cancer patients receiving one of three standard of care immunotherapy drugs including nivolumab, pembrolizumab or atezolizumab. 3D-EX will be performed on biopsies from patients enrolled in the study to correlate with the patient's evaluation of response by RECIST.
62381064|NCT05075434|EXPERIMENTAL|Intervention Group|This group will receive the protocol prescribed by the health centre (calf stretching exercises, plantar fascia, proprioception exercises, ultrasound, magnet therapy and gait re-education and proprioceptive exercises for 40-45 minutes). In addition, you will receive 15 minutes of the instrumental technique of diacutaneous fibrolysis. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
62381065|NCT05075434|ACTIVE_COMPARATOR|Control Group|This protocol will be the one prescribed by the health centre. It consists of calf stretching exercises, plantar fascia, proprioceptive exercises, ultrasound, magnetic therapy and gait re-education and proprioceptive exercises for 40-45 minutes. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
62381066|NCT01097564||COL4A1 genetic testing|COL4A1 genetic testing
62760617|NCT01680692|ACTIVE_COMPARATOR|Continuous femoral and single shot sciatic nerve block|Will receive pre-operative continuous femoral catheter \& post-operative single shot sciatic with both given an initial bolus of 30 mL (femoral) 0.5% Ropivicaine \& 20mL (sciatic) 0.2% Ropivicaine. Following surgery the femoral infusion will be started, which will be running Ropivicaine 0.2 at 10cc/hr.
62381067|NCT01497665|EXPERIMENTAL|GRN1005 alone|GRN1005 alone
62381068|NCT03376776||Eyes with epiretinal proliferation|The eyes with epiretinal proliferation around the macular hole detected with optical coherence tomography
62381069|NCT03376776||Eyes without epiretinal proliferation|The eyes without epiretinal proliferation around the macular hole detected with optical coherence tomography
62381070|NCT02133144|EXPERIMENTAL|High fat diet|Intervention: overeating high fat diet (1000 extra calories per day) for 3 weeks
62381071|NCT02133144|EXPERIMENTAL|High carbohydrate diet|Intervention: overeating high carbohydrate diet (1000 extra calories per day) for 3 weeks
62381072|NCT04257006|EXPERIMENTAL|patients undergoing CRRT with oXiris membrane|"Elective cardiac surgery patients undergoing CPB we will range in 2 groups: I- with Prismaflex set oXiris (SCUF) after CPB, II- standard protocol.~Indications for CRRT (SCUF) with oXiris after ICU admission:~1. Signs of pulmonary edema after cardiac surgery, verified with X-ray control.~Or high risk of pulmonary edema after cardiac surgery:~1. Fluid overload ≥ 10%, measured with equation (%fluid overload= ((total fluid in- total fluid out)/admission body weight\*100)~2. CVP (central venous pressure) ˃ 12 mm H2O.~3. PAWP (pulmonary arterial wedge pressure) ˃ 12 mm Hg, measured by Swan-Ganz catheter.~In this arm the treatment of fluid overload will be provided via SCUF with oxiris membrane"
62558612|NCT03715920|SHAM_COMPARATOR|Isometric Exercise|"Isometric or static strength training is exercises performed without joint movement and changing muscle length during muscle contraction.~The body and knee of the participants in the isometric exercise group were positioned and stabilized at 75 ° flexion and 60 ° flexion angle, respectively as in the stimulation groups. Participants were asked to do 10 repetitions as 10 seconds of maximum voluntary contractions and 10 seconds of rest."
62558613|NCT05317312|EXPERIMENTAL|MR-107A-02 1.25 mg twice in a 24 hour period|Oral tablet, one day of dosing
62558614|NCT05317312|EXPERIMENTAL|MR-107A-02 5 mg twice in a 24 hour period|Oral tablet, one day of dosing
62558615|NCT05317312|EXPERIMENTAL|MR-107A-02 15 mg twice in a 24 hour period|Oral tablet, one day of dosing
62558616|NCT05317312|PLACEBO_COMPARATOR|Placebo twice in a 24 hour period|Oral tablet, one day of dosing
62558617|NCT03154125|EXPERIMENTAL|Abdomen|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
61987457|NCT02526940||blood CD4 cells count < 200/mm3|"patients with blood CD4 cells count at the time of initiation of HAART\< 200/mm3.~Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years"
62381073|NCT04257006|NO_INTERVENTION|standard protocol|"Elective cardiac surgery patients undergoing CPB we will range in 2 groups: I- with Prismaflex set oXiris (SCUF) after CPB, II- standard protocol.~Indications for CRRT (SCUF) with oXiris after ICU admission:~1. Signs of pulmonary edema after cardiac surgery, verified with X-ray control.~Or high risk of pulmonary edema after cardiac surgery:~1. Fluid overload ≥ 10%, measured with equation (%fluid overload= ((total fluid in- total fluid out)/admission body weight\*100)~2. CVP (central venous pressure) ˃ 12 mm H2O.~3. PAWP (pulmonary arterial wedge pressure) ˃ 12 mm Hg, measured by Swan-Ganz catheter.~In this arm the management of fluid overload will be provided via diuretics or IHD (in condition diuretics treatment resistance)"
62381074|NCT02114359|EXPERIMENTAL|Platinum/fluoropyrimidine combination chemotherapy|
62381075|NCT02114359|ACTIVE_COMPARATOR|Fluoropyrimidine monochemotherapy|
62381076|NCT00750867|EXPERIMENTAL|1|Interventions included monthly infusions of intravenous immunoglobulin.
62381077|NCT04182165|EXPERIMENTAL|Subjects measured by the study staff|Subjects measured by the study staff via the investigational device at the hospital (up to 50 subjects).
62381078|NCT04182165|EXPERIMENTAL|Subjects measuring themselves autonomously|Subjects measuring themselves autonomously with the investigational device at their homes (up to 10 subjects from the first arm).
62381079|NCT01732861|EXPERIMENTAL|CC-292 + Lenalidomide|
62381080|NCT02298699||Observation|Patients with Sly disease or high-grade suspicion for Sly disease
62381081|NCT04184921||osimertinib and aspirin|Osimertinib and Aspirin starting at a dose of 80 mg and 100mg once a day, orally with meals. Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
62381082|NCT04184921||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
62381083|NCT02365324|EXPERIMENTAL|Peer-education Family Fitness Program|Peer educators (children in grade 8) recruited from the schools participating in the study will be trained and will then be implementing the 12 week Peer-education Family Fitness Program (PE-FFP) intervention to children in 6th and 7th grade.
62381084|NCT02365324|OTHER|Family Fitness Program (FFP)|Adult educators recruited from the University of Illinois Extension or the community will be trained and will then be implementing the 12 week Family Fitness Program (FFP) intervention to children in 6th and 7th grade.
62381085|NCT03224936||DISE group|All patients in this study group will receive a propofol PSI controlled DISE (drug induced sleep endoscopy).
62381086|NCT03709914|EXPERIMENTAL|ZTI-01 Cohort 1 ≥ 6 to <12 years of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to \< 97th percentile for age
62381087|NCT03709914|EXPERIMENTAL|ZTI-01 Cohort 2 ≥ 2 to <6 years of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to \< 97th percentile for age
62381088|NCT03709914|EXPERIMENTAL|ZTI-01 Cohort 3a Birth to < 3 mos of age|ZTI-01 (fosfomycin IV) 75 mg/kg (single dose) Subjects weighing within the 3rd to \< 97th percentile for age
62760618|NCT01680692|EXPERIMENTAL|Continuous femoral and tibial peripheral nerve catheters|Patients will receive pre-operative continuous femoral catheter \& post-operative continuous tibial catheter with an initial bolus of 30 mL 0.5% Ropivicaine (femoral) \& 20mL 0.2% Ropivicaine (tibial), which will be followed by infusions post-operatively running at 10cc/hr.
62760619|NCT01813838|EXPERIMENTAL|ACADESINE 140mg/kg/d|3 patients will be included at the initial dose of Acadesine 140mg/kg/d
62760620|NCT01813838|EXPERIMENTAL|ACADESINE 210mg/kg/d|In absence of toxicity at the dose of 140mg/kg/d. There is a dose escalation of acadesine at the dose of 210mg/kg/d for 3 additionnal patients
62381089|NCT03709914|EXPERIMENTAL|ZTI-01 Cohort 3b ≥ 3 to < 6 mos of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to \< 97th percentile for age
62381090|NCT03709914|EXPERIMENTAL|ZTI-01 Cohort 3c ≥ 6 to < 24 mos of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to \< 97th percentile for age
62381091|NCT00740688|EXPERIMENTAL|Experimental Group|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
62381092|NCT00740688|SHAM_COMPARATOR|Sham Group|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
62381093|NCT01509157|EXPERIMENTAL|MDRS system|Participants will be using the MDRS system combined with their regular treatment with Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
62558618|NCT03154125|EXPERIMENTAL|Upper thigh|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
62760621|NCT01813838|EXPERIMENTAL|ACADESINE 315mg/kg/d|In absence of toxicity at the dose of 210mg/kg/d. There is a dose escalation of acadesine at the dose of 315mg/kg/d for 3 additionnal patients
62381094|NCT01509157|ACTIVE_COMPARATOR|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
62381095|NCT03884803|OTHER|HealthyMoms web-based program|An on-line self-help psychoeducational website for new moms that includes educational learning modules and tools to prevent/reduce depression. .
62558619|NCT03154125|EXPERIMENTAL|Back of the upper arm|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
62381096|NCT03884803|OTHER|Control group|No access to the intervention but to continue with standard care. Will complete the same questionnaires as the HealthyMoms group.
62381097|NCT01879891|OTHER|Non-Biopsy|"The Non-Biopsy group will complete a VO2 maximum test, are provided food 2 days prior to assessments, exercise in the metabolic chamber, have a Resting Energy Expenditure test, complete a DEXA and have blood drawn. This group will stay overnight in the metabolic chamber and have the clamp procedure. Exercise training is exactly the same for both groups.~Those who select the Non-Biopsy group, in lieu of the biopsy test, will complete an Activities of Daily Living (ADL) test that involves sub-maximal VO2 assessment. The participants will also be asked to where an accelerometer home for 4 consecutive days after the ADL test."
62558620|NCT01894087|ACTIVE_COMPARATOR|Therapist-led brief intervention (TBI) - Cohort 1|"Participants will receive a therapist-led, computer-assisted intervention session with a master's level therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
62760622|NCT02621398|EXPERIMENTAL|Treatment (paclitaxel, carboplatin, radiation, pembrolizumab)|Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Patients undergo 3D CRT or IMRT QD 5 days a week for 6 weeks. Beginning 2-6 weeks after, 2 weeks before the end, or at the start of chemotherapy and radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
62760623|NCT03749096|ACTIVE_COMPARATOR|Intravenous immunoglobulin|IVIg dose will be 2g/kg ideal body weight every 4 weeks (in 2 divided doses on consecutive days) for 12 weeks (3 cycles total).
62760624|NCT03749096|PLACEBO_COMPARATOR|Placebo|
62760625|NCT04656795|EXPERIMENTAL|Subjects with severe renal impairment|
62760626|NCT04656795|EXPERIMENTAL|Subjects with normal renal function|
62760627|NCT04656795|EXPERIMENTAL|Subjects with moderate renal impairment|
62760628|NCT04656795|EXPERIMENTAL|Subjects with mild renal impairment|
62760629|NCT06235762|NO_INTERVENTION|Conventional Medical Evaluation|Participants in the control group will only undergo conventional medical evaluation.
62760630|NCT06235762|ACTIVE_COMPARATOR|Conventional Medical Evaluation Plus Nutritional Assessment|Participants in the intervention group will undergo the same medical care, concomitantly with nutritional assessment.
62760631|NCT04287803|EXPERIMENTAL|intervention Arm|Methoxyflurane will be introduced and data will be captured to inform future multicentred step wedge design study. (This study is a feasibility study)
62760632|NCT02361424|EXPERIMENTAL|PXT00864 Dose 1|1 orange capsule containing 0.4 mg of acamprosate , and 1 white capsule containing 6 mg of baclofen These 2 capsules are taken orally b.i.d. during 8 weeks.
62760633|NCT02361424|EXPERIMENTAL|PXT00864 Dose 2|"1 orange capsule containing 1 mg of acamprosate , and 1 white capsule containing 15 mg of baclofen .~These 2 capsules are taken orally b.i.d. during 8 weeks."
62760634|NCT02361424|EXPERIMENTAL|PXT00864 Dose 3|"1 orange capsule containing 20 mg of acamprosate , and 1 white capsule containing 12 mg of baclofen .~These 2 capsules are taken orally b.i.d. during 8 weeks."
62760635|NCT02361424|PLACEBO_COMPARATOR|Placebo of PXT00864|"1 orange capsule containing placebo of acamprosate , and 1 white capsule containing placebo of baclofen .~These 2 capsules are taken orally b.i.d. during 4 weeks"
62760636|NCT00830713|EXPERIMENTAL|MKTP treatment|subject will undergo MKTP
62760637|NCT00676624||Uveitis|Patients suffering from uveitis, who have vitrectomy performed for diagnostic purpose
62558621|NCT01894087|NO_INTERVENTION|Enhanced usual care - Cohort 1|
62760638|NCT00676624||Control group|"Patients suffering from either Epiretinal fibrosis og Macula hole who have vitrectomy performed for curative reasons"
62760639|NCT00047333|EXPERIMENTAL|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62760640|NCT02103374|EXPERIMENTAL|Atrovent + Bricanyl or Atrovent + Ventolin|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form Atrovent 0,5mg/1ml Bricanyl 5mg/2ml Ventolin 5mg/2,5ml
62760641|NCT02103374|PLACEBO_COMPARATOR|Placebo|1 capsule per day lactose (in addition to the standard optimized treatment)
62760642|NCT02996799|NO_INTERVENTION|Deferred Cord Clamping|Neonate is held at the level of placenta (level of introitus (vaginal delivery ) and mother's thigh or operating table (C/S) and cord clamping is deferred for 60 seconds.
62760643|NCT02996799|EXPERIMENTAL|Umbilical cord milking|Manually stripping 20cm of cord segment toward the umbilicus over a period of 2-3 seconds three times before cord clamping.
62760644|NCT01787318|EXPERIMENTAL|ePID closed loop system using Insupatch|Insupatch activated at mealtimes
62760645|NCT01787318|ACTIVE_COMPARATOR|ePID closed loop system without InsuPatch|InsuPatch will not be activated at mealtimes
62760646|NCT03691350|ACTIVE_COMPARATOR|Group I (usual cigarette brand)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Participants continue to smoke their usual brand of cigarettes. Participants undergo a second bronchoscopy on day 71.
62760647|NCT03691350|EXPERIMENTAL|Group II (SREC with nicotine)|Participants undergo bronchoscopy over 30-60 minutes at baseline. After the baseline bronchoscopy, participants learn to use the SREC with nicotine for 2 weeks and switch completely to the SREC with nicotine starting day 15 for 8 weeks. Participants undergo a second bronchoscopy on day 71.
62381098|NCT01879891|OTHER|Biopsy|The Biopsy group will also complete a VO2 maximum test, are provided food 2 days prior to assessments, exercise in the metabolic chamber, have a Resting Energy Expenditure test, complete a DEXA and have blood drawn. As with the Non-Biopsy group, this group will stay overnight in the metabolic chamber and have the clamp procedure. Exercise training is exactly the same for both groups. One week following the overnight metabolic chamber visit, participants in this group will undergo a muscle biopsy. This group will not complete the Activities of Daily Living (ADL) test nor will they be asked to wear an accelerometer.
62381099|NCT02600663||acute back pain|
62381100|NCT03001726||Gastrectomy plus chemotherapy|In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
62381101|NCT03001726||chemotherapy alone|Patients received chemotherapy alone.All patients received oral S1 80 mg/m2 per day (80-120 mg/day total dose depending on the patient's body surface area as follows: \<1.25 m2, 80 mg; 1.25-1.5 m2, 100 mg; and \>1.5 m2, 120 mg) on days 1-21 of every 3-week cycle, oxaliplatin 100 mg/m2 on day 1 of every 3-week cycle and docetaxel 40mg/m2 on day 1 of every 3-weeks cycle.
62760648|NCT03691350|EXPERIMENTAL|Group III (SREC without nicotine)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the SREC without nicotine for 2 weeks and switch completely to the SREC without nicotine starting day 15 for 8 weeks. Participants will be offered varenicline to aid cessation. Participants undergo a second bronchoscopy on day 71.
62381102|NCT05745506||CRD|patients whose PSQI score\>5
62381103|NCT05745506||non-CRD|patients whose PSQI score ≦ 5
62760649|NCT03691350|EXPERIMENTAL|Group IV (Nicotine Replacement Therapy [NRT])|Participants undergo bronchoscopy over 30-60 minutes at baseline. One week before the day 15 quit date, participants stop smoking using NRT comprising either patch, gum, or lozenge for 8 weeks. Participants undergo a second bronchoscopy on day 71.
62760650|NCT04584346|EXPERIMENTAL|Arm A|Ketogenic Diet
62381104|NCT00476502||1|patients involved in structured interruption therapy
62381105|NCT02258516|EXPERIMENTAL|behavioral intervention|"Patient education for self-management called CHIME 3-M will be delivered"
62381106|NCT02258516|ACTIVE_COMPARATOR|control|attention control arm received phone calls to discuss non-heart failure related health topics
62381107|NCT04554394|EXPERIMENTAL|CellFX Treated Wart|Treated wart with CellFX device intervention
62381108|NCT04554394|NO_INTERVENTION|Non-treated Wart|Control wart for each enrolled subject without intervention
62381109|NCT04764591|ACTIVE_COMPARATOR|Lateral sagittal approach|Patients in this group will be randomized to receive a lateral sagittal approach for Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
62381110|NCT04764591|ACTIVE_COMPARATOR|Costoclavicular approach|Patients in this group will be randomized to receive a costoclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
62760651|NCT04584346|ACTIVE_COMPARATOR|Arm B|Standard American Diet
62760652|NCT04646161||prostaglandins before iud insertion group|this group will receive 200 mcg prostaglandins in form of misoprostol 2 hrs before mirena iud insertion
62760653|NCT04646161||placebo group|this group will receive placebo tablet before mirena iud insertion
62760654|NCT02024022|ACTIVE_COMPARATOR|Standard approach|"patients will be randomized to one of the 2 currently used bowel preparation regimens in our clinic:~* 4L split polyethylene glycol solution~* split magnesium citrate/sodium picosulphate preparation regimen"
62760655|NCT02024022|EXPERIMENTAL|Individualized approach|patients will receive either the 4L split polyethylene glycol bowel prep regimen or the sodium picosulphate/magnesium citrate split prep regimen according to personal characteristics assessed using a self-administered questionnaire (including bowel habits, the preference for large-volume preparation and education level)
62760656|NCT05655143|EXPERIMENTAL|Balance Training|
62760657|NCT05655143|NO_INTERVENTION|Control|
62760658|NCT01812356|EXPERIMENTAL|Argon gas probe|Cryomaze procedure using Argon gas probe
62760659|NCT01812356|ACTIVE_COMPARATOR|Nitrous oxide probe|Cryomaze procedure using Nitrous oxide probe
62760660|NCT02088593|EXPERIMENTAL|DAWN simulation|Simulated Dawn Light box
62760661|NCT02088593|ACTIVE_COMPARATOR|Sleep hygiene instructions read aloud|Standard sleep hygiene instructions were read aloud.
62760662|NCT04433559|ACTIVE_COMPARATOR|Group Active Tadalafile|One oral tablet of 1.5 mg IPDE daily for 14 weeks of treatment.
62760663|NCT04433559|PLACEBO_COMPARATOR|Group Placebo|One oral tablet of placebo daily for 14 weeks of treatment.
62760664|NCT05744375|EXPERIMENTAL|Trastuzumab deruxtecan (T-DXd)|"All patients enrolled will be treated with trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (± 3 days).~The subject's weight at baseline will be used to calculate the initial dose. If during the course of treatment the subject's weight changes by ± 10% of the baseline weight, the subject's dose will be recalculated based on the subject's updated weight.~Patients will receive T-DXd until unacceptable toxicity, progressive disease (PD), informed consent withdrawal, or other discontinuation criterion is met."
62760665|NCT04634708||Pediatric patients on EXCOR VAD support|
62760666|NCT04750980||Food allergy|Childen with food allergy
62760667|NCT04750980||Respiratory allergy|Children with respiratory allergy
62760668|NCT04750980||Healthy controls|Healthy subjects
62760669|NCT00511056||HIVNAT 006|HIVNAT 006 is a long term follow up cohort. The primary objective of this study is to collect and evaluate the long-term clinical outcomes of HIV infected patients have participated in HIV-NAT studies. These subjects will be used to test our hypothesis.
62760670|NCT03705780|OTHER|the short OSAS scale|In preoperative interview，distributing the short OSAS screening scales to children's parents，and the scale was completed preoperative，calculate the score of the scale
62760671|NCT03705780|EXPERIMENTAL|fentanyl test|In the operating room，giving 1 mcg/kg fentanyl when the End-tidal concentrations of sevoflurane were maintained at 3.0 and the spontaneous respiratory frequency was stable after eyelash reflex disappeared and pharyngeal airway insertion, observing the changes of respiratory rate
62381111|NCT02113644||Overweight or obese children|Overweight or obese children according to the International Obesity Task Force (IOTF) criteria following the lifestyle intervention in the Centre for Overweight Adolescent and Children's Healthcare
62381112|NCT02113644||Lean children|Lean children according to the International Obesity Task Force (IOTF) criteria admitted at de pediatric ward for a planned surgery, for example the correction of floppy ears
62381113|NCT01240772|EXPERIMENTAL|DGALM|doppler-guided arterial ligation with mucopexy
62381114|NCT01240772|ACTIVE_COMPARATOR|SH|stapled haemorrhoidopexy according to Longo
62381115|NCT00928733|EXPERIMENTAL|alcohol|Intraduodenal infusion of ethanol
62381116|NCT00928733|OTHER|Ethanol|
62381117|NCT00928733|EXPERIMENTAL|Placebo|Intraduodenal infusion of tap water
62381118|NCT03665233|SHAM_COMPARATOR|Sh-group|The patients in this arm get standard treatment, together with a sham version of a VR session.
62381119|NCT03665233|ACTIVE_COMPARATOR|VR-group|These patients get a VR session with the standard treatment
62381120|NCT01064986|PLACEBO_COMPARATOR|A|IV Endotoxin plus saline vehicle (placebo)
62381121|NCT01064986|ACTIVE_COMPARATOR|B|IV Endotoxin plus IV hydrocortisone
62381122|NCT02485405||stressed|stressed volunteers perform Trier social stress test
62381123|NCT02485405||non-stressed|non-stressed volunteers perform Trier social stress test
62381124|NCT06372405|EXPERIMENTAL|Cognitive Reappraisal|Cognitive reappraisal is a psychotherapeutic strategy utilized to regulate emotions by reinterpreting the meaning of stimuli. Participants will receive instructions on generating and implementing cognitive reappraisal in both misophonic and non-misophonic contexts and will be practicing it within psychotherapeutic sessions. The program consists of four weekly online psychotherapeutic sessions: the first session will be a 90-minute group session, followed by three individual sessions, each lasting 30 minutes.
62381125|NCT06372405|ACTIVE_COMPARATOR|Schultz Autogenic Training|Schultz Autogenic Training is a relaxation technique aimed at promoting relaxation and reducing physiological arousal. It consists of six exercises focusing on sensations of heaviness, warmth, heartbeat, breathing, abdominal warmth, and coolness of the forehead.
62381126|NCT02186886|OTHER|Golimumab|Golimumab: Patients with body weight less than 80 kg initial dose of 200 mg, followed by 100 mg at week 2, then 50 mg every 4 weeks, thereafter // Patients with body weight greater than or equal to 80 kg initial dose of 200 mg, followed by 100 mg at week 2, then 100 mg every 4 weeks, thereafter
62381127|NCT01614366|ACTIVE_COMPARATOR|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
62381128|NCT01614366|EXPERIMENTAL|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
61987458|NCT02526940||blood CD4 cells count : 200 - 300/mm3|patients with blood CD4 cells count at the time of initiation of HAART between 200 and 300/mm3 Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years
61987459|NCT02526940||blood CD4 cells count >350/mm3|"patients with blood CD4 cells count at the time of initiation of HAART\> 350/mm3.~Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years"
62381129|NCT01614366|EXPERIMENTAL|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
62760672|NCT02448979|ACTIVE_COMPARATOR|Left thoracotomy|Esophagectomy through left side transthoracic approach, with esophagogastric anastomosis above aortic arch and two-field lymphadenectomy (thoracic and abdominal lymph node)
62381130|NCT01614366|EXPERIMENTAL|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
62381131|NCT05378893|EXPERIMENTAL|Single-ascending dose：Part1：DR10624|Escalating doses of DR10624 for injection administered subcutaneously in healthy participants or obese but otherwise healthy participants
62381132|NCT05378893|PLACEBO_COMPARATOR|Single-ascending dose：Part1：placebo|Escalating doses of placebo for injection administered subcutaneously in in healthy participants or obese but otherwise healthy participants
62760673|NCT02448979|ACTIVE_COMPARATOR|Right thoracotomy|Esophagectomy through right side transthoracic approach, with esophagogastric anastomosis above azygos vain arch or on the top of chest cavity and two-field lymphadenectomy (thoracic and abdominal lymph node)
62760674|NCT04542460|NO_INTERVENTION|Optimal Medical Treatment|CTO patients receiving optimal medical treatment
62760675|NCT04542460|ACTIVE_COMPARATOR|Optimal Medical Treatment and PCI|CTO patients receiving PCI in ajunction to optimal medical treatment
62760676|NCT01090934|EXPERIMENTAL|high resolution EEG|
62760677|NCT01090934|ACTIVE_COMPARATOR|Stereo Electroencephalography|
61987460|NCT01370226|ACTIVE_COMPARATOR|CBI|Computer delivered Brief Intervention
62760678|NCT03875807|ACTIVE_COMPARATOR|0 degree Knee Flexion Angle ACLR|At the time of surgery, tunnel position and surgical technique will be standardized for transtibial and anteromedial portal ACLR. Individuals randomized to this arm intra-operatively to undergo fixation of the ACL graft on the tibial side at a KFA of 0 degrees as measured by a sterile goniometer. Grafts will be tensioned according to the maximum surgeon-applied tension at the designated KFA. After surgery, patients will be treated with a standardized accelerated physical therapy protocol
61987461|NCT01370226|ACTIVE_COMPARATOR|TBI|Therapist delivered Brief Intervention
61987462|NCT01370226|NO_INTERVENTION|EUC|Enhanced Usual Care
61987463|NCT00927433|NO_INTERVENTION|Standard care|Patients received standard education about fatigue by clinicians.
61987464|NCT00927433|EXPERIMENTAL|Education arm|Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions.
61987465|NCT00429507|EXPERIMENTAL|Samarium 153-EDTMP + Stem Cell Transplant|Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) by vein On Day 1. If enough study drug goes to bones, will receive a higher dose of 153 Sm-EDTMP, called a therapy dose, 7-14 days after the tracer dose. Stem Cell Transplant on Day 0, about 14-21 days after Samarium 153-EDTMP. Questionnaires taking about 15 minutes to complete.
61987466|NCT01412203|NO_INTERVENTION|Usual Practice|School continues with regular programming
61987467|NCT01412203|EXPERIMENTAL|Action Schools! BC|School adopts the AS!BC model
61987468|NCT00906152||Subacute low back pain; chronic low back pain|Patients with subacute or chronic low back pain seen in the Primary Care Centers participating in the study.
61987469|NCT02608554|EXPERIMENTAL|Taichi|The 24 forms of simplified TCC recommended as the popular health sport by the General Administration of Sport of China were applied.
61987470|NCT02608554|ACTIVE_COMPARATOR|Self-monitored exercise|Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise.
61987471|NCT02046460|ACTIVE_COMPARATOR|Oral Anticoagulation|Vitamin K-Antagonists, target INR 2.0-3.0
61987472|NCT02046460|EXPERIMENTAL|Antiplatelets|Acetylsalicylic acid, 300mg o.p.d.
61987473|NCT06151587|EXPERIMENTAL|QLM3004 Concentration 1|Solution low dose
61987474|NCT06151587|EXPERIMENTAL|QLM3004 Concentration 2|Solution medium dose
62381133|NCT05378893|EXPERIMENTAL|Multiple-ascending dose：Part2：DR10624|Escalating doses of DR10624 for injection administered subcutaneously in obese adult subjects with moderate hypertriglyceridemia
62381134|NCT05378893|PLACEBO_COMPARATOR|Multiple-ascending dose：Part2：placebo|Escalating doses of placebo for injection administered subcutaneously in obese adult subjects with moderate hypertriglyceridemia
62381135|NCT04180475|EXPERIMENTAL|MedRem application|MedRem smartwatch application
61987475|NCT06151587|EXPERIMENTAL|QLM3004 Concentration 3|Solution high dose
61987476|NCT06151587|PLACEBO_COMPARATOR|Placebo|Placebo Ophthalmic Solution
61987477|NCT06456333||Adolescent idiopathic scoliosis patients（Observation Group）|Acquisition equipment：SAGA high-density electromyography system (TMSi, New Zealand).Acquisition site: paravertebral muscle at the L1-L3 level, with the electrode sheet placed 1.5 cm adjacent to the spinous process.Acquisition process: ① Place the electrode sheet and fix it. ② The subject was instructed to complete the specified movements according to the experimental paradigm and the EMG signals were recorded simultaneously.Experimental Paradigm:Biering-Sorensen test,BST：The subject was lying prone on the bed, with the upper half of the body poking out of the bed, the anterior superior iliac spine located at the edge of the bed, both lower limbs partially immobilized on the bed with straps, both hands crossed in front of the chest grasping the contralateral shoulder and tightly pressed against the chest wall, and the torso was suspended in the air and parallel to the floor, and the patient stopped the test when he/she maintained this position for 90s.
61987478|NCT06456333||Healthy population（Control Group）|Same intervention as the observation group.
61987479|NCT04035161|EXPERIMENTAL|Investigational Product|Skin will be prepared with investigational product
61987480|NCT04035161|OTHER|Reference Standard|Skin will be prepared with reference standard
61987481|NCT04035161|ACTIVE_COMPARATOR|Active Control|Skin will be prepared with active comparator
61987482|NCT04035161|OTHER|Negative Control|Skin will be prepared with negative control
61987483|NCT04028752||Males and females|The investigators are interested in sampling a wide variety of individuals from varying ethnic groups, sex, and age range.
61987484|NCT03897179|EXPERIMENTAL|INVSENSOR00032 and INVSENSOR00033 test group|All subjects will be enrolled into the test group and will receive the INVSENSOR00032 and/or INVSENSOR00033 device.
61987485|NCT03631901|ACTIVE_COMPARATOR|Melatonin|melatonin 0.3mg/kg/8 hours, orally. Given only during the febrile illness.
61987486|NCT03631901|ACTIVE_COMPARATOR|Diazepam|oral diazepam 1mg/kg/day divided into 3 doses. Given only during the febrile illness.
61987487|NCT02164305|EXPERIMENTAL|Strengthening group|4-week exercise training, 3 times a week, 30 minutes per visit.
61987488|NCT02164305|EXPERIMENTAL|Neuromuscular group|4-week exercise training, 3 times a week, 30 minutes per visit
61987489|NCT02164305|SHAM_COMPARATOR|Control|Only have 2 assessments.
61987490|NCT05466747|EXPERIMENTAL|Part A: RYMPHYSIA 60 mg/kg|Participants will receive 60 mg/kg RYMPHYSIA, intravenous (IV) infusion, once every week for up to 104 weeks.
61987491|NCT05466747|ACTIVE_COMPARATOR|Part A: Another Available A1PI 60 mg/kg|Participants will receive 60 mg/kg of another available A1PI, IV infusion, once every week for up to 104 weeks.
61987492|NCT05466747|EXPERIMENTAL|Part B: RYMPHYSIA 60 mg/kg|Participants will receive 60 mg/kg RYMPHYSIA, IV infusion, once every week for up to 104 weeks.
61987493|NCT05466747|EXPERIMENTAL|Part B: RYMPHYSIA 120 mg/kg|Participants will receive 120 mg/kg RYMPHYSIA, IV infusion, once every week for up to 104 weeks.
61987494|NCT05042947|EXPERIMENTAL|DLCT|After finding polyps that meet the inclusion criteria, the surgical method for resection was selected according to the operator's preferences, and the experimental group used double-loop coil clamp technology to treat the wound.
61987495|NCT05042947|ACTIVE_COMPARATOR|Traditional technology|After finding polyps that meet the inclusion criteria, the surgical method for resection was selected according to the operator's preferences.The control group used the traditional hemostatic clip technique to treat the wound
61987496|NCT05851859|EXPERIMENTAL|Complementary respiratory training to cardiac coherence (CC)|"The  intervention  group will benefit from a complementary respiratory training to CC during 6 months in addition to the usual care procedure."
61987497|NCT05851859|NO_INTERVENTION|Usual care procedure in the event of Long COVID|"The  control  group will follow a usual care procedure in the event of Long COVID"
61987498|NCT06528522||non-smoking - periodontally healthy|Participants eligible for inclusion are those who have reported a lifetime history of never smoking and exhibit periodontal health.
61987499|NCT06528522||smoking - periodontally healthy|"Tobacco Use: Participants must have a documented history of smoking more than 10 cigarettes per day.~Periodontal Health: Participants must exhibit clinically verified periodontal health, characterized by the absence of clinical attachment loss, probing depths within normal ranges, and no radiographic evidence of alveolar bone loss."
62381136|NCT01688427|EXPERIMENTAL|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper.
62381137|NCT01688427|EXPERIMENTAL|Standard DOVE intervention|The standard DOVE intervention has already been developed and tested (NR009093). The standard DOVE intervention is a brochure based 10 minute intervention that the home visitor reviews with the women. It consists of information about IPV, its effects on pregnancy and infant health, community resources and a plan for individual safety options. For the eMOCHA DOVE intervention, the DOVE 10 minute brochure intervention will be converted from the paper format to a visually colorful interactive presentation loaded into the home visitor device using the eMOCHA application. The format will be completely activated and implemented by the women. She uses small ear buds and a touch screen, so how she responds and interacts with the media enhanced eMOCHA DOVE intervention is private.
61987500|NCT06528522||non-smoking - periodontitis|"Non-smokers: Only participants who have reported never smoking will be considered.~Clinical Attachment Loss: Participants must exhibit a clinical attachment loss (CAL) of ≥3 mm in more than 30% of sites.~Probing Depth: A probing depth (PD) of ≥5 mm must be present in at least six teeth.~Radiographic Bone Loss: Participants must show radiographic evidence of bone loss extending to or beyond the middle third of the root in the coronal third."
61987501|NCT06528522||smoking - periodontitis|"Smoking History: Participants must have reported smoking more than 10 cigarettes per day for a period exceeding 5 years.~Clinical Attachment Loss (CAL): Participants must exhibit a clinical attachment loss of ≥3 mm in more than 30% of examined sites.~Probing Depth (PD): A probing depth of ≥5 mm must be present in at least six teeth.~Radiographic Bone Loss: Participants must demonstrate radiographic evidence of bone loss extending to or beyond the middle third of the root in the coronal third."
61987502|NCT00680433|EXPERIMENTAL|Active|Ketamine
61987503|NCT00680433|PLACEBO_COMPARATOR|Placebo|Saline (placebo)
61987504|NCT03371628|EXPERIMENTAL|Group VNI 1h|Intervention: Non invasive ventilation, applied for 1 hour
61987505|NCT03371628|NO_INTERVENTION|Group O2|Oxygen therapy
61987506|NCT06101199|ACTIVE_COMPARATOR|AIHH + tSCS-paired Strength Training|Participants will receive exposure to AIHH followed by transcutaneous spinal cord stimulation-paired respiratory and upper extremity strength training.
61987507|NCT06101199|EXPERIMENTAL|SHAM AIHH + tSCS-paired Strength Training|Participants will receive exposure to SHAM AIHH followed by transcutaneous spinal cord stimulation-paired respiratory and upper extremity strength training.
62381138|NCT04651647||Bone graft group|The bone graft group (n=19) who underwent open nailing with open bone graft for aseptic subtrochanteric nonunion
62381139|NCT04651647||Non bone graft group|The non-BG group (n=18) who underwent closed reamed nailing without bone graft for aseptic subtrochanteric nonunion
62381140|NCT01352624|EXPERIMENTAL|Experimental|$teps for Achieving Financial Empowerment ($AFE)
62381141|NCT01352624|NO_INTERVENTION|Usual Care|Veterans in control arm will receive usual care at VA
62760679|NCT03875807|ACTIVE_COMPARATOR|30 degree Knee Flexion Angle ACLR|At the time of surgery, tunnel position and surgical technique will be standardized for transtibial and anteromedial portal ACLR. Individuals randomized to this arm intra-operatively to undergo fixation of the ACL graft on the tibial side at a KFA of 30 degrees as measured by a sterile goniometer. Grafts will be tensioned according to the maximum surgeon-applied tension at the designated KFA. After surgery, patients will be treated with a standardized accelerated physical therapy protocol
62760680|NCT06375642|EXPERIMENTAL|Study arm|"Surufatinib: 100 mg orally qd, Adebrelimab: 1200 mg, IV, q3w, HAIC: Irinotecan liposome 30 mg/m2, leucovorin 200 mg/m2, 5-FU 200 mg/m2 bolus followed by continuous infusion of 5-FU 1200 mg/m2 5-FU q3W for 24 h. Dose adjustment was allowed for instilled drugs during treatment, and delayed administration was allowed for up to 8 weeks, calculated from the last administration time, otherwise treatment was terminated.~Tumor assessment will be performed by imaging method every 3 cycles (± 7 days) in 21-day cycles until disease progression (RECIST 1.1) or death (during treatment), and tumor treatment and survival status after disease progression will be recorded."
62381142|NCT05373186|EXPERIMENTAL|BC Combo THDB0207|Single administration of BC Combo THDB0207
62381143|NCT05373186|ACTIVE_COMPARATOR|Humalog® Mix25|Single administration of Humalog® Mix25
62381144|NCT05373186|ACTIVE_COMPARATOR|Humalog® and Lantus®|Simultaneous administration of Humalog® and Lantus®
62381145|NCT03990441|EXPERIMENTAL|Intervention|TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.
62381146|NCT03990441|PLACEBO_COMPARATOR|Placebo|Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
62381147|NCT04498585|EXPERIMENTAL|Intervention|Participants who will be receiving standard ICU care and additionally the VR stimulation during their ICU stay.
62381148|NCT04498585|NO_INTERVENTION|Control|Patients in the ICU who will be receiving standard ICU care during their ICU stay. Participants in this arm will not be receiving VR stimulation.
62381149|NCT02292524|NO_INTERVENTION|Arm I: Control|Men in this group consumed a tomato free diet for the duration of the study (less than or equal to 5 mg lycopene/day) and, thus, did not consume a tomato intervention product.
62381150|NCT02292524|EXPERIMENTAL|Arm II: Juice|Commercially-available tomato food product: men in this group consumed V8® juice (11-16.5 fl. oz./day).
62381151|NCT02292524|EXPERIMENTAL|Arm III: Soup|Commercially-available tomato food product: men in this group consumed Campbell's® Tomato Soup (2-2 ¾ cups/day).
62381152|NCT02292524|EXPERIMENTAL|Arm IV: Sauce|Commercially-available tomato food product: men in this group consumed Prego® spaghetti sauce (5-7 oz./day).
62381153|NCT01050140|EXPERIMENTAL|fructose|25% dietary energy from fructose
62381154|NCT01050140|ACTIVE_COMPARATOR|glucose|25% dietary energy from glucose
62760681|NCT05185895|SHAM_COMPARATOR|Start with: Concentric (normal) cycling|
62760682|NCT05185895|EXPERIMENTAL|Start with: Eccentric cycling|
62760683|NCT04841161|OTHER|Healthy subjects|The healthy adults who have not any neurological, musculoskeletal or rhematogical disease, a history of orthopedic surgery on spine or lower extremity. Their age should be ranged between 20 - 75 years.
62381155|NCT05639361||Standard Condensed|"Will complete a traditional schedule of 10 exposures over a 2-week period followed by a one-month break period before the final assessment. Because this schedule of exposure has been used most frequently in repeated exposure studies, this group will serve as the reference group."
62381156|NCT05639361||Periodic|Will complete a schedule of 5 exposures over a 2-week period, followed by a 2-week break, and then another 5 exposures over an additional 2-week period.
62381157|NCT05639361||Extended|Will complete a schedule of 10 exposures over a continuous 6-week period of time (approximately one exposure every 3-5 days).
62381158|NCT03652506|ACTIVE_COMPARATOR|Group A|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
62381159|NCT03652506|ACTIVE_COMPARATOR|Group E|Thoracic Epidural block +The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
62381160|NCT03652506|ACTIVE_COMPARATOR|Group Q|Ultrasound guided unilateral anterior Quadratus Lumborum block +The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
61987508|NCT06101199|SHAM_COMPARATOR|SHAM AIHH + SHAM tSCS-paired Strength Training|Participants will receive exposure to SHAM AIHH followed by SHAM transcutaneous spinal cord stimulation-paired respiratory and upper extremity strength training.
61987509|NCT06101199|EXPERIMENTAL|AIHH + SHAM tSCS-paired Strength Training|Participants will receive exposure to AIHH followed by SHAM transcutaneous spinal cord stimulation-paired respiratory and upper extremity strength training.
61987510|NCT01273792||Patients with Susac syndrome|
62381161|NCT04104893|EXPERIMENTAL|Single Arm|This is a single-arm, open-label study of the checkpoint inhibitor, pembrolizumab, in Veterans with mCRPC who have progressed on at least 1 prior novel androgen receptor (AR) signaling inhibitor, inclusive of abiraterone acetate, enzalutamide, apalutamide, and darolutamide. In addition to progressive mCRPC, a patient must have a somatic tumor mutation characterized by dMMR or CDK12-/- detected by next generation sequencing (NGS). Patients enrolled in this study will be treated with pembrolizumab at the FDA approved dosage of 200 mg intravenously every 3 weeks (21 days) until disease progression or unacceptable toxicity. During study, patients will maintain a castrate level of testosterone, = 50 ng/dL by ongoing treatment with a GnRH analogue or prior bilateral orchiectomy. Prior to initiating treatment with pembrolizumab, patients will undergo a baseline biopsy of a metastatic lesion. An additional biopsy of a metastatic lesion at the time of progression will be encouraged as well.
62381162|NCT03481634|EXPERIMENTAL|Brolucizumab 3 mg|"Brolucizumab 3 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP)."
61987511|NCT01273792||Matched healthy controls|
61987512|NCT04546347|EXPERIMENTAL|14CAZD9833 Infusion NMT 22.8 kBq/5mL|Dose 1 14CAZD9833 Solution for Infusion
61987513|NCT04546347|EXPERIMENTAL|AZD9833 film-coated tablet A Dose 1|Dose 1 AZD9833 film-coated tablet type A
62381163|NCT03481634|EXPERIMENTAL|Brolucizumab 6 mg|"Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP)."
62381164|NCT03481634|ACTIVE_COMPARATOR|Aflibercept 2 mg|"Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP)."
62381165|NCT06069622||Overweight and Obese individuals|A group of overweight and obese men and women whose body mass index (BMI) is ≥30.0 kg/m2 or ≥27.0 kg/m2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, prediabetes, dyslipidemia, obstructive sleep apnea whose treating clinicians have elected to start on semaglutide.
62381166|NCT05131815|EXPERIMENTAL|Virtual Group-Based Physical Activity (BurnAlong) and Discussion Board|Participants will be asked to complete a 12 week virtual physical activity program delivered by the BurnAlong app, participate in a discussion board, and engage in live physical activity sessions with an exercise physiologist.
62381167|NCT05326932|EXPERIMENTAL|Intervention group|Mechanical thrombectomy to be initiated as soon as possible after randomisation.
62381168|NCT05326932|NO_INTERVENTION|Control group|Patients assigned to the control group will avoid treating MT and only receive the standard medical treatment according to local guidelines.
62760684|NCT04841161|EXPERIMENTAL|Stroke subjects|Stroke patients were included if they were: (1) diagnosed with unilateral ischemic or hemorrhagic stroke; (2) a minimum of six months post stroke ; (2) able to stand without support for 1 minutes; (3) able to understand and follow verbal instructions. and (4) medically stable with physician release.
61987514|NCT04546347|EXPERIMENTAL|AZD9833 Oral Solution|Dose 1 AZD9833 oral solution
61987515|NCT04546347|EXPERIMENTAL|AZD9833 film-coated tablet B Dose 1|Dose 1 AZD9833 film-coated tablet type B
61987516|NCT04546347|EXPERIMENTAL|AZD9833 film-coated tablet A Dose 2|Dose 2 AZD9833 film-coated tablet type A
61987517|NCT04546347|EXPERIMENTAL|AZD9833 film-coated tablet B Dose 2|Dose 2 AZD9833 film-coated tablet type B
61987518|NCT04665921|EXPERIMENTAL|SGN-STNV|SGN-STNV monotherapy
61987519|NCT02310685|ACTIVE_COMPARATOR|Intervention|Active Comparator: Intervention The primary focus is CVD risk factors. Subjects will be shown how to update Cardiovascular Age or Cardiometabolic Age on website. Pharmacists will give overview of comprehensive ehealth wellness program. Subjects will complete additional health assessments which include questionnaires considered gold standard. Pharmacists will explain that participants have access to ehealth coaching based educational modules with information relevant to a better understanding of cardiovascular risk factors. The ehealth coaching modules are guides to help understand risk factors and importance of making lifestyle changes. As information alone is often insufficient to promote change, participants will have access to online physical activity challenges.
62182510|NCT01836198|EXPERIMENTAL|LY2409021+Ketoconazole (Part A, Cohort 2)|Part A, Period 2. Participants will receive a once-daily 400-mg oral dose of ketoconazole on Days 1-21 and a single 20-mg oral dose of LY2409021 on Day 4.
62182511|NCT01836198|EXPERIMENTAL|LY2409021+Clarithromycin (Part B)|Part B. Participants will receive a twice-daily 500-mg oral dose of clarithromycin on Days 1-21 and a single 20-mg oral dose of LY2409021 on Day 4.
62182512|NCT05623813||Individual-based education|Participants in the individual-based education would receive tailored education on sternal precautions to facilitate engagement in daily activities.
62381169|NCT04945499|OTHER|D-glucose|During the dynamic glucose scan, a brief hyperglycemic state was established by intravenous infusion of hospital-grade D50 glucose (D50, 25 g of dextrose in 50 mL of water sterile solution), followed by 20 mL of saline solution in 1 arm. The glucose infusion was performed using a power injector at an infusion rate of 0.2 mL/s, corresponding to total infusion times 250 seconds.
62760685|NCT00552630|EXPERIMENTAL|1|This group will receive d-penicillamine for 6 weeks
62760686|NCT00552630|PLACEBO_COMPARATOR|2|This group will receive placebo for 6 weeks
62760687|NCT00871039|EXPERIMENTAL|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
62381170|NCT01985412||Adult Heart Transplant Recipients|Patients \>18 yrs old that received a heart-only transplant and are followed at Stanford Hospital
62760688|NCT00871039|EXPERIMENTAL|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
62760689|NCT02582281|EXPERIMENTAL|Non touch technique|"the intrauterine device TCu 380A will be inserted in the conventional method as follows: First, insert the speculum and view the cervix. The position of the cervix will very often confirm if the uterus is anteverted or retroverted. Second, using the Allis forceps hold the back of a cotton-ball swab and dip it into a povidine-iodine disinfectant solution, or equivalent. Swab the cervix. Then cut the threads to the appropriate length and remove the speculum.~This technique omits the sounding of the uterus which is considered a quintessential procedure before IUD insertion for which there is no one established piece of evidence.The IUD is checked afterwards by transvaginal ultrasound."
62760690|NCT02582281|EXPERIMENTAL|Traditional IUD insertion|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound.
62760691|NCT06196398||Decompensated blood flow reserve|ICAS patients with decompensated cerebral blood flow reserve diagnosed by MR-FFR (FFR baseline≥0.81).
62760692|NCT06196398||Normal blood flow reserve|ICAS patients with normal cerebral blood flow reserve determined by MR-FFR (FFR baseline\<0.81).
62381171|NCT01985412||Pediatric Heart Transplant Recipients|Patients \<18 yrs old that received a heart-only transplant and are followed at Lucile Packard Hospital
62381172|NCT01985412||Adult Lung Transplant Recipients|Patients \>18 yrs old that received a lung-only transplant and are followed at Stanford Hospital
62760693|NCT01174017|ACTIVE_COMPARATOR|Standard loose Iodine 125 seeds|Prostate brachytherapy implant to be performed with standard format loose Iodine 125 seeds
62760694|NCT01174017|EXPERIMENTAL|AnchorSeed Iodine 125 implant|Prostate brachytherapy implant to be performed with a new design of Iodine 125 seed that has a coating to increase adherence to tissue
62760695|NCT06472869|EXPERIMENTAL|NJOY ACE e-cigarette provision|"Device: NJOY ACE e-cigarette, 5% nicotine in tobacco flavor~Patients will be provided with a NJOY ACE electronic cigarette for 4 weeks and asked to use the NJOY ACE as a substitute for smoking combustible cigarettes during the 4 weeks."
62760696|NCT01715350|PLACEBO_COMPARATOR|Placebo group|"• Drug : Placebo 2 tablet~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
62760697|NCT01715350|EXPERIMENTAL|Dose group 1|"* Drug : Placebo 1 tablet + Study drug 1 tablet~* Study drug(650-mg PM012 tablet)~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
62760698|NCT01715350|EXPERIMENTAL|Dose group 2|"* Drug : Study drug 2 tablet~* Study drug (650-mg PM012 tablet)~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
62381173|NCT01985412||Pediatric Lung Transplant Recipients|Patients \<18 yrs old that received a lung-only transplant and are followed at Lucile Packard Hospital
62381174|NCT01985412||Kaiser Adult Heart Transplant Recipients|Patients \>18 yrs old that received a heart-only transplant at Stanford Hospital but are followed at Kaiser Permanente in Santa Clara
62381175|NCT00499161|NO_INTERVENTION|1|Control group received usual care
62381176|NCT00499161|EXPERIMENTAL|2|Received intervention New model of nursing care
62760699|NCT06037850|EXPERIMENTAL|Treatment|Randomized to Treatment
62760700|NCT06037850|ACTIVE_COMPARATOR|Control|Randomized to Control
62760701|NCT03990207|EXPERIMENTAL|PowerSpiral Enteroscopy System|Subjects who have a medical indication for antegrade enteroscopy
62760702|NCT05899231|EXPERIMENTAL|Prehabilitation Group|The prehabilitation group will be provided with access to the online digital web platform which contains the weekly acceptance and commitment therapy based education videos, nutrition intervention, and exercise intervention.
62760703|NCT05899231|NO_INTERVENTION|Usual Care|This group will receive standard care for LT candidates with cirrhosis and will be provided with standard online exercise, nutrition, and behavioural resources. Control participants will not receive access to the online digital platform.
62381177|NCT00766272|EXPERIMENTAL|Arm 1|Body-weight supported treadmill training
62381178|NCT05119244|EXPERIMENTAL|cannabis smokers|
62381179|NCT05119244|EXPERIMENTAL|Tobacco smokers|
62381180|NCT05119244|EXPERIMENTAL|Non-smoking patients|
62381181|NCT02299544|EXPERIMENTAL|OAB|"Patients with overactive bladder (OAB) with or without urge incontinence.~Two patient populations will be enrolled in the study:~Patients with no previous treatment with percutaneous tibial nerve stimulation (PTNS) \[de novo patient group\] and Patients with a documented success on PTNS therapy \[prior-PTNS group\]. Documented success on PTNS is defined by a ≥50% reduction in urinary frequency, and/or ≥50% fewer incontinence episodes, or a return to normal voiding frequency \[\<8 voids/day\], based on retrospective diary review.~All patients will be treated with BlueWind Medical System."
62760704|NCT05743075|EXPERIMENTAL|Ensifentrine|"Eligible subjects will be randomly assigned in a 5:3 ratio to receive either Ensifentrine or placebo. Doses and methods of administration are as follows:~Ensifentrine (RPL554) 3 mg BID or placebo BID will be administered by aerosol inhalation for 24 weeks; each nebulization time wil be approximately 5 minutes."
62760705|NCT05743075|PLACEBO_COMPARATOR|Placebo|"Eligible subjects will be randomly assigned in a 5:3 ratio to receive either Ensifentrine or placebo. Doses and methods of administration are as follows:~Ensifentrine (RPL554) 3 mg BID or placebo BID will be administered by aerosol inhalation for 24 weeks; each nebulization time wil be approximately 5 minutes."
62760706|NCT04103541|EXPERIMENTAL|IP-Colombia|
62760707|NCT04103541|NO_INTERVENTION|Waitlist control|
62760708|NCT02387164|EXPERIMENTAL|Alum-GAD, Vitamin D3|Two doses à 20 microgram of subcutaneous alum-GAD (Diamyd), 30 Days apart. Vitamin D 2000 U/Daily with start 30 days before the first injection of Diamyd. Vitamin D treatment will continue throughout the whole study period of 5 years.
61987520|NCT02310685|NO_INTERVENTION|No Intervention|Individuals randomized to the non active intervention group will have access to modified version of ehealth website. The pharmacist will show participants how to update Cardiovascular Age or Cardiometabolic Age on website. They will have access to health assessments but not ehealth coaching educational modules or challenges. They will have online support tools including public domain education material on exercise, healthy eating, understanding and managing blood pressure, diabetes and smoking cessation. Participants will return to the pharmacist for follow-up visits at 3, 6 months and one year. The pharmacist will update their cardiovascular risk profile with current information At the first follow up visit and at 1 year participants will be asked to have blood lipids reassessed.
62381182|NCT04477668|EXPERIMENTAL|Helmet group|Patients will be allocated to helmet non-invasive ventilation
62760709|NCT02387164|PLACEBO_COMPARATOR|Placebo, Vitamin D3|Two doses of subcutaneous placebo, 30 Days apart. Vitamin D 2000 U/Daily with start 30 days before the first injection of Diamyd. Vitamin D treatment will continue throughout the whole study period of 5 years
61987521|NCT01787227||Blinded, Pre-selected Arm|For targets that exhibit lower prevalence rates in the intended use population, banked, pre-selected, positive clinical specimens will be tested.
61987522|NCT01787227||Blinded, Prospective Arm|Diagnostic accuracy for the more prevalent targets will be evaluated in prospectively collected, de-identified, left-over, clinical specimens accrued during the 2012/2013 flu season.
61987523|NCT04640090|EXPERIMENTAL|Smartphone app|All participants in this single-arm study will receive two months of subsidized, full access to the smartphone wellness application.
61987524|NCT03974971||BPDCN diagnosis group|By review medical records Enroll patients diagnosed with BPDCN from January 1, 2000 to October 31, 2018
61987525|NCT05567055|EXPERIMENTAL|Capmatinib|400 mg orally, twice daily
61987526|NCT03755986|OTHER|ATOMO Diagnostic Test|All patients will receive an ATOMO diagnostic test to use. There is no comparative arm.
61987527|NCT03441841|EXPERIMENTAL|Lidocaine + prilocaine|Single topical dose of a combination of nanoencapsulated lidocaine (2.5%) and prilocaine (2.5%) formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
61987528|NCT03441841|ACTIVE_COMPARATOR|Lidocaine|Single topical dose of lidocaine nanoencapsulated gel (2.5 %) formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
61987529|NCT03441841|ACTIVE_COMPARATOR|Prilocaine|Single topical dose of prilocaine (2.5 %) nanoencapsulated gel formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
62760710|NCT03671408||periodontitis|periodontitis patients which were diagnosed based on clinical parameters
61987530|NCT04566315|OTHER|ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS|SYMPTOMATIC EFFECTIVENESS OF MICROPARTICLE ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS WITH PAIN RESISTANT TO MEDICAL TREATMENT
61987531|NCT01991158|EXPERIMENTAL|GAD-M regimen|GAD-M regimen means High dose of methotrexate combined with gemcitabine, pegaspargase and dexamethasone
61987532|NCT02308462|EXPERIMENTAL|CHIMPs intervention|Family-Intervention
61987533|NCT02308462|NO_INTERVENTION|Control|"The long-term effectiveness of the CHIMPs intervention under conditions of practice will be examined in comparison to a control condition receiving the usual after care (Treatment as usual = TAU); this testing of effectiveness will be performed in due consideration of the health economic aspects.~The treatment as usual implies that families of the control Group receive the Treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every Family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system."
62760711|NCT03671408||gingivitis/healthy|gingivitis healthy patients which were diagnosed based on clinical parameters
62760712|NCT03383783|OTHER|Treatment Period 1|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
61987534|NCT05237479|PLACEBO_COMPARATOR|Control Group|DAA THA under spinal anesthesia ( standard of care at Montefiore)
61987535|NCT05237479|ACTIVE_COMPARATOR|Intervention Group|DAA THA under spinal anesthesia and a preoperative supra-inguinal fascia iliac compartment block (S-FICB)
61987536|NCT05824533|EXPERIMENTAL|TKA with onlay patella button|Total knee arthroplasty (TKA) with a patella placed with the use of the CORI based on pre-operative 4DCT images of the knee.
62760713|NCT03383783|OTHER|Treatment Period 2|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
62760714|NCT03383783|OTHER|Treatment Period 3|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
62760715|NCT03383783|OTHER|Treatment Period 4|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
62760716|NCT03110653|ACTIVE_COMPARATOR|Remifentanil|Remifentanil TCI: gradual withdrawal: reduction of 30% / 15 mins (2 -\> 1.4 -\> 1 -\> 0.7-\> 0.5 -\> 0.35 -\> 0.25 -\> 0 ng/ml)
62760717|NCT03110653|PLACEBO_COMPARATOR|NaCl 0.9%|Remifentanil abrupt discontinuation / NaCl 0.9% (control group with a reduction of 30% /15 mins) (2 -\> 1.4 -\> 1 -\> 0.7-\> 0.5 -\> 0.35 -\> 0.25 -\> 0 ng/ml)
62760718|NCT01202604||Outpatients with bipolar disorder I or II (as per DSM-IV)|The percentage of patients who experience a relapse episode during the first 9 months after a mood event (manic or depressive).
61987537|NCT05824533|ACTIVE_COMPARATOR|TKA without onlay patella button|Total knee arthroplasty (TKA) placed with the use of the CORI based on pre-operative 4DCT images of the knee.
62381183|NCT04477668|NO_INTERVENTION|Control group|Patients will be allocated to standard of care
62381184|NCT03748654|EXPERIMENTAL|Single Arm|Patients will perform visual field testing with the Humphrey Field Analyzer and with the Virtual Reality Headset
62381185|NCT01884155|EXPERIMENTAL|Allogeneic umbilical cord blood therapy|Allogeneic umbilical cord blood therapy
61987538|NCT05402150|EXPERIMENTAL|Behavioral Activation|14 days of daily excercises
61987539|NCT05402150|EXPERIMENTAL|Mindfulness and Gratitude|14 days of daily excercises
61987540|NCT05402150|EXPERIMENTAL|Combination: Behavioral Activation and Mindfulness and Gratitude|14 days of daily excercises
61987541|NCT05402150|NO_INTERVENTION|Waitlist control group|Will receive the intervention (combination) after two weeks of intervention time of the other groups.
61987542|NCT05683899||Group A|141 days with AI scores displayed
61987543|NCT05683899||Group B|141 days with AI scores not displayed
61987544|NCT06436573||Retrospective cohort|"Consecutive adult patients (age ≥18 years-old), submitted to Cardiac Magnetic Resonance independently by the clinical suspicions in the first semester of 2019 (from January to June 2019) that have signed an Informed Consent authorizing data collection for future retrospective clinical research protocols.~Timelapse has been chosen to avoid the impact of COVID-19 pandemic."
61987545|NCT05798390||Bempedoic acid and/or fixed-dose combination with ezetimibe|Participants with primary hypercholesterolemia or mixed dyslipidemia who received bempedoic acid and/or its fixed-dose combination with ezetimibe.
61987546|NCT00708942|ACTIVE_COMPARATOR|1|HAL suppository (single administration, HAL 100mg), laser illumination (50J/cm2)
61987547|NCT00708942|PLACEBO_COMPARATOR|2|Placebo suppository (single administration), laser illumination (50J/cm2)
61987548|NCT00708942|NO_INTERVENTION|3|
61987549|NCT00708942|ACTIVE_COMPARATOR|4|HAL ointment (5%, 100mg, single administration), LED diode illumination (50J/cm2)
61987550|NCT00708942|PLACEBO_COMPARATOR|5|Placebo ointment (single administration), no illumination
61987551|NCT03337282||Observational cohort|Adults 70 years of age or older undergoing major noncardiac surgery under protocolized general anesthesia
62760719|NCT05550623|EXPERIMENTAL|Transfemoral amputation performed with tourniquet application|"Group 1:Randomized to procedure with Tourniquet application Sterile wash to groin and placement of sterile tourniquet. The amputation level approximately 10-15 cm above the upper edge of patella is marked and the anterior and posterior flaps are measured and drawn out.~The leg is lifted, and the tourniquet is inflated. The pressure is set to 250 mmHg. Starting time is noted. Incision through skin, fascia and musculature. The femoral vessels are clamped, cut and ligated. With an oscillating saw the femoral bone is cut, and the leg can be removed The tourniquet is deflated. Tourniquet time is noted. Rest of procedure as listed in arm2~Weight of the leg is noted. Weight of surgical swabs is noted, to estimate intraoperative blood loss."
62760720|NCT05550623|NO_INTERVENTION|Transfemoral amputation performed without tourniquet application|"Group 2: Randomized to procedure without Tourniquet The amputation level approximately 10-15 cm above the upper edge of patella is marked and the anterior and posterior flaps are measured and drawn out. Incision through skin, fascia and musculature. The femoral vessels are clamped, cut and ligated. With an oscillating saw the femoral bone is cut, and the leg can be removed.~The edge of the femoral bone is rasped smooth. A myodesis is performed, attaching the adductor muscle to the end of the femoral bone. Nervus Ischiadicus is dissected as proximal as possible and protected within a purse string suture to avoid development of neuroma.~Ligation of bleeding vessels. Fascia and skin is closed with sutures. A soft compression bandage is applied to the stump.~* Weight of the leg is noted.~* Weight of surgical swabs is noted, to estimate intraoperative blood loss."
61987552|NCT05020314|EXPERIMENTAL|Clinically Based: Healthy Weight Clinic|
61987553|NCT02064010|EXPERIMENTAL|SNC-102, low dose|SNC-102 (Acamprosate calcium) tablet 4 week duration dosing
61987554|NCT02064010|EXPERIMENTAL|SNC-102, high dose|SNC-102 (Acamprosate calcium) tablet 4 week duration dosing
61987555|NCT02064010|PLACEBO_COMPARATOR|Placebo|Placebo tablet 4 week duration dosing
61987556|NCT05863377||Adjuvant Chemotherapy Group|The patients of this group receive adjuvant chemotherapy after surgery.
61987557|NCT05863377||No-Further Treatment Group|The patients of this group only receive regular follow-up without adjuvant therapy.
61987558|NCT06475482|PLACEBO_COMPARATOR|Petroleum gel (Vaseline)|control group
61987559|NCT06475482|ACTIVE_COMPARATOR|Lip hydrant|experimental group
61987560|NCT06539559|EXPERIMENTAL|eribulin+bevacizumab|eribulin 1.4 mg/m2 iv d1,8 + bevacizumab 7.5mg/kg ivgtt d1/q21d
61987561|NCT06539559|ACTIVE_COMPARATOR|eribulin|eribulin 1.4 mg/m2 iv d1,8/q21d
61987562|NCT04363021||cases|Cases will be defined as women with systemic sclerosis, specific vascular complications (digital ulcers, specific cardiac involvement of systemic sclerosis including pulmonary arterial hypertension, renal crisis) and with a previous pregnancy longer than 6 months before systemic sclerosis diagnosis.
61987563|NCT04363021||controls|Controls will be defined as women with systemic sclerosis, no specific vascular complication and with a previous pregnancy longer than 6 months before systemic sclerosis diagnosis.
61987564|NCT05326594|EXPERIMENTAL|Physical Therapy|
61987565|NCT04384510||Patients with placenta accreta spectrum (PAS)|This cohort presents patients who were suspected or diagnosed either antenatal or intrapartum with placenta accreta spectrum
61987566|NCT02130661|EXPERIMENTAL|Part A|Subjects will receive 250 mg of rilapladib once daily (QD) for 14 days (Days 1-14)
61987567|NCT02130661|EXPERIMENTAL|Part B|Subjects will receive 25 mg of rilapladib QD for 1 day (Day 1), 200 mg of itraconazole twice daily (BID) for 1 day (Day 8) and QD for 2 days (Days 9-10). Subjects will receive 25 mg of rilapladib + 200 mg of itraconazole for 1 day (Day 11) and 200 mg of itraconazole QD for 6 days (Day 12-17)
61987568|NCT02804984||ICUS|idiopathic cytopenia of undetermined significance (ICUS)
61987569|NCT01273402|EXPERIMENTAL|TF2 and IMP288|TF2 will be administered at least 4 days before the radiolabeled IMP-288.
61987570|NCT03098173|EXPERIMENTAL|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
61987571|NCT03098173|ACTIVE_COMPARATOR|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
61987572|NCT04415281|EXPERIMENTAL|Active PBM|PBM has been used clinically in the treatment of musculoskeletal and other pain conditions for over 30 years. Despite the low quality of the existing evidence, PBM has been increasingly used in other countries for the treatment of TMD. However, in the US PBM is not widely used for the treatment of TMD pain. Due to the multifactorial nature of chronic TMD pain, we propose that a multimodal PBM protocol targeting multiple pathophysiological mechanisms will be the optimal approach for PBM implementation in patients with TMD.
61987573|NCT04415281|SHAM_COMPARATOR|Sham PBM|When applying PBM therapy, there are some heating elements in the treatment device, and most of the sham treatment devices available do not offer this feature, which increases the likelihood of unblinding both the patient and the interventionist. The THOR® LX2.3 PBM machine includes this new feature, such that the sham condition mimics the heating activity of the active treatment.
61987574|NCT06065579|EXPERIMENTAL|Intervention Group|Intervention group will receive intervention
61987575|NCT06065579|NO_INTERVENTION|Control Group|Control group will not receive intervention
61987576|NCT06088550|NO_INTERVENTION|Group-1|received standard care
61987577|NCT06088550|ACTIVE_COMPARATOR|Group-2|received BCAA
61987578|NCT06088550|ACTIVE_COMPARATOR|Group-3|Recieved Exercice
61987579|NCT06088550|ACTIVE_COMPARATOR|Group-4|Received a combined BCAA + Exercise
61987580|NCT01742507|ACTIVE_COMPARATOR|Medtronic Resolute Integrity Stent|Medtronic Resolute Integrity Stent
61987581|NCT01742507|ACTIVE_COMPARATOR|Biomatrix stent|Biomatrix stent
61987582|NCT05228145|EXPERIMENTAL|Cohort 1|The study treatment is a recombinant serotype 9 adeno-associated virus encoding a codon-optimized human CLN5 transgene (hCLN5opt).
62381186|NCT04526444|EXPERIMENTAL|Ftiness tracker|Participants in the group A will be provided the fitness tracker Mi Smart Band 5 with the computational algorithm PAI.
62381187|NCT04526444|EXPERIMENTAL|Home training platform and fitness tracker|Participants in group B will be provided with both the fitness tracker Mi Smart Band 5 with the computational algorithm PAI and access to Les Mills On Demand to perform training classes from home.
62381188|NCT04526444|EXPERIMENTAL|Peer support, home training platform and fitness tracker and|Participants in group C will be offered the fitness tracker Mi Smart Band 5 with the computational algorithm PAI, Les Mills On Demand and additional peer support via social media.
62381189|NCT03086954|EXPERIMENTAL|single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:The first day,the second day,29 days,injection once a day in this three days Duration:Only injection three times
62760721|NCT05479435|EXPERIMENTAL|Blue Prescription Group|Participants will get an exercise program, which is designed by their needs, desires and abilities. They will perform a desired exercise program 3 days a week and they will make an interview for motivation and/or modifying the program one day a week. They will write an activity diary.
61987583|NCT05228145|EXPERIMENTAL|Cohort 2|The study treatment is a higher dose of recombinant serotype 9 adeno-associated virus encoding a codon-optimized human CLN5 transgene (hCLN5opt).
61987584|NCT05228145|EXPERIMENTAL|Cohort 3|The study treatment is a higher dose of recombinant serotype 9 adeno-associated virus encoding a codon- optimized human CLN5 transgene (hCLN5opt).
61987585|NCT02003131|OTHER|Intra-articular knee injection of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered intra-articularly.
61987586|NCT02003131|OTHER|Subcutaneous injection of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered subcutaneously once per week for 12 weeks.
61987587|NCT00788892|EXPERIMENTAL|Arm A: CPX-351|First induction: CPX-351 at 100u/m2 administered on days 1, 3 and 5 Second induction: CPX-351 at 100u/m2 administered on days 1 and 3 Consolidation: CPX-351 at 100u/m2 administered on days 1 and 3
61987588|NCT00788892|ACTIVE_COMPARATOR|Arm B: Cytarabine + Daunorubicin|First induction: Cytarabine at a dose of 100mg/m2/day on days 1-7, Daunorubicin at dose of 45 or 60mg/m2 on days 1-3 Second induction: Cytarabine at a dose of 100mg/m2/day on days 1-5, Daunorubicin at a dose of 45 or 60 mg/m2/day on days 1 and 2 Consolidation: Investigator's Choice
62381190|NCT00114764|EXPERIMENTAL|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
62381191|NCT00114764|ACTIVE_COMPARATOR|filgrastim|Filgrastim given daily after induction chemotherapy
62760722|NCT05479435|ACTIVE_COMPARATOR|Video Based Home Exercise Group|Participants will get videos by different ways (closed link youtube, whatsapp, flash driver etc.). They will perform exercises 3 days a week. İnvestigator will phone them to ask whether they do the program or not. They will write an activity diary.
61987589|NCT03322033|EXPERIMENTAL|Type A Dissection|High risk subjects with ascending thoracic aortic pathologies including type A aortic dissection who are suitable for endovascular repair
61987590|NCT00451321|EXPERIMENTAL|otelixizumab|
61987591|NCT01200654|EXPERIMENTAL|MRSA Infections|Methicillin-Resistant Staphylococcus aureus Infections
61987592|NCT03449160|ACTIVE_COMPARATOR|Physical Therapy|Receive standard physical therapy
61987593|NCT03449160|EXPERIMENTAL|posture training device|Receive a posture training device in addition to standard physical therapy
61987594|NCT03559179|EXPERIMENTAL|Waivered Providers Receive the Opioid Wizard|All providers who have a buprenorphine waiver will receive the OUD clinical decision support tool (Opioid Wizard).
61987595|NCT03559179|NO_INTERVENTION|Does not Receive the Opioid Wizard|All non-buprenorphine waivered providers will be randomized to receive or not receive the Opioid Wizard. This arm of providers will continue to treat their patients as usual.
61987596|NCT03559179|EXPERIMENTAL|Non-Waivered Providers who receive Opioid Wizard|All non-buprenorphine waivered providers will be randomized to receive or not receive the Opioid. This arm of providers will receive the OUD clinical decision support tool (Opioid Wizard).
61987597|NCT04540289|ACTIVE_COMPARATOR|Optimal Medical Therapy without ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will not receive an ICD device
62381192|NCT01373099|EXPERIMENTAL|Static Spacer|Patients in this group will be randomized to a static, nonarticulating, antibiotic-impregnated cement spacer.
62381193|NCT01373099|EXPERIMENTAL|Articulating spacer|Patients in this group will be randomized to an articulating antibiotic-impregnated cement spacer.
62558622|NCT01894087|ACTIVE_COMPARATOR|Therapist-led brief intervention (TBI) - Cohort 2|"Participants will receive a therapist-led, computer-assisted intervention session with a master's level therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
62558623|NCT01894087|NO_INTERVENTION|Enhanced usual care - Cohort 2|
62381194|NCT04562233|EXPERIMENTAL|Intervention arm|Participants will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer. Once a week, the exercise trainer and participant will each log on to Zoom from their locations to begin the supervised exercise session. The exercise trainer will record all sessions. Sessions will be 30 to 45 minutes long and be structured as follows: review of previous session and an opportunity to ask questions; 5-minute warm-up; 20- to 25-minute workout; 5- to10-minute cool down and reminder of next session and/or data collection time period. Supervised sessions will be scheduled once a week over the 12-week intervention. Participants will be expected to complete their resistance-based physical activity program for an additional 1-2 days a week as per the intervention schedule to meet as physical activity guidelines. The exercise trainer will track participant attendance. During the session, participants must have another person in the same location in case of an emergency.
62381195|NCT04562233|OTHER|Control Arm|"The attention control arm will include a printed, individualized resistance-based physical activity program.~Participants randomized to the control arm will be given a printed or digital individualized, resistance-based physical activity program and told to aim to for three exercise sessions per week. Control participants will follow the same measurement schedule as intervention participants."
62381196|NCT05197985|EXPERIMENTAL|Integrated Early Childhood Development Intervention|Integrated Early Childhood Development Intervention is one intervention package. Inclusion criteria are adults (age 18+) who are primary caregiver of one or more children under the age of 5 years; and pregnant women (age 18+).
62760723|NCT05479435|ACTIVE_COMPARATOR|Supervised Exercise Group|Participants will perform an exercise program 3 days a week with a physiotherapist. The group will be held maximum 10 people.
62760724|NCT04367103|ACTIVE_COMPARATOR|NEP group|Norepinephrine infusion of 0.025 µg/kg/min and 6 µg bolus will be used if BP is reduced 20 % below baseline.
62760725|NCT04367103|PLACEBO_COMPARATOR|PHE group|Phenylephrine will be started at 25µg/min immediately after the intrathecal local anaesthetic injection and titrated according to blood pressure and pulse rate.
62760726|NCT02257177|ACTIVE_COMPARATOR|0.15 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 0.15mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
62760727|NCT02257177|ACTIVE_COMPARATOR|1.5 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 1.5mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
62381197|NCT05197985|NO_INTERVENTION|Control Arm|This is the control arm that receives no intervention. Inclusion criteria are adults (age 18+) who are primary caregiver of one or more children under the age of 5 years; and pregnant women (age 18+).
62381198|NCT04780594||Pre-pandemic COVID-19 group (PreCOVID)|All patients who underwent surgery from 13th January until 29th February 2020, which are considered free of COVID-19 patients, therefore pre-pandemic period.
62381199|NCT04780594||Pandemic COVID-19 group (COVID)|All patients who underwent surgery from 11th March 2020 until 15th May 2020, which were done during the first wave of the pandemic crisis.
62381200|NCT03196206|EXPERIMENTAL|Group A|Normal Renal Function
62381201|NCT03196206|EXPERIMENTAL|Group B|Moderate Renal Impairment
62760728|NCT02257177|ACTIVE_COMPARATOR|3 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 3mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
62760729|NCT02257177|ACTIVE_COMPARATOR|10 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 10mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
62381202|NCT03196206|EXPERIMENTAL|Group C|Severe Renal Impairment
62760730|NCT02257177|ACTIVE_COMPARATOR|20 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 20mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
62760731|NCT02257177|ACTIVE_COMPARATOR|50 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 50mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
62760732|NCT02257177|PLACEBO_COMPARATOR|Placebo Part 1|12 Healthy Subjects are administered placebo inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
62760733|NCT02257177|ACTIVE_COMPARATOR|0.3 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 0.3mg TD139 once daily for 14 days inhaled as a dry powder.
62381203|NCT01427829|EXPERIMENTAL|Intervention (CaPRA)|
62381204|NCT01427829|NO_INTERVENTION|Control (usual care)|
62381205|NCT00957060|EXPERIMENTAL|glimepiride|The initial dose is 2 mg once a day. At week 2, the dose can be increased to 4 mg once a day according to the titration. At week 4 and 12, the dose can be increased from 2 mg to 4 mg or from 4 mg to 6 mg according to the titration.
62381206|NCT00957060|ACTIVE_COMPARATOR|sitagliptin|100 mg once a day. The dose will not be titrated.
62381207|NCT02455596|EXPERIMENTAL|Experimental|Recombinant anti-tumor and anti-virus protein for injection(Novaferon), three times per week.
62381208|NCT01890733|SHAM_COMPARATOR|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridment, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
62558624|NCT06300190|OTHER|Biceps tenodesis alone|
62558625|NCT06300190|OTHER|Biceps tenodesis and repair labrum|
62558626|NCT00696215|PLACEBO_COMPARATOR|1|
62381209|NCT01890733|ACTIVE_COMPARATOR|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridment, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
62381210|NCT04562727|EXPERIMENTAL|Only MWA|Only preform MWA, chemotherapy isn't necessary
62381211|NCT04562727|ACTIVE_COMPARATOR|MWA combined with perioperative chemotherapy|MWA combined with perioperative chemotherapy. Chemotherapy was preformed before MWA and after MWA
62381212|NCT04562727|EXPERIMENTAL|MWA combined with postoperative chemotherapy|MWA combined with perioperative chemotherapy. Chemotherapy was preformed after MWA
62381213|NCT05701085|EXPERIMENTAL|PRE-ACT Adaptation|"At the scheduled oncologic visit: consent obtained and all participants will complete the Demographics/Clinical Characteristics survey and Pre-Intervention Survey~Within 3 months of consent: tailored educational intervention and patient navigation program will take place and the scored Pre-Intervention survey will be used to generate a list of barrier for each patient. The patient will be asked to view educational videos on an iPad that correspond with each identified barrier. Afterwards, the patient navigator will lead a discussion based on the topics discussed.~Within 4 weeks of the educational video: the participant will be contacted via phone to complete a Post-Intervention Survey that assesses knowledge, attitudes, and preparation related to participation in clinical trials~Two years after intervention: chart review will be performed to assess if the patient participated in a clinical trial."
62381214|NCT04090827|EXPERIMENTAL|Intervention|Nurse-led transition intervention and access to the iHeartChange website
62381215|NCT05907083||Adult CBCT Scan|CBCT Radiation
62381216|NCT01161433|EXPERIMENTAL|Intervention|Virtually delivered spirometry quality improvement program
62381217|NCT01161433|NO_INTERVENTION|Standard of Care|
62381218|NCT03322592|ACTIVE_COMPARATOR|EUS-FNB with ROSE|Intervention: Rapid on-site evaluation (ROSE) In the EUS-FNB with ROSE arm, the material obtained with the first pass will be processed for ROSE using the touch imprint technique. The biopsy specimen is carefully pressed onto the slide, allowing the superficial cells to adhere, and then gently lifted with forceps thereby creating a touch imprint of the specimen on the slide. In case of inadequate sample, a second pass will be done and the touch imprint technique will be repeated up to a maximum of 3 passes. In case of adequate ROSE at the first or the second pass, the additional passes will be performed as EUS-FNB and the material obtained placed directly into formalin or other fixative for subsequent histopathological evaluation.
61987598|NCT04540289|EXPERIMENTAL|Optimal Medical Therapy with ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will receive an ICD device
62381219|NCT03322592|ACTIVE_COMPARATOR|EUS-FNB without ROSE|Intervention: histologic evaluation In the FNB alone arm, 3 needle passes will be performed and the samples obtained will be placed directly in a vial containing formalin (or other fixative according to the local individual protocol). Macroscopic on-site evaluation (MOSE) of acquired sample will be then performed by the endoscopist.
62381220|NCT05649046|OTHER|patients|
62381221|NCT05108311|EXPERIMENTAL|Treatment|The Treatment sequence including joint Manual therapy techniques and soft tissue release techniques is proposed.
62381222|NCT01840215||Controls|Patients scheduled for elective ophthalmic surgery with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
62381223|NCT01840215||Primary open-angle Glaucoma|Patients scheduled for an elective glaucoma surgery that present with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of \>21 mmHg required
62381224|NCT01840215||Normal Tension Glaucoma|Patients scheduled for an elective glaucoma surgery that present with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of \< 21 mmHg.
62381225|NCT02346955|EXPERIMENTAL|Cohort A Monotherapy Dose Escalation|Participants will be enrolled in a staggered manner starting at a dose of 0.01 mg/kg of CM-24 (MK-6018) and continuing to 0.03, 0.1, 0.3, 1.0, 3.0, and 10 mg/kg to determine the recommended Phase 2 dose (RP2D). The dose will be escalated after a 6- to 8-week DLT window. Participants will be treated for 12 weeks during Cycle 1. Afterwards participants with clinical benefit and no dose-limiting toxicites (DLTs) are treated for up to 6 cycles.
62381226|NCT02346955|EXPERIMENTAL|Cohort B Combination Dose Escalation|Participants will be enrolled at the recommended phase 2 dose (RP2D) of CM-24 (MK-6018), determined by escalation studies, minus 1 dose level of MK-6018 in combination with a fixed dose of 200 mg pembrolizumab. Participants will be escalated to the RP2D of MK-6018 + 200 mg pembrolizumab. If the RP2D of MK-6018 + 200 mg pembrolizumab is not tolerated, the dose of MK-6018 will be de-escalated but will not fall below 1 mg/kg. Participants will be treated for 6 weeks during Cycle 1 and 2. Afterwards participants with clinical benefit and no DLTs are treated for up to 35 cycles.
62381227|NCT02346955|EXPERIMENTAL|Cohort C Monotherapy Expansion|Participants with advanced or recurrent cutaneous melanoma will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
62558627|NCT00696215|ACTIVE_COMPARATOR|2|Rasagiline
61987599|NCT00913809|EXPERIMENTAL|1|Desipramine HCL 100 mg Tablets Cord Laboratories
61987600|NCT00913809|ACTIVE_COMPARATOR|2|Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc
61987601|NCT04139954||Rheumatoid arthritis and Spondyloarthritis|Patients using Biological or Targeted Synthetic DMARDs
61987602|NCT03720496|EXPERIMENTAL|CD19-TriCAR-T|Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously
61987603|NCT02446236|EXPERIMENTAL|Dose Escalation Study|Ibrutinib 560 mg/daily rituximab 375mg/m2 IV Day 1 Lenalidomide 10-25 mg PO days 1-21
61987604|NCT05362747|EXPERIMENTAL|ProduceRx|Participants in the ProduceRx intervention group will be provided with BWL and produce vouchers for fresh fruits and vegetables.
62760734|NCT02257177|ACTIVE_COMPARATOR|3 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 3mg TD139 once daily for 14 days inhaled as a dry powder.
62760735|NCT02257177|ACTIVE_COMPARATOR|10 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 10mg TD139 once daily for 14 days inhaled as a dry powder.
62760736|NCT02257177|PLACEBO_COMPARATOR|Placebo Part 2|9 Patients with IPF are administered placebo inhaled as a dry powder.
62760737|NCT01633515|OTHER|Intralesional cryotherapy|10 BCC (skin lesions) in the lower extremity of elderlies with risk factors for surgical complications.
62760738|NCT00410826|EXPERIMENTAL|Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer)|Patients receive cisplatin IV on days 1, 22, and 43 and undergo 3-dimensional conformal or intensity modulated radiotherapy once daily, 5 days per week, on days 1-47. Patients also receive erlotinib hydrochloride PO once daily on days -7 to 47.
62381228|NCT02346955|EXPERIMENTAL|Cohort D Monotherapy Expansion|Participants with advanced or recurrent colorectal cancer will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
62381229|NCT02346955|EXPERIMENTAL|Cohort E Monotherapy Expansion|Participants with advanced or recurrent gastric cancer will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
62381230|NCT02346955|EXPERIMENTAL|Cohort C1 Combination Expansion|Participants with advanced or recurrent cutaneous melanoma will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
62381231|NCT02346955|EXPERIMENTAL|Cohort D1 Combination Expansion|Participants with advanced or recurrent colorectal cancer will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
62381232|NCT02346955|EXPERIMENTAL|Cohort E1 Combination Expansion|Participants with advanced or recurrent gastric cancer will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
62760739|NCT00410826|ACTIVE_COMPARATOR|Arm II (chemotherapy, radiotherapy)|Patients receive cisplatin and radiotherapy as in Arm I.
62760740|NCT01884493|EXPERIMENTAL|real iTBS|The paradigm will use a theta burst stimulation pattern (TBS) in which 3 pulses of stimulation will be given at 50Hz, repeated every 200 ms. In the iTBS, a 2-second train of TBS is repeated every 10 seconds for a total of 190 seconds (600 pulses). Subjects will be 8 courses of iTBS stimulation in 10 business days.
62760741|NCT01884493|SHAM_COMPARATOR|sham iTBS|Subjects will be 8 courses of sham iTBS stimulation in 10 business days.
62760742|NCT01261169||Myfortic|
62760743|NCT03001115||Participants with Hidradenitis suppurativa (HS)|Participants with HS treated with adalimumab (HUMIRA®) in routine clinical practice.
62760744|NCT01256463|NO_INTERVENTION|Comparison|
62760745|NCT01256463|EXPERIMENTAL|HIV prevention intervention|The HIV prevention intervention will be delivered to HIV-seropositive patients in HIV care and treatment clinics during all routine visits. Health care providers (including physicians, clinical officers, and nurses) will deliver HIV prevention messages on correct and consistent condom use, disclosure of serostatus, partner HIV testing, adherence and alcohol reduction during clinic visits. Health care providers will also assess and treat sexually transmitted infections (STIs), and provide basic contraceptives and brief safer pregnancy counseling.
62760746|NCT03223077||Acute Campylobacter|We will enroll 150 patients with acute Campylobacter infection. Our microbiology laboratory will inform us of a culture or PCR positive case of Campylobacter infection as soon as that test result is available.
62760747|NCT00570934|EXPERIMENTAL|Placebo|order of interventions placebo,calcium, cholecalciferol, calcium plus cholecalciferol
62760748|NCT00570934|EXPERIMENTAL|Calcium|order of treatment calcium, placebo, calcium plus cholecalciferol, cholecalciferol
62558628|NCT04908514|EXPERIMENTAL|ADX-629 250 mg administered orally twice daily (BID) for approximately 12 weeks.|
62558629|NCT01497028||Plicated Gastric Banding|
62558630|NCT01497028||Standard Gastric Banding|
62558631|NCT00954759|EXPERIMENTAL|Chiropractic treatment|Manipulation and/or mobilisation
62558632|NCT00954759|PLACEBO_COMPARATOR|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
62760749|NCT00570934|EXPERIMENTAL|Cholecalciferol|order of treatments cholecalciferol, calcium and Cholecalciferol, placebo, and calcium
62760750|NCT00570934|EXPERIMENTAL|Calcium and cholecalciferol|order of treatment calcium and cholecalciferol, cholecalciferol, calcium, placebo
62760751|NCT05799001|EXPERIMENTAL|experimental|4 months of dance workshop with a Professional dance teacher
62760752|NCT05799001|OTHER|Control|First, patients will have usual activities for 4 months and in a second time, they will have 4 months of dance class with a nurse previously trained by the dance teacher
62760753|NCT02031224|EXPERIMENTAL|Keto-diet (KD)|Patients in the intervention arm (KD group) will receive a vegetarian very low protein diet (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.
62760754|NCT02031224|ACTIVE_COMPARATOR|Low Protein Diet group (LPD)|"The patients in the control arm (LPD group) will continue their conventional low protein diet, with 0.6 g/kg per day (including high biological value proteins).~The total recommended energy intake is of 30 kcal/kg of ideal dry body weight per day in both arms."
62760755|NCT02387736|EXPERIMENTAL|Dialectical Behaviour Therapy-6 months|6 months of standard dialectical behaviour therapy treatment.
62760756|NCT02387736|ACTIVE_COMPARATOR|Dialectical Behaviour Therapy-12 months|12 months of standard dialectical behaviour therapy treatment
62760757|NCT04214431|EXPERIMENTAL|Mindfulness-Based Childbirth Education|Women in the experimental group received eight week mindfulness-based childbirth education program delivered one class each week.
62760758|NCT04214431|NO_INTERVENTION|Control group|Women in the control group received standardized care.
62760759|NCT03578484||Volunteer female subjects|Females age 18-35 years of age. 3D breast scan will be performed and followed over 15 years. No therapeutic interventions will be performed.
61987605|NCT05362747|NO_INTERVENTION|Waitlist Control|Participants in the WLC group with be asked to stay weight stable, not to make changes in their eating and physical activity behaviors, and not to seek treatment for weight or eating during the waiting period.
61987606|NCT04428996|EXPERIMENTAL|Arm AB|"A means SCIT program, and B means treatment as usual. Arm AB will receive a 60-minutes manual-guide SCIT session each week for 20 times first, then receive treatment as usual.~Before the SCIT session, after the SCIT session and after 20 weeks treatment as usual, participants receive evaluations of clinical symptoms, emotional perception, theory of mind, and attributional bias.~There are three main themes of the SCIT: 1) introduction and emotion, 2) figuring out situation and 3) integration: checking it out. After each theme of the intervention, participants will fill out a satisfaction survey."
62381233|NCT02346955|EXPERIMENTAL|Cohort F Combination Expansion|Participants with advanced or recurrent non-small cell lung adenocarcinoma will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
62381234|NCT05822349|ACTIVE_COMPARATOR|intervention group|they will receive the usual diabetes care routine plus a pictogram-enriched label.
62760760|NCT04384380|EXPERIMENTAL|HCQ in adult Patients with COVID-19|The administration plan of HCQ is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
62760761|NCT04384380|NO_INTERVENTION|standard of care treatment (SOC)|The comparison group will receive standard of care, i.e., supportive treatment for subjects with mild COVID-19 clinical illness.
62760762|NCT03372551|EXPERIMENTAL|somofilcon A 1 day test lens|Subjects wearing the somofilcon A 1 day test lens for one week, either randomized as the first or second pair.
62760763|NCT03372551|ACTIVE_COMPARATOR|somofilcon A 1 day control lens|Subjects wearing the somofilcon A 1 day control lens for one week, either randomized as the first or second pair.
62760764|NCT05938920|EXPERIMENTAL|INS018_055|"Group 1: INS018_055 once daily up to 12 weeks, low dose~Group 2: INS018_055 twice daily up to 12 weeks, low dose~Group 3: INS018_055 once daily up to 12 weeks, high dose"
62760765|NCT05938920|PLACEBO_COMPARATOR|Placebo|Group 4: Placebo once or twice daily up to 12 weeks
62760766|NCT05787132|EXPERIMENTAL|Group A (Balance Board Therapy)|30 minutes of Balance board therapy along with conventional physical therapy
62760767|NCT05787132|EXPERIMENTAL|Group B (Perceptual Motor Therapy)|30 minutes of Perceptual Motor therapy along with conventional physical therapy
62760768|NCT00794365||Open-label|
62760769|NCT00919867|ACTIVE_COMPARATOR|A: SPD503 (4mg)|
62760770|NCT00919867|ACTIVE_COMPARATOR|B: VYVANSE (50mg)|
61987607|NCT04428996|EXPERIMENTAL|Arm BA|"A means SCIT program, and B means treatment as usual. Arm BA will first receive treatment as usual, then a 60-minutes manual-guide SCIT session each week for 20 times.~At the first week, before and after the SCIT session, participants receive evaluations of clinical symptoms, emotional perception, theory of mind, and attributional bias.~There are three main themes of the SCIT: 1) introduction and emotion, 2) figuring out situation and 3) integration: checking it out. After each theme of the intervention, participants will fill out a satisfaction survey."
62381235|NCT05822349|PLACEBO_COMPARATOR|control group|they will receive the usual diabetes care routine.
62381236|NCT02469597|EXPERIMENTAL|Single Dose of Furosemide|Furosemide 1 dose
62381237|NCT02469597|PLACEBO_COMPARATOR|Placebo|Normal saline 1 dose
62381238|NCT03971227|EXPERIMENTAL|Acuity 200 contact lens|Rigid gas permeable contact lens for daily wear, fluoroxyfocon A
62760771|NCT00919867|ACTIVE_COMPARATOR|C: SPD503 (4mg) + VYVANSE (50mg)|
62760772|NCT00852527||Subjects with mild TBI|Presence of mild TBI defined by positive reference test
62760773|NCT00852527||Subjects without mild TBI|Absence of mild TBI defined by negative reference test
62760774|NCT02248207||Parkinson Disease patients|
62760775|NCT01882517|ACTIVE_COMPARATOR|Yogurt that contains plant stanol esters|Dietary Supplement: Yogurt that contains plant stanol esters
62760776|NCT01882517|PLACEBO_COMPARATOR|Placebo yogurt|Dietary Supplement: Placebo yogurt
62760777|NCT04871802|EXPERIMENTAL|Taxifolin Aqua group|Taxifolin Aqua 30 mg per day in addition to standard therapy
62760778|NCT04871802|NO_INTERVENTION|Control group|No intervention
62760779|NCT00662376|EXPERIMENTAL|Test|oral nutritional supplement (assignment: according to consecutive random numbers)
62381239|NCT03971227|ACTIVE_COMPARATOR|Acuity 100 contact lens|Rigid gas permeable contact lens for daily wear, hexafocon A
62558633|NCT03644342|EXPERIMENTAL|Niraparib Arm - 100 mg|For the purposes of this study, two dose levels of Niraparib (100 mg will be evaluated concomitant with the concurrent administration of pelvic radiotherapy.
62381240|NCT00908895|EXPERIMENTAL|Radio-radial fixator|Patients are operated on using a radio-radial fixator (Distal radius fixator, Synthes)
62381241|NCT00908895|ACTIVE_COMPARATOR|Percutaneous pinning|Two K-wires inserted on a percutaneous way (dorsally and from the styloid), with a cast for 6 weeks
62760780|NCT00662376|PLACEBO_COMPARATOR|Control|placebo (assignment: according to consecutive random numbers)
62760781|NCT01738113|EXPERIMENTAL|open kinetic chain exercise|Open kinetic chain exercise
62760782|NCT01738113|EXPERIMENTAL|Closed Kinetic chain exercise|Closed kinetic chain exercise
62760783|NCT05737277|EXPERIMENTAL|GABAPRAL|Children with irritative bowel sindrome who received 20 Mld UFC of Bifidobacterium adolescentis PRL 2019 once a day for 12 weeks
62760784|NCT05737277|PLACEBO_COMPARATOR|Placebo|Children with irritative bowel sindrome who received placebo once a day for 12 weeks
62760785|NCT05026372|EXPERIMENTAL|Mindfulness + Compassion (MC)|For participants randomized to the MC condition will focus on compassion and creating positive emotions. This session will include techniques such as guided visualizations and a loving kindness meditation that are intended to facilitate connection with their partners. During this session, couples will also learn the ground rules of mindful and compassionate listening and sharing, as they will be asked to engage in an emotional disclosure task. The instructor will go over the homework assignment. The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
62760786|NCT05026372|EXPERIMENTAL|Mindfulness + Gratitude (MG)|Session 2 for participants randomized to group MG will focus on gratitude. Participants will be taught to reflect on things, events, and people which they are grateful for via a gratitude meditation. Couples will share their experiences of practicing gratitude. The instructor will remind the couple of ground rules prior to the emotional disclosure exercise and facilitate if necessary during the sharing. Each member of the couple will take turn in sharing with and listening to their partner. The instructor will go over the homework assignment. The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
61987608|NCT01312818|EXPERIMENTAL|Chemotherapy|Bortezomib IV Vorinostat PO Dexamethasone PO Intrathecal Methotrexate Imatinib Mesylate PO (for Ph+ ALL patients only)
61987609|NCT04716127|EXPERIMENTAL|Women 50 to 65 years with no regular cervical cancer screening|Women aged 50 to 65 years with no cervical smear or no gynecological examination for more than three years, attending the mobile unit for breast cancer screening in the Department of Hérault, or the Medical and Social Care Center in the Department of Aude.
61987610|NCT04341909||Trainee Group|Patients who undergo ERCPs with trainee involvement
61987611|NCT04341909||control group|Patients who undergo ERCPs without any trainee involvement
61987612|NCT01178593|NO_INTERVENTION|Standard Medical Therapy (SMT)|standard medical treatment (care as usual) with supportive talks
61987613|NCT01178593|ACTIVE_COMPARATOR|Gut focused hypnotherapy|weekly sessions of gut focused hypnotherapy in groups (10 sessions within 12 weeks)
61987614|NCT00451867|ACTIVE_COMPARATOR|A|2000 mg per day of CellCept (MMF) divided into 2 equal doses.
62381242|NCT01250782|PLACEBO_COMPARATOR|Physiological Serum|
62381243|NCT01250782|ACTIVE_COMPARATOR|Glutamine|
62381244|NCT04437602|EXPERIMENTAL|CEM|Patients in experimental arm will go through additional preoperative staging with contrast enhanced mammography
62381245|NCT04437602|NO_INTERVENTION|No CEM|Patients in No intervention arm will go through no additional preoperative imaging
62381246|NCT01225211|PLACEBO_COMPARATOR|Cohort 1: Placebo|Participants homozygous (HO) for the F508del-CF transmembrane conductance regulator gene (CFTR) mutation received lumacaftor matched placebo once daily (qd) (Day 1 through Day 14), followed by lumacaftor matched placebo qd in combination with ivacaftor matched placebo every 12 hours (q12h) (Day 15 through Day 21).
61987615|NCT00451867|PLACEBO_COMPARATOR|B|Placebo
61987616|NCT01751386|EXPERIMENTAL|Baclofen|Baclofen 10 mg t.i.d.
61987617|NCT01751386|PLACEBO_COMPARATOR|Placebo|Placebo t.i.d.
61987618|NCT05787314|EXPERIMENTAL|Control Diet|"1. For the Control Diet, a medical nutrition therapy with calorie and fat content was prepared to ensure weight loss of individuals without considering the glycemic index.~2. The aim of this diet is to achieve weight loss, but not to focus on the content of carbohydrates. 3) In the macro element distribution of the CD, 50-55% carbohydrates, 10-15% protein and 20-25% fat distribution Other name (CD Group)"
61987619|NCT01984008|EXPERIMENTAL|picosulfate,MgO, citric acid, bowel preparation, powder|colonoscopy picosulfate,MgO, citric acid, bowel preparation, powder
62381247|NCT01225211|EXPERIMENTAL|Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 150 mg q12h|Participants homozygous for the F508del-CFTR mutation received 200 milligram (mg) of lumacaftor (LUM) qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 150 mg of ivacaftor (IVA) q12h (Day 15 through Day 21).
62381248|NCT01225211|EXPERIMENTAL|Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h|Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 15 through Day 21).
62381249|NCT01225211|PLACEBO_COMPARATOR|Cohort 2 and 3: Placebo (HO and HE)|Participants homozygous or heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo qd (Day 1 through Day 28), followed by lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 29 through Day 56).
62381250|NCT01225211|EXPERIMENTAL|Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
62381251|NCT01225211|EXPERIMENTAL|Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 400 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
62381252|NCT01225211|EXPERIMENTAL|Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO&HE)|Participants homozygous or heterozygous for the F508del-CFTR mutation received 600 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 600 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
62558634|NCT03644342|EXPERIMENTAL|Niraparib Arm - 200 mg|For the purposes of this study, two dose levels of Niraparib (200 mg) will be evaluated concomitant with the concurrent administration of pelvic radiotherapy.
62381253|NCT01225211|EXPERIMENTAL|Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone q12h (Day 1 through Day 28), followed by 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
62381254|NCT01225211|PLACEBO_COMPARATOR|Cohort 4: Placebo|Participants heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 1 through Day 56).
62381255|NCT01225211|EXPERIMENTAL|Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h|Participants heterozygous for the F508del-CFTR mutation received 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 1 through Day 56).
62381256|NCT02227433|EXPERIMENTAL|brentuximab vedotin (BV)|
61987620|NCT01984008|ACTIVE_COMPARATOR|polyethylene glycol, bisacodyl,|colonoscopy polyethylene glycol,powder bisacodyl,tablet
62381257|NCT04745065|EXPERIMENTAL|Connect2BWell Condition|The Connect2BWell program delivers feedback on SUD risk, 3 brief online intervention sessions over 3 months, and text messages for 6 months. Sessions and text messages are tailored to the patient's most problematic drug based on the ASSIST; stage of change for quitting or reducing use of that drug; and stage of change for seeking treatment, if indicated. Online sessions are followed by a dashboard-guided telehealth session with a nurse care manager. The dashboard summarizes the patient's ASSIST risk scores and stage of change data; presents patients' responses to key questions in the online session; and provides tools for collaborating with the patient to select action steps matched to risk level and stage and stage of change for seeking treatment, if indicated. The program provides a patient portal with activities, resources, and tools for tracking progress on action steps.
62381258|NCT04745065|NO_INTERVENTION|Comparison Condition|Patients assigned to the Comparison Condition will receive a brief SBIRT session delivered via telehealth by a member of their clinic care team. The session will include the clinic's standard scripted feedback matched to level of risk for alcohol use and for other drug use; encouragement to quit; and referral to specialty treatment, if indicated.
62381259|NCT01751243|PLACEBO_COMPARATOR|Group 0|Haploidentical transplantation of hematopoietic progenitors
62381260|NCT01751243|EXPERIMENTAL|Group 1|Allo-depleted lymphocyte infusion dose: 1x105 CD3/Kg
62381261|NCT01751243|EXPERIMENTAL|Group 2|Allo-depleted lymphocyte infusion dose: 3x105 CD3/Kg
62381262|NCT01751243|EXPERIMENTAL|Group 3|Allo-depleted lymphocyte infusion dose: 5x105 CD3/Kg
62381263|NCT01751243|EXPERIMENTAL|Group 4|Allo-depleted lymphocyte infusion dose: 1x106 CD3/Kg
62381264|NCT01751243|EXPERIMENTAL|Group 5|Allo-depleted lymphocyte infusion dose: 3x106 CD3/Kg
62381265|NCT03796923|ACTIVE_COMPARATOR|Intervention I|Intervention (I): early follow-up visit from the community nurse within 24 hours after discharge
62381266|NCT03796923|EXPERIMENTAL|Intervention II|Intervention (II): early follow-up by the geriatric team within 24 hours after discharge
62381267|NCT03796923|OTHER|Control|Usual care: individualized follow-up performed by the GP and municipality services
62381268|NCT06409975|EXPERIMENTAL|Mindful Self-Compassion Intervention|All enrolled participants will complete the remotely delivered 8 week MSC intervention (described in interventions). Participants are encouraged to practice the formal meditations and/or informal skills taught each week between sessions. Participants will give feedback on self-compassion activities and the overall intervention. They will also complete several measures before, during, and after the intervention and at 3-month follow-up.
62381269|NCT02559830|EXPERIMENTAL|transduced CD34+ hematopoietic stem cell|Transplantation of autologous CD34+ hematopoietic stem cells transduced with ARSA/ABCD1 encoding lentiviral vector. Dosage: 2x10\^6/Kg （Minimum）to 20x10\^6/Kg （Maximum） transduced CD34+ cells at bedside for infusion
62381270|NCT01590810|EXPERIMENTAL|Panel A-Healthy|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel A will be 2.0 mg to 90 mg.
62381271|NCT01590810|EXPERIMENTAL|Panel B-Healthy|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel B will be 5.0 mg to 160 mg.
62381272|NCT01590810|EXPERIMENTAL|Panel C-Mild/Moderate Hypertension|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel C will be 160 mg to 1200 mg.
62381273|NCT01590810|EXPERIMENTAL|Panel D-Healthy|Within each panel, 8 subjects will be randomly assigned to MK-8150 and 2 subjects will be randomly assigned to placebo throughout the 5 periods according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel D will be 50 mg to 500 mg.
62381274|NCT00284609|EXPERIMENTAL|1|
62381275|NCT00284609|ACTIVE_COMPARATOR|2|
62381276|NCT01815099|EXPERIMENTAL|rTMS Treatment|Clinical participants will receive rTMS
61987621|NCT02740166|NO_INTERVENTION|Banding ligation group|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
61987622|NCT02740166|EXPERIMENTAL|Propranolol group|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
62381277|NCT05140486|EXPERIMENTAL|Shortwave diathermy and perceptual training|The subjects in this group will receive shortwave diathermy 5 days per week for 4 weeks and perceptual training 5 days per week for 10 weeks after endoscopic optic nerve decompression surgery.
61987623|NCT03369054|EXPERIMENTAL|Minority Stress|"The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?)."
61987624|NCT03369054|ACTIVE_COMPARATOR|Treatment as Usual|Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
61987625|NCT00977132|EXPERIMENTAL|Lenalidomide|Lenalidomid in combination valproic acid
61987626|NCT04400903||Observational (HRV monitoring, questionnaire)|Participants undergo HRV monitoring using an activity monitor (WHOOP) for a minimum of 5 days weekly for up to 1 year in patients with newly-diagnosed PDAC and up to 5 years for patients in high risk group.
61987627|NCT04796376|OTHER|Cutting seton|A piece of surgical thread that's left in the fistula for several weeks to keep it open. This allow it to drain and help its heal.
62381278|NCT05140486|NO_INTERVENTION|Nonrehabilitation|The subjects in the nonrehabilitation group will not only receive any rehabilitation therapy after endoscopic optic nerve decompression surgery.
62381279|NCT05763329|EXPERIMENTAL|Lemborexant|Patients will receive two treatment sequences. Participants will complete two overnight sleep studies and cross-over with 1-week wash-out period The participants will receive Lemborexant 5 mg per day 5 minutes before lights-out for one dose for the first overnight sleep test of the experiment. After 1 week wash-out period, the participants will cross to the placebo arm and receive placebo 5 minutes before lights-out for one dose for the second overnight sleep test of the experiment.
62381280|NCT05763329|PLACEBO_COMPARATOR|Placebo|Patients will receive two treatment sequences. Participants will complete two overnight sleep studies and cross-over with 1-week wash-out period The participants will receive placebo 5 minutes before lights-out for one dose for the first overnight sleep test of the experiment. After 1 week wash-out period, the participants will cross to the Lemborexant arm and receive Lemborexant 5 mg per day 5 minutes before lights-out for one dose for the second overnight sleep test of the experiment.
62381281|NCT01242072|EXPERIMENTAL|PaCE|Palifosfamide, Carboplatin and Etoposide
62381282|NCT02362256|EXPERIMENTAL|Intervention|"Opioid antagonist induction. Day 4. Duration 12-16 hours.~Naltrexone gradual increase from 50 µg p/o to a total dose of 12,5 mg according to a predefined protocol:~1. st hour 50 µg~2. nd hour 50 µg~3. rd hour 100 µg~4. th hour 100 µg~5. th hour 200 µg~6. th hour 400 µg~7. th hour 800 µg~8. th hour 1600 µg~9. th hour 3200 µg~10. th hour 6000 µg~Correction of symptoms for opioid abstinence:~Clonidine 150 µg p/o every 4 hours (Day 3 and Day 4) Lorazepam 5 mg p/o every 4 hours (Day 3 and Day 4), Lorazepam 2,5 mg po every 4 hours (Day 5, Day 6)"
62381283|NCT02362256|ACTIVE_COMPARATOR|Control|"Opioid antagonist induction. Day 4. Duration 12-16 hours. Naltrexone single dose 12,5 mg p/o~Correction of symptoms for opioid abstinence:~Clonidine 150 µg p/o every 4 hours (Day 3 and Day 4) Lorazepam 5 mg p/o every 4 hours (Day 3 and Day 4), Lorazepam 2,5 mg po every 4 hours (Day 5, Day 6)"
62381284|NCT02141854|EXPERIMENTAL|FS MDPI 200 / 12.5 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 200 mcg (for a total daily dose of 400 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
61987628|NCT01769833|ACTIVE_COMPARATOR|PEG-interferon-alfa 2A|PEG-interferon-alfa 2A
61987629|NCT01769833|PLACEBO_COMPARATOR|Nucleosides|Nucleosides
61987630|NCT02917031|ACTIVE_COMPARATOR|Saxagliptin|one tablet of saxagliptin 5 mg or 2.5 mg + one placebo capsule matching sitagliptin
61987631|NCT02917031|ACTIVE_COMPARATOR|Sitagliptin|one capsule of sitagliptin 100 mg or 50 mg + one placebo tablet matching saxagliptin
61987632|NCT02917031|PLACEBO_COMPARATOR|Placebo|one placebo tablet matching saxagliptin + one placebo capsule matching sitagliptin
61987633|NCT03930706|EXPERIMENTAL|Group A|Group A will include all the patient that will start with progesterone ((P), Utrogestan®) supplementation after 7 days of E2 (Progynova®) intake and that will perform the FET (after 13 days of E2 and 6 days of P).
61987634|NCT03930706|ACTIVE_COMPARATOR|Group B|Group B will include the patients that will perform 14 days of E2 intake (Progynova®, 6 mg per day (2 mg every 8 hours) those patients will be asked to perform a supplementary blood test and ultrasound on day 14 of E2 intake, afterwards, they will start with P supplementation (Utrogestan®, 800 mg per day, 400 mg every 12 hours) from day 15 of E2 for 6 days and they will get their FET day 20 of the cycle (after 14 days of E2 and 6 days of P)
62381285|NCT02141854|EXPERIMENTAL|FS MDPI 100 / 12.5 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
62381286|NCT02141854|EXPERIMENTAL|Fp MDPI 200 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg for 12 weeks.
61987635|NCT06057792|EXPERIMENTAL|NEGATIVE PULSED PRESSURE INTERVENTION GROUP|The number of treatment sessions will consist of a total of 6 sessions, so there will be two sessions over 3 weeks. The evaluations of the participants will be carried out before and after the first session, after the last session of the treatment program received, 15 days and one month after finishing the treatment.
61987636|NCT01774786|EXPERIMENTAL|Pertuzumab + Trastuzumab + Chemotherapy|Participants will receive pertuzumab in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive pertuzumab and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
61987637|NCT01774786|PLACEBO_COMPARATOR|Placebo + Trastuzumab + Chemotherapy|Participants will receive placebo in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive placebo and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
61987638|NCT03560050|EXPERIMENTAL|Behavioral: Nutrition assistance|three encounters with Intervention team over three months: two home-based visits for 90 minutes each scheduled at the convenience of the provider and a 3- hour group class session with other providers.
61987639|NCT03560050|EXPERIMENTAL|Behavioral: Children's environmental health|three encounters with Intervention team over three months: two home-based visits for 90 minutes each scheduled at the convenience of the provider and a 3- hour group class session with other providers.
62381287|NCT02141854|EXPERIMENTAL|Fp MDPI 100 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg for 12 weeks.
62381288|NCT02141854|PLACEBO_COMPARATOR|Placebo MDPI|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of placebo for 12 weeks.
62760787|NCT05026372|EXPERIMENTAL|Mindfulness + Value-Based Living (MV)|Session 2 for participants randomized to group MV will focus on learning strategies to live life according to their values. They will first engage in a reflection exercise to help identify their values, and then complete a worksheet. Couples will brain storm together strategies to ensure that their lives reflect their self-identified values. The instructor will go over the homework assignment. The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
62760788|NCT05026372|NO_INTERVENTION|Attention Control (AC)|For participants randomized to the AC condition, both sessions will focus on discussing issues and themes that emerge for couples, such as communication and perceived supportiveness. Utilizing a reflective listening approach, the interventionist will focus on encouraging participants to share concerns related to their daily experiences. Unlike in the MC, MG, and MV groups, the interventionist will not offer advice, support (other than reflective listening) or any other tools to participants. Additionally, the interventionist will not probe for deep emotional disclosure. Please see the appendix for the session outline. We believe a control group that discusses daily relationship-related concerns serves as an excellent comparison condition in this study since it is viewed as credible by participants and equates for time and attention as well as nonspecific treatment effects such as those provided through social interactions.
61987640|NCT00302458|EXPERIMENTAL|OROS-MPH + OROS-MPH|OROS-Methylphenidate Will be administered during the first part of the day, and again during the separate part of the day.
61987641|NCT00302458|EXPERIMENTAL|IR MPH + IR MPH|Immediate release methylphenidate will be administered in the first part of the day followed by Immediate release methylphenidate in the second part of the day.
61987642|NCT00302458|PLACEBO_COMPARATOR|Plabebo + Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
61987643|NCT00302458|EXPERIMENTAL|OROS MPH+ IR MPH|Concerta will be administered in the first part of the day, followed by Immediate Release Methylphenidate in the second part of the day.
61987644|NCT00302458|EXPERIMENTAL|IR MPH + OROS MPH|Immediate release Methylphenidate will be administered in the first part of the day, followed by Concerta in the second part of the day
61987645|NCT03427736||Drug of Interest|Individuals receiving anesthetics or analgesics per standard of care
61987646|NCT04894396|EXPERIMENTAL|Prefabricated Orthotics with metatarsal pad|Participants in Group A will receive the Orthotic with the metatarsal pad (L 2305) according to participants shoe size (https://www.aetrex.com/search?q=l2305\&search-button=\&lang=en_US). When the investigators provide the Orthotics, an instruction sheet will also be provided, explaining how to use the orthotic. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. Participants will be required to use the Orthotic wherever possible for a period of 6 weeks, whilst continuing with usual activities.
62381289|NCT01002196|EXPERIMENTAL|stimulus fading procedures|
62381290|NCT01002196|ACTIVE_COMPARATOR|guidance of defocused communication|
62381291|NCT06183255||Infertile men|Men with a diagnosis of pure Male Factor Infertility, as for WHO criteria
62381292|NCT06183255||Fertile men|Fathers with at least one child, spontaneously conceived, with a time-to-pregnancy within 12 months, as for WHO criteria
62381293|NCT04040166|OTHER|PET/MRI scan with 68Ga DOTATATE|PET/MRI scan with 68Ga DOTATATE of carotid arteries in in patients following head and neck radiation therapy
62381294|NCT04312815|EXPERIMENTAL|SM03 600 mg|"SM03: 600 mg intravenous (IV) Randomizd period:on week 0,2,4 and 12,14,16;Participants with inadequate response (defined as less than 10% improvement from baseline in TJC and SJC by Week 12) were rescued with open label SM03 600 mg IV treatment.~Open-lable treatment on week 24,30,36,42,48; Methotrexate: 7.5-20 mg/wk oral."
62558635|NCT00806429|EXPERIMENTAL|1|transvaginal appendectomy
62558636|NCT00806429|NO_INTERVENTION|2|
61987647|NCT04894396|ACTIVE_COMPARATOR|Prefabricated Orthotics without metatarsal pad.|Participants in Group B will receive the neutral Orthotic with a cupped heel (L 2300) according to participants shoe size (https://www.aetrex.com/search?q=l2300\&search-button=\&lang=en_US). When the investigators provide the Orthotics, an instruction sheet will also be provided, explaining how to use the Orthotic. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. Participants will be required to use the Orthotic wherever possible for a period of 6 weeks, whilst continuing with usual activities
61987648|NCT01697865|ACTIVE_COMPARATOR|Transfer group|The first surgical technique includes a concomitant latissimus and teres major transfer (transfer group).
61987649|NCT01697865|ACTIVE_COMPARATOR|Control group|The second technique does not include a concomitant latissimus and teres major transfer (control group).
62760789|NCT06396715|EXPERIMENTAL|30-minute tDCS with mCIMT|"tDCS: the tDCS montage will be of a bi-hemispheric and the stimulation will be applied simultaneously to the upper extremity motor training session carried out in the hospital. There will be a total of 18 sessions with 30 minutes of tDCS stimulation (2 mA intensity), with a frequency of three times a week for six weeks.~mCIMT: during a period of five days a week, for six weeks, both groups will perform a mCIMT protocol. On days when the patient does not go to the hospital for treatment, they must perform the activities at home with the support of a family member or caregiver if necessary.~1. Restriction of movements of the unaffected hand through the use of a glove for 6 hours per day: the glove limits the mobility of the fingers but allows free movement of the wrist, elbow and shoulder.~2. Intensive and individualized training of the affected arm for 2 hours a day."
62760790|NCT06396715|ACTIVE_COMPARATOR|20-minute tDCS with mCIMT|"tDCS: the tDCS montage will be of a bi-hemispheric and the stimulation will be applied simultaneously to the upper extremity motor training session carried out in the hospital. There will be a total of 18 sessions with 20 minutes of tDCS stimulation (2 mA intensity), with a frequency of three times a week for six weeks.~mCIMT: during a period of five days a week, for six weeks, both groups will perform a mCIMT protocol. On days when the patient does not go to the hospital for treatment, they must perform the activities at home with the support of a family member or caregiver if necessary.~1. Restriction of movements of the unaffected hand through the use of a glove for 6 hours per day: the glove limits the mobility of the fingers but allows free movement of the wrist, elbow and shoulder.~2. Intensive and individualized training of the affected arm for 2 hours a day."
62760791|NCT05044104|EXPERIMENTAL|Wearable technology in endoscopic gastrointestinal procedures with sedation|Subjects undergoing a endoscopic gastrointestinal procedure with sedation as part of standard of care will wear a consumer-facing wearable smart watch for the duration of the procedure.
61987650|NCT06086028|EXPERIMENTAL|Real time access start arm|"The participants will receive real-time access to their biometric data via the Biostrap API (immediate information condition). After 1 week washout the arms will cross-over, and the delayed access start arm will receive real-time access to their biometrics via the Biostrap API while real time access start arm is blinded to their biometric report until the end of the control period."
61987651|NCT06086028|EXPERIMENTAL|Delayed access start arm|"The participants are blinded to their biometrics until the control period is over (information delayed condition). After 1 week washout the arms will cross-over, and the delayed access start arm will receive real-time access to their biometrics via the Biostrap API while real time access start arm is blinded to their biometric report until the end of the control period."
62760792|NCT00342771||NCI Maryland pop-based controls|population-based controls
62760793|NCT00342771||NCI-Maryland Prostate Cancer Cases|prostate cancer cases
62760794|NCT04922931||Post-COVID-19 group|The Post-COVID-19 group or case group includes post-COVID patients (confirmed by PCR) \>18 years undergoing scheduled surgery without pulmonary disease prior to SARS-CoV-2 infection that at the time of surgery present negative PCR and absence of clinic due to SARS-CoV-2.
62760795|NCT04922931||Control group|The control group includes patients over the age of 18 who did not have COVID-19 and without moderate-severe pulmonary pathology prior to surgery and in conditions of hemodynamic and respiratory stability at time of surgery.
62760796|NCT00609791|EXPERIMENTAL|nab-paclitaxel|
61987652|NCT03044405|OTHER|Responders and non-responders|Fluid challenge of 500 ml of crystalloids over 15 minutes is given. Positive fluid responsiveness is defined by an increase in stroke volume (SV) of at least 15% assessed by focused transthoracic echocardiography.
62381295|NCT04312815|PLACEBO_COMPARATOR|Placebo|"placebo: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16;Participants with inadequate response (defined as less than 10% improvement from baseline in TJC and SJC by Week 12) were rescued with open label SM03 600 mg IV treatment.~SM03: 600 mg intravenous (IV) on week 24,30,36,42,48; Methotrexate: 7.5-20 mg/wk oral."
62381296|NCT01431456|ACTIVE_COMPARATOR|Dabigatran|Dabigatran
62760797|NCT02787590|ACTIVE_COMPARATOR|Simvastatin|A one month low dose phase of 40mg oral simvastatin daily will be followed by a 23 month high dose phase of 80mg oral simvastatin daily and a final two month phase off trial medication
62760798|NCT02787590|PLACEBO_COMPARATOR|Matched Placebo|A one month low dose phase of 40mg matched placebo daily will be followed by a 23 month high dose phase of 80mg matched placebo daily and a final two month phase off trial medication
62760799|NCT00871546|EXPERIMENTAL|Participants with MCL randomized to SCH 727965|
62760800|NCT00871546|ACTIVE_COMPARATOR|Participants with MCL randomized to bortezomib|
62760801|NCT00871546|EXPERIMENTAL|MCL treated w/SCH 727965 after progression on bortezomib|
62760802|NCT00871546|EXPERIMENTAL|Participants with B-CLL randomized to SCH 727965|
62760803|NCT00871546|ACTIVE_COMPARATOR|Participants with B-CLL randomized to alemtuzumab|
62760804|NCT00871546|EXPERIMENTAL|B-CLL treated w/ SCH 727965 after progression on alemtuzumab|
62760805|NCT00808457||patients with suspected pneumonia|
62760806|NCT01440517|EXPERIMENTAL|Tc99m-Maraciclatide|
61987653|NCT06162156|EXPERIMENTAL|back massage group|Volunteer women who meet the inclusion criteria after cesarean delivery will be selected by a random method, and verbal and written consent will be obtained from those included in the intervention group. Pre-test data twelve hours after cesarean delivery: 'Personal Information Form', 'Trait-Trait Anxiety Inventory', 'Postpartum Comfort Scale (PCS)', 'Bristol Breastfeeding Assessment Tool (BBAT)', 'Uterine Involution Evaluation Form ( UIEF)' 'Physiological Parameter Form (PPF)' and 'Visual Analog Scale (VAS)' will be filled in by the participants themselves using face-to-face interview technique in approximately twenty minutes. The intervention group will receive a twenty-minute back massage after the initial data is received. One hour after the massage, 'VAS' and 'PPF data will be filled in again. Post-test data twenty-four hours after the massage; 'Richard Campbell Sleep Scale', 'VAS, 'Trait-Trait Anxiety Inventory', 'PCS', 'BBAT, 'UIEF, 'PPF will be filled in again..
62381297|NCT01431456|ACTIVE_COMPARATOR|Rivaroxaban|Rivaroxaban
62381298|NCT01431456|ACTIVE_COMPARATOR|Nadroparin|Nadroparin
62168193|NCT02867332|PLACEBO_COMPARATOR|Comparable group|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10\^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment."
62381299|NCT02071342||acute coronary syndrome|patients with acute myocardial infarction who are undergoing coronary angioplasty. MACE at 30 days and 1 year will be assessed . The acute recoil after implantation of bioabsorbable stents will also be assessed
62381300|NCT04663828|OTHER|Structured counseling|Patients will receive a structured counseling therapy
62381301|NCT04663828|OTHER|Hearing Aids|Patients will receive hearing aids support
62381302|NCT04663828|OTHER|Cognitive behavioral therapy|Patients will receive cognitive behavioral therapy
62381303|NCT04663828|OTHER|Sound therapy|Patients will follow a sound therapy program
62381304|NCT04663828|OTHER|Combination of sound therapy and cognitive behavioral therapy|Patients will receive a combination of sound therapy and cognitive behavioral therapy
62381305|NCT04663828|OTHER|Combination of hearing aids and cognitive behavioral therapy|Patients will receive a combination of hearing aids and cognitive behavioral therapy
62381306|NCT04663828|OTHER|Combination of hearing aids and structured counseling|Patients will receive a combination of hearing aids and structured counseling
62381307|NCT04663828|OTHER|Combination of structured counseling and sound therapy|Patients will receive a combination of structured counseling and sound therapy
62381308|NCT04663828|OTHER|Combination of hearing aids and sound therapy|Patients will receive a combination of hearing and sound therapy
62381309|NCT04663828|OTHER|Combination of cognitive behavioral therapy and sound therapy|Patients will receive a combination of cognitive behavioral therapy and sound therapy
62381310|NCT05592600|EXPERIMENTAL|Neurofeedback|Subjects will undergo one session where they will visualize real-time feedback of signals recorded from their brains.
62381311|NCT04898088|EXPERIMENTAL|Conventional Therapy|
62381312|NCT04898088|EXPERIMENTAL|Conventional Therapy with Add-On MSC therapy|
62381313|NCT05763472||Patients with germline BRCA1/2 patitents|Women with germline BRCA-1/2 mutations, previously treated or undergoing treatment with platinum-based chemotherapy and/or PARP inhibitors for ovarian cancer, who have developed breast cancer, subjected to genomic profiling of breast and ovarian tumor samples.
62381314|NCT05684315|EXPERIMENTAL|soft tissue flossing therapy right lower limb|The study will be conducted in two rounds, 4 weeks apart. In round one, subjects will have their right leg flossed while performing the fatigue protocol.
62381315|NCT05684315|EXPERIMENTAL|soft tissue flossing therapy left lower limb|The study will be conducted in two rounds, 4 weeks apart. In round one, subjects will have their left leg flossed while performing the fatigue protocol.
62381316|NCT03671434|EXPERIMENTAL|RPC Researchers|Researchers who are assigned to the experimental group that is eligible to receive the full RPC intervention
62381317|NCT03671434|EXPERIMENTAL|RPC Congressional Offices|Congressional offices that are assigned to the experimental group that is eligible to receive the full RPC intervention
62381318|NCT03671434|ACTIVE_COMPARATOR|Control Researchers|Researchers who are assigned to an Active Comparator control group that is enrolled in a light-touch intervention
62381319|NCT03671434|NO_INTERVENTION|Control Congressional Offices|Congressional offices that are assigned to the control group that receives no intervention
62381320|NCT05510791|EXPERIMENTAL|Nuun Sport|Citric Acid, Dextrose, Sodium Carbonate, Potassium Bicarbonate, Sodium Bicarbonate, Natural Flavors, Potassium Chloride, Magnesium Oxide, Calcium Carbonate, Stevia Leaf Extract, Avocado Oil, Riboflavin (for color).
62381321|NCT05510791|SHAM_COMPARATOR|Control|Water
62381322|NCT03200028|EXPERIMENTAL|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 30 treatment sessions, up to 5 sessions per week, 30 minutes per session.
62381323|NCT05165264||Cohort 1|Participants with previously untreated advanced or metastatic gastric cancer (GC), gastro-oesophageal junction (GEJ) or oesophageal adenocarcinoma (EAC)
62381324|NCT03096691|ACTIVE_COMPARATOR|short cervix group|cervical pessary in group with first pregnancy or no preterm labor
62381325|NCT03096691|ACTIVE_COMPARATOR|group with cervical insufficiency|cervical pessary in group with multiple preterm labor
62381326|NCT01996228|EXPERIMENTAL|Cord Blood-derived multipotent stem cells|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations in patients.
62381327|NCT01228084|EXPERIMENTAL|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
62381328|NCT02306291|EXPERIMENTAL|Arm A (Phase I)|GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
61987654|NCT06162156|NO_INTERVENTION|control group|Volunteer women who meet the inclusion criteria after cesarean delivery will be selected by random method, and verbal and written consent of those included in the control group will be obtained. Pre-test data twelve hours after cesarean delivery: 'Personal Information Form', 'Trait-Trait Anxiety Inventory', 'Postpartum Comfort Scale (PCS)', 'Bristol Breastfeeding Assessment Tool (BBAT)', 'Uterine Involution Evaluation Form ( UIEF)' 'Physiological Parameter Form (PPF)' and 'Visual Analog Scale (VAS)' will be filled in by the participants themselves using face-to-face interview technique in approximately twenty minutes. The control group will not be massaged anywhere in the study. Thirteen hours after cesarean delivery, 'VAS' and 'PPF data will be filled in again. Posttest data twenty-four hours after cesarean delivery; 'Richard Campbell Sleep Scale', 'VAS, 'Trait-Trait Anxiety Inventory', 'PCS', 'BBAT, 'UIEF, 'PPF will be filled in again.
62760807|NCT03466138||General Anesthesia|subjects requiring a surgical procedure under general anesthesia. monitored by PMD-200
62760808|NCT03836326|EXPERIMENTAL|Sensorimotor intervention|Is a 15-minute intervention consisting of tactile (i.e., stroking the whole body) and oral input (i.e., stroking the oral structures) for 15 minutes duration. The program will start 24 hours after nasal continuous positive airway pressure (NCPAP) is discontinued and 24 hours after 80 ml/kg/day of enteral feeds are tolerated. The program will be administered once a day for 10 days, within a 14-day period. The parents will perform all the interventions in the NICU. The infants will remain in the isolette for the duration of the program. This intervention does not involve any drugs or medical procedures. It is an intervention commonly used by occupational and physical therapists in the neonatal intensive care unit.
62381329|NCT02306291|EXPERIMENTAL|Arm B (Phase II Arm A)|GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
62381330|NCT02306291|EXPERIMENTAL|Arm C (Phase II Arm B)|GMI-1271 in combination with cytarabine and idarubicin (7+3 regimen) in newly diagnosed subjects 60 years and older
62381331|NCT02130635|EXPERIMENTAL|Part A: GSK2269557 1000 MCG|Subjects will receive 2 inhalations (2 x GSK2269557 500 mcg = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
62381332|NCT02130635|PLACEBO_COMPARATOR|Part A: PLACEBO|Subjects will receive 2 inhalations of placebo once daily for 14 consecutive days
62381333|NCT02130635|EXPERIMENTAL|Part B: GSK2269557 100 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 100 mcg and 3 x Placebo = total dose of 100 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
62381334|NCT02130635|EXPERIMENTAL|Part B: GSK2269557 200 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 200 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
62760809|NCT03836326|OTHER|Control|Infants in the control group will receive standard care only.
62381335|NCT02130635|EXPERIMENTAL|Part B: GSK2269557 500 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg and 3 x Placebo = total dose of 500 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days, once daily for 14 consecutive days
62381336|NCT02130635|EXPERIMENTAL|Part B: GSK2269557 700 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg, 2 x GSK2269557 100 mcg and 1 x Placebo = total dose of 700 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
62381337|NCT02130635|EXPERIMENTAL|Part B: GSK2269557 1000 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
62381338|NCT02130635|EXPERIMENTAL|Part B: GSK2269557 2000 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 2000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
62381339|NCT02130635|PLACEBO_COMPARATOR|Part B: PLACEBO|Subjects will receive 4 inhalations of placebo once daily for 14 consecutive days
62381340|NCT01780285|ACTIVE_COMPARATOR|Nitinol-framed PTFE mesh hiatal repair|Nitinol-framed lightweight PTFE mesh for hiatal repair
62381341|NCT01780285|ACTIVE_COMPARATOR|Lightweight mesh hiatal repair|Partially absorbable lightweight mesh for hiatal repair
62381342|NCT06231927|EXPERIMENTAL|Single arm|This is an open feasibility trial with single group of individuals receiving the SOLAR intervention program.
62381343|NCT00645736||1|Single cohort
62381344|NCT03018340|EXPERIMENTAL|Pimavanserin 34 mg + SSRI/SNRI|Drug- pimavanserin, 34 mg, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
61987655|NCT02373020||group 1|colonoscopic biopsies from patients with colorectal cancer patients
62381345|NCT03018340|PLACEBO_COMPARATOR|Placebo + SSRI/SNRI|Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
61987656|NCT02373020||(Group 2|colonoscopic biopsies from healthy controls
62168194|NCT02794558|EXPERIMENTAL|Treatment Arm|Subjects in this arm are treated once with MRgFUS device
62168195|NCT00935129|EXPERIMENTAL|OmniPod system|At this arm patients will be treated with the OmniPod system for 12 weeks
62381346|NCT03479840||Patients undergoing PCI|all-comer population undergoing PCI
62760810|NCT03237130||preoperative enhanced chest CT|The cohort contains patients with preoperative therapies and patients without preoperative therapies. Each patient receives regular preoperative enhanced chest CT; for patients with preoperative therapies, they usually undergo twice enhanced chest CT examination at before and after preoperative therapies, the CT images after preoperative therapies will be used for analysis
62760811|NCT06051747|EXPERIMENTAL|Treated|Three-dimensional patient-specific bioprinting trachea implantation
62760812|NCT02393846|EXPERIMENTAL|ketoprofen|Topical ketoprofen (gel) is the experimental drug that is applied to the ankle in a dose of 2 gr.
62760813|NCT02393846|PLACEBO_COMPARATOR|Placebo|Topical placebo (gel) is identical in colour, form and smell with the ketoprofen gel.
61987657|NCT03720470|EXPERIMENTAL|PF-04965842 100 mg + Placebo Inj followed by PF-04965842 100mg|Once-daily oral PF-04965842 100 mg + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral PF-04965842 100 mg from Week 16 to Week 20
61987658|NCT03720470|EXPERIMENTAL|PF-04965842 200 mg + Placebo Inj followed by PF-04965842 200mg|Once-daily oral PF-04965842 200 mg + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral PF-04965842 200 mg from Week 16 to Week 20
62760814|NCT05618886|ACTIVE_COMPARATOR|control group|Education given to all participants included before randomization. Information about UI, PFM and PFMT, together with lifestyle advices such as using the 'knack' (pre-contracting the PFM before coughing and sneezing), maintaining healthy weight, toilet habits, and reducing constipation and intra-abdominal pressure. The education session will last 30 minutes, and include a video (https://www.youtube.com/watch?v=XsDpfq10JMI) and a leaflet containing the information given.
62760815|NCT05618886|EXPERIMENTAL|intervention group|Along with education session, twelve weekly face-to-face sessions of PFMT with exercises individually or in groups with the women's health physiotherapist will be offered. PFMT will be taught on the basis of observation, vaginal palpation and camtech manometry, and will be individualized initially to suit each participant's ability within a protocol encouraging 10 close-to-maximum contractions and 6-8-second hold with a 10-second rest between contractions. During the first two appointments, participant will be instructed to perform two sessions with rest in between and thereafter three times 10 contractions if possible during each visit. The participants will be encouraged to perform daily PFMT (10 contraction x 3 10times, 3 sets) at home and will be asked to record their PFMT in an exercise diary
62760816|NCT02805400|OTHER|Neurocognitive performance|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.~For these methods only commercially available CE marked devices will be used."
62760817|NCT02144545|EXPERIMENTAL|Bougie Size 33Fr Distance pylorus 2 cm|Sleeve gastrectomy with a 33Fr bougie size and 2 cm distance from the pylorus.
62760818|NCT02144545|EXPERIMENTAL|Bougie Size 33Fr Distance pylorus 5 cm|Sleeve gastrectomy with a 33Fr bougie size and 5 cm distance from the pylorus
62760819|NCT02144545|EXPERIMENTAL|Bougie Size 42Fr Distance pylorus 2 cm|Sleeve gastrectomy with a 42Fr bougie size and 2 cm distance from the pylorus
62760820|NCT02144545|EXPERIMENTAL|Bougie Size 42Fr Distance pylorus 5 cm|Sleeve gastrectomy with a 42Fr bougie size and 2 cm distance from the pylorus
62760821|NCT06608381|ACTIVE_COMPARATOR|Total omentectomy group|During minimally invasive radical gastrectomy and D2 lymph node dissection, total omentectomy will be performed.
62760822|NCT06608381|EXPERIMENTAL|Partial omentectomy group|During minimally invasive radical gastrectomy and D2 lymph node dissection, partial omentectomy will be performed.
62760823|NCT01442064|EXPERIMENTAL|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) for 24 months.
62760824|NCT01789983||Breast Cancer Patients 60+|Breast Cancer Patients age 60 and older who have histologically confirmed stage I, II or III disease.
61987659|NCT03720470|ACTIVE_COMPARATOR|Dupilumab Injection + Oral Placebo followed by Oral Placebo|Dupilumab injected subcutaneously once every 2 weeks + once-daily oral Placebo from Day 1 until Week 16 followed by once-daily oral Placebo from Week 16 to Week 20
61987660|NCT03720470|PLACEBO_COMPARATOR|Oral Placebo + Placebo Inj followed by 100 mg PF-04965842|Once-daily oral Placebo + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral 100 mg PF-04965842 from Week 16 to Week 20
62381347|NCT05421585|ACTIVE_COMPARATOR|QL2 block|Posterior QLB process After aseptic conditions are provided, the convex US probe will be covered with a sterile sheath, and an 80-100 mm block needle will be used. After imaging the abdominal muscles with the anterior approach, the needle will be advanced in the Petit triangle and 1-2 ml of saline will be injected into the posterior border of the quadratus lumborum muscle. After the block location is confirmed, 20 ml of local anesthetic infiltration at a concentration of 0.25% will be applied. The same procedure will be applied to the other side. A total of 30 ml of local anesthetic solution will be used.
62558637|NCT02287181|ACTIVE_COMPARATOR|remifentanil effect site concentration 0ng/ml|remifentanil run as an infusion using the minto TCI model, at an effect site concentration of 0 nano grams per millilitre, commenced from start of proposal infusion to point at which patient is anaesthetised and not responding to painful stimuli.
62760825|NCT01789983||Lung Cancer Patients 60+|Lung Cancer Patients age 60 and above who have stage I, II or III disease
62760826|NCT01789983||Colon Cancer Patients 60+|Colon cancer patients age 60 and above who have stage II or III disease.
61987661|NCT03720470|PLACEBO_COMPARATOR|Oral Placebo + Placebo Inj followed by 200 mg PF-04965842|Once-daily oral Placebo + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral 200 mg PF-04965842 from Week 16 to Week 20
62760827|NCT00499382||PET/CT scan + NM cardiac scan|
62760828|NCT04348175|EXPERIMENTAL|Mild impairment|
61987662|NCT05278078|OTHER|psychological support|Psychological support will be given to the experimental group.
61987663|NCT05278078|OTHER|nutritional education|Nutrition education will be given to the experimental group.
61987664|NCT05278078|OTHER|psychological support and nutritional education|psychological support and nutritional education will be given to the experimental group.
61987665|NCT05278078|OTHER|no intervation|No intervention will be applied to the control group
61987666|NCT01198054|EXPERIMENTAL|Lenalidomine|Post-induction lenalidomide in patients with de novo AML with deletion 5q cytogenetic abnormality (del (5q)) or monosomy 5 (-5)
61987667|NCT05792228|EXPERIMENTAL|The intervention group|The intervention group will receive evidence-based, nurse-led standardized management of CINV, including nurse-led risk assessment, education on prevention and control of CINV, antiemetics following guidelines, dietary strategies, relaxation therapy, and follow up.
61987668|NCT05792228|NO_INTERVENTION|The control group|The control group will receive the routine CINV management. Patients are given drugs to prevent and control emesis according to the physicians' individual prescriptions. Nurses provide related education about nausea and vomiting control and recommend patients to drink more water and eat light food. Patients will be given Metoclopramide when they are vomiting.
61987669|NCT02311738|EXPERIMENTAL|High intensity training group|"HIE will consist of the following:~1. 10 minute warm up at 70% of maximal heart rate.~2. 4 minute exercise intervals at 90-95% of maximal heart rate.~3. 4 minute interval bouts repeated 4 times.~4. Between each bouts there will be a 3 minute active recovery at 70% of maximal heart rate~5. After all four bouts are completed; 5 minute cool-down at 70% of maximal heart rate."
62381348|NCT05421585|ACTIVE_COMPARATOR|TLIP block|Classic TLIP block After providing aseptic conditions, the high frequency linear US probe will be covered with a sterile sheath, and a 50 mm block needle will be used. The ultrasound probe will be placed vertically at the level of the L3 vertebra. After visualizing the guiding point spinous process and interspinal muscles, the probe will be moved laterally to visualize the longissimus and multifidus muscles. By using the in-plane technique, the block needle will be directed from medial to lateral, and after reaching the interfacial area between the longissimus and multifidus muscles, the block area will be confirmed by administering 5 ml of serum physiologically. Then, 20 ml of 0.25% local anesthetic will be administered. The same procedure will be applied to the other side. A total of 40 ml of local anesthetic solution will be used.
62381349|NCT00795938|ACTIVE_COMPARATOR|Conventional Oral Tablet With Water|
61987670|NCT02311738|EXPERIMENTAL|Moderate intensity training group|"MIE will consist of the following:~1. 10 minute warm up at 50% of maximal heart rate.~2. 35 minutes exercise at 70% of maximal heart rate.~3. 4 minute cool-down at 50% of maximal heart rate."
61987671|NCT04508842|EXPERIMENTAL|CD19/CD22-Dual-STAR-T|CD19/CD22-Dual-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of Dual-STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 500mg/m2 for 3 days and take a rest for 2 days before infusion. Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.
61987672|NCT04538144||Younger participants|Individuals aged 18-39 years
62760829|NCT04348175|EXPERIMENTAL|Moderate impairment|
61987673|NCT04538144||Older participants|Individuals aged 65 years or older
61987674|NCT01077947|ACTIVE_COMPARATOR|Functional anesthetic discography|"The patients disc levels for surgical treatment will be based exclusively on their Functional anesthetic discography results. The discography will be performed at a maximum of two disc levels. Discs showing the following MRI findings will be considered for discography:~1. Loss of disc signal intensity on T-2 weighted sagittal MR images.~2. Loss of disc height on sagittal MR images.~Patients will be followed-up at 3 weeks, 3 months, 6 months and 1 year after the surgery by research personnel. Patients will be asked to complete questionnaires before their discography and at every follow-up visit."
62168196|NCT00935129|ACTIVE_COMPARATOR|patient's conventional pump|At this arm patients will be treated with their conventional pump for 12 weeks
62168197|NCT01764152|EXPERIMENTAL|Nasopharyngeal sample|one will be taken nasopharyngeal all patients hospitalized for 24 hours with ILI in the last seven days.
62168198|NCT02551471||French patients|
62168199|NCT02551471||Australians patients|
62760830|NCT04348175|EXPERIMENTAL|Severe impairment|
62760831|NCT04348175|EXPERIMENTAL|Normal (control)|
62760832|NCT04490980|EXPERIMENTAL|Observed group|
62760833|NCT04490980|NO_INTERVENTION|Control group|
62760834|NCT04079543|OTHER|Strict NPO|NPO after midnight. No solids or liquids after midnight.
62760835|NCT04079543|OTHER|Liberal NPO|No solids after midnight. Clear liquids up to 2 hours prior to surgery.
62760836|NCT02075632|EXPERIMENTAL|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% will be applied by the participants topically on the affected areas per label instructions for 14 days.
62760837|NCT01291693|EXPERIMENTAL|Personal counseling|
62760838|NCT01291693|EXPERIMENTAL|Computer generated feedback letters|
61987675|NCT01077947|ACTIVE_COMPARATOR|Provocative Discography|"The patients disc levels for surgical treatment will be based exclusively on their Provocative Discography results. The discography will be performed at a maximum of two disc levels. Discs showing the following MRI findings will be considered for discography:~1. Loss of disc signal intensity on T-2 weighted sagittal MR images.~2. Loss of disc height on sagittal MR images.~The control disc, in the case provocative discography group must appear normal on the MRI - must have preserved disc height and central disc signal intensity on T-2 weighted images. The provocative discography will be performed using the standard IASP criteria. The patients will be followed-up at 3 weeks, 3 months, 6 months and 1 year after the surgery."
61987676|NCT03170128|ACTIVE_COMPARATOR|Outpatient Physical Therapy|
61987677|NCT03170128|ACTIVE_COMPARATOR|Home Exercises|
61987678|NCT04357015|EXPERIMENTAL|intravenous tranexamic acid|The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
61987679|NCT04357015|ACTIVE_COMPARATOR|intravenous carbetocin|The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
62760839|NCT01291693|NO_INTERVENTION|Control group|Treatment as usual
62760840|NCT02677636|EXPERIMENTAL|MSRD-100|MSRD-100 is a topical gel with an active ingredient in a vehicle. Excipients are purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. Application is twice daily for 28 days.
62760841|NCT02677636|PLACEBO_COMPARATOR|Placebo Comparator|The vehicle is a topical gel and contains excipients of the formulation: purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. It does not contain the active ingredient MSRD-100. Application is twice daily for 28 days.
62760842|NCT02170363|EXPERIMENTAL|HeartMate 3|Left Ventricular Assist System (LVAS) to be used on Subjects with advanced refractory left ventricular heart failure
61987680|NCT04357015|PLACEBO_COMPARATOR|placebo|the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
61987681|NCT04173117|EXPERIMENTAL|Intervention|Low energy meal replacement plan 12 weeks
61987682|NCT01588691|ACTIVE_COMPARATOR|Low frequency|Programming parameters with the Eon Mini will be set at a low frequency. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
61987683|NCT01588691|ACTIVE_COMPARATOR|High frequency|Programming parameters with the Eon Mini will be set at a low frequency. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
61987684|NCT01588691|PLACEBO_COMPARATOR|No stimulation|Programming parameters will be set to the lowest possible level and minimal power will be generated. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
61987685|NCT02608931|EXPERIMENTAL|Dranabinol Capsules|The initial dose will be 2.5 mg BID (5 mg/day), and the maximum dose will be 10 mg TID (30 mg/day).
61987686|NCT02608931|PLACEBO_COMPARATOR|Placebo Capsules|placebo
62381350|NCT00795938|EXPERIMENTAL|Experimental Tablet With Water|
62381351|NCT00795938|EXPERIMENTAL|Experimental Tablet Without Water|
62760843|NCT03554772|EXPERIMENTAL|DFN-15 (Celecoxib Oral Solution) 62.5 mg|Single dose containing 62.5 mg of celecoxib in 10 ml solution
62760844|NCT03554772|EXPERIMENTAL|DFN-15 (Celecoxib Oral Solution) 125 mg|Single dose containing 125 mg of celecoxib in 10 ml solution
62760845|NCT03554772|EXPERIMENTAL|DFN-15 (Celecoxib Oral Solution) 250 mg|Single dose containing 250 mg of celecoxib in 10 ml solution
61987687|NCT05218018|OTHER|Intervention|Only one arm of study
61987688|NCT05464459|EXPERIMENTAL|HAPY interposition elbow replacement|HAPY is a pyrocarbon sphere for use as an interposition joint replacement. In this study, the implant is being used as a novel procedure in the Elbow (outside approved label usage)
61987689|NCT05595681|EXPERIMENTAL|Treatment group|20 x 1000000 C2C_ASCs on top of standard care.
61987690|NCT05595681|NO_INTERVENTION|Control group|Control group with standard care.
61987691|NCT03832621|EXPERIMENTAL|temozolomide + nivolumab + ipilimumab|Temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks, for two cycles followed by TC scan assessment: if SD/PR/CR second treatment phase with nivolumab 480 mg i.v. every 4 weeks, low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks and temozolomide at the previously adopted schedule
61987692|NCT04896710|EXPERIMENTAL|Self administration|The participant will self administer the SD Biosensor. Their rapid antigen test result will be compared to health care professional administered SD Biosensor
62381352|NCT02579525|EXPERIMENTAL|Targeted tissue perfusion guidance (TTP)|TTP-guidance based on clinical signs of peripheral perfusion.
62381353|NCT02579525|ACTIVE_COMPARATOR|Macrocirculatory - guidance (MCG)|MCG-guidance based on recommended macrocirculatory parameters.
62381354|NCT04238286|EXPERIMENTAL|Dry needling group|Patients treated with dry needling
62381355|NCT04238286|SHAM_COMPARATOR|Sham group|Patients treated with a simulated dry needling
62381356|NCT04238286|NO_INTERVENTION|Control|Patients never treated
62381357|NCT04525989|EXPERIMENTAL|Proton therapy|5 x 5 Gy External radiation therapy with Protons
62381358|NCT04525989|ACTIVE_COMPARATOR|Photon therapy|5 x 5 Gy External radiation therapy with Photons
62760846|NCT03554772|PLACEBO_COMPARATOR|Placebo|Single dose containing 0 mg of celecoxib in 10 ml solution
62760847|NCT05187754|EXPERIMENTAL|Intervention Group|
62381359|NCT02029365|OTHER|Without eating disorders|Women consulting for infertility but without diagnosis of eating disorder.
62381360|NCT02029365|OTHER|With Eating disorders|Womenconsulting for infertility for which eating disorder is diagnosed.
62760848|NCT05187754|NO_INTERVENTION|Control Group|
62760849|NCT05314192||Healthy|Healthy cohorts with no underlying systemic or periodontal disease
62760850|NCT05314192||stage 2 periodontitis|patients with periodontitis but no underlying systemic periodontal disease
62760851|NCT05314192||MI patients with stage 4 periodontitis|patients who had MI and having stage 4 periodontitis patients
62760852|NCT05314192||MI patients without periodontitis|patients who had MI without periodontitis
62760853|NCT05995223|EXPERIMENTAL|Down syndrome|Participants will complete a submaximal walking protocol on a motorized treadmill, which consists of 4 times 6 minutes of walking at a moderate intensity speed and incline while their breathing, cardiac output, and muscle oxygen use is measured, with 10 minutes rest in between each bout.
62760854|NCT05995223|EXPERIMENTAL|control without Down syndrome|This group of age- and sex-matched participants without Down syndrome will undergo the same testing as participants with Down syndrome
62760855|NCT02168972|EXPERIMENTAL|Global mapping and ablation device|
62760856|NCT03524287|EXPERIMENTAL|No.10 lymph node dissections|Patients with locally advanced upper third gastric carcinoma will performed robotic assisted spleen-preserving No.10 lymph node dissections. After the surgery the patients will be treated with oxaliplatin or platinum-based chemotherapy.
62760857|NCT06115694|ACTIVE_COMPARATOR|Experimental group：TCI Articulating Introducer|Tracheal intubation was performed using a TCI core under a visual laryngoscope
62760858|NCT06115694|PLACEBO_COMPARATOR|Control group：GlideRite® Rigid Stylet|Tracheal intubation was performed under a visual laryngoscope using a common tube core
62381361|NCT05868408|ACTIVE_COMPARATOR|Control formula|CTRL, an infant formula with minimum protein content of 1.8g intact protein/100kcal
62381362|NCT05868408|EXPERIMENTAL|Experimental formula 1|EXPL1, an infant formula with minimum protein content of 1.9g hydrolyzed protein/100kcal
62760859|NCT02104271|EXPERIMENTAL|Argon Plasma Coagulation|"Argon Plasma Coagulation (APC) treatment will be delivered using a spray-painting technique, with short applications at 40W power and argon gas flow of 1.2 L/min. The APC equipment consists of a high frequency electrosurgical generator combined with a source of argon gas (Argon + SS601MC 4 , WEM Electronic Equipment Ltda , Ribeirão Preto , Brazil ). A flexible catheter of 2.3 mm diameter ( WEM ) Teflon coated and with a hint of heat resistant ceramic is inserted through the working channel of the colonoscope and connected to the current generator and the gas source for APC implementation."
62760860|NCT02104271|ACTIVE_COMPARATOR|Historical control|"Argon Plasma Coagulation (APC) treatment was delivered using a spray-painting technique, with short applications at 40-50W power and argon gas flow of 2.0 - 2.5 L/min. The APC equipment consists of a high frequency electrosurgical generator combined with a source of argon gas (Argon + SS601MC 4 , WEM Electronic Equipment Ltda , Ribeirão Preto , Brazil ). A flexible catheter of 2.3 mm diameter ( WEM ) Teflon coated and with a hint of heat resistant ceramic is inserted through the working channel of the colonoscope and connected to the current generator and the gas source for APC implementation."
62760861|NCT03236168|OTHER|Intervention Arm|This study consists of a single treatment arm. Patients will receive Ivermectin or where contraindicated (Pregnancy, Breastfeeding, Weight \<15kg) Permethrin Cream and Malathion shampoo
62760862|NCT02075047|PLACEBO_COMPARATOR|1|
62760863|NCT02075047|EXPERIMENTAL|ziprasidone|
62760864|NCT06053957|EXPERIMENTAL|Mobilization|Patients undergoing early mobilization program
62760865|NCT06053957|NO_INTERVENTION|mobilization free|Patients not subjected to early mobilization program
62760866|NCT04461574|PLACEBO_COMPARATOR|Cervex Brush|
62760867|NCT04461574|ACTIVE_COMPARATOR|Orcellex Brush|
62760868|NCT05148416|EXPERIMENTAL|Laser group|"1. Experimental group (A) the laser group (n=20) which received~1. high intensity laser therapy(HILT)~2. knee osteoarthritis conventional exercises program in form of stretching exercises for both vastus medialis and gastrocnemius muscles , ROM exercises for knee flexion and extension , and isometric strengthening exercise of previously mentioned muscles .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
62760869|NCT05148416|SHAM_COMPARATOR|the sham group group( B)|"the Sham group (n= 20) which received~1. sham HILT~2. knee osteoarthritis conventional exercises program previously mentioned .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
62381363|NCT05868408|EXPERIMENTAL|Experimental formula 2|EXPL2, an infant formula identical to EXPL1 but manufactured using a different partially hydrolyzed milk protein base
62381364|NCT01569724|EXPERIMENTAL|bexarotene|
62381365|NCT03263169||WE Health Tapestry|Completion of baseline measures then enrolled in a community-based personalized care intervention that consists of four core elements: volunteer support, interprofessional care, technology, social network linkage
62381366|NCT03263169||Usual Care|Completion of baseline measures with six-month delayed community-based personalized care intervention: volunteer support, interprofessional care, technology, social network linkage
62381367|NCT01885962|NO_INTERVENTION|Treatment as Usual (TAU)|Participants in this group engage in typical rehabilitation and perform usual skin care routine.
62381368|NCT01885962|EXPERIMENTAL|TAU + iSHIFTup|Participants in this group engage in typical rehabilitation and use iSHIFTup, Internet Skin Health Intervention for Targeted Ulcer Prevention. Participants are instructed to perform program recommendations to engage in preventive skin care behaviors.
62760870|NCT05411861|EXPERIMENTAL|CPL-01|Low dose of CPL-01
62760871|NCT05411861|ACTIVE_COMPARATOR|Ropivacaine HCl|Low dose of Ropivacaine HCl
62760872|NCT05411861|PLACEBO_COMPARATOR|Placebo|Low volume of placebo
62381369|NCT02878135|EXPERIMENTAL|fast vulsellum|rapid ratchet of the vulsellum
62760873|NCT03177447|OTHER|Summative evaluation trial of ENABLE CHF-PC|Single arm summative evaluation study was selected for several reasons: 1) to continue to determine recruitment feasibility; 2) retention- our prior work has demonstrated fairly equal dropouts in the intervention and control conditions, hence we believe we will be able to judge retention in a single arm design; 3) using a small randomized controlled trial (RCT) for power estimates runs a high risk of either overestimating or underestimating treatment effects; and 4) most importantly, the primary purpose of this study is to determine intervention efficacy. Therefore delivering the intervention to the maximum number of participants given the limitations of 2-year pilot funding allows the investigators to obtain the maximal input and experience with the intervention that is needed to achieve the study's Aim 1.
62760874|NCT01093781|EXPERIMENTAL|Aliskiren|Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
62760875|NCT01930552|EXPERIMENTAL|Cohort 1|aflibercept IV infusion for 1 hour followed by FOLFIRI IV infusion every 2 weeks
62760876|NCT02986243|EXPERIMENTAL|Treatment|Subjects receive a diet plan and exercise regimen.
62760877|NCT01325090|EXPERIMENTAL|BOTOX|Patients will receive in one session multiple intradermal injections of Botox, in order to cover the whole painful area
62760878|NCT01325090|PLACEBO_COMPARATOR|PLACEBO|Patients will receive in one session multiple intradermal injections of placebo , in order to cover the whole painful area
62760879|NCT03379987|EXPERIMENTAL|PVB morphine|
62760880|NCT03379987|ACTIVE_COMPARATOR|PVB bupivacaine|
62760881|NCT04612842|EXPERIMENTAL|Motivational Interviewing (MI) goup|The MI experimental group will receive the same measurements as the control group, and in addition, receive MI-based communication about fall prevention at eight occasions during the 6-month period. MI is an evidence-based communication approach for various health behavior change.
62760882|NCT04612842|NO_INTERVENTION|Control group|The control group participants will take part in study measurements (self-report and physiologic assessment) for 12-months. Primary assessment measures are at baseline, 6-, and 12-months and will be conducted via phone survey, video assessment, or mail-in calendar.
62760883|NCT04159363|EXPERIMENTAL|Intervention group|Participants in the intervention group will receive an interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage) in addition to routine care provided by the respective hospitals.
62760884|NCT04159363|NO_INTERVENTION|Control group|Participants in the control group will receive routine care provided by the respective hospitals . The routine care includes normal consultation with their attending physician, information concerning treatment plans, such as surgical procedures and its associated risks, preoperative preparations and postoperative care, treatment after discharge and/or subsequent adjunct therapy if required.
61987693|NCT05921019|EXPERIMENTAL|laser acupuncture group|"This study will use the Handylaser Trion laser manufactured by RJ Laser, Germany.~It will be used for 40 seconds to deliver 6 J of energy as a pulsed wave (Noiger E) at each acupoint near palms or plantar, such as bilateral LI 4, PC6, KI 3, LR 3.~For distal points in the four limbs, the laser will be used for 40 seconds at each acupoint to deliver 6J of energy as a pulsed wave (Noiger B), such as bilateral LI11, GB 34, ST 36, SP 6."
61987694|NCT05921019|SHAM_COMPARATOR|sham laser acupuncture group|This study will use the sham Handylaser Trion laser manufactured by RJ Laser, without any laser beam delivering. The acupoints of the sham-laser acupuncture are the same as those of the laser acupuncture group.
62381370|NCT02878135|ACTIVE_COMPARATOR|slow vulsellum|Placement of the tenaculum over 7-10 seconds and not allowing the vulsellum to ratchet audibly.
62381371|NCT03128372|EXPERIMENTAL|Desaturation|Volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
62760885|NCT02793830|EXPERIMENTAL|Mobile App Group|Participants in the experimental group will receive daily reminders and educational materials from mobile applications.
62760886|NCT02793830|ACTIVE_COMPARATOR|Control Group|The control group will receive the same educational materials, but no daily reminder.
62760887|NCT00839865|EXPERIMENTAL|herb ointment dressing change group|This group of patients in the ointment dressing every 2 days until Wound Healing or 6 months
62760888|NCT00839865|NO_INTERVENTION|Conventional dressing change group|This group of patients in the Conventional dressing every 2 days until Wound Healing or 6 months
62760889|NCT02262442|EXPERIMENTAL|Working channel|Patients will receive local anaesthetics via the working channel of the bronchoscope.
62760890|NCT02262442|EXPERIMENTAL|Enk Fiberoptic Atomizer|Patients will receive the local anaesthetics for the flexible bronchoscopy via the nebulizer Enk Fiberoptic Atomizer.
61987695|NCT03229824|EXPERIMENTAL|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
62760891|NCT02523131|EXPERIMENTAL|24/7 closed loop insulin delivery|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature over a 12-week period using 24/7 Medtronic insulin pump 640G and Android smartphone.
62760892|NCT02523131|ACTIVE_COMPARATOR|Sensor augmented pump therapy|Insulin pump therapy combined with unmasked real-time continuous glucose monitoring system for 12 weeks using Medtronic insulin pump 640G. Pump suspend features will be turned off.
61987696|NCT03229824|NO_INTERVENTION|Standard care|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site and the tubing with a cotton swab dipped in rubbing alcohol.
61987697|NCT03807011|ACTIVE_COMPARATOR|fentanyl|A bolus dose of fentanyl 2 μg/kg was administered intravenously at anesthetic induction
61987698|NCT03807011|ACTIVE_COMPARATOR|remifentanil|Remifentanil was continuously infused at a rate of 0.2 μg/kg/min from anesthetic induction to the end of surgery
61987699|NCT03904758|EXPERIMENTAL|Monitoring of pH with Restech|The patients with EER randomized into this arm will undergo pH monitoring using Restech system
61987700|NCT03904758|EXPERIMENTAL|Monitoring of oesophageal impedance|The patients with EER randomized into this arm will undergo monitoring of oesophageal impedance
61987701|NCT03586388|EXPERIMENTAL|Oral immunotherapy protocol|Eligible children receive the oral food challenge (OCD) protocol
61987702|NCT03817242|ACTIVE_COMPARATOR|tympanoplasty with tragal cartilage|Tympanoplasty was performed using tragal cartilage graft
61987703|NCT03817242|ACTIVE_COMPARATOR|tympanoplasty with temporalis fascia|Tympanoplasty was performed using temporalis fascia graft
61987704|NCT02500784|ACTIVE_COMPARATOR|Formoterol A|12 months, formoterol, 20microgram/2ml, inhaler, BID
61987705|NCT02500784|PLACEBO_COMPARATOR|Formoterol B|12 months, normal saline, 2ml, inhaler, BID
62760893|NCT02721121|ACTIVE_COMPARATOR|circumferential pulmonary vein isolation|circumferential pulmonary vein isolation
61987706|NCT06051188|EXPERIMENTAL|FCV-PCV|90 minutes of flow-controlled ventilation followed by 90 minutes of pressure-controlled ventilation.
61987707|NCT06051188|EXPERIMENTAL|PCV-FCV|90 minutes of pressure-controlled ventilation followed by 90 minutes of flow-controlled ventilation.
61987708|NCT01948817|EXPERIMENTAL|Deferasirox|Deferasirox 20mg/kg taken BID
61987709|NCT03169465|EXPERIMENTAL|open group|patients with posterior calcaneal deformity
61987710|NCT03169465|ACTIVE_COMPARATOR|endoscopic group|patients with posterior calcaneal deformity
61987711|NCT02747420|EXPERIMENTAL|Post Tibial Nerve Stimulation Group (PTNS)|
61987712|NCT02747420|SHAM_COMPARATOR|Sham Group|
62760894|NCT02721121|EXPERIMENTAL|Linear ablation in addiction to pulmonary vein isolation|Linear ablation in addiction to pulmonary vein isolation
62381372|NCT01070628|EXPERIMENTAL|Stalevo (levodopa/carbidopa/entacapone)|"125mg or 75mg of levodopa during treatment period 1 in groups 1 and 2 respectively.~150mg or 100mg of levodopa during treatment period 2 in groups 1 and 2 respectively."
62381373|NCT01070628|ACTIVE_COMPARATOR|Sinemet (levodopa/carbidopa)|150mg or 100mg of levodopa during treatment period 3 in study groups 1 and 2 respectively
62381374|NCT06282952|EXPERIMENTAL|Fecal microbiota transplant from biobank|The newborns receive fecal microbiota transplant from their own mother (50 newborns).
62381375|NCT06282952|ACTIVE_COMPARATOR|Fecal microbiota transplant from own mother|Newborns receive fecal microbiota transplant from normal weight, healthy female donor from the Microbiome Biobank (50 newborns).
61987713|NCT05771207|EXPERIMENTAL|soy protein intervention|This group received dietary guidance and soy protein intervention for 3 months
61987714|NCT05771207|EXPERIMENTAL|whey protein intervention|This group received dietary guidance and whey protein intervention for 3 months
61987715|NCT05771207|PLACEBO_COMPARATOR|control|This group received dietary guidance and ｍltodextrin for 3 months
62381376|NCT06282952|NO_INTERVENTION|The observational cohort|"If mother has Group B streptococcus (GBS) colonization or other infectious, and microbiota transplant cannot be given or if mother will have non-elective-CS and the microbiome transplant is not available, the mother is included in the observational cohort, which is open (not blinded)."
62381377|NCT01685060|EXPERIMENTAL|LDK378|Patients treated with ceritinib/LDK378 750 mg once-daily, fasted
62381378|NCT03727802|EXPERIMENTAL|TRK-250|
62381379|NCT03727802|PLACEBO_COMPARATOR|Placebo|
62381380|NCT06502509|ACTIVE_COMPARATOR|interventional (Lemon kombucha tea) arm|
62381381|NCT06502509|PLACEBO_COMPARATOR|controlled (Lemon tea) arm|
62760895|NCT05242354||Periodontal health|Periodontally healthy individuals (2017 Classification of Periodontal Diseases and Conditions) who are planned to receive crown lengthening / gingivectomy of tooth extraction involving at least one site with pocket depth ≤3mm, bleeding on probing -
61987716|NCT03137693|OTHER|Change in Procedure Scheduling|Pre-Surgery SABR: Treatment with Stereotactic Ablative Body Radiation Therapy (SABR) followed by breast-conserving surgery. The usual treatment for patients with early-stage breast cancer who have breast-conserving treatment (BCT) is to receive radiotherapy AFTER surgery, targeting either the whole breast or part of the breast.
61987717|NCT01257958|EXPERIMENTAL|19 nor vitamin d|
61987718|NCT03316885|EXPERIMENTAL|Clareon IOL|Clareon® aspheric hydrophobic acrylic intraocular lens implanted with the Alcon Monarch III-D delivery system as a replacement of the human crystalline lens during cataract surgery
62381382|NCT00794989|EXPERIMENTAL|Arm 1: Intervention|Patients ingest ground flaxseed daily, with already prepared foods, for 6 months.
62760896|NCT05242354||Peri-implant health|Periodontally healthy individuals (2017 Classification of Periodontal Diseases and Conditions) with at least one partially-exposed dental implant with no bone loss prior to the prosthetic rehabilitation
62760897|NCT05242354||Periodontitis|Generalized Stage III Grade C periodontitis patients (2017 Classification of Periodontal Diseases and Conditions) having at least one site with pocket depth ≥6mm, bleeding on probing +
62760898|NCT05242354||Peri-implantitis|Individuals with at least one implant site with radiographic bone loss, pocket depth ≥6mm and bleeding on probing +
62760899|NCT04978870||1 - Validation|Group 1 will be screened for delirium during the PACU stay using the CAM-PACU. Delirium criteria as defined by ICD-10 will be assessed in comparison. A subgroup of patients will receive an additional delirium screening using the CAM-PACU. This screening will be performed by another operator blinded for the results from the initial delirium screening.
62760900|NCT04978870||2 - Cognition|"Group 2 will be screened for delirium during the PACU stay using the CAM-PACU. Delirium criteria as defined by ICD-10 will be assessed in comparison.~This group will undergo additional assessment of preoperative and postoperative cognitive function as well as a POD screening using the 3D-CAM starting at postoperative day 1 until discharge from hospital but no longer than postoperative day 5."
62760901|NCT05093920|ACTIVE_COMPARATOR|Drug Eluting Bead Transarterial Chemoembolization|Drug Eluting Bead Transarterial Chemoembolization
62760902|NCT05093920|ACTIVE_COMPARATOR|conventional Transarterial Chemoembolization|conventional Transarterial Chemoembolization
62760903|NCT01646619|ACTIVE_COMPARATOR|Hypothermia + Magnesium Sulphate|
62760904|NCT01646619|PLACEBO_COMPARATOR|Hypothermia+ Placebo|
62760905|NCT06607276|EXPERIMENTAL|Adebrelimab and capecitabine|
62760906|NCT06607276|ACTIVE_COMPARATOR|capecitabine|
61987719|NCT02299557|EXPERIMENTAL|Treatment|Intra-anal Oxymetazoline gel once daily
61987720|NCT02299557|PLACEBO_COMPARATOR|Placebo|Intra-anal Placebo gel once daily
61987721|NCT02304263||Younger (18-35 years old)|iohexol
62381383|NCT00794989|OTHER|Arm 2: Observational|Patients do not receive ground flaxseed.
62381384|NCT05541159|EXPERIMENTAL|Group 1|Healthy control participants with normal renal function
61987722|NCT02304263||Older (>60 years old)|iohexol
61987723|NCT04273646|EXPERIMENTAL|UC-MSCs Treatment Group|"Conventional treatment plus UC-MSCs:~Participants will receive conventional treatment plus 4 times of UC-MSCs(0.5\*10E6 UC-MSCs/kg body weight intravenously at Day 1，Day 3，Day 5，Day7)."
61987724|NCT04273646|PLACEBO_COMPARATOR|Conventional Control Group|"Conventional treatment plus Placebo:~Without UC-MSCs Therapy but conventional treatment should be received. Participants will receive conventional treatment plus 4 times of Placebo intravenously at Day 1，Day 3，Day 5，Day7)."
61987725|NCT05275647|EXPERIMENTAL|Treatment group : BoNT-A 100 U in Normal saline|BOTOX 100U in normal saline (BoNT-A/NS) 30ml in single intravesical instillation
61987726|NCT05275647|PLACEBO_COMPARATOR|Placebo group : Normal saline|Normal saline (N/S) 30ml in single intravesical instillation
62381385|NCT05541159|EXPERIMENTAL|Group 2|Mild renal impairment
62381386|NCT05541159|EXPERIMENTAL|Group 3|Moderate renal impairment
62381387|NCT05541159|EXPERIMENTAL|Group 4|Severe renal impairment
62760907|NCT02539498|ACTIVE_COMPARATOR|Control|Control post menopausal women without PHPT
62760908|NCT02539498|EXPERIMENTAL|Experimental|Post menopausal women with PHPT followed for one year
62760909|NCT06000631|ACTIVE_COMPARATOR|2-hour session of ROC-Stand training for a total of 48 hours (ROC-Stand(2-hr))|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for 2 hours/per session, 2 sessions/per week for a total of 12-week intervention based on ecological and dynamic systems theories. Each week the participant will wear a light-weight, head-mounted eye-tracker for recording the first 10-minute of driving and natural play sessions in a 2-hour training session. The 2-hour training session is composed of a 70-minute driving session and a 50-minute natural play session. Training will concentrate on building the concept of casual-effect on the control system and car motion, practicing goal-oriented driving in certain public spaces, upper limb use in functional tasks for exploration in driving sessions, and applying various motor skills for mobility and socialization in natural play sessions. The program will be discussed by the family and the treating therapist.
62760910|NCT06000631|ACTIVE_COMPARATOR|1-hour session of ROC-Stand training for a total of 48 hours (ROC-Stand(1-hr))|The same therapist for the ROC-Stand(2-hr) group will be responsible for the program. The training frequency and guidelines are the same as the ROC-Stand(2-hr) group, except for the training intensity of 1-hour per session and intervention duration for 24 weeks. Each 1-hour session will include a 35-minute car play and a 25-minute natural play. The participants will also wear the head-mounted eye tracker in one training session for recording 20 minutes (the first 10-minute of driving and the first 10-minute of natural play) every week.
61987727|NCT04741828|EXPERIMENTAL|Vi-DT Typhoid Conjugate Vaccine|Participants receive 1 dose (0.5ml) Vi-DT Typhoid Conjugate Vaccine, intramuscularly.
62760911|NCT06000631|ACTIVE_COMPARATOR|1-hour session of conventional therapy for a total of 48 hours (Control(1-hr))|Another licensed, independent therapist will provide the training program to the Control(1-hr) group for 1 hours/per session, 2 sessions/per week for a total of 24-week intervention. The conventional therapy provided in the Control(1-hr) group is based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve certain mobility, socialization and upper limb use in functional tasks. Each participant will have the opportunity to walk on the same public space as the ROC training groups and interact with the therapist and caregivers depending on his/her motor abilities. The participants will also wear the head-mounted eye-tracker for the first 20 minutes in one training session every week.
62760912|NCT04400084||Pregnant mothers|Pregnant mothers who have a normal pregnancy
62760913|NCT01811303|EXPERIMENTAL|D-fagomine|Measure the changes produced on the postprandial Glycaemic response to 50 g of sucrose containing 40 mg D-fagomine, in 200 ml water
61987728|NCT00373867|ACTIVE_COMPARATOR|Standard|Standard treatment-based classification physical therapy
61987729|NCT00373867|ACTIVE_COMPARATOR|Graded exercise|Treatment-based classification physical therapy plus graded exercise
61987730|NCT00373867|EXPERIMENTAL|Graded exposure|Treatment-based classification physical therapy plus graded exposure
61987731|NCT01642017|EXPERIMENTAL|Pazopanib|Pazopanib : 3 dose levels are defined : 400, 600 and 800 mg per day.
61987732|NCT04536155||patient with chronic pain|
61987733|NCT05132504|EXPERIMENTAL|Neoadjuvant Folfirinox and Pembrolizumab followed by sx for patients with pancreatic cancer|Patients will receive 6 cycles of Folfirinox (Oxaliplatin 85 mg/m2, Leucovorin 400 mg/m2, Irinotecan 150 mg/m2, 5-Fluorouracil 2,400 mg/m2) with 2 cycles of Pembrolizumab 400 mg before surgical resection. Following surgery patients will receive 5-Fluorouracil based chemotherapy for up to 6 cycles with 7 more cycles of Pembrolizumab. Patients will receive a total of 9 doses of Q6week cycles of Pembrolizumab.
61987734|NCT04094922|EXPERIMENTAL|Intervention|Free access to the Swedish PTSD Coach smartphone app for three months.
61987735|NCT04094922|NO_INTERVENTION|Waitlist|Delayed access to the Swedish PTSD Coach smartphone app. Access is given after post-intervention data collection at three months.
61987736|NCT02273895|ACTIVE_COMPARATOR|Control|Scopolamine
61987737|NCT02273895|ACTIVE_COMPARATOR|MCI|Scopolamine
62558638|NCT02287181|ACTIVE_COMPARATOR|remifentanil effect site concentration 3ng/ml|remifentanil run as an infusion using the minto TCI model, at an effect site concentration of 3 nano grams per millilitre, commenced from start of proposal infusion to point at which patient is anaesthetised and not responding to painful stimuli.
61987738|NCT02273895|ACTIVE_COMPARATOR|AD|Scopolamine
61987739|NCT04222582|ACTIVE_COMPARATOR|Active tDCS|"Administration of a 2 milliamp (mA) current delivered via two scalp electrodes for 20 minutes (ramp-in + ramp-out periods, 30s total) 2 times per day for 5 consecutive days, \>3 hour interval between sessions, for a total of 10 tDCS sessions.~tDCS will be administered with a constant current regulator (NeuroConn DC-Stimulator Plus®, Germany) using 2 saline-soaked sponge electrodes applied over the scalp. Using the 10-20 international EEG system for tDCS electrode placement, the anode will be positioned midway between F3 and Fp1 (left DLPFC) and the cathode midway between T3 and P3 (left TPJ)."
61987740|NCT04222582|SHAM_COMPARATOR|Sham tDCS|Administration of 2mA tDCS for 30 seconds followed by 19.5 minutes of no current via two scalp electrodes for 20 min (2X/day for 5 consecutive days) with \>3 hours interval between sessions, for a total of 10 tDCS sessions.
61987741|NCT04222582|OTHER|Open-label Active tDCS|Subjects who have received sham tDCS will be given the option to subsequently receive 10 sessions of open-label active tDCS (2X/day for 5 consecutive days) with \>3 hours interval between sessions, for a total of 10 tDCS sessions.
61987742|NCT04222582|NO_INTERVENTION|Healthy Control|Healthy volunteers will complete the same questionnaires, EEG recording procedures, and neuroimaging scans as the schizophrenia patient group, but will not undergo tDCS.
61987743|NCT00819468|EXPERIMENTAL|Participants with Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh score of 7-9) will receive 20 mg of teduglutide.
61987744|NCT00819468|ACTIVE_COMPARATOR|Healthy Volunteers|Healthy volunteers with normal hepatic function matched to hepatic impaired participants by age, gender, BMI, and renal function as measured by creatinine will receive 20 mg of teduglutide.
61987745|NCT06250023||Standart of care|"Standard of care (comparator)~* Uncomplicated PVO: 2 weeks IV ABs followed by oral ABs for 4 weeks.~* Complicated PVO: 2-4 weeks IV ABs followed by oral ABs for 8 weeks."
61987746|NCT06250023||Early shift|"Early shift to oral ABs (intervention)~* Uncomplicated PVO: 1 week IV ABs followed by 5 weeks of oral ABs.~* Complicated PVO: 1 week IV ABs followed by 11 weeks of oral ABs."
61987747|NCT03465332||Lung specialist|Approximately 30 lung specialists in Germany with a sufficient number of COPD subjects under supervision will be enrolled in the study to document physician's attitudes on COPD diagnosis and therapy, and to document data on about 250 subjects with COPD.
61987748|NCT03465332||Subjects with COPD|Data from approximately 250 subjects with COPD under supervision of lung specialists enrolled in the study will be analyzed.
61987749|NCT06146582|EXPERIMENTAL|Intervention Arm|Group received support from Laguna Coaches
61987750|NCT06146582|NO_INTERVENTION|Control Arm|Group received no support from Laguna Coaches
61987751|NCT03922451||Pediatric patients supported on ECMO|
62760914|NCT01811303|PLACEBO_COMPARATOR|Control|Sucrose 50 g without d-fagomine, in 200 ml water
62760915|NCT03024645|EXPERIMENTAL|BeAMom|High-risk (HR) women will receive a web-based preventive intervention for PPD (the Be a Mom program). In addition, women will receive postpartum and and pediatric treatment as usually performed in primary care settings (TAU).
62760916|NCT03024645|ACTIVE_COMPARATOR|Control|High-risk (HR) women will receive postpartum and pediatric treatment as usually performed in primary care settings (TAU). During medical appointments, health professionals may ask women and provide information about psychological problems during the postpartum period.
62760917|NCT01976858|EXPERIMENTAL|PEX168 50 microgram|PEX168 50 microgram qw sc. and the medication continued for 8 weeks
62760918|NCT01976858|EXPERIMENTAL|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 8 weeks
62760919|NCT01976858|EXPERIMENTAL|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication continued for 8 weeks
62760920|NCT01976858|EXPERIMENTAL|PEX168 300 microgram|PEX168 300 microgram qw sc. and the medication continued for 8 weeks
62760921|NCT01976858|PLACEBO_COMPARATOR|Placebo|Placebo qw sc. and the medication continued for 12 weeks
62760922|NCT04609930||The study population|Patients in the University Hospitals of Montpellier system who have received anti-PD-1 and/or anti-PD-L1
62760923|NCT00906451|NO_INTERVENTION|No lipid-lowering|No lipid-lowering treatment during the first 7 days and then simvastatin 20 mg/day for three additional weeks, till the endothelial function assessment
62760924|NCT00906451|EXPERIMENTAL|Simvastatin 20 mg|Simvastatin 20 mg/day for 30 days, till the endothelial function assessment
61987752|NCT00846755|ACTIVE_COMPARATOR|Levothyroxine, Propylthiouracil|Drugs for the treatment of thyroid disease, are administered, when necessary, in high risk women, either in case finding, or in Universal Screening Group
62760925|NCT00906451|EXPERIMENTAL|Simvastatin 40 mg|Simvastatin 40 mg/day for 7 days and then switched to simvastatin 20mg/day for additional 3 weeks, till the endothelial function assessment
62760926|NCT00906451|EXPERIMENTAL|Simvastatin 80 mg|Simvastatin 80 mg/day for 7 days and then switched to simvastatin 20 mg/day for additional 3 weeks, till the endothelial function assessment
62760927|NCT01357876|OTHER|Type two diabetics|Type two diabetics
62760928|NCT03655223||Newborn infants born in North Carolina|All newborn infants in North Carolina will have the opportunity to participate in Early Check. Those who screen positive for the conditions identified in the study will be subject to confirmatory testing.
62760929|NCT03655223||Birthing Mothers in North Carolina|All birthing mothers in North Carolina will have the opportunity to participate in Early Check.
62760930|NCT02168738|ACTIVE_COMPARATOR|13-C labeled PC-DHA|
62760931|NCT02168738|ACTIVE_COMPARATOR|13-C labeled TG-DHA|
62760932|NCT02168738|EXPERIMENTAL|13-C labeled AceDoPC-DHA|
62760933|NCT05203978||Virtual reality colonoscopy|using virtual reality with glasses and sound no anaesthesia
62760934|NCT05203978||General anaesthesia colonoscopy|gold standard
62760935|NCT05597644|EXPERIMENTAL|females with adenomyosis|
62760936|NCT01484834|EXPERIMENTAL|Exercise and Education|Company A received intervention of exercise in the workplace, posters with tips on health and quality of life computer software. The interventions with physical exercise in the workplace, were performed in the morning shift and had duration of three months with 15 minutes each and were applied three times per week every other day. In order to keep the workers motivated and participating in the exercise in the workplace, the sessions were very varied, using broomstick, latex tubes, exercises in pairs, massage, sitting exercises and relaxation on mats.
62760937|NCT01484834|ACTIVE_COMPARATOR|Exercise|The intervention with physical exercise in the workplace, were performed in the morning shift and had duration of three months with 15 minutes each and were applied three times per week every other day. In order to keep the workers motivated and participating in the exercise in the workplace, the sessions were very varied, using broomstick, latex tubes, exercises in pairs, massage, sitting exercises and relaxation on mats.
62760938|NCT01484834|ACTIVE_COMPARATOR|Educational Intervention|This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
62760939|NCT01484834|PLACEBO_COMPARATOR|Control Company|No intervention
62760940|NCT03762616|EXPERIMENTAL|Micro-Ultrasound Biopsy|
62760941|NCT03762616|EXPERIMENTAL|MRI Targeted Biopsy|
61987753|NCT00846755|NO_INTERVENTION|clinical checks|Low risk women whose sera are tested postpartum. Then patients with undiagnosed thyroid disease, are not treated
62760942|NCT05891028|EXPERIMENTAL|68Ga-EB-ss-CPT PET/CT scan|68Ga-EB-ss-CPT PET/CT scan Dosimetry study about 6 patients were injected with 3 (MBq) per kilogram body weight of 68Ga-EB-ss-CPT PET/CT in one dose intravenously and underwent wholebody scan at 5min#30min#60min#120min#240min, then analysis of dosimetric distribution ofradiopharmaceuticals in human body by HERMES software.
61987754|NCT02770586|OTHER|Breast PET|Breast PET
61987755|NCT02952339|EXPERIMENTAL|RSV LID ΔM2-2 1030s vaccine|Participants will receive a single dose of the RSV LID ΔM2-2 1030s vaccine at Day 0.
62760943|NCT05891028|EXPERIMENTAL|64Cu-EB-ss-CPT PET/CT scan|64Cu-EB-ss-CPT PET/CT scan Dosimetry study about 6 patients were injected with 2 (MBq) per kilogram body weight of 64Cu-EB-ss-CPT PET/CT in one dose intravenously and underwent wholebody scan at 30min#8h#12h#24h#48h, then analysis of dosimetric distribution ofradiopharmaceuticals in human body by HERMES software.
62760944|NCT03470129|ACTIVE_COMPARATOR|Helioseal F|fissure sealing with the conventional product
62760945|NCT03470129|EXPERIMENTAL|Helioseal F Plus|fissure sealing with the new product
62760946|NCT05010941||Hypotension prediction index|prediction of hypotension events
62760947|NCT05030064|EXPERIMENTAL|Intestinal flora capsule(FMT)|The group includes 27patients.They will receive 16 capsules of intestinal bacteria each time, once a week, 4 times in a row.Each capsule contains 200mg of fecal bacteria.
61987756|NCT02952339|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo vaccine at Day 0.
62760948|NCT05030064|PLACEBO_COMPARATOR|Placebo group|The group includes 27patients.They will receive 16 Placebo capsules each time, once a week, 4 times in a row.
62760949|NCT03279523||F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
62760950|NCT05472077|EXPERIMENTAL|Participants with COVID-19 Symptom(s)|Participants 4 years old or older with at least one COVID-19 symptom being tested for the virus
62760951|NCT00183963|NO_INTERVENTION|1|
62760952|NCT00183963|ACTIVE_COMPARATOR|2|Tamoxifen 20 mg
62760953|NCT00183963|ACTIVE_COMPARATOR|3|Fulvestrant 250mg
62760954|NCT00183963|ACTIVE_COMPARATOR|4|Fulvestrant 500mg IM
62760955|NCT02933567|EXPERIMENTAL|CSC OnDemand Pilo|Pilot Intervention
62760956|NCT05694910|EXPERIMENTAL|Reiki Group|Personal Information Form (PIF), Visual Analog Scale (VAS), and National Cancer Institute (NCI) -Common Terminology Criteria for Adverse Events (CTCAE) will be administered to the patients. Then vital signs and laboratory findings will be recorded. After the protests will be completed, the primary investigator with Reiki second degree will apply Reiki to the patients for 30 minutes. On the second day and the third day, 30 minutes distance Reiki will be applied to the patients. Post-tests will be applied to all patients after one week and vital signs and laboratory findings will be recorded.
62760957|NCT05694910|NO_INTERVENTION|Control Group|Personal Information Form (PIF), Visual Analog Scale (VAS), and National Cancer Institute (NCI) -Common Terminology Criteria for Adverse Events (CTCAE) will be administered to the patients. Then vital signs and laboratory findings will be recorded. After a week, the posttest will be applied to the patients and vital signs and laboratory findings will be recorded.
62760958|NCT02372708||Experimental|diluted dinitrophenyl(DNP) Vaseline (which equaled to 2% DNP 0.1ml) was started to be directly spread on the surfaces of primary or metastatic tumors of malignant melanoma patients since the first day of every circle of chemotherapy, simultaneously laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2. The tumors were wrapped and blocked for two days to induce contact dermatitis. If lymph nodes had been cleared, sensibilization of 2×2cm was performed at occipital region. It was repeated once a week.
62760959|NCT02372708||Control|only diluted DNP Vaseline was spread and the operation were the same with the treatment group
62760960|NCT05625373|EXPERIMENTAL|Vancomycin powder|Women randomized to receive vancomycin powder will receive 1g into each of the irrigated inguinal surgical beds (maximum of 2g dose per patient). After dissection and irrigation of the surgical bed, the operating room staff will open the medication vial and sterilely dispense the medication into a sterile container. The surgeon will place the medication powder into the irrigated and hemostatic surgical bed. The procedure will be repeated on the opposite side after dissection.
62760961|NCT05625373|NO_INTERVENTION|No vancomycin powder|Patient randomized to the no vancomycin arm will not receive the intraoperative antibiotic. Their surgery will follow standard protocol. No placebo will be utilized.
62760962|NCT05551676|ACTIVE_COMPARATOR|Transforaminal group|Transforaminal steroid injection will be applied, 30 patients
62760963|NCT05551676|ACTIVE_COMPARATOR|Lateral parasagittal group|Lateral parasagittal steroid injection will be applied, 30 patients
62760964|NCT01192503|ACTIVE_COMPARATOR|rasagiline|
62760965|NCT01192503|PLACEBO_COMPARATOR|placebo (sugar pill)|
62760966|NCT00650520|EXPERIMENTAL|1|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL)and BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
62760967|NCT00650520|ACTIVE_COMPARATOR|2|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL) and Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
62760968|NCT03034512||Patients with Alpers-Huttenlocher|Patients confirmed to have Alpers Huttenlocher Syndrome
61987757|NCT04965545||Wilson's disease cohort|Patients were clinically diagnosed according to the Leipzig Score and included in the study when they were confirmed to carry ATP7B pathogenic variants in 2 different alleles.
62760969|NCT03034512||Siblings|Siblings of patients with Alpers Huttenlocher Syndrome
61987758|NCT01378221||Group 1|cardiac surgery patients age 65 years and less
61987759|NCT01378221||Group 2|cardiac surgery patients aged 75 years and over
62760970|NCT06256354|PLACEBO_COMPARATOR|Routine thermal management|Patients assigned to routine thermal management will not be pre-warmed and ambient intraoperative temperature will be maintained near 20°C per routine. Only transfused blood will be warmed. An upper- or lower-body forced-air cover will be positioned over an appropriate non-operative site but will not initially be activated. Should core temperature decrease to 35.5°C, the warmer will be activated as necessary to prevent core temperature from decreasing further. The target nasopharyngeal temperature is 35.5°C.
62760971|NCT06256354|EXPERIMENTAL|Target temperature management|"Pre-warming is performed with a full-body forced-air cover and electrically heated blanket for about 30 minutes before induction of anesthesia. The warmer will initially be set to high which corresponds to about 43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be warmed during surgery using two forced-air covers or combining forced-air covers with electric heating blanket when clinically practical. All intravenous fluids will be warmed to body temperature. There is no need to control ambient temperature since ambient temperature has little effect on core temperature in patients warmed with forced air. The target nasopharyngeal temperature is 36.8°C."
61987760|NCT05643261|EXPERIMENTAL|Intervention group|All players in the intervention group will complete the targeted muscle and technique training integrated into their handball training. There will be a training of the coaches on site, who assess the training of the intervention group during the entire period and document the participation of the players accordingly.
61987761|NCT05643261|NO_INTERVENTION|Control group|Players in the control group only continue their regular handball training.
61987762|NCT00149747|EXPERIMENTAL|Exercise training|Group based exercise training. Two weekly classes including aerobic endurance physical activity and strength and flexibility training, and up to three home-based sessions of similar composition of aerobic endurance, strength and flexibility training.
62760972|NCT01920633||People with Down syndrome|
62760973|NCT05273021||participants with substance use problems|"There are 2 subgroups:~* Participants without intellectual disabilities~* Participants with intellectual disabilities with and without severe mental illness"
62381388|NCT04994886|EXPERIMENTAL|Targeted Epidural Spinal Stimulation|"Participants will undergo a surgery for Targeted Epidural Spinal Stimulation (TESS). The neurostimulation system will be used to manage blood pressure instability.~Patients will then proceed to one month of an intensive device configuration protocol to configure the TESS settings of their investigational device to regain hemodynamic stability. After the intensive device configuration phase, daily supervised at-home hemodynamic TESS will be tested for 5 sessions per week for two weeks. Thereafter, and up to 10 months post-implant, patients will have a minimum of 5 TESS supported at-home sessions per week and one laboratory visit per month during a long-term at-home hemodynamic TESS phase. Finally, patients will have to undergo additional testing during a configuration of additional TESS programs phase. During this phase TESS configurations for hemodynamic stability, respiratory function, trunk stability and spasticity will be tested."
62760974|NCT05765149||Sleep Cohort|This is an observational study. We plan to recruit 1000 pregnant women during 10-13 weeks gestational age to build a sleep cohort. Their sleep changes during pregnancy will be recorded for identifying similar groups.
62760975|NCT03236012|EXPERIMENTAL|Botulinum Toxin Therapy|"Test the effectiveness of Botulinum Toxin therapy in subjects who fail or do not tolerate Aluminum Chloride.~We plan to conduct an open label study of Botox, up to 400 units, in amputees who have failed treatment with a topical antiperspirant."
62760976|NCT00420173||Patients with CLE|
62760977|NCT05349292||Acute Normovolemic Hemodilution|Patients undergoing CABG surgery with acute normovolemic hemodilution and autologous blood donation
62760978|NCT05349292||non Acute Normovolemic Hemodilution|Patients undergoing CABG surgery without acute normovolemic hemodilution and autologous blood donation
62760979|NCT01144260|EXPERIMENTAL|Bafetinib|
62760980|NCT05913102|EXPERIMENTAL|experimental|administer PDLLA
62381389|NCT04932681||Qualitative group|Interview about the use of Complementary and Alternative Medecine
62381390|NCT04932681||Quantitative group|Questionnaire about the use of Complementary and Alternative Medecine
62381391|NCT06065787|EXPERIMENTAL|NeuroGlove Treatment Arm|Subjects will receive treatment using the NeuroGlove. The treatment regimen at home will include 1 hour of therapy per day (two 30-minute sessions, one using each hand) for 4 weeks.
61987763|NCT00149747|PLACEBO_COMPARATOR|2|Attention-control of exposure to study staff. Weekly general health education classes conducted in group sessions.
61987764|NCT01746979|ACTIVE_COMPARATOR|Gemcitabine plus TH-302|
61987765|NCT01746979|PLACEBO_COMPARATOR|Gemcitabine plus placebo|
61987766|NCT05110456|NO_INTERVENTION|Access to an online cognitive behavioural intervention without telephone support|The control group will receive a fully automated version of the virtual intervention without telephone support
62381392|NCT06258772||Severe, uncontrolled CRSwNP patients in therapy with Mepolizumab|
62381393|NCT03124524|NO_INTERVENTION|Control group|33 healthy controls
62760981|NCT05913102|ACTIVE_COMPARATOR|active comparator|administer saline
62760982|NCT03396055|EXPERIMENTAL|Treatment group|Specific rehabilitation exercise
62760983|NCT03396055|NO_INTERVENTION|Control|No intervention
62760984|NCT04881851|EXPERIMENTAL|Inositol + alpha lipoic acid|Inositol 1000 mg + alpha lipoic acid 400 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
61987767|NCT05110456|EXPERIMENTAL|Cognitive-Behavioral Therapy (CBT) and interpersonal counseling with telephone support.|The experimental group will receive an online cognitive behavioural intervention with weekly telephone support
61987768|NCT02877784||Screening|Participants enrolled will undergo testing of the swallowing mechanism
62760985|NCT04881851|EXPERIMENTAL|Inositol|Inositol 1000 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
62760986|NCT04881851|PLACEBO_COMPARATOR|Folic acid|Folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
62760987|NCT04206553|EXPERIMENTAL|dupilumab|
62760988|NCT04206553|EXPERIMENTAL|Matching placebo|
62760989|NCT04151251|ACTIVE_COMPARATOR|Sleep Kit Alone|Patients who are not randomized into the I-SLEEP intervention will receive a sleep kit that includes an eye mask, earplugs, and headphones.They will still receive the usual standard of care provided by clinicians which includes measures to reduce unnecessary nighttime disruptions and limiting excessive noise within the hospital setting.
62760990|NCT04151251|EXPERIMENTAL|Sleep Kit + Empowerment|"A short video will be shown on iPads and a brochure will be given that both describe the importance of good sleep and how to facilitate it with good sleep hygiene.~The video will show a few reasons why someone might not get optimal sleep while in a hospital, and offer advice to address this from a doctor. The brochure will be kept to no higher than a 6th grade reading level, considered optimal for health education materials. Text will be kept brief and to the point. To account for vision problems, we will use \>12-point font \& leave a large portion of each page empty. Visual Aids \& graphics will be employed when possible.~All of this is given in addition to the usual standard of care provided by clinicians."
62760991|NCT05716412||Adopted adolescents and their adoptive parents|Adopted before the age of one, currently between 12 to 18 years old
62760992|NCT05716412||Adolescents and their biological related parents|Matched to adoptive adolescents
62760993|NCT05716412||Additional community sample|
62760994|NCT00357656|EXPERIMENTAL|BI|Bolus infusion of rAHF-PFM
62760995|NCT00357656|EXPERIMENTAL|CI|Continuous infusion of rAHF-PFM
62760996|NCT03175484||Observation TLX|surgical specialty ( including anesthesia) residents and nurses undergoing High Fidelity Simulation scenarios.
62760997|NCT03634371|EXPERIMENTAL|Test Formulation of Levothyroxine|Levothyroxine sodium tablets 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2
62760998|NCT03634371|ACTIVE_COMPARATOR|Reference formulation of Levothyroxine|Eutirox 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2
62760999|NCT04801888|EXPERIMENTAL|Combined immunization group|The combined immunization group is randomly divided into two subgroups, 120 subjects in each group. The combined immunization subgroup Ⅰ receive SARS-CoV-2 inactivated vaccine (Vero cell)\&Quadrivalent Influenza Vaccine on day0 and SARS-CoV-2 inactivated vaccine (Vero cell) (second dose) on day 28.The combined immunization subgroup Ⅱ receive SARS-CoV-2 inactivated vaccine (Vero cell) on day 0 and SARS-CoV-2 inactivated vaccine (Vero cell) (second dose) \& Quadrivalent Influenza Vaccine on day 28.
62761000|NCT04801888|EXPERIMENTAL|Non combined immunization group|The non combined immunization group receive SARS-CoV-2 inactivated vaccine (Vero cell)(first dose) on day 0, Quadrivalent Influenza Vaccine on day 14 and SARS-CoV-2 inactivated vaccine (Vero cell)(second dose) on day 28.
62761001|NCT02001896|EXPERIMENTAL|erlotinib combine with chemotherapy|Drug: gemcitabine 1000mg/m2 iv on days 1 of each 4 week cycle for 6 cycles Drug: Platinum chemotherapy (cisplatin or carboplatin) cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles Drug: Erlotinib\[Tarceva\] po on days 15-28 of each 4 week cycle until disease progression
62761002|NCT02001896|ACTIVE_COMPARATOR|erlotinib along|Drug: erlotinib \[Tarceva\] 150mg/day po until disease progression
62761003|NCT03813004|EXPERIMENTAL|Young healthy adults|
62761004|NCT04081415||Group with FPIES|Not yet healed children with FPIES
62761005|NCT02194920||Parathyroid reimplantation|
62761006|NCT04503590|EXPERIMENTAL|Minimally invasive micro sclerostomy (MIMS)|create a drainage channel at the sclera-corneal junction
62761007|NCT05932121||PTC patients underwent thyroid lobectomy via trans-axillary approach|Case: PTC patients underwent thyroid lobectomy via trans-axillary approach.
62761008|NCT05932121||PTC patients underwent thyroid lobectomy via open approach|Controls: PTC patients underwent thyroid lobectomy via open approach.
62761009|NCT00689000|EXPERIMENTAL|CHR-2797 (tosedostat)|oral, once daily administration of CHR-2797 to determine safety \& anti-disease activity.
62381394|NCT03124524|ACTIVE_COMPARATOR|Qlarista Group|group who were administered estradiol valerate/dienogest
62761010|NCT03061786||AKI|
62761011|NCT03061786||non-AKI|
62761012|NCT00619346|PLACEBO_COMPARATOR|1|Placebo tablets resembling 100 mg tablet of active drug BID X 14 days
62761013|NCT00619346|ACTIVE_COMPARATOR|2|Pafuramidine maleate, 100 mg tablet, BID X 14 days
62761014|NCT05027620|EXPERIMENTAL|Home training|Participants train 3 times weekly in their home environment with help of a digital training app, over a 10-week period.
62761015|NCT02617940|EXPERIMENTAL|fissure sealant|single placement of resin-based sealant on occlusal surface and oral hygiene orientation
62761016|NCT02617940|PLACEBO_COMPARATOR|oral hygiene orientation|single application of water on occlusal surface and oral hygiene orientation
62381395|NCT03124524|ACTIVE_COMPARATOR|Yasmin Group|group who were administered ethinylestradiol and drospirenone
62761017|NCT02011490|EXPERIMENTAL|Severe Renal Insufficiency Participants: Part 1|Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
62761018|NCT02011490|EXPERIMENTAL|Moderate Renal Insufficiency Participants: Part 1|Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
62761019|NCT02011490|EXPERIMENTAL|Healthy Control Participants: Part 1|Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
62761020|NCT02011490|EXPERIMENTAL|Severe Renal Insufficiency Participants: Part 2|Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
62761021|NCT02011490|EXPERIMENTAL|Moderate Renal Insufficiency Participants: Part 2|Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
62761022|NCT02011490|EXPERIMENTAL|Healthy Control Participants: Part 2|Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
62381396|NCT01252927|EXPERIMENTAL|ASIST intervention|The gatekeeper training intervention group received the Applied Suicide Intervention Skills Training (ASIST) 10.0 in addition to TAU. ASIST is a two-day (fourteen hour), intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The intervention was offered to students on a weekend and was conducted by three senior ASIST trainers and one junior trainer, with two trainers assigned to each training group.
62381397|NCT01252927|NO_INTERVENTION|Control group: training as usual|Training as usual consisted of didactic teaching and a tutorial with case-based examples around suicide risk factors in their first year of medical school. Third- and fourth-year students may also have the opportunity to practice their skills with real patients during their clerkship rotations or in the emergency department.
62381398|NCT04474210|EXPERIMENTAL|Part A: Group 1|Participants with severe renal impairment and/or kidney failure (estimated glomerular filtration rate \[eGFR\] less than \[\<\] 30 milliliter\[mL\]/minute but not yet on hemodialysis) will receive a single oral dose of JNJ-56136379.
62381399|NCT04474210|ACTIVE_COMPARATOR|Part A: Group 2|Healthy participants with normal renal function (eGFR greater than or equal to \[\>=\] 90 mL/minute), will receive a single oral dose of JNJ-56136379.
62381400|NCT04474210|EXPERIMENTAL|Part B: Group 3 (Optional)|Participants with mild renal impairment (eGFR: 60 to 89 mL/minute) will receive a single oral dose of JNJ-56136379.
62381401|NCT04474210|EXPERIMENTAL|Part B: Group 4 (Optional)|Participants with moderate renal impairment (eGFR: 30 to 59 mL/minute) will receive a single oral dose of JNJ-56136379.
62381402|NCT04474210|EXPERIMENTAL|Part B: Group 5 (Optional)|Participants with kidney failure (eGFR: \<15 mL/minute and on hemodialysis; pharmacokinetic \[PK\] to be evaluated during non-dialysis days) will receive a single oral dose of JNJ-56136379.
62761023|NCT06414421|EXPERIMENTAL|TENS|In TENS group patients, 4 electrodes of the TENS device (2 on the front side: on the anterior right and left groin skin, 2 on the back side: on the right and left presacral skin) were placed 3-5 minutes before the biopsy procedure, and the application was started and TENS was applied throughout the procedure. continued. TENS was applied again for 30 minutes 2 hours after the procedure. Frequency of the TENS program applied in the conventional model: 100 Hz; pulse width: 150 μs; duration:30 minutes; The current intensity (amplitude: highest level 60 mA) is adjusted (according to individual tolerance by asking the patient) to create a tingling or pricking sensation that does not disturb the patient.Data were collected in three stages.
62761024|NCT06414421|NO_INTERVENTION|CONTROL|"TENS application was not performed. Data were collected in three stages. The first (before biopsy) and second (during and after biopsy) stages were carried out face to face, and the third stage (after discharge) was conducted by telephone interview technique.~Research data; The data were collected by the researcher using face-to-face and telephone interview techniques using the Personal Information Form, Pain Evaluation Form, TRUSG-PBx Complication Monitoring Form and Perianesthesia Comfort Scale, which evaluate the personal and disease-related characteristics of the patients."
62761025|NCT06378645|ACTIVE_COMPARATOR|Intervention group: Propofol|The patients in the intervention group are receiving a general anesthesia with Propofol.
62761026|NCT06378645|ACTIVE_COMPARATOR|Control group: Sevoflurane|The patients in the control group are receiving a general anesthesia with Sevoflurane.
62761027|NCT02680574|EXPERIMENTAL|Vadadustat|
62761028|NCT02680574|ACTIVE_COMPARATOR|Darbepoetin alfa|
62761029|NCT02226198|ACTIVE_COMPARATOR|Rosuvastatin|6-week treatment period, and after crossover finished a 12-week efficacy maintenance phase for all patients
62761030|NCT02226198|PLACEBO_COMPARATOR|Placebo|6 weeks treatment during crossover
62761031|NCT04851821|EXPERIMENTAL|Quercetix group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.
62761032|NCT04851821|PLACEBO_COMPARATOR|Placebo Group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.
61987769|NCT00844363|OTHER|NB-UVB|Regular, monitored NB-UVB treatment. Patients will be treated 3 times per week, and a full course of therapy is 12 weeks. NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
61987770|NCT00525668|ACTIVE_COMPARATOR|verum|Sunphenon plus glatiramer acetate
61987771|NCT00525668|ACTIVE_COMPARATOR|placebo|placebo plus glatiramer acetate
61987772|NCT04615611|EXPERIMENTAL|salbutamol|salbutamol, 800 microgram from metered dose inhaler
61987773|NCT04615611|PLACEBO_COMPARATOR|placebo|placebo
61987774|NCT01225575|ACTIVE_COMPARATOR|co.don chondrosphere®, 3-7 spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group A is 3-7 spheroids/cm2 defect"
62761033|NCT04539522|EXPERIMENTAL|Three-dimensionally corrective exercise for scoliosis|Experimental group will perform three-dimensionally corrective exercise for scoliosis for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 40-min period per day under the supervision of the parents at home.For moderate patients, additional brace treatment for more than 22 hours a day.The treatment regimens lasted for 12 months.
61987775|NCT01225575|ACTIVE_COMPARATOR|co.don chondrosphere®,10-30spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group B is 10-30 spheroids/cm2 defect"
61987776|NCT01225575|ACTIVE_COMPARATOR|co.don chondrosphere®,40-70spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group C is 40-70 Spheroids/cm2 defect"
61987777|NCT06427018||Asthma group|No intervention.
61987778|NCT06427018||Non-asthma group|No intervention.
62761034|NCT04539522|ACTIVE_COMPARATOR|Conventional exercise|Control subjects will perform conventional exercise for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 40-min period per day under the supervision of the parents at home. For moderate patients, additional brace treatment for more than 22 hours a day.The treatment regimens lasted for 12 months.
62761035|NCT02270762|EXPERIMENTAL|1) Rest in bed|First evaluation of EIT with patient in bed at 30º of head inclination during 5 minutes.
62761036|NCT02270762|EXPERIMENTAL|2) Passive Verticalization|Second evaluation of EIT with patient in tilt table at 60º of verticalization during 10 minutes.
62761037|NCT02270762|EXPERIMENTAL|3) Rest in bed|Last evaluation of EIT with patient in bed at 30º of head inclination during 20 minutes.
62761038|NCT00808535||diabetics|
62761039|NCT00808535||healthy controls|
62761040|NCT00912080|EXPERIMENTAL|good signature|"Patients who have a good signature for the genomic analysis. They will receive the standard chemotherapy."
62761041|NCT05507632|EXPERIMENTAL|single-arm|All patients treatment with Donafenib plus Sintilimab in combination with TACE
62761042|NCT03254277|EXPERIMENTAL|Group 1A|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 3 mg/kg.
62761043|NCT03254277|EXPERIMENTAL|Group 1B|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 10 mg/kg.
62761044|NCT03254277|EXPERIMENTAL|Group 1C|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
62761045|NCT03254277|EXPERIMENTAL|Group 2B|HIV-infected individuals on ART with HIV-1 plasma RNA levels \< 20 copies/ml or off ART for at least 8 weeks with HIV-1 plasma RNA levels \< 100,000 copies/ml, will be administered one infusion of 3BNC117-LS dosed at 10 mg/kg.
62761046|NCT03254277|EXPERIMENTAL|Group 2C|HIV-infected individuals on ART with HIV-1 plasma RNA levels \< 20 copies/ml, or off ART for at least 8 weeks with HIV-1 plasma RNA levels \< 100,000 copies/ml, will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
62761047|NCT03254277|EXPERIMENTAL|Group 1D|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
62761048|NCT03254277|EXPERIMENTAL|Group 2D|HIV-infected individuals on ART with HIV-1 plasma RNA levels \< 20 copies/ml will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
62761049|NCT03254277|EXPERIMENTAL|Group 1E|HIV-uninfected individuals will be administered a single 1 mL (approximately 150 mg) subcutaneous injection of 3BNC117-LS or placebo in a 3:1 ratio.
62761050|NCT03254277|EXPERIMENTAL|Group 1F|HIV-uninfected individuals will be administered a single 2 mL (approximately 300 mg) subcutaneous injection of 3BNC117-LS or placebo in a 3:1 ratio.
62761051|NCT03159507|EXPERIMENTAL|MAG-EPA|MAG-EPA softgel (500mg), daily dose between 1g and 3.5g
62761052|NCT00791557|EXPERIMENTAL|Infliximab|Single arm open label IV Infliximab given at weeks 1,2,14,22
62761053|NCT04218162|EXPERIMENTAL|Lasmiditan 50mg|
62761054|NCT04218162|EXPERIMENTAL|Lasmiditan 100mg|
62761055|NCT04218162|PLACEBO_COMPARATOR|Placebo|
62761056|NCT05302258||Obesity|BMI of 95 th percentile or more
62761057|NCT05302258||Normal weight|BMI of 85 th percentile or less
62761058|NCT02010736|EXPERIMENTAL|Spastic Hemiparetic Cerebral Palsy|Single treadmill gait training with additional loading
62761059|NCT02745847|EXPERIMENTAL|Re-irradiation with SBRT|Patients with relapsed pancreatic cancer meeting all inclusion criteria will receive re-irradiation with SBRT.
62761060|NCT04914754||Long COVID with mild exercise impairment|Patients with prior serological or clinical diagnosis of CoV-2 infection and a referred to the UCLH Long-COVID clinic for persistent fatigue or exercise intolerance.
62761061|NCT04914754||Healthy Control|Healthy sex-matched and age-matched to within 5 years of Long Covid participants were recruited from UCL staff and students.
62761062|NCT04914754||Long COVID with severe exercise impairment|Patients with prior serological or clinical diagnosis of CoV-2 infection and a referred to the UCLH Long-COVID clinic for persistent fatigue or exercise intolerance and an abnormal walk test criteria included: peripheral oxygen desaturation, \<85% predicted walk distance, a lactate rise\> 1.0 from baseline or a Borg score \> 5 for breathlessness or fatigue at end of test.
62761063|NCT04194918|EXPERIMENTAL|Prevention (Flexiquit+, text message, handout)|Individuals will be recruited to use the Flexiquit+ program consisting of 6 sessions, each lasting approximately 25 minutes. Participants will also receive text messages providing motivational messages and review information discussed in the program. At the end of the intervention, participants will receive an email with all of the session handouts.
62761064|NCT03270267||Patients with IBD|
62761065|NCT03371173|EXPERIMENTAL|Ferric maltol 30 mg (Feraccru®)|Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks
62761066|NCT01289223|ACTIVE_COMPARATOR|Treatment of Physicians Choice|Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
62761067|NCT01289223|EXPERIMENTAL|Bendamustine IV|Up to 8 cycles of Bendamustine (120mg/m2 Days 1 and 2, every 21 days (+ 3 days).
62761068|NCT05529355|EXPERIMENTAL|Envafolimab plus Endostar and S-1|Envafolimab (300 mg subcutaneously each time, using 4-6 cycles), Recombinant Human Endostartin Injection (210 mg, d1-7 pumps, repeat every 3 weeks, using 4-6 cycles), Tegafur,Gimeracil and Oteracil Porassium Capsules (40 mg Bid, take 2 weeks stop for 1 week, use 4-6 cycles)
62761069|NCT05529355|ACTIVE_COMPARATOR|Envafolimab plus Endostar|Envafolimab (300 mg subcutaneously each time, using 4-6 cycles), Recombinant Human Endostartin Injection (210 mg, d1-7 pumps, repeat every 3 weeks, using 4-6 cycles),
62761070|NCT05529355|ACTIVE_COMPARATOR|Envafolimab plus S-1|Envafolimab (300 mg subcutaneously each time, using 4-6 cycles), Tegafur,Gimeracil and Oteracil Porassium Capsules (40 mg Bid, take 2 weeks stop for 1 week, use 4-6 cycles)
62761071|NCT05962034|EXPERIMENTAL|Aspirin|one dose of aspirin
62761072|NCT05962034|PLACEBO_COMPARATOR|Placebo|Placebo pill
62761073|NCT03920267|EXPERIMENTAL|BMS-986165 Dose 1|
62761074|NCT03920267|EXPERIMENTAL|BMS-986165 Dose 2|
62761075|NCT03920267|EXPERIMENTAL|BMS-986165 Dose 3|
62761076|NCT05448404|EXPERIMENTAL|18F-PSMA-1007 and 18F-FDG PET/CT scan|Patients of multiple myeloma PET/CT imaging: Within one week each patient underwent a PET/CT scan 60-min after intravenous administration of 18F-PSMA-1007 and 18F-FDG, respectively.
62761077|NCT03614559||CTO PCI group and non CTO PCI group|CTO PCI group： Succession of CTO revascularization non CTO PCI group： Failure or not tried to revascularization
62761078|NCT03614559||Initially attempted and re-attempted|PCI initially attempted group： First time to try to revascularization PCI re-attempted group: Second or more time to try to revascularization
61987779|NCT02256761|EXPERIMENTAL|BIRT 2584 XX - single dose|"Part 1 - bioavailability/food effect~two single doses, 30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served"
61987780|NCT02256761|PLACEBO_COMPARATOR|Placebo|Part 2
62761079|NCT03614559||PCI during China Club or not|PCI during Chronic Total Occlusion Club， China Club : CAG in 2016.11.04 Another group: CAG in other time
62761080|NCT03614559||Morning，Afternoon，Night|Morning group:（8:00-12:59） Afternoon group：（13:00-17:59） Night group：（after 18:00）
62761081|NCT02262104|EXPERIMENTAL|Intensive exercise|Intensive strengthening and balance exercises 1 hour twice a week 12 weeks. Lead by physiotherapists.
62761082|NCT02262104|PLACEBO_COMPARATOR|Control|Control group activities: Social activities one hour twice a week. Light physical activities, reading, conversation, games. Lead by occupational therapist or nursing staff
62761083|NCT03538184|EXPERIMENTAL|Piezosurgery|Osteotomy preparation entirely with piezosurgery tips and equicrestal placement of a 4.1 mm implant in the piezosurgery (test) group were performed as follows: 1.15 mm initial MB1 tip, 1.95 mm MB2 tip, control of depth, diameter and direction of osteotomy with 2.0 mm paralleling pin, 2.5 mm MB3 tip, 2.8 mm MB4 tip, 2.8 mm paralleling pin, 3.05 mm MB5 tip, 3.3 mm MB6 tip, control of final diameter of the osteotomy with 3.5 mm paralleling pin, placement of the 4.1 mm diameter implant and connection of a 4 mm-wide healing abutment.
62761084|NCT03538184|ACTIVE_COMPARATOR|Drill|Preparation of an implant recipient site entirely with relevant drills were performed as follows: Osteotomy preparation and equicrestal placement of a 4.1 mm diameter implant in the drill (control) group were performed as follows: initial trispade drill, 2.0 mm pilot drill, control of depth, diameter and direction of osteotomy with 2.0 mm paralleling pin, 2.5 mm drill, 2.8 mm drill, 2.8 mm paralleling pin, 3.5 mm drill, control of final diameter of the osteotomy with 3.5 mm paralleling pin, placement of the 4.1 mm diameter implant and connection of a 4 mm wide healing abutment.
62761085|NCT06326749|EXPERIMENTAL|Modified Graded Motor Imagery and Conventional Treatment Group:|The modified DMI program consists of 4 stages: lateralization, open motor imagery including action observation training, mirror therapy and upper extremity functional exercise. The program will be implemented for 8 weeks, 3 days a week, under the supervision of a physiotherapist. Lateralization training will be applied in the first 2 weeks. Motor imagery training will be implemented in the 3rd and 4th weeks. For the second stage, the application will be combined with action observation training. As the 3rd stage, mirror therapy will be performed in the 5th and 6th weeks. The participant will be asked to perform some exercises while watching the reflection of the intact extremity in the mirror. In the final stage, they will be asked to physically perform upper extremity functional exercises. The total treatment time will be 40-50 minutes, with patients receiving 20-30 minutes of modified grade motor imagery and 20 minutes of conventional treatment.
62761086|NCT06326749|EXPERIMENTAL|Graded Motor Imagery and Conventional Treatment Group:|The DMI program consists of 3 stages: lateralization, open motor imagery and mirror therapy. The program will be implemented for 8 weeks, 3 days a week, under the supervision of a physiotherapist. First, lateralization training will be applied. In the second stage, motor imagery training will be applied. This phase will be carried out in a quiet environment by asking the participants to fully focus on the visualization of the movements. Two methods will be used for the imagined movements. In particular, visuals of the shoulder and hand used in the lateralization phase will be used to visualize movements related to the normal movement of the upper extremity. Participants will also be asked to imagine different activities in daily life. In the final stage, mirror therapy will be applied. The participant will be asked to perform some exercises while watching the reflection of the intact extremity in the mirror.
62381403|NCT02293200|EXPERIMENTAL|Traditional learning|chest compression group learning without CPR feedback device. After a month of quality control of chest compressions is made also without the device.
62761087|NCT06326749|EXPERIMENTAL|Conventional Treatment Group:|Within the scope of the conventional treatment Bobath Method, facilitating movement and functional activities in the upper and lower extremities, activating trunk muscles, facilitating basic functional activities such as turning in bed, coming to sit and standing, improving weight bearing while sitting and standing, postural control, balance and walking. A targeted exercise program will be created. In line with this goal, upper and lower extremity exercises; don't turn around, don't come to sit, don't stand up; Exercises to activate core muscles; such as bridging, functional reaching; weight bearing and balance training; It is planned to implement walking training. Treatment time will be 40-50 minutes.
62761088|NCT05378932|EXPERIMENTAL|Hypohidrotic ectodermal dysplasia|Patients aged 3 to 40 years old with hypohidrotic ectodermal dysplasia.
62761089|NCT05378932|ACTIVE_COMPARATOR|Healthy controls|Healthy controls aged 3 to 40 years old without hypohidrotic ectodermal dysplasia.
62761090|NCT02251717|EXPERIMENTAL|LDV/SOF 12 wk|Participants will receive LDV/SOF FDC for 12 weeks.
62761091|NCT02251717|EXPERIMENTAL|LDV/SOF 24 wk|Participants will receive LDV/SOF FDC for 24 weeks.
62761092|NCT05669586|EXPERIMENTAL|Organoid-Guided Antitumor therapy|lung cancer specimens are obtained from lung tumor surgery or biopsy or malignant pleural effusion are used to grow organoids. Then organoids are used for drug sensitivity tests to obtain the sensitivity to drugs. Patients will receive a relatively sensitive antitumor regimen based on the test results.
62761093|NCT05669586|NO_INTERVENTION|Physician-decided Antitumor therapy|According to the National Comprehensive Cancer Network's (NCCN) Guidelines for lung Cancer, physicians will determine antitumor protocols or case report. They're also not sure what the drug susceptibility test says.
62761094|NCT00922818||Radical perineal prostatectomy patients|Radical perineal prostatectomy patients
62761095|NCT01617135|EXPERIMENTAL|CVT-301 Low Dose|CVT-Low; levodopa inhalation powder (LIP)
62761096|NCT01617135|EXPERIMENTAL|CVT-301 High Dose|CVT-High; levodopa inhalation powder (LIP)
62761097|NCT01617135|PLACEBO_COMPARATOR|Inhaled Placebo|Inhaled placebo powder
62761098|NCT01617135|ACTIVE_COMPARATOR|Oral Sinemet (carbidopa/levodopa)|Open-label oral carbidopa/levodopa (CD/LD)
62761099|NCT05718193|EXPERIMENTAL|The DeFrame Group|Subjects in the DeFrame group were treated with a real-time computer-aided polyp detection system named DeFrame during colonoscopy.
62761100|NCT05718193|EXPERIMENTAL|The Classified DeFrame Group|Subjects in the Classified DeFrame group were treated with a real-time computer-aided polyp detection and classification system named Classified DeFrame during colonoscopy.
62761101|NCT05718193|EXPERIMENTAL|The Control Group|Subjects in the control group underwent standard colonoscopy.
62761102|NCT05551975|ACTIVE_COMPARATOR|Control Product|Control Human Milk Fortifier added to human milk feedings
61987781|NCT02256761|EXPERIMENTAL|BIRT 2584 XX - multiple escalating dose|Part 2 - multiple escalating dose, 14 days and 28 days
62381404|NCT02293200|EXPERIMENTAL|Experimental learning|Training is done using TrueCPR feedback device. After a month of quality control of chest compressions is made without the device. To do this will be indicated on the impact of the use of feedback devices for improving the effectiveness of training in CPR.
62381405|NCT00216086|EXPERIMENTAL|Investigational Treatment|"* Irinotecan 200 mg/m2 IV, day 1~* Capecitabine 1000\* mg/m2 po bid day 1-14; repeat every three weeks for two cycles~  * For calculated creatinine clearance of 30-50 mL/min or patients \> 70 years old, capecitabine starting dose is 825 mg/m2 po bid~* EUS~* Neoadjuvant Chemotherapy~* Preoperative Radiation~* Surgery~* Adjuvant Chemotherapy (at discretion of treating physician)"
62381406|NCT03819023|NO_INTERVENTION|Normal subjects|
62761103|NCT05551975|EXPERIMENTAL|Product 1|Study Human Milk Fortifier added to human milk feedings
62761104|NCT05551975|EXPERIMENTAL|Product 2|Study Human Milk Fortifier added to human milk feedings
62761105|NCT04178993|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
62381407|NCT03819023|ACTIVE_COMPARATOR|respiratory suppressing drugs|
62381408|NCT05796024||Derivation Cohort|The derivation cohort will correspond to approximately 70% of the total sample to be analyzed in the study. The Ex-Care II risk model will build upon it. It is composed of patients operated in the participating institutions.
62381409|NCT05796024||Validation Cohort|Composed of the remaining 30% of the sample. It will be used for the external validation of the Ex-Care II model
62381410|NCT04771650|EXPERIMENTAL|CAMI/CAMI booster|Culturally Adapted Motivational Interview. Participants will receive a single session, 75 minute addiction counseling discussion that focuses on the causes of addictive behavior. They will receive a CAMI booster session at 2 months and standard care in a primary care setting.
62761106|NCT04178993|ACTIVE_COMPARATOR|Active Comparator: Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.
62761107|NCT01827813|ACTIVE_COMPARATOR|Saturation biopsy|Saturation biopsy was performed in left lateral decubitus position after application of sedo-analgesia by the anesthesiologists on an outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. After injecting 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region, prostatic size was measured and changes in the zonal anatomy and ultrasonographic view of the tissue were defined. Next, biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen. As a total,24,26 or 28 biopsies were taken depending on prostate volume.
62761108|NCT01827813|ACTIVE_COMPARATOR|10-12 core biopsy|10-12 core biopsy was performed in left lateral decubitus position without sedo-analgesia on an outpatient basis. After preparation of the probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. After injecting 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region, prostatic size was measured and changes in the zonal anatomy and ultrasonographic view of the tissue were defined. Next, biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. As a total 10 or 12 core biopsies were taken depending on prostate volume. The biopsies were taken form right base, right mid, right apex, right far-lateral base, right far-lateral mid and left base, left apex, left far-lateral base, and left far-lateral mid in 10 core biopsy, also two additional transitional zone biopsies were taken in 12 core biopsies.
62761109|NCT03110445|EXPERIMENTAL|rVV-740CTA vaccine|
62761110|NCT04504890||Adults - Diagnosis|Adults seeking treatment for an attention-related disorder
62761111|NCT04504890||Adults - Prescribed|Adults who have been diagnosed with ADHD and prescribed medication treatment for the disorder
62761112|NCT04504890||Children - Diagnosis|Children seeking treatment for an attention-related disorder
62761113|NCT04504890||Children - Prescribed|Children who have been diagnosed with ADHD and prescribed medication treatment for the disorder
62761114|NCT05786339|EXPERIMENTAL|Reference formulation|Irbesartan tablet (0.15g/tablet) , Manufacturer: Sanofi Clir SNC
62761115|NCT05786339|EXPERIMENTAL|Test formulation|Irbesartan tablet (0.15g/tablet) , Manufacturer: Shenzhen Haibin Pharmaceutical Co., Ltd.
62381411|NCT04771650|NO_INTERVENTION|Control|Assessment plus standard care. Participants will complete an assessment, including measures on drinking and drug use. They will also receive standard care in a primary care setting.
62761116|NCT00775112|EXPERIMENTAL|1|with pillow
62761117|NCT00775112|NO_INTERVENTION|2|without pillow
62761118|NCT00137696|EXPERIMENTAL|Cohort A-WHO/EPI Schedule|Received IPV at ages 6, 10, and 14 weeks (this schedule is also approved for use in the United States if an accelerated schedule is needed.
62761119|NCT00137696|ACTIVE_COMPARATOR|Cohort A-US Schedule|Received IPV at ages 8, 16, and 24 weeks.
62761120|NCT05255042||Trial Participants|"Overall Description of Trial Participants: The liver organ samples included in this project will be from patients undergoing elective surgery for a lesion in the liver in the HPB Unit of the Leicester General Hospital. No change in the surgical procedure or recruiting results from this study and the use of the samples.~Inclusion Criteria: The samples included in this project will be from patients undergoing elective liver surgery in the HPB Unit of the Leicester General Hospital. The criteria for inclusion of liver segment samples from radical surgery are adult age and presence of hepatic tissue in the discarded material after hepato-pancreato-biliary surgery.~Exclusion Criteria: The main exclusion criterion is acute invasive infection, but these patients are automatically excluded from major surgery. Vulnerable groups will not be recruited."
62761121|NCT02719145||Control group (group 1)|10 healthy volunteer subjects.
62761122|NCT02719145||Asthma group (group 2)|10 asthmatic patients.
62761123|NCT02719145||COPD group (group 3)|10 COPD patients.
62761124|NCT05705752|EXPERIMENTAL|Balance|Balance training group.
61987782|NCT02373787|EXPERIMENTAL|creos xenoprotect|resorbable collagen membrane
62761125|NCT05705752|ACTIVE_COMPARATOR|Pilates|Pilates group.
61987783|NCT02373787|ACTIVE_COMPARATOR|Bio-Gide|Bio-Gide, resorbable collagen membrane
61987784|NCT02259361|ACTIVE_COMPARATOR|Experimental|Intervention: Sustained-release oral dalfampridine, one 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) for 14 consecutive days.
62761126|NCT04840563|EXPERIMENTAL|Kalifilcon A lenses|Commercially available kalifilcon A lenses (Bausch + Lomb)
62761127|NCT04840563|ACTIVE_COMPARATOR|Dailies Total1|Dailies Total1 (Alcon)
62761128|NCT04840563|ACTIVE_COMPARATOR|Precision1|Precision1 (Alcon)
62761129|NCT02252601|EXPERIMENTAL|Well patients aged 11 and over|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
62761130|NCT02252601|EXPERIMENTAL|Acute exacerbation aged 11 and over|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity at the beginning of a course of IV antibiotics and at their convalescent clinic visit.
62761131|NCT02252601|EXPERIMENTAL|Children with CF aged 5-10 years|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
62761132|NCT02252601|ACTIVE_COMPARATOR|Healthy Control Children age 5-10 years.|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
62381412|NCT02886442|EXPERIMENTAL|Cohort 3|"This is a sub-study testing how the adhesion of two adhesives is influenced by exposure to real output.~There are two kinds of visits:~Visit 1:~Two adhesive strips (standard adhesive strip) are applied on the peristomal skin; one strip is exposed to real output (contained in a sleeve) and the other strip is not.~Visit 2:~Two adhesive strips (new adhesive strip) are applied on the peristomal skin; one strip is exposed to real output (contained in a sleeve) and the other strip is not.~Visit 2:"
62761133|NCT02982018|EXPERIMENTAL|Investigational Contact Lens with UV Blocker|Subjects will be dispensed the investigational contact lens with UV blocker to wear daily for a period of 12 weeks with follow-up visits occurring after 1, 2, 4, 8, and 12 weeks. Afterwards, the subjects will wear their habitual contact lenses for a period of two weeks with weekly visits.
62761134|NCT02982018|ACTIVE_COMPARATOR|Marketed Contact Lens|Subjects will be dispensed the marketed contact lens to wear daily for a period of 12 weeks with follow-up visits occurring after 1, 2, 4, 8, and 12 weeks. Afterwards, the subjects will wear their habitual contact lenses for a period of two weeks with weekly visits.
62761135|NCT06183372|EXPERIMENTAL|Lemon balm|300mg Lemon balm and Maltoxdextrin capsules
62761136|NCT06183372|PLACEBO_COMPARATOR|Placebo|300mg Maltodextrin capsules
62761137|NCT02146677|OTHER|Sham|newborns will be osteopathically evaluated and softly touched
62761138|NCT02146677|OTHER|Usual care|newborns will be undergone usual routine neonatology care
62761139|NCT02146677|OTHER|OMT|newborns will receive osteopathic evaluation and treatment according to international guidelines. Osteopathic treatment use will be indirect techniques.
62761140|NCT06465264|EXPERIMENTAL|Allisartan Isoproxil/Amlodipine group 1|Patients will be treated with one Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Amlodipine during the double-blind period (Week 4\~Week 16) and one Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily.
62761141|NCT06465264|ACTIVE_COMPARATOR|Amlodipine group 1|Patients will be treated with one Amlodipine (5 mg) tablet and one placebo of Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the double-blind period (Week 4\~Week 16) and one Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily.
62761142|NCT06465264|EXPERIMENTAL|Allisartan Isoproxil/Amlodipine group 2|Patients will be treated with one Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Allisartan Isoproxil tablet during the double-blind period (Week 4\~Week 16) and one Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily.
62761143|NCT06465264|ACTIVE_COMPARATOR|Allisartan Isoproxil group 2|Patients will be treated with one Allisartan Isoproxil (240 mg) and one placebo of Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the double-blind period (Week 4\~Week 16) and one Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily.
62761144|NCT05206071|EXPERIMENTAL|SL 19+22 CAR-T|
62761145|NCT01650714|EXPERIMENTAL|Full thickness gastric biopsy|Full thickness gastric biopsy
62761146|NCT03515941|EXPERIMENTAL|Arm 1: Adjuvant Chemotherapy|Three cycles of chemo with CAPEOX (Oxaliplatin:130 mg/m2 by IV and Capecitabine: 625 or 1000 mg/m2 by PO (BID) on 21 day-cycle or FOLFOX (Oxaliplatin:85 mg/m2 by IV, Leucovorin:400 mg/m2 by IV,5-fluorouracil: 400 mg/m2 and 2400 mg/m2 by IV) on 14 day-cycle
62761147|NCT03515941|EXPERIMENTAL|Arm 2: Adjuvant Chemoradiation|Three cycles of chemo with Capecitabine: 750 mg/m2 by PO BID on days 1-14 of a 28 day-cycle or 5-fluorouracil (Leucovorin:400 mg/m2 by IV,5-fluorouracil: 400 mg/m2 and 1200 mg/m2 by IV) on days 1 and 15 of a 28 day cycle After 1st chemo cycle above, chemoradiation for 5 weeks with 45 Gy in 1.8 Gy/fraction, 5 days a week, to the entire gastric bed (including anastomosis) and draining lymph nodes, and a single agent fluoropyrimidine, either capecitabine or 5-fluorouracil After 5 weeks chemoradiation, 2 cycles of chemo as described above.
62761148|NCT01428336|ACTIVE_COMPARATOR|Patients|Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test
62761149|NCT01428336|ACTIVE_COMPARATOR|Volunteers|Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test
62761150|NCT05736289||Percutaneous mitral valve repair|Patients undergoing percutaneous mitral valve repair under general anesthesia for mitral valve regurgitation.
62761151|NCT05736289||Surgical mitral valve repair or replacement|Patients undergoing surgical mitral valve repair or replacement for mitral valve regurgitation.
62761152|NCT00085982|EXPERIMENTAL|Leptin Treatment|300 mg of study drug administered via subcutaneous (SC) injections.
62761153|NCT02585648|EXPERIMENTAL|Patients with dry eye syndrome 1|20 patients with dry eye syndrome, they will receive intervention 1 for one week and then cross over to intervention 2
62761154|NCT02585648|EXPERIMENTAL|Patients with dry eye syndrome 2|20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1
62761155|NCT03223467|ACTIVE_COMPARATOR|Biliopancreatic diversion|Study participants will undergo biliopancreatic diversion which is a type of bariatric surgery where a part of the stomach are removed and the remaining stomach is attached to a distal segment of the small intestine.
62761156|NCT03223467|ACTIVE_COMPARATOR|Gastric sleeve|Study participants will undergo sleeve gastrectomy which is a restrictive form av bariatric surgery where the size of the stomach is reduced.
62381413|NCT03606889|EXPERIMENTAL|Quadratus Lumborum block group|Quadratus Lumborum block group (QL) patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
62381414|NCT03606889|EXPERIMENTAL|Transversus abdominis plane block group|Transversus abdominis plane block (TAP) patients will receive a bilateral TAP block using Bupivicaine 0.125%
62381415|NCT00256204|EXPERIMENTAL|1mg rasagiline|1mg early start active treatment arm (72 weeks active)followed by 1mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active)
62761157|NCT03223467|ACTIVE_COMPARATOR|Gastric bypass|Study participants will undergo gastric bypass which is a type of bariatric surgery where a small pouch of the stomach is created and attached to a segment of the small intestine.
62381416|NCT00256204|EXPERIMENTAL|2mg rasagiline|2mg early start active treatment arm (72 weeks active)followed by 2mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active)
62381417|NCT00256204|PLACEBO_COMPARATOR|Placebo|Each arm is followed by 36 weeks of placebo
62381418|NCT06000566||Pediatric JIA patients|No interventions will be administered
62381419|NCT01816880||Healthy Elderly|Age 90 and over Gender: Male and Female Enrolled in the Healthy Elderly (HEAL) study prior to enrollment in this sub-study Blood sample of approximately 20mL is drawn.
62381420|NCT03323385|EXPERIMENTAL|N1539 30 mg|N1539 (meloxicam injection for IV use) 30 mg every 24 hours
62761158|NCT03223467|NO_INTERVENTION|No intervention|Study participants that do not want to undergo surgical treatment.
62761159|NCT02557113|ACTIVE_COMPARATOR|Vertebroplasty|This Group Underwent the Vertebroplasty Procedure (Injection of Bone Cement into the Fractured Osteoporotic Vertebral Body)
62761160|NCT02557113|EXPERIMENTAL|Cavuplasty|This Group Underwent the Cavuplasty Procedure (Small Cavity was Created in the Vertebral Body Prior to Injection of Bone Cement)
62761161|NCT00431951|EXPERIMENTAL|ST-246|250 mg, 400 mg or 800 mg of ST-246 given once daily for 21 days
62381421|NCT03323385|PLACEBO_COMPARATOR|IV Placebo|IV Placebo every 24 hours
62381422|NCT01694667|ACTIVE_COMPARATOR|Omega-3 Fatty Acids|Omega-3 Fatty Acids: Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA
62381423|NCT01694667|PLACEBO_COMPARATOR|Placebo|Placebo packets will have same orange-flavored pudding with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
62381424|NCT03319329||critically ill adult patients|"Part I: A cross-sectional study to compare validity of several predictive equations used to predict REE in critically ill adult patients for staying ≤ 5 days, 6 - 10 days and \> 10 days by using indirect calorimetry (IC) as the reference standard.~Part II: To develop predictive equation for the estimation of energy requirement by identifying variables that might influence REE of mechanically ventilated critically ill patients.~Part III: To validate the newly developed predictive equation for the estimation of energy requirement by using Ten fold cross-validation approach"
62381425|NCT05237024||Physiology Monitoring|The study's objective is to test the hypothesis that immune system activation and subsequent systemic inflammation can be detected through continuously tracking multiple bio signals including physiologic variables (ECG, skin temperature and their derivatives) and behavioral variables (activity and sleep from accelerometers) collected during routine activities of daily living using wearable biosensors.
62761162|NCT00431951|PLACEBO_COMPARATOR|placebo|Placebo to match ST-246
62761163|NCT01342744|EXPERIMENTAL|Metformin|Metformin (850mg) 1 tab oral twice a day
62761164|NCT01342744|PLACEBO_COMPARATOR|Placebo|Placebo 1 tab oral twice a day
62761165|NCT01711281|EXPERIMENTAL|Intracardiac Impedance Measurement|
62761166|NCT00716898||1|"A. Patients with pathologically or cytologically confirmed diagnosis of advanced solid malignancy.~B. Venous thromboembolism: Deep vein thrombosis (DVT) confirmed by Doppler ultrasound, or pulmonary embolism confirmed by lung ventilation perfusion scan, or computerized tomography.~C. Treatment with therapeutic dose of low molecular weight heparin. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. Serum creatinine level \< 1.5 mg/dl. G. Informed consent"
62761167|NCT00716898||2|"A. Patients with unstable angina pectoris/ atypical chest pain, with no evidence of acute myocardial infarction.~B. Treatment with therapeutic dose of low molecular weight heparin. C. No evidence of VTE. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. No history of malignancy. G. Serum creatinine level \< 1.5 mg/dl. H. Informed consent"
62761168|NCT02312765|EXPERIMENTAL|Intervention|Study participants will receive a tablet computer with the AirCare system.
62761169|NCT02312765|NO_INTERVENTION|Control|Standard care
62761170|NCT04304183||slow transit constipation|patients diagnosed with slow transit constipation had undergone surgery.
62761171|NCT06010381|ACTIVE_COMPARATOR|Muscle energy technique|This group includes 15 patients who received muscle energy technique post-surgery in addition to traditional shoulder exercise, 3 sessions/week for four weeks.
62381426|NCT05237024||Physiology & Immune Monitoring|A limited sub-study including 30 individuals enrolled in the primary study (not retrospective group) will incorporate serial blood draws relative to the vaccine doses. The purpose of the serologies and immunoassays is to explore the correlation an individual's development of a vaccine-induced immune response with changes in the continuous physiologic data surrounding the immunization process.
62381427|NCT01430910|EXPERIMENTAL|1|CAZ104 (2000mg Ceftazidime/500mg Avibactam)
62761172|NCT06010381|ACTIVE_COMPARATOR|Maitland mobilization|This group includes 15 patients who received mobilization in addition to traditional shoulder exercise, 3 sessions/week for four weeks.
62761173|NCT01739933|ACTIVE_COMPARATOR|Dexmedetomidine|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 5 mcg/mL dexmedetomidine. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr."
62381428|NCT01430910|ACTIVE_COMPARATOR|2|500mg Avibactam
62761174|NCT01739933|ACTIVE_COMPARATOR|Propofol|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 10 mg/mL propofol. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the propofol group, dose will range from 5-50 mcg/kg/min."
62761175|NCT04014543|EXPERIMENTAL|Gastrostomy|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
62761176|NCT01243684|ACTIVE_COMPARATOR|Healty volunteers|
62381429|NCT01430910|ACTIVE_COMPARATOR|3|2000mg Ceftazidime
62381430|NCT05247515|EXPERIMENTAL|Treated group: Nexpowder application on the scar after EMR with coagulation of visible vessels|To compare of the risk of bleeding after EMR application of nexpower (not a drug but a device with CE mark) on the resect area (scar) to cover the whole surface of mucosal resection.
62381431|NCT05247515|NO_INTERVENTION|standard procedure : EMR with coagulation of visible vessels|After EMR with coagulation of visible vessels, if the patient is randomized in the comparative group, not nexpowder will be applied on the scar (common practice)
62761177|NCT01243684|EXPERIMENTAL|Patients|
62761178|NCT00737594|PLACEBO_COMPARATOR|Placebo TID|Participants receive matching placebo capsules three times daily (TID)
62761179|NCT00737594|EXPERIMENTAL|12 mcg TID|Participants receive 12 mcg Cobiprostone TID
62761180|NCT00737594|EXPERIMENTAL|18 mcg TID|Participants receive 18 mcg Cobiprostone TID
62381432|NCT04727411|EXPERIMENTAL|Gel Stent implantation|XEN gel stent: a clear cornea incision in the inferotemporal quadrant was performed, injecting the XEN 45 device into the superonasal quadrant using an ab interno approach. Approximately 15 min before inserting the implant, 0.1 ml of a MMC solution (0.01%) was injected into the superior conjunctiva. Both stand-alone and combined phaco-glaucoma procedures were used.
62381433|NCT04727411|EXPERIMENTAL|Trabeculectomy|Trabeculectomy: the surgical technique is as follows: retro/peribulbar o subtenon's anesthesia, superior corneal traction suture, phacoemulsification through 2.2 with in-the-bag IOL implantation, a fornix-based conjunctival flap, sufficient but not excessive cauterization, application MMC 0,2 mg/ml for 2 minutes under the conjunctiva, then MMC was washed out with 100 ml of saline solution, then a scleral flap (4x3 mm in the trabeculectomy) is dissected. A sclerectomy with punch and peripheral iridectomy were performed, and suture nylon 10/00 sutures was used to place 3 or 4 stiches in the scleral flap
62761181|NCT02757443|EXPERIMENTAL|Phosphocreatine|"Participants randomly assigned to the phosphocreatine arm receive:~* after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV);~* together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L);~* immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV;~* immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV"
62761182|NCT02757443|PLACEBO_COMPARATOR|Control|"Participants randomly assigned to the placebo arm receive:~* after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes;~* together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany);~* immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes;~* immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes"
62761183|NCT04831528||No secondary changes of drug resistance|
62761184|NCT04831528||Secondary mutations of RAS|
62761185|NCT04831528||Secondary mutation of BRAF|
62761186|NCT04831528||HER2 amplification|
62761187|NCT04831528||Other secondary mutations|
62761188|NCT04656106||Ryzodeg|Patients treated with any basal-insulin or premix-insulin for at least 26 weeks prior to switching to Ryzodeg® and treated for at least 26 weeks after switching to Ryzodeg®.
62761189|NCT03954847||Lung cancer patients|Lung cancer patients with PET/CT or CT examination before any cancer-specific treatment
62761190|NCT03417596|EXPERIMENTAL|Vestibular Rehabilitation|"Adaptation Exercises The exercises were performed in horizontal and vertical planes, for a period of one minute each, three times a day.~Substitution Exercises Standing dynamic balance exercises: The patient stands and moves without walking. The patient might march in place, step forward or backward, step to the side, step up or down, or turn around.~Habituation exercises: These exercises that cause mild to moderate difficulty in daily life was given as an exercise to the patient. These exercises involved movements and positions sufficient to cause mild-to-moderate symptoms during the patient's daily activities Ambulation exercises: Exercises that include walking with head moving towards different sides.~The exercise program consisted of one session per week for a period of eight weeks. Each session lasted approximately 30-45 minutes and was conducted in the rehabilitation unit."
62761191|NCT03417596|EXPERIMENTAL|Vestibular Rehabilitation+Pharmacological Therapy|"Same exercises that were applied in first group were also applied to this group.~For pharmacological therapy, patients were assessed by a neurologist and appropriate drug options were applied based on patients' needs and features. Propranolol was selected primarily and other prophylactic drugs were used in the case of its' being contraindicated."
62761192|NCT03417596|OTHER|Pharmacological Therapy only|Patients were assessed by a neurologist and appropriate drug options were applied based on patients' needs and features. Propranolol was selected primarily and other prophylactic drugs were used in the case of its' being contraindicated.
62761193|NCT04469231|EXPERIMENTAL|Synergy Disc|The Synergy Disc is a cervical disc prosthesis that can be inserted between C3-C7 in skeletally mature patients after anterior discectomy to provide restoration of motion to the functional spinal unit. The Synergy Disc is designed to restoring kinematics to the cervical spine. The Synergy Disc is intended for use in the cervical spine for reconstruction of the disc following a single level discectomy for intractable radiculopathy and/or myelopathy.
62761194|NCT01047800|EXPERIMENTAL|Counseling group|Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician
62761195|NCT01047800|NO_INTERVENTION|Control|Usual management in GI specialty clinic
62761196|NCT01041443|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive FdCyd IV over 3 hours and THU IV over 3 hours on days 1-10. Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.
62761197|NCT01767077|PLACEBO_COMPARATOR|Butter oil|Daily intake of 40 g butter oil
62761198|NCT01767077|ACTIVE_COMPARATOR|Cream|Daily intake of 100 g cream (40%)
62761199|NCT04024904|NO_INTERVENTION|control group|In the control group, the patient received the standard pharmacologic intravenous sedation before the regional anaesthesia (2 mg midazolam + 5 µg de sufentanil) without VRHD (Virtual Reality Hypnosis Distraction).
62761200|NCT04024904|EXPERIMENTAL|VRHD1|In the study group VRHD (Virtual Reality Hypnosis Distraction) 1, the patient received the VHRD technique during the peripheral nerve block and received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score \>3).
62761201|NCT04024904|EXPERIMENTAL|VRHD2|In the study group VRHD (Virtual Reality Hypnosis Distraction) 2, the patient received the VHRD technique for the first time before the regional procedure and a second time during the peripheral nerve block. The patient received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score \>3).
62381434|NCT04677803|EXPERIMENTAL|Treatment|"Subcutaneous (SC) injection:~BT200 dose 3 mg on Day 0, Day 4, and again on Day 7 BT200 dose titrated thereafter between 3 and 9 mg on Days 14, 21, and 28. It is anticipated that dose adjustments will be performed in 2 mg steps. The 9 mg dose will only be applied on day 28 in exceptional circumstances, if no relevant changes in pharmacodynamic and safety parameters will be observed on day 21."
62761202|NCT02351349|EXPERIMENTAL|multidisciplinary intervention|Due to the problem of randomization, the study became a before and after assessment in the one group that completed the 12 week exercise program and received nutritional support
62761203|NCT02351349|NO_INTERVENTION|Non adherence|Those who were offered the program but did not complete the prescription
62761204|NCT00098722|EXPERIMENTAL|1|
62761205|NCT00098722|PLACEBO_COMPARATOR|2|
62381435|NCT01040494|EXPERIMENTAL|Aliskiren, add-on|HF patients will be randomized to receive add-on aliskiren 150 mg for 6 months
62381436|NCT01040494|PLACEBO_COMPARATOR|placebo, add-on|patients will be randomized to receive add-on placebo for 6 months
62381437|NCT06089772|EXPERIMENTAL|Group I|Group I (n=14) received HVLA spinal manipulation
62381438|NCT06089772|ACTIVE_COMPARATOR|Group II|Group II (n=14) underwent foam roller stretching,
62381439|NCT06089772|ACTIVE_COMPARATOR|Group III|Group III (n=14) received a combination of HVLA spinal manipulation and foam roller stretching,
62381440|NCT06089772|SHAM_COMPARATOR|Group IV|Group IV (n=14) underwent sham manipulation as the control group
61987785|NCT02259361|PLACEBO_COMPARATOR|Placebo|Placebo, one 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) for 14 consecutive days.
62381441|NCT04397757|EXPERIMENTAL|COVID-19 Convalescent plasma|COVID-19 Convalescent plasma on Study Day 1 in addition to standard care
62381442|NCT04397757|NO_INTERVENTION|Standard care|Standard care alone
62381443|NCT02223949|EXPERIMENTAL|Cook double balloon catheter|Insertion of the Cook double balloon catheter to the cervix until both balloons are properly located in the cervical canal. After properly located it is inflated with 20 ml of saline. Then both balloons are additionally inflated to a total of 80 ml each balloon. Twelve hours later the balloons are deflated and the device is removed.
62381444|NCT02223949|ACTIVE_COMPARATOR|PGE1 tablet insertion|Insertion of 25 mg PGE1 (Prostaglandin E1) tablet is inserted in the posterior fornix. The patient woll the be instructed to stay in bed for the next 60 minutes. After six hours a repeated dose will be administered. Total of 4 PGE1 doses within 24 hours.
62381445|NCT01332006|EXPERIMENTAL|Intra-bone injection|Intra-bone transplantation of hematopoietic stem cells from cord blood
62381446|NCT04651751|NO_INTERVENTION|Control|No Intervention: Control Participants exercised on their own without receiving any instructions.
62761206|NCT00098722|EXPERIMENTAL|3|
62761207|NCT04734821|EXPERIMENTAL|NIR Fluorescence guided lymphadenectomy and anastomosis|
62761208|NCT03958760||Diabetic patients with CVD, CKD or at risk|The group A include all diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
62761209|NCT03958760||Diabetic patients without CVD, CKD or at risk|The group B include all diabetic patients without established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
62761210|NCT03958760||Non-diabetic patients with CVD, CKD or at risk|The group C included all non-diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
62761211|NCT03958760||Health controls|The group D included non-diabetic patients without established cardiovascular disease, chronic kidney disease, and not at high cardiovascular risk.
62761212|NCT00711490|EXPERIMENTAL|Sirolimus|The study eye was treated with sirolimus.
62761213|NCT03263312|EXPERIMENTAL|Fontan Patients|All Fontan patients included in this study will be part of an exercise intervention 2-6 times/week for 3-6 months.
62761214|NCT02333149|EXPERIMENTAL|Melatonin|Dietary supplement: Melatonin 3 mg or 6 mg
62761215|NCT02333149|PLACEBO_COMPARATOR|Placebo|Drug: Placebo
62761216|NCT01707589|EXPERIMENTAL|Neonates admitted to the NICU|Neonates admitted to the NICU for a variety of medical reasons will be the cohort group. Those whose parents give informed consent will compose the subjects of the study
62761217|NCT06422858|EXPERIMENTAL|Serplulimab and S1 Chemotherapy Post-Concurrent Chemoradiation|
62761218|NCT04373447|ACTIVE_COMPARATOR|fundus-calot laparoscopic cholecystectomy|use laparoscopic fundus first then calot dissection cholecystectomy
62761219|NCT04373447|ACTIVE_COMPARATOR|open cholecystectomy|open cholecystectomy
62761220|NCT05819073|EXPERIMENTAL|PROP non-taster subjects|This arm will comprise of PROP non-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day plain water-rinse period.
62761221|NCT05819073|EXPERIMENTAL|PROP super-taster subjects|This arm will comprise of PROP super-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day plain water-rinse period.
62761222|NCT00661024|PLACEBO_COMPARATOR|1|RLN visualization alone
62761223|NCT00661024|EXPERIMENTAL|2|IONM of the RLN
62761224|NCT00016367|EXPERIMENTAL|Regimen A|Gemcitabine IV followed by Cisplatin IV Day 1 and Trastuzumab (Herceptin) IV Day 2; Trastuzumab IV followed by Gemcitabine IV Day 8 and Trastuzumab IV Day 15.
62761225|NCT00016367|EXPERIMENTAL|Regimen B|Starting Day 22 of regimen A, Trastuzumab IV, Gemcitabine IV, and Cisplatin IV Day 1. Trastuzumab IV followed by Gemcitabine IV Day 8 and Trastuzumab IV Day 15. Repeats every 21 days for up to 5 courses.
62761226|NCT05942378|EXPERIMENTAL|HRXG-K-1939 Combined with Adebrelimab|"Dose Escalation:~HRXG-K-1939 at escalated dosages with Adebrelimab Experimental: Dose Expansion HRXG-K-1939 at recommended dose with Adebrelimab"
62761227|NCT00706329|EXPERIMENTAL|Deflux|Treatment with Deflux.
62761228|NCT02120495|EXPERIMENTAL|intraoral condylectomy via coronoid process resction|This procedure has no facial nerve injury and skin scar,little injury to TMJ anatomy and function.
62761229|NCT04517786|EXPERIMENTAL|MINIject CS627 implant|MINIject 627 implant is used to reduce intra-ocular pressure in the eye. It is implanted through a minimally-invasive glaucoma surgical intervention in a stand alone procedure.
62381447|NCT04651751|EXPERIMENTAL|Intervention|Those who were randomized into the intervention group attended a workshop where the PI delivered a presentation that focused on establishing a preparatory exercise habit by using the M-PAC approach and proposed habit model. Participants were then provided with instructions on completing their exercise plan sheet.
62381448|NCT02331706|EXPERIMENTAL|Subject Recipients|
62381449|NCT02331706|EXPERIMENTAL|Subject Donors|
62761230|NCT05105893|OTHER|Dates group|The experimental group of women was given several dates orally and instructed to take seven a day and record their consumption until the beginning of the active phase of labor. Seven pieces of dates are about 80g of daily consumption
62761231|NCT05105893|OTHER|No dates|This group wasnt provided dates.
62761232|NCT04276688|ACTIVE_COMPARATOR|Study group|triple combination
62761233|NCT04276688|ACTIVE_COMPARATOR|Control group|single
62761234|NCT01829282|EXPERIMENTAL|Risk Reduction|"The Risk Reduction group will receive the Eban II Intervention upon enrollment. This group will do the following:~* Provide HIV and STI test results~* First Interview~* Attend 8 sessions - 1 session per week~* Second interview occurs immediately following the 8th session with HIV and STI tests~* Third interview occurs 3 months after the 8th session with HIV and STI tests"
62761235|NCT01829282|ACTIVE_COMPARATOR|Waitlist|"The Waitlist group will receive the same intervention after waiting for the Risk Reduction group to complete the entire intervention.~* Provide HIV and STI test results~* First Interview~* No sessions for 8 weeks~* Second interview and proof of HIV and STI status occurs after the 8 weeks from when you were enrolled~* Third interview occurs 3 months after the 8th session with HIV and STI tests The Waitlist Group will then be invited to participate in the Risk Reduction group activities.~* Attend 8 sessions - 1 session per week~* Fourth interview occurs immediately after the 8th session with HIV and STI tests~* Fifth interview occurs 3 months after the 8th session with HIV and STI tests"
62761236|NCT02849782|EXPERIMENTAL|Fampridine responder|"Persons who have been diagnosed as Multiple Sclerosis according to Mc Donald Criteria : person with Multiple Sclerosis (PwMS).~Fampridine was prescribed according to the guidelines issued by the French National Security Agency of Medicines and Health Products (ANSM) at the dose of 10 mg twice a day. According to official ANSM guidelines, the prescription is initially limited to 2 weeks of therapy, at which point a new assessment is performed by the medical practitioner to evaluate the clinical benefits. Fampridine responder is a PwMS with an improvement in the judgment of the practitioner."
62761237|NCT02849782|ACTIVE_COMPARATOR|Fampridine non responder|"Persons who have been diagnosed as Multiple Sclerosis according to Mc Donald Criteria : person with Multiple Sclerosis (PwMS).~Fampridine was prescribed according to the guidelines issued by the French National Security Agency of Medicines and Health Products (ANSM) at the dose of 10 mg twice a day. According to official ANSM guidelines, the prescription is initially limited to 2 weeks of therapy, at which point a new assessment is performed by the medical practitioner to evaluate the clinical benefits. Fampridine non responder is a PwMS without any improvement in the judgment of the practitioner."
62761238|NCT01637389|NO_INTERVENTION|Control Arm|All communities (independent units/clusters) start in the control and have no intervention. All control communities cross-over to the intervention in a randomized sequence over the course of 12-15 month study.
62761239|NCT01637389|EXPERIMENTAL|Basic Safe Water Program|The Basic program represents a variation in the implementation of the overall intervention: a community level safe-water program that is initiated with promotional meetings and followed by the offer to install Mesita Azul disinfection systems at the household level. Communities (independent units/cluster) cross-over from the control group to the intervention group in a randomized stepped-wedge fashion -- within each crossover group of 4 clusters, 2 are randomized to the Basic program.
62761240|NCT01637389|EXPERIMENTAL|Enhanced Safe Water Program|The Enhanced program represents a variation in the implementation of the overall intervention: a community level safe-water program that is initiated with promotional meetings and followed by the offer to install Mesita Azul disinfection systems at the household level. Communities (independent units/cluster) cross-over from the control group to the intervention group in a randomized stepped-wedge fashion -- within each crossover group of 4 clusters, 2 are randomized to the Enhanced program.
62761241|NCT03816280||Group T2DM-alpha|Patients with diabetes mellitus undergoing CPB with alpha-stat acid-base management
62761242|NCT03816280||Group T2DM-pH|Patients with diabetes mellitus undergoing CPB with pH-stat acid-base management
62761243|NCT03816280||Group Ctrl-alpha|Control patients undergoing CPB with alpha-stat acid-base management
61987786|NCT01652521||candidates for pleural fluid drainage|patients who are candidates for pleural fluid drainage.
62381450|NCT02375529|EXPERIMENTAL|Single Incision Cholesystectomy (SILC)|Single Incision Laparoscopic Cholecystectomy (SILC): The umbilicus is grasped and a 2 cm vertical skin and fascial incision is performed. A multiport (TriPort®) is inserted under direct vision. Principles of cholecystectomy are the same as traditional laparoscopic cholecystectomy.
62761244|NCT03816280||Group Ctrl-pH|Control patients undergoing CPB with pH-stat acid-base management
61987787|NCT03210610||FMF patients|fmf patients under a constant colchicine dose
61987788|NCT05715372|ACTIVE_COMPARATOR|Intervention group of menopausal women on hormone replacement|This group of women on hormone replacement will have specific, structured diet, physical activity, and mindfulness-based stress reduction programs.
61987789|NCT05715372|PLACEBO_COMPARATOR|Control group of menopausal women on hormone replacement|This group of women on hormone replacement will be given unstructured guidelines for diet, physical activity, and stress-reduction.
61987790|NCT05715372|ACTIVE_COMPARATOR|Intervention group of menopausal women without hormone replacement|This group of women will have specific, structured diet, physical activity, and mindfulness-based stress reduction programs.
62381451|NCT02375529|ACTIVE_COMPARATOR|Four Ports Cholecystectomy (4PCL)|Four Ports Conventional laparoscopic cholecystectomy (4PCL): A 10mm supraumbilical incision is made and the pneumoperitoneum insufflated through a Veress needle. 4 ports are introduced: 2 of 10mm in supraumbilical and left flank and 2 of 5mm in epigastric and right flank.
62761245|NCT02161276|EXPERIMENTAL|TNTL capsule and Placebo|3-4 capsules 3 times a day Used before meals
62761246|NCT05256784||Probiotic 1|Four members of an extended family: 1 white man of 71 years, 1 white woman of 75 years, 1 white man of 44 years, and 1 white woman of 44 years.
62761247|NCT01414764|ACTIVE_COMPARATOR|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The red blood cells will be discarded, and the supernatant containing ACP (with additional CaCl to activate the ACP and local anaesthetic) is injected into the tendon bone junction and adjacent area under ultrasound guidance. No adverse consequences are anticipated by using the Arthrex ACP injection.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively~Other Names:~Platelet rich plasma (PRP)"
62761248|NCT01414764|PLACEBO_COMPARATOR|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively"
62761249|NCT04133896||Group 1 Male|group 1 (22 lean men),
62761250|NCT04133896||Group 2 Male|group 2 (22 class I obese men),
62761251|NCT04133896||Group 3 Male|group 3 (22class II obese men),
62761252|NCT04133896||Group 4 Male|group 4 (22 class III obese men).
62761253|NCT04133896||Group 1 Female|group 1 (22 lean women),
62761254|NCT04133896||Group 2 Female|group 2 (22 class I obese women),
62761255|NCT04133896||Group 3 Female|group 3 (22 class II obese women),
62761256|NCT04133896||Group 4 Female|group 4 (22 class III obese women).
62761257|NCT00376805|EXPERIMENTAL|All Treated Patients|All patients with advanced metastatic breast cancer treated with natural killer cells after receiving fludarabine, cyclosphosphamide and total body irradiation.
62761258|NCT00868218|ACTIVE_COMPARATOR|1|30µg HA vaccine Intramuscularly administered
62761259|NCT00868218|ACTIVE_COMPARATOR|2|1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
62381452|NCT04839211|EXPERIMENTAL|Inspiratory muscle training|High-intensity interval-based inspiratory muscle training
62381453|NCT04839211|SHAM_COMPARATOR|Sham inspiratory muscle training|Unloaded inspiratory muscle training
62381454|NCT03512028|EXPERIMENTAL|Remote Limb Ischemic Conditioning (RLIC)|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the dominant arm. RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-8.
62381455|NCT03512028|SHAM_COMPARATOR|Sham Conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-8.
62381456|NCT02532816|EXPERIMENTAL|HND-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + fortified biscuit (ferrous fumarate 83.5 mg, zinc oxide 50.95 mg, Calcium carbonate 3104.05 mg, Thiamine Mononitrate1.85 mg, Nicotinic Acid 30.45 mg, Pyridoxine Hydrocloride 2.90 mg, Pteroyl monoglutamic acid 764.90 mcg, Cyanocobalamin 0.95 mcg, Retinol Palmitate (dry) 742.50 mcgRE)
62761260|NCT00868218|ACTIVE_COMPARATOR|3|7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
62761261|NCT00868218|ACTIVE_COMPARATOR|4|30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
62761262|NCT06511297||Lean, young adults|
62761263|NCT06511297||Overweight, young adults|
62761264|NCT06511297||Lean, older adults|
62761265|NCT06511297||Overweight, older adults|
62761266|NCT06511297||Nonagenerians Age ≥ 90|Note: Nonagenarian Group will only be phenotyped once
62761267|NCT04668235|EXPERIMENTAL|Arm AZVUDINE|"Experimental:~AZVUDINE 1mg tablet,~Interventions:~AZVUDINE 1mg tablet, 5 tablets QD + standard treatment for up to 14 days"
62761268|NCT04668235|PLACEBO_COMPARATOR|Arm Placebo|"Control:~AZVUDINE placebo,~Interventions:~AZVUDINE placebo, 5 tablets QD + standard treatment for up to 14 days"
62761269|NCT02916407|ACTIVE_COMPARATOR|Sevoflurane Group|The patients will maintained general anesthesia with sevoflurane.
62761270|NCT02916407|EXPERIMENTAL|Desflurane Group|The patients will maintained general anesthesia with desflurane.
62381457|NCT02532816|ACTIVE_COMPARATOR|SND-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + fortified biscuit (ferrous fumarate 32.6 mg, zinc oxide 3.78 mg, Calcium carbonate 874.12 mg, Thiamine Mononitrate1.25 mg, Nicotinic Acid 17.95 mg, Pyridoxine Hydrocloride 1.10 mg, Pteroyl monoglutamic acid 329.90 mcg, Cyanocobalamin 0.55 mcg)
62381458|NCT02532816|PLACEBO_COMPARATOR|NDN-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + non fortified biscuit
62761271|NCT04883840|PLACEBO_COMPARATOR|Placebo|
62761272|NCT04883840|EXPERIMENTAL|Rosuvastatin 10 mg|
62381459|NCT04625530|EXPERIMENTAL|ferric carboxymaltose|ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7.
62761273|NCT03889236|EXPERIMENTAL|Fasting mimicking diet|5-day Fasting mimicking diet Prolon. In total 3 cycles of the FMD in three months.
62381460|NCT04625530|EXPERIMENTAL|tranexamic acid|tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively
62761274|NCT03889236|EXPERIMENTAL|Food supplement|4 capsules a day of the food supplement Endocalyx for 3 months.
62761275|NCT03889236|PLACEBO_COMPARATOR|Placebo|4 capsules a day of the placebo for 3 months.
62761276|NCT04883528|EXPERIMENTAL|Sacubitril/valsartan|"Initial dose for patients randomized to sacubitril/valsartan (LCZ696) will be determined by the blood pressure at the time of randomization. Study treatment will be titrated to the next highest dose (dose level 2 or 3) based on blood pressure at the time of visit 2/titration visit. Dose adjustments are only allowed if indicated per protocol defined criteria and per investigator judgement of safety and tolerability.~Sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.~Other Name: LCZ696"
62761277|NCT04883528|PLACEBO_COMPARATOR|Placebo|"Initial dose for patients randomized to sacubitril/valsartan matching placebo will be determined by the blood pressure at the time of randomization. Study treatment will be titrated to the next highest dose (dose level 2 or 3) based on blood pressure at the time of visit 2/titration visit. Dose adjustments are only allowed if indicated per protocol defined criteria and per investigator judgement of safety and tolerability.~Sacubitril/valsartan matching placebo with minimum dose matching the 24/26 mg dose, maximum dose matching the 97/103 mg dose, administered twice daily orally."
62761278|NCT03703310|EXPERIMENTAL|Patidegib Topical Gel, 2%,|Participants will be randomized to receive Patidegib Topical Gel, 2%. The Patidegib Topical Gel, 2% will be dispensed to participants at each study visit and applied topically twice daily to the face.
62761279|NCT03703310|PLACEBO_COMPARATOR|Patidegib Topical Gel, Vehicle|Participants will be randomized to receive Vehicle. The Patidegib Topical Gel, Vehicle will be dispensed to participants at each study visit and applied topically twice daily to the face.
62761280|NCT02244177||normotension group|Until 11,March, 2015, 31 cases are collected.
62761281|NCT02244177||hypertension group without treatment|Until 11,March, 2015, 60 cases are collected.
62761282|NCT02244177||hypertension group with antihypertensive treatment|"(ACEI, beta-blocker, Ca blocker, Diuretics) prior to the surgery.~Until 11,March, 2015, 59 cases are collected."
62761283|NCT04720768|EXPERIMENTAL|Dose escalation phase|"Encorafenib (tablet) 450mg PO daily~Binimetinib (tablet) 45mg PO BD~Palbociclib (tablet) variable dose PO daily for 21 consecutive days on treatment, followed by 7 consecutive days off treatment in a 28 day cycle"
62381461|NCT04625530|EXPERIMENTAL|ferric carboxymaltose and tranexamic acid|"ferric carboxymaltose (Ferinject® 1000 mg/20 ml) between day -27 and day~-7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by Infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively will be administered."
62381462|NCT04625530|NO_INTERVENTION|"no treatment accordingly current standard of care"|"no treatment accordingly current standard of care will be given"
62381463|NCT03062605|ACTIVE_COMPARATOR|Treatment(TX)|. Participants were assigned randomly to one of two treatment groups and continued in parallel for the three-month duration of the study. The first treatment group (TX) rinsed with NaOCL (0.3%) for one minute followed by rinsing with iodine (10%) for one minute
62761284|NCT05396729|EXPERIMENTAL|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 30 minutes
62761285|NCT05396729|NO_INTERVENTION|Control|Electrodes are placed at acupoints but no electrical stimulation is given
62761286|NCT00219882|EXPERIMENTAL|1|standardized turmeric root extract
62761287|NCT04698135||morbid obesity|Patients with morbid obesity
62761288|NCT04698135||Metabolically healthy obesity|Patients with metabolically healthy obesity
62761289|NCT04698135||Healthy volunteers|Healthy volunteers
62761290|NCT03447093||Control group|30 healthy volunteers were included in the healthy control group
62761291|NCT03447093||Drug treatment group|30 GD patients who received treatment with Methimazole Pill or propylthiouracil pill
62761292|NCT03447093||Incipient group|30 untreated GD patients
62761293|NCT03447093||Hashimoto's thyroiditis group|30 HT patients
62761294|NCT04441164|EXPERIMENTAL|Observation of Virtual Actions (steps 1 and 3)|If the patient is included in the Virtual Reality group, he/she will be asked to observe Virtual Motor Actions (their own avatar moving in a virtual environment) using a headset once a day for 9 days during 5 minutes, followed by 5 minutes of relaxation performed using soothing music played through headphones.
62761295|NCT04441164|PLACEBO_COMPARATOR|Relaxation|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
62761296|NCT04441164|OTHER|Patients|It will be offered to patients hospitalized in these 2 services and presenting post-resuscitation ICU-weakness, especially in the aftermath of COVID infection, to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
62761297|NCT04441164|OTHER|Caregivers|It will be offered to caregivers of the ICU of the Rennes University Hospital, to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
62381464|NCT03062605|ACTIVE_COMPARATOR|Control (CT)|. Participants were assigned randomly to one of two treatment groups and continued in parallel for the three-month duration of the study. The control group (CT) rinsed with iodine (10%) for minute. The CT group was a positive control. Both of these treatments were done only once at the baseline. The reminder of the three-month study was to obtain saliva samples at specific times to determining microbial levels.
62381465|NCT00864539|EXPERIMENTAL|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 mL
62761298|NCT04441164|EXPERIMENTAL|Relaxation (step 3)|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
62761299|NCT04441164|EXPERIMENTAL|Performing Virtual Actions|If the patient is included in the group Performing Virtual Actions, he/she will be asked to perform Virtual Actions of the lower limbs by controlling the legs of his avatar (virtual double) in order to move around in a virtual environment for 10 minutes per day, once a day for 9 days.
62761300|NCT04441164|PLACEBO_COMPARATOR|Observation of Virtual Actions|If the patient is included in the Observation of Virtual Actions group, he/she will be asked to observe for 10 minutes once a day for 9 days Virtual Motor Actions (avatar moving in a virtual environment) using a Virtual Reality headset.
62761301|NCT04441164|EXPERIMENTAL|Haptic stimulation|Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of step 4 in combination with haptic stimulation (sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
62381466|NCT00864539|ACTIVE_COMPARATOR|plain milk|daily intake of 200 mL plain milk
62381467|NCT00864539|EXPERIMENTAL|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium
62761302|NCT04441164|PLACEBO_COMPARATOR|Without haptic stimulation|Without haptic stimulation Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of Step 4 in combination without haptic stimulation (without sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
62761303|NCT00203112|ACTIVE_COMPARATOR|Glatiramer Acetate injection with oral minocycline|Glatiramer Acetate 20mg with oral minocycline 100mg
62761304|NCT00203112|EXPERIMENTAL|Glatiramer Acetate with placebo|Glatiramer acetate injection 20mg with oral placebo
62761305|NCT05267132|EXPERIMENTAL|Kindness to Others with Reflection|Participants will complete the 'Other-Focused Acts of Kindness Intervention' by performing acts of kindness for others and will also complete a reflection component. They will be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day. At the end of each intervention week, they will be asked to reflect upon their experience of performing kind acts for others.
62761306|NCT05267132|ACTIVE_COMPARATOR|Kindness to Others|Participants will complete the 'Other-Focused Acts of Kindness Intervention' by performing acts of kindness for others. They will be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
62761307|NCT05267132|SHAM_COMPARATOR|Daily Report|Participants will complete the 'Daily Reports' and be asked to report their daily activities throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will list activities from their day.
62761308|NCT03483870|PLACEBO_COMPARATOR|Morphine sulphate & Placebo|20 parturients under intrathecal anesthesia will receive 200 ug morphine sulphate intrathecally and 2 mL of normal saline 0.9% (placebo) IV injection preoperative.
62761309|NCT03483870|ACTIVE_COMPARATOR|Morphine sulphate & Granisetron|20 parturients under intrathecal anesthesia will receive 200 ug morphine sulphate intrathecally and 2 mL of 2 mg granisetron IV injection preoperative.
62381468|NCT00864539|ACTIVE_COMPARATOR|plane juice|subjects receiving plain orange juice
62761310|NCT06185634|EXPERIMENTAL|Group 1|Group starting with the dietary intervention of eating pasta at dinner for 3 months.
62761311|NCT06185634|EXPERIMENTAL|Group 2|Group starting with the dietary intervention of eating pasta at lunch for 3 months.
62381469|NCT00864539|EXPERIMENTAL|vitamin D-Ca supplement|Subjects receiving daily supplement containing 500 mg + 200 IU vitamin D
62381470|NCT00864539|PLACEBO_COMPARATOR|Placebo|Subjects receiving daily placebo containing 1g starch
62381471|NCT01056601|EXPERIMENTAL|Pancreatic Cancer Patients|Pancreatic cancer patients who received treatment with bortezomib and panobinostat after progressing on gemcitabine.
62381472|NCT06278584|ACTIVE_COMPARATOR|iLUX Treatment System|The eyelid tissue is warmed by light energy produced by LEDs in the Instrument and transmitted through the precise Outer Pad. The Inner Pad and Eye Shield block light transmission directly into the eye during a treatment temperature sensor and measure the inner and outer eyelid temperatures to maintain a meibum melt temperature of 38-42°C.
62381473|NCT06278584|ACTIVE_COMPARATOR|Mechanical Meibomian Gland Expression|"1. Local heat using an electrical warming mask for 5 minutes.~2. Using a standardized device (Arita Meibomian Gland Compressor, Katena) to apply a standard force to individual glands"
62381474|NCT01188785|EXPERIMENTAL|1 arm|SOC + siG12D LODER
62381475|NCT05524259|ACTIVE_COMPARATOR|Myo-inositol and routinely recommended folic acid|Myo-inositol is a naturally occurring substance, with a structure quite similar to glucose, which forms an essential component of the cell membrane and is known to support several cellular processes in all living organisms. It is present in nature in high abundance and can be found in many food products. Myo-inositol was historically considered part of the vitamin-B complex and can safely be used as a dietary supplement. In humans, it is synthesized de novo from glucose-6-phosphate in many tissues, mainly in the kidney. Under normal circumstances, the kidneys produce large quantities of myo-inositol, estimated at about 4 grams of endogenous production per day. Myo-inositol has been shown to have a physiological role in supporting the effects of insulin in all living beings. It fulfils a second messenger role in the insulin signalling pathway by enhancing the translocation of GLUT-4 receptors on the plasma membrane and thereby facilitates the intra-cellular uptake of glucose.
62761312|NCT03282773|EXPERIMENTAL|Deferred stent implantation|Drug-eluting stents are implanted 4-10 days after primary angiography and restoration of blood flow in left main coroanry artery in a secondary PCI
62761313|NCT03282773|ACTIVE_COMPARATOR|Immediate stent implantation|Drug-eluting stents are implanted immediately after primary angiography and restoration of blood flow in left main coroanry artery
62761314|NCT04333940|EXPERIMENTAL|1. 3D CBCT GROUP|Preoperative 3-dimensional CBCT will be taken.
62761315|NCT04333940|ACTIVE_COMPARATOR|2D PR GROUP|Preoperative 2-dimensional periapical radiographs will be taken using paralleling technique with customized Jig
62761316|NCT04000334|EXPERIMENTAL|Cerebral hypoperfusion (group A)|Cerebral hypoperfusion will be defined by an abnormal TCD at inclusion (t0) when two of the three measured values are abnormal using the following thresholds: Vm \< 30 cm/s, Vd \< 20 cm/s, PI \> 1.4.
62761317|NCT04000334|ACTIVE_COMPARATOR|Normal cerebral perfusion (group B)|Normal cerebral perfusion will be defined by a normal TCD at inclusion (t0) when two of the three measured values are normal using the following thresholds: Vm \> 30 cm/s, Vd \> 20 cm/s, PI \< 1.4.
62381476|NCT05524259|PLACEBO_COMPARATOR|Routinely recommended folic acid|Folic acid supplements are part of routine pregnancy care and frequently used as background supplements in previous trials on myo-inositol supplementation in pregnancy.
62381477|NCT05258565|ACTIVE_COMPARATOR|acute ischemic stroke without covid -19 infection|Administration of IV tPA: the dose of activase is ,9 mg /kg (not exceeding 90 mg total treatment dose) Infused over 90 minutes.
62381478|NCT05258565|ACTIVE_COMPARATOR|acute ischemic stroke associated with covid -19 infection|Administration of IV tPA: the dose of activase is, 9 mg /kg (not exceeding 90 mg total treatment dose) Infused over 90 minutes.
62381479|NCT04108598||Adults presenting with SSNHL|Adults presenting with SSNHL to NHS
62381480|NCT04974944|EXPERIMENTAL|Camrelizumab + Apatinib|On Day 1 and Day 15 of each 28-day cycle, participants receive an intravenous (IV) infusion of camrelizumab 200 mg Plus an oral apatinib 250 mg once daily. Apatinib will be administered 250 mg once every other day when completing twice tumor assessement. All treatments are administered until disease progression or unacceptable toxicity.
62381481|NCT04974944|ACTIVE_COMPARATOR|Paclitaxel + Cisplatin/Carboplatin + Bevacizumab|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of paclitaxel 175 mg/m\^2 PLUS cisplatin 50 mg/m\^2 WITH bevacizumab 15 mg/kg OR paclitaxel 175 mg/m\^2 PLUS carboplatin Area Under the Curve (AUC) 5, WITH bevacizumab 15 mg/kg). All treatments are administered until disease progression or unacceptable toxicity.
62381482|NCT06058338|EXPERIMENTAL|Intervention Arm|Intervention arm participants will receive produce prescription services for a defined period of time (4-6months)
62381483|NCT06058338|NO_INTERVENTION|Control Arm|Control arm participants will not receive produce prescriptions but will receive standard of care services for diabetes management
62381484|NCT04681742|EXPERIMENTAL|CO-OP Group|10, 45-60 minute Cognitive Orientation to daily Occupational Performance intervention sessions
62381485|NCT01882439|EXPERIMENTAL|Treatment Sequence A|Tofacitinib 5 mg BID for 6 months
62761318|NCT01046227||Serology after Novel H1N1 vaccination|This study is designed to investigate the antibodies titers before and after the novel H1N1 influenza vaccination in pediatric haemato-oncology patients.
62761319|NCT01768104|EXPERIMENTAL|ESTD|Endoscopic submucosal tunnel dissection (ESTD) for patients with upper gastrointestinal submucosal tumors (SMTs)
62761320|NCT01768104|ACTIVE_COMPARATOR|VATS|Video-assisted thoracoscopic surgery (VATS) for patients with upper gastrointestinal submucosal tumors (SMTs)
62381486|NCT01882439|EXPERIMENTAL|Treatment Sequence B|Tofacitinib 10 mg BID for 6 months
62761321|NCT01341301|EXPERIMENTAL|Allogeneic HSCT|"CONDITIONING: Patients undergo Total Body Irradiation (TBI) twice daily (BID) on days -10 to -7. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients receive DLI on day -6 and undergo cluster of differentiation 34 (CD34+) selected allogeneic HSCT on day 0~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO on days -1 with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID or PO on days -1 to 28."
61987791|NCT05715372|PLACEBO_COMPARATOR|Control group of menopausal women without hormone replacement|This group of women will be given unstructured guidelines for diet, physical activity, and stress-reduction.
62381487|NCT01882439|PLACEBO_COMPARATOR|Treatment Sequence C|Placebo for 3 months then tofacitinib 5 mg BID for 3 months
62381488|NCT01882439|PLACEBO_COMPARATOR|Treatment Sequence D|Placebo for 3 months then tofacitinib 10 mg BID for 3 months
62381489|NCT04229082||lean|BMI between 18-25
62381490|NCT04229082||obese|BMI between 27.5-35
62381491|NCT04479306|EXPERIMENTAL|Arm A (osimertinib, alisertib)|Patients receive osimertinib PO QD on days 1-28 and alisertib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease may crossover to Arm B.
62381492|NCT04479306|EXPERIMENTAL|Arm B (osimertinib, sapanisertib)|Patients receive osimertinib PO QD on days 1-28 and sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease may crossover to Arm A.
62381493|NCT04834258|EXPERIMENTAL|Walking and respiratory muscle training group|"Walking and respiratory muscle training group (W+ RMT) received walking training in addition to respiratory muscle training for a period of 8 weeks.~Walking training was performed at least 5 days a week, twice a day, for 15 min. Walking distance was calculated according to patients' 6 minute walking distance.~Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training.~Patients were called for the hospital once a week to asses mouth pressure and 6 minute walking test (6 MWT) and their training intensity was arranged."
62761322|NCT01098877|PLACEBO_COMPARATOR|Placebo|
62761323|NCT01098877|EXPERIMENTAL|Cohort 1, 1mg|
62761324|NCT01098877|EXPERIMENTAL|Cohort 1, 3mg|
62761325|NCT01098877|EXPERIMENTAL|Cohort 1, 10mg|
62761326|NCT01098877|EXPERIMENTAL|Cohort 2, 30mg|
62761327|NCT01098877|EXPERIMENTAL|Cohort 2, 100mg|
62761328|NCT01098877|EXPERIMENTAL|Cohort 2, 300mg|
61987792|NCT01799499|EXPERIMENTAL|Group A: 20 mg MMC mixed with 60cc TC-3|Group A: 20 mg MMC mixed with 60cc TC-3 hydrogel. (n=8)
61987793|NCT01799499|EXPERIMENTAL|• Group B: 40 mg MMC mixed with 60cc TC-3|• Group B: 40 mg MMC mixed with 60cc TC-3 hydrogel (n=8)
61987794|NCT01799499|EXPERIMENTAL|• Group C: 80 mg MMC mixed with 60cc TC-3 hydrogel (n=8)|• Group C: 80 mg MMC mixed with 60cc TC-3 hydrogel (n=8)
62761329|NCT01098877|EXPERIMENTAL|Cohort 3, 600mg|
62761330|NCT01098877|EXPERIMENTAL|Cohort 3, 900mg|
62761331|NCT01098877|EXPERIMENTAL|Cohort 3, up to 900mg (fed)|
62761332|NCT01098877|PLACEBO_COMPARATOR|Cohort 3, placebo (fed)|
62381494|NCT04834258|ACTIVE_COMPARATOR|Respiratory muscle training group|In the Respiratory muscle training group (RMT), Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training. Patients were called for the hospital once a week to asses mouth pressure and their training intensity was arranged
61987795|NCT02601287|EXPERIMENTAL|BOTOX® 100U|Botulinum Toxin Type A 100U into the detrusor muscle on Day 1 in patients with Overactive Bladder
62381495|NCT00681902|EXPERIMENTAL|1|Jet lidocaine
62381496|NCT00681902|PLACEBO_COMPARATOR|2|Jet saline
62761333|NCT00490139|ACTIVE_COMPARATOR|Arm 1: Trastuzumab|"Design 1: Trastuzumab 8mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks for a total of 52 weeks.~Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab administered every 3 weeks (6mg/kg IV without loading dose) for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab (6mg/kg without loading dose) every 3 weeks for an additional 40 weeks (52 weeks total)."
62761334|NCT00490139|EXPERIMENTAL|Arm 2: Lapatinib|"Based on the IDMC results from 18 August 2011, any patient enrolled onto Arm 2 should be considered for a new treatment strategy based on discussion with their physician.~Design 1: Lapatinib 1500mg oral daily for a total of 52 weeks.~Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, oral lapatinib administered at 1500mg daily for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, the dose of lapatinib will be increased to 1500mg oral daily for an additional 40 weeks (52 weeks total)."
62761335|NCT00490139|EXPERIMENTAL|Arm 3: Trastuzumab followed by Lapatinib|"Design 1: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total).~Design 2: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks administered concomitantly and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles; followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) followed by a 6 week treatment-free interval followed by oral lapatinib 1500 mg daily for 28 weeks (52 weeks total)."
62761336|NCT00490139|EXPERIMENTAL|Arm 4: Lapatinib in combination with Trastuzumab|"Design 1: Oral lapatinib 1000 mg daily concurrent with trastuzumab 8 mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks (52 weeks total).~Design 2: Trastuzumab (4mg/kg loading dose followed by 2mg/kg IV weekly) concurrent with oral lapatinib 750 mg daily and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles (12 weeks). After completion of chemotherapy, the dose of lapatinib will be increased to 1000mg daily concurrently with trastuzumab every 3 weeks (6mg/kg without loading dose) for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concurrently with oral lapatinib 750mg plus weekly trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV. After the completion of chemotherapy, trastuzumab will be administered every 3 weeks (6mg/kg without loading dose) concurrent with lapatinib 1000mg daily for an additional 40 weeks (52 weeks total)."
62761337|NCT03529097|ACTIVE_COMPARATOR|Fluids|Intervention: 2 liters of 0.9% NaCl IV during the ER stay with pain killers. For placebo purposes this arm participants will get an infusion with black cover so they could not tell if it drips or not
61987796|NCT02601287|EXPERIMENTAL|BOTOX® 200U|Botulinum Toxin Type A 200U into the detrusor muscle on Day 1 in patients with Neurogenic Detrusor Overactivity
62381497|NCT04850885|EXPERIMENTAL|Dexamethasone Group ( Group DXN)|Group DXN has received 4 ml Mixture B (2ml Lignocaine 2%+ 2ml dexamethasone 4mg/ml)
62381498|NCT04850885|ACTIVE_COMPARATOR|Adreanaline Group ( Group ADN)|Group ADN has received 4 ml Mixture A ( 2ml Lignocaine 2%+ 2ml freshly prepared solution of adrenaline 0.01mg/ml in normal saline)
62381499|NCT01896466|ACTIVE_COMPARATOR|Young Adults - Intervention|Healthy subjects between the ages of 18-39 will participate in Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
62381500|NCT01896466|ACTIVE_COMPARATOR|Healthy Older Adults - Control|Healthy subjects between age 65+ will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
61987797|NCT05004376|NO_INTERVENTION|Non-adherent control|Control subjects will receive no text intervention and a 150 day follow-up phone call.
62381501|NCT01896466|ACTIVE_COMPARATOR|Healthy Older Adults - Intervention|Healthy subjects age 65+ will participate in Cranial Nerve Non-Invasive Neuromodulation enhanced gait and balance training.
62381502|NCT01896466|SHAM_COMPARATOR|Older Fallers - Control|Subjects who are age 65+ with a history of 1-3 falls in the previous six months will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
62761338|NCT03529097|PLACEBO_COMPARATOR|Placebo|No interventions, Only pain killers. For placebo purposes this arm participants will get an infusion with black cover so they could not tell if it drips or not
62761339|NCT00580125|EXPERIMENTAL|A2|
62761340|NCT00580125|PLACEBO_COMPARATOR|A5|
62761341|NCT00580125|ACTIVE_COMPARATOR|A4|
62761342|NCT00580125|EXPERIMENTAL|A3|
62761343|NCT00580125|EXPERIMENTAL|A1|
62761344|NCT00821249|EXPERIMENTAL|ARRY-520|
62761345|NCT00821249|EXPERIMENTAL|ARRY-520 + G-CSF support|
62381503|NCT01896466|EXPERIMENTAL|Older Fallers - Intervention|Subjects who are age 65+ with a history of 1-3 falls in the previous six months will participate in Cranial Nerve Non-Invasive Neuromodulation enhanced gait and balance training.
62761346|NCT00821249|EXPERIMENTAL|ARRY-520 + dexamethasone + G-CSF support|
62761347|NCT04054492|EXPERIMENTAL|sIPV+bOPV+bOPV|202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively
62381504|NCT01896466|ACTIVE_COMPARATOR|Young Adult - Control|Healthy subjects between the ages of 18-39 will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
62381505|NCT05643170|EXPERIMENTAL|KarXT|
62381506|NCT06129006|ACTIVE_COMPARATOR|group A shoulder anterior capsular infiltration plus hydrodilatation with steroids.|25 patients with frozen shoulders treated with ultrasound-guided shoulder anterior capsular infiltration plus hydrodilatation with steroids.
62381507|NCT06129006|ACTIVE_COMPARATOR|groupB shoulder anterior capsular infiltration plus hydrodilatation with hyalase.|25 patients with frozen shoulders treated with ultrasound-guided shoulder anterior capsular infiltration plus hydrodilatation with hyalase.
62381508|NCT02089191|OTHER|DACP/MyDay|Nelfilcon A contact lenses worn in Period 1, with stenfilcon A contact lenses in Period 2. Each product worn bilaterally for 12 hours over 1 day.
62381509|NCT02089191|OTHER|MyDay/DACP|Stenfilcon A contact lenses worn in Period 1, with nelfilcon A contact lenses in Period 2. Each product worn bilaterally for 12 hours over 1 day.
62381510|NCT00663533|NO_INTERVENTION|Device study only.|
62381511|NCT05516615||Healthy volunteers|"1. Aged more than 35~2. No known current or pre-existing problems that would affect the cardiovascular or respiratory system"
62381512|NCT05516615||Patient population|"1. Aged more than 35~2. Referral of subjects with known or suspected CAD for adenosine stress first-pass perfusion MRI based on the clinical judgement of their referring physician"
62761348|NCT04054492|ACTIVE_COMPARATOR|sIPV+sIPV+bOPV|197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively
62761349|NCT04054492|ACTIVE_COMPARATOR|sIPV+sIPV+sIPV|205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively
62761350|NCT01485380|EXPERIMENTAL|Active study arm|Subjects recruited into this study will be required to undergo two magnetic resonance imaging- positron emission tomography (MRI-PET) scans of the brain in addition to high density electroencephalogram (EEG) acquisition. The first scan will be a baseline scan while the second scan will be performed while dexmedetomidine is being infused.
62761351|NCT00835809||Acute respiratory diseases.|Patient admit in emergency or intensive care unite with acute respiratory insufficiency.
62761352|NCT06138444|EXPERIMENTAL|Male received functional beverages|Male received single oral dose of functional beverages from submerged fermentation of Cordyceps militaris (FCM)
62761353|NCT06138444|PLACEBO_COMPARATOR|Male received placebo|Male received placebo
62761354|NCT06138444|EXPERIMENTAL|Female received functional beverages|Female received single oral dose of functional beverages from submerged fermentation of Cordyceps militaris (FCM)
62761355|NCT06138444|PLACEBO_COMPARATOR|Female received placebo|Female received placebo
62761356|NCT02358044|EXPERIMENTAL|Grazoprevir + Elbasvir|Participants receive a fixed-dose combination (FDC) tablet of 100 mg grazoprevir and 50 mg elbasvir for 12 weeks, followed by 24 weeks of follow-up.
62381513|NCT02061540|EXPERIMENTAL|LUM001|LUM001 administered orally once each day
62381514|NCT02109939|ACTIVE_COMPARATOR|GeneSight Psychotropic Tested|Subjects being tested with GeneSight Psychotropic
62761357|NCT02358044|ACTIVE_COMPARATOR|SOF + PR|Participants receive SOF (400 mg) combined with PegIntron (1.5 mcg/kg) plus RBV (1000-1200 mg weight-based dose) for 12 weeks, followed by 24 weeks of follow-up.
62761358|NCT03224403|EXPERIMENTAL|Test acetaminophen|Test acetaminophen 1000 mg dose
62761359|NCT03224403|ACTIVE_COMPARATOR|Commercial acetaminophen|Commercial acetaminophen 1000 mg dose
62761360|NCT03224403|ACTIVE_COMPARATOR|Commercial ibuprofen|Commercial ibuprofen, 400 mg dose
62761361|NCT03224403|PLACEBO_COMPARATOR|Placebo|Placebo
62761362|NCT01661998||Harms Study Group|
62761363|NCT05993273|EXPERIMENTAL|Epidural|In patients randomized to this Arm, before the induction of general anesthesia, the epidural catheter is placed in the intervertebral space (T4-T5, T5-6 or T6-T7) and used intra and post-operatively for administration of local anesthetics.
62761364|NCT05993273|EXPERIMENTAL|ESP block|In patients randomized to this Arm, after induction of general anesthesia the Erector spinae plane (ESP) block is performed with a catheter introduced and left in place for continuous postoperative infusion of local anesthetics.
62761365|NCT05993273|EXPERIMENTAL|Cryoanalgesia|In patients randomized to this Arm, after induction of general anesthesia and single lung ventilation the first thoracoscopic surgical access is performed. A cryoanesthesia device with a dedicated atraumatic angled-tip cryoprobe is inserted through the thoracoscopic access and the active tip of the probe is positioned in contact with the intercostal nerves from T3 to T8.
62761366|NCT03963089|EXPERIMENTAL|Study group|"Measure pulse pressure variation and systolic pressure variation after each set of tidal volume to 6mL/kg, 10mL/kg and 14mL/kg. Measure respiratory variation of aortic blood flow peak velocity via transesophageal echocardiography at tidal volume of 10mL/kg.~Measure stroke volume index via transesophageal echocardiography before and 5 min after fluid loading with 10mL/kg of crystalloid."
62761367|NCT03286777|PLACEBO_COMPARATOR|Placebo|Mannitol and silicon dioxide
62761368|NCT03286777|EXPERIMENTAL|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide
62761369|NCT03286777|EXPERIMENTAL|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant
62761370|NCT01933126|EXPERIMENTAL|HCG administration|Intrauterine HCG injection
62761371|NCT01933126|PLACEBO_COMPARATOR|Placebo|G2 Medium
62761372|NCT01548976||The study population|Patients suffering from pelvic organ prolapse and/or urinary incontinence and/or fecal incontinence. See inclusion/exclusion criteria.
62761373|NCT01768156|EXPERIMENTAL|Study arm|
62761374|NCT02670798|NO_INTERVENTION|Control|Standard of care hematologic management in the operating room
61987798|NCT05004376|EXPERIMENTAL|Non-adherent intervention|Intervention subjects will receive the text messaging intervention and a 150 day follow-up phone call.
62761375|NCT02670798|EXPERIMENTAL|Study|Standard of care hematologic management plus additional monitoring with the intervention of Thromboelastography laboratory testing and use of a thromboelastography-guided transfusion protocol.
62761376|NCT03887065|EXPERIMENTAL|Starting dose|Three to five patients will receive a daily dose of 1 mg/kg JM-4 (in normal saline) delivered via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
62761377|NCT03887065|EXPERIMENTAL|Intermediate dose of JM-4|Three to five patients will receive a daily dose of 4 mg/kg of JM-4 (in normal saline) via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
62761378|NCT03887065|EXPERIMENTAL|High dose of JM-4|Three to five patients will receive a daily dose of 9 mg/kg of JM-4 (in normal saline) via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
62761379|NCT02102542||Antisialagouge|A group of patients enrolled to prove efficacy of Glyco-P for reduction of secretions.
62761380|NCT02102542||Bradycardia|A group of patients enrolled to prove efficacy of Glyco-P for modest increase of heart rate.
62761381|NCT02102542||For reversal of neuromuscular blocking agents|Group of patients enrolled to prove efficacy of Glyco-P when used in combination with neostigmine to reserve neuromuscular blocking agents.
62761382|NCT02332772||Data Collection Endoscopy of Colon Polyps|Data collected from endoscopy reports and electronic medical record system to complete a descriptive analysis of the 1) demographics, 2) colonoscopy resection procedure, and 3) outcome of resection - immediate and delayed complications, tumor recurrence, and cancer during follow-up 01/01/2014 - 12/31/2025.
62761383|NCT04575818|EXPERIMENTAL|GLPG4059 SAD|Single doses of GLPG4059 at up to 6 dose levels in ascending order
62761384|NCT04575818|PLACEBO_COMPARATOR|Placebo SAD|Single doses of placebo
61987799|NCT01820455|ACTIVE_COMPARATOR|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal Mupirocin ointment daily for 5 days
62381515|NCT02109939|PLACEBO_COMPARATOR|Treatment As Usual|This group of subjects will not see their GeneSIght results or know whether or not they are in either arm until after week 12.
62381516|NCT06365957|EXPERIMENTAL|High-intensity interval exercise (HIIE)-Ketone Supplementation (KT) condition|High-intensity interval exercise (HIIE) with ketone supplements \[R-1,3-butanediol; San Francisco\].
62381517|NCT06365957|EXPERIMENTAL|MICE-KT condition|moderate-intensity continuous exercise (MICE) with ketone supplements.
62381518|NCT06365957|EXPERIMENTAL|Nonexercise (NE)-KT condition|Non-exercise with ketone supplements.
62761385|NCT04575818|EXPERIMENTAL|GLPG4059 rBA/FE oral suspension fasted|Single dose of GLPG4059 in fasted state
62761386|NCT04575818|EXPERIMENTAL|GLPG4059 rBA/FE tablet fed|Single dose of GLPG4059 in fed state
62761387|NCT04575818|EXPERIMENTAL|GLPG4059 rBA/FE tablet fasted|Single dose of GLPG4059 in fasted state
62761388|NCT01416441|EXPERIMENTAL|Aripiprazole|Participants received oral aripiprazole tablets once weekly (QW) with a titrated dose starting from 52.5 milligram (mg), on Day 1 and increasing to 77.5 mg and 110 mg for the remainder of the trial (Up to Week 52), the dose could be adjusted between these 3 dose levels as determined by investigator's discretion based on safety and tolerability.
62761389|NCT00837876|EXPERIMENTAL|Treatment|Sorafenib + Erlotinib
61987800|NCT01820455|PLACEBO_COMPARATOR|Soap baths, Lubricating jelly|Soap and water baths with lubricating jelly to each nare daily for 5 days
62761390|NCT03776773|ACTIVE_COMPARATOR|patients AR (+) and sleep apnea (+)|Patients with AR and obstructive sleep apnea (OSA) will have sleep and pollution exposure recordings
62761391|NCT03776773|ACTIVE_COMPARATOR|AR (-) and sleep apnea (+)|Patients without allergic rhinitis (+ sleep apnea) will have sleep and pollution exposure recordings
62761392|NCT03776773|ACTIVE_COMPARATOR|AR (+) and sleep apnea (-)|Patients with allergic rhinitis but no sleep apnea will have sleep and pollution exposure recordings
62761393|NCT03776773|SHAM_COMPARATOR|AR (-) and sleep apnea (-)|Volunteers without allergic rhinitis and no sleep apnea will have sleep and pollution exposure recordings
62761394|NCT06456125|EXPERIMENTAL|amber SEL-P Treatment|Patients requiring peripheral embolization: vascular anomalies, hemorrhages, aneurysms, and pseudoaneurysms, varicose veins (including varicocele and pelvic congestion syndrome), portal vein, hypervascular tumors, type -II endoleaks, and pathological organs.
61987801|NCT01028508|ACTIVE_COMPARATOR|PHARM|lithium and venlafaxine
61987802|NCT01028508|EXPERIMENTAL|STABLE|ECT + VLF + Li
62381519|NCT06365957|EXPERIMENTAL|HIIE-Placebo (PLA) condition|HIIE with taste-matched placebo
62381520|NCT06365957|EXPERIMENTAL|MICE-PLA condition|MICE with taste-matched placebo
61987803|NCT03342547|EXPERIMENTAL|Intestinal stem cell-derived enteroids|Duodenal biopsy samples and saliva will be collected from participants and then processed in laboratory to generate intestinal stem cell-derived enteroids.
62381521|NCT06365957|EXPERIMENTAL|NE-PLA condition|Non-exercise with taste-matched placebo
62381522|NCT05487976|EXPERIMENTAL|Recombinant human activated coagulation factor VII for injection|Each subject in this study received on-demand treatment with recombinant human activated coagulation factor VII for injection for 24 weeks. The single dose for each bleeding event was 90 μg/kg, and the number of doses was increased according to the remission after treatment.
62761395|NCT02128243|EXPERIMENTAL|Arm A: De-escalation therapy|Patients in Arm A will continue with S-1 de-escalation phase starting at week 13 until disease progression, toxicities requiring discontinuation, withdrawal of consent, pregnancy, death or lost to follow up whichever occurs first. In patients with drug-related severe toxicity S-1 dose will be adjusted or study treatment will be terminated.
62761396|NCT02128243|EXPERIMENTAL|Arm B: Chemotherapy by Investigator's choice|Patients in Arm B will continue to receive the same polychemotherapy as during induction therapy until tumor progression, toxicities requiring discontinuation, withdrawal of consent, pregnancy, death or loss to follow up whichever occurs first.
62761397|NCT03023696|EXPERIMENTAL|Foraminotomy Group|Prophylactic bilateral cervical keyhole foraminotomy will be done in addition to their decompression surgery
62761398|NCT03023696|ACTIVE_COMPARATOR|Control Group|Cervical decompression will be done without prophylactic bilateral foraminotomy
62761399|NCT04562597|PLACEBO_COMPARATOR|Dose Response Curve Placebo|5 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
62761400|NCT04562597|ACTIVE_COMPARATOR|Dose Response Curve N-acetylcysteine 50 mg/kg|5 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
62761401|NCT04562597|ACTIVE_COMPARATOR|Dose Response Curve N-acetylcysteine 100 mg/kg|5 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.
62761402|NCT04562597|ACTIVE_COMPARATOR|Dose Response Curve N-acetylcysteine 150 mg/kg|5 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
62761403|NCT04562597|ACTIVE_COMPARATOR|Opioid Reduction with Optimal N-acetylcysteine Dose|Once the optimal N-acetylcysteine dose is identified, 15 additional participants will be randomized to the optimal dose to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose. Primary and secondary outcomes will only be evaluated for the placebo group and optimal NAC group.
62761404|NCT04562597|PLACEBO_COMPARATOR|Placebo|15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose. Primary and secondary outcomes will only be evaluated for the placebo group and optimal NAC group.
62761405|NCT01994863|EXPERIMENTAL|First Coloplast Test product; then Standard Care (see below)|"The subjects are randomised to test Coloplast Test product first and thereafter test Standard Care.~Standard Care is a collection of three different already marketed 1-piece flat ostomy appliances. These are Coloplast Sensura 1-piece; Hollister: Moderma 1-piece and B.Braun Flexima 1-piece.~The three Standard Care products were tested in a 1:1:1 randomisation."
62761406|NCT01994863|EXPERIMENTAL|First Standard Care (see below); Then coloplast test product|"The subjects are randomised to test Standard care first and thereafter test Coloplast test product.~Standard Care is a collection of three different already marketed 1-piece flat ostomy appliances. These are Coloplast Sensura 1-piece; Hollister: Moderma 1-piece and B.Braun Flexima 1-piece.~The three Standard Care products were tested in a 1:1:1 randomisation."
62761407|NCT04039607|EXPERIMENTAL|Nivolumab + Ipilimumab|
62761408|NCT04039607|ACTIVE_COMPARATOR|Sorafenib/lenvatinib|
62381523|NCT00193726|EXPERIMENTAL|Arm B- Experimental|Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
62381524|NCT00193726|PLACEBO_COMPARATOR|Arm A - Placebo|Tab Placebo once a day for 5 days prior to each cycle of chemotherapy
62761409|NCT00413374|OTHER|Enoxaparin|
62761410|NCT06521073|EXPERIMENTAL|Experimental|Before Surgery HBF ONE SAO Patient Education Material Post-Operation (1st, 2nd, 3rd day) ONE SAO Patient Education Material 10-14. BI and PSA will be applied on days and 6 weeks.
62761411|NCT06521073|NO_INTERVENTION|Control|Before Surgery HBF ONE SAO Routine verbal training of the clinic Post-Operation (1st, 2nd, 3rd day) ONE SAO Routine verbal training of the clinic 10-14. BI and PSA will be applied on days and 6 weeks.
62761412|NCT02441348||CTT group|CTT will be initiated in a prospective fashion to study population
62761413|NCT01444586||Group 1|
62761414|NCT01667146|EXPERIMENTAL|PHARLAP ventilation group|PHARLAP mechanical ventilation strategy
62381525|NCT02790450|EXPERIMENTAL|Benzbromarone|1x200mg Benzbromarone
62381526|NCT05797727|EXPERIMENTAL|LifeChamps Platform|Participants will be asked to use the LifeChamps platform and will be provided with the study equipment.
62381527|NCT05797727|EXPERIMENTAL|LifeChamps Platform HCP|Participating Healthcare professionals will be asked to use the LifeChamps Dashboard
62381528|NCT02850276|EXPERIMENTAL|Pyridostigmine|30mg PO three times a day
62381529|NCT03206606||Control Group|Primary care physicians and residents in family medicine of family medicine units affiliated with Laval University.
62381530|NCT03206606||Experimental Group|Primary care physicians and residents in family medicine of family medicine units affiliated with Laval University that will use the mobile application SPIRO(c) for a period of four months.
62381531|NCT03598140|PLACEBO_COMPARATOR|Placebo oral capsule|If randomized to placebo, the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
62381532|NCT03598140|ACTIVE_COMPARATOR|Sildenafil Citrate|If randomized to sildenafil (60mg), the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
61987804|NCT04964128|EXPERIMENTAL|meal gesture dosing for unannounced meals within the AHCL System|
62381533|NCT00352170|EXPERIMENTAL|1|calcium supplementation
62381534|NCT00352170|EXPERIMENTAL|2|calcium and vitamin D3 supplementation
62381535|NCT00352170|EXPERIMENTAL|3|placebo
62381536|NCT03494946|EXPERIMENTAL|Arm A|Patients that suffer from Colorectal cancer and metastasis to liver that are randomized to Group A, will undergo Liver transplantation
62381537|NCT03494946|ACTIVE_COMPARATOR|Arm B|Patients that suffer from Colorectal cancer and metastasis to liver that are randomized to Group B, will be given chemotherapy, TACE, SIRT or other available treatment options.
62381538|NCT05824611||participants|patients with epilepsy included in the study at one of the study locations
62381539|NCT00033293|EXPERIMENTAL|Arm I (chemotherapy, immunoglobulin therapy)|"Patients with intermediate-risk or high-risk neuroblastoma receive chemotherapy (including cyclophosphamide) according to the standard of care for the stage of primary neuroblastoma, beginning on day 0. Patients with low-risk neuroblastoma (and not receiving other chemotherapy) receive cyclophosphamide IV over 1 hour on day 0. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. All patients receive oral prednisone twice daily for 3 months and then every other day for 7-15 months.~Patients receive immune globulin IV on days -2 and -1, at weeks 4, 8, 12, 16, 20, and 24, and then at months 8, 10, and 12 after therapy. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with no response after 6 months go off treatment."
62761415|NCT01667146|ACTIVE_COMPARATOR|Control group ventilation|Control group mechanical ventilation strategy
62761416|NCT04859257||Disease Group|Cohort 1 (Disease Group) of the study will collect blood and urine samples from participants who are either diagnosed with Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) or experience symptoms of profound fatigue based on the cohort specific inclusion criteria.
62761417|NCT04859257||Control Group|Cohort 2 (Control Group) of the study will collect blood and urine samples from participants who have NOT been diagnosed with Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) or experience symptoms of profound fatigue based on the cohort specific exclusion criteria.
62761418|NCT04542096||Group1|Patients receiving invasive respiratory therapy (intubated)
62761419|NCT04542096||Group2|Patients receiving non-invasive respiratory therapy.
62761420|NCT03523273|EXPERIMENTAL|Liraglutide|Liraglutide initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
62761421|NCT03523273|EXPERIMENTAL|Placebo|Placebo initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
62761422|NCT05564884||Unvaccinated, Prior natural COVID-19 infection|Unvaccinated, Prior natural COVID-19 infection
62761423|NCT05564884||Vaccinated, No prior natural COVID-19 infection|Vaccinated, No prior natural COVID-19 infection
62761424|NCT05564884||Vaccinated, Prior natural COVID-19 infection|Vaccinated, Prior natural COVID-19 infection
62761425|NCT01611051|EXPERIMENTAL|Pegylated rhG-CSF: 100µg/kg|Chemtherapy naive patients receiving chemotherapy and Pegylated rhG-CSF 100µg/kg
62761426|NCT01611051|EXPERIMENTAL|Pegylated rhG-CSF: 6mg|Chemtherapy naive patients receiving chemotherapy and Pegylated rhG-CSF 6mg
62761427|NCT01611051|ACTIVE_COMPARATOR|rhG-CSF 5ug/kg/day|Chemtherapy naive patients receiving chemotherapy and rhG-CSF 5ug/kg/day
62761428|NCT03990103|EXPERIMENTAL|Experimental arm|S1+Paclitaxel (IV\&IP)+Bevacizumab (IP)
62761429|NCT03990103|ACTIVE_COMPARATOR|Control arm|S1+Oxaliplatin (IV)
62761430|NCT05258084|EXPERIMENTAL|initiative group|1st and 2nd year nursing students who have not received education for sexual minorities before and continue their education at a university. Sexual minority awareness training will be applied to this group
62761431|NCT05258084|NO_INTERVENTION|control group|1st and 2nd year nursing students who have not received education for sexual minorities before and continue their education at a university. Sexual minority awareness training will not be applied to this group
62761432|NCT02650271|EXPERIMENTAL|Entecavir|Patients will be received entecavir (10 mg/d) after 3 days of liver resection.
62761433|NCT02650271|ACTIVE_COMPARATOR|Tenofovir|Patients will be received tenofovir (1#/d) after 3 days of liver resection.
62761434|NCT02635334|EXPERIMENTAL|Montelukast 10 mg daily for 8 weeks|Study subjects will take montelukast 10 mg orally daily for 8 weeks
61987805|NCT00714519|EXPERIMENTAL|1|
61987806|NCT00714519|PLACEBO_COMPARATOR|2|
62761435|NCT02635334|PLACEBO_COMPARATOR|Placebo daily for 8 weeks|Study subjects will take placebo orally daily for 8 weeks
62761436|NCT01503996||glaucoma|hospitalized glaucoma patients
62761437|NCT01503996||controls|hospitalized patients without glaucoma
62761438|NCT02956304|OTHER|Group iTBS-cTBS-SHAM|PMv stimulation (iTBS) at session 2, PMv inhibition (cTBS) at session 3, and control (SHAM) at session 4
62761439|NCT02956304|OTHER|Group iTBS-SHAM-cTBS|PMv stimulation (iTBS) at session 2, control (SHAM) at session 3, and PMv inhibition (cTBS) at session 4
62761440|NCT02956304|OTHER|Group cTBS-iTBS-SHAM|PMv inhibition (cTBS) at session 2, PMv stimulation (iTBS) at session 3, and control (SHAM) at session 4
62761441|NCT02956304|OTHER|Group cTBS-SHAM-iTBS|PMv inhibition (cTBS) at session 2, control (SHAM) at session 3, and PMv stimulation (iTBS) at session 4
62761442|NCT02956304|OTHER|Group SHAM-iTBS-cTBS|control (SHAM) at session 2, PMv stimulation (iTBS) at session 3, and PMv inhibition (cTBS) at session 4
62182513|NCT05623813||Group-based education|"Participants in the group-based education would receive the same education on sternal precautions to facilitate engagement in daily activities.The group-based education included between two and five participants.~They were invited to ask questions about their recovery and voice any concerns they had about being discharged home specific to their needs, covering a tailored portion of the education. Participants in group-based education had a chance to share their experiences and concerns with the group members."
62381540|NCT00033293|ACTIVE_COMPARATOR|Arm II (chemotherapy, observation)|"Patients with intermediate-risk or high-risk neuroblastoma receive chemotherapy (including cyclophosphamide) according to the standard of care for the stage of primary neuroblastoma, beginning on day 0. Patients with low-risk neuroblastoma (and not receiving other chemotherapy) receive cyclophosphamide IV over 1 hour on day 0. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. All patients receive oral prednisone twice daily for 3 months and then every other day for 7-15 months.~Patients do not receive immune globulin. Patients with unresponsive opsoclonus-myoclonus-ataxia syndrome after 2 months or progression after 6 months may cross over to arm I."
62381541|NCT02481986|EXPERIMENTAL|Community health worker|Participants in this arm will be offered 10 home visits in a 12-month period from community health workers (CHWs). Visits will cover a core asthma curriculum and provide social support.
62381542|NCT02481986|ACTIVE_COMPARATOR|Certified asthma educator|Participants in this arm will be offered 2 education sessions with a certified asthma educator in the clinic at start of the study and again at 6-months. These sessions will be followed by a telephone call from the certified asthma educator several weeks after the sessions.
62381543|NCT00826540|EXPERIMENTAL|Treatment (sorafenib tosylate and bevacizumab)|Patients receive sorafenib tosylate orally twice daily on days 1-5 and 8-12 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Blood samples are collected at baseline and then periodically during study treatment for laboratory biomarker and pharmacogenetic studies
62381544|NCT00794235|OTHER|Sorafenib and Dacarbacine|
62381545|NCT03704428|EXPERIMENTAL|Cohort 1|Multiple subcutaneous injections of SHR-1314 dose 1
62381546|NCT03704428|EXPERIMENTAL|Cohort 2|Multiple subcutaneous injections of SHR-1314 dose 2
62761443|NCT02956304|OTHER|Group SHAM-cTBS-iTBS|control (SHAM) at session 2, PMv inhibition (cTBS) at session 3, and PMv stimulation (iTBS) at session 4
62761444|NCT01188148|ACTIVE_COMPARATOR|VPA & Placebo|VPA \& Placebo
62761445|NCT01188148|EXPERIMENTAL|VPA & memantine|
62761446|NCT03467490|EXPERIMENTAL|Treatment|65 participants will be invited to receive a one-day educational intervention (first study visit) at the Ivey Eye Institute. The educational intervention includes watching a short video series and receiving educational handouts which summarize the content of the videos. Participants will have access to the educational handbook for reference. At two months post-intervention, participants will be invited back to St. Joseph's Hospital to complete the second administration of the heiQ and OSDI. Participants will have an opportunity to ask the ophthalmologist any question during the question and answer period. Participants will then be asked to provide feedback on the video series using a participation satisfaction survey and will be given an educational handbook which may be used to as a reference/guide on how to self-manage
62761447|NCT03467490|NO_INTERVENTION|Control|Patients will continue with treatment as usual without any educational intervention. They will complete the heiQ and OSDI at baseline and 2 months later during a routine office visit. At the 2-month visit, participants will be asked to complete the second administration of the heiQ and OSDI before being offered the opportunity to view the videos series, receive the educational handbook, and provide feedback on the educational material.
62761448|NCT04161378||RHB-SG 01|Patients with early mobilization (\< 2 days after the onset of symptoms)
62761449|NCT04161378||RHB-SG 02|Patients with delayed mobilization after AMI (\>2 days after the onset of symptoms)
62761450|NCT00751283|EXPERIMENTAL|1|GRST Peripheral Catheter System
62761451|NCT03582813|EXPERIMENTAL|Self-directed care|Subjects receive traditional behavioral health and non-traditional services via a self-directed care model in which they develop a person-directed plan and create a budget for the purchase of medically necessary goods and services. Program staff acting as service brokers help them secure needed goods and services from within or outside the public behavioral health provider system. A fiscal intermediary manages financial resources to pay providers and enable the purchase of approved goods..
62761452|NCT03582813|ACTIVE_COMPARATOR|Services as usual|Subjects receive traditional behavioral health services as usual via the traditional service delivery system and its network of providers.
62761453|NCT00685646|EXPERIMENTAL|Arm I|Patients receive maximum androgen-blockade therapy and zoledronic acid for up to 24 courses.
62761454|NCT00685646|ACTIVE_COMPARATOR|Arm II|Patients receive maximum androgen-blockade therapy for up to 24 courses.
62381547|NCT03704428|EXPERIMENTAL|Cohort 3|Multiple subcutaneous injections of SHR-1314 dose 3
62381548|NCT03704428|EXPERIMENTAL|Cohort 4|Multiple subcutaneous injections of SHR-1314 dose 4
62381549|NCT03704428|EXPERIMENTAL|Cohort 5|Multiple subcutaneous injections of SHR-1314 dose 5
62761455|NCT02189499|EXPERIMENTAL|Coronary Scaffold Implantation|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
62761456|NCT06287619|EXPERIMENTAL|Intervention Group|Patients randomized to the IV iron group will receive 1000 mg ferric derisomaltose (Monoferric) diluted in 100 mL of 0.9 % sodium chloride solution, via intravenous infusion over 1 hour using an opaque IV bag and tubing for blinding.
62761457|NCT06287619|PLACEBO_COMPARATOR|Control group|Patients randomized to the placebo group will receive 100 mL of 0.9 % sodium chloride solution via intravenous infusion using an opaque IV bag and tubing for blinding.
62761458|NCT02885857|EXPERIMENTAL|Shenyan kangfu Tablets|Shenyan Kangfu Tablets；Each weighing 0.48g；Oral；Once five, three times a day
62761459|NCT02523625||Healthy volunteers|Age and gender matched to patient groups to undergo ultrasound of temporal and axillary arteries
62761460|NCT02523625||Patients with headache|Patients with new headache not due to GCA to undergo ultrasound of temporal and axillary arteries
62761461|NCT02523625||Patients with GCA (new)|Patients with new diagnosis of GCA to undergo ultrasound of temporal and axillary arteries
62761462|NCT02523625||Patients with GCA (flare)|Patients with apparent flare of GCA to undergo ultrasound of temporal and axillary arteries
62381550|NCT04835740|ACTIVE_COMPARATOR|Conventional Rehabilitation|Based on the functional capacity of each participant, customized Aerobic exercise plan was designed by the on-site physiotherapist.
62381551|NCT04835740|EXPERIMENTAL|Combined Training (conventional rehabilitation plus high-intensity interval training):|The patients received 40 minutes of High intensity interval treadmill training in addition to their normal conventional rehabilitation.
62381552|NCT04475029|EXPERIMENTAL|Methadone|A 10 ml syringe with 2 mg/ml of methadone will be prepared and and study drug will be administered as intravenous bolus dose (0.15 mg/kg treatment weight (height (cm) - 100)). The study drug will be administered 1 hour prior to expected extubation.
62381553|NCT04475029|ACTIVE_COMPARATOR|Morphine|A 10 ml syringe with 2 mg/ml of morphine will be prepared and and study drug will be administered as intravenous bolus dose (0.15 mg/kg treatment weight (height (cm) - 100)). The study drug will be administered 1 hour prior to expected extubation.
62761463|NCT06225947||Lemborexant(LEM)|Subjects will be administered with Lemborexant(LEM). The dosage of LEM is 5 mg or 10mg taken no more than once per night during the study.
62761464|NCT00123266|EXPERIMENTAL|Active|
62761465|NCT01497821|EXPERIMENTAL|Dose exploration|Pre-specified nominal doses are proposed in the dose exploration at two dosing frequencies: every two weeks and every three weeks. Intermediate doses may also be used if required based on the Continuous Reassessment Method (CRM) design.
62761466|NCT01497821|EXPERIMENTAL|Dose expansion|Dose and dosing frequency selected from Part 1 dose exploration.
62761467|NCT04773873|ACTIVE_COMPARATOR|Arm 1: Porcelain fused to metal (PFM)|Implant screw-retained PFM crown fabricated by a laboratory using a gold coping cast-on synOcta gold abutment (Ceramicor) for wide (WN) or regular (RN) neck
62381554|NCT00138853|ACTIVE_COMPARATOR|Tantalum knee|Tantalum Tibial component, uncemented
62761468|NCT04773873|EXPERIMENTAL|Arm 2: Hybrid abutment Lithium disilicate (e.max CAD)|Hybrid crown abutment: chairside-made perforated CAD-CAM Lithium disilicate crown (IPS e.max CAD LT A16) adhesively cemented to a TiBase and screw-retained to a Straumann titanium implant (regular and wide neck)
62381555|NCT00138853|ACTIVE_COMPARATOR|Titanium Knee|Titanium Tibial Component, screw fixed
62381556|NCT06177210||Lifestyle intervention|Participants who achieved type 2 diabetes (T2D) remission through lifestyle interventions.
62381557|NCT06177210||Bariatric surgery|Participants who achieved type 2 diabetes (T2D) remission through bariatric surgery.
62381558|NCT03770936|NO_INTERVENTION|Control group|No intervention
62381559|NCT03770936|ACTIVE_COMPARATOR|Candesartan|Candesartan 8 mg/day
62381560|NCT03770936|ACTIVE_COMPARATOR|Ramipril|Ramipril 1.25 mg/day
62761469|NCT04773873|EXPERIMENTAL|Arm 3:Hybrid abutment ceramic polymer infiltrated (Enamic)|Hybrid crown abutment: chairside-made perforated CAD-CAM ceramic-polymer infiltrated crown (Enamic) adhesively cemented to a TiBase and screw-retained to a Straumann titanium implant (regular and wide neck)
62761470|NCT03819608|EXPERIMENTAL|real APT+ real iTBS|real APT+ real iTBS included 30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. iTMS will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (\~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right dorsolateral prefrontal cortex at 80% active motor threshold .
62761471|NCT03819608|ACTIVE_COMPARATOR|real APT + placebo iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
62761472|NCT03819608|ACTIVE_COMPARATOR|placebo APT+ real iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Bursts of TMS pulses will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (\~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right DLPFC at 80% active motor threshold .
62761473|NCT03819608|ACTIVE_COMPARATOR|placebo APT+ placebo iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
62381561|NCT01920516||Melphalan|"Day +1:~Intra femoral infusion of Melphalan at the dosage 1mg/ Kg~Intra femoral infusion of Melphalan Second ILI treatment can be repeated at side effects recovery ( following oncologist ' s planning of cure).~Day +30: The above procedure is repeated.~Day +90: In case of response, a third administration following the above procedures will be repeated."
62381562|NCT01513694|EXPERIMENTAL|MSC seeded onto a phosphate ceramic|Instrumented posterolateral fusion and autologous mesenchymal stem cells arranged in a phosphate ceramic.
62381563|NCT03474627|ACTIVE_COMPARATOR|Non-coated HA/TCP particles|Biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
62381564|NCT03474627|EXPERIMENTAL|PLGA-coated HA/TCP particles|Biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
62381565|NCT02366715|EXPERIMENTAL|HeatedHumidifiedHighFlowNasalCannula|Treatment for moderate-severe cases of Bronchiolitis while monitoring medical parameters
62381566|NCT01279954|EXPERIMENTAL|open-label abatacept first, then 5 mg/kg abatacept|10 mg/kg abatacept (6 months). Then 5 mg/kg abatacept (18 months)
62761474|NCT02606435|EXPERIMENTAL|thrombus aspiration with PCI|patient will receive manual thrombus aspiration with percutaneous coronary intervention (PCI)
62761475|NCT02606435|ACTIVE_COMPARATOR|PCI alone|patients will receive percutaneous coronary intervention (PCI) alone including stent implantation
62761476|NCT04952038||ALS patients with sleep disorder|
62381567|NCT01279954|EXPERIMENTAL|open-label abatacept first, then 10 mg/kg abatacept|10 mg/kg abatacept (6 months). Then 10 mg/kg abatacept (18 months)
62381568|NCT06128642||Toe separator orthosis|The silicone toe spreader orthosis does not use tape or straps to separate the first and second toes and pull them medially to realign the first metatarsal. Orthotics reduce the pain in the bunion area by reducing the high friction between the shoe and the bunion. Participants will be asked to use their orthoses for an average of 8 hours per day for 1 month.
62381569|NCT06128642||Dynamİc orthosis|The dynamic orthosis contains a free joint that does not hinder the movement of the first metatarsophalangeal joint. The working principle of the orthosis is to provide healing of the deformity with low torque and long-term stretching. The dynamic orthosis corrects the hallux valgus angle by realigning the hallux, thus allowing plantarflexion and dorsiflexion. Participants will be asked to use their orthoses for an average of 8 hours per day for 1 month.
62381570|NCT06324175||Observational Prospective Cohort|
62381571|NCT02088736|ACTIVE_COMPARATOR|Intravenous and Intraosseous|'IV + IO' Intravenous fluids or medications needed and a peripheral IV given 2 attempts or 90 seconds. If IV is unsuccessful, IO will attempt at the Primary site (proximal tibia). If IO is unsuccessful at scene, 2nd attempt can be done in the ambulance. Adrenaline will be delivered as according to protocol.
62381572|NCT02088736|EXPERIMENTAL|Intravenous|Intravenous fluids or medications needed and a peripheral IV given 2 attempts or 90 seconds. If 1st IV is unsuccessful at scene, 2nd IV attempt can be done in the ambulance. Adrenaline will be delivered according to protocol.
62761477|NCT04952038||ALS patients without sleep disorder|
62761478|NCT01592617|EXPERIMENTAL|S-488410|
62761479|NCT02764554||Lenvatinib 4 milligram (mg) and 10 mg capsule|Participants who are prescribed with Lenvatinib per approved prescribing information of lenvatinib in normal clinical practice setting.
62182514|NCT01086384|EXPERIMENTAL|Fluticasone furoate/GW642444|
62182515|NCT01086384|EXPERIMENTAL|fluticasone furoate|
62182516|NCT03361098|EXPERIMENTAL|SGLT2 inhibitor + GLP-1 receptor agonist|dapagliflozin 10 mg tablet /day and exenatide twice daily subcutaneous injection (week 1-4; 5 microgram, week 5 -16; 10 microgram)
62182517|NCT03361098|ACTIVE_COMPARATOR|GLP-1 receptor agonist (exenatide) and placebo|GLP-1 receptor agonist exenatide twice daily in combination with placebo dapagliflozin
62381573|NCT02131571||HIV patients older than 50 years|HIV infected patients older than 50 years in current follow up
62381574|NCT00748111|EXPERIMENTAL|1|Sudden cardiac death hospitalized
62381575|NCT00748111|EXPERIMENTAL|2|Acute myocardial infarction
62381576|NCT00748111|EXPERIMENTAL|3|Angioplasty procedures programmed
62381577|NCT00748111|EXPERIMENTAL|4|Sudden cardiac death hospitalized without coronary syndrome
62381578|NCT04338542||neoadjuvant chemotherapy plus bevacizumab|Patients treated with surgery of the primary tumor, neoadjuvant chemotherapy plus bevacizumab and, finally, the surgical resection of liver metastasis.
62381579|NCT04338542||neoadjuvant chemotherapy|Patients treated with surgery of the primary tumor, neoadjuvant chemotherapy and, finally, the surgical resection of liver metastasis.
62381580|NCT04338542||control group|Patients presenting with synchronous primary tumour and metastasis resected without any preoperative systemic therapy.
62381581|NCT01782976|EXPERIMENTAL|Cilengitide + Bevacizumab|Cilengitide administered intravenously at 2000 mg twice weekly, while Bevacizumab administered intravenously at 10 mg/kg every other week. Each cycle of therapy will be 4 weeks long.
62761480|NCT02536300|EXPERIMENTAL|Idelalisib 150 mg BID|"Participants will receive idelalisib 150 mg twice daily continuously.~For participants enrolled prior to protocol amendment 5: Based on the independent review committee (IRC) response assessment, participants may be discontinued from the study or may receive blinded or open-label idelalisib 150 mg twice daily."
62381582|NCT04729699|EXPERIMENTAL|Intervention group|Intervention group (n=10) received 12 physiotherapy sessions and exercises for TMJ 30-45 minutes 2 days per week.
62381583|NCT04729699|ACTIVE_COMPARATOR|Control group|Control group (n=9) was introduced with physiotherapy program in order to perform it independently at home.
62381584|NCT06447935||Acute Eosinophilic Myocarditis|"Patients affected by Acute Eosinophilic Myocarditis with the following inclusion criteria:~1. histologically EM proven borderline (presence of inflammatory infiltrate) or active (presence of inflammatory infiltrate plus myocardial necrosis) myocarditis, according to the Dallas criteria;~2. acute presentation defined by the onset of cardiac symptoms within 30 days before admission."
62761481|NCT02536300|EXPERIMENTAL|Idelalisib 100 mg BID|"Participants will receive idelalisib 100 mg twice daily continuously. Based on the IRC response assessment, participants may either be dose escalated to open-label 150 mg twice daily or maintain blind and continue on idelalisib 100 mg twice daily.~As of protocol amendment 5, enrollment to this arm has been closed."
62761482|NCT02536300|EXPERIMENTAL|Idelalisib 150 mg BID INT|Participants will receive idelalisib 150 mg twice daily in 28-day cycles with 21 days on-treatment and 7 days off-treatment.
62761483|NCT03698175|EXPERIMENTAL|Three good things exercise|
62761484|NCT03698175|PLACEBO_COMPARATOR|Unspecific childhood memory recall exercise|
62761485|NCT02253056|EXPERIMENTAL|Fasting|Intermittent fasting over 8 weeks (one day per week)
62761486|NCT02253056|ACTIVE_COMPARATOR|Healthy diet|Regular healthy diet according to current German (DGE) guidelines for healthy nutrition.
62761487|NCT02905617||Primary Augmentation|Subjects undergoing general breast enlargement receiving Sientra Style 207 Silicone Gel Breast Implant.
62761488|NCT02905617||Revision Augmentation|Subjects undergoing revision surgery with Sientra Style 207 Silicone Gel Breast Implant to revise or improve the result of a primary breast augmentation surgery.
62761489|NCT00755469|EXPERIMENTAL|1|
62761490|NCT05892367|OTHER|Control group|Application of a compression bandage following transbrachial puncture for 24 hours
62761491|NCT05892367|ACTIVE_COMPARATOR|Study group|Application of a compression bandage and a positioning splint following transbrachial puncture for 24 hours
62381585|NCT00808028|EXPERIMENTAL|1|dose level 1 rLP2086 vaccine
62381586|NCT00808028|EXPERIMENTAL|2|dose level 2 rLP2086 vaccine
62381587|NCT00808028|EXPERIMENTAL|3|dose level 3 rLP2086 vaccine
62381588|NCT00808028|PLACEBO_COMPARATOR|4|normal saline (placebo)
62381589|NCT00303329|EXPERIMENTAL|Deferasirox|Deferasirox daily oral dose between 5-40 mg/kg/day
62381590|NCT03602742|OTHER|24-hour Holter and 14-day EZYPRO®|This is an open-label study to investigate the functional features of prolonged monitoring by 14-day EZYPRO® to improve the medical care and/or diagnosis for the patient with arrhythmia. One arm included.
62381591|NCT05322538|OTHER|Controls|Healthy controls with no known vestibular disease
62381592|NCT05322538|EXPERIMENTAL|Definite Meniere's disease|Patients with Definite Meniere's disease
62381593|NCT05289999|EXPERIMENTAL|Using the virtual reality headset for the first injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset, then the second injection following the usual conditions of care without the device
62381594|NCT05289999|EXPERIMENTAL|Using the virtual reality headset for the second injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus following the usual conditions of care, then the second injection using the virtual reality headset
62381595|NCT00928499|OTHER|Interstim - continuous|Continuous stimulation
62381596|NCT00928499|OTHER|Interstim - cyclic|Cyclic stimulation
62761492|NCT01404013|ACTIVE_COMPARATOR|Montelukast|Monotherapy with Montelukast 10mg, take orally ,every night,for 8 weeks
62761493|NCT01404013|ACTIVE_COMPARATOR|ICS/LABA and Montelukast|Combination therapy with inhaled corticosteroid/β2 agonist 160/4.5ug,twice a day and Montelukast 10mg，take orally,every night for 8 weeks
62761494|NCT01404013|ACTIVE_COMPARATOR|ICS/LABA|Monotherapy with corticosteroid/β2 agonist 160/4.5ug,inhaled, twice a day, for 8 weeks
62761495|NCT05516849|EXPERIMENTAL|Oxandrolone|Participants will be randomly assigned in a 1:1 fashion to one of the two treatment arms using the REDCap database randomization procedure.
62761496|NCT05516849|PLACEBO_COMPARATOR|Placebo|Participants will be randomly assigned in a 1:1 fashion to one of the two treatment arms using the REDCap database randomization procedure.
62761497|NCT03301064|EXPERIMENTAL|Intervention Condition: MET/SBCM|The combined Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM) intervention will be used in the proposed study. The intervention consists of three 1-hour sessions. The sessions are structured to provide feedback to participants about their risks associated with alcohol use and to help them identify barriers and motivators to change. The sessions will aim to reduce drinking by promoting self-efficacy to change, setting goals and fostering utilization of medical, mental health and social services as needed. A comprehensive list of referrals will be provided. Sessions will occur 1-2 weeks apart.
62761498|NCT03301064|ACTIVE_COMPARATOR|Control Condition: Alcohol education brochure|Participants randomized to the control condition will be receive a Spanish-language version of an alcohol education brochure. Participants will be encouraged to read the brochure. The brochure will provide information about defining heavy drinking, harmful effects of drinking and symptoms of an alcohol use disorder. Control group participants will also receive a list of available clinics and resources from Providence staff. After the baseline visit participants in the control group will be contacted by phone twice over the next 4 weeks by the promotores to remind them about the 3-month follow-up appointment.
62761499|NCT06508645|PLACEBO_COMPARATOR|Part1 Treatment Group_1|"Part1 Treatment Group_1_low dose DWP14012 injection Amg, Multiple administration, 7 days~Placebo: Normal saline"
62761500|NCT06508645|PLACEBO_COMPARATOR|Part1 Treatment Group_2|"Part1 Treatment Group_2_medium dose DWP14012 injection Bmg, Multiple administration, 7 days~Placebo: Normal saline"
62761501|NCT06508645|PLACEBO_COMPARATOR|Part1 Treatment Group_3|"Part1 Treatment Group_3_high dose DWP14012 injection Cmg, Multiple administration, 7 days~Placebo: Normal saline"
62761502|NCT06508645|EXPERIMENTAL|Part2 Treatment Group|"Part2 Treatment Group_continuous intravenous administration~- DWP14012 injection Dmg, Loading dose / DWP14012 injection Emg for 3 days, Maintenance dose"
62381597|NCT05086640|EXPERIMENTAL|Lemon foot|Application of Lemon in the Prevention of Blisters on one feet
62182518|NCT03361098|ACTIVE_COMPARATOR|SGLT2 inhibitor (dapagliflozin) and placebo|SGLT2 inhibitor dapagliflozin 10 mg tablet /day in combination with placebo GLP-1 receptor agonist exenatide twice daily
62182519|NCT03361098|PLACEBO_COMPARATOR|double placebo|placebo dapagliflozin and placebo exenatide twice daily
62182520|NCT00626015|EXPERIMENTAL|Arm I|Temozolomide, PEP-3-KLH conjugate vaccine, and daclizumab
62182521|NCT00626015|EXPERIMENTAL|Arm II|Temozolomide, PEP-3-KLH conjugate vaccine, and normal saline
62381598|NCT05086640|NO_INTERVENTION|Control foot without lemon|No application of Lemon or any other prevention cream in the Prevention of Blisters on one feet
62381599|NCT02622802|EXPERIMENTAL|ex-vivo placenta perfusion|ex vivo placenta perfusion study with exposure to paracetamol, erythromycin and azithromycin
62381600|NCT03869632|EXPERIMENTAL|YL-13027|YL-13027 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
62381601|NCT03538899|EXPERIMENTAL|Gene therapy (AProArt)|Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells. The CliniMACS® CD34 Reagent System sorter device will be used to select CD34 cells. Patients will be conditioned with low dose busulfan prior to transplant.
62381602|NCT01829672|EXPERIMENTAL|Other: pulmonary vascular disease|Dual-energy computed tomography investigation
62761503|NCT04579172|EXPERIMENTAL|Group A|Circular isthmic-cervical sutures
62761504|NCT04579172|EXPERIMENTAL|Group B|Resection of the infiltrated part of anterior uterine wall
62761505|NCT01066780|EXPERIMENTAL|Group A: ClearVoice Medium|Chronic use of ClearVoice MEDIUM for two weeks followed by chronic use of ClearVoice HIGH for two weeks.
62761506|NCT01066780|EXPERIMENTAL|Group B: ClearVoice High|Chronic use of ClearVoice HIGH for two weeks followed by chronic use of ClearVoice MEDIUM for two weeks.
62761507|NCT03007186||Case group|The oral glucose tolerance test that these women undergo in pregnancy between 24+0 and 28+0 showed pathological measurements.
62761508|NCT03007186||Control group|The oral glucose tolerance test of these women showed no pathological measurements.
62381603|NCT00755521|NO_INTERVENTION|B|
62761509|NCT02948907|OTHER|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes, endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological results obtained by EBUS-TBNA."
62761510|NCT00970450|EXPERIMENTAL|Paracetamol|
62381604|NCT00755521|EXPERIMENTAL|A|adding Etoricoxib to the basic therapeutic regimen
62381605|NCT01792024|EXPERIMENTAL|Treatment (LITT)|Patients undergo Magnetic Resonance imaging (MR) guided laser thermal therapy with Visualase Thermal Therapy device.
62381606|NCT00829010|EXPERIMENTAL|HIV+/+ Group|Infants born from a HIV positive mother and confirmed as HIV infected. Subjects received 3 primary doses (at 6, 10 \& 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 \& 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 \& 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age \& 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered intramuscularly in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
62381607|NCT00829010|EXPERIMENTAL|HIV+/- Group|Infants born from a HIV positive mother and confirmed as HIV exposed uninfected. Subjects received 3 primary doses (at 6, 10 \& 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 \& 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 \& 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age \& 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
62381608|NCT00829010|EXPERIMENTAL|HIV- (3+1) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected. Subjects received 3 primary doses (at 6, 10 \& 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 \& 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 \& 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age \& 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
62558639|NCT01006278||Surgical group with knee pain|patients 18 years of age or greater with a history of knee pain for more than three but less than six months who failed conservative management with the presence of mechanical symptoms including locking, catching, or giving way; positive physical exam findings including joint line tenderness, McMurray's exam, or Steinman's exam; and MRI of the knee positive for meniscus tear in a location correlating with physical examination. Exclusion criteria were as follows: the presence of high grade gonarthrosis including Kellgren-Lawrence grade IV; a history of prior knee surgery or trauma; ligamentous incompetence on examination or MRI; and diagnosis of inflammatory arthritides, crystalline arthropathies, or other rheumatologic diseases.
62558640|NCT01006278||Group 2|volunteer group
62761511|NCT00970450|EXPERIMENTAL|Paracetamol/Tropisetron|
62761512|NCT00970450|PLACEBO_COMPARATOR|Saline|Proband will receive Saline
62761513|NCT00970450|ACTIVE_COMPARATOR|Tropisetron|Proband will receive Tropisetron alone
62761514|NCT00273754|PLACEBO_COMPARATOR|Placebo|Saline
62761515|NCT00273754|ACTIVE_COMPARATOR|Caffeine|Caffeine benzoate
62761516|NCT04907435||patient with simultaneous laparoscopic operations|
62761517|NCT04907435||patient with simultaneous open operations|
62761518|NCT05785507||Cases|Women with PCOS according to the Rotterdam criteria.
62761519|NCT05785507||Controls|Women with PCOS.
62761520|NCT03765151|EXPERIMENTAL|LLLT group|Low-level laser therapy and orthodontic retention
62761521|NCT03765151|PLACEBO_COMPARATOR|control group|orthodontic retention and no laser treatment.
62761522|NCT04495868|EXPERIMENTAL|Bacteriostatic Normal Saline then 1% Lidocaine|Participants undergoing a lumbar medial branch block who are randomized to receive an intradermal administration of bacteriostatic normal saline followed by an intradermal administration of 1% lidocaine.
62761523|NCT04495868|ACTIVE_COMPARATOR|1% Lidocaine then Bacteriostatic Normal Saline|Participants undergoing a lumbar medial branch block who are randomized to receive an intradermal administration of 1% lidocaine followed by an intradermal administration of bacteriostatic normal saline.
62761524|NCT01708447|ACTIVE_COMPARATOR|Topical anesthetic - L.M.X.4.® cream|Topical anesthetic cream, L.M.X.4.® cream, applied to one side of the face and neck prior to Ulthera System treatment.
62381609|NCT00829010|EXPERIMENTAL|HIV- (EPI) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected.Subjects received 3 primary doses of Synflorix™ vaccine (at 6, 10 \& 14 weeks of age, at study Months 0, 1 and 2). Subjects in the group also received 3 primary vaccine doses (at 6, 10 \& 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 \& 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age \& 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
62381610|NCT00829010|EXPERIMENTAL|HIV- (2+1) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected.Subjects received 2 primary doses (at 6 \& 14 weeks of age at study Months 0 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 \& 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 \& 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age \& 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
62381611|NCT04453345|EXPERIMENTAL|TPM regimen|thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.
62761525|NCT01708447|PLACEBO_COMPARATOR|Placebo cream|A placebo cream with similar consistency and color will be applied to the other side of the face and neck prior to Ulthera System treatment.
62761526|NCT00836459|NO_INTERVENTION|Control|
62182522|NCT00626015|EXPERIMENTAL|Basiliximab|Patients will receive basiliximab 20 mg IV with vaccine # 1 only and continue with PEP-3-KLH, temozolomide.
62761527|NCT00836459|EXPERIMENTAL|Mini Booster|
62761528|NCT00836459|EXPERIMENTAL|Full Booster|
62761529|NCT04234087|NO_INTERVENTION|Control group|The supervised exercise program included: continues endurance training on cycle ergometers (6 sessions a week). Every session included warm up (\<50% target intensity 2 min, gradually increasing load 1-10 w/min up to target intensity within 5 - 10 min); exercise phase (100% of the target intensity (30-50% watts or 30-50% HRmax), starting with \>5 minutes and gradually prolonged up to 30 min); cool down with gradual reduction of the load within 3 minutes); additional aerobic exercises performed sitting and/or standing (30 minutes, 5 days/week); respiratory muscle training (7 days/week, for 15 minutes) using ball trainer.
62761530|NCT04234087|OTHER|Intervention group|Exercise program as for a control group together with additional resistance and balance training 3 sessions/week. The resistance training was started with low intensity (\<30% 1-RM, RPE ≤ 11, 5-10 repetitions), increased gradually to moderate intensity (30-50% and up to 60% 1-RM, RPE 12-13, after 8-15 repetitions) with 3 sets and 3 minute rest between sets, if tolerated. The balance training included exercises to improve static as well as dynamic balance ability. It was performed on 2-3 days/week for 10-15 minutes. The complexity of the balance exercises was selected and incremented individually by changing the stand-position, the base on which the stands were performed and/or using unstable surfaces. If tolerated, the visual information was varied and/or additional tasks performed while balancing. After completion participants were encouraged to continue exercise training at home according to recommendations.
62381612|NCT03021707|EXPERIMENTAL|UV-FS laser|WaveLight® Ultraviolet Femtosecond Laser System during UV-Femto, single session (one treatment per eye per participant)
62381613|NCT03336281||Participants with Psoriatic Arthritis: Dermatologist Cohort|Participants who will receive ustekinumab (as a first or second line of biologic disease modifying anti-rheumatic drug \[bDMARD\] therapy) along with other co-medications as per clinical dematologist's discretion will be observed in this study. Ustekinumab will not be provided by the sponsor. The treatment by ustekinumab must have been decided by the physician prior to the decision to include the participant in the study. Only data available from a participant's source medical records will be collected. Additionally investigators will be asked to obtain (or record where available) Patient-Reported Outcome (PRO) data from participants participating in this study.
62381614|NCT03336281||Participants with Psoriatic Arthritis: Rheumatologist Cohort|Participants who will receive ustekinumab (as a first or second line of bDMARD therapy) along with other co-medications as per clinical rheumatologist's discretion will be observed in this study. Ustekinumab will not be provided by the sponsor. The treatment by ustekinumab must have been decided by the physician prior to the decision to include the participant in the study. Only data available from a participant's source medical records will be collected. Additionally investigators will be asked to obtain (or record where available) PRO data from participants participating in this study.
62381615|NCT03841773|EXPERIMENTAL|TNX-102 SL Tablet 2.8 mg|2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
62381616|NCT03841773|PLACEBO_COMPARATOR|Placebo SL Tablet|2 x Placebo Tablets taken sublingually each day at bedtime for 12 weeks.
62381617|NCT02986425|EXPERIMENTAL|STRIP intervention|The intervention will take place during the initial hospital admission (Index Hospitalisation) or an equivalent situation for outpatients. STRIP is a structured method to perform pharmacotherapy optimisation. The STRIP-intervention consists of 9 steps.
62381618|NCT02986425|SHAM_COMPARATOR|Control|Participants in the control group will receive medication review by the prescribing physicians in accordance with usual care. If an extended drug review is in place in a ward/specialty corresponding characteristics are collected on cluster level.
62381619|NCT04321291|EXPERIMENTAL|Nurse information|The patient will receive a generic information leaflet plus an Individual information by nurse on biosimilars
62381620|NCT04321291|OTHER|Information Leaflet|The patient will receive a generic information leaflet only
62381621|NCT05790499|EXPERIMENTAL|Atorvastatin|
62381622|NCT00935701|EXPERIMENTAL|Acupuncture and Acupressure|In Phase 1, 10 children with ASD will receive acupressure for four weeks. At week 5, they will be introduced to acupuncture which will be continued throughout the rest of the study as tolerated. In Phase 2, 40 children with ASD will receive acupressure twice weekly for 12 weeks. Parents will be trained in the acupressure techniques and will be asked to do this daily, at bedtime, and/or as requested by the child or deemed needed by the parent. Children will begin to be assessed for their ability to participate in acupuncture treatment between weeks 5 and 7 at the discretion of the acupuncturist. By week 7, all children will have been introduced to acupuncture/needling. If needling is still refused at this time, acupressure will continue for the remainder of the study.
62381623|NCT02108795|EXPERIMENTAL|remifentanil group|Remifentanil 0.05 ug/kg/min is infused to the patients.
62381624|NCT02108795|PLACEBO_COMPARATOR|control|Normal saline 0.2 ml/kg/hour is infused to the patients
62381625|NCT03008889|EXPERIMENTAL|Participants taking NAC|Participants randomized to the active treatment study arm will receive gradually increasing doses of N-acetylcysteine (NAC) given as a dissolving tablet in juice or water. NAC is an over-the-counter oral dietary supplement that will be used a higher than usual doses in this study.
62381626|NCT03008889|PLACEBO_COMPARATOR|Participants taking Placebo|Participants randomized to placebo will receive dissolving tablets identical in size and appearance to the active treatment. Placebo capsules contain inactive ingredients.
62558641|NCT06581289||anesthesia for cardiovascular surgery using cardiopulmonary bypass|patients scheduled for cardiovascular surgery with CPB which requires anesthesia in the operating room
62558642|NCT02390947|EXPERIMENTAL|Famitinib arms|Famitinib 25 mg p.o. qd and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
61987807|NCT03510286||Pregnant women|Pregnant women attending ANC clinics in Techiman Holy Family Hospital and Kintampo North and South districts (all hospitals and clinics inclusive where ANC services are provided) are the primary participant group- primarily women of reproductive age. Pregnant women attending routine ANC will be enrolled. In addition to routine ANC, pregnant women will be tested with the Test-it™ PrCr Urinalysis Strips. Pregnant women are a potentially vulnerable population whose participation in this research is necessary given the target use case for this diagnostic tool: providing reliable and accurate point of care screening of proteinuria in ANC settings. The legal age of consent in Ghana is 18 years and women under the age of 18 will not be recruited for this study.
61987808|NCT04076995|EXPERIMENTAL|High Water intake|High water intake of 3.0 L/day in males and 2.0 L/day in females
62558643|NCT02390947|PLACEBO_COMPARATOR|Control arms|Placebo 25 mg p.o. qd and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
62558644|NCT05125640|EXPERIMENTAL|Treatment A|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)"
62761531|NCT01305603|ACTIVE_COMPARATOR|Dual TAP block|Dual TAP block on one side on the abdomen. Classical (or single) TAP on the contra lateral side of the abdomen; supplemented with a sham injection to ensure double blindness.
61987809|NCT04076995|ACTIVE_COMPARATOR|Low Water Intake|Low water intake of 0.5 L/day in males and 0.4 L/day
61987810|NCT01797289|EXPERIMENTAL|First episode of loss of consciousness|
62761532|NCT01305603|ACTIVE_COMPARATOR|Classical (or single) TAP block|Dual TAP block on one side on the abdomen. Classical (or single) TAP on the contra lateral side of the abdomen; supplemented with a sham injection to ensure double blindness
62761533|NCT05008484|EXPERIMENTAL|NMES Plus Vitamin D|Subjects will undergo 4.5 months of open kinematic chain resistance training followed by 4.5 months of closed kinematic chain using simple rowing approach and 2000IU oral vitamin D supplementation daily for 9 months.
62761534|NCT05008484|EXPERIMENTAL|Passive movement plus vitamin D|Subjects will undergo 9 months of simple passive movement exercise at home and 2000IU oral vitamin D supplementation daily for 9 months.
62761535|NCT04783649||High risk group|Women in the age group between 25 and 65 years old without prior history of malignancy referred to colposcopy
62761536|NCT04783649||Population sample|A population sample of women in the age group between 25 and 65 years old from several primary healthcare facilities to primary cervical screening
62761537|NCT02953236|EXPERIMENTAL|Instrumented massage|
62761538|NCT02953236|ACTIVE_COMPARATOR|Manual massage|
62761539|NCT01530841|EXPERIMENTAL|AVAPS|Arm assigned to AVAPS mode for nocturnal ventilation with the same setting than bilevel pressure support but with AVAPS mode activated
62761540|NCT01530841|ACTIVE_COMPARATOR|Bilevel pressure|Arm treated only with bilevel pressure support for nocturnal ventilation without activation of AVAPS mode
62381627|NCT00114257|EXPERIMENTAL|Arm I|"Patients receive decitabine IV over 1 hour on days 1-5 and 8-12 and FR901228 (depsipeptide) IV over 4 hours on days 5 and 12 OR days 5, 12, and 19. Treatment repeats every 4-6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing complete remission for 1 year are removed from the study.~Cohorts of 6 patients receive escalating doses of decitabine and FR901228 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
62381628|NCT02220660|ACTIVE_COMPARATOR|Free dose combination|
62381629|NCT02220660|EXPERIMENTAL|Fixed dose combination|
62381630|NCT02065635|EXPERIMENTAL|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
62381631|NCT02065635|ACTIVE_COMPARATOR|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
62381632|NCT02933489|EXPERIMENTAL|Arm A (DBT, AB-MR)|Participants undergo DBT followed by AB-MR for under 10 minutes on the same day or within 24 hours at baseline and then after 1 year.
62381633|NCT02933489|EXPERIMENTAL|Arm B (AB-MR, DBT)|Participants undergo AB-MR for under 10 minutes followed by DBT on the same day or within 24 hours at baseline and then after 1year.
62381634|NCT04622163|EXPERIMENTAL|Secondary Mentor Plus Career Development Resources|Subjects will be assigned a secondary mentor for 6 months. Subjects will also receive career development resources.
62381635|NCT04622163|OTHER|Career Development Resources Alone|Subjects will not be assigned a secondary mentor. Subjects will receive career development resources only.
62381636|NCT03147495||the study group|The participants with medial compartment knee osteoarthritis and without lateral compartment knee osteoarthritis according to the Ahlbäck classification.
62381637|NCT03147495||the control group|The healthy volunteers without knee osteoarthritis according to the American College of Rheumatology criteria for the classification and reporting of OA of the knee joint. Radiographic evidence of the knee with Ahlbäck classification grade 0.
62381638|NCT01947127||High lactate|Initial venous lactate level equal to or more than 2.0 mmol/L
62381639|NCT01947127||Low lactate|Initial venous lactate level less than 2.0 mmol/L
62381640|NCT00989664|EXPERIMENTAL|open-label single arm|Tositumomab and Iodine-131 Tositumomab radioimmunotherapy for chemotherapy-refractory low-grade B-cell lymphomas and low-grade lymphomas that have transformed to higher grade histologies.
62381641|NCT04754568|EXPERIMENTAL|Virtual reality instructional design|Completion of virtual reality simulation of an outpatient physical therapy evaluation.
62381642|NCT04754568|ACTIVE_COMPARATOR|Role-playing instructional design|Completion of traditional role-playing of a scripted outpatient physical therapy evaluation
62381643|NCT00957463||smoker, with high apnea-hypopnea index|subjects who smoke either in the past or currently, with confirmed moderate-severe OSA
62381644|NCT00957463||smoker, mild OSA or without OSA|subjects who smoke either in the past or currently, with mild OSA or without OSA
62381645|NCT00957463||nonsmoker, with high apnea-hypopnea index|subjects who never smoke, with confirmed moderate-severe OSA
62381646|NCT00957463||nonsmoker, with mild OSA or without OSA|subjects who never smoke, with mild OSA or without OSA
62381647|NCT00547729|EXPERIMENTAL|HeartPOD™ System|Implantation of HeartPOD™ Heart Failure Management System with DynamicRx®
62381648|NCT06230003|ACTIVE_COMPARATOR|Intervention group|Ultrasound guided bilateral ESP block either with local anesthetic
62381649|NCT06230003|PLACEBO_COMPARATOR|Control group|Ultrasound guided bilateral ESP block either with normal saline
62381650|NCT05008302|EXPERIMENTAL|To improve the coordination of the wrist and hand after stroke in three age groups.|The test consisted of two motor tasks, carried out in two different starting positions: sitting and lying down (supine). During the first examination, the subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position).
62381651|NCT05008718|ACTIVE_COMPARATOR|38% SDF group|38% silver diamine fluoride will be applied on caries lesions on deciduous teeth with a minimum score of 05 as defined by the International Caries Detection and Assessment System (ICDAS)
62381652|NCT05008718|PLACEBO_COMPARATOR|5% NaF group|5% sodium fluoride will be applied on caries lesions on deciduous teeth with a minimum score of 05 as defined by the International Caries Detection and Assessment System (ICDAS)
62381653|NCT03089489||Lung recipients with PGD|in the first 72 hours following lung transplantation, the lung recipients have blood gases and chest X-Ray to assess the occurrence of primary graft dysfunction. Chest X-Ray infiltrate and pathological PaO2/FiO2 ratio describe PGD occurence
62761541|NCT05536622|EXPERIMENTAL|Infrared imaging of affected tibia|All eligible children will have infrared imaging undertaken of both affected limb and unaffected limb simultaneously.
62381654|NCT03089489||Lung recipients PGD Free|In the first 72 hoours following lung transplantation, if the Cest X-ray is normal, the patient is considered PGD-free
62381655|NCT04399993|EXPERIMENTAL|Intervention Protocol in Diaphragm|"In each volunteer, after a brief questionnaire, it will be measured the center of gravity and the range of movement of the lumbar spine before the technique.~Each volunteer will stay in supine position with arms along their body, in which their legs may be either extended or flexed.~Next, the researcher will perform the intervention protocol in Diaphragm. Then, all the measurements described before, will be repeated by the assessor right after the technique."
62761542|NCT00740714|EXPERIMENTAL|A|Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)
62381656|NCT04399993|SHAM_COMPARATOR|Sham Technique|"In each volunteer, after a brief questionnaire, it will be measured the center of gravity and the range of movement of the lumbar spine before the technique.~Each volunteer will stay in supine position with arms along their body, in which their legs may be either extended or flexed.~Next, the researcher will perform the Sham technique. Then, all the measurements described before, will be repeated by the assessor right after the technique."
62381657|NCT03125681|EXPERIMENTAL|Remote ischemic conditioning|Applying pneumatic cuff on upper extremity (5 minutes cycles of limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times) before and after coronary anastomoses.
62381658|NCT03125681|PLACEBO_COMPARATOR|Control|All the procedures were the same in the control group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
61987811|NCT03872089|EXPERIMENTAL|Study participants|Measurements of the temperature of the plantar arch by thermal imaging. Result analysis regarding podologic grade ( 0-1-2-3)
62761543|NCT00740714|EXPERIMENTAL|B|Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)
62761544|NCT00740714|PLACEBO_COMPARATOR|C|Placebo (with vitamin E 1200 IU/day)
62761545|NCT04970160||TSARP|Is a surgical procedure
62761546|NCT04970160||ASARP classic|Surgical procedure
62761547|NCT04970160||PSARP|Surgical procedure
62761548|NCT04970160||Modified ASARP|Surgical procedure
62761549|NCT02819960|ACTIVE_COMPARATOR|active probiotic formula|"Intervention: Probiotic formula Probio-Tec® BG-VCap-6.5 will be administered at a dose of 3x1 cps per day orally for 6 weeks. No premedication or patient monitoring after administration of probiotic formula is required. Probiotic formula may be taken after meals or snacks to reduce stomach upset. Swallow the capsule or in case of problems with swallowing, capsule can be opened, content mixed with small amount of food. Food must not be hot.~Patients should receive full supportive care during the study, including transfusion of blood and blood products, treatment with antibiotics, anti-emetics, anti-diarrheal agents, analgesics, erythropoetin, or bisphosphonates, when appropriate."
62761550|NCT02819960|PLACEBO_COMPARATOR|placebo|"Intervention: Maltodextrin will be used for placebo group and will be administered at a the same dose as active formula (3x1 cps per day orally for 6 weeks).~Patients should receive full supportive care during the study, including transfusion of blood and blood products, treatment with antibiotics, anti-emetics, anti-diarrheal agents, analgesics, erythropoetin, or bisphosphonates, when appropriate."
61987812|NCT05533918|ACTIVE_COMPARATOR|Text Messaging (TM) + No Patient Navigation|"Bidirectional text messaging with a one-touch response to connect patients to vaccination or mailed at-home rapid test kits for use as needed.~Patients will not receive patient navigation."
61987813|NCT05533918|ACTIVE_COMPARATOR|Text Message (TM) + Request (RPN)|"Bidirectional text messaging with a one-touch response to connect patients to vaccination or mailed at-home rapid test kits for use as needed.~RPN will provide patients the opportunity to reply PERSON (for connection to a PN) in response to a TM offering connection to testing and/or vaccination."
62381659|NCT03310099|EXPERIMENTAL|Dietary Intervention|Dietary intervention aimed at increasing UFA consumption. The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated \[MUFA\] and polyunsaturated fatty acids \[PUFA\]), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
62381660|NCT01804504|NO_INTERVENTION|Control|"Food Frequency Questionnaire(FFQ) and KAP Questionnaire will be carried out before and after the trial to evaluate changes in calorie and nutrients intake, dietary structure, and KAP scores.~Physical examination and biochemical examination before and after the trial."
62381661|NCT01804504|EXPERIMENTAL|Nutrition education|"FFQ and KAP Questionnaire will be carried out before and after the trial to evaluate changes in calorie and nutrients intake, dietary structure, and KAP scores.~Physical examination and biochemical examination before and after the trial.~Do nutrition education"
62381662|NCT00890201||Normal Gallbladder|"Patients with normal gallbladder (without gallstones) evidenced by preoperative ultrasonography (and postoperative biopsy) submitted to elective gastroesophageal surgery (gastrectomy for gastric cancer, bariatric surgery or esophageal surgery such as Nissen plicature or miotomy for achalasia).~The pancreaticobiliary junction must be normal as evidenced by intraoperative cholangiography. Preoperative values of amylase and lipase must be normal."
62558645|NCT05125640|ACTIVE_COMPARATOR|Treatment B|Utrogestan® 200 mg Soft Capsule (Manufacturer by: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)
62761551|NCT02495064|EXPERIMENTAL|Mometasone Furoate Cream(MF)|"participants will be given conventional Chemoradiotherapy and MF.~MF Brief introduction:~Generic name :Mometasone Furoate Cream. Dosage form:Each gram of Mometasone Furoate Cream contains mometasone furoate, USP in a cream base of hexylene glycol, phosphoric acid, propylene glycol stearate, stearyl alcohol and ceteareth-20, titanium dioxide, aluminum starch octenylsuccinate, white wax, white petrolatum, and purified water.~Dosage:Apply a thin film of Mometasone Furoate Cream to the affected skin areas once daily during radiotherapy.~It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."
62761552|NCT02495064|NO_INTERVENTION|Chemoradiotherapy|conventional Chemoradiotherapy only
62761553|NCT05492760||ablation group|
62761554|NCT01162174|EXPERIMENTAL|100 mg of Oligonol|
61987814|NCT01091389|EXPERIMENTAL|GP ablation|Thoracoscopic PV isolation with GP ablation
62381663|NCT00890201||Gallbladder with gallstones|"Patients submitted to elective cholecystectomy for diseased gallbladders (gallbladder with gallstones evidenced by preoperative ultrasound).~The pancreaticobiliary junction must be normal as evidenced by intraoperative cholangiography and the preoperative amylase and lipase levels must also be normal."
62381664|NCT01551381|EXPERIMENTAL|EV-077|Oral administration
62761555|NCT01162174|EXPERIMENTAL|200 mg of Oligonol|
62761556|NCT01162174|PLACEBO_COMPARATOR|0 mg of Oligonol|
62761557|NCT03983772|EXPERIMENTAL|RS10-10-10|First 2 weeks is for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 10 g RS blend. Fourth 2 weeks is 10 g RS blend.
62761558|NCT03983772|EXPERIMENTAL|RS10-20-20|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 20 g RS blend. Fourth 2 weeks is 20 g RS blend.
62761559|NCT03983772|EXPERIMENTAL|RS10-20-30|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 20 g RS blend. Fourth 2 weeks is 30 g RS blend.
62761560|NCT03983772|PLACEBO_COMPARATOR|Placebo10-10-10|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g placebo. Third 2 weeks is 10 g placebo. Fourth 2 weeks is 10 g placebo.
62761561|NCT05873036|OTHER|Aerobic Training|
62761562|NCT05873036|EXPERIMENTAL|Progressive Resistance Training|
62761563|NCT00162461|EXPERIMENTAL|Phenytoin|
61987815|NCT01091389|EXPERIMENTAL|No GP ablation|Thoracoscopic PV isolation with no GP ablation
62381665|NCT01551381|PLACEBO_COMPARATOR|Placebo|Oral administration
62381666|NCT02994199|EXPERIMENTAL|Active video gaming|Participants will engage in active video game play.
62381667|NCT02099292|EXPERIMENTAL|Rituximab and DexaBEAM|Rituximab and DexaBEAM
62761564|NCT05231200|ACTIVE_COMPARATOR|Control Arm- Current management|NICUs in the control arm can continue conducting QI activities relevant to current practice and current standard of care, but without receiving the interventions until they transition to the intervention arm.
62761565|NCT05231200|EXPERIMENTAL|Intervention Arm- Collaborative Quality implementation Strategies|The study intervention is a constellation of collaborative QI strategies: 1) QI Team Building; 2) QI Education; 3) Implementation of 2 standardized practice care bundles (Respiratory Care, and Nutritional Care); 4) QI mentoring; and 5) Collaborative networking.
62761566|NCT03728491|EXPERIMENTAL|Healthy Figurant|Hands-on training on healthy figurants for gaining competence in TUS
62761567|NCT03728491|EXPERIMENTAL|Simulator|Hands-on training on US Mentor simulator for gaining competence in TUS
62761568|NCT03728491|NO_INTERVENTION|Controls|Controls with no hands-on training
62761569|NCT00319657|EXPERIMENTAL|Immune tolerance, kidney transplantation|Intervention: Participants will receive hematopoietic cell transplantation and Total lymphoid irradiation. The intervention is intended to induce immune tolerance in HLA-matched living donor kidney transplantation, to allow withdrawal of the immunosuppressive drugs. Immune tolerance is achieved through the development of donor/recipient mixed chimerism following combined kidney and hematopoietic stem cell transplantation from the living donor.
62381668|NCT02881151|EXPERIMENTAL|Treatment|Subjects will be treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that will be undertaken to assess for any possible therapeutic effect.
62381669|NCT02859480|EXPERIMENTAL|Rosuvastatin 5mg|Patients are treated with Rosuvastatin 5mg/day for 30 months after percutaneous coronary intervention
62381670|NCT02859480|ACTIVE_COMPARATOR|Rosuvastatin 20mg|Patients are treated with Rosuvastatin 20mg/day for 30 months after percutaneous coronary intervention
61987816|NCT01853046|EXPERIMENTAL|Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment|Participants with normal/mild renal impairment received Regorafenib 160 mg o.d.as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.
62381671|NCT02629887|ACTIVE_COMPARATOR|Face Mask|Standard Face Mask with T piece resuscitator for neonatal resuscitation. Face mask placement per Neonatal Resuscitation Program resuscitation guideline.
62381672|NCT02629887|ACTIVE_COMPARATOR|Non-inflatable supraglottic airway|Use of non-inflating supraglottic airway with T-piece resuscitator instead of Standard Face Mask with T piece resuscitator for neonatal resuscitation, replacing standard of care face mask in Neonatal Resuscitation Program guideline.
62381673|NCT05496166|EXPERIMENTAL|surgery group|SHR-1316+chemotherapy+surgery
62381674|NCT05496166|ACTIVE_COMPARATOR|radiotherapy group|SHR-1316+chemotherapy+radiotherapy
62381675|NCT05183594|EXPERIMENTAL|TSupport group|"Subjects will receive TSupport 4 sachets (5 grams/sachet) orally twice daily. Morning dose and evening dose should be administrated at about the same time every day and irrelevant to meals.~Supportive care duration: 24 weeks."
62761570|NCT04214886|EXPERIMENTAL|CAR 5 x 105 transduced T cells/kg (Dose Level -1)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 5 x 105 transduced T cells/kg.
62761571|NCT04214886|EXPERIMENTAL|CAR 1 x 106 transduced T cells/kg (Dose Level 1)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 1 x 106 transduced T cells/kg.
62761572|NCT04214886|EXPERIMENTAL|CAR 1.5 x 106 transduced T cells/kg (Dose Level 2)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 1.5 x 106 transduced T cells/kg.
62381676|NCT01293214|EXPERIMENTAL|Transplantation|Subjects will undergo single or multiple limb transplantation
62381677|NCT02477800|EXPERIMENTAL|Low Dose|Monthly intravenous (IV) infusion
62381678|NCT02477800|EXPERIMENTAL|High Dose|Monthly intravenous (IV) infusion
62381679|NCT04804072|EXPERIMENTAL|Integrated health services delivered in the mobile unit and peer navigation|Participants in the intervention arm will be provided integrated health services delivered in the mobile unit and peer navigation for 26 weeks.
62381680|NCT04804072|ACTIVE_COMPARATOR|Peer navigation to connect them to health services available at community-based agencies|Participants in the active control arm will be provided 26 weeks of peer navigation to connect them to health services available at community-based agencies.
62381681|NCT03273868|EXPERIMENTAL|High velocity low amplitude manipulation|
62761573|NCT04214886|EXPERIMENTAL|CAR 2 x 106 transduced T cells/kg (Dose Level 3)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 2 x 106 transduced T cells/kg.
62761574|NCT03597178|EXPERIMENTAL|senofilcon A|Subjects that are of at least 60 years of age and non-habitual contact lens wearers will receive instructions to insert and remove a contact lens from each eye.
62761575|NCT02607540|EXPERIMENTAL|Two cycles PF-radiotherapy|"2 cycles cisplatin-5-fluorouracil: cisplatin: 75mg/m2 d1，29；5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.~radiotherapy： 50Gy，2 Gy/d，5d/w."
62761576|NCT02607540|ACTIVE_COMPARATOR|Four cycles PF-radiotherapy|"4 cycles cisplatin-5-fluorouracil: cisplatin: 75mg/m2 d1，29, 57, 85；5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.~radiotherapy： 50Gy，2 Gy/d，5d/w."
62761577|NCT04217161|EXPERIMENTAL|Dexcom G6 Continuous Glucose Monitor|
62761578|NCT00768404|EXPERIMENTAL|A|
62761579|NCT00003671|EXPERIMENTAL|Chemotherapy Treatment|See detailed description.
62761580|NCT01945775|EXPERIMENTAL|talazoparib|Patient will be randomized 2:1 to receive talazoparib oral capsules (1.0 mg) once daily for 21 continuous days
62381682|NCT03273868|SHAM_COMPARATOR|Sham manipulation|
62381683|NCT06045936|EXPERIMENTAL|Lidocaine Group|Subjects will receive a lidocaine injection in the back of their residual limb.
62381684|NCT06045936|PLACEBO_COMPARATOR|Sham Group|Subjects will receive a placebo injection in the back of their residual limb.
62381685|NCT00215904|PLACEBO_COMPARATOR|1|
62381686|NCT00215904|EXPERIMENTAL|2|
62381687|NCT01021839|ACTIVE_COMPARATOR|Bovine Carotid Artery Graft|
62381688|NCT01021839|ACTIVE_COMPARATOR|Expanded Polytetrafluoroethylene Grafts|
62381689|NCT03094481|ACTIVE_COMPARATOR|US guided SCPB medial fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
62381690|NCT03094481|ACTIVE_COMPARATOR|US guided ISB medial fracture|Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
62381691|NCT03094481|ACTIVE_COMPARATOR|US guided SCPB + ISB medial fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
62381692|NCT03094481|ACTIVE_COMPARATOR|US guided SCPB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
62381693|NCT03094481|ACTIVE_COMPARATOR|US guided ISB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
62381694|NCT03094481|ACTIVE_COMPARATOR|US guided SCPB + ISB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
62381695|NCT04155190|EXPERIMENTAL|Patidegib Topical Gel, 2%|Participants will be randomized (1:1) to receive Patidegib Topical Gel, 2% for 9 months
62381696|NCT04155190|ACTIVE_COMPARATOR|Patidegib Topical Gel, Vehicle|Participants will be randomized (1:1) to receive Patidegib Topical Gel, Vehicle for 9 months
62761581|NCT01945775|ACTIVE_COMPARATOR|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
62381697|NCT00796809||Biologics|Patients receiving TNF inhibitors or biologic agents
62381698|NCT00796809||DMARD|Patients receiving methotrexate without any biologic
62761582|NCT04266509|EXPERIMENTAL|Rifampin and PF-06651600 DDI|In Period 1, participants will receive a single oral 50 mg dose of PF-06651600. In Period 2, participants will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, in the morning of Day 8 participants will be administered with rifampin 600 mg 2 hour prior to administration of a single 50 mg oral dose of PF-06651600.
62761583|NCT01237262|ACTIVE_COMPARATOR|TNF alfa inhibitors|Male and female adult patients with a diagnosis of moderate to severe psoriasis (when PASI score is \> 10 and BSA is \> 10%). The overall study enrolment plan is 20 patients. Patients will be screened before the beginning of clinical trial by blood sample in order to exclude major contraindications to use of anti TNF α drugs.
62761584|NCT02080572||Parkinson's Disease with DBS|Individuals with Parkinson's disease and deep brain stimulation will be recruited.
62761585|NCT04147299||HFrEF|Heart Failure with Reduced Ejection Fraction
62761586|NCT04147299||HFpEF|Heart Failure with Preserved Ejection Fraction
62761587|NCT04147299||Elite Athletes|Endurance athletes
62761588|NCT06122883|EXPERIMENTAL|Distraction in the reception area.|
62761589|NCT06122883|EXPERIMENTAL|Distraction in the treatment area.|
61987817|NCT01853046|EXPERIMENTAL|Regorafenib (Stivarga, BAY73-4506)-Severe Renal Impairment|Participants with severe renal impairment received Regorafenib 160 mg o.d. as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.
62381699|NCT04610320|EXPERIMENTAL|Daratumumab-SC Injection|"* Participants will receive a subcutaneous dose of Daratumumab-SC (1800 mg) weekly for 8 doses and then every other week for 2 doses.~* Participants will undergo laboratory testing, including for circulating antibodies, at baseline, prior to each infusion session, and at the end of the study."
62381700|NCT02198313|EXPERIMENTAL|BIIX 1 XX - D1|
62381701|NCT02198313|EXPERIMENTAL|BIIX 1 XX - D2|
62381702|NCT02198313|EXPERIMENTAL|BIIX 1 XX - D3|
62381703|NCT02198313|PLACEBO_COMPARATOR|Placebo|
62381704|NCT01609361|NO_INTERVENTION|1: Standard surgery + Standard care|standard surgery and Standard care after surgery
62761590|NCT06122883|EXPERIMENTAL|Distraction in both treatment and reception area.|
62381705|NCT01609361|OTHER|2: Laparoscopy + Rehabilitation program|Laparoscopic colorectal surgery with rehabilitation program
62381706|NCT00877890|EXPERIMENTAL|1|
62381707|NCT00877890|ACTIVE_COMPARATOR|2|
62381708|NCT00141544|EXPERIMENTAL|1|
62381709|NCT00141544|ACTIVE_COMPARATOR|2|
62381710|NCT06150352||Subjective or mild cognitive impairment patients|Subjective or mild cognitive impairment patients with or without CPAP treatment
62381711|NCT00001242||Study Cohort|Patients of any age or sex with vitamin D resistance, rickets, osteomalacia, pseudohypoparathyroidism, pseudo- pseudohypoparathyroidism, or suspicion of these or related disorders
62381712|NCT01519180||Control group|Healthy volunteers
62761591|NCT06122883|OTHER|Basic behavior guidance techniques without using any type of distraction aids.|
62761592|NCT01801176|EXPERIMENTAL|Initial monitoring group|
62761593|NCT02576665|EXPERIMENTAL|Toca 511/Toca FC|"Toca 511: 14 mL intravenously daily for 3 days followed by up to 4 mL intratumorally or into resection cavity walls following biopsy or resection. Cutaneous melanoma patients may receive intralesional injections (up to 4 mL) daily for 5 days.~Toca FC: 220 mg/kg/day orally starting at Week 5-6. Cycles are 5- to 7- day courses of treatment every 4 to 6 weeks."
62761594|NCT00747344|PLACEBO_COMPARATOR|Placebo - Controlled Period (CP)|
62761595|NCT00747344|EXPERIMENTAL|Ustekinumab 45 mg - CP|
62761596|NCT00747344|EXPERIMENTAL|Placebo to ustekinumab 45 mg - after CP|
62761597|NCT00747344|EXPERIMENTAL|Ustekinumab 45 mg - after CP|
62761598|NCT01731353||Emerging fungal infections|Web-based registry of invasive infections by emerging fungi
62761599|NCT02716701|EXPERIMENTAL|Exercise Group|Subjects will wear a wristband activity tracker to monitor their physical activity and will be asked to increase their activity level, with a goal of at least doubling their average daily activity (steps)
62761600|NCT02716701|ACTIVE_COMPARATOR|Control Group|Subjects will wear a wristband activity tracker to monitor their physical activity and will not be encouraged to increase their activity level
62761601|NCT04174300|EXPERIMENTAL|Manual Therapy|8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N
62761602|NCT05221112|EXPERIMENTAL|diagonal pattern training|diagonal pattern training group will involve performance of proprioceptive neuromuscular facilitation technique's chopping and lifting pattern to create 10 movements.
62761603|NCT05221112|ACTIVE_COMPARATOR|control group|in control group patients will perform movements in single plane
62761604|NCT00732355||I|known syphilis infected patients
62761605|NCT00732355||U|presumed uninfected patients
62761606|NCT01083459||PCV13 immunized|Children who receive the 13-valent pneumococcal conjugate vaccine
62761607|NCT01083459||PCV13 unimmunized|PCV13 unimmunized Household members of PCV13 immunized children
62381713|NCT01519180||Idiopathic gastroparesis|Idiopathic gastroparesis
62761608|NCT02815436|ACTIVE_COMPARATOR|Telephone reminder|subjects in this arm will receive a telephone reminder
62761609|NCT02815436|ACTIVE_COMPARATOR|SMS reminder|Subjects in this arm will receive a SMS reminder
62761610|NCT02815436|NO_INTERVENTION|No reminder|usual care, where no additional intervention will be offered
62761611|NCT02838615|ACTIVE_COMPARATOR|epidural steroid injection|TF epidural steroid (dexamethasone) injection
62761612|NCT02838615|ACTIVE_COMPARATOR|IL epidural steroid injection|PS interlaminar epidural steroid(dexamethasone) injection
62761613|NCT04423458||Transplanted kidney|No intervention is required. Routine Doppler assessment + 3D scan + Shear wave elastography + MicrFlow Imaging will be immediately recorded afterwards
62761614|NCT05863234|EXPERIMENTAL|Treatment with PPMX-T003|
62761615|NCT03900923|EXPERIMENTAL|98% pure CBD|98% pure CBD. The CBD will be 100mg/mL oral solution provided by Greenwich Biosciences, Inc.
62761616|NCT02852941||Patients after kidney transplantation|The study included who had been admitted to a nephrology-transplantation outpatient clinic 0.5 to 30 years after kidney transplantation.
62761617|NCT02852941||Healthy subjects|Medical staff: medical doctors, nurses
62761618|NCT01430325|SHAM_COMPARATOR|Sea Level Equivalent 1.2 atm abs (air)|"Sham Chamber Session~Sea Level Equivalent 1.2 atm abs (2.6 psig) breathing regular air 20-chamber excursion"
62381714|NCT00682292|ACTIVE_COMPARATOR|1, ATG|Thymoglobulin induction during 8 days (1.25 mg/kg per day) associated with tacrolimus, mycophenolate mofetil and steroids
62761619|NCT01430325|EXPERIMENTAL|Sea Level Equivalent 1.5 atm abs (O2)|"Hyperbaric Oxygen (1.5 atm abs)~Sea Level Equivalent 1.5 atm abs (6.2 psig) breathing 100% oxygen 20-minute chamber excursion"
62761620|NCT01430325|SHAM_COMPARATOR|Altitude Equivalent 1.2 atm abs (air)|"Sham Chamber Session~Altitude Equivalent 1.2 atm abs (5.1 psig) breathing regular air 20-minute chamber excursion"
62761621|NCT01430325|EXPERIMENTAL|Altitude Equivalent 1.5 atm abs (O2)|"Hyperbaric Oxygen (1.5 atm abs)~Altitude Equivalent 1.5 atm abs (9.6 psig) breathing 100% oxygen 20-minute chamber excursion"
62761622|NCT04225442|OTHER|Fatty meal|To study how a fatty meal modifies the physiological chronobiome in young and old, an isocaloric controlled liquid high fat meal (ICLHFM) will be consumed within 5 min. The ICLHFM contains an equivalent to 35% of the estimated total daily energy requirements (TDE), 60% of kcal delivered from fat while 13% come from protein and 27 % from carbohydrate.
62761623|NCT05443282||POI group (Study group)|"* The study group included 68 women with POI.~* The POI cases had been diagnosed as idiopathic POI.~* The POI diagnosis was based on the presence of amenorrhea before the age of 40, increased serum FSH level higher than 40 mIU/ml, and decreased estradiol levels lesser than 50 pg/mL."
62761624|NCT05443282||Normally menstruating women (Control group)|"* Control group consisted of 65 healthy, regularly menstruating women.~* The women were at the age of lesser than 40 years old.~* The women were recruited consecutively from those that applied to outpatient clinics to get counselling for family planning."
62761625|NCT06305195||Non-diabetic individuals|adults (18-70 Years) with glycated hemoglobin (HBA1C) \<5.7 and/or Fasting blood glucose \<100 mg/L and with no classic symptoms of hyperglycemia
62761626|NCT06305195||Pre-diabetic:|"adults (18-70 Years) who fulfil one of the American Diabetes Association (ADA) criteria :~* glycated hemoglobin (HBA1C) =5.7-6.4%~* Fasting blood glucose 100 mg/dL to 125 mg/dL. Fasting is deﬁned as no caloric intake for at least 8 hours."
62761627|NCT06305195||Diabetic patients :|"adults (18-70 Years) who fulfil one of the American Diabetes Association (ADA) criteria:~* glycated hemoglobin (HBA1C) ≥6.5%~* Fasting blood glucose ≥126 mg/dL.~* A random plasma glucose ≥200 mg/dL. Random is any time of the day without regard to the meals."
62761628|NCT05556629||NATPARA: Participants|Participants who have been approved for NATPARA and a part of the special use program (SUP) prior to survey implementation will participate in the survey via telephone or internet.
62761629|NCT05556629||NATPARA: Healthcare Provider (Prescribing Physician)|Healthcare provider (HCPs)/Prescribing physician who can provide a 10-digit National Provider Identifier (NPI) number and who are certified in the NATPARA risk evaluation and mitigation strategy (REMS) by successfully completing the NATPARA REMS program training module for prescribing physicians, including the knowledge assessment, and submitting a NATPARA REMS Program Prescriber Enrollment Form will participate in the survey via telephone or internet.
62761630|NCT01609335|OTHER|Cognitively Normal Subjects|Study participation will consist of tests of memory and thinking, a MRI, and two PET scans. F-18 FDG and C-11 Pittsburgh compound B (PiB) are two drugs used in PET scans.
62761631|NCT00738764|EXPERIMENTAL|Cohort 1|PDL192 Dose Level 1
62761632|NCT00738764|EXPERIMENTAL|Cohort 2|PDL192 Dose Level 2
62761633|NCT00738764|EXPERIMENTAL|Cohort 3|PDL192 Dose Level 3
62761634|NCT00738764|EXPERIMENTAL|Cohort 4|PDL192 Dose Level 4
62761635|NCT00738764|EXPERIMENTAL|Cohort 5|PDL192 Dose Level 5
62761636|NCT00738764|EXPERIMENTAL|Cohort 6|PDL192 Dose Level 6
62761637|NCT04693572||Parturients undergoing repeated caesarean sectiona|
62761638|NCT01081301|EXPERIMENTAL|Living with Hope Program|Receive Living with Hope Program
62761639|NCT03184363|EXPERIMENTAL|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
62761640|NCT06284616|EXPERIMENTAL|JASP-1 group|Participants were recruited from August 2019 to April 2022. The JASP-1 group consisted of children 0-16 years old who were diagnosed with JIA at their first visit to the PRC and their parents
62761641|NCT06284616|NO_INTERVENTION|Control group|The control group consisted of children 1-16 years old, who were diagnosed with JIA at their first visit at the PRC who were receiving standard care after the diagnosis, and their parents
62761642|NCT06450860|OTHER|Nutrition Intervention|Participants receive an individualized food provision and/or supplemental food support referral based on responses to the NSAT.
62761643|NCT04841525||Autism Spectrum Disorder|During Screening Visits, the Autism Diagnostic Observational Schedule (ADOS) will be administered to confirm diagnosis. Criteria for group inclusion is: diagnosis of Autism Spectrum Disorder based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the Autism Diagnostic Observation Schedule (ADOS-G), and the Autism Diagnostic Interview-Revised, short form (ADI-R). Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
62761644|NCT04841525||Typical Development|Typically Developing (TD) participants from each site will be roughly matched by age and sex to the ASD group.
62381715|NCT00682292|ACTIVE_COMPARATOR|2, Daclizumab|Dacluzamb induction (five infusions, 1 mg/kg per infusion) associated with tacrolimus, mycophenolate mofetil and steroids
62381716|NCT03478592|EXPERIMENTAL|reference technique slow freezing|In reference technique slow freezing arm, embryon will be frozen with the conventional slow freezing procedure with the Freezal device apply a slow decreasing in temperature with moderate cryoprotector concentration
62381717|NCT03478592|EXPERIMENTAL|vitrification technique|In vitrification technique arm, embryon will be frozen with automated vitrification system
62761645|NCT00937118||Injury Management|Patients with full thickness duodenal laceration undergoing laparotomy and surviving more then 72 hours at our level 1 trauma center in the years 1989-2009. Patients requiring pancreaticoduodenectomy were excluded.
62761646|NCT01209663|ACTIVE_COMPARATOR|Ward Care|Protocol based discharge to the surgery ward. Observation and treatment is conducted by ward nurses and general surgeons (current treatment).
62761647|NCT01209663|EXPERIMENTAL|Intermediate Care|Observation and treatment in an intermediate care bed in a minimum of 48 hours after randomization. Daily rounds will be carried out by both general surgeons and intensive care physicians.
62761648|NCT04741191|EXPERIMENTAL|Cycle ergometer training|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown)
62761649|NCT04741191|ACTIVE_COMPARATOR|Conventional therapy|Patient education and counseling, In bed activities, Ambulation
61987818|NCT00326443|EXPERIMENTAL|1|14 subjects Oral CVD 909 with buffer on Day 0. Parental Vi polysaccharide vaccine on Day 21.
61987819|NCT00326443|PLACEBO_COMPARATOR|2|14 subjects oral buffer placebo. Parental Vi polysaccharide vaccine on Day 21.
62381718|NCT01823666||Mild cognitive impairment|People with cognitive complaint will be recruited. Who can be diagnosed as mild cognitive impairment will be enrolled according to the MCI criteria.
62381719|NCT01823666||Control|Normal cognition.
62761650|NCT04945265||Women aged <30|
62761651|NCT04945265||Women aged 30-36|
62761652|NCT04945265||Women aged 37-40|
61987820|NCT03830944||G1|"Study subjects with STEMI and increased inflammatory response at 7 days after STEMI~Interventions:~* Blood sampling~* transthoracic echocardiography~* Late Gadolinium-Enhancement Cardiac Magnetic Resonance~* Coronary Angio Computed Tomography"
62761653|NCT04945265||Women aged >40|
62761654|NCT04945265||Women undergoing egg freezing/male factor infertility/genetic testing|
61987821|NCT03830944||G2|"Study subjects with STEMI and no increased inflammatory response at 7 days after STEMI~Interventions:~* Blood sampling~* transthoracic echocardiography~* Late Gadolinium-Enhancement Cardiac Magnetic Resonance~* Coronary Angio Computed Tomography"
61987822|NCT06446765|EXPERIMENTAL|mindfulness-based Neurofeedback|Participants will participate in one session of mindfulness-based fMRI neurofeedback followed by 20 weeks of remote online weekly Dialectical Behavior Therapy skills group.
61987823|NCT06446765|OTHER|control Neurofeedback|Participants will participate in one session of control fMRI neurofeedback followed by 20 weeks of remote online weekly Dialectical Behavior Therapy skills group.
61987824|NCT04283006|EXPERIMENTAL|Administration of CD20/CD22 dual Targeted CAR T-cells|A dose levels of 3-5\*10E6/kg are administrated for each subject.
61987825|NCT02044133|OTHER|Dosage of vitamine D : inclusion and 6 month|Participant will have one dosage of vitamine D to entrance of prison and one dosage of vitamine D 6 month after entry
61987826|NCT02044133|OTHER|Dosage of Vitamine D 6 month|Participant will have one dosage of vitamine D 6 month after entry to prison
61987827|NCT04863755|OTHER|DASH diet only|Patients receive a DASH diet and orientation to maintain their physical activity
61987828|NCT04863755|OTHER|DASH diet with pedometer|Patients receive a DASH diet and orientation to increase their physical activity with a pedometer steps count
62761655|NCT04945265||unidentified cause of infertility|
62761656|NCT04945265||PCOS|
62761657|NCT04945265||endometriosis|
62761658|NCT04945265||tubal disorders|
62761659|NCT04945265||ovulatory disorders|
62761660|NCT04945265||other causes of infertility e.g., fibroids.|
62761661|NCT00659217|EXPERIMENTAL|2|mesenchymal stem cell Autologous MSC transplantation
62761662|NCT03116542|EXPERIMENTAL|Diagnostic (18F-FLT PET/CT)|"Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-L-thymidine) PET/CT (Positron Emission Tomography/Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. \[18F\] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) \[18F\] FLT by intravenous infusion."
62761663|NCT05947630|EXPERIMENTAL|AFO (ankle foot orthosis) dynamic and correctional|Groep A with AFO (ankle foot orthosis) dynamic and correctional
62761664|NCT05947630|NO_INTERVENTION|AFO or KAFO (knee ankle foot orthosis) correctional|Groep B with AFO or KAFO (knee ankle foot orthosis) and only correctional
62761665|NCT05947630|EXPERIMENTAL|KAFO dynamic and correctional|Groep C with KAFO dynamic and correctional
62761666|NCT05947630|NO_INTERVENTION|KAFO correctional|Groep D with KAFO only correctional
62761667|NCT06323798||cases|patients with a paranasal sinus mri and a confirmed pyocele at bacteriologic sample reviewed in the medical file
62761668|NCT06323798||controls|patients with a paranasal sinus mri and a confirmed simple retention mucus at bacteriologic sample reviewed in the medical file
62761669|NCT06453603|EXPERIMENTAL|PRP injection|receive pes anserinus PRP injection
62761670|NCT06453603|ACTIVE_COMPARATOR|Corticosteroid injection|receive pes anserinus corticosteroid injection
62761671|NCT03233022|ACTIVE_COMPARATOR|Unchanged Happify|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
62761672|NCT03233022|ACTIVE_COMPARATOR|Negatively-focused tracks|"Participants use two pre-selected Happify tracks that focus on remediating negatives (e.g. conquering negative thoughts and managing stress). Several engagement elements are missing, including social forums, regular informational emails, and the ability to play games. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period."
62761673|NCT03233022|ACTIVE_COMPARATOR|Positively-focused tracks|Participants use two pre-selected Happify tracks that focus on improving positives (e.g. building well-being, using one's strengths). Several engagement elements are missing, including social forums, regular informational emails, and the ability to play games. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
62381720|NCT01364948|EXPERIMENTAL|Coconut oil application|The oil (coconut oil) was applied by the trained nurse to the entire body surface of infant except the face two times a day starting at 12 hrs of life. Four ml of coconut oil was applied using both hands of the caregiver in four strokes. First stroke was from the clavicles over the chest and abdomen till the groin, second from the front of thighs over the knee and leg upto the sole, the third one from the shoulders over the arm and forearm till the palm continuing medially over the forearm and arm till the axilla and the final stroke was used for the back, starting from the upper back, continuing over the back of the thighs till the heel. Just prior to the first application, and thereafter prior to the subsequent applications the TEWL was recorded using the portable closed chamber evaporimeter. The oil application was continued twice daily (every 12 hrs at the same time as the hour of birth e.g. 11 am and 11pm) till the completion of the seventh day (168 hrs of life).
62761674|NCT03233022|PLACEBO_COMPARATOR|Placebo condition|Participants complete a Happify program that is designed to engage with specific activities, but that does not aim to promote positive emotion or reduce negative emotion. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
62761675|NCT03233022|SHAM_COMPARATOR|Distraction condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
62761676|NCT04902651|EXPERIMENTAL|HM242-Gel|
62761677|NCT04902651|ACTIVE_COMPARATOR|Intrasite Gel|
62761678|NCT00520013|EXPERIMENTAL|carboplatin/paclitaxel/bevacizumab then bevacizumab|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation (A): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 1 year."
62761679|NCT00520013|EXPERIMENTAL|carboplatin/paclitaxel/bevacizumab then bevacizumab/erlotinib|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation (AE): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle and oral erlotinib 150mg daily for 1 year."
61987829|NCT05459922|EXPERIMENTAL|Bright light therapy group|Participants will receive 30-minute morning bright light therapy for 2 weeks. Participants will start the therapy within a few minutes of their designated wake up time, which is determined by their average wake time from the baseline week of sleep assessment.
61987830|NCT05459922|PLACEBO_COMPARATOR|Dim light (placebo) group|Participants will receive 30-minute dim light (placebo) therapy for 2 weeks. Participants will start the therapy within a few minutes of their designated wake up time, which is determined by their average wake time from the baseline week of sleep assessment.
62381721|NCT01364948|NO_INTERVENTION|No Oil Application|Babies in this group were not subjected to oil application. TEWL measurement was recorded every 12 hrs for the first week of life, at the same time as the hour of birth.
62381722|NCT00058318|EXPERIMENTAL|Treatment|Gemcitabine + Capecitabine
62381723|NCT03497390|ACTIVE_COMPARATOR|EMERALD|Patients will have 1-year multicomponent program (EMERALD) intervention including a total of 6 interactive workshops focusing on empowerment skills, healthy eating and exercise. Please refer to the protocol for further details.
62381724|NCT03497390|PLACEBO_COMPARATOR|Usual care|Usual management without any workshop or program
62381725|NCT05267899|EXPERIMENTAL|WGI-0301|
62381726|NCT04050540|EXPERIMENTAL|dPEP Intervention Arm|Participants assigned to dPEP will be instructed to take doxycycline 200 mg (two 100mg capsules) orally within 24 hours and up to 72 hours after each condomless sex act
62381727|NCT04050540|NO_INTERVENTION|Standard of Care Arm|Participants assigned to Standard of Care
62381728|NCT00722410|NO_INTERVENTION|A|
62381729|NCT00722410|EXPERIMENTAL|B|VSL#3 for 4 weeks
62381730|NCT00722410|EXPERIMENTAL|C|Mechanical bowel cleansing followed by VSL#3 for 4 weeks.
62381731|NCT00967343|EXPERIMENTAL|ATIR|
62381732|NCT01651676|EXPERIMENTAL|COPD arm|"VQ11 validation:~Stage II, III or IV COPD patients justifying a LABD will benefit from the studied VQ11 questionnaire"
62381733|NCT05876949|EXPERIMENTAL|Experimental Arm AVT03 120mg|AVT03 is the proposed biosimilar for Xgeva (denosumab). Subjects in this arm will receive a single 120mg dose of AVT03 as a subcutaneous injection
62381734|NCT05876949|ACTIVE_COMPARATOR|Active Comparator Xgeva 120mg|Xgeva (denosumab) is the proposed active comparator for AVT03. Subjects in this arm will receive a single 120mg dose of Xgeva (denosumab) as a subcutaneous injection
62381735|NCT01933399|OTHER|Standard of Care|Medication based on physician prescriptions or overcounter use not germane to the study. Subjects also receive physical therapy for 2 weeks.
62381736|NCT01933399|EXPERIMENTAL|Extensible lumbosacral orthoses plus standard of care|This group receives a flexible/extensible lumbosacral orthosis, one that is commonly available over the counter
62381737|NCT01933399|EXPERIMENTAL|Inextensible lumbosacral orthoses and standard of care|This group receives an inextensible lumbosacral orthoses which leads to 14% increase in trunk stiffness compared to the other conditions.
62381738|NCT02882451|EXPERIMENTAL|pinaverium bromide|take 50 mg pinaverium bromide three times a day 1 days before and then 100 mg 1 hour before the examination orally
62381739|NCT02882451|PLACEBO_COMPARATOR|Vitamin C|take 50 mg Vitamin C three times a day 1 days before and then 100 mg 1 hour before the examination orally
62381740|NCT01092572|EXPERIMENTAL|Simvastatin 40 mg/d|simvastatin 40 mg per day taken orally
62381741|NCT01092572|PLACEBO_COMPARATOR|Sugar pill|
62381742|NCT04704206|ACTIVE_COMPARATOR|Active Interactive Media Group|"AIMG children will perform active activities on the interactive tablet media. The games and applications that will be used during this intervention were selected through a search in the online application store compatible with the tablet used during the intervention (Google Play). The search term used was games for children aged 2 to 3 years and they were analyzed for the following criteria: (1) interactivity: critical thinking, active participation, decision making; (2) learning: activities that stimulate cognitive development, fine motor, receptive language, expressive and social-emotional language (see table 1 to view activities); (3) suitability: age, period of development, multiple domains and (4) results: challenging activity, not frustrating, providing feedback"
62381743|NCT04704206|ACTIVE_COMPARATOR|Passive Interactive Media Group|PIMG children will go to the intervention room where they will use interactive tablet media in passive activities, such as: watching videos and children's stories that they often watch at home. This survey will be possible thanks to the questionnaire on the Use of Interactive Media where parents will list which drawings, stories and videos children use to watch.
62381744|NCT04011462|EXPERIMENTAL|Prewarming 20 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
62381745|NCT04011462|EXPERIMENTAL|Prewarming 30 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
62381746|NCT04011462|NO_INTERVENTION|Standard care|warming with cotton sheet and blanket for 20 minutes.
62381747|NCT05209204||40 pateint glucoma suspect|ASOCT
62381748|NCT02029885|EXPERIMENTAL|Investigational Therapy (Surround Sound)|Investigational Therapy using external focused ultrasound
62761680|NCT00520013|EXPERIMENTAL|carboplatin/paclitaxel/bevacizumab|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation: None"
62381749|NCT02029885|SHAM_COMPARATOR|Sham Control|Blinded Sham Control Arm
62381750|NCT03928990|EXPERIMENTAL|Experimental arm|
62381751|NCT05747768|EXPERIMENTAL|Healthy Volunteers|Healthy volunteer received drug combinations（10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin） on an empty stomach
62381752|NCT05747768|EXPERIMENTAL|Patients with mild-to-moderate renal impairment|Patients with mild-to-moderate renal impairment received drug combinations（10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin） on an empty stomach
62381753|NCT05747768|EXPERIMENTAL|Patients with moderate to severe renal impairment|Patients with moderate to severe renal impairment received drug combinations（10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin） on an empty stomach
62381754|NCT05747768|EXPERIMENTAL|Patients with severe renal impairment|Patients with severe renal impairment received drug combinations（10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin） on an empty stomach
62761681|NCT05991765||Digit Tip Wound|Experimental Wound Exudate from Digit Tip Wounds
61987831|NCT06496009||immunotherapy group|advanced or metastatic non-small cell lung cancer who are PD-L1 negative and receiving first-line immunotherapy in routine clinical practice
62381755|NCT05747768|EXPERIMENTAL|Patients with end-stage renal disease|Patients with end-stage renal disease received drug combinations（10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin） on an empty stomach
62381756|NCT00017173|EXPERIMENTAL|surgery with INGN 201 followed by chemo/RT|intraoperative and postoperative injections of INGN 201 into the tumor bed, followed by cisplatin and radiation therapy
62381757|NCT04889937||PC004 Cohort|The study will include a sample of patients with specific cancer types visiting the outpatient hematologic oncology clinic for their standard of care chemotherapy administration. Participants will need to be willing to participate and be able to provide written informed consent
62381758|NCT05419284|EXPERIMENTAL|patient|GAPP+Care
62381759|NCT05419284|EXPERIMENTAL|caregiver|+Care
62381760|NCT05419284|OTHER|healthcare professional of the ward|observation of GAPP+Care
62381761|NCT05669573|EXPERIMENTAL|Early feeding group|Patients in the early diet group started oral intake 6 hours after ESWL of the day of procedure with a soft diet comprised 200 mL with 170 kilocalories. Observe closely until 24h, and then continue to fasting until the next ESWL/ERCP or change the diet to the general diet according to the actual clinical needs.
62381762|NCT05669573|ACTIVE_COMPARATOR|Standard fasting group|Patients in the standard fasting group were fasted for 24 hours after the first ESWL operation, and close observation during this fasting period. After 24 hours, according to the actual clinical needs, continue to fast until the next ESWL/ERCP operation, or change the diet to a general diet.
62381763|NCT05192044|EXPERIMENTAL|Group A|Fast track Care (Enhanced recovery after)pancreatico-duodenectomy
62381764|NCT05192044|ACTIVE_COMPARATOR|Group B|Conventional Care pancreatico-duodenectomy.
62381765|NCT01481259|EXPERIMENTAL|Immunotherapy|Subjects receive autologous cytokine-induced killer cell infusion every 21 days
62761682|NCT05991765||Split Skin Donor Site Wound|Active Comparator Wound Exudate from Split Skin Donor Site Wound
62381766|NCT01481259|ACTIVE_COMPARATOR|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days
62761683|NCT04129905|EXPERIMENTAL|Symptomatic HCM patients|30 subjects (25-26 sarcomeric, 4-5 Fabry).
62761684|NCT04129905|ACTIVE_COMPARATOR|Healthy controls subjects|10 subjects (matched in age and sex to HCM patients) to obtain reference values of endothelial dysfunction.
61987832|NCT01135758|EXPERIMENTAL|ketamine 0.5 mg/kg i.v.|Single administration of ketamine 0.5 mg/kg i.v.
62381767|NCT04547127|EXPERIMENTAL|Convalescent anti-SARS-CoV-2 MBT Plasma + SMT|Participants will receive 2 consecutive transfusions of 200 to 250 milliliters (ml) of ABO-compatible convalescent plasma with each unit of plasma, obtained from the same convalescent donor, which will be administered on Day 1 using standard procedures for administration of fresh frozen plasma. Participants weighing less than 45 kilograms (kg) will receive two transfusions of 10 ml of convalescent plasma per kilogram of body weight with each unit of plasma obtained from the same convalescent donor. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
62381768|NCT04547127|ACTIVE_COMPARATOR|Standard Medical Treatment|Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29.
62381769|NCT01729611||Scleroderma|60 patients with scleroderma - 30 with and 30 without Pulmonary Arterial Hypertension
62381770|NCT01729611||Cirrhosis|60 patients with cirrhosis - 30 with and 30 without Pulmonary Arteria Hypertension
62761685|NCT02741570|EXPERIMENTAL|Nivolumab and Ipilimumab|Specified dose on specified days
62761686|NCT02741570|ACTIVE_COMPARATOR|Extreme Regimen|Specified dose on specified days
62761687|NCT01776671|OTHER|Gralise|Efficacy of Gralise
62381771|NCT04102657|EXPERIMENTAL|Intermittent Fasting with Left Arm Exercise|Healthy volunteers willing to fast for a 16-hour period daily for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
62761688|NCT04082910|EXPERIMENTAL|Conditional therapy mode group|Metoprolol (12.5-25 mg per dose, every 12 hours) was initially given from the day of CRS diagnosis confirmation post CAR T cell infusions till CRS remission in patients without bulky tumor burden. For all metoprolol-treated patients, the use of antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
62761689|NCT04082910|EXPERIMENTAL|Prophylactic therapy mode group|Metoprolol (12.5-25 mg per dose, every 12 hours) was given starting from the day before CAR T infusion till CRS remission in patients with bulky disease. For all metoprolol-treated patients, the use of antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
62761690|NCT02725112|EXPERIMENTAL|Pregabalin ER- Target Release 330mg|A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
62761691|NCT02725112|EXPERIMENTAL|Pregabalin ER - Slow Release 330mg|B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
62761692|NCT02725112|EXPERIMENTAL|Pregabalin ER - Fast Release 330mg|C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
62761693|NCT02725112|EXPERIMENTAL|Pregabalin IR - 300mg|D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
62761694|NCT02725112|EXPERIMENTAL|Pregabalin ER - Target Release 82.5mg|E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
62761695|NCT02725112|EXPERIMENTAL|Pregabalin ER - Aberrant Fast 330mg|F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
62761696|NCT01811576|ACTIVE_COMPARATOR|recombinant human growth hormone|Daily subcutaneous dose
62761697|NCT01811576|EXPERIMENTAL|TV-1106|Titration dose levels of TV-1106
62761698|NCT02004145|EXPERIMENTAL|Positive Psychology|"The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.~Exercises:~Gratitude for positive events~Gratitude letter~Performing acts of kindness~Using personal strengths~Enjoyable and meaningful activities:~Repeating one of the previous exercises."
62761699|NCT02004145|SHAM_COMPARATOR|Organizational Skills|"The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.~Exercises:~Daily Events~Health Events~Morning and Evening Events~Interactions with Others~Leisure Time Activities~Repeating one of the previous exercises."
62761700|NCT04911712|ACTIVE_COMPARATOR|Randomly selected malnourished patients for normal protein liquid diet supplementation|Randomly selected malnourished patients for normal protein liquid diet supplementation
62761701|NCT04911712|EXPERIMENTAL|Randomly selected Malnourished patients with high protein liquid diet supplementation|Malnourished patients with high protein liquid diet supplementation
62761702|NCT01382004|ACTIVE_COMPARATOR|Penicillin-G-Benzathine|penicillin-G-Benzathine : 50,000 UI/Kg single dose(maximum 2.4 million units IM)
62761703|NCT01382004|EXPERIMENTAL|Azithromycin|Azithromycin: 30 mg/kg single dose (Maximum: 2.000 mg.)
62761704|NCT00033540|EXPERIMENTAL|Capecitabine + Gemcitabine|Capecitabine 650 mg/m\^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days; Gemcitabine 1000 mg/m\^2, intravenous (IV) over 100 minutes, Days 1, 8, every 21 days
62761705|NCT05639322|ACTIVE_COMPARATOR|Ketamine only|
62761706|NCT05639322|ACTIVE_COMPARATOR|Psychotherapy only|
62381772|NCT04102657|EXPERIMENTAL|Intermittent Fasting with Right Arm Exercise|Healthy volunteers willing to fast for a 16-hour period daily for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
62761707|NCT05639322|EXPERIMENTAL|Ketamine + Psychotherapy|
62761708|NCT00227513|EXPERIMENTAL|Arm I|"Patients receive oral vorinostat (SAHA) twice daily on days 1-14 in step A. Patients receive oral vorinostat (SAHA) twice daily on days 1-4 and 8-11 in Step B and bortezomib IV over 3-5 seconds on days 2, 5, 9, and 12 during the first course and on days 1, 4, 8, and 11 during subsequent courses in both steps A and B. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 6 additional patients receive bortezomib at the MTD. Subsequent cohorts of 3-6 patients receive escalating doses of SAHA until the MTD of that drug is determined."
62761709|NCT06289088|EXPERIMENTAL|First Intervention|The application will be done sequentially: without orthosis, with adaptation and with orthosis.
62761710|NCT06289088|EXPERIMENTAL|Second Intervention|The application will be done sequentially: with adaptation, with orthosis and without orthosis
62761711|NCT06289088|EXPERIMENTAL|Third Intervention|The application will be done sequentially: with orthosis, without orthosis, and with adaptation
62761712|NCT03313284|EXPERIMENTAL|Study Group|
62761713|NCT03950713|EXPERIMENTAL|Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)|Participants in the intervention group received the MBSR-T in addition to routine care.
62761714|NCT03950713|NO_INTERVENTION|Routine care|The control group received the routine care provided in facilities, including routine check-ups at diabetes clinics as necessary.
62761715|NCT00143533|OTHER|1|
62761716|NCT01390207|EXPERIMENTAL|16mm follicles|
62381773|NCT04102657|EXPERIMENTAL|Free-living Diet with Left Arm Exercise|Healthy volunteers maintaining their current diet for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
62381774|NCT04102657|EXPERIMENTAL|Free-living Diet with Right Arm Exercise|Healthy volunteers maintaining their current diet for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
62381775|NCT05093244|EXPERIMENTAL|SeQuent Please ReX|Drug coated balloon (DCB) catheter.
62381776|NCT05093244|ACTIVE_COMPARATOR|Plain old balloon angioplasty (POBA)|
62381777|NCT03634852|ACTIVE_COMPARATOR|Topical|Moxifloxacin hydrochloride 0.5% eye drops and dexamethasone 0.1% eye drops were prescribed four times a day for 1 month postoperatively.
62381778|NCT03634852|ACTIVE_COMPARATOR|Intracameral - Subconjunctival|Intracameral Moxifloxacin 0.1% with Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml had been administered at the conclusion of the surgery
62761717|NCT05484817||Normal cardiac function groups|Patients admitted to the hospital or recruited from the community with diabetes mellitus are screened for cardiovascular diseases by echocardiography. Global longitudinal strain (GLS) is measured by speckle tracking echocardiography. The 2015 American Society of Echocardiography guidelines recommended a mean of -20% for GLS in healthy subjects, while the upper normal limit is -18%. Therefore, the normal cardiac function groups are defined as GLS \< -18%.
62381779|NCT02689089|OTHER|3HP|The interrupted time series design aims to collect data at multiple time points before (standard regimen) and after the introduction of the new 3HP regimen (interruption) to detect if a significant increase in the number of completions has occurred with the new regimen
62381780|NCT04775966||The study population|Patients meeting eligibility criteria (see appropriate section).
62381781|NCT00761033|EXPERIMENTAL|music|children will listen to music during procedure
62381782|NCT00761033|OTHER|Standard care|Standard care
62381783|NCT02434250|EXPERIMENTAL|SLT arm|Patient receiving 'Selective Laser Trabeculoplasty' (SLT) due to failed Phacoemulsification Cataract Extraction with Intraocular Lens Implantation combined with Eximer Laser Trabeculectomy (phaco-ELT) in Open Angle Glaucoma and Ocular Hypertension to control intraocular pressure and/or glaucoma progression.
62381784|NCT02774863||"Group Maternal and Child Protection"|Followed by the doctor and pediatric nurse of the Maternal and Child Protection . A child psychiatric consultation (usual care) can take place during the monitoring of this patient.
62381785|NCT02774863||"Group Home passages"|A child psychiatric consultation is scheduled in the month following the inclusion and three home passages between the 2nd and 3rd months of follow up.
62381786|NCT03460665|EXPERIMENTAL|Microparticles|arteriography and an injection of inert microparticles of 75 µm in neovessels
62381787|NCT03460665|PLACEBO_COMPARATOR|Placebo|knee arteriography and injection of saline solution in neovessels
62381788|NCT02117973|ACTIVE_COMPARATOR|Conventional Technique using Persona prosthesis|The surgeon will realize the implantation of the Persona prosthesis according to the surgical technique. Potential variables such as methodology for determining tibial rotation, measuring of bone cuts, and any intra-operative adjustments will be captured on the operative case report form.
62381789|NCT02117973|EXPERIMENTAL|iAssist Technique using Persona prosthesis|iAssist is an electronic displacement sensor based instrumentation system that provides intra-operative verification at each surgical step (bone cuts alignment and resection level); in order to help reduce bone cuts errors. iAssist features simple and intuitive instrumentation that is based on conventional total knee arthroplasty instrumentation. iAssist should take less than 2-3 minutes (on average) to setup
62381790|NCT06481605|EXPERIMENTAL|C-REX|Patients will receive the C-REX device during anastomosis construction
62381791|NCT05049122|EXPERIMENTAL|Dupilumab|Dupilumab every 2 weeks (q2w). Dosing interval may be changed from q2w to q4w at week 24
62381792|NCT02385292|EXPERIMENTAL|Intranasal then Extranasal Application|Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.
62381793|NCT02385292|ACTIVE_COMPARATOR|Extranasal then Intranasal Application|Extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.
62381794|NCT01351415|EXPERIMENTAL|Bevacizumab + Standard of Care|Participants will receive bevacizumab on Day 1 of every 21-days cycle along with standard of care (Erlotinib or Docetaxel or Pemetrexed) as second line treatment, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).
62381795|NCT01351415|ACTIVE_COMPARATOR|Standard of Care|Participants will receive investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).
62381796|NCT03427762|EXPERIMENTAL|Healthy cycling group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Then there is a bicycle every 1 hour.
62381797|NCT03427762|EXPERIMENTAL|Healthy xbox group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Then they will train 1 hour every day on an xbox program.
62381798|NCT03427762|NO_INTERVENTION|Healthy controll group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Thereafter, the group does not move only in everyday life.
62761718|NCT05484817||Impaired cardiac function groups|Patients admitted to the hospital or recruited from the community with diabetes mellitus are screened for cardiovascular diseases by echocardiography. Global longitudinal strain (GLS) is measured by speckle tracking echocardiography. The 2015 American Society of Echocardiography guidelines recommended a mean of -20% for GLS in healthy subjects, while the upper normal limit is -18%. Therefore, the impaired cardiac function groups are defined as GLS ≥ -18%.
62761719|NCT00151034|EXPERIMENTAL|Herceptin|"Herceptin - 4mg/kg day 1 of cycle 1; 2mg/kg day 8 and 15 of cycle 1 and subsequent cycles.~Paclitaxel - 200mg/m\^2 on day 1 Carboplatin - AUC 5 on day 1 Gemcitabine - 800 mg/m\^2 on day 1 and 8"
62761720|NCT02689076|EXPERIMENTAL|HIE Notification plus Care Coordination|VA provider notification of non-VA hospitalization via electronic health information exchange (HIE) plus post-hospital geriatric care transitions intervention
62761721|NCT02689076|ACTIVE_COMPARATOR|HIE Notification alone|VA provider notification of non-VA hospitalization via electronic health information exchange (HIE) followed by usual post-hospital care
62381799|NCT03427762|EXPERIMENTAL|PD groupe|"Patients with PD have already been evaluated and compared to the results of a healthy group within a separate experiment.~The study and the results have been completed. Clinical trial number:NCT03193268"
62761722|NCT02689076|NO_INTERVENTION|Usual Care (No HIE Notification and No Care Coordination)|Absence of VA provider notification of non-VA hospitalization via HIE plus Absence of post-hospital geriatric care transitions intervention \[Usual Care\]
62761723|NCT01303146|EXPERIMENTAL|Enzyme replacement therapy|intravenous infusion 100U/kg every other week for 18 months
62761724|NCT00819377|PLACEBO_COMPARATOR|Normal saline|Normal saline by inhalation over 15 min
62761725|NCT00819377|ACTIVE_COMPARATOR|Milrinone|Inhaled milrinone 5 mg(as for the injectable solution)
62761726|NCT05289583||Dialectical Behavior Therapy|The program's purpose is to help patients achieve the following therapeutic goals: (1) reduction of suicidal behaviors, (2) reduction of therapy-interfering behaviors, and (3) other risky or destabilizing behaviors. Standard DBT aims to achieve these goals by (1) conveying behavioral capabilities (skills), (2) motivation for applying these skills, (3) generalization of learned skills to the patient's natural environment, (4) structuring the treatment environment to reinforce functional behavior, and (5) conveying therapeutic resources and motivation to effectively treat patients with BPD.
62761727|NCT03251586|EXPERIMENTAL|20-29|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
62761728|NCT03251586|EXPERIMENTAL|30-39|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
62381800|NCT01199640|EXPERIMENTAL|MLN1202|
62381801|NCT06147544|EXPERIMENTAL|PB-718|"Low dose level of PB-718 administered on the first day of week 1-12(for cohort 1 and 2) or week 1-18(for cohort 3) according to the dose-escalation design~Medium dose level of PB-718 administered on the first day of week 1-12(for cohort 1 and 2) or week 1-18(for cohort 3) according to the dose-escalation design~High dose level of PB-718 administered on the first day of week 1-12(for cohort 1 and 2) or week 1-18(for cohort 3) according to the dose-escalation design"
62381802|NCT06147544|PLACEBO_COMPARATOR|Placebo|Matched placebo administered on the first day of week 1-12(for cohort 1 and 2) or week 1-18(for cohort 3) according to the dose-escalation design
62381803|NCT03491475||Negative Ajmaline test|No appearance of a type 1 ECG during Ajmaline test
62761729|NCT03251586|EXPERIMENTAL|40-49|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
62761730|NCT03251586|EXPERIMENTAL|50-59|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
62761731|NCT03251586|EXPERIMENTAL|60-69|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
62761732|NCT03251586|EXPERIMENTAL|70-79|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
62761733|NCT03251586|EXPERIMENTAL|80-89|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
62761734|NCT03251586|EXPERIMENTAL|90-99|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
62381804|NCT03491475||Positive Ajmaline test|Appearance of a type 1 ECG during Ajmaline test
62381805|NCT05801185|EXPERIMENTAL|Unilateral lower limb suspension|Participants will perform a 5-day unloading intervention using the ULLS model. Short-length crutches, aided by handgrip and forearm support distal to the elbow will be used to assist in any upright or ambulatory activity. One foot (randomized in a counterbalance manner) will be equipped with a shoe having a 10-cm thick sole, which permits the unloaded limb to move passively about the hip joint while adopting a near straight position.
62381806|NCT03099512|EXPERIMENTAL|Ex+SFE Group|Individuals in this group who will perform exercises for knee and also short foot exercise
62761735|NCT05729698|EXPERIMENTAL|polyethylene bag method|polyethylene bag method: preterm babies will be placed in polythene bags after birth
62761736|NCT05729698|EXPERIMENTAL|baby warmer swaddle method|baby warmer swaddle group: preterm babies will be placed in baby warmer swaddle after birth
62761737|NCT00902148|NO_INTERVENTION|Control Group|Colorectal Surgery without use of SurgiWrapTM
62761738|NCT00902148|ACTIVE_COMPARATOR|Test Group|Colorectal Surgery with use of SurgiWrapTM film secured directly below the abdominal incision
62381807|NCT03099512|ACTIVE_COMPARATOR|Ex Group|Individuals in this group who will perform exercises for knee only
62381808|NCT05433233|EXPERIMENTAL|HAPA|Participants assigned additional 3,000 steps/day on 5 days/week. Participants also received an additional 15 minutes of structured conversation with research personnel following the Health Action Process Approach Theory for behavior change.
62381809|NCT05433233|EXPERIMENTAL|No HAPA|Participants assigned additional 3,000 steps/day on 5 days/week and general conversation with researchers in regard to behavior change, not following a structured dialogue.
62381810|NCT04383665|SHAM_COMPARATOR|STN DBS off|
62381811|NCT04383665|EXPERIMENTAL|STN DBS 10Hz|
62381812|NCT04383665|ACTIVE_COMPARATOR|STN DBS 130Hz|
62381813|NCT02281604||0.2/1.2 microliter filter|Use of 0.2/1.2 microliter filters for intravenous drug administration
62381814|NCT02281604||5 mircroliter filter|Use of 5 microliter filters for intravenous drug administration
62761739|NCT03346265|EXPERIMENTAL|Group A|"Treatment A consisted in a combined exercise program of 40 min duration RMP (Monari, 2004; Monari et al., 2016) and 20 min duration of gait training with sensory cues.~RMP. RMP protocol was based on lengthening and muscular recruitment exercises by means of complex motor skills involving muscular kinetic chains in lower limbs and trunk. Each session was divided into muscular stretching exercise, aiming to increase step length and rotating trunk movements, and tailored progressive exercise therapy."
62381815|NCT06220227||embryologist freezing the embryo|
62381816|NCT06220227||embryologist thawing the embryo|
62381817|NCT02056665|EXPERIMENTAL|MINOCYCLINE 8 weeks|"Duration of treatment: 8 weeks~* Patients \<35 kg. 100 mg / day. Administered at a dose of one capsule of 50 mg breakfast and dinner.~* Patients 35 - 50 kg. 150 mg / day. Administered at a dose of 2 capsules of 50 mg breakfast and 1 capsule of 50mg dinner.~* Patients \> 50 kg. 200 mg / day. Administered at a dose of two capsules of 50 mg of breakfast and dinner."
62381818|NCT02056665|PLACEBO_COMPARATOR|PLACEBO 8 weeks|Pill manufactured to mimic Minocycline 50 mg capsule
62761740|NCT03346265|EXPERIMENTAL|Group B|Treatment B Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code): trunk (s760), pelvis (s750), lower extremity (s750), and upper extremity (s730) including shoulder region (s720). Domains focused on were (1) warm-up exercises, (2) trunk mobility exercises, (3) postural stability (b715), and (4) transferring oneself (d420) and changing body positions (d410).
62761741|NCT05257148|ACTIVE_COMPARATOR|Zofenopril arm|MONOTHERAPY PERIOD (one month): patients will be treated with Zofenopril 30 mg. COMBINATION THERAPY PERIOD (two months) patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Nebivolol 5mg
62761742|NCT05257148|ACTIVE_COMPARATOR|Nebivolol arm|MONOTHERAPY PERIOD (one month): patients will be treated with Nebivolol 5 mg. COMBINATION THERAPY PERIOD (two months) patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Nebivolol 5 mg
62761743|NCT03378583||control,|control normal ventilation
62761744|NCT03378583||sellick,|ventilation while sellick manoeuvre is applied
62761745|NCT03378583||low paratracheal esophagus compression|ventilation while low paratracheal esophagus compression is applied
62761746|NCT00378911|EXPERIMENTAL|Treatment (sunitinib malate)|Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
62761747|NCT00970983|ACTIVE_COMPARATOR|QUART|Patients in this arm will receive quadrantectomy, axillary dissection and radiotherapy (the current standard therapy).
62761748|NCT00970983|EXPERIMENTAL|QURT (SN-)|Patients will receive quadrantectomy, sentinel node investigation and radiotherapy. Selective axillary dissection will be performed if sentinel node is positive.
62761749|NCT03100721|EXPERIMENTAL|PNE+Physiotherapy|Pain neuroscience education (PNE) can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system. It will be applied one time (at baseline). Physiotherapy includes kinesitherapy and exercises.
62761750|NCT03100721|ACTIVE_COMPARATOR|Physiotherapy|Physiotherapy includes kinesitherapy and exercises.
62761751|NCT03627312|EXPERIMENTAL|Omega-3|this group receives a fruit juice drink containing omega-3
62761752|NCT03627312|PLACEBO_COMPARATOR|Placebo|this group receives the same fruit juice drink as in the experimental group, but it does not contain omega-3
62761753|NCT03627312|OTHER|Treatment as Usual|this group do not receive a fruit juice drink
62761754|NCT04902521|EXPERIMENTAL|Transcranial magnetic stimulation with constraint induced movement therapy|CIMT/TMS: Five participants will receive a one-hour weekly occupational therapy session of CIMT with 2-hours of daily home program for a total of 6 weeks; immediately prior to initiation of each CIMT session, participants will receive 20 minutes of TMS 1HZ.
62761755|NCT04902521|SHAM_COMPARATOR|constraint induced movement therapy Sham transcrianial magnetic stimulation|(CIMT/sham TMS): Five participants will receive a one-hour weekly session of CIMT with 2-hours daily of home program for a total of 6 weeks; immediately prior to initiation of each CIMT session, participants will receive 20 minutes of sham TMS 1HZ.
62761756|NCT01068782|EXPERIMENTAL|Arm 1|
62761757|NCT01068782|EXPERIMENTAL|Arm 2|
62761758|NCT01068782|EXPERIMENTAL|Arm 3|
62761759|NCT01068782|EXPERIMENTAL|Arm 4|
62761760|NCT01044316|ACTIVE_COMPARATOR|Arm 1|
62761761|NCT01044316|ACTIVE_COMPARATOR|Arm 2|
62761762|NCT02480400|EXPERIMENTAL|Supported Escitalopram|Escitalopram, with assessment visits at baseline, and weeks 2, 4, 6 and 8
62761763|NCT02480400|ACTIVE_COMPARATOR|Escitalopram|Escitalopram, with assessment visits at baseline, week 4 and week 8, and a safety visit at week 2
62761764|NCT02408081|NO_INTERVENTION|Treatment as usual|Pharmacological treatment, patient information and counselling according to international and national guidelines by health professionals specialized in elderly medical patients.
62761765|NCT02408081|EXPERIMENTAL|Family Focused Nursing|Family Focused Nursing and treatment as usual
62761766|NCT06520631|ACTIVE_COMPARATOR|Cryotherapy to arteriovenous fistula puncture site|This group of patients receives ice pack applied on the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis.
62761767|NCT06520631|ACTIVE_COMPARATOR|Cryotherapy to site opposite to arteriovenous fistula puncture site|This group of patients receives ice pack applied on contralateral to the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis.
62761768|NCT02609048|PLACEBO_COMPARATOR|Placebo Dose|Placebo Capsule Two Capsules Daily
62761769|NCT02609048|EXPERIMENTAL|Seladelpar / MBX-8025 50 mg Dose|MBX-8025 50 mg capsule One Capsule Daily
62761770|NCT02609048|EXPERIMENTAL|Seladelpar / MBX-8025 200 mg Dose|MBX-8025 100 mg capsules (2 taken once daily)
62761771|NCT02494843|ACTIVE_COMPARATOR|Online haemodiafiltration|
62761772|NCT02494843|ACTIVE_COMPARATOR|Haemodialysis|
62761773|NCT03356977|EXPERIMENTAL|Crisaborole ointment 2%|Subjects will be dosed for 28 days. A thin layer of ointment will be applied to all areas designated for treatment.
62761774|NCT04326036|EXPERIMENTAL|Lipoaspiration|Closed sterile, disposable microcannula of small volume adipose tissue, including the stromal vascular fraction (SVF) (cells and stromal tissue
62761775|NCT04326036|EXPERIMENTAL|Isolation & Concentration of cSVF|Isolation \& Concentration of cellular stromal vascular fraction (cSVF) using Healeon Centricyte 1000 Centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocols
62182523|NCT03862209|EXPERIMENTAL|Community mental health team (CMHT)|CMHTs will be multidisciplinary; that is, staff will be appointed to the CMHTs that include nurses, social workers, psychiatrists, psychologists, and in this project, a peer expert (a person with lived experience of mental health services). All staff within the CMHT will have defined roles and responsibilities that align with the staff functions, roles and linkages detailed in evidence-based service delivery models for community mental health teams. Participant will randomly be assigned to CMHT that will provide outreach mental health care during the project.
62761776|NCT04326036|EXPERIMENTAL|Delivery cSVF via Intravenous|cSVF from Arm 2 is suspended in a 250 cc of sterile Normal Saline IV solution and deployed though 150 micron in-line filtration and intravenous route over 30-60 minute timeframe
62761777|NCT04326036|OTHER|Liberase TM|Use of sterile Liberase TM enzyme to allow cSVF separation and isolation
62761778|NCT04326036|OTHER|Sterile Normal Saline|250 cc of sterile Normal Saline for Intravenous with sterile 150 micron in-line filtration for suspension of the concentrated cSVF and deployment IV
62761779|NCT03368014|EXPERIMENTAL|Lyrics-writing and singing show|The one-hour lyrics-writing and singing workshop was conducted first at the beginning of the programme for the intervention group, followed by two small workshops teaching lyrics-writing skills and the lyrics-writing competition after the workshop. A lyrics writing and singing show and an award ceremony will be held at the end.
62761780|NCT03368014|NO_INTERVENTION|Waitlist control|The workshops will not be provided to the control schools during the evaluation period and will be provided after the evaluation period.
62761781|NCT04167215|EXPERIMENTAL|perforator flap augmentation|Doppler probe is used to locate perforating vessels from the superior gluteal artery. . Flaps or lumbar artery flap will be designed to allow deepithelialization and dissection laterally to medially to identify the perforator . then sketolization is performed A gluteal pocket will then create for the augmentation flaps by undermining in a plane just superficial to the gluteal muscle extending to within 5 cm of the inferior gluteal crease. The deepithelialized flaps will then transpose inferomedially , and tacked to the fascia with several sutures.to be used as autologus buttock augmentation flap
62761782|NCT04167215|EXPERIMENTAL|fat injection|liposuction is performed firstly to parts where excess fat is exist and we will prepare the aspirated fat for injection as a graft in subcutaneous tissue of the buttock regoin
62761783|NCT00575432||1|
62761784|NCT03897946|EXPERIMENTAL|Group A: Hepatitis B exposed, with birth dose|"The 100 HBV-exposed (born to HBsAg-positive mothers) infants who are already enrolled in the parent AVERT study will also be enrolled in the current study, as the HBV-exposed cohort (Group A). These exposed infants will not receive additional interventions on top of the AVERT study since they will already be receiving a birth dose vaccine through the AVERT study."
62761785|NCT03897946|NO_INTERVENTION|Group B: Hepatitis B unexposed, no birth dose|"For the HBV-unexposed cohort in this study, the investigators will enroll 200 infants born to HBsAg-negative mothers. Half (100) of these infants will receive the routine three-dose series of HBV vaccine according to the standard EPI schedule in the DRC with no additional birth dose vaccine (Group B)."
62761786|NCT03897946|EXPERIMENTAL|Group C: Hepatitis B unexposed, with birth dose|"Group C will consist of the other half (100) of infants in the HBV-unexposed cohort who will receive four doses of HBV vaccine including a birth dose vaccine prior to the routine EPI schedule."
62381819|NCT02056665|EXPERIMENTAL|MINOCYCLINE 16 weeks|"Duration of treatment: 16 weeks~Patients \<35 kg. 100 mg / day. Administered at a dose of one capsule of 50 mg breakfast and dinner.~Patients 35 - 50 kg. 150 mg / day. Administered at a dose of 2 capsules of 50 mg breakfast and 1 capsule of 50mg dinner.~Patients \> 50 kg. 200 mg / day. Administered at a dose of two capsules of 50 mg of breakfast and dinner."
62381820|NCT01924260|EXPERIMENTAL|Treatment (alisertib, gemcitabine)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62381821|NCT02699840||Menactra Study Group 1|Participant aged 2 through 11 years at vaccination
62381822|NCT02699840||Menactra Study Group 2|Participant aged 12 through 17 years at vaccination
62381823|NCT02699840||Menactra Study Group 3|Participant aged 18 through 55 years at vaccination
62381824|NCT02365272|ACTIVE_COMPARATOR|amikacin standard dose|amikacin in a single standard dose
62381825|NCT02365272|ACTIVE_COMPARATOR|amikacin dose for critical care patients|amikacin in a single dose for critical care patients
62761787|NCT03000504|EXPERIMENTAL|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned chest drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
62182524|NCT03862209|NO_INTERVENTION|Standard care|Health care settings and their providers randomised to the control condition receive usual care: participant will gain standard care; ambulatory care, day hospitals or hospital admission.
62381826|NCT00498927|EXPERIMENTAL|Temozolomide|Following diagnosis of tumor recurrence or progression, all patients will receive of daily low dose temozolomide given at 50mg/m2/d without interruption. Brain imaging will be performed at baseline and every 2 months (standard of care). The treatment will be administered until development of toxicity, evidence of progression of disease or death.
62381827|NCT01495689|ACTIVE_COMPARATOR|Usual Care|Usual care for smoking cessation will be delivered to the control arm which comprises of strong physician advice, brief counseling from the clinic nurse +/- a prescription for smoking cessation aid if requested and willing
62381828|NCT01495689|EXPERIMENTAL|Ottawa Model with SmartCard|On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
62761788|NCT03000504|ACTIVE_COMPARATOR|Standard intercostal drain|Patients will have a standard 12F-16F Rocket Medical chest drain inserted as per usual clinical guidelines, using the Seldinger technique.
62761789|NCT03871348|EXPERIMENTAL|SAR441000 Dose Escalation Phase|SAR441000 will be administered as intratumoral injection as monotherapy in patients with solid tumors over a 28-day cycle
62381829|NCT00099606|EXPERIMENTAL|A1|
62381830|NCT03552809|ACTIVE_COMPARATOR|Conventional Frenectomy|For the conventional surgery, after application of local infiltration anesthesia of articaine HCL associated with epinephrine 1:100,000, the frenulum was grasped with a straight haemostat inserted into the depth of the vestibule; the tissue adjacent to the upper and lower surfaces of the haemostat was incised with a no.15 scalpel. After the diamond shaped resected portion of the frenulum was removed with the haemostat, muscle dilatations were excised on the submucosa of the lateral walls of the cavity. Horizontal incision was made on the periosteum with the help of a scalpel following the procedure. At the end of the operation, the wound was closed with absorbable sutures (4-0, Pegelak®, Doğsan Turkey).
62761790|NCT03871348|EXPERIMENTAL|SAR441000 + cemiplimab - Dose Escalation Phase|SAR441000 will be administered as intratumoral injection in patients with solid tumors in combination with cemiplimab over a 21-day cycle
62182525|NCT00556647||A|Fast-track diagnosis
62381831|NCT03552809|EXPERIMENTAL|Diode Laser Frenectomy|For the laser frenectomy, a diode laser device (λ = 810 nm, W: 4, GIGA Cheese II, China) was used to perform the procedure. The procedure was performed under local infiltration anesthesia with articaine HCL associated with epinephrine 1:100,000. The frenlum was held by a haemostat inserted into the depth of the vestibule while laser energy was applied to the upper and lower parts of the frenulum adjacent to the haemostat via a fibre tip (400 µm diameter, plain-ended, optical ﬁbre). The laser was carefully applied to the tissue and care was taken to avoid local necrosis of the periosteum or any bone structure.Following the bleeding control, the wound site was left to secondary healing. No sutures were necessary after procedure.
62381832|NCT03552809|EXPERIMENTAL|Laser Frenectomy with Incision|For the laser frenectomy, a diode laser device (λ = 810 nm, W: 4, GIGA Cheese II, China) was used to perform the procedure. The procedure was performed under local infiltration anesthesia with articaine HCL associated with epinephrine 1:100,000. The frenulum was held by a haemostat inserted into the depth of the vestibule while laser energy was applied to the upper and lower parts of the frenulum adjacent to the haemostat via a fibre tip (400 µm diameter, plain-ended, optical ﬁbre). The laser was carefully applied to the tissue and care was taken to avoid local necrosis of the periosteum. Horizontal incision was made on the periosteum with the help of a scalpel, additionally. No sutures were necessary after procedure.
62381833|NCT04049344|EXPERIMENTAL|Combination of decitabine with oxaliplatin treatment|Patients receive Decitabine 10 mg/day for 5 consecutive days (d1-5) plus Oxaliplatin 75mg/m2 2-week-cycle (d6, d20) within 4 weeks. One cycle is defined as 4 weeks of treatment and total of 6 cycles are designed for patients.
62381834|NCT01060150|EXPERIMENTAL|OROS Methylphenidate HCl|
62761791|NCT03871348|EXPERIMENTAL|SAR441000 + cemiplimab Expansion Melanoma, anti-PD-1 failure|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced melanoma who have failed anti-PD-1/PD-L1 therapy. Treatment is administered over a 21-day cycle
62761792|NCT03871348|EXPERIMENTAL|SAR441000 + cemiplimab Expansion Melanoma, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve melanoma over a 21-day cycle
62761793|NCT03871348|EXPERIMENTAL|SAR441000 + cemiplimab Expansion CSCC, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve Cutaneous Squamous Cell Carcinoma (CSCC) over a 21-day cycle
62761794|NCT03871348|EXPERIMENTAL|SAR441000 + cemiplimab Expansion HNSCC, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve Head and Neck Squamous Cell Cancer (HNSCC) over a 21-day cycle
62761795|NCT00751309||1|Lung and heart-lung transplanted subjects.
62761796|NCT04545437||ICU|Patients treated on a general adult intensive care unit
62381835|NCT02428387|EXPERIMENTAL|Intervention|"The intervention group (Group 1) will receive instructions on how to access My Tools 4 Care for 3 months."
62381836|NCT02428387|NO_INTERVENTION|Educational Control|An educational control group (Group 2) will receive a copy of the Alzheimer's Society' The Progression of Alzheimer's Disease - Overview Booklet.
62761797|NCT03790358|PLACEBO_COMPARATOR|Placebo|Placebo
62761798|NCT03790358|EXPERIMENTAL|low dose MDMA|6.5ug dose of serotonin agonist
62761799|NCT03790358|EXPERIMENTAL|medium dose|13ug dose of serotonin agonist
62761800|NCT03790358|EXPERIMENTAL|high dose|26ug dose of serotonin agonist
62761801|NCT03984149||FH pediatric patients|1000 clinically diagnosed FH pediatric patients (age \<18 years) included in the LIPIGEN (Lipid TransPort Disorders italian Genetic Network) database
62761802|NCT03226756|EXPERIMENTAL|Nivolumab|All patients enrolled in the study will received Nivolumab injections, 3mg/kg IV, every 2 weeks, up to 12 cycles (1 cycle = 28 days).
62761803|NCT01920763||Surgical Patients|Patients with intracerebral hemorrhage who have been offered a parafascicular, minimally-invasive procedure for hematoma drainage, by the treating neurosurgeon.
62381837|NCT04906733||Cancer patient|RAS/RAF wild-type metastatic right colon cancer patients receiving chemotherapy or chemotherapy combined target therapy treatment.
62381838|NCT02030457|EXPERIMENTAL|Treatment A|Treatment A: beclomethasone dipropionate BAI, 160 mcg - a single administration of 4 inhalations (40 mcg/inhalation)
62381839|NCT02030457|EXPERIMENTAL|Treatment B|Treatment B: beclomethasone dipropionate BAI, 320 mcg - a single administration of 4 inhalations (80 mcg/inhalation)
62381840|NCT02030457|EXPERIMENTAL|Treatment C|Treatment C: beclomethasone dipropionate MDI, 320 mcg - a single administration of 4 inhalations (80 mcg/inhalation)
62381841|NCT01775995|EXPERIMENTAL|Meditation-CBT|Participants receiving the meditation-CBT intervention, in addition to usual care for CLBP and opioid therapy management.
62381842|NCT01775995|OTHER|Wait-list Control|Participants receiving usual care for CLBP and opioid therapy management.
62761804|NCT03221608|ACTIVE_COMPARATOR|surgery alone(open/laparoscopic)|The patients with colorectal cancer (T4N0-2M0) who have a high risk of developing colorectal Peritoneal Carcinomatosis (PC) undergo curative surgery(open/laparoscopic).
62761805|NCT03221608|EXPERIMENTAL|surgery and HIPEC|Standard surgical treatment and HIPEC with Lobaplatin.
62761806|NCT02688868|EXPERIMENTAL|new specifications (Diameter 2.25mm)of Firehawk stent|Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
62761807|NCT02608450|EXPERIMENTAL|CB-03-01 cream|CB-03-01 cream, 1% applied twice daily for 12 weeks
62761808|NCT02608450|PLACEBO_COMPARATOR|Vehicle cream|Vehicle cream applied twice daily for 12 weeks
62761809|NCT05471102|ACTIVE_COMPARATOR|Study group|Cases managed by uterine lower segment resection with ligation ((suturing)) of the anterior division of the internal iliac artery (4 cm distal to the bifurcation of the common iliac artery); in addition to the bilateral uterine artery ligation at 2 levels; bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision.
62761810|NCT05471102|PLACEBO_COMPARATOR|Control group|Cases managed by uterine lower segment resection without ligation of the anterior division of the internal iliac artery. (i.e., only bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision).
62761811|NCT02060994||37-38 weeks|"Children who were born by elective Cesarean section after 37-38 gestational weeks.~Intervention: No intervention."
62761812|NCT02060994||39 week or more|Children who were born by elective Cesarean section after 39 gestational weeks or more Intervention: No intervention.
62761813|NCT05104619||tumor samples|(SCC of the tongue)
62761814|NCT05104619||healthy tissues|
62761815|NCT06313840||Case group - subjects with central sleep apnea|Patients with moderate to severe CSA defined by an apnea hypopnea index (AHI) ≥ 15 events per hour and a central apnea hypopnea index (CAHI) ≥ 50% of total AHI.
62761816|NCT06313840||Control group - subjects with no sleep disordered breathing|Patients with no SDB defined by an AHI \< 5 events per hour.
62761817|NCT06313840||Other SDB group - subjects with other forms of sleep disordered breathing|Patients that do not meet criteria for CSA or no SDB
62761818|NCT02366767|EXPERIMENTAL|automatic closed-loop insulin delivery|The closed-loop arm will consist of participants wearing a sensor and transmitter which transmits sensor glucose data. The algorithm determines insulin delivery rates and this is delivered in microboluses every 5 minutes
62381843|NCT03894501|EXPERIMENTAL|Mindfulness Oriented Recovery Enhancement|The Mindfulness Oriented Recovery Enhancement arm will participate in eight, weekly, two-hour group sessions.MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
62381844|NCT03894501|OTHER|Methadone program behavioral treatment as usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
62182526|NCT06309264|EXPERIMENTAL|Speech-based hearing aid fitting|Half of the study participants receive a hearing aid with gain settings determined via speech-based audiometry. Other hearing aid features such as noise reduction and directional microphones are disabled. Of this group of subjects, half are assigned to use the hearing aid daily for six weeks, while the remainder are followed for the same six-week period but use their hearing aids only to complete outcomes testing.
62381845|NCT03316898|PLACEBO_COMPARATOR|Placebo|Two placebo capsules once daily for 28 Days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
62381846|NCT03316898|EXPERIMENTAL|AGN-242071 5 mg|One AGN-242071 5 mg capsule plus one placebo capsule once daily for 28 days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
62381847|NCT03316898|EXPERIMENTAL|AGN-242071 15 mg|AGN-242071 starting at a dose of one 5 mg capsule plus one placebo capsule once daily for 5 days followed by AGN-242071 15 mg total dose (one 5 mg and one 10 mg capsules) once daily on Days 6 to 28. Dose can be adjusted based on safety and tolerability. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
62381848|NCT03316898|EXPERIMENTAL|AGN-242071 25 mg|AGN-242071 starting at a dose of one 5 mg capsule plus one placebo capsule once daily for 5 days followed by AGN-24071 15 mg total dose (one 5 mg and one 10 mg capsules) once daily on Days 6 to 10 followed by AGN-242071 25 mg total dose (one 5 mg and one 20 mg capsules) on Days 11 to 28. Dose can be adjusted based on safety and tolerability. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
62381849|NCT06371989|EXPERIMENTAL|Image-Guided Vacuum assisted biopsy of Tumor Site|Image-guided biopsy of the tumor bed and coil area performed before surgery
62381850|NCT02736942|ACTIVE_COMPARATOR|Laparoscopic|Laparoscopic TME
62381851|NCT02736942|EXPERIMENTAL|Transanal|TaTME
62761819|NCT02366767|ACTIVE_COMPARATOR|Control|The subjects in the control arm will wear the 530G system using Enlite and MiniLink transmitter and threshold suspend.
62761820|NCT06128980|NO_INTERVENTION|Standard of Care|Patients will be treated with GDMT for heart failure during the trial follow-up of 1 year.
62381852|NCT00325949|EXPERIMENTAL|arm label (1) hydrocodone/acetaminophen extended release|
62381853|NCT00325949|EXPERIMENTAL|arm label (2) hydrocodone/acetaminophen extended release|
62381854|NCT00325949|PLACEBO_COMPARATOR|Arm label (3) placebo|
62381855|NCT00201058|EXPERIMENTAL|1|Receives tailored web-based program
62761821|NCT06128980|ACTIVE_COMPARATOR|Weaning|Patients will be weaned from GDMT in a sequential order.
62761822|NCT03481920|EXPERIMENTAL|PEGPH20 + Avelumab|PEGPH20, a multi-site PEGylated enzyme generated by conjugating N-hydroxysuccinimidyl ester of methoxypoly(ethylene glycol)-butanoic acid (MSBA30K/B or PEG) and recombinant human hyaluronidase (rHuPH20). PEGPH20 has a half-life of approximately 2 days, thereby enabling systemic activity and sustained duration of action to degrade HA. In many different tumor types tested in murine xenograft models, response to PEGPH20 has been shown to be more robust for tumors characterized by higher HA expression.
62761823|NCT03378648|EXPERIMENTAL|CHF6366 active|
62381856|NCT00201058|ACTIVE_COMPARATOR|2|Control students receive existing web-based, generic asthma education
62381857|NCT03534466|EXPERIMENTAL|intervention group|Baby treadmill + conventional physical rehabilitation training
62381858|NCT03534466|ACTIVE_COMPARATOR|positive control group|Conventional physical rehabilitation training only
62761824|NCT03378648|PLACEBO_COMPARATOR|CHF6366|
62761825|NCT03378648|ACTIVE_COMPARATOR|Comparator|
62761826|NCT05628051||Hypotension after anesthetic induction group|Patients with hypotension after anesthetic induction
62761827|NCT05628051||Non-hypotension after anesthetic induction group|Patients without hypotension after anesthetic induction
62761828|NCT00353873|ACTIVE_COMPARATOR|Fluticasone propionate (FLIXOTIDE™)|Fluticasone propionate (FLIXOTIDE™) at a dose of 200μg twice daily
62381859|NCT00519220||I|Patients will answer symptom questionnaires and have their charts reviewed for relevant medical information.
62381860|NCT00065715|NO_INTERVENTION|A|No pills
62381861|NCT00065715|PLACEBO_COMPARATOR|B|Blinded placebo
62381862|NCT00065715|EXPERIMENTAL|C|Echinacea - Blinded
62381863|NCT00065715|EXPERIMENTAL|D|Echinacea - Unblinded, Open Label
62381864|NCT01108263|ACTIVE_COMPARATOR|Integra Flowable on wound bed|INTEGRA™ Flowable is a wound Matrix made of bovine (cow) collagen. It provides a scaffold for cellular and capillary growth. Dosage is dependent on the size of the wound. It will be applied once.
62381865|NCT01108263|ACTIVE_COMPARATOR|INTEGRA Flowable on wound & injected subcutaneously|INTEGRA™ Flowable is a wound Matrix made of bovine (cow) collagen. It provides a scaffold for cellular and capillary growth. Dosage is dependent on the size of the wound. It will be applied once.
62381866|NCT04697888|EXPERIMENTAL|Overall Study|Use of Omegaven for patients with parenteral nutrition associated liver disease.
62381867|NCT05232344|EXPERIMENTAL|Estradiol / Progesterone treatment|Estradiol (Provames®, 3 mg morning and evening, or 6 mg per day) Vaginal progesterone (400 mg, Progestan®, evening and morning, ie 800 mg per day).
62381868|NCT01157585|OTHER|drug|
62381869|NCT00281528|EXPERIMENTAL|260 mg/m^2 ABI-007 every 3 weeks|260 mg/m\^2 every 3 weeks and 15 mg/kg bevacizumab every 3 weeks
62761829|NCT00353873|EXPERIMENTAL|Fluticasone propionate/salmeterol (SERETIDE™)|Salmeterol/fluticasone propionate combination (SERETIDE™) at a dose of 50/100μg twice daily
62761830|NCT02182908|OTHER|Non surgical aneurysm of abdominal aorta|PET-Scan
62761831|NCT00787137|EXPERIMENTAL|PG102 0.3 mg/kg|Lowest dose PG102
62761832|NCT00787137|EXPERIMENTAL|PG102 1 mg/kg|Second dose PG102
62761833|NCT00787137|PLACEBO_COMPARATOR|Placebo (phosphate-buffered saline)|Control
62761834|NCT02146703|EXPERIMENTAL|gemcitabine and S-1|
62381870|NCT00281528|EXPERIMENTAL|260 mg/m^2 ABI-007 every 2 weeks|260 mg/m\^2 ABI-007 every 2 weeks and 10 mg/kg bevacizumab every 2 weeks
62381871|NCT00281528|EXPERIMENTAL|130 mg/m^2 ABI-007 weekly|130 mg/m\^2 ABI-007 weekly (without a week of 'rest') and 10 mg/kg bevacizumab every 2 weeks
62381872|NCT02798172|EXPERIMENTAL|Alogliptin+metformin|Alogliptin (alogliptin benzoate) is the most recent DPP-4 inhibitor; it entered the market in 2006. It is a potent and highly selective DPP-4 inhibitor with oral antidiabetic activity; Metformin is the most commonly prescribed first-line drug worldwide for the treatment of T2DM, it acts by decreasing both hepatic glucose production and intestinal glucose absorption, while improving insulin sensitivity, metformin as a safe and valid oral antidiabetic drug was recommended to the obese patients with a body mass index (BMI) \>30 kg/m2, it has some value in reducing or preventing weight gain and changes in metabolic parameters during treatment, and it can be combinated with other antidiabetic drug
62381873|NCT02798172|EXPERIMENTAL|metformin|Metformin is the most commonly prescribed first-line drug worldwide for the treatment of T2DM, it acts by decreasing both hepatic glucose production and intestinal glucose absorption, while improving insulin sensitivity, metformin as a safe and valid oral antidiabetic drug was recommended to the obese patients with a body mass index (BMI) \>30 kg/m2, it has some value in reducing or preventing weight gain and changes in metabolic parameters during treatment, and it can be combinated with other antidiabetic drug
62381874|NCT01795716|EXPERIMENTAL|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
62381875|NCT01795716|ACTIVE_COMPARATOR|Glivec|Single and multiple oral Glivec 400mg qd
62761835|NCT00758121||Observation|Heart failure patients with an implanted CRT-D
62761836|NCT05827562||patients group|". Inclusion criteria:~* Patients with RA who fulfilled the 2010 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) revised criteria for RA (1~* Patients having knee effusion .~Exclusion criteria:~* Patients with autoimmune diseases other than RA.~* Patients or controls with tumors, infections, or other severe organ damage."
62761837|NCT05827562||controls group|healthy subjects
62761838|NCT06096974|EXPERIMENTAL|Dose Escalation and Expansion|Dose escalation of YL-17231 to determine maximum tolerated dose.Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of YL-17231 to recommend Phase 2 regimens
62761839|NCT00666497|EXPERIMENTAL|A|Azacitidine
62761840|NCT00666497|EXPERIMENTAL|B|MGCD0103
62761841|NCT00666497|EXPERIMENTAL|C|Azacitidine + MGCD0103
62761842|NCT03908190|NO_INTERVENTION|Treatment As Usual|Participants will receive treatment as usual within the VHA Women's Wellness Clinic including any appropriate treatment or treatments for their medical and psychosocial concerns as determined by their primary care teams.
62761843|NCT03908190|EXPERIMENTAL|Treatment As Usual Plus Personalized Support for Progress|In addition to treatment as usual, women will receive the Personalized Support for Progress intervention.
62761844|NCT03590132|EXPERIMENTAL|SAAF|participants in this arm receive the SAAF intervention at age 11-12.
62381876|NCT04102410|EXPERIMENTAL|Experimental group|Patient with acute coronary syndrome will be included. They will have sprints, vertical jumps, questionary Short Form-12 (SF-12), activity actigraph and program composed of two 2 training strategies.
62381877|NCT04102410|SHAM_COMPARATOR|Control group|Patient with acute coronary syndrome will be included. They will have sprints, vertical jumps, questionary Short Form-12 (SF-12), activity actigraph and program of usual practice.
62381878|NCT04728789|EXPERIMENTAL|Avatrombopag treatment group|Avatrombopag would be started with 20mg/day. The dosage would be increased by 20 mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L. The dosage could range from 20mg/week to 60mg/day.
62381879|NCT02002637|EXPERIMENTAL|Latella Knee Implant System|
62761845|NCT03590132|EXPERIMENTAL|SAAF-T|participants in this arm receive the SAAF-Teen intervention at age 14-15.
62761846|NCT03590132|EXPERIMENTAL|SAAF SAAF-T|participants in this arm receive SAAF at age 11-12 and later receive SAAF-Teen at age 14-15
62761847|NCT03590132|NO_INTERVENTION|Control|These participants receive no interventions.
62761848|NCT06149117|EXPERIMENTAL|"test product (T) azithromycin capsule and reference product (R) azithromycin capsule Sumamed®"|TR
62761849|NCT06149117|EXPERIMENTAL|"reference product (R) azithromycin capsule Sumamed®and test product (T) azithromycin capsule"|RT
62761850|NCT00334581|EXPERIMENTAL|1|Irbesartan 150mg
62761851|NCT00334581|EXPERIMENTAL|2|Irbesartan 300mg
62761852|NCT03928288|EXPERIMENTAL|Intervention|Cabergoline 0.5 mg PO twice weekly for 6 months
62761853|NCT03928288|PLACEBO_COMPARATOR|Placebo|Placebo capsule PO twice weekly for 6 months
62761854|NCT02834923|ACTIVE_COMPARATOR|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change. CTH utilizes web-based interactive behavior change technology, based on a logic model of behavior and maintenance that is informed by social-cognitive and social ecological theories. Prior to diabetes visits with a clinician, health educator, or care manager, patients complete a pre-visit CTH assessment at their practice through a tablet computer or computer kiosk. CTH assesses multiple diabetes management behaviors (diet, physical activity, medication adherence, alcohol and tobacco use, stress, mood) using brief assessment measures, each with cut-points highlighting areas of deficit. Action planning plays a central role, through a web-based platform that allows the patient and health care team to select and set goals collaboratively.
62761855|NCT02834923|EXPERIMENTAL|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH seamlessly integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol specifically designed to enhance patient engagement in SMS activities. Key components of MI have been incorporated into a practical and systematic engagement protocol that includes: (1) acknowledging the patient's point of view; (2) identifying and labeling the patient's ambivalence (both the good reasons for making the change and the good reasons for not making the change); (3) evaluating whether change is really worth the effort; (4) identifying, reflecting and labeling accompanying feelings and concerns about change; and (5) establishing a small and meaningful goal by the end of the encounter.
62761856|NCT02033590|EXPERIMENTAL|SERI® Surgical Scaffold|
62381880|NCT03847272|EXPERIMENTAL|Patients|
62761857|NCT00990145|EXPERIMENTAL|Intervention|EDP-322 v. Placebo
62761858|NCT02078102|OTHER|Treatment|"Meloxicam and Filgrastim will be administered in fixed doses to each patient enrolled on this study. The treatments will be administered in a staggered dose schedule for a total treatment duration of 7 days prior to apheresis.~15 mg tablets of Meloxicam will be taken orally for 5 consecutive days.~10 µg/kg of Filgrastim will be subcutaneously injected for 5 consecutive days. Filgrastim may be subcutaneously injected for an additional 3 days if patients do not meet the primary endpoint for cell collection."
62761859|NCT05680155|EXPERIMENTAL|C1-XW003|High dosage of XW003 once weekly
62761860|NCT05680155|PLACEBO_COMPARATOR|C1-Placebo|Matched Placebo once weekly
62761861|NCT05680155|EXPERIMENTAL|C2-XW003|Low dosage of XW003 once weekly
62761862|NCT05680155|PLACEBO_COMPARATOR|C2-Placebo|Matched Placebo once weekly
62381881|NCT05750615||Quantitative phase|Pessary using women
62761863|NCT04793997|ACTIVE_COMPARATOR|Verum Microbiome spray group|Daily use of microbiome spray for two weeks
62761864|NCT04793997|PLACEBO_COMPARATOR|Placebo spray group|Daily use of placebo spray for two weeks
62761865|NCT04793997|NO_INTERVENTION|Household member group|No use of spray
62761866|NCT02423499||Autism Spectrum Disorder|Autism Spectrum Disorder adults without intellectual disability
62761867|NCT02423499||Bipolar Disorder|Bipolar Disorder adults during normothymic phase of illness
62761868|NCT02423499||Healthy Volonteers|Healthy adults
62761869|NCT00695656||1|
62381882|NCT05750615||Qualitative phase|Pessary using women
62381883|NCT05750615||Intervention development phase|Pessary using women and pessary practitioners
62761870|NCT03778320|EXPERIMENTAL|CTP-692|
62761871|NCT03778320|ACTIVE_COMPARATOR|D-Serine|
62761872|NCT03454815|EXPERIMENTAL|Patency Group|apical patency was maintained during chemomechanical preparation
62761873|NCT03454815|NO_INTERVENTION|Non Patency Group|Apical patency was not maintained during chemomechanical preparation
62761874|NCT05828420|EXPERIMENTAL|The pain effect of listening to white noise on newborn babies|Each baby was listened to white noise 10 minutes before, during and 20 minutes after the painful attempt.
62761875|NCT05828420|EXPERIMENTAL|The pain effect of listening to heart sound on newborn babies|Each baby listened to heart sounds at an average rate of 70 beats 10 minutes before, during and 20 minutes after the painful procedure.
62381884|NCT05750615||Pilot phase|Pessary using women
62761876|NCT05828420|EXPERIMENTAL|The pain effect of listening to music on newborn babies|Each baby was listened to the music that the mother listened to the most during pregnancy restriction 10 minutes before, during and after the painful attempt.
62761877|NCT00944736|ACTIVE_COMPARATOR|VSL#3|
62381885|NCT00523744|EXPERIMENTAL|Amlodipine(AML)+olmesartan, AML+valsartan, AML+valsartan+HCTZ|During the Treatment Phase 1, participants received 1 week of treatment with olmesartan 10 mg and amlodipine 5 mg once daily in free combination, followed by three weeks of treatment with olmesartan 20 mg plus amlodipine 10 mg once daily in free combination. During the treatment Phase 2 of the study participants received amlodipine 10 mg plus valsartan 160 mg for 4 weeks. During the Extension Phase, participants received 4 weeks treatment with amlodipine 10 mg plus valsartan 160 mg plus hydrochlorothiazide (HCTZ) 12.5 mg.
62381886|NCT04184466|EXPERIMENTAL|Insulin Aspart|Single subcutaneous administration of Insulin Aspart in dose 0.3 IU / kg
62381887|NCT04184466|ACTIVE_COMPARATOR|NovoRapid® Penfill®|Single subcutaneous administration of NovoRapid® Penfill® in dose 0.3 IU / kg
62381888|NCT02462200|ACTIVE_COMPARATOR|BCS Arm (breast-conserving surgery - standard of care)|"* Defined as partial mastectomy, lumpectomy, or local excisional biopsy with or without needle/wire localization~* The ICG will be prepared per manufacturer instructions and diluted to allow for intravenous dosing up to 0.5 mg/kg (except for those patients with iodine or seafood allergies or in cases where the goggles are unavailable for use).~* Following the BCS procedures, the surgeon or a study team member will don the goggles and state the NIR fluorescence margin information of the excised primary tumor specimen and of and CSM that are taken."
62381889|NCT02462200|EXPERIMENTAL|CSM Arm (breast-conserving surgery with cavity shave margins)|"* Partial mastectomy, lumpectomy, or local excisional biopsy with or without needle/wire localization with the addition of additional tissue specimens from all 6 margins (anterior, posterior, superior, inferior, medial, lateral) of the wound cavity if possible. In cases where an additional margin would involve the skin at the anterior margin and/or the pectoral muscle at the posterior margin, only the 4 (or 5) remaining margins should be obtained~* A margin thickness of 1 cm will be the defined goal to establish uniformity among different surgeons and allow for appropriate pathological evaluation~* The ICG will be prepared per manufacturer instructions and diluted to allow for intravenous dosing up to 0.5 mg/kg (no iodine or seafood allergies).~* Following the BCS procedures, the surgeon or a study team member will don the goggles and state the NIR fluorescence margin information of the excised primary tumor specimen and of any CSM that are taken."
62381890|NCT02143336|EXPERIMENTAL|Subcuticular suture|Subcuticular suture (absorbable) for skin closure
62761878|NCT00944736|PLACEBO_COMPARATOR|Placebo|
62182527|NCT06309264|ACTIVE_COMPARATOR|Audiogram-based hearing aid fitting|Half of the study participants receive a hearing aid with gain settings determined by applying the NAL-NL2 prescriptive formula to the pure-tone audiogram. Other hearing aid features such as noise reduction and directional microphones are disabled. Of this group of subjects, half are assigned to use the hearing aid daily for six weeks, while the remainder are followed for the same six-week period but use their hearing aids only to complete outcomes testing.
62381891|NCT02143336|ACTIVE_COMPARATOR|Skin staples|Standard skin staples for wound closure
62381892|NCT00278486|EXPERIMENTAL|stem cell transplantation|
62381893|NCT03516227|EXPERIMENTAL|HRVBF|Heart rate variability biofeedback
62381894|NCT03516227|NO_INTERVENTION|Control|Usual Care
62381895|NCT03131258|OTHER|Donor Nephrectomy|Donor Nephrectomy
62761879|NCT00003787||Intervention|high fiber, high vegetable, low-fat diet
62761880|NCT00003787||Control|NCI-recommended diet
62761881|NCT02446873|NO_INTERVENTION|Control|Control group
62761882|NCT02446873|EXPERIMENTAL|Treatment|Egg supplementation
62761883|NCT01804569|EXPERIMENTAL|moxa|moxibustion treatment 3 times a week for 3 weeks
62761884|NCT06174389|EXPERIMENTAL|Behavioral Weight Loss|Participants will undergo a behavioral weight loss program.
62761885|NCT03781791|EXPERIMENTAL|Active Treatment|ENT-01 tablet will be taken once daily by mouth.
62761886|NCT03781791|PLACEBO_COMPARATOR|Placebo Treatment|Placebo tablet will be taken once daily by mouth.
62761887|NCT01999218|EXPERIMENTAL|Ertugliflozin 5 mg|Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104
62381896|NCT02990065|EXPERIMENTAL|PROTEIN-FORTIFIED DIET|The protein-fortified diet consists on an energy goal based on REE measurement and a protein target based on the most recent literature recommendations (1.2-2 g/kg/die) (2). Daily caloric requirement, and subsequent protein content, of patients enrolled in the intervention group will be calculated using formulas in Table 1 (10, 12, 13). For each patient will be calculated the Resting Energy Expenditure (REE) and daily protein requirement (1.2-2g/kg/die of body weight registered at the admission) and the corresponding caloric intake (1g = 4 kcal). Finally, total daily caloric intake will be calculated by adding kcal from protein (1g = 4kcal) on kcal from non-protein (50% of REE).
62381897|NCT02990065|NO_INTERVENTION|STANDARD DIET|The standard diet consists on an energy goal based on weight formula (20-25 kcal/kg/die). According to the ICU nutritional protocol, EN is started at an initial rate of 10ml/h, and increased by 20ml/h every 12 hours in the absence of significant gastric residuals (\<250ml), with the aim of reaching the energy goal within 72 hours from admission. The EN formulae used are standard (1-1,5 kcal/ml, 40g/l protein). If enteral nutrition is not tolerated or is not indicated, supplemental PN is used to make up the energy shortfall. The PN formula used is standard (1000 kcal/l, 37 g/l protein).
62381898|NCT03698370|EXPERIMENTAL|Arm I (Ga68-NeoBOMB1 and Ga68 PSMA-R2|Participants receive gallium Ga 68 DOTA-NeoBOMB1 IV and 45 minutes later, undergo PET/MRI. Within 2 weeks, participants receive gallium Ga 68 PSMA-R2 IV then undergo PET/MRI 45-60 minutes later.
62381899|NCT03698370|EXPERIMENTAL|Arm II (Ga68 PSMA-R2 and Ga 68-NeoBOMB1)|Participants receive gallium Ga 68 PSMA-R2 IV and 45-60 minutes later undergo PET/MRI. Within 2 weeks, participants receive gallium Ga 68 DOTA-NeoBOMB1 IV then undergo PET/MRI 45 minutes later.
62381900|NCT03272009|EXPERIMENTAL|Treatment A|oral EYP001a
62381901|NCT03272009|EXPERIMENTAL|Treatment B|oral EYP001a
62761888|NCT01999218|EXPERIMENTAL|Ertugliflozin 15 mg|Ertugliflozin 15 mg QD from Day 1 to Week 104
62761889|NCT01999218|ACTIVE_COMPARATOR|Glimepiride up to 8 mg|Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104
62761890|NCT01735669|EXPERIMENTAL|Remifentanil|External cephalic version at term under Remifentanil perfusion
62761891|NCT01735669|ACTIVE_COMPARATOR|Nitrous oxide|External cephalic version at term under Nitrous oxide inhalation
62761892|NCT03700450|EXPERIMENTAL|Cyclophosphamid post Tranplant|Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
62761893|NCT01452295|EXPERIMENTAL|AOCH patients|Patients with acute on chronic hepatitis
62761894|NCT01452295|EXPERIMENTAL|AAH patients|Patients with acute alcoholic hepatitis
62182528|NCT03623477|ACTIVE_COMPARATOR|Cognitive Remediation (CRT)|Participants assigned to CRT alone will complete 24 hours of neurocognitive training activities and 12 hours of control computer activities.
62381902|NCT03272009|EXPERIMENTAL|Treatment C|oral EYP001a
62381903|NCT03272009|EXPERIMENTAL|Treatment D|oral EYP001a
62381904|NCT03272009|PLACEBO_COMPARATOR|Treatment E|oral placebo
62381905|NCT03272009|ACTIVE_COMPARATOR|Treatment F|oral Entecavir
62381906|NCT03272009|EXPERIMENTAL|Treatment G|oral EYP001a plus subcutaneous injection of Peg-INFα2a
62381907|NCT03272009|EXPERIMENTAL|Treatment H|oral EYP001a plus subcutaneous injection of Peg-INFα2a
62381908|NCT03272009|PLACEBO_COMPARATOR|Treatment I|oral placebo plus subcutaneous injection of Peg-INFα2a
62381909|NCT03281356|EXPERIMENTAL|Intervention Group|
62381910|NCT05159063||Right heart catheterization|
62381911|NCT01277666|PLACEBO_COMPARATOR|Placebo|orally administered
62381912|NCT01277666|EXPERIMENTAL|GSK1605786A 500mg once daily|orally administered
62381913|NCT01277666|EXPERIMENTAL|GSK1605786A 500mg twice daily|orally administered
62761895|NCT00289198|EXPERIMENTAL|Fluticasone furoate|Participants were instructed to administer two sprays into each nostril once daily every morning of fluticasone furoate 110 μg
62761896|NCT00289198|PLACEBO_COMPARATOR|Placebo|Participants were instructed to administer two sprays into each nostril once daily every morning of placebo
62761897|NCT00094718|EXPERIMENTAL|1|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10\^3 PFU dose) into the deltoid region of either arm.
62761898|NCT00094718|EXPERIMENTAL|2|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10\^4 PFU dose) into the deltoid region of either arm. This arm may enroll after the results from Arm 1 are analyzed.
62761899|NCT00094718|EXPERIMENTAL|3|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10\^5 PFU dose) into the deltoid region of either arm. This arm may enroll after the results from Arm 2 are analyzed.
62761900|NCT00094718|PLACEBO_COMPARATOR|4|One subcutaneous vaccination with placebo vaccine into the deltoid region of either arm.
62761901|NCT01563289|PLACEBO_COMPARATOR|placebo|
62381914|NCT03792412|EXPERIMENTAL|Intervention: Usability Questionnaire|Patients hand over the usability questionnaire to evaluate the self developed structured follow-up program in form of a so-called pass to their family doctor twice in six months. Family doctors examine the postbariatric patient using the pass and evaluate the usability by filling out the questionnaire and return the usability questionnaire to the investigator.
62761902|NCT01563289|EXPERIMENTAL|Ibuprofen|
62761903|NCT01012206|NO_INTERVENTION|Control group|Children in control group obtained no lifestyle counseling (intervention).
62761904|NCT01012206|ACTIVE_COMPARATOR|Intervention group|Children in the intervention group and their parents were given lifestyle counseling and participated in an intervention program regarding food habits and physical activity.
62761905|NCT01411358|EXPERIMENTAL|AdimFlu-S 2011-2012|
62761906|NCT00495924||PD|Patients undergoing pancreaticoduodenectomy for pancreatic or peri-ampullary tumours.
62761907|NCT04094649|SHAM_COMPARATOR|Sham vs Active Stimulation Positions|Adults with Diabetes Mellitus Type 2 (DMT2) will be recruited and randomized to active uVNS or sham across two sessions according to a 2x2 crossover design. Sham uVNS will be delivered with the same stimulation parameters as active uVNS, but will be targeted to the left sternocleidomastoid muscle \~2 cm away from the vagus nerve.
62761908|NCT04094649|ACTIVE_COMPARATOR|Active uVNS|Active stimulations will be targeted with the ultrasound beam of the DECIMA device .Active uVNS will be delivered to the left cervical vagus nerve following the OGTT through the 60-min time point.
62761909|NCT01568372|EXPERIMENTAL|Nurse telephone follow-up|This group received a telephone follow-up by a nurse following discharge from the hospital and up until the 10th postoperative day, which is considered as the usual period of healing for a tonsillectomy
62381915|NCT03792412|OTHER|Control: Usability Questionnaire|"Patients hand over the usability questionnaire to evaluate the state of the art guideline for postbariatric follow up appointments in form of a folder Metabolische Chirurgie und die perioperative Betreuung to their family doctor twice in six months. Family doctors examine the postbariatric patient using the guideline and evaluate the usability by filling out the questionnaire and return the usability questionnaire to the investigator."
62381916|NCT02998931|EXPERIMENTAL|Glutamin|Intervention patients will be received enteral formula and glutamine 0.3 g/kg/day given via nasogastric tube as boluses q 4hrs.
62381917|NCT02998931|PLACEBO_COMPARATOR|maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
62381918|NCT00427739||CCT exam|
62381919|NCT03123549|EXPERIMENTAL|Simplify Disc|Simplify Disc at two levels of the cervical spine
62761910|NCT01568372|NO_INTERVENTION|Standard care group|This group received the standard care which consisted of an informative session before discharge and no follow-up once discharged home.
62761911|NCT02610491|PLACEBO_COMPARATOR|Placebo|Cellulose
62761912|NCT02610491|ACTIVE_COMPARATOR|Hesperidin|Citrus peel extract
62761913|NCT01690624|EXPERIMENTAL|Patients with relapsed or refractoryAML|Patients with acute myeloid leukemia who have relapsed after 1 prior treatment.
62761914|NCT01143922||Patients with gastrointestinal tract malignancies|All patients with GI tract malignancies undergoing surgery will be subjected to intraoperative ultrasound
62761915|NCT02096666|EXPERIMENTAL|Single arm|
62381920|NCT03123549|NO_INTERVENTION|Historical Control|This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm of a previously completed two level cervical disc trial.
62381921|NCT05591573|EXPERIMENTAL|Low glycemic index drink|Fruit drink containing low glycemic index sugar.
62381922|NCT05591573|EXPERIMENTAL|High glycemic index drink|Fruit drink containing high glycemic index sugar.
62381923|NCT01396486|ACTIVE_COMPARATOR|Omega-3/Placebo|Combination Omega-3 and Placebo treatment.
62761916|NCT03182595|EXPERIMENTAL|open---label|An open---label, single centre, nonrandomized clinical study in healthy volunteers, with intervention over a 13---week period.
62761917|NCT01229748|EXPERIMENTAL|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth.(Liddle, 2002) considered in the U.S. and abroad as an empirically supported Best Practice treatment for teen substance abuse and delinquency (USDHHS 2002; Drug Strategies 2003; NIDA 1999; Rigter et al 2004).
62761918|NCT01229748|EXPERIMENTAL|Family Motivational Interviewing|Motivational Interviewing (MI; Miller 1983; Miller \& Rollnick 1991), is a client-centered treatment designed to strengthen clients' commitment and empower them to change their substance use behavior (Miller \& Rollnick 2002).
62381924|NCT01396486|ACTIVE_COMPARATOR|Placebo/Inositol|Combination Placebo and Inositol treatment.
62381925|NCT01396486|ACTIVE_COMPARATOR|Omega-3/Inositol|Combination Omega-3 and Inositol treatment.
62381926|NCT03619369|ACTIVE_COMPARATOR|Early Circumcision|
62381927|NCT03619369|PLACEBO_COMPARATOR|Routine Circumcision|
62381928|NCT03619369|ACTIVE_COMPARATOR|Delayed Circumcision|
62381929|NCT04312061|EXPERIMENTAL|oral tramadol|oral tramadol tablet 5o mg given 1 hour before LNG-IUD insertion
62381930|NCT04312061|PLACEBO_COMPARATOR|placebo|oral placebo tablet given 1 hour before LNG-IUD insertion
62761919|NCT01229748|OTHER|Standard Care|The standard care condition will represent typical services for teens with alcohol problems in the community: assessment and referral for treatment
62761920|NCT02606760|EXPERIMENTAL|P-3073|P-3073
62381931|NCT01937949|OTHER|Endovascular|"The study will include patients treated by endovascular aortic repair of juxtarenal, suprarenal and type IV thoracoabdominal aortic aneurysms using custom-made Cook Zenith® Fenestrated AAA Endovascular Graft. The graft includes combinations of scallops, holes (fenestrations) or cuffs (side branches) . These small holes or branches are the investigational part of this research study. The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches.~Other names:~Endovascular stent Stent-graft"
62381932|NCT03065166|EXPERIMENTAL|Raisin Treatment|3.2 ounces of dried Cabernet wine grapes.
62381933|NCT03065166|OTHER|Bagel Control|One 95g whole wheat bagel.
62381934|NCT05892302|ACTIVE_COMPARATOR|Access to Asma Guardian website/app|Participants who are randomized to the Asma Guardian website at their baseline visit will have access to the website for 6 months starting at baseline. Access will be turned off at 6 months.
62761921|NCT02606760|PLACEBO_COMPARATOR|vehicle of P-3073|vehicle of P-3073
62761922|NCT02072187|EXPERIMENTAL|Active|"The vitamin D formula that will be used is Bio-D Mulsion 1000, produced by Biotics Research Corporation. This formula contains: Vitamin D (cholecalciferol), water and acacia gum and sesame oil.~Participants will be provided with a dose of vitamin D at each visit beginning at the Baseline visit. The weekly dose of vitamin D will be 28 000IU (the equivalent of 4000IU daily) for a period of eight weeks. If baseline or week 4 serum vitamin D levels are measured as \>100nmol/L, the dose will be reduced to 14 000IU (the equivalent of 2000IU daily). The dose will be dispensed, using the bottle dropper, onto a disposable plastic spoon which the participant will insert into their mouth."
62761923|NCT02072187|PLACEBO_COMPARATOR|Placebo|"The placebo formula, also produced by Biotics Research Corporation, will contain all of the non-medicinal ingredients but no vitamin D. It will be identical in appearance and taste.~Participants will be provided with a dose of the placebo at each visit beginning at the Baseline visit. The weekly dose will be 28 drops or 14 drops if serum Vitamin D levels are \>100nmol/L. The dose will be dispensed, using the bottle dropper, onto a disposable plastic spoon which the participant will insert into their mouth."
62381935|NCT05892302|OTHER|No Access to Asma Guardian website/app for 6 months|Note: Participants who are randomized to no access will not receive access during the 6 months of the study; however they will receive 1 month of access after their 6 month study visit but any information gained during this time will not be part of analysis.
62761924|NCT05110560|NO_INTERVENTION|control group|step counts will be followed
62761925|NCT05110560|EXPERIMENTAL|intervention group|The Stay at Home Take a Step Program consisting of video or audio calls four times, sending Short Message Service messages containing reminders to encourage walking, and daily step count and weight tracking will be implemented.
62761926|NCT02386215|EXPERIMENTAL|HIV Self-test|Following a baseline interview, participants in the intervention group will be shown how to correctly use the self-tests and given two HIV self-tests. Subsequently, we will contact participants periodically over a 3 month period to see if they have used the test(s) with their sexual partners and conduct a follow-up interview.
62761927|NCT02386215|NO_INTERVENTION|Control|Following the baseline interview, participants in the control group will be given referral vouchers for themselves and their partners to obtain HIV testing at Voluntary Counseling \& Testing (VCT) centers. We will contact the participants at the end of 3 months to see if they and/or their partner(s) have sought HIV testing.
62761928|NCT02516826|EXPERIMENTAL|Rosuvastatin Arm|Rosuvastatin 10mg in combination with placebo of Olmesartan 20mg plus placebo of Olmesartan/Rosuvastatin(Combination) 20/10mg orally once daily
62761929|NCT02516826|EXPERIMENTAL|Olmesartan Arm|Olmesartan 20mg in combination with placebo of Rosuvastatin 10mg plus placebo of Olmesartan/Rosuvastatin(Combination) 20/10mg orally once daily
62761930|NCT02516826|EXPERIMENTAL|Combination Arm|Olmesartan/Rosuvastatin(Combination) 20/10mg in combination with placebo of Rosuvastatin 10mg plus placebo of Olmesartan 20mg
62761931|NCT01235364|EXPERIMENTAL|Digital|The patient was randomized to digital insertion of the Foley catheter
62761932|NCT01235364|EXPERIMENTAL|Speculum|
62761933|NCT01605942|EXPERIMENTAL|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
62761934|NCT01605942|PLACEBO_COMPARATOR|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
62761935|NCT02813642|EXPERIMENTAL|Cardiovascular risk evaluation|Measurement of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 2 year follow-up
62761936|NCT05610306||Inherited ichthyosis patients|Interviews
62761937|NCT00526110|EXPERIMENTAL|5-Fluorouracil + Docetaxel + Oxaliplatin|5-Fluorouracil 2.2 Gm/m\^2 intravenously (IV) over 48 hours on Day 1. Docetaxel 20 mg/m\^2 IV over 60 minutes. Oxaliplatin 85 mg/m\^2 IV over 120 minutes on Day 1.
62182529|NCT03623477|EXPERIMENTAL|CRT+ Social Cognition Training|Participants assigned to the combination of CRT and SCT will complete 24 hours of computerized neurocognitive training in memory, attention, and processing speed, and 12 hours of computerized social cognition training focused on improving emotion recognition, social perspective taking, and mentalizing abilities.
62381936|NCT02263742|EXPERIMENTAL|Peer whole health|Peer whole health intervention will be compared to the treatment as usual at Wellness Center to assess healthcare choice and outcomes
62761938|NCT01630551|ACTIVE_COMPARATOR|Fishoil nutritional supplement|90 day supply of daily oral administration of a fish oil nutritional supplement (TheraTears Nutrition; Advanced Vision Research, Woburn, MA)
62761939|NCT01630551|PLACEBO_COMPARATOR|Olive oil capsules|90 day supply of a daily dose of placebo olive oil capsules
62761940|NCT01816906|ACTIVE_COMPARATOR|MCP Insole|"The intervention is Footwear: MCP. MCP insoles are commonly used within Diabetic sandals in India."
62761941|NCT01816906|ACTIVE_COMPARATOR|PU insole|"The intervention is Footwear: PU. Insoles made of Polyurethane(PU) are given to the participants in the intervention arm."
62761942|NCT04069247|EXPERIMENTAL|E-based cognitive behavioral therapy for insomnia (eCBT-I)|The eCBT-I will be delivered by a mobile application (eSleep) developed by BestCare \& SuMian BioTech Co., Ltd. which contains a digital, self-paced, and highly interactive programme. It consists of six weekly sessions with animated elements, including an overview of sleep, sleep restriction, stimulus control, cognitive therapy, structured worry time and relapse prevention. Participants will have access to the eCBT-I treatment for 12 weeks.
62761943|NCT04069247|ACTIVE_COMPARATOR|Health education (HE)|The HE, a psychoeducation/information-approach, also consists of six consecutive sessions which contains information about general sleep knowledge, functions of human organs, nutrition, environmental health, brain health, identification and treatments of common diseases, but the contents are not related to any active therapeutic components of cognitive behavioral therapy for insomnia (CBT-I).Participants will have access to the intervention for 12 weeks.
62761944|NCT00700102|ACTIVE_COMPARATOR|Chemotherapy|Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
62761945|NCT00700102|EXPERIMENTAL|Chemotherapy + Bevacizumab|Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal
62761946|NCT00966290|EXPERIMENTAL|ACC group|Anticoagulant clinic-based shared-care group
62761947|NCT00966290|ACTIVE_COMPARATOR|UC group|Usual care group
62761948|NCT01669018|ACTIVE_COMPARATOR|Lumbar ultrasound trident (LUT)|Lumbar plexus block using LUT technique
62761949|NCT01669018|EXPERIMENTAL|Supra Sacral Parallel Shift (SSPS)|Lumbar plexus block using SSPS technique
62761950|NCT01898104|ACTIVE_COMPARATOR|SCRT|short course radiotherapy (SCRT) alone 25 Gy in 5 fractions over one week.
62761951|NCT01898104|ACTIVE_COMPARATOR|V-SCRT|Valproic acid (V) + short course radiotherapy
62761952|NCT01898104|ACTIVE_COMPARATOR|C-SCRT|capecitabine (C) + short course radiotherapy
62761953|NCT01898104|ACTIVE_COMPARATOR|VC-SCRT|valproic acid + capecitabine + short course radiotherapy
62761954|NCT03354832||Foetal death|In-utero dead foetus weighting at least 500 g or 22-amenorrhea weeks old. In utero death means that death occurs during delivery or per partum
62761955|NCT03354832||New-born death|New-born dead during post-birth hospital stay and at least 23-amenorrhea weeks old.
62761956|NCT03354832||Birth control for foetal death|Same gender child born, and alive, in the same hospital, and born on time (37-41 amenorrhea weeks old).
62761957|NCT03354832||Birth control for new-born death|"Same gender infant born, and alive, in the same hospital, and:~* for 23-amenorrhea weeks old new-born death: control new-born are born on time (37-41 amenorrhea weeks old).~* for 24 to 31-amenorrhea weeks old new-born death: control new-born are premature infant (24-31 amenorrhea weeks old), and are included when their hospital stay ends.~* for 32 and more-amenorrhea weeks old new-born death: control new-born are 32 and more-amenorrhea weeks old infant"
62761958|NCT01251198||Acute coronary Syndrome|Patients affected are patients with acute coronary syndrome with ST segment elevation ST (myocardial infarction) in 48 hospitalized in one of the centers (emergency, ambulance, intensive care unit, cardiac catheterization lab).
62761959|NCT02830607|EXPERIMENTAL|Xiaomi Mi Band|participants will wear Xiaomi Mi Band .the device measures their daily steps number before and after epidural steroid injection for treatment of low back pain.
62761960|NCT01741831||Darunavir|Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking darunavir as per recommended doses.
62761961|NCT01482897|EXPERIMENTAL|corticoïd|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
62761962|NCT01482897|PLACEBO_COMPARATOR|physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
62761963|NCT01482897|SHAM_COMPARATOR|feigning of peridural infiltration|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
62761964|NCT01482897|NO_INTERVENTION|no intervention|natural evolution of discal sciatica
62761965|NCT01918969||Blood donors|Blood donors with no exclusion criteria i.e with a very low probability to have an aortic aneurysm
62761966|NCT03275688||Stage 1 Lung Cancer (Case)|These are the participants with identified stage 1 lung cancer.
62761967|NCT03275688||Type 1 Control|These are participants who have similar clinical characteristics as our cases, but do not have any history of cancer.
62761968|NCT03275688||Type 2 Control|These are housemates of the participants with stage 1 lung cancer (cases).
62761969|NCT00152568|EXPERIMENTAL|Child Passenger Safety Technician services|
62761970|NCT01332188|EXPERIMENTAL|AC-170 0.05%|
62761971|NCT01332188|EXPERIMENTAL|AC-170 0.1%|
62761972|NCT01332188|EXPERIMENTAL|AC-170 0.24%|
62761973|NCT01332188|PLACEBO_COMPARATOR|AC-170 0%|
62761974|NCT01845584|EXPERIMENTAL|NPB-01|Intravenous immunoglobulin
62761975|NCT05586672||ASD group|Participants aged from 3 years to 4 years and half at inclusion will be clinically evaluated with standardized scales and tests and will performed an EEG-HR recording while listening to successive soundtracks at several times.
62761976|NCT05586672||Control group|Participants aged from 3 years to 4 years and half at inclusion will be clinically evaluated with standardized scales and tests and will performed an EEG-HR recording while listening to successive soundtracks in inclusion visit.
62761977|NCT05753930|EXPERIMENTAL|Imlifidase|Imlifidase is administered intravenously as one infusion of 0.25 mg/kg over 15 minutes within 24 hours prior to transplantation.
62761978|NCT06035744|EXPERIMENTAL|CLN-617 Dose Escalation (Part A)|Patients with Advanced Solid Tumors enrolled in dose escalation cohorts treated with CLN-617 alone and in combination with pembrolizumab
62761979|NCT06035744|EXPERIMENTAL|CLN-617 Dose Optimization (Part B)|Patients with Advanced Solid Tumors enrolled in dose optimization receiving selected doses of CLN-617 in combination with pembrolizumab
62761980|NCT06035744|EXPERIMENTAL|CLN-617 Dose Expansion (Part C)|Patients with Advanced Melanoma or Head and Neck Squamous Cell Carcinoma (HNSCC) enrolled in dose expansion treated with CLN-617 in combination with pembrolizumab
62761981|NCT01120314|EXPERIMENTAL|Severe renal impairment population|
62761982|NCT01120314|EXPERIMENTAL|Moderate renal impairment population|
62761983|NCT01120314|EXPERIMENTAL|Mild renal impairment population|
62761984|NCT01120314|EXPERIMENTAL|Healthy population|Healthy matched subjects
62761985|NCT04579094||1/elderly dependent persons|
62761986|NCT04579094||2/healthcare workers (HCW)|
62761987|NCT04932213|ACTIVE_COMPARATOR|Tropicamide 0.5%|This group receives tropicamide 0.5% (one drop every 5 minutes for 2 times) drops.
62381937|NCT02263742|ACTIVE_COMPARATOR|EBPs at Wellness Center|EBPs at Wellness Center will be the active comparative to measure healthcare choice and outcomes with the peer whole health intervention
62761988|NCT04932213|ACTIVE_COMPARATOR|Tropicamide 1%|This group receives tropicamide 1% (one drop every 5 minutes for 2 times) drops.
62761989|NCT06464094|OTHER|User-testing of Vitaliti Continuous Vital Sign Monitor Model CVSM-1A|Participants enrolled to engage in user-testing of the Vitaliti Continuous Vital Sign Monitor Model CVSM-1A to examine user-acceptance and user experiences, while soliciting user feedback on wearability compliance (patient) and proposed clinical workflows using the most recent Vitaliti™ CVSM device.
62761990|NCT02535260||Fertility Monitor|Clearblue Fertility Monitor
62761991|NCT02012088|EXPERIMENTAL|RCOMP|"R-COMP Regimen:~Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles"
62761992|NCT02012088|ACTIVE_COMPARATOR|RCHOP|"R-CHOP Regimen:~Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles"
62761993|NCT01565941|ACTIVE_COMPARATOR|Tight Glycemic Control 1 (TGC-1)|Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm.
62761994|NCT01565941|ACTIVE_COMPARATOR|Tight Glycemic Control 2 (TGC-2)|Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm.
62381938|NCT01315873|EXPERIMENTAL|Bortezomib and Bendamustine|
62761995|NCT05018806|PLACEBO_COMPARATOR|BID cohort: Placebo|Participants received placebo matched to rilzabrutinib orally BID from Day 1 up to Week 16. Consecutive doses were ideally administered 12 hours apart (and not less than 8 hours apart).
62761996|NCT05018806|EXPERIMENTAL|BID cohort: Rilzabrutinib|Participants received rilzabrutinib 400 milligrams (mg) orally BID from Day 1 up to Week 16. Consecutive doses were ideally administered 12 hours apart (and not less than 8 hours apart).
62761997|NCT05018806|PLACEBO_COMPARATOR|TID cohort: Placebo|Participants received placebo matched to rilzabrutinib orally TID from Day 1 up to Week 16. Consecutive doses were ideally administered at least 6 hours apart (and not less than 4 hours apart).
62182530|NCT06101472||Pseudophakic subjects implanted with the ASQELIO toric IOL|Adult subjects undergoing cataract surgery by routine clinical practice with ASQELIO Toric Biaspheric Monofocal Lens in at least one eye.
62381939|NCT05051306|EXPERIMENTAL|High-load resistance exercise|4 high-load resistance exercises that target all major muscle groups.
62381940|NCT05051306|EXPERIMENTAL|Low-load resistance exercise|4 low-load resistance exercises that target all major muscle groups.
62381941|NCT05051306|NO_INTERVENTION|Sedentary control|Subjects in control trial stayed sedentary during the period.
62381942|NCT04303091|EXPERIMENTAL|Exercise group|Single-arm study. Participants enrolled engaged in a 12-week exercise program.
62381943|NCT03287726|EXPERIMENTAL|probiotics|
62761998|NCT05018806|EXPERIMENTAL|TID cohort: Rilzabrutinib|Participants received rilzabrutinib 400 mg orally TID from Day 1 up to Week 16. Consecutive doses were ideally administered at least 6 hours apart (and not less than 4 hours apart).
62381944|NCT03287726|PLACEBO_COMPARATOR|placebo|
62381945|NCT01542632|EXPERIMENTAL|Group 1|Takeda's Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and placebo, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.
62381946|NCT01542632|EXPERIMENTAL|Group 2|TDV, 0.5 mL, subcutaneous injection in one arm and TDV 0.5 mL, subcutaneous injection in the other arm on Day 0. Placebo, 0.5 mL, subcutaneous injection on Day 90.
62761999|NCT03112746|EXPERIMENTAL|Cognitive Orientation to daily Occupational Performance|One group was submitted to the CO-OP approach to learn cognitive strategies to perform the chosen tasks.
62762000|NCT02435017||Adults 20-85 years|Data from adults 20-85 years old will be evaluated for serum phosphorus concentration.
62762001|NCT03141463|EXPERIMENTAL|Vvax001 therapeutic cancer vaccine|Patients will receive three consecutive doses of Vvax001, with an interval of 3 weeks
62762002|NCT00523835||KS|Patients with Klinefelter syndrome verified by chromosome analysis
62762003|NCT00523835||Normal|Normal men Age matched to KS patients
62762004|NCT00951249|EXPERIMENTAL|A|HIV-infected and uninfected black MSM
62762005|NCT03244319|EXPERIMENTAL|Edoxaban|
62762006|NCT03244319|ACTIVE_COMPARATOR|Warfarin|
62762007|NCT02980094|PLACEBO_COMPARATOR|Milk Control group(C)|Using a randomized block design, 25 institutionalized elderly to receive the milk 3 times per day produced by lactating cows fed with the following diet, one of the group is control (C), without vitamin E, selenium, sunflower oil in the cow's food.
62762008|NCT02980094|EXPERIMENTAL|Milk Antioxidant group(A)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diet: control (C) +vitamin E+ selenium (A).
62762009|NCT02980094|EXPERIMENTAL|Milk Oil group(O)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).
62762010|NCT02980094|EXPERIMENTAL|Milk Antioxidant and oil(AO)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diets: control C+sunflower oil+vitamin E+selenium (AO) .
62762011|NCT03606447|EXPERIMENTAL|Single IV administration of [14C]-Uproleselan|
62762012|NCT01024491|EXPERIMENTAL|paroxetine 15mg|Active treatment with daily dose of paroxetine 15mg.
62182531|NCT03588598|EXPERIMENTAL|SHC014748M treatment|SHC014748M capsule， 50, 100, 150, 200, 250 mg, QD, 28 days for each cycle
62381947|NCT01542632|EXPERIMENTAL|Group 3|TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.
62381948|NCT01542632|EXPERIMENTAL|Group 4|TDV new formulation, 0.5 mL, subcutaneous injection in one arm and new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.
62381949|NCT01542632|EXPERIMENTAL|Group 5|TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.
62381950|NCT01542632|EXPERIMENTAL|Group 6|1/10 TDV, 0.5 mL, subcutaneous injection on Days 1 and 90.
62381951|NCT01431794|EXPERIMENTAL|Phase I-Gem,nab-paclitaxel,LDE225-600mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 600 mg daily.
62381952|NCT01431794|ACTIVE_COMPARATOR|Phase II-Arm A:Gem,nab-paclitaxel,LDE225|Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.
62381953|NCT01431794|ACTIVE_COMPARATOR|Phase II-Arm B:Gem,nab-paclitaxel|Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days.
62381954|NCT01431794|EXPERIMENTAL|Phase I-Gem,nab-paclitaxel,LDE225-400mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 400 mg daily.
62381955|NCT01431794|EXPERIMENTAL|Phase I-Gem,nab-paclitaxel,LDE225-800mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 800 mg daily.
62381956|NCT04258761|EXPERIMENTAL|10XB-101 Solution for Injection 1.25%|Participants receive 10XB-101 Solution for Injection, 1.25% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
62381957|NCT04258761|EXPERIMENTAL|10XB-101 Solution for Injection 2.0%|Participants receive 10XB-101 Solution for Injection, 2.0% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
62381958|NCT04258761|EXPERIMENTAL|10XB-101 Solution for Injection 3.0%|Participants receive 10XB-101 Solution for Injection, 3.0% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
62381959|NCT04258761|EXPERIMENTAL|10XB-101 Solution for Injection 4.5%|Participants receive 10XB-101 Solution for Injection, 4.5% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
62381960|NCT04258761|EXPERIMENTAL|10XB-101 Solution for Injection 6.0%|Participants receive 10XB-101 Solution for Injection, 6.0% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
62381961|NCT03278210||with EEG-fMRI data|EEG-fMRI was performed during the pre surgical evaluation, and its results were provided to the clinicians before surgery planification. The final surgery strategy was decided with EEG-fMRI results.
62381962|NCT03278210||without EEG-fMRI data|EEG-fMRI was performed during the pre surgical evaluation, but clinicians were blinded to the results. The final surgery strategy was decided without EEG-fMRI results.
62381963|NCT00388128|PLACEBO_COMPARATOR|A|
62381964|NCT02289144|EXPERIMENTAL|Ceritinib|
62381965|NCT04835389|EXPERIMENTAL|AlloGen Liquid|A single-dose, intra-articular (IA) injection of 2.0 mL of AlloGen Liquid administered to the affected knee.
62381966|NCT04835389|PLACEBO_COMPARATOR|Saline|A single-dose, intra-articular (IA) injection of 2.0 mL of saline administered to the affected knee.
62381967|NCT05350800|EXPERIMENTAL|BMS-986369, Part 1 dose escalation|
62381968|NCT05350800|EXPERIMENTAL|BMS-986369 under fasted conditions, Part 2 Food effect|
62762013|NCT01024491|EXPERIMENTAL|paroxetine 20 mg|Active treatment daily dose of paroxetine 20 mg
62762014|NCT01024491|EXPERIMENTAL|placebo|placebo
62762015|NCT00993109|EXPERIMENTAL|Arm 1|
62762016|NCT00993109|ACTIVE_COMPARATOR|Arm 2|
62762017|NCT04312607||Philadelphia chromosome positive|according to PCR detection of BCR-ABL gene CD26 expression on stem cells
62762018|NCT04312607||Philadelphia chromosome negative|according to PCR detection of BCR-ABL gene CD26 expression on stem cells
62762019|NCT00714766|EXPERIMENTAL|A|
62762020|NCT02740413||Patients with Haemophilia A|Patients in The MHR diagnosed with Haemophilia A
62182532|NCT00940654||Patients with fever|
62182533|NCT00940654||Patients without any fever|
62182534|NCT02208037|EXPERIMENTAL|Tacrolimus/Methotrexate/Bortezomib|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Methotrexate, and Bortezomib.
62381969|NCT05350800|EXPERIMENTAL|BMS-986369 under fed conditions, Part 2 Food effect|
62762021|NCT02740413||Patients with Haemophilia B|Patients in The MHR diagnosed with Haemophilia B
62762022|NCT01059253|EXPERIMENTAL|Training|15 training sessions
62762023|NCT03859739|EXPERIMENTAL|Panel A. MK-8558 400 mg|Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.
62762024|NCT03859739|EXPERIMENTAL|Panel B. MK-8558 at dose level 2|Single oral dose of MK-8558 administered at dose level 2 following a 10-hour fast. Dose level 2 shall not exceed 900 mg. Per protocol, dose will be selected following review of data from panel A.
62762025|NCT03859739|EXPERIMENTAL|Panel C. MK-8558 at dose level 3|Single oral dose of MK-8558 administered at dose level 3 following a 10-hour fast. Dose level 3 shall not exceed 1600 mg. Per protocol, dose will be selected following review of data from panel B.
62762026|NCT03859739|EXPERIMENTAL|Panel D. MK-8558 at dose level 4|Single oral dose of MK-8558 administered at dose level 4 following a low-fat breakfast. Dose level 4 shall not exceed 1600 mg. Per protocol, Panel D is optional pending results of Panels A-C, and dose will be selected following review of data from panel C.
62762027|NCT05754060||Saint-Louis Lille Battery (SSLIB)|"Saint-Louis Lille Battery (SSLIB) is composed of three tests studying the speed of cognitive processing and proposed to the subjects on a tactile tablet. These three tasks are:~(a) Reaction time tasks specifically developed for this study b) A digital adaptation of the WAIS-IV code subtest c) A digital version of the Trail Making Test (A and B)"
62762028|NCT03278431|ACTIVE_COMPARATOR|Albendazole triple combi|Albendazole (400 mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
62762029|NCT03278431|EXPERIMENTAL|Pyrantel pamoate double combi|Pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
62762030|NCT03278431|EXPERIMENTAL|Albendazole double combi|Albendazole (400 mg) + oxantel pamoate (20 mg/kg)
62762031|NCT03278431|EXPERIMENTAL|Mebendazole triple combi|Mebendazole (500mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
62762032|NCT00866346|EXPERIMENTAL|PR1-CTL|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg."
62762033|NCT02770976|EXPERIMENTAL|NAVA|Seven increasing and decreasing NAVA levels (0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0 and 0.5 cmH2O/uV) will applied to 20 preterm infants each for 10 minutes.
62762034|NCT00235391|EXPERIMENTAL|Deferasirox|Deferasirox was administered orally once a day, 30 minutes prior to breakfast. Dosage was based on participant's body weight. Starting dose was determined by the frequency of blood transfusions and recommended initial daily dose of deferasirox is 20 mg/kg body weight for patients receiving blood transfusion, 10 mg/kg for patients receiving less frequent transfusion/exchange transfusion and 30 mg/kg for patients receiving more frequent blood transfusions.
62762035|NCT03090074|ACTIVE_COMPARATOR|Moderate carbohydrate restriction and traditional support|Moderate carbohydrate restriction and traditional support with group meetings
62762036|NCT03090074|ACTIVE_COMPARATOR|Extreme low carbohydrate diet and traditional support|Extreme carbohydrate restriction and traditional support with group meetings
62762037|NCT03090074|ACTIVE_COMPARATOR|Moderate carbohydrate restriction and ACT support|Moderate carbohydrate restriction and psychological support based on acceptance and commitment therapy
62762038|NCT03090074|ACTIVE_COMPARATOR|Extreme carbohydrate restriction and ACT support|Extreme carbohydrate restriction and psychological support based on acceptance and commitment therapy
62762039|NCT01928823|EXPERIMENTAL|D-Cycloserine + CBT|Patients receiving CBT (cognitive behavioral therapy) and D-Cycloserine (3 times, 50 mg, oral) directly after an exposure
62762040|NCT01928823|PLACEBO_COMPARATOR|Placebo + CBT|Patients receiving CBT (cognitive behavioral therapy) and a placebo pill (3 times, looking identical to the DCS pill) directly after an exposure
62762041|NCT01107561|EXPERIMENTAL|Seldinger technique|Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire.
62762042|NCT01107561|ACTIVE_COMPARATOR|Surgical airway approach|The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
62381970|NCT03962413|ACTIVE_COMPARATOR|The middle meatal antrostomy approach.|"The middle turbinate will be gently moved medially. Then uncinectomy is the next step which will be performed in numerous ways. Once the natural ostium will be identified, an ostium seeker will be placed through the ostium and then carefully will be pushed posteriorly to widen the ostium.~Using a through-cutting forceps, the ostium will be enlarged."
62762043|NCT02463032|EXPERIMENTAL|GTx-024 9 mg|Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg
62762044|NCT02463032|EXPERIMENTAL|GTx-024 18 mg|Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg
62762045|NCT05615857|NO_INTERVENTION|Colonoscopy without Endocuff|No Endocuff inserted proximally to colonoscope and use of retroflexion
62762046|NCT05615857|EXPERIMENTAL|Colonoscopy with Endocuff|Endocuff inserted proximally to colonoscope, no use of retroflexion
62762047|NCT06153433|ACTIVE_COMPARATOR|Rosuvastatin IR Tablet|Rosuvastatin Immediate-Release Tablet (IRT) 10mg
62762048|NCT06153433|EXPERIMENTAL|SUVARO®OD Tablet|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg
62762049|NCT01304810||NicVAX|NicVAX vaccine
62762050|NCT01304810||Placebo vaccine|Placebo vaccine
62762051|NCT01688843|EXPERIMENTAL|INGEVITY lead|INGEVITY lead implant
62762052|NCT00346840|EXPERIMENTAL|MVI 25|Misoprostol vaginal insert 25 mcg
62762053|NCT00346840|EXPERIMENTAL|MVI 50|Misoprostol vaginal insert 50 mcg
62762054|NCT00346840|EXPERIMENTAL|MVI 100|Misoprostol vaginal insert 100 mcg
62762055|NCT00346840|EXPERIMENTAL|MVI 200|Misoprostol vaginal insert 200 mcg
62762056|NCT02221518|EXPERIMENTAL|Patients with OCD|Behavioral: Exposure \& Response Prevention (EX/RP)
62762057|NCT03173911|ACTIVE_COMPARATOR|Ankle|composed by 12 participants who will receive the application of the bandage for the ankle strategy in both lower limbs, being determined the application of the technique in I without fixed point, from medial malleolus to lateral malleolus passing under the hindfoot, finally a cleavage technique passing over the malleoli and ending in the anterior region of the ankle joint. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
62762058|NCT03173911|ACTIVE_COMPARATOR|Hamstrings|composed by 12 participants who will receive the application of the bandage for the posterior thigh (hamstrings) strategy in both lower limbs. The technique will be determined in I with fixed point of the skin of the ischial tuberosity and moving point until the Lateral tibia (near the head of the fibula) and medial tibia (goose-foot insertion). The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
62762059|NCT03173911|ACTIVE_COMPARATOR|Lumbar|composed by 12 participants who will receive the application of the bandage for the hip (lumbar) strategy, being determined the application of the technique in I with fixed point in the ischial tuberosity and moving point until the height of the last ribs, making a cleavage in the Height of the superior iliac spine. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
62762060|NCT03173911|ACTIVE_COMPARATOR|Total|composed by 12 participants who will receive the application of the bandage for all strategies in both lower limbs, being determined the application of the technique in I with fixed point in the II and III toes and moving point until the height of the last ribs , Passing through the entire posterior region. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
62762061|NCT03377738|NO_INTERVENTION|anti-smoking therapy|All patients will be given only an intervention for tobacco cessation which will depend on the individual's cessation phase
62762062|NCT03377738|EXPERIMENTAL|anti-smoking therapy + spirometry|All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase. In addition, in this group will be given a spirometry test as a motivational element for dishabituation.
62762063|NCT00839267||Unstable|Patient with acute myocardial infarction plus severe hemodynamical instability. It means, on mechanical ventilation and catecholamine support
62381971|NCT03962413|ACTIVE_COMPARATOR|The endoscopic prelacrimal recess approach|A curved incision will be made between the anterior aspect of the IT and the posterior end of the nasal vestibule.the mucoperiosteum will be lifted posteriorly.Bone removal will be achieved. the anterior bony portion of the medial wall of the MS will be removed, .then the IT-NLD flap will be formed.The prelacrimal recess will be opened
62381972|NCT03962413|ACTIVE_COMPARATOR|The canine fossa approach.|"It will be done either transnasally or transorally:~\*\* The transoral approach through a sublabial incision : CFA consist in a trocar placed in the canine fossa.After removal of the trocar a 4-mm microdebrider blade will be placed through the passage created by the trocar.~\*\* The transnasal approach: A curved incision will be made between the anterior aspect of the Inferior Turbinate and the posterior end of the nasal vestibule,the mucoperiosteum will be lifted posteriorly Then the investigators will reach the anterior wall of the maxillary sinus through bone removal which will be achieved using a gauch and hammer and a high-speed electric drill."
62381973|NCT03351140||Subjects with breast cancer|Approximately 30 subjects who have confirmed diagnosis of breast cancer will be included in the study
62762064|NCT00839267||Stable|Patients with myocardial infarction hemodynamically completely (Killip I)stable.
62762065|NCT00385723|EXPERIMENTAL|1|1.25 g/d
62762066|NCT00385723|EXPERIMENTAL|2|2.496 g/d
62762067|NCT00385723|PLACEBO_COMPARATOR|3|
62762068|NCT04868487|EXPERIMENTAL|Intervention|The intervention group received four weekly training sessions of health literacy education. Each educational session lasted an average of 50 minutes. The students were divided into four groups with an average of 25 students in each group.
62762069|NCT04868487|NO_INTERVENTION|Control|The control group had no educational interaction with the researcher after the pre-test. The control group was administered the one-week and three-month posttest THLS-32 by the researcher simultaneously with the intervention group.
62762070|NCT02688582|EXPERIMENTAL|TCI group|Patients who receive cefepime based on TCI for a maximum of 5 days with a target concentration of cefepime of 16 mg/L.
62762071|NCT01969617|EXPERIMENTAL|Nalmefene 18 mg, then placebo|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
62762072|NCT01969617|PLACEBO_COMPARATOR|Placebo, then Nalmefene 18 mg|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
62762073|NCT05778773||TAVR|"Patients undergoing aortic valve replacement through the Transcatheter Aortic Valve Replacement procedure.~For all the patients a set of clinical, anatomical, and procedural details will be obtained and registered. The outcome at the hospital discharge and at the 12-month follow-up will be collected, as well. The quality of life questionnaire will be administered to all the patients at the hospital discharge, at the 12-month follow-up (mandatory), and then at annual base (facultative)."
62762074|NCT05778773||AVR|"Patients undergoing aortic valve replacement through conventional open-heart surgery (sternotomy and biological valve implantation).~For all the patients a set of clinical, anatomical, and procedural details will be obtained and registered. The outcome at the hospital discharge and at the 12-month follow-up will be collected, as well. The quality of life questionnaire will be administered to all the patients at the hospital discharge, at the 12-month follow-up (mandatory), and then at annual base (facultative)."
62762075|NCT05945459|EXPERIMENTAL|Intervention arm|High-calorie density formula (1 kcal/ml)
62762076|NCT05945459|PLACEBO_COMPARATOR|Control arm|Standard formula (0.67 kcal/ml)
62762077|NCT03745352|EXPERIMENTAL|Arm A (pevonedistat, azacitidine)|Patients receive pevonedistat intravenously (IV) over 60 minutes on days 1, 3, and 5 and azacitidine IV over 10-40 minutes or subcutaneously (SC) on either days 1-7, or days 1-5 and 8-9, or days 1-6 and 8. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62762078|NCT03745352|ACTIVE_COMPARATOR|Arm B (azacitidine)|Patients receive azacitidine IV or SC as in Arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62762079|NCT02120963|EXPERIMENTAL|intervention program|Person-centered physical therapy intervention program
62762080|NCT02120963|NO_INTERVENTION|Control group|Health care as usual
62381974|NCT03351140||Subjects with prostate cancer|Approximately 30 subjects who have confirmed diagnosis of prostate cancer will be included in the study
62381975|NCT03351140||Subjects with NSCLC|Approximately 30 subjects who have confirmed diagnosis of NSCLC will be included in the study
62762081|NCT01509677|ACTIVE_COMPARATOR|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
62762082|NCT01509677|PLACEBO_COMPARATOR|Placebo|tablet, once daily, oral administration in the morning after breakfast
62762083|NCT04519047|EXPERIMENTAL|Rejoint|Rejoint+PRP
62381976|NCT03351140||Subjects with multiple myeloma|Approximately 30 subjects who have confirmed diagnosis of multiple myeloma excluding smoldering/asymptomatic multiple myeloma will be included in the study
62381977|NCT03351140||Subjects with DLBCL or follicular lymphoma|Approximately 30 subjects who have confirmed diagnosis of DLBCL or follicular lymphoma will be included in the study
62381978|NCT00644033|ACTIVE_COMPARATOR|1|
62381979|NCT00644033|ACTIVE_COMPARATOR|2|
62762084|NCT04519047|ACTIVE_COMPARATOR|Control|Saline+PRP
62381980|NCT00644033|PLACEBO_COMPARATOR|3|
62762085|NCT01476280|SHAM_COMPARATOR|Palonosetron|
62381981|NCT04236440|EXPERIMENTAL|Part A: A1A2+Part B+Part C|"Part A: Participants will receive a single dose administration of BAY2586116 (A1) in treatment period 1, and a single dose administration of placebo (A2) in treatment period 2.~Part B: After successfully completing Part A, participants will proceed to Part B of the study.~Participants will receive a single dose administration of BAY2586116 (B1) in treatment period 3.~Based on the result of the interim analysis there are two possible scenarios regarding mode of application and doses of BAY2586116 to be administered in treatment period 4: 1) a single dose administration of BAY2586116 (B2) Or 2) a single dose administration of BAY2586116 (B3).~Part C: Participants completing Part B will be invited to participate in an additional treatment period with a single dose BAY2586116 (C)."
62762086|NCT01476280|SHAM_COMPARATOR|Ramosetron|
62762087|NCT03283436|EXPERIMENTAL|Superior hypogastric plexus block|Prior to the laparoscopic hysterectomy and any additional procedures, the SHPB will be performed on patients in the treatment arm. The block will contain 10 mL of 0.25% bupivacaine hydrochloride (Bupivacaine; 2.5 mg/mL = 25 mg). The anesthetic works by blocking nerve conduction and the steroid by reducing inflammation. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.
62762088|NCT03283436|NO_INTERVENTION|No block|Patients in the control arm will undergo the hysterectomy with no intervention.
62762089|NCT01478841|EXPERIMENTAL|Polyphenols|9 weeks of supplementation with polyphenols(D56) and during the last week supplementation with polyphenols associated with a fructose load during the last 6 days (D63).
62762090|NCT01478841|PLACEBO_COMPARATOR|placebo|9 weeks of supplementation with placebo (D56) and during the last week supplementation with placebo associated with a fructose load during the last 6 days (D63).
62762091|NCT02675192||Proof cohort : muscular assessment|"* Clinical examination : Body weight, BMI, cardiac frequency, muscular examination,...~* Blood appraisal : glycaemia, lipidic appraisal, leptin, albumin, coagulation, metabolome and epigenetic tests,...~* Urinary collection : metabolome tests~* Maximal voluntary quadriceps strength (MVC)~* Checking muscle functional skills~* Muscular biopsy"
62762092|NCT05066646|EXPERIMENTAL|CT103A in relapsed and refractory multiple myeloma patients|CT103A autologous CAR-T cells will be infused at RP2D of 1.0 x 10\^6 CAR+ T cells after receiving lymphodepleting chemotherapy
62762093|NCT03854890|NO_INTERVENTION|Lymphadenectomy without indocyanine green injection|Laparoscopic lymphadenectomy will be performed in a standard way.
62762094|NCT03854890|EXPERIMENTAL|Lymphadenectomy with indocyanine green injection|Injection of indocyanine green to the submucosal layer around rectal cancer 1 day before surgery. Laparoscopic proctectomy with lymph nodes dissection will be performed under near-infrared imaging.
62762095|NCT03815994|EXPERIMENTAL|Experimental: group 1|Neuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.
62762096|NCT03815994|SHAM_COMPARATOR|group 2|Decubitus Position with the limbs raised withou tNeuromuscular Electrical Stimulation and after Neuromuscular Electrical Stimulation.
62567613|NCT05496647|EXPERIMENTAL|Music Therapy|"Music Therapy Application During the surgical procedure, an mp3 player, and music therapy CDs of uşşak and Hüseyni will be used. (Oline will also create a list from music platforms (fizzy-Spotify, etc.)) Before starting the procedure, the patients will be asked about their music preferences and the music will be played to the patients (20 minutes) during the procedure in line with their preferences. Headphones provided by the researcher will be used for patients with headphones, and for patients without headphones.~The music authorities used (hüseyni and uşşak) will be provided and used by order, by obtaining the necessary permissions from the official site of TÜMATA."
62762097|NCT06430190|EXPERIMENTAL|Lesional group|
62762098|NCT06430190|EXPERIMENTAL|Systemic group|
62762099|NCT06430190|ACTIVE_COMPARATOR|Control group|
62762100|NCT04177420|EXPERIMENTAL|Experiment Group|lay on the FIR-C mattress with cover the FIR-C abdominal pad on abdominal part and Knee part during the sleeping time. The controller will switch on and switch off rotated in each hour for whole night.
62762101|NCT04177420|PLACEBO_COMPARATOR|Control Group|lay on the FIR-C mattress with cover the FIR-C abdominal pad on abdominal part and Knee part during the sleeping time. The controller will switch on and switch off rotated in each hour for whole night. the FIR-C mattress and the FIR-C abdominal pad is malfunction and it can not produce the FIR-C.
62762102|NCT05088993|EXPERIMENTAL|Antigravity Treadmill Group|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
62762103|NCT05088993|ACTIVE_COMPARATOR|Conventional Exercise Group|This group received the conventional exercise program only.
62762104|NCT05433038|ACTIVE_COMPARATOR|skeletal expander with microosteoperforation in mid palatine|group1.will include ten patients undergo skeletally anchored maxillary expander with microosteoperforation in mid palatine suture
62762105|NCT05433038|ACTIVE_COMPARATOR|skeletal expander with microosteoperforation in mid palatine and buccally|group2.will include ten patients undergo skeletally anchored maxillary expander with microosteoperforation in mid palatine suture and buccally
62762106|NCT03710239|ACTIVE_COMPARATOR|Dilapan-S|Synthetic osmotic dilator
62762107|NCT03710239|ACTIVE_COMPARATOR|Laminaria|Seaweed-based osmotic dilator
62762108|NCT05162001|EXPERIMENTAL|Disulfiram|A group of adults with a body mass index bigger than 22, treated with disulfiram
62762109|NCT05554978|EXPERIMENTAL|Landiolol|initial dose: 20mg target dose: repeated dose (20mg) possible, max. 40mg (total)
62381982|NCT04236440|EXPERIMENTAL|Part A: A2A1+Part B+Part C|"Part A: Participants will receive a single dose administration of placebo (A2) in treatment period 1, and a single dose administration of BAY2586116 (A1) in treatment period 2.~Part B: After successfully completing Part A, participants will proceed to Part B of the study.~Participants will receive a single dose administration of BAY2586116 (B1) in treatment period 3.~Based on the result of the interim analysis there are two possible scenarios regarding mode of application and doses of BAY2586116 to be administered in treatment period 4: 1) a single dose administration of BAY2586116 (B2) Or 2) a single dose administration of BAY2586116 (B3).~Part C: Participants completing Part B will be invited to participate in an additional treatment period with a single dose BAY2586116 (C)."
62381983|NCT05010291|EXPERIMENTAL|Standard of Care (SOC) messaging|Participants randomized into this arm will receive standard voice call reminders + the Standard of Care (SOC) text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include the SOC text
62381984|NCT05010291|EXPERIMENTAL|Loss aversion messaging|Participants randomized into this arm will receive standard voice call reminders + loss aversion text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include loss aversion framing.
62381985|NCT05010291|EXPERIMENTAL|Social norms messaging|Participants randomized into this arm will receive standard voice call reminders + social norms text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include social norms framing.
62381986|NCT05010291|EXPERIMENTAL|Altruism messaging|Participants randomized into this arm will receive standard voice call reminders + altruism text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include altruism framing.
62381987|NCT04383743|EXPERIMENTAL|Treatment (pembrolizumab, aMVAC)|Patients receive pembrolizumab IV over 30 minutes on day 1 of weeks 0, 3, and 6 and methotrexate IV, vinblastine IV, doxorubicin IV, and cisplatin IV on day 1 of weeks 0, 2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim SC on day 1 or 2 of weeks 0, 2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care radical cystectomy.
62381988|NCT06272279|EXPERIMENTAL|Spinal cord stimulation|Spinal cord stimulation will be administered to participants for 15 min.
62762110|NCT05554978|PLACEBO_COMPARATOR|Placebo|Sodium Chlorid 0,9%
62762111|NCT06099106|EXPERIMENTAL|Implantable device|Endomatic SEPIOLA System
62762112|NCT04415879|ACTIVE_COMPARATOR|No Mask|Individuals will perform a Modified Balke Treadmill test with no mask and their estimated VO2 peak will be calculated based off of peak workload.
62762113|NCT04415879|EXPERIMENTAL|N-95 Respirator|Individuals will perform a Modified Balke Treadmill test while wearing a N-95 Respirator and their estimated VO2 peak will be calculated based off of peak workload.
62762114|NCT04415879|EXPERIMENTAL|Cloth Mask|Individuals will perform a Modified Balke Treadmill test while wearing a cloth mask and their estimated VO2 peak will be calculated based off of peak workload.
62762115|NCT03216486|EXPERIMENTAL|BPS804 Dose 1|BPS804 IV Infusion
62762116|NCT04421859|EXPERIMENTAL|EyeCU App|"Augmented reality mobile application called EyeCU which simulates glaucoma progression and enhances understanding about the disease and its course. It is a bilingual (English/Spanish) application that is free-to-download on the Android and Apple app store. It will be delivered on a hospital owned tablet device and patients will be instructed to complete two sections, taking approximately 10 minutes."
62381989|NCT06272279|SHAM_COMPARATOR|Shamspinal cord stimulation|Sham spinal cord stimulation will be administered to participants for 15 min.
62762117|NCT03236870||Participants with moderate to severe plaque psoriasis in China|Participants with moderate to severe plaque psoriasis in China receiving adalimumab in daily clinical practice.
62762118|NCT00733772|EXPERIMENTAL|A|healthy lifestyle counseling + 30 grams/day supplement of Flaxseed
62762119|NCT00733772|SHAM_COMPARATOR|B|TLC diet
62762120|NCT01461070||Breast Cancer Cases|Breast Cancer Cases
62762121|NCT01461070||Controls|Controls
62762122|NCT03701997||EXCOR Pediatric|Pediatric (age 0 - 21) patients who are transplant eligible in need of mechanical circulatory support and are supported with the EXCOR® Pediatric
62762123|NCT04790812|PLACEBO_COMPARATOR|Celecoxib plus Placebo|Single oral dose of celecoxib 200 mg with placebo 30 to 60 minutes prior to the dental procedure
62762124|NCT04790812|ACTIVE_COMPARATOR|Celecoxib plus Acetaminophen|Single oral dose of celecoxib 200 mg in combination with acetaminophen 1000 mg 30 to 60 minutes prior to the dental procedure.
62762125|NCT04006301|EXPERIMENTAL|Part 1: Dose Escalation|Participants with advanced solid tumors harboring the kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation will receive oral administration of JNJ-74699157. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
62762126|NCT04006301|EXPERIMENTAL|Part 2: Dose Expansion|Two groups of participants with either non-small cell lung cancer or other solid tumors harboring KRAS G12C mutation will receive JNJ-74699157 at RP2D determined in Part 1.
62762127|NCT05766904|EXPERIMENTAL|Intervention|Intramuscular injection of 2 doses of 0.5mL 4CMenB vaccine 1 month apart
62762128|NCT05766904|PLACEBO_COMPARATOR|Control|Intramuscular injection of 2 doses of 0.5mL placebo 1 month apart
62762129|NCT04962230|EXPERIMENTAL|Period 1|PF-07321332/ritonavir orally as a single dose
62762130|NCT04962230|EXPERIMENTAL|Period 2|Carbamazepine + PF-07321332/ritonavir orally.
62381990|NCT06481410|EXPERIMENTAL|Methylene Blue Intervention Group|Methylene blue injection, 2.5 mg/kg loading dose over 15 minutes, followed by a continuous infusion of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first.
62762131|NCT04175522|EXPERIMENTAL|Experimental|Investigational product(IP)
62762132|NCT02609685|OTHER|Active Surveillance|Active surveillance instead of standard of care immediate surgery. Patients will be closely monitored every six months until disease is stable for a two-year period and then annually thereafter.
62762133|NCT02609685|NO_INTERVENTION|Immediate Surgery|"Patients who choose to get surgery immediately after diagnosis may choose to enroll in a questionnaire sub-study that will compare quality of life and anxiety scores to patients who enroll in the active surveillance study. This is considered no intervention because the protocol is not directing treatment. Surgery is the standard treatment for papillary thyroid microcarcinoma."
62762134|NCT00722189||A|All patients treated
62762135|NCT05236985|ACTIVE_COMPARATOR|Bolus arm|Patients will receive 3 IU oxytocin IV bolus over 15 seconds after delivery of the baby/uterine cord clamping and a maintenance infusion of 0.9% Saline will be started at 225ml/hr. If uterine tone is inadequate after 3 minutes, a second bolus of 3 IU oxytocin will be given. If uterine tone is inadequate after an additional 3 minutes, a third bolus of 3 IU Oxytocin IV is given over 15 seconds. If after an additional 3 mins uterine tone is still inadequate, a second infusion consisting of oxytocin 3 IU/hr is started at 100ml/hrs and continued for a total of 4 hours, second line uterotonic agents (Methergine, Hemabate and/ or Cytotec) will be given, and the maintenance 0.9% Saline infusion will be changed to 450 ml/hr for a total of 1 hour, then changed to 38 ml/ hour for the following 3 hours. If uterine tone is considered adequate at 3, 6 or 9 minutes, a second infusion of oxytocin 3 IU/hr (100ml/hr) is started and maintained for 4 hours.
62762136|NCT05236985|ACTIVE_COMPARATOR|Infusion arm|Patients will receive a bolus of IV 0.9% Saline over 15 seconds after delivery of the baby/uterine cord clamping and a maintenance infusion of 18 IU/hr Oxytocin IV (225ml/hr). If uterine tone is inadequate after 3 minutes, a second bolus of 0.9% Saline will be given. If uterine tone is inadequate after another 3 minutes, a third bolus of 0.9% Saline will be given. If after another 3 mins uterine tone is inadequate, a second infusion of 0.9% Saline will be started for 4 hours, second line uterotonic agents (Methergine, Hemabate and/or Cytotec) will be given, and the Oxytocin infusion will be changed to 36 IU/hour (450 ml/hr) for a total of 1 hour, and then changed to 38 ml/hr for the following 3 hours. If uterine tone is considered adequate at 3, 6 or 9 minutes, a second infusion of 0.9% Saline at 100 ml/hr will be started and maintained for 4 hours, along with the maintenance infusion of 18 IU/hr (225 ml/ hr) for a total of 1 hour, then changed to 38 ml/hr for an additional 3 hours.
62381991|NCT06481410|PLACEBO_COMPARATOR|Normal Saline Control Group|Normal saline solution, administered in the same manner and duration as the methylene blue intervention.
62381992|NCT06496789|EXPERIMENTAL|Neoadjuvant chemotherapy|
62381993|NCT01276795|EXPERIMENTAL|Glucose and whey protein|Patients who are randomly allocated to this group will receive a drink made of anhydrous beet dextrose and pressurized whey protein in water (200 g/L + 100g/L). Patients will sip the drink for 4 hours of the 6 hour study.
62381994|NCT01276795|ACTIVE_COMPARATOR|Glucose only|The patients who are randomly allocated to this arm will receive a drink composed of anhydrous beet dextrose in water (200g/L). They will sip the drink for 4 hours of the 6 hour study.
62762137|NCT04542668|OTHER|Cycling as first intervention|Cycling -\> Running -\> Inotropy -\> Resting
62762138|NCT04542668|OTHER|Running as first intervention|Running -\> Cycling -\> Inotropy -\> Resting
62762139|NCT04304794||Group with prophylaxis|Group of 13 patients with euthyroid goiter who received prophylactic treatment before and after iodinated contrast medium (ICM) injection. 6 patients received thiamazole with sodium perchlorate, one day prior to ICM and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily). 7 patients received only thiamazole as prophylactic treatment due to lack of sodium perchlorate at the time.
62381995|NCT01109589||Children aged 0-2 yrs|
62381996|NCT01109589||Women aged 15-60 yrs|
62381997|NCT02692976|EXPERIMENTAL|Myeloid dendritic cells (mDC) vaccinations|Patients will be vaccinated intranodally three times biweekly with mDC (5x 106 cells; n=7, arm A). DC will be loaded with major histocompatibility complex (MHC) class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA and loaded with keyhole limpet hemocyanin (KLH) as an immune control.
62762140|NCT04304794||Group without prophylaxis|Group of 23 patients with euthyroid goiter who received no prophylactic treatment before iodinated contrast medium injection.
62762141|NCT01018095|ACTIVE_COMPARATOR|Single dose|Metronidazole 2 gm single dose
62381998|NCT02692976|EXPERIMENTAL|Plasmacytoid dendritic cells (pDC) vaccinations|Patients will be vaccinated intranodally three times biweekly with pDC (3x 106 cells; n=7, arm B). DC will be loaded with MHC class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA.
62381999|NCT02692976|EXPERIMENTAL|mDC and pDC vaccinations|Patients will be vaccinated intranodally three times biweekly with the combination of mDC and pDC (5x 106 mDC/ 3x 106 pDC; n=7, arm C). DC will be loaded with MHC class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA and loaded with KLH (mDC only) as an immune control.
62382000|NCT03042663|EXPERIMENTAL|Intervention group|In patients meeting the inclusion criteria and with absence of any exclusion criteria, and after taking PI and Doppler Blood flow values hourly for 3 hours (control values), the procedure for administering the USG Stellate ganglion block on the side of the arterial cannula will be started
62762142|NCT01018095|ACTIVE_COMPARATOR|7 day dose|Metronidazole 500 mg dose x 7 days
62762143|NCT02156557|EXPERIMENTAL|peptide application|"Investigational Agent Administration~* KCCFPAQ-GGGSK-(5-FITC)-NH2~* 1.2 mg lyophilized powder per single-use amber vial~* Lyophilized powder reconstituted with 10 mL of 0.9% NaCl~* Final concentration of 76.4 μM for single, one-time topical application~* The entire 10 mL solution will be sprayed topically onto area of interest by the Clinical Research Associate (CRA)/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)"
62762144|NCT06012279|EXPERIMENTAL|Dapagliflozin group|This group will receive oral Dapagliflozin 10 mg once daily within 24 hours from hospital admission, in addition to the standard treatment for acute heart failure.
62382001|NCT05972343||Cryoablation|Following pre-procedural imaging evaluation, patients will receive ultrasound-guided percutaneous cryoablation as part of their routine treatment of their breast cancer. Follow up imaging (if tolerated) will be performed at 6 months and 12 months and annually thereafter for until 3 years post-procedure. Data will be collected on patient demographics, disease characteristics, treatment, treatment complications, follow-up imaging, response (for 3 years post-procedure), and quality of life.
62382002|NCT01696708|OTHER|Patients|31-Phosphorus RMN Spectroscopy
62762145|NCT06012279|NO_INTERVENTION|Standard group|This group will only receive the standard treatment for acute heart failure.
62762146|NCT01318070|EXPERIMENTAL|Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD|
62762147|NCT01318070|EXPERIMENTAL|Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD|
62762148|NCT01318070|ACTIVE_COMPARATOR|Pioglitazone (15mg or 30mg ) QD|
62382003|NCT01696708|OTHER|Volunteers|31-Phosphorus RMN Spectroscopy
62382004|NCT04071639|EXPERIMENTAL|Group 1|Mild to moderate HD patients receive medicine treatment with different doses of Deutetrabenazine(Austedo), Risperidone, Zoloft+Idebenone, according to their symptoms. The mode of administration is oral. Capsules will be swallowed whole with water. Zoloft should be taken 50mg once in the morning and Risperidone 1mg once at night. Deutetrabenazine(Austedo) should be taken 6mg once a day, or increase dose according to AUSTEDO® tablets Prescribing Information. Idebenone should be taken 30mg three times a day. Study drug can be taken irrespective of meals. Duration:5 years.
62382005|NCT04071639|EXPERIMENTAL|Group 2|Mild to moderate HD patients receive medicine treatment with different doses of Haloperidol, Risperidone, Zoloft+Idebenone, according to their symptoms. The mode of administration is oral. Capsules will be swallowed whole with water. Haloperidol should be taken 0.5mg\~1mg three times a day. The administration of Zoloft, Risperidone and Idebenone are same as group 1. Study drug can be taken irrespective of meals. Duration:5 years.
62762149|NCT00103519|EXPERIMENTAL|DITPA 180 mg/day|DITPA 180 mg/day BID
62762150|NCT00103519|EXPERIMENTAL|DITPA 360 mg/day|DITPA 360 mg/day BID
62762151|NCT00103519|PLACEBO_COMPARATOR|Placebo|Placebo BID
62382006|NCT02283229|ACTIVE_COMPARATOR|Active|Newborns with preventive caring advices
62762152|NCT01158027||children|
62762153|NCT01891344|EXPERIMENTAL|Ovarian cancer|rucaparib
62762154|NCT00576030|OTHER|H|habitual coffee drinkers
62762155|NCT00576030|OTHER|N|non-habitual coffee drinkers
62762156|NCT04879849|EXPERIMENTAL|Combination Dose Escalation Phase: Radiation + Pembrolizumab + TAK-676|Participants will receive image-guided radiation therapy between Day -8 and Day -2. Participants will then receive pembrolizumab 200 milligram (mg), infusion, intravenously (IV), once on Day 1 of Cycle 1 and then every 3 weeks in each 21-day treatment cycle, followed by TAK-676 infusion with escalating doses (0.2 mg and above), IV, once on Days 1, 8, 15 in each 21-day treatment cycle until disease progression, intolerance to pembrolizumab or TAK-676 or withdrawal of consent, whichever occurs first.
62762157|NCT00802789||1|Mild to moderate adult asthmatics (≥18years of age) insufficiently treated with ICS or ICS + LABA.
62762158|NCT00534378|NO_INTERVENTION|1|
62762159|NCT00570583||Depressed|Older individuals with major depression
62762160|NCT00570583||Non-depressed|Older individuals without psychiatric disorder
62762161|NCT04642924|EXPERIMENTAL|Locally Advanced Rectal Cancer|Patients included with locally advanced rectal cancer SGM-101 10mg, 3-5 days prior to surgery
62762162|NCT04642924|EXPERIMENTAL|Recurrent rectal cancer|Patients included with (locally) recurrent rectal cancer SGM-101 10mg, 3-5 days prior to surgery
62762163|NCT04623515||Surgery Only Group|Participants will complete a questionnaires regarding demographics and medical history on a secured REDCap link.
62762164|NCT04623515||Surgery and Radiation Therapy Group|Participants will complete a questionnaires regarding demographics and medical history on a secured REDCap link.
62762165|NCT01304368|ACTIVE_COMPARATOR|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
62762166|NCT01304368|NO_INTERVENTION|Waiting list|Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
62382007|NCT02283229|PLACEBO_COMPARATOR|Surveillance|Newborns with normal caring advices
62382008|NCT04270890|EXPERIMENTAL|Study participants|Patients will be dual scanned; one with 4D-CT in free-breathing and one wearing the compression belt.Organ motion will then be quantified using Eclipse. This facilitates a direct comparison to determine the efficacy of the compression belt. Patients with reduction in organ motion will be treated wearing the abdominal compression belt. The alignment scale will be recorded to facilitate accurate placement each fraction. The belt will be inflated to a tolerable level by the patient and recorded for consistency each fraction. The position of the belt will be referenced to the anterior and lateral tattoos to ensure accurate and consistent placement each fraction.
62382009|NCT03225027|EXPERIMENTAL|Patients with schizophrenia|Emotional judgment task, post-experimental questionnaire, recognition task, detection task, questionnaire CAPE-42, trait emotional intelligence questionnaire and positive and negative syndrome scale.
62382010|NCT03225027|EXPERIMENTAL|Few psychotic experiences|Healthy participants with few psychotic experience. Participants with the lowest score to the CAPE-42 test. Mini International Neuropsychiatric Interview
62382011|NCT03225027|EXPERIMENTAL|Several psychotic experiences|Healthy participants with several psychotic experiences. Participants with the highest score to the CAPE-42 test. Mini International Neuropsychiatric Interview
62382012|NCT01526928|EXPERIMENTAL|Rociletinib <900 mg BID FB formulation|Rociletinib free base (FB) dose \<900 mg twice a day (BID)
62762167|NCT00785551|EXPERIMENTAL|1|quinine sulfate 648mg in subjects with normal renal function (CLcr \> 80mL/min)
62762168|NCT00785551|EXPERIMENTAL|2|quinine sulfate 648mg in subjects with mildly impaired renal function (CLcr \> 50 to 80 mL/min)
62182535|NCT02208037|EXPERIMENTAL|Tacrolimus/Methotrexate/Maraviroc|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Methotrexate, and Maraviroc.
62382013|NCT01526928|EXPERIMENTAL|Rociletinib 900 mg BID FB formulation|Rociletinib free base (FB) dose 900 mg twice a day (BID)
62382014|NCT01526928|EXPERIMENTAL|Rociletinib 500 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID)
62762169|NCT00785551|EXPERIMENTAL|3|quinine sulfate 648mg in subjects with moderately impaired renal function (CLcr 30 to 50mL/min)
62762170|NCT04557475|EXPERIMENTAL|ASA Group|Receives standard of care and intervention.
62762171|NCT04557475|NO_INTERVENTION|SOC Group|Receives standard of care (SOC), only
62762172|NCT03172065|OTHER|control group|will receive 3.5 ml (17.5 mg) hyperbaric Bupivacaine + 0.5 ml saline
62762173|NCT03172065|OTHER|Dexmedetomidine group|will receive 3.5 ml (17.5 mg) hyperbaric Bupivacaine + 0.5 ml dexmedetomidine (0.5 mic)
62762174|NCT03538444|EXPERIMENTAL|Active rTMS|Participants will receive 18 sessions of active repetitive Transcranial Magnetic Stimulation over a period of three days. TMS consists of 3000 pulses of 10Hz stimulation applied to the left DLPFC using the beam F3 method
62762175|NCT03538444|PLACEBO_COMPARATOR|Sham rTMS|Participants will receive 18 sessions of sham rTMS over a period of three days.
62762176|NCT04510883|EXPERIMENTAL|PACO|Participants are asked to use the intervention for eight weeks.
62182536|NCT02208037|EXPERIMENTAL|Tacrolimus/MMF/Cyclophosphamide|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Mycophenolate Mofetil (MMF), and Cyclophosphamide.
62182537|NCT01584011||Middle ear disease|
62182538|NCT05305677|EXPERIMENTAL|NMN intervention|8 weeks of NMN
62382015|NCT01526928|EXPERIMENTAL|Rociletinib 625 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID)
62762177|NCT04510883|OTHER|Waiting list + PACO|Participants receive the same intervention, but only after a waiting period of four weeks.
62762178|NCT06293638||Essential Tremor with DBS|"1. 40-80 years of age~2. Diagnosis of ET~3. Previously implanted with a DBS system for disease management per standard of care"
62762179|NCT06293638||Essential Tremor without DBS|"1. 40-80 years of age~2. Diagnosis of ET~3. Has not been previously implanted with a DBS system for disease management per standard of care"
62382016|NCT01526928|EXPERIMENTAL|Rociletinib 750 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID)
62382017|NCT01526928|EXPERIMENTAL|Rociletinib 1000 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID)
62382018|NCT02975206|EXPERIMENTAL|Serlopitant High Dose|serlopitant tablets - high dose
62382019|NCT02975206|EXPERIMENTAL|Serlopitant Low Dose|serlopitant tablets - low dose
62382020|NCT02975206|PLACEBO_COMPARATOR|Placebo Oral Tablet|matching placebo tablets
62382021|NCT04265027|EXPERIMENTAL|Group 1 (50 mg Dose)|"Test IMP: 50 mg BIA 9 1067 and Reference IMP: 50 mg Ongentys. The IMPs were administered fasted (after an overnight fast of at least 8 h) with 240 mL water once daily on Days 1 and Days 3 to 12. Subjects remained fasted and sitting upright for at least 4 h after dose. No fluids (apart from water taken with dose) were allowed from 1 h prior to dosing until 1 h afterwards.~There were at least 14 days between the last dose of treatment period 1 and the first dose of treatment period 2."
62382022|NCT04265027|EXPERIMENTAL|Group 2 (25 mg Dose)|"Test IMP: 25 mg BIA9 1067 and Reference IMP: 25 mg Ongentys. The IMPs were administered fasted (after an overnight fast of at least 8 h) with 240 mL water once daily on Days 1 and Days 3 to 12. Subjects remained fasted and sitting upright for at least 4 h after dose. No fluids (apart from water taken with dose) were allowed from 1 h prior to dosing until 1 h afterwards.~There were at least 14 days between the last dose of treatment period 1 and the first dose of treatment period 2."
62382023|NCT03700424|EXPERIMENTAL|Trehalose|Participants will be received intravenous trehalose infusion weekly (15 g/week) for a period of 12 weeks
62382024|NCT03700424|PLACEBO_COMPARATOR|Placebo|Participants will be received equal volume of normal saline weekly for a period of 12 weeks
62382025|NCT05072834||Cohort A|children with chronic malnutrition who do not respond to adequate supplemental feeding will undergo Upper Gastrointestinal Endoscopy
62382026|NCT05072834||Cohort B|Children 6 months to 24 months old who are undergoing Upper Gastrointestinal endoscopy for any appropriate indication
62382027|NCT00472823|EXPERIMENTAL|vitamin D3 400 IU daily|vitamin D3 400 IU daily
62382028|NCT00472823|EXPERIMENTAL|vitamin D3 800 IU daily|vitamin D3 800 IU daily
62382029|NCT00472823|EXPERIMENTAL|vitamin D3 1600 IU daily|vitamin D3 1600 IU daily
62382030|NCT00472823|EXPERIMENTAL|vitamin D3 2400 IU daily|vitamin D3 2400 IU daily
62382031|NCT00472823|EXPERIMENTAL|vitamin D3 3200 IU daily|vitamin D3 3200 IU daily
62382032|NCT00472823|EXPERIMENTAL|vitamin D3 4000 IU daily|vitamin D3 4000 IU daily
62762180|NCT06293638||No Known Neurological Disease or Disorder|"1. 40-80 years of age~2. No known neurological disease or disorder"
62762181|NCT04918953|EXPERIMENTAL|group 1|oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days
62382033|NCT00472823|EXPERIMENTAL|vitamin D3 4800 IU daily|vitamin D3 4800 IU daily
62382034|NCT00472823|PLACEBO_COMPARATOR|placebo|matched to vitamin D tablet
62567614|NCT05496647|EXPERIMENTAL|Stress Ball Application|"Stress Ball Application A sufficient number of stress balls will be provided by the investigator for each patient to use separately before starting the study. Before starting the day-to-day gynecological surgery, patients in the stress ball group will be given a round, colored, medium-hard, compressible Knaftmed ball made of high-quality silicone. To avoid implying that the procedure is inherently stressful, it will be referred to as a squeezing ball when instructing patients about stress ball application.~During the surgical procedure, it will be said that he can squeeze the stress ball as often as he wants for about 20-25 minutes and the stress ball will be given to each patient."
62762182|NCT04918953|EXPERIMENTAL|group 2|oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days
62762183|NCT04918953|EXPERIMENTAL|group 3|budesonide atomization suspension (AstraZeneca Trading Co., Ltd, AU.) inhaled through the nose atomized with an air compression atomizer for 4 weeks, 2 mg for the first 2 weeks and reduced to 1 mg for the last 2 weeks.
62762184|NCT00868257||CHARTA study cohort|Primarily 5- to 10-year-old Ugandan children with HIV or AIDS who are taking ART, with some 1- to 4-year-olds included because of recent trends in treating younger children
62567615|NCT05496647|EXPERIMENTAL|Control|During the process; Women in the control group will not undergo any intervention other than routine surgery.
62762185|NCT02278614|EXPERIMENTAL|T2347|T2347: fixed combination Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops
62762186|NCT02278614|ACTIVE_COMPARATOR|Xalacom|Xalacom®: Latanoprost 0.005% + Timolol 0.5% preserved eye drops
62762187|NCT03628638||Lung Cancer Screening Patients - No Nodules|Subjects in an low dose CT screening program that present no nodules.
62762188|NCT03628638||Lung Cancer Screening Patients - Nodules|Subjects in an low dose CT screening program that present nodules. Additional follow-up data will be collected for up to 12 months and an additional blood sample collected
62762189|NCT04526717|OTHER|MPT0B640|There is single Arm in this clinical trials.
62762190|NCT05736705|ACTIVE_COMPARATOR|Monopolar Electrocautery tool|Patients randomized into this group will receive the standard of care monopolar tool for their endoscopic submucosal dissection procedure.
62762191|NCT05736705|EXPERIMENTAL|Bipolar Electrocautery tool|Patients randomized into this group will receive the standard of care bipolar tool for their endoscopic submucosal dissection procedure.
62762192|NCT04341987|EXPERIMENTAL|brief Imagery Rehearsal Therapy|"The brief two-session, behaviorally-based imagery rehearsal intervention is based on components from previous group and individual formats that have been published, but will be presented in an abbreviated manner. In the first session, Veterans will be presented with psychoeducation about dreaming, basics of sleep hygiene and stimulus control techniques, how to change negative dreams from a learned habit perspective, re-scripting, and how to rehearse new dream imagery. They will then be asked to complete in-session practice of imagery rehearsal with the new imagery developed. Veteran will be instructed in practice post-session."
62762193|NCT04341987|OTHER|Treatment As Usual|Patients in this condition are free to receive treatment as usual for nightmares, which may be a medication, supportive counseling or no treatment.
62762194|NCT05960305|ACTIVE_COMPARATOR|Tobacco Flavor|Can choose between 2 different tobacco flavor variants at 2 different nicotine levels (1.5% and 5%)
62762195|NCT05960305|ACTIVE_COMPARATOR|Menthol Flavor|Can choose between 2 different menthol flavor variants at 2 different nicotine levels (1.5% and 5%)
62762196|NCT05960305|ACTIVE_COMPARATOR|NTNM Flavor|Can choose between 2 different non tobacco/non menthol flavor variants at 2 different nicotine levels (1.5% and 5%)
62762197|NCT05675761||Combined bacterial and fungal infection|Combined bacterial and fungal infection
62762198|NCT05675761||No bacterial and fungal infection|No bacterial and fungal infection
62762199|NCT01083498|EXPERIMENTAL|Ablative fractional laser|"In each patient, a square test region of 5-10 cm2 was treated with ablative fractional laser in three sessions in combination with intermittent topical bleaching with triple topical therapy (hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream) to prevent laser-induced postinflammatory hyperpigmentation.~Note: this study had a split-lesion design. In each patient, two test regions were randomized to receive either ablative fractional laser therapy or no treatment."
62762200|NCT01083498|NO_INTERVENTION|Control|"In each patient, a square test region of 5-10 cm2 was treated with topical bleaching with triple topical therapy (hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream)alone (to allow comparison of the regions).~Note: this study had a split-lesion design. In each patient, two test regions were randomized to receive either ablative fractional laser therapy or no treatment."
62762201|NCT02395055|EXPERIMENTAL|BCD-057 group|BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
62762202|NCT02395055|ACTIVE_COMPARATOR|Humira group|Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
62762203|NCT03694873|EXPERIMENTAL|tramadol|one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
62762204|NCT03694873|ACTIVE_COMPARATOR|celecoxib|one tablet of Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
62762205|NCT03207945|EXPERIMENTAL|Alirocumab|Patients randomized into the alirocumab arm will start off with 75 mg alirocumab administered every two weeks for two doses and will be upwardly titrated to 150 mg alirocumab if subjects demonstrate LDL ≥ 50 mg/dL at week 4. Subjects demonstrating LDL-C \<50mg/dl will remain on the same 75mg dose throughout the trial.
62762206|NCT03207945|PLACEBO_COMPARATOR|Placebo|Patients randomized into the placebo arm will receive 75 mg or 150 mg or placebo administered once every two weeks throughout the trial
62762207|NCT04243395|EXPERIMENTAL|Pork|1 ounce lean pork
62762208|NCT04243395|EXPERIMENTAL|Egg|1 large whole egg
62762209|NCT04243395|EXPERIMENTAL|Black beans|0.5 cups of cooked black beans
62762210|NCT04243395|EXPERIMENTAL|Almonds|0.5 ounce of whole almonds
62762211|NCT02526862|NO_INTERVENTION|A-Mask or direct interface|Mask or direct interface
62182539|NCT05305677|PLACEBO_COMPARATOR|Placebo|8 weeks of NMN-free placebo
62182540|NCT02357914||Individuals with paraplegia|Individuals with a spinal cord injury below T1
62182541|NCT03575195|EXPERIMENTAL|Intervention|Rifaximin
62182542|NCT03575195|PLACEBO_COMPARATOR|Placebo|Matching placebo
62762212|NCT02526862|ACTIVE_COMPARATOR|B-Autoadhesive polyurethane dressing|Protection of the dermis with autoadhesive polyurethane dressing (Allevyn Thin®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
62558646|NCT05575882|ACTIVE_COMPARATOR|Investigational product (BI 479 V1)|"The study product or placebo will be applied twice daily on a clean and dry skin for 120 days. Follow 3-6-9 method as follows: for babies (6 months to 24 months) use 3 pumps for the whole body (1 pump for face, 1 pump for trunk and arms and 1 pump for lower limbs), for children from 25 months: use 6 pumps for the whole body (1 pump for face, 3 pumps for trunk and arms and 2 pumps for lower limbs) and for children with height greater than 1.5 meters: use 9 pumps for the whole body (1 pump for face, 1 pump for chest, 1 pump for back, 1 pump per arm (x2) and 2 pumps per leg (x2). It will be applied from inclusion visit simultaneously with topical treatment in the following order: first the study product or placebo on the whole body followed by the topical treatment on the flare-up areas."
62762213|NCT02526862|ACTIVE_COMPARATOR|C-Semi-permeable hydrogel-foam|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing (Askina Transorbent Border®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
62762214|NCT02526862|ACTIVE_COMPARATOR|D-Hyper hydrogenated fatty acids|Protection of the dermis with hyper hydrogenated fatty acids (Linovera®) in the contact areas with the NIVM interface or mask. It will apply with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
62762215|NCT01811602|OTHER|Training|Pelvic floor muscle training delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction
62762216|NCT01811602|OTHER|Usual Care Control|Participants randomized to this arm will receive a 1-page educational pamphlet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
62762217|NCT06357273||Control (CONT)|Obese patients who did not receive any drugs or herbal supplement were offered to be included in the CONT group.
62762218|NCT06357273||Orlistat (ORL)|Obese patients who were treated with orlistat were offered to be included in the ORL group.
62762219|NCT06357273||Metformin (METF)|Obese patients who were treated with metformin were offered to be included in the METF group.
62762220|NCT06357273||White Tea (WT)|Obese patients who did not receive any drugs, but were taking white tea were offered to be included in the WT group.
62762221|NCT02311569|EXPERIMENTAL|Arm Mirabegron|Mirabegron treatment of at least 24 weeks with an initial dose of 25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
62762222|NCT03973463|SHAM_COMPARATOR|Low fat diet,12 weeks low oil balance 1200 kcal / day|12 weeks low oil balance 1200 kcal / day
62762223|NCT03973463|EXPERIMENTAL|12-week resistance exercise 3 times a week|12-week stretch with resistance exercise, 3 times a week
62762224|NCT03973463|EXPERIMENTAL|12 weeks low oil balance and resistance exercise|12 weeks low oil balance 1200 kcal / day and 12-week stretch with resistance exercise, 3 times a week
62762225|NCT01993316|EXPERIMENTAL|neurofeedback training|Subjects will undergo neurofeedback training to either the right primary motor cortex or the right superior parietal gyrus. The EEG measurements will be analyzed using LORETA.
62762226|NCT04804735|EXPERIMENTAL|REV : local anesthesia and virtual reality|Use of virtual reality device in Implanted Venous Access Device (IVAD) procedure under local anesthesia
62762227|NCT04804735|EXPERIMENTAL|MUS : local anesthesia and music therapy|Use of musicotherapy tool in Implanted Venous Access Device (IVAD) procedure under local anesthesia
62762228|NCT04804735|NO_INTERVENTION|CONTROL : standard local anesthesia|Implanted Venous Access Device (IVAD) procedure under local anesthesia as standard of care
62762229|NCT02649855|EXPERIMENTAL|Arm A/Sequential Docetaxel followed by PROSTVAC|Standard androgen deprivation therapy (ADT) followed by sequential docetaxel + prostvac
62762230|NCT02649855|EXPERIMENTAL|Arm B/ Combined Docetaxel with PROSTVAC|Standard androgen deprivation therapy (ADT) followed by combined docetaxel + prostvac
62762231|NCT02649855|EXPERIMENTAL|Arm C/ PROSTVAC Prior to Docetaxel|Standard androgen deprivation therapy (ADT) followed by prostvac, then docetaxel. No ADT for less than 28 days, prostvac prior to docetaxel.
62762232|NCT03515174|EXPERIMENTAL|Interventional Program|Patients will participate in a structured supportive care program.
62762233|NCT03515174|ACTIVE_COMPARATOR|Control Group|Patients in the control group will receive usual care.
62762234|NCT04399954|EXPERIMENTAL|Ketoflo|Ketoflo to be incorporated into each participant's usual ketogenic diet for 28 days. Amount taken and frequency of intake to be determined by the dietitian.
62762235|NCT02823184||Patients|ET or PV patients diagnosed before acceleration phase and treated by hydroxyurea with a follow up period of at least 6 months following treatment start, with a RNA sample of total leukocytes before start of treatment available
62762236|NCT02333981|EXPERIMENTAL|Passive oral motor therapy group|All the subjects received passive treatment which included light touch, stroking, vibration, tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
62762237|NCT05122117|EXPERIMENTAL|Methylene blue mediated photodynamic therapy|Methylene blue (MB) with a concentration of 10 mg/mL was delivered inside the periodontal pocket. MB was injected inside in the selected periodontal pockets 4 - 6 mm with the help of a blunt needle and left for 1 min. Later, the periodontal pockets were flushed with distilled water for 3 min to remove the excess MB. The diode laser HELBO® TheraLite - Bredent Medical, Germany) of diameter 200 µm was used to deliver the light to initiate the disinfection process. Each participant underwent single session of laser exposure. The laser parameters such as wavelength, spot area, power output and laser energy were set at 660 nm, 0.028 cm2, 60 mW/cm2, and 150 mW, respectively. The laser was subjected for a period of 30 s in each pocket.
62382035|NCT02663206|OTHER|Botulinum toxin injection|"Drug/Device: Botulinum toxin injection; Endoscopic Botulinum toxin (BTX) injection at lower esophagus; Upper endoscopy with Botulinum toxin injection.~The procedure will be performed as an outpatient basis by an endoscopist. Sedation can be in form of conscious sedation, monitored anesthesia care or general anesthesia. An upper endoscope will be inserted into the patient's mouth and advanced into lower esophagus. Botulinum toxin (Botox@) 100 units 8-10 (25 units/mL) will be injected in 1-ml portion in each of four quadrants about 1 cm above the Z-line (the LES region).~* At 1 month follow-up, patients who do not response to the first botox injection (Eckardt score \> 3) will receive the second botox injection.~* At 3-month follow-up, POEM will be offered as a rescue therapy to both non-responders (Eckardt score \> 3 at 3-month follow-up after the procedure) and relapsers (Eckardt score ≤ 3 at 3-month follow-up but becomes \> 3 during the follow-up)"
62762238|NCT05122117|PLACEBO_COMPARATOR|Scaling and root planing|A single session of full-mouth ultrasonic scaling using a sterilized scaler was rendered to the control group. Deep pockets were additionally approached and cleaned by using manual 'After Fives' Gracey curette for root planning (Hu Friedy Gracey After Five Vision curette; HuFriedy, Chicago, USA). This session was followed by a polishing session. A motivational session was conducted where the patients were educated on the importance of maintaining a good oral hygiene by brushing their teeth twice daily followed by the regular use of dental floss and chlorhexidine mouth wash twice daily, respectively.
62762239|NCT00885768||A|patients with renal artery stenosis
62762240|NCT00584571|ACTIVE_COMPARATOR|Sensory Adaptation training|a large compliant balloon is placed in the rectum attached to a barostat. The balloon is distended in 1 mm increments until patient reports moderate discomfort and then increased in 1 mm increments until maximum tolerable pressure. Gradually over 6 training sessions, administered biweekly, the maximum tolerable pressure is increased over 3 months, if treatment is successful.
62762241|NCT00584571|EXPERIMENTAL|Escitalopram Therapy|Patients randomized to this arm will receive daily 10 mg escitalopram for 3 months. If the medication is effective their bowel symptoms and pain thersholds will improve.
62762242|NCT03423108|NO_INTERVENTION|Control|Participants randomized to this group will perform monthly cohabitation meetings.
62762243|NCT03423108|EXPERIMENTAL|G150|Participants randomized to this group will be enrolled to a 150 min/week structured and supervised exercise training. The program consists of 3 sessions in a week, each of these lasting 50 minutes. The session will be composed of aerobic training (25 minutes at 60-75% of HRmax) and strength training (25 minutes, 8 whole-body exercises at up to 8-12 maximal repetitions).
62762244|NCT03423108|EXPERIMENTAL|G300|Participants randomized to this group will be enrolled to the same structural settings of G150 group (type of exercise, exercise intensity and weekly frequency). They will receive twice the G150 group dose's. To do so, each session will last 100 minutes (50 minutes of aerobic exercise training and 50 minutes of strength training).
62762245|NCT05215015|EXPERIMENTAL|Anti-CD33/CLL1 CAR-NK Cells|The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10\^9 cells.
62762246|NCT05782192|EXPERIMENTAL|SAL067|SAL067 12mg once daily
62558647|NCT05575882|PLACEBO_COMPARATOR|Placebo (BI 006)|Same instructions of use as active comparator.
62558648|NCT01287806|SHAM_COMPARATOR|blank control group|
62762247|NCT05782192|ACTIVE_COMPARATOR|Alogliptin|Alogliptin 25mg once daily
62762248|NCT05782192|PLACEBO_COMPARATOR|placebo|placebo once daily
62762249|NCT01731834|ACTIVE_COMPARATOR|Aspiration of secretion|10 children are evaluated at rest, during and after aspiration technique secretion
62762250|NCT01731834|EXPERIMENTAL|Vibrocompression|10 children will be assessed at rest, during and after the maneuver vibrocompression
62762251|NCT00627536|EXPERIMENTAL|1|Avotermin 5ng/100μL/linear cm wound margin
62558649|NCT01287806|EXPERIMENTAL|ulinastatin group|ulinastatin is a multivalent kunitz-type serine protease inhibitor refined from human urine
62762252|NCT00627536|PLACEBO_COMPARATOR|2|Placebo
62762253|NCT00627536|EXPERIMENTAL|3|Avotermin 50ng/100μL/linear cm wound margin
62762254|NCT00627536|PLACEBO_COMPARATOR|4|Placebo matched to avotermin 50ng/100μL/linear cm
62762255|NCT00627536|EXPERIMENTAL|5|Avotermin 200ng/100μL/linear cm
62558650|NCT04982861|EXPERIMENTAL|Cefixime trihydrate 100 mg/5 mL dry syrup|Cefixime trihydrate 100 mg/5 mL dry syrup was dissolved by 20 mL of water split in 2 portions. Then the drug was shaken well for at least 30 seconds at each addition of water.
62762256|NCT00627536|PLACEBO_COMPARATOR|6|Placebo matched to avotermin 200ng/100μL/linear cm
62762257|NCT00627536|EXPERIMENTAL|7|Avotermin 500ng/100μL/linear cm wound margin
62762258|NCT00627536|PLACEBO_COMPARATOR|8|Placebo matched to avotermin 500ng/100μL/linear cm
62762259|NCT01336751|EXPERIMENTAL|Insulin glargine|"Lantus (insulin glargine) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by Self-monitoring blood glucose (SMBG).~The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator."
62762260|NCT01336751|ACTIVE_COMPARATOR|Lispro mix|"Humalog Mix 75/25 (lispro mix) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by self-monitoring blood glucose (SMBG).~The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator."
62762261|NCT01670565|EXPERIMENTAL|Mycophenolate mofetil + Belimumab|All patients who enroll in this trial will FIRST receive mycophenolate mofetil (MMF, Cellcept), which is a drug commonly given to patients with scleroderma in clinical practice. This drug will be given at no cost to the patient. After the patient has been titrated to 2 grams of MMF per day, the patient will receive EITHER a 10 mg/kg belimumab (Benlysta) intravenous infusion OR a placebo (saline) infusion. This medication and infusion will of course be covered by the study.
62762262|NCT01670565|PLACEBO_COMPARATOR|Mycophenolate Mofetil + Saline (placebo)|In order to observe the difference between belimumab/MMF compared to MMF alone, half of the patients will receive a normal saline infusion that appears identical to the belimumab infusion.
62762263|NCT03453866|EXPERIMENTAL|Warmed Arthroscopic Fluids|Arthroscopic Fluids will be warmed to 38 degrees Celsius during procedure with active warming device. Temperature will be measured in real time.
62382036|NCT02663206|OTHER|peroral endoscopic myotomy|"Procedure/Surgery: peroral endoscopic myotomy.~The procedure will be performed by an endoscopist (gastroenterologist or surgeon). General anesthesia will be started and upper endoscope will be inserted into the patient's mouth and advanced into the stomach. Endoscopic myotomy will be performed. Mucosal entry will then be closed using endoscopic clips or endoscopic suturing.~All patients will recover from their procedures according to standard practice. They will remain nothing per oral (NPO) the night after the procedure and started on intravenous proton pump inhibitors. A gastrografin esophagram will be obtained the next day and if no evidence of leak, the diet will be advanced to a soft diet for two weeks. The patients will be evaluated by study coordinator/PI on a daily basis during their hospitalization."
62382037|NCT02237573|EXPERIMENTAL|Intervention|Written medical report and standardized medical advices
62762264|NCT03453866|ACTIVE_COMPARATOR|Room Temperature Arthroscopic Fluids|Arthroscopic fluids will be kept at room temperature and will not be warmed per current standard of care. Temperature will be measured in real time.
62762265|NCT04094233|EXPERIMENTAL|Beetroot Extract|Capsule containing 600mg of beetroot extract.
62762266|NCT04094233|EXPERIMENTAL|Placebo|Capsule containing 600mg of starch.
62382038|NCT02237573|ACTIVE_COMPARATOR|Control|Standardized medical advice only
62762267|NCT02211118|EXPERIMENTAL|IN-DEX|Subjects will be administered 1 mcg/kg or 1.5 mcg/kg intranasal dexemdetomidine (IN-DEX) and monitored for up to 5 hours.
62762268|NCT03468972|EXPERIMENTAL|Immunosuppression|corticosteroids or cyclophosphamide added on corticosteroids
62762269|NCT03468972|ACTIVE_COMPARATOR|Intensive supportive care|intensive supportive care with RAS blockers, blood pressure control, and protein restriction diet
62762270|NCT04181580|OTHER|Fit test of made-to-measure garments|Healthy subjects will test maximum 2 compression garments out of 6 garments under investigation
62762271|NCT00984607|EXPERIMENTAL|barium sulfate tablet|After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring.
62762272|NCT02111655|OTHER|Clasical Surveillance of AVF|"Classical evaluation of AVF includes:~1. Vital sings and predialysis physical examination of AVF every dialysis session.~2. Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session.~3. Weekly ktv test using biosensors or monthly if using monocompartimental Daugirdas equation.~4. Quarterly recirculation with urea method.~Following Spanish Nephrology VA guidelines will be consider as alarm criteria:~1.25% Increased venous pressure. 2.25% Decreased pump blood flow. 3.0,2 ktv decreased compared with previous measurement. 4.\> 10% recirculation using urea method. 5.Prolonged coagulation time or cannulation difficulties in 3 consecutive dialysis sessions.~6.Pathologic physical examination with any other criteria."
62182543|NCT02492698|EXPERIMENTAL|Probiotic group|consumed 2 g of powder of a dual probiotic strains containing Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, twice a day after breakfast and dinner.
62182544|NCT02492698|PLACEBO_COMPARATOR|Placebo group|consumed 2g of powder that did not contain any probiotics, twice a day after breakfast and dinner.
62182545|NCT00868764|EXPERIMENTAL|Sancuso® patch|Subjects receiving 1 Sancuso® patch worn for 7 days
62558651|NCT04982861|ACTIVE_COMPARATOR|Suprax® 100 mg/5 mL dry syrup|Suprax® 100 mg/5 mL dry syrup was dissolved by 33 mL of water split in 2 portions. Then the drug was shaken well for at least 30 seconds at each addition of water.
62558652|NCT03805386|ACTIVE_COMPARATOR|Standard of Care|Subjects will be prescribed the standard amount of opioids that are typically prescribed by our practice after surgery. Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.
62558653|NCT03805386|EXPERIMENTAL|Patient Directed Care|Subject directed arm will be prescribed the number of opioids that the patient decides to be appropriate after discussion with the surgeon. This can be as low as 0 pills and as much as 30 pills as described in the standard care.
62558654|NCT05232760||SUPERA peripheral stent system|
62182546|NCT02949856|EXPERIMENTAL|Tapered|Mallinckrodt, COVIDIEN
62182547|NCT02949856|ACTIVE_COMPARATOR|Cylindrical|Endotracheal tube, Unomedical
62762273|NCT02111655|EXPERIMENTAL|Second generation surveillance of AVF|"In addition to the classical surveillance and monitoring methods, in the experimental group Doppler ultrasound and transonic dilution method will be performed on a quarterly basis.~In addition to the classical alarm criteria and derived from the results in Doppler ultrasound an transonic dilution method the following alarm criteria would also be considered in the experimental group:~1. 25% or higher decreased in QA compared with previous measurement.~2. QA lower than 500 ml/min.~3. Stenotic area with a higher than 50% reduction of blood vessel lumen would be considered as alarm criteria only if it comes with a haemodynamic repercussion criteria defined as Peak systolic velocity (PSV) higher than 400 cm/sc, aliasing, or PSV ratio stenosis/pre-stenosis higher than 3."
62762274|NCT05013268|EXPERIMENTAL|Tislelizumab plus TP regimen as neoadjuvant therapy for local advanced cervical carcinoma|"Experimental:~Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin The subjects enrolled in this trial will receive tislelizumab 200mg ivgtt d1, paclitaxel (175mg/m2 ivgtt d1) or docetaxel (75mg/m2 ivgtt d1), cisplatin (75mg/m2 ivgtt d1) or carboplatin (AUC=5 ivgtt d1). The regimen will be repeated every 3 weeks for 3 cycles. Chemotherapy regimen will be selected by investigators.~Subjects will be enrolled serially."
62762275|NCT02922842|ACTIVE_COMPARATOR|Tibial Nerve|Transcutaneous electrical stimulation will be placed on the posterior tibial nerve.
62762276|NCT02922842|ACTIVE_COMPARATOR|Parasacral|Transcutaneous electrical stimulation will be placed on the lower back near the s3 foramina.
62762277|NCT02922842|SHAM_COMPARATOR|Shoulder|Transcutaneous electrical stimulation will be placed on the shoulder.
62762278|NCT03622021|EXPERIMENTAL|AK111 30mg|Single dose of 30mg AK111 or placebo is administered subcutaneously to healthy subjects
62762279|NCT03622021|EXPERIMENTAL|AK111 75mg|Single dose of 75mg AK111 or placebo is administered subcutaneously to healthy subjects
62762280|NCT03622021|EXPERIMENTAL|AK111 150mg|Single dose of 150mg AK111 or placebo is administered subcutaneously to healthy subjects
62762281|NCT03622021|EXPERIMENTAL|AK111 300mg|Single dose of 300mg AK111 or placebo is administered subcutaneously to healthy subjects
62762282|NCT03622021|EXPERIMENTAL|AK111 450mg|Single dose of 450mg AK111 or placebo is administered subcutaneously to healthy subjects
62762283|NCT03622021|EXPERIMENTAL|AK111 600mg|Single dose of 600mg AK111 or placebo is administered subcutaneously to healthy subjects
62762284|NCT02688088|ACTIVE_COMPARATOR|Drug Cocktail - Period 1|Single dose of drug cocktail: 100 milligram (mg) caffeine,10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg midazolam administered orally on Day 1 in Period 1.
62762285|NCT02688088|EXPERIMENTAL|200 mg Abemaciclib + Drug Cocktail - Period 2|200 mg Abemaciclib administered orally every 12 hours (Q12H) on Days 1 - 12 in Period 2 with a single dose of drug cocktail: 100 mgcaffeine,10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg midazolam administered orally on Day 8 in Period 2.
62762286|NCT02688088|EXPERIMENTAL|200 mg Abemaciclib - Period 3|200 mg Abemaciclib administered orally Q12H on Days 13 to 28 in Period 3. Participants may continue to receive abemaciclib until discontinuation criteria are met.
62182548|NCT01321723|EXPERIMENTAL|PTH analog tablet|PTH(1-31) 5 mg tablet, once daily
62558655|NCT00137176|EXPERIMENTAL|Rebif + Lipitor|
62762287|NCT02688088|EXPERIMENTAL|200 mg Abemaciclib - Period 4|200 mg Abemaciclib administered orally Q12H on Days 1 to 28 in Period 4. Participants may continue to receive abemaciclib until discontinuation criteria are met.
62762288|NCT02688088|EXPERIMENTAL|Safety Extension Period|200 mg Abemaciclib administered orally Q12H on Days 1 to 28 onwards in extension period. Participants may continue to receive abemaciclib until discontinuation criteria are met.
62762289|NCT03720600|EXPERIMENTAL|MAB Intervention|Participants in this condition will be asked to come into the laboratory twice. At Time 1 (T1), participants in this condition will watch a voice-guided PowerPoint on MAB strategies for coping with discrimination. For the following two weeks, they will be asked to complete multiple momentary assessments daily for two weeks. After two weeks, participants will return to the laboratory to complete a final battery of questionnaires and complete a qualitative exit-interview.
62182549|NCT01321723|PLACEBO_COMPARATOR|Placebo|Placebo matching tablet, once daily
62382039|NCT04027842|EXPERIMENTAL|Prewarming group|Participants in Prewarming group was warmed with forced air warming device (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) over the entire body for 10 minutes before anesthesia was induced in the operating theater. All participants received active warming with forced air warming system from the initiation of anesthetic induction until end of surgery.
62382040|NCT04027842|NO_INTERVENTION|Non-prewarming group|In Non-prewarming group, no active warming was conducted before induction of anesthesia. Only standard care was provided with introperative active warming with forced air warming system from the initiation of anesthetic induction until end of surgery.
62762290|NCT03720600|OTHER|Waitlist-Control|"Participants in the waitlist-control condition will be asked to come into the laboratory twice. At Time 1 (T1), participants in this condition will complete an initial set of questionnaires. For the following two weeks, they will be asked to complete multiple daily momentary assessments daily. After two weeks, participants will return to the laboratory to complete a final battery of questionnaires, watch a voice-guided PowerPoint on MAB strategies for coping with discrimination, and complete a qualitative exit-interview."
62762291|NCT03720600|NO_INTERVENTION|No-EMA Control|"Participants in the No-EMA Control condition will only complete questionnaires at T1 and T2."
62762292|NCT03303898|OTHER|asymptomatic carriers|
62762293|NCT03303898|OTHER|uninfected patient|
62762294|NCT05140837||cross-sectional study|
62762295|NCT05140837||real-world cohort study|
62762296|NCT04900610|ACTIVE_COMPARATOR|Vitamin K2|1mg/day per os
62762297|NCT04900610|PLACEBO_COMPARATOR|Placebo|matching placebo
62762298|NCT06260137|ACTIVE_COMPARATOR|Rhomboid İntercostal Block (RIB)|
62762299|NCT06260137|ACTIVE_COMPARATOR|Rhomboid intercostal and subserratus plane block (RISS)|
62762300|NCT06073639|EXPERIMENTAL|Dentin graft|
62762301|NCT06073639|NO_INTERVENTION|Conventional|
62762302|NCT03079401|EXPERIMENTAL|Treatment Arm|"Those randomized to the treatment arm will receive MPCs injected directly into the LV endocardium following clinical surgical maneuvers to recruit the LV (mitral valve repair, aortic valve repair, and/or resection of endocardial fibroelastosis) or BDG.~MPCs will be delivered directly into the LV endocardium via a 23-25 gauge needle following completion of all surgical procedures. A total dose of 20 million cells will be delivered, divided evenly into \~11 injections of 50 µL each. The total volume is not to exceed 2.0 mL."
62762303|NCT03079401|NO_INTERVENTION|Control Arm|Those subjects randomized to the control arm will receive standard LV recruitment or BDG with no injection.
62762304|NCT03224871|EXPERIMENTAL|Nivolumab|Intralesional IL-2, Radiotherapy will be given to all patients. Immune checkpoint blockade with Nivolumab will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks.
62762305|NCT03224871|EXPERIMENTAL|Pembrolizumab|Intralesional IL-2, Radiotherapy will be given to all patients. Immune checkpoint blockade with Pembrolizumab will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks.
62762306|NCT03383757|EXPERIMENTAL|SpO2 Sensor Application & Blood draw|All subjects will undergo the same study procedures of having their SpO2 levels measured with an external sensor applied to the skin and blood SpO2 level measured
62762307|NCT06373770|EXPERIMENTAL|Ayres sensory integration therapy|A. Jean Ayres, is a theory and practice that targets a person's ability to process and internally integrate sensory information from their body and environment.
62762308|NCT06373770|OTHER|Behaviour therapy|The current treatment options for the core symptoms of autism are limited to psychosocial therapies, such as applied behavior analysis.
62762309|NCT01603381|EXPERIMENTAL|CBT-I|Cognitive Behavioral Therapy for Insomnia
62762310|NCT01603381|NO_INTERVENTION|Monitor Only (M.O.)|
62762311|NCT04076345||Bacterial group|Newborns or infants less dans 3 months old with fever and positive bacterial sample.
62382041|NCT04283773||Malignant ovarian germ cell tumors ( MOGCTs).|22 cases of malignant ovarian germ cell tumors ; include Dysgerminoma , yolk sac tumor and immature teratomas will be treated by anti P16 antibody and Ki67 antibody.
62762312|NCT04076345||Viral group|Newborns or infants less dans 3 months old with fever and positive viral sample.
62182550|NCT01321723|ACTIVE_COMPARATOR|Forsteo|Forsteo (teriparatide) 20 mcg SC Injection, once daily
62382042|NCT04283773||Mature cystic teratomas.|20 cases of mature teratomas will be treated by anti P16 antibody .
62382043|NCT04283773||Normally apparent ovaries.|20 cases of normally apparent ovaries will be treated by anti P16 antibody .
62382044|NCT04026633|EXPERIMENTAL|Experimental: Enhanced Intervention|Participants assigned to this arm will complete a personal writing task about alcohol use.
62382045|NCT04026633|PLACEBO_COMPARATOR|Placebo Comparator|Participants assigned to this arm will complete a personal writing task about eating behaviors.
62762313|NCT04076345||Negatives Microbiological samples|Newborns or infants less dans 3 months old with fever and negatives microbiological samples.
62762314|NCT05049330||Derivation Cohort|The derivation cohort collected data to derive the clinical decision rule.
62762315|NCT05049330||Validation Cohort|The validation cohort collected data to validate the clinical decision rule
62762316|NCT00003963|EXPERIMENTAL|Vinorelbine and Rituxan|"Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Rituxan given every 2 weeks. Vinorelbine given weekly x3, with one week off.~Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
62762317|NCT03397134|EXPERIMENTAL|Roluperidone 64 mg|Roluperidone 64 mg for entire study
62762318|NCT03397134|EXPERIMENTAL|Roluperidone 32 mg|Roluperidone mg for entire study
62762319|NCT03397134|PLACEBO_COMPARATOR|Placebo-1|Placebo for 12 weeks followed by Roluperidone 64 mg during open-label extension
62762320|NCT03397134|PLACEBO_COMPARATOR|Placebo-2|Placebo for 12 weeks followed by Roluperidone 32 mg during open-label extension
62762321|NCT02863523|EXPERIMENTAL|Integrated Behavioral Intervention|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
62382046|NCT00599144|EXPERIMENTAL|1|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
62382047|NCT00599144|EXPERIMENTAL|2|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
62762322|NCT02863523|NO_INTERVENTION|Usual Care|Patients receive usual care
62762323|NCT04272710||ACEI treatment|hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
62182551|NCT00719212|EXPERIMENTAL|AMG 479|AMG 479 administered on day 1 of each 21-day cycle up to disease progression, unacceptable toxicity, withdrawal of consent or sponsor decision to stop the study.
62382048|NCT00599144|NO_INTERVENTION|3|Group3: control group without any local anesthetic use.
62382049|NCT01987609|EXPERIMENTAL|Hylenex|Psoriatic plaques in this arm will be injected with Hylenex every week for 4 weeks.
62382050|NCT01987609|PLACEBO_COMPARATOR|Normal Saline|Psoriatic plaques in this arm will be subcutaneously injected with sterile normal saline every week for four weeks
62382051|NCT01577927|ACTIVE_COMPARATOR|Usual home care|No assistance or care by PT.
62382052|NCT01577927|EXPERIMENTAL|PT-assisted home rehabilitation|Assisted home care is supported by a PT at least 2 times/month. Few brief educational lessons preceeded the training activity that the patient performs by himself at home.
62382053|NCT02261311||Quality of Life, tissue collection|All participants will complete the GAD-7 and Cancer Locus of Control Scale - Course of Illness Subscale questionnaires and additional tissue will be collected at the time of the diagnostic biopsy.
62382054|NCT01641029||pyelonephritis|Patients \> 18 years of age with flank pain and/or costovertebral angle tenderness, documented temperature in the emergency department of ≥38°C/100.4°F by any method of measurement, and clinically suspected acute pyelonephritis. Patients will be identified by their emergency department treating physicians.
62382055|NCT04890782||MMD group|Consecutive patients diagnosed with MMD during hospitalization in Beijing Tiantan Hospital, Capital Medical University will be recruited.
62382056|NCT04890782||Healthy control group|Age and sex matched subjects will be invited to join the study as the control.
62382057|NCT04700891|EXPERIMENTAL|Patients scheduled for elective surgery aged 65 and +|
62382058|NCT03362723|EXPERIMENTAL|Treatment Sequence 1: ABCD|Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 1 (one cycle is 28 days). Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 8. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 15. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
62182552|NCT05383625|EXPERIMENTAL|Quadrivalent vaccine|Patient receive 0.1 ml of quadrivalent HPV vaccine intralesional every two weeks
62382059|NCT03362723|EXPERIMENTAL|Treatment Sequence 2: ABDC|Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 1 (one cycle is 28 days). Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 8. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 15. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
62762324|NCT04272710||Control|hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China
62762325|NCT03981666|EXPERIMENTAL|Patients with insomnia|adult outpatients with a localized or metastatic breast, colorectal, pulmonary or urological cancer
62762326|NCT05904522|EXPERIMENTAL|lesional skin|lesional skin of mycosis fungoides stage 1A patients
62762327|NCT05904522|EXPERIMENTAL|non-lesional skin|non-lesional skin of mycosis fungoides stage 1A patients
62762328|NCT05942118||ROLL|Prior to surgery, an ultrasound-guided localization will be performed and albumin marked with Technetium 99m will be injected close to the tumor and in the subareolar area. During surgery, a specific probe will be used to locate the lesion and sentinel lymph node.
62762329|NCT05942118||SEED|During diagnostic biopsy or prior to surgery, a magnetic clip will be placed in the breast lesion; during surgery, localization will be performed using a specific probe, while sentinel lymph node localisation, when needed, will be performed even with indocyanine green dye (ICG) or methylene blue dye
62762330|NCT02576860|EXPERIMENTAL|Treatment|CLS001 (Omignan) gel applied once daily
62762331|NCT02576860|PLACEBO_COMPARATOR|Vehicle Gel|Vehicle gel applied once daily
62762332|NCT04836390|EXPERIMENTAL|Treatment Arm|All subjects will receive NK infusions.
62762333|NCT04488744|EXPERIMENTAL|nicotine infusion 0.2mg|"nicotine infusion~0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) The day order will be randomized over 5 days."
62762334|NCT04488744|EXPERIMENTAL|nicotine infusion 2.0mg|0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries),
62762335|NCT04488744|EXPERIMENTAL|nicotine infusion 1.0mg|1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries)
62762336|NCT04488744|EXPERIMENTAL|nicotine infuison 1.0mg|1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).
62762337|NCT04488744|PLACEBO_COMPARATOR|Saline|saline delivered over 2minutes ,2.5minutes,10 minutes
62762338|NCT05182580|EXPERIMENTAL|Intervention Group|Autonomous AI results are used to evaluate if the participant needs to see the retina specialist (positive result) or not (negative result).
62762339|NCT05182580|NO_INTERVENTION|Control Group|All participants see the retina specialist irrespective of the results of their autonomous AI evaluation.
62762340|NCT04233658|PLACEBO_COMPARATOR|Placebo|
62762341|NCT04233658|EXPERIMENTAL|Cynara Scolymus|
62762342|NCT04493684|EXPERIMENTAL|Part 1: Cohort 1: Participants receiving GSK3739937|Part 1 cohort 1 may contain up to 4 escalating doses (Period 1- 10 milligram \[mg\], Period 2- 80 mg, and Period 3- 320 mg, Period 4- 800 mg) of GSK3739937.
62762343|NCT04493684|PLACEBO_COMPARATOR|Part 1: Cohort 1: Participants receiving Placebo|In this cohort, participants will be randomized to receive placebo.
62762344|NCT04493684|EXPERIMENTAL|Part 1: Cohort 2: Participants receiving GSK3739937|Part 1 cohort 2 may contain up to 3 escalating doses ( Period 1- 30 mg, Period 2- 160 mg, and Period 3- 640 mg) of GSK3739937.
62762345|NCT04493684|PLACEBO_COMPARATOR|Part 1: Cohort 2: Participants receiving Placebo|In this cohort, participants will be randomized to receive placebo.
62762346|NCT04493684|EXPERIMENTAL|Part 2: Cohort 3: Participants receiving GSK3739937|Eligible participants in part 2 cohort 3, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of 25 mg GSK3739937 for 14 days.
62762347|NCT04493684|PLACEBO_COMPARATOR|Part 2: Cohort 3: Participants receiving Placebo|Eligible participants in part 2 cohort 3, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 14 days.
62762348|NCT04493684|EXPERIMENTAL|Part 2: Cohort 4: Participants receiving GSK3739937|Eligible participants in part 2 cohort 4, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of 50 mg GSK3739937 for 14 days.
62762349|NCT04493684|PLACEBO_COMPARATOR|Part 2: Cohort 4: Participants receiving Placebo|Eligible participants in part 2 cohort 4, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 14 days.
62762350|NCT04493684|EXPERIMENTAL|Part 2: Cohort 5: Participants receiving GSK3739937|Eligible participants in part 2 cohort 5, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of 100 mg GSK3739937 for 18 days.
62762351|NCT04493684|PLACEBO_COMPARATOR|Part 2: Cohort 5: Participants receiving placebo|Eligible participants in part 2 cohort 5, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 18 days.
62762352|NCT04493684|EXPERIMENTAL|Part 2: Cohort 6: Participants receiving GSK3739937|Eligible participants in part 2 cohort 6, will consist of approximately 10 participants out of 7 participants will be randomized to receive three 500 mg doses of GSK3739937 administered at once weekly intervals over two weeks.
62558656|NCT02201537|OTHER|Imag-NCT|"The ultrasound functional imaging will be performed at J15 (before the patient is discharged from service Transplantation) and at 3 and 12 months after the transplant.~The functional imaging examinations will be held as follows:~* 1st stage - the conventional Doppler ultrasound:~* 2nd stage - the elastography:.~* Step 3 - CEUS: It is performed on an ultrasound machine with a specific module with the same probes as conventional ultrasound. It requires the injection of 1.5 ml of SonoVue ®, a contrast ultrasound.~Renal biopsy will be performed after the functional ultrasound at 3 and 12 months."
62762353|NCT04493684|PLACEBO_COMPARATOR|Part 2: Cohort 6: Participants receiving placebo|Eligible participants in part 2 cohort 6, will consist of approximately 10 participants out of 3 participants will be randomized to receive three doses of placebo administered at once weekly intervals over two weeks.
62762354|NCT04493684|EXPERIMENTAL|Part 3: Cohort 7: Participants receiving treatment sequence ABC|Participants will receive Treatment A: GSK3739937 PiB, 100 mg administered under moderate fat conditions in Period 1; Treatment B: GSK3739937 Tablet, 100 mg administered under moderate fat conditions in Period 2; and Treatment C: GSK3739937 Tablet, 100 mg administered under fasted conditions in Period 3.
62762355|NCT04493684|EXPERIMENTAL|Part 3: Cohort 7: Participants receiving treatment sequence BCA|Participants will receive Treatment B: GSK3739937 Tablet, 100 mg administered under moderate fat conditions in Period 1; Treatment C: GSK3739937 Tablet, 100 mg administered under fasted conditions in Period 2; and Treatment A: GSK3739937 PiB, 100 mg administered under moderate fat conditions in Period 3.
62762356|NCT04493684|EXPERIMENTAL|Part 3: Cohort 7: Participants receiving treatment sequence CAB|Participants will receive Treatment C: GSK3739937 Tablet, 100 mg administered under fasted conditions in Period 1; Treatment A: GSK3739937 PiB, 100 mg administered under moderate fat conditions in Period 2; and Treatment B: GSK3739937 Tablet, 100 mg administered under moderate fat conditions in Period 3.
62182553|NCT05383625|EXPERIMENTAL|Bivalent Vaccine|Patient received 0.1 ml of bivalent HPV vaccine intralesional once every two weeks
62762357|NCT02898961|EXPERIMENTAL|The study population|"ICU patients with severe sepsis treated with aminoglycosides were recruited.~Intervention: 30 mg/kg amikacin or 8 mg/kg gentamicin"
62762358|NCT05104632||Breast conserving surgery only|Patients who receive breast conserving surgery.
62762359|NCT05104632||Mastectomy only|Patients who receive mastectomy surgery.
62762360|NCT05104632||Mastectomy & breast reconstruction|Patients who receive mastectomy and breast reconstruction.
62762361|NCT01329614|EXPERIMENTAL|Nicotine Replacement Therapy, 7mg dose|
62762362|NCT01329614|EXPERIMENTAL|Nicotine Replacement Therapy, 21mg dose|
62382060|NCT03362723|EXPERIMENTAL|Treatment Sequence 3: BACD|Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 1 (one cycle is 28 days). Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 8. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 15. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
62762363|NCT01329614|PLACEBO_COMPARATOR|Nicotine Replacement Therapy, Placebo|
62762364|NCT01329614|EXPERIMENTAL|Nicotine Replacement Therapy, 42mg dose|
62762365|NCT04401345|EXPERIMENTAL|Experimental Group (GP)|Patients will receive 0.2 mg (1 ml) glycopyrrolate before phenylephrine infusion is initiated at 25mcg/min.
62762366|NCT04401345|PLACEBO_COMPARATOR|Placebo Group(NS)|patients will receive 1 ml normal saline (0.9%) before phenylephrine infusion is initiated at 25 mcg/min
62762367|NCT03763344|EXPERIMENTAL|Cohort C|"Older adults over the age of 60 years old with subjective memory complaints that underwent:~* the first cognitive assessment (Baseline),~* intervention is fourteen sessions of Perceptual Cognitive Training (PCT) for seven weeks,~* a post-treatment cognitive assessment (Week 7), and~* a follow up cognitive assessment (Week 11)"
62567616|NCT06162949|EXPERIMENTAL|Vonoprazan-based triple therapy|Vonoprazan tablets 20 mg twice daily plus Amoxicillin 50 mg/kg/day capsules or suspension \[maximum daily dose 2 g\] plus Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose 1 g\] The triple combination will be given for 14 days
62762368|NCT03763344|NO_INTERVENTION|Cohort D|"Older adults over the age of 60 years old with subjective memory complaints that underwent:~* the first cognitive assessment (baseline),~* seven weeks of no intervention,~* a post-treatment cognitive assessment (week 7), and~* a follow up cognitive assessment (week 11)"
62762369|NCT05911438|EXPERIMENTAL|Experimental group|
62762370|NCT05911438|PLACEBO_COMPARATOR|Control group|
62762371|NCT04333602|EXPERIMENTAL|Screening and Treatment of Asymptomatic Bacteriruria|All patients assigned to this arm will be screen with urine culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. If we detect asymptomatic bacteriuria specific treatment will be instituted.
62762372|NCT04333602|NO_INTERVENTION|Screening and NO treatment of Asymptomatic Bacteriuria|All patients assigned to this arm will be screen with urine culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. No treatment will be instituted.
62762373|NCT01989702|ACTIVE_COMPARATOR|Fermented blueberry product|
62762374|NCT01989702|PLACEBO_COMPARATOR|Placebo|
62762375|NCT01989702|ACTIVE_COMPARATOR|Probiotic bacteria|
62762376|NCT05239221|EXPERIMENTAL|AZP-3601|subcutaneous (sc) administration once daily
62762377|NCT05239221|PLACEBO_COMPARATOR|Placebo (Parts A and B)|subcutaneous (sc) administration once daily
62182554|NCT05383625|PLACEBO_COMPARATOR|Saline control|Patient received 0.1 ml of intralesional saline once every two weeks
62182555|NCT04622475|EXPERIMENTAL|Treatment|Fecal Microbiota Transplant (FMT) Capsule
62762378|NCT05133869|EXPERIMENTAL|Baseline + intervention + follow up|All participants receive the same treatment in the same order. First there is a phase without treatment, the baseline phase. The length of this phase is randomly assigned to each participant. Then all participants follow a 42 day intervention, in which direct training and metacognitive training is combined. Afterwards they have a follow-up period, this length of this period is counterbalanced with the length of the baseline period so that the full study adds up to 150 days.
62762379|NCT01414205|EXPERIMENTAL|Obinutuzumab 1000 mg|Participants received a 1000 mg intravenous (IV) infusion, on days 1 (split dose 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1 and day 1 of cycles 2 - 8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
62762380|NCT01414205|EXPERIMENTAL|Obinutuzumab 2000 mg|Participants received a 2000 mg IV infusion, on days 1 (split dose 100 mg Day 1, 900 mg Day 2 and 1000 mg Day 3), 8 and 15 of cycle 1 and day 1 of cycles 2 -8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
62762381|NCT00990912|EXPERIMENTAL|Carboplatin|
62762382|NCT00990912|EXPERIMENTAL|Irinotecan (12 (9) mg/m²/day)|
62762383|NCT00990912|ACTIVE_COMPARATOR|Irinotecan (10 (10) mg/m²/day|
62762384|NCT01522144|EXPERIMENTAL|Asthma clinical decision support|decision support compared to no decision support in a cluster-randomized trial by practise
62762385|NCT02252809|ACTIVE_COMPARATOR|adalimumab|adalimumab 40 mg by subcutaneous way 7 days before endotoxin inhalation
62762386|NCT02252809|ACTIVE_COMPARATOR|methylprednisolone|methylprednisolone 20 mg daily , 7 days before endotoxin inhalation
62762387|NCT02252809|NO_INTERVENTION|control|no intervention, 7 days before endotoxin inhalation
62762388|NCT01633346||Tocilizumab treated patients|Rheumatoid arthritis patients
62762389|NCT02634021|ACTIVE_COMPARATOR|dexmedetomidine group|dexmedetomidine 1 mcg/kg intravenous loading followed by dexmedetomidine continuous infusion at the rate of 0.5 mcg/kg/hr
62762390|NCT02634021|EXPERIMENTAL|midazolam group|midazolam 0.1 mg/kg intravenous loading followed by dexmedetomidine continuous infusion at the rate of 0.5 mcg/kg/hr
62762391|NCT00682513||ATP1A3 Mutation|Those with RDP, AHC, unaffected carriers of ATP1A3 mutations, and non-carrying family members
62762392|NCT03527628|OTHER|Patients with PET-2 Negative Result|"After 2 ABVD cycles an interim PET-2 will be performed, and treatment will be adapted according to to PET results~PET-2 negative patients will be treated with 4 cycles of ACVD (Adriamycin, Cyclophosphamide, Vinblastine And Dacarbazine)"
62762393|NCT03527628|OTHER|Patients with PET-2 Positive Result|"After 2 ABVD cycles an interim PET-2 will be performed, and treatment will be adapted according to to PET results~PET-2 positive patients will be treated with 4 cycles of ACVD with addition of Brentuximab Vedotin"
62762394|NCT00750529|EXPERIMENTAL|Galantamine|
62762395|NCT05890378||Cohort by Water Source|Using existing secondary data available on the research communities as well as qualitative inquiry, we will purposefully select 40 water sources for the water analysis across from the communities selected for the implementation research (up to 30 communities with a maximum of 5 water sources per community). The selection of water sources will be stratified by type of water sourceand near the route for long-term animal migration. For each water source, we will aim to have a water sample collected at all water sources twice a day (morning and later afternoon) once a week for four weeks, varying the day of the week. Thus, we will collect a total of 320 water samples in the course of four weeks at the end of the dry season before the rains start.
62382061|NCT03362723|EXPERIMENTAL|Treatment Sequence 4: BADC|Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 1 (one cycle is 28 days). Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 8. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 15. Treatment C: A single dose of new tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
62762396|NCT04081961||Asymptomatic current smokers|No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)
62762397|NCT04081961||"Grey zone current smokers"|Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.
62762398|NCT04081961||Current smokers with COPD|Current smokers with a confirmed diagnosis of COPD (GOLD stage I-III)
62762399|NCT06055816|EXPERIMENTAL|Gemcitabine Combined With Endostar and Envafolimab|Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.
62762400|NCT03458858|OTHER|Mixed Berry Diet|Participants will receive between 400 to 800 grams of mixed berries daily, as a proportion of their daily caloric intake added to their base diet. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
62762401|NCT03458858|OTHER|Carbohydrate Control Jello|Participants will receive between 400 to 800 grams of strawberry jello daily, as a proportion of their daily caloric intake added to their base diet. The jello will be matched to the mixed berries in both total carbohydrate level and gram quantity. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
62762402|NCT03458858|OTHER|Fiber Enriched Jello|Participants will receive between 400 to 800 grams of fiber enriched strawberry jello daily, as a proportion of their daily caloric intake added to their base diet. The jello will be matched to the mixed berries in both total carbohydrate level and fiber content, and in the same gram quantity. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
62382062|NCT03362723|EXPERIMENTAL|Optional Treatment Extension Arm|Following completion of the BE/rBA cycle (Cycle 1), participants who have no clinically defined progressive disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and who recover from any prior treatment toxicity to Grade \</=1 may enter the optional treatment extension phase. Participants will receive 200 mg idasanutlin orally (200-mg tablet reference formulation) daily for 5 days, followed by 23 days of rest. This extension phase will continue for additional 28-day cycles or until disease progression or unacceptable toxicity is observed.
62382063|NCT02814799||bone donors|
62382064|NCT05701475|NO_INTERVENTION|Control/Single prevention|Standard pre-operative cutaneous disinfection using iodine.
62382065|NCT05701475|EXPERIMENTAL|Double prevention|Pre-operative cutaneous and subcutaneous disinfection using iodine.
62382066|NCT05701475|EXPERIMENTAL|Triple prevention|Pre-operative cutaneous and subcutaneous disinfection using iodine and preparation of the skin with benzoyl peroxide in the days prior to surgery.
62382067|NCT05960656|EXPERIMENTAL|Empagliflozin|Empagliflozin 25 mg/day
62382068|NCT05960656|PLACEBO_COMPARATOR|Placebo/Control Group|Placebo control
62382069|NCT05960656|EXPERIMENTAL|Pioglitazone|Pioglitazone 30 mg/day
62382070|NCT05960656|EXPERIMENTAL|Empagliflozin + pioglitazone|Combination of empagliflozin (25 mg/day) plus pioglitazone (30 mg/day)
62382071|NCT03267511|EXPERIMENTAL|Test Product 1|Participants will be instructed to apply experimental dentifrice containing 5% potassium nitrate (KNO3) / 0.2542% sodium fluoride (NaF) dentifrice with 0.5% spherical silica.
62382072|NCT03267511|EXPERIMENTAL|Test Product 2|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP.
62382073|NCT03267511|ACTIVE_COMPARATOR|Reference Product 1|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica.
62382074|NCT03267511|ACTIVE_COMPARATOR|Reference Product 2|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP.
62382075|NCT02455544||Pregnant Women|Any pregnant women that is referred to or presents to our tertiary care facility with concern for preeclampsia, will have a Congo Red Dot test preformed by research nurses. The research nurses are not involved in patient management and the results are blinded to the clinical providers and have no impact on clinical diagnosis or patient management.
62567617|NCT06162949|ACTIVE_COMPARATOR|"Proton pump-based triple therapy standard triple therapy"|Esomeprazole tablets \[20 mg/day if \< 30 kg and 40 mg/daily if ≥ 30 kg\] on two divided daily doses plus Amoxicillin 50 mg/kg/day capsules or suspension \[maximum daily dose 2 g\] plus Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose 1 g\] The triple combination will be given for 14 days
62182556|NCT01125462||Subjects previously treated with Gonal-f|Subjects who had undergone at least one treatment cycle with Gonal-f powder and solvent for solution for injection within the past 12 months (equivalent to 75 IU/ml, 450 IU/0.75ml or 1050 IU/1.75 ml)
62382076|NCT03703661|OTHER|Control|primary closure with gauze and adhesive/occlusive dressing
62382077|NCT03703661|EXPERIMENTAL|Negative Pressure|primary closure with gauze and adhesive/occlusive dressing under negative pressure
62382078|NCT05505201|EXPERIMENTAL|Active stimulation group|Fifteen sessions of inhibitory repetitive transcranial magnetic stimulation (rTMS) treatment at 1 Hz frequency will be applied to the contralesional primary motor cortex (hand region). The application will be performed with Neurosoft-Neuro MS / D device. 120% of the resting motor threshold will be used in the stimulation. One session of stimulation will last for a total of 30 minutes and a total of 1800 pulses in the form of 1 Hz stimulation.
62762403|NCT03458858|OTHER|Low Fiber Mixed Berry Juice|Participants will receive 1 liter per day of low fiber mixed berry juice added to their base diet. The juice will be squeezed from the mixed berries, then filtered. The sugar level of the juice will match that of the mixed berries. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
62762404|NCT06480175|EXPERIMENTAL|cervical plexus block|patients will receive cervical radiofrequency nerve ablation on both sides and after 2 weeks will be readmitted and will receive superficail cervical plexus block on only one side
62762405|NCT06087900|EXPERIMENTAL|Moderate continuous training (MICT)|The participants received a moderate continuous training (MICT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 50 minutes of exercise at 65-70% of maximal heart rate, and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise increases to 70-75% of maximal heart rate at week 7-12.
62762406|NCT06087900|EXPERIMENTAL|High intensity interval training (HIIT)|The participants received a 7x2 high intensity interval training (HIIT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 28 minutes of exercise (2 minutes of high intensity at 85-90% of maximal heart rate interval with 2 minutes of low intensity at 50-55% of maximal heart rate 7 times), and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise at high intensity increases to 90-95% of maximal heart rate at week 7-12.
62762407|NCT06087900|EXPERIMENTAL|Inspiratory muscle training (IMT)|The participants received Powerbreathe ® ClassicLight in this training program. The IMT group demonstrated the training 8 cycles of 30 breath, 5 days/week with progressive load 50% of maximal inspiratory pressure (MIP) at week 1-3, 60% of MIP at week 4-6, 70% of MIP at week 7-9, and 80% of MIP at week 10-12. Every first day of the week participants had to undergoing load adjustment at laboratory
62762408|NCT06087900|SHAM_COMPARATOR|Control|The CON group did not have any intervention but usual care.
62382079|NCT05505201|SHAM_COMPARATOR|Sham stimulation group|Fifteen sessions of sham repetitive transcranial magnetic stimulation (rTMS) treatment will be applied to the contralesional primary motor cortex (hand region). The application will be performed with Neurosoft-Neuro MS / D device. The probe of the device will be held in an upright position and stimulation will be performed at the 10% of the resting motor threshold.
62382080|NCT04374526|EXPERIMENTAL|Convalescent plasma|Patients receive COVID-19 Convalescent Plasma (CCP) in addition to standard therapy
62762409|NCT03920059|PLACEBO_COMPARATOR|FD arm|MMF will be prescribed at a starting dose of 1.5 g/day and increased to 2 g/day at week 4 (if body weight ≥ 45 kg) and continue the same dose until week 24. After week 24, MMF will be lowered to 1.5 g/day.
62762410|NCT03920059|ACTIVE_COMPARATOR|CC Arm|MMF will be prescribed at a starting dose of 1.5 g/day. MPA-C0 (trough) level will be measured weekly and MMF dose will be increased by 500 mg/day every week until the MPA-C0 level ≥ 3 mg/L or the MMF dosage is 3000 mg/day. After achieving the targeted MPA-C0 level, the MMF dose adjustment will be allowed only if the MPA-C0 levels are lower than 3 mg/L for two consecutive monitoring visits. After week 12, MMF will be maintained at the same dose until week 48
62762411|NCT04175574|EXPERIMENTAL|Intervention group|The intervention consist of the patients in the experimental group listening to pre-recorded music played through a set of noise cancelling Sony headphones which are padded for extra comfort from a Sony Digital Walkman. The duration of the intervention is 30 minutes without interruption, such as eating, talking and being on their mobile phones.
62762412|NCT04175574|NO_INTERVENTION|Control group|Whereas, patients in the control group will be given similar headphones but without any music. They will also be briefed not to eat, talk and being on their mobile phones.
62762413|NCT03242772|ACTIVE_COMPARATOR|ESDM informed parent coaching + Amphetamine|Amphetamine regimen (11 weeks total duration) will begin 2 weeks prior to initiation of ESDM informed parent coaching (8 weekly sessions) and continue through the week 11 endpoint assessment. The drug is an orally dissolvable, extended-release form of d- and l-amphetamine.
62762414|NCT03242772|PLACEBO_COMPARATOR|ESDM informed parent coaching + Placebo Oral Tablet|Placebo regimen (11 weeks total duration) will begin 2 weeks prior to initiation of ESDM informed parent coaching (8 weekly sessions) and continue through the week 11 endpoint assessment. The placebo contains no active drug and appears identical to the amphetamine (active drug).
62762415|NCT05481424|EXPERIMENTAL|Biodynamic Condition followed by an Active Placebo Condition.|Each lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The order of conditions will be randomized.
62382081|NCT04374526|NO_INTERVENTION|Standard therapy|Patients receive standard therapy alone
62762416|NCT05481424|EXPERIMENTAL|Active Placebo Condition followed by Biodynamic Condition|Each lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The order of conditions will be randomized.
62382082|NCT01878786|EXPERIMENTAL|ERL & TAC|Concentration controlled everolimus(ERL) \& Low dose tacrolimus(TAC) + corticosteroid withdraw
62382083|NCT01878786|EXPERIMENTAL|ERL & TAC --> MMF/MPA|Concentration controlled everolimus \& low dose tacrolimus --\> mycophenolate mofetil (MMF) at Month 3 + corticosteroid
62382084|NCT01878786|EXPERIMENTAL|Standard dose TAC + MMF/MPA|Standard dose of tacrolimus + mycophenolate mofetil + corticosteroid withdraw
62382085|NCT04254575||body dysmorphic disorder (BDD)|Adults with a current primary diagnosis of body dysmorphic disorder (BDD)
62567618|NCT05348772|ACTIVE_COMPARATOR|AmnioPul-02 Dose level 1|AmnioPul-02 Dose level 1
62567619|NCT05348772|ACTIVE_COMPARATOR|AmnioPul-02 Dose level 2|AmnioPul-02 Dose level 2
62567620|NCT06487923||Postpartum Women|298 primiparous women who have given birth vaginally in the last year
62762417|NCT02914548|EXPERIMENTAL|0.3% OPA-15406|Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.
62762418|NCT02914548|EXPERIMENTAL|1% OPA-15406|Subjects were treated with assigned 1% OPA-15406 ointment twice daily.
62762419|NCT02914548|PLACEBO_COMPARATOR|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
62762420|NCT04119622|EXPERIMENTAL|XELOX combined with Toripalimab|
62762421|NCT06605196|EXPERIMENTAL|Implementation Arm|The implementation arm will receive tailored, guided support to improve their AHD partnerships.
62762422|NCT06605196|ACTIVE_COMPARATOR|Control Arm|The control arm will be referred to existing resources in the Learning Community but will not receive new resources or guided facilitation.
62762423|NCT02822378|EXPERIMENTAL|Ca2+/VitD Control|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Participants will be asked to refrain from consumption of dried plums for the duration of the intervention (52 weeks).
62762424|NCT02822378|EXPERIMENTAL|50g Dried Plums|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 6 (50g) dried plums per day for the duration of the intervention (52 weeks).
62762425|NCT02822378|EXPERIMENTAL|100g Dried Plums|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 12 (100g) dried plums per day for the duration of the intervention (52 weeks).
62382086|NCT04563130|EXPERIMENTAL|Cryocompression|Patients will be randomized to receive cryocompression on one hand and foot using ice bags and compression socks.
62762426|NCT03444766|EXPERIMENTAL|Monotherapy|administering nivolumab only
62762427|NCT03333395|ACTIVE_COMPARATOR|HS Group (study group)|
62762428|NCT03333395|ACTIVE_COMPARATOR|S Group (control group)|
62762429|NCT01596335|EXPERIMENTAL|TA-650|
62762430|NCT01596335|ACTIVE_COMPARATOR|VGIH|
62762431|NCT04035564|ACTIVE_COMPARATOR|Sodium < 1mEq/kg/day|Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life one
62762432|NCT04035564|EXPERIMENTAL|Sodium 5mEq/kg/day|Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life one
62762433|NCT05561465|EXPERIMENTAL|Pterygomaxillary disjunction|
62182557|NCT01125462||Subjects previously treated with urine-derived FSH|Subjects which had undergone at least one treatment cycle with urine-derived FSH therapy with vials within the past 12 months
62382087|NCT04563130|NO_INTERVENTION|Control|Patients will be randomized to receive no intervention on the opposite hand and foot.
62382088|NCT02570581|PLACEBO_COMPARATOR|Plain jelly control|Plain jelly control
62382089|NCT02570581|ACTIVE_COMPARATOR|Jelly with: Paracetamol|"Jelly with:~Paracetamol"
62382090|NCT02570581|ACTIVE_COMPARATOR|Jelly with Furosemide|Jelly with Furosemide
62382091|NCT02570581|ACTIVE_COMPARATOR|Jelly with Levothyroxine sodium salt|Jelly with Levothyroxine sodium salt
62382092|NCT02570581|ACTIVE_COMPARATOR|Jelly with memantine|Jelly with memantine
62382093|NCT02570581|ACTIVE_COMPARATOR|jelly with zopiclone|Jelly with zopiclone
62762434|NCT01742572|EXPERIMENTAL|Vegan|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
62762435|NCT01742572|EXPERIMENTAL|Vegetarian|A vegetarian diet is one that does not contain meat, fish, or poultry but does contain eggs and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
62762436|NCT01742572|EXPERIMENTAL|Pesco-Vegetarian|A pesco-vegetarian diet is one that does not contain meat or poultry but does contain fish and shellfish, eggs, and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
62762437|NCT01742572|EXPERIMENTAL|Semi-Vegetarian|A semi-vegetarian diet is one that contains all foods, including meat, poultry, fish and shellfish, eggs, and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. However, red meat is limited to one time per week and poultry is limited to 5 times per week or less. We will also ask you to keep foods low in fat and low in glycemic index.
62762438|NCT01742572|ACTIVE_COMPARATOR|Omnivorous|An omnivorous diet contains all food groups. However, as part of this study, we will ask participants in this group to keep foods low in fat and low in glycemic index. Participants in this group will not need to attend weekly meetings but will receive information via e-mail each week.
62762439|NCT01328041|EXPERIMENTAL|dolutegravir|dolutegravir plus background antiretroviral therapy optimised at Day 8
62762440|NCT01718249|OTHER|deep brain stimulation|
62762441|NCT03968159|EXPERIMENTAL|Drug - pimavanserin|Pimavanserin 34 mg tablets
62762442|NCT03968159|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62762443|NCT02907853|EXPERIMENTAL|Contingency Management|In exchange for consecutive urine samples documenting methamphetamine abstinence, participants receive increasingly valuable reinforcers.
62762444|NCT02266277|ACTIVE_COMPARATOR|Arm 1: E-portal message with IVR call|Patients identified as e-portal users will receive an e-portal message with IVR call
62762445|NCT02266277|ACTIVE_COMPARATOR|Arm 2: E-portal message with no IVR call|Patients identified as e-portal users will receive an e-portal message only
62762446|NCT02266277|ACTIVE_COMPARATOR|Arm 3: No e-portal message with IVR call|Patients identified as e-portal users will receive an IVR call only
62762447|NCT02266277|NO_INTERVENTION|Arm 4: No E-portal message with no IVR call|Patients identified as e-portal users will receive neither an e-portal message nor an IVR call
62762448|NCT02266277|ACTIVE_COMPARATOR|Arm 5: IVR call|Patients identified as non e-portal users will receive an IVR call only
62762449|NCT02266277|NO_INTERVENTION|Arm 6: No IVR call|Patients identified as non e-portal users will not receive any outreach
62762450|NCT03844113|ACTIVE_COMPARATOR|Intervention|Each participant will be given a daily oral dose 2 g of carnosine for 6 months
62182558|NCT05239598|EXPERIMENTAL|Povidone-iodine 0.5% antiseptic mouth rinse|Subjects will be asked to rinse/gargle one time with 10 mL of Povidone-iodine 0.5% antiseptic mouth rinse for 30 seconds.
62762451|NCT03844113|PLACEBO_COMPARATOR|Control|Each participant will be given a daily oral dose 2 g of placebo for 6 months
62762452|NCT06467669|EXPERIMENTAL|Participants|Patients with 1st CMC arthritis with Eaton stage 2 or 3 disease
62762453|NCT03452436||Testicular cancer patients|Forty testicular cancer patients included after orchiectomy but prior to any further treatment.
62762454|NCT03452436||Prostate cancer patients|Forty prostate cancer patients included prior to medical castration and radiotherapy.
62762455|NCT03452436||Healthy controls|Forty age- and education-matched healthy controls (20 matched to testicular cancer patients, 20 matched to prostate cancer patients).
62762456|NCT03512431||Study group|Only one arm in the present study
62762457|NCT04247191|EXPERIMENTAL|P-Chat|The P-Chat is a brief individually delivered intervention
62762458|NCT04247191|EXPERIMENTAL|PBI|The PBI is a handbook developed by the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
62762459|NCT04247191|EXPERIMENTAL|P-Chat+|The P-Chat+ is a combination of the P-Chat and PBI described above.
62762460|NCT04247191|NO_INTERVENTION|Control|This group will only complete assessments and will not receive any intervention.
62762461|NCT02410824|EXPERIMENTAL|stenfilcon A toric lens|Participants were randomized to wear stenfilcon A toric lens for one week during the cross over study.
62762462|NCT02410824|ACTIVE_COMPARATOR|etafilcon A toric lens|Participants were randomized to wear etafilcon A toric lens for one week during the cross over study.
62762463|NCT02502513|EXPERIMENTAL|Intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department and completion of intrusive memory diary"
62762464|NCT02502513|NO_INTERVENTION|Control|Usual care in the maternity department plus completion of intrusive memory diary
62762465|NCT01683513|NO_INTERVENTION|humaan chorion gonadotropine|ovulation induction with 5000E hCG
62762466|NCT01683513|ACTIVE_COMPARATOR|GnRH agonist + 1500E hCG|ovulation induction with GnRH agonist and 1500E hCG one hour after egg retrieval
62762467|NCT05297487|EXPERIMENTAL|standard care associated with daily and early use of (IPPB) intermittent positive pressure breathing|
62762468|NCT05297487|NO_INTERVENTION|standard care alone|
62762469|NCT01903395|EXPERIMENTAL|Nurse-led counselling|First-degree relatives of patients undergoing active treatment for colorectal cancer are offered a nurse-led counselling by telephone regarding emotional and cognitive barriers to screening utilization.
62762470|NCT01903395|NO_INTERVENTION|Usual Care|Usual print media, offered standardly by the recruiting centres.
62762471|NCT03640637||Suspected IBD|A prospective study of 50 pediatric patients suspected of IBD. Participants will undergo routine diagnostic procedures for evaluation of pediatric IBD including blood samples, faecal samples, endoscopies (colonoscopy and gastroscopy with biopsy/histology) and MRI of the abdomen. In addition, a PET scan will be performed in this protocol and combined with MRI. For accuracy measures, PET/MRI scan will be compared to the combined findings of endoscopy, histology and severity of inflammation by clinical scoring systems (weighted Pediatric Crohn's Disease Activity Index (wPCDAI) for CD and Pediatric Ulcerative Colitis activity Index (PUCAI) for CU), faecal calprotectin and biochemistry.
62762472|NCT03640637||Treatment response group|A pilot study of 10-15 patients previously diagnosed with CD who will undergo PET/MRI scan as an investigational procedure before initiation of biological treatment with an anti-TNF-alpha antibody (infliximab, adalimumab) because of disease relapse or steroid dependent disease. Patients will be scheduled for a PET/MRI again after one month. This study will evaluate if PET/MRI can diagnose a flare in CD and if PET/MRI is a reliable imaging tool to monitor intestinal inflammation. In this study the patient will act as his/her own control.
62762473|NCT00906724||aerobic exercise|Aerobic exercise in Insulin Resistant Minority Adolescents
62762474|NCT04690192|EXPERIMENTAL|CNCT19 following ASCT|Participants will receive high-dose chemotherapy followed by stem-cell reinfusion, and a fixed dose of CNCT19 (2×10\^6/kg) will be infused in a single-dose on day +2, +3 or +4.
62762475|NCT03180398|EXPERIMENTAL|Multi-parametric MRI for Prostate Cancer|MRI will be acquired for prostate cancer patients undergoing radiation treatment.
62762476|NCT06516263|EXPERIMENTAL|The effect of Leukocyte and platelet rich fibrin on Implant Stability and Marginal Bone Levels.|Standard Implant placement with Leukocyte and platelet rich fibrin
62762477|NCT06516263|PLACEBO_COMPARATOR|The Effect of standard implant placement on implant Stability and Marginal Bone Levels.|standard implant placement
62762478|NCT01236872|EXPERIMENTAL|Beetroot juice|250ml beetroot juice ingestion
62762479|NCT01236872|PLACEBO_COMPARATOR|Water|250ml low-nitrate water placebo
62762480|NCT05003661|EXPERIMENTAL|Mother's voice|Neonates receive the intervention that recording of mother's voice of reading children's book. And the pain of high-risk newborns was measured with the Heartbeat, Respiration, SPO2 and Neonatal Infant Pain Scale (NIPS) in three minutes before the heel puncture, during the puncture, and the first, fifth and tenth minutes after the puncture.
62762481|NCT05003661|EXPERIMENTAL|Father's voice|Neonates receive the intervention that recording of father's voice of reading children's book. And the pain of high-risk newborns was measured with the Heartbeat, Respiration, SPO2 and Neonatal Infant Pain Scale (NIPS) in three minutes before the heel puncture, during the puncture, and the first, fifth and tenth minutes after the puncture.
62762482|NCT05003661|NO_INTERVENTION|control group|When the infants undergoing heel puncture procedure, the control group were under routine care. And the pain of high-risk newborns was measured with the Heartbeat, Respiration, SPO2 and Neonatal Infant Pain Scale (NIPS) in three minutes before the heel puncture, during the puncture, and the first, fifth and tenth minutes after the puncture.
62762483|NCT03994315|EXPERIMENTAL|B. infantis EVC001 + LNT (3 g/L then 8 g/L)|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10\^9 CFU) mixed with infant formula for 28 consecutive days. Group 1 \[B. infantis + LNT (3 g/L then 8 g/L)\] will also receive two dose-escalated concentrations of the prebiotic supplement (LNT) mixed with their infant formula for every formula preparation during the 28-day supplementation period. They will receive a concentration of 3 g/L for 2 weeks followed by 8 g/L for the next 2 weeks, without a washout period in between.
62382094|NCT02570581|ACTIVE_COMPARATOR|jelly with alprazolam|elly with alprazolam
62762484|NCT03994315|EXPERIMENTAL|B. infantis EVC001 + LNT (6 g/L then 12 g/L)|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10\^9 CFU) mixed with infant formula for 28 consecutive days. Group 2 \[B. infantis + LNT (6 g/L then 12 g/L)\] will also receive two dose-escalated concentrations of the prebiotic supplement (LNT) mixed with their infant formula for every formula preparation during the 28-day supplementation period. They will receive a concentration of 6 g/L for 2 weeks followed by 12 g/L for the next 2 weeks, without a washout period in between.
62762485|NCT03994315|ACTIVE_COMPARATOR|B. infantis EVC001 alone|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10\^9 CFU) mixed with infant formula for 28 consecutive days.
62762486|NCT00499408|EXPERIMENTAL|Soy and Vitamin D|Patients will receive oral supplementation with both 2,000 IU per day of vitamin D (cholecalciferol) and soy (160 mg per day soy isoflavones). Serum PSA and plasma levels of vitamin D will be assessed monthly. Soy isoflavones levels will be assessed every three months.
62762487|NCT01731730|PLACEBO_COMPARATOR|Placebo (Vehicle) Injection|Single Intrathecal (spinal) administration of Placebo Injection just prior to intrathecal administration of spinal anesthetic for knee surgery
62182559|NCT05239598|PLACEBO_COMPARATOR|Placebo|Subjects will be asked to rinse/gargle one time with 10 mL of placebo mouth rinse for 30 seconds.
62382095|NCT02570581|ACTIVE_COMPARATOR|jelly with Oxazepam|Jelly with Oxazepam
62382096|NCT02570581|ACTIVE_COMPARATOR|jelly with donepezil|jelly with donepezil
62382097|NCT02570581|ACTIVE_COMPARATOR|Jelly with clopidogrel|jelly with clopidogrel
62382098|NCT02570581|ACTIVE_COMPARATOR|jelly with ramipril|jelly with ramipril
62382099|NCT02570581|ACTIVE_COMPARATOR|jelly with Paracetamol + Furosemide + Levothyroxine sodium sa|Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
62382100|NCT02570581|PLACEBO_COMPARATOR|Plain apple compote control|Plain apple compote control
62382101|NCT02570581|ACTIVE_COMPARATOR|Apple compote Paracetamol|Apple compote Paracetamol
62382102|NCT02570581|ACTIVE_COMPARATOR|Apple compote Furosemide|Apple compote Furosemide
62382103|NCT02570581|ACTIVE_COMPARATOR|Apple compote Levothyroxine sodium salt|Apple compote Levothyroxine sodium salt
62382104|NCT02570581|ACTIVE_COMPARATOR|Apple compote Memantine|Apple compote Memantine
62762488|NCT01731730|EXPERIMENTAL|AYX1 Injection 110 mg|Single Intrathecal (spinal) administration of AYX1 Injection (110 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
62762489|NCT01731730|EXPERIMENTAL|AYX1 Injection 330 mg|Single Intrathecal (spinal) administration of AYX1 Injection (330 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
62382105|NCT02570581|ACTIVE_COMPARATOR|Apple compote Zopiclone|Apple compote Zopiclone
62762490|NCT05100823|EXPERIMENTAL|Nasal cells sampling and/or rectal biospy|"Depending of the patient' genotype, specific ONB-CFTR (50 nM) will be incubated at the apical face of in vitro epithelium, alone and in combination with CFTR modulators. Efficacy of ONB will be compared to a condition with oligonucleotide control incubation.~Rectal biopsies from volunteer patients were stored as a bio-bank of organoids."
62762491|NCT04619446||Removable Twin Block appliance group|Patient to be treated with removable twin block appliance that are known Class II skeletal and dental subjects.
62762492|NCT04619446||Fixed Functional Appliance AdvanSync group|Patients to be treated with fixed functional appliance, AdvanSync (Molar-to-Molar) Class II Corrector
62382106|NCT02570581|ACTIVE_COMPARATOR|Apple compote Alprazolam|Apple compote Alprazolam
62382107|NCT02570581|ACTIVE_COMPARATOR|Apple compote Oxazepam|Apple compote Oxazepam
62382108|NCT02570581|ACTIVE_COMPARATOR|Apple compote Donepezil|Apple compote Donepezil
62382109|NCT02570581|ACTIVE_COMPARATOR|Apple compote Clopidogrel|Apple compote Clopidogrel
62382110|NCT02570581|ACTIVE_COMPARATOR|Apple compote Ramipril|Apple compote Ramipril
62382111|NCT02570581|ACTIVE_COMPARATOR|Apple Paracetamol Furosemide Levothyroxine NACL Memantine Zopi|Apple Paracetamol Furosemide Levothyroxine NACL Memantine Zopiclone Alprazolam
62382112|NCT00626795|EXPERIMENTAL|1|
62382113|NCT00626795|EXPERIMENTAL|2|
62382114|NCT00626795|ACTIVE_COMPARATOR|3|
62382115|NCT03097562|EXPERIMENTAL|CT1|"FLACS- Initial Wound parameters (CT1)~Sample size calculation based on woundleak incidence estimated from preliminary results:~* For CT1 vs MT, we will only need 10 per group to have 80% power assuming a 1:1 ratio of CT to MT and 5% type 1 error.~* For CT1 vs CT2, we will need 22 per group to have 80% power (assuming 60% wound leakage in CT1 and 20% wound leakage in CT2, a 1:1 ratio, and a 5% type 1 error rate)~* A total of 253 patients are eligible for this study, 101 with FLACS and 152 with Manual Cataract Surgery. We thus expect that our study population will allow adequate analysis of the main outcome parameters proposed herein."
62382116|NCT03097562|EXPERIMENTAL|CT2|"The revised profile CT2, consists of a wider anterior side cut angle (beveled corneal undercut) and a narrower posterior side cut angle compared to the initial CT1 profile. This new corneal incision profile is constructed to ensure a tigher wound closure and a better corneal wound reapposition.~The traditional manual wound performed with a standard keratome wil be used as a reference."
62382117|NCT03097562|ACTIVE_COMPARATOR|MT control group|Standard manual technique (MT)
62382118|NCT00062842|EXPERIMENTAL|Irinotecan weekly|Irinotecan was administered over 90 min weekly 4x, every 6 weeks.
62382119|NCT01524094|EXPERIMENTAL|Arm A: CRS plus postop intraperitoneal chemotherapy.|Cytoreductive surgery and postoperative intraperitoneal chemotherapy.
62382120|NCT01524094|ACTIVE_COMPARATOR|Arm B: Systemic chemotherapy alone|Systemic chemotherapy alone
62382121|NCT04638036|EXPERIMENTAL|NIR endoscopy and surgery with cetuximab-IRDye800CW|In this non-randomized, non-blinded, prospective, feasibility study, cetuximab-IRDye800CW will be administered to a total of 15 patients with proven locally advanced rectal cancer
62382122|NCT03371004|EXPERIMENTAL|DM-CHOC-PEN + Radiation|4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) - 39-89.7 MG/M2 iv once and then 3-weeks later radiation - 15-30 Gy will be administered
62382123|NCT03706144|EXPERIMENTAL|Prodigy Intervention Group|Teachers will use the Prodigy Math Training with their students in school for at least 20 minutes per day, 3 days per week, from August to December 2018.
62382124|NCT03706144|NO_INTERVENTION|Control Group|Instruction as usual = TAU
62382125|NCT05980390||Active vitiligo|
62762493|NCT00434759|ACTIVE_COMPARATOR|SCP|SCP is a stepped-care program with a self-help module with minimal therapist contact (8 sessions) as first step, followed by therapist-guided intervention depending on status of remission (8 sessions up to a maximum of 16 sessions).
62762494|NCT00434759|ACTIVE_COMPARATOR|ST|A standard therapy which means a therapist-guided intervention with 16 sessions face-to-face therapy.
62382126|NCT05980390||Stable vitiligo|
62382127|NCT05980390||Normal controls|
62382128|NCT03436095||research group|bundle measures to help patient to weaning ventilator
62382129|NCT03436095||historical control group|retrospect the patients who were difficult to wean from ventilator and collect some materials to compare.
62762495|NCT02606227|EXPERIMENTAL|Experimental group:financial incentives|Vouchers for show up + Vouchers at increasing amount to reward tobacco abstinence
62382130|NCT03436095||External control group|contrast other same level hospitals measures to patients who are difficult to wean ventilator.
62382131|NCT02993289|ACTIVE_COMPARATOR|Detoxification and pharmacological prophylactic treatment|Group A: Two months detoxification program combined with pharmacological prophylactic treatment from start.
62382132|NCT02993289|ACTIVE_COMPARATOR|Pharmacological prophylactic treatment|Pharmacological prophylactic treatment from start without detoxification.
62382133|NCT02993289|ACTIVE_COMPARATOR|Detoxification|Two months detoxification program with postponed pharmacological prophylactic treatment after ended detoxification.
62382134|NCT02993289|NO_INTERVENTION|Control group 1: Episodic migraine|
62382135|NCT02993289|NO_INTERVENTION|Control group 2: Healthy volunteers|
62762496|NCT02606227|OTHER|Control group:no financial intervention|Vouchers for show up only, no financial incentive for rewarding tobacco abstinence
62762497|NCT00566865|EXPERIMENTAL|2|mitiglinide + gemfibrozil
62762498|NCT00566865|PLACEBO_COMPARATOR|1|mitiglinide + placebo for gemfibrozil
62762499|NCT03343080|EXPERIMENTAL|Buffered Lidocaine|"At the induction of anesthesia, patients will be breathing 100% oxygen via a face mask and then, become anesthetized according to a standard protocol and at the discretion of the attending anesthesiologist.~For cardiac surgery patients randomized to the buffered lidocaine arm, the operating room registered respiratory therapist (OR RRT) will inflate the endotracheal tube cuffs with the study drug containing 1.8% lidocaine plus 0.76% sodium bicarbonate until abatement of the air leak at 20 cm of water.~The intervention will take place while in the operating room. The room nurse anesthetist (CRNA) or anesthesiologist will be aware of the amount of solution instilled in the ETT cuff. The patient will remain intubated after the surgery is complete and will be taken to the cardiac surgical ICU."
62762500|NCT03343080|PLACEBO_COMPARATOR|Air|"At the induction of anesthesia, patients will be breathing 100% oxygen via a face mask and then, become anesthetized according to a standard protocol and at the discretion of the attending anesthesiologist.~For cardiac surgery patients randomized to the air arm, the operating room registered respiratory therapist (OR RRT) will inflate the endotracheal tube cuffs with air until abatement of the air leak at 20 cm of water.~The intervention will take place while in the operating room. The room nurse anesthetist (CRNA) or anesthesiologist will be aware of the amount of air in the ETT cuff. The patient will remain intubated after the surgery is complete and will be taken to the cardiac surgical ICU."
62762501|NCT05818761|EXPERIMENTAL|virtual reality|watching the application by wearing virtual glasses to the child during the phlebotomy
62762502|NCT05818761|EXPERIMENTAL|Stress ball|a stress ball will be given to the child's hand, and he will be asked to squeeze continuously before the blood draw attempt begins, and to continue squeezing during the procedure.
62762503|NCT05818761|NO_INTERVENTION|control|standard approach
62762504|NCT03453255|EXPERIMENTAL|t(8;21)AML|chemotherapy 5-Aza-2'-deoxycytidine IV 20mg/m2 d8-12 homoharringtonine IV 2mg d1-5 chidamide P.O. 30mg twice/W cytarabine IV 1000mg/m2(\<60 year old) 500mg/m2(\>60 year old) IV q12h d1,3,5
62762505|NCT03579446|EXPERIMENTAL|Supportive care (levorphanol, opioid regimen)|Patients receive levorphanol PO every 8 or 12 hours for 30 days. Patients may receive opioid regimen including hydrocodone, morphine, hydromorphone, oxycodone, and oxymorphone for breakthrough pain. Patients may continue levorphanol for an additional 6-8 months if it is determined by the Principal Investigator the patient can continue.
62762506|NCT02648022|EXPERIMENTAL|Integrated Care|Consisted of brief mental health interventions and case management provided in a collaborative treatment environment.
62762507|NCT02648022|NO_INTERVENTION|Usual Care|"The usual care group received standard of care required for HCV patients as currently performed in each clinic. All usual care patients were evaluated by their HCV Clinic treatment team, usually consisting of clinical nursing staff, the treating physician, and a clinic psychiatrist or psychologist"
62762508|NCT00149994|EXPERIMENTAL|Cyclosporine A|Cyclosporine A was given in a twice-daily schedule at 12-hour intervals. It was administered within the first 4 hours post-operatively (study day 1), at an initial dose of 10-15mg/kg/day in two doses, as close as possible to 15mg/kg/day. After the first oral administration, the dose of Cyclosporine A was adjusted to bring the sample taken 2 hours after oral dose (C-2h) level into the target range by Days 3-5 post-transplantation. C-2h target ranges post-transplantation: 0-3 months: range of 800-1200 ng/ml with midpoint of 1000 ng/ml; 4-6 months: range of 700-900 ng/ml with midpoint of 800 ng/ml; \> 6 months: range of 500-700 ng/ml with midpoint of 600 ng/ml is recommended. During the course of the study, the dose of Cyclosporine A was adjusted as necessary to achieve and maintain the C-2h blood Cyclosporine A (CsA) concentrations within the target ranges.
62762509|NCT00149994|ACTIVE_COMPARATOR|Tacrolimus|Tacrolimus was given on a twice-daily schedule at 12-hour intervals which had to be maintained throughout the study period. Tacrolimus was administered within the first 24 hrs postoperatively (Study Day 1) at an initial dose of 0.1-0.15 mg/kg/day in two divided oral doses either by mouth or via an enteral feeding tube until the patient can swallow. The initial dosing level was determined by the patient's overall post-operative condition. During the course of the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain the pre-dose blood concentration (C-0h) (trough) tacrolimus concentrations. C-0h target ranges post-transplantation: 0-3 months: 10-15 ng/ml; 4-6 months: 5-10 ng/ml; \> 6 months: range of 5-10 ng/ml is recommended.
62762510|NCT06343038|ACTIVE_COMPARATOR|Cross-Over Group A|"Cross-over design (n=10, random allocation at a 1:1 ratio). Event order:~1. Injection of 1 GBq of 161Tb-SibuDAB,~2. 3 weeks washout period,~3. Injection of 1GBq of 177Lu-PSMA-I\&T"
62762511|NCT06343038|ACTIVE_COMPARATOR|Cross-Over Group B|"Cross-over design (n=10, random allocation at a 1:1 ratio). Event order:~1. Injection of 1 GBq of 177Lu-PSMA-I\&T,~2. 3 weeks washout period,~3. Injection of 1GBq of 161Tb-SibuDAB"
62182560|NCT03516045|EXPERIMENTAL|18F-AlF-NOTA-neurotensin PET/CT|One injection of the radioligand 18F-AlF-NOTA-neurotensin Device: PET/CT Following injection of 18F-AlF-NOTA-neurotensin the participants will be subjected to whole body PET/CT
62382136|NCT01031108|OTHER|Type 2 Diabetic Group|The Type 2 Diabetic Treatment Group will be randomized to receive test material (2.0g SRT2104 or placebo) in the form of 8 capsules per day for 28 days. After 28 days of dosing, subjects will cross over to receive placebo or 2.0g SRT2104 for an additional 28 days. Dosing of SRT2104 or placebo will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized morning meal (220 cc of Ensure Plus®). Subjects must wait at least 1-2 hours after dosing before consuming additional calories. Water is permitted ad libitum.
62762512|NCT06343038|EXPERIMENTAL|Dose Escalation Study|Arm composed of 5 patient cohorts each with 3-patients. Treatment consists of 4 cycles of 161Tb-SibuDAB based on the available MTD and DLT findings. Safety and efficacy evaluation performed after each therapy cycle.
62762513|NCT05976451|EXPERIMENTAL|collagen matrix|melatonin in collagen matrix with Modified Coronally Advanced Tunneling Technique (MCAT)
62762514|NCT05976451|ACTIVE_COMPARATOR|connective tissue graft (CTG)|connective tissue graft with Modified Coronally Advanced Tunneling Technique (MCAT)
62762515|NCT01189058|EXPERIMENTAL|rTMS and CIMT|This group will receive both rTMS and CIMT.
62762516|NCT01189058|EXPERIMENTAL|rTMS and no CIMT|This group will receive rTMS only.
62762517|NCT01189058|EXPERIMENTAL|Sham and CIMT|This group will receive CIMT and sham rTMS.
62762518|NCT01189058|NO_INTERVENTION|Sham and no CIMT|This group will receive sham rTMS and no CIMT.
62762519|NCT06157320|EXPERIMENTAL|Shenfu Injection group|within 24 hours after the diagnosis of sepsis, Shenfu injection 100 ml/day, intravenous use, continuous application for 7 days.
62762520|NCT06157320|PLACEBO_COMPARATOR|Control group|sepsis was treated with standardized western medicine methods
62762521|NCT04149574|EXPERIMENTAL|Arm A: nivolumab + Bacillus Calmette-Guérin (BCG)|
62762522|NCT04149574|PLACEBO_COMPARATOR|Arm B: placebo +BCG|
62762523|NCT03069287|EXPERIMENTAL|Patient-caregiver dyads|Dyads will include family caregivers and patients with a diagnosis of cancer who agreed to participate in a therapeutic clinical trial.
62762524|NCT03208530|EXPERIMENTAL|Intervention Arm|This is a single arm study with all enrolled patients receiving the same brief motivational interview intervention.
62382137|NCT01031108|OTHER|Otherwise Healthy Cigarette Smoking Group|The Otherwise Healthy Cigarette Smoking Treatment Group will be randomized to receive test material (2.0g SRT2104 or placebo) in the form of 8 capsules per day for 28 days. After 28 days of dosing, subjects will cross over to receive placebo or 2.0g SRT2104 for an additional 28 days. Dosing of SRT2104 or placebo will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized morning meal (220 cc of Ensure Plus®). Subjects must wait at least 1-2 hours after dosing before consuming additional calories. Water is permitted ad libitum.
62382138|NCT01707940|EXPERIMENTAL|BI 144807|subjects receive an oral single dose of BI 144807
62382139|NCT01707940|EXPERIMENTAL|BI 144807 plus Ketoconazole|subjects receive bid ketoconazole plus an oral single dose of BI 144807
62762525|NCT00313768|ACTIVE_COMPARATOR|B|Standard of care chemotherapy
62762526|NCT00313768|EXPERIMENTAL|A|Standard of care chemotherapy plus experimental intervention (PF-3512676)
62182561|NCT00661544|EXPERIMENTAL|Arsenic Trioxide + Vitamin C + Melphalan|Arsenic Trioxide + Ascorbic Acid + Melphalan as a preparative regimen for autologous stem cell transplantation (delivered on Day 0)
62762527|NCT00997425|EXPERIMENTAL|Door Cover/Floor Cover|Baseline One (14 days), First Intervention (14 days), Baseline Two (14 days), Second Intervention (14 days)
62762528|NCT04268875|EXPERIMENTAL|OCT|"Patient witch coronary artery disease who has been stented and is hospitalised for stable angina or acute coronary syndrome requiring a further coronary angiogram (regardless of time since implantation or type of the initial stent.~- Identification of intrastent restenosis during coronary angiography and realisation of an immediate or deferred OCT."
62762529|NCT03398265|EXPERIMENTAL|Intervention|Initial discussion regarding opioid treatment options followed by 6 months of treatment navigation.
62762530|NCT03398265|OTHER|Control|Referrals to treatment from corrections staff.
62762531|NCT02998047|EXPERIMENTAL|IV infusion of Lintuzumab AC225|"Starting dose - 0.5 μCi/Kg IV infusion of Lintuzumab AC225 on Day 1 of each cycle with dose escalation 1 μCi/Kg and 1.5 μCi/Kg or de-escalation to 0.25 μCi/Kg.~1 cycle = 28 days, up to 3 to 8 cycles (depending on the cohort)."
62762532|NCT00543296|EXPERIMENTAL|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
62762533|NCT02109874|EXPERIMENTAL|AERAS-404 (mcg H4/nmol IC31) 5/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
62762534|NCT02109874|EXPERIMENTAL|AERAS-404 (mcg H4/nmol IC31) 15/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
62762535|NCT02109874|EXPERIMENTAL|AERAS-404 (mcg H4/nmol IC31) 50/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
62762536|NCT02109874|EXPERIMENTAL|AERAS-404 (mcg H4/nmol IC31) 150/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
62762537|NCT02109874|PLACEBO_COMPARATOR|Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl|Placebo: Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl. This is the identical buffer solution in which IC31 is formulated.
62762538|NCT01826266|PLACEBO_COMPARATOR|PER977-Dose 1|Dose titration
62762539|NCT01826266|PLACEBO_COMPARATOR|PER977-Dose 2|Dose Titration
62762540|NCT01826266|PLACEBO_COMPARATOR|PER977-Dose 3|Dose Titration
62762541|NCT01826266|PLACEBO_COMPARATOR|PER977-Dose 4|Dose Titration
62762542|NCT01826266|PLACEBO_COMPARATOR|PER977-Dose 5|Dose Titration
62762543|NCT01826266|PLACEBO_COMPARATOR|PER977-Dose 6|Dose Titration
62762544|NCT01826266|PLACEBO_COMPARATOR|PER977-Dose 7|Dose Titration
62762545|NCT00894478||1|12 children with MRI-negative partial epilepsy who are being worked-up for epilepsy surgery
62762546|NCT00894478||2|12 children with MRI-visible FCD who are being worked-up for epilepsy surgery
62762547|NCT00894478||3|Control Group- Healthy Volunteers
62382140|NCT05830656|EXPERIMENTAL|Control, Then exposure to nearby nature, Then exposure to virtual nature|During the first week, the participants continue their normal routine at work and in leisure time. On the second week, the participants visit a nearby natural area after finishing their workday on three days (Tuesday, Wednesday, and Thursday). On the third week, the participants watch virtual nature videos with Virtual Reality (VR) goggles after finishing their workday on three days (Tuesday, Wednesday, and Thursday).
62762548|NCT01459991|EXPERIMENTAL|Mediterranean|Participants in this arm will follow a Mediterranean style diet, rich in olive oil and fruits and vegetables, and also consume 1 ounce of walnuts daily.
62382141|NCT05830656|EXPERIMENTAL|Control, Then exposure to virtual nature, Then exposure to nearby nature|During the first week, the participants continue their normal routine at work and in leisure time. On the second week, the participants watch virtual nature videos with Virtual Reality (VR) goggles after finishing their workday on three days (Tuesday, Wednesday, and Thursday). On the third week, the participants visit a nearby natural area after finishing their workday on three days (Tuesday, Wednesday, and Thursday).
62382142|NCT05150171|EXPERIMENTAL|e-self-management intervention|Patients will receive the HAPPY Hands e-self-management intervention delivered through a smartphone app.
62762549|NCT01459991|ACTIVE_COMPARATOR|MyPyramid|
62382143|NCT03717727|EXPERIMENTAL|Exergame|Home-based exergame intervention and usual treatment.
62762550|NCT00693654|EXPERIMENTAL|Sarna Lotion|1% pramoxine Sarna lotion
62762551|NCT00693654|PLACEBO_COMPARATOR|Placebo Cetaphil lotion|Placebo Cetaphil lotion
62762552|NCT02753127|EXPERIMENTAL|Napabucasin plus FOLFIRI|Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m\^2 together with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion or at least 2 hours following the first daily dose of napabucasin if bevacizumab is not administered. 5-FU 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.
62762553|NCT02753127|ACTIVE_COMPARATOR|FOLFIRI|Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m\^2 together with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion. 5-FU 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.
62762554|NCT06197464|ACTIVE_COMPARATOR|control|psychoeducation on emotional regulation and distraction strategy + Application
62762555|NCT06197464|EXPERIMENTAL|experimental|psychoeducation on emotional regulation and distraction strategy + Application with the FLOAT app
62762556|NCT03897894|EXPERIMENTAL|Enhanced Service Package|"The enhanced service package provides 40 sequential sessions selected by CFS program staff in advance and implemented over a twelve-week period. Activities are meant to build upon and reinforce one another and are organized into seven psychosocial themes: 1) Building community: Our space together, 2) Emotional learning: My feelings, 3) Wellbeing and coping: Feeling good, 4) Social support: My friends and family, 5) Relating to others: Being a good friend, 6) Protection and boundaries: My safety, and 7) Building on strengths: All my supports. Each session takes approximately 1.5 - 2 hours to facilitate and will conclude with 1-1.5 hours unstructured free play time."
62762557|NCT03897894|EXPERIMENTAL|Basic Service Package|The basic service package offers a mixture of recreational and non-formal education activities over a twelve-week period. Each session lasts around 1.5 - 3 hours. Structured activities offered include basic literacy and numeracy lessons, life skills exercises, health and hygiene sessions, and traditional song and dance. Many activities are centered around various forms of play that enable expression and age-appropriate skill development. Unstructured free play and playground time is allocated throughout the daily session.
62762558|NCT03897894|NO_INTERVENTION|Control|Waitlist control will receive delayed treatment of intervention after the primary assessment period.
62182562|NCT00781417|ACTIVE_COMPARATOR|1|Cholecalciferol 50,000 IU once a week for 12 weeks then every other week for 40 weeks
62182563|NCT00781417|PLACEBO_COMPARATOR|Placebo|Placebo
62182564|NCT00236184|PLACEBO_COMPARATOR|Placebo|Oral placebo tablet
62182565|NCT00236184|EXPERIMENTAL|Rabeprazole sodium 10 mg|oral rabeprazole 10 mg enteric-coated tablet
62382144|NCT03717727|EXPERIMENTAL|Control|Home-exercise by standard protocol and usual treatment.
62382145|NCT02814747|EXPERIMENTAL|quantitive study: 500 patients likely to be candidates for HTS|quantitive study: 500 patients likely to be candidates for HTS at CR in Dijon and Lyon, that is to say patients with development anomalies and/or intellectual deficiency with no etiological diagnosis.
62382146|NCT02814747|EXPERIMENTAL|qualitative study: 30 patients who have benefited from HTS and|qualitative study: 30 patients who have benefited from HTS and the medical geneticists who accompanied them in this approach.
62382147|NCT01587599|ACTIVE_COMPARATOR|Pharmaceutical care|
62382148|NCT01587599|PLACEBO_COMPARATOR|Standard care|
62382149|NCT00968929|EXPERIMENTAL|r-SK group|Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
62382150|NCT00968929|ACTIVE_COMPARATOR|UK group|Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
62382151|NCT01176864|ACTIVE_COMPARATOR|Double-balloon enteroscopy|DBE for suspected or known small-bowel bleeding
62762559|NCT04108715|ACTIVE_COMPARATOR|ESPB GROUP|Erector spina plane block group
62762560|NCT04108715|ACTIVE_COMPARATOR|SAPB group|Deep Serratus anterior plane block group
62762561|NCT02443493|EXPERIMENTAL|Treatment group|Treatment group (receives low-level laser therapy (2x/week) in combination with standard skin care starting from day 1 of radiotherapy)
62762562|NCT02443493|SHAM_COMPARATOR|Control group|Control group (receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy)
62762563|NCT03801746|EXPERIMENTAL|Vadadustat, Cyclosporine|Part 1: Arm 1: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with oral cyclosporine 500 mg in a crossover design
62762564|NCT03801746|EXPERIMENTAL|Vadadustat; Probenecid|Part 1: Arm 2: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with oral Probenecid 500 mg Q12h in a fixed sequence design
62762565|NCT03801746|EXPERIMENTAL|Vadadustat and Rifampin|Part 2: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with IV rifampin 600 mg in a cross-over design
62762566|NCT01124227|SHAM_COMPARATOR|Standard Care|
62762567|NCT01124227|ACTIVE_COMPARATOR|2 Icodextrin PD changes / day|
62382152|NCT01176864|ACTIVE_COMPARATOR|Single-balloon enteroscopy|SBE for suspected or known small-bowel bleeding
62382153|NCT03058276|EXPERIMENTAL|Exposure|Exposure to a 5 minutes video related to alcohol consumption (updating/retrieval), followed by 10 minutes of the alcohol- AAT(Approach Avoidance Task) (extinction), during 4 days of training (2 weeks).
62382154|NCT03058276|ACTIVE_COMPARATOR|No exposure|Exposure to a 5 minutes video with neutral content (no retrieval) followed by 10 minutes of the alcohol- AAT (Approach Avoidance Task) , during 4 days of training.
62382155|NCT03058276|EXPERIMENTAL|Active rTMS|Each session (5 sessions along 2 weeks), patients receive active stimulation with repetitive transcraneal magnetic stimulation (rTMS) of the right dorsolateral prefrontal cortex.
62382156|NCT03058276|SHAM_COMPARATOR|SAM|Pacients receiving a sham stimulation (SAM), with a similar procedure to the experimental condition
62382157|NCT02203006|OTHER|OVIHD|Cohort and a blood sample collection will be done with data and blood of HIV infected patients
62382158|NCT04898036|EXPERIMENTAL|Sham First, then Experimental|Participants in this group will receive the sham treatment first, then the experimental treatment.
62382159|NCT04898036|EXPERIMENTAL|Experimental First, then Sham|Participants in this group will receive the experimental treatment first, then the sham treatment.
62382160|NCT04125199|EXPERIMENTAL|experimental group|
62382161|NCT04125199|PLACEBO_COMPARATOR|control group|
62382162|NCT04778644|EXPERIMENTAL|Patients with psychosis|People who are part of a dimensionally-organized psychosis sample spanning several serious mental illness diagnoses including schizophrenia, schizoaffective disorder, or psychotic bipolar I disorder. Eligible participants will be scheduled for two dose visits where they will receive a 600mg CBD dose on one day and a placebo dose on the other day. Doses will be randomized and double-blind. Doses will be administered via oral gel capsules.
62762568|NCT01124227|ACTIVE_COMPARATOR|1 Icodextrin PD change/day|
62762569|NCT01745523|EXPERIMENTAL|Vitrified oocytes using HPC+Trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
62762570|NCT01745523|ACTIVE_COMPARATOR|Vitrified oocytes using SSS+ Sucrose|Oocytes are vitrified using the SSS containing HSA and sucrose
62382163|NCT04778644|EXPERIMENTAL|Healthy controls|People who do not have a diagnosis of schizophrenia, schizoaffective disorder, or psychotic bipolar I disorder. Eligible participants will be scheduled for two dose visits where they will receive a 600mg CBD dose on one day and a placebo dose on the other day. Doses will be randomized and double-blind. Doses will be administered via oral gel capsules.
62382164|NCT04184752||Detrusor underactivity|The DU was defined when the PdetQmax was less than 20 cmH2O, the Qmax was less than 15 mL/s, and the bladder voiding efficiency (BVE) was less than 90 %. BVE = voided volume / (voided volume+ PVR) x 100%.
62382165|NCT04184752||Bladder outlet obstruction|The BOO was defined when the PdetQmax was not less than 40 cmH2O, and the Qmax was less than 12 mL/s.
62762571|NCT03194191|EXPERIMENTAL|Regular acupuncture needles|"Real acupuncture procedure The real acupuncture will be performed by means of standard stainless-steel needles (0.30-mm diameter, 30-mm length/Gauge 8 x 1.2), located bilaterally in 5 real acupoints."
62762572|NCT03194191|SHAM_COMPARATOR|Sham acupuncture needles|Sham acupuncture with a no penetrating sham needle (blunt and telescopic), giving the impression of insertion but without penetrating the skin will be placed bilaterally in 5 false acupoints
62762573|NCT01705158|EXPERIMENTAL|carboplatin and liposomal doxorubicin|carboplatin and liposomal doxorubicin in ovarian cancer in realapse
62762574|NCT03879044|EXPERIMENTAL|Transcranial Direct Current Stimulation|Active tDCS for 30 minutes before their scheduled work hours at least 3x/week for two consecutive weeks.
62762575|NCT03663374|EXPERIMENTAL|Odelepan|One tablet once daily
62182566|NCT02720185|EXPERIMENTAL|Dasatinib 100mg|Dasatinib 100mg for 7-10 days until day prior to surgery
62182567|NCT04077814|ACTIVE_COMPARATOR|ShamtDCS+FDS|Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Sham Transcranial direct brain stimulation (tDCS)
62382166|NCT04184752||Non-DU/BOO group|Those women without DU or BOO were allocated to the non-DU/BOO group.
62382167|NCT01599585|EXPERIMENTAL|In Home|Participants in this condition will receive 8 sessions of BA treatment over the course of approximately 8 weeks (one session per week). The sessions will be conducted in their homes using an Army approved secure web-based video conferencing system. BA has been successfully delivered in this time frame, and it has been delivered via in-home video conferencing technology.
62382168|NCT01599585|ACTIVE_COMPARATOR|In-Person|Participants in this condition will receive 8 sessions of BA treatment over the course of approximately 8 weeks (one session per week with allowance for rescheduled sessions). The sessions will be conducted in a clinic setting at The National Center for Telehealth \& Technology.
62382169|NCT00869063|EXPERIMENTAL|Diclofenac Sodium Patch|
62382170|NCT00869063|PLACEBO_COMPARATOR|Placebo Patch|
62382171|NCT01063361|EXPERIMENTAL|Low glycemic Index Diet|Low glycemic Index Diet, emphasizing pulses
62382172|NCT01063361|ACTIVE_COMPARATOR|High Cereal Fibre Diet|
62762576|NCT03663374|PLACEBO_COMPARATOR|Placebo|One tablet once daily
62762577|NCT03627065|EXPERIMENTAL|Parsaclisib|
62762578|NCT05883332|EXPERIMENTAL|SANO (1), Oxygen (2)|"All participants will receive self-administered nitrous oxide (SANO) at a range of 25-50% immediately before and during catheter placements. At this time, a participant-preferred level of SANO will be determined.~At the start of the first UDS run, SANO will continue at the participant-preferred level that was determined during catheter placement, ensuring that the patient is relaxed but still conversant through the procedure.~At the end of the first UDS run, SANO will be turned down to 0%. Participants will then receive 100% oxygen at 10 liters/minute for the duration of their second UDS run."
62762579|NCT05883332|EXPERIMENTAL|Oxygen (1), SANO (2)|"All participants will receive self-administered nitrous oxide (SANO) at a range of 25-50% immediately before and during catheter placements. At this time, a participant-preferred level of SANO will be determined.~After catheter placement, SANO will be turned down to 0%. Participants will receive 100% oxygen at 10 liters/minute for the duration of their first UDS run.~At the end of the first UDS run, SANO will start at the participant-preferred level that was determined during catheter placement, ensuring that the patient is relaxed but still conversant through the procedure. SANO will be given for the duration of their second UDS run."
62762580|NCT04949568|EXPERIMENTAL|Diabetes Self-Management Behaviors|Self-Management Education Program The culturally tailored Diabetes Self-Management Education Program involves the following: 1) an initial 45-minute face-to-face private consultation collaboratively determining goals; followed by 2) six 2-hour weekly educational interactive sessions in a format TBD by aim 1. We will deliver culturally targeted written materials and presentations in these sessions. Participants will be asked to practice self-management behaviors concurrently and for four additional weeks.
62762581|NCT04949568|NO_INTERVENTION|Usual Type 2 Diabetes Care|The usual care arm will receive the clinic's standard type 2 diabetes care and remain under their providers' care for the duration of the study.
62762582|NCT05324423|OTHER|Cohort 1|"Colchicine 0.5 mg Oral Tablet Day-7\~Day25 qd, Febuxostat 40 mg Oral Tablet Day1 and Day14 qd, XNW3009 0.5 mg Oral Tablet Day8\~Day21 qd.~Interventions:~Drug: Colchicine Drug: Febuxostat Drug: XNW3009"
62762583|NCT02251132|EXPERIMENTAL|TPV/RTV Low 1|
62762584|NCT02251132|EXPERIMENTAL|TPV/RTV Low 2|
62762585|NCT02251132|EXPERIMENTAL|TPV/RTV Low 3|
62762586|NCT02251132|EXPERIMENTAL|TPV/RTV Medium 1|
62762587|NCT02251132|EXPERIMENTAL|TPV/RTV Medium 2|
62762588|NCT02251132|EXPERIMENTAL|TPV/RTV High 1|
62762589|NCT02251132|EXPERIMENTAL|TPV/RTV High 2|
62762590|NCT02251132|EXPERIMENTAL|TPV/RTV High 3|
62762591|NCT01283906|EXPERIMENTAL|MuGard|Mucoadhesive Oral Wound Rinse
62762592|NCT01283906|SHAM_COMPARATOR|Control Rinse|Aqueous Control Rinse.
62762593|NCT05788705|ACTIVE_COMPARATOR|"apigenin and glycyrrhizin"|Patients will receive one capsule contains 10 mg of apigenin (Matricaria chamomilla L extract) and one capsule contains glycyrrhizin 50(licorice extract) twice daily for 6 months
62762594|NCT05788705|ACTIVE_COMPARATOR|"boswellic acid and glycyrrhizin"|Patients will receive one capsule contains 200 mg boswellic acid (Boswellia serrata extract) and one capsule contains glycyrrhizin 50(licorice extract) twice daily for 6 months
62762595|NCT05788705|PLACEBO_COMPARATOR|"placebo"|Patients will receive daily two capsules contain placebo for 6 months
62762596|NCT05304429|EXPERIMENTAL|nutritional counseling group|This group will have nutrition education sessions every fifteen days and will keep track of 10 healthy behaviors through goal setting and self-monitoring.
62762597|NCT05304429|NO_INTERVENTION|group without nutritional counseling|This group will have sessions every fifteen days of reading, knitting and other activities unrelated to health.
62762598|NCT04261959||myoActivation only|Participants who receive one or more sessions of myoActivation. They may receive 1:1 counselling also, but will not receive physiotherapy or group counselling
62382173|NCT02802735|EXPERIMENTAL|Part 1: Apremilast 20 mg|A single oral dose of 20 mg apremilast.
62382174|NCT02802735|EXPERIMENTAL|Part 1: Apremilast 30 mg|A single oral dose of 30 mg apremilast.
62762599|NCT04261959||Physiotherapy only|Participants who receive one or more sessions of physiotherapy. They may receive 1:1 counselling also, but will not receive myoActivation or group counselling
62762600|NCT04261959||myoActivation and Physiotherapy|Participants who receive one or more sessions of myoActivation AND one or more sessions of physiotherapy. They may receive 1:1 counselling also, but will not receive group counselling
62762601|NCT00975819|EXPERIMENTAL|Sirolimus|
62762602|NCT03208920|EXPERIMENTAL|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 4400 mg/day x 6 months (Nordic Naturals, Watsonville, CA, USA)
62762603|NCT03208920|PLACEBO_COMPARATOR|Placebo|Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4400mg/day x 6 months
62762604|NCT05518370|EXPERIMENTAL|Hippotherapy simulator training group|Hippotherapy simulator training group will receive a traditional physiotherapy and hippotherapy simulator training, two days a week for a total of 8 weeks (30 minutes traditional physiotherapy session+15 minutes hippotherapy simulator training).
62762605|NCT05518370|ACTIVE_COMPARATOR|Traditional physiotherapy group|Traditional physiotherapy group individuals will be given a traditional physiotherapy two days per week for a total of 8 weeks (traditional physiotherapy session will last 45 minutes).
62762606|NCT01638208|EXPERIMENTAL|VSL#3|Patients with IBS-D as per ROME III
62762607|NCT01638208|NO_INTERVENTION|Healthy Controls|Healthy controls
62382175|NCT02802735|EXPERIMENTAL|Part 1: Apremilast 40 mg|A single oral dose of 40 mg apremilast.
62382176|NCT02802735|EXPERIMENTAL|Part 2: Apremilast 30 mg BID|30 mg apremilast orally twice a day (BID) for 14 days.
62382177|NCT02802735|PLACEBO_COMPARATOR|Part 2: Placebo|Matching placebo orally twice a day for 14 days.
62382178|NCT00086489|EXPERIMENTAL|10 mg/kg|pts treated at 10 mg/kg dose level on a monthly regimen
62382179|NCT00086489|EXPERIMENTAL|15 mg/kg|pts treated at 15 mg/kg dose level on a quarterly regimen
62762608|NCT02840786|ACTIVE_COMPARATOR|Intervention: Stents|Stents group
62762609|NCT02840786|ACTIVE_COMPARATOR|Intervention: Atherectomy|directional atherectomy group
62762610|NCT01652352||Individuals with Disability|Power wheelchair-bound individuals with conditions which affect upper and lower body mobility, strength, or dexterity. Such conditions may include but are not limited to spinal cord injury, Multiple Sclerosis, Cerebral Palsy, or other conditions which affect overall mobility.
62762611|NCT01652352||Able-Bodied Individuals|Those who possess no condition or injury resulting in loss of mobility.
62762612|NCT00640640|EXPERIMENTAL|A|All study patients will be evaluated in a similar way
62762613|NCT02568449|EXPERIMENTAL|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62762614|NCT01322217||AMTU Clients|All HIV-infected adolescents and young adults engaged in care at sites newly participating in ATN III and their affiliates who are between 12 and 24 years of age, inclusive, are aware of their HIV status and understand written and/or verbal English will be eligible for inclusion in the study. In addition, new patients who have their initial clinic visit within the enrollment period will also be eligible for participation.
62762615|NCT02330523|ACTIVE_COMPARATOR|allograft + x-link collagen membrane|Demineralized freeze-dried allograft + x-linked collagen membrane will be used for guided bone regeneration of dehiscence buccal defects post extraction.
62382180|NCT05875194|EXPERIMENTAL|active transcranial direct current stimulation (tDCS)|A single application of transcranial direct current stimulation (tDCS), anodal stimulation of the left dlPFC placed (10-20 position F3) and the reference electrode on the arm, intensity 2mA, with retangular electrodes, size 35cm2, current intensity is ramped up to 2mA over a period of 20 seconds, duration 15 minutes
62762616|NCT02330523|ACTIVE_COMPARATOR|xenograft + non-x-link collagen|Xenograft + non-x-linked collagen membrane will be used for guided bone regeneration of dehiscence buccal defects post extraction.
62762617|NCT01765426|EXPERIMENTAL|Group 1: TDV using PharmaJet® Injector|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) \[previously DENVax\] one dose injection in arm 1 and placebo: phosphate buffered saline (PBS) one dose injection in arm 2, using needle-free PharmaJet® Injector, intradermal, on Day 0 and TDV, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
62762618|NCT01765426|EXPERIMENTAL|Group 2: TDV using PharmaJet® Injector|TDV injection, one dose in each arm, using needle-free PharmaJet® Injector, intradermal, on Day 0 and placebo: PBS, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
62762619|NCT01765426|EXPERIMENTAL|Group 3: TDV using Needle and Syringe|TDV one dose injection in arm 1 and placebo: PBS one dose injection in arm 2, using needle and syringe, intradermal, on Day 0 and TDV injection using needle and syringe, intradermal, one dose on Day 90.
62762620|NCT01765426|EXPERIMENTAL|Group 4: TDV using PharmaJet® Injector|TDV injection, one dose in each arm, using needle-free PharmaJet® Injector, intradermal, on Day 0 and TDV, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
62762621|NCT00795912|ACTIVE_COMPARATOR|1|Atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
62762622|NCT00795912|NO_INTERVENTION|2|Usual medical care of heart failure
62762623|NCT01969877|EXPERIMENTAL|Arm 1|Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 1-4).
62762624|NCT01969877|EXPERIMENTAL|Arm 2|Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 3-4).
62382181|NCT05875194|SHAM_COMPARATOR|sham transcranial direct current stimulation (tDCS)|A single application of transcranial direct sham stimulation (tDCS), with sponge electrodes, placed over left dlPFC (10-20 position F3) and the reference electrode on the arm, with retangular electrodes 35cm2,intensity is ramped up to 2mA over a period of 20 seconds duration and then switched off again at the end of 20 s ramp. To ensure that there are no differences in perception, this is applied in both verum and sham stimulation, duration 15 min
62382182|NCT03626844|EXPERIMENTAL|Manual Lysis after 15 minutes (Intervention)|Manual Lysis of Placenta 15 minutes after Delivery.
62382183|NCT03626844|ACTIVE_COMPARATOR|Manual lysis after 30 minutes (Control)|Waiting 30 minutes after delivery and then manual lysis of the placenta.
62762625|NCT01969877|EXPERIMENTAL|Arm 3|Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 1-4).
62762626|NCT01969877|EXPERIMENTAL|Arm 4|Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 3-4).
62762627|NCT04785625|EXPERIMENTAL|INL-001 (bupivacaine hydrochloride) implant|INL-001 (bupivacaine hydrochloride) implant
62762628|NCT04785625|PLACEBO_COMPARATOR|Placebo implant|Placebo collagen-matrix implant
62762629|NCT04932603||experimental|Patients with AF, hospitalized in one of the 6 geriatrics units participating in the study, aged 75 years or over, without evaluation of their antithrombotic treatment by the multidisciplinary team. The lack of review of patient's file by the multidisciplinary team is based on physician decision.
62762630|NCT04932603||Standard of care|
62762631|NCT05867290|NO_INTERVENTION|Baseline Phase|Randomly allocated baseline phase (no intervention) of 7, 11 or 15 days.
62762632|NCT05867290|EXPERIMENTAL|Intervention Phase|5 week mindful-music listening intervention including sleep hygiene
62762633|NCT03147313|SHAM_COMPARATOR|Sham|
62762634|NCT03147313|ACTIVE_COMPARATOR|Shockwave 300 pulses|300 pulses of extracorporeal shock wave will be applied
62762635|NCT03147313|ACTIVE_COMPARATOR|Shockwave 500 pulses|500 pulses of extracorporeal shock wave will be applied
62762636|NCT03698786||European males|"This study will involve a cohort of 15 White European men, between the ages of 18-50 years. Participants will be non-smokers, not dieting, and physically well to participate.~Participants will be required to exercise on one occasion."
62762637|NCT03698786||South Asian males|"This study will involve a cohort of 15 South Asian (India, Pakistan, Sri Lanka, Nepal, Bangladesh, Maldives and Bhutan), men, between the ages of 18-50 years. Participants will be non-smokers, not dieting, and physically well to participate.~Participants will be required to exercise on one occasion."
62762638|NCT02827500|ACTIVE_COMPARATOR|ivabradine|Active Comparator: ivabradine
62762639|NCT02827500|PLACEBO_COMPARATOR|usual care|Placebo Comparator: usual care
62762640|NCT02751034|EXPERIMENTAL|Neuramis® Deep Lidocaine|Neuramis® Deep Lidocaine Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
62762641|NCT02751034|ACTIVE_COMPARATOR|Restylane® PERLANE-L|Restylane® PERLANE-L Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
62762642|NCT00554619|EXPERIMENTAL|GSK1325760A|
62762643|NCT02578433|EXPERIMENTAL|Mindful Self Compassion|Participants will receive a shortened form (6 weeks) of mindful self compassion meditation, once a week for 75 minutes, furthermore they get an audio cd and a handout to practice during the week
62762644|NCT02578433|OTHER|Progressive Muscle Relaxation|Participants will receive progressive muscle relaxation once a week for 75 minutes, furthermore they get an audio cd and a handout to practice during the week
62762645|NCT04702906|ACTIVE_COMPARATOR|control group|All patients will continue to receive the standard treatment, which is determined by the attending physician who maintains clinical responsibility for all patients. Conventional standard treatment included using inotropes, fluids and electrolytes resuscitation, intubation, mechanical ventilation, and antiarrhythmic agents if indicated.
62762646|NCT04702906|ACTIVE_COMPARATOR|trimetazidine group|"The trimetazidine group will receive conventional standard treatment plus Trimetazidine dihydrochloride metacardia ® (20 mg three times daily produced by Pharco-Egypt) will be administered twice every 24 hours until at least treatment is no longer needed."
62762647|NCT06394752|EXPERIMENTAL|Visual Saline Infusion|Visual Saline Infusion is intended to perform direct visual evaluation of the intrauterine space using a 2.7mm, steerable tip catheter with a camera.
62762648|NCT06394752|ACTIVE_COMPARATOR|Hydrosonography|Hydrosonography is the standard of care for intrauterine evaluation. It is performed by inserting a slim 2 mm catheter into the uterine cavity and infusing saline solution to expand the uterus, and using abdominal ultrasound to detect intrauterine pathology.
62762649|NCT06370234|OTHER|PET/MR scanning for neoadjuvant chemotherapy breast cancer patients|"From April 2015 to June 2019, women with breast cancer who underwent neoadjuvant chemotherapy were enrolled.~Arranged for at least three PET/MR scans during NAC: the first \[R0\], pre-treatment; and the second\[R1\], after two cycles of chemotherapy (post-treatment) and the third \[R2\] before surgery."
62762650|NCT05420220|EXPERIMENTAL|KN046+Axitinib|Eligible subjects will receive KN046 5 mg/kg Q3W IV in combination with Axitinib 5 mg bid po, until progressive disease as judged by the investigator per RECIST v1.1
62762651|NCT05129514|EXPERIMENTAL|Manual Lymphatic Drainage (MLD)|
62762652|NCT04436471|EXPERIMENTAL|Component 1|"rAd26 Component, 1 vaccination~Component 1 consists of a recombinant adenovirus vector based on the human adenovirus type 26, containing the SARS-CoV-2 S protein gene"
62762653|NCT04436471|EXPERIMENTAL|Component 2|"rAd5 Component, 1 vaccination~Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene."
62762654|NCT04436471|EXPERIMENTAL|Prime-Boost Immunization|Day 1 rAd26 Component Day 21 rAd5 Component
62762655|NCT04546295|EXPERIMENTAL|Brushlink|This group will use Brushlink and interdental cleaner. The Brushlink app downloaded to participant's cell phone. A small Brushlink device is attached to participant's toothbrush. When participant's brush their teeth, the device on the toothbrush will send information to the app on your phone about how long teeth are brushed and at what angle the toothbrush is being held against the tooth.
62382184|NCT05273294|EXPERIMENTAL|Ultrasound group|Anesthesiologist will convenient color ultrasound high frequency 12MHZ array probe perpendicular to the neck, by the glottal down, until the thyroid isthmus, and ring cartilage level, ring cartilage level diameter by ultrasound, to avoid the effect of inspiration and breath on airway diameter, measurement timing should choose after anesthesia induction, mask pressure gas 1min, suspended pressure ventilation for 5s, ultrasonic measurement time is not more than 10s.Repeated measurements were averaged three times, and the maximum outer diameter of the catheter was selected, that is, the maximum outer diameter was selected closest to the measured value.
62382185|NCT05273294|NO_INTERVENTION|Control group|tracheal catheter models are usually selected through traditional experience, according to the age formula in Clinical Anesthesiology, People's Health Press (i. e., 2.5 for preterm infants, 3.5 at 1-6 months, 4.0 at 6-12 months).
62382186|NCT03560479|EXPERIMENTAL|alpha1H, 7.4 mg/mL|alpha1H (7.4 mg/mL), solution for instillation, 30 mL
62382187|NCT03560479|PLACEBO_COMPARATOR|placebo|Placebo, 0.9% NaCl (sodium chloride), 30 mL
62382188|NCT03560479|EXPERIMENTAL|alpha1H, 37 mg/mL|alpha1H (37 mg/mL), solution for instillation, 30 mL
62762656|NCT04546295|ACTIVE_COMPARATOR|Water-flosser|This group will brush their teeth using a waterflosser that sprays the tooth with a small jet of water.
62762657|NCT04546295|PLACEBO_COMPARATOR|Interproximal Brush|This group will brush their teeth with only a toothbrush.
62762658|NCT00657371|EXPERIMENTAL|Third Eye Retroscope|Colonoscopy exam using the Third Eye Retroscope device
62762659|NCT01248754|EXPERIMENTAL|18F-DOPA PET imaging|Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
62762660|NCT01437644|ACTIVE_COMPARATOR|Botulinum Toxin TypeA|"A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. A total of 2 ml of isotonic saline will be used to dissolve the contents of the trial vial of Botox. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo arm of the study."
62762661|NCT01437644|PLACEBO_COMPARATOR|Saline|The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Injections of normal saline will be administered in those children randomised to the placebo arm of the study. The volume of normal saline injected will be equal to the volume of normal saline that would have been used if the child had been randomised to botulinum toxin. The injector will be blinded, as the solution is drawn up by unblinded nurses.
62762662|NCT02792491|EXPERIMENTAL|Reduced dose R-CHOP|"Reduced dose R-CHOP is regimen including Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.~In this study, Rituximab 375 mg/m2, Cyclophosphamide 600 mg/m2, Doxorubicin 30 mg/m2 and Vincristine fixed dose of 1mg will be administrated through intravenous on day 1. and Prednisone 40mg will be administrated orally on day 1-5. This chemotherapy will be repeated every 21 days."
62382189|NCT03560479|EXPERIMENTAL|alpha1H, 74 mg/mL|alpha1H (74 mg/mL), solution for instillation, 30 mL
62762663|NCT01332838|EXPERIMENTAL|Sigvaris special compression stocking|
62762664|NCT01332838|ACTIVE_COMPARATOR|Standard Compression|
62762665|NCT03905317|EXPERIMENTAL|Bevacizumab|The patients receive SBRT radiotherapy for the primary (if any) and metastatic lesions or divided radiotherapy with or without concurrent chemotherapy.Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.
62762666|NCT03697993|EXPERIMENTAL|Strategy 1|Fosfomycin 3 g orally once daily for 5-7 days as initial or step-down oral therapy for complicated urinary tract infections (cUTI) without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy. N=317
62382190|NCT05349474|EXPERIMENTAL|Metformin Treatment|Metformin 500 mg tablets up to 2,000 mg (4 tablets) a day divided into two doses. Patients will start on 500 mg Qday and a titration to maximum dose will be attempted during the first 30 day period of the study.
62762667|NCT03697993|EXPERIMENTAL|Strategy 2|Levofloxacin 750 mg orally once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therap, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.y. N=317
62762668|NCT05229263|EXPERIMENTAL|Healthy volunteers|
62762669|NCT05229263|EXPERIMENTAL|CKD patients|
62762670|NCT02571660|ACTIVE_COMPARATOR|conventional treatment|GINA treatment fot asthma +vit.D low supplementation dose
62762671|NCT02571660|EXPERIMENTAL|conventional treatment + vitamin D3|GINA treatment fot asthma +vit.D high supplementation dose
62762672|NCT04638842|EXPERIMENTAL|Grief COVID intervention|Participants in this group will receive 12 sessions of a multi-component psychological intervention focused on the reduction of symptoms of anxiety, depression, hopelessness, and post-traumatic stress, and the increase of the quality of sleep and perception of the quality of life.
62762673|NCT04638842|NO_INTERVENTION|Waiting List group|The participants in this group will not receive the treatment, just waiting list. They will be measured one time and then a second time 3 months after. Calculating when 3 months corresponding to 12 sessions will receive the intervention.
62762674|NCT06229665|EXPERIMENTAL|Photobiomodulation (PBM)|The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
62762675|NCT04401670|OTHER|Triage with different options|"* Self-Collection: hrHPV and Biomarkers Testing (among hrHPV+)~* ThinPrep Specimen: Liquid-Based Cytology (LBC), hrHPV Testing, and Biomarker Testing (among hrHPV+)~* Visual Inspection after Acetic Acid (VIA)"
62382191|NCT05349474|PLACEBO_COMPARATOR|Placebo Treatment|Placebo tablets identical to metformin 500 mg tablets divided into two doses. Patients will be started on 1 tablet a day and a titration to maximum dose (4 tablets) will be attempted during the first 30 day period of the study.
62382192|NCT03611179|EXPERIMENTAL|advanced ovarian cancer cases|patients with advanced ovarian cancer will receive Bevacizumab 15 mg/kg every 21 days with chemotherapy (Paclitaxel 175 mg/m2 \& Carboplatin AUC 5 every 21 days)
62382193|NCT06186089||Probiotics (PR)|Patients undergoing total gastrectomy take probiotics qd for 3 months after surgery.
62382194|NCT06186089||Total gastrectomy (TG)|Patients undergoing total gastrectomy
62382195|NCT06186089||Double-tract reconstruction (DTR)|Patients undergoing double-tract reconstruction
62382196|NCT00916994|EXPERIMENTAL|SpaceGuard Balloon implantation|
62382197|NCT05874700|EXPERIMENTAL|Sivelestat sodium group|sivelestat sodium
62382198|NCT05874700|PLACEBO_COMPARATOR|Placebo control group|Placebo control
62382199|NCT00862329|EXPERIMENTAL|Casein|
62382200|NCT00862329|EXPERIMENTAL|MSP|
62182568|NCT04077814|EXPERIMENTAL|tDCS+FDS|Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Transcranial direct brain stimulation (tDCS)
62382201|NCT00862329|EXPERIMENTAL|Casein/MSP|
62382202|NCT00862329|EXPERIMENTAL|Soy protein|
62382203|NCT02709889|EXPERIMENTAL|Rovalpituzumab Tesirine|Rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
62382204|NCT03421236|EXPERIMENTAL|non muscle invasive bladder cancer patient|intravesical instillation of Ty21a in patients not requiring BCG
62382205|NCT01295632|EXPERIMENTAL|Ridaforolimus 20 mg + MK-2206 90 mg|
62382206|NCT01295632|EXPERIMENTAL|Ridaforolimus 20 mg + MK-2206 135 mg|
62382207|NCT01295632|EXPERIMENTAL|Ridaforolimus 30 mg + MK-2206 90 mg|
62762676|NCT01287377|EXPERIMENTAL|Pre-Patch and Telephone Counseling|"Nicotine patches (2 weeks' worth) are mailed directly to the subject. Clients will be encouraged to start using these patches PRIOR to their quit date.~Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls."
62762677|NCT01287377|ACTIVE_COMPARATOR|Post-Patch and Telephone Counseling|"Nicotine patches (2 weeks' worth) are mailed directly to the subject. Clients are encouraged to start using their patches ON their quit date.~Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls."
62382208|NCT01295632|EXPERIMENTAL|Ridaforolimus 30 mg + MK-2206 135 mg|
62382209|NCT01295632|EXPERIMENTAL|Ridaforolimus 30 mg + MK-2206 200 mg|
62382210|NCT01295632|EXPERIMENTAL|Ridaforolimus 40 mg + MK-2206 135 mg|
62382211|NCT01295632|EXPERIMENTAL|Ridaforolimus 40 mg + MK-2206 200 mg|
62762678|NCT01287377|ACTIVE_COMPARATOR|Telephone Counseling and no patches sent|Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls.
62762679|NCT00622947|ACTIVE_COMPARATOR|repetitive transcranial magnetic stimulation|Low frequency ( 1 HZ) rTMS of the right prefrontal cortex. On each of 15 consecutive week days (apart from weekends), the patients received two 60-second1-Hz trains delivered at an intensity of 110% of motor thresholdand with a 180 seconds' intertrain interval.
62382212|NCT01295632|EXPERIMENTAL|Ridaforolimus 20 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
62382213|NCT01295632|EXPERIMENTAL|Ridaforolimus 30 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
62382214|NCT01295632|EXPERIMENTAL|Ridaforolimus 40 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
62382215|NCT01149161|ACTIVE_COMPARATOR|C group|Routine central neck dissection
62382216|NCT01149161|NO_INTERVENTION|N group|No central neck node dissection
62382217|NCT00125268|ACTIVE_COMPARATOR|MIRE|Subjects randomized to this arm will receive treatment with monochromatic near infrared photo energy (MIRE).
62382218|NCT00125268|SHAM_COMPARATOR|Sham|Subjects randomized to this arm will receive treatment with the sham device, which is non-active but otherwise identical to the study device.
62382219|NCT03770689|EXPERIMENTAL|Peposertib 50 mg + RT + Capecitabine|Participants received peposertib 50 milligram (mg) once daily in combination with capecitabine 825 milligram per square meter (mg/m\^2) twice daily 5 days per week and radiotherapy (RT) of 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks treatment period.
62762680|NCT00622947|SHAM_COMPARATOR|Placebo stimulation|Sham- rTMS of the right prefrontal cortex. On each of 15 consecutive week days (apart from weekends), the patients received two 60-second1-Hz trains delivered at an intensity of 110% of motor thresholdand with a 180 seconds' intertrain interval.
62762681|NCT02605811|EXPERIMENTAL|temozolomide|temozolomide oral 150mg/m2 d1-5/28d for 12 cycles
62762682|NCT02605811|ACTIVE_COMPARATOR|prophylaxis cranial radiotherapy|prophylaxis cranial radiotherapy,25-30Gy/10Fra
62762683|NCT00961792|EXPERIMENTAL|Beverage with Heavy Alcohol Dose|Beverage containing 0.8 g/kg alcohol
62762684|NCT00961792|EXPERIMENTAL|Beverage with Low Alcohol Dose|Beverage containing 0.4 g/kg alcohol
62762685|NCT00961792|PLACEBO_COMPARATOR|Beverage with No alcohol (Placebo)|Beverage containing 0.0 g/kg alcohol to act as placebo
62762686|NCT00961792|EXPERIMENTAL|Beverage with Diphenhydramine|Beverage containing 1.5 standard dose of Diphenhydramine (Benadryl)
62762687|NCT00961792|EXPERIMENTAL|Beverage with Caffeine|Beverage containing the equivalent of 1.5 times participant's average caffeine consumption
62762688|NCT00961792|NO_INTERVENTION|Beverage in Natural Environment|Participant consumes alcohol containing beverages or non-alcohol beverages in natural environment
62762689|NCT01004016|PLACEBO_COMPARATOR|Placebo|
62382220|NCT03770689|EXPERIMENTAL|Peposertib 100 mg + RT + Capecitabine|Participants received peposertib 100 mg once daily in combination with capecitabine 825 mg/m\^2 twice daily 5 days per week and RT of 50 to 50.4 Gy to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks treatment period.
62762690|NCT01004016|EXPERIMENTAL|KPS-0373|
62182569|NCT02151630|ACTIVE_COMPARATOR|Pyruvic acid|Patients will receive pyruvic acid solution 70% prepared by solving of pyruvic acid in water/ethanol solution. Patients will be advised to apply the solution twice daily for a period of four weeks. Application of petrolatum to the surrounding normal skin protects against the corrosive effect of the concentrated acid.
62182570|NCT02151630|ACTIVE_COMPARATOR|Salicylic acid|Patients will receive a combination of salicylic acid 16.7%, lactic acid 16.7%, and collodion 100%. Patients will be advised to apply the solution twice daily for a period of four weeks. Application of petrolatum to the surrounding normal skin protects against the corrosive effect of the concentrated acid.
62762691|NCT05223062||Psoriatic arthritis|Patients with psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR).
62762692|NCT03342352|EXPERIMENTAL|Arm A|Nivolumab plus epacadostat in combination with platinum (carboplatin/cisplatin) plus 5-fluorouracil.
62762693|NCT03342352|ACTIVE_COMPARATOR|Arm B|EXTREME regimen.
62762694|NCT03342352|EXPERIMENTAL|Arm C|Nivolumab plus placebo for epacadostat in combination with platinum (carboplatin/cisplatin) plus 5-fluorouracil.
62762695|NCT01149486|EXPERIMENTAL|Generic Test Product|Losartan potassium/Hydrochlorothiazide 100/25 mg Tablets
62762696|NCT01149486|ACTIVE_COMPARATOR|Reference Listed Drug|Hyzaar® 100/25 mg Tablets
62762697|NCT03490149||ECT|
62762698|NCT03490149||Medication - Treatment as usual|
62762699|NCT03490149||Healthy controls|
62762700|NCT04333342|EXPERIMENTAL|Wearable device group|Participants use wearable device and their heart rate and activity are monitored. If their resting heart rate (rHR) increase beyond the set range or they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. If their rHR stay within set range and they have no symptoms and signs, they come to hospital and get tests for thyroid function 6 months after discontinuing anti-thyroid drugs.
62762701|NCT04333342|NO_INTERVENTION|Control group 1|articipants don't use wearable devices. If they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. If they have no symptoms and signs, they come to hospital and get tests for thyroid function 6 months after discontinuing anti-thyroid drugs.
62762702|NCT04333342|NO_INTERVENTION|Control group 2|Participants don't use wearable devices. If they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. If they have no symptoms and signs, they come to hospital and get tests for thyroid function 3 and 6 months after discontinuing anti-thyroid drugs.
62762703|NCT02370095|ACTIVE_COMPARATOR|Treprostinil inhalation solution|Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
62762704|NCT02370095|PLACEBO_COMPARATOR|Placebo|Placebo administration will be administered as above for the active arm
62762705|NCT03084913|ACTIVE_COMPARATOR|Prostate Cancer Foundation diet|Intervention: 8-weeks of a Prostate Cancer Foundation diet
62762706|NCT03084913|EXPERIMENTAL|plant- based, olive oil diet|Intervention: 8 weeks of a plant-based, olive oil diet
62762707|NCT01262170|EXPERIMENTAL|CigRx Lozenge|CigRx Lozenge
62762708|NCT01262170|ACTIVE_COMPARATOR|Tobacco Lozenge|Tobacco Lozenge
62762709|NCT03653468|NO_INTERVENTION|Control group|No-exercise
62382221|NCT03770689|EXPERIMENTAL|Peposertib 150 mg + RT + Capecitabine|Participants received peposertib 150 mg once daily in combination with capecitabine 825 mg/m\^2 twice daily 5 days per week and RT of 50 to 50.4 Gy to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks treatment period.
62762710|NCT03653468|EXPERIMENTAL|Endurance training plus resistant training|Concurrent training
62762711|NCT04104022|NO_INTERVENTION|OAT as usual|Those randomized to OAT as usual will continue to receive standard buprenorphine or methadone treatment and complete assessments of PTSD symptom severity, psychosocial functioning and drug use at intake and Study Weeks 4, 8, and 12.
62762712|NCT04104022|ACTIVE_COMPARATOR|OAT+PET|In addition to receiving OAT and completing monthly assessments, OAT+PET participants will receive 12 weekly PET sessions with a trained therapist.
62762713|NCT04104022|EXPERIMENTAL|OAT+PET+|OAT+PET+ participants will receive the procedures for the OAT+PET group plus monetary incentives contingent upon completion of PET sessions
62762714|NCT06149039||Nonmyopathic dermatomyositis with interstitial lung disease|
62762715|NCT06149039||Classical dermatomyositis with interstitial lung disease|
62762716|NCT06149039||Rheumatic disease with interstitial lung disease in non-inflammatory myopathy|
62762717|NCT06149039||Healthy adult|
62762718|NCT02762747|EXPERIMENTAL|Drain|preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
62382222|NCT03770689|EXPERIMENTAL|Peposertib 250 mg + RT + Capecitabine|Participants received peposertib 250 mg once daily in combination with capecitabine 825 mg/m\^2 twice daily 5 days per week and RT of 50 to 50.4 Gy to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks treatment period.
62382223|NCT03814057||Elderly Medical Patients at hospital admission|
62762719|NCT02762747|NO_INTERVENTION|No-drain|No drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
62762720|NCT05458089||tuberculous pericarditis with 18F-FDG uptake|patients confirmed with tuberculous pericarditis presenting 18F-FDG uptake
62762721|NCT05458089||tuberculous pericarditis without 18F-FDG uptake|patients confirmed with tuberculous pericarditis presenting no 18F-FDG uptake
62762722|NCT00016744|ACTIVE_COMPARATOR|1|"Subjects will be randomized to receive either the Phenylbutyrate or placebo tablets for 4 days~Every participant will receive Genistein during the NPD."
62762723|NCT00016744|PLACEBO_COMPARATOR|2|
62762724|NCT05720364|EXPERIMENTAL|TP-05, Fasted Group|Single dose of TP-05 (lotilaner oral), fasted
62762725|NCT05720364|EXPERIMENTAL|TP-05, High-Fat Group|Single dose of TP-05 (lotilaner oral) following a high-fat meal
62762726|NCT05720364|EXPERIMENTAL|TP-05, Low-Fat Group|Single dose of TP-05 (lotilaner oral) following a low-fat meal
62762727|NCT03653572|OTHER|Eligible Subjects|All subjects will be enrolled into a single arm and will undergo an ultrasound exam, per the protocol.
62762728|NCT01034618|PLACEBO_COMPARATOR|Placebo|
62762729|NCT01034618|EXPERIMENTAL|Intact protein|
62762730|NCT01034618|EXPERIMENTAL|Protein hydrolysate|
62762731|NCT03824405|ACTIVE_COMPARATOR|BTX 1204|BTX 1204 twice daily
62762732|NCT03824405|PLACEBO_COMPARATOR|Vehicle|Vehicle twice daily
62762733|NCT00322946|EXPERIMENTAL|1|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10\^5 PFU dose) into the deltoid region of either arm.
62762734|NCT00322946|EXPERIMENTAL|2|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10\^3 PFU dose) into the deltoid region of either arm. This arm will enroll after Arm 1.
62762735|NCT00322946|EXPERIMENTAL|3|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10\^1 PFU dose) into the deltoid region of either arm. This arm will enroll after Arms 1 and 2.
62762736|NCT00322946|PLACEBO_COMPARATOR|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
62382224|NCT00979862|EXPERIMENTAL|Treatment cediranib maleate, cilengitide)|"Part A (dose finding): Patients receive cediranib maleate PO once daily on days 1-28 and cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Part B (dose expansion): Patients are assigned to 1 of 2 groups according to prior anti-VEGF therapy (yes vs no). Patients in both groups receive cediranib maleate (administered at the safe dose determined in part A) and cilengitide as in part A."
62762737|NCT01560052|ACTIVE_COMPARATOR|oral methylprednisolone|"oral methylprednisolone~Original Cohort:~Methylprednisolone group; start at 0.8mg/kg/day with a maximal 48mg/kg/day x 2months, taper by 8mg/day every month with optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines.~Low Dose Cohort:~Methylprednisolone group; start at 0.4mg /kg/day with a maximal dose of 32mg/day and a minimum dose of 24mg/day, reducing over 6-9months.~All participants will also receive standard guideline based care, without steroid therapy. Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months in the low-dose cohort, after randomisation, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
62382225|NCT03773068|EXPERIMENTAL|Group 1 - BAY1817080 Dose 1|Participants will receive one single oral dose of BAY1817080 - Formulation B at dose 1 under fasted condition
62762738|NCT01560052|PLACEBO_COMPARATOR|placebo|"Original Cohort:~Matching placebo; Optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines; Low Dose Cohort; Matching placebo: Optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines.~All participants will also receive standard guideline based care, without steroid therapy. Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months in the low-dose cohort, after randomisation, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
62762739|NCT01757223|EXPERIMENTAL|Part A, Group 1 - 10^8 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10\^8, 10\^9, and 10\^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10\^8 particle units.
62382226|NCT03773068|EXPERIMENTAL|Group 2 - BAY1817080 Dose 2|Participants will receive a) one single oral dose of BAY1817080 - Formulation A at dose 2 with moderate-fat, moderate-calorie meal (MF, MC); b) one single oral dose of BAY1817080 - Formulation B at dose 2 along with one intravenous (i.v.) infusion of 0.1 mg \[13C715N\]-BAY1817080; and c) one single oral dose of BAY1817080 - Formulation B at dose 2 with high-fat, high-calorie meal (HF, HC). The 3 treatments will be administered with a randomized sequence
62382227|NCT03773068|EXPERIMENTAL|Group 3 - BAY1817080 Dose 3|Participants will receive a) one single oral dose of BAY1817080 - Formulation B at dose 3 under fasted condition; followed by one single oral dose of BAY1817080 - Formulation A at dose 3 with MF, MC; and followed by one single oral dose of BAY1817080 - Formulation B at dose 3 with HF, HC. The 3 treatments will be administered with a fixed sequence
62182571|NCT03895502|EXPERIMENTAL|12-month Edoxaban|Edoxaban for 12 months
62382228|NCT05675202|EXPERIMENTAL|TQ-B3525 tablet|100 µ Ci \[14C\] TQ-B3525, 20mg, once in total
62382229|NCT04671576|ACTIVE_COMPARATOR|Control Formula|A standard, milk-based, infant formula.
62382230|NCT04671576|EXPERIMENTAL|Investigational Formula|An organic milk-based infant formula.
62382231|NCT02581852|OTHER|Single arm assessment|Cross sectional assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning of rheumatoid arthritis patients with different disease activity levels.
62382232|NCT03822286|EXPERIMENTAL|Intervention|E-training course programs, counseling mentoring supports and support group gatherings meeting.
62382233|NCT03822286|ACTIVE_COMPARATOR|Control|Traditional classroom teaching course programs.
62382234|NCT04056715||HCM Group|Eligible HCM subjects will be monitored for arrhythmias with a 2-week ECG patch.
62382235|NCT00476190|EXPERIMENTAL|Arm A|Complete remission achieved after Induction Phase
62382236|NCT00476190|EXPERIMENTAL|Arm B|Failure to achieve complete remission after the Induction Phase
62382237|NCT02504957|OTHER|Photodynamic therapy|Patients who underwent photodynamic therapy for malignant biliary obstruction.
62382238|NCT03316599|EXPERIMENTAL|Ficlatuzumab + Gemcitabine and Nab-Paclitaxel|"* Ficlatuzumab will be administered intravenously days 1 and 15 of a 28 day cycle~* Gemcitabine 1000 mg/m2 and Nab-Paclitaxel 125mg/m2 will be administered IV days 1, 8, and 15 of a 28 day cycle.~* Dosage of Ficlatuzumab is determined by dose level to which the patient is assigned at time of enrollment."
62182572|NCT03895502|ACTIVE_COMPARATOR|3-month Edoxaban|Edoxaban for 3 months
62382239|NCT03325933|EXPERIMENTAL|Resistance Training 1|Participants will perform resistance training with high training loads and low repetitions (high load/low rep resistance training).
62382240|NCT03325933|EXPERIMENTAL|Resistance Training 2|Participants will perform resistance training with low training loads and high repetitions (Low load/high rep resistance training).
62382241|NCT03325933|NO_INTERVENTION|Wait-list control|This group will be offered the option of participating in either experimental group after the study is completed.
62382242|NCT02605889|EXPERIMENTAL|Group A|Laser acupuncture
62762740|NCT01757223|EXPERIMENTAL|Part A, Group 2 - 10^9 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10\^8, 10\^9, and 10\^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10\^9 particle units.
62762741|NCT01757223|EXPERIMENTAL|Part A, Group 3 - 10^10 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10\^8, 10\^9, and 10\^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10\^10 particle units.
62182573|NCT01837498||Neostigmine group|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
62762742|NCT01757223|EXPERIMENTAL|Part B, Group 1 - AdVEGF-All6A+|Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 1 will receive AdVEGF-All6A+ at the highest tolerable dose determined in Part A.
62762743|NCT01757223|EXPERIMENTAL|Part B, Group 2 - AdNull placebo|Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 2 will receive AdNull, the placebo vector.
62182574|NCT01837498||Sugammadex group|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
62382243|NCT02605889|SHAM_COMPARATOR|Group B|Simulation Laser acupuncture
62382244|NCT02010229||women at high risk of placenta accreta|Parturient women with placenta praevia and at least one previous caesarean delivery
62382245|NCT00285246||Group 1|Army Reserve and National Guard soldiers deploying to a hazardous deployment from Fort Dix, NJ and Camp Shelby, MS
62382246|NCT02853903|EXPERIMENTAL|Allogenic NK immunotherapy|In this group, the patients will receive more than 4 times of allogenic NK immunotherapies in 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62382247|NCT02853903|ACTIVE_COMPARATOR|Autogenic NK immunotherapy|In this group, the patients will receive more than 4 times of autogenic NK immunotherapies in 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62382248|NCT01962909|EXPERIMENTAL|PTP-01|single IV bolus dose 24 hours prior to surgery
62382249|NCT05924997|EXPERIMENTAL|Interventional arm|
62382250|NCT02312375|EXPERIMENTAL|Fimasartan|Expreimental drug is fimasartan.
62382251|NCT02312375|ACTIVE_COMPARATOR|Amlodipine|Active comparator is amlodipine.
62382252|NCT00904436|EXPERIMENTAL|1|Spinal Cord Injury: subjects who have cervical spinal cord injury and complaints of dyspnea
62382253|NCT00904436|NO_INTERVENTION|2|Controls
62382254|NCT04604028|EXPERIMENTAL|Lenalidomide and low-dose cyclophosphamide|Oral lenalidomide and low-dose cyclophosphamide (LC: lenalidomide \[Leavdo®\] 15 mg daily, day 1 to day 21; cyclophosphamide \[Endoxan\] 50 mg daily, day 1 to day 21; courses will be repeated every 28 days
62382255|NCT04083521|EXPERIMENTAL|Treatment|Subjects received a once daily dose of Bacillus subtilis DE111® 1x10\^9 CFU for 90-days.
62382256|NCT04083521|NO_INTERVENTION|Placebo|Subjects received a once daily dose of maltodextrin for 90-days.
62382257|NCT04249466||Patient with cystic fibrosis|
62382258|NCT03849092|EXPERIMENTAL|Financial incentive|3 municipalities will receive 120.000 DKK for financial incentives.
62382259|NCT03849092|EXPERIMENTAL|Campaigns|3 municipalities will receive 120.000 DKK for campaigns.
62382260|NCT03849092|NO_INTERVENTION|Control|"6 clean control municipalities perform their smoking cessation activities as usual. They wont receive any financial resources. These muncipalities have not been randomly selected but have been matched (by number of smokers attending the smoking cessation groups in the municipality in 2017, the year before the intervention). 3 of them are Campaing Control group and 3 are Finacial Incentives Control group."
62382261|NCT04282967|EXPERIMENTAL|Exercise|For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist (EP) for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.
62382262|NCT04735432|EXPERIMENTAL|efgartigimod PH20 SC|Patients receiving efgartigimod PH20 subcutaneous (SC) treatment
62382263|NCT04735432|EXPERIMENTAL|efgartigimod|Patients receiving efgartigimod intravenous (IV) treatment
62382264|NCT02730546|EXPERIMENTAL|Treatment (pembrolizumab, chemotherapy, radiation, surgery)|See Detailed Description
62382265|NCT01334463||mTBI+PTSD|History of active duty-related mild TBI and history of active duty-related PTSD
62382266|NCT01334463||mTBI Only|History of active duty-related mild TBI and no history of active duty-related PTSD
62382267|NCT01334463||PTSD Only|No history of active duty-related mild TBI and history of active duty-related PTSD
62382268|NCT01334463||No mTBI, No PTSD|No history of active duty-related mild TBI and no history of active duty-related PTSD
62382269|NCT01195636|EXPERIMENTAL|XPF-002|
62382270|NCT01195636|PLACEBO_COMPARATOR|Placebo|
62382271|NCT06351735||Surgery|Patients undergo deep cervical lymph node-vein bypass surgery
62382272|NCT03056209|EXPERIMENTAL|KL1333 25mg|Group 1
62382273|NCT03056209|EXPERIMENTAL|KL1333 50mg|Group 2
62382274|NCT03056209|EXPERIMENTAL|KL1333 100mg|Group 3
62382275|NCT03056209|EXPERIMENTAL|KL1333 200mg|Group 4
62762744|NCT05650138|EXPERIMENTAL|jacobson's progressive muscular relaxation technique|Questionnaire will be used as subjective measurements of activity of daily living and Bp will be monitored for initial readings. They will receive Jacobsons muscle relaxation technique. Patients will be demonstrated with the technique to contract and relax various groups of muscles, to coordinate contractions and relaxations with deep breaths and to perform the entire procedure with eyes closed in supine lying down position. Every subject will perform this supervised relaxation for 6 repetitions during a single session on once a day basis twice a week for four weeks. At the end of 4 weeks of treatment session blood pressure will be recorded questionnaire will be filled
62762745|NCT05650138|ACTIVE_COMPARATOR|30 min walk|4 weeks, twice a week, 30 minutes walk
62762746|NCT04126564|EXPERIMENTAL|IEO Intervention Group|The Group 1 is the active study group which receives the online mindfulness intervention first.
62762747|NCT04126564|ACTIVE_COMPARATOR|Control Group|Group 2 will be asked to read a book or journal of their choice for first 30 days, and then recieve online mindfulness intervention (IEO).
62762748|NCT05364736|EXPERIMENTAL|Highland barley β-glucan group|Participants will be given oral liquids mainly containing highland barley β-glucan once daily for 12 weeks followed by comprehensive physical and clinical examinations.
62762749|NCT05364736|PLACEBO_COMPARATOR|Placebo group|Participants will be given oral liquids mainly containing Corn starch once daily for 12 weeks followed by comprehensive physical and clinical examinations.
62762750|NCT03812185|OTHER|TEE image before and after suctioning orogastric tube|for intraoperative TEE used cardiac or transplant cases, TEE images will be stored before and after suctioning orogastric tube which is attached to TEE probe cover. This Arm is TEE image BEFORE suctioning.
62762751|NCT05081947|OTHER|Heart failure patients|patients will try the Compass intervention
62762752|NCT06268327|EXPERIMENTAL|cisplatin and gemicitabine|patients with triple negative breast cancer will recieve adjuvant cisplatin and gemicitabine in non pathological complete response after neo-adjuvant standard chemotherapy with dose of cisplatin 70mg/m2 at day one and gemicitabine 1000mg/m2 day one and day eight every 21 day for six cycle
62762753|NCT06268327|EXPERIMENTAL|capecitabine|patients with triple negative breast cancer will recieve adjuvant capecitabin in non pathological complete response after neo-adjuvant standard chemotherapy with dose of capecitabine 1000-1250 mg/m2 every 21 day for six cycle
62762754|NCT01390324|EXPERIMENTAL|Fixed-dose combination of naratriptan+naproxen|Fixed-dose combination of naratriptan+naproxen
62762755|NCT01390324|ACTIVE_COMPARATOR|Naratriptan|Naratriptan
62762756|NCT01390324|ACTIVE_COMPARATOR|Naproxen|Naproxen
62382276|NCT03056209|EXPERIMENTAL|KL1333 400mg|Group 5
62762757|NCT03165214|ACTIVE_COMPARATOR|coil group|micro coils
62762758|NCT03165214|EXPERIMENTAL|glue group|hystoacryl mixed with lipidol
62762759|NCT01659281|ACTIVE_COMPARATOR|1|2-day oral treatment with: Artesunate 6mg/kg at 0 and 24 hours Mefloquine 25 mg/kg total dose split into 2 doses of 15 mg/kg at 0 hours and and 10 mg/kg given 6-24 hours later Primaquine 0.5 mg/kg single dose at 24 hours
62382277|NCT03056209|EXPERIMENTAL|KL1333 600mg|Group 6
62382278|NCT03056209|EXPERIMENTAL|KL1333 800mg|Group 7
62762760|NCT01659281|ACTIVE_COMPARATOR|2|3 days oral treatment with: Artesunate 4 mg/kg/day for 3 days Mefloquine 8 mg/kg/day for 3 days Primaquine 0.5 mg/kg single dose at 24 hours
62762761|NCT03476616|ACTIVE_COMPARATOR|Eplerenone (-based therapy) arm|"Obese pts with hypertension, starting treatment with eplerenone 25mg twice daily (BD). ABPM wil be scheduled at wks 8, 16 and 24.~At wk 8 if mean ABPM \< 130/80mm Hg will continue to monotherapy with eplerenone. If not controlled (mean ABPM \> 130/80mm Hg) at wk8, amlodipine 5mg OD will be added.~At wk 16 if mean ABPM \< 130/80mm Hg will continue to monotherapy with eplerenone, or dual therapy with eplerenone and amlodipine. If not controlled (mean ABPM \> 130/80mm Hg) at wk16, indapamide 1,5mg OD will be added. All patients will be followed up for 24 weeks."
62762762|NCT03476616|ACTIVE_COMPARATOR|Valsartan (-based therapy) arm|"Obese pts with hypertension, starting treatment with valsartan 160mg once daily (OD). ABPM wil be scheduled at wks 8, 16 and 24.~At wk 8 if mean ABPM \< 130/80mm Hg will continue to monotherapy with valsartan. If not controlled (mean ABPM \> 130/80mm Hg) at wk8, amlodipine 5mg OD will be added.~At wk 16 if mean ABPM \< 130/80mm Hg will continue to monotherapy with valsartan, or dual therapy with valsartan and amlodipine. If not controlled (mean ABPM \> 130/80mm Hg) at wk16, indapamide 1,5mg OD will be added. All patients will be followed up for 24 weeks."
62382279|NCT04450862|EXPERIMENTAL|Intervention arm|Participants randomised to the intervention arm will receive a CBT informed, self-help intervention for anxiety in PH. This will be based on the four factor model, which is a trans-diagnostic approach to help understanding and identify behaviour change methods (Padesky \& Mooney, 1990).
62382280|NCT04450862|NO_INTERVENTION|Control arm|A waiting-list will be used as a control condition. If the self-management intervention is found to be acceptable and not associated with any risk, then participants in the control condition will receive the intervention.
62382281|NCT00945594|EXPERIMENTAL|Flexible cystoscopy|16F flexible cysto urethroscope (Storz, Culver city, CA)
62382282|NCT00945594|EXPERIMENTAL|Rigid cystoscopy|17F, 70° scope (Storz, Culver city, CA)
62382283|NCT03479541|EXPERIMENTAL|Physical Therapy (Early)|"Two sub-arms include Vestibular Rehabilitation  n=40, and Vestibular Rehabilitation with Home Monitoring n=40"
62382284|NCT03479541|EXPERIMENTAL|Physical Therapy (Standard of Care)|"Two sub-arms include Vestibular Rehabilitation  n=40, and Vestibular Rehabilitation with Home Monitoring n=40"
62382285|NCT02962102|EXPERIMENTAL|Calcifediol|Calcifediol 400mcg orally x 1, followed by 200mcg orally daily x 4
62382286|NCT02962102|EXPERIMENTAL|Calcitriol|Calcitriol 4mcg orally daily x 5 days
62382287|NCT02962102|PLACEBO_COMPARATOR|Placebo|Equal volume of medium chain triglyceride (MCT) oil orally daily x 5 days
62382288|NCT01287858|PLACEBO_COMPARATOR|Placebo|Placebo
62382289|NCT01287858|ACTIVE_COMPARATOR|AC430|AC430
62762763|NCT04143165|ACTIVE_COMPARATOR|Epidural block|Group I patients received caudal epidural injections with 1% lidocaine hydrochloride (xylocaine Astra Zeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
62762764|NCT04143165|NO_INTERVENTION|control group|patients did not receive injection
62762765|NCT05796115|ACTIVE_COMPARATOR|Antibiotic prophylaxis for EOS|
62762766|NCT05796115|EXPERIMENTAL|Procalcitonin/Presepsin guided antibiotic prophylaxis for EOS|
62762767|NCT00205543|EXPERIMENTAL|1|suture palate after resection
62762768|NCT00205543|EXPERIMENTAL|2|suture one side of palate afer resection
62762769|NCT00205543|EXPERIMENTAL|3|no sutures in palate after resection
62762770|NCT01636713|EXPERIMENTAL|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
62762771|NCT01636713|EXPERIMENTAL|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
62762772|NCT01636713|PLACEBO_COMPARATOR|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
62762773|NCT05351723|EXPERIMENTAL|Exercise + cognitive training + education|Intervention group: each session comprises (1) 50 min of physical exercise, (2) 20 min of break time or education on dementia and lifestyle habits, and (3) 50 min of cognitive training.
62762774|NCT05351723|OTHER|Education|Control group: education on dementia and lifestyle habits.
62762775|NCT04275609|EXPERIMENTAL|Artificial Intelligence generating endoscopic report|In this group, the endoscopic report was generated by artificial intelligence (AI) based on the structured diagnostic report generation system.
62762776|NCT04275609|ACTIVE_COMPARATOR|Physicians writing endoscopic report|In this group, the endoscopic report was writing by physicians.
62762777|NCT03461406|EXPERIMENTAL|Fibrin Sealant Grifols|Participants topically applied FS Grifols, which consisted of component 1: human fibrinogen (80 mg/mL) and component 2: human thrombin with calcium chloride (500 IU/mL) solutions filled in syringes and assembled on a syringe holder.
62762778|NCT03461406|ACTIVE_COMPARATOR|EVICEL|Participants topically applied EVICEL, which consisted of component 1: Concentrate of human fibrinogen (BAC 2) (55-85 mg/mL) and component 2: human thrombin (800-1200 IU/mL) solutions. The 2 components (BAC2 and thrombin) were mixed and applied topically.
62762779|NCT04114799|ACTIVE_COMPARATOR|Group A invasive haemodynamical measurement|No continuous infusion of fluids will be used intraoperatively. A defined amount of fluid (20 ml of Plasmalyte, Baxter) will be used to flush the anesthetics and other drugs only. Fluid bolus will be applied in case of protocol defined hypotension according to the value of systolic pressure variation SPV (Aisys GE). The value of SPV (tidal volume 6 ml/kg) above 8% will be used to predict fluid responsiveness. In case of fluid responsiveness, bolus of 2ml/kg of Plasmalyte will be given within 10 minutes. Boluses will be repeated in hypotensive patients if fluid responsiveness persists. Norepinephrine will be used in hypotensive patients without predicted fluid responsiveness.
62762780|NCT04114799|EXPERIMENTAL|Group B non-invasive haemodynamical measurement|No continuous infusion of fluids will be used intraoperatively. A defined amount of fluid (20 ml of Plasmalyte, Baxter) will be used to flush the anesthetics and other drugs only. Fluid management and the use of norepinephrine will follow a protocol based on the values of cardiac index level, systemic vascular resistance and systolic volume variation (SVV) (ClearSight, Edwards).
62762781|NCT01460407|EXPERIMENTAL|LY2216684 + Clarithromycin|Participants will receive a single 18-mg oral dose of LY2216684 on Days 1 and 10. Clarithromycin (500 mg) will be administered twice a day (BID) on Days 6 through 13.
62762782|NCT02534662|EXPERIMENTAL|Treatment Arm|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
62762783|NCT02657564|OTHER|Polyethylene glycol (PEG)|3-L polyethylene glycol (PEG) is provided for colonoscopy preparation. Patients receive blood tests for renal function and electrolytes before and after colonoscopy.
62762784|NCT03914248||Active large vessel vasculitis|PET/MR scan
62762785|NCT03724656|EXPERIMENTAL|acupuncture treatment|"Patients in the TAES treatment group received Transcutaneous Acupoint Electrical Stimulation(TAES) 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation."
62762786|NCT03724656|SHAM_COMPARATOR|Sham acupuncture treatment|"The control group was treated with non-acupoint shallow acupuncture method. The needle was inserted 5 cm beside the acupoint and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided."
62762787|NCT04827797|EXPERIMENTAL|birth ball|The positions and movements for birth ball in the active and latent phases: kneeling on the ground and leaning on the spherical birthing ball, sitting on the ball with front support, sitting positions on the spherical birthing ball, full rotation of hip, moving to the right/left, back and forth. Positions and movements were repeated every 30 minutes. The 30-minute intervals were interrupted in cases where the women were not feeling well.
62382290|NCT00601510|EXPERIMENTAL|Imatinib mesylate|Imatinib mesylate 300mg/day(maximum dose will be 800 mg) on day -4, -3, -2, -1, 1, 2, 3 through d21 in combination with capecitabine 1250 mg/m2 twice daily (d1-d14) and iv cisplatin 60mg/m2
62762788|NCT04827797|EXPERIMENTAL|peanut ball|The positions and movements for the pregnant women in peanut ball: upright sitting position, forward bending positions, with backward and forward movement and swaying right and left on the peanut ball
62762789|NCT01762267|ACTIVE_COMPARATOR|diet intervention, DASH diet|intervention: nutrition intervention: DASH diet
62762790|NCT01762267|NO_INTERVENTION|not intervention, control diet|control weight loss diet
62762791|NCT03430271|ACTIVE_COMPARATOR|Physical Activity (PA) Intervention|
62762792|NCT03430271|PLACEBO_COMPARATOR|Health Education (HE) Intervention|
62762793|NCT03974672||T drain|Patients treated with a T drain approach
62762794|NCT03974672||Stoma|Patients treated with a stoma
62762795|NCT02437786|EXPERIMENTAL|GRAZAX|GRAZAX
62762796|NCT03580824|EXPERIMENTAL|Group 1|Group 1 adults (n=20) will be administered 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the non-dominant arm). A booster dose will be administered at 9-25 months post 3rd dose.
62762797|NCT03580824|EXPERIMENTAL|Group 2|"Group 2A children 1-5 years (n=3) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 2B children 1-5 years (n=17) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid). A booster dose will be administered at 9-25 months post 3rd dose."
62762798|NCT03580824|EXPERIMENTAL|Group 3|"Group 3A infants 5-\<12 months (n=3) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3B infants 5-\<12 months (n=3) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3C infants 5-\<12 months (n=15) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3D infants 5-\<12 months (n=15) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3E infants 5-\<12 months (n=15) will be receiving 5mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~A booster dose will be administered at 9-25 months post 3rd dose."
62762799|NCT02833792|EXPERIMENTAL|Stem Cells|Stem cells
62382291|NCT05260476||Reablement group|"The home reablement program will be implemented by a physical therapist according to Long-term Care Reablement Operational Guidelines announced by the Ministry of Health and Welfare of Taiwanese government"
62382292|NCT05260476||Non-reablement group|This group will only receive general home care service without the reablement program.
62382293|NCT01315457||Alemtuzumab|Patients treated with alemtuzumab
62382294|NCT02742155|EXPERIMENTAL|Play2Sleep|For the experimental intervention, Play2Sleep consists of video-recording the mother and father separately while engaged in a structured play session. Immediately following the play session, the home visitor will review the video recording with each parent separately to provide positive feedback on parental behaviors that promotes contingent interaction and identification of infant cues. At the end of the visit, standard public health handouts on infant sleep will be provided to both parents.
62382295|NCT02742155|ACTIVE_COMPARATOR|Comparison|In the comparison group, only standard public health handouts on infant sleep will be reviewed with parents.
62382296|NCT00606931|EXPERIMENTAL|one arm|
62762800|NCT02833792|PLACEBO_COMPARATOR|Placebo|Lactated Ringer's Solution
62762801|NCT01359462|EXPERIMENTAL|Tolvaptan 15mg tablet|
62762802|NCT01509469|EXPERIMENTAL|Low dose casein|Ileal infusion of low dose casein
62762803|NCT01509469|EXPERIMENTAL|High dose casein|Ileal infusion of high dose casein
62762804|NCT01509469|EXPERIMENTAL|Low dose sucrose|Ileal infusion of low dose sucrose
62762805|NCT01509469|EXPERIMENTAL|High dose sucrose|Ileal infusion of high dose sucrose
62762806|NCT01509469|PLACEBO_COMPARATOR|Placebo|Ileal infusion saline
62762807|NCT01509469|ACTIVE_COMPARATOR|Safflower oil|Ileal infusion safflower oil
62762808|NCT06400732||Treatment Group|Participants treated for a limb defect with the Fitbone Transport and Lengthening System
62762809|NCT04472325||Atypical Parkinson's Disease patients|This group consists of patients includes 35 patients with Progressive Supranuclear Paralysis (PSP), 35 patients with Multiple System Atrophy (MSA), and 35 patients with Cortico-Basal Degeneration (CBD).
62382297|NCT04650685|EXPERIMENTAL|The novel Salvadora persica toothbrush|The novel toothbrush is under Al-Abyad Miswak brand that will be supplied by Insight Prestige Sdn Bhd. Participants are expected to use this oral hygiene tool for 3 weeks.
62762810|NCT04472325||Idiopathic Parkinson's Disease patients|This group consists of patients starting from 2012 to 2013 and includes 87 patients with typical Parkinson's Disease (PD)
62762811|NCT04472325||Healthy volunteers|"The 96 healthy volunteers should meet the following criteria:~1. Between 50-80 years old~2. Right-handed~3. MMSE score greater than or equal to 26~4. Able to understand study requirements and give informed consent"
62762812|NCT01224821|EXPERIMENTAL|Tositumomab and Iodine I-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
62762813|NCT05749653|OTHER|bi-annual CDTI|bi-annual CDTI with high coverage
62762814|NCT03452904|EXPERIMENTAL|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
62762815|NCT03452904|ACTIVE_COMPARATOR|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting stent
62762816|NCT05942794|EXPERIMENTAL|Screening examination|All patients will undergo a screening examination (with or without GOCCLES ® glasses) by all three operators.
62382298|NCT04650685|EXPERIMENTAL|The Salvadora persica (miswak) chewing sticks|The chewing sticks are under the brand of Al-Khair. They will be prepared into equal length of 15 cm with uniform diameter of 1.0-1.5 cm and are sealed in airtight plastic bags. Participants are expected to use this oral hygiene tool for 3 weeks.
62382299|NCT04650685|OTHER|Standard toothbrush and toothpaste (control)|Participants will be given straight-handle soft-bristle Oral-B™ standard toothbrush and Colgate® fluoride tooth. Participants are expected to use this oral hygiene tool for 3 weeks.
62382300|NCT03813576|OTHER|All participants|Only 1 arm in the study. All women will undergo both self-collected swab and clinician-collected swab
62182575|NCT01617798|PLACEBO_COMPARATOR|Control-- furosemide (lasix) only|"Control arm receives standard of care diuresis with furosemide(lasix)only. The treatment team will decide the dosing of furosemide (lasix).~No actual placebo is administered."
62762817|NCT05531721||pediatric patients affected by hemophagocytic lymphohistiocytoses|pediatric patients with HLH
62762818|NCT01077180|EXPERIMENTAL|Rheos Device|
62762819|NCT01077180|ACTIVE_COMPARATOR|Medical Management|
62762820|NCT05593614|EXPERIMENTAL|ATX01 10%|A bottle of hydrogel formulation containing 10% amitriptyline hydrochloride w/w for topical use on the hands and/or feet, morning and night for 3 months.
62762821|NCT05593614|EXPERIMENTAL|ATX01 15%|A bottle of hydrogel formulation containing 15% amitriptyline hydrochloride w/w for topical use on the hands and/or feet, morning and night for 3 months.
62762822|NCT05593614|PLACEBO_COMPARATOR|ATX01 Placebo|A bottle of hydrogel formulation containing no active ingredient, for topical use on the hands and/or feet, morning and night for 3 months.
62762823|NCT02525094|EXPERIMENTAL|MEDI9929 280 mg|Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
62762824|NCT02525094|PLACEBO_COMPARATOR|Placebo|Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
62762825|NCT05764031|EXPERIMENTAL|Clinical pilates group|The clinical pilates group received a total of 40 min of exercise training, including 5 min of warm-up exercises, 30 min of clinical pilates exercises and 5 min of cooldown exercises. Clinical Pilates training was performed as group sessions under the supervision of a physiotherapist Exercise training was provided to the clinical pilates group 2 days a week over a period of 8 weeks.
62382301|NCT00818636|EXPERIMENTAL|Expressive Writing|In addition to attending group therapy as usual, participants write about their feelings about an issue of their choosing three times during a two week period for at least 20 minutes each time.
62382302|NCT00818636|ACTIVE_COMPARATOR|Treatment as Usual|Participants attend group therapy as usual only.
62382303|NCT01741584|EXPERIMENTAL|stationary bike exercise|6 months of exercise (60% of anaerobic threshold)
62382304|NCT01741584|PLACEBO_COMPARATOR|aerobic|6 months of exercise \<30% anaerobic threshold
62382305|NCT04262674|EXPERIMENTAL|Cognitive-motor training|Simultaneous cognitive-motor training (i.e. exergame) and strength training
62382306|NCT04262674|NO_INTERVENTION|Control|Passive control group
62382307|NCT02537275|EXPERIMENTAL|wearing contact lense group|normal subjects after wearing tinted/normal contact lenses
62382308|NCT03075865||OmniMax MMF|Patients involved in trauma events will receive intermaxillary fixation with OmniMax MMF system for temporary stabilization of mandibular fracture(s) to maintain proper occlusion during surgery and allow for postoperative fracture healing.
62382309|NCT05608694|OTHER|High Risk- Positive Germline Mutation (n=40):|Men who harbor known germline mutations that have been associated with an increased risk of prostate cancer and aggressive disease (e.g. BRCA2, ATM, PALB2, etc.) with or without a known family history of prostate cancer.
62382310|NCT05608694|OTHER|High Risk- High GRS (n=40):|Men who harbor significantly increased disease risk based upon genetic risk score (GRS) value \>1.5 with or without a known family history of prostate cancer.
62382311|NCT05608694|OTHER|High Risk- Family History (n=45):|Men with a family history of prostate cancer in at least one sibling, father, uncle, or grandfather but no known increased genetic risk of prostate cancer (has no pathogenic or likely pathogenic mutation along with a low genetic risk score (GRS\<1.5).
62382312|NCT05608694|OTHER|Low Risk (n=125):|No known germline mutation, low genetic risk score (GRS \<1.5), and no known family history of prostate cancer.
62382313|NCT01594489|EXPERIMENTAL|Aminophylline|Additional Aminophylline therapy to hydration (sodium bicarbonate) and N-acetilcysteine
62382314|NCT01594489|ACTIVE_COMPARATOR|Control group|Control group treated with hydration (sodium bicarbonate) and N-acetilcysteine
62382315|NCT05669144|EXPERIMENTAL|exosome therapy|"a) Intracoronary and intra-myocardial injection of exosomes (5 patients)~1 mL of exosomes containing 100 micrograms of exosomes"
62382316|NCT05669144|EXPERIMENTAL|mitochondria therapy|"b) Intracoronary and intra-myocardial injection of mitochondria (5 patients)~1 mL of exosomes containing 10 million mitochondria"
62382317|NCT05669144|EXPERIMENTAL|co-transplantation of mitochondria and exosome therapy|"c) co-transplantation Intracoronary and intra-myocardial injection of exosomes and mitochondria (5 patients)~1 mL of exosomes containing 100 micrograms of exosomes~1 mL of exosomes containing 10 million mitochondria"
62382318|NCT05669144|PLACEBO_COMPARATOR|placebo|1 mL of placebo solution
62382319|NCT01349491|EXPERIMENTAL|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated.
62382320|NCT01349491|PLACEBO_COMPARATOR|Placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion.
62382321|NCT00654056|EXPERIMENTAL|L1|Actrapid infusion, 0.5 mU/kg/min.
62382322|NCT00654056|EXPERIMENTAL|L2|Actrapid infusion 1.5 mU/kg/min
62382323|NCT00654056|EXPERIMENTAL|H1|Actrapid infusion 3.0 mU/kg/min
62382324|NCT00654056|EXPERIMENTAL|H2|Actrapid infusion 5.0 mU/kg/min
62382325|NCT05859776|EXPERIMENTAL|Low Dose|AXT107 0.125 mg/eye
62382326|NCT05859776|EXPERIMENTAL|Mid Dose|AXT107 0.250 mg/eye
62382327|NCT05859776|EXPERIMENTAL|High Dose|AXT107 0.500 mg/eye
62382328|NCT02197351|EXPERIMENTAL|Gastric Symptoms|Patients with gastric symptoms including dyspepsia undergoing upper endoscopy will undergo white light biopsy narrow band imaging guided biopsy protocolled biopsy
62382329|NCT05779176|NO_INTERVENTION|Normothermia arm|Patients randomized to normothermia will be maintained at 36-37°C during the entire study period.
62382330|NCT05779176|EXPERIMENTAL|Therapeutic hypothermia arm|Patients assigned to TH will receive intravascular temperature management to achieve the target temperature of 34-35 °C
62382331|NCT00748176||A|
62382332|NCT06160362|EXPERIMENTAL|double-target CART-19 and 20|Patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of double-target CART-19 and 20 cells. The double-target CART-19 and 20 cells are to be administered on day0.
62382333|NCT01563224|EXPERIMENTAL|single group, crossover, 3 interventions|
62382334|NCT03737344|ACTIVE_COMPARATOR|IL-1Ra Kineret®|100mg doses of the trial drug Kineret® will be administered subcutaneously (SC) twice daily (12 hourly) starting within 8 hours of symptoms onset for a maximum of 3 days from symptoms onset (or sooner if discharged from neurosurgical centre).
62382335|NCT03737344|PLACEBO_COMPARATOR|IL-1Ra Placebo|100mg doses of the placebo will be administered subcutaneously (SC) twice daily (12 hourly) starting within 8 hours of symptoms onset for a maximum of 3 days from symptoms onset (or sooner if discharged from neurosurgical centre).
62382336|NCT05993455|EXPERIMENTAL|Oral sotorasib + IV Panitumumab|Oral sotorasib at a dose of 960 mg once daily with Panitumumab is administered intravenously (IV) at a dose of 6 mg/kg every 14 days, infused over 60 minutes (≤ 1,000 mg) or 90 minutes (\> 1,000 mg).
62382337|NCT00952471|NO_INTERVENTION|Baseline Period|Patients in the baseline period were cared for using the standard historical electronic order set.
62382338|NCT00952471|ACTIVE_COMPARATOR|Post Intervention Period|Patients in the Post intervention period were cared for with evidence-bsed modified order set changes
62382339|NCT04173910||LPEC/Sellick ultrasound|
62382340|NCT04953663|EXPERIMENTAL|Low dose group|0.5 × 10 \^ 6 / kg (body weight) of it-hMSC per person
62382341|NCT04953663|EXPERIMENTAL|Middle dose group|1 × 10 \^ 6 / kg (body weight) of it-hMSC per person
62382342|NCT04953663|EXPERIMENTAL|High dose group|2 × 10 \^ 6 / kg (body weight) of it-hMSC per person
62382343|NCT04953663|EXPERIMENTAL|Highest dose cell group|Highest dose of it-hMSC
62382344|NCT04953663|EXPERIMENTAL|Sub high dose cell group|Sub high dose of it-hMSC
62382345|NCT04953663|PLACEBO_COMPARATOR|placebo group|placebo
62382346|NCT01676649|EXPERIMENTAL|A|Arm A: Carboplatin (week 1, week 4, week 7, week 10, and week 13) Paclitaxel (week 1, week 4, week 7, week 10, and week 13) Ipilimumab (week 4, week 7, week 10, and week 13)
62182576|NCT01617798|ACTIVE_COMPARATOR|Study Arm|Study arm receives evolving standard of care diuresis with furosemide and metolazone.
62182577|NCT04699097||azytromycin|children who recieved azithromycin due to COVID 19 infection
62382347|NCT01676649|EXPERIMENTAL|B|Carboplatin (week 1, week 4, week 7, week 10, and week 13) Paclitaxel (week 1, week 4, week 7, week 10, and week 13) Ipilimumab (week 5, week 8, week 11, and week 14)
62382348|NCT06228365|ACTIVE_COMPARATOR|usual neuroleptanalgesic treatment|- Group 1: local anaesthesia by tumescence + neuroleptanalgesia
62382349|NCT06228365|EXPERIMENTAL|use of a device incorporating virtual reality software|- Group 2: local anaesthesia by tumescence with virtual reality software
62382350|NCT03170765|EXPERIMENTAL|GROUP A|measles vaccine at 6 months and 9 months of age
61987833|NCT01969812|EXPERIMENTAL|Evie Slow-Release Insemination Device|Preliminary studies in Europe have shown increased pregnancy rates using slow-release insemination. Evie slow-release insemination device is a device that is FDA approved. This device has been used in Europe, it has not yet been used at Carolinas Medical Center, by the Women's Institute. The technique for using this device involves loading a pump syringe with the prepared sperm, placing a balloon-secured catheter and syringe in the patient's sounded uterus, and connecting the insemination syringe to the catheter. The slow-release insemination occurs for 4 hours after the insertion of the catheter. The removal procedure, which can be performed by the patient if desired, involves deflating the catheter balloon and removing the catheter.
61987834|NCT01969812|ACTIVE_COMPARATOR|Traditional Intrauterine Insemination|Traditional IUI is one of the treatment modalities for infertility that allows sperm to bypass the cervix and shortens the distance to the fallopian tubes for fertilization. The pregnancy rates for IUI with clomiphene citrate for couples with relatively unexplained infertility have been found to be 7.6% (for women 21-39 years old with up to 3 cycles of IUI with clomiphene).
62382351|NCT03170765|EXPERIMENTAL|GROUP B|measles vaccine at 7.5 months and 9 months of age
62382352|NCT03170765|ACTIVE_COMPARATOR|GROUP C|measles vaccine at 9 months of age (current practice)
62382353|NCT04919135|EXPERIMENTAL|Treatment (UC-MSC trasnplatation)|1.5 x 10\^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication
61987835|NCT01094496|EXPERIMENTAL|CDX-1307 Vaccine Regimen|Chemotherapy with CDX-1307 vaccine regimen (neoadjuvant phase), followed by bladder removal surgery (cystectomy). CDX-1307 vaccine regimen will continue to be given for up-to 1 year post-surgery (adjuvant/long-term follow-up phase).
62382354|NCT04919135|OTHER|control arm|standard frailty treatment and supplementary medication
62382355|NCT05310006|EXPERIMENTAL|High Speed Resistance Exercise (HSRE)|Exercise sessions performed using eight times (sets) with 4-5 repetitions at 70-75% of the maximal strength. The concentric phase was performed as fast as possible, and the eccentric phase was carried out for 2 s.
62382356|NCT05310006|EXPERIMENTAL|Traditional Resistance Exercise (TRE)|Exercise sessions were performed using four sets of 8-10 repetitions at 70-75% of the maximal strength. The concentric and eccentric phases were carried out for 2 s.
62382357|NCT05310006|NO_INTERVENTION|Control Session (CS)|Participants remained seated in a comfortable chair listening to music and/or talking with study investigators for approximately 30 min.
62382358|NCT01202643|EXPERIMENTAL|G-CSF|G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation
62382359|NCT01202643|PLACEBO_COMPARATOR|Saline|Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation
62382360|NCT00089505|EXPERIMENTAL|NVP/NVP|For participants who had SD NVP exposure prior to study entry. FTC, TDF, and NVP daily the first 14 days, then twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV twice daily plus two more NRTIs.
62382361|NCT00089505|EXPERIMENTAL|NVP/LPV_r|For participants who had SD NVP exposure prior to study entry. FTC and TDF daily and LPV/RTV twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily for 14 days before taking it twice daily. plus 2 more NRTIs.
62382362|NCT00089505|EXPERIMENTAL|NoNVP/NVP|For participants who did NOT have SD NVP exposure prior to study entry.FTC, TDF, and NVP daily the first 14 days, then twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV twice daily plus two more NRTIs.
62382363|NCT00089505|EXPERIMENTAL|NoNVP/LPV_r|For participants who did NOT have SD NVP exposure prior to study entry. FTC and TDF daily and LPV/RTV twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily for 14 days before taking it twice daily. plus 2 more NRTIs.
62382364|NCT02439866|PLACEBO_COMPARATOR|prescription placebo|control Group consisted of 30 patients who received gelatinous capsules filled with sugar as placebo
62382365|NCT02439866|ACTIVE_COMPARATOR|prescription Intravenous methylprednisolone|Group 2 or steroid consisted of 30 patients received methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day
62762826|NCT05764031|EXPERIMENTAL|Aerobic exercise group|The aerobic exercise group received a total of 40 min of aerobic exercise training, including 5 min of warm-up exercises, 30 min of aerobic cycling exercise and 5 min of cooldown exercises. Aerobic exercises were performed individually under the supervision of a physiotherapist. Aerobic exercises were performed using an upright bike (HS-1200; Hattrick-Pro, Istanbul, Turkey). The exercises were planned as moderate-intensity exercises, at 60-70% of the maximum heart rate (MHR). Exercise training was provided to the aerobic exercise group 2 days a week over a period of 8 weeks.
62382366|NCT02439866|ACTIVE_COMPARATOR|prescription normobaric oxygen with face mask|Thirty patients in group 3 or oxygen received 100% normobaric oxygen with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
62382367|NCT00392210|NO_INTERVENTION|Spontaneous Fill|
62762827|NCT03002454|EXPERIMENTAL|99mTc MDP Injection:neutron-bombardment|Oncologic indication for which a bone scan would normally be indicated. Participant having recently had a bone scan using Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from fission-sourced 99Mo. The images of the 99mTc MDP Injection-neutron-bombardment will be compared to the previous (on file) images from the 99mTc MDP Injection-fission
62762828|NCT01628861|ACTIVE_COMPARATOR|education only|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet with the same message is also provided.
62382368|NCT00392210|ACTIVE_COMPARATOR|Retrograde Fill|
62382369|NCT04787744|ACTIVE_COMPARATOR|Standard Systemic Therapy (SST)|All Veterans will receive SST (if De novo, Veterans will receive prostate-directed radiation).
62382370|NCT04787744|EXPERIMENTAL|SST + PET-directed local therapy|In addition to SST, all Veterans will receive PET-directed local therapy to all metastases using surgery or radiation. If De novo, Veterans will also receive prostate-directed radiation or radical prostatectomy to treat the prostate/prostate bed. The best course of treatment will be determined using shared decision-making between the physician and Veteran.
62762829|NCT01628861|EXPERIMENTAL|prompt + education|"A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet with the same message is also provided. Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
62762830|NCT06330155||Alzheimer's dementia patient and healthy subjects|
62762831|NCT05577364|EXPERIMENTAL|Selinexor in Combination With R-CHOP|"Patients with untreated EBV-positive diffuse large B-cell lymphoma will receive sequentially higher doses of selinexor in combination with R-CHOP regimen from the second cycle of R-CHOP (3 weeks per cycle).The initial dose of selinexor is 40mg qw po.~After 8 cycles of induction therapy, if the response is assessed as complete remission (CR), maintenance therapy with selinexor will be conducted."
62762832|NCT03419390|OTHER|Healthy subjects|One eye of each participant will be scanned with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
62762833|NCT03419390|OTHER|Diseased groups|lf one eye is affected, this will be chosen. lf both eyes are be affected, the eye with the severest symptoms will be chosen. Scanning with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
62762834|NCT03419390|OTHER|Diseased subgroups|"Every second subject will be allocated to the subgroup.~1. Scanning with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)~2. Thickness measurement with reference medical device."
62762835|NCT03738007|EXPERIMENTAL|HA IDF II|
62762836|NCT03738007|ACTIVE_COMPARATOR|Perlane|
62762837|NCT01303302|ACTIVE_COMPARATOR|GCM stimulation|The patient will be implanted with a gastric contractility modulation (GCM) stimulation system using the TANTALUS System for treatment of type 2 diabetic patients.
62762838|NCT01303302|SHAM_COMPARATOR|Device off|The TANTALUS System is implanted but is off
62762839|NCT01100528|EXPERIMENTAL|Arm I|Patients receive dacarbazine IV on days 1 and 29. Beginning 4 weeks after the second dose of dacarbazine, patients receive recombinant interferon alfa-2b subcutaneously 3 times a week for 24 weeks in the absence of disease progression or unacceptable toxicity.
62762840|NCT00868673|ACTIVE_COMPARATOR|Low fructose arm|"Overweighted or obese previously healthy adults (with no other comorbidities, defined as: Diabetes (DM1 or DM2), hypertension, chronic kidney disease (CKD), hepatic damage, dyslipidemia medication, anemia, malignancy or pregnancy), with a Body Mass Index (BMI) of \>25 kilograms(weight)/ squared meters (height).~They will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and rest energy (without exercise).~This group will be assigned to a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of less than 20 grams/day fructose diet levels.~Total Time of intervention 6 weeks for each patient"
62382371|NCT01392079|EXPERIMENTAL|Alemtuzumab|"30 mg alemtuzumab will be administered subcutaneously 3 times weekly for 4 weeks (total of 12 doses of 30 mg alemtuzumab) with premedication (as needed) and infection prophylaxis; combined with oral dexamethasone 40 mg total dose for 4 days every 2 weeks; evaluation at end of cycle (i.e. after 12 doses of 30 mg alemtuzumab).~If CR is documented after week 4 (12 doses of 30 mg alemtuzumab) or 8 (24 doses of 30 mg alemtuzumab), maintenance treatment with alemtuzumab or withdrawal from the study and stem cell transplantation will be instituted at this time point.~After a maximum of three 4-week cycles (total of 36 doses of 30 mg alemtuzumab, in case of interruptions this may take longer than 12 weeks), maintenance treatment with alemtuzumab or withdrawal from the study and stem cell transplantation will be instituted. Maintenance treatment with alemtuzumab will continue for a maximum of two years, with evaluation every three months, unless there is PD."
62382372|NCT00147082||COPD|Patients with COPD - no intervention
62762841|NCT00868673|ACTIVE_COMPARATOR|Normal fructose arm|"Overweighted or obese previously healthy adults (with no other comorbidities; defined as: Diabetes Mellitus (DM1 or DM2), hypertension, chronic kidney disease (CKD), hepatic damage, dyslipidemia medication, anemia, malignancy or pregnancy), with a Body Mass Index (BMI) of \>25 kilograms(weight)/ squared meters (height).~Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet (of 15% proteins, 30% lipids and 55% carbohydrates); calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise).~This group will receive a controlled fructose diet between 50 and 70 grams/day of fructose intake.~Total time of intervention:6 weeks for each patient"
61987836|NCT02596269|EXPERIMENTAL|Nefopam(NF) group|Received i.v. PCA with the same volume of solution containing 1250 µg fentanyl plus 120 mg of nefopam in normal saline (fentanyl 12.5 µg/ml and nefopam 1.2 mg/ml).
62382373|NCT00147082||Smokers without COPD|Smokers without COPD - no intervention
62382374|NCT00147082||Non-smokers|Non-smokers with no history of respiratory disease - no intervention
62762842|NCT04534907|ACTIVE_COMPARATOR|VR(ERP）|The combination of exposure and response prevention (ERP) and VR will be applied twice a week for the fist two weeks. For the next four weeks, this treatment will be applied once a week. 8 times in total
62762843|NCT04534907|ACTIVE_COMPARATOR|traditional ERP|The traditional ERP will be applied twice a week for the fist two weeks. For the next four weeks, this treatment will be applied once a week. 8 times in total
62762844|NCT05407961|EXPERIMENTAL|LY3532226 + Dulaglutide (Part A)|LY3532226 administered subcutaneously (SC) followed by dulaglutide administered SC.
62762845|NCT05407961|PLACEBO_COMPARATOR|Placebo + Dulaglutide (Part A)|Placebo administered SC followed by dulaglutide administered SC.
62762846|NCT05407961|ACTIVE_COMPARATOR|Dulaglutide + Placebo (Part B)|Dulaglutide administered SC in combination with placebo given SC.
61987837|NCT02596269|PLACEBO_COMPARATOR|Saline(SF) group|Received i.v. PCA with 100 ml solution containing 1250 µg of fentanyl in normal saline (12.5 µg/ml),
61987838|NCT01163279|EXPERIMENTAL|Cognitive Training|
61987839|NCT01163279|ACTIVE_COMPARATOR|Psychosocial Education|
61987840|NCT01487590|ACTIVE_COMPARATOR|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
62382375|NCT00934791|ACTIVE_COMPARATOR|Control Group|Tacrolimus, mycophenolate mofetil, and prednisone
62382376|NCT00934791|ACTIVE_COMPARATOR|Sirolimus Group|Sirolimus, mycophenolate mofetil, and prednisone
62382377|NCT05734144|ACTIVE_COMPARATOR|"Laparo-endoscopic rendezvous technique"|the first group was treated by a single-step procedure combining LC and IOES
62382378|NCT05734144|OTHER|POES followed by LC|the second (control) group was treated by 2-stage (sequential treatment) POES followed by LC.
62762847|NCT05407961|EXPERIMENTAL|LY3532226 + Dulaglutide (Part B)|LY3532226 administered SC in combination with Dulaglutide given SC.
62382379|NCT06100367|EXPERIMENTAL|11C-metomidate PET-CT|All patients will undergo standard-of-care investigations (CT imaging of adrenals and AVS) and the research test (11C-metomidate PET-CT) with a dose of 100 - 300 Megabecquerel (MBq) (11C-metomidate) to identify functional unilateral adrenal disease
62762848|NCT05407961|EXPERIMENTAL|LY3532226 + Placebo (Part B)|LY3532226 administered SC in combination with placebo given SC.
62762849|NCT00605553|EXPERIMENTAL|1|Active medication Tozadenant 20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
62762850|NCT00605553|PLACEBO_COMPARATOR|2|Crossover from arm 1 to arm 2 with one week washout. One of the arms is placebo control
62762851|NCT03734068||Chemoembolization|Chemoembolization Using LifePearl and Doxorubicin
62762852|NCT04353219|EXPERIMENTAL|research group|training program with compression stocking
62382380|NCT05495009|NO_INTERVENTION|Standard of care|Introductory information form (IIF), labor follow-up form (FFL) and VAS-P, VAS-A were filled in the latent phase (1-3 cm). At the beginning of the active (4 cm) and transitional phases (8 cm), FFL, VAS-P and VAS-A were filled and no intervention was applied. 20 min in active phase. then, FFL, VAS-P and VAS-A were filled after 10 min in the transition phase. The Perception of Birth Scale is filled after birth.
62382381|NCT05495009|EXPERIMENTAL|Standard of care+ virtual reality glasses|Introductory information form (IIF), labor follow-up form (FFL) and VAS-P, VAS-A were filled in the latent phase (1-3 cm). At the beginning of the active (4 cm) and transitional phases (8 cm), after filling FFL, VAS-P and VAS-A, video was watched with virtual reality glasses. 20 minutes in active phase after watching the video. then, FFL, VAS-P and VAS-A were filled after 10 min in the transition phase. After the birth, the Perception of Birth Scale and Virtual Reality Satisfaction Form were filled.
62382382|NCT03603340|EXPERIMENTAL|Intervention group|
62382383|NCT03603340|ACTIVE_COMPARATOR|Control group|
62382384|NCT02865772||observational|healthy newborns
62382385|NCT05488028|EXPERIMENTAL|Piezosurgery|Patients needing lower third molar surgery, in which the osteotomy is performed by the use of a piezo-electric instrument
62382386|NCT05488028|EXPERIMENTAL|Conventional bur|Patients needing lower third molar surgery, in which the osteotomy is performed by the use of a drilling bur
62382387|NCT04516629||Experimental|subjects with sub-health status
62382388|NCT00554424|ACTIVE_COMPARATOR|LA|Intravaginal and pre-peritoneal injection of 1% lignocaine into each side of the upper vagina under ultrasound guidance immediately prior to ultrasound guided transvaginal oocyte retrieval
62382389|NCT00554424|PLACEBO_COMPARATOR|P|Intravaginal saline placebo injection into each side of upper vagina under ultrasound guidance immediately prior to transvaginal oocyte retrieval
62382390|NCT00886314|ACTIVE_COMPARATOR|midazolam|
62382391|NCT00886314|ACTIVE_COMPARATOR|clown doctor|
62382392|NCT05950373|EXPERIMENTAL|Intervention group|"The Intervention group will get access to a six-minute long education video five days after being discharges from the hospital. The video is focusing on protein and energy meals for older adults.~The educational film is available via a link on a tablet/ computer or mobile phone.~The education video vil only be given one time."
62382393|NCT05950373|NO_INTERVENTION|Control group|The control group will not be given any intervention.
62382394|NCT04411472|EXPERIMENTAL|active|recombinant human alkaline phosphatase 1.6mg/kg 3 daily 1 hour infusions
62382395|NCT04411472|PLACEBO_COMPARATOR|placebo|matching placebo
62382396|NCT00748449|ACTIVE_COMPARATOR|1|CT Colonography
62382397|NCT00748449|ACTIVE_COMPARATOR|2|Colonoscopy
62382398|NCT04081740||Asthma|The patients included in this group will have asthma, as specified in the inclusion criteria.
62382399|NCT04081740||COPD|The patients included in this group will have COPD, as specified in the inclusion criteria.
62382400|NCT04081740||Bronchiectasis|The patients included in this group will have bronchiectasis, as specified in the inclusion criteria.
61987841|NCT01487590|PLACEBO_COMPARATOR|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
61987842|NCT02344680||Adults with HIV-HBV co-infection|Adults with HIV-HBV co-infection who are receiving antiretroviral therapy
62382401|NCT03696498|EXPERIMENTAL|Partial caries excavation (1 step)|"Patients with radiographical caries within the pulpal ¼ of the dentine with the presence of a radiodense zone separating the pulp from the demineralised dentine is candidates for the treatment. Local anaesthesia shall be used. as this procedure is identical for the two interventions tested in this trial. A partial removal of carious dentine is performed with superficial removal of the outermost infected and necrotic part of the demineralised dentine.~Intervention: A permanent resin restoration is placed on top of the remained caries."
62382402|NCT03696498|ACTIVE_COMPARATOR|Partial caries excavation (2 steps)|"Patients with radiographical caries within the pulpal ¼ of the dentine with the presence of a radiodense zone separating the pulp from the demineralised dentine is candidates for the treatment. Before randomisation, the participants receive the first excavation procedure as this procedure is identical for the two interventions tested in this trial. A partial removal of carious dentine is performed with superficial removal of the outermost infected and necrotic part of the demineralised dentine.~Intervention: After randomisation, a calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months, the temporary restoration is removed, final excavation is carried out with hand excavators until firm but stained dentine remains, and a permanent resin restoration is placed."
62382403|NCT05193292|EXPERIMENTAL|Camrelizumab combined with trastuzumab and chemotherapy|Camrelizumab: 200mg, iv, 21d for a treatment cycle Trastuzumab: 8 mg/kg loading dose, followed by 6 mg/kg maintenance, iv, 21d for a treatment cycle Chemotherapy will either be XELOX, mFOLFOX6, FOLFIRI, mXELIRI or mIRIS
62382404|NCT02532829||GROUP NS-A|Healthy Participants: No known disease, no previous surgery, HbA1c\<5.7%, BMI\<25 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
62762853|NCT04353219|ACTIVE_COMPARATOR|control group|training program without compression stocking
62762854|NCT01760473|EXPERIMENTAL|Bup 8|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally.
62762855|NCT01760473|EXPERIMENTAL|Bup 16|Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally.
62762856|NCT01760473|EXPERIMENTAL|Bup/Nal 8/2|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 2 mg of Naloxone.
62762857|NCT01760473|EXPERIMENTAL|Bup/Nal 8/8|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 8 mg of Naloxone.
62182578|NCT04421313|EXPERIMENTAL|Rhumatoid Arthritis|The patients with Rheumatoid arthritis receive 12 g/day of INULIN or 10,5g/day of maltodextrine during 30 days
62382405|NCT02532829||GROUP NS-B|Obese, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI\>30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
62382406|NCT02532829||GROUP NS-C|Non-obese, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI\<30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
62382407|NCT02532829||GROUP NS-D|Obese non-diabetic: HbA1c\<5.7%, No signs and history of T2D, and BMI\>30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
62762858|NCT01760473|EXPERIMENTAL|Bup/Nal 8/16|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 16 mg of Naloxone.
62762859|NCT01760473|EXPERIMENTAL|Bup/Nal 16/4|Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally with 4 mg of Naloxone.
62762860|NCT01760473|ACTIVE_COMPARATOR|Heroin|Intranasal challenge drug: 24 mg of heroin administered intranasally.
61987843|NCT01556581|ACTIVE_COMPARATOR|Usual Care (UC)|The usual care (UC) group will be managed with stepped care approach, receiving a screening exam, advice, education, activity limitation profile and medications if needed, but no early physical therapy.
61987844|NCT01556581|ACTIVE_COMPARATOR|Early Physical Therapy (PT)|All subjects in this group will get usual care approach in addition to immediately receiving eight sessions of physical therapy based on a pragmatic treatment based classification system for treating low back pain.
62382408|NCT02532829||Group SG|Type 2 Diabetic participants who underwent a sleeve gastrectomy, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
62382409|NCT02532829||Group MGB|Type 2 Diabetic participants who underwent a mini-gastric bypass, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
62382410|NCT02532829||Group IT|Type 2 Diabetic participants who underwent a sleeve gastrectomy with ileal transposition, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
62382411|NCT02532829||Group TB|Type 2 Diabetic participants who underwent a sleeve gastrectomy with transit bipartition, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
62382412|NCT01128855|EXPERIMENTAL|Cohort 1|3 mg/kg GSK2402968 / placebo
62382413|NCT01128855|EXPERIMENTAL|Cohort 2|6 mg/kg GSK2402968 / placebo
62382414|NCT01128855|EXPERIMENTAL|Cohort 3|9 mg/kg GSK2402968 / placebo
62382415|NCT01128855|EXPERIMENTAL|Cohort 4|12 mg/kg GSK2402968 / placebo
62382416|NCT02971449|EXPERIMENTAL|Tablets only|100 VHTs will receive Amazon Fire Tablets with pre-loaded instructional videos; this is the intervention arm since this involves introduction of a new technology to this realm
62382417|NCT02971449|ACTIVE_COMPARATOR|ICCM traditional training|100 VHTs will receive traditional 1 day 'in-person' training as an active comparator intervention, but participants in this arm will not receive any tablets
62382418|NCT04449614||1|"Inclusion criteria: All consenting Infants and children who have had A Congenital Pulmonary Airway Malformation (CPAM) surgically removed by thoracoscopy over a 10 year period (2008-2017) in a regional centre.~Exclusion criteria: Non consenting participants"
62382419|NCT04601779|OTHER|Cluster I|Cluster I is randomized to start the VIPP-PUF intervention phase May 1, 2022
62382420|NCT04601779|OTHER|Cluster II|Cluster II is randomized to start the VIPP-PUF intervention phase November 1, 2022
62382421|NCT04601779|OTHER|Cluster III|Cluster IiI is randomized to start the VIPP-PUF intervention phase March 1, 2023
62382422|NCT01935284||Healthy Volunteers|
62382423|NCT00779233|EXPERIMENTAL|1|Zidovudine tablets 300 mg of Ranbaxy
62382424|NCT00779233|ACTIVE_COMPARATOR|2|RETROVIR ® 300 mg tablets (GlaxoSmithKline)
62382425|NCT04502394|EXPERIMENTAL|Cohort 1 (R/R DLBCL)|"KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.~Acalabrutinib at 100 mg twice a day (BID) continuously starting on Day 1 in a 28-day cycle."
62382426|NCT04502394|EXPERIMENTAL|Cohort 2 (R/R CLL)|"KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.~Acalabrutinib at 100 mg twice a day (BID) continuously starting on Day 1 in a 28-day cycle."
62762861|NCT01760473|SHAM_COMPARATOR|Placebo|Intranasal challenge drug: Intranasal lactose powder.
61987845|NCT05337215|ACTIVE_COMPARATOR|Control group|While the IIF was applied to control group at the first meeting in the postpartum ward, FIAS was administered by phone or home visit in the third month after the face-to-face interview.There was any intervention for this group
62382427|NCT01371799|EXPERIMENTAL|Study drug at 4mg|GSK1034702 at 4mg
62762862|NCT01760473|ACTIVE_COMPARATOR|Naloxone 4 mg|Intranasal challenge drug: Intranasal Naloxone 4mg.
62762863|NCT06344572|EXPERIMENTAL|SAT-001|SAT-001(Software as Medical Device)+single vision spectacles
62762864|NCT06344572|ACTIVE_COMPARATOR|Single vision spectacles|Wearing single vision spectacles
62762865|NCT02696408|EXPERIMENTAL|Laser treatment|preventive treatment performed by nurses of mucositis by laser treating daily by scanning the entire oral cavity for 2 minutes with a power of 250 mW associated with mouthwashes several times a day (standard preventive treatment of mucositis)
62762866|NCT02696408|PLACEBO_COMPARATOR|laser-off|daily laser-off session performed by nurses associated with mouthwashes several times a day (standard preventive treatment of mucositis)
62382428|NCT01371799|EXPERIMENTAL|Study drug at 8mg|GSK1034702 at 8mg
62382429|NCT01371799|PLACEBO_COMPARATOR|Placebo|Placebo
62382430|NCT05724654|EXPERIMENTAL|Experimental|Skin roasted peanuts
62382431|NCT05724654|NO_INTERVENTION|Control|No skin roasted peanuts
62382432|NCT02005718|EXPERIMENTAL|Vitamin D|Cholecalciferol 300,000 twice
62382433|NCT01021553|PLACEBO_COMPARATOR|placebo|placebo
62382434|NCT01021553|ACTIVE_COMPARATOR|50 mg|50 mg GSK557296
61987846|NCT05337215|EXPERIMENTAL|kangaroo father care|While the IIF was applied to control group at the first meeting in the postpartum ward, FIAS was administered by phone or home visit in the third month after the face-to-face interview.. the first KC was applied within the first 4-6 hours after birth, and the second KC was applied in the postpartum ward under the supervision of the researcher on the first day after birth. The third KC was performed by the fathers themselves at home on the third postpartum day after discharge. Immediately afterwards, the researcher observed the father and baby from an appropriate distance, and the father and the baby had skin-to-skin contact for mean 15-20 minutes.
62382435|NCT01021553|ACTIVE_COMPARATOR|150 mg|150 mg GSK557296
62382436|NCT01063114|EXPERIMENTAL|Proton Beam Radiation|Proton Beam Radiation
62382437|NCT00852124|PLACEBO_COMPARATOR|Placebo|Packets similar to VSL#3 will be taken 2 X daily but not containing active bacteria
62382438|NCT00852124|ACTIVE_COMPARATOR|VSL#3|Packets of VSL#3 (powder containing 8 bacteria believed to be beneficial) will be taken 2 x daily in food or a cool beverage.
62382439|NCT00753025|EXPERIMENTAL|CD133|
62382440|NCT00753025|EXPERIMENTAL|TNC|
62382441|NCT00753025|PLACEBO_COMPARATOR|Placebo|
62382442|NCT06085040|EXPERIMENTAL|Intervention|
62382443|NCT04427904|EXPERIMENTAL|Bupivacaine|Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
62382444|NCT04427904|ACTIVE_COMPARATOR|Lidocaine|Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
62382445|NCT04815226|OTHER|Using Peristeen Transanal Irrigation|All participants in the trial will use Peristeen Transanal Irrigation. Eligible volunteers will be those patients who have failed conventional supportive bowel care, have neurogenic bladder, and use CIC (ClC: Clean Intermittent Catheterization) daily.
62382446|NCT04384991|EXPERIMENTAL|HU007 Eye drop|"Adminster twice a day(one drop would be administered to both eyes once a time). When being administered, the IP should be mixed by upside down.~Medication is recommended at 9AM(±1H) and 9PM(±1H)"
62382447|NCT04384991|ACTIVE_COMPARATOR|Restasis Eye drop 0.05% (Cyclosporine)|"Adminster twice a day(one drop would be administered to both eyes once a time). When being administered, the IP should be mixed by upside down.~Medication is recommended at 9AM(±1H) and 9PM(±1H)"
62382448|NCT01753843|ACTIVE_COMPARATOR|early cord clamping|cord clamping within 20 sec
62382449|NCT01753843|EXPERIMENTAL|brief delay in cord clamping|cord clamping delayed by 30 to 60 seconds
61987847|NCT04176276||Patients with Type2 Diabetes|200 patients with type 2 diabetes consecutively enrolled among those referring to our Diabetes outpatient clinic.
62382450|NCT04433936||Thyroid Gland Dysfunction|Patients with a recent diagnosis of TGD (the study group) were recruited from endocrinology outpatient clinic of Specialized Medical Hospital, Mansoura University. Diagnosis of TGD was based on précised history, clinical examination and laboratory investigations. In order to avoid bias, patients with history of intake of any thyroid-related medications (antithyroid medications or thyroxine replacement), radioactive iodine or thyroidectomy were excluded from the study.
62382451|NCT04433936||Control|fifty age and gender matched healthy subjects without known personal or family history of thyroid disease or any autoimmune diseases were recruited from candidates of refractive surgery referred to the outpatient clinic of Mansoura Ophthalmology Center for pentacam assessment and who were proved to have normal corneal pentacam parameters. They were further examined by the endocrinologist to exclude thyroid dysfunction; this was supported by normal thyroid function profile (serum TSH and free T4) and negative anti-TPO and antithyroglobulin antibodies.
62382452|NCT00871468|ACTIVE_COMPARATOR|superior plate|Clavicle plate on the superior surface of the bone
62382453|NCT00871468|EXPERIMENTAL|anterior inferior plate|plate placed on anterior inferior surface of bone
62382454|NCT04651699|EXPERIMENTAL|Active Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation (a-tDCS) will be applied over the Primary Motor Cortex during 10 sessions of 20 minutes at 2 milli amps.
62382455|NCT04651699|SHAM_COMPARATOR|Sham Transcranial Direct Current Stimulation|Sham Transcranial Direct Current (s-tDCS) will be applied over the Primary Motor Cortex during 10 sessions of 20 minutes.
62382456|NCT04352686|ACTIVE_COMPARATOR|Buspirone|Buspirone 20 mg per oral
62382457|NCT04352686|PLACEBO_COMPARATOR|Placebo|Placebo
62382458|NCT04560179|EXPERIMENTAL|Treatment Arm - 78mg|The phase 1 trial will begin with a dose of 78mg. All treatment arms will administer study drug every 12 hours for up to 14 days (28 doses). Up to 6 infants in this arm will receive the 78mg dose of tobramycin solution for inhalation administered via vibrating mesh nebulizer. During the trial, infants in each treatment arm will undergo blood and tracheal aspirate sampling and respiratory mechanics measurements at pre-specified time points to assess dose safety and potential efficacy. Continuous pulse oximetry monitoring for the duration of the trial will also occur. Clinical data will also be recorded daily throughout the trial in all participants.
62382459|NCT04560179|EXPERIMENTAL|Treatment Arm - 150mg|If tolerability is demonstrated in the 78mg treatment arm following the 3+3 trial design, up to 6 infants will then be enrolled and receive 150mg of tobramycin solution for inhalation every 12 hours. The same monitoring procedures will be performed in this treatment arm as in the prior.
62382460|NCT04560179|EXPERIMENTAL|Treatment Arm - 216mg|If tolerability is demonstrated in the 150mg treatment arm following the 3+3 trial design, up to 6 infants will then be enrolled and receive 150mg of tobramycin solution for inhalation every 12 hours. The same monitoring procedures will be performed in this treatment arm as in the prior.
62382461|NCT04560179|EXPERIMENTAL|Treatment Arm - 300mg|If tolerability is demonstrated in the 216mg treatment arm following the 3+3 trial design, up to 6 infants will then be enrolled and receive 150mg of tobramycin solution for inhalation every 12 hours. The same monitoring procedures will be performed in this treatment arm as in the prior.
62382462|NCT04560179|NO_INTERVENTION|Observational Arm|Enrolled infants who are eligible to participate in the phase-1 trial may be enrolled in an untreated observational cohort at parental discretion. This cohort will undergo collection of clinical and respiratory mechanics data for 14 days after enrollment but will not receive the study drug.
62762867|NCT04047420|EXPERIMENTAL|Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Insert|On the first dosing visit (Visit 3), participants will receive a single TAF/EVG Insert for rectal administration. On the second dosing visit (Visit 7), after a washout period of at least 7 days, participants will receive two TAF/EVG Inserts for rectal administration. Each participant will be on study for approximately 6-13 weeks.
62762868|NCT03306641|ACTIVE_COMPARATOR|Test Contact Lens|Per randomized schedule, subject will wear a pair of the test lens or control lens for one week and then cross-over with the control pair for 1 week.
62762869|NCT03306641|ACTIVE_COMPARATOR|nelfilcon A lens (control)|Per randomized schedule, subject will wear a pair of the control lens for one week and then cross-over with the test pair for 1 week.
62762870|NCT01157208|EXPERIMENTAL|Diet A|This diet is high in omega-3 fatty acids, low in trans fatty acids, and low in omega-6 fatty acids. Subjects are encouraged to eat fatty fish daily (e.g., salmon), to limit vegetable oil intake, and to eat fruits, vegetables and whole grains. Specifically formulated and other provided foods for this group will include salmon-salad sandwiches, hummus with olive oil, other bean dips and bean dishes, frozen and canned fish, and blueberry-flax muffins.
61987848|NCT04176276||Patients without Type2 Diabetes|100 patients without diabetes among those referring to our outpatient clinic most of them affected by hypercholesterolemia, obesity or CV disease.
61987849|NCT02112669|EXPERIMENTAL|AV fistula with VasQ|Implant VasQ over AV fistula
61987850|NCT02112669|NO_INTERVENTION|AV fistula|AV fistula without any adjunct device
61987851|NCT02517996|EXPERIMENTAL|1% Lidocaine|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters 1% lidocaine after anesthesia induction.
61987852|NCT02517996|PLACEBO_COMPARATOR|Normal Saline|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
61987853|NCT01180673|EXPERIMENTAL|MINT-TLC|
61987854|NCT01180673|ACTIVE_COMPARATOR|Control Condition|
61987855|NCT04809220|EXPERIMENTAL|Dulaglutide 1.5 milligram (mg)|Participants received 1.5 mg of dulaglutide given weekly subcutaneously (SC) during the 52-week treatment period. Dulaglutide will be given alone or in combination with 1 oral antihyperglycemic medication (OAM). Participants on dipeptidyl peptidase-4 inhibitors (DPP-4i) discontinued DPP-4i at randomization and was regarded as monotherapy of dulaglutide, other OAMs continued at same dose during study period and were regarded as combination therapy with dulaglutide.
61987856|NCT04809220|ACTIVE_COMPARATOR|Dulaglutide 0.75 mg|Participants received 0.75 mg of dulaglutide given weekly SC during the 52-week treatment period. Dulaglutide will be given alone or in combination with 1 OAM. Participants on DPP-4i discontinued DPP-4i at randomization and was regarded as monotherapy of dulaglutide, other OAMs continued at same dose during study period and were regarded as combination therapy with dulaglutide.
61987857|NCT03929861|EXPERIMENTAL|Fluconazole, period 1|Subjects were randomized to receive a single dose of 150 mg fluconazole on Day 1 of period 1 after an overnight fast of at least 10 hours
61987858|NCT03929861|EXPERIMENTAL|Fluconazole, period 2|Subjects were randomized to receive a single dose of 150 mg fluconazole on Day 1 of period 2 after an overnight fast of at least 10 hours
61987859|NCT04127786|EXPERIMENTAL|Group1:VRVg2 Cohort1(C1)-1ry Series:pediatric & adult participants-Booster:102 adult participants|"VRVg-2, 3 injections at Day 0, Day 7, and Day 28~Booster dose of VRVg-2 for a subset of 102 adult participants at Month 12"
61987860|NCT04127786|ACTIVE_COMPARATOR|Group 2:Verorab C1-1ry Series:pediatric&adult participants-Booster Phase:34 adult participants|"Verorab, 3 injections at Day 0, Day 7, and Day 28~Booster dose of VRVg-2 for a subset of 34 adult participants at Month 12"
61987861|NCT04127786|ACTIVE_COMPARATOR|Group 3:Imovax Rabies C1-1ry Series:pediatric&adult participants-Booster Phase:34 adult participants|"Imovax Rabies, 3 injections at Day 0, Day 7, and Day 28~Booster dose of VRVg-2 for a subset of 34 adult participants at Month 12"
61987862|NCT04127786|EXPERIMENTAL|Group 4:VRVg-2 Cohort 2(C2)-1ry Series:Adult participants-Booster Phase:138 adult participants|"VRVg-2, 2 injections at Day 0 and Day 7~Booster dose of VRVg-2 for a subset of 138 adult participants between Month 24 up to Month 36"
61987863|NCT04127786|ACTIVE_COMPARATOR|Group 5:Verorab C2-1ry Series:adult participants-Booster Phase:46 adult participants|"Verorab, 2 injections at Day 0 and Day 7~Booster dose of VRVg-2 for a subset of 46 adult participants between Month 24 up to Month 36"
61987864|NCT04127786|ACTIVE_COMPARATOR|Group 6:Imovax Rabies C2-1ry Series:adult participants-Booster Phase:46 adult participants|"Imovax Rabies, 2 injections at Day 0 and Day 7~Booster dose of VRVg-2 for a subset of 46 adult participants between Month 24 up to Month 36"
61987865|NCT05350319||Patients planning for total or reverse shoulder arthroplasty|Adult patients who are planning to undergo a total or reverse shoulder arthroplasty
61987866|NCT05350319||Retrospective group of patients who have already undergone preoperative planning|Retrospective cohort of patients who have undergone preoperative planning with a conventional shoulder CT for total or reverse shoulder arthroplasty.
61987867|NCT01770483|EXPERIMENTAL|study group|Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months
61987868|NCT01770483|ACTIVE_COMPARATOR|control group|Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months
61987869|NCT02191228|EXPERIMENTAL|Group 1|Linagliptin in subjects with normal renal function
62382463|NCT02897011|SHAM_COMPARATOR|Group 1: MTX continue|Group will continue MTX after vaccination
62382464|NCT02897011|EXPERIMENTAL|Group 2: MTX hold|will hold MTX for 2 weeks after vaccination
62382465|NCT00984009|ACTIVE_COMPARATOR|Colchicine alone|baseline colchicine pharmacokinetics
62382466|NCT00984009|EXPERIMENTAL|Colchicine with Grapefruit Juice|colchicine pharmacokinetics in presence of grapefruit juice
62382467|NCT01688479|EXPERIMENTAL|Calendula Weleda® cream (Weleda)|Calendula Officinalis (marigold plant) is applied twice daily on the skin in the radiated area during the entire treatment period and until the skin reaction subsided
62382468|NCT01688479|ACTIVE_COMPARATOR|Essex® cream (Schering-Plough)|Essex cream is applied twice daily on the skin in the radiated area during the entire treatment period and until the skin reaction subsided
61987870|NCT02191228|EXPERIMENTAL|Group 2|Linagliptin in patients with mild renal insufficiency (RI)
62382469|NCT03946189||P/F less than 100|Patients receiving mechanical ventilation with paO2/FiO2 less than 100
62382470|NCT03946189||P/F between 100 and 200|Patients receiving mechanical ventilation with paO2/FiO2 between 100 and 200
62382471|NCT03946189||P/F between 200-300|Patients receiving mechanical ventilation with paO2/FiO2 between 200 and 300
62382472|NCT04905563|OTHER|Control|Standard of care- weight based dose of liquid acetaminophen-hydrocodone- 0.15 mg/kg/dose every six hours with a max dose of 10 mg/dose
61987871|NCT02191228|EXPERIMENTAL|Group 3|Linagliptin in patients with moderate RI
61987872|NCT02191228|EXPERIMENTAL|Group 4|Linagliptin in patients with severe RI
61987873|NCT02191228|EXPERIMENTAL|Group 5|Linagliptin in patients with end-stage renal disease (ESRD)
61987874|NCT02191228|EXPERIMENTAL|Group 6|Linagliptin in patients with severe RI and Type 2 diabetes mellitus (T2DM)
61987875|NCT02191228|EXPERIMENTAL|Group 7|Linagliptin in patients with normal renal function and T2DM
62382473|NCT04905563|EXPERIMENTAL|Treatment|Weight based dose of liquid acetaminophen and ibuprofen- acetaminophen 15 mg/kg/dose and ibuprofen 10 mg/kg/dose every six hours with a max dose of 650 mg/dose of acetaminophen and 600 mg/dose of ibuprofen.
62382474|NCT04581057|EXPERIMENTAL|First CVE|
62382475|NCT01992744||Healthy Pregnant Women|Participants 8 to 12 weeks gestational age as determined by their physician.
62382476|NCT01802242|EXPERIMENTAL|Active Radiation Treatment (Cohort 2)|
62382477|NCT01802242|OTHER|Prior Radiation Treatment (Control Cohort)|Patients who received 78Gy RT to the prostate gland 3-4.5 years prior to enrollment. This group will not be receiving any active treatment
61987876|NCT05700435|EXPERIMENTAL|Randomization|At two study sites, we will randomly assign participants to the VTC/in-person group or CBT group using a ratio of 2:1 to assign participants to the VTC/in-person or CBT training modalities. We anticipate 84 participants (42 per site) will be assigned to the CBT modality and 168 (84 per site) will be assigned to the VTC/in-person modality.
61987877|NCT05700435|ACTIVE_COMPARATOR|Self-selection|At two study sites, participants will be able to self-select which SMART training modality they will complete (VTC/in-person or CBT).We aim to recruit 250 participants in the self-selection arm.
61987878|NCT03403959|EXPERIMENTAL|SAD|Persons with visual impairment and SAD are assessed by clinical interview, depression rating, diurnal saliva melatonin and cortisol and chromatic pupillometry during symptomatic winter phase and asymptomatic summer phase. Winter assessment is followed by a 6 week light therapy protocol ending with assessment of depression severity and repeated pupillometry.
61987879|NCT03403959|NO_INTERVENTION|non-SAD|Control participants with similar visual impairment but without SAD/sSAD are assessed by clinical interview, depression rating, diurnal saliva melatonin and cortisol and chromatic pupillometry in winter and summer.
61987880|NCT01834287|EXPERIMENTAL|Physical Activity Intervention|Motivationally-tailored, Spanish Language, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
61987881|NCT01834287|ACTIVE_COMPARATOR|Wellness Control|Internet-based, Spanish language, Wellness Contact control intervention addressing relevant health topics other than Physical Activity.
61987882|NCT05352009|EXPERIMENTAL|Sling exercise training group|Participants will practice core muscle exercise in different positions with sling systems (Redcord®, Norway).
61987883|NCT05352009|ACTIVE_COMPARATOR|Conventional training group|Participants will practice balance exercise, including sit-to-stand, forward reaching, postural training on the therapeutic ball, maintaining standing balance with eyes open and progress to eyes close, and tandem stance.
61987884|NCT00657241|ACTIVE_COMPARATOR|(A) ARB first, beta-blocker second|Valsartan 160 mg daily (one week) and valsartan 320 mg daily (3 weeks) followed by carvedilol CR 20 mg daily (one week) and carvedilol CR 40 mg daily (3 weeks)
61987885|NCT00657241|ACTIVE_COMPARATOR|(B) Beta-blocker first, ARB second|carvedilol CR 20 mg daily (one week) and carvedilol CR 40 mg daily (3 weeks) followed by valsartan 160 mg daily (1 week) and valsartan 320 mg daily (3 weeks).
61987886|NCT01854905||Patients Attending Consultation for LASIK|Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
61987887|NCT00685581|EXPERIMENTAL|A|Arms A: the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period
61987888|NCT00685581|EXPERIMENTAL|B|Arms B: the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed.
61987889|NCT00685581|EXPERIMENTAL|C|Arms C: the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed.
61987890|NCT01415063|EXPERIMENTAL|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
61987891|NCT01415063|EXPERIMENTAL|TACE-RFA|TACE first, then RFA within 2 weeks
61987892|NCT05552677|NO_INTERVENTION|Control Group (CG)|Patients will recieve no intervention for the period of 12 weeks
61987893|NCT05552677|EXPERIMENTAL|Exercise Group (EG)|Patients will undergo a 12 week multicomponent training program
61987894|NCT05365633|OTHER|Empowerment activity-enhanced tobacco cessation assistance|Single arm pilot intervention design to assess feasibility and acceptability
61987895|NCT01990274|EXPERIMENTAL|Novel|Patients in this arm will receive 3 sputum samples for GeneXpert MTB/RIF assay and MGIT liquid TB culture.
61987896|NCT01990274|ACTIVE_COMPARATOR|Standard|Patients in this arm will receive 2 sputum samples for fluorescence smear microscopy and MGIT liquid TB culture.
61987897|NCT02046408|EXPERIMENTAL|Tablet Intervention|Primary care providers will be randomized into intervention or control conditions. The patients of intervention providers will be given a computer tablet that provides 5A's for smoking cessation counseling. Patients of control providers will not receive a tablet intervention.
61987898|NCT02046408|NO_INTERVENTION|Control|Primary care providers will be randomized into intervention or control conditions. The patients of intervention providers will be given a computer tablet that provides 5A's for smoking cessation counseling. Patients of control providers will not receive a tablet intervention.
61987899|NCT01548612|EXPERIMENTAL|Sodium nitroprusside|
61987900|NCT01548612|PLACEBO_COMPARATOR|Placebo|Glucose solution 5%
61987901|NCT03403465|OTHER|Single arm interventional study|Research FDG-PET scan obtained before radiation therapy; a second research FDG-PET scan is obtained at about 3-5 weeks after treatment has started.
62182579|NCT04421313|PLACEBO_COMPARATOR|Control Subjects|The patients with Control Subjects receive 12 g/day of INULIN or 10,5g/day of maltodextrine during 30 days
61987902|NCT00918021|ACTIVE_COMPARATOR|olanzapine (B)|Group B: In addition to clozapine, the participants receive their normal dosage of olanzapine (=the same as on the hospital ward) for 12 weeks, next the decreasing dosage of olanzapine for four weeks and subsequently placebo for 8 weeks.
61987903|NCT00918021|PLACEBO_COMPARATOR|placebo (A)|Group A: : In addition to clozapine the participants receive the decreasing dosage of olanzapine for four weeks, next placebo for 8 weeks, after that the increasing dosage of olanzapine for four weeks and subsequently the normal dosage of olanzapine for 8 weeks.
61987904|NCT06023732|EXPERIMENTAL|Baseline 7 days|Behavioral activation and emotion-focused interventions Baseline randomized length 7-14 days
61987905|NCT06023732|EXPERIMENTAL|Baseline 8 days|Behavioral activation and emotion-focused interventions Baseline randomized length 7-14 days
61987906|NCT06023732|EXPERIMENTAL|Baseline 9 days|Behavioral activation and emotion-focused interventions Baseline randomized length 7-14 days
61987907|NCT06023732|EXPERIMENTAL|Baseline 10 days|Behavioral activation and emotion-focused interventions Baseline randomized length 7-14 days
61987908|NCT06023732|EXPERIMENTAL|Baseline 11 days|Behavioral activation and emotion-focused interventions Baseline randomized length 7-14 days
61987909|NCT06023732|EXPERIMENTAL|Baseline 12 days|Behavioral activation and emotion-focused interventions Baseline randomized length 7-14 days
61987910|NCT06023732|EXPERIMENTAL|Baseline 13 days|Behavioral activation and emotion-focused interventions Baseline randomized length 7-14 days
61987911|NCT06023732|EXPERIMENTAL|Baseline 14 days|Behavioral activation and emotion-focused interventions Baseline randomized length 7-14 days
61987912|NCT00188513|EXPERIMENTAL|Conformal intensity modulated radiotherapy (IMRT)|All patients shall receive a continuous course of intensity modulated conformal radiotherapy consisting of 66 Gy in 22 (3 Gy) fractions over 4.5 weeks.
61987913|NCT01109225|EXPERIMENTAL|Myocardial infarction|"All patients. Patients hospitalized for a first myocardial infarction with known shift of the segment ST revascularized in acute phase by primary angioplasty and dated less than 4 days.~Intervention:~* blood sample~* MRI~* echocardiography~* urine sample~* pulmonary echography~* vascular check~* renal echography"
61987914|NCT02275481|EXPERIMENTAL|BROVANA|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
61987915|NCT02275481|ACTIVE_COMPARATOR|SPIRIVA|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
61987916|NCT02590939|EXPERIMENTAL|Active device|60 minutes of active external trigeminal nerve stimulation with a CEFALY Active device
61987917|NCT02590939|SHAM_COMPARATOR|Sham device|60 minutes of placebo external trigeminal nerve stimulation with a CEFALY Placebo device
61987918|NCT01486654|ACTIVE_COMPARATOR|Anodal stimulation|
61987919|NCT01486654|ACTIVE_COMPARATOR|Cathodal stimulation|
61987920|NCT01486654|PLACEBO_COMPARATOR|Sham stimulation|
61987921|NCT06038279|EXPERIMENTAL|Arm 1 (SAD)- INI-2004 Dose Cohort 1|Healthy Participants will be enrolled and randomised to receive a single dose of INI-2004 or placebo intranasally (ratio 3:1 active: placebo).
61987922|NCT06038279|EXPERIMENTAL|Arm 2 (SAD)- INI-2004 Dose Cohort 2|Healthy Participants will be enrolled and randomised to receive a single dose of INI-2004 or placebo intranasally (ratio 3:1 active: placebo).
61987923|NCT06038279|EXPERIMENTAL|Arm 3 (SAD)- INI-2004 Dose Cohort 3|Healthy Participants will be enrolled and randomised to receive a single dose of INI-2004 or placebo intranasally (ratio 3:1 active: placebo).
61987924|NCT06038279|EXPERIMENTAL|Arm 4 (SAD)- INI-2004 Dose Cohort 4|Healthy Participants will be enrolled and randomised to receive a single dose of INI-2004 or placebo intranasally (ratio 3:1 active: placebo).
61987925|NCT06038279|PLACEBO_COMPARATOR|Placebo|Healthy Participants will be enrolled and randomised to receive a single dose of INI-2004 or placebo intranasally (ratio 3:1 active: placebo).
61987926|NCT06038279|EXPERIMENTAL|Arm 1 (MAD) - INI-2004 Dose Cohort 1|Participants with allergic rhinitis will be enrolled and randomised (ratio 3:1 active:placebo) to receive INI-2004 or placebo intranasally once per week for a total of 4 weeks.
61987927|NCT06038279|EXPERIMENTAL|Arm 2 (MAD) -INI-2004 Dose Cohort 2|Participants with allergic rhinitis will be enrolled and randomised (ratio 3:1 active:placebo) to receive INI-2004 or placebo intranasally once per week for a total of 4 weeks.
61987928|NCT06038279|EXPERIMENTAL|Arm 3 (MAD) - INI-2004 Dose Cohort 3|Participants with allergic rhinitis will be enrolled and randomised (ratio 3:1 active:placebo) to receive INI-2004 or placebo intranasally once per week for a total of 4 weeks.
61987929|NCT06038279|PLACEBO_COMPARATOR|Placebo (MAD)|Participants with allergic rhinitis will be enrolled and randomised (ratio 3:1 active:placebo) to receive INI-2004 or placebo intranasally once per week for a total of 4 weeks.
61987930|NCT05648370||oligometastatic disease|Dynamic blood samples before and after surgery and tissue samples from oligometastatic NSCLC undergone surgery will be obtained for exploratory analysis.
61987931|NCT05505032|EXPERIMENTAL|Group F30|In these patients, the FiO2 value will be adjusted to 30% in the perioperative period.
61987932|NCT05505032|EXPERIMENTAL|Group F50|In these patients, the FiO2 value will be adjusted to 50% in the perioperative period.
61987933|NCT05505032|EXPERIMENTAL|Group F80|In these patients, the FiO2 value will be adjusted to 80% in the perioperative period.
61987934|NCT00923559|EXPERIMENTAL|Mother-Infant Psychoanalytic treatment;MIP|MIP intervention
61987935|NCT00923559|ACTIVE_COMPARATOR|TAU at Child Health Centres|Regular nurse visits at Child Health Centres according to Swedish infant health care.
61987936|NCT01170494|ACTIVE_COMPARATOR|D2 2000 IU daily|
61987937|NCT01170494|ACTIVE_COMPARATOR|D3 2000 IU daily|
61987938|NCT01170494|ACTIVE_COMPARATOR|D2 1000 IU + D3 1000 IU daily|
61987939|NCT01170494|ACTIVE_COMPARATOR|D2 25000 IU Q2wk|
61987940|NCT01170494|ACTIVE_COMPARATOR|D3 25000 IU Q2wk|
61987941|NCT01170494|ACTIVE_COMPARATOR|D2 50000 IU Q4wk|
62762871|NCT01157208|EXPERIMENTAL|Diet B|This diet is low in trans fatty acids and low in omega-6 fatty acids. Subjects are encouraged to to limit vegetable oil intake, to replace meats and eggs with beans and lean fish/shellfish, and to eat fruits, vegetables and whole grains. Specifically formulated and other provided foods for this group will include hummus with olive oil, other bean dips and bean dishes, lean fish and shellfish,and blueberry muffins.
62762872|NCT02061046||On CPAP therapy|OSA patients assessed before and after 8 weeks of CPAP therapy
61987942|NCT01170494|ACTIVE_COMPARATOR|D3 50000 IU Q4wk|
61987943|NCT01170494|PLACEBO_COMPARATOR|placebo daily|
61987944|NCT00192504|EXPERIMENTAL|Motavizumab, 3 mg/kg as a single intravenous dose|Motavizumab, 3 mg/kg as a single intravenous dose administered on Day 0
61987945|NCT00192504|EXPERIMENTAL|Motavizumab, 15 mg/kg as a single intravenous dose|Motavizumab, 15 mg/kg as a single intravenous dose administered on Day 0
61987946|NCT00192504|EXPERIMENTAL|Motavizumab, 30 mg/kg as a single intravenous dose|Motavizumab, 30 mg/kg as a single intravenous dose administered on Day 0
61987947|NCT00192504|PLACEBO_COMPARATOR|Placebo, as a single intravenous dose|Placebo, as a single intravenous dose administered on Day 0
61987948|NCT05150353|EXPERIMENTAL|Patients with cardiac amyloidosis|
61987949|NCT05150353|PLACEBO_COMPARATOR|Healthy volunteers|
61987950|NCT01318096|EXPERIMENTAL|A:Raltegravir + tenofovir+lamivudine|
61987951|NCT01318096|ACTIVE_COMPARATOR|B:Efavirenz+tenofovir+lamivudine|
62762873|NCT02369666|EXPERIMENTAL|LycoRed (code 40051) product|Dietary supplement, LycoRed (code 40051) product, experimental: Mixture of tomato-based carotenoids and phytochemicals in medium chain triglycerides (MCT). One capsule each day with the morning meal, for 4 weeks.
62762874|NCT02369666|PLACEBO_COMPARATOR|Placebo|Dietary supplement placebo: Only MCT oil. One capsule each day with the morning meal, for 4 weeks.
62762875|NCT02944565|EXPERIMENTAL|Treatment (daratumumab)|Patients receive daratumumab IV over 1.5 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.
61987952|NCT02921048||omega-3|individuals voluntarily taking at least 3 g/wk of EPA and DHA from dietary sources including fish oil supplements and ocean fish/shellfish consumption for a period of at least 6 months prior to enrollment in the study
61987953|NCT02921048||control|individuals who have consumed no more than 1 serving size (4-6 oz)/month of ocean fish/shellfish, or no more than 1 pill/month of fish oil supplement during the 6 month period preceding enrollment
61987954|NCT01142310|ACTIVE_COMPARATOR|Lamotrigine|Dose titration: begin at Baseline at 25mg PO QD for two weeks. Increase to 50mg PO QD at Week 2 for two weeks. Increase to 100mg PO QD at Week 4. Increase to 150mg PO QD at Week 5. Increase to 200mg PO QD at Week 6. Increase to 250mg PO QD at Week 7. Increase to 300mg PO QD at Week 8. Increase to 350mg PO QD at Week 9. Increase to 400mg PO QD at Week 10. Stay at 400mg PO QD from Week 10 to Week 48.
61987955|NCT01142310|PLACEBO_COMPARATOR|Placebo|Placebo administered the same as the Lamotrigine just described.
61987956|NCT03341832|EXPERIMENTAL|NVP-1203|NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose
61987957|NCT03341832|ACTIVE_COMPARATOR|NVP-1203-R|NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose
61987958|NCT03341832|PLACEBO_COMPARATOR|Placebo|NVP-1203 placebo plus NVP-1203-R placebo for up to 7 days, oral dose
61987959|NCT06451042||Post-Operative GBM Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI)|0-(2-18F-Fluoroethyl)-L-Tyrosine (FET) PET/MRI for planning of radiation therapy of post-operative glioblastoma multiforme patients
61987960|NCT04033601|EXPERIMENTAL|non-pharmacological intervention group|
61987961|NCT04033601|EXPERIMENTAL|control group|
61987962|NCT01614990|ACTIVE_COMPARATOR|Macimorelin|
61987963|NCT01614990|PLACEBO_COMPARATOR|Placebo|
61987964|NCT05481177|NO_INTERVENTION|Long Haul COVID|Persistent signs and/or symptoms \>12 weeks post Covid-infection N = 200 evaluable subjects.
61987965|NCT05481177|NO_INTERVENTION|Post COVID without LHC|No persistent signs and/or symptoms \>12 weeks N = 50 evaluable subjects.
62762876|NCT02337699||Treated Subjects|All subjects recruited into the main study treated with the Axium neurostimulator
62762877|NCT02337699||QST Group|A sub-set of the main study group who also consent to take part in the Quantitative Sensory Testing based feasibility study
61987966|NCT05481177|PLACEBO_COMPARATOR|Ivabradine RCT Arms|"If POTS or IST is present for participants within either of these cohorts, then they will be assigned to one of two arms of the Ivabradine RCT \[2:1 treatment:control\].~RCT Arms: at least 36 evaluable subjects will be enrolled to two arms in a 2:1 ratio. More may be enrolled, depending on the number from the overall COVID-19 cohort who qualify.~IVA (Ivabradine) - at least 24 evaluable subjects Placebo - at least 12 evaluable subjects"
61987967|NCT03496948|EXPERIMENTAL|TeGeCoach|Home-based exercise program consisting of telephone health coaching, remote walking exercise monitoring based on wearable monitors and intensified primary care.
61987968|NCT03496948|NO_INTERVENTION|Usual care group (TAU)|Patients randomized to TAU receive written information about courses offered by their statutory health insurance. Health insurance companies offer a variety of courses to encourage regular exercise and to promote lifestyle changes, including SEPs (vascular and cardio exercise), physical therapy, nutritional assistance programs, smoking cessation programs, weight loss programs, and patient education programs for obesity and diabetes.
62382478|NCT02084940||GnRH antagonist depot, Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
62762878|NCT03190694|EXPERIMENTAL|Dapagliflozin 10mg Tablet, then Placebo|"Participants first received Dapagliflozin 10mg tablet for 6 weeks. After a washout period of 6 weeks, they then received Placebo tablet for 6 weeks (matching Dapagliflozin 10mg).~Dapagliflozin 10 mg: Green, plain, diamond shaped, film coated tablet (orally) Placebo: Green, plain, diamond shaped, film coated tablet. Does not contain active ingredient"
62762879|NCT03190694|PLACEBO_COMPARATOR|Placebo, then Dapagliflozin|"Participants first received Placebo tablet for 6 weeks. After a washout period of 6 weeks, they then received Dapagliflozin 10mg tablet for 6 weeks (matching Dapagliflozin 10mg).~Placebo: Green, plain, diamond shaped, film coated tablet. Does not contain active ingrediënt Dapagliflozin 10 mg: Green, plain, diamond shaped, film coated tablet (orally)"
62762880|NCT04672525|ACTIVE_COMPARATOR|RIFAMPICIN|Patient with staphylococcal PJI, treated with DAIR strategy, and randomized in the control group will receive rifampicin in association with another antibiotic except rifabutin, as-per recommendations for 12 weeks.
62762881|NCT04672525|EXPERIMENTAL|RIFABUTIN|Patient with staphylococcal PJI treated with DAIR strategy, and randomized in the experimental group, will receive rifabutin in association with another antibiotic except rifampicin, as-per recommendations for 12 weeks.
62762882|NCT03299231|ACTIVE_COMPARATOR|Aerobika|Group of participants with COPD, hospitalized for severe exacerbation and using the active oscillating positive expiratory pressure device (OPEP). The device is a hand held one. Used mostly in subjects with bronchiectasis for mucus clearing. Estimated number of subjects in this arm is 80. The device has an adjustable resistance which will be set by a health care provider in the study team. The device is to be used three times daily from 10 to 20 minutes according to subject's effort.
62762883|NCT03299231|SHAM_COMPARATOR|Sham device|Group of participants using the same looking device which is devoid from nebulizer port valve so it is not functioning (sham device). The sham arm is a control arm. It will be used as the active comparator three times daily for 10 to 20 minutes according to subject's effort
62762884|NCT03081676|ACTIVE_COMPARATOR|Glimepiride + GIP|Tablet Glimepiride + infusion of GIP
61987969|NCT02784821|OTHER|Group A - Antibiotics Indicated|"These neonates have a clinical indication to receive antibiotics such as symptoms out of expected for gestation OR delivered to moms with high perinatal infectious risks.~The standard of care antibiotics include Ampicillin and Gentamicin or Cefotaxime.~Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome."
61987970|NCT02784821|OTHER|Group B - antibiotics not indicated|"These neonates are asymptomatic AND are delivered to moms with low perinatal infectious risk factors.~Antibiotics is not indicated for this group as standard of care.~Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome."
61987971|NCT02784821|OTHER|Group CI/randomized to antibiotics|"This group will be randomized to receive standard of care antibiotics which include Ampicillin and Gentamicin or Cefotaxime.~Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome."
62382479|NCT03449186||Pregnancy group|Women, who were in their second trimester (weeks 16-24) or third trimester (weeks 25-34)selected for the study. Saliva and GCF samples were collected and clinical periodontal measurements were made gently
62762885|NCT03081676|ACTIVE_COMPARATOR|Placebo + GIP|Placebo tablet + infusion of GIP
62762886|NCT03081676|ACTIVE_COMPARATOR|Glimepiride + GLP-1|Glimepiride + infusion of GLP-1
62762887|NCT03081676|ACTIVE_COMPARATOR|Placebo + GLP-1|Placebo tablet + infusion of GLP-1
62762888|NCT03081676|ACTIVE_COMPARATOR|Glimepiride + Placebo|Glimepiride + infusion of placebo (saline)
61987972|NCT02784821|OTHER|Group CII/randomized to no antibiotics|"This group will be randomized not to receive standard of care antibiotics.~Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome."
61987973|NCT05750927||ASCoP (severe Aortic Stenosis with Complex PCI features)|Subjects with severe aortic stenosis undergoing transcatheter aortic valve intervention and with concomitant, complex coronary artery disease with a clinical indication for percutaneous coronary intervention
62762889|NCT03081676|PLACEBO_COMPARATOR|Placebo + Placebo|Placebo tablet + infusion of placebo (saline)
61987974|NCT05819333|EXPERIMENTAL|Respiratory Strength Training|In addition to the Exercise Program of Flexibility, Strengthening and Cardiovascular training, subjects assigned to the Respiratory Strength Training group will use a threshold training device to resist inspiration and expiration (Orygen Dual Valve, Forumed). The respiratory ports are held closed by adjustable-tension springs, and subjects must overcome the tension to inhale or exhale air from the lung. Subjects will complete 5 sets of 5 maximal volume and speed breaths, and rest \~1 minute between sets. Inspiratory muscle training (5 sets of 5 breaths) and expiratory muscle training (5 sets of 5 breaths) will be conducted separately. Initial intensity will be 50-70% of the maximal inspiratory and expiratory pressures the subject can generate.
61987975|NCT05819333|ACTIVE_COMPARATOR|Respiratory Relaxation Training|"In addition to the Exercise Program of Flexibility, Strengthening and Cardiovascular training, subjects assigned to the Respiratory Relaxation Training group will be issued the Threshold Positive Expiratory Pressure training device modified to partially inactivate the one-way valve to remove resistance. Much like the Respiratory Strength Training device, the RRT device was selected for its simplicity and adaptability. This device has been used in prior controlled studies as a placebo RST device. Subjects will be instructed to breathe slowly through the device, 5 sets of 5 breaths, with \~1 minute of rest between sets. These 5 sets of 5 breaths will occur twice during the intervention session, one near the beginning of the session and one near the end. While effects of relaxation breathing exercises may include a modest lowering of systolic BP in some hypertensive patients, this group primarily serves as an active control."
61987976|NCT04151290|EXPERIMENTAL|Cognoa Assessment|Cognoa diagnostic ASD device.
62382480|NCT03449186||Postpartum group|Postpartum women 6 months after giving birth recalled. Saliva and GCF samples were collected and clinical periodontal measurements were made.
62382481|NCT01054339|EXPERIMENTAL|Low dose|rAAV1-CB-hAAT at dosage level of 6 x 10e11 vg/kg
62382482|NCT01054339|EXPERIMENTAL|Middle dose|rAAV1-CB-hAAT at dosage level of 1.9 x 10e12 vg/kg
62382483|NCT01054339|EXPERIMENTAL|High dose|rAAV1-CB-hAAT at dosage level of 6 x 10e12 vg/kg
62382484|NCT05357586|EXPERIMENTAL|Transdiagnostic cognitive behavioral therapy|Transdiagnostic cognitive behavioral therapy
62382485|NCT00641979|EXPERIMENTAL|1|Rhinocort
62382486|NCT00641979|PLACEBO_COMPARATOR|2|
62382487|NCT03234257|OTHER|patients with carotid stenosis.|asymptomatic patients with carotid stenosis.
62762890|NCT00390117|EXPERIMENTAL|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
62762891|NCT02156544|EXPERIMENTAL|CKD-519 25mg|CKD-519 25mg or placebo
62762892|NCT02156544|EXPERIMENTAL|CKD-519 50mg|CKD-519 50mg or placebo
62762893|NCT02156544|EXPERIMENTAL|CKD-519 100mg|CKD-519 100mg or placebo
61987977|NCT02503332|EXPERIMENTAL|Pegcetacoplan 15 mg/100 µL Monthly for 12 months|A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every month for 12 consecutive months.
61987978|NCT02503332|EXPERIMENTAL|Pegcetacoplan 15 mg/100 µL EOM for 12 months|A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month (EOM) for 12 consecutive months.
61987979|NCT02503332|SHAM_COMPARATOR|Sham Monthly for 12 months|Subjects will receive a Sham procedure every month for 12 consecutive months.
62382488|NCT03669263|EXPERIMENTAL|Fentanyl buccal soluble film (FBSF)|Single arm
62382489|NCT06250452|EXPERIMENTAL|experimental group|"Personal Information Form, SPO2 measurement and Asthma Symptom and Treatment Need Scoring / Daily Follow-up Form will be applied to the children in the experimental group before they are taken to the salt therapy room."
62762894|NCT02156544|EXPERIMENTAL|CKD-519 200mg|CKD-519 200mg or placebo
62762895|NCT02156544|EXPERIMENTAL|CKD-519 400mg|CKD-519 400mg or placebo
62762896|NCT01840358|OTHER|Patients starting pump therapy|
62762897|NCT04412122|EXPERIMENTAL|Kinesio Taping|Kinesio taping is thought to remove the barriers that slow the healing process, activate neurological suppression and reduce pain (El-Refayea, El Nahasa \& Ghareebb, 2016; Kamali, Sinaei \& Taherkhan, 2018). Kinesio tape stimulates cutaneous mechanoreceptors. Mechanoreceptors decrease sympathetic nervous system activity and increase parasympathetic activity, which can improve intestinal control (Azam, 2017; Szczegielniak, Krajczy, Bogacz, Luniewski \& Sliwinski, 2007). Kinesio taping changes skin contours and accelerates blood flow. Increased blood flow brings more oxygen and nutrients to the area. This phenomenon contributes to the natural healing process (Kafa et al., 2015).
62762898|NCT04412122|EXPERIMENTAL|Breathing Exercise|Breathing exercise is accepted as a key to relaxation or cooling down (El-Refayea et al., 2016). It is stated that breathing exercises reduce anxiety by preventing the transmission of pain messages to the spinal cord (Rejeh et al., 2013), reducing the catecholamine response (Rakel \& Herr, 2004) and muscle tension by distracting subjects (Kelle, Güzel \& Sakallı, 2016).
62762899|NCT04412122|EXPERIMENTAL|Kinesio Taping and Breathing Exercise|According to the application protocols, two applications were made together.
62762900|NCT04412122|OTHER|Control Group|No intervention was performed to reduce pain in the control group.
62762901|NCT03002623|EXPERIMENTAL|Group|CUDC-907 for thyroid cancer
62762902|NCT04866875|ACTIVE_COMPARATOR|Rapid weight loss|Participants in this group will be deprived in 1000 kcal/day (calculated based on their individual energy requirements) for 10 weeks
62762903|NCT04866875|EXPERIMENTAL|Slow weight loss|Participants in this group will be deprived in 500 kcal/day (calculated based on their individual energy requirements) for 20 weeks
62762904|NCT02317952|EXPERIMENTAL|New Extensively Hydrolyzed Formula|Administered in context of oral food challenge and then for 16 weeks.
62762905|NCT02317952|ACTIVE_COMPARATOR|Comparator Formula|Administered in context of oral food challenge and then for 16 weeks.
62762906|NCT03697278|NO_INTERVENTION|Control group|Using clinical routinely regime device to use and monitor postoperative controlled pain (PCA) after surgery.
62382490|NCT06250452|EXPERIMENTAL|Control Group|The same procedure will be applied to the children in the control group. In the study planned to be carried out for 6 weeks, it is recommended that children repeat the session for 10 minutes daily, the first 5 sessions every day and the other 5 weeks once a week.
62762907|NCT03697278|EXPERIMENTAL|Smith medical CADDsolis|This study group use a new device to use and monitor postoperative controlled pain (PCA) after surgery.
62762908|NCT00693004|PLACEBO_COMPARATOR|Placebo|
62762909|NCT00693004|EXPERIMENTAL|PRX-03140|
62762910|NCT00693004|ACTIVE_COMPARATOR|donepezil|
62762911|NCT04015869|ACTIVE_COMPARATOR|allopregnanolone|allopregnanolone
62762912|NCT04015869|PLACEBO_COMPARATOR|placebo|placebo
62762913|NCT01669408|ACTIVE_COMPARATOR|Cold infusions|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
62382491|NCT05124327|OTHER|Intervention Group|Implementation of quality improvement initiative to utilize RPM in PP HDP. Patients will utilize remote monitoring technology and bluetooth enabled BP buff to self monitor BPs- autopopulate to provider portal, and then have a telemedicine appointment at 48 hours post hospital discharge.
62382492|NCT01272544||participation in a dental health program|Group 1 - children who participated to a dental health program Group 2 - children who did not participate to dental health program
62382493|NCT01272544||participation in a preventive program|Group 1 - children who participated to the preventive program Group 2 - children who did not participate
62382494|NCT05367921|EXPERIMENTAL|CPM#1|Compartment compressibility ratio measurement using the CPM#1 device
62762914|NCT01669408|NO_INTERVENTION|Control group|Best medical treatment following international stroke guidelines
62762915|NCT05845944|EXPERIMENTAL|Video-supported education group|"All participants in this group were given the Knowledge Test on Nasogastric Tube Feeding in Pediatric Patients prepared by the researchers as a pre-test.~The participants of this group, who were determined by randomization, were given education prepared using the video-supported education method. The education took 35 minutes. After the training, the Knowledge Test on Nasogastric Tube Feeding in Pediatric Patients was applied as a post-test."
62762916|NCT05845944|NO_INTERVENTION|Control Group|"No intervention was made. All participants in this group were given the Knowledge Test on Nasogastric Tube Feeding in Pediatric Patients prepared by the researchers as a pre-test.~Afterward, theoretical information on the subject was given. After theoretical information, the Knowledge Test on Nasogastric Tube Feeding in Pediatric Patients was applied as a post-test."
62762917|NCT04413903|ACTIVE_COMPARATOR|Pressure controlled ventilation, Volum controlled ventilation|Undergoing laparoscopic cholecystectomy surgery according to mechanical ventilator mode; Group P (n: 30) Pressure controlled ventilation was randomly divided into Group V (n: 30) volume controlled ventilation settings were adjusted to be 50% O2- 50% air, 8ml / kg TV (tidal volume) and PEEP 5.
61987980|NCT02503332|SHAM_COMPARATOR|Sham EOM for 12 months|Subjects will receive a Sham procedure every other month (EOM) for 12 consecutive months.
61987981|NCT04518514|EXPERIMENTAL|Preoperative evaluation and risk assessment via telemedicine|
62382495|NCT02509663|ACTIVE_COMPARATOR|Sinuplasty balloon|Patients will receive the innovative health technology to treat frontal sinusitis : a balloon sinuplasty
62382496|NCT02509663|ACTIVE_COMPARATOR|Conventional surgical procedure|Patients will be treated with the conventional procedure : a sinus surgery with rigide instrumentation
62382497|NCT02331173||Main Study Group|All subjects enrolled in this study will be seen every 6 months following the screening visit. During the 3 main study visits, a series of tests will be performed to assess visual function. Some of these tests are part of routine care that patients would receive on an annual basis regardless of study participation. Other tests are being performed to determine if they are effective at monitoring disease progression in this population. For each of the 3 main study visits, testing may be spread over multiple days to ensure completion of all tests.
62762918|NCT04413903|ACTIVE_COMPARATOR|Optic Nerve Sheath Diameter|In optic nerve diameter measurements; A layer of water-soluble sterile gel was applied to the closed upper eyelid. The linear 10-5 MHz ultrasound probe was carefully placed on the upper eyelid over the gel. The entrance of the optic nerve to the orbital globe in 2D mode was displayed on the monitor without applying too much pressure. After finding the optimal contrast between the retrobulbar echogenic fat tissue and vertical hypoechoic band 23, the diameter of the optic nerve sheath was measured 3 mm behind the optic disc using an electronic caliper.
62762919|NCT01910870|EXPERIMENTAL|Cisplatin - Metronomic Cyclophosphamide|Cisplatin 25 mg/m² (day 1 to day 3) every 3 weeks Metronomic cyclophosphamide 150 mg (day 1 to day 14) every 3 weeks
62762920|NCT03340194||Systemic sclerosis patients|
62762921|NCT02302183|EXPERIMENTAL|Experimental: device FreeO.|Automatic adjustment of oxygen
62762922|NCT02302183|ACTIVE_COMPARATOR|Manual oxygenation|Manual adjustment of oxygen
62762923|NCT03691779|EXPERIMENTAL|Part A: ELX/TEZ/IVA|Participants in Part A received ELX 100 milligrams (mg) once daily (qd)/TEZ 50 mg qd/IVA 75 mg every 12 hours (q12h) in the treatment period for 15 days.
62762924|NCT03691779|EXPERIMENTAL|Part B: ELX/TEZ/IVA|Participants in Part B weighing less than (\<) 30 kilograms (kg) at Day 1 received ELX 100 mg qd/TEZ 50 mg qd/IVA 75 mg q12h and participants weighing greater than equals to (\>=) 30 kg at Day 1 received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.
62762925|NCT03757130|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses.
62762926|NCT03757130|ACTIVE_COMPARATOR|Placebo + Liraglutide|Participants received placebo subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5.
62382498|NCT02331173||Carbonic anhydrase inhibitor sub-study|Subjects with maculoschisis may be offered topical treatment with CAIs. These subjects will be asked to visit the study site at 1 month and 3 months after starting topical treatment. During these additional visits, subjects will undergo a dilated eye exam, BCVA, and SD-OCT imaging to assess efficacy of treatment (i.e. reduction of maculoschisis).
62382499|NCT03702452|EXPERIMENTAL|Experimental group|Patients in experimental group were graded with modified Barthel index score, and according to the functional score of patients, the corresponding rehabilitation method was selected for functional rehabilitation from functional rehabilitation nursing program,twice a day with 30 min each time, last 1 week.
62762927|NCT03757130|EXPERIMENTAL|AMG 598 70 mg|Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses.
62762928|NCT03757130|EXPERIMENTAL|AMG 598 70 mg + Liraglutide|Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5.
61987982|NCT02157155|EXPERIMENTAL|Intervention|Insulin reduction and mimic infection with LPS
61987983|NCT02157155|NO_INTERVENTION|Control|Normal insulin and no LPS
62382500|NCT03702452|EXPERIMENTAL|control group|Patients in control group were given conventional bedside rehabilitation ,twice a day with 30 min each time, last 1 week.
62382501|NCT00790491|EXPERIMENTAL|Lifestyle counseling|
62382502|NCT01714336|PLACEBO_COMPARATOR|placebo|Normal saline will be administered intravenously in two doses of 15 mg/kg each administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
62382503|NCT01714336|ACTIVE_COMPARATOR|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg each administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
62762929|NCT03757130|EXPERIMENTAL|AMG 598 210 mg|Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses.
62762930|NCT03757130|EXPERIMENTAL|AMG 598 210 mg + Liraglutide|Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5.
61987984|NCT00706979|EXPERIMENTAL|1|Practice Quit Attempt plus Nicotine Replacement Therapy
61987985|NCT00706979|ACTIVE_COMPARATOR|2|Practice Quit Attempt only
61987986|NCT03098537|ACTIVE_COMPARATOR|Enteral nutrion only|
61987987|NCT03098537|OTHER|Enteral nutrion + proton pump inhibitor|
61987988|NCT02229318|EXPERIMENTAL|FruitiVits|Daily administration of FruitiVits dietary supplement
61987989|NCT03768596|EXPERIMENTAL|Nudge|receiving nudge and form
61987990|NCT03768596|ACTIVE_COMPARATOR|No nudge|receiving the same form without nudge (only questions about their opinion/attitudes about vaccination)
61987991|NCT03768596|NO_INTERVENTION|No intervention|receiving no nudge nor form
61987992|NCT00279734|EXPERIMENTAL|Group 1|
61987993|NCT00279734|ACTIVE_COMPARATOR|Group 2|
61987994|NCT00279734|ACTIVE_COMPARATOR|Group 3|
61987995|NCT00279734|ACTIVE_COMPARATOR|Group 4|
61987996|NCT05393141|EXPERIMENTAL|diet group|weight loss diet intervention for 12 weeks
61987997|NCT05393141|EXPERIMENTAL|diet+bety group|weight loss diet intervention for 12 weeks and exercise-based biopsychosocial approach (Cognitive Exercise Therapy Approach-BETY) intervention for 12 weeks
61987998|NCT05393141|NO_INTERVENTION|control group|no intervention, control
61987999|NCT02976974|EXPERIMENTAL|Manual therapy (MT)|MT: Manual Therapy. Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
62382504|NCT00983944|EXPERIMENTAL|Arm I (EPOCH-R)|Patients receive rituximab IV on day 1; etoposide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV continuously over 96 hours on days 1-4; cyclophosphamide IV over 30 minutes on day 5; and oral prednisone twice daily on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62762931|NCT03757130|EXPERIMENTAL|AMG 598 420 mg|Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses.
62762932|NCT03757130|EXPERIMENTAL|AMG 598 420 mg + Liraglutide|Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5.
61988000|NCT02976974|EXPERIMENTAL|Therapeutic exercise (E)|"E: Therapeutic Exercise.~Shoulder extension: Elastic bands. Shoulder flexion: Elastic bands Shoulder external rotation: Elastic bands. Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.~Thoracic column movements: Flexion-extension"
61988001|NCT03340025|EXPERIMENTAL|negative pressure wound therapy|PICO Single Use Negative Pressure Wound Therapy System
61988002|NCT03340025|PLACEBO_COMPARATOR|conventional dressing|traditional surgical wound dressing of xeroform gauze and padding
61988003|NCT01655017|EXPERIMENTAL|biopsy|Obesity with BMI\> 40 kg/m² or obesity with BMI between \>35 kg/m² with comorbidities (OSA, type 2 diabetes, hypertension etc...)
61988004|NCT01655017|NO_INTERVENTION|healthy volunteers|biopsy during a surgery
61988005|NCT01318447|EXPERIMENTAL|CyberKnife SBRT|
61988006|NCT02175420|ACTIVE_COMPARATOR|TFV alone|Typhim Vi
61988007|NCT02175420|EXPERIMENTAL|BCG+TFV|BCG (SSI, Denmark) followed after 14 days by Typhim Vi
61988008|NCT05133518|ACTIVE_COMPARATOR|MELT-300|Participants will receive a single dose of MELT-300 sublingual, rapidly dissolving tablet containing 3 mg of midazolam and 50 mg of ketamine.
61988009|NCT05133518|ACTIVE_COMPARATOR|Midazolam alone|Participants will receive a single dose of midazolam 3 mg sublingual tablet.
61988010|NCT05133518|ACTIVE_COMPARATOR|Ketamine alone|Participants will receive a single dose of ketamine 50 mg sublingual tablet.
61988011|NCT05133518|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of a matching placebo sublingual tablet.
61988012|NCT03646682|EXPERIMENTAL|caffeine group|180mg of caffeine will be given orally one jour before vitrectomy with membrane peeling
61988013|NCT03646682|ACTIVE_COMPARATOR|control group|no caffeine will be given before vitrectomy with membrane peeling, patients are drinking no coffee in general
61988014|NCT02353585||Intracranial hemorrhage|Intracranial hemorrhage occuring in patients on novel oral anticoagulants (NOAC) or vitamin-K antagonists
61988015|NCT02353585||Acute ischemic stroke|Acute ischemic stroke occuring in patients on novel oral anticoagulants (NOAC) or vitamin K antagonists (VKA)
61988016|NCT06050499||Irreversible ischaemia|patients undergoing elective amputation of a limb (e.g. peripheral vascular disease)
61988017|NCT06050499||Reversible ischaemia|patients undergoing an operation with a limb tourniquet or intentional controlled reduction in blood flow to the lower limb (e.g. aortic cross clamping for vascular surgery).
61988018|NCT00616460|EXPERIMENTAL|Bivalirudin|
62762933|NCT06036329|EXPERIMENTAL|Group A provided with 1 Whitsundays Nasal mask without a spare mask cushion|• Provided with 1 Whitsundays Nasal mask without a spare mask cushion (To be provided as requested)
62762934|NCT06036329|EXPERIMENTAL|Group B provided with 1 Whitsundays Nasal mask with 2 spare mask cushions|• Provided with 1 Whitsundays Nasal mask with 2 spare mask cushions
62382505|NCT00983944|EXPERIMENTAL|Arm II (R-VACOP-B)|Patients receive rituximab IV and doxorubicin hydrochloride IV on day 1 of weeks 1, 3, 5, 7, 9, and 11; cyclophosphamide IV over 30 minutes on day 1 of weeks 1, 5, and 9; etoposide IV over 1 hour on day 1 and then orally on days 2 and 3 of weeks 3, 7, and 11; bleomycin sulfate IV and vincristine sulfate IV on day 1 of weeks 2, 4, 6, 8, 10, and 12; and oral prednisone on days 1-7 of week 1 and then every other day in weeks 2-10.
62382506|NCT05551234||Isolated senior|
62382507|NCT05551234||Children|
62382508|NCT05864391|OTHER|Cohort 1|Dose A cohort: 20 participants; n=15 on AZD7503 dose A, n=5 on Placebo
62382509|NCT05864391|OTHER|Cohort 2|Dose B cohort: 20 participants; n=15 on AZD7503 dose B, n=5 on Placebo.
62762935|NCT02761577|NO_INTERVENTION|control|perorally 1500 ml water on the day of the procedure
62762936|NCT02761577|EXPERIMENTAL|Sodium bicarbonate|3 mL/kg/hour IV (in vein) of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography
62762937|NCT02761577|EXPERIMENTAL|N-acetylcysteine plus Sodium bicarbonate|N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure in addition to Sodium bicarbonate solution on the day of the angiography.
61988019|NCT02381444||Standard of Care|Participants with advanced Parkinson's Disease
61988020|NCT02381444||Levodopa Carbidopa Intestinal Gel|Participants with advanced Parkinson's Disease
62762938|NCT00702455|ACTIVE_COMPARATOR|Self-Directed|
62762939|NCT00702455|ACTIVE_COMPARATOR|Guided|
62382510|NCT05864391|OTHER|Cohort 3|Dose C cohort: 20 participants n=15 on AZD7503 dose C, n=5 on Placebo.
61988021|NCT03997656|EXPERIMENTAL|MyDipp|The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program. Each lesson will take 30 to 60 minutes to complete. The lesson will be considered complete if the participants clicked through all of the pages and answered multiple choice questions to indicate engagement and understanding.
62382511|NCT03678766|EXPERIMENTAL|Regulation of Cues (ROC)|The ROC program provides psychoeducation, coping skills, self-monitoring and experimental learning.
62382512|NCT03678766|EXPERIMENTAL|Cognitive Behavior Therapy (CBT)|CBT provides coping skills, self-monitoring, and goal setting.
62382513|NCT01276873|EXPERIMENTAL|Closed System|Application of Tracheal aspiration closed system, controlled by the use of Open system to tracheal aspiraiton.
62382514|NCT00982267|EXPERIMENTAL|SU014813|
62182580|NCT02101658||weight data assessors|students recruited to weigh individuals in a research-based clinic
62182581|NCT04764201|OTHER|Sequence 1|Period 1: HGP2001, Period 2: HIP2001
62182582|NCT04764201|OTHER|Sequence 2|Period 1: HIP2001, Period 2: HGP2001
62382515|NCT05369572||Bile Reflux Group|"Gastroscopic reports of enrolled patients will be extracted and patients will be identified as having bile reflux according to Kellosalo J classification.~Grade I: small amount of yellowish reflux emerging from the pyloric orifice and/or yellowish staining of the mucus lake, which is pale yellow in colour.~Grade II: intermittent gush of reflux from the pyloric opening and/or yellowish staining of the mucus lake, which is dark yellow.~Grade III: frequent gush of yellow-green reflux from the pyloric orifice and/or yellow-green mucus covering the stomach."
62382516|NCT05369572||Non-biliary reflux group|Gastroscopic reports will be extracted from patients enrolled in the group that do not meet the Kellosalo J classification as the non-biliary reflux group.
62382517|NCT03933553|EXPERIMENTAL|Easy sleep complex essential oil|Aromatherapy for 2 hours starting 10 minutes before sleep with 5 drops of the essential oil diluted in 50ml water
62382518|NCT03933553|ACTIVE_COMPARATOR|Lavender essential oil|Aromatherapy for 2 hours starting 10 minutes before sleep with 5 drops of the essential oil diluted in 50ml water
62382519|NCT01943136|EXPERIMENTAL|papaya 1% extract ointment|papaya 1% extract ointment twice a day for 1 week
62382520|NCT01943136|ACTIVE_COMPARATOR|mupirocin 2% ointment|mupirocin 2% ointment twice a day for 1 week
62762940|NCT01388751|NO_INTERVENTION|no night splinting|
62762941|NCT01388751|ACTIVE_COMPARATOR|night splinting|Night Splinting for 4 weeks after removal of initial cast
62762942|NCT06083532|EXPERIMENTAL|PAP induced at an intensity of 70% 1RM（One-Repetition Maximum）combined with complex training|PAP induced at an intensity of 70% 1RM combined with complex training was shown over the 12 weeks.
62762943|NCT06083532|EXPERIMENTAL|PAP induced at an intensity of 80% 1RM combined with complex training|PAP induced at an intensity of 80% 1RM combined with complex training was shown over the 12 weeks.
62762944|NCT06083532|EXPERIMENTAL|PAP induced at an intensity of 90% 1RM combined with complex training|PAP induced at an intensity of 90% 1RM combined with complex training was shown over the 12 weeks.
62762945|NCT06083532|ACTIVE_COMPARATOR|Routine warm-up combined with complex training|Routine warm-up combined with complex training was shown over the 12 weeks.
62762946|NCT05453162|EXPERIMENTAL|Early morning PE|26 participants randomized to 10 weekly PE sessions in early morning (between 07:00-10:00) with homework exposures occurring occur at this same time of day.
61988022|NCT03997656|OTHER|Control|Participants in the control group (usual care) will receive standard health education from primary care providers in the clinic. In addition, they also will be provided with pamphlets and booklets about various health topics. They will be given a diary to record their weights, diet, physical activities and blood test result.
62382521|NCT01675401|EXPERIMENTAL|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
62762947|NCT05453162|EXPERIMENTAL|Late afternoon PE|26 participants randomized to 10 weekly PE sessions in late afternoon (16:00 or later) with homework exposures occurring occur at this same time of day.
62762948|NCT02581930|EXPERIMENTAL|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61988023|NCT00462761|EXPERIMENTAL|AC220|Determine safety, tolerability and pharmacokinetic (PK) parameters of AC220
61988024|NCT03149692|EXPERIMENTAL|Penile allograft|Penile human allografts transplanted
62762949|NCT01615055|EXPERIMENTAL|Fluoxetine tablets|
61988025|NCT01066754|EXPERIMENTAL|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets of Dr. Reddy's Laboratories Limited
61988026|NCT01066754|ACTIVE_COMPARATOR|Allegra|Allegra Tablets 180 mg of Aventis Pharmaceuticals Inc.,
61988027|NCT01206647|NO_INTERVENTION|Control arm|The patients randomized to the control arm will continue their current therapy, as individually prescribed. Insulin will be administered via subcutaneous injection and OADs (if applicable) will be administered orally, as individually prescribed.
62382522|NCT01675401|OTHER|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
62382523|NCT01126385||Transpedicular stabilization|Patients undergoing transpedicular stabilization of the spine
62382524|NCT04033029||Patients under CVVHDF with high adsorption membrane|Continuous venovenous hemodiafiltration mode (CVVHDF) using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
62382525|NCT04926870|EXPERIMENTAL|PACS group|PACS administration during teaching
62762950|NCT01615055|PLACEBO_COMPARATOR|Placebo tablets|
62762951|NCT04547114||SARS-CoV-2- infected|Detection of SARS-CoV-2 RNA by PCR in nasopharyngeal/oropharyngeal swabs
61988028|NCT01206647|EXPERIMENTAL|Saxagliptin & metformin|Saxagliptin and metformin tablets will be administered orally. Pioglitazione (Rescue medication) tablets will be administered orally. Insulin glargine (Rescue medication) will be administered via subcutaneous injection as individually prescribed.
61988029|NCT01927406|EXPERIMENTAL|Prostaglandin Analog vs Timolol|In this group, with thyroid eye disease and increased intraocular pressure in both eyes, prostaglandin analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one - randomised eye. Timolol 0.5% eye drop will be administered topically in second, control eye, two times a day.
61988030|NCT01927406|EXPERIMENTAL|Prostaglandin Analog|In this group, with thyroid eye disease and increased intraocular pressure in only one eye Prostaglandin Analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one, affected eye.
61988031|NCT00445965|EXPERIMENTAL|131I-3F8|This is a phase II single-arm open-label study that will define responses to therapy with weekly intrathecal 131I-3F8 in patients with central nervous system/leptomeningeal GD2-expressing disease.
62182583|NCT02277197|EXPERIMENTAL|Ficlatuzumab and Cetuximab|"Ficlatuzumab will be administered as an IV infusion over 30-60 minutes, once every 2 weeks. Ficlatuzumab will be administered 30-60 minutes after the completion of the cetuximab infusion.~Cetuximab will be administered as an IV infusion once every 2 weeks. The first dose will be administered over 120 minutes (± 15 minutes). Subsequent doses may be infused over 60 minutes (± 15 minutes). The starting dose of cetuximab (dose tier 1) will be 500 mg/m2. Cetuximab will be administered prior to ficlatuzumab."
62382526|NCT04926870|ACTIVE_COMPARATOR|Traditional group|Traditional teaching without PACS
62762952|NCT04547114||non infected|Lack of detection of SARS-CoV-2 RNA by PCR in nasopharyngeal/oropharyngeal swabs
62762953|NCT02018874|EXPERIMENTAL|LY2780301|
62762954|NCT01400243|PLACEBO_COMPARATOR|Placebo Patch|Placebo patch for 15-day quit period
62762955|NCT01400243|ACTIVE_COMPARATOR|Nicotine Patch|7 mg Habitrol nicotine patch-15 day quit period
62762956|NCT04570683|ACTIVE_COMPARATOR|AFL monotherapy|Singe dose AFL as monotherapy, 100 mJ
62762957|NCT04570683|ACTIVE_COMPARATOR|AFL+nivolumab|Single dose AFL 100 mJ followed by immediate intratumoral injection of nivolumab 10% 0.1 ml/cm2 tumor
62762958|NCT04570683|ACTIVE_COMPARATOR|nivolumab monotherapy|Intratumoral injection of nivolumab 10% 0.1 ml/cm2 tumor
61988032|NCT02625090|EXPERIMENTAL|UCB0942|"UCB0942 400 mg bid or a tapered UCB0942 dose of 200 mg bid.~The Investigator will be allowed to increase or decrease the dose of UCB0942 to optimize tolerability and seizure control for each subject. Increases or decreases to the dose of UCB0942 should be made in steps not exceeding 200 mg/day per week; an exception is Taper Week 1 where a step of 800 mg/day to 500 mg/day is allowed. A faster decrease of the dose than 200 mg/day per week is allowed when it is clinically appropriate in the Investigator's medical judgment. Daily UCB0942 doses during this study may be 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid); intermediate doses will not be allowed except for tapering and titration unless agreed by the UCB Study Physician or PRA Medical Monitor. The dose of UCB0942 must always be administered as bid morning and evening doses, approximately 12 hours apart."
61988033|NCT05152888|EXPERIMENTAL|Evolocumab|Informed consent will be obtained from study participants willing to participate in EMPOWER. Study participants will then undergo the baseline rest/stress cardiac PET scan along with CCTA. The final PET scan and CCTA will occur at 12 months after the intervention.
61988034|NCT05152888|NO_INTERVENTION|Control|Informed consent will be obtained from study participants willing to participate in EMPOWER. Study participants will then undergo the baseline rest/stress cardiac PET scan along with CCTA. The final PET scan and CCTA will occur at 12 months after the baseline.
62762959|NCT02406352|EXPERIMENTAL|Routine colposcopy and MDC with probe|The intervention which consists of obtaining cervical images with the MDC and spectroscopic data with the probe will be applied to all participants who agreed to participate in the study during their visit for a colposcopy exam or treatment with a LEEP procedure. A control biopsy will also be obtained from patients who agree to provide it. The control biopsy is a biopsy of cervical tissue that does not appear to have atypical changes when observed through a standard of care colposcope.
62762960|NCT06027411||Pre-implementation of qER|"Baseline data:~During the pre-implementation phase, we will be gathering data around the technical requirements for integrating qER into the radiology workflow. A random sample of 500 scans per site will be sent for the ground-truthing process for the purpose of technical evaluation.~We will also be collecting data on the baseline status of all the endpoints including TAT. The reporting of NCCT scans will follow the same workflow as the current standard of care (i.e., the images/cases will appear in the RIS chronologically and the radiologist either follows this order or prioritises some cases based on communication from ED)."
62762961|NCT06027411||Post-implementation of qER|"Post-implementation (Trial Intervention)~In the post-implementation phase, there will be a notification (prioritised flag) in RIS. The order of the cases in RIS will not be altered. When the radiologist clicks a case in RIS, a secondary capture of qER along with the original images will be available in PACS. This secondary capture will have a contour showing the algorithm's attention point for a specific abnormality. The radiologist can then choose to agree with qER findings as it is or modify or ignore it according to their clinical judgement, writing and finally signing off the report. For scans which were not processed by qER the radiologist can prioritise and report as per the standard of care."
62762962|NCT02246192|EXPERIMENTAL|control group|sinus pilonidal excision and standard cares
62762963|NCT02246192|EXPERIMENTAL|PRGF group|sinus pilonidal excision+ PRGF
62762964|NCT02305628||Cohort|Method of continuous surveillance per standard of care
62762965|NCT03535285|EXPERIMENTAL|Surgical modification side|Periodontal ligament distraction without the oblique cuts but with apical horizontal cut
62762966|NCT03535285|ACTIVE_COMPARATOR|Conventional surgery|Periodontal ligament distraction
62762967|NCT01688739|EXPERIMENTAL|Erenumab|Participants received a single dose of erenumab by subcutaneous injection at doses of 1 mg, 7 mg, 21 mg, 70 mg, 140 mg, and 210 mg or by IV injection at a dose of 140 mg.
62762968|NCT01688739|PLACEBO_COMPARATOR|Placebo|Participants received a single dose of matching placebo administered by SC or IV injection.
62762969|NCT00901511|EXPERIMENTAL|GM-CSF Group|"Scheduled Baseline WLL: All participants will receive scheduled bilateral WLL at baseline (month 0).~GM-CSF induction treatment: All participants will receive inhaled GM-CSF (250 mcg daily, 7 consecutive days every other week for 12 weeks beginning 1 week after the scheduled baseline WLL).~Washout period: All participants will not receive inhaled GM-CSF treatment for 4 weeks immediately following GM-CSF induction treatment.~GM-CSF maintenance treatment: All participants will receive inhaled GM-CSF (250 mcg daily on days 1 and 3 of every consecutive 14-day period for 6 months beginning 17 weeks after the scheduled baseline WLL).~Unscheduled Rescue WLL: Any participant experiencing progression of aPAP lung disease (defined as the disease progression resulting in respiratory failure (PaO2 at rest \<60 mmHg of PaO2 \> 60 mmHg at rest AND desaturation \<90% at rest OR decline in SpO2 of 5% or more during exercise testing) will receive unscheduled rescue WLL."
61988035|NCT03574740||Entire population|All patients included in this retrospective study. These patients were analyzed following their tobacco smoking habits.
62168200|NCT06584682|EXPERIMENTAL|Sub-occipital muscle inhibition technique|Therapist puts finger pads just beneath the superior nuchal line (below the occiput and above the C2 vertebra), and lifts the patient head slightly and apply an anterior force with cephalic traction on cervical spine this area. Then straighten the fingers to press the finger tips into muscle and hold until relaxation(30 sec) and then drop the head into palm in new position, give this technique in 10 rep/2 sets (each set have 5 repetitions).hot packs for 15 minutes prior to session, cervical muscle stretching,cervical mechanical traction for 8-10 minutes, force is applied 1/6th of the patient body weight, for C1-C2 at 0 degree of cervical flexion and for below C2 at 20 degree of cervical spine flexion. and cervical muscle Muscle Energy Techniques.
62382527|NCT01849549|EXPERIMENTAL|brain damaged subjects|patients with circumscribed brain injury, selective disorders of cognitive development or degenerative disorders responsible for focal troubles
62382528|NCT01849549|SHAM_COMPARATOR|healthy volunteers|healthy controls
62382529|NCT01321333|EXPERIMENTAL|HuCNS-SC cells|Single dose intramedullary administration of HuCNS-SC cells
62382530|NCT01392391|EXPERIMENTAL|Exercise|Task-oriented exercise training (aerobic, strength, and balance exercises)
62382531|NCT01392391|ACTIVE_COMPARATOR|Stroke Care|"Best Medical Care in Jamaica adapted from the American Stroke Association Get with the Guidelines."
62382532|NCT05956080|OTHER|Allergy testing|
62762970|NCT00901511|OTHER|Control Group|"Scheduled Baseline WLL: All participants will receive a scheduled bilateral WLL at baseline (month 0).~Unscheduled Rescue WLL: Any participant experiencing progression of aPAP lung disease (defined as the disease progression resulting in respiratory failure (defined by a resting PaO2 \<60 mmHg or \> 60 mmHg and desaturation \<90% at rest or decline in SpO2 of 5% or more during exercise testing) will receive unscheduled rescue WLL."
62762971|NCT01279005||20-50 YEARS OLD MSM|
62762972|NCT05828472|EXPERIMENTAL|Group 1：Dose1|8 subjects received Dose 1 of MY008211A Tablets, and 2 subjects received placebo, continually 7 days
62762973|NCT05828472|EXPERIMENTAL|Group 2：Dose2|8 subjects received Dose 2 of MY008211A Tablets, and 2 subjects received placebo, continually 7 days
62762974|NCT05828472|EXPERIMENTAL|Group 3：Dose3|8 subjects received Dose 2 of MY008211A Tablets, and 2 subjects received placebo, continually 7 days
62762975|NCT05828472|EXPERIMENTAL|Group 4: Dose4|8 subjects received Dose 4 of MY008211A Tablets, and 2 subjects received placebo, continually 7 days
62762976|NCT06239090|EXPERIMENTAL|intervention group (IG)|During each session IG patients will view their recorded brain waves and physiological responses in a computer screen, while a professional will explain to them what they need to do to intervene and make corrective changes to their brain waves.
62382533|NCT01022918|EXPERIMENTAL|Bevacizumab/Irinoecan|"Neoadjuvant Treatment Patient will receive bevacizumab 10mg/kg plus irinotecan 125mg/m² 4 times every two weeks.~Radiochemotherapy Then they will receive conformational radiotherapy for 6 weeks (30 Gy, 2Gy/fractions) associated with Temodal ( 75mg/m²/day) from first day up to the end of radiotherapy and 4 injections of Avastin (15mg/kg Day 1, day 15, day 29 and day 43).~Adjuvant treatment:~Patients will receive bevacizumab 15mg/kg plus irinotecan 125mg/m² 12 times every two weeks."
62762977|NCT06239090|SHAM_COMPARATOR|sham group (SG)|SG patients will be given irrelevant information (recorded data of other patients) and thus, they cannot modulate their cortical activation.
62762978|NCT00023751|EXPERIMENTAL|surgery + leucovorin + fluorouracil + radiation|"Patients with T3 disease or positive surgical margins after surgery are removed from study. Patients with T1 disease and negative surgical margins after surgery are observed. Patients with T2 disease and negative surgical margins after surgery receive adjuvant therapy.~Beginning 42 days after surgery, T2 patients receive leucovorin calcium (CF) IV over 2 hours with fluorouracil (5-FU) IV bolus 1 hour into the infusion once weekly for 6 weeks. Beginning 2 weeks after the completion of chemotherapy, patients receive chemoradiotherapy comprising radiotherapy once daily 5 times a week for 5 weeks and 5-FU IV continuously while receiving radiotherapy. Beginning 2 weeks after the completion of chemoradiotherapy, patients again receive CF IV over 2 hours with 5-FU IV bolus 1 hour into the infusion once weekly for 6 weeks. Chemotherapy repeats after 2 weeks rest for a total of 2 courses.~Patients are followed every 3 months for 2 years and then every 6 months for 5 years."
62382534|NCT01022918|ACTIVE_COMPARATOR|Stupp|patient will receive 6 weeks chemotherapy treatment associating conformational 30 Gy (2Gy/ fraction)and Temodal(75mg/m²/day, followed by 6 months adjuvant therapy consisting in 5 days every 28 days of Temodal (150-200mg/m².
62382535|NCT03689270||Subluxation|Nucleus is hydrodissected until it lilts above the capsular bag, rotated to face the incision then tumbled and emulsification continues from the opposite equator outside in until complete
62382536|NCT03689270||Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
62382537|NCT05507515|EXPERIMENTAL|Part A: Cohort A1 ONO-2020 or Placebo - fasted|Single ascending doses of ONO-2020 orally under fasted conditions
62382538|NCT05507515|EXPERIMENTAL|Part A: Cohort A2 ONO-2020 or Placebo - fasted and fed|Single ascending doses of ONO-2020 orally under fasted and fed conditions
62382539|NCT05507515|EXPERIMENTAL|Part A: Cohort A3 ONO-2020 or Placebo - fasted|Single ascending doses of ONO-2020 orally under fasted conditions
62382540|NCT05507515|EXPERIMENTAL|Part A: Cohort A4 ONO-2020 or Placebo - fasted and fed|Single ascending doses of ONO-2020 orally under fasted and fed conditions
62762979|NCT01557881|EXPERIMENTAL|Diagnostic (PET/MRI)|After undergoing standard PET/CT, patients undergo PET/MRI.
62762980|NCT04533399|EXPERIMENTAL|Cohort 1 (HIV negative) 5 μg SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
62762981|NCT04533399|PLACEBO_COMPARATOR|Cohort 1 (HIV negative) Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
62762982|NCT04533399|EXPERIMENTAL|Cohort 2 (HIV positive) 5 μg SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
62762983|NCT04533399|PLACEBO_COMPARATOR|Cohort 2 (HIV positive) Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
62762984|NCT04761744|EXPERIMENTAL|Nivolumab|
62382541|NCT05507515|EXPERIMENTAL|Part A: Cohort A5 ONO-2020 or Placebo - fasted|Single ascending doses of ONO-2020 orally under fasted conditions
62382542|NCT05507515|EXPERIMENTAL|Part A: Cohort A6 ONO-2020 or Placebo - fasted|Single ascending doses of ONO-2020 orally under fasted conditions
62382543|NCT05507515|EXPERIMENTAL|Part B: Cohort B1 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days
62382544|NCT05507515|EXPERIMENTAL|Part B: Cohort B2 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days
61988036|NCT00826800|EXPERIMENTAL|Neoadjuvant FOLFOX Plus Bevacizumab|FOLFOX and bevacizumab will be given to colon cancer patients for 4 cycles over 8 weeks; an additional 2 cycles of FOLFOX without bevacizumab will be given for a total of 12 weeks of pre-operative chemotherapy.Restaging will be performed within 3 weeks of the 6th chemotherapy cycle. Colon surgery will be performed between weeks 3 and 6 subsequent to the 6th cycle of FOLFOX. Patients receiving preoperative chemotherapy without radiation will wait a minimum of 3 weeks from their last dose of chemotherapy, and 6 weeks from their last dose of bevacizumab, before proceeding to surgery. Specifically, it is intended that patients will undergo surgery between 3-6 weeks from completion of their neoadjuvant therapy as deemed clinically appropriate by their surgeon and medical oncologist. This permits a 7-10 week interval between the 4th bevacizumab administration and colon surgery.
61988037|NCT05447364|EXPERIMENTAL|75 mg of Pregabalin|Participant received 1 tab of 75 mg of Pregabalin and 1 tab of placebo
61988038|NCT05447364|ACTIVE_COMPARATOR|150 mg of Pregabalin|Participant received 2 tabs of 75 mg of Pregabalin
61988039|NCT04662801|EXPERIMENTAL|Behavioral Weight Loss|
61988040|NCT04662801|EXPERIMENTAL|Behavioral Weight Loss + Medication|
61988041|NCT02369341|EXPERIMENTAL|Fluarix Tetra (Southern Hemisphere) Adult Group|Subjects aged 18-60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
62382545|NCT05507515|EXPERIMENTAL|Part B: Cohort B3 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days
62382546|NCT05507515|EXPERIMENTAL|Part B: Cohort B4 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days
62382547|NCT05507515|EXPERIMENTAL|Part B: Cohort B5 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days
62382548|NCT05507515|EXPERIMENTAL|Part C: Cohort C1 ONO-2020|Single dose of ONO-2020 orally for CSF sampling
62382549|NCT05507515|EXPERIMENTAL|Part C: Cohort C2 ONO-2020|Single dose of ONO-2020 orally for CSF sampling
62382550|NCT05507515|EXPERIMENTAL|Part D: Cohort D1 ONO-2020 or Placebo|Single dose of ONO-2020 orally in elderly healthy volunteers
62382551|NCT05507515|EXPERIMENTAL|Part E: Cohort E1 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days in Japanese healthy volunteers
62382552|NCT05507515|EXPERIMENTAL|Part E: Cohort E2 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days in Japanese healthy volunteers
62382553|NCT01558791|NO_INTERVENTION|Arm 1|"Participants will be screened as usual. These participants will have the TBI screening as usual, without the educational intervention."
62382554|NCT01558791|EXPERIMENTAL|Arm 2|Participants will be given the TBI handout (educational intervention) along with the usual TBI screen.
62382555|NCT06374316|EXPERIMENTAL|Ceiling-Mounted Air Purifiers|Classrooms in this arm will have ceiling-mounted air purifiers installed. Air quality will be monitored throughout the study period.
62382556|NCT06374316|EXPERIMENTAL|Portable Air Purifiers|Classrooms in this arm will have portable air purifiers installed. Air quality will be monitored throughout the study period.
62382557|NCT06374316|EXPERIMENTAL|Both Portable and Ceiling-Mounted Air Purifiers|"Classrooms in this arms will have both portable and ceiling-mounted air purifiers installed. The rooms will alternate weekly between having no air purifiers on, or only ceiling-mounted air purifier on, or only portable air purifier on.~Air quality will be monitored throughout the study period."
62382558|NCT01681537|EXPERIMENTAL|Treatment Arm|Lenalidomide and re-induction chemotherapy
62382559|NCT02182856|EXPERIMENTAL|Ipratropium bromide/salbutamol sulphate|"Randomised sequence of four different treatments~1. Ipratropium bromide 500 µg/salbutamol sulphate 3 mg~2. Ipratropium 500 µg~3. Salbutamol sulphate 3 mg~4. Salbutamol sulphate 6 mg"
62382560|NCT06319066|EXPERIMENTAL|CFO with W1|The therapists will propose the orthotic wedges after examining the foot angles following the foot assessment from the study of Root, the forefoot angle will be determined for both the forefoot and rearfoot wedges. Previous studies recommended the posting at 60% of the measured forefoot angle, up to a maximum of 8 degrees, for extrinsic forefoot varus wedge and the posting at 50% of the measured forefoot angle, up to a maximum of 6 degrees, for extrinsic rearfoot varus wedge. After the posting, all participants will be asked to test the provided foot orthoses within their footwear. If any disturbance has been found during testing, the adjustment will be performed.
62382561|NCT06319066|EXPERIMENTAL|CFO with W2|The therapists will propose the orthotic wedges after examining the foot angles following the foot assessment from the study of Monaghan et al., the forefoot will be posted at 50% of the measured forefoot angle, and the rearfoot will be posted at 20% of the measured rearfoot angle. After the posting, all participants will be asked to test the provided foot orthoses within their footwear. If any disturbance has been found during testing, the adjustment will be performed.
62762985|NCT05976464|ACTIVE_COMPARATOR|erector spinae plane block|Ultrasound-guided Erector spinae plane (ESP) block will be done with the patient in a sitting position depending on the surgical site (lt. or Rt.) ESP block will be given using high-frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to the thoracic third and sixth spinous process, the erector spinae muscle, is identified from the surface, we will deposit 20 ml of 0.25% levobupivacaine into interfacial plane below erector spinae muscle.
62762986|NCT05976464|EXPERIMENTAL|magnesium sulfate as an adjuvant in erector spinae plane block|Ultrasound-guided Erector spinae plane (ESP) block will be done with the patient in a sitting position depending on surgical site (lt. or Rt.) ESP block will be given using high-frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to the thoracic third and sixth spinous process, the erector spinae muscle, is identified from the surface, we will deposit 20 ml of 0.25% levobupivacaine and magnesium sulfate into interfacial plane below erector spinae muscle.
62762987|NCT01001546|EXPERIMENTAL|Arm 1|Internet-based smoking cessation
62762988|NCT01001546|OTHER|Arm 2|Clinic-based smoking cessation
62762989|NCT06031545|EXPERIMENTAL|Long peripheral venous catheters|In the test group used LPCs during the perioperative period in obese patients
62762990|NCT06031545|OTHER|Midline catheters|In the control group used LPCs during the perioperative period in obese patients
62762991|NCT05909774|EXPERIMENTAL|Exoskeleton second|"This group first perform tests without Atalante exoskeleton and secondly with Atalante exoskeleton. A second randomization is performed inside each group, with half of the patients first performing walk test with the Continuous walk and then with the Push \& Swing walk, and the other half doing the opposite."
62762992|NCT05909774|ACTIVE_COMPARATOR|Exoskeleton first|"This group first perform tests with Atalante exoskeleton and secondly without Atalante exoskeleton. A second randomization is performed inside each group, with half of the patients first performing walk test with the Continuous walk and then with the Push \& Swing walk, and the other half doing the opposite."
62762993|NCT00690287|EXPERIMENTAL|Part A, arm 1|1) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo together with food
62762994|NCT00690287|EXPERIMENTAL|Part A, arm 2|1) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo without food
62762995|NCT00690287|EXPERIMENTAL|Part B, arm1, 2, and 3|"1. AZD6370 dose x mg o.d.~2. dose x/2 mg b.i.d.~3. dose x/4 mg q.i.d."
62762996|NCT00690287|EXPERIMENTAL|Part B, arm 4|4) Placebo
62762997|NCT04654871|EXPERIMENTAL|Experimental Group|
62762998|NCT04654871|EXPERIMENTAL|Active Comparator Group|
62762999|NCT01519739|EXPERIMENTAL|MediGuide Arm|
62763000|NCT02212171|EXPERIMENTAL|TRIAP intervention|
62763001|NCT02212171|NO_INTERVENTION|Usual care|Usual care: Patients in the control group will be treated according to Osakidetza recommendations.
62382562|NCT06319066|ACTIVE_COMPARATOR|CFO without wedge|The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.
62763002|NCT03421743|EXPERIMENTAL|Inhaled molgramostim/antimycobacterials|Inhaled molgramostim administered in participants who remain sputum culture positive while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 6 months prior to the Baseline Visit
62168201|NCT06584682|OTHER|conventional therapy|stretching of hamstring muscle, METs, sciatic nerve glides, lower limb neurodynamic.
62382563|NCT06212518|EXPERIMENTAL|GENPOP passive dehydration|In the 24 hours between the first and last face scan, reduce fluid intake by approximately 75% (equating to approximately 700 ml (women) and 800 ml (men)). Participants will be provided pre-filled water bottles and asked to only ingest fluid in bottle until second morning face scan.
62382564|NCT06212518|EXPERIMENTAL|GENPOP ad libitum fluid intake|No fluid restriction
62382565|NCT06212518|EXPERIMENTAL|ATHLETE with fluid restriction|For 24 hours prior to the study session, encouraged to drink sufficient fluid to maintain euhydration. Asked to refrain from alcohol 24 hours prior to session. Not permitted to drink during training session.
62382566|NCT06212518|EXPERIMENTAL|ATHLETE ad libitum fluid intake|For 24 hours prior to the study session, encouraged to drink sufficient fluid to maintain euhydration. Asked to refrain from alcohol 24 hours prior to session. Permitted to drink during training session.
62382567|NCT01550315|ACTIVE_COMPARATOR|High Sodium - POTS & Controls|Subjects will receive a high sodium diet for 4-5 days prior to study day. Procedures include: blood work, urine collection, Pulsitile Arterial Tonometry (PAT), PAT analysis, Calf Blood Flow in Reactive Hyperemia (CBF-RH), \& evaluation of forearm-mediated dilation.
62382568|NCT01550315|OTHER|Low Sodium Diet (POTS & Controls)|"Participants will consume a very low sodium diet (10 mEq/day) for 4-5 days prior to study day.~Procedures include: blood work, urine collection, Pulsitile Arterial Tonometry (PAT), PAT analysis, Calf Blood Flow in Reactive Hyperemia (CBF-RH), \& evaluation of forearm-mediated dilation."
62382569|NCT00039104|EXPERIMENTAL|Arm I (rebimastat, zoledronic acid)|Patients receive zoledronate IV over at least 15 minutes on day 1 and oral BMS-275291 daily on days 1-28.
62382570|NCT00039104|EXPERIMENTAL|Arm II (zoledronic acid)|Patients receive zoledronate as in Arm I.
62382571|NCT01749436||Lung ultrasound imaging|Lung ultrasound imaging examinations performed during the perioperative period for the monitoring of atelectasis associated with laparoscopic surgery
62382572|NCT02831894|SHAM_COMPARATOR|0% Hypnotic Medication Taper|In this condition patients will be maintained on their baseline hypnotic medication dosage throughout a 20-week double-blinded tapering period.
62382573|NCT02831894|ACTIVE_COMPARATOR|25% Hypnotic Medication Taper|In this condition patients will have their current hypnotic medication dosage reduced by 25% every 2 weeks throughout a 20-week double-blinded tapering period.
62382574|NCT02831894|ACTIVE_COMPARATOR|10% Hypnotic Medication Taper|In this condition patients will have their current hypnotic medication dosage reduced by 10% every 2 weeks throughout a 20-week double-blinded tapering period.
62382575|NCT00244803||HIV Positive FRAM 1 Participant|
62382576|NCT06264336|EXPERIMENTAL|High-intensity interval treadmill training|Walking with high intensity intervals interspersed.
62382577|NCT06264336|ACTIVE_COMPARATOR|Moderate-intensity continuous treadmill training|Continuous walking at a moderate intensity
62382578|NCT03506828|ACTIVE_COMPARATOR|Surgical sympathectomy|All patients in this group will have standard surgical procedure
62382579|NCT03506828|ACTIVE_COMPARATOR|Radiofrequency ablation with phenol injection|patient will receive radiofrequency ablation of T2 and T3 sympathetic ganglia + phenol 6% (0.5ml) injection
62382580|NCT06319677||ECMO treatment group|Critically ill adult patients treated with ECMO using one or more antimicrobial agents
62382581|NCT06319677||Non-ECMO treatment group|Critically ill adult patients using one or more antimicrobial agents not receving ECMO
62382582|NCT05760651||Multiple Sclerosis Patients|Patients diagnosed with multiple sclerosis.
62382583|NCT02879864|EXPERIMENTAL|Light therapy|Light therapy takes place in the patient's home the day following receipt of the equipment and for at least 7 days before the start of chemotherapy and according to current recommendations: daily exposure to a high intensity light (10,000 lux) in the morning at a time to be adapted to the patient according to his chronotype), for 30 minutes. Light therapy begins immediately after receipt of the luminometer. The total duration of daily outpatient therapy program is 6 months. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at the inclusion visit and at weeks 12 and 24. They will complete the same day or the day before, and / or before any chemotherapy. A follow-up visit will be performed 1 month after the end of therapy (week 28).
62382584|NCT02879864|ACTIVE_COMPARATOR|usual care|usual care in oncology: The patient will be taken care of according to local chemotherapy in routine care and the recommendations. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24. They will complete the same day or the day before, and / or chemotherapy before . A follow-up visit will be performed 1 month after the last visit (week 28). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before
62763003|NCT03421743|EXPERIMENTAL|Inhaled molgramostim|Inhaled molgramostim administered in participants who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance, or who never started such treatment
62763004|NCT03452033|PLACEBO_COMPARATOR|H-1337 Placebo|H-1337 Placebo
62763005|NCT03452033|EXPERIMENTAL|H-1337 [1]|H-1337 \[1\]
62763006|NCT03452033|EXPERIMENTAL|H-1337 [2]|H-1337 \[2\]
62763007|NCT03452033|EXPERIMENTAL|H-1337 [3]|H-1337 \[3\]
62763008|NCT06270251|EXPERIMENTAL|Study group|Youth ages 12-21 years with chronic tics will complete a course of 10 outpatient, weekly CBIT sessions with pre-, post-, 1-month and 3-month follow up assessments.
62763009|NCT05735522|ACTIVE_COMPARATOR|Active group|"We are using an extracorporeal magnetic stimulation chair with two magnetic stimulators, one under the seat and one in the backrest, that generate the magnetic field. The treatment lasts for 30 minutes and has 5 steps. Each step has a defined duration and a defined frequency of magnetic field pulsations. In each step, it is also defined, which of the magnetic field generators are working. The pulsations last for 6 seconds followed by 6 seconds of rest.~Step 1: 10Hz, 7 minutes, 6 seconds on, 6 seconds off, both stimulators generate the magnetic field. Step 2: 10Hz, 4 minutes, the stimulator under the seat generates the magnetic field. Step 3: 10Hz, 7 minutes, the stimulator in the backrest generates the magnetic field. Step 4: 30Hz, 10 minutes, both stimulators generate the magnetic field. Step 5: After 5 minutes, both stimulators generate the magnetic field.~During the treatment, we adjusted the magnetic field density. It varied from 2-100%. The maximum was 3 Teslas."
62763010|NCT05735522|SHAM_COMPARATOR|Sham group|We are using extracorporeal magnetic stimulation, a chair with two magnetic stimulators, one under the seat and one in the backrest, that generate the magnetic field. The treatment lasts for 30 minutes and has 5 steps. We used the same program as in the active group with the difference that the magnetic field density was always at 2% so the effects of the pulsating are negligible.
62763011|NCT01155921|EXPERIMENTAL|Risperidone Orally Disintegrating|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
62763012|NCT01155921|ACTIVE_COMPARATOR|Risperdal M-TAB|(Risperdal M-TAB) 1 mg risperidone orally disintegrating tablets Janssen Pharmaceutica Products
62763013|NCT03048838|EXPERIMENTAL|Risk reduction behavioral intervention|"Couples randomized to the risk reduction behavioral intervention (Conectando Latinos en Pareja) will participate in four weekly sessions with a facilitator. Each session will last 2 hours. Participants will receive information and complete activities, participate in games and discussions to improve their relationship and improve health."
62763014|NCT03048838|ACTIVE_COMPARATOR|Wellness Promotion Intervention|Couples randomized to the wellness promotion control group will receive the same number of hours of attention as the active experimental group but will not receive the risk reduction intervention. Information presented will consist of topics related to general health.
62763015|NCT01618279||Tryptase|Patients with clinical manifestations have been discovered and documented symptoms of coronary heart
62763016|NCT02486991|ACTIVE_COMPARATOR|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
62763017|NCT02486991|EXPERIMENTAL|Tunnel + AlloDerm® + Verticals|The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
62763018|NCT01726673|EXPERIMENTAL|tDCS + robotic arm therapy|Transcranial Direct Current Stimulation (tDCS) 2mA for 20 minutes over the primary motor cortex (M1) in the affected hemisphere immediately followed by robotic arm therapy for 60 minutes, 3x per week for 12 weeks (36 sessions total)
62763019|NCT01726673|PLACEBO_COMPARATOR|tDCS sham + robotic arm therapy|Transcranial Direct Current Stimulation sham condition (0 mA) for 20 minutes over the primary motor cortex (M1) in the affected hemisphere immediately followed by robotic arm therapy for 60 minutes, 3x per week for 12 weeks (36 sessions total)
62763020|NCT04021524|ACTIVE_COMPARATOR|Hibiclens Soap|
62763021|NCT04021524|EXPERIMENTAL|BPO Soap|
62763022|NCT00810901|EXPERIMENTAL|Organ Donor|Intervention used a DVD, text messaging, emails, a website, US Mail, and telephone calls to educate teens about their choice to become a designated organ donor on their first driver's license application.
62763023|NCT00810901|ACTIVE_COMPARATOR|Alcohol Prevention|Intervention used a DVD and text messages, to educate teens about the laws that prohibit underage minors purchasing and consuming alcohol
62763024|NCT03847857|EXPERIMENTAL|Surgery+PFS|Arm A consists of the concurrent application of Porcine Fibrin Sealant (PFS) on the gastroesophageal anastomosis during McKeown esophagectomy.
62382585|NCT03500419|ACTIVE_COMPARATOR|Control|No treatment will be administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes.
62763025|NCT03847857|PLACEBO_COMPARATOR|Surgery|Arm B underwent conventional anastomosis during McKeown esophagectomy.
62763026|NCT04159532|EXPERIMENTAL|Monoglyceride (MAG)|Group A will receive the omega-3 fatty acids in monoglyceride formulation (MAG). Subjects will receive 1.5g per day of MAG-EPA/MAG-DHA in a proportion of 460:200 for 12 consecutive weeks.
62763027|NCT04159532|ACTIVE_COMPARATOR|Triglyceride (TG)|Group B will receive the omega-3 fatty acids in triglyceride formulation (TG). Subjects will receive 1.5g per day of TG-EPA/TG-DHA in a proportion of 460:200 for 12 consecutive weeks.
62763028|NCT04159532|ACTIVE_COMPARATOR|Ethyl Ester(EE)|Group C will receive the omega-3 fatty acids in Ethyl ester formulation (EE). Subjects will receive 1.5g per day of EE-EPA/EE-DHA in a proportion of 460:200 for 12 consecutive weeks.
62763029|NCT06294938|ACTIVE_COMPARATOR|Dextrose|Dextrose matched for available carbohydrate
61988042|NCT02369341|EXPERIMENTAL|Fluarix Tetra (Southern Hemisphere) Elderly Group|Subjects aged \>60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
62168202|NCT00717925|EXPERIMENTAL|1|
62382586|NCT03500419|EXPERIMENTAL|Group AB - PTT 1-2x daily x 5-7 days/week x 5 months|Men will utilize penile traction therapy for 30 minutes 1-2 times daily, 5-7 times a week, beginning 4 weeks post-prostatectomy. Men will remain in this phase for a period of 5 months.
62382587|NCT04852666||Crohn's Disease (Vedolizumab)|Participants with Crohn's disease (CD) who reported taking vedolizumab.
62763030|NCT06294938|EXPERIMENTAL|Cacao fruit pulp|Cacao fruit pulp matched for available carbohydrate
62763031|NCT01231815|EXPERIMENTAL|PET|15O-H2O PET
62763032|NCT01231815|EXPERIMENTAL|MRI|MRI
62763033|NCT04911764|EXPERIMENTAL|Three-min Step Test and Exercise desaturation detection in COPD|Each patient recruited will performed both field tests, being therefore his or her own witness.
61988043|NCT05863637|EXPERIMENTAL|Treated|Participants are their own controls when they are on the waiting list before treatment, and they will later be treated with the ISTDP.
62382588|NCT04852666||Crohn's Disease (Ustekinumab)|Participants with Crohn's disease (CD) who reported taking ustekinumab.
62382589|NCT04852666||Ulcerative Colitis (Vedolizumab)|Participants with Ulcerative colitis (UC) who reported taking vedolizumab.
62382590|NCT04852666||Ulcerative Colitis (Tofacitinib)|Participants with Ulcerative colitis (UC) who reported taking tofacitinib.
62382591|NCT00260806||1|Children perinatally infected with HIV with exposure to highly active anti-retroviral therapy (HAART).
62382592|NCT00260806||2|Children with perinatally acquired HIV infection enrolled on the P2C2 Study, not exposed to HAART therapy.
62382593|NCT04912297||PCV10 2+1 schedule|Ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10; GlaxoSmithKline) administered with a 2+1 schedule (two vaccinations with minimum 8-week intervals followed by a booster dose at least 4 months after the last primary dose).
62382594|NCT04912297||PCV10 3+1 schedule|Ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10; GlaxoSmithKline) administered with a 3+1 schedule (three vaccinations with minimum 4-week intervals, followed by a booster dose at least 4 months after the last primary dose).
61988044|NCT05693285||Preterm birth|Women with spontaneous preterm birth in first pregnancy
61988045|NCT05693285||Controls|Matched controls with spontaneous delivery in normal time in first pregnancy
61988046|NCT03668626|NO_INTERVENTION|Term infants|Healthy term infants
61988047|NCT03668626|NO_INTERVENTION|Usual care program (UCP)|In-hospital and after-discharge intervention (telephone calls)
61988048|NCT03668626|EXPERIMENTAL|Family-centered intervention program (FCIP)|In-hospital and after-discharge intervention (clinic and home visits)
61988049|NCT05441527|EXPERIMENTAL|MI Paste, then, Biotene Dry Mouth Gel|Subjects in this arm will use 1 milliliter of MI Paste daily for 7 days. Then, the subjects in this arm will use 1 milliliter of Biotene Dry Mouth gel daily for 7 days. There will be no wash-out period between the two products.
62382595|NCT01813149|EXPERIMENTAL|phenylephrine and clonidine|Subjects will be injected with phenylephrine and clonidine at affected and unaffected sites.
62382596|NCT00309192|EXPERIMENTAL|1|Triamcinolone acetonide + Grid Laser
62382597|NCT00309192|SHAM_COMPARATOR|2|Sham procedure + Grid laser
62382598|NCT03701932|EXPERIMENTAL|TMS and Lumosity® cognitive retraining|Group will receive TMS and will concurrently engage in cognitive retraining exercises comprised of the Lumosity® battery.
62382599|NCT03701932|ACTIVE_COMPARATOR|TMS and non cognitive computer games|Group will receive TMS while concurrently engaging in selected computer games from several gaming software that includes Play 101 Games and Hoyle Puzzle and Board Games®. They will also be allowed to spend time on gaming activities of their choice in order to keep them engaged
62382600|NCT05748366|EXPERIMENTAL|Serratus Anterior Plane Block|Subjects will undergo serratus anterior plane block, in addition to standard of care analgesic medications at the discretion of the treatment team.
62382601|NCT05748366|ACTIVE_COMPARATOR|Standard Analgesic Medications|Subjects will receive standard of care analgesic medications at the discretion of the treatment team.
62382602|NCT05143853|ACTIVE_COMPARATOR|group with tape augmentation of acromioclavicular (AC) joint|patients randomised in this group will have additional tape fixation around AC joint. Both groups will however have fixation in CC area.
62382603|NCT05143853|SHAM_COMPARATOR|group without tape augmentation of AC joint|patients randomised in this group will not have additional tape fixation around AC joint. Both groups will however have fixation in CC area.
62382604|NCT03898856|EXPERIMENTAL|Crofelemer and Diagnostic tests for cause of chronic diarrhea|125 mg tablets taken by mouth twice daily for 28 days
62382605|NCT03615690|EXPERIMENTAL|Fasting Mimicking Diet|Three cycles of a 5-day reduced calorie diet
62763034|NCT02989844|EXPERIMENTAL|N-803|
62763035|NCT06515314|EXPERIMENTAL|HRYZ-T102 Injection|Patients will undergo lymphocytapheresis, then treatment with HRYZ-T102 TCR-T cells.
61988050|NCT05441527|EXPERIMENTAL|Biotene Dry Mouth Gel, then, MI Paste|Subjects in this arm will use 1 milliliter of Biotene Dry Mouth gel for 7 days. Then, the subjects in this arm will use 1 milliliter of MI Paste for 7 days. There will be no wash-out period between the two products.
61988051|NCT02744573||General Anaesthesia|ANI and SPI values under general anaesthesia
61988052|NCT02744573||Spinal Anaesthesia|ANI and SPI values under spinal anaesthesia
62763036|NCT02462408|EXPERIMENTAL|Posterior approach|The main difference between this block approach and the conventional infraclavicular approach is the site and angle of needle insertion. Otherwise, the end point of local anaesthetic injection remained the same for both approaches.
62763037|NCT02462408|ACTIVE_COMPARATOR|Conventional approach|The main difference between this block approach and the conventional infraclavicular approach is the site and angle of needle insertion. Otherwise, the end point of local anaesthetic injection remained the same for both approaches.
62763038|NCT02152514|ACTIVE_COMPARATOR|Intrathecal Morphine/Sufentanil and PCA|Patients will receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will have a PCA for analgesia rescue in the post-operative period.
62763039|NCT02152514|PLACEBO_COMPARATOR|PCA alone|Patients will NOT receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will only have a PCA for analgesia in the post-operative period.
62763040|NCT05394480|EXPERIMENTAL|clinical treatment|"4 dentist treated 36 patient in clinical group~- For treatment in a clinic, children with positive or definitely positive (Frankl 3 and 4) behaviour according to the Frankl Scale (Behavior Evaluation Scale) 28, with the data observed in the first session, were included in the clinical treatment group. According to the clinical examination of these patients, 36 healthy children aged 5-6 years who did not require pulpal treatment and whose caries level was 1-4 according to the ICDAS (International Caries Detection And Assessment System) 29 scoring were selected. The limits of the treatment were determined as compomer filling applied to 2 primary molars after local anaesthesia, and the duration of the treatment was limited to 30 to 60 minutes."
62763041|NCT05394480|EXPERIMENTAL|deep sedation|"4 dentist treated 36 patient in clinical group~- Children aged 48-72 months, children with negative or absolutely negative behaviour (Frankl 1 and 2) according to the Frankl Scale, were reserved for treatment under deep sedation. In order to provide standardization among patients suitable for sedation, 36 children (n=9) whose dmft (decayed, missing, filled teeth index) were less than their age, and the duration of the procedure would be limited to between 30 and 40 minutes, were included in the study."
62763042|NCT05394480|EXPERIMENTAL|general anaesthesia|"4 dentist treated 36 patient in clinical group~- Children aged 48-72 months, children with negative or definitely negative behaviour according to the Frankl Scale (Frankl 1 and 2), were reserved for treatment under general anaesthesia. In order to provide standardization among patients suitable for general anaesthesia, 36 healthy children (n=9) whose dmft was equal to, or higher than their age were allocated. In addition, patients whose treatment time would be limited to 30 to 60 minutes were included."
62763043|NCT06183879|ACTIVE_COMPARATOR|Medtronic 4th gen balloon|Cryoballoon pulmonary vein isolation with Medtronic Artic Front Advance Pro 28 mm fixed size cryoballoon
62382606|NCT03615690|PLACEBO_COMPARATOR|Regular Diet Control Arm|
62382607|NCT02045615||Conventional|Conventional technique for Wichita nail extraction
62382608|NCT02045615||New|Proposed technique for Wichita nail extraction
62382609|NCT05240781|ACTIVE_COMPARATOR|Zotarolimus Eluting Stent|High Bleeding Risk patients to be treated with drug-eluting stents (DES). Includes both stable Coronary Artery Disease (CAD) and Acute Coronary Syndrome (ACS) patients undergoing elective PCI.
62382610|NCT05240781|EXPERIMENTAL|Sirolimus Eluting Stent|High Bleeding Risk patients to be treated with drug-eluting stents (DES). Includes both stable CAD and ACS patients undergoing elective PCI.
62382611|NCT02315794|EXPERIMENTAL|SPI®ART|in test group after a three month healing period a zirconia abutment was connected to the implant to realize the prosthetic restoration
62763044|NCT06183879|ACTIVE_COMPARATOR|Boston 2nd gen balloon|Cryoballoon pulmonary vein isolation with Polar X Fit, 28 to 31 mm expandable cryoballoon
62763045|NCT02159118|ACTIVE_COMPARATOR|Manual bone marrow aspiration and biopsy procedure|Manual bone marrow aspiration and biopsy device
61988053|NCT02744573||Spinal Anaesthesia + Sedation|ANI and SPI values under spinal anesthesia in combination with sedation
61988054|NCT02744573||Control|ANI and SPI values under no anaesthesia
61988055|NCT02057471|EXPERIMENTAL|Intravenous Ferric Carboxymaltose|All recruited patients will be allocated to this treatment. 1 gram of Ferric carboxymaltose (FERINJECT) to be given at recruitment
62168203|NCT00998114|EXPERIMENTAL|Exercise and diastolic dysfunction|Aerobic exercise for 30-45 minutes five times a week for six months
62382612|NCT02315794|ACTIVE_COMPARATOR|SPI®EASY|in control group a three month healing period a titanium abutment was connected to the implant for the prosthetic restoration
62382613|NCT03008928|NO_INTERVENTION|Control|No intervention
62382614|NCT03008928|EXPERIMENTAL|Alcooquizz app|Alcooquizz is a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazarzdous fashion
62382615|NCT05998902|ACTIVE_COMPARATOR|Full enteral feeding|Patients will receive full enteral feeding through nasogastric tube or nasointestinal tube.
62382616|NCT05998902|EXPERIMENTAL|Trophic enteral feeding combined with supplemental parenteral nutrition|Patients will receive trophic enteral feeding combined with supplemental parenteral feeding.
62382617|NCT05555914|EXPERIMENTAL|Neurostimulation|Implantation of 3 multicontact cuff electrodes in the upper limb of patients with tetraplegia
62382618|NCT02357524|EXPERIMENTAL|Oritavancin|Subject will receive a single oritavancin dose of 1200 mg in 1000 mL of D5W administered as a constant rate IV infusion over 3 hours via a single dedicated peripheral venous line.
62382619|NCT06377215||Older listeners with hearing loss|Test group, tested with and without the intervention (openMHA device) fit to their audiometric profile.
62382620|NCT06377215||Older listeners with normal hearing|Control group, no intervention.
62763046|NCT02159118|ACTIVE_COMPARATOR|Powered bone marrow aspiration and biopsy procedure|Powered bone marrow aspiration and biopsy device
62763047|NCT02008513|ACTIVE_COMPARATOR|Group 1|AFF006 Placebo groups receive 6 AFFITOPE® AD02 vaccinations
62763048|NCT02008513|ACTIVE_COMPARATOR|Group 2|AFF006 verum groups receive 3 Placebo injections then followed by 3 AFFITOPE® AD02 vaccinations
62763049|NCT01653899|EXPERIMENTAL|IDN-6556|Drug
62763050|NCT01730963||Pregnant, Preterm, In Labor|Gestation Age at or less than 36 weeks, clinically determined to be in labor
62763051|NCT01730963||Pregnant, Preterm, Nonlaboring|Gestation Age at or less than 36 weeks, clinically determined to not be in labor
62763052|NCT01730963||Pregnant, Term, Nonlaboring|Gestation Age more than 36 weeks, clinically determined to not be in labor
62763053|NCT05000268|ACTIVE_COMPARATOR|Painful Healthcare Workers with COVID-19|Healthcare workers who have had COVID-19 infection in the past and are now in pain without COVID-19 infection
62182584|NCT01127321|PLACEBO_COMPARATOR|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
62382621|NCT06377215||Younger listeners with normal hearing|Control group, no intervention.
62382622|NCT00519415|EXPERIMENTAL|A|
62382623|NCT00519415|EXPERIMENTAL|B|
62382624|NCT05213689|EXPERIMENTAL|HIV self-testing + educational comic book|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, in addition to contact information for confirmatory testing and linkage to care at local clinics. Participants will also receive an educational comic book focused on HIV testing information and decision making that was developed with qualitative data collected from an earlier study phase. PNs will meet with small groups of participants to read through and discuss the comic book together.
62763054|NCT05000268|ACTIVE_COMPARATOR|Painful Health Care Workers without COVID-19|Healthcare workers with past and present pain without COVID-19 infection
62763055|NCT01689350|NO_INTERVENTION|Control Group|The cases in control group received traditional therapy that the initial dose of cyclophosphamide (CPA) was 0.2-0.6g/week injection according to clinical experience.
62382625|NCT05213689|ACTIVE_COMPARATOR|HIV self-testing|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, in addition to contact information for confirmatory testing and linkage to care at local clinics.
62763056|NCT01689350|EXPERIMENTAL|Experimental Group|Genetic: Genotype Detection To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM),with initial dose of CPA as 0.2g, 0.4g and 0.6g per week by injection, respectively.
62763057|NCT02673567|EXPERIMENTAL|TEV-48125 - 1|Dose Regimen 1
62763058|NCT02673567|EXPERIMENTAL|TEV-48125 - 2|Dose Regimen 2
62763059|NCT02673567|EXPERIMENTAL|TEV-48125 - 3|Dose Regimen 3
62763060|NCT02673567|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62382626|NCT05213689|ACTIVE_COMPARATOR|Educational comic book|Participants will receive an educational comic book focused on HIV testing information and decision making that was developed with qualitative data collected from an earlier study phase. PNs will meet with small groups of participants to read through and discuss the comic book together.
62382627|NCT05213689|NO_INTERVENTION|Standard of Care|PNs will provide information about HIV testing, care and support services at local clinics.
62382628|NCT03500315|EXPERIMENTAL|HIV D+/R+|HIV-infected individuals that accept an organ from an HIV-infected deceased donor - enrollment 100
62763061|NCT03541187|EXPERIMENTAL|G. cockroach allergenic extract|"Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm.~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. After maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months."
62763062|NCT03541187|PLACEBO_COMPARATOR|Placebo|"Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm.~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. Once the maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months."
62182585|NCT01127321|EXPERIMENTAL|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
62182586|NCT01127321|EXPERIMENTAL|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
62382629|NCT03500315|NO_INTERVENTION|HIV D-/R+|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor -enrollment 100
62382630|NCT03500315|NO_INTERVENTION|HIV D-/R+ (observational)|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and randomized to observational group - enrollment 200
62382631|NCT03040479|EXPERIMENTAL|Mild hepatic impairment|lasmiditan 200 mg single dose
62763063|NCT00661388|EXPERIMENTAL|Continuous erythropoietin receptor activator (C.E.R.A.)|Eligible participants will be administered C.E.R.A subcutaneously, every 4 weeks for 44 weeks. The initial dose of C.E.R.A. will be 1.2 micrograms/kilogram. Subsequent doses will be adjusted to maintain the individual participant's hemoglobin within the target range of 10.0 and 12.0 grams/deciliter.
62763064|NCT04258995|EXPERIMENTAL|GBS6 no aluminum phosphate (GBS6 no AlPO4)|
62763065|NCT04258995|EXPERIMENTAL|GBS6 with aluminum phosphate (GBS6 with AlPO4)|
62763066|NCT01049802|EXPERIMENTAL|Active rTMS|Experimental subjects will receive subthreshold or suprathreshold rTMS to contralesional hemisphere for up to 20 minutes at 1 Hz followed by task oriented arm and hand therapy to affected limb.
62763067|NCT01049802|PLACEBO_COMPARATOR|Sham rTMS|Subject will receive sham rTMS to contralesional hemisphere for up to 20 minutes followed by task-oriented arm and hand rehabilitation to affected limb
61988056|NCT00352521|EXPERIMENTAL|Bevacizumab and irinotecan|The bevacizumab will be dosed at 10 mg/kg every 14 days (days 1, 15 and 29) and the irinotecan on days 2, 15, and 29 of the first six week schedule. The irinotecan dose will depend on whether the patient is on an enzyme-inducing antiepileptic drug (EIAED). If the patient is on an EIAED, the patient will receive 340 mg/m2 on days 2, 15, and 29 of the first six week schedule. If the patient is not on an EIAED, the dose of irinotecan will be 125 mg/m2 on days 2, 15, and 29 of the first six week schedule. After the first cycle, the irinotecan and bevacizumab will be given on days 1, 15 and 29.
61988057|NCT06434662|EXPERIMENTAL|MAV regimen|mitoxantrone hydrochloride liposome injection, cytarabine combined with venetoclax
62382632|NCT03040479|EXPERIMENTAL|Moderate hepatic impairment|lasmiditan 200 mg single dose
62382633|NCT03040479|EXPERIMENTAL|Healthy participants|lasmiditan 200 mg single dose
62382634|NCT04327115|OTHER|Arm 1|"(C-I-I-I) : the centers apply the Control strategy in Period 1 and then apply the Intervention strategy in Periods 2 to 4."
62382635|NCT04327115|OTHER|Arm 2|"(C-C-I-I) : the centers apply the Control strategy in periods 1 and 2 and then apply the Intervention strategy in periods 3 and 4."
62382636|NCT04327115|OTHER|Arm 3|"(C-C-C-I) : the centers apply the Control strategy in periods 1, 2 and 3 and then apply the Intervention strategy for period 4."
62382637|NCT02186340|EXPERIMENTAL|Inspiratory muscle training|
62382638|NCT04143256|EXPERIMENTAL|Group I|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Virginia Tobacco and 3% Virginia Tobacco
62382639|NCT04143256|EXPERIMENTAL|Group II|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mint and 3% Mint
62382640|NCT04143256|EXPERIMENTAL|Group III|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Menthol and 3% Menthol
62382641|NCT04143256|EXPERIMENTAL|Group IV|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mango and 3% Mango
62382642|NCT04143256|EXPERIMENTAL|Group V|Subjects with cigarette user history will be assigned to use US Cigarette, Non-Menthol Flavor (Marlboro Gold King Size)
62382643|NCT04143256|EXPERIMENTAL|Group VI|Subjects with cigarette user history will be assigned to use US Cigarette, Menthol Flavor (Newport King Size)
62382644|NCT02366806||In-Depth Education|A. Standard radiotherapy discussion including rationale, number of fractions, side effects, +/- beam arrangements, potential and likely short and long-term toxicity, status checks, skin care, nursing and physician accessibility B. Radiotherapy plan review to include, but not limited to: beam arrangement, total dose, dose per fraction, target area(s), description of isodose lines, DVH review and discussion of prescription constraints for OARs
62382645|NCT00447395||GROUP 1|Recurrent miscarriage, \<40 year-old-men, \< 38 year-old-women, normal or mild affected sperm, normal parents karyotype, no thrombophilia, normal uterus, no endocrinopathy
62382646|NCT00447395||GROUP 2|•Recurrent miscarriage, \<40 year-old-men, \< 38 year-old-women, oligozoospermia (1-5 mill/ml), normal parents karyotype, no thrombophilia, normal uterus, no endocrinopathy
62382647|NCT00447395||GROUP 3|•Oligozoospermia (1-5 mill/ml), \< 40 year-old-men, no recurrent miscarriages
62382648|NCT00447395||GROUP 4|•Healthy young sperm donors
62382649|NCT03066687|EXPERIMENTAL|Treatment Sequence 1: Erdafitinib 9 mg|Participants will receive 9 milligram (mg) dose of erdafitinib under fasted condition \[Treatment A\] in Period 1, and under fed (with high-fat and high-calorie breakfast) condition \[Treatment B\] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.
61988058|NCT01048723|EXPERIMENTAL|RAD001 Administration|RAD001 was administered orally as once daily dose of 10 mg PO daily x 2 weeks (14 X 10 mg tablets) continuously from study day 1 until the end of therapy (2 weeks later) or unacceptable toxicity.
62382650|NCT03066687|EXPERIMENTAL|Treatment Sequence 2: Erdafitinib 9 mg|Participants will receive 9 mg dose of erdafitinib under fed (high-fat and high-calorie breakfast) condition \[Treatment B\] in Period 1, and under fasted condition \[Treatment A\] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.
62182587|NCT01127321|EXPERIMENTAL|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
62382651|NCT03102424|EXPERIMENTAL|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
62382652|NCT03102424|PLACEBO_COMPARATOR|Sham DW1330 device|The 20 weeks of treatment of the Sham DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
62382653|NCT03735186|NO_INTERVENTION|Control|Participants will rest in the laboratory on day 1 and day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
62382654|NCT03735186|EXPERIMENTAL|Exercise|Participants will complete 60 min of treadmill exercise on day 1 (14:30-15:30). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
62382655|NCT03195231|EXPERIMENTAL|Wuling Powder Group|Take Wuling Powder 3 times a day，3 pills each time for 12 weeks
62382656|NCT03195231|PLACEBO_COMPARATOR|Placebo Group|Take placebo drug which cannot be distinguished from the experimental drug 3 times a day，3 pills each time for 12 weeks
62382657|NCT03338699|EXPERIMENTAL|ShangRing|Topical anesthesia based, no-flip ShangRing circumcision.
62382658|NCT03338699|ACTIVE_COMPARATOR|Mogen clamp|Mogen clamp circumcision.
62382659|NCT05835544|ACTIVE_COMPARATOR|HIIT Control|High intensity interval cycling
62382660|NCT05835544|EXPERIMENTAL|HIIT + BFR between cycling sets|High intensity interval cycling with blood flow restriction applied between sets of cycling
62382661|NCT05835544|EXPERIMENTAL|HIIT + BFR moderate occlusion during cycling|High intensity interval cycling with moderate blood flow restriction applied during cycling
62382662|NCT05835544|EXPERIMENTAL|HIIT + BFR high occlusion during cycling|High intensity interval cycling with high blood flow restriction applied during cycling
62382663|NCT01409265||No treatment|
62382664|NCT05850962|NO_INTERVENTION|Standard MAP target|The comparator or the control group will be comprised of patients assigned to standard care, where vasopressor support will be titrated to maintain a default MAP of 65 mmHg, unless the treating clinician considers a different MAP target as more appropriate.
62382665|NCT05850962|ACTIVE_COMPARATOR|Individualised MAP target|"In the intervention arm, a patient's own pre-illness mean arterial pressure (MAP) would be targeted (range: 55-95 mmHg) during vasopressor support in ICU. The pre-illness MAP will be estimated from most recent pre-illness BP readings following a standardized method (Panwar et al,. Blood Press. 2017:1-9) and will be targeted for the duration of vasopressor therapy for up to a maximum of five days. The treating clinician can tailor these BP targets as deemed suitable for current clinical state. The type of vasopressor that will be used is at the discretion of the treating clinician.~Study intervention will cease if a patient is considered well enough by the treating clinician for discharge out of ICU. If a patient is transported out of ICU for procedural intervention, then standard (non-study) treatment should be provided."
62382666|NCT05968794|EXPERIMENTAL|Cerclage|A vaginal cerclage is a short and minor surgical procedure performed under general or regional anesthesia. An unabsorbable suture is placed around/through the cervix to close the cervical canal and to increase its firmness, in order to reduce cervical insufficiency.
62382667|NCT05968794|NO_INTERVENTION|Standard care|The comparator will be standard treatment according to the current Dutch (NVOG) guideline from 2018, which is to not perform or offer an intervention such as vaginal cerclage. This is in line with the standard care in the participating hospitals in Belgium.
62382668|NCT05381194|EXPERIMENTAL|single arm (investigational arm)|BPaLM
62382669|NCT06144333|OTHER|Observational arm|
62382670|NCT06208410|EXPERIMENTAL|Arm A:JS105+Fulvestrant Injection|JS105 administered orally, Fulvestrant intramuscularly
62382671|NCT06208410|EXPERIMENTAL|Arm B:JS105+Fulvestrant Injection+Dalpiciclib Isetionate Tablets|JS105 administered orally, Dalpiciclib administered orally, Fulvestrant intramuscularly
62382672|NCT06208410|EXPERIMENTAL|Arm C:JS105+Toripalimab Injection|JS105 administered orally, Toripalimab intravenous infusion
62382673|NCT06208410|EXPERIMENTAL|Arm D:JS105+Paclitaxel for Injection (Albumin Bound)|JS105 administered orally, Paclitaxel (Albumin Bound) intravenous infusion
62382674|NCT06208410|EXPERIMENTAL|Arm E:JS105+Fluzoparib Capsules|JS105 administered orally, Fluzoparib administered orally
62382675|NCT06208410|EXPERIMENTAL|Arm F:JS105+Pyrotinib Maleate Tablets+Capecitabine Tablets|JS105 administered orally, Pyrotinib administered orally,Capecitabine administered orally
62382676|NCT06208410|EXPERIMENTAL|Arm G:JS105+Toripalimab Injection+Paclitaxel for Injection (Albumin Bound)|JS105 administered orally, Toripalimab intravenous infusion, Paclitaxel (Albumin Bound) intravenous infusion
62382677|NCT01917136|EXPERIMENTAL|11c-acetate and 18F-FDG, and cardiac MRI|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate and a 10 millicurie injection of 18F-FDG At baseline/6 months follow up, a cardiac MRI will be performed.
62382678|NCT01943396|EXPERIMENTAL|Rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. Best-corrected visual acuity, electroretinography and drusenoid retinal pigment epithelium detachment area will be examined. Changes of selected special immunologic parameters will be measured.
62382679|NCT01943396|NO_INTERVENTION|without rheohemapheresis|Into the group the patients will be randomized with the same disease but without rheohemapheresis
62382680|NCT01433328|EXPERIMENTAL|Lidocaine|
62382681|NCT01433328|PLACEBO_COMPARATOR|Placebo|Remodulin only
62382682|NCT02324049|EXPERIMENTAL|SBC-103|"Part A (Initial therapy): Participants received SBC-103, 0.3, 1.0, or 3.0 mg/kg QOW for 24 weeks, followed by a ≥ 4-week treatment break. Participants enrolled in the lowest dosage first.~Part B: Participants were escalated to the next highest dose that was considered safe (1.0 or 3.0 mg/kg QOW) for ≥ 8 weeks. Participants who received doses of 0.3 mg/kg in Part A were considered for a second dose escalation to 3.0 mg/kg at any time during Part B provided that they tolerated at least 2 doses of 1.0 mg/kg in Part B. Participants who received and tolerated at least 4 doses of SBC-103 QOW at 3.0 mg/kg were considered for participation in Part C.~Part C: Participants received SBC-103 5.0 or 10.0 mg/kg administered IV QOW. Dosing in Part C began at the 5.0 mg/kg dose level. The decision to begin dosing the first participant at 10.0 mg/kg was based on the review of safety data at 5.0 mg/kg."
62382683|NCT02256150|EXPERIMENTAL|Mizoribine (MZR)|Oral administration, daily dose of 150mg (50mg/tablet, t.i.d) All study subjects will receive standard steroid therapies during the study.
62382684|NCT02256150|ACTIVE_COMPARATOR|Cyclophosphamide (CTX)|"Intravenous injection with between 0.5 to 1.0 g/m2 body surface area each time (the maximum dose is 1.0 g/day each time).~All study subjects will receive standard steroid therapies during the study."
62763068|NCT03964753|EXPERIMENTAL|Neo-adjuvant chemotherapy group|"cisplatin and nab-paclitaxel: Nab-paclitaxel, 125mg/m(2), d1,d8, Cisplatin, 75mg/m(2), d1, 3 week, 2 cycles.~Surgery:~4-6weeks after Neo-adjuvant chemotherapy"
62763069|NCT03964753|ACTIVE_COMPARATOR|Surgery alone|Surgery alone
62182588|NCT01127321|EXPERIMENTAL|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
61988059|NCT00211029||Participants Receiving Epoetin Alfa or Another Erythropoietin|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
62382685|NCT06373224|EXPERIMENTAL|Flush Group|After identifying the lymph node or lesion to be biopsied on ultrasound, using the endobronchial ultrasound scope, two 60mL syringes of cold saline will be inserted, through the biopsy channel of the endobronchial ultrasound scope, directly onto the bronchial wall where the biopsies are to be performed. The saline will then be sucked out of the airway using the endobronchial ultrasound scope.
62382686|NCT06373224|NO_INTERVENTION|Standard Care Group|No irrigation before the biopsy
62382687|NCT02180464|EXPERIMENTAL|LAS41004|Topical application of approximately 2 - 6 mg/cm2 to an area of 20 - 300 cm2, each once daily
62382688|NCT02180464|ACTIVE_COMPARATOR|control|Topical application of approximately 2 - 6 mg/cm2 of IMPs 1 and 2 to an area of 20 - 300 cm2, each once daily
62382689|NCT05030662|EXPERIMENTAL|Experimental:Walking stick exercise|"The experimental:Walking stick exercise~1. Education of walking stick exercise by research nurses twice before discharge (on the day before surgery and before discharge)~2. The video clip of walking stick exercise is available to the patients.~3. The research nurses encourage our patients to keep rehabilitation by phone calls once a week after discharge."
61988060|NCT01002833|EXPERIMENTAL|PfA|Exposure of human volunteers to bites of mosquitoes infected with the A strain of Plasmodium falciparum
61988061|NCT01002833|EXPERIMENTAL|PfB|Exposure of human volunteers to bites of mosquitoes infected with the B strain of Plasmodium falciparum
61988062|NCT01002833|ACTIVE_COMPARATOR|NF54|Exposure of human volunteers to bites of mosquitoes infected with the NF54 strain of Plasmodium falciparum
61988063|NCT00901758|PLACEBO_COMPARATOR|2|Placebo solution was normal saline. After an initial 1mL dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL.
61988064|NCT00901758|ACTIVE_COMPARATOR|1|Treatment solution consisted of 100micrograms/mL of nitroglycerin. After an initial 1mL dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL.
62382690|NCT05030662|NO_INTERVENTION|Control group: conventional physical therapy.|"1. Perform bed mobility and transfers with the least amount of assistance while maintaining appropriate weight bearing (WB) precautions.~2. Ambulate with an assistive device for 25-100 feet and ascend/descend stairs to allow for independence with household activities while maintaining appropriate WB.~3. Verbalize understanding of post-operative activity recommendations/precautions including use of proper positioning of the lower extremity, range of motion and strengthening exercises."
62382691|NCT03200418|EXPERIMENTAL|Test of new adhesives|"On the peristomal area four different patches are applied to the skin. There is a bag welded on each patch. The bag contains real output.~The difference between the four patches is that they consist of different adhesives.~One patch is made of a standard hydrocolloid adhesive~The primary endpoint is maesured after 8 hours and 24 hours And the three other patches consist of the newly developed adhesives. P-4 P-15 P-16"
62382692|NCT01599611||Exposed group|Children age 5-10 years old who had a total serum bilirubin \> 450 umol/L in the neonatal period
62382693|NCT01599611||Non-exposed group|Matched 1:1 to the exposed group on gender, age, gestational age and municipality of residence
62382694|NCT04286737|EXPERIMENTAL|Intervention Group|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
62382695|NCT04286737|NO_INTERVENTION|Control Group|The therapeutic touch will not be applied to the control group infants. However, the routine follow-up and behavior of the weekly baby will be evaluated to ensure that parents are blind.
61988065|NCT03161028|EXPERIMENTAL|Arm 1: Lipoic Acid|59 subjects receive oral lipoic acid 1200mg daily
61988066|NCT03161028|PLACEBO_COMPARATOR|Arm 2: Placebo|59 subjects receive placebo daily
61988067|NCT02023450|EXPERIMENTAL|micro/low dose saquinavir and ritonavir|To determine if micro dose and low dose SQV+RIT mediates parameters of chronic inflammation in patients with IPAH.
61988068|NCT02023450|EXPERIMENTAL|standard dose saquinavir and ritonavir|To determine if short-term use of SQV+RIT reduces parameters of chronic inflammation and PA pressure of IPAH based on echocardiographic parameters. Safety issue also evaluated at the same time.
61988069|NCT05333900|ACTIVE_COMPARATOR|Plant-based then animal based|plant based: diet low in sulfur-containing amino acids (Low-S diet), emphasizing plant-based foods and fat sources animal based: A diet high in sulfur-containing amino acids (High-S diet), emphasizing animal protein and fat sources
61988070|NCT05333900|ACTIVE_COMPARATOR|Animal-based then plant based|plant based: diet low in sulfur-containing amino acids (Low-S diet), emphasizing plant-based foods and fat sources animal based: A diet high in sulfur-containing amino acids (High-S diet), emphasizing animal protein and fat sources
62382696|NCT01236131||Endometrial biospy samples|The Endometrial Biopsy samples will be provided by women enrolled in the University of Pittsburgh IRB PRO10010112 and PRO10010159
62763070|NCT05789186|EXPERIMENTAL|Test group|CAVO aromatherapy patch at 3% concentration （continue sniffing for 15 minutes ）and Fluoxetine Hydrochloride mimetic （20mg/tablet，once a day，10mg each time）
62763071|NCT05789186|ACTIVE_COMPARATOR|Positive drug group|CAVO aromatherapy patch at 0.1% concentration（continue sniffing for 15 minutes ） and Fluoxetine hydrochloride tablet （20mg/tablet，once a day，10mg each time)
61988071|NCT02940288|EXPERIMENTAL|Intervention|Participants will be randomized to receive bilateral auricular acupuncture for postoperative pain.
62382697|NCT02495714|EXPERIMENTAL|Intervention schools|Active Learning; One hour each schoolday of physical Activity as part of academic learning Dietary councelling; teaching children and parents about a healty diet
62763072|NCT05789186|SHAM_COMPARATOR|Blank control group|Concentration 0.1% CAVO aromatherapy patch（continue sniffing for 15 minutes）and fluoxetine hydrochloride mimetic（20mg/tablet，once a day，10mg each time）
62763073|NCT01842594|EXPERIMENTAL|Sirolimus and hydroxychloroquine|Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally once daily(QD) for 2 cycles . Each treatment cycle is 28 days.
62382698|NCT02495714|NO_INTERVENTION|Control schools|No intervention
62382699|NCT05753124||Pregnant women with obesity/GDM/T2DM|Pregnant women with obesity/GDM/T2DM
62382700|NCT05753124||Pregnant women with obesity/GDM/T2DM- Controls|Pregnant women with normal BMI/ no GDM orT2DM
62382701|NCT05753124||Post-bariatric pregnant women|Pregnant women with previous bariatric surgery
62382702|NCT05753124||Pregnant no bariatric women- Controls|"There will be two control groups of women with no previous bariatric surgery:~1. Pregnant women with booking BMI similar to the booking BMI of the post-bariatric ones and 2. Pregnant women with booking BMI similar to the pre-surgery BMI of the post-bariatric ones."
62382703|NCT01678794|EXPERIMENTAL|Candesartan|
62382704|NCT01678794|PLACEBO_COMPARATOR|Placebo|
62382705|NCT00053482|EXPERIMENTAL|Group 1: ACAM2000|Participants will receive dose 1 of the ACAM2000 smallpox vaccine
62382706|NCT00053482|EXPERIMENTAL|Group 2: ACAM2000|Participants will receive dose 2 of the ACAM2000 smallpox vaccine
62382707|NCT00053482|EXPERIMENTAL|Group 3: ACAM2000|Participants will receive dose 3 of the ACAM2000 smallpox vaccine
62382708|NCT00053482|EXPERIMENTAL|Group 4: ACAM2000|Participants will receive dose 4 of the ACAM2000 smallpox vaccine
61988072|NCT02940288|SHAM_COMPARATOR|Control|Participants will be randomized to receive bilateral sham acupuncture.
61988073|NCT02864849|EXPERIMENTAL|TNT|"Patients with MRI defined high-risk rectal cancer will receive chemotherapy before and after chemoradiation, and will not receive adjuvant treatment. This arm is called total neoadjuvant treatment (TNT). The neoadjuvant chemotherapy regimen is designed as 3 cycles of CapeOX (Capecitabine+Oxaliplatin) over a period of approximately 8 weeks. Tumor response will be evaluated after chemotherapy. Then patients will undergo 22f-IMRT (Intensity modulated radiotherapy) with capecitabine. Patients will receive two more cycles of consolidation CapeOX if tolerable when there was no progressed disease in induction CapeOX.~Finally, patients will receive TME (Total mesorectal excision) following TNT if no metastasis occurs."
62382709|NCT00053482|ACTIVE_COMPARATOR|Group 5: Dryvax®|Participants will receive dose 1 of Dryvax® smallpox vaccine.
61988074|NCT00218296|ACTIVE_COMPARATOR|Usual Care Group|Usual care for cessation with immediate quit date scheduled and two weeks of nicotine patch supplied.
62382710|NCT03312127|EXPERIMENTAL|GORE Excluder|GORE Excluder Iliac Branch Endoprosthesis arm with 'ILIAC ENDOPROSTHESIS GORE EXCLUDER'
62382711|NCT05853640|ACTIVE_COMPARATOR|Usual care|Participants in this group will undergo usual care at the orthopedic department and will get a recommendation for physical therapist-led treatment in primary care.
62382712|NCT05853640|EXPERIMENTAL|HIPSTER|Participants in this group will undergo usual care at the orthopedic department and will also receive a semi-structured intervention according to the HIPSTER treatment model.
62382713|NCT00743184|PLACEBO_COMPARATOR|Placebo + Placebo|Participants will receive Placebo + Placebo on Days 0 and 14 of each 6-month course.
62382714|NCT00743184|EXPERIMENTAL|15 mg Ozarelix + 15 mg Ozarelix|Participants will receive 15 mg Ozarelix + 15 mg Ozarelix on Days 0 and 14 of each 6-month course.
62382715|NCT00743184|EXPERIMENTAL|30 mg Ozarelix + 15 mg Ozarelix|Participants will receive 30 mg Ozarelix + 15 mg Ozarelix on Days 0 and 14 of each 6-month course.
62382716|NCT00868738|ACTIVE_COMPARATOR|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU), given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
62382717|NCT00868738|PLACEBO_COMPARATOR|Placebo|Subjects will be provided a placebo, given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
62382718|NCT02176226|EXPERIMENTAL|8-Week Single Arm Field Trial|Use of IntelliCare program for 8 weeks.
62382719|NCT02207738|EXPERIMENTAL|microneedling radiofrequency device|microneedling radiofrequency
62763074|NCT01890395|OTHER|blood collection|procedure: Blood draws as the intervention
62763075|NCT00746733|EXPERIMENTAL|Vyvanse (LDX)|
62382720|NCT02207738|ACTIVE_COMPARATOR|bipolar radiofrequency device|bipolar radiofrequency treatment
62382721|NCT03066505|ACTIVE_COMPARATOR|Active MeRT Treatment|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks.
62382722|NCT03066505|SHAM_COMPARATOR|Sham MeRT Treatment|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks. Sham treatment mimicks same noise and sensation of active treatment but provides no treatment.
62382723|NCT01768039|ACTIVE_COMPARATOR|Vitamin D|treatment with weekly 50000IU vitamin D
62382724|NCT01768039|PLACEBO_COMPARATOR|Placebo|Treatment with placebo
62382725|NCT00397891|EXPERIMENTAL|1|bapineuzumab 0.15 mg/kg or placebo
62382726|NCT00397891|EXPERIMENTAL|2|bapineuzumab 0.5 mg/kg or placebo
62382727|NCT00397891|EXPERIMENTAL|3|bapineuzumab 1.0 mg/kg or placebo
62382728|NCT05961514|OTHER|Traditional|The traditional/control arm consists of systematic biopsies of the prostate if PSA\>4ng/ml.
62382729|NCT05961514|EXPERIMENTAL|Experimental|The experimental arm consists of MRI tests and targeted biopsies if PI-RADS scores ≥3 or systematic biopsies if PSA\>10ng/ml.
62382730|NCT02910492|EXPERIMENTAL|Investigational Enlighten Device|Laser treatment for facial skin rejuvenation with the experimental enLighten Laser
62763076|NCT00746733|EXPERIMENTAL|Adderall XR (AXR)|
62763077|NCT01195688|EXPERIMENTAL|BI 638683|1 single dose per subject as oral solution
62763078|NCT01195688|PLACEBO_COMPARATOR|Placebo solution|1 single dose per subject as oral solution
62763079|NCT05154760|ACTIVE_COMPARATOR|one on one video conference|Pelvic floor muscle training, diaphragmatic breathing exercise, core strengthening exercise will continue for 8 weeks. Participants will be asked to practice the exercises at least 4 days in a week, and the program will be continued in the form of one on one interviews with video conference method once a week.
61988075|NCT00218296|EXPERIMENTAL|Reduction Group|Reduction in nicotine exposure for 6 weeks prior to quit date using medicinal nicotine lozenge or reduced nicotine smokeless tobacco.
61988076|NCT05449054|ACTIVE_COMPARATOR|Continuous stitches for anterior colporrhaphy|Continuous stitches will be used for plication during anterior colporrhaphy. Sutures will be at a distance of no more than 0.5 cm. Trimming of the vagina will be performed if necessary. The anterior vaginal skin is closed with continuous 2/0 vicryl sutures.
61988077|NCT05449054|ACTIVE_COMPARATOR|Interrupted stitches for anterior colporrhaphy|Interrupted stitches will be used for plication during anterior colporrhaphy. Sutures will be at a distance of no more than 0.5 cm. Trimming of the vagina will be performed if necessary. The anterior vaginal skin is closed with continuous 2/0 vicryl sutures.
61988078|NCT00081354||Barrett's esophagus|Barrett's esophagus
61988079|NCT00081354||Controls negative for Barrett's esophagus|Controls negative for Barrett's esophagus
61988080|NCT04221685|ACTIVE_COMPARATOR|Artinibsa|Powerful local anaesthetic with a short latency time. Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.4%Articaine 1:100000.
61988081|NCT04221685|EXPERIMENTAL|Artpharma|ArtPharma is a unique amide local anesthetic that is currently Used in dentistry Amides has taken over their predecessors esters with their enhanced performance.Each ml Articaine (D.C.I) 40.00 mg hydrochloride,Epinephrine (D.C.I) (tartrate) 0.01 mg
61988082|NCT02261714|EXPERIMENTAL|TG01/GM-CSF and Gemcitabine|
61988083|NCT03078621|EXPERIMENTAL|Stem Cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
61988084|NCT04713826|EXPERIMENTAL|BAY2586116_Placebo|"Male or female participants aged above or equal to 18 years diagnosed with moderate to severe OSA will be allocated randomly to this intervention sequence.~Participants will receive BAY2586116 in treatment period 1, and placebo in treatment period 2.~Each intervention will be applied at home for 6 days (+1 optional day) followed by one in-house application for the overnight PSG (polysomnography).~In total, each participant will receive up to a maximum of 7 single doses (8 single doses if optional day is used) of BAY2586116 and up to 7 single doses of placebo (8 single doses if optional day is used)."
61988085|NCT04713826|EXPERIMENTAL|Placebo_BAY2586116|"Male or female participants aged above or equal to 18 years diagnosed with moderate to severe OSA will be allocated randomly to this intervention sequence.~Participants will receive placebo in treatment period 1, and BAY2586116 in treatment period 2.~Each intervention will be applied at home for 6 days (+1 optional day) followed by one in-house application for the overnight PSG.~In total, each participant will receive up to a maximum of 7 single doses (8 single doses if optional day is used) of BAY2586116 and up to 7 single doses of placebo (8 single doses if optional day is used)."
62382731|NCT03720067|ACTIVE_COMPARATOR|Phase 1: Propranolol (PPL)|Hepatic venous pressure gradient (HVPG) will be measured before and after 120 minutes of a loading dose of Propranolol (PPL) 80 mg PO. Thereafter, patients will receive maintenance therapy with Propranolol (40 to 320 mg / day) adjusted according to blood pressure and heart rate. After 28 days of reaching the maximum tolerated dose, a new HVPG measurement will be performed.
62382732|NCT03720067|ACTIVE_COMPARATOR|Phase 1: Carvedilol (CVD)|HVPG will be measured before and after 120 minutes of a loading dose of Carvedilol (CVD) 12.5 mg PO. Thereafter, patients will receive maintenance therapy with Carvedilol (6.25 - 25 mg / day) adjusted according to blood pressure. After 28 days of reaching the maximum tolerated dose, a new HVPG measurement will be performed.
62763080|NCT05154760|ACTIVE_COMPARATOR|group videoconference|Pelvic floor muscle training, diaphragmatic breathing exercise, core strengthening exercise will continue for 8 weeks. Participants will be asked to practice the exercises at least 4 days in a week, and the program will be continued in the form of group interviews with video conference method once a week.
61988086|NCT01707953|EXPERIMENTAL|Midodrine|Midodrine Hydrochloride (5mg) administered as capsule 5 and 23 hours after end of surgery.
61988087|NCT01707953|PLACEBO_COMPARATOR|Placebo|Placebo administered as capsule 5- and 23 hours after end of surgery.
61988088|NCT02310464|EXPERIMENTAL|Dose escalation|Each subject will be given a total of 10 doses of OBI-833/OBI-821 subcutaneously at weeks 1,2,3,4,6,8,12,16,20,and 24 (Visits 1,2,3,4,5,6,7,8,9 and 10, respectively). Post treatment, subjects will be continually evaluated for safety and immune response every 4 weeks until the end of study, which is 12 weeks after the last dose, i.e., week 36. Subsequently, subjects will be followed for survival every 8 weeks up to 12 months after the end of study.
61988089|NCT02310464|EXPERIMENTAL|Cohort expansion phase|Each subject will be given OBI-833/OBI-821 at Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, and every 8 weeks thereafter (Visits 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and every 8 weeks thereafter) until disease progression. For the subjects discontinued treatment because of disease progression, subjects will be continually evaluated for safety and immune response every 8 weeks until the end of the study, which is 24 weeks after the last dose.
62382733|NCT03720067|ACTIVE_COMPARATOR|Phase 2: PPL non-responders/rosuvastatin|Patients treated with PROPRANOLOL (PPL) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of ROSUVASTATIN 20 mg /day PO. HVPG will be measured again after 56 days.
62382734|NCT03720067|PLACEBO_COMPARATOR|Phase 2: PPL non-responders/placebo|Patients treated with PROPRANOLOL (PPL) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of PLACEBO 1 tablet PO. HVPG will be measured again after 56 days.
62382735|NCT03720067|ACTIVE_COMPARATOR|Phase 2: CVD non-responders/rosuvastatin|Patients treated with CARVEDILOL (CVD) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of ROSUVASTATIN 20 mg /day PO. HVPG will be measured again after 56 days.
62382736|NCT03720067|PLACEBO_COMPARATOR|Phase 2: CVD non-responders/placebo|Patients treated with CARVEDILOL (CVD) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of PLACEBO 1 tablet PO. HVPG will be measured again after 56 days.
62382737|NCT03853057|EXPERIMENTAL|non-invasive ventilation|Non-invasive positive pressure at different body positions: sitting - supine - prone - right lateral and left lateral.
62763081|NCT05389501|EXPERIMENTAL|Intervention Group|"The Experiment Group will receive the following services from the community social worker:~1. Developing Database on Digital App 2. Community Needs Assessment 3 Pre-Post Test Survey 4. Existing services by government of Pakistan (BHU/ LHW)~Additionally, the Experiment Group will receive the following services from the health social worker:~1. Psychosocial needs assessment and mental health awareness~2. Measurement of Basic Health Clinical Indicators~33. Health Awareness \& Literacy for following areas:~1. Reproductive and Child Health~2. Hygiene and Sanitation \& Nutrition and Immunity Building~3. Health-Risk Behavior Modification"
62763082|NCT05389501|ACTIVE_COMPARATOR|Control Group|"The Control Group will receive the following services from the community social worker:~1. Developing Database on Digital App~2. Community Needs Assessment 3 Pre-Post Test Survey~4. Existing services by government of Pakistan (BHU/ LHW)"
62763083|NCT03927287||Radical prostatectomy (RP cohort)|Our institutional prostate cancer database was queried for all patients between 2000-2017 who had a biochemical recurrence (BCR) after radical prostatectomy (RP) (Total PSA\>=0.2 ng/ml) and had at least one post-BCR free PSA ratio (FPSAR) blood test (RP cohort). FPSAR ascertainments were performed incidentally or reflexively (e.g. PSA in the range of 4-10 ng/ml, as per Institutional policy). If multiple FPSAR tests were performed, only the first FPSAR test was analyzed. otal PSA and Free PSA data was performed with the Abbott Architect analytical platform, according to the instructions of the manufacturer.
61988090|NCT01772303|EXPERIMENTAL|HO/03/03 10-40 micro gram|Topically treatment with HO/03/03 10-40µg once daily for up to 24 weeks. Subjects will receive treatment with HO/03/03 10µg at a dose of 1-4 vials (i.e. 10-40 µg/administration) daily depending on their wound size.
61988091|NCT04055831||GD1 subjects with no bone complications|1. GD1 subjects with no bone complications (n=10)
61988092|NCT04055831||GD1 patients with mild bone complication|2. GD1 subjects with mild bone complications
61988093|NCT04055831||GD1 with severe bone complications|3. GD1 subjects with severe bone complications
62382738|NCT03696576|ACTIVE_COMPARATOR|PhoRTE|This group will undergo standard PhoRTE therapy.
62382739|NCT03696576|EXPERIMENTAL|PhoRTE + EMST|This group will undergo standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.
62382740|NCT06430736|EXPERIMENTAL|Tocilizumab prophylactic|In the experimental arm, patients will receive a single standard dose of Tocilizumab (Actemra®) 8 mg/kg b.w. intravenously infused over 1 hour in 250 ml NaCl 0.9%, with completion of the infusion 1 hour prior to the infusion of the CAR-T cells. Prior to Tocilizumab administration, no specific premedication is given. The treatment of eventual subsequent CRS will be identical as in patients in the standard arm.
62382741|NCT06430736|ACTIVE_COMPARATOR|Tocilizumab on demand|In the standard arm, patients will receive conventional antipyretics and Tocilizumab at first clinical signs (being grade 1 or higher) of emerging CRS. Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously over one hour in 250 ml NaCl 0.9%, and it will be repeated after 8 hours for a maximum of four administrations in patients with ongoing signs of CRS. Prior to Tocilizumab administration, no specific premedication is given.
62382742|NCT05265494|EXPERIMENTAL|NESA INTERVENTION|"Group 1: Application of Nesa microcurrents through the NXSIGNAL® generator twice a week.~The study volunteers are treated with the NXSIGNAL® device in sessions of 60 minutes, twice a week and for 5 weeks (10 sessions)."
62382743|NCT05265494|NO_INTERVENTION|CONTROL-NO INTERVENTION|Group 2: Control group without NESA XSIGNAL® application The same protocol for the analysis of variables is followed, but without performing any type of treatment with the NESA XSIGNAL device.
62382744|NCT03164031|EXPERIMENTAL|Close-fitting orthotic shorts condition|Orthotic shorts will be made to measure for each participant, designed to provide some compression to the hips, pelvis and thighs and to provide support. Shorts will be worn during objective testing of walking ability and then taken home. Wear will be increased gradually over 5 days but then worn every day during normal daily activity.
62382745|NCT03164031|ACTIVE_COMPARATOR|Looser fitting shorts condition|Looser shorts will be made to measure for each participant, designed to look similar to the orthotic shorts but provide minimal support or compression. Shorts will be worn during objective testing of walking ability and then taken home. Wear will be increased gradually over 5 days but then worn every day during normal daily activity.
61988094|NCT04055831||No bone disease|Controls with no known bone disease (n=10)
61988095|NCT05078853||Formal/standard evaluation of a suspected cervical lymph node|"Patient with cervical lymph node suspected as differentiated thyroid carcinoma metastasis will be evaluated according to the current accepted American Thyroid Association Guidelines.~Two clinical scenarios, for each one of them the formal evaluation is described below:~1. Fine needle aspiration Clinic (a patient with known or suspected differentiated thyroid carcinoma is evaluation for suspicious cervical lymph node): the formal evaluation will include cytology and formal thyroglobulin measurement from the needle washout.~2. Operating room (evaluation of suspicious cervical lymph node found during partial or complete thyroidectomy in patient with known or suspected differentiated thyroid carcinoma): the formal evaluation will include frozen section and/or final histology."
61988096|NCT05078853||Point of care assay for thyroglobulin (POC-Tg) evaluation of a suspected cervical lymph node|"Patient with cervical lymph node suspected as differentiated thyroid carcinoma metastasis will be evaluated using the study kit: Novel rapid POC-Tg.~Two clinical scenarios, for each one of them the performance of the study kit (POC-Tg) will be valuated in parallel to the formal evaluation:~1. Fine needle aspiration Clinic (a patient with known or suspected differentiated thyroid carcinoma is evaluation for suspicious cervical lymph node): the suspected cervical lymph node will be evaluated using the POC-Tg in parallel to the formal evaluation.~2. Operating room (evaluation of suspicious cervical lymph node found during partial or complete thyroidectomy in patient with known or suspected differentiated thyroid carcinoma): the suspected cervical lymph node will be evaluated using the POC-Tg in parallel to the formal evaluation."
62382746|NCT05309499|ACTIVE_COMPARATOR|FCM group|The ferric carboxymaltose doses were determined using the patient's screening visit body weight measurement and haemoglobin value. Patients receives all doses during hospitalization accordance with the drug local labels.
61988097|NCT06541184||Patients treated by ziconotide-based intrathecal analgesia (ITA)|Patients followed during 2 years after an initiation of ziconotide. These patients will be recruited retrospectively or prospectively.
61988098|NCT05793346||Dataset 1: National Registry of Rare Kidney Diseases|This dataset is the: National Registry of Rare Kidney Diseases from the UK Renal Registry, this is a UK-wide, linked dataset. This cohort includes any woman who has previously had a previous diagnosis of kidney disease in the UK with maternity records and who has consented to participate.
61988099|NCT05793346||Dataset 2: Kent Integrated Data|Maternal and laboratory data from East and West Kent in the UK.
61988100|NCT05793346||Dataset 3: Stockholm Creatinine Measurement|An observational dataset with laboratory data from individuals in Stockholm (Sweden)
61988101|NCT05793346||Dataset 4: Ontario Renal Network Pregnancy Cohort|A population-based cohort of women in Ontario who had an obstetric delivery with outpatient laboratory data.
61988102|NCT05793346||Dataset 5: Combined cohort of three obstetric studies within the UK|A combined cohort derived from three obstetric studies within the UK.
62382747|NCT05309499|ACTIVE_COMPARATOR|Ferrous sulphate group|100 mg of ferrous sulphate is administrated 2 times per day during hospitalization and continue within next 2 month.
62382748|NCT05309499|NO_INTERVENTION|Group with normal iron status|Patiants with normal iron status
62382749|NCT01601093|EXPERIMENTAL|High dose|Ceftazidime 3g
62382750|NCT01601093|EXPERIMENTAL|Low dose|Ceftazidime 2g
62382751|NCT01601093|ACTIVE_COMPARATOR|CFP/SUB|Cefoperazone and sulbactam sodium for injection(2:1)
61988103|NCT01603446|EXPERIMENTAL|MELAS Patients|Three siblings with MELAS (A3243G) syndrome (1 male; 2 females) aged 17-23 years, followed or previously followed in the Neurometabolic Clinic at the Hospital for Sick Children will be studied.
61988104|NCT01603446|NO_INTERVENTION|Control Group|Four age- and sex-matched controls and female controls will be matched according to phase in menstrual cycle corresponding with their age-matched MELAS subjects
61988105|NCT01892631|OTHER|Standard care|Practices in the standard care arm will proceed with their seasonal influenza campaign as planned.
61988106|NCT01892631|EXPERIMENTAL|Text messaging intervention|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
62382752|NCT00820014|EXPERIMENTAL|1|ESBA105 eye drops
62382753|NCT00820014|PLACEBO_COMPARATOR|2|Placebo control (vehicle)
62382754|NCT05456516|EXPERIMENTAL|Health|Children will rate foods on health
62382755|NCT05456516|EXPERIMENTAL|Taste|Children will rate foods on taste
62382756|NCT05456516|EXPERIMENTAL|Wanting|Children will rate foods on desire to eat
62382757|NCT01058395|EXPERIMENTAL|800 mg loading then 200 mg Q12|Minocycline 800 mg. loading followed by 200 mg. Q 12 hours.
62382758|NCT01058395|EXPERIMENTAL|800 mg loading then 400 mg Q12|Minocycline 800 mg. loading followed by 400 mg. Q 12 hours.
62382759|NCT04093544|ACTIVE_COMPARATOR|Standard Stimulation|Participants will receive stimulation using the best contact combination in ring mode.
62382760|NCT04093544|EXPERIMENTAL|Directional Stimulation|Participants will receive stimulation using the best segmented (steered) contacts.
62382761|NCT04352244||Surgical Participants|Individuals undergoing abdominal surgery or radiologically-guided biopsies for clinical indications will be recruited prior to the planned procedures.
62382762|NCT06402149||Grup I|Patients who underwent infraclavicular block by lateral sagittal method under USG guidance by adding 2ml dexamethasone (8mg) 3cc 0.9% NaCl to local anesthetic containing 10 ml of bupivacaine (0.5%) and 5cc of prilocaine (2%) will be included in Group I.
62382763|NCT06402149||Grup II|Patients who underwent infraclavicular block by lateral sagittal method under USG guidance by adding 10 ml of bupivacaine (0.5%) and 5ml of prilocaine (2%) and 5 cc of 0.9% NaCl will be included in Group II.
62382764|NCT01207921|EXPERIMENTAL|Arm 1|"Lenalidomide 15 mg/day Cycle 1 (28 days).~If no unacceptable side effects Cycle 2 (28 days) will be lenalidomide 20 mg/day.~If no unacceptable side effects Cycles 3 thru 18 (28 days for each cycle) will be lenalidomide 25 mg/day."
62382765|NCT05985616|EXPERIMENTAL|Group A|"High intensity (80-85% of 1RM) will be administered at alternative days for 16 weeks.~The exercise will have three phases; Phase I consists of 2-3 sets of 8-15 repetitions, Phase II will follow the single set approach and Phase III will have the Superset approach.~The following activities will be incorporated via resistance training: latissimus front pulleys, rowing, back extension, inverse fly, bench press, shoulder press, lateral raises, butterfly with extended arms, crunches, leg presses, leg extension and curls, leg adduction, abduction."
62382766|NCT05985616|NO_INTERVENTION|Group B|No intervention will be provided in this group. The participants in this group will follow their usual daily activities.
62382767|NCT02287363||TPP group|TPP patients(between episodes of paralysis), the inclusion criteria consisted of a certain history of acute limb muscle weakness, hypokalemia and decreased TSH with elevated free FT4, FT3. Subjects who suffered from hyperthyroid myopathy with long term muscle weakness, family periodic paralysis, renal tubular acidosis, hyperaldosteronism, hemiplegia, paraplegia, or any history of other metabolic or traumatic muscular disease were excluded.
62763084|NCT03927287||Radiotherapy cohort|Our institutional database was queried or all patients between 2000-2017 who had a rising PSA after radiotherapy (RT) for intermediate- and high-risk prostate cancer, and at least one post-treatment free PSA ratio (FPSAR) blood test (RT cohort). As in the RP cohort, FPSAR was performed either incidentally or reflexively, and the first FPSAR test was used for the analyses. Total PSA and Free PSA data was performed with the Abbott Architect analytical platform, according to the instructions of the manufacturer.
62763085|NCT03927287||Biobank surgical cohort|To validate our findings in the two retrospective cohorts (RP and RT), we analyzed a third cohort of prospectively collected biobank specimens of patients who underwent RP and developed biochemical recurrence(Biobank cohort). The retrieved samples were batched and tested for FPSAR levels to determine the results in lower PSA ranges and also to account for intrinsic analyte measurements variability in the retrospective cohorts. For his cohort we used the Roche Elecsys analytical platform, according to the instructions of the manufacturer.
62763086|NCT01133015|EXPERIMENTAL|Intermediate lesion|Intermediate lesion will be evaluated by both IVUS and FFR
62763087|NCT04347980|EXPERIMENTAL|Dexamethasone and Hydroxychloroquine (HCQ/DXM)|"Patients included in the HCQ / DXM group will benefit from standardized ventilatory management and administration of HCQ in the same manner as the HCQ group. They will receive in addition to DXM at a rate of 20 mg intravenously for 15 min once a day for 5 days (D1 to D5) then at a rate of 10 mg per day from D6 to D10. If the patient is extubated before the 10th day, he will receive his last dose of DXM before."
62763088|NCT04347980|ACTIVE_COMPARATOR|Hydroxychloroquine (HCQ)|"Patients included in the HCQ  group will benefit from standardized ventilatory management. Patients included in the HCQ group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days. If the patient is extubated before the 10th day, he will receive his last dose of HCQ before."
62763089|NCT04135859|ACTIVE_COMPARATOR|Fitbit Only|In the Fitbit Only arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, and a Fitbit. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
61988107|NCT01808430||VATS for NSCLC patients|VATS for confirmed non-small cell lung cancer (NSCLC)
61988108|NCT03999190||30 subjects with schizophrenia|
61988109|NCT03999190||30 healthy controls|
61988110|NCT04391790|ACTIVE_COMPARATOR|Control|Study subject will cohere to current national guidlines with a cystectomy and standard urinary conduit ad modum Bricker
61988111|NCT04391790|EXPERIMENTAL|Intervention|Subject in the interventional arm, will be treated with a cystectomy and modified retrosigmoid conduit
61988112|NCT03936361|ACTIVE_COMPARATOR|Statin|The same statin agent and dose that subjects were using at the time of ICH onset.
62763090|NCT04135859|EXPERIMENTAL|Fitbit + Coaching Sessions|In the Fitbit + Coaching Sessions arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, a Fitbit, and will have 8 sessions with a coach (interventionist) over the course of 20 weeks. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
62763091|NCT01643876|EXPERIMENTAL|Palatal brushing|Palatal brushing after each meal for 3 months.
62763092|NCT05734274|EXPERIMENTAL|Probiotics Lozenge|Subjects are instructed to take a lozenge twice a day, after brushing, in the morning and the evening.
62763093|NCT05734274|SHAM_COMPARATOR|Negative control Lozenge|Subjects are instructed to take a lozenge twice a day, after brushing, in the morning and the evening.
62763094|NCT06357468||physician-led births|
62763095|NCT06357468||midwife-led births|
62763096|NCT04676867|ACTIVE_COMPARATOR|900 mg dose|Patients will receive Dalcetrapib 900 mg for 10 days
62763097|NCT04676867|ACTIVE_COMPARATOR|1800 mg dose|Patients will receive Dalcetrapib 1800 mg for 10 days
62763098|NCT04676867|ACTIVE_COMPARATOR|3600 mg dose|Patients will receive Dalcetrapib 3600 mg for 10 days
62763099|NCT04676867|PLACEBO_COMPARATOR|Placebo tablets|Patients will receive Placebo for 10 days
62763100|NCT01333670|EXPERIMENTAL|Prontosan wound irrigation solution|
62763101|NCT01333670|ACTIVE_COMPARATOR|Standard care|
62763102|NCT03577392|EXPERIMENTAL|XELOX chemotherapy with recombinant human endotatin|Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
62763103|NCT03577392|ACTIVE_COMPARATOR|XELOX chemotherapy without recombinant human endotatin|Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
61988113|NCT03936361|NO_INTERVENTION|No-statin|Subjects will discontinue the statin agent that they were taking at the time of ICH onset. No placebo will be prescribed for these subjects.
61988114|NCT02436278||IPF_MORT|Patients diagnosed with Idiopathic Pulmonary Fibrosis according to NICE guidelines.
61988115|NCT00470574|EXPERIMENTAL|Vaccine Therapy and QS21|"Patients receive sialyl Lewisª -keyhole limpet hemocyanin conjugate vaccine subcutaneously (SC) and QS21 immunoadjuvant SC once in weeks 1, 2, 3, 7, and 19 in the absence of disease progression or unacceptable disease.~Blood samples are collected periodically and evaluated for circulating tumor cells and reactivity against sialyl Lewisª antigen in ELISA and/or immunoprecipitation-western blot assays.~After completion of study treatment, patients are followed every 3 months"
61988116|NCT05289323|EXPERIMENTAL|The Intervention group (N)|0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 μg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
62763104|NCT04528615|EXPERIMENTAL|CCK In-Person Sessions|This group received the in-person CCK intervention.
62763105|NCT04528615|ACTIVE_COMPARATOR|CCK Printed Materials|This group received select printed CCK materials.
62763106|NCT06254664|EXPERIMENTAL|Tiotropium 18 µg inhalation powder, hard capsule once daily (QD)|"Interventions:~Drug: Tiotropium 18 µg inhalation powder, hard capsule~Device: Zephir inhaler"
62763107|NCT02036736|EXPERIMENTAL|Propofol|Intraoperative anesthetic strategy by Propofol versus Desflurane
62763108|NCT02036736|EXPERIMENTAL|Desflurane|Intraoperative anesthetic strategy by Desflurane versus Propofol
62382768|NCT02287363||hyperthyroidism group|Control group, we included subjects with evidence of aberrant thyroid function (decreased TSH, elevated FT4, FT3) without paralysis. Graves' disease(GD) was preferred which required information concerning either increased thyrotrophin receptor antibody(TRAb) level, ophthalmopathy or diffusively enlarged goiter. Individuals with pure thyroid associated ophthalmopathy, history of thyroidectomy due to malignancy or adenoma as well as subacute thyroiditis and pituitary hyperthyroidism were excluded.
62382769|NCT04875195|EXPERIMENTAL|Arm 1|Pembrolizumab (MK-3475), 400 mg, Q6W, intravenous (IV) infusion, Day 1 then Q6W up to 18 doses.
62382770|NCT02478658|EXPERIMENTAL|Intervention|"The acute intervention will consist of 1 session of training following the program:~Resistance Training Exercises. Each participant in the intervention group will perform resistance-training exercises in the form of a circuit. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Initial intensity 6-7 of RPE and ending the set at 9-10. Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round."
62382771|NCT02478658|NO_INTERVENTION|Control|No intervention
62382772|NCT01062516|ACTIVE_COMPARATOR|1|oral esomeprazole 20 mg daily
62763109|NCT00031980|EXPERIMENTAL|cyclosporine|"Patients receive oral cyclosporine every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed every 4 months for 1 year and then every 6 months for 9 years."
62763110|NCT02159677||Healthy Subjects|Healthy subjects aged 21-80 years with no history of present or past disabling back or neck pain, sciatica, cervical radiculopathy, or any generalized neuromuscular condition except for mild polyneuropathy or common mononeuropathies (e.g. carpal tunnel syndrome, ulnar neuropathy at the elbow.) Additionally, subjects cannot have any history of any moderate-to-severe ongoing medical condition producing generalized disability, such as advanced cardiac or renal disease, or metal spine implants of any type.
62763111|NCT02159677||Radiculopathy Subjects|Subjects aged 21-80 years with a history consistent with radiculopathy based on clinical, radiologic, and standard electrophysiological criteria, as determined by spine expert.
62382773|NCT01062516|ACTIVE_COMPARATOR|2|oral famotidine 40mg daily
62382774|NCT03870646|EXPERIMENTAL|Hypertonic saline|Nebulized hypertonic saline of NaCl (7%) in combination with hyaluronic acid
62382775|NCT03870646|PLACEBO_COMPARATOR|Isotonic saline|Nebulized isotonic saline of NaCl (0,9%)
62382776|NCT05502120|ACTIVE_COMPARATOR|Macintosh blade|Visualisation of entrance to larynx using Standard Macintosh blade laryngoscope followed by Visualisation of entrance to larynx using Vie-Scope laryngoscope
62382777|NCT05502120|EXPERIMENTAL|Vie-Scope|Visualisation of entrance to larynx using Vie-Scope laryngoscope after visualisation using Macintosh blade laryngoscope
62763112|NCT02159677||Musculoskeletal Back Pain Subjects|Subjects aged 21-80 years with low back or neck pain without evidence to suggest neuropathic component; i.e. without radiation of pain, sensory loss or weakness.
62763113|NCT02159677||Undiagnosed Lower Back or Neck Pain Subjects|Subjects aged 21-80 years with a major complaint of lower back or neck pain.
62763114|NCT05052060|EXPERIMENTAL|Group A|19 patients will be treated with pelvic tilt exercises
62763115|NCT05052060|ACTIVE_COMPARATOR|Group B|19 patients will be treated with pelvic tilt exercises and facet joint manipulation.
62763116|NCT01960088||Adolescents and their parents|Pharmacy demonstration project: HPV vaccine delivery
62382778|NCT05569915|EXPERIMENTAL|Trauma Expressive Writing|In the trauma condition, we ask participants to write about a traumatic experience, prompting them to write their very deepest thoughts and feelings about the most traumatic experience of their entire life or an extremely important stressful, upsetting, or emotional issue that has affected them.
62382779|NCT05569915|EXPERIMENTAL|Stigma Expressive Writing|In the stigma condition, we ask participants to write about an experience of stigma, prompting them to write about their very deepest thoughts and feelings about the most difficult or painful experience of stigma or bias (e.g., prejudice, bullying, rejection, discrimination) based on one or more of their identities (e.g., race/ethnicity, gender identity, sexual identity, religion) that they have faced.
62382780|NCT05569915|PLACEBO_COMPARATOR|Control|In the control condition, we ask participants to write about their day, prompting them to write about what they did yesterday from the time they got up until the time they went to bed.
62382781|NCT02504424|EXPERIMENTAL|AeroForm Tissue Expander|AeroForm Tissue Expansion inflation with carbon dioxide by remote control
62763117|NCT02960646|EXPERIMENTAL|Treatment (peripheral blood stem cell transplantation)|Patients receive melphalan IV over 30 minutes on day -6 and fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo TBI on day -2 and CD45RA depleted peripheral blood stem cell transplantation on day 0. Patients also receive cyclophosphamide IV over 3 hours on days 3-4. Beginning on day 5, patients receive tacrolimus IV for 2 weeks and PO for at least 4 months. Beginning on day 7, patients receive filgrastim SC daily. Patients with CD20 positive lymphoma may receive rituximab IV on days -13, -6, 1, and 8.
62763118|NCT00290875|OTHER|Arm 1|We randomly allocated sites to either intervention or control. At the intervention sites, active strategies were employed to implement the rule into practice, including education, policy, and real-time reminders on radiology requisitions.
62382782|NCT00002852|ACTIVE_COMPARATOR|Arm I (surgery, observation)|Patients receive no further therapy.
62382783|NCT00002852|EXPERIMENTAL|Arm II (surgery, chemotherapy)|Patients receive adjuvant therapy comprising paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on day 1. Treatment continues every 3 weeks for 4 courses.
61988117|NCT05289323|PLACEBO_COMPARATOR|The control group (C)|one ml of normal saline 0.9 % will be mixed with 4 ml dextrose 5 % in the five-milliliter syringe. 0.2 ml of this mixture will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
61988118|NCT04087460|EXPERIMENTAL|Low-dose Group A|Subjects received three doses of PBPV with 20μg each antigen
61988119|NCT04087460|PLACEBO_COMPARATOR|Low-dose Group B|Subjects received three doses of placebo
61988120|NCT04087460|EXPERIMENTAL|Middle-dose Group A|Subjects received three doses of PBPV with 50μg each antigen
61988121|NCT04087460|PLACEBO_COMPARATOR|Middle-dose Group B|Subjects received three doses of placebo
62382784|NCT04765839|EXPERIMENTAL|Intervention Arm - Receives COVID-19 Vaccine messages|Group to receive COVID-19 Vaccine messages during the first two weeks of the study.
62382785|NCT04765839|EXPERIMENTAL|Delayed Intervention Arm|Group to receive COVID-19 Vaccine messages during the last two weeks of the study.
62382786|NCT00775138|EXPERIMENTAL|Cohort 1 - 280 mg Arikayce™|Subjects in this arm of the cohort 1 will receive 280 mg of Arikayce™
62382787|NCT00775138|PLACEBO_COMPARATOR|Cohort 1 - Placebo|Subjects in this arm of the cohort 1 will receive matching placebo.
62382788|NCT00775138|EXPERIMENTAL|Cohort 2 - 560 mg Arikayce™|Subjects in this arm of the cohort 2 will receive 560 mg of Arikayce™
62382789|NCT00775138|PLACEBO_COMPARATOR|Cohort 2 - Placebo|Subjects in this arm of the cohort 2 will receive matching placebo
62382790|NCT04143828|EXPERIMENTAL|Mobile Mindfulness Programme|The mobile mindfulness program is delivered via a mobile application.
62382791|NCT04143828|NO_INTERVENTION|Wait-list control condition|When assigned to the control condition, participants will be wait-listed for 3 months during the study. After the final assessment participants will receive access to the mobile mindfulness program.
62382792|NCT04623281||Observational group|Observational group of 10 haemodialysis patients following usual care for 3 weeks.
62382793|NCT01017640|EXPERIMENTAL|Arm I (veliparib)|Patients receive veliparib PO BID in the absence of disease progression or unacceptable toxicity.
62763119|NCT04101617|EXPERIMENTAL|Experimental group|Participants will receive previously designed educational material with recommendations for healthy habits and oral health recommendations. Also, pediatricians will give the parents oral health education. Parents and their children will receive toothbrushes as well as toothpaste.
62763120|NCT04101617|NO_INTERVENTION|Control Group|Parents and their children will receive toothbrushes as well as toothpaste.
62763121|NCT06108843|EXPERIMENTAL|Myofascial arm pull technique and Active Release Technique|Participant will receive both Myofascial arm pull and active release technique along with Ultrasound therapy.
62382794|NCT01017640|EXPERIMENTAL|Arm II (veliparib and mitomycin C)|Patients receive veliparib PO BID on days 1-7, 1-14, or 1-21. Patients also receive mitomycin C IV over 10-20 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62382795|NCT01931774||Acne Patients|
61988122|NCT04087460|EXPERIMENTAL|High-dose Group A|Subjects received three doses of PBPV with 100μg each antigen
61988123|NCT04087460|PLACEBO_COMPARATOR|High-dose Group B|Subjects received three doses of placebo
61988124|NCT02196272|EXPERIMENTAL|Nurse-led email program through email|In addition to usual care and educational program, the intervention group will also receive email alerts and phone calls from the nurse care manager (NCM).
61988125|NCT02196272|NO_INTERVENTION|Management of diabetic patients|Usual care, educational program and usual management of Diabetic patients
62382796|NCT01931774||Control Subjects|From General Population
62382797|NCT03013335|EXPERIMENTAL|Nivolumab|"The dose and schedule of nivolumab in this study will be 3 mg/kg every 2 weeks. Infusion of nivolumab will be performed in 30 minutes (± 5 minutes).~Nivolumab will be administered every 2 weeks until death, disease progression, unacceptable toxicity or withdrawal of the informed consent"
61988126|NCT01742741|EXPERIMENTAL|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs)system running in Control to Range (CTR) or in Safety Only mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct the hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
61988127|NCT01742741|NO_INTERVENTION|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. Subjects will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
61988128|NCT02943733|EXPERIMENTAL|TAS-102 and TMZ|"Part 1: dose-escalation phase to determine MTD of TAS-102 in combination with Temozolomide (TMZ). Treatment cycles are 28 days, with TAS-102 administered orally twice daily days 1-5 and 8-12, and TMZ administered orally days 8-12. No treatment medications administered days 13-28 of each cycle. Growth factor support is required during Part 1 and should be dosed per institutional standards.~Part 2: expansion phase to evaluate preliminary efficacy of MTD. Subjects treated with the recommended phase 2 drug doses determined in part 1. Treatment will continue for up to 13 cycles (approx. 12 months). Growth factor support is allowed during Part 2 and should be dosed per institutional standards."
61988129|NCT01522365|ACTIVE_COMPARATOR|Abutment-supported XiVE CAD/CAM bridge|After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed on an abutment.
61988130|NCT01522365|ACTIVE_COMPARATOR|Implant-supported XiVE CAD/CAM bridge|After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed directly on an implant.
61988131|NCT05188651||dental professionals wearing FFP2/N95 masks|
61988132|NCT05188651||dental professionals wearing type IIR fluid resistant surgical masks|
62763122|NCT06108843|ACTIVE_COMPARATOR|Myofascial arm pull technique|Participant will receive Myofascial arm pull along with ultrasound therapy.
61988133|NCT01678417|EXPERIMENTAL|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
61988134|NCT00409617|EXPERIMENTAL|Open Label|
61988135|NCT01807897|EXPERIMENTAL|CPAP|Nocturnal continuous positive airway pressure
61988136|NCT01807897|EXPERIMENTAL|NSO|Nocturnal supplemental oxygen
61988137|NCT01807897|OTHER|HLSE|Healthy lifestyle and sleep education control
61988138|NCT02469428|SHAM_COMPARATOR|Clean air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
61988139|NCT02469428|EXPERIMENTAL|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
61988140|NCT05094219||Observation group|Patients with a confirmed diagnosis of Parkinson's disease will be followed up for 12 months from the date of enrollment.
61988141|NCT01828892|EXPERIMENTAL|PRFG treatment|As described in our previous study, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage. Prior to application, frozen cryoprecipitate and thrombin stored were thawed in a 37°C water bath. Aminomethylbenzoic Acid (1ml: 1mg, Sigma-Aldrich, St Louis, MO) was added into the cryoprecipitate in the volume ratio of 1:10.
62763123|NCT05434013|EXPERIMENTAL|Cigarillo warnings-Surgeon General Text-Only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Surgeon General Text-Only format.
62763124|NCT05434013|EXPERIMENTAL|Cigarillo warnings-FDA proposed text-only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the FDA Proposed Text-Only format.
62763125|NCT05434013|EXPERIMENTAL|Cigarillo warnings-Pictorial|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Pictorial format.
62763126|NCT00320138|ACTIVE_COMPARATOR|Acupuncture|
62763127|NCT00320138|NO_INTERVENTION|Wait List|Usual Care
61988142|NCT01828892|SHAM_COMPARATOR|Control|Patients in this group only received standard of care when their fistula output \< 200ml/24h.
62763128|NCT06224361||Reliability|"Participants will be evaluated with the Postural Stability Test, Limits of Stability Test, Sensory Integration Test and Bilateral Comparison Test within the AlBalance Balance Evaluation System. To calculate the test-retest reliability of the device, these measurements will be made by the same evaluator, will last 30 seconds and will be repeated a total of 3 times with a 1-minute rest between tests. These measurements will be repeated after 7 days to evaluate reliability. Then, parallel clinical tests will be applied to the participants, Functional Reaching Test and One Leg Standing Test."
62763129|NCT06421402||Follow-up 200 high-risk chronic respiratory outpatients for 2 years.|"The INTERVENTION (PHASE I, 2024) will have four components: i) Assessment of Lung Function Testing, ii) Monitoring of IAQ at patients' homes (and analysis of the relationships between IAQ and health events), iii) Evaluation of advanced digital support to a novel clinical process to enhance early identification and management of exacerbations (questionnaires, chat, patients' self-capturing sensors, and iv) Development, and refinement, of machine learning-based predictive modelling for supporting clinical decision making.~During PHASE II (2025), the INTERVENTION will consist of the assessment (Quintuple Aim) of the novel integrated care service, as well as the evaluation of its potential for scalability (CFIR).~See inclusion/exclusion criteria and planned measurements in the enclosed documents."
61988143|NCT01828892|EXPERIMENTAL|Commercial FG|Commercial FG (Zhejiang Puji Porcine fibrin sealant) was applied to close fistulas.
62382798|NCT06093152||Before salbutamol|Participants before the administration of salbutamol
62382799|NCT06093152||After salbutamol|Participants after the administration of salbutamol
62382800|NCT02367196|EXPERIMENTAL|Part A: CC-90002|CC-90002 will be given by intravenous (IV) infusion on a 28 day cycle
62382801|NCT02367196|EXPERIMENTAL|Part B: CC-90002 with Rituximab|CC-90002 in combination with Rituximab will be given by intravenous (IV) infusion on a 28 day cycle in subjects with CD20-positive NHL
62382802|NCT02053649|ACTIVE_COMPARATOR|Usual Care|Usual Care will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
62382803|NCT02053649|EXPERIMENTAL|Triple Chronotherapy + Usual Care|triple chronotherapy (TC) will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
62382804|NCT01402622|ACTIVE_COMPARATOR|Control group|balanced anaesthesia with antiemetic prophylaxis
61988144|NCT04177602|EXPERIMENTAL|Trifluridine/tipiracil based radiotherapy|Trifluridine/tipiracil based chemoradiotherapy (CRT)
61988145|NCT04177602|ACTIVE_COMPARATOR|standard calibration arm (internal control)|capecitabine based chemoradiotherapy
61988146|NCT01168635|EXPERIMENTAL|Intervention|Virtually-delivered spirometry quality improvement program
61988147|NCT01168635|NO_INTERVENTION|Standard of Care|
61988148|NCT01820754|EXPERIMENTAL|Ipilimumab|Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery) Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses
62382805|NCT01402622|ACTIVE_COMPARATOR|TIVA group|TIVA without antiemetic prophylaxis
61988149|NCT01386736|ACTIVE_COMPARATOR|Vitamin D|Subjects will randomly be assigned to Vitamin D drops versus placebo drops.
61988150|NCT01386736|PLACEBO_COMPARATOR|Placebo|Subjects will randomly be assigned to Vitamin D drops versus placebo drops.
61988151|NCT05487742|PLACEBO_COMPARATOR|Group I (control group):|Patients of this group receive placebo infusion for 72 hours.
61988152|NCT05487742|ACTIVE_COMPARATOR|Group II (DEX group):|Patients of this group receive 0.5 ug/kg/hr dexmedetomidine continuous infusion for 72 hour
61988153|NCT06310330|ACTIVE_COMPARATOR|Usual care|Standard of care echocardiographic follow-up
61988154|NCT06310330|EXPERIMENTAL|Simplified care|Simplified echocardiographic follow-up
62382806|NCT01402622|ACTIVE_COMPARATOR|TIVA-P group|TIVA with antiemetic prophylaxis
62382807|NCT01208844||Posttraumatic Stress|
62382808|NCT01208844||Depression|
62382809|NCT01208844||Healthy|
62382810|NCT00951912|PLACEBO_COMPARATOR|Placebo|10g soy protein isolated powder patch by mouth everyday for 6months
62382811|NCT00951912|EXPERIMENTAL|Daidzein|10g soy protein isolated plus 50mg daidzein powder patch by mouth everyday for 6 months
62382812|NCT00951912|EXPERIMENTAL|Genistein|10g soy protein isolated plus 50mg genistein powder patch by mouth everyday for 6 months
62382813|NCT03660566|EXPERIMENTAL|Test - Implant with L-PRF|Patients requiring single implants placement in the esthetic area of maxilla will receive the implant placement with the use of Leucocyte- and Platelet-rich fibrin (L-PRF) membranes.
62382814|NCT03660566|ACTIVE_COMPARATOR|Control - Implant without L-PRF|Patients requiring single implants placement in the esthetic area of maxilla will receive the implant placement only.
62382815|NCT04984811|EXPERIMENTAL|NT-I7 and atezolizumab|Participants with no prior systemic therapy for advanced NSCLC will receive 1200 μg/kg NT-I7 IM on Day 1 and every 6 weeks and atezolizumab IV 1200 mg every 3 weeks until disease progression.
62382816|NCT04059354|EXPERIMENTAL|Speech therapy|Direct speech therapy will be provided for a 12 week period with up to three one-hour sessions per week.
62382817|NCT02714894||Clozapine Responders (Non-URS)|"Definition of non-URS~(1) ≥30% decrease in the PANSS positive subscale score, CGI-severity ≤3 and CGI-Improvement ≤2 after 12 weeks of treatment."
62382818|NCT02714894||Clozapine Non-Responders (URS)|"Definition of URS~1. Taking clozapine for ≥ 12 weeks, attaining a plasma clozapine level ≥350 ng/ml.~2. CGI-Severity score of ≥4 and score of ≥4 on 2 PANSS positivesymptom items."
62382819|NCT02714894||Healthy Controls|Healthy controls will be matched as closely as possible on age and gender with participants in the patient groups.
62382820|NCT01015066|ACTIVE_COMPARATOR|buprenophine/naloxone|Participants with this arm will receive 4-16 mg/d buprenorphine/naloxone (Suboxone).
62382821|NCT01015066|EXPERIMENTAL|Naltrexone|Participants assigned to this arm will receive 50 mg/d naltrexone.
61988155|NCT06220708|EXPERIMENTAL|The intervention group|The intervention group underwent dance movement therapy.
62382822|NCT01962272|EXPERIMENTAL|Nutritional counseling and Forticare®|Weekly nutritional counseling and Forticare®. The goal being an intake that met the protein and energy requirements according to Harris-Benedict equation multiplied with an individual activity factor (1,1-1,5) and a stress factor (1,0-1,1). Daily protein requirements were estimated to 1,5 g/kg per day. In addition to the counseling, the patients in the intervention group were offered a high-protein nutrition supplement containing n-3 fatty acids (Forticare®, Nutricia). The recommended daily dose contained 2531 kJ, 33.8 g protein and 2.2 g EPA.
62382823|NCT01962272|ACTIVE_COMPARATOR|Control|"The control group was nutritionally instructed by the nurses with the possibility to call for a dietician not related to the study if needed. No fixed schemes.~Apart from the nutritional element the patients had the same care and therapy, including treatment of pain and side-effects to the treatment."
62382824|NCT06406829|EXPERIMENTAL|Local analgesic techniques + dexmedetomidine group|The patients in this group will be received scalp nerve block before surgery with 0.5% ropivacaine. The patients also will be given dexmedetomidine intravenously at a rate of 0.4 μg/kg/h from skin incision until the beginning of dura mater closure, and will be adjusted to 0.05 μg/kg/h for 48 hours after surgery.
62382825|NCT06406829|EXPERIMENTAL|Local analgesic techniques and placebo dexmedetomidine group|The patients in this group will be received scalp nerve block before surgery with 0.5% ropivacaine. For dexmedetomidine placebo group, normal saline will be infused at the same rate as dexmedetomidine during surgery and for 48 hours after surgery.
62382826|NCT06406829|EXPERIMENTAL|Placebo local analgesic techniques and dexmedetomidine group|The patients in this group will not receive scalp nerve block. The patients will be given dexmedetomidine intravenously at a rate of 0.4 μg/kg/h from skin incision until the beginning of dura mater closure, and will be adjusted to 0.05 μg/kg/h for 48 hours after surgery.
62382827|NCT06406829|PLACEBO_COMPARATOR|Placebo local analgesic techniques and placebo dexmedetomidine group|The patients in this group will not receive scalp nerve block before surgery . For dexmedetomidine placebo group, normal saline will be infused at the same rate as dexmedetomidine group during surgery and for 48 hours after surgery.
62382828|NCT02382276|EXPERIMENTAL|Nalmefene hydrochloride 20 mg|As-needed; tablets, orally
62382829|NCT02461576||HIV-1 infected|this is a study comparing Xpert HIV-1 VL assay quantitation to an already FDA approved HIV-1 quantitative HIV-1 RNA assay in known HIV-1 infected individuals
62382830|NCT02621281|ACTIVE_COMPARATOR|cold storage|In this randomized clinical trial, 200 kidney pairs from deceased donors will be included in the study, which will be randomly assigned, one kidney to machine perfusion and the other to cold storage. In machine perfusion group, patients will be analyzed by two subgroups based on pressure, resistance index and perfusion time duration.
62382831|NCT02621281|ACTIVE_COMPARATOR|Kidney Transporter machines|In this randomized clinical trial, 200 kidney pairs from deceased donors will be included in the study, which will be randomly assigned, one kidney to machine perfusion and the other to cold storage. In machine perfusion group, patients will be analyzed by two subgroups based on pressure, resistance index and perfusion time duration.
62382832|NCT02014285||Muscle Ultrasound/Sample|30 subjects enrolled from Wake Forest Baptist Health Intensive Care Units. Each study subject will undergo an ultrasound to examine the size and echogenicity of their muscles and a muscle biopsy from the rectus femoris. The muscles studied will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior.
62382833|NCT03480841|EXPERIMENTAL|LENA with Feedback|Mothers who will run the Language ENhancement Assessment/intervention system with their young children, and will receive initial feedback from researchers on LENA output and how to enhance the language the home language environment.
62382834|NCT01560013|EXPERIMENTAL|Naltrexone|Treatment with naltrexone for two months together with psycho-social support
62382835|NCT01363154|ACTIVE_COMPARATOR|Mozart K448|Treatment: music exposure to Mozart K448
62382836|NCT01363154|PLACEBO_COMPARATOR|Beethoven's Für Elise|Placebo: music exposure to Beethoven's Für Elise for piano
62382837|NCT01363154|NO_INTERVENTION|No music exposure|Control: no music exposure
62382838|NCT05567679|EXPERIMENTAL|Tazemetostat|Tazemetostat 200 mg oral tablets; 800 mg by mouth twice daily for 28 days
62382839|NCT02241356|ACTIVE_COMPARATOR|single vision glasses|single vision glasses
62382840|NCT02241356|EXPERIMENTAL|bifocals|bifocal glasses
61988156|NCT06220708|OTHER|The control group|The control group received yoga training.
61988157|NCT06322329|EXPERIMENTAL|Full cohort|All subjects are included in the same arm.
61988158|NCT03554226|EXPERIMENTAL|AD Patients with NeuroPsychiatric Inventory Clinician (NPI-C)|The investigation aims to study the natural evolution of type A / A SPCDs in patients with AD. In this study, patients will receive optimized management based on existing best practice recommendations (HAS Recommendations 2009). It will therefore be a standard care study, since this survey applies the current recommendations on tools for the evaluation of SPCDs and the management of behavioral disorders in Alzheimer's disease (Recommendations HAS 2009).
62382841|NCT03961529|EXPERIMENTAL|0.3% OPA-15406 ointment|Twice daily
62382842|NCT03961529|EXPERIMENTAL|1% OPA-15406 ointment|Twice daily
62763130|NCT06421402||Control Group|"The control group will be introduced in Phase II (2025) to estimate the potential for healthcare value generation of the novel integrated care service. It will include patients with equivalent characteristics who receive standard of care practice, without the interventions carried out in the cohort group.~The control group will be shaped using 1-to-1 propensity score matching techniques. Data from the control group will be obtained from electronic medical records and registry information. In a randomly selected subset of 50 individuals from the control group a Quintuple Aim assessment will be done."
62763131|NCT02351687|NO_INTERVENTION|No Intervention|No specific intervention given after recovery from moderate acute malnutrition.
62763132|NCT02351687|EXPERIMENTAL|Package of interventions|Package of interventions given after recovery from moderate acute malnutrition -- includes lipid-nutrient supplement for 2 months, malaria chemoprophylaxis for 3 months during malaria season, an insecticide-treated bed net, a one-time albendazole treatment, and 14 days of zinc.
62763133|NCT01790555|EXPERIMENTAL|Namisol|The study medication is given from the day before surgery (day -1: 5 mg in the afternoon and in the evening) up to the fifth day after surgery (day 0 to +5: 5 mg four times daily).
62763134|NCT01790555|OTHER|Diazepam/Placebo|"The study medication is given from the day before surgery (day -1: 5 mg in the afternoon and in the evening) up to the fifth day after surgery (day 0 to +5: 5 mg four times daily).~Before surgery, diazepam is used as an active comparator, to aid in blinding. After surgery, an inactive placebo is used as an inactive comparator."
62382843|NCT04718883|EXPERIMENTAL|JWCAR029 treatment|JWCAR029 be administrated at dose level: 1 x 10\^8 CAR+T cells
62763135|NCT04266470|EXPERIMENTAL|Lara Device Scan|This imaging study will be obtained strictly for the research purposes of mid-treatment assessment of blood flow and uptake kinetics analysis
62763136|NCT03602885|EXPERIMENTAL|Chemotherapy education intervention arm|Patients randomized to the chemotherapy education intervention (CEI) arm will be given regimen specific written and video chemotherapy educational materials developed by the study team. The treating oncologist will identify which chemotherapy regimen(s) are being considered, in order to select the appropriate chemotherapy educational tool(s) to give the patient. The patient may be given more than one CEI tool if they are considering more than one regimen. Patients randomized to the intervention arm may receive the intervention in addition to OR in place of the standard institutionally approved chemotherapy information sheets (both are acceptable); this is at the discretion of the treating site or the treating physician.
62763137|NCT03602885|ACTIVE_COMPARATOR|Usual chemotherapy education arm|Patients randomized to the usual chemotherapy education (CE) arm will undergo the standard institutional practice of chemotherapy education. The oncologist may also choose to give the patient the institutionally approved chemotherapy information sheets according to site-specific policies and clinical practice.
62763138|NCT04806360|EXPERIMENTAL|ACRF group|ACRF is a new surgical procedure that previously proposed by our team, it combines the advantages of both the conventional anterior and posterior approach. Eligible patients in this group will receive ACRF surgery.
62763139|NCT04806360|ACTIVE_COMPARATOR|conventional anterior surgery group|Eligible patients in this group will receive conventional anterior surgery, including anterior cervical discectomy and fusion surgery or anterior cervical corpectomy and fusion surgery.
62763140|NCT04806360|ACTIVE_COMPARATOR|conventional posterior surgery group|Eligible patients in this group will receive conventional posterior surgery, including laminectomy and fusion surgery or laminoplasty surgery.
62763141|NCT03406416|EXPERIMENTAL|Suprachoroidal retinal prosthesis|Prototype wide view suprachoroidal retinal prosthesis
62763142|NCT01301105|PLACEBO_COMPARATOR|Health Enhancement Program (HEP)|Intervention designed to be effective and structurally equivalent to Mindfulness Based Stress Reduction (MBSR) but without a mindfulness component. Designed as an active control for MBSR to isolate mindfulness as an active ingredient.
62763143|NCT01301105|ACTIVE_COMPARATOR|Mindfulness Based Stress Reduction (MBSR)|
61988159|NCT02617823|NO_INTERVENTION|semi-recumbent|rutine positioning at the hospital today
61988160|NCT02617823|EXPERIMENTAL|lateral position|experimental position to be evaluated against rutine
62382844|NCT03513575|ACTIVE_COMPARATOR|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink."
62763144|NCT03889210|ACTIVE_COMPARATOR|HVMN ketone drink|HVMN ketone drink will be given in a total volume of 100 ml.
61988161|NCT04754737|OTHER|Prophylactic antibiotic|These patients will receive the current standard of care, which is to receive a single dose of prophylactic antibiotics just prior to receiving intravesical injection of Onabotulinumtoxin A via cystoscopy. The specific prophylactic antibiotics will vary depending on patient's prior urine culture sensitivities and patient medication allergies/sensitivities and medical comorbidities.
61988162|NCT04754737|EXPERIMENTAL|No antibiotics|These patients will receive no prophylactic antibiotics prior to receiving intravesical injection of Onabotulinumtoxin A via cystoscopy.
61988163|NCT05948202|EXPERIMENTAL|mPRT|mindfulness-enhanced Pivotal Response Treatment: group pivotal response training for parents that is supplemented with mindfulness strategies
62763145|NCT03889210|PLACEBO_COMPARATOR|Placebo|Placebo will be given in a total volume of 100 ml.
62763146|NCT00539929|EXPERIMENTAL|E6201 0.005% BID|Participants applied E6201 0.005% cream to a pre-identified marker lesion twice a day (BID) for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
62763147|NCT00539929|EXPERIMENTAL|E6201 0.01% BID|Participants applied E6201 0.01% cream to a pre-identified marker lesion BID for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
62763148|NCT00539929|EXPERIMENTAL|E6201 0.03% BID|Participants applied E6201 0.03% cream to a pre-identified marker lesion BID for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
62763149|NCT00539929|EXPERIMENTAL|E6201 0.03% QD|Participants applied E6201 0.03% cream to a pre-identified marker lesion once a day (QD) for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
62763150|NCT02768025|EXPERIMENTAL|Intervention group|NRT, counselling, traditional \& complementary medicine treatment (Body acupuncture, Ear acupuncture and aromatic therapy).
61988164|NCT05948202|ACTIVE_COMPARATOR|pPRT|psychoeducation-enhanced Pivotal Response Treatment: group pivotal response training for parents that is supplemented with psychoeducation about stress and stress reduction
61988165|NCT06185959||Patients in a Psychoeducation and Process Group for Asian and Asian American Psychiatric Outpatients|
61988166|NCT02989350|ACTIVE_COMPARATOR|Lactobacillus reuteri DSM 17938|2 x 10(8) CFU. Both L reuteri DSM 17938 and placebo will be taken orally, twice daily 5 drops, for consecutive 5 days.
61988167|NCT02989350|PLACEBO_COMPARATOR|Placebo|Placebo consists of an identical formulation, except active substance.
61988168|NCT04253288|OTHER|Patients with severe radiation toxicity|Patients who received radiotherapy and developed abnormal radiation-induced toxicity
62763151|NCT02768025|ACTIVE_COMPARATOR|Control group|NRT, counselling
62763152|NCT04022018|EXPERIMENTAL|Adaptive radiotherapy group|Concurrent adaptive external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of adaptive radiotherapy group patients. CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.
62763153|NCT04022018|ACTIVE_COMPARATOR|Control group|Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients.
62763154|NCT01052961|NO_INTERVENTION|Non-intervention arm|patients may receive oseltamivir 75 mg bd for 5 days, decided by the managing physicians
62763155|NCT01052961|ACTIVE_COMPARATOR|oseltamivir, higher dose|oseltamivir 150 mg bd for 5 days for patients presented within 96 hours from onset
62763156|NCT05181202||Hypersensitivity reaction group|The patients get hypersensitivity after Pegylated liposomal doxorubicin injection.
62763157|NCT05181202||None hypersensitivity reaction group|The patients do not get hypersensitivity after Pegylated liposomal doxorubicin injection.
62763158|NCT01998893|EXPERIMENTAL|MabThera/Rituxan|
62763159|NCT03679637|EXPERIMENTAL|Intervention group|Each participant will receive a tablet-based aphasia therapy
62763160|NCT03620357|EXPERIMENTAL|Continuous Glucose Monitor (CGM) Group|
62763161|NCT03620357|ACTIVE_COMPARATOR|SMBG Group|
62763162|NCT05309213|EXPERIMENTAL|IM19 CAR-T cells|
62763163|NCT06103227|EXPERIMENTAL|Low dose of prednisone group|Low doses of an intermediate acting corticosteroids (CS) administered three weeks after two-day tocolysis and respiratory distress syndrome (RDS) prophylaxis, plus neuroprotection with magnesium sulphate.
62763164|NCT06103227|ACTIVE_COMPARATOR|Standard therapy group|Two-day tocolysis and RDS prophylaxis, plus neuroprotection with magnesium sulphate.
62763165|NCT03554980|EXPERIMENTAL|Group 1|"38% silver diamine fluoride liquid will be applied twice annually and patients will be followed up at 0,1,3,6, 9 and 12.~SDF is a brush-on liquid."
62763166|NCT03554980|ACTIVE_COMPARATOR|Group 2|5% sodium fluoride varnish will be applied four times annually and patients will be followed up at 0,1,3,6,9 and 12.
62763167|NCT06216314|ACTIVE_COMPARATOR|Heart rate (HR)|Three physiological zones were established according to the results of the treadmill test. The HR group completed training sessions based on HR values and velocities associated with ventilatory thresholds (i.e., Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold. Runners trained 4 times a week.
62763168|NCT06216314|EXPERIMENTAL|Race pace based approach (RP)|For the race pace based approach (RP), intensity zones were established by calculating the percentage of the average speed achieved in the 7-km time trial (TT) and 3 zones were established. Kenneally's model was used to determine the race intensity zones by analyzing 7-km TT performance. Z1 corresponds to less than 80% of race pace, Z2 is between 80-95%, and Z3 corresponds to over 95% of race pace. Runners trained 4 times a week.
61988169|NCT05071183|EXPERIMENTAL|TPX-0005 + Trametinib|"TPX-0005 + Trametinib Dose Escalation and Dose Expansion~Dose escalation: KRAS G12D mutant advanced solid tumors. Dose expansion: KRAS G12D locally advanced or metastatic NSCLC"
61988170|NCT05217251||exposed group|Parturient women will be identified with frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor and will then be allocated to vaginal delivery with alpha asymmetry group in hospital.
61988171|NCT05217251||control group|Parturient women will be identified without frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor and will then be allocated to vaginal delivery without alpha asymmetry group in hospital.
61988172|NCT02879409|EXPERIMENTAL|Treatment arm 1|"75 Type 2 diabetic patients with a gender balance who will have the intervention if/when their FBG \>140mg/dl~Intervention: intensify treatment until their FBG is \<90mg/dl, using whatever treatment is clinically appropriate for them using different interventions (Metformin, Gliclazide, Sitagliptin, Dapagliflozin, Liraglutide, Pioglitazone, human insulin), and only intensify it further if their FPG rises to \>140mg/dl again."
62382845|NCT03513575|EXPERIMENTAL|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
62382846|NCT03513575|EXPERIMENTAL|Group 3: 0.2% chlorhexidine|"The subject collects unstimulated saliva in a sterile glass dish for measurement of baseline pH of saliva. The subject is then given 100ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will use 10 ml of 0.2% Chlorhexidine mouthrinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected thereafter to measure and record the pH of saliva at 15, 30 and 45 minutes after subject completes the gargle as an intervention."
62763169|NCT06216314|EXPERIMENTAL|Heart rate + heart rate variability (HRV)|The HR+HRV group completed training sessions based on HR values and velocities associated with ventilatory thresholds (i.e., Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold. The training sessions were based on physiological thresholds and daily HRV cues. Runners trained 4 times a week.
62763170|NCT04832139|EXPERIMENTAL|Marstacimab Prefilled Pen (PFP), then marstacimab Preflled Syringe (PFS)|Participants will first receive single dose PFP, then PFS, then repeating single dose PFP, then single dose PFS with a minimum of 21 days between single doses.
62382847|NCT03513575|EXPERIMENTAL|Group 4: fluoridated tooth paste|"The subject collects unstimulated saliva in a sterile glass dish for measurement of baseline pH of saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will brush with fluoridated toothpaste (Colgate Total®, Colgate-Palmolive Co., Mumbai, India) for 2 minutes using soft brush. Unstimulated saliva samples are collected thereafter to measure and record the pH of saliva at 15, 30 and 45 minutes after subject completes the brushing as an intervention."
62763171|NCT04832139|EXPERIMENTAL|Marstacimab PFS, then marstacimab PFP|Participants will first receive single dose PFS, then PFP, then repeating single dose PFS, then single dose PFP with a minimum of 21 days between single doses.
62763172|NCT04254016|EXPERIMENTAL|Non-randomized single-arm of HIBISTEVER1|"Non-randomized single-arm clinical trial with a before and after design. The study population consisted on all type 2 diabetes mellitus (T2DM) patients with a target population of T2DM patients with HbA1c between 42 to 64mmol/mol (6-8%) with no change in anti-diabetic treatment during the last three months, previous the study.~The intervention consisted on the administration of Hibiscus-Stevia drink at a dose of 4 mg / kg / day / for Stevia and 4 g / day for Hibiscus for a period of 8 weeks and after meals."
61988173|NCT02879409|EXPERIMENTAL|Treatment arm 2|"75 Type 2 diabetic patients with a gender balance who will have the intervention if/when their FBG \>115mg/dl~Intervention: intensify treatment until FBG is \<=115 mg/dl and intensify further if \>115 mg/dl again, using what ever clinical treatment is necessary (Metformin, Gliclazide, Sitagliptin, Dapagliflozin, Liraglutide, Pioglitazone, human insulin)."
61988174|NCT02283710|EXPERIMENTAL|Pentoxifylline + lifestyle modification|Pentoxifylline for 6 months plus obtaining ideal body weight by calorie restriction diet and programmed physical activity.
62763173|NCT01582737||Group 1|Patients treated with Xarelto for the purpose of prevention of ischemic stroke and systemic embolism
62763174|NCT05642143||T2D F-/N-|Subjects with T2D and no previous history of any fractures or diabetic neuropathy (n=160)
62763175|NCT05642143||T2D F+|Subjects with T2D with a previous history of a fracture(s) (any fracture, major osteoporotic fracture (MOF) and peripheral) (n=100)
62763176|NCT05642143||T2D N+|Subjects with T2D matched by age and sex with severe peripheral (vibration perception threshold (VPT) \> 50) or a history of autonomic neuropathy (n=40)
61988175|NCT02283710|EXPERIMENTAL|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity.
61988176|NCT00974012|EXPERIMENTAL|Divalproex Sodium|500 mg Extended Release Tablet
61988177|NCT00974012|ACTIVE_COMPARATOR|Depakote®|500 mg Extended Release Tablet
62763177|NCT02327936|EXPERIMENTAL|Fesoterodine 4mg|Fesoterodine 4 mg Po Die, dose could be increased to 8mg Po Die after 4 weeks, for a total of 8 weeks
61988178|NCT03024723||FmCPAP|CPAP ventilation administered via face mask
61988179|NCT02109146|EXPERIMENTAL|Adjuvant TACE|Patients receive adjuvant Transcatheter Arterial Chemoembolization (TACE) following curative resection of HCC.
61988180|NCT02109146|ACTIVE_COMPARATOR|Observation|Patients do not receive TACE or any other adjuvant therapy following curative resection of HCC.
61988181|NCT01802658|ACTIVE_COMPARATOR|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times over two years.
62763178|NCT02327936|ACTIVE_COMPARATOR|Oxybutynin XL 10mg|Oxybutynin XL 10 mg Po Die, dose could be increased to 20 mg Po Die after 4 weeks, for a total of 8 weeks
62763179|NCT03071991||Study group|Preincisional bupivacain will be used
62382848|NCT03513575|EXPERIMENTAL|Group 5: Polyol containing gum|"The subject collects unstimulated saliva in a sterile glass dish for the measurement of baseline pH of saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will chew polyol containing gum (Orbit®, Wrigley Company) for 5 minutes and spit. Unstimulated saliva samples are thereafter collected from to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
62763180|NCT03071991||Control group|No preincisional anesthetic drug will be used
62763181|NCT02564861|EXPERIMENTAL|DS-1971a (Low Dose)|Participants in Cohort 1 who receive a low dose of DS 1971a in an oral suspension
62763182|NCT02564861|EXPERIMENTAL|DS-1971a (Mid dose)|Participants in Cohort 2 who receive a mid dose of DS 1971a in an oral suspension
62763183|NCT02564861|EXPERIMENTAL|DS-1971a (High dose)|Participants in Cohort 3 who receive a high dose of DS 1971a in an oral suspension
62763184|NCT02564861|EXPERIMENTAL|Pooled placebo|Participants in Cohort 1, 2 or 3 who receive matching DS-1971a Placebo
62763185|NCT01905722|OTHER|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
62763186|NCT01905722|EXPERIMENTAL|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
62763187|NCT05510882|OTHER|three groups of different treatment modalities for OSA|Group I: patients were treated with CPAP. Group II: patients were treated with digitally fabricated MAD. Group iII: patients were treated with oral myofunctional therapy.
62763188|NCT01983280|EXPERIMENTAL|Healing Touch|
62763189|NCT06136572|EXPERIMENTAL|Rathus Assertiveness scale|All participants
62763190|NCT02291393|OTHER|Patient|Patients with previously confirmed Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
62763191|NCT02291393|OTHER|Healthy volunteers|Aged and gender matched healthy controls.
61988182|NCT01802658|PLACEBO_COMPARATOR|NACL|NACl 100 ml IV. 3 infusions. Administration 3 times over two years.
62763192|NCT05532267|EXPERIMENTAL|Test Product (T)|subjects were administered a single film-coated tablet of 750 mg Ciprofloxacin with approximately 240 ml water after an overnight fast of 10 hours
62763193|NCT05532267|ACTIVE_COMPARATOR|Reference Product (R)|subjects were administered a single film-coated tablet of 750 mg Ciprofloxacin with approximately 240 ml water after an overnight fast of 10 hours
62763194|NCT05097300|EXPERIMENTAL|Manual therapy and vagus nerve stimulation group|Patients will recibe 4 sessions, each of the duration of 20 minutes. Manual therapy consist in: suboccipital inhibition (during 10 minutes) and ischemic pressure and passive stretching of three muscles (superior trapezius, temporal muscle and sternocleidomastoid muscle). Vagus nerve stimulation will be performed through a diaphragmatic breathing exercise, during 5 minutes, adding neural tension of median nerve.
62763195|NCT05097300|ACTIVE_COMPARATOR|Manual therapy group|Patients will recibe 4 sessions, each of the duration of 20 minutes. Manual therapy consist in: suboccipital inhibition (during 10 minutes) and ischemic pressure and passive stretching of three muscles (superior trapezius, temporal muscle and sternocleidomastoid muscle).
62763196|NCT02485925|EXPERIMENTAL|Treatment group|THERMOCOOL® SMARTTOUCH™
62763197|NCT04251975|EXPERIMENTAL|CPAP treatment|Group of patients who will receive CPAP treatment
62763198|NCT04251975|NO_INTERVENTION|Conservative measures|Group of patients who will receive conservative treatment based on hygienic-dietetic measures
62763199|NCT01974752|EXPERIMENTAL|selumetinib 75mg twice daily|selumetinib 75mg twice daily in combination with dacarbazine.
62763200|NCT01974752|PLACEBO_COMPARATOR|placebo twice daily|placebo twice daily in combination with dacarbazine.
62763201|NCT05840692|ACTIVE_COMPARATOR|Cipralex|Escitalopram 20 mg x 1 for 12 weeks
62763202|NCT05840692|PLACEBO_COMPARATOR|Placebo|Placebo 20 mg x 1 for 12 weeks
62763203|NCT00229580|EXPERIMENTAL|1|Motivational feedback
61988183|NCT02086864|NO_INTERVENTION|Usual care|
62763204|NCT00229580|ACTIVE_COMPARATOR|2|treatment as usual
62763205|NCT02514668|EXPERIMENTAL|Isatuximab|Isatuximab (escalating dose) on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression
62763206|NCT00722202|ACTIVE_COMPARATOR|ERB-257|7 IV single doses of ERB-257 will be given to 6 healthy subjects per group - 1, 4, 15, 45, 90, 180, and 300 mg
62763207|NCT00722202|PLACEBO_COMPARATOR|placebo|2 placebo subjects per group
62763208|NCT02126566|EXPERIMENTAL|Single Arm|Administration of light therapy - measurement of results before and after therapy
62763209|NCT03464422|EXPERIMENTAL|Young gay and bisexual men of color|Approximately 30 young MSM of color will take part in weekly 90-minute group treatment sessions over 10 weeks. All participants will complete outcome assessments at baseline and three months post-treatment, as well as an exit interview.
62382849|NCT03513575|EXPERIMENTAL|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
62763210|NCT05027932|EXPERIMENTAL|Group A|15 participants receiving IM BPL1357 \&amp; IN Placebo
61988184|NCT02086864|ACTIVE_COMPARATOR|Individualized homeopathic medicine treatment|Participant will have a homeopathic consultation and be given a homeopathic medicine. Homeopathic medicines are chosen from those available for sale in Canada.
62382850|NCT06356441||AI-supported reading|The AI model predicts the incidence of local recurrence. If the incidence is below 60%, one radiologist will interpret the MR images. If the incidence is above 60%, two radiologists will interpret the MR images. The radiologists will be provided with the predictive incidence and contours in their interpretation if desired. If two radiologists provide contradictory interpretations, a third radiologist will participate in the discussion to reach a consensus.
62382851|NCT06356441||Standard double reading|The MR images will be interpreted by two radiologists, and in cases of disagreement, a third radiologist will be consulted to reach a consensus.
62382852|NCT03961724||ESRD group|
62382853|NCT03961724||Control group|
62763211|NCT05027932|EXPERIMENTAL|Group B|15 participants receiving IN BPL1357 \&amp; IM Placebo
62763212|NCT05027932|SHAM_COMPARATOR|Group C|15 participants receiving IM and IN placebo
62763213|NCT04090034||Treated w PRRT|Patients who received treatment of gastroenteropancreatic primary NETs with PRRT per the treating physicians discretion.
62763214|NCT05713084|EXPERIMENTAL|mandibular setback using low medial cut ostetomy|mandibular setback using low medial cut ostetomy by keeping the cut ''low'' or close to the mandibular occlusal plane and ''short'' or terminating anterior to the lingula.
62763215|NCT05713084|ACTIVE_COMPARATOR|mandibular setback using high medial cut ostetomy|mandibular setback by placement of the medial ramus osteotomy cut 'high', just a few millimeters above the lingula, superior and lateral to the entrance point of the inferior alveolar nerve (IAN) into the mandibular foramen ,
62763216|NCT06375785|EXPERIMENTAL|Group 1 - Otago-based (slow rhythmic) exercise group|
62763217|NCT06375785|EXPERIMENTAL|Group 2 - LSVT BIG-based (large amplitude) exercise group|
62763218|NCT01349062|OTHER|"Kallunk oxide (Immunotherapy)"|"The participants will be received a daily regimen of Kallunk oxide(Immunotherapy) ."
62763219|NCT00364533|PLACEBO_COMPARATOR|003|Placebo Fixed Dose Matching placebo for 3 days
62763220|NCT00364533|ACTIVE_COMPARATOR|002|Oxycodone HCL IR Fixed Dose 10 mg BID for 3 days
62763221|NCT00364533|EXPERIMENTAL|001|Tapentadol IR (CG5503) Fixed Dose 50, 75, \& 100 mg BID for 3 days
62763222|NCT00364533|OTHER|004|Tapentadol IR (CG5503) Flexible Dose q4-6 hr Tapentadol IR 50 \& 100 mg BID for 9 days
62763223|NCT03230812|EXPERIMENTAL|Experimental: carnitine intervention (in all participants)|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
62763224|NCT04423601|EXPERIMENTAL|Treatment|subjects receiving a single oral dose of SHR6390 tablets, then itraconazole capsules 200 mg/day orally with a single oral dose of SHR6390 tablets co-administered.
62763225|NCT04701580|EXPERIMENTAL|HD patients|At baseline and 2-year follow-up
61988185|NCT02086864|PLACEBO_COMPARATOR|Unmedicated lactose/sucrose pill|Participant will receive a homeopathic consultation and receive an unmedicated lactose/sucrose pill.
61988186|NCT00003901|EXPERIMENTAL|Surgery|"All patients undergo complete lymph node sampling or dissection. A small portion of rib is removed at this time. Some patients may have primary tumor completely removed.~Lymph nodes and bone marrow from the rib section are examined for occult metastases using immunohistochemical staining methods and standard staining methods.~Patients are followed at 1, 4, 8, and 12 months, every 6 months for 2 years, and then annually for 2 years."
62763226|NCT04701580|ACTIVE_COMPARATOR|Healthy controls|At baseline and 2-year follow-up
62763227|NCT04412694|EXPERIMENTAL|supplementation group|Patients will receive preoperative oral supplementation of 8mg of dexamethasone (Dexamethasone Krka tablets (8mg), Warsaw, Poland) in a single dose taken once one hour before surgery. At 6 and 24 hour after surgery, clinical and laboratory parameters will be measured and evaluated.
62763228|NCT04412694|PLACEBO_COMPARATOR|placebo group|Patients will receive preoperative oral supplementation of sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria) taken once in a single dose one hour before surgery. At 6 and 24 hour after surgery, clinical and laboratory parameters will be measured and evaluated.
62763229|NCT02263456|ACTIVE_COMPARATOR|Current Factor IX|
62763230|NCT02263456|EXPERIMENTAL|Replenine®-VF|
62763231|NCT01198457||Group 1|
62763232|NCT00825396|EXPERIMENTAL|C-KAD Ophthalmic Solution|
62763233|NCT00128713|ACTIVE_COMPARATOR|1|Lower Dose Prophylactic Platelets
62763234|NCT00128713|ACTIVE_COMPARATOR|2|Medium Dose Prophylactic Platelets
62763235|NCT00128713|ACTIVE_COMPARATOR|3|Higher Dose Prophylactic Platelets
62763236|NCT06184841|EXPERIMENTAL|esophageal squamous cell carcinoma with liver metastasis|Patients with esophageal squamous cell carcinoma with liver metastasis have poor response to first-line treatment, especially those with advanced esophageal cancer with progression or recurrence in the liver.
61988187|NCT02664909|EXPERIMENTAL|Tranexamic Acid|Patients will receive 1 gram of topically applied tranexamic acid into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. 1 gram of tranexamic acid will be mixed with normal saline to a total volume of 50 cc, half of which will be delivered intra-articularly and half of which will be delivered in the subfascial space.
61988188|NCT02664909|PLACEBO_COMPARATOR|Placebo|Patients will receive 50 cc of topically applied normal saline into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. Half of this 50 cc dose of normal saline will be delivered intra-articularly and half will be delivered in the subfascial space.
61988189|NCT03870828||Study group IPAF|"Patients with IPAF which is defined according to the Work Group of the European Respiratory Society/American Thoracic Society.~The interventions to be administered include:bronchoalveolar lavage and taking bronchial mucosa samples lung function tests,6 minute walk test, use of cough and dyspnea scales, transthoracic echocardiography, blood testing, arterial blood gas and pulse oximetry"
61988190|NCT03870828||Control group CTD-ILD|Patients with connective tissue disease associated intestitial lung disease: rheumatoid arthritis - RA, systemic sclerosis - SSc, polymyositis - PM, dermatomyositis - DM, (anti-synthetase syndrome - AS, Sjögren's syndrome - SjS, mixed connective tissue disease - MCTD ,systemic lupus erythematosus - SLE, diagnosed according to diagnostic criteria issued by European League Against Rheumatism (EULAR) and/or American College of Rheumatology (ACR)
61988191|NCT03870828||Control group ILD|Idiopathic interstitial pneumonia group: idiopathic pulmonary fibrosis - IPF, nonspecific interstitial pneumonia - NSIP, cryptogenic organizing pneumonia - COP, acute interstitial pneumonia - AIP; respiratory bronchiolitis associated interstitial lung disease - RB-ILD, desquamative interstitial pneumonia - DIP, lymphocytic interstitial pneumonia - LIP).
61988192|NCT01733446|NO_INTERVENTION|Standard anesthesia regimen|Positive pressure ventilation will be stopped at the same time infusions of anesthetic agents and spontaneous ventilation employed until emergence from anesthesia is observed. (This is standard protocol for everyday anesthesia management of this population.)
62763237|NCT06244836|NO_INTERVENTION|Baseline group|Patients included in the Catalan Nosocomial Infection surveillance Program (VINCat) program, and operated on colorectal surgery before bundle implementation, from January 2011 to June 2016
62763238|NCT06244836|EXPERIMENTAL|Implementation of a six-measures Bundle-1 (Bundle 1 Group)|Bundle-1 period after the implementation of a six-measure bundle, from July 2016 to June 2018
62763239|NCT06244836|EXPERIMENTAL|Implementation of a ten-measures Bundle-2 (Bundle 2 Group)|Bundle-2 period after the implementation of a ten-measure bundle, from July 2018 to December 2022
62763240|NCT05327283||Sporadic POI|"Idiopathic, sporadic POI Caucasian cases. The inclusion criteria will be:~* age at diagnosis \<38 years;~* a normal 46,XX karyotype (no FRM1 premutation);~* at least one marker of ovarian reserve not age-appropriate:~  * baseline FSH levels \> cut-off \[1\] and/or~ * age-specific AMH \< cut-off \[2\] and/or~ * AFC \< 5; and/or~* cancellation of a PMA cycle because of poor response (\<3 follicles) to high-dose gonadotrophins (250 U/die) and/or~* retrieval of \< 4 oocytes in response to high-dose stimulation protocols (3000 U of gonadotrophins)."
62763241|NCT05327283||Familial POI|Familial POI cases and not-affected members of pedigrees.
62763242|NCT04973462|ACTIVE_COMPARATOR|Triazavirin group|Patients will take the standard treatment COVID-19 + Triazavirin 250mg three times daily for 7 days\]
62763243|NCT04973462|ACTIVE_COMPARATOR|Oseltamivir group|Patients will take the standard treatment COVID-19 + Oseltamivir 75 mg twice daily for 7 days\]
62763244|NCT05315375||Corpectomy|surgical procedure using expandable cage
62763245|NCT03635034|EXPERIMENTAL|No Bladder catheter|"Subjects will not have bladder catheter inserted during their ablation procedure.~Intervention: No catheter"
61988193|NCT01733446|EXPERIMENTAL|Continuation of High Frequency Jet Ventilation ( HFJV)|In Group B after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
61988194|NCT05071885|EXPERIMENTAL|Game-based Exercise program|"Each exercise session would last 45 minutes and supervised by study staff at First Step Wellness center you will be shown how to handle and move the joystick and how to play a group of computer games. The game activities will require you to move the joystick at various speeds, movement' amplitudes and in different directions. Each game will be played for 2-3 minutes.~A variety of therapy handles of different shapes and sizes have been produced that Snap-On to joystick handle. These are designed to practice a broad range of manual dexterity skills involving the thumb, fingers, wrist and elbow, o Different games will also be used to vary the movement types and precision levels. To note you will be able to choose the types of movement exercises and games to use."
61988195|NCT05071885|ACTIVE_COMPARATOR|Range of motion and Strength Exercise program.|"This will involve stretching, range of motion and strength exercises as set out by training staff at the First Step Wellness center.~On completion of the ten week exercise program, you will be invited to take part in a 30-minute interview to discuss the experiences you had on receiving the specific hand exercise program. The whole interview session will be audio taped. Your identity will be protected and your privacy will be maintained. All the information discussed and shared during the interview will be kept confidential and safely protected."
62763246|NCT03635034|ACTIVE_COMPARATOR|Bladder catheter inserted|"Bladder catheter will be inserted prior to starting ablation procedure after the subject is under general anesthesia.~Intervention: bladder catheter inserted"
62763247|NCT00975065|EXPERIMENTAL|Galvus group|"the combination of metformin plus Vildagliptin:~* vildagliptin 50 mg bid plus metformin 1500mg~* Additional SU therapy(After 12th week only under the following conditions): If A1c is ≥ 7.0% or investigator determines that the patient have metabolic problems at 12th week of therapy, investigator can prescribe additional sulfonylurea(glimepiride) to the current therapy."
62763248|NCT00975065|ACTIVE_COMPARATOR|Diabex group|"metformin alone arm:~* metformin 1500mg plus metformin 500mg or 1000mg~* Additional SU therapy(After 12th week only under the following conditions): If A1c is ≥ 7.0% or investigator determines that the patient have metabolic problems at 12th week of therapy, investigator can prescribe additional sulfonylurea(glimepiride) to the current therapy"
61988196|NCT04900688|OTHER|Ureteroscopy (URS) with the LithoVue Elite disposable flexible ureteroscope|Ureteroscopy will be done using the LithoVue Elite disposable flexible ureteroscope instead of the satandard ureteroscope
61988197|NCT04991545|NO_INTERVENTION|Group A: control group (intubation without IRD/IRRIS device)|Group A = control group (intubation without IRD/IRRIS device) (15 subjects) The first operator experienced with video-laryngoscopy intubation will do the endotracheal intubation after induction of anesthesia.
62382854|NCT00346294|OTHER|Single-Arm|Open-lable Single Arm Study
62382855|NCT05071222|EXPERIMENTAL|ARTEGENE drug product|Autologous purified CD34+ cells transduced with a self-inactivated lentiviral vector, expressing the DCLRE1C gene (alias Artemis)
62382856|NCT01566006|NO_INTERVENTION|control group|group receiving the conventional treatment for DN
62382857|NCT01566006|EXPERIMENTAL|cellcept group|additional to the conventional treatment patients will receive cellcept
62382858|NCT01566006|EXPERIMENTAL|carnitine group|aside to the conventional treatment patients will receive carnitine
62382859|NCT01566006|EXPERIMENTAL|PDE5 group|aside to the conventional treatment patients will receive PDE5 inhibitor
62382860|NCT00566475|NO_INTERVENTION|1|Usual care of type 1 diabetes at the diabetes center
62763249|NCT04878744|EXPERIMENTAL|Noticing the good things about green spaces|"The intervention condition will prompt participants once a day to notice the good things about green spaces, write notes about the 'good things in nature' and answer 4 questions about the context (e.g. were they alone or in company, exercising or passing through, did they feel comfortable in the place, what were their perceived levels of species variety).~Participants were initially asked to use the app for one month. This was found to be associated with poor engagement at feasibility testing and so participants were asked to use the app for 7 days for the evaluation.~Both the intervention and active control conditions are based on gratitude interventions. Practicing gratitude in controlled psychological intervention settings has been shown to have lasting effects on dispositional gratitude and psychological wellbeing (Seligman et al. 2005)."
62763250|NCT04878744|ACTIVE_COMPARATOR|Noticing the good things about built spaces|"In the control condition, participants will not be prompted to notice nature, rather they will be prompted to record the good things about the built environment, write notes about the 'good things in built spaces' and answer 4 questions about the context (e.g. were they alone or in company, exercising or passing through, did they feel comfortable in the place, what were their perceived levels of the area being built-up).~Participants were initially asked to use the app for one month. This was found to be associated with poor engagement at feasibility testing and so participants were asked to use the app for 7 days for the evaluation."
62763251|NCT01241760|EXPERIMENTAL|001 T(q8h) / PR|Telaprevir (T) 750 mg (2 oral tablets) every 8 hours for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
62763252|NCT01241760|EXPERIMENTAL|002 T(b.i.d.) / PR|Telaprevir (T) 1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
62763253|NCT04284813|EXPERIMENTAL|Telemedicine|Community Reinforcement and Family Training for first episode psychosis delivered via telemedicine (CRAFT-FT) with 6-8 weekly sessions of 60-minute therapy.
62763254|NCT01900977|ACTIVE_COMPARATOR|Arm A Universal Testing w/Immediate ART|
62763255|NCT01900977|ACTIVE_COMPARATOR|Arm B ART according to National Guidelines|
62763256|NCT01900977|OTHER|Standard of Care|"Includes:~Strengthening of HIV testing and ART services according to national guidelines at health facilities and other venues; Strengthening of male circumcision and PMTCT services available at health facilities and other venues in the community; and Treatment of STIs and provision of condoms at health facilities and other venues in the community."
62763257|NCT01196494|EXPERIMENTAL|intraoperative colon lavage|
62763258|NCT01196494|ACTIVE_COMPARATOR|stent and deferred surgery|
62763259|NCT03752268|NO_INTERVENTION|Enhancing Cancer Pain Management Part 1|"* Will collect information from participants via self-report assessment at two time points: at baseline (i.e. study enrollment) and approximately 8 weeks post-baseline~* Will then use MEMS to monitor LA opioid intake over approximately 8 weeks~* A subset of enrolled participants (n=20) will be invited to participate in an optional one-time qualitative exit interview with a study staff member trained in conducting qualitative interviews"
62763260|NCT03752268|EXPERIMENTAL|Enhancing Cancer Pain Management Part 2|"* Enhancing Cancer Pain Management will consist of 3 individual manualized sessions~* The 3 individual manualized sessions will be conducted (approximately 20 minutes each), led by a nurse practitioner, to provide sufficient dose for change in adherence behaviors.~* Learning and practicing skills for managing cancer-related pain and adhering to prescribed LA opioid regimens.~* Study staff will provide participants with MEMS caps and bottles at time of enrollment, to monitor LA opioid intake over approximately 14 weeks."
62763261|NCT06508931|EXPERIMENTAL|zamtocabtagene autoleucel (MB-CART2019.1)|
62763262|NCT03455439||Rivaroxaban|Adult patients diagnosed with Atrial Fibrilation and Heart Failure who started treatment with rivaroxaban at least 4 months prior to inclusion
62763263|NCT00801060|EXPERIMENTAL|Treatment Group A|"FCR + Lumiliximab (L)~L (Lumiliximab): Day 2 50 mg/m2, Day 4 450 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks.~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
62763264|NCT00801060|ACTIVE_COMPARATOR|Treatment Group B|"FCR~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
62763265|NCT05529979||Intervention with the EPIONE® device|Patients treated by percutaneous CT-guided procedures in the abdomen with the EPIONE® device
62763266|NCT01846559|EXPERIMENTAL|Clopidogrel & Endotoxin|"Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily~E.coli Endotoxin Day 7 - 2 ng/kg"
62763267|NCT01846559|PLACEBO_COMPARATOR|No antiplatelet medication & Endotoxin|"No antiplatelet medication~E.coli Endotoxin Day 7 - 2 ng/kg"
62763268|NCT01846559|EXPERIMENTAL|Ticagrelor & Endotoxin|"Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily~E.coli Endotoxin Day 7 - 2 ng/kg"
62763269|NCT02869412|EXPERIMENTAL|Group I (BCG website)|Patients use the BCG website which will collect personal information including individual health priorities/goals, demographics (i.e. age, ethnicity), health information (i.e. weight, height, cancer history, other health conditions), individual capabilities, physical activity level, and exercise preferences. Patients then receive a report with a personalized physical activity plan.
62763270|NCT02869412|ACTIVE_COMPARATOR|Group II (passive website)|Patients use a passive website (American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Survivors).
62763271|NCT05363865|EXPERIMENTAL|Virtual Community Intervention|Participants will participate in an online community with structured sessions as well as the ability to communicate freely with others.
62763272|NCT05363865|ACTIVE_COMPARATOR|Standard of Care|Participants will be exposed to what's disseminated within their communities
62763273|NCT05094479|EXPERIMENTAL|Health information delivered via health app|Use of a health app with health information
62763274|NCT05094479|NO_INTERVENTION|Control|Use of a health app without health information
62763275|NCT06398964|ACTIVE_COMPARATOR|3-hydroxybutyrate|
62763276|NCT06398964|PLACEBO_COMPARATOR|Isocaloric placebo drink|
62763277|NCT02279836|OTHER|Single arm post-marketing Study|SC20 Colonoscope and Colonoscopy System For Colonoscopy
62763278|NCT04787068|EXPERIMENTAL|Treatment group|Intervention is occupational therapy support
62763279|NCT04787068|NO_INTERVENTION|Control group|No intervention was provided, only educational material was given.
62763280|NCT04141813||"Pilgrims doing the Camino de Santiago (any route)"|"In the present study we utilized the Ultreya dataset. The Ultreya study is an online longitudinal study aimed at evaluating the effects of the pilgrimage on the Way of Saint James on mental health and wellbeing (www.estudiocamino.org). This pilgrimage involves hundreds of paths around Europe with a common termination at Santiago de Compostela (Spain), and it was one of the most important Christian pilgrimages during the Middle Ages. Currently, it is walked by thousands of people (\>300,000 per year)."
62763281|NCT04798742|EXPERIMENTAL|Gait performance preop vs postop|Pre and postop
62763282|NCT04798742|EXPERIMENTAL|Gait performance postop vs controls|Postop vs controls
62763283|NCT04577079||IPMF Screened|Patient screened and assessed by intelligent patient flow management system.
62763284|NCT02513758||HIV patients|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
62763285|NCT04173195|EXPERIMENTAL|Intervention arm|The CT intervention will be administered by the nurse in charge of the chemotherapy 5 min after the initiation. the CT content will be partially script.
62382861|NCT00566475|EXPERIMENTAL|2|Usual care at the diabetes center supplemented by a telemedicine intervention in the school involving school personnel, the child with diabetes and at least 1 parent of the child. The diabetes center NP conducts videovisits with the school nurse, patient (child) +/- parent monthly.
62763286|NCT04173195|NO_INTERVENTION|No intervention arm|Patients assigned to this arm will received current care.
62763287|NCT04527523||Endothelial Dysfunction Cohort|All patients enrolled in the study will receive a baseline Optical Coherence Tomography scan (OCT) within 4 weeks prior to surgery. Two additional OCT scan will be performed 6 weeks and 3 months after surgery.
62763288|NCT06508138|ACTIVE_COMPARATOR|Blood and Bone Marrow Donation for Recipient Patient's alloBMT|Donor patients receive the vaccination series. This will be followed by a bone marrow harvest under anesthesia that will be given to the donor's related recipient patient on the J21112 study. Then, depending on recipient response to allogeneic BMT, donor may return for collection of peripheral blood used to create CD8-depleted donor lymphocyte infusion (DLI) which will be given to the donor's related recipient patient on D90.
62763289|NCT06508138|ACTIVE_COMPARATOR|Blood Donation Only for Recipient's CD-8 Depleted DLI|Donor patients receive the vaccination series followed by collection of peripheral blood. This blood will be used to create the CD8-depleted donor lymphocyte infusion (DLI) which will be given to the donor's related recipient patient on the J21112 study.
62763290|NCT02583971||Patients with AF|"Split into 3:~Those patients on treatment for AF involving blood thinning medicines (anticoagulants) +/- heart rate limiting drugs such as B blockers or digoxin. 100 patients in this group.~Patients undergoing direct current cardioversion (DCCV) to temporarily restore normal (sinus) rhythm. 100 patients in this group.~Patients undergoing an AF ablation to permanently restore sinus rhythm. 300 patients in this group."
62763291|NCT00121394|EXPERIMENTAL|Chlorhexidine|
62763292|NCT02165462||Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task
62763293|NCT05014503|EXPERIMENTAL|Adaptive version of the therapeutic game|The adaptive therapeutic game will use a game-entry level that is based on the individual visual perceptual profile of the child. Children with higher visual perceptual capacities will be able to start the game at a higher entry level compared to children with lower visual perceptual capacities. Thereby, the entry level will also be different for the different games. In addition, the adaptive game uses an in-game adaptivity system that has been developed using artificial intelligence (more specifically, reinforcement learning): this means that the game can adjust the difficulty automatically, based on the game-behaviour and success of the child. Children learning fast, will more quickly move to higher difficulty levels compared to children learning slower. Thereby, this in-game adaptivity also enables children to return to lower difficulty levels when a difficulty level is too high.
61988198|NCT04991545|EXPERIMENTAL|Intervention group using Infrared (Active IRD/ IRRIS) device|Group B = intervention group using Infrared active IRD/IRRIS device (15 subjects) Before inducing anesthesia, the second operator will open the randomization envelope and adhere IRRIS/IRD device to the anterior skin of the neck above the sternal notch according to the group of patients. After confirming lack of discomfort during application of the IRRIS/IRD device, anesthesia will be induced
61988199|NCT05240404|OTHER|Arm A|Patients with recurrent hepatocellular carcinoma would be treated with curative-intent ablation alone.
62763294|NCT05014503|ACTIVE_COMPARATOR|Non-adaptive version of the therapeutic game|The non-adaptive therapeutic game will use the same, lowest entry level for all children. During game play, a fixed stepwise increase in difficulty will be built in, not adjusted to the gaming behaviour or success of the child. All children will follow the same, gradual approach in difficulty and a fixed number of trials is set for each difficulty level. To prevent extreme frustration however, a safety margin is integrated by preventing the difficulty level to increase further when a child has more than a predefined number of unsuccessful trials. Likewise, the stepwise increase in difficulty level will only continue after a fixed, predefined number of successful trials. A child will also never return to a lower difficulty level, once a difficulty level is reached.
62763295|NCT02223611|EXPERIMENTAL|S1 capsule plus Cisplatin|"S1: 40mg, bid, when body surface area (BSA)\<1.25 m2, 50mg; bid when 1.25 m2≤BSA\<1.5 m2; 60mg, bid when 1.5 m2≤BSA 60mg from day 1 to 14. Cisplatin: 75 mg/m2 on day 1.~3 weeks/4cycles"
62763296|NCT02223611|ACTIVE_COMPARATOR|Vinorelbine plus Cisplatin|"Vinorelbine: 25 mg/m2 intravenously on day 1, and day 8. Cisplatin: 75 mg/m2 intravenously on day 1.~3 weeks/4cycles"
62763297|NCT02032641|EXPERIMENTAL|Laser Treatment Side|"Each patient was randomized to have one of two scars treated with Laser Genesis. The treatment was administered by manually scanning the rapidly pulsed laser in an even, painting motion throughout the entire treatment zone. The eyebrow hairs were covered with white tape to prevent inadvertent alopecia. The laser handpiece was oriented perpendicular to the skin at all times, at a distance of 1-2 cm. Patients were instructed throughout to give verbal feedback regarding if the area was too hot as an additional safeguard against epidermal damage."
61988200|NCT05240404|EXPERIMENTAL|Arm B|Patients with recurrent hepatocellular carcinoma would be treated with curative-intent ablation and adjuvant immunotherapy with toripalimab.
61988201|NCT04425395|EXPERIMENTAL|Healthy adult population aged 18 to 60 years.|Their pain tolerance will be tested using the Cold Pressor Task while producing vocalisations. Produced vocalisations will be audio recorded and physiological measures will be taken using two techniques: Nociception Level Index and video pupillometry.
61988202|NCT01089439|ACTIVE_COMPARATOR|1: INOMAX|"Nitric oxide by inhalation INOMAX:~active arm treated with nitric oxide"
62382862|NCT04492306|ACTIVE_COMPARATOR|3M single bond, etch and rinse adhesive|"O.I. will clean the labial surface of tooth with polishing paste and brush Roughening of the surface may be needed by diamond point The tooth will be isolated by rubber dam. Apply etchant for 30 s for enamel and 15 s for dentin. Rinse thoroughly with water for 10 s. blot-drying with paper tissue was carefully performed leaving the dentin surface slightly moist.~Apply 2 to 3 consecutive coats of the adhesive for 15 s. Gently air for 5 s. Light cure for 10 s. Composite build ups (Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA) were performed in increments and individually light-cured for 40 s. Light curing of all resin materials was performed using a LED device (Bluephase 20i, Ivoclare Vivadent, Schaan, Liechtenstein) delivering 1100 mW/cm2."
61988203|NCT01089439|PLACEBO_COMPARATOR|2: Placebo|placebo arm treated with placebo at the same conditions
61988204|NCT00929682|EXPERIMENTAL|Levobupivacaine 0.568mg.mL|
61988205|NCT00929682|OTHER|Levobupivacaine 1.136mg.mL|
61988206|NCT01877629|EXPERIMENTAL|ACT-129968 tablet/capsules|Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period.
61988207|NCT01877629|EXPERIMENTAL|ACT-129968 capsules/tablet|Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period.
61988208|NCT02910193||alcohol-dependent patients|
62763298|NCT02032641|NO_INTERVENTION|Control side|Each patient had a scar which was randomized to not undergo treatments with Laser Genesis, and was used as a control. Patients were not allowed to undergo laser or any other scar treatments with the exception of sun protection for the control scar for the duration of the study.
62763299|NCT01182974|ACTIVE_COMPARATOR|paracetamol treatment|
62763300|NCT01182974|ACTIVE_COMPARATOR|control- dypirone treatment|
62763301|NCT02087202|EXPERIMENTAL|magnesium|magnesium is added perioperatively to those patients undergoing staged total knee arthroplasty and other surgeries.
62763302|NCT02087202|EXPERIMENTAL|ketamine|ketamine is administered to those patients undergoing stated TKA and other operations.
62763303|NCT02087202|PLACEBO_COMPARATOR|control|normal saline (placebo) is administered to the patients.
62763304|NCT01561547|EXPERIMENTAL|Kangaroo Mother Care|Infant is held in skin-to-skin contact with mother at least 15 minutes prior to painful procedure, remains in that position throughout the procedure and after the procedure at least until heart rate returns to baseline. Infant is given sterile water by mouth. This is for every heel lance and venipuncture, and if possible for tape removal.
62763305|NCT01561547|ACTIVE_COMPARATOR|Sucrose|Two minutes before the painful procedure and at the moment of the procedure, the infant will be given 24% sucrose by mouth. The volume is determined by body weight and is not important in terms of efficacy, it is the percentage of sweetness that is important.
62763306|NCT01561547|EXPERIMENTAL|Combination Kangaroo Mother Care and Sucrose|Infant is held in skin-to-skin contact with mother at least 15 minutes prior to painful procedure, remains in that position throughout the procedure and after the procedure at least until heart rate returns to baseline. Infant is given sucrose water by mouth. This is for every heel lance and venipuncture, and if possible for tape removal.
62763307|NCT02511600|EXPERIMENTAL|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest. Participants complete pain scale 3 times each day while in the hospital.
62763308|NCT02511600|ACTIVE_COMPARATOR|Standard of Care|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest. Participants complete pain scale 3 times each day while in the hospital.
62763309|NCT02772796|EXPERIMENTAL|SENS-218|2 x 10 mg administered once on Day 1.
62763310|NCT01136070||Burn Trauma Patients|
62763311|NCT05260333|EXPERIMENTAL|Transperineal ultrasound cervical exam followed by Digital (manual) cervical exam|Patients will undergo transperineal cervical exam via Butterfly iQ ultrasound. Patients will then undergo traditional digital cervical exam via examiner's fingers.
62763312|NCT01504230||health older adults|
62763313|NCT01504230||Osteoporosis participants|
62763314|NCT05473013|ACTIVE_COMPARATOR|Base BT (Skills Monitoring Off + No Micro-Interventions)|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns). This will include traditional self-monitoring of participants' eating patterns, binging, and (if applicable) compensatory behaviors via a smartphone application.
62763315|NCT05473013|EXPERIMENTAL|Base BT + Skills Monitoring On + No Micro-Interventions|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns). This will include a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors.
62763316|NCT05473013|EXPERIMENTAL|Base BT + Skills Monitoring On + Automated Reminder Messages|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).This will include a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors. It will also include participants receiving two randomly time automated push notifications from the application each week to remind them about skills they have learned in session to encourage skill use.
61988209|NCT02910193||first-degree relatives|Parents, children, siblings of alcohol-dependent patients
61988210|NCT02910193||healthy control subjects|
62763317|NCT05473013|EXPERIMENTAL|Base BT + Skills Monitoring On + JITAIs|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns). This will include a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors. It will also include participants receiving push notifications each week to remind them about skills they have learned in session to encourage skill use during app-identified moments of need (i.e., JITAIs, just-in-time adaptive interventions).
62763318|NCT05473013|EXPERIMENTAL|Base BT + Skills Monitoring Off + Automated Reminder Messages|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns). This will include traditional self-monitoring of participants' eating patterns, binging, and (if applicable) compensatory behaviors via a smartphone application. It will also include participants receiving two randomly time automated push notifications from the application each week to remind them about skills they have learned in session to encourage skill use.
61988211|NCT05614375||soft tissue sarcoma with endoscopic surgery|patients with soft tissue sarcoma accept endoscopic surgery
61988212|NCT00729729|PLACEBO_COMPARATOR|1|Placebo
61988213|NCT00729729|EXPERIMENTAL|2|Slow release PCA derivative
61988214|NCT00729729|EXPERIMENTAL|3|Slow release PCA derivative higher dose
61988215|NCT02497027|OTHER|4-Week Group|Pharmacogenetic testing released to physician at 4 weeks following enrollment into study
61988216|NCT02497027|OTHER|12-Week Group|Pharmacogenetic testing released to physician at 12 weeks following enrollment into study
61988217|NCT00896337|EXPERIMENTAL|ORION|All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with iliac artery stenting with the Epic™ Nitinol Stent System.
61988218|NCT00056030|EXPERIMENTAL|cetuximab + oxaliplatin + leucovorin + fluorouracil|"Patients receive cetuximab IV over 1 hour (over 2 hours on day 1 of course 1 only) on days 1 and 8. Patients also receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously on days 1-2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity, for a minimum of 12 courses or until deemed to have resectable disease.~Quality of life is assessed at baseline and prior to each treatment course.~Patients are followed every 3 months for 1 year and then every 6 months for 3 years."
61988219|NCT00939809|EXPERIMENTAL|Treatment (urokinase-derived peptide A6)|Patients receive A6 subcutaneously once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61988220|NCT02385266|EXPERIMENTAL|D-Cycloserine and Acetominophen|D-cycloserine 200mg/bid and Acetaminophen prn
61988221|NCT02385266|PLACEBO_COMPARATOR|Placebo and Acetominophen|Placebo capsules (lactose)/bid and Acetaminophen prn
61988222|NCT05853302||Laparoscopic TLA|Patients who underwent laparoscopic lateral transabdominal unilateral adrenalectomy
62382863|NCT04492306|EXPERIMENTAL|DMSO pre-treatment before 3M single bond application|The same steps of the comparator group with additional step, after dentin etching and humidity control, dentin pretreatments were performed consisting of active application of 1% DMSO/H2O solutions on etched-dentin followed by blot drying until paper filters no longer absorbed liquids from the bonding surface by capillarity then apply adhesive.
62382864|NCT02393365|OTHER|HCV screening|All patients admitted to the one day clinic for surgery and gastroenterology.
62382865|NCT00372944|ACTIVE_COMPARATOR|1|Xeloda
61988223|NCT05853302||Robotic TLA|Patients who underwent robotic lateral transabdominal unilateral adrenalectomy
61988224|NCT01312090|ACTIVE_COMPARATOR|Conventional weight loss treatment group|Eating and physical activity counseling and behavioral therapy for weight loss.
61988225|NCT01312090|EXPERIMENTAL|Cryo group|"Eating and physical activity counseling and behavioral therapy for weight loss will be provided to all subjects.~The subjects in the cryo group will be given whole-body cryotherapy 1-3 times a week for the 4-month-treatment period"
62382866|NCT00372944|EXPERIMENTAL|2|AZD6244
62382867|NCT00002625|EXPERIMENTAL|Arm I|Radiosensitization plus Radiotherapy. Topotecan hydrochloride, TOPO, NSC-609699; plus external-beam irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons acceptable for the boost field).
62763319|NCT05473013|EXPERIMENTAL|Base BT + Skills Monitoring Off + JITAIs|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns). This will include traditional self-monitoring of participants' eating patterns, binging, and (if applicable) compensatory behaviors via a smartphone application. It will also include participants receiving push notifications each week to remind them about skills they have learned in session to encourage skill use during app-identified moments of need (i.e., JITAIs, just-in-time adaptive interventions).
61988226|NCT04375488|EXPERIMENTAL|Resistance Exercise Training Group|Resistance exercise training for 8 major muscle groups and 150 min per week walking suggestions were given
61988227|NCT04375488|EXPERIMENTAL|Inspiratory Muscle Training Group|Resistance exercise training for 8 major muscle groups and inspiratory muscle strength training and 150 min per week walking suggestions were given
61988228|NCT04375488|NO_INTERVENTION|Control Group|150 min per week walking suggestions were given.
61988229|NCT02382458|EXPERIMENTAL|Lifestyle intervention|Participants will receive a year-long comprehensive, dietary, exercise, and stress management intervention. They will be asked to bring a partner of their choosing with them for support. The intervention will include a behavioral program to reduce inflammation.
61988230|NCT02382458|ACTIVE_COMPARATOR|Information intervention|Participants will receive a year-long intervention that will involve receiving weekly (for the first 3 months) and then monthly (for the following 9 months) newsletters on cancer prevention and control (via e-mail or mail) that will provide the participant with information about cancer prevention and control strategies.
61988231|NCT01410045|EXPERIMENTAL|Surgery|Ovariectomy
62382868|NCT03420989|ACTIVE_COMPARATOR|Active snack food|snack food with carob and seaweeds 50 gr per day
62382869|NCT03420989|PLACEBO_COMPARATOR|Control snack food|snack food without carob and seaweeds 50 gr per day
62382870|NCT05786404|EXPERIMENTAL|Experimental: PRIM-DJ2727 - FROZEN|
62382871|NCT05786404|EXPERIMENTAL|Experimental: PRIM-DJ2727 - CAPSULES|
61988232|NCT03359642|EXPERIMENTAL|Patients with anti-TNF alpha|12 spondyloarthritis and 24 inflammatory bowel diseases patients (12 Crohn's disease and 12 ulcerative colitis), in which a first anti-TNF alpha treatment is indicated.
61988233|NCT03359642|ACTIVE_COMPARATOR|mirror group|"A mirror group of 12 spondyloarthritis and 24 inflammatory bowel diseases patients (12 Crohn's disease and 12 ulcerative colitis), in which an all but anti-TNF alpha or biotherapy treatment is indicated will be included to distinguish the specific effects on microbiota of anti-TNF alpha."
62763320|NCT03958656|EXPERIMENTAL|1/Conditioning Chemotherapy Plus Chimeric Antigen Receptor (CAR) T-cells Dose Escalation|Patients will receive escalating doses (up to 4 planned) of Anti-Signaling lymphocytic activation molecule F7 (SLAMF7)-CAR+ T cells infused on day 0 + Cyclophosphamide: 300 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg/m\^22 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
62763321|NCT03958656|EXPERIMENTAL|2/Conditioning Chemotherapy Plus Chimeric Antigen Receptor (CAR) T-cells Expansion Phase|Maximum tolerated dose (MTD) dose of Anti-Anti-Signaling lymphocytic activation molecule F7 (SLAMF7)- CAR T Cells + Cyclophosphamide: 300 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30mg/m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
62763322|NCT03759041|PLACEBO_COMPARATOR|Placebo (after placebo pre-treatment)|Once-daily dosing of Placebo (after placebo pre-treatment)
62763323|NCT03759041|EXPERIMENTAL|SER-287 Induction Dosing (after vancomycin pre-treatment)|Once-daily dosing of SER-287 (Induction Dose, after vancomycin pre-treatment)
61988234|NCT04572607|NO_INTERVENTION|Control group 1|
62763324|NCT03759041|EXPERIMENTAL|SER-287 Step-Down Induction Dosing (after vancomycin pre-treatment)|Once-daily dosing of SER-287 (Step-Down Induction Dose, after vancomycin pre-treatment)
62763325|NCT03622437|EXPERIMENTAL|Patient-led follow-up|Participants in the experimental arm are enrolled in a patient-led follow-up program, based on patient-education and self-referral, in addition to recommendations from national guidelines for follow-up.
62763326|NCT03622437|ACTIVE_COMPARATOR|Standard follow-up|Participants in this control group follow standard care for follow-up after rectal cancer treatment, as described in local and national guidelines.
62763327|NCT02322294|EXPERIMENTAL|Glucodia™|
62763328|NCT02322294|PLACEBO_COMPARATOR|Placebo|
61988235|NCT04572607|NO_INTERVENTION|Control group 2|
61988236|NCT04572607|NO_INTERVENTION|Control group 3|
61988237|NCT04572607|NO_INTERVENTION|Control group 4|
61988238|NCT04572607|NO_INTERVENTION|Control group 5|
61988239|NCT04572607|NO_INTERVENTION|Control group 6|
61988240|NCT04572607|NO_INTERVENTION|Control group 7|
62763329|NCT03560817||breast cancer|No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.
62763330|NCT03560817||colorectal cancer|No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.
62763331|NCT06113224|ACTIVE_COMPARATOR|Control patients|Patients with an indication for cardiac surgery with extracorporeal circulation but without homograft
62763332|NCT06113224|EXPERIMENTAL|Lung homograft patients|patients requiring lung homograft implantation
62763333|NCT02983591|EXPERIMENTAL|Misoprostol|Rectal misoprostol
62763334|NCT02983591|EXPERIMENTAL|Oxytocin|intravenous oxytocin
62763335|NCT05352269|EXPERIMENTAL|Cohort 1 XBI-302|40 XBI-302 capsules in 1 day
62763336|NCT05352269|PLACEBO_COMPARATOR|Cohort 1 Placebo|40 placebo capsules in 1 day
61988241|NCT04572607|EXPERIMENTAL|Honey group 1|
61988242|NCT04572607|EXPERIMENTAL|Honey group 2|
61988243|NCT04572607|EXPERIMENTAL|Honey group 3|
61988244|NCT04572607|EXPERIMENTAL|Honey group 4|
62763337|NCT05352269|EXPERIMENTAL|Cohort 2 XBI-302|80 XBI-302 capsules over 2 days
62763338|NCT05352269|PLACEBO_COMPARATOR|Cohort 2 Placebo|80 placebo capsules over 2 days
62763339|NCT05352269|EXPERIMENTAL|Cohort 3 XBI-302|40 XBI-302 capsules per day, once a week for 4 weeks.
62763340|NCT05352269|PLACEBO_COMPARATOR|Cohort 3 Placebo|40 placebo capsules per day, once a week for 4 weeks.
62763341|NCT05352269|EXPERIMENTAL|Cohort 4 XBI-302|80 XBI-302 capsules over 2 days, once a week for 4 weeks.
62763342|NCT05352269|PLACEBO_COMPARATOR|Cohort 4 Placebo|80 placebo capsules over 2 days, once a week for 4 weeks.
61988245|NCT04572607|EXPERIMENTAL|Honey group 5|
61988246|NCT04572607|EXPERIMENTAL|Honey group 6|
61988247|NCT01498458|EXPERIMENTAL|pazopanib plus capecitabine|
62763343|NCT01982500||Avastin regimens|Patients who are going to receive chemotherapy plus Avastin (bevacizumab)
61988248|NCT05531435|EXPERIMENTAL|SleeperOne|SleeperOne S4 (Revello S.p.A., Verona, Italy) appliance will be used for the administration of local anesthetic.
61988249|NCT05531435|ACTIVE_COMPARATOR|Traditional anesthesia|Local anesthesia will be performed with a traditional syringe (0480-1, ASA Dental, Massarosa, LU, Italy).
61988250|NCT02762266|ACTIVE_COMPARATOR|Arm I (TACE)|Patients undergo TACE.
61988251|NCT02762266|EXPERIMENTAL|Arm II (SBRT)|Beginning within 2 weeks of the radiation set-up scan and within 4 weeks of fiducial seed implantation (if applicable), patients undergo image guided SBRT 3 fractions within 1 week or 5 fractions within 2 weeks.
61988252|NCT04710446||NSTEMI Patients presenting with normal ECG|NSTEMI Patients presenting with normal ECG
62763344|NCT03788447|EXPERIMENTAL|High CO2 group|end tidal CO2 : 40-45 mmHg
62763345|NCT03788447|PLACEBO_COMPARATOR|Low CO2 group|end tidal CO2 : 30-35 mmHg
62763346|NCT06427070|EXPERIMENTAL|Irrigating solutions|Group 1 sodium hypochlorite Group 2 saline Group 3 chlorohexidine
62763347|NCT04229212|NO_INTERVENTION|No drainage|No drainage
61988253|NCT04710446||NSTEMI Patients presenting with isolated T wave inversion|NSTEMI Patients presenting with isolated T wave inversion
61988254|NCT04710446||NSTEMI Patients presenting with transient ST-segment elevation|NSTEMI Patients presenting with transient ST-segment elevation
61988255|NCT04710446||NSTEMI Patients presenting with resting U wave inversion|NSTEMI Patients presenting with resting U wave inversion
61988256|NCT04710446||NSTEMI Patients presenting with low QRS voltage|NSTEMI Patients presenting with low QRS voltage
62382872|NCT01078974|EXPERIMENTAL|pomalidomide, dexamethasone, rituximab|"Drug: pomalidomide Taken orally once a day~Drug: dexamethasone Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15~Drug: rituximab Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15"
62763348|NCT04229212|EXPERIMENTAL|Drainage|a hemovac drain (Zimmer Biomet, Autotransfusion System \[HAS\], United State) was placed
62763349|NCT04739397||Cataract|Patients with bilateral cataracts with Lens grade 2+ or greater, cataract classification nuclear, cortical or posterior subcapsular
62763350|NCT04739397||Non-Cataract|patients with bilateral clear lenses (no cataracts)
61988257|NCT05346809|EXPERIMENTAL|Isatuximab and Standard Procedures|Subjects will receive the study drug Isatuximab in addition to standard procedures for transplant
61988258|NCT05346809|EXPERIMENTAL|Standard procedures|Subjects will receive standard procedures for transplant.
61988259|NCT03809442|EXPERIMENTAL|Ropivacaine with Ketamine|"Ropivacaine is a propyl analog of bupivacaine with longer duration of action with much safer cardiotoxicity profile than bupivacaine. Ropivacaine has the same analgesic effects as bupivacaine and levobupivacaine, but it is associated with a low incidence of motor block. Thus, ropivacaine appears to be an important component for local anesthesia and postoperative analgesia.~Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that possesses both central and peripheral analgesic effects. Preincisional infiltration of ketamine prolongs the time to first analgesic requirement and also decreases the total amount of analgesics used postoperatively.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group)."
62382873|NCT05986006|ACTIVE_COMPARATOR|Anterior Cervical Discectomy and Fusion (ACDF) w/Machined Allograft|Participant will undergo primary, elective one-level to four-level ACDF and will be randomized to machined bone allograft
62382874|NCT05986006|ACTIVE_COMPARATOR|Anterior Cervical Discectomy and Fusion (ACDF) w/Iliac Crest Allograft|Participant will undergo primary, elective one-level to four-level ACDF and will be randomized to iliac crest bone allograft
62763351|NCT00983736|EXPERIMENTAL|Active|
62763352|NCT00983736|PLACEBO_COMPARATOR|Placebo|
62763353|NCT00030771|ACTIVE_COMPARATOR|Arm A|Neoadjuvant Chemoradiotherapy + Chemotherapy + Surgery
62763354|NCT00030771|ACTIVE_COMPARATOR|Arm B|Neoadjuvant Chemotherapy + Surgery
62763355|NCT03276052|EXPERIMENTAL|Aclidinium Bromide 400 μg|One inhalation from the 400 μg Aclidinium Bromide inhaler.
62763356|NCT03984630|NO_INTERVENTION|Control Arm|Participants were informed to continue to receive usual care by their Obstetrician and were asked to send in body weights weekly.
62763357|NCT03984630|EXPERIMENTAL|Intervention Arm|Received snacks high in fiber, attended weekly phone calls, recorded daily food intake and reported weekly body weight for 12 weeks.
62763358|NCT03980821|EXPERIMENTAL|AZD4635 monotherapy|Dose escalation of AZD4635 monotherapy for patients with advanced solid malignancies
62763359|NCT01555554|EXPERIMENTAL|Propranolol Hydrochloride|
62763360|NCT01555554|PLACEBO_COMPARATOR|Placebo Group|
62763361|NCT00283816|ACTIVE_COMPARATOR|1|metformin
62763362|NCT00283816|PLACEBO_COMPARATOR|0|placebo
62763363|NCT01634529|EXPERIMENTAL|Single Ascending Dose|Single ascending doses of V158866 compared to Placebo
62763364|NCT01634529|EXPERIMENTAL|Multiple ascending doses|Multiple ascending doses of V158866 compared to Placebo
62763365|NCT02452853|EXPERIMENTAL|HR combined with FOLFOX4|"1. HR ;~2. FOLFOX4 4 weeks after HR"
62763366|NCT03747900|EXPERIMENTAL|BTX-A|Patients underwent 200 U BTX-A injections in biceps brachii muscle.
62763367|NCT03747900|ACTIVE_COMPARATOR|BTX-A+Dry needling|Dry needling was administered for 4 times in total after the BTX-A injection.
61988260|NCT03809442|EXPERIMENTAL|Ropivacaine with Tramadol|"Tramadol hydrochloride is a synthetic analog of codeine that acts on both opioid (weak mu receptor agonist) and nonopioid receptors (inhibits reuptake of nor-adrenaline and serotonin as well as release stored serotonin from nerve endings) which play a crucial role in pain inhibition pathway.~It also blocks nerve conduction which imparts its local anesthetics like action on peripheral nerves.~In one study it was found that the addition of tramadol or midazolam to caudal epidural ropivacaine prolongs the duration of analgesia without causing significant side effects.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group)."
62382875|NCT02415582|EXPERIMENTAL|Aerobic exercise|Aerobic exercise on treadmill at 65-70% of the heart rate reserve during a session.
62382876|NCT02415582|EXPERIMENTAL|Combined exercises|A session combines resistance and aerobic exercises, with aerobic exercise on treadmill at 65-70% of the heart rate reserve, followed by 60 minutes for cardiorespiratory recovery, and resistance exercise.
62382877|NCT02415582|SHAM_COMPARATOR|Control|Participants do not exercise and remain sitting for 45 minutes
62382878|NCT04847167|EXPERIMENTAL|Single balloon enteroscopy assisted ERCP using a mechanistic loop resolution strategy group|All ERCP was performed with the patient in the prone position using a SBE (SIF-H290S; Olympus Corp., Japan) under CO2 insufflation and conscious sedation. A soft transparent hood (D-201-11804; Olympus Corp., Japan) was used in all cases. The SBE was introduced alternately with an overtube apparatus (ST-SB1S; Olympus Corp., Japan) following the mechanistic loop resolution strategy under endoscopic and fluoroscopic guidance. The overtube was advanced along the enteroscope, by gently pulling the enteroscope, like as ERCP accessory advancement over the guidewire.
62382879|NCT01728610|ACTIVE_COMPARATOR|Active high|Probiotic, high dose
62382880|NCT01728610|ACTIVE_COMPARATOR|Active low|Probiotic, low dose
62763368|NCT05969717|EXPERIMENTAL|GD-iExo-001 treatment|Group1 (low-dose group), 8 papatients are treated with 10 μg/mL GD-iExo-001. Group2 (high-dose group), 8 papatients are treated with 50 μg/mL GD-iExo-001. One drop (about 50 μL) of GD-iExo-001 was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
62763369|NCT05969717|PLACEBO_COMPARATOR|Normal saline control|Group1 (low-dose group), 2 papatients are treated with normal saline. Group2 (high-dose group), 2 papatients are treated with normal saline. One drop (about 50 μL) of normal saline was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
62763370|NCT04337736|ACTIVE_COMPARATOR|Aerobic training|12-weeks, 3-days-a week, supervised aerobic (Nordic walking or Walking) physical exercise (PhE) protocol; duration of each PhE session: 70 minutes; rate of perceived exertion (RPE): 10-11 (1st-4th week); 12-13 (5th-8th week); 13-14 (9th-12th week).
62763371|NCT04337736|ACTIVE_COMPARATOR|Resistance training|12-weeks, 2.3-days-a week (total of 28 lessons), supervised resistance physical exercise (PhE) protocol; duration of each PhE session: 50 minutes.
62763372|NCT00180167|ACTIVE_COMPARATOR|Daunorubicin + Ara-C|
62763373|NCT00180167|EXPERIMENTAL|Mitoxantrone + Ara-C|
62763374|NCT02321891|EXPERIMENTAL|Treatment 1|NeuroConn DC Stimulator Plus, tDCS treatment protocol no 1
62763375|NCT02321891|EXPERIMENTAL|Treatment 2|NeuroConn DC Stimulator Plus, tDCS treatment protocol no 2
62382881|NCT01728610|PLACEBO_COMPARATOR|Placebo|Placebo
62382882|NCT03869931|EXPERIMENTAL|Fenofibrate|(Refer to intervention)
62382883|NCT02260791|EXPERIMENTAL|FKB327|Patients will receive FKB327 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
62382884|NCT02260791|ACTIVE_COMPARATOR|Humira®|Patients will receive Humira® 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
62763376|NCT05598723|ACTIVE_COMPARATOR|OnabotulinumtoxinA (BOTOX®)|OnabotulinumtoxinA (BOTOX®) Group: Administration consists of 31 injections (5 onabotulinumtoxinA (BOTOX®) units per injection, for a total of 155units) in the head and neck at two time points (12 weeks apart). Injection sites include the forehead, temples, back of the head, upper neck, and the junction of the shoulder and the neck. A very small (e.g., 30-gauge), very sharp needle will be used to perform the injections.
62763377|NCT05598723|EXPERIMENTAL|IncobotulinumtoxinA (XEOMIN®)|IncobotulinumtoxinA (XEOMIN®) Group: Administration consists of 31 injections (5 incobotulinumtoxinA (XEOMIN®) units per injection, for a total of 155 units) in the head and neck at two time points (12 weeks apart). Injection sites include the forehead, temples, back of the head, upper neck, and the junction of the shoulder and the neck. A very small (e.g., 30-gauge), very sharp needle will be used to perform the injections.
62763378|NCT00390481|OTHER|Intervention|EC-IC Bypass
62763379|NCT00390481|NO_INTERVENTION|Control|Best Medical Therapy
62763380|NCT02897752|EXPERIMENTAL|WalkAide|
62763381|NCT02897752|ACTIVE_COMPARATOR|Usual gait Training|
62763382|NCT02728414|EXPERIMENTAL|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
62763383|NCT02728414|OTHER|placebo|the patients in this arm will receive placebo with similar appearance of probiotics.
62763384|NCT04402294|EXPERIMENTAL|Optimized TMS frequency, Then Sub-Optimal TMS Frequency|In the first neuromodulation session, participants will receive rTMS using their optimal TMS frequency. After washout period of 1 week (minimum), the participants will start their second neuromodulation session using their sub-optimal TMS frequency instead.
62763385|NCT04402294|EXPERIMENTAL|Sub-Optimal TMS Frequency, Then Optimized TMS frequency|In the first neuromodulation session, participants will receive rTMS using their sub-optimal TMS frequency. After washout period of 1 week (minimum), the participants will start their second neuromodulation session using their optimal TMS frequency instead.
62382885|NCT00453453|EXPERIMENTAL|Nesiritide|Subjects who come into the ED with CHF will be treated with nesiritide
62382886|NCT00453453|NO_INTERVENTION|Standard care|Subjects who come into the ED with CHF will receive standard care treatment
62382887|NCT00090844|EXPERIMENTAL|triptorelin|GnRH analogue (triptorelin) during chemotherapy
62382888|NCT00090844|NO_INTERVENTION|no triptorelin|No GnRH analogue (triptorelin) during chemotherapy
62763386|NCT05568030|EXPERIMENTAL|Mindfulness|
62763387|NCT05568030|ACTIVE_COMPARATOR|Psycho-education|
62763388|NCT00048750|EXPERIMENTAL|1|
62763389|NCT00048750|PLACEBO_COMPARATOR|2|
62763390|NCT03242018|PLACEBO_COMPARATOR|Placebo|Following a 2-week run-in phase, participants received two placebo tablets (identical to sotagliflozin 200 milligrams \[mg\] in appearance) orally once daily for up to 56 weeks.
61988261|NCT03809442|EXPERIMENTAL|Ropivacaine with Midazolam|"The analgesic effect of extradurally administered midazolam is through γ-amino butyric acid (GABA)/benzodiazepine system of spinal cord.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group)."
61988262|NCT03809442|EXPERIMENTAL|Ropivacaine with Dexamethasone|"The glucocorticoid dexamethasone appears to be effective in a small number of preclinical and clinical studies and found that dexamethasone prolongs analgesia from interscalene blocks using ropivacaine or bupivacaine, with the effect being stronger with ropivacaine.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group)."
61988263|NCT03809442|EXPERIMENTAL|Ropivacaine with Dexmedetomidine|"Dexmedetomidine is a new highly selective alpha2 (a2) agonist with known sedative, antihypertensive, anxiolytic, and analgesic properties.~In one study, it was found that wound infiltration with combined ropivacaine and dexmedetomidine found to be significantly superior for postoperative analgesia compared with either combined ropivacaine and tramadol or ropivacaine alone for lumbar discectomies.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kgdexmedetomidine (8mL per incision) (Dexmedetomidine group)."
61988264|NCT03809442|PLACEBO_COMPARATOR|Ropivacaine|"Ropivacaine is a propyl analog of bupivacaine with longer duration of action with much safer cardiotoxicity profile than bupivacaine. Ropivacaine has the same analgesic effects as bupivacaine and levobupivacaine, but it is associated with a low incidence of motor block. Thus, ropivacaine appears to be an important component for local anesthesia and postoperative analgesia.~Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg."
61988265|NCT00814086|EXPERIMENTAL|Treatment (paclitaxel, cisplatin)|Patients receive paclitaxel IV over 3 hours and cisplatin intraperitoneally (IP) on day 1 and paclitaxel IP on day 8. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
61988266|NCT02436759|EXPERIMENTAL|RVL-1201|RVL-1201 Ophthalmic Solution 0.1% 1 drop per eye QD for 6 weeks
62763391|NCT03242018|EXPERIMENTAL|Sotagliflozin 200 mg|Following a 2-week run-in phase, participants received two tablets, one sotagliflozin 200 mg tablet and one placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily for up to 56 weeks.
62763392|NCT03242018|EXPERIMENTAL|Sotagliflozin 400 mg|Following a 2-week run-in phase, participants received sotagliflozin 400 mg, administered as 2 sotagliflozin 200 mg tablets, orally once daily for up to 56 weeks.
62763393|NCT05341999|EXPERIMENTAL|Final irrigation with cold saline (cryotherapy).|20ml of 2.5°C cold saline for 5 min
62763394|NCT05341999|EXPERIMENTAL|Ibuprofen post-operative medication.|a single dose of Ibuprofen 400 mg immediately after completion of root canal treatment
62763395|NCT05341999|ACTIVE_COMPARATOR|Final irrigation with normal saline, and no post-operative medication|final irrigation will be done using normal saline at room temperature.
62763396|NCT00882908|EXPERIMENTAL|TMC435 75 mg 12 Wks + PR 24/48|Participants will receive TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
62763397|NCT00882908|EXPERIMENTAL|TMC435 75 mg 24 Wks + PR 24/48|Participants will receive TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
62763398|NCT00882908|EXPERIMENTAL|TMC435 150 mg 12 Wks + PR 24/48|Participants will receive TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
62763399|NCT00882908|EXPERIMENTAL|TMC435 150 mg 24 Wks + PR 24/48|Participants will receive TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
62763400|NCT00882908|PLACEBO_COMPARATOR|Placebo 24 Wks + PR48|Participants will receive Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.
62763401|NCT01987219|ACTIVE_COMPARATOR|Albuterol-sulphate|Albuterol-sulphate (Proventil ®) Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
62763402|NCT01987219|ACTIVE_COMPARATOR|Ipratropium-bromide (Atrovent ®)|IpratroAnti-cholinergic(Atrovent ®) 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.pium-bromide
62763403|NCT01987219|PLACEBO_COMPARATOR|Placebo|Placebo Saline solution 3 cc NA
62763404|NCT02182609|EXPERIMENTAL|99mTc-rhAnnexin V-128|
61988267|NCT02436759|PLACEBO_COMPARATOR|RVL-1201 Vehicle Placebo|RVL-1201 Ophthalmic Solution vehicle (placebo) 1 drop per eye QD for 6 weeks
61988268|NCT01477060|OTHER|ARM A - Lapatinib|hormonal therapy + lapatinib (1250mg/die) until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
61988269|NCT01477060|OTHER|ARM B - Metformin|Hormonal therapy + metformin until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
62382889|NCT03258762|EXPERIMENTAL|Healthy Japanese male subjects|Healthy Japanese male subjects will receive a single oral dose of Pyrimethamine 50 mg in the fasted state co-administered with calcium folinate 15 mg on Day 1. Oral calcium folinate will be administered once daily until Day 8. Blood samples for PK analysis will be collected prior to administering first dose of Pyrimethamine and over 22 days post dose. Each subject will participate in the study for a duration of approximately 2 months from screening to follow-up.
62382890|NCT03258762|EXPERIMENTAL|Healthy Caucasian male subjects|Healthy Caucasian male subjects will receive a single oral dose of Pyrimethamine 50 mg in the fasted state co-administered with calcium folinate 15 mg on Day 1. Oral calcium folinate will be administered once daily until Day 8. Blood samples for PK analysis will be collected prior to administering first dose of Pyrimethamine and over 22 days post dose. Each subject will participate in the study for a duration of approximately 2 months from screening to follow-up.
62763405|NCT05186441|ACTIVE_COMPARATOR|DMPFC iTBS|DMPFC iTBS group has 30 patients. Each receive 20 times DMPFC iTBS therapy. During the iTBS, a 5-min train treatment(110%RMT, 2s on and 8s off, 900 pulses in total）was applied to the left DMPFC.
62763406|NCT05186441|ACTIVE_COMPARATOR|DLPFC iTBS|DLPFC iTBS group has 30 patients. Each receive 20 times DMPFC iTBS therapy. During the iTBS, a 5-min train treatment(110%RMT, 2s on and 8s off, 900 pulses in total）was applied to the left DMPFC.
62763407|NCT05186441|SHAM_COMPARATOR|placebo|The placebo research received similar pseudo-stimulation treatment, which was the same as the treatment site and method of true stimulation, but during stimulation, the coil used B65 8 zigzag coil, which was flipped 180 degrees, and only produced stimulation sound during treatment, but did not produce irritating magnetic field. It can produce a placebo effect.
62763408|NCT03285958|EXPERIMENTAL|STEPS Intervention Group|Participants will receive a wearable physical activity monitor and will be asked to report their daily step count in 3 different ways (2 weeks each of SMS text messages, Interactive Voice Response calls (IVR), automatic upload) during the 6-week study period.
62763409|NCT03285958|NO_INTERVENTION|STEPS Control Group|Participants in this group will not receive a wearable physical activity monitor and will not be asked to report their step count.
62763410|NCT03403985|EXPERIMENTAL|calcium hydroxide direct pulp capping|calcium hydroxide (Ca(OH)2 direct pulp capping will be performed in this group
62763411|NCT03403985|EXPERIMENTAL|MTA direct pulp capping|Mineral Trioxide Aggregate (MTA) direct pulp capping will be performed in this group
62763412|NCT06263049|ACTIVE_COMPARATOR|group A|(TURP group underwent traditional TURP)
62763413|NCT06263049|ACTIVE_COMPARATOR|group B|TURP with preserved urethral mucosa at the prostatic apex
62763414|NCT05418153||Synergy IOL|Patients implanted with the Synergy IOL in both eyes.
62763415|NCT01344629|EXPERIMENTAL|Telmisartan80mg/Amlodipin5mg FDC|single-dose, four-period replicated crossover design
62763416|NCT01344629|EXPERIMENTAL|Telmisartan80mgtab + Amlodipin5mg tab|single-dose, four-period replicated crossover design
62763417|NCT01943019|EXPERIMENTAL|Linagliptin|Linagliptin daily
62763418|NCT03696082|EXPERIMENTAL|Aerobic Activity|Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
62763419|NCT03696082|EXPERIMENTAL|Resistance Training|Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
62763420|NCT03696082|EXPERIMENTAL|Yoga|Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
62763421|NCT03696082|EXPERIMENTAL|Health Education|This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
62382891|NCT04214470||Irritable Bowel Syndrome Patients|Patients with IBS.
62763422|NCT03287570|EXPERIMENTAL|Cettum (Electric moxibustion)|The patients in this group receive Cettum (Electric moxibustion) treatment prescribed by a certified Korean Medicine Doctor with more than 6 years of Oriental Medicine College education.
62763423|NCT03287570|ACTIVE_COMPARATOR|Traditional indirect moxibustion|The patients in this group receive traditional indirect moxibustion treatment using the same points, applied by a certified Korean Medicine Doctor with more than 6 years of Oriental Medicine College education.
62763424|NCT03287570|OTHER|Usual care|The patients in this group maintain the usual treatment and self-care.
62763425|NCT04927104|EXPERIMENTAL|PEEK Knee Prosthesis|In this study, 10 subjects will be underwent total knee arthroplasty with PEEK knee prosthesis.
62763426|NCT05794711||Clinical T1N0M0 lung adenocarcinoma patients eligible for surgery.|
62763427|NCT01228292|ACTIVE_COMPARATOR|Standard Anticoagulation|Hemodialysis is performed using standard anticoagulation using unfractionated heparin if no contra-indications for the use of heparin exist. If contra-indications for heparin exist a heparin coated hemofilter (Evodial) will be used. The use of unfractionated heparin or no heparin (with coated hemofilter) is a decision to be taken before every hemodialysis.
61988270|NCT01477060|OTHER|ARM C - Lapatinib + Metformin|Hormonal therapy + lapatinib + metformin until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
62763428|NCT01228292|EXPERIMENTAL|Citrasate|Hemodialysis is performed with Citrasate
61988271|NCT00206947|ACTIVE_COMPARATOR|1|
61988272|NCT00206947|PLACEBO_COMPARATOR|2|
62382892|NCT04787276|EXPERIMENTAL|E.coli Nissle 1917|probiotic, oral, for the first 4 days, 1 capsule, and then 2 capsules per day for 1 month treatment
62382893|NCT04787276|ACTIVE_COMPARATOR|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day, 1 months of treatment
62763429|NCT00914550||Procalcitonin level, caregiver informed|Procalcitonin level for patients with lung infiltrates:caregivers know/ do not know results
62763430|NCT05162742|ACTIVE_COMPARATOR|Colchicine|75 patients will receive colchicine tablets
62763431|NCT05162742|PLACEBO_COMPARATOR|Placebo|75 patients will receive placebo tablets
62763432|NCT00603070||1|All physicians and nurse practitioners at 1 ambulatory care clinics
62763433|NCT00603070||2|All physicians and nurse practitioners at 1 ambulatory care clinics
62763434|NCT05132517||Stroke Patients|Ischemic-/hemorragic stroke patients, who admitted on the stroke unit.
62763435|NCT00359567|EXPERIMENTAL|1|palonosetron
62763436|NCT00359567|ACTIVE_COMPARATOR|2|granisetron hydrochloride
62763437|NCT01420627|EXPERIMENTAL|Adagen/EZN-2279|Patients started on Adagen and crossed over to experimental EZN-2279 treatment after at least a 3 week Lead-in Period on Adagen
62763438|NCT03050515|EXPERIMENTAL|Fecal Transplant|"Enrolled and screened patients will receive a donor directed fecal transplant via retention enema. This procedure will take place at the University of California Irvine Women's Health Center on the day of the participant's choosing.~The day prior to the procedure, the participant will undergo a bowel prep and stop all prophylactic antibiotics. On the day of procedure, the patient will present to the clinic and undergo a simple, retention enema. This procedure takes about 30-40 minutes to complete and does not require any anesthesia or sedation."
62763439|NCT03036462|EXPERIMENTAL|Verum group (FCM)|I.v. iron administration in the form of FCM will be carried out according to SmPC. I.v. iron bolus administration (1000 mg) will be followed by an optional administration of 500-1000 mg within the first 4 weeks, (up to a total of 2000 mg which is in-label), according to the approved dosing rules, followed by administration of 500 mg FCM at every 4 months, except when haemoglobin is \> 16.0 g/dL or ferritin is \> 800 µg/L .In the verum group, all patients will receive a saline administration, when no iron is indicated at the time of the visit and according to the values listed above.
62763440|NCT03036462|PLACEBO_COMPARATOR|Placebo group (NaCL)|Administration of i.v. NaCl at a volume according to the dosing rules for FCM, i.e. as described for the verum group.
62763441|NCT02111291|EXPERIMENTAL|SANTYL®|
62763442|NCT02111291|SHAM_COMPARATOR|Supportive Care|
62763443|NCT01113034|ACTIVE_COMPARATOR|DAS181 Dry Powder 10 mg qd x 3 days|
62382894|NCT04787276|ACTIVE_COMPARATOR|Rifaximin|rifaximin, oral, 500 mg BID, 1 months of treatment
62763444|NCT01113034|PLACEBO_COMPARATOR|Lactose Placebo|
62763445|NCT00494559|EXPERIMENTAL|Actos|Actos group: pioglitazone 15mg or 30mg
62763446|NCT00494559|PLACEBO_COMPARATOR|Placebo|Placebo group: placebo without active medication
62763447|NCT02002572|EXPERIMENTAL|Mimic facial muscle from 3T MRI data|
62382895|NCT04038437|EXPERIMENTAL|CPX-351 and Venetoclax|CPX-351 and Venetoclax will be administered over 28 day cycles
62382896|NCT06214039|ACTIVE_COMPARATOR|One session therapy|One session exposure therapy followed by 4 weeks of internet-delivered self-help with therapist support on demand
62382897|NCT06214039|EXPERIMENTAL|One session therapy - divided into 3|Three session exposure therapy followed by 4 weeks of internet-delivered self-help with therapist support on demand
62763448|NCT05268744|EXPERIMENTAL|Micronutrient|In this open-label trial, all subjects will receive the daily dose of micronutrient, in the form of one lightning stick per day, which contains 2.9 grams of micronutrients per stick. It will be delivered in a powder form taken sublingually.
62763449|NCT05834491|EXPERIMENTAL|Minimal Footwear (Vivobarefoot)|The experimental intervention involves the combination of foot strengthening/stretching and minimal footwear to promote the foot strengthening beyond the exercise program to mitigate weakening from chronic support.
62763450|NCT05834491|ACTIVE_COMPARATOR|Supportive Footwear|The control intervention is considered the standard of care and involves combination of foot stretching and the addition of supportive shoes and foot orthoses.
62763451|NCT05823844|EXPERIMENTAL|Suvorexant administration|"Subjects will receive 20 mg Suvorexant beginning the first in-hospital night (day 0) and continuing for their hospital stay. If the dose is not well tolerated (e.g., daytime sleepiness), then the dose may be decreased to 10 mg of Suvorexant. For blinding purposes, each arm will receive two tablets (two 10 mg tablets or one 10 mg tablet and a placebo). Suvorexant will be administered beginning on the night after surgery and through the hospitalization period (it is estimated that stays will be 1-3 days; subjects will be followed for a maximum of 5 days)."
62763452|NCT05823844|PLACEBO_COMPARATOR|Placebo administration|Subjects will receive a placebo (two tablets) and treatment as usual. The placebo will be administered beginning on the night after surgery and through the hospitalization period (it is estimated that stays will be 1-3 days; subjects will be followed for a maximum of 5 days).
62763453|NCT03077698|EXPERIMENTAL|Sodium Cridanimod & progestin therapy|Sodium Cridanimod and progestin therapy (megestrol acetate) combination
62763454|NCT03302455|EXPERIMENTAL|eCBTI|This group will receive a 1-week of eCBTI treatment and will receive 3 months of follow-up.
62763455|NCT03302455|NO_INTERVENTION|Control|This group does not receive any interventions during first 3 months of clinical study. If the participants still have no remission from insomnia after 3 months, will be recommended to enter the standardized insomnia treatment (medication and / or non-drug treatment).
62763456|NCT01270204||Normal Volunteers|Patients older than 55 years of age with no history of voice, swallowing, reflux, or progressive neurologic disease affecting the swallowing mechanism.
62763457|NCT01270204||Patients with Dysphagia|Patients older than 55 years of age with the following condition: Dysphagia (the sensation of swallowing difficulty), globus, gastroesophageal reflux, or any other condition requiring referral for a dynamic swallowing study.
62382898|NCT05421416|EXPERIMENTAL|Loratadine Arm|Loratadine 10mg, administered initially 3 hours before the first dose of G-CSF in the autologous stem cell mobilization protocol, and then daily for a minimum of 8 days.
62382899|NCT05421416|PLACEBO_COMPARATOR|Placebo Arm|Placebo capsule, administered initially 3 hours before the first dose of G-CSF in the autologous stem cell mobilization protocol, and then daily for a minimum of 8 days.
62382900|NCT03620500||Children with Cochlear Implants|Children with sensory neural hearing loss who undergo cochlear implantation will be monitored to see if balance develops normally in this population
62382901|NCT03444246|EXPERIMENTAL|Iodine free diet group|The arm with non iodized salt，the subject in the non iodized salt group used the iodized salt for the first three months, and the iodized salt was changed after three months.
62382902|NCT03444246|ACTIVE_COMPARATOR|Normal iodine diet group|The arm with iodized salt，the subject in the control group were consumed with iodized salt within six months.
62382903|NCT04265859|EXPERIMENTAL|Depressed|Participants in this group will be randomized to receive either the CBT training (n=10) or Mindfulness training (n=10).
62382904|NCT04265859|OTHER|Healthy Control|Participants in this group will be randomized to receive either the CBT training (n=10) or Mindfulness training (n=10).
62382905|NCT05713331|EXPERIMENTAL|CLS-R|Web-based remote training for school mental health providers
62382906|NCT05713331|ACTIVE_COMPARATOR|CLS|In-person training for school mental health providers
62382907|NCT05610670|OTHER|Patients who underwent a kidney/pulmonary transplant before the age of 40|The questionnaire will allow us to complete the information not obtained from the patients' files on the one hand, and to collect their experiences regarding the desire and/or achievement of a pregnancy, but also their gynecological follow-up in the broad sense, on the other hand.
62382908|NCT01729806|EXPERIMENTAL|Arm A (ipilimumab and rituximab)|Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 1, 4, 7, and 10. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
62382909|NCT01729806|EXPERIMENTAL|Arm B (ipilimumab and rituximab)|Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 3, 6, 9, and 12. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
62382910|NCT00979004|EXPERIMENTAL|ICA-105665|
62382911|NCT02706535|EXPERIMENTAL|Part 1 Cohort 1|Subjects will receive a single dose of GSK525762 10 mg on Day 1 followed by 200 mg Itraconazole two times a day (BID) on Day 3. On Day 4 to Day 6 inclusive subjects will receive a single dose of itraconazole 200 mg in the morning. On Day 7 subjects will receive a single dose of GSK525762 5 mg one hour after receiving 200 mg dose of itraconazole. On day 8 and 9 subjects will receive a single dose of 200 mg itraconazole in the morning.
62382912|NCT02706535|EXPERIMENTAL|Part 1 Cohort 2|Subjects will receive a single dose of GSK525762 10 mg on day 1 followed by 200 mg Itraconazole BID on day 3. On day 4 to day 6 inclusive subjects will receive a single dose of itraconazole 200 mg in the morning. On day 7 subjects will receive a single dose of GSK525762 5 mg or GSK525762 10 mg one hour after receiving 200 mg dose of itraconazole. On day 8 and 9 subjects will receive a single dose of 200 mg itraconazole in the morning.
62763458|NCT05769166||School children|school children aged from five to seven years
62763459|NCT05579873||Single plating technique|Choice of implant used for single plating left at descretion of treating surgeon.
62763460|NCT05579873||Double plating technique|Double plating consist of one VariAx 2.0mm plate positioned on the superior aspect of the clavicula and a second VariAx 2.4mm or 2.7 mm on the anterior side. Use of this implant will be according to the device's cleared indications of use.
62763461|NCT05497258|EXPERIMENTAL|Experimental: with Artificial intelligence assistant system|"The physicians were additionally provided with the feature extracted by the system, a list of suspicious diagnoses predicted by IDEAS-AAP, and corresponding diagnostic criteria according to guidelines. After the readers get the examination results, the IDEAS-AAP will renew its diagnosis prediction.~IDEAS-AAP extracted feature from electronic health record, provided a list of suspicious diagnoses, and corresponding diagnostic criteria according to guidelines. After the readers get the examination results, the IDEAS-AAP will renew its diagnosis prediction."
62763462|NCT05497258|NO_INTERVENTION|No Intervention: without Artificial intelligence assistant system|
62763463|NCT02425800||Ancillary-Correlative (human prostate tissue model)|Tissue samples are collected from patients with benign prostatic hyperplasia for decellularization and preparation as human extracellular matrix for growing human prostate CSCs. Tissue samples are also collected from patients with prostate cancer for the analysis of TROP2+ cells by flow cytometry. Cytology Specimen Collection Procedure. Laboratory Biomarker Analysis.
62763464|NCT04956055|EXPERIMENTAL|Experiment group|Experimental group to be applied hand reflexology
61988273|NCT05571605|EXPERIMENTAL|Exercise Training|Participants will exercise 3 times a week on a stationary bicycle. Exercise intensity will begin at low levels (50% of maximal heart rate reserve) and increase as tolerated to a maximum of 80% of maximal heart rate reserve. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes per session.
61988274|NCT05571605|PLACEBO_COMPARATOR|Stretching|Participants will undergo progressive whole body stretching and balance exercises. This type of low intensity exercise is designed not to increase heart rate but rather to improve joint mobility and the ability to perform activities of daily living. This will serve as the control group to the exercise group. The control group will come in for stretching sessions 3 times per week for 20-45 minutes.
61988275|NCT05160688|EXPERIMENTAL|Contingency management|Contingency management (CM) is an incentive-based intervention providing patients with tangible rewards as reinforcement for positive behaviors like abstinence from drug use. Incentives are provided with each urine sample that is drug-free and are increased with each subsequent drug-free urine sample. Participants in the CM condition will receive increasing payments for abstinence: $30 on day 3, $45 on day 5, $60 on day 7, $75 on day 14, $90 on day 21, $105 on day 28, and $120 on day 42. Participants in both conditions also receive increasing payment for visit attendance: $10 on day 1, $15 on day 3, $20 on day 5, $25 on day 7, $30 on day 14, $35 on day 21, $45 on day 28, and $55 on day 42. At the end of the baseline visit, participants in the CM condition will sign a behavioral contract with study staff that clearly outlines expectations as well as the payment schedule.
62763465|NCT04956055|NO_INTERVENTION|Control group|experimental group for which hand reflexology will not be applied
62763466|NCT05928832|EXPERIMENTAL|Intervention group|Patients in the intervention group will receive an information letter on their discharge presenting the follow-up from which they will benefit: call from the case-manager and access to the internet platform.
62763467|NCT05928832|NO_INTERVENTION|Control group|Patients randomized to the control group will receive the usual practices
62763468|NCT03985007|EXPERIMENTAL|CDIAG|Relapsed or refractroy acute myeloid leukemia patients reveive chidamide, decitabine combined with priming IAG regimen treatment.
62763469|NCT01247363|EXPERIMENTAL|LY2608204|Oral capsules of LY2608204 given once daily at a starting dose of 160 milligram (mg), which may be titrated in 3 dose escalations to 240 mg, 320 mg and 400 mg, with a 7-day treatment duration at each dose level for up to 28 days total treatment.
62382913|NCT02706535|EXPERIMENTAL|Part 2|Subjects will receive a single dose of GSK525762 10 mg on day 1. From day 3 to 17 inclusive, subjects will receive a single dose of 600 mg rifampicin in fasting conditions. On day 18 subjects will receive single dose of GSK525762 either 20 or 30 mg along with 600 mg dose of rifampicin. On day 19 subjects will receive a single dose of rifampicin 600 mg.
62382914|NCT01301209||treatment|patients undergoing treatment
62763470|NCT01605487|OTHER|Rupatadine 20mg - Placebo - Rupatadine 40mg|
62763471|NCT01605487|OTHER|Rupatadine 20mg - Rupatadine 40mg - Placebo|
62763472|NCT01605487|OTHER|Placebo - Rupatadine 20mg - Rupatadine 40mg|
62763473|NCT01605487|OTHER|Rupatadine 40mg - Placebo - Rupatadine 20mg|
62763474|NCT01605487|OTHER|Placebo - Rupatadine 40mg - Rupatadine 20mg|
62763475|NCT01605487|OTHER|Rupatadine 40mg - Rupatadine 20mg - Placebo|
62763476|NCT00654004||Subjects|Subjects are patients with a long-chain fatty acid oxidation disorder including CPT2, VLCAD, TFP or LCHAD deficiency.
62763477|NCT00654004||Controls|Subjects do not have a fatty acid oxidation disorder.
62763478|NCT05069207||Monosymptomatic Enuresis|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
62763479|NCT05069207||Non-monosymptomatic Enuresis|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
62763480|NCT05069207||Daytime Urinary Incontinence|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
62382915|NCT02863406|EXPERIMENTAL|Healthy volunteers|Bronchoalveolar lavage in healthy volunteers
62382916|NCT02863406|EXPERIMENTAL|Patients suffering from sarcoidosis|Bronchoalveolar lavage in patients suffering from sarcoidosis
62382917|NCT03058809|EXPERIMENTAL|Metastatic Breast, Colon and Prostate Cancer|Metastatic breast, colon or prostate cancer patients will have their CTC levels determined on 3 days before treatment with the Viatar Oncopheresis System to establish a baseline value, a pretreatment value, a post treatment value and on 4 additional instances over a period of 7 days post treatment to establish a CTC rebound profile using a validated CTC enumeration system.
62382918|NCT01082042||Standard Care|Individuals who attended the local falls group
62382919|NCT01082042||Intervention group|Individuals who undertook the 12 week exercise (Nintendo WiiFit) intervention
62382920|NCT02811640||Study Participants|Adults with chronic kidney disease who will have a PD catheter inserted at the Ottawa Hospital
62763481|NCT05069207||Control Group Healthy Individuals|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
62763482|NCT02976025|EXPERIMENTAL|Longitudinal Remote Consultation|This is the active treatment arm consisting of 10 cluster randomized health centers receiving both training in collaborative care and longitudinal remote consultation (LRC) support.
62763483|NCT02976025|ACTIVE_COMPARATOR|Collaborative Care|This comparator arm will consist of 10 cluster randomized health centers who receive training in collaborative care.
62763484|NCT03740789||HBeAg positive|HBeAg positive：group A(ALT≤ULN),group B(ALT 1-2ULN),group C(ALT≥2ULN) and treated subgroup (A1,B1,C1) and untreated subgroup (A2,B2,C2).
62763485|NCT03740789||HBeAg negative|HBeAg negative：group A(ALT≤ULN),group B(ALT 1-2ULN),group C(ALT≥2ULN) and treated subgroup (A1,B1,C1) and untreated subgroup (A2,B2,C2).
62763486|NCT01183819|EXPERIMENTAL|Space Fortress and Exercise|Participants engage in aerobic exercise 4 times week and Space Fortress sessions 3 times a week for a total of 12 weeks.
61988276|NCT05160688|NO_INTERVENTION|No intervention|Participants in this condition will be monitored and will not receive any compensation for cannabis abstinence.
61988277|NCT01359254|EXPERIMENTAL|Conditioning Regimen I|Arm I contains fludarabine, melphalan, and antithymocyte globulin (ATG)
61988278|NCT01359254|EXPERIMENTAL|Conditioning Regimen II|Arm II contains fludarabine, busulfan, antithymocyte globulin (ATG), and total body irradiation (TBI).
61988279|NCT04703439|EXPERIMENTAL|Experimental group|This group consisted of 116 participants who received a medication-taking reminder every morning at a random time between 7-8 am on WeChat app. Also, participants received a piece of educational material every five days at a random time between 8 am and 9 am regarding improving medication adherence and preventing coronary heart disease.
61988280|NCT04703439|PLACEBO_COMPARATOR|Control group|This group consisted of 114 participants who only received a piece of educational material every five days at a random time between 8 am and 9 am. The educational materials sent to this group were general medical information, which were not specifically about improving medication adherence or preventing coronary heart disease.
61988281|NCT03637803|EXPERIMENTAL|MRx0518 with pembrolizumab|Subjects will receive IV infusion of pembrolizumab once every 3 weeks until disease progression, unacceptable AEs or withdrawal of consent up to a maximum of 35 cycles (approx. 2 years). Starting on the day of first pembrolizumab dose, subjects will take one capsule of MR0518 twice daily until the end of the treatment period.
61988282|NCT05891678|NO_INTERVENTION|Control group (N)|Central retinal artery Doppler in patient with normal ICP
61988283|NCT05891678|ACTIVE_COMPARATOR|Intervention group (H)|Central retinal artery Doppler in patient with increased ICP
61988284|NCT03744533|EXPERIMENTAL|head-down position treatment|
61988285|NCT03744533|ACTIVE_COMPARATOR|guideline-based treatment|
61988286|NCT00703885|ACTIVE_COMPARATOR|1|"0.25 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan.~One-time, single dose.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
62382921|NCT02638740|ACTIVE_COMPARATOR|SCALING AND ROOT PLANING (SRP)|Scaling and root planning with ultrasonic scalar
62382922|NCT02638740|EXPERIMENTAL|MUSTARD OIL AND SALT MASSAGE WITH SRP|Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
62382923|NCT00722735|EXPERIMENTAL|1|Group I: Finafloxacin tablets + Ciprofloxacin placebo capsule
62382924|NCT00722735|ACTIVE_COMPARATOR|2|Group II: Ciprofloxacin capsule + Finafloxacin placebo tablets
62382925|NCT03590613|EXPERIMENTAL|Sequence 1: Placebo TID then 60 TID then 120 TID then 240 TID|The eligible subjects in this arm will receive placebo TID in TP1, GSK2982772 60 mg TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
62763487|NCT01183819|ACTIVE_COMPARATOR|Control Games and Exercise|Participants engage in aerobic exercise 4 times a week and control game sessions 3 times a week for a total of 12 weeks.
62763488|NCT01183819|ACTIVE_COMPARATOR|Control Games and Stretching|Participants engage in stretching/toning exercises 4 times a week and control game sessions 3 times a week for a total of 12 weeks.
62763489|NCT05092165|ACTIVE_COMPARATOR|Methylene Blue|Methylene blue will be infused during renal replacement therapy
18632337|NCT06553599|EXPERIMENTAL|Arm 2|00mg dose or placebo
62763490|NCT05092165|OTHER|Control|usual care
18632338|NCT06553599|EXPERIMENTAL|Arm 3|00mg dose or placebo
18632339|NCT06553599|EXPERIMENTAL|Arm 4|00mg dose or placebo
18632340|NCT06553599|EXPERIMENTAL|Arm 5|00mg dose or placebo
18632341|NCT06553599|EXPERIMENTAL|Arm 1|00mg dose or placebo
62763491|NCT03423836||High Risk Infants|Motor infants born prior to 35 weeks gestational age, or, infants small (\<10th percentile) for gestational age.
61988287|NCT00703885|ACTIVE_COMPARATOR|2|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~One-time, single dose.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
61988288|NCT00703885|PLACEBO_COMPARATOR|Placebo|"Inactive ingredient in liquid matching appearance and volume of the two active alprazolam dose comparators.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
61988289|NCT00813085|OTHER|Electronic disease management decision support|An electronic Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS).
61988290|NCT00813085|NO_INTERVENTION|2|Usual care by Family Physician
61988291|NCT01678963|EXPERIMENTAL|Squalamine|Squalamine eye drop 0.2%
61988292|NCT01678963|PLACEBO_COMPARATOR|Vehicle Control|Eye drop vehicle control
61988293|NCT04722796|EXPERIMENTAL|TAVR with Supra-annular sizing strategy|"Experimental: Supra-annular sizing strategy (Hangzhou Solution).~Pre-dilation with balloon size (20/23/26mm Z-MED) just below the annular size.~Waist sign with less than mild contrast regurgitation: Venus A plus Valve down size and Target implant depth 0-2mm.~No waist sign and/or contrast regurgitation or unable to finish supra-annular sizing: annular sizing Venus A plus Valve with implant depth 4-6mm."
62763492|NCT03423836||Low Risk Infants|Motor infants born after the completion of the 37th week of gestation and appropriate for gestational age.
62382926|NCT03590613|EXPERIMENTAL|Sequence 2: 60 TID then Placebo TID then 120 TID then 240 TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, placebo TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
62763493|NCT01312649|EXPERIMENTAL|Arm 1|Healthy volunteers
62763494|NCT01312649|EXPERIMENTAL|Arm 2|Schizophrenia with history of delusions of control
62763495|NCT01312649|EXPERIMENTAL|Arm 3|Schizophrenia without history of delusions of control
62763496|NCT01312649|EXPERIMENTAL|Arm 4|Bipolar disorders
62763497|NCT01312649|ACTIVE_COMPARATOR|Arm 5|Matched healthy controls
62763498|NCT04117763|EXPERIMENTAL|Empagliflozin|Empagliflozin 25 mg once daily for 3 months
62763499|NCT06434129||Cases|cases with SNHL
62763500|NCT06434129||Controls|Normal people
62382927|NCT03590613|EXPERIMENTAL|Sequence 3: 60 TID then 120 TID then Placebo TID then 240 TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, placebo TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
62763501|NCT04912895|EXPERIMENTAL|SARS-CoV-2 Positive|Participants who test positive for SARS-CoV-2 with the Polymerase Chain Reaction (PCR) test.
62763502|NCT04912895|ACTIVE_COMPARATOR|Non-COVID-19 Acute Respiratory Illness|Participants who have an acute respiratory illness other than SARS-CoV-2 infection.
62763503|NCT04912895|OTHER|Healthy Controls|Participants without any acute respiratory illness.
62763504|NCT00733135|OTHER|Atherectomy with embolic protection|All subjects were treated with atherectomy (with SilverHawk or TurboHawk device) in conjunction with embolic protection (SpiderFX device).
62763505|NCT03923582|EXPERIMENTAL|Intervention Arm|A four-day comprehensive sexual health curriculum tailored for Africa.
62763506|NCT03923582|NO_INTERVENTION|Waitlist control|Participants in this arm completed a follow-up survey and were scheduled to receive the intervention after the end of the trial.
62763507|NCT01333995|NO_INTERVENTION|Usual Health Message|No intervention mothers will recieve standard maternal and child care education
62763508|NCT01333995|SHAM_COMPARATOR|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
62763509|NCT00755534|EXPERIMENTAL|1|Irinotecan+Erbitux -\> XELOX+Erbitux
62763510|NCT00755534|EXPERIMENTAL|2|XELOX+Erbitux -\>Irinotecan+Erbitux
61988294|NCT04722796|OTHER|TAVR with Annulus based sizing strategy|"Control: Traditional sizing strategy (Annulus based sizing strategy).~Pre-dilation with balloon size (20/23/26mm Z-MED) just below the annular size.~Annular sizing Venus A plus Valve with implant depth 4-6mm."
62763511|NCT02857192|EXPERIMENTAL|Horton|
62763512|NCT02857192|PLACEBO_COMPARATOR|control|
62763513|NCT02961192|NO_INTERVENTION|Control|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts.
62763514|NCT02961192|EXPERIMENTAL|Supportive|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In addition to playing the game, participants will identify a family member or friend to receive updates and support them in their progress.
62763515|NCT02961192|EXPERIMENTAL|Competitive|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In this arm, participants will be placed into competitive groups with one or two other participants to play the game.
62763516|NCT02961192|EXPERIMENTAL|Collaborative|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In this arm, participants will be placed into collaborative groups with one or two other participants to play the game.
62763517|NCT03167489|EXPERIMENTAL|Lifestyle Plus Emotional Regulation|The core intervention will last 5 months. Nutrition content: Mediterranean diet education, social support, self-regulation techniques, and environmental support. Physical activity content: education, guidance in starting a routine, and a walking program with pedometers, weekly physical activity tips and step goals. Emotion regulation content: based on Dialectical Behavior Therapy adapted to binge eating disorders and other ER sources, emphasizing identifying emotions, recognizing the causes of emotions, accepting and tolerating negative emotions, effective self-support and self-compassion, and the ability to manage situations that elicit negative emotions, as well as re-appraisal skills, which are identified as particularly influential on eating behaviors.
62763518|NCT03597607|EXPERIMENTAL|Intensive Smoking Cessation Group|This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have session ranging from 15 mins to 1 hour. Follow-up sessions will occur during quit week(week 1) and at weeks 2, 3, 4, 6, 8, 10, 12 and at 6 months.
62763519|NCT03597607|EXPERIMENTAL|Abbreviated Smoking Cessation Group|This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have brief sessions (15-30 mins) at the end of week 1, week 4, week 12 and at 6 months.
62763520|NCT06002984|EXPERIMENTAL|Using neuromonitoring to find EBSLN|With neuromonitoring of the EBSLN using nerve monitoring system Intervention Device: Neuromonitoring to find EBSLN
62763521|NCT06002984|NO_INTERVENTION|No using neuromonitoring to find EBSLN|Without neuromonitoring of the EBSLN using nerve monitoring system
62763522|NCT01276366|ACTIVE_COMPARATOR|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
62763523|NCT01276366|ACTIVE_COMPARATOR|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
62763524|NCT01276366|ACTIVE_COMPARATOR|Breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
62763525|NCT01254968||examining group|20 healthy subjects (11 men, 9 women, average age 23.94)
62763526|NCT01254968||control group|6 healthy subjects (3 men, 3 women, average age 23.6)
62382928|NCT03590613|EXPERIMENTAL|Sequence 4: 60 TID then 120 TID then 240 TID then Placebo TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, GSK2982772 240 mg TID in TP3 and placebo TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
62763527|NCT02744807||non-Chronic endometritis|patients with intrauterine adhesion only
62763528|NCT02744807||Chronic endometritis|patients with intrauterine adhesion as well as Chronic endometritis
62763529|NCT06339138||Observational|Participants may undergo blood, urine, and tissue sample collection on study. Participants' medical records are also reviewed.
62763530|NCT05547529|ACTIVE_COMPARATOR|Neoadjuvant Chemoradiotherapy|"Carboplatin (AUC 2 mg/mL per min) and Paclitaxel (50 mg/m2 of body-surface area) were administered intravenously for five cycles, starting on days 1, 8, 15, 22, and 29. A total radiation dose of 41,4 Gy was given in 23 fractions of 1,8 Gy, 5 days per week.~After neoadjuvant therapy, patients receive Ivor-Lewis or Mckeown Esophagectomy."
62763531|NCT05547529|EXPERIMENTAL|Neoadjuvant Chemotherapy|"4 cycles of DCF regimen (docetaxel 75 mg/m2 day, CDDP 75 mg/m2 and 5FU at 750 mg/m2/ day for 5 days) every 3 weeks. Patients with dysphagia 3 оr with weight loss more then 10% 6 cycles of modified-DCF regimen will be performed (mDCF, docetaxel 50 mg/m2 day, CDDP 50 mg/m2 day and 5-FU at 2400 mg/m2/day for 2 days) every 3 weeks.~After neoadjuvant therapy, patients receive Ivor-Lewis or Mckeown Esophagectomy."
62763532|NCT04211987|ACTIVE_COMPARATOR|Fast track care protocol|patients treated using fast track care protocol
62763533|NCT04211987|ACTIVE_COMPARATOR|Standard care protocol|patients treated using standard care protocol
62763534|NCT03730766|EXPERIMENTAL|Bismuth Plus triple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
62763535|NCT00468936|NO_INTERVENTION|1|Usual medications (Cellcept)
62763536|NCT00468936|ACTIVE_COMPARATOR|2|Patients taking Myfortic
62763537|NCT02033213|ACTIVE_COMPARATOR|Restrictive group|Patients who received ≤ 8ml/kg/h of intraoperative fluid. A fluid administered during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
62763538|NCT02033213|ACTIVE_COMPARATOR|Liberal group|Patients who received \> 8 ml/kg/h of fluid. A fluid used during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
62763539|NCT03895177|EXPERIMENTAL|low kVp high mAs CT group|doing pancreatic CT with 80 kVp tube current with more than 500 mA tube current for the evaluation of pancreatic cancer resectability
62763540|NCT03002688||Sequential Cataract Surgery with Survey|Subjects eligible for the study will fall into the sequential cataract surgery group and be administered brief surveys.
62763541|NCT03906656|ACTIVE_COMPARATOR|KAFO/SCO|Home use of 3 months with existing knee ankle foot orthosis (KAFO) or existing stance control orthosis (SCO)
62763542|NCT03906656|EXPERIMENTAL|C-Brace|Home use of 3 months with newly fitted C-Brace microprocessor-controlled stance and swing control orthosis.
62763543|NCT06508684||BTK inhibitor treated|investigate the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, including the efficacy and safety, the drug swith between different BTKis，the BTKi based timed limited therapy, etc
62382929|NCT01970124|EXPERIMENTAL|KPS-0373|
62763544|NCT04095689|EXPERIMENTAL|Experimental|docetaxel chemotherapy and pembrolizumab plus IL-12 gene therapy.
62382930|NCT04093401|NO_INTERVENTION|Control|Subjects will be assigned to the control arm if their subject ID is an odd number. Control arm subjects will not receive counseling for individualized risk assessment for developing a second basal cell carcinoma.
62382931|NCT04093401|EXPERIMENTAL|Individualized risk assessment|Subjects will be assigned to the intervention arm (i.e., informed of their individualized risk assessment) if their subject ID is an even number. Subjects in the intervention arm will be informed of their estimated 1-year, 3-year, and 5-year risk of developing a second basal cell carcinoma.
62382932|NCT04541836||healthy control|healthy volunteer with no clinically relevant finding on physical examination at screening visit will receive one baseline 18F-PMPBB3 tau PET scan, and another follow up scan 1.5yr later.
62382933|NCT04541836||PSP|"Patients fulfill the criteria of NINDS-SPSP clinical criteria for the diagnosis of PSP as possible or probably PSP will receive one baseline 18F-PMPBB3 tau PET scan, and another follow up scan 1.5yr later."
62382934|NCT01943266|EXPERIMENTAL|protein intake|protein intake randomly fed from deficient to excess
62382935|NCT01327586|EXPERIMENTAL|ATM|Advisor-Teller Money Manager
62382936|NCT01327586|ACTIVE_COMPARATOR|Individual Drug Counseling|
62382937|NCT06095999|EXPERIMENTAL|'Perfect Fit' virtual coaching intervention|Due to the single-arm design, all participants will receive the Perfect Fit intervention, a personalized eHealth intervention that supports them to stop smoking and increase their PA using a virtual coach (i.e., chatbot).
62382938|NCT04659447|EXPERIMENTAL|Platelet-Rich Plasma|Four semitendinosus tendons and gracilis tendons are prepared. 4 ml platelet-rich plasma is completely absorbed by a gelatin sponge and fixed in the center of the four tendons. 4-0 absorbable line is used for fixation.Then we use conventional surgical techniques to reconstruct the ACL.
62382939|NCT04659447|NO_INTERVENTION|control group|We performed conventional surgical techniques to reconstruction without using platelet-rich plasma.
62382940|NCT03998345|EXPERIMENTAL|609A group|Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation Level cohort 1. Dose 1 mg/kg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 2. Dose 3 mg/kg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 3. Dose 200mg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 4. Dose 10 mg/kg, Q3W, IV. Subjects 3-6. If 10mg/kg cannot be tolerated, add a dose level of 400mg to assess the tolerance
62382941|NCT05490849|EXPERIMENTAL|68Ga-HX01 PET scanning|Determine if 68Ga-HX01 PET is safe and effective method for imaging of malignant tumors
62382942|NCT05386641||Experimental Group|Breast cancer survivors with shoulder joint motion restriction
62382943|NCT05386641||Control group|Breast cancer survivors without shoulder joint motion restriction
62382944|NCT00712764|ACTIVE_COMPARATOR|1|
62382945|NCT00712764|PLACEBO_COMPARATOR|2|
62382946|NCT02306525||Ptt. with Femoracetabular Impingement|Enrollment anticipated: 60 Arthroscopic surgery of the hip joint
62382947|NCT02306525||Healthy volunteers|Enrollment anticipated: 30
62382948|NCT00657748|EXPERIMENTAL|1|
62382949|NCT03974711||All study subjects|"Note: No interventions are administered under this evaluation.~This is a real-world population. The determination to undergo a lateral lumbar interbody fusion procedure is made outside of this evaluation and is a standard of care, on-label procedure."
62382950|NCT05305742|EXPERIMENTAL|Protaper Ultimate|
62382951|NCT05305742|ACTIVE_COMPARATOR|Protaper Gold|
62382952|NCT01835236|ACTIVE_COMPARATOR|Trastuzumab, Pertuzumab, T-DM1|First line therapy: Trastuzumab, Pertuzumab Second line therapy: T-DM1
62382953|NCT01835236|ACTIVE_COMPARATOR|Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine plus T-DM1|First line therapy: Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine Second line therapy: T-DM1
62382954|NCT06432361|EXPERIMENTAL|Resource Allocation Intervention|"Participants will complete a 3 week monitoring period of daily surveys assessing time spent in various domains during the time, alcohol use, personal goals, and money spent on alcohol and substance-free activities. Each daily survey should take no longer than 5 minutes to complete.~Those in the intervention condition will receive weekly personalized information summarizing the previous week's resource allocation (e.g., personalized information on how they spent their time and money) in relation to their personal goals, interests, and alcohol use. They will also see a summary of how they spent their time and money in relation to their set goals for the week. The information in the intervention feedback will be obtained from participant's responses to the daily surveys on how they spent their time and money each day. Reviewing the intervention feedback should take no longer than 10 minutes."
62382955|NCT06432361|ACTIVE_COMPARATOR|Assessment only control|Participants will complete a 3 week monitoring period of daily surveys assessing time spent in various domains during the time, alcohol use, personal goals, and money spent on alcohol and substance-free activities. Each daily survey should take no longer than 5 minutes to complete.
62382956|NCT05948722|EXPERIMENTAL|Motivational Interview Group (MIG)|Participants assigned to this arm will complete three to five MI sessions
62382957|NCT05948722|ACTIVE_COMPARATOR|Conventional treatment group (CTG)|Participants assigned to this arm will receive the conventional treatment
62382958|NCT00856115||African American Female|
62382959|NCT00856115||African American Male|
62382960|NCT00856115||Caucasian Female|
62382961|NCT00856115||Caucasian Male|
62382962|NCT04808167|EXPERIMENTAL|Therapeutic Group|Therapeutic group receives remote ischemic conditioning.
62382963|NCT04808167|NO_INTERVENTION|Control Group|Control group does not receive remote ischemic conditioning.
62382964|NCT02939196||Group(A)|2.7 mm rigid hysteroscopy.
62382965|NCT02939196||Group(B)|2.9 mm rigid hysteroscopy.
62382966|NCT02136264|ACTIVE_COMPARATOR|PCFA interventional dietary counselling|personalized categorical food avoidance dietary counselling
62382967|NCT02136264|SHAM_COMPARATOR|conventional DASH diet counselling|"DASH = conventional dietary approach to stop hypertension"
62382968|NCT03928249|ACTIVE_COMPARATOR|Grupo A|Group A (n = 20) will receive 200 mg / d of eriocitrin for 12 weeks, washout for 2 weeks and then receive 200 mg / d of placebo for 12 weeks
62382969|NCT03928249|PLACEBO_COMPARATOR|GRUPO B|group B (n = 20) will receive 200 mg / d placebo for 12 weeks with washout for 2 weeks and then receive 200 mg / d placebo for 12 weeks
62382970|NCT03049852|EXPERIMENTAL|CBT-001 Ophthalmic Solution Single dose|One drop in the study administered one time only for one day
62382971|NCT03049852|PLACEBO_COMPARATOR|Vehicle|One drop in the study administered three times daily (TID) for 4 weeks
62382972|NCT03049852|EXPERIMENTAL|CBT-001 Ophthalmic Solution Multidose|One drop in the study administered three times daily (TID) for 4 weeks
62382973|NCT05237609|EXPERIMENTAL|rehabilitation with muscle strengthening + Oral Nutritional Supplements|Participants will receive weekly physical therapy sessions for 20 weeks, during their usual follow-up at the day hospital. In addition to the standard treatment, muscle strengthening exercises using elastic bands of varying resistance will be performed. These sessions can be completed by a muscle strengthening session at home during the week, given by a private physiotherapist according to the indication given by a doctor taking care of the patient, during and outside the periods of follow-up at the day hospital. In addition to muscle strengthening, participants will receive a systematic protein intake via Oral Nutritional Supplements (ONS) to improve muscle strength. Compliance with these oral nutritional supplements will be monitored by means of a booklet filled in by the patient or his entourage.
62382974|NCT05237609|ACTIVE_COMPARATOR|standard rehabilitation +/- Oral Nutritional Supplements|"The participants in the control group will receive the usual care at the day hospital, i.e. a rehabilitation program focused on the prevention of falls. The prescription of ONS will be made on a case-by-case basis by the day hospital's physician. If participants require follow-up by a physiotherapist at home, sessions will be prescribed.~After the treatment, participants in the experimental group will be advised to continue the muscle strengthening sessions independently at least once a week. All participants, regardless of their group, who require follow-up by a physiotherapist will benefit from it."
62382975|NCT05473442|EXPERIMENTAL|EQU-001 60 mg|EQU-001 60 mg (3 x 20 mg pills)
62382976|NCT05473442|EXPERIMENTAL|EQU-001 20 mg|EQU-001 20 mg (1 x 20 mg pill + 2 x matching placebo pills)
62382977|NCT05473442|PLACEBO_COMPARATOR|EQU-001 0 mg|EQU-001 0 mg (3 x matching placebo pills)
62382978|NCT04581291|EXPERIMENTAL|Intervention group|
62382979|NCT04581291|EXPERIMENTAL|Control group|
62382980|NCT04334902||Abnormal|The person who visits parkinsonism symptoms and has been diagnosed with neurodegenerative parkinsonism
62382981|NCT04334902||Normal|The person who visits parkinsonism symptoms but is not or is normal for neurodegenerative parkinsonism
62382982|NCT02672982|EXPERIMENTAL|new combined NUTPSY treatment|2-month combined nutrition and psychosocial intervention
62382983|NCT02672982|ACTIVE_COMPARATOR|standard NUT treatment|2-month of standard nutritional treatment only
62382984|NCT00018694|OTHER|Arm 1|
61988295|NCT01650662|EXPERIMENTAL|Cyclosporine A|"The investigational active treatment is CsA, an immunosuppressant indicated for the prevention of acute rejection after organ transplant, including cardiac transplantation.~The preparation used in the trial will be Sandimmun IV, containing CsA 50 mg/ml, Cremophor® EL and 94% ethyl alcohol in a 5 ml vial.~Patients will received Cyclosporine A on the top of recommended standard care for acute myocardial infarction."
61988296|NCT01650662|EXPERIMENTAL|Control group|The control group received on the top of recommended standard care for acute myocardial infarction.
61988297|NCT04339699|ACTIVE_COMPARATOR|NobleStitch™EL|Participants treated with the NobleStitch™EL device
61988298|NCT04339699|ACTIVE_COMPARATOR|Amplatzer PFO Occluder|Participants treated with the Amplatzer PFO Occluder device
61988299|NCT02657707|EXPERIMENTAL|Single-arm, open label|To evaluate the safety and effectiveness of MicroVention, Inc. Roadsaver™ Carotid Stent System used in conjunction with the Nanoparasol® embolic protection system for the treatment of carotid artery stenosis in patients with elevated risk for adverse events following carotid endarterectomy.
61988300|NCT00969865||Individualized Managment Group|Participants receiving, in addition to standard of care, blood tests for markers of heart disease, DNA and RNA analysis, and coronary artery calcium scan.
61988301|NCT00969865||Standard Management Group|Participants who receive standard of care.
61988302|NCT05815316|EXPERIMENTAL|18F-PSMA-1007|All patients undergo the same experimental procedure
62382985|NCT04016727|EXPERIMENTAL|PRP group|patients in which 60 units of prp was injected
62382986|NCT04016727|NO_INTERVENTION|Control group|patients not given any intervention
62382987|NCT04096469|EXPERIMENTAL|Motivational Interviewing|The intervention group received a guidance regarding their diet and physical activity using the motivational interviewing strategy to improve adherence to healthy behaviors. Participants received a guide with a motivational interviewing approach, which served as the basis for the interview process. The objectives in the intervention group were to consume four vegetables and two fruits a day, seven days a week, increase fiber consumption to more than 30 g daily, reduce fat consumption to no more 20% of the total energy consumed, decrease the consumption of sugary drinks and increase protein intake. Another goal was to increase the number of steps to 4,000 additional steps to those who have already walked.
62382988|NCT04096469|ACTIVE_COMPARATOR|Traditional Education|The comparison group received a guide on medical care and nutrition with a traditional educational approach. The indication was to read and learn about the health-related topics included in the booklet that was given to them. These participants were visited in the same way as the intervention group to answer questions and monitor participation throughout the intervention.
61988303|NCT06514963|EXPERIMENTAL|single ascending dose (SAD) cohorts|Subjects will be assigned to one of 5 planned dose cohorts and receive single dose of HRS-9813 or placebo
61988304|NCT06514963|EXPERIMENTAL|multiple ascending dose (MAD) cohorts|Subjects will be assigned to one of 3-4 planned dose cohorts and receive multiple doses of HRS-9813 or placebo
61988305|NCT04246606||ER+/HER2- infiltrating early breast cancer|Patients with ER+/HER2- infiltrating early breast cancer for which EndoPredict molecular signature was performed.
62382989|NCT03313752|PLACEBO_COMPARATOR|A - placebo|Green, plain, diamond shaped, film coated tablet (orally), not containing active ingredient; once daily, for 4 weeks
62382990|NCT03313752|EXPERIMENTAL|B - experimental drug|Dapagliflozin tablet available at dose of 10 mg, once daily, for 4 weeks
62382991|NCT01113411|ACTIVE_COMPARATOR|Intensive Rehabilitation|
61988306|NCT01132482|EXPERIMENTAL|Sildenafil|Subjects will receive escalating doses of sildenafil
62382992|NCT01113411|ACTIVE_COMPARATOR|Standard Rehabilitation|
62382993|NCT05540015|ACTIVE_COMPARATOR|Group with impacted third molar, extracted by cutting and rotary tools|The study group will include 28 patients with indications (impacted third molars that exerts pressure on the adjacent tooth and cause inflammation process in the surrounding tissue; absence of antagonist; pericorinitis; periodontitis; periodontal pockets) for the impacted third molar extraction. Patients will be comparable by gender and age, the patients age will be between 18 and 70 years. Patients should be with therapeutic and surgical oral hygiene and without co-morbidities.
62763545|NCT01632241|PLACEBO_COMPARATOR|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kilogram (kg) IV every 28 days for an additional 6 months.
62763546|NCT01632241|EXPERIMENTAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
62382994|NCT05540015|ACTIVE_COMPARATOR|Group with impacted third molar, extracted by erbium laser 2.94 nm|The study group will include 28 patients with indications (impacted third molars that exerts pressure on the adjacent tooth and cause inflammation process in the surrounding tissue; absence of antagonist; pericorinitis; periodontitis; periodontal pockets) for the impacted third molar extraction.Patients will be comparable by gender and age, the patients age will be between 18 and 70 years. Patients should be with therapeutic and surgical oral hygiene and without co-morbidities.
62763547|NCT05832112|EXPERIMENTAL|Out of the Cage Robotic Lobectomy|Consented patients will undergo lobectomy by OTC RATS following the exact standard steps usually done by VATS/RATS, except for the incisions, that will consist in 1 to 4 subcostal ports, based on the patient and case characteristics.
61988307|NCT01132482|PLACEBO_COMPARATOR|Placebo|During the placebo arm, subjects receiving placebo will have sham dose escalation to maintain blinding.
61988308|NCT06007599|ACTIVE_COMPARATOR|Group A: suture with skin adhesive|After surgery the closure technique utilized by the surgeons will be subcuticular running 3-0 monocryl sutures without skin adhesive
62763548|NCT02525991|EXPERIMENTAL|Staccato® Delivery System Loxapine|Staccato® Delivery System Loxapine, 9.1 mg one dose
61988309|NCT06007599|ACTIVE_COMPARATOR|Group B: suture without skin adhesive|After surgery the closure technique utilized by the surgeons will be subcuticular running 3-0 monocryl sutures with skin adhesive.
61988310|NCT03758196|EXPERIMENTAL|Renal sympathetic denervation from the adventitia|Renal sympathetic denervation from the adventitia of renal artery and optimized medication regimen
62382995|NCT02746991|SHAM_COMPARATOR|Sham Injection|Sham Injection
62382996|NCT02746991|EXPERIMENTAL|FAI Insert|FAI Insert (0.18 mg fluocinolone acetonide)
62763549|NCT01386242|EXPERIMENTAL|The first group|Recombinant anti-tumor and anti-virus protein for injection, twice per week
62763550|NCT01386242|EXPERIMENTAL|The second group|Recombinant anti-tumor and anti-virus protein for injection, three times per week
62382997|NCT00692991||1|People undergoing percutaneous coronary interventions.
62763551|NCT01386242|PLACEBO_COMPARATOR|Placebo group|Saline Injection, three times per week
62763552|NCT01386242|EXPERIMENTAL|The third group|High dose of recombinant anti-tumor and anti-virus protein for injection, three times per week
61988311|NCT03758196|NO_INTERVENTION|optimized medication regimen|optimized medication regimen
61988312|NCT03975907|EXPERIMENTAL|CAR-BCMA T Cells|Phase I: The subjects are enrolled into 2 dose level cohorts in sequence. Phase II: Single arm
62763553|NCT05961176||Infants and Children Admitted to the CCCU at SickKids|Inclusion Criteria: Patients from 1 month of age to 12 years of age who are admitted to SickKids CCCU with expected stays in CCCU longer than 12 hours including those for medical management and post-surgical patients.
62763554|NCT06146868||Staff|A cross-sectional survey will be conducted.
62763555|NCT06146868||User|A cross-sectional survey will be conducted.
62763556|NCT06146868||Caregiver|A cross-sectional survey will be conducted.
62763557|NCT06146868||Supplier|A cross-sectional survey will be conducted.
61988313|NCT02009631|EXPERIMENTAL|Sequence Group A|200 mg Veliparib
61988314|NCT02009631|EXPERIMENTAL|Sequence Group B|400 mg Veliparib
61988315|NCT02009631|PLACEBO_COMPARATOR|Sequence Group C|Placebo
62763558|NCT02749942|ACTIVE_COMPARATOR|AutoRIC: Remote Ischemic Conditioning|Daily cuff treatment of arm with 4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG of pressure) on top of standard care.
62763559|NCT02749942|SHAM_COMPARATOR|AutoRIC: Sham device treatment|Daily sham device treatment of arm, 4 cycles of 5 minute (0 mmHG of pressure) on top of standard care. No ischemia induced.
61988316|NCT01668706||Methadone maintenance treatment (MMT)|
61988317|NCT01668706||Buprenorphine-Naloxone treatment (BNT)|
62382998|NCT01969604|EXPERIMENTAL|Motivational lifestyle counselling|This arm will include 1) Three individual motivational counselling sessions including handouts of four key messages regarding reduction of daily sitting time in combination with 2) Individual Short Text Message (SMS) reminders.
62763560|NCT02084238|EXPERIMENTAL|Interleukin-2|Interleukin-2 to treat activated SLE.
62763561|NCT00866671||Nelarabine|nelarabine 650mg/m2 IV daily for 5 days. repeat every 21 days.
62763562|NCT05607329|EXPERIMENTAL|Secondary cytoreduction followed by chemotherapy|
62763563|NCT05607329|ACTIVE_COMPARATOR|chemotherapy alone|
62763564|NCT02682615||requirement of norepinephrine|requirement of norepinephrine \<0,1 µg/kgKG/min versus ≥0,1 µg/kgKG/min
62763565|NCT04427735||before COVID-19|Patients with myocardial infarction from January 24, 2019 to June 24, 2019
62382999|NCT01969604|NO_INTERVENTION|Control Group|A control group will be encouraged to maintain their usual lifestyle during the 16-week intervention period.
62383000|NCT06091306||Participants in a multifamily therapy group for adolescents, their parents and siblings|"The study is therefore being proposed to all the families who have taken part in the multifamily therapy for anorexia nervosa, i.e. the adolescents being followed, their parents and siblings.~The investigators propose to use a qualitative methodology aimed at collecting the experiences of patients suffering from anorexia nervosa, their parents and their siblings, using alternately, depending on the group, data collection by focus group or by individual semi-structured interview according to a semi-structured interview guide specifically designed by the research team. The data was collected 4 to 6 months after the tenth and final session of the multi-family group."
62383001|NCT06077123|EXPERIMENTAL|Telemonitoring Platform|Patients allocated to the active intervention group will receive a smartphone application called Contigo. This tool aims to detect signs and symptoms of oncology drug toxicity and delivering educational content that enables the patient to have tools to address common clinical situations associated with the diagnosis and treatment of their disease.
62763566|NCT04427735||after COVID-19|Patients with myocardial infarction from January 24, 2020 to June 24, 2020
62763567|NCT05336825|EXPERIMENTAL|CO2 laser|Mona Lisa CO2 laser will be applied externally to the vulvar vestibule in three sessions over a three month period.
62763568|NCT05336825|ACTIVE_COMPARATOR|Lidocaine|5% topical lidocaine will be applied nightly via a cotton square in participants
61988318|NCT01668706||Medication-free ex-addicts(MF)|
61988319|NCT01668706||Normal control (NC)|
62763569|NCT00973102|EXPERIMENTAL|Premarin IV|Patients who were randomized to receive a single dose of 0.5 mg/kg Premarin® IV.
62763570|NCT00973102|PLACEBO_COMPARATOR|Placebo|Patients who were randomized to receive a single dose of 0.5 mg/kg placebo. Due of the faint yellow color of the reconstituted Premarin®, the placebo dose will be prepared with 0.14 ml of Vial 1 of Infuvite Adult Multivitamin and 14 ml of sterile water to generate a similar color and volume. This aliquot will be used only for those study patients who are randomized to the placebo arm. The placebo volume will be approximately equal to the volume which the patient would have received had the patient been randomized to the Premarin arm Considering the small amount of IV multivitamin needed for fluid tinting, it is not expected that the IV multivitamin will have any effect on patients with hemorrhagic shock.
62763571|NCT03411109||Opioid Only Intrathecal|
62763572|NCT03411109||Opioid + Local Anesthetic Intrathecal|
62763573|NCT00885638|PLACEBO_COMPARATOR|Placebo|A placebo tablet is given before ingestion of macronutrients
62763574|NCT00885638|ACTIVE_COMPARATOR|Sitagliptin|Sitagliptin is given before ingestion of macronutrients
62763575|NCT05079633|ACTIVE_COMPARATOR|Moderna COVID-19 vaccine (mRNA 1273)|110 participants will be randomly assigned to Moderna COVID 19
62763576|NCT05079633|EXPERIMENTAL|Medigen COVID-19 vaccine (MVC COV1901)|110 participants will be randomly assigned to Medigen COVID 19 vaccine
62763577|NCT01288612|ACTIVE_COMPARATOR|Sedated Endoscopy|Sedated esophagogastroduodenoscopy with biopsy
62763578|NCT01288612|ACTIVE_COMPARATOR|Transnasal Endoscopy at Hospital Unit|Unsedated transnasal endoscopy at hospital unit.
62763579|NCT01288612|ACTIVE_COMPARATOR|Transnasal Endoscopy at Mobile Unit|Unsedated transnasal endoscopy in mobile research van
62763580|NCT03288194|EXPERIMENTAL|Problem-Solving Treatment|Problem-Solving Treatment is a structured, yet flexible, form of cognitive-behavioral psychotherapy intended to increase problem-solving skills.
62763581|NCT03288194|ACTIVE_COMPARATOR|Time Management|Time Management is a structured, yet flexible, intervention intended to increase creativity.
62763582|NCT01741714|ACTIVE_COMPARATOR|Chiropractic Spinal Manipulative Therapy|Active chiropractic spinal manipulative treatment
61988320|NCT06052007|EXPERIMENTAL|LC-Based Debriefing|LC-based debriefing session in one intervention group.
61988321|NCT06052007|EXPERIMENTAL|3D Model-Based Debriefing|One facilitator conducted a 3D model-based debriefing session in the other intervention group.
61988322|NCT06052007|NO_INTERVENTION|Standard Debriefing|One facilitator conducted a non-model-based unstructured debriefing session in the control group
61988323|NCT06316752||Patients with sialidosis type 1|Patients with a definite diagnosis of this disease are candidates for this study.
62763583|NCT01741714|SHAM_COMPARATOR|Sham manipulation|Sham chiropractic manipulative therapy
62763584|NCT01741714|NO_INTERVENTION|Control group|No intervention, follow headache diary
62763585|NCT04836416||Young Adult/Normal|Age 18-35, BMI 18.5-24.9
62763586|NCT04836416||Young Adult/Overweight and Obese|Age18-35, BMI greater than 25.0
62763587|NCT04836416||Adult/Normal|Age 36-50, BMI 18.5-24.9
62763588|NCT04836416||Adult/Overweight and Obese|Age 36-50, BMI greater than 25.0
62763589|NCT04836416||Older Adult/Nornal|Age 51-65, BMI 18.5-24.9
62763590|NCT04836416||Older Adult/Overweight and Obese|Age 51-65, BMI greater than 25.0
62763591|NCT05090514|EXPERIMENTAL|Reading and Growth Mindset Intervention Group|Parents and students receive a packet of age-appropriate books and educational materials on how to read together/promote reading with their child using growth mindset strategies and where to find other reading materials. Parents also receive 2 weekly text messages with tips and reminders to read with their child daily for 20 minutes over the course of 8 weeks. The messages contain a link to a secure Redcap survey to log days and time spent reading the prior week.
62763592|NCT05090514|ACTIVE_COMPARATOR|Wait-list Control Group|Parents and students receive a packet of age-appropriate books at the same time as the intervention group, but do not receive specialized instruction or reminders to read.
62763593|NCT04588506|ACTIVE_COMPARATOR|Cuff tear without subscapularis tear-Lower Trapezius group|Rotator cuff tears excluding the subscapularis muscle repaired using Lower Trapezius tendon
62763594|NCT04588506|ACTIVE_COMPARATOR|Cuff tear without subscapularis tear-Latissimus Dorsi group|Rotator cuff tears excluding the subscapularis muscle repaired using Latissimus Dorsi tendon
62763595|NCT04588506|ACTIVE_COMPARATOR|Cuff tear involving subscapularis tear-Pectoralis group|Rotator cuff tears involving the subscapularis muscle repaired using Pectoralis tendon
62763596|NCT04588506|ACTIVE_COMPARATOR|Cuff tear involving subscapularis tear-Latissimus Dorsi group|Rotator cuff tears involving the subscapularis muscle repaired using Latissimus Dorsi tendon
62763597|NCT03631212|NO_INTERVENTION|Waitlist control|Wait-list control group
62763598|NCT03631212|EXPERIMENTAL|Flexiquit|Digital ACT-based intervention for smoking cessation
62763599|NCT00769028|EXPERIMENTAL|AIMSPRO|
62763600|NCT00769028|PLACEBO_COMPARATOR|Placebo|
62763601|NCT01632644||Physicians|Physicians performing skin biopsies
62383002|NCT06077123|NO_INTERVENTION|Traditional Follow-Up|Those assigned to the traditional follow-up group will receive standard care and in-person check-ups as determined by their attending physician.
62763602|NCT01632644||Patients|Patients who have had skin biopsies
62383003|NCT00302029||CMV positive|CMV +, N=500/167
62763603|NCT04836676|EXPERIMENTAL|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid Cath or C-REX RectoAid Cath.
62383004|NCT00302029||CMV negative|CMV -, N=500/167
62383005|NCT06168929|EXPERIMENTAL|Treatment group A|
62383006|NCT06168929|EXPERIMENTAL|Treatment group B|
62763604|NCT02827383|EXPERIMENTAL|Stair Climbing 4x/day|Participants use the stair climber 4 times per day, for 4 minutes at a time. Total dose = 16 minutes.
62763605|NCT02827383|EXPERIMENTAL|Stair Climbing 8x/day|Participants use the stair climber 8 times per day, for 2 minutes at a time. Total dose = 16 minutes.
62763606|NCT03315169|ACTIVE_COMPARATOR|Packing of perianal abscess cavity|Internal packing of perianal abscess cavity as per normal practice.
62763607|NCT03315169|EXPERIMENTAL|External dressing|External application of a non-adherent dressing to the perianal abscess cavity.
62763608|NCT05881720|EXPERIMENTAL|Group 1 (N = 40)|Group 1 (N = 40) received sacubitril/valsartan (target dose, 100 mg twice daily) in addition to recommended therapy according to physician's judgment.
62763609|NCT05881720|EXPERIMENTAL|Group 2 (N = 40)|group 2 received valsartan (target dose, 80 mg twice daily) in addition to recommended therapy according to physician's judgment.
62763610|NCT06105294|EXPERIMENTAL|time-restricted eating|Post-baseline, participants will be asked to restrict their eating to a 10-hour window.
62763611|NCT02043197||Outpatients with neurological disorders and depression.|Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.
62763612|NCT02630368|EXPERIMENTAL|Experimental phase I dose escalating|"Prospective open-labeled phase I trial.~Combination of cyclophosphamide and JX-594 dose escalation. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 14"
62763613|NCT02630368|EXPERIMENTAL|Experimental group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide|"Randomized non comparative phase II clinical trial : Arm 1.~Experimental phase II soft-tissue sarcoma :~Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 48"
62763614|NCT02630368|EXPERIMENTAL|Control group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide|"Randomized non comparative phase II clinical trial : Arm 2.~Control-arm phase II soft-tissue sarcoma :~Patients will be treated by metronomic cyclophosphamide. Cyclophosphamide will be administered 50 mg twice daily orally, one week on/one week off. One cycle consits of 28 days.~Number of subjects : 24"
61988324|NCT04669587|EXPERIMENTAL|Part A: Dose Escalation of ZB716 monotherapy (with Food Effect Cohort)|Cohorts will follow a 3+3 study design. Approx. 3 to 6 subjects will be enrolled in each dose cohort (6 subjects in Cohort A6; food-effect evaluation). (Dose levels: 50, 100, 200, 300, 400 mg, orally QD in a 28 day cycle) The overall DLT observation period of ZB716 monotherapy will be 4 weeks following the initial dose of study drug on Cycle 1 Day 1. There will be 2 \~ 6 days between dose escalations to allow sufficient time for an adequate safety review. The max. dose may be lower than 400 mg. In the first dosing group of Part A (Cohort A1), subject dosing will be staggered such that administration of the first dose is separated by at least 7 days between the first 2 subjects. In each of Cohorts A1 to A5, 3 to 6 subjects will receive ZB716 doses according to the assigned dose level in the fasted state. For Cohort A6, Period 1, doses will be administered in the fasted state in Treatment Period 1 and 2, doses will be given 30 min. after starting a standard high fat breakfast.
61988325|NCT04669587|EXPERIMENTAL|Part B: Dose Expansion of ZB716 monotherapy|"Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration. Subjects will come to the clinical site before the first dose of study drug to confirm eligibility. Cohorts will be enrolled sequentially based on an optional Simon 2-stage study design.~Approx. 29 subjects may be enrolled in the dose expansion cohorts of Part B. For Part B, doses will be administered (self-administered by subjects at home or administered by subjects under observation of clinical staff during clinic visits) at the determined monotherapy RD of ZB716 (based on Part A) QD in a 28-day cycle. Doses will be administered in the dietary status for dosing as determined from Part A fed/fasted comparison."
61988326|NCT04669587|EXPERIMENTAL|Part C: Dose Escalation of ZB716 in combination with palbociclib|Cohorts will follow a 3+3 study design. Approx. 6 to 12 subjects will be enrolled in the dose escalation phase of ZB716 in combination with Palbociclib. For Part C, doses will be administered at escalating doses starting with 1 dose level below the monotherapy RD (determined in Part A) and Palbociclib will be dosed at the fixed standard dose of 125 mg QD. ZB716 will be administered on a 28 day cycle and Palbociclib will be administered for 21 days in the cycle with 7 days off treatment. Administration of the higher dose level (at monotherapy RD) of ZB716 (with the standard dose of Palbociclib) to subsequent subjects will be based on the occurrence of DLTs during the DLT observation period (Cycle 1), until MAD of ZB716 with combination of Palbociclib is reached. Doses will be administered in the dietary status for dosing as determined from Part A fed/fasted comparison.
61988327|NCT04669587|EXPERIMENTAL|Part D: Dose Expansion of ZB716 in combination with palbociclib|"Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration. Subjects will come to the clinical site before the first dose of study drug to confirm eligibility. Cohorts will be enrolled sequentially based on an optional Simon 2-stage study design.~Approx. 29 subjects may be enrolled in the dose expansion cohorts of Part D. For Part D, doses will be administered (self-administered by subjects at home or administered by subjects under observation of clinical staff during clinic visits) at the determined RD of ZB716 QD for 28 days from Part C in combination with the standard dose of Palbociclib (125 mg QD for 21 days with 7 days off treatment). Doses will be administered in the dietary status for dosing as determined from Part A fed/fasted comparison."
61988328|NCT06387992|EXPERIMENTAL|Three-dimensional dental acquisition by a nurse|Consultation with a trained nurse who will perform a three-dimensional dental acquisition using a 3D intraoral camera
61988329|NCT05070065|EXPERIMENTAL|virtual reality|The experimental group A receives the cognitive remedy intervention with virtual reality (CEREBRUM)
61988330|NCT05070065|OTHER|waiting list|waiting list
62567621|NCT01088763|EXPERIMENTAL|Arm I|"GROUP A: Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~GROUP B: Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-5, 8-12, 15-19, and 22-26. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients may also receive concurrent oral dexamethasone twice daily on the days of gamma-secretase inhibitor RO4929097 administration.~Once the MTD or recommended phase II dose of RO4929097 plus dexamethasone in children with solid tumors, including CNS tumors, or lymphoma has been identified, this dose is used for patients with relapsed-refractory T-ALL (phase 2 portion of the study) to evaluate RO4929097 in combination with dexamethasone using one of the studied schedules."
62383007|NCT04248972|EXPERIMENTAL|Intervention|A treatment with whole body red light therapy (NovoTHOR®) will be carried out
62763615|NCT02630368|EXPERIMENTAL|Experimental group breast cancer, treatment by JX-594 + Metronomic cyclophosphamide|"Single-arm phase II clinical trial.~Experimental phase II Group breast cancer :~Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 32"
62383008|NCT04248972|PLACEBO_COMPARATOR|PLACEBO INTERVENTION|A placebo whole body red light will be carried out
62383009|NCT05497622|EXPERIMENTAL|Healthy participants|Non-invasive quantitative ultrasound (B-mode image, ultrasound elastography), EMG, and osteopathic assessment (TART assessments) will be performed on the upper trapezius muscle in healthy participants one time at the time of the enrollment.
62383010|NCT05497622|EXPERIMENTAL|Patients with chronic neck pain|Non-invasive quantitative ultrasound (B-mode ultrasound, ultrasound elastography), EMG, osteopathic assessment, and osteopathic manipulative treatment (OMT) of the upper trapezius muscle will be performed on participants with chronic neck pain 3 times. All ultrasound, EMG biomarkers and TART assessments will be collected before and after OMT.
62383011|NCT01183572|ACTIVE_COMPARATOR|Folic Acid and Iron|0.4mg of folic acid and 30 mg elemental iron taken daily for 6 months
62383012|NCT01183572|PLACEBO_COMPARATOR|Folic Acid|0.4mg of folic acid taken daily for 6 months
62383013|NCT01183572|ACTIVE_COMPARATOR|Multivitamins, Folic Acid, and Iron|A multivitamin and micronutrient supplement that constitutes 1 RDA of Vitamins A (2500 IU), B1 (1.4 mg), B2 (1.4 mg), B6 (1.9 mg), B12 (2.6 ug), niacin (18 mg), C (70 mg), E (10 mg), and folic acid (0.4 mg)along with 30 mg of elemental iron taken daily for 6 months.
62383014|NCT00419029|ACTIVE_COMPARATOR|control|brief telephone check-in (no motivational interviewing)
61988331|NCT01003509|NO_INTERVENTION|study, control|Control: Only modified shouldice repair performed Study: Modified Shouldice + Moloney repairs performed
61988332|NCT01003509|NO_INTERVENTION|modified shouldice and double|one arm is only modified shouldice, other one is double
61988333|NCT02514837||Temperature measured by RTM device|Both the internal temperature and skin temperature will be measured non-invasively through the skin.
61988334|NCT01785979|EXPERIMENTAL|Prednisone induction - chloroquine|0.5 mg/Kg daily of prednisone for 4 weeks after randomization, 0.25 mg daily for weeks 5-6, 0.15 mg daily for week 7 and 2.5 mg daily for week 8 and chloroquine at a fixed dose (300 mg base per week) for months 1-12
61988335|NCT01785979|ACTIVE_COMPARATOR|chloroquine|chloroquine at a fixed dose (300 mg base per week) for months 1-12
61988336|NCT04674046|EXPERIMENTAL|Nonoperative treatment if deltoid ligament is intact|AirCast Air-stirrup (DJO Global) functional orthosis for 6 weeks.
61988337|NCT04674046|EXPERIMENTAL|Operative treatment if deltoid ligament is ruptured|Open reduction, internal fixation of the fibular fracture using plate and screws.
62383015|NCT00419029|EXPERIMENTAL|telephone-administered motivational interviewing|motivational interviewing sessions
62383016|NCT00490477|NO_INTERVENTION|CONVENTIONAL|
62383017|NCT00490477|ACTIVE_COMPARATOR|POLYMYXIN-B|an extracorporeal LPS removal
62383018|NCT03566563||Ex-Drug Users|These are ex drug users residing at halfway houses
62383019|NCT04755699|ACTIVE_COMPARATOR|Healthy Volunteers|This arm consists of healthy volunteers receiving transcutaneous electrical stimulation to the arms, legs, and/or spinal column to evoke various arm/hand and leg/foot movements.
62383020|NCT04755699|EXPERIMENTAL|Individuals with a Spinal Cord Injury|This arm consists of individuals with a spinal cord injury receiving transcutaneous electrical stimulation to the arms/hand and/or spinal column to evoke various arm/hand movements.
62383021|NCT04755699|EXPERIMENTAL|Individuals with a Stroke|This arm consists of individuals with a stroke receiving transcutaneous electrical stimulation to the arms/hand and/or spinal column to evoke various arm/hand movements.
62763616|NCT02630368|EXPERIMENTAL|Experimental group soft-tissue sarcoma, treatment by Avelumab + ITJX-594 + Metronomic CP|"Experimental phase II soft-tissue sarcoma :~Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide.~Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 (impregnation phase).~JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections.~Number of subjects : 47"
61988338|NCT01017237|ACTIVE_COMPARATOR|Dex plus midazolam|Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg i.v.
61988339|NCT01017237|ACTIVE_COMPARATOR|Dex plus midazolam and ketamine|Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg and 0.25 mg/kg ketamine i.v.
61988340|NCT00559546|ACTIVE_COMPARATOR|1|3 weeks of Montelukast and 3 weeks of placebo treatment
62383022|NCT04755699|EXPERIMENTAL|Individuals with other Brain or Nerve Injuries|This arm consists of individuals with a other brain and nerve injuries receiving transcutaneous electrical stimulation to the arms/hand, legs/foot, and/or spinal column to evoke various arm/hand or leg/foot movements.
62383023|NCT02733276|EXPERIMENTAL|Electroacupuncture|Using electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes. Acupoints are: 6 needles in each lower limb, 8 abdominal, 3 in upper extremity and 3 on the front
62383024|NCT02733276|SHAM_COMPARATOR|Electroacupuncture sham|Using electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes. Acupoints are: needles on each forearm on nonselective points
62763617|NCT02630368|EXPERIMENTAL|Experimental group breast cancer, treatment by Avelumab + IT JX-594 + Metronomic CP|"Experimental phase II breast cancer :~Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide.~Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 (impregnation phase).~JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections.~Number of subjects : 32"
62763618|NCT00837668||sarcoidosis|sarcoidosis patients undergoing clinical bronchoscopy
62763619|NCT00859339|EXPERIMENTAL|Experimental Treatment|Neoadjuvant cisplatin, gemcitabine and sunitinib malate followed by radical cystectomy
62763620|NCT04239794|ACTIVE_COMPARATOR|Inhalation anesthesia|Patients are anesthetized with sevoflurane and remifentanil infusion for maintenance of anesthesia during the surgery
62763621|NCT04239794|EXPERIMENTAL|Total intravenous anesthesia|Patients are anesthetized with target-controlled intravenous infusion of propofol and remifentanil infusion for maintenance of anesthesia during the surgery
62763622|NCT03582904|EXPERIMENTAL|Real tDCS|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered via saline-soaked sponge electrodes (anode, 8 cm\^2; cathode 38.4 cm\^2) at an intensity of 1.5 milliamperes over \< 30 minutes.
62763623|NCT03582904|SHAM_COMPARATOR|Control|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered via saline-soaked sponge electrodes (anode, 8 cm\^2; cathode 38.4 cm\^2) at an intensity of 1.5 milliamperes over 2 minutes.
62763624|NCT03780959|PLACEBO_COMPARATOR|Etanercept/Placebo|Participants received 0.4 mg/kg etanercept twice weekly for 90 days during Part 1. In Part 2 participants were randomized to receive placebo subcutaneous injection twice weekly for up to 4 months.
62763625|NCT03780959|EXPERIMENTAL|Etanercept/Etanercept|Participants received 0.4 mg/kg etanercept twice weekly for 90 days during Part 1. In Part 2 participants were randomized to continue receiving etanercept twice weekly for up to 4 additional months.
62763626|NCT04453813|EXPERIMENTAL|Toripalimab plus concurrent chemo-radiotherapy arm|Concurrent chemo-radiotherapy plus concurrent and adjuvant toripalimab.
62763627|NCT04453813|ACTIVE_COMPARATOR|Concurrent chemo-radiotherapy arm|Concurrent chemo-radiotherapy alone.
62763628|NCT04077294||Preoperative BNP used for cardiac risk stratification|Cohort of patients recruited in the pre-admission clinic who qualified for, and underwent, preoperative BNP screening according to CCS guidelines.
62763629|NCT04077294||Preoperative BNP not used for cardiac risk stratification|Cohort of patients from patient care database (SPOR) who qualified for preoperative BNP screening according to CCS guidelines, but did not receive screening due to surgery occurring before the implementation of the CCS guidelines.
62763630|NCT01243567|ACTIVE_COMPARATOR|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
62763631|NCT01243567|ACTIVE_COMPARATOR|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
62763632|NCT01439074|ACTIVE_COMPARATOR|Mepilex Ag|Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
62383025|NCT02733276|NO_INTERVENTION|Control|Initially no intervention. In a second period in this group we will perform EAP
62383026|NCT00443794|EXPERIMENTAL|1, POLYCAP|Combination of 3 anti hypertensives, lipid lowering agent and anti platelet agent
62763633|NCT01439074|ACTIVE_COMPARATOR|Silver Sulphadiazine Ag cream|SSD Ag cream is white cream, 1% SSD Ag, 40g/tube This cream is indicated for prevent and treat secondary wound infection of small area, mild burn/scald.
62383027|NCT00443794|ACTIVE_COMPARATOR|2 B|Diuretic antihypertensive
62383028|NCT00443794|ACTIVE_COMPARATOR|3 C|Thiazide plus Angiotensis converting enzyme inhibitor - combination antihypertensive.
61988341|NCT00559546|ACTIVE_COMPARATOR|2|3 weeks of placebo and 3 weeks of montelukast treatment
62383029|NCT00443794|ACTIVE_COMPARATOR|4 D|Diuretic with Beta blocker combination antihypertensive
62383030|NCT00443794|ACTIVE_COMPARATOR|5, E|ACE inhibitor plus Beta blocker combination antihypertensive
62383031|NCT00443794|ACTIVE_COMPARATOR|6, F|Combination antihypertensive of ACE inhibitor, diuretic and beta blocker
62383032|NCT00443794|ACTIVE_COMPARATOR|7,G|Combination of ACE inhibitor, betablocker, diuretic and Antiplatelet
62383033|NCT00443794|ACTIVE_COMPARATOR|8,H|Lipid lowering agent
62383034|NCT00443794|ACTIVE_COMPARATOR|9,A|Antiplatelet
62763634|NCT02428920|EXPERIMENTAL|Peer Groups|Individuals in Intervention Group Arm will attend biweekly or monthly peer support groups (approximately 10 people per group) for evaluating changes and promoting mutual support. 12-month duration.
62763635|NCT02428920|NO_INTERVENTION|Control Arm|The control arm, will attend the initial educational group lectures at baseline assessment and will receive no intervention thereafter.
62763636|NCT03454516|NO_INTERVENTION|Standard Care|This group is the usual standard treatment group
62763637|NCT03454516|OTHER|Telemonitoring group|This group will followed up with telemonitoring
62763638|NCT04279145|EXPERIMENTAL|pulmonary hypertension group 1|each patient will be submitted to : swan-ganze catheterization detailed echocardiography blood sample for biomarkers (troponin, uric acid and micro RNA)
62763639|NCT05709522||Pediatric brain tumor patients|The study participants will be 5 to 21 years old children with newly diagnosed brain tumors presenting with any stage, who have not undergone any treatment
62763640|NCT05709522||Blood cancer children|The study participants will be 5 to 21 years old children with newly diagnosed blood cancer presenting with any stage, who have not undergone any treatment
62763641|NCT04798469|EXPERIMENTAL|Testosterone|Intramuscular injections of testosterone undecanoate 750 mg.
62763642|NCT04798469|PLACEBO_COMPARATOR|Placebo|Intramuscular injections of placebo.
62763643|NCT01576328|EXPERIMENTAL|Cohort 1|MPC dose 1 or Placebo
61988342|NCT00360828|EXPERIMENTAL|Irinotecan Treatment|Participants were given irinotecan at a fixed dose: \[350 mg/m2 in patients either not on anti-seizure drugs or on anti-seizure drugs which do not interfere with the metabolism of Irinotecan; 600 mg/m2 in patients on anti-seizure drugs which interfere with the metabolism of Irinotecan\] once every 21 days. Depending on how many side effects were experienced with the first cycle \[first 21 days\], the dose of both drugs may remain the same or may be decreased to make the treatment better tolerated with less side effects. The irinotecan was given to through a vein over 90 minutes.
62383035|NCT05135507|EXPERIMENTAL|An interactive stress reduction and behavioral parent training program|This feasibility evaluation will track and analyze individual program usage and examine changes in parents' psychological flexibility, parents' stress, parenting self-efficacy, parents' mindfulness and child behavior in a within subject pretest and posttest design with 50 parents of children who have DD
61988343|NCT05889598|EXPERIMENTAL|Ballistic resistance exercise training|This arm will perform the exercises in a hack squat machine using low loads and explosive high-velocity (as if trying to jump)
61988344|NCT05889598|EXPERIMENTAL|Conventional resistance exercise training|This arm will perform the exercises in a hack squat machine using high-load and low-velocity (conventional training)
61988345|NCT05889598|NO_INTERVENTION|Control|Continue usual life
62383036|NCT03154918|EXPERIMENTAL|GLIDE|Treated with GLIDE regiment chemotherapy for 4 cycles.
62383037|NCT02827084|EXPERIMENTAL|Kinesio Taping|Apply the Kinesio Taping with tension in the vatus mediallis
62383038|NCT02827084|PLACEBO_COMPARATOR|Placebo|Apply the Kinesio Taping without tension in the vatus mediallis
62383039|NCT02827084|NO_INTERVENTION|Control|It will not apply Kinesio.
62383040|NCT00286156|EXPERIMENTAL|1|Arm 1 Rapamune dose 2-6mg aimed at maintaining trough levels 5-8 ng/ml
62383041|NCT00286156|EXPERIMENTAL|2|Arm 2 Rapamune dose 2-6 mg aimed at maintaining trough levels of 2-5ng/ml
62763644|NCT01576328|EXPERIMENTAL|Cohort 2|MPC dose 2 or Placebo
61988346|NCT03760796|EXPERIMENTAL|Corrie Health Digital Platform group|Receives the Corrie Health intervention plus the standard of care
61988347|NCT00441311|EXPERIMENTAL|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
62763645|NCT01576328|EXPERIMENTAL|Cohort 3|MPC dose 3 or Placebo
61988348|NCT00441311|NO_INTERVENTION|Service-as-Usual|Control Arm
61988349|NCT02831166|ACTIVE_COMPARATOR|Transradial approach|Transradial approach primary percutaneous coronary intervention using the TR Band device to obtain hemostasis (n=125).
62383042|NCT00286156|NO_INTERVENTION|3|Standard Care
62383043|NCT03256123|EXPERIMENTAL|red palm shortening group|A group receiving the supplementation of red palm shortening biscuits. The subjects are expected to receive 630 µg RE of vitamin A/day by consuming the biscuits four days a week.
62383044|NCT03256123|PLACEBO_COMPARATOR|palm shortening group|A group receiving supplementation of palm shortening biscuits with corresponding fatty acids as red palm shortening group.
62383045|NCT01927640|EXPERIMENTAL|Dexmedetomidine and intranasal cocaine|Intranasal cocaine administration (2 mg/kg) then Dexmedetomidine (0.3-0.6 mcg/kg) infusion
62763646|NCT03817294|ACTIVE_COMPARATOR|Eccentric cycling|
62763647|NCT03817294|ACTIVE_COMPARATOR|Concentric cycling|
62763648|NCT03817294|ACTIVE_COMPARATOR|Single leg cycling|
62763649|NCT03817294|ACTIVE_COMPARATOR|Lower limb resistance training|
62763650|NCT00247832|NO_INTERVENTION|1|
62763651|NCT00247832|EXPERIMENTAL|2|Self-directed motivation
62763652|NCT00247832|EXPERIMENTAL|3|Personal motivational interviewing
62763653|NCT05672355|EXPERIMENTAL|Arm I (GEO-CM04S1)|Patients receive GEO-CM04S1 vaccine IM on days 0 and 84 on study. Patients undergo blood sample collections throughout the study and are monitored for 1 year.
62763654|NCT05672355|ACTIVE_COMPARATOR|Arm II (mRNA Covid-19 Vaccine)|Patients receive mRNA vaccine injection IM on days 0 and 84 on study. Patients undergo blood sample collections throughout the study and are monitored for 1 year.
62763655|NCT03489967|ACTIVE_COMPARATOR|16g of carbohydrates - Glucose levels < 3.0 mmol/L|Hypoglycemia treatment with 16g of carbohydrates will be given when glucose levels are below 3.0 mmol/L.
62763656|NCT03489967|ACTIVE_COMPARATOR|16g of carbohydrates - Glucose levels 3.0-3.5 mmol/L|Hypoglycemia treatment with 16g of carbohydrates will be given when glucose levels are between 3.0 and 3.5 mmol/L.
62763657|NCT03489967|ACTIVE_COMPARATOR|32g of carbohydrates - Glucose levels < 3.0 mmol/L|Hypoglycemia treatment with 32g of carbohydrates will be given when glucose levels are below 3.0 mmol/L
62383046|NCT01927640|PLACEBO_COMPARATOR|Normal saline and intranasal cocaine|Intranasal cocaine administration (2 mg/kg) then Saline (over 10 minutes I.V. infusion)
62383047|NCT01162967|ACTIVE_COMPARATOR|Benznidazole|
62383048|NCT01162967|EXPERIMENTAL|Posaconazole, low dose|
62383049|NCT01162967|EXPERIMENTAL|Posaconazole, high dose|
62383050|NCT02967965||Cohort|Clinical Evaluation, Coronarography, Imagery by MRI, Echocardiography and Biological samples will be collected for each patient.
62383051|NCT02967406|EXPERIMENTAL|Lifestyle modification|4 x 4 lifestyle modification intervention, addressing four health behaviors including physical activity, diet, smoking and alcohol drinking, at four different levels, i.e. individual, household, group/ knowledge management, and community levels
62383052|NCT02967406|NO_INTERVENTION|Control|No special intervention will be given. Prevention and treatment in normal practice is allowed
62383053|NCT06504433||MITO participants/patients|400 MITO patients will be observed over 10 years and having a confirmed variant/deletion in either nuclear or mitochondrial genes involved in the mitochondrial respiratory chain, or patients meeting the clinical diagnostic criteria for MITO using consensus scoring systems such as the Walker Criteria, or the Nijmegen criteria
62383054|NCT06504433||Patients with a clinically confirmed non-MITO neuromuscular disorder|"The study will form a 10-year, longitudinal, non-randomised, retrospective, and prospective, observational study of patients with MITO using controls who may be:~* asymptomatic biological relatives of MITO participants/patients~* patients with a clinically confirmed non-MITO neuromuscular disorder, or"
62383055|NCT06504433||Age and gender-matched healthy controls.|Age/gender-matched healthy controls will be recruited from the NeuRA database of volunteers
62383056|NCT05696652|EXPERIMENTAL|Active arm: Acute exercise + 12 weeks Cardiac Rehabilitation|This arm includes two-thirds of enrollees and focuses on both acute and chronic effects of exercise. Qualifying participants with heart failure randomized to this arm will undergo a 40 minute bout of moderate intensity exercise on a date prior to beginning in cardiac rehabilitation. Blood samples will be collected before and after the acute bout at 10, 30, and 210 minutes after exercise. Participants will then go to cardiac rehabilitation for a 12 week period. A single blood sample will be obtained at 6 weeks. The participants will return after the 12 weeks of cardiac rehabilitation for a second bout of acute exercise and blood sampling identical to the first. Finally, 12 weeks after completion of cardiac rehab, patients will return for another single blood sample.
62383057|NCT05696652|ACTIVE_COMPARATOR|Control arm: No exercise|This arm includes one-third of enrollees and serves as control. Qualifying participants with heart failure randomized to this arm will begine with a 40 minute period of rest on a date prior to beginning in cardiac rehabilitation. Blood samples will be collected before and after the the 40 minute period at 10, 30, and 210 minutes after exercise. Participants will then defer cardiac rehabilitation for a 12 week period. A single blood sample will be obtained at 6 weeks of this control intervention period. The participants will return after the 12 weeks of control intervention for an actual bout of acute exercise and blood sampling identical to those completed by the active arm. They will then enter cardiac rehabilitation as per standard of care. Finally, 12 weeks after completion of cardiac rehab, patients will return for another single blood sample.
62383058|NCT00979264|NO_INTERVENTION|Control|Standard quality improvement approaches available through participation in Get With the Guidelines - Heart Failure.
62383059|NCT00979264|ACTIVE_COMPARATOR|Intervention|Enhanced and/or intensive quality improvement approaches, coupled with standard approaches available through participation in Get With the Guidelines - Heart Failure.
62383060|NCT00688194|ACTIVE_COMPARATOR|Arm I|Patients receive fulvestrant intramuscularly (IM) on days 0, 14, and 28 of course 1 and on day 1 of all subsequent courses. Patients also receive oral placebo once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62383061|NCT00688194|ACTIVE_COMPARATOR|Arm II|Patients receive fulvestrant and placebo as in arm I. Patients also receive aromatase inhibitor (AI) therapy (e.g., exemestane, anastrozole, or letrozole) according to standard treatment regulations.
62567622|NCT04557579||Bifocal group|Patients in bifocal group implanted with Restor +2.5D IOL (Alcon, Fort Worth, TX, USA) in bilateral eyes
61988350|NCT02831166|ACTIVE_COMPARATOR|Transfemoral approach|Transfemoral approach primary percutaneous coronary intervention using a vascular closure device to obtain hemostasis (n=125).
61988351|NCT04546165|ACTIVE_COMPARATOR|manipulation group|manipulation plus exercise
61988352|NCT04546165|ACTIVE_COMPARATOR|myofascial release group|suboccipital inhibition plus exercise
61988353|NCT04546165|ACTIVE_COMPARATOR|exercise group|only exercise
62383062|NCT00688194|ACTIVE_COMPARATOR|Arm III|Patients receive fulvestrant as in arm I and oral lapatinib tosylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62383063|NCT00688194|ACTIVE_COMPARATOR|Arm IV|Patients receive fulvestrant as in arm I and lapatinib as in arm III. Patients also receive AI therapy according to standard treatment regulations.
62383064|NCT03574987|ACTIVE_COMPARATOR|CONTROL|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
62763658|NCT03489967|ACTIVE_COMPARATOR|32g of carbohydrates - Glucose levels 3.0-3.5 mmol/L|Hypoglycemia treatment with 32g of carbohydrates will be given when glucose levels are between 3.0 and 3.5 mmol/L.
62763659|NCT05781958|EXPERIMENTAL|Cadonilimab+Gem/Cis|
62763660|NCT03855202|EXPERIMENTAL|infusion froup 1|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
62383065|NCT03574987|EXPERIMENTAL|LOW SUG|Diet consisting of 50% carbohydrate (\<5% sugar), 15% protein, 35% fat
62383066|NCT03574987|EXPERIMENTAL|LOW CHO|Diet consisting of \<8% carbohydrate (\<5% sugar), 15% protein, \>77% fat
62383067|NCT02938975|PLACEBO_COMPARATOR|Placebo|placebo group receiving untreated army combat uniform and placebo lotion. Assigned interventions: Placebo lotion - a liposome lotion with no DEET Army combat uniform - army combat uniform with no permethrin
62383068|NCT02938975|ACTIVE_COMPARATOR|Combo|"Combined intervention group of receiving Permethrin treated uniform 0.52% w/w and 30% DEET liposome formula.~Ultra 30 Insect Repellent Lotion (30% Lipo DEET) One application of Lipo DEET protects for up to 12 hours. DEET is a broad spectrum insect repellent that has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors.~Permethrin Factory-Treated Army Combat Uniforms treated by the military apparel contractor Warmkraft Permethrin is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings."
62383069|NCT02938975|ACTIVE_COMPARATOR|Permethrin|"permethrin intervention group receiving Permethrin treated uniform 0.52% w/w and placebo lotion.~Permethrin Factory-Treated Army Combat Uniforms treated by the military apparel contractor Warmkraft~Placebo lotion: liposome lotion with no DEET"
62383070|NCT02938975|ACTIVE_COMPARATOR|DEET|"DEET intervention group receiving untreated army combat uniform and 30% DEET liposome formula.~Ultra 30 Insect Repellent Lotion (30% Lipo DEET) Army combat uniform with no permethrin"
62383071|NCT04429828|EXPERIMENTAL|e-package: psychological wellbeing for healthcare workers|A COVID-19 educational package on psychological wellbeing for healthcare workers, accessible to all healthcare students.
62763661|NCT03855202|EXPERIMENTAL|infusion group 2|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
62763662|NCT03855202|EXPERIMENTAL|infusion group 3|PS,dose is 70mg/kg
62763663|NCT03855202|PLACEBO_COMPARATOR|Placebol|0.9% sodium chloride installation after 24 hours
62763664|NCT00712218|ACTIVE_COMPARATOR|A|
62763665|NCT00712218|EXPERIMENTAL|B|
62763666|NCT06100094||juvenile sex offender psychoeducation group|The psychoeducation group consists of 10 sessions of approximately 1.5 hours each, once a week or every two weeks depending on the availability of the therapists. Among the sessions, 9 correspond to a specific theme: reminder of the law and violence, sexism, consent, control, social pressure, self-control, empathy, seduction and romantic relationships, sex under the influence. The last session is devoted to a resumption of all the themes previously discussed. Semi-structured qualitative interviews addressing their feelings regarding the psychoeducation group, what they learned from it, what they had difficulty with.
61988354|NCT04535895|EXPERIMENTAL|Simultaneous integrated boost arm|
61988355|NCT04291339|EXPERIMENTAL|High-flow nasal oxygen technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
61988356|NCT04291339|ACTIVE_COMPARATOR|Mask ventilation technique|Oxygen will be supplied through the mouth and nose to the patients using facial mask during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
61988357|NCT02696642|EXPERIMENTAL|Control group|Anetumab ravtansine was given at 6.5 mg/kg body weight (BW) as a 1 hour intravenous (IV) infusion once every 3 weeks (Q3W) for subjects with adequate hepatic and renal function.
61988358|NCT02696642|EXPERIMENTAL|mild HI group|Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with mild hepatic impairment (HI).
62763667|NCT00378599|EXPERIMENTAL|PEG-Intron plus Rebetol (RBV)|PEG-Intron plus RBV treatment for up to 48 weeks with 24-week follow up. SCH 54031 PEG-Intron 1.5 ug/kg SC per week plus SCH 18908 REBETOL twice daily (BID) PO with food, dosed as followed: Weeks 1 and 2, RBV Dose 400 mg (2 capsules, 1 AM and 1 PM). At the end of Weeks 2 and 4 of Treatment (tx), a complete blood count (CBC) was performed. An increase in RBV dose was permitted only if the hemoglobin was \>10 g/dL. At Weeks 3 and 4, RBV dose was 800 mg (4 capsules, 2 AM and 2 PM). From Weeks 5 to 48, RBV doses could be increased based on subject body weight. For subjects weighing \<65 kg, maximum dose of RBV was to be 800 mg (4 capsules, 2 AM and 2 PM), for subjects weighing 65-85 kg, max dose of RBV was 1000 mg/day (5 capsules, 2 AM and 3 PM), for subjects weighing \>85 kg, max dose of RBV was 1200 mg/day, 6 capsules, 3 AM and 3 PM).
61988359|NCT02696642|EXPERIMENTAL|moderate HI group|Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with moderate hepatic impairment (HI).
61988360|NCT02696642|EXPERIMENTAL|moderate RI group|Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with moderate renal impairment (RI).
61988361|NCT03493984|EXPERIMENTAL|Ginger exosomes|
62383072|NCT04759040|ACTIVE_COMPARATOR|MigraineGuard|Active supplement treatment , MigraineGuard capsule containing Coq10 , Magnesium ,Vit B2 , Skullcap Extract , Feverfew Extract , Piperine
62383073|NCT04759040|PLACEBO_COMPARATOR|Placebo for MigraineGuard|Placebo capsules non identifiable from Migraineguard capsules were used as control comparator
62383074|NCT01115114|PLACEBO_COMPARATOR|Treatment as Usual (TAU)|Study Intervention 1 Treatment as usual (TAU) will be psychiatry follow-up at local Community Mental Health Clinic at least every 3 months.
62383075|NCT01115114|ACTIVE_COMPARATOR|IMBED|Study Intervention 2 A Primary Care Provider (PCP) will be located within the community mental health clinic one day weekly to specifically run a Metabolic Syndrome Clinic.
62383076|NCT01115114|ACTIVE_COMPARATOR|Liaison|Study Intervention 3 A Medical Case Manager(MCM) will be assigned to a patient who is identified on the basis of routine screening to need medical follow-up for metabolic syndrome.
62383077|NCT01682759|EXPERIMENTAL|Omarigliptin|Participants will receive omarigliptin, 25 mg once weekly and placebo matching glimepiride once daily for up to 54 weeks.
62383078|NCT01682759|ACTIVE_COMPARATOR|Glimepiride|Participants will receive glimepiride titrated to a maximum of 6 mg, once daily, and placebo to omarigliptin, once weekly for up to 54 weeks.
62383079|NCT04822090||Group I|HHA patients with acute symptomatic HPV-B19 infection
62383080|NCT04822090||Group II|HHA patients without acute symptomatic HPV-B19 infection
62763668|NCT03883334|EXPERIMENTAL|Immunomodulator group|Metisoprinol 1 gr every 8 h per ten days during three months plus the combine antiretroviral therapy.
62763669|NCT03883334|NO_INTERVENTION|Control group|combine antiretroviral therapy only
62763670|NCT01342549|ACTIVE_COMPARATOR|Arm 1|sodium valproate
62763671|NCT01342549|ACTIVE_COMPARATOR|Arm 2|naltrexone
62763672|NCT04857645|EXPERIMENTAL|ASTX727 treatment|
61988362|NCT03493984|EXPERIMENTAL|Aloe exosomes|
61988363|NCT03493984|EXPERIMENTAL|Ginger and aloe exosomes|
61988364|NCT03493984|PLACEBO_COMPARATOR|Placebo|
62383081|NCT04999319|ACTIVE_COMPARATOR|PVB Group|Paravertebral block administered group
62383082|NCT04999319|ACTIVE_COMPARATOR|ESPB group|Erector spinae plane block administered group
62383083|NCT02880930|EXPERIMENTAL|Vitamin D supplement (Cholecalciferol)|Participants will be given oral Fultium-D3 drops (Internis) contain 400 IU cholecalciferol/day for a period of 3 months. Daily vitamin D3 supplementation dose will be increased to 1,000 IU for an additional 3 months if plasma 25(OH)D still below 75 nmol/L.
62763673|NCT06258057||Adacel-Exposed Cohort|Cohort will include all pregnant individuals with a record of Adacel vaccination during the third trimester of pregnancy (ie, first day of 27th week of gestation up to the end of pregnancy) and their offspring
62763674|NCT06258057||Tdap-Unvaccinated Comparator Cohort|Cohort will include all pregnant individuals meeting eligibility criteria and with no record of any Tdap vaccination from pregnancy onset date until the end of pregnancy and their offspring
61988365|NCT01908361|EXPERIMENTAL|Unilateral Hybrid (InMotion3 plus CIT) Intervention|Participants will receive 3 weeks of robot-assisted therapy (RT) using the InMotion3 Wrist Robot, followed by 3 weeks of CIT training.
61988366|NCT01908361|EXPERIMENTAL|Bilateral Hybrid (BMT plus BAT) Intervention|Participants in this bilateral treatment group will receive 3 weeks of RT using the Bi-Manu-Track (BMT) robot (Reha-Stim Co., Berlin, Germany), followed by 3 weeks of therapist-based BAT.
61988367|NCT01908361|ACTIVE_COMPARATOR|Conventional Rehabilitation (CR)|The CR intervention will be designed to match the duration and intensity of the hybrid interventions.
61988368|NCT01139450|EXPERIMENTAL|Test|Test product that contains the active pharmaceutical ingredient
61988369|NCT01139450|ACTIVE_COMPARATOR|Reference|Reference product that contains the active pharmaceutical ingredient
62383084|NCT05022303|PLACEBO_COMPARATOR|Placebo|Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
62763675|NCT04336371||Anxiety level|patient's psychological experience the anxiety level
62763676|NCT02900638|EXPERIMENTAL|Intervention (Mentor/Mentee)|
62763677|NCT02900638|NO_INTERVENTION|Wait list control|
62763678|NCT05278364|EXPERIMENTAL|Dose-escalation and Dose-expansion|"Dose-escalation Phase:~Multiple doses of SY-5007 for oral administration.~Dose Expansion Phase:~RP2D of SY-5007 as determined during Dose Escalation."
62763679|NCT04813172|EXPERIMENTAL|Head and neck cancer patients|Patients from the Eye and Ear Institute Survivorship Clinic who are diagnosed with head and neck cancer.
62763680|NCT01295736|ACTIVE_COMPARATOR|Actif arm|Sildenafil 20mg TID during 90 days
62763681|NCT01295736|PLACEBO_COMPARATOR|Sugar pill|Placebo pills TID during 90 days
62763682|NCT02893826|EXPERIMENTAL|EG-1962 Group|1 dose of intracisternal EG-1962 (nimodipine microparticles) 600 mg
62763683|NCT02893826|ACTIVE_COMPARATOR|Enteral Nimodipine Group|Up to a total of 21 days of enteral nimodipine (including nimodipine received prior to randomization)
62763684|NCT05079399||Healthy Control|
62763685|NCT05079399||Diabetes but no retinopathy|
62763686|NCT05079399||Mild non proliferative diabetic retinopathy|
61988370|NCT01139450|PLACEBO_COMPARATOR|Vehicle|Placebo that contains no active pharmaceutical ingredient
62383085|NCT05022303|EXPERIMENTAL|Larazotide Acetate|AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.
62763687|NCT05079399||Moderate non proliferative diabetic retinopathy|
62763688|NCT05079399||Severe non proliferative diabetic retinopathy|
61988371|NCT04353011||patient with chronic painful|
62763689|NCT05079399||Proliferative diabetic retinopathy|
62763690|NCT06458231||No of Positive CLABSI|No of +ve CLABSI in different types of cases,
61988372|NCT00424138|EXPERIMENTAL|Group A - 3 FDG-PET/CT Scans|Two FDG-PET/CT scans prior to 1st cycle of chemotherapy, plus 2 optional volumetric CT scans. One FDG-PET/CT after 1st cycle of chemotherapy, plus 1 optional volumetric CT scan.
62383086|NCT00135408|ACTIVE_COMPARATOR|A1|
62383087|NCT00135408|ACTIVE_COMPARATOR|A2|
62383088|NCT04823858||Examination Group|There will only be one arm of subjects in this study. The arm will include subjects who plan to undergo a single-level TLIF/PLIF stabilized with pedicle screws and meet all of the eligibility criteria.
61988373|NCT00424138|EXPERIMENTAL|Group B - 2 FDG-PET/CT + 1 Optional|One FDG-PET/CT prior to 1st cycle of chemotherapy; 1 FDG-PET/CT after the 1st cycle of chemotherapy; 1 optional FDG-PET/CT after the 2nd cycle of chemotherapy. All three with optional volumetric CT scans.
62383089|NCT05299411|EXPERIMENTAL|IVI|patients group with intravenous iron infusion
62383090|NCT05299411|ACTIVE_COMPARATOR|OI|patients group with oral iron supplement
62383091|NCT06092411|EXPERIMENTAL|CBT for Depression + Bright Light Therapy (CBTD+BLT)|N = 54
62383092|NCT06092411|ACTIVE_COMPARATOR|CBT for Depression + Placebo Light (CBTD-BLT)|N = 54
62383093|NCT06092411|NO_INTERVENTION|Waitlist Control (WL)|N = 54
62383094|NCT05733468|EXPERIMENTAL|Theracal LC Pulpotomy|36 children with the cariously exposed mature permanent molar teeth indicated for pulpotomy and fulfilling the inclusion criteria will be taken for the study and coronal pulpotomy will be done till the level of root canal orifice.
62763691|NCT06458231||Primary Blood stream infection|Participant with blood stream infection not related to other other infection in the body
62763692|NCT06458231||Secondary Blood stream infection|Blood stream infection occur as a complication to infection in other parts of the body
62763693|NCT06458231||Blood Prevalence of types microorg.|% and Prevalence of different microorg causing Blood stream infection
62763694|NCT02000011|OTHER|standard strategy|
62763695|NCT02000011|EXPERIMENTAL|experimental strategy|
62763696|NCT05305547|EXPERIMENTAL|S-217622|S-217622 will be administered orally for 5 days.
62763697|NCT05305547|PLACEBO_COMPARATOR|Placebo|Placebo matching to S-217622 will be administered orally for 5 days.
62383095|NCT05733468|ACTIVE_COMPARATOR|MTA Pulpotomy|36 children with the cariously exposed mature permanent molar teeth indicated for pulpotomy and fulfilling the inclusion criteria will be taken for the study and coronal pulpotomy will be done till the level of root canal orifice.
62763698|NCT04866355|EXPERIMENTAL|Lumbar spine manipulation|Application of lumbar spine manipulation by a physical therapist.
62763699|NCT04866355|ACTIVE_COMPARATOR|Lumbar spine manipulation plus pharmacological therapy|Application of lumbar spine manipulation by a physical therapist along with pharmacological therapy.
62763700|NCT04866355|ACTIVE_COMPARATOR|Pharmacological therapy|Application of pharmacological therapy
62763701|NCT02968381|EXPERIMENTAL|Imagery Intervention|Participants will receive imagery intervention which includes 6 telephone sessions, an introduction to guided imagery, setting a quit date, setting guided imagery schedule, and a description of and instructions for using the study website.
62763702|NCT02968381|ACTIVE_COMPARATOR|Control Condition|Participants will receive an attention control condition which includes 6 telephone sessions, an introduction to cognitive behavioral telephone coaching, setting a quit date, creating a quit plan, and a description of and instructions for using the Arizona Smokers' Help Line website.
62763703|NCT03808753|EXPERIMENTAL|Treatment - hemodynamic tests: EEOT and mFC|Interventions: all the enrolled patients will be tested using the EEOT and the mFC.
62763704|NCT01246479|OTHER|No treatment|subjects will be followed up on immunity (analysis of blood samples) and safety
62763705|NCT05077462|EXPERIMENTAL|Sequence A|Period 1: C52R1M(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose Period 2: AJU-C52H(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose
62763706|NCT05077462|EXPERIMENTAL|Sequence B|Period 1: AJU-C52H(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose Period 2: C52R1M(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose
62763707|NCT02067325|EXPERIMENTAL|Thai massage|The participants will receive thirty minutes session of Thai massage onto the trapezius muscle for 1 sessions
62383096|NCT05798702|ACTIVE_COMPARATOR|intensive lifestyle modifications|VLCD 800-850 Kcal/day
62383097|NCT05798702|ACTIVE_COMPARATOR|Roux-en-y-gastric bypass|laparoscopic RYGB
62383098|NCT01238757|ACTIVE_COMPARATOR|Non-Invasive Pressure support|"in this arm, non-invasive pressure support will be recorded under 3 conditions:~with the initial Expiratory Trigger Setting (ETS) with ETS +15% with ETS -15%"
62383099|NCT01238757|ACTIVE_COMPARATOR|NAVA|"Neurally Adjusted ventilatory Assist is a ventilation mode where the ventilator is piloted by the electrical activity of the diaphragm. Ventilation is triggered and cycled off by the electrical activity of the diaphragm, the pressure delivered being proportional to this activity.~The proportion named gain is chosen to obtain under NAVA the same peak pressure than during Presure Support"
62383100|NCT06381310|EXPERIMENTAL|Ultrasound-guided group|
62383101|NCT06381310|NO_INTERVENTION|control group|
62383102|NCT00457158|EXPERIMENTAL|1|ALN optional filter
62763708|NCT02067325|SHAM_COMPARATOR|Sham Microwave diathermy|The participants will receive thirty minutes session of Sham Microwave diathermy onto the trapezius muscle for 1 sessions
62763709|NCT05927545|ACTIVE_COMPARATOR|Home Exercise: Patient Education and Preventive Exercise|Group 1: The home Exercise Program includes an educational training program about parafunctional activities and correction exercises for patients having TMD-related headaches. The program includes tongue resting position, diaphragmatic breathing, head posture correction exercises, stretching and strengthening exercises for shoulder and back muscles, and active cervical and thoracic mobilization.
62763710|NCT05927545|ACTIVE_COMPARATOR|Manual Therapy Combined with Home Exercise|Group 2: MT group includes in addition to the home exercise program, deep friction massage, myofascial release techniques and stretching techniques to masticatory and neck muscles, temporomandibular joint and cervical mobilization will be applied.
62763711|NCT05927545|ACTIVE_COMPARATOR|Cognitive Exercise Therapy Approach Combined with Home Exercise|Group 3: Cognitive Exercise Therapy Approach (CETA) includes cognitive exercise therapy and the home exercise program. The Cognitive Exercise Therapy approach is an innovative exercise approach that aims to change the patient's cognition about the disease through exercise and is suitable for the biopsychosocial model. CETA is an exercise approach aimed at changing the patient's cognitive perception of the disease through exercise, placing the responsibility of disease management on the patient. The approach will be explained in the first session, and patients will be taught proper posture for the neck, shoulders, thoracic, and lumbopelvic region, as well as correct breathing control. Each 1-hour session will include a warm-up, exercise period, and cool-down.
62383103|NCT00457158|NO_INTERVENTION|2|No ALN optional filter
62383104|NCT05723211|EXPERIMENTAL|Vinyasa yoga group|The vinyasa yoga practice will be 60 minutes in duration and includes standing, seated, and supine postures in the following sequences in order: integration, sun salutations, crescent lunge series, balancing, standing, back bending, and restorative series. Participants will be instructed to follow the cues provided in the video and to take any necessary modifications to make each yoga pose more accessible. Vinyasa yoga intervention level 1 will be performed for week 1, level 2 will be performed for week 2, and level 3 will be performed for weeks 3 and 4 of the intervention.
62383105|NCT05723211|OTHER|Non-active control group|The participants in the non-active control condition will serve as a control group. They will be asked to maintain their current lifestyle habits and refrain from starting a new exercise and/or yoga program. A staff member will contact each participant weekly to check in and review any changes to their medical history or activity levels.
62383106|NCT06253624|OTHER|ATFL surgery|All participants will undergo all arthroscopic ATFL repair surgery.
62383107|NCT04109066|EXPERIMENTAL|Arm A: Nivolumab combined with neoadjuvant CT and adjuvant ET|Nivolumab with paclitaxel followed by nivolumab with anthracycline + cyclophosphamide as neoadjuvant (pre-surgery) treatment, then nivolumab with adjuvant (post-surgery) endocrine therapy of investigator's choice
62383108|NCT04109066|PLACEBO_COMPARATOR|Arm B: Placebo combined with neoadjuvant CT and then adjuvant ET|Nivolumab placebo with paclitaxel followed by nivolumab placebo with anthracycline + cyclophosphamide as neoadjuvant (pre-surgery) treatment, then adjuvant (post-surgery) endocrine therapy of investigator's choice
62383109|NCT04403074||Chronic Pancreatitis Patients|Patients that have Chronic Pancreatitis and the current treatment with Celiac Plexus Blocks (CPB) are providing minimal relief of pain (CPB provide less than one month of pain relief). These patient will then receive a Celiac Plexus Neurolysis.
62383110|NCT04955236|EXPERIMENTAL|Partial scalp block|Bilateral block of the greater lesser and third occipital nerves using bupivacaine 0.25% with epinephrine 1:200,000
62383111|NCT04955236|ACTIVE_COMPARATOR|Fentanyl group|Fentanyl infusion will be administered till time of dural closure
62383112|NCT00934752|EXPERIMENTAL|Lutonix Catheter|
62383113|NCT02116192|ACTIVE_COMPARATOR|General Healthy Diet|Control: General Healthy Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat)
62763712|NCT01797848|EXPERIMENTAL|pegIFNα 2a + Ribavirin + Placebo|"pegIFNα 2a 180 µg, Solution for injection, Subcutaneous, Once weekly, 48 weeks~Ribavirin 200 mg Tablets, by mouth, 400-600mg AM, 600 mg PM, 48 weeks~Placebo 0 mg Tablets, by mouth, Once daily, 24 weeks"
61988374|NCT00424138|EXPERIMENTAL|Group C - Test-Retest|Test-retest sequence for FDG-PET/CT; two scans with optional volumetric CT to be completed prior to 1st cycle of chemotherapy.
61988375|NCT01648855||Preterm babies|Intra uterine growth restricted preterm babies born before 30 weeks of gestational age from mother with preeclampsia
62383114|NCT02116192|EXPERIMENTAL|Low-fructose, reduced carbohydrate diet|"Intervention: Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)~● Aim for less than 25g fructose daily."
61988376|NCT04477811|ACTIVE_COMPARATOR|vitamin k1|vitamin k1 will be given 10 mg thrice a week for 3 months
61988377|NCT04477811|ACTIVE_COMPARATOR|vitamin k2|vitamin k2 (menaquinone) will be given 90 ug per day orally
61988378|NCT04477811|PLACEBO_COMPARATOR|placebo|placebo will be given daily per oral for 3 months
61988379|NCT04455269|EXPERIMENTAL|Full-Mouth Erythritol Powder Air-polishing Therapy (FM-EPAPT)|"The quadrants allocated to FM-EPAPT underwent the following steps:~* Decontamination of soft tissues with air-polishing and erythritol powder;~* Supra-gingival removal biofilm with air-polishing and erythritol powder;~* Sub-gingival removal of biofilm with air-polishing and erythritol;~* Calculus removal with a piezoceramic scaler."
61988380|NCT04455269|ACTIVE_COMPARATOR|Ultrasonic debridement and abrasive paste (US+P)|"The quadrants allocated to US+P treatment underwent the following steps:~* Full-mouth ultrasonic debridement with piezoceramic scaler;~* Plaque removal and polishing with soft rubber cup and low-RDA polishing paste"
62383115|NCT05138965||using the mCP|When the secretion reducing or the wound suture being removed, two pieces of 5cm×7cm-12p sterile gauzes will be crimped by the long side as the center of the reel,and be made as cylindrical gauze rolls with about D=1.5cm. After cleaning the wound, the cylindrical gauze rolls with its surface covered by alginates dressing will be placed above the vaginal wound with the help of endoscope.Itself tension of the rolls pressuring on the wound and the deep tissue can promote the wound healing. The rolls will be placed on about 5-6 hours every time, 2 times a day, for 7 days.Then observing the wound, if necessary, the method will be executed for another 7 days.
62383116|NCT05138965||no using the mCP|When the secretion reducing or the wound suture bing removed, only alginates dressing will be placed above the vaginal wound with the help of endoscope, without any pressure, being placed about 5-6 hours every time, 2 times a day, for 7 days.
62383117|NCT01401127||Type 1 Diabetes|Participants with type 1 Diabetes running their insulin pump at 70% of usual basal rate
62383118|NCT01401127||Participants without diabetes|Participants without diabetes or evidence of impaired glucose regulation
62383119|NCT03553264|EXPERIMENTAL|Head Mounted Device|"In addition to the Vestibular Rehabilitation protocol, each HMD group patient will perform Virtual Reality Rehabilitation by means of the game protocol Track Speed Racing 3D uninterruptedly for 20min/day, while sitting on a chair or sofa, after the smartphone accommodation into the HMD 'Revelation' 3D VR Headset. The game consists of a point-of-view race in which the car is steered from the cockpit by tilting the head to the left and to the right to avoid swerving off the road and to achieve all the goals before finishing the lap. During this real car experience, the visual background and the scenario change perspective according to the patients' left or right tilted head movements, possibly emulating eye-head exercises that induce visual-vestibular conflicts."
62383120|NCT03553264|ACTIVE_COMPARATOR|Vestibular Rehabilitation|Patients will be actively involved in adapting the exercise program to suit their symptoms, capabilities, and lifestyle. Following previous protocols, the home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises, and all chronic unilateral vestibular hypofunction patients will be seen twice a week for 4 weeks for 30-45 min and monitored for adherence. Between supervised sessions, patients will perform a twice-daily home exercise program for a total of 30-40min/day.
62567623|NCT04557579||Extended depth of focus group|Patients in extended depth of focus group implanted with EDOF Symfony IOL (AMO, Santa Ana, CA, USA) in bilateral eyes
61988381|NCT02606188|ACTIVE_COMPARATOR|Modified High-flow nasal cannula therapy|Patients undergoing bronchoscopy are given Modified High-flow nasal cannula oxygen therapy all the time.
61988382|NCT02606188|ACTIVE_COMPARATOR|Nasal cnnnula therapy|Patients undergoing bronchoscopy are given nasal cannula oxygen therapy all the time.
61988383|NCT05361317|OTHER|Hallux valgus correction|Hallux valgus correction for all patients : intervention during intraoperative visit, with Nexis® PECA Bunion Implantable Osteosynthesis Medical Device
61988384|NCT03602469|EXPERIMENTAL|Bupivacaine|Ultrasound-guided suprascapular nerve block using bupivacaine will be performed before induction of general anesthesia
61988385|NCT03602469|ACTIVE_COMPARATOR|Bupivacaine-magnesium|Ultrasound-guided suprascapular nerve block using bupivacaine in conjunction of magnesium sulfate will be performed before induction of general anesthesia
61988386|NCT03287167|EXPERIMENTAL|1 month DAPT intervention|After implantation of Firehawk coronary stents, 860 subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 1 month， then will be given aspirin and placebo for next 5 months.
62383121|NCT03719716|EXPERIMENTAL|Early support group|This group receive the Anticipatory care planning letter to take to their GP and the GP receives a copy of the Scottish Anticipatory Care Planning information leaflet and a short communication guide about ACP.
62383122|NCT03719716|NO_INTERVENTION|Usual care group|No change to standard care from oncology services and primary care
62763713|NCT01797848|EXPERIMENTAL|pegIFNα 2a + Ribavirin + Daclatasvir|"pegIFNα 2a 180 µg, Solution for injection, Subcutaneous, Once weekly, 24 or 48 weeks depending on response~Ribavirin 1000-1200 mg Tablets, by mouth, 400-600mg AM, 600 mg PM, 24 or 48 weeks depending on response~Daclatasvir 60 mg Tablets, by mouth, Once daily, 24 weeks"
62763714|NCT01741337|EXPERIMENTAL|Patients treated by ventilation|Adaptive servo-ventilation post-operative treatment for 6 months
62763715|NCT01741337|NO_INTERVENTION|Patients not treated by ventilation|Patients not treated during 6 months by an adaptive servo-ventilation
62763716|NCT02667782|EXPERIMENTAL|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is developed by Jon Kabat-Zinn in 1979 (Kabat-Zinn, 1990). It is an eight-week Program that includes practices such as gentle mindful movement (awareness of the body), a body scan (to systematically nurture awareness of the body region by region), and sitting meditation (awareness of the breath to include the four foundations of mindfulness, namely, body, feeling tone, mental state, and mental content) (Cullen, 2011).
62763717|NCT02667782|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT), developed by Zindel Segal, Mark Williams and John Teasdale, employs a cognitive theoretical framework (Cullen, 2011; Segal, Williams, \& Teasdale, 2002). It is also delivered as an eight-session group treatment. The first four sessions teach the fundamental concepts and skills of the practice of mindfulness. The remaining four sessions teach the individual how to notice his/her own thoughts and the impact of such thoughts on his/her own physical and emotional experiences.
61988387|NCT03287167|ACTIVE_COMPARATOR|6 months DAPT intervention|After implantation of Firehawk coronary stents, 860 subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 6 months.
61988388|NCT03461900|EXPERIMENTAL|Minifluid challenge|100 ml of 4% Albumin will be deliver to assess fluid responsiveness
61988389|NCT03461900|EXPERIMENTAL|Control|Patient will be treated as defined by most recent surviving sepsis campaign guidelines
61988390|NCT05185960|EXPERIMENTAL|ALLSWEET®|ALLSWEET® will be mixed with 250ml of water and an additional 125ml of water. Fingerprick blood samples will be taken for 2 hours following consumption of beverage in order to assess the glycemic response.
62383123|NCT03318822||Q-Collar|Subjects wearing the Q-Collar
62383124|NCT06135558||T3|patient staged T3 without marginal acute inflammation
62763718|NCT00542737|ACTIVE_COMPARATOR|Early Intervention Group|
62763719|NCT00542737|ACTIVE_COMPARATOR|Delayed Intervention Group|
62763720|NCT00371969|ACTIVE_COMPARATOR|1 - enhanced MI|Enhanced brief motivational interview (including an IVR component for alcohol self-monitoring purposes)
62763721|NCT00371969|ACTIVE_COMPARATOR|2- standard MI|The intervention consists of a standard motivational interview or viewing a DVD on HIV self-care.
61988391|NCT05185960|EXPERIMENTAL|ALLSWEET® consumed with sucrose|ALLSWEET® and sucrose will be mixed with 250ml of water and an additional 125ml of water. Fingerprick blood samples will be taken for 2 hours following consumption of beverage in order to assess the glycemic response.
61988392|NCT05185960|ACTIVE_COMPARATOR|Sucrose|Sucrose will be mixed with 250ml of water and an additional 125ml of water. Fingerprick blood samples will be taken for 2 hours following consumption of beverage in order to assess the glycemic response.
62383125|NCT06135558||MAI|patient with marginal acute inflammation
62383126|NCT06135558||T4|patient staged T4 without marginal acute inflammation
62383127|NCT04852484|ACTIVE_COMPARATOR|local anesthetic and morphine group|paravertebral block with local anesthetic and morphine, followed by a continuous infusion of local anesthetic and morphine in the paravertebral space
62383128|NCT04852484|ACTIVE_COMPARATOR|local anesthetic and ketamine group|paravertebral block with local anesthetic and ketamine, followed by a continuous infusion of local anesthetic and ketamine in the paravertebral space
62383129|NCT04852484|ACTIVE_COMPARATOR|local anesthetic group|paravertebral block with local anesthetic only, followed by a continuous infusion of local anesthetic only in the paravertebral space
62383130|NCT05453929|EXPERIMENTAL|Deep NMB|A TOF count of 0, and a PTC of 1 to 3 will be maintained, as close to 2 twitches as possible
62383131|NCT05453929|ACTIVE_COMPARATOR|Moderate NMB|A TOF count of 1 to 3 will be maintained, as close to 2 twitches as possible
62383132|NCT00923806|EXPERIMENTAL|Gene Therapy Treatment|
62763722|NCT03149952|OTHER|Patient hospitalized for allogeneic haematopoietic stem cells|
61988393|NCT02574247|EXPERIMENTAL|Training|Participants in the Training arm will undergo 15 hours of computerized auditory training across 10 laboratory visits. Medial olivocochlear reflex function and speech perception abilities will be measured before, during, and after the training visits to examine the changes in the measurements across time.
62383133|NCT02624024||Acute chest pain or equivalent ischemic symptoms|acute chest pain or equivalent ischemic symptoms suggestive of acute coronary syndromes (ACS) or acute myocardial infarction (MI)
62383134|NCT03312075||cystic fibrosis patients|Sputum and blood samples
62383135|NCT00528814|EXPERIMENTAL|Two Step Hand-Hygiene|Hand washing plus hand sanitizer
62383136|NCT00528814|NO_INTERVENTION|Usual Care Hand Hygiene|
62383137|NCT04772287|EXPERIMENTAL|Toripalimab|
62383138|NCT04772287|PLACEBO_COMPARATOR|Placebo|
62383139|NCT06000462|EXPERIMENTAL|Dapagliflozin arm|10 mg strength will be used in this study. The drug is usually taken orally once a day, preferably in the morning. The participants will be using the medication for 32 weeks only, then continue follow up for another 16 weeks (off drug therapy) with behavior weight management program only. The patients will be informed from the beginning of the study with the general side effects of medication (patient information sheet) that should be reported if experienced.
61988394|NCT02574247|NO_INTERVENTION|Control|Participants in the Control arm will undergo the same number of visits as the Training arm, but will not participate in computerized auditory training. Medial olivocochlear reflex function and speech perception abilities will be measured at each visit to establish the test-retest reliability of these measurements in the absence of any training.
62763723|NCT04332614||Control|A standard marketing message encouraging activation and describing the benefits of myGeisinger
61988395|NCT02574247|NO_INTERVENTION|Speech Group|Participants in the Speech Group will undergo 1 visit. Medial olivocochlear reflex function and speech perception abilities will be measured at this visit to establish the correlation between these measures in the absence of any training.
61988396|NCT01420289|EXPERIMENTAL|HPIPC|High Pressure Intermittent Pneumatic compression (HPIPC)to be performed for 45 minutes twice daily
61988397|NCT01420289|ACTIVE_COMPARATOR|Excercise|Walking on a graded treadmill for 45 minutes once daily
61988398|NCT03134755||Study cohort (all children with asthma)|300 children with asthma will receive the same inhaled corticosteroid (ICS) for six weeks, in order to assess response to ICS.Bronchodilator response will be measured before and after ICS therapy. Stress levels (the exposure of interest) will be assessed with a validated questionnaire, before ICS administration (thus, it is an observational study of whether stress is related to treatment response)
61988399|NCT03812055||LSD|Subjects diagnosed or suspected to have any of the following lysosomal storage diseases: Gaucher disease, Fabry disease, Pompe disease, Mucopolysaccharidoses.
61988400|NCT03812055||Control|Subjects with no known lysosomal storage disorder
61988401|NCT02121483|EXPERIMENTAL|empagliflozin high dose|Patient to receive a high dose of empagliflozin
61988402|NCT02121483|EXPERIMENTAL|empagliflozin medium dose|Patient to receive a medium dose of empagliflozin
61988403|NCT02121483|EXPERIMENTAL|empagliflozin low dose|Patient to receive a low dose of empagliflozin
61988404|NCT00973024|EXPERIMENTAL|JNJ-42160443 1 mg|
61988405|NCT00973024|EXPERIMENTAL|JNJ-42160443 3 mg|
62383140|NCT06000462|ACTIVE_COMPARATOR|Metformin arm|1000 mg strength will be used once daily dose. Medication will be provided randomly to the patient according to the corresponding number. The patients are informed to declare any experienced side effects that has been stated in the patient information sheet without informing the name of drugs.
61988406|NCT00973024|EXPERIMENTAL|JNJ-42160443 6 mg/3mg|
62383141|NCT06000462|PLACEBO_COMPARATOR|Placebo arm|receive a harmless substance or treatment that has no therapeutic effect, once daily.
62383142|NCT03287830|EXPERIMENTAL|Intervention|Text message influenza vaccine reminders
62383143|NCT03287830|NO_INTERVENTION|Usual care|"Season 2017-18: Usual care has no text message~Season 2018-19: Usual care includes on text message with a link to American Academy of Pediatrics parenting information page. The purpose is to provide those randomized to usual care with tangible benefit that is not related to the study."
62763724|NCT04332614||Focused on provider communication|A simple message focused on one benefit of myGeisinger: communicating easily with providers
61988407|NCT00973024|EXPERIMENTAL|JNJ-42160443 10 mg|
61988408|NCT05481567||Stage III|Patients diagnosed with periodontitis stage III
62763725|NCT04332614||Focused on scheduling|A simple message focused on one benefit of myGeisinger: scheduling and managing appointments online
62763726|NCT04332614||Focused on medical information access|A simple message focused on one benefit of myGeisinger: accessing medical information, like test results
62763727|NCT04332614||Social proof|A message similar to control, but including information about how many other patients are using myGeisinger
61988409|NCT05481567||Stage IV|Patients diagnosed with periodontitis stage IV
61988410|NCT00119392|EXPERIMENTAL|Treatment (90Y ibritumomab tiuxetan, hematopoietic transplant)|See Detailed Description
61988411|NCT03171987|EXPERIMENTAL|Lidocaine patch|Lidocaine patch local application 1 piece per day for 28 days at back pain area.
61988412|NCT03171987|ACTIVE_COMPARATOR|Flurbiprofen patch|Flurbiprofen patch local application 1 piece per day for 28 days at back pain area.
61988413|NCT06127459|EXPERIMENTAL|Parental Guidance+Virtual Reality Game|
61988414|NCT06127459|NO_INTERVENTION|Control Group|This group implement the rehabilitation plan drawn up in specialized medical care (treatment as usual).
61988415|NCT03989440|EXPERIMENTAL|AXER-204|Part 1 - Single ascending doses; Part 2 - Repeated dose
61988416|NCT03989440|PLACEBO_COMPARATOR|Placebo|Part 2 only - Repeated dose
61988417|NCT00911677||Open Aortic Repair|Patients 60 years of age and older undergoing open repair of the abdominal aorta
61988418|NCT01085799|EXPERIMENTAL|Health Education Intervention|Groups of schools receiving the health education intervention
61988419|NCT01085799|NO_INTERVENTION|Control Schools - Regular curriculum|Groups of schools not receiving the health education intervention
61988420|NCT04307446|EXPERIMENTAL|10 Minutes/20 Minutes|Subject takes part in 10 minute VR experience first and 20 minute VR experience second
61988421|NCT04307446|EXPERIMENTAL|20 Minutes/10 Minutes|Subject takes part in 20 minute VR experience first and 10 minute VR experience second
61988422|NCT02690610|EXPERIMENTAL|Patients with mediastinal lesions|EBUS TBNA of mediastinal lesions or lymph nodes
61988423|NCT04460820|EXPERIMENTAL|Doxorubicin Hydrochloride Liposome Injection|50mg/m2 ,IV on Day 1 of each cycle
61988424|NCT04460820|ACTIVE_COMPARATOR|Doxorubicin Hydrochloride Liposome Injection(Caelyx®)|50mg/m2 ,IV on Day 1 of each cycle
61988425|NCT03892356||Concussion Group|Participants (age group 18-60) who presents to the emergency department in the University Health Network within 7 days of concussion
61988426|NCT03892356||Healthy Controls Group|Participants (age group 18-60) with no previous history of concussions who are age, education and sex-matched to the patients' group will be recruited from the community.
61988427|NCT03323346|EXPERIMENTAL|Disulfiram with copper|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed. Patients will take disulfiram after their evening meal.~Patients will avoid alcohol and other disulfiram-drug interactions will be considered.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
62383144|NCT01266876|PLACEBO_COMPARATOR|Placebo|Placebo SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
62763728|NCT04332614||Endowment / decision staging|"A message similar to control, but framing myGeisinger as something that patients already have, and just need to take one more step to activate.~Endowment: Give patients the impression they already have the account, so they value it more.~Decision staging: Break down the process into multiple stages - having an account and activating that account- and giving the impression that they are almost there because the first stage is complete"
61988428|NCT02206828||1 GROUP|Only 1 group not predetermined
62383145|NCT01266876|EXPERIMENTAL|Alirocumab 150 mg Q4W|Alirocumab 150 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
62383146|NCT01266876|EXPERIMENTAL|Alirocumab 200 mg Q4W|Alirocumab 200 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
62383147|NCT01266876|EXPERIMENTAL|Alirocumab 300 mg Q4W|Alirocumab 300 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
62383148|NCT01266876|EXPERIMENTAL|Alirocumab 150 mg Q2W|Alirocumab 150 mg SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
61988429|NCT02168010|EXPERIMENTAL|Experiment|Test Drug Group: 2 times a day; 4 tablets per time (2 tablets of Analgecine and 2 tab. of placebo)
61988430|NCT02168010|ACTIVE_COMPARATOR|PosCtrl|PosCtrl: Positive Control Group. 2 times a day; 4 tablets / time (2 tab. of Neurotropin and 2 placebo tablets).
61988431|NCT02168010|PLACEBO_COMPARATOR|Placebo|Placebo Group: 2 times a day; 4 tablets / time (4 placebo tablets).
61988432|NCT06362434|EXPERIMENTAL|Intervention - No Intervention|8-week audiovisual stimulation followed by 8-week no intervention
61988433|NCT06362434|NO_INTERVENTION|No Intervention - Intervention|8-week no intervention followed by 8-week audiovisual stimulation
61988434|NCT01073852|PLACEBO_COMPARATOR|Placebo|Patients will be taking placebo medication throughout study.
61988435|NCT01073852|ACTIVE_COMPARATOR|Hydroxychloroquine|Patients will be taking hydroxychloroquine throughout study.
61988436|NCT03560531|EXPERIMENTAL|ZN-c5 monotherapy|Dose escalation cohorts are planned to determine maximum tolerated dose(MTD) or recommended phase 2 dose (RP2D) of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.
62763729|NCT04184128||Detrusor underactivity|The DU was defined when the PdetQmax was less than 20 cmH2O, the Qmax was less than 15 mL/s, and the bladder voiding efficiency (BVE) was less than 90 %. BVE = voided volume / (voided volume+ PVR) x 100%.
62763730|NCT04184128||Bladder outlet obstruction|The BOO was defined when the PdetQmax was not less than 40 cmH2O, and the Qmax was less than 12 mL/s.
62763731|NCT04184128||Non-DU/BOO group|Those women without DU or BOO were allocated to the non-DU/BOO group.
62763732|NCT03454867|EXPERIMENTAL|Hemofiltration (treatment)|Standard acute ischemic stroke treatment + hemofiltration Standard treatment included thrombolytic therapy for eligible candidates (tPA 0,9 mg/kg, max dose 90 mg)
62763733|NCT03454867|ACTIVE_COMPARATOR|Control|Standard acute ischemic stroke treatment Standard treatment included thrombolytic therapy for eligible candidates (tPA 0,9 mg/kg, max dose 90 mg)
62763734|NCT03132519|EXPERIMENTAL|Sevo-2.0|This group will maintain remifentanil infusion by TCI to 2 ng/ml during emergence and extubation after have received sevoflurane during procedure.
62763735|NCT03132519|EXPERIMENTAL|Sevo-2.5|This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.
62763736|NCT03132519|EXPERIMENTAL|Des-2.0|This group will maintain the remifentanil infusion by TCI to 2.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
62763737|NCT03132519|EXPERIMENTAL|Des-2.5|This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
62763738|NCT03132519|ACTIVE_COMPARATOR|Sevo-Control|This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.
62763739|NCT03132519|ACTIVE_COMPARATOR|Des-Control|This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
62763740|NCT05118815|ACTIVE_COMPARATOR|Conventional straight esthetic abutment|After implant surgery, 30 patients will have a 3 mm high conventional straight esthetic abutment placed. The implant placement will follow the manufacturer's instructions and the operator's expertise to achieve stability with an insertion torque of at least 40 N, recording the final torque with a calibrated torque wrench. The implant will be placed whenever bone and gingival availability allows it, juxta-osseous to avoid collateral damage in the peri-implant perimetral soft tissue excision (donut). The abutment will be placed at 30 N as indicated by the manufacturer. After removal of the donut, a new abutment will be placed and left in place up to 3 months to allow healing and complete osseointegration. Patients will receive prosthodontic loading following standard metal-ceramic rehabilitation protocols and the manufacturer's recommendation. The prosthesis will be screw-retained, on the abutment placed after excision of the donut, screwed at 25 N.
62763741|NCT05118815|EXPERIMENTAL|Slim (New Slim) transepithelial abutment|After surgery, 30 patients will have a 3 mm high transepithelial New Slim abutment placed. The implant placement will follow the manufacturer's instructions and the operator's expertise to achieve stability with an insertion torque of at least 40 N, recording the final torque with a calibrated torque wrench. The implant will be placed whenever bone and gingival availability allows it, juxta-osseous to avoid collateral damage in the peri-implant perimetral soft tissue excision (donut). The abutment will be placed at 30 N as indicated by the manufacturer. After removal of the donut, a new abutment will be placed and left in place up to 3 months to allow healing and complete osseointegration. Patients will receive prosthodontic loading following standard metal-ceramic rehabilitation protocols and the manufacturer's recommendation. The prosthesis will be screw-retained, on the abutment placed after excision of the donut, screwed at 25 N
62763742|NCT03825692|EXPERIMENTAL|Zhizhu Kuanzhong Capsule|Zhizhu Kuanzhong Capsule Arm is Zhizhu Kuanzhong Capsule, Specification: 0.43 g/granule; Manufacturer: Lonch Group, Shuangren Pharmaceutical Co., Ltd. ; Approval number: NMPA approval number: GUOYAOZHUNZI Z20020003; Dosage and administration: 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals
62763743|NCT03825692|PLACEBO_COMPARATOR|Zhizhu Kuanzhong Placebo Capsule|Zhizhu Kuanzhong Placebo Capsule Arm is Zhizhu Kuanzhong Capsule Mimics composed of microcrystalline cellulose, mannitol and magnesium stearate, which used for filling agent and lubricant respectively; Specification: 0.43 g/granule; Manufacturer: Lonch Group, Shuangren Pharmaceutical Co., Ltd.; Dosage and administration: Be identical with the investigational drug.
62763744|NCT01679015||Dry Eyes, Eye Allergies|Patients with ocular allergies and those with dry eyes.
62763745|NCT00784732|EXPERIMENTAL|1|
62763746|NCT00784732|EXPERIMENTAL|2|
62763747|NCT00784732|ACTIVE_COMPARATOR|3|
62383149|NCT02059174|EXPERIMENTAL|MK-1293 / EU-Lantus™ / MK-1293 / EU-Lantus™|MK-1293 or EU-Lantus™ 0.4 units/kg administered subcutaneously on Day 1 in 2 out of 4 study periods in a replicate crossover design with a minimum of 7 days between each treatment period
62383150|NCT02059174|EXPERIMENTAL|EU-Lantus™ / MK-1293 / EU-Lantus™ / MK-1293|MK-1293 or EU-Lantus™ 0.4 units/kg administered subcutaneously on Day 1 in 2 out of 4 study periods in a replicate crossover design with a minimum of 7 days between each treatment period
62383151|NCT05542472|NO_INTERVENTION|Control group|No intervention will perform on the caregivers in the control group. The patients will continue to receive care under public services.
62763748|NCT05997667|EXPERIMENTAL|experimental group|Subjects in this arm will receive stimulation of DBS system within 1 month after surgery.
61988437|NCT03560531|EXPERIMENTAL|ZN-c5 + palbociclib combination therapy|Dose escalation cohorts are planned to determine maximum tolerated dose(MTD) or recommended phase 2 dose (RP2D) of ZN-c5 in combination with palbociclib as well as a Phase 2 cohort.
62763749|NCT05997667|OTHER|control group|Subjects in this arm will receive stimulation of DBS system at 3 months after surgery.
62383152|NCT05542472|EXPERIMENTAL|Interventional group|"A Family Support Program Based on the Nurse-Led Case Management Model will create for the caregivers in the intervention group. The nurse-led case management model is made up of five basic nursing activities.~First Nursing Activity: Determining individuals who can benefit from the case management model Second Nursing Activity: Establishing individuals' problems and care needs Third Nursing Activity: Planning nursing activities to meet the determined needs Fourth Nursing Activity: Implementing nursing activities Fifth Nursing Activity: Regular review, monitoring and assessment of nursing activities"
62383153|NCT03181672|ACTIVE_COMPARATOR|Stellate ganglion block|Stellate ganglion block
62763750|NCT02754583|EXPERIMENTAL|WASH arm (WUHA)|"WUHA I, Behavioral: Water, sanitation, and hygiene (WASH) intervention: Communities will receive the water, sanitation, and hygiene (WASH) intervention including community water point construction, hygiene and sanitation education and promotion, community-based hygiene promotion workers, household wash stations, household WASH education books, household soap distribution, and a hygiene curriculum for primary schools.~WUHA II, Behavioral and Treatment: WASH intervention communities will continue to receive the water, sanitation, and hygiene (WASH) intervention.~A single mass azithromycin distribution will be given in all 40 WUHA I communities (both intervention and control) after the final study visit (i.e., month 36). Children 6 months and up will be offered azithromycin 20mg/kg; those under 6 months will be offered tetracycline."
62383154|NCT03181672|PLACEBO_COMPARATOR|control group|Deltoid muscle injection
62383155|NCT00928642|EXPERIMENTAL|Oral Imatinib plus intravenous gemcitabine|"All research subjects receive oral imatinib 400mg days 1-5 and 8-12 of a 21 day cycle.~All research subjects received IV gemcitabine 1000mg/m2 days 3 and 10 of a 21-day cycle. .~All subjects had epithelial ovarian cancer or primary peritoneal carcinomatosis and had failed to respond to prior chemotherapy or progressed after prior chemotherapy."
62383156|NCT05038111||Dex|Dexmedetomidine infusion during the perioperative period
62763751|NCT02754583|OTHER|Standard of care WASH arm (WUHA)|"WUHA I: Standard of care WASH intervention: Communities will continue to receive the standard of care WASH programming offered by the Ethiopian government.~WUHA II: Standard of care WASH intervention and treatment: Communities will continue to receive the standard of care WASH programming offered by the Ethiopian government.~A single mass azithromycin distribution will be given in all 40 WUHA I communities (both intervention and control) after the final study visit (i.e., month 36). Children 6 months and up will be offered azithromycin 20mg/kg; those under 6 months will be offered tetracycline.~These communities will receive a WASH package at the conclusion of the SWIFT II study, including water point construction, hygiene and sanitation promotion, and educational materials."
61988438|NCT03043625|EXPERIMENTAL|Visceral manipulation Group (VMG)|The VMG wil be treated with visceral manipulation to the stomach and liver
61988439|NCT03043625|PLACEBO_COMPARATOR|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
62383157|NCT05038111||Non-Dex|Did not have dexmedetomidine infusion during the perioperative period
62763752|NCT02754583|EXPERIMENTAL|Targeted antibiotics arm (TAITU)|Targeted antibiotic treatment: Communities will receive targeted antibiotic treatments for children testing positive for ocular chlamydia at 3, 6, 9, and 12 months after baseline testing. After testing for ocular chlamydia at 12 months, any children testing positive at this time point will receive antibiotic treatments at 15, 18, 21, and 24 months. Children 6 months and up will be offered azithromycin 20mg/kg; those under 6 months will be offered tetracycline.
62383158|NCT04025749|EXPERIMENTAL|Immediate intervention group|Thirty children with CP aged 8 to 12 years (or fifteen with neuroimage data) will participate in a computerized executive training program from home (12 weeks, 5 days a week, 30 min a day).
62383159|NCT04025749|OTHER|Wait-list delayed intervention|Thirty children with CP (or fifteen with neuroimage data) matched by age, sex, motor and cognitive impairment severity.
62383160|NCT06355024|EXPERIMENTAL|Inosine|oral inosine arm
62567624|NCT04557579||Monofocal group|Patients in monofocal group implanted with Sensar AR40e IOL (AMO, Santa Ana, CA, USA) in bilateral eyes
62567625|NCT01789112|EXPERIMENTAL|CCM aggregate|Taking of 10 blood samples
62567626|NCT05057130|EXPERIMENTAL|Three-component chemotherapy|Doxorubicin 25 mg / m2 IV on days 1-3, Cisplatin 120 mg / m2 IV on day 1 against the background of hyperhydration. G-CSF support from 4 to 13 days. Methotrexate 12 g / m2 at 28 and 35 days IV with leucovorin 60 mg / m2 in the first 5 days after each administration of methotrexate. The interval between cycles is 42 days
62763753|NCT02754583|OTHER|Delayed mass antibiotics arm (TAITU)|Delayed mass antibiotic treatment: Communities will receive no mass azithromycin treatment during the study period. Communities in this treatment group have previously received at least 8 rounds of mass azithromycin treatment. These clusters will be enrolled in an antibiotics treatment program (azithromycin or tetracycline) after the completion of the study.
62763754|NCT02754583|ACTIVE_COMPARATOR|Mass antibiotics arm (TAITU)|Mass antibiotic treatment: Communities will receive mass azithromycin treatment of all individuals aged 6 months and up (20mg/kg for children; 1 g for adults); those younger than 6 months, pregnant, or allergic to macrolide antibiotics will be offered a 2-week course of tetracycline.
62763755|NCT00996801|PLACEBO_COMPARATOR|Placebo|Participants received either matching placebo to alendronate (administered orally, once-weekly) or matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
62383161|NCT04465240|EXPERIMENTAL|Virtual reality simulation of neighborhood disadvantage|Participants will attend one study session. They will watch a video during a baseline rest period. Participants will be assigned to navigate and explore the virtual neighborhood representative of disadvantage they were assigned to. Then they will watch a video again during a recovery period.
62383162|NCT04465240|ACTIVE_COMPARATOR|Virtual reality simulation of neighborhood affluence|Participants will attend one study session. They will watch a video during a baseline rest period. Participants will be assigned to navigate and explore the virtual neighborhood, representative of affluence they were assigned to. Then they will watch a video again during a recovery period.
62383163|NCT04352049|ACTIVE_COMPARATOR|3TV group|Patients were randomly assigned to receive either three minutes tidal volume (3TV) with a fresh gas flow (FGF 100% O2) via facemask of 5 L/min
62383164|NCT04352049|ACTIVE_COMPARATOR|8DB group|Or eight vital capacity breaths for 1 minute with FGF of 10 L/min
62383165|NCT02943863|ACTIVE_COMPARATOR|HFNC first|"Patients in HFNC first receive oxygen therapy using HFNC in ahead of conventional nasal cannula oxygen therapy. After 20 minutes of HFNC therapy, patients receive conventional nasal cannula oxygen therapy."
62383166|NCT02943863|ACTIVE_COMPARATOR|LFS first|"Patients in LFS first receive oxygen therapy using conventional nasal cannula in ahead of HFNC therapy. After 20 minutes of conventional nasal cannula oxygen therapy, patients receive HFNC oxygen therapy."
62763756|NCT00996801|EXPERIMENTAL|MK-5442 5 mg|Participants received 5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
62763757|NCT00996801|EXPERIMENTAL|MK-5442 7.5 mg|Participants received 7.5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
62763758|NCT00996801|EXPERIMENTAL|MK-5442 10 mg|Participants received 10 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
62763759|NCT00996801|EXPERIMENTAL|MK-5442 15 mg|Participants received 15 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
62763760|NCT00996801|ACTIVE_COMPARATOR|Alendronate 70 mg|Participants received 70 mg alendronate (orally, once-weekly) plus matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
62763761|NCT00497237|EXPERIMENTAL|1|Foster
62763762|NCT00497237|ACTIVE_COMPARATOR|2|Seretide
62763763|NCT01406496|EXPERIMENTAL|Timing of insulin administration|
62383167|NCT05202106|NO_INTERVENTION|Control|Families in the control group will not receive any interventions and will simply complete baseline and endline surveys.
62383168|NCT05202106|EXPERIMENTAL|Home visits|Families in the home visiting arm will receive visits by trained child development agents every two weeks between enrollment and 2 years of age.
62383169|NCT05202106|EXPERIMENTAL|Afini|Families in the Afini arm will be introduced to the Afini app on Messenger and encouraged to use this platform throughout the study.
62383170|NCT00510406|PLACEBO_COMPARATOR|A|
62383171|NCT00510406|ACTIVE_COMPARATOR|B|
62383172|NCT00510406|ACTIVE_COMPARATOR|C|
62763764|NCT04220437||CAG and OCT group|Images of CAG and OCT patients obtained from ISR patients were retrospectively collected and analyzed.
62383173|NCT00510406|ACTIVE_COMPARATOR|D|
62383174|NCT00510406|ACTIVE_COMPARATOR|E|
62383175|NCT00510406|ACTIVE_COMPARATOR|F|
62383176|NCT00510406|ACTIVE_COMPARATOR|G|
62383177|NCT00510406|ACTIVE_COMPARATOR|H|
62383178|NCT01193361|EXPERIMENTAL|Arm 1 - BMS-791325 plus peg-interferon alfa-2a and ribavirin|
62383179|NCT01193361|EXPERIMENTAL|Arm 2 - BMS-791325 plus peg-interferon alfa-2a and ribavirin|
62383180|NCT01193361|PLACEBO_COMPARATOR|Arm 3 - Placebo plus peg-interferon alfa-2a and ribavirin|
62763765|NCT00892359|EXPERIMENTAL|Anidulafungin|
62763766|NCT04657640|EXPERIMENTAL|weekly iron and folic acid supplementation (IFA)|
62763767|NCT04657640|EXPERIMENTAL|daily multiple micronutrient supplement (MMS)|
62763768|NCT04657640|NO_INTERVENTION|control|
62383181|NCT01934166|EXPERIMENTAL|Nalmefene 18 mg|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
62383182|NCT02129192|EXPERIMENTAL|T80/A5/H12.5 mg FDC|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet
62383183|NCT02129192|ACTIVE_COMPARATOR|T80/H12.5 FDC + A5 mono|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet and Amlodipine 5 mg capsule
62763769|NCT01952990|EXPERIMENTAL|Kovacaine Mist|"Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - Total dose is based on weight. Subjects weighing 10 to \<20 kg will receive 1 intranasal spray of 100 μL. Subjects weighing 20 to \<40 kg will receive 2 intranasal sprays of 100 μL (total dose 200 μL.~Subjects weighing 40 kg or more will receive 2 intranasal sprays of 200 μL (total dose 400 μL)."
62763770|NCT06521437|EXPERIMENTAL|Experiment 1|Subjects will be tested for baseline performance on a memory task while in an MRI scanner and with scalp EEG. Subjects will then receive multiple sessions, of repetitive transcranial magnetic stimulation. Post-treatment, baseline assessments will be repeated. Overall study period per subject: 2 months
62383184|NCT01969227|EXPERIMENTAL|Cohort|Adult mechanically ventilated patients who are deemed eligible for a spontaneous breathing trial and are candidates to receive subanesthetic ketamine by the primary critical care team.
62383185|NCT01711333|EXPERIMENTAL|Pletaal SR capsule|
62383186|NCT06183060||difficult laryngoscopy group|Cormack-Lehane (C-L) scale: class III-IV
62383187|NCT06183060||easy laryngoscopy group|Cormack-Lehane (C-L) scale: class I-II
62383188|NCT01713569|ACTIVE_COMPARATOR|Subject 1|Ulthera treatment will be administered to both pre-auricular regions using a 4 MHz, 4.5mm depth transducer at 1.2 Joules and 30 Watts on the Left side versus 0.9 Joules and 30 Watts on the Right side.
62383189|NCT01713569|ACTIVE_COMPARATOR|Subject 2|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm depth transducer at 1.05 Joules and 25 Watts on the Left side versus 0.75 Joules and 25 Watts on the Right side.
62763771|NCT02017145|NO_INTERVENTION|no reapplication|This group will not have chloraprep reapplied after their surgery and prior to dressing application.
61988440|NCT01669447|EXPERIMENTAL|ranibizumab|"Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment."
61988441|NCT00564655|ACTIVE_COMPARATOR|1|Patients in the control group will receive localized infiltration of local anesthesia at the beginning of the procedure as is current standard practice.
61988442|NCT00564655|EXPERIMENTAL|2|Patients in the experimental group will receive a regional anesthetic blockade of the anterior abdominal wall via the transversus abdominis plane.
62383190|NCT01713569|ACTIVE_COMPARATOR|Subject 3|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm depth transducer at 0.45 Joules and 15 Watts on the Left side versus 0.35 Joules and 14 Watts on the Right side.
62383191|NCT01713569|ACTIVE_COMPARATOR|Subject 4|Ulthera treatment will be administered to both pre-auricular regions using a 10 MHz, 1.5mm depth transducer at 0.25 Joules and 5 Watts on the Left side versus 0.18 Joules and 5 Watts on the Right side.
62383192|NCT01713569|ACTIVE_COMPARATOR|Subject 5|Ulthera treatment will be administered to both pre-auricular regions using a 4 MHz, 4.5mm depth transducer at 0.9 Joules and 30 Watts on the Left side versus 7 MHz, 4.5mm 0.9 Joules and 25 Watts on the Right side.
62383193|NCT01713569|ACTIVE_COMPARATOR|Subject 6|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm transducer at 0.35 and 14 Watts, and a 4 MHz, 4.5mm depth transducer at 0.9 Joules and 30 Watts on the Left side versus a 7 MHz, 3.0mm depth and 4.5mm depth transducer at 2.0 Joules and 40 Watts on the Right side.
62383194|NCT03386864||Control|Control
62383195|NCT03386864||Insulin Resistant|Insulin Resistant
62383196|NCT03386864||Type 2 Diabetes|Type 2 Diabetes
62383197|NCT03098576||Matched|Matched targeted drug treatment
62383198|NCT03098576||Control|Unmatched standard of care
62383199|NCT03080506|EXPERIMENTAL|Binder|Each woman will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
62383200|NCT03080506|NO_INTERVENTION|No binder|The women will not be given a chance to wear abdominal binder or the likes.
62383201|NCT02454140|EXPERIMENTAL|Cohort 1|SBRT 40 Gy in 5 fractions
62383202|NCT02454140|EXPERIMENTAL|Cohort 2|SBRT 45 Gy in 5 fractions (starting dose level)
62567627|NCT05057130|ACTIVE_COMPARATOR|Two-component chemotherapy|Doxorubicin 25 mg / m2 IV on days 1-3, Cisplatin 120 mg / m2 IV on day 1 against the background of hyperhydration. G-CSF support from 4 to 13 days. The interval between cycles is 28 days
62763772|NCT02017145|EXPERIMENTAL|reapplication|This group will have chloraprep reapplied following their lower extremity surgical procedure and prior to dressing application.
62763773|NCT05107973|EXPERIMENTAL|intervention|in this arm of participants will be receiving the Baduajin intervention.
62763774|NCT05107973|NO_INTERVENTION|control|in this arm of participants will not receive any intervention
62763775|NCT02466113|EXPERIMENTAL|An experimental group|A 6 microRNA stratified tool is applied in this group.Investigators defined high risk patient and low risk patient according to the microRNA stratified tool.The high risk group should receive adjuvant chemotherapy while the low risk group observation.
62383203|NCT02454140|EXPERIMENTAL|Cohort 3|SBRT 50 Gy in 5 fractions
62383204|NCT02454140|EXPERIMENTAL|Cohort 4|SBRT 55 Gy in 5 fractions
62383205|NCT02454140|EXPERIMENTAL|Cohort 5|SBRT 60 Gy in 5 fractions
62383206|NCT01341574|EXPERIMENTAL|Early phase, experimental|Neglect patients, randomized in the experimental group (Prism adaptation, optical shift of 10 degrees) in the early phase after stroke.
62383207|NCT01341574|EXPERIMENTAL|Delayed phase, experimental|Neglect patients, randomized in the experimental group (Prism adaptation, optical shift of 10 degrees) in the delayed phase after stroke.
62383208|NCT01341574|PLACEBO_COMPARATOR|Early phase, placebo|Neglect patients, randomized in the placebo group (Prism adaptation, optical shift of 0 degrees) in the early phase after stroke.
62383209|NCT01341574|PLACEBO_COMPARATOR|Delayed phase, placebo|Neglect patients, randomized in the placebo group (Prism adaptation, optical shift of 0 degrees) in the delayed phase after stroke.
62383210|NCT01341574|EXPERIMENTAL|Delayed phase postural, experimental|Neglect patients, randomized in the experimental group (Prism adaptation, optical shift of 10 degrees) in the delayed phase after stroke. In this group, postural aspects are taken into account.
62383211|NCT05422027|EXPERIMENTAL|Selinexor-VRd（XVRd）|bortezomib SC 1.3mg/sqm on day 1,4,8,11, lenalidomide oral 25 mg on day 1-14, and dexamethasone 40mg on day 1,8,15 in a 21-day cycle; Selinexor dose escalation: 40，60mg respectively on day 1,8,15 for 21-days cycles. Then Selinexor will be given at the recommended dose level on phase II.
62383212|NCT01476033|ACTIVE_COMPARATOR|fruit, berry and vegetable concentrate|20 ladies receive an encapsulated, powdered fruit, berry and vegetable concentrate for 8 weeks
62383213|NCT01476033|PLACEBO_COMPARATOR|20 women with placebo|placebo for 8 weeks
62383214|NCT04337879|EXPERIMENTAL|AL2846 + mFOLFOX6|AL2846 capsule administered orally,once daily in 28-day cycle; oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle；calcium folate 400mg/ ㎡ IV on day 1, day 15 in 28-day cycle；5-fu 2800mg/ ㎡ IV on day 1, 2, 15, 16 in 28-day cycle.
62383215|NCT04337879|EXPERIMENTAL|AL2846 + FOLFIRI|AL2846 capsule administered orally,once daily in 28-day cycle; irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle; calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle; 5-fu 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.
61988443|NCT01184547|EXPERIMENTAL|COMBEX|Community Based Exercise Program or exercise group and quality of life Intervention- The community-based exercise program consisted of 12 weeks of exercise with a community-based trainer after hospital discharge.
61988444|NCT01184547|ACTIVE_COMPARATOR|Standard Of Care|Standard of Care group, group with no exercise and quality of life. Intervention- No exercise training received.
61988445|NCT00988754|ACTIVE_COMPARATOR|A|Medical examination once per year, school and family-based lifestyle intervention including a weekly health lesson, school-affiliation to sports clubs and regularly trainings for teachers and parents
61988446|NCT00988754|NO_INTERVENTION|B|Medical examination and information on a healthy lifestyle.
61988447|NCT00584558||1|Patients undergoing catheter ablation.
61988448|NCT02226003|EXPERIMENTAL|Ertugliflozin 5 mg and Sitagliptin 100 mg|Ertugliflozin, 5 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks. Placebo to ertugliflozin, 10 mg, administered orally, once daily for 26 weeks.
61988449|NCT02226003|EXPERIMENTAL|Ertugliflozin 15 mg and Sitagliptin 100 mg|Ertugliflozin, 15 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
61988450|NCT02226003|PLACEBO_COMPARATOR|Placebo to Ertugliflozin and Placebo to Sitagliptin|Placebo to ertugliflozin, 5 mg and 10 mg, administered orally, once daily for 26 weeks. Placebo to sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
61988451|NCT03895983||Thrombus aspiration group|Will include 135 patients who will have PPCI with thrombus aspiration
61988452|NCT03895983||Standard PPCI group|Will include 135 patients who will have PPCI without thrombus aspiration
62383216|NCT05499091|EXPERIMENTAL|Study Arm|"Specific interventions:~Blood samples, skin biopsy, urine collection or operational waste qualified as research sample."
62763776|NCT02466113|OTHER|A control group|A classic stratified tool is applied in this group. Investigators defined high risk and low risk patient according to classical pathological features.The high risk group should receive adjuvant chemotherapy while the low risk group observation.
61988453|NCT02959047|EXPERIMENTAL|Alirocumab|Alirocumab 150mg SQ every 2 weeks
61988454|NCT02959047|PLACEBO_COMPARATOR|Placebo|Matched placebo
61988455|NCT00791518||No group|No group
61988456|NCT00109395|ACTIVE_COMPARATOR|Lorazepam Intermittent bolus|lorazepam administered by intermittent bolus
61988457|NCT00109395|ACTIVE_COMPARATOR|lorazepam continuous infusion|lorazepam administered by continuous infusion
61988458|NCT00109395|ACTIVE_COMPARATOR|midazolam continous infusion|midazolam administered by continous infusion
61988459|NCT03395912|EXPERIMENTAL|Intervention|Infiltration of the subcutaneous layer with local anesthetic and combined with adrenaline.
61988460|NCT03395912|NO_INTERVENTION|control|Abdominal layers will be closed without Infiltration .
62383217|NCT06335589|EXPERIMENTAL|EBP-Massed|PTSD evidence-based psychotherapies are delivered in a massed format (e.g., intended be delivered at least three times per week).
62383218|NCT06335589|ACTIVE_COMPARATOR|EBP-TAU|PTSD evidence-based psychotherapies are delivered treatment as usual, which is typically once per week.
62763777|NCT02446470|EXPERIMENTAL|Sinus Tarsi approach|The Sinus Tarsi approach is the surgical approach for the incision.
62763778|NCT02446470|ACTIVE_COMPARATOR|Extensile Lateral approach|The Extensile Lateral approach is the surgical approach for the incision.
62763779|NCT05595018||End user|A Delphi study will be conducted with two rounds to reach consensus
62763780|NCT05595018||Demand side management|A Delphi study will be conducted with two rounds to reach consensus
62763781|NCT05595018||Supply side|A Delphi study will be conducted with two rounds to reach consensus
62763782|NCT05595018||Funder|A Delphi study will be conducted with two rounds to reach consensus
62763783|NCT05595018||Academia|A Delphi study will be conducted with two rounds to reach consensus
62383219|NCT04706715|EXPERIMENTAL|Dose finding cohort|In part A of this imaging trial, a dose finding study will be performed to establish safety, to assess the appropriate protein dose for PET-scanning and to assess the appropriate PET scanning interval. After completion of imaging, patients will start treatment with cemiplimab with or without platinum-based chemotherapy.
62383220|NCT04706715|EXPERIMENTAL|Feasibility cohort|The purpose of part B of the study is to analyze the PK of 89Zr-DFO-REGN3767 in patients before and during treatment with cemiplimab with or without platinum-based chemotherapy.
62763784|NCT05748704|EXPERIMENTAL|Short-term modified fasting|The STMF regimen consists of a low-calorie diet lasting five days and aimed at providing between 800 and 1,000 kcal/day (tentatively 10% carbohydrates, 15% proteins, 75% lipids).
61988461|NCT05398432|EXPERIMENTAL|control|The control group did not intervene
62383221|NCT04164264|EXPERIMENTAL|Intravenous Propofol Infusion|Quantification of the dose of propofol required to produce loss of consciousness and apnea.
62383222|NCT01038635|EXPERIMENTAL|5-Azacytidine + Lenalidomide|5-Azacytidine 75 mg/m\^2 by vein daily x 5 days on days 1 to 5. Lenalidomide starting dose 10 mg orally daily x 5 days on days 6 to 10.
62383223|NCT04343027|NO_INTERVENTION|Standard of care group|Participants who did not have their physicians review their patient-reported outcome measurements with them during the office visit.
62383224|NCT04343027|EXPERIMENTAL|Consultation group|Participants who had their physicians review their patient-reported outcome measurements reviewed with them during the office visit.
62383225|NCT03475355|EXPERIMENTAL|EG1|Each patient will be instructed to carefully observe the finalized movement of the upper limb of an experimenter seated in front (the experimenter's left hand is right in front of the patient's right hand), without moving or imagining the movement.
62383226|NCT03475355|EXPERIMENTAL|EG2|Each patient will be instructed to look at a computer screen that is in front of him that will show a daily routine task (actions).
62383227|NCT03475355|EXPERIMENTAL|EG3|Each patient will be instructed to carefully observe the finalized movement performed by an experimenter standing in front of him (the examiner's left leg will be in front of the patient's right leg).
62383228|NCT03475355|EXPERIMENTAL|EG4|Each patient will be instructed to look at a computer screen that is in front of him that will show a daily routine task (actions).
62383229|NCT03475355|ACTIVE_COMPARATOR|CG1|"Participants will be shown for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. For each CGail patient condition a sequence of images will be presented for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, will be displayed together with an intrusive image (intruder) that the patient will be asked to identify so that his attention span can be controlled in real time. Participants will then be invited to perform movements of the limbs as far as possible for 2 minutes according to a standard sequence that involves articular mobilizations of upper limbs and simulates that performed by the experimental groups."
62567628|NCT01783990||Active|Complete blood counts (CBCs), reticulocytes, differential, lactate dehydrogenase (LDH), bilirubin and alanine transaminases (ALTs), cystatin C, blood urea nitrogen (BUN), Creatinine, fetal hemoglobin (HbF), pit counts, Howell Jolly Body (HJB), and urine microalbumin:creatinine ratio were collected at study entry, annually, and exit to Follow-Up Study II. Variable-diversity-joining (VDJ) and a stored blood sample were collected at study entry and study exit. Additional tests that include liver/spleen scan, abdominal sonogram, pulmonary function testing, magnetic resonance imaging (MRI) / magnetic resonance angiography (MRA), cardiac echocardiogram, or neuropsychology testing were collected once during the study when the child was 10 years old.
62763785|NCT04757948|EXPERIMENTAL|Acupuncture|Sterile needles are inserted into acupuncture points P-6 and St-36 bilaterally and retained for a total of 20 minutes. Halfway through the treatment, the needles are manipulated in order to re-create the acupuncture sensation. The needles are removed after 20 minutes of treatment prior to the second gag measurement.
62763786|NCT04757948|EXPERIMENTAL|TENS|Gel pads are affixed to the acupuncture points P-6 and St-36, bilaterally. The amplitude of the TENS device will be gradually increased up to a maximum setting of 8/10, with the subject asked to notify the examiner as soon as any sensation is noticed. Once a gentle buzzing sensation is noticed, the amplitude will be reduced slightly for comfort and then the device will remain for the duration of 20 minutes. The pads are then removed prior to the second gag reflex measurement.
61988462|NCT05398432|EXPERIMENTAL|experiment|"Initial data were collected after meeting the patients. Then, a total of 6 seans, 1 seans per week, were performed on the patients. Self-care training was given in the 1st, 2nd and 3rd seans. Motivational interviews were conducted in the 4th, 5th and 6th seans. After the first seans of the self-care supported motivational interview, the Self Care and Adaptation Training Guide prepared by the researcher in line with the literature was given to the experimental group. Second data were collected from patients after 6 weeks. Follow-up data were collected for 4 weeks without any intervention."
62763787|NCT04757948|PLACEBO_COMPARATOR|Sham-TENS|For the sham-TENS group, the protocol is identical to the TENS group, however the electrical wires have been severed and re-attached in the control unit. As such, the unit will flash a light but there will be no current delivered. The subject is told that no sensation is required. The amplitude will be turned up to a maximum setting of 8/10 and left there for 20 minutes, then the device turned off and pads removed.
62763788|NCT00287937|EXPERIMENTAL|Treatment (vorinostat, paclitaxel, carboplatin)|Patients receive oral SAHA once or twice daily on days 1-14\* and paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have stable disease after the completion of 6 courses may receive single-agent SAHA at the discretion of the treating physician.
62763789|NCT01356342|EXPERIMENTAL|AdimFlu-S 2010-2011, 6 months~<3 years|
62763790|NCT01356342|EXPERIMENTAL|AdimFlu-S 2010-2011,3~<9 years|
62763791|NCT01356342|EXPERIMENTAL|AdimFlu-S 2010-2011,9~<18 years|
62763792|NCT00857948|EXPERIMENTAL|0.15% ivermectin|Participant on 0.15% ivermectin treatment conditioner
62763793|NCT00857948|EXPERIMENTAL|0.25% ivermectin|Participants on 0.25% ivermectin treatment conditioner
62763794|NCT00857948|EXPERIMENTAL|0.50% ivermectin|Participants on 0.50% ivermectin treatment conditioner
62763795|NCT00857948|PLACEBO_COMPARATOR|Placebo|participants on Placebo (Vehicle control)
62763796|NCT03399357||≥ 65 Years old|Healthy community-dwelling elderly (men and women) age 65 and above who are eligible for influenza vaccine and fulfil inclusion and exclusion criteria
62763797|NCT00524589|EXPERIMENTAL|Dexamethasone and Calcitriol|Patients receive oral dexamethasone once on days 1 and 2 and calcitriol IV over 1 hour on day 2. Treatment repeats weekly.
62763798|NCT03627169||MATRx plus/PSG group|Healthy individuals, individuals suspected of having OSA, and individuals with a previous diagnosis of OSA will spend a single night in a sleep laboratory and undergo a standard polysomnogram simultaneously with a Level III sleep study using the MATRx plus device. There is no interventional aspect to the study.
62763799|NCT00366028|OTHER|Organizational Model|Organizational Model: Participants in this arm of the study will receive information regarding the organizational model and work closely with the research team throughout the project to implement various aspects of the model. Participants in this arm of the study will be interviewed and participate in the data feedback portion of the study as well.
61988463|NCT06252220|ACTIVE_COMPARATOR|Part 1 - Single Ascending Dose|Single doses of DA-1726 in adult participants (aged 18 to 65 years) with obesity (BMI ≥30 - 45 kg/m2). DA-1726 will be administered via subcutaneous (SC) injection within the clinic setting.
62763800|NCT00366028|OTHER|Data Feedback|Data Feedback Only: Participants in this arm will be interviewed periodically and participate in the data feedback portion of the study.
62763801|NCT05709925|OTHER|Group A|Group A will be receiving moist heat for 10 minutes followed by myofascial release through stripping technique to the lumbar region. After that post-treatment stretching would be performed. Total treatment plan would be of 30 minutes, comprising of total 9 sessions (3 weeks), 3 sessions on alternate days
61988464|NCT06252220|PLACEBO_COMPARATOR|Part 2 - Multiple Ascending Dose|Multiple doses of DA-1726 in adult participants (aged 18 to 65 years) with obesity (BMI ≥30 - 45 kg/m2). DA-1726 will be administered via subcutaneous (SC) injection within the clinic setting.
62763802|NCT05709925|EXPERIMENTAL|Group B|Group B will be receiving moist heat for 10 minutes followed by Instrument Assisted Soft Tissue Mobilization using long bar tool for 5-7 minutes with gentle horizontal stroking at an angle of 45 degrees. After that, post treatment stretching consisting of 2-3 sets of 10 repetitions of the targeted muscle group will be performed.Total treatment plan will be of 3 weeks comprising of total 9 sessions, 3 sessions on alternate days.
62763803|NCT05528367|EXPERIMENTAL|CRT with Tirelizumab|"Chemotherapy+Tirelizumab:PS regimen:S-1:BSA \<=1.25 m2 ,80 mg daily; 1.25 m2 \<BSA \<1.5 m2,100 mg daily; BSA\>=1.5 m2 ,120 mg daily.~Nab-PTX:preoperation：130mg/m2,d1，8，q3w；adjuvant:100mg/m2,d1，8，q3w； Tirelizumab：200mg d1 q3w.~Concurrent Chemoradiotherapy:~Radiation: 45-50Gy/25Fx;During radiation: Nab-PTX:100mg qw,Tirelizumab：200mg d1 q3w.~Chemotherapy+Tirelizumab:PS regimen:S-1:BSA \<=1.25 m2 ,80 mg daily; 1.25 m2 \<BSA \<1.5 m2,100 mg daily; BSA\>=1.5 m2 ,120 mg daily.~Nab-PTX:preoperation：130mg/m2,d1，8，q3w； Tirelizumab：200mg d1 q3w.~We will evaluate whether the tumor could be resectable through CT scan and Endoscope after two cycles of Chemotherapy+Tirelizumab and CRT.If it could be resctable,three cycles of adjuvant chemotherapy+Tirelizumab will be arranged;If not,another three cycles of chemotherapy+Tirelizumab will be arranged，then evaluate again."
62763804|NCT03919513|EXPERIMENTAL|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, combined CPAP and inspiratory pressure threshold device and continue oxygen therapy randomly.
62763805|NCT03919513|EXPERIMENTAL|normal respiratory muscle|Patients with normal respiratory muscle are performing the inspiratory pressure threshold device, combined CPAP and inspiratory pressure threshold device and continue oxygen therapy randomly.
62763806|NCT04299763|EXPERIMENTAL|Beta-Glucan (BETA)|experimental group, received a supplement of oats beta-glucan (5 g) for 12 weeks.
61988465|NCT01193569||Standard of Care|Standard of Care for stroke except mechanical therapy
61988466|NCT00491387|EXPERIMENTAL|metoprolol succinate|Subjects will undergo I-123 MIBG testing before and after sustained-release beta-adrenergic blockade.
62763807|NCT04299763|PLACEBO_COMPARATOR|Control (CN)|placebo group, received a supplement of cellulose microcrystalline (5g) for 12 weeks.
62763808|NCT06299722|EXPERIMENTAL|STEEL|STEEL strength training will consist of progressive periodised training, in which the intensity is set to fit the individual's starting level and then gradually increases. During Week 1 to Week 5, the relative load will correspond to a 12-repetition maximum (RM). During Week 5 to Week 10, the relative load will be 10 RM, and during Week 11 to Week 16, the relative load will be 8 RM. The exercises will mostly consist of compound movements that activate the large muscle groups of the legs, back, arms and torso.
61988467|NCT01470742|ACTIVE_COMPARATOR|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
61988468|NCT01470742|EXPERIMENTAL|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
61988469|NCT03011255|EXPERIMENTAL|peptide specific CTL arm|peptide specific CTL, radiation
61988470|NCT01425554|NO_INTERVENTION|Diagnostic study|
61988471|NCT00735774|EXPERIMENTAL|11C-ORM-13070|
61988472|NCT05083793|EXPERIMENTAL|Study group|patients have spine surgery receive oral pregabalin 150 mg 1 hour before surgery
61988473|NCT05083793|PLACEBO_COMPARATOR|Placebo group|patients will receive placebo 1 hour before surgery with a sip of water.
61988474|NCT06036420|EXPERIMENTAL|1) Flashed Light Therapy, 2) Flashed Light Therapy with Cognitive Behavioral Therapy|"Treatment Phase 1 (2 weeks duration): light flashes administered for 60 minutes daily beginning 75 minutes prior to the participant's average morning wake time and ending 15 minutes before average morning wake time.~Treatment Phase 2 (4 weeks duration): will begin immediately following phase 1 and involve daily light flashes (as described above) combined with weekly 50-minute videoconference-delivered cognitive-behavioral therapy."
61988475|NCT04954963||conventional examination|patients undergo conventional examination
61988476|NCT04954963||Reduce metal artifacts examination|patients undergo reduce metal artifacts examination
61988477|NCT00460031|EXPERIMENTAL|Ketoconazole Plus Lenalidomide|
61988478|NCT01907503|OTHER|Patients with Primary hip osteoarthritis|Patients with Primary hip osteoarthritis
61988479|NCT01907503|OTHER|Healthy volunteer|Healthy volunteer
61988480|NCT00725218|PLACEBO_COMPARATOR|1|Saline 5 ml injection 10 min prior to propofol administration.
61988481|NCT00725218|EXPERIMENTAL|2|Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
61988482|NCT05315518|EXPERIMENTAL|single shade universal resin composite (omnichroma) with blocker|(OMNICHROMA BLOCKER) is indicated for preventing shade-matching interference in Class IV restorations, Masking dark dentition and dentin. In cases where there is a lack of tooth structure to bond to, (BLOCKER) works as a supplementary product to provide a lingual wall to the restoration, prevent shade-match obstruction and mask staining.
61988483|NCT05315518|ACTIVE_COMPARATOR|single shade universal resin composite(GC solare sculpt) with chameleon effect|One-shade universal resin composite (GC solare sculpt) gives very natural appearance, High gloss retention over time, time saving regarding to layering technique, wide shade matching range (chameleon effect) and delivering lifelike aesthetic restorations. These features can be offered by supra-nano spherical filler which have controlled refractive index, records excellent esthetic properties in small and medium class IV restorations.
61988484|NCT03160742||Non-invasive monitoring|In addition to standard monitoring, the Mespere VENUS 200CVP system will be used to record central venous pressures.
61988485|NCT05109507|EXPERIMENTAL|Visitor Mindset|Single-session, self-guided web-based intervention (\~30 to 45 minutes) hosted on Qualtrics with animated videos, audio-guided exercises, graphics, text-based material, and interactive questions. The intervention is designed to enhance emotional awareness, clarity, and acceptance, as well as modify beliefs about the duration and usefulness of negative emotions.
61988486|NCT05109507|ACTIVE_COMPARATOR|Relaxing with Nature|Single-session self-guided web-based intervention (\~30 to 45 minutes) hosted on Qualtrics with videos (real-life images), text-based material, and questions. There are five videos showing different types of nature (e.g., forest scenes, beach scenes, etc.). Each video includes a sequence of pleasant nature photos (shown about 6 seconds each) with relaxing music in the background.
61988487|NCT01917266||Concordant|
61988488|NCT01917266||Discordant|
61988489|NCT03030690|EXPERIMENTAL|Glass Carbomer Cement|GCP Glass Fill, Glass Carbomer™Tech, Ridderkerk, Netherlands
61988490|NCT03030690|ACTIVE_COMPARATOR|Resin Modified Glass Ionomer Cement|GC Fuji II LC Capsule, GC International, Tokyo, Japan
61988491|NCT03030690|ACTIVE_COMPARATOR|Composite Resin|Filtek Z250, 3M ESPE, St Paul, MN, USA
61988492|NCT00278109|EXPERIMENTAL|PBI with Concurrent Chemotherapy|Phase I Single Arm study of PBI with concurrent chemotherapy. Primary endpoint is radiation toxicity. The intervention is partial breast radiation with doxorubicin and cyclophosphamide.
61988493|NCT05041296||Chronic group|Chronic epilepsy with recurrent seizures
61988494|NCT05041296||Acute group|Epilepsy and short-term history of seizures
61988495|NCT05041296||Control group|Healthy participants
61988496|NCT06244069||GCA patients|Patients who are going to be diagnosed with GCA and for which a fast track is available for a rapid diagnostic work-up including pre-treatment temporal artery biopsy. The main biopsy specimen will be sent for histopathology for clinical diagnosis or final validation, while the remaining specimen (at least 5 mm in length) will be digested to use for research purposes. In the fast-track, patients should rapidly receive a multi-dimensional diagnostic assessment including ultrasonography of the temporal and axillary arteries. Screening for large vessels involvement should be performed according to the local practice by a combination of ultrasonography, Position Emission Tomography (PET) and Magnetic Resonance (MR). Ideally, this assessment should be performed within five days from clinical evaluation.
61988497|NCT06244069||Healthy subjects|Healthy controls matched with GCA patients for age, sex, smoking status, previous cardiovascular events, BMI, history of cancer and cytotoxic chemo/radiotherapy.
62383230|NCT03475355|ACTIVE_COMPARATOR|CG2|"Participants will be shown for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. For each CGail patient condition a sequence of images will be presented for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, will be displayed together with an intrusive image (intruder) that the patient will be asked to identify so that his attention span can be controlled in real time. Participants will then be invited to perform movements of the limbs as far as possible for 2 minutes according to a standard sequence that involves articular mobilizations of lower limbs and simulates that performed by the experimental groups."
62383231|NCT00643851|EXPERIMENTAL|Arm 1|Dapagliflozin (5 mg) + Metformin XR (up to 2000 mg)
62383232|NCT00643851|EXPERIMENTAL|Arm 2|Dapagliflozin (5 mg)
62763809|NCT06299722|ACTIVE_COMPARATOR|Circuit training|There will be 10 stations that include both strengthening and cardiovascular exercises, such as squats, hopping, crunches, stationary running, front-lying swimming, ski jumps, push-ups, ball throws, ring pulls, and hopscotch. Each station lasts 45 seconds, and there will be a 15-second break between each station. The circuit is repeated for three rounds. To ensure progression in intensity similar, we will progress the participants' rating of perceived exertion (RPE) over time. During Week 1 to Week 5, the RPE during exercises will be 6-7. During Week 5 to Week 10, the RPE will be 8-9, and during Week 11 to Week 16, the RPE will be 10.
61988498|NCT00919776|EXPERIMENTAL|ciclosporin|ciclosporin reducing regimen lasting 16 weeks (additional prednisolone given for the first four weeks)
62383233|NCT00643851|ACTIVE_COMPARATOR|Arm 3|Metformin XR (500 mg up to 2000 mg)
62383234|NCT01414439||Congestive Heart Failure Patients|40 patients diagnosed with heart failure at levels III and IV, according to the classification of the NYHA will participate in the research. The researchers will randomly allocate the patients to the treatment group or the control group. The subjects in the treatment group will participate in Existential Group Therapy, while the subjects in the control group will not participate in the treatment until after the completion of the study. Psychological data will be collected in the form of a self-reported questionnaire completed by all participants prior to the beginning of the research and again upon completion of the final group session.
62383235|NCT01545089|EXPERIMENTAL|Mattress protector days 1,2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
61988499|NCT00919776|ACTIVE_COMPARATOR|Prednisolone|standard course of prednisolone given in a reducing regimen over 16 weeks
61988500|NCT04105998|EXPERIMENTAL|Oxytocin First, then Placebo|Subjects in this arm will receive Intramuscular injection of Oxytocin (Pitocin®), 10 International Units (IU) at the first visit. Then at the next visit, they will receive Intramuscular injection of (1 milliliter) saline.
61988501|NCT04105998|EXPERIMENTAL|Placebo, Then Oxytocin|Subjects in this arm will receive intramuscular injection of (1 milliliter) saline at the first visit. Then at the next visit, they will receive Intramuscular injection of Oxytocin (Pitocin®), 10 International Units (IU).
61988502|NCT02726074|EXPERIMENTAL|Perampanel 12 mg|During the Titration Period, participants will receive perampanel 2 milligrams per day (mg/day) and be up-titrated in no less than 2-week intervals in increments of 2 mg up to 12 mg according to the investigator's judgment. Upon entering the Maintenance Period, participants will receive the last dose they achieved at the end of the Titration Period and will continue receiving this dose once daily for the remainder of the study.
61988503|NCT02419404||Patients having cardiac surgery|Patients having cardiac surgery who have a pulmonary artery catheter will be eligible for inclusion in this study
62383236|NCT01545089|EXPERIMENTAL|Mattress protector days 3,4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
62763810|NCT03972319|EXPERIMENTAL|Omega-3 Supplementation|Proof of Concept and Safety Study of 4 weeks of Omega-3 supplementation pre- Bariatric Surgery
62763811|NCT06385535|EXPERIMENTAL|Habit Reversal Training (HRT)|All participants receive 4 sessions of HRT (Habit Reversal Training) to treat their tics.
62763812|NCT04058704|EXPERIMENTAL|Early intervention|Icotinib is administered orally three times per day. Radiation therapy (SRS/ WBRT/ HA-WBRT/SMART) start in 1 month since take icotinib orally.
62763813|NCT04058704|EXPERIMENTAL|Late intervention|Icotinib is administered orally three times per day. Until emerge the progression of the disease, then is given radiation therapy (SRS/WBRT/HA-WBRT/SMART)
62763814|NCT00837018|EXPERIMENTAL|Physical exercise program|45 min, 3 times a week
61988504|NCT05217407||Rare cancer|Malignancies with an annual incidence of less than 6 cases per 100,000 population; malignancies categorized as rare cancers in the European RARECARE report; malignancies that are difficult to develop treatments; common cancers with rare tissue subtypes; common cancers that can be regarded as rare based on biological demographics such as age or sex; and cancers of unknow primary are eligible for this study.
62383237|NCT05235802||Patients with traumatic brain injury about 10 years ago|Patients that had suffered a TBI and being managed at the Neurosurgical Department at the Karolinska University Hospital between 2007 and 2015.
62383238|NCT02485431|EXPERIMENTAL|Deflazacort, fasted|36mg of Deflazacort with 240 ml of room-temperature, non-carbonated water in Fasted state.
62763815|NCT05586958|EXPERIMENTAL|Tigulixostat 100mg|Tigulixostat 100mg, Once a day (QD) for up to 6 months
62763816|NCT05586958|EXPERIMENTAL|Tigulixostat 200mg|Tigulixostat 200mg, Once a day (QD) for up to 6 months
62383239|NCT02485431|EXPERIMENTAL|Deflazacort, high-fat meal|36mg of Deflazacort with 240 ml of room-temperature, non-carbonated water with high fat meal served 30 minutes prior to dosing.
62763817|NCT05586958|EXPERIMENTAL|Tigulixostat 300mg|Tigulixostat 300mg (100mg + 200mg), Once a day (QD) for up to 6 months
62763818|NCT05586958|PLACEBO_COMPARATOR|Placebo|Placebo, Once a day (QD) for up to 6 months
62763819|NCT00630227|EXPERIMENTAL|Single|all patients are treated with the experimental therapy
62763820|NCT01328262|EXPERIMENTAL|Hemoglobin dose|Intervention: Calculated red blood cell transfusion
62763821|NCT01328262|ACTIVE_COMPARATOR|Standard treatment|Intervention: Standard red blood cell transfusion
62763822|NCT04349241|EXPERIMENTAL|favipiravir|favipiravir in a regimen of 3200 mg (1600 mg 12 hourly) loading dose on day-1 followed by 1200 mg maintenance dose (600 mg 12 hourly daily) on day-2 to day-10
62168204|NCT00093743|EXPERIMENTAL|Treatment (allogeneic bone marrow or PBSC transplantation)|"NON-MYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2, cyclosporine IV every 8-12 hours on days -3 to 0, and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic bone marrow or PBSC transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV every 8-12 hours on days 1-100 with taper to day 177, and mycophenolate mofetil PO or IV every 8 hours on days 0-40 with taper to day 96."
62168205|NCT05128539|EXPERIMENTAL|JS001(Toripalimab)+JS002|
62383240|NCT02485431|EXPERIMENTAL|Deflazacort, crushed, fasted|36mg of Deflazacort crushed and mixed with apple sauce.
62383241|NCT02485431|EXPERIMENTAL|Deflazacort alternate strength,fasted|Investigational Formulation Deflazacort tablet (6 X 6mg).
62763823|NCT04349241|ACTIVE_COMPARATOR|Standard of care therapy|oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10.
62763824|NCT01403545|EXPERIMENTAL|Liposomal Curcumin|Single dose, dose escalation
62763825|NCT01403545|PLACEBO_COMPARATOR|5% Glucose|
62763826|NCT02955680|EXPERIMENTAL|Group M|At the end of surgery, patients were stimulated to wake up by recorded mother's voice, which was recorded before the operation.
62763827|NCT02955680|ACTIVE_COMPARATOR|Group S|At the end of surgery, patients were stimulated to wake up by recorded stranger's voice, which was recorded before the operation.
62763828|NCT02725879||AIT Subclinical Hypothyroid Group|"30 children and adolescents with subclinical hypothyroidism due to Hashimoto's thyroiditis.~No special intervention is to be administered, only routine LT4 treatment. Reassessment at 6 months."
62763829|NCT02725879||Control Group|"30 healthy individuals with no chronic autoimmune thyroiditis and normal thyroid function (age- and sex-matched with the AIT Subclinical Hypothyroid Group).~No special intervention is to be administered. No reassessment at 6 months."
62763830|NCT02725879||AIT Euthyroid Group|"30 children and adolescents with chronic autoimmune thyroiditis and euthyroidism (age- and sex-matched with the AIT Subclinical Hypothyroid Group).~No special intervention is to be administered. No reassessment at 6 months."
62763831|NCT04484623|EXPERIMENTAL|Arm A: Belantamab mafodotin plus Pomalidomide and Dexamethasone|
62763832|NCT04484623|ACTIVE_COMPARATOR|Arm B: Bortezomib plus Pomalidomide and Dexamethasone|
62763833|NCT02788201|EXPERIMENTAL|Treatment Regimen|Treatment regimen selected by CO eXpression ExtrapolatioN (COXEN) model
62763834|NCT06484010|ACTIVE_COMPARATOR|SNAPPS Group|The intervention was the implementation of the SNAPPS model as a method of case presentation in out-patient settings.
62763835|NCT06484010|NO_INTERVENTION|Control Group|In the control group, as both learners and preceptors are familiar with the traditional method of case presentation, no special training was required.
62383242|NCT02485431|EXPERIMENTAL|Deflazacort suspension with apple juice|Deflazacort oral suspension (36mg) mixed with 100ml apple juice in fasted state.
62383243|NCT02785861|EXPERIMENTAL|supervised practice|"brisk walking program twice a week over a period of 6 weeks, at an intensity of 60% of HR pic during 20 minutes.~Biweekly session from 60% of the heart rate pic during 20 minutes will be proposed.~Each patient of supervised walking group will meet the student each session"
62383244|NCT02785861|EXPERIMENTAL|distance supervised physical activity|"brisk walking program twice a week over a period of 6 weeks, at an intensity of 60% of HR pic during 20 minutes.~Biweekly session from 60% of the heart rate pic during 20 minutes will be proposed.~Each patient of home-based walking group will be called by phone every week by the student to inform the patient of the progress of the training, collect the work and answer any questions"
62383245|NCT01778140|EXPERIMENTAL|Patient-specific reminder|Intervention: Patient-specific computerized reminder. The physicians assigned to this arm will use the patient-specific CDSS on CPOE. The patient-specific reminder is designed as a real-time CDSS implemented on CPOE to monitor physician's contrast-enhanced image study orders. Computerized pop-up reminders provide the patient-specific CIN risk profile and optimal decision options which are generated when patients with high risk or with unknown risk of CIN are encountered.
62383246|NCT01778140|ACTIVE_COMPARATOR|Non-patient-specific reminder|Intervention: Non-patient-specific Computerized reminder. The physicians assigned to this arm will use the Non-patient-specific reminders through CPOE. Non-patient-specific reminders always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
62383247|NCT01778140|NO_INTERVENTION|Control Arm|The physicians assigned to this arm will not use and any computerized reminder.
62567629|NCT01783990||Passive|Complete blood counts (CBCs), reticulocytes, differential, lactate dehydrogenase (LDH), bilirubin and alanine transaminases (ALTs), cystatin C, blood urea nitrogen (BUN), Creatinine, fetal hemoglobin (HbF), pit counts, Howell Jolly Body (HJB), variable-diversity-joining (VDJ), urine microalbumin:creatinine ratio and a stored blood sample were collected at study entry and exit to Follow-Up Study II. Additional tests that include liver/spleen scan, abdominal sonogram, pulmonary function testing, MRI/MRA, cardiac echocardiogram, or neuropsychology testing were collected as part of clinical care.
62763836|NCT02225912|EXPERIMENTAL|PrevinC|PrevinC contains isopropyl alcohol, sesame oil, aloe vera oil extract, and lemon oil.
62763837|NCT02225912|PLACEBO_COMPARATOR|Control solution|The control solution (distilled water and lemon oil) was similar in color, oily consistency and odor to that of PrevinC.
62763838|NCT01862341|EXPERIMENTAL|Milk powder|ANMUM In-Shape Nutritional Milk Powder for Active Mothers. The dose of the milk powder is 40g added to 200ml of drinkable water and will be taken twice a day.
62763839|NCT02558400|EXPERIMENTAL|PG324 Ophthalmic Solution 0.02%/0.005%|Fixed combination of netarsudil 0.02%, latanoprost 0.005% ophthalmic solution
62763840|NCT02558400|ACTIVE_COMPARATOR|AR-13324 Ophthalmic Solution 0.02%|Netarsudil 0.02% ophthalmic solution
62763841|NCT02558400|ACTIVE_COMPARATOR|Latanoprost Ophthalmic Solution 0.005%|Latanoprost 0.005% ophthalmic solution
62763842|NCT01189357||failed meniscal transplantation|
62763843|NCT01527383|EXPERIMENTAL|V212|Participants receive V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
62763844|NCT01527383|PLACEBO_COMPARATOR|Placebo|Participants receive placebo as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
62763845|NCT02995226|OTHER|Anorexia nervosa|"Patients with DSM-5 criteria of anorexia nervosa"
62763846|NCT02995226|OTHER|First degree relatives|First degree relatives (of patients suffering from anorexia nervosa) with no eating disorder
62763847|NCT02995226|OTHER|Controls (with no eating disorder)|Other
62763848|NCT00926133||STEMI patients|Patients with acute STEMI treated by PCI without previously known type 2 diabetes.
62763849|NCT04665115|EXPERIMENTAL|Cohort I (ibrutinib)|Patients may continue to receive ibrutinib PO daily or stop ibrutinib per provider's discretion.
62763850|NCT04665115|EXPERIMENTAL|Cohort II Arm 2A (ibrutinib)|Patients continue to receive ibrutinib PO daily in the absence of disease progression or unacceptable toxicity.
62763851|NCT04665115|EXPERIMENTAL|Cohort II Arm 2B (temporary interruption)|Patients undergo temporary interruption of ibrutinib for up to 28 days unless they are discharged home and are thought to be medically fit by the primary caregiver to resume therapy according to their primary treating oncologist.
62763852|NCT00272116|EXPERIMENTAL|1|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children and Vitamin A 100,000 IU to infants and 200,000 IU to older children
62763853|NCT00272116|PLACEBO_COMPARATOR|2|
62763854|NCT02654418|EXPERIMENTAL|SIC 8000, 10 mL ampoules|Procedure/Surgery: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size) with SIC 8000 injectate solution.
62763855|NCT02654418|ACTIVE_COMPARATOR|reference comparator|Procedure/Surgery: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size) with Reference Comparator Injectate solution (site standard of care injectate solution).
62763856|NCT05045170|EXPERIMENTAL|propofol group|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test≥26, trauma surgery under spinal anesthesia with propofol sedation
62763857|NCT05045170|EXPERIMENTAL|dexmedetomidine group|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test≥26, trauma surgery under spinal anesthesia with dexmedetomidine sedation
62763858|NCT05045170|PLACEBO_COMPARATOR|control group|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test≥26, trauma surgery under spinal anesthesia without sedation
62383248|NCT02146885||Weight Control|Weight Control
62763859|NCT01533090|ACTIVE_COMPARATOR|polyethylene glycol (PEG)|
62383249|NCT02065479|ACTIVE_COMPARATOR|Ticagrelor|The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.
62383250|NCT02065479|EXPERIMENTAL|Prasugrel|The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.
62383251|NCT02995018|EXPERIMENTAL|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62763860|NCT01533090|EXPERIMENTAL|PEG low volume with bisacodyl|
62763861|NCT04624334||Children with motility disorder|
62383252|NCT04494087|ACTIVE_COMPARATOR|Hernia video|The video of the intervention group will provide a short (\< 5 min) summary explaining the basic principles of endoscopic extraperitoneal hernia repair, its possible complications and the postoperative course. After carefully watching the video, participants should be able to correctly answer to a multiple-choice test consisting of 12 questions related to the aforementioned topics.
62383253|NCT04494087|PLACEBO_COMPARATOR|Mock video|"This video is a general documentation of the typical day of surgery in the day clinic. The information is essentially limited to the pictorial representation of the individual wards which the patient will pass through during the operation (arrival at the clinic, admission, transport to the operating theatre, recovery room, discharge).~The video explicitly does not transport any information that could be helpful for answering the quiz questions or for medical understanding of the operation itself."
62567630|NCT04528667|EXPERIMENTAL|STI-5656|STI-5656 (abivertinib maleate) capsules administered orally 100 mg QD for 7 days, in addition to standard of care
62763862|NCT04624334||Healthy children|
62763863|NCT04624334||Adults with motility disorder|
62763864|NCT04624334||Healthy adults|
62763865|NCT00906269|ACTIVE_COMPARATOR|1|
62763866|NCT00906269|SHAM_COMPARATOR|2|
62763867|NCT06138925|ACTIVE_COMPARATOR|healthy children|
62763868|NCT06138925|EXPERIMENTAL|hildren with cerebral palsy|
62763869|NCT01036529|EXPERIMENTAL|Precision Spinal Cord Stimulator|Spinal Cord Stimulation
62763870|NCT01036529|ACTIVE_COMPARATOR|Back Surgery|Discectomy, laminotomy, laminectomy, foraminotomy, fusion with or without instrumentation
62763871|NCT05208736||5-year nonsurvival or transplantation|Patients who died or underwent liver transplantation within 5 years since admission.
62763872|NCT05208736||5-year transplantation-free survival|Patients who survival without liver transplantation at 5 years since admission.
62763873|NCT00795834|PLACEBO_COMPARATOR|Beverage|
62763874|NCT00795834|ACTIVE_COMPARATOR|High Polyphenol Beverage|
62763875|NCT01071356|EXPERIMENTAL|Intensive MI|9 hours of Motivational Interviewing + outpatient substance abuse treatment
62383254|NCT04494087|SHAM_COMPARATOR|Control group|The link of the third group leads to a digital version of the information sheet, which has already been discussed with all patients during the informed consent discussion. The digital version of the informed consent form allows the patient to read the information again. The third group thus corresponds to the standard of care.
62383255|NCT05603481||CGM|
62763876|NCT01071356|ACTIVE_COMPARATOR|Single session MI|1.5 hours of Motivational Interviewing + 8 hours of time equivalent nutrition classes +outpatient substance abuse treatment
62763877|NCT03442517|EXPERIMENTAL|Group-based phone counseling (GBPC)|Participants will take part in weekly group-based phone counseling sessions for 6 weeks starting between 16-30 weeks of pregnancy.
62763878|NCT03442517|ACTIVE_COMPARATOR|Usual prenatal care|Participants will continue their usual prenatal care.
62763879|NCT04234958|EXPERIMENTAL|Experimental|Participants received osteopathic treatment
62763880|NCT04234958|SHAM_COMPARATOR|Sham|Participants received sham therapy
62763881|NCT04234958|NO_INTERVENTION|Control|Participants received no intervention
62763882|NCT03785587|EXPERIMENTAL|Gel, 15%|Sofpironium Bromide Gel, 15%, applied once daily to each axilla for 24 weeks
62763883|NCT00350623|EXPERIMENTAL|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 4 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
62383256|NCT03437811||Active Treatment|Active arm, Electro Flo Percussor, Model 5000 airway clearance system for daily basis as needed (pro re nata).
62383257|NCT05891301||questionnaires assessed patient with colorectal cancer after surgery|Patients with colorectal cancer who had a radical resection surgery.
62383258|NCT04630561|EXPERIMENTAL|Intervention Group|Subjects will participate in a 15 minute postural intervention program 2-3 times per week
62383259|NCT04630561|NO_INTERVENTION|Control Group|Subjects will NOT participate in any postural intervention.
62383260|NCT03549637|EXPERIMENTAL|Psychiatric population|"At inclusion: Patients will have A Lipid Panel Test, other biological analyzes and a clinical assessment. In case of a low LDL-C level (≤ 0, 50 g/L), genetic analyzes will be performed to screen for genetic forms of hypobetalipoproteinemia (HBL).~At 2- 4 weeks: for patients with HBL (LDL-C ≤ 0,50 g/L with no secondary cause of LDL-C reduction), another Lipid Panel Test will be performed to confirm the maintenance of the low LDL-C level.~At 6 months : Patients with a HBL will perform a full biological examination, and the LDL-C levels and genetic analyzes will be confirmed. A dietary survey will be performed, together with a psychiatric assessment. The same numbers of matched controls will performed a quick telephone interview to collect the psychiatric characteristics."
62383261|NCT01930396|EXPERIMENTAL|Tinzaparin|
62383262|NCT01930396|ACTIVE_COMPARATOR|Unfractionated Heparin|
62383263|NCT00653198||A|Cases
62383264|NCT00653198||B|Controls
62383265|NCT00305773|EXPERIMENTAL|Arm I (once daily vorinostat)|Patients receive oral vorinostat (SAHA) once a day on days 1-21. In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
62763884|NCT00350623|EXPERIMENTAL|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 8 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
62763885|NCT00350623|EXPERIMENTAL|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10\^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
62763886|NCT06441292|ACTIVE_COMPARATOR|conventional biopsy group|undergo standard prostate biopsy procedures without additional technological assistance
62763887|NCT06441292|EXPERIMENTAL|AI-assisted biopsy group|utilize advanced deep learning models that integrate multi-modal image fusion from multi-parameter ultrasound and MRI to guide the biopsy process
62763888|NCT02448888|EXPERIMENTAL|Adapted exercise|The experimental group is going to follow a home-exercise program designed specifically to compensate the overloads and strength necessities of the workplace, the patient enter the description of the workplace in a mobile application and the APP shows the specific exercise that the patient needs to practice and general exercise recommendations.
62383266|NCT00305773|EXPERIMENTAL|Arm II (thrice daily vorinostat)|Patients receive oral SAHA three times a day on days 1-14. In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
62763889|NCT02448888|EXPERIMENTAL|General exercise recommendations|The control group is going to receive general exercise recommendations (ACSM recommendations) with the same kind of APP to control the amount of exercise that each patient performs during the week.
62763890|NCT05210634|PLACEBO_COMPARATOR|Group 1: Placebo|Single oral administration of 4 ml of Placebo MCT oil
62763891|NCT05210634|ACTIVE_COMPARATOR|Group 2: 12.5 mg THCv (CHI-915)|Single oral administration of 12.5 mg THCv in MCT oil
62763892|NCT05210634|ACTIVE_COMPARATOR|Group 3: 25 mg THCv (CHI-915)|Single oral administration of 25 mg THCv in MCT oil
62763893|NCT05210634|ACTIVE_COMPARATOR|Group 4: 50 mg THCv (CHI-915)|Single oral administration of 50 mg THCv in MCT oil
62763894|NCT05210634|ACTIVE_COMPARATOR|Group 5: 100 mg THCv (CHI-915)|Single oral administration of 100 mg THCv in MCT oil
61988505|NCT05217407||Cholangiocarcinoma cohort|This study is a part of MASTER KEY Asia study and designed to be conducted on the patients of cholangiocarcinoma only. The primary endpoint is assigned to the frequency of FGFR2 fusion gene positive cholangiocarcinoma detected by fluorescence in situ hybridization (FISH) in Asian countries. The genetic analysis is performed not only by FISH, but also by next generation sequencing (NGS), so that genetic alterations other than the FGFR2 fusion gene in alterations can be confirmed. To improve outcomes, collecting clinical information is very important to study the relationship between genetic alterations and prognosis, effect of treatments, and the incidence of genomic alterations in cholangiocarcinoma to discover more specific and effective treatment.
62383267|NCT04313894|EXPERIMENTAL|Stem Cell Therapia Group|A total of 11 patients with Kellgren-Lawrence grade II-III knee OA who were admitted to the outpatient clinic with knee pain and who had received conservative treatment for a period of 6 months and who had not benefited from it will be taken. Patients will be evaluated 7 (V1-7) during the study period. Patients who comply with the study criteria will be included in the study. The clinical, immunological and radiological efficacy of the treatment and clinical improvement will be evaluated in all follow-up patients at the beginning and at the beginning of the treatment.
62383268|NCT01997333|ACTIVE_COMPARATOR|Capecitabine|Capecitabine will be administered on Days 1 through 14 of each 21 day cycle.
62383269|NCT01997333|EXPERIMENTAL|Drug: CDX-011|CDX-011 administered as an intravenous infusion on Day 1 of each 21 day cycle.
62383270|NCT06326073|EXPERIMENTAL|Group I: SP|smokers with periodontitis
62383271|NCT06326073|EXPERIMENTAL|Group II: P|non-smokers with periodontitis
62763895|NCT05210634|ACTIVE_COMPARATOR|Group 6: 200 mg THCv (CHI-915)|Single oral administration of 200 mg THCv in MCT oil
62763896|NCT03395730|EXPERIMENTAL|"• Group (A) Study Group 1:"|"In the labor room women in Group A (n = 50):~* Clamping and cutting the placental cord after delivery of the baby.~* Immediate intraumbilical vein injection of Oxytocin (Syntocinon®) 20 units diluted in 20 ml of 0.9% saline solution"
62763897|NCT03395730|EXPERIMENTAL|"• Group (B) Study Group 2:"|"In the labor room women in Group B (n = 50):~* Clamping and cutting the placental cord after delivery of the baby.~* Immediate unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes."
61988506|NCT00851799||Cohort A|"ATV/RTV + FTC/TDF~Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily."
61988507|NCT00851799||Cohort B|"RAL + FTC/TDF~FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily."
62383272|NCT06326073|NO_INTERVENTION|Group III: SH|smokers with periodontal healthy individuals
62383273|NCT06326073|NO_INTERVENTION|Group IV: H|non-smokers with periodontal healthy individuals
62383274|NCT05563441||laparoscopic surgery|Patients over 70 years old underwent laparoscopic colorectal resection were enrolled.
62383275|NCT05563441||laparotomic surgery|Patients over 70 years old underwent laparotomic colorectal resection were enrolled.
62383276|NCT06116474|EXPERIMENTAL|Web based intervention group|The web-based intervention group participated in an 8-week exercise program, which consisted of three sessions per week, each lasting approximately 20 to 35 minutes.
62567631|NCT04528667|PLACEBO_COMPARATOR|Placebo|Placebo capsules administered orally daily for 7 days, in addition to standard of care
62763898|NCT03395730|ACTIVE_COMPARATOR|"• Group (C) Control Group:"|"In the labor room women in Group C (n = 50):~* Clamping and cutting the placental cord after 2 minutes of delivery of the baby.~* Placenta will be delivered spontaneously after appearance of clinical signs of placental separation"
62763899|NCT00246506|ACTIVE_COMPARATOR|I.|Those randomized to have clomiphene/IUI treatments first will initiate therapy with two cycles of the fertility pill called clomiphene combined with (IUI) intrauterine insemination. If not pregnant after 2 IUI cycles, the couples will then proceed to IVF.
62763900|NCT00246506|ACTIVE_COMPARATOR|II.|Those randomized to have gonadotropins/IUI treatments first will initiate therapy with two cycles of the fertility injections called FSH or gonadotropins combined with (IUI) intrauterine insemination. If not pregnant after 2 IUI cycles, the couples will then proceed to IVF.
62763901|NCT00246506|ACTIVE_COMPARATOR|III.|Those couples randomized to (IVF) in vitro fertilization will bypass IUI treatments and start IVF therapy immediately.
62763902|NCT02876497|EXPERIMENTAL|Study arm|
62763903|NCT04364061|EXPERIMENTAL|Women with overweight or obesity|
62763904|NCT02737995|EXPERIMENTAL|Iron Replacement|
62763905|NCT02726191|EXPERIMENTAL|Posit Science|
62763906|NCT02726191|EXPERIMENTAL|Lumosity|
62763907|NCT02020772|EXPERIMENTAL|coordinating primary health care 1|musculoskeletal pain care by a coordinating team of one general practitioner and two physical therapists
62763908|NCT02020772|ACTIVE_COMPARATOR|usual primary health care 1|usual care of musculoskeletal pain in general practice
62763909|NCT02020772|EXPERIMENTAL|coordinating primary health care 2|musculoskeletal pain care by a coordinating team of one general practitioner and two physical therapists
62383277|NCT06116474|NO_INTERVENTION|Control Group|The control group did not engage in any prescribed exercise protocol.
62383278|NCT06178835|EXPERIMENTAL|Erythropoietin|500 IU/kg of EPO given intramuscularly 3 times for each patient
62567632|NCT01155934|EXPERIMENTAL|Risperidone Orally Disintegrating|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
62763910|NCT02020772|ACTIVE_COMPARATOR|usual primary health care 2|usual care of musculoskeletal pain in general practice
62383279|NCT06178835|PLACEBO_COMPARATOR|Control|Same amount of normal saline given intramuscularly 3 times for each patient
62383280|NCT00095394|EXPERIMENTAL|A1|
62383281|NCT00095394|ACTIVE_COMPARATOR|A2|
62383282|NCT03180320|EXPERIMENTAL|BESMILE-HF group|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines. In addition, patients will receive the BESMILE-HF program.
62383283|NCT03180320|OTHER|Control|Patients in the control group will receive only the usual medications, since patients typically do not receive exercise-based cardiac rehabilitation in this kind of setting.
61988508|NCT00851799||Cohort C|"DRV/RTV + FTC/TDF~FTC/TDF, darunavir (DRV), and RTV, orally, once daily."
62763911|NCT01470833|NO_INTERVENTION|Non-weight-bearing|"The group of non-weightbearing is instructed as follows:~Week 1 to 6 No weightbearing. Crutches are obligatory. Week 7 to 8 Full weightbearing is allowed.~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
62763912|NCT01470833|EXPERIMENTAL|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:~Week 1 to 2 Weightbearing is allowed with in pain limit. Crutches are recommended.~Week 3 to 4 Full weightbearing is allowed. Week 5 to 8 Full weightbearing is allowed. Crutches should be avoided."
62763913|NCT00601913|EXPERIMENTAL|Erlotinib|Erlotinib
62383284|NCT02835391|ACTIVE_COMPARATOR|PerClot|PerClot® Polysaccharide Hemostatic System (PerClot) is a medical device composed of absorbable polysaccharide particles (AMPs) and delivery applicators. Investigators will have the option to choose 3g or 5g dependent on the requirements of the patient
62383285|NCT02835391|ACTIVE_COMPARATOR|Usual Care|Usual care will consist of any other haemostat the Investigator would normally use in the control of bleeding i.e arista, Floseal, surgical, surgiflo. If the Investigator would not normally use a haemostat to control bleeding then electrocautery or diathermy may be used in this arm
62763914|NCT05300841|ACTIVE_COMPARATOR|Dydrogesterone group|Pretreatment with dydrogestrone (Duphaston, Abott Healthcare, Egypt) will be administered during the cycle preceding the ICSI cycle in a daily dose of 20 mg/ day starting 10 days before the presumed onset of menses
62383286|NCT01100203|ACTIVE_COMPARATOR|Treatment|
62567633|NCT01155934|ACTIVE_COMPARATOR|Risperdal M-TAB|(Risperdal M-TAB) 1 mg risperidone orally disintegrating tablets Janssen Pharmaceutica Products
62763915|NCT05300841|ACTIVE_COMPARATOR|Dydrogesterone plus estradiol valerate group|will receive dydrogestrone 10mg /day plus estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Schering, Germany) for 10 days.
62763916|NCT03362697|EXPERIMENTAL|Probiotic|5\*10\^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 \& Lactobacillus reuteri DSM 17938, PAC-A and Zinc
62763917|NCT03362697|ACTIVE_COMPARATOR|Antibiotic|Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick
62763918|NCT05326360|NO_INTERVENTION|group C|receive ramosetron i.v. 0.3mg at the end of surgery without additional ramosetron
62763919|NCT05326360|EXPERIMENTAL|group B|receive ramosetron i.v. 0.3mg at the end of surgery with two additional doses of ramosetron at 12- and 24- hour postoperative time points
62763920|NCT05326360|EXPERIMENTAL|group M|receive ramosetron i.v. 0.3mg at the end of surgery followed ramosetron 0.6 mg mix with the patient-controlled analgesia (PCA) regimen
61988509|NCT01352312|EXPERIMENTAL|Treatment (pentostatin, bendamustine, ofatumumab)|Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, pentostatin IV on day 1, and ofatumumab IV on day 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62763921|NCT02482857|EXPERIMENTAL|Acetylsalicylic acid 75 mg twice daily|Aspirin 75 mg BID is a new experimental dosing regimen which has shown improved efficiency regarding laboratory parameters in several studies, mainly in diabetic patients.
61988510|NCT04424238|NO_INTERVENTION|Standard Clinic Prenatal Care (Control Group)|pregnancy's prenatal care appointment would be changed to once every two weeks when diagnosed with GDM. Doctors generally ask GDM women record their daily diet, exercise, weight, BG and blood pressure for at least three days between two visits and give lifestyle guidance according to the records. If they fail to show diaries, doctors would ask them come back with record next week. If BG control is poor, medicine intervention would be considered.
62383287|NCT01100203|NO_INTERVENTION|Control|
62383288|NCT02879435|EXPERIMENTAL|bupivacaine|Intervention
62383289|NCT02879435|PLACEBO_COMPARATOR|Placebo|Control
62383290|NCT05679076||Fabry patients|Fabry patients
62763922|NCT02482857|ACTIVE_COMPARATOR|Acetylsalicylic acid 160 mg once daily|Aspirin 160 mg OD is an accepted and used dosage after CABG.
62763923|NCT02482857|ACTIVE_COMPARATOR|Acetylsalicylic acid 75 mg once daily|Aspirin 75 mg OD is an accepted and used dosage after CABG.
62383291|NCT05199558||eclamptic patients|
62383292|NCT05199558||preeclamptic patients|
62383293|NCT05199558||healthy pregnant women of same gestation and parity|
62383294|NCT03430726|EXPERIMENTAL|Healthy Kids Probiotic Yogurt Drink Group|Healthy children will be given a commercially available yogurt drink containing a multi-strain probiotic, Bio-Kidz® (12.5 billion CFU/98g; Lactobacillus acidophilus CL1285®, Lactobacillus casei LBC80R® and Lactobacillus rhamnosus CLR2®), daily for 14 days.
62383295|NCT00170846|ACTIVE_COMPARATOR|Group A: No RAD|Calcineurin Inhibitors (CNI) ± Mycophenolate Acid (MPA)/Azathioprine (AZA) ± Steroids
62383296|NCT00170846|EXPERIMENTAL|Group B : CNI Withdrawal|Initiation of everolimus (8-12 ng/mL) with discontinuation of CNI. Everolimus(RAD001) 4 mg initial daily dose.
62383297|NCT00170846|EXPERIMENTAL|Group C: CNI Reduction|Initiation of everolimus (3-8 ng/mL) with reduction by 70-90% in CNI blood levels. Everolimus (RAD001) 3 mg initial daily dose.
62383298|NCT01854957|EXPERIMENTAL|Autologous Mesenchymal Stem Cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
62763924|NCT05502666|EXPERIMENTAL|Intervention Arm|Intervention Arm: ¡Salud! Por la vida Educational Intervention After completing eligibility and baseline surveys, trained lay health workers delivered an educational intervention for colorectal cancer screening with included a tailored interactive multimedia intervention (TIMI), newsletter, infographics, and a provider prompt for colorectal cancer screening. This educational session was delivered at intervention clinics and lasted about 1 hour. Follow-up data was collected starting at 6 months post educational session.
62763925|NCT05502666|NO_INTERVENTION|Control Arm|Control Arm: No intervention was delivered. At baseline, participants completed eligibility and baseline surveys. Follow-up data was collected 6 months post-baseline survey.
62763926|NCT04465318|EXPERIMENTAL|E-cigarettes (EC)|EC + Counseling
62763927|NCT04465318|ACTIVE_COMPARATOR|Nicotine Replacement Therapy (NRT)|NRT + Counseling
62763928|NCT03675425|EXPERIMENTAL|Group 1: non chest shielding|non chest shielding generic name: non dosage: non frequency and duration: in first 48 h eco with pad diameter will be measured in before and after phototherapy,
62763929|NCT03675425|PLACEBO_COMPARATOR|Group 2: chest shielding|chest shielding generic name: Phototrephy dosage: non frequency and duration: in first 48 h echo with pad diameter will be measured in before and after phototherapy,
62763930|NCT01752400|EXPERIMENTAL|AUY922|Via intravenous infusion on Days 1, 8 and 15 of each 21 day cycle (once per week). Infusion lasts approximately 60 minutes
62763931|NCT05036200|EXPERIMENTAL|four pulsed dye laser sessions were administered every eight weeks in the 21 patients|
62763932|NCT04534101||Inpatient Subjects|Inpatients will be presented with an informed consent. If they sign the consent, they will then be given a VR headset pre- programmed with content that they may use for the duration of their stay. GI patients headsets will be collected when they are discharged. There are pain and anxiety analog scales at the end of each program. This data will be downloaded to Stanford. Patient's will not be entering their PHI. we will know who has headsets, as they will be numbered. Patient who are hospitalized for chronic pain will be allowed to take the VR headset home for month and be asked to return it at their followup outpatient visit.
62763933|NCT04534101||Outpatient Subjects|Outpatient: Patient's who are about to undergo gastrointestinal disease testing or be seen for an outpatient GI appointment will be presented with an informed consent. If they sign the consent, they will be given the VR headset to use prior to their procedure. There are pain and anxiety analog scales at the end of each program. This data will be downloaded to Stanford Medicine Box.Patient's will not be entering their PHI. we will know who has headsets, as they will be numbered.
62763934|NCT02544256|EXPERIMENTAL|Mild hypothermia|After induction to general anaesthesia the patients will be cooled to 33° C. Targeted body temperature 33,8° C - 34,8° will be maintained up to the end of microcirculation measurement after aneurysm clipping.
62763935|NCT02544256|NO_INTERVENTION|Normothermia|The body temperature will be maintained in the range 35,8° C - 36,8° C.
62763936|NCT04779086||1. group|Scale score results of first year physiotherapy and rehabilitation department students
62763937|NCT04779086||2. group|Scale score results of 2nd year physiotherapy and rehabilitation department students
62763938|NCT04779086||3. group|Scale score results of 3rd year physiotherapy and rehabilitation department students
62763939|NCT04779086||4. group|Scale score results of 4th year physiotherapy and rehabilitation department students
62763940|NCT01283490|ACTIVE_COMPARATOR|DASD Group|Benzocaine 20% will be placed using the DASD for one minute. Immediately after DASD application a needle puncture with a 27 gauge needle to the depth of 3 millimeters will be performed.
62763941|NCT01283490|SHAM_COMPARATOR|Sonic Vibration (SV)|A modified tooth brush which only allows sonic vibration (SV), that has the appearance and sound of the DASD will be used to apply the benzocaine 20% for one minute. Following application with the SV a needle puncture with a 27 gauge needle to the depth of 3millimeters.
62763942|NCT05256797||Rivaroxaban|Reference group
61988511|NCT04424238|EXPERIMENTAL|m-health group (Intervention Group)|participants were managed continuously through WeChat group chat.
61988512|NCT02285907|EXPERIMENTAL|Macronutrient and Fiber Matched BEEF|The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
62763943|NCT05256797||Apixaban|Exposure group
62763944|NCT00392808|EXPERIMENTAL|MENC-CRM/MENC-CRM|Children primed with 3 doses of MenC-CRM vaccine, Intervention: boosted with one dose of MenC-CRM vaccine
62763945|NCT00392808|EXPERIMENTAL|MENC-CRM/MENC-TT|Children Primed with three doses of MenC-CRM vaccine. Intervention: boosted with one dose of MenC-TT
62763946|NCT00392808|EXPERIMENTAL|MENC-TT/MENC-CRM|Children primovacccinated with two MenC-TT vaccine doses. Intervention: boosted with one dose MenC-CRM vaccine
62763947|NCT00392808|EXPERIMENTAL|MENC-TT/MENC-TT|Children primovacccinated with two MenC-TT vaccine doses. Intervention boosted with one dose MenC-TT vaccine
61988513|NCT02285907|EXPERIMENTAL|Macronutrient and Fiber Matched SOY|The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
61988514|NCT02285907|EXPERIMENTAL|Serving Size Matched BEEF|The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
61988515|NCT02285907|EXPERIMENTAL|Serving Size Matched SOY|The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
61988516|NCT00751348|EXPERIMENTAL|PRIORIX-TETRA GROUP|Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix-Tetra® vaccine at Day 0, administered subcutaneously in the deltoid region of the left upper arm.
61988517|NCT00751348|ACTIVE_COMPARATOR|PRIORIX + VARILRIX GROUP|Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix™ vaccine together with one dose of Varilrix™ vaccine at Day 0, administered subcutaneously in the deltoid regions of the left or right upper arm, respectively.
61988518|NCT04797949|ACTIVE_COMPARATOR|Randomized to USPSTF Criteria|Women randomized to knowing their risk of preeclampsia and therefore, candidates for low dose aspirin.
61988519|NCT04797949|ACTIVE_COMPARATOR|Randomized to Universal aspirin receipt|Women randomized to receiving low dose aspirin without knowing their risk status.
61988520|NCT04765150||Observational (electronic health record review, 3 T MRI)|"RETROSPECTIVE: Patients' medical records are reviewed.~PROSPECTIVE: Patients undergo additional 3T MRI imaging over 30 minutes before, during, or after their standard of care 3T MRI for a total of 1.5 hours."
62763948|NCT01100567|PLACEBO_COMPARATOR|Placebo platform|Randomized to stand on placebo platform for 10 minutes/day
62763949|NCT01100567|ACTIVE_COMPARATOR|Low-magnitude mechanical stimulation|Randomized to stand on LMMS platform 10 minutes/daily
62763950|NCT00283868||Telemedicine|Patients randomized to this group were evaluated using the digital observation camera and DICOM evaluations for telemedicine
62763951|NCT00283868||Telephone|Patients randomized to this group were evaluated using telephone only and no use of the digital observation camera or DICOM
62763952|NCT04600336|EXPERIMENTAL|low-dose oxybutynin|Patients receive low-dose oxybutynin chloride (2.5 mL twice daily) PO BID on days 8-49 (6 weeks) in the absence of unacceptable toxicity.
62763953|NCT04600336|EXPERIMENTAL|high-dose oxybutynin chloride|Patients receive high-dose oxybutynin chloride (5.0 mL twice daily) PO BID on days 8-49 (6 weeks) in the absence of unacceptable toxicity.
62763954|NCT04600336|PLACEBO_COMPARATOR|low-dose placebo|Patients receive a low-dose placebo (2.5 mL twice daily) PO BID on days 8-49 (6 weeks). After 6 weeks, patients may cross over to experimental arm - low-dose oxybutynin per physician discretion.
62763955|NCT04600336|PLACEBO_COMPARATOR|high-dose placebo|Patients receive a high-dose placebo (5.0 mL twice daily) PO BID on days 8-49 (6 weeks). After 6 weeks, patients may cross over to experimental arm - high-dose oxybutynin chloride per physician discretion.
62763956|NCT01216943|EXPERIMENTAL|Triple Combination Therapy|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
62763957|NCT03109262|EXPERIMENTAL|Yttrium Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans|All participants receive both Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans
62763958|NCT06126367||Patients identified as eligible for treatment with either a PCSK9i or inclisiran|
62763959|NCT06126367||Patients with moderate or severe aortic calcification identified by non-enhanced cardiac CT scan|
62763960|NCT02275728|EXPERIMENTAL|Pelvic Floor Muscle Training(PFMT)|The conducted training by two groups, consisting of phasic contractions (3 sets of 10 repetitions of maximal contraction for two seconds to double or triple rest), endurance (two sets of six repetitions of sustained contractions of 6-10 seconds with the same rest time) and training effort, requesting the anticipated contraction of the abdominal pelvic floor coughing effort. We used the same protocol in the supine position, sitting and standing, as evolution of the patient. Both were treated 2 times per week, 20 minutes, totaling 8 sessions.
62763961|NCT02275728|ACTIVE_COMPARATOR|EMG Biofeedback treatment|In this group, the same protocol of the TMAP will be held, however, emg biofeedback is used during training for 20 minutes, 2 times a week, 8 sessions.
61988521|NCT06167993|EXPERIMENTAL|Group receiving CDP in patients who underwent LVA|LVA: Group that underwent lymphovenous anastomosis surgery and CDP applied groups CDP:Complex Decongestive Physiotherapy
61988522|NCT06167993|ACTIVE_COMPARATOR|Group receiving CDP after lymphedema|Only CDP applied groups
61988523|NCT05419076|EXPERIMENTAL|Participants with small cell lung cancer with brain metastases|Participants may be newly diagnosed small cell lung cancer with brain metastases at initial staging, or can alternatively be patients who develop brain metastases on therapy or during surveillance of systemic disease.
61988524|NCT03061110|ACTIVE_COMPARATOR|Usual Care|Subjects in the Usual Care arm will receive typical therapies to manage the symptoms of dry mouth including but not limited to: chewing gum, sucking sugar-free candy, sipping water, mouth rinses and over-the-counter artificial saliva preparations.
61988525|NCT03061110|EXPERIMENTAL|Stromal Vascular Fraction|Subjects in the Stromal Vascular Fraction arm will receive single injections into each of the six (6) peri-oral salivary glands (parotid, submandibular, sublingual).
62168206|NCT01948882|EXPERIMENTAL|ESS505|All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.
62168207|NCT03861429|EXPERIMENTAL|Me & My Wishes Intervention/Group 1|In Group 1 (early intervention group) NHs, video recording, editing, and viewing will occur within three months of baseline.
62763962|NCT02275728|NO_INTERVENTION|no treatment|In this group, will be held only the initial assessment, you will not receive treatment for a month and will be reevaluated after being serviced this period.
62763963|NCT02899923||Autoimmune bullous dermatoses|Patients with autoimmune bullous dermatoses
62763964|NCT06477471|EXPERIMENTAL|Recurrent Kidney Stone with Colicky Pain|Take one slow-release capsule twice a day, after meal, orally.
62763965|NCT05359133|ACTIVE_COMPARATOR|Tetrodotoxin for injection|30 µg, 1 ml SC injection in the thigh or abdomen, twice daily for 4 Days
62763966|NCT05359133|PLACEBO_COMPARATOR|Placebo|1.0 mL of placebo, SC injection in the thigh or abdomen, twice daily for 4 Days
62763967|NCT04138719|EXPERIMENTAL|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles；
62763968|NCT04138719|ACTIVE_COMPARATOR|Nab-paclitaxel + Epirubicin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and epirubicin given IV at 75 mg/m\^2 on days 1 every 21 days x 6 cycles；
62763969|NCT02552251|EXPERIMENTAL|A: hydrocortisone|hydrocortisone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
62763970|NCT02552251|EXPERIMENTAL|B :dexamethasone (DECTANCYL)|dexamethasone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
61988526|NCT06240156|EXPERIMENTAL|3D arch pad design Insole group|This study utilizes a custom-made arch support pad with a 3D three-dimensional design that is already available on the market (patent number I315187). Its arch support principle is designed using 3DBS (Three-Dimensional Biomechanics System - 3DBS), which can conform to the user's feet. In this type, the bottom layer provides an overall shock-absorbing function.
61988527|NCT06240156|PLACEBO_COMPARATOR|flat Insole group|General Insole without any special features
62763971|NCT02552251|EXPERIMENTAL|C : prednisone (CORTANCYL)|prednisone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
62763972|NCT06230315||Cervical spine surgery patients|Patients undergoing multilevel cervical spine surgery at Upstate University hospital
62763973|NCT05021692|EXPERIMENTAL|Intervention|Intervention group: Pregnant women with preeclampsia who receive a web-based support program based on the Health Promotion Model in addition to routine clinical care will form the intervention group.
62763974|NCT05021692|NO_INTERVENTION|Control|Pregnant women who receive routine clinical care applied to pregnant women with preeclampsia will constitute the control group.
62383299|NCT01854957|PLACEBO_COMPARATOR|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
62383300|NCT04693091|EXPERIMENTAL|Senti Arm|"In stage 1 of this study (6 patients), the patient will apply the device and complete the initial patient survey; questions are around usability, comfort (including feelings of pressure), and acceptability. The Investigator will record the time taken to apply the device. A brief 30 seconds of chest sounds will be recorded from each of the nine sensors on the device in three different settings: standing up, lying down, walking around.~In stage 2 of this study (10 patients; 6 of whom would be re-recruited from the first stage), the participant will use the device at home over five days. The Investigator will assess the participant daily for any signs of pressure sores or complications from using the device (including topical allergic reactions). The participant will complete a daily survey. The participant is encouraged to remove the device and apply it at their discretion. The participant can opt-out of wearing the device at any stage."
62383301|NCT01183611|EXPERIMENTAL|A1|health neonates born to mother with positive for both HBsAg and e antigen
61988528|NCT02823275|ACTIVE_COMPARATOR|Functional mobilisation|
61988529|NCT02823275|EXPERIMENTAL|plaster cast fixation|
62383302|NCT01183611|ACTIVE_COMPARATOR|A2|health neonates born to mother with positive for both HBsAg and e antigen
62383303|NCT01183611|EXPERIMENTAL|B1|health neonates born to a mother positive for HBsAg, negative for the hepatitis B e antigen
62383304|NCT01183611|ACTIVE_COMPARATOR|B2|health neonates born to a mother positive for HBsAg, negative for the hepatitis B e antigen
62383305|NCT01183611|EXPERIMENTAL|C1|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
62383306|NCT01183611|ACTIVE_COMPARATOR|C2|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
62383307|NCT01183611|PLACEBO_COMPARATOR|C3|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
62383308|NCT01584128||Oxidized regenerated cellulose|Patients undergoing laparoscopic hysterectomy who have oxidized regenerated cellulose placed at the vaginal cuff at the time of their surgery.
62383309|NCT02940353|OTHER|Treatment with Trefoil concept|Treatment
62383310|NCT05312359|NO_INTERVENTION|Healthy control group|No intervention is conducted in the healthy control group.
62763975|NCT04764734|EXPERIMENTAL|PSG and NightOwl|During the study, for each execution day, all patients that have been scheduled for a PSG will be presented with the informed consent form. All recruited patients shall be a part of the study during which they wear the NightOwl Sensor while undergoing the PSG exam.
61988530|NCT06224933|EXPERIMENTAL|Patients Undergoing Augmented Reality Image-Guided Needle Procedures|Patients will undergo their standard of care image-guided needle biopsy, aspiration, or injection with the Augmented Reality system. Patients will be monitored for adverse events for two weeks following their procedure.
61988531|NCT04828889|EXPERIMENTAL|research|The subjects in the study group will undergo a series of 4 treatments by 2 certified physiotherapists for pelvic floor treatment that will include instruction in self-use of anal dilators once a week for four weeks. The anal dilation will be performed using Dilatan® anal dilators (Enterprises Sapimed, Alessandria) in varying sizes of 22, 23 and 27 mm. In the first week, a 20 mm dilator will be inserted twice a day for at least 10 minutes. In the second week, a 23 mm extender will be inserted into the anus, twice a day for at least 10 minutes. In the last two weeks, a 27 mm extender will be inserted twice a day for at least 10 minutes. To facilitate the insertion of the extender, patients will use lubricating cream. At the end of each week, patients will meet with a pelvic floor physiotherapist to make sure that the insertion is done properly, that there are no side effects and that it is possible to move on to the next step.
61988532|NCT04828889|NO_INTERVENTION|waiting|The subjects in the waiting group will be able after a month to choose to undergo surgery or also receive treatment by extenders.
61988533|NCT04828889|ACTIVE_COMPARATOR|surgery|The subjects in the surgery group will undergo surgical treatment only.
61988534|NCT02210936|OTHER|PDMP Data|
61988535|NCT02036502|EXPERIMENTAL|Part 1:pembro 2mg/kg+len 25mg+dex 40 mg|Participants in Part 1 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 2 mg/kg once every 2 weeks (Q2W) (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg once weekly (Q1W) during Cycle 1 (28-day cycle).
61988536|NCT02036502|EXPERIMENTAL|Part 1:pembro 2mg/kg+len 10 mg+dex 40 mg|Participants in Part 1 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 2 mg/kg Q2W (Days 1 and 15) in combination with lenalidomide 10 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).
61988537|NCT02036502|EXPERIMENTAL|Part 2:pembro 200 mg+len 25 mg+dex 40 mg|Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).
61988538|NCT02036502|EXPERIMENTAL|Part 2:pembro 200 mg+len 25 mg+dex 20 mg|Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 20 mg Q1W during Cycle 1 (28- day cycle).
61988539|NCT02036502|EXPERIMENTAL|Part 2:pembro 200 mg+len 10 mg+dex 40 mg|Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 10 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).
61988540|NCT02036502|EXPERIMENTAL|Part 3:pembro 200 mg+len 25 mg+dex 40 mg|Participants in Part 3 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg Q1W weekly during each 28-day cycle.
61988541|NCT02036502|EXPERIMENTAL|Part 3:pembro 200 mg+len 25 mg+dex 20 mg|Participants in Part 3 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 20 mg Q1W weekly during each 28-day cycle.
61988542|NCT02036502|EXPERIMENTAL|Part 3:pembro 200 mg+carf 56 mg/m^2+dex 20 mg|Participants in Part 3 with relapsed or refractory multiple myeloma (rMM) received pembrolizumab 200 mg Q3W in combination with carfilzomib 56 mg/m\^2 (Days 1, 2, 8, 9, 15, 16) and dexamethasone 20 mg once or twice weekly (Days 1, 2, 8, 9, 15, 16, 22, 23) during each 28-day cycle.
61988543|NCT04738916|EXPERIMENTAL|Vibration Group|The vibration group was included in the low frequency (25 Hz), low amplitude (2mm), fixed six-week training on two non-consecutive days of the week.
61988544|NCT04738916|NO_INTERVENTION|Control Group|No training was given to the control group.
61988545|NCT02909452|ACTIVE_COMPARATOR|ENT 1mg daily with pembro every 3 weeks|Entinostat daily in combination with pembrolizumab every three weeks
61988546|NCT02909452|ACTIVE_COMPARATOR|ENT 5mg weekly with pembro every 3 weeks|Entinostat once weekly in combination with pembrolizumab every three weeks
61988547|NCT02909452|ACTIVE_COMPARATOR|ENT 10mg bi-weekly with pembro every 3 weeks|Entinostat once every other week in combination with pembrolizumab every three weeks
62383311|NCT05312359|EXPERIMENTAL|Intervention group of amphetamine addiction|A 20-minute tACS intervention of real-stimulus is conducted twice a day for a total of 10 days in the intervention group of amphetamine addiction.
62383312|NCT05312359|SHAM_COMPARATOR|Control group of amphetamine addiction|A 20-minute tACS intervention of sham-stimulus is conducted twice a day for a total of 10 days in the control group of amphetamine addiction.
62383313|NCT05312359|EXPERIMENTAL|Intervention group of alcohol addiction|A 20-minute tACS intervention of real-stimulus is conducted twice a day for a total of 10 days in the intervention group of alcohol addiction.
62763976|NCT05667805|ACTIVE_COMPARATOR|Liberal substitution of human prothrombin complex and/or platelet concentrates|If INR \< 1,5: 10 I.E. human prothrombin complex/kg bodyweigt/0,5 INR AND/OR If platelets \< 50 G/l: ((50 G/l - measured thrombocyte concentration G/l) x total blood volume) platelet concentrate
62763977|NCT05667805|EXPERIMENTAL|Restrictive substitution of human prothrombin complex and/or thrombocytes|No substitution of blood products described in the Active Comparator group.
62763978|NCT00841750|EXPERIMENTAL|No chest tube|No chest tube left in the pleural cavity at the end of a VATS pulmonary wedge resection.
62763979|NCT00841750|ACTIVE_COMPARATOR|Chest tube|Chest tube left in the pleural cavity at the end of a VATS pulmonary wedge resection.
61988548|NCT04548921||Participants with Friedreich's Ataxia|Participant diagnosed with Friedreich's Ataxia aged between 2 and 50 years of age
62383314|NCT05312359|SHAM_COMPARATOR|Control group of alcohol addiction|A 20-minute tACS intervention of sham-stimulus is conducted twice a day for a total of 10 days in the control group of alcohol addiction.
62383315|NCT00529152|OTHER|A|Ferriprox Oral Solution single treatment
62383316|NCT03397199|EXPERIMENTAL|Apatinib + S-1|Apatinib + S-1
62383317|NCT01246024|EXPERIMENTAL|Hypoxia|
62383318|NCT03264027|EXPERIMENTAL|Carbon dioxide|Argon fulguration will be performed using CO2 for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
62763980|NCT02714270|ACTIVE_COMPARATOR|modified partograph|routine modified partograph
62763981|NCT02714270|ACTIVE_COMPARATOR|paperless partograph|paperless partograph with no graph paper
62383319|NCT03264027|ACTIVE_COMPARATOR|Ambient air|Argon fulguration will be performed using ambient air for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
62383320|NCT02853318|EXPERIMENTAL|Treatment (pembrolizumab, bevacizumab, cyclophosphamide)|Patients receive pembrolizumab IV over 30 minutes and bevacizumab IV over 30-90 minutes on day 1 and cyclophosphamide PO QD on days 1-21. Treatment repeats every 3 weeks for up to 17 courses in the absence of disease progression or unacceptable toxicity. Patients without evidence of disease progression may continue treatment in the absence of disease progression or unacceptable toxicity.
62383321|NCT01089933|EXPERIMENTAL|Thoracic PVB + multimodal anesthesia|Thoracic PVB + multimodal anesthesia
62763982|NCT05563116||People living with HIV (PLHIV)|"Adults over 18 living with HIV. Participants were referred to one of our two study centers for cardiovascular assessment as part of their routine care.~PLHIV are at intermediate cardiovascular risk, they present at least one cardiovascular risk factor without established cardiovascular disease.~NB: all tests performed are part of routine care for cardiac prevention in France (no study specific interventions were performed.)"
62763983|NCT05563116||HIV negative subjects|"Adults over 18 without HIV infection. Participants were referred to one of our two study centers for cardiovascular assessment as part of their routine care.~HIV- subjects are at intermediate cardiovascular risk, they present at least one cardiovascular risk factor without established cardiovascular disease.~NB: all tests performed are part of routine care for cardiac prevention in France (no study specific interventions were performed.)"
62763984|NCT06506994|EXPERIMENTAL|Treatment group A: HRS-9057/ Tolvaptan|
62763985|NCT06506994|EXPERIMENTAL|Treatment group B: HRS-9057/ Tolvaptan|
62763986|NCT00001464||Group 1|Smokers exposed to oxygen
62763987|NCT04103463|EXPERIMENTAL|Interactive stepping exercise group|
62383322|NCT01089933|ACTIVE_COMPARATOR|Local anesthetic + multi-modal analgesia|Local anesthetic + multi-modal analgesia
62383323|NCT02067546|EXPERIMENTAL|Experimental toilet seat|Experimental toilet seat for 1 month
62383324|NCT02067546|SHAM_COMPARATOR|Standard toilet seat|Standard toilet seat for 1 month
62383325|NCT01309646|EXPERIMENTAL|Infanrix-IPV+Hib Group|Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.
61988549|NCT03418909||Oropharyngeal carcinoma (excluding M+ stage)|"Eligible patients with histologically verified early stage squamous cell carcinoma of the oropharynx.~Patients will be treated in accordance with current hospital protocols with transoral robotic surgery (T1-2, N1, M0) or radio(chemo)therapy (any T-stage, any N-stage, M0)."
61988550|NCT03458533||Group 1|Obese patients with indication to bariatric surgery
62763988|NCT04103463|ACTIVE_COMPARATOR|Home exercise group|
62763989|NCT00276627|ACTIVE_COMPARATOR|communication lecture|
62763990|NCT00276627|EXPERIMENTAL|lecture plus CD-ROM|
62763991|NCT00554099|PLACEBO_COMPARATOR|Placebo|Days 1 thru Days 10 to 14 (Visit 2): daily antibiotic therapy, dietary advice, and 6 placebo tablets (matching mesalamine) once a day. Visit 2 thru Week 12 : 1 placebo capsule (matching probiotic) and 6 placebo tablets (matching mesalamine) daily.
62763992|NCT00554099|ACTIVE_COMPARATOR|Mesalamine|Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once a day. Visit 2 thru Week 12: 1 placebo capsule (matching probiotic) and 6 - 400 mg mesalamine tablets daily.
62763993|NCT00554099|ACTIVE_COMPARATOR|Mesalamine & Probiotic|Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once daily. Visit 2 thru Week 12: 1- Bifidobacterium infantis 35624 capsule and 6 - 400 mg mesalamine tablets daily
62763994|NCT03066362|EXPERIMENTAL|Echocardiography-Doppler|Ultrasonographic recordings, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
61988551|NCT03458533||Group 2|Overweight or obese patients without indication to bariatric surgery, able to obtain weight loss trough diet and lifestyle changes
61988552|NCT03458533||Group 3|Overweight or obese patients without indication to bariatric surgery, not able to obtain weight loss trough diet and lifestyle changes
62383326|NCT01309646|ACTIVE_COMPARATOR|Infanrix IPV Group|Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.
62383327|NCT00757289|EXPERIMENTAL|1|PRP injection
62383328|NCT00757289|ACTIVE_COMPARATOR|2|Corticosteroid Injection
62383329|NCT06354920|EXPERIMENTAL|Bonding Bundle Intervention|Doctors in the intervention arm will be asked to use suggested approaches while meeting with their hospitalized patients. The goal of these strategies is to improve the relationship and interactions between patients and physicians.
62383330|NCT06354920|NO_INTERVENTION|Control|Doctors in the control arm will be asked to visit with their patients as they would normally.
62383331|NCT04627233|PLACEBO_COMPARATOR|No intervention:control group|
62383332|NCT04627233|EXPERIMENTAL|Experimental:Intervention group|
62383333|NCT03236935|EXPERIMENTAL|L-NMMA Plus Pembrolizumab|L-NMMA and pembrolizumab will be administered for 6 cycles. Cycle length will be 21 days. L-NMMA will be administered as a 2-hour intravenous (IV) infusion on Days 1-5 at each cycle. The dose levels of L-NMMA are as follows: Dose Level -1, 12.5 mg/kg; Dose Level 0 (starting dose), 15.0 mg/kg; and Dose Level 1, 20 mg/kg. L-NMMA dose will escalate/de-escalate based on the occurrence of dose-limiting toxicities. Pembrolizumab at a fixed dose of 200 mg will be IV infused over 30 minutes on Day 5 at each cycle. Pembrolizumab will be administered 1 hour after L-NMMA infusion on Day 5 at each cycle. Subjects without disease progression after 6 cycles of L-NMMA and pembrolizumab will continue pembrolizumab until disease progression or unacceptable AEs.
62383334|NCT06104709||LUAD patients undergoing cryoablation|No interventions.
62383335|NCT06071533||Danshen Injection(DS group)|patients received Danshen Injection
62383336|NCT06071533||Sportive Care group (SC group)|patients received sportive care without Danshen Injection
62383337|NCT01183130|EXPERIMENTAL|Compliance monitoring in real time|Patients get their opioid substitution medications in electronic compliance monitoring devices and send information of their medication intakes with mobile phone to the clinic every day during the two month study period.
62383338|NCT01183130|ACTIVE_COMPARATOR|Compliance monitoring|Patients get their opioid substitution medications in electronic compliance monitoring devices. Information of their medication intakes will be reviewed during the weekly visits to the clinic.
62383339|NCT02572869||segmental mandibulectomy and free fibular flap reconstruction|Patients who underwent segmental mandibulectomy and free fibular flap reconstruction at MSK between 1987 and 2014
62383340|NCT00395720|ACTIVE_COMPARATOR|1|Group 1 (10 volunteers): 5 x 10\^7 pfu
62763995|NCT01359605|EXPERIMENTAL|varespladib methyl|
61988553|NCT03525015|EXPERIMENTAL|A decision aid booklet|A decision aid booklet about cataract surgery choice
61988554|NCT03525015|ACTIVE_COMPARATOR|An usual booklet|An usual booklet about cataract and cataract surgery
62168208|NCT03861429|OTHER|Me & My Wishes Wait-list control/Group 2|In Group 2 (delayed sharing) NHs, residents will be on a wait-list; after the delayed start, their video will be produced and viewed within three months.
62383341|NCT00395720|ACTIVE_COMPARATOR|2|Group 2 (10 volunteers): 1 x 10\^8 pfu
62383342|NCT06330649|EXPERIMENTAL|Energy Drink|A commercially available caffeine drink containing 200 mgs of caffeine.
62383343|NCT06330649|PLACEBO_COMPARATOR|Water|This will be 12 fl oz of commercially available water .
62383344|NCT00642122|EXPERIMENTAL|1|Pulmicort RESPULES
62383345|NCT00642122|EXPERIMENTAL|2|Pulmicort TURBUHALER
62383346|NCT02842255|EXPERIMENTAL|Healthy volunteers|
62383347|NCT01584115|EXPERIMENTAL|NY-ESO-1|NY-ESO-1 combined with MPLA vaccine
62383348|NCT02469506|EXPERIMENTAL|NMES group|Patients will receive twice daily sessions of neuromuscular electrical stimulation (NMES).
62383349|NCT02469506|NO_INTERVENTION|Control group|Patients will receive daily visits by the investigator to check progress.
62383350|NCT04056962|EXPERIMENTAL|patients treated with tacrolimus 0.03% ointment|patients treated with tacrolimus 0.03% ointment
62383351|NCT04056962|ACTIVE_COMPARATOR|patients treated with tacrolimus 0.1% ointment|patients treated with tacrolimus 0.1% ointment
62383352|NCT03187626|EXPERIMENTAL|Intra-articular botulinum toxin A and splinting|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
62383353|NCT03187626|ACTIVE_COMPARATOR|Intra-articular saline and splinting|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
62383354|NCT03116633||Arm A|1st line setting-approx. 150 patients. collect tissue biopsy per standard of care \& one blood draw (40ml)
62383355|NCT03116633||Arm B|1st line setting- approx. 100 patients one blood draw (40ml)
62383356|NCT03116633||Arm C|Approx. 10 patients tissue collection optional 3 blood draws (40ml) over 5 days
62763996|NCT03227068|EXPERIMENTAL|PEDSS - symptom management|Content for the PEDSS - symptom management includes the most commonly experienced treatment-related physical symptoms, descriptions of each symptom, strategies to reduce symptom distress, and when and how to contact the cancer care team.
62763997|NCT03227068|EXPERIMENTAL|PEDSS - support for the caregiver|Content for the PEDSS - support for the caregiver includes five topics and suggestions on how caregivers can care for themselves during this time.
62763998|NCT01335841|EXPERIMENTAL|3D fluoroscopy and navigation station|
62763999|NCT01335841|ACTIVE_COMPARATOR|2D and anatomical landmarks|
62764000|NCT01798641|EXPERIMENTAL|Open Shunt|The programmable valve, MIETHKE proGAV® / MIETHKE proSA®, will be open at this time. The adjustment is done in the out-patient clinic.
62764001|NCT01798641|PLACEBO_COMPARATOR|Closed Shunt|The programmable valve, MIETHKE proGAV® / MIETHKE proSA®, will be closed during this time. The adjustment is done in the out-patient clinic.
62764002|NCT01150201|EXPERIMENTAL|Aliskiren|Aliskiren
62764003|NCT01150201|ACTIVE_COMPARATOR|Losartan|ARB
62764004|NCT00539422||I|group I of 15 women with benign breast lesion
62764005|NCT00539422||II|group II of 16 women with breast cancer
62764006|NCT00539422||III|13 women were taken as a control group
62764007|NCT00650455|ACTIVE_COMPARATOR|Arm 2|
62764008|NCT00650455|PLACEBO_COMPARATOR|Arm 3|
62383357|NCT02429206|ACTIVE_COMPARATOR|Positive Control|Each volunteer will be asked to self-apply a standard moisturizing cream (Glaxal Base) on one side of their body. Application twice a day during 14 days.
62764009|NCT00650455|ACTIVE_COMPARATOR|Arm 1|
62764010|NCT04828291|EXPERIMENTAL|Online Mindfulness Intervention (OMI)|Before beginning the daily practices, this group will be introduced to the OMI via an online platform and answer any questions about the practice. Then, each day, this group will be guided through a series of mindfulness practices offered online (www.bemindfulonline.com) delivered on their smartphones or laptops.
62764011|NCT04828291|EXPERIMENTAL|OMI paired with peer support (OMI+)|Before beginning the daily OMI, in addition to being briefed, this group will be paired with a peer to be in touch with and guide and support each other in this process. Then they will start the OMI program and will follow parallel instructions as the OMI group. The peer support will include five brief (30-minute) weekly meetings to support and encourage each other to continue practicing mindfulness and to complete the online intervention. Each week we will provide prompts and topics for participants to discuss and at the end of each meeting, participants will then complete a short, 5-10 minute post-meeting survey to assess the well-being and attitudes of their partner (see additional materials for meeting prompts and post-meeting survey questions). The first of these meetings will occur on Day 8, and subsequent weekly meetings during the intervention period will be scheduled based on the shared availability of both participants in each pair.
62764012|NCT04828291|ACTIVE_COMPARATOR|Active control receiving cognitive exercises|Instead of the OMI, this group will be receiving cognitive exercises in the intervention period.
62764013|NCT02772978|ACTIVE_COMPARATOR|tolcapone arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
62764014|NCT02772978|PLACEBO_COMPARATOR|placebo arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
62764015|NCT04175067||Endometrium cancer|stage I endometrium cancer n=57
62764016|NCT04175067||Healthy controls|Healthy volunteers n=60
62764017|NCT05270226|EXPERIMENTAL|Group A|After being randomly allocated, group A participants had first evaluation (out of 3, pre-intervention) and immidiatlly recived Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE).
62764018|NCT05270226|EXPERIMENTAL|Group B|After being randomly allocated, group B participants had first evaluation (out of 4), then waiting-phase of 10-11 weeks, and after second evaluation (pre-intervention) start Work-MATE intervention process.
62764019|NCT06076928|SHAM_COMPARATOR|Conventional supervised occupational therapy (CT)|CT consists of standard occupational therapy for hand function which includes but not limited to the following treatment (1) passive and active mobilisation; (2) spasticity management; (3) training with use of various modalities/equipment; (4) gross and fine motor training including reach and grasp/release functions, and object manipulation; (5) grasp training: cylindrical, spherical, intrinsic, 2-finger pincer and 3-finger grip.
62764020|NCT06076928|ACTIVE_COMPARATOR|HandyRehab (HR) with supervised training by OT|HR training consists of (1) passive and active mobilisation (2) spasticity management (3) gross motor training with HR applied (4) grasp training: cylindrical, spherical, intrinsic, 2-finger pincer and 3-finger grip.
62764021|NCT06076928|EXPERIMENTAL|HandyRehab integrated with BCI (BCI-HR) with supervised training by OT|BCI-HR training consists of (1) passive and active mobilisation (2) spasticity management (3) gross motor training with BCI-HR applied (4) grasp training: cylindrical, spherical, intrinsic, 2-finger pincer and 3-finger grip.
62764022|NCT05900570|EXPERIMENTAL|Urodynamic testing and LLP with and without pudendal nerve stimulation|Commercially available stimulation needles or leads will be inserted into the peri-urethral space targeting the perineal branch of the pudendal nerve. An external neurostimulator settings will be adjusted to deliver acute stimulation. Urodynamic testing will be completed by filling the bladder to a set volume and observing for urinary leakage. The assessment will be completed with stimulation turned on and off. The neurostimulator device settings will be adjusted by the investigator to stay within safe and comfortable levels for each individual study participant.
62764023|NCT03619226|EXPERIMENTAL|test patch|two adhesive patches are applied to the abdominal area
62764024|NCT00803413|OTHER|Back School|Participants received weekly sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)
62764025|NCT00803413|OTHER|Supervised Walking|Participants received weekly sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group
62168209|NCT02800135|EXPERIMENTAL|Furosemide stress test|
62764026|NCT00803413|OTHER|Back School and Walking|Participants received weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening); 30 minutes of on-place supervised walking in group
62764027|NCT00803413|OTHER|Control Group|Participants received weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
62764028|NCT03385278|EXPERIMENTAL|real-sham|the group first received real rTMS,then sham one.
62764029|NCT03385278|EXPERIMENTAL|sham-real|the group first received sham rTMS,then real one.
62764030|NCT04945967|EXPERIMENTAL|New Method|This intervention will be given once a day, 30 minutes before feeding schedule based on the neonatologist. Each session of intervention will take time about 18 minutes.
62764031|NCT04945967|ACTIVE_COMPARATOR|Conventional Method|This intervention will be given once a day, 30 minutes before feeding schedule based on the neonatologist. Each session of intervention will take time about 15 minutes.
62764032|NCT04816383|EXPERIMENTAL|Experimental Arm|The participant will receive usual breastfeeding care such as counseling by her physician, access to lactation consults, nursing assistance in the hospital, access to our online resources. The participant will also receive the Apple breastfeeding application in the office once enrolled in the study between 32 to 36 weeks gestation. The participant will be taught how to use the application, and will have access to the study to continue use throughout the duration of follow-up.
62764033|NCT04816383|NO_INTERVENTION|Control Arm|The participant will receive usual breastfeeding care such as counseling by her physician, access to lactation consults, nursing assistance in the hospital, access to our online resources.
62764034|NCT00300677|EXPERIMENTAL|voriconazole|voriconazole twice daily
62764035|NCT02320851|EXPERIMENTAL|SVD-tailored Integrative Psychotherapy (IPT)|IPT is a short-term psychotherapy aiming to ameliorate both physical and psychosocial distress. It emanates from a multidirectional and dynamic relationship among body, mind, and environment irrespective of causality. In a multi-component approach, other elements are integrated into it, such as cognitive-behavioral and psychodynamic techniques, psychoeducation and body-oriented techniques. The IPT intervention tailored to SVD will be delivered for 16 weeks in a manualised setting with one group session per week (à 90 minutes) and one additional booster session three months after the end of the therapy. The group psychotherapy is on a 6-8:1 basis and will be conducted by a psychotherapist trained on the basis of the manual and under regular clinical supervision.
62383358|NCT02429206|EXPERIMENTAL|Experimental Cream|Each volunteer will be asked to self-apply the experimental product (SQIN with CanSATs technology) on the other side of their body. Application twice a day during 14 days.
62383359|NCT03884049|EXPERIMENTAL|Embolization group|Group undergoes transcatheter arterial embolization of neovessels around the knee.
62383360|NCT03884049|SHAM_COMPARATOR|Sham Embolization Group|Group undergoes sham embolization
62383361|NCT01790763|ACTIVE_COMPARATOR|Keramatrix|Keramatrix
62383362|NCT01790763|ACTIVE_COMPARATOR|Mepilex|Mepilex
62383363|NCT03802201|EXPERIMENTAL|PTG-300 Active|Drug: PTG-300 Subcutaneous
62383364|NCT02010073||One Group|This is a prospective observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
62383365|NCT03725566|EXPERIMENTAL|Experimental|Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
62383366|NCT02827331||Patients exposed to benzodiazepines|"Data to be collected are :~* Administrative and medical data~* Exposition to hypnotics or anxiolytics benzodiazepines"
62383367|NCT02827331||Patients not exposed to benzodiazepines|"Data to be collected are :~* Administrative and medical data~* Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics"
62383368|NCT02827331||Control group|"Data to be collected are :~* Administrative and medical data~* Medical consultation without prescription of interest"
62383369|NCT00045019||discharged cancer patients|patients discharged from a surgery or medical ward of oncology institutes in Belgium, France, Germany, Italy, Poland, Spain, Sweden, Taiwan and United Kingdom (as part of a larger psychometric validation study) were asked to rate there level of satisfaction, using the EORTC QLQ-SAT32.
62567634|NCT05306912|EXPERIMENTAL|blood sampling|blood sample (2 tubes of 7.5 mL of blood = 15 mL) during the preoperative check-up on the day of the ultrasound-bronchoscopy in order to compare the sensitivity of the analysis of free circulating DNA present in the supernatant of pulmonary nodules less than 20 mm samples taken under ultrasound-bronchoscopy to that present in the plasma
61988555|NCT04881357|EXPERIMENTAL|Experimental Group|The experimental group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).
61988556|NCT04881357|PLACEBO_COMPARATOR|Control Group|The control group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the control mouth rinse (Lacer Oros Acción Integral - new formula, without active ingredients, Barcelona, Spain).
61988557|NCT05751239||Bisexual-Biromantic|People that self-identify as bisexual-biromantic
61988558|NCT05751239||Heterosexual-heteroromantic|People that self-identify as heterosexual-heteroromantic
61988559|NCT05751239||Homosexual-homoromantic|People that self-identify as homosexual-homoromantic
61988560|NCT05751239||Pansexual-panromantic|People that self-identify as pansexual-panromantic
61988561|NCT00790439|EXPERIMENTAL|LMW-SD|18 participants randomized to immunosuppression with Low Molecular Weight Sulfated Dextran (LMW-SD)
61988562|NCT00790439|ACTIVE_COMPARATOR|Control Group, Standard of Care|18 participants randomized to immunosuppression without Low Molecular Weight Sulfated Dextran (LMW-SD)
61988563|NCT05931328|EXPERIMENTAL|thiotepa+pomalidomide|thiotepa combined with pomalidomide: thiotepa 30mg/m2,intravenously guttae, on day 1; pomalidomide 12mg orally daily for 2 weeks. A chemotherapy cycle lasts for 3 weeks.
61988564|NCT01157507|ACTIVE_COMPARATOR|Botulinum A toxin|Botulinum A toxin intravesical injection.
61988565|NCT01157507|SHAM_COMPARATOR|Bladder overdistension|Standard treatment: bladder overdistension
61988566|NCT01157507|PLACEBO_COMPARATOR|Placebo|
62764036|NCT02320851|ACTIVE_COMPARATOR|Self-help group (SHG)|The experimental condition will be compared to moderated self-help groups without the implementation of additional therapeutic interventions. Those can be classified as low-level non-placebo control. Treatment will consist of 16 weekly moderated SHG sessions (one weekly session à 90 minutes) and one additional booster-session at three months after the end of the control intervention to be delivered on a 6-8:1 basis by a trained SHG moderator under clinical supervision.
61988567|NCT05817019|EXPERIMENTAL|Sugammadex|sugammadex 2mg/kg
61988568|NCT05817019|ACTIVE_COMPARATOR|Neostigmine|neostigmine 50µg/kg + glycopyrollate 0.01mg/kg
61988569|NCT05659628|EXPERIMENTAL|CAR-T combined with anti-PD1 treatment group|CD19-7×19 CAR-T combined with Tislelizumab
61988570|NCT03024307|EXPERIMENTAL|Involvement of pharmacists in improving medication|Pharmacists involved care group. Tools used to improve medication adherence, (1)Patient medication guide (2)tailored Short Messaging Service (SMS) (3)Pharmaceutical follow-up
62764037|NCT02002468|EXPERIMENTAL|Test result sent by letter|The pap-smear test result is sent by letter directly to the women. Women in need of follow up are in the letter recommended to contact their general practitioner.
62764038|NCT02002468|ACTIVE_COMPARATOR|Test result conveyed by general practitioners|In Denmark it is a standard procedure that general practitioners convey the pap-smear test results to the women.
62764039|NCT03118999|EXPERIMENTAL|OM3-FFA|Omega3 linked to free fatty acids
62764040|NCT03118999|EXPERIMENTAL|OM3 -MAG|Omega3 linked to Monoacylglycerol
62764041|NCT03118999|EXPERIMENTAL|OM3-EE|Omega3 linked to ethylester
61988571|NCT03024307|NO_INTERVENTION|usual care only|Patients were provided with usual care.
61988572|NCT00382954|EXPERIMENTAL|Phase 1 escalation|
61988573|NCT01218555|EXPERIMENTAL|Lenalidomide combination with everolimus|Non-randomized study of escalating doses of daily, orally administered lenalidomide in combination with standard doses of everolimus, an orally available mammalian target of rapamycin (mTOR) inhibitor.
61988574|NCT02482103||Patients treated with renal denervation|Patients treated with RD in the Netherlands. The decision to perform RD was made by the treating physician in the participating hospitals.
61988575|NCT00697515|ACTIVE_COMPARATOR|Lisdexamfetamine Dimesylate (LDX, SPD489)|
61988576|NCT00697515|PLACEBO_COMPARATOR|Placebo|
61988577|NCT05142423|EXPERIMENTAL|AK109+AK104|AK104: 10mg/kg (d1, q3w); AK109: 10mg/kg or 15mg/kg(d1, q3w)
61988578|NCT02493699|EXPERIMENTAL|Exercise|physical exercise- based intervention (Karate techniques training)
61988579|NCT02493699|NO_INTERVENTION|Control|Not participating in physical exercise- based intervention (Karate techniques training)
61988580|NCT02221375|EXPERIMENTAL|BHT low|
61988581|NCT02221375|EXPERIMENTAL|BHT medium|
61988582|NCT02221375|EXPERIMENTAL|BHT high|
61988583|NCT02221375|EXPERIMENTAL|BI 54903 XX low|
61988584|NCT02221375|EXPERIMENTAL|BI 54903 XX medium 1|
61988585|NCT02221375|EXPERIMENTAL|BI 54903 XX medium 2|
61988586|NCT02221375|EXPERIMENTAL|BI 54903 XX high|
61988587|NCT02221375|EXPERIMENTAL|BI 54903 XX medium single dose|
61988588|NCT02221375|ACTIVE_COMPARATOR|Ciclesonide|
61988589|NCT03133156|EXPERIMENTAL|Moderate Intensity Training-Healthy Lean|Eligible subjects will undergo a 10-week moderate intensity exercise program.
61988590|NCT03133156|EXPERIMENTAL|Moderate Intensity Training-Healthy Overweight/Obese|Eligible subjects will undergo a 10-week moderate intensity exercise program.
62764042|NCT06390787|ACTIVE_COMPARATOR|Metoclopramide Group|This group of 50 patients with vomiting were given Metoclopramide only for vomiting.
62764043|NCT06390787|ACTIVE_COMPARATOR|Zofran Group|This group of 50 patients with vomiting were given Zofran only for vomiting.
62764044|NCT06390787|EXPERIMENTAL|B6 and Metoclopramide Group|This group of 50 patients with vomiting were given B6 and Metoclopramide combination for vomiting.
62764045|NCT06390787|NO_INTERVENTION|Control Group|This group of 50 patients with vomiting were given nothing for vomiting.
62764046|NCT06390787|ACTIVE_COMPARATOR|Vitamin B6 Group|This group of 50 patients with vomiting were given Vitamin B6 only for vomiting.
62764047|NCT04154319|ACTIVE_COMPARATOR|HPV Vaccination|Mothers participated in educational/behavior change sessions to promote HPV vaccination among their 9-12 year old daughters
62764048|NCT04154319|ACTIVE_COMPARATOR|Healthy Eating|Mothers and daughters participated in educational/behavior change sessions to promote healthy eating and appropriate nutrition label interpretation
62764049|NCT04278937|ACTIVE_COMPARATOR|Azithromycin group|women will receive 500mg Azithromycin (Zithrokan®, Hikma, Egypt) one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks in addition to routine usual antenatal care.
62764050|NCT04278937|NO_INTERVENTION|Control group|women will receive routine antenatal care without antibiotic prophylaxis after cerclage.
62764051|NCT01789528|EXPERIMENTAL|CAZ-AVI or CXL|"Cohort 1: CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) by intravenous infusion given over 2 hours, every 8 hours~Cohort 2: CXL (600 mg ceftaroline fosamil and 600 mg avibactam)"
62764052|NCT04104919|EXPERIMENTAL|Brivoligide Injection 660 mg/6 mL|Subjects randomized to the brivoligide treatment group will receive a single 660 mg/6 mL intrathecal administration of brivoligide injection while in the lateral decubitus position at lumbar interspace L3/4 or higher. After injection subjects will be placed supine in a 15-degree head down tilt (Trendelenburg position) for 5 minutes and then returned to supine horizontal for surgery.
62764053|NCT04104919|PLACEBO_COMPARATOR|Placebo 6 mL|Subjects randomized to the placebo group will receive a single 6 mL intrathecal administration of placebo while in the lateral decubitus position at lumbar interspace L3/4 or higher. After injection subjects will be placed supine in a 15-degree head down tilt (Trendelenburg position) for 5 minutes and then returned to supine horizontal for surgery.
62764054|NCT02714361|ACTIVE_COMPARATOR|Vitamin D3 supplement|Participants will be asked to take 1 capsule of vitamin D3 supplement (1500 IU) (37.5ug) daily for a total duration of 8 weeks.
62764055|NCT02714361|PLACEBO_COMPARATOR|Placebo|Participants will be asked to take 1 capsule of placebo (65% olive oil) daily for a total duration of 8 weeks.
62764056|NCT04581343|EXPERIMENTAL|Canakinumab, spartalizumab, nab-paclitaxel and gemcitabine|Spartalizumab (PDR001),IV infusion, 400 mg, D1 of each 28-day cycle; Canakinumab (ACZ885), s.c. injection, 250 mg, Day 1 of each 28- day cycle; Gemcitabine, IV Infusion, 1000 mg/m2, Days 1, 8, 15 of each 28-day cycle; Nab-paclitaxel, IV Infusion, 125 mg/m2, Days 1, 8, 15 of each 28-day cycle.
62764057|NCT05128006||In-person new VA dermatology patients|In-person dermatology patients that are new patients at three facilities
62764058|NCT05128006||New patient consultative Teledermatology users|New patient consultative Teledermatology users at three facilities
62764059|NCT05128006||New patient Mobile teledermatology users|New patient Mobile teledermatology users at three facilities
62764060|NCT05128006||In-person new patient in Community Care|In-person new patient in Community Care
62764061|NCT00773240|EXPERIMENTAL|1|Grazax
61988591|NCT03133156|EXPERIMENTAL|Moderate Intensity Training-Overweight/Obese Type 2 Diabetes|Eligible subjects will undergo a 10-week moderate intensity exercise program.
61988592|NCT03133156|EXPERIMENTAL|High Intensity Training-Healthy Lean.|Eligible subjects will undergo a 10-week high intensity exercise program
61988593|NCT03079609|EXPERIMENTAL|microsurgery urology|20 patients with varicocele (grade II or III) undergoing subinguinal microsurgery varicocelectomy due to infertility and/or pain in the scrotum.
61988594|NCT03079609|ACTIVE_COMPARATOR|open general surgery|20 patients (without varicocele) undergoing open hernia repair.
61988595|NCT04219982|EXPERIMENTAL|DPI-386 Nasal Gel|Active DPI-386 Nasal Gel
62567635|NCT01188031|EXPERIMENTAL|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, single dose
62567636|NCT01188031|ACTIVE_COMPARATOR|NIRAVAM TM|NIRAVAM TM 2 mg orally disintegrating tablets, single dose
62764062|NCT00773240|PLACEBO_COMPARATOR|2|
62764063|NCT01071005|EXPERIMENTAL|Test|Lorelin Depot - Bergamo
62764064|NCT01071005|ACTIVE_COMPARATOR|comparator|Lupron Depot® - Abbott
62764065|NCT00369226|EXPERIMENTAL|Bortezomib/Tacrolimus/Methotrexate post HSCT|
62764066|NCT04879394|EXPERIMENTAL|Hypnosis|4 weekly hypnosis sessions, aiming at pain control and distress management. The 90 min. sessions will be conducted in group format by a doctorate-level psychologist trained in hypnosis. Contents will be detailed on hypnosis protocols to ensure standardization.
62764067|NCT04879394|NO_INTERVENTION|Control|Receives standard care as usual. Assessments will be made in the same time points as experimental group, but without undergoing intervention.
62764068|NCT03047018|EXPERIMENTAL|CHANGE Program|Participants with ASD will complete the The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) program.
62764069|NCT03414112|PLACEBO_COMPARATOR|Intranasal Oxytocin Placebo|Intranasal placebo
62764070|NCT03414112|EXPERIMENTAL|Intranasal Oxytocin|Intranasal oxytocin
62764071|NCT00693641|ACTIVE_COMPARATOR|1|"Safe Sea™ jellyfish sting inhibitor (barrier, or repellent) lotion"
62764072|NCT00693641|PLACEBO_COMPARATOR|2|Regular sun lotion
62764073|NCT03612323|EXPERIMENTAL|Intra-ligamentary Piroxicam|Piroxicam is a long acting potent Non steroidal anti-inflammatory drug (NSAID)with half life of 50 hours in plasma, is given as intervention to assess the pain,will be administered by intra-ligamentary technique by injecting 0.4 milliliter (mL) of 20 milligram (Mg) piroxicam.
62764074|NCT03612323|ACTIVE_COMPARATOR|Intra-ligamentary Articaine|Articaine is a local anesthetic agent, will be administered by intraligamentary technique by injecting 0.4 milliliter (mL) of 4% articaine
62764075|NCT03692481|EXPERIMENTAL|18FDG-PET scan|18FDG PET scan will be performed in each patient before initiation of pirfenidone and after 12 weeks of treatment
62764076|NCT04100434|EXPERIMENTAL|the evolocumab plus statin therapy|Patients with ACS are treated with atorvastatin (20mg) daily and evolocumab (140 mg) every two weeks throughout the study period
62764077|NCT04100434|NO_INTERVENTION|the statin alone therapy|Patients with ACS are treated with atorvastatin (20mg) daily throughout the study period.
62764078|NCT04969848||eMSGait|Record of IGP using IMU sensor (Metamotion R mbientlab) during T25FW.
62764079|NCT00680368||Residents and Attending Physicians|This group contains the residents and the attending physicians who consented to participate in the study. They participated in a survey administered by a research assistant. Both physician resident and attending physicians were administered the survey twice within 24-hours and their test-retest responses were compared for reliability. Responses to attending and resident physicians covering the care for the patient and clinical care encounter were compared for accuracy.
62764080|NCT01573637|EXPERIMENTAL|Raloxifene hydrochloride 60 mg|"Patients fulfilling inclusion criteria and those giving the general informed consent for the study will be randomly allocated to one of the two groups in the trial (placebo or raloxifene) in a 1:1 proportion and in blocks of 4 patients, using the random number tables designed for this purpose.~The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Both drugs will be given orally in capsule form. The medication of each of the treatment groups (lactose as placebo, raloxifene) will be introduced into dark green gelatin capsules to guarantee the blinding."
62764081|NCT01573637|PLACEBO_COMPARATOR|Lactosa (placebo)|"Patients fulfilling inclusion criteria and those giving the general informed consent for the study will be randomly allocated to one of the two groups in the trial (placebo or raloxifene) in a 1:1 proportion and in blocks of 4 patients, using the random number tables designed for this purpose.~The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Both drugs will be given orally in capsule form. The medication of each of the treatment groups (lactose as placebo, raloxifene) will be introduced into dark green gelatin capsules to guarantee the blinding."
62764082|NCT00612625|EXPERIMENTAL|GLP-1|A graded glucose infusion with an infusion of GLP-1 (1½ pmol/kg/min)
62764083|NCT00612625|EXPERIMENTAL|Saline|A graded glucose infusion together with a continuous infusion of saline
62764084|NCT05400902|EXPERIMENTAL|HAIC Combined with Sintilimab and Bevacizumab|
62764085|NCT02775942|EXPERIMENTAL|IPOVAC 1.5:5:5|IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
62764086|NCT02775942|EXPERIMENTAL|IPOVAC 3:10:10|IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
62764087|NCT02775942|EXPERIMENTAL|IPOVAC 6:20:20|IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
62764088|NCT02775942|ACTIVE_COMPARATOR|IMOVAC-POLIO|IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval
62764089|NCT05203367|EXPERIMENTAL|BAR 502|Each subject will receive an oral single-dose of BAR 502.
62764090|NCT05203367|PLACEBO_COMPARATOR|Placebo|Each subject will receive an oral single-dose of placebo.
61988596|NCT04219982|PLACEBO_COMPARATOR|DPI-386 Placebo Nasal Gel|Placebo Nasal Gel
61988597|NCT04219982|ACTIVE_COMPARATOR|Transderm Scop® (TDS)|FDA approved Transderm Scop® (TDS).
61988598|NCT03935009|ACTIVE_COMPARATOR|Manual toothbrush with electric toothbrush N°1|Participants will receive manual toothbrush (Curaprox 5460 ultra soft, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chums) and an electric toothbrush N°1 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App) and will be instructed to use them for six weeks.
61988599|NCT03935009|ACTIVE_COMPARATOR|Manual toothbrush with electric toothbrush N°2|Participants will receive manual toothbrush (Curaprox 5460 ultra soft, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chums) and an electric toothbrush N°2 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia) and will be instructed to use them for six weeks.
62764091|NCT00428220|EXPERIMENTAL|A|"Sunitinib will be administered in a continuous daily dose (oral, once per day). Starting dose will be 37.5 mg daily unless the patient was on a different dose (25 mg or 50 mg daily) on the previous trial. In that case, they will begin treatment on this study at the same dose used at the end of the previous study.~The protocol now allows for patients on dosing regimens other than only continuous dosing (e.g. 4/2, etc.) to be enrolled if eligible."
62764092|NCT03519334||Chronic health condition group/study|People with any of the following chronic health conditions: Diabetes, Chronic obstructive Pulmonary Disease, Major Depression, Dysthymia, Migraine, Back \& Neck Pain, Cancer, Ischemic Heart Disease
62764093|NCT03519334||Expert consultation group/study|Relevant contacts from advocacy organizations operating at European level for the professional integration of people with chronic health conditions.
62764094|NCT02365285|EXPERIMENTAL|Galantamine 16 mg then placebo|Galantamine 16 mg po one time dose then placebo on 2nd visit
61988600|NCT03935009|ACTIVE_COMPARATOR|Electric toothbrush N°1 with electric toothbrush N°2|Participants will receive an electric toothbrush N°1 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App) and an electric toothbrush N°2 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia) and will be instructed to use them for six weeks.
61988601|NCT01422863|EXPERIMENTAL|Lifestyle Intervention|
61988602|NCT02428881|EXPERIMENTAL|Complete retention- onabotulinumtoxinA|Women in complete urinary retention receiving onabotulinumtoxinA
62764095|NCT02365285|PLACEBO_COMPARATOR|Placebo then Galantamine 16 mg|Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit
62764096|NCT06013956|EXPERIMENTAL|eiDBS suppression|Closed-loop evoked interference DBS that suppresses beta oscillations.
62764097|NCT06013956|NO_INTERVENTION|Off DBS|Off-stimulation and off-medication
61988603|NCT02428881|EXPERIMENTAL|Obstructed voiding- onabotulinumtoxinA|Women with obstructed voiding receiving onabotulinumtoxinA
61988604|NCT00587483|ACTIVE_COMPARATOR|Lidocaine 1.5 mg /kg|Lidocaine is a class I (sodium channel block) antiarrhythmic drug.
62168210|NCT03941990|EXPERIMENTAL|Nitrous oxyde|will inhale experimental treatment throughout the entire procedure (50% N2O - 50% 02)
62383370|NCT05515653||Case - atherosclerotic cardiovascular disease|Patients with the first atherosclerotic cardiovascular event (Acute Myocardial Infarction, Stroke and Peripheral Artery Thrombotic-Ischemic Events)
62764098|NCT06013956|EXPERIMENTAL|eiDBS amplification|Closed-loop evoked interference DBS that amplifies beta oscillations.
62764099|NCT06013956|EXPERIMENTAL|Levodopa medication|On-medication, off-stimulation
62764100|NCT06356012|EXPERIMENTAL|Imiquimod treatment plus Loop Electrosurgical Excision Procedure|36 patients diagnosed with CIN 3 who will be undergone 16 applications of 5g imiquimod twice a week and then Loop Electrosurgical Excision Procedure will procedure (60 days). Pathological analysis will evaluate the lesion histologically after immunomodulatory treatment. The individual's immunological response will also be evaluated during applications and after surgical intervention.
62764101|NCT06356012|ACTIVE_COMPARATOR|Loop Electrosurgical Excision Procedure|30 patients diagnosed with CIN 3 who will be undergone Loop Electrosurgical Excision Procedure (60 days). Pathological analysis will evaluate the lesion histologically after treatment (LEEP). The individual's immunological response will also be evaluated after surgical intervention.
62383371|NCT05515653||Control - without atherosclerotic cardiovascular disease ou healthy|Patients who sought medical care at the same site as cases without atherosclerotic cardiovascular event (Acute Myocardial Infarction, Stroke and Peripheral Artery Thrombotic-Ischemic Events) or healthy individuals
62383372|NCT05737004||Prostate cancer group|Prostate cancer was confirmed by biopsy, and fMRI examination 、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II were performed in these patients within 1 week before biopsy .
62383373|NCT05737004||Non-Prostate cancer group|Non-Prostate cancer was confirmed by biopsy, and fMRI examination 、 Zung Self Rating Anxiety Scale and Beck Depression Inventory-II were performed in these patients within 1 week before biopsy .
62383374|NCT01676428|EXPERIMENTAL|Radiotherapy|"The interventional treatment will be prescribed as a 2-tiered dose scheduled dependant of target size.~For lesions \<5cm, a single fraction of 26 Gy will be prescribed. For lesions ≥5cm a fractionated course of 15Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
62383375|NCT03761628|EXPERIMENTAL|pHyph, Gedea Pessary|Clinical performance, tolerability, safety and user experience of Gedea Pessary, a slow-release vaginal tablet for the treatment of VVC.
62764102|NCT06356012|NO_INTERVENTION|healthy population|Immunological markers will be evaluated in a healthy population that had negative screening tests for cervical lesions to compare to the population in the injury and intervention groups.
61988605|NCT00587483|ACTIVE_COMPARATOR|Amiodarone 300 mg|Amiodarone is used to treat and prevent certain types of serious, life-threatening ventricular arrhythmias (a certain type of abnormal heart rhythm) when other medications did not help or could not be tolerated. Amiodarone is in a class of medications called antiarrhythmics. It works by relaxing overactive heart muscles.
61988606|NCT00587483|PLACEBO_COMPARATOR|placebo (saline)|
61988607|NCT04130451|ACTIVE_COMPARATOR|Pre pleurodesis Procedure Fever Pulse rate Respiratory rate Pa|Pre pleurodesis Fever Pulse rate Respiratory rate Pain thresholds total leukocytes procedure 24 hours before 16 hours before 8 hours before
62383376|NCT03566849|EXPERIMENTAL|KC group|It mainly involve all segment in kinetic chain, not only shoulder girdle, include exercise training 3 times a week for a total 4 weeks.
62383377|NCT03566849|EXPERIMENTAL|CT group|It involve shoulder girdle only, include exercise training 3 times a week for a total 4 weeks.
62383378|NCT05647928||retinal redetachment after silicone oil removal|
62383379|NCT05647928||NO retinal redetachment after silicone oil removal|
62383380|NCT00326976|EXPERIMENTAL|1|400 mg injected in 2 divided boluses
62168211|NCT03941990|PLACEBO_COMPARATOR|Placebo|will inhale medical air throughout the entire procedure (22% O2 + N2 Q.S.)
62383381|NCT00326976|PLACEBO_COMPARATOR|2|Matching placebo
62383382|NCT02926690|EXPERIMENTAL|OTS167PO|
62383383|NCT02894606||Thymoglobulin Induction|Patient receiving thymoglobulin as an induction therapy for renal transplant
62383384|NCT02894606||Basiliximab Induction|Patient receiving basiliximab as an induction therapy for renal transplant
62383385|NCT01177826||Group 1|Cases
62383386|NCT01177826||Group 2|Controls
62383387|NCT01157962|EXPERIMENTAL|Group A Sentinel lymphadenectomy|In group A exclusively sentinel lymphadenectomy is performed
62383388|NCT01157962|ACTIVE_COMPARATOR|Group B radical pelvine lymphadenectomy|in group B radical systematic pelvic lymphadenectomy is done. In patients with tumor free lymph nodes either radical hysterectomy or, in women seeking parenthood, radical trachelectomy is performed. If lymph nodes are tumor-involved systematic pelvic and paraaortic lymphadenectomy followed by primary chemoradiation is recommended.
62383389|NCT01724164|EXPERIMENTAL|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
62383390|NCT01724164|EXPERIMENTAL|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
62383391|NCT01724164|ACTIVE_COMPARATOR|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
62764103|NCT05825144|EXPERIMENTAL|Robotic group|This group receives conventional rehabilitation plus robotic exoskeleton-assisted gait rehabilitation.
62764104|NCT05825144|ACTIVE_COMPARATOR|Control group|This group receives conventional rehabilitation alone.
62764105|NCT02127034|EXPERIMENTAL|Digoxin / digoxin + solifenacin and mirabegron|Digoxin alone then followed by digoxin with solifenacin and mirabegron
62764106|NCT02127034|EXPERIMENTAL|Digoxin + solifenacin and mirabegron / digoxin|Digoxin with solifenacin and mirabegron then followed by digoxin alone
62764107|NCT01500369|ACTIVE_COMPARATOR|remote ischemic conditiong|"Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
62764108|NCT01500369|PLACEBO_COMPARATOR|Standard Care|Patients in the control group will have the sphygmomanometer cuff placed on their right upper arm, but the cuff will not be inflated. Similar to patients in the treatment group, patients in the control group will undergo the same 30 minute delay before induction of anesthesia and surgery
62764109|NCT04616209|EXPERIMENTAL|PB103 (donor-derived NK cells) infusion|Cohort 1: 0.5×10\^9，Cohort 2:1×10\^9 or Cohort 3: 1.5×10\^9 cells
62764110|NCT00901797|ACTIVE_COMPARATOR|Arthroscopic Bankart repair|
62764111|NCT00901797|ACTIVE_COMPARATOR|ABR+ARIC|
62764112|NCT06383741||ICH study cohort|Patients with intracerebral haemorrhage associated with factor Xa-inhibitor treatment treated at one of the participating centres.
62764113|NCT02922166|EXPERIMENTAL|SRX246|SRX246 oral dosage capsules, daily dose to be taken bid, for up to 7 days
62764114|NCT02922166|PLACEBO_COMPARATOR|Placebo|Placebo oral dosage capsules, daily dose to be taken bid, for up to 7 days
62764115|NCT05864131|ACTIVE_COMPARATOR|Lying|
62764116|NCT05864131|EXPERIMENTAL|Holding|
62764117|NCT03978780|PLACEBO_COMPARATOR|Control Group|Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block (see above) under ultrasound guidance to stimulate a real block procedure.
62764118|NCT03978780|EXPERIMENTAL|Erector spinae plane (ESP) block group|Local anaesthetic infiltration utilising 1% lidocaine will occur, and an 80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
62764119|NCT00442091|OTHER|10 ml of dandelion juice twice daily|
62764120|NCT01706042|PLACEBO_COMPARATOR|white bread|White bread (based on 35 g available carbohydrates)
62764121|NCT01706042|ACTIVE_COMPARATOR|Legume meal|Legumes are consumed as a late evening meal(based on 35 g available carbohydrates)
62764122|NCT02492074|EXPERIMENTAL|THC|Subjects receive 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) and corresponding cannabidiol placebo capsules.
61988608|NCT04130451|ACTIVE_COMPARATOR|After Pleurodesis procedure Fever Pulse rate Respiratory rate|Post pleurodesis Fever Pulse rate Respiratory rate Pain thresholds total leukocytes procdure 24 hours before 16 hours before 8 hours before
62168212|NCT04468633|ACTIVE_COMPARATOR|Baerveldt 350 implant|
62383392|NCT01724164|EXPERIMENTAL|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
62764123|NCT02492074|EXPERIMENTAL|CBD|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and corresponding delta-9-tetrahydrocannabinol placebo capsules.
62764124|NCT02492074|EXPERIMENTAL|CBD+THC|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each)
62764125|NCT02492074|PLACEBO_COMPARATOR|Placebo|Subjects receive corresponding delta-9-tetrahydrocannabinol and cannabidiol placebo capsules
62764126|NCT03000777|EXPERIMENTAL|Melatonin plus Zinc|Melatonin plus Zinc
62764127|NCT03000777|PLACEBO_COMPARATOR|Placebo|Isomaltose
62764128|NCT01668641|EXPERIMENTAL|capsule, 30mg GLPG0634 once a day|3 capsules of 10 mg once a day
62764129|NCT01668641|EXPERIMENTAL|capsules, 75mg GLPG0634 once a day|3 capsules of 25mg once a day
62764130|NCT01668641|EXPERIMENTAL|capsules, 150mg GLPG0634 once a day|3 capsules of 50mg once a day
62764131|NCT01668641|EXPERIMENTAL|capsules, 300mg GLPG0634 once a day|3 capsules of 100mg once a day
62764132|NCT01668641|PLACEBO_COMPARATOR|capsules, placebo once a day|3 capsules placebo once a day
62764133|NCT03078738|EXPERIMENTAL|OMT-28-SAD|OMT-28-SAD, Single ascending dose levels 1 - 3 of OMT-28 (15, 30, 60 mg) Oral, healthy young male
62764134|NCT03078738|EXPERIMENTAL|OMT-28-MAD|Multiple ascending dose of dose levels 1 - 3 of OMT-28 over 14 days (4, 12, 36 mg) Oral, healthy young male
62764135|NCT03078738|EXPERIMENTAL|OMT-28- Food Effect|Single dose of OMT-28 (4 mg) Oral, healthy young male
62764136|NCT03078738|EXPERIMENTAL|OMT-28-Gender|Single dose of OMT-28 (4 mg) Oral, healthy non-child bearing potential female
62764137|NCT03078738|PLACEBO_COMPARATOR|Placebo-SAD|Single dose levels 1 - 3 of matching placebo, Oral, healthy young male
62764138|NCT03078738|PLACEBO_COMPARATOR|Placebo MAD|Multiple dose levels 1 - 3 of matching placebo over 14 days Oral, healthy young male
62764139|NCT03078738|PLACEBO_COMPARATOR|Placebo-Gender|Single dose of matching Placebo Oral, healthy non-child bearing potential female
62764140|NCT02492360||Severe Toxicity Group|Diagnosis of testicular cancer; History of any grade 3 or higher peripheral neuropathy after receiving standard dose cisplatin completed more than 1 year but within the last 5 years; Long-term persistence (\> 6 months) of grade 2 or higher peripheral neuropathy after completion of a cisplatin containing regimen. Interventions: blood sample collection and report of peripheral neuropathy after cisplatin therapy.
62764141|NCT02492360||Control Group|Diagnosis of testicular cancer; No history of neurotoxicity (grade 0-1) after completion of a standard cisplatin-containing chemotherapy regimen completed more than 1 year but within the last 5 years; Matched to a specified subject with neurotoxicity based on age (within 10 years), chemotherapy regimen or total cisplatin dosage. Interventions: blood sample collection and report of peripheral neuropathy after cisplatin therapy.
62168213|NCT04468633|ACTIVE_COMPARATOR|Ahmed ClearPath 350 implant|
62383393|NCT01724164|PLACEBO_COMPARATOR|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
62383394|NCT06025656|OTHER|Experimental group|adolescent tennis player
62383395|NCT04052906|EXPERIMENTAL|Intervention Group|Planned Inhaler Medication Training
62383396|NCT04052906|NO_INTERVENTION|Control Group|usual care
62383397|NCT05606549|EXPERIMENTAL|marital self disclosure|
62383398|NCT05606549|NO_INTERVENTION|Routine care|
62383399|NCT01216644|EXPERIMENTAL|FLOT|Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP
62383400|NCT01216644|ACTIVE_COMPARATOR|ECF|Epirubicin 50 mg/m2, d1 Cisplatin 60 mg/m², d1 5-FU 200 mg/m², d1-d21 every 3 weeks (q3w) 3 cycles (9 weeks) pre-OP and 3 cycles (9 weeks) post-OP
62383401|NCT03186079|ACTIVE_COMPARATOR|Xiaojidaozhi Decoction|Xiaojidaozhi Decoction and Fiberform and Toilet training are used for treatment of childhood Constipation
62383402|NCT03186079|PLACEBO_COMPARATOR|non-Xiaojidaozhi Decoction|Placebo and Fiberform and Toilet training are used for treatment of childhood Constipation
62383403|NCT03350724|EXPERIMENTAL|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
62383404|NCT03350724|ACTIVE_COMPARATOR|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
62383405|NCT05644613|ACTIVE_COMPARATOR|GROUP A|will consist of (20) adolescent girls age ranged from 14-17 suffering from PMS without any pathological cause they will receive an aerobic exercise on land in form of walking on the treadmill for 20 min 3 times per week for 3 months.
62168214|NCT04193397|EXPERIMENTAL|Exercise training|Post-bariatric patients - Intervention group
62168215|NCT04193397|NO_INTERVENTION|No intervention|Post-bariatric patients - Non-exercised control group
62168216|NCT00558220|EXPERIMENTAL|A|Intensive induction followed by high-dose consolidation with stem cell support ± radiotherapy
62168217|NCT06551064|EXPERIMENTAL|FYB206|
62383406|NCT05644613|ACTIVE_COMPARATOR|GROUP B|will consist of (20) adolescent girls age ranged from 14-17 suffering from PMS without any pathological cause they will receive an aerobic exercises in water in form of walking on the treadmill for 20 min 3 times per week for 3 months
62383407|NCT04467866|EXPERIMENTAL|ROC-Stand(Mild) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as mild motor delay. Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training.
62383408|NCT04467866|EXPERIMENTAL|ROC-Stand(Mod) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as moderate motor delay. Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training.
62383409|NCT04467866|ACTIVE_COMPARATOR|Control(Mild) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as mild motor delay. The other occupational therapist will be responsible for regular therapy.
62383410|NCT04467866|ACTIVE_COMPARATOR|Control(Mod) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as moderate motor delay. The other occupational therapist will be responsible for regular therapy.
62383411|NCT05330429|EXPERIMENTAL|Safety Run-in Cohort: Magrolimab + Bevacizumab + FOLFIRI|Participants will receive magrolimab in de-escalating doses to establish recommended Phase 2 dose (RP2D) in combination with + bevacizumab (5 mg/kg every 2 weeks) + FOLFIRI (irinotecan 180 mg/m\^2 + leucovorin 400 mg/m\^2 + fluorouracil 400 mg/m\^2 bolus followed by 2400 mg/m\^2 continuous on Days 1, 2, 15, and 16 of a 28-Day Cycle).
62567637|NCT02852174|EXPERIMENTAL|Mindfulness group|The treatment groups will participate in a mindfulness intervention training that will meet for 2 hours once a week for eight weeks. The 8-week program provides participants with 2-hour weekly instruction designed to teach specific skills and how to apply them during stressful situations (e.g., when caring for or advocating for the veteran).Mindfulness training also requires that participants engage in daily home practice for 30 to 40 minutes. Participants will be required to record the duration of the meditation in log sheets.
62168218|NCT06551064|ACTIVE_COMPARATOR|Keytruda|
62764142|NCT04684732||Apixaban dose concordant to leaflet|Patients who were prescribed apixaban dose concordant to apixaban leaflet approved by Thai FDA
62764143|NCT04684732||Apixaban dose discordant to leaflet|Patients who were prescribed apixaban dose discordant to apixaban leaflet approved by Thai FDA
62764144|NCT00623545|EXPERIMENTAL|Exenatide|Exenatide. Dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks Each subject serves as their own control for outcome measures taken before and during drug treatment.
61988609|NCT06326294|OTHER|Thermo ablation treatment|"Participants allocated in this group will be treated with thermo ablation. Before TA, perform biopsies of any acetowhite lesions by colposcopy and/or positive by AVE and an endocervical curettage (ECC); In women who do not have any lesions noted by colposcopy or AVE, one random cervical biopsy at the squamocolumnar junction and an endocervical curettage (ECC) will be obtained.~TA is performed during the same exam (immediately following biopsies/ECC)TA will be done according to the manufacturer's instructions and specifications."
62764145|NCT05158985|EXPERIMENTAL|group A|diclofenac sodium phonophoresis using continuous ultrasound with a frequency of 1MHz, an intensity of 1.5W/Cm2 for 4 minutes
62764146|NCT05158985|EXPERIMENTAL|group B|diclofenac sodium phonophoresis using pulsed US with 1:1 duty cycle with a frequency of 1MHz, an intensity of 1.5W/Cm2 for 4 minutes
62764147|NCT05158985|EXPERIMENTAL|group C|diclofenac sodium phonophoresis using pulsed US with 1:4 duty cycle with a frequency of 1MHz, an intensity of 1.5W/Cm2 for 10 minutes
61988610|NCT06326294|OTHER|LEEP treatment|Participants allocated in this group will be treated with LEEP. LEEP will be done according to standard procedure. No biopsies are taken, only LEEP is performed, unless clinically indicated.
61988611|NCT00912314|ACTIVE_COMPARATOR|Monthly Maintenance PTNS|After 12 weeks of PTNS, patients will be randomized to either the monthly PTNS arm, or the no maintenance PTNS arm.
61988612|NCT00912314|NO_INTERVENTION|No maintenance PTNS|After 12 weeks of PTNS, patients will either be randomized to the Monthly PTNS arm or the No maintenance PTNS arm.
61988613|NCT00108160|ACTIVE_COMPARATOR|Mupirocin Ointment [Treatment]|Treatment arm or active comparator \[mupirocin 2% polyethylene glycol (PEG) ointment\] will be compared with its placebo comparator \[polyethylene glycol (PEF) in patients with a prior history of S. aureus infection. Drug or placebo will be applied topically to nares and/or wounds twice daily for 14 days at 3 month intervals for up to 18 months
61988614|NCT00108160|PLACEBO_COMPARATOR|Polyethylene Glycol Ointment [Placebo]|Treatment arm or active comparator \[mupirocin 2% polyethylene glycol (PEG) ointment\] will be compared with its placebo comparator \[polyethylene glycol (PEF) in patients with a prior history of S. aureus infection. Drug or placebo will be applied topically to nares and/or wounds twice daily for 14 days at 3 month intervals for up to 18 months
61988615|NCT04508374|EXPERIMENTAL|1470 nm diode laser treatment of right HS-fistula|This is an intra-person study, comparing outcomes within participants. All participants will receive active 1470 nm intra-lesional diode laser treatment on one HS tunnel. Half of the enroled patients will receive active treatment of the right side, while the HS tunnel on the left side will be left as an untreated control.
61988616|NCT04508374|EXPERIMENTAL|1470 nm diode laser treatment of left HS-fistula|This is an intra-person study, comparing outcomes within participants. All participants will receive active 1470 nm intra-lesional diode laser treatment on one HS tunnel. Half of the enroled patients will receive active treatment of the left side, while the HS tunnel on the right side will be left as an untreated control.
62764148|NCT05158985|EXPERIMENTAL|group D|exercises only in form of (strengthening, stretching and occupational exercises).
62764149|NCT00739466|EXPERIMENTAL|low dose|Liposomal Alendronate dose of 0.001 mg
62764150|NCT00739466|EXPERIMENTAL|high dose|Liposomal Alendronate dose of 0.01 mg
62764151|NCT00739466|PLACEBO_COMPARATOR|placebo|IV saline infusion
62764152|NCT01442792|ACTIVE_COMPARATOR|Arm 1|
62764153|NCT01442792|EXPERIMENTAL|Arm 2|
62764154|NCT01442792|EXPERIMENTAL|Arm 3|
62764155|NCT01442792|EXPERIMENTAL|Arm 4|
62764156|NCT03476876|EXPERIMENTAL|Dermacell|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Dermacell acellular matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
62764157|NCT03476876|ACTIVE_COMPARATOR|Integra|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Integra bilayer cross-linked matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
62764158|NCT04403594||MS with spasticity of one lower extremity|A person diagnosed with Multiple Sclerosis and spasticty of one lower extremity. The person must be able to walk 25 feet and cannot have had Botox in the lower extremity on the last 6 months.
62764159|NCT02767479|ACTIVE_COMPARATOR|rabeprazole group|rabeprazole-based regimen. This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
62764160|NCT02767479|ACTIVE_COMPARATOR|esomeprazole group|'esomeprazole\^based regimen. This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
62764161|NCT02513823|EXPERIMENTAL|Intervention|2,000 IU of vitamin D given to African American women for 10 weeks
62764162|NCT01873053|EXPERIMENTAL|1st group : WIN-34B 900mg|Patients assigned to 1st group take WIN-34B 450mg BID for 12weeks
62764163|NCT01873053|EXPERIMENTAL|2nd group : WIN-34B 1800mg|Patients assigned to 2nd group take WIN-34B 900mg BID for 12weeks
62764164|NCT01873053|PLACEBO_COMPARATOR|3rd group : Placebo|Patients assigned to 3rd group take Placebo BID for 12weeks
62764165|NCT01283308|ACTIVE_COMPARATOR|Standard of Care|Participants randomized to the standard of care group will receive standard lifestyle advice for diabetes prevention consistent with expert recommendations for a healthy lifestyle, including losing 5-10% of their excess body weight, following standard dietary recommendations to reduce calorie and fat intake, and exercising at least 150 minutes per week.
62764166|NCT01283308|EXPERIMENTAL|Lifestyle Intervention|Intervention arm participants will participate in a step-wise model of diabetes prevention with the goal of reducing diabetes risk, primarily through (1) a weight loss of at least 7% and (2) 150 minutes or more per week of moderate level physical activity.
62764167|NCT05697666||Moderate to severe ARDS adult patients under mechanical ventilation and neuromuscular blockade|no intervention
61988617|NCT05980533|EXPERIMENTAL|Ultrasound|Ultrasound at hospital discharge and at follow up in 7-10 days
62764168|NCT04810936|EXPERIMENTAL|Early ONS intervention group|Patients in early ONS intervention group will receive nutritional counseling (follow-up visits once a week during radiotherapy and at the 1st and 3rd months after radiotherapy) and ONS intervention in the beginning of radiotherapy. The ONS is prescribed to increase oral intake of patients and to ensure total energy supply is more than 30 kcal/kg/day and protein intake more than 1.2 g/kg/day.
62764169|NCT04810936|NO_INTERVENTION|Standard nutrition intervention group|Patients in standard nutrition intervention group will receive nutritional counseling (follow-up visits once a week during radiotherapy and at the 1st and 3rd months after radiotherapy).
62764170|NCT02256410|EXPERIMENTAL|Stimulation|Patients will undergo 6 sessions, each including 20 minutes of stimulation. These are given after the Nervomatrix device determines the peak pain regions for each patient, and selects to stimulate the top 10 regions with least skin resistance. The frequency of stimulation is 8Hz, at an intensity matched for each patient's tolerance, without inflicting any pain. The location of the stimulations will change in accordance to the changes in the peak pain regions, reflecting changes in tissue physiology possibly linked to clinical improvements.
62383412|NCT05330429|EXPERIMENTAL|Randomized Cohort: Magrolimab + Bevacizumab + FOLFIRI|Participants will receive the RP2D determined in the Safety Run-in cohort of magrolimab in combination with bevacizumab (5 mg/kg every 2 weeks) + FOLFIRI (irinotecan 180 mg/m\^2 + leucovorin 400 mg/m\^2 + fluorouracil 400 mg/m\^2 bolus followed by 2400 mg/m\^2 continuous on Days 1, 2, 15, and 16 of a 28-Day Cycle).
62764171|NCT02256410|SHAM_COMPARATOR|sham stimulation|Patients will undergo 6 sessions, each including 20 minutesof sham stimulation (no stimulation). These are given after the Nervomatrix device determines the peak pain regions for each patient, and selects to stimulate the top 10 regions with least skin resistance.
62764172|NCT06213337|NO_INTERVENTION|control group|No intervention will be applied to this group.
62383413|NCT05330429|ACTIVE_COMPARATOR|Randomized Cohort: Bevacizumab + FOLFIRI|Participants will receive bevacizumab (5 mg/kg every 2 weeks) + FOLFIRI (irinotecan 180 mg/m\^2 + leucovorin 400 mg/m\^2 + fluorouracil 400 mg/m\^2 bolus followed by 2400 mg/m\^2 continuous on Days 1, 2, 15, and 16 of a 28-Day Cycle).
62764173|NCT06213337|EXPERIMENTAL|virtual classroom group|Participants in this group will be given virtual classroom training on foot care.
62764174|NCT06213337|EXPERIMENTAL|SMS support group|Information regarding foot care will be sent via SMS to the participants in this group.
62764175|NCT06213337|EXPERIMENTAL|SMS supported virtual classroom training group|Participants in this group will be given virtual classroom training with SMS support.
62764176|NCT03205904|ACTIVE_COMPARATOR|Intervention group|Group that will be receive the diet
62764177|NCT03205904|NO_INTERVENTION|control|Group that will not receive the diet
62764178|NCT05840107|EXPERIMENTAL|GC012F treatment|CAR-T will be infused at a dose of 0.6,1.5,3 x 10\^5 CAR-T cells/kg after receiving lymphodepleting chemotherapy. Lenalidomide maintenance therapy will be given post month 6 at physicians' choice.
62764179|NCT01591863|EXPERIMENTAL|fidaxomicin|
62764180|NCT03926962|EXPERIMENTAL|WCK 4873|100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
62764181|NCT03926962|PLACEBO_COMPARATOR|Placebo|Visually matching placebo
61988618|NCT00110409|EXPERIMENTAL|1|Intervention participants will receive information focusing on asthma self-management, education, self-efficacy, and social support while in the hospital emergency room. Telephone reinforcement will occur for 8 weeks following study entry.
62383414|NCT05290441|ACTIVE_COMPARATOR|None involement|In the pathological examination, the group of patients without EGFR involvement in the biopsy material.
62764182|NCT06138405|EXPERIMENTAL|Immediate Intervention Group|"Experiential, interactive, skills-oriented workshop for oral healthcare providers (i.e., dentists, hygienists, and assistants) involving simulated patients and immediate pre- and post-workshop testing. The workshop involves didactics on developmentally-appropriate child behavior in the dental setting, and over-practice of skills, to the point of habit, by providers."
61988619|NCT00110409|ACTIVE_COMPARATOR|2|Participants in the control group will receive standard emergency room education about asthma.
61988620|NCT05718830||patients with traumatic lung injury (TLI)|
61988621|NCT05718830||patients with inhalation injury (ILI)|
61988622|NCT05718830||health controls(HCs)|
61988623|NCT04354207||Atopic dermatitis|
62383415|NCT05290441|ACTIVE_COMPARATOR|Mild|In the pathological examination, the group of patients mild EGFR involvement in the biopsy material.
62383416|NCT05290441|ACTIVE_COMPARATOR|Moderate|In the pathological examination, the group of patients moderate EGFR involvement in the biopsy material.
61988624|NCT04354207||Asthma|
61988625|NCT04354207||Healthy individuals|
61988626|NCT06143670|EXPERIMENTAL|Test Product|Participants will be instructed to brush their teeth with full ribbon of toothpaste (0.454% w/w SnF2) on head of toothbrush provided for at least one (timed) minute twice a day (morning and evening) for 12 weeks.
62383417|NCT05290441|ACTIVE_COMPARATOR|Severe|In the pathological examination, the group of patients severe EGFR involvement in the biopsy material
62383418|NCT02473380|EXPERIMENTAL|Intraoperative fluorescence spectroscopy|The experimental device will be assessed during an open surgical approach for surgical removal of the tumors
62764183|NCT06138405|ACTIVE_COMPARATOR|Delayed Intervention Group|The delayed intervention group will receive the same experiential, interactive, skills-oriented workshop, but two months after the immediate intervention group.
62764184|NCT03861130||Kawasaki disease|Kawasaki disease affected children
62764185|NCT03861130||parent of Kawasaki disease affected child|
62764186|NCT02177409|EXPERIMENTAL|Telmisartan|4-week placebo run-in, 8-week fixed dose period
62764187|NCT02177409|ACTIVE_COMPARATOR|Amlodipine|4-week placebo run-in, 8-week fixed dose period
62764188|NCT02165293|EXPERIMENTAL|RO7033877|
62764189|NCT01430676||Danish Ventral Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
62764190|NCT01615601||darunavir (PREZISTA)|PREZISTA co-administered with 100 mg ritonavir as per Canadian Product Monograph. (Observational Study)
62764191|NCT01615601||etravirine (INTELENCE)|INTELENCE co-administered with other antiretroviral medicinal products as per Canadian Product Monograph (Observational Study)
62764192|NCT04214912|NO_INTERVENTION|General module|"General module will serve as a roadmap plan which will cover the most common problems and major issues related to current and future treatments, side effects, psychological distress, daily function and physical condition. The contents will be developed based on empirical review, our current research findings in Taiwan, OC health care experts' suggestions."
62764193|NCT04214912|EXPERIMENTAL|Personalized module|Personalized Survivor Care Plan (PSCP) will deliver based on what we assess or interview about patients' distress, concerns and care needs in each interview or/and assessment. We will assess OC patients of the above items by valid assessment tools. For the factors or concerns about RTW assessment, we will develop and test a modified instrument for the study purpose. For each assessment, the computer -assisted assessment will help the OC educator to immediately catch the patients care distress and care needs. It will provide the direction for caring of their personalized distress, concerns and needs.
62764194|NCT03322423|ACTIVE_COMPARATOR|Test 1 Multifocal/Test 2 Multifocal OR Test 2 Alternative|Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 1 Multifocal then Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power), for approximately 8-12 days of wear with an approximately 4-8 day washout period.
62764195|NCT03322423|ACTIVE_COMPARATOR|Test 2 Multifocal OR Test 2 Alternative/Test 1 Multifocal|Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power) then Test 1 Multifocal, for approximately 8-12 days of wear with an approximately 4-8 day washout period.
62764196|NCT01604655|ACTIVE_COMPARATOR|Coronary CT Angiography|Patient admitted with chest pain is randomized to CCTA for assessment.
62764197|NCT01604655|ACTIVE_COMPARATOR|Stress Test|Patients admitted with chest pain are randomized to a stress test (stress SPECT or Echocardiography) for assessment.
62764198|NCT04286672||Group 1:|• 35 bladder cancer patients diagnosed by biopsy before treatment.
62764199|NCT04286672||Group 2:|35 apparently healthy individuals who were matched by age and sex .
62764200|NCT03234348|EXPERIMENTAL|Magmaris|Percutaneous coronary intervention by means of Magnesium-based sirolimus-eluting bioresorbable scaffold implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.
62764201|NCT03234348|PLACEBO_COMPARATOR|Orsiro|Percutaneous coronary intervention by means of Biodegradable polymer sirolimus-eluting stent implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.
62764202|NCT05838014|ACTIVE_COMPARATOR|Normal sleep|Participants will complete three 30-minute bouts of semi-recumbent cycling at incrementally increasing fixed metabolic heat loads (150, 200 and 250 W/m2) in a hot, dry condition (40°C, 15% relative humidity). Each exercise bout will be separated by a 15 minute period of rest, with the final recovery 1 hour in duration. Exercise will commence between the hours of 7 AM and 9 AM following a period of normal sleep (\~8 hours) (Control condition).
62764203|NCT05838014|EXPERIMENTAL|Sleep deprivation|Participants will complete three 30-minute bouts of semi-recumbent cycling at incrementally increasing fixed metabolic heat loads (150, 200 and 250 W/m2) in a hot, dry condition (40°C, 15% relative humidity). Each exercise bout will be separated by a 15 minute period of rest, with the final recovery 1 hour in duration. Exercise will commence between the hours of 7 AM and 9 AM following a period of 24 hour of sleep deprivation (Sleep deprivation condition).
62764204|NCT05618782|ACTIVE_COMPARATOR|0.3 mg/kg dose intravenous infusion of LEVI-04|LEVI- 04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc).It modulates the nerve growth factor (NGF) pathway, clinically proven to provide effective analgesia.
62383419|NCT03018028|EXPERIMENTAL|Oral semaglutide 3 mg|
62764205|NCT05618782|ACTIVE_COMPARATOR|1.0 mg/kg dose intravenous infusion of LEVI-04|LEVI- 04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc).It modulates the nerve growth factor (NGF) pathway, clinically proven to provide effective analgesia.
62764206|NCT05618782|ACTIVE_COMPARATOR|2.0 mg/kg dose intravenous infusion of LEVI-04|LEVI- 04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc).It modulates the nerve growth factor (NGF) pathway, clinically proven to provide effective analgesia.
62764207|NCT05618782|PLACEBO_COMPARATOR|Placebo dose intravenous infusion|
62383420|NCT03018028|EXPERIMENTAL|Oral semaglutide 7 mg|
62764208|NCT00860015|EXPERIMENTAL|Alimta/Gemcitabine|IV administration of drugs for 14 days for up to 4 cycles
62764209|NCT02080325|OTHER|High Protein-Weight loss-Meat/High Protein-Weight loss Soy|After 3 Days - Normal Protein Maintenance diet (NP- MTD, 3 days), there is the first arm of the study, Days 14 days- randomised to High Protein-Weight loss-Meat with High Protein-Weight loss-Soy
62764210|NCT02080325|OTHER|High Protein-Weight loss-Soya/High Protein Weight loss-meat|After 3 Days - Normal Protein Maintenance diet (NP- MTD, 3 days), there is the first arm of the study, Days 14 days- randomised to High Protein-Weight loss-Soy with High Protein-Weight loss-Meat
62764211|NCT04792333|EXPERIMENTAL|Treatment|500 mg (2 capsules of 250 mg)
62764212|NCT02315508|EXPERIMENTAL|AUT00063|4 capsules of 200 mg of the new medicine, AUT00063, to take orally with food for 4 weeks.
62383421|NCT03018028|EXPERIMENTAL|Oral semaglutide 14 mg|
62383422|NCT03018028|PLACEBO_COMPARATOR|Oral placebo|
62383423|NCT03018028|ACTIVE_COMPARATOR|Liraglutide 0.9 mg|
62764213|NCT02315508|PLACEBO_COMPARATOR|Placebo|4 capsules of placebo, to take orally with food for 4 weeks.
62764214|NCT01243528||Patients in neurological rehabilitation|Patients suffering from a neurological disease
62383424|NCT03701373|EXPERIMENTAL|S-1 maintenance group|S-1 maintenance
62383425|NCT03701373|OTHER|Observation group|Observation without anti-tumor treatment
62764215|NCT05609344|EXPERIMENTAL|SBIRT|Each intervention barbershop, will hold screening days, where a trained community health worker will be onsite to provide Screening, Brief Intervention, and Referral to Treatment (SBIRT).
62764216|NCT05609344|OTHER|Usual-care|Six months after completion of Time 1, barbershops in the usual-care arm will receive the intervention.
62764217|NCT03146780|PLACEBO_COMPARATOR|Conventional|
62764218|NCT03146780|ACTIVE_COMPARATOR|Digital 1|
62764219|NCT03146780|ACTIVE_COMPARATOR|Digital 2|
62764220|NCT03146780|ACTIVE_COMPARATOR|Digital 3|
62764221|NCT02601092|EXPERIMENTAL|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.~No drugs or devices will be used."
62764222|NCT02601092|ACTIVE_COMPARATOR|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.~No drugs or devices will be used."
62383426|NCT03907943|OTHER|Surgical treatment of carotid endarterectomy|The change in the cognitive function will be assessed in all patient undergoing carotid endarterectomy.
62383427|NCT00694265||1|Surgical treatment
62764223|NCT01344044|ACTIVE_COMPARATOR|BCI treatment|BCI treatment will commence during the week of the Baseline.
62764224|NCT01344044|OTHER|Wait-list control|BCI treatment will commence 8 weeks after Baseline
62764225|NCT01344044|EXPERIMENTAL|BCI pilot arm|This is a experimental arm to test out the safety and effectiveness of BCI in improving ADHD symptoms. This pilot arm is necessary as the BCI device, incorporating dry electrode sensors and intervention game, is newly developed and have not been tested out in children with ADHD. This preliminary study will also allow us to test out the treatment protocol (24 sessions of BCI training over 8 weeks) to see if it is efficacious.
62764226|NCT04319744||Assistants who have a habit of playing video|"Group I:Anesthesia assistants who have a habit of playing video games before Video game will be played for 5 days a day with 0.5 hours mobile phone (Pubg mobile) for those who have previous game experience.~Intubation training will be provided with video style.Within the scope of this training, 1-All participants will watch videos about Video style application.~2-Verbal explanation will be made by the responsible and investigators of the study 3- All participants will practice on the model first~4-Responsible investigators will practice and show on the real patient.~5-Then all participants will perform the application on the real patient under the supervision of responsible and investigators.~Tracheal intubation time, success rate, number of interventions will be recorded by responsible and investigators."
62764227|NCT04319744||Assistants who do not have the habit of playing video|"Group II:Anesthesia assistants who do not have the habit of playing video games No video game will be played before intubation with video style for this group.~Intubation training will be provided with video style. Within the scope of this training, 1-All participants will watch videos about Video style application.~2-Verbal explanation will be made by the responsible and investigators of the study 3- All participants will practice on the model first~4-Responsible investigators will practice and show on the real patient.~5-Then all participants will perform the application on the real patient under the supervision of responsible and investigators.~Tracheal intubation time, success rate, number of interventions will be recorded by responsible and investigators."
62764228|NCT02986100|EXPERIMENTAL|C-14 labeled rucaparib|"Each patient will receive a single oral dose of 600 mg \[14C\] rucaparib (approximately 140 µCi) in the fasted state. Patients will be confined at the study site for the collection of blood samples and excreta for a maximum of 13 days, from Day -1. The patient can be discharged sooner than Day 13, if the discharge criteria are met.~After completion of Part I, patients with a deleterious BRCA mutation will have the option to participate in Part II by receiving 600 mg BID rucaparib tablets orally in 28 day cycles until disease progression, unacceptable toxicity, death, or discontinuation for other reasons"
62764229|NCT03794869|EXPERIMENTAL|Exercise program|It will be consist in a program of lumbo-pelvic stabilization exercises and strengthening of the core: awareness of breathing, front and side plate abdominal, glute bridge/hip elevations, lift extended leg, pelvic tilt, hamstring stretch, strengthening lower abdominals, cat-camel posture, trunk rotations with flexed knees, rolling in sitting and lumbar extension with hip extensión in prone
62764230|NCT03794869|ACTIVE_COMPARATOR|Percutaneous electrostimulation treatment (EPS)|Apply dry needles in a tight band of some of the muscles that most affect the appearance of low back pain, such as: paravertebral, lumbar quadrate, gluteus medius and pyramidal, and administer analgesic microcurrents.
62383428|NCT00694265||2|Conservative treatment
62383429|NCT01977040||Vasa Previa|Women with the diagnosis of Vasa Previa made during the pregnancy or at time of delivery who delivered between January 1, 2000 and December 31, 2012.
62383430|NCT03348644|EXPERIMENTAL|Phosphate tablets.|800 mg oral phosphor supplement distributed over five times a day independently of any prior treatment dose.
62383431|NCT03348644|ACTIVE_COMPARATOR|High cheese intake.|Cheese with an estimated phosphate content of 800 mg distributed over 5 meals.
62383432|NCT03348644|ACTIVE_COMPARATOR|High milk intake.|800 ml of milk daily corresponding to approximately 800 mg phosphor per day.
62383433|NCT01896648||Type 2 diabetic women|
62383434|NCT00739440|EXPERIMENTAL|I|Patients 15 to 60 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex
62383435|NCT00739440|EXPERIMENTAL|II|Patients 15 to 60 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)
62383436|NCT03539900|EXPERIMENTAL|NB Medication|Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
62764231|NCT03322501|EXPERIMENTAL|Intervention|The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
62764232|NCT01667562|EXPERIMENTAL|Erlotinib|Erlotinib will be administered as a single daily oral dose of 150 milligrams until disease progression, death or unacceptable toxicity.
62383437|NCT03539900|PLACEBO_COMPARATOR|Placebo|Placebo will be inactive and taken daily in pill form.
62383438|NCT00798733||Non-Operative|Surgeon treated the patient non-operatively
62764233|NCT01667562|NO_INTERVENTION|Diagnostic Phase|Participants with advanced or metastatic NSCLC were tested for EGFR mutations. Participants who did not have an EGFR mutation were excluded from the study.
62383439|NCT00798733||Operative|Surgeon treated the patient operatively
62383440|NCT04267939|EXPERIMENTAL|Dose escalation of elimusertib_Part A.1|Dose escalation will initiate with Part A.1 in which niraparib is used at a lower fixed dose.
62383441|NCT04267939|EXPERIMENTAL|Dose escalation of elimusertib_Part A.2|If the starting dose level in Part A.1 is tolerated, dose escalation in Part A.2 may be initiated on an optional basis. In Part A.2, niraparib is used at a higher fixed dose.
62383442|NCT04267939|EXPERIMENTAL|Dose expansion_sub-population 1_lower dose of niraparib|"MTDs and/or candidate RP2Ds for elimusertib used in combination with niraparib at a lower fixed dose.~MTD: Maximum tolerated dose. RP2D: Recommended phase 2 dose."
62383443|NCT04267939|EXPERIMENTAL|Dose expansion_sub-population 2_lower dose of niraparib|MTDs and/or candidate RP2Ds for elimusertib used in combination with niraparib at a lower fixed dose.
62383444|NCT04267939|EXPERIMENTAL|Dose expansion_sub-population 1_higher dose of niraparib|MTDs and/or candidate RP2Ds for elimusertib used in combination with niraparib at a higher fixed dose.
62383445|NCT04267939|EXPERIMENTAL|Dose expansion_sub-population 2_higher dose of niraparib|MTDs and/or candidate RP2Ds for elimusertib used in combination with niraparib at a higher fixed dose.
62383446|NCT01246921|ACTIVE_COMPARATOR|fluticasone proprionate 0.05 %|Group reveiving 12 months NB-UVB phototherapy twice a week in combination with fluticasone proprionate 0.05 % cream in an intermittent scheme
62383447|NCT01246921|NO_INTERVENTION|no intervention|Group receiving 12 months NB-UVB phototherapy twice weekly, without any topical treatment
62383448|NCT04319835|EXPERIMENTAL|Microdialysis catheter|Surface Microdialysis catheter will be placed onto the surgical reconstruction after esophagectomy and will be evaluated for clinical safety and performance. The metabolic profile as measured by Microdialysis will be correlated to the clinical outcome. No interventions based on the results will be performed.
62383449|NCT02504606|EXPERIMENTAL|Besylsartan|amlodipine besylate 6.944mg+losartan K 100mg
62383450|NCT02504606|ACTIVE_COMPARATOR|Amosartan|amlodipine besylate 7.841mg+losartan K 100mg
62383451|NCT02327182|EXPERIMENTAL|MT-4666 low dose|Low Dose, Tablet, Once Daily, For 52 Weeks
62383452|NCT02327182|EXPERIMENTAL|MT-4666 high dose|High Dose, Tablet, Once Daily, For 52 Weeks
62383453|NCT01842334|EXPERIMENTAL|D-cycloserine|250 mg D-cycloserine once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy.
62383454|NCT01842334|PLACEBO_COMPARATOR|Placebo|one placebo capsule once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy
62383455|NCT03188133|EXPERIMENTAL|VH|schizophrenia patients with visual hallucinations
62383456|NCT03188133|ACTIVE_COMPARATOR|AH/NH|schizophrenia patients with auditory hallucinations or no hallucinations
62383457|NCT03188133|ACTIVE_COMPARATOR|C|healthy controls
62383458|NCT00906542||Acute ischemic stroke patients|Acute ischemic stroke patients admitted to the neurological intensive care unit or stroke unit within 24 hours after stroke onset in whom ischemic brain lesion was clearly assessed on CT and/or MRI
62383459|NCT00187733||Fasting|Other: Fasting blood and urine collection
62383460|NCT05840627|EXPERIMENTAL|Fruit juice|
62567638|NCT02852174|NO_INTERVENTION|Control|Participants in the control may receive the mindfulness training after the wait period ends at which point they may receive the treatment as described above.
62383461|NCT01197976|EXPERIMENTAL|TEPSO socks|This arm include all patients sides (left or right) treated with TEPSO socks.
62567639|NCT04107545|EXPERIMENTAL|athletes|48 elite athletes, 24 men and 24 women, experiencing regular weight cycling.
62567640|NCT03925948|EXPERIMENTAL|Intervention|This is a one arm study with all participants enrolled into this arm.
62567641|NCT00984542|EXPERIMENTAL|Bendamustine|
62764234|NCT04091113||Participants with Hereditary Angioedema|Participants older than 18 years that are clinically diagnosed with Hereditary Angioedema type 1/2 and experienced ≥4 HAE attacks within last 12 month before the enrollment
62764235|NCT02242175|OTHER|normal group|
62764236|NCT02242175|OTHER|irritable bowel syndrome group|
62764237|NCT05021549|ACTIVE_COMPARATOR|nasal prong.|the apneic preoxygenation group (30 patients), will receive 10 L/ min of O2 via nasal prong.
62764238|NCT05021549|NO_INTERVENTION|conventional|the conventional preoxygenation group (30 patients)
62764239|NCT06179420||standard IVF regime protocol based on clinician decision|The dosage of gonadotrophin and time of transvaginal ultrasound decided by clinician
62764240|NCT06179420||clinical decision support tool, Opt-IVF for IVF regime protocol|The dosage of gonadotrophin and time of transvaginal ultrasound decided by a clinical decision support tool ( OPt -IVF)
62383462|NCT01197976|PLACEBO_COMPARATOR|Standard socks|This arm include all patients sides (left or right) treated with standard cotton socks.
62383463|NCT02268942|EXPERIMENTAL|HeartWare HVAD via Thoracotomy|HeartWare HVAD implanted via thoracotomy
62764241|NCT01307202|EXPERIMENTAL|Gabapentin|Gabapentin 600 mg will be given per oral two hours preoperatively and 200 mg three times daily after surgery (600 mg/day).
62764242|NCT01307202|PLACEBO_COMPARATOR|Placebo|Placebo will match the the gabapentin pill and will be given orally.
62764243|NCT04291794|ACTIVE_COMPARATOR|Conventional bolus induction|Hypnotic component of general anesthesia induction will be a single bolus of propofol 2mg/kg followed by turning on sevoflurane 2% at a fresh gas flow of 2L/min.
62383464|NCT00757354|EXPERIMENTAL|Metal on Metal cementless hip|Metal on Metal cementless hip arthroplasty
62764244|NCT04291794|EXPERIMENTAL|Target-controlled induction|Hypnotic component of general anesthesia induction will be target-controlled propofol infusion tritiated to loss of consciousness. Propofol target-controlled infusion will be maintained.
62764245|NCT01863134|EXPERIMENTAL|Eptifibatide|Patients were given a bolus of eptifibatide (Integrillin; 180µg/kg of body weight) and an intravenous infusion of 2 µg/kg/min followed by acetylsalicylic acid (150mg orally daily until the day of the procedure) and enoxaparin (1mg/kg subcutaneous - with the last dose 12 hours before surgery).
62764246|NCT01863134|PLACEBO_COMPARATOR|Placebo|Patients were given placebo infusion (0,9% Natrium Chloride) and an intravenous infusion of 2 µg/kg/min followed by acetylsalicylic acid (150mg orally daily until the day of the procedure) and enoxaparin (1mg/kg subcutaneous - with the last dose 12 hours before surgery).
62764247|NCT04075409|EXPERIMENTAL|Extensive metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
62764248|NCT04075409|EXPERIMENTAL|Intermediate metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
62764249|NCT04075409|EXPERIMENTAL|Poor metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
62764250|NCT03930550|EXPERIMENTAL|Infrared guidance first|"In this arm the infra red guidance is applied to the first passage of the flexible scope to the trachea.~The second passage of the flexible scope is without the infrared light"
62764251|NCT03930550|ACTIVE_COMPARATOR|Infrared guidance last|"In this arm NO infra red guidance is applied to the first passage of the flexible scope to the trachea.~The second passage of the flexible scope is with the infrared light as guide"
62764252|NCT04342689|EXPERIMENTAL|Intervention|Subjects will receive a dietary supplement containing resistant starch and be instructed to take 2 tablespoons (\~20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days prior to increasing to 2 tablespoons twice daily.
62383465|NCT05096455||severe acute pancreatitis|Patients 18 years of age or older admitted to intensive care or resuscitation for severe acute pancreatitis (AP) with hypertriglyceridemia (HTG)
62383466|NCT02941861||recurrence rate of HCC after surgery|There were 33 for Hepatocellular carcinoma between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.
62383467|NCT02941861||recurrence rate of CCA after surgery|There were 34 patients underwent liver resection for Cholangiocarcinoma between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.
62383468|NCT04001699|EXPERIMENTAL|Intervention|Preoperative assessment conducted by an interprofessional team
62383469|NCT04001699|ACTIVE_COMPARATOR|Usual care|Usual care
62383470|NCT00807456|EXPERIMENTAL|Subjects treated with ASTRA TECH Implant System, OsseoSpeed™ Profile implant|
62383471|NCT04247724|EXPERIMENTAL|Active group of men|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:~\*1 group of men playing recreational handball"
62383472|NCT04247724|EXPERIMENTAL|Active group of women|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:~\*1 group of women playing recreational handball"
62567642|NCT01061112||CYP2C9*1/*1 Genotype|This genotype is considered the wild type genotype. Individuals with the CYP2C9\*1/\*1 genotype have two \*1 alleles and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen \& Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen \& Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide \& Fluconazole.
62764253|NCT04342689|PLACEBO_COMPARATOR|Control|Subjects will receive a placebo starch, consisting of non resistant starch and be instructed to take 2 tablespoons (\~ 20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days.
62764254|NCT05157347|EXPERIMENTAL|Robot-assisted Training Group|- After the baseline test, the training is performed with 20 sessions in total (60 min / session); five sessions a week for four weeks. The robot-assisted training group is given 30 min conventional gait training and another 30 min (excluding robot attachment and detachment time) gait training using an exoskeletal wearable robot, while the control group is given 1 hr conventional gait training for the same time as the robot-assisted training group. In all participants in each group, no other robot-assisted rehabilitation such as Lokomat, Erigo, or Morning Walk could be performed.
62764255|NCT05157347|OTHER|Control Group|- After the baseline test, the training is performed with 20 sessions in total (60 min / session); five sessions a week for four weeks.
62764256|NCT05793606|ACTIVE_COMPARATOR|Deltoid repaired|
62764257|NCT05793606|NO_INTERVENTION|non-deltoid repaired|
62764258|NCT04251780|EXPERIMENTAL|Hyperaldosteronism treatment|Patients with Hyperaldosteronism will either be treated by adrenalectomy (adrenal adenoma) or receive medical treatment (Spironolactone/Eplerenone; bilateral hyperplasia) as indicated by the Endocrinological Guideline (J Clin Endocrinology \& Metabolism, May 2016). Before and after intervention tissue sodium and tissue potassium amount will be assessed by MRI.
62764259|NCT04304911|EXPERIMENTAL|UP in blended format|Clinicians will follow the UP therapist manual, 2nd edition, recently translated by Osma and Crespo (13,14). The same contents through a digital material (video and audio) will be integrated in the UP-APP. The program can be developed in a range of 12 to 16 sessions. The UP includes 8 modules
62764260|NCT04304911|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Cognitive Behavioral Therapy in individual format is the treatment of choice (TAU) by psychologists and psychiatrists at the collaborating Public Mental Health Centers and Primary Care Centers, together with pharmacological treatment (i.e., antidepressants and / or anxiolytics).
62764261|NCT03054597|EXPERIMENTAL|Adults|"The arm consisted of adult participants who underwent:~Circular Light Motion exercises: 4 times over 2 weeks Diagonal Light Motion exercises: 4 times over 2 weeks Peripheral Light Motion exercises: 4 times over 2 weeks"
62764262|NCT03054597|EXPERIMENTAL|Children|"The arm consisted of child participants who underwent:~Circular Light Motion exercises: 4 times over 2 weeks Diagonal Light Motion exercises: 4 times over 2 weeks"
62764263|NCT03093636|EXPERIMENTAL|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App, study insulin, and study CGM at home for 12 weeks.
62764264|NCT03093636|PLACEBO_COMPARATOR|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use study insulin and the study CGM alone at home for 12 weeks.
61988627|NCT06143670|ACTIVE_COMPARATOR|Negative Control|Participants will be instructed to brush their teeth with full ribbon of toothpaste (0.243% w/w Sodium fluoride) on head of toothbrush provided for at least one (timed) minute twice a day (morning and evening) for 12 weeks.
62764265|NCT06302894|NO_INTERVENTION|Control group|Internet addiction scale, family harmony scale and loneliness scale for children will be applied to the control group after 6 weeks without any intervention.
62764266|NCT06302894|EXPERIMENTAL|Experimental group|"In order to reduce problematic internet use and protect the experimental group from addiction, different online applications and trainings based on the Health Belief Model, enriched with web 2.0 technologies, will be provided and followed every week (6 weeks in total).~At the end of 6 weeks, the internet addiction scale, family harmony scale and loneliness scale for children will be administered."
62764267|NCT03508323|EXPERIMENTAL|Teneligliptin|
62764268|NCT03508323|PLACEBO_COMPARATOR|Placebo|
61988628|NCT01830439|EXPERIMENTAL|Fed PA-824 200mg|200 mg PA-824 (4 x 50 mg tablets) in Phase A was administered 30 minutes after the start of a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
62764269|NCT02183129|EXPERIMENTAL|Meloxicam|
62764270|NCT02183129|ACTIVE_COMPARATOR|Diclofenac|
61988629|NCT01830439|EXPERIMENTAL|Fasted PA-824 200 mg|200 mg PA-824 (4 x 50 mg tablets) in Phase A was administered 30 minutes after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
61988630|NCT01830439|EXPERIMENTAL|Fed PA-824 50mg|50 mg PA-824 (1 x 50 mg tablets) in Phase B was administered 30 minutes after the start of a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
61988631|NCT01830439|EXPERIMENTAL|Fasted PA-824 50mg|50 mg PA-824 (1 x 50 mg tablets) in Phase B was administered after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
62764271|NCT01107119|EXPERIMENTAL|Integrated care pathway|"program for~1. communication and information flow aimed at collaboration between hospitals, general practitioners and home care services~2. systematic patient follow-up in home care services by using checklists"
62764272|NCT01107119|ACTIVE_COMPARATOR|usual care|usual care
62764273|NCT03256747|EXPERIMENTAL|NMES group|NMES will be placed at the knee extensors, with maximal intensity tolerance evaluated by to induce visible contractions.
62764274|NCT03256747|PLACEBO_COMPARATOR|NMES-placebo group|NMES-placebo will be placed at the knee extensors, with minimal intensity to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
62383473|NCT04247724|EXPERIMENTAL|Inactive group of men|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:~\*1 group of men continuing their normal lifestyle patterns"
62383474|NCT04247724|EXPERIMENTAL|Inactive group of women|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:~\*1 group of women continuing their normal lifestyle patterns"
62764275|NCT03927352|EXPERIMENTAL|SCT630|"Participants received 80 mg SCT630 subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~Participants with a PASI 50 response at week 16 continued to receive 40 mg SCT630 until week 48."
62764276|NCT03927352|ACTIVE_COMPARATOR|adalimumab-EU source|"Participants received 80 mg adalimumab subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~At week 16 participants with a PASI 50 response were re-randomized to treatment with adalimumab or were transitioned to SCT630 until week 48"
62764277|NCT02927275|EXPERIMENTAL|Standing Modality|Performance on computerized cognitive tests while standing at a desk. Experimental: Standing Modality
62764278|NCT02927275|EXPERIMENTAL|Biking Modality|Performance on computerized cognitive tests while biking at user's preferred speed on stationary bicycle. Experimental: Biking Modality
62764279|NCT02927275|EXPERIMENTAL|Walking Modality|Performance on computerized cognitive tests while walking at 1mph. Experimental: Walking Modality
61988632|NCT05584553||ToggleLoc 2.9 mm soft tissue device|Patients who already received the ToggleLoc 2.9 mm soft tissue device in the shoulder. No additional surgery will be performed.
61988633|NCT05584553||JuggerLoc soft tissue device|Patients who already received the JuggerLoc soft tissue device in the shoulder. No additional surgery will be performed.
61988634|NCT01867905||Severe sepsis and septic shock|Patients who present in severe sepsis or septic shock will have blood cultures taken before and after antibiotic administration. The antibiotic choice will be determined by the emergency physician and the patients will be treated as per routine hospital protocol. No therapeutic interventions will be administered.
61988635|NCT05874752||nonsignificant coronary artery stenosis group|Exclusion criteria: ≥70% proximal luminal stenosis in at least one major coronary vessel based on coronary angiography
61988636|NCT05874752||significant coronary artery stenosis group|Defined as ≥70% proximal luminal stenosis in at least one major coronary vessel based on coronary angiography
62383475|NCT03683680|EXPERIMENTAL|MRiS|"* The specimens to be collected will include at least five pleural biopsy samples~* MPT test and the CLDN15/VIM test will be performed"
62168219|NCT05980247|NO_INTERVENTION|Control|No application and no thimble patch.
62168220|NCT05980247|EXPERIMENTAL|Use of the thimble application but not the thimble patch|Use of the thimble application but not the thimble patch
62168221|NCT05980247|EXPERIMENTAL|Use of the thimble patch but not the thimble application|Use of the thimble patch but not the thimble application
62764280|NCT02927275|OTHER|Seated Modality|Performance on computerized cognitive tests while sitting. No Intervention: Seated Modality
62764281|NCT04202198|EXPERIMENTAL|pinhole surgical technique with Platelet Rich Fibrin|minimally invasive tunneling procedure followed by coronal advancement with placement of Platelet Rich Fibrin membrane
62764282|NCT04202198|ACTIVE_COMPARATOR|pinhole surgical technique only|coronal advancement following minimally invasive tunneling procedure
62764283|NCT00494715|EXPERIMENTAL|Benazepril|
62764284|NCT00494715|EXPERIMENTAL|valsartan|
62764285|NCT00494715|EXPERIMENTAL|benazepril/valsartan|
62764286|NCT03796754|ACTIVE_COMPARATOR|YoBEKA Intervention|
62764287|NCT03796754|NO_INTERVENTION|Control group|
62764288|NCT02982499||control group|Healthy participants will receive a one-time assessment of quantitative Magnetic Resonance Imaging (MRI) and spectrum domain optical coherence tomography (OCT).
62383476|NCT02036476|EXPERIMENTAL|Cabozantinib|Cabozantinib 60 mg given orally daily for 28 days (4 weeks) each cycle. Participants were treated until disease progression, unacceptable toxicity or withdrawal for other reasons.
62383477|NCT03268057|EXPERIMENTAL|VX15/2503 + avelumab|VX15/2503 at a concentration of 5 mg/kg, 10 mg/kg or 20 mg/kg with a fixed dose of avelumab at 10 mg/kg, administered intravenously on a bi-weekly dosing cycle.
62383478|NCT05981872|EXPERIMENTAL|post covid-19 patients with neurological symptoms as study group|•Study group (A) will receive cognitive rehabilitation (Rehacom ) for 30 minutes and selected physical therapy program(that included aerobic, strength, and balance training for 30 minutes, with total duration 60 minutes. 3 sessions per week for 12 weeks.
62383479|NCT05981872|ACTIVE_COMPARATOR|post covid-19 patients with neurological symptoms as control group|"Control group (B) which will include 18 patients who will receive only selected physical therapy program (that included aerobic, strength, and balance training ).~The treatment will conducted for 60 minutes, 3 sessions per week for 12 weeks"
62383480|NCT02525835|EXPERIMENTAL|Low Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) or a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
62764289|NCT02982499||optic neuropathy group|Participants with optic neuropathy will receive a one-time assessment of quantitative Magnetic Resonance Imaging (MRI) and spectrum domain optical coherence tomography (OCT).
62764290|NCT04639817||Levofloxacin targeted therapy|Patients with Stenotrophomonas maltophilia bacteremia or lower respiratory tract infection who received Levofloxacin from day of culture positivity (day 0) through day +7.
62764291|NCT04639817||TMP/SMX targeted therapy|Patients with Stenotrophomonas maltophilia bacteremia or lower respiratory tract infection who received TMP/SMX from day of culture positivity (day 0) through day +7.
62764292|NCT04744012||unique group|"After local anesthesia, a full thickness flap was elevated from the lingual wall and a partial thickness flap was performed in the buccal one. After that, the buccal periosteum was detached and dental implants were placed following the biological drilling protocol, getting autologous bone particles from the implant site.~Patient's blood collection was performed and the plasm obtained was poured down on a sterile container and mixed with autologous bone particles collected previously during the drilling procedure. Finally the graft was placed in the pocket prepared previously and the surgical wound was sutured in two planes."
61988637|NCT02676505||1|"Group (I)(Coached group):~It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds."
62383481|NCT02525835|EXPERIMENTAL|High Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) or a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
62383482|NCT02021864|EXPERIMENTAL|vitamin D3, prenatal multivitamin|vitamin D3 50,000 unit/week for 8 weeks, daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
62383483|NCT02021864|ACTIVE_COMPARATOR|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
62383484|NCT05570747|EXPERIMENTAL|In-House Usability Study Group|Human subjects will interact with two different CPAP interfaces including a traditional CPAP mask and the 2nd generation DreamPort-Eclipse. Subjects will be requested to put on each of the different CPAP interface options a total of three times for a total of 6 trials. The order of device tries will be randomized.
62383485|NCT03552614||children with brain damage|Patients undergo physiotherapy + Upper limb robot-assisted rehabilitation
62383486|NCT04041258|EXPERIMENTAL|evaluation of clinical and radiographic findings after surgical treatment|Evaluation of clinical and radiographic findings at least 1 year after surgical treatment for pseudoarthrosis of clavicle
62383487|NCT00409149|EXPERIMENTAL|CALM BP|dietary approach, education on cooking and food consumption choices, walking physical exercise, Qi Gong - a form of Chinese slow movement exercise combined with relaxation breathing and imagery and group therapy coaching in stress management techniques and mind-body balancing techniques.
62383488|NCT00409149|ACTIVE_COMPARATOR|DASH|standard dietary DASH approach in hypertensive patients
62383489|NCT02777008|EXPERIMENTAL|CTP-543 Single Dose|Single oral dose
62383490|NCT02777008|EXPERIMENTAL|CTP-543 Multiple Dose|Multiple oral dose for 7 consecutive days
62383491|NCT02219516|EXPERIMENTAL|Cohort 1: Mild renal impairment|RDEA3170 15 mg once daily fasted
62383492|NCT02219516|EXPERIMENTAL|Cohort 2: Moderate renal impairment|RDEA3170 15 mg once daily fasted
62383493|NCT02219516|EXPERIMENTAL|Cohort 3: Severe renal impairment|RDEA3170 15 mg once daily fasted
62383494|NCT02219516|EXPERIMENTAL|Cohort 4: Control subjects with normal renal function|RDEA3170 15 mg once daily fasted
62383495|NCT03799523|EXPERIMENTAL|Subjects undergoing breast radiotherapy|At the time of CT simulation study participants will receive temporary skin markings to be covered in clear medical grade tape. Light-based surface imaging will be used to determine alignment between the patient and the radiation machine. Radiation treatment will proceed as standard of care.
62764293|NCT02847858|EXPERIMENTAL|Health-E You App Participants|
62383496|NCT04087967|EXPERIMENTAL|Decitabine combined with HAAG|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed AML patients younger than 60.
62383497|NCT04087967|ACTIVE_COMPARATOR|IA Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed AML patients younger than 60.
62383498|NCT02895542||Oral Anti-Cancer Agent|No intervention
62383499|NCT05588011|ACTIVE_COMPARATOR|LivaNova Inspire|A high pressure oxygenator (LivaNova) will be used during cardiopulmonary bypass.
62383500|NCT05588011|ACTIVE_COMPARATOR|Terumo|A low pressure oxygenator (Terumo) will be used during cardiopulmonary bypass.
62764294|NCT02847858|NO_INTERVENTION|Control Group|
62764295|NCT05866120|ACTIVE_COMPARATOR|Individuals with Parkinson's Disease to perform physiotherapy on the ground.|The protocols will last for 12 weeks, with a frequency of 2 times a week.
62383501|NCT01072656|ACTIVE_COMPARATOR|Treatment group|Active stimulation and programmed to the settings found to be optimal during the titration process.
62764296|NCT05866120|ACTIVE_COMPARATOR|Individuals with Parkinson's Disease to undergo aquatic physiotherapy|The protocols will last for 12 weeks, with a frequency of 2 times a week.
62764297|NCT04392921|EXPERIMENTAL|Intervention Arm|Patients randomized to amiodarone treatment
62764298|NCT04392921|PLACEBO_COMPARATOR|Control Arm|Patients randomized to placebo treatment
62764299|NCT00571207||I|Drivers suspected of driving under the influence of drugs
62168222|NCT05980247|EXPERIMENTAL|Use of both thimble application and thimble patch|Use of both thimble application and thimble patch
62383502|NCT01072656|SHAM_COMPARATOR|Control group|IPG is set to ON but the voltage is set to 0V.
62383503|NCT06083428|ACTIVE_COMPARATOR|PENG Block group|ultrasound guided PENG block - 20ml 0,2% ropivacaine
62383504|NCT06083428|ACTIVE_COMPARATOR|ESPB group|ultrasound guided erector spinae plane block - 20ml 0,2% ropivacaine
62383505|NCT06083428|ACTIVE_COMPARATOR|Control group|Only spinal anesthesia - No peripheral nerve block
62383506|NCT01173874|EXPERIMENTAL|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
62383507|NCT01173874|NO_INTERVENTION|Cognitive activity control group|This is a non-specific mental activity control condition, conducted two times per week for a total of 30 sessions.
62764300|NCT00571207||II|Drivers not suspected of driving under the influence of drugs
62764301|NCT03246490|OTHER|All Participants|All participants complete the same study procedures, which involve drinking alcohol to a .08 blood alcohol level and walking short distances while their blood alcohol level is increasing to .08 and decreasing down to .00.
62764302|NCT00724412|ACTIVE_COMPARATOR|Systane|Systane
62764303|NCT00724412|ACTIVE_COMPARATOR|Optive|Optive
61988638|NCT02676505||2|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth.
62383508|NCT04793893|EXPERIMENTAL|Treatment of residual hypermetropia refraction after LASIK|"The main problem at young patients post - LASIK after one year is residual hypermetropic refractive errors (especially accommodation problem) The method used in Eye Hospital is treatment with implantation of human fresh corneal lenticule (min. -1.50D) taken from myopic patients in post - LASIK patients with residual hypermetropic refractive error (min. +1.0D).~The flap of LASIk is lifted,cleaned and then the lenticule gently inserted.The lenticule was positioned according the K2 values when is astigmatism residual refractive error.In cases where is not astigmatism the lenticule was positioned in central position under the flap."
62383509|NCT03878420|EXPERIMENTAL|PBM Treatment|The Valeda™ Light Delivery System will deliver 590, 660 and 850 nm wavelengths together.
62383510|NCT03878420|SHAM_COMPARATOR|Sham Treatment|The Valeda™ Light Delivery System will deliver non-effective treatment of the 590 and 660 nm wavelengths together.
62383511|NCT00434876|EXPERIMENTAL|1|Quetiapine XR
62383512|NCT00434876|PLACEBO_COMPARATOR|2|Placebo
62383513|NCT02984735||Evaluation of children with spastic CP|Children with a diagnosis of spastic CP aged 2 to 12 years who were referred due to chewing/swallowing problems by pediatric neurologists were included. The inclusion criteria were above the age of 24 months, and had complaints about chewing function. Children under the age of 24 months, requiring tube feeding or taking any oral nutritional supplements, and used any medicine and/or oral appliances that could affect the chewing performance, were excluded.
62383514|NCT04374149|EXPERIMENTAL|1 - TPE Alone|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or fresh frozen plasma (FFP) replacement if underlying coagulopathy
62383515|NCT04374149|EXPERIMENTAL|2 - TPE Plus Ruxolitinib|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or fresh frozen plasma (FFP) replacement if underlying coagulopathy combined with ruxolitinib 5mg po twice daily (BID) beginning day prior to first TPE and continuing BID for total of 14 days.
62764304|NCT04900948|EXPERIMENTAL|Experimental group №1|proactive therapy with local calcineurin inhibitors + emollients
62764305|NCT04900948|ACTIVE_COMPARATOR|Experimental group №2|proactive therapy with local glucocorticosteroids + emollients
62567643|NCT01061112||CYP2C9*1/*3 Genotype|Individuals with the CYP2C9\*1/\*3 genotype have one \*1 allele and one \*3 allele and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen \& Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen \& Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide \& Fluconazole.
62764306|NCT05053841|NO_INTERVENTION|Control group|fifteen obese females who received letrozole only
62764307|NCT05053841|ACTIVE_COMPARATOR|metformin group|fifteen obese females who received the same dose of letrozole plus metformin (2000 ± 500) mg daily
62764308|NCT05053841|NO_INTERVENTION|lean group|fifteen non- obese breast cancer females who received letozole for six months, treatment period
62764309|NCT04240093|EXPERIMENTAL|Experimental|Experimental: Behavioral Activation (8 sessions) + Substance Abuse and Health Navigation Counseling (2 sessions) + Meds
61988639|NCT03456596||Institution|Community cancer centers implementing ENABLE
62383516|NCT04598100|ACTIVE_COMPARATOR|FOCUS-EC|"FOCUS-EC provides developmental guidance, parent education, and key resilience skills that promote positive individual and family coping, including emotional regulation, problem solving, goal setting, communication, and management of deployment \& combat stress reminders, which foster parent-child and family cohesion. The intervention is delivered in six 90-minute sessions in the family home. Each session is structured with a check-in, review of the previous week's home activity, primary activity and discussion, selection of a new home activity, and a closing check-out. The family learns and practices the skills during the sessions, commits to practicing the skills during the week, and reports on their experiences the following session so that skills can be reinforced and adjustments made. FOCUS-EC promotes parenting skills and more cohesive family relationships in two key phases: 1) creating a family deployment and reintegration timeline and 2) enhancing parent-child interactions."
62764310|NCT04240093|ACTIVE_COMPARATOR|Standard of Care|Substance Abuse and Health Navigation Counseling (2 sessions) + Meds
62764311|NCT02254785|EXPERIMENTAL|Cabazitaxel|
62764312|NCT02254785|ACTIVE_COMPARATOR|Abiraterone or enzalutamide|
62383517|NCT04598100|NO_INTERVENTION|Web-Based Family Education|Families in the WB condition will be provided access to online educational materials covering topics such as typical child development, effects of early childhood separations, common child reactions to family stress, and the importance of self-care. CDM families in this condition will also have access to the standard services that are available to OEF/OIF/OND veterans through the VHA system, TriCare, and California Department of Veterans Affairs.
62383518|NCT02265445|ACTIVE_COMPARATOR|Maintaining carbapenem therapy|Intravenous therapy, Maintaining carbapenem therapy
62764313|NCT05259644|ACTIVE_COMPARATOR|Conservative treatment group|Obese patients treated with conservative approach - diet.
62764314|NCT05259644|ACTIVE_COMPARATOR|Laparoscopic sleeve gastrectomy|Obese patients treated with laparoscopic sleeve gastrectomy.
62764315|NCT05259644|ACTIVE_COMPARATOR|endoscopic gastric plication|Obese patients treated with endoscopic gastric plication.
62764316|NCT02431390|EXPERIMENTAL|RAPAELⓇ Smart Glove group|The experimental group includes 40 stroke patients. The group will receive the conventional occupational therapy(30min per session, 5 times per week, during 4 weeks of hand dexterity training) and RAPAELⓇ Smart Glove digital treatment system training. RAPAELⓇ Smart Glove digital treatment training will consist of games and play to facilitate the function of upper limbs and brain plasticity. RAPAELⓇ Smart Glove group will be provided the 20 training session. (30min per session, 5 times per week, during 4 weeks)
62764317|NCT02431390|ACTIVE_COMPARATOR|Additional occupation therapy group|The active comparator group includes 40 stroke patients.The occupational therapy group will receive the conventional occupational therapy(30min per session, 5 times per week, during 4 weeks of hand dexterity training) sessions twice. Additional conventional occupational therapy sessions are comprised of the training for upper limb and cognition. The additional occupational therapy group will be provided the 20 additional session (30min per session, 5 times per week, during 4 weeks)
62764318|NCT03205852||group A (benefit-inform)|filling questionnaire based on benefits of surgery
62764319|NCT03205852||group B (side effect-inform)|filling questionnaire based on side-effects of surgery
62383519|NCT02265445|ACTIVE_COMPARATOR|Deescalation therapy|Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE. Deescalation therapy
62764320|NCT02818114|EXPERIMENTAL|PEET|Peer support interventions as an adjunct to prolonged exposure
62764321|NCT02288013|OTHER|Stratafix Tissue control device|Closure of Uterine incision at C section
62764322|NCT02288013|OTHER|Vicryl suture|Closure of uterine incision at C section
62764323|NCT05479929||Patients with Respiratory Symptoms|The Canadian Triage Assessment Scale (CTAS) will be assessed via patient survey form and electronic chart review.
62764324|NCT01448655||Test group with Iscador® Qu|The test group will receive the mistletoe extract Iscador® Qu as supportive treatment in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
62764325|NCT01448655||Control group|The parallel control group will receive no mistletoe but only post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
62764326|NCT04594460|EXPERIMENTAL|experimental Group|the experimental arm will receive hydrogen-oxygen mixed gas inhalation (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, output: 3 L/min (hydrogen concentration: 66.7%, oxygen concentration: 33.3%)) ,the treatment duration will be 8 hours per day, for 12 weeks.
62764327|NCT04594460|ACTIVE_COMPARATOR|Control Group|the control arm will receive oxygen inhalation (OLO-1 Medical Molecular Sieve Oxygen Generator, output: 3 L/min (oxygen concentration: 33.3%), Shanghai Ouliang Medical Devices Co., Ltd.)the treatment duration will be 8 hours per day, for 12 weeks.
62764328|NCT06397508|EXPERIMENTAL|1|ABC with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions
62764329|NCT06397508|EXPERIMENTAL|2|CAB with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions
62764330|NCT06397508|EXPERIMENTAL|3|BCA with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions
62764331|NCT06397508|EXPERIMENTAL|4|CBA with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions
62383520|NCT02079701|EXPERIMENTAL|23-valent pneumococcal vaccine|single dose, 23-valent pneumococcal vaccine, 0.5ml, intramuscular (IM)
62764332|NCT06397508|EXPERIMENTAL|5|BAC with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions
62764333|NCT06397508|EXPERIMENTAL|6|ACB with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions
62383521|NCT02079701|PLACEBO_COMPARATOR|placebo|0.5 ml injectible saline, IM
62383522|NCT05780164||Intervention|Nurse participants will be provided with a research readiness tool to facilitate their discussions with lung cancer patients about clinical trial opportunities. The tool will be used by nurses over a six month period, alongside usual care.
62383523|NCT05780164||Control|No intervention. Nurse participants will provide usual care to lung cancer patients.
62764334|NCT03618914||Non-anemic women|
62764335|NCT03618914||anemic women|anemia due to iron deficiency
62764336|NCT04723225|EXPERIMENTAL|Experimental|Cat-Cow is one of the essential postures in yoga for its beneficial reasons. It is an alternate shift of posture from flexion of the back (rounded) to the extension of the back (arched). During each set of movement, inhalation and exhalation will be guided.
62764337|NCT04723225|NO_INTERVENTION|Control|In control intervention group usual care will be provided.
62764338|NCT05506488|ACTIVE_COMPARATOR|Dasatinib plus Quercetin|Day 0: (15 per arm, randomization). week 7: blood, fibroscan, ECG, questionnaires. week 14: blood, fibroscan, ECG, questionnaires. Week 21: blood, fibroscan, ECG, questionnaires, liver biopsy. end of study
62764339|NCT05506488|PLACEBO_COMPARATOR|placebo|Day 0: (15 per arm, randomization). week 7: blood, fibroscan, ECG, questionnaires. week 14: blood, fibroscan, ECG, questionnaires. Week 21: blood, fibroscan, ECG, questionnaires, liver biopsy. end of study
62383524|NCT04036006|EXPERIMENTAL|Group-Based|The Group-based Program uses an ecologically valid setting in which participants exercise, prepare foods, and eat together to facilitate the emergence of old habits and replace them with healthy alternatives. The intervention team consists of a health psychologist, registered dietitian, and health coach. They co-facilitate group meetings for 15 participants that are held weekly for 3 months, bi-weekly for 3 months, and then monthly in participant-led maintenance meetings. Each session includes: weigh-in and physical activity (20 min), cooking demonstration (20 min), and a shared vegetable dish with discussion (50 min). The maintenance phase (months 7 to 24 post randomization) consists of support and health-related topics of the participants' own choosing. Progress reports with lab results are sent to participants and primary care physicians.
62383525|NCT04036006|ACTIVE_COMPARATOR|Self-Directed|The Self-Directed lifestyle program represents enhanced usual care based upon what is currently offered in primary care in the United States for lifestyle treatments for adults with metabolic syndrome. Usual care is enhanced by: 1) lifestyle education for management of metabolic syndrome provided in evidence-based tip sheets from nationally recognized organizations; 2) provision of a Fitbit for self-monitoring physical activity; 3) access to a website containing all education materials; and 4) progress report letters with lab results sent to participants and primary care physicians after completion of each assessment
62764340|NCT01417117||Spontaneous Intracerebral Hemorrhage|Patients with primary intracerebral hemorrhage within 24 hours of admission diagnosed by non-contrast head computed tomography (CT)
62764341|NCT03289169|EXPERIMENTAL|MEDITOXIN|Meditoxin(Botulinum toxin type A)
62764342|NCT04104659||MK 6240|
62764343|NCT03395561|ACTIVE_COMPARATOR|green coffe|2 capsuls of green coffe
62383526|NCT05288179|EXPERIMENTAL|Pirfenidone group|Patient takes pirfenidone 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
62383527|NCT05288179|PLACEBO_COMPARATOR|placebo group|Patients take a placebo 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
62764344|NCT03395561|PLACEBO_COMPARATOR|control|2 capsuls
62764345|NCT05566262|EXPERIMENTAL|Bodewell Treatment|All patients will be treated with the active product, Bodewell. Bodewell will be applied topically twice a day to all active lesions.
62764346|NCT00946725|EXPERIMENTAL|1|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)
62764347|NCT00946725|ACTIVE_COMPARATOR|2|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)
62764348|NCT03908645|EXPERIMENTAL|Artificial Intelligence assisted Scoring Group|Patients in this group go through colonoscopy under the AI monitoring device.
62764349|NCT03908645|ACTIVE_COMPARATOR|Conventional Human Scoring Group|Patients in this group go through conventional colonoscopy without AI monitoring device.
62764350|NCT05896852|EXPERIMENTAL|Intervention Arm|Participants will increase their physical activity over 6 months as tolerated,
62764351|NCT01377948|OTHER|ACT with RAGE-Control|all subjects are assigned to this arm. This is an open feasability proof of concept trail with a single experimental group with all subjects receiving the intervention being studied.
62764352|NCT04301180|EXPERIMENTAL|Experimental|"The experimental group conducted 10 weekly sessions, with an approximate duration of 45 minutes per session, which consisted of the presentation of food education content while conducting an orchard with seasonal vegetables. Simple recipes were also described in which these vegetables were included to be made at home, along with information on children's books that dealt with the topic of food and were available in the public library.~All children in the experimental groups were given written instructions so that they could perform at their home, together with their parents, the manipulative activities suggested each week. All these contents were common for all the participants in the study. Session material was renewed weekly."
61988640|NCT05112380||Sedentary adults|"* Do not practice overhead sport~* No pain or history of shoulder pain"
61988641|NCT05112380||Overhead athletes|"* Practice an overhead sport at least five hours a week~* No pain or history of shoulder pain"
62764353|NCT04301180|NO_INTERVENTION|Control|"The control group received the usual training corresponding to the contents of the human body module that is currently taught in each center."
62764354|NCT06162091||Patients with severe acquired brain injuries|Patients with severe acquired brain injuries admitted at intensive Rehabilitation Units for severe acquired brain injury within 3 months from occurrence
62764355|NCT05648149|EXPERIMENTAL|hierarchical multi-dimensional cognitive training scheme based on computer|Cognitive training was carried out by three trained and certified nurses in accordance with the cognitive training program. Twice a day, 30min each time, for 4 weeks, the difficulty of the training content is divided into 2 levels, the correct rate of more than 80% can enter the next level. During hospitalization, the patients and their families were taught how to use cognitive training programs. After discharge, special personnel were assigned to supervise and urge the patients to carry out cognitive training through the background.
62764356|NCT05648149|NO_INTERVENTION|routine rehabilitation|Routine treatment, rehabilitation and care
62383528|NCT00068549|EXPERIMENTAL|Treatment|Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 in the absence of disease progression or unacceptable toxicity. Patients also undergo external whole pelvis radiotherapy once daily on days 1-5, 8-13, 15-20, 22-27, and 29-34. After completion of external beam radiotherapy, patients undergo intracavitary radiotherapy and parametrial radiotherapy. The total elapsed time for completion of all radiotherapy is not more than 8 weeks.
62764357|NCT02654236|PLACEBO_COMPARATOR|Placebo|Heavy Drinkers on placebo
62383529|NCT01696396|PLACEBO_COMPARATOR|Placebo Q4W/Abrilumab 210 mg Q3M|"Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
62383530|NCT01696396|EXPERIMENTAL|Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
62383531|NCT01696396|EXPERIMENTAL|Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
62764358|NCT02654236|EXPERIMENTAL|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 4 weeks.
62764359|NCT02654236|NO_INTERVENTION|Non-drinking Controls|Non-drinking healthy controls
62764360|NCT06279793|EXPERIMENTAL|Treatment group|Patients will receive 0.20 g fish oil/kg BW/d (≙2 mL Omegaven®/kg BW/d).
62764361|NCT06279793|PLACEBO_COMPARATOR|Control group|Patients will receive 0,9% NaCl in volume 2 mL/kg BW/d (placebo).
62764362|NCT03109028|ACTIVE_COMPARATOR|Treatment as Usual|Regular standard psychiatric health care including all feasible interventions including medication, psychotherapy and social work.
62764363|NCT03109028|EXPERIMENTAL|Stepped and Collaborative Care Modell|A stepped and collaborative treatment model with varying stepped psychotherapeutic interventions for adult and adolescent refugees.
62764364|NCT04066569|ACTIVE_COMPARATOR|OGTT Tests and Placebo Test|Patients with acromegaly
62764365|NCT04066569|ACTIVE_COMPARATOR|OGTT Tests|age and sex matched healthy volunteers
62764366|NCT04355858|EXPERIMENTAL|NF1 mutated|If a patient were NF1 mutated, she would receive SHR7390(MEK1/2 inhibitor) and Faminitib.
62764367|NCT04355858|EXPERIMENTAL|gBRCA mutated|If a patient were gBRCA mutated, she would receive SHR3162 (PARP inhibitor)and SHR6390(CDK4/6 inhibitor) .
62764368|NCT04355858|EXPERIMENTAL|HER2 activated mutated|If a patient were HER2 activated mutated and had not previously used capecitabine, she would receive Pyrotinib and Capecitabine , while if the patient have previously used capecitabine, she would only use pyrotinib as a single agent.
62764369|NCT04355858|EXPERIMENTAL|PDGFRb mutated|If a patient were PDGFRb mutated, she would receive Faminitib.
62764370|NCT04355858|EXPERIMENTAL|CD8 ≥10%|In the arm which IHC showed CD8 ≥10%, this arm will be subdivided into 6 sub-arms, in which Arm 5A-4D, we choose the patients who had CDK4/6 inhibitor before while in Arm 5E, we choose the patients who secondarily resistant to adjuvant endocrine therapy , and in Arm 5FF, we choose the patients who is in stage IV without precious treatment or sensitively recurrence. A patient would receive SHR1210(PD-1 antibody) ,nab-paclitaxel and Faminitib in Arm-5A. A patient would receive SHR1210(PD-1 antibody) and VEGF inhibitor in Arm-5B. A patient would receive SHR1701(PD-L1/TGF-βRII inhibitor) in Arm-5C. A patient would receive SHR1701(PD-L1/TGF-βRII inhibitor) and SHR6390(CDK4/6 inhibitor) in Arm-5D. A patient would receive SHR1210(PD-1 antibody) and SHR6390(CDK4/6 inhibitor) and SERD in Arm-5E. A patient would receive SHR1210(PD-1 antibody) and SHR6390(CDK4/6 inhibitor) and AI in Arm-5F.
62764371|NCT04355858|EXPERIMENTAL|PAM pathway mutated|If a patient had any PAM pathway mutation, she would receive Everolimus(mTOR inhibitor) combined with nab-paclitaxel.
61988642|NCT05041712||Case cohort|Observational study of children between the ages of 2 days to \< 18 years who are cannulated onto ECMO at participating sites
61988643|NCT05041712||Control cohort|Observational study of children between the ages of 2 days to \< 18 years admitted to the Johns Hopkins Pediatric Intensive Care Unit (PICU) or Pediatric Cardiac Intensive Care Unit (PCICU) for any reason.
61988644|NCT01344187|EXPERIMENTAL|riboflavin solution and KXL System|Subjects will receive riboflavin solution followed by UVA irradiation for 4 minutes
62764372|NCT04355858|EXPERIMENTAL|AR≥10%|If a patient's IHC showed AR≥10% , she would receive SHR2554(EZH2 inhibitor) and SHR3680(AR inhibitor).
62764373|NCT04355858|EXPERIMENTAL|Epigenetic Cohort|In this cohort, a patient would receive SHR2554(EZH2 inhibitor) and SHR3162 (PARP inhibitor).
62764374|NCT04355858|EXPERIMENTAL|Combined Immunity Cohort|In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with SHR1701(anti-PD-L1/TGF-βRII bifunctional fusion protein) .
62764375|NCT04213144|EXPERIMENTAL|Magdent Cap MED|Soft and hard tissue healing with electomagnetic healing abutment.
62764376|NCT04213144|SHAM_COMPARATOR|Sham MED|Soft and hard tissue healing with a regular healing abutment.
62764377|NCT04231214|EXPERIMENTAL|Treatment sequence 1|Spiolto® Respimat® on Day 1 0.9% nebulized saline on Day 9 Spiolto® Respimat® from Day 10 to Day 24
62764378|NCT04231214|EXPERIMENTAL|Treatment sequence 2|0.9% nebulized saline on Day 1 Spiolto® Respimat® on Day 9 Spiolto® Respimat® from Day 10 to Day 24
62764379|NCT02990195|OTHER|Double enterostomy|
62764380|NCT00316888|EXPERIMENTAL|Arm I (closed to accrual as of 11/3/2008)|Patients receive cisplatin IV over 60 minutes on days 1, 29, 57, and 85 and fluorouracil IV continuously over 96 hours on days 1-4, 29-32, 57-60, and 85-88. Patients also receive cetuximab IV over 120 minutes on day 50 and then IV over 60 minutes on days 57, 64, 71, 78, 85, 92, and 99 and undergo radiotherapy once daily 5 days a week for 5 weeks, beginning on day 57. Treatment continues in the absence of disease progression or unacceptable toxicity.
61988645|NCT01344187|PLACEBO_COMPARATOR|placebo solution and KXL System|Subjects will receive placebo solution followed by UVA irradiation for 4 minutes
62764381|NCT00316888|EXPERIMENTAL|Arm II (open to accrual on 8/18/2009)|Patients receive cetuximab IV over 120 minutes on day 1 and then IV over 60 minutes on days 8, 15, 22, 29, 36, 43, and 50. Patients also receive cisplatin IV over 60 minutes on days 1 and 36, fluorouracil IV continuously over 96 hours on days 8-11 and 36-39, and undergo radiotherapy once daily 5 days a week for 5 weeks beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
62764382|NCT04861246|EXPERIMENTAL|Experimental|Epidermal pigmented lesion
62764383|NCT01569061|ACTIVE_COMPARATOR|Active Laser Group (ALG)|
61988646|NCT04434365|EXPERIMENTAL|Berberine+standard therapy Arm|In the Berberine Arm, patients will receive berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4±1 weeks (Stage 3) in addition to standard treatment, including aspirin (100mg/day), clopidogrel (75mg/day), statins, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, beta-blockers, and/or antidiabetic therapy (including insulin or oral medication) was decided on an individual basis by the attending physician for 12±1 weeks.
62764384|NCT01569061|SHAM_COMPARATOR|Sham Laser Group (SLG)|
62383532|NCT01696396|EXPERIMENTAL|Abrilumab 210 mg/Abrilumab 210 mg Q3M|"Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M)for 108 weeks."
62764385|NCT03405935|EXPERIMENTAL|B/F/TAF|B/F/TAF FDC for at least 96 weeks.
62764386|NCT01786460||Healthy Volunteers|
62764387|NCT05755555|EXPERIMENTAL|Diabetes specialist|Message with a note from a diabetes specialist
61988647|NCT04434365|ACTIVE_COMPARATOR|Standard therapy Arm|In the Control Arm, patients will receive standard treatment, including aspirin (100mg/day), clopidogrel (75mg/day), statins, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, beta-blockers, and/or antidiabetic therapy (including insulin or oral medication) was decided on an individual basis by the attending physician for 12±1 weeks.
61988648|NCT01471379|EXPERIMENTAL|Group A (50mg - 100mg)|Group A will begin treatment with Milnacipran 50mg BID (n=20) during Phase I and will be increased to 100mg BID during Phase II
61988649|NCT01471379|ACTIVE_COMPARATOR|Group B (50mg x12)|Subjects in this arm will be maintained at Milnacipran 50mg BID for the entirety of the 12 weeks of the study.
61988650|NCT01471379|PLACEBO_COMPARATOR|Group C (Placebo - 50mg)|Group C will begin treatment with Placebo BID (n=20) during Phase I and will be given 50mg BID during Phase II
62383533|NCT04129242|ACTIVE_COMPARATOR|"paired taVNS + Task Specific Training"|
62764388|NCT05755555|EXPERIMENTAL|Someone like you|"Message with a note from a person like you"
62764389|NCT05755555|EXPERIMENTAL|Vitality doctor|Message with a note from the Vitality doctor
62764390|NCT05841199||Controls|10 patients with unobstructed coronary arteries, normal microvascular function and normal LV function.
61988651|NCT03447509|ACTIVE_COMPARATOR|Experiment 1a|Examine physiological mechanisms contributing to the control of precision and power grip behaviors. To accomplish this aim the investigators propose to complete one main experiment. The investigators will test the hypotheses that there are two fundamentally distinct modes of hand operation after SCI. One involves brainstem pathways, and permits whole-hand 'power grip', while the other involves corticospinal and motor cortical connections, and allows a wide range of fractionated finger movements (precision grip) after SCI. Measurements of corticospinal, reticulospinal, and motoneuron excitability will be tested during index finger abduction, precision and power grip.
62168223|NCT00965302|ACTIVE_COMPARATOR|Intensive medical management of Type 2 DM|Intensive medical management of Type II diabetes will include visits every three months for a year with an endocrinologist, with lifestyle counseling, weight management, regular exercise, and glucose control forming the core of the medical therapy.
62383534|NCT04129242|ACTIVE_COMPARATOR|"unpaired taVNS + Task Specific Training"|
62383535|NCT02405091|EXPERIMENTAL|Dose Group 1|Fixed dose of NBI-98854 administered once daily for 48 weeks
62764391|NCT05841199||Coronary artery disease|25 patients with severe, single-vessel coronary artery disease of the proximal LAD or proximal other dominant vessel awaiting PCI.
62764392|NCT05841199||Microvascular dysfunction|15 patients with without severe disease in any coronary artery, impaired microvascular function and normal LV function.
62764393|NCT05841199||Heart failure|20 patients with LV systolic dysfunction (LVEF\<40%).
62764394|NCT04051554|EXPERIMENTAL|Neuromuscular and Proprioceptive Training|Myklebust's training program
62764395|NCT04051554|ACTIVE_COMPARATOR|Conventional Training|Running, Sprints, Agility training, and Dynamic stretching
62764396|NCT04564248|EXPERIMENTAL|website access for families|
62764397|NCT04564248|NO_INTERVENTION|standard care|
62764398|NCT02483130||NAC or Placebo|Participants will receive 2400mg capsules of N-Acetylcysteine or placebo
62764399|NCT01335529|EXPERIMENTAL|Boceprevir, PegIFN alfa 2b, Ribavirin|"Standard Treatment :~* Peg-Interferon (PegIFN) alfa 2b by subcutaneous injection 1,5 µg/kg/week~* Ribavirin capsules 200mg: dosage delivered in weight categories (\< 65 kg: 800 mg ; 65-80 kg: 1000 mg; 81-105 kg: 1200mg; \> 105 kg: 1400mg)~Three-drug-regimen:~* Peg-Interferon alfa 2b by subcutaneous injection 1,5 µg/kg/week~* Ribavirin capsules 200mg: dosage delivered in weight categories like in standard treatment~* Boceprevir tablets 200mg: 800 mg 3 times a day (2400 mg/j) with food"
62383536|NCT02405091|EXPERIMENTAL|Dose Group 2|Fixed dose of NBI-98854 administered once daily up to 48 weeks
62764400|NCT05183269|EXPERIMENTAL|Virtual reality|Normal procedure with the use of a virtual reality monitor
62764401|NCT05183269|NO_INTERVENTION|no virtual reality|Normal procedure without the use of a virtual reality monitor
62764402|NCT04602767|EXPERIMENTAL|Vasopressin|Low dose vasopressin as first line vasopressor in cardiac surgery.
62764403|NCT04602767|EXPERIMENTAL|Phenylephrine|Low dose phenylephrine as first line vasopressor in cardiac surgery
62764404|NCT02335632|PLACEBO_COMPARATOR|Placebo|For Probiotics, 7 days
62764405|NCT02335632|ACTIVE_COMPARATOR|Probiotics|Probiotics of 120 mg/day for 7days
62764406|NCT01863251|EXPERIMENTAL|Atomoxetine|Patients assigned to atomoxetine will receive atomoxetine 40 mg daily, beginning on Day 5. Atomoxetine dose will be increased to 80 mg daily for all patients beginning on Day 12. Atomoxetine will be increased to 120 mg daily for patients with persistent ATS use after 4 weeks of treatment.
62764407|NCT01863251|PLACEBO_COMPARATOR|Placebo|Placebo inactive medication
61988652|NCT03447509|ACTIVE_COMPARATOR|Experiment 1b|To accomplish this aim the investigators propose to complete one main experiment. The investigators will use iTMS and/or an acoustic startle stimuli to test the hypothesis that induced-plasticity protocols (iTMS and startle stimuli) will enhance EMG and force output in hand muscles during grasping. In a randomized sham crossover design, SCI and controls will be assigned to two groups: (1) iTMS applied during precision and power grip (two randomized sessions), and (2) startle applied during precision and power grip (two randomized sessions).
62764408|NCT03823872|EXPERIMENTAL|Overweight|Participants with BMI 25-29.9 kg/m2 undergo structured exercise for weight loss. They are randomized to the following interventions: 1) time restricted feeding = only eat between 12pm-8pm or 2) normal feeding= eat on normal schedule.
62764409|NCT03823872|EXPERIMENTAL|Obese|Participants with BMI 29.9-34.9 kg/m2 undergo structured exercise for weight loss. They are randomized to the following interventions: 1) time restricted feeding = only eat between 12pm-8pm or 2) normal feeding= eat on normal schedule.
62764410|NCT04941937|EXPERIMENTAL|Arm I: Selinexor+Thalidomide+Dexamethasone|Arm I is given XTd regimen Selinexor 60mg/d QW, Thalidomide 100mg/d, d1-28 and Dexamethasone 40mg/d QW) in approximately 30 subjects. 4 weeks per cycle and include a total of 12 cycles.
62764411|NCT04941937|EXPERIMENTAL|Arm II: Selinexor+Lenalidomide+Dexamethasone|Arm II is given XRd regimen Selinexor 60mg/d QW, Lenalidomide 25mg/d, d1-21 and Dexamethasone 40mg/d QW) in approximately 30 subjects. 4 weeks per cycle and include a total of 12 cycles.
62764412|NCT04941937|EXPERIMENTAL|Arm III: Selinexor+Pomalidomide+Dexamethasone|Arm III is given XPd regimen Selinexor 60mg/d QW, Pomalidomide 4mg/d, d1-21 and Dexamethasone 40mg/d QW) in approximately 30 subjects. 4 weeks per cycle and include a total of 12 cycles.
62764413|NCT03753100|ACTIVE_COMPARATOR|Periprosthetic BMD; anterolateral approach|Periprosthetic bone mineral density will be measured using a DXA scanner from GE Lunar Prodigy. The initial scan was performed post-operatively during hospitalization
62764414|NCT03753100|ACTIVE_COMPARATOR|Periprosthetic BMD; lateral approach|Periprosthetic bone mineral density will be measured using DXA scanner from GE Lunar Prodigy.The initial scan was performed post-operatively during hospitalization.
62764415|NCT02130986|EXPERIMENTAL|Procalcitonin (PCT) group|Procalcitonin (PCT) level; Results of procalcitonin level to treating clinician; Provide procalcitonin guideline to treating clinician; Telephone Visit at Day 15 and Day 30
62764416|NCT02130986|ACTIVE_COMPARATOR|Usual Care group|Telephone Visit at Day 15 and Day 30
62764417|NCT05301738|EXPERIMENTAL|Plyometric exercise group|Participants in this group received the plyometric training program
62764418|NCT05301738|ACTIVE_COMPARATOR|Control group|Participants in this group received the standard physical rehabilitation program
62764419|NCT01437176|EXPERIMENTAL|Unstable intertrochanteric fracture fixed with novel nail|AO/OTA A2 fracture fixed with novel nail
62764420|NCT01437176|EXPERIMENTAL|unstable intertrochanteric fracture fixed with PFNA|AO/OTA A2 fracture fixed with PFNA
62764421|NCT02120365|EXPERIMENTAL|Perampanel 6mg|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with daily perampanel 2mg days prior to each test day, and then observed dosing moderate 6mg dose perampanel in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses \[target Breath Alcohol Concentration (BrAc) =20mg%, 60mg%, and 100mg%\] in a step-wise fashion.
62764422|NCT02120365|PLACEBO_COMPARATOR|Placebo|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with placebo 7 days prior to each test day, and then observed dosing of placebo in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses \[target Breath Alcohol Concentration (BrAc) =20mg%, 60mg%, and 100mg%\] in a step-wise fashion.
62764423|NCT02120365|EXPERIMENTAL|Perampanel 10 mg|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with daily perampanel 2mg 7 days prior to each test day, and then observed dosing of high dose perampanel (10mg) in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses \[target Breath Alcohol Concentration (BrAc) =20mg%, 60mg%, and 100mg%\] in a step-wise fashion.
62764424|NCT01847105|EXPERIMENTAL|RevitaLens|AMO's RevitaLens contact lens solution
62764425|NCT04053595|EXPERIMENTAL|Estimated Oxygen Extraction|
62764426|NCT04053595|ACTIVE_COMPARATOR|Dynamic Parameters|
62764427|NCT05857904|EXPERIMENTAL|CT-FFR guided group|Patients randomized to the experimental group (CT-FFR guided group) will undergo coronary artery three-dimensional reconstruction and CT-FFR calculation using the coronary CT angiography (CCTA) images and RuiXin-FFR software. The researchers will interpret and analyze the clinical outcomes based on CT-FFR results. If CT-FFR is \>0.8, the patient will be treated with medical therapy alone. If CT-FFR is ≤0.8, further examination with coronary angiography will be performed. During the angiography examination, the operator will determine the treatment strategy (PCI, CABG, or medical therapy alone) based on the anatomical features of the lesion and the CT-FFR results.
62764428|NCT05857904|ACTIVE_COMPARATOR|QFR guided group|Patients randomized to the control group (QFR-guided group) will undergo invasive coronary angiography (ICA) in the catheterization lab, and QFR will be calculated using the ICA images. The researchers will interpret and analyze the clinical outcomes based on QFR results. If QFR is ≤0.8 and the lesion is suitable for intervention, the patient will undergo percutaneous coronary intervention (PCI) treatment. If QFR is \>0.8, the patient will be recommended for medical treatment alone.
62764429|NCT02804308|NO_INTERVENTION|Group Control with breast cancer and without breast cancer|Stretching exercises, lasting 40 minutes each session, 2 times a week for nine months
62764430|NCT02804308|EXPERIMENTAL|Combined Training with breast cancer and without breast cancer|Combined Training: 36 weeks duration, 3 times a week on nonconsecutive days. The combined training program lasts 70 minutes per session, with 40 minutes of resistance training and 30 minutes of aerobic training.
62764431|NCT01145053||Treatment|
62764432|NCT03514498||Autism Spectrum Disorder|Children aged 4-12 years with a clinical diagnosis of mild-to-moderate Autism Spectrum Disorder undergoing dental surgery
62764433|NCT03514498||Typically Developed Controls|Children with no neurodevelopmental delays matched to Autism Spectrum Disorder participants according to age (within 6 months), gender, and ASA physical status level, scheduled to undergo dental surgery
62764434|NCT00955604||Group R+AD|Group R+AD Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) for at least 14 days
62764435|NCT00955604||Group R|At least 2 months of rasagiline
62764436|NCT00955604||Group AD|At least 2 months of Anti-PD and Rasagiline
62764437|NCT01754298|ACTIVE_COMPARATOR|Retro-articular drilling|Retro-articular drilling goes through the cortical margin of the affected condyle, thereby sparing the articular surface and physes.
61988653|NCT03447509|ACTIVE_COMPARATOR|Experiment 2|To accomplish this aim the investigators propose to complete one main experiment. The investigators will combine iTMS and/or acoustic startle with precision and power grip training to test the hypothesis that 'precision and power grip training outcomes will be enhanced by iTMS and startle induced plasticity'. In a randomized sham controlled design, SCI and control subjects will be assigned to: training+iTMS and training+sham iTMS and training+startle and training+sham startle.
61988654|NCT02113865||Grupo 0|Null or mild fibrosis
61988655|NCT02113865||Grupo 1|Cirrhosis
61988656|NCT02113865||Grupo 2|HCC diagnosis
61988657|NCT01979315||patients with LBP|
61988658|NCT01979315||healthy individulas|
61988659|NCT00817115|NO_INTERVENTION|1|Subjects undergoing routine cardiac catheterization or interventional procedures using the standard fluoroscopy system.
62764438|NCT01754298|ACTIVE_COMPARATOR|Trans-articular drilling|Trans-articular drilling penetrates the articular cartilage through multiple sites to create subchondral penetrations.
61988660|NCT00817115|EXPERIMENTAL|2|Subjects undergoing routine cardiac catheterization or interventional procedures using the region-of-interest fluoroscopy (x-ray fovea imaging) system.
62383537|NCT03729128|EXPERIMENTAL|dextromethorphan and memantine (DM+MM)|The patients with Amphetamine-type stimulants use disorder will be recruited and received treatment of add-on dextromethorphan 30mg/day and memantine 5mg/day combination (DM+MM) for 12 weeks.
62383538|NCT03729128|PLACEBO_COMPARATOR|Placebos|The patients with Amphetamine-type stimulants use disorder will be recruited and received treatment of add-on placebos for 12 weeks.
62764439|NCT05759468|ACTIVE_COMPARATOR|Investigational Product - MIB 626|The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.
62764440|NCT05759468|PLACEBO_COMPARATOR|Placebo|Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
62764441|NCT01730404|EXPERIMENTAL|CHF6001|CHF6001 DPI (Dry Powder Inhaler) once daily
62764442|NCT01730404|ACTIVE_COMPARATOR|Roflumilast|Roflumilast, tablet, once daily
62764443|NCT01730404|PLACEBO_COMPARATOR|placebo|Placebo
62764444|NCT00240110|PLACEBO_COMPARATOR|Lithium carbonate add on Placebo|Lithium carbonate started and stabilized then participants randomized to placebo
62764445|NCT00240110|EXPERIMENTAL|Lithium carbonate add on Valproate|Lithium carbonate started and stabilized then participants randomized to Valproate
62764446|NCT03084042||Depression patients (MDD)|Patients with diagnosis of major depression according to DSM criteria
62764447|NCT03084042||Anxiety patients (GAD)|Patients with generalized anxiety disorder according to DSM criteria
62764448|NCT03084042||Healthy controls|Demographically matched healthy controls.
62764449|NCT01756859||Patients with HVPG measurements|Patients having HVPG measurements for clinical reasons will be recruited to undergo research MRI scan.
62764450|NCT03417817|OTHER|Healthy subjects|Bravo wireless pH monitoring over 96 hours
62764451|NCT05692310|EXPERIMENTAL|Patients will have a central venous line placed using an ultraportable ultrasound device.|
62383539|NCT04619563|EXPERIMENTAL|Anlotinib hydrochloride plus Docetaxel|Paticipants receive 4 to 6 cycles (21 days per cycle) combined administration period of Anlotinib Hydrochloride and Docetaxel, and then Anlotinib Hydrochloride maintenance treatment.
62383540|NCT00050440|EXPERIMENTAL|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days. Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose.
62764452|NCT05692310|SHAM_COMPARATOR|Patients will benefit from the technique of central venous line placement by conventional ultrasound|
62764453|NCT00391391|EXPERIMENTAL|1|Split, Inactivated, Trivalent Influenza Vaccine
62764454|NCT00391391|EXPERIMENTAL|2|Split, Inactivated, Trivalent Influenza Vaccine
61988661|NCT01476696|EXPERIMENTAL|Part A: Prasugrel Single Dose|Prasugrel 0.03 milligrams per kilogram (mg/kg) to 0.60 mg/kg dosage to be titrated up or down based on desired platelet inhibition, administered orally \[oral-disintegrating tablet (ODT)\], single dose given up to 3 occasions, at different strengths, with up to 18 days between doses.
62383541|NCT02297295|EXPERIMENTAL|Physiotherapy|Comparing the patients to themselves (spontaneus evolution) before intervention.
62383542|NCT05158244|EXPERIMENTAL|PF-07081532|multiple dosing, once-daily for 42 days
62567644|NCT01061112||CYP2C9*3/*3 Genotype|Individuals with the CYP2C9\*3/\*3 genotype have two \*3 alleles and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen \& Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen \& Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide \& Fluconazole.
62567645|NCT00616837|ACTIVE_COMPARATOR|Standard consultation|Standard care in orthopaedic outpatient clinic
62764455|NCT00391391|ACTIVE_COMPARATOR|3|Split, Inactivated, Trivalent Influenza Vaccine
62764456|NCT00391391|ACTIVE_COMPARATOR|4|Split, Inactivated, Trivalent Influenza Vaccine
62764457|NCT00539617|EXPERIMENTAL|Tarceva and FOLFOX|"COMBINATION THERAPY PHASE: Patients receive erlotinib hydrochloride orally (PO) once daily (QD) on days 1-56. Patients also receive FOLFOX6 therapy comprising oxaliplatin intravenously (IV) over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1, 15, 29, and 43. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable disease or no evidence of disease after course 2 or subsequent courses continue on to maintenance phase.~MAINTENANCE PHASE: Patients receive erlotinib hydrochloride PO QD on days 1-42. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity."
62764458|NCT03738319||HGSOC group|This group includes patients of high grade serous ovarian cancer (HGSOC).
62764459|NCT03738319||Control group|This group includes patients of benign gynecologic diseases as control.
62764460|NCT01457677|PLACEBO_COMPARATOR|Placebo|
62764461|NCT01457677|EXPERIMENTAL|RO4995819 15 mg|
62764462|NCT01457677|EXPERIMENTAL|RO4995819 30 mg|
62764463|NCT01457677|EXPERIMENTAL|RO4995819 5 mg|
62764464|NCT00969436|EXPERIMENTAL|Priorix-Tetra Group|Subjects received 2 doses of Priorix-Tetra® vaccine, 1 at Day 0 and 1 at Month 6, administered subcutaneously in the left anterolateral thigh.
62764465|NCT00969436|EXPERIMENTAL|Priorix/ Priorix-Tetra Group|Subjects received 1 dose of Priorix™ vaccine at Day 0 and 1 dose of Priorix-Tetra® vaccine at Month 6, both administered subcutaneously in the left anterolateral thigh.
62764466|NCT00969436|ACTIVE_COMPARATOR|Control Group|Subjects received 1 dose of Priorix™ vaccine at Day 0 and 1 dose of Priorix™ vaccine co-administered with Varilirix™ vaccine at Month 6, administered subcutaneously in the left and right anterolateral thigh.
62764467|NCT02606266|EXPERIMENTAL|Valganciclovir|Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension), at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
62764468|NCT02606266|NO_INTERVENTION|Control group|Control group with standard care who do not receive the investigational medicinal product
62764469|NCT03507959|EXPERIMENTAL|OLP scientifically-objective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
61988662|NCT01476696|EXPERIMENTAL|Part B: Prasugrel Once-Daily Dose|Daily prasugrel dose (mg/kg) that is expected to achieve mean platelet activation inhibition of 30% administered orally, once daily for 10-18 days and then followed by prasugrel dose (mg/kg) that is expected to achieve mean platelet activation inhibition of 50% administered orally, once daily for 10-18 days, for a total of 20-36 days.
62383543|NCT05158244|PLACEBO_COMPARATOR|Placebo|multiple dosing, once-daily for 42 days
62383544|NCT01758367|EXPERIMENTAL|Decitabine+DLI|Patients with relapsed AML after Allo-HSCT will be treated with decitabine and DLI.
62764470|NCT03507959|EXPERIMENTAL|OLP personally-affective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.
61988663|NCT05266092||Participants with chronic kidney disease undergoing hemodialysis|
62383545|NCT05231694|OTHER|sham EA + placebo group|sham EA + placebo group contain sham EA intervention and placebo injection
62383546|NCT05231694|OTHER|sham EA + NGF group|sham EA + NGF group contain sham EA intervention and NGF injection
62764471|NCT03507959|EXPERIMENTAL|DP scientifically-objective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.
62764472|NCT03507959|EXPERIMENTAL|DP personally-affective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
62764473|NCT03507959|NO_INTERVENTION|Control group|This group does not take the nasal spray.
62764474|NCT05013658|ACTIVE_COMPARATOR|junior|their anesthesia experiences are between 1 months and 1 year,
62383547|NCT05231694|OTHER|EA + placebo group|EA + placebo group contain EA intervention and placebo injection
62764475|NCT05013658|ACTIVE_COMPARATOR|senior|Their anesthesia experiences are more than 4 years
62383548|NCT05231694|OTHER|EA + NGF group|EA + NGF group contain EA intervention and NGF injection
62383549|NCT01185613|EXPERIMENTAL|Therapy™ Cool Flex Ablation Catheter|
62764476|NCT02267954|EXPERIMENTAL|50% Prices/50% Calories|"The participant is exposed to the baseline menu, but the prices are edited to be at 50% of the actual price (e.g., a $1 coffee is listed as costing $.50) and the calorie labels are edited to be at 50% of the actual content (e.g., a 500 calorie Large Fries is listed as having 250 calories). In addition, the baseline mistakes are still included.~This is the Menu edited intervention."
62764477|NCT03220607||Medical induced abortion|120 singleton nulliparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were nulliparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
62764478|NCT02501564|EXPERIMENTAL|Naproxen Sodium Codeine|One tablet twice a day
62764479|NCT02501564|PLACEBO_COMPARATOR|Placebo|One tablet twice a day
61988664|NCT05266092||Participants with chronic kidney disease, not in dialysis|
61988665|NCT05266092||Participants with chronic kidney disease undergoing peritoneal dialysis|
62383550|NCT02783261||Post Y90 hypertrophy measurement|All prospective patients who undergo unilobar SIRT for HCC at SGH or NCC are potential candidates for this study. The study aims to recruit 25 subjects and it is anticipated that 50% will be from SGH and 50% will be from NCC
62383551|NCT02425813|EXPERIMENTAL|Treatment (methylprednisolone sodium succinate, budesonide)|"STUDY AGENT: Patients receive methylprednisolone sodium succinate IA QD on days 1-3.~CONVENTIONAL THERAPY: Patients also receive conventional therapy comprising methylprednisolone sodium succinate IV every 12 hours on for 7-14 days beginning on day 1 and budesonide PO on days 1-56. Patients with response by day 7-14 may begin taper and receive methylprednisolone PO on days 28-56. Treatment continues in the absence of disease progression or unacceptable toxicity.~IST: Patients receive conventional IST or continue their previous prophylactic regimen beginning on day 1 to 56 (or beyond) at the discretion of the treating physician."
62567646|NCT00616837|EXPERIMENTAL|Telemedicine consultation|Orthopaedic care in outpatient clinic by use of telemedicine.
62567647|NCT00828568|EXPERIMENTAL|Imiquimod 5% Taro|Imiquimod 5% manufactured by Taro applied for 16 weeks
62764480|NCT05740917|EXPERIMENTAL|Part 1: XZB-0004|
62764481|NCT00573807|OTHER|1|
62764482|NCT05512702||Thrombolytic Treatment Group|These are the patients with intermediate-high riskPE and consulted by EGEPET. They received reduced dose thrombolytic treatment.
62764483|NCT05512702||Anticoagulation Treatment Group|This group includes patients who diagnosed wit PE before the establishment of EGEPET. And these patients are classed into intermediate-high risk based on early mortality and received anticoagulation treatment, not thrombolytic treatment.
62764484|NCT03308045|EXPERIMENTAL|pEYS606|Cohort 1 (pEYS606 lower dose); Cohort 2 (pEYS606 intermediate dose); Cohort 3 (pEYS606 higher dose); Extension Cohort (pEYS606 maximum tolerated dose)
61988666|NCT05266092||Healthy participants|
61988667|NCT03491995|EXPERIMENTAL|Quadruple therapy|Moxifloxacin, Nitazoxanide, Omeprazole sodium bicarbonate, Doxycyclin
61988668|NCT03491995|ACTIVE_COMPARATOR|Classic treatment|Omeprazole, clarithromycin, amoxicillin
61988669|NCT02413541|EXPERIMENTAL|High EAA and use Polymyxin-B Hemoperfusion|EAA level \> 0.6 or EAA = 0.6 and use Polymyxin-B Hemoperfusion
62383552|NCT03946592|PLACEBO_COMPARATOR|Placebo group|Inject the Drug into submental fat via subcutaneous
62383553|NCT03946592|EXPERIMENTAL|DWJ211 group|Inject the Drug into submental fat via subcutaneous
62383554|NCT03225833|EXPERIMENTAL|WVE-120101 (Dose A) or placebo|
62383555|NCT03225833|EXPERIMENTAL|WVE-120101 (Dose B) or placebo|
62383556|NCT03225833|EXPERIMENTAL|WVE-120101 (Dose C) or placebo|
62383557|NCT03225833|EXPERIMENTAL|WVE-120101 (Dose D) or placebo|
62383558|NCT03225833|EXPERIMENTAL|WVE-120101 (Dose E) or placebo|
62567648|NCT00828568|ACTIVE_COMPARATOR|Aldara - Imiquimod 5%|Aldara, Imiquimod 5% applied for 16 weeks
62567649|NCT00828568|PLACEBO_COMPARATOR|Vehicle|Imiquimod vehicle applied for 16 weeks
62764485|NCT03422692|EXPERIMENTAL|BioXlude memebrane|Subjects in this arm will receive demineralized freeze dried bone allograft covered with BioXclude amnion-chorion membrane following tooth extraction
62764486|NCT03422692|ACTIVE_COMPARATOR|Mem-Lok|subjects in this arm will receive demineralized freeze dried bone allograft covered with Mem-Lok collagenous membrane following tooth extraction
62764487|NCT04127799|EXPERIMENTAL|Hospital-Community-Family-Care Management Platform Online|Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital
62764488|NCT04127799|ACTIVE_COMPARATOR|Subjects with AF conventional treatment|Subjects with AF via conventional clinic visit according to the latest relevant guidelines
62764489|NCT03791853||Light-CT|All specimens are detected using Light-CT
62764490|NCT02382848|ACTIVE_COMPARATOR|Prazosin, Then Placebo|Participants first received Prazosin. A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily. After a washout period, they then receive Placebo
62764491|NCT02382848|PLACEBO_COMPARATOR|Placebo, Then Prazosin|Participants first received Placebo (matching Prazosin) for a 3 consecutive week period during the 7 week study period. After a washout period, they then received Prazosin. The starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
62764492|NCT00136825|PLACEBO_COMPARATOR|2|Identical appearing placebo pill containing lactose powder, packaged to have similar odor as N-Acetylcysteine in capsule form
62383559|NCT05858567|EXPERIMENTAL|Total Neoadjuvant Therapy with Short-course Radiation followed by Envafolimab plus CAPEOX|"The enrolled patients with MSS-type advanced ultra low rectal cancer will receive a combined regimen of neoadjuvant chemoradiotherapy combined with immunotherapy and biopsy or local excision.~1. Radiotherapy uses a short-range mode, irradiating the primary tumor and high-risk areas with dose of 25 Gy.~2. After radiotherapy, PD-L1 antibody (150mg/week, subcutaneous injection × 24 weeks) immunotherapy combined with 8 courses of CAPEOX chemotherapy was performed.~3. Two weeks after the end of the combined treatment plan in step 2), biopsy or local excision of the lesion is performed."
62383560|NCT01871909||Physical trauma|Patients with report of physical trauma within 24 hours of presentation to the hospital.
62383561|NCT03831607|EXPERIMENTAL|KHK7791|Patients start at KHK7791 30 mg BID and can down titrate weekly to 20, 15, 10, and 5 mg BID, sequentially based on a GI tolerability question.
62764493|NCT00136825|EXPERIMENTAL|1|N-Acetylcysteine
62383562|NCT00413231|EXPERIMENTAL|Valiant Thoracic Stent Graft System|"160 subjects were enrolled into the study, including 157 subjects treated with the study device and three subjects classified as intent-to-treat who did not receive the study device.~There were no other arms for this study."
62383563|NCT01058356||IBD research group in KASID|KASID is Korean Association Study of Intestinal Disease. It has several research group suh as inflammatory bowel disease (IBD) research group.
62383564|NCT02642458||trastuzumab plus chemotherapy|Treatment with trastuzumab plus chemotherapie as first line therapy, administered intravenously/subcutaneously in a three weekly frequency. Docetaxel is recommended as chemotherapy, however, any treatment choice or change in regimen is performed at the discretion of the treating physician.
62383565|NCT02642458||pertuzumab plus trastuzumab plus chemotherapy|Treatment with with pertuzumab plus trastuzumab plus chemotherapy as first line therapy, administered intravenously/subcutaneously in a three weekly frequency. Docetaxel is recommended as chemotherapy, however, any treatment choice or change in regimen is performed at the discretion of the treating physician.
62764494|NCT02535299|EXPERIMENTAL|insulin|basic insulin treatment：glargine 10-30 units once a day based on the glucose control for 6 months.
62764495|NCT05394532|EXPERIMENTAL|Steno Diabetes Dialogue Cards|
62764496|NCT00581867|EXPERIMENTAL|Intranasal Insulin Aspart|Participants were administered intranasal insulin aspart (40 IU) in a double-blinded fashion approximately 30 minutes prior to functional MRI scanning. After a washout period of 48 hours, participants completed the other arm. The order of saline vs. insulin was counterbalanced.
62764497|NCT00581867|ACTIVE_COMPARATOR|Intranasal Saline (placebo)|Participants were administered intranasal saline (placebo) in a double-blinded fashion approximately 30 minutes prior to functional MRI scanning. After a washout period of 48 hours, participants completed the other arm. The order of saline vs. insulin was counterbalanced.
62383566|NCT02067104|PLACEBO_COMPARATOR|Placebo|receive 150 mg of oral placebo daily for a period of 2 months
62383567|NCT02067104|EXPERIMENTAL|Vismodegib|receive 150 mg of vismodegib daily for a period of 2 months
62764498|NCT00613080|OTHER|IMRT + Chemotherapy , Resection, Postoperative Chemotherapy|Radiation therapy (intensity modulated radiation therapy \[IMRT\] + three dimensional conformal radiation therapy \[3D-CRT\]) + neoadjuvant chemotherapy (capecitabine and oxaliplatin) followed by resection and postoperative chemotherapy (FOLFOX)
62764499|NCT00744666|EXPERIMENTAL|1|Patients receive Prednisolone 1% 1gtt qid x 4 weeks. If the intraocular pressure (IOP) after the 4 weeks is \> or equal to 21 mmHg, then IVTA will be withheld. If the IOP \< 21mmHg, then patients will receive an injection of IVTA.
62764500|NCT00744666|NO_INTERVENTION|2|Patients will receive an injection of IVTA (no trial of Prednisolone gtts is given).
62764501|NCT04041206||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
62764502|NCT04041206||Healthy group|This group will include 40 healthy volunteers.
62383568|NCT03874208|OTHER|Patient group|To assess the predictive accuracy of comaScore evaluated in the day 7 - day 45 period post brain injury to predict unfavorable outcome at 1-year after the first insult in patients admitted in ICU after CA, TBI and aSAH, that remain comatose at least 7 days after brain injury.
62383569|NCT03874208|OTHER|Test group|MRI calibration in each center : test protocol compliance, data transfer procedures and quality of the MRI sequences
62383570|NCT00460499|ACTIVE_COMPARATOR|B Low dose GIK|This group will have low doses of glucose and insulin
62383571|NCT00460499|ACTIVE_COMPARATOR|C High Dose GIK|This group will have high doses of insulin and glucose
62383572|NCT00460499|ACTIVE_COMPARATOR|A Insulin|This group will receive only an intravenous insulin infusion
62383573|NCT03686579||chest trauma|"1. Early detection and diagnosis of associated thoracic injuries .~2. decrease of costs required for investigations . 3- sensitivity and specificity of the investigations"
62383574|NCT02733887|EXPERIMENTAL|lymphoma|The lymph nodes or masses, fludeoxyglucose F18 positron emission tomography/computed tomography(PET/CT) standard uptake value(SUV) results, whole body magnetic resonance imaging(MRI) intravoxel incoherent motion(IVIM) sequence D, D\*,f values and MRI volumes of lymphoma were compared before and after the chemotherapy in this project prospectively to provide data for evaluating the dependency and differences of PET/CT and whole body MRI in lymphoma staging and therapeutic evaluation.
62383575|NCT05476094|EXPERIMENTAL|Experimental: AYP-101 1|0.2 mL injections, 1.0 cm apart, up to 10.0 ml, Single administration
62383576|NCT05476094|EXPERIMENTAL|Experimental: AYP-101 2|0.2 mL injections, 1.0 cm apart, up to 10.0 ml, Single administration
62383577|NCT05476094|PLACEBO_COMPARATOR|Placebo|0.2 mL injections, 1.0 cm apart, up to 10.0 ml, Single administration
62383578|NCT02527031|ACTIVE_COMPARATOR|Pre hospital ECMO|ECMO Insertion on pre hospital setting for a refractory cardiac arrest
62383579|NCT02527031|ACTIVE_COMPARATOR|In Hospital ECMO|ECMO Insertion on in hospital setting for a refractory cardiac arrest
62383580|NCT01959594|EXPERIMENTAL|Cohort 1|
62383581|NCT01959594|EXPERIMENTAL|Cohort 2|
62383582|NCT01959594|EXPERIMENTAL|Cohort 3|
62383583|NCT01959594|EXPERIMENTAL|Optional Cohort 4|
62383584|NCT01959594|EXPERIMENTAL|Optional Cohort 5|
62383585|NCT00552006|EXPERIMENTAL|NET|
62383586|NCT00552006|ACTIVE_COMPARATOR|AC|
62383587|NCT00552006|NO_INTERVENTION|WL|Waiting list
62764503|NCT05050396|EXPERIMENTAL|Cooled radio frequency|In CRF, water circulates inside the probe to remove heat, modulating the thermal heat in the tissue to around 60°C, and alters the overall size, shape, and projections of lesions compared to conventional RFA. It is postulated that the greater sized CRF lesions may reduce the number of technical failures in the setting of a complex and variable neuronal innervation to the knee. The ability to target a greater amount of neuronal tissue is believed to produce long-term pain relief at least to the duration of relief produced by conventional RFA \[27\]
61988670|NCT02413541|EXPERIMENTAL|High EAA and not use Polymyxin-B Hemoperfusion|EAA level \> 0.6 or EAA = 0.6 and not use Polymyxin-B Hemoperfusion
62383588|NCT04134949|EXPERIMENTAL|CBT|consists of eight weekly treatment sessions of 45 to 60 minutes.
62383589|NCT04134949|EXPERIMENTAL|MCBT|consists of eight weekly treatment sessions of 45 to 60 minutes.
62383590|NCT01077193|OTHER|Gastric Plication Surgery|
62383591|NCT03963076|EXPERIMENTAL|allergic rhinitis|administration of a nasal hypertonic spray twice a day for one month
62383592|NCT00672750||I|Patients of Dr C Miller who have undergone laparoscopic myomectomy from 1999- to present
62383593|NCT05936476||Skeletal Class I (Control Group)|
62383594|NCT05936476||Skeletal Class II|Class II malocclusion is characterized by the upper jaw (maxilla) being positioned more forward in relation to the lower jaw (mandible), resulting in an overbite.
62383595|NCT05936476||Skeletal Class III|Class III malocclusion is characterized by the lower jaw (mandible) being positioned more forward in relation to the upper jaw (maxilla), resulting in an underbite.
61988671|NCT02413541|ACTIVE_COMPARATOR|Low EAA|EAA level \< 0.6 and not use Polymyxin-B Hemoperfusion
61988672|NCT06020560|ACTIVE_COMPARATOR|Dalteparin|
61988673|NCT06020560|ACTIVE_COMPARATOR|Tinzaparin|
61988674|NCT01263756||ASD group|Adolescents and adults with Autism Spectrum Disorders (ASDs).
62383596|NCT05936476||Anterior Open Bite|Anterior open bite is characterized by a lack of vertical overlap or contact between the upper and lower front teeth when the back teeth are in contact (occlusion).
62383597|NCT04882930|EXPERIMENTAL|Functional Near-Infrared Spectroscopy (fNIRS) acquisitions|The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
62383598|NCT02646332|EXPERIMENTAL|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
62383599|NCT02646332|ACTIVE_COMPARATOR|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
61988675|NCT01296256|EXPERIMENTAL|Bendamustine-EAM|
62383600|NCT00514241|EXPERIMENTAL|A|The arm utilizes the GPS™ II Platelet Concentrate Separation Kit.
62383601|NCT00514241|NO_INTERVENTION|B|This arm utilizes standard leg wound closure procedures.
62383602|NCT03824444|EXPERIMENTAL|Treatment|Implant and followup
62383603|NCT00458601|EXPERIMENTAL|CDX-110 with GM-CSF|
62383604|NCT05189535|EXPERIMENTAL|pentoxifylline 400 mg|Patients will receive paclitaxel 80 mg/m2 once per week for 12 weeks and pentoxifylline 400 mg twice daily for the paclitaxel treatment period.
62383605|NCT05189535|PLACEBO_COMPARATOR|Placebo|Patients will receive paclitaxel 80 mg/m2 once per week for 12 weeks and placebo twice daily for the paclitaxel treatment period..
62383606|NCT04610827|ACTIVE_COMPARATOR|Ferrous sulfate daily|Subject will take 3 mg/kg oral iron in the morning
61988676|NCT01637974|EXPERIMENTAL|with INTERCOAT|injection of intercoat into the euterine cavity at the end of hysteroscopy
62383607|NCT04610827|ACTIVE_COMPARATOR|Ferrous sulfate twice daily|Subjects will take 1.5 mg/kg oral iron twice daily
62383608|NCT04610827|ACTIVE_COMPARATOR|Ferrous sulfate every other day|6 mg/kg oral iron every other day in the morning
62383609|NCT04896840|EXPERIMENTAL|Treatment group|Telerehabilitation and motor learning principles will be applied.
62383610|NCT04896840|EXPERIMENTAL|Control Group|Motor learning principles will be applied in the clinic.
62383611|NCT00171964|EXPERIMENTAL|zoledronic acid + radiotherapy|zoledronic acid every 4 weeks in combination with radiotherapy
62764504|NCT05050396|EXPERIMENTAL|Thermocoagulant radio frequency|Conventional radiofrequency Ablation RFA of the knee can be performed under fluoroscopic, or other imaging, guidance, with a cannula advanced into the joint towards the area connecting the shaft to the epicondyle. The area is stimulated to identify the nerve position and to ensure that no motor nerves are activated, as evidenced by absence of fasciculations. The RF electrode is then advanced through the cannula to the target area \[18\] The electrode tip heats up targeted local tissue within a few millimeters to a temperature typically greater than 47°C (ranging from 70°C to 90°C) for 120 130 seconds, generated through an electromagnetic field with a frequency of 250 kHz . \[15,18\] The ablative heat is provided via flow of electrical current, generating a well-delineated lesion \[24\]
62764505|NCT01521910|EXPERIMENTAL|Low protein diet|
62764506|NCT01521910|ACTIVE_COMPARATOR|Normal protein diet|
62764507|NCT01479946|EXPERIMENTAL|Early Electrochemotherapy|Electrochemotherapy is given as early as possible after the discovery of skin metastases
62764508|NCT01479946|NO_INTERVENTION|Delayed or no Electrochemotherapy|patients are to be treated for their breast cancer according to clinical routine with electrochemotherapy as an option only after 6 months from randomization
62383612|NCT01743066|EXPERIMENTAL|Arsenicosis patients|Vitamin E (200 IU, caplet) daily orally for 20 weeks
62383613|NCT01743066|ACTIVE_COMPARATOR|Arsenic exposed controls|vitamin E (200 IU, caplet) daily orally for 20 weeks
62383614|NCT01743066|ACTIVE_COMPARATOR|Heathy volunteers|Vitamin E (200 IU, caplet) daily orally for 20 weeks
62383615|NCT03480529||Arthritis or lupus or CLS induced by a drug|Case reported in the World Health Organization (WHO) of arthritis or lupus, or Hepatitis, or capillary leak syndrome of patient treated by a drug, with a chronology compatible with the drug toxicity
62383616|NCT01627379|ACTIVE_COMPARATOR|Arm A: Cisplatin, 5-Fluorouracil|Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.
62567650|NCT06359769|EXPERIMENTAL|Group Cognitive Evolutionary Therapy|In-person therapy groups
62567651|NCT06359769|NO_INTERVENTION|Waitlist|Waitlist. No intervention for this arm.
62567652|NCT02116933|ACTIVE_COMPARATOR|Level I|A small, level I study will compare autologous fat grafting alone to stromal vascular fraction SVF enriched autologous fat grafting int he same patient. One breast will be treated with AFG alone and act as the control, and the other breast will be treated with SVF enriched AFG adn act as the experimental side exploring the efficacy of adipose derived stem cells.
62764509|NCT00377559|EXPERIMENTAL|1.|Myocet+docetaxel
62764510|NCT03202108|EXPERIMENTAL|Consumption of Krio|Incorporation of Krio into the daily diet.
61977736|NCT02715414|ACTIVE_COMPARATOR|Multiple Family Group (MFG)|A multiple family group (MFG) is a 12-week, family-centered, group delivered intervention consists of six to eight families (caregiver/child dyads). Groups meet for approximately two hours per week, and sessions focus on targeting family-level factors that are associated with child problem behaviors. Specifically, eight of the 12 sessions are devoted to establishing rules (family organization, consistent discipline), responsibilities (inter-connectedness, expectancies), relationships (family warmth, within family support), respectful communication (family communication and conflict). An additional four sessions are focused on factors that impact the ability of families to incorporate new behaviors (family stress and social support).
61988677|NCT01637974|NO_INTERVENTION|without INTERCOAT|without INTERCOAT
61988678|NCT05450471|EXPERIMENTAL|L-lactide and trimethynele carbonate Terpolymers polymer implant|The polymer implant will be placed in the ethmoidal region, at the same time that the nasal endoscopic examination will be performed. The polymer in this study is biocompatible. The polymers will be made in the biomaterials laboratory located at the Pontifical Catholic University of São Paulo (PUC-SP), located in the city of Sorocaba-SP. Polymers will be provided free of charge for the study.
61988679|NCT05450471|PLACEBO_COMPARATOR|Placebo polymer implant|Placebo polymer implant
62383617|NCT01627379|EXPERIMENTAL|Arm B: Cisplatin, 5-Fluorouracil and Panitumumab|Chemotherapy plus Panitumumab will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.
62383618|NCT00111176|OTHER|1|Endovascular Repair
62383619|NCT00111176|OTHER|2|Surgical
62764511|NCT04705415|EXPERIMENTAL|ANA001|"For the single ascending dose (SAD) portion of the study, subjects will receive their assigned treatment as a single oral dose (1000 mg, 2000 mg, or 3000 mg of ANA001) with a standardized light meal. Each capsule is 250 mg.~For the multiple ascending dose (MAD) portion of the study, subjects will receive their assigned treatment twice daily (BID) or thrice daily (TID) (total daily dose is to be determined following the completion of the SAD portion of the study and will not exceed 2000 mg ANA001) with a standardized light meal for 7 consecutive days. Each capsule is 250 mg."
62764512|NCT04705415|PLACEBO_COMPARATOR|Matching Placebo|"For the single ascending dose (SAD) portion of the study, subjects will receive their assigned matching placebo (hydroxypropylmethylcellulose (HPMC) as a single dose (4, 8, or 12 capsules) with a standardized light meal.~For the multiple ascending dose (MAD) portion of the study, subjects will receive their assigned matching placebo (hydroxypropylmethylcellulose (HPMC) dose twice daily (BID) or thrice daily (TID) with a standardized light meal."
62764513|NCT03888677|ACTIVE_COMPARATOR|Standard|Standard FEC (F600, E60, C600) every 3rd week.
62764514|NCT03888677|EXPERIMENTAL|Tailored|Tailored FEC (F600, E75-90, C900-1200) every 3rd week.
62383620|NCT02699047|EXPERIMENTAL|Fish oil|3.6 g/day of the encapsulated fish oil (2 capsules/day) providing 1.55 g/d of the n-3 polyunsaturated fatty acids (EPA and DHA) during 9 weeks
62764515|NCT03888677|ACTIVE_COMPARATOR|Registered|Non-randomized arm with patients with grade 3-4 leukopenia after first cycle and treated with standard FEC (F600, E60, C600) every 3rd week.
62764516|NCT02636075||Upper 1/3 of thyroid tissue|
62764517|NCT02636075||Middle 1/3 of thyroid tissue|
62383621|NCT02699047|PLACEBO_COMPARATOR|Control group|3.2 g/day of the olive oil (2 capsules/day) without n-3 polyunsaturated fatty acids
62383622|NCT03646812|OTHER|Glucose Reference 1|50g of glucose dissolved in 250ml of water to be consumed.
62383623|NCT03646812|OTHER|Glucose Reference 2|50g of glucose dissolved in 250ml of water to be consumed.
62764518|NCT02636075||Lower 1/3 of thyroid tissue|
62383624|NCT03646812|OTHER|Glucose Reference 3|50g of glucose dissolved in 250ml of water to be consumed.
62383625|NCT03646812|EXPERIMENTAL|Semolina Penne|70g of semolina penne boiled in 1 Litre of water for 11 minutes. Drained and consume immediately.
62383626|NCT03646812|EXPERIMENTAL|Wholegrain Penne|76g of wholegrain penne boiled in 1 Litre of water for 9 minutes. Drained and consume immediately.
62764519|NCT02636075||Below thyroid tissue|
62764520|NCT01253265|EXPERIMENTAL|30 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
62764521|NCT01253265|EXPERIMENTAL|80 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
62764522|NCT01253265|EXPERIMENTAL|180 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
61988680|NCT01498250||basal cell carcinoma|
62383627|NCT03646812|EXPERIMENTAL|Semolina Spaghetti|71g of semolina spaghetti boiled in 1 Litre of water for 8 minutes. Drained and consume immediately.
62383628|NCT03646812|EXPERIMENTAL|Wholegrain Spaghetti|76g of wholegrain spaghetti boiled in 1 Litre of water for 8 minutes. Drained and consume immediately.
62764523|NCT01253265|PLACEBO_COMPARATOR|Placebo|Placebo is administered subcutaneously in the same manner as active drug in each dose group
62764524|NCT01253265|EXPERIMENTAL|120 mg LY2439821|Administered subcutaneously at 240 mg as a single loading dose followed by 120 mg every week
62764525|NCT00755547|EXPERIMENTAL|High Intensity|70-85% of peak oxygen uptake for 30 min 3-5 days/week.
62764526|NCT00755547|EXPERIMENTAL|Low Intensity|40-55% of peak oxygen uptake for 60 min 3-5 days/week
62383629|NCT03646812|EXPERIMENTAL|Jasmine rice|63g of rice cook with 150g of water. Served and consume immediately.
62383630|NCT03646812|EXPERIMENTAL|Asian Noodles|92.4g of Asian Noodles cook in boiling water for 45 seconds. Drained and consume immediately
62567653|NCT02116933|ACTIVE_COMPARATOR|Level II|A larger, level II study comparing Autologous Fat Grafting to SVF enriched AFG in different patients. In this study, patients can choose to have AFG in both breasts or SVF enriched AFG in both breasts. The two patient groups will be compared. Here the group with the AFG in both breasts will be the control and the SVF enriched AFG in both breasts will be the experimental group exploring the efficacy of adipose derived stem cells.
62764527|NCT00755547|NO_INTERVENTION|Sedentary Control|Regular activities of daily living for 6 months
62764528|NCT04194723|EXPERIMENTAL|Antireflux Mucosectomy|Antireflux mucosectomy targeted at resection of gastric cardia muocsa to induce fibrosis and improve on the flap value over the gastroesophageal junction
62764529|NCT01812369|EXPERIMENTAL|GC|gemcitabine 1250 mg/m2 D1 and D8 cisplatine 70 mg/m2 D1 each cycle every 3 weeks, 4 cycles
61988681|NCT01498250||non-lesional skin|
61988682|NCT03591016||Difficult intravenous access|Recording number of IV attempts in the operating room prior to surgery start.
62383631|NCT02660073|EXPERIMENTAL|NMES+FES group|NMES+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of surface NMES and ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks +3 weeks for measurements.
62383632|NCT02660073|EXPERIMENTAL|Control+FES group|Control+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of passive leg extension/flexion with no ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks+3 weeks for measurements.
62383633|NCT01852591|EXPERIMENTAL|PCV 13|Pneumococcal conjugate vaccine (PCV 13), 0.5ml, 3 to 30 days prior to transplant and then again at 7-10 and 21-24 days after transplant
62383634|NCT00609089|EXPERIMENTAL|I|Community Reinforcement and Family Training for Retention in Treatment and Recovery and Reduction of HIV Risk Behavior (CRAFT-T)
62383635|NCT00609089|ACTIVE_COMPARATOR|II|Treatment As Usual
62383636|NCT03091569|ACTIVE_COMPARATOR|Vitamin K|
62383637|NCT03091569|PLACEBO_COMPARATOR|Control|
62764530|NCT01812369|ACTIVE_COMPARATOR|MVAC-HD|Methotrexate 30 mg/m2 D1 Vinblastine 3 mg/m2 D2 Doxorubicine 30 mg/m2 D2 Cisplatine 70 mg/m2 D2 G-CSF D3 and D9 Each cycle every 2 weeks, 6 cycles
62764531|NCT00946322|EXPERIMENTAL|Arm 1: CTAP|Couple-Based Treatment for Alcohol Use Disorders and PTSD
62383638|NCT03480620|EXPERIMENTAL|Telerehabilitation|Participant randomized into the telerehabilitation group will receive verbal and written discharge recommendations from each member of the team as usual. They will also be given a login to the online telerehabilitation platform where they will find the designated flexibility routines which can be accessed from a computer, tablet/slate, or smart phone at any time. Participant will receive electronic reminders via email and/or text message to perform their home program and complete the follow up questionnaires. Other physical therapy exercises may be recommended based on individual patient's need. These exercises will be provided in verbal and written form.
62764532|NCT05424263|EXPERIMENTAL|Acetate|Subjects will be orally supplemented with calcium acetate for 12 weeks. Subjects will be instructed to take a volume of the oral liquid solution that contains 1,334 mg of calcium acetate 3x per day with meals, for a total dose of 4,000 mg/day. Calcium acetate will be compounded by the CU Anschutz Medical Campus Research Pharmacy and dispensed to subjects in 4-week supplies.
62764533|NCT05424263|PLACEBO_COMPARATOR|Placebo|Subjects will be orally supplemented with calcium carbonate for 12 weeks. This placebo has been selected to match any potential effects of calcium and phosphate binding of the calcium acetate, i.e., we will isolate the effects of acetate. Subjects will be instructed to take a volume of the oral liquid solution equal to that of the calcium acetate group 3x per day with meals. To match the amount of elemental calcium between calcium acetate and calcium carbonate, this dose of calcium carbonate will contain 833 mg of calcium carbonate, for a total dose of 2,500 mg/day. Calcium carbonate will be compounded by the CU Anschutz Medical Campus Research Pharmacy, visually identical to calcium acetate including the packaging, and dispensed to subjects in 4-week supplies.
61988683|NCT02881242|EXPERIMENTAL|Treatment (trametinib)|Patients receive trametinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
61988684|NCT03963115|ACTIVE_COMPARATOR|Coated syringe with epinephrine|Epinephrine was coated syinge before drawing the allergen to filled in.
62764534|NCT02707211|EXPERIMENTAL|Anti-oxLDL IgM antibodies|administration Anti-oxLDL IgM antibodies
61988685|NCT03963115|PLACEBO_COMPARATOR|placebo|Normal saline was coated syinge before drawing the allergen to filled in.
62764535|NCT00596141|EXPERIMENTAL|1|Conventional postoperative care and instructions on dental hygiene will be provided along with the TOWE treatment which consists of the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site 3 times daily for a period of 7 days. At three (3) days and seven (7) days postoperatively, photographs will be taken of all vertical releasing incisions (before suture removal).
62383639|NCT03480620|ACTIVE_COMPARATOR|Usual care|Participants randomized into the usual care group will receive verbal and written discharge recommendations from each member of the team as usual. They will be provided with a copy of the DVD and instructed to practice one of the two routines at least 5 days per week. They will also be given a login to the online platform but will only have access to complete the follow up questionnaires. Participant will receive electronic reminders via email and/or text message to complete the follow up questionnaires. Other physical therapy exercises may be recommended based on individual patient's need. These exercises will be provided in verbal and written form.
62383640|NCT02961348|ACTIVE_COMPARATOR|Early start of NOAC|Day 1 to day 4 after ischemic stroke onset
62764536|NCT00596141|NO_INTERVENTION|2|Conventional postoperative care and instructions on dental hygiene.
62764537|NCT00711113|EXPERIMENTAL|A|
62764538|NCT02338934|EXPERIMENTAL|Cinacalcet with Vitamin D arm|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal \<2.4 mmol/L - Start Cinacalcet 25mg OD \& Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if \>2.54 mmol/L - Start Cinacalcet 25mg OD \& Maintain active Vit D dose. Then they will go to maintenance phase.
62764539|NCT01180608|ACTIVE_COMPARATOR|Pregabalin|
62764540|NCT01180608|PLACEBO_COMPARATOR|placebo + pregabalin|
62764541|NCT06508606|EXPERIMENTAL|anti-CD47 (AK117) + anti-EGFR|Patients meeting the inclusion criteria were given AK117 45mg/kg (D1, IVGTT, Q3W) in combination with anti-EGFR (initial dose 400mg/m2, subsequent doses of 250mg/m2, D1, QW) maintained for one year or until progression or intolerable toxicity occurred
62764542|NCT01724424|EXPERIMENTAL|melatonin 20mg|2 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
61988686|NCT01653496|EXPERIMENTAL|Enhanced recovery after surgery|Patients who receive ERAS program after gastric cancer surgery
61988687|NCT02890979|EXPERIMENTAL|Screening (cytology collection)|Patients undergo cytology specimen collection procedure using a swallowable sponge cell sampling device.
61988688|NCT02894177|EXPERIMENTAL|tcPCO2 measurement arm|Patients will be monitored by tcPCO2 during spontaneous breathing trials
61988689|NCT00694759|ACTIVE_COMPARATOR|A|Pioglitazone will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
61988690|NCT00694759|ACTIVE_COMPARATOR|B|Metformin will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
61988691|NCT00694759|PLACEBO_COMPARATOR|C|Placebo will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
61988692|NCT00589316|EXPERIMENTAL|Treatment (chemo, TBI, transplant, immunosuppression)|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 via central line on day -14.~NONMYELOABLATIVE CONDITIONING: Patients receive FLU IV over 30 minutes on days -6 to -2 and CY IV over 1 hour on days -6 and -5. Patients undergo TBI on day -1.~TRANSPLANTATION: Patients undergo allogeneic bone marrow transplantation on day 0.~POST-TRANSPLATATION IMMUNOSUPPRESSION: Patients receive CY IV over 1-2 hours on day 3, MMF IV or PO TID on days 4 to 35, and tacrolimus IV over 1-2 hours or PO on days 4 to 180 with taper on day 84."
61988693|NCT01599507|EXPERIMENTAL|FG-4592|Active Drug
61988694|NCT01599507|PLACEBO_COMPARATOR|Placebo|
61988695|NCT03890770|EXPERIMENTAL|Normal renal function|Single dose
62764543|NCT01724424|EXPERIMENTAL|melatonin 30mg|3 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
62764544|NCT01724424|EXPERIMENTAL|Melatonin 50mg|5 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
61988696|NCT03890770|EXPERIMENTAL|Mild renal disease|Single dose
61988697|NCT03890770|EXPERIMENTAL|Moderate renal failure|Single dose
61988698|NCT03890770|EXPERIMENTAL|Severe renal failure|Single dose
62383641|NCT02961348|ACTIVE_COMPARATOR|Late start of NOAC|Day 5 to day 10 after ischemic stroke onset
62383642|NCT01492660|EXPERIMENTAL|Echogenic needle and catheter|The echogenic needle will be positioned using ultrasonography and neurostimulation with an end point of plantar or dorsiflexion with 0.6mA of current strength. The catheter will be inserted using ultrasonography alone. 20 Ml of 2% mepivacaine will be inserted using the catheter. The distribution of drug will be evaluated using short axis and long axis views. Sensory motor block evaluation every 5 minutes for 30 minutes. Duration of block procedure, number of passes and success will be evaluated
62383643|NCT01492660|ACTIVE_COMPARATOR|Neurostimulation|The non echogenic needle will be positioned using ultrasonography and neurostimulation with plantar or dorsiflexion as the end point with 0.6mA current.The catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current.
62383644|NCT00329992|EXPERIMENTAL|Treatment group|16 sessions Brief Eclectic Psychotherapy
62383645|NCT00329992|PLACEBO_COMPARATOR|Control group|Minimal attention waitlist group
62383646|NCT06370065|EXPERIMENTAL|HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04）|Procedure: HAIC (Hepatic arterial infusion chemotherapy) Drug: HLX10 (PD-1 antibody) Drug: HLX04 (VEGF antibody) HAIC: FOLFOX, q3w, up to 8 times; HLX10: 4.5mg/kg, iv, q3w, ; HLX04: 10mg/kg, iv, q3w.
62383647|NCT05384821|EXPERIMENTAL|Single Arm - Vincristine + Irinotécan + Témozolomide + Etoposide + Cis-Retinoic acid|Metronomic chemotherapy : Vincristine + Irinotécan + Témozolomide + Etoposide + Cis-Retinoic acid
62764545|NCT01724424|EXPERIMENTAL|Melatonin 100mg|10 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
62764546|NCT05490589|EXPERIMENTAL|EQUIPE Program|
62764547|NCT01399632|EXPERIMENTAL|High Fat and Low Carbohydrate Diet|
62764548|NCT01399632|EXPERIMENTAL|Low Fat and High Carbohydrate Diet|
61988699|NCT03890770|EXPERIMENTAL|End-stage renal disease requiring dialysis|Two single doses administered with washout
62383648|NCT02630459|PLACEBO_COMPARATOR|Double Blind Treatment Phase (DBTP): Placebo|Participants received placebo by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
62383649|NCT02630459|EXPERIMENTAL|DBTP: Erenumab 28 mg QM|Participants received erenumab 28 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
62383650|NCT02630459|EXPERIMENTAL|DBTP: Erenumab 70 mg QM|Participants received erenumab 70 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
62383651|NCT02630459|EXPERIMENTAL|DBTP: Erenumab 140 mg QM|Participants received erenumab 140 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
62383652|NCT02630459|EXPERIMENTAL|Open-Label Treatment Phase (OLTP): Erenumab 70-140 mg QM|Participants received an erenumab dose of 70 and/or 140 mg QM SC (depending on the participant's visit completion status after Institutional Review Board \[IRB\] approval of Protocol Amendment 2) in the OLTP for a total of 76 weeks.
62383653|NCT02630459|EXPERIMENTAL|CHU Sub-Study: Two 70 mg/mL AI/pens|A subset of participants in the OLTP randomized to self administer erenumab via two 70 mg/mL autoinjector (AI)/pens on day 29 and day 57 of the CHU Sub-Study
61988700|NCT03815097|EXPERIMENTAL|Intervention|Monitored anesthesia care with a mapleson circuit and nasal trumpet
61988701|NCT03815097|NO_INTERVENTION|Standard of care|Standard monitored anesthesia care
62383654|NCT02630459|EXPERIMENTAL|CHU Sub-Study: One 140 mg/mL AI/pen|A subset of participants in the OLTP randomized to self administer erenumab via one 140 mg/mL AI/pen on day 29 and day 57 of the CHU Sub-Study
62383655|NCT01486992|EXPERIMENTAL|Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
62764549|NCT05466695|EXPERIMENTAL|tadalfil group|Patients will use daily tadalafil 5 mg for 2 months
62764550|NCT05466695|EXPERIMENTAL|sildenafil group|Patients will use daily sildenafil 25 mg for 2 months
61988702|NCT00323492|EXPERIMENTAL|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization
62764551|NCT04581382|EXPERIMENTAL|Treatment (radiation therapy, plasma exchange, immunotherapy)|Patients undergo radiation therapy daily on days 1-5 (weekdays). Patients then undergo therapeutic plasma exchange over 1-2 hours on the first session starting on the last day of radiation therapy and the last session ending prior to immunotherapy. Beginning day 5, patients receive pembrolizumab IV or nivolumab IV. Treatment with pembrolizumab continues every 3 weeks or treatment with nivolumab continues every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection throughout the study and SOC CT, PET, and/or MRI scans as clinically indicated during follow-up.
62764552|NCT05656833|ACTIVE_COMPARATOR|Fractional 1927nm Low-Powered Diode Laser combined with Topical Cysteamine|One side of the face of participants will be randomized to receive fractional 1927nm Low-Powered Diode Laser in combination with topical cysteamine. There are 3 total treatments with the laser, in combination with using the topical cysteamine cream every day for the duration of the study (12 weeks)
61988703|NCT00323492|ACTIVE_COMPARATOR|Maintain Baseline Regimen|Maintain baseline regimen
61988704|NCT00323492|EXPERIMENTAL|Delayed Truvada|Truvada once daily with NNRTI or PI (participants from the comparator group who switched to Truvada during Study Phase 2)
61988705|NCT00323492|EXPERIMENTAL|All Truvada|Truvada once daily with NNRTI or PI (all participants who received Truvada during the study, i.e., participants in the Truvada and Delayed Truvada groups)
61988706|NCT02052232|ACTIVE_COMPARATOR|Control|Control protein powder sachet
61988707|NCT02052232|EXPERIMENTAL|Experimental|Experimental protein powder sachet
61988708|NCT03886220|EXPERIMENTAL|Elagolix 150 mg|Elagolix 150 mg once daily (QD)
61988709|NCT03886220|EXPERIMENTAL|Placebo|Placebo QD
62383656|NCT05093842|EXPERIMENTAL|Sedentary Behavior Reduction Intervention|Biweekly virtual health coaching, height-adjustable work station, and fitbit - targetting decreasing sedentary behavior, increasing standing, and increasing steps per day. Printable information on physical activity recommendations also provided.
62383657|NCT05093842|ACTIVE_COMPARATOR|Usual Care Control|Printable information on physical activity recommendations only
62383658|NCT02992054||Stimulating activities with the use of tactile tablet computer|Stimulating activities through the use of a tactile tablet computer. These tablets are linked to an internet-based service platform and offer a very easy and intuitive interaction for the user, even when this person is suffering from a moderate cognitive and/or physical impairment.
62383659|NCT02992054||Stimulating activities with usual stimulation activity program|No Stimulating activities through the use of a tactile tablet computer
62383660|NCT01706744|EXPERIMENTAL|Intermediate care unit|Follow-up treatment and care in a intermediate care unit after discharge from hospital
62383661|NCT01706744|ACTIVE_COMPARATOR|Local health care 1|Discharge from hospital to usual care as provided by the local health and social care (Verdal)
62383662|NCT01706744|ACTIVE_COMPARATOR|Local health care 2|Discharge from hospital to usual care as provided by the local health and social care (Stjørdal)
62383663|NCT03932292|ACTIVE_COMPARATOR|Ectoin Mouth Wash|30 patients obtaining EML03 treatment
62383664|NCT03932292|ACTIVE_COMPARATOR|Supersaturated solution of calcium and phosphate ions|20 patients taking standard treatment (calcium phosphate mouth wash)
62383665|NCT03435328|EXPERIMENTAL|TENS intervention|"one group receiving TENS:~- The electrode of TENS unit will be placed vertically, externally on skin overlying the parotid gland, in the preauricular area bilaterally, 1 cm in front of the tragus area."
62383666|NCT01816516|EXPERIMENTAL|Healthy Babies|Participants receive the Healthy Babies curriculum via 6 in home lessons and 3 follow up telephone calls delivered by Extension paraprofessionals.
62383667|NCT01816516|ACTIVE_COMPARATOR|EFNEP|Participants receive the Expanded Food and Nutrition Education Program (EFNEP) curriculum via 6 in home lessons delivered by Extension paraprofessionals.
62383668|NCT03866239|EXPERIMENTAL|Obinutuzumab Pretreatment (OpT) + Cibisatamab + Atezolizumab|Participants will receive obinutuzumab approximately 2 weeks before receiving atezolizumab and cibisatamab on Day 1 of each treatment cycle (cycle = 21 days).
62383669|NCT03636009|EXPERIMENTAL|Concurrent traction|Concurrent traction and neuromobilization technique at each scheduled session Active exercise program (4-5 exercises) at each session Manual therapy to cervical and thoracic spine at each session
62383670|NCT03636009|ACTIVE_COMPARATOR|Sequential traction|Sequential traction and neuromobilization technique at each scheduled session Active exercise program (4-5 exercises) at each session Manual therapy to cervical and thoracic spine at each session
62383671|NCT00298792|EXPERIMENTAL|Individualized Assessment & treatment|Individualized treatment for alcohol dependent persons, based on momentary assessment of high-risk situations and recorded coping abilities.
62383672|NCT00298792|ACTIVE_COMPARATOR|Packaged Cognitive-Behavioral Treatment|Manualized cognitive-behavioral treatment for alcohol dependent persons.
62383673|NCT03759444||women with eating disorders|"women with eating disorders (age: M = 26.88; SD = 5.82)~The three measures applied in this group were: the Time Metaphors Questionnaire by Sobol-Kwapinska (2007), the Time Perspective Inventory by Zimbardo (1999), and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al. (1990)."
62383674|NCT03759444||healthy female controls.|"healthy female controls (age: M = 24.27; SD = 6.49)~The three measures applied in this group were: the Time Metaphors Questionnaire by Sobol-Kwapinska (2007), the Time Perspective Inventory by Zimbardo (1999), and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al. (1990)."
62383675|NCT01657903|EXPERIMENTAL|NaF/KNO3 toothpaste, Low RDA|Participants to brush with 1.5 g of low RDA gel to foam toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% weight by weight (w/w) KNO3.
62383676|NCT01657903|EXPERIMENTAL|NaF/KNO3 toothpaste, Medium RDA|Participants to brush with 1.5 g of medium RDA gel to foam toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% w/w KNO3.
62383677|NCT01657903|ACTIVE_COMPARATOR|NaF/KNO3 toothpaste|Participants to brush with 1.5 g of NaF/KNO3 toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% w/w KNO3.
62383678|NCT01657903|PLACEBO_COMPARATOR|No fluoride/KNO3 toothpaste|Participants to brush with a fluoride free toothpaste (0 ppmF). All study treatments contain 5% w/w KNO3.
61988710|NCT06115811|EXPERIMENTAL|Radiation Treatment Plan Evaluation Learning Module|"Radiation oncology resident physicians will complete study procedures as below:~* Initial survey and pre-module examination.~* Learning module.~* Post-module survey and examination."
62383679|NCT03419741|ACTIVE_COMPARATOR|Active rTMS treatment|Transcranial Magnetic Stimulation Clinical Research System will be used for the active rTMS treatment. Stimulation frequency for all active subjects: 10 Hertz - Pulse train duration (on time) 5 seconds, Inter-train interval (off time) 10 seconds (15 second cycle time), Power (intensity) level 100% resting motor threshold, Total 60 trains, 15 minutes, Total pulses 3000 per day, 3000 x 5 = 15000 pulses for 5 sessions.
62383680|NCT03419741|SHAM_COMPARATOR|Sham rTMS treatment|Transcranial Magnetic Stimulation Clinical Research System -sham TMS will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
62383681|NCT05654727||Type 2 Diabetes Mellitus|
62383682|NCT05654727||Prediabetes|
62383683|NCT05654727||Healthy Control|
62383684|NCT04686539|EXPERIMENTAL|Recipients of CBD oil|Patients receiving Cannabidiol oil drops, administered sublingual, 3 times a day, while hospitalized. Dosing and administration frequency would be assessed bi-daily by the medical staff.
62383685|NCT04686539|PLACEBO_COMPARATOR|Recipients of Placebo|Patients receiving placebo oil, administered sublingual, 3 times a day, while hospitalized.
62383686|NCT04079322|EXPERIMENTAL|Exercise|During the exercise arm, volunteers will complete a planned workout, as prescribed by the coach. The workout will be designed to be strenuous and induce an inflammatory response.
62383687|NCT04079322|EXPERIMENTAL|Rest|"The rest arm will be coordinated with a planned non-workout day, as prescribed by the coach, where volunteers are either scheduled to not run or go for an easy recovery run (\<6 miles at a self-described easy pace) later in the afternoon."
62383688|NCT05132140|EXPERIMENTAL|normal healthy group|Adaptive optics system: this system controls the optical quality of the eye at the peripheral visual field temporarily.
62383689|NCT01138605|EXPERIMENTAL|005|Darunavir 400 mg tablet intake of 2 tablets once daily in combination with ritonavir
62764553|NCT05656833|ACTIVE_COMPARATOR|Topical Cysteamine Alone|The other side of the face that is not randomized to receive laser treatment will be subject to treatment with the topical cysteamine cream alone. Participants will use the topical cysteamine cream every day for the duration of the study (12 weeks).
62383690|NCT01138605|EXPERIMENTAL|006|Ritonavir Liquid formulation 80 mg/ml taken in combination with Darunavir
62383691|NCT01138605|EXPERIMENTAL|007|Ritonavir 100 mg capsule to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
62383692|NCT01138605|EXPERIMENTAL|008|Ritonavir 100 mg tablet to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
62764554|NCT02574741|ACTIVE_COMPARATOR|Aripiprazole|Aripiprazole oral solution (1mg/mL) for 12 weeks. dosages range from 2-10mg per day.
62383693|NCT01138605|EXPERIMENTAL|001|Darunavir Oral suspension 100 mg/ml 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
62383694|NCT01138605|EXPERIMENTAL|002|Darunavir 375 mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight between 20 and 30 kg
62383695|NCT01138605|EXPERIMENTAL|003|Darunavir 450 mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight between 30 and 40 kg
62383696|NCT01138605|EXPERIMENTAL|004|Darunavir 600mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight as of 40 kg
62383697|NCT01138605|EXPERIMENTAL|009|Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.
62383698|NCT01485185|EXPERIMENTAL|Gabapentin lower dose alone|low dose
62383699|NCT01485185|ACTIVE_COMPARATOR|Gabapentin higher dose alone|higher dose
62383700|NCT01485185|EXPERIMENTAL|Gabapentin in combination with donepezil|Gabapentin lower dose and donepezil
62383701|NCT01485185|PLACEBO_COMPARATOR|Placebo|Placebo
62383702|NCT02552537|ACTIVE_COMPARATOR|Omeprazole|patients will take Omeprazole 40mg, in capsules, once a day, during five days before walnut challenge
62383703|NCT02552537|SHAM_COMPARATOR|Placebo|patients will take Mannitol, in capsules, once a day, during five days before walnut challenge
62383704|NCT02485340|ACTIVE_COMPARATOR|Sumatriptan|headache is induced with 5-ISMN. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg
62764555|NCT02574741|ACTIVE_COMPARATOR|Placebo|50% will be randomized to placebo.
62383705|NCT02485340|PLACEBO_COMPARATOR|Placebo|headache is induced with 5-ISMN. This headache is treated double-blinded with 1 tablet of placebo (the tablet is similar to the active tablet)
62383706|NCT04678973|EXPERIMENTAL|Intervention|Participants in the intervention group will receive a 4 week program delivered via text message. Week 1 will include psychoeducation delivered via brief readings and video. Weeks 2-4 will include daily guided mindfulness practice focusing on self-compassion and weight and body image concerns.
62383707|NCT04678973|NO_INTERVENTION|Wait-list control|Participants in the control group will receive no study content during the 4 week intervention period. They will receive access to intervention content (text messages, audio files) after completing end-of-treatment surveys 4 weeks after randomization.
62383708|NCT00751335|EXPERIMENTAL|CPAP with ThermoSmart, then CPAP without ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
62383709|NCT00751335|EXPERIMENTAL|CPAP without ThermoSmart, then CPAP with ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
62383710|NCT03010059|EXPERIMENTAL|Panel 1: Treatment ABC|Participants will receive 240 milligram (mg) JNJ-64041575 as 6.0 milliliter (mL) of a 40-milligram per milliliter (mg/mL) current oral suspension formulation (reference 1) under fasted conditions (Treatment A) in period 1, then 4.0 mL of a 60-mg/mL new concept oral suspension formulation (test 1) under fasted conditions (Treatment B) in period 2 followed by 4.0 mL of a 60-mg/mL new concept oral suspension formulation (test 2) under fed conditions (Treatment C) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
62764556|NCT02574741|ACTIVE_COMPARATOR|Behavioral Intervention|All subjects will receive behavioral therapy, in addition to either active study drug (aripiprazole) or placebo.
61988711|NCT05992597|EXPERIMENTAL|rituximab, lenalidomide, and zebutinib,RDHAP|
62168224|NCT00965302|EXPERIMENTAL|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy is performed as part of a bariatric surgical program emphasizing healthy dietary choices, regular exercise, and glucose control.
62383711|NCT03010059|EXPERIMENTAL|Panel 1: Treatment BCA|Participants will receive Treatment B (test 1) in period 1, then Treatment C (test 2) in period 2 followed by Treatment A (reference 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
62383712|NCT03010059|EXPERIMENTAL|Panel 1: Treatment CAB|Participants will receive Treatment C (test 2) in period 1, then Treatment A (reference 1) in period 2 followed by Treatment B (test 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
62383713|NCT03010059|EXPERIMENTAL|Panel 1: Treatment ACB|Participants will receive Treatment A (reference 1) in period 1, then Treatment C (test 2) in period 2 followed by Treatment B (test 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
62383714|NCT03010059|EXPERIMENTAL|Panel 1: Treatment BAC|Participants will receive Treatment B (test 1) in period 1, then Treatment A (reference 1) in period 2 followed by Treatment C (test 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
62383715|NCT03010059|EXPERIMENTAL|Panel 1: Treatment CBA|Participants will receive Treatment C (test 2) in period 1, then Treatment B (test 1) in period 2 followed by Treatment A (reference 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
62764557|NCT00886119|OTHER|Lotrafilcon B / Omafilcon A|Lotrafilcon B, followed by Omafilcon A
62764558|NCT00886119|OTHER|Omafilcon A / Lotrafilcon B|Omafilcon A, followed by Lotrafilcon B
62764559|NCT01632098||extremely obese|BMI ≥35kg/m2
62764560|NCT01632098||obese|BMI 30-34.9kg/m2
61988712|NCT05698147|EXPERIMENTAL|X-MTX-Ritu|"Escalating doses of oral ATG-010 weekly in a 3+3 design. ATG-010 dose level (DL) 1, 2 and 3 are 60, 80 and 100mg respectively respectively on day 1,8,15,22 for 28-days cycle.and the phase 2 expansion at the recommended dose level based on phase 1b trial. And，~Methotrexate 3.5 g/m2, d1 and Rituximab 375 mg/m2, d0, 28-days cycle.The total 6 cycles, 28 days per cycle."
61988713|NCT04335279|EXPERIMENTAL|SPIN-CHAT: Videoconference Intervention|Participants in the SPIN-CHAT videoconference intervention group will receive a brief group videoconference intervention aimed at the management of worry and anxiety 3 times per week for 4 weeks during the COVID-19 crisis. Each group will include 8 participants and sessions will be approximately 60- to 90-minutes each. Each intervention group will be moderated by a member of the research team or by leaders who have been trained in our SPIN support group leader training program.
61988714|NCT04335279|NO_INTERVENTION|Wait-list Control|Participants in the wait-list control group will not receive the training program and will have no access to the resources indicated above for the duration of the trial. Wait-list controls will be given access to the program post-trial.
61988715|NCT04136392||Eligible Patients|The population to be enrolled in this study includes patients whose intended treatment is to receive mechanical circulatory support with the ABIOMED, Inc. hemodynamic support devices per the treating physician's discretion and best practices.
62383716|NCT03010059|EXPERIMENTAL|Panel 2: Treatment DEF|Participants will receive JNJ-64041575 as 1 tablet of the 250-mg current oral tablet formulation (reference 2) under fasted conditions (Treatment D) in period 1, then 1 tablet of the 250-mg new concept oral tablet formulation (test 3) under fasted conditions (Treatment E) in period 2 followed by 1 tablet of the 250-mg new concept oral tablet formulation (test 4) under fed conditions (Treatment F) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
62383717|NCT03010059|EXPERIMENTAL|Panel 2: Treatment EFD|Participants will receive Treatment E (test 3) in period 1, then Treatment F (test 4) in period 2 followed by Treatment D (reference 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
62383718|NCT03010059|EXPERIMENTAL|Panel 2: Treatment FDE|Participants will receive Treatment F (test 4) in period 1, then Treatment D (reference 2) in period 2 followed by Treatment E (test 3) then in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
62168225|NCT01391533|EXPERIMENTAL|Dose Escalation|Dose escalation phase: The starting dose of SAR125844 will be 50 mg/m\^2 up to 960 mg/m\^2
62383719|NCT03010059|EXPERIMENTAL|Panel 2: Treatment DFE|Participants will receive Treatment D (reference 2) in period 1, then Treatment F (test 4) in period 2 followed by Treatment E (test 3) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
62383720|NCT03010059|EXPERIMENTAL|Panel 2: Treatment EDF|Participants will receive Treatment E (test 3) in period 1, then Treatment D (reference 2) in period 2 followed by Treatment F (test 4) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
62383721|NCT03010059|EXPERIMENTAL|Panel 2: Treatment FED|Participants will receive Treatment F (test 4) in period 1, then Treatment E (test 3) in period 2 followed by Treatment D (reference 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
62383722|NCT01185912||Cardiomyocyte apoptosis|Elective aortic valve replacement patience
62383723|NCT01072500|ACTIVE_COMPARATOR|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
62383724|NCT01072500|ACTIVE_COMPARATOR|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
62383725|NCT02168816|ACTIVE_COMPARATOR|Midfoot|Individuals with an infection on the midfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
62383726|NCT02168816|ACTIVE_COMPARATOR|Hindfoot|Individuals with an infection on the hindfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
62383727|NCT02168816|ACTIVE_COMPARATOR|Toe|Individuals with an infection on the toe are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
62764561|NCT01744717||Critically ill uncommunicative patients|Critically ill non-communicative patients, on mechanical ventilation
62764562|NCT02916225|ACTIVE_COMPARATOR|High intensity interval training|exercise protocol for high intensity/aerobic interval training as described by ESC statement (Mezzani et al.)
62764563|NCT02916225|PLACEBO_COMPARATOR|Moderate Continuous Training|exercise protocol for continuous aerobic training as described by ESC statement (Mezzani et al.)
62764564|NCT01813123|NO_INTERVENTION|Control|
62764565|NCT01813123|EXPERIMENTAL|Intervention|RealTeen
62764566|NCT02702531|EXPERIMENTAL|FloShield|FloShield Air Laparoscopic Cleaning and Defogging System used during laparoscopic surgery
62764567|NCT02702531|EXPERIMENTAL|Water + Povidone-iodine Solution|Clearify Visualization with Water + Povidone-iodine Solutionused during laparoscopic surgery
62764568|NCT03797092|ACTIVE_COMPARATOR|Active|Allogeneic adipose-derived stromal cells (CSCC_ASC)
62764569|NCT03797092|NO_INTERVENTION|Control group|No treatment
61988716|NCT03812692||MATRx plus test|All participants will complete the MATRx plus test unattended in the home. Not all participants will be predicted responders to oral appliance therapy; both predicted responders and non-responders will undergo an outcome home sleep apnea test with a custom oral appliance in place to validate the prediction made by the test. Twenty participants will also complete an in-lab sleep study prior to the home study.
61988717|NCT05162209|EXPERIMENTAL|Synbiotic|Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Enterococcus faecium (total 2.5 x10 9CFU/sachet), fructooligosaccharydes (FOS) 625 mg, oral sachet daily, for 12 weeks
61988718|NCT05162209|PLACEBO_COMPARATOR|Placebo|Oral sachet daily for 12 weeks
61988719|NCT01824407|ACTIVE_COMPARATOR|Active device plus standard of care|Active device plus standard of care
61988720|NCT01824407|SHAM_COMPARATOR|Sham device plus standard of care|dermaPACE device that uses a dummy applicator that does not emit shock waves
61988721|NCT01329640|EXPERIMENTAL|Paclitaxel, trastuzumab, doxorrubicin, ciclophosphamide|
61988722|NCT02968563|EXPERIMENTAL|Tirabrutinib + Idelalisib|Tirabrutinib 80 mg (4 x 20 mg tablets/2 x 40 mg tablets/1 x 80 mg tablet) once daily + idelalisib 100 mg (1 x 100 mg tablet) once daily for up to 104 weeks.
61988723|NCT02968563|EXPERIMENTAL|Tirabrutinib + Idelalisib + Obinutuzumab|Tirabrutinib 80 mg (4 x 20 mg tablets/ 2 x 40 mg tablets/ 1 x 80 mg tablet) once daily + idelalisib 100 mg (1 x 100 mg tablet) once daily for up to 104 weeks + obinutuzumab 100 mg on Day 1, 900 mg on Day 1 or 2, and 1000 mg subsequently for up to 8 doses on Day 1 of Weeks 2, 3, 5, and then every 4 weeks through Week 21.
61988724|NCT01971450||Iloprost|The patients with pulmonary hypertension with inhaled treatment with Ventavis according to routine practice meeting the criteria of inclusion.
61988725|NCT02190227|OTHER|Tumor RDA biopsy|Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.
61988726|NCT04851795|EXPERIMENTAL|supervised physical exercise sessions|Participants assigned to the supervised exercise group will perform a supervised routine of approximately 30 minutes, 2 days per week (Monday and Wednesday at the Txagorritxu hospital, and Tuesday and Thursday at the Santiago hospital from 7:15 to 7:45 and from 15:15 to 15:45).
61988727|NCT04851795|OTHER|unsupervised physical exercise sessions|For the non-supervised group, we will propose climbing the stairs from floor 0 to floor 7 three times during the working day and doing planks and stretching exercises outside of work. For the latter, an educational session will be given at the beginning of the study to explain how to perform them correctly.
61988728|NCT02635516|EXPERIMENTAL|Treatment|Only one arm was used and this arm received Near-Infrared Phototherapy.
61988729|NCT05621343||Latent TB on treatment|"Treatment according to existing Swedish guidelines with:~Oral rifampicin 10 mg/kg (max 600mg) once daily during 4 months OR Oral isoniazide 5 mg/kg (max 300mg) once daily in combination with 40mg vitamin B6 (pyridoxin) during 6 months"
61988730|NCT05621343||Latent TB not on treatment|Latent TB without indication for treatment OR patient who do not want to receive treatment
61988731|NCT05621343||Active TB with treatment|Treatment according to existing Swedish guidelines. Duration and choice of antibiotic therapy depending on the condition.
61988732|NCT05621343||Healthy control|Healthy
62383728|NCT04759729|EXPERIMENTAL|PRO+D group|Participants will receive probiotic as well as vitamin D supplementation.
61988733|NCT05689307|EXPERIMENTAL|SIVA-MVP|Wearable cough detection device with a corresponding smartphone application and charging device.
62383729|NCT04759729|EXPERIMENTAL|PL+D group|Participants will receive placebo instead of probiotics and vitamin D supplementation.
62383730|NCT01728454|PLACEBO_COMPARATOR|Placebo|Following the Stage 1 no treatment baseline assessment period, placebo matching capsules, orally, once daily for 18 weeks in Stage 2. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 12 milligrams (mg)/day separated by an off-drug interval (ODI) in Stage 3.
61988734|NCT04928677|EXPERIMENTAL|Codrituzumab|For Phase A of the study, we will use the 3+3 study design, with 2 planned dose levels, starting at 50% of the adult RP2D to confirm the pediatric RP2D/MTD. 6-9,43 Phase B will include an expansion cohort for patients with hepatoblastoma.
61988735|NCT05524181|EXPERIMENTAL|Intervention|Individuals in the intervention group will undergo a series of two telehealth video visits and a series of survey assessments at baseline, 3, 6, 9, and 12 months.
61988736|NCT05524181|NO_INTERVENTION|Control|Individuals in the control group will continue with their usual standard of care and undergo a series of survey assessments at baseline, 3, 6, 9 and 12 months.
61988737|NCT03988491||End stage renal disease on maintanance hemodialysis|End-stage renal disease due to any etiology on maintenance hemodialysis and consented to participate in the study.
61988738|NCT01764568|EXPERIMENTAL|Metacognitive Training for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will receive Metacognitive Training twice weekly for 8 weeks (16 sessions).
62764570|NCT02258555|EXPERIMENTAL|GS-9901|Participants will receive one of 6 escalating doses of GS-9901 once daily until unacceptable toxicity, substantial noncompliance, disease progression, pregnancy, initiation of another anti-cancer or experimental therapy, or other protocol-specified reasons for GS-9901 discontinuation.
62764571|NCT02909855||Participants|Parents of children aged 2-4 who will receive the child flu vaccine from their general practitioner (GP)
62764572|NCT04479683|OTHER|standard care|continuation of full-time hospitalization until the minimum healthy weight is reached, defined as the weight corresponding to the return to the previous BMI corridor (previous BMI +/- 1 BMI corridor, e.g. change from 25th to 10th percentile). This management combines bi-weekly medical follow-up by a senior psychiatrist, weekly family work, weekly therapeutic education group, weekly cognitive remediation group and bi-weekly dietary follow-up with therapeutic meals.
62764573|NCT04479683|EXPERIMENTAL|FTH (full-time hospitalisation) then day hospitalization)|"FTH output and DH relay one day a week until the minimum healthy weight. This treatment combines over one day a medical evaluation by a senior psychiatrist, family work (parents group and multi-family therapy session), a therapeutic education group, a cognitive remediation group and a dietary follow-up with therapeutic meals.~During this phase, all children are evaluated once a week on a somatic level."
62764574|NCT00320372||1. 500 VNS Patients|VNS Patients - Treatment-resistant depression patients treated with VNS Therapy.
61988739|NCT01764568|EXPERIMENTAL|Cognitive Remediation for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will receive Cognitive Remediation treatment twice weekly for 8 weeks (16 sessions).
61988740|NCT01764568|NO_INTERVENTION|Treatment as Usual for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will continue to receive treatment as usual (TAU) as defined by their health care team (i.e., medication, other therapies) while still taking part in baseline, midpoint, and end-point assessments.
62764575|NCT00320372||2. 300 Non-VNS Patients|Non-VNS Patients - Treatment-resistant depression patients not receiving VNS Therapy.
62764576|NCT03397992|ACTIVE_COMPARATOR|Group A|Treatment with high dialysate temperature first followed by low dialysate temperature and alternating thereafter.
62764577|NCT03397992|ACTIVE_COMPARATOR|Group B|Treatment with low dialysate temperature first followed by high dialysate temperature and alternating thereafter
62764578|NCT00974285|ACTIVE_COMPARATOR|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
62764579|NCT00974285|PLACEBO_COMPARATOR|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
62764580|NCT00766246|EXPERIMENTAL|First-line|Carboplatin, docetaxel, bevacizumab Open-label, single arm with treatment period up to 6 cycles. Patients completing a total of 2 to 6 cycles of first-line without disease progression will be eligible for maintenance.
62764581|NCT00766246|EXPERIMENTAL|Maintenance|Bevacizumab Open-label, single arm with treatment period up to 18 cycles.
61988741|NCT05754151|EXPERIMENTAL|MAYA Mobile App|Participants receive treatment with the MAYA application for 6 weeks
61988742|NCT02013713||Family Hypercholesterolemia in cardiology|
61988743|NCT01353417||Renal allograft|
61988744|NCT04495127|EXPERIMENTAL|Selumetinib|
62764582|NCT05009602||Participating Centre|To complete all index tests and reference scan
62764583|NCT05052437|EXPERIMENTAL|Utidelone|
62764584|NCT05052437|EXPERIMENTAL|Utidelone plus capecitabine|
62764585|NCT06008483|OTHER|Dose Level 1|Everyone gets a first dose of 0.5 mCi/kg dose and then in 7 days a second dose of 0.5 mCi/kg
62764586|NCT06008483|OTHER|Dose Level 2|Everyone gets a first dose of 0.5 mCi/kg dose and then in 7 days a second dose of 1.0 mCi/kg
62764587|NCT06008483|OTHER|Dose Level 3|Everyone gets a first dose of 0.5 mCi/kg dose and then in 7 days a second dose of 2.0 mCi/kg
62764588|NCT06008483|OTHER|Dose Level 4|Everyone gets a first dose of 0.5 mCi/kg dose and then in 7 days a second dose of 3.0 mCi/kg
62764589|NCT03845972|NO_INTERVENTION|before SSFTB|
62764590|NCT03845972|EXPERIMENTAL|after SSFTB|
62764591|NCT03542851|EXPERIMENTAL|Subject Receives BTD001 first|
62764592|NCT03542851|EXPERIMENTAL|Subject Receives Placebo first|
62764593|NCT05365737|PLACEBO_COMPARATOR|placebo oral rinse|Placebo comparator Volume Time Active molecule 15 mL 1 min No
62764594|NCT05365737|ACTIVE_COMPARATOR|CPC oral rinse|Volume Time Active molecule 15 mL 1 min CPC containing oral rinse
62764595|NCT05365737|ACTIVE_COMPARATOR|Cymenol oral rinse|Volume Time Active molecule 15 mL 1 min Cymenol containing oral rinse
62764596|NCT05365737|ACTIVE_COMPARATOR|CPC + Cymenol oral rinse|Volume Time Active molecule 15 mL 1 min CPC+cymenol containing oral rinse
62764597|NCT00711802|EXPERIMENTAL|Daptomycin|"Administered intravenously (IV) every 24 hours for up to 14 days at the following age-dependent dosages.~Participants ages 7 to 17 years: daptomycin was dissolved in a volume of 50 milliliters (mL) 0.9% sodium chloride for injection over 30 minutes (min) with an infusion rate of 1.67 mL/min.~Participants 1 to 6 years-old: daptomycin was dissolved in a volume of 25 mL 0.9% sodium chloride for injection over 60 min with an infusion rate was 0.42 mL/min.~Age Group 1 (for ages 12 to 17 years): 5 milligrams/kilogram (mg/kg)~Age Group 2 (for ages 7 to 11 years): 7 mg/kg~Age Group 3 (for ages 2 to 6 years): 9 mg/kg~Age Group 4 (for ages 1 to \<2 years): 10 mg/kg"
62764598|NCT00711802|ACTIVE_COMPARATOR|Standard of Care (SOC)|The comparator agent for this study was the SOC treatment and dosage deemed appropriate by the Investigator. The recommended SOC agents were IV vancomycin, IV clindamycin, and IV semisynthetic penicillins every 24 hours for up to 14 days.
62764599|NCT03560466|EXPERIMENTAL|Dupilumab|Doses of dupilumab will be administered every 2 weeks or every 4 weeks added to current controller medications for 52 weeks
62764600|NCT04660227|EXPERIMENTAL|Exercise Group|Participants in the online exercise program group will be given a treatment protocol consisting of aerobic exercise and strengthening exercises in the presence of a physiotherapist for a total of 8 weeks, 2 days a week for 1 hour.
61988745|NCT01883687|EXPERIMENTAL|Septoplasty|patients will receive septoplasty together with Le Fort I osteotomy
61988746|NCT01883687|NO_INTERVENTION|No septoplasty|patient will only receive Le Fort I osteotomy
61988747|NCT05945277|NO_INTERVENTION|Control|
62383731|NCT01728454|EXPERIMENTAL|Telapristone acetate 6 mg|Following the Stage 1 no treatment baseline assessment period, telapristone acetate (Proellex®) 6 mg capsules, orally once daily for 18 weeks in Stage 2. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 6 mg/day separated by an ODI in Stage 3.
62383732|NCT01728454|EXPERIMENTAL|Telapristone acetate 12 mg|Following the Stage 1 no treatment baseline assessment period, telapristone acetate (Proellex®) 12 mg capsules, orally once daily for 18 weeks. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 12 mg/day separated by an ODI in Stage 3.
62383733|NCT01008228|ACTIVE_COMPARATOR|tube thoracic drainage|drainage performed with tube drainage CH 16 or ch 20
62383734|NCT01008228|EXPERIMENTAL|exsufflation|exsufflation with a specific thoracentesis system
62764601|NCT04660227|OTHER|Control Group|Participants in the control group will be put on the waiting list after all assessment methods have been applied and will be re-evaluated at the end of 8 weeks.
62383735|NCT02498340|EXPERIMENTAL|Diet challenge|The patients will have a single blood test after dietetic challenge, they will be subjected to eat non- fava beans diet at doses of 10 -30 gm of 3 different types of non- fava beans( each one will be given once daily for 3 days).
62383736|NCT02142673|ACTIVE_COMPARATOR|Filling pressure 80|The hysteroscope filling pressure will be 80mm Hg
62383737|NCT02142673|ACTIVE_COMPARATOR|Filling pressure 60|The hysteroscope filling pressure will be to 50mm Hg
62383738|NCT02142673|ACTIVE_COMPARATOR|Filling pressure 40|The hysteroscope filling pressure will be to 40mm Hg
62383739|NCT03580902|ACTIVE_COMPARATOR|Standard Buprenorphine|Participants assigned to this arm will received buprenorphine treatment consistent with standard practice at the study site. This includes induction by a physician, regular meetings with a physician for medical management, urine monitoring, and prescription of buprenorphine, with access to behavioral support services.
62764602|NCT00391001|EXPERIMENTAL|1|
62764603|NCT00391001|PLACEBO_COMPARATOR|2|
62764604|NCT03741803|ACTIVE_COMPARATOR|Delayed cord clamping|
62764605|NCT03741803|ACTIVE_COMPARATOR|Early cord clamping|
62764606|NCT05007977|EXPERIMENTAL|Treatment order: placebo, low dose, high dose|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
62764607|NCT05007977|EXPERIMENTAL|Treatment order: placebo, high dose, low dose|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
62764608|NCT05007977|EXPERIMENTAL|Treatment order: low dose, placebo, high dose|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
62764609|NCT05007977|EXPERIMENTAL|Treatment order: low dose, high dose, placebo|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
62764610|NCT05007977|EXPERIMENTAL|Treatment order: high dose, placebo, low dose|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
61988748|NCT05945277|EXPERIMENTAL|Intervention|
61988749|NCT04528979|EXPERIMENTAL|Primary root canal treatment|Primary root canal treatment sealed with guttapercha and AH Plus® or BioRoot RCS® root canal sealers
61988750|NCT04528979|EXPERIMENTAL|Secondary root canal treatment|Secondary root canal treatment sealed with guttapercha and AH Plus® or BioRoot RCS® root canal sealers
62168226|NCT06584981|ACTIVE_COMPARATOR|Patients who underwent block|Patients who underwent pectoral nerve block (PECS II), parasternal and serratus plane blocks will be included in this group.
62168227|NCT06584981|OTHER|Patients who did not receive block|Patients who were not given a block and received standard intravenous analgesics will be included in this group.
62168228|NCT01378533|EXPERIMENTAL|AC-T（dose-dense）|AC-T(dose-dense) EPI（Pharmorubicin） CTX（cyclophosphamide） PTX（Paclitaxel） G-CSF
61988751|NCT04007861||Patients with pain|"This will be the group of patients in whom pain is a significant enough problem, that they have been referred to the specialist Pain Management Team. These patients will be identified retrospectively.~Patients seen in Pain Management Clinics between 1st of January 2016 and 31st of December 2018, who have consented to be included in the Pain Management database and have a clinician specified pain diagnosis of pain persistent post-surgical pain following breast cancer treatment will be identified. If these patients have an unclear pain diagnosis, they will not be included."
61988752|NCT04007861||Patients without pain|"This will be the group of patients in whom pain is deemed not to be a significant problem.~Once again, these patients will be identified retrospectively. Appropriately matched patients to the 52 patients in the patients with pain will be identified using records of hospital operating lists by the peri-operative medicine team.~Patients will be matched based upon the following details:~* Age (within 5 years of matched case)~* Surgical procedure (matched for the following elements:~  * Surgery to breast tissue (biopsy, lumpectomy, wide-local excision or mastectomy)~ * +/- Sentinal lymph node biopsy or axillary dissection~ * +/- Reconstruction~* Surgical procedure within 3-months of matched case.~Provided these individuals have not had an appointment with or referral to the Pain Management Team, they will be included in the matched controls."
61988753|NCT03204981|EXPERIMENTAL|Intramural Needle Ablation|
61988754|NCT01747109|EXPERIMENTAL|PREOXYFLOW|"Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction"
61988755|NCT01747109|ACTIVE_COMPARATOR|STANDARD FACE MASK|"Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. No specific trademark is requested by the protocol."
61988756|NCT03632187|EXPERIMENTAL|Experimental group|Subcutaneous abatacept every weeks during 3 months (W0 to W11). Then, at W12, if PMR-AS\>10, they will receive GCs according to the PMR-AS (PMR-AS≤10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS\> 30: 20mg/d). Dosage of GCs will be decreased between W16 and W24 (1mg every week) in each arm according to PMR-AS (PMR-AS \< 10: decrease, PMR-AS \> 17 increase to previous dosage, 10 ≤ PMR-AS ≤ 17: stable dose). If PMR-AS ≤10, the patients wont receive any treatment until a flare.
61988757|NCT03632187|PLACEBO_COMPARATOR|Control group|Subcutaneous placebo every week during 3 months (W0 to W11). Then, at week 12, if PMR-AS\>10, they will receive GCs according to the PMR-AS (PMR-AS≤10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS\> 30: 20mg/d). Dosage of GCs will be decreased between W16 and W24 (1mg every week) in each arm according to PMR-AS (PMR-AS \< 10: decrease, PMR-AS \> 17 increase to previous dosage, 10 ≤ PMR-AS ≤ 17: stable dose). If PMR-AS ≤10, the patients won't receive any treatment until a flare.
61988758|NCT05078164|NO_INTERVENTION|Treatment as Usual|Youth who will not receive BTG services and will receive treatment as usual (TAU) in the hospital.
61988759|NCT05078164|EXPERIMENTAL|Bridging the Gap (BTG)|Youth randomized to Bridging the Gap (BTG) services will receive a hospital-based violence prevention program with 3-months of community case management and a firearm counseling program.
61988760|NCT01116258|EXPERIMENTAL|1|
62383740|NCT03580902|EXPERIMENTAL|Standard Buprenorphine plus CBT4CBT-Buprenorphine|Participants in this condition will receive Standard Buprenorphine as described above, with the addition of access to the CBT4CBT-Buprenorphine program, which is a web-based program that covers basic knowledge about buprenorphine treatment as well as teaches cognitive and behavioral coping skills.
62383741|NCT01603628|EXPERIMENTAL|BOTOX® 4 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 U per kg of body weight (4 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly physical therapy (PT).
62383742|NCT01603628|EXPERIMENTAL|BOTOX® 8 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 8 U per kg of body weight (8 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
62383743|NCT01603628|PLACEBO_COMPARATOR|Normal Saline (Placebo)|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
62383744|NCT04087824|EXPERIMENTAL|AI monitoring colonoscopy|Patients in this group go through colonoscopy under the AI monitoring device.
62383745|NCT00671411|EXPERIMENTAL|1|Patients entering into this protocol will also have a preoperative renal contrast enhanced US for this research study. Renal mass US contrast enhancement results will be compared with surgical pathological findings to determine if contrast enhancement patterns of the renal masses correlate with benign and malignant histopathology, and/or malignant histologic subtype.
62383746|NCT04835935||subject who developed atopic disease|
62383747|NCT04835935||subject who did not develop atopic disease|
62383748|NCT04211740|ACTIVE_COMPARATOR|OCH-NCNP1 3 mg|
62383749|NCT04211740|PLACEBO_COMPARATOR|Placebo|
62383750|NCT02865278|EXPERIMENTAL|Polyphenol-rich drink|The participants consume the polyphenol-rich drink. After 3 hours they consume a standard meal to evaluate whether the metabolic response may be influenced by polyphenols.
62383751|NCT02865278|PLACEBO_COMPARATOR|Placebo drink|The participants consume the control drink.After 3 hours they consume a standard meal to evaluate the metabolic response after a placebo.
62383752|NCT01308151|EXPERIMENTAL|Experimental Arm|Culturally Adapted Manualised Cognitive Behavioral Therapy (CBT) Sessions will be offered weekly in the first month and then fortnightly.
62383753|NCT01308151|NO_INTERVENTION|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
62383754|NCT05564364|EXPERIMENTAL|Healthy Controls 1|Healthy individuals participating in the study will be divided into two groups.
62383755|NCT05564364|EXPERIMENTAL|Healthy Controls 2|Healthy individuals participating in the study will be divided into two groups.
62383756|NCT03377166|ACTIVE_COMPARATOR|Vertigo|Participants with vestibular disorder
62383757|NCT03377166|ACTIVE_COMPARATOR|Control|Participants without vestibular disorder
62383758|NCT05844592|PLACEBO_COMPARATOR|A|Dose A
62383759|NCT05844592|PLACEBO_COMPARATOR|B|Dose B
62383760|NCT05844592|PLACEBO_COMPARATOR|C|Dose C
62383761|NCT05844592|PLACEBO_COMPARATOR|D|Dose D
61988761|NCT01116258|PLACEBO_COMPARATOR|2|
61988762|NCT04445428|EXPERIMENTAL|Intervention|Standard dose bivalent oral polio vaccine, 0.1ml, and information regarding prevention of COVID-19
61988763|NCT04445428|OTHER|Control|Information regarding prevention of COVID-19
61988764|NCT04483713|ACTIVE_COMPARATOR|Educational Workshop|Will receive theoretical and practical training in EBP through a workshop in a structured model with themes related to the introduction to EBP, with the final proposal of a practical class that aims to structure and describe an individual case through an exercise formulated to go through the phases of a project of EBP, to base this exercise we will use a finished and consolidated project, this will be used as a template of the exercise, the description of this exercise is in the programmatic content.
61988765|NCT04483713|ACTIVE_COMPARATOR|Educational Workshop plus J. H. N. EBP Guide Tools|"Will receive the same training as group Educational Workshop, plus the presentation and availability of the Johns Hopkins Nursing Evidence-based Practice guide tools to be used in the practice class for the structuring and individual description of the EBP exercise case. The same theme of the case will be used in both groups."
61988766|NCT00673179|EXPERIMENTAL|Outpatient Chemotherapy|Pre-Surgery, Regimen 1: Doxorubicin intravenous (IV) 90 mg daily, Cisplatin 60 mg/m\^2/day for 2 days, Methotrexate 12 gm/m\^2, Leucovorin Rescue 10 mg IV, with 10 mg orally every 6 hours; Surgery; Post-Surgery, Regimen 1: Methotrexate 12 gm/m\^2, Doxorubicin IV 90 mg, Cisplatin 60 mg/ m\^2 twice daily, Leucovorin Rescue.
62383762|NCT05844592|PLACEBO_COMPARATOR|E|Dose E
62764611|NCT05007977|EXPERIMENTAL|Treatment order: high dose, low dose, placebo|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
62764612|NCT02704611|ACTIVE_COMPARATOR|Group I|Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week).
62764613|NCT02704611|SHAM_COMPARATOR|Group II|Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec.
62764614|NCT02316210|EXPERIMENTAL|Digitimer stimulation|
62764615|NCT02745717|EXPERIMENTAL|cord blood and IST group|Administration of antithymocyte ( Thymoglobulin ) 3.5mg/kg/d for 5 days, Cyclosporine Oral Product 5mg/kg/d with trough serum concentration of 200-300ng/ml, plus one unit of at least 4/6 HLA loci matched cord blood transfusion 24 hours after last dose of ATG.
62764616|NCT02745717|ACTIVE_COMPARATOR|IST group|Antithymocyte ( Thymoglobulin ) 3.5mg/kg/d for 5 days , Cyclosporine Oral Product 5mg/kg/d with trough serum concentration of 200-300ng/ml.
62764617|NCT05805748|ACTIVE_COMPARATOR|Group 1|Each patient received 2 rehabilitations : a serious game training and a conventional rehabilitation first (during 3 weeks) and then conventional rehabilitation alone (during 3 weeks)
62764618|NCT05805748|ACTIVE_COMPARATOR|Group 2|Each patient received 2 rehabilitations for 3 weeks: a conventional rehabilitation first (during 3 weeks) and then both serious game training and a conventional rehabilitation (during 3 weeks)
61988767|NCT00673179|EXPERIMENTAL|Additional Risk-Adapted Outpatient Chemotherapy|Pre-Surgery, Regimen 2: Dexrazoxane 900 mg/m\^2 intravenous (IV) then Doxorubicin IV 90 mg daily, Cisplatin 120 mg/m\^2 (intra-arterial); Surgery; Post-Surgery, Regimen 2: Methotrexate 12 gm/m\^2, Leucovorin Rescue 10 mg IV, with 10 mg orally every 6 hours; Ifosfamide 2.8 grams m\^2/day and Mesna 2.8 gm/m\^2/day continuous IV over 6 days; Lung-Directed Chemotherapy, Regimen 2: Gemcitabine, Sargramostim Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg).
61988768|NCT01995084|EXPERIMENTAL|Optimization|Patients undergo a \[F-18\]HX4 PET/CT scan 2,3 and 4h after \[F-18\]HX4 injection.
61988769|NCT01995084|EXPERIMENTAL|Reproducibility|Patients undergo two \[F-18\]HX4 PET/CT scans 3.5h after \[F-18\]HX4 injection within a 10-day time frame.
61988770|NCT01474044|PLACEBO_COMPARATOR|Placebo|
61988771|NCT01474044|ACTIVE_COMPARATOR|Gastropyloric Complex Capsules|
61988772|NCT05190198|EXPERIMENTAL|Experimental group|"The experimental group will receive ankle proprioceptive training.~Ankle proprioceptive training includes the following group of exercises:~1. Training on the floor for 10 minutes (1-8 weeks)~2. Training on balance pad for 10 minutes (1-4 weeks)~3. Training on rocked balance board for 10 minutes (5-8 week)"
61988773|NCT05190198|ACTIVE_COMPARATOR|Conventional therapy group|"The control group will receive Traditional physical therapy exercises.~1. Active range of motion exercises for ankle and subtalar joints for 5 minutes.~2. Functional balance training for 15 minutes involving~3. Gait training for 10 minutes."
61988774|NCT04824170|EXPERIMENTAL|Neural glide|Neural mobilization of median nerve which includes gliding and sliding was given
61988775|NCT04824170|EXPERIMENTAL|Rhythmic stabilization technique|Proprioceptive Neuromuscular Facilitation (Rhythmic stabilization technique will be Given)
61988776|NCT05719805|EXPERIMENTAL|Mavacamten Dose 1|
62383763|NCT02055872|EXPERIMENTAL|Intravenous albumin|Administration of 25% albumin by intravenous infusion, twice daily for a total of 72 hours (6 treatments)
62383764|NCT02055872|PLACEBO_COMPARATOR|Normal saline|Administration of 100 mL normal saline by intravenous infusion, twice daily, for 72 hours (6 treatments)
62383765|NCT02668679|ACTIVE_COMPARATOR|Children and their parents with the presence of Dream Doctors|The DD will use various methods for entertaining the child and alleviate stress . The parents and the children will be given anxiety and satisfaction questionnaires. The children and parents will perform Pre-Pulse inhibition (PPI) test and GSR. In addition, stress hormones will be assessed (cortisol, epinephrine, and norepinephrine) and the following physical indices will be measured: blood pressure, pulse, saturation and body temperature. The amount of drugs given for deep sedation will be evaluated.
62764619|NCT00473603|EXPERIMENTAL|LHI|to perform an i.v. lipid heparin infusion for 4 h
62764620|NCT00473603|SHAM_COMPARATOR|SHI|to perform an i.v. saline heparin infusion for 4 h
62764621|NCT01968577|EXPERIMENTAL|Rosuvastatin 40 mg|Administration of rosuvastatin 40 mg 2 to 6 hours before percutaneous coronary intervention
61988777|NCT05719805|EXPERIMENTAL|Mavacamten Dose 2|
61988778|NCT04482504||healthy pregnant women|"200 healthy pregnant women in 36.-38. Week of pregnancy. The investigators involve every healthy pregnant woman in 36.-38. week of pregnancy.~Exclusion criteria:~1. Unwilling to participate~2. Minors (under 18 years old)~e) Unfamiliar with slovak language f) Multiple pregnancy g) Musculoskeletal and neurological abnormalities"
62764622|NCT01968577|NO_INTERVENTION|Control group|The group of patients that do not receive rosuvastatin, 40 mg, before percutaneous coronary intervention.
62764623|NCT04174651|EXPERIMENTAL|Participants with AD with MRI|Participants that are diagnosed with AD will receive both the acute stress condition (TSST) and the control condition (watching a landscape video). The order when the 2 conditions will be provided is randomized per participant and completed 2 weeks apart. These subjects will be evaluated with MRI.
62764624|NCT04174651|EXPERIMENTAL|Healthy Participants with MRI|Healthy participants will receive both the acute stress condition (TSST) and the control condition (watching a landscape video). The order when the 2 conditions will be provided is randomized per participant and completed 2 weeks apart. These subjects will be evaluated with MRI.
62764625|NCT00393341||Case|Women with breast cancer
62764626|NCT00393341||Control|Women without breast cancer
62764627|NCT03095586|ACTIVE_COMPARATOR|News with Spin|News items reporting results of RCTs with spin
62764628|NCT03095586|EXPERIMENTAL|News without spin|News items reporting results of RCTs without spin
62764629|NCT01268917|EXPERIMENTAL|preoperative aspirin use|
62764630|NCT01268917|NO_INTERVENTION|preoperative aspirin nonuse|
62764631|NCT00432744|ACTIVE_COMPARATOR|CoenzymeQ10|CoenzymeQ10: patients will be randomized to receive CoenzymeQ10 in either Period #1 (Months 0-6) or Period #2 (Months 7-12).
62764632|NCT00432744|PLACEBO_COMPARATOR|Placebo|Placebo: patients will be randomized to receive placebo either ion Period #1 (months 1-6) or Period #2 (months 7-12).
61988779|NCT04482504||non-pregnant women|"30 non-pregnant healthy control women The investigators involve every healthy non-pregnant woman.~Exclusion criteria:~1. Unwilling to participate~2. Minors (under 18 years old)~e) Unfamiliar with slovak language f) Pregnancy g) Musculoskeletal and neurological abnormalities"
61988780|NCT01154309|EXPERIMENTAL|1|Clients are invited to attend 18 group CBT sessions
61988781|NCT01154309|NO_INTERVENTION|2|Clients receive usual care
62764633|NCT01546714||AAWSW/AAWSWM|African American Women Who Have Sex with Women/African American Women Who Have Sex with Women and Men
62764634|NCT03564821|EXPERIMENTAL|Ivosidenib (500mg/day)|-Ivosidenib will be administered orally every day
62764635|NCT03564821|EXPERIMENTAL|Ivosidenib (250mg/day)|-Ivosidenib will be administered orally every day
62764636|NCT04276155|EXPERIMENTAL|Device|Acute Coranary Syndrome and de novo Atrial Fibrilation patients treated by DAPT only, in association with an implantable cardiac monitoring device and a follow-up by telecardiology. The anticoagulant treatment will only be administered to patients presenting a recurrence of Atrial Fibrilation
61988782|NCT03424265|EXPERIMENTAL|9g of EAA mixture supplement|Twice a day for 12 consecutive weeks.
61988783|NCT03424265|EXPERIMENTAL|9g of placebo (whey protein)|Twice a day for 12 consecutive weeks.
61988784|NCT03365700|ACTIVE_COMPARATOR|Cryoballoon ablation|Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line.
61988785|NCT03365700|ACTIVE_COMPARATOR|Radiofrequency Ablation|Contact force-sensing radiofrequency left atrial ablation with 3D mapping system.
61988786|NCT02149927|EXPERIMENTAL|Sevoflurane|Single arm: dose escalation of study medication
61988787|NCT05287633|ACTIVE_COMPARATOR|A : Proton Pump Inhibitors|Patients are given proton pump inhibitors tablets once a day
61988788|NCT05287633|PLACEBO_COMPARATOR|B: Placebo|Patients are given a placebo instead of proton pump inhibitors active drug
61988789|NCT00177970|ACTIVE_COMPARATOR|IVIG|
61988790|NCT00177970|PLACEBO_COMPARATOR|Placebo|
61988791|NCT06432179||hospice volunteer|Pathways to hospice volunteering: a grounded theory study
61988792|NCT01147861|PLACEBO_COMPARATOR|Placebo|Subjects will receive 2 placebo tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
61988793|NCT01147861|OTHER|5mg BID|Subjects will receive 1 x 5mg tablet and 1 placebo tablet in the morning, and 1 x 5mg tablet and 1 placebo tablet in the evening on Day 1 and Day 2.
61988794|NCT01147861|OTHER|10mg QD|Subjects will receive 2 x 5mg tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
62168229|NCT01378533|EXPERIMENTAL|chemotherapy:PC|PTX（Paclitaxel） CBP（carboplatin）
62168230|NCT00306735|EXPERIMENTAL|Palonosetron|
62764637|NCT04276155|NO_INTERVENTION|Control|Acute Coranary Syndrome and de novo Atrial Fibrilation patients with standard management: DAPT in association with an anticoagulant treatment.
62764638|NCT02267304|EXPERIMENTAL|Morphine/placebo/naxolone|
62764639|NCT02267304|EXPERIMENTAL|Naxolone/morphine/placebo|
62764640|NCT02267304|EXPERIMENTAL|placebo/naxolone/morphine|
62764641|NCT03216759|NO_INTERVENTION|control group|Tourniquet would be tied to left upper limb of Patients who undergoing laparotomy for 30 minutes after the induction of anesthesia,but put no press on it. Other processes are consistent with conventional methods.
62764642|NCT03216759|EXPERIMENTAL|intervention|"1. After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning.~2. At the beginning of anesthesia induction, 3 μg / kg / h of dexmedetomidine was infused and adjusted to 0.3 ug / kg / h after 10 min of infusion until 30 minutes before the end of the procedure.~3. Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap."
62764643|NCT02035956|EXPERIMENTAL|IVAC MUTANOME RBL001/RBL002|All participants will be treated with the personalized IVAC MUTANOME vaccine with or without prior treatment with RBL001/RBL002 vaccine depending on expression of these two antigens. Vaccines will be administered intra-nodally.
62764644|NCT03571165|EXPERIMENTAL|Intervention|The intervention group received information on accessing My Tools 4 Care - In Care for 2 months.
62764645|NCT01032317|OTHER|Single-arm Study|This study was completed prior to the implementation of the requirement for specific identification of study arms. As the requirement was not made retroactive to completed studies, we believe this study to be exempt from the stipulation. Also, per PRS definition, since this is for a single-arm/feasibility study, the data elements are optional.
62764646|NCT05792592||Uncontrolled Severe asthmatics|Uncontrolled Severe asthmatics
62764647|NCT03700814|EXPERIMENTAL|Antibiotics group|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which will be injected 30 minutes prior to the incision during surgery.
62764648|NCT03700814|NO_INTERVENTION|No antibiotics group|Patients belonging to this group will not receive any systemic antibiotic during intraoperative or post-operative period.
61988795|NCT01147861|OTHER|25mg BID|Subjects will receive 1 x 25mg tablet and 1 placebo tablet in the morning, and 1 x 25mg tablet and 1 placebo tablet in the evening on Day 1 and Day 2.
61988796|NCT01147861|OTHER|50mg QD|Subjects will receive 2 x 25mg tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
62383766|NCT02668679|PLACEBO_COMPARATOR|Children and their parents without the presence of DD|No DD during the gastroscopy. The parents and the children will be given anxiety and satisfaction questionnaires. The children and parents will perform Pre-Pulse inhibition (PPI) test and GSR. In addition, stress hormones will be assessed (cortisol, epinephrine, and norepinephrine) and the following physical indices will be measured: blood pressure, pulse, saturation and body temperature. The amount of drugs given for deep sedation will be evaluated.
62383767|NCT05877495|EXPERIMENTAL|Nutrition Education Group|"The experimental group which is given the nutrition education about food security, safety and prevention food waste.~First of all, a data collection form will be applied to the participants. This form contains food insecurity experience scale, food consumption frequency form, determination of waste level form, safety knowledge, attitudes and behaviors. The they will receive a 14-session training created by the researchers by examining the literature and various guides. This training includes about, prevention food waste with kitchen activities, food safety, food security and waste control. After this education participants will be answered the same questions again."
62383768|NCT05877495|NO_INTERVENTION|Control Group|"The control group will be asked the same data collection form with no intervention.~After the post-tests the control group will be given the same education."
62764649|NCT02644356|EXPERIMENTAL|Online CE/CME course|Participant in taking the three course modules and completing pre- and post-course data collection.
62764650|NCT02032342|ACTIVE_COMPARATOR|Fuji Uni-blocker|Fuji Uni-blocker for selective lobar deflation
61988797|NCT00005828|EXPERIMENTAL|green tea extract|Patients receive oral green tea extract six times daily for 4 months. Patients with a 50% decline in PSA, complete or partial response, or stable disease after 4 months continue treatment in the absence of disease progression or unacceptable toxicity. Patients with disease progression after 4 months receive no further treatment. Patients are followed every 3 months for 5 years or until disease progression. If disease progression, patients are followed every 6 months for 5 years.
62168231|NCT00911183|EXPERIMENTAL|Arm I (R-COP regimen)|Patients receive rituximab IV, cyclophosphamide IV, and vincristine sulfate IV on day 1. Patients also receive oral prednisone on days 1-5 and filgrastim subcutaneously (SC) on days 8-14 or pegfilgrastim SC on day 2. Treatment repeats every 21 days for at least 3 courses.
62764651|NCT02032342|ACTIVE_COMPARATOR|Cohen blocker|Cohen blocker for selective lobar deflation
62764652|NCT02032342|ACTIVE_COMPARATOR|Arndt® blocker|Arndt® blocker for selective lobar deflation
62168232|NCT00911183|EXPERIMENTAL|Arm II (R-COPY regimen)|Patients receive rituximab, cyclophosphamide, vincristine sulfate, prednisone, and filgrastim or pegfilgrastim as in arm I. Patients also receive liposome-encapsulated doxorubicin citrate IV on day 1. Treatment repeats every 21 days for at least 3 courses.
62383769|NCT02367157|EXPERIMENTAL|Experimental: Kinesio taping|Epicondilar and epitroclear muscle Kinesio Taping with a Space Correction on the wrist according Kenzo Kase Method
62383770|NCT02367157|NO_INTERVENTION|No intervention: Control|
62383771|NCT03800758|EXPERIMENTAL|Expressive Helping writing|"Writing sessions 1-3: Participants complete one 20-minute expressive writing session at three time points: 1) after hospitalization but prior to transplant infusion, (2) approximately 3 days after hospital discharge, and (3) approximately 2 weeks after completion of writing session 2.~Writing session 4: One 20-40 minute peer support writing session about 1 week after completion of writing session 3."
62383772|NCT03800758|ACTIVE_COMPARATOR|Factual Writing|"Writing sessions 1-3: Participants complete one 20-minute factual session at three time points: 1) after hospitalization but prior to transplant infusion, (2) approximately 3 days after hospital discharge, and (3) approximately 2 weeks after completion of writing session 2.~Writing session 4: One 20-40 minute factual writing session about 1 week after completion of writing session 3."
62383773|NCT03378284|EXPERIMENTAL|Tegoprazan(Test drug)|Tegoprazan drug QD for 7 days
62383774|NCT03378284|ACTIVE_COMPARATOR|Active comparator drug|Active comparator drug QD for 7 days
62383775|NCT02205177|ACTIVE_COMPARATOR|Face-to-Face w/ Anxiety Coach (FTF-AC)|In this condition therapists will provide 6 to 12 50-minute, face-to-face therapy sessions using Anxiety Coach. The sessions are expected to initially occur weekly and be within the office although the therapist can leave the office to conduct exposure. The therapist is expected to utilize Anxiety Coach within the session, encourage the patient to use the application to complete homework, and review progress in-session via the web-based portal.
62383776|NCT02205177|EXPERIMENTAL|Minimal Contact w/ Anxiety Coach (MC-AC)|In this condition the therapist will meet with the patient and primary care giver for an initial 50-minute, face-to-face session to provide a tutorial on the use of Anxiety Coach. The therapist is expected to review the patient's progress via the web-based portal and communicate with the patient electronically at least once per week for a total of at least 6 and up to 12 weeks of intervention. Therapists will be allowed 2 additional face-to-face sessions if necessary and still remain in protocol.
62383777|NCT01181336|EXPERIMENTAL|Group 2|"FLU-v Low Dose with adjuvant. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.~10 subjects."
62383778|NCT01181336|EXPERIMENTAL|Group 3|"FLU-v High Dose with water for injection. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.~10 subjects."
62383779|NCT01181336|EXPERIMENTAL|Group 4|High Dose FLU-v with adjuvant FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection. 10 subjects
62383780|NCT01181336|EXPERIMENTAL|Group 1|FLU-v Low Dose with water for injection FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection 10 subjects
62383781|NCT01181336|PLACEBO_COMPARATOR|Control Group|Placebo with adjuvant (4 subjects) or Placebo without adjuvant (4 subjects)
62383782|NCT05520489|ACTIVE_COMPARATOR|treatment as usual, physiotherapy|Exercises were performed by using different objects for task orientated movements. The therapist provided assistance as needed and encouraged participants to complete the tasks. Training was divided to 3 sessions for fine motor training and complex training and 1 session for shoulder girdle and complex training per week for 3 weeks, in addition to usual care. Each session lasts 1 hour and estimated time is 2-5 min to each exercise section
62383783|NCT05520489|ACTIVE_COMPARATOR|Transcranial magnetic stimulation|"Participants received 15 sessions (15 daily session - Monday to Friday) of active rTMS over the 'hotspot M1 area of the unaffected hemisphere leading to a response in the contralateral thenar muscle using Visor2-navigation system and MagstimRapid -magnetic stimulator. Low frequency rTMS was applied at 80-90% resting motor threshold (rMT) intensity, 1 Hz, 600+600 pulses, inbetween 10 minutes break. Intensity was increased after each 2-3 treatment to keep motor threshold 90%."
62764653|NCT02032342|PLACEBO_COMPARATOR|Endobronchial double lumen tube|Endobronchial double lumen tube for one lung ventilation
62764654|NCT02713529|EXPERIMENTAL|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
62764655|NCT03132025|EXPERIMENTAL|"A: apatinib and capecitabine"|"Arm A: apatinib and capecitabine apatinib 250mg qdpo; capecitabine 1000mg/m2 qdpo d1-14 q3w"
62764656|NCT03132025|ACTIVE_COMPARATOR|"B: capecitabine single drug"|"Arm B: capecitabine single drug capecitabine 1000mg/m2 qdpo d1-14 q3w"
62764657|NCT05453994||Non-bismuth group|Tegoprazan 50 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid for 14 days
62764658|NCT05453994||Bismuth group|Tegoprazan 50 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid, tripotassium dicitrate bismuthate (DENOL) 300 mg bid for 14 days
62764659|NCT05792267|EXPERIMENTAL|AI-assisted group|Subjects will undergo EUS examination with the assistance of artificial intelligence(AI) system.
62764660|NCT05792267|NO_INTERVENTION|Non-assisted group|Subjects will undergo EUS examination without the assistance of artificial intelligence(AI) system.
62764661|NCT01735071|EXPERIMENTAL|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
62764662|NCT01735071|EXPERIMENTAL|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1-6, bevacizumab given as 1 hour infusion will be followed by carboplatin area under curve 4 (AUC 4) and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
62764663|NCT04625868|EXPERIMENTAL|Soft tissue surgery - preoperative video|Patients \> 18 years old undergoing elective hand surgery (soft tissue) for which the surgeon is planning to prescribe opioids for postoperative pain control.
62764664|NCT04625868|NO_INTERVENTION|Soft tissue surgery - no video|Patients \> 18 years old undergoing elective hand surgery (soft tissue) for which the surgeon is planning to prescribe opioids for postoperative pain control.
62764665|NCT04625868|EXPERIMENTAL|Bone/joint surgery - preoperative video|Patients \> 18 years old undergoing elective hand surgery (bone/joint) for which the surgeon is planning to prescribe opioids for postoperative pain control.
62764666|NCT04625868|NO_INTERVENTION|Bone/joint surgery - no video|Patients \> 18 years old undergoing elective hand surgery (bone/joint) for which the surgeon is planning to prescribe opioids for postoperative pain control.
62764667|NCT02166645|EXPERIMENTAL|Prone position|Prone position per 48 hours after extubation
62764668|NCT02166645|ACTIVE_COMPARATOR|Supine position|Supine position per 48 hours after extubation
62764669|NCT00913393|PLACEBO_COMPARATOR|1|Placebo IV
62764670|NCT00913393|EXPERIMENTAL|2|3 mg/kg FG-3019 IV
62764671|NCT00913393|EXPERIMENTAL|3|10 mg/kg FG-3019 IV
62764672|NCT05788315|EXPERIMENTAL|Cultural Formulation Interview|The 16 semi-structured questions of the CFI cover the cultural definition of the problem, cultural perception of its cause, context and support, cultural aspects of coping, and past and present help-seeking behavior. The CFI informant version consists of 17 questions about the same themes. The CFI aims to bridge cultural differences by explicitly asking about the client's cultural background and its influence on the presented problems
62764673|NCT05788315|ACTIVE_COMPARATOR|Standard Care|Standard intake and care
62764674|NCT03894384||Group:1|Gastric cancer patients
62764675|NCT03894384||Group:2|Patients with benign gastric diseases
62383784|NCT05520489|ACTIVE_COMPARATOR|robot assisted training|"This was delivered using the Diego and Pablo (Tyromotion GmBH) robotic gym system. Participants receive robot-assisted training for up to 60 min per day, four days per week for 3 weeks, in addition to usual care. Robotic devices enable 3D interactive exercising, using weight reducing system in Diego and fine motor training in Pablo. Exercises can be one- or two-handed and/or symmetrical. Patient performs 150-400 repetitions in one therapy session. Estimated time is 2-3 minutes per one exercise section. Standard minimum program includes 4 games: swimming, shooting, ship and apple orchard. The therapist instructs the patient and assure the position of trunk and shoulder girdle."
62383785|NCT00072098|EXPERIMENTAL|Experimental Group|Direct intratumoral injection of metastatic hepatic tumors using an adenoviral vector expressing the human recombinant interleukin-12 gene
62383786|NCT03830463|EXPERIMENTAL|CTP-692|
62383787|NCT03830463|PLACEBO_COMPARATOR|Placebo|
62764676|NCT05691023||Vivistim|All subjects will be commercially implanted with the Vivistim System® after an ischemic stroke prior to Study treatment.
62764677|NCT06446908|EXPERIMENTAL|Coaching Intervention|"This study is an open-label, mono-centred, single-case experimental design with multiple base levels. The study will comprise 3 phases, alternating periods of observation (A) and 1 period of counselling (B) with an A1-B-A2 design.~PA will be assessed continuously using an accelerometer for 7 to 14 days per (A) phase. During phase (B), participants will receive the intervention, i.e. 6 x 45-minute, real-time, face-to-face, virtual sessions with a PA counsellor."
62383788|NCT00005838|EXPERIMENTAL|Arm I (shark cartilage extract AE-941)|"Patients receive oral AE-941 (Neovastat) twice daily beginning on day 1 or within 10 days of initiation of chemotherapy.~All patients receive induction chemotherapy with 1 of the following platinum-based regimens: cisplatin IV on days 1, 22, 50, and 71 and vinorelbine IV on days 1, 8, 22, 29, 50, 57, 71, and 78 carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on days 1, 22, 50, 57, 64, 71, 78, and 85.~All patients receive radiotherapy beginning on day 50 for 6 weeks. Treatment in both arms continues in the absence of unacceptable toxicity."
62764678|NCT05586698|EXPERIMENTAL|Group A|57 participant received auricular acupressure at Zero point on the left ear. Heart rate, HRV, and elements of HRV will be recorded every 5 minutes.
62764679|NCT05586698|EXPERIMENTAL|Group B|57 participant received sham acupressure at Zero point on the left ear. Heart rate, HRV, and elements of HRV will be recorded every 5 minutes.
62764680|NCT02662114||Tresiba®|
62764681|NCT03493789|EXPERIMENTAL|Diagnostic (FDG-PET, SBRT)|Participants receive fludeoxyglucose F-18 IV and after 60 minutes undergo positron emission tomography (PET) within 4 weeks of the first planned stereotactic body radiation therapy (SBRT) fraction, prior to the second planned fraction, and prior to the fifth planned fraction.
62764682|NCT01529736|EXPERIMENTAL|High torque insertion|High torque insertion
62764683|NCT01529736|ACTIVE_COMPARATOR|Low torque insertion|Low torque insertion
62764684|NCT01403376|EXPERIMENTAL|Teriflunomide 7 mg|Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months
62764685|NCT01403376|EXPERIMENTAL|Teriflunomide 14 mg|Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months
62764686|NCT01403376|ACTIVE_COMPARATOR|IFN-β-1|Influenza vaccine in participants treated with a stable dose of Interferon-β-1 (IFN-β-1) for at least 6 months
62764687|NCT00690807|EXPERIMENTAL|1|PH-10 treatment
62764688|NCT06105658|EXPERIMENTAL|Chemotherapy+unrelated umbilical cord blood microtransplantation|"Intermittent infusion of HLA mismatched or incompletely matched granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (G-PBSC) during routine chemotherapy without the use of immunosuppressants, abbreviated as microtransplantation."
62764689|NCT05017129|EXPERIMENTAL|Inmates Care modules|This is a within-subjects, pre-post design with a single intervention. The intervention is a 6 module computer-based learning program for training peer caregivers in end-of-life care.
62764690|NCT04695028||Persons with crystal related arthropathies|
62383789|NCT00005838|PLACEBO_COMPARATOR|Arm II (placebo)|"Patients receive oral placebo twice daily beginning on day 1 or within 10 days of initiation of chemotherapy.~All patients receive induction chemotherapy with 1 of the following platinum-based regimens: cisplatin IV on days 1, 22, 50, and 71 and vinorelbine IV on days 1, 8, 22, 29, 50, 57, 71, and 78 carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on days 1, 22, 50, 57, 64, 71, 78, and 85.~All patients receive radiotherapy beginning on day 50 for 6 weeks. Treatment in both arms continues in the absence of unacceptable toxicity."
62383790|NCT00562081|PLACEBO_COMPARATOR|1|Patient does not have 24/7 access to a Certified Asthma Educator.
62383791|NCT00562081|ACTIVE_COMPARATOR|2|Patient has 24/7 access to a Certified Asthma Educator.
62383792|NCT04501419|EXPERIMENTAL|Trained radiologists|Trainers will successfully train Nigerian radiologists
62383793|NCT04501419|EXPERIMENTAL|Patients with a suspicious breast mass|Women that present to the hospital with a suspicious breast mass
62764691|NCT03381313|EXPERIMENTAL|Anomic Patients|Pure Anomic Patients underwent to conditioned word repetition training or traditional one.
62383794|NCT05743439|EXPERIMENTAL|Early Augmentative and Alternative Communication (AAC) Intervention|After a period of stable baseline performance (3 to 5 sessions) on parent and child outcomes, the interventionist will apply the early AAC intervention.
62764692|NCT01838785|EXPERIMENTAL|18F-DTBZ AV-133|18F-DTBZ AV-133 imaging
62764693|NCT06001528||Discovering cohort|Discovering cohort was used for the discovery and screening of metabolic differences. Two groups were included-SLN+ group and SLN- group, meaning the breast cancer patients with/without sentinel lymph node metastasis respectively. Abundance and distribution of serum and tissue metabolites in this cohort of patients would be observed.
62383795|NCT00859144|EXPERIMENTAL|BART|Participants will complete the Becoming a Responsible Teen (BART) program.
62764694|NCT06001528||Modeling cohort|Modeling cohort refer to the cohort of patients included for targeted metabolites detection. Two groups were included-SLN+ group and SLN- group. Abundance and distribution of targeted metabolites in this cohort of patients would be detected, and a predictive model would be established using the data of this cohort.
62764695|NCT06001528||Validation cohort|Validation cohort means a cohort of patients included to validate the prediction model established in the modeling stage. Patients of validation cohort will be enrolled from several different hospitals. Also, it included SLN+ group and SLN- group. Abundance and distribution of targeted metabolites in this cohort of patients would be detected, and the accuracy and stability of prediction model will be verified in this cohort.
62764696|NCT06054854||Patients with lung nodule or lung cancer|Patients suspected of or suffering from early stage (supracentimetric nodule) or advanced thoracic cancer
62383796|NCT00859144|EXPERIMENTAL|Reducing the Risk|Participants will complete the Reducing the Risk program.
62383797|NCT00859144|ACTIVE_COMPARATOR|Be Proud Be Responsible|Participants will complete the Be Proud! Be Responsible! program.
62383798|NCT02487901|ACTIVE_COMPARATOR|Ultrasonic osteotome|making gutter on the hinge side of lamina with ultrasonic osteotome
62383799|NCT02487901|SHAM_COMPARATOR|Drill|making gutter on the hinge side of lamina with conventional drill
62383800|NCT06172829||At least 3 subjects shall be <1,000g in weight|
62383801|NCT06172829||At least 3 subjects shall be 1,000g to 2,000g in weight|
62764697|NCT01340781||Hospitalized medical patients|"Adult age 18-65 years old admitted to the general medical floors at MetroHealth Medical Center who are expected to stay a minimum of 48 hours.~Potential subjects cannot have a known diagnosis of OSA, a tracheostomy, respiratory failure requiring noninvasive ventilation, currently pre or post surgical intervention, or clinically unstable patients with plans for transfer to a higher acuity of care or transferred from intensive care."
62764698|NCT02241187|EXPERIMENTAL|PEGPH20 And Cetuximab|5 participants will undergo DW- \& DCE-MRI for sequence parameter optimization. The 1st stage of the study, patients (n = 5) will have the option to undergo (DW-) \& (DCE)-MRI for repeatability investigation \& T1 mapping. Optional DW- \& DCE-MRI will be repeated 2 to 5 days later, followed shortly by administration of 1 intravenous dose of cetuximab at 250 mg/m2/60 min. Pancreatic tumor resection will be performed 1 to 2 days later.Blood samples will be drawn at various time points. The resected tumor specimen will be studied. If deemed safe, we will proceed to the second stage of the study. Patients (n = 5) will have the option to undergo DW- \& DCE-MRI. 1 to 3 days later, patients will receive 1 IV dose of PEGPH20 at 3 μg/kg/10 min. Optional DW- \& DCE-MRI will be repeated 1 to 2 days after PEGPH20 administration, followed on that day by administration of 1 IV dose of cetuximab at 250 mg/m2/60 min. Pancreatic tumor resection will be performed 1 to 2 days later.
62764699|NCT01881022|EXPERIMENTAL|Psychosexual Intervention|The intervention will consist of 6 weekly sessions of couples psychosexual counseling delivered via videoconferencing.
62764700|NCT05207969|NO_INTERVENTION|Control Arm|Cystoscopy procedure will be done based on cystoscopy protocol. During scope procedure patient will not giving instruction to urinate during the procedure.
62764701|NCT05207969|EXPERIMENTAL|Experimental Arm|Cystoscopy procedure will be done based on cystoscopy protocol. During scope procedure, patient will be ask to urinate and this will lead to contraction of urinary bladder and relaxation of external urethral sphincter. Scope will then pass through external urethral sphinter and go to the urinary bladder
62764702|NCT03558074|EXPERIMENTAL|Active|ALK4290 800 mg daily
62764703|NCT00568477|EXPERIMENTAL|Arm 1|Treatment with rituximab
62764704|NCT00568477|NO_INTERVENTION|Arm 2|Treatment without rituximab
62764705|NCT05957029|EXPERIMENTAL|Nuera Tight RF System|Subjects will receive an RF treatment session on the periorbital area and cheeks with a frequency of 1 and 4 MHz. Each subject will be treated on one side of the face using a 10 mm capacitive electrode, and on the other side using a 20 mm capacitive electrode. The target temperature will be set at 42 C.
62764706|NCT04172961|EXPERIMENTAL|Nanomicellular Cyclosporine 0.09 prior to surgery|50 subjects receive nanomicellular cyclosporien 0.09% prior to elective ophthalmic surgery
62764707|NCT04172961|ACTIVE_COMPARATOR|Lifitegrast 5.0%|50 subjects receive liftigrast 5.0% prior to elective ophthalmic surgery
62764708|NCT02534116|EXPERIMENTAL|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will have incisional vacuum-assisted closure (VAC) therapy performed.
62764709|NCT02534116|ACTIVE_COMPARATOR|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision.
62764710|NCT02374658|EXPERIMENTAL|Arts Intervention|This group will receive the weekly one-hour Living Through the Arts program in addition to their standard program of rehabilitation activities
62764711|NCT02374658|NO_INTERVENTION|Control Group|This group of patients will only receive their standard program of rehabilitation activities
62764712|NCT01151761|EXPERIMENTAL|SBRT, Chemo and Liver Transplantation|The patients received Stereotactic Body Radiotherapy and Chemotherapy followed by a liver transplantation. The chemo could be any combination of the following: Gemcitabine, Cisplatin, Carboplatin, Capecitabine and 5FU
62764713|NCT06233864|EXPERIMENTAL|Disitamab Vedotin combined with Gemcitabine，2L|Disitamab Vedotin 2.5 mg/kg，iv，Q3W; Gemcitabine 1g/m2，iv，d1, d8 Q3W; Disitamab Vedotin+Gemcitabine is used as second-line treatment for HER2-expressive patients who have failed first-line gemcitabine-free regimen or are intolerant to gemcitabine-containing regimen.
62764714|NCT06233864|EXPERIMENTAL|Disitamab Vedotin，3L|Disitamab Vedotin 2.5 mg/kg，iv，Q3W; Disitamab Vedotin in HER2-expressive patients who have failed at second-line standard treatment or are intolerant
62764715|NCT00186537|ACTIVE_COMPARATOR|fenofibrate|160 mg daily for 12 weeks
62764716|NCT00186537|ACTIVE_COMPARATOR|rosiglitazone|4 mg/daily 4 weeks followed by 4 mg 2 x daily for 8 weeks
62764717|NCT00186537|ACTIVE_COMPARATOR|calorie restricted diet|calorie restricted to achieve 0.5 kg weight loss/week x 12 weeks
62383802|NCT06172829||At least 3 subjects shall be >2,000g|
62383803|NCT06172829||At least 3 subjects shall be >/= 29 days and < 1 year of age|
62383804|NCT06172829||At least 3 subjects shall be >/= 1 year and <3 years of age|
62764718|NCT04448015|EXPERIMENTAL|Enhanced Perinatal Care|Pregnant women enrolled in the study will receive enhanced perinatal care from community healthcare providers that have participated in the perinatal OUD education curriculum.
62764719|NCT03097575|EXPERIMENTAL|ICG Intervention|The intervention to be administered is the indocyanine green for NIR Lymphatic Mapping. All study subjects will receive this same intervention; there is only one arm.
62764720|NCT04593459|EXPERIMENTAL|Probiotic|"Probiotic product consisting of these 7 bacterial strains:~* Lactobacillus salivarius W57~* Lactobacillus casei W56~* Lactobacillus rhamnosus W71~* Lactococcus lactis W58~* Enterococcus faecium W54~* Lactobacillus plantarum W62~* Lactobacillus acidophilus W22~Additional ingredients: Corn starch, maltodextrin, fructo-oligosaccharides, galacto-oligosaccharides, polydextrose, plant proteins, potassium chloride, magnesium sulfate, bacterial strains, manganese sulfate, lactose, 2000 IU vitamin D~Participants ingest one sachet of powder (5 grams) in 200 ml of water per day for 6 months"
62764721|NCT04593459|PLACEBO_COMPARATOR|Placebo|"Similar to probiotic product in optics and smell, less ingredients and no bacterial strains or vitamin D~Ingredients: Corn starch, maltodextrin, potassium chloride, magnesium sulphate, manganese sulphate"
62764722|NCT04593459|ACTIVE_COMPARATOR|Metformin|"Metformin is an established drug for treating PCOS-related symptoms. The investigators are comparing the probiotic not only to a placebo group, but also to the benchmark treatment.~Participants in the metformin arm will start treatment with 500 mg daily for the first week, then increasing the dose to 2x500 mg daily for the duration of the intervention."
62764723|NCT00621829|ACTIVE_COMPARATOR|1|"High susceptibility ALOX5 gene polymorphisms. Patients will be classified as having high susceptibility ALOX5 gene polymorphisms based on the number of repeats of the SP1 promoter."
62764724|NCT00621829|ACTIVE_COMPARATOR|2|"Low susceptibility ALOX5 gene polymorphisms. Low susceptibility ALOX5 gene polymorphisms. Patients will be classified as having high susceptibility ALOX5 gene polymorphisms based on the number of repeats of the SP1 promoter."
62764725|NCT02177513|ACTIVE_COMPARATOR|1|
62764726|NCT02177513|ACTIVE_COMPARATOR|2|
62764727|NCT02177513|ACTIVE_COMPARATOR|3|
62764728|NCT02177513|PLACEBO_COMPARATOR|4|
62764729|NCT02177513|ACTIVE_COMPARATOR|5|
61988798|NCT01505608|ACTIVE_COMPARATOR|Arm A- Temozolomide and Irinotecan|"1. Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle.~2. Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.~Patients who show progression on the I+TMZ arm may crossover to the I+TMZ+TPI 287 arm at anytime during cycles 1 to 6. If there is evidence of progression after completion of the I+TMZ arm (after completion of cycle 6) then the patient will have been considered to have completed therapy and is not eligible for the crossover."
62764730|NCT05479123|EXPERIMENTAL|ter in die (TID)three times a day|
62764731|NCT05479123|EXPERIMENTAL|bis in die (BID)twice a day|
62764732|NCT05479123|ACTIVE_COMPARATOR|Control|
62764733|NCT06486272|EXPERIMENTAL|Financial Navigator Intervention|
61988799|NCT01505608|EXPERIMENTAL|Arm B- Temozolomide/Irinotecan + TPI 287|"Cycle 1 to 6: Irinotecan and Temozolomide in combination with TPI 287~1. Intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.~2. Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle.~3. Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle."
61988800|NCT00745992||Fungal infections|"1. Patients with invasive fungal infections; and~2. Patients who receive PO or IV voriconazole for more than 3 days"
61988801|NCT01483079||Former preterm infants|A cohort of infants less than or equal to 1250 grams birth weight that received donor human milk products in the NICU will be recruited and followed. Some infants recruited will be from a previously studied population of very low birth weight infants receiving donor human milk products in the NICU at Texas Children's Hospital.
61988802|NCT01623323|OTHER|Fluticasone|
61988803|NCT02356692|EXPERIMENTAL|enfilcon A|participants randomized to wear the Enfilcon A (test) lens in one eye and Senofilcon A (control) lens in the other eye.
61988804|NCT02356692|ACTIVE_COMPARATOR|senofilcon A|participants randomized to wear the Enfilcon A (test) lens in one eye and Senofilcon A (control) lens in the other eye.
61988805|NCT01544751|ACTIVE_COMPARATOR|Low dose Metformin|500 mg twice a day for one year
61988806|NCT01544751|ACTIVE_COMPARATOR|Metformin|1000 mg twice a day for one year
61988807|NCT01544751|ACTIVE_COMPARATOR|Atorvastatin|20 mg day
62764734|NCT05154604|EXPERIMENTAL|Treatment group: SHR-A1921|
62764735|NCT03777124|EXPERIMENTAL|SHR-1210 +apatinib|subject will receive SHR-1210 200mg every 2 weeks, apatinib 250mg every day
62764736|NCT03777124|ACTIVE_COMPARATOR|chemotherapy|Pemetrexed 500mg/m2, Day 1 of each 21 day, 4 cycles carboplatin AUC 5 on Day 1 of each 21 day, 4 cycles followed by pemetrexed 500mg/m2 until progression Q3W
62764737|NCT03432416|EXPERIMENTAL|Regimen 1: Continuous Usage|Contraceptive vaginal ring delivering a daily dose of Nestorone® and estradiol (NES-E2 CVR) worn continuously for 91 days.
62764738|NCT03432416|EXPERIMENTAL|Regimen 2: Cyclical Usage|Contraceptive vaginal ring delivering a daily dose of Nestorone® and estradiol (NES-E2 CVR) worn for 91 days, but is removed for 2 days each month (days 29-30, 59-60, and 90-91).
62764739|NCT02495688|EXPERIMENTAL|Regional anesthesia|Patients are anesthezised with local aneshtetics administered with ultrasound guidance in the nerval plexus of the arm.
62764740|NCT02495688|ACTIVE_COMPARATOR|General anesthesia|Patients are anesthezised with general anesthesia and orotrachial airway. Local anesthetics (Chirocaine 5 mg/ml, 10 ml) is administered in the surgical wound during surgery.
62764741|NCT03494218|EXPERIMENTAL|vegetative state|patients with vegetative state lack awareness of self and environment even in the presence for eye-opening and sleep-wake cycles using CRS-R. The nailbed pressure was applied for 5 seconds and ended as soon as the behavioral response were captured. The raters recorded patients' behavioral responses using Nociception Coma Scale (NCS) during 10 seconds after each noxious stimulus.
62764742|NCT03494218|EXPERIMENTAL|minimally conscious state|Patients with minimally conscious state display inconsistent, but reproducible and discernible signs of awareness using CRS-R. The nailbed pressure was applied for 5 seconds and ended as soon as the behavioral response were captured. The raters recorded patients' behavioral responses using Nociception Coma Scale (NCS) during 10 seconds after each noxious stimulus.
62764743|NCT02809053|EXPERIMENTAL|SAIT101|
62764744|NCT02809053|ACTIVE_COMPARATOR|MabThera®|
62764745|NCT02593708|EXPERIMENTAL|Cohort 0|"1. Neratinib: 80 mg, daily, oral~2. Paclitaxel: 80 mg/m2, weekly, intravenously~3. Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~4. Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
62764746|NCT02593708|EXPERIMENTAL|Cohort 1|"1. Neratinib: 120 mg, daily, oral~2. Paclitaxel: 80 mg/m2, weekly, intravenously~3. Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~4. Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
61988808|NCT06449963|EXPERIMENTAL|Health Belief Model Education Group|"Participants in this arm will receive a structured educational program aimed at increasing their daily water intake. The program is based on the principles of the Health Belief Model (HBM) and includes the following components:~Educational Sessions: Weekly group sessions led by trained health educators, focusing on the importance of hydration, the benefits of adequate water intake, and strategies to incorporate more water into daily routines.~Behavioral Strategies: Practical tips and techniques to overcome barriers to water intake, such as setting daily water goals, using water bottles, and incorporating water-rich foods into the diet.~Personalized Feedback: Individualized feedback and support provided through weekly one-on-one meetings with a health coach to track progress and address any challenges.~Educational Materials: Distribution of printed and digital materials, including pamphlets and interactive tools, to reinforce learning and support behavior change."
62383805|NCT06435455|EXPERIMENTAL|"GH21 + D-1553 Group"|GH21 capsules combined with D-1553 tablets were administrated orally
62383806|NCT00564135|EXPERIMENTAL|A B C|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
62383807|NCT01264562||Chemotherapy group|Breast cancer patients treated with chemotherapy
62383808|NCT01264562||Non-chemotherapy group|Breast cancer patients not treated with chemotherapy
62764747|NCT02593708|EXPERIMENTAL|Cohort 2|"1. Neratinib: 160 mg, daily, oral~2. Paclitaxel: 80 mg/m2, weekly, intravenously~3. Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~4. Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
62383809|NCT01264562||Healthy controls|Women without a cancer diagnosis, matched for age and education
62383810|NCT02603380||Clinical staff|Clinicians in the Royal Infirmary of Edinburgh.
62383811|NCT02603380||Patients|Patients in intensive care units and general wards in the Royal Infirmary of Edinburgh.
62383812|NCT06085768|EXPERIMENTAL|VRE intervention group|"The intervention group will receive 2 VR exposure interventions, once a week, and each intervention will experience 2 complete flight processes for about 90 minutes each time. A complete flight process includes: (1) waiting for the airport bus at the station, (2) check-in, security check, waiting, and boarding at the airport, (3) taxiing, taking off, cruising, landing, and leaving the aircraft during flight. Among them, the flight process requires the participant to sit on the flight seat, which takes about 24 minutes each time.~A scale assessment and skin electrode and heart rate data collection will be conducted before and after each intervention. The participants' skin electrode and heart rate data will also be collected during the intervention. They will be followed up in the 2nd week after the intervention. Follow-up content includes scale evaluation and safety evaluation."
62383813|NCT06085768|NO_INTERVENTION|wait-list control group|The control group will receive scale assessments in weeks 1, 2, and 4, and after the waiting period, receive the same VR exposure intervention once a week for 2 weeks as the intervention group.
62383814|NCT02912793|ACTIVE_COMPARATOR|Hydroxypropyl-beta-cyclodextrin IV 1500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
62383815|NCT02912793|ACTIVE_COMPARATOR|Hydroxy-propyl-beta-cyclodextrin IV 2000 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
62383816|NCT02912793|ACTIVE_COMPARATOR|Hydroxypropyl-beta-cyclodextrin IV 2500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
62383817|NCT01625364|EXPERIMENTAL|Open Airways for Schools|OAS is a school-based non-academic asthma health education program for elementary students with asthma and their parents.
62383818|NCT01625364|EXPERIMENTAL|SHARP program|The Staying Health-Asthma Responsible \& Prepared (SHARP) program is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregiver.
62383819|NCT01888367|EXPERIMENTAL|DFA-02 Antibiotic Gel|Up to 20 mL of DFA-02 antibiotic gel will be placed in the surgical incision after closure of the fascia and before skin closure.
62383820|NCT01888367|PLACEBO_COMPARATOR|DFA-02 Placebo Gel|Up to 20 mL of DFA-02 placebo gel will be placed in the surgical incision after closure of the fascia and before skin closure.
62764748|NCT02593708|EXPERIMENTAL|Cohort 3|"1. Neratinib: 200 mg, daily, oral~2. Paclitaxel: 80 mg/m2, weekly, intravenously~3. Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~4. Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
62764749|NCT05729139|EXPERIMENTAL|Cemiplimab and Pegylated Interferon-alpha (PEG-IFN-alpha)|Cemiplimab administered at 350 mg intravenous (IV) every three weeks for up to 2 years. PEG-IFN-alpha administered subcutaneously weekly at doses of 45 mcg to 135 mcg for up to 1 year. Exact dosing will depend on when the participant is enrolled in the study and the number of serious adverse effects that have been encountered by previous participants, if any.
62383821|NCT01888367|NO_INTERVENTION|Standard of Care|Prior to final closure of the surgical incision, the incision will be irrigated with normal saline and no gel will be applied.
62383822|NCT05940051|EXPERIMENTAL|R/R Diffuse Large B-cell Lymphoma|
62383823|NCT00266695|EXPERIMENTAL|Ruboxistaurin|
62383824|NCT01957111||Individuals with insomnia|
62383825|NCT01957111||Good sleepers|
62383826|NCT03943394||Denovo MDS/ AML|"Patients with de-novo myeloid neoplasm either myelodysplastic syndrome and/ or acute myeloid leukemia which are diagnosed by complete blood count , blood film, bone marrow aspirate, bone marrow biopsy , immunophenotyping and bone marrow biopsy with these inclusion criteria • Myelodysplastic syndromes: the diagnosis of MDS must be confirmed by a bone marrow aspirate and/or biopsy : blast count must be \< 20%;~• Acute myeloid leukemia with multilineage dysplasia: the diagnosis of AML-TLD must be confirmed by a bone marrow aspirate and/or biopsy NOTE: there must be evidence of \>= 20% blasts on the review of the bone marrow aspirate and/or biopsy;"
62383827|NCT03943394||therapy related MDS/ AML|PCM1-JAK2 fusion gene detection in patients with therapy related Myelodysplastic syndrome / Acute myeloid leukemia patients
62383828|NCT02363244||Pap group|Per speculum examination will be done.Pap test will be collected for the women as per allotement.A via (visual inspection with acedic acid)test will be done.A repeat cervical cell for pap test will be collected and send to laboratory for further evaluation.
62764750|NCT01740544|EXPERIMENTAL|Cathodal tDCS in young study participants|Cathodal tDCS in young study participants
62764751|NCT01740544|EXPERIMENTAL|Cathodal tDCS in elderly study participants|Cathodal tDCS in elderly study participants
62764752|NCT01740544|SHAM_COMPARATOR|Sham tDCS in young study participants|Sham tDCS in young study participants
62764753|NCT01740544|SHAM_COMPARATOR|Sham tDCS in elderly study participants|Sham tDCS in elderly study participants
62764754|NCT05714943|EXPERIMENTAL|Educational website intervention|Participants will have access to an intervention between pre-test and post-test assessments. The intervention, DigiKnowIt News: Teen, is an educational website designed to teach youth (12-17 years) about pediatric clinical trials and give parents and youth resources for communication and shared decision-making about research.
62764755|NCT05714943|NO_INTERVENTION|Wait-List Control|Participants will not have access to the educational website between the pre-test and post-test assessments. After completing the post-test questionnaires, participants in the wait-list control group will receive access to the intervention (DigiKnowIt News: Teen).
62764756|NCT05455008|EXPERIMENTAL|Remotely-delivered health coaching intervention|Single-arm remotely-delivered health coaching intervention to increase physical activity and reduce sedentary behavior during pregnancy, consisting of 12 health coaching sessions.
62764757|NCT04794660|ACTIVE_COMPARATOR|Arm 1|In this arm, HPV-positive women will undergo a Visual Inspection with Acetic Acid (VIA) triage test followed by biopsies. Treatment by thermal ablation (or cryotherapy in South Africa) will be applied to VIA positive women eligible for ablative treatment. Non eligible women will be referred to colposcopy.
62764758|NCT04794660|ACTIVE_COMPARATOR|Arm 2|In this arm, HPV positive women will get biopsies and receive an ablative treatment by thermal ablation (or cryotherapy in South Africa) if they are eligible to ablative treatment. Non eligible women will be referred to colposcopy
62764759|NCT03772418|PLACEBO_COMPARATOR|Cream base|A group of volunteers receiving placebo medications without natural extracts of ginkgo biloba and Pomegranate.
62764760|NCT03772418|ACTIVE_COMPARATOR|Pomegrante and Ginkgo biloba group|A group of volunteers with the aging state receiving natural extracts of ginkgo biloba and Pomegranate in different topical dosage forms.
62764761|NCT03654287||Treatment with CPFA|The critically ill children who treated by CRRT and CRRT mode is decide as CPFA.
62764762|NCT03654287||Treatment with TPE+CVVHDF|The critically ill children who treated by CRRT and CRRT mode is decide as TPE+CVVHDF.
62764763|NCT03654287||Treatment with CVVHDF|The critically ill children who treated by CRRT and CRRT mode is decide as CVVHDF.
62764764|NCT03654287||Treatment without CRRT/ECMO|The critically ill children who are not treated by CRRT or ECMO.
62764765|NCT03654287||Treatment with ECMO|The critically ill children who are treated by ECMO whether treated by CRRT
62764766|NCT04239300|EXPERIMENTAL|Main group|The participant in main group have water labour
62764767|NCT04239300|NO_INTERVENTION|Control group|The participant in control group will not have water labour
62764768|NCT01441375||Sickle cell patients non-transfused|
61988809|NCT06449963|NO_INTERVENTION|No Education Control Group|Participants in this arm will not receive any specific education or intervention and will follow their usual routines. This group will serve as a control to compare the effectiveness of the Health Belief Model-based education program administered to the intervention group. The daily water intake of participants in this group will be recorded using standardized intake diaries, and averages will be calculated weekly.
62383829|NCT02363244||HPVDNA GROUP|Per speculum examination will be done.HPVDNA test will be collected for the women as per allotement.A via (visual inspection with acedic acid)test will be done.A repeat cervical cell for HPVDNA will be collected and send to laboratory for further evaluation.
62383830|NCT02422537|ACTIVE_COMPARATOR|Unmodified wheat bran|One single dose om 20 g
62764769|NCT01441375||Sickle cell patients transfused with no ICT|
62764770|NCT01441375||Sickle cell patients transfused with ICT|
62764771|NCT05736939||Men with long COVID-19 syndrome|Patients were male adults (\>18 years), with persistent symptoms more than 3 months since the acute phase of the COVID-19.
62764772|NCT05736939||Women with long COVID-19 syndrome|Patients were women adults (\>18 years), with persistent symptoms more than 3 months since the acute phase of the COVID-19.
62764773|NCT00993733|EXPERIMENTAL|CVVHDF on-line|CVVHDF using a central water treatment plant, providing dialysate directly to the patient. They will perform a continuous veno-venous haemodiafiltration.
62764774|NCT00993733|EXPERIMENTAL|classical CVVHDF|CVVHDF using a mobile generator with dialysate bags. They will perform a continuous veno-venous haemodiafiltration.
62764775|NCT05681260|EXPERIMENTAL|Standard risk Arm A|Any pediatric patients with newly diagnosed T-LBL Stage II to IV who achieve at least a PR at the end of Induction (EOI). Induction I followed by consolidation, Capizzi escalating methotrexate (interim maintenance) , delayed intensification and maintenance therapy. Triple intrathecal injections.
62383831|NCT02422537|ACTIVE_COMPARATOR|Wheat bran with reduced particle size|One single dose of 20 g
62383832|NCT02422537|ACTIVE_COMPARATOR|Destarched pericarp-enriched wheat bran|One single dose of 20 g
62383833|NCT02422537|OTHER|No bran-based dietary platform|No wheat bran fractions is administered
62383834|NCT04185792||Patients with spinal cord injury|NBSS, Qualiveen and SF-Qualiveen questionnaires will be administered to participants.
62383835|NCT04185792||Patients with multiple sclerosis|NBSS, Qualiveen and SF-Qualiveen questionnaires will be administered to participants.
62764776|NCT05681260|EXPERIMENTAL|Standard risk Arm B|Any pediatric patients with newly diagnosed T-LBL Stage II to IV who achieve at least a PR at the end of Induction (EOI). Induction I followed by consolidation, high dose methotrexate (interim maintenance) , delayed intensification and maintenance therapy. Triple intrathecal injections.
62764777|NCT05681260|EXPERIMENTAL|High Risk T-LBL|Any pediatric patients with newly diagnosed T-LBL Stage II to IV who fail to achieve at least a PR at the end of Induction (EOI). Induction I followed by 6 intensive polychemotherapy blocks (HR1'-HR2'-HR3'-HR1'-HR2'-HR3'), deIayed intensification, and maintenance therapy. Triple intrathecal injections.
62383836|NCT03919760||NAVIGATE EPI|"This group of first episode psychosis patients is receiving NAVIGATE early psychosis intervention (EPI) as their regular clinical standard of care.~The project team is implementing NAVIGATE at several early psychosis intervention (EPI) programs in different geographic regions of Ontario. The team will recruit consecutive referrals to these programs in order to determine longitudinal change in functioning and symptoms (hypothesis #3).~Additionally, the primary data collected for these patients will be linked deterministically to data sources held at the Institute for Clinical Evaluative Sciences (ICES) via their unique health card number. Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
62383837|NCT03919760||Non-NAVIGATE EPI|"This group of first episode psychosis patients received early psychosis intervention other than NAVIGATE as their regular clinical standard of care.~The data already collected for these patients (not as a part of study/recruitment) is held at the Institute for Clinical Evaluative Sciences (ICES). Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
62764778|NCT01522404|EXPERIMENTAL|Atomoxetine / Inactive Compound|Participants in this arm received atomoxetine, starting with 10 mg po daily and increasing weekly by increments to a maximum of 100 mg po daily or the maximum tolerated dose for up to weeks 29 and are then crossed over to Inactive compound group
61988810|NCT01464346|EXPERIMENTAL|Enlite sensor, Abdomen/Abdomen|Subjects wearing 2 Enlite sensors in Abdomen
61988811|NCT01464346|EXPERIMENTAL|Enlite sensor, Abdomen/Buttock|Subjects wearing 2 Enlite sensors in Abdomen/Buttock
61988812|NCT01464346|EXPERIMENTAL|Enlite sensor, Buttock/Buttock|Subjects wearing 2 Enlite sensors in Buttock/Buttock
62764779|NCT01522404|PLACEBO_COMPARATOR|Inactive compound / Atomoxetine|Subjects in this arm received a matching placebo that have inactive compound for up to weeks 29 and then are crossed over to receive active treatment of Atomoxetine
61988813|NCT04422028|EXPERIMENTAL|Desogestrel Test Product|Participants received two tablets of the test formulation containing Desogestrel 0.075 mg. The tablets were taken with water and in a fasting condition.
62383838|NCT03919760||Non-EPI|"This group of first episode psychosis patients did not receive early psychosis intervention as their regular clinical standard of care.~The data already collected for these patients (not as a part of study/recruitment) is held at the Institute for Clinical Evaluative Sciences (ICES). Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
62383839|NCT00784160|EXPERIMENTAL|1|Lactic Acid
62383840|NCT06037499|EXPERIMENTAL|Subject glucometer measurement|
62764780|NCT02570243|ACTIVE_COMPARATOR|Standard dose of Heparin|50IU/Kg heparin intravenously
61988814|NCT04422028|ACTIVE_COMPARATOR|Desogestrel Reference Product|Participants received two tablets of the marketed reference formulation containing Desogestrel 0.075 mg. The tablets were taken with water and in a fasting condition.
62383841|NCT01219166||laparoscopic Roux-en-Y-gastric-bypass without cholecystectomy|
62764781|NCT02570243|EXPERIMENTAL|High dose of Heparin|100IU/Kg heparin intravenously
61988815|NCT05749042|EXPERIMENTAL|Sintilimab+Cisplatin+Radiotherapy|
61988816|NCT05749042|ACTIVE_COMPARATOR|Cisplatin+Radiotherapy|
61988817|NCT01632202|ACTIVE_COMPARATOR|Seprafilm Slurry|The investigators hypothesize that by placing a slurry of Seprafilm in the intrauterine cavity and creating a temporary physical barrier between the walls of the uterus, that we will be able to prevent iatrogenic intrauterine adhesions. Given that approximately 24 to 48 hours after placement, the membrane becomes a hydrated gel that is slowly resorbed within one week, we anticipate that the patient will have minimal to no discomfort; since no physical device is being left in the endometrial cavity, the uterus will not be contracting more than it does in its normal postoperative state.
61988818|NCT01632202|PLACEBO_COMPARATOR|Placebo|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
61988819|NCT02162290|EXPERIMENTAL|Interval exercise|Exercise bouts in low and high intensities
61988820|NCT02162290|EXPERIMENTAL|Continuous exercise|Exercise continuously with moderate intensity
61988821|NCT02865993|OTHER|Betadine Group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
61988822|NCT02865993|OTHER|No Betadine Group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
61988823|NCT03524807|EXPERIMENTAL|Electrophysiologic therapy group|apply electrophysiologic therapy after surgery
62764782|NCT02303899|EXPERIMENTAL|Gemcitabine & Imatinib mesylate|Gemcitabine 1000 mg/m2, i.v., days 3 and 10 of a 21-days schedule; Imatinib mesylate 400 mg/die orally on days 1-5 and 8-12 of a 21-days schedule.
62764783|NCT03770247|EXPERIMENTAL|intraoperative group (IOCPN group)|Intraoperative celiac plexus neurolysis Before closure of the abdomen the surgeon will expose the aorta at the level of the celiac trunk.With the stomach retracted inferiorly, the index and second finger of the surgeon's left hand straddle the aorta with the index finger placed on the splenic artery and the second finger on the common hepatic artery. we will use of a 20- gauge spinal needle (in contrast to the usual short intravenous needle) allows better visualization and access to this area, especially in deep patients, while a 10 ml syringe permits the surgeon to control the injection with the right hand alone.(10) Twenty ml of 90 % alcohol, five ml lidocaine 2%, five mg dexamethasone will be injected in each side of the aorta after aspiration to exclude intravascular or subarachnoid injection.
61988824|NCT03524807|NO_INTERVENTION|non-electrophysiologic therapy group|do not apply electrophysiologic therapy after surgery
61988825|NCT06315699|EXPERIMENTAL|Clemastine|Clemastine，tablet，0.15mg/kg/d，two months
61988826|NCT06315699|PLACEBO_COMPARATOR|fructose|
61988827|NCT02515045|ACTIVE_COMPARATOR|TriMoxiVanc|The formulation containing triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin used as an injection at the end of the uneventful phacoemulsification procedure. The compounded Tri-Moxy-Vanco will be delivered into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
61988828|NCT02515045|ACTIVE_COMPARATOR|TriMoxiVanc + Ilevro|Nepafenac ophthalmic suspension 0.3% will be started 3 days prior to surgery QD and continue QD for 4 weeks after surgery. The compounded Tri-Moxy-Vanco will be injected into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
61988829|NCT02515045|ACTIVE_COMPARATOR|Control|"Moxifloxacin HCl 0.1%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.~Nepafenac ophthalmic suspension 0.3% : 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.~Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued."
61988830|NCT02206555|EXPERIMENTAL|Treatment group (TRUVADA)|Homosexual men and heterosexual men and women at high risk of HIV infection
61988831|NCT03774589|EXPERIMENTAL|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis.
61988832|NCT03774589|ACTIVE_COMPARATOR|Traditional Manual Anastomosis|A handsewn technique will be used during bilioenteric anastomosis.
61988833|NCT02496247|EXPERIMENTAL|Immediate Herring|Participants in this arm will receive the Canned Herring intervention. Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child), which will be distributed weekly by community health workers. Families will be instructed to feed the study child half a can of herring per day (without reducing usual home food given to the child), and to not share the remaining herring with individuals who are in the Delayed Herring study arm. When families come to collect their weekly distribution they will be asked to bring in at least 7 empty herring cans in order to receive the next ration, and will answer a question about how often the child eats the herring.
62383842|NCT01219166||laparoscopic Roux-en-Y-gastric baypass with cholecystectomy|
62383843|NCT03977506|EXPERIMENTAL|Behavoiral|The evaluation will be realized on two different assessment grids during the test on the road
61988834|NCT02496247|NO_INTERVENTION|Delayed Herring (Control)|Families with children in this study arm will not receive any herring during the 8-10 week period when Immediate Herring families receive a weekly ration of herring. After the 8-10 week (end line) measurements, an equal amount of herring will be distributed to the family.
61988835|NCT00634088|EXPERIMENTAL|Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|Dose Level 1
61988836|NCT00634088|EXPERIMENTAL|Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|Dose Level 2
61988837|NCT00634088|EXPERIMENTAL|Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|Dose Level 3
61988838|NCT00634088|EXPERIMENTAL|Ixabepilone + Lapatinib + Capecitabine|Triplet Combination
61988839|NCT02945176|EXPERIMENTAL|ARGOS-IO system|"The ARGOS-IO system is a non-European Community (CE) marked investigational medical device composed of the implant and its accessories.~Implant: ARGOS-IO pressure sensor implant for sulcus placement or transcleral fixation~Accessories: MESOGRAPH reading device, Implant Injector"
61988840|NCT01062555|ACTIVE_COMPARATOR|Phase I Arm 1|CSA and MMF
61988841|NCT01062555|ACTIVE_COMPARATOR|Phase I Arm 2|FK and MMF
61988842|NCT01062555|ACTIVE_COMPARATOR|Phase II Arm 1|Low CNI and MMF
61988843|NCT01062555|ACTIVE_COMPARATOR|Phase II Arm 2|Rapa and MMF
61988844|NCT01042704|EXPERIMENTAL|Bendamustine, Lenalidomide and Dexamethasone|Treatment with Bendamustine in combination with Lenalidomide and Dexamethasone will be administered on an outpatient basis. Each treatment cycle will be 28 days dosed according to the Dose Escalation Schema.
61988845|NCT00945581|EXPERIMENTAL|AN777|Powder twice a day
61988846|NCT00945581|PLACEBO_COMPARATOR|Placebo powder|Powder twice a day
61988847|NCT03805932|EXPERIMENTAL|Moxetumomab - Dose Escalation 30 mcg/kg|Arm 1 Moxetumomab Pasudotox-tdfk + Rituximab
61988848|NCT03805932|EXPERIMENTAL|Moxetumomab - Dose Expansion 40 mcg/kg|Arm 1 and Arm 2 Moxetumomab Pasudotox-tdfk + Ruxience
62383844|NCT06154460||Laterjet Surgery Group|This group will consist of individuals who underwent laterjet surgery.
62383845|NCT06154460||Reimplissage Surgery Group|This group will consist of individuals who underwent reimplissage surgery.
62764784|NCT03770247|ACTIVE_COMPARATOR|CT group (CTCPN group)|CT guided celiac plexus neurolysis After one week of the operation and the patient completely awake, the patient will be transferred to CT lab. The procedure will be done after attachment of basic monitors and transfusion of 500 ml saline in 20 G cannula before starting the procedure and the patient will be given 5 mg midazolam as a sedation. The procedure will be done by anesthetist and radiologist who had a good experience in celiac plexus neurolysis. In our study we will use the classic posterior bilateral approach. The patient will be in the prone position. After sterilization of the back by chlorohixidine 10 % , subcutaneous injection of 5 ml lidocaine as a local anaesthesia until a wheel will be formed then the procedure will be done. We will use 20 G Chiba needle under guidance of CT. Twenty ml of 95% alcohol , five ml lidocaine 2 % and five mg dexamethasone in each side of the aorta after aspiaration to exclude intravascular injection and subarachnoid injection
61988849|NCT06226779|EXPERIMENTAL|Baduanjin|Parcipants will practice baduanjin exercise.
61988850|NCT06226779|ACTIVE_COMPARATOR|Brisk walking|Parcipants will perform brisk walking activities.
61988851|NCT06226779|OTHER|health education|Parcipants will receive health education classes and watch sport related videos.
61988852|NCT00402961|ACTIVE_COMPARATOR|1|Acupuncture is the insertion of needles at certain body points.
61988853|NCT00402961|SHAM_COMPARATOR|2|sham acupuncture
61988854|NCT03389009||smartphone abusers|"Auto refractometer without cycloplegia Uncorrected visual acuity (logMAR conversion). Anterior segment slit lamp examination UBM examination settings :Supine decubitus position.5150 Vumax (Sonomed, USA) under standard illumination Parameters that will be measured: corneal thickness, anterior chamber depth, angle to angle distance, cornea-posterior capsular lens distance, lens thickness, pupillary diameter, angle of anterior champer and trabecular-ciliary process distance.~Cycloplegic refraction UBM examination will be repeated after cycloplegia with the same settings. The patients found to have spasm of accommodation will be subjected to ways to relief the spasm of accommodation and repetition of UBM if possible"
62764785|NCT02230683|EXPERIMENTAL|IDN-6556 - Overall population|Overall evaluable population treated with IDN-6556 25 mg twice daily
62764786|NCT02230683|EXPERIMENTAL|IDN-6556 - Subgroup with Baseline HVPG < 12 mmHg|Subgroup for patients with Baseline HVPG \< 12 mmHg that have been treated with IDN-6556 25 mg twice daily
61988855|NCT03389009||smartphone non users|"Auto refractometer without cycloplegia Uncorrected visual acuity (logMAR conversion). Anterior segment slit lamp examination UBM examination settings :Supine decubitus position.5150 Vumax (Sonomed, USA) under standard illumination Parameters that will be measured: corneal thickness, anterior chamber depth, angle to angle distance, cornea-posterior capsular lens distance, lens thickness, pupillary diameter, angle of anterior champer and trabecular-ciliary process distance.~Cycloplegic refraction UBM examination will be repeated after cycloplegia with the same settings. The patients found to have spasm of accommodation will be subjected to ways to relief the spasm of accommodation and repetition of UBM if possible"
61988856|NCT04599296|ACTIVE_COMPARATOR|Hip Brace|This group will be assigned to wear a hip brace post surgery.
61988857|NCT04599296|NO_INTERVENTION|No Intervention|This group will not be assigned a hip brace after surgery.
61988858|NCT06421389|EXPERIMENTAL|Intervention group|All patients will receive the standard endoscopic hemostasis by either epinephrine injection, hemoclipping, heat coagulation, or band ligation. After then, patients in intervention group will receive 2g of sucralfate powder, 1g of tranexamic acid powder, and 1g of barium spray through the endoscopy precisely on the bleeding site.
61988859|NCT06421389|NO_INTERVENTION|Control group|All patients will receive the standard endoscopic hemostasis by either epinephrine injection, hemoclipping, heat coagulation, or band ligation.
61988860|NCT04220372|EXPERIMENTAL|Tongxinluo Capsule|
61988861|NCT04220372|PLACEBO_COMPARATOR|Placebo Capsule|
62383846|NCT06154460||Capsular Reconstruction Surgery Group|This group will consist of individuals who underwent capsular reconstruction surgery.
62383847|NCT05165186|EXPERIMENTAL|Video Intervention Arm|For participants randomized to the video intervention arm, participants will be shown two videos about Advanced Care Planning, and then they will be asked questions regarding the usefulness of the video and their comfort with the video
62383848|NCT05165186|NO_INTERVENTION|Control Arm|For participants randomized to the control group arm, participants will review an informational sheet, which covers the same information as the videos shown to the intervention arm.
61988862|NCT04612647|EXPERIMENTAL|Workshop group|Participants in the workshop group will be offered four one-day workshops (3-hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Aquatic Opportunities, and 4) Physical activity and Sports (during intervention)-\[Parents and Children-Workshop Group\]. In addition to the workshops, this group and the home-based group will receive information (activity booklets) and physical education (physical activity)-related equipment.
62383849|NCT01342627|EXPERIMENTAL|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to protocol.~In case of disease progression Sorafenib administration will be discontinued."
62383850|NCT05507190|EXPERIMENTAL|One arm|Self-management group. This pilot-study uses a one-group before-after design.
62383851|NCT04493736||Case|Any person receiving services from a mental health provider who is able to either consent or for whom parental consent is able to be obtained.
62383852|NCT02576171|EXPERIMENTAL|Group-therapy + ICBT|This is an open trial with only one study arm
62383853|NCT05841615|SHAM_COMPARATOR|PVI alone|Participants only experience PVI operations
62383854|NCT05841615|EXPERIMENTAL|PVI and RDN|Participants experience both PVI and RDN operations
62383855|NCT02365740|EXPERIMENTAL|Cases|gastric emptying test gut hormones determination Continuous Glucose Monitoring Insulin single bolus Insulin double-wave bolus
62764787|NCT02230683|EXPERIMENTAL|IDN-6556 - Subgroup Baseline HVPG ≥ 12 mmHg|Subgroup for patients with Baseline HVPG ≥ 12 mmHg that have been treated with IDN-6556 25 mg twice daily
62764788|NCT03761394|EXPERIMENTAL|Intervention Group|Testing devices plus Cardea Solo device by Cardiac Insight for 14-day period.
62764789|NCT03761394|ACTIVE_COMPARATOR|Control Group|Only Cardea Solo device by Cardiac Insight for 14-day period.
62764790|NCT03761394|EXPERIMENTAL|Intervention Group for Extended Use|30-additional days of extended use of testing devices for adherence plus Kardia Mobile ECG device by AliveCor.
62383856|NCT02365740|SHAM_COMPARATOR|Controls|gastric emptying test gut hormones determination
62383857|NCT02306928||Piperacillin pharmacokinetics|Patients with suspected septic shock who are treated with piperacillin/tazobactam.
62764791|NCT03761394|NO_INTERVENTION|Control Group for Extended Use|No device usage for 30-days following completion of the original 14-day period.
62764792|NCT04552548|NO_INTERVENTION|Control group|the patients will receive regular analgesics (1 µg /kg fentanyl with induction and 15mg/kg paracetamol before extubation)
62764793|NCT04552548|ACTIVE_COMPARATOR|TAP group|the patients will receive bilateral TAP block using (0.5 ml/ kg bupivacaine 0.25%) in each side + regular analgesics.
62764794|NCT04552548|ACTIVE_COMPARATOR|quadratus lumborum group|the patients will receive bilateral quadratus lumborum block using (0.5 ml/ kg bupivacaine 0.25%) in each side + regular analgesics.
61988863|NCT04612647|EXPERIMENTAL|Home-based group|Participants in the home-based group will not participate in the four half-day workshops, but they will receive the same information (activity booklets) and physical activity equipment as the workshop group (during intervention)-\[Parents and Children-Home Group\].
62383858|NCT02367690|EXPERIMENTAL|Cohort 1|"Cohort 1 will be randomized to one of the following treatment groups:~a) Standard-of-care (SOC) + Selinexor gel, 10 μM~, b) SOC + vehicle gel c) SOC alone."
62383859|NCT02367690|EXPERIMENTAL|Cohort 2|"Cohort 2 will be randomized to one of the following treatment groups:~1. Standard-of-care (SOC) + Selinexor gel, 30 μM~2. SOC + vehicle gel~3. SOC alone."
62383860|NCT02367690|EXPERIMENTAL|Cohort 3|"Cohort 3 will be randomized to one of the following treatment groups:~1. Standard-of-care (SOC) + Selinexor gel, 70 μM~2. SOC + vehicle gel~3. SOC alone."
62383861|NCT02543762||Inflammatory Bowel Disease|"Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis and Crohn disease.~Ulcerative colitis is a chronic inflammatory condition characterized by relapsing and remitting episodes of inflammation limited to the mucosal layer of the colon. It almost invariably involves the rectum and typically extends in a proximal and continuous fashion to involve other portions of the colon.~Crohn disease is characterized by transmural inflammation and by skip lesions. The transmural inflammatory nature of Crohn disease may lead to fibrosis and strictures, and to obstructive clinical presentations that are not typically seen in ulcerative colitis. More commonly, the transmural inflammation results in sinus tracts, giving rise to microperforations and fistulae.~Crohn disease may involve the entire gastrointestinal tract from mouth to perianal área patients with long-standing inflammatory bowel disease are prone to the development of colorectal cancer"
62383862|NCT01729065|NO_INTERVENTION|Home Program|Participants perform home program only.
62383863|NCT01729065|EXPERIMENTAL|Physical Therapy Intervention|Physical therapy intervention provided for first 12 weeks following surgery.
62383864|NCT03161951||Neuroinfections|Patients with acute neuroinfections of bacterial and viral ethology.
62383865|NCT03161951||Intestinal Infectious Diseases|Patients with acute intestinal infectious diseases of bacterial and viral ethology.
62383866|NCT03161951||Control group|Control group of healthy persons
62383867|NCT04145310|EXPERIMENTAL|Arm A|
62383868|NCT04145310|PLACEBO_COMPARATOR|Arm B|
62383869|NCT04205604|EXPERIMENTAL|Single Arm,|Patients with clinically diagnosed congenital hyperinsulinism
62383870|NCT03818399|EXPERIMENTAL|overdose patients|subjects that receive acute administration of SUBOXONE sublingual film in the ED followed by SUBLOCADE administration in the ED and referral to an affiliated outpatient treatment clinic, and receive monthly SUBLOCADE injections for 6 months in the context of outpatient treatment.
62764795|NCT03036436|EXPERIMENTAL|Intervention|Participants in this group will receive the intervention. They will receive a Fitbit activity tracker, and will also receive support and goal setting with a view to improving their daily physical activity.
61988864|NCT04612647|NO_INTERVENTION|wait-listed home-based group|Wait-list home-based group will serve as the control group (during intervention)-\[Parents and Children-Control Group\]. This group will be instructed to continue their typical routines and activities for the duration of the intervention. They will be asked to attend the pre and posttest, as well as a follow up three weeks and 3 months after the completion of the 12-week period. Immediately following the follow-up test (3 months after the intervention), participants in the wait-list home-based group will be offered the home-based program (e.g., receiving the same intervention protocol and materials (physical education equipment and lesson plans/workbook) following all procedures as described for that group previously.
62764796|NCT02616393|EXPERIMENTAL|Cohort A: Brain Metastases (BM)|Tesevatinib 300 mg orally (PO) once daily (QD) administered to subjects with NSCLC who had progressed with brain metastases (BM)
62383871|NCT03677661|ACTIVE_COMPARATOR|Conventional approach|Graded aerobic exercise and advice for graded cognitive stimulation approach based on the 2016 Berlin consensus
62383872|NCT03677661|EXPERIMENTAL|Personalized rehabilitation program|Cervico-vestibular rehabilitation personalized patient-centered clinical program combined with the exercise and advice of the conventional approach
62383873|NCT04187586||Extracorporeal shock wave therapy group|The ESWT group received shock waves with low-energy flux density (0.05-0.30 mJ/mm2). The interval between treatments is a 1-week. To evaluate the effect of ESWT, we reviewed the skin test results (thickness, melanin, erythema, TEWL, sebum, and skin elasticity levels) immediately before ESWT and immediately after the sixth session. And also the ESWT group received the standard treatment, which involved medication, scar lubrication, burn rehabilitation massage therapy, and physical therapy.
62383874|NCT04187586||conventional therapy without extracorporeal shock wave therapy|Conventional therapy group received the standard treatment, which involved medication, scar lubrication, burn rehabilitation massage therapy, and physical therapy.
62383875|NCT06405256||BM patients receiving MRIgART|"For it's an observational study, all patients eligible will be divided into the group BM patients receiving MRIgART"
62764797|NCT02616393|EXPERIMENTAL|Cohort B: Leptomeningeal Metastases (LM)|Tesevatinib 300 mg PO QD administered to subjects with NSCLC who had progressed with leptomeningeal metastases (LM)
62764798|NCT02616393|EXPERIMENTAL|Cohort C: Brain Metastases at Initial Presentation (BM-IP)|Tesevatinib 300 mg PO QD administered NSCLC who presented initially with BM at initial presentation
61988865|NCT03788096|EXPERIMENTAL|PS-PICS Peer Support Intervention|ICU mentors will be responsible for providing support to survivor participants randomized to the PS-PICS peer support intervention. Mentors will be trained in motivational interviewing techniques to engage mentees in goal setting and emotional management that is not readily accessible as part of discharge planning.
61988866|NCT03788096|PLACEBO_COMPARATOR|Usual Care Group|A control intervention will be used to provide comparison data consistent with usual care (absence of structured peer support telephone intervention) to evaluate the impact of the PS-PICS peer support intervention.
62383876|NCT02543879|EXPERIMENTAL|Dose Escalation FT-1101|Following a 3+3 dose escalation strategy, the first cohort of patients will be administered FT-1101 at 10 mg, oral capsules, once weekly on a continuous basis. Subsequent cohorts dose and frequency will be determined by investigators and sponsor following observations of previous cohorts. Dose escalation will continue until the MTD is determined.
61988867|NCT02725047|EXPERIMENTAL|TREATMENT - CRYOTHERAPY|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
61988868|NCT02725047|PLACEBO_COMPARATOR|PLACEBO - SAND|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
61988869|NCT02482987|EXPERIMENTAL|Cytoplast|Patients will receive ridge preservation procedure with a Cytoplast barrier membrane
61988870|NCT02482987|EXPERIMENTAL|BioXclude|Patients will receive ridge preservation procedure with a BioXclude barrier membrane
61988871|NCT04528043||critically ill patients|critically ill patients admitted in one of the 5 ICUs of the university hospital of Nancy during the year 2016 with documented third group enterobacteriaceae infection and/or colonization with third group enterobacteriaceae
61988872|NCT01533454|NO_INTERVENTION|Control|Control participants will attend a 4-month structured weight-loss program and attend subsequent follow-ups at 4-month intervals upon completion of the program.
62383877|NCT02543879|EXPERIMENTAL|Dose Expansion FT-1101|Once the MTD is determined, the Recommended Phase 2 Dose (RP2D) will be identified. 3 Expansion cohorts of up to 20 patients each will be treated with the RP2D of FT-1101
62383878|NCT02543879|EXPERIMENTAL|Dose Escalation FT-1101 + azacitidine|Following a 3+3 dose escalation strategy, the first cohort of AML/MDS patients will be administered FT-1101 at approximately 50% or lower than the MTD identified for the single agent FT-1101. Subsequent cohorts dose will be determined by investigators and sponsor following observations of previous cohorts. Dose escalation will not exceed the dose determined to be the single agent MTD for that schedule.
62383879|NCT02543879|EXPERIMENTAL|Dose Expansion FT-1101 + azacitidine|Once the MTD is determined, the Recommended Phase 2 Dose (RP2D) will be identified. 1 Expansion cohorts of up to 20 AML/MDS patients each will be treated with the RP2D of FT-1101 in combination with azacitidine.
62383880|NCT02331927|NO_INTERVENTION|Randomized Part: Arm A|Conventional switch of chemotherapy together with the antiangiogenic treatment: Bevacizumab and mFOLFOX6 (continuation of same regimen until progressive disease (PD) according to RECIST v1.1, followed by switch to aflibercept and FOLFIRI after PD).
62383881|NCT02331927|EXPERIMENTAL|Ramdomized Part: Arm B|Early marker-driven switch of anti-angiogenic agent and maintenance of chemotherapy: Bevacizumab and mFOLFOX6 will be administered until change of the CAF-profile and at least stable disease according to RECIST v1.1. Change to Aflibercept and mFOLFOX6 (change of bevacizumab to aflibercept and continuation of mFOLFOX6) until PD according to RECIST v1.1, followed by change to FOLFIRI after PD).
62383882|NCT03604094||Group I|0-1 month old newborns
62383883|NCT03604094||Group II|1 month-2 year-old pediatric patients
62383884|NCT02013076||Oral corticosteroids (OCS)|"All patients receive:~1. Prednisone or Prednisolone at 1 mg/kg (in 1 site) or 2 mg/kg (in all other sites) (max. 50 mg); if vomiting prednisone/prednisolone: they receive dexamethasone (0.3 mg/kg, max. 10 mg)~2. 2 to 3 doses of salbutamol within the first hour of therapy according to severity Those with severe exacerbations receive 3 treatments with salbutamol and ipratropium bromide within the initial hour of therapy."
62383885|NCT03622268||Indirect calorimetry measurement|Using indirect calorimetry for measure resting energy expenditure
62383886|NCT02576652|OTHER|Osteoarthritis Participants|Participants previously treated with denosumab and planning to undergo total hip replacement (THR) received one cycle of tetracycline administered at either 250 mg four times a day or 500 mg twice a day for 3 days and one cycle of demeclocycline administered at either 150 mg four times a day or 300 mg twice a day for 3 days, ten days after last dose of tetracycline in cycle 1. THR surgery was performed 5 to 42 days after the last dose of demeclocycline.
62383887|NCT02023515|EXPERIMENTAL|Stress Management|Approximately half of the participants will be randomized to a stress management arm. Participants will undergo Emotional Brain Training during a 90 minute session once per week for ten weeks in order to rewire the brain and improve stress management techniques.
62383888|NCT02023515|ACTIVE_COMPARATOR|standard behavioral weight loss|Half of participants will receive a standard behavioral weight loss program in 90 minute sessions once per week for 10 weeks
62383889|NCT04864184|EXPERIMENTAL|Breathing intervention|Participants will complete 2-minute breathing exercises following the Breathing App every 15 minutes during a 4-hour postprandial period following high-fat meal consumption.
62383890|NCT05605691|EXPERIMENTAL|Renuvion APR System Treatment|Subject will be treated with the Renuvion APR system in the lower eyelid (periorbital) area.
62383891|NCT05976061||Low risk patients|Low risk actinic keratosis patients referred by the general practitioner and diagnosed as actinic keratosis by the dermatologist in 2018 and 2019.
62764799|NCT02679872||VATS team 1|Video-assisted thoracoscopic surgery team, from institution/hospital 1.
61988873|NCT01533454|EXPERIMENTAL|Incentives|Incentive arm participants will be offered an additional program (in addition to the COMM program) where they can earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
61988874|NCT03554356|EXPERIMENTAL|Cryoballoon Focal Ablation System (CbFAS) Treatment|Subjects undergoing CbFAS treatment as part of their clinical care for their condition.
62764800|NCT02679872||VATS team 2|Video-assisted thoracoscopic surgery team, from institution/hospital 2.
62764801|NCT02679872||VATS team 3|Video-assisted thoracoscopic surgery team, from institution/hospital 3.
62764802|NCT02679872||VATS team 4|Video-assisted thoracoscopic surgery team, from institution/hospital 4.
62764803|NCT03198364|EXPERIMENTAL|START + Mobile Augmentation|4 Sessions of In-Person Psychoeducation called Safety and Recovery Therapy (START) with 12 weeks of augmentation by use of automated software to prompt users to engage in personalized adaptive coping
62764804|NCT03198364|ACTIVE_COMPARATOR|START|4 Sessions of In-Person Psychoeducation called Safety and Recovery Therapy (START)
62764805|NCT02144155|EXPERIMENTAL|Oxytocin: 24 IU - 168 IU|Oxytocin twice daily for 3 weeks
62764806|NCT02144155|SHAM_COMPARATOR|Vehicle placebo|Placebo for 3 weeks
62764807|NCT06463353|EXPERIMENTAL|Trilinolein cream group|receiving trilinolein cream twice a day,in the morning and evening, for a period of 12 weeks.
62764808|NCT06463353|PLACEBO_COMPARATOR|cream base group|receiving cream base twice a day,in the morning and evening, for a period of 12 weeks.
62764809|NCT02584387|EXPERIMENTAL|3D VVRET|"Behavioral: 3D Video Virtual Reality Exposure Therapy (VVRET)~1 30 minute 3D VRET treatment session for arachnophobia."
62383892|NCT05976061||High risk patients|High risk actinic keratosis patients referred by the general practitioner and diagnosed as actinic keratosis by the dermatologist in 2018 and 2019.
62764810|NCT02584387|NO_INTERVENTION|Waitlist|Participants randomized to the waitlist group will complete all study procedures except the 3D VVRET. After the conclusion of their sessions, these participants will be offered the full 3D-VVRET treatment.
62764811|NCT03802539|EXPERIMENTAL|Glass Liner|Tooth restoration with a glass ionomer liner material under a nanohybrid composite resin
62764812|NCT03802539|NO_INTERVENTION|No liner|Tooth restoration without a glass ionomer liner material under a nanohybrid composite resin
62764813|NCT04628949|EXPERIMENTAL|aScope™ Duodeno endoscope and aBox™ Duodeno|Eligible subjects who are undergoing non-emergent, clinically indicated ERCP using aScope™ Duodeno endoscope and aBox™ Duodeno.
62383893|NCT05902533|EXPERIMENTAL|Reduced Elective Dose + Concurrent Capecitabine/Mitomycin C|Reduced elective nodal dose (30.6 Gy); (28- 30 fractions given M-F for approximately 5.5 to 6 weeks) Capecitabine 825 mg/m2 BID on days with RT Mitomycin C 10 mg/m2 slow IV push Days 1 and 29
62764814|NCT01492413|EXPERIMENTAL|Online basic lifestyle counseling (OBLI)|Subjects receive one online informational class.
62764815|NCT01492413|EXPERIMENTAL|Online lifestyle counseling (OLC)|Subjects receive 12 weekly online classes with a focus on behavior modification for weight loss.
62764816|NCT01492413|EXPERIMENTAL|OBLI intervention plus a fortified diet beverage (BEV)|Subjects receive online basic lifestyle information (OBLI) plus a fortified diet beverage.
62764817|NCT01492413|EXPERIMENTAL|OLC plus fortified diet beverage (BEV)|Subjects receive OLC plus diet beverage (BEV).
62764818|NCT02921009|EXPERIMENTAL|Crosslinking at different fluence rates|The study will investigate the effectiveness of Transepithelial riboflavin .25% treated with Ultraviolet light at fluence rates of 9mw/cm2 and 18mw/cm2 in the treatment of diagnosed keratoconus, pellucid marginal degeneration or post-LASIK ectasia.
62764819|NCT05012007|NO_INTERVENTION|Control arm: No Reminder|Usual care
62764820|NCT05012007|EXPERIMENTAL|Automated phone reminder|Standard reminder via phone (audiocare)
62764821|NCT05012007|EXPERIMENTAL|Text reminder|Standard reminder via text (VEText)
62383894|NCT02036983|ACTIVE_COMPARATOR|Ultrasound guided bilateral TAP block|Ultrasound guided TAP Block with local anesthetic and dexamethasone.
62383895|NCT02036983|ACTIVE_COMPARATOR|Instillation of surgical site with local anesthestic.|Instillation of surgical site under direct visualization with local anesthetics and dexamethasone.
62383896|NCT02036983|PLACEBO_COMPARATOR|Control Group|Standard anesthetic technique
62383897|NCT05439200|EXPERIMENTAL|Asynchronous movies|Asynchronous 3D movies
62764822|NCT03677479|EXPERIMENTAL|socket preservation with camelline bone|natural hydroxyapatite derived from camels prepared by investigator
62764823|NCT03677479|ACTIVE_COMPARATOR|socket preservation with bovine bone|natural hydroxyapatite derived from cows (Bio-Oss)
62764824|NCT04032080|EXPERIMENTAL|LY3023414 + prexasertib|Patients with metastatic TNBC who meet the enrollment criteria will receive LY3023414 and prexasertib until disease progression. Patients whose disease does not respond to the combination of LY3023414 and prexasertib may be treated with standard of care breast cancer therapies off study, at the recommendation of the treating physician.
62764825|NCT03099148|EXPERIMENTAL|LY3337641 (R-fasted)|A single, PO dose of reference formulation (R) given orally with water after an overnight fast in one of four periods.
62764826|NCT03099148|EXPERIMENTAL|LY3337641 (T1-fasted)|A single, PO dose of LY3337641(20mg) test formulation 1 (T1) given orally with water after an overnight fast in one of four periods.
62764827|NCT03099148|EXPERIMENTAL|LY3337641 (T1-fed)|A single, PO dose of LY3337641 (20mg) test formulation 1 (T1) given orally with water after a high fat meal in one of four periods.
62764828|NCT03099148|EXPERIMENTAL|LY3337641 (T2-fasted)|A single, PO dose of LY3337641 (20 mg) test formulation 2 (T2) given orally with water after an overnight fast in one of four periods.
62764829|NCT01557959|EXPERIMENTAL|Treatment (chemo, chemoprotection, antiangiogenesis therapy)|Patients receive docetaxel IV over 1 hour on day 1, cisplatin IV over 1 hour on day 1, and pegfilgrastim subcutaneously on day 2. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of docetaxel, cisplatin, and pegfilgrastim, patients receive oral erlotinib hydrochloride once daily in the absence of disease progression or unacceptable toxicity.
62764830|NCT06030492|EXPERIMENTAL|hydrogen peroxide group|hydrogen peroxide group Irrigation of the placental bed with 100 ml 3% hydrogen peroxide , followed by packing with a towel highly soaked hydrogen peroxide solution (Pozitif Kimya, İstanbul, Turkey) , freshly prepared by a 50% dilution with a normal saline solution.(
62764831|NCT06030492|PLACEBO_COMPARATOR|normal Saline solution|Packing the placental bed with a towel soaked with normal Saline solution
62764832|NCT03571672|EXPERIMENTAL|DEFINITY|Each patient will undergo an unenhanced ultrasound examination and a DEFINITY contrast-enhanced ultrasound
62383898|NCT05439200|ACTIVE_COMPARATOR|Standard-of-care patching with an adhesive patch|Standard-of-care patching with an adhesive patch
62383899|NCT01849289|EXPERIMENTAL|Insulin Degludec|
62764833|NCT03361189|EXPERIMENTAL|CLS-On|Subjects in this arm will be programmed to CLS-on to received closed loop stimulation-based pacing for 3 months, followed by a standard rate response for 3 months.
62764834|NCT03361189|ACTIVE_COMPARATOR|CLS-Off|Subjects in this arm, will be placed in a standard rate response for 3 months, followed by CLS-on to received closed loop stimulation-based pacing for 3 months.
62764835|NCT05162053|EXPERIMENTAL|Ultra-rapid metabolizers group|A 7-day cross-dosing of vicagrel and clopidogrel between two cycles
62764836|NCT05162053|EXPERIMENTAL|Rapid metabolizers group|A 7-day cross-dosing of vicagrel and clopidogrel between two cycles
62764837|NCT05162053|EXPERIMENTAL|Normal metabolizers group|A 7-day cross-dosing of vicagrel and clopidogrel between two cycles
62764838|NCT05162053|EXPERIMENTAL|Intermediate metabolizers group|A 7-day cross-dosing of vicagrel and clopidogrel between two cycles
62764839|NCT05162053|EXPERIMENTAL|Poor metabolizers group|A 7-day cross-dosing of vicagrel and clopidogrel between two cycles
62764840|NCT00687609|EXPERIMENTAL|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
62764841|NCT01757483||Prescribers|
61977737|NCT02715414|EXPERIMENTAL|MFG + Clinic Implementation Team|This condition consists of service providers, directors, and clinic staff who will create site-specific plans to enhance uptake and implementation of MFG. CITs address potential barriers to implementation and adjust the format and structure of MFG as needed in order to be implemented as part of clinic care.
61977738|NCT02715414|NO_INTERVENTION|Standard Care|Standard Care consists of services including outpatient individual and family therapy, which are offered as part of clinic care.
62383900|NCT01849289|EXPERIMENTAL|Insulin Glargine|
62383901|NCT06389994||Patients undergoing oral immunotherapy|All patients will have esophageal string test
62764842|NCT02025595||Monozygotic twin pairs|15 monozygotic twin pairs discordant for obesity
62764843|NCT02025595||Genetic predisposition for obesity|15 obese and 15 non-obese individuals with a high genotype obesity risk score and 15 obese and 15 non-obese individuals with a low genotype obesity risk score. Genotype obesity risk score will be based on genome wide association single-nucleotide polymorphisms (SNP's) associated with obesity.
62383902|NCT02263924|EXPERIMENTAL|Experimental: Tocotrienol|Mixed tocotrienol 200mg twice a day for 6 months
62383903|NCT02263924|PLACEBO_COMPARATOR|Placebo (for tocotrienol)|Placebo capsules, 1 capsule twice a day for 6 months
62383904|NCT00887094|EXPERIMENTAL|Aerobic exercise|One bout of aerobic physical training will be performed on a cycle ergometer for 50 min
62383905|NCT00887094|EXPERIMENTAL|Aerobic-resistance exercise|One bout of aerobic-resistance physical training will be performed on a cycle ergometer added by a strenght training for 50 min (total)
62383906|NCT00942292|ACTIVE_COMPARATOR|Lipidem (fish oil)|Lipidem (TPN containing fish oil)
62383907|NCT00942292|ACTIVE_COMPARATOR|Lipofundin (TPN)|Control arm (no fish oil)
62383908|NCT02659839||Cancer patients admitted to the ICU|Patients with cancer admitted to the ICU. No intervention will be administered.
62383909|NCT02871024|EXPERIMENTAL|Intervention arm|Usual care with two sessions of 2-hour hemoperfusion with Toraymyxin in 24 hours apart
62383910|NCT03700866|EXPERIMENTAL|(Functional splinting time)|"Teeth with crown root fracture will be surgically extruded and splinted then the Periotest values will determine when the splint should be removed which will indicate the functional periodontal healing and as well the functional splinting time.~The Periotest readings will be repeated with one week time interval between each series When the Periotest values of the traumatized tooth reach or even approximate the values of the corresponding normal tooth the splint will be removed."
62383911|NCT03700866|ACTIVE_COMPARATOR|(IADT splinting time)|Teeth with crown root fracture in this group will be surgically extruded and splinted for two weeks according to the international association of dental traumatology (IADT) splinting time two ,weeks splinting, regardless the Periotest score.
62383912|NCT00198510|EXPERIMENTAL|Vitrase|A single dose of 0.05 cc of Vitrase (hyaluronidase) for ophthalmic intravitreal injection is injected into the vitreous chamber.
62383913|NCT00198510|NO_INTERVENTION|Observation|Observation only, no medication or intravitreal injection
62383914|NCT02023892|EXPERIMENTAL|atorvastatin|atorvastatin 20mg tablet, single dose of 80mg by mouth
62383915|NCT02023892|PLACEBO_COMPARATOR|placebo|placebo 20mg tablet, single dose of 80mg by mouth
62383916|NCT02994576|EXPERIMENTAL|Stage IB(≥ 2 cm)-IIIA non N2, resectable and untreated NSCLC|
62383917|NCT02994576|NO_INTERVENTION|Comparative cohort (patients receiving standard treatment)|
62383918|NCT00732199|OTHER|Arm 1|Determine the apneic threshold and carbon- dioxide reserve using noninvasive positive pressure ventilation during NREM sleep and determine the effect effect of episodic hypoxia on ventilatory long-term facilitation during NREM sleep in Young adults.
62383919|NCT00732199|EXPERIMENTAL|Arm 2|Determine the apneic threshold and carbon- dioxide reserve using noninvasive positive pressure ventilation during NREM sleep and determine the effect of episodic hypoxia on ventilatory long-term facilitation during NREM sleep in Older adults.
62383920|NCT02411994|EXPERIMENTAL|Pyronaridine-artesunate|pyronaridine-artesunate: recommended dose according to body weight, once a day for three days.
62383921|NCT02411994|ACTIVE_COMPARATOR|Artemether-lumefantrine|artemether-lumefantrine: recommended dose according to body weight, twice a day for three days.
62383922|NCT03691649|EXPERIMENTAL|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
62383923|NCT03691649|ACTIVE_COMPARATOR|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
62383924|NCT01491711|ACTIVE_COMPARATOR|Fractionated 5-ALA HCl 20% gel PDT|Twice on day 1
62764844|NCT00823277||1|Overweight and obese Children (BMI SDS \> 90th percentile according to Danish BMI sheets) 5-20 Years of age. Recruited from the Paediatric department, University Hospital Holbaek, Region Zealand, Denmark, University of Copenhagen
61988875|NCT04530006|EXPERIMENTAL|GBM Patients|"This cohort of patients will be asked to orally ingest 200mg dose of FDA approved drug amantadine hydrochloride. This will be done at the following timepoints:~1. Within 4 weeks of the start of treatment; but as close to commencement of treatment (Day 1 of radiotherapy) as possible for newly diagnosed patients.~2. Cycle 1, Day 1 of chemotherapy (temozolomide or lomustine) +/- 7 days~3. Day 1 +/- 7 days for each visit where MRI is obtained (typically every 8-12 weeks - pre-cycles 4, 7, 10, for temozolomide or pre-cycles 3, 5, and 7 for lomustine)"
61988876|NCT00785109|EXPERIMENTAL|1|100 patients daily additional intake of 2mg vitamin k1
61988877|NCT00785109|PLACEBO_COMPARATOR|2|100 patients no additional intake of vitamin K
61988878|NCT05828199|ACTIVE_COMPARATOR|Dexmedtomidine group|About 40 patients will receive bolus dose of dexmedetomidine 0.5-1 μg/kg in 100 mL of normal saline over 10 minutes then, continuous infusion dose of dexmedetomidine 0.2 ug/kg/hr.
61988879|NCT05828199|ACTIVE_COMPARATOR|ketamin group|About 40 patients will receive a ketamine bolus dose (0.3 mg/kg IV slowly), then continuous infusion dose of ketamine (0.2 mg/kg/hr).
61988880|NCT03836963|EXPERIMENTAL|cognitive and memory strategy training|The cognitive training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours. For memory strategy training, strategies will be performed daily; this will take only a few minutes a day to accomplish.
61988881|NCT03836963|ACTIVE_COMPARATOR|cognitive and memory strategy control training|The cognitive training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours. For the active control of memory strategy training, strategies will be performed daily; this will take only a few minutes a day to accomplish.
61988882|NCT03836963|ACTIVE_COMPARATOR|active control for cognitive and memory strategy training|The cognitive training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours. For the active control of memory strategy training, strategies will be performed daily; this will take only a few minutes a day to accomplish.
61988883|NCT01722253||placebo, electroacupuncture|"Electroacupuncture before and after surgery (40min and 60 min respectively) with frequency 2 Hz, and 'frequency scanning mode'.~Placebo electroacupuncture, in which the needles are secured (without penetrating the skin) and connected to the electrical device, which is not functional."
61988884|NCT05153109||Community sample|Participants will be recruited from families in Bochum who take part in experiments and studies at the department of delevopmental psychology at the Ruhr-University. The department of developmental psychology organizes a panel every year inviting all parents of newborn babies in Bochum to register if they want to participate in research.
61988885|NCT05153109||Clinical sample|Participants will be recruited from families in Bochum and Munich who seek treatment in the outpatient treatment centers at both sites. Both study sites offer special counselling for parents who experience difficulties with a child from zero to five years of age.
61988886|NCT03830060||Group I:|Fifty AP patients on admission
62383925|NCT01491711|ACTIVE_COMPARATOR|Methylaminolevulinate PDT in 2 sessions|On day 1 and 8
62383926|NCT01256957|ACTIVE_COMPARATOR|Indoor air HEPA filtration|HEPA filters operating in the participant's bedroom and living room.
62383927|NCT01256957|NO_INTERVENTION|Control|Control
62383928|NCT03111810|ACTIVE_COMPARATOR|Active|Prednisolone 20mg once daily and AZD4017 400mg twice daily for 7 days.
62383929|NCT03111810|PLACEBO_COMPARATOR|Placebo Oral Tablet|Prednisolone 20mg once daily and placebo twice daily for 7 days.
62764845|NCT04787380|EXPERIMENTAL|LOVE-HF Arm A (Full data analysis mode of Heartfelt + weight + symptoms reporting)|Participants in LOVE-HF Arm A (Full data analysis mode of Heartfelt + weight + symptoms reporting) will not know if they are assigned to LOVE-HF Arm A or LOVE-HF Arm B. The Heartfelt device will be in 'full data analysis' mode and participants will follow standard care recommendations for weighing themselves and reporting their symptoms. 'Full data analysis' mode means that the device will be fully operational and will be detecting and reporting changes in foot volume over time. The device will have been allocated to the 'full data analysis' mode prior to shipping. Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per usual advice given to patients, thus taking part in the study should not change their behaviour.
61988887|NCT03830060||Group II:|The previous AP patients after 72 hours
62764846|NCT04787380|NO_INTERVENTION|LOVE-HF Arm B (Technical checks only mode of Heartfelt + weight + symptoms reporting)|Participants in LOVE-HF Arm B (Technical checks mode of Heartfelt + weight + Symptoms reporting) will not know if they are assigned to LOVE-HF Arm A or LOVE-HF Arm B. The Heartfelt device will be in 'technical checks only' mode where the data analysis pipeline is blocked and changes in foot volume over time will not be processed or reported. However, technical checks on device functioning and image quality (e.g. camera being blocked) will be made as usual. The device will have been allocated to the 'technical checks only' mode prior to shipping. Participants will follow standard care recommendations for weighing themselves and reporting their symptoms. Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per usual advice given to patients, thus taking part in the study should not change their behaviour.
62764847|NCT04731207|OTHER|Healthy pregnant women|All participants will be investigated by Optovue® in follicular phase, ovulatory phase, luteal phase of menstrual cycle. The investigation will be done between 12 PM and 1 PM at each phase. Urine pregnancy testing was done at first and last visits. LH ovulation test was performed by the participants own. if the ovulation was detected by urine strip test, the participant have to underwent the Optovue® within 48 hours.
62764848|NCT06025799|EXPERIMENTAL|"Mindfulness-based stress reduction intervention"|patients who will be under routine hospital care as well as Mindfulness-Based Stress Reduction (MBSR) program The Mindfulness-Based Stress Reduction (MBSR) program consists of eight sessions focusing on reducing stress and improving well-being. Participants learn and practice mindfulness techniques such as mindful eating, breathing, body scan, and meditation. The program emphasizes self-responsibility, developing coping strategies, and applying mindfulness daily. Participants engage in formal mindfulness practices, reflect on their experiences, and receive guidance on continuing their mindfulness journey after the program. The goal is to cultivate resilience, enhance well-being, and reduce stress.
62764849|NCT06025799|NO_INTERVENTION|" routine hospital care"|Female cancer patients who will be under routine hospital care
61988888|NCT06278246||Patients with Schizophrenia|Antipsychotic-free patients with schizophrenia or schizophreniform disorder
61988889|NCT06278246||Healthy Controls|Healthy controls matched for age, sex, cannabis, and nicotine consumption to the 29 patients
62764850|NCT02771626|EXPERIMENTAL|Telaglenastat 600 mg + Standard Dose Nivolumab|Telaglenastat 600 mg in combination with standard dose nivolumab in participants with advanced/metastatic clear cell renal cell carcinoma (ccRCC), melanoma, and non-small cell lung cancer (NSCLC).
61988890|NCT00854074|NO_INTERVENTION|2|Subject will be observed until recovery of normal GI function
61988891|NCT00854074|EXPERIMENTAL|1|Spinal neurostimulation
61988892|NCT05609955|EXPERIMENTAL|MgSO4|The treatment group received intravenous magnesium sulfate therapy with a 20% magnesium sulfate regimen, 39mg/kg body weight dissolved in 100ml NaCl in 1 hour intravenously.
61988893|NCT05609955|PLACEBO_COMPARATOR|Placebo|The treatment group who received intravenous placebo therapy with a regimen of 100 ml NaCl in 1 hour intravenous
61988894|NCT00857220|EXPERIMENTAL|2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs)|
62383930|NCT04565535|EXPERIMENTAL|Intervention arm|Liver donors undergoing lifestyle optimisation
62383931|NCT04565535|NO_INTERVENTION|Control arm|Liver donors who continue normal lifestyle.
61988895|NCT03617081|EXPERIMENTAL|NNC0113-2023|Participants will receive increasing doses of NNC0113-2023 on day 1. Each participant will receive only a single dose.
61988896|NCT03617081|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo (NNC0113-2023)
61988897|NCT00799578|EXPERIMENTAL|Cystagon-EC|
61988898|NCT02045680||deep block|deep block
61988899|NCT02045680||non deep block (historical control)|non deep block (historical control)
61988900|NCT01094548|EXPERIMENTAL|Tecemotide (L-BLP25) plus single low dose cyclophosphamide|
61988901|NCT01094548|EXPERIMENTAL|Tecemotide (L-BLP25) plus multiple low dose cyclophosphamide|
61988902|NCT05537571|EXPERIMENTAL|SLN360 Dose 1|SLN360 for subcutaneous injection
61988903|NCT05537571|EXPERIMENTAL|SLN360 Dose 2|SLN360 for subcutaneous injection
61988904|NCT05537571|EXPERIMENTAL|SLN360 Dose 3|SLN360 for subcutaneous injection
61988905|NCT05537571|PLACEBO_COMPARATOR|Placebo Dose 1|Sodium chloride for subcutaneous injection
61988906|NCT05537571|PLACEBO_COMPARATOR|Placebo Dose 2 and 3|Sodium chloride for subcutaneous injection
61988907|NCT04574804|EXPERIMENTAL|online training program|online training program Participants receive access to online training program consisting of 6 e-learning modules on topics of weight management in osteoarthritis, which they will be instructed to and encourage to complete over the 6 intervention period.
62383932|NCT04313595|EXPERIMENTAL|Breathing frequency monitoring|
62383933|NCT01497002|ACTIVE_COMPARATOR|standard arm|standard treatment arm
62764851|NCT02771626|EXPERIMENTAL|Telaglenastat 800 mg + Standard Dose Nivolumab: ccRCC Naïve to Checkpoint Inhibitors|Telaglenastat 800 mg/standard dose nivolumab combination in participants with advanced/metastatic ccRCC who have previously received at least one tyrosine kinase inhibitor (TKI) but are treatment naïve to checkpoint modulators programmed death-1/programmed death ligand-1 (PD-1/PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), or any other agent that specifically targets a T-cell checkpoint or co-stimulation pathway.
62764852|NCT02771626|EXPERIMENTAL|Telaglenastat 800 mg + Standard Dose Nivolumab: ccRCC Recently Treated With Nivolumab|Telaglenastat 800 mg/standard dose nivolumab combination in participants with advanced/metastatic ccRCC who received nivolumab in most recent treatment line that had documented radiological disease progression OR are currently receiving nivolumab with stable disease for at least 24 weeks.
62764853|NCT02771626|EXPERIMENTAL|Telaglenastat 800 mg + Standard Dose Nivolumab: ccRCC With Prior PD-1 Therapy|Telaglenastat 800 mg/standard dose nivolumab combination in participants with advanced/metastatic ccRCC that had documented radiological disease progression while receiving an anti-PD-1/PD-L1 therapy in any prior line of therapy.
62764854|NCT02771626|EXPERIMENTAL|Telaglenastat 800 mg + Standard Dose Nivolumab: Melanoma With Prior PD-1 Therapy|Telaglenastat 800 mg/standard dose nivolumab combination in participants with unresectable or metastatic melanoma that had documented radiological disease progression while receiving an anti-PD-1 therapy in their most recent line of therapy.
62764855|NCT02771626|EXPERIMENTAL|Telaglenastat 800 mg + Standard Dose Nivolumab: NSCLC With Prior PD-1 Therapy|Telaglenastat 800 mg/standard dose nivolumab combination in participants with NSCLC that does not harbor an activating mutation in the epidermal growth factor receptor (EGFR) oncogene and who received nivolumab in most recent treatment line and had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.
62764856|NCT00504140|EXPERIMENTAL|Interferon Alpha + Etoposide|Interferon Alpha 5x10\^6 mu/m\^2 subcutaneously and Etoposide 100 mg/m\^2 intravenously, both daily for 5 days
62764857|NCT02302235|ACTIVE_COMPARATOR|Ketogenic Diet|Treatment will consist of ketogenic diet. KGD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction. Diet will be started at the time of initiation of radiation treatment.
62764858|NCT02302235|OTHER|Standardized diet|The subjects will be taken standard diet in a 1:1 ratio.
62764859|NCT05894525||Cohort 1|Participants received 2 doses of mRNA-1273 vaccine approximately 4 weeks apart.
62764860|NCT01495520|ACTIVE_COMPARATOR|Ranolazine|Patients will receive ranolazine 750 mg bid for 30 days
62764861|NCT01495520|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo for 30 days
62764862|NCT04327635|EXPERIMENTAL|PEP in Coronary Stent Implantation|Patients undergoing a percutaneous coronary intervention (PCI) and possible stent placement procedure will receive a one-time intracoronary infusion of PEP within 20 minutes after stent placement or post-dilation (whichever comes last).
62764863|NCT03177096|EXPERIMENTAL|Peds QL questionnaire and diabetes modulate|Routine practice of a continuous measure sensor of the glycemia with insulin pump for children aged 2 to 13 years followed at Mulhouse Hospital for type 1 diabetes : 5 sessions after enrollment visit(V1) (1 session 2 months, 4 months, 6 months, 8 months and 10 months) This study will be proposed to patients treated for type 1 diabetes enrolled in kindergarten, primary school, attending a nursery or a childcare center (patient's participation = 10 months) and will evaluate the child quality of life and the parents and staffs in preschool and school felt too.
62764864|NCT00334282|PLACEBO_COMPARATOR|placebo arm|matching placebo (800 mg tablet) once daily
62764865|NCT00334282|EXPERIMENTAL|pazopanib arm|Oral pazopanib tablet 800 mg once daily continuously
62764866|NCT05261581|EXPERIMENTAL|Intervention|Patients that will get ESPB, NSAID and exercise programme
62764867|NCT05261581|ACTIVE_COMPARATOR|Control|Patients that will only get NSAID and exercise programme
62764868|NCT03266913|ACTIVE_COMPARATOR|Probiotic|Routine phototherapy plus probiotic oral drops at the dose of 10 drops daily
62764869|NCT03266913|NO_INTERVENTION|No probiotic|Routine phototherapy
62764870|NCT01853072|EXPERIMENTAL|Nepafenac|With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
62764871|NCT01853072|PLACEBO_COMPARATOR|Vehicle|With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
61988908|NCT04574804|NO_INTERVENTION|control group|control group Participants do NOT receive access to the online training program consisting of 6 e-learning modules on topics of weight management in osteoarthritis during the intervention period.
62764872|NCT00620152|EXPERIMENTAL|1|Low glycemic load diet
62764873|NCT00620152|ACTIVE_COMPARATOR|2|Low fat diet
62764874|NCT01948232|EXPERIMENTAL|Perindopril|
61988909|NCT02641769|OTHER|Stem Cell Transplantation|intervention with transplantation of autologous purified stem cells
61988910|NCT00455507|EXPERIMENTAL|1|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
62383934|NCT01497002|EXPERIMENTAL|OSHO - intensified consolidation|Intermediate dose AraC
62383935|NCT01497002|EXPERIMENTAL|OSHO - allografting as consolidation|allogeneic stem cell Transplantation versus no transplantation
62764875|NCT02933840|EXPERIMENTAL|AlertWatch|Patients will receive standard monitoring and in addition the AlertWatch software will alert the intensive care physician if there is a value that meets criteria for alerting. The care team will be the orthopedic surgery team in addition to the intensive care physician being involved as a consultant if he/she receives an alert.
62764876|NCT02933840|NO_INTERVENTION|No AlertWatch|Patients will receive standard monitoring without the AlertWatch software. The care team will be the orthopedic surgery team without the intensive care physician being involved as a consultant.
61988911|NCT00455507|EXPERIMENTAL|2|40mg KW-6002 per day (two 20 mg KW-6002 tablets orally once daily for 12 weeks)
62383936|NCT05348499||People with T1D participating in the NHS funded pilot of HCL therapy|"The questionnaires to be administered to people with type 1 diabetes, over 3 months after starting hybrid closed loop insulin pump therapy as part of the NHS pilot are:~* Gold Score~* Patient health questionnaire-9 (PHQ-9)~* Diabetes distress score-T1~* Hypoglycaemia confidence scale~* INSPIRE survey~* EQ5D5L~* Diabetes Treatment Satisfaction Questionnaire (DTSQs) and Diabetes Treatment Satisfaction Questionnaire change (DTSQc) version~* Bespoke questionnaire using domains that are important to people with diabetes~* System usability scale~Approximately 15 participants with type 1 diabetes will be asked to participate in semi-structured qualitative interviews at \>3 months after the person with type 1 diabetes starts the HCL."
61988912|NCT00455507|PLACEBO_COMPARATOR|3|Two placebo tablets once daily for 12 weeks
61988913|NCT01791842|EXPERIMENTAL|Tocilizumab first, then placebo|one IV infusion per month of Tocilizumab for 6 months followed by 1 infusion per month of placebo, for 6 months.
61988914|NCT01791842|EXPERIMENTAL|Placebo first, then Tocilizumab|one IV infusion per month of Placebo for 6 months followed by 1 infusion per month of Tocilizumab, for 6 months.
61988915|NCT05440279|NO_INTERVENTION|Standard Care (SC)|Treatment in the control group takes place as standard care that includes an education session with a respiratory therapist about OSA and its consequences, proper use and maintenance of the CPAP device and mask, and therapy and study expectations, provision with a fixed or auto CPAP device (prismaSMART/ prismaSOFT, Löwenstein Medical Technology GmbH \& Co. KG), a heated humidifier (prismaAQUA, Löwenstein Medical Technology GmbH \& Co. KG) if needed, and a fitting interface, the initiation of therapy with anamnesis, diagnosis night, titration night, education, etc., as well as standardized therapy control after 12 weeks.
62383937|NCT05348499||Partners of people with T1D participating in the NHS funded pilot of HCL therapy|"Partners of people with type 1 diabetes will be invited to complete three validated questionnaires that have been specifically developed for partners and one bespoke questionnaire:~* Diabetes distress score - partner~* Hypoglycaemia confidence scale - partner~* INSPIRE - partner~* Bespoke questionnaire~Approximately 15 partners of people with type 1 diabetes will be asked to participate in semi-structured qualitative interviews at \>3 months after the person with type 1 diabetes starts the HCL."
62383938|NCT06481007||Cholecystectomy|patient opérated ( cholecystectomy) and responding to inclusion criteria
62383939|NCT04107935|EXPERIMENTAL|Intervention|
62383940|NCT04107935|OTHER|Usual Care|
62567654|NCT01672554|OTHER|Seroquel XR|Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
62567655|NCT00348777|ACTIVE_COMPARATOR|1|group with 18 days thermal cure
61977739|NCT06122129|EXPERIMENTAL|Flexible ureteroscope with ureteral access sheath|Stones will be treated by flexible ureteroscope with ureteral access sheath
61977740|NCT06122129|ACTIVE_COMPARATOR|Flexible ureteroscope without ureteral access sheath|Stones will be treated by flexible ureteroscope without ureteral access sheath
61977741|NCT00560079|EXPERIMENTAL|1|Lithium 900mg/day plus allopurinol 600mg/day
61977742|NCT00560079|ACTIVE_COMPARATOR|2|
61977743|NCT00560079|PLACEBO_COMPARATOR|3|
61977744|NCT04290689||Botulinum Toxin-A injection treatment|Toe walking Cerebral Palsy subject who are subject to Botulinum toxin-A injection treatment. The dosage will be determined by the Orthopaedic Consultant
62764877|NCT02753686||Cohort 1: Endocrine Therapy (ET)|HR+ HER2- male, female pre/postmenopausal advanced breast cancer patients being treated with endocrine therapy
62764878|NCT02753686||Cohort 2: Endocrine Therapy (ET) plus Targeted Therapy (TT)|HR+ HER2- male, female pre/ postmenopausal advanced breast cancer patients being treated with endocrine therapy in combination with targeted therapy including CDK4/6 inhibitor therapy
62764879|NCT00581828|EXPERIMENTAL|1|Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).
62764880|NCT03688698||PAH|
62764881|NCT03688698||Controls|
62764882|NCT05189249||Case|Patients who have undergone repeat revascularization within 5 years of undergoing index PCI at Aga Khan University Hospital Karachi.
62764883|NCT05189249||Control|Patients who have not undergone repeat revascularization within 5 years of undergoing index PCI at Aga Khan University Hospital Karachi.
62764884|NCT00721721|EXPERIMENTAL|1|Participants will follow a low sodium diet for Days 1 through 7, a high sodium diet for Days 7 through 14, and a high sodium diet plus potassium supplement regimen for Days 14 through 21.
62168233|NCT05464199|EXPERIMENTAL|Participants receiving neurofeedback intervention|Self administered neurofeedback training - Use of Headset and tablet with software App for playing a selected neurofeedback game. The EEG headset and tablet-based application is designed with the purpose of alleviating chronic pain by providing the user with feedback of, and allowing them to modulate, their own EEG signals associated with activity in brain networks related to pain perception and pain modulation.
62168234|NCT06645574|EXPERIMENTAL|Girls practizing gymnastics 8 to 15 yo|
62168235|NCT03216252|OTHER|biological samples|biological samples on patients with MITOCHONDRIAL DISEASES
61977745|NCT04290689||Serial casting stretching treatment|Toe walking Cerebral Palsy subject who are subject to serial casting stretching treatment.
62383941|NCT06000826|EXPERIMENTAL|Neonatal|"* A trained study nurse or clinician will transfer the enrolled participant to the study location and place the infant on the Celsi Warmer mattress.~* A trained study nurse or clinician will attach the Celsi Warmer temperature sensor to the abdomen and secure it with the abdominal belt according to the device's instruction manual~* A trained study nurse or clinician will wrap the baby according to the standard care at the hospital.~* Study personnel may observe the participant during the intervention period and annotate timestamped events that might affect temperature measurement and/or thermoregulation support intervention.~* Study personnel will perform routine abdominal skin assessments as often as every two hours and at least every 8 hours to observe for skin irritation or indentation.~* Thermoregulation support intervention will be provided as long as the infant continues to meet criteria for continued care at clinician's discretion."
62383942|NCT02948244|ACTIVE_COMPARATOR|Group A - Active/Placebo|Participants will receive 3 months of creatine monohydrate followed by a 6 week washout period followed by 3 months of placebo.
61988916|NCT05440279|ACTIVE_COMPARATOR|Standard Care (SC) + digital patient support (DPS) tool|"Treatment in the intervention group takes place as standard care (please see description of arm 1 - control group) and electronic therapy support in addition. The electronic therapy support consists of:~1. Emails to patients with personalized, automated feedback on their therapy (derived from device data received via modem or data entered by the patient via electronic questionnaire),~2. electronic questionnaires (web-based) on possible problems during therapy, personal adherence goals and subjective therapy success,~3. possibility to set personal adherence goals every week,~4. links to explanations and videos on therapy and the handling of therapy equipment and accessories,~5. provision of data for the trial center in the event of contact by the patient, as well as for routine therapy monitoring."
61988917|NCT01237873|EXPERIMENTAL|Ali/Amlo|Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg
61988918|NCT01592344|EXPERIMENTAL|StimRouter - active stimulation|StimRouter- active electrical stimulation is applied transdermally to a targeted peripheral nerve. This is accomplished via a fully implanted StimRouter lead that receives energy from a rechargeable programmed external pulse transmitter (EPT) with attached gel electrodes. The EPT receives radio frequency (RF) commands from a Patient Programmer. A StimRouter Clinician Programmer is used to program the StimRouter EPT and Patient Programmer. Up to eight stimulation programs may be saved on a Patient Programmer for on-demand selection by the study patient.
61988919|NCT01592344|SHAM_COMPARATOR|StimRouter - Control|StimRouter- Electrical stimulation is withheld from the targeted peripheral nerve after fully implanting the StimRouter lead. The rechargeable programmed external pulse transmitter (EPT) with attached gel electrodes is placed for transdermal stimulation but no stimulation is delivered. The EPT which normally receives radio frequency (RF) commands from a Patient Programmer is not activated. A StimRouter Clinician Programmer is used to program the StimRouter EPT and Patient Programmer such that no stimulation occurs in the Control Arm of the study.
62383943|NCT02948244|ACTIVE_COMPARATOR|Group B - Placebo/Active|Participants will receive 3 months of placebo followed by a 6 week washout period followed by 3 months of creatine monohydrate.
62383944|NCT03049839|EXPERIMENTAL|Intervention_ structured|One year Structured intervention program for members of high-risk group (People with glucose intolerance in the OGTT and FINDRISC score ≥12 points) 10 educational group sessions where they will receive information to change lifestyle (1 per 1.5 month)
62383945|NCT03049839|EXPERIMENTAL|Intervention_ Informative|"Program information intervention for the group with moderate risk. One year Informative intervention program (People with normotolerant or impaired fasting glucose in the OGTT and FINDRISC score ≥12 points).~There is a single group session where they receive information to prevent cardiomatabolic risk factors"
62383946|NCT03049839|EXPERIMENTAL|Intervention_ Communitarian|"One year, Intervention program at Community level. People with a FINDRISC less than 12 points.~Campaigns are carried out at the community level with different strategies (leaflets, booklets) to prevent cardiomatabolic risk factors"
62383947|NCT03958409|EXPERIMENTAL|Rigorous evaluation|Participants will be evaluated for the rigorous evaluation received.
62383948|NCT03958409|ACTIVE_COMPARATOR|Standard care|The participants will be evaluated for the standard of care received.
62383949|NCT00543842|EXPERIMENTAL|Bevacizumab + Erlotinib + Capecitabine + Radiation Therapy|Bevacizumab 5 mg/kg intravenous (IV) every 2 weeks for 3 Doses (Weeks 1, 3, 5). Erlotinib starting dose 50 mg orally daily Weeks 1-3. Capecitabine starting dose 650 mg/m\^2 orally twice daily Monday-Friday for 6 Weeks. Radiation Therapy 30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments. At least 8 weeks after radiation therapy, surgical removal of rectal tumor.
62383950|NCT04385667|ACTIVE_COMPARATOR|levonorgestrel intrauterine system (LNG-IUD)|"levonorgestrel intrauterine system (LNG-IUD) applied.~* Follow up endometrial sampling will be scheduled for all study patients in 3 months manner for at least one year. Specimens will be reviewed by single expert pathologist.~* Patients with persistent atypical hyperplasia in specimens done after 6 months of start of therapy will be considered resistant to therapy and hysterectomy will be done.~* Primary and secondary outcome data will be collected in tables with the other demographic data. All will be processed in tables for statistical analysis."
62567656|NCT00348777|SHAM_COMPARATOR|2|group with no thermal cure but only access 3 days to watering place 6 months after inclusion
62567657|NCT04937777||Group pre-2010|Patients who initiated first-line treatment between 2004 and 2010 (pre-2010).
61988920|NCT02448238|EXPERIMENTAL|probiotic|This is a single arm study all subjects will receive the study VSL#3 probiotic. Subjects will take 1 sachet of powder orally daily for 12 weeks
61988921|NCT04829877|EXPERIMENTAL|Web-based mind-body intervention with HRVB|Both standard usual care and the web-based mind-body intervention with HRV biofeedback (MBI-HRVB) will be provided to the participants. The web-based mind-body intervention with HRV biofeedback program consisted of 5-week training sessions and breathing training.
61988922|NCT04829877|EXPERIMENTAL|Web-based mind-body intervention|Both standard usual care and the web-based mind-body intervention will be provided to the participants. The web-based mind-body intervention program consisted of 5-week training sessions.
61988923|NCT04829877|NO_INTERVENTION|Control|The women in the control group will receive the standard usual care provided at the fertility clinic. The standard care protocols encompass elements such as routine assessment and health education at each visit. Participants enrolled in the control group will be approached once a week by a nurse to provide health consultation about fertility treatment, medication, signs, and symptoms of discomfort for five weeks.
62567658|NCT04937777||Group post-2010|Patients who initiated first-line treatment between 2011 and 2018 (post-2010).
62764885|NCT03946865|EXPERIMENTAL|Hospitalized hematology/oncology cancer subjects|Hospitalized hematology/oncology cancer will participate in Reiki Therapy
62764886|NCT05287048||Patients with postmenopausal bleeding|Patients attending a gynaecology clinic for investigation of postmenopausal bleeding and undergoing a transvaginal ultrasound (TVUS).
61988924|NCT03406858|EXPERIMENTAL|Treatment (pembrolizumab, HER2Bi-armed activated T cells)|Patients receive pembrolizumab IV over 30 minutes every 3 weeks. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. Beginning at least 1 week after pembrolizumab, patients receive HER2Bi-armed activated T cells IV over 5-15 minutes 2 times a week for 4 weeks in the absence of disease progression or unacceptable toxicity.
61988925|NCT02916615|ACTIVE_COMPARATOR|High nitrate vegetables|During 5 weeks subjects receive 100-150 g of a leafy green vegetable (High nitrate vegetables) per day and placebo pills containing 300 mg KCl (2 x 150 mg).
62383951|NCT04385667|ACTIVE_COMPARATOR|Megestrol acetate (MA)|"Megesterol arm will receive 160 mg daily~* Follow up endometrial sampling will be scheduled for all study patients in 3 months manner for at least one year. Specimens will be reviewed by single expert pathologist.~* Patients with persistent atypical hyperplasia in specimens done after 6 months of start of therapy will be considered resistant to therapy and hysterectomy will be done.~* Primary and secondary outcome data will be collected in tables with the other demographic data. All will be processed in tables for statistical analysis."
62383952|NCT01901809|ACTIVE_COMPARATOR|Bolus furosemide and no dopamine|"If the patient is not on a prior diuretic dose, a standard dose of furosemide 40mg IV every 12 hrs, with total dose of 80 mg IV over 24 hrs will be initiated.~If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose every 12 hrs. (i.e if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose will be furosemide 80mg IV twice daily)."
62383953|NCT01901809|ACTIVE_COMPARATOR|Continuous infusion furosemide and no dopamine|"If the patient is not on a prior diuretic dose, a standard dose of furosemide 80mg IV over 24 hrs, will be initiated.~If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose continuously over 24 hrs. . (i.e. if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose would be furosemide 160mg IV to be administered continuously over 24 hrs)."
62383954|NCT01901809|ACTIVE_COMPARATOR|Bolus furosemide plus dopamine|Intermittent furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min
62383955|NCT01901809|ACTIVE_COMPARATOR|Continuous furosemide plus dopamine|Continuous furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min
62383956|NCT01523613|ACTIVE_COMPARATOR|ROCK - Single Restorations|ChemFil Rock glassionomer restoration
62383957|NCT01523613|ACTIVE_COMPARATOR|Fuji IX GP - Single Restorations|Fuji IX GP Extra glassionomer restoration
62383958|NCT01523613|ACTIVE_COMPARATOR|Rock AND Fuji - Paired Restorations|"ChemFil Rock glassionomer restoration AND Fuji IX GP Extra glassionomer restoration.~While this is not truly a separate arm for outcome analysis, this arm represents those individuals who had paired restorations, one of each: 1 ChemFil Rock restoration and 1 Fuji IX GP restoration."
62383959|NCT02045823||Normal|Normal results from clinical exam and free of ocular pathology
62764887|NCT02736513|EXPERIMENTAL|AZD9291 80 mg - naive patients|naive patients with tumors harbouring either exon 19 deletion, L858R, T790M, or uncommon sensitizing EGFR mutations, will be treated with AZD9291 80 mg/day
61988926|NCT02916615|PLACEBO_COMPARATOR|Low nitrate vegetables|During 5 weeks subjects receive 100-150 g of tomatoes/sweet pepper (Low nitrate vegetables) per day and placebo pills containing 300 mg KCl (2 x 150 mg).
62383960|NCT02045823||Glaucoma|Clinical exam with results consistent with glaucoma and visual field defects consistent with glaucoma
62383961|NCT02045823||Retina|clinical exam with results consistent with retina pathology
62764888|NCT02736513|EXPERIMENTAL|AZD9291 80 mg - previously treated T790M was diagnosed|Patients previously treated with first and second generation EFGR TKIs (either Gefitinib, Erlotinib or Afatinib) in whom T790Mwas diagnosed either in the tumor specimen or in the ctDNA after testing it following the most recent disease progression, will be treated with AZD9291 80 mg/day
62764889|NCT02736513|EXPERIMENTAL|AZD9291 80 mg - previously treated unrelated to T790M|patients advanced NSCLC previously treated with 1st/2nd generation EGFR TKIs (either gefitinib. erlotinib or afatinib) who progressed unrelated to T790M (T790M-). No restriction regarding the number of prior EGFR TKIs or cytotoxic chemotherapy lines of treatment is applied.
62764890|NCT01920152|EXPERIMENTAL|Autologous PRP Hip Injection|Patients randomized to this group of treatment will receive 3 blinded hip intra-articular injections of autologous Platelet-Rich Plasma one week apart from each other.
62764891|NCT01920152|ACTIVE_COMPARATOR|Hyaluronic Acid Hip Injection|Patients randomized to this group of treatment will receive 3 blinded hip intra-articular injections of hyaluronic acid (SUPARTZ hyaluronate/2.5ml) one week apart each other.
62764892|NCT04403243|EXPERIMENTAL|1. Colchicine|30 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
62764893|NCT04403243|EXPERIMENTAL|2. Ruxolitinib|10 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
61988927|NCT02916615|ACTIVE_COMPARATOR|Low nitrate vegetables + nitrate|During 5 weeks subjects receive 100-150 g of tomatoes/sweet pepper (Low nitrate vegetables) per day and nitrate pills containing 300 mg KNO3 (2 x 150 mg).
61988928|NCT04324801|EXPERIMENTAL|Single arm|This is a within-subject repeated-measures design.
61988929|NCT00982709|ACTIVE_COMPARATOR|Exercise Types|comparing two different exercise programs for PD
62383962|NCT01597934|ACTIVE_COMPARATOR|Group A:|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
62383963|NCT01597934|EXPERIMENTAL|Group B|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
62764894|NCT04403243|EXPERIMENTAL|3.Secukinumab|10 Patients with mild and severe COVID 19 Patients will get investigated therapy singly. Patients will be follow-up during 45 days after randomization
62764895|NCT04403243|ACTIVE_COMPARATOR|4.Standard treatment|-30 patients Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
62764896|NCT04959812|EXPERIMENTAL|Sufentanil|Sufentanil (30 microgram tablet) will be administered via a sublingual pill
62764897|NCT04959812|PLACEBO_COMPARATOR|Placebo|Placebo will be administered via a sublingual pill
61988930|NCT03048656|EXPERIMENTAL|Individuals with leg-length discrepancy|Patients of Department of Paediatric Orthopaedics and Traumatology, Poznan University of Medical Sciences diagnosed with leg-length discrepancy. The examination of participants included a measurement of the length of lower limbs and the weight distribution as well as performing the static posturography.
61988931|NCT03048656|ACTIVE_COMPARATOR|control group|The group with healthy individuals; without leg-length discrepancy. The examination of participants included a measurement of the weight distribution as well as performing the static posturography.
62383964|NCT04789005|ACTIVE_COMPARATOR|Phenylephrine group|Phenylephrine 100mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
62383965|NCT04789005|EXPERIMENTAL|Norepinephrine group|Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
62383966|NCT04879511|ACTIVE_COMPARATOR|Receiving metformin|Active group receiving metformin with basal /bolus insulin
62764898|NCT04316806|EXPERIMENTAL|Probiotic|Treatment with probiotic formula
62764899|NCT04316806|OTHER|Antibiotic|Treatment with antibiotic rifaximin
62764900|NCT01134926|NO_INTERVENTION|intra-uterine residua. expectant management|The patients in this arm will not get any treatment and be followed up by US examinations
62383967|NCT04879511|PLACEBO_COMPARATOR|Placebo|Control group receiving Placebo with basal/bolus insulin
62383968|NCT00606918||1|Individuals with ALS
62383969|NCT00606918||2|Healthy Adults
62383970|NCT06428175|ACTIVE_COMPARATOR|Focused Dose Hospital-to-Home Transitional Care Interventions|
62764901|NCT01134926|EXPERIMENTAL|Intra-uterine residua. misoprostol|The patients in this arm will be treated with misoprostol at the recruitment day. If there will be sonographic evidence of intra-uterine residua the day after, they'll gat another dose.
61988932|NCT05282082||Patients at the moment of their admission to the hospital in one of the three cities|Swabs will be taken from patients who are willing to participate.
62383971|NCT06428175|ACTIVE_COMPARATOR|Extended Dose Hospital-to-Home Transitional Care Interventions|
62383972|NCT03527927|EXPERIMENTAL|LABA/LAMA inhaler|Patients on a combination of inhaled corticosteroid (ICS), long acting beta agonist (LABA) and long acting muscarinic antagonist (LAMA) will be taken off their current ICS/LABA/LAMA combination inhalers and will commence on a single LABA/LAMA inhaler (any LABA/LAMA) of their choice.
62383973|NCT05071794|ACTIVE_COMPARATOR|Propofol|Subhypnotic dose of propofol, 0.5mg/kg, 10 - 15 min before end of surgery
62764902|NCT05593276|NO_INTERVENTION|Waitlist|
62764903|NCT05593276|EXPERIMENTAL|Internet-based program|
62764904|NCT05367141|ACTIVE_COMPARATOR|CDSS|patient management with aid of CDSS
62764905|NCT05367141|NO_INTERVENTION|standart care|patient management with standard care according to guidelines
62383974|NCT05071794|PLACEBO_COMPARATOR|Placebo|Normal saline 0.9%, 10 mL , 10 - 15 min before end of surgery
62383975|NCT01314261|EXPERIMENTAL|ABT-267 (5 mg) once daily + pegIFN/RBV|Participants were given 5 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
62383976|NCT01314261|EXPERIMENTAL|ABT-267 (50 mg) once daily + pegIFN/RBV|Participants were given 50 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
62383977|NCT01314261|EXPERIMENTAL|ABT-267 (200 mg) once daily + pegIFN/RBV|Participants were given 200 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
62383978|NCT01314261|PLACEBO_COMPARATOR|Placebo + pegIFN/RBV|Participants were given matching placebo to ABT-267 once daily in combination with pegIFN/RBV for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
62383979|NCT04723342|EXPERIMENTAL|Blinatumomab|Consolidation therapy with Blinatumomab administration
62383980|NCT02009501|ACTIVE_COMPARATOR|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins .125% instillation will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4.
62383981|NCT02009501|ACTIVE_COMPARATOR|VAC Ulta Therapy|VAC ULTA Therapy will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4.
62383982|NCT04615728||pre-COVID cohort|Patients recruited from 1st November 2019 to 9th March 2020
62383983|NCT04615728||COVID cohort|Patients recruited from 10th March 2020 to 5th July 2020
62383984|NCT01444144||Ankle Fracture|Patients aged 55 years at time of surgery undergoing treatment for ankle fractures.
62383985|NCT04337203|EXPERIMENTAL|SHARE-S|Three components consisting of electronic referral, health coaching and tailored text/email messages for patients that have been referred to the cancer survivorship clinic.
62383986|NCT02193685||Subjects with HAEC|There is no intervention involvement. The clinical data and biologic specimens collected during the study will serve as an invaluable resource for a wide spectrum of clinical and translational ancillary studies directly related to the aims and goals of the study.
62383987|NCT02193685||Subjects without HAEC|A subgroup of children who have Hirschsprung Disease may or may not develop enterocolitis; therefore we will be identifying the bio-markers in children with or without associated enterocolitis.
62383988|NCT02062216||STEMI|Patients with ST-elevation myocardial infarction (STEMI) with angiographic evidence of massive thrombosis in the culprit artery undergoing primary percutaneous coronary intervention (PCI)
62383989|NCT02062216||STABLE ANGINA|Patients with coronary artery disease in stable conditions scheduled to undergo elective percutaneous coronary intervention and patients with Class I indication to elective percutaneous coronary intervention
62383990|NCT04605341|ACTIVE_COMPARATOR|group one|patient with metacarpal fracture that will use minipate for fixation
62383991|NCT04605341|ACTIVE_COMPARATOR|gruop two|patient with metacarpal fracture that will use buried k wires for fixation
62383992|NCT01183728|EXPERIMENTAL|MSV autologous transplantation|Bone marrow collected from patient will be used for mesenchymal stem cells isolation and expansion under GMP conditions at IBGM-Valladolid (MSV). Autologous MSV implanted in knee by articular injection
62383993|NCT01968629|EXPERIMENTAL|Eovist at 24 Hour Delayed Imaging|This study will evaluate uptake of the hepatobiliary magnetic resonance imaging (MRI) contrast agent gadolinium ethoxybenzyl dimeglumine, or Eovist (Bayer Imaging, Wayne, NJ) within hepatocellular carcinomas (HCCs) at delayed, 24 hour imaging. The recommended dose of Eovist is 0.1 mL/kg, or 0.025 mmol/kg.
62383994|NCT04360889|EXPERIMENTAL|Tocopherol|patients with lower limb lymphedema who will receive conservative therapy with elastic compression and an antioxidant (Tocopherol-400 IU/day) - 90 days
62383995|NCT04360889|EXPERIMENTAL|Micronised purified flavonoid fraction|patients with lower limb lymphedema who will receive conservative therapy with Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)-1000mg/day) in addition to elastic compression - 90 days
61988933|NCT05282082||"Healthy volunteers living in high-risk areas in one of the three cities."|Swabs will be taken from healthy volunteers who are willing to participate.
62383996|NCT04360889|OTHER|Elastic compression|patients with lower limb lymphedema who will be treated with elastic compression - 90 days
62383997|NCT04360889|NO_INTERVENTION|Healthy volunteers|healthy volunteers with no history or clinical signs of venous or lymphatic disease - 90 days
62383998|NCT01908335|EXPERIMENTAL|A (PEG-IFN-SA /RBV low dose)|PEG-IFN-SA 0.75μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW\<75kg，1000mg/d；BW≥75kg，1200mg/d）
62383999|NCT01908335|EXPERIMENTAL|B (PEG-IFN-SA /RBV middle dose)|PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW\<75kg，1000mg/d；BW≥75kg，1200mg/d）
62384000|NCT01908335|EXPERIMENTAL|C (PEG-IFN-SA /RBV high dose)|PEG-IFN-SA 2.0μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW\<75kg，1000mg/d；BW≥75kg，1200mg/d）
61988934|NCT01137942||H. pylori eradication failure|Those who eradicated Helicobacter pylori with appropriate antibiotic therapy and those who did not.
62384001|NCT01908335|ACTIVE_COMPARATOR|D (Pegasys /RBV)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW\<75kg，1000mg/d；BW≥75kg，1200mg/d）
62384002|NCT02691078|EXPERIMENTAL|Adult patients with neuroendocrine tumors|
61988935|NCT03265197|EXPERIMENTAL|Intratympanic injection of drugs;|intervention by Intratympanic injection of drugs in two studied groups; group A, injection of combined 2 drugs( lidocaine and dexamethasone) and group B, injection of one drug (dexamethasone only).
61988936|NCT03265197|ACTIVE_COMPARATOR|Data management of Intratympanic drugs|intervention by Manage data of two study group as blind statistical between group A, injection of combined 2 drugs( lidocaine and dexamethasone) and group B, injection of one drug (dexamethasone only).
62764906|NCT04556032|EXPERIMENTAL|L-Ergothioneine 10 mg/d|Participants will receive L-Ergothioneine 10 mg capsule orally once daily for 16 weeks.
62384003|NCT03385629|EXPERIMENTAL|CSM theory-based Arm|CSM theory-based didactic education and skills training Practice EMR changes
62764907|NCT04556032|EXPERIMENTAL|L-Ergothioneine 25 mg/d|Participants will receive L-Ergothioneine 25 mg capsule orally once daily for 16 weeks.
62764908|NCT04556032|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo orally once daily for 16 weeks.
62764909|NCT02541136|EXPERIMENTAL|Exercise|Participants in this arm took part in the aerobic exercise component of the study and attended St. James's Hospital in Dublin twice a week for 16 weeks. Furthermore, exercising participants were asked to engage in recorded aerobic activity outside of the class, which followed a standardised progression from 1-3 additional sessions, at the same intensity as the week's class.
62764910|NCT02541136|NO_INTERVENTION|Control|Participants in the control group didn't change their sedentary habits.
62764911|NCT02675335|ACTIVE_COMPARATOR|Sitagliptin|Sitagliptin tablets, 100mg per day, 12 weeks treatment
62764912|NCT02675335|PLACEBO_COMPARATOR|Placebo|Placebo tablets, 1 tablet per day, 12 weeks treatment
62764913|NCT02713516|EXPERIMENTAL|Single Arm|The children in this study will have a single visit. During this visit the child and their parent will be introduced to the virtual reality (VR) system. The child will interact with the VR system and after they have finished, they will be asked questions about their experience with the VR system.
62764914|NCT03008382|OTHER|Double-Blind Randomized Drug|"Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol.~This intervention aims at finding if subjects with IC/BPS have higher baseline HR compared to HCs. After 4 weeks baseline, subjects will receive a bottle with capsules containing 25 mg of metoprolol tartrate or placebo distributed in a double-blind manner by each site's investigational pharmacy. Subjects will start at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week, if HR has not decreased below 55 bpm at rest. Subjects will report daily rest HR for the first week. The subjects will then washout for 4 weeks and enter crossover in similar manner."
62764915|NCT03008382|OTHER|Double-Blind Randomized Placebo|"Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol.~This intervention aims at finding if subjects with IC/BPS have higher baseline HR compared to HCs. After 4 weeks baseline, subjects will receive a bottle with capsules containing 25 mg of metoprolol tartrate or placebo distributed in a double-blind manner by each site's investigational pharmacy. Subjects will start at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week, if HR has not decreased below 55 bpm at rest. Subjects will report daily rest HR for the first week. The subjects will then washout for 4 weeks and enter crossover in similar manner."
62384004|NCT03385629|ACTIVE_COMPARATOR|AAP-based Arm|AAP-based didactic education
62384005|NCT01273506|EXPERIMENTAL|001|tapentadol (CG5503) ER 25-mg TRF 50 mg TRF single oral dose
62384006|NCT01273506|EXPERIMENTAL|002|tapentadol (CG5503) ER 50-mg TRF 50 mg TRF single oral dose
62764916|NCT05543018|ACTIVE_COMPARATOR|Silicon oil group|Patients diagnosed with retinal detachment and undergone vitrectomy operation with silicon oil tamponade.
62764917|NCT05543018|ACTIVE_COMPARATOR|Air tamponade|Patients diagnosed with retinal detachment and undergone vitrectomy operation with air tamponade.
62764918|NCT05543018|ACTIVE_COMPARATOR|Non-expansile gas|Patients diagnosed with retinal detachment and undergone vitrectomy operation with non-expansile gas tamponade (sulfur hexafluoride).
62764919|NCT00489736|EXPERIMENTAL|Dronedarone 400mg bid|dronedarone 400mg tablets administered twice a day (bid) and matching over-encapsulated tablets of placebo of amiodarone 200mg
62764920|NCT00489736|ACTIVE_COMPARATOR|Amiodarone 600mg/200mg od|over-encapsulated tablets of amiodarone 200mg (600mg daily for 28 days then 200mg daily) administered once daily (od) and matching placebo of dronedarone 400mg tablets
62384007|NCT02155712|ACTIVE_COMPARATOR|Triathlon Tritanium Knee|Cases are enrolled in the Cohort 1 (cementless) until a total of 356 cases receive the Triathlon Tritanium Tibial Baseplate, Triathlon Tritanium Patella, Triathlon CR or PS Beaded Femur with PA and the Triathlon Tibial Insert. All components in this cohort must used in a cementless application.
62384008|NCT02155712|ACTIVE_COMPARATOR|Triathlon Knee|Enrollment in Cohort 2 (cemented) will begin upon completion of enrollment into the Cohort 1 (cementless), and will continue until a total of 144 cases receive the Triathlon Tibial Tray, Triathlon Patella, Triathlon CR or PS Femur and Triathlon Tibial Insert. All components in this cohort must be used in a cemented application.
62384009|NCT04828304|NO_INTERVENTION|control group|Standard of care
62384010|NCT04828304|EXPERIMENTAL|treatment group|Standard of care + PLASOMA treatment
62384011|NCT02063932||endomicroscopy|
62384012|NCT00198042|EXPERIMENTAL|Surgical Reconstruction of the ACL|
62384013|NCT01548729|EXPERIMENTAL|Patient with cystic fibrosis|Patients with end-stage cystic fibrosis
62384014|NCT05450133||R-ax-Spa|Radiographic axial spondyloarthritis
62384015|NCT05450133||nR-ax-Spa|Non-radiographic axial spondyloarthritis
62384016|NCT05450133||Control|Healthy Controls
62384017|NCT00556309||Diagnostic Tool|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
62384018|NCT03444831|EXPERIMENTAL|Buspirone plus Omeprazole|
62384019|NCT03444831|PLACEBO_COMPARATOR|Placebo plus Omeprazole|
62384020|NCT05914844||Group 1:|Proliferative phase endometrium (PPE)
62384021|NCT05914844||Group 2:|Secretory phase endometrium
62384022|NCT05914844||Group 3:|Benign endometrial hyperplasia
62384023|NCT05914844||Group 4:|Endometrial intraepithelial neoplasia
62384024|NCT05914844||Group 5:|Early stage of endometrial carcinoma
62384025|NCT05914844||Group6:|Advanced stage of endometrial carcinoma
62384026|NCT04885660|EXPERIMENTAL|Compound lisinopril tablets|a single oral of Compound lisinopril tablets test formulation( Lisinopril 10mg/Levamlodipine besylate 5mg)
62764921|NCT03562234||Pre-op Chemotherapy for CLM: MR & LiMAx|"Patients undergoing pre-operative chemotherapy for colorectal liver metastases being treated at the Christie NHS (National Health Service) Foundation Trust.~No intervention - participants will continue with standard care. Observation of changes in liver fat and liver function measured by MR (Magnetic Resonance) scan and LiMAx test (Maximum liver capacity)."
62764922|NCT05393453||patients with acute on chronic liver failure|All subjects will receive the currently routine treatment of liver failure and corresponding etiological treatment if needed. The researchers will collect various clinical examination results of the subjects in the process of diagnosis and treatment, including but not limited to blood routine, biochemistry, coagulation function, liver imaging, therapeutic drugs, etc. Complications and prognosis of patients will be recorded. Blood samples, urine and stool samples of all subjects will be collected after enrollment and stored for probably testing in the future. This study has no additional intervention and treatment for subjects.
62764923|NCT06161285|OTHER|Severe bronchiolitis|venous blood samples. Buccal, nasopharyngeal and rectal swabs
62764924|NCT06161285|OTHER|Non-hospitalized bronchiolitis|Capillary blood samples. Buccal, nasopharyngeal and rectal swabs
62764925|NCT02659553||mild steatosis|5% - 30% of hepatocytes have fatty infiltration
62764926|NCT02659553||moderate steatosis|30% - 60% of hepatocytes have fatty infiltration
62764927|NCT02659553||No steatosis|No or less than 5% of hepatocytes have fatty infiltration
62764928|NCT02707393|EXPERIMENTAL|single arm|Fludarabine intravenous - daily dose: 40mg/sqm on day -7, -6, -5, -4; Thiotepa intravenous - daily dose: 2 x 5mg/kg on day -3; Melphalan intravenous - daily dose: 140/mg/sqm on day - 2; ATG intravenous - dose according to local standards on day -3, -2, -1; bone marrow or peripheral blood stem cells of an HLA identical sibling or matched unrelated donor on day 0; GvHD propyhlaxis with Mycophenolate Mofetil and Cyclosporine A
62764929|NCT00221975|ACTIVE_COMPARATOR|Lithium + Divalproex + Lamictal|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL. Divalproex was then initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL. Patients meeting the criteria of being non-responsive to lithium plus divalproex were randomly assigned to receive lamotrigine or placebo. Patients randomized to the lamotrigine group were titrated up to a minimum dose of 150 mg and maximum dose of 200 mg per day.
62764930|NCT00221975|PLACEBO_COMPARATOR|Lithium + Divalproex + Placebo|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL. Divalproex was then initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL. Patients meeting the criteria of being non-responsive to lithium plus divalproex were randomly assigned to receive lamotrigine or placebo. Patients randomized to the placebo group were giving matching placebo.
62764931|NCT06177470|ACTIVE_COMPARATOR|active accelerated deep TMS|Accelerated dTMS on anterior cingulate cortex and medial prefrontal cortex.
62764932|NCT06177470|SHAM_COMPARATOR|sham TMS|Sham TMS on anterior cingulate cortex and medial prefrontal cortex
62764933|NCT02017561|ACTIVE_COMPARATOR|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of regular moderate-intensity physical activity and healthy diet.
62764934|NCT02017561|EXPERIMENTAL|Metformin + Lifestyle Counseling|Metformin: maximum dose of 1000mg twice daily. Lifestyle counseling: Written and individualized information during the interview in all clinic visits, emphasizing the importance of regular moderate-intensity physical activity and healthy diet.
62384027|NCT04885660|ACTIVE_COMPARATOR|Compound lisinopril tablets(Lisonorm®)|a single oral of Compound lisinopril tablets reference formulation( Lisinopril 10mg/Levamlodipine besylate 5mg)
61988937|NCT00464425|EXPERIMENTAL|Electroacupuncture (EA)|EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles
62764935|NCT02757794|ACTIVE_COMPARATOR|Cognitive remediation parents|
62764936|NCT02757794|PLACEBO_COMPARATOR|Remediation standard|
62764937|NCT03412149|ACTIVE_COMPARATOR|Mini Gastric Bypass|Mini Gastric Bypass: The gastric pouch will be performed starting below the incisura angularis (transverse resection 4 cm) on the lesser curvature (18).Then the stomach will be transected against a 36 Fr bougie up to the gastro-esophageal junction Then 1/3 of the small bowel will be excluded (approximately 200cms) and 3.5-4 cm gastro-jejunostomy will be performed by linear stapler.
61988938|NCT00464425|SHAM_COMPARATOR|Sham Acupuncture (SA)|Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used
61988939|NCT00464425|NO_INTERVENTION|No Acupuncture (NA)|Control
61988940|NCT03210870|OTHER|Intervention|In-person nutritional education classes
61988941|NCT03210870|NO_INTERVENTION|Control|no in-person nutritional education classes
61988942|NCT02202733|OTHER|Cooking|A skill-based cooking intervention for caretakers of an overweight/obese child aged 3-10 years.
61988943|NCT04822207|EXPERIMENTAL|Acupuncture group|In the acupuncture group, those patients undergo acupuncture at the beginning of embryo transfer cycle three times a week until 14 days after embryo transfer. These patients should be checked including endometrial receptivity index and fill in SAS anxiety scale form.
61988944|NCT04822207|NO_INTERVENTION|Control group|In the control group, these patients do not receive any treatments during embryo transfer cycle. These patients should be checked including endometrial receptivity index and fill in SAS anxiety scale form.
61988945|NCT02472938|EXPERIMENTAL|BG00012|120 mg capsule oral twice daily (BID) during the first week and 240 mg BID thereafter.
61988946|NCT02472938|PLACEBO_COMPARATOR|Placebo|Placebo capsules orally twice a day.
61988947|NCT01822080|EXPERIMENTAL|Dienogest|50% of the participants will be randomized to this arm and will receive 2 mg dienogest (DNG) once daily by mouth from 0-52 weeks
61988948|NCT01822080|PLACEBO_COMPARATOR|Placebo|50% of the participants will be randomized to this arm and will receive placebo once daily by mouth from 0-24 weeks then switch to 2 mg dienogest (DNG) once daily by mouth from 25-52 weeks
61988949|NCT05766930|EXPERIMENTAL|The genital itching and one treatment|Participants with itching genitalia will receive one treatment with the device and complete the questionnaire.
61988950|NCT05851430||Aliya PEF ablation|Patients will undergo PEF ablation per institutional standard of care
61988951|NCT02564614|EXPERIMENTAL|RO7070179|Participants will receive RO7070179, 13 mg/kg/week, 2-hour IV infusion every week in a 6-week cycle, after two loading doses in Week 1 of Cycle 1 on Day 1 and Day 4. If a dose-limiting toxicity (DLT) occurs in more than 33% of participants at any time, the dose will be reduced to 10 mg/kg/week. The dose will be further reduced to 6 mg/kg/week if more than 33% of treated participants have a DLT.
61988952|NCT03226431|EXPERIMENTAL|ARINA-1|Ascorbic acid (ARINA-1) (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
61988953|NCT05283187|EXPERIMENTAL|MBCT|Mindfulness Based Cognitive Therapy
61988954|NCT05283187|NO_INTERVENTION|Control Group|No intervention
61988955|NCT04311879|EXPERIMENTAL|Soft tissue laser Diode laser application|Endodontically treated teeth by virtue of a dental applicator positioned at a right angle to the mucosa at the level of the apices. Application of the laser probe was applied to both the buccal and lingual mucosae overlying the apices of the target tooth. Total exposure time for each tooth was 60 seconds (a dose = 70 j/cm2 for analgesia) The laser unit used in this study used was a diode laser (Lite Medics 1.00Watt serial number 148 Ver.SwvM. 150VS108VT.100) of wavelength 980nm and Max power 15WCW Class IV Laser Product
62764938|NCT03412149|ACTIVE_COMPARATOR|Roux en Y Gastric Bypass|Roux en Y Gastric Bypass: The steps of the standard double loop RYGB technique will be followed (17). The gastric pouch will be created 7 cm from the gastro-esophageal junction to obtain a volume of 30-40 ml, and the length of the alimentary limb will be 150 cm and 3.5-4 cm gastro-jejunostomy will be performed by linear stapler. The length of the biliopancreatic limb will be from 65 to 75 cm beyond the ligament of Treitz. The lengths of both limbs should carefully measured with a graduated instrument. The mesenteric defects will be closed.
62764939|NCT03945019|EXPERIMENTAL|CT-P13 SC|
61988956|NCT04311879|PLACEBO_COMPARATOR|conventional root canal treatment|Placebo : conventional root canal conventional root canal treatment with irrigation of sodium hypochlorite 2.5% with mock laser intervention
62384028|NCT01593176||Distal Femur Fracture, LISS Plate|Patients presenting with a distal femur fracture requiring surgical fixation with a Less Invasive Stabilization System (LISS) plate will have placement of RSA beads for analysis.
61988957|NCT02877277|EXPERIMENTAL|Vitamin C|Oral intake of vitamin C tablet (500 mg) daily for 56 days
61988958|NCT02877277|PLACEBO_COMPARATOR|Placebo|Oral intake of placebo tablet daily for 56 days
61988959|NCT00679185|EXPERIMENTAL|Experimental-EW|four emotion focused writing assignments
61988960|NCT00679185|ACTIVE_COMPARATOR|control group|non-emotional writing control
61988961|NCT04327219|EXPERIMENTAL|CDED diet|The CDED will be divided into 3 stages: 0-6 weeks- induction phase (phase 1), weeks 7-12 step-down phase (phase 2), week 13 -24 maintenance phase (phase 3). During these weeks the diet is structured and contains a list of allowed/disallowed foods, and mandatory foods with specific daily/weekly amounts. Patients will be asked to progress with the diet if they respond to the diet clinically. Patients who do not improve, but show a clinicaly significant trend in symptoms, may be asked to prolong a dietary phase until reaching clinical reaction.
61988962|NCT04327219|NO_INTERVENTION|standard diet|The control standard diet will be personally tailored for nutritional needs according to patient's daily recommended intake (DRI) for calories and protein intake (25kcal/kg and 0.8-1gr/kg per day respectivlly), and will follow the clinical guidelines for dietary therapy of patients with IBD.
61988963|NCT02081833||Reminder group|the reminder group receives every 2 weeks a reminder to fill out the symptom diary (postcard or SMS)
61988964|NCT02642432|EXPERIMENTAL|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
62384029|NCT04834375|NO_INTERVENTION|Standard dexamethasone dose|Dexamethasone 6 mg IV daily for 10 days
62384030|NCT04834375|EXPERIMENTAL|Weight-based dexamethasone dose|Dexamethasone 0.2 mg/kg/day IV (maximum 20 mg daily) for 10 days
62384031|NCT05506813|EXPERIMENTAL|experimental group|cognitive training and conventional training
62384032|NCT05506813|ACTIVE_COMPARATOR|control group|motor dual task training and conventional training
62384033|NCT03161015|EXPERIMENTAL|GBT440 Dose 1: Severe Renal Impairment|eGFR \< 30 mL/min/1.73m2, not on dialysis
62384034|NCT03161015|EXPERIMENTAL|GBT440 Dose 1: Moderate Renal Impairment|30 mL/min/1.73m2 = or \< eGFR \< 60 mL/min/1.73m2
62384035|NCT03161015|EXPERIMENTAL|GBT440 Dose 1: Mild Renal Impairment|60 mL/min/1.73m2 = or \< eGFR \< 90 mL/min/1.73m2
62384036|NCT03161015|EXPERIMENTAL|GBT440 Dose 1: Normal Renal function|eGFR \> or = 90 mL/min/1.73m2
62384037|NCT01591044|ACTIVE_COMPARATOR|R940343 2mg, 2 puffs bid|R343 2mg, 2 puffs bid
62384038|NCT01591044|PLACEBO_COMPARATOR|Placebo|
62764940|NCT03945019|PLACEBO_COMPARATOR|Placebo SC|
62384039|NCT01591044|ACTIVE_COMPARATOR|R940343 1mg, 1 puff bid|R343 1mg, 1 puff bid
62384040|NCT04566523||Control Group|Chronic respiratory patients who undergo a home-based exercise training program with a rehabilitation coach supervision.
62384041|NCT04566523||Tele Group|Chronic respiratory patients who undergo a home-based exercise training program online.
62384042|NCT03799133|EXPERIMENTAL|Patients with Florence device|Patients with the Florence catheter placed and connected to the Florence monitor to measure XL trend.
62384043|NCT00953784|NO_INTERVENTION|1|Standard management
62384044|NCT00953784|ACTIVE_COMPARATOR|2|Extended management: with no bowel prep except enema,restricted fluids, increased O2,body warming and use of skin protectors during surgery as previously described
62384045|NCT02765191|EXPERIMENTAL|Study group|Subjects investigated according to protocol after administration of bolus of Ringer's Acetate
62384046|NCT00323804|EXPERIMENTAL|Randomised PegIFN alfa 2b + ribavirin (RBV) arm|Combination of ribavirin capsules 200 mg, weight-based daily dose ( \<75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
62384047|NCT00323804|PLACEBO_COMPARATOR|Randomised PegIFN alfa 2b + ribavirin-placebo arm|Combination of ribavirin-placebo capsules 200 mg, weight-based daily dose ( \<75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
62384048|NCT02750436|EXPERIMENTAL|Ultrasound guided|Ultrasound guided sacral lateral branch block
62384049|NCT02750436|ACTIVE_COMPARATOR|Fluoroscopy guided|Fluoroscopically guided sacral lateral branch block
62384050|NCT02781246|ACTIVE_COMPARATOR|saline (Group A)|perineural ropivacaine
62384051|NCT02781246|ACTIVE_COMPARATOR|0.5 mcg/kg dexmedetomidine (Group B)|(perineural ropivacaine plus 0.5 mcg/kg dexmedetomidine),
62384052|NCT02781246|ACTIVE_COMPARATOR|1 mcg/kg dexmedetomidine (Group C)|(perineural ropivacaine plus 1 mcg/kg dexmedetomidine)
62384053|NCT02781246|ACTIVE_COMPARATOR|1.5 mcg/kg dexmedetomidine (Group D)|(perineural ropivacaine plus 1.5mcg/kg dexmedetomidine)
62384054|NCT02781246|ACTIVE_COMPARATOR|2 mcg/kg dexmedetomidine (Group E)|(perineural ropivacaine plus 2 mcg/kg dexmedetomidine)
62384055|NCT02368158|EXPERIMENTAL|Cardiologic Patient|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors
62384056|NCT02368158|EXPERIMENTAL|Control Proband|"The same intervention as in arm cardiologic patients :Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors"
62384057|NCT04698954|EXPERIMENTAL|AIMS intervention group|A nurse-delivered behavioural intervention focussing on medication adherence, physical activity, and symptom management integrated in routine clinical care. AIMS-CHF incorporates nurse-counselling and feedback from electronic monitoring of medication use (using MEMS-buttons) and physical activity (using pedometers).
62384058|NCT04698954|ACTIVE_COMPARATOR|Treatment-as-usual group|Participants in the control group will receive treatment as usual. They will visit the out patient clinic each 3 or 6 months for 30 minutes.
62384059|NCT03562728|ACTIVE_COMPARATOR|ECMO- Bridge to Transplant|Interventions: MRP+MNES(neuromuscular electric stimulation).Patients in the treatment arm will receive additional physical therapy(arm and leg exercises, using light weight machines, hand weights, or rubber bands, exercise machines such as portable arm or seated bikes) as well as therapy with an electric stimulator device. This device uses weak electric impulses to involuntarily exercise the muscles(one-two sessions a day).Four muscle groups(quadriceps and dorsiflexors bilaterally) will be stimulated using surface electrodes .In addition, patients in the experimental group will receive nutrition supplementation with essential amino acids 3 times a day in their feeding to prevent muscle breakdown and promote positive nitrogen balance.
62384060|NCT03562728|OTHER|ECMO- Bridge to Transplant Control Group|"Interventions: standard of care~Patients are not going to receive any additional intervention."
62384061|NCT03562728|ACTIVE_COMPARATOR|Transplant|Interventions: MRP+MNES(neuromuscular electric stimulation).Patients in the treatment arm will receive additional physical therapy(arm and leg exercises, using light weight machines, hand weights, or rubber bands, exercise machines such as portable arm or seated bikes) as well as therapy with an electric stimulator device. This device uses weak electric impulses to involuntarily exercise the muscles(one-two sessions a day).Four muscle groups(quadriceps and dorsiflexors bilaterally) will be stimulated using surface electrodes .In addition, patients in the experimental group will receive nutrition supplementation with essential amino acids 3 times a day in their feeding to prevent muscle breakdown and promote positive nitrogen balance.
62384062|NCT03562728|OTHER|Transplant Control Group|"Interventions: standard of care.~Patients are not going to receive any additional intervention."
62384063|NCT05986890|OTHER|Roux-en-Y Bypass|laparoscopic Roux-en-Y (R-Y) procedure is a well-established procedure, commonly utilized in the setting of bariatric- and gastric cancer surgery. The procedure establishes intestinal continuity that bypasses the distal stomach and duodenum. This is achieved by dividing the jejunum 30-40 cm distal to the ligament of Treitz, bringing the distal end of jejunum up anterior to the transverse colon to be anastomosed to the back wall of the stomach (forming the Roux-limb). The proximal cut end of jejunum then gets anastomosed to the downstream roux-limb (forming the Y-limb). The benefits of this reconstruction include less chance of gastric contents travelling into the afferent limb and similarly, avoiding bile reflux from the afferent limb with associated bile gastritis.
62384064|NCT05986890|OTHER|Gastrojejunostomy|surgical gastrojejunostomy, a procedure dating back to the late 1800's.5 This surgical bypass consists of connecting the stomach to a loop of proximal small bowel, thus bypassing any duodenal or distal gastric obstruction.
62384065|NCT06033495||Patients with refractory angina undergoing coronary sinus reduction stent implantation|
62384066|NCT05585801|EXPERIMENTAL|Intervention Group|
62384067|NCT05585801|ACTIVE_COMPARATOR|Control Group|
62384068|NCT05245838|EXPERIMENTAL|Z-1018 Dose Level 1|100 mcg gE + 3000 mcg CpG 1018
62384069|NCT05245838|EXPERIMENTAL|Z-1018 Dose Level 1a|100 mcg gE + 3000 mcg CpG 1018 + alum
62384070|NCT05245838|EXPERIMENTAL|Z-1018 Dose Level 2|100 mcg gE + 6000 mcg CpG 1018
61988965|NCT02874742|EXPERIMENTAL|Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd)|Participants will receive lenalidomide, bortezomib, dexamethasone and daratumumab.
61988966|NCT02874742|EXPERIMENTAL|Lenalidomide+Bortezomib+Dexamethasone (RVd)|Participants will receive lenalidomide, bortezomib and dexamethasone.
62384071|NCT05245838|EXPERIMENTAL|Z-1018 Dose Level 2a|100 mcg gE + 6000 mcg CpG 1018 + alum
62384072|NCT05245838|ACTIVE_COMPARATOR|Shingrix|
62384073|NCT02253173|EXPERIMENTAL|Estradiol 4mcg Vaginal Softgel Capsule|Estradiol 4mcg Vaginal Softgel Capsule
62384074|NCT02253173|EXPERIMENTAL|Estradiol 10mcg Vaginal Softgel Capsule|Estradiol 10mcg Vaginal Softgel Capsule
62764941|NCT03043495|ACTIVE_COMPARATOR|Group A|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 0.5ml (2mg) Dexamethasone, 1.5ml Normal saline.
62384075|NCT02253173|EXPERIMENTAL|Estradiol 25mcg Vaginal Softgel Capsule|Estradiol 25mcg Vaginal Softgel Capsule
62384076|NCT02253173|PLACEBO_COMPARATOR|Placebo Vaginal Softgel Capsule|Placebo Vaginal Softgel Capsule
62764942|NCT03043495|ACTIVE_COMPARATOR|Group B|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 1ml (4mg) Dexamethasone, 1ml Normal saline.
62764943|NCT03043495|ACTIVE_COMPARATOR|Group C|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml (8mg) Dexamethasone.
62764944|NCT03043495|ACTIVE_COMPARATOR|Group Control|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml Normal saline.
62764945|NCT01201512||Temporomandibular disorders|
62764946|NCT02614482|EXPERIMENTAL|Fesoterodine 4mg|Fesoterodine 4 mg Po Die, dose could be increased to 8mg Po Die after 1 month and 4 months.
62764947|NCT05665699|EXPERIMENTAL|Cohort A|week 1: D-0120 low dose in combination with Allopurinol week 2-12: D-0120 increased dose in combination with Allopurinol
61988967|NCT02741908|EXPERIMENTAL|Fixed diet plan|Patients received a fixed diet plan to assist in the choice of foods aimed at changing eating behavior. Dietary intake was evaluated by using 3 nonconsecutive 24-hour dietary recalls collected at each visit. Received a reduction of 500 calories in the total energy expenditure calculated by the equation predicted by Dietary Reference Intake (DRI) from the Institute of Medicine (2005). Also received qualitative information regarding healthy food behaviours, by a same dietitian, based on the DRI for Acceptable Macronutrient Ranges, appropriated for age and gender.
61988968|NCT02741908|EXPERIMENTAL|Calorie counting diet|Patients underwent a calorie counting diet, in which each patient has received a table list with equivalent points for food and drinks, and was instructed to record all daily food or drink intake and calculate the total score of points consumed (1 point = 3.6 calories). They were allowed to eat any food but were limited to the recommended amount of points (or calories equivalents). Received a reduction of 500 calories in the total energy expenditure calculated by the equation predicted by Dietary Reference Intake (DRI) from the Institute of Medicine (2005). Also received qualitative information regarding healthy food behaviours, by a same dietitian, based on the DRI for Acceptable Macronutrient Ranges, appropriated for age and gender.
62384077|NCT03862781|OTHER|Intra-corporeal|Right Hemicolectomy
62384078|NCT03862781|OTHER|Extra-corporeal|Right Hemicolectomy
62384079|NCT00554229|EXPERIMENTAL|ZD4054|ZD4054 10 mg oral tablet once daily
62384080|NCT00554229|PLACEBO_COMPARATOR|Placebo|Matching Placebo, oral tablets once daily
62384081|NCT05754736|EXPERIMENTAL|Ametinib combined with bevacizumab|Ametinib 110 mg po qd bevacizumab 15mg/kg ivdrip q3w
62384082|NCT03210415||Study group|Pregnant women ≥35 years old would have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model.
62384083|NCT03210415||Control group|Pregnant women ≥35 years old would not have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model.
62384084|NCT01992900|EXPERIMENTAL|Eurartesim dispersible oral tablets|Each patient will receive a specific amount of drug according to his/her body weight, once a day for three consecutive days (from 5 to \<7 kg: 1 tablet containing 80 mg PQP and 10 mg DHA; from 7 to \< 13 kg: 1 tablet containing 160 mg PQP and 20 mg DHA).
62384085|NCT01992900|ACTIVE_COMPARATOR|Eurartesim film coated tablet|Each patient will receive a specific amount of drug according to his/her body weight, once a day for three consecutive days (from 5 to \<7 kg: half tablet equal to 80 mg PQP and 10 mg DHA; from 7 to \< 13 kg: 1 tablet containing 160 mg PQP and 20 mg DHA).
62384086|NCT05371249|EXPERIMENTAL|Vonoprazan-based triple therapy group|Including patients receiving vonoprazan-based triple therapy (vonoprazan 20mg + amoxicillin 1000 mg + clarithromycin 500 mg twice daily for seven days)
62384087|NCT05371249|ACTIVE_COMPARATOR|Extended sequential therapy group|Including patients receiving extended sequential therapy (lansoprazole 30mg + amoxicillin 1000mg twice daily for 7 days, followed by lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg twice daily for 7 days)
62384088|NCT04885205|EXPERIMENTAL|CBT-I Initial Group|The CBT-I Initial Group will start the CBT-I intervention immediately following baseline assessments. After re-assessment 1, participants in the CBT-I Initial Group will continue with typical activities while the WL group will receive the CBT-I intervention. After re-assessment 2, both groups continue typical activities. All participants will complete a third re-assessment 21 weeks after starting the study.
62384089|NCT04885205|ACTIVE_COMPARATOR|Wait List Group|The WL will wait 6 weeks before starting the CBT-I intervention. After re-assessment 1, participants in the CBT-I Initial Group will continue with typical activities while the WL group will receive the CBT-I intervention. After re-assessment 2, both groups continue typical activities. All participants will complete a third re-assessment 21 weeks after starting the study.
62764948|NCT05665699|EXPERIMENTAL|Cohort B|week 1: D-0120 low dose in combination with Allopurinol week 2: D-0120 increased dose in combination with Allopurinol week 3-12: D-0120 high dose in combination with Allopurinol
62764949|NCT00532792|EXPERIMENTAL|Group 1|
62764950|NCT00532792|EXPERIMENTAL|Group 2|
62764951|NCT00532792|EXPERIMENTAL|Group 3|
62764952|NCT00532792|EXPERIMENTAL|Group 4|
62764953|NCT00532792|EXPERIMENTAL|Group 5|
62384090|NCT02194634|EXPERIMENTAL|Conbercept treatment group|Conbercept injection and sham laser treatment at day 0 for 1st time, the investigators will decide whether the subjects need to get repeated treatment according to monthly assessment.
62384091|NCT02194634|ACTIVE_COMPARATOR|Laser treatment group|Laser treatment and sham injection at day 0 for 1st time, the investigators will decide whether the repeated laser treatment is needed according to monthly results during the visit after 3 months.
62384092|NCT03115164||Patients with DIA / DIG treated at the French SFCE pediatric|
62384093|NCT01134328|EXPERIMENTAL|AC-150 Combo|
62384094|NCT01134328|ACTIVE_COMPARATOR|AC-150A 0.1%|
62384095|NCT01134328|ACTIVE_COMPARATOR|AC-150B 0.005%|
62384096|NCT01134328|OTHER|Vehicle|
62764954|NCT00532792|EXPERIMENTAL|Group 6|
62764955|NCT00532792|EXPERIMENTAL|Group 7|
62764956|NCT00532792|EXPERIMENTAL|Group 8|
62764957|NCT00532792|EXPERIMENTAL|Group 9|
62764958|NCT00532792|PLACEBO_COMPARATOR|Group 10|
62764959|NCT03262207||testicular tumours|
61988969|NCT03391596|EXPERIMENTAL|Internet-based ACT intervention|"Group Internet-based ACT intervention will receive a 12-week Internet-based, acceptance and commitment therapy intervention"
62384097|NCT00679354|EXPERIMENTAL|Treatment (cilengitide)|Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62384098|NCT00812552||Case|Late or very late drug-eluting stent thrombosis
62384099|NCT00812552||Control|No drug-eluting stent thrombosis
62384100|NCT06421194|EXPERIMENTAL|Treatment 1 Animal-based protein meal|Animal-based protein meal; Isoproteic at \~30g of total protein per meal. Siew mai (6 pieces) - steamed Ngoh Hiang (2 pieces) - oven baked
62384101|NCT06421194|EXPERIMENTAL|Treatment 2 Animal-based protein meal|Animal-based protein meal; Isoproteic at \~30g of total protein per meal. Gyoza (11 pieces) - steamed Luncheon meat (5 pieces) - oven baked
62384102|NCT06421194|EXPERIMENTAL|Treatment 3 Plant-based protein meal|Plant-based protein meal; Isoproteic at \~30g of total protein per meal. Siew mai (6 pieces) - steamed Ngoh Hiang (1 piece cut into 2) - oven baked
62384103|NCT06421194|EXPERIMENTAL|Treatment 4 Plant-based protein meal|Plant-based protein meal; Isoproteic at \~30g of total protein per meal. Gyoza (11 pieces) - steamed Luncheon meat (5 pieces) - oven baked
62384104|NCT04691622|EXPERIMENTAL|Norovirus -specific T-cell (NST) therapy for chronic norovirus infection|"This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or with primary immunodeficiency disorders (PID) who have not undergone HSCT. There are two arms in this study:~1. Arm A: Participants who receive donor-derived NST therapy after HSCT~2. Arm B: Participants who receive partially HLA matched NSTs. The following participants apply:~   * Participants with PID who have not undergone HSCT~  * Participants who undergo HSCT but do not have available donor derived NSTs~  * Participants who have donors from whom NSTs cannot be generated due to norovirus seronegativity"
62764960|NCT03262207||fertile|
62764961|NCT03262207||infertile|
62764962|NCT04376957|ACTIVE_COMPARATOR|Counselled with Current Standard Care|Standard of care consists of standard counselling and written materials provided by the oncologist or pharmacy (e.g. instructions and information on the regimen, common side effects, symptom management, medication safety and how to contact a clinician for any problems encountered).
62764963|NCT04376957|EXPERIMENTAL|Counselled with MASCC Oral agent Teaching Tool (MOATT)|This group will receive counselling using the MASCC Oral Agent Teaching Tool and be compared with the standard of care counselling.
62764964|NCT03474081|EXPERIMENTAL|Subjects receiving FF/UMEC/VI + Placebo to match tiotropium|Eligible subjects will receive FF/UMEC/VI at a dose of 100/62.5/25 microgram (mcg) administered once daily in the morning via ELLIPTA along with placebo to match tiotropium administered once daily in the morning via HANDIHALER. Subjects will self-administer 4 puffs of rescue medication (Albuterol/salbutamol) via metered dose inhaler (MDI).
62764965|NCT03474081|EXPERIMENTAL|Subjects receiving Tiotropium + Placebo to match FF/UMEC/VI|Eligible subjects will receive Tiotropium at a dose of 18 mcg administered once daily in the morning via HANDIHALER along with placebo to match FF/UMEC/VI administered once daily in the morning via ELLIPTA. Subjects will self-administer 4 puffs of rescue medication (Albuterol/salbutamol) via MDI.
62764966|NCT02958306|EXPERIMENTAL|platelet rich plasma|autologous blood product
62764967|NCT02958306|NO_INTERVENTION|no platelet rich plasma|control
62764968|NCT03480789|EXPERIMENTAL|eye patch|wearing the eye patch from 22:00 to 6:00 of the next day
62764969|NCT03480789|EXPERIMENTAL|Dexmedetomidine|given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
62764970|NCT03480789|EXPERIMENTAL|eye patch + DEX|given dexmedetomidine to meet RASS -1 and wearing the eye patch from 22:00 to 6:00 of the next day
62764971|NCT03480789|NO_INTERVENTION|usual treatment|treatment as usual
62764972|NCT05569876|OTHER|Controlled hypoglycemic state|
62764973|NCT05491421|EXPERIMENTAL|A (ZT002)|"Drug: ZT002~Dose level:~SAD dose (Cohort 1-4)~* 0.03 mg/kg, 0.09 mg/kg, 0.18 mg/kg, 0.3 mg/kg;~MAD dose (Cohort 1-3)~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings~Dose: Subcutaneous Injection"
62764974|NCT05491421|PLACEBO_COMPARATOR|B (Placebo)|"Dose level:~SAD dose (Cohort 1-4)~* 0.03 mg/kg, 0.09 mg/kg, 0.18 mg/kg, 0.3 mg/kg;~MAD dose (Cohort 1-3)~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings~Dose: Subcutaneous Injection"
62764975|NCT01852383|EXPERIMENTAL|Duloxetine|"A minimum 1-week psychotropic medication washout, and a washout of 3 weeks for fluoxetine and monoamine oxidase inhibitors(MAOIs), was required. Duloxetine was prescribed at 20 mg daily for the first week, 30 mg daily for the second week, then 60 mg daily for another 4 weeks. Patients could subsequently be raised to 90 mg daily for another 2-4 weeks and then to a maximum dose of 120 mg daily.~At all visits, the study psychiatrist had the option of adjusting the dose based on clinical response and side effects.~Administration was as a single a.m. dose."
62764976|NCT00260065|EXPERIMENTAL|1|
62764977|NCT03379142|OTHER|Behavioral: Faith-Based messages|We will send faith-based messages one week prior to Ramadan and twice a day during Ramadan.
61988970|NCT03391596|ACTIVE_COMPARATOR|Standardized rehabilitation|"Group Standardized rehabilitation will receive a standardized rehabilitation program in the rehabilitation center"
62764978|NCT06119438|ACTIVE_COMPARATOR|Saline group|Only saline solution was applied to the placebo group. The nebulizer was prepared and operated in the room where the prostate biopsy would be performed before the procedure. Patients were taken to the room 5 minutes before the procedure and the nebulizer was operated on during the procedure
62764979|NCT06119438|ACTIVE_COMPARATOR|Levander group|Levander oil was added to the nebulizer at a rate of 2%. The nebulizer was prepared and operated in the room where the prostate biopsy would be performed before the procedure. Patients were taken to the room 5 minutes before the procedure and the nebulizer was operated during the procedure.
62764980|NCT06119438|ACTIVE_COMPARATOR|Frankincense group|Frankincense oil was added to the nebulizer at a rate of 2%. Only saline solution was applied to the placebo group. The nebulizer was prepared and operated in the room where the prostate biopsy would be performed before the procedure. Patients were taken to the room 5 minutes before the procedure and the nebulizer was operated during the procedure.
62764981|NCT01099657|EXPERIMENTAL|Virtual Reality Hypnosis|Virtual Reality Hypnosis for chronic pain
62764982|NCT01099657|EXPERIMENTAL|Virtual Reality Distraction|Virtual Reality Distraction for Chronic Pain
62764983|NCT04094961|EXPERIMENTAL|ixazomib plus pomalidomide and dexamethasone|"The study drugs will be administered within a 21-day cycle~* Phase I will follow a standard 3 +3 dose escalation design: Starting with the first cohort, 3 to 6 patients will be treated at this and each subsequent dose level.~* The Phase II portion of the study will be a single-arm open-label enrollment with dosing based on the MTD determination in the Phase I portion of the study"
62764984|NCT06296641|EXPERIMENTAL|Needs Navigation Intervention|Individuals who screen positive will all move forward to receive this intervention. This includes connection to community partners with financial education and easily accessible resources, and a vocational navigation and support consultation for caregivers for 6-months.
61988971|NCT03391596|OTHER|Support by caregiver associations|"Group Support by voluntary caregiver associations will receive support given by caregiver associations"
61988972|NCT06186037|EXPERIMENTAL|Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg|Ezetimibe 10 mg/Rosuvastatin 5 mg, Oral administration once a day, taking it for 3 years
61988973|NCT06186037|ACTIVE_COMPARATOR|Mono drug group of Rosuvastatin 20 mg|Rosuvastatin 20 mg , Oral administration once a day, taking it for 3 years
61988974|NCT05875233|ACTIVE_COMPARATOR|Group One: PCOS & Hormonal Birth Control|All participants will have a diagnosis of PCOS and be regularly taking hormonal birth control.
61988975|NCT05875233|ACTIVE_COMPARATOR|Group Two: PCOS with No Hormonal Birth Control|All participants will have a diagnosis of PCOS and must not be taking any hormonal birth control.
61988976|NCT03849404|EXPERIMENTAL|AVT02 100mg/mL (Adalimumab Biosimilar)|Patients will be randomized to AVT02 on 1: 1 basis from the dosing day of Day 1 until week 48
62384105|NCT01970436|EXPERIMENTAL|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
62384106|NCT01970436|NO_INTERVENTION|Usual Prenatal Care|Usual, in-person prenatal care.
62384107|NCT02423733|NO_INTERVENTION|Control|In addition to their usual clinical care will also be given written information about web sites that provide information on depression but will not be specifically directed to The Journal.
62764985|NCT05343234|EXPERIMENTAL|patients receiving the placebo medication|tree different placebo drugs with tree different names and symbols one will be given twice daily one once in the morning one once before bedtime
62764986|NCT03094858|ACTIVE_COMPARATOR|Comparison group|Equipment only comparison group will use Smartphone and Wristband to monitor sedentary behavior
62764987|NCT03094858|EXPERIMENTAL|Intervention group|Intervention group will receive prompts from Smartphone to reduce sedentary behavior using information from Wristband
62764988|NCT01555515|EXPERIMENTAL|EPODURE Low dose|EPODURE pump secreting hEPO 18-25 IU/kg/day
62764989|NCT01304329|EXPERIMENTAL|treatment A, reference|1 tablet BI 10773, oral administration with 240 ml water
61988977|NCT03849404|EXPERIMENTAL|EU-Humira 100mg/mL (Adalimumab Originator)|Patients will be randomized to EU-Humira on 1: 1 basis from the dosing day of Day 1 until week 48
61988978|NCT02816840|EXPERIMENTAL|PET-CT|Patients in this arm take radiotherapy positioning with PET-CT.
61988979|NCT02816840|EXPERIMENTAL|PET-MRI|Patients in this arm take radiotherapy positioning with PET-MRI.
61988980|NCT02816840|NO_INTERVENTION|Computed Tomography|Patients in this arm take radiotherapy positioning with CT.
61988981|NCT04025996||Diseased Group|Patients with type 2 diabetic retinopathy and known cardiac dysfunction.
61988982|NCT05752110|ACTIVE_COMPARATOR|Ketamine|Received 0.5mg/kg IV single dose ketamine in addition to propofol and fentanyl anesthesia at induction period of anesthesia.
61988983|NCT05752110|PLACEBO_COMPARATOR|Control|Received 0.05ml/kg IV % 0.9 saline in addition to propofol and fentanyl anesthesia at induction period of anesthesia.
61988984|NCT03604042|ACTIVE_COMPARATOR|Weight-driven protein fortification|Individualized protein fortification based on weight gain
61988985|NCT03604042|EXPERIMENTAL|BUN-driven protein fortification|Individualized protein fortification based on BUN concentrations
62764990|NCT01304329|EXPERIMENTAL|treatment B, reference|1 tablet simvastatin, oral administration with 240 ml water
62764991|NCT01304329|EXPERIMENTAL|treatment C, test|1 tablet BI 10773 + 1 tablet simvastatin, oral administration with 240 ml water
62764992|NCT05610956|PLACEBO_COMPARATOR|placebo group|Patients will receive conventional treatment only (corticosteroids +immune suppressive +amino salicylic acid) for 4 months.
62764993|NCT05610956|EXPERIMENTAL|empagliflozin group|Patients will receive conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid) and empagliflozin (0.4 - 0.5mg/kg/day) orally (maximum dose 25mg per day)for 4months.
62764994|NCT02236416|EXPERIMENTAL|Intervention group|Physical exercise
62764995|NCT02236416|OTHER|Control group|Posture Education/Unchanged condition
62764996|NCT00823212|ACTIVE_COMPARATOR|PROMUS|Patients who received the PROMUS (XIENCE V) Everolimus-Eluting Coronary Stent
62764997|NCT00823212|EXPERIMENTAL|PROMUS Element|Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent
62764998|NCT04557787|ACTIVE_COMPARATOR|Intermittent catheter; SpeediCath® Standard female|Participants underwent two catheterizations with standard of care intermittent catheter: The first was performed by a trained nurse, the second by the participant later the same day.
62764999|NCT04557787|EXPERIMENTAL|New intermittent catheter Variant 1 for females|Participants underwent two catheterizations with the new intermittent catheter variant 1 for females: The first was performed by a trained nurse, the second by the participant later the same day.
61988986|NCT00527943|PLACEBO_COMPARATOR|Placebo|Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.
62765000|NCT04557787|EXPERIMENTAL|New intermittent catheter Variant 2 for females|Participants underwent two catheterizations with the new intermittent catheter variant 2 for females: The first was performed by a trained nurse, the second by the participant later the same day.
62765001|NCT03576105|EXPERIMENTAL|experimental group|G1 - 17 patients Photodynamic therapy with convention methylene blue as photosesintizer irrigation /sterile saline Conventional methylene blue as photosensitizer -Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes Photodynamic therapy -Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
62765002|NCT03576105|ACTIVE_COMPARATOR|positive control group|G2 - 17 patients Photodynamic therapy with oral formula of methylene blue as photosesintizer, treatment identical to G1, however methylene blue will be delivered in a new formulation for oral use (patent aplicattion INPI BR1020170253902) irrigation /sterile saline Photodynamic therapy -Methylene blue for oral use as photosensitizer-Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
62765003|NCT03897218|PLACEBO_COMPARATOR|Group 1|Patients consuming placebo (millet flakes) each day
62765004|NCT03897218|EXPERIMENTAL|Group 2|Patients consuming oatmeal flakes with a low dosage of prebiotic food supplements
62765005|NCT03897218|EXPERIMENTAL|Group 3|Patients consuming oatmeal flakes with a high dosage of prebiotic food supplements
62765006|NCT04808271|ACTIVE_COMPARATOR|Bif195 capsules|The capsule will contain approximately 15\*10\^9 CFU of Bif195 per day. Excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
62765007|NCT04808271|PLACEBO_COMPARATOR|Placebo capsules|The capsule contain only excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
62765008|NCT02182674|EXPERIMENTAL|Combivent HFA|
62765009|NCT02182674|ACTIVE_COMPARATOR|Combivent (CFC)|
61988987|NCT00527943|EXPERIMENTAL|Vorapaxar|Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.
61988988|NCT01040377||Inadequate initial weight loss after gastric bypass|
62567659|NCT04289441|ACTIVE_COMPARATOR|probiotic treatment|"For the first 8 weeks was administered 1 sachet in the morning and 1 in the evening, for the last 8 weeks was administered 1 sachet per day~Lactobacillus salivarius LS01 (DSM 22775): 10\^9 CFU Bifidobacterium breve B632 (DSM 24706): 10\^9 CFU Maltodextrin and silicon dioxide"
62765010|NCT02087813|EXPERIMENTAL|A1AT|Alpha1-antitrypsin 120mg/kg once weekly for a total of 4 doses, to be given intravenously. This will be given in addition to standard of care 3-5 days of 1000mg IV methylprednisolone.
62765011|NCT02087813|ACTIVE_COMPARATOR|Standard of care|Patients that do not wish to receive study treatment but agree to otherwise follow study protocol will also be enrolled in an observational cohort. They will receive the standard of care 3-5 days 1000mg IV methylprednisolone.
62765012|NCT01444027|NO_INTERVENTION|Attention Control|"This group receives standard care with the attention of social support/ friendly interactions and serves as an attention control group."
62765013|NCT01444027|EXPERIMENTAL|Intervention Group 1 (Face to Face)|This group receives Problem Solving Therapy in face to face visits.
62765014|NCT01444027|EXPERIMENTAL|Intervention Group 2 (Video)|This group receives Problem Solving Therapy via video.
62765015|NCT03839836|NO_INTERVENTION|Baseline|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack without the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
61988989|NCT05840354|ACTIVE_COMPARATOR|active repetitive transcranial magnetic stimulation + steroid joint injection|"Active transcranial stimulation will be delivered for a total of 11 sessions. Each session will consist of 40 trains of 5s delivered at 10 Hz, at an intensity of 85% of the resting motor threshold for the first dorsal interosseous muscle and an intertrain interval of 25s (total of 2000 stimulations in a 20-minute session).~The steroid joint injection will be given 1-4 week before rTMS begins. A dose of 0.5mL of 40mg/mL triamcinolone and 0.5mL of 2% lidocaine will be given per joint via spinal needle. The treatment team will determine how many joints will be injected based on their standard clinical assessment. Usually, about 2-4 joints are injected depending on a person's pain presentation. Standard practice is to place the needle in the region of the steroid joint opening, resulting in a peri- +/- intra-articular infusion of the injectate. This project will utilize standard clinical practice without modification."
62765016|NCT03839836|EXPERIMENTAL|5% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 5%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
62765017|NCT03839836|EXPERIMENTAL|10% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 10%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
61988990|NCT05840354|SHAM_COMPARATOR|sham repetitive transcranial magnetic stimulation + steroid joint injection|"The sham repetitive transcranial magnetic stimulation coil will be delivered using a sham coil of identical colour, size, and shape as the active rTMS coil. The sham coil uses a magnetic shield that blocks the magnetic field from being delivered to the scalp while producing a similar auditory click during discharge. All other aspects of the rTMS protocol will be identical between the active and sham conditions.~The steroid joint injection will be given 1-4 week before sham rTMS begins and will also follow the same protocol as the active rTMS group."
61988991|NCT04577287|EXPERIMENTAL|Cathodal tDCS & PT|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hour). Cathode on the on the motor area (M1) of the affected hemisphere, anode on the supraorbital area of the unaffect hemisphere.Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
62168236|NCT03450018|EXPERIMENTAL|SLC-0111 + Gemcitabine|"Dose Level 1 - SLC-0111 (500 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m\^2 IV on day 1, 8, and 15)~Dose Level 2 - SLC-0111 (750 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m\^2 IV on day 1, 8, and 15)~Dose Level 3 - SLC-0111 (1000 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m\^2 IV on day 1, 8, and 15)"
62384108|NCT02423733|EXPERIMENTAL|Computerized Therapy|In addition to their usual clinical care they will receive an invitation to use The Journal supported by an e-therapy coach who will provide patients with weekly email or telephone contact. The e-therapy coach will have a guideline script for each lesson of The Journal to reinforce the topic of each lesson, help identify and support patients in their goals and to coach them in goal setting and the techniques of problem solving.
62384109|NCT02807376|ACTIVE_COMPARATOR|Surgeon's 'standard of care' stapler|Surgeon's standard of care stapler
62384110|NCT02807376|EXPERIMENTAL|Ethicon Powered Vascular Stapler|Ethicon Powered Vascular Stapler
62384111|NCT02619461|EXPERIMENTAL|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes.
62384112|NCT02619461|NO_INTERVENTION|Control|Resting
62384113|NCT00417235|EXPERIMENTAL|3-days dressing frequency/CHX sponge|"Interventions:~Device: 'Chlorhexidine Sponge (Biopatch TM)' on the insertion site"
62384114|NCT00417235|EXPERIMENTAL|7-days dressing frequency/CHX sponge|"Interventions:~Behavioural: 7-day catheter dressing frequency Device: 'Chlorhexidine Sponge (Biopatch TM)' on the insertion site"
62384115|NCT00417235|NO_INTERVENTION|3-days dressing frequency/No CHX sponge|No intervention, classical protocol of dressing frequency every 3-days and no other device
62384116|NCT00417235|EXPERIMENTAL|7-days dressing change/No CHX sponge|Interventions:Behavioural: 7-day catheter dressing frequency
62384117|NCT06119828|EXPERIMENTAL|Parallel Asignment|Power analysis was performed using the G\*Power(v3.1.9) program to determine the sample size. The power of the study is expressed as 1-β (β = probability of type II error) and in general, studies must have 80% power. According to the effect size coefficients determined by Cohen, assuming that the evaluations to be made between two independent groups will have a medium effect size (d = 0.5), α = 0.05 and β = 0.20, it was determined that there should be at least 64 people in each group, according to the calculation.
62384118|NCT00531310|EXPERIMENTAL|Matched Family Donor|Matched Family Donor
62384119|NCT00531310|EXPERIMENTAL|Unrelated Donor|Unrelated Donor Transplant/ Cord Blood Transplant
62384120|NCT00779597|NO_INTERVENTION|Care as usual|Care as usual, i.e. standard pain treatment and standard care
62384121|NCT00779597|EXPERIMENTAL|SCION-PAIN program|SCION-PAIN program - Additionally to standard pain treatment, patients from the intervention wards received, the SCION-PAIN program consisting of 3 modules: pharmacologic pain management, non-pharmacologic pain management and discharge management.
62765018|NCT03839836|EXPERIMENTAL|15% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 15%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
62384122|NCT04390360|OTHER|Protective ventilation with HME|Protective ventilation + HME
62384123|NCT04390360|OTHER|Protective ventilation with Heated humidifier|Protective ventilation + HH
62765019|NCT03839836|EXPERIMENTAL|20% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 20%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
62765020|NCT04590690|EXPERIMENTAL|Roux-en-y gastric bypass subjects|"Inclusion Criteria: Age 18-70. Participants pre-Roux-en-y gastric bypass (RYGB) who are approved and planned for Roux-en-y gastric bypass surgery in the Bariatric Surgery Center at the UCM.~Exclusion Criteria: Patients with primary kidney diseases, kidney stone disease, or kidney impairment (eGFR \< 90). Patients with known bladder voiding problems.~Participants will complete a diet record and a 24-hour urine collection both before and after surgery.~Participants will consume a 3 day fixed diet and present to the clinical research center for timed blood and urine draws. They will do this before and twice after (1 month and 1 year) surgery."
62765021|NCT04590690|EXPERIMENTAL|Sleeve gastrectomy subjects|"Inclusion Criteria: Age 18-70. Participants pre-sleeve gastrectomy who are approved and sleeve gastrectomy in the Bariatric Surgery Center at the UCM.~Exclusion Criteria: Patients with primary kidney diseases, kidney stone disease, or kidney impairment (eGFR \< 90). Patients with known bladder voiding problems.~Participants will complete a diet record and a 24-hour urine collection both before and after surgery.~Participants will consume a 3 day fixed diet and present to the clinical research center for timed blood and urine draws. They will do this before and twice after (1 month and 1 year) surgery."
62765022|NCT05956808|EXPERIMENTAL|New BTE hearing aid first, then legacy BTE hearing aid|All participants who complete speech intelligibility testing and subjective listening effort ratings with both devices, first with the new hearing aid, and then with the legacy hearing aid.
62765023|NCT05956808|EXPERIMENTAL|Legacy BTE hearing aid first, then new BTE hearing aid|All participants who complete speech intelligibility testing and subjective listening effort ratings with both devices, first with the new hearing aid, and then with the legacy hearing aid.
62765024|NCT04226976|EXPERIMENTAL|Otoband efficacy on AUV|Participants will wear the Otoband during the single site visit against the skin, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. Half the participants will be given the Otoband at power level 96db and half will be given the Otoband at power level 98db (all bone conduction levels re:1dyne). This will be randomized and neither the participant nor the investigator will know what power level the Otoband is set at. The participants will be fitted with the Otoband and will undergo the vestibular battery test. The investigator will record the outcome measurements.
61988992|NCT04577287|EXPERIMENTAL|Anodal-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anode on the motor are (M1) of the affected hemisphere, and cathodal on the supraorbital area of unaffected hemisphere. Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
61988993|NCT04319042|ACTIVE_COMPARATOR|Immediate Loading|Group A. The implant receives an artificial tooth the same day as it is placed.
62384124|NCT04390360|OTHER|Implementation of protective ventilation|Protective ventilation implementation
62384125|NCT04390360|OTHER|Tidal Volume reduction|Tidal volume reduction
62765025|NCT04226976|PLACEBO_COMPARATOR|Placebo device efficacy on AUV|Participants will wear the placebo device during the single site visit against the skin, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. The placebo device will be set at a power level of 90db (bone conduction level re:1dyne). Neither the participant nor the investigator will know that this device is the placebo device. The participants will be fitted with the placebo device and will undergo the vestibular battery test. The investigator will record the outcome measurements.
62765026|NCT00979849|EXPERIMENTAL|A|AZD8683
62765027|NCT00979849|PLACEBO_COMPARATOR|B|Placebo
62765028|NCT03610139|ACTIVE_COMPARATOR|low dose vitamin D3 supplementation|Patients in this group will take 800 IU daily dose of vitamin D supplementation. They will be kept on 800 IU for 6 months. If they still had low vitamin D at 3 months, they will be asked about their adherence to the supplement, the investigators will remind them to take it as prescribed, and the investigators will keep the 800 IU vitamin D supplement dose for another 3 months. If they were still deficient at 6 months, the investigators will switch them to 10,000 IU weekly dose.
61988994|NCT04319042|ACTIVE_COMPARATOR|Early Loading|Group B. The implant receives an artificial tooth 4 weeks after placement.
62384126|NCT03452397|ACTIVE_COMPARATOR|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
62384127|NCT03452397|ACTIVE_COMPARATOR|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
62384128|NCT03452397|ACTIVE_COMPARATOR|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
62384129|NCT03452397|PLACEBO_COMPARATOR|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
62384130|NCT01520675|ACTIVE_COMPARATOR|Surgery|Patients will be randomized to surgery
62384131|NCT01520675|ACTIVE_COMPARATOR|Endotherapy|Patients will be randomized to endoscopic therapy
62384132|NCT04282499|EXPERIMENTAL|combined exercise|combined exercise (aerobic+resistance training)
62384133|NCT04282499|ACTIVE_COMPARATOR|aerobic exercise|aerobic exercise only
61988995|NCT06190431|ACTIVE_COMPARATOR|Only physiotherapist guidance|The aim of this study is to test whether the use of a coaching module (playful visual stimulation) in addition to guidance by a physiotherapist improves the learning and effectiveness of the technique compared to guidance alone.
61988996|NCT06190431|ACTIVE_COMPARATOR|Physiotherapist guidance + coaching module|The aim of this study is to test whether the use of a coaching module (playful visual stimulation) in addition to guidance by a physiotherapist improves the learning and effectiveness of the technique compared to guidance alone.
62384134|NCT02648867|EXPERIMENTAL|Patients receiving PushCoach feedback|Patients will receive continuous maternal feedback from the PushCoach device, which includes both audio and visual feedback of fetal head movement during the second stage of labor
61988997|NCT02211131|OTHER|Surgery|Surgical resection of melanoma tumor lesion(s)
61988998|NCT02211131|EXPERIMENTAL|Talimogene Laherparepvec|Talimogene laherparepvec for 6 doses followed by surgical resection of melanoma tumor lesion(s).
62765029|NCT03610139|EXPERIMENTAL|high dose vitamin D3 supplementation|"Patients in this group will take 50,000 IU weekly dose of vitamin D supplementation. Patients who will reach normal serum vitamin D level, between 40-80 ng/ml, at 3 or 6 months will be asked to decrease their Vitamin D3 supplementation as follows: Those who will reach levels between 40-60ng/ml will be switched to 10,000 IU three times per week, and those who reach levels between 60-80 ng/ml will be switched to 10,000 IU once weekly.~If they did not have any improvement in their levels of vitamin D at 3 or 6 months, they will be asked about their adherence to the supplement and the investigators will remind them to take it as prescribed and the investigators will keep them at the 50,000 IU weekly dose."
62765030|NCT02498574|EXPERIMENTAL|Group 1|Non-invasive brain stimulation protocol expected to improve performance, with cognitively challenging game
62384135|NCT02648867|ACTIVE_COMPARATOR|Patients blinded to PushCoach feedback|Patients will not receive continuous maternal feedback from the PushCoach device (it will be in place and collect data), but will receive normal feedback from the clinician during the second stage of labor.
62765031|NCT02498574|PLACEBO_COMPARATOR|Group 2|Non-invasive brain stimulation protocol not expected to improve performance, with cognitively challenging game
61988999|NCT04059731|EXPERIMENTAL|Surmimed®OPD Drink|Normocaloric oligomeric-hyperprotein supplement
61989000|NCT04059731|ACTIVE_COMPARATOR|Atempero® or Impact®|Inmunonutrition
61989001|NCT04426682||post-operative urinary incontinents|In patients who have previously had incontinence surgery due to stress incontinence, symptoms may return in the following years, and the patient may reapply with urinary incontinence. The first group will consist of postoperative urinary incontinence recurrent patients. Patients whose urodynamics are reperformed due to recurrence are the study group.
61989002|NCT04426682||without postoperative urinary incontinence|Patients who previously had incontinence surgery due to stress incontinence and who did not have postopertive urinary incontinence but whose urodynamics were repeated during the routine controls will constitute the control group.
61989003|NCT05695924|EXPERIMENTAL|BioBridge treatment group|Vascularized Lymph Node Transplant surgery (VLNT) supplemented by BioBridge Collagen Matrix implantation
61989004|NCT05695924|ACTIVE_COMPARATOR|Control group|Vascularized Lymph Node Transplant surgery (VLNT) only
62384136|NCT00792324|ACTIVE_COMPARATOR|Group 1|Four 100mg Etravirine tablets plus one Efavirenz (EFV) placebo tablet once daily
62765032|NCT04869033|EXPERIMENTAL|Farinelli's breathing group|Complete Farinelli's breathing exercise 5 times per week for 8 weeks.
62765033|NCT04869033|OTHER|Diaphragmatic breathing group (control group)|Complete Diaphragmatic breathing exercise 5 times per week for 8 weeks.
62765034|NCT02994368||Primary Cohort|No intervention
62765035|NCT02994368||Expansion Cohort|No intervention
62765036|NCT05113667|EXPERIMENTAL|Clinical pharmacist-led services|Clinical Pharmacist-led Appropriate Acid Suppression Therapy Stewardship Program
62765037|NCT05113667|NO_INTERVENTION|Control group|Usual care
61989005|NCT03632655|ACTIVE_COMPARATOR|Transrectal Ultrasound Guided Biopsy (TRUS)|Patients will receive a transrectal guided prostate biopsy
61989006|NCT03632655|ACTIVE_COMPARATOR|Transperineal Prostate Biopsy|Patients will receive a transperineal prostate biopsy
61989007|NCT03686410|EXPERIMENTAL|1. Therapeutic Educational Intervention|"The subjects assigned to this group will follow a web-based therapeutic educational intervention on pain and poor sleep quality.~All the subjects assigned to this intervention will have free access to the website from any device with internet access and will be able to consult it as many times as they wish during the intervention. The intervention will last for four weeks."
61989008|NCT03686410|ACTIVE_COMPARATOR|2. Convetional Tretament|"The subjects assigned to this condition will continue with their usual treatment is based on the recommendations of the clinical practice guideline for the treatment of fibromyalgia Guide of Fibromyalgia developed by the Department of Health of the Generalitat de Catalunya and the Servei Català de Salut."
61989009|NCT05442944|EXPERIMENTAL|A study group with physiotherapeutic intervention.|The study group - 30 people - participated in the three-week physiotherapy program.
61989010|NCT05442944|NO_INTERVENTION|A Control group without physiotherapeutic intervention|The control group - 30 people - did not participate in the program.
61989011|NCT04668950|EXPERIMENTAL|Fluvoxamine|Start fluvoxamine 50mg capsule once, then 100mg twice daily. May reduce dose for tolerability reasons. Will be followed in the RCT for approximately 15 days.
62384137|NCT00792324|ACTIVE_COMPARATOR|Group 2|One 600mg EFV tablet plus four Etravirine placebo tablet tablets once daily
62384138|NCT02250586|EXPERIMENTAL|CBT-CSO|"The CBT-CSO program will be based on concepts from cognitive-behavioral therapy and motivational interviewing, and is specifically developed for use with CSOs of treatment refusing problem gamblers. The program resembles the community reinforcement and family training approach that has been successfully used with CSOs of substance abusers.~The program will be given as guided self-help with guidance given via email and telephone. There are 8 modules, which all contain homework exercises and about 5-10 pages of text."
62384139|NCT02250586|NO_INTERVENTION|Wait-list|The participants allocated to the control condition will be put on a waiting list and offered the CBT-CSO program after 10 weeks. The CSOs will receive information about available treatment options-in their area and web-based-for the problem gambler.
62384140|NCT02698917|ACTIVE_COMPARATOR|Group 1|Low normal PaCO2, low normal PaO2, low normal MAP
62384141|NCT02698917|ACTIVE_COMPARATOR|Group 2|High normal PaCO2, low normal PaO2, low normal MAP
62765038|NCT05562349|EXPERIMENTAL|Clavulanic Acid|Participants may receive 500 mg of CLAV at baseline. Subjects who are using cocaine once per week or more and who can tolerate 500 mg/day for 4 weeks, will have a dose escalation to 750 mg/day. If tolerated, 750mg/day will be maintained for 8 weeks, otherwise the dose will decrease to 500mg/day.
62765039|NCT05562349|PLACEBO_COMPARATOR|Placebo|"Participants may receive placebo and serve as a control group. They will be blinded to their condition and will have a dose escalation at the same time as the experimental group, and be given additional placebo pills to match the number given to the experimental group."
62765040|NCT05291936|EXPERIMENTAL|TEST/CONTROL|Eligible subjects that are habitual contact lens wearers will be randomized into the (TEST/CONTROL) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period.
62765041|NCT05291936|EXPERIMENTAL|CONTROL/TEST|Eligible subjects that are habitual contact lens wearers will be randomized into the (CONTROL/TEST) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period.
62765042|NCT04326764|EXPERIMENTAL|Panobinostat|Panobinostat 20 mg oral three times weekly every second week
62765043|NCT04326764|NO_INTERVENTION|Standard of Care|Treatment according to local standards
62765044|NCT01124877|OTHER|Open|
62765045|NCT03502304|ACTIVE_COMPARATOR|Control group|No-exercise
62765046|NCT03502304|EXPERIMENTAL|Endurance training plus resistant training|To concurrent training (endurance training plus resistant training, RT) program will be use cycle ergometers adapted for obese adults (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) were used. Prior to the CT intervention, all subjects were familiarized (during 3 sessions) with the training protocols. The CT intervention included 3 weekly sessions of both ET and RT. The core part of each session included RT followed by ET exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
62765047|NCT02989129|EXPERIMENTAL|Chemotherapy Induced Neuropathic Pain (CINP) Treatment Group|"Questionnaires completed at Baseline and at End of Study Visit.~Participants take Quercetin tablets by mouth 2 times every day for 12 weeks."
62765048|NCT02989129|EXPERIMENTAL|Chemotherapy Induced Neuropathic Pain (CINP) Prevention Group|"Questionnaires completed at Baseline and at End of Study Visit.~Participants take Quercetin tablets by mouth 2 times every day for 12 weeks."
62765049|NCT00330928|EXPERIMENTAL|1|Subjects undergoing elective percutaneous coronary intervention
62765050|NCT00699218|EXPERIMENTAL|rTMS treatment|Active rTMS treatment. Transcranial magnetic stimulation using a device called MagStim
62765051|NCT05259761||PLHIV Kalangala District|250 People living with HIV registered for care at Bufumira Health Centre and Mazinga Health Centre, Kalangala District
62765052|NCT05259761||NonPHLIV Kalangala District|100 People not living with HIV attending for medical services at Bufumira Health Centre and Mazinga Health Centre, Kalangala District
62765053|NCT05259761||COVID Suspects Moyo District|1200 people attending for COVID tests at Moyo Hospital
62765054|NCT00652899|EXPERIMENTAL|Total Body Irradiation|"This group includes patients that received all chemotherapy, infusion of natural killer (NK) cells and total body irradiation per protocol.~1. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m\^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m\^2 on Days 6 through 2 preceding NK cell infusion. 4. Radiation: total-body irradiation 200 cGy Day 1 preceding NK cell infusion. 5. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 \* 10\^7/kg. 6. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0."
62765055|NCT00652899|EXPERIMENTAL|No Total Body Irradiation|"This group includes patients that received chemotherapy and infusion of natural killer cells, but did not receive total body irradiation.~1. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m\^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m\^2 on Days 6 through 2 preceding NK cell infusion. 4. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 \* 10\^7/kg. 5. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0."
62765056|NCT05953116|ACTIVE_COMPARATOR|Intervention Group|A protein product (combination of whey protein and plant-derived protein) in powdered form with flavoring. Product will be added to 180-200 mL of warm water prior to consumption.
62765057|NCT05953116|PLACEBO_COMPARATOR|Placebo Group|An isocaloric product (made with maltodextrin) in powdered form with flavoring. Product will be added to 180-200 mL of warm water prior to consumption.
61989012|NCT04668950|PLACEBO_COMPARATOR|Placebo|Start placebo one capsule, twice daily. May reduce dose for tolerability reasons. Will be followed in RCT for approximately 15 days.
61989013|NCT00665977|SHAM_COMPARATOR|A|"To enter into the single-blind placebo phase, subjects will be setup with a Fisher \& Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily."
62168237|NCT06176378|EXPERIMENTAL|Traditional Pulpotomy procedures|In the traditional pulpotomy group, the coronal pulp was removed by the traditional method the the capping material applied
61989014|NCT00665977|ACTIVE_COMPARATOR|Double Blind Treatment Group 2|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher \& Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
62765058|NCT00806442|EXPERIMENTAL|1: Borage Seed Oil and Echium Seed Oil|Borage/Echium plant seed oils: 2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
62765059|NCT00806442|PLACEBO_COMPARATOR|2: Placebo Comparator|Placebo comparator: 9 g/day corn oil
62384142|NCT02698917|ACTIVE_COMPARATOR|Group 3|Low normal PaCO2, high normal PaO2, low normal MAP
62384143|NCT02698917|ACTIVE_COMPARATOR|Group 4|High normal PaCO2, high normal PaO2, low normal MAP
62384144|NCT02698917|ACTIVE_COMPARATOR|Group 5|Low normal PaCO2, low normal PaO2, high normal MAP
62384145|NCT02698917|ACTIVE_COMPARATOR|Group 6|High normal PaCO2, low normal PaO2, high normal MAP
62384146|NCT02698917|ACTIVE_COMPARATOR|Group 7|Low normal PaCO2, high normal PaO2, high normal MAP
62384147|NCT02698917|ACTIVE_COMPARATOR|Group 8|High normal PaCO2, high normal PaO2, high normal MAP
61989015|NCT00665977|ACTIVE_COMPARATOR|Double Blind Treatment Goup 1|a Fisher \& Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
61989016|NCT04222569|EXPERIMENTAL|T-piece and PSV 7 PEEP 0 and PSV 0 PEEP 0|First T-piece trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min.
61989017|NCT04222569|EXPERIMENTAL|T-piece and PSV 0 PEEP 0 and PSV 7 PEEP 0|First T-piece trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min.
62384148|NCT04717856|OTHER|drug users|
62384149|NCT04735289||GROUP 1 - 215 Patients and 430 Control cases (1:2)|"Patients of \>= 12 years old (pediatric and adults) with new diagnosis of osteosarcoma and Ewing sarcoma will be included~* Localized and metastatic~* Male and female~Control cases matched by age, sex and italian geographic area"
62384150|NCT04735289||GROUP 2 - Pilot Phase :55 Patients and 110 Control cases (1:2)|"* Patients of \>= 12 years old (pediatric and adults) with new diagnosis of osteosarcoma and Ewing sarcoma will be included Localized and metastatic Male and female~* Control cases matched by age, sex, and geographic area"
62384151|NCT05224856|EXPERIMENTAL|CT-P63 and CT-P66|
62384152|NCT05224856|PLACEBO_COMPARATOR|Placebo|
62384153|NCT01540110|EXPERIMENTAL|Docetaxel + cyclophosphamide|
62384154|NCT05577351|EXPERIMENTAL|Treatment Arm|Each subject will undergo baseline evaluation for acute ischemic stroke due to large vessel occlusion, per standard of care and undergo mechanical thrombectomy procedure, aspiration to remove thrombus in the neuro-vasculature using the RapidPulseTM (feasibility) device.
62384155|NCT05949528||Healthy controls (HCs)|Healthy controls (HCs)
62384156|NCT05949528||Emerged from Minimally Conscious State (EMCS)|Emerged from Minimally Conscious State (EMCS): recovery of functional object uses or communication from chronic
62384157|NCT05949528||Minimally conscious state (MCS)|Minimally conscious state (MCS): have reproducible signs of awareness and exhibit fluctuations in consciousness
62384158|NCT05949528||Vegetative state (VS)|Vegetative state (VS): can open their eyes and preserve sleep-wake cycles, but unaware of themselves and their surroundings
62384159|NCT01148836|EXPERIMENTAL|Coenzyme Q 10 and Pulmonary Hypertension|PAH subjects to take Co-Q daily for three months
62384160|NCT01148836|EXPERIMENTAL|Coenzyme Q 10 and Normal Controls|Normal controls to take Co-Q daily for three months
62567660|NCT04289441|PLACEBO_COMPARATOR|Placebo treatment|"For the first 8 weeks was administered 1 sachet in the morning and 1 in the evening, for the last 8 weeks was administered 1 sachet per day~Maltodextrin and silicon dioxide"
62765060|NCT05878587|EXPERIMENTAL|Group A|thermotherapy+ TENS+ low intensity high repetition exercises and Buerger Allen.
62765061|NCT05878587|ACTIVE_COMPARATOR|Group B control group|Thermotherapy+ TENS+ low intensity high repetition exercises.
62765062|NCT02009293||Cough IPF|Male and female with idiopathic pulmonary fibrosis and cough and about to start on Pirfenidone according to regular practice will be asked to wear a cough monitor 24 hours before starting Pirfenidone and twice 24 hours while using Pirfenidone. Patients will also be asked to fill in questionnaires about quality of life and cough.
62384161|NCT05534594|EXPERIMENTAL|Patients with Medullary Thyroid Cancer undergoing 18F-PSMA PET/CT|"Only 1 arm exists in this study.~Patients with Medullary Thyroid Cancer undergo a PET/CT after receiving the Fluorine-18 labeled prostate specific membrane antigen (18F-PSMA-1007) tracer intravenously. Each patient will undergo this process one time. Patients will receive 3 MBq/kg (+- 10%) in 8,3 ml (maximum 400 MBq). Waiting time after injection is 60 minutes. Scanning time is approximately 45 minutes."
62765063|NCT01727011|EXPERIMENTAL|IPAS|Once the patient recorded in the trial, and after completion of a post-implant dosimetry scanner to analyze the dose distribution within the target volume and organs at risk, the patient is treated by irradiation and partial accelerated breast brachytherapy using high dose rate, delivering a total dose of 16 Gy in one fraction
62765064|NCT01971268||Platform-Switch Group|T3 dental implant, with platform-switch dental implant platform concept, measure marginal bone loss
62765065|NCT01971268||Platform-Matched Group|T3 dental implant, platform-matched dental implant platform concept, measure marginal bone loss
62765066|NCT04754685|ACTIVE_COMPARATOR|Mild knee osteoarthritis|30 patients had mild knee osteoarthritis
62765067|NCT04754685|ACTIVE_COMPARATOR|Moderate knee osteoarthritis|30 patients had moderate knee osteoarthritis
62765068|NCT04754685|ACTIVE_COMPARATOR|Severe knee osteoarthritis|30 patients had severe knee osteoarthritis
62765069|NCT02724735||Longitudinal Observational Cohort|Following completion of the NS2014-1 final study visit procedures, Subjects will be offered the opportunity to enroll in this longitudinal observational cohort protocol to monitor their depression and to assess durability of effect and long-term safety of NSI-189.
62765070|NCT05323123|EXPERIMENTAL|Intervention|Participants will receive PrEP and motivational counseling and adherence support
62765071|NCT05323123|ACTIVE_COMPARATOR|Control|Participants will receive PrEP and counseling
62765072|NCT03729193||soccer players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 soccer players.
62765073|NCT03729193||basketball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 basketball players.
62765074|NCT03729193||volleyball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 volleyball players.
62765075|NCT03729193||archers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 archers.
62765076|NCT03729193||kickboxers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 kickboxers.
62765077|NCT03729193||table tennis athletes|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 table tennis athletes.
62765078|NCT03729193||runners|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 runners.
62765079|NCT03729193||field tennis athletes|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 field tennis athletes.
61989018|NCT04222569|EXPERIMENTAL|PSV 0 PEEP 0 and PSV 7 PEEP 0 and T-piece|First PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min.
62384162|NCT03557801|ACTIVE_COMPARATOR|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard of care protocol.
62765080|NCT00376701|EXPERIMENTAL|1|Reduced fluence PDT plus intravitreal Kenalog (2 mg) plus intravitreal Avastin 1.25 mg
62765081|NCT00376701|EXPERIMENTAL|2|Reduced fluence PDT plus intravitreal Avastin
61989019|NCT04222569|EXPERIMENTAL|PSV 0 PEEP 0 and T-piece and PSV 7 PEEP 0|First PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min.
61989020|NCT04222569|EXPERIMENTAL|PSV 7 PEEP 0 and T-piece and PSV 0 PEEP 0|First PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min.
61989021|NCT04222569|EXPERIMENTAL|PSV 7 PEEP 0 and PSV 0 PEEP 0 and T-piece|First PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min.
61989022|NCT02430337|EXPERIMENTAL|Technology-Assisted SafeCare|A modified version of SafeCare, using a tablet and online program to complete a portion of the session
62567661|NCT02481206|EXPERIMENTAL|Wearable Cardioverter Defibrillator|End Stage Renal Disease (ESRD) patients beginning hemodialysis will use a Wearable Cardioverter Defibrillator for six months
62567662|NCT02481206|NO_INTERVENTION|Conventional Treatment|Conventional Treatment
62567663|NCT04771286|EXPERIMENTAL|BI 1015550 (C-14)|
62765082|NCT00376701|EXPERIMENTAL|3|Intravitreal Avastin and sham reduced fluence PDT
62765083|NCT02680210|OTHER|cognitive measures and questionnaires|the material of the study will consist of cognitive measures and questionnaires in order to (1) compare the cognitive performances and behavioral manifestations between patients with TBI and volunteers without neurological disorders and (2) to analyze the links between cognitive and behavioural measures in the TBI population
62765084|NCT00111540|EXPERIMENTAL|Exenatide|Exenatide 5 mcg for 4 weeks (transition) then 10 mcg to study termination
62765085|NCT03294070|EXPERIMENTAL|Fimasartan 60 mg + amlodipine besylate 5 mg|Fimasartan 60 mg + amlodipine besylate 5 mg. In subjects with a DBP equal to or greater than 90 mmHg and / or SBP equal to or greater than 140 mmHg at week 8, the investigator will have the option, according to his clinical criteria, to add 12.5 mg of HCTZ QD (in these cases, the subject will receive one 60 mg Fimasartan tablet plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate tablet.
62765086|NCT00892203|EXPERIMENTAL|Active|
62765087|NCT00892203|ACTIVE_COMPARATOR|Comparator|
62765088|NCT00892203|PLACEBO_COMPARATOR|Placebo|
62765089|NCT01788579|EXPERIMENTAL|Multimedia WINGS|A one-hour session of a self-paced multimedia IPV screening, brief intervention and referral service delivered on a computer.
62765090|NCT01788579|ACTIVE_COMPARATOR|Caseworker Delivered WINGS|A one-hour session of IPV screening, brief intervention and referral service delivered by a case manager.
62765091|NCT04401839|ACTIVE_COMPARATOR|Control group|153 patients received Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby according to the WHO recommendation for both groups in prevention of postpartum haemorrhage,followed by active management of the third stage of labor by administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
62765092|NCT04401839|ACTIVE_COMPARATOR|Study group|156 patients received Oxytocin 10 IU I.V shot at the time of delivery of the of the anterior shoulder of the baby according to the WHO recommendation .Then oxytocin is stopped and cervical traction (Amr maneuver )is applied.
62765093|NCT02179255|EXPERIMENTAL|Human Growth Hormone|1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) plus FSH 450 to 600 units per day administered subcutaneous (SQ) daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
62384163|NCT03557801|EXPERIMENTAL|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, women in the intervention arm 1 will participate in a 20-30 minute educational session alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
62384164|NCT03557801|EXPERIMENTAL|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
62384165|NCT01927276|PLACEBO_COMPARATOR|Gluten Free Flour (Control)|Gluten Free Flour 10 grams daily
62384166|NCT01927276|ACTIVE_COMPARATOR|Wheat Flour|Wheat Flour 10 grams daily
62384167|NCT01886144||Knee OA|People with knee OA of one knee
62384168|NCT04437589||Exposure group|In this group the treatment applied for postoperative pain involves Free-opioid anesthesia (LKDi).
62384169|NCT04437589||Control group|In this group the treatment applied for postoperative pain involves an opioid-based anesthesia.
62384170|NCT01524900||nevirapine extended release|
62384171|NCT01931020|ACTIVE_COMPARATOR|Sucrose|1ml of 24%sucrose will be administered prior to heel lance
62765094|NCT02179255|ACTIVE_COMPARATOR|Follicle Stimulating Hormone|FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
61989023|NCT02430337|ACTIVE_COMPARATOR|SafeCare-as-usual|SafeCare as it is usually delivered
61989024|NCT01299623|ACTIVE_COMPARATOR|Evidential Group|Participants in this group will receive education about breast cancer prevention and specific information about African American women and breast cancer risk.
62384172|NCT01931020|EXPERIMENTAL|Glucose|1ml of 25% glucose will be administered prior to heel lance
62384173|NCT05850429|PLACEBO_COMPARATOR|Control|0.6g/kg body mass maltodextrin in solution.
62384174|NCT05850429|EXPERIMENTAL|Low protein|0.6g/kg body mass maltodextrin PLUS 0.075g/kg body mass protein from Biodulse, in solution
62384175|NCT05850429|EXPERIMENTAL|Medium protein|0.6g/kg body mass maltodextrin PLUS 0.15g/kg body mass protein from Biodulse, in solution
62384176|NCT05110495|EXPERIMENTAL|Xentuzumab|All patients will be allocated to receive Xentuzumab
62384177|NCT03599284|EXPERIMENTAL|Experimental group 1|Experimental group 1: Vicagrel 20mg loading followed by 5mg/day for 28 days
62384178|NCT03599284|EXPERIMENTAL|Experimental group 2|Experimental group 2: Vicagrel 24mg loading followed by 6mg/day for 28 days
62384179|NCT03599284|EXPERIMENTAL|Experimental group 3|Experimental group 3: Vicagrel 30mg loading followed by 7.5mg/day for 28 days
62384180|NCT03599284|ACTIVE_COMPARATOR|Control group|Control group: Clopidogrel 300mg loading followed by 75mg/day for 28 days
61989025|NCT01299623|ACTIVE_COMPARATOR|Non-Evidential Group|Participants in this group will receive general information about breast cancer prevention without anything specific to African American women.
61989026|NCT04087707|EXPERIMENTAL|Step 1;TS-142|
61989027|NCT04087707|EXPERIMENTAL|Step 2;TS-142|
62384181|NCT01630629||African-American Lactating Women|Healthy African-American women who are exclusively breast-feeding.
62384182|NCT01630629||Caucasian Lactating Women|Healthy Caucasian women who are exclusively breast-feeding.
62384183|NCT03653039|EXPERIMENTAL|Tritube|
61989028|NCT04087707|PLACEBO_COMPARATOR|Step 2;Placebo|
61989029|NCT01113762|EXPERIMENTAL|resurfacing|a hip replacement that leaves most of the underlying bone intact and mimics the natural biomechanical features of the hip joint
62384184|NCT03653039|ACTIVE_COMPARATOR|Standard endotracheal tube|
62384185|NCT05632705|EXPERIMENTAL|Intervention arm|In this arm, prior to closing the sheath and skin, unused drapes, gloves and instruments will be used to close the sheath and the skin.
62384186|NCT05632705|NO_INTERVENTION|Control arm|In this arm sheath and skin closure will be according to the standard protocol
62384187|NCT03280186|EXPERIMENTAL|Patients With SVMs|Patients with SVMs will be included in the group and undergo surgery.
62567664|NCT02323542|EXPERIMENTAL|High-SDS biscuit|Biscuit with high Slowly Digestible Starch content
62765095|NCT01838577||Case cohort|"Patients with proven EGFR mutation in exons 18-21 from tumor material. Patients with unknown or failed tumor EGFR genotyping will be ineligible. Patients subsequently undergoing re-genotyping which demonstrates an EGFR mutation will become eligible for the case cohort.~No known somatic KRAS, HER2, LKB1, BRAF, or PI3K, mutation or ALK gene rearrangement (or ALK3+ immunohistochemistry). If these mutations are known to be present the patient will be ineligible. However, patients will not be tested specifically for these mutations for this study and patients with unknown status are acceptable. If patients are subsequently tested after enrollment and found to harbor any of these mutations they will be considered ineligible and will be replaced.~No known Li Fraumeni, Li Fraumeni-like, or Peutz Jeghers syndrome family, or known germline carriers of mutant LKB1 or TP53. Patients will not have to be tested specifically for these syndromes to be eligible for this study."
62765096|NCT01838577||Control cohort|"Patients known to be somatic EGFR wild-type, i.e. no mutation detected in exons 18-21 from tumor material.~Patients with unknown or failed EGFR genotyping will be ineligible. Patients subsequently undergoing re-genotyping which demonstrates an EGFR wild-type will become eligible for the control cohort.~Never smoker (\<100 cigarettes in lifetime) or ex-light smoker (stopped ≥1 year ago and smoked ≤10 pack-years)."
62765097|NCT01167868|EXPERIMENTAL|FosD|Four sequential cohorts of Japanese subjects are planned with doses ranging from 50mg once daily to a maximum of 200mg twice daily. One cohort of White subjects is also planned to receive the same dose regimen as the third dose level in Japanese subjects
62765098|NCT01167868|PLACEBO_COMPARATOR|Placebo|Placebo given (2 subjects in each cohort)
62765099|NCT01184573||Mild to Moderate CP|Subjects must have a history compatible with chronic pancreatitis.
62765100|NCT01184573||Healthy Controls|Subjects must be in good health of greater than 18 years of age.
62765101|NCT05786365||The group given 0.5 mg/kg ketamine|In this group we will give 0.5 mg/kg ketamine and we observe for disphoric reaction
62765102|NCT05786365||The group given 1 mg/kg ketamine|In this group we will give 1 mg/kg ketamine and we observe for disphoric reaction
61989030|NCT01113762|EXPERIMENTAL|large head THA|a standard stemmed THA but with a large metal head, and a metal-metal articulation
61989031|NCT01113762|ACTIVE_COMPARATOR|28 mm ceramics-polyethylene|a standard 28 mm head uncemented THA
62567665|NCT02323542|ACTIVE_COMPARATOR|Low-SDS cereal product|Cereal product with low Slowly Digestible Starch content
62765103|NCT05246826|EXPERIMENTAL|Clinical Pilates Exercises|Pilates exercises will be performed 3 days a week, for a total of 18 sessions for 6 weeks.
62765104|NCT05246826|EXPERIMENTAL|Clinical Pilates Exercises and Conventional Treatment|In addition to Pilates exercises, conventional treatment will be performed 3 days a week, for 6 weeks, a total of 18 sessions.
62765105|NCT06282965|EXPERIMENTAL|Ang 1-7 100 mcg/kg/day|Angiotensin I/II (1-7) acetate will be delivered as a subcutaneous injection at a dose of 100 micrograms per kilogram per day for 21 days.
62765106|NCT06282965|EXPERIMENTAL|Ang 1-7 200 mcg/kg/day|Angiotensin I/II (1-7) acetate will be delivered as a subcutaneous injection at a dose of 200 micrograms per kilogram per day for 21 days.
62765107|NCT06282965|PLACEBO_COMPARATOR|Placebo|Sterile saline (NaCl) will be delivered as a subcutaneous injection for 21 days.
62765108|NCT04017689||Verbal Information Group|Verbal Information
62765109|NCT04017689||Photo Group|Information by photos
62765110|NCT04017689||Video Group|Information by video
62765111|NCT01278784|EXPERIMENTAL|Healthy volunteer|
62765112|NCT03371953|ACTIVE_COMPARATOR|Vecuronium group|Vecuronium 0.08 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
62765113|NCT03371953|ACTIVE_COMPARATOR|Atracurium group|Atracurium 0.6 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
62765114|NCT03371953|ACTIVE_COMPARATOR|Vecuronium-Atracurium group|Vecuronium 0.04 mg/kg + atracurium 0.3 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
62765115|NCT00512018|ACTIVE_COMPARATOR|Isokinetic Exercise only|Individuals were asked to perform a 8-session training, twice a week, in which they trained the knee extensors muscles in an isokinetic dynamometer, 3 sets of 10 repetitions.
62765116|NCT00512018|EXPERIMENTAL|Isokinetic exercise + NMES|In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES).
61989032|NCT01113762|ACTIVE_COMPARATOR|28 mm metal-polyethylene THA|a standard stemmed uncemented THA
62168238|NCT06176378|EXPERIMENTAL|Diode laser Pulpotomy procedures|in the low-level diode laser pulpotomy group, the radicular pulp was biostimulated using low-level diode laser before application of capping material
62567666|NCT03070236|EXPERIMENTAL|Patient-reported Outcomes Survey|The survey will administered online, over the phone, or via mail.
62765117|NCT03913845|EXPERIMENTAL|0.5% lidocaine with epinephrine|On the day of surgery, the operating room pharmacist will prepare 20 cc of either study drug (0.5% lidocaine with epinephrine 1:200,000) or normal saline with epinephrine 1:200,000) in identical appearing 20cc syringes to be injected retropubically. Our group's routine clinical practice is to inject 20cc of 0.5% lidocaine with epinephrine 1:200,000 retropubically along the path of the midurethral sling trocars. Suburethral injection of local anesthestic will be performed at surgeon discretion. Surgical teams, anesthesia teams and patients will be blinded to allocation assignment. The investigational drug pharmacist will maintain the randomization sequence.
62765118|NCT03913845|ACTIVE_COMPARATOR|Normal saline with epinephrine|On the day of surgery, the operating room pharmacist will prepare 20 cc of either study drug (0.5% lidocaine with epinephrine 1:200,000) or normal saline with epinephrine 1:200,000) in identical appearing 20cc syringes to be injected retropubically. Our group's routine clinical practice is to inject 20cc of 0.5% lidocaine with epinephrine 1:200,000 retropubically along the path of the midurethral sling trocars. Suburethral injection of local anesthestic will be performed at surgeon discretion. Surgical teams, anesthesia teams and patients will be blinded to allocation assignment. The investigational drug pharmacist will maintain the randomization sequence.
62765119|NCT01547312|EXPERIMENTAL|Main Pt. 2: 800 mg Grazoprevir + Peg-IFN/RBV|800 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.
62765120|NCT01547312|EXPERIMENTAL|Main Pt. 2: 100 mg Grazoprevir + Peg-IFN/RBV|100 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.
62765121|NCT01547312|EXPERIMENTAL|Main Pt.1: 800 mg Grazoprevir|800 mg Grazoprevir.
62765122|NCT01547312|EXPERIMENTAL|Procedural Pilot|Optimization of FNA procedure.
62765123|NCT01680627||ADOLESCENT|
62765124|NCT01842581|EXPERIMENTAL|Rifaximin 550 mg BID|Participants will receive rifaximin 550 milligrams (mg) tablet orally twice daily (BID) for 24 weeks.
62765125|NCT01842581|EXPERIMENTAL|Rifaximin 550 mg BID + Lactulose|Participants will receive rifaximin 550 mg tablet orally BID with lactulose solution for 24 weeks. Lactulose dose will be self-titrated by the participant to produce 2 to 3 soft stools per day.
61989033|NCT03429179|EXPERIMENTAL|High anxiety butorphanol group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in high anxiety butorphanol group were \>10，and received an intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
61989034|NCT03429179|PLACEBO_COMPARATOR|High anxiety 0.9% saline group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in high anxiety 0.9% saline group were \>10, and received an infusion of the same volume of 0.9% saline
62168239|NCT06296888|EXPERIMENTAL|Radiofrequency balloon catheter ablation|Enrolled patients will undergo PVI by radiofrequency balloon ablation.
62384188|NCT02334813|ACTIVE_COMPARATOR|Arm A: daily prednisone|During the first week of treatment patients in both arms receive prednisone at 1 mg/kg/d. In arm A prednisone is continued at 1 mg/kg/d for a second week. If platelets increase to ≥50/nl, its dose is reduced to \<25 mg/d by week 14 and \<7.5 mg/d by week 20 according to a step-wise reduction scheme provided in the protocol. In patients without response after 2 weeks of treatment, the prednisone dose is increased to 2 mg/kg/d for another 2 weeks, then tapered as described above.
62384189|NCT02334813|ACTIVE_COMPARATOR|Arm B: pulsed dexamethasone|During the first week of treatment patients in both arms receive prednisone at 1 mg/kg/d. In arm B patients subsequently receive six 21-day courses of pulsed dexamethasone (0.6 mg/kg/d, days 1-4).
62384190|NCT01365468|EXPERIMENTAL|Everolimus (RAD001)|enrolled patients received everolimus (RAD001) in an open label manner. Recommended starting dose of everolimus depend on body surface area, starting from 2.5 mg once daily to 7.5 mg once daily.
62384191|NCT04464876|EXPERIMENTAL|Treatment|SATURN TA TMVR Device implanted
62384192|NCT06303362|EXPERIMENTAL|Elastic band excercises|Elastic band excercises and stretching is given to shoulder muscles (deep neck flexors, pectoralis major and minor, rhomboids and trapezius)
62384193|NCT06303362|ACTIVE_COMPARATOR|strengthening with conventional physical therapy|strengthening with conventional physicaltherapy is given to shoulder muscles (deep neck flexors, pectoralis major and minor, rhomboids and trapezius)
62384194|NCT03436992|EXPERIMENTAL|Women with type 1 diabetes|Women with type 1 diabetes will be randomly assigned to 1 of the 3 interventions (Antioxidant cocktail, Resveratrol, or placebo)
62384195|NCT03436992|NO_INTERVENTION|Healthy control women|Healthy women who participate will receive no intervention and serve as controls.
62384196|NCT03436992|EXPERIMENTAL|Men with type 1 diabetes|Men with type 1 diabetes will be randomly assigned to 1 of the 3 interventions (AOX cocktail, Resveratrol, or placebo)
62384197|NCT04765306|ACTIVE_COMPARATOR|Traditional Direct Fascial Closure|At the beginning of the laparoscopic procedure, all patients will receive 5 mL of 0.5% ropivacaine into each laparoscopic incision site. Patients in this group will have fascia closed under traditional direct visualization without laparoscopic guidance using a single interrupted suture of 0-vicryl.
62384198|NCT04765306|ACTIVE_COMPARATOR|Fascial Closure Device|At the beginning of the laparoscopic procedure, all patients will receive 5 mL of 0.5% ropivacaine into each laparoscopic incision site. Patients in this group will have fascia closed using direct laparscopic visualization with the Carter-Thomason fascial closure device with a single interrupted suture of 0-vicryl.
62384199|NCT04065516|EXPERIMENTAL|Argon Plasma Coagulation of the gastroesophageal junction|Participants with abnormal acid exposure after peroral endoscopic myotomy for achalasia, will be treated by ablation of the gastroesophageal junction with hybrid argon plasma coagulation
62384200|NCT01739192|PLACEBO_COMPARATOR|Arm 1|Placebo oral daily for approximately six (6) weeks.
62384201|NCT01739192|EXPERIMENTAL|Arm 2|Naltrexone (25 mg) oral daily for approximately six (6) weeks.
62384202|NCT01739192|EXPERIMENTAL|Arm 3|Naltrexone (50 mg) oral daily for approximately six (6) weeks.
62384203|NCT00582764||1|Any patient undergoing MRI guided preoperative needle localization or MRI guided biopsy of the breast.
62384204|NCT04605133||ARDS|Patients with mild or severe ARDS necessitating of prone position during mechanical ventilation
62384205|NCT00400868|ACTIVE_COMPARATOR|standard joint protection education|psycho-educational joint protection vs. usual care (standard joint protection education)
62384206|NCT01306240|EXPERIMENTAL|Early strategy|Intratracheal poractant alpha (Curosurf®) after tracheal intubation
62384207|NCT01306240|ACTIVE_COMPARATOR|Delayed strategy|Nasal Continous Positive Airways Pressure. Intratracheal poractant alpha as a rescue treatment if FiO2 \> 60%
62384208|NCT00758420|ACTIVE_COMPARATOR|1|Varisolve (polidocanol endovenous mircofoam)
62384209|NCT00758420|PLACEBO_COMPARATOR|2|Agitated saline
62384210|NCT00307736|EXPERIMENTAL|Chemotherapy and radiation|Continuous infusion 5-fluorouracil 225 mg/M2/d, bevacizumab 5 mg/kg IV q 14 days, erlotinib 50-150 mg orally daily for duration of radiation.
62384211|NCT01880489|EXPERIMENTAL|MI + CBST Intervention|Seven sessions of Motivational Interviewing and Cognitive Behavioral Skills Training
62765126|NCT05070910|EXPERIMENTAL|NDT|Therapy will be provided 2 days to 4 days per week for one-hour sessions
62765127|NCT03657147|EXPERIMENTAL|Question Prompt List and Video|Participants will watch an educational video and question prompt list will be provided. Glaucoma visits will be audio-taped. A 15-20-minute interview will be conducted after the visit by a research assistant.
62765128|NCT03657147|NO_INTERVENTION|Usual Care|The usual care group will not receive any intervention. Glaucoma visits will be audio-taped. A 15-20-minute interview will be conducted after the visit by a research assistant.
62765129|NCT01460719|EXPERIMENTAL|V212|Participants receive V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
62384212|NCT01880489|NO_INTERVENTION|Wait List Control Condition|
62384213|NCT00554840|ACTIVE_COMPARATOR|varenicline|
62384214|NCT00554840|PLACEBO_COMPARATOR|placebo|
62384215|NCT01372189||colorectal cancer|Patients with colorectal carcinoma during conventional endoscopic imaging.
62765130|NCT03188835|OTHER|Isocaloric Diet|Two weeks of isocaloric diet
62765131|NCT03188835|OTHER|Fructose diet|Two weeks of hypercaloric diet supplemented with fructose
62765132|NCT03188835|OTHER|Glucose diet|Two weeks of hypercaloric diet supplemented with glucose
62765133|NCT04842474|EXPERIMENTAL|Gaze stability and balance exercises|Gaze stability exercises will be performed while patients are in a seated position. Each exercise will last for 30 seconds and be done in phases that included; eyeball movement, saccadic eye movement, pursuit eye movement, vergence eye movement, and vestibular-ocular reflex exercise. Balance exercises will be performed in a standing position including both static and dynamic training with or without closing eyes.
62765134|NCT03821272|EXPERIMENTAL|PepCan|Four injections (one every 3 weeks) of PepCan, then three injections (one every 3 months) of PepCan for a total of 7 injections.
62765135|NCT03821272|PLACEBO_COMPARATOR|Placebo|Four injections (one every 3 weeks) of placebo, then three injections (one every 3 months) of placebo for a total of 7 injections.
62765136|NCT01247935|EXPERIMENTAL|Acupuncture|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
62765137|NCT01247935|EXPERIMENTAL|transcutaneous electrical stimulation|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
62765138|NCT01247935|NO_INTERVENTION|Control|patient are monitored for pain and discomfort
62765139|NCT02359214|ACTIVE_COMPARATOR|Vitamin D3 Supplement|This group will receive a daily dose of 5000IU (125µg) vitamin D3 (which is half of the recommended safe tolerable upper intake level of vitamin D for healthy individuals) for eight weeks.
62765140|NCT02359214|PLACEBO_COMPARATOR|Placebo|This group will receive 100% lactose placebo daily for eight weeks.
62765141|NCT03225261|EXPERIMENTAL|Citrus extract|Citrus extract
62765142|NCT03225261|PLACEBO_COMPARATOR|Placebo|Maltodextrin
61989035|NCT03429179|EXPERIMENTAL|Low anxiety butorphanol group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in low anxiety butorphanol group were ≤10,and received an intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
62168240|NCT03612492|ACTIVE_COMPARATOR|Esmolol Group|Patients will receive esmolol during induction of anesthesia
62384216|NCT01372189||colorectal adenoma|Patients with colorectal adenoma during conventional endoscopic imaging.
62384217|NCT04983004|EXPERIMENTAL|experimental group (tele-rehabilitation)|"Each patient will go on a treatment with 10 sections, and each section is 15 or 30 minutes depends on patient's ability.~The intervention is used by the communication software to interact with each other in real time. The treatment plan and treatment method are set according to the individual's movement needs, and the individual's movement instructions are clearly given during treatment."
62384218|NCT04983004|ACTIVE_COMPARATOR|control group (bedside rehabilitation)|Each patient will go on a treatment with 10 sections, and each section is 15 or 30 minutes depends on patient's ability. It is carried out by the bedside therapist. The treatment plan and treatment method are set according to the individual's movement needs, and the individual's movement instructions are clearly given during treatment.
62384219|NCT06320964|EXPERIMENTAL|TARANG arm|The newly married women received 16 weekly group sessions and one rapport-building session, while the husbands and mothers-in-law received four group sessions each over four months. The TARANG intervention was delivered via gender-matched moderators from Vikalp Sansthan and uses three overarching themes: sexual and reproductive health, gender norms, and empowerment.
62384220|NCT04383691|EXPERIMENTAL|Lurasidone|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.
62384221|NCT04383691|PLACEBO_COMPARATOR|Placebo|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Placebo.
62384222|NCT03230266|OTHER|collection|collection of biological and device samples
62384223|NCT06366685|EXPERIMENTAL|Exercise training|Implementing only exercise intervention for participants, including aerobic exercise, breathing exercises, resistance exercises, with specific exercise regimes tailored to the participants' physical conditions.
62384224|NCT06366685|EXPERIMENTAL|Mindfulness-Based Stress Reduction Therapy|Implementing only mindfulness-based stress reduction therapy as the main psychological intervention for participants, and dynamically adjusting based on the participants' psychological states.
62384225|NCT06366685|EXPERIMENTAL|Exercise combined with Mindfulness-Based Stress Reduction Therapy|Implementing intervention combining exercise with mindfulness-based stress reduction therapy for participants, and dynamically adjusting based on the participants' physical and mental recovery status.
62384226|NCT06366685|NO_INTERVENTION|Routine care|Implementing only the department's routine care for esophageal cancer surgical patients.
62765143|NCT01519674|ACTIVE_COMPARATOR|BIAsp 30 BID + sitagliptin + metformin|
62765144|NCT01519674|ACTIVE_COMPARATOR|BIAsp 30 BID + metformin|
62765145|NCT01519674|ACTIVE_COMPARATOR|BIAsp 30 OD + sitagliptin + metformin|
62765146|NCT03033953|PLACEBO_COMPARATOR|Milk supplementation|11 (elderly) or 12 (young) weeks of strength training and daily supplementation of 2x20g milk protein.
62765147|NCT03033953|EXPERIMENTAL|Native whey|11 (elderly) or 12 (young) weeks of strength training and daily supplementation of 2x20g native whey protein.
62765148|NCT05766033|EXPERIMENTAL|Novel etchent paste|
62765149|NCT05766033|ACTIVE_COMPARATOR|Phosphoric acid 37%|
62765150|NCT03112304|EXPERIMENTAL|MATCH-ADTC Wave 1|Wave 1 clinicians received MATCH training at the beginning of the project and used MATCH to treat participating children from their clinic for two years, with weekly case consultation from MATCH experts who were part of the study team, and then received consultation from their own clinic supervisors who had been trained as MATCH Associate Consultants (ACs), supported by the TRAC system.
62765151|NCT03112304|EXPERIMENTAL|MATCH-ADTC Wave 2|Wave 2 clinicians provided treatment as usual (e.g., usual care) with the children they treated during the initial two years of the project. Afterwards, they trained in MATCH and used it to treat children in their clinics with weekly case consultation from our study team of MATCH experts, supported by the TRAC system.
62765152|NCT03734029|EXPERIMENTAL|Trastuzumab deruxtecan|HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a
61989036|NCT03429179|PLACEBO_COMPARATOR|Low anxiety 0.9% saline group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in low anxiety 0.9% saline group were ≤10, and received an infusion of the same volume of 0.9% saline
62384227|NCT03960164|EXPERIMENTAL|Patient group|The group of patients included in the study following inclusion criteria with local (wound) and systemic test values prior and after to the application of the DRPM.
62384228|NCT06295822|EXPERIMENTAL|Nuan-gong-ye|
62765153|NCT03734029|ACTIVE_COMPARATOR|Physician's Choice|"HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options:~* Capecitabine~* Eribulin~* Gemcitabine~* Paclitaxel~* Nab-paclitaxel"
61989037|NCT05839457|EXPERIMENTAL|Intervention group|Empowerment Pilot
61989038|NCT05839457|NO_INTERVENTION|Control group|
61989039|NCT01695694|ACTIVE_COMPARATOR|community support group|
61989040|NCT01695694|EXPERIMENTAL|supporting positive and healthy relationships|
61989041|NCT00815438|EXPERIMENTAL|Surgical Procedure|Laparoscopic transvaginal cholecystectomy with endoscopic assistance.
61989042|NCT04709328|EXPERIMENTAL|SCTA01 low dose +SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
61989043|NCT04709328|EXPERIMENTAL|SCTA01 middle dose+SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
61989044|NCT04709328|EXPERIMENTAL|SCTA01 High dose +SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
61989045|NCT04709328|PLACEBO_COMPARATOR|Placebo+SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
61989046|NCT00026793||Kaposi's Sarcoma|Adult patients with biopsy-proven cutaneous Kaposi's sarcoma. Some participants received interleukin-12 and liposomal doxorubicin. However, the therapy was administered on a different protocol and was not part of this study.
61989047|NCT02994732|EXPERIMENTAL|[14C]-BVD-523 600mg single dose|Open-label, nonrandomized, absorption, metabolism, and excretion study of \[14C\]-BVD-523 administered as a 600 mg (approximately 200 µCi) oral dose to 6 healthy male subjects following at least an 8-hour fast from food (not including water).
61989048|NCT05957783||Group 1|Preoperative patient group with diplegic or hemiplegic cerebral palsy
61989049|NCT05957783||Group 2|Postoperative patient group with diplegic or hemiplegic cerebral palsy
61989050|NCT05957783||Control group|5-15 age healthy children.
61989051|NCT03278990|EXPERIMENTAL|Future Self - Value Affirmation|This is a behavioral intervention whereby participants write (Value Affirmation and Future Selves Combination) for 5 minutes about 1-2 values that are important to them, as well as about a time in their life when they were particularly important. Next, for five minutes, they write a letter to themselves in 20 years.
62384229|NCT06295822|PLACEBO_COMPARATOR|Placebo|
62384230|NCT05528068|PLACEBO_COMPARATOR|control group|standard care, physiological monitoring by wearable devices and healthy lifestyle education
62384231|NCT05528068|EXPERIMENTAL|supervised lifestyle intervention group|standard care, physiological monitoring by wearable devices and personalized and supervised lifestyle intervention including dietary and physical activity modification
62384232|NCT00113035||Patients with late onset Pompe Disease|
62384233|NCT02147431|EXPERIMENTAL|Semaglutide|
62384234|NCT02147431|PLACEBO_COMPARATOR|Placebo|
62384235|NCT02557633|PLACEBO_COMPARATOR|Placebo|2% w/v L-Tyrosine
62384236|NCT02557633|EXPERIMENTAL|Grass MATA MPL 10200 SU|Grass MATA MPL cumulative dose 10200 SU given as six injections of placebo, placebo, 600SU, 1600SU, 4000SU and 4000SU.
61989052|NCT03278990|SHAM_COMPARATOR|Control|In this sham comparator, participants will also write (Control Writing Exercise) --similar to the intervention above. However, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
61989053|NCT00017147|EXPERIMENTAL|O6-BG + BCNU + Radiation Therapy|O6-BG: 120 mg/m\^2 IV over 1 hour on day 1 of each cycle BCNU: 40 mg/m\^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose. Radiation Therapy: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
61989054|NCT00017147|ACTIVE_COMPARATOR|BCNU + Radiation Therapy|BCNU: 40 mg/m\^2 IV over 1 hour on day 1 of each cycle. Radiation Therapy: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
62765154|NCT04721522||356 case will be enrolled|Pituitary suppression will be achieved by long or antagonist protocol. For long protocol, GnRH agonist will be administered for 10-14 days starting from mid-luteal phase of preceding cycle. After confirmation of down regulation, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). Gonadotropins therapy will be tailored according to age, BMI, antral follicle count, antimullerian hormone and previous response. In antagonist protocol, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). GnRH antagonist will be adjusted according to patient response. On the 5th -6th day of stimulation, sonography will be performed and repeated every 1-3 days with regular estradiol assessment. When at least 3 follicles reach ≥ 17 mm in mean diameter, trigger will be given. Oocytes pick up will be performed 34-36 hour after triggering.
62765155|NCT03449433|EXPERIMENTAL|LY900014|T1DM participants received a single, individualized, subcutaneous (SC) dose of LY900014.
61989055|NCT02347189|OTHER|Melody TPV PB1016|
61989056|NCT00426582|EXPERIMENTAL|Patupilone only|Cycle 1 patupilone alone Cycle 2 and onward patupilone and carboplatin
61989057|NCT00426582|ACTIVE_COMPARATOR|Carboplatin alone|Cycle 1 Carboplatin alone Cycle 2 and onward patuilone and carboplatin
61989058|NCT04754776|EXPERIMENTAL|Low dose|5 x 10\^9 vp ChAdOx1 RVF delivered intramuscularly
61989059|NCT04754776|EXPERIMENTAL|Medium dose|2.5 x 10\^10 vp ChAdOx1 RVF delivered intramuscularly
61989060|NCT04754776|EXPERIMENTAL|High dose|5 x 10\^10 vp ChAdOx1 RVF delivered intramuscularly
62765156|NCT03449433|ACTIVE_COMPARATOR|Insulin Lispro (Humalog®)|T1DM participants received a single, individualized, SC dose of insulin lispro.
62765157|NCT03449433|ACTIVE_COMPARATOR|Insulin Aspart (NovoRapid®)|T1DM participants received a single, individualized, SC dose of insulin aspart.
62765158|NCT03449433|ACTIVE_COMPARATOR|Insulin Aspart (Fiasp®)|T1DM participants received a single, individualized, SC dose of insulin aspart.
62765159|NCT03449433|NO_INTERVENTION|Healthy Participants|Healthy participants who received no study drug.
62765160|NCT00003847|EXPERIMENTAL|Treatment|
62765161|NCT01592019|EXPERIMENTAL|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
61989061|NCT06264206|EXPERIMENTAL|KIR AA|Patients from arm KIR AA received immunomodulatory treatment, and the pregnancy rate was calculated after this treatment, and compared to the one before the treatment
61989062|NCT06264206|NO_INTERVENTION|KIR BX|Patients from arm KIR BX did not receive immunomodulatory treatment, and the pregnancy rate was calculated and compared with the ones from arm KIRR AA- before and after immunomodulatory treatment
61989063|NCT04295421|ACTIVE_COMPARATOR|Canal adductor block|ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.
61989064|NCT04295421|EXPERIMENTAL|IPACK block|"IPACK was realized after spinal anesthesia. Patient was placed in a supine position and knee placed in position of 90° flexion. A low-frequency ultrasound probe was positioned in the popliteal crease, and the needle was inserted from medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle was placed 1-2 cm beyond the lateral edge of the artery, and 20 ml of 0.2% ropivacaine was injected for each side.~A ACB was done postoperatively with 20 ml ropivacaine 0.2% and a catheter was kept for 48H with 4 ml/h saline"
62168241|NCT03612492|ACTIVE_COMPARATOR|Lidocaine Group|Patients will receive lidocaine during induction of anesthesia
62765162|NCT01592019|EXPERIMENTAL|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
62765163|NCT01592019|EXPERIMENTAL|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
62765164|NCT01592019|EXPERIMENTAL|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
62384237|NCT02557633|EXPERIMENTAL|Grass MATA MPL 18200 SU|Grass MATA MPL cumulative dose 18200 SU given as six injections of 600SU, 1600SU, 4000SU, 4000SU, 4000SU and 4000SU.
62384238|NCT03137433|EXPERIMENTAL|Meal-Replacements|Participants will be asked to strictly follow the individually-prescribed eating regimen, which will include shakes (breakfast and lunch) and pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables per day. Daily caloric allotment will be tailored for each individual (number of shakes and frozen meals) by calculating the average daily caloric deficit necessary to achieve negative energy balance (using the metabolic rate/energy expenditure data).
62384239|NCT03137433|EXPERIMENTAL|Meal-Replacements Plus|Participants will be asked to strictly follow the individually-prescribed eating regimen, which will include shakes (breakfast and lunch) and pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables per day. Daily caloric allotment will be tailored for each individual (number of shakes and frozen meals) by calculating the average daily caloric deficit necessary to achieve negative energy balance (using the metabolic rate/energy expenditure data). This group will be provided additional information to go along with meal-replacements.
62384240|NCT03513432|EXPERIMENTAL|Beer with 5.20 % alcohol|330 ml beer (5.20 % alcohol)/day
62765165|NCT03587753|ACTIVE_COMPARATOR|Unsaturated|A test meal containing a unsaturated fatty acid labelled with 13C to measure hepatic fatty acid partitioning.
62765166|NCT03587753|ACTIVE_COMPARATOR|Saturated|A test meal containing a saturated fatty acid labelled with 13C to measure hepatic fatty acid partitioning
62765167|NCT03935555|EXPERIMENTAL|Oral - 50mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
62384241|NCT03513432|EXPERIMENTAL|Non-alcoholic beer with 0.45 % alcohol|330 ml non-alcoholic beer (0.45 % alcohol)/day
62384242|NCT03513432|EXPERIMENTAL|Non-alcoholic beer with 0.00 % alcohol|330 ml non-alcoholic beer (0.00 % alcohol)/day
62384243|NCT00969735|ACTIVE_COMPARATOR|Cryoablation|Deflectable over-the-wire cryoablation balloon catheter (Arctic Front®, Cryocath Technologies)
62384244|NCT00969735|ACTIVE_COMPARATOR|Radiofrequency ablation|Open irrigation ablation catheter (Navistar® Thermo-cool®, Biosense Webster Inc).
62765168|NCT03935555|EXPERIMENTAL|Oral -100 mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
62765169|NCT03935555|EXPERIMENTAL|Oral - 200 mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
62765170|NCT03935555|EXPERIMENTAL|Oral - 300 mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
62765171|NCT02973191|EXPERIMENTAL|JCAR015 administration|Single dose of 1.0-3.0 mg/m\^2 IV cyclophosphamide, JCAR015 Dose 1 1x10\^6 Tcells/kg, JCAR015 Dose 2 3x10\^6 Tcells/kg
62765172|NCT00724906|EXPERIMENTAL|Parkinsonian Syndromes|Subjects with Parkinsonian Syndromes
62765173|NCT00724906|EXPERIMENTAL|Non-Parkinsonian Syndromes|Subjects with Non-Parkinsonian Syndromes
62765174|NCT03426631|PLACEBO_COMPARATOR|Placebo|Placebo before sleep
62765175|NCT03426631|EXPERIMENTAL|DAW1033B2 oral capsule|DAW1033B2 before sleep
62765176|NCT05302141|EXPERIMENTAL|3D printing assistive device group|experimental (3D printing assistive device) groups for 4 weeks of treatment (thirty minutes a time, twice a week).
62384245|NCT06095349|EXPERIMENTAL|Bone turnover markers|Concentrations of bone turnover markers will be assessed before and after treatment. Correlation will be sought for with H2S levels and clinical features of the patients
62384246|NCT01738672|EXPERIMENTAL|Nitrous Oxide|Parturients who request labor analgesia will be offered inhaled nitrous oxide for labor analgesia.
62384247|NCT01435564|ACTIVE_COMPARATOR|pedometer|
62384248|NCT01435564|EXPERIMENTAL|Mobile phone physical activity intervention|
62384249|NCT01432236|EXPERIMENTAL|Pregabalin|Group 1 as Pregabalin vs. Placebo (cross over study in which period one has this group)
62384250|NCT01432236|PLACEBO_COMPARATOR|Placebo|Group 2 as placebo vs. pregabalin (cross over study in which period two will have this group)
62384251|NCT04152538||healthy subjects|Healthy subjects matched with TKA patients
62384252|NCT04152538||TKA patients|age greater than 18 years old and a recent TKA.
62384253|NCT02865317||Study group|Patients with obstetrical brachial plexus injury involving upper trunk (C5-6)
62765177|NCT05302141|ACTIVE_COMPARATOR|universal cuff groups|control (universal cuff) groups for 4 weeks of treatment (thirty minutes a time, twice a week).
62765178|NCT02418988|EXPERIMENTAL|TACE plus rAd-p53|TACE plus rAd-p53 artery injection'
62765179|NCT02418988|ACTIVE_COMPARATOR|TACE|TACE will be applied alone
62765180|NCT05612360|EXPERIMENTAL|"Control condition with waiting for you message"|This control condition will use the text message that the investigators found to be the best performing in their last mega-study of vaccine text messages to recommend a COVID vaccination.
62765181|NCT05612360|EXPERIMENTAL|Message encouraging vaccination in preparation for the holidays|This condition will use a text message to encourage a COVID vaccination in preparation for the holidays.
62765182|NCT04825990|EXPERIMENTAL|Single Arm Treatment|Patients will receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week dosing cycle (Q3W) and olaparib 300 mg capsules twice a day (BID) every day starting from Day 1 of Cycle 1. Treatment with protocol therapy will continue until objective disease progression, any prohibitive toxicity or until a maximum of 35 treatment cycles (up to 2 years).
62384254|NCT03020797|EXPERIMENTAL|perampanel|perampanel 2mg QD for 2 weeks perampanel 4mg QD for 2 weeks perampanel 6mg QD for 2 weeks perampanel 8mg QD for 30 weeks
62765183|NCT00641342|ACTIVE_COMPARATOR|onlay mesh|
62765184|NCT00641342|ACTIVE_COMPARATOR|sublay mesh|
62765185|NCT00641342|NO_INTERVENTION|no mesh|
62765186|NCT05281094|PLACEBO_COMPARATOR|Placebo|One dose of placebo on Day 1 and one dose of placebo between Day 29 and Day 57.
62765187|NCT05281094|EXPERIMENTAL|Experimental|One dose of HIL-214 on Day 1 and one dose of HIL-214 between Day 29 and Day 57.
62765188|NCT03910166|EXPERIMENTAL|DCB group|use DEB catheter(trade name:Orchid/Dhalia) to treat the stenosis or occlusion in Vertebral Artery Ostium Stenosis of experimental arm
62765189|NCT03910166|ACTIVE_COMPARATOR|BMS group|use Intracranial artery stent system(trade name:Apollo) to treat stenosis or occlusion in Vertebral Artery Ostium Stenosis of control group
62765190|NCT05505188|OTHER|Population|no arm, single cohort follow-up
62765191|NCT02988999|EXPERIMENTAL|D-allulose|D-allulose 5 gm 3 times a day
62765192|NCT02988999|ACTIVE_COMPARATOR|erythritol|erythritol 5 gm 3 times a day
62765193|NCT01394614||Narcoleptics exposed to A/H1N1 vaccine|Adjuvanted (ASO3) A/H1N1 pandemic vaccine
62765194|NCT01394614||Narcoleptics unexposed to A/H1N1 vaccine|Narcoleptic subjects who were unexposed (non-vaccinated or vaccinated after onset) to adjuvanted (ASO3) A/H1N1 pandemic vaccine.
62765195|NCT04743960|EXPERIMENTAL|Nighttime cycled parenteral feeds followed by daytime cycled parenteral feeds|Patients will follow nighttime feeding regimen for one week, and then advance their feeds (approximately 12 hours earlier) to daytime feeding regimen for one week.
62765196|NCT05886530||HIV treatment survey participants|HIV treatment patients eligible to be enrolled in the patient survey
62765197|NCT05886530||Provider survey participants|HIV treatment providers eligible to be enrolled in the provider survey
62765198|NCT05886530||Time and motion observation participants|HIV treatment providers eligible to be enrolled in the time and motion observation study
62384255|NCT03020797|PLACEBO_COMPARATOR|placebo|placebo 1 tablet QD for 2 weeks placebo 2 tablets QD for 2 weeks placebo 3 tablets QD for 2 weeks placebo 4 tablets QD for 2 weeks
62384256|NCT04340804|EXPERIMENTAL|Kcal labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time kcal counter synchronised with the food amount changes (i.e., increasing/decreasing).
62384257|NCT04340804|EXPERIMENTAL|PACE labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes (i.e., increasing/decreasing) with 4 min being equivalent to 20 kcal.
62765199|NCT05886530||HIV testing survey participants|Individuals presenting for HIV testing eligible to be enrolled in the HIV testing survey
62765200|NCT06504927||A - High risk cohort|"i. Male or female subjects aged 30 and above. ii. No previous history of any cancers. iii. Able to provide X-ray and/or LDCT results. iv. Have one of the following conditions:~1. COPD~2. Pulmonary nodules measuring less than 11mm, or deemed not for biopsy by attending physician~v. Willing to go back for a follow-up X-ray or LDCT scan in the next clinical follow up as per standard of care.~vi. Willing to provide up to 30mL of blood in month-0 (first visit) and up to 21mL in the next standard of care follow up visit (second visit)."
62765201|NCT06504927||B - Highly suspicious of lung cancer|"i. Male or female subjects aged 30 and above. ii. No previous history of any cancers. iii. Able to provide X-ray and/or LDCT results. iv. Have one of the following conditions:~1. Suspicious nodules measuring more than 11mm.~2. Imaging diagnosis suggestive of lung cancer.~v. Willing to enrol for biopsy for confirmation. vi. Willing to provide up to 39mL of blood in month-0 (first visit) and up to 21mL in the next standard of care follow up visit (second visit)."
62765202|NCT00731965|EXPERIMENTAL|1|Measles, mumps, rubella booster vaccination within 3 months after randomisation
62765203|NCT00731965|NO_INTERVENTION|2|Booster vaccination performed by regular health authorities at age 9; at least 1 year after randomisation
62384258|NCT04340804|EXPERIMENTAL|Kcal and PACE labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time kcal and PACE counters synchronised to the food amount changes (i.e., increasing/decreasing).
62384259|NCT04340804|NO_INTERVENTION|No labelling|Participants allocated to this group will only see on the screen the amount of food increasing or decreasing based how many times they tap on the corresponding keys.
62765204|NCT04147975||Patients Suspected of Bloodstream Infection|No intervention(s) to be administered.
62765205|NCT03460548|EXPERIMENTAL|Remogen|
62765206|NCT03460548|ACTIVE_COMPARATOR|Cationorm|
62765207|NCT04384107|EXPERIMENTAL|V114|Participants will receive a single 0.5 mL subcutaneous injection of V114 administered at 2 to 6 months of age, and second and third dose is administered at an interval of ≥27 days from the prior dose. The fourth dose is administered at 12 to 15 months of age.
62765208|NCT04384107|ACTIVE_COMPARATOR|Pneumococcal 13-valent Conjugate Vaccine (PCV13)|Participants will receive a single 0.5 mL subcutaneous injection of PCV13 administered at 2 to 6 months of age, and second and third dose is administered at an interval of ≥27 days from the prior dose. The fourth dose is administered at 12 to 15 months of age.
62765209|NCT03418558|EXPERIMENTAL|HERACLES RESCUE|Patients will receive trastuzumab-emtansine, iv 3,6 mg/kg every 21 days. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first
62765210|NCT04500340|EXPERIMENTAL|Group Cognitive Behavioral Therapy (Group CBT)|Intervention Group will receive ten-session group CBT for test anxiety. Two sessions will be carried out each week.
62384260|NCT02054572|EXPERIMENTAL|[¹⁴C]Etelcalcetide|Participants received a single dose of 10 mg radiolabelled etelcalcetide administered by intravenous (IV) bolus injection at the end of hemodialysis on day 1.
62765211|NCT04500340|NO_INTERVENTION|Control Group|The Control group will be waiting for the control group who will receive intervention if they demand after final assessment for outcome measure.
62765212|NCT05536856|EXPERIMENTAL|Control group|30 patients will apply the 5-Fluorouracil plain powder on the selected patch followed by 3 milliliters of water till complete dissolution of the powder.
62765213|NCT05536856|EXPERIMENTAL|Study group|30 patients will apply a new effervescent mixture formula of 5-Fluorouracil prepared at faculty of pharmacy (Girls) - Al-Azhar university
62765214|NCT05117619|EXPERIMENTAL|HOME for Us|The HOME intervention is the delivery of an in-home, family inclusive, rehabilitation intervention in eight sessions. Six of the sessions will occur in the home, and two will be over the phone. The in-home sessions will be about 1 ½ hrs. each, and the phone sessions will be about 15 minutes each. The sessions are delivered by an occupational therapist (OT).
62384261|NCT00793715|ACTIVE_COMPARATOR|1|Decompressive laparotomy with temporary abdominal closure
62384262|NCT00793715|ACTIVE_COMPARATOR|2|Patients who will receive percutaneous puncture with placement of abdominal catheter
62384263|NCT01930487|EXPERIMENTAL|supplement w/ antioxidants then placebo|dietary supplement with antioxidants, followed by placebo supplement
62384264|NCT01930487|EXPERIMENTAL|placebo then supplement w/ antioxidants|placebo supplement, followed by dietary supplement with antioxidants
62384265|NCT01998854||VizAblate treatment|VizAblate System with subject serving as her own control
62384266|NCT02985385||Abnormal Fetal Ultrasounds|"Abnormal fetal ultrasounds:~1. Those consistent with lethal malformations are provided with palliative management without providing respiratory support. Are given feeding and oxygen~2. Those compatible with life are managed by full investigation and given standard care for each case"
62384267|NCT02985385||Normal Fetal Ultrasounds|Given normal care
62384268|NCT02409251|EXPERIMENTAL|Education and feedback|The intervention consisted of a one-hour, small group educational session. During this session information on rational ANA testing was provided and feedback on current ANA testing was provided to the rheumatologists. A booster session with the same components was held 6 months after the first session.
62384269|NCT03322540|EXPERIMENTAL|Pembrolizumab + Epacadostat|Participants received pembrolizumab 200 mg as an intravenous (IV) infusion, every three weeks (Q3W) starting on Day 1 of each cycle for up to 35 administrations in combination with epacadostat 100 mg orally, twice daily. Epacodostat administration was discontinued after the implementation of protocol amendment 05.
62384270|NCT03322540|ACTIVE_COMPARATOR|Pembrolizumab + Placebo|Participants received pembrolizumab 200 mg by IV infusion, Q3W starting on Day 1 of each cycle for up to 35 administrations in combination with matching placebo orally, twice daily. Placebo administration was discontinued after the implementation of protocol amendment 05.
62384271|NCT01615094||High-risk Stage B Heart Failure Patients|American College of Cardiology/American Heart Association (ACC/AHA) asymptomatic Stage B patients with B-Type natriuretic peptide (BNP) ≥ 65pg/ml
62384272|NCT00652964||Observation|a family of congenital central hypoventilation syndrome
62384273|NCT00959192|EXPERIMENTAL|ACC-001 + QS-21|Active vaccine + adjuvant, IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
62384274|NCT00959192|PLACEBO_COMPARATOR|QS-21|Adjuvant, IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
62384275|NCT04972097|EXPERIMENTAL|IRE Treatment Arm|All patients enrolled in this trial will receive IRE treatment with the NanoKnife System
62384276|NCT01098942||Surgical|Roux-en-Y gastric bypass surgery
62384277|NCT01098942||Non-surgical|Non-surgical lifestyle weight management
62384278|NCT04915937|EXPERIMENTAL|Study Infant Formula|Feed ad libitum during study period
62567667|NCT01772810|EXPERIMENTAL|Surgical implantation of human spinal cord stem cells|Surgical implantation of human spinal cord derived neural stem cells.
62765215|NCT05117619|ACTIVE_COMPARATOR|Attention Control|The Attention-control condition is the delivery of educational materials over 8 contacts. Three of the contacts are by video conferences or phone calls and last 1 to 2 hours each. Two of the contacts are mailings of educational materials for discussion during the longer sessions. Three of the contacts are phone calls lasting about 10-15 minutes each to check for general updates, health care utilization/access, and study reminders.
62168242|NCT06472414|EXPERIMENTAL|Women-Focused Group (WFG)|Following baseline assessments, participants will be contacted for the first of four individualized counselling sessions. These sessions will happen following baseline assessments, after 1 month of enrolment, 3 months after mid-term assessments and following 6-month assessments. Five pre-recorded women focused educational sessions will be sent, one per month. After the first individualized session, participants will enrol exercise sessions (two or three times per week) at a supervised community based mixed-sex phase III cardiovascular rehabilitation program.
62765216|NCT06346249|EXPERIMENTAL|Experimental Group|The overall objective of this study is to determine the efficacy of a physical therapy intervention based on manual therapy, therapeutic exercise and application of electrical stimulation therapy in healthcare workers with non-specific neck pain.
62765217|NCT06346249|NO_INTERVENTION|Control Group|The control group will not undergo any physiotherapy treatment therapy for neck pain.
62765218|NCT01556061|EXPERIMENTAL|D-MAC video laryngoscopy|The Dblade is used to perfom laryngoscopy first but second laryngoscopy and intubation is performed with CMAC blade.
62765219|NCT01556061|ACTIVE_COMPARATOR|C-MAC video laryngoscopy|The CMAC blade is used to perfom laryngoscopy first but second laryngoscopy and intubation is performed with D-blade
62765220|NCT03382067|ACTIVE_COMPARATOR|High Epicatechin/ Melissa|Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa ® chocolate + 7.2g caster sugar + 5g Melissa containing 374 mg (-)-Epicatechin/100g chocolate and 2,69% of rosmarinic acid in Melissa leaves
62765221|NCT03382067|PLACEBO_COMPARATOR|Low Epicatechin/ Oat bran|Single consumption of a 55g bar of white chocolate containing: 50g Lindor ® chocolate + 5g oat bran containing \< 0,0009 mg (-)-Epicatechin/100g
62765222|NCT03921398||Patients with ESRD|Patients with history of biopsy-proven lupus nephritis (all classes of lupus nephritis)
62765223|NCT03921398||Patients with active lupus prior to treatment and no ESRD|Patients with biopsy-proven ACTIVE lupus nephritis
62384279|NCT04121182|EXPERIMENTAL|Nursing home with On-line training|"25 randomized residents will be included by nursing home Half of the institutions (randomized too) will benefit from an on-line training on the prevention and management of resident lung diseases"
62384280|NCT04121182|ACTIVE_COMPARATOR|Nursing home with usual practice|This group of Institutions continue their usual practice (routine care) and will not benefit from training during the study period.
62384281|NCT01001884|EXPERIMENTAL|counseling|caregiver psychoeducational consultation program (CPCP)
62765224|NCT03921398||Healthy individuals|Healthy individuals
62765225|NCT02192229|ACTIVE_COMPARATOR|intervention group|The intervention group will be supplemented with 50.000 IU vitamin D3 every week for 12 consecutive weeks
62765226|NCT02192229|PLACEBO_COMPARATOR|Placebo group|The placebo group will receive placebo Tablet which will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
62765227|NCT02190305|EXPERIMENTAL|Diagnostic: Multiplo HBc/HIV/HCV + Reveal HBsAg|Subjects tested with investigational devices and approved comparator assay algorithms for HIV and hepatitis B and C.
62384282|NCT02939456|OTHER|DIR-MRI|Participants will have Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) as well as the standard Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
62384283|NCT03524586|EXPERIMENTAL|Ipsilateral rotation of head|Head was laterally rotated to the same side against fixed tube
62384284|NCT03524586|ACTIVE_COMPARATOR|Contralateral rotation of head|Head was laterally rotated to the opposite side against fixed tube
62384285|NCT01211067||Patients age: 15 - 40 years-old|Patients within the 15 to 40 years-old age-group
62384286|NCT01211067||Patients age: 41 to 60 years-old|Patients within the group-age from 41 to 60 years-old
62384287|NCT01211067||Patients age: older than 61 years-old|Patients within the group-age from 61 years-old and older
62384288|NCT03356327|EXPERIMENTAL|Group 1|Group 1 consisting of 30 children treated with Actitan F and standard oral rehydration (SOR)
62384289|NCT03356327|ACTIVE_COMPARATOR|Group 2|Group 2 consisting of 30 children who received only SOR.
62384290|NCT06083376|EXPERIMENTAL|exercise group|
62384291|NCT06083376|ACTIVE_COMPARATOR|control group|
62384292|NCT00620672|OTHER|1|The dietary supplement is 400 mg/day of the omega 3 fatty acid docosahexaenoic acid . The docosahexaenoic acid is provided in triglycerides from Martek Biosciences, Maryland. The supplement is a blend of soybean and canola oil, blended to resemble the usual fat composition of the diet. Both the supplement and placebo provide a total of about 10 calories per day to the diet.
62384293|NCT00620672|OTHER|2|Dietary supplement is vegetable oil, the placebo.
62384294|NCT04524013||School aged children|
62384295|NCT04524013||Pregnant women|
62384296|NCT04531345||Case Group|Patients with Covid 19 PCR (+) results
62384297|NCT04531345||Control Group|Healthy volunteers
62384298|NCT03699501||Patients|
62384299|NCT03699501||Voluntary patients|
62384300|NCT02347124|ACTIVE_COMPARATOR|Usual Care Control|Standard tobacco quitline counseling program and materials + attention-matched text messaging.
62384301|NCT02347124|EXPERIMENTAL|Enhanced Intervention|Standard tobacco quitline counseling program and materials + multi-modal oral health promotion program .
62765228|NCT01007422||Supportive Care|
62384302|NCT03040180|EXPERIMENTAL|Electrochemotherapy with bleomycin|"Systemic injection of bleomycin followed by electroporation of the primary tumor. Bleomycin administration: 15.000 IU/m2 BSA.~BSA by Du Bois formula."
62384303|NCT03040180|NO_INTERVENTION|Standard care|Standard care
62384304|NCT05060003|EXPERIMENTAL|Arm 1: Atezolizumab + Tiragolumab|"* Atezolizumab is given as an IV infusion every 4 weeks at a dose of 1680 mg over 60 minutes (+/- 15 minutes).~* Tiragolumab is given as an IV infusion every 4 weeks at a dose of 840 mg over 60 minutes (+/- 15 minutes).~* Treatment can continue for up to 13 cycles."
62765229|NCT03287674|EXPERIMENTAL|Patient group|"All patients receive the same treatment. All patients are treated with one dose of Ipilimumab 14 days prior to surgical removal of tumor tissue for TIL expansion. Hospitalization for TIL treatment is approximately 3 weeks.~The patients are admitted to hospital on day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine= on day -7 to day -1. The first of 4 doses of Nivolumab is administered on day -2 and every 2 weeks for at total of 4 doses.~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 13.~Interleukin-2 is administered as a daily low-dose subcutaneous injection for a total for 14 days."
62765230|NCT05895903|ACTIVE_COMPARATOR|Screw expansion group|threadform screw expanders with special condensing burs for lateralization and compaction of bone while simultaneously placing dental implants
62765231|NCT05895903|ACTIVE_COMPARATOR|Osseodensification group|special drills to expand narrow alveolar ridges.These drills share similar advantages with osteotomes in terms of greater tactile sensitivity, faster speed, and low heat generation, all of which help to maintain healthy bone and enhance implant osseointegration.
62765232|NCT04524650||stage 0|without liver function injury or splenomegaly
62765233|NCT04524650||stage 1|occurrence of liver function injury (ALT or AST \> 2 ULN (upper limit of normal)
62765234|NCT04524650||stage 2|occurrence of splenomegaly or reduced platelet count (\<150 X10\^9/L)
62765235|NCT04524650||stage 3|occurrence of portal hypertension and/or gastroesophageal varices
62765236|NCT03542916|EXPERIMENTAL|CJ-40001|CJ-40001 60ug SC, IV injection
62765237|NCT03542916|ACTIVE_COMPARATOR|NESP|NESP 60ug SC, IV injection
62765238|NCT02794389|EXPERIMENTAL|N-acetyl cysteine|1200mg for 2 days 2400mg for 7 days
62765239|NCT02794389|PLACEBO_COMPARATOR|Placebo|Magnesium stearate capsules
62765240|NCT00913614|EXPERIMENTAL|Age Group 6-11 year old - Dose level 1|
62765241|NCT00913614|EXPERIMENTAL|Age Group 6-11 year old - Dose Level 2|
62765242|NCT00913614|EXPERIMENTAL|Age Group 6-11 year old - Dose Level 3|
62765243|NCT00913614|EXPERIMENTAL|Age Group 12-17 year old - Dose level 1|
62765244|NCT00913614|EXPERIMENTAL|Age Group 12-17 year old - Dose level 2|
62384305|NCT05060003|ACTIVE_COMPARATOR|Arm 2: Atezolizumab|"* Atezolizumab is given as an IV infusion every 4 weeks at a dose of 1680 mg over 60 minutes (+/- 15 minutes).~* Treatment can continue for up to 13 cycles."
62384306|NCT01116726|EXPERIMENTAL|Motivational interviewing and enhanced community services|Motivational interviewing sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries, provided shortly after childbirth, and at 6, 12, and 18 months. Enhanced community services will involve development of culturally appropriate messages related to the mitigation of risk factors for ECC through public service announcements and brochures.
62384307|NCT01116726|ACTIVE_COMPARATOR|Enhanced community services|Enhanced community services will involve development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
62567668|NCT01898507|EXPERIMENTAL|Low nicotine cigarettes|"Participants will smoke their own brand cigarettes during a baseline 5 day period, followed by a 15-day period of smoking low nicotine content cigarette level 1: 0.25 mg nicotine content, followed by a 15-day period of smoking low nicotine content cigarette level 2: 0.08 mg nicotine content.~Other: Low nicotine cigarettes"
62765245|NCT00913614|EXPERIMENTAL|Age Group 12-17 year old - Dose level 3|
62765246|NCT04338633|ACTIVE_COMPARATOR|Conventional calcium hydroxide paste|Application of Conventional calcium hydroxide paste
62765247|NCT04338633|EXPERIMENTAL|Calcium hydroxide nanoparticle|Application of Calcium hydroxide nanoparticle
62765248|NCT04338633|EXPERIMENTAL|Combined Calcium hydroxide with silver nanoparticle|Application of Combined Calcium hydroxide with silver nanoparticle
62765249|NCT04478032|SHAM_COMPARATOR|sham stimulation|20 patients will be randomly allocated into this group,they will receive sham stimulation.
62765250|NCT04478032|ACTIVE_COMPARATOR|real stimulation dTMS targeting the ACC|20 patients will be randomly allocated into this group,they will receive real stimulation.
62765251|NCT02741037|EXPERIMENTAL|Dyadic lifestyle intervention|Mothers and daughters participate in the Unidas partner intervention together.
62765252|NCT02741037|EXPERIMENTAL|Individual lifestyle intervention|Mothers participate in the Unidas intervention alone, without their related daughters. Unrelated daughters participate in the Unidas intervention alone without their related mothers.
62765253|NCT02741037|OTHER|Usual Care|Mothers and daughters receive usual care.
62765254|NCT02547493|ACTIVE_COMPARATOR|pneumococcal polysaccharide vaccine|Patients are vaccinated vith Peumo23/Pneumovax on the first day. Abatacept started on frst day.
62765255|NCT02547493|ACTIVE_COMPARATOR|pneumococcal conjugate vaccine|"Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.~Abatacept started on frst day."
62765256|NCT05378295|ACTIVE_COMPARATOR|isocaloric fermentable oligosaccaride|isocaloric fermentable oligosaccaride
62765257|NCT05378295|EXPERIMENTAL|Personalized fiber mixture|12 g for 2 weeks, followed by 24 g for 10 weeks
62765258|NCT03510871|EXPERIMENTAL|nivolumab plus ipilimumab|nivolumab plus ipilimumab
62765259|NCT01702740|EXPERIMENTAL|Part A, 1 mg/kg CNTO 136|
62765260|NCT01702740|EXPERIMENTAL|Part A, 4 mg/kg CNTO 136|
62765261|NCT01702740|EXPERIMENTAL|Part A, 10 mg/kg CNTO 136|
62765262|NCT01702740|EXPERIMENTAL|Part B, 10 mg/kg CNTO 136/placebo|
62765263|NCT04460586|EXPERIMENTAL|Omadacycline IV followed by PO|Omadacycline 100mg IV, Omadacycline 300 mg tablet
62765264|NCT03140982|ACTIVE_COMPARATOR|GR fast induction|propofol TCI effect site mode infusion using the PK Marsh model ke0 1,21 min-1 target 5.4 ug/ml (LOC EC95) util loss of consciousness (LOC) After LOC we maintain initial target during 10 min without intervention, except respiratory support if required.
62765265|NCT03140982|ACTIVE_COMPARATOR|GL slow induction|propofol infused at 10 mg/kg/h with CeCALC PK Marsh model ke0 1,21 min-1 same PK model After LOC we maintain the CeCALC observed al LOC during 10 min without intervention, except respiratory support if it was required.
62765266|NCT05493189|NO_INTERVENTION|Control Group|Participants with no additional autonomous training sessions.
62765267|NCT05493189|EXPERIMENTAL|Intervention Group|Participants exposed to 2 additional autonomous training sessions (after 2 and 6 months).
62765268|NCT01219933|EXPERIMENTAL|1|
62765269|NCT03411564|EXPERIMENTAL|Group 1|Students enrolled in one or two targeted secondary schools in each city who are going to receive the intervention (workshop)
62765270|NCT03411564|NO_INTERVENTION|Grup 0|Students from other centers with similar socioeconomic characteristics (relating to social characteristics and school location) to the centers.
62765271|NCT06275750|EXPERIMENTAL|Patients treated with non-surgical spinal decompression|The patients were positioned in supine with adjustable lumbar, and thoracic belts attached to the traction cord. After tightening the belts, the M7 position was selected to achieve hip and knee flexion, and posterior pelvic tilt of 25° was added. Before starting the therapy, the weight of the subject was entered in the panel, and a short tolerance test was carried out. Patients were provided with a manual switch to stop treatment any time. Preset lumbar disc herniation protocol was used. Each session lasted fifteen minutes, applied force had 100-gram step increments, and did not exceed 50% of the weight of the patient. At the end of the therapy, the cord was disconnected and belts were removed. Participants were asked to sit for three minutes to identify any adverse reaction.
62765272|NCT01760811|OTHER|Cetuximab ,neoadjuvant administration|Drug administration ,Cetuximab(merck Serono )given neoadjuvant ,3 courses prior surgery followed by post operatve radiation and Cetuximab
62765273|NCT01545050|EXPERIMENTAL|Induction Cohort: Placebo matching with BMS-945429 (Clazakizumab)|
62765274|NCT01545050|EXPERIMENTAL|Induction Cohort: BMS-945429 (Clazakizumab)(600 IV/200 SC mg)|
62765275|NCT01545050|EXPERIMENTAL|Induction Cohort: BMS-945429 (Clazakizumab)(300 IV/100 SC mg)|
62384308|NCT04670042|EXPERIMENTAL|SPRINT® Peripheral Nerve Stimulation (PNS) System|SPRINT PNS System will be offered to patients with postoperative knee pain following primary unilateral total knee arthroplasty (TKA) who meet eligibility criteria and consistent with established coverage policy. SPRINT PNS System will be implanted for 60 days. At the discretion of the physician, the first lead may be placed to stimulate the nerve innervating the region of greatest pain. If pain is not adequately addressed by the first lead when assessed at 10 days, a second lead may be placed approximately 2 weeks following the initial lead placement.
62384309|NCT02275949|EXPERIMENTAL|Study group|acupuncture, electroacupuncture and intradermal acupuncture are done at every session.
62384310|NCT02275949|SHAM_COMPARATOR|Control group|Mock transcutaneous electrical nerve stimulation(mock TENS) and sham intradermal acupuncture are carried out.
62384311|NCT01440231|PLACEBO_COMPARATOR|Arm 1|
62384312|NCT01440231|EXPERIMENTAL|Arm 2|
62384313|NCT01440231|EXPERIMENTAL|Arm 3|
62384314|NCT01440231|EXPERIMENTAL|Arm 4|
62384315|NCT01440231|EXPERIMENTAL|Arm 5|
62384316|NCT02736149|EXPERIMENTAL|ubenimex|"ubenimex capsules 150 mg three times a day (TID), administered orally, minimum of 24 weeks for all patients.~The maximum anticipated time an individual patient will participate will vary because treatment will continue until the last patient enrolled has received at least 24 weeks of open-label treatment."
62384317|NCT05178329|ACTIVE_COMPARATOR|Intervention group|The patients undergoing intervention exercise.
62384318|NCT05178329|PLACEBO_COMPARATOR|Control Group|The patients undergoing the normal exercise program
62384319|NCT05231551||Single-group study|Patients having first trimester voluntary termination of pregnancy in Montpellier university hospital.
62384320|NCT03935893|EXPERIMENTAL|Tumor Infiltrating Lymphocytes (TIL)|Patients with locally advanced, recurrent, or metastatic gastric/esophagogastric, colorectal, pancreatic, sarcoma, mesothelioma, neuroendocrine, cutaneous/anal squamous cell, Merkel cell, cancers refractory to systemic therapy, and those with deficient mismatch repair and/or microsatellite instability cancers will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of up to 2x10\^11 lymphocytes infused through a central vein catheter and administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
62765276|NCT01545050|EXPERIMENTAL|Induction Cohort: BMS-945429 (Clazakizumab)(150 IV/100 SC mg)|
62765277|NCT01545050|EXPERIMENTAL|Induction Cohort: BMS-945429 (Clazakizumab)(400 SC/200 SC mg)|
62765278|NCT01545050|EXPERIMENTAL|Maintenance Cohort: Placebo matching with BMS-945429 (Clazakizumab)|
62765279|NCT01545050|EXPERIMENTAL|Maintenance Cohort: BMS-945429 (Clazakizumab)(100 SC mg)|
62765280|NCT01545050|EXPERIMENTAL|Maintenance Cohort: BMS-945429 (Clazakizumab)(200 SC mg)|
62765281|NCT01545050|EXPERIMENTAL|Open Label Cohort: BMS-945429 (Clazakizumab)(200 SC mg)|
62765282|NCT03070197||Case/CHD with deleterious mutations|Participants with CHD with damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing
62765283|NCT03070197||Control/CHD without deleterious mutations|Participants with CHD without damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing
62765284|NCT03305380||Patients with a pulmonary event|(under anti-PD1 or anti-PD-L1) This is the first group of the retrospective part of the study.
62765285|NCT03305380||Patients without a pulmonary event|(under anti-PD1 or anti-PD-L1) This is the second group of the retrospective part of the study.
62765286|NCT05517902|EXPERIMENTAL|2 to < 12 years Age Group Cohort|Participants of age 2 to \< 12 years will receive a single application of StrataGraft to 0.5% to 10% total body surface area (TBSA) on Day 1.
62765287|NCT05517902|EXPERIMENTAL|12 to ≤ 17 years Age Group Cohort|Participants of age 12 to ≤ 17 years will receive a single application of StrataGraft to 0.5% to 10% TBSA on Day 1.
62765288|NCT00680758|EXPERIMENTAL|Therapeutic Intervention|
62765289|NCT03926312|EXPERIMENTAL|Smart device-based rehabilitation|One month after myocardial infarction, patients will receive a smart band and a cellphone in order to transmit data on physical activity to electronic health record. A study nurse will periodically check compliance with recommended physical activity and intervene in the case of non-compliance.
62765290|NCT03926312|NO_INTERVENTION|Control group|Patients will receive a guideline directed recommendation to increase physical activity to 30 minutes of moderate physical activity a week.
62384321|NCT04927611||Gastroenteropancreatic neuroendocrine neoplasms|Collect biopsy/surgical fresh tissue of gastroenteropancreatic neuroendocrine neoplasms.
62765291|NCT04014621|ACTIVE_COMPARATOR|Treated|Treated arm patients will be implanted and treated with one session of SPG stimulation for 6 hours and 5 additional consecutive sessions (4 hours each) of SPG stimulation, the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation.
62384322|NCT04927611||Pancreatic ductal adenocarcinoma|Collect biopsy/surgical fresh tissue of pancreatic ductal adenocarcinoma.
62384323|NCT03474172|EXPERIMENTAL|Genuine Tuina|Participants will receive genuine tuina manipulated on their skin in addition to the conventional therapy given by the doctors. The whole process of the Tuina, which may last for 15 minutes, should be completed under the Cloak Shape device. After that the parents and the observers may be required to fill out corresponding questionnaires. The outcomes assessors will ask the child the sense perception of the manipulation via a questionnaire if he is equal or older than 3 years old.
62384324|NCT03474172|SHAM_COMPARATOR|Sham Tuina|Except for the conventional therapy given by doctors, participants in this group will receive sham Tuina. A cloak shape device will be adopted, while inside the cover the therapist will use one hand to hold the childrens' hand or just put one hand on childrens' body and the other hand will do the manipulations on the therapist's own hand instead of childrens' hand or childrens' body. The acupoints and the manipulation time are the same as real Tuina group. Same questionnaires as those adopted in real Tuina group are also required to be completed.
62384325|NCT02796495|EXPERIMENTAL|Operation of hand prosthesis with direct nerve stimulation|"A system composed by the integration of the following non-CE marked medical devices specifically designed for the study will be used in one or two amputees:~* STIMEP (multichannel electrical stimulator for the peripheral nervous system; AXONIC)~* TIME-4H Intraneural Electrodes (ALBERT-LUDWIGS-UNIVERSITAET FREIBURG)~* Sensorized Hand Prosthetics for amputees IH2 Prosthetic Azurra Prensilia (Prensilia Ltd.)~* Prosthetics sensorized hand for amputees DLR/HIT Hand II (Wessling Robotics)~* ODROID software integration within the afferent and efferent bi-directional control of the robotic hand~* The EPIONE Psychophysical Testing Platform software for stimulator control"
62384326|NCT01931189|EXPERIMENTAL|NI-071|
62384327|NCT01931189|ACTIVE_COMPARATOR|Infliximab|
62384328|NCT00103935|PLACEBO_COMPARATOR|Group A1|Placebo lead-in followed by placebo equivalent volume to 0.8 mg exenatide LAR
62384329|NCT00103935|PLACEBO_COMPARATOR|Group A2|Placebo lead-in followed by placebo equivalent volume to 2.0 mg exenatide LAR
62384330|NCT00103935|EXPERIMENTAL|Group B|Exenatide lead-in followed by exenatide LAR 0.8 mg weekly
62558657|NCT06213376|EXPERIMENTAL|Intervention|"20 sessions/4 weeks:~Video Feedback:~S1) Participant (P1) views recording of previous session with the clinician \& judges whether the production is intelligible.~S2) S1 \& the clinician identifies changes in motor movements that are influencing performance.~S3+S4) S1+S2 \& given support from the clinician, P1 identifies techniques improving intelligibility \& modifies behavior accordingly.~MIT (Albert et al., 1973; Helm-Estabrooks et al., 2014):~Humming - Clinician introduces the target phrase by showing a visual cue, humming the phrase, then intoning the phrase while P1 taps left-hand.~Simultaneous production with melody - The Clinician and P1 melodically produce the target phrase \& tap together.~Simultaneous melodic production accompanied by gradual reduction of clinician support.~Immediate repetition response to probe question - Following P1's successful repetition, the clinician melodically produces a question and P1 melodically produces the target."
62168243|NCT06472414|ACTIVE_COMPARATOR|Standard Care Group (SCG)|Participants will be allocated to a supervised community based mixed-sex phase III cardiovascular rehabilitation program and contacted to enrol two or three times per week.
62384331|NCT00103935|EXPERIMENTAL|Group C|Exenatide lead-in followed by exenatide LAR 2.0 mg weekly
62384332|NCT00640575|EXPERIMENTAL|A|Local
62384333|NCT00640575|ACTIVE_COMPARATOR|B|Systemic
62384334|NCT02243163|EXPERIMENTAL|Yoga exercise|Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
62384335|NCT04765449|EXPERIMENTAL|ARM A: Covid-19 Patients Receiving CTLs|Patients who have an HLA antigen in common with COVID-19 fighting T cells will receive the COVID-19 T cells. They will be premedicated with diphenhydramine and acetaminophen before the cells are infused intravenously. Close monitoring will continue in the patients' homes for 14 days. Three to six patients will receive a specific dose of T cells, and then if there are no serious side effects, the dose will be increased for the next group of patients. There are 4 doses of T cells to be tested, and each patient will complete a 14 day monitoring period before the next patient can be treated.
62168244|NCT02228083|ACTIVE_COMPARATOR|Safety of dental anesthesia|Application of local dental anesthesia with two cartridges (5,6 mL) of the lidocaine 2% with epinephrine 1:100.000 in heart failure patients in functional class III or IV.
62558658|NCT01152073|PLACEBO_COMPARATOR|Placebo|Study participants whose drink formulation contains no active ingredients but will appear and taste similar to the two other formulations. This will form the control formulation
62558659|NCT01152073|ACTIVE_COMPARATOR|Second Formulation|Study participants' drink formulation will include Red Yeast Rice 600mg, Niacin 12.5mg, Phytosterol esters 650mg, L-Carnitine 150mg, vitamin C 500mg, and Co-Q-10 25mg.
62765292|NCT04014621|SHAM_COMPARATOR|Control|Control arm patients will be implanted and receive 6 hours of sham stimulation and 5 additional consecutive sessions (4 hours each) of sham stimulation, the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation.
62765293|NCT02598128|EXPERIMENTAL|RELiZORB|Treatment (RELiZORB)
62765294|NCT02598128|PLACEBO_COMPARATOR|Control|Placebo control
61989065|NCT03603444||First study group: patients with PHPT|"Patients aged between 18-90 years old with primary hyperparathyroidism who had been diagnosed in the Unit of Endocrinology of the University of Modena and Reggio Emilia.~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) \<30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI \> 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
62558660|NCT01152073|ACTIVE_COMPARATOR|Third Formulation|The third formulation will be identical to the second, but without the Red Yeast Rice.
62558661|NCT03881293|PLACEBO_COMPARATOR|Placebo Lubricant Gel|5 ml water-soluble gel instilled transurethrally ten minutes prior to catheter insertion
62384336|NCT04765449|NO_INTERVENTION|ARM B: Covid-19 Patients Not Receiving CTLs|Patients in the observation arm will not have inherited an HLA antigen in common with the COVID-19 T cells and so cannot receive the T cells. They will be monitored by the study staff for the 14 day monitoring period in their homes. They will be taught to record their own blood pressure, temperature, and oxygen level (pulse oximetry) at home and report this information, as well as their progress in getting over the COVID-19 infection, to the study staff every day by phone. The outcomes of patients on arm B will be compared to the outcomes of patients treated on Arm A to see if the T cells made a difference in how patients recovered from COVID-19. Patients in Arm B are not prevented from being treated with any available COVID-19 therapy.
62384337|NCT04914091||Patients with diffuse large B-cell lymphoma treated with CART-cells|
62384338|NCT05190328|EXPERIMENTAL|Muscle Energy Technique|"Experimental: Muscle Energy Technique Post isometric relaxation: Patient will perform isometrics on upper trapezius and levator scapulae one by one. Each isometric contraction will be held for 10 seconds and then participants will be asked to relax the contraction with exhalation. This will be repeated five times in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with the Muscle energy technique."
62384339|NCT05190328|EXPERIMENTAL|Active Release Technique|"Experimental: Active Release Technique: The therapist will apply deep pressure on both sides of levator scapulae and upper trapezius muscles (over the area of tenderness) and the patient will be instructed to actively move the muscle from a shortened to lengthened position and thereby breaking adhesions.1 set of 5 repetitions in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with active release technique"
62384340|NCT03903861|EXPERIMENTAL|Glucose alone|Participants will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
62384341|NCT03903861|EXPERIMENTAL|Galactose alone|Participants will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
62384342|NCT03903861|EXPERIMENTAL|Glucose and galactose|Participants will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
62765295|NCT02973776|EXPERIMENTAL|LEO 90100 aerosol foam|"LEO 90100 calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate) aerosol foam~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
62765296|NCT02973776|ACTIVE_COMPARATOR|Dermoval®/Dermovate®|"Dermoval®/Dermovate® (clobetasol propionate 0.05%) cream~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
62765297|NCT02973776|ACTIVE_COMPARATOR|Diprosone®|"Diprosone® betamethasone 0.5 mg/g (as dipropionate) ointment~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
62765298|NCT02973776|ACTIVE_COMPARATOR|Elocon®|"Elocon® mometasone furoate 0.1% cream~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
62558662|NCT03881293|ACTIVE_COMPARATOR|Lidocaine 2% Gel|5 ml lidocaine 2% gel instilled transurethrally ten minutes prior to catheter insertion
62558663|NCT00550511|OTHER|Ultrasound|Surgeon-performed ultrasound as intervention, as a complement to clinical investigation and standardized laboratory testing.
62558664|NCT00550511|NO_INTERVENTION|Control|Control group examined with clinical examination including standardized laboratory tests.
62567669|NCT06217705|EXPERIMENTAL|Project Calm|Project Calm is a \~30-minute self-guided digital intervention designed to teach children and adolescents empirically supported emotion regulation skills to facilitate self-calming when faced with intense negative emotions. Project Calm uses vignettes, interactive activities, and engaging graphics to teach youth calming skills.
62765299|NCT02973776|ACTIVE_COMPARATOR|Locoid®|"Locoid® hydrocortisone-17-butyrate 0.1% ointment~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
62384343|NCT01700127|OTHER|Breastfeeding|Breastfeeding Encouraged
62558665|NCT02847260|EXPERIMENTAL|Remodulin|Remodulin will be initiated, whilst subjects are hospitalized (minimum of 72 hours) and under medical supervision, at approximately 2 ng/kg/min as a continuous SC infusion with dose increments of 1-2 ng/kg/min applied approximately every 12 hours according to clinical response and tolerability. Following discharge, dose rate increments are permitted at 1-2 ng/kg/min with a minimum of 24 hours between each dose up-titration. Once a dose rate of 20 ng/kg/min is achieved, the dose increments can be increased up to 4 ng/kg/min with dose increments separated by at least 24 hours. The aim is to achieve a target dose of 10, 20, and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively.
62765300|NCT02973776|PLACEBO_COMPARATOR|LEO 90100 foam vehicle|"LEO 90100 foam vehicle~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
62765301|NCT04042272||Healthy volunteers|Healthy volunteers group; Kidney donor groups; Course of the research: Blood samples from all groups shall be taken for S100β, NSE, and GFAP in the preoperative period, in the operating room and after 1st, 7th day and the first following month in the postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients with S100β, NSE, and GFAP. Patients' demographic data, accompanying diseases, American Society of Anesthesiology classification, main etiology, preoperative laboratory values shall be recorded accordingly. In addition, routinely taken anesthetics, duration of the operation, duration of anesthesia, duration before the reperfusion, duration of postperfusion, graft hot and cold ischemia durations, first measured central venous pressure, volume replacement therapy, blood component transfusion, and immunosuppressive drugs are given during the operation shall be recorded.
62765302|NCT04042272||Living kidney graft recipients|Kidney transplant group; Course of the research: Course of the research: Blood samples from all groups shall be taken for S100β, NSE, and GFAP in the preoperative period, in the operating room and after 1st, 7th day and the first following month in the postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients with S100β, NSE, and GFAP. Patients' demographic data, accompanying diseases, American Society of Anesthesiology classification, main etiology, preoperative laboratory values shall be recorded accordingly. In addition, routinely taken anesthetics, duration of the operation, duration of anesthesia, duration before the reperfusion, duration of postperfusion, graft hot and cold ischemia durations, first measured central venous pressure, volume replacement therapy, blood component transfusion, and immunosuppressive drugs are given during the operation shall be recorded.
62765303|NCT02403895|EXPERIMENTAL|Open-label AZD2014|Open-label AZD2014 given twice daily 3 days on, 4 days off during weekly paclitaxel
62765304|NCT01013779|EXPERIMENTAL|Arm A|Conventional radical radiotherapy in this trial means that those patients with microscopic disease receive a dose of 50Gy using daily incremental fractions of 2Gy over 25 fractions and those with macroscopic disease receive 54Gy in 27 fractions.
62765305|NCT05451680|EXPERIMENTAL|Negative-pressure treatment|A negative pressure wound dressing is placed over the skin graft. Patients are started on compression therapy after surgery, unless there are contraindications, and standard oral and written postoperative immobilization and other treatment instructions are given.
62765306|NCT05451680|ACTIVE_COMPARATOR|Conventional treatment|A conventional antimicrobial wound dressing is placed on top of the graft. Patients are started on compression therapy after surgery, unless there are contraindications, and standard oral and written postoperative immobilization and other treatment instructions are given.
62765307|NCT01299571||Dutasteride|Patients administrated dutasteride at the site
62765308|NCT01201200||Group 1 - Obstructive Sleep Apnea (OSA)|Fifty-six patients with Obstructive Sleep Apnea
62765309|NCT01201200||Group 2 - Non-OSA Controls|Fifty individuals without OSA with similar age, gender and body mass index (BMI)
62765310|NCT01201200||Group 3 - Treatment|Fifteen patients with moderate and severe sleep apnea from group 1 underwent treatment with continuous positive airway pressure
62765311|NCT01201200||Group 4 - Placebo|Fifteen patients with moderate/severe sleep apnea underwent to placebo
62384344|NCT01700127|ACTIVE_COMPARATOR|Breastfeeding Withheld|Breastfeeding Withheld
62384345|NCT01710215|NO_INTERVENTION|Usual Care|"* No outreach mailed invitations.~* Ordering of colonoscopy or FIT for screening at the discretion of the primary provider.~* Follow up of abnormal tests and results reporting to the patient at the discretion of primary and specialty providers."
62558666|NCT03086655|EXPERIMENTAL|Tel-me-box with reminder features|Participants randomly assigned to the intervention reminder condition will choose from the reminders available and convey their preferences regarding when reminders should be sent for the tel-me-box device.
62765312|NCT03311984||LMWH qd|receiving Low-molecular-weight Heparin（LMWH）qd
62765313|NCT03311984||LMWH q12h|receiving Low-molecular-weight Heparin（LMWH）q12h
62765314|NCT01171586|EXPERIMENTAL|SMS Only|"The SMS only group will receive hints, tips, strategies, and questions related to weight loss behaviors, physical activity, nutrition, and motivation. The messages will be pushed to participants (i.e. no response needed) and pulled from participants (i.e. response is needed). The SMS only group will also receive a brief printed or web based outline on weight loss resources and information."
62765315|NCT01171586|EXPERIMENTAL|SMS + Phone Counseling|"This group will receive hints, tips, strategies, and questions related to weight loss behaviors, physical activity, nutrition, and motivation. The messages will be pushed to participants (i.e. no response needed) and pulled from participants (i.e. response is needed). The group will also receive monthly counseling calls from a Health Coach to discuss barriers and solutions and will receive a brief printed or web based outline on weight loss resources and information."
62765316|NCT01171586|NO_INTERVENTION|Control|The Control group will receive a binder with an attractive set of Standard Print Materials related to weight loss that is comparable to what one would receive from community resources such as libraries, magazines and national non-profit or governmental organizations such as 5-A Day, American Heart Association and the like.
62765317|NCT01595581|EXPERIMENTAL|Testosterone|Weekly injection of testosterone enanthate 200mg
62765318|NCT01595581|PLACEBO_COMPARATOR|Placebo|Weekly injection of saline as the placebo
62765319|NCT05358431|EXPERIMENTAL|participants|Patients fulfilling the El Escorial criteria for probable or definite ALS with a C9orf72 mutation or asymptomatics being a first-degree to a person carrying a C9orf72 mutation or Healthy controls
62168245|NCT02228083|OTHER|Oral health profile|An oral health profile of patients with heart failure will be described based in oral clinical examination.
62765320|NCT05977348|NO_INTERVENTION|Healthy Bodies Project Comparison (HBP)|All classrooms will receive the Eating the Alphabet curriculum, which includes 27 lessons that introduce children to a new fruit or vegetable from A-Z each week. Parents in comparison and intervention classrooms will receive access to web-based parent resources related to the Eating the Alphabet curriculum (e.g., food of the week fact sheets with recipes and suggestions for use, and coloring pages).
62765321|NCT05977348|EXPERIMENTAL|Healthy Bodies Project Plus (HBP+)|Intervention classrooms will receive the Eating the Alphabet curriculum described above for comparison classrooms, in addition to (1) the Healthy Eating curriculum, (2) classroom materials and teacher training designed to improve the classroom food and mealtime environment in ways that increase food acceptance, and (3) parent/caregiver education on responsive food parenting.
62765322|NCT04504942|EXPERIMENTAL|Leronlimab 525mg|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
62765323|NCT03349866|EXPERIMENTAL|apatinib XELOX and radiotherapy|apatinib：250mg qd po XELOX：Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
62765324|NCT03349866|ACTIVE_COMPARATOR|XELOX and radiotherapy|XELOX：Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
62168246|NCT04905511|EXPERIMENTAL|TRUE Vascular Graft|Patients will be implanted with the TRUE Vascular Graft in the upper arm or forearm
62168247|NCT01535196|EXPERIMENTAL|25-OH-D3 vitamin|180 000 IU 25-OH-D3 vitamin oil per os, per month in the 0, 1, 2, 3, and 6 month at the visit. The patient take the drug under medical control
62384346|NCT01710215|EXPERIMENTAL|FIT Screening Strategy|"* Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).~* Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~* Centralized processes to promote guideline-based follow up."
62765325|NCT04738253||Study group|Stroke patients with limitation of range of motion on the affected shoulder.
62765326|NCT05229796|ACTIVE_COMPARATOR|Fasting state|
62765327|NCT05229796|ACTIVE_COMPARATOR|Fed state|
62765328|NCT06355115|ACTIVE_COMPARATOR|Three days dose prophylaxis|Intravenous (iv) injection of Cefazolin 1 gram 1-hour pre-procedure followed by iv injection of Cefazolin 1 gram every 12 hours for 3 days post-procedure (6 doses)
62765329|NCT06355115|EXPERIMENTAL|Single dose prophylaxis|Intravenous injection of Cefazolin 1 gram 1-hour pre-procedure
62765330|NCT04284566|EXPERIMENTAL|TAU + multicomponent treatment FIBROWALK|FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
62765331|NCT04284566|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of prescribing drugs adapted to the symptomatic profile of each patient. The patients were instructed to continue their baseline medical treatment with no change throughout the 3-month period. In Spain, some counselling about aerobic exercise adjusted to patients' physical limitations is usually provided by first-line clinicians and specialists, but pharmacotherapy it's still the dominant treatment option. Patients were offered the opportunity to participate in the next wave of group intervention at the end of the study (3 months).
62765332|NCT02023021|EXPERIMENTAL|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m\^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m\^2 on days 1, 8, and 15
62765333|NCT03356509|EXPERIMENTAL|Exercise|They will do a 26-min bout of high intensity interval exercise.
62765334|NCT03356509|NO_INTERVENTION|No exercise|They will sit quietly for 26 minutes without access to electronic devices or reading materials.
62765335|NCT04528459|ACTIVE_COMPARATOR|Traditional fluoroscopy|Cohort 1 will consist of patients with closed peritrochanteric femur fractures who undergo open reduction internal fixation with a Stryker© Gamma™ cephalomedullary nail using traditional fluoroscopy for insertion of the lag screw (current standard of care).
62765336|NCT04528459|EXPERIMENTAL|Stryker© ADAPT™ platform|Cohort 2 will consist of patients with closed peritrochanteric femur fractures who undergo open reduction internal fixation with a Stryker© Gamma™ cephalomedullary nail using the Stryker© ADAPT™platform to assist with insertion of the lag screw.
62384347|NCT01710215|EXPERIMENTAL|Colon Screening Strategy|"* Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.~* Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~* Centralized processes to promote guideline-based follow up."
62765337|NCT03790800|EXPERIMENTAL|Intervention group|If systolic blood pressure\>180:IV Urapidil 25mg If systolic blood pressure\>150 (or 5 mins after first bolus) : IV Urapidil 25mg and to maintain this level after admission to hospital in those with confirmed acute stroke for the next 7 days (or hospital discharge if earlier)
62765338|NCT03790800|NO_INTERVENTION|control group|To receive blood pressure management according to standard local guidelines which recommend blood pressure lowering in hospital if systolic level is \>220mmHg. This level will be considered by ambulance staff as a threshold for treatment if considered clinically important.
62765339|NCT02360293|EXPERIMENTAL|Stay Strong w/coaching|participants in the Stay Strong w/coaching (Experimental) arm are provided a wearable device, scale, telephone coaching, tailored push notifications, personalized goals, and enhanced online/app support.
62765340|NCT02360293|ACTIVE_COMPARATOR|Stay Strong|participants in the Stay Strong (active comparison) arm will only be provided a wearable device with standard online/app support.
62384348|NCT02425891|EXPERIMENTAL|Atezolizumab Plus Nab-Paclitaxel|Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
62384349|NCT02425891|PLACEBO_COMPARATOR|Placebo Plus Nab-Paclitaxel|Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
62384350|NCT03684460|EXPERIMENTAL|Bright Light|"Intervention: Daytime Bright Light~Patients will be eligible if they were admitted within 30 hours of noon on enrollment day (e.g. at or after 06:00 on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 09:00 to 13:00 starting on study day 2 and continuing through study day 5 or MICU discharge whichever is longer up to 30 days. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor, if the patient is transferred (prior to study day 5). Feasibility metrics will also be collected."
62558667|NCT03086655|OTHER|Tel-me-box with no reminder features|The control arm will include tel-me-box monitoring only. No reminder features will be included with the device.
62558668|NCT01250210|EXPERIMENTAL|AG200-15|Drug intervention with levonorgestrel and ethinyl estradiol : AG200-15 a transdermal contraceptive system containing 2.60 mg of levonorgestrel and 2.30 mg of ethinyl estradiol.
62558669|NCT01250210|EXPERIMENTAL|AG200|Drug intervention with levonorgestrel and ethinyl estradiol: AG200 a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.92 of ethinyl estradiol.
62765341|NCT03173352||Infant hemangioma(IH)|Infant hemangioma(IH) is the most common benign vascular tumor of infancy with the estimated incidence varies 1% to 12%.However, in China, the incidence of infant hemangioma and related epidemiological data remains unclear. So, We designed the study to collect data about both epidemiology related risk ractors of infantile hemangioma in China.
62765342|NCT01341626|EXPERIMENTAL|Treatment Foster Care Oregon (TFCO)|Youth are placed individually in well-trained and supervised foster homes. Basic components include: (a) daily telephone contact with TFCO parents using the Parent Daily Report; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation.
62765343|NCT01341626|ACTIVE_COMPARATOR|Group Care|Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%).
62765344|NCT03889548|EXPERIMENTAL|Mental Imagery|
62765345|NCT03889548|NO_INTERVENTION|Control|
62765346|NCT00657150|EXPERIMENTAL|Dabigatran etexilate|220 mg once daily
62558670|NCT01250210|EXPERIMENTAL|AG200LE|Drug intervention with levonorgestrel and ethinyl estradiol: AG200LE a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.28 mg of ethinyl estradiol.
62765347|NCT00657150|ACTIVE_COMPARATOR|Enoxaparin|40 mg once daily
62765348|NCT02776033|EXPERIMENTAL|GSK2982772 receivers in Cohort 1|Randomized subjects will receive GSK2982772 BID (approximately 12 hours apart) via oral route for 84 days.
62765349|NCT02776033|PLACEBO_COMPARATOR|Placebo receivers in Cohort 1|Randomized subjects will receive placebo BID via oral route for 84 days.
62765350|NCT02776033|EXPERIMENTAL|GSK2982772 receivers in Cohort 2|Randomized subjects will receive GSK2982772 TID (approximately 8 hours apart) via oral route for 84 days
62765351|NCT02776033|PLACEBO_COMPARATOR|Placebo receivers in Cohort 2|Randomized subjects will receive placebo TID via oral route for 84 days.
62558671|NCT05868369|EXPERIMENTAL|Standard regimen +iVR Group|postoperative iVR therapy in addition to the standard multimodal pain regimen (including a preoperative local field block
62558672|NCT05868369|ACTIVE_COMPARATOR|Standard regimen|hip arthroscopy patients who receive only the standard regimen (including field block) in the acute postoperative ambulatory setting
62558673|NCT05765864||Patients|The Enrollment Kit and Time1 Kit will be administered at enrollment, Time2 Kit will be administered before discharge and Time 3 kit after 6 and 18 months post hospitalization (see Detailed description and Study Protocol). The interventions will be Treatment as usual.
62558674|NCT05765864||Controls|The Enrollment Kit and the Time Kit1 will be administered (see Detailed description and Study Protocol).
62558675|NCT06045013|ACTIVE_COMPARATOR|5% dextrose injection|Ultrasound-guided 4 ml single injection of 5% dextrose
62765352|NCT05393739|EXPERIMENTAL|Intermittent theta burst|The total TBS time is about 1 to 3 minutes and the subjects have to look at at a visual stimulus on a computer monitor while receiving TBS and continue the visual training until 20 minutes after the treatment. In iTBS group, the subjects look at the visual stimulus with amblyopic eye while in cTBS group, subjects look at visual stimulus with non-amblyopic eye. The subjects will receive three times of stimulations in one week. The visual function evaluation includes BCVA, contrast sensitivity and stereoacuity. Visual functions will be evaluated right after TBS session (t1). Participant will receive same type of treatment for another 2 times within one week followed by visual function tests (t2). To evaluate the long-term effect, participants will be followed for another visual function tests (t3) after 2 weeks.
62765353|NCT05393739|EXPERIMENTAL|Continuous theta burst|The total TBS time is about 1 to 3 minutes and the subjects have to look at at a visual stimulus on a computer monitor while receiving TBS and continue the visual training until 20 minutes after the treatment. In iTBS group, the subjects look at the visual stimulus with amblyopic eye while in cTBS group, subjects look at visual stimulus with non-amblyopic eye. The subjects will receive three times of stimulations in one week. The visual function evaluation includes BCVA, contrast sensitivity and stereoacuity. Visual functions will be evaluated right after TBS session (t1). Participant will receive same type of treatment for another 2 times within one week followed by visual function tests (t2). To evaluate the long-term effect, participants will be followed for another visual function tests (t3) after 2 weeks.
61989066|NCT03603444||Second study group: patients with HypoP|"Subjects with reduced serum P, but normal serum Ca, will be enrolled among HIV-infected patients on HAART treatment from the Modena cohort.~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) \<30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI \> 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
62168248|NCT01535196|PLACEBO_COMPARATOR|MCT oil|9 ml MCT oil as placebo in the 0,1,2,3,6 month at the visit, under medical contol
62168249|NCT01309399|ACTIVE_COMPARATOR|teriparatide|six weeks of teriparatide
62168250|NCT01309399|PLACEBO_COMPARATOR|placebo|placebo identical in appearance to teriparatide
62168251|NCT02218671|EXPERIMENTAL|WE 941 OD under deglutition|
62168252|NCT02218671|EXPERIMENTAL|WE 941 OD under non-deglutition|
62168253|NCT06589453|ACTIVE_COMPARATOR|Nasal stent with Digital Nasoalveolar molding|
62168254|NCT06589453|EXPERIMENTAL|Nasal elevator with Digital Nasoalveolar molding|Nasal elevator will be used in conjunction with digital nasoalveolar molding appliance to improve nasolabial esthetics in bilateral cleft lip and palate infants.
62765354|NCT05393739|SHAM_COMPARATOR|Sham theta burst|The stimulus intensity in sham group is about half of that in iTBS/cTBS groups, and the subjects receive a placebo stimulation with the coil orientation tilted to 90°. The visual function evaluation includes BCVA, contrast sensitivity and stereoacuity. Visual functions will be evaluated right after TBS session (t1). Participant will receive same type of treatment for another 2 times within one week followed by visual function tests (t2). To evaluate the long-term effect, participants will be followed for another visual function tests (t3) after 2 weeks.
62765355|NCT04545047||Exposed|Veterans who received COVID-19 convalescent plasma therapy within 2 days of eligibility
62765356|NCT04545047||Unexposed|Veterans who did not receive COVID-19 convalescent plasma therapy
62765357|NCT05254561|ACTIVE_COMPARATOR|purified protein derivative (PPD)|Group A
62765358|NCT05254561|ACTIVE_COMPARATOR|Candida antigen.|Group B
62765359|NCT05254561|ACTIVE_COMPARATOR|Measles, Mumps and Rubella vaccine (MMR).|Group C
62765360|NCT05254561|ACTIVE_COMPARATOR|Triple combination of PPD, Candida antigen and MMR|Group D
62765361|NCT04320511||Patients with SARS-COV 2|Patients with SARS-COV 2 undergoing CT-V
62168255|NCT02459132|EXPERIMENTAL|Exercise Group|Subjects in the exercise group will attend supervised exercise sessions three times a week, for 12 weeks. The exercise intervention will consist of uphill walking or jogging on a treadmill between 50% and 95% of VO2peak for 35 minutes (including a 5-minute warm up and cool down). The participants will complete four, 4-minute, high-intensity intervals at 85-95% of VO2peak. The work period intervals will be interspersed with three, 3-minute periods of active recovery at an intensity below that of their ventilatory threshold.
62384351|NCT03684460|ACTIVE_COMPARATOR|Usual Light|"Intervention: Usual Care~Patients will be eligible if they were admitted within 30 hours of noon on enrollment day (e.g. at or after 06:00 on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), but otherwise, have usual care."
62384352|NCT00082238|EXPERIMENTAL|Cystic fibrosis (CF)|
62384353|NCT00082238|ACTIVE_COMPARATOR|Healthy volunteers|
62384354|NCT05860595|EXPERIMENTAL|KL003 cell injection Drug Product|Each recruited subject will accept KL003 Transplantation.
62384355|NCT04772651|EXPERIMENTAL|Mediterranean Diet and dietary coaching|Patients receive 3 Mediterranean meals a day for 4 weeks and dietary coaching sessions (á 50 minutes once a week for 4 weeks)
62558676|NCT06045013|ACTIVE_COMPARATOR|5% dextrose injections with methylprednisolone acetate|Ultrasound-guided single injection of 3 ml 5% dextrose plus 1 ml 40 mg/ml methylprednisolone acetate
62558677|NCT03571828|EXPERIMENTAL|Part 1: Dose Exploration|Dose exploration cohorts to estimate the MTD, safety, tolerability, and PK of different doses of AMG 562 in subjects with relapsed/refractory DLBCL, MCL or FL using a Bayesian logistic regression model (BLRM; Neuenschwander et al, 2008).
62558678|NCT03571828|EXPERIMENTAL|Part 2: Dose Expansion|dose expansion part to gain further clinical experience, safety and efficacy data for AMG 562 in subjects with relapsed / refractory DLBCL. The dose to be evaluated will be at or below the MTD estimated in the dose exploration cohorts.
62765362|NCT02188498||Polysomnography with Holter monitoring|Patients will undergo resting electrocardiogram (ECG) test at the beginning of the night and be monitored by a Holter device for the duration of the sleep study.
62765363|NCT02124772|EXPERIMENTAL|Part A - TMT 0.0125 mg/kg/day|Participants treated with trametinib 0.0125 mg/kg/day
62765364|NCT02124772|EXPERIMENTAL|Part A - TMT 0.025 mg/kg/day|Participants treated with trametinib 0.025 mg/kg/day
62765365|NCT02124772|EXPERIMENTAL|Part A - TMT 0.032 mg/kg/day|Participants under 6 years of age treated with trametinib 0.032 mg/kg/day
62765366|NCT02124772|EXPERIMENTAL|Part A - TMT 0.04 mg/kg/day|Participants treated with trametinib 0.04 mg/kg/day
62765367|NCT02124772|EXPERIMENTAL|Part B - Neuroblastoma|Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day
62765368|NCT02124772|EXPERIMENTAL|Part B - LGG fusion|Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day
62765369|NCT02124772|EXPERIMENTAL|Part B - NF-1 with PN|Participants with neurofibromatosis Type -1 associated plexiform neurofibromas (NF-1 with PN) treated with trametinib 0.025 mg/kg/day
62765370|NCT02124772|EXPERIMENTAL|Part B - BRAF V600 mutant solid tumor|Participants with BRAF V600 mutant solid tumors treated with trametinib 0.025 mg/kg/day
62765371|NCT02124772|EXPERIMENTAL|Part C - TMT 0.025 mg/kg/day + 50% DRB RP2D|Participants treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 50% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (2.63 mg/kg/day for \<12 years old subjects and 2.25 mg/kg/day for ≥12 years old subjects)
62384356|NCT04772651|PLACEBO_COMPARATOR|Diet as usual and psychoeducation for depression|Patients receive normal hospital diet with 3 meals a day for 4 weeks and psychoeducation sessions (á 50 minutes once a week for 4 weeks)
62384357|NCT03459963|EXPERIMENTAL|group C|indwelling urinary catheter
62384358|NCT03459963|NO_INTERVENTION|group N|Non cathetrized patients
62384359|NCT01612611||a cohort using Shenmai injection|
62384360|NCT05750901|OTHER|Treatment Arm|Patients will receive fractional ablative treatment for laxity.
62384361|NCT00672139|EXPERIMENTAL|Methylnaltrexone bromide|"Methylnaltrexone subcutaneously as needed no more than 1 dose in a 24-hour period for a maximum of 10 weeks in this study.~Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; or 0.4 mL (8 mg) every other day if weight between 38 and \<62 kg. Subjects with impaired kidney function received reduced doses according to instructions in the Relistor prescribing information."
62384362|NCT03459105|EXPERIMENTAL|Ultrasound-assisted|Preprocedural ultrasound-assisted paramedian spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
62384363|NCT03459105|ACTIVE_COMPARATOR|Landmark-guided|Landmark-guided spinal anesthesia will be performed, via either midline or paramedian approach. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
62384364|NCT04812236|EXPERIMENTAL|Single decoction group: Wulingsan single decoction granules|Wulingsan single decoction granules, Alisma orientalis (15g), Polyporus (10g), Baizhu (10g), Poria (10g), Guizhi (6g). Take 1 bag each time with warm water twice a day.Take 12 weeks as a course of treatment.
62765372|NCT02124772|EXPERIMENTAL|Part C - TMT 0.025 mg/kg/day + 100% DRB RP2D|Participants treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for \<12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
62765373|NCT02124772|EXPERIMENTAL|Part C - TMT 0.032 mg/kg/day + 100% DRB RP2D|Participants under 6 years of age treated with a combination therapy of trametinib (0.032 mg/kg/day) with 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day)
62765374|NCT02124772|EXPERIMENTAL|Part D - LGG|Participants with low grade glioma (LGG) treated with a combination therapy of trametinib (0.032 mg/kg/day for \< 6 years old subjects and 0.025 mg/kg/day for ≥ 6 years old subjects) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for \<12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
62765375|NCT02124772|EXPERIMENTAL|Part D - LCH|Participants with Langerhans cell histiocytosis (LCH) treated with a combination therapy of trametinib (0.032 mg/kg/day for \< 6 years old subjects and 0.025 mg/kg/day for ≥ 6 years old subjects) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for \<12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
62765376|NCT01828138|OTHER|Preeclampsia|"patients with preeclampsia are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement."
62765377|NCT01828138|OTHER|Controls|"Controls are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement"
62765378|NCT01828138|OTHER|not-pregnant women|"This arm is also a control- group. Controls are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement"
61989067|NCT03603444||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their calcium-phosphorus metabolism state with normal results.~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) \<30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI \> 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
62765379|NCT02611141|OTHER|Patient with Retromolar Gap|20 patients with a retromolar gap between the last erupted molar and the ascending ramus at the right lower mandible.
62765380|NCT02611141|OTHER|Patient without a Retromolar Gap|20 patients without a retromolar gap between the last erupted molar and the ascending ramus at the right lower mandible.
61989068|NCT05126147|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine 200mg twice daily for 6 months.
61989069|NCT05126147|NO_INTERVENTION|Control|Observation and active surveillance.
61989070|NCT04690543|ACTIVE_COMPARATOR|z-plasty|Z-plasty: It will be defined as a local transposition flap that will be used to improve the functional and cosmetic appearance of scars. It will be involved creating two triangular flaps of equal dimensions that will be transposed.
61989071|NCT04690543|EXPERIMENTAL|square flap|Square flap: It will be defined as is another local transposition flap which will be used for release of contractures. Square will be marked on one side of the contracture, and two triangles will be marked on the other side, with the length of all the flaps equal, which will be then transposed.
61989072|NCT02320500|ACTIVE_COMPARATOR|standard physiotherapy|Standard of care physiotherapy for knee osteoarthritis (OA) patients who have been diagnosed with knee OA and may be candidates for total knee replacement (TKA)
61989073|NCT02320500|EXPERIMENTAL|Myofascial-specific therapy|Patient undergo myofascial pain-specific therapy which includes trigger point injections at the same time points as the comparator (1 session every 2 weeks for 8 weeks)
61989074|NCT01689129|EXPERIMENTAL|New formulation of insulin glargine|once daily in the evening on-top of mealtime insulin
61989075|NCT01689129|ACTIVE_COMPARATOR|Lantus (insulin glargine)|once daily in the evening on-top of mealtime insulin
61989076|NCT01176266|EXPERIMENTAL|Asfotase alfa|A total of 6 mg/kg/week of asfotase alfa administered by SC injection (either 1 mg/kg asfotase alfa 6 times per week, or 2 mg/kg asfotase alfa 3 times per week)
61989077|NCT03221803|EXPERIMENTAL|OT Vertical attachment|The attachment consists of a male part that is in the form of a steady with a central hole. This part is attached to the abutments .the female component is a white standard retentive clip engaging the outer walls of a steady male. It is incorporated in the partial denture together with a castable balancing pin that fits into the central hole of the steady male and aids in centering the prosthesis during the final stage of insertion; thereby ensuring a longer life to the retentive clips.
62558679|NCT02961595|NO_INTERVENTION|Inactivated Polio Vaccine (IPV)|The control group received inactivated poliovirus vaccine (IPV) at the age of 6 and 12 months according to the national immunization protocol in Finland at that time.
62765381|NCT05045677|EXPERIMENTAL|Digital DBT intervention group|Digital intervention group plus standard care
62765382|NCT05045677|ACTIVE_COMPARATOR|Standard care|Standard care alone
62765383|NCT01314560|EXPERIMENTAL|1|experimental
62765384|NCT05482659|EXPERIMENTAL|Experimental|Health education on healthy nutrition and regular physical activity based on the transtheoretic model was given to overweight university students in the experimental group once a week (every 4 weeks) using the online education method.
61989078|NCT03221803|ACTIVE_COMPARATOR|OT Cap attachment|Beveled castable bar with micro-size sphere located in first molar region, and attached to the distal surface of the waxed crowns to be cast as one piece, Nylone caps of standard retention for micro size sphere this nylon caps fit onto their spheres and located in metal housing at fitting surface on the denture and Positioning rings to maintain the space for nylon cap during construction of the partial denture metal framework.
62558680|NCT02961595|ACTIVE_COMPARATOR|Oral Polio Vaccine (OPV)|Intervention group were given doses of oral polio vaccine OPV (Polio Sabin®) at the age of 2, 3, 6 and 12 months.
62765385|NCT05482659|NO_INTERVENTION|control group|No attempt was made to the students in the control group during the intervention process. When the intervention process of the experimental group was finished, the materials used in health education were shared with the students.
62765386|NCT04317157|EXPERIMENTAL|Caffeine Clinical Trial|Participants will ingest 6 mg.kg-1 of caffeine \~45 minutes before the trial, in a double-blinded, randomized clinical trial fashion.
62765387|NCT04317157|PLACEBO_COMPARATOR|Placebo Clinical Trial|Participants will ingest placebo \~45 minutes before the trial, in a double-blinded, randomized clinical trial fashion.
62765388|NCT04317157|EXPERIMENTAL|Placebo-deceived Caffeine|Participants will be lead to believe that they are ingesting 6 mg.kg-1 of caffeine \~45 minutes before the trial.
62765389|NCT04317157|PLACEBO_COMPARATOR|Placebo-deceived Placebo|Participants will be informed they are ingesting placebo \~45 minutes before the trial.
62765390|NCT04317157|ACTIVE_COMPARATOR|Control-Caffeine|Participants will be informed they are ingesting 6 mg.kg-1 of caffeine \~45 minutes before the trial.
61989079|NCT03380585|EXPERIMENTAL|Reciproc|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit. In this group, intervention will be carried out by the Reciproc motor (VDW, Germany) and Reciproc single-file system. The intervention is foraminal enlargement with the Reciproc single-file system.
62765391|NCT04317157|NO_INTERVENTION|Control|Participants will perform a baseline trial with no intervention.
61989080|NCT03380585|ACTIVE_COMPARATOR|ProTaper Next|The active comparator is foraminal enlargement with the ProTaper Next multi-file system. Endodontic treatment is identical to experimental group except file systems used. In this group, ProTaper Next multi-file system will be used in enlarging apical foramina.
61989081|NCT05657691|EXPERIMENTAL|10 mg Xanamem™|10 mg Xanamem™ capsule, to be administered orally once every morning with or without food
61989082|NCT05657691|PLACEBO_COMPARATOR|Placebo|Placebo capsule, to be administered orally once every morning with or without food
61989083|NCT03476291||Normal|normal macular structure of horizontal OCT B-scans
61989084|NCT03476291||Abnormal|abnormal macular structure of horizontal OCT B-scans, including many sub-categories of pathological features, like epiretinal membrane, pigment epithelium detachment, ect.
61989085|NCT02128191|ACTIVE_COMPARATOR|Oral ibuprofen|Initial dose of 10 mg/kg of oral ibuprofen, followed by 2 doses of 5 mg/kg 24 and 48 h later
61989086|NCT02128191|PLACEBO_COMPARATOR|Normal saline|Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
61989087|NCT04148950|EXPERIMENTAL|Kinesio Taping|Kinesio Taping group consisted of 29 patients with CVD. Kinesio Taping was applied once a week for a period of 4 weeks. Closed Fan and Closed Basketweave techniques were applied according to the clinical manifestations, intensity of symptoms, and the needs for the areas to be taped. Basketweave technique was used generally for the thigh, and the areas rich in lymph nodes while closed fan technique was used for cruris, and regions of less severe venous reflux or obstruction. Kinesio Taping was slowly removed by the patient 4 days after the application to prevent any allergic reactions. In addition, patients were given calf muscle pump exercises, flexibility exercises, diaphragmatic breathing exercises, and lower extremity elevation.
61989088|NCT04148950|ACTIVE_COMPARATOR|Compression Stockings|Compression stockings group consisted of 29 patients with CVD. Patients were recommended medium pressure (23-32 mmHg) compression stockings by the physician. Knee high or thigh high compression stockings were given according to the level of symptoms and signs. In addition, patients were given calf muscle pump exercises, flexibility exercises, diaphragmatic breathing exercises, and lower extremity elevation.
61989089|NCT01768351|ACTIVE_COMPARATOR|Control|Patients receiving treatment for secondary hyperparathyroidism with calcitriol. The calcitriol dosage schedule provided for an initial dose of 0.5 mch every other day and titration was performed on the basis of the serum levels of intact PTH (iPTH) (target 150-300 pg/mL), Ca, P and Ca x P product as suggested by the US National Kidney Foundation Dialysis outcomes Quality Initiative (NKF-DOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.
62558681|NCT05106179|ACTIVE_COMPARATOR|Previously treated + Atenolol|The investigators suppose the outcome might be compromised if patient has been previously treated, that's why it is going to be compared to the main cohort. The results are going to be analysed separately
62765392|NCT02706561|EXPERIMENTAL|Standard care plus the ACT intervention (ACT-ED)|SC + ACT-ED-Group A uses Acceptance and Commitment Therapy (ACT). In this group, men focus on: long-term goals of rehabilitation; acceptance of the frustration related to ED; identifying and overcoming barriers; and committing to an erectile rehabilitation program. All participants will be asked to complete a set of questionnaires (baseline). The participants can complete it using your personal computer, one of MSKCC computers, in-person or over the phone. The questionnaires will take about 45-60 minutes to complete. You will also complete the same set of questionnaires at 6, 12, 18, and 24 months following study entry. In both groups, the participant will receive three in-person sessions or phone (30-45 minutes), six brief telephone sessions (5-10 minutes), and six monthly phone calls (5-10 minutes)
61989090|NCT01768351|EXPERIMENTAL|Paricalcitol|Patients treated by Paricalcitol for hyperparathyroidism. The paricalcitol initial dose was 1 mcg/die, and titration was performed on the basis of the serum levels of iPTH, Ca, P and Ca x P product as suggested by the NKF-DOQI and KDIGO guidelines.
61989091|NCT04245384|EXPERIMENTAL|Internet-based treatment|Internet-based dietetic treatment with video calls, no physical meetings
61989092|NCT04245384|ACTIVE_COMPARATOR|Standard treatment|Dietetic treatment with physical meetings
62765393|NCT02706561|EXPERIMENTAL|SC plus nurse Enhanced Monitoring and Education (EME)|SC + EME-Group B uses enhanced monitoring and education. This group focuses on answering questions about the rehabilitation program, manage technical issues related to injections, and the dose titration of injection medication. Participants in this group will also receive education on the side effects and impact of prostate cancer surgery, and strategies for restarting sexual activity. All participants will be asked to complete a set of questionnaires (baseline). You can complete it using your personal computer, one of MSKCC computers, in-person or over the phone. The questionnaires will take about 45-60 minutes to complete. The participant will also complete the same set of questionnaires at 6, 12, 18, and 24 months following study entry. In both groups, the participant will receive three in-person sessions or phone (30-45 minutes), six brief telephone sessions (5-10 minutes), and six monthly phone calls (5-10 minutes).
62765394|NCT01193166|EXPERIMENTAL|001|paliperidone palmitate 78 117 156 or 234 mg monthly injection for 12 months
62765395|NCT01193166|ACTIVE_COMPARATOR|002|olanzapine flexible dosing as prescribed by the study doctor for 12 months
62765396|NCT01193166|ACTIVE_COMPARATOR|003|paliperidone flexible dosing as prescribed by the study doctor for 12 months
62765397|NCT01193166|ACTIVE_COMPARATOR|004|aripiprazole flexible dosing as prescribed by the study doctor for 12 months
62765398|NCT01193166|ACTIVE_COMPARATOR|005|haloperidole flexible dosing as prescribed by the study doctor for 12 months
62765399|NCT01193166|ACTIVE_COMPARATOR|006|perphenazine flexible dosing as prescribed by the study doctor for 12 months
62765400|NCT01193166|ACTIVE_COMPARATOR|007|quetiapine flexible dosing as prescribed by the study doctor for 12 months
62765401|NCT01193166|ACTIVE_COMPARATOR|008|risperidone flexible dosing as prescribed by the study doctor for 12 months
62765402|NCT00214474|ACTIVE_COMPARATOR|ATSM Intervention|ATSM Intervention: Automated Telephone Self-Management Support
62765403|NCT00214474|ACTIVE_COMPARATOR|GMV Intervention|GMV Intervention: Group Medical Visits
62765404|NCT00214474|NO_INTERVENTION|Usual Care|Usual Care: Standard care for diabetic patients
62765405|NCT04841603|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual
62765406|NCT04841603|EXPERIMENTAL|Mindshift CBT|Treatment as usual + Access to Mindshift CBT app
62765407|NCT01361932|EXPERIMENTAL|Video of ED Discharge Instructions|
62765408|NCT01361932|NO_INTERVENTION|Control (usual standard of care)|
62765409|NCT06147921|EXPERIMENTAL|SAD Dose Level 1|Sinonasal irrigation of lowest dose Verasone vs placebo
62765410|NCT06147921|EXPERIMENTAL|SAD Dose Level 2|Sinonasal irrigation of second lowest dose Verasone vs placebo
62765411|NCT06147921|EXPERIMENTAL|SAD Dose Level 3|Sinonasal irrigation of third lowest dose Verasone vs placebo
62765412|NCT06147921|EXPERIMENTAL|SAD Dose Level 4|Sinonasal irrigation of highest dose Verasone vs placebo
62765413|NCT06147921|ACTIVE_COMPARATOR|Crossover Component|Each active component from the highest well tolerated dose of Verasone will be administered via sinonasal irrigation alone in a within subject crossover to compare plasma drug levels to that seen when dosed with Verasone.
62765414|NCT06147921|EXPERIMENTAL|MAD Dose Level 1|The next to highest well tolerated dose of Verasone in the SAD study will be compared to one of the active components in Verasone and to placebo in a 5 day b.i.d. dosing regimen
62765415|NCT06147921|EXPERIMENTAL|MAD Dose Level 2|The highest well tolerated of Verasone in the SAD study will be compared to one of the active components in Verasone and to placebo in a 5 day b.i.d. dosing regimen.
61989093|NCT01220258|EXPERIMENTAL|Azithromycin ophthalmic solution, 1%|
62765416|NCT02433873|PLACEBO_COMPARATOR|Placebo|Ingredients that are in the placebo are: high maltose corn syrup (Satin Sweet™), water, and mannitol. Both Supplement A and Supplement B will be compared to this placebo arm.
62765417|NCT02433873|EXPERIMENTAL|Supplement A|Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Supplement A and B differ by degrees of polymerization.
62765418|NCT02433873|EXPERIMENTAL|Supplement B|Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Supplement A and B differ by degrees of polymerization.
62765419|NCT00831701|ACTIVE_COMPARATOR|Tamsulosin|Tamsulosin treatment
62765420|NCT00831701|PLACEBO_COMPARATOR|Placebo|Placebo treatment
62765421|NCT04713618||Supportive Care (pelvic exam, survey)|Patients undergo standard of care pelvic exam at baseline and 1, 3, 6, 12, and 24 month follow ups. Patients also complete patient reported outcome measures at baseline and 1, 3, 6, 12, 18, and 12 month follow ups.
61989094|NCT01482793|ACTIVE_COMPARATOR|AVAMAX|Avamax vertebroplasty kits provided by Care Fusion
62765422|NCT05153824||Healthy volunteers|Healthy volunteers
62765423|NCT04637919|EXPERIMENTAL|IN-B001 EV71 A dose|Inactivated EV71 vaccine(A dose) or placebo in 10 healthy adults (three doses, 28 days interval)
62765424|NCT04637919|EXPERIMENTAL|IN-B001 CVA16 B dose|Inactivated CVA16 vaccine(B dose) or placebo in 10 healthy adults (three doses, 28 days interval)
62765425|NCT04637919|EXPERIMENTAL|IN-B001 Bivalent C dose|Inactivated EV71/CVA16 vaccine(C dose) or placebo in 10 healthy adults (three doses, 28 days interval)
62765426|NCT00436254|EXPERIMENTAL|Arm I|Patients receive pNGVL3-hICD vaccine admixed with GM-CSF intradermally once a month for 3 months in the absence of disease progression or unacceptable toxicity.
61989095|NCT01482793|NO_INTERVENTION|Simulated injection procedure|Patient will be unaware as to whether the control procedure or vertebroplasty had been performed since full sterile preparation, sedation and simulated injection procedure will be used.
62765427|NCT00460590|EXPERIMENTAL|1|12 adults with prior BCG
62765428|NCT00460590|EXPERIMENTAL|2|12 adults without prior BCG
62765429|NCT00460590|EXPERIMENTAL|3|12 Adolescents
62765430|NCT04382521|EXPERIMENTAL|Text Message Intervention (TMI)|Participants in the TMI condition will receive daily text messages through an adaptive algorithm plus separate twice-weekly tailored messages focused on a specific health goal.
62384365|NCT04812236|OTHER|Co-decocting group: Wulingsan co-decocting granules|Wulingsan co-decoction granules, Alisma orientalis (15g), Polyporus (10g), Atractylodes (10g), Poria (10g), Guizhi (6g). Take 1 bag each time with warm water twice a day.Take 12 weeks as a course of treatment.
61989096|NCT01290666||GORE® BIO-A® Fistula Plug|All patients in study receive the GORE® BIO-A® Fistula Plug.
61989097|NCT02490722|ACTIVE_COMPARATOR|Intervention|Four times two hours interdisciplinary patient education and usual care
62765431|NCT04382521|OTHER|Wait-list Control Group (WLC)|Waitlist Control group participants will begin to receive the full 12-week Text Message Intervention (with all components, e.g., phone check-ins) after completing follow-up assessments at Weeks 12 and 24. Participants in this group will receive no text messages or other study-specific interventions during the first 24 weeks of the study.
61989098|NCT02490722|NO_INTERVENTION|Control|Usual care
61989099|NCT01525147|EXPERIMENTAL|YHB1411-2: Level 2|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
61989100|NCT01525147|EXPERIMENTAL|YHB1411-2: Level 3|The ratio of Test Drug(YHB1411-2) to Placebo is 13 :2.
61989101|NCT01525147|EXPERIMENTAL|YHB1411-2: Level 4|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
61989102|NCT01525147|EXPERIMENTAL|YHB1411-2: Level 5|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
61989103|NCT01525147|EXPERIMENTAL|YHB1411-2: Level 1|All investigational products are YHB1411-2(This level is pilot study).
61989104|NCT01085097|PLACEBO_COMPARATOR|Placebo|Participants will receive 2 capsules of placebo matching to laquinimod orally once daily (QD) for 24 weeks, MMF 500 mg tablet orally twice daily (BID) for the first week then 1 gram (g) BID from Week 2 to Week 28, and MP 500 mg/day intravenously (IV) from Days 1 through 3, followed by oral prednisolone/prednisone (initial dose 40 mg/day which is tapered to 10 mg/day or less by the end of Week 20, on a fixed steroid-tapering regimen) from Day 4 through Week 28.
61989105|NCT01085097|EXPERIMENTAL|Laquinimod 0.5 mg|Participants will receive 1 capsule of laquinimod 0.5 mg and 1 capsule of placebo matching to laquinimod orally QD for 24 weeks, MMF 500 mg tablet orally BID for the first week then 1 g BID from Week 2 to Week 28, and MP 500 mg/day IV from Days 1 through 3, followed by oral prednisolone/prednisone (initial dose 40 mg/day which is tapered to 10 mg/day or less by the end of Week 20, on a fixed steroid-tapering regimen) from Day 4 through Week 28.
61989106|NCT01085097|EXPERIMENTAL|Laquinimod 1 mg|Participants will receive 2 capsules of laquinimod 0.5 mg orally QD for 24 weeks, MMF 500 mg tablet orally BID for the first week then 1 g BID from Week 2 to Week 28, and MP 500 mg/day IV from Days 1 through 3, followed by oral prednisolone/prednisone (initial dose 40 mg/day which is tapered to 10 mg/day or less by the end of Week 20, on a fixed steroid-tapering regimen) from Day 4 through Week 28.
61989107|NCT04582110||Patients with Beta Thalassemia|Patients with previous diagnosis of Beta Thalassemia
61989108|NCT04582110||Control Group|Healthy fellow eyes without actual and previous ocular trauma
61989109|NCT02735551|ACTIVE_COMPARATOR|Non-LARC Group: Short Acting Method|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice, as is the current practice for students who present for contraceptive services"
61989110|NCT02735551|ACTIVE_COMPARATOR|Control Group: Referral for LARC Placement|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to referral for LARC placement to local clinic."
61989111|NCT02735551|ACTIVE_COMPARATOR|LARC Group: Same Day LARC Placement|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to same day LARC placement (intervention)."
61989112|NCT02342340|ACTIVE_COMPARATOR|Navy Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked navy beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
61989113|NCT02342340|ACTIVE_COMPARATOR|Red Kidney Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked red kidney beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
61989114|NCT02342340|ACTIVE_COMPARATOR|Pinto Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked pinto beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
62168256|NCT02459132|NO_INTERVENTION|Usual Care|The usual care group will not receive an intervention, and they will be asked to maintain baseline physical activity levels throughout the observation period.
62384366|NCT04812236|OTHER|Powder group: Wuling powder powder|Wuling powder is composed of Alisma, Polyporus, Atractylodes, Poria, Guizhi. Take 5g each time with warm water twice a day.Take 12 weeks as a course of treatment.
62384367|NCT04812236|PLACEBO_COMPARATOR|Simulant group: Simulant of granular dosage form|Granule simulant, the composition is Alisma orientalis (15g), Polyporus (10g), Atractylodes (10g), Poria (10g), Guizhi (6g). Take 1 bag each time with warm water twice a day. Take 12 weeks as a course of treatment.
62384368|NCT03438591|EXPERIMENTAL|Cerclage-CRT (medtronic 4196 lead)|trans-coronary sinus intraseptal pacing (cerclage pacing) which technology to position the pacemaker lead into the septum for 'parahisian pacing'
62765432|NCT04109846|EXPERIMENTAL|Non-euploid Transfer|Patients desiring pregnancy who have no acceptable euploid embryos available for transfer who chose to undergo embryo transfer of a non-euploid embryo (either aneuploid or mosaic).
62765433|NCT04109846|ACTIVE_COMPARATOR|Euploid Transfer|Patients desiring pregnancy who are undergoing euploid embryo transfer
62765434|NCT00093886|EXPERIMENTAL|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
62765435|NCT00093886|ACTIVE_COMPARATOR|nitroglycerin|Nitroglycerin (NTG) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
62765436|NCT05478291|EXPERIMENTAL|Vitamin D supplementation|"Appropriate diet and physical activity counselling~Supplementation with Vitamin D and oral Calcium- Doses of cholecalciferol (commercial name, Calcirol) 60,000 international units (sachets, dissolved in half glass milk) once per week for eight weeks to intervention group and placebo (Lactose granules) to the placebo group according to the random numbers generated by the computer.~After every 24 weeks blood 25 (OH) D levels will be assessed. If the subjects are found to be still deficient then supplementation of cholecalciferol 60,000 IU per week for eight weeks will be repeated. If the 25 (OH) D levels are normal, then cholecalciferol supplementation in doses of 200 international units per day will be given as a maintenance dose."
62765437|NCT01656369|ACTIVE_COMPARATOR|Group I delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed. Postoperatively, minimal pain medication was required. Early ambulation was encouraged, and patients' diets were advanced as tolerated.
62765438|NCT01656369|ACTIVE_COMPARATOR|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
62384369|NCT03958461|OTHER|Calculus removement|Anti-infective treatment of teeth
62765439|NCT01535794||18-26 year old men who have sex with men|
62765440|NCT04008992|EXPERIMENTAL|Part A SAD - A1 Cohort|Single Ascending Dose
62765441|NCT04008992|EXPERIMENTAL|Part A SAD - A2 Cohort|Single Ascending dose
61989115|NCT02342340|ACTIVE_COMPARATOR|Black Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked navy beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
62384370|NCT01694459|ACTIVE_COMPARATOR|Standard dose heparin|Bolus of 100 UI/Kg of heparin. Activated clotting time (ACT) \> 300 sec. during the procedure
62384371|NCT01694459|EXPERIMENTAL|Low-dose heparin|Bolus of 50 UI/Kg heparin with a target ACT during the procedure of \>200 sec.
62384372|NCT03345875|OTHER|HPV Screening|Study eligible participants will be screened for HPV using a self collected vaginal sample using a collection device and kit. Those who test positive for HPV will be offered visual assessment of the cervix for treatment (VAT) and treatment as appropriate.
62384373|NCT04537364||pediatric patients with CAKUT|"This cohort is composed of pediatric children diagnosed of CAKUT from Shanghai peri-conceptional parent-offspring cohort (SPCC) clinic research related outpatient and high-risk newborns referral outpatient, and those who are enrolled in nephrology department and urinary surgery department with CAKUT diagnosis.~By diagnostic tests for predicting renal parenchymal damage in this cohort, data of kidney images, urinary biomarkers and disease genes can be collected."
62384374|NCT03433391|OTHER|Surgery Plus Oxiplex|Oxiplex will be applied after hemostasis is achieved and prior to closure, in adult patients undergoing single level partial discectomy.
62384375|NCT03433391|OTHER|Surgery Only|Standard of care procedures for adult patients undergoing single level partial discectomy will be followed.
62384376|NCT03755037|ACTIVE_COMPARATOR|Estradiol and cc|"Group 1 received estradiol, cc and placebo simillar to sildenafil for induction of ovulation.~CC 50 mg (clomid) orally twice daily from 3rd day to 7th day of menstrual cycle of the patient then ethinyl estradiol 0.05mg orally twice daily on the 8th day of same cycle till 11th day."
62384377|NCT03755037|ACTIVE_COMPARATOR|Sildenafil and cc|Group 2 received CC 50 mg (clomid) orally twice daily from 3rd day to 7th day of menstrual cycle of the patient, sildenafil citrate (Respatio) 20 mg tab orally 3 times daily from8th day of same cycle till 11th day and placebo simillar to estradiol.
62384378|NCT03755037|PLACEBO_COMPARATOR|Placebo and cc|Group 3 received cc and placebo similar to sildenafil and placebo similar to estradiol with the same doses.
62384379|NCT04686110|OTHER|Patients Amyotrophic Lateral Sclerosis|
62384380|NCT04686110|OTHER|Control subjects|
62384381|NCT00193856|ACTIVE_COMPARATOR|A|LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 mths)
62384382|NCT00193856|ACTIVE_COMPARATOR|B|LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 months) + bisphosphonate therapy.
62384383|NCT00193856|EXPERIMENTAL|C|LH-RH analogue as for arm A, but continued for further 12 months (total 18 months)
62384384|NCT00193856|EXPERIMENTAL|D|LH-RH analogue as for arm A, but continued for further 12 months (total 18 months) + bisphosphonate therapy.
62384385|NCT03163121|EXPERIMENTAL|Group 1 - PfSPZ-GA1 Vaccine|"Group 1 will comprise of 3 volunteers who will receive one immunization of 1.35 x 10\^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
62384386|NCT03163121|EXPERIMENTAL|Group 2 - PfSPZ-GA1 Vaccine|"Group 2 will comprise of 3 volunteers who will receive one immunization of 4.5 x 10\^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
62384387|NCT03163121|EXPERIMENTAL|Group 3 - PfSPZ-GA1 Vaccine|"Group 3 will comprise of 13 volunteers who will receive one immunization of 9.0 x 10\^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
62765442|NCT04008992|EXPERIMENTAL|Part A SAD- A3 Cohort|Single Ascending dose
62765443|NCT04008992|EXPERIMENTAL|Part A SAD- A4 Cohort|Single Ascending dose
62765444|NCT04008992|EXPERIMENTAL|Part A SAD - A5 Cohort|Single Ascending dose
62384388|NCT03163121|EXPERIMENTAL|Group 4 - PfSPZ-GA1 Vaccine|"Group 4 will comprise of 13 volunteers who will receive 3 immunizations of 9.0 x 10\^5 PfSPZ of PfSPZ-GA1 Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
62765445|NCT04008992|EXPERIMENTAL|Part A SAD- A6 Cohort|Single Ascending dose
62765446|NCT04008992|EXPERIMENTAL|Part B MAD- B1 Cohort|Multiple Ascending Dose
62765447|NCT04008992|EXPERIMENTAL|Part B MAD - B2 Cohort|Multiple Ascending Dose
62765448|NCT04008992|EXPERIMENTAL|Part B MAD - B3 Cohort|Multiple Ascending Dose
62765449|NCT04008992|EXPERIMENTAL|Part B MAD - B4 Cohort|Multiple Ascending Dose
62765450|NCT04008992|EXPERIMENTAL|Part C JMAD - C1 Cohort|Japanese Multiple Ascending Dose
62384389|NCT03163121|EXPERIMENTAL|Group 5 - PfSPZ-GA1 Vaccine|"Group 5 will comprise of 13 volunteers who will receive 3 immunizations of 4.5 x 10\^5 PfSPZ of PfSPZ-GA1 Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
62765451|NCT04008992|EXPERIMENTAL|Part C JMAD - C2 Cohort|Japanese Multiple Ascending Dose
62765452|NCT04008992|EXPERIMENTAL|Part C JMAD - C3 Cohort|Japanese Multiple Ascending Dose
62765453|NCT01025570|EXPERIMENTAL|Gem/Bos|"Gemcitabine 1000 mg/m2, D1,8,15 of each cycle~Bostutinib 400 mg daily concurrently with Gemcitabine"
62765454|NCT01102894|EXPERIMENTAL|Low fiber and High Fiber|Subjects consume a low fiber cereal and swallow the SmartPill device that measures gastrointestinal transit time Subjects consume a high fiber cereal along with swallowing the SmartPill device that measures gastrointestinal transit time
62765455|NCT01739803|EXPERIMENTAL|Intervention Group|Behavioral contract intervention
62384390|NCT03163121|EXPERIMENTAL|Group 6 - PfSPZ Vaccine|"Group 6 will comprise of 13 volunteers who will receive 3 immunizations of 4.5 x 10\^5 PfSPZ of PfSPZ Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
61989116|NCT02342340|ACTIVE_COMPARATOR|Lentils (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked lentils. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
62384391|NCT03163121|PLACEBO_COMPARATOR|Group 7 - Normal Saline Placebo control|"Group 7 will comprise of 9 volunteers who will receive 3 injections of normal saline placebo 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
62384392|NCT06193733|EXPERIMENTAL|Procedure: injection of the cell therapy product|"Procedures per cycle (total of 3 cycles):~8 days before autologous cell injection: Cytapheresis - Autologous cell injection - 2 days after cell injection: lab assessment."
62384393|NCT03369340|ACTIVE_COMPARATOR|Product Sequence 1|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 2 on Day 2; P3P 4 on Day 3; P3P 1 on Day 4"
62384394|NCT03369340|ACTIVE_COMPARATOR|Product Sequence 2|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 4 on Day 2; P3P 1 on Day 3; P3P 2 on Day 4"
62384395|NCT03369340|ACTIVE_COMPARATOR|Product Sequence 3|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 1 on Day 2; P3P 2 on Day 3; P3P 4 on Day 4"
62384396|NCT03369340|ACTIVE_COMPARATOR|Product Sequence 4|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 1 on Day 2; P3P 4 on Day 3; P3P 2 on Day 4"
62384397|NCT03369340|ACTIVE_COMPARATOR|Product Sequence 5|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 2 on Day 2; P3P 1 on Day 3; P3P 4 on Day 4"
62765456|NCT01739803|NO_INTERVENTION|Control Group|No intervention
61989117|NCT02342340|PLACEBO_COMPARATOR|White Rice (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked white rice. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
61989118|NCT03302013|EXPERIMENTAL|Vanguard XP Knee Replacement Surgery|Participants randomised in this group will receive the Vanguard XP Bi-cruciate Retaining Knee Replacement System. This total knee replacement device (Vanguard XP) and surgical procedure retain the anterior cruciate ligament in the knee.
61989119|NCT03302013|ACTIVE_COMPARATOR|Vanguard CR Knee Replacement Surgery|Participants randomised to this group will receive the Vanguard CR Single Cruciate Retaining Knee Replacement Surgery. This total knee replacement device (Vanguard CR) and surgical procedure sacrifice the anterior cruciate ligament and replaces it with artificial support. This is currently the standard practice for knee replacement surgery in the NHS.
61989120|NCT04369794|ACTIVE_COMPARATOR|BCG vaccine|BCG Group (n = 200): 0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
61989121|NCT04369794|PLACEBO_COMPARATOR|Placebo|Placebo group (n = 200): 0.9% saline solution in the same volume as BCG vaccine in a single dose.
61989122|NCT01207518|EXPERIMENTAL|Intervention Group|For the intervention group, there will be a Guide facilitator provided by the project team, normally the Project Manager or their delegate. The role of the Guide facilitator will be to provide basic information about the Guide and to facilitate the use of the web-based tools.
61989123|NCT01207518|ACTIVE_COMPARATOR|Control Group|The Control Group will be asked to provide immunization rates for the base year and two years of the study, and will be asked about their influenza immunization campaign activities to use as a comparator. They will receive the Guide and web-based tools following completion of the study.
62384398|NCT03369340|ACTIVE_COMPARATOR|Product Sequence 6|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 4 on Day 2; P3P 2 on Day 3; P3P 1 on Day 4"
62384399|NCT00917878|EXPERIMENTAL|Milk|500 mL low-fat milk added to high-fat meal
62384400|NCT00917878|EXPERIMENTAL|Protein|Milk protein in 500 mL water added to high-fat meal
62384401|NCT00917878|EXPERIMENTAL|Calcium|Milk calcium in 500 mL water added to high-fat meal
62765457|NCT04515953|ACTIVE_COMPARATOR|Control|Standard practice of pain management for post-TKA
62765458|NCT04515953|EXPERIMENTAL|ND-340|ND-340 90mg\~320mg at dose escalations
62765459|NCT03369431|OTHER|Vivomixx, then placebo|This group starts with Vivomixx probiotic for the first 12 weeks then crosses over to have the placebo after a 4-week washout.
62765460|NCT03369431|OTHER|Placebo, then Vivomixx|This group starts with the placebo for the first 12 weeks then crosses over to have Vivomixx probiotic after a 4-week washout.
62765461|NCT02345356||Standard-of-Care|the standard clinical approach will be followed
62384402|NCT00917878|EXPERIMENTAL|Control|Lactose in 500 mL water added to high-fat meal (control condition)
62765462|NCT02345356||Genotype-guided|algorithmically guided personalized therapy of warfarin, using a pharmacogenetic model developed in Caribbean Hispanics
62384403|NCT00066443|EXPERIMENTAL|Pegfilgrastim, docetaxel and epirubicin|
62384404|NCT03137524|EXPERIMENTAL|Hand Held Fan Therapy|
62384405|NCT03137524|NO_INTERVENTION|No Intervention|
62384406|NCT02192190|PLACEBO_COMPARATOR|Placebo|Placebo capsule orally, once daily for approximately 16 weeks. Placebo subcutaneous (SC) once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
62384407|NCT02192190|ACTIVE_COMPARATOR|Celecoxib + Placebo|Celecoxib 200 milligram (mg) capsule orally once daily for approximately 16 weeks. Placebo SC once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
62384408|NCT02192190|EXPERIMENTAL|LY2951742 5 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 5 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
62765463|NCT02048215|ACTIVE_COMPARATOR|Ephedrine + Caffeine + diet|Ephedrine 20 mg + Caffeine 200 mg capsule t.i.d. for one month plus hypocaloric diet
62765464|NCT02048215|PLACEBO_COMPARATOR|Placebo + diet|Similarly-looking placebo capsule t.i.d. for one month plus hypocaloric diet
62765465|NCT04376827|EXPERIMENTAL|Guselkumab+Standard of Care|Participants will receive guselkumab Dose 1 intravenously (IV) at Weeks 0, 4 and 8 and guselkumab Dose 2 subcutaneous (SC) every 4 weeks (q4w) from Week 12 through Week 48 along with standard-of-care treatment of mycophenolate mofetil (MMF)/mycophenolic acid (MPA) and glucocorticoids. Participants who achieved complete renal response (CRR) at Week 48 and 52 and have completed the Week 52 assessment may have the option to participate in the long-term extension (LTE).
62765466|NCT04376827|PLACEBO_COMPARATOR|Placebo+Standard of Care|Participants will receive placebo IV at Weeks 0, 4 and 8 and placebo SC q4w from Week 12 through Week 48 along with standard-of-care treatment of MMF/MPA and glucocorticoids. Participants who achieved complete renal response (CRR) at Week 48 and 52 and have completed the Week 52 assessment may have the option to participate in the LTE of the study.
62384409|NCT02192190|EXPERIMENTAL|LY2951742 50 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 50 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
62384410|NCT02192190|EXPERIMENTAL|LY2951742 120 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 120 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
62384411|NCT02192190|EXPERIMENTAL|LY2951742 300 mg + Placebo|Placebo capsule orally, once daily for 16 weeks. SC injections of 300 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
62384412|NCT05670028|EXPERIMENTAL|CA-guided BP|The upper and lower limits of autoregulation determined by ICM+ software are used to guide the range of blood pressure control, but no more than 40% above or below the usual BP. From when the upper or lower limit of autoregulation appeared in ICM+ software to 48h after revascularization, the total time of actual BP beyond the CA range will be no more than two hours through drug intervention.
62384413|NCT05670028|ACTIVE_COMPARATOR|Fixed target BP|After randomization to 48h after endovascular therapy, the target of BP was determined by clinicians according to current guidelines, i.e. \<180/105mmHg.
62765467|NCT00404170|EXPERIMENTAL|B-CIT and SPECT imaging|To assess B-CIT injection and SPECT scanning. Optional ongoing B-CIT SPECT imaging scans at follow-up visits
62765468|NCT05549739||Control Group|Individuals without cardiac and pulmonary disease
62765469|NCT05549739||Study Group|Individuals with coronary artery disease
62765470|NCT06506006||post COVID|patients with proximal humerus fracture with concommitant COVID postive status receiving delayed treatment
62384414|NCT01334008|OTHER|Blood sampling|
62384415|NCT03132129||Type 2 diabetics|Participants will be aged (≥18 and ≤75 years) with T2D and no prior history of cardiovascular disease.
62384416|NCT03132129||Healthy controls|Cases will be compared with age-, gender- and ethnicity-matched healthy controls.
62384417|NCT01137851||New to bDMARD|New to bDMARD RA patients with high and low cost share who continue or discontinue treatment
62765471|NCT06506006||Non COVIID|patients with proximal humerus fracture without concommitant COVID postive status receiving usual treatment
62765472|NCT00607854|EXPERIMENTAL|Zevalin|Zevalin associated with a Fludarabine-based reduced-intensity conditioning regimen,all patients will receive Zevalin in the conditioning regimen
62765473|NCT02079935|EXPERIMENTAL|Cognitive Behaviour Therapy|Treatment with small groups following a modified protocol first described by Fairburn 2008
62765474|NCT02079935|EXPERIMENTAL|Physical activity and dietary therapy|Treatment with guided physical activity and dietary therapy in small groups
62765475|NCT02178046||Gingivitis|optical measurements
62765476|NCT00469963|EXPERIMENTAL|SIR-SPHERES|
62765477|NCT01116427|EXPERIMENTAL|Abatacept|Receives abatacept during first course of treatment, switching to placebo during extension phase.
62765478|NCT01116427|PLACEBO_COMPARATOR|Placebo, followed by abatacept|Receives a placebo for first course of treatment, switching to abatacept in the extension phase.
62765479|NCT04326660|NO_INTERVENTION|Control|Participants in the control group will receive a Fitbit Alta-Heart Rate (HR) and 12 weekly non-tailored educational modules via WeChat on general health topics that are important to 20-45 year-old women in China. Topics include intimate partner violence, anxiety, depression, sexually transmitted infections, HIV, unintended pregnancy, hepatitis B, and general cancer prevention.
62765480|NCT04326660|EXPERIMENTAL|SCOPE-Chinese Women Intervention|"SCOPE-Chinese Women intervention content and methods: SCOPE-Chinese Women is a smartphone- based intervention.~Component 1. All study participants will receive a Fitbit Alta-HR tracking device to wear daily. Each participant will receive in-person, training on how to access the app and their tracking data. If a participant has not used the fitness device and app for more than one week, a WeChat reminder message will be sent to the participant.~Component 2. Participants will receive 12 weekly culturally appropriate and evidence-based SCOPE-Chinese Women educational modules along with tailored tips and messages via WeChat. Each module will include three educational sessions that last less than 45 minutes total.~Component 3. Six bi-weekly messages will be sent to participants via WeChat to encourage positive behavioral changes. Each participant's message content will be based on the participant's tracker information, personal goals, and preferences."
62765481|NCT03899064|EXPERIMENTAL|Induction:MC2-01 Cream, irradiation|Applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), followed by irradiation
62765482|NCT03899064|EXPERIMENTAL|Induction: MC2-01 Cream, no irradiation|Applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), no irradiation
62765483|NCT03899064|EXPERIMENTAL|Induction: MC2-01 vehicle, irradiation|Applications with MC2-01 vehicle, followed by irradiation
62765484|NCT03899064|EXPERIMENTAL|Induction: MC2-01 vehicle, no irradiation|Applications with MC2-01 vehicle, no irradiation
62765485|NCT03899064|EXPERIMENTAL|Challenge: MC2-01 Cream, irradiation|Application with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), followed by irradiation
62765486|NCT03899064|EXPERIMENTAL|Challenge: MC2-01 Cream, No irradiation|Application with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), no irradiation
62765487|NCT03899064|EXPERIMENTAL|Challenge: MC2-01 vehicle, irradiation|Application with MC2-01 vehicle, followed by irradiation
62765488|NCT03899064|EXPERIMENTAL|Challenge: MC2-01 vehicle, no irradiation|Application with MC2-01 vehicle, no irradiation
62765489|NCT03899064|EXPERIMENTAL|Challenge: Control, irradiation|No application, but irradiation
62765490|NCT03067285|ACTIVE_COMPARATOR|Arm 1|Patients who postpone switching from DTG/3TC/ABC to ELV/COBI/FTC/TAF four weeks:
62765491|NCT03067285|EXPERIMENTAL|Arm 2|Patients who switch from DTG/3TC/ABC to ELV/COBI/FTC/TAF during the baseline visit
62765492|NCT02389205|PLACEBO_COMPARATOR|control group|physical therapy
61989124|NCT02013167|EXPERIMENTAL|Blinatumomab|"Participants received blinatumomab by continuous intravenous infusion (CIVI) over 4 weeks followed by a 2 week treatment-free interval for 2 induction cycles. Participants who achieved a bone marrow response, complete remission, or complete remission with partial or incomplete hematologic recovery (CR/CRh\*/CRi) within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.~Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh\*/CRi could continue to receive blinatumomab for an additional 12 months (4 cycles), where 1 cycle consisted of 4 weeks of CIVI followed by an 8-week treatment-free period.~The initial dose of blinatumomab was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 through day 29 and for all subsequent cycles."
62384418|NCT06110091|EXPERIMENTAL|Integrated Behavioral Therapy Program|Integrated Behavioral Therapy consists of 5 weekly one-hour sessions (face-to-face either through video or in-person) + 2 telephone check-in with an interventionist. This program integrates cognitive-behavioral treatment for nocturia and insomnia. Brief telephone check-ins will be comprised of review of topics discussed during the sessions.
62384419|NCT06110091|PLACEBO_COMPARATOR|Health Education Program|The Health Education Program consists of 5 weekly one-hour sessions (face-to-face either through video or in-person) + 2 telephone check-in with an interventionist. The program modules focus on brain health and includes topics such physical activity, social engagement, sleep topics (e.g., changes in sleep that occur with aging, effects of poor sleep on health), medications/medical conditions, vision and hearing impairment. Brief telephone check-ins will be comprised of review of health topics discussed during the sessions.
62765493|NCT02389205|ACTIVE_COMPARATOR|kinesio group|kinesio taping for ankle joint
62765494|NCT01665989|EXPERIMENTAL|Group Lifestyle program|The group lifestyle program used in the IDOLc study is adapted from the first 6 months of the Look AHEAD program and will include 19 group sessions offered over a six month period. Each of 2 groups will contain up to 15 patients with type 2 diabetes and will last 1-1.5 hours. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. The program fosters the development of knowledge and lifestyle skills to change diet and exercise habits through use of goal setting, problem solving, stimulus control and other behavioral techniques that have resulted in weight loss, weight maintenance and improved glycemic control.
62765495|NCT01665989|ACTIVE_COMPARATOR|Usual Care|A research assistant will provide the usual care group participants with brief (\~15-20 minutes) counseling which reviews an educational handout emphasizing that modest weight loss (5 - 10%) via caloric restriction and gradual adoption of moderate increases in daily physical activity (equivalent to brisk walking for 30 minutes daily) is safe and effective in managing diabetes; and refer them to Nutrition Services for follow up.
62765496|NCT04615325|EXPERIMENTAL|Single Ascending Dose Stage|Participants will receive a single dose of RO7303359, in multiple escalating cohorts (A-D).
62765497|NCT04615325|EXPERIMENTAL|Expansion Cohort Stage|Participants will receive the maximum tolerated dose (MTD) or the maximum tested dose (MTeD) as determined in the single ascending dose stage.
62168257|NCT06233045|EXPERIMENTAL|Sequence 1- Dapagliflozin test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Dapagliflozin tablet 10 mg test product, treatment 2= Dapagliflozin tablet 10 mg reference product.
62765498|NCT04615325|EXPERIMENTAL|Optional Cohort E|An optional additional cohort may be added with the dose not exceed the MTD or MTeD.
62765499|NCT04615325|EXPERIMENTAL|Optional cohort F|An optional additional cohort may be added with the dose not exceed the MTD or MTeD.
62765500|NCT00892606|EXPERIMENTAL|Methadone|Patients received 2 µg/kg fentanyl, 0.2 mg/kg ketamine and 0.2 mg/kg of methadone IV with induction of general anesthesia.
62765501|NCT00892606|ACTIVE_COMPARATOR|Control|Patients received 2 µg/kg fentanyl, 0.2 mg/kg ketamine, and 0.2 mg/kg morphine (standard of care)
62765502|NCT03987932|EXPERIMENTAL|NEAT!2|Participants will be asked to use the NEAT!2 app for 3 months after randomization. App use between 4-6 months is optional.
62765503|NCT03987932|EXPERIMENTAL|NEAT!2+Calls|Participants will be asked to use the NEAT!2 app for 3 months after randomization. In addition, participants will receive bi-weekly coaching calls over 3 months. App use between 4-6 months is optional.
62765504|NCT03987932|OTHER|Delayed NEAT!2|Participants will receive the NEAT!2 app to use between 3 and 6 months.
62765505|NCT00869830|EXPERIMENTAL|biofeedback|
62765506|NCT02119156|EXPERIMENTAL|Treatment Holiday Group|Subjects in the Treatment Holiday Group will undergo a 6 month belimumab treatment holiday while remaining on standard of care SLE therapy, then re-start belimumab therapy for 6 months while receiving standard of care SLE therapy.
62765507|NCT02119156|ACTIVE_COMPARATOR|Control Group|Subjects in the Control Group will continue to receive monthly belimumab therapy, in addition to standard of care SLE therapy for 52 weeks.
62765508|NCT02119156|NO_INTERVENTION|Long-Term Discontinuation Group|Subjects in the Long-Term Discontinuation Group have elected to discontinue further belimumab therapy and will remain on standard of care SLE therapy as directed by the investigator, and agree to return for monthly visits for 52 weeks.
62765509|NCT01964599|OTHER|PF-RS|14 days consuming the PF-RS containing 30 g fiber and then 14 days consuming the control containing no fiber
62765510|NCT01964599|OTHER|PF-RO1|14 days consuming the PF-RO1 containing 30 g fiber and then 14 days consuming the control containing no fiber
62765511|NCT01964599|OTHER|PF-RO2|14 days consuming the PF-RO2 containing 30 g fiber and then 14 days consuming the control containing no fiber
62765512|NCT04498377|EXPERIMENTAL|F-652|Patient receives standard care plus F-652
62765513|NCT04498377|PLACEBO_COMPARATOR|Placebo|Patient receives standard care plus placebo
62765514|NCT02892721|NO_INTERVENTION|Control group|The control group will not receive the one-day training course or access to the online educational module. Test sets will be administered in the same manner as for the intervention group, but the control group will not receive any feedback on performance during the 12 month assessment phase. Feedback on test performance will only be provided after the 12 month period has ended.
62765515|NCT02892721|OTHER|Training with feedback|See intervention description
62765516|NCT01565564|ACTIVE_COMPARATOR|The usual care arm|
62765517|NCT01565564|ACTIVE_COMPARATOR|The shared care arm|
62384420|NCT04173169|ACTIVE_COMPARATOR|Pre-IVF Treatment with 60 day course of oral GnRH antagonist|For those who agree to be randomized, subjects will be randomized to elagolix 200mg BID. The medication will be taken orally and subjects will be counseled to take the medication at the same time each day. This arm will also include participants who do not want to be randomized while choose elagolix.
62765518|NCT02303782|EXPERIMENTAL|OTX015 + azacitidine|
62765519|NCT02303782|EXPERIMENTAL|Azacitidine|
62765520|NCT04596865||Pancreatic ductal adenocarcinoma|Patients who underwent pancreaticoduodenectomy for PDAC between 01/06/2010 and 31/05/2015
62765521|NCT04596865||Ampullary cancer|Patients who underwent pancreaticoduodenectomy for ampullary cancer between 01/06/2010 and 31/05/2015
62765522|NCT04596865||Distal extrahepatic cholangiocarcinoma|Patients who underwent pancreaticoduodenectomy for distal extrahepatic cholangiocarcinoma between 01/06/2010 and 31/05/2015
62765523|NCT02532920||Atopic dermatitis|Atopic dermatitis is diagnosis as Hanifin and Rajka from physician.
62765524|NCT06157944|ACTIVE_COMPARATOR|GPT-4|Group will be given access to GPT-4.
62765525|NCT06157944|NO_INTERVENTION|Usual resources|Group will not be given access to GPT-4 but will be encouraged to use any resources they wish besides large language models (UpToDate, Dynamed, google, etc).
62765526|NCT05583149|EXPERIMENTAL|ACALABRUTINIB and LISOCABTAGENE MARALEUCEL|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits, as tolerated for one year~* Liso-cel~* Acalabrutinib"
62765527|NCT02358655|OTHER|Phase 1: Retrospective Chart Review|Retrospective chart review of all patients who presented to the emergency department (ED) with ECG-documented AF during 1 year prior to study commencement. The main purpose of Phase 1 is to determine if oral anticoagulants were prescribed for eligible AF patients at ED discharge.
62765528|NCT02358655|OTHER|Phase 2: Low-Intensity Intervention|Low-intensity intervention will be applied in the ED during 6 months, involving physician education, distribution of an AF patient education package, short-term oral anticoagulant prescription, and a follow-up letter to the patient's family physician.
62765529|NCT02358655|OTHER|Phase 3: High-Intensity Intervention|Phase 3 incorporates the Phase 2 intervention, and adds immediate follow-up (within 48-72 hours) in a community AF clinic run by a nurse/pharmacist who is supervised by a specialist in AF.
62765530|NCT00633230|ACTIVE_COMPARATOR|1|standardized herbal formula, Sho-saiko-to (SST): 3 capsules containing 700 mg of the SST herbal extract/capsule and 28 mg of the excipients, magnesium stearate and silicon dioxide/capsule 2 x day
62765531|NCT00633230|PLACEBO_COMPARATOR|2|placebo capsules that look and smell identical to the active Sho-saiko-to (SST) capsules
62765532|NCT04485689|EXPERIMENTAL|Capsaicin - alone|5x7 cm2 capsaicin patch
62765533|NCT04485689|PLACEBO_COMPARATOR|Placebo - alone|5x7 cm2 placebo patch alone
62765534|NCT04485689|EXPERIMENTAL|Capsaicin - ice|5x7 cm2 capsaicin patch - plus ice
62765535|NCT04485689|PLACEBO_COMPARATOR|Placebo - ice|5x7 cm2 placebo patch - plus ice
62765536|NCT01367392|EXPERIMENTAL|interventional procedure|The patients undergo the required interventional procedure, biopsy or ablation
62765537|NCT03384823|EXPERIMENTAL|EDP-938 SAD Cohorts|EDP-938 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration
62765538|NCT03384823|EXPERIMENTAL|EDP-938 MAD Cohorts|EDP-938 Dose 1, Dose 2, Dose 3, and Dose 4 oral suspension, once daily for 7 days
62765539|NCT03384823|PLACEBO_COMPARATOR|EDP-938 SAD Placebo Cohort|Matching placebo, oral suspension, once daily in one single administration
62765540|NCT03384823|PLACEBO_COMPARATOR|EDP-938 MAD Placebo Cohort|Matching placebo, oral suspension, once daily for 7 days
62765541|NCT04065594|EXPERIMENTAL|PRP dressing|
62384421|NCT04173169|OTHER|Pre-IVF Treatment with 60 day course of Placebo or SOC IVF|For those who agree to be randomized, subjects will be randomized to placebo, BID. The medication will be taken orally and subjects will be counseled to take the medication at the same time each day. This arm will also include participants who want to continue their ongoing or planned IVF and follow standard of care (SOC) (SOC IVF) if they do not want to delay the IVF procedure.
62384422|NCT04193137||Primary Aldosteronism(PA)|plasma aldosterone /renin ratio (ARR)\>10 pg/μIU and plasma aldosterone concentration(PAC) post-FST≥60pg/ml；or PAC\>200 pg/ml，plasma renin concentration(PRC)\<2.5μIU/ml，with hypokalemia
62558682|NCT05106179|ACTIVE_COMPARATOR|Previously treated + Propranolol|The investigators suppose the outcome might be compromised if patient has been previously treated, that's why it is going to be compared to the main cohort. The results are going to be analysed separately
62558683|NCT01000155|EXPERIMENTAL|Vorinostat|Patients received vorinostat in a pulsed fashion, once a day for 3 consecutive days every week to a maximum dose of 400 mg per dose (1200 mg/wk), for 12 to 16 weeks at the maximum dose. The first 3 patients were enrolled in an intrapatient dose escalation schedule of 100 mg/d, then 200 mg/d, each for 3 consecutive days a week for 4 weeks, and then 400 mg/d, 3 consecutive days per week for 16 weeks. The last 2 patients were enrolled to receive 400 mg/d, 3 consecutive days per week for 12 weeks, without an initial dose escalation.
62558684|NCT06581159|EXPERIMENTAL|Investigational Product|HS135 Subcutaneous Injection
62765542|NCT04065594|EXPERIMENTAL|conventional ordinary dressing|
62765543|NCT03059771|EXPERIMENTAL|Mobile Enhancement of Motivation (MEMS)|Facilitators will first collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006). Participants will then receive three sets of interactive text messages each weekday for eight weeks to reinforce and cue goal completion.
62765544|NCT03059771|ACTIVE_COMPARATOR|Control|Participants will only engage in a goal-setting session where facilitators will collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006).
62765545|NCT02631733|EXPERIMENTAL|Treatment (liposomal irinotecan, veliparib)|Patients receive liposomal irinotecan IV over 90 minutes on days 1 and 15 and veliparib PO BID on days 5-12 and 19-25 or 3-12 and 17-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Within 2-6 days prior to beginning liposomal irinotecan treatment, patients may optionally receive FMX IV and undergo MRI at baseline and 24 hours after FMX infusion.
62765546|NCT04591249|OTHER|Usual postoperative care|Participants randomized to usual care group will receive postoperative care as determined by their treating surgeon.
62765547|NCT04591249|EXPERIMENTAL|Usual postoperative care + Physical activity intervention|Participants randomized to the physical activity intervention group will receive usual postoperative care as determined by their treating surgeon and novel physical activity intervention.
62765548|NCT02279498|EXPERIMENTAL|Liprotamase|Individually-optimized dose to be administered orally
62765549|NCT02279498|ACTIVE_COMPARATOR|porcine (pig) PERT|Individually-optimized dose to be administered orally
62765550|NCT03217032|EXPERIMENTAL|YUVA-GT-F801|Gene transfer to treat Hemophilia A
62765551|NCT01020708|ACTIVE_COMPARATOR|Comparator|Mesalamine enema
62765552|NCT01020708|EXPERIMENTAL|ALTH12-1:4|ALTH12-1:4 experimental treatment dose
62765553|NCT01020708|EXPERIMENTAL|ALTH12-2:4|ALTH12-2:4 experimental treatment dose
62765554|NCT03130426|EXPERIMENTAL|Intervention|Drug: iGlarLixi - sc injection; Drug: metformin - oral administration; Drug: insulin glargine - sc injection; Behavioral: lifestyle therapy, diet and exercise
62765555|NCT03130426|NO_INTERVENTION|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
62765556|NCT04973345|EXPERIMENTAL|Terbutaline Arm A|• Arm A: (n=6) IV bolus (0.25 mg) over 5 minutes SQ administration (0.25 mg) Participants in Part 1 Arms A and B (n=12) will be randomized to one of two treatment arms.No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.
62765557|NCT04973345|EXPERIMENTAL|Terbutaline Arm B|• Arm B: (n=6) SQ administration (0.25 mg) IV bolus (0.25 mg) over 5 minutes Participants in Part 1 Arms A and B (n=12) will be randomized to one of two treatment arms.No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.
62765558|NCT04973345|EXPERIMENTAL|Terbutaline Arm C|• Arm C: (n=6) SQ (0.25 mg) IV low dose over 5 minutes IV medium dose over 5 minutes IV high dose over 5 minutes Participants in Part 2 (n=18) will be randomized to one of three treatment arms. To maintain masking the first treatment will be 0.25 mg of study drug SQ, followed by one of three IV dose regimes (low, medium, high) below, which are estimated to be 0.1 mg, 0.5 mg, 1.0 mg, but may be adjusted based on the interim analysis completed in Part 1. No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.
62168258|NCT06233045|EXPERIMENTAL|Sequence 2-Dapagliflozin reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Dapagliflozin tablet 10 mg test product, treatment 2= Dapagliflozin tablet 10 mg reference product.
62558685|NCT06581159|PLACEBO_COMPARATOR|Placebo|Subcutaneous Injection
62558686|NCT00469924|EXPERIMENTAL|Alerting system ON|Alerting system is ON
62558687|NCT00469924|NO_INTERVENTION|Alerting system OFF|Alerting system is OFF
62558688|NCT00998504|PLACEBO_COMPARATOR|placebo|starch pill
62168259|NCT03043950||low risk|Low risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
62558689|NCT00998504|ACTIVE_COMPARATOR|resVida|synthetic pill containing 75 mg of resveratrol
62558690|NCT03411863|ACTIVE_COMPARATOR|Participants without neurological disease|Participants without neurological disease. All subjects undergo the same full protocol.
62558691|NCT03411863|EXPERIMENTAL|Participants with ALS|Participants with ALS. All subjects undergo the same full protocol.
62558692|NCT06230042|EXPERIMENTAL|Parylene-Coated Catheter|The type of catheter used during a patient's indwelling urinary catheterization is Parylene-Coated Catheter
62558693|NCT06230042|ACTIVE_COMPARATOR|Silicone Catheter|The type of catheter used during a patient's indwelling urinary catheterization is Silicone Catheter
62765559|NCT04973345|EXPERIMENTAL|Terbutaline Arm D|• Arm D: (n=6)SQ (0.25 mg) IV medium dose over 5 minutes IV high dose over 5 minutes IV low dose over 5 minutes Participants in Part 2 (n=18) will be randomized to one of three treatment arms. To maintain masking the first treatment will be 0.25 mg of study drug SQ, followed by one of three IV dose regimes (low, medium, high) below, which are estimated to be 0.1 mg, 0.5 mg, 1.0 mg, but may be adjusted based on the interim analysis completed in Part 1. No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.
62765560|NCT04973345|EXPERIMENTAL|Terbutaline Arm E|• Arm E: (n=6) SQ (0.25 mg) IV high dose over 5 minutes IV low dose over 5 minutes IV medium dose over 5 minutes Participants in Part 2 (n=18) will be randomized to one of three treatment arms. To maintain masking the first treatment will be 0.25 mg of study drug SQ, followed by one of three IV dose regimes (low, medium, high) below, which are estimated to be 0.1 mg, 0.5 mg, 1.0 mg, but may be adjusted based on the interim analysis completed in Part 1. No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.
62765561|NCT02782325|ACTIVE_COMPARATOR|Active FMT, then open label FMT|Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
62765562|NCT02782325|PLACEBO_COMPARATOR|Placebo FMT, then open label FMT|Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
62765563|NCT03808363|EXPERIMENTAL|High Intensity Interval Training Group|Approximately eight individuals with spinal cord injuries will participate in high intensity interval training for 6 weeks
62765564|NCT05275946|OTHER|Treatment group|
62765565|NCT05610046|SHAM_COMPARATOR|Non-heated sauna session|The test days will consist of sitting in an infrared sauna cabin (HM-LSE-3 Professional edition, Health Mate, Belgium). Participants will sit in an infrared sauna at 21° Celsius for a total of 40 minutes.
62765566|NCT05610046|EXPERIMENTAL|Heated sauna session|The test days will consist of sitting in an infrared sauna cabin (HM-LSE-3 Professional edition, Health Mate, Belgium). Participants will sit in an infrared sauna at 60° Celsius (humidity not controlled in an infrared sauna) for a total of 40 minutes.
62765567|NCT03803813||sepsis group|Patients have developed sepsis at ICU admission or during their ICU stay.
62765568|NCT03803813||non-sepsis group|Patients do not develope sepsis at ICU admission or during their ICU stay.
62765569|NCT01634672||hemodialysis patients|
62765570|NCT01634672||Peritoneal dialysis patients|
62765571|NCT02287753|EXPERIMENTAL|Vascular occlusion test (VOT)|Pediatric patients aged under 8 years old are enrolled in this study. VOT is performed in 3 times : after induction of anesthesia, during cardiopulmonary bypass (CPB) for main surgical procedure and after weaning from CPB. The relationship between postoperative outcome variables and the dynamic parameters from VOT, such as desaturation and reoxygenation rate, and reactive hyperemic area, will be evaluated.
62765572|NCT05117021|EXPERIMENTAL|Group of Bupivacaine injection in Caudal block group|The children will receive of 0.25% plain bupivacaine infiltration as caudal block for post operative analgesia in infraumblical surgeries
62765573|NCT05117021|EXPERIMENTAL|Group 2 : Group of Bupivacaine injection in TAP block group|The children will receive of 0.25% plain bupivacaine infiltration as Transversus Abdominis Plane Block for post operative analgesia in infraumblical surgeries
62765574|NCT04139720|EXPERIMENTAL|e-book|e-book learning mode of sexual harassment prevention training
62765575|NCT04139720|NO_INTERVENTION|audio-visual and booklet|sexual harassment prevention audio-visual and booklet learning mode
62765576|NCT01502150||Pediatric Proton Therapy Patients|Data collection of MDACC patients under the age of 18 treated with proton radiotherapy. Proton dosimetry data collection, corresponding radiation dose distribution and imaging data in order to correlate normal tissue response with dose distribution.
62765577|NCT01988545|ACTIVE_COMPARATOR|GLP-1|1,5 nmol/kg,GLP-1 sc injection
62384423|NCT04193137||non Primary Aldosteronism|ARR\<10 pg/μIU or ARR\>10 pg/μIU and PAC post FST\<60pg/ml
62558694|NCT06385678|EXPERIMENTAL|Arm 1|For HRS-4642 in combination with Adebrelimab or in combination with Adebrelimab and chemotherapy for advanced solid tumors with KRAS G12D mutations.
62765578|NCT01988545|ACTIVE_COMPARATOR|GLP-1 9-36amide|1,5 nmol/kg GLP-1 9-36amide, sc injection
62765579|NCT01988545|ACTIVE_COMPARATOR|Exendin-4|Exendin-4 ;10 ug,sc injection
62765580|NCT01988545|PLACEBO_COMPARATOR|isotonic saline|2 ml of isotonic saline, sc injection
61989125|NCT02013167|ACTIVE_COMPARATOR|Standard of Care Chemotherapy|"Participants received one of four prespecified, investigator-chosen chemotherapy regimens for 2 induction cycles. Participants who achieved a bone marrow response, CR/CRh\*/CRi within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of SOC chemotherapy.~Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh\*/CRi could continue to receive SOC therapy for an additional 12 months."
62558695|NCT06385678|EXPERIMENTAL|Arm 2|For HRS-4642 in combination with SHR-A1921，for advanced solid tumors with KRAS G12D mutations.
61989126|NCT01318031|EXPERIMENTAL|DDI|
62384424|NCT02356042||Nursing home residents practicing GIA activity|
62384425|NCT02356042||Nursing home residents no practicing GIA activity|
62384426|NCT00724594|EXPERIMENTAL|N-acetylcysteine|Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.
62384427|NCT00724594|ACTIVE_COMPARATOR|Control|Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.
62765581|NCT00086502|ACTIVE_COMPARATOR|Sitagliptin 100 mg|Sitagliptin 100 mg
62765582|NCT00086502|PLACEBO_COMPARATOR|Placebo|Placebo
61989127|NCT03181854|EXPERIMENTAL|Intervention group|Consultation with PCT doctor every 3 weeks. Telephone coaching once a week for 3 months and once in 2 weeks for another 3 months.
62384428|NCT00581724||1|"First 50 breast cancer survivors and then after demonstrating feasibility of the study design in the first 50 participants, recruitment will be opened to the other services Colorectal, Genitourinary, Head and Neck, and Thoracic.~Participants will be recruited in allotments of 50 patients from each service."
62765583|NCT00461305|EXPERIMENTAL|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
62765584|NCT00461305|EXPERIMENTAL|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
62765585|NCT02953665|ACTIVE_COMPARATOR|Liraglutide|Liraglutide 6 mg/ml (Novo Nordisk A/S) will be self-administered subcutaneously once daily at a maximum dose of 1.8 mg after a 2 week titration schedule.
62765586|NCT02953665|PLACEBO_COMPARATOR|Placebo|Placebo will be self-administered subcutaneously once daily according to the same schedule.
62765587|NCT05252221|NO_INTERVENTION|Usual Care|"Usual Care (UC) will consist of treatment as usual, standard and systematic alcohol screening as part of the rooming process conducted by medical assistants, and brief interventions and referrals to addiction treatment delivered by PCPs. PCPs can also prescribe the same AUD medications as those in the ATC arm."
62765588|NCT05252221|ACTIVE_COMPARATOR|ATC Service (intervention)|"ATC components include in-exam-room, real-time videoconferencing or phone contact with the PCPs and their patients, asynchronous, rapid response consultation via email or phone. ATC consultants will offer a flexible service that includes:~1. Direct patient contact, via video or telephone, during primary care visits~2. Motivational Interviewing (MI) - informed facilitation of patient engagement in addiction treatment,~3. Advice to PCP regarding patient-specific treatment options, including pharmacotherapy, addiction treatment, and combined treatments"
62765589|NCT01866033|EXPERIMENTAL|PCI-32765|During Period 1, all patients will receive PCI-32765 560 mg administered by mouth (Treatment A). In Periods 2 and 3, patients will receive PCI-32765 560 mg administered by mouth without grapefruit juice (Treatment B) and PCI-32765 140 mg administered by mouth with grapefruit juice (Treatment C) according to a randomization schedule. An intravenous dose of 13C6 PCI-32765 will be administered 2 hours after each oral dose for reference purposes.
62765590|NCT04789694|NO_INTERVENTION|A|Patients will be provided with a basic information and standard of care support.
62765591|NCT04789694|EXPERIMENTAL|B|Active prehabilitation will be provided, composed of i) three physical activity-related interventions provided by a physical and rehabilitation medicine (PRM) specialist; iii) three 30 min consultations regarding nutritional status with physician or nutrition specialist; ii) three sessions with psychologist.
62765592|NCT01152515|NO_INTERVENTION|Control|stopping of propofol and remifentanil infusion
62765593|NCT01152515|ACTIVE_COMPARATOR|Remifentanil|stopping of propofol and maintenance of remifentanil infusion
62765594|NCT01551277|PLACEBO_COMPARATOR|Control Group|
62765595|NCT01551277|EXPERIMENTAL|BREATH STACKING|
62384429|NCT02716532|OTHER|Peptamen AF|over 7 days
62384430|NCT02607735|EXPERIMENTAL|SOF/VEL/VOX (Primary Study)|SOF/VEL/VOX for 12 weeks
62558696|NCT04492228|EXPERIMENTAL|Ketogenic diet group|patients with COVID-19 feeding with a ketogenic diet (4.1 formula)
62765596|NCT04346030|EXPERIMENTAL|steroid and hydrodissection|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
62384431|NCT02607735|EXPERIMENTAL|Placebo (Primary Study)|Placebo to match SOF/VEL/VOX for 12 weeks
62384432|NCT02607735|EXPERIMENTAL|SOF/VEL/VOX (Deferred Treatment Substudy)|SOF/VEL/VOX for 12 weeks for eligible participants initially randomized to receive placebo
62384433|NCT00195702|EXPERIMENTAL|DB adalimumab 20 mg ew|Subjects received 20 mg adalimumab subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.
62384434|NCT00195702|EXPERIMENTAL|DB adalimumab 40 mg eow|Subjects received 40 mg adalimumab subcutaneously (SC) every other week (eow) and concomitant methotrexate (MTX) during the double-blind (DB) phase. Subjects received placebo injections SC and concomitant MTX on the alternate weeks during the DB phase.
62558697|NCT04492228|NO_INTERVENTION|Standard diet group|patients with COVID-19 feeding with a standard diet
61989128|NCT03181854|NO_INTERVENTION|Control Group|Usual palliative care can be provided if desired.
62168260|NCT03043950||medium risk|Medium risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
62168261|NCT03043950||high risk|High risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
62384435|NCT00195702|PLACEBO_COMPARATOR|DB placebo ew|Subjects received placebo subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.
62558698|NCT03479398||App Condition|Although we will be mostly observing routine practice, we will randomize patients into either an App condition or paper condition. The App condition refers to patients completing routine Cognitive Behavioral Therapy (CBT) worksheets on a mobile application during session. Everything else that occurs in treatment sessions will be consistent with routine care practices.
62765597|NCT04346030|ACTIVE_COMPARATOR|steroid only|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine)
62765598|NCT02008422|EXPERIMENTAL|Oxaliplatin & Endostar injection|Oxaliplatin, 130 mg/m2 , iv, 3-4h, d1; Gimeracil and Oteracil Potassium Capsules, 40 mg/m2, po., Bid., d1-14; Endostar injection, 7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10; 21 d as a cycle.
62765599|NCT02008422|ACTIVE_COMPARATOR|Oxaliplatin|Oxaliplatin, 130 mg/m2 , iv, 3-4h, d1; Gimeracil and Oteracil Potassium Capsules, 40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
62765600|NCT01038726|ACTIVE_COMPARATOR|Exercise Training|
62765601|NCT01038726|ACTIVE_COMPARATOR|Combined Cognitive/Exercise Training|
62765602|NCT01038726|ACTIVE_COMPARATOR|Cognitive Training|
62765603|NCT01038726|ACTIVE_COMPARATOR|Combined Low Intensity Training|
62765604|NCT02458547|EXPERIMENTAL|Group D|General anesthesia with desflurane
62765605|NCT02458547|ACTIVE_COMPARATOR|Group P|General anesthesia with propofol total intravenous anesthesia
62384436|NCT00195702|EXPERIMENTAL|DB adalimumab 20 mg ew/OL adalimumab 40 mg eow|Subjects received adalimumab 20 mg subcutaneously (SC) once weekly (ew) during the double-blind (DB) phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
62384437|NCT00195702|EXPERIMENTAL|DB adalimumab 40 mg eow/OL adalimumab 40 mg eow|Subjects received adalimumab 40 mg subcutaneously (SC) every other week (eow) with placebo on alternate weeks during the double-blind (DB) phase, then adalimumab 40 mg SC eow during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
62384438|NCT00195702|EXPERIMENTAL|DB placebo ew/OL adalimumab 40 mg eow|Subjects received placebo subcutaneously (SC) once weekly (ew) during the double-blind phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
62765606|NCT02458547|ACTIVE_COMPARATOR|Group S|Spinal anesthesia with 0.5% bupivacaine
62765607|NCT03358641||Wuchuan residents|All residents that meet the criteria can be enrolled in this group, receiving a home interview (including IPA-Q to assess the level of physical activity) and a weight-bearing posteroanterior semiflexed view of radiographs at tibiofemoral (TF) joints at baseline and 3 years later.
62765608|NCT06508372|EXPERIMENTAL|topical thymoquinone ointment|One plaque on one side of the body per every patient will be selected, whose diameter would not exceed 5-10 cm2 to apply Thymoquinone ointment as a monotherapeutic ttt twice daily for 3 months.
62765609|NCT06508372|PLACEBO_COMPARATOR|topical placebo ointment|In each patient a single similar psoriatic plaque on the other side of the body \[as regard anatomical site, size and TES (thickness, erythema, scales) score\] will be treated with placebo ointment twice daily for 3 months as a control.
62765610|NCT02795013||Participants with Hodgkin Lymphoma|Those with a confirmed diagnosis of Hodgkin Lymphoma (HL) and family members who consent and enroll in this study.
62765611|NCT02795013||Family Members without Hodgkin Lymphoma|Those unaffected by HL will serve as a control group to compare with those with HL.
62765612|NCT05995977|EXPERIMENTAL|Intervention Group that applied nursing interventions|The intervention consists of two components and is planned to last 14 weeks. The first component consists of hypertension education based on the Protection Motivation Theory. The second component is the sending of regularly delivered Protection Motivation Theory-based SMS messages aimed at reminding, encouraging and motivating patients to maintain medication adherence and healthy lifestyle changes.
62765613|NCT05995977|NO_INTERVENTION|Individuals who do not apply nursing interventions based on protection motivation theory|Control Group: Individuals who did not apply nursing interventions based on protection motivation theory in patients with hypertension
62384439|NCT03784716|EXPERIMENTAL|Ketogenic Diet|Ketogenic Diet for 28 Days
62384440|NCT03784716|ACTIVE_COMPARATOR|Standard Weight Loss Diet|Standard Weight Loss Diet for 28 Days
62384441|NCT00144456|EXPERIMENTAL|1|
62384442|NCT00144456|ACTIVE_COMPARATOR|2|
62384443|NCT00833066|PLACEBO_COMPARATOR|Placebo|
62384444|NCT00833066|EXPERIMENTAL|gpASIT 25|
62765614|NCT03504566|OTHER|Intervention|All patients recieve, in randomomized order a four way treatment schedule. Due to the nature of the study, the individual patient will serve as his/hers own comparator.
62765615|NCT00595933|EXPERIMENTAL|1|Each participant will receive an unidentified product to use for a one week period. This will continue until all 7 dry-mouth products have been evaluated.
62765616|NCT04207918|EXPERIMENTAL|Neoadjuvant Chemoradiotherapy（NCRT）|NCRT arm receives intensity-modulated radiotherapy concurrently with S-1（40-60/m2/d，orally twice a day） and nimotuzumab（400mg/d，by intravenous infusion once a week）.
62765617|NCT01516567|EXPERIMENTAL|DA-EPOCH-R|6 courses of Dose Adjusted-EPOCH-Rituximab
62765618|NCT00386477|EXPERIMENTAL|Vag prep|Vagina cleansed prior to performing cesarean
62765619|NCT01765075||Patients undergoing cardiac ablation for permanent AF|
62765620|NCT01433341||Young athletes|
62765621|NCT01638559|EXPERIMENTAL|Immunosuppression withdrawal|Gradual withdrawal of immunosuppressive treatment withdrawal as per protocol.
62765622|NCT06147687||Patients with endometriosis and Healthy controls|5 000 people with endometriosis will be enrolled and followed up for 1one year. To participate in the study, the women must meet the inclusion criteria.
62765623|NCT06147687||Control|5 000 people in a control group will be enrolled and followed up for 1one year. To participate in the study, the women must meet the inclusion criteria.
62765624|NCT05953948|EXPERIMENTAL|Intelligent case manage platform (ICMP) and self-management program|The experimental group received ICMP information. They could interact with the care manager via chatbot. The ICMP was established with information related to care instruction after liver transplantation.
62765625|NCT05953948|NO_INTERVENTION|usual care|Participants in the control only received the usual care that included wound care, medication, and infection control.
62765626|NCT01903889|ACTIVE_COMPARATOR|Clinic based intervention|basic intervention is introduced, whereby HIV/AIDS providers are trained on contraception for HIV-positive women. They are charged with counseling C\&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
62765627|NCT01903889|EXPERIMENTAL|clinic and community based intervention|The basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services. This includes training of C\&T providers on gender-based influences on health behaviors; provision of couples' HIV testing and FP counseling services; and community-based education for men to promote gender equitable norms and male participation in health services.
62384445|NCT00833066|EXPERIMENTAL|gpASIT 100|
62765628|NCT01562405|EXPERIMENTAL|ACE-011 (sotatercept)|ACE-011, Lenalidomide or pomalidomide, Dexamethasone
62765629|NCT05308498||ESView software with ProScan|evaluate the performance of the NaviCam SB Capsule System ProScan software feature in comparison with the PillCam SB3 Capsule system SBI feature
62765630|NCT05308498||Rapid software with SBI|evaluate the performance of the NaviCam SB Capsule System ProScan software feature in comparison with the PillCam SB3 Capsule system SBI feature
62765631|NCT02227823|EXPERIMENTAL|significant decrement|Patients with significant decrement at electromyogram will be treated by pyridostigmine bromide 60mg 3 times a day for patients older than 18 and 1.5mg/kg 3 times a day for children less than 40kg
62765632|NCT02227823|NO_INTERVENTION|no decrement|Patient without significant decrement will not receive any treatment and will be the control group
62765633|NCT04921085||adult inpatients|adult inpatients with 7 categories of diseases (including digestive system, respiratory system, cardiovascular and endocrine system, tumor, nervous system, and urinary system)
62765634|NCT00419315|EXPERIMENTAL|Alcohol Care Management|Care management for alcohol dependence delivered in primary care
62765635|NCT00419315|ACTIVE_COMPARATOR|Usual Care|Usual care included a referral to specialty addiction treatment
62765636|NCT03445910|EXPERIMENTAL|Human chorionic gonadotrophin|The hCG Group included 50 patients who had an intrauterine injected of 500 IU of hCG on the day of ovum pick-up
62765637|NCT03445910|NO_INTERVENTION|control|The Control Group included 50 patients who went through the ICSI conventional protocol without intrauterine injection.
62765638|NCT00692068||A|with residual renal function
62765639|NCT00692068||B|without residual renal function
62765640|NCT01274611|ACTIVE_COMPARATOR|Suction-Curettage|
62384446|NCT00833066|EXPERIMENTAL|gpASIT 400|
62384447|NCT00411606||1|Subjects with no allergies
62567670|NCT06217705|OTHER|Delayed Receipt of Project Calm Control Condition|No intervention for first two months; will receive Project Calm after 2-months and become a second-wave intervention condition.
62765641|NCT01274611|EXPERIMENTAL|Botox|
62765642|NCT05275322|EXPERIMENTAL|Treatment group|
62765643|NCT05275322|NO_INTERVENTION|Waiting list group|
62765644|NCT03816683||Single cohort (registry) of MCL patients|Patients diagnosed with MCL who have initiated a novel therapy meeting inclusion/exclusion criteria in the past 6 months and treatment is ongoing at the time of enrollment.
62765645|NCT02920957|ACTIVE_COMPARATOR|comfilcon A|Participants are randomized to wear the comfilcon A lens for one month during the cross over study.
62765646|NCT02920957|ACTIVE_COMPARATOR|senofilcon C|Participants are randomized to wear the senofilcon C lens for one month during the cross over study.
62765647|NCT02273570|ACTIVE_COMPARATOR|control|Control group: standard care. The iPTH target in this group is 300-540 pg/ml
62765648|NCT02273570|EXPERIMENTAL|Optimal CKD-MBD control|Optimal CKD-MBD control: in this group the PTH target is150-300 pg/ml to be achieved with a therapeutic algorithm
62765649|NCT03858504|EXPERIMENTAL|Yoga Group|The yoga program will include breathing exercises, different postures, and meditation. The yoga will be performed in groups. The program will be supervised a physical therapist for two times in a week for eight weeks . A session will be fifty minutes (5-10 minutes: warming-up, 20-25 minutes: postures, 10-15 minutes: cooling down).
62384448|NCT02757651|EXPERIMENTAL|Radiotherapy + radiation sensitizer|Patients in phase I and patients randomised to the test group in phase II will receive standard radiotherapy for breast cancer + a radiation sensitizer
62765650|NCT03858504|ACTIVE_COMPARATOR|Home Exercise Group|Home exercise program will consist of trunk strengthening exercises. The patients will be asked to check the exercise days. Patients will be contacted with telephone once a week.
62765651|NCT05184790||Brain cancer|Patients having radiation therapy for treatment of brain cancer.
62765652|NCT05184790||Breast cancer|Patients having radiation therapy for treatment of breast cancer.
62765653|NCT05184790||Head and neck cancer|Patients having radiation therapy for treatment of head and neck cancer.
62765654|NCT05184790||Kidney cancer|Patients having radiation therapy for treatment of kidney cancer.
62765655|NCT05184790||Liver cancer|Patients having radiation therapy for treatment of liver cancer.
62765656|NCT05184790||Pancreatic cancer|Patients having radiation therapy for treatment of pancreatic cancer.
62765657|NCT05184790||Prostatic cancer|Patients having radiation therapy for treatment of prostate cancer.
62765658|NCT05184790||Spinal neoplasm|Patients having radiation therapy for treatment of spinal cancer.
62765659|NCT05184790||Cardiac arrhythmia|Patients having radiation therapy for treatment of cardiac arrhythmia
62765660|NCT05996614|EXPERIMENTAL|group with PRP|Group of patients with post burn raw areas treated with application of platelet rich plasma
62765661|NCT05996614|EXPERIMENTAL|group without PRP|Group of patients with post burn raw areas treated with conventional methods
62765662|NCT04673916|ACTIVE_COMPARATOR|Clobetasol treatment|The clobetasol group was treated with clobetasol propionate 0.05%, while the anti-inflammatory group was treated with mouthwash. The drug used consisted of Clobetasol propionate 0.05%, Ethyl alcohol 96° (50%), Hydroxyethylcellulose (4%); Preserved water (just enough to 100%) that was topically applied \[11\]. This drug was produced as a galenic formulation. Clobetasol propionate twice a day (every 12 hours) to the lesions with a soft bristle brush and were advised not to drink or eat during the hour following application of the medication.
62765663|NCT04673916|ACTIVE_COMPARATOR|Anti-inflammatory mouthwash|In patients of the anti-inflammatory group, the mouthwash was used pure and without dilution at a dosage of 20 ml 3 times a day, immediately after normal daily oral hygiene was prescribed. It contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins. Patients were instructed to rinse for at least 5 minutes over the entire oral mucosa, with particular emphasis on the regions where the lesions are located.
62765664|NCT02994693||OFDI capsule imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
62765665|NCT01969500|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as usual includes outpatient case management, linkage to services and medication monitoring.
62765666|NCT01969500|EXPERIMENTAL|Mobile Application|Mobile Application system designed to improve coping with psychotic symptoms, social functioning, and medication adherence.
62765667|NCT00591669|EXPERIMENTAL|1|IBD patients
62765668|NCT00591669|OTHER|2|Control subjects
62765669|NCT06013280|EXPERIMENTAL|Relaxing Exercise Group|Relaxing exercise group participants applied 40 minutes of progressive muscle relaxation and breathing exercises, 3 times a week for 4 weeks
62765670|NCT06013280|NO_INTERVENTION|Control Group|This group received no intervention, continued their daily life as usual.
62765671|NCT06406803|EXPERIMENTAL|Dietary energy restriction|
62765672|NCT06406803|EXPERIMENTAL|Daily exercise|
62765673|NCT06406803|NO_INTERVENTION|Control|
62765674|NCT03329963|EXPERIMENTAL|Lifestyle intervention Group|Behavioral therapy for weight loss and Exercise Training
62765675|NCT03329963|ACTIVE_COMPARATOR|Healthy lifestyle intervention Group|Group education sessions that focus on diet exercise and social support.
62765676|NCT00589810||Controls|Controls = Patients in Genebank that had BMS placed that did not go on to have ISR within 1 year of BMS placement and have not had prior ISR in any vessel ever. If testing is available, the Control status will be further verified by angiographic documentation of \<50% luminal loss with the stent or negative stress test six or more months after stenting.
62765677|NCT00589810||Cases|Cases = Patients in Genebank that had BMS placed that went on to have ISR which is defined as PCI or CABG to the Target Vessel within 1 year of the BMS placement.
62765678|NCT00849875|EXPERIMENTAL|Group A|All patients are to receive the same treatment consisting of 24 injections of the immunotherapeutic GSK2132231A combined with a course of 8 cycles of dacarbazine given at the beginning of the treatment
62765679|NCT01617447|PLACEBO_COMPARATOR|Placebo|administered orally once daily
62765680|NCT01617447|EXPERIMENTAL|Aripiprazole|administered orally once daily
62765681|NCT02421601|EXPERIMENTAL|SI-6603|SI-6603: SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
62765682|NCT01164332|OTHER|Method A|First experimental detection method
62765683|NCT01164332|OTHER|Method B|Second experimental detection method
62765684|NCT01711866|EXPERIMENTAL|Rotigotine|"First application of Rotigotine patch for 24 hours on Day 1, followed by application of a new patch each day of the Treatment Period.~* Subjects on lower doses switch from Pramipexole or Ropinirole to equivalence doses of Rotigotine on Day 1 of the 28 days Treatment Period. On Day 8 (Visit 3) the dose will be evaluated and potentially adjusted up to a maximum dose of 8 mg / 24 hours.~* Subjects on higher doses switch from the equivalent dose to 8 mg / 24 hours Rotigotine of Pramipexole or Ropinirole to 8 mg / 24 hours Rotigotine on Day 1 and the remainder of the dose of Pramipexole or Ropinirole is to be switched on Day 8 of the 28 days Treatment Period. On Day 15 (Visit 4) the dose will be evaluated and potentially adjusted up to a maximum dose of 16 mg / 24 hours."
62765685|NCT05929339|EXPERIMENTAL|Intravenous Oxytocin|Two 30 minute infusion of oxytocin, 17 micrograms with will be administered. The second infusion will be given 30 minutes after the completion of the first infusion.
62765686|NCT01586104|EXPERIMENTAL|Treatment (IMRT)|Patients undergo cardiac-sparing whole lung IMRT.
62765687|NCT05749354|EXPERIMENTAL|liver meridian group|Four acupoints; LR3 Taichong, LR5 Ligou, LR8 Ququan, and LR12 Jiman. Based on the national standard of the People's Republic of China in 2006 (GB/T 12346-2006). The patient will be in a supine position. Taichong will be punctured at a 25-mm depth using a 0.35×25-mm filiform needle, Ligou will be punctured at a 15-20-mm depth with a 0.35×25-mm filiform needle, Ququan at a 20-25-mm depth with a 0.30×40-mm filiform needle, and an acute pulse of 15-20 mm. Each acupoint will be subject to a small amount of uniform lifting and twisting to the degree of local acid distension. An auxiliary needle (0.16×13 mm) will be inserted approximately 5 mm into the needle, 2 mm proximal to the heart of each acupoint along the meridian. The negative electrode will be connected to the main point, and the positive electrode will be connected to the auxiliary needle, and connect the electroacupuncture instrument. The needles will be retained for 30 min respectively, once every other day, 24 treatments.
62765688|NCT05749354|ACTIVE_COMPARATOR|stomach meridian group|Four acupoints have been selected for the gastric meridian group, including ST42 Chongyang, ST40 Fenglong, ST36 Zusanli, and ST31 Biguan. The acupoint locations are based on the national standard of the People's Republic of China in 2006 (GB/T 12346-2006). The patient will be supine during the procedure, and the needles will be routinely sterilized. Straight needling will be performed in the hip region using a 0.30×50-mm-filiform needle, a 0.30×50-mm filiform needle in Zusanli, and a 0.30×40-mm filiform needle in Fenglong. A 0.35×25-mm filiform needle will be used to stimulate Chongyang for 10-15 mm, and each acupoint will be gently and evenly lifted, inserted, and twisted to local acid distension. Electroacupuncture will be applied in the same manner as for the liver meridian group. The needles will be retained for 30 min respectively, once every other day, then thrice weekly for a total of 24 treatments in the three groups.
62765689|NCT05749354|PLACEBO_COMPARATOR|non-acupoint group|Four points: (1) On the lateral thigh, between the vastus lateralis and biceps femoris, the midpoint of the popliteal stria, and the highest point of the greater trochanter. (2) On the lateral side of the calf, beside the level of Zusanli, and at the lateral edge of the tibia. (3) On the fibular side of the calf, the midpoint of the stomach meridian, and the bile meridian, 3 cm above the tip of the lateral malleolus and in front of the hanging bell. (4) On the lateral side of the calcaneus, and the servant enters the midpoint of the line connecting the posterior edge of the calcaneus at the same level. The 0.30×25-mm filiform needles are inserted straight for 3-5 mm at the points, the needles can stand without Deqi. The auxiliary needle will be inserted and electroacupuncture will be connected (same as in the other group). The internal wire of the electroacupuncture instrument will be interrupted, no current passed through. The treatment time is the same as the other two groups.
62765690|NCT02427724|ACTIVE_COMPARATOR|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
62765691|NCT02427724|ACTIVE_COMPARATOR|lidocaine 7%/tetracaine 7% topical anesthetic|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
62765692|NCT02427724|PLACEBO_COMPARATOR|placebo vehicle|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
62765693|NCT00450736|EXPERIMENTAL|Single Arm|
62765694|NCT05205369|EXPERIMENTAL|Yi Jin Bang group|Participants in this group will perform a 10-week home-based Yi Jin Bang exercise program.
62765695|NCT05205369|EXPERIMENTAL|Usual exercise therapy group|Participants in this group will perform a 10-week home-based usual exercise therapy program.
62765696|NCT05205369|NO_INTERVENTION|Waitlist control group|Participants in the waitlist control group will be informed that they will receive either Yi Jin Bang training or exercise therapy after ten weeks have passed. This will be done only for motivational reasons and not for evaluation.
62765697|NCT06226168|NO_INTERVENTION|Control group|The control group will not undergo the training program.
62765698|NCT06226168|EXPERIMENTAL|Training in normobaric hypoxia|Training performed under normobaric hypoxia (Week I-1600m above sea level; Week II-1800m above sea level; Week III-2200m above sea level; Week IV-2600m above sea level) and thermoneutral conditions (21°C) and constant humidity (40%).
62765699|NCT06226168|EXPERIMENTAL|Training in normoxia|Description: Training performed in normoxia (223 m above sea level) and thermoneutral conditions (21°C) and constant humidity (40%).
62765700|NCT06226168|EXPERIMENTAL|Passive exposure to normobaric hypoxia|Passive exposure to normobaric hypoxia conditions (Week I -1600m above sea level; Week II -1800m above sea level; Week III -2200m above sea level; Week IV-2600m above sea level) and thermoneutral conditions (21°C) and constant humidity (40%).
62765701|NCT04129710|EXPERIMENTAL|I-MRE|"Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.~Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.~Rituximab 375 mg/m2 conventional infusion d1.Etoposide 250 mg/m2 over 3 hours on day3.~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol."
62765702|NCT04129710|EXPERIMENTAL|L-MRE|"Oral lenalidomide 25mg/day (starting dose) between days 4 and 24 of each cycle for six cycles.Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.~Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.~Rituximab 375 mg/m2 conventional infusion d1.~Etoposide 250 mg/m2 over 3 hours on day3.~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol."
61989129|NCT01191580|EXPERIMENTAL|Interpersonal Psychotherapy|Interpersonal Psychotherapy is a brief, manualized therapy that has shown efficacy in treating major depression in several controlled trials including a large trial for depressed HIV-infected individuals and other randomized trials in depressed individuals with other comorbid medical illnesses. Research shows that Interpersonal Psychotherapy improves social skills and functioning. Interpersonal Psychotherapy has shown remarkable flexibility and efficacy across age ranges, cultures, formats, and modes of delivery. We recently obtained promising pilot data in a small open trial on the acceptability and efficacy of individual IPT for depressed breast cancer patients of diverse ethnic background, socioeconomic status, and cancer progression stage.
62384449|NCT02757651|NO_INTERVENTION|Radiotherapy alone|Patients randomised to the control group in phase II will receive standard radiotherapy for breast cancer alone.
62384450|NCT01326481|EXPERIMENTAL|Single|All patients received TRC105 + capecitabine
62765703|NCT04129710|ACTIVE_COMPARATOR|MRE|"Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.~Rituximab 375 mg/m2 conventional infusion d1.~Etoposide 250 mg/m2 over 3 hours on day3.~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol.~Patients who will not achieve SD or better after the 4th course, as well as those who will experience Progressive Disease (PD) at any time will be randomly allocated to the Experimental groups."
62765704|NCT04942223|OTHER|Subjects undergoing virtually planned GBR for extended and complex alveolar defects.|"Subjects undergoing virtually planned GBR for extended and complex alveolar defects.~The subjects were selected from the population of patients referring to the Oral \& Maxillofacial Surgery Unit of S.Orsola-Malpighi University Hospital for oral function rehabilitation. Eligibility criteria were: the presence of horizontal and vertical alveolar defects in both jaws, inadequate for the placement of at least two fixtures, even ≤6 mm long ones; ≥ 18 years; informed consent signed."
62765705|NCT04361890|OTHER|Women with predominant SUI|All women with predominant SUI will be referred to a physiotherapist for PFMT as usually. They will have an ultrasound evaluation before and after the session
62765706|NCT02459275|EXPERIMENTAL|PEP uP Protocol|Participants will receive the PEP uP protocol with the pro motility agent. The intervention will be provided until the tube feeds are stopped or patient is fed meals orally and will be tracked until hospital discharge or 60 days which ever occur first.
62765707|NCT02459275|NO_INTERVENTION|Standard of Care|Standard formula polymeric tube feeds started at a rate of 20 ml/hour. Gastric residual volume (GRV) will be checked every 4 hours. GRV is reinfused to the patient each time it is checked. GRV threshold is 200-500 ml. If the patient is tolerating tube feeds as determined by measuring the GRV, the rate is advanced by 20 ml/hour every 4 hours up to the goal rate. Participants will be followed until the tube feeds are stopped or patient is fed meals orally and will be tracked until hospital discharge or 60 days which ever occur first.
62765708|NCT01656226|EXPERIMENTAL|Eryfotona AK-NMSC® cream|
62765709|NCT01656226|OTHER|Sunscreen SPF 50+|
62765710|NCT01883752|NO_INTERVENTION|Control|Baseline crystalloid infusion of 5 mL/kg/hr of body weight.
62765711|NCT01883752|EXPERIMENTAL|Goal-directed Therapy group|Goal-direct therapy
62765712|NCT06105359|EXPERIMENTAL|experimental group|Patients in this group will be treated with dignity therapy by the researcher.
62765713|NCT06105359|ACTIVE_COMPARATOR|control group|Patients in this group will receive standard care and no treatment will be performed by the researcher.
62765714|NCT00964847|ACTIVE_COMPARATOR|Blood pressure education/walking program|
62765715|NCT00964847|ACTIVE_COMPARATOR|Combined intervention|
62765716|NCT00964847|EXPERIMENTAL|Yoga Exercise Program|
62765717|NCT02270723|ACTIVE_COMPARATOR|"Human Albumin  Behring"|Infusion of 5% Human Albumine, maximal 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
62765718|NCT02270723|PLACEBO_COMPARATOR|Lactated Ringer|Infusion of Lactated Ringer solution 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
62765719|NCT00908115||Infanrix Group|Subjects received one dose of Infanrix™ at 2, 4 and 6 months of age (primary vaccination), one dose at 15-18 months of age (booster vaccination) and one dose at 4-6 years of age (booster vaccination).
62765720|NCT06110455|EXPERIMENTAL|Neuromuscular Exercise Training (NMT)|"The 8-week exercise intervention program consists of group sessions of Neuromuscular training supervised by a physical therapist 3 times per week. Patients will be taught and familiarized with the proper way to do the exercises on a separate day prior to the start of their actual rehabilitation program.~Each session consists of a 5 minute submaximal warm-up followed by 25 minutes of NMT.~Every 2 weeks, there will be a progression that will be achieved by increasing the difficulty level of each exercise. We will take under consideration the individuality each patient has on how much progression is needed every two weeks and it will be done by maintaining a proper quality of performance, minimal exertion and control of the movement. Participants will be given special equipment including sliders and elastic tubing"
62765721|NCT06110455|EXPERIMENTAL|Progressive Resistance Training (PRT)|"The 8-week exercise intervention program consists of group sessions of progressive resistance training supervised by a physical therapist 3 times per week. Patients will be taught and familiarized with the proper way to do the exercises on a separate day prior to the start of their actual rehabilitation program.~Each session consists of a 5 minute submaximal warm-up followed by 25 minutes of PRT, targeting hip and knee muscles, such as hip abductors, knee flexors and extensors. The exercise intensity will be monitored by the physical therapist, as determined by the patients' ability to complete 3 sets of 8-12 repetitions for a given exercise and a Borg Rating of Perceived Exertion (RPE) of 6-8.~Every 2 weeks, progression will be achieved by changing the resistance based on VAS and RPE, with an elastic tubing"
62765722|NCT05665400|EXPERIMENTAL|Bloomlife Lovelace FT|
61989130|NCT01191580|EXPERIMENTAL|Problem-Solving Therapy|Problem-Solving Therapy is a brief, manualized form of cognitive-behavioral therapy (CBT) that has been adapted to treat depression in cancer patients, and has shown highly promising results.
62168262|NCT02921438||Chest pain patients presenting to the ED|All patients that present to the emergency department with chest pain and potentially other symptoms consistent with ACS and meet all eligibility criteria will undergo VitalScan Magnetocardiograph.
62384451|NCT02532998|EXPERIMENTAL|Treatment Sequence 1|Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
62558699|NCT03479398||Paper Condition|Although we will be mostly observing routine practice, we do randomize patients into either an App condition or paper condition. The paper condition refers to patients completing routine CBT worksheets on paper (the current standard) during session.
62765723|NCT01689545|EXPERIMENTAL|Individual level|
62765724|NCT01689545|EXPERIMENTAL|Structural level|
62765725|NCT01689545|EXPERIMENTAL|Combined individual & structural level|
62765726|NCT01689545|ACTIVE_COMPARATOR|Standard of Care|
62765727|NCT06518707|NO_INTERVENTION|Control group|No intervention will be performed; all protocols during surgery will follow the clinical routine.
62765728|NCT06518707|EXPERIMENTAL|PNS + TOF 0|Patients in this group will receive PNS during surgery, with the train-of-four (TOF) maintained at a level of 0. Additionally, to ensure complete blockade of the neuromuscular system, the Post-Tetanic Count (PTC) will be monitored and maintained at less than or equal to 3 simultaneously.
62765729|NCT06518707|EXPERIMENTAL|PNS + TOF 1-2|Patients in this group will receive PNS during surgery, and the TOF will be maintained at levels 1-2. In this group, the neuromuscular junction will not be fully blocked.
62765730|NCT06103929||Adults referred to eating disorder services|A cohort of adults referred to a specialist adult eating disorders service will be recruited. A stratified sample of patients will be approached about participating in the study, providing the study inclusion criteria are met, and their responsible clinician does not express concerns about their participation. All study participants will be assessed with the SCAN semi-structured interview (including version 2 of the SCAN, SCANv3s0, SCANv3s1, and SCANv3s9) and will also complete two self-completion measures, the EDE-QS and the SCOFF, randomly ordered. The SCAN items will be asked about in the context of the past 4 weeks and the directly preceding 11 months (i.e., the past year), unless otherwise stated. Additionally, a subset of study participants (n = 25) will be reassessed with the SCANv3s0, SCANv3s1, SCANv3s9, EDE-QS, and SCOFF, for test-retest reliability.
62765731|NCT04411537|EXPERIMENTAL|Treatment Arm|A total of 50 MSS LARC patients will receive 2 cycles of PD-1 antibody, followed by capecitabine plus irinotecan radiosensitized neoadjuvant chemoradiotherapy, and another 3 cycles of PD-1 antibody, finally received the total mesorectal excision (TME) and 6 cycles of adjuvant chemotherapy of XELOX.
62765732|NCT00281190||Healthy smokers|Smokers with normal pulmonary function
62765733|NCT00281190||COPD patients|COPD patients
62765734|NCT00369694|ACTIVE_COMPARATOR|1|72 hours of Terlipressin
62765735|NCT00369694|PLACEBO_COMPARATOR|2|24 hours of Terlipressin \& then next 48 hours of Dummy of Terlipressin
61989131|NCT01191580|ACTIVE_COMPARATOR|Brief Supportive Psychotherapy|Brief Supportive Psychotherapy, a relatively unstructured psychotherapy commonly used in clinical practice, focuses on the patient's affect. It builds a strong therapeutic alliance through careful, empathic listening and validating and encouraging toleration of the patient's emotions. It has shown promising results in depressed individuals with cancer and other medical illnesses.
61989132|NCT04404738|EXPERIMENTAL|MicroPort® Surgical System|robot-assisted surgeries, for instance, prostatectomy, cystectomy or nephrectomy will be performed using MicroPort® surgical system
61989133|NCT04404738|ACTIVE_COMPARATOR|da Vinci Surgical System|robot-assisted surgeries, for instance, prostatectomy, cystectomy or nephrectomy will be performed using da Vinci surgical system
61989134|NCT00089349|EXPERIMENTAL|Arm I|"Course 1: Patients receive alemtuzumab IV over 2 hours on days 1-5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission (CR), partial remission (PR), or cytolytic PR at day 29, or patients with CNS disease that achieve a CNS 1 or CNS 2 status, proceed to course 2.~Courses 2 and 3: Patients receive alemtuzumab IV over 2 hours on days 1, 8, 15, and 22; methotrexate IV continuously over 24 hours on day 1 and then orally once daily on days 8, 15, and 22; and oral mercaptopurine once daily on days 1-28. Patients with a CR or PR at day 29 proceed to course 3. In course 3, patients receive alemtuzumab, methotrexate, and mercaptopurine as in course 2.~CNS prophylaxis\*: Patients receive methotrexate intrathecally on day 1 of courses 2 and 3 on day 1 of courses 2 and 3.~NOTE: \* CNS-negative patients receive methotrexate intrathecally on day 15 of course 1 and day 1 of courses 2 and 3."
62765736|NCT04668924|EXPERIMENTAL|Epi-on PiXL in high oxygen|Photorefractive intrastromal corneal crosslinking without epithelium debridement during humidified high oxygen flow.
62765737|NCT03693339|EXPERIMENTAL|Capmatinib|Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
62765738|NCT01203358|ACTIVE_COMPARATOR|Surfactant 1|Exosurf Neonatal (Burroughs Wellcome Co.)
62765739|NCT01203358|ACTIVE_COMPARATOR|Surfactant 2|Survanta (Ross Laboratories)
62765740|NCT03381417|EXPERIMENTAL|Pegcyte (Nanogen pegfilgrastim)|6 mg in each cycle
62765741|NCT03381417|ACTIVE_COMPARATOR|Neulastim (Roche pegfilgrastim)|6 mg in each cycle
62765742|NCT00343915|EXPERIMENTAL|2-Dose Engerix|subjects received 2 doses of adult (thiomersal-free) HBV formulation, one at 0 and 6 months, respectively and placebo (physiological saline) at 1 month.
62765743|NCT00343915|ACTIVE_COMPARATOR|3-Dose Engerix|subjects received 3 doses of paediatric (preservative-free) HBV formulation one at 0, 1 and 6 months, respectively.
62765744|NCT06308250|EXPERIMENTAL|GROUP A ( MIME THERAPY)|"Group A will receive mime therapy of 30 minutes with short resting intervals. Treatment will be given 5 times per week for 6 weeks. Mime therapy consist of:~1. Self massage of 10 minutes,~2. Breathing and relaxation exercises of 5 minutes,~3. Articulation of 5 minutes and~4. Facial expression exercises of 10 minutes."
62765745|NCT06308250|EXPERIMENTAL|GROUP B (ACTION OBSERVATION THERAPY)|"Group B will receive action observation therapy of 30 minutes with short resting interval. The treatment will be given 5 times per week for 6 weeks.~During the presentation of a video clip, patients sit relaxed in front of the computer screen while observing it.~After observing a motor act for 3 min (observation phase) patients are required to imitate what they observed for 2 min (execution phase)."
62765746|NCT03234296|ACTIVE_COMPARATOR|Antibiotic treatment|Ertapenem 1 g x 1 intravenously for 3 days, followed by per oral levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 4 days, duration of treatment 7 days.
62765747|NCT03234296|ACTIVE_COMPARATOR|Placebo|Intravenous placebo once a day for 3 days, followed by per oral placebo for 4 days with similar p.o. tablets as in the antibiotic group.
62765748|NCT02679820|EXPERIMENTAL|PostPlacental IUD insertion|Copper T intrauterine device will be inserted immediately following delivery of the placenta in cases of cesarean section deliveries.
62765749|NCT02679820|NO_INTERVENTION|Control|IUD will be offered as a method of contraception after puerperium
62765750|NCT06027346|EXPERIMENTAL|Bio-008 0.3mg/kg|group1
62765751|NCT06027346|EXPERIMENTAL|Bio-008 1.0mg/kg|group2
62765752|NCT06027346|EXPERIMENTAL|Bio-008 3.3mg/kg|group3
62765753|NCT06027346|EXPERIMENTAL|Bio-008 10.0mg/kg|group4
62765754|NCT06027346|EXPERIMENTAL|Bio-008 20.0mg/kg|group5
62765755|NCT06027346|EXPERIMENTAL|Bio-008 30.0mg/kg|group6
62765756|NCT06027346|EXPERIMENTAL|Bio-008 40.0mg/kg|group7
62765757|NCT05053412||HCC diagnosed Stage 1 (both A and B)|200 stage 1 (A and B) HCC diagnosed patients
62765758|NCT05053412||HCC diagnosed Stage 2|150 stage 2 HCC diagnosed patients
62765759|NCT05053412||HCC diagnosed Stage 3|100 stage 3 HCC diagnosed patients
62765760|NCT05053412||HCC diagnosed Stage 4|50 stage 4 HCC diagnosed patients
62765761|NCT05053412||Control liver cancer surveillance subjects|500 patients total: 250 Subjects with liver cirrhosis, 250 subjects without liver cirrhosis
62765762|NCT02993042|EXPERIMENTAL|Robot-assisted gait training|Robot-assisted gait training using an exoskeletal robot (Walkbot_S; P\&S Mechanics Co. Ltd., Seoul, Korea)
62765763|NCT01651832|NO_INTERVENTION|usual care|routine care and case management
62765764|NCT01651832|EXPERIMENTAL|SCAN-Intervention|
62765765|NCT04904809|EXPERIMENTAL|All Registered Patients|All registered patients will have multiple access sites in a single vein closed utilizing the Perclose ProGlide SMC System and/or Perclose ProStyle SMCR System.
62765766|NCT01366612|ACTIVE_COMPARATOR|Group 1|FLUDARABINE AND BUSULFAN
62765767|NCT01366612|EXPERIMENTAL|Group 2|FLUDARABINE, BUSULFAN AND LOW DOSE TOTAL BODY IRRADIATION
62765768|NCT00971529||lifestyle|70 volunteers were double-blinded, placebo-controlled and randomized into 2 groups (smoking with tea filters or regular filters).
62765769|NCT00971529||tea filter|The investigators then recruited 59 volunteers with longer smoking history and stronger desire for quitting smoking for smoking cessation test using the tea filter.
62765770|NCT03299543||Healthy adults|Healthy adults who are able to provide duplicate breath samples and pin-drop blood samples
62765771|NCT04855071|ACTIVE_COMPARATOR|Interventional group|"The intervention will consist of supervised individualized sessions that will include application of exercises to balance the pelvis and their muscles, treatment of trigger points, teaching activation of the transverse abdominis with ultrasound biofeedback and teaching reflex activation exercises of the transverse abdominis and pelvic floor muscles in different body positions. In addition, standards of water, urination, food, defecation, postural hygiene and physical activity will be provided. It is also recommended different life habit advices related to tobacco use, constipation, etc.~Furthemore, active RF will be applied intracavitary, in monopolar application, reaching a temperature between 42-45ºC in the tissues (according to the patient's tolerance), and with a power of 50% until the desired temperature is reached. It will be applied with a dose of approximately between 3-4 KJ depending on the application time (20 minutes / session)."
62765772|NCT04855071|SHAM_COMPARATOR|Comparator group|The intervention will be the same that in IG (exercises to balance the pelvis and their muscles, etc) an also standards of water, urination, food, defecation, postural hygiene and physical activity for their generalization at home and life habit advices. The application of RF in the control group will follow the same application procedure as in the intervention group with the only difference that no parameter is applied to the RF device (in terms of temperature, power, frequency and dose); that is, it remains off for the entire duration of the session.
62765773|NCT01206686|EXPERIMENTAL|1 Hour Planning Prompt|
61989135|NCT04643262||Intraoperative morbidity and mortality|Intraoperative complications (i.e. splenectomy, bleeding, positive leak test if performed) and type treatment are collected and recorded.
62168263|NCT05760885|EXPERIMENTAL|Sensory Augmentation|Participants will receive sensory augmentation in the form of non-invasive vibration, while balance training is performed as described below.
62765774|NCT01206686|EXPERIMENTAL|2 Hour Planning Prompt|
62765775|NCT01206686|EXPERIMENTAL|1 Day Planning Prompt|
62765776|NCT01206686|EXPERIMENTAL|Default Planning Prompt|
62765777|NCT01206686|ACTIVE_COMPARATOR|Control|
62765778|NCT02677844|EXPERIMENTAL|Abemaciclib|200 - 600 mg single increasing oral dose of abemaciclib on Day 1 of up to 3 study periods.
62765779|NCT02677844|PLACEBO_COMPARATOR|Placebo|Single oral dose of placebo on Day 1 of 1 study period.
62765780|NCT02677844|ACTIVE_COMPARATOR|Loperamide|Cohort 2, only. 8 mg Loperamide given orally once in 1 of 4 study periods.
62765781|NCT02677844|EXPERIMENTAL|Loperamide + Abemaciclib|Cohort 2, only. 8 mg Loperamide co-administered with abemaciclib given orally once in up to 1 of 4 study periods.
62765782|NCT02677844|ACTIVE_COMPARATOR|Loperamide + Placebo|Cohort 2, only. 8 mg Loperamide co-administered with placebo given orally once in up to 1 of 4 study periods.
62384452|NCT02532998|EXPERIMENTAL|Treatment Sequence 2|Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
62384453|NCT02532998|EXPERIMENTAL|Treatment Sequence 3|Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
62384454|NCT02532998|EXPERIMENTAL|Treatment Sequence 4|Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
62384455|NCT02532998|EXPERIMENTAL|Treatment Sequence 5|Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
62384456|NCT02532998|EXPERIMENTAL|Treatment Sequence 6|Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
62384457|NCT02532998|EXPERIMENTAL|Treatment Sequence 7|Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
62384458|NCT02532998|EXPERIMENTAL|Treatment Sequence 8|Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + AZD9977 Period 3: fludrocortisone + eplerenone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
62384459|NCT03820518|EXPERIMENTAL|High-dose|Receiving 60 ng/kg/day of calcitriol and 30 mg/kg/day of elemental phosphorus.
62384460|NCT03820518|EXPERIMENTAL|Low-dose|Receiving 20 ng/kg/day of calcitriol and 30 mg/kg/day of elemental phosphorus.
62384461|NCT02094339|EXPERIMENTAL|Local analgesic|This group uses local analgesia infusion pump of 0.2% ropivacaine 360ml through periarticular infiltration for postoperative analgesia.
62384462|NCT02094339|ACTIVE_COMPARATOR|Nerve Block|People in this group will receive a postoperative pain management by continuous lumbar plexus block with 0.2% ropivacaine.
62384463|NCT02094339|ACTIVE_COMPARATOR|Intravenous analgesic|This group is treated with intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg.
62384464|NCT02217046|EXPERIMENTAL|device replacement|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
62384465|NCT02217046|NO_INTERVENTION|control group|remove previously inserted cardiac device and the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
62384466|NCT01272245|EXPERIMENTAL|Omacetaxine and Cytarabine|Omacetaxine 1.25 mg/m2 SQ every 12 hours x 3 days + Cytarabine 20 mg SQ x 7 days of 4-7 week cycle.
62384467|NCT01662752|OTHER|Indocyanine green|Indocyanine green is used for intraoperative identification of sentinel lymph nodes in patients with early colonic cancer using near infrared laparoscopic imaging
62384468|NCT05538689|EXPERIMENTAL|Study drug Myfembree|Participants will be asked to take a once-daily tablet of Myfembree ( relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for 24 months.
62384469|NCT05538689|NO_INTERVENTION|Standard of Care|The standard of care will depend on the participant's type of surgery, health history, and clinical symptoms. It often includes pain management, bleeding management, physical exams, pelvic ultrasound, birth control, and Surgical reintervention.
62765783|NCT00697437|EXPERIMENTAL|docetaxel only|
62765784|NCT00697437|EXPERIMENTAL|docetaxel with ketoconazole|
62765785|NCT01152060||prednisone|
62567671|NCT04363320|EXPERIMENTAL|High-Dose NIATx Coaching & ECHO|"* Attend an in-person Kick-Off Meeting with Study Team \& Coaches~* 4-hour onsite visit (NIATx Training)~* 11 monthly (one-hour) NIATx coaching calls~* Prescribers participate in 12 monthly (one-hour) ECHO video conference calls"
62765786|NCT01152060||prednisone and anti-virus|
62765787|NCT06349135||Management of Mandibular Fractures via Intraoral approach.|Management of Mandibular Fractures via Intraoral approach.
62765788|NCT06349135||Management of Mandibular Fractures via Extraoral approach.|Management of Mandibular Fractures via Extraoral approach.
62765789|NCT03157583|ACTIVE_COMPARATOR|Reference product (for SPFi calculation)|This arm will include all the test sites on the participants back where reference product (P3 standard sunscreen) will be applied.
62765790|NCT03157583|EXPERIMENTAL|Test product 1|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 1 will be applied for SPF testing.
62765791|NCT03157583|EXPERIMENTAL|Test product 2|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 2 will be applied for SPF testing.
62765792|NCT03157583|EXPERIMENTAL|Test product 3|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 3 will be applied for SPF testing.
62765793|NCT03157583|EXPERIMENTAL|Test product 4|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 4 will be applied for SPF testing.
62168264|NCT05760885|ACTIVE_COMPARATOR|Control|Participants will receive balance training, without any sensory augmentation.
61989136|NCT04643262||peri-operative morbidity and mortality (<30 days)|Perioperative complications (\<30 days) considered are mortality, morbidity (i.e. leak, bleeding, occlusion, pneumonia, vascular complications, portal pulmonary-splenic embolism) and type treatment.
61989137|NCT04643262||Post-operative morbidity and mortality (>30 days)|Postoperative complications (\>30 days) considered are morbidity, mortality (i.e. leak, embolism, Incisional trocar hernia, other) and type treatment
61989138|NCT03942354||Intervention arm|"A total of 54 intervention arm trial patients (from TB-PRACTECAL trial) are anticipated across all three sites: South Africa, Belarus, and Karakalpakstan.~54 matched healthy controls are anticipated."
61989139|NCT03942354||Standard therapy|"54 standard therapy trial patients (from TB-PRACTECAL trial) will be recruited across all three sites. Patients will complete measures at baseline, 3 months, 6 months and 12 months.~54 matched healthy controls are anticipated."
61989140|NCT02067910|ACTIVE_COMPARATOR|Abatacept SC|Weekly subcutaneous administration of 125 mg Abatacept during 48 weeks
61989141|NCT02067910|PLACEBO_COMPARATOR|Placebo|First phase: Weekly subcutaneous administration of placebo during 24 weeks. Second phase: Weekly subcutaneous administration of 125 mg Abatacept during 24 weeks.
61989142|NCT02064881|EXPERIMENTAL|metformin glycinate|"620mg tablets of metformin glycinate: 1 tablet by mouth at night for 3 days, 1 tablet in the morning and evening for 3 days, 1 tablet in the morning and 2 tablets in the evening for 3 days and 2 tablets in the evening and 2 tablets in the morning until the end of the study.~Total study dose: 1240mg every 12 hours."
62384470|NCT05538689|OTHER|Parallel group for participants who opt not to be randomized|patients who do not consent to randomization or opt to be in a specific group will be included in a parallel observational study and be administered their preferred treatment.
61989143|NCT02064881|ACTIVE_COMPARATOR|metformin hydrochloride|"500mg tablets of metformin hydrochloride:1 tablet by mouth at night for 3 days, 1 tablet in the morning and evening for 3 days, 1 tablet in the morning and 2 tablets in the evening for 3 days and 2 tablets in the evening and 2 tablets in the morning until the end of the study.~Total study dose: 1000mg every 12 hours."
62384471|NCT06282731|OTHER|urine growth factor|"Previous studies have showed that overactive bladder syndrome (urge, frequency, nocturia or urinary incontinence) has been considered as an important factor to predict successful treatment.~Urine nerve growth factor level, brain-derived neurotrophic factor and endothelium vascular growth factor have been proved as a simple and noninvasive biomarker for diagnosing overactive bladder."
62384472|NCT03909724|ACTIVE_COMPARATOR|TAS-102 (Lonsurf)|35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period.
62384473|NCT03909724|EXPERIMENTAL|High Dose Intermittent Sunitinib|700 mg once every 2 weeks.
62384474|NCT05944861|EXPERIMENTAL|Combined ultrasonography and flouroscopy guided injeciton|In 17 patients selected after randomization, the procedure will first be started with ultrasound and then continued with fluoroscopy.
62384475|NCT05944861|ACTIVE_COMPARATOR|Flouroscopy guided injection|In 17 patients selected after randomization, the procedure will be performed only through fluoroscopy.
62384476|NCT03586076|EXPERIMENTAL|JHL1922|
62384477|NCT03586076|ACTIVE_COMPARATOR|Pulmozyme|
62384478|NCT00642824|EXPERIMENTAL|1|
62384479|NCT00638989|EXPERIMENTAL|CAT-354 150 mg (intravenous)|A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
62384480|NCT00638989|EXPERIMENTAL|CAT-354 150 mg (subcutaneous)|A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
62558700|NCT04395482||covid-19 pneumonia related patients|The study aims to collect the highest number possible of lung CT scan images performed in patients with COVID-19, in order to obtain a large sample size that will allow us to characterize the extent of lung injury, the presence of specific patterns of lung alteration, and their potential association with the outcome of patients - in view of assisting the medical staff in better understanding the grade of the severity impairment in these patients which might be potentially candidates to more intensive therapeutic strategies.
62558701|NCT04218318|ACTIVE_COMPARATOR|Low-threshold group|Neonates in the low-threshold group phototherapy will be stopped if TSB reached ˃100 µmol/L below the AAP phototherapy threshold.
62558702|NCT04218318|ACTIVE_COMPARATOR|High-threshold group|Neonates in high-threshold group phototherapy will be ceased if TSB level is 50-100 µmol/L below the appropriate AAP phototherapy threshold.
62558703|NCT04540809||Psoriatic arthritis group (PsAG)|The evaluation was made using dynamometer, goniometer, mobile application, and Purdue pegboard test.
62558704|NCT00449904|EXPERIMENTAL|Liprotamase|Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units) administered orally with each of three meals and two snacks daily for 12 months.
62558705|NCT00065156|EXPERIMENTAL|Lenalidomide|
62558706|NCT05662176|EXPERIMENTAL|Experimental: Supportive Care based on trauma informed care|Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care based on trauma informed care was provided to the experimental group during birth.
61989144|NCT02232581|EXPERIMENTAL|Alovudine - low|
61989145|NCT02232581|EXPERIMENTAL|Alovudine - medium|
61989146|NCT02232581|EXPERIMENTAL|Alovudine - high|
61989147|NCT02232581|PLACEBO_COMPARATOR|Placebo|
61989148|NCT01263301|ACTIVE_COMPARATOR|carotid duplex for hemolytic patients wtih SSS|assigned intervention:carotid duplex
61989149|NCT01263301|ACTIVE_COMPARATOR|carotid duplex for nonhemolytic patients with SSS|
61989150|NCT02120950|EXPERIMENTAL|Aflibercept + Sham PDT|Participants received 2 milligram (mg) Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus sham photodynamic therapy (only in subjects qualifying for rescue therapy)
62384481|NCT00638989|EXPERIMENTAL|CAT-354 300 mg (subcutaneous)|A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
62384482|NCT01828463|NO_INTERVENTION|no treatment|comparrator
62384483|NCT01828463|EXPERIMENTAL|Nitisinone 1mg|interventional
62384484|NCT01828463|EXPERIMENTAL|Nitisinone 2mg|interventional
62384485|NCT01828463|EXPERIMENTAL|Nitisinone 4mg|interventional
62384486|NCT01828463|EXPERIMENTAL|Nitisinone 8mg|interventional
62765794|NCT03157583|NO_INTERVENTION|Negative control (for SPFi calculation)|This arm will include all the test sites on the participants back which will be left unprotected.
62765795|NCT03157583|ACTIVE_COMPARATOR|Reference (for UVAPFi calculation)|This arm will include test plates treated with reference sunscreen formulation S2.
62765796|NCT03157583|OTHER|Blank control (for UVAPFi calculation)|This arm will include blank test plates treated with glycerin.
62765797|NCT03993223|EXPERIMENTAL|MTrP group|Healthy overhead athletes with upper trapezius myofascial trigger point
62765798|NCT03993223|SHAM_COMPARATOR|Control group|Healthy overhead athletes without upper trapezius myofascial trigger point
62765799|NCT05588037|EXPERIMENTAL|RRD group|to evaluate the efficacy and complications of a new minimally invasive vitreoretinal surgery combined with FLACS in the treatment of rhegmatogenous retinal detachment complicated with cataract.
62765800|NCT05588037|EXPERIMENTAL|ERM group|to evaluate the efficacy and complications of a new minimally invasive vitreoretinal surgery combined with FLACS in the treatment of epiretinal membrane complicated with cataract.
62765801|NCT05588037|EXPERIMENTAL|MH group|to evaluate the efficacy and complications of a new minimally invasive vitreoretinal surgery combined with FLACS in the treatment of macular hole complicated with cataract.
62765802|NCT05588037|EXPERIMENTAL|Vitreous cloudy group|to evaluate the efficacy and complications of a new minimally invasive vitreoretinal surgery combined with FLACS in the treatment of vitreous opacity complicated with cataract.
62765803|NCT05919641||+CGA|Patients randomised to undergo a Comprehensive Geriatric Assessment (CGA)
62765804|NCT05919641||-CGA|Patients not randomised to undergo a Comprehensive Geriatric Assessment (CGA)
62765805|NCT02639338|EXPERIMENTAL|SOF/VEL/VOX|SOF/VEL/VOX tablet for 8 weeks
62765806|NCT02639338|EXPERIMENTAL|SOF/VEL|SOF/VEL tablet for 12 weeks
62765807|NCT03826680|ACTIVE_COMPARATOR|Flexible fiberoptic laryngoscopy|Patients who will undergo thyroidectomy will be evaluated by an ENT physician by flexible fiberoptic laryngoscopy before the surgery
61989151|NCT02120950|EXPERIMENTAL|Aflibercept + Active PDT|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus active photodynamic therapy (only in subjects qualifying for rescue therapy)
61989152|NCT00006101|EXPERIMENTAL|eflornithine|500mg/d for 12 months
62765808|NCT03826680|ACTIVE_COMPARATOR|Direct laryngoscopy|The same patients evaluated by flexible fiberoptic laryngoscopy will be evaluated by an anesthesiologist by direct laryngoscopy during surgery under general anesthesia
62765809|NCT02331979|EXPERIMENTAL|Stimulation of Non-Naive|Evaluate neuromodulation in 6 subjects with prior motor training.
62765810|NCT02331979|EXPERIMENTAL|Stimulation of Naive|Evaluate neuromodulation in 6 naive subjects.
62765811|NCT02331979|EXPERIMENTAL|Stimulation|Apply parameters discovered in Arm 1 and Arm 2 to evaluate neuromodulation in 12 naive subjects.
62765812|NCT01610596|EXPERIMENTAL|Halobetasol Propionate Lotion 0.05%|Topical lotion, applied twice daily
62765813|NCT01610596|PLACEBO_COMPARATOR|Vehicle Lotion|Topical lotion, applied twice daily
62765814|NCT03618940|EXPERIMENTAL|School-based educational intervention|"1. assessed for knowledge and attitude on burn injury prevention~2. underwent the School-based educational intervention~3. impact evaluation~4. Output evaluation 3 months after School-based educational intervention"
62765815|NCT01064687|EXPERIMENTAL|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
62765816|NCT01064687|EXPERIMENTAL|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
61989153|NCT00006101|PLACEBO_COMPARATOR|Placebo|placebo for 12 months
62765817|NCT01064687|ACTIVE_COMPARATOR|Exenatide|"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
62765818|NCT01064687|PLACEBO_COMPARATOR|Placebo|"Placebo: subcutaneous (SC), once weekly for 26 weeks~LY2189265 (Dulaglutide): After 26 weeks, participants were randomized to receive either 0.75 milligrams (mg) or 1.5 mg, SC, once weekly for an additional 26 weeks (from week 26 through week 52).~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
62765819|NCT01655381|EXPERIMENTAL|Tocilizumab|Tocilizumab 8 milligrams per kilogram (mg/kg) administered intravenously once every 4 weeks during a minimum of 104 weeks.
62765820|NCT03324425|EXPERIMENTAL|Simvastatin|Simvastatin 80 mg in combination with anti-HER2 therapy regimen
62765821|NCT00475865|PLACEBO_COMPARATOR|Placebo + GA|Placebo (for teriflunomide) once daily concomitantly with glatiramer acetate (GA) for 24 weeks
62765822|NCT00475865|EXPERIMENTAL|Teriflunomide 7 mg + GA|Teriflunomide 7 mg once daily concomitantly with glatiramer acetate (GA) for 24 weeks
62765823|NCT00475865|EXPERIMENTAL|Teriflunomide 14 mg + GA|Teriflunomide 14 mg once daily concomitantly with glatiramer acetate (GA) for 24 weeks
62765824|NCT01883011|EXPERIMENTAL|Piracetam|"IV infusion 12 g piracetam in 60 ml~IV Ampoules 3 g piracetam in 15 ml~Oral solution 33 % piracetam (bottle of 125 ml)~Oral tablets 1200 mg piracetam (blisters of 10 tablets)"
62765825|NCT01883011|PLACEBO_COMPARATOR|Placebo|"IV infusion 12 g placebo in 60 ml~IV Ampoules 3 g placebo in 15 ml~Oral solution 33% placebo (bottle of 125 ml)~Oral tablets 1200 mg placebo (blisters of 10 tablets)~All IV forms were identical in presentation, size and color to allow a double blind design.~All oral forms were identical in shape, size, color and taste to allow a double blind design."
62765826|NCT01056120||ENERGY-Population|"Patient population in standard clinical care, according to the instructions for use and the inclusion / exclusion criteria. Registry patients should be enrolled consecutively to represent a typical set of patients at each site.~The registry will collect clinical data from patients that have given their prior written consent. All data will be anonymized prior to data entry."
62765827|NCT03023163||Older SCI|Individuals that are between the ages of 50-75 years old, have a traumatic SCI, level of injury between C1-T12, non-ambulatory (wheelchair dependent), AIS grade A, B, or C, and injury occurred more than 1 year ago.
62765828|NCT03023163||Older Able-Bodied Controls|Individuals that are between the ages of 50-75 years old and primary language is English.
62384487|NCT05729165|EXPERIMENTAL|Experimental group (S-G)|"20 minutes of local vibration treatment with the Novafon® Pro medical device followed by 20 minutes of traditional speech therapy, for a total duration of 40 minutes. Therefore, using this instrument, local vibration therapy will be applied at the level of (i) the orbicular muscles of the upper and lower lips, (ii) the masticatory muscles (masseter, temporalis, pterygoid), and (i) local intra-oral and tongue. The Novafon® Pro medical device will be used with the following external and intraoral heads: set senses roller, ball head, disc head, ball head, arrow head, spoon head, and tongue depressor head.~Traditional speech therapy treatment will be carried out with the same tools and activities already described in the C-G."
62384488|NCT05729165|ACTIVE_COMPARATOR|Control group (C-G)|40 minutes of conventional speech treatment. Specifically, maneuvers will be performed for (i) extra-oral and intra-oral passive thermal stimulation, (ii) extra-oral and intra-oral passive tactile stimulation, and for (iii) elicitation of active bucco-lingual and laryngeal muscle movements. The following instruments will be used for this purpose: ice cubes, ice tubes, sterile gauze, tongue depressors, swabs, 10 mm laryngeal mirrors.
62384489|NCT04151758|EXPERIMENTAL|Docosahexaenoic Acid Supplementation, lifestyle intervention|Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day. Physical activity and healthy eating habits will be encouraged.
62384490|NCT03099811|EXPERIMENTAL|Intervention: Financial incentives + Smoking cessation program|Caregiver and a social network member will receive financial incentives, in additional to enrollment in a state-sponsored smoking cessation program, based on nicotine biomarker measurements.
62384491|NCT03099811|OTHER|Intervention: Smoking cessation program|Caregiver and a social network member will be enrolled in a state-sponsored smoking cessation program.
62765829|NCT03023163||Longitudinal SCI|Individuals that are between the ages of 28-54 years old and previously participated in the Impact of Age on Cardiovascular, Cerebrovascular, and Cognitive Health study in a 3-5 year span.
62765830|NCT03023163||Longitudinal Able-Bodied Controls|Individuals that are between the ages of 28-54 years old and previously participated in the Impact of Age on Cardiovascular, Cerebrovascular, and Cognitive Health study in a 3-5 year span.
62765831|NCT03037541|EXPERIMENTAL|Group 1 Carac (fluorouracil) 0.5% cream|Carac cream (fluorouracil) 0.5% applied daily on the face for one week
61989154|NCT05796674||Clareon UVA IOL|Eyes that underwent cataract surgery and received a Clareon UVA IOL with the use of the WaveTec Optiwave Refractive Analysis (ORA) System
61989155|NCT04076735|EXPERIMENTAL|Distal femoral replacement (DFR)|"Distal femoral replacement will be performed by excising the distal portion of the femur (up to two thirds) and replacing with a prosthesis incorporating a hinged total knee replacement.~Surgical approach and implant selection will be at the discretion of the treating surgeon and within the standard of care. Surgeons performing this procedure will be qualified by training and experience in arthroplasty."
62384492|NCT01250236||verum|brimonidine 0.1% eye drops twice daily
62384493|NCT01250236||placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
62384494|NCT03235999||Talc pleurodesis|Up to 10 patients who have had talc pleurodesis
62765832|NCT03037541|PLACEBO_COMPARATOR|Group 2 Placebo|Placebo Cetaphil cream applied daily on the face for one week
62765833|NCT02163551||Spinal Cord Injury|Participants with spinal cord injury (n = 20) will be age 30-60 years with motor complete spinal cord injuries, otherwise known as American Spinal Injury Association (ASIA) classification A or B, between the levels of C3 and T12. Patients will have to be able to breathe independently without the use of a ventilator. Subjects will be divided equally into four different injury level categories. The four categories are high tetraplegia (C3 - C5), low tetraplegia (C6-C8), high paraplegia (T1-T6), and low paraplegia (T7-T12).
62765834|NCT02163551||Controls|Twenty healthy age-matched adults will also participate.
62765835|NCT00569088|EXPERIMENTAL|B|A combined treatment would be used in the arm.That means Chinese herb formula would be used with the current Modern Medicine therapy for stroke in this arm.
62765836|NCT00569088|ACTIVE_COMPARATOR|A|just the current Modern Medicine therapy for stroke would be available in the arm.
62765837|NCT05510661|EXPERIMENTAL|Intervention Group|Manual thrombus aspiration (use of export catheter) followed by primary PCI
62765838|NCT05510661|ACTIVE_COMPARATOR|Control group|Predilatation with balloon catheter (≤2.00 mm diameter) followed by primary PCI
62384495|NCT03235999||IPC|Up to 10 patients who have had indwelling pleural catheters (IPC)
62384496|NCT03812224|EXPERIMENTAL|Erenumab|Participants were to receive erenumab 70 mg once a month for 24 weeks during the double-blind treatment period followed by erenumab 70 mg once a month for 28 weeks during the open-label treatment period.
62384497|NCT03812224|PLACEBO_COMPARATOR|Placebo|Participants were to receive placebo to erenumab once a month for 24 weeks during the double-blind treatment period followed by erenumab 70 mg once a month for 28 weeks during the open-label treatment period.
62384498|NCT00838968|ACTIVE_COMPARATOR|interferon-alpha (IFN-alpha)|the interferon-alpha is intramuscular injected 3,000,000U three times a week for 18 months
62384499|NCT00838968|NO_INTERVENTION|control|no interventions were assigned
62765839|NCT03605069|OTHER|First TWA (A)|"In each subject up to two target wound areas (TWA) are randomized, one each to active treatment or placebo.~In the first arm; randomization of the first selected TWA to active treatment or placebo"
61989156|NCT04076735|ACTIVE_COMPARATOR|Surgical Fixation (ORIF)|Surgical fixation of the distal femoral fracture will be performed with the goals of obtaining and maintaining anatomic reduction and stable fixation of the distal portion of the femur. Surgical approach and implant selection for the surgical fixation (ORIF) will be at the discretion of the treating surgeon and within the standard of care. Surgeons performing this procedure will be qualified by training and experience in trauma of the knee.
62384500|NCT06280755||Data from real-world clinical practice|Retrospective, real-world clinical data obtained via the 6 participating clinical centers in the study.
62384501|NCT06280755||Data from the control arms of relevant clinical trials|Data from the control arms of relevant clinical trials obtained via the 4 participating pharmaceutical partners in the study.
62558707|NCT05662176|OTHER|Control: Standart care|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
62765840|NCT03605069|OTHER|Second TWA (B)|In each subject, in the second arm; allocation of the second selected target wound area (TWA) to the alternative treatment. Second arm in the same subject as the first arm.
62765841|NCT01231321|EXPERIMENTAL|adalimumab|Adalimumab / pre-filled syringe 40 mg/0.8 ml
62765842|NCT00506597|EXPERIMENTAL|Erwinase|6 doses of 25,000 Units/m\^2 Erwinase® intramuscular/subcutaneously every other day to replace each dose of Pegylated Asparaginase
62765843|NCT01386268||Group 1|
62765844|NCT03873961|EXPERIMENTAL|High-intensity laser therapy|The participants received stretching and exercise guidance and underwent the BTL-6000 High Intensity Laser 12 W with 10 mm pen applicator high intensity laser procedures (mode = continuous, power = 7 W, dose = 120 J/cm2, total time= 7 min. 8 sec.) 3 times per week (total of 8 procedures).
62765845|NCT03873961|ACTIVE_COMPARATOR|Low-level laser therapy|The participants received stretching and exercise guidance underwent the LAS-Expert with laser shower applicator Low-level Laser therapy procedures (785 nm wavelength, 4,0 J/cm2, 35cm2, 6:40 min) 3 times per week (total of 8 procedures).
62765846|NCT00764907|EXPERIMENTAL|Arm I|During reinduction, patients receive 1 course of protocol II.
62765847|NCT00764907|EXPERIMENTAL|Arm II|During reinduction, patients receive 2-3 course of protocol III and interim maintenance therapy.
62384502|NCT00621764|EXPERIMENTAL|JE-CV/Hepatitis A (Group 1)|Participants aged 2 to 5 years at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
62384503|NCT00621764|EXPERIMENTAL|Hepatitis A/JE-CV (Group 2)|Participants aged 2 to 5 years at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)
62384504|NCT00621764|EXPERIMENTAL|JE-CV/Hepatitis A (Group 3)|Participants aged 12 to 24 months at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
62384505|NCT00621764|EXPERIMENTAL|Hepatitis A/JE-CV (Group 4)|Participants aged 12 to 24 months at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)
62384506|NCT01690013||Klinefelter|Men with Klinefelter syndrome
62384507|NCT01690013||Control|Men from the general population, matched by age, education and zipcode.
62765848|NCT00764907|EXPERIMENTAL|Arm III|During reinduction, patients are receive 2 courses of protocol II and interim maintenance therapy OR 3-block consolidation regimen and 1 course of protocol II.
62384508|NCT04216628|OTHER|Early amniotomy group|Amniotomy will be performed as the exclusive primary intervention. Oxytocin infusion will begin as per local standard dose protocol no earlier than 2 hours following amniotomy.
62765849|NCT03624088|EXPERIMENTAL|Single-Arm Intervention|Participants will complete a baseline questionnaire. They will then self-administer the web-based decision aid, RealRisks. Upon completion, they will complete two more surveys: one within 1 month of completing RealRisks and one six months after completing RealRisks.
62765850|NCT05251532|EXPERIMENTAL|Kinesio Taping Group (KTG)|Distortion taping with Kinesio Tex will be applied to the patients in addition to conventional rehabilitation through a pediatric physiotherapist.
62765851|NCT05251532|ACTIVE_COMPARATOR|Conventional Rehabilitation Group (CRG)|Conventional rehabilitation program will be applied to the patients through a pediatric physiotherapist.
62765852|NCT02624193|EXPERIMENTAL|MBSR Program|"MBSR Program:~The MBSR intervention is a nine-week program designed to cultivate mindfulness, a focused non-judgmental awareness of the present moment. It consists of eight 2-hour weekly sessions and one 3-hour retreat and the content includes three main components: 1) material related to mindfulness, meditation, yoga, and the mind-body connection; 2) experiential practice of mindful meditation (sitting, lying down, walking), gentle mindful yoga, and body scan during group meetings and encouragement of home practice; and 3) group discussion focused on problem-solving related to barriers to effective practice. HIV disease will not be discussed as a group topic, unless it is brought up by participants."
62765853|NCT02624193|PLACEBO_COMPARATOR|HT Program|"Healthy Topics Program:~The health education program Healthy Topics (HT) will serve as an attention control group. The HT program is focused on providing age-appropriate health information and education. There is minimal content overlap in the MBSR and HT programs regarding self-care and healthy eating; however, the style, structure, and content of the MBSR and HT programs are distinct. HT participants will receive no training in MBSR or meditation. Topics covered include physical activity, nutrition, managing weight, building health, personal care, understanding adolescence, tobacco, alcohol, and other drugs. HIV disease will not be discussed as a group topic, unless it is brought up by participants."
62765854|NCT00647660|EXPERIMENTAL|1|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
61989157|NCT00205426|EXPERIMENTAL|Natrecor infusion|Nesiritide
62384509|NCT04216628|OTHER|Late amniotomy group|Oxytocin infusion will begin as per local standard dose protocol. Amniotomy will be performed no earlier than 2 hours following the commence of oxytocin infusion
62384510|NCT00354627|EXPERIMENTAL|TMC125|TMC125 200 mg b.i.d. till commercially available.
62384511|NCT01874587|NO_INTERVENTION|standard radiotherapy|single pre-treatment planning before radiotherapy
62384512|NCT01874587|EXPERIMENTAL|adaptative radiotherapy|adaptive Radiotherapy based on a weekly replanning
62384513|NCT04734249|EXPERIMENTAL|Advanced CRC|Patients with Advanced CRC were given Surufatinib Combined With Chemotherapy
62384514|NCT02800122||Patients with acute dyspnea|"Patients with acute dyspnea treated by a medical team of emergencies of CHRU of Nancy.~All patients admitted to the emergencies in the last 5 years matching the inclusion criteria will be evaluated. About 4,000 patients will be affected, including more than 800 patients with acute heart failure. (Figures based on export of ICD X codes (R06.0: Dyspnea) of patients cared in extra-hospital for acute dyspnea (diagnosis Dyspnea + Heart Failure) over the last 5 years)."
62384515|NCT02308709|EXPERIMENTAL|Ventilation image-guided radiotherapy|Patients will receive 4D CT ventilation image-guided personalized radiotherapy treatment that selectively avoids irradiating highly-functional lung regions
62765855|NCT00647660|ACTIVE_COMPARATOR|2|Corzide® Tablets 80 mg/5 mg
62765856|NCT04180787|EXPERIMENTAL|Keto Coffee|VPX Bang® Keto Coffee beverage
62765857|NCT04180787|PLACEBO_COMPARATOR|Placebo|Flavor-matched placebo beverage
62384516|NCT05200468|EXPERIMENTAL|Ketogenic diet|Weekly menus will be delivered according to diet with the following macronutrient distribution: 25% protein, 10% carbohydrate, 65% fat. Participants will receive a 30-day food menu guide.
62384517|NCT05200468|EXPERIMENTAL|Caloric restriction diet|Weekly menus will be provided according to their usual diet with 500 kcal restriction with the following macronutrient distribution 25-35% protein, 45-55% carbohydrates, 20-30% fat. Participants will receive a 30-day food menu guide.
62765858|NCT01922375|EXPERIMENTAL|Naftopidil dose 2|PO administration
62765859|NCT01922375|PLACEBO_COMPARATOR|Placebo|PO administration
62765860|NCT01922375|EXPERIMENTAL|Naftopidil dose 1|PO administration
62765861|NCT03071484|EXPERIMENTAL|Transcranial Direct Current Stimulation|After being randomly allocated, the experimental group will receive a 20 minutes of active 2-mA tDCS once a day on 10 consecutive weekdays.
62765862|NCT03071484|PLACEBO_COMPARATOR|Sham - tDCS|The control group will receive a sham stimulation, which chosen parameters consists in after 40 seconds of real stimulation (2 mA), only a small current pulse occurred every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
62765863|NCT01356732|EXPERIMENTAL|Sufentanil|
62765864|NCT01189292|ACTIVE_COMPARATOR|Dexamethasone injection|Administration of 8mg(2ml) intravenous Dexamethasone (Mephameson®)
62765865|NCT01189292|PLACEBO_COMPARATOR|Placebo (NaCl 0.9%)|
62384518|NCT05200468|EXPERIMENTAL|Intermittent fasting 16/8|Calorie-restricted menus will be provided with a 16:8 time-restricted feeding. The feeding window will be 8 hours with a fasting time of 16 hours (04.00 pm- 08.00 am or 05.00 pm - 09.00 am), during the fasting window participants will only be allowed to drink water, unsweetened tea, mineral water and coffee without added sugar. Participants will receive a 30-day food menu guide.
62384519|NCT05200468|NO_INTERVENTION|habitual diet|Participants will be advised to follow their usual diet until the end of the study.
62384520|NCT05536544|OTHER|IBDMED-ISR|Patients with newly diagnosed CD in Israel
62384521|NCT05536544|OTHER|IBDMED-IND|Patients with newly diagnosed CD in India
62384522|NCT01725724|ACTIVE_COMPARATOR|Allogeneic blood|Allogeneic blood transfusion. Patients in this group will receive allogeneic red cell transfusions.
62384523|NCT01725724|EXPERIMENTAL|Autologous blood|Autologous blood transfusion. Patients in this arm will receive per- and postoperatively collected autologous blood collected with the Sangvia Blood Collection System. If teh amount of autologous blood is too small for the clinical need, additional allogeneic blood will be transfused.
62384524|NCT03027180|ACTIVE_COMPARATOR|0 (zero) cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 0 cmH2O
62765866|NCT01187459|EXPERIMENTAL|10 ug/day|
62765867|NCT01187459|EXPERIMENTAL|50 ug/day|
62765868|NCT02068118|NO_INTERVENTION|Standard care|Standard follow-up, with conventional monitoring involving consultations and monitoring by their general practitioners or referring cardiologists
62765869|NCT02068118|EXPERIMENTAL|Tele-cardiology group|Telecardiology Program
62765870|NCT04438876|EXPERIMENTAL|Function power training|12-week structured FPT program, conducted by a certified trainer from a community service provider. Sessions were held twice weekly at the respective community senior activity centers, each lasting 60 minutes in duration.
62765871|NCT04438876|ACTIVE_COMPARATOR|Usual care|Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
62765872|NCT04928209|NO_INTERVENTION|Usual Care (High-Income)|This group will receive comprehensive assessments every 9 months for the 18-month period of enrollment, for a total of 3 assessments. They will not be randomized to receive supplemental teletherapy (intervention) and usual care.
62765873|NCT04928209|NO_INTERVENTION|Usual Care (Low-Income)|"This group includes the low-income families who satisfy the criteria to receive supplemental speech-language teletherapy but are not randomized to receive the intervention after allocation. Like the Usual Care (High-Income) arm, they will only receive comprehensive assessments every 9 months for the 18-month period of enrollment, for a total of 3 assessments and usual care."
62765874|NCT04928209|EXPERIMENTAL|Usual Care + Teletherapy (Low-Income)|This group includes the low-income families who satisfy the criteria to receive supplemental speech-language teletherapy and are randomized to receive the intervention. They will receive both 3x comprehensive assessments every 9 months AND access to supplemental speech-language teletherapy for the 18-month study period.
62765875|NCT02317809|EXPERIMENTAL|First Liquid Pergoveris, Then Freeze-dried Pergoveris|
62765876|NCT02317809|EXPERIMENTAL|First Freeze-dried Pergoveris, Then Liquid Pergoveris|
62765877|NCT03303118|OTHER|Left|No product administration will be done in this study.
62765878|NCT00797238||NSCLC stage III|Taiwanese NSCLC patients with stage III
62765879|NCT01483209|EXPERIMENTAL|Botox injection|Use of botulinum toxin A to determine efficacy in treating vasopressor-induced digital ischemia
62765880|NCT06158230|ACTIVE_COMPARATOR|Amitriptyline-Propranolol|"Combination of amitriptyline and propranolol.~Initial 2 weeks:~Amitriptyline 10 mg at bedtime Propranolol 20mg twice daily~Next 2 weeks:~Amitriptyline 25 mg at bedtime Propranolol 20mg three times daily~Next 8 weeks:~Amitriptyline 25 mg at bedtime Propranolol 40mg twice daily"
62765881|NCT06158230|EXPERIMENTAL|Pizotifen|"Pizotifen~Initial 2 weeks:~Pizotifen 0.5 mg at bedtime~Next 2 weeks:~Pizotifen 1 mg at bedtime~Next 8 weeks:~Pizotifen 1.5 mg at bedtime"
62765882|NCT02644902|EXPERIMENTAL|Technology Arm|5 days training of health workers in THP through avatar assisted cascade training and supervision
62765883|NCT02644902|ACTIVE_COMPARATOR|Specialist Arm|5 days training and supervision of health workers in THP by specialists
62765884|NCT02467920|EXPERIMENTAL|glargine + exenatide|Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily).
62765885|NCT02467920|ACTIVE_COMPARATOR|aspart 30|Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to aspart 30 ( subcutaneous injection, twice daily).
62765886|NCT05682300||Patient under regional anesthesia|patients who recieve peripheral nerve blocks as analgesic technique
62765887|NCT05665049|NO_INTERVENTION|Control Group|Only educational materials focused on the benefits of exclusive breastfeeding and the current international recommendations are provided.
62765888|NCT05665049|EXPERIMENTAL|Intervention Group 1 - Non-Conditional Social Transfer|Educational materials focused on the benefits of exclusive breastfeeding and the current international recommendations are provided. At the baseline visit, participants are told that at the 6-month visit, they will receive a gift of their choice - which is meant to show our appreciation and support for their efforts in breastfeeding.
62765889|NCT05665049|EXPERIMENTAL|Intervention Group 2 - Conditional Social Transfer|Educational materials focused on the benefits of exclusive breastfeeding and the current international recommendations are provided. At the baseline visit, participants are told that at the 6-month visit, they will receive a gift of their choice if they are still exclusively breastfeeding.
62765890|NCT03785951|EXPERIMENTAL|Whey Protein Isolate|Subjects are asked to supplement their habitual diet with 56 g of whey protein isolate a day for 8 weeks
62765891|NCT03785951|EXPERIMENTAL|Wheat Protein|Subjects are asked to supplement their habitual diet with 56 g of wheat protein a day for 8 weeks
62765892|NCT03785951|EXPERIMENTAL|Wheat protein with leucine|Subjects are asked to supplement their habitual diet with 56 g of wheat protein with leucine a day for 8 weeks
62765893|NCT01821456||Antiinfectives|To analyze the efficacy of antiinfectives at high risk patients
62765894|NCT04893083||LRRK2 Mutant PD|Patients with a G2019S mutation
62765895|NCT04893083||LRRK2 Wild Type PD Low burden|Patients with a low burden of genetic modifiers
62765896|NCT04893083||LRRK2 Wild Type High burden|Patients with a high burden of genetic modifiers
62765897|NCT04041427|EXPERIMENTAL|Fasting|Albendazole 400mg will be ingested by study participants with an 8-hour fasting diet.
62765898|NCT04041427|EXPERIMENTAL|High fat content diet|Albendazole 400mg will be ingested by study participants 15 to 30 minutes after a meal with high fat content (40 grams of fat).
62765899|NCT04041427|EXPERIMENTAL|Moderate fat content diet|Albendazole 400mg will be ingested by study participants 15 to 30 minutes after a meal with moderate fat content (15 grams of fat).
62765900|NCT01166061|EXPERIMENTAL|Cohort 1|Subjects to receive either active or placebo
62765901|NCT01166061|EXPERIMENTAL|Cohort 2|Subjects to receive either active or placebo comparator
62765902|NCT01166061|EXPERIMENTAL|Cohort 3|Subjects to receive either active or placebo comparator
62765903|NCT01166061|EXPERIMENTAL|Cohort 4|Subjects to receive either active or placebo comparator
62765904|NCT01166061|EXPERIMENTAL|Cohort 5|Subjects to receive either active or placebo comparator
62765905|NCT00871923|EXPERIMENTAL|Tarceva + RT|Tarceva (Erlotinib hydrochloride) + Radiation Therapy. Tarceva 150 mg by mouth every day beginning Day 1. Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
62765906|NCT01831440|OTHER|medicine combined CBT|Besides clinical routine antidepressant treatment,participants receive CBT weekly for 8 weeks and monthly until the end of the study.
62765907|NCT01831440|OTHER|medicine (SSRI antidepressants)|clinical routine antidepressant treatment--Selective serotonin reuptake inhibitors（SSRIs）.
62765908|NCT03242252|PLACEBO_COMPARATOR|Placebo|Following a 2-week run-in period, participants received two placebo tablets (identical to sotagliflozin 200 mg in appearance), orally once daily, before the first meal of the day for up to 54 weeks.
62765909|NCT03242252|EXPERIMENTAL|Sotagliflozin 200 mg|Following a 2-week run-in period, participants received two tablets, 1 sotagliflozin 200 mg tablet and 1 placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily, before the first meal of the day for up to 58 weeks.
62765910|NCT03242252|EXPERIMENTAL|Sotagliflozin 400 mg|Following a 2-week run-in period, participants received sotagliflozin 400 mg, administered as two 200 mg sotagliflozin tablets, orally once daily, before the first meal of the day for up to 60 weeks.
62765911|NCT05135611|EXPERIMENTAL|4-channel Sequential NMES|"After diagnosis of sleep apnea, the registered patient group receives sufficient explanations from the researcher and uses sequential 4-channel electrical stimulation therapy at home, 5 times a week, 60 minutes each, for 8±2 weeks.~During 4-channel electrical stimulation treatment, study participants kept a treatment log including the number of applications, intensity (mA), and treatment time at home."
62765912|NCT02783378|OTHER|Gaviscon syrup|"Gaviscon will be given to threat patients with reflux after first 24 hours of oesophagal pH-monitoring.~This is a syrup and will be given after every meal. dosage depends from age between 1ml and 5ml after every meal"
62765913|NCT00527020|EXPERIMENTAL|Part A: Subjects receiving treatment in cohort A|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
62765914|NCT00527020|EXPERIMENTAL|Part A: Subjects receiving treatment in cohort B|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
62765915|NCT00527020|EXPERIMENTAL|Part A: Subjects receiving treatment in cohort C|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
62765916|NCT00527020|EXPERIMENTAL|Part B: Subjects in 5 period crossover period|Eligible subjects (first 14 subjects) will be randomized to one of the following 14 sequences as a 5 period crossover with sequences; LMNOQ, MNOLQ, NOLMQ, OLMNQ, ONMLQ, NMLOQ, MLONQ, LONMQ, LNMOQ, NMOLQM MOLNQ, OLNMQ, OMNLQ and MNLOQ) (L= 80 milligrams GSK1018921 given in fasted state, M= 200 milligrams GSK1018921 given in fasted state, N= nicotine lozenge, O= placebo and Q= 80 milligrams GSK1018921 in fed state).
62384525|NCT03027180|EXPERIMENTAL|4 cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 4 cmH2O
62384526|NCT03027180|EXPERIMENTAL|15 cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 15 cmH2O
62384527|NCT03810781||Cervical Spondylotic Myelopathy (CSM)|Degenerative cervical myelopathy, encapsulates a cascade of events leading to significant degenerative changes in discs, formation of osteophytes, facet hypertrophy, calcification of the posterior longitudinal ligament and ligamentous flavum with resultant canal stenosis and segmental instability.
62384528|NCT01906489|EXPERIMENTAL|AKB-6548|
62384529|NCT01906489|PLACEBO_COMPARATOR|Placebo|
62384530|NCT02909504|OTHER|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels \> 0.6 mEq/L
62384531|NCT00955682|EXPERIMENTAL|Group A|Subjects who received GSK vaccine 134612 in the primary vaccination study 109069 and will be boosted 4 years after primary vaccination with the same meningococcal vaccine as given in the primary study.
62384532|NCT00955682|ACTIVE_COMPARATOR|Group B|Subjects who received Meningitec™ vaccine in the primary vaccination study 109069 and will be boosted 4 years after primary vaccination with the same meningococcal vaccine as given in the primary study.
62384533|NCT05044715|EXPERIMENTAL|Treatment as Usual|Participants in this arm will receive treatment as usual (TAU) as an intervention.
62384534|NCT05044715|EXPERIMENTAL|Compassion-Focused Therapy|Participants in this arm will be enrolled in a CFT group intervention.
62384535|NCT05780099||Cases|patients treated at internal medicine wards
62384536|NCT04284033|EXPERIMENTAL|Standard then Extended Infusion Set|Participants will start with wearing the standard infusion set for up to 7 days, then switch to the Extended Wear infusion set for up to 7 days, then repeat the cycle for a total of 4 weeks
62384537|NCT04284033|EXPERIMENTAL|Extended then Standard Infusion Set|Participants will start with wearing the Extended Wear infusion set for up to 7 days, then switch to the standard infusion set for up to 7 days, then repeat the cycle for a total of 4 weeks
62384538|NCT03276494|OTHER|Intraosseous|Administration of intraosseous hypertonic saline
62558708|NCT01458665|EXPERIMENTAL|PRP group|
62558709|NCT01458665|PLACEBO_COMPARATOR|Conventional group|
62765917|NCT00527020|EXPERIMENTAL|Part B: Subjects in 4 period crossover period|Eligible subjects (last 7 subjects) will be randomized to one of the following 7 sequences as a 4 period crossover with sequences; NLOM, LOMN, OLNM, LNMO, NMOL, MOLN, and MNLO.
62765918|NCT03056963|EXPERIMENTAL|Positive Self-Reference Training|Participants in this arm will complete the Positive Self-Reference Training (PSRT).
62384539|NCT05536934|EXPERIMENTAL|Arginase inhibition|Endothelium dependent and -independent vasodilatation before and after 120min intra-arterial administration of arginase the inhibitor N-omega-hydroxy-nor-l-arginine (nor-NOHA) is started and is maintained for 120 min at a rate of 0.1 mg/min
62384540|NCT02290990|EXPERIMENTAL|Multiple Sclerosis patients|Patients with MS
62384541|NCT02290990|EXPERIMENTAL|Insomnia patients|Patients with insomnia
62384542|NCT02290990|EXPERIMENTAL|Health professionists|Health professionists as healthy volunteers
62384543|NCT02290990|ACTIVE_COMPARATOR|Waiting list MS|pw MS filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated
61989158|NCT05106192|EXPERIMENTAL|Cutaneous T-cell lymphomas (CTCL) Participants|"The first plaque will be treated using standard of care topical bexarotene or nitrogen mustard for participants with CTCL (cutaneous T-cell lymphomas)~The second plaque will be treated using a needle-free injector system.~After the treatment, the participants will be followed for another three visits over the course of 4 months to see how the treated areas responded."
62384544|NCT02290990|ACTIVE_COMPARATOR|Waiting list arm Insomnia|pw INS Insomnia Subject filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated
62384545|NCT02290990|ACTIVE_COMPARATOR|Waiting list arm Health professionists|Health professionist filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated.
62384546|NCT03952676|EXPERIMENTAL|Moving cupping intervention|Participants will received moving cupping therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
62384547|NCT03952676|PLACEBO_COMPARATOR|Moving cupping placebo control|Participants will received moving cupping placebo therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
62384548|NCT01501474||CholangioFlex and Fluorescent in situ Hybridization(FISH)|
62384549|NCT03844581|ACTIVE_COMPARATOR|interferential current|interferential current with a constant frequency of 100Hz for pain relief, then using rhythmic frequency of 1-100 Hz that help to disperse infiltration and adhesions for 8 successive weeks
62384550|NCT03844581|ACTIVE_COMPARATOR|anticholinergics|anticholinergics (propiverine hydrochloride 20 mg/once per day in the morning) for 8 successive weeks
62384551|NCT05156697|PLACEBO_COMPARATOR|Placebo + Exercise|Placebo pills + 60 min of aerobic exercise
62384552|NCT05156697|EXPERIMENTAL|Dihydrocapsiate + Exercise|12 mg of dihydrocapsiate pills + 60 min of aerobic exercise
62384553|NCT01839760||Inpatient cohort|Patients admitted to general wards
62384554|NCT01839760||ICU cohort|Patients admitted to ICU
62384555|NCT00680966|EXPERIMENTAL|TX1|Functional Family Therapy (FFT) followed by Adolescent Coping With Depression (ACWD)
62765919|NCT03056963|PLACEBO_COMPARATOR|Neutral Training Control|Participants in this arm will complete the neutral training paradigm.
62765920|NCT02071186|EXPERIMENTAL|Virtual Reality training|Subjects will be asked to walk on a treadmill while negotiating virtual obstacles. The VR system includes a camera based motion capture and a computer generated simulation. The camera is used to capture the movement of the participant's feet. These images are then transferred to the computer simulation and projected to the patient on a screen. The speed, orientation, size, frequency of appearance and shape of the targets are manipulated to increase task difficulty. The Virtual environment imposes a cognitive load requiring attention and response selection as well as processing of rich visual stimuli involving several perceptual processes. The system provides visual and auditory feedback of task performance to enhance motor learning.
62384556|NCT00680966|EXPERIMENTAL|TX 2|ACWD (Adolescent Coping With Depression) followed by FFT (Functional Family Therapy)
62384557|NCT00680966|EXPERIMENTAL|TX 3|Combination of an augmented FFT and ACWD - Integrated treatment
62384558|NCT02624661|EXPERIMENTAL|Glycerol injection|The patients will be injected with glycerol using a new neuronavigation-based technique in the trigeminal ganglion.
62384559|NCT01032265|ACTIVE_COMPARATOR|Web-based treatment|Web-based treatment with information (including life style), PFMT, elements of CBT and regular mail contact with an urotherapist
62384560|NCT01032265|ACTIVE_COMPARATOR|Pamphlet treatment|Information (including life style), and PFMT exercises.
62384561|NCT02561273|EXPERIMENTAL|Treatment (combination chemotherapy, lenalidomide)|"Patients receive cyclophosphamide IV, doxorubicin hydrochloride IV and vincristine sulfate IV on day 1, etoposide IV over 30-60 minutes on days 1-3, prednisone PO on days 1-5, and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients responding after 6 courses of treatment may then undergo an autologous stem cell transplant or receive maintenance lenalidomide at the discretion of the physician or patient choice as follows:~TRANSPLANT: Patients undergo autologous stem cell transplant per standard of care.~MAINTENANCE LENALIDOMIDE: Patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
62384562|NCT00632372||HeartPOD™ System with Cardiac Resynchronization Therapy|All patients will receive both a HeartPod device and a CRT-D device.
62384563|NCT01148433||TESTIM® - drug given by prescription|Male patients with Hypogonadism
62384564|NCT01416259||APF530 Exposure, Granisetron and Moxifloxacin, Placebo|Arm 1:APF530 Exposure Arm 2:Granisetron IV Arm 3:Moxifloxacin Arm 4:Placebo
62384565|NCT05791357|EXPERIMENTAL|Endocarditis patients|Patients with endocarditis who respect including criteria
62384566|NCT00137267|EXPERIMENTAL|Arm 1|This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
61989159|NCT05106192|EXPERIMENTAL|Cutaneous B-cell lymphomas (CBCL) Participants|"The first plaque will be treated using standard of care intralesional TAC (triamcinolone acetonide) using a syringe/needle with participants with CBCL (cutaneous B-cell lymphomas).~The second plaque will be treated using a needle-free injector system.~After the treatment, the participants will be followed for another three visits over the course of 4 months to see how the treated areas responded."
61989160|NCT03010111|OTHER|health care workers|health care workers including doctors, nurses, technicians and orderly who were hired in 2016 at the Hanyang University Hospital
62384567|NCT00137267|ACTIVE_COMPARATOR|Arm 2|This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
62384568|NCT00696774|EXPERIMENTAL|Duloxetine|Patients who met criteria in Study Period I (screening) were treated with duloxetine 60 milligrams (mg) once daily (QD) in an open-label manner for 4 weeks (Study Period II). Study Period II was considered the acute therapy period. Study Period III was a 4-week interval where patients who did not respond during Study Period II had their duloxetine doses optimized to 120 mg.
62384569|NCT05365984|EXPERIMENTAL|innavative modeled strategy|In this arm, the risk evaluation before discharge for hyperbilirubenemia needing further intervention is based on Bhutani nomogram and end tidal carbon monoxide corrected for ambient carbon monoxide. Assessment result includes high risk, median risk, low risk and delayed discharge. Internet Plus technology is applied in follow-up management.
62558710|NCT02463370|EXPERIMENTAL|Group II|Group II patients will receive local anesthetic infiltration in two injections on each side of the face at the maxillary and infra-orbital areas and the remaining injections are placebo (saline).
62765921|NCT02071186|EXPERIMENTAL|Computerized Cognitive Remediation|"The AttenGo program will be used for neuro-cognitive remediation aimed at enhancing attention, concentration, working memory, and executive function. The program has shown to be effective in improving attention and executive function in children with ADHD. The training is composed of cognitive exercises that challenge subjects with problem solving, information processing, response inhibition and dividing attention. The users receive immediate feedback from the system when losing focus. The program is adaptive and progresses according to the subjects abilities."
62765922|NCT02071186|ACTIVE_COMPARATOR|Control group|Subjects in this group will be assessed based on the study protocol but will receive no treatment other than their standard of care which could include pharmacological or/ and non-pharmacological treatment.
62765923|NCT03075995|EXPERIMENTAL|lapatinib administered with hight-fat breakfast|
62765924|NCT00276614|EXPERIMENTAL|Velcade|Velcade IV twice a week for two weeks on Days 1, 4, 8 and 11 of each cycle. A 10 day-rest period (Days 12-21) with no Velcade will follow the 2 weeks of treatment in each cycle. one cycle = 21 days
62765925|NCT03761212||Patient with ankylosing spondylitis or axial spondyloarthritis|No intervention - observational study
62765926|NCT03761212||Healthy controls|Age and sex matched healthy controls
61989161|NCT01218074|ACTIVE_COMPARATOR|Thromboelastography alone|Patients undergo standard of care Thromboelastography to evaluate overall coagulation performances.
61989162|NCT01218074|EXPERIMENTAL|Aggregometry+Tromboelastography|Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
61989163|NCT06030882|EXPERIMENTAL|Biologic Care Pathway|Care through a biologic care pathway
61989164|NCT06030882|NO_INTERVENTION|Control|Care as usual
62765927|NCT02532712|EXPERIMENTAL|Single dose group-Group 1-Experimental|Single dose, 500mg of Study drug(EC-18)
62765928|NCT02532712|PLACEBO_COMPARATOR|Single dose group-Group 1-Placebo|Single dose, 500mg of Placebo
62765929|NCT02532712|EXPERIMENTAL|Single dose group-Group 2-Experimental|Single dose, 1000mg of Study drug(EC-18)
62765930|NCT02532712|PLACEBO_COMPARATOR|Single dose group-Group 2-Placebo|Single dose, 1000mg of Placebo
62765931|NCT02532712|EXPERIMENTAL|Single dose group-Group 3-Experimental|Single dose, 2000mg of Study drug (EC-18)
61989165|NCT04211701|EXPERIMENTAL|Connective Tissue Massage|Connective tissue massage will be applied to the lumbo-sacral region, lower thoracic, scapular and interscapular regions, respectively. The treatment will be administered for four weeks, five days a week.
61989166|NCT04211701|EXPERIMENTAL|Classical Massage|Classic massage will be applied to the lower back and upper back, respectively, while the patient is lying in the prone position. The treatment will be administered for four weeks, five days a week.
62558711|NCT02463370|EXPERIMENTAL|Group V|Group V patients will receive local anesthesia in five injections on each side of the face at the infra-orbital area, supratrochlear area, medial to the medial canthus, nasal still and anterior septum. The remaining maxillary injection is placebo.
62558712|NCT04412356|EXPERIMENTAL|Early tracheotomy|Tracheotomy within 7 days after intubation.
62558713|NCT04412356|ACTIVE_COMPARATOR|Late tracheotomy|Tracheotomy after at least 10 days after intubation.
62765932|NCT02532712|PLACEBO_COMPARATOR|Single dose group-Group 3-Placebo|Single dose, 2000mg of Placebo
61989167|NCT06504199|EXPERIMENTAL|ZGR followed short cycle of Obinutuzumab and Cytarabine|All patients were treated with ZGR regimen for 6 cycles after enrollment, followed by 3 cycles of Obinutuzumab and Cytarabine in 28-day cycles. Obinutuzumab: 1000 mg, intravenous drip, administered on d1, d8 and d15 of the first cycle, and administered on the first day of each cycle starting from the second cycle. Zanubrutinib: 160 mg, bid, continuous oral. Lenalidomide: 20 mg/d, qd, oral, d1-d21.Cytarabine: for young tolerable patients, the dose is 2 g/m2, q12h, intravenous drip, d1-2ND for elderly/intolerant patients, the dose is 500 mg/m2, q12h, intravenous drip, completed 2-3 hours, d1-3. The specific dose is determined by the investigator according to the actual situation of the patient. Zanubrutinib for 2 years combination with Lenalidomide for 1 year was used for maintenance treatment in non-high-risk patients and in high-risk patients after recovery of hemogram 2 months after CAR-T.
61989168|NCT04930848|EXPERIMENTAL|Intervention Arm|Euphorbia hirta
62765933|NCT02532712|EXPERIMENTAL|Single dose group-Group 4-Experimental|Single dose, 4000mg of Study drug (EC-18)
62765934|NCT02532712|PLACEBO_COMPARATOR|Single dose group-Group 4-Placebo|Single dose, 4000mg of Placebo
62765935|NCT02532712|EXPERIMENTAL|Multiple dose group-Group 1-Experimental|Multiple dose, Study drug(EC-18) 500mg, Once daily, for 14 days
62765936|NCT02532712|PLACEBO_COMPARATOR|Multiple dose group-Group 1-Placebo|Multiple dose, Placebo 500mg, Once daily, for 14 days
62765937|NCT02532712|EXPERIMENTAL|Multiple dose group-Group 2-Experimental|Multiple dose, Study drug(EC-18) 1000mg, Once daily, for 14 days
61989169|NCT04930848|PLACEBO_COMPARATOR|Placebo Arm|Terminalia arjuna and Terminalia bellerica
61989170|NCT04918212|EXPERIMENTAL|Fabulous Stent Graft System|All patients received endovascular surgery using fabulous stent graft system
61989171|NCT05778396|ACTIVE_COMPARATOR|Active spinal manual therapy protocol|(1) Side-lying lumbar spine manipulation, (2) prone lumbar spine mobilization, and (3) prone thoracic spine manipulation.
61989172|NCT05778396|SHAM_COMPARATOR|Control spinal manual therapy protocol|(1) Control side-lying lumbar spine manipulation, (2) control prone lumbar spine mobilization, and (3) control prone thoracic spine manipulation.
61989173|NCT06069479||Conservative group|Children with trigonocephaly that are treated conservatively.
62384570|NCT05365984|NO_INTERVENTION|traditional strategy|In this arm, the risk evaluation before discharge for hyperbilirubenemia needing further intervention is based on Bhutani nomogram and the follow-up table advised by the Chinese guideline for neonatal hyperbilirubinemia. Assessment result includes high risk, median risk and low risk. Traditional outpatient is applied in follow-up management.
62384571|NCT00688649|ACTIVE_COMPARATOR|1|Standard ONS
62384572|NCT00688649|ACTIVE_COMPARATOR|2|High Energy ONS
62384573|NCT01533285|OTHER|Group 1|Treatment AB: Treatment A (Placebo vaccination) administered \[Period 1\], after the washout period (7-14 days) Treatment B (typhoid vaccination) administered \[Period 2\]
61989174|NCT06069479||Surgical group|Children with trigonocephaly that are treated surgically.
61989175|NCT04714996|EXPERIMENTAL|ES-481|
61989176|NCT04714996|PLACEBO_COMPARATOR|Placebo|
61989177|NCT04714996|OTHER|Open-Label Extension Study|
62384574|NCT01533285|OTHER|Group 2|Treatment BA: Treatment B (typhoid vaccination) administered \[Period 1\], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered \[Period 2\]
62384575|NCT01533285|OTHER|Group 3|Treatment AC: Treatment A (Placebo vaccination) administered \[Period 1\], after the washout period (7-14 days) Treatment C (TSST+Placebo vaccination) administered \[Period 2\]
62384576|NCT01533285|OTHER|Group 4|Treatment CA: Treatment C (TSST+Placebo vaccination) administered \[Period 1\], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered \[Period 2\]
62384577|NCT01533285|OTHER|Group 5|Treatment AD:Treatment A (Placebo vaccination) administered \[Period 1\], after the washout period (7-14 days) Treatment D (TSST+typhoid vaccination) administered \[Period 2\]
62384578|NCT01533285|OTHER|Group 6|Treatment DA:Treatment D (TSST+typhoid vaccination) administered \[Period 1\], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered \[Period 2\]
62765938|NCT02532712|PLACEBO_COMPARATOR|Multiple dose group-Group 2-Placebo|Multiple dose, Placebo 1000mg, Once daily, for 14 days
62384579|NCT05212623|EXPERIMENTAL|Group A|"Subjects received 2 doses of 0.25 mL of quadrivalent influenza vaccine, 4 weeks apart.~Each 0.25-ml dose contained 7.5 μg of hemagglutinin per strain (Four types of virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata)."
62384580|NCT05212623|EXPERIMENTAL|Group B|Subjects received 2 doses of 0.5 mL of quadrivalent influenza vaccine, 4 weeks apart. Each 0.5-ml dose contained 15 μg of hemagglutinin per strain.(Four types of virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata).
62765939|NCT02532712|EXPERIMENTAL|Multiple dose group-Group 3-Experimental|Multiple dose, Study drug(EC-18) 2000mg, Once daily, for 14 days
62765940|NCT02532712|PLACEBO_COMPARATOR|Multiple dose group-Group 3-Placebo|Multiple dose, Placebo 2000mg, Once daily, for 14 days
62765941|NCT02532712|EXPERIMENTAL|Multiple dose group-Group 4-Experimental|Multiple dose, Study drug(EC-18) 4000mg, Once daily, for 14 days
62765942|NCT02532712|PLACEBO_COMPARATOR|Multiple dose group-Group 4-Placebo|Multiple dose, Placebo 4000mg, Once daily, for 14 days
62765943|NCT04591743|EXPERIMENTAL|Experimental group|
62765944|NCT04591743|PLACEBO_COMPARATOR|Placebo group|
62765945|NCT05782114|EXPERIMENTAL|The experimental Group A|"Extracorporeal Shockwave therapy (four sessions one session per week)~+Traditional physical therapy program (Instruction to wear Thumb Spica splint, Ultrasound therapy, stretching exercise \& strengthening exercise) (two sessions per week for 4 weeks)."
62765946|NCT05782114|ACTIVE_COMPARATOR|The control Group B|Traditional physical therapy program (Instruction to wear Thumb Spica splint, Ultrasound therapy, stretching exercise \& strengthening exercise) (two sessions per week for 4 weeks).
62765947|NCT04625556||Prostate cancer|Patients diagnosed as prostate cancer and have undergone prostatectomy
62765948|NCT04625556||Renal cell cancer|Patients diagnosed as renal cell cancer and have undergone partial or radical nephrectomy
62765949|NCT04625556||Bladder cancer|Patients diagnosed as bladder cancer and have undergone radical or partial cystectomy
62765950|NCT04625556||Ureter cancer|Patients diagnosed as ureter cancer and have undergone nephroureterectomy or ureterectomy
62765951|NCT03855800|EXPERIMENTAL|Clinical Follow-up|"Participants not undergoing surgery will be assigned to the Clinical Follow-up study group. Blood, stool, pancreatic juice and cyst fluid collection will be done as per protocol. All participants in the Clinical Follow-up group will be contacted yearly for a telephone interview until they undergo surgery, die, receive a diagnosis that excludes them from the study, or for 5 years, and interval medical records will be obtained and reviewed. During follow-up results of clinically indicated follow-up imaging studies will be abstracted"
62765952|NCT03855800|OTHER|Surgical|"Participants scheduled for surgical resection after their initial clinical evaluation will be assigned to the Immediate Surgery study group. Blood, stool, pancreatic juice and cyst fluid collection will be done as per protocol. Participants in the Immediate Surgery group will be followed until the surgical pathology of their pancreatic cyst is known."
62765953|NCT01316952||LabRx database Oct. 1st 2004 to Sep. 30th 2009|The study cohort from which cases and controls are drawn is all subjects in the LabRx database between Oct. 1st 2004 to Sep. 30th 2009.
62765954|NCT02496169|EXPERIMENTAL|eucaLimus|Percutaneous Coronary Intervention (PCI)
62765955|NCT04566653||dialysis-dependent|chronic kidney disease patients with hyperkalaemia and dialysis-dependent
62765956|NCT04566653||non-dialysis-dependent|chronic kidney disease patients with hyperkalaemia and non-dialysis-dependent
62765957|NCT03597477||Autism Spectrum Disorder|Patients with a diagnosis of autism spectrum disorder
62765958|NCT03597477||Control|Patients with no developmental diagnoses
62765959|NCT01313819|ACTIVE_COMPARATOR|Group 1|Give IV amantadine first then IV placebo(normal saline) drug
62765960|NCT01313819|ACTIVE_COMPARATOR|Group 2|Give IV placebo drug first then IV amantadine
62765961|NCT00780481|EXPERIMENTAL|Bradykinin|Patients will have flow mediated vasodilation and radial artery tonometry performed. They will then receive 0, 10, 20, 40 ng/100cc/min of intrabrachial bradykinin. Strain gauge plethysmography and blood sampling at each dose will be done to evaluate t-PA release. Blood will also be drawn for other biomarkers.
62765962|NCT06020846|EXPERIMENTAL|Soleus Pushup Exercise group A|soleus push up exercise
61989178|NCT05988398|EXPERIMENTAL|RTS Intervention|RTS intervention will include a total of one 120-minute session of programming delivered to school personnel, and six, 45-minute sessions (total = 4.5 hours) for students. There are five components in this intervention that both students and school personnels will receive: 1) Psychoeducation on CSEC, 2) Healthy relationship skills training, 3) Programming components to enhance valuing of self and others, 4) Bystander intervention skills, and 5) Social norms for both students and school personnel. Students will additionally receive programming on Identification of safe people and resources, while school personnel will receive programming on Responding to Student Disclosures, and Cultural Humility.
61989179|NCT05669820|ACTIVE_COMPARATOR|Salovum|Salovum, an egg yolk powder will be orally at dose of 11 g 3 times daily.
62765963|NCT06020846|ACTIVE_COMPARATOR|Treadmill group 2|treadmill walk
62765964|NCT06112652|ACTIVE_COMPARATOR|4 session rTMS|Four sessions of active rTMS would be delivered to the left DLPFC daily, with a session of 1800 pulse.
62765965|NCT06112652|ACTIVE_COMPARATOR|6 session rTMS|Six sessions of active TMS would be delivered to the left DLPFC daily, with a session of 1800 pulse.
62384581|NCT05212623|ACTIVE_COMPARATOR|Group C|Subjects received 2 doses of 0.25 mL of influenza vaccine, 4 weeks apart. Each 0.25-ml dose contained 7.5 μg of hemagglutinin per strain (3 type of virus strains, including BY).
62384582|NCT05212623|ACTIVE_COMPARATOR|Group D|Subjects received 2 doses of 0.25 mL of influenza vaccine, 4 weeks apart. Each 0.25-ml dose contained 7.5 μg of hemagglutinin per strain (3 types of virus strains, including BV).
62765966|NCT06112652|ACTIVE_COMPARATOR|8 session rTMS|Eight sessions of active rTMS would be delivered to the left DLPFC daily, with a session of 1800 pulse.
62765967|NCT06112652|ACTIVE_COMPARATOR|10 session rTMS|Ten sessions of active rTMS would be delivered to the left DLPFC daily, with a session of 1800 pulse.
62765968|NCT06112652|SHAM_COMPARATOR|sham rTMS|Subjects were randomized to receive 4 sessions or 6 sessions or 8 sessions or 10 sessions of sham rTMS to the left DLPFC daily in a 1:1:1:1 ratio.
62765969|NCT00424190|EXPERIMENTAL|Ceftaroline for Injection|
62765970|NCT00424190|ACTIVE_COMPARATOR|IV Vancomycin and IV Aztreonam|
61989180|NCT05669820|PLACEBO_COMPARATOR|Placebo|Placebo, an egg yolk powder will be orally at dose of 11 g 3 times daily.
62765971|NCT02044666|EXPERIMENTAL|Treatment|
62765972|NCT00334360|EXPERIMENTAL|1|dexmedetomidine
62765973|NCT00334360|EXPERIMENTAL|2|Buspirone
62765974|NCT00334360|EXPERIMENTAL|3|Buspirone and dexmedetomidine
62765975|NCT00334360|PLACEBO_COMPARATOR|Control|No drug
62765976|NCT00841399|EXPERIMENTAL|E75 + GM-CSF vaccine|The dose escalation scheme is for three patients to receive each of the doses, 100, 500, and 1,000 mcg of peptide + 250 mcg GM-CSF each month for 6 months until the maximum tolerated dose is determined. Patients who receive the vaccine are HLA-A2+ and/or HLA-A3+. Responses to the vaccine are measured via immunologic assays.
62765977|NCT00841399|NO_INTERVENTION|Control/observation|HLA-A2- and HLA-A3- patients do not receive the E37 + GM-CSF vaccine, but are instead enrolled to the control arm for observation.
62765978|NCT00817648|EXPERIMENTAL|1|Quetiapine fumarate, flexible doses(600-750 mg/d)
62765979|NCT00817648|ACTIVE_COMPARATOR|2|risperidone, flexible doses(3-6 mg/d)
62765980|NCT05722041||Customized Abutment|Customized abutment will be placed after molar immediate implant placement.
62765981|NCT05722041||Conventional Abutment|Conventional abutment will be placed after molar immediate implant placement.
62765982|NCT00907296|PLACEBO_COMPARATOR|Placebo|Participants received subcutaneous injections of matching placebo on day 1 and at weeks 2, 6, and 12.
62765983|NCT00907296|EXPERIMENTAL|Romosozumab 70 mg: 2 Doses|Participants received subcutaneous injections of 70 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
62765984|NCT00907296|EXPERIMENTAL|Romosozumab 70 mg: 3 Doses|Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
62765985|NCT00907296|EXPERIMENTAL|Romosozumab 70 mg: 4 Doses|Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2, 6, and 12.
62765986|NCT00907296|EXPERIMENTAL|Romosozumab 140 mg: 2 Doses|Participants received subcutaneous injections of 140 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
61989181|NCT01016444||Albuterol responsive|Those who respond clinically to albuterol.
62384583|NCT02545686|EXPERIMENTAL|one|"this is a single arm study. All subjects treated the same way, and undergo four interventions:~1. Chest wall movement assessment without CPAP~2. Breath hold assessment without CPAP~3. Chest wall movement assessment with CPAP~4. Breath hold assessment with CPAP"
62384584|NCT03845010|ACTIVE_COMPARATOR|Sotalol|
62384585|NCT03845010|ACTIVE_COMPARATOR|Flecainide and verapamil|
62384586|NCT03845010|ACTIVE_COMPARATOR|Catheter ablation|
62384587|NCT04470349||LITOS|Patients who received a LITOS dynamic distraction system after 31.12.2017
62558714|NCT06084299|EXPERIMENTAL|Treatment (autologous tumor infiltrating lymphocytes)|Post-NMA lymphodepletion, patients are infused with their autologous TIL followed by IL-2 administration.
62384588|NCT04470349||Ligamentotaxor|Patients who received a Ligamentotaxor dynamic distraction system after 31.12.2017
62765987|NCT00907296|EXPERIMENTAL|Romosozumab 140 mg: 3 Doses|Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
62765988|NCT00907296|EXPERIMENTAL|Romosozumab 140 mg: 4 Doses|Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2, 6, and 12.
62765989|NCT00907296|EXPERIMENTAL|Romosozumab 210 mg: 2 Doses|Participants received subcutaneous injections of 210 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
62765990|NCT00907296|EXPERIMENTAL|Romosozumab 210 mg: 3 Doses|Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
62765991|NCT00907296|EXPERIMENTAL|Romosozumab 210 mg: 4 Doses|Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2, 6, and 12.
62765992|NCT01352637|PLACEBO_COMPARATOR|Placebo + Prolonged Imaginal Exposure|Drug: Placebo (sugar pill) + Prolonged Imaginal Exposure (PE) PTSD treatment
62765993|NCT01352637|PLACEBO_COMPARATOR|Placebo + VR exposure|Drug: Placebo (sugar pill) + Virtual Reality Exposure (VR) PTSD treatment
62765994|NCT01352637|ACTIVE_COMPARATOR|DCS + Prolonged Imaginal Exposure|Drug: 50mg DCS (D-Cycloserine ) + Prolonged Imaginal Exposure (PE) PTSD treatment
62765995|NCT01352637|ACTIVE_COMPARATOR|DCS+VR exposure|Drug: 50mg DCS (D-Cycloserine ) + Virtual Reality Exposure (VR) PTSD treatment
62765996|NCT02177019|EXPERIMENTAL|Development of personal health plan|Personal Health Plan
62765997|NCT01672866|EXPERIMENTAL|SIM 75 mg|During the Randomized Double-Blind Phase, participants will receive SIM 75 mg via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
62765998|NCT01672866|EXPERIMENTAL|SIM 125 mg|During the Randomized Double-Blind Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
61989182|NCT01016444||Albuterol unresponsive|Albuterol non-responsiveness is defined as a failure of the PEFR in an acutely ill asthmatic to exceed 40% of predicted following ≥7.5 mg of albuterol (2.5 mg albuterol aerosols q.20 min x3).
61989183|NCT02930421|EXPERIMENTAL|Exercise training (ET)|Patients will enter an 8-week ET program of 3 days per week supervised exercise training at the Rehabilitation Physiotherapy Gymnasium. Exercise training will include high-intensity endurance training at 60-80% of baseline peak work rate and strength training of upper and lower limbs with 3 sets of 6 repetitions at 50% of one repetition maximum. Each session will be 60 min duration, 30 min dedicated to cycle exercise.
62384589|NCT01536418|EXPERIMENTAL|GSK1605786A, 500 milligrams, once daily|500 milligrams once daily, orally administered for 12 weeks
62384590|NCT01536418|EXPERIMENTAL|GSK1605786A, 500 milligrams twice daily|500 milligrams twice daily, orally administered for 12 weeks
62558715|NCT02810873|EXPERIMENTAL|F-18-FDG Whole body Scan|STAGE I: Patients with a positive biopsy and abnormal (positive) fludeoxyglucose F18-labeled PET whole-body scan undergo a whole-body copper Cu 64 TP3805-labeled PET scan.
62558716|NCT02810873|EXPERIMENTAL|No F-18-FDG Scan|STAGE II: Patients with a positive biopsy, but no fludeoxyglucose F18 scan undergo a breast fludeoxyglucose F18-labeled PEM Positron Emission Mammography scan followed by a breast copper Cu 64 TP3805-labeled PEM scan.
61989184|NCT02930421|NO_INTERVENTION|Usual care (UC)|The UC group will receive usual outpatient care and follow-up.
61989185|NCT03849742|EXPERIMENTAL|Heath services research (Uber rides)|Patients receive Uber rides to and from scheduled radiotherapy appointments for up to 6 months.
61989186|NCT00112658|EXPERIMENTAL|Folfirinox|
61989187|NCT00112658|ACTIVE_COMPARATOR|Gemcitabine|
62384591|NCT00004842|EXPERIMENTAL|Budesonide|Oral budesonide
62558717|NCT06535516|ACTIVE_COMPARATOR|Standard Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)|TF-CBT will be administered as typically implemented at Pediatric Behavioral Health and Wellness outpatient clinic
62558718|NCT06535516|EXPERIMENTAL|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) and Racial Socialization|TF-CBT will be implemented enhanced with racial socialization components
62765999|NCT01672866|PLACEBO_COMPARATOR|Placebo|During the Randomized Double-Blind Phase, participants will receive placebo to match SIM via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
61989188|NCT03536403|EXPERIMENTAL|healthy volunteers|EOS X-rays is done with et without a kyphosis induced corset and 8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
62766000|NCT05020964|EXPERIMENTAL|Experimental Arm|Trastuzumab and Pyrotinib
61989189|NCT06404632|EXPERIMENTAL|Lev-g (group intervention)|Lev-g includes three sessions + a booster session using psychoeducation, motivational interviewing, and applied behavioral analyses. Lev-g is done in groups to enable support and tips from others. There is no control condition. Only one arm to test feasibility.
62384592|NCT06353529|EXPERIMENTAL|Bupivacaine injection|This group will receive bilateral injection of 0.5% bupivacaine with 1:200,000 epinephrine using a 20G needle and comprising 2mL of fluid on each side (4mL total) into the sphenopalatine ganglion.
62384593|NCT06353529|PLACEBO_COMPARATOR|Placebo Control|This group will receive bilateral injection of 0.9% saline solution using a 20G needle and comprising 2mL of fluid on each side (4mL total) into the sphenopalatine ganglion.
62766001|NCT04512638|ACTIVE_COMPARATOR|Conservative treatment|Amoxicillin-based antibiotics and chlorhexidine oral rinse. Minor debridement. Primary wound closure is not part of this treatment strategy.
62766002|NCT04512638|EXPERIMENTAL|Minimally invasive approach + LPRF|Amoxicillin-based antibiotics and chlorhexidine oral rinse. Minimally-invasive surgical treatment, including sequestrectomy, debridement of soft tissue, and application of LPRF membranes before tension-free wound closure is obtained. Marginal resection of all necrotic bone is not part of this treatment strategy.
62384594|NCT04451369|NO_INTERVENTION|Control group|Group without prehabilitation program before surgery
62384595|NCT04451369|EXPERIMENTAL|Prehabilitation group|Group will follows a prehabilitation program before surgery
62384596|NCT00715039|ACTIVE_COMPARATOR|lorazepam|
62384597|NCT00715039|PLACEBO_COMPARATOR|placebo|
62384598|NCT00715039|ACTIVE_COMPARATOR|paroxetine|
62384599|NCT05455723|ACTIVE_COMPARATOR|Inflation-Deflation Group|
62384600|NCT05455723|ACTIVE_COMPARATOR|Magill Forceps Group|
62384601|NCT02571829|EXPERIMENTAL|ribociclib|single arm ribociclib Oral 600 mg x 1 a day duration according to response.
62384602|NCT03236649|EXPERIMENTAL|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
62384603|NCT03236649|ACTIVE_COMPARATOR|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
62384604|NCT02840903||Setting 1 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
62766003|NCT04512638|EXPERIMENTAL|Primary surgical management|Amoxicillin-based antibiotics and chlorhexidine oral rinse. Removal of the necrotic bone without excessive resection of healthy bone. Buccal mucoperiosteal flaps will be used to achieve a tension-free mucosal coverage.
62766004|NCT04527419|ACTIVE_COMPARATOR|Systematically mediastinal lymph node dissection group|Systematically mediastinal lymph node dissection will be performed.
62766005|NCT04527419|EXPERIMENTAL|No mediastinal lymph node dissection group|Mediastinal lymph node dissection will not be performed.
62766006|NCT04034940|OTHER|primary PCI STEMI patients|All Patients with AMI refered for primary PCI in single center
62766007|NCT02089152|OTHER|Cluster A|General education for prevention of diabetic complications in year 1, Melioidosis prevention education in years 2, 3 and 4.
62766008|NCT02089152|OTHER|Cluster B|General education for prevention of diabetic complications in year 1 and 2, Melioidosis prevention education in year 3 and 4.
62766009|NCT02089152|OTHER|Cluster C|General education for prevention of diabetic complications in year 1, 2 and 3, Melioidosis prevention education in year 4.
62766010|NCT02773771|PLACEBO_COMPARATOR|Placebo + Vital HP|GROUP 1 will receive Placebo (within 24 hours of ICU admission) and Vital HP ® (while on tube feeds). Vital HP® is on the Massachusetts General hospital formulary, but it is often restricted to patients with malabsorption due to its higher cost compared to other standard enteral nutrition formulas.
62766011|NCT02773771|EXPERIMENTAL|B-hydroxy-B-methylbutyrate (HMB) + Vital HP|GROUP 2 will receive beta-hydroxy-beta-methylbutyrate (within 24 hours of ICU admission) and Vital HP ® (while on tube feeds). Vital HP® is on the Massachusetts General hospital formulary, but it is often restricted to patients with malabsorption due to its higher cost compared to other standard enteral nutrition formulas. The investigators will limit HMB dosing to 3g/day since this is the most widely studied dose.
62766012|NCT02634606|ACTIVE_COMPARATOR|Gamma Delta Tocotrienols - Low Dose|33 subjects with cholesterol level (\>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (63mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
62766013|NCT02634606|ACTIVE_COMPARATOR|Gamma Delta Tocotrienols - High Dose|33 subjects with cholesterol level (\>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (127mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
62766014|NCT02634606|PLACEBO_COMPARATOR|Sugar Pill|33 subjects with cholesterol level (\>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the Placebo arm of the study to evaluate the cholesterol suppressive actions of Placebo. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
62766015|NCT02646839|EXPERIMENTAL|KIR Favorable Transplant|To assess in a multi-center setting whether the disease-free survival (DFS) at one-year post-HCT for children with high-risk ALL, AML and MDS can be improved following favorably KIR-mismatched haplo-HCT using a graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells from CliniMacs TCR alpha-beta-Biotin system
62766016|NCT06169800|EXPERIMENTAL|MPFL repair with Biobrace augmentation|Patients presenting with first-time lateral patellofemoral dislocation within the previous 7 days will be offered a patellofemoral stabilization procedure, including knee arthroscopy and an MPFL repair augmented with Biobrace® synthetic ligament.
62766017|NCT02102126|EXPERIMENTAL|Renal denervation|Subjects are treated with the renal denervation procedure after randomization and are maintained on baseline anti-hypertensive medications
62766018|NCT02102126|NO_INTERVENTION|Control group|Subjects are maintained on baseline anti-hypertensive medications.
62766019|NCT00137189|EXPERIMENTAL|Music therapy|See published study protocol
62766020|NCT00137189|OTHER|Standard care|See published study protocol
62766021|NCT02170766|EXPERIMENTAL|BIBR 1048 low1|"Two treatments of one single dose of BIBR 1048 12.5 mg without or with Pantoprazole~1. BIBR 1048 12.5 mg without Pantoprazole~2. BIBR 1048 12.5 mg with 40 mg Pantoprazole (bid)"
62766022|NCT02170766|EXPERIMENTAL|BIBR 1048 low2|"Two treatments of one single dose of BIBR 1048 25 mg without or with Pantoprazole~1. BIBR 1048 25 mg without Pantoprazole~2. BIBR 1048 25 mg with 40 mg Pantoprazole (bid)"
62766023|NCT02170766|EXPERIMENTAL|BIBR 1048 medium|"Two treatments of one single dose of BIBR 1048 50 mg without or with Pantoprazole~1. BIBR 1048 50 mg without Pantoprazole~2. BIBR 1048 50 mg with 40 mg Pantoprazole (bid)"
62766024|NCT02170766|EXPERIMENTAL|BIBR 1048 high|"Two treatments of one single dose of BIBR 1048 100 mg without or with Pantoprazole~1. BIBR 1048 100 mg without Pantoprazole~2. BIBR 1048 100 mg with 40 mg Pantoprazole (bid)"
62384605|NCT02840903||Setting 2 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.65 ml/kg BW, tube voltage = 80 kvp
62766025|NCT05590000|EXPERIMENTAL|Gemini rechargeable Spinal Cord Stimulation (SCS) System|Patients will be implanted with the Gemini rechargeable SCS System
62766026|NCT00748709|EXPERIMENTAL|BIBW 2992 (Afatinib)|BIBW 2992 (Afatinib) for patients FISH positive for/or harboring EGFR or HER2 Mutation
62766027|NCT01272791|EXPERIMENTAL|Gemcitabine, bavituximab|Gemcitabine will be administered on Days 1, 8, 15 of each 28-day (4 weeks) cycle until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will receive 3 mg/kg weekly (in addition to gemcitabine) until disease progression or unacceptable toxicities
62766028|NCT01272791|ACTIVE_COMPARATOR|Gemcitabine|Patients randomized to Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities.
62384606|NCT02840903||Setting 3 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
62766029|NCT06320548|EXPERIMENTAL|Low-residue diet|Patients received clear explanations, practical schemes, and a list of allowed foods, tailored to fit individual needs.
62766030|NCT06320548|ACTIVE_COMPARATOR|Free diet|Patients had free diet.
62766031|NCT00027586|EXPERIMENTAL|Imatinib Mesylate|400 mg twice a day orally
62766032|NCT00933920|ACTIVE_COMPARATOR|Fed Group|
62766033|NCT00933920|ACTIVE_COMPARATOR|Fasted group|
62766034|NCT06453564||18.5≤ BMI <23.9|The investigators planned to recruit 10 volunteers with a BMI between 18 and 23. Half male, half female. There are no age restrictions. Because there are large differences in body composition among people with different BMI, there are also differences between men and women. The investigators will look at the differences in body composition measured by different methods for each individual in this group.
62766035|NCT06453564||24≤BMI<27.9|The investigators planned to recruit 10 volunteers with a BMI between 23 and 30. Half male, half female. There are no age restrictions. The volunteers in this group were relatively underweight. The investigators will look at the differences in body composition measured by different methods for each individual in this group.
62766036|NCT06453564||28≤BMI<35|The investigators planned to recruit 10 volunteers with a BMI between 30 and 35. Half male, half female. There are no age restrictions. The volunteers in this group were obese patients. The investigators will look at the differences in body composition measured by different methods for each individual in this group.
62766037|NCT04913701||1 - Health workers|A total number of 200-300 healthcare workers, exposed to close contact with patients, will be asked to participate to the study and will be asked to sign the informed consent.
62766038|NCT04913701||2 - Patients|A total number of 100-200 patients admitted to the rehabilitation facility, referred from other healthcare facilities or from their own home, will be asked to participate to the study.
61989190|NCT03961542|EXPERIMENTAL|Intervention Group|"This study aims to assess the impact of enhanced chewing on glycaemic control in females with newly diagnosed GDM. It is hypothesised, that a fixed amount of gum chewed for 20 minutes before starting each meal could improve hyperglycaemia. The impact of chewing on postprandial capillary blood glucose (measured at one hour after breakfast, lunch and dinner) is determined as the primary outcome of this study.~Differences in fasting glucose and longitudinal changes over the study period should be additionally examined."
61989191|NCT03961542|NO_INTERVENTION|Control Group|Participants will be randomized to either treatment (chewing gum) or control group (routine care) in a 1:1 ratio. The minimisation method \[Pocock 1975\] will be used to minimize the imbalance between the groups according to the preconceptional overweight/obesity status with three strata: i. normal weight (i.e. BMI below 25 kg/m²); ii. overweight (BMI 26 - 30 kg/m²); iii. obesity (BMI and above 30 kg/m²).
61989192|NCT06308809|EXPERIMENTAL|PNF training group|The experimental group will undergo 60 minutes of PNF training.
61989193|NCT06308809|OTHER|Control training group|The control group will follow the curriculum standards set by the Sports University.
61989194|NCT01869296|ACTIVE_COMPARATOR|higher flow rates endoscope pump|higher flow rates endoscope water pump : 10.4 ml/sec
62766039|NCT04913701||3 - Real life participants|A total number of 100 real-life participants, will be represented by volunteers (other employees, staff not in contact with patients
62766040|NCT04292990|EXPERIMENTAL|Fentanyl|Intervention: Drug: Fentanyl Transdermal Patch
62766041|NCT04292990|ACTIVE_COMPARATOR|Morphine|Intervention: Drug: Morphine Controlled-Release Tablets
62766042|NCT03275948|EXPERIMENTAL|whole grain|
62558719|NCT04579354|NO_INTERVENTION|Standardized Anaesthesia briefing|standardised anaesthesia information sessions, consisting of a detailed explanation of the anaesthesia procedure by the anaesthetist A specific information sheet is used to explain the procedure and the form of anaesthesia. This corresponds to the current procedure before an operation.
62766043|NCT03275948|OTHER|refrence|white wheat based product
62766044|NCT00787202|EXPERIMENTAL|15 mg BID|
62766045|NCT00787202|EXPERIMENTAL|10 mg BID|
61989195|NCT01869296|EXPERIMENTAL|lower flow rates endoscope water pump|lower flow rates endoscope water pump : 1.7 ml/sec
61989196|NCT06358105|EXPERIMENTAL|Simulator-based training group|Interventional cardiology fellows will undergo a two-day training program on high-fidelity simulators
61989197|NCT06358105|ACTIVE_COMPARATOR|Standard group|Interventional cardiology fellows will undergo standard training based on master-apprentice model
61989198|NCT01393405|ACTIVE_COMPARATOR|Methotrexate|25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
61989199|NCT01393405|PLACEBO_COMPARATOR|Placebo|Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
62766046|NCT00787202|EXPERIMENTAL|3 mg BID|
62766047|NCT00787202|EXPERIMENTAL|0.5 mg BID|
62766048|NCT00787202|PLACEBO_COMPARATOR|Placebo|
62766049|NCT00316693|EXPERIMENTAL|Cervarix Group|Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.
62766050|NCT00316693|ACTIVE_COMPARATOR|Aimmugen Group|Subjects received 3 doses of Aimmugen™ (Hepatitis A \[HAV\] vaccine) according to a 0, 1, 6-month schedule.
62766051|NCT06358586|EXPERIMENTAL|Tachipirina® 120 mg/5 mL oral suspension, strawberry flavour|All healthy paediatric volunteers administered with the mediation
62766052|NCT01048866|EXPERIMENTAL|flurbiprofen 8.75 mg lozenge|Participants were instructed to suck one study (flurbiprofen 8.75 mg) lozenge and efficacy assessments were taken in the clinic. Upon discharge, participants were instructed to use another study medication lozenge every 3-6 hours, up to a total of 5 study lozenges in 24 hours. Following efficacy assessments, participants were again instructed to use study medication lozenge every 3-6 hours, up to a total of 5 study lozenges per day (plus rescue medication if needed) for the remaining time in the 7 day study.
61989200|NCT02473315|EXPERIMENTAL|cryotherapy|
61989201|NCT02473315|PLACEBO_COMPARATOR|light cryotherapy|
62384607|NCT02840903||Setting 4 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 100 kvp
62384608|NCT02840903||Setting 5 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
62766053|NCT01048866|PLACEBO_COMPARATOR|placebo lozenge|Participants were instructed to suck one study (placebo) lozenge and efficacy assessments were taken in the clinic. Upon discharge, participants were instructed to use another lozenge every 3-6 hours, up to a total of 5 study lozenges in 24 hours. Following efficacy assessments, participants were again instructed to use a lozenge every 3-6 hours, up to a total of 5 study lozenges per day (plus rescue medication if needed) for the remaining time in the 7 day study.
62766054|NCT01048450|EXPERIMENTAL|Treatment|Those who were diagnosed with hallux limitus/rigidus (end stage degeneration at the 1st metatarsal phalangeal joint)
62766055|NCT02259140|ACTIVE_COMPARATOR|Proximal Femoral Resection Arthroplasty|A 10-12 cm direct lateral incision will be made distally from the greater trochanter. The abductors of the hip are detached with sharp dissection. A capsulotomy is performed. The femur is exposed in a supra-periosteal manner (2 cm distal to the lesser trochanter) at the level of the ischium; transverse osteotomy will then be performed. The joint capsule will be sutured to itself. The iliopsoas tendon and the abductor tendons are attached to the capsule. The quadriceps will be brought around the proximal femoral stump and sutured to medial tissues.
62766056|NCT02259140|EXPERIMENTAL|Subtrochanteric Valgus Osteotomy|A 10-12 cm direct lateral incision will be made distally from the greater trochanter. The medial half of the abductors may be incised off the greater trochanter for repair. The femoral head is resected at the base of the neck. The ligamentum teres is incised off the head and preserved. A lateral closing wedge osteotomy is performed below the lesser trochanter. 3.5 or 4.5 5 hole locking/non-locking surgeon-contoured plate ( 45⁰) will be used to stabilize the osteotomy. Femoral torsion will be corrected. The psoas tendon will attach the ligamentum teres to the lesser trochanter. The anterior and posterior capsule is sutured together creating interposition tissue. If the ligamentum teres was sutured to the lesser trochanter, the capsule will not close, but will be covered by the psoas tendon.
62766057|NCT02871687|PLACEBO_COMPARATOR|Placebo|Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital
62766058|NCT02871687|ACTIVE_COMPARATOR|Simvastatin|Subjects in the simvastatin arm will receive simvastatin 20 mg daily for 6 weeks before having their lipids checked. If their LDL-c decreases by less than 35% from screening, then the dose of simvastatin is increased to 40 mg daily for the following 6 weeks.
62766059|NCT02871687|ACTIVE_COMPARATOR|Pravastatin|Subjects in the pravastatin arm will receive pravastatin 40 mg daily for 6 weeks before having their lipids checked. If their LDL-c decreases by less than 35% from screening, then the dose of pravastatin is increased to 80 mg daily for the following 6 weeks.
62766060|NCT02623075|EXPERIMENTAL|Transplant recipients (Chimeric)|Adults who have received a kidney/stem cell transplant and have achieved chimerism will receive the IIV4 (influenza vaccine).
62766061|NCT02623075|EXPERIMENTAL|Transplant recipients (IS)|Adults who have received a kidney/stem cell transplant and are currently maintained on standard immunosuppressive therapy will receive the IIV4 (influenza vaccine).
62766062|NCT02623075|ACTIVE_COMPARATOR|Controls|Healthy adults who meet inclusion and exclusion criteria will receive the IIV4 (influenza vaccine).
62766063|NCT04147598|EXPERIMENTAL|Low Fat Diet (LFD) to Standard American Diet (SAD)|Week 1 to 4 participants will receive a LFD followed by a washout period of 2 weeks and then week 6 to 10 SAD.
62766064|NCT04147598|EXPERIMENTAL|SAD to LFD|Week 1 to 4 participants will receive a SAD followed by a washout period of 2 weeks and then week 6 to 10 LFD.
62766065|NCT05616884|EXPERIMENTAL|Cementless|Cementless fixation partial knee replacement
62766066|NCT05616884|ACTIVE_COMPARATOR|Cemented|Cemented fixation partial knee replacement
62766067|NCT01357954|EXPERIMENTAL|Targeted Training|
62766068|NCT01357954|OTHER|Control|
62766069|NCT01541917|EXPERIMENTAL|Web-based coping skills training|Involves completion of a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support.
62766070|NCT01541917|ACTIVE_COMPARATOR|Online disease education|Involves viewing 12 educational websites about Juvenile Idiopathic Arthritis over the course of 12 weeks.
62766071|NCT02673320|EXPERIMENTAL|Early surgery|Early surgery within 48 hours
62766072|NCT02673320|OTHER|Delayed surgery|Delayed surgery at 15 days
62766073|NCT01275092|EXPERIMENTAL|CorPath robotic-assisted PCI|CorPath 200 robotic-assisted PCI
62766074|NCT01538940|ACTIVE_COMPARATOR|HIV+, CD4<200, ID vaccine|Humoral and cell-mediated immune responses among HIV-infected individuals with CD4 cell counts less than 200 per microliter will be compared to immune responses in HIV-infected individuals with CD4 cell counts of 200 per microliter or greater.
62766075|NCT01538940|ACTIVE_COMPARATOR|HIV+, CD4<200, IM vaccine|Humoral and cell-mediated immune responses among HIV-infected individuals with CD4 cell counts less than 200 per microliter will be compared to immune responses in HIV-infected individuals with CD4 cell counts of 200 per microliter or greater.
62766076|NCT01538940|ACTIVE_COMPARATOR|HIV+, CD4>=200, ID vaccine|Humoral and cell-mediated immune responses among HIV-infected individuals with CD4 cell counts less than 200 per microliter will be compared to immune responses in HIV-infected individuals with CD4 cell counts of 200 per microliter or greater.
62766077|NCT01538940|ACTIVE_COMPARATOR|HIV+, CD4 >=200, IM vaccine|Humoral and cell-mediated immune responses among HIV-infected individuals with CD4 cell counts less than 200 per microliter will be compared to immune responses in HIV-infected individuals with CD4 cell counts of 200 per microliter or greater.
62766078|NCT01538940|OTHER|HIV-, ID vaccine|A small HIV-uninfected MSM control group will be enrolled (with persons randomized into either an intramuscular or intradermal TIV arm) to serve as a comparator group for the cell-mediated immunity studies.
62766079|NCT01538940|OTHER|HIV-, IM vaccine|A small HIV-uninfected MSM control group will be enrolled (with persons randomized into either an intramuscular or intradermal TIV arm) to serve as a comparator group for the cell-mediated immunity studies.
62766080|NCT01897545|ACTIVE_COMPARATOR|PV isolation|
62766081|NCT01897545|ACTIVE_COMPARATOR|PV isolation+renal denervation|
62766082|NCT04944732||Patients with Creutzfeldt Jakob disease|Patients with Creutzfeldt Jakob disease
62766083|NCT01837667|EXPERIMENTAL|LB-100 for Injection and Docetaxel|Part 1: LB-100 infusion. Part 2: LB-100 infusion and docetaxel infusion.
62766084|NCT00142623|EXPERIMENTAL|1|"Use of five tailored take-home DVDs aimed at reducing exposure to ETS"
62766085|NCT00142623|NO_INTERVENTION|2|Usual care
62766086|NCT01958892||TURP|
62766087|NCT01958892||TUERP|
62766088|NCT00012363|EXPERIMENTAL|Gemcitabine + Irinotecan|Gemcitabine 1000mg/m2 IV over 30 min on Days 1,8 q21days; Irinotecan 100mg/m2 IV over 90 min on Days 1,8 q21days
62384609|NCT02840903||Setting 6 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.65 ml/kg BW, tube voltage = 80 kvp
61989202|NCT03837873|EXPERIMENTAL|DLCL002 protocol|Patients will receive R-DA-EDOCH(rituximab, etoposide, dexamethasone, vincristine, cyclophosphamide, doxorubicin) as induction therapy and be evaluated by PET CT after the fourth cycle. Patients achieve CR at interim-PET will receive either ASCT or the remaining 4 cycles of R-DA-EDOCH, while those achieve PR(Deauville score 4-5) will be rescued by two courses of R(2)-DHAP(rituximab, lenalidomide(only for patients with non-GCB DLBCL), dexamethasone, cisplatin, cytarabine). Patients who achieved CR+good PR(Deauville score 4) after the rescue therapy will be consolidated with ASCT,and those remain in PR(Deauville score 5) will receive other rescue treatments.
62384610|NCT02840903||Setting 7 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
62766089|NCT01407523|EXPERIMENTAL|Levetiracetam|Twice daily intravenous (IV) infusion of Levetiracetam solution equivalent (mg-for-mg) to oral dose of Levetiracetam.
62766090|NCT03755232|EXPERIMENTAL|scFOS treatment #1|Phase 1: 10g of scFOS Phase 2: 50g dextrose +15g scFOS Phase 3: 50g avCHO from white bread +15g scFOS
62766091|NCT03755232|EXPERIMENTAL|scFOS treatment #2|Phase 1: n/a Phase 2: 35g Dextrose +15g scFOS Phase 3: 35g avCHO from white bread +15g scFOS
61989203|NCT05354128|EXPERIMENTAL|Thrombolysis Group|Patients who meet the conditions for intravenous thrombolysis are included in the intravenous thrombolysis group. Regardless of whether the thrombolysis is successful or not, CAG examination is performed afterwards to clarify the vascular condition, and PCI is performed if necessary.
61989204|NCT05354128|OTHER|PCI Group|Eligible patients undergoing primary PCI.
61989205|NCT02506504|EXPERIMENTAL|Inspiratory help then sham ventilation|The initial evaluation is performed using an Inspiratory Pressure Support. After the training, the final evaluation is performed using an Inspiratory help (sham ventilation).
61989206|NCT02506504|EXPERIMENTAL|Sham ventilation then Inspiratory help|"The initial evaluation is performed using an inspiratory help (sham ventilation).~After the training, the final evaluation is performed using an Inspiratory Pressure Support."
61989207|NCT04009655|EXPERIMENTAL|music therapy|The infant will receive music therapy over 3 consecutive days and will obtain standard care as usual
62384611|NCT02840903||Setting 8 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 100 kvp
62766092|NCT03755232|ACTIVE_COMPARATOR|Control #1|Phase 1: Water control (negative control) Phase 2: 35g Dextrose control 1 Phase 3: 35g avCHO from white bread (control 1)
62766093|NCT03755232|ACTIVE_COMPARATOR|Control #2|Phase 1: 10g Dextrose (positive control) Phase 2: 50g Dextrose control 2 Phase 3: 50g avCHO from white bread (control 2)
61989208|NCT04009655|NO_INTERVENTION|control|The infant does not receive any sound emission because the headphone will be turned off and will obtain standard care as experimental
62384612|NCT03968523|ACTIVE_COMPARATOR|TAP block|TAP block technique.
62766094|NCT00989391|EXPERIMENTAL|Cohort 1|Subjects will be assigned to receive either PF-03654764 or placebo.
62766095|NCT00989391|EXPERIMENTAL|Cohort 2|Subjects will be assigned to receive either PF-03654764 or placebo.
62766096|NCT00989391|EXPERIMENTAL|Cohort 3|Subjects will be assigned to receive either PF-03654764 or placebo.
62766097|NCT05901324|EXPERIMENTAL|Maintenance therapy with lenalidomide as the maintenance therapy for patients with PCNSL or PVRL|
62766098|NCT05792644|EXPERIMENTAL|Experimental|Patients with positive ALK phosphorylation expression were treated with crizotinib 250 mg/day orally. A treatment cycle was defined as 30 days of once-daily crizotinib treatment. Treatment with crizotinib continued until the patient experienced unacceptable toxicity, was pregnant, or started new cancer therapy.
62384613|NCT03968523|EXPERIMENTAL|Novel local infiltration technique|Local analgesic infiltration in the mesh fixation site
62384614|NCT04081142||acute respiratory failure group|acute respiratory failure (ARF) group: arterial oxygen partial pressure to fractional inspired oxygen ratio, PaO2/FiO2\<300 mmHg and/or peripheral oxygen saturation SaO2\<94% under air condition and/or severe dyspnea with respiratory rate \>30bpm.
62384615|NCT04081142||control group|postoperative ICU patients without ARF were included
62384616|NCT02815475|PLACEBO_COMPARATOR|Placebo|Starch filled capsule
62766099|NCT05577546|EXPERIMENTAL|Brace group|"Fifteen patients with AIS will be included in this group. The scoliosis brace, whose characteristics are described below under the Brace heading, will be worn by the patient for 12 weeks. Although the daily brace wearing time varies between 20-23 hours, depending on the patient, it will be determined according to the physician's recommendation. Compliance regarding the brace will be monitored from the parent-controlled charts where the daily wearing time is recorded by the patient"
62384617|NCT02815475|EXPERIMENTAL|Curcumin|400mg of Curcumin via capsule to be consumed every other day
62384618|NCT02815475|ACTIVE_COMPARATOR|Turmeric powder|2 teaspoons of dried turmeric powder to be consumed every other day
62766100|NCT05577546|EXPERIMENTAL|Brace and Schroth exercise group|Fifteen patients with AIS will be included in this group, they will be treated by brace and exercise during 12 weeks. The same brace treatment protocol as the brace group will be applied for this group. Additionally, Schroth Three-Dimensional Scoliosis Exercise Treatment will be applied to this group by the researcher physiotherapist at the brace center. Exercise therapy will be carried out at the brace center once a week with the researcher physiotherapist, and 45 min a day, 4 days a week in the form of home exercises. The number of exercise sets and repetitions will be determined by the researcher physiotherapist according to the patient, considering deformity severity and flexibility, generalized joint hypermobility, bone maturation, menarche status and the risk of progression. Compliance with the home exercise program (frequency and duration) will be recorded by the patients in a home exercise diary for 12 weeks.
62766101|NCT05577546|NO_INTERVENTION|Healthy control group|Fifteen healthy volunteers between the ages of 10-18 will be included in this group. No intervention will be applied to this group and they will only be assessed, and their findings obtained from the gait analysis will compare with the patient groups.
62384619|NCT04880642|EXPERIMENTAL|C21|50 mg capsules, oral administration twice daily,for 14 days
62558720|NCT04579354|EXPERIMENTAL|Virtual reality (VR) tour|standardised anaesthesia information sessions, consisting of a detailed explanation of the anaesthesia procedure by the anaesthetist A specific information sheet is used to explain the procedure and the form of anaesthesia.Subsequently, the patients are shown a virtual tour of the operation using VR glasses. This includes the way through the clinic to the operating theatre: Admission -\> inpatient preparation for the operation -\> administration of premedication -\> way to the operating theater -\> OP preparation (holding) -\> safe surgery
62558721|NCT06509802|EXPERIMENTAL|Web-based Single-session Intervention of Mindset on Intelligence, Failure, and Emotion (We-SMILE)|We-SMILE introduces growth mindsets about intelligence, failure, and negative emotions to pre-practicum trainees, consisting of five components: (a) an introduction to a proactive mindset, including neuroplasticity, the malleability of intelligence and emotion, and the importance of failure and feedback in the learning process; (b) stories and testimonials during practicum which emphasise the belief in change; (c) short videos about allegories of developing intelligence, emotion, and failure mindsets; (d) common questions and misconceptions about growth mindsets; and (e) self-persuasive writing exercises in which participants write down their thoughts and suggestions for others about growth mindsets.
62558722|NCT06509802|NO_INTERVENTION|Training as usual group|The training-as-usual group will continue the normal training and will be provided with repeated assessments at the same timeframe as the intervention group. Participants in training-as-usual group will receive the intervention course after finishing the eight-week follow-up questionnaire.
62558723|NCT01934439|EXPERIMENTAL|PAAD (Proximal Arm AMES Device)Treatments|"The PAAD flexes and extends the elbow, and it abducts and adducts the shoulder, where abduction is away from the side of the body, and adduction is towards it. Elbow extension occurs simultaneously with shoulder abduction, and elbow flexion occurs simultaneously with shoulder adduction. At the same time as the movements, vibrators are utilized to activate muscle spindle Ia receptors in the muscles of the arm to exaggerate the perception of movement."
62558724|NCT01473264|PLACEBO_COMPARATOR|Control|
62558725|NCT01473264|EXPERIMENTAL|High dose rhCC10|5 mg/kg study drug (rhCC10)
62558726|NCT01473264|EXPERIMENTAL|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)
62558727|NCT04823065|NO_INTERVENTION|Control group|4FMFES injection is performed as usual, no supplemental medication is used.
62558728|NCT04823065|EXPERIMENTAL|Loperamide|Patients will receive 4 mg loperamide per os 15 minutes prior injection of the 4FMFES radiotracer dose. As a peristalsis inhibitor, it is expected that this medication will slow down the intestinal progression of the radio-metabolite bolus and thus spare the lower abdomen (where the assessed organs of interest are) of overwhelming background that could impair diagnosis.
62558729|NCT04823065|EXPERIMENTAL|Hyoscine-N-butylbromide|In a similar fashion that what is used for some gastro-intestinal radiological examinations, repeated intravenous injection of 20 mg hyoscine-N-butylbromide will be applied at 0, 20 and 40 minutes following 4FMFES injection. As a peristalsis inhibitor, it is expected that this medication will slow down the intestinal progression of the radio-metabolite bolus and thus spare the lower abdomen (where the assessed organs of interest are) of overwhelming background that could impair diagnosis.
62558730|NCT03046732|EXPERIMENTAL|Explore Transplant Ontario|"Intervention 'Implementing Explore Transplant Education'"
62558731|NCT03046732|NO_INTERVENTION|Control|The control arm (Usual Treatment) is at the Toronto General Hospital dialysis center.
62558732|NCT04067050|EXPERIMENTAL|comfilcon A asphere|Subjects will wear their comfilcon A asphere contact lenses for two months. Lenses will be worn on a daily wear, reusable basis for at least 8 hours per day, 5 days per week.
62558733|NCT04067050|ACTIVE_COMPARATOR|Habitual Spectacles|Subjects will wear their single vision habitual spectacles for two months for at least 8 hours per day, 5 days per week.
62558734|NCT01988181|ACTIVE_COMPARATOR|Best clinical practice HD|All study patients will be dialyzed with the Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany) using high flux dialyzers. For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
61989209|NCT04260737|NO_INTERVENTION|Standard Care|The control group will receive standard care for localized prostate cancer, i.e., information from their doctor and an information brochure.
62384620|NCT04880642|PLACEBO_COMPARATOR|Placebo|placebo capsules, oral administration twice daily,for 14 days
62384621|NCT04854226|EXPERIMENTAL|Macronutrient_CARB|High carbs, low fat composition.
62384622|NCT04854226|ACTIVE_COMPARATOR|Macronutrient_FAT|Low carbs, high fat composition.
62384623|NCT02286336|EXPERIMENTAL|middle aged group|brachial plexus block with ropivacaine 40ml, MEC90 for USG-SCB
62384624|NCT02286336|ACTIVE_COMPARATOR|young group|brachial plexus block with ropivacaine 40ml, MEC90 for USG-SCB
62766102|NCT03107923||Preoperative myocardial reserve yes/no|Patients with extensive myocardial fibrosis typically presents with limited myocardial contractile reserve that can be assessed by a dobutamine stress test. The patients will be allocated to a responder and non-responder group according to the results from this test.
61989210|NCT04260737|EXPERIMENTAL|Decision Aid + Standard Care|"The intervention group will receive standard care and intervention that includes a website with the Decision Aid which covers the following:~1. An overview about prostate cancer;~2. An overview of different treatment options (e.g. surgery and active surveillance)~3. The pros and cons of different treatment options (e.g., physical, emotional, social).~4. A value clarification exercise that is designed to assist participants to weigh the pros and cons of each prostate cancer management option."
62558735|NCT01988181|EXPERIMENTAL|Best clinical practice plus BVM-guided UF biofeedback|Patients in the BVM-guided UF biofeedback (intervention) phase will have the same prescription as the control group but will also have the ultrafiltration rate automatically adjusted by the Fresenius 5008 HD machine based on the changes in the relative blood volume.
62558736|NCT02380339|ACTIVE_COMPARATOR|Psych-Educational and Bio Feedback (BF_|Participants in the control group will undergo Psych-Educational and BF sessions in which they will receive information about FOH and about ways of coping with FOH and BF training. More specifically, they will learn about factors associated with FOH, behavioral manifestations of FOH, negative consequences of these behavioral manifestations and about ways of coping with FOH. They will be instructed to practice BF for 15 minutes, at home for 5 initial training sessions during a week. After which they will receive another session of BF training and will be instructed to practice it at home for 10 sessions course, (5 weekly sessions for 2 weeks). Each session will be for 15 minutes.
61989211|NCT04255355|ACTIVE_COMPARATOR|Pelvic alignment and forceful expiration exercise|
61989212|NCT04255355|EXPERIMENTAL|Pelvic repositioning exercise|
61989213|NCT04255355|EXPERIMENTAL|Diaphragmatic breathing exercise|
61989214|NCT04959968|EXPERIMENTAL|Intervention group|An eye patch and earplug will be applied to the intervention group in the intensive care unit on the day of craniotomy and on the post-operative 1st day between 22:00 and 06:00
61989215|NCT04959968|NO_INTERVENTION|Control group|Standard care procedure will be applied to the control group
61989216|NCT01242956|EXPERIMENTAL|Verum group|video-based training after stroke
62766103|NCT01009346|EXPERIMENTAL|RAD001|Daily RAD001 in combination with weekly cetuximab and cisplatin/ carboplatin on Day 1, 8 of each 28 day cycle.
61989217|NCT01242956|PLACEBO_COMPARATOR|Placebo group|non-video group
61989218|NCT00625976|EXPERIMENTAL|1|
62766104|NCT05015790|EXPERIMENTAL|use of virtual reality Bliss Solution|in the experimental arm the patient will receive the usual practice associated with a virtual reality session (20 minutes renewable) in a world chosen with the patient beforehand
62766105|NCT05015790|NO_INTERVENTION|current practice, without Bliss Solution|patient will receive the usual practice, local anesthesia
62766106|NCT00408590|EXPERIMENTAL|Experimental Arm|
62766107|NCT04124614|EXPERIMENTAL|Brexpiprazole + Sertraline|3 pills: Dose of up to 3 mg /day may be administered of brexpiprazole, dose up to 150 mg/day may be administered of sertraline. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
61989219|NCT00625976|EXPERIMENTAL|2|
61989220|NCT01923454|EXPERIMENTAL|Paracentesis|"Immediate anterior chamber paracentesis (ACP) with a 30-gauge needle as an initial treatment for acute primary angle closure.~Acetamide, given in this study, is a standard treatment for acute angle-closure glaucoma. The participant will receive 1 tablet(250mg) at 1 hours after paracentesis. The following dose will be adjusted according to the level of IOP. The maximal dose is 4 tablets per day. It will be discontinued if the IOP is less than 21 mmHg.~All affected eyes will receive laser peripheral iridotomy with 24 hours after presentation. This a standard treatment for Acute angle-closure glaucoma"
61989221|NCT06112028|EXPERIMENTAL|Experimental group|In addition to oral aspirin enteric coated tablets (0.1g qd), Clopidogrel bisulfate tablets (75mg qd), rosuvastatin calcium tablets (10mg qd) or atorvastatin calcium tablets (20mg qd), Tongxinluo capsule (Shijiazhuang Yilin Pharmaceutical Co., LTD.) was added to 0.78g TID for continuous treatment for 12 months.
61989222|NCT06112028|SHAM_COMPARATOR|control group|Take aspirin enteric coated tablets (0.1g qd), Clopidogrel bisulfate tablets (75mg qd), Rosuvastatin calcium tablets (10mg qd) or atorvastatin calcium tablets (20mg qd) orally.
61989223|NCT01315756|NO_INTERVENTION|Control group|Treatment as usual.
61989224|NCT01315756|EXPERIMENTAL|Few Touch Application (FTA)|"This arm will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user."
61989225|NCT01315756|EXPERIMENTAL|FTA and health counseling|This arm will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via sms from the diabetes nurse which is based on the patient's initiative (via sms). In addition, the diabetes nurse will call the patients three times during this period and discuss progress.
61989226|NCT03535428||VENOUS exploration|
61989227|NCT02520011|EXPERIMENTAL|ACM (Stage 1 / Stage 2)|A: alvocidib, 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
61989228|NCT02520011|ACTIVE_COMPARATOR|CM (Stage 2)|C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 1-3; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
61989229|NCT02603835|EXPERIMENTAL|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
61989230|NCT05463510||Pediatric melanocytic nevus|50 patients and 301 pediatric nevi were evaluated
62766108|NCT04124614|EXPERIMENTAL|Sertraline|3 pills: Dose up to 150 mg/ day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
62766109|NCT04124614|OTHER|Placebo|3 pills: Brexpiprazole-matched placebo tablets and Sertraline-matched placebo tablets may be administered. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
62766110|NCT00586443|OTHER|I|This is a Phase I safety study. There is only one arm.
62766111|NCT00005632|EXPERIMENTAL|Vaccine|Patients sequentially will receive glycosylated MUC-1-KLH vaccines at 3ug per vaccination.
62766112|NCT02784015|EXPERIMENTAL|Unresectable localized soft tissue sarcoma|"1. Six cycles of chemotherapy with cisplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen.~2. Surgery, if possible~3. Concurrent chemoradiotherapy according to the treatment response (necrosis rate, tumor volume reduction, and residual FDG uptake in PET scan)~4. Tandem high dose chemotherapy (HDCT) and autologous stem cell transplantation, if there are still residual tumors after 9 cycle of chemotherapy, surgery, and radiotherapy.~   * 1st HDCT: carboplatin, thiotepa, etoposide~  * 2nd HDCT: cyclophosphamide, melphalan"
62766113|NCT01574846||Vantas|
61989231|NCT00138944|PLACEBO_COMPARATOR|1|Placebo
61989232|NCT00138944|ACTIVE_COMPARATOR|2|Eplerenone
61989233|NCT03398031|ACTIVE_COMPARATOR|Magnesium supplement|90 female pregnant after ICSI after biochemical diagnosis of pregnancy will receive 500 mg magnesium supplement
62766114|NCT06140797|EXPERIMENTAL|PREERAS group|"Pre-operative risk assessment combined with targeted intervention During the planning phase of the study, we assembled a multidisciplinary team consisting of geriatrician, spine surgeons, nurses, rehabilitation specialists, anesthesiologists, neurologists, nutritionist, and social workers. Then, the multimodal prehabilitation combined with perioperative ERAS care (PREERAS) programme was conducted based on previous studies and surgical guideline.~Participants randomised to the intervention group will receive PREERAS management. PREERAS mainly consists of geriatric assessment, Vivifrail multicomponent exercise, nutritional intervention, cognitive prehabilitation and brain protection."
61989234|NCT03398031|PLACEBO_COMPARATOR|placebo|90 female pregnant after ICSI after biochemical diagnosis of pregnancy will receive placebo oral tablet
61989235|NCT00800228||1|Eight men and eight women to define the time course of changes in MBG \\ and OLC accompanying sodium loading
61989236|NCT00800228||2|32 additional women to determine whether breathing pattern is predictive of sodium sensitivity in that gender. Women are being studied in the second experiment because they, but not men, have been shown to have an association of breathing pattern with high perceived stress11 and an association of high resting end tidal CO2 with high resting blood pressure.
61989237|NCT03444922|PLACEBO_COMPARATOR|Placebo|Participants consume Vanilla Wafer cookie
61989238|NCT03444922|EXPERIMENTAL|BPA 4 ug/kg BW|Participants consume 4 ug/kg BW of BPA on a Vanilla Wafer Cookie
61989239|NCT03444922|EXPERIMENTAL|BPA 50 ug/kg BW|Participants consume 50 ug/kg BW of BPA on a Vanilla Wafer Cookie
62384625|NCT04013633|EXPERIMENTAL|Lifesaver virtual reality (VR) training|Training using the Lifesaver VR application. Lifesaver VR is an interactive game that can be played on smartphones allowing users to 'resuscitate' a victim of cardiac arrest, while wearing VR-goggles showing a filmed CPR-scenario
62558737|NCT02380339|EXPERIMENTAL|Psych-Educational session and virtual reality (VR)|Participants in the intervention group will receive Psych-Educational session as the control group and in addition they will participate in training for VR system and will be asked to use it at home for 5 initial training sessions during a week. During this week, they will practice reducing their GSR levels as indicated by the BF device. Following this they will receive a combined biofeedback-virtual reality system and use it at home for a 10 sessions course, (5 weekly sessions for 2 weeks). Each session will be for 15 minutes.
62558738|NCT05747105|EXPERIMENTAL|Sleep Extension Intervention|All participants will receive the 16-week sleep extension intervention aimed to lengthen nighttime sleep duration by at least 30-60 minutes per night. No prescription for daily calorie/dietary intake or physical activity will be provided in this study, except behaviors consistent with sleep hygiene recommendations.
62558739|NCT04238078||Polycystic ovary syndrome|Women with PCOS diagnosed according to Rotterdam criteria
62558740|NCT04238078||Healthy control|Healthy women without any feature of ovulatory dysfunction or androgen excess
62766115|NCT06140797|NO_INTERVENTION|Control group|The control group will receive standard of enhanced recovery after surgery (ERAS) care that is provided as part of the perioperative surgical procedure and subsequent rehabilitation
61989240|NCT02245256|PLACEBO_COMPARATOR|Normal saline|same infusion rate as experimental group (dexmedetomidine)
61989241|NCT02245256|EXPERIMENTAL|dexmedetomidine|0.1mcg/kg/hr of dexmedetomidine infusion started after induction of anesthesia for liver transplantation and continued until 48 hours after surgery.
61989242|NCT03084887|EXPERIMENTAL|manuals and follow-up|distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
61989243|NCT03084887|NO_INTERVENTION|controlled group|no intervention until secondary hospital
62558741|NCT02971774||questionnary|self administered questionnary
61989244|NCT00528723|EXPERIMENTAL|A|BDP/salbutamol HFA pMDI
61989245|NCT00528723|ACTIVE_COMPARATOR|B|BDP/salbutamol CFC pMDI
61989246|NCT03089203|EXPERIMENTAL|Cohort 1|CART-PSMA-TGFβRDN cells 1-3x10\^7 Day 0
61989247|NCT03089203|EXPERIMENTAL|Cohort 2|CART-PSMA-TGFβRDN cells 1-3x10\^8 Day 0
61989248|NCT03089203|EXPERIMENTAL|Cohort -3|CART-PSMA-TGFβRDN cells 1-3x10\^7 Day 0
61989249|NCT03089203|EXPERIMENTAL|Cohort 4|CART-PSMA-TGFβRDN cells 0.70-1.00 x 10\^8 Day 0
61989250|NCT03089203|EXPERIMENTAL|Cohort 3|CART-PSMA-TGFβRDN cells at the MTD (established by Cohorts 1-2) on day 0
61989251|NCT02621242||Cohort|All subjects will undergo all procedures
61989252|NCT03171454|EXPERIMENTAL|Delayed Intrauterine Balloon therapy|In the delayed balloon group,a Foley catheter will be inserted into the uterine cavity 2 weeks after the surgery, the balloon will be inflated with normal saline (from 3ml to 5ml) then deflated, and the procedure repeated three time over 3 minutes or so, then the cavity will be flushed with 10 mls of normal saline solution after via the irrigating channel of the Foley catheter before removal. The whole procedure will be repeated a further 2 weeks later.
62384626|NCT04013633|ACTIVE_COMPARATOR|Face-to-face training|A short face-to-face CPR training based on international guidelines provided by certified instructors
62384627|NCT00848172|ACTIVE_COMPARATOR|Octanoic Acid|
62384628|NCT00848172|PLACEBO_COMPARATOR|Placebo|
62766116|NCT04247126|EXPERIMENTAL|Group 1: Single Agent Dose Escalation|Dose escalation phase to explore maximum tolerated dose of SY-5609 given as a single agent.
61989253|NCT03171454|EXPERIMENTAL|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
61989254|NCT05957796|ACTIVE_COMPARATOR|Regular eye shield after surgery|Alcon eye shield after surgery
61989255|NCT05957796|EXPERIMENTAL|Novel prototype eye shield after surgery|Novel prototype eye shield after surgery
61989256|NCT06325956|EXPERIMENTAL|Metformin therapy|Metformin intervention, 1000mg daily for the first week, 1500mg daily starting in the second week until six months of treatment.
62384629|NCT05734040|EXPERIMENTAL|OVX836 480µg + Fluarix Tetra at commercial dose|OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the influenza virus. One single administration intramuscularly of 480µg dose on Day 1 AND Fluarix Tetra: Inactivated and purified split influenza vaccine. One single administration intramuscularly in the opposite arm on Day 1.
62384630|NCT05734040|EXPERIMENTAL|OVX836 480µg + Afluria Quad at commercial dose|OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the influenza virus. One single administration intramuscularly of 480µg dose on Day 1 AND Afluria Quad: Inactivated and purified split influenza vaccine. One single administration intramuscularly in the opposite arm on Day 1.
62384631|NCT05734040|ACTIVE_COMPARATOR|Fluarix Tetra at commercial dose + Placebo|"Fluarix Tetra: Inactivated and purified split influenza vaccine. One single administration intramuscularly in the opposite arm on Day 1.~AND Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50 milliliter. One single administration intramuscularly of a 0.8 milliliter dose in the opposite arm on Day 1."
61989257|NCT06463951||Subjects starting psychotherapy at the HCC Italy Clinical and Psychotherapy Research Center|The population that decides to undertake psychotherapy is diverse, including individuals of various ages, genders, socioeconomic backgrounds, and occupations. Motivations can vary widely, but often include management of mental disorders, relationship problems, stress, and personal growth. Despite existing barriers, a growing number of people are recognizing the importance of mental well-being and seeking professional support: increasing awareness and reduced stigma related to psychological symptoms are making psychotherapy an increasingly considered option for improving mental well-being and quality of life.
61989258|NCT03608579|EXPERIMENTAL|Single Injection|Single administration of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip by single ultrasound guided injection
61989259|NCT03608579|EXPERIMENTAL|Two Injections|Two-dose administration (2 x ultrasound guided injections) of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip with one month interval between doses
61989260|NCT00931749|EXPERIMENTAL|Low intensity Ultrasound group|
61989261|NCT00931749|SHAM_COMPARATOR|Sham ultrasound group|
61989262|NCT01488331||Cohort|
61989263|NCT01526265|ACTIVE_COMPARATOR|Usual Care|Participants will be offered free smoking cessation programs, and be provided web-based education regarding the health and economic benefits of smoking cessation. Participants will also have the opportunity to submit weekly reports on their smoking habits. They will be informed that they will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
61989264|NCT01526265|EXPERIMENTAL|Individual Rewards|Same as USUAL CARE arm, plus financial incentive as follows: if participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators.
62384632|NCT05734040|ACTIVE_COMPARATOR|Afluria Quad at commercial dose + Placebo|"Afluria Quad: Inactivated and purified split influenza vaccine. One single administration intramuscularly on Day 1.~AND Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50 milliliter. One single administration intramuscularly of a 0.8 milliliter dose in the opposite arm on Day 1."
62766117|NCT04247126|EXPERIMENTAL|Group 2: SY-5609 + Fulvestrant|Participants with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer (BC) that has progressed following prior treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with hormonal therapy will receive SY-5609 in combination with fulvestrant.
62766118|NCT04247126|EXPERIMENTAL|Group 3: SY-5609 + Gemcitabine|Participants with PDAC will receive SY-5609 in combination with gemcitabine in Safety Lead-in to identify a recommended combination dose for the expansion. The expansion part will assess the safety, tolerability, and preliminary clinical activity of SY-5609 in combination with gemcitabine at the recommended combination dose.
61989265|NCT01526265|EXPERIMENTAL|Fixed Deposits|Same as USUAL CARE arm, plus financial incentive as follows: participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
61989266|NCT01526265|EXPERIMENTAL|Competitive Deposits (Pari-Mutuel)|"Same as USUAL CARE, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
62384633|NCT05734040|PLACEBO_COMPARATOR|OVX836 480µg + Placebo|OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the influenza virus. One single administration intramuscularly of 480µg dose on Day 1 AND Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50 milliliter. One single administration intramuscularly of a 0.8 milliliter dose in the opposite arm on Day 1.
62766119|NCT04247126|EXPERIMENTAL|Group 4: SY-5609 + Gemcitabine + Nab-paclitaxel|Participants with PDAC will receive SY-5609 in combination with gemcitabine plus nab-paclitaxel in Safety Lead-in to identify a recommended combination dose for the expansion. The expansion part will assess the safety, tolerability, and preliminary clinical activity of SY-5609 in combination with gemcitabine plus nab-paclitaxel at the recommended combination dose.
62766120|NCT01127841|EXPERIMENTAL|Rituximab and Bendamustine|
62766121|NCT03346551|EXPERIMENTAL|women with postnatal depression|
62766122|NCT03346551|OTHER|women without postnatal depression|
62766123|NCT03622177||HIV+|
62766124|NCT03622177||HIV- STI+|
62766125|NCT03622177||HIV- STI-|
61989267|NCT01526265|EXPERIMENTAL|Collaborative Rewards|"Same as USUAL CARE arm, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking."
61989268|NCT03976063|ACTIVE_COMPARATOR|Nifedipine|
61989269|NCT03976063|PLACEBO_COMPARATOR|Placebo|
61989270|NCT04849806||COPD patients (n=60)|"The following parameters will be determined in 60 consecutive patients with COPD without established cardiovascular disease (i.e. without an indication for beta blocker therapy or other pharmacological treatments attacking on the neurohormonal pathways like angiotensin-converting enzyme inhibitors or mineralocorticoid receptor antagonists).~1. OSA severity.~2. Determination of PH and right HF severity (defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography;~3. Comprehensive lung function and inspiratory muscle function testing ;Assessment of daytime hypoxia (PaO2 \<55 mmHg) and hypercapnia (PaCO2 \>45 mmHg) using capillary blood gas analysis;~4. Assessment of systemic inflammation"
61989271|NCT04849806||Controls (n=20)|(and in a group of healthy controls \[3:1\] matched for age, sex and BMI).
62384634|NCT05734040|PLACEBO_COMPARATOR|Placebo + Placebo|Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50 milliliter. One single administration intramuscularly of a 0.8 milliliter dose on Day 1 AND Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50 milliliter. One single administration intramuscularly of a 0.8 milliliter dose in the opposite arm on Day 1.
62766126|NCT04728594|NO_INTERVENTION|Delayed Contact|This group will not receive an email for at least two days.
62766127|NCT04728594|EXPERIMENTAL|Social Proof|This group will receive an email that points out that vaccine availability for employees will soon be limited. It also emphasizes how many fellow health care workers have been vaccinated. Seeing the behaviors of other people might encourage recipients to copy that behavior.
62766128|NCT04728594|EXPERIMENTAL|Reframing Side Effects and Adverse Reactions|This group will receive an email that points out that vaccine availability for employees will soon be limited. It also addresses concerns about the side effects and adverse reactions of the vaccine. Due to potentially overblown concerns about the vaccine caused by the salience of side effects in the (social) media, the email attempts to reframe the risks by explicitly noting the small possibility of being affected by serious side effects and by contrasting that to the more severe effects of COVID-19. As a result of this reframing, recipients might recalibrate their perception of risks and benefits and opt for vaccination.
62766129|NCT00625612|PLACEBO_COMPARATOR|2|
62766130|NCT00625612|EXPERIMENTAL|1|Denufosol Tetrasodium (INS37217) Inhalation Solution
62766131|NCT03840525|EXPERIMENTAL|Qigong Intervention|The qigong intervention consists of 1 hour/week qigong classes for 12 weeks to be delivered virtually. The first 2 weeks will include 2 hours/week classes. In addition, each participant will be instructed to practice qigong at home for 90 minutes.
62766132|NCT03840525|SHAM_COMPARATOR|Sham Qigong|This group will also have 1 hour/weekly class delivered virtually that includes movements that are similar to qigong but will not include the meditation or breathwork that will be included in the actual qigong intervention arm.
62766133|NCT03840525|NO_INTERVENTION|Treatment-as-usual|This group will receive no classes.
62766134|NCT04500236|ACTIVE_COMPARATOR|General Anesthesia (GA)|Patients undergoing thyroid or breast cancer surgery under general anesthesia
62766135|NCT04500236|PLACEBO_COMPARATOR|Hypno-analgesia (Hyp)|Patients undergoing thyroid or breast cancer surgery under Hypno-analgesia; i.e.hypnosis combined with the use of analgesics.
62766136|NCT03302286|ACTIVE_COMPARATOR|Mannitol Prime|This group will undergo cardiac surgery with heart-lung machine with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
62766137|NCT03302286|ACTIVE_COMPARATOR|NonMannitol Prime|This group will receive a priming solution of Ringer´s acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
62766138|NCT02789410|ACTIVE_COMPARATOR|Intrathecal hydromorphone|Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.
62766139|NCT02789410|ACTIVE_COMPARATOR|Intrathecal morphine|Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.
62766140|NCT03783611|EXPERIMENTAL|Intervention group|The intervention group has access to the MyPlan 2.0. eHealth intervention. MyPlan is a eHealth intervention designed to increase physical activity. The intervention is based on the self-regulation theory and focuses on pre- and post-intentional processes to increase physical activity.
62384635|NCT04389931|PLACEBO_COMPARATOR|Periodontal treatment, lactose tab|Periodontal treatment (scaling and root planning) and two tablets containing lactose once a day for 90 days immediately after the scaling and root planning.
62766141|NCT03783611|NO_INTERVENTION|control group|The control group receives no intervention
62766142|NCT06461728|ACTIVE_COMPARATOR|conventional group|Each canal will be prepared using Reciproc Blue nickel titanium file 25/08 and sonic activation of NaOCl
62766143|NCT06461728|EXPERIMENTAL|conservative technique|"in the conservative technique, a size 10 FlexoFile will be introduced ,a glide path will be established using the size 10 FlexoFile to the WL, than Proglider 16.02 to the foramen.~than heating and activation of NaOCl will be done with a prototype needle"
62766144|NCT00707746|PLACEBO_COMPARATOR|Placebo|1 mL placebo saline, weekly subcutaneous injections for 26 weeks
62766145|NCT00707746|EXPERIMENTAL|Mipomersen|200 mg (1 mL), weekly subcutaneous injections for 26 weeks
62766146|NCT04782947|EXPERIMENTAL|EAW+ES+RT|The exoskeletal assisted walking with epidural simulation and resistance training (EAW+ES+RT) group will undergo 6 months of supervised EAW +ES (3X per week) followed by additional 6 months of EAW+ES (3X per week) and progressive RT twice weekly (2X per week). In the EAW+ES+RT group, RT will be administered for 12 weeks using an open kinematic chain approach of applying surface NMES and ankle weights followed by 12 weeks twice weekly of gradually using the implanted ES to perform sit-to-stand approach (i.e. using their body weights to load the exercising muscles in a closed kinematic fashion).
62766147|NCT04782947|EXPERIMENTAL|EAW+ delayed-ES +no-RT|The control exoskeletal assisted walking with delayed epidural simulation and without resistance training (EAW+ delayed-ES +no-RT) group will enroll in 6 months of EAW without ES (3X per week) and then this will be followed by additional 6 months (3x per week) of EAW+ES (i.e., delayed entry approach) without conducting RT and will perform either passive movement of passive stretching (2X per week).
62766148|NCT05162261|EXPERIMENTAL|Tixel Group|Screening and baseline visits, Treatment- 3 treatment sessions, followed by 2 Follow up sessions, 1and 3 months after the last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
62766149|NCT05162261|ACTIVE_COMPARATOR|LipiFlow|LipiFlow: Screening and baseline visits,Treatment session, followed by 2 Follow up sessions, 1and 3 months after the last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
62766150|NCT00382915||1|Smokers with schizophrenia
62766151|NCT00382915||2|Smokers with bipolar disorder
62766152|NCT00382915||3|Smokers without any mental illness
61989272|NCT03809520|EXPERIMENTAL|Experimental: pedCAT|Subjects in this group will undergo weight-bearing CT (pedCAT) imaging at 6 months, 12 months, and 18 months post-ankle injury.
62384636|NCT04389931|EXPERIMENTAL|Periodontal treatment, Omega 3|Periodontal treatment (scaling and root planning) and two tablets containing 1g of Omega 3 once a day for 90 days immediately after the scaling and root planning.
62384637|NCT02027285|EXPERIMENTAL|fortified milk|The subjects assumed daily 250 ml of fortified milk for 12 weeks. Then, after a period of wash-out of 12-14 weeks they start to assume placebo milk for 12 weeks.
62384638|NCT02027285|PLACEBO_COMPARATOR|placebo milk|The subjects assumed daily 250 ml of placebo milk. Then, after a period of wash-out of 12-14 weeks they start to assume fortified milk for 12 weeks.
62384639|NCT05504928|EXPERIMENTAL|Experimental: Implementation of a dedicated school nurse program|School nurse program providing health care through assessment, intervention and follow-up of group A β-hemolytic streptococcal pharyngitis and facilitation of secondary antibiotic prophylaxis for children with latent rheumatic heart disease.
62384640|NCT06337942|EXPERIMENTAL|Bladder Transplantation|Patients with terminal bladders who do not have kidney failure and who qualify for the study may undergo bladder transplantation.
62384641|NCT06337942|EXPERIMENTAL|Combined Kidney and Bladder Transplantation|Patients with terminal bladders who also have kidney failure and who qualify for the study may undergo combined kidney and bladder transplantation.
62384642|NCT06436170||30 patiens with IGS mean age 70 ±6|
62384643|NCT06436170||30 healthy controls mean age 70 ±5|
62384644|NCT05241470|ACTIVE_COMPARATOR|Low Dose ST-100 Ophthalmic Solution|Low Dose ST100-001 Ophthalmic solution, 20mcg/ml
62384645|NCT05241470|ACTIVE_COMPARATOR|High Dose ST-100 Ophthalmic Solution|High Dose ST100-001 Ophthalmic Solution, 50mcg/ml
62766153|NCT04095130||Healthy subjects|those without a condition
62766154|NCT04095130||Psoriasis patients|those with a condition
62766155|NCT00844805|EXPERIMENTAL|Infliximab + Naproxen|Infliximab administered at a dose of 5 mg/kg intravenously on Day 1 of Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks during the 28-week treatment phase.
62766156|NCT00844805|PLACEBO_COMPARATOR|Placebo + Naproxen|Placebo administered intravenously on Day 1 at Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks, during the 28-week treatment phase.
62766157|NCT00844805|EXPERIMENTAL|Naproxen Only (Follow-Up)|For participants who achieved partial remission during 28-week treatment phase, naproxen was continued at a daily dose of 1000 mg administered orally for an additional 24 weeks in the follow-up phase.
62766158|NCT00844805|NO_INTERVENTION|No Treatment (Follow-Up)|For participants who achieved partial remission during Treatment phase, no treatment was administered for an additional 24 weeks in the follow-up phase.
62766159|NCT05933629|ACTIVE_COMPARATOR|Standard Training|Participants assigned to this arm will complete a 3-hour training workshop on the intervention. After completing the training, participants will be asked to implement the intervention into their routine clinical practice.
62766160|NCT05933629|EXPERIMENTAL|Extended Training|Participants assigned to this arm will complete the same 3-hour training workshop on the intervention as Arm #1. After completing the training, participants will also be asked to implement the intervention into their routine clinical practice. However, participants in this group will be asked to attend bi-weekly consultation sessions with members of the study team for 3 months following training.
62766161|NCT05042960|EXPERIMENTAL|50% brightness group|Participants will be using a computer screen reducing screen brightness 50%.
62766162|NCT05042960|EXPERIMENTAL|Light App group|Participants in this group will use a modulating computer screen tone with flux or night shift app.
62384646|NCT05241470|PLACEBO_COMPARATOR|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution (vehicle)
62766163|NCT05042960|NO_INTERVENTION|Control group|Participants in this group will be a control with no change in screen features
62384647|NCT03046069||Subjects included in telephone interviews|Approximately 10 subjects with COPD per country will be included in qualitative concept elicitation telephone interviews.
62384648|NCT03046069||Subjects included in in-person focus groups|1 in-person focus-group per country including up to 5 subjects with COPD will be included in the qualitative analysis.
62384649|NCT03046069||Subjects included in DCE surveys- cognitive interviews|Up to six subjects with COPD in each of the UK, US and Germany will be asked to complete and provide feedback on the surveys.
62384650|NCT03046069||Subjects included in modified DCEs|Up to 20 subjects with COPD in each country will be included in pilot testing of the modified DCEs.
62766164|NCT05835921|EXPERIMENTAL|Virtual Reality|"Participants in this arm will receive the following interventions:~Virtual Reality Park Virtual Reality Avatar"
62766165|NCT05835921|PLACEBO_COMPARATOR|Treatment As Usual|"Participants in this arm will receive the following interventions:~Virtual Reality Park"
62766166|NCT04700956|ACTIVE_COMPARATOR|the primary suture group|The linea alba will be closed to a ratio of 5mm / 5mm. Only the fascia will be sutured ; fat or muscle tissue will be avoided. Subcutaneous tissue will be closed with polyglactin 3/0 suture. The skin will be closed with a stapler.
62766167|NCT04700956|EXPERIMENTAL|mesh group|After the fascia was closed with the same method, 5 cm of subcutaneous tissue will be dissected around the incision. The mesh will be placed in the supra-aponeurotic area (onlay) to a distance of laterally and cranial-caudally 5 cm from the fascia margins. The mesh used will be partially absorbable, light and large porous. After this procedure, the borders of the mesh will be fixed circumferentially on the abdominal wall using polypropylene suture to prevent the intestines from herniating on the mesh. Two subcutaneous drainage catheters will be placed in all patients with mesh.
62384651|NCT03046069||Subjects included in Final DCE|150 subjects with COPD in each of the UK, US and Germany will be included in the final online market specific DCE survey.
62384652|NCT06381752|OTHER|Patients in inpatient rehabilitation randomly assigned to this group Assigned intervention: CPM the|Invervention group
62384653|NCT06381752|OTHER|Patients in inpatient rehabilitation randomly assigned to this group Assigned intervention: group p|Control group
62384654|NCT05248542|EXPERIMENTAL|Virtual Reality group|Each participant in the experimental group received a 30 minutes of individualized VR-based simulation education in a dedicated oral skills training room.
62384655|NCT05248542|NO_INTERVENTION|Control group|The control group only received repeated questionnaires and did not receive any education about geriatric oral hygiene.
62384656|NCT02374944|EXPERIMENTAL|Hardware Removal|Removal of hardware at 6 months.
62384657|NCT02374944|NO_INTERVENTION|Hardware Retention|Retention of hardware at 6 months
62384658|NCT00596713||1|Both genders aged 20 to 80 years and living in private households in the city of São Paulo. Pregnant or lactating women, people with physical or mental impairment and workers in night shifts are not part of the population of interest.
62384659|NCT01633567|EXPERIMENTAL|Culturally Targeted Cessation Program|The culturally targeted program will include the same cognitive and behavioral approaches and smoking education content that is used in the standard program. As such, we will maintain the integrity of the core program. However, cultural targeting of that program has been informed by local LGBT focus group input and testing, the available literature on LGBT smoking rates and behaviors, feedback from a panel of LGBT health experts, and data collected as part of a previous study.
62384660|NCT01633567|ACTIVE_COMPARATOR|Non-Targeted Cessation Program|Non-culturally targeted program with cognitive and behavioral approaches and smoking education content.
62384661|NCT06331806|OTHER|Evaluation of myocardial fibrosis|Echocardiogram with left ventricular ejection fraction (LVEF) evaluation (biplane method) and CMR with contrast media agent
62384662|NCT02875184||Psoriatic arthritis patients treated with apremilast|Psoriatic arthritis patients who are treated with apremilast according to daily practice
62384663|NCT01208025||symptomatic carotid stenosis 30-69%|Patients with neurological symptoms due to ischemia in the carotid artery territory and with a carotid stenosis between 30% and 69% according to the European Carotid Surgery Trial (ECST) criteria.
62384664|NCT06042179|NO_INTERVENTION|Standard of Care PT|Standard of care PT services to included 3 to 5 therapy sessions per week, each session averaging between 20 to 50 minutes, delivered throughout the hospitalization. No specific instructions will be given to therapists providing standard of care PT, except that they cannot implement error augmentation training. Generally, standard of care PT during the initial hospitalization following acute stroke is provided with targeted patient-specific goals and typically primarily focuses on mobility and gait training. Most sessions are geared toward bed mobility, transfers and gait training with therapeutic exercises provided to target any muscle weakness identified.
62384665|NCT06042179|EXPERIMENTAL|Frequent PT services|This group will receive physical therapy services twice a day Monday through Friday and daily Saturday and Sunday. Most sessions are geared toward bed mobility, transfers and gait training with therapeutic exercises provided to target any muscle weakness identified.
62384666|NCT06042179|EXPERIMENTAL|Error Augmentation Training|Will receive error augmentation training 3-5x/wk while inpatient Standard of care PT with the addition of error augmentation principles (making hard tasks harder and increasing difficulty of tasks with added resistance to already weakened muscles) to address at least 2 stroke deficits or limitations.
62766168|NCT05120947|EXPERIMENTAL|42 Gray (Gy) Radiation|42 gy of radiation therapy will be administered in 10 fractions.
62766169|NCT05120947|EXPERIMENTAL|39 Gray (Gy) Radiation|39 gy of radiation therapy will be administered in 8 fractions.
62766170|NCT05120947|EXPERIMENTAL|32.5 Gray (Gy) Radiation|32.5 gy of radiation therapy will be administered in 5 fractions.
62766171|NCT03345524|EXPERIMENTAL|Peer-buddy system|Will meet with peer-buddy who will help with them with CPAP usage. Also will receive standard of care CPAP educational training
62766172|NCT03345524|ACTIVE_COMPARATOR|Usual Care|Will receive educational material at the same frequency that those in the experimental arm. Will also receive standard of care CPAP educational training.
61989273|NCT01436981||CABG with papaverine|Patients with CABG procedure
62384667|NCT06042179|EXPERIMENTAL|Frequent Intense PT|This group will receive therapy services twice per day Monday through Friday and daily Saturday and Sunday, with implementation of error augmentation training each session. This includes standard of care PT with the addition of error augmentation principles (making hard tasks harder and increasing difficulty of tasks with added resistance to already weakened muscles) to address at least 2 stroke deficits or limitations.
62766173|NCT04596085|ACTIVE_COMPARATOR|Investigational product|Experimental, Investigational Product Ingredient : ViraCide Dosage form softgels . Fequency: 3 soft gels, two times every day after breakfast and dinner . Duration: 14 days+ SOC Therapy
62766174|NCT04596085|PLACEBO_COMPARATOR|Placebo|Ingredient, Placebo Ingredient Starch softgels. Frequency: 3 soft gels, two times everyday after breakfast and dinner . Duration:14 days + SOC Therapy
62766175|NCT03201692|ACTIVE_COMPARATOR|Treadmill Training|40' treadmill training walking holding the handrail
62766176|NCT03201692|EXPERIMENTAL|Virtual Reality Treadmill Training|40' treadmill training walking with virtual visual and auditory cues
62766177|NCT02082106||males/females|Participants should be capable of alpine skiing and cross country skiing.
62766178|NCT03156959|EXPERIMENTAL|EMDR plus CBT-Eb|"20 CBT-Eb sessions will be mandatory for patients with BMI\>17.5 and 40 CBT-Eb sessions will be mandatory for patients with BMI≤17.5. In the EMDR plus CBT-Eb arm, 16 EMDR sessions will be mandatory in adjunction to the CBT-Eb sessions, irrespectively of the BMI. EMDR will use an eight-phase approach that will include having the patient recall distressing images while receiving one of several types of bilateral sensory input, such as side to side eye movements.~Patients will follow psychopharmacological treatment for anxiety and depression symptoms if needed, and their parents will be invited to participate to a cycle of eight family meetings on eating disorders and psychological support following ECHO approach (Rhind et al., 2014)."
62766179|NCT03156959|ACTIVE_COMPARATOR|CBT-Eb alone|"20 CBT-Eb sessions will be mandatory for patients with BMI\>17.5 and 40 CBT-Eb sessions will be mandatory for patients with BMI≤17.5.~Patients will follow psychopharmacological treatment for anxiety and depression symptoms if needed, and their parents will be invited to participate to a cycle of eight family meetings on eating disorders and psychological support following ECHO approach (Rhind et al., 2014)."
62766180|NCT04141189|EXPERIMENTAL|weekly|weekly fetal surveillance
62766181|NCT04141189|ACTIVE_COMPARATOR|bi-weekly (twice-weekly)|bi-weekly fetal surveillance
62766182|NCT06450613|OTHER|percutaneous ethanol injection|early-stage hepatocellular carcinoma within the Milan criteria, listed for LT and with indication for neoadjuvant treatment were eligible for enrollment submitted to percutaneous ethanol injection
62766183|NCT06450613|OTHER|Radiofrequency ablation|early-stage hepatocellular carcinoma within the Milan criteria, listed for LT and with indication for neoadjuvant treatment were eligible for enrollment submitted to Radiofrequency ablation
62766184|NCT05538351||Fluid assessment|All patients enrolled in this study will have a clinical assessment to identify hydration status, patient reported signs and symptoms of hydration and Bioimpedance using the Body composition Monitor (BCM).
62766185|NCT02189408|EXPERIMENTAL|PRP|one intraoperative application of PRP in the interventional group
62766186|NCT02189408|NO_INTERVENTION|Control|No application of any substance during knee arthroscopy
61989274|NCT06134479|ACTIVE_COMPARATOR|150μg CFA at SD 1 following by rFSH 200IU daily from SD 8|
62384668|NCT03406806|EXPERIMENTAL|GaitBox|
61989275|NCT06134479|EXPERIMENTAL|150μg CFA at stimulation day (SD) 1 and 100μg CFA at SD 5|
61989276|NCT04064918|OTHER|Netarsudil 0.02% QD|4 weeks of Netarsudil 0.02% QD, then a 4 Week washout, followed by 4 weeks of Timolol maleate 0.5% BID
61989277|NCT04064918|OTHER|Timolol maleate 0.5% BID|4 weeks of Timolol maleate 0.5% BID, then a 4 Week washout, followed by 4 weeks of Netarsudil 0.02% QD
61989278|NCT06353880||Normal BMI Group|Participants with a body mass index (BMI) within the normal range, without obesity-related fat accumulation around the testicles.
62384669|NCT03406806|ACTIVE_COMPARATOR|Sprint System device|
62384670|NCT03406806|ACTIVE_COMPARATOR|NIH Toolbox 4 meter test|
62384671|NCT05779501|EXPERIMENTAL|Intervention group|The experimental arm will receive the online strengths use intervention program over a period of 4 weeks, through an LMS software solution.
62384672|NCT05779501|OTHER|Waiting-list control group|The waiting-list control arm will receive the same intervention immediately after the intervention group finishes and will have filled in the post-test outcomes measures.
62766187|NCT04595877|EXPERIMENTAL|Dipyrone group|Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
62766188|NCT04595877|PLACEBO_COMPARATOR|Placebo group|The placebo will be matched to the study drug for, color, and size. Placebo will be administered in a single dose in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
62766189|NCT01608503|EXPERIMENTAL|respiration cycle|lung inflation and deflation
62766190|NCT06519383|EXPERIMENTAL|Implant placement by static computer assisted implant placement(fully guided).|The Digital Imaging and Communications in Medicine (DICOM) file from the CBCT examination and the Standard Tessellation Language (STL) file from the surface scan will be imported and merged in planning software .The virtual implant planning for all patients will be performed in 3shape software.Surgical guide with embedded sleeve will be designed and 3D printed using computer-aided design/computer-aided manufacturing (CAD/CAM) technology.Fit and stability of static CAD\\CAM surgical guide for test group will be verified through window areas of guide on top of the teeth.A flapless implant placement protocol will be performed for all implants.
61989279|NCT06353880||Obese without Pudendal Fat Group|Participants with obesity, characterized by excess adiposity, but without significant accumulation of fat around the testicles.
61989280|NCT06353880||Obese with Pudendal Fat Group|Participants with obesity and notable accumulation of fat around the testicles (pudendal fat), contributing to the study of its specific impact on sperm quality.
61989281|NCT05383079|EXPERIMENTAL|Radium-223 and Lutetium-177 PSMA-I&T|In this single-arm study, patients will receive 7.4 GBq of 177Lu-PSMA-I\&T on Day 1 of every 6 week Cycle. Radium-223 will be administered concurrently every 6 weeks. The dose of Radium-223 will vary in dose-escalation. Up to 6 Cycles will be given.
62384673|NCT01844414|EXPERIMENTAL|Parolee Comprehensive Care + Phone Coach|PCPC Intervention: Eight specialized nurse case managed hepatitis education sessions, the Hepatitis A/B vaccine series and coach-facilitated mentoring.
62766191|NCT06519383|EXPERIMENTAL|Implant placement by conventional cast based partially guided implant placement(partially guided).|A conventional acrylic stent with radiopaque marker (barium sulphate) will be fabricated which will serve as radiographic template.A CBCT (cone beam computed tomography) examination will be performed with the patient wearing radiographic template.The DICOM file will be then imported in planning software. Virtual implant planning will be performed in 3 shape software.A surgical stent will be produced in a conventional laboratory manner. A flapless implant placement protocol will be performed.
62766192|NCT03078933|ACTIVE_COMPARATOR|Standard of Care|Standard of care for diabetic foot ulcer wound care
61989282|NCT00151320|EXPERIMENTAL|Arm 1|"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles~Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by a dose escalation schedule."
62384674|NCT01844414|EXPERIMENTAL|Parolee Brief HBV program + Phone Coach|PBPC Intervention: Eight twenty minute hepatitis education sessions, coach facilitated mentoring and the Hepatitis A/B vaccine series.
62384675|NCT01844414|ACTIVE_COMPARATOR|Usual Care Group|UC Control Group: One brief general health information program, one-on-one coaching and the Hepatitis A/B vaccine.
62766193|NCT03078933|EXPERIMENTAL|APT001NitricOxide tx 2x week 6 min+ SOC|APT001 Nitric OxideTherapy 2x week for 6 min. treatment time plus standard of care
62766194|NCT03078933|EXPERIMENTAL|APT001Nitric Oxide tx 2x week 12 min+SOC|APT001Nitric Oxide Therapy 2x week for 12 min. treatment time plus standard of care
62766195|NCT03078933|EXPERIMENTAL|APT001Nitric Oxide tx 4x week 6 min+SOC|APT001 Nitric Oxide Therapy 4x week for 6 min. treatment time plus standard of care
62766196|NCT03078933|EXPERIMENTAL|APT001Nitric Oxide tx 4x week 12 min+SOC|APT001Nitric Oxide Therapy 4x week for 12 min. treatment time plus standard of care
62766197|NCT06000306||ddPCR MRD positivity|
62766198|NCT06000306||ddPCR MRD negativity|
62766199|NCT02091284|EXPERIMENTAL|real tDCS|Ten sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
62766200|NCT02091284|SHAM_COMPARATOR|sham-tDCS|Ten sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current was delivered for 20 seconds and was turned off for the rest of the stimulation period. In this way, subjects experienced the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
62766201|NCT05414955|EXPERIMENTAL|Treated|Patients implanted with neuromodulation
62766202|NCT02221154|EXPERIMENTAL|Inofolic®|standard ovarian stimulation and Inofolic®
61977746|NCT05741008|EXPERIMENTAL|Reduced target radiotherapy|"According to our institutional guidelines, GTVnx included the primary tumor volume and the enlarged retropharyngeal nodes, while GTVnd was the volume of involved gross cervical lymph nodes.~The clinical tumor volume (CTV) includes the primary tumor with potential subclinical disease. The high-risk clinical target volume (CTV1) was defined as the GTVnx plus a 5-mm margin to encompass the high-risk sites of microscopic extension, the whole nasopharynx, retropharyngeal nodal regions and . The low-risk clinical target volume (CTV2) was defined as the whole neck area.(Ib, VIIb, and the commom carotid artery are not included)."
61977747|NCT01920217||normal control|
61989283|NCT00912990|PLACEBO_COMPARATOR|Normal saline|Normal saline volume calculated to be equal to the volume of cisatracurium 0.2mg/kg
61989284|NCT00912990|ACTIVE_COMPARATOR|Cisatracurium|Subjects in this arm will be given Cisatracurium 0.2mg/kg IV dose one time prior to intubation.
62384676|NCT01567072|EXPERIMENTAL|NSAIDs in 7 days|NSAIDs (Ibuprofen) in 7 days
62384677|NCT01567072|ACTIVE_COMPARATOR|NSAIDs in 3 days|NSAIDs (Ibuprofen) in the first 3 days and placebo in the last 4 days
62384678|NCT01567072|PLACEBO_COMPARATOR|Placebo|Only placebo in 7 days
62766203|NCT02221154|ACTIVE_COMPARATOR|Gonadotropins;Folic Acid|standard ovarian stimulation without Inofolic®
62766204|NCT00678535|EXPERIMENTAL|Cetuximab plus Capecitabine plus Cisplatin|
62766205|NCT00678535|ACTIVE_COMPARATOR|Capecitabine plus Cisplatin|
62766206|NCT00964301|EXPERIMENTAL|Intervention Group|Participants, caregivers and school nurse will attend telemedicine education sessions at school.
62766207|NCT00964301|ACTIVE_COMPARATOR|Usual care|Usual care participant will receive routine care from their primary care provider.
62766208|NCT01710735|EXPERIMENTAL|Dry needling (deep)|Subjects receive dry needle insertion deeper than 1,5cm below the skin of the Trapezius.
62766209|NCT01710735|ACTIVE_COMPARATOR|Dry needling (superficial)|Insertion of dry needle less than 1cm.
62766210|NCT02778139||youth smokers|
62766211|NCT02778139||non-smokers|
62384679|NCT03082066||Children|Younger 18 years: Newborns, infants, small child, school child, teens
62766212|NCT05644795|ACTIVE_COMPARATOR|Active Comparator: wheat/milk free diet (W/MFD) group|Patients randomized to intervention group will go to a 2 months elimination diet (wheat and cow's milk products). After 2 months of elimination diet they will go to an open challenge, with reintroduction of wheat. After 2 weeks of open diet or whenever rheumatologic, intestinal and/or extraintestinal symptoms should return or intensify, patients will end the study.
62766213|NCT05644795|PLACEBO_COMPARATOR|Placebo Comparator: rice/turkey free diet (R/TFD) group|Patients randomized to control group will go to a 2 months elimination diet (rice and turkey's meat). After 2 months of elimination diet they will crossover to a 2 months elimination diet (wheat and cow's milk products). After 2 months of elimination diet they will go to an open challenge, with reintroduction of wheat. After 2 weeks of open diet or whenever rheumatologic, intestinal and/or extraintestinal symptoms should return or intensify, patients will end the study.
61989285|NCT05140031|ACTIVE_COMPARATOR|Usual care|Participants will initially undergo 2 weeks of usual care.
62384680|NCT03082066||Adults|Even or older 18 years
62384681|NCT02883881||No eye rubbing|
62384682|NCT02883881||with eye rubbing|
62766214|NCT03990805|EXPERIMENTAL|JOINTSTEM|Autologous Adipose Tissue derived MSCs
62766215|NCT03990805|PLACEBO_COMPARATOR|saline|saline
62766216|NCT04947306||All subjects|"Adult patients \>18 years of age, who are scheduled to undergo any elective procedure under general anesthesia at our Institution in which the administration of rocuronium for neuromuscular blockade is anticipated.~All participants will be monitored with both TOF Watch and Tetragraph neuromuscular monitors."
62766217|NCT02117635|EXPERIMENTAL|allogeneic human neural stem cell|"CTX DP~human neural stem cell product, single dose once only injection"
62766218|NCT04152434||Reduction in monthly migraine days all cohorts at 4 months|Migraineurs with 15-30 headache days per month at baseline were clustered in 3 categories. Failure of Erenumab was defined as no improvement in the frequency of monthly headache days. Group I: no preventive therapy, prior to the start of Erenumab. (No botox cohort). Group II: on Botulinum Toxin A (Botox), prior to the add on therapy with Erenumab. (Botox cohort).Group III: on an oral preventive drug, prior to the add on therapy with Erenumab. (No Botox cohort)
62766219|NCT04152434||Selection of elegible paitients|A total of 158 patients were involved in this study. 118 patients (75%), received Erenumab 140 mg., and 40 patients (25%) received 70 mg. In the Botox cohort, of 650 patients, 90 (13%) patients were eligible. In the no Botox cohort, 533 patients, 83 (15%) patients were eligible.
62766220|NCT04152434||Rate of adverse events related to Erenumab|72 adverse events were experienced during the 4 months of treatment, mostly with the 140 mg. dose. The most frequent were: constipation 34%, fatigue 19%, itching 7.5%, muscle cramps 6.3%, increased headache 4.4%, rhinitis 4.4%, injection site discomfort 3.7%, lack of energy 3.1%
62766221|NCT01801852|EXPERIMENTAL|NKT cells|NKT cells treatment plus regular treatment
62766222|NCT02227836|EXPERIMENTAL|Allergy Patch Testing APT|"Patient will undergo APT testing per the following protocol:~* 2g of dry foods will be placed in 2ml of isotonic saline solution. The mixtures will then be placed in aluminum cups (ie Finn chambers) measuring 6 or 12 mm in diameter and adhered to the patient's back.~* Foods to be included will be milk, wheat, egg, soy, peanut, tree nut, fish, shellfish, beef, corn, chicken, potato, pork, legumes, barley, rye, tomato, rice, fruits~* The patches will be removed at 48 hours, and results read at 72 and 120 hours after application~* Reactions will be classified as negative, + (erythema and scattered papules), ++ (erythema and papules), and +++ (erythema and vesicles)."
62766223|NCT03823950|EXPERIMENTAL|Receive G-CSF 72 hours following chemotherapy|"Children will be enrolled during the first four rounds of chemotherapy. Upon enrollment, children will receive G-CSF at 24 hours following chemotherapy. G-CSF will be discontinued when absolute neutrophil count (ANC) has increased post nadir in accord with G-CSF administration guidelines. Parents and children will then complete questionnaires to determine rates of side effects and needle distress at the end of G-CSF during their next regular outpatient oncology clinic visit.~Following children's next course of chemotherapy, G-CSF will be started 72 hours after completion of chemotherapy."
62766224|NCT03823950|NO_INTERVENTION|Historical Controls|Four matched historical controls who received G-CSF at 24 hours following chemotherapy for each patient enrolled will be selected as each enrolled patient completes G-CSF therapy.
62766225|NCT02421263|EXPERIMENTAL|Immediate Participation Group|Participants will begin psilocybin intervention immediately after study enrollment.
62766226|NCT02421263|ACTIVE_COMPARATOR|Delayed Participation Group|Participants will begin the psilocybin intervention 6 months after study enrollment.
62766227|NCT01694277|EXPERIMENTAL|Masitinib|Participants receive masitinib (12 mg/kg/day), given orally twice daily.
62766228|NCT01694277|ACTIVE_COMPARATOR|Sunitinib|Participants receive sunitinib, given at 50 mg/day for 4 consecutive weeks out of 6 weeks, orally
62766229|NCT01635764|EXPERIMENTAL|Adalimumab Every Week|Adalimumab 40 mg every week.
62766230|NCT02290938|ACTIVE_COMPARATOR|Community Wellness Gatherings|All youth will attend a CWG, which is a monthly gathering focused on making healthy choices and learning about Native American culture
62384683|NCT05170581|EXPERIMENTAL|PD-1 inhibitor combined with chemotherapy|Sintilimab will be administered one day before platinum-containing chemotherapy.
62384684|NCT03088345|EXPERIMENTAL|Vasopressin, Arginine|Patients randomized to this arm will receive a continuous arginine vasopressin in normal saline carrier infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.
62384685|NCT03088345|PLACEBO_COMPARATOR|Placebo|Patients randomized to this arm will receive a continuous normal saline carrier infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.
62766231|NCT02290938|EXPERIMENTAL|Community Wellness Gathering + MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
62766232|NCT02426151|EXPERIMENTAL|BEPO-A|Single subcutaneous injection of BEPO-A 4000 IU (Bioreactor manufacturing process)
62384686|NCT03865160|EXPERIMENTAL|Arm A, Interventional group|Treatment period 1: Atropine eye drops, 0.02%, 1 drop/eye, daily for 12 months Treatment period 2: Atropine eye drops, 0.02%, 1 drop/eye, daily for 12 months Treatment period 3: Placebo (NaCl 0.9%) eye drops, 1 drop/eye, daily for 12 months
62766233|NCT02426151|ACTIVE_COMPARATOR|REPO-A|Single subcutaneous injection of REPO-A 4000 IU (Roller bottle manufacturing process)
62766234|NCT05867537|ACTIVE_COMPARATOR|Gluten-free diet in Crohn disease|
62766235|NCT05867537|ACTIVE_COMPARATOR|Gluten-free diet in ulcerative colitis|
62766236|NCT05867537|ACTIVE_COMPARATOR|Gluten-free diet in Primary sclerosing cholangitis|
61977748|NCT01920217||Sepsis group|
61989286|NCT05140031|EXPERIMENTAL|PNE4Adults|Participants will undergo 2 sessions (1-2 weeks) where they will be introduced to the PNE4Adult board.
62558742|NCT03668808|EXPERIMENTAL|Insulin Degludec|Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Degludec and the TRESIBA® FLEXTOUCH® pens during a long-haul flight and randomized to this arm first or second.
62766237|NCT05042609|EXPERIMENTAL|TRS01|
62766238|NCT05042609|ACTIVE_COMPARATOR|Active comparator|
62766239|NCT04552327|EXPERIMENTAL|Solcera|
62766240|NCT04552327|PLACEBO_COMPARATOR|Placebo|
62766241|NCT04552327|ACTIVE_COMPARATOR|Solaraze|
62766242|NCT02332733|EXPERIMENTAL|TV003 Vaccine|Participants will receive a single injection of TV003 at Days 0 and 180.
61989287|NCT01047956|EXPERIMENTAL|MethNAC|Methadone and N-acetylcysteine for opioids abstaining
62766243|NCT02332733|PLACEBO_COMPARATOR|Placebo vaccine for TV003|Participants will receive a single injection of placebo for TV003 at Days 0 and 180.
62766244|NCT01711593|EXPERIMENTAL|Allergic Asthmatic, Non-allergic non-asthmatics(HC)|Track 1: Adult subjects who are allergic asthmatics or non-allergic non-asthmatics(Healthy Controls) will not receive segmental allergen challenge to the lung but will have their blood drawn at 1 time point. Track 2: Adult subjects who are allergic asthmatics will receive segmental allergen challenge to the lung and have their blood drawn at 2 time points.
62766245|NCT01075971|EXPERIMENTAL|Buprenorphine hydrochloride|
62384687|NCT03865160|EXPERIMENTAL|Arm B, Control group|Treatment period 1: Placebo (NaCl 0.9%) eye drops, 1 drop/eye, daily for 12 months Treatment period 2: Atropine eye drops, 0.01%, 1 drop/eye, daily for 12 months Treatment period 3: Atropine eye drops, 0.01%, 1 drop/eye, daily for 12 months
62384688|NCT04461457|EXPERIMENTAL|Intraperitoneal Radioimmunotherapy boost|Four groups of 3 patients with recurring ovarian cancer treated by salvage chemo-therapy and being in complete or good partial remission will receive one IP dose of 211astatine-MX35 F(ab'2). Starting at 50 MBq/L. Dose escalation 100 Mbq/L, 200 MBq/L and finally 300 MBq/L.
62384689|NCT05248776|EXPERIMENTAL|CPL207280 60 mg|16 participants are to receive IMP at dose 60 mg.IMP will be administered for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized.
62384690|NCT05248776|EXPERIMENTAL|CPL207280 120 mg|16 participants are to receive IMP at dose 120 mg. IMP will be administered for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized.
62766246|NCT05280249|EXPERIMENTAL|Both aerobic and resistance exercises in the green exercise concept|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. Participants in this group will be given aerobic and resistance exercises in the open air. For 20 participants who met the inclusion criteria, first 10 minutes of warm-up exercises, then 20 minutes of moderate-intensity (65% of heart rate) walking, followed by 15 minutes of low-intensity (50% of the maximum repetitions) resistance exercises will be trained in the presence of a physiotherapist. resistance exercises will be performed for shoulder flexors and abductors, elbow flexors and extensors, hip flexors and extensors, knee flexors and extensors, hip abductor muscle groups. At the end of each session, 5 minutes of stretching exercises will also be trained.
62766247|NCT05280249|NO_INTERVENTION|Control group|The exercise program will not be implemented. Evaluations will be made at the beginning and end of the study.
62766248|NCT04018313|EXPERIMENTAL|CT-P39 (Part 1)|150 mg/mL, Solution for injection in PFS
62766249|NCT04018313|ACTIVE_COMPARATOR|EU-approved Xolair (Part 1)|150 mg/mL, Solution for injection in PFS
62766250|NCT04018313|EXPERIMENTAL|CT-P39 (Part 2)|150 mg/mL, Solution for injection in PFS
62766251|NCT04018313|ACTIVE_COMPARATOR|EU-approved Xolair (Part 2)|150 mg/mL, Solution for injection in PFS
62766252|NCT04018313|ACTIVE_COMPARATOR|US-licensed Xolair (Part 2)|150 mg/mL, Solution for injection in PFS
61989288|NCT01047956|ACTIVE_COMPARATOR|Methadone|Methadone alone
61989289|NCT04131634|EXPERIMENTAL|SAbR 6 measurable lesions|PD-L1 assessment on biopsy of metastatic site (biopsy will be performed if no prior metastasis sample available)
61989290|NCT01224847|ACTIVE_COMPARATOR|Tetracaine gtt|Pre-Intravitreal injection - 1 gtt Tetracaine topically
61989291|NCT01224847|ACTIVE_COMPARATOR|Tetraciane gtt + Lidocaine pledget|1 gtt Tetracaine pre-IVT injection + application Lidocaine pledget to injection site
61989292|NCT01224847|ACTIVE_COMPARATOR|Cocaine gtt alone|1 gtt pre-IVT injection
61989293|NCT01829776|EXPERIMENTAL|education|Educational intervention
61989294|NCT01357265|OTHER|1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
61989295|NCT06061627|EXPERIMENTAL|LOT-CRT group|"In this arm, an right artrial (RA) lead, an implantable cardioverter defibrillator (ICD) lead and a LV pacing lead are placed are conventionally implanted.~A left bundle branch pacing(LBBP) lead is attempted to be placed."
61989296|NCT06061627|ACTIVE_COMPARATOR|BiVP group|In this arm, an RA lead , an ICD lead and a LV pacing lead are placed.
61989297|NCT03860428|ACTIVE_COMPARATOR|Rectal ibuprofen|Early treatment of PDA that starts within the first 3 days of life using rectal ibuprofen q24h for 3 days, dosages: 20 mg/kg + 10 mg/kg + 10 mg/kg
62384691|NCT05248776|EXPERIMENTAL|CPL207280 240 mg|16 participants are to receive IMP at dose 240 mg. IMP will be administered for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized.
61989298|NCT03860428|ACTIVE_COMPARATOR|Intravenous paracetamol|Early treatment of PDA that starts within the first 3 days of life using intravenous paraceta-mol 15 mg/kg q6h for 3 days
61989299|NCT03860428|SHAM_COMPARATOR|Expectant Treatment|Expectant PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA unless defi-nitely needed based of the predefined infant's condition.
62766253|NCT04035096|EXPERIMENTAL|The high-dose vitamin C with very low carbohydrate diet group|"1. Initiation of High dose IVC therapy: start with 25g IVC biweekly for one week; 50g IVC biweekly for one week; 75g biweekly for one week.~2. Blood vitamin C level measurement: Confirm the plasma vitamin C level above 350 mg/dl by Arkray company PocketChem VC ( Kyoto, Japan) from the 75g/dose~3. Once the target blood level is confirmed, the dose remains g biweekly for 12 weeks. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level. The blood vitamin C level will be checked again and record. The final dose will be kept for 12 weeks.~4. The Riordan IVC protocol (Taiwan)~5. Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks~6. The infusion schedule change within 2 weeks is accepted with the fixed frequency per week or month~7. VLCD intervention in the first 12 weeks"
61989300|NCT03155074|EXPERIMENTAL|High-Intensity Training|
62384692|NCT05248776|EXPERIMENTAL|CPL207280 480 mg|16 participants are to receive IMP at dose 480 mg. IMP will be administered for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized
61989301|NCT03155074|NO_INTERVENTION|Usual Care|
61989302|NCT00481195|ACTIVE_COMPARATOR|Armodafinil|
61989303|NCT00481195|PLACEBO_COMPARATOR|Placebo|
61989304|NCT05673642|EXPERIMENTAL|Working group|A total of 10 sessions will be applied myofascial release technique for 4 weeks, 3 times a week for the first 2 weeks, and 2 times a week for the next 2 weeks. Evaluations will be made at the beginning of the study and at the end of 4 weeks
61989305|NCT05673642|EXPERIMENTAL|Exercise group|The stretching exercises that we planned to give to the exercise group were planned for the muscles to which we will apply myofascial technique. Evaluations will be made at the beginning of the study and at the end of 4 weeks
61989306|NCT05673642|EXPERIMENTAL|Control group|No application will be made to the control group. Evaluations will be made at the beginning of the study and at the end of 4 weeks
62766254|NCT04035096|ACTIVE_COMPARATOR|The control group|"1. Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs~2. Usual care"
62766255|NCT03605290|ACTIVE_COMPARATOR|Mechanically aligned TKR|patients were operated using the standard mechanically aligned technique
61989307|NCT01197131||autistic boys|Boys with autism spectrum disorder, age 5-15 years, diagnosis meets DSM-IV criteria ascertained by ADI-R or ADOS schedule or specialised paediatrician
61989308|NCT01197131||autistic girls|Girls with autism spectrum disorder, age 5-15 years, diagnosis meets DSM-IV criteria ascertained by ADI-R or ADOS schedule or specialised paediatrician.
61989309|NCT01197131||control boys|"Healthy boys, age 5-15 years, mental status assessed by Marburger Beurteilungsskala zum Asperger-Syndrome (MBAS)."
61989310|NCT01197131||control girls|"Healthy girls, age 5-15 years, mental status assessed by Marburger Beurteilungsskala zum Asperger Syndrome (MBAS)."
62766256|NCT03605290|EXPERIMENTAL|Kinematically aligned TKR|patients were operated using the newer mechanically aligned technique
61989311|NCT00704028|EXPERIMENTAL|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
61989312|NCT00704028|ACTIVE_COMPARATOR|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
61989313|NCT06388395|EXPERIMENTAL|Accuracy of full-arch surgical guides|Two surgical guides (milled and 3D printed) will be used randomly to assess the accuracy of the guides following guided implant surgery.
61989314|NCT06388395|EXPERIMENTAL|Survival and complications of the prostheses|The clinical performance of the two different treatment concepts during the follow up period of 3 years concerning screw loosening, veneering material chipping, wear or staining, prosthesis survival and success will be assessed.
61989315|NCT06388395|EXPERIMENTAL|Survival and complications of the implants|The implants survival and success rates will be evaluated after 1, 2 and 3 years of prostheses insertion.
61989316|NCT06388395|EXPERIMENTAL|Conventional implant-supported prosthesis|Full-arch implant-supported conventional (metal-resin) prosthesis will be constructed and assessed for up to 3 years
62384693|NCT05248776|PLACEBO_COMPARATOR|Placebo|16 participants are to receive masking placebo tablets once daily for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized
62384694|NCT04306692|EXPERIMENTAL|Inositol group|Myo-inositol 4000 mg Dosing: 2 x 1 bag per day, per os (subjects can take myo-inositol during the meal but it is not obliged) during 3 consecutive treatment cycles.
62384695|NCT04306692|ACTIVE_COMPARATOR|Clomiphene citrate group|Each tablet contains 50 mg of clomiphene citrate Dosing: 1 tablet per day, per os, from cycle day 3 until 7 (extremes included), stepping up until a maximum dose of 3 tablets per day for 5 consecutive days during 3 consecutive treatment cycles.
62384696|NCT04343612|EXPERIMENTAL|Anodal|Anode placer over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation
62384697|NCT04343612|EXPERIMENTAL|Bilateral|Anode placer over the affected primary motor cortex, cathode over unaffected motor cortex. 2 mA, 20min stimulation
61989317|NCT06388395|EXPERIMENTAL|PEEK implant-supported prosthesis|Full-arch implant-supported PEEK prosthesis will be constructed and assessed for up to 3 years
61989318|NCT02143609|ACTIVE_COMPARATOR|Oxygen|oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
61989319|NCT02143609|PLACEBO_COMPARATOR|Sham oxygen|sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
61989320|NCT02154555|NO_INTERVENTION|no debridement|The postoperative clinical visits will occur at one week, one month, and three months following surgery. During all three postoperative visits, no debridement will be performed.
61989321|NCT02154555|EXPERIMENTAL|debridement|The postoperative clinical visits will occur at one week, one month, and three months following surgery. During the one week postoperative visit, the randomized unilateral debridement will be performed. Debridement includes removing any crust or mucous in the nose. During the one month and three month visit, the PI will only examine the nose.
61989322|NCT03063476|EXPERIMENTAL|Healthy|"Two healthy subjects will be enrolled and each will undergo study procedures at one visit. After screening and consent have been conducted over the phone, subjects will participate in the study procedures. Subjects will arrive in a fasting state (no eat or drink for 8 hours, excluding water). Following collection of blood pressure, height, weight, and a urine and blood sample, subjects will be given an oral bolus of C-13 labeled lysine (5 g) in 50 ml water. This amount of lysine is equivalent to that which is found in a 5oz. serving of beef. Subjects will provide additional urine and blood samples serially post-ingestion. Because blood draws will be collected through an IV, Normal (0.9%) Saline (NS) will be infused at a rate of approximately 10 ml/hr to flush the canula prior to each blood draw.~All subjects will undergo the same procedures and interventions."
61989323|NCT01458158||Diabetic nephropathy|Diabetic nephropathy in patients with type 2 diabetes
61989324|NCT01458158||chronic glomerulonephritis|chronic glomerulonephritis in patients without diabetes mellitus
61989325|NCT01458158||controls|participants without diabetic nephropathy and chronic glomerulonephritis
61989326|NCT02647086|EXPERIMENTAL|Period 1|Patients will receive selected Cytochrome P450 substrates (Midazolam, Omeprazole, Warfarin, Caffeine, Metoprololin) in period 1 (day 1)
61989327|NCT02647086|EXPERIMENTAL|Period 2|Patients will receive dupilumab starting in Period 2 (day 8) and continue weekly through day 50; Patients will receive selected Cytochrome P450 substrates (Midazolam, Omeprazole, Warfarin, Caffeine, Metoprolol) in period 2 (at day 36).
61989328|NCT00187460|ACTIVE_COMPARATOR|Early Feedback Arm|Hospital corporations randomized to receive early feedback in the form of a report card
61989329|NCT00187460|ACTIVE_COMPARATOR|Delayed Feedback Arm|Hospitals randomized to receive delayed feedback in the form of a hospital report cared, 21 months after the early feedback arm.
62384698|NCT04343612|EXPERIMENTAL|Cathodal|Cathode placer over the unaffected primary motor cortex, anode over contralateral supra orbital area. 2 mA, 20min stimulation
62384699|NCT04343612|PLACEBO_COMPARATOR|Placebo|anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation
61989330|NCT02177448|EXPERIMENTAL|BIBR277 and placebo matching enalapril|
61989331|NCT02177448|ACTIVE_COMPARATOR|Enalapril and placebo matching BIBR277|
61989332|NCT00370253|ACTIVE_COMPARATOR|2|Terlipressin
61989333|NCT00370253|EXPERIMENTAL|1|Noradrenalin
61989334|NCT02014363|EXPERIMENTAL|ETS6103 (low dose)|ETS6103 (low dose) extended release tablets (encapsulated) taken once daily orally for the duration of randomised phase of the study (8 weeks).
61989335|NCT02014363|EXPERIMENTAL|ETS6103 (high dose)|ETS6103 (high dose) extended release tablets (encapsulated) taken once daily orally for the duration of randomised phase of the study (8 weeks).
61989336|NCT02014363|ACTIVE_COMPARATOR|Amitriptyline|Amitriptyline tablets (encapsulated) Standard dosing regime
61989337|NCT02014363|NO_INTERVENTION|Lead-in phase|"Citalopram tablets:~Standard dosing regime"
62384700|NCT00315692||Premenopausal women|
62558743|NCT03668808|ACTIVE_COMPARATOR|Insulin Glargine U100|Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Glargine U100 and the LANTUS® SOLOSTAR® INSULIN PEN during a long-haul flight and randomized to this arm first or second.
61989338|NCT01011842|EXPERIMENTAL|radiation therapy arm|
62384701|NCT00315692||Postmenopausal women|
62384702|NCT05272969||LOPD group|50 Patients with genetically confirmed late-onset Pompe disease.
62384703|NCT05272969||Control group|15 Patients with histologically confirmed inclusion body myositis (IBM), 15 patients with genetically confirmed spinal muscular atrophy type 3 (SMA3) and 15 patients with genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD) will serve as a control group.
62384704|NCT06127394|EXPERIMENTAL|espb group|Block will be performed with median technique at the level of sacral 2nd vertebrae.
62384705|NCT06127394|ACTIVE_COMPARATOR|pudendal group|Bilateral transperineal block will be performed
62384706|NCT01070186|EXPERIMENTAL|Treatment|See intervention descriptions
62558744|NCT04600947|EXPERIMENTAL|LP002|Participants will receive LP002 10 mg/kg by intravenous (IV) infusion every 2 weeks (Q2W) for up to 24 months.
62558745|NCT03631589|EXPERIMENTAL|MSCs treated|
62766257|NCT00046930|EXPERIMENTAL|Zosuquidar|Induction treatment with daunorubicin, cytarabine and zosuquidar (details provided in Intervention section), followed by consolidation with Cytarabine (1500 mg/m2 every 12 hours for 6 days), then additional consolidation with the same regimen as received during induction.
62766258|NCT00046930|ACTIVE_COMPARATOR|Placebo|Induction treatment with daunorubicin, cytarabine and placebo (details provided in Intervention section), followed by consolidation with Cytarabine (1500 mg/m2 every 12 hours for 6 days), then additional consolidation with the same regimen as received during induction.
62766259|NCT01109771|ACTIVE_COMPARATOR|absorbable fixation left side|
62766260|NCT01109771|ACTIVE_COMPARATOR|absorbable fixation right side|
62766261|NCT02300597|EXPERIMENTAL|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
62766262|NCT02300597|NO_INTERVENTION|Treatment as usual (TAU)|A comparison group matched for age, gender and neuropsychiatric diagnosis is offered treatment as usual and is assessed at the same time points as the intervention group.
62766263|NCT02706028|ACTIVE_COMPARATOR|ultrasound group|Patients in the ultrasound group received underwater US therapy to both hands and wrists for 7 minutes with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
62766264|NCT02706028|SHAM_COMPARATOR|control group|The control group received sham treatment (the ULTRON home OE-302® device was not turned on) during 10 sessions for 7 minutes per session.
62766265|NCT02416700|EXPERIMENTAL|immediate implant surgery|Immediate implant surgery in one site.
62766266|NCT02416700|ACTIVE_COMPARATOR|conventional implant surgery|Conventional implant surgery in another site
62766267|NCT04533074|EXPERIMENTAL|Single-visit regeneration protocol|
62766268|NCT04533074|ACTIVE_COMPARATOR|Multiple-visits regeneration protocol|
62766269|NCT05988320|EXPERIMENTAL|Experimental: Applications to the Intervention Group|Pranayama breathing will be performed by the caregivers of cancer patients in the Medical Oncology clinic for a total of 4 weeks, covering 15-20 minutes every day, for a total of 4 weeks. information will be given about the benefits and benefits, and any questions will be answered. The application steps will be repeated both by explaining and showing, until the caregiver learns, and if there are any points that they cannot do, they will be corrected. When the caregivers are observed to perform the application fully, they will be asked to do the pranayama breathing exercise every day for 4 weeks and will provide the effectiveness and continuity of the application by providing the same researcher 3 days a week (Tuesday, Thursday, Saturday) with a smartphone WhatsApp video call.
62766270|NCT05988320|NO_INTERVENTION|Applications to the Control Group|Only the pre-test will be applied to the caregivers of cancer patients in the Medical Oncology clinic in the control group. After the caregiver introduction form and Piper fatigue scale application, no breathing exercises will be performed. Individuals will continue their daily lives. Four weeks later the Piper fatigue scale will be administered again. After the Piper fatigue scale is applied, pranayama breathing exercise training will be given to all control group patients and they will be applied for 2 sessions.
62766271|NCT03556098|ACTIVE_COMPARATOR|GIP|Infusion of Glucose-dependent insulinotropic peptide
62766272|NCT03556098|ACTIVE_COMPARATOR|GIP[3-30]|Infusion of GIP\[3-30\]
62558746|NCT00793455|EXPERIMENTAL|Intervention Group|Received Educational Outreach
62558747|NCT00793455|NO_INTERVENTION|Usual Care Control Group|Participants in this arm will receive normal care until outcome assessment is performed at 6 months following the placement of the order for the preventive service. They will be sent a letter reminding them to obtain the ordered preventive service test.
62558748|NCT03829605||Group I:|Fifty AMI patients on admission
62558749|NCT03829605||Group II:|The previous AMI patients after 12 hours
62558750|NCT06150248|OTHER|Intervention group|"Intervention group: Participants assigned to the intervention group will receive educational intervention program to improve their knowledge and promote lifestyle adherence in terms of healthy diet behaviour and physical activity among the undergraduate students. This program will include educational booklets and educational classes include six weeks of in-person education sessions and six weeks of social media messaging. The course will include six weekly teaching units (lectures and group discussions, 45-60 minutes each):~Topic 1: To understand the causes and prevention strategies for overweight and obesity.~Topic 2: To understand food based approaches to reduce or prevent overweight and obesity.~Topic 3: To understand the importance of regular physical activity. Topic 4: To demonstrate how snacking can be a healthy habit. Topic 5: To learn how to read and interpret food labels. Topic 6: To understand how to prepare healthy meals."
62558751|NCT06150248|OTHER|Control group: No Intervention|Participants randomized to the control group in this study will not receive any intervention (They will have their regular curriculums and normal physical activity routine).
61989339|NCT04558931|EXPERIMENTAL|A - Isatuximab/CellProtect|"Isatuximab will be given intravenously (IV) at the dose of 10 mg/kg on Days 1, 8, 15, 22 (cycle 1), 36, 50 (cycle 2), 64, 78 (cycle 3) and monthly thereafter (cycles 4-36).~CellProtect will be given IV infusion at the dose of 3x10\^7 cells/kg day 29 , 43 and 3-10x10\^7 on day 57.~Each cycle will be 28 days, after completion of third cycles, patients will continue with Isatuximab alone until disease progression, unacceptable AE, death, completion of 3 years of treatment or patient's decision to discontinue, whichever occurs first."
61989340|NCT04558931|ACTIVE_COMPARATOR|B - Isatuximab|"Isatuximab will be given intravenously (IV) at the dose of 10 mg/kg on Days 1, 8, 15, 22 (cycle 1), 36, 50 (cycle 2), 64, 78 (cycle 3) and monthly thereafter (cycles 4-36).~Each cycle will be 28 days, after completion of third cycles, patients will continue with Isatuximab alone until disease progression, unacceptable AE, death, completion of 3 years of treatment or patient's decision to discontinue, whichever occurs first."
62558752|NCT06281964|EXPERIMENTAL|PLB1004|PLB1004 given alone as monotherapy
62558753|NCT06281964|ACTIVE_COMPARATOR|platinum-based chemotherapy with or without Sintilimab|platinum-based chemotherapy with or without Sintilimab
62558754|NCT00320203|EXPERIMENTAL|Anecortave Acetate 3 mg Depot|Single injection, anterior juxtascleral depot (AJD)
62558755|NCT00320203|EXPERIMENTAL|Anecortave Acetate 15 mg Depot|Single injection, anterior juxtascleral depot (AJD)
62558756|NCT00320203|EXPERIMENTAL|Anecortave Acetate 30 mg Depot|Single injection, anterior juxtascleral depot (AJD)
62558757|NCT00320203|OTHER|Anecortave Acetate Vehicle|Single injection, anterior juxtascleral depot (AJD)
62558758|NCT05429125|ACTIVE_COMPARATOR|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with an endotracheal tube + stylet.
62558759|NCT05429125|ACTIVE_COMPARATOR|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
62558760|NCT04911517|EXPERIMENTAL|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
62558761|NCT01390025|EXPERIMENTAL|TCN-032|
61989341|NCT05141721|EXPERIMENTAL|Vaccine Arm|After receiving up to 24 weeks induction therapy with a fluoropyrimidine/oxaliplatin/bevacizumab (with or without irinotecan), per standard of care and after completing vaccine production screening, patients will receive a total of 6 administrations of GRT-C901/GRT-R902 plus ipilimumab co-administered only with the first dose of GRT-C901 and GRT-R902. All patients will receive atezolizumab in addition to maintenance therapy of a fluoropyrimidine and bevacizumab according to standard of care.
62558762|NCT01390025|PLACEBO_COMPARATOR|Placebo|
62766273|NCT03556098|PLACEBO_COMPARATOR|Saline|Infusion of saline
62766274|NCT03633669|ACTIVE_COMPARATOR|Tight control|Group that will receive fecal calprotectin testing every 3 months
62766275|NCT03633669|PLACEBO_COMPARATOR|Standard care|Routine clinical care
62766276|NCT02131519||internal jugular vein catheter|pediatric patients required internal jugular vein catheter
62766277|NCT01532544|EXPERIMENTAL|Integrilin and Ilomedin given as continous infusion|
62766278|NCT01532544|PLACEBO_COMPARATOR|Standard treatment daily doses of low molecular weight heparin|Standard treatment daily doses of low molecular weight heparin.
62766279|NCT01815632|EXPERIMENTAL|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow (without myeloablation) on the day of bone marrow harvest. Infusion of autologous blood at one year post-harvest
62766280|NCT01815632|EXPERIMENTAL|Late infusion of autologous marrow|Intravenous infusion of autologous blood on the day of bone marrow harvest. Infusion of autologous bone marrow (without myeloablation) at one year post-harvest
62766281|NCT04701203|EXPERIMENTAL|TransCon PTH|TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection
62766282|NCT04701203|PLACEBO_COMPARATOR|Placebo|Placebo for TransCon PTH delivered once daily by subcutaneous injection
62558763|NCT04813484|EXPERIMENTAL|Kicking it with the Gurlz|This multicomponent intervention includes a violence and gender affirmation screening tool, a peer delivered adaptation of the group-level Seeking Safety Program, and individual-level peer navigation sessions.
61989342|NCT05141721|ACTIVE_COMPARATOR|Control Arm|After receiving up to 24 weeks induction therapy with a fluoropyrimidine/oxaliplatin/bevacizumab (with or without irinotecan), per standard of care and undergoing vaccine production screening, patients will receive maintenance therapy of a fluoropyrimidine and bevacizumab according to standard of care.
62384707|NCT02929875|EXPERIMENTAL|Case (Educational based on TPB)|"Educational intervention delivered to subjects. The content of education includes:~Three training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions."
62384708|NCT02929875|NO_INTERVENTION|Control (No intervention)|No educational intervention provided to subjects in control group
62384709|NCT02098733||Pioglitazone/glimepiride|Pioglitazone/glimepiride 15 mg/1 mg or 30 mg/3 mg, orally once daily before or after breakfast
62558764|NCT03022370|EXPERIMENTAL|Stepping Stones and Creating Futures|Participants receive the Stepping Stones and Creating Futures intervention, comprising of 21 participatory/inter-active sessions, delivered by a trained facilitators. Each session last approximately 3 hours. Sessions are delivered twice a week. Sessions are primarily single sex, with 20 participants per group.
62558765|NCT03022370|NO_INTERVENTION|Wait-list control|Participants receive no intervention until after final data collection occurs, at which point they will be offered Stepping Stones and Creating Futures.
62558766|NCT06499402|NO_INTERVENTION|control group|
62558767|NCT06499402|EXPERIMENTAL|experimental group|
62384710|NCT06099496||Disease group|Collect data from patients with cardiovascular and neurological diseases, including blood and stool samples. Genome and transcriptome sequencing was performed on the collected blood samples. For fecal samples, metagenomic sequencing and metometabolic and proteomic sequencing were performed.
62384711|NCT06099496||Healthy control group|Collect data from healthy people, including blood and stool samples. Genome and transcriptome sequencing was performed on the collected blood samples. For fecal samples, metagenomic sequencing and metometabolic and proteomic sequencing were performed.
62384712|NCT03164213|EXPERIMENTAL|Experimental tDCS|TDCS stimulation at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).
62384713|NCT03164213|SHAM_COMPARATOR|sham tDCS|Sham tDCS at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).
62766283|NCT03166579|EXPERIMENTAL|Dialectical Behaviour Therapy|"Participants receive the standard 12 month DBT programme where all four modes of treatment are delivered including: individual therapy, group skills training, telephone coaching and DBT team consultation."
62766284|NCT05361642|ACTIVE_COMPARATOR|regional nasal block|sphenopalatine ganglion block with general anesthesia
62766285|NCT05361642|ACTIVE_COMPARATOR|dexmedetomidine|use the drug with general anesthesia
62766286|NCT00663299|OTHER|Trufill Detachable Coil System|There is only one treatment arm in the registry and it is all patients receiving treatment with Trufill Detachable Coil System. The use of bare platinum coils for the endovascular occlusion of cerebral aneurysms.
62766287|NCT01451190|EXPERIMENTAL|Treated|
62766288|NCT04524455|EXPERIMENTAL|Blinatumomab and AMG 404|
62766289|NCT05004974|EXPERIMENTAL|Sintilimab with Pemigatinib|Sintilimab combined with Pemigatinib every 3 weeks (Q3W): Sintilimab is administered every 3 weeks (200mg, IV), Pemigatinib 13.5 mg once daily (QD) orally, continuous administration.
62766290|NCT06026995|EXPERIMENTAL|experimental group|
62766291|NCT06026995|ACTIVE_COMPARATOR|control group|
62766292|NCT06040580||Patients|Preoperative patients in need of brain surgery for varying brain pathology who require presurgical brain mapping with MRI (fMRI, and dMRI)
62766293|NCT03518268|ACTIVE_COMPARATOR|Dietary supplement Vivomixx|Vivomixx sachets contains a mixture of 450 billion viable lyophilized bacteria from 8 strains: Lactobacillus paracasei DSM 24733, Lactobacillus plantarum DSM 24730, Lactobacillus acidophilus DSM 24735, Lactobacillus delbrueckii subspecies bulgaricus DSM 24734, Bifidobacterium longum DSM 3 24736, Bifidobacterium infantis DSM 24737, Bifidobacterium breve DSM 24732, and Streptococcus thermophilus DSM 24731
62766294|NCT03518268|PLACEBO_COMPARATOR|Placebo|The placebo sachets contain the inactive ingredients maltose and silicon dioxides
62766295|NCT03817073|EXPERIMENTAL|Iowa Oral Performance Instrument (IOPI)|All MS patients will be included in this arm to compare with a historical control arm. Iowa Oral Performance Instrument (IOPI).
62766296|NCT00725244|ACTIVE_COMPARATOR|1|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
62766297|NCT00725244|ACTIVE_COMPARATOR|2|"Argon Plasma Coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
62766298|NCT03632603|EXPERIMENTAL|Radiotherapy 20 Gy / 4 F|Radiotherapy 20 Gy / 4 F
62766299|NCT03632603|ACTIVE_COMPARATOR|Radiotherapy 30 Gy/ 10 F|Radiotherapy 30 Gy/ 10 F
62766300|NCT04186247|OTHER|Standard of Care|SOC induction (nutritional therapy) for up to 12 weeks, as assigned by the treating gastroenterologist prior to study entry.
62766301|NCT04186247|EXPERIMENTAL|Standard of Care + Antibiotics|"SOC induction (nutritional therapy) for up to 12 weeks, as assigned by the treating gastroenterologist prior to study entry.~Azithromycin (weeks 4-12)~Metronidazole (weeks 4-12)"
62766302|NCT01930760|EXPERIMENTAL|Educational Intervention Group|
62766303|NCT01930760|EXPERIMENTAL|Behavioural Intervention Group|
62384714|NCT05481190|EXPERIMENTAL|Tele-exercise program to Child with Cystic Fibrosis|"Inclusion criteria were Voluntary to participate in the study, Getting consent from parents, Being a child with cystic fibrosis between the ages of 10-18, Having no psychological health problems, No physical problems that would prevent the child from exercising and Computer/ owning a smart phone and being able to use these devices, Having an internet connection at home.~The exclusion criteria were Not volunteering to participate in the study, Not being able to get consent from their parents, Being under the age of 10 or over the age of 18 with a diagnosis of Cystic Fibrosis, Having a psychological health problem, Having a physical problem that prevents the child from exercising and Not having a computer/smart phone and not being able to use these devices and Not having an internet connection at home.~Exclusion criteria are Not participating in the exercise regularly (at least 2 times), Not wanting to continue working out."
62384715|NCT05481190|EXPERIMENTAL|Without exercise Child with Cystic Fibrosis|"Inclusion criteria were Voluntary to participate in the study, Getting consent from parents, Being a child with cystic fibrosis between the ages of 10-18, Having no psychological health problems, No physical problems that would prevent the child from exercising and Computer/ owning a smart phone and being able to use these devices, Having an internet connection at home.~The exclusion criteria were Not volunteering to participate in the study, Not being able to get consent from their parents, Being under the age of 10 or over the age of 18 with a diagnosis of Cystic Fibrosis, Having a psychological health problem, Having a physical problem that prevents the child from exercising and Not having a computer/smart phone and not being able to use these devices and Not having an internet connection at home.~Exclusion criteria are Not participating in the exercise regularly (at least 2 times), Not wanting to continue working out."
62384716|NCT06283615|EXPERIMENTAL|Vitamin D|Experimental group: In addition to conventional treatment, additional intramuscular injection of vitamin D2 was given once every two weeks, each dose of 600,000 units, and the treatment lasted for 12 weeks.
62384717|NCT06283615|NO_INTERVENTION|Control|Control group: routine treatment only, no additional vitamin D intervention therapy.
62384718|NCT01697371|EXPERIMENTAL|Proton Radiation|
62384719|NCT04568629|EXPERIMENTAL|Algorithm Arm|Participants received prognostic advice from a prognostic algorihm.
62384720|NCT04568629|EXPERIMENTAL|Clinician arm|Participants recieved prognostic advice from another clinician.
62766304|NCT02804750|EXPERIMENTAL|Group 1: Low-dose Group|100 mg/day for 4 weeks in Period 1, then 150 mg/day for 4 weeks in Period 2, then 200 mg/day for 4 weeks in Period 3. There was no washout between treatment periods. Period 3 was followed by a 4-week follow-up period. Per-protocol, Group 1 did not participate in treatment Period 4.
62766305|NCT02804750|EXPERIMENTAL|Group 2: High-dose Group|250 mg/day for 4 weeks in Period 1, then 300 mg/day for 4 weeks in Period 2, then 350 mg/day for 4 weeks in Period 3, then 400 mg/day for 4 weeks in Period 4. There was no washout between treatment periods. Period 4 was followed by a 4-week follow-up period.
62766306|NCT06182605|EXPERIMENTAL|Multi-functional instruments|Patients undergoing cataract with lens subluxation surgery with Multifunctional cataract-assisted retractor
62766307|NCT06182605|ACTIVE_COMPARATOR|Traditional instruments|Patients undergoing cataract with lens subluxation surgery with traditional capsule retractor
62766308|NCT03041142|EXPERIMENTAL|Interdisciplinary Intervention|"Children 3 sessions/week 50-60 minutes of physical activity;~1 session/week 60 minutes nutrition education week;~1 session/week 120 minutes behaviour therapy.~Mothers~1 sessions/week 50-60 minutes of physical activity;~1 session/week 60 minutes nutrition education week;~1 session/week 120 minutes behaviour therapy."
62766309|NCT03041142|ACTIVE_COMPARATOR|Routine|Mothers and children followed their routine activities
62766310|NCT03123614|ACTIVE_COMPARATOR|Loteprednol Etabonate 0.5% Oph Gel|Group 1 will use loteprednol 0.5% gel in both eyes, starting at a frequency of four times per day for the first week and then tapered off based on clinical judgement of the corneal healing response.
62766311|NCT03123614|ACTIVE_COMPARATOR|Prednisolone acetate 1% Oph Susp|Group 2 will use prednisolone acetate 1% suspension in both eyes, starting at a frequency of four times per day for the first week, then tapered down to a regimen of fluorometholone 0.1% suspension, which will then be tapered off based on clinical judgement of the corneal healing response.
62766312|NCT06373783|ACTIVE_COMPARATOR|de-epithelise|In combination with Zuchelli's coronally positioned flap technique, gingival recession in the upper jaw premolar region was treated using a de-epithelialized gingival graft. The gingival graft was taken in a rectangular shape from the area located on the palatal side of the maxillary canine and the first molar tooth, and then it was de-epithelised with the help of a scalpel.
62384721|NCT02161614|PLACEBO_COMPARATOR|Placebo|Patients will use placebo for 30 days
62384722|NCT02161614|EXPERIMENTAL|Estradiol Valerate|patients will use estradiol valerate 1mg/day during 30 days
62384723|NCT06065410|EXPERIMENTAL|Patients with knee osteoarthritis|
62384724|NCT04522193|EXPERIMENTAL|Experimental group|All children born at the Lille University Hospital during the investigation period with esophageal atresia type III or IV
62384725|NCT05608265|EXPERIMENTAL|Retinal Imaging using the OSNAT800 IO device|Patients will have their eyes imaged with the OSNAT800 IO device in addition to a routine standard of care appointment.
62384726|NCT03446664|EXPERIMENTAL|Microburst Stimulation|Microburst stimulation to tolerability and effectiveness
62384727|NCT00682409|OTHER|1|Analysis of the value of the imaging of distribution and the late sequence to differentiate the cholesteatoma of the fibrosis in the follow-up operating post at the child
62384728|NCT05466604|EXPERIMENTAL|hyaluronidase|
62384729|NCT05466604|NO_INTERVENTION|hyaluronidase control|
62384730|NCT05466604|EXPERIMENTAL|dexamethasone|
62384731|NCT05466604|NO_INTERVENTION|dexamethasone control|
62384732|NCT00890396||Active Follow-up|An active follow-up involved the performance of many of the laboratory tests and procedures done during BABY HUG clinical trials study. These included, but not limited to, serial laboratory parameters that were not part of routine clinical care such as Hgb F levels, pitted cell count, Howell-Jolly Body determination, a liver-spleen scan, diethylenetriaminepentaacetic acid (DTPA) glomerular filtration rate (GFR) measurement, creatinine clearance, Cystatin C, urine concentrating ability, transcranial Doppler, and neuropsychological testing.
62384733|NCT00890396||Passive Follow-up|A passive follow-up involved the abstraction of clinical data from the medical record. Results of physical examinations and laboratory tests performed as part of routine clinical care were recorded.
62384734|NCT02181335|EXPERIMENTAL|Respimat ® Budesonide low dose + Turbohaler® Placebo|
62384735|NCT02181335|EXPERIMENTAL|Respimat ® Budesonide high dose + Turbohaler® Placebo|
62384736|NCT02181335|ACTIVE_COMPARATOR|Turbohaler® Budesonide + Respimat Placebo®|
62384737|NCT01969565|EXPERIMENTAL|Carfilzomib in combination with dexamethasone|Carfilzomib will be administered at a dose of 20 mg/m², with a dose escalation to 36 mg/m² after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m², with a dose escalation to 45 mg/m² after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment naïve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.
62384738|NCT02068261|EXPERIMENTAL|Cogmed working memory training|30-40 minutes of Cogmed computerized working memory training 3-5 days a week for 5-8 weeks. Every training session consists of a set of visual- and verbal working memory tasks that are trained on during the session.
62384739|NCT02068261|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment. After a 8 week period participants in this arm well be offered Cogmed working memory training.
62384740|NCT03184805|ACTIVE_COMPARATOR|Continuing aspirin|Patients in the group may continue the administration of aspirin during perioperative period.
62384741|NCT03184805|EXPERIMENTAL|Stopping aspirin|Patients in the group may stop medication of antiplatelet drugs during perioperative period.
62384742|NCT05241756||FLACS using FEMTO LDV-Z8|
62558768|NCT05871814|EXPERIMENTAL|Colon preparation guided by an artificial intelligence device|Regular oral and written information will be provided to this group. In addition, participants will take a picture of the last rectal effluent with the smart phone that have to upload to a server. A convolutional neural network will assess whether the bowel preparation is correct or not (clean or not). The system will issue specific recommendations based on the quality of cleansing.
61989343|NCT04914845|ACTIVE_COMPARATOR|De-escalation Cohort; 20mg|For the purposes of dose escalation decisions, a standard 3+3 dose escalation design will be used.The initial cohort, Cohort 1, will consist of 3 enrolled patients who will be treated at 30 mg. If the MTD is exceeded at cohort 1, de-escalation to cohort 0 (20 mg) will occur. If the MTD is not exceeded in cohort 1, dose escalation will continue based on a standard 3+3 design at the dose levels.
61989344|NCT04914845|ACTIVE_COMPARATOR|Cohort 1; 30 mg|The initial cohort, Cohort 1, will consist of 3 enrolled patients who will be treated at 30 mg.
62384743|NCT06323863||patients who underwent stapes surgery at our instution|patients with otosclerosis who underwent stapedectomy in our institution
62384744|NCT02216630|EXPERIMENTAL|Adipose-Derived Stem Cell (ADSC) Therapy|This arm, as the sole arm, will consist of the ADSC treatment procedure. Intervention will consist of Adipose Derived Stem Cell (ADSC) Therapy
62384745|NCT00718887|EXPERIMENTAL|Entecavir, 0.5 mg QD|
62384746|NCT00718887|OTHER|Adefovir, 10 mg QD/Entecavir, 0.5 mg QD|Control
62384747|NCT02246309|EXPERIMENTAL|Embryoscope Time Lapse System|All embryos from patients randomized to this arm will be cultured in the Embryoscope culture system from the time of insemination until the time of transfer on day 3. All staff interaction with the embryos or with maintenance or supervision of the system will be timed.
62384748|NCT02246309|ACTIVE_COMPARATOR|Standard Embryo Culture|All embryos from patients randomized to this arm will be cultured in the standard embryo culture system from the time of insemination until the time of transfer on day 3. All staff interaction with the embryos or with maintenance or supervision of the system will be timed.
62384749|NCT00082628|PLACEBO_COMPARATOR|Period I: Placebo|Subjects will receive placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.
62384750|NCT00082628|EXPERIMENTAL|Period I: Serostim® 4 mg|Subjects will receive Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.
62384751|NCT00082628|EXPERIMENTAL|Period II: Serostim® 4 mg to Placebo|All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive placebo matched to Serostim® on alternate days for 24 weeks in Period II.
62558769|NCT05871814|ACTIVE_COMPARATOR|Control group|Regular oral and written information will be provided to this group
62558770|NCT01814943||Patients with prescription for low dose ASA (75-300 mg/day)|
62558771|NCT03793608|EXPERIMENTAL|Dupilumab|Open label weight base subcutaneous (SC) injection every two (Q2) weeks.
62384752|NCT00082628|EXPERIMENTAL|Period II: Serostim® 4 mg to Serostim® 2 mg|All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive Serostim® 2 mg on alternate days for 24 weeks in Period II.
62384753|NCT00082628|EXPERIMENTAL|Period II: Placebo to Placebo/Serostim® 4 mg|All subjects who will be initially randomized to Placebo arm in Period I continue receiving placebo matched to Serostim® on alternate days for 12 weeks followed by Serostim® 4 mg daily 12 weeks.
62384754|NCT03845504|EXPERIMENTAL|Open Label|Open-label rTMS sessions will occur within \~2 days after the baseline session with daily sessions delivered to left DLPFC over 2-6 weeks.
62766313|NCT06373783|ACTIVE_COMPARATOR|subepithelial|In combination with Zuchelli's coronally positioned flap technique, gingival recession in the upper jaw premolar region was treated using a subepithelial gingival graft. Connective tissue taken from the upper jaw-palate region with a single incision technique was used.
61989345|NCT04914845|ACTIVE_COMPARATOR|Cohort 2; 40mg|Dose escalation to 40 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
61989346|NCT04914845|ACTIVE_COMPARATOR|Cohort 3; 60mg|Dose escalation to 60 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
61989347|NCT04914845|ACTIVE_COMPARATOR|Cohort 4; 80mg|Dose escalation to 80 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
61989348|NCT04914845|ACTIVE_COMPARATOR|Cohort 5; 100mg|Dose escalation to 100 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
61989349|NCT03599050|EXPERIMENTAL|Communication Simulation|Nurses will use simulation over 12 weeks while fidelity is monitored using the NIH Behavior Change Consortium Treatment Fidelity Guidelines.
61989350|NCT03031093|EXPERIMENTAL|Healthy, non obese + HFNC|Healthy, non obese participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
62766314|NCT04907968|EXPERIMENTAL|Dose Escalation - Module A (UPGRADE-A)|XMT-1536 (Upifitabmab Rilsodotin) + carboplatin is administered in groups of patients who will receive doses of XMT-1536 that increase over time.
62384755|NCT02397980|NO_INTERVENTION|Control|Basic information about dementia
62384756|NCT02397980|ACTIVE_COMPARATOR|Behavioral intervention|"Individual, 90 min a day, with an interval of 2 weeks~* Education about dementia~* psychological counselling~* cognitive behavioral therapy"
62766315|NCT04907968|EXPERIMENTAL|Dose Expansion - Module A (UPGRADE-A)|Once the MTD or RP2D is achieved in dose escalation, a new group of patients will receive XMT-1536 (Upifitamab Rilsodotin) at this fixed-dose + carboplatin.
62766316|NCT03814434|EXPERIMENTAL|Smokers with Periimplantitis group|Heavy smokers patients with periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
62766317|NCT03814434|EXPERIMENTAL|Type 2 Diabetes with Periimplantitis group|Patients diagnosed with Type 2 Diabetes with periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
62384757|NCT05516316|EXPERIMENTAL|EP395 high dose|EP395 in repeated doses. Orally, once-daily administration of 3 EP395 capsules for 21 days
62384758|NCT05516316|EXPERIMENTAL|EP395 low dose|EP395 in repeated doses. Orally, once-daily administration of 1 EP395 capsule and 2 placebo capsules for 21 days
62766318|NCT03814434|EXPERIMENTAL|Chronic Periodontitis with Periimplantitis group|Patients diagnosed with Chronic Periodontitis and periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
62766319|NCT03814434|EXPERIMENTAL|Control with Periimplantitis group|Systemically healthy patients with periimplantitis will be included in this group. Patients will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
62384759|NCT05516316|PLACEBO_COMPARATOR|Placebo|Matched placebo capsule, once-daily administration of 3 placebo capsules for 21 days
62384760|NCT04679896|EXPERIMENTAL|MagnetOs Putty|MagnetOs Putty use in instrumented posterolateral fusion, 7cc-10cc mixed with autograft bone in a 1:1 ratio per spine level at the randomized assigned side.
62384761|NCT04679896|OTHER|Local autograft|
62384762|NCT01959269||Regorafenib|Patients treated with Stivarga as 3rd or 4th line treatment, no intervention
62384763|NCT01412333|ACTIVE_COMPARATOR|Interferon beta-1a 44 mcg SC|Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
62384764|NCT01412333|EXPERIMENTAL|Ocrelizumab|Ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.
62384765|NCT02469662|EXPERIMENTAL|Retrospective|Patients who have had primary or revision total elbow arthroplasty using the Nexel Total Elbow, and who have surgical details available
62384766|NCT02469662|EXPERIMENTAL|Prospective|Patients who are having primary or revision total elbow arthroplasty who will receive the Nexel Total Elbow
62558772|NCT01576354|ACTIVE_COMPARATOR|Prolonged-release Fampridine|
62558773|NCT01576354|PLACEBO_COMPARATOR|Placebo|
62558774|NCT04076930||ACEI/ARB users|
62766320|NCT05832736|EXPERIMENTAL|Patients with unilateral prostate cancer|Patients with unilateral prostate cancer
62766321|NCT04340440|ACTIVE_COMPARATOR|D1 lymphadenectomy|Operable gastric cancer was treated by radical gastrectomy and limited D1 lymphadenectomy
62766322|NCT04340440|ACTIVE_COMPARATOR|D2 lymphadenectomy|Operable gastric cancer was treated by radical gastrectomy and extended D2 lymphadenectomy
62766323|NCT00762996|ACTIVE_COMPARATOR|etafilcon A/etafilcon A|Period 1: etafilcon A, Period 2: etafilcon A
62766324|NCT00762996|ACTIVE_COMPARATOR|etafilcon A/omafilcon A|Period 1: etafilcon A, Period 2: omafilcon A
62766325|NCT00762996|ACTIVE_COMPARATOR|omafilcon A/etafilcon A|Period 1: omafilcon A, Period 2: etafilcon A
62766326|NCT00762996|ACTIVE_COMPARATOR|omafilcon A/omafilcon A|Period 1: omafilcon A, Period 2: omafilcon A
62766327|NCT06077370|ACTIVE_COMPARATOR|dTMS group|dTMS on anterior cingulate cortex and medial prefrontal cortex.
62766328|NCT06077370|SHAM_COMPARATOR|sham TMS|Sham TMS on anterior cingulate cortex and medial prefrontal cortex.
62766329|NCT05351268|EXPERIMENTAL|3DPCT and CT guided RISI|All patients were treated with clinical routine treatment: 3DPCT combined with CT guided radioactive seed implantation. Collect patient information and treatment information for analysis.
62766330|NCT02800590|EXPERIMENTAL|ABP-700 30 μg/kg/min|Starting intravenous (IV) infusion rate of 50 micrograms per kilogram per minute (μg/kg/min) for 5 minutes, followed by 30 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
62766331|NCT02800590|EXPERIMENTAL|ABP-700 40 μg/kg/min|Starting IV infusion rate of 70 μg/kg/min for 3 minutes, followed by 40 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
62766332|NCT02800590|EXPERIMENTAL|ABP-700 45 μg/kg/min|Starting IV infusion rate of 80 μg/kg/min for 3 minutes, followed by 45 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
62766333|NCT03443232|EXPERIMENTAL|Cryoballoon ablation group|Persistens atrial fibrillation in Cryoballoon ablation group will apply cryoablation
61989351|NCT03031093|ACTIVE_COMPARATOR|Healthy, non obese|Healthy, non obese participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
61989352|NCT03031093|EXPERIMENTAL|COPD, non obese + HFNC|non obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
62766334|NCT03443232|OTHER|Radiofrequency ablation group|Persistens atrial fibrillation in Radiofrequency ablation group will apply Radiofrequency ablation
62766335|NCT01196845|OTHER|obese + cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
62766336|NCT01196845|OTHER|obese + Sham cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
62766337|NCT01196845|OTHER|non-obese + cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
62766338|NCT01196845|OTHER|non-obese + Sham cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
62766339|NCT06323031||Patients with DoC consecutively admitted to participating units and met the inclusion criteria|Patients in VS or MCS due to severe acquired brain injury with different etiology (traumatic, anoxic, vascular) consecutively admitted at participating neurorehabilitation units. The total sample will be composed of 70 patients (n=9 pts per participating unit).
62766340|NCT02159378|OTHER|GD with Insulin treatment|"At the end of the study patients will be divided into two groups: GD with Insulin treatment versus GD without Insulin treatment In each group, the serum fructosamines rate will be estimated with a confidence interval of 95% and compared from a Student test."
62766341|NCT02159378|OTHER|GD without Insulin treatment|"At the end of the study patients will be divided into two groups: GD with Insulin treatment versus GD without Insulin treatment In each group, the serum fructosamines rate will be estimated with a confidence interval of 95% and compared from a Student test."
62766342|NCT05750433|EXPERIMENTAL|PreforPro+B. subtilis DE111 probiotics|PreforPro is a prebiotic which is a bacteriophage-based product. This prebiotic was used in combination with Bacillus subtilis probiotics.
62558775|NCT04076930||ACEI/ARB non-users|
62558776|NCT01202175|EXPERIMENTAL|Nebivolol|
62558777|NCT01202175|PLACEBO_COMPARATOR|Sugar pill|
62558778|NCT00627159|OTHER|1|high risk
62766343|NCT05750433|PLACEBO_COMPARATOR|Placebo(maltodextrin)|Maltodextrin was used as a placebo.
62766344|NCT05750433|ACTIVE_COMPARATOR|B. subtilis DE111 alone|Bacillus subtilis probiotics was used in this arm alone to compare with the experimental arm.
62766345|NCT02595697|EXPERIMENTAL|J-EMT for Toddlers with Autism|The J-EMT intervention:(a) teach foundational social communicative behaviors, (b) teach related skills that predict long term language outcomes, (c) teach a range of communicative functions, (d) target specific spoken language skills as well as foundational skills, (e) incorporate instructional methods, contexts, and partners that increase social use of language in natural contexts, and (f) promote generalization and maintenance of newly learned skills to everyday activities and routines. In addition, because parents are essential partners for young children with ASD who are learning to communicate, studies are needed that (g) include parents and (h) specify the method and fidelity of parent instruction and fidelity and dosage with which parents use the trained strategies
62766346|NCT02595697|NO_INTERVENTION|Business as Usual Control Group|All children, regardless of group assignment will participate in all assessments. Children randomized to the control group will not receive intervention, but will complete all other research procedures. Other treatments that all children receive in the community will be recorded with bi-monthly surveys.
62766347|NCT03801330|ACTIVE_COMPARATOR|Usual Care|Participants in the Usual Care Pulmonary Rehabilitation will receive usual care pulmonary rehab program. Usual care programs typically consist of exercises including upper extremity strengthening, lower extremity strengthening, aerobic exercises such as walking and balance training. Each program is personalized as per the participant's ability. The intervention is usual care exercise and education, which is personalized for each participant. No drugs are being tested in this study.
62384767|NCT02320591|EXPERIMENTAL|Treatment group|Practices assigned to the treatment group received per member per month care management fees for each Medicare beneficiary attributed to their practice. They also received quarterly feedback reports on their patients' average Medicare expenditures and use of hospital and emergency room services. Practices also had access to regional learning faculties for technical assistance with transformation activities and to share lessons across practices.
62384768|NCT02320591|NO_INTERVENTION|Comparison group|Within each of the 7 regions, this group is comprised of practices that were matched to the treatment practices on a wide range of baseline characteristics of the practices (including their service utilization patterns) and their patients. Comparison practices were selected from a pool of practices including those that applied to participate but were not selected, and practices serving nearby external comparison areas.
62384769|NCT03990155|EXPERIMENTAL|HFNCOT+ECCO2R|Patients on NIV+ECCO2R who have reached at least for 4 consecutive hours, a RR \<25 bpm + pH \>7.35 + absence of clinical signs of respiratory distress after treatment with NIV+ECCO2R
62384770|NCT03263767|EXPERIMENTAL|LYMPHOID HEMOPATHY without ATG|patients with lymphoid hemopathy
62384771|NCT03263767|EXPERIMENTAL|MYELOID HEMOPATHY without ATG|patients with myeloid hemopathy
62384772|NCT03263767|EXPERIMENTAL|LYMPHOID HEMOPATHY witH ATG|patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence
62384773|NCT03263767|EXPERIMENTAL|MYELOID HEMOPATHY with ATG|patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence
62384774|NCT05393778|EXPERIMENTAL|Measured Technique|Patients in this group will have pre-operative planning done using the measured technique.
62384775|NCT05393778|EXPERIMENTAL|Navigated Technique|Patients in this group will have pre-operative planning done using the navigated technique.
62384776|NCT01590524|EXPERIMENTAL|CAM group|Subjects receiving the interventions and standard psychological care
62384777|NCT01590524|NO_INTERVENTION|No-CAM group|Parents receiving only standard psychological care
62384778|NCT05285397|EXPERIMENTAL|Liraglutide|drug starts 6 weeks post-operative until 6 months SC injection dose starting 0.6 mg/day and weekly up titrated until 3.0 mg/day
62384779|NCT05285397|NO_INTERVENTION|Control|Patients with no weight loss drug intervention after bariatric surgery
62384780|NCT04852809||Questionnaire|Observational
62384781|NCT04852809||Focus Group|Observational
62384782|NCT03265431|ACTIVE_COMPARATOR|Control|Normal subjects without history of cardiac disease or arrhythmia
62384783|NCT03265431|EXPERIMENTAL|Arrhythmia|This cohort consist of patients with history of recurrent VT and scheduled for EAM-guided catheter ablation as part of their clinical treatment
62384784|NCT03265431|EXPERIMENTAL|Treatment Failure|A subset of the Arrhythmia cohort, this group will undergo a second imaging session. This subset corresponds to patients from the Arrhythmia cohort presenting with recurrent ventricular arrhythmia following initial EAM-guided catheter ablation and requiring repeated ablation. It is estimated that 30% of the Arrhythmia cohort patients will require repeat ablation based on rate of repeat ablation procedures at MGH. T
62384785|NCT05504811|EXPERIMENTAL|Experimental: FitMi AD Exercise Program|Participants will perform exercises by interacting with FitMi pucks, as described and monitored on a tablet computer. Participants will be asked to exercise at least 30 minutes per day for 3 months.
62384786|NCT05504811|ACTIVE_COMPARATOR|Active Comparator: Conventional booklet of exercise program|Participants will perform exercises described in a booklet similar to what is typically provided to individuals. Participants will be asked to exercise at least 30 minutes per day for 3 months.
62384787|NCT03037489|EXPERIMENTAL|MIV-711|MIV-711 for a total of 26 weeks
62384788|NCT00204763|ACTIVE_COMPARATOR|2|Solid state catheter
62384789|NCT00204763|EXPERIMENTAL|A|
62384790|NCT00963469|EXPERIMENTAL|1|montelukast
62384791|NCT00963469|ACTIVE_COMPARATOR|2|loratadine
62384792|NCT00963469|PLACEBO_COMPARATOR|3|placebo
62384793|NCT04555876|EXPERIMENTAL|high tone external muscle stimulation|"- HiTop 191 appliance (gbo Medizintechnik AG, Rimbach, Germany) Device HiToP® 4 touch gbo Medizintechnik AG, this modern high-tech design with brushed aluminum surface and the 15 TFT LC D full color touch screen monitor offer to the health care professional an indispensable feature."
62384794|NCT04555876|EXPERIMENTAL|stationary bicycle|supervised regular aerobic exercise program on stationary bicycle with moderate intensity, (score 12-14 on Borg scale for rate of perceived exertion) 40 minutes per session, 3 times per week, for 10 weeks.
62384795|NCT00659009|ACTIVE_COMPARATOR|1|Barometric pressure equivalent to sea level (760 mm Hg).
62384796|NCT00659009|EXPERIMENTAL|2|Barometric pressure equivalent to 6000 feet (609 mm Hg)
62384797|NCT00659009|EXPERIMENTAL|3|Barometric pressure equivalent to 8000 feet (565 mm Hg).
62558779|NCT00627159|OTHER|2|low to moderate risk
62558780|NCT00748592|PLACEBO_COMPARATOR|Placebo|
62384798|NCT04380480|EXPERIMENTAL|Experiment|"One or two weeks before CCRT, all patients will undergo a percutaneous endoscopic gastrostomy (PEG) to be administered enteral nutrition support(30-35 kcal/kg of energy, 1.2-1.5g/kg of protein and electrolyte supplementation each day). Nutritional supplements will be administered till 1 month after CCRT.~All patients will receive definitive radiotherapy combined with three cycles of S-1 (40mg/2, BID, po) on D1-14, D22-35, D43-56."
61989353|NCT03031093|ACTIVE_COMPARATOR|COPD, non obese|non obese COPD participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
62384799|NCT01024946|EXPERIMENTAL|Pts getting everolimus|This is a multicenter, open label, phase II study of everolimus as a second or third line therapy for the treatment of advanced malignant pleural mesothelioma, which will also evaluate Merlin/NF2 loss as a biomarker to predict sensitivity to everolimus. Patients who have disease progression after one or two prior chemotherapy regimens will be eligible. In the first stage of this design, 19 patients will be accrued. If 6 or less patients among the first 19 patients show clinical benefit, then the study will be terminated and declared negative. If 7 or more patients show clinical benefit, than an additional 20 patients will be accrued to the second stage. At the end of the study, if 17 or more patients show clinical benefit out of a total of 39 patients enrolled, the regimen will be considered worthy of further investigation.
62384800|NCT02008461|ACTIVE_COMPARATOR|RFA|Mapping and radiofrequency ablation are performed by using standard methods.
62384801|NCT02008461|ACTIVE_COMPARATOR|RFA+BT injection|"Mapping and radiofrequency ablation are performed by using standard methods.~Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster)."
62384802|NCT00665249|ACTIVE_COMPARATOR|Full Motivational Interviewing|"This condition consisted of all the standard elements of MI, both the non-directive and directive strategies (Miller \& Rollnick, 2002). Rogerian elements, such as warmth, egalitarianism, genuineness, and a client-centered approach to the therapeutic relationship, are commonly referred to as MI Spirit (Moyers, Martin, Manual, Hendricksen, \& Miller, 2005). MI is comprised of MI spirit and includes specific directive strategies geared to focus the client toward targeted behavior change, such as confidence and importance rulers, visualization of behavior change, or a decisional balance. The directive elements of MI are those that selectively reinforce positive change talk or enhance discrepancy between a client's wish to change and stay with the status quo."
62384803|NCT00665249|ACTIVE_COMPARATOR|No Intervention: Self Change|Participants in this condition were not assigned to treatment, but were asked to attempt to change on their own during the 8-week follow-up period. SC participants were told that research had shown that some individuals could reduce their drinking without professional help; that participating in the IVR might facilitate their efforts; and that they would be offered professional treatment at the end of the 8-week period. As noted in the Introduction, SC was selected rather than a traditional wait-list control because the aim of the study was to decompose MI into its 3 hypothesized components that include self-change.
62384804|NCT00665249|ACTIVE_COMPARATOR|Spirit-Only Motivational Interviewing|While this condition retained the Rogerian elements to MI, directive elements were excluded. For example, SOMI consisted of the non-directive elements including therapist stance (warmth, genuineness, egalitarianism), emphasis on client responsibility to change, extensive use of reflective listening skills (e.g., open-ended questions, simple reflections), and avoidance of MI-inconsistent behaviors (advise, confront, take expert role, interpretation). Reflective listening was focused on the whole experience of the client and the client's affect, and targeting a particular behavior or eliciting change talk about drinking was proscribed. Furthermore, tools utilized frequently in MI to develop discrepancy, such as amplified or double-sided reflections, were proscribed.
62384805|NCT02497599|EXPERIMENTAL|Intraoperative dual-modality imaging|Patients receive a single intravenous dose of Indium-111-DOTA-Girentuximab-IRDye800CW. At day 4 or 5 after antibody injection a whole body planar scan and SPECT/CT scan will be acquired. At day 7 standard of care (partial) nephrectomy will be performed. This will be extended with the use of dual-modality imaging.
62384806|NCT01201291|ACTIVE_COMPARATOR|Fraction of inspired oxygen of 0.4|Fraction of inspired normobaric oxygen of 0.4 (low oxygen group)
62384807|NCT01201291|ACTIVE_COMPARATOR|Fraction of inspired oxygen of 0.7|Fraction of inspired normobaric oxygen of 0.7 (high oxygen group)
62384808|NCT02610231|EXPERIMENTAL|Istradefylline 20 mg or 40 mg|Treatment for 52 weeks
62384809|NCT03389594|NO_INTERVENTION|Surgical guide designed from voxel size 0.2mm|Surgical guide will be designed based on CBCT voxel size 0.2mm
62384810|NCT03389594|ACTIVE_COMPARATOR|Surgical guide designed from voxel size 0.4m|Surgical guide will be designed based on CBCT voxel size 0.4 mm
62384811|NCT04997564|EXPERIMENTAL|non-cirrhotic patients|patients will be discontinued TAF once daily therapy at the end of week 28 if no HBV reactivation occurs during treatment
62384812|NCT04997564|OTHER|cirrhotic patients|patients will be received TAF once daily for 64 weeks. In this study, after week 64, and patients will continue NUC treatment but pay by themselves.
62384813|NCT01719042|ACTIVE_COMPARATOR|Zofran (8mg)|Participant will take Zofran (8mg) once per day before taking their antibiotic regimen
62384814|NCT01719042|ACTIVE_COMPARATOR|Ensure|Subject will drink a can of Ensure before taking their antibiotic regimen
62558781|NCT00748592|EXPERIMENTAL|PD 0200390, 5 mg|
62558782|NCT00748592|EXPERIMENTAL|PD 0200390, 15 mg|
62558783|NCT00748592|EXPERIMENTAL|PD 0200390, 30 mg|
62766348|NCT03801330|EXPERIMENTAL|Software Tool|Participants in the Pulmonary Rehabilitation Software-Based Home Program will use a digital software tool (APP) to obtain the pulmonary rehab home program. Home programs typically consist of exercises including upper extremity strengthening, lower extremity strengthening, aerobic exercises such as walking and balance training. Each program is personalized as per the participant's ability. The intervention is exercise and education, which is personalized for each participant. No drugs are being tested in this study.
61989354|NCT03031093|EXPERIMENTAL|healthy, obese + HFNC|Healthy obese participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
61989355|NCT03031093|ACTIVE_COMPARATOR|healthy, obese|Healthy obese participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
61989356|NCT03031093|EXPERIMENTAL|COPD, obese + HFNC|Obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
61989357|NCT03031093|ACTIVE_COMPARATOR|COPD, obese|Obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
61989358|NCT02203487|EXPERIMENTAL|BIIF 1149 BS - single rising dose|
61989359|NCT02203487|PLACEBO_COMPARATOR|Placebo|
61989360|NCT00942396|EXPERIMENTAL|mammography|Women must be at least 40 years of age, presenting for routine breast cancer screening or presenting with one or both breasts scored 4 or 5 on the BI-RADS scale as a result of SFM either for routine breast cancer screening or for follow-up or diagnostic mammography
61989361|NCT06114147|EXPERIMENTAL|pregnant women|pregnant women with eligibility criteria with gestational age from 12 to 16+6/7 WA and then from 32 to 36+6/7 WA.
62384815|NCT03529162|ACTIVE_COMPARATOR|Suture Anchor Technique (SA)|If randomized to this group, the patient will receive an open subpectoral long head of biceps tenodesis technique whereby the long head of biceps is re-attached to the humerus using an FDA-approved suture anchor (SA) device for the suture anchor technique. The device to be used will be the Mitek Super Quick Anchor.
62384816|NCT03529162|ACTIVE_COMPARATOR|Pectoralis Major Technique (PMT)|If randomized to this group, the patient will receive an open subpectoral long head of biceps tenodesis technique whereby the long head of biceps is re-attached by suturing the biceps tendon into the pectoralis major tendon.
62558784|NCT03103087|EXPERIMENTAL|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
62558785|NCT03103087|EXPERIMENTAL|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
62558786|NCT03103087|PLACEBO_COMPARATOR|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
62558787|NCT02414958|EXPERIMENTAL|Empagliflozin low dose|Empagliflozin tablets once daily
62558788|NCT02414958|EXPERIMENTAL|Empagliflozin high dose|Empagliflozin tablets once daily
62558789|NCT02414958|PLACEBO_COMPARATOR|Placebo|Placebo tablets matching empagliflozin once daily
62558790|NCT01125917|EXPERIMENTAL|BTDS|Buprenorphine transdermal patch
62558791|NCT03593837|EXPERIMENTAL|Experimental group|Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg).
62558792|NCT03593837|PLACEBO_COMPARATOR|Placebo group|Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg).
62558793|NCT00578474|EXPERIMENTAL|Moxidex|Moxidex otic solution
62558794|NCT00578474|ACTIVE_COMPARATOR|FLOXIN|Ofloxacin otic solution
62384817|NCT00529113|EXPERIMENTAL|Phase 1 Cohort 1|Bardoxolone methyl 150 mg/day x 21 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
62384818|NCT00529113|EXPERIMENTAL|Phase 1 Cohort 2|Bardoxolone methyl 300 mg /day for 21 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
62384819|NCT00529113|EXPERIMENTAL|Phase 1 Cohort 3|Bardoxolone methyl 150 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
62384820|NCT00529113|EXPERIMENTAL|Phase 1 Cohort 4|Bardoxolone methyl 200 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
61989362|NCT05845879||"Women who planned to deliver at the brith center un nid pour naître"|"Women who planned to deliver at the brith center un nid pour naître"
61989363|NCT01540708|EXPERIMENTAL|SERETIDE Rotacaps|Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a capsule-based inhaler (Rotahaler). Devices with varying airflow resistance, low, intermediate and high, will be used.
62384821|NCT00529113|EXPERIMENTAL|Phase 1 Cohort 5|Bardoxolone methyl 250 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
62384822|NCT00529113|EXPERIMENTAL|Phase 1 Cohort 6|Bardoxolone methyl 300 mg/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
61989364|NCT01540708|ACTIVE_COMPARATOR|SERETIDE Diskus|Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a multi-dose dry powder inhaler
62766349|NCT05809804|EXPERIMENTAL|Age range of 18 to 44 years olds|The initial dose of esketamine was set as 0.06 mg / kg, and the injection time of esketamine was 5 s. One minute after injection of esketamine, sufentanil 0.4 μg / kg was injected within 5 s, and the number of coughs within 1 min after injection was recorded. According to the evaluation of sufentanil-induced cough, the dose of esketamine was adjusted. If the patient had no cough ( negative reaction ), the dose of esketamine in the next patient was reduced until the cough reaction occurred. If the patient had a cough reaction ( positive reaction ), the dose of esketamine in the next patient was increased until the cough disappeared. The dose ratio of adjacent esketamine was 1.1. Each group was selected from the previous patient with positive reaction until the 7 groups of positive and negative reactions appeared alternately, and the test was completed.
61989365|NCT02270164|EXPERIMENTAL|Artichoke Leaf Extract|Pycrinil® 100 mg/flaxseed oil 380 mg liquid filled hard plant based capsules (Licaps®) twice daily with food
61989366|NCT02270164|PLACEBO_COMPARATOR|Placebo|Placebo/flaxseed oil 380 mg liquid filled hard plant based capsules (Licaps®) twice daily with food
61989367|NCT00549562|OTHER|Paliperidone ER|8-Week Open-Label
62384823|NCT00529113|EXPERIMENTAL|Phase 1 Cohort 7|Bardoxolone methyl 350 mg/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
62384824|NCT00529113|EXPERIMENTAL|Phase 2 Cohort 1|Bardoxolone methyl maximum tolerated dose(as determined in the Phase 1 portion of the study)/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
62766350|NCT05809804|EXPERIMENTAL|Age range of 45 to 59 years olds|The initial dose of esketamine was set as 0.06 mg / kg, and the injection time of esketamine was 5 s. One minute after injection of esketamine, sufentanil 0.4 μg / kg was injected within 5 s, and the number of coughs within 1 min after injection was recorded. According to the evaluation of sufentanil-induced cough, the dose of esketamine was adjusted. If the patient had no cough ( negative reaction ), the dose of esketamine in the next patient was reduced until the cough reaction occurred. If the patient had a cough reaction ( positive reaction ), the dose of esketamine in the next patient was increased until the cough disappeared. The dose ratio of adjacent esketamine was 1.1. Each group was selected from the previous patient with positive reaction until the 7 groups of positive and negative reactions appeared alternately, and the test was completed.
62766351|NCT02674425||Young adults (18-40)|Healthy adult volunteers, aged between 18 and 40, with no prior/current eye problems or family history of genetic eye diseases and good general health.
62766352|NCT02674425||Older adults (50-70)|Healthy adult volunteers, aged between 50 and 70, with no prior/current eye problems or family history of genetic eye diseases and good general health.
62766353|NCT04643119|ACTIVE_COMPARATOR|Cruciate-Retaining Insert|
62766354|NCT04643119|EXPERIMENTAL|Medial-Congruent Insert|
62766355|NCT05173935|ACTIVE_COMPARATOR|PEG Group|Subjects will gastrostomy tube placement via percutaneous endoscopic gastrostomy (PEG) method.
61989368|NCT03409926|ACTIVE_COMPARATOR|Microcrystalline Cellulose (MCC) 10 grams/day|non-fermentable active control
61989369|NCT03409926|EXPERIMENTAL|Acacia Gum 5 grams/day|fermentable dietary fiber
61989370|NCT03409926|EXPERIMENTAL|Acacia Gum 10 grams/day|fermentable dietary fiber
61989371|NCT06047353|EXPERIMENTAL|Motivational Enhancement Therapy (MET)|Participants in this group will receive intervention with MET along with PAP therapy. Participants will be in this group for approximately 3 months.
62384825|NCT00529113|PLACEBO_COMPARATOR|Phase 2 Cohort 2|Placebo capsules/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
62384826|NCT01869686|EXPERIMENTAL|Denosumab|single subcutaneous injection
62384827|NCT05879380||Suspicion of pulmonary embolism|The group suspected of a pulmonary embolism will receive standard care, consisting of the CTPA to see wether they have a pulmonary embolism or not. Additional to this imaging they will receive a MRPA.
62384828|NCT03819504|EXPERIMENTAL|4-D navigated stereotactic radiosurgical ablation|Patients with structural heart disease and sustained monomorphic ventricular tachycardia/tachycardias will undergo 4-D navigated stereotactic radiosurgical ablation
62384829|NCT01292733|EXPERIMENTAL|Ovarian Cancer Screening|CA125 tumor marker, Transvaginal Ultrasound, Health Status Questionnaires
62384830|NCT03594422|EXPERIMENTAL|HQP1351 30mg|30 mg QOD(Minor subjects will be enrolled based on weight)
62384831|NCT03594422|EXPERIMENTAL|HQP1351 40mg|40 mg QOD(Minor subjects will be enrolled based on weight)
62384832|NCT03594422|EXPERIMENTAL|HQP1351 50mg|50 mg QOD
62384833|NCT03594422|EXPERIMENTAL|HQP1351 20mg|20 mg QOD (Minor subjects will be enrolled based on weight)
62766356|NCT05173935|ACTIVE_COMPARATOR|RIG Group|Subjects will have the placement of a gastrostomy tube via radiologically-inserted gastrostomy (RIG) method.
62384834|NCT04203290|ACTIVE_COMPARATOR|General anesthesia|Patients will be applyed 0.03 mg/kg midazolam, 2 mcg/kg fentanyl, propofol until reaching the appropriate anesthetic depth by observing entropy value (40-60) and 0.5 mg/kg rocuronium for anesthesia induction, after intubation sevoflurane will be used for anesthesia maintenance with low flow anesthesia (0.5 l/min).
62384835|NCT04203290|ACTIVE_COMPARATOR|General anesthesia combined with thoracic epidural anesthesia|Before anesthesia induction epidural catheter will be inserted giving 7 ml bupivacaine %0.25 in saline + 50 mcg fentanyl after confirming the location of catheter, following 15 minutes the standard anesthesia induction will be applied ( 0.03 mg/kg midazolam, 2 mcg/kg fentanyl, propofol until reaching the appropriate anesthetic depth by observing entropy value (40-60) and 0.5 mg/kg rocuronium ). For anesthesia maintenance epidural infusion will be applied ( 7ml/h %0.25 bupivacaine solution) together with low flow (0.5 l/min) sevoflurane anesthesia.
62384836|NCT05330806|EXPERIMENTAL|Collagenase chemonucleolysis|"After local anesthesia, and the puncture point was 8-12cm on the side of the paraspinous process under C arm fluoroscopy. The needle was punctured though the skin with an angle of 45-60 to the posterior of the vertebral via safe entry zone to the herniated site outside the intervertebral disc under the epidural space. The syringe was drawn back to confirm that no blood or cerebrospinal fluid was flowing out, Contrast agents were injected to make sure no flows out of the spinal canal. 600 unit collagenase was dissolved in 2ml normal saline and injected slowly with rate of 1ml per minute. The needle was removed and keep the dorsal elevated position for 6-8 hours. Keep away from load bear of lumbar for 3 months."
62384837|NCT05330806|ACTIVE_COMPARATOR|Percutaneous endoscopic lumbar discectomy (PELD)|For L1-L4 segment, percutaneous endoscopic transforaminal discectomy(PETD) will be performed. An 1cm length incision was made at 8-14cm lateral of the paraspinous process, where a needle puncture to the superior articular process of the lower involved vertebrae of the herniated disc. A series of conical rods are to be introduced, subsequently a reamer is to be introduced through the cannula. After removal of the disc herniation, the cannula and endoscope are to be removed. For L5/S1 segment, percutaneous endoscopic interlaminar discectomy(PEID) was performed. An incision of nearly 7 mm was made at the entry point of the skin, and a series of expansion channels were sequentially inserted into the surface of the ligamentum flavum.Then, the ligamentum flavum and soft tissue around it were removed. Then, the tongue of the working cannula was inserted and rotated into the lateral nerve root. Removed the prominent nucleus pulposus by various nucleus pulposus forceps.
62384838|NCT01643109|EXPERIMENTAL|CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
62384839|NCT01643109|NO_INTERVENTION|Comparison|Standard therapy.
62384840|NCT04754867|EXPERIMENTAL|"discontinued-smoker age-progressed"|"Participants in the discontinued smoker age-progressed virtual reality condition will see two rendering of themselves in optimal health twenty years into the future, a frontal and profile view."
62384841|NCT04754867|EXPERIMENTAL|"discontinued-smoker + continued smoking age-progressed"|"Participants in the discontinued smoker + continued smoking age-progressed virtual reality condition will see two frontal renderings of themselves twenty years in the future, one in optimal health and one incorporating appearance-related medical consequences of moderate-heavy smoking over twenty years (e.g., skin that is dry and discolored, increased wrinkles, etc.)."
62384842|NCT04754867|EXPERIMENTAL|Current self virtual reality images|Participants in the current self virtual reality condition will see their present age self in a virtual reality rendering.
62766357|NCT06280534|EXPERIMENTAL|Single dose group|Single doses of 12.5mg (Group 1), 25mg (Group 2), 37.5mg (Group 3), 62.5mg (Group 4, Group A), 125mg (Group 5), 250mg (Group 6), alternative groups (Groups 7-10, 400-800mg).
62766358|NCT06280534|EXPERIMENTAL|Multiple dosing group|Multiple administrations of 125mg, 250mg (groups 11, 12) Select one or both groups.
62766359|NCT06280534|EXPERIMENTAL|Food Impact Group|62.5 mg (i.e., single dose Group 4)
62766360|NCT03329716|OTHER|Immediate Brace Weaning|Immediate weaning of brace
62766361|NCT03329716|OTHER|Gradual Brace Weaning|Nocturnal brace wearing for 6 months prior to stopping brace
62766362|NCT04432805|EXPERIMENTAL|Pregnant women|Pregnant women suspected of COVID-19
62766363|NCT00496132|EXPERIMENTAL|1|
62766364|NCT03364972|EXPERIMENTAL|Experimental intraocular lens implant|'Alcon Clareon' : New monofocal, hydrophobic acrylic intraocular lens implant
62766365|NCT03364972|ACTIVE_COMPARATOR|Standard intraocular lens implant|Abbott Tecnis PCB00- Standard monofocal,hydrophobic acrylic intraocular lens implant
62766366|NCT02230371|EXPERIMENTAL|Granisetron|Granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden) is injected into a maximum of six muscle sites in each patient. The most painful sites to palpation of the masticatory muscles is chosen, either in the same muscle (maximum 3 sites per muscle) or in a different. The injected volume into each site is0.5 mL, hence the maximum dose of granisetron a patient can receive is 3 mg per treatment. This is repeated after one and two weeks.
61989372|NCT06047353|ACTIVE_COMPARATOR|PAP therapy|Participants in this group will receive PAP therapy which is the standard of care. Participants will be in this group for approximately 3 months.
61989373|NCT05577676|EXPERIMENTAL|Hydrodissection with Normal Saline|This group will be hydrodissected by 5 ml of normal saline, will take Gabapentin 300 mg twice daily, Neurotropic B vitamin twice daily, wear a static wrist splint in neutral position overnight, perform tendon gliding exercises 10 repetitions three times daily and maintain ADL advices.
61989374|NCT05577676|ACTIVE_COMPARATOR|Hydrodissection with Combination of Triamcinolone, Lidocaine, Normal Saline|This group will be hydrodissected by 5 ml combination of 1 ml of triamcinolone, 1 ml of lidocaine \& 3 ml of normal saline, will take Gabapentin 300 mg twice daily, Neurotropic B vitamin twice daily, wear a static wrist splint in neutral position overnight, perform tendon gliding exercises 10 repetitions three times daily and maintain ADL advices.
61989375|NCT02732483|EXPERIMENTAL|Endo-Clot(TM)|
62766367|NCT02230371|PLACEBO_COMPARATOR|Control (placebo)|Placebo (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden) is injected into a maximum of six muscle sites in each patient. The most painful sites to palpation of the masticatory muscles is chosen, either in the same muscle (maximum 3 sites per muscle) or in a different. The injected volume into each site is 0.5 mL. This is repeated after one and two weeks.
62766368|NCT02333890|EXPERIMENTAL|Chloroquine|The daily oral dose per patient is 500 mg of chloroquine. Patients may be taking the drug for 2-6 weeks leading up to the date of the surgery. The last dose will be taken the evening before surgery.
61989376|NCT06363656||single-group|Participants who declare having problems with sleeping/insomnia
61989377|NCT03355586||Suspected lung cancer|"* Patients referred as part of a first diagnostic evaluation of newly detected pulmonary lesion(s) or when an indication for an invasive diagnostic procedure is found during follow-up of earlier detected pulmonary lesion.~* Patients identified during per protocol CT imaging follow-up of known lesions when growth of the lesion is found and an indication for biopsy is determined by the treating physician and/or multidisciplinary board.~* Patients identified when referred for surgical biopsy in case of nodule location inaccessible for CT-guided TTNA.~These will be subjected to a combined approach of modalities with the main intervention being electromagnetic navigation."
61989378|NCT05468437|EXPERIMENTAL|Immediate treatment|Three months of treatment followed by a 3 month durability phase
61989379|NCT05468437|EXPERIMENTAL|Delayed Treatment|A 3 month waitlist period followed by 3 months of treatment
61989380|NCT03899376|ACTIVE_COMPARATOR|Conventional radiotherapy|patients with gynecological cancer treated with adjuvant conventional radiotherapy
61989381|NCT03899376|EXPERIMENTAL|Volumetric modulated arc therapy|Patients with gynecological cancer treated with adjuvant VMAT radiotherapy
62766369|NCT02333890|PLACEBO_COMPARATOR|Placebo|The daily oral dose per patient is 500 mg of placebo (lactose). Patients may be taking the drug for 2-6 weeks leading up to the date of the surgery. The last dose will be taken the evening before surgery.
62766370|NCT03333148|EXPERIMENTAL|Arm A - Nestle IMPACT Immunonutrition|Treatment Arm A (n=146) - Nestlé IMPACT Advanced Recovery:Along with standard of care nutritional therapy patients will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
62766371|NCT03333148|OTHER|Arm B- Standard of Care|No intervention standard of care nutrition (n=146).
62766372|NCT02544334||RA - naïve to biologics|This group will consist of 25 Rheumatoid Arthritis (RA) adult subjects who have not been treated with biologics (naïve to biologics). During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
62766373|NCT02544334||Healthy Controls|This group will consist of 25 adult subjects which will be healthy controls from members of the same household as the 25 naive to biologics, and be of the same age. During the exam the following will take place: dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
62766374|NCT02544334||RA responsive to anti-TNF|This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who have been responsive to first line anti-TNF-alpha therapy. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
62766375|NCT02544334||RA non responsive to anti-TNF|This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who are resistant to two or more anti-TNF-alpha therapies, and be of the same age as the RA responsive to anti-TNF group. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
62766376|NCT01024699||XLIF|This group will have the XLIF procedure done.
62766377|NCT01024699||MAS TLIF|This group will have the MAS TLIF procedure done.
62766378|NCT01690351|EXPERIMENTAL|PF-05089771 Oral Dispersion fasted|Oral dispersion TS formulation- fasted
62766379|NCT01690351|EXPERIMENTAL|PF-05089771 TS formulation fasted|Capsules TS formulation- fasted
62766380|NCT01528748||Chronically Depressed, Alcohol Dependent|Participants who have been formally diagnosed with a clinical diagnosis of Chronic Depression and Alcohol Dependence.
62766381|NCT02817347|EXPERIMENTAL|YH1177 (4/0.5%+0.1%)|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%
62766382|NCT02817347|EXPERIMENTAL|YH1177 (8/1.0%+0.1%)|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%
61989382|NCT01960946|ACTIVE_COMPARATOR|Modified Citrus Pectin (MCP)|Dietary Supplement: Modified Citrus Pectin (MCP, PectaSol-C), 5 grams by mouth three times a day
61989383|NCT01960946|PLACEBO_COMPARATOR|Placebo|Matched placebo 5 grams by mouth three times a day
62766383|NCT02817347|EXPERIMENTAL|YH1177-D (2/0.25%)|piperacillin 2% + tazobactam 0.25%
62766384|NCT02817347|EXPERIMENTAL|YH1177-D (4/0.5%)|piperacillin 4% + tazobactam 0.5%
62766385|NCT02817347|EXPERIMENTAL|YH1177-D (8/1.0%)|piperacillin 8% + tazobactam 1.0%
62766386|NCT01259453|ACTIVE_COMPARATOR|Standard vaccination schedule|Standard dosing at 0, 1, and 6 months
62766387|NCT01259453|ACTIVE_COMPARATOR|Accelerated Schedule|Accelerated dosing at 0, 1, and 2 months
62766388|NCT01355796|EXPERIMENTAL|Aerosolized Hypertonic xyltiol|Aerosolized xylitol (5 ml) twice daily for 14 days
62766389|NCT01355796|ACTIVE_COMPARATOR|Hypertonic saline|Aerosolized 7% hypertonic saline (4 ml) twice daily for 14 days
62384843|NCT01607996|ACTIVE_COMPARATOR|Patient controlled intravenous analgesia|Fentanyl (10 microg/ml) continuous intravenous infusion at a rate of 10 to 20 microg/h
62384844|NCT01607996|EXPERIMENTAL|Epidural anesthesia|Carbostesin (0.1%) and Fentanyl (2 microg/ml) at a continuous flow of 6 to 15 ml/hour
62384845|NCT02003586|OTHER|Plant-based ingredient to a starchy meal|Plant-based ingredient
62766390|NCT03689075|NO_INTERVENTION|Immediate release tacrolimus|Patients will continue on immediate release tacrolimus
62766391|NCT03689075|ACTIVE_COMPARATOR|Extended release tacrolimus|
62766392|NCT02122809|EXPERIMENTAL|Chiauranib|Patients take a single dose of Chiauranib capsules for the pharmacokinetic study,then off for 5 days before the first cycle begins. In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle.
62766393|NCT02723890|EXPERIMENTAL|Tyto Device|examination with Tyto device carried out by a nurse and sent online to the principle and co-investigators for remote analysis.
62766394|NCT05690620|EXPERIMENTAL|Laughter Yoga|In a systematic review study, it was determined that it was appropriate to practice laughter yoga for at least 4 weeks. Therefore, the laughter yoga program; It was planned as a face-to-face group session, for four (4) weeks, twice a week, for a total of eight (8) sessions and 20-25 minutes.
62766395|NCT05690620|ACTIVE_COMPARATOR|Control|"No intervention will be applied to the students in the control group. Students will be followed for four weeks. Before the study, data collection tools will be applied to the students. Again, after the study starts and the study ends, all other data collection tools except the Student Information Form will be applied."
62766396|NCT04118907|EXPERIMENTAL|acoustic stimulation|Pink noise in both ears is given to tinnitus patients. The pink noise is removed by notch filter from tinnitus frequencies that are 20 decibel higher than the threshold.
62766397|NCT04118907|EXPERIMENTAL|somatic stimulation|Three stimulation points were selected for each ear of tinnitus patients, namely ear door (CN.V), auditory Palace (CN.VII) and Yifeng (C2/3). The stimulation intensity should be needle-sensed.
62766398|NCT04118907|EXPERIMENTAL|vestibular stimulation|The patient sat on a rotating chair with sinusoidal harmonic acceleration and rotated without causing the greatest frequency of discomfort.
62766399|NCT04118907|EXPERIMENTAL|acoustic + somatic stimulation|Combination of auditory and somatic stimulation for tinnitus patients
62766400|NCT04118907|EXPERIMENTAL|acoustic + vestibular stimulation|Combination of auditory and vestibular stimulation for tinnitus patients
62766401|NCT04118907|EXPERIMENTAL|acoustic + somatic + vestibular stimulation|Combination of auditory stimulation, somatic stimulation and vestibular stimulation for tinnitus patients
62766402|NCT03823846|EXPERIMENTAL|Experimental Group|Patients in the experimental group were received doctor-nurse-patient cooperative analgesic linkage program.
62766403|NCT03823846|ACTIVE_COMPARATOR|control group|Patients in the control group were received routine analgesic and functional rehabilitation.
62766404|NCT00895960|EXPERIMENTAL|Dasatinib Plus RT + TMZ|Dasatinib (Sprycel) with Radiotherapy (RT) and 6 weeks of concomitant Temozolomide (TMZ)
62766405|NCT04170387|EXPERIMENTAL|Relaxometer fibromyalgia cases|Repetition 6 minutes pre-set programme with the relaxometer 60 seconds 34 movements/minute 3 seconds 55 movements/minute 60 seconds 34 movements/minute 60 seconds 55 movements/minute 90 seconds 34 movements/minute 5 seconds 55 movements/minute 90 seconds 34 movements/minute
62766406|NCT04170387|ACTIVE_COMPARATOR|Relaxometer controls|Repetition 6 minutes pre-set programme with the relaxometer 60 seconds 34 movements/minute 3 seconds 55 movements/minute 60 seconds 34 movements/minute 60 seconds 55 movements/minute 90 seconds 34 movements/minute 5 seconds 55 movements/minute 90 seconds 34 movements/minute
62766407|NCT06318611||Case group|Children and adolescents diagnosed with type 1 diabetes aged between 6 to 18 years
62766408|NCT06318611||Control group|Children and adolescents without type 1 diabetes between the ages of 6 and 18.
61989384|NCT02319031|ACTIVE_COMPARATOR|Arm1: Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks)|Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
61989385|NCT02319031|ACTIVE_COMPARATOR|Arm2 : Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)|Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
62384846|NCT02003586|OTHER|Starchy meal alone|No plant-based ingredient
62384847|NCT02896998|OTHER|Control group|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
62384848|NCT02896998|EXPERIMENTAL|Intervention|The syndesmotic screw will only be removed in case of symptomatic implants (e.g. implants causing pain or restricted range of motion)
62384849|NCT04075240|ACTIVE_COMPARATOR|THA-control arm|Total Hip Arthroplasty: 5 days of rivaroxaban, followed by 30 days of aspirin
62384850|NCT04075240|EXPERIMENTAL|THA-study arm|Total Hip Arthroplasty: 35 days of aspirin
62384851|NCT04075240|ACTIVE_COMPARATOR|TKA-control arm|Total Knee Arthroplasty: 5 days of rivaroxaban, followed by 9 days of aspirin
62384852|NCT04075240|EXPERIMENTAL|TKA-study arm|Total Knee Arthroplasty: 14 days of aspirin
62384853|NCT02382887|ACTIVE_COMPARATOR|Tracheal intubation with Fiberscopy|tracheal intubation with a fiberscope
62384854|NCT02382887|EXPERIMENTAL|Tracheal intubation with Airtraq|tracheal intubation with an Airtraq
62384855|NCT03307395|EXPERIMENTAL|Middle Meningeal Artery Embolization|
62384856|NCT01784900|EXPERIMENTAL|Schema B (140µg)|"* D0 : 20 μg of catumaxomab~* D2 : 40 μg~* D4 : 80 μg"
62384857|NCT01784900|EXPERIMENTAL|Schema A (100µg)|"* D0 : 10 μg of catumaxomab~* D2 : 30 μg~* D4 : 60 μg"
61989386|NCT05896553|EXPERIMENTAL|Oxytoxin group|Drug: intranasal Oxytocin(24IU)
61989387|NCT05896553|PLACEBO_COMPARATOR|Placebo group|Drug: intranasal Placebo
61989388|NCT01016535||Children, Health Professionals|
62384858|NCT04019860|EXPERIMENTAL|High Intensity Interval Training|High intensity interval training for seven weeks. Three weekly, supervised training sessions.
62384859|NCT04019860|EXPERIMENTAL|Time-Restricted Eating|Time-restricted eating for seven weeks. Maximal daily eating window of 10 hours.
62384860|NCT04019860|EXPERIMENTAL|High Intensity Interval Training & Time-Restricted Eating|
62384861|NCT04019860|NO_INTERVENTION|Control|Will be given information about the recommended level of physical activity for health benefits and a healthy diet.
62384862|NCT04715958|EXPERIMENTAL|Diagnostic (CEUS, Definity)|Patients undergo CEUS and receive perflutren lipid microspheres IV over 10-15 minutes before NAC, after 10% of NAC, and after 30% of NAC. Patients also undergo unenhanced baseline ultrasound imaging before NAC, after 10% of NAC, after 30% of NAC, and after 100% of NAC
62384863|NCT03809403||"No touch group:"|Patients with left sided colic adenocarcinoma who underwent left colectomy with an early ligation of mesenteric vessels
62384864|NCT03809403||"Mobilisation first group"|patients with right colic adenocarcinoma who underwent right colectomy with early mobilisation of the tumor followed by the ligation of the vessels.
62384865|NCT00596622|EXPERIMENTAL|Bipolar Manic Subjects Treated|Bipolar mania picture response during fMRI before and after treatment with lithium
62384866|NCT00596622|EXPERIMENTAL|Bipolar Depressed Subjects Treated|Bipolar depression picture response during fMRI before and after treatment with lithium
62384867|NCT00596622|EXPERIMENTAL|Bipolar Euthymic Subjects Treated|Bipolar euthymia picture response before and after treatment with lithium
62384868|NCT02652286|OTHER|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
62384869|NCT01531244|EXPERIMENTAL|Treatment (targeted gene therapy and ILI)|Patients receive melphalan and dactinomycin via ILI. Patients then receive CRAd 3/5-delta via ILI.
62384870|NCT05345431|OTHER|The control group|Treating with balloon dilation or stent implantation only,
62384871|NCT05345431|EXPERIMENTAL|The EDN group|Treating with EDN at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation.
62384872|NCT05871008|EXPERIMENTAL|IA3-CP with SDoH|Assess IA3-CP with SDoH and provide feedback (provider \& patient)
61989389|NCT03841734|EXPERIMENTAL|Treatment bosentan|
61989390|NCT01569958|ACTIVE_COMPARATOR|tDCS|
62384873|NCT05871008|EXPERIMENTAL|IA3-CP only|Assess IA3-CP only without added SDoH and provide feedback (provider \& patient)
62384874|NCT05871008|NO_INTERVENTION|Control - usual care|Usual care: Assess IA3-CP without providing the feedback report
62384875|NCT01432756|NO_INTERVENTION|Wait-list control|Participants in the wait-list control group will not receive the intervention until after the 3-month follow-up assessment.
62384876|NCT01432756|EXPERIMENTAL|Let's Talk Worskite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
61989391|NCT01569958|SHAM_COMPARATOR|sham|
62384877|NCT04851041|EXPERIMENTAL|Potato group|The participants in this group consume every day 150g of boiled potatoes for 12 weeks, preferably during dinner. The participants are allowed to eat this portion during lunch as well
62384878|NCT04851041|ACTIVE_COMPARATOR|Pasta/rice|"The participants in this group consume every day either rice or pasta for 12 weeks, preferably during dinner. The participants are allowed to eat this portion during lunch as well.~The portion of rice and pasta must be as isocaloric as 150g of boiled potatoes."
61989392|NCT02680028|ACTIVE_COMPARATOR|Standard length intramedullary nail|220mm intramedullary nail
61989393|NCT02680028|EXPERIMENTAL|Short length intramedullary nail|175mm intramedullary nail
61989394|NCT01012011||Group 1|
61989395|NCT04630951|EXPERIMENTAL|Strength training based on low loads with blood flow restriction (Experimental group I)|"1. Squat~2. Single Deadlift~3. Back Squat"
61989396|NCT04630951|EXPERIMENTAL|Strenght training based on high loads (Experimental group II)|"1. Squat~2. Single Deadlift~3. Back Squat"
62384879|NCT02392091||critically ill patients|critically ill patients at the age ≥18, expected to stay in the ICU for ≥24h, with the clinical necessity for a urinary catheter and the absence of anuria
62384880|NCT04252924||students|medical student, dental medicine student, pharmacy student, nursing student, physiotherapy student, dietetics student, kinesiology student, biomedical laboratory techniques student, biomolecular science student, psychology student, economy student, student of maritime sciences
62384881|NCT02997111|OTHER|Energy drink|Single group study. Platelet function analyzed with PFA-100 before and 60 minutes after ingestion of 250 ml sugar-free energy drink
62766409|NCT02984059||IBD w/abdominal pain|"Patients with IBD with abdominal pain. Extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for both genomic DNA and calprotectin, and stool analyzed for microbiome. If no blood is drawn then a buccal swab done for the genomic DNA analysis and stool analyzed for calprotectin.~Pain questionnaires:~Pain Frequency-Severity-Duration Scale Pain Catastrophizing Scale-Child Version Pain Burden Interview Pediatric Quality of Life Inventory Adolescent Pediatric Pain Tool Anxiety/Depression Questionnaires Revised Children's Anxiety and Depression Scale Children's Somatization Inventory Adult Responses to Children's Symptoms"
62766410|NCT02984059||IBD w/out abdominal pain|"Patients with IBD and no abdominal pain. Colonoscopy done for standard of care, extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for genomic DNA and calprotectin and stool analyzed for microbiome. If no blood is drawn then a buccal swab for the genomic DNA analysis and stool analyzed for calprotectin.~Pain questionnaires:~Pain Frequency-Severity-Duration Scale Pain Catastrophizing Scale-Child Version Pain Burden Interview Pediatric Quality of Life Inventory Adolescent Pediatric Pain Tool Anxiety/Depression Questionnaires Revised Children's Anxiety and Depression Scale Children's Somatization Inventory Adult Responses to Children's Symptoms"
62766411|NCT02984059||Colonoscopy other reasons no abd pain|Patients who have a colonoscopy for other reasons, rectal bleeding or polyp surveillance, no abdominal pain. Extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for genomic DNA and calprotectin and stool analyzed for microbiome. If no blood is drawn then a buccal swab for the genomic DNA analysis and stool analyzed for calprotectin.
62766412|NCT06476158|ACTIVE_COMPARATOR|Digital follow-up with e-PROs|
62766413|NCT06476158|NO_INTERVENTION|Standard clinical follow-up|
62766414|NCT00475215|EXPERIMENTAL|Rocuronium + Sugammadex 2.0 mg/kg|After the IV intubation dose (0.6 mg/kg) or last maintenance dose (0.15 mg/kg) of rocuronium, at reappearance of T2, participants will receive IV sugammadex 2.0 mg/kg.
62766415|NCT00475215|EXPERIMENTAL|Rocuronium + Sugammadex 4.0 mg/kg|After the IV intubation dose (0.6 mg/kg) or last maintenance dose (0.15 mg/kg) of rocuronium, at reappearance of T2, participants will receive IV sugammadex 4.0 mg/kg.
62766416|NCT05227599|OTHER|Daily Diary Method Cohort|"Participants will be asked to complete a self-report questionnaire that has been validated to assess daily affect. There are 5 items assessing positive affect (joyful, cheerful, happy, lively, proud) and 5 items assessing negative affect (miserable, mad, afraid, scared sad). The respondent is asked to rate these 10 different feelings on a 5-point Likert scale from 1, not much or not at all to 5, a lot."
62766417|NCT03481491|SHAM_COMPARATOR|Sham cerebellar stimulation|Participants will receive a Sham stimulation (inefficient probe) applied over the cerebellum.
62766418|NCT03481491|ACTIVE_COMPARATOR|Real cerebellar stimulation|Participants will receive a real continuous theta burst stimulation (cTBS) applied over the cerebellum.
62766419|NCT00712582|EXPERIMENTAL|Consolidation A|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Patients whose disease is FDG-PET negative or patients whose FDG-PET scan is positive but repeat biopsy is negative and whose initial Ki-67 expression is \< 80% will receive 3 cycles of standard dose ICE Chemotherapy."
62766420|NCT00712582|EXPERIMENTAL|Consolidation B|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Patients whose disease is FDG-PET negative or patients whose FDG-PET scan is positive but repeat biopsy is negative and whose initial Ki-67 expression is ≥80% will receive 2 cycles of augmented RICE Chemotherapy (as per MSKCC protocol 03-075)."
62384882|NCT02500706|EXPERIMENTAL|Mealtime faster-acting insulin aspart and insulin degludec|
62384883|NCT02500706|ACTIVE_COMPARATOR|Mealtime NovoRapid® and insulin degludec|
62384884|NCT02500706|EXPERIMENTAL|Postmeal faster-acting insulin aspart and insulin degludec|
62384885|NCT05389865||Surgical cohort|Adult patients (18 years of age and above) who have had a surgical intervention on the proximal aorta in the three Scottish Cardiothoracic Surgery units based in Glasgow, Edinburgh, Aberdeen.
62384886|NCT05389865||Non-surgical cohort|"- Adult patients (18 years of age and above) who have a diagnosis of proximal aortopathy, but have not had surgical intervention (non-surgical/un-intervened proximal aortopathy). This cohort will be obtained from three sources:~1. Scottish national radiological database based on specific imaging codes~2. Regional genetic/inherited cardiac conditions services~3. Public Health Scotland via specific diagnostic ICD-10 codes."
62384887|NCT02939326|PLACEBO_COMPARATOR|Placebo|"Intervention: Drug: Placebo~Single Injection of placebo into five (5) 0.1 mL IM injections into glabellar area."
62384888|NCT02939326|ACTIVE_COMPARATOR|EB-001 Dose 1 (1X)|"Intervention: Drug: EB-001~Single Injection of Low Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
62384889|NCT02939326|ACTIVE_COMPARATOR|EB-001 Dose 2 (3X)|"Intervention: Drug: EB-001, 3X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
62558795|NCT05519748|EXPERIMENTAL|Online psychoeducational program|The intervention group will receive an online psychoeducational program for 8 weeks. The psychoeducation package consists of 16 different sets of reading materials and post-session writing/reflection exercises, which will be delivered to the participants twice a week. The program is designed to be a brief, trauma-informed, dissociation-focused education package that aims to enable users to better understand and cope with their post-traumatic and dissociative reactions and related life challenges. There are specific psychoeducation elements in each session, such as: (1) safety issues planning, (2) understanding the impacts of trauma and stress, (3) understanding the concept of dissociation and integration of the personality, (4) identifying and coping with the post-traumatic and dissociative symptoms, (5) identifying trauma-related cognitive distortions.
62558796|NCT05519748|OTHER|Waitlist control|The waitlist control group will receive an online psychoeducational program for 8 weeks a week after the completion of the two-month follow-up in the intervention group. The psychoeducation package is identical to the program in the intervention group.
62558797|NCT02115269||primary headaches|Adults taking IndoProCaf for acute treatment of their primary headache attacks (migraine and/or episodic tension-type headache) as per routine clinical practice
62558798|NCT05824624|EXPERIMENTAL|study group|Animal-supported application will be made to the children in the study group.
62558799|NCT05824624|EXPERIMENTAL|control group|Routine care will be given to the children in the control group.
62766421|NCT00712582|EXPERIMENTAL|Consolidation C|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Consolidation C: Patients with biopsy proven disease after induction therapy. Patients whose bone marrow remain positive at interim restaging will have the option of getting an allogeneic\[m3\] stem cell transplant, in lieu of an ASCT, if they have an acceptable HLA match donor. The allogeneic\[m4\] stem cell transplant regimen will be decided by the MSK Bone Marrow Transplant Service."
62766422|NCT05529966|EXPERIMENTAL|NGENUITY|Research fellow participants utilize NGENUITY during micro-stent placement
62766423|NCT05529966|ACTIVE_COMPARATOR|Conventional microscope|Research fellow participants utilize conventional microscope during micro-stent placement
62384890|NCT02939326|ACTIVE_COMPARATOR|EB-001 Dose 3 (9X)|"Intervention: Drug: EB-001, 9X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
62384891|NCT02939326|ACTIVE_COMPARATOR|EB-001 Dose 4 (12X)|"Intervention: Drug: EB-001, 12X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
62384892|NCT02939326|ACTIVE_COMPARATOR|EB-001 Dose 5 (16X)|"Intervention: Drug: EB-001, 16X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
62384893|NCT02939326|ACTIVE_COMPARATOR|EB-001 Dose 6 (21X)|Intervention: Drug: EB-001, 21X Dose 1 Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area
62384894|NCT02939326|ACTIVE_COMPARATOR|EB-001 Dose 7 (28X)|"Intervention: Drug: EB-001, 28X Dose 1~Single Injection of Highest Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
62384895|NCT00747942|NO_INTERVENTION|A|exercise referral to lifestyle activities at the level of moderate intensity without support
62384896|NCT00747942|ACTIVE_COMPARATOR|B|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
62384897|NCT04601194|EXPERIMENTAL|Coaching and Virtual Provider Group|Mental Health Coaching and assigned practice with a Virtual Provider Program
62384898|NCT03006276|EXPERIMENTAL|DFN-15 Active|DFN-15 Active
62384899|NCT03006276|PLACEBO_COMPARATOR|DFN-15 Placebo|DFN-15 Placebo
62384900|NCT05932160|ACTIVE_COMPARATOR|Experimental group|Patients in the experimental group were infused intravenously with 5% dextrose (400 ml/h) in the PACU. The study outcomes were collected at three assessment periods, 0-0.5 h, 0.5-6 h, 6-24 h, after anesthesia by an independent investigator.
62384901|NCT05932160|ACTIVE_COMPARATOR|Control group|Patients in the control group were infused intravenously with ringer lactate solution (400 ml/h) in the PACU. The study outcomes were collected at three assessment periods, 0-0.5 h, 0.5-6 h, 6-24 h, after anesthesia by an independent investigator.
62766424|NCT00848341||Control|
62384902|NCT05869981||Postpartum women|Postpartum women (6-8 weeks to 6 months after delivery) Age 25-35 years
62384903|NCT03820804||Diet-treated|Patients with Phenylketonuria under dietary treatment.
62384904|NCT03820804||Sapropterin-treated|Patients with Phenylketonuria under sapropterin treatment.
62384905|NCT04974931|ACTIVE_COMPARATOR|Patients applied with PREVENA system|This arm relates to the group of participants applied with PREVANA system post reversal of colostomy/ileostomy.
62384906|NCT04974931|NO_INTERVENTION|Patients applied with conventional dressings|This arm relates to the group of participants applied with conventional dressings post reversal of colostomy/ileostomy
62384907|NCT03941327|PLACEBO_COMPARATOR|Control|Patients who provide consent for implant placement but do not receive the implant.
62384908|NCT03941327|EXPERIMENTAL|Interventional|Patients who provide consent for implant placement and do receive the implant.
62384909|NCT05815576|EXPERIMENTAL|Intrinsic foot muscle fatigue|The fatigue protocol will consist of repeated movements of doming (short foot exercise), combined with electrostimulation of the abductor hallucis muscle, while standing on both feet. Participants will be familiarized with doming and electrostimulation during five minutes. They will then have a rest period of at least 5 minutes The electrostimulation electrodes will be placed behind the head of the first metatarsal bone and in front of the medial tubercule of the calcaneus, on the most affected side of subjects with chronic ankle instability (according to CAIT questionnaire scores).
62766425|NCT02008409|EXPERIMENTAL|EndoLift Liver Retractor|"During surgery, the surgeon will use the new internal liver retractor device. The device will retract the subject's liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends."
62766426|NCT05197582|ACTIVE_COMPARATOR|Tele-monitoring group|The researchers called the patients in the experimental group on the first day of the quarantine and explained the topics covered in the COVID 19 patient education booklet to the patients. Patient education and follow-up in quarantine took approximately 25-30 minutes for each patient in the experimental group. The patients in quarantine were followed up by the researchers two more times, on the 5th and 9th days of the quarantine. On the 10th and last day of the quarantine, post-test online questionnaires were sent to the patients for the second time, and the data collection phase was ended.
62766427|NCT05197582|NO_INTERVENTION|Plasebo group|The patients in the control group were called by the researchers on the first day of the quarantine and asked to fill in the online pre-test forms. On the 10th day, the last day of the quarantine, the patients were called and the online post-test forms were sent for the second time, and the data were collected. There was no telephone follow up in the control group and the patients received only routine care in the home
62766428|NCT01169584|EXPERIMENTAL|Single Arm - JX-594|Intratumoral injection of JX-594
62766429|NCT01531972|EXPERIMENTAL|SEP-228432 (Cohort 1)|Subjects will receive 40 mg of SEP-228432 (titration) orally once per day for 3 days; followed by (steady state) at a dose of 200 mg orally once per day for 5 days.
62384910|NCT05815576|NO_INTERVENTION|No intrinsic foot muscle fatigue|No fatigue of the intrinsic foot muscles.
62766430|NCT01531972|EXPERIMENTAL|SEP-228432 (Cohort 2)|Subjects will receive 40 mg of SEP-228432 (titration) orally once per day for 3 days followed by a dose (TBD) of SEP 228432 ≤ 300mg, orally once per day for 5 days.
62766431|NCT01531972|EXPERIMENTAL|SEP-228432 (Cohort 3)|Subjects will receive 40 mg of SEP-228432 (titration) 40 mg of SEP 228432 orally once per day for 3 days followed by a dose (TBD) of SEP 228432 ≤ 300mg, orally once per day for 5 days.
62766432|NCT00002762||Patient interviewing + blood sampling|"Patients were interviewed at the time of the primary cancer surgery to determine the menstrual history. Blood sampling occurred within 1 day of surgery, and serum samples were shipped frozen to a central laboratory (Mayo Medical Laboratory, Rochester, MN) for E2, Pg, and LH determinations. Serum hormone levels, menstrual cycle length, and day of last menses were used to determine the menstrual phase at which surgery occurred.~Patients were observed every 6 months for the first year postregistration and annually for the next 2 to 10 years postregistration for adjuvant therapy information, disease recurrence, and death."
62766433|NCT03510351||Treated subjects|All patients with Pseudomonas infections treated with ceftolozane-taezobactam who meet the inclusion criteria
62766434|NCT04784312|EXPERIMENTAL|9MW1411 injection|
62766435|NCT04784312|EXPERIMENTAL|9MW1411 injection placebo|
62384911|NCT05178563|EXPERIMENTAL|IPT+PDT|The experimental arm consist of performing IPT in randomly assigning patients to receive local use of photodynamic therapy (PDT).
62766436|NCT00204867||A|In vivo surveillance of 6-9 mm polyps detected at CTC
62766437|NCT03947528|EXPERIMENTAL|Anpl-one SR Tab. 300mg|a single oral dose administration in healthy volunteers under fed condition
62766438|NCT03947528|ACTIVE_COMPARATOR|Sarpodipil SR Tab. 300mg|a single oral dose administration in healthy volunteers under fed condition
62766439|NCT03496636|EXPERIMENTAL|Ovarian tissue transplant|Transplantation of ovarian tissue into the abdomen. Only for patients who have previously frozen ovarian tissue
62384912|NCT05178563|SHAM_COMPARATOR|; IPT+Placebo|This experimental arm consist of performing IPT in randomly assigning patients to receive sham use of photodynamic therapy(PDT).
62766440|NCT02714881|OTHER|Tumor necrosis factor inhibitor|Subjects who are about to start on a tumor necrosis factor inhibitor (TNFi) as part of usual care will be recruited. They will have measurements including routine lipids, advanced lipoproteins, and coronary flow reserve (CFR) before and after their TNFi.
62766441|NCT02154685|OTHER|Retrieval-Extinction: Smoking Cues|A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.
62766442|NCT02154685|OTHER|Non-Retrieval Extinction: Neutral Cues|This is the group that will not receive retrieval-extinction training and will be exposed to neutral cues.
62766443|NCT04292457|EXPERIMENTAL|Propofol|Anesthesia is maintained with Propofol
62766444|NCT04292457|EXPERIMENTAL|Sevoflurane|Anesthesia is maintained with Sevoflurane
62766445|NCT04254874|EXPERIMENTAL|Abidol hydrochloride|Standard symptomatic support therapy (SMT) plus abidol hydrochloride(0.2g, 3 times a day).
62766446|NCT04254874|EXPERIMENTAL|Abidol Hydrochloride combined with Interferon atomization|Interferon(PegIFN-α-2b) atomization was added(45ug, add to sterile water 2ml, twice a day) on the basis of group I.
62766447|NCT03939078||Vaginal Laser Intervention|Patients will be submitted to vaginal biopsy before and after three laser sections, and therefore will be their own comparative group to see the improvement associated with the laser effects.
62766448|NCT03143998|EXPERIMENTAL|HCV GT1a TN|Participants with HCV GT1a infection who are TN will take MK-5172A for 12 weeks.
62766449|NCT03143998|EXPERIMENTAL|HCV GT1a TE|Participants with HCV GT1a infection who are TE will take MK-5172A for 12 weeks.
62766450|NCT03143998|EXPERIMENTAL|HCV GT1b TN|Participants with HCV GT1b infection who are TN will take MK-5172A for 12 weeks.
62766451|NCT03143998|EXPERIMENTAL|HCV GT1b TE|Participants with HCV GT1b infection who are TE will take MK-5172A for 12 weeks.
62766452|NCT01986972|ACTIVE_COMPARATOR|Toothbrushing With Dentifrice|After 72 hours of absence oral hygiene, patients performed toothbrushing with common dentifrice.
62766453|NCT01986972|EXPERIMENTAL|Toothbrushing Without Dentifrice|After 72 hours of absence oral hygiene, patients performed toothbrushing without dentifrice.
62766454|NCT00495755|EXPERIMENTAL|Campath (alemtuzumab)|
62766455|NCT02723175|EXPERIMENTAL|Sham tDCS Stimulation|"30 minutes of the sham transcranial Direct Current Stimulation~Transcranial Direct Current Stimulation: Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people."
62766456|NCT02723175|EXPERIMENTAL|Anodal tDCS Stimulation of DLPFC|"30 minutes of the active transcranial Direct Current Stimulation (tDCS)~Transcranial Direct Current Stimulation: Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people."
62766457|NCT03721809|OTHER|macrophage activation syndrome secondary to bacterial sepsis|Patients hospitalized in medical intensive care for macrophage activation syndrome secondary to bacterial sepsis
62766458|NCT03721809|OTHER|bacterial sepsis/septic shock|Patients hospitalized in medical intensive care for sepsis / septic shock
62766459|NCT06508736|EXPERIMENTAL|Storytelling Grup|Participants will receive 4 sessions of storytelling intervention with expert reviewed stories.
62766460|NCT06508736|ACTIVE_COMPARATOR|Active Comparator Grup|Participants will be trained on cyberbullying in 4 sessions.
62766461|NCT04086446|ACTIVE_COMPARATOR|active tDCS|Cathode transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
62766462|NCT04086446|SHAM_COMPARATOR|sham tDCS|The sham transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
62766463|NCT01762254|ACTIVE_COMPARATOR|incisionless laparoscopic colectomy|incisionless laparoscopic colectomy: Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
62766464|NCT01762254|ACTIVE_COMPARATOR|conventional laparoscopic colectomy|conventional laparoscopic colectomy: The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
62766465|NCT05135481|ACTIVE_COMPARATOR|CONTROL GROUP|The qualification for phrenectomy in group 1 will be made based on the Amir scale, i.e. a score of 4 and fewer points for the language function.
62766466|NCT05135481|EXPERIMENTAL|STUDY GROUP|"Management in group 2 will include increased lactation care both during hospital stay and post discharge.~Increased lactation care will consist of:~individual consultations on how to properly attach the baby to the breast (at least 3 meetings during hospitalization with personnel trained in lactation counselling), regular (at least once a week) contact with a breastfeeding consultant as part of a closed group on social media or by phone, if necessary (expressed by the mother or based on a referral by a member of the lactation team) an outpatient appointment at the breastfeeding clinic."
62766467|NCT02024880|EXPERIMENTAL|Protective catheter group|Protective catheter group uses Guardia™ Pro Protective ET catheter from Cook.
62766468|NCT02024880|ACTIVE_COMPARATOR|Conventional catheter group|Conventional catheter group uses Sydney IVF catheter from Cook.
62766469|NCT04943692|EXPERIMENTAL|Group A: Metformin glycinate 1050 mg|Metformin glycinate 1050 mg Orally twice a day.
62766470|NCT04943692|ACTIVE_COMPARATOR|Group B: Metformin hydrochloride 850 mg|Metformin hydrochloride 850mg Orally twice a day.
62766471|NCT04243928|ACTIVE_COMPARATOR|control group|15 diplegic children received regular exercise program including balance exercise
62766472|NCT04243928|EXPERIMENTAL|study group|15 diplegic children recieved regular exercise program plus putting kinesiotape
62766473|NCT00403780|ACTIVE_COMPARATOR|A|Active intervention with pregabalin
62766474|NCT00403780|PLACEBO_COMPARATOR|B|placebo arm with capsule Lyrica Placebo
62766475|NCT02089113|EXPERIMENTAL|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
62766476|NCT02089113|PLACEBO_COMPARATOR|PV|PV (placebo drug delivery vehicle)
62766477|NCT02525913|OTHER|Bi-lateral mastectomy|
61989397|NCT02979145||Patients with CMT|Two groups of patients will be included: Group 1 (Definitive): Children with known CMT where genetic testing confirms the diagnosis, or children with a clinical diagnosis including electrophysiology confirming the presence of CMT and a corresponding family history where a first or second degree relative has a genetic diagnosis; or Group 2 (At risk): A clinical diagnosis of CMT awaiting genetic testing or confirmatory electrophysiology and evidence of a genetic diagnosis in a first or second degree relative; or individuals identified as being at risk of a CMT diagnosis (prodromal patients), without the onset of signs or symptoms.
61989398|NCT02979145||Controls|Healthy controls will be included from unaffected family members or friends accompanying patients at INC sites. Healthy controls are defined as boys and girls aged 0-≤4 years without a diagnosis of CMT or any of the other study exclusion criteria.
61989399|NCT05840146|EXPERIMENTAL|Kinesiotaping group|Kinesiotape was applied to the lateral side of the affected hip for gluteus medius muscle. Each patient was positioned lying down with the affected side up, and two I-strips were used.
61989400|NCT05840146|SHAM_COMPARATOR|Sham taping group|Sham tape was applied with a single I-strip without tension in tape or muscle stretch. After paper backing was completely removed, tape was essentially placed on the skin across the lateral side of the affected hip.
61989401|NCT03455660||Pre-January 2015|Patients who underwent cesarean delivery between February 2013 and December 2014.
61989402|NCT03455660||Post-January 2016|Patients who underwent cesarean delivery between February 2016 and December 2017.
61989403|NCT02578654|EXPERIMENTAL|Interventions|"Additional HIV care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment. These interventions are specifically added on routine care during the post-intervention period. The routine care does not include the additional round and the three telephone calls and is assessed during the pre-intervention period."
61989404|NCT01324349|EXPERIMENTAL|Veriset Hemostatic Patch|Veriset Hemostatic Patch
61989405|NCT01324349|ACTIVE_COMPARATOR|Fibrin Sealant (TachoSil®)|Fibrin Sealant (TachoSil®)
61989406|NCT02374645|EXPERIMENTAL|Volitinib (AZD6094) 600mg + gefitinib 250 mg|Cohort 1: Volitinib（AZD6094） 600 mg od + gefitinib 250 mg od
61989407|NCT02374645|EXPERIMENTAL|Volitinib (AZD6094) 800mg + gefitinib 250 mg|Cohort 2: Volitinib（AZD6094） 800 mg od + gefitinib 250 mg od
61989408|NCT06067945||NP is given to the non polished group which is group 2|Out of two groups, group 2 is a test group to which rough preparations are assigned
61989409|NCT05173649|EXPERIMENTAL|Calisthenic Training|Calisthenic Training Group
61989410|NCT05173649|EXPERIMENTAL|Neuromuscular Training Group|Neuromuscular Training Group
62384913|NCT05129917|PLACEBO_COMPARATOR|Placebo|consume 1 sachet per day for 14 day
61989411|NCT02311439|EXPERIMENTAL|FOLFIRINOX + CRT|FOLFIRINOX regimen, consisted of oxaliplatin, irinotecan, leucovorin and fluorouracil (5-FU), for 4 cycles, followed by consolidation radiotherapy concurrent with capecitabine 625mg/m2 BID in non-progressed cases, in treating patients with locally advanced cancer pancreas.
62384914|NCT05129917|EXPERIMENTAL|Gojinsen® drinks|consume 1 sachet per day for 14 day
61989412|NCT02449174|ACTIVE_COMPARATOR|Frozen Microbiota|Donor stool (greater than 150 grams) was collected \<4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was kept at -80C labeled with ID and expiration date which was 6 months after preparation. Intervention - Frozen Microbiota will be delivered via enema
61989413|NCT02449174|ACTIVE_COMPARATOR|Lyophilized Microbiota|Lyophilized Microbiota_Donor stool (greater than 150 grams) was collected \<4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was starting lyophilization process within 30 minutes after completion of stool filtration. Lyophilized microbiota products were kept at 4C and were used within 6 months after preparation. Intervention - Lyophilized Microbiota will be delivered orally
61989414|NCT00004078|EXPERIMENTAL|Treatment (irinotecan hydrochloride)|Patients receive irinotecan IV over 60 minutes on days 1-5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months for 4 years and then annually thereafter until death or until patient enters another POG study.
61989415|NCT00387478|EXPERIMENTAL|1|modified Tree pollen allergen absorbed to Tyrosine and containing MPL adjuvant
61989416|NCT00387478|EXPERIMENTAL|2|modified Tree pollen allergen absorbed to Tyrosine
61989417|NCT00387478|PLACEBO_COMPARATOR|Placebo|4 injections of placebo 0.5 ml (2% tyrosine)
62384915|NCT01397331|ACTIVE_COMPARATOR|Inhalational anesthesia|Group of patients undergoing the surgery under anesthesia based on inhalational anesthetic
62384916|NCT01397331|ACTIVE_COMPARATOR|TIVA|Group of patients undergoing the surgery under total intravenous anesthesia
62567672|NCT04363320|EXPERIMENTAL|Low-Dose NIATx Coaching & ECHO|"* Attend an in-person Kick-Off Meeting with Study Team \& Coaches~* One-hour conference call with Executive Sponsor~* Two-hour NIATx webinar training with Change Leader/Team~* Three (one-hour) coaching calls at months 4, 8, and 12 with Change Leader/Team~* Prescribers participate in 12 monthly (one-hour) ECHO video conference calls"
62766478|NCT04569812|EXPERIMENTAL|Standard CPR|After Informed Consent Document (ICD) signature, participants were randomised (to the Standard CPR group) to perform standard CPR (30:2) in a flowchart-assisted resuscitation for 5min in a manikin model
61989418|NCT03448185|PLACEBO_COMPARATOR|Control|Subjects randomized to control group will receive olive oil placebo capsules and yoga intervention for 1 year.
61989419|NCT03448185|EXPERIMENTAL|Exercise and omega-3 fatty acids|Subjects will receive high dose omega-3 fatty acids as well as aerobic exercise intervention for 1 year.
61989420|NCT03448185|ACTIVE_COMPARATOR|Yoga and omega-3 fatty acids|Subjects will receive high dose omega-3 fatty acids as well as yoga intervention for 1 year.
61989421|NCT03448185|ACTIVE_COMPARATOR|Exercise control|Subjects will receive olive oil placebo as well as aerobic exercise intervention for 1 year.
61989422|NCT02066467||Heart failure patients|"* Subjects with art failure who receive stable optimal pharmacologic therapy~* Moderate to severe heart failure (NYHA Class III-IV) with ejection fraction (EF) ≤ 35% and QRS duration ≥ 120 ms~* Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure.~The study is collecting observational data on regular CRT-D device implants with special focus on the left ventricular ACUITY X4® Lead Family' ."
61989423|NCT05451979|EXPERIMENTAL|MedBIKE HIIT|Participants will complete the baseline assessments and begin the MedBIKE HIIT Exercise Program intervention within 2-weeks. After the completion of the 12-week program, participants will return for follow-up assessments which will be repeated at 6- and 12-months post intervention.
61989424|NCT05451979|NO_INTERVENTION|Standard of Care|Participants will complete the baseline assessments and continue with standard of care (no intervention) for 12-weeks then return for a repeat assessment. Participants will then crossover into the MedBIKE HIIT Exercise Program intervention group for 12-weeks. A post-intervention assessment will be completed and follow-up assessments at 6- and 12-months post intervention.
61989425|NCT04773444|EXPERIMENTAL|Eccentric cycling training|Moderate intensity cycling training in eccentric type
61989426|NCT04773444|EXPERIMENTAL|Concentric cycling training|Moderate intensity cycling training in concentric type (intensity matched the eccentric training)
61989427|NCT04773444|NO_INTERVENTION|Control group|without receiving any exercise training
61989428|NCT03829748|EXPERIMENTAL|Intermittent aspiration|Empty syringe of 10cc and intermittent aspiration during puncture
61989429|NCT03829748|NO_INTERVENTION|Continous/standard aspiration|Empty syringe of 10cc and continous aspiration during puncture
61989430|NCT04901494||SSRI for at least one year prior to the diagnosis of MCI|subjects with an initial diagnosis of MCI who were treated with an SSRI for at least one year prior to the diagnosis of MCI
62384917|NCT02275559|EXPERIMENTAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
62384918|NCT02275559|ACTIVE_COMPARATOR|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
62384919|NCT03132038|EXPERIMENTAL|Nivolumab|Nivolumab will be given every two weeks for a maximum of one year (12 cycles) at a dose of 3 mg/kg to be administered as a 60 minute IV infusion
62384920|NCT06164418|PLACEBO_COMPARATOR|a nanohybrid resin composite material with a universal adhesive|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
61989431|NCT04901494||SSRI at the time of diagnosis and treated with it for at least 6 months after the diagnosis of MCI|SSRI at the time of diagnosis and treated with it for at least 6 months after the diagnosis of MCI
62567673|NCT04363320|EXPERIMENTAL|High-Dose NIATx Coaching & No ECHO|"* Attend an in-person Kick-Off Meeting with Study Team \& Coaches~* 4-hour onsite visit~* 11 monthly (one-hour) NIATx coaching calls"
62766479|NCT04569812|EXPERIMENTAL|Chest compressions only|After ICD signature, participants were randomised (to the CC only CPR group) to perform chest compressions only in a flowchart-assisted resuscitation for 5min in a manikin model
61989432|NCT04901494||Subjects without SSRI use|Subjects without SSRI use
61989433|NCT03511612|OTHER|Pattern A|Intervention : Each subject has 3 measurements of ABI starting with oscillometric device and then using the Doppler method.
62384921|NCT06164418|ACTIVE_COMPARATOR|a nanohybrid resin composite material with a fluoride-releasing universal adhesive|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
62384922|NCT06164418|PLACEBO_COMPARATOR|ion-releasing restorative material with a universal adhesive|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
62567674|NCT04363320|EXPERIMENTAL|Low-Dose NIATx Coaching & No ECHO|"* Attend an in-person Kick-Off Meeting with Study Team \& Coaches~* One-hour conference call with Executive Sponsor~* Two-hour NIATx webinar training with Change Leader/Team~* Three (one-hour) coaching calls at months 4, 8, and 12 with Change Leader/Team"
62766480|NCT02402686||Tocilizumab for RA in Routine Clinical Practice|Participants from routine clinical practice in Hungary who are receiving treatment for RA with tocilizumab SC according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling and who have no contraindication to tocilizumab therapy as per the local label are eligible for observation.
62766481|NCT00778492||No Treatment|Patients with the history of ingestion of aspirin and/or ADP receptor antagonist (clopidogrel or ticlopidine) for at least 7 days prior the surgery. All patients undergoing cardiac surgery with the use of cardiopulmonary bypass on elective and urgent basis.
62766482|NCT06334757|EXPERIMENTAL|Serplulimab+Bevacizumab+Pemetrexed+Carboplatin|Using Serplulimab in combination with bevacizumab, carboplatin and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.
62766483|NCT02610933|NO_INTERVENTION|Vitamin K antagonist|Vitamin K antagonist treatment targeting an international normalized ratio of 2 to 3 for 18 months
62766484|NCT02610933|ACTIVE_COMPARATOR|rivaroxaban|Rivaroxaban 10 mg tablet by mouth once daily for 18 months
62766485|NCT02610933|ACTIVE_COMPARATOR|rivaroxaban and vitamin K2|Rivaroxaban 10 mg tablet by mouth once daily and MK-7 2000 microgram tablet by mouth thrice weekly for 18 months
62766486|NCT03300297|ACTIVE_COMPARATOR|Cervical Spine Thrust Joint Manipulation|Thrust Manipulation delivered to C0/1 and C2/3 on both the right and left side
62766487|NCT03300297|SHAM_COMPARATOR|Cervical Spine Sham Manipulation|Sham Manipulation delivered to C0/1 and C2/3 on both the right and left side
62766488|NCT04352257||ultrasonography|pelvic and transrectal ultrasound
62766489|NCT00378248|EXPERIMENTAL|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group- and individual psychotherapy
62766490|NCT00378248|ACTIVE_COMPARATOR|Outpatient individual psychotherapy|Eclectic individual psychotherapy in outpatient private practice
62766491|NCT05849818|EXPERIMENTAL|Effect of fully immersive VR + school regular activities on cognitive functions of Down children|Children in this group will practice the same activities as control group in addition to virtual reality session using fully-immersive VRapeutic software gaming technology (Viblio module)for 20 min/3sessions/week for 8 weeks.
62766492|NCT05849818|NO_INTERVENTION|Effect of school regular activities on cognitive functions of down children|Children in this group will practice their regular activities of school and daily living (receive no treatment).
62766493|NCT04860622||Pregnant women|500 pregnant women with a singleton pregnancy, free of pre-existing thyroid disease, that do not use thyroid interfering medication, that did not undergo IVF treatment, and are TPOAb negative. Serum thyroid function tests will be obtained on the first visit.
62766494|NCT05585515|NO_INTERVENTION|Control|16/8 hours wake/sleep regime for 3 consecutive days at home and for consecutive 2 days in sleep laboratory
62766495|NCT05585515|EXPERIMENTAL|Sleep restriction|18/6 hours wake/sleep regime for 3 consecutive days at home and one day in sleep laboratory, followed by recovery night of 8 hours sleep
62766496|NCT05585515|EXPERIMENTAL|Sleep deprivation|16/8 hours wake/sleep regime for 3 consecutive days at home, one night of sleep deprivation (24/0 hours) in sleep laboratory, followed by recovery night of 8 hours sleep
62766497|NCT02363231||patients under mechanical ventilation|
62766498|NCT01995552|OTHER|External Loop Recorder|This is a non-randomized study. All the patients will be enrolled will received the ELR system.
62766499|NCT05545865|PLACEBO_COMPARATOR|Low Flavanol Cocoa Powder|12 g of Low Flavanol Cocoa Powder (30 mg of cocoa flavanols) provided as a beverage mixed in water
62766500|NCT05545865|EXPERIMENTAL|High Flavanol Cocoa Powder|High Flavanol Cocoa Powder (435 mg of flavanols) will be provided as a beverage mixed in water.
62766501|NCT05545865|EXPERIMENTAL|Two Servings of Vine to Bar Chocolate|Two servings (60g, 6 pieces) of Vine to Bar Chocolate providing both cocoa flavanols and Chardonnay marc.
62766502|NCT05545865|EXPERIMENTAL|One Serving of Vine to Bar Chocolate|A single serving (30g, 3 pieces) of Vine to Bar Chocolate providing both cocoa flavanols and Chardonnay marc.
62766503|NCT05545865|EXPERIMENTAL|Vine to Bar Chocolate covered Almonds|11 pieces (45g) of Vine to Bar Chocolate providing both cocoa flavanols and Chardonnay marc, with almonds
62766504|NCT01167907|EXPERIMENTAL|0.2% ropivacaine|Patients with evidence of sciatic and saphenous nerve block will be randomized to receive a postoperative continuous infusion of either saline (control) or 0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement.
62766505|NCT01167907|PLACEBO_COMPARATOR|Saline|Patients with evidence of sciatic and saphenous nerve block will be randomized to receive a postoperative continuous infusion of either saline (control) or 0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement.
62766506|NCT02046694|EXPERIMENTAL|Allopurinol|Patients will stop taking their 6-MP and methotrexate at week 0. One week later (week 1), patients will begin allopurinol daily (100 mg for weight \>30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks). Dose adjustments of 6-MP and methotrexate will be directed by the guidelines outlined in the study protocol.
62766507|NCT03938675||Raw maternal own milk before day 7|"Without any intervention, investigators observed whether neonates received raw MOM during the first week of life. Accordingly, the neonates were grouped as exposed when they received any raw MOM before day 7, versus unexposed when they did not receive any raw MOM before day 7."
61989434|NCT03511612|OTHER|Pattern B|Intervention : Each subject has 3 measurements of ABI starting with Doppler method and then using oscillometric device.
61989435|NCT03626714|EXPERIMENTAL|Sustained Release Tacrolimus|All subjects will be treated with a single dose injection of sustained-release Tacrolimus
62766508|NCT03938675||No Raw maternal own milk before day 7|"Without any intervention, investigators observed whether neonates received raw MOM during the first week of life. Accordingly, the neonates were grouped as exposed when they received any raw MOM before day 7, versus unexposed when they did not receive any raw MOM before day 7."
62766509|NCT02447094||Exposed|AIS patients evaluated through RTP and who receive i.v. tPA
62766510|NCT02447094||Un-exposed|AIS patients evaluated through RTP and who do not receive i.v. tPA
62766511|NCT02132273|EXPERIMENTAL|Educational Story|Participants receiving this intervention will have access to the educational story as they prepare for the overnight sleep study.
61989436|NCT00537381|ACTIVE_COMPARATOR|Docetaxel + Prednisone + Placebo|Matching placebo as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) every week for initial 6 weeks, then every 3 weeks; along with docetaxel 75 milligram per square meter (mg/m\^2) as intravenous infusion every 3 weeks and prednisone 5 mg orally twice daily were administered till 6 months or disease progression.
62384923|NCT06164418|ACTIVE_COMPARATOR|ion-releasing restorative material with a fluoride-releasing universal adhesive|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
62384924|NCT06110962||Patients|Sleep clinic patients undergoing polysomnography sleep studies for diagnosis of sleep apnea
62384925|NCT05030506|EXPERIMENTAL|Belzutifan + Lenvatinib|Participants will receive a daily oral dose of 120 mg of belzutifan monotherapy for 3 weeks, followed by a combination of a daily oral dose of 120 mg of belzutifan with a daily oral dose of 20 mg of lenvatinib until progressive disease or discontinuation.
62384926|NCT05030506|EXPERIMENTAL|Belzutifan + Lenvatinib + Pembrolizumab|Participants will receive an intravenous dose of 400 mg of pembrolizumab once every six weeks for up to 18 infusions (up to 2 years) in combination with a daily oral dose of 120 mg of belzutifan and a daily oral dose of 20 mg of lenvatinib until progressive disease or discontinuation.
62766512|NCT02132273|NO_INTERVENTION|Typical Preparation|Participants will receive traditional materials, directions, what to bring list, only. They will not recieve access to educational story
62384927|NCT05954273||Sinus membrane perforation|Sinus membrane perforation incidences to measure the perforation rate.
62384928|NCT05954273||Alveolar bone height below the maxillary sinus floor|Pre-sinus augmentation alveolar bone ridge height.
62766513|NCT03924999|EXPERIMENTAL|Combined decongestive treatment & Combined exercise|"Combined decongestive treatment consists of manual lymphatic drainage and compression bandaging for 5 days a week, for 6 weeks (totally, 30 sessions).~All participants received 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises."
62766514|NCT03924999|EXPERIMENTAL|Intermittent pneumatic compression & Combined exercise|"Intermittent pneumatic compression for 5 days a week, for 6 weeks (totally, 30 sessions).~All participants received 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises."
62766515|NCT03924999|ACTIVE_COMPARATOR|Combined exercise|All participants received 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises.
62766516|NCT02212158|EXPERIMENTAL|motivational interviewing group|"Motivational Group Intervention:~Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies."
62766517|NCT00849602|PLACEBO_COMPARATOR|1|
62766518|NCT00849602|ACTIVE_COMPARATOR|2|
62766519|NCT05105113|EXPERIMENTAL|Zirconia dental implant|Patients treated with zirconia dental implant (Tav-dental) to replace missing tooth
62766520|NCT02195804|EXPERIMENTAL|Ranitidine HCL ODT Vanilla-Mint|
62766521|NCT02195804|EXPERIMENTAL|Ranitidine HCL ODT RM Vanilla-Mint|
62766522|NCT02195804|ACTIVE_COMPARATOR|Ranitidine HCL|Maximum Strength ZANTAC 150®
62766523|NCT04187742|ACTIVE_COMPARATOR|LTC Physicians Receive Social Comparison Email|All LTC physicians who receive a social comparison email
62766524|NCT04187742|NO_INTERVENTION|LTC Physicians Do Not Receive Social Comparison Email|All LTC physicians who do not receive a social comparison email
62766525|NCT04187742|ACTIVE_COMPARATOR|LTC Physicians Receive Maintenance Certification Email|All LTC physicians who receive a maintenance certification email
62384929|NCT05954273||Maxillary sinus augementation level|Vertical graft height in the maxillary sinus.
62384930|NCT05954273||Implants length and width|Placed implants length and width
62384931|NCT05510999|PLACEBO_COMPARATOR|Placebo|Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit. If a dose is missed participants are instructed to take the missed dose with the next scheduled dose. Participants will be advised not to exceed 3 capsules daily.
62766526|NCT04187742|NO_INTERVENTION|LTC Physicians Do Not Receive Maintenance Certification Email|All LTC physicians who do not receive a maintenance certification email
62766527|NCT04187742|ACTIVE_COMPARATOR|LTC Physician Has (or has not) Opened Prior Report|LTC physicians who opened (or has not opened) at least one report receive an email informing them of their report opening status
62766528|NCT04187742|NO_INTERVENTION|LTC Physician Has (or has not) Opened Prior Report (Control)|LTC physicians who opened (or has not opened) at least one report receive a standard email without report opening status
62766529|NCT02362971||Included|Patients included into the randomized controlled trial
62766530|NCT02362971||Non-consenters|Patients eligible for participation in the randomized controlled trial but did not give their informed consent and thus excluded in the randomized controlled trial.
62766531|NCT02362971||Excluded|Patients, by different reasons excluded from participation in the randomized controlled trial.
62766532|NCT06386341||Intervention group|Patiënts who underwent MMA surgery for OSA.
62766533|NCT06386341||Control group|Patiënts who underwent MMA surgery for other reasons than OSA.
62766534|NCT00927615|EXPERIMENTAL|intracoronary abciximab|intracoronary administration of abciximab (0.25 mg/kg body weight)
62766535|NCT00927615|ACTIVE_COMPARATOR|intravenous abciximab|intravenous administration of abciximab (0.25 mg/kg body weight)
62766536|NCT00764257|EXPERIMENTAL|PREVELLE Shape|
62766537|NCT00764257|ACTIVE_COMPARATOR|Restylane|
61989437|NCT00537381|EXPERIMENTAL|Docetaxel + Prednisone + Intetumumab|Intetumumab 10 mg per kilogram (mg/kg) as intravenous infusion every week for initial 6 weeks, then every 3 weeks; along with docetaxel 75 mg/m\^2 as intravenous infusion every 3 weeks and prednisone 5 mg orally twice daily were administered till 6 months or disease progression.
62766538|NCT03730077|EXPERIMENTAL|18F-MISO PET/CT Test Retest|Up to 5 of the 30 intended subjects will participate in a test-retest group that will undergo a second 18F-FMISO scan. Subjects will undergo biopsy as part of their clinical care. Subjects will be asked to consent to allow archived excess tissue to be accessed for the purposes of this study
62766539|NCT03730077|EXPERIMENTAL|18F-MISO PET/CT|The investigators anticipate enrolling up to 30 subjects who will undergo 18F-FMISO PET/CT.Subjects will undergo biopsy as part of their clinical care. Subjects will be asked to consent to allow archived excess tissue to be accessed for the purposes of this study
62766540|NCT05478668||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury. In all patients, the assessment of anesthetic risk was carried out according to the ASA scale. The basic tool for pain intensity research was a visual analog scale. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the Didier Bouhassiraa neuropathic pain diagnostic questionnaire. Study of the presence of an acute stress reaction scale The Hospital Anxiety and Depression Scale. Research on the presence of post-traumatic stress disorders was carried out using the Mississippi scale of post-traumatic stress disorders (military version). Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
62766541|NCT05478668||prospective study|"Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022. Data collection was carried out during the Russian invasion of Ukraine and the offensive on Kyiv. All patients with gunshot wounds were evacuated to the stage of treatment - the National Military Medical Clinical Center Main Military Clinical Hospital. The research was conducted using the same methods as during the retrospective analysis. The exception was the study period during treatment at the military medical clinical center: here it was 14 days."
62766542|NCT02261233|EXPERIMENTAL|Immediate treatment|This arm receives osteopathic manipulative treatment shortly after enrollment
62766543|NCT02261233|EXPERIMENTAL|Delayed treatment|This arm receives osteopathic manipulative treatment approximately 4 weeks after enrollment
62766544|NCT05123404|EXPERIMENTAL|intervention arm|Patients will undergo MRI followed by TURBT
62766545|NCT01328340|ACTIVE_COMPARATOR|High-speed power training|Volunteers randomized into SHPT will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength for leg press (LP) and seated knee extension (KE) exercises.
62766546|NCT01328340|ACTIVE_COMPARATOR|Slow-speed strength training|Volunteers randomized into STR will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength for LP and KE exercises.
62766547|NCT01328340|NO_INTERVENTION|Control|Volunteers randomized into CON will undergo a placebo exercise intervention consisting of lower extremity range of motion and flexibility exercises performed 2 times per week with the assistance of the research staff.
62766548|NCT05497856|EXPERIMENTAL|Integrated neuromuscular inhibition technique|ischemic compression, strain counter strain, muscle energy techniques
62766549|NCT05497856|ACTIVE_COMPARATOR|Myofascial Release|Deep sustained pressure on the trigger points
62384932|NCT05510999|EXPERIMENTAL|Water soluble pollen extract fraction|The experimental product contains 180mg (360mg/day) of water soluble pollen extract fraction. Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit. If a dose is missed participants are instructed to take the missed dose with the next scheduled dose. Participants will be advised not to exceed 3 capsules daily.
61989438|NCT01860755|EXPERIMENTAL|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport. This group also received the control intervention.
62766550|NCT06508879|ACTIVE_COMPARATOR|Control Group|a standard wound dressing composed of sterile gauze and adhesive tape was applied under sterile conditions. In the absence of bleeding, excessive wound secretion, or detachment, the dressing was left on the wound until the second postoperative day (POD 2), otherwise, it was changed immediately. Starting at POD 2, the dressing was changed daily under aseptic conditions until the wound remained dry (between POD 3-5). In the absence of bleeding, excessive wound secretion, or detachment, the wound was then left uncovered. This practice corresponded to the standard treatment of cardiothoracic patients in our department at the time of initiating this study.
61989439|NCT01860755|ACTIVE_COMPARATOR|Control|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
62766551|NCT06508879|EXPERIMENTAL|Test Group|directly after closing the wound, an occlusive hydrocolloid silver-containing wound dressing (Aquacel Ag Surgical®, ConvaTec, Oklahoma City, OK, USA) was applied under sterile conditions and, in the absence of bleeding; excessive wound secretion, or detachment, was maintained on the wound until POD 5, at which time the dressing was removed. In case of bleeding, excessive wound secretion, or detachment, the dressing was removed, the wound was cleaned, and a new sterile hydrocolloid wound dressing applied under aseptic conditions.
62766552|NCT02469714|EXPERIMENTAL|Peer Navigator Intervention|Integrated care with a peer navigator to be provided for one year, where data will be collected at baseline, 4, 8 and 12 months.
62766553|NCT02469714|NO_INTERVENTION|Controlled|Integrated care without a peer navigator, where data will be collected at baseline, 4, 8 and 12 months
62766554|NCT00601861|EXPERIMENTAL|A|
62766555|NCT03435562|EXPERIMENTAL|electronic cigarette vs own brand use|Participants will come in for three session. During one session, participants will first complete a 10-puff product use bout with JUUL, and then a 90-minute ad lib product use bout with JUUL (the session will be approximately 3 hours). During one session, participants will first complete a 10-puff product use bout with IQOS, and then a 90-minute ad lib product use bout with IQOS (the session will be approximately 3 hours). During one session, participants will first complete a 10-puff product use bout with their own brand cigarettes, and then a 90-minute ad lib product use bout with their own brand cigarette (the session will be approximately 3 hours). The order of the sessions will be determined randomly and data about session will not be recorded or used in the analysis.
62766556|NCT02051023|EXPERIMENTAL|FML 0.1% eyedrops|FML (fluorometholone) 0.1% eyedrops 4 times a day in both eyes for 22 days
62766557|NCT02051023|ACTIVE_COMPARATOR|Liquifilm artificial tears eyedrops|Topical application 4 times a day in both eyes for 22 days
62766558|NCT03829345|EXPERIMENTAL|Olaparaib|Olaparib will be given 300mg bd for a 28 day cycle.
62766559|NCT05410262||Mechanical power and risk of ventilator-induced lung injury in patients with ARDS|This study will prospectively evaluate patients consecutively admitted with ARDS, as defined according to the Berlin expert consensus
62766560|NCT06008899|ACTIVE_COMPARATOR|ultrasound (US) assisted caudal epidural pulsed radiofrequency|
62766561|NCT06008899|NO_INTERVENTION|conventional medical treatment|
62766562|NCT04069377||Manuel chest compression|Manuel chest compressions will be handled by human efforts.
61989440|NCT00998543||Smallpox Vaccine (LISTER Strain) Group|Participants were vaccinated with the second-generation smallpox vaccine in Study VVL04 (NCT 00258947).
61989441|NCT00149916|EXPERIMENTAL|Mycophenolate sodium (enteric coated)|
61989442|NCT04848935|EXPERIMENTAL|CURATE.AI|A cognitive evaluation and a Digital Diagnostic (DD) session performed anytime before radiotherapy will serve as the baseline. After the radiotherapy treatment, which can last between 1 to 6.5 weeks, patients will have a variable recovery time (0 to 4 weeks). Subsequently, patients will be subject to a cognitive evaluation and a DD session, right before starting the Digital Intervention (DI) training. This training will comprise ten weeks of DI (three 10-15 minute sessions per week). Patients will complete cognitive evaluations and DD sessions at the end of DI, and 16 and 32 weeks after the end of DI.
62766563|NCT04069377||Mechanical chest compression|In the study, chest compression in the mechanical cardiopulmonary resuscitation group was performed with the Lund University Cardiopulmonary Assist System (LUCAS) Chest Compression System (LUCAS 2).
62766564|NCT05549310|ACTIVE_COMPARATOR|CPAP group|"CPAP group : The first stage:receiving CPAP treatment for 6 hours / night, for 1 month. Patients in the treatment group first use pressure titration, select the appropriate pressure after treatment.~The second stage ( cohort study ) : After one month of the first stage of treatment, patients voluntarily continued to receive treatment and observers were included in the second stage of treatment. CPAP group continued to receive corresponding treatment for 6 months."
62766565|NCT05549310|EXPERIMENTAL|HFNC group|"HFNC group : The first stage:receiving HFNC treatment for 6 hours / night, for 1 month. Patients in the treatment group first use pressure titration, select the appropriate pressure after treatment.~The second stage ( cohort study ) : After one month of the first stage of treatment, patients voluntarily continued to receive treatment and observers were included in the second stage of treatment. HFNC group continued to receive corresponding treatment for 6 months."
62766566|NCT06187025|OTHER|Standardized clinical evaluations, and screening of substance use|Standardized clinical evaluations, and screening of substance use will be performed for all using the World Health Organization Alcohol, Smoking and Drug Abuse Screening Test (ASSIST).
62766567|NCT01363583|ACTIVE_COMPARATOR|epoprostenol, Flolan®|Measurement on the effect of epoprostenol on lactate/pyruvate ratio measured by cerebral microdialysis
62766568|NCT01363583|PLACEBO_COMPARATOR|normal saline|Effect of saline on the lactate/pyruvate ratio measured by cerebral microdialysis
62766569|NCT03047291|PLACEBO_COMPARATOR|Control group: placebo oral tablet|Placebo tablets. Intervention: 30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
62766570|NCT03047291|EXPERIMENTAL|Test group: probiotic oral tablet|Probiotic tablets (Periobalance®, Sunstar, Switzerland). Intervention: 30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
62766571|NCT04073160|EXPERIMENTAL|Decipher Bladder test subtype non-basal|Subjects with localized muscle invasive urothelial carcinoma of the bladder, whose tumor is Decipher Bladder test subtype non-basal
62766572|NCT04073160|EXPERIMENTAL|Decipher Bladder test subtype basal and cisplatin-ineligible|Subjects with localized muscle invasive urothelial carcinoma of the bladder, whose tumor is Decipher Bladder test subtype basal and the subject is cisplatin-ineligible
62766573|NCT04966000|EXPERIMENTAL|Prism Adaptation Therapy|10 sessions (60 trials each) 1x/day of Prism Adaptation Therapy
62766574|NCT00599456|EXPERIMENTAL|1|Omega 3 vitamin supplements
61989443|NCT00070265|EXPERIMENTAL|Treatment (oxaliplatin, capecitabine, and surgery)|"Neoadjuvant chemotherapy: Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Surgery: Four to six weeks after the completion of chemotherapy, patients undergo surgical resection of the tumor.~Adjuvant chemotherapy: Patients with satisfactory response to therapy receive 4 additional courses of oxaliplatin and capecitabine after surgery."
61989444|NCT01316276|EXPERIMENTAL|LAI|590 mg LAI QD via a PARI Investigational eFlow® Nebulizer System (eFlow®) for 28 days followed by a 28-day off-treatment period. This cycle (28 days on treatment, 28 days off treatment) was to be repeated for up to 12 cycles, divided into 2 periods of 6 cycles each (approximately 12 months each).
62766575|NCT00599456|PLACEBO_COMPARATOR|2|Placebo capsule
62766576|NCT05990023|ACTIVE_COMPARATOR|Traditional vestibule rehabilitation training|The intervention for the control group primarily follows conventional rehabilitation methods but incorporates the computerized training system developed in this project.
61989445|NCT01216475|ACTIVE_COMPARATOR|Femtosecond LASIK|2 lasers refractive procedure
62558800|NCT05332301|EXPERIMENTAL|High-fat test meal|All participants will consume a high-fat breakfast after an overnight fast. This meal will consist of a flour tortilla, eggs, bacon, cheddar cheese, mayonnaise, and hashbrowns. After the initial blood sample (0 min) is drawn during Visit 2, we will ask participants to consume this breakfast within 10 minutes. This meal has been designed to mimic the amount of energy (calories) and fat contained in a typical fast-food breakfast (e.g., from Tim Hortons or McDonalds). Each meal will provide 846 kcal, derived from 54 g fat (58% energy), 61 g carbohydrate (29% energy), and 29 g protein (13% energy).
62558801|NCT01107691|EXPERIMENTAL|Resistance training|1 set of progressive resistance training per session
62558802|NCT01107691|EXPERIMENTAL|3 sets per session|3 sets of progressive resistance training per session
62766577|NCT05990023|EXPERIMENTAL|Dual-task vestibule rehabilitation training|The intervention for the experimental group is based on the intervention for the control group, with additional components based on the findings from the second year of the study. These dual-task exercises are integrated into the training using the computerized training system and provided to the experimental group.
62766578|NCT01768936||eliminated infectious abdominal focus|
62766579|NCT01768936||persisting/progressing infectious abdominal focus|
62766580|NCT05915624|EXPERIMENTAL|telephone counseling group|After signing the voluntary informed consent form, the patients in the experimental group were given a Preoperative Patient Information Brochure, prepared by the researcher when they came to the hospital for the surgery date. Data will be collected using the Introductory Information Form and the Surgery-Specific Anxiety Scale, and counseling was provided by tele-nursing information about the surgery process one day before the surgery.
61989446|NCT01216475|EXPERIMENTAL|SMILE|Small incision lenticule extraction (SMILE)
62558803|NCT01107691|NO_INTERVENTION|Control|Non exercise control group
62558804|NCT01683396|PLACEBO_COMPARATOR|Placebo|
62766581|NCT05915624|NO_INTERVENTION|Control group|The patients in the control group were given a Preoperative Patient Information Brochure, which was prepared by the researcher on the day of the surgery, when they came to the hospital for the surgery date after signing the voluntary informed consent form.
62766582|NCT01237782|EXPERIMENTAL|Propolis solution|A proprietary denture cleanser with propolis as the active agent.
62766583|NCT01237782|PLACEBO_COMPARATOR|Saline solultion|Physiologic saline solution.
62766584|NCT03550404||Navigators|"AIE Navigators will use the Seasons of Care app in the context of their everyday outreach work with AIEs over two four-month intervention periods (P1 and P2). Their goal will be to facilitate health literacy to shift attitudes, beliefs, and behaviors to create a Culture of Coverage for AIEs at individual, organizational/community, and policy levels. Separated by distance, the AIE Navigators will receive coaching as necessary, using virtual meeting space, to help refine their implementation skills from a member of the research team with experience in AIE health outreach."
62766585|NCT03550404||American Indian Elders (AIEs)|Elders will be exposed to the Seasons of Care app when they reach out to navigators for assistance navigating the healthcare system.
62766586|NCT03550404||Healthcare providers/staff|This cohort will be exposed to the Seasons of Care app via navigators and their patients.
62766587|NCT05479149|EXPERIMENTAL|Experimental: Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
61989447|NCT03096327|EXPERIMENTAL|Intervention (Montelukast)|Aireez contains Montelukast which is a potent and selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
61989448|NCT03096327|PLACEBO_COMPARATOR|Placebo|Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured.
62558805|NCT01683396|EXPERIMENTAL|gevokizumab|
62558806|NCT00513240|EXPERIMENTAL|EPO group|Patients randomized to receive the 3 doses of erythropoetin.
62766588|NCT05479149|ACTIVE_COMPARATOR|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
62766589|NCT02813395|NO_INTERVENTION|Control group|Volunteers remained at rest before and after the fatigue protocol.
62558807|NCT00513240|PLACEBO_COMPARATOR|Control group.|Patients randomized to receive 3 doses of normal saline control.
62558808|NCT04233294|EXPERIMENTAL|chidamide in combination with camrelizumab plus decitabine|chidamide 10mg/day, days 1-4, 20mg/day, day 8, 11, 15, 18; camrelizumab 200mg d6; decitabine 10 mg/day, days 1-5, every 3 weeks
61989449|NCT02149173|EXPERIMENTAL|Diagnostic (F-18 FES PET/CT)|Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.
61989450|NCT04623918|EXPERIMENTAL|Iron-biofortified rice|Iron-biofortified rice (IR68144-2B-2-2-3)
62384933|NCT05510999|EXPERIMENTAL|Lipid soluble pollen extract fraction + water soluble pollen extract fraction|The experimental product is a combination of 9 mg lipid soluble pollen extract fraction (18mg/day) and 180 mg water soluble pollen extract fraction (360mg/day). Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit. If a dose is missed participants are instructed to take the missed dose with the next scheduled dose. Participants will be advised not to exceed 3 capsules daily.
62558809|NCT04891757|EXPERIMENTAL|FHD-286 Monotherapy|Closed to Enrollment
62558810|NCT04891757|EXPERIMENTAL|FHD-286 in Combination with LDAC|FHD-286 administered orally + LDAC administered subcutaneously
62766590|NCT02813395|PLACEBO_COMPARATOR|Placebo group|Volunteers were subjected to laser application simulation for approximately four minutes with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
62766591|NCT02813395|EXPERIMENTAL|Laser before|Volunteers received effective application of laser before fatigue protocol.
62766592|NCT02813395|EXPERIMENTAL|Laser after|Volunteers received effective application of laser after fatigue protocol.
62766593|NCT02127294|EXPERIMENTAL|Transcatheter closure group|Migraine patients with patent foreman ovale (PFO)，who meet the criteria and agree to conduct closure of patent foramen ovale will be selected to this group.
62766594|NCT02127294|NO_INTERVENTION|Contrast group|Migraine patients with PFO，who meet the criteria but don't agree to conduct closure of patent foramen ovale will be selected to this group.
62766595|NCT02391376|EXPERIMENTAL|moist heat pack group|Three sessions of 15 minutes of superficial heat through a moist heat pack on the lower back of healthy subjects
62766596|NCT02391376|EXPERIMENTAL|seed pack group|Three sessions of 15 minutes of superficial heat through a seed pack on the lower back of healthy subjects
62766597|NCT02391376|EXPERIMENTAL|gel pack group|Three sessions of 15 minutes of superficial heat through a gel pack on the lower back of healthy subjects
62558811|NCT04891757|EXPERIMENTAL|FHD-286 in Combination with Decitabine|FHD-286 administered orally + decitabine administered intravenously (IV)
61989451|NCT04623918|ACTIVE_COMPARATOR|Control rice|Control rice (C4)
61989452|NCT01204476|EXPERIMENTAL|Treatment (cixutumumab, octreotide acetate, everolimus)|Patients receive cixutumumab IV over 60-90 minutes and octreotide acetate IM on day 1 and everolimus PO QD on days 1-21. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
61989453|NCT03993197|EXPERIMENTAL|Patients suffering from severe endometriosis and chronic pain|Patients suffering from severe endometriosis and chronic pain that have been identified during a gynecological consultation (individual or during a multidisciplinary team meetings) or during a pain consultation on the same site of the Croix-Rousse Hospital and having signed a consent form
62558812|NCT00716391|ACTIVE_COMPARATOR|Group A|TPF plus concomitant treatment with cisplatin and conventional radiotherapy.
62558813|NCT00716391|EXPERIMENTAL|Group B|TPF plus concomitant treatment with cetuximab and conventional radiotherapy
62766598|NCT04943562||Healthy participants|Participants from 20 to 40 years old, from both genders and with no sleep disorders
62766599|NCT04943562||Participants with sleep disorders|one sleep disorder or complaint. Among these, at least 30% of the sample should have moderate to severe insomnia (as measured by the insomnia severity index), 30% should have high risk to sleep apnea (as measured by the STOP-BANG questionnaire) and 70% should have excessive sleepiness scale (as measured by the Epworth sleepiness scale).
62558814|NCT00523939|EXPERIMENTAL|Lymphomatous|Subjects with Lymphomatous Meningitis
62558815|NCT00523939|EXPERIMENTAL|Leukemic|Subjects with Leukemic Meningitis
62766600|NCT03186014|EXPERIMENTAL|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
62766601|NCT03052530|EXPERIMENTAL|Sapphire II PRO|Single arm with investigational Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters
62766602|NCT02410577|EXPERIMENTAL|89Zr-J591|Patients will not be required to fast prior to imaging with 89Zr-J591 injection or imaging. The total dose of humanized mAb J591 will be 20mg. Patients will first receive an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody (IND11407) followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg). Administration of the cold antibody will be followed by the labeled compound.
62766603|NCT02522442|EXPERIMENTAL|Auto BiLevel Group|Auto Bilevel; auto-titrating bilevel positive airway pressure device with pressure flexing used as experimental treatment for obstructive sleep apnea
62766604|NCT02522442|ACTIVE_COMPARATOR|CPAP Group|CPAP; continuous positive airway pressure used as comparator treatment for obstructive sleep apnea
62766605|NCT02666794|ACTIVE_COMPARATOR|Puncture epidural|Women in labor the epidural group will receive epidural bupivacaine with vasoconstrictor 0.125% 10 ml plus 20 micrograms sufentanil, followed by the placement of the epidural catheter
62766606|NCT02666794|ACTIVE_COMPARATOR|Puncture combined spinal-epidural|The mothers of the combined spinal-epidural analgesia group will receive intrathecal hyperbaric bupivacaine solution 0.5% 2.5 mg plus 5.0 micrograms of sufentanil and plus 60 micrograms of morphine, followed by placement of an epidural catheter to the catheter through technical needle
62766607|NCT01519999|EXPERIMENTAL|Shared Decision Making|
62766608|NCT01519999|NO_INTERVENTION|Comparison (control)|
62766609|NCT01616979||OPCAB surgery|Fifteen elective OPCAB surgery patients who undergo grafting in the left circumflex artery territory due to three-vessel disease
62384934|NCT05510999|EXPERIMENTAL|Lipid soluble pollen extract fraction|The experimental product contains 9mg (18mg/day) of lipid soluble pollen extract fraction. Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit. If a dose is missed participants are instructed to take the missed dose with the next scheduled dose. Participants will be advised not to exceed 3 capsules daily.
62558816|NCT03559972|EXPERIMENTAL|Treatment Group #1|"Subject in Treatment group 1 will apply the following products in the morning and evening.~1. SkinMedica Facial Cleanser~2. Hulk (cosmetic investigational)~3. Marvel AM (cosmetic investigational)~4. Marvel PM (cosmetic investigational)~5. SkinMedica HA5 Rejuvenating Hydrator~6. SkinMedica Rejuvenative Moisturizer~7. SkinMedica Essential Defense Mineral Shield SPF 35 Sunscreen"
61989454|NCT06406673|EXPERIMENTAL|Cohort_1|Cohort_1 patients with no history of previous systemic treatment for ES-SCLC received cadonilimab with EC/EP and received concurrent palliative RT.
62766610|NCT03276949||Healthy volunteers|Non-diabetic healthy men/women in between age group 18-80 years (all races and ethnicity) will be included for blood glucose measurements
62766611|NCT05147103|EXPERIMENTAL|Duration Trials|Six different durations (three intermittent and three continuous) of LIFU application will be tested across six study sessions. Response recorded using TMS and EMG.
62766612|NCT03899792|EXPERIMENTAL|LOXO-292|Phase 1- Dose Escalation and determination of MTD; multiple dose levels of LOXO-292 to be evaluated; Phase 2 - The MTD/recommended dose from Phase 1
62766613|NCT03296631||children|"Enrollment of 15 to 20 children (\< 9 months old) at the early beginning of their entry in nursery (crèche) between August and November 2017.~This cohort will be followed during a maximum period of 36 months . Diapers with fresh stools will be collected once a week per child and then frozen.~Spontaneous personal day care informations given by the parents to the nurses and recorded in each child's daily logbook will be collected for the research. No specific interviews will be conducted."
62766614|NCT05042180|EXPERIMENTAL|Virtual Reality Cognitive Behavioral Therapy (VRCBT)|The VR exposure is performed to induce alcohol craving and high-risk induced reactions during the therapy session, in order to trigger a lifelike response to alcohol, while the therapist is present and able to train the participant in applying CBT-based coping strategies to deal with the alcohol cravings.
62766615|NCT05042180|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT)|CBT is made up of the following elements: i) recognition (ii) avoiding and (iii) overcoming drinking cravings in high-risk situations with the aim of preventing relapse.
62766616|NCT04846530||Approved products will be placed in small boluses (0.2 mL) intradermally|Subjects will be assigned to receive two products each from the RHA® line of products (RHA® 1, RHA® 2, RHA® 3, and RHA® 4).
62766617|NCT02449018|EXPERIMENTAL|QBW251|QBW251 will be provided to participants during 70 days
62766618|NCT02449018|PLACEBO_COMPARATOR|Placebo|Placebo will be provided to participants during 70 days
61989455|NCT06406673|EXPERIMENTAL|Cohort_2|Cohort_2 patients with recurrent SCLC and after at most one systemic treatment received cadonilimab plus vorolanib.
61989456|NCT02292290|ACTIVE_COMPARATOR|Monotherapy 2|addition of Sulfonylurea or Pioglitazone to Metformin
61989457|NCT02292290|EXPERIMENTAL|Dual Therapy 1|Swap Liraglutide for sulfonylurea or pioglitazone taken as second line therapy (Metformin) first line)
61989458|NCT02292290|ACTIVE_COMPARATOR|Dual therapy 2|Maintain sulfonylurea or pioglitazone as second line therapy (Metformin first line)
61989459|NCT02292290|EXPERIMENTAL|Monotherapy|Addition of Liraglutide to Metformin
61989460|NCT01170806|ACTIVE_COMPARATOR|Orlistat (Lipiblock) treatment|Lipiblock is a new Orlistat formulation, produce by Germed Pharma, Brazil. Capsule 120mg
61989461|NCT01170806|ACTIVE_COMPARATOR|Orlistat (Xenical) treatment|Xenical is a innovator Orlistat formulation, produced by Roche
61989462|NCT05164237|EXPERIMENTAL|group A|17 subjects will receive multimodal approach of electrotherapy (LLLT , US and IFC) with conventional physical therapy modalities in the form of ( splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
62558817|NCT03559972|EXPERIMENTAL|Treatment group #2|"Subject in Treatment group 2 will apply the following products in the morning and evening.~1. SkinMedica Facial Cleanser~2. SkinMedica TNS Essential Serum~3. Marvel AM (cosmetic investigational)~4. Marvel PM (cosmetic investigational)~5. SkinMedica HA5 Rejuvenating Hydrator~6. SkinMedica Rejuvenative Moisturizer~7. SkinMedica Essential Defense Mineral Shield SPF 35 Sunscreen"
62558818|NCT00470470|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive oral imatinib mesylate twice daily for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
62558819|NCT03839069|EXPERIMENTAL|Minor Salivary Gland Transplantation|Cicatrizing conjunctivitis patients that received minor salivary gland transplantation for dry eye treatment.
61989463|NCT05164237|EXPERIMENTAL|group B|17 subjects will receive NFT with conventional physical therapy modalities in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
61989464|NCT05164237|EXPERIMENTAL|group C|17 subjects will receive with conventional physical therapy modalities only in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
61989465|NCT01433679|EXPERIMENTAL|Website intervention|Participants randomly assigned to the Website Intervention arm receive access to the motivational rewards website. The website displays the individual's physical activity data and allocates reward points based on the amount and intensity of physical activity. The website also allows reward points to be redeemed for various rewards such as gift cards to retail outlets, donations to charities, small tangible goods, and customization of participants' cartoon-like avatars on the website.
61989466|NCT01433679|NO_INTERVENTION|Control|Participants in the control group will not have access to the motivational website. No other product or intervention will be introduced to the control group.
61989467|NCT02695745|EXPERIMENTAL|V116517|V116517 aqueous suspension; 300 mg
61989468|NCT02695745|ACTIVE_COMPARATOR|Celecoxib|Celecoxib capsules; 400 mg (2 capsules of 200 mg each)
61989469|NCT02695745|PLACEBO_COMPARATOR|Placebo|Placebo
62766619|NCT01143896|EXPERIMENTAL|Arm 1: Depression Collaborative Care|Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
62766620|NCT01143896|NO_INTERVENTION|Arm 2: Usual Care|Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.
62766621|NCT03096873|NO_INTERVENTION|No Exercise (CON)|Twenty obese adolescent girls. This arm did not perform any exercise training for 12 weeks. Caloric intake: 1921.7 kcal/day
62766622|NCT03096873|EXPERIMENTAL|Exercise (EX)|Twenty obese adolescent girls. This arm performed combined exercise training 5 times a week for 12 weeks. Caloric intake: 1921.7 kcal/day
62766623|NCT01612650|ACTIVE_COMPARATOR|breast cancer histologically proven|Patient with breast cancer histologically proven, addressed to Oscar Lambret Center for treatment
62766624|NCT01612650|ACTIVE_COMPARATOR|surveillance of a treated breast cancer|surveillance of patient already treated for breast cancer must have annual mammography
62766625|NCT01612650|ACTIVE_COMPARATOR|diagnosis of a detected anomaly|patient addressed for diagnosis of a detected anomaly
62766626|NCT03075605||Subjects with acute pancreatitis|Subjects with acute pancreatitis
62766627|NCT03075605||Subjects with previous attack|Subjects with previous attack
62766628|NCT03075605||Controls|Controls
62766629|NCT01999075|PLACEBO_COMPARATOR|Conventional Treatment|Conventional Treatment
62766630|NCT01999075|ACTIVE_COMPARATOR|Lung Volume Recruitment|Conventional treatment plus the use of Lung Volume Recruitment (LVR) twice per day
62766631|NCT03664804|OTHER|Participants with Early Manifest Stage I or II HD|No study drug was administered in this study
62766632|NCT05995197|EXPERIMENTAL|action observation therapy group|Children will watch the action observation therapy video on the computer screen placed 1 m in front of a chair in which they can sit comfortably, but they will not be allowed to move while watching the video. Children will watch the video of the exercise offered by the therapist and then practice the exercise. The watching time for each exercise is 3 minutes, and after watching 3 minutes, they will do the exercise in the video for 3 minutes.In order to increase the effectiveness of the action observation training. Children will be instructed to concentrate on the video at 1-minute intervals to allow children's attention span. The treatment program will be applied for 30 minutes, 5 days a week for 3 weeks. The first session of the exercise program will be held face-to-face and the other sessions will be followed online. Treatment will be started within the first 48 hours after the evaluation. After the applications, the evaluations at the beginning of the treatment will be repeated.
62766633|NCT05995197|NO_INTERVENTION|control group|Children with CP will watch the video on the computer screen placed 1 m in front of a chair in which they can sit comfortably, but they will not be allowed to move while watching the video. The therapist will explain the exercises verbally. Children will practice the exercise after watching cartoons. The watching time for each exercise is 3 minutes, and after watching 3 minutes of cartoons, they will do the exercise for 3 minutes. Children will be instructed to concentrate on the video at 1-minute intervals to allow children's attention span. The treatment program will be applied for 30 minutes, 5 days a week for 3 weeks. The first session of the exercise program will be held face-to-face and the other sessions will be followed online. Treatment will be started within the first 48 hours after the evaluation. After the applications, pre-treatment evaluations will be repeated.
62766634|NCT02811783|ACTIVE_COMPARATOR|Naloxone Hydrochloride Lotion, 0.5%|Naloxone Hydrochloride Lotion 0.5%
62384935|NCT05510999|EXPERIMENTAL|Water soluble pollen extract fraction + cranberry powder|The experimental product is a combination of 42 mg water soluble pollen extract fraction (84 mg/day) and 125 mg cranberry powder (250 mg/day). Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit. If a dose is missed participants are instructed to take the missed dose with the next scheduled dose. Participants will be advised not to exceed 3 capsules daily.
62766635|NCT02811783|PLACEBO_COMPARATOR|Placebo Lotion|Placebo Lotion
61989470|NCT06167109|EXPERIMENTAL|Optimized CTV|The contralateral CTV1 was defined as a subclinical disease consisting of 5mm margin surrounding GTVnx.The CTV2 was defined as potentially involved regions consisting of 5mm margin surrounding CTV1, and contralateral CTV2 only included the pharyngeal recess.
61989471|NCT06167109|NO_INTERVENTION|Conventional CTV|The CTV1 was defined as GTVnx + 5 mm + entire nasopharynx mucosa .The CTV2 was defined as GTV1+ 5 mm + corresponding anatomical structures.
61989472|NCT01170182|EXPERIMENTAL|Omeprazole|Omeprazole Delayed Release Capsules of Dr. Reddy's Laboratories Limited
61989473|NCT01170182|ACTIVE_COMPARATOR|Prilosec|Prilosec® 40 mg Merck \& Co. Inc
62384936|NCT02871232||Intentional exposures among adolescents and adults|
62384937|NCT02871232||Unintentional exposures among infants and children|
62384938|NCT01080339||Physical Activity and Nutrition|Supervised physical activity in the form of novel gaming and exercise equipment several times per week for 12 weeks will be provided in addition to weekly nutrition education sessions.
62766636|NCT06046690|EXPERIMENTAL|MV Modification Group|Participant in this group will be applied inspiratory muscle training with trigger system modification in addition to conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization, twice a day until the day of extubation.
62766637|NCT06046690|EXPERIMENTAL|External Device Group|Participant in this group will be applied inspiratory muscle training with Inspiratory Muscle Training (IMT) device in addition to conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization, twice a day until the day of extubation.
62766638|NCT01708395||Cohort 1|First 50 patients
62766639|NCT01708395||Cohort 2|2nd group of 50 patients
62766640|NCT00117793|ACTIVE_COMPARATOR|Arm 1|Current clinical practice
62766641|NCT00117793|EXPERIMENTAL|Arm 2|Novel socket system
62766642|NCT01973608|EXPERIMENTAL|MSB0010445 Low Dose Cohort 0.3 mg/kg|
62766643|NCT01973608|EXPERIMENTAL|MSB0010445 Intermediate Dose Cohort 1.0 mg/kg|
62766644|NCT01973608|EXPERIMENTAL|MSB0010445 High Dose Cohort 1.8 mg/kg|
62766645|NCT01973608|EXPERIMENTAL|MSB0010445 High Dose Cohort 2.4 mg/kg|
62766646|NCT05641987|EXPERIMENTAL|Educator Well-being Program|Staff at participating schools will experience the Educator Well-being Program process and complete pre- and post-intervention survey.
62766647|NCT05641987|ACTIVE_COMPARATOR|Delayed Intervention|Status quo program remains in place with new ongoing data collection, then experimental intervention as above.
62766648|NCT02805595|EXPERIMENTAL|Hypertonic Saline|23.4% Hypertonic Saline injection(s) with a maximum of 0.4cc per treatment. If necessary every two weeks, with a maximum of three treatments.
62766649|NCT04373473|EXPERIMENTAL|Patients with UC will receive FMT capsules|Patients with ulcerative colitis will receive fecal microbiota capsules from 3 healthy donors
62766650|NCT04373473|PLACEBO_COMPARATOR|Patients with UC will receive placebo|Patients with ulcerative colitis will receive matching placebo capsules. Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
62766651|NCT03101007|EXPERIMENTAL|ATTUNE|Total Knee Replacement Surgery with cementless ATTUNE Rotating Platform Knee Prosthesis by DePuy
62766652|NCT03101007|ACTIVE_COMPARATOR|LCS|Total Knee Replacement Surgery with cementless LCS Rotating Platform Knee Prosthesis by DePuy
62766653|NCT03997643|ACTIVE_COMPARATOR|Standard Radiotherapy|Radiotherapy to all dissected areas
62384939|NCT01080339||Nutrition Education Only|Children in this group will receive weekly group nutrition sessions, identical to those provided for the Physical Activity + Nutrition group
62384940|NCT03621111|EXPERIMENTAL|Adherence plan|At the discharge, the hospital pharmacist will complete the medication reconciliation and assess the patient's medications. All patients enrolled will undergo three interventions in order to improve medication adherence: counseling, pill counts and self-questionnaire. The adherence plan concerns 6 classes of drugs recommended by the European Society of Cardiology in acute myocardial infarction. The adherence plan is performed by the community pharmacists. The hospital pharmacist will complete the discharge care form for the community pharmacist who has in charge the patient. Each patient will be scheduled for the first meeting with his community pharmacist within one month from the hospital discharge; afterward the adherence plan will be submitted every 3 months.
62766654|NCT03997643|EXPERIMENTAL|Radiotherapy to smaller treatment area|Omit radiation to pN0 neck
62766655|NCT04467476|ACTIVE_COMPARATOR|tDCS (anodal)|tDCS: 20 minutes, 2mA, over the motor cortex representation of lower limbs.
62766656|NCT04467476|SHAM_COMPARATOR|tDCS (sham)|tDCS: 20 minutes (but 30s ON), 2mA, over the motor cortex representation of lower limbs.
62766657|NCT00416715|EXPERIMENTAL|Treatment (letrozole)|Patients receive letrozole PO QD. Patients, who experience muscle pain, joint pain, or joint stiffness that requires an intervention and who are found to be vitamin D deficient, also receive calcium and vitamin D3 PO. Treatment continues for up to 28 weeks in the absence of disease progression or unacceptable toxicity.
62766658|NCT03590925||new screening and referring system of ICD|Non-randomized, non-blinded, multi-center study receiving new screening and referring system of ICD
62766659|NCT02917720|EXPERIMENTAL|TKI-stop, pre-treatment with nilotinib|"Treatment after unsuccessful 1st or 2nd discontinuation at least two year with nilotinib (300 mg/bid). In total, retreatment with TKI for at least 3 years before entering screening for stopping phase is warranted. Clinical monitoring every 3 months during this 2 years.~Patients who re-achieved and maintained MR4 for at least 12 months and MR4.5 for at least 6 months can enter screening phase for TFR .If MR4.5 is confirmed by an validated laboratory, patient may enter stopping phase of the study. Patient not fulfilling these criteria can be screened again every 3 months until month 48. After TKI-stop hematological monitoring and quantitative PCR of BCR/ABL1 (month 1-6 after stopping: monthly; month 7-12 after stopping: every 1.5 months, thereafter once every three months, for 3 years in total.~Relapse is defined as BCR-ABL1 \> 0.1% on IS at a single time point (loss of MMR) In case of relapse restart of TKI. In general, the same TKI (nilotinib) as before second stop is recommended"
62766660|NCT05570890|EXPERIMENTAL|Sham stimulation on stable surface|The participant will not receive stimulation and will stand on flat ground.
62766661|NCT05570890|EXPERIMENTAL|Noise stimulation on stable surface|The participant will receive stimulation with intensity set at 90% of their sensory threshold and will stand on flat ground.
62766662|NCT05570890|EXPERIMENTAL|Sham stimulation on unstable surface|The participant will not receive stimulation and will stand on foam.
61989474|NCT02443142|EXPERIMENTAL|Ibuprofen|Ibuprofen is a nonselective NSAID that inhibits both COX-1 and COX-2 isoenzymes. COX-2 inhibition prevents arachidonic acid from converting to vasoactive prostaglandins and reactive oxygen species in brain cell. The analgesic, antipyretic, and antiinflammatory activity of ibuprofen operates mainly through inhibition of COX-2. The experimental treatment oral doses of either ibuprofen (800 mg three times per day). Subjects will receive the first medication dose in the emergency department and will be given the remaining 5 doses to take over 48 hours as outpatients.
61989475|NCT02443142|ACTIVE_COMPARATOR|Acetaminophen|Acetaminophen is a poor inhibitor of both COX isoenzymes in the CNS and has significantly weaker antiinflammatory effects than NSAIDs. Acetaminophen does not inhibit COX in peripheral tissues and is less effective in the presence of peroxides. The active comparator treatment is oral doses of acetaminophen (1000 mg three times per day). Subjects will receive the first medication dose in the emergency department and will be given the remaining 5 doses to take over 48 hours as outpatients.
62384941|NCT03621111|NO_INTERVENTION|Control group|All the patients discharged from the cardiological ward between September 2017 and February 2018 with a primary diagnosis of acute myocardial infarction has been enrolled in the control arm. These patients have been discharged with the current standard therapy and without any adherence plan performed by the community pharmacists. The investigators will collect the data from the administrative pharmaceutical databases throughout 12 months from the hospital discharge.
62766663|NCT05570890|EXPERIMENTAL|Noise stimulation on unstable surface|The participant will receive stimulation with intensity set at 90% of their sensory threshold and will stand on foam.
62766664|NCT02887755|EXPERIMENTAL|Amputee Group|In this study n=20 returning US military combatants between 18 and 45 years of age who have unilateral transtibial or transfemoral amputation will be asked to perform two aerobic exercise tests while we4aring the NIRS sensor. Subjects must be medically cleared and able to complete approximately 30 minutes of physical activity.
62766665|NCT05390541|ACTIVE_COMPARATOR|Educational Control|Participants will receive a generic standard of care via a combination of videos, audio, and text/graphics across 5 sessions during 4 weeks.
62766666|NCT05390541|EXPERIMENTAL|Empowered to Test Yourself|There will be 5 tailored web based sessions of the intervention over 4 weeks, all of which will follow the same format.
62766667|NCT01319721|ACTIVE_COMPARATOR|Group LCAG|After extensive excision of recurrent pterygium, intraoperative 0.2 mg/ml MMC (0.02%) for 3 minutes will be applied topically onto the exposed surgical area and then limbal conjunctival autograft for repairing the conjunctival defect.
62766668|NCT01319721|ACTIVE_COMPARATOR|Group AMG|After excision of recurrent pterygium, intraoperative 0.2 mg/ml MMC (0.02%) for 3 minutes will be applied topically onto the exposed surgical area and then an amniotic membrane graft for repairing the conjunctival defect.
62766669|NCT02190110||Suspected pulmonary embolism patients|Adult patients (more than 18 years old) suspected of PE will be recruited at the time of the medical evaluation and before a final diagnosis is established
62766670|NCT04415996|EXPERIMENTAL|HVLA L3/4 Group|"In each participant, blind assessors will perform pre-intervention measurements of dislocation of center of pressure (CoP), plantar pressure mean and plantar contact area in a baropodometric pressure platform.~Next, the investigator will perform the HVLA technique in L3/L4 joint articulation.~Then, the same measurements before described will be repeated, by the assessors 1 minute after the intervention."
62766671|NCT04415996|SHAM_COMPARATOR|Control Group|"In each participant, blind assessors will perform pre-intervention measurements of dislocation of center of pressure (CoP), plantar pressure mean and plantar contact area in a baropodometric pressure platform.~Next, the investigator will perform a Sham technique. Then, the same measurements before described will be repeated, by the assessors 1 minute after the intervention."
62766672|NCT01932775|EXPERIMENTAL|GlucoTab System|
62766673|NCT06172920|ACTIVE_COMPARATOR|Tramadol|Tramadol receiving group
62766674|NCT06172920|ACTIVE_COMPARATOR|Aldolan|Aldolan receiving group
62766675|NCT06172920|ACTIVE_COMPARATOR|Morphine|Morphine receiving group
62766676|NCT01030185|EXPERIMENTAL|NovaShunt's Automated Fluid Shunt|The Automated Fluid Shunt (AFS) Device
62766677|NCT01965223|EXPERIMENTAL|Multi-fraction SABR|Radiotherapy: 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
62766678|NCT01965223|EXPERIMENTAL|Single fraction SABR|Radiotherapy: 28Gy delivered in 1 fraction
62766679|NCT04713033|EXPERIMENTAL|Experiment 1|Experiment 1 (Aim 1) will utilize a 16-channel sEMG array to characterize cervical-cranial muscle activity networks in typical speakers at baseline and after a vocal loading task. Flexible laryngoscopy will be performed to exclude any existing pathology and confirm eligibility in the healthy control group. Aim 2 will quantify how cervical muscle networks are perturbed in patients with two different types of dysphonia and examine if standard-of-care treatment restores cervical-cranial muscle networks to more typical states.
61989476|NCT01424423|EXPERIMENTAL|Subjects receiving GSK1223249 in cohort 1|Eligible subjects will receive intravenous infusion of GSK1223249 with a starting dose of 0.02 milligrams per kilograms, followed by 0.2, 2, 10 and 30 milligrams per kilograms, administered by a programmable syringe pump.
62766680|NCT04713033|EXPERIMENTAL|Experiment 2|In Experiment 2 (Aim 2), the study will measure muscle networks in patients with muscle tension dysphonia before and after a course of voice therapy. Patients with muscle tension dysphonia represent an intact but potentially maladaptive network.
62766681|NCT04713033|EXPERIMENTAL|Experiment 3|In Experiment 3 (Aim 2), the study will measure patients with unilateral vocal old paralysis, representing a neurologically impaired network, before and after a vocal fold medialization procedure.
62384942|NCT01229592|EXPERIMENTAL|Ethanol|Every three day lock using Ethanol in all the lumen of the Catheter
62766682|NCT04687423|EXPERIMENTAL|Experimental: phase I dose exploration|FCN-011 will be given orally in ascending doses in patients with advanced solid tumor , until the maximum tolerated dose or recommended dose is reached.
62384943|NCT01229592|ACTIVE_COMPARATOR|Heparine|Every three day lock using Heparine in all the lumen of the Catheter
62384944|NCT05990257|EXPERIMENTAL|HHB+TAPB+and LA|Group A: patients who received a HHB, TAPB, and LA
62766683|NCT04485260|EXPERIMENTAL|Part A, Arm 1, Cohort 1|KRT-232 by mouth once daily for Days 1-7, off treatment for Days 8-28 (28 day cycle)
62766684|NCT00797680|EXPERIMENTAL|72 hours hypothermia|72 hours hypothermia
62766685|NCT00797680|EXPERIMENTAL|24 hours hypothermia|24 hours hypothermia
62766686|NCT00068510|EXPERIMENTAL|autologous tumor lysate-pulsed DC|
62384945|NCT05990257|EXPERIMENTAL|HHB+LA|Group B: patients who received HHB and LA
62384946|NCT05990257|EXPERIMENTAL|TAPB+LA|Group C: patients who received TAPB and LA
62384947|NCT03206190|EXPERIMENTAL|Mutation carrier|The participants will be tested genetically if they carry a disease causing mutation or not. Depending on their genetic test result they will at the end of the study divided into two groups. The clinician will be blinded throughout the entire study to the genetic results.
62384948|NCT03206190|EXPERIMENTAL|Non-mutation carrier|The participants will be tested genetically if they carry a disease causing mutation or not. Depending on their genetic test result they will at the end of the study divided into two groups. The clinician will be blinded throughout the entire study to the genetic results.
62384949|NCT03206190|EXPERIMENTAL|Known-mutation carriers but presymptomatic|In a third arm (open arm) we will also include positive predictive tested participants which know that they are carrying a known mutation but are at inclusion into the study asymptomatic (according to the inclusion / exclusion criteria).
62384950|NCT02751606|EXPERIMENTAL|Breast and rectal cancer|Subjects will receive intravenous dose of ferumoxtran-10. 24-36 hours later a 7 Tesla MRI scan will be performed, to detect lymph node metastases. In rectal cancer patients the mesorectum will be imaged and for breast cancer patients this will be performed in the ipsilateral axilla. Subjects will also undergo a 3 Tesla MRI scan as a comparison to the 7 Tesla MRI scan.
62384951|NCT03720158|EXPERIMENTAL|Omega 3 Group|Five mL of an Omega-3 highly concentrated substance (containing 2.25 g of EPA and 1.08 g of DHA) will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
62384952|NCT03720158|PLACEBO_COMPARATOR|Placebo or Control Group|Five mL of pigmented and flavored corn oil will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
62384953|NCT03087474||VKA patients|Vitamin K antagonist (VKA) patients
62766687|NCT01441011|EXPERIMENTAL|Group (GRP) phone counseling|The group phone counseling includes 26 bi-weekly phone sessions from 6 to 18 months and focuses on group problem-solving. Women continue in the same group as in weight loss intervention phase.
62766688|NCT01441011|ACTIVE_COMPARATOR|Mail-based Comparison Condition|Participants in this group will receive a newsletter by mail every other week for 12 months starting after the initial 6 month weight loss period. The newsletters will provide problem-solving tips and will review nutrition and physical activity information.
62766689|NCT00617955||Surgical|Cardiac surgery patients that received Aprotinin or Amicar
62766690|NCT00955149|EXPERIMENTAL|Arm A|Erlotinib (Tarceva) 25 mg by mouth once daily.
62766691|NCT00955149|EXPERIMENTAL|Arm B|Erlotinib (Tarceva) 50 mg by mouth once daily for 6 months
61989477|NCT01424423|PLACEBO_COMPARATOR|Subjects receiving placebo in cohort 1|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
62766692|NCT01902459|ACTIVE_COMPARATOR|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch consists of human fibrinogen and human thrombin embedded in a flexible composite patch component.
62766693|NCT01902459|OTHER|Standard of Care|Standard of Care (SoC) is manual compression with or without a topical absorbable hemostat.
62384954|NCT03087474||NOAC patients|nonvitamin K antagonist oral anticoagulants (NOAC) patients
62384955|NCT03365401|EXPERIMENTAL|grade 1|Decompression surgery
62384956|NCT03365401|ACTIVE_COMPARATOR|grade 2|nonsurgical treatment
62384957|NCT03973775|EXPERIMENTAL|Test Drug Treatment Arm|Permethrin Cream 5%, Saptalis Pharmaceuticals, LLC
62384958|NCT03973775|ACTIVE_COMPARATOR|Reference Drug Treatment Arm|Elimite™ (Permethrin Cream 5%), Prestium Pharma, Inc.
62384959|NCT06376942|EXPERIMENTAL|Glycopyrronium|Nebulized glycopyrronium 50 mcg (2 ml) administered via a jet nebulizer over 10 minutes
62384960|NCT06376942|ACTIVE_COMPARATOR|Ipratropium|Nebulized ipratropium bromide 500 mcg (2 ml) administered via a jet nebulizer over 10 minutes
62384961|NCT06376942|PLACEBO_COMPARATOR|Saline|Nebulized saline 0.9% (2 ml) administered via a jet nebulizer over 10 minutes
62384962|NCT01663298||Control group|Subjects must have never smoked and must be non-diabetic.
62384963|NCT01663298||Smoking group|Subjects must have had at least 5 pack-years of self-reported smoking history, must be currently smoking and must be non-diabetic.
62766694|NCT05190861|EXPERIMENTAL|droplet digital PCR method|Pathogen detection by droplet digital PCR method as an adjunct to traditional microbiological assessments including blood culture
61989478|NCT01424423|EXPERIMENTAL|Subjects receiving GSK1223249 in cohort 2|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 0.2 milligrams per kilograms administered by a programmable syringe pump.
62766695|NCT05190861|ACTIVE_COMPARATOR|blood culture only|Pathogen detection by microbiological assessments including blood culture
62766696|NCT00509093|EXPERIMENTAL|Imatinib Mesylate|
62766697|NCT01213823||Cases|Potential cases were defined as patients with a diagnosis of severe hepatic injury identified in the acute-care inpatient cohort using ICD-9 codes associated with the case definition of severe liver injury. Case status was validated by a Consultant Gastroenterologist blinded to study drug exposure via medical record review using an apriori algorithm. Only validated cases were included in the analysis (N=69)
62384964|NCT01663298||Diabetic group|Subjects must have type 2 diabetes. The condition must be diagnosed subjects must be treated by medications and/or insulin. A HbA1C test result either within past 3 months or performed in the first visit must be available. They must have never smoked.
62766698|NCT01213823||Controls|Controls were defined as patients without a diagnosis of severe hepatic injury (i.e. with no ICD-9 codes associated with the case definition of severe liver injury) selected at random from the same acute-care inpatient cohort as cases (N=467)
62766699|NCT06036953|NO_INTERVENTION|No EMS|
62766700|NCT06036953|EXPERIMENTAL|EMS|
62384965|NCT01174602|EXPERIMENTAL|Exposure Therapy for AN (AN-EX/RP)|Exposure Therapy and Ritual Prevention (AN-EX/RP) includes 12 sessions of confronting feared eating situations without the use of anxiety reducing behaviors.
62384966|NCT01174602|ACTIVE_COMPARATOR|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT)
62766701|NCT06416293||BC Patients|Patients with diagnosis of breast cancer or DCIS
62766702|NCT06416293||Physicians|Physicians treating patients with breast cancer
62766703|NCT00583791|EXPERIMENTAL|Main Cohort|Device closure with the AMPLATZER Muscular VSD Occluder for patients with muscular ventricular septal defects which are hemodynamically significant and are either isolated or present in conjunction with other congenital heart defects.
62766704|NCT05036850||Incident and Prevalent Patients|Incident and prevalent patients diagnosed with a kidney disease at participating centres
62766705|NCT00181610|ACTIVE_COMPARATOR|1|Placebo group normal saline twice per day
62766706|NCT00181610|ACTIVE_COMPARATOR|2|Recombinant human prolactin 60 mcg/kg every 12 hours
62766707|NCT00181610|ACTIVE_COMPARATOR|3|Recombinant human prolactin 60 mcg/kg alternating with normal saline placebo every 12 hours
62766708|NCT02983422|ACTIVE_COMPARATOR|Group aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
62766709|NCT02983422|PLACEBO_COMPARATOR|Group frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h，with placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
62766710|NCT01293643|EXPERIMENTAL|clindamycin/ketoconazole combination|
62384967|NCT00863135|EXPERIMENTAL|Continuous Positive Airway Pressure|nocturnal continuous positive airways pressure
62384968|NCT00863135|OTHER|Control|Waiting list,3 months without any change in their treatment, come into the CPAP procedure after that time
62384969|NCT05240872|ACTIVE_COMPARATOR|Group A|Platelet Rich Plasm (PRP) injection group
62384970|NCT05240872|ACTIVE_COMPARATOR|Group B|Autologous Blood injection (ABI) group
62384971|NCT02840760|ACTIVE_COMPARATOR|tardive dyskinesia group|tardive dyskinesia group will be delivered at an intensity that is 80% of the resting motor threshold (RMT). Stimulation will be delivered at 10 Hz with 60 stimulation trains of 30 stimuli each (i.e., 1800 stimuli) and an intertrain interval of 12 sec in primary motor cortex（M1）.
62384972|NCT02840760|NO_INTERVENTION|Healthy control group|
62766711|NCT01293643|ACTIVE_COMPARATOR|tetracycline hydrochloride/amphotericin B combination|
62766712|NCT06385717||Prophylactic chemoradiotherapy|pT1a -MM and pT1b-SM1 without pathological risk factors
62766713|NCT06385717||Intensive chemoradiotherapy|pT1b-SM2; pT1a -MM and pT1b-SM1 with pathological risk factors
62766714|NCT06385717||Radical chemoradiotherapy|Positive vertical margin or unknown margin
62766715|NCT04316156|EXPERIMENTAL|Exercise using Uincare Homeplus|Uincare Homeplus
62766716|NCT04316156|ACTIVE_COMPARATOR|Exercise using brochure|brochure
62766717|NCT00535821|EXPERIMENTAL|MiCHO|A 6-hour resuscitation protocol utilizing the esophageal Doppler monitoring (EDM)
62766718|NCT00535821|ACTIVE_COMPARATOR|EGDT|A 6-hour resuscitation protocol utilizing CVP/ScvO2
62766719|NCT01176955|EXPERIMENTAL|Internet survey|Subjects will receive a weekly email link to complete an internet survey about their acne and use of the study medication.
62766720|NCT01176955|PLACEBO_COMPARATOR|Control|Subjects will receive standard-of-care treatment with the study medication, without internet surveys.
62766721|NCT01164553|EXPERIMENTAL|Group 2, 0.5 mL TIV|Naive cohort participants (n=180) receive 0.25 mLTrivalent Inactivated Vaccine (TIV) in two intramuscular doses 28-42 days apart. Fully Primed cohort participants (previously vaccinated) (n=40) will receive 0.5 mL Trivalent Inactivated Influenza Vaccine (TIV) in one intramuscular dose.
62766722|NCT01164553|ACTIVE_COMPARATOR|Group 1, 0.25 mL TIV|Naive cohort participants (n=90) receive 0.25 mLTrivalent Inactivated Vaccine (TIV) in two intramuscular doses 28-42 days apart. Fully Primed cohort participants (previously vaccinated) (n=20) will receive 0.25 mL Trivalent Inactivated Influenza Vaccine (TIV) in one intramuscular dose
62766723|NCT02972541|EXPERIMENTAL|Stenting with neoadjuvant chemotherapy|After clinical success of colonic stenting, patients will receive neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 3-5 weeks after the last cycle of chemotherapy, type and extent of the surgery will be selected by the surgeon.
62766724|NCT02972541|ACTIVE_COMPARATOR|Stenting with Immediate Surgery|After clinical success of colonic stenting, patients will undergo surgery 7-14 days after inclusion. Type and extent of the elective surgery will be selected by the surgeon.
62766725|NCT04148612|EXPERIMENTAL|Opti-Me|Patients in this group will be treated based on the Opti-Me algorithm recommended treatment.
62766726|NCT04148612|NO_INTERVENTION|Randomization|Patients in this group will be treated by random assignment of treatment.
62766727|NCT02698904|EXPERIMENTAL|Guided Relaxation Technique|Forced Vital Capacity (FVC), Forced Expiratory Volume in the First Second (FEV1), FEV1/FVC, Heart Rate Variability (HRV), airway resistance (kPa/l/s), before and after an 11 minutes, one-session, guided relaxation technique Following 30-40 minutes questionnaire, 5 minutes heart rate (HR) and oxygen saturation (SpO2) recording, 11 minutes relaxation technique (listening via headphone to audio recording. In the meanwhile, heart rate and saturation are recording) to be completed by second heart rate (HR) and oxygen saturation (SpO2) recording. Entire procedure 60-80 minutes.
62766728|NCT02698904|SHAM_COMPARATOR|Documentary movie|"Forced Vital Capacity (FVC), Forced Expiratory Volume in the First Second (FEV1), FEV1/FVC, Heart Rate Variability (HRV), airway resistance (kPa/l/s), before and after an 11 minutes documentary movie.~Following 30-40 minutes questionnaire, 5 minutes heart rate (HR) and oxygen saturation (SpO2) recording, 11 minutes documentary movie (listening via headphone. In the meanwhile, heart rate and saturation are recording) to be completed by second heart rate (HR) and oxygen saturation (SpO2) recording. Entire procedure 60-80 minutes."
62384973|NCT03356301|EXPERIMENTAL|Triathletes|Every triathlete will realize three cardiac MRI exams.The second of those will be done at the fitness peak, 2-3 weeks before the main objective of the sports season. Training will be increased between the study beginning and the first MRI, and the second exam. After each cardiac MRI, an applanation tonometry examination will aslo be performed.
62384974|NCT03356301|EXPERIMENTAL|Controls|Every control subject will also realize three cardiac MRI exams if possible at the same time as the triathletes.They must be not engaged in physical activity more than 150 minutes a week on average. After each cardiac MRI, an applanation tonometry examination will aslo be performed.
62384975|NCT05619939|EXPERIMENTAL|Pea protein to egg white protein|This arm will receive 10 days of pea protein isolate followed by 10 days of consuming egg white protein isolate, with the two treatment periods separated by a 14-day washout period.
62384976|NCT05619939|EXPERIMENTAL|Egg white protein to pea protein|This arm will receive 10 days of egg white protein isolate followed by 10 days of consuming pea protein isolate, with the two treatment periods separated by a 14-day washout period.
62558820|NCT04712214|EXPERIMENTAL|Patients with brain tumours candidate for neurosurgery|Patients will be recruited following the inclusion criteria: any patient with a diagnosis of brain tumour, age ranging from 18 with no upper limit, who will agree to the operation and to take part of the present study, will be enrolled. During surgery, multispectral and/or hyper spectral acquisition of images from the surgical field will be performed. Each patient will have an average acquisition of 6 datasets. As each dataset will correspond to an image, this will be divided into many reading regions (from 10 to 20) for a total of approximatively 60 measurements per patient.
62558821|NCT00075816|ACTIVE_COMPARATOR|Bone Marrow Transplant|Allogeneic bone marrow transplantation
62558822|NCT00075816|ACTIVE_COMPARATOR|Blood Stem Cell Transplant|Peripheral blood stem cell transplantation
62558823|NCT00782054|ACTIVE_COMPARATOR|Active|moisturizer with endopeptidases
62558824|NCT00782054|PLACEBO_COMPARATOR|Placebo|moisturizer without endopeptidases
62558825|NCT05861518|EXPERIMENTAL|Group 1|.Participants, who had been receiving treatment for FMS for at least six months at the physical therapy and rehabilitation outpatient clinic .Participants continued their current drug treatment. In the hypnosis group, the patients were given 3 hypnosis sessions once a week. in groups of 3, each standardized for approximately 30 minutes.
62558826|NCT05861518|NO_INTERVENTION|Group 2|.Participants, who had been receiving treatment for FMS for at least six months at the physical therapy and rehabilitation outpatient clinic .Participants continued their current drug treatment.
62558827|NCT04200820|EXPERIMENTAL|Trampoline|The participants will jump on a mini-trampoline for 30 seconds and then will have a 30 seconds break. This will be repeated 16 times. This resulted in a cumulative total intervention time of 8 minutes.
62558828|NCT01304056||Critically ill patients|Patients that are treated in intensive care unit and given ventilatory therapy.
62558829|NCT01304056||Interventional volunteer group|Healthy volunteers
62558830|NCT03527069|EXPERIMENTAL|CIPROS 10|"The study is double-Masked, the patient wil take 2 tablets, as follow:~1 tablet Cipros 10 association; and~1 tablet crestor placebo Oral, once a day."
62558831|NCT03527069|ACTIVE_COMPARATOR|Crestor|"The study is double-Masked, the patient wil take 2 tablets, as follow:~1 tablet Crestor 10mg; and~1 tablet Cipros association placebo Oral, once a day."
62558832|NCT01977417|EXPERIMENTAL|Salsalate|3.0 grams/day salsalate (1.5 g twice per day)
62558833|NCT01977417|PLACEBO_COMPARATOR|Placebo|Placebo capsule twice per day
62558834|NCT01009814|EXPERIMENTAL|BMS-663068 600 mg Q12H + RTV 100 mg Q12H|All participants received BMS-663068 600 milligram (mg) and Ritonavir (RTV) 100 mg every 12 hours (Q12H) from Day 1 to Day 8.
62558835|NCT01009814|EXPERIMENTAL|BMS-663068 1200 mg QHS + RTV 100 mg QHS|All participants received BMS-663068 1200 mg and RTV 100 mg every night (quaque hora somni \[QHS\]) from Day 1 to Day 8.
62558836|NCT01009814|EXPERIMENTAL|BMS-663068 1200 mg Q12H + RTV 100 mg Q12H|All participants received BMS-663068 1200 mg and RTV 100 mg Q12H from Day 1 to Day 8.
62558837|NCT01009814|EXPERIMENTAL|BMS-663068 1200 mg Q12H + RTV 100 mg QAM|All participants received BMS-663068 1200 mg Q12H and RTV 100 mg every 24 hours in the morning (quaque ante meridiem \[QAM\]) from Day 1 to Day 8.
62558838|NCT01009814|EXPERIMENTAL|BMS-663068 1200 mg Q12H|All participants received BMS-663068 1200 mg Q12H from Day 1 to Day 8.
62558839|NCT06084793|EXPERIMENTAL|Music|All participants will listen to music throughout their time in the pre-transfer room and the designated embryo transfer room. The music will begin playing as soon as participants enter the room and will continue until their departure. Participants will curate a personalized playlist.
62558840|NCT06084793|NO_INTERVENTION|No music|No music is played (usual care) in the embryo transfer room.
62558841|NCT04821726|EXPERIMENTAL|Drug eluting balloon (Vmoky)|A paclitaxel eluting balloon produced by Yinyi (Liaoning) Biotech Co., Ltd. Balloon length: 8-40 mm, diameter：1.25-5.00 mm.
62558842|NCT04105673||Shaken Baby Syndrome|Realization of a clinical examination and survey on children with a past history of a Shaken Baby Syndrome
62766729|NCT06075992|EXPERIMENTAL|Premature babies in this group will be massaged.|On the first day of the study and at the end of the 4th week, the Infant Motor Performance Test (TIMP) will be used to evaluate the infant's motor performance consisting of postural control and selective extremity movements. Anthropometric measurements of all babies included in the study immediately afterwards; The baby's body weight, height and head circumference will be checked on the first day of the study and at the end of the 4th week. The stress level of babies will be evaluated by looking at cortisol and ACTH (Adrenocorticotropic hormone) hormones. Massage therapy will be given according to the Field medium pressure massage therapy protocol. In addition to the medical treatment, the application group will be massaged by an experienced physiotherapist according to the Field baby massage therapy protocol, at least 1 hour after the babies are fed, 3 days a week, 2 times a day and for 4 weeks.The massage will be applied for 15 minutes.
62766730|NCT06075992|NO_INTERVENTION|An experimental application will not be made to premature babies in this group.|No application will be made other than medical treatment. On the first day of the study and at the end of the 4th week, the Infant Motor Performance Test (TIMP) will be used to evaluate the infant's motor performance consisting of postural control and selective extremity movements. Anthropometric measurements of all babies included in the study immediately afterwards; The baby's body weight, height and head circumference will be checked on the first day of the study and at the end of the 4th week. The stress level of babies will be evaluated by looking at cortisol and ACTH (Adrenocorticotropic hormone) hormones.
62766731|NCT00663286|EXPERIMENTAL|1|
62384977|NCT02053597|EXPERIMENTAL|doxorubicin and paclitaxel|All patients will receive four cycles of doxorubicin (A) (50 mg/m2) and paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
62384978|NCT01350466||FESS patients|
62766732|NCT00663286|ACTIVE_COMPARATOR|2|
62766733|NCT00663286|ACTIVE_COMPARATOR|3|
62766734|NCT00663286|PLACEBO_COMPARATOR|4|
62766735|NCT04405271|EXPERIMENTAL|FTC/TAF|Emtricitabine/Tenofovir alafenamide (FTC/TAF) in 200 mg/25 mg tablets. A dose of 1 tablet per day will be administered for a total of 12 weeks.
62766736|NCT04405271|PLACEBO_COMPARATOR|Placebo|Identical tablets to the active experimental tablets with the same characteristics and packaging. A dose of 1 tablet per day will be administered for a total of 12 weeks
62766737|NCT05858957|EXPERIMENTAL|Magnesium|Magnesium sulfate 30 mg/kg with 100 ml saline will apply in 10 min before induction of general anesthesia (maximum magnesium dose 2g) (Group M) . When the magnesium infusion completed, general anesthesia induction will start.
62766738|NCT05858957|ACTIVE_COMPARATOR|Saline|saline 100 ml will apply in 10 min before induction of general anesthesia (Group S) . When the saline infusion completed, general anesthesia induction will start.
62766739|NCT01989611|OTHER|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year.
62766740|NCT04523090|EXPERIMENTAL|Nitazoxanide|Nitazoxaninde, 1000mg (2pills), oral, twice daily for 7 days. To be taken with food.
62384979|NCT01350466||Controls|
62384980|NCT04604015|EXPERIMENTAL|NeuralBot Investigational System/TTE Std of Care|Investigational Robotic Transcranial Doppler (TCD)/TTE Std of Care
62384981|NCT02548091|ACTIVE_COMPARATOR|Preventive non invasive ventilation|Patients will receive the non invasive ventilation (NIV) systematically during the whole procedure of pulmonary angioplasty, and then systematically in post procedure period, 1 hour every 4 hours, during the whole hospitalization in post anesthesia care unit (PACU).
62766741|NCT04523090|PLACEBO_COMPARATOR|Placebo|Placebo, 2 pills, oral, twice daily for 7 days. To be taken with food.
62766742|NCT05216276|ACTIVE_COMPARATOR|TEP|Patient with uni- or bilateral inguinal hernia receiving a laparoscopic totally extra-peritoneal (TEP) inguinal hernia repair.
62766743|NCT05216276|EXPERIMENTAL|rTAPP|Patient with uni- or bilateral inguinal hernia receiving a robotic transabdominal preperitoneal (TAPP) inguinal hernia repair.
62766744|NCT05970094|EXPERIMENTAL|Low PRAL diet|Crossover design: 1 arm consisting of three consecutive periods of two weeks (control, intervention and follow up).
62766745|NCT00160654|EXPERIMENTAL|Levetiracetam|Subjects received open-label Levetiracetam.
62766746|NCT00343863|ACTIVE_COMPARATOR|Dexamethasone + Ondansetron IV on Day 1|"All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.~Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)."
62384982|NCT02548091|OTHER|Non invasive ventilation on demand|Patients will not receive the NIV during the procedure of pulmonary angioplasty; in case of respiratory decompensation in post procedure period they will receive NIV during the whole hospitalization in PACU according to the following criteria: paradoxical breathing, respiratory rate above 25/minutes, a ratio of arterial oxygen pressure to fraction of inspired oxygen values (PaO2/FiO2) below 200.
62384983|NCT03705156|EXPERIMENTAL|ZL-2306|The starting dose is 300 mg or 200 mg based on patient's body weight.
62384984|NCT03705156|PLACEBO_COMPARATOR|Placebo|The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
62384985|NCT02522091|OTHER|young healthy volunteers (18-44 years old)|young healthy volunteers (18-44 years old)
62384986|NCT02522091|OTHER|healthy volunteers (45-69 years old)|healthy volunteers (45-69 years old)
62384987|NCT02522091|OTHER|Mild Cognitive Impairment Patients|Mild Cognitive Impairment Patients
62384988|NCT02522091|OTHER|Alzheimer's Disease patient|Alzheimer's Disease patient
62384989|NCT02522091|OTHER|old healthy volunteers (70+ years old)|old healthy volunteers (70+ years old)
62384990|NCT00650715|ACTIVE_COMPARATOR|VG|Vibration Group (VG) underwent a protocol with whole-body vibration exercise twice a week for a total of six weeks. The group continued with their usual pharmacological treatment.
62558843|NCT04042506|EXPERIMENTAL|Extracranial SBRT and Nivolumab|"Stereotactic body radiation therapy (SBRT) will be given to a single extracranial metastatic site in combination with nivolumab.~Patients will receive nivolumab 480mg intravenously (IV) every 4 weeks (1 cycle = 8 weeks), as well as SBRT dose of 8-10 Gy x 3 fractions (at maximum 3 doses per week) delivered to 1 extracranial site between days 1-14 of Cycle 1.~Nivolumab will be continued until confirmed progression, unacceptable toxicity, or total of 6 Cycles (whichever occurs first)."
62766747|NCT00343863|EXPERIMENTAL|Dexamethasone + Palonosetron IV on Day 1|"All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.~Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)."
62558844|NCT04571853|EXPERIMENTAL|PNE-explained group|The participants in the PNE-explained group will be explained the fact sheets with an explanatory video (due to COVID-19 circumstances) conducted by the therapist M.S. The video will last one hour approximately and it contains a presentation by Mayte Serrat with a view of the fact sheets. This group will be given one week to watch the video and comprehend its content.
62558845|NCT04571853|ACTIVE_COMPARATOR|PNE-read group|The PNE-read group will receive the fact sheets via email along with instructions regarding the content and the procedure to read the content. Instructions will suggest to read only two fact sheets per day during 4,5 days. It will be suggested to take 30 minutes at least for each fact sheet.
62558846|NCT04571853|ACTIVE_COMPARATOR|TAU group|Participants allocated into this group will maintain treatment as usual (TAU) and will follow the recommendations by their usual health professional.
62766748|NCT01022359|ACTIVE_COMPARATOR|Tesio Catheter|Patients randomised to receive the established catheter type in use at our centre \[control\]
62766749|NCT01022359|ACTIVE_COMPARATOR|LifeCath|Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)
62766750|NCT03980717|EXPERIMENTAL|Fetal Endotracheal Occlusion (FETO)|Placement and retrieval of the GoldBAL4 or GoldBAL2 Detachable balloon using the plug/unplug method, using BALTACCIDBPE100 Delivery Catheter.
62766751|NCT03980717|NO_INTERVENTION|non-FETO|The control group will consist of patients who did not undergo the FETO procedure who fit the same fetal inclusion/exclusion criteria as our FETO subjects and will be matched by variables including maternal age, body mass index, gestational age, severity of CDH and site of CDH (left- or right-sided).
62766752|NCT00841048|EXPERIMENTAL|1|AZD4017 in ascending doses (start dose 75mg od)
62766753|NCT00841048|PLACEBO_COMPARATOR|2|Placebo
62766754|NCT00862472|EXPERIMENTAL|DuoTrav APS|DuoTrav APS QD AM
62558847|NCT04119362||Patients with pancreatic adenocarcinoma|Patients with metastatic pancreatic cancer receiving will be asked to fill in an EORTC QLQ-C30 questionnaire and additional questionnaires on worries about quality of life impairments and physical constitiution every 8 weeks, over the entire course of treatment, starting with neo-/adjuvant or 1st line therapy follow. There is no restriction on type of therapy. No further intervention.
62558848|NCT00739713|EXPERIMENTAL|SB|Sea buckthorn oil group
61989479|NCT01424423|PLACEBO_COMPARATOR|Subjects receiving placebo in cohort 2|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
62384991|NCT00650715|PLACEBO_COMPARATOR|CG|The Control Group (CG) underwent the same protocol of exercises than VG but without vibratory stimulus. The CG continued with their usual pharmacological treatment.
62558849|NCT00739713|PLACEBO_COMPARATOR|PL|Placebo group
62558850|NCT04164004|EXPERIMENTAL|Routine Collection of Patient-Reported Health Status (KCCQ-12 Arm)|Patients in the KCCQ-12 arm will undergo KCCQ-12 assessment of patient-reported heart failure health status in the electronic health record at each heart failure clinic visit beginning at the start of the trial. Assessment results will be available to clinicians in the electronic health record when making treatment decisions during each clinic visit.
62558851|NCT04164004|ACTIVE_COMPARATOR|Usual Care|Patients in the usual care arm will not complete KCCQ-12 assessments in the electronic health record with clinic visits. They will complete a KCCQ-12 assessment at baseline that will not be available to the treating clinician.
62558852|NCT03726060|OTHER|splint therapy|"Alginate impressions will be taken and the plaster models of the dental arches will be made.~The splint will be subsequently delivered to the patient with the relative indications of use.~The splint therapy consist in the use of neuromuscoral splint every the night for 6 months."
62766755|NCT00862472|ACTIVE_COMPARATOR|DuoTrav|DuoTrav QD AM
62766756|NCT03597282|EXPERIMENTAL|NEO-PV-01 + adjuvant + nivolumab|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously.
62766757|NCT03597282|EXPERIMENTAL|Nivolumab + adjuvant|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive Poly-ICLC (adjuvant) administered subcutaneously.
62558853|NCT03726060|OTHER|physical therapy with splint therapy|"The treatment consists of a series of interventions: advice on self-treatment techniques to be performed at home and administering manual therapy techniques addressed to: temporomandibular district, cervical and cervico-thoracic junction.~Each session will be carried out individually and will last for 45 minutes. This duration will be divided as follows: 25 minutes dedicated to the temporomandibular district, 15 minutes to the cervical and cervico-thoracic junction, 5 minutes to teaching self-treatment techniques to be carried out at home and to verify the correct way of performing them.~The cycle will consist of 10 sessions distributed over 3 months."
62558854|NCT00218946|NO_INTERVENTION|control|no fluid, no pacifier
62766758|NCT03597282|EXPERIMENTAL|NEO-PV-01 + adjuvant + nivolumab on alternate schedule|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant, administered on an alternative schedule, subcutaneously.
62384992|NCT05832866|EXPERIMENTAL|"Clinical Based Isometric contraction strengthening Exercises using Thera band CBG"|Participants underwent strengthening exercises to the quadriceps and harmstring using thera band at the hospital. The band was attached around the ankle for strengthening of the quadriceps and hamstring muscles using isometric muscle contraction using a standard protocol. The patient performed four sets of eight repetitions for each of the exercises.
62766759|NCT03597282|EXPERIMENTAL|NEO-PV-01 + adjuvant + nivolumab + APX005M|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously. Patients on this arm will also receive APX005M at a dose of 0.1 mg/kg administered by IV infusion at Week 12, Week 15, and Week 19.
62766760|NCT03597282|EXPERIMENTAL|Nivolumab + APX005M|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, Week 15, and Week 19, all patients, regardless of their disease status, will receive APX005M at a dose of 0.1 mg/kg administered by IV infusion.
62766761|NCT03597282|EXPERIMENTAL|NEO-PV-01 + adjuvant + nivolumab + ipilimumab|Nivolumab at a dose of 240 mg administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously. Patients on this arm will also receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion at Week 12 and Week 19.
62766762|NCT03597282|EXPERIMENTAL|Nivolumab + ipilimumab|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12 and Week 19, all patients, regardless of their disease status, will receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion.
61989480|NCT01424423|EXPERIMENTAL|Subjects receiving GSK1223249 in cohort 3|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 2 milligrams per kilograms administered by a programmable syringe pump.
61989481|NCT01424423|PLACEBO_COMPARATOR|Subjects receiving placebo in cohort 3|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
61989482|NCT01424423|EXPERIMENTAL|Subjects receiving GSK1223249 in cohort 4|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 10 milligrams per kilograms administered by a programmable syringe pump.
61989483|NCT01424423|PLACEBO_COMPARATOR|Subjects receiving placebo in cohort 4|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
61989484|NCT01424423|EXPERIMENTAL|Subjects receiving GSK1223249 in cohort 5|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 30 milligrams per kilograms administered by a programmable syringe pump.
61989485|NCT01424423|PLACEBO_COMPARATOR|Subjects receiving placebo in cohort 5|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
61989486|NCT00588822|EXPERIMENTAL|Rituximab|"Subjects will receive rituximab administered at the standard dose and schedule as an initial cycle of therapy, followed by a re-evaluation at 6 months. If the neuropathy is stable or responding at 6 months, the subject will receive Cycle 2 of rituximab, followed by a re-evaluation at 12 months.~Rituximab will be given as a 375 mg/m\^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22)."
61989487|NCT00477672|EXPERIMENTAL|2|Pimavanserin tartrate (ACP-103), 10 mg, tablet, once daily by mouth, 6 weeks
62384993|NCT05832866|EXPERIMENTAL|"Telemonitored Home based Isometric Contraction strengthening exercises using Thera band THB"|Participants underwent strengthening exercises to the quadriceps and harmstrings with thera band but doing the intervention at home but monitored with telephone call. The band was attached around the ankle for strengthening of the quadriceps and hamstring muscles using isometric muscle contraction using a standard protocol. The patient performed four sets of eight repetitions for each of the exercises.
61989488|NCT00477672|EXPERIMENTAL|3|Pimavanserin tartrate (ACP-103), 40 mg, tablet, once daily by mouth, 6 weeks
62384994|NCT03297554|EXPERIMENTAL|m-health approach|See intervention description
61989489|NCT00477672|PLACEBO_COMPARATOR|1|Placebo tablet, once daily by mouth, 6 weeks
62384995|NCT03531918|EXPERIMENTAL|Treatment (GO, GCLAM)|"INDUCTION THERAPY: Participants receive gemtuzumab ozogamicin IV either as a single dose on day 1, or as three doses on days 1, 4, and 7. Participants also receive G-CSF SC on days 0-5, cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, and mitoxantrone hydrochloride IV on days 1-3. Patients who do not achieve a CR or CRi following the first cycle of induction are eligible for a second cycle, which is given without gemtuzumab ozogamicin. Participants with a CR or CRi may then proceed to Post-Remission Therapy.~POST-REMISSION THERAPY: Participants receive G-CSF, cladribine, and cytarabine as in Induction Therapy during cycle 1, and cytarabine IV every 12 hours on days 1-6 of cycles 2-3. Treatment repeats every month for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
61989490|NCT03168152|EXPERIMENTAL|MWA|MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
61989491|NCT03168152|EXPERIMENTAL|SBRT|SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
61989492|NCT05805787|EXPERIMENTAL|Acupressure group|Acupressure will be applied to the elderly in the experimental group once a day, 5 days a week (Monday-Friday) for a week. The application will last for 2 weeks. A total of 10 sessions of acupressure will be applied. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the elderly are in supine position, pressure will be applied to each acupressure point, respectively, Tianshu (ST25), Guanyuan (CV4) and Hegu (LI4) for 2 minutes for a total of 6 minutes.
61989493|NCT05805787|NO_INTERVENTION|Control group|No intervention will be applied
61989494|NCT01442415|OTHER|Lifestyle Modification|Weekly 2 hour study sessions for 10 weeks; each session includes one hour of physical activity and one hour of dietary counseling
61989495|NCT03720912|EXPERIMENTAL|Online Family Education Modules|Patients will receive online family education modules.
61989496|NCT03720912|NO_INTERVENTION|Control|Patients will not receive any intervention.
62766763|NCT04807803|EXPERIMENTAL|Patients with compensated cirrhosis and portal hypertension|
61989497|NCT04486846|EXPERIMENTAL|eVisit|The study intervention will be an electronically performed surveillance program replacing face-to-face clinic follow-up visits. At 3 month intervals for 1 year, the patient will receive an email reminder generated by the patient portal to complete lab testing and eVisit questionnaire.
61989498|NCT04699682|EXPERIMENTAL|Control|During follow-up visits, as part of this research, additional stool samples are taken every month (M1 to M12).
61989499|NCT04699682|EXPERIMENTAL|BHR Case|"During follow-up visits, compared to the usual management of patients with BHRe (monthly sampling for 6 consecutive months), additional samples are taken as described below:~- stool samples taken at different times:~* every 7 days during the first month (M1)~* every 14 days for the following months until the end of the patient's participation (M2 to M12)."
61989500|NCT04421911|EXPERIMENTAL|ketoprofen|
62384996|NCT05179291|EXPERIMENTAL|Buzzy Group|In this group external cold and vibration-Buzzy was applied to the children during phlebotomy.
62384997|NCT05179291|EXPERIMENTAL|Virtual Realitiy-VR Group|In this group Virtual Realitiy-VR was applied to the children during phlebotomy.
62384998|NCT05179291|NO_INTERVENTION|Control Group|In this group, children received routine phlebotomy procedure
62766764|NCT02577185|EXPERIMENTAL|botulinum toxin type A|Experimental drug
62766765|NCT02577185|PLACEBO_COMPARATOR|sodium chloride 9 mg/ml|Vehicle drug
61989501|NCT04421911|ACTIVE_COMPARATOR|Diclofenac|
61989502|NCT05184374|EXPERIMENTAL|subcutaneous injection of gonadorelin is facilitated by GnRH pump|After non-dose GnRH stimulation test on day 1, GnRH pump pulse subcutaneous injection of gonadorelin on the next day until one month.
61989503|NCT03869450|EXPERIMENTAL|Restylane Volyme|According to the treatment algorithm, treated with Restylane Volyme
61989504|NCT03869450|EXPERIMENTAL|Restylane Defyne|According to the treatment algorithm, treated with Restylane Defyne
61989505|NCT03869450|EXPERIMENTAL|Restylane Lyft Lidocaine|According to the treatment algorithm, treated with Restylane Lyft Lidocaine
61989506|NCT05210166|ACTIVE_COMPARATOR|Active tSCS and Lokomat|"20 sessions, 5 sessions per week of active transcutaneous spinal cord stimulation (tSCS) combined with Lokomat will be performed.~The duration of Lokomat will be 30 minutes, of which the first 20 minutes tSCS will be applied at the beginning of each session."
61989507|NCT05210166|PLACEBO_COMPARATOR|Sham tSCS and Lokomat|"20 sessions, 5 sessions per week of sham transcutaneous spinal cord stimulation (sham-tSCS) combined with Lokomat will be performed.~The duration of Lokomat will be 30 minutes, of which the first 20 minutes sham-tSCS will be applied at the beginning of each session."
62558855|NCT00218946|EXPERIMENTAL|water|water, no pacifier
62558856|NCT00218946|EXPERIMENTAL|sucrose|Sucrose, no pacifier
62766766|NCT03690180||Diabetics with microalbuminuria|"Diabetics with micro albuminuria will be subjected to full clinical examination.~Measurement of weight, height, waist, hip and calculation of BMI and waist hip ratio,laboratory assessment of serum creatinine,HbA1C,magnesium and urinary albumin creatinine ratio"
61989508|NCT00139828|OTHER|A|The amount of Nonafact® to be administered and the frequency of treatment is based on the SmPC and should always be determined on the basis of the clinical effectiveness in the individual patient
61989509|NCT03930888||Patients with nutritional support|Evaluation of changes in muscle strength, muscle mass and self-sufficiency (ADL-Activites of Daily Living) over a 5-day time period in patients nutritionally supported by nutritional supplements.
61989510|NCT03930888||Patients without nutritional support|Evaluation of changes in muscle strength, muscle mass and self-sufficiency (ADL-Activites of Daily Living) over a 5-day time period in patients without special nutritional supplements.
61989511|NCT01630512|EXPERIMENTAL|MBCT|
62558857|NCT00218946|EXPERIMENTAL|pacifier|No fluid, pacifier
62766767|NCT03690180||Diabetics with normal albuminuria|"Diabetics with micro albuminuria will be subjected to full clinical examination.~Measurement of weight, height, waist, hip and calculation of BMI and waist hip ratio,laboratory assessment of serum creatinine,HbA1C,magnesium and urinary albumin creatinine ratio"
62766768|NCT06222489|OTHER|Patritumab Deruxtecan|5.6 mg/kg patritumab deruxtecan every 3 weeks
62766769|NCT01676519||PCI|diabetic patients undergoing percutaneous coronary intervention
62384999|NCT02255162|EXPERIMENTAL|Lenalidomide|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Participants will receive the following:~* Cytarabine-intravenous, fixed dosage, given 5 times during cycle~* HLA-mismatched stem-cell microtransplantation~* Lenalidomide-administered daily per cycle"
62766770|NCT04852510|ACTIVE_COMPARATOR|Group A|Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA).
61989512|NCT01630512|EXPERIMENTAL|CBT|
61989513|NCT01630512|NO_INTERVENTION|Waitlist|
61989514|NCT05659810|ACTIVE_COMPARATOR|Preoperative oral gabapentin before spinal anesthesia|The participants will receive 900 mg of gabapentin before surgery in 2 divided doses; 300 mg 10 hours prior to surgery and 600 mg 2 hours before surgery.
61989515|NCT05659810|PLACEBO_COMPARATOR|Preoperative oral placebo before spinal anesthesia|The participants will receive 1 tablet 10 hours prior to surgery, and then 2 tablets 2 hours prior to surgery
61989516|NCT01321125|EXPERIMENTAL|Whole group of 30 volunteers|The arm is composed of 30 human volunteers to test 2% chlorhexidine gluconate in 70% isopropyl alcohol (ChloraPrep ®, Enturia, Texas, USA ), hypochlorite 10% of electrochemical production (Except 10% ®, Pisa, Guadalajara, Mexico), and two controls.
61989517|NCT01321125|EXPERIMENTAL|test group of substantivity|The arm is composed of 10 human volunteers to test 2% chlorhexidine gluconate in 70% isopropyl alcohol (ChloraPrep ®, Enturia, Texas, USA ), hypochlorite 10% of electrochemical production (Except 10% ®, Pisa, Guadalajara, Mexico), and 10% povidone-iodine (Isodine Solucion ®, Boehringer-Ingelheim Promeco, Mexico City)
62385000|NCT04252560||Colorectal|30 patients operated for colorectal cancer
61989518|NCT02859051|NO_INTERVENTION|control|No intervention
62385001|NCT04252560||HIPEC|15 patients operated with CRS+HIPEC for peritoneal carcinomatosis
62385002|NCT03665129|EXPERIMENTAL|Dose escalation|IPH5401 at different doses and schedule + Durvalumab
62385003|NCT03665129|EXPERIMENTAL|Cohort expansion NSCLC anti-PD-(L)1 pretreated|IPH5401 at recommended dose and schedule + Durvalumab in NSCLC anti-PD-(L)1 pretreated patients
62385004|NCT03665129|EXPERIMENTAL|Cohort expansion HCC anti-PD-(L)1 naive|IPH5401 at recommended dose and schedule + Durvalumab in HCC anti-PD-(L)1 naive patients
62766771|NCT04852510|ACTIVE_COMPARATOR|Group B|A combination of Metformin 500 mg three times daily with meals (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA) and Thymoquinone (TQ) in the form of Black Cumin oil (Cumin Mar® Black cumin oil 500 mg soft gel capsules, MARNYS. Spain) three times daily before meals for 6 months.
62766772|NCT06486688|ACTIVE_COMPARATOR|Usual Care/Traditional SBIRT|Clinics where appointment-based brief interventions are delivered by a behavioral health clinician assigned to the clinic (Traditional SBIRT arm)
61989519|NCT02859051|EXPERIMENTAL|robot|Humanoid robot interacts with child, teaching breathing and coping strategies.
61989520|NCT01060033|OTHER|Arm 1|"* Clinical T1/T2-weighted MRI sequence per standard of care before treatment, during treatment per standard protocol, and at 3 months.~* Patients may have one or all of the following sequences in addition to the standard MRI imaging:~  * MR Spectroscopy~ * Fat-saturation and Diffusion-Weighted Imaging~ * Dynamic Contrast Enhancement MRI (MR-DCE)~ * Diffusion Tensor Imaging (DTI)"
61989521|NCT05188092|NO_INTERVENTION|Control|Routine fluid deresuscitation in which fluid withdrawal is started and continued at the discretion of the treating physician.
62385005|NCT03665129|EXPERIMENTAL|Cohort expansion HCC anti-PD-(L)1 pretreated|IPH5401 at recommended dose and schedule + Durvalumab in HCC anti-PD-(L)1 pretreated patients
62385006|NCT04524507|EXPERIMENTAL|High-Titer (CCP1)|Within 8 days of COVID symptom onset and no more than 48 hours following hospitalization, participants will be randomized to and receive high-titer ABO-compatible convalescent COVID-19 plasma (CCP1) within 24 hours following random assignment.
62385007|NCT04524507|ACTIVE_COMPARATOR|Standard-Titer (CCP2)|Within 8 days of COVID symptom onset and no more than 48 hours following hospitalization, participants will be randomized to and receive standard-titer ABO-compatible convalescent COVID-19 plasma (CCP2) within 24 hours following random assignment.
62558858|NCT00218946|EXPERIMENTAL|water and pacifier|water, pacifier
62558859|NCT00218946|EXPERIMENTAL|sucrose and pacifier|sucrose, pacifier
62385008|NCT02790749|EXPERIMENTAL|PAO with adjunctive hip arthroscopy|Patients undergoing periacetabular osteotomy (PAO) with adjunctive hip arthroscopy.
62385009|NCT02790749|ACTIVE_COMPARATOR|PAO WITHOUT adjunctive hip arthroscopy|Patients undergoing periacetabular osteotomy (PAO) WITHOUT adjunctive hip arthroscopy.
62385010|NCT05343962||Parkinson's Disease (PD)|Subjects with a medical diagnosis and currently cursing with Parkinson's Disease (PD)
62766773|NCT06486688|EXPERIMENTAL|CV SBIRT|Clinics where brief interventions are delivered virtually by video or telephone by a centralized behavioral health clinician (CV-SBIRT arm)
62766774|NCT04235569|EXPERIMENTAL|Group I|"a group of 25 patients received 5mg Marevan ® tablets as initiation warfarin dose in combination of enoxaparin (Clexane® ) as a bridging agent.INR was monitored daily and dose adjustments were done to reach therapeutic INR range (2-3) at which the Enoxaparen was discontinued.Follow up was continued till first INR reading in therapeutic range.~Bleeding events due to overanticoagulation were monitored through the follow up period."
62766775|NCT04235569|EXPERIMENTAL|Group II|"a group of 25 patients received 3mg Marevan ® tablets as initiation warfarin dose in combination of enoxaparin (Clexane® ) as a bridging agent.INR was monitored daily and dose adjustments were done to reach therapeutic INR range (2-3) at which the Enoxaparen was discontinued.Follow up was continued till first INR reading in therapeutic range.~Bleeding events due to overanticoagulation were monitored through the follow up period."
62766776|NCT00806923|EXPERIMENTAL|1|
62766777|NCT00806923|EXPERIMENTAL|2|
61989522|NCT05188092|ACTIVE_COMPARATOR|Intervention|Deresuscitation is guided by lung ultrasound observations.
61989523|NCT03318315|EXPERIMENTAL|Group 1|3.75 mcg HA per 0.5 mL dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant and 0.5 ml dose of IIV4 vaccine, both administered intramuscularly within 15 minutes on day 1, and 3.75 mcg HA per 0.5 mL dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant intramuscularly on day 22, n=60
61989524|NCT03318315|EXPERIMENTAL|Group 2|0.5 ml dose of IIV4 vaccine intramuscularly on day 1 and 3.75 mcg HA per 0.5 ml dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant intramuscularly on day 22 and day 43, n=60
61989525|NCT03318315|ACTIVE_COMPARATOR|Group 3|0.5 ml dose of IIV4 vaccine intramuscularly on day 1, n=30
61989526|NCT05707117|EXPERIMENTAL|Group A: Tendon neuroplastic training (TNT)|the strength training of the wrist extensors are being done with the help of an externally pace device
61989527|NCT05707117|ACTIVE_COMPARATOR|Group B: Conventional treatment|static stretching and myofascial release on wrist extensors
62385011|NCT05343962||Diabetes Mellitus type I and II (DM I/II)|Subjects with a medical diagnosis and currently cursing or who have cursed at some point in the past with SARS Covid-19 Infection (COVID-19)
62385012|NCT05343962||SARS Covid-19 Infection (COVID-19)|Subjects with a medical diagnosis and currently cursing or who have cursed at some point in the past with SARS Covid-19 Infection (COVID-19)
62385013|NCT05343962||Chronic obstructive pulmonary disease (COPD)|Subjects with a medical diagnosis and currently cursing with Chronic obstructive pulmonary disease (COPD).
62766778|NCT00806923|PLACEBO_COMPARATOR|3|
62766779|NCT02301481|EXPERIMENTAL|Neoadjuvant Chemoradiotherapy (NCRT)|NCRT arm receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (45.1Gy and 40.04Gy in 22 fractions) concurrently with oral S-1(40mg/m2, orally twice daily every weekday) followed by surgery and four to six cycles of SOX at the same dosage with NCT arm.
62766780|NCT02301481|ACTIVE_COMPARATOR|Neoadjuvant Chemotherapy (NCT)|NCT arm consists of neoadjuvant three cycles of SOX(S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle followed by radical surgery and another postoperative three cycles of SOX.
62766781|NCT05988190|EXPERIMENTAL|Contextual Word Learning Intervention|Intervention will consist of a metalinguistic intervention with novel words (n=9), based on Cain (2007), administered across three sessions, and spaced one week apart. Semantic diversity will vary across items.
62766782|NCT03659058|ACTIVE_COMPARATOR|study group|200 patients with compensated liver cirrhosis (F4) by fibroscan; Child Turcotte Pugh score A, after achieving sustained virological response will be treated by anti-fibrotic agents
62766783|NCT03659058|PLACEBO_COMPARATOR|control group|200 patients with compensated liver cirrhosis (F4) by fibroscan; Child Turcotte Pugh score A, after achieving sustained virological response will be followed up without any intervention
61989528|NCT00816075|EXPERIMENTAL|1, Distilled water|the group of patients with superficial bladder cancer in the intermediate risk group who had their first recurrence after 6 months from the initial TUR. We plan to administer 200 ml of distilled water as immediate instillation for 2 hours
61989529|NCT05086887||Migrants from malaria endemic countries arriving to or living in Sweden|The study population consists of participants born in a malaria endemic country living in Sweden, irrespective of time of residency in Sweden (e.g newly arrived migrants as well as individuals with longer residency in Sweden or another non-endemic country). Participants of all ages can be included in the study.
61989530|NCT03568357||Reoxygenation|After one minute of full bypass, fraction of inspired oxygen (FiO2) in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 40%-80% adjusted reoxygenation to maintain PO2 in the range of 250mm Hg-300 mm Hg or more during the bypass.
62385014|NCT05343962||Stroke (ST)|Subjects with a medical diagnosis and who have cursed at some point with Stroke, either ischemic or hemorrhagic (ST)
62385015|NCT05343962||Healthy population (HP)|Healthy population (HP). No chronic or acute conditions declared.
62385016|NCT02993640|EXPERIMENTAL|vasopressin + nitro|vasopressin + nitroglycerin in simultaneous infusion
62385017|NCT02068391|EXPERIMENTAL|Exercise|This group will perform the 'Exercise Program' for months 0 to 6, and will be unsupervised for months 7 to 12.
62766784|NCT00499655|ACTIVE_COMPARATOR|Arm I|Patients receive oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.
62766785|NCT00499655|EXPERIMENTAL|Arm II|Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily on days 1-28.
62766786|NCT05825625|EXPERIMENTAL|Platinum-based chemotherapy in combination with atezolizumab and tiragolumab|"Patients will receive 2 cycles of SOC platinum-based chemotherapy as per investigator's choice in combination with atezolizumab and tiragolumab administrated by IV infusion.~Curative intended surgery will follow after last dose of neoadjuvant treatment. After surgery, patients will receive adjuvant treatment including 2 cycles of platinum-based chemotherapy and atezolizumab plus tiragolumab for up to 1 year. Patients who achieved pCR will receive only atezolizumab plus tiragolumab for up to one year as maintenance therapy."
62385018|NCT02068391|ACTIVE_COMPARATOR|Stretching|This group will perform the 'Stretching Program' for months 0 to 6, and the 'Exercise Program' for months 7 to 12.
62385019|NCT05386979|OTHER|Opioid anesthesia group|Anesthesia induction with propofol 2.5mg/kg, rocuronium bromide 0.6mg/kg, sufentanil 0.3μg/kg, intubation was performed when BIS value reached 40-60. Intraoperative pump injection of propofol 4-12 mg/kg·h and remifentanil 0.2-0.5 μg/kg·min to maintain anesthesia. Ultrasound-guided transversus abdominis plane block (with 0.375% ropivacaine 40ml) will be implemented preoperatively. Ondansetron 8mg and sufentanil 10 μg will be given after surgery. For PCA, sufentanil 2μg/kg + dexmedetomidine 2μg/kg + ondansetron 24mg.
61989531|NCT02618434|EXPERIMENTAL|Low dose SPN-810 (18 mg)|Oral
61989532|NCT02618434|EXPERIMENTAL|High dose SPN-810 (36 mg)|Oral
61989533|NCT02618434|PLACEBO_COMPARATOR|Placebo|Oral
61989534|NCT02871388|EXPERIMENTAL|CONECT|12 week program with additional follow up at 24 weeks.
61989535|NCT02871388|NO_INTERVENTION|Control|Waitlist control. No intervention for first 12 weeks. Participants given the option to participate in the program after 24 weeks.
61989536|NCT04945629|ACTIVE_COMPARATOR|Simple suture|Atraumatic exodontia followed by simple suture
61989537|NCT04945629|EXPERIMENTAL|PRGF-Endoret|Atraumatic exodontia followed by simple suture
61989538|NCT06011018|EXPERIMENTAL|Mirror therapy|
61989539|NCT06011018|EXPERIMENTAL|Mirror Therapy + Electrical Stimulation|
61989540|NCT06011018|EXPERIMENTAL|Mirror Therapy + Binaural Beat|
61989541|NCT03131336|EXPERIMENTAL|PeproStat|PeproStat 2.5mg/mL soaked into haemostatic gelatin sponge, applied to a target bleeding site
61989542|NCT03131336|PLACEBO_COMPARATOR|Saline|Saline soaked into haemostatic gelatin sponge, applied to a target bleeding site
61989543|NCT05339620|EXPERIMENTAL|mop group|a group of patients with a class 2 divsion 1 dental malocclusion, overjet greater than 9 mm, extraction of upper first premolars planned, and it has been 3 months post extraction and before canine retraction is commenced.
61989544|NCT05339620|ACTIVE_COMPARATOR|mop group ( same)|a group of patients with a class 2 divsion 1 dental malocclusion, overjet greater than 9 mm, extraction of upper first premolars planned, and it has been 3 months post extraction and before canine retraction is commenced.
61989545|NCT00623727|EXPERIMENTAL|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight of BAY79-4980 1x/week plus 2 dummy injections/week (dummy = rFVIII (recombinant factor VIII)-FS (formulated with sucrose) excipient reconstituted in WFI (sterile water for injection))
61989546|NCT00623727|ACTIVE_COMPARATOR|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight of rFVIII-FS 3x/week (employing 1 percent POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)-alone liposome (rFVIII-FS-POPC) as blinding agent used for first weekly injection and rFVIII-FS in WFI for 2nd and 3rd injection)
61989547|NCT02338765|EXPERIMENTAL|Buddy|Physical activity plus having a buddy
61989548|NCT02338765|ACTIVE_COMPARATOR|Control|Physical activity only
61989549|NCT01527682|OTHER|Latanoprost, Dorzolamide|According to intraocular (IOP) assessment, the eye will receive Latanoprost, Dorzolamide or both.
61989550|NCT01127308|EXPERIMENTAL|[14C]Ertugliflozin|Single dose - oral dosing suspension
61989551|NCT03266991|EXPERIMENTAL|RPT-INH|Participants treated with weekly rifapentine and isoniazid for twelve weeks.
61989552|NCT03266991|ACTIVE_COMPARATOR|control|Participants treated with daily isoniazid for six months
61989553|NCT04184531||Children with Sensenbrenner Syndrome|Children with Sensenbrenner followed from 2005. Variable phenotype related to the mutation gene will be analysed to determine some possible prognostic factors of the risk of developing end-stage kidney disease.
62385020|NCT05386979|EXPERIMENTAL|Opioid free anesthesia group|Anesthesia induction with propofol 2.5mg/kg, rocuronium bromide 0.6mg/kg, naborphine 0.2mg/kg，esketamine 0.3mg/kg, intubation was performed when BIS value reached 40-60. Intraoperative pump injection of propofol 4-12 mg/kg·h and esketamine 0.3～0.5mg/kg·h. Ultrasound-guided transversus abdominis plane block (with 0.375% ropivacaine 40ml) will be implemented preoperatively. Ondansetron 8mg and naborphine 0.2mg/kg will be given after surgery. For PCA, naborphine 2mg/kg + dexmedetomidine 2μg/kg + ondansetron 24mg.
62385021|NCT06477523|EXPERIMENTAL|LDRT+AK104+chemotherapy|AK104(IV, D1) + Cisplatin (IV, D1)/Carboplatin (IV, D1) +Etoposide (IV, D1-D3) were administrated on a 21-day cycle for four cycles. Concurrent LDRT (15 Gy/5f) were conducted from D1-D5 in the first cycle. Then pts received LDRT and AK104 maintenance until loss of clinical benefit or unacceptable toxicity.
62385022|NCT03445780|EXPERIMENTAL|First Group|Skin cooling with ethyl chloride spray will be used for 5 seconds prior to injection
62385023|NCT03445780|EXPERIMENTAL|Second Group|The skin between the distal palmar crease and the palmo-digital crease and the palmo-digital crease will be pinched for 5 seconds prior to injection
62385024|NCT03445780|EXPERIMENTAL|Third Group|Skin cooling with ethyl chloride spray will be used for 5 seconds prior to injection as well as a second pinch to the skin between the distal palmar crease and the palmo digital crease
62385025|NCT03445780|EXPERIMENTAL|Fourth Group|Subjects will sit behind a screen with a small opening large enough to introduce the injection hand. They will not see any of the procedure.
62385026|NCT05057377||Post-TBI Participants|Over a 2-day period post-TBI adults age 18 years and older, will undergo overground assessments with a questionnaire regarding motivation during day 1, followed by robotic safety-environment assessments during day 2.
62385027|NCT02449629||TGMY in HIV Care|TGMY (16-24 years of age) currently in HIV care at an Adolescent Medicine Trials Unit (AMTU) site or elsewhere.
62385028|NCT02449629||TGMY Not in HIV Care|TGMY (16-24 years of age) not currently in care who are living with HIV, not living with HIV, or those who are unaware of their HIV status.
62385029|NCT02449629||Health Care and Social Service Providers|Health care and social service providers who work with TGMY at AMTU sites or elsewhere that serve TGMY within the AMTU cities.
62385030|NCT01186133||DESSIAN|consecutive patients receiving CYPHER stent
62385031|NCT01186133||K-XIENCE|consecutive patients receiving Xience stent
62385032|NCT01186133||GENOUS|consecutive patients receiving GENOUS stent
62385033|NCT01186133||ELEMENT|consecutive patients receiving PROMUS-ELEMENT stent
62385034|NCT01186133||PRIME|consecutive patients receiving XIENCE-PRIME stent
62558860|NCT05814731|EXPERIMENTAL|MA-BUCY2|Mitoxantrone liposome 20mg/m2，ivgtt，d-11 ；Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2；
61989554|NCT03862274||CLN2 Natural History Control Group|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are untreated or not receiving cerliponase alfa.
62385035|NCT01186133||NOBORI|consecutive patients receiving NOBORI stent
62385036|NCT01186133||INTEGRITY|consecutive patients receiving RESOLUTE-INTEGRITY stent
62385037|NCT01186133||XPEDITION|consecutive patients receiving XIENCE-XPEDITION stent
62385038|NCT01186133||BIOMATRIX|consecutive patients receiving BIOMATRIX stent
62385039|NCT01186133||CILOTAX|consecutive patients receiving CILOTAX stent
62385040|NCT01186133||DEB|consecutive patients receiving Drug eluting balloon
62385041|NCT01186133||DESYNE|consecutive patients receiving DESYNE stent
62385042|NCT01186133||PREMIER|consecutive patients receiving PROMUS-PREMIER stent
62385043|NCT01186133||ORSIRO|consecutive patients receiving ORSIRO stent
62385044|NCT01186133||ONYX|consecutive patients receiving ONYX stent
62385045|NCT01186133||BVS|consecutive patients receiving Bioresorbable Vascular Scaffold
62385046|NCT01186133||BVS AMI|consecutive acute myocardial infarction patients receiving Bioresorbable Vascular Scaffold
62385047|NCT01186133||Ultimaster|consecutive patients receiving Ultimaster stent
62385048|NCT01186133||Synergy|consecutive patients receiving Synergy stent
62385049|NCT01186133||Biofreedom|consecutive patients receiving Biofreedom stent
62385050|NCT01186133||Firehawk|consecutive patients receiving Firehawk stent
62385051|NCT01186133||DESyne X2|consecutive patients receiving DESyne X2 stent
62385052|NCT01186133||Sierra|consecutive patients receiving Sierra stent
62385053|NCT01186133||Tansei|consecutive patients receiving Tansei stent
62385054|NCT01186133||Synergy XD and Synergy Megatron™|consecutive patients receiving Synergy XD or Synergy Megatron™ stent
62385055|NCT01186133||Xience-Skypoint|consecutive patients receiving Xience-Skypoint stent
62385056|NCT01186133||Coroflex ISAR NEO|consecutive patients receiving Coroflex ISAR NEO stent
62385057|NCT02447393|OTHER|levocetirizine|Study Drug
62385058|NCT02447393|OTHER|cetirizine|Study Drug
62385059|NCT02447393|OTHER|placebo|Study Drug
62385060|NCT00808132|EXPERIMENTAL|1|bazedoxifene 20 mg/conjugated estrogens 0.45 mg
62766787|NCT02559414|NO_INTERVENTION|Control|This arm of 10 subjects will be assigned randomly via a computer generated treatment sequence, and then be given no antiplatelet medication.
62766788|NCT02559414|ACTIVE_COMPARATOR|Aspirin|This arm of 20 subjects will be assigned randomly via a computer generated treatment sequence, and then be given aspirin.
62766789|NCT02559414|ACTIVE_COMPARATOR|Clopidogrel|This arm of 20 subjects will be assigned randomly via a computer generated treatment sequence, and then be given clopidogrel.
61989555|NCT03862274||CLN2 Treatment Group|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
61989556|NCT04409743|ACTIVE_COMPARATOR|Immediate Treatment|The sleep treatment is Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants randomized to this arm will begin treatment immediately after randomization.
61989557|NCT04409743|OTHER|Waitlist|The subjects assigned to the Waitlist condition will receive the same CBT-I treatment 7 months after randomization.
62385061|NCT00808132|EXPERIMENTAL|2|bazedoxifene 20 mg/conjugated estrogens 0.625 mg
62385062|NCT00808132|EXPERIMENTAL|3|bazedoxifene 20 mg
62385063|NCT00808132|ACTIVE_COMPARATOR|4|Prempro
62766790|NCT05571956|EXPERIMENTAL|Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group|If a sufficient visible core was obtained on macroscopic inspection, the tissue materials from the following one needle pass were placed into the transfer medium for organoid generation. Using a tiny portion (about 20%) of the FNB sample, we isolated CAFs u
62766791|NCT00993499|EXPERIMENTAL|BIBW 2992 + Sirolimus|Dose escalation of the combination BIBW 2992 plus Sirolimus.
62766792|NCT05530889|EXPERIMENTAL|TEST/CONTROL|Eligible subjects who suffer from ocular allergies and who wear contact lenses will be randomized into the wear sequence (TEST/CONTROL) to wear the study lenses during each dispensing period (12-16 days).
62766793|NCT05530889|EXPERIMENTAL|CONTROL/TEST|Eligible subjects who suffer from ocular allergies and who wear contact lenses will be randomized into the wear sequence (CONTROL/TEST) to wear the study lenses during each dispensing period (12-16 days).
61989558|NCT02782533|EXPERIMENTAL|DBS V3|Deep Brain Stimulation V3
61989559|NCT00844272|EXPERIMENTAL|Psychoeducation|"PE group sessions lasted 60 minutes and were carried out under continuous supervision. The manualised program was especially tailored to (former) IDUs in HCV treatment, containing the following aspects:~* Module 1: HCV infection and symptoms, course of illness, interaction with opioid dependence, further problems and risk factors~* Module 2: HCV treatment, side effects, psychiatric and somatic comorbidities, reinfection and drug use, risk behaviour~* Module 3: Coping strategies, resources and self-help, effective use of health-care support, the role of social environment, healthy living \& nutrition"
61989560|NCT00844272|NO_INTERVENTION|Treatment as usual|Control group did not received no intervention.
61989561|NCT03800927|PLACEBO_COMPARATOR|Sham Ultrasound Device|No ultrasound treatment
61989562|NCT03800927|ACTIVE_COMPARATOR|Active Ultrasound Device|Active treatment
62385064|NCT00808132|PLACEBO_COMPARATOR|5|Placebo
62385065|NCT05633290||ICU Survivors of Sepsis|ICU survivors of sepsis who would routinely attend ICU follow-up.
61989563|NCT02602587|EXPERIMENTAL|blood samples and bone marrow samples|The patients included in this study will be processed according to the standard treatment in force for their disease. This study does not in any way interfere with this treatment regimen, and is only based on additional samples of blood and bone marrow in acts planned in the prognostic or follow-up protocols. Treatment shall start within the 15 days following inclusion and first sampling.
61989564|NCT03676322|EXPERIMENTAL|Part A: M5049|
61989565|NCT03676322|PLACEBO_COMPARATOR|Part A: Placebo|
61989566|NCT03676322|EXPERIMENTAL|Part B: M5049|
62385066|NCT00482209|ACTIVE_COMPARATOR|1|200mg mifepristone followed by 400mcg misoprostol
61989567|NCT03676322|PLACEBO_COMPARATOR|Part B: Placebo|
62385067|NCT00482209|ACTIVE_COMPARATOR|2|200mg mifepristone followed by 800mcg misoprostol
62385068|NCT01206933||Detectable HIV RNA and HCV RNA|HIV and HCV co-infected with detectable HIV RNA and HCV RNA
62385069|NCT01206933||Undetectable HIV and Detectable HCV|HIV and HCV infected, HIV RNA Undetectable(treated) and Detectable HCV RNA.
61989568|NCT03676322|EXPERIMENTAL|Part C: M5049|
61989569|NCT00935870||A|DEPRESSED LATERAL CONDYLE FRACTURE
61989570|NCT00935870||B|BENIGN BONE TUMOR
61989571|NCT00935870||C|SPINAL FUSION
62385070|NCT01206933||Undetectable HIV and HCV|HIV and HCV infected, Undetectable HIV RNA and HCV RNA
62385071|NCT01206933||Undetectable HCV|HCV(mono-infected,) HCV RNA undetectable
62385072|NCT01206933||Detectable HCV RNA|Monoinfected HCV, detectable RNA
62385073|NCT01206933||Detectable HIV RNA|Monoinfected HIV, Detectable RNA
62766794|NCT04215432|EXPERIMENTAL|Test group|Gel contained in tubes with the same appearance (30g), identical in colour, flavour and density, with the following components: Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethylene glycol, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate, Deionized Water, Propolis Extract (2%), Ascorbic Acid (0.2%) and Tocopherol Acetate (0.2%).
62766795|NCT04215432|PLACEBO_COMPARATOR|Placebo group|Gel contained in tubes with the same appearance (30g), identical in colour, flavour and density, with the following components: Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethylene glycol, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate, Deionized Water and E155/151 coloring.
62766796|NCT04689971|EXPERIMENTAL|Experimental Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline and vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily (experimental group).
62766797|NCT04689971|ACTIVE_COMPARATOR|Control Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline.
61989572|NCT04529590||Patients with cardiovascular events after 18 years|"Analyzing metabolic markers screened and optimized by multivariate statistical with plasma metabolic profiles from peripheral blood samples of different groups.~Positive patients' samples will be collected at baseline."
61989573|NCT04529590||Patients without cardiovascular events after 18 years|For negative patients' samples will be collected at baseline as negative control.
61989574|NCT01087086|EXPERIMENTAL|Crononutrition|"Dietary pattern:~* Personalized diet~* Caloric restriction (-30% Total energy intake)~* High adherence to the Mediterranean Diet~* Macronutrient distribution (30% Protein, 40% Carbohydrates and 30% Fat)~* Low glycemic index/load~* Increased antioxidant capacity of the diet"
61989575|NCT01087086|PLACEBO_COMPARATOR|American Heart Association|"Dietary pattern:~* Personalized diet~* Caloric diet (-30% Total energy intake)~* Macronutrients distribution according to the American Heart Association (AHA) guidelines"
61989576|NCT04026607|EXPERIMENTAL|Whey Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
61989577|NCT04026607|EXPERIMENTAL|Pea Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
61989578|NCT04026607|EXPERIMENTAL|Collagen Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
61989579|NCT04757636|EXPERIMENTAL|2.0 mg aflibercept with Standard Dosing 2.0 mg OPT-302|"2.0 mg aflibercept intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals.~2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals."
61989580|NCT04757636|EXPERIMENTAL|2.0 mg aflibercept with Extended Dosing 2.0 mg OPT-302|"2.0 mg aflibercept intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals.~2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals, with sham intravitreal injection administered at visits when OPT-302 is not."
62385074|NCT04597424|EXPERIMENTAL|doxycycline and Bexsero® vaccine|-doxycycline will be taken by participants as PEP (prophylaxy post exposition) and participants will received Meningococcal B vaccine (Bexsero®) at D0 and M2
62558861|NCT05814731|ACTIVE_COMPARATOR|BUCY2|Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2；
61989581|NCT04757636|SHAM_COMPARATOR|2.0 mg aflibercept with sham|"2.0 mg aflibercept intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals.~Sham intravitreal injection administered at 4-weekly intervals."
61989582|NCT01132547|EXPERIMENTAL|Arm I cyproheptadine hydrochloride|Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.
61989583|NCT01132547|PLACEBO_COMPARATOR|Arm II placebo|Patients receive an oral placebo twice daily for 8 weeks.
61989584|NCT01793727|EXPERIMENTAL|Glidescope intubation|Comparison of direct laryngoscopy and Glidescope videolaryngoscopy
61989585|NCT02075138||Grass-Induced Rhinoconjunctivitis Subjects|
61989586|NCT03605797||No intervention|To study the indication and results of fixing the sacral fracture by tension band plating
61989587|NCT04067128|EXPERIMENTAL|Health coaching arm|For the health coaching arm, an unlicensed, trained health coach called patients three times to identify and resolve barriers to adherence, including lack of understanding of their condition or the treatment, discomfort in acclimating to treatment, technical difficulties in mask fit or device settings, and challenges in navigating durable medical equipment providers.
61989588|NCT04067128|NO_INTERVENTION|Usual care arm|Patients assigned to usual care had access to all other available resources, including technical support from durable medical equipment providers, respiratory therapist visits with the Sleep Clinic, group visits, or visits with their primary care provider.
62385075|NCT04597424|EXPERIMENTAL|doxycycline|-doxycycline will be taken by participants as PEP (prophylaxy post exposition)
62385076|NCT04597424|EXPERIMENTAL|Bexsero® vaccine|-Meningococcal B vaccine (Bexsero®) at D0 and M2
62385077|NCT04597424|NO_INTERVENTION|No treatment|-no doxycycline and no Bexsero® vaccine
62558862|NCT04045769|EXPERIMENTAL|Study Treatment 1|Saroglitazar magnesium 4 mg
61989589|NCT05387317|EXPERIMENTAL|Pfizer-BioNTech Standard dose after CoronaVac priming|"Pfizer-BioNTech (BNT162b2, or Comirnaty®) Dose: 30ug in 0.3ml~The 50 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
61989590|NCT05387317|EXPERIMENTAL|Pfizer-BioNTech Fractional dose after CoronaVac priming|"Pfizer-BioNTech (BNT162b2, or Comirnaty®) Dose: 15ug in 0.15ml~The 50 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
61989591|NCT05387317|EXPERIMENTAL|AstraZeneca Standard dose after CoronaVac priming|"AstraZeneca (ChAdOx1-S, Vaxzevria®). Dose: 0.5ml~The 50 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
62385078|NCT02833727||Asthmatic smokers (AS)|"Asthmatics will fulfill the following definition of asthma: reversible airflow obstruction and/or a provocative concentration of methacholine inducing a 20% fall in FEV1 (PC20) \< 8 mg/ml with a diagnosis of asthma made by a respirologist.~Smokers or ex smokers will be defined by a smoking history of ≥ 10 pack/year."
62558863|NCT04045769|EXPERIMENTAL|Study treatment 2|Saroglitazar magnesium 20 mg
62558864|NCT04045769|PLACEBO_COMPARATOR|Placebo|Placebo
62558865|NCT04045769|ACTIVE_COMPARATOR|Active Control|Moxifloxacin 400 mg
62558866|NCT01280643|EXPERIMENTAL|Arm A|Patients receive FOLFIRI (FOLolinic acid (leucovorin) Fluorouracil (5-FU) IRInotecan (irinotecan)) chemotherapy comprising fluorouracil intravenously (IV) over 46 hours continuously, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
62385079|NCT02833727||Asthmatic non-smokers (ANS)|"Asthmatics will fulfill the following definition of asthma: reversible airflow obstruction and/or a PC20 \< 8 mg/ml with a diagnosis of asthma made by a respirologist.~Never smokers will have a life-long history without smoking."
62385080|NCT01643889|EXPERIMENTAL|Sequence group ADBC|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
62385081|NCT01643889|EXPERIMENTAL|Sequence group BACD|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
62385082|NCT01643889|EXPERIMENTAL|Sequence group CBDA|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
62385083|NCT01643889|EXPERIMENTAL|Sequence group DCAB|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
62385084|NCT05807815|NO_INTERVENTION|Control group|Patients with oxygen saturation \> 97% will only be observed. ORi values will be recorded blindly from the clinician. Adjustments to be made in FiO2 will be determined by the intensive care doctor independently of the study, and only observation will be made in this group.
62385085|NCT05807815|ACTIVE_COMPARATOR|ORi+SpO2 (oxygen saturation) group|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation≤%98
62385086|NCT00997906|EXPERIMENTAL|Arm I|Patients receive cisplatin IV over 2 hours once weekly on weeks 1-8 and undergo intensity-modulated radiotherapy once daily, 5 days a week, on weeks 1-7 (6½ weeks for a total of 33 fractions).
62385087|NCT00997906|EXPERIMENTAL|Arm II|Patients receive induction chemotherapy comprising gemcitabine hydrochloride IV over 30 minutes, carboplatin IV over 1 hour, and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning at least 3 weeks after the last dose of induction chemotherapy, patients receive cisplatin and undergo radiotherapy as in arm I.
62385088|NCT02976194|EXPERIMENTAL|pro-re-nata|Ranibizumab 0.5mg is injected in to the vitreous cavity. An injection is given every 4 weeks three times, and then the patient will be followed up every 4 weeks. An addition injection is given as needed. Recurrence is defined as increase of exudative changes, or increase of 10% or more in central subfield macular thickness (CSMT) measured using optical coherence tomography. Aqueous humor is sampled from the anterior chamber before injection at baseline, 8 weeks and 20 weeks.
62385089|NCT02908841|OTHER|Control|30 patients randomized to the control group and will receive standard of care. Control patients will be managed with direct compression with gauze pads or laparotomy pads for four minutes. If hemostasis is not achieved by compression after four minutes, the source and rate of bleeding will be reevaluated and management will be determined by the surgeon. If the surgeon uses SurgicelSnow to achieve hemostasis at some point after 4 minutes, the patient will be included in the control group, but the data will be and flagged for the analysis. If failure of hemostasis at 4 minutes with an estimated loss of ≥25 cc/min, patient will be managed as per judgment of surgeon. Persistent bleeding at the 10 minute observation point will be treated as per the surgeon's judgment.
62385090|NCT02908841|OTHER|Treatment|"30 patients randomized to the treatment group will receive Surgicel Snow. For patients with qualifying bleeding (rated on initial evaluation as at least mild) who have been randomized to receive Surgicel Snow, a single thin layer of dry Surgicel Snow will be applied over the area of bleeding and positioned firmly in direct contact to the areas of bleeding with blunt surgical instruments. Surgicel Snow will be left in the cavity to be absorbed. Dry gauze will not be placed over the material. No adjuncts will be added to the enhance hemostasis, but patients with small arteriolar bleeding will have pressure maintained on the bleeding site for 60 seconds. Hemostatic failure at 4 minutes will be reassessed for rate of blood loss and if the rate of loss is estimated at less than 25 cc per minute, additional observations will be made at 7 and 10 minutes."
62385091|NCT01684085|PLACEBO_COMPARATOR|Encouragement to sleep|Encouraging explanation to sleep, rest and receiving Lorazepam 1mg in the first night post trauma
62558867|NCT01280643|EXPERIMENTAL|Arm B|Patients receive FOLFOX (FOL- Folinic acid (leucovorin) F - Fluorouracil (5-FU) OX - Oxaliplatin (Eloxatin)) chemotherapy comprising fluorouracil IV over 46 hours continuously on day 1 and leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
62558868|NCT01280643|EXPERIMENTAL|Arm C|Patients receive FOLFIRI chemotherapy as in Arm A and bevacizumab IV over 30-90 minutes on days 1 and 15.
62558869|NCT01280643|EXPERIMENTAL|Arm D|Patients receive FOLFOX chemotherapy as in Arm B and bevacizumab IV over 30-90 minutes on days 1 and 15.
62558870|NCT01280643|EXPERIMENTAL|Arm E|Patients receive CapeIRI (Capecitabine and Irinotecan) chemotherapy comprising capecitabine orally (PO) twice daily (BID) on days 1-14 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
62766798|NCT00862914||1|benign melanocytic naevi
62766799|NCT00862914||2|dysplastic melanocytic naevi
62766800|NCT00862914||3|cutaneous malignant melanoma
62766801|NCT05644093|EXPERIMENTAL|Psychedelic Experienced IM then IV crossover|Participants will be dosed with IM SPL026 then IV SPL026 2-3 weeks later.
62766802|NCT05644093|EXPERIMENTAL|Psychedelic Naive IM dosing only|Participants will be dosed with IM SPL026 one time.
62766803|NCT01981889|OTHER|Prednisone|Participants who are started on Prednisone 40 mg per day for 2 weeks and then tapered.
62766804|NCT05140551|EXPERIMENTAL|COMPASS|This is a single arm study. We are investigating COMPASS digital CBT.
62766805|NCT02046070|EXPERIMENTAL|Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (NDMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until progressive disease (PD)/death or unacceptable toxicity \[13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months\] and cyclophosphamide (CYC) 300 mg/m\^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients \>75 years) of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity in participants with NDMM.
61989592|NCT05387317|EXPERIMENTAL|AstraZeneca Fractional dose after CoronaVac priming|"AstraZeneca (ChAdOx1-S, Vaxzevria®). Dose: 0.25ml~The 50 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
61989593|NCT05387317|EXPERIMENTAL|Moderna Standard Dose after CoronaVac priming|"Moderna (mRNA-1273 or Spikevax®) Dose: 50ug in 0.25ml~The 100 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
62385092|NCT01684085|EXPERIMENTAL|Encouragement to deprived sleep|Encouraging explanation to deprived sleep in the first night post trauma
61989594|NCT05387317|EXPERIMENTAL|Moderna Fractional Dose after CoronaVac priming|"Moderna (mRNA-1273 or Spikevax®) Dose: 20ug in 0.1ml~The 100 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
61989595|NCT05387317|EXPERIMENTAL|Pfizer-BioNTech Standard dose after AstraZeneca priming|"Pfizer-BioNTech (BNT162b2, or Comirnaty®) Dose: 30ug in 0.3ml~The 50 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
61989596|NCT05387317|EXPERIMENTAL|Pfizer-BioNTech Fractional dose after AstraZeneca priming|"Pfizer-BioNTech (BNT162b2, or Comirnaty®) Dose: 15ug in 0.15ml~The 50 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
61989597|NCT05387317|EXPERIMENTAL|AstraZeneca Standard dose after AstraZeneca priming|"AstraZeneca (ChAdOx1-S, Vaxzevria®). Dose: 0.5ml~The 50 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
61989598|NCT05387317|EXPERIMENTAL|AstraZeneca Fractional dose after AstraZeneca priming|"AstraZeneca (ChAdOx1-S, Vaxzevria®). Dose: 0.25ml~The 50 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
61989599|NCT05387317|EXPERIMENTAL|Moderna Standard Dose after AstraZeneca priming|"Moderna (mRNA-1273 or Spikevax®) Dose: 50ug in 0.25ml~The 100 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
62385093|NCT05895422|EXPERIMENTAL|vascular hitch|displacement of the lower polar crossing vessels causing the UPJO
61989600|NCT05387317|EXPERIMENTAL|Moderna Fractional Dose afterAstraZeneca priming|"Moderna (mRNA-1273 or Spikevax®) Dose: 20ug in 0.1~The 100 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
61989601|NCT04749953|ACTIVE_COMPARATOR|Autogenous bone graft alone|Maxillary sinus floor augmentation with particulated autogenous bone graft alone from the zygomatic buttress area and simultaneously implant placement
61989602|NCT04749953|EXPERIMENTAL|Mixture of 50% autogenous bone graft and 50% Symbios biphasic biomaterial|Maxillary sinus floor augmentation with a mixture of 50% particulated autogenous bone graft from the zygomatic buttress area and 50% Symbios biphasic bone graft material (Biomaterial, 1.0 mm to 2.0 mm) with simultaneously implant placementand
62385094|NCT05895422|ACTIVE_COMPARATOR|Dismembered pyeloplasty|classic Anderson-Hynes procedure
62385095|NCT02288416|ACTIVE_COMPARATOR|Group I (standard of care)|Patients receive standard of care following LCS consisting of routine visits and telephone contact with the LCS program nurse practitioner and coordinator.
62385096|NCT02288416|EXPERIMENTAL|Group II (video-based intervention)|Patients undergo a video-based intervention prior to undergoing LCS. Patients watch a 5-minute video that focuses on preparing patients for LCS by providing information on the following: program team and contact information; reason to be screened; screening eligibility; how screening is performed; what to expect on the day of screening; what to expect after screening; what to expect if result is positive; what to expect if result is negative; and risks of screening. Patients also receive an educational handbook. Patients with positive scans (a Lung-RADS 3 or 4) receive additional brochure and nursing support within 1 week after notification of scan results.
62385097|NCT01474993|PLACEBO_COMPARATOR|Placebo|inactive placebo.
62385098|NCT01474993|EXPERIMENTAL|Interventional|sulforaphane-rich Broccoli Sprout Extract.
61989603|NCT04749953|EXPERIMENTAL|Mixture of 50% autogenous bone graft and 50% Symbios xenograft granules|Maxillary sinus floor augmentation with a mixture of 50% particulated autogenous bone graft from the zygomatic buttress area and 50% Symbios xenograft granules (Biomaterial, 1.0 mm to 2.0 mm) with simultaneously implant placement
61989604|NCT04939415|EXPERIMENTAL|modified Qing Fei Pei Du Tang|encapsulated modified Qing Fei Pai Du Tang
61989605|NCT04939415|PLACEBO_COMPARATOR|Placebo|Organic brown rice
61989606|NCT04745403|EXPERIMENTAL|mRNA HBV/TCR T-cells|Escalating regime from 1x10e5 to 5-10x10e6 cells/kg bodyweight (BW) every 2 weeks.
61989607|NCT05048121|EXPERIMENTAL|CLS02021 - Investigational Product arm|Cosmetic cream with proprietary cosmetic ingredient CLS02021.
61989608|NCT05048121|PLACEBO_COMPARATOR|PLC01021 - Placebo Control arm|Cosmetic cream, identical to the studied product but without cosmetic ingredient. Color, texture, scent and the packaging are identical as a IP.
62385099|NCT06031064||Patients with chronic watery diarrhoea and clinical suspicion of MC|
62385100|NCT03115021|EXPERIMENTAL|Active tPCS / Sham tDCS|All subject will receive active tPCS and sham tDCS for 20 minutes simultaneously.
61989609|NCT03402009|EXPERIMENTAL|Experimental|independent meditation using web-based tools, apps, and EEG neurofeedback
61989610|NCT03402009|ACTIVE_COMPARATOR|Active Control|independent meditation using web-based tools and apps
62385101|NCT03115021|EXPERIMENTAL|Sham tPCS / Active tDCS|All subject will receive sham tPCS and active tDCS for 20 minutes simultaneously.
62385102|NCT03115021|EXPERIMENTAL|Sham tPCS / Sham tDCS|All subject will receive sham tPCS and sham tDCS for 20 minutes simultaneously.
62385103|NCT04286724|EXPERIMENTAL|Intervention|
62385104|NCT03175822|EXPERIMENTAL|Visual Arts Training|Visual Arts Training
62385105|NCT03175822|NO_INTERVENTION|Waitlist Control|Waitlist Control
62385106|NCT03347279|EXPERIMENTAL|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
62385107|NCT03347279|PLACEBO_COMPARATOR|Placebo|Placebo: Placebo subcutaneous injection
62385108|NCT02401945|EXPERIMENTAL|DE-120 Monotherapy|DE-120 intravitreal injection given as monotherapy on a PRN basis
62385109|NCT02401945|EXPERIMENTAL|Eylea® and DE-120 Concomitant Therapy|DE-120 intravitreal injection given on a PRN basis after Aflibercept (Eylea®) injection as an induction therapy.
62385110|NCT03943004|EXPERIMENTAL|DFP-14927|DFP-14927: weekly IV infusion, 28 day treatment cycle
62385111|NCT03431467|NO_INTERVENTION|Control|VA-ECMO alone per standard clinical protocol.
61989611|NCT01024049||Asymptomatic LVD|patients over 18 years old with patients with cardiovascular risk (obesity, diabetes, dyslipidemia, arterial hypertension, age, gender, familial history) and asymptomatic left ventricular dysfunction (LVD).
61989612|NCT01024049||healthy controls|individuals over 18 years old free of disease and treatments.
61989613|NCT01024049||patients with cardiovascular risk|patients with cardiovascular risk (obesity, diabetes, dyslipidemia, arterial hypertension, age, gender, familial history)
61989614|NCT01024049||chronic heart failure patients|patient with chronic heart failure
61989615|NCT01024049||acute heart failure patients|acute heart failure patients
61989616|NCT03627819|ACTIVE_COMPARATOR|Plant sterol-enriched margarine|Intake of 20 gram margarine with added plant sterol esters, providing 3 gram plant sterols per day for 1 year
61989617|NCT03627819|ACTIVE_COMPARATOR|Plant stanol-enriched margarine|Intake of 20 gram margarine with added plant stanol esters, 3 gram plant stanols per day for 1 year
61989618|NCT03627819|PLACEBO_COMPARATOR|Control margarine|Intake of 20 gram margarine without any addition, every day for 1 year
61989619|NCT05270655|EXPERIMENTAL|Cognitive-behavioural intervention|Five sessions of cognitive-behavioural intervention will be delivered on a weekly basis.
61989620|NCT05270655|NO_INTERVENTION|Usual care|Participants in the control group will receive the usual psychosocial care provided by the staff nurses. To offer them attention, a research assistant in each hospital will meet them every week for 30 minutes to ask them about treatment adherence and any other concerns. The parents will be invited to attend it if they want to do so. Each participant will be given an appointment slip and reminded with a phone call two days before the next appointment. For participants whose medical appointment is more than a week, the research will contact them via phone.
61989621|NCT06145360|EXPERIMENTAL|Empagliflozin 10mg|Group A: Empagliflozin 10 mg once daily with antidiabetic drugs
61989622|NCT06145360|ACTIVE_COMPARATOR|regimen of Insulin+Metformin+DPP4 inhibitor (DPP4I)|Group B: usual care group \[Insulin+Metformin+DPP4 inhibitor (DPP4I)\] but without Empagliflozin with adjustment of therapy as the standard of care.
61989623|NCT06460064|EXPERIMENTAL|combination of fH1 2 ug and DSP-0546LP 2.5 ug|The study vaccine (fH1 2 ug and DSP-0546LP 2.5 ug) will be administered IM into the deltoid muscle of the non-dominant upper arm whenever possible. Subjects will receive 2 administrations at 3-week intervals.
61989624|NCT06460064|EXPERIMENTAL|combination of fH1 8 ug and DSP-0546LP 2.5 ug|The study vaccine (fH1 8 ug and DSP-0546LP 2.5 ug) will be administered IM into the deltoid muscle of the non-dominant upper arm whenever possible. Subjects will receive 2 administrations at 3-week intervals.
61989625|NCT06460064|EXPERIMENTAL|combination of fH1 2 ug and DSP-0546LP 5 ug|The study vaccine (fH1 2 ug and DSP-0546LP 5 ug) will be administered IM into the deltoid muscle of the non-dominant upper arm whenever possible. Subjects will receive 2 administrations at 3-week intervals.
61989626|NCT06460064|EXPERIMENTAL|combination of fH1 8 ug and DSP-0546LP 5 ug|The study vaccine (fH1 8 ug and DSP-0546LP 5 ug) will be administered IM into the deltoid muscle of the non-dominant upper arm whenever possible. Subjects will receive 2 administrations at 3-week intervals.
61989627|NCT06460064|EXPERIMENTAL|combination of fH1 2 ug and DSP-0546LP 10 ug|The study vaccine (fH1 2 ug and DSP-0546LP 10 ug) will be administered IM into the deltoid muscle of the non-dominant upper arm whenever possible. Subjects will receive 2 administrations at 3-week intervals.
61989628|NCT06460064|EXPERIMENTAL|combination of fH1 8 ug and DSP-0546LP 10 ug|The study vaccine (fH1 8 ug and DSP-0546LP 10 ug) will be administered IM into the deltoid muscle of the non- dominant upper arm whenever possible. Subjects will receive 2 administrations at 3-week intervals.
61989629|NCT06460064|EXPERIMENTAL|fH1 2 ug|The study vaccine (fH1 2 ug) will be administered IM into the deltoid muscle of the non- dominant upper arm whenever possible. Subjects will receive 2 administrations at 3-week intervals.
61989630|NCT06460064|EXPERIMENTAL|fH1 8 ug|The study vaccine (fH1 8 ug) will be administered IM into the deltoid muscle of the non-dominant upper arm whenever possible. Subjects will receive 2 administrations at 3-week intervals.
61989631|NCT06460064|EXPERIMENTAL|DSP-0546LP 2.5 ug|The study vaccine (DSP-0546LP 2.5 ug) will be administered IM into the deltoid muscle of the non-dominant upper arm whenever possible. Subjects will receive 2 administrations at 3-week intervals.
61989632|NCT06460064|EXPERIMENTAL|DSP-0546LP 5 ug|The study vaccine (DSP-0546LP 5 ug) will be administered IM into the deltoid muscle of the non- dominant upper arm whenever possible. Subjects will receive 2 administrations at 3-week intervals.
61989633|NCT06460064|EXPERIMENTAL|DSP-0546LP 10 ug|The study vaccine (DSP-0546LP 10 ug) will be administered IM into the deltoid muscle of the non- dominant upper arm whenever possible. Subjects will receive 2 administrations at 3-week intervals.
61989634|NCT06460064|PLACEBO_COMPARATOR|Placebo|The study vaccine (placebo) will be administered IM into the deltoid muscle of the non- dominant upper arm whenever possible. Subjects will receive 2 administrations at 3-week intervals.
61989635|NCT00492310|EXPERIMENTAL|1|Cognitive-behavioral smoking cessation with yoga
61989636|NCT00492310|ACTIVE_COMPARATOR|2|smoking cessation with twice weekly wellness program
61989637|NCT04230837|EXPERIMENTAL|A: Abutments of 1 mm|Definitive abutments of 1 mm height were located.
61989638|NCT04230837|EXPERIMENTAL|B: Abutments of 3 mm|Definitive abutments of 3 mm height were located.
61989639|NCT03445819|OTHER|Group A: Surgical Treatment|Open reduction and internal fixation (ORIF) of the patellar fracture will be performed using screws, wires, pins, or plate fixation at the discretion of the treating surgeon. The trial is designed in a pragmatic fashion to allow participating surgeons from the multiple participating sites to perform fixation as per the standard of care at their institution. Post-operative care will include standard-of-care antibiotics and deep vein thrombosis (DVT) prophylaxis, both prescribed at the discretion of the attending surgeon.
61989640|NCT03445819|OTHER|Group B: Conservative Treatment|Patients randomized to non-operative treatment will receive identical treatment to the operative group, minus the surgery. Patients will be weight bearing as tolerated immediately in a removable knee immobilizer, with progressive range-of-motion exercises begun at two weeks following randomization
62385112|NCT03431467|EXPERIMENTAL|Experimental|VA-ECMO with early institution of Impella CP LV venting
62385113|NCT03870139|ACTIVE_COMPARATOR|Cerebral stimulation|"Active transcranial direct current stimulation~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the dominant lower limb) and supraorbital cathode (ipsilateral to the dominant lower limb)."
62385114|NCT03870139|EXPERIMENTAL|Combined stimulation 1|"Active peripheral electrical stimulation (PES_sensorial) combined with active transcranial direct current stimulation~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~PES_sensorial: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
62385115|NCT03870139|ACTIVE_COMPARATOR|Peripheral stimulation|"Active peripheral electrical stimulation (PES_motor).~PES: 15 minutes, 30Hz (frequency), 100µs (pulse duration), intensity at motor level."
62385116|NCT03870139|EXPERIMENTAL|Combined stimulation 2|"Active sensorial peripheral electrical stimulation (PES_sensorial) combined with active motor peripheral electrical stimulation (PES_motor)~PES_sensorial: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level~PES_motor: 15 minutes, 30Hz (frequency), 100µs (pulse duration), intensity at motor level."
62385117|NCT02400593|EXPERIMENTAL|Lovingkindness|A six-week formal meditation workshop for 1 hour per week.
62385118|NCT02400593|PLACEBO_COMPARATOR|Mindfulness|A six-week formal meditation workshop for 1 hour per week.
62385119|NCT06332274|EXPERIMENTAL|Arm A. MRD(+) - Tislelizumab treatment|Systemic treatment with tislelizumab monotherapy at the recommended dose of 400 mg administered intravenously every 6 weeks for a maximum of 9 cycles and followed-up as per standard of care (clinical examination plus imaging every 3 months the first year and every 6 months the second year) in addition to ctDNA (circulating tumoral DNA) analysis at M6 and M12.
62385120|NCT06332274|PLACEBO_COMPARATOR|Arm B. MRD(+) - placebo treatment|Control arm for MRD (+) subjects who will be administered with placebo instead of tislelizumab
62385121|NCT06332274|EXPERIMENTAL|Arm C. MRD(-) - De-escalated follow-up|De-escalated follow-up: clinical examination plus imaging every 6 months the first year and yearly the second year) with standard of care in addition to biobanking at M12 for subsequent ctDNA analyses.
62385122|NCT06332274|OTHER|Arm D. MRD(-) - De-escalated follow-up|Control arm for MRD (-) subjects , followed up as per standard of care (clinical examination plus imaging every 3 months the first year and every 6 months the second year) in addition to biobanking at M12 for subsequent ctDNA analyses.
62385123|NCT00145379|EXPERIMENTAL|Metformin|
62385124|NCT00145379|PLACEBO_COMPARATOR|Placebo comparator|
62385125|NCT00779181|EXPERIMENTAL|ADX415 (high dose)|A high dose of ADX415
62385126|NCT00779181|EXPERIMENTAL|ADX415 (mid level dose)|A mid level dose of ADX415
62385127|NCT00779181|EXPERIMENTAL|ADX415 (low dose)|A low dose of ADX415
62385128|NCT00779181|PLACEBO_COMPARATOR|Placebo|
62385129|NCT01833351|EXPERIMENTAL|Phase I, IV Vitamin C Healthy Normals|Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.
62385130|NCT01833351|EXPERIMENTAL|Phase 1 IV Vitamin C- Cancer Patients|Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.
62385131|NCT05166031|ACTIVE_COMPARATOR|bOPV dose|Naïve infants to receive two doses of bOPV at 2 and 3 months of age.
62385132|NCT05166031|ACTIVE_COMPARATOR|nOPV2 dose|Naïve infants to receive two doses of nOPV2 at 2 and 3 months of age.
62385133|NCT05166031|EXPERIMENTAL|bOPV + nOPV2 dose|Naïve infants to receive two doses of nOPV2 and bOPV at 2 and 3 months of age.
62385134|NCT05116904|OTHER|Children with Smith Magenis Syndrome|
62385135|NCT05116904|OTHER|Children with Autism Spectrum Disorders|
62385136|NCT01680835|EXPERIMENTAL|Study cohort|All patients enrolled in this study will be treated with the EverFlex™ Self-Expanding Peripheral Stent System.
62385137|NCT00095836|EXPERIMENTAL|Gefitinib 250mg|
62385138|NCT04874129|OTHER|A Group|Two-way Crossover
62385139|NCT04874129|OTHER|B Group|Two-way Crossover
62385140|NCT04098172|EXPERIMENTAL|Pressure Guidewire test subject|Stable patients with suspected or known CAD, who are scheduled for diagnostic angiography and pressure wire assessment, and signed the informed consent, will be screened for enrollment in this study.
62385141|NCT04205188|EXPERIMENTAL|exercises and verbal information|therapeutic exercises 3 days in a week and total 8 weeks and 60 minutes verbal information
62385142|NCT04205188|NO_INTERVENTION|verbal information|60 minutes information about effects of exercises on joint functions
62385143|NCT03925493|NO_INTERVENTION|Control Group Procedures (RPE based exercise)|Patients in the control group will follow standard exercise prescription protocols in CR. Exercise intensity will be guided by the patient's reported rating of perceived exertion (RPE). The modified Borg scale will be used by the patients to determine their RPE. Therefore, a scale of 1-10 will be used. The general goal will be to exercise between intensity level 3 or 4 (i.e. moderate intensity), per current program standards. Based on exercise levels achieved on the first day, patients will be given exercise recommendations for their 2nd session of CR and so forth. As the patients progress in CR, patients will increase their time, intensity, and mode of exercise as appropriate. Exercise progression will be guided by RPE and clinical assessment.
62385144|NCT03925493|EXPERIMENTAL|Exercise Test and Heart Rate Range|Patients randomly assigned to this group will complete a graded exercise test (GXT) per standard protocols. The researchers will obtain the patients peak heart rate from this stress test. Obtaining an accurate peak heart rate will allow for the calculation of a target heart rate range (THRR) using the Karvonen formula. Based upon the Karvonen formula, the THRR will be between 60-80% of the patient's heart rate reserve. The Karvonen formula can be calculated as follows ((peak heart rate - resting heart rate) X % intensity (0.6 or 0.8) + resting heart rate)). An example would be: (155 -75) X (.6) + 75) = 123; ((155 - 75) X (.8) + 75 = 139) THRR: 123 - 139. Patients will then adjust their exercise intensity to match this target heart rate range for the duration of their time in cardiac rehabilitation. Cardiac rehabilitation staff will provide feedback about heart rate when they are able.
62385145|NCT03925493|EXPERIMENTAL|Exercise Test, Heart Rate Range, and Heart Rate Monitor|"Patients randomly assigned to this group will also undergo a stress test (GXT) and exercise within a target heart rate range (THRR) during cardiac rehabilitation comparable to second arm of the trial. Additionally, they will receive a personal heart rate monitor (HRM). This monitor will consist of a polar heart rate chest strap and polar watch. Patients will be asked to wear this during cardiac rehabilitation and adjust their own exercise intensity. This will provide continuous feedback to the patient about their heart rate. Cardiac rehabilitation staff will also provide feedback when available.~The investigators are using the heart rate monitors because cardiac rehab staff are not always able to adjust exercise intensity for all patients, and telemetry is not always used."
62168265|NCT01536535|EXPERIMENTAL|Mild UC|"Mild = Initiated on mesalazine, or on oral CS with Pediatric Ulcerative Colitis Activity Index (PUCAI) \< 45~Patients can be treated with any of the therapies noted below:~Mesalazine: doses is rounded to the nearest 500mg increment, maximum dose of 75 mg/kg/day Oral corticosteroids:1-1.5 mg/kg/day, rounded up to the nearest 5 mg value~IV corticosteroids:~Additional Therapies:~Calcineurin inhibitor (cyclosporine, tacrolimus) or anti-Tumour Necrosis Factor alpha (TNFα) therapy: These therapies may also be instituted if in the judgment of the attending physician is needed.~Immunomodulator or biologic therapy: thiopurine then dosing of azathioprine:2.5-3 mg/kg/day; 6-MP at 1-1.5 mg/kg/day Colectomy"
62385146|NCT06203028|EXPERIMENTAL|Experimental Group|The 'Cyberbullying Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours.
62385147|NCT06203028|NO_INTERVENTION|Control Group|The Cyberbullying Awareness Training program will not be applied to students in the control group.
62385148|NCT05290935|EXPERIMENTAL|Study group|The patients in the study group would accept the treatment of a combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel.
62385149|NCT01634867||Intraosseous (IO) drug delivery|patients in whom intraosseous (IO) vascular access has been established for rapid sequence intubation drug delivery.
62385150|NCT01634867||Peripheral intravenous (IV) drug delivery|patients in whom peripheral intravenous (IV) vascular access has been established for rapid sequence intubation drug delivery.
62766806|NCT02046070|EXPERIMENTAL|Ixazomib 4.0 mg + CYC 400 mg/m^2 + DEX 40 mg (NDMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until PD/death or unacceptable toxicity \[13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months\] and cyclophosphamide (CYC) 400 mg/m\^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients \>75 years) of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity in participants with NDMM.
62385151|NCT01070654|EXPERIMENTAL|40/30 Recruitment Manoeuvre|Patients with respiratory failure that will be first ventilated for 30 minutes according to standardized baseline protective ventilation and after that will receive the recruitment manoeuvre
62385152|NCT04057313|ACTIVE_COMPARATOR|Group 1|Group 1 will receive 80 cc of coffee in the dialysis session
62385153|NCT04057313|PLACEBO_COMPARATOR|Group 2|Group 2 will receive 80 cc of decaffeinated coffee in the dialysis session
62385154|NCT05529030|NO_INTERVENTION|Standard question|Question with no additional text or framing
62558871|NCT01280643|EXPERIMENTAL|Arm F|Patients receive CapeOX (capecitabine (Xeloda) and oxaliplatin (Eloxatin)) chemotherapy comprising capecitabine PO BID on days 1-14 and oxaliplatin IV over 2 hours on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
62558872|NCT01280643|EXPERIMENTAL|ARM G|Patients receive CapeIRI chemotherapy as in Arm E and bevacizumab IV over 30-90 minutes on day 1.
62558873|NCT01280643|EXPERIMENTAL|Arm H|Patients receive CapeOX chemotherapy as in Arm F and bevacizumab IV over 30-90 minutes on day 1.
62766807|NCT02046070|EXPERIMENTAL|Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (RRMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle and cyclophosphamide 300 mg/m\^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients \>75 years) of a 28-day cycle until PD/death or unacceptable toxicity in participants with RRMM.
62385155|NCT05529030|EXPERIMENTAL|Question with salient Omicron message|Question indicates that the bivalent booster can protect the respondent from the Omicron variant
62385156|NCT05529030|EXPERIMENTAL|Question with patient protection message|Question indicates that the bivalent booster can protect patients (only presented to patient-facing employees)
62385157|NCT05529030|EXPERIMENTAL|Question with salient Omicron and patient protection message|Question indicates that the bivalent booster can protect patients from the Omicron variant (only presented to patient-facing employees)
62385158|NCT00730665|EXPERIMENTAL|100ug|
62385159|NCT00730665|EXPERIMENTAL|300ug|
62385160|NCT00730665|EXPERIMENTAL|1mg|
62558874|NCT01280643|EXPERIMENTAL|Arm I|Patients receive treatment as in Arm D.
62558875|NCT06313710|NO_INTERVENTION|control|
62766808|NCT01747252|EXPERIMENTAL|RGC1|RGC containing the equivalent of 50 mg resveratrol
62766809|NCT01747252|ACTIVE_COMPARATOR|Resveratrol|The equivalent of 150 mg resveratrol
62766810|NCT01747252|EXPERIMENTAL|RGC2|RGC containing the equivalent of 150 mg resveratrol
62766811|NCT06103487||RGX-111 Recipients|Subjects who have received RGX-111 in a separate parent study.
62385161|NCT00730665|EXPERIMENTAL|3mg|
62385162|NCT00730665|PLACEBO_COMPARATOR|Placebo|
62385163|NCT03268395|OTHER|CO2 Measurement|Each subject will received simultaneous arterial blood gas CO2 and transcutaneous CO2 monitor assessments. The correlation of these two measurements will be compared.
62385164|NCT06133790||HPV + Group|Patients with positive HPV diagnosis
62385165|NCT06133790||HPV - Group|Patients with negative HPV diagnosis
62385166|NCT02764931|EXPERIMENTAL|Oat meal 1|A single gluten-free oat containing meal number 1 before ingesting the SmartPill capsule. Dietary intervention. Gluten free oats and gastrointestinal health
62385167|NCT02764931|PLACEBO_COMPARATOR|Placebo meal|A single meal which does not contain oats before ingesting the SmartPill capsule. Dietary intervention: gluten-free oats and gastrointestinal health.
62558876|NCT06313710|EXPERIMENTAL|low dose of head down position|-10° Trendelenburg for 30 min
62558877|NCT06313710|EXPERIMENTAL|high dose of head down position|-10° Trendelenburg for 60 min
62558878|NCT06531837|SHAM_COMPARATOR|Patients without pain|
62558879|NCT06531837|EXPERIMENTAL|Patients with chronic pain treated with esketamine|
62558880|NCT06531837|EXPERIMENTAL|Patients with chronic pain treated with remifentanil|
62558881|NCT06531837|EXPERIMENTAL|Patients with chronic pain treated with flurbiprofen|
62558882|NCT04540991|ACTIVE_COMPARATOR|Ankylos dental implant group|Patients are divided into two groups depending on the dental implant system used in the therapy. Ankylos dental implants (Dentsplay Sirona, Charlotte, USA) areused in the first group of patients.
62558883|NCT04540991|ACTIVE_COMPARATOR|Dentium SuperLine implant group|Patients are divided into two groups depending on the dental implant system used in the therapy. Dentium SuperLine implants (Dentium Co., Seoul, Korea) is used in the second group of patients-.
61989641|NCT02098109|EXPERIMENTAL|XM02 Filgrastim (Granix) and Plerixafor|"* XM02 Filgrastim (Granix) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)~* Plerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)~* Apheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)~* Patients who undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be followed through Day +100 post-infusion (+/- 30 days) to assess for transplant outcomes (neutrophil and platelet engraftment, and readmission rate). Patients who successfully mobilize \> 2.0 x 10\^6 CD34+ cells/kg but do not undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be discontinued from follow-up."
62385168|NCT02764931|EXPERIMENTAL|Oat meal 2|A single gluten-free oat containing meal number 2 before ingesting the SmartPill capsule. Dietary intervention. Gluten free oats and gastrointestinal health
62385169|NCT03364114|EXPERIMENTAL|EndoRotor Resection|For the purpose of this study the EndoRotor System is investigationally indicated for use during endoscopic procedures to resect and remove refractory Barrett's esophagus tissue in conjunction with a submucosal saline injection mix using adrenaline and dye. Subjects randomized to the EndoRotor arm will be treated up to 3 times through the 9 month follow-up period to remove gross visible Barrett's.
62385170|NCT03364114|ACTIVE_COMPARATOR|Continued Ablation (Control)|The investigator shall exercise standard of care for subjects undergoing continued ablative therapies (RFA and/or Cryotherapy). These will constitute the control devices. The investigator will choose the system in this arm. Operation of each system will be done according to the manufacturer's IFU. Subjects randomized to the control arm may be treated up to 3 time through the 9 month follow-up period to remove gross visible Barrett's.
62385171|NCT05521542|EXPERIMENTAL|SirPlux™ Duo Dual-API Coated PTCA Balloon Catheter|Subjects who meet the inclusion criteria and agree to participate in the study will be enrolled and undergo a planned percutaneous coronary intervention with SirPlux™.
62385172|NCT00736385|ACTIVE_COMPARATOR|Metformin|Metformin XR (extended-release) 2000 mg daily
62385173|NCT00736385|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62385174|NCT03663361|EXPERIMENTAL|SMART Intervention|"The SMART intervention will utilize the elements of the Standard of Care intervention, and will also include Sensorimotor Improvements and other specific additions that will focus on sensory inputs, motor outputs, and integration of the sensory and motor pathways."
62385175|NCT03663361|ACTIVE_COMPARATOR|Standard of Care Intervention|The Standard of Care intervention will include restoration of ankle joint range of motion, strength and functional movement.
62385176|NCT04045314|EXPERIMENTAL|Before-and-after|54 Healthy adults 18 years of age or older at the visit or will receive the first application and will be evaluated according to the objectives defined in the study (short-term data) and to evaluate the long-term effects, two other visits will be made at intervals of 2 weeks to evaluate the impact of topical skin application according to the parameters defined in the study.
62385177|NCT05474885|EXPERIMENTAL|BCMA-CD19 cCAR T cells|Dose escalation phase: patient's T cells will be transduced with a lentiviral vector to express a BCMA-CD19 cCAR. with an escalation approach.
62385178|NCT00847249|EXPERIMENTAL|1|Solution for nebulisation, inhaled
62385179|NCT00847249|PLACEBO_COMPARATOR|2|Solution for nebulisation, inhaled
62385180|NCT01146691||Standard staffing model|All patients in participating ICUs during the blocks of time when a single intensivist staffs a participating ICU for a 7 day period. The intensivist will be present during daytime hours, and takes call from home afterwards.
62385181|NCT01146691||24-7 shiftwork staffing model|All patients in participating ICUs during the blocks of time when the 24-7 in-hospital intensivist coverage model is in place. This model is enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am. Call rooms will be provided to allow the night shift intensivist to sleep, if the workload permits.
62385182|NCT05458674|EXPERIMENTAL|Tucatinib/Eribulin/Trastuzumab|"* The initial dose of trastuzumab will be given as a loading dose of 8 mg/kg intravenously (IV), unless trastuzumab was administered within the prior 4 weeks, then the initial dose of trastuzumab will be administered at a dose of 6 mg/kg. Each trastuzumab dose is given once every 21 days, except in specific circumstances where it may be given weekly to compensate for modifications in treatment schedule~* Tucatinib 300 mg orally twice daily (PO BID) every day (Days 1-21) of each 21-day cycle using a modified schedule of events. Subcutaneous trastuzumab is given only once every three weeks as there is no allowance for weekly dosing.~* Eribulin will be given at a dose of 1.4 mg/M2 intravenously over a 2-5 minute period on days 1 and 8 of each 21-day cycle."
62385183|NCT02876315|EXPERIMENTAL|Redoxon VI|2 film coated tablets Redoxon VI oral intake daily for 12 weeks
62385184|NCT02876315|PLACEBO_COMPARATOR|Placebo|2 film coated tablets placebo oral intake daily for 12 weeks
62385185|NCT02893332|ACTIVE_COMPARATOR|TKI without SBRT|"Newly diagnosed Patients will be placed on EGFR-TKI, ,Gefitinib 250mg po qd or Tarceva 150mg po qd for their metastatic EGFR-mutant stage IV oligometastatic disease.~The oligometastatic disease will not receive SBRT"
62385186|NCT02893332|EXPERIMENTAL|TKI with SBRT|"experimental: Oligometastatic Non-Small Cell Lung Cancer Newly diagnosed patients will be placed on EGFR-TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, and SBRT at the same time.~SBRT to up to 5 sites. The SBRT dose range from 5 Gy per fraction to 8 Gy per fraction. SBRT deliver within 5 fractions."
62385187|NCT01882036|ACTIVE_COMPARATOR|Gastric Bypass w/ matched hypocaloric diet|
62385188|NCT01882036|ACTIVE_COMPARATOR|Hypocaloric Diet|
62385189|NCT04488406||Graves' Orbitopathy|Graves' Orbitopathy patients who undergoing orbital decompressive surgery
62385190|NCT04488406||Control Patients|Patients undergoing eye surgery for unrelated reasons
62385191|NCT02200510|OTHER|Self-Management Group|Self-management intervention for Adolescents with SCD - 6 week self-management group
62385192|NCT02200510|OTHER|Patient Portal|Patient Portal Intervention for Adolescents with SCD - 6 week individual patient portal intervention
62558884|NCT04688671|EXPERIMENTAL|ETX-018810|1000 mg BID for 4 weeks
62385193|NCT03233308|EXPERIMENTAL|Netarsudil Ophthalmic Solution 0.02%|Netarsudil Ophthalmic Solution 0.02% was administered in one eye and Placebo comparator in contralateral eye
62385194|NCT03233308|PLACEBO_COMPARATOR|Placebo Comparator|Placebo comparator administered in one eye and Netarsudil Ophthalmic Solution 0.02% in contralateral eye
62385195|NCT00809627|EXPERIMENTAL|1|IV caffeine with saline and opiate
62385196|NCT00809627|PLACEBO_COMPARATOR|2|IV saline with opiate
62385197|NCT02292615||cervical cancer|Group 1: Patients with newly diagnosed gynecologic cancers (including cervical, endometrial, and ovarian cancers).
62385198|NCT02292615||endometrial cancer|Group 2: Patients with suspicious recurrent gynecologic cancers (including cervical, endometrial, and ovarian cancers).
62385199|NCT02292615||ovarian cancer|Group 3: Patients with ovarian cancer who had debulking surgery and are going to receive adjuvant chemotherapy.
62385200|NCT01512849|EXPERIMENTAL|TA-7284 Low|
62766812|NCT04108728|EXPERIMENTAL|HIV exposed children during pregnancy|children born from HIV-infected mother, exposed to antiretroviral drugs during pregnancy and in the neonatal period; aged 3 years-old +/- 3 months on the date of inclusion. Parents mastering french language
61989642|NCT02098109|ACTIVE_COMPARATOR|Filgrastim (Neupogen) and Plerixafor|"* Filgrastim (Neupogen) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)~* Plerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)~* Apheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)~* Patients who undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be followed through Day +100 post-infusion (+/- 30 days) to assess for transplant outcomes (neutrophil and platelet engraftment, and readmission rate). Patients who successfully mobilize \> 2.0 x 10\^6 CD34+ cells/kg but do not undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be discontinued from follow-up."
62385201|NCT01512849|EXPERIMENTAL|TA-7284 High|
62385202|NCT01875731|EXPERIMENTAL|BPS (Bacterial Pneumonia Score)|Strategy based on BPS guided antibiotic use
62385203|NCT01875731|ACTIVE_COMPARATOR|Guideline|Strategy based on enforced guideline guided antibiotic use
62385204|NCT03435289|OTHER|CPI-613, Gemcitabine and Nab-paclitaxel|CPI-613 in Combination With Gemcitabine 1000mg/m2 iv and Nab-paclitaxel 125mg/m2 iv
62385205|NCT03730870|EXPERIMENTAL|Pharmacogenomics report|Clinician reviews pharmacogenomics report for subject prior to prescribing FDA-approved medications.
62385206|NCT03730870|NO_INTERVENTION|Control|"Clinician prescribes FDA-approved medications as customarily performed without additional guidance from pharmacogenomics report (treatment-as-usual)."
62766813|NCT04108728|OTHER|control children|children, aged 3 years +/- 3 months on the date of inclusion, from the same socio-economic and cultural environment, not infected or affected by HIV. Parents mastering French language.
62766814|NCT02340390|EXPERIMENTAL|Hip implant1|The Biomet G7 Acetabular System is a modular acetabular system, offering two types of acetabular shells. The shells are available in either a solid shell design, with an apical plug, or a limited hole with an apical plug and optional screw holes. Components are available in numerous designs and sizes intended for both primary and/or revision applications.
62766815|NCT02340390|EXPERIMENTAL|Hip implant2|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
62766816|NCT01260025|EXPERIMENTAL|PEDylated Recombinant Human Endostatin|PEDylated Recombinant Human Endostatin
62766817|NCT04897607|ACTIVE_COMPARATOR|Treatment Plan Option 1 (Standard Care)|Standard smoking cessation counseling will be offered + participant choice of nicotine patches or varenicline. Participants are also free to decline either medication.
62766818|NCT04897607|EXPERIMENTAL|Treatment Plan Option 2 (Precision Pharmacotherapy)|Standard smoking cessation counseling will be offered + a recommendation to take either the nicotine patch or varenicline based on the results of the NMR test. Regardless of the recommendation, it would still remain the participant's choice to be prescribed either nicotine patches or varenicline. Participants are also free to decline either medication.
62766819|NCT04507165|EXPERIMENTAL|opioid-free general anesthesia|under opioid-free general anesthesia
61989643|NCT04758377|EXPERIMENTAL|Arm 1|Serial MRI scans of patients with acute cervical SCI to quantify hemorrhage.
62385207|NCT00600665|ACTIVE_COMPARATOR|Usual Care|In Part 1 of the study, participants will access PAINReportIt and computer games. PAINReportIt helps the patient describe the pain experienced. In Part 2 of the study, participants will continue to access PAINReportIt when they are seen in the clinic, emergency department (ED), acute care center (ACCA), and hospital. They will gain access to the PAINUCope computer-based programs, which provides multimedia education tailored to the patient's misconceptions about pain management. They will receive medial usual care at the outpatient clinic, ED, ACC, and hospital.
62385208|NCT00600665|EXPERIMENTAL|PAINUCope/PAINConsultN|In Part 1 of the study, participants will access PAINReportIt and PAINUCope computer-based programs. PAINReportIt helps the patients describe the pain experiences and PAINUCope provides multimedia education tailored to the patient's misconceptions about pain management. In Part 2 of the study, participants will continue to access PAINReportIt and PAINUCope programs when they are seen in the clinic, emergency department (ED), acute care center (ACC), and hospital. Their doctors will have access to PAINConsultN when seen at the ED, ACC, and hospital. PAINConsultN is just-in-time decision support for the physicians with the pain data summarized and suggestions for analgesics that may be useful to help manage the patient's pain.
62385209|NCT00382382|OTHER|Children with Autism|A diffusion tensor imaging (DTI) will be done to examine the integrity of the white matter pathways in high functioning austistic children.
62385210|NCT00382382|OTHER|Healthy Volunteers|A diffusion tensor imaging (DTI) will be done to examine the integrity of the white matter pathways in healthy volunteers.
62558885|NCT04688671|PLACEBO_COMPARATOR|Placebo|matching placebo BID for 4 weeks
62558886|NCT02812524|EXPERIMENTAL|Intratumoral Ipilimumab|Patients receive a 3mg intratumoral injection of ipilimumab during a biopsy procedure.
62766820|NCT04507165|ACTIVE_COMPARATOR|opioid based general anesthesia|under opioid based general anesthesia
62385211|NCT02650804|EXPERIMENTAL|BPM31510 plus gemcitabine|"BPM31510 Nanosuspension Injection (40 mg/mL) will be administered IV over 144 hours at the starting dose of 110 mg/kg. Each patient will receive 2 consecutive 72-hour infusions per week (Tuesday-Friday and Friday-Monday). The patient will be subsequently treated with gemcitabine IV once weekly at a starting dose of 1000 mg/m2.~Cycle 1 of combination therapy is 6 weeks in duration for patients with BPM31510 administered twice weekly on Tuesdays and Fridays for 6 weeks and gemcitabine administered on Mondays, Days 21, 28 and 35. Cycles 2-12 are 4 weeks in duration with BPM31510 administered twice weekly on Tuesdays and Fridays for 4 weeks and gemcitabine administered on Mondays, Days 7, 14 and 21."
62385212|NCT05703789|EXPERIMENTAL|Oral rehabilitation|Name Oral rehabilitation. Patients receiving dental treatment will be allocated to one of two different treatment groups based on individual treatment need and proven experience. Patients in group 1 will be treated with minimal invasive treatment, with restorative composite fillings. Patients in group 2 will be treated with prosthetic rehabilitation, dental crowns.
62385213|NCT05703789|OTHER|Waiting list|Name: Waiting list. Patients in waiting list will receive no treatment. After four months they will be offered to be included in the oral rehabilitation arm.
62385214|NCT00005066|EXPERIMENTAL|Arm A|O6-BG as an intravenous infusion (through your vein) over 1 hour followed 1 hour later by BCNU intravenously over 15 minutes. chemotherapy every 6 weeks.
62385215|NCT03365531|EXPERIMENTAL|Alternate Daily Fasting (ADF)|Participants randomized to the ADF group will alternate between a day of ad lib feeding and a day of nearly no energy intake. Participants will be prescribed a core diet for feeding days that meets 110% of their estimated calorie needs within the fixed macronutrient distribution of 50% CHO, 20% PRO, and 30% FAT. In accordance with the ad lib feeding protocol, optional modules of similar macronutrient content will be prescribed, each providing an additional 200 kcals. Meal timing will not be restricted on these days. On fasting days, participants will be asked to consume 16 oz. of G2 Gatorade (40 kcal) in the morning and then only water or non-caloric beverages for the rest of the day.
62385216|NCT03365531|ACTIVE_COMPARATOR|Caloric Restriction|Participants randomized to the CR group will consume a diet of fixed energy designed to yield a 500 kcal/d deficit with a macronutrient distribution of 50% CHO, 20% PRO, and 30% FAT. Meal timing and caloric distribution will not be restricted.
62385217|NCT02987166|EXPERIMENTAL|Arm A: HDCRT administered with first dose of pembrolizumab|"Pembrolizumab (200 mg) plus HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) are both administered beginning on day 1.~Pembrolizumab (200 mg) will be administered on days 1, 43, 64, 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the 4 doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 1."
62385218|NCT02987166|EXPERIMENTAL|Arm B: HDCRT administered between doses 1& 2 of pembrolizumab|"Pembrolizumab (200 mg) begins on day 1. HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) begins on day 22.~Pembrolizumab (200 mg) will be administered on days 1, 43, 64, 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the 4 doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 22."
62385219|NCT02987166|EXPERIMENTAL|Arm C: HDCRT administered prior to first dose of pembrolizumab|"Pembrolizumab (200 mg) begins on day 1. HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) begins on day 1.~Pembrolizumab will be administered on days 22, 43, 64, and 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the four doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 1."
62385220|NCT05976711||Surveillance|20 AAA patients will undergo two MRI scans with a half year interval to assess a possible correlation between MRI derived biomarkers and the clinical standard to assess aneurysm progression (maximum AAA diameter).
62385221|NCT05976711||EVAR planning|10 patients will undergo magnetic resonance angiography next to the standard of CT angiography (CTA). It is investigated whether EVAR planning is feasible based on MRA and if or how measurements between MRA and CTA differ.
62385222|NCT05976711||EVAR follow-up|30 AAA patients who underwent EVAR will be included in three groups: 10 patients with ten complication free years after EVAR or sac regression, 10 patients with endoleak type I and 10 patients with endoleak type II. It is investigated whether MRI can provide extra information for the detection of endoleaks after EVAR.
62385223|NCT01694966|ACTIVE_COMPARATOR|Methylene Blue MMX® 200mg|Oral dose, 8 Methylene Blue MMX® tablets over a 4hr schedule
62385224|NCT01694966|ACTIVE_COMPARATOR|Methylene Blue MMX® 100mg|Oral dose, 4 Methylene Blue MMX® tablets and 4 Placebo tablets over a 4hr schedule
62385225|NCT01694966|PLACEBO_COMPARATOR|Placebo|Oral dose, 8 Placebo tablets over a 4hr schedule
62385226|NCT05284604|EXPERIMENTAL|Group 1|Peripheral IV Infusion of 100 million MSCs at baseline and repeated at three months
62558887|NCT05957601||Women with pelvic floor dysfunction or healthy|All women who met the inclusion criteria, whether pelvic floor dysfunction or healthy, were included. If necessary, grouping can be done during statistics.
62558888|NCT02640482|EXPERIMENTAL|Arm A DB Active Drug|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (double-blind \[DB\] treatment period)
62766821|NCT04311827||Serratus anterior plane block and traditional analgesia|Serratus anterior plane block (Bupivacaine 75mg injected into facial plane once) Acetaminophen 1000mg IV every 6 hours as needed Toradol 15mg IV every 6 hours as needed Morphine 4mg every 2 hours as needed Hydromorphone 0.5mg IV every 2 hours as needed
62766822|NCT04311827||Traditional analgesia|Serratus anterior plane block (Bupivacaine 75mg injected into facial plane once) Acetaminophen 1000mg IV every 6 hours as needed Toradol 15mg IV every 6 hours as needed Morphine 4mg every 2 hours as needed Hydromorphone 0.5mg IV every 2 hours as needed
62385227|NCT05284604|EXPERIMENTAL|Group 2|Peripheral IV Infusion of 100 million MSCs at baseline and peripheral IV infusion of placebo at three months
62385228|NCT05284604|PLACEBO_COMPARATOR|Group 3|Peripheral IV infusion of placebo at baseline and repeated at three months
62385229|NCT01914900|EXPERIMENTAL|induction TPF chemotherapy|Each patient will receive induction CT, consisting of TPF (docetaxel 75 mg/sm and cisplatin 80 mg/sm day 1 and 5 fluorouracil 800 mg/sm each day in continuous infusion day 1-4, according to Paccagnella et al, ASCO 2008) for 3 cycles every 21 days, followed by surgery.
62558889|NCT02640482|EXPERIMENTAL|Arm B DB Placebo|Placebo for ABT-493/ABT-530 QD for 12 weeks (DB treatment period)
62385230|NCT02678702|EXPERIMENTAL|CBT-I|Behavioral intervention: CBT-I
62385231|NCT02678702|ACTIVE_COMPARATOR|Treatment as usual|Intervention: Control group receiving treatment as usual
62385232|NCT03970967|EXPERIMENTAL|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62385233|NCT02405676|OTHER|Risk group 1|Complete resection of stage I or II disease: 3 courses (A-B-A) and 3 intrathecal injections(Cytarabine/Methotrexate/Dexamethasone, age adjusted);
62385234|NCT02405676|OTHER|Risk group2|Not or incompletely resected stage I/II disease and LDH \<2 times NL: 5 courses (A--B--A--B--A) and 8 intrathecal injections;
62385235|NCT02405676|OTHER|Risk group3|Stage III with high LDH \< 4 times NL, or Stage I,II with LDH \>=2 times NL: Preface followed by 6 courses (P(Cyclophosphamide/Vincristine/Prednisone)-A-BB-AA-BB-AA-BB) and 13 intrathecal injections; Dosage of Cytarabine, Methotrexate and Etoposide was increased in AA or BB compared with A or B. Vindelsine was used in AA/BB instead of Vincristine in A/B.
62385236|NCT02405676|OTHER|Risk group4|Stage III with LDH≥4N, or Stage IV, or B-AL: Preface followed by 4 dose of rituximab (375mg/m2) combined 6 courses of chemotherapy, together with 13 intrathecal injections: P-A-(Rituximab)BB-(Rituximab)AA-(Rituximab)BB-(Rituximab)AA-BB; rituximab is at D0 of each course.
62385237|NCT02251574|EXPERIMENTAL|Low Calorie Diet|Participants will take part in an experimental weight management program involving a low calorie diet (LCD), about 1200-1500 calories per day.
62558890|NCT02640482|EXPERIMENTAL|Arm B OL Active Drug|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (open-label \[OL\] treatment period)
62385238|NCT02251574|EXPERIMENTAL|Very Low Calorie Diet|Participants will take part in an experimental weight management program involving a low calorie diet (LCD), about 520-800 calories per day.
62558891|NCT03064204||OSA+CPAP+HIV+|Individuals (40 years or older) diagnosed with OSA and using CPAP, also with HIV treated to viral suppression.
62558892|NCT03064204||OSA+CPAP+HIV-|Individuals (40 years or older) diagnosed with OSA and using CPAP.
62558893|NCT00574002||Group A|Patients that have their chest tube removed when drainage is 400mL or less in 24 hours.
62766823|NCT04810611|EXPERIMENTAL|Arm 1: MBG453 single agent|Treatment with MBG453 single agent Q4W to confirm safety and tolerability of RD.
62385239|NCT02251574|ACTIVE_COMPARATOR|Standard Care|Participants will receive normal care.
62558894|NCT00574002||Group B.|Patients that have their chest tube removed when drainage is 200mL or less in 24 hours.
62766824|NCT04810611|EXPERIMENTAL|Arm 2: NIS793 single agent|Treatment with NIS793 single agent Q3W to establish RD in this indication and confirm safety and tolerability.
62766825|NCT04810611|EXPERIMENTAL|Arm 3: canakinumab single agent|Treatment with single agent canakinumab Q4W to confirm safety and tolerability of RD.
62766826|NCT04810611|EXPERIMENTAL|Arm 4: MBG453 + NIS793 combination|Treatment with combination of MBG453 and NIS793 Q3W to confirm safety and tolerability of combination RD.
62385240|NCT04882839|EXPERIMENTAL|Active participants|Participants undertaking to full therapeutic protocol including psychotherapy sessions and Psilocybin sessions
62385241|NCT01373294|EXPERIMENTAL|A: Combination Arm|"Bacille Calmette-Guerrin (BCG) and lenalidomide.~Participants were assigned to receive BCG or BCG and lenalidomide based on their cancer. This group received BCG + lenalidomide)"
62385242|NCT01373294|ACTIVE_COMPARATOR|B: Control Arm|"Bacille Calmette-Guerrin (BCG) only.~Participants were assigned to receive BCG or BCG and lenalidomide based on their cancer.~This group was not eligible to receive the combination of BCG + lenalidomide."
62385243|NCT04833972|EXPERIMENTAL|Experimental: V1: Binary Response Options|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. Each question in this version of the survey questionnaire has binary (yes/no) response options."
62385244|NCT04833972|EXPERIMENTAL|Experimental: V2: Categorical Response Options|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. Each question in this version of the survey questionnaire has categorical response options: all or almost all; more than half, but fewer than 90%; fewer than half, but more than 10%; very few, or no one"
62558895|NCT01851252|EXPERIMENTAL|Methacetin (for BT) before / after Propanolol treatment.|The methacetin breath test (MBT) will be performed before and after (within 2 hours) injection of Propanolol (BB) dose and once again after 60 days of oral administration of Propanolol.
62558896|NCT04047992|EXPERIMENTAL|Exoskeleton Users|All participants will receive 36 sessions of supervised EAW training using Indego™ for 12 weeks (3 to 4 sessions per week, 4-6 hours per week). The goal is to complete all 36 sessions in 12 weeks, but allowing for a two-week carryover to accommodate schedule conflicts or missed sessions.
62558897|NCT05638464|EXPERIMENTAL|multisite HD-tDCS with EMG-driven robot hand group|The stimulation electrodes are fixed on the ipsilesional sensorimotor cortex according to the brain activation map detected by task based fMRI.
62558898|NCT05638464|SHAM_COMPARATOR|Sham HD-tDCS EMG-driven robot hand group|The stimulator will be applied for 20 minutes with only 30s ramp-up and ramp-down stimulation delivered.
62558899|NCT00578591|EXPERIMENTAL|Patient|Four Rituximab doses administered to patients who have developed SR-aGVHD following allogeneic hematopoietic transplant (AHT)
62766827|NCT04810611|EXPERIMENTAL|Arm 5: MBG453 + canakinumab combination|Treatment with MBG453 + canakinumab combination Q4W to confirm safety and tolerability of combination RD.
62766828|NCT00469326|ACTIVE_COMPARATOR|atorvastatin|atorvastatin pre-treatment group (80mg atorvastatin two days before PCI)
62766829|NCT00469326|NO_INTERVENTION|control|PCI without atorvastatin pretreatment
62766830|NCT03517995|ACTIVE_COMPARATOR|Sulforaphane Plus Surgery|Sulforaphane Administration prior to bladder cancer surgery.
62766831|NCT03517995|PLACEBO_COMPARATOR|Placebo Plus Surgery|Placebo Administration prior to bladder cancer surgery.
62766832|NCT05335902||standard cardiopulmonary bypass|patients 18 year or older undergoing heart surgery with standard cardiopulmonary bypass
62766833|NCT05335902||mini-cardiopulmonary bypass|patients 18 year or older undergoing heart surgery with standard mini-cardiopulmonary bypass
62766834|NCT03323606|ACTIVE_COMPARATOR|Gambling Internet Intervention|The gambling only Internet intervention (G-only) will consist of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
62766835|NCT03323606|EXPERIMENTAL|Gambling Internet Intervention + CYD|The G+A intervention condition will consist of the G-only intervention and an online intervention for drinking. The online drinking intervention chosen is Check Your Drinking, a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
61989644|NCT01184274|EXPERIMENTAL|SB939|
61989645|NCT02807350|EXPERIMENTAL|Overminus Treatment|spectacles with full cycloplegic refraction plus 2.50 D overminus added to the sphere
61989646|NCT02807350|ACTIVE_COMPARATOR|Non-overminus Treatment|spectacles with full cycloplegic refraction without overminus
61989647|NCT06146946|EXPERIMENTAL|Omitting dissection of the No.253 lymph node|Perform surgery based on the principle of Total Mesorectal Excision (TME), without denuding the root of the Inferior Mesenteric Artery (IMA) and without dissection of the No.253 lymph node. Ligation of the IMA is performed at a low position distal to the origin of the left colonic artery.
61989648|NCT06146946|ACTIVE_COMPARATOR|Dissection of the No.253 lymph node|Perform surgery based on the principle of Total Mesorectal Excision (TME). During the procedure, fully expose the root of the Inferior Mesenteric Artery (IMA), thoroughly dissect the No.253 lymph node, and perform a high ligation along the artery at the root of the IMA; or expose the bifurcation of the left colonic artery, ligating the IMA at a low position distal to the origin of the left colonic artery, ensuring the dissection of the No. 253 lymph node while preserving the left colonic artery.
61989649|NCT02522208|EXPERIMENTAL|BiDil Extended Release (XR)|BiDil XR isosorbide dinitrate 40 mg and hydralazine hydrochloride 75 mg 2 capsules 9 hours apart for one day
61989650|NCT02522208|ACTIVE_COMPARATOR|BiDil Immediate Release (IR)|BiDil isosorbide dinitrate 20 mg and hydralazine hydrochloride 37.5 mg 3 tablets 6 hours apart for one day
61989651|NCT01814501|EXPERIMENTAL|Treatment (panitumumab, combination chemotherapy)|5-Fluorouracil, irinotecan, and panitumumab
61989652|NCT04702477|EXPERIMENTAL|Only Arm|This is a single-arm, paired-sample pilot intervention study among participants with pre-diabetes or diabetes. Goal to integrate a MBSR intervention into a group-based, lifestyle intervention among patients with prediabetes or diabetes in the primary care setting
61989653|NCT01625143||Observational|Archived bone marrow samples, collected at the time of diagnosis and relapse, are analyzed for gene expression and histone modifications by microarray, chromatin immunoprecipitation (ChIP) sequencing, and quantitative real-time polymerase chain reaction (qRT-PCR).
61989654|NCT01045109|EXPERIMENTAL|open-label vitamin D3|One arm: open-label receiving vitamin D3 4,000 IU daily
61989655|NCT00032643|OTHER|Arm 1|
61989656|NCT04070131|NO_INTERVENTION|Control Group|Regular follow ups.
61989657|NCT04070131|EXPERIMENTAL|Intervention Group|One weekly session (1 hour) of Horse-Assisted Rehabilitation, 24 weeks.
62385245|NCT04833972|EXPERIMENTAL|Experimental: V3: Open-Ended Numerical Estimate|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. Each question in this version of the survey questionnaire permits the study participant to provide an open-ended numerical estimate."
62385246|NCT03167866|PLACEBO_COMPARATOR|control group|DM patients who receive a weekly informational Short Message Service (SMS) by phone for 26 weeks. informational SMS
62385247|NCT03167866|EXPERIMENTAL|test group|DM patients who receive a weekly motivational Short Message Service (SMS) for 26 weeks. motivational SMS
62385248|NCT04804111|PLACEBO_COMPARATOR|Placebo|maintain the initial dose, without increasing the dose.
62385249|NCT04804111|ACTIVE_COMPARATOR|URC102 3mg|Administer 3 mg of URC102 for 12 weeks
62385250|NCT04804111|ACTIVE_COMPARATOR|URC102 6mg|Administer 3 mg of URC102 for 1 week and 6 mg of URC102 for 11 Weeks.
62385251|NCT04804111|ACTIVE_COMPARATOR|URC102 9mg|Administer 3 mg of URC102 for 1 week and 6 mg of URC102 for 1 Weeks, maintain 9 mg of URC102 dose
62385252|NCT04804111|OTHER|Febuxostat 80 mg|maintain the initial dose, without increasing the dose.
61989658|NCT03020823|EXPERIMENTAL|SCB01A alone|intra-subject dose escalation starting from 12 mg/m2, then to18 mg/m2, and finally to 24 mg/m2 if no DLT
62766836|NCT03074266||Blood coagulation test 1|"Therapeutic: Waste blood from heparinized patients undergoing interventional procedures (standard of care) in different clinical settings will be used to conduct coagulation tests using GEM Hemochron 100 during the course of the procedure before (baseline) and after heparin administration.~There is no drug administration or therapeutic intervention in this study. The interventional procedure (described above) is standard of care and all results of blood coagulation testing using GEM Hemochron 100 performed in this study are not used to influence that care."
62766837|NCT03074266||Blood coagulation test 2|"Therapeutic: Waste blood from heparinized patients undergoing interventional procedures (standard of care) in different clinical settings will be used to conduct duplicate coagulation tests using Signature Elite during the course of the procedure before (baseline) and after heparin administration.~There is no drug administration or therapeutic intervention conducted in the course of this study. The interventional procedure (described above) is standard of care. The only difference in standard of care is that the blood coagulation test is run in duplicate."
61989659|NCT05224505|EXPERIMENTAL|GNT0006 - Stage 1|6 patients treated with GNT0006 in Stage 1 (open label) 2 dose cohorts : Cohort 1: single intravenous injection 9.0E+12 vg/Kg Cohort 2: single intravenous injection 2.7E+13 vg/Kg
62385253|NCT05459519|EXPERIMENTAL|Intervention group A|Dengzhanxixin Capsules plus Placebo Capsules
62385254|NCT05459519|EXPERIMENTAL|Intervention group B|Dengzhanxixin Capsules plus Placebo Capsules
62385255|NCT05459519|PLACEBO_COMPARATOR|Control group|Placebo Capsules
62385256|NCT01170481||papilloedema without glaucoma|
62385257|NCT01170481||papilloedema with glaucoma|
62385258|NCT01170481||glaucoma without papilloedema|
62385259|NCT00126763|EXPERIMENTAL|Matrix Transdermal Fentanyl Patch|
62558900|NCT06086106||group B systemic opioids for pain relive|systemic opioids belong to a class of analgesics, they act by attaching to opioid receptors in the brain and spinal cord. For relief of pain, they are frequently utilized in a variety of surgical procedures and can be given intravenously, and in intramuscular injections. Although opioids are considered highly effective in pain control, they can lead to several adverse effects, such as nausea, vertigo, and respiratory depression, some of which can be dangerous.
61989660|NCT05224505|EXPERIMENTAL|GNT0006 - Stage 2|"22 patients randomized in single intravenous GNT0006 arm at selected dose in Stage 2 (double blind).~The patients will receive placebo one year after to maintain the blind"
62385260|NCT04062942||DDD patients|All patients presenting to the neurosurgical department of the Kantonsspital St. Gallen (KSSG) or the Univesity Hospital Zürich (USZ) with DDD fulfilling the inclusion criteria and scheduled for ESI or TFESI will be considered for this study.
62385261|NCT01979003|EXPERIMENTAL|Fluorescein Injection|All research participants will receive fluorescein injection through existing intravenous line during the operative procedure. This will consist of one ampule (5 cc) injected intravenously 5- 10 minutes prior to ligation of the uterine arteries.
62385262|NCT00003556|EXPERIMENTAL|Arm I|Patients receive ALVAC-hB7.1 alone or combined with ALVAC-hIL-12 intratumorally on days 1, 4, 8, and 11. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at each dose level of ALVAC-hB7.1. The maximum tolerated dose is defined as the dose of ALVAC-hB7.1 at which no more than 1 of 5 patients experiences dose limiting toxicity.
61989661|NCT05224505|PLACEBO_COMPARATOR|Placebo - Stage 2|11 patients randomized in placebo arm in Stage 2 (double blind). The patients will receive single intravenous GNT0006 at selected dose one year after to maintain the blind
62385263|NCT04922814|NO_INTERVENTION|Control group(group A)|Only sedation for mechanically ventilated COVID patients
62385264|NCT04922814|EXPERIMENTAL|Muscle relaxant group(group B)|They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.
62766838|NCT03009643|EXPERIMENTAL|iNO Group|Patients are treated with iNO at a concentration of 5-10 ppm for 3-5 days according to the clinical conditions
62766839|NCT03009643|OTHER|Control|Patients are treated without iNO.
62766840|NCT03567018|EXPERIMENTAL|Healthy volunteer population|We plan to enroll 25 healthy volunteers.
62385265|NCT03756636|OTHER|"Underwater mucosectomy"|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"
62385266|NCT05043194|EXPERIMENTAL|ursodeoxycholic acid arm|Premature infants who meet the inclusion criteria take preventive oral ursodeoxycholic acid on the 7th day after birth. ursodeoxycholic acid capsules (Ursofalk, 250 mg/capsules), starting with oral administration of pharmacologic doses of 20-25mg/kg/d, twice daily, until they were discharged .
62766841|NCT03567018|EXPERIMENTAL|Patient population|We plan to enroll 50 clinical patients who are receiving flap procedures at the Ohio State Medical Center.
62766842|NCT05179499|ACTIVE_COMPARATOR|Intervention Arm|Participants will receive peripheral vasopressor infusion of norepinephrine (16 micrograms/ml) during the initial 48 hour study period. All other care will be as per local protocol.
61989662|NCT03704961|EXPERIMENTAL|classical music|
61989663|NCT03704961|EXPERIMENTAL|Turkish music|
62385267|NCT05043194|SHAM_COMPARATOR|the control arm|The control group was treated with UDCA after the occurrence of cholestasis.ursodeoxycholic acid capsules (Ursofalk, 250 mg/capsules), starting with oral administration of pharmacologic doses of 20-25mg/kg/d, twice daily, until they were discharged .
62385268|NCT02212249|ACTIVE_COMPARATOR|Systemic sclerosis|patients with systemic sclerosis
62385269|NCT02212249|SHAM_COMPARATOR|primary raynaud disease|patients with primary raynaud disease
62385270|NCT00932399||Group 1|Underwent a procedure at a VA medical facility in VISN 20 for a lower limb amputation between 1997 and 2008
62385271|NCT00932399||Group 2|No history of lower limb amputation
62385272|NCT01796795|PLACEBO_COMPARATOR|vehicle gel|The vehicle gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
62558901|NCT00280735|OTHER|Single Arm Trial|adjuvant carboplatin plus docetaxel carboplatin area under curve (AUC) = 6 IV on day 1 every 3 weeks for 4 cycles docetaxel 75 mg/m² IV on day 1 every 3 weeks for 4 cycles
61989664|NCT03704961|EXPERIMENTAL|audiobook|
62766843|NCT05179499|PLACEBO_COMPARATOR|Standard care|Participants allocated to the control arm will receive standard care as defined by the UK NICE guidelines and the Surviving Sepsis Campaign guidelines during the 48 hour study period post randomisation. All other care will be as per local protocol.
62766844|NCT06252818|EXPERIMENTAL|ReHub|ReHub is a medical device designed to assist rehabilitation professionals by providing information for the design, monitoring, and analysis of therapeutic exercise programs for respiratory functional rehabilitation. Patients use the platform to follow the exercise program designed by their therapist from the location that suits them best.
61989665|NCT02049333|ACTIVE_COMPARATOR|Phacoemulsification|Cataract extraction alone
61989666|NCT02049333|EXPERIMENTAL|Phacoemulsification with Endoscopic Cycloplasty (ECPL)|Cataract extraction combined with endoscopic cycloplasty
62766845|NCT05961449|EXPERIMENTAL|Experimental condition|Participants will complete an experimental exercise that will consist in 25 minutes of cycling between 60-80 Revolution Per Minute (RPM) on a cycle ergometer (CST BX40; Cardiostrong; Germany) at ≥ 70% of the Heart Rate Reserve (HRR).
62766846|NCT05961449|SHAM_COMPARATOR|Control condition|The control condition will include an exercise design similar to the experimental condition except that the resistance will be kept at 25 W and the RPM below 50. The intensity of the exercise will be kept at minimal levels by ensuring that the heart rate does not increase \>25% from baseline
62766847|NCT01864161|EXPERIMENTAL|oral liposomal iron|patients receive a dose of liposomal 30 mg/die iron (equivalent to 1 cp Sideral forte).
62766848|NCT01864161|ACTIVE_COMPARATOR|endovenous iron|patients receive a total dose 1000 mg of intravenous iron gluconate divided into administrations of 125 mg diluted in 250 mL normal saline infused weekly for 3 months
62766849|NCT04838704|EXPERIMENTAL|RUX group|
62766850|NCT04838704|ACTIVE_COMPARATOR|Control group|
62766851|NCT04313491|EXPERIMENTAL|Yoga@Work|
61989667|NCT02612428|EXPERIMENTAL|ELAD System|This group will receive treatment with ELAD plus standard of care therapy.
61989668|NCT02612428|OTHER|Standard of Care (Control)|This group will receive standard of care therapy as defined in the protocol.
62385273|NCT01796795|ACTIVE_COMPARATOR|SR-T100 gel with 1.0% of SM|SR-T100 contains 1.0% SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
62385274|NCT01796795|ACTIVE_COMPARATOR|SR-T100 gel with 2.3% of SM|SR-T100 contains 2.3%SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
62385275|NCT04441658|EXPERIMENTAL|experimental group|The volunteers of the experimental group will be given peripheral intravenously a dose of 0.75\*10\^6/ kg human umbilical cord mesenchymal stem cells at 0,1,5,6 week.
62766852|NCT03684304|NO_INTERVENTION|Control / No Binder|Patients randomized to routine care / no abdominal binder use will not use an abdominal binder during their post operative course.
62766853|NCT03684304|EXPERIMENTAL|Abdominal binder|Patients randomized abdominal binder use will have an abdominal binder placed on them in the operating room once their surgery has been completed.
61989669|NCT05533047|ACTIVE_COMPARATOR|Bipolar TURP|Patients thats will undergo bipolar TURP
61989670|NCT05533047|ACTIVE_COMPARATOR|Monopolar TURP|Patients thats will undergo monopolar TURP
62385276|NCT04441658|PLACEBO_COMPARATOR|control group|The control group will be given the same dose of saline containing human albumin.
62385277|NCT05626959|EXPERIMENTAL|NTI164|"Full-Spectrum Medicinal Cannabis Plant Extract with less than 0.08% THC (NTI164)~Randomised Controlled Phase:~Part A: 5mg/kg, 10mg/kg, 15mg/kg, 20mg/kg (1 week each, total duration = 4 weeks) Part B: 20mg/kg or maximum tolerated dose (total duration = 4 weeks).~Open-Label Phase 20mg/kg or maximum tolerated dose (total duration = 8 weeks).~Extension Phase 20mg/kg or maximum tolerated dose (total duration = 36 weeks)."
62385278|NCT05626959|PLACEBO_COMPARATOR|Placebo|"Randomised Controlled Phase:~Part A: 5mg/kg, 10mg/kg, 15mg/kg, 20mg/kg (1 week each, total duration = 4 weeks) Part B: 20mg/kg or maximum tolerated dose (total duration = 4 weeks)."
62385279|NCT04715867|EXPERIMENTAL|Test Group for intramuscular route|110 adult participant will get Ravix-VC
62766854|NCT06243120|EXPERIMENTAL|Study group|"The study group will receive lidocaine (2%) 1mg/ kg iv diluted by normal saline to a volume of 100 ml. The VAS will be assessed every 10 minutes for 60minutes after the treatment. A regression of more than 4 points of VAS score is considered a success and if less than 4 points, it is considered as a failure.~If intravenous lidocaine failed to manage pruritus after 30 minutes the patient will receive 20 mg intravenous propofol."
62766855|NCT06243120|PLACEBO_COMPARATOR|Control group|"The control group will receive 100 ml of normal saline as placebo effect and VAS will be assessed every 10 minutes for 60minutes after the treatment. A regression of more than 4 points of VAS score is considered a success and if less than 4 points, it is considered as a failure.~If intravenous lidocaine failed to manage pruritus after 30 minutes the patient will receive 20 mg intravenous propofol."
62766856|NCT03715192|EXPERIMENTAL|LY3462817 - IV|Escalating doses of LY3462817 administered as a single intravenous (IV) infusion in healthy participants
62766857|NCT03715192|PLACEBO_COMPARATOR|Placebo|Normal saline administered as a single IV infusion in healthy participants
62766858|NCT03715192|EXPERIMENTAL|LY3462817 - SC|Single dose of LY3462817 administered as subcutaneous (SC) injections in healthy participants
62766859|NCT06176508|EXPERIMENTAL|HS-10374 Dose 1|
61989671|NCT06284226|EXPERIMENTAL|A group|
61989672|NCT01165138|EXPERIMENTAL|Fluticasone furoate/Vilanterol (GW642444)|Fluticasone furoate/Vilanterol inhalation powder once daily for 12 weeks
61989673|NCT01165138|EXPERIMENTAL|Fluticasone Furoate|Fluticasone furoate inhalation powder once daily for 12 weeks
61989674|NCT01165138|PLACEBO_COMPARATOR|Placebo|Placebo inhalation powder once daily for 12 weeks
62766860|NCT06176508|EXPERIMENTAL|HS-10374 Dose 2|
62766861|NCT06176508|PLACEBO_COMPARATOR|Placebo|
61989675|NCT02820012|OTHER|Scoliosis|"Preoperative data: demographics, clinical diagnosis and etiology, relevant prior medical treatment, x-rays, and patient questionnaire will be completed in the database.~The self-questionnaire (SAQ parents, patients, SR22) provided will assess the state of health and disability of patients.~After surgery: the clinical questionnaire will be completed by the investigator to collect the parameters of the operation and the patient's clinical data Immediate Postoperative visit: J1 to S1: radiological and clinical examinations .~Visit Month 1 to M3, M 12, M 24 , M 36 , M 60 : During these visits, clinical and radiological examinations will be realized."
61989676|NCT00304356|OTHER|active drug|500 mg nitazoxanide bid given to patient
62385280|NCT04715867|ACTIVE_COMPARATOR|Comparator group for intramuscular route|110 adult participant will get Rabipur
62385281|NCT04715867|EXPERIMENTAL|Test Group for Intradermal Route|110 adult participant will get Ravix-VC
62385282|NCT04715867|ACTIVE_COMPARATOR|Comparator Group for Intradermal Route|110 adult participant will get Rabipur
62385283|NCT03109418|PLACEBO_COMPARATOR|Control Group|OSA patients will receive standard inhaled anesthesia with normal saline infusion
62558902|NCT01371604|EXPERIMENTAL|IDX184 50 mg + Peg-IFN/RBV|IDX184 50 mg and matching placebo once daily plus peginterferon alfa-2a (Peg-IFN) weekly and ribavirin (RBV) daily for 12 weeks followed by Peg-IFN weekly and RBV daily for an additional 12 or 36 weeks.
62558903|NCT01371604|EXPERIMENTAL|IDX184 100 mg + Peg-IFN/RBV|IDX184 100 mg once daily plus Peg-IFN weekly and RBV daily for 12 weeks followed by Peg-IFN weekly and RBV daily for an additional 12 or 36 weeks.
61989677|NCT04751149|EXPERIMENTAL|Early Urinary Catheter Removal|Urinary Catheter will be removed the first postoperative day after rectal resection
61989678|NCT04751149|EXPERIMENTAL|Medium Urinary Catheter Removal|Urinary Catheter will be removed the third postoperative day after rectal resection
61989679|NCT04751149|EXPERIMENTAL|Late Urinary Catheter Removal|Urinary Catheter will be removed the fifth postoperative day after rectal resection
61989680|NCT00590109||1|
61989681|NCT00862186|OTHER|Self-Management Arm|Behavioral: 'Fatigue Facts \& Fixes'
62385284|NCT03109418|ACTIVE_COMPARATOR|Ketamine Group|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion.
62385285|NCT01861158|EXPERIMENTAL|Parenting Wisely|Immediate access to the online Parenting Wisely program
62385286|NCT01861158|ACTIVE_COMPARATOR|Parenting Wisely + Community Forum|Immediate access to the online Parenting Wisely program, as well as access to a community form where parents can receive social support from other online users of the program and a moderator
62385287|NCT01861158|NO_INTERVENTION|Delayed Parenting Wisely|Delayed (6-month) access to the Parenting Wisely program. Parents will receive access to PW after the final, 6-month, follow-up assessment.
61989682|NCT03676881||Mild Cognitive Impairment (MCI)|30 MCI patients their study partners will be part of the 'Computerized cognitive battery- Cognigram (CG) project and 30 MCI with their study partners will be part of The NeuroCatch™ Platform (NCP) project.
61989683|NCT03676881||Cognitively normal subjects (CN)|30 CN participants who are cognitively normal that will be part of the 'Computerized cognitive battery- Cognigram (CG) project and 30 CN will be part of The NeuroCatch™ Platform (NCP) project.
62385288|NCT02111031||Case|Patients with documented (histologically/pathologically confirmed) mBC diagnosis, at lease 65 years of age at documented mBC diagnosis, and actively treated by a physician at a participating cancer center who routinely (i.e., test at lease every quarter) use CTC testing (excluding patients who sought consults or second opinions).
62385289|NCT00756223|EXPERIMENTAL|Arm A|BI 831266 24h infusion on day 1 and day 15 every 4 weeks
62385290|NCT00756223|EXPERIMENTAL|Arm B|BI 831266 24h infusion on day 1 every 3 weeks
62385291|NCT01901679|EXPERIMENTAL|Celebrex|10 days treatment with Celebrex to evaluate reduction of PGE-M in urine
62385292|NCT05507294|EXPERIMENTAL|SCC244：Fasting+High-fat meal+Low-fat meal|Participants will receive a single oral dose of Glumetinib tablet in fasting condition on Day 1 of treatment period 1 followed by a single oral dose of Glumetinib tablet in fed condition(High-fat meal) on Day 1 of treatment period 2.Then，Participants will receive a single oral dose of Glumetinib tablet in fed condition （Low-fat meal）on Day 1 of treatment period 3. The time interval between two adjacent dosages was at least 14 days.
61989684|NCT04347382|EXPERIMENTAL|Nigella Sativa & Honey Group|"Drug: Nigella Sativa seed Powder 80 mg/Kg/day grinded in capsule upto a max of 14 days) Drug: Natural Honey 1gm/kg/day orally upto a max of 14 days)~along with standard medical care"
61989685|NCT04347382|PLACEBO_COMPARATOR|Standard Medical Care|Standard supportive medical care prescribed by treating physician, Lahore which includes standard symptomatic care along with use of antibacterial or antiviral (if advised by pulmonologist or infectious disease specialist)
62385293|NCT05507294|EXPERIMENTAL|SCC244：Fasting+Low-fat meal+High-fat meal|Participants will receive a single oral dose of Glumetinib tablet in fasting condition on Day 1 of treatment period 1 followed by a single oral dose of Glumetinib tablet in fed condition(Low-fat meal) on Day 1 of treatment period 2.Then，Participants will receive a single oral dose of Glumetinib tablet in fed condition （High-fat meal）on Day 1 of treatment period 3. The time interval between two adjacent dosages was at least 14 days.
62558904|NCT05935410|EXPERIMENTAL|DM Social Needs Intervention|A trained health educator will deliver the manualized DM Social Needs intervention. Participants will receive 6-monthly sessions of diabetes education and skills training, and problem solving and resolution of social needs via telephone.
62558905|NCT05935410|ACTIVE_COMPARATOR|Usual Care|Participants in the usual care arm will receive mailed diabetes education materials in accordance with recommendations from the American Diabetes Association (ADA) monthly
62558906|NCT02199964|EXPERIMENTAL|Cyclosporin 0.05% emulsion|used in the eye 4 times a day
61989686|NCT04139967|EXPERIMENTAL|Elderly rectal cancer patients|
61989687|NCT06233487|OTHER|Double measurements|All included children will have double measurements of the investigated ultrasound methodologies performed by two separate musculoskeletal radiologists.
61989688|NCT03254186|EXPERIMENTAL|Propranolol Hydrochloride|Two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks then will remain on a stable dose for six weeks. The patients will be treated for eight weeks, complete a one week washout and then crossed over to another arm for eight weeks.
62385294|NCT05507294|EXPERIMENTAL|SCC244：High-fat meal+Fasting+Low-fat meal|Participants will receive a single oral dose of Glumetinib tablet in fed condition（High-fat meal） on Day 1 of treatment period 1 followed by a single oral dose of Glumetinib tablet in fasting condition on Day 1 of treatment period 2.Then，Participants will receive a single oral dose of Glumetinib tablet in fed condition(Low-fat meal) on Day 1 of treatment period 3. The time interval between two adjacent dosages was at least 14 days.
62385295|NCT05507294|EXPERIMENTAL|SCC244：High-fat meal+Low-fat meal+Fasting|Participants will receive a single oral dose of Glumetinib tablet in fed condition（High-fat meal） on Day 1 of treatment period 1 followed by a single oral dose of Glumetinib tablet in fed condition（Low-fat meal） on Day 1 of treatment period 2.Then，Participants will receive a single oral dose of Glumetinib tablet in fasting condition on Day 1 of treatment period 3. The time interval between two adjacent dosages was at least 14 days.
62385296|NCT05507294|EXPERIMENTAL|SCC244：Low-fat meal+Fasting+ High-fat meal|Participants will receive a single oral dose of Glumetinib tablet in fed condition（Low-fat meal） on Day 1 of treatment period 1 followed by a single oral dose of Glumetinib tablet in fasting condition on Day 1 of treatment period 2.Then，Participants will receive a single oral dose of Glumetinib tablet in fed condition(High-fat meal) on Day 1 of treatment period 3. The time interval between two adjacent dosages was at least 14 days.
62385297|NCT05507294|EXPERIMENTAL|SCC244：Low-fat meal +High-fat meal +Fasting|Participants will receive a single oral dose of Glumetinib tablet in fed condition（Low-fat meal） on Day 1 of treatment period 1 followed by a single oral dose of Glumetinib tablet in fed condition（High-fat meal） on Day 1 of treatment period 2.Then，Participants will receive a single oral dose of Glumetinib tablet in fasting condition on Day 1 of treatment period 3. The time interval between two adjacent dosages was at least 14 days.
62385298|NCT01102816|EXPERIMENTAL|Individualized acupuncture|
62385299|NCT01102816|NO_INTERVENTION|Routine care|
62385300|NCT05256511||SARS-CoV-2 first wave|Patients with confirmed SARS-CoV-2 infection and receiving invasive mechanical ventilation for more than 48h, in the first wave of the pandemic, starting on 01-01-2020
62385301|NCT05256511||SARS-CoV-2 second wave|Patients with confirmed SARS-CoV-2 infection and receiving invasive mechanical ventilation for more than 48h, in the second wave of the pandemic, starting on 10-01-2020
62385302|NCT01450566|EXPERIMENTAL|Lidocaine|Use of lidocaine
62385303|NCT01450566|PLACEBO_COMPARATOR|No lidocaine|No lidocaine/standard of care
62385304|NCT00735163|EXPERIMENTAL|A|improved model predictive control algorithm (eMPC) for glycaemic control in ICU patients
62385305|NCT06421363|NO_INTERVENTION|CONTROL GROUP|
62385306|NCT06421363|EXPERIMENTAL|INTERVENTIONAL GROUP|
62385307|NCT02005679|EXPERIMENTAL|deaf persons with potential dementia|
62385308|NCT03793010|EXPERIMENTAL|FX006|FX006 32mg
62385309|NCT03793010|PLACEBO_COMPARATOR|Normal Saline|Normal Saline
61989689|NCT03254186|PLACEBO_COMPARATOR|Placebo Oral Tablet|Identical placebo. The patients will be treated for eight weeks, complete a one week washout and then crossed over to another arm for eight weeks.
61989690|NCT02706509|ACTIVE_COMPARATOR|oral tramadol|Patients will receive oral Tramadol 50 mg capsules (n=50)' . After an hour, Jaydess intrauterine device will be inserted.
62766862|NCT06176508|ACTIVE_COMPARATOR|tofacitinib|
62385310|NCT04907942|ACTIVE_COMPARATOR|EMA Alone|3 weeks of EMA, consisting of 2 surveys per day delivered via text message and email during waking hours to prompt participants to complete the survey.
62766863|NCT01897649|EXPERIMENTAL|NUTRIOSE|group of volunteers fed with NUTRIOSE
61989691|NCT02706509|SHAM_COMPARATOR|verbal anesthesia|'verbal anesthesia' (n=50) After an hour, Jaydess intrauterine device will be inserted
61989692|NCT06414967|EXPERIMENTAL|Music Intervention|The rythm of the music sessions will be 1 per week in the first month and every 15 days in the second and third month.
61989693|NCT01428180||Indomethacin|Infants treated with Indomethacin
62385311|NCT04907942|EXPERIMENTAL|EMA + Automated Text Message Intervention|"* 1 week of EMA, consisting of 2 surveys per day delivered via text message and email during waking hours to prompt participants to complete the survey followed by~* 2 additional weeks of EMA in combination with 2 text messages per day with content related to stress management techniques."
62385312|NCT05306860||Grade B-C stage III-IV periodontitis group|"Grade B-C stage III-IV periodontitis group Grade B: Moderate Moderate bone loss is observed compared to biofilm and % Root Bone Loss/age 0.25 to 1.0 is determined as grade B.~Stage III: Severe Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≤4.~Grade C: Rapid Rapid bone loss is observed compared to biofilm and % Root Bone Loss/age \>1.0 is determined as grade C.~Stage IV:Advanced Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≥5. Need for complex rehabilition due to: Masticatory dysfunction, Secondary occlusal trauma(tooth mobility degree ≥2) Severe ridge defect,Bite collapse, drifting, flaring. Less than 20 remaining teeth (10 opposing pairs)"
62385313|NCT05306860||Healthy control group|Consisted of individuals with clinically healthy gingiva on an intact periodontium who had a BOP score less than 10% and PD≤3mm, showed no attachment loss or radiographic bone loss.
62385314|NCT01296464|EXPERIMENTAL|Stalevo|levodopa/carbidopa/entacapone
62385315|NCT01296464|PLACEBO_COMPARATOR|Placebo|
62385316|NCT01462851|EXPERIMENTAL|Dose Escalation|Ascending doses in healthy volunteers
62385317|NCT01462851|EXPERIMENTAL|Part 2: CSF PKPD|Pharmacokinetic and pharmacodynamic cerebrospinal fluid assessment
62385318|NCT04229186|EXPERIMENTAL|Patients with assumption of EVOO-C|12 patients with Mild Cognitive Impairment or Mild Alzheimer's Disease will receive 10 mg EVOO-C
62385319|NCT04229186|EXPERIMENTAL|Patients with assumption of ROO|12 patients with Mild Cognitive Impairment or Mild Alzheimer's Disease will receive 10 mg ROO
62385320|NCT05883566|EXPERIMENTAL|behaviour|
62385321|NCT05883566|NO_INTERVENTION|control|
62385322|NCT04810806|EXPERIMENTAL|Immediate coronary angiography group|Immediate coronary angiography group will routinely receive coronary angiography within 2 hours after randomization.
62558907|NCT02199964|ACTIVE_COMPARATOR|Endura Refresh, Artificial Tears|Over the Counter artificial tears used in the eye 4 times a day
62766864|NCT01897649|ACTIVE_COMPARATOR|GLUCIDEX|gruop of volunteers fed with GLUCIDEX
62766865|NCT00944463|EXPERIMENTAL|Gemcitabine+simvastatin|Gemcitabine and simvastatin
62766866|NCT00944463|PLACEBO_COMPARATOR|Gemcitabine+Placebo|Gemcitabine plus Placebo
62766867|NCT01565395|EXPERIMENTAL|Xeomin Injections|Fifteen units (0.15 ml) of incobotulinum toxin A injected into each parotid gland and 20 units (0.2 ml) to each submandibular gland for a total dose of 70 units using anatomical landmarks for ALS Twenty units (0.2ml) injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks for PD/parkinsonism
62766868|NCT01565395|PLACEBO_COMPARATOR|Placebo|0.15 ml sterile 0.9% saline injected into each parotid gland and 0.2 ml to each submandibular gland using anatomical landmarks for ALS 0.2ml injected into each parotid gland and 0.3 ml to each submandibular gland using anatomical landmarks for PD/parkinsonism
62766869|NCT04576078|EXPERIMENTAL|NEFOPAM 60mg PO/ 8 hours|Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h.
62766870|NCT04576078|PLACEBO_COMPARATOR|Placebo|Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h.
61989694|NCT01428180||Ibuprofen|Infants treated with Ibuprofen
62385323|NCT04810806|ACTIVE_COMPARATOR|Delayed coronary angiography group|Delayed coronary angiography group will receive coronary angiography during hospitalization after stabilization of symptoms and signs of heart failure.
62385324|NCT02582619||Rehabilitation Professionals|Focus group consisting of rehabilitation professionals that will inform the study on vocational rehabilitation interventions rendered during acute to in-patient rehabilitation in KwaZulu-Natal.
62385325|NCT02582619||People living with Spinal Cord Injuries (PLWSCI)|"Focus group consisting of PLWSCI that will inform the study on the perspective of the patient on vocational rehabilitation needs or desires during acute care and in-patient rehabilitation.~This group will inform the study on the employment rate amongst people living with spinal cord injuries as well as factors that influence employment.~This group will also inform the study on the perceived barriers and facilitators of employment"
62385326|NCT02582619||Stakeholders|"Representatives from the following departments or organisations will be invited to participate in the interviews and focus groups:~Government Departments:~Education Social Development Health Labour Transport~Private Companies:~Insurance Companies and Health Risk Management companies Non-profit Organisations QASA DPSA"
62385327|NCT02582619||Experts|A delphi technique will be used to get an expert opinion and consensus on the aspects of the model to be developed.
62385328|NCT05511636|EXPERIMENTAL|those that receive the conventional oxygen|This study will be conducted on 180 patients who will be undergoing lung resection (wedge resection, segmentectomy, metastasectomy, lobectomy, or pneumonectomy) surgery at the Cardiothoracic department, Ain Shams University Hospitals; patients are to be extubated intraoperative, and at the ICU will be given HFNC . The endpoints of the study are to investigate whether high-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy for reducing hypoxemia and postoperative pulmonary complications in extubated patients after lung resection.
62385329|NCT05511636|EXPERIMENTAL|those that receive the high flow oxygen therapy.|This study will be conducted on 180 patients who will be undergoing lung resection (wedge resection, segmentectomy, metastasectomy, lobectomy, or pneumonectomy) surgery at the Cardiothoracic department, Ain Shams University Hospitals; patients are to be extubated intraoperative, and at the ICU will be given standard oxygen therapy . The endpoints of the study are to investigate whether high-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy for reducing hypoxemia and postoperative pulmonary complications in extubated patients after lung resection.
62558908|NCT04937140||rheumatoid arthritis patients|90 RA patients diagnosed according to the American college of rheumatology (ACR) -EULAR RA classification criteria 2010
62766871|NCT02062983||Herceptin|The study will be carried in prospective manner enrolling all patients diagnosed with breast cancer and over expressed human epidermal growth factor receptor 2 (HER2) and they are requiring Trastuzumab Neu adjuvant/ adjuvant /metastatic therapy as per standard care.
62766872|NCT04905355|ACTIVE_COMPARATOR|Virtual Reality (VR)|Patient with VR experience during the ambulatory orthopedic surgery
62766873|NCT04905355|NO_INTERVENTION|NO VR|Patient without any VR experience during the ambulatory orthopedic surgery
61989695|NCT01428180||Ligation|Infants undergoing surgical ligation
61989696|NCT03030079|EXPERIMENTAL|Experimental Electrical stimulation Regimen|Explore the efficacy of an electrical stimulus regimen on the treatment of chronic phantom limb pain using a standard-of-care electrical stimulation system
61989697|NCT00802399|OTHER|Partial Lacrimal Punctual Occlusion|Cauterization of the edge of all lacrimal punctum was carried out in all patients
62385330|NCT04591340||test group|all the patients treated with HSCT are with nutrition risk, so they will be all included to accept nutrition therapy.
62385331|NCT01985035|EXPERIMENTAL|Obese Apneic carbohydrate diet|Obese apneic individuals will be subject to a energy restriction diet rich in carbohydrates
62558909|NCT04937140||control group|50 age and sex matched healthy controls. All
62766874|NCT00552448|EXPERIMENTAL|1|Use of the HFCC device in addition to standard therapy for status asthmaticus. The use of HFCC will not affect the therapy received
62766875|NCT00552448|NO_INTERVENTION|2|This group will not use the VEST or HFCC. They will just have standard therapy for status asthmaticus. The standard therapy will not be affected if they are in this group.
62766876|NCT04402541|EXPERIMENTAL|CB-5339|Orally administered CB-5339
61989698|NCT02293226|EXPERIMENTAL|Child ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
61989699|NCT02293226|EXPERIMENTAL|Infant ETI with chest compressions|endotracheal intubation (ETI) during infant mannikin resuscitation with uninterrupted chest compressions
61989700|NCT03211949|EXPERIMENTAL|axillary block with infiltration MCAN|With the performance of the axillary blok, 2 ml of scandicaine will be placed around the medial cutaneous ante brachial nerve (MACN)
61989701|NCT03213821|EXPERIMENTAL|high protein intake|Study participants will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg Ideal Body Weight)
61989702|NCT03213821|ACTIVE_COMPARATOR|GFR based protein intake|Study participants will receive GFR based protein diet to preserve renal function.
61989703|NCT01524861|PLACEBO_COMPARATOR|Placebo|30 subjects receive placebo (placebo group)
61989704|NCT01524861|EXPERIMENTAL|alpha-lipoic acid|30 subjects receive alpha-lipoic acid, 400 mg/day per os bis in die (800 mg/day)(ALA group)
61989705|NCT01524861|EXPERIMENTAL|L-acetil-carnitine|30 subjects receive L-acetyl carnitine, 500 mg per os bis in die (1000 mg/day) (LAC group)
61989706|NCT00885339||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases.
61989707|NCT05694728|EXPERIMENTAL|The Group of Investigational Vaccine|"For Mid-dosage group, 0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30μg#40μg#60μg#40μg#20μg#20μg#20μg#20μg and 20μg respectively, totaling 270μg of antigens.~For High-dosage group, 0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30μg#40μg#80μg#60μg#30μg#30μg#30μg#30μg and 30μg respectively, totaling 360μg of antigens."
61989708|NCT05694728|ACTIVE_COMPARATOR|The Group of Active Control Vaccine|0.5-mL suspension for injection, each 0.5-mL single-dose syringe contains approximately 20 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 40 mcg of HPV Type 16 L1 protein, 20 mcg of HPV Type 18 L1 protein, totaling 120 mcg of antigens.
61989709|NCT01682590|EXPERIMENTAL|Early initiation of RRT|Start of RRT within a maximum of 12 hours after randomisation.
61989710|NCT01682590|ACTIVE_COMPARATOR|Deferred RRT|Start of RRT between 48 and 60 hours after randomisation.
61989711|NCT03693079|EXPERIMENTAL|Wet Cupping|wet cupping therapy will be applied to all participants
61989712|NCT01059370|EXPERIMENTAL|Autonomic dysrefleksia|Autonomic dysreflexia in SCI when emptying bowels or filling bladder
61989713|NCT03451318|ACTIVE_COMPARATOR|drug therapy|Nasonex(mometasone furoate),1 spray,QD (Quaque Die in Latin),for 3 months.
61989714|NCT03451318|ACTIVE_COMPARATOR|tonsillar adenoidectomy|tonsillar adenoidectomy
61989715|NCT03451318|ACTIVE_COMPARATOR|orthodontic treatment|Apply Twin-block appliance combined with maxillary expander
62385332|NCT01985035|EXPERIMENTAL|Obese Apneic protein diet|Obese apneic individuals will be subject to a energy restricted diet rich in protein
62385333|NCT01985035|EXPERIMENTAL|Obese Non Apneic carbohydrate diet|Obese individuals without Obstructive sleep apnea will be subjected to a energy restricted diet rich in carbohydrates
62385334|NCT01985035|EXPERIMENTAL|Obese Non Apneic protein diet|Obese individuals without Obstructive Sleep Apnea will be subjected to a energy restricted diet rich in protein
62766877|NCT03986047|EXPERIMENTAL|Thermal care|Participants will be asked to wear a heat wrap over the lower lumbar spine, during the day for 8 hours on 7 consecutive days. The Thermal care group will also receive education by a physiotherapist on acute low back pain management.
62766878|NCT03986047|EXPERIMENTAL|Thermal care + exercises|In addition to heat wrap and pain management education as for Thermal care group, participants of this group will be asked to perform exercises at home over 7 days, targeted on functional capacity, lumbar mobility, and slight contraction of trunk muscle (posture and/or cognitive).
61989716|NCT03451318|ACTIVE_COMPARATOR|tonsillar adenoidectomy plus orthodontic treatment|Apply Twin-block appliance combined with maxillary expander one month after tonsillar adenoidectomy .
61989717|NCT01232920|ACTIVE_COMPARATOR|Methotrexate|
62385335|NCT05920655||1( Surgical menopause)|Surgical menopause : At least 6 months after hysterectomy and salphingo-oopherectomy
62385336|NCT05920655||2 ( Natural menopause )|Natural menopause :Healthy female patients who have not had a menstrual period for at least 1 year and have not received any treatment for this reason before
61989718|NCT01232920|ACTIVE_COMPARATOR|Mycophenolate mofetil|
61989719|NCT03274986|EXPERIMENTAL|DFT015|ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
61989720|NCT03274986|ACTIVE_COMPARATOR|SN60WF|ACRYSOF® IQ Monofocal IOL, bilateral implantation
61989721|NCT04178746||IVH subjects in the Hyper-Acute Phase|The purpose of this prospective, single center, single arm registry is to assess technical feasibility, peri-procedural complications, post-procedure imaging outcomes, and 30-day safety outcomes in approximately 20 subjects with intracerebral hemorrhages utilizing the Artemis Neuro Evacuation Device in the hyper-acute phase. For the purposes of this registry, the hyper-acute phase as defined by initiation of the MIS procedure no longer than 12 hours from initial NCCT scans and no longer than 18 hours since time patients last known well.
61989722|NCT05934877|EXPERIMENTAL|ASK-PrEP|"ASK-PrEP is a 5-session PrEP navigation intervention, with text-messaging support, to advance through the PrEP Care Continuum by identifying the individual needs and barriers to PrEP care, including substance use and behavioral health needs; adherence goal(s); and methods to achieve adherence.~Intervention/treatment: PrEP navigation + text messaging Participants receive 5 PrEP navigation sessions within 3 months plus a weekly culturally specific, scripted text message. Participants that do not respond to the ASK-PrEP intervention at the 3-month assessment are re-randomized (1:1) and stepped up to receive ASK-PrEP plus CM or CM alone."
62385337|NCT05920655||3 (Control )|Healthy women aged 30-45 years with regular menstrual cycles and no symptoms of menopause
62385338|NCT02114099|EXPERIMENTAL|Atorvastatin|prescribe Atorvastatin to see its effect
62385339|NCT01915355|EXPERIMENTAL|Pulsed Dye Laser for fungus treatment|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
62385340|NCT06126289||Pain-free control subjects|According to the 11th Revision of International Classification of Diseases (ICD-11) of International Association for the Study of Pain(IASP) in 2019, diagnose whether patients have CPSP . Patients with no postoperative chronic pain after open reduction and internal fixation of lower limb fractures.
62385341|NCT06126289||Patients with chronic postsurgical pain|According to the 11th Revision of International Classification of Diseases (ICD-11) of International Association for the Study of Pain(IASP) in 2019, diagnose whether patients have CPSP . Patients with postsurgical chronic pain after open reduction and internal fixation of lower limb fractures.
62385342|NCT02296528|OTHER|Swallowing Expansion Device|Titanium swallowing expansion device
62385343|NCT06102993||COPD GOLD 1|
61989723|NCT05934877|EXPERIMENTAL|Education and Information|"The Standard of Care (SOC) intervention includes a 20-30-minute session of PrEP information and where to access PrEP in Los Angeles. The same session is repeated at the 3-month assessment.~Participants randomized to the SOC arm receive 2 educational/informational sessions on PrEP misconceptions, uptake, and adherence. The sessions occur at baseline and the 3-month assessment."
62385344|NCT06102993||COPD GOLD 2|
62766879|NCT03986047|SHAM_COMPARATOR|Control|Participants in the control group will receive the same education program as those of the two other groups. A sham non-heating wrap will be used to control for potential supportive and sensory influence of the heat wrap.
62766880|NCT04208087|EXPERIMENTAL|SI-722|
62766881|NCT04208087|PLACEBO_COMPARATOR|Placebo|
62766882|NCT04264143|EXPERIMENTAL|MTX110 and CED|All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered by the CED delivery system directly into the tumor over 9-11 days.
62766883|NCT03283150|ACTIVE_COMPARATOR|Remifentanil|Remifentanil will be administered to subjects during microelectrode recordings (MER).
62766884|NCT03283150|ACTIVE_COMPARATOR|Propofol|Propofol will be administered to subjects during MER.
62766885|NCT03283150|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine will be administered to subjects during MER.
62766886|NCT06233994|EXPERIMENTAL|ZG005+Donafenib|Participants will receive ZG005 plus Donafenib until unacceptable toxicity or loss of clinical benefit.
62766887|NCT06233994|EXPERIMENTAL|ZG005+Bevacizumab|Participants will receive ZG005 plus bevacizumab until unacceptable toxicity or loss of clinical benefit.
62766888|NCT03189654||Treatment group|Non-invasive ventilation after pleurocentesis
62766889|NCT03189654||Control group|Oxygen Administration via nasal tube
61989724|NCT02146573|EXPERIMENTAL|CCI Provider for Parent-patient dyad|Parents and patients are randomly assigned to a Continuity Care Intensivist (CCI) Provider who has received specialized communication training. The parent-patient dyad will receive standardized care from the CCI throughout their time in the PICU in addition to being assigned a rotating physician of record.
61989725|NCT02146573|NO_INTERVENTION|Usual Care for Parent-patient dyad|Patients and parents randomly assigned to usual care in the PICU which includes the rotation of the physician of record approximately every 7 days. There is no standardized process by which patients may be assigned a primary attending who would follow them throughout their stay. In the usual care arm it may never happen that they are assigned a primary intensivist, regardless of the length of their hospitalization.
61989726|NCT04238351|EXPERIMENTAL|Control|usual mask ventilation during anethesia induction
61989727|NCT04238351|ACTIVE_COMPARATOR|THRIVE|Applying Transnasal humidified rapid insufflation ventilator exchange during anesthesia induction
61989728|NCT04318496|EXPERIMENTAL|Acupuncture with press tack needle group (Acu)|the press tack needles (PYONEX Φ0.20×0.6 mm made by Seirin Corporation) has a diameter of 0.2 mm and length of 0.6 mm will be used on the following bilateral points; GB 36 (Waiqiu), GB 34 (YangLingQuan), ST 36 (Zusanli), LI 4 (HeGu), LU 7 (LieQue), TH 5 (Waiguan) press tack needles retention time will be 4 days.
61989729|NCT04318496|PLACEBO_COMPARATOR|Placebo group (Con)|The pess tack placebo is PYONEX sticker and pack that is identical to the press needle, except that the needle part was removed. The acupuncturist will apply the stickers on the following bilateral acupoints: GB 36 (Waiqiu), GB 34 (YangLingQuan), ST 36 (Zusanli), LI 4 (HeGu), LU 7 (LieQue), TH 5 (Waiguan) press tack stickers retention time will be 4 days.
61989730|NCT06287983|EXPERIMENTAL|EXERCISE GROUP|The Sample Spondylitis Exercise Program
62766890|NCT00000572|EXPERIMENTAL|Extracorporeal membrane oxygenation (CO2 removal)|Detailed Electronic Protocol Controlled Extracorporeal CO2 Removal with reduced positive-pressure ventilation
61989731|NCT06287983|ACTIVE_COMPARATOR|EXERCISE+ Inspiratory muscle trainer (IMT) GROUP|The Sample Spondylitis Exercise Program Inspiratory muscle training will also be added to the intervention group.
61989732|NCT02790970|EXPERIMENTAL|PReDicT Test|To determine whether use of the PReDicT Test to direct antidepressant treatment results in an increased proportion of depressed patients showing a response to treatment at week 8
61989733|NCT02790970|PLACEBO_COMPARATOR|Treatment as usual|Treat patients as usual without using the predict test to determine treatment.
61989734|NCT05279820|ACTIVE_COMPARATOR|Partial Pulpotomy|After pulp exposure 2-3 mm of the pulp tissue will be amputated, a calcium silicate based material will be placed over the pulp and the tooth will be restored.
62385345|NCT06102993||COPD GOLD 3|
62385346|NCT06102993||COPD GOLD 4|
62766891|NCT00000572|ACTIVE_COMPARATOR|Protocol Controlled positive-pressure vent|Detailed Electronic Protocol Controlled positive-pressure ventilation
62766892|NCT06414330|EXPERIMENTAL|HTK custidiol|will receive HTK (Histidine, Tryptophan and Ketoglutarate solution) consisting of (1000ml distilled water, sodium 15mmol/L, potassium 9mmol/L, magnesium 4mmol/L, calcium 0.015 mmol/L, histidine 129mmol/L, tryptophan 2mmol/L, ketoglutarate 1mmol/L, mannitol 30mmol and pH 7.02 - 1.2). Dose will be 10 - 20 ml/kg and can be repeated once after 120 minutes.
62766893|NCT06414330|EXPERIMENTAL|Del Nido|will receive modified Del Nido cardioplegia (Ringer acetate 1000ml, mannitol 20% 17 ml, magnesium sulphate 10% 20ml, sodium bicarbonate 8.4% 16ml, potassium chloride 7.5% 13ml and lidocaine 2% 8 ml). Crystalloid to blood ratio will be 80% to 20% respectively. Dose will be 15 - 20 ml/kg in first dose then 8 - 10 ml/kg every 60 minutes
62766894|NCT03913195|EXPERIMENTAL|Sentinel Group|Five (5) participants will receive two successive doses of 800mg ibalizumab administered in accordance with the prescribing information followed by five (5) successive 800mg doses on a schedule gradually increasing drug concentration and decreasing administration time.
62385347|NCT06102993||Control group|
62385348|NCT06102993||Exacerbated COPD|
62385349|NCT02523742|OTHER|Neuropsychiatric Disorders|Neuropsychiatric Disorders patients
62385350|NCT02523742|OTHER|Healthy volunteers|control subjects matched to patients by age, sex, socio-cultural level and laterality
62385351|NCT01205646|EXPERIMENTAL|Zometa & PET Scans|Zoledronate therapy \& PET scan ;2 scans \[about 1-2 weeks apart\] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility, Bone scan (within 4 weeks prior to registration), bone turnover markers, and PSA will be obtained pretherapy. After that, Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration.
62385352|NCT05588076||normal endometrial|
62766895|NCT03913195|EXPERIMENTAL|Core Group|HIV-infected Core Group participants will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via undiluted IV Push over 30 seconds. Healthy Volunteer Core Group participants will receive a single 2000mg loading dose followed by three successive doses of 800mg in accordance with the prescribing information in order to reach steady state. Thereafter, Healthy Volunteers will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via undiluted IV Push over 30 seconds.
62385353|NCT05588076||endometrial lesions|
62385354|NCT04296344|EXPERIMENTAL|Treatment|Participants with chronic pain to receive acupuncture therapy treatments and yoga therapy sessions.
62385355|NCT02828202||Prospective cohort Resectable stage II or III|Patients with resectable stage II or III melanoma
62385356|NCT02828202||Prospective cohort Unresectable stage III or stage IV (resectable or not) or unresectable primary|Patients with unresectable stage III, or stage IV (resectable or not) or unresectable primary melanoma
62385357|NCT06292429|EXPERIMENTAL|Complex Training|
62385358|NCT06292429|ACTIVE_COMPARATOR|Conventional Training|
62385359|NCT06292429|OTHER|Control Group|
62385360|NCT05143294|EXPERIMENTAL|Modern board and card games group|The program consisted of 12 one-hour intervention sessions. The sessions were biweekly with a total duration of 6 weeks. The modern board and card games used in the program were Bee Alert (Knizia, 2012), Monster Match (Gruhl \& Weir, 2018), Kaleidos Junior (Albertarelli, 1997), Sherlock Express (Kermarrec, 2019), Alles Kanone! (Knizia, 2007), Halli Galli (Shafir, 1990), Bananazul (Warsch, 2019), Blurble (Bernard, 2013), La Morada Maldita (Ortiz, 2020), Dice Academy (Gobert, 2019) and Streams (Itsubaki, 2011). Play sessions will be held in subgroups of 3-5 children within the class group. In each session, each subgroup will play two games. The games used in the program have an average duration of approximately 20-30 minutes (filler games). All subgroups will play all games in the program the same number of times with the same rules. The game program will be the same in all participating centers to guarantee the homogeneity of its implementation.
62385361|NCT05143294|NO_INTERVENTION|Wait-list group|Wait-list. They will do the usual classes without modern board games. At the end of the post-intervention evaluation, the Conectar Jugando game program will be implemented under the same conditions as the experimental group.
62385362|NCT04005781|EXPERIMENTAL|Hydroxychloroquine sulphate|Plaquenil (hydroxychloroquine sulphate) will be acutely administered per os with 240 ml of water. Two tablets of 200 mg hydroxychloroquine sulphate each will be given.
62385363|NCT04005781|PLACEBO_COMPARATOR|Placebo|Two placebo tablets will be acutely administered per os with 240 ml of water.
62385364|NCT03618433|EXPERIMENTAL|Study group|"Standart exercise protocol and KİNECT® video based physiotherapy~The treatment protocol of the study group will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises.In total, a 25-minute Kincet® video game program will be applied in addition to the 15-minute basic and standart exercise program."
62385365|NCT03618433|ACTIVE_COMPARATOR|Control group|"Standart exercise protocol and Upper extremity rehabilitation~The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol"
62385366|NCT02092142|EXPERIMENTAL|Vaccinated|The vaccine will be administered subcutaneously in the upper outer aspect of the arm (triceps area) with 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 (which equals 30 μg)
62385367|NCT01729481|EXPERIMENTAL|RASH positive|"Run-In-Phase during 4 weeks:~Gemcitabine 1000 mg/m², weekly Erlotinib 100 mg, weekly~Thereafter Treatment in patients with RASH-positve outcome after 4 weeks."
62385368|NCT01729481|ACTIVE_COMPARATOR|RASH-negative|"Run-In-Phase during 4 weeks:~Gemcitabine 1000 mg/m², weekly Erlotinib 100 mg, weekly~RASH-negative patients quit treatment with Gemcitabine + Erlotinib and continue treatment with FOLFIRINOX:~Oxaliplatin 85mg/m2 Irinotecan 180 mg/m2 Folinic acid 400 mg/m2 5-FU 400 mg/m2 bolus iv 5-FU 2400 mg/m2 46-hours continous infusion"
62385369|NCT03098667|EXPERIMENTAL|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated
62558910|NCT01809912|EXPERIMENTAL|Greenstatin|"Cohort 1 : 6 mg/m2 Cohort 2 : 12 mg/m2 Cohort 3 : 24 mg/m2 Cohort 4 : 48 mg/m2 Cohort 5 : 96 mg/m2 Cohort 6 : 192 mg/m2 28 Day Course Subjects will receive MG1102 (Recombinant human apolipoprotein(a) Kringle V ) by IV administration on Day 0. If no DLTs are observed during the 6 days following the initial infusion, the same dose will be administered once daily for 5 consecutive days followed by a 2-day rest period three times (over 21 days), completing the course on Day 27.~Additional 21 Day Courses In the absence of a DLT, and in the case of stable disease or better, a subject may continue to receive MG1102 (Recombinant human apolipoprotein(a) Kringle V~) on a compassionate use basis at the same dose and regimen ."
61989735|NCT05279820|ACTIVE_COMPARATOR|Full Pulpotomy|After pulp exposure the entire coronal pulp to the level of canal orifices will be amputated , calcium silicate based material will be placed over the pulp and the tooth will be restored.
61989736|NCT02153255||Children With Mucopolysaccharidosis Type IVa|
61989737|NCT02912234|EXPERIMENTAL|Apixaban and Clarithromycin|
61989738|NCT03561623||Patients with Post Polio Syndrome|Post Polio syndrome diagnosed according to March of Dimes Criteria; 'magnetic resonance (MR) Imaging' will be performed including a 'quantitative muscle force assessment'
61989739|NCT03561623||Healthy controls|subjects age- and sex-matched; 'magnetic resonance (MR) Imaging' will be performed including a 'quantitative muscle force assessment'
61989740|NCT02233244|OTHER|CTX-4430 and midazolam|Midazolam 2 mg solution once, CTX-4430 100 mg tablet once per day for 7 days, Midazolam 2 mg solution once
61989741|NCT03362281|EXPERIMENTAL|Ilaprazole|
61989742|NCT03362281|ACTIVE_COMPARATOR|omeprazole|
61989743|NCT05796011||Age-related hearing loss patients with hearing aid(s)|Age-related hearing loss patients who were fitted with at least one hearing aid.
61989744|NCT05796011||Age-related hearing loss patients without an hearing aid|Age-related hearing loss patients who were treated without hearing intervention.
61989745|NCT05796011||Elderly healthy control|healthy elderly with normal hearing tested by pure tone audiometry.
61989746|NCT06457841|EXPERIMENTAL|Direct Discrimination|Simulated experience with direct incidents of everyday differential treatment that targets the participant's racial and ethnic background
61989747|NCT06457841|EXPERIMENTAL|Vicarious Discrimination|Simulated experience with indirect incidents of differential treatment as recalled by another Black person
61989748|NCT06457841|PLACEBO_COMPARATOR|Non-Racism Daily Hassles|Simulated stress-inducing experience in day-to-day lives appropriate for participant's age and educational/vocational backgrounds
62558911|NCT03170544|EXPERIMENTAL|Part 1, MK-1092, 4.0 nmol/kg|MK-1092, 4.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
61989749|NCT04510779|EXPERIMENTAL|Heart Failure Patients|This will be a single arm study of heart failure patients with acute decompensation
61989750|NCT01770561|EXPERIMENTAL|Integrated sensor and infusion set.|All subjects must have been previously diagnosed Type 1 Diabetics and being used to sensor augumented pumps
61989751|NCT00271947|EXPERIMENTAL|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after the conditioning regimen
61989752|NCT02424929|OTHER|Awake|"Original surgery intervention.~Patient will have DBS surgery done in the normal fashion. Asleep for the drilling of the burr holes, then awakened for the placement of the electrodes. No intervention will be given."
61989753|NCT02424929|OTHER|Asleep|"Sedation intervention.~Surgical intervention, anesthesia will be administered during entire placement of the system. Patient will not be awake at any point during procedure. All other aspects of surgery will be conducted normally."
61989754|NCT03200899|EXPERIMENTAL|Memory, Attention, Problem Solving Skills in MS (MAPSS-MS)|Participants randomized to this arm receive the MAPSS-MS intervention. The MAPSS-MS is an an 8 week computer assisted cognitive rehabilitation intervention. The group based component of the intervention emphasizes use of compensatory cognitive strategies as well as lifestyle modifications to enhance cognition. Participants also complete home computer training (minimum 3 times per week for 45 minutes) using a special suite of games designed by Lumosity.
61989755|NCT03200899|ACTIVE_COMPARATOR|Usual Care plus Computer games|Participants randomized to this arm receive usual care and are referred to MY BRAIN GAMES web site.
62385370|NCT03098667|ACTIVE_COMPARATOR|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
62385371|NCT05514093||App users|As this is a single cohort study, there is only one group consisting of the Beyond Silence app users.
62385372|NCT04557696|NO_INTERVENTION|Control Group|Standard oncology curriculum for medical trainees in oncology programs.
62385373|NCT04557696|EXPERIMENTAL|Reflective Group|Standard oncology curriculum with standardized patient simulation, in addition to the REFLECT Curriculum workshops for medical trainees in oncology programs.
62385374|NCT03742258|EXPERIMENTAL|Treatment (R-CHOP, TAK-659)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV over 3-5 minutes, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning in course 2, patients also receive spleen tyrosine kinase inhibitor TAK-659 PO QD on days 1-21. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
62385375|NCT00696644||Patients with severe osteoporosis|Postmenopausal women and men aged \> 21 years old affected by severe osteoporosis
62385376|NCT05454631|EXPERIMENTAL|patient present at the respiratory SSR department of the Pitié-Salpêtrière hospital|All the participants will evaluate 5 different types of surgical mask, in random order.
62385377|NCT00430924|ACTIVE_COMPARATOR|1|Eplerenone
62385378|NCT00430924|NO_INTERVENTION|2|Control
62385379|NCT01919749|OTHER|treatment|recommended treatment
62385380|NCT00743041|EXPERIMENTAL|1|Standard of Care plus EFT (Emotional Freedom Techniques)
62385381|NCT00743041|NO_INTERVENTION|2|Standard of Care (SOC)
62385382|NCT03125902|PLACEBO_COMPARATOR|Placebo and Paclitaxel|Participants will receive placebo matching to atezolizumab via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg/m\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
62385383|NCT03125902|EXPERIMENTAL|Atezolizumab and Paclitaxel|Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m\^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
62385384|NCT00606021|EXPERIMENTAL|A: Pemetrexed + Best Supportive Care|"Pemetrexed: 500 milligrams per square meter (mg/m²) , intravenous (IV), Day 1 of each 21-day cycle for 6 cycles~Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."
62385385|NCT00606021|ACTIVE_COMPARATOR|B: Best Supportive Care|Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
62385386|NCT00695318|EXPERIMENTAL|A, 2, I 0.2 µg/Day + Sham|0.2 µg/Day
62385387|NCT00695318|EXPERIMENTAL|A, 2, II 0.5 µg/Day + Sham|0.5 µg/Day
62385388|NCT00585104|EXPERIMENTAL|1|All randomized patients receive drug.
62385389|NCT02666118|ACTIVE_COMPARATOR|Preemptive Interscalene Block - Single Shot|
62385390|NCT02666118|ACTIVE_COMPARATOR|Postoperative Interscalene Block - Single Shot|
62385391|NCT02666118|ACTIVE_COMPARATOR|Preemptive Interscalene Block - Catheter|
62558912|NCT03170544|EXPERIMENTAL|Part 1, MK-1092, 8.0 nmol/kg|MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
62558913|NCT03170544|EXPERIMENTAL|Part 1, MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
62385392|NCT02666118|ACTIVE_COMPARATOR|Postoperative Interscalene Block - Catheter|
62385393|NCT04937608||COVID-19 group|men aged 18 to 45 who have been infected with SARS-CoV-2 in the past 6 months
62385394|NCT04937608||Control group|healthy men aged 18 to 45 with normal sperm parameters (WHO 2010 criteria) and who have never contracted COVID-19
62385395|NCT04101994|EXPERIMENTAL|VCT and real rTMS|In virtual cycling training and intermittent theta burst stimulation group (VCT + iTBS group), they received VCT and iTBS (80% of active motor threshold) on affected hemisphere.
62385396|NCT04101994|EXPERIMENTAL|VCT and sham rTMS|In virtual cycling training and sham theta burst stimulation group (VCT + iTBS group), they received VCT and sham TBS stimulation.
62385397|NCT04101994|EXPERIMENTAL|real rTMS|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
62385398|NCT04101994|SHAM_COMPARATOR|sham rTMS|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
62385399|NCT04101994|EXPERIMENTAL|VCT and real TES|In virtual cycling training and transcranial electric stimulation group (VCT + TES group), they received TES stimulation over motor cortex.
62385400|NCT04101994|EXPERIMENTAL|VCT and sham TES|In virtual cycling training and sham transcranial electric stimulation group (VCT + sham TES group), they received VCT and sham TES stimulation.
62385401|NCT04101994|EXPERIMENTAL|real TES|In transcranial electric stimulation group (TES group), they received TES stimulation over motor cortex.
62385402|NCT04101994|SHAM_COMPARATOR|sham TES|In sham transcranial electric stimulation group (sham TES group), they received sham TES stimulation.
62385403|NCT01494727|EXPERIMENTAL|CJ Amlodipine/Valsartan 10/160mg|
62385404|NCT01494727|ACTIVE_COMPARATOR|Novartis Exforge 10/160mg|
62385405|NCT05978804|EXPERIMENTAL|Active tDCS on the DLPFC + Cognitive Intervention(s)|Participants will receive active tDCS on DLPFC + Cognitive Intervention(s) first and then receive only active tDCS Intervention after a three-month washout period.
62385406|NCT05978804|EXPERIMENTAL|Active tDCS on the DLPFC only|Participants will receive active tDCS on the DLPFC-only intervention first and then receive active tDCS + Cognitive Intervention(s) after a three-month washout period.
62385407|NCT04791241|EXPERIMENTAL|check-list with ultrasound|check-list including lung ultrasound for the management of patients with acute respiratory failure at the emergency department during the COVID-19 era
62385408|NCT01766401|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets, oral administration
62385409|NCT01766401|EXPERIMENTAL|Vilazadone|Vilazadone tablets, oral administration
62385410|NCT00087594|EXPERIMENTAL|Direct Observed Therapy|Participants will receive the peginterferon alfa-2a plus ribavirin at the clinic as: subcutaneous peginterferon alfa-2a 180 microgram (mcg) (once in a week) for 24 weeks for Genotype 2 or 3 (G2/3), and for 48 weeks for Genotype 1 (G1); oral ribavirin 800 milligram (mg)/day (twice in a day) for 24 weeks for G2/3, and 1000 or 1200 mg/day (twice in a day) for 48 weeks for G1.
62385411|NCT00087594|EXPERIMENTAL|Self-Administration Therapy|Participants will receive the peginterferon alfa-2a plus ribavirin at home as: subcutaneous peginterferon alfa-2a 180 mcg (once in a week) for 24 weeks for G2/3, and for 48 weeks for G1; oral ribavirin 800 mg/day (twice in a day) for 24 weeks for G2/3, and 1000 or 1200 mg/day (twice in a day) for 48 weeks for G1.
62766896|NCT03913195|EXPERIMENTAL|Intramuscular Injection Group|HIV-infected Intramuscular Injection Group participants will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via Intramuscular Injection. Healthy Volunteer Intramuscular Injection Group participants will receive a single 2000mg loading dose followed by three successive doses of 800mg in accordance with the prescribing information in order to reach steady state. Thereafter, Healthy Volunteers will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via intramuscular injection.
62385412|NCT05425537||Fatal drowning|Fatal drowning incident where the patient died because of the drowning process
62385413|NCT05425537||Non-fatal drowning|Non-fatal drowning incident where the patient was drowning and can be ascertained to have been experiencing either mild, moderate, or severe respiratory impairment immediately after the drowning process ended but survived.
62558914|NCT03170544|EXPERIMENTAL|Part 1, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
62558915|NCT03170544|EXPERIMENTAL|Part 1, MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
62558916|NCT03170544|ACTIVE_COMPARATOR|Part 1, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
62766897|NCT02723370|EXPERIMENTAL|Initial Intervention|Staff will receive the intervention during the initial intervention period.
62766898|NCT02723370|EXPERIMENTAL|Delayed Intervention|Staff will receive the intervention during the replication study.
62385414|NCT02981745|EXPERIMENTAL|CT-1530|
62385415|NCT02589873|ACTIVE_COMPARATOR|In-Person Diabetes Prevention Program|An in-person group delivery modality of a CDC recognized Diabetes Prevention Program (DPP), delivered by the Young Men's Christian Association (YMCA). This group receives lifestyle coaching in a group setting, meeting weekly for 16 weeks followed by 3 biweekly sessions, and 5 monthly maintenance sessions.
62385416|NCT02589873|ACTIVE_COMPARATOR|Online Diabetes Prevention Program|An online delivery modality of a CDC recognized Diabetes Prevention Program (DPP), delivered by Canary Health's Virtual Lifestyle Management program. This group completes online learning sessions weekly for 16 weeks followed by 8 monthly maintenance sessions.
62385417|NCT04498949|EXPERIMENTAL|Exprimental|"The unified protocol modules are as follows:~Module 1: Setting the treatment goals and motivation augmentation Module 2: Using psychoeducation to learn the function of emotions and their development Module 3: Mindful (present-focused and non-judgmental) emotional awareness- Core module Module 4: Cognitive flexibility- Core module Module 5: Identifying and countering emotional avoidance behaviors- core module Module 6: Increasing awareness and confronting physical sensations/ interoceptive sensitivity- core module Module 7: Both situational and interoceptive emotion-focused exposures- Core module Module 8: Recognizing accomplishments and looking to the future (relapse prevention)"
62385418|NCT04498949|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual care, Recieve consulting not included unified protocol Recieve supportive cares
62385419|NCT05709470||Children and adolescents with congenital heart defects|Children and adolescent between 5-18 years of age, born with a congenital heart defect, living in Denmark at the inclusion time. A parent to each child/adolescent should also participate. Participants are found though the Danish registries by a diagnosis of congenital heart defect. The diagnosis of Congenital Heart Defect most be giving at one of the four University Hospitals in Denmark. These criteria were applied to ensure the validity of the diagnoses.
62385420|NCT05709470||Heart-healthy children and adolescents|Heart-healthy, sex- and age matched children and adolescents (5-18y). A parent to each child/adolescent should also participate. Participants are found though the Danish registries by not having a diagnosis of congenital heart defect.
62385421|NCT05979857|EXPERIMENTAL|Dose Escalation|For part 1 dose escalation, one patient per dose cohort will be initially recruited (accelerated titration dose-escalation, single-patient cohorts/dose level) for the first two dose levels or until the first instance of a ≥ Grade 2 toxicity (excluding Grade 2 neutropenia and lymphopenia and adverse events unequivocally due to the underlying disease or to an extraneous cause), or dose-limiting toxicity (DLT), whichever occurs earlier. Further cohorts will be recruited in blocks of three patients, i.e., 3+3 dose escalation design.
62558917|NCT03170544|EXPERIMENTAL|Part 2, MK-1092, 8.0 nmol/kg + lispro, 1.2 nmol/kg|MK-1092, 8.0 nmol/kg dose selection based on Part 1 + lispro (Humalog®), 1.2 nmol/kg, as a single dose, in healthy participants
62558918|NCT03170544|EXPERIMENTAL|Part 3, MK-1092, 8.0 nmol/kg|MK-1092, (8.0 nmol/kg based on Part 1), SC, in participants with T1DM.
61989756|NCT02325011|EXPERIMENTAL|Treatment Sequence 1|"During each of the four Inpatient Periods (Visit 2 to Visit 5 inclusive), healthy subjects with a history of cannabis use will either receive a single dose of Sativex® alone (Treatment A) or a single-dose of Sativex coadministered with the interaction drug, fluconazole (Treatment B) on a repeated, cross-over basis.~Subjects will be randomly assigned to one of two treatment sequences. Treatment sequence 1 is as follows;~* Visit 2 (Treatment A)~* Visit 3 (Treatment B)~* Visit 4 (Treatment A)~* Visit 5 (Treatment B)~The crossover treatments will be separated by a washout period of at least 10 days, but no more than 12 days, between each Sativex® dose."
62385422|NCT05979857|EXPERIMENTAL|Dose Optimization|For part 2 dose selection optimization, two dose levels will be selected by the Safety Review Committee (SRC) based on review of all available data on safety, tolerability, PK, PD, and preliminary efficacy from part 1. The dose selection optimization will include only patients with R/R DLBCL and will randomize 1:1 approximately 30 new patients at the two selected dose levels (15 patients to each of the two selected dose levels) before declaring the RP2D. Assessment of PK/PD of SP-3164 will be included in part 2 dose selection optimization.
62558919|NCT03170544|EXPERIMENTAL|Part 3, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose, in participants with T1DM
62558920|NCT03170544|ACTIVE_COMPARATOR|Part 3, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose, in participants with T1DM
62558921|NCT03170544|EXPERIMENTAL|Part 4, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose, in participants with T2DM
62558922|NCT03170544|EXPERIMENTAL|Part 4, MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose, in participants with T2DM
62558923|NCT03170544|EXPERIMENTAL|Part 4, MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose, in participants with T2DM
62558924|NCT03170544|ACTIVE_COMPARATOR|Part 4, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose, in participants with T2DM
62558925|NCT01153828||(1) Age <9 months|Age at time of prescription was \<9 months
62385423|NCT00105833|EXPERIMENTAL|Arm 1|Multifaceted collaborative intervention for depression based in primary care
62385424|NCT00105833|NO_INTERVENTION|Arm 2|Treatment as usual
62558926|NCT01153828||(2) 9 months to 6 years|Age at time of prescription was 9 months to 6 years
62558927|NCT01153828||(3) 7 years to 18 years|Age at time of prescription was 7 years to 18 years
62558928|NCT01153828||(4) 19 to 65 years|Age at time of prescription was 19 to 65 years
62558929|NCT01153828||(5) 66 years and older|Age at time of prescription was 66 years and older
62558930|NCT02532686|EXPERIMENTAL|DAAOI-2|DAAOI-2: 500-2000mg/d
62558931|NCT02532686|PLACEBO_COMPARATOR|placebo|
62558932|NCT02765997|ACTIVE_COMPARATOR|Unmanipulated UCB|Subjects will receive unmanipulated umbilical cord blood transplantation after a myeloablative CY/FLU/TBI conditioning.
62558933|NCT02765997|EXPERIMENTAL|StemRegenin-1 UCB|Subjects will receive StemRegenin-1 (SR-1) cultured umbilical cord blood transplantation after a myeloablative CY/FLU/TBI conditioning.
62558934|NCT02389283||Rheumatoid arthritis(RA) patients|The patients will be evaluated according to clinical practice (clinical evaluation and inflammation markers) at baseline and 3 and 6 months after the initiation of the treatment with the biologic DMARD.
62558935|NCT05196113|EXPERIMENTAL|sipIT|Participants receive education and a digital tool to monitor their fluid intake and remind them when they have lapsed in regular fluid intake.
62558936|NCT05196113|NO_INTERVENTION|Control|Participants receive usual care (i.e., education about fluid intake guidelines and encouragement to meet those guidelines).
62558937|NCT03347682||Test group: Transtibial amputees|After translation/retranslation of the Prosthesis donning and doffing questionnaire, transtibial amputees will be asked to complete a quality of life evaluation Nottingham Health Profile-NHP, a satisfaction evaluation Satisfaction with Prosthesis -SATPRO and the Turkish version of the Prosthesis donning and doffing questionnaire twice (1-3 days apart).
62558938|NCT02279966|EXPERIMENTAL|Vortioxetine 10 mg|daily, encapsulated, orally
62558939|NCT02279966|OTHER|Paroxetine 20 mg (active reference)|daily, encapsulated, orally
62558940|NCT02279966|PLACEBO_COMPARATOR|Placebo|capsules, orally
62558941|NCT01308203|EXPERIMENTAL|Extended release niacin /laropiprant|The patients will be randomized to one of two arms. The intervention is with the extended release niacin laropiprant combination, that is an add on of the usual medication that the primary care physician gave them to treat their lipid disorder (statin, ezetimibe or the combination of both).
62558942|NCT01308203|PLACEBO_COMPARATOR|placebo|The patients will received placebo added to the usual therapy their primary care physician gave them to treat their lipid disorder (statin, ezetimibe or the combination of both).
62558943|NCT01800747|ACTIVE_COMPARATOR|Direct antibiotic treatment|The doctor gives to parents an antibiotic prescription for their son's respiratory infection which he should start immediately.
62558944|NCT01800747|NO_INTERVENTION|No antibiotic treatment|The doctor does not give to parents an antibiotic prescription for their son's respiratory infection.
62558945|NCT01800747|EXPERIMENTAL|Delayed antibiotic prescription|The doctor gives to parents an antibiotic prescription for their son's respiratory infection with the advice to use it if needed, in case of worsening of symptoms or not improve.
62558946|NCT06152432|ACTIVE_COMPARATOR|Maxilillary implant overdenture retained by bars|Patients treated with 4 dental implants in the edentulous maxilla and an overdenture retained by bars
62385425|NCT05926895|EXPERIMENTAL|Patients with subacromial impingement syndrome (central sensitization positive)|Subacromial steroid injection While the patient is in a sitting position the subacromial space and the rotator cuff will be evaluated with the sonosite-m turbo ultrasonography device linear probe. The area where the rotator cuff and subacromial bursa are most prominent will be determined under the deltoid muscle. The injection site is first covered with povidone iodine and then with 80% alcohol solution will be wiped to provide antisepsis. The subacromial bursa between the deltoid muscle and the rotator cuff will be advanced from lateral to medial with an inplane approach with a 21 g 38 mm needle under the guidance of ultrasonography. Bleeding after making sure that the needle tip is in the bursa by checking, 1 cc betamethasone dipropionate + betamethasone sodium phosphate and 4 cc 2% prilocaine mixture will be injected, showing that it is evenly distributed in the bursa.
62385426|NCT05926895|EXPERIMENTAL|Patients with subacromial impingement syndrome (central sensitization negative)|Subacromial steroid injection While the patient is in a sitting position the subacromial space and the rotator cuff will be evaluated with the sonosite-m turbo ultrasonography device linear probe. The area where the rotator cuff and subacromial bursa are most prominent will be determined under the deltoid muscle. The injection site is first covered with povidone iodine and then with 80% alcohol solution will be wiped to provide antisepsis. The subacromial bursa between the deltoid muscle and the rotator cuff will be advanced from lateral to medial with an inplane approach with a 21 g 38 mm needle under the guidance of ultrasonography. Bleeding after making sure that the needle tip is in the bursa by checking, 1 cc betamethasone dipropionate + betamethasone sodium phosphate and 4 cc 2% prilocaine mixture will be injected, showing that it is evenly distributed in the bursa.
62385427|NCT00925522|EXPERIMENTAL|Therapy Cool Path Duo Cardiac Ablation System|All patients who are eligible receive cardiac ablation procedure for Ischemic Ventricular Tachycardia
62385428|NCT02830295|EXPERIMENTAL|Basic Body Awareness Therapy|The Basic Body Awareness Therapy is usual therapy of physiotherapy in health mental in nord of europe. BBAT is based in twelve movements and massage that improve the movement quality of patient, also BBAT improves others movement qualities like biomechanical, physiologic, socio-cultural and existential.
62385429|NCT02830295|NO_INTERVENTION|control|the patients which below receive the treatment as usual, according the clinic guidelines of Health government
62385430|NCT01078181|ACTIVE_COMPARATOR|banded gastric bypass|Banded gastric bypass (circular anastomosis 21mm) using the A.M.I. B-Band (Soft Gastric Bypass Band)
61989757|NCT02325011|EXPERIMENTAL|Treatment Sequence 2|"During each of the four Inpatient Periods (Visit 2 to Visit 5 inclusive), healthy subjects with a history of cannabis use will either receive a single dose of Sativex® alone (Treatment A) or a single-dose of Sativex coadministered with the interaction drug, fluconazole (Treatment B) on a repeated, cross-over basis.~Subjects will be randomly assigned to one of two treatment sequences. Treatment sequence 2 is as follows;~* Visit 2 (Treatment B)~* Visit 3 (Treatment A)~* Visit 4 (Treatment B)~* Visit 5 (Treatment A)~The crossover treatments will be separated by a washout period of at least 10 days, but no more than 12 days, between each Sativex® dose."
61989758|NCT03143699|EXPERIMENTAL|Immediate feedback|Submitted to a training on blood pressure measurement skills and an immediate feedback after their encounter with an standardized patient - SP
62385431|NCT01078181|ACTIVE_COMPARATOR|non-banded gastric bypass|non-banded gastric bypass (circular anastomosis 21mm)
62385432|NCT02510885|EXPERIMENTAL|SD-OCT Angiography|Study participants will undergo imaging of both eyes with the AngioVue unit (approximately 60 seconds/eye), per standard operating protocol. Imaging is noncontact, and pharmacologic dilation will not be used for the purposes of this study. In most instances, study participants will undergo only a single imaging session on a single day. However, potential participants will be asked to consent for additional imaging sessions (up to 12) that may occur over the course of subsequent future visits to the clinic. Additionally, study participants will be asked to consent to prospective collection of clinical and demographic data, to correlate findings of OCT-A imaging to subsequent clinical course.
62385433|NCT05170516|EXPERIMENTAL|Experimental Group A|In experimental group A, 4°C saline irrigation was used for removal of the bone surrounding the right or left third molars.
62385434|NCT05170516|EXPERIMENTAL|Experimental Group B|In experimental group B, 10°C saline irrigation was used for removal of the bone surrounding the right or left third molars.
62385435|NCT05170516|ACTIVE_COMPARATOR|Control Group A|In control group A, room temperature saline was used for the other side extractions of patients whose impacted tooth was extracted under 4 °C saline irrigation on one side.
62385436|NCT05170516|ACTIVE_COMPARATOR|Control Group B|In control group B, room temperature saline was used for the other side extractions of patients whose impacted tooth was extracted under 10 °C saline irrigation on one side.
62385437|NCT01614951|EXPERIMENTAL|Pulmonary perfusion|
62385438|NCT01614951|EXPERIMENTAL|Pulmoplegia|
62385439|NCT01614951|OTHER|Control group|
62385440|NCT03731065|ACTIVE_COMPARATOR|Fructose-maltodextrin ingestion|Ingestion of fructose and maltodextrin (glucose polymers) at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
62385441|NCT03731065|EXPERIMENTAL|Fructose-maltodextrin hydrogel ingestion|Ingestion of fructose and maltodextrin (glucose polymers) encapsulated in alginate-pectin hydrogel, drinks at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
62385442|NCT03731065|ACTIVE_COMPARATOR|Glucose-maltodextrin ingestion|Ingestion of glucose and maltodextrin (glucose polymers) at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
61989759|NCT03143699|NO_INTERVENTION|Students with no immediate feedback|Submitted to a training on blood pressure measurement skills, but without an immediate feedback after their encounter with an standardized patient - SP
61989760|NCT05109663|EXPERIMENTAL|Dose Escalation Cohort 1: single oral dose of SKLB1028|Eligible subjects received a single dose of SKLB1028 50 mg on Day 1.
62385443|NCT01428479|EXPERIMENTAL|Treatment Arm A|In Arm A subjects will receive 100 mg of GR121167 in Period 1 and 300 mg of GR121167 in Period 2. In Period 3 subject will receive single doses of placebo on Day 1 and multiple doses of placebo from Day 3 to Day 8
62385444|NCT01428479|EXPERIMENTAL|Treatment Arm B|In Arm B subjects will receive 100 mg of GR121167 in Period 1 and placebo in Period 2. In Period 3 subject will receive 600 mg of GR121167 as single dose on Day 1 and multiple doses of GR121167 from Day 3 to Day8
62385445|NCT01428479|EXPERIMENTAL|Treatment Arm C|In Arm C subjects will receive placebo in Period 1, 300 mg of GR121167 in Period 2. In period 3 subject will receive 600 mg of GR121167 single dose on Day 1 and multiple doses from Day 3 to Day 8
62385446|NCT03670056|EXPERIMENTAL|Nivolumab and Ipilimumab|Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
62385447|NCT04901286|NO_INTERVENTION|Seated Rest|Behavioral: Seated Rest In the seated rest control condition, participants will sit on the bike for 30 minutes. Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart rate will be recorded every two minutes and perceived exertion will be reported every four minutes.
62385448|NCT04901286|ACTIVE_COMPARATOR|Exercise Only|Behavioral: Exercise Only In the exercise-only condition, participants will complete a total of 30-minutes on the stationary bike. This will include a) 5-min warm-up at low resistance, b) 20 minutes of moderate-vigorous intensity cycling, and c) a 5-min cool-down at low resistance. Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart rate will be recorded every two minutes and perceived exertion will be reported every four minutes.
62168266|NCT01536535|EXPERIMENTAL|Moderate to Severe UC|"Moderate/Severe = Initiated on IV CS, or oral CS with PUCAI ≥45~Patients can be treated with any of the therapies noted below:~Mesalazine: doses is rounded to the nearest 500mg increment, maximum dose of 75 mg/kg/day Oral corticosteroids:1-1.5 mg/kg/day, rounded up to the nearest 5 mg value~IV corticosteroids:~Additional Therapies:~Calcineurin inhibitor (cyclosporine, tacrolimus) or anti-TNFα therapy: These therapies may also be instituted if in the judgment of the attending physician is needed.~Immunomodulator or biologic therapy: thiopurine then dosing of azathioprine:2.5-3 mg/kg/day; 6-Mercaptopurine (MP) at 1-1.5 mg/kg/day Colectomy"
62385449|NCT04901286|EXPERIMENTAL|Exercise + Non-Immersive Virtual Reality|"Behavioral: Exercise + Non-Immersive Virtual Reality In the exercise with non-immersive Virtual Reality condition, participants will complete a total of 30-minutes on the stationary bike while watching a video on an iPad. The cycling session will be identical to that in the Exercise Only condition (5-min warm-up, 20 minutes of moderate-vigorous intensity cycling, and 5-min cool down). During cycling, a YouTube video called 360° VR Cycling Newport Back Bay Sunset \[30 MIN - NO MUSIC\]) will play on an iPad placed on the front of the bike. Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart rate will be recorded every two minutes and perceived exertion will be reported every four minutes."
62385450|NCT04901286|EXPERIMENTAL|Exercise + Immersive Virtual Reality|"Behavioral: Exercise + Immersive Virtual Reality In the exercise with immersive virtual reality condition, participants will complete a total of 30-minutes on the stationary bike while wearing Oculus Quest 2 goggles. The bout of cycling will be identical to the prescription given in the exercise only condition (5-min warm-up, 20 minutes of moderate-vigorous intensity cycling, and 5-min cool down). During cycling, the Oculus YouTubeVR app will play a 360° version of the YouTube video called 360° VR Cycling Newport Back Bay Sunset \[30 MIN - NO MUSIC\]). Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart Rate will be recorded every two minutes and perceived exertion will be reported every four minutes."
62385451|NCT00673140|EXPERIMENTAL|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
62385452|NCT04915209|OTHER|Narrative interviews|Narratives are stories that are based on the unfolding of events or actions from the perspective of a patient's life experience. Patients and care partners tell their stories of illness and how they live with illness over time . The researcher could focus on the care priorities, the support needed, the information needed and the challenges faced. The narrative interview will be used to get an overview of the patient's trajectory.
62385453|NCT06317298|EXPERIMENTAL|Fruquintinib(3mg) plus Everolimus|Fruquintinib 3mg Qd 21 days on 7 days off; Everolimus 5mg Qd; 28 day cycle until disease progression or intolerable adverse events
62385454|NCT06317298|EXPERIMENTAL|Fruquintinib(4mg) plus Everolimus|Fruquintinib 4mg Qd 21 days on 7 days off; Everolimus 5mg Qd; 28 day cycle until disease progression or intolerable adverse events
62385455|NCT06317298|EXPERIMENTAL|Fruquintinib(5mg) plus Everolimus|Fruquintinib 5mg Qd 21 days on 7 days off; Everolimus 5mg Qd; 28 day cycle until disease progression or intolerable adverse events
62385456|NCT01218477|EXPERIMENTAL|Dasatinib, 100/140 mg QD|Participants received dasatinib, 100/140 mg once daily (QD), depending on cohort (100 mg for those with chronic myeloid leukemia \[CML\]-chronic phase; 140 mg for those with CML-advanced phase)
62385457|NCT01218477|EXPERIMENTAL|Dasatinib, 100/140 mg QD + BMS-833923, 50 mg QD|Participants received dasatinib, 100/140 mg once daily (QD), depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase) plus BMS-833923, 50 mg, QD
62385458|NCT01218477|EXPERIMENTAL|Dasatinib, 100/140 mg QD + BMS-833923, 100 mg BID/QD|Participants received BMS-833923, 100 mg twice daily (BID) for 7 days then once daily (QD) + dasatinib, 100/140 mg QD, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
62385459|NCT01218477|EXPERIMENTAL|Dasatinib, 100 /140 mg QD+ BMS-833923, 200 mg BID/QD|Participants received BMS-833923, 200 mg twice daily (BID) for 7 days then 200 mg once daily (QD) plus dasatinib, 100 /140 mg QD), depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
62385460|NCT04528433|EXPERIMENTAL|Medical-education-community Collaborated Intervention|
62385461|NCT04528433|ACTIVE_COMPARATOR|routine clinical care|
62385462|NCT05095779|ACTIVE_COMPARATOR|Oklahoma Tobacco Helpline (OTH)|Participants randomized to OTH will be offered coaching calls and nicotine replacement therapy.
62385463|NCT05095779|EXPERIMENTAL|OTH + Financial Incentives (OTH+FI)|Participants will receive standard OTH care (coaching calls + nicotine replacement therapy) and escalating financial incentives for completing up to 5 coaching calls.
62385464|NCT03883659|ACTIVE_COMPARATOR|traditional paper hangouts group|patients use the traditional paper hangouts to conduct the home exercise program at home
61989761|NCT05109663|EXPERIMENTAL|Dose Escalation Cohort 2: single oral dose of SKLB1028|Eligible subjects received a single dose of SKLB1028 100 mg on Day 1.
62168267|NCT05823051|EXPERIMENTAL|VASIDS-TP and Counseling Practice|Video-Assisted Sudden Infant Death Syndrome Prevention Training Program (VASIDS-TP) and Counseling Practice
61989762|NCT05109663|EXPERIMENTAL|Food Effect Cohort A: SKLB1028, fasted dosing followed by fed dosing|Eligible subjects received a single dose of SKLB1028 150 mg on Day 1 in a fasting state, and a single dose of SKLB1028 150 mg on Day 11 in a fed state, with a 10-day washout period between the 2 doses.
61989763|NCT05109663|EXPERIMENTAL|Food Effect Cohort B: SKLB1028, fed dosing followed by fasted dosing|Eligible subjects received a single dose of SKLB1028 150 mg on Day 4 in a fed state, and a single dose of SKLB1028 150 mg on Day 14 in a fasting state, with a 10-day washout period between the 2 doses.
62766899|NCT02601547|EXPERIMENTAL|intervention|"1. PET-FDG brain imaging and NPT should be performed at T0 (within the 15 days before chemotherapy), at Tf (within 1 month after chemotherapy termination), T+12 (Tf+12 months: within the first month after one year of achievement of chemotherapy). Several PET parameters should be calculated: minimal Standard Uptake Value (SUV), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.~2. NPT scores (3 values) should be correlated with the five better values on PET-FDG.~3. Each patient will be monitored along a time period of 18 months.~4. Duration of the study: one year to include the 15 patients with all the exams; 18 months follow-up for each; total of 30 months."
62766900|NCT03299569||Takotsubo cardiomyopathy|All patients diagnosed with Takotsubo cardiomyopathy in Scotland since 2010.
61989764|NCT03214159|EXPERIMENTAL|group 1|"During the study session, healthy subjects will be administered a single dose of Ritonavir or Tablet 100mg or NORVIR tablet 100mg under fasting condition.~Intervention:~cylcle 1 Drug: Ritonavir tablet 100mg cylcle 2 Drug: NORVIR tablet 100mg cylcle 3 Drug: Ritonavir tablet 100mg cylcle 4 Drug: NORVIR tablet 100mg"
61989765|NCT03214159|EXPERIMENTAL|group 2|"During the study session, healthy subjects will be administered a single dose of Ritonavir or Tablet 100mg or NORVIR tablet 100mg under fasting condition.~Intervention:~cylcle 1 Drug: NORVIR tablet 100mg cylcle 2 Drug: Ritonavir tablet 100mg cylcle 3 Drug: NORVIR tablet 100mg cylcle 4 Drug: Ritonavir tablet 100mg"
61989766|NCT03322488|EXPERIMENTAL|Patients with Crohn's Disease|20 patients with Crohn's Disease. Intervention: Fistulodesis
61989767|NCT03322488|EXPERIMENTAL|Patients without IBD|20 patients without underlying Inflammatory Bowel Disease. Intervention: Fistulodesis
61989768|NCT05877092|ACTIVE_COMPARATOR|acrylic resin denture base|complete overdenture constructed from heat cured acrylic resin for Group I
61989769|NCT05877092|ACTIVE_COMPARATOR|thermoplastic denture|complete thermoplastic denture was constructed for Group II
61989770|NCT04579042|EXPERIMENTAL|Septoplasty Using Cartilaginous Batten Graft|septoplasty using cartilaginous batten graft in cases with caudal septal deviation
61989771|NCT05021367|EXPERIMENTAL|TQB3823 tablets|Subjects receive TQB3823 in the first cycle for a total of 28 days , a single dose on Day 1. Day 2 to Day 7 are the elution period, and the continuous doses are from Day 8 to Day 21. From the second cycle, continuous treatment for 28 days is as a treatment cycle.
61989772|NCT03320564|EXPERIMENTAL|Infiltration|Repeat F-18 FDG PET
61989773|NCT04227821||Hemodynamically instable pediatric patients|Pediatric patients admitted to the pediatric intensive care unit with the need of vasopressor and/or inotrope therapy due to hemodynamic instability
61989774|NCT02298881||Dry eye group|People with dry eye symptoms
61989775|NCT02298881||Non-dry eye group|People with no dry eye symptoms
61989776|NCT06160063|EXPERIMENTAL|Experimental group|"It is planned to meet with the experimental group 3 times in total. In the first interview, first of all, Diabetes Child Diagnosis Form and Diabetes Health Literacy Scale for Acute Complications in Children will be applied. Then the diabetes health literacy board game will be played. For this, groups of 4 will be formed and care will be taken to ensure that children of similar age groups are together while forming groups. In the clinic, they will be asked to play a diabetes health literacy (DISOY) board game in a quiet, bright room, a room with a table and 4 chairs. DISOY board game averages 45-60 minutes. and the first meeting will end here. Each child will be given one game to play with their parents at least twice at home.~The second interview will be provided 1 month after the first interview. The third interview will be held in the third month. Data collection forms will be filled out again at each interview."
61989777|NCT06160063|NO_INTERVENTION|control|"control group; It is planned to meet with the control group 3 times in total. In the first, second and third interviews, only the data collection forms will be filled by the children.~After collecting all the data of the experimental group, a board game will be given to the parents and children in the control group."
61989778|NCT04490447||Bronchiectasis|"Patient meets diagnose of bronchiectasis refering to BTS guideline 2010 will be included."
62385465|NCT03883659|EXPERIMENTAL|smartphone group|patients use the smartphone to conduct the home exercise program at home
62558947|NCT06152432|ACTIVE_COMPARATOR|Maxilillary implant overdenture retained by Locators|Patients treated with 4 dental implants in the edentulous maxilla and an overdenture retained by solitary abutments (Locators)
62558948|NCT06350981|EXPERIMENTAL|Exparel TLIP Injection|Subjects will receive 20 mL of EXPAREL 266mg mixed with 10 mL of 0.25% bupivacaine. A total of 30 mL of mixed solution is injected into the thoracolumbar interfacial plane.
62766901|NCT03299569||Myocardial Infarction|An equal number of myocardial infarction patients in NHS Grampian since 2010.
61989779|NCT04490447||Healthy control|Healthy volunteers will be included.
61989780|NCT00234988|EXPERIMENTAL|1|
61989781|NCT01148511|EXPERIMENTAL|Treat and Extend|Patients received ranibizumab 0.5 mg intravitreally (ivt) once a month for 3 months. If the disease was inactive 4 weeks later, the next visit was postponed 2 weeks to 6 weeks later. If the disease was inactive during subsequent visits, the next visit was postponed an additional 2 weeks to 8 weeks later, the maximum interval between visits. If the disease became active at any visit, the patient received ranibizumab 0.5 mg ivt and the follow-up schedule started over.
61989782|NCT01148511|ACTIVE_COMPARATOR|Treat and Observe|Patients received ranibizumab 0.5 mg intravitreally (ivt) once a month for 3 months. All subsequent visits occurred monthly. If the disease was active, the patient received ranibizumab 0.5 mg ivt. If the disease was inactive, no treatment was administered and the patient was instructed to return 1 month later.
62558949|NCT06350981|ACTIVE_COMPARATOR|Bupivicaine HCL TLIP Injection|Standard of care will consist of 0.25% Bupivacaine HCl TLIP injection. Subjects will receive 30 mL of the solution, injected into the thoracolumbar interfacial plane.
62766902|NCT04371341|EXPERIMENTAL|E1|will receive erector spinae block with 0.25% bupivacaine volume of 2.5 ml/segment
62766903|NCT04371341|EXPERIMENTAL|E2|will receive erector spinae block 0.25% bupivacaine with volume of 3.4ml/segment
61989783|NCT01673035|EXPERIMENTAL|internet-based CBT|Cognitive behavior therapy delivered via the internet: 12 weeks, therapist-guided
61989784|NCT01673035|ACTIVE_COMPARATOR|internet-based BSM|behavioral stress management delivered via the internet: 12 weeks, therapist-guided
61989785|NCT05104515|EXPERIMENTAL|OVM-200|"2 mg/mL OVM-200 solution. Proposed dose levels for Phase 1a: 250, 500, and 1000 μg. The planned doses may be adjusted based on SRC recommendations. Following review of the data, 1 additional dose level may be added up to a maximum of 2000 μg.~The dose level for Phase 1b will be selected following review of the data from Phase 1a and will not exceed the dose safely administered in Phase 1a."
61989786|NCT03360370||6 to 66 months children with significant CHD|"Children with significant congenital heart disease (CHD) aged from 6 to 66 months at the time of the study and fulfilling inclusion criteria for whom an age-appropriate questionnaire completed by parents (Ages \& Stages Questionnaires, Third Edition in French (ASQ-3™) will be used to screen developmental delays."
61989787|NCT03338426|EXPERIMENTAL|Experimental|Co-administration of a fixed dose combination of Fimasartan 120mg and Atorvastatin 40mg
62385466|NCT00845299|EXPERIMENTAL|1|Latanoprost punctal plug and use of artificial tears containing Benzalkonium Chloride
62385467|NCT00845299|EXPERIMENTAL|2|Latanoprost punctal plug only
61989788|NCT03338426|ACTIVE_COMPARATOR|Active Comparator 1|Co-administration of Fimasartan 120mg and Placebo for Atorvastatin 40mg
61989789|NCT03338426|ACTIVE_COMPARATOR|Active Comparator 2|Co-administration of Atorvastatin 40mg and Placebo for Fimasartan 120mg
61989790|NCT01023646|OTHER|carbohydrate load|Food challenge - Carbohydrate load
61989791|NCT01023646|OTHER|Carbohydrate + Protein|Food challenge - carbohydrate + protein
61989792|NCT01023646|OTHER|Carbohydrate + Fat|Food challenge - carbohydrate + fat
61989793|NCT01023646|OTHER|Fiber|Food challenge - carbohydrate + fiber
62385468|NCT01957033|EXPERIMENTAL|Duration 6 weeks, frequency 3/week|Exercise and education 3 times/week for 6 weeks Manual therapy 3 times/week for 6 weeks
62385469|NCT01957033|EXPERIMENTAL|Duration 6 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks Manual therapy twice/week for 6 weeks
62385470|NCT01957033|EXPERIMENTAL|Duration 6 weeks, Frequency once/week|Exercise and education once/week for 6 weeks Manual therapy once/week for first 6 weeks
61989794|NCT02741700|EXPERIMENTAL|Gout storytelling video|Participants view culturally relevant patient narrated storytelling in African-American Veterans' own voices about their experience with gout and its treatment and a patient narrated slide show of gout and its treatment.
61989795|NCT02741700|ACTIVE_COMPARATOR|Video about management of another chronic condition|Participants view a patient narrated slide show of roughly the same duration as the experimental arm, summarizing the management of stress, a non-gout chronic condition.
61989796|NCT03094845|PLACEBO_COMPARATOR|Placebo|
61989797|NCT03094845|EXPERIMENTAL|hdmASIT+TM|
61989798|NCT00625677|EXPERIMENTAL|1|"Pediacel - 2,3,4 months Prevenar - 2,4 months Menjugate - 3 months Hib/ pneumo conjugate/ Men C conjugate - 12 months~Blood collected - 4,5,12,13 months"
61989799|NCT00625677|EXPERIMENTAL|2|"Pediacel - 2,3,4 months Prevenar - 2,4 months Neis-vacC - 3 months Hib/ pneumo conjugate/ Men C conjugate - 12 months~Blood collected - 4,5,12,13 months"
61989800|NCT03902951|EXPERIMENTAL|Treatment (leuprolide, apalutamide, abiraterone acetate, SBRT)|Patients receive leuprolide SC on day 1, Patients receive a single dose of leuprolide SC on day 1 and apalutamide PO QD and abiraterone acetate PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity. Beginning 2 months of initiation of ADT, patients also receive SBRT over 1, 3, or 5 fractions in the absence of disease progression or unacceptable toxicity.
61989801|NCT01319877||First Line Treatment|Participants received bevacizumab in combination with 5-FU based chemotherapy as a first line therapy.
61989802|NCT01319877||Second Line Treatment|Participants received bevacizumab in combination with 5-FU based chemotherapy as a second line therapy.
61989803|NCT00620438|EXPERIMENTAL|1|nevirapine arm
61989804|NCT00620438|EXPERIMENTAL|2|efavirenz arm
61989805|NCT00620438|EXPERIMENTAL|3|Rifampicin arm
61989806|NCT04413084|EXPERIMENTAL|Gaze stability exercises|Group I will receive Gaze stability exercises.
61989807|NCT04413084|EXPERIMENTAL|Brandt-Daroff Exercises|Group II will receive Brandt-Daroff Exercises.
61989808|NCT03338062|EXPERIMENTAL|Theragnostic SBRT Planning|The theragnostic SBRT plan using the HIDA scan was chosen as the plan that reduced the dose of radiation to functional liver without compromising target coverage or tumor control.
61989809|NCT03338062|NO_INTERVENTION|Standard SBRT Planning|The standard SBRT plan was chosen as the plan that reduced the dose of radiation to functional liver without compromising target coverage or tumor control.
61989810|NCT01384396|EXPERIMENTAL|KW-3357|
61989811|NCT00003120|ACTIVE_COMPARATOR|paclitaxel 3 cycles|paclitaxel given for 3 cycles
61989812|NCT00003120|EXPERIMENTAL|paclitaxel for 12 cycles|paclitaxel given for 12 cycles
61989813|NCT02088983|EXPERIMENTAL|CDP-Choline|Single dose of 500 mg, 1000 mg, or 2000 mg given in one of 4 test sessions
62385471|NCT01957033|EXPERIMENTAL|Duration 3 weeks, Frequency 3 times/week|Exercise and education 3 times/week for 6 weeks Manual therapy 3 times/week for first 3 weeks
62385472|NCT01957033|EXPERIMENTAL|Duration 3 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks Manual therapy twice/week for first 3 weeks
62385473|NCT01957033|EXPERIMENTAL|Duration 3 weeks, frequency once/week|Exercise and education once/week for 6 weeks Manual therapy once/week for first 3 weeks
62385474|NCT01957033|EXPERIMENTAL|Duration 0 weeks, Frequency 3 times/week|Exercise and education 3 times/week for 6 weeks No manual therapy
62385475|NCT01957033|EXPERIMENTAL|Duration 0 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks. No manual therapy
62385476|NCT01957033|EXPERIMENTAL|Duration 0 weeks, Frequency once/week|Exercise and education once/week for 6 weeks No manual therapy
62385477|NCT03714451|EXPERIMENTAL|Onyx Group|Patients with T2DM will receive food products containing onyx sorghum (Onyx Group).
62385478|NCT03714451|ACTIVE_COMPARATOR|Wheat Flour Group|Patients with T2DM will receive food products with wheat flour.
62385479|NCT04194086|EXPERIMENTAL|posaconazole as antifungal prophylaxis|
62385480|NCT02987205|EXPERIMENTAL|Revanesse Ultra|Revanesse Ultra in the NLF on one side of the face
62385481|NCT02987205|ACTIVE_COMPARATOR|Restylane|Restylane injection in the NLF on the other side of the face to optimal correction
61989814|NCT02088983|PLACEBO_COMPARATOR|Placebo (cellulose)|Given randomly in one of the 4 testing sessions as a comparison
61989815|NCT06429501|EXPERIMENTAL|Bupivacaine injection|The surgeon will be provided with a 10 mL syringe, and he/she will be blinded to the contents of the syringe. The appropriate landmarks will be identified, and a 21, 25, or 27- gauge needle will be used to perform the nerve block with 0.25% bupivacaine.
62766904|NCT04371341|EXPERIMENTAL|E3|will erector spinae block receive 0.25% bupivacaine with volume of 6.6 ml/segment
62766905|NCT04371341|NO_INTERVENTION|C|will not receive erector spinae block
61989816|NCT06429501|PLACEBO_COMPARATOR|Saline injection|The placebo sham injection will be performed in an identical fashion as the nerve block with the exception of using 10 mL of 0.9% saline injection instead of bupivacaine.
61989817|NCT06271733|ACTIVE_COMPARATOR|Active TMS|
61989818|NCT06271733|SHAM_COMPARATOR|Sham|
62385482|NCT02763605||patients diagnosed with acanthamoeba keratitis|"Inclusion Criteria:~- All patients presenting to National Taiwan University Department from Jun. 1st, 2003 to dec. 30th , 2016 with the tissue proven corneal AK will be included.~Exclusion Criteria~- Patients with tissue proven corneal AK during from Jun. 1st, 2003 to dec. 30th , 2016, but without in vivo confocal data, or complete chart records."
61989819|NCT02021747||Individuals with TB|"Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~1. Symptoms consistent with TB~2. Chest X-rays and or chest CT consistent with TB~3. Positive PPD test~4. Positive sputum test"
61989820|NCT02021747||Smokers|"Active smoker as evidenced by self report and urine nicotine \>30 ng/mL and urine cotinine \>50 ng/mL~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~1. Symptoms consistent with TB~2. Chest X-rays and or chest CT consistent with TB~3. Positive PPD test~4. Positive sputum test"
61989821|NCT02021747||Non-smokers|"Never smokers is defined as someone who has smoked \< 100 cigarettes per lifetime and whose urine nicotine \<2 ng/mL and urine cotinine \<5 ng/mL, at entry into the study~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~1. Symptoms consistent with TB~2. Chest X-rays and or chest CT consistent with TB~3. Positive PPD test~4. Positive sputum test"
61989822|NCT02021747||Individuals with COPD|"All study subjects should meet the Lung Disease protocol criteria for having COPD may be of any stage (GOLD I - IV), be ambulatory and have no evidence of respiratory failure~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~1. Symptoms consistent with TB~2. Chest X-rays and or chest CT consistent with TB~3. Positive PPD test~4. Positive sputum test"
61989823|NCT02110576||Healthy Controls|Healthy controls in general good health, without chronic disease/illness, including but not limited to: cancer, diabetes mellitus, renal disease, cardiac disease, hypertension, lung disease, liver disease, complications of morbid obesity, autoimmune/inflammatory disease, or any condition of sufficient severity that it requires daily medication to manage
62558950|NCT03222310|EXPERIMENTAL|Ipatasertib|Participants will receive one 100 milligram (mg) ipatasertib tablet orally on Day 1 of treatment in treatment period 1 followed by two 100 mg itraconazole capsules orally on Days 15 to 23 along with one 100 mg of ipatasertib on Day 19 in treatment period 2. Both the treatment period will be separated by a washout period of 14 days.
62766906|NCT03609476|ACTIVE_COMPARATOR|Standard of care group|No saline instillation
62385483|NCT01359813|NO_INTERVENTION|Usual treatment|intravenous injection of Human Albumin. 1,5g/kg on first day and 1g/kg on third day
62385484|NCT01359813|EXPERIMENTAL|Human Albumin|1,5g/kg on first day and 1g/kg on third day.
62385485|NCT00661362|EXPERIMENTAL|1|Metformin + Saxagliptin
62766907|NCT03609476|ACTIVE_COMPARATOR|Room temperature saline group|room temperature saline instillation
61989824|NCT04166838|EXPERIMENTAL|CD19 UCAR-T|
61989825|NCT00918515|EXPERIMENTAL|AZD3043|Intravenous solution
61989826|NCT04216927|EXPERIMENTAL|Nitric Oxide|Intraoperative NO entrained at 20 ppm into the oxygenator of the CPB circuit with standard care
62766908|NCT03609476|ACTIVE_COMPARATOR|Warmed saline group|warmed saline instillation
62766909|NCT02185989|ACTIVE_COMPARATOR|Electrical muscle stimulation and bicycling|Patients will undergo early electrical stimulation of the quadriceps and early leg bicycling in addition to routine care (which comprises early standard mobilization)
62766910|NCT02185989|NO_INTERVENTION|Standard early passive/active rehabilitation|In this control group, patients will undergo routine care that comprises standard early passive/active rehabilitation delivered by physiotherapist with the assistance of ICU nurses
62766911|NCT02604758|EXPERIMENTAL|Tidal Model|the psychiatric nursing approach based on the Tidal Model
62385486|NCT00661362|PLACEBO_COMPARATOR|2|Metformin + Placebo
62385487|NCT04046666|OTHER|COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
62766912|NCT02604758|NO_INTERVENTION|control group|The control group received routine treatment and follow-up in the Alcohol and Substance Addiction Treatment Clinic.
62766913|NCT01611220|NO_INTERVENTION|Control|Standard cognitive behavior inpatient treatment
62766914|NCT01611220|EXPERIMENTAL|RePAN|Standard cognitive behavior inpatient treatment plus 8 dissonance relapse prevention groups
62766915|NCT03751514|EXPERIMENTAL|Phase A - SI|"Phase A aims to determine a 'standard inoculum' dose (SI), which results in safe colonisation of 70% of volunteers.~The SI will be identified in a dose escalating or de-escalating experiment commencing at 10-3 colony forming units B. pertussis administered intranasally. Each group of volunteers will be inoculated at half log-fold increasing/decreasing doses until the endpoint is reached. The experiment will be continued until the SI yields 10 subjects who are colonised at day 14.~Intervention to be administered: Bordetella Pertussis B1917"
61989827|NCT04216927|PLACEBO_COMPARATOR|Oxygen|Standard CPB without NO administered at any point intraoperatively
61989828|NCT01706003||Telemedicine Group|People who suffer from Migraine Headaches who own a computer and have internet access and will be treated via telemedicine for migraine headaches
62385488|NCT04046666|OTHER|Healthy group|This group will include 40 healthy volunteers.
62558951|NCT02147977|ACTIVE_COMPARATOR|dietary supplement: n-3 PUFA|"n-3 polyunsaturated fatty acids from fish oil~capsules of 500 mg. 2 g a day."
62558952|NCT02147977|PLACEBO_COMPARATOR|olive oil|Capsules of 500 mg. 2 g a day.
62385489|NCT04046666|OTHER|Healthy intervention group|This group will include 40 healthy volunteers, who will receive moxibustion intervention.
62385490|NCT05042804|EXPERIMENTAL|Machine Learning Assistance|Clinicians in the Anesthesia Control Tower will review patient data using the electronic health record and using AlertWatch, and they will also view the machine learning display. They will then predict how likely the patient is to experience postoperative death and postoperative acute kidney injury.
62385491|NCT05042804|NO_INTERVENTION|No Assistance|Clinicians in the Anesthesia Control Tower will review patient data using the electronic health record and using AlertWatch, but they will not view the machine learning display. They will then predict how likely the patient is to experience postoperative death and postoperative acute kidney injury.
61989829|NCT01706003||In-Office Group|People who suffer from Migraine Headaches who own a computer and have internet access and will be treated in the clinician's office for migraine headaches
61989830|NCT02459028|EXPERIMENTAL|T3P Intervention group|"Intervention group: Participants are instructed to practice 4 out of 10 different Positive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks."
61989831|NCT02459028|ACTIVE_COMPARATOR|Control group|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
62385492|NCT02390323|EXPERIMENTAL|Lumbar Sympathetic Block|Patients receiving a Lumbar Sympathetic Block as treatment for lower extremity pain. Skin conductance algesimeter will be used to measure sympathetic activity.
62385493|NCT04770701|EXPERIMENTAL|Ahah drug|"Participants have a decline in CD4 + T-lymphocytes is the hallmark of the human immunodeficiency virus (HIV)-1 infection.~Characterized by rapid loss of resistance: AIDS~* Dermatitis, mouth ulcers, skin rash, itching, weight loss~* Hepatitis C virus (HCV) (+), Hepatitis B virus (HBV) (+), Tuberculosis (+)~Ahah composition contains the following ingredients (concentrated extracts of plants):~Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg"
62385494|NCT04770701|EXPERIMENTAL|Ahah Placebo|"Participants have a decline in CD4 + T-lymphocytes is the hallmark of the human immunodeficiency virus (HIV)-1 infection.~Characterized by rapid loss of resistance: AIDS~* Dermatitis, mouth ulcers, skin rash, itching, weight loss~* Hepatitis C virus (HCV)(+), Hepatitis B virus (HBV)(+), Tuberculosis (+)~Ahah composition placebo (Ahah not containing concentrated extracts of plants Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg)"
62385495|NCT05830331|NO_INTERVENTION|Control|
62385496|NCT05830331|EXPERIMENTAL|Treatment|
62385497|NCT03839576|EXPERIMENTAL|Computerized cognitive training|The computerized cognitive training will take place at each participant's residence. Participants will be asked to practice at least 1 session a day for 6 months, and a session lasts for 60 minutes.
62385498|NCT03839576|EXPERIMENTAL|Lower extremity strengthening|"This exercise will comprise stretching, muscle strengthening, and balance training at increasing difficulty levels, tailored and supervised by a physical therapist, and will take place at a subject's residence or in the neighborhood once a week for 6 months.~Each session will last 60 min."
62385499|NCT03839576|EXPERIMENTAL|Tai chi chuan|The 8-form Yang-style tai chi intervention will take place at a subject's residence or the neighborhood once a week for 6 months, and each session will last for 60 minutes.
62385500|NCT03839576|NO_INTERVENTION|Social interaction|Immediately after the baseline assessment, the care manager will visit the subject in this group once for comparability with the other two intervention groups.
62385501|NCT05720936||patients with electric storm|patients with electric storm defined as the occurrence of at least three episodes of ventricular fibrillation/tachycardia in 24 hours
61989832|NCT05165615|EXPERIMENTAL|AndroidAPS versus Control-IQ|Patients with use of the Control-IQ system (closed-loop hybrid system) and previous users of AndroidAPS (closed-loop hybrid system)
61989833|NCT04330742||0 mL crystalloid|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 0, at which time 0 mL of fluids will have been administered.
62385502|NCT00538486|EXPERIMENTAL|Group T|Telmisartan
62385503|NCT00538486|EXPERIMENTAL|Group T+M|Telmisartan plus Metformin
62385504|NCT00538486|EXPERIMENTAL|Group C|Candesartan
62385505|NCT00538486|EXPERIMENTAL|Group C+M|Candesartan pus Metformin
62385506|NCT00538486|ACTIVE_COMPARATOR|Group A|Amlodipine
62385507|NCT00538486|EXPERIMENTAL|Group A+M|Amlodipine plus Metformin
62385508|NCT00692159|EXPERIMENTAL|1|Dose finding single arm
62385509|NCT04126187||Panoptix|Bilateral implantation of the Panoptix trifocal IOL
62558953|NCT05760963||Adult with lumbar echography indication|Adult with lumbar echography indication will be included.
62385510|NCT03469206|SHAM_COMPARATOR|Direct MT|Direct mechanical thrombectomy (MT) with no intravenous thrombolysis
62385511|NCT03469206|ACTIVE_COMPARATOR|IVT combine with MT|Intravenous thrombolysis before mechanical thrombectomy
62558954|NCT02573597|ACTIVE_COMPARATOR|Part A Group 1|CEI bupivacaine and CEI sufentanil
62385512|NCT04657003|EXPERIMENTAL|10 milligrams (mg) Tirzepatide|10 mg Tirzepatide administered subcutaneously (SC) once weekly (QW)
62558955|NCT02573597|ACTIVE_COMPARATOR|Part A Group 2|PIEB bupivacaine and PIEB sufentanil
62558956|NCT02573597|ACTIVE_COMPARATOR|Part B Group 3|CEI bupivacaine and PIEB sufentanil
61989834|NCT04330742||250 mL crystalloid.|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 1, after the spinal has been placed and approximately 250 mL fluids has been administered.
61989835|NCT04330742||500 mL crystalloid|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 2, at which time 500 mL of fluids will have been administered.
61989836|NCT04330742||1000 mL crystalloid|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 3, at which time 1000 mL of fluids will have been administered.
61989837|NCT01301495|EXPERIMENTAL|HANAROSTENT covered Esophageal Stent|
61989838|NCT03483675|ACTIVE_COMPARATOR|Arm I (discontinued IST)|Participants have their IST tapered and discontinued per the plan.
61989839|NCT03483675|EXPERIMENTAL|Arm II (continued IST)|Participants continue to receive a fixed dose IST for an additional 9 months with no taper.
61989840|NCT04264910|EXPERIMENTAL|Calm Meditation|Participants (n=49) will be provided free access to and asked to register for the consumer-based mobile meditation app on their phone. Participants (n=49) will then receive an email containing 28 weeks of free access to Calm. Participants (n=49) will be asked to use Calm at least 10 minutes per day and encouraged to use it as much as they would like during the intervention. This prescription mimics how a new, paying member would use the app (full exposure with autonomy).
62558957|NCT02573597|ACTIVE_COMPARATOR|Part B Group 4|PIEB bupivacaine and CEI sufentanil
62558958|NCT04992078|EXPERIMENTAL|Robotic-Unicompartmental Knee Replacement (R-UKR)|NAVIO/CORI Surgical System
62558959|NCT04992078|ACTIVE_COMPARATOR|Conventional-Unicompartmental Knee Replacement (C-UKR)|Non-robotic conventional instrumentation
61989841|NCT04264910|NO_INTERVENTION|Control|The control group will be asked to maintain normal activity and refrain from using Calm meditation app.
61989842|NCT05261867||Diabetic patients treated with SGLT2-I|Diabetic patients treated with SGLT2-I alone or in combination with other oral anti-diabetic (OAD) agents. Patients were considered in the SGLT2-I group if it was started at least 1 month prior to index hospitalization.
61989843|NCT05261867||Diabetic patients treated with other oral anti-diabetic (OAD) agents|Diabetic patients treated with other oral anti-diabetic agents alone.
61989844|NCT05667922||Remission|
61989845|NCT05667922||Non-remission|
62385513|NCT04657003|EXPERIMENTAL|15 mg Tirzepatide|15 mg Tirzepatide administered SC QW
62558960|NCT03843060|EXPERIMENTAL|Single AZD9977|During this treatment period, healthy participants will be administered with a single AZD9977 (Dose 1) dose, in the fed state, on Day 1 followed by at least 3 days washout period.
62558961|NCT03843060|EXPERIMENTAL|Itraconazole + AZD9977|During this treatment period, healthy participants will be administered with Itraconazole (Dose 2) from Day 4 to Day 8 plus will be administrated with AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole will be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
62558962|NCT04525534||Placenta accreta spectrum|Mother-infant dyads with suspected or confirmed diagnosis of placenta accreta spectrum
61989846|NCT02646033||robotic surgery|all those patients aged 40 - 60 years undergoing robotic surgeries, who does not have any ophthalmic complains.
61989847|NCT03733288|EXPERIMENTAL|SLAMM|Multi-component intervention (Education and training sessions, Support emails, Team leader training)
61989848|NCT03733288|EXPERIMENTAL|SLAMM+|Multi-component intervention (Education and training sessions, Support emails, Team leader training, Height-adjustable workstation)
62385514|NCT04657003|PLACEBO_COMPARATOR|Placebo|Placebo administered SC QW
62385515|NCT04018391|EXPERIMENTAL|Stepped care for non-adherence and depression|Participants will be randomized approximately two weeks post-baseline. Those randomized to the experimental condition will receive the Intervention and Stepped Care Treatment Protocol
62558963|NCT04525534||Phenotypically-matched controlled group|Mother-infant dyads admitted for delivery without placenta accreta spectrum
62558964|NCT01012895|EXPERIMENTAL|Arm 1: Sentinel A|BMS-790052 (60mg) once daily + BMS-650032 (600 mg) twice daily
62558965|NCT01012895|EXPERIMENTAL|Arm 2: Sentinel B|BMS-790052 (60mg) once daily + BMS-650032 (600mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
62558966|NCT01012895|EXPERIMENTAL|Arm 3: Expansion A1|BMS-790052 (60mg) once daily + BMS-650032 (200mg) twice daily
62558967|NCT01012895|EXPERIMENTAL|Arm 4: Expansion A2|BMS-790052 (60mg) once daily + BMS-650032 (200mg) once daily
61989849|NCT06092099|EXPERIMENTAL|Intervention|Subjects wear the sensor part of the Change indicator system during a 15-day period.
61989850|NCT04782856|ACTIVE_COMPARATOR|Single therapy|"Levothyroxine (LT4) and placebo (a look-alike inactive substance, a sugar pill) Patients in the LT4 group will be started at a dose of 1.6 mcg/Kg (52 The VCU Investigational Pharmacy will over-encapsulate LT4 plus placebo, in AM and PM color coded capsules. Patients will be instructed to take the AM drug first thing in the morning with water only, and to wait at least 30 minutes before taking other medications coffee or breakfast. The PM dose will be taken at least 30 minutes before dinner. Dose adjustments will be performed at the 6-week and 3-month follow up visits by an unblinded endocrinologist (Dr. Yavuz) aiming to achieve and maintain a target TSH within the normal range and within ± 0.5 mcIU/ml from the baseline (pre-surgery) TSH, Doses will be rounded to the nearest available formulation."
62385516|NCT04018391|ACTIVE_COMPARATOR|Enhanced Usual Care|Participants will be randomized two weeks post-baseline. Those randomized to the control condition will receive Enhanced Usual Care.
62385517|NCT03395704|ACTIVE_COMPARATOR|LJPC-401|LJPC-401 solution for subcutaneous injection only, 5mg/1 mL (5mg/mL) or 10mg/1mL (10mg/mL) single use vial
62385518|NCT03395704|PLACEBO_COMPARATOR|Placebo|0.9% Sodium Chloride Injection, USP, or equivalent
62385519|NCT06250712|EXPERIMENTAL|Continous ECG Patch|In this arm, continuous patch ECG was used.
62385520|NCT06250712|ACTIVE_COMPARATOR|Intermittent handheld ECG|In this arm, intermittent handheld ECG was used.
62558968|NCT01012895|EXPERIMENTAL|Arm 5: Expansion B1|BMS-790052 (60mg) once daily + BMS-650032 (200 mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
62558969|NCT01012895|EXPERIMENTAL|Arm 6: Expansion B2|BMS-790052 (60mg) once daily + BMS-650032 (200 mg) once daily + Pegylated-interferon alfa-2a + Ribavirin
62766916|NCT03751514|EXPERIMENTAL|Phase B Inoculum|"Phase B, using study data from phase A, will be used to design a more practical model - if possible conducted partially in an outpatient setting, which will be conditional on safety and transmission evidence. The final protocol for phase B will be presented as a protocol amendment, it will be based on the SI and colonisation period identified in Phase A.~The SI determined in phase A will be used for all volunteers and eradication therapy will be given after the colonisation period based on the data of phase A. Approximately 30 individuals will receive the intranasal SI and will be treated with azithromycin for three days at the end of the colonisation period.~Intervention to be administered: Bordetella Pertussis B1917"
62766917|NCT03751514|EXPERIMENTAL|Phase B Sham|"Phase B, using study data from phase A, will be used to design a more practical model - if possible conducted partially in an outpatient setting, which will be conditional on safety and transmission evidence.~Approximately 15 individuals will not receive the Bordetella Pertussis B1917, instead they will be given an intranasal sham of sterile saline and will be treated with azithromycin 500mg for three days at the end of the 'colonisation' period."
62766918|NCT04467970|EXPERIMENTAL|Unicompartmental Knee Replacement|
62766919|NCT04467970|EXPERIMENTAL|High Tibial Osteotomy|
62766920|NCT01295684|PLACEBO_COMPARATOR|placebo|Base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage.
62766921|NCT01295684|EXPERIMENTAL|Cranberry Juice|Base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day.
62766922|NCT03530332|EXPERIMENTAL|Treatment|
62766923|NCT03530332|NO_INTERVENTION|Control|
62766924|NCT02535416|EXPERIMENTAL|ARC-520 Cohort 1|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.6 mL/min + cetirizine
62766925|NCT02535416|EXPERIMENTAL|ARC-520 Cohort 2A|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.9 mL/min + cetirizine
62766926|NCT02535416|EXPERIMENTAL|ARC-520 Cohort 2|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.75 mL/min + diphenhydramine
62766927|NCT02535416|EXPERIMENTAL|ARC-520 Cohort 3|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.9 mL/min + diphenhydramine
62558970|NCT01012895|EXPERIMENTAL|Arm 7: Expansion B3|BMS-790052 (60 mg) once daily + BMS-650032 (200 mg) twice daily + Ribavirin
62558971|NCT02687451|EXPERIMENTAL|Oxymorphone HCl Open-Label Phase|Oxymorphone HCl Immediate Release Oral Liquid and Oxymorphone HCl Injection; open-label, single-dose, dose selection phase.
62558972|NCT02687451|EXPERIMENTAL|Oxymorphone HCl Multiple-Dose Phase|Oxymorphone HCl Immediate Release Oral Liquid and Oxymorphone HCl Injection; placebo controlled, randomized, double-blinded multiple-dose phase.
62766928|NCT02535416|EXPERIMENTAL|ARC-520 Cohort 4|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 1.2 mL/min + diphenhydramine
62766929|NCT02535416|EXPERIMENTAL|ARC-520 Cohort 5|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 1.5 mL/min + diphenhydramine
62766930|NCT02535416|EXPERIMENTAL|ARC-520 Cohort 6|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 5 minute slow bolus push + diphenhydramine
62766931|NCT02535416|EXPERIMENTAL|ARC-520 Cohort 7|Single dose, intravenous administration of ARC-520 at 5.0 mg/kg 0.9 mL/min + diphenhydramine
62766932|NCT02535416|EXPERIMENTAL|ARC-520 Cohort 8|Single dose, intravenous administration of ARC-520 at 6.0 mg/kg 0.9 mL/min + diphenhydramine
62766933|NCT02830204|EXPERIMENTAL|Mitral Valve Replacement with Sapien3|subjects with surgical MVR with Sapien3
62766934|NCT05221775|EXPERIMENTAL|experimental arm|
62766935|NCT04641949|ACTIVE_COMPARATOR|Methoxyflurane|Inhalation methoxyflurane 99,9%, 3 ml, single dose. Intravenous NaCl 9 mg/ml, XX ml, single dose.
61989851|NCT04782856|EXPERIMENTAL|Combination therapy|"Liothyronine/levothyroxine (LT3/LT4) combination therapy. LT4/LT3 group will have 25 mcg of LT4 substituted with 5 mcg LT3 twice daily, to mimic the average daily T3 production form the thyroid The VCU Investigational Pharmacy will over-encapsulate LT4 plus 5 mcg LT3 in AM and PM color coded capsules. Patients will be instructed to take the AM drug first thing in the morning with water only, and to wait at least 30 minutes before taking other medications coffee or breakfast. The PM dose will be taken at least 30 minutes before dinner. Dose adjustments will be performed at the 6-week and 3-month follow up visits by an unblinded endocrinologist (Dr. Yavuz) aiming to achieve and maintain a target TSH within the normal range and within ± 0.5 mcIU/ml from the baseline (pre-surgery) TSH, Doses will be rounded to the nearest available formulation. No changes will be made in LT3."
61989852|NCT06485063|EXPERIMENTAL|Myofascial Reorganization Group|Each participant will receive 12 sessions of Myofascial Reorganization
61989853|NCT06485063|PLACEBO_COMPARATOR|Placebo Myofascial Reorganization|Each participant will receive 12 sessions of Myofascial Reorganization Placebo
61989854|NCT03710655|EXPERIMENTAL|treatment group|skin test, dose escalation, final dose of 1.5mg weekly over 16 weeks of Apitox pure honeybee toxin
61989855|NCT03710655|PLACEBO_COMPARATOR|placebo group|histamine placebo administered intradermally in dose escalation, final dose of 1.5mg weekly over 16 weeks
61989856|NCT03474887||DIGI-Throat|Patients choosing to seek primary care through an online consultation with chief complaint sore throat.
62385521|NCT05288049|EXPERIMENTAL|Intervention aiming to enhance cognitive reserve (CR)|The psychological intervention to enhance cognitive reserve (CR) will be conducted in a group format (6-8 individuals). Each session will last approximately 60 minutes. The full psychological intervention will have 12 sessions (1 per week) and will last three months. Moreover, to remind the participants of the contents of the intervention, a follow-up session will be held every two months between the last session of the psychological intervention and the 12-month assessment. Most of the tasks of the psychological intervention will use pen and paper with audiovisual support. However, some sessions will use mobile apps and virtual reality. Virtual reality will be implemented for each patient in the sessions focusing on mindfulness training. The contents of the sessions are adapted to the different ages of the attendees. Groups with adolescents and those with young adults will be run separately.
62385522|NCT05288049|ACTIVE_COMPARATOR|Support therapy|The support control group will have weekly meetings with assistants to talk about the difficulties they had during the week, without receiving a specific intervention. After the 12-month assessment, subjects in the support group will be offered the intervention although this will be out of the scope of this study.
61989857|NCT03474887||DIGI-Resp|Patients choosing to seek primary care through an online consultation with chief complaint cough/common cold/influenza.
61989858|NCT03474887||DIGI-Dysuria|Patients choosing to seek primary care through an online consultation with chief complaint dysuria.
61989859|NCT03474887||PHYSI-Throat+CONTROL-Throat|"Patients choosing to seek primary care through physical consultation with chief complaint sore throat.~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of sore throat."
61989860|NCT03474887||PHYSI-Resp+CONTROL-Resp|"Patients choosing to seek primary care through physical consultation with chief complaint cough/common cold/influenza.~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of cough/common cold/influenza."
62385523|NCT05118893||Ablation-based rhythm-control|Ablation-based rhythm-control consisted of pulmonary vein isolation in paroxysmal atrial fibrillation, and additional ablation for persistent atrial fibrillation
62385524|NCT05118893||Rate-control|Rate-control included AV-nodal blocking agents and AV node ablation with permanent pacing
62385525|NCT00075634|EXPERIMENTAL|Arm I|"PART A (solid tumor patients): Patients receive decitabine IV over 1 hour on days 0-6 and doxorubicin IV over 15 minutes and cyclophosphamide IV over 1 hour on day 7. Patients then receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8 or 9\*. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~PART B (neuroblastoma patients): Once the MTD is determined for part A, patients are treated as in part A at the MTD."
62385526|NCT01066546|EXPERIMENTAL|Dimebon|
62385527|NCT03524664|NO_INTERVENTION|"Delayed tuning in to kids intervention"|Children with fetal alcohol spectrum disorder and their parents
62385528|NCT03524664|EXPERIMENTAL|"Tuning in to kids intervention"|Children with fetal alcohol spectrum disorder and their parents
62385529|NCT04249076|EXPERIMENTAL|Clobetasol propionate|First dose of the drug will be dispensed at the end of the Baseline visit at the study center. Then, study medication will be dispensed to the participant for self-administration at a dosage ofe one drop four (4) times a day during 14 days
62385530|NCT04249076|PLACEBO_COMPARATOR|Vehicle|First dose of the drug will be dispensed at the end of the Baseline visit at the study center. Then, study medication will be dispensed to the participant for self-administration at a dosage ofe one drop four (4) times a day during 14 days
62385531|NCT03030092|NO_INTERVENTION|Control group|Today's standard care
62385532|NCT03030092|EXPERIMENTAL|Intervention group|Maximal Strength Training
62558973|NCT02687451|PLACEBO_COMPARATOR|Placebo|Sodium Chloride 0.9% solution; comparator for multiple-dose phase.
62558974|NCT05268653|EXPERIMENTAL|Motivational İnterviewing Group|For the Motivational Interviewing (MI) treatment group, a clinical public health nursing doctoral student trained in Motivational Interviewing administered six motivational interviewing therapy sessions, each 30 minutes long. A 3-month follow-up will then be applied.
61989861|NCT03474887||PHYSI-Dysuria+CONTROL-Dysuria|"Patients choosing to seek primary care through physical consultation with chief complaint dysuria~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of dysuria."
61989862|NCT05851183|ACTIVE_COMPARATOR|Therapeutic lifestyle change|Therapeutic lifestyle change only
61989863|NCT05851183|EXPERIMENTAL|Therapeutic lifestyle change plus Vitis Vinifera extract therapy|Therapeutic lifestyle change plus Vitis Vinifera extract medication therapy
61989864|NCT01277523|EXPERIMENTAL|A|
61989865|NCT01277523|EXPERIMENTAL|B|
61989866|NCT01277523|PLACEBO_COMPARATOR|C|
61989867|NCT01933854||Riverside group|Women aged 20 years or over who are not pregnant living riverside area of the Amapa State Brazil.
61989868|NCT01933854||urban group|women aged 20years or over not pregnant and living urban area
62385533|NCT06462079|EXPERIMENTAL|Group|Patients were treated with Sacituzumab Govitecan 10 mg/kg in 21-day treatment cycles with intravenous infusions on days 1 and 8 and continued until disease progression or unacceptable toxicity. Radiotherapy was administered after the second infusion of Sacituzumab Govitecan, on day 9 after the start of this regimen. The radiotherapy regimen was: brain metastases at a dose of 60 Gy/20 doses. For lesions located adjacent to the brainstem and optic nerve, 54 Gy/20 doses were given. For patients with ≥5 lesions, whole-brain radiotherapy at 40 Gy/20 doses was synchronized with radiotherapy to localized brain metastases.
62385534|NCT05146531|ACTIVE_COMPARATOR|McCoy group|Patients were intubated with McCoy laryngoscope.
62385535|NCT05146531|EXPERIMENTAL|C-MAC group|Patients were intubated with C-MAC D-blade video laryngoscope.
62385536|NCT04641013||People with HIV over the age of 55 years|
62385537|NCT04641013||People without HIV over the age of 55 years|
62385538|NCT04280185|EXPERIMENTAL|Hyperthermic Intraperitoneal chemotherapy|Hyperthermic Intraperitoneal chemotherapy was started immediately after CRS, or the first HIPEC was completed within 48 hours after surgery: temperature 43℃, duration 60 minutes, Paclitaxel (60mg/m2) was selected. The second HIEPC was completed 7 days after the first HIPEC: temperature 43℃, duration 60min, carboplatin AUC (5-6) was selected. 30 minutes before using Paclitaxel, 10ML saline + 10mg dexamethasone intravenous infusion, 20mg diphenhyramine intramuscular injection, and 100ML saline + 0.3g cimetidine intravenous infusion. On the eighth day, intravenous chemotherapy with Paclitaxel (135mg/m2) was finally completed. 5 courses of TC intravenous chemotherapy were performed after 3 weeks
62385539|NCT04280185|NO_INTERVENTION|intravenous chemotherapy|intravenous chemotherapy were performed 6 Cycles after CRS. Paclitaxel: 175mg/m2, iv infusion, no less than 3h per infusion, followed by carboplatin: AUC 5-6, iv infusion, no less than 1h per infusion, 1 dose on the first day of a week, 1 cycle every 3 weeks, a total of 6 cycles. Paclitaxel should be pretreated to prevent severe allergic reactions.
62385540|NCT03145857|EXPERIMENTAL|[68]Ga-HA-DOTATATE|All participants will be imaged with \[68\]Ga-HA-DOTATATE PET/CT or PET/MRI for uptake by somatostatin receptor positive tumours. Up to seven \[68\]Ga-HA-DOTATATE scans may be performed per participant, as clinically indicated.
62385541|NCT02943577|EXPERIMENTAL|Rapastinel 450 mg|Rapastinel 450 mg weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
62385542|NCT02943577|PLACEBO_COMPARATOR|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
62385543|NCT02411968||111In-Girentuximab DOTA SPECT|Patients \>50 years of age with renal tumours ≤4 cm highly suspicious for a malignancy planned to undergo cryotherapy will undergo 111In-Girentuximab DOTA SPECT scanning.
62385544|NCT05853926|EXPERIMENTAL|Spinal Manipulation With Laser Therapy|
62385545|NCT05853926|OTHER|Dry Needling|
62385546|NCT06117644||Furmonertinib|The subjects will be treated with Furmonertinib (double dose, 160mg). The subjects were treated with drugs for 24 months until the tumor progressed (worsened) or died.
62385547|NCT02255240|EXPERIMENTAL|Physical activity intervention|This arm will receive the physical activity intervention, which consists of three individual meetings, weekly brief counseling phone calls for 6 weeks, and provision of a video game console with three active video games.
62385548|NCT06160531|EXPERIMENTAL|CC-42344 Dose 1|Low dose group
62385549|NCT06160531|EXPERIMENTAL|CC-42344 Dose 2|High dose group
62385550|NCT06160531|PLACEBO_COMPARATOR|Placebo|
62385551|NCT01829542|ACTIVE_COMPARATOR|319 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
62385552|NCT01829542|ACTIVE_COMPARATOR|639 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
61989869|NCT04713475|EXPERIMENTAL|Part 1: Dose I of Dose Escalation Cohorts designed to identify the optimal dose of PBGM01|"Assigned Intervention:~PBGM01 Dose I: 3.3 x 10\^10 GC/g estimated brain weight, single dose of PBGM01 via intra cisterna magna in Late Onset Infantile GM1 Gangliosidosis (Type 2a) and Early Onset Infantile GM1 Gangliosidosis (Type 1)"
61989870|NCT04713475|EXPERIMENTAL|Part 1: Dose II of Dose Escalation Cohorts designed to identify the optimal dose of PBGM01|"Assigned Intervention:~PBGM01 Dose II: 1.1 x 10\^11 GC/g estimated brain weight, single dose of PBGM01 via intra cisterna magna in Late Onset Infantile GM1 Gangliosidosis (Type 2a) and Early Onset Infantile GM1 Gangliosidosis (Type 1)"
61989871|NCT04713475|EXPERIMENTAL|Part 1: Dose III of Dose Escalation Cohorts designed to identify the optimal dose of PBGM01|"Assigned Intervention:~PBGM01 Dose III: 2.2 x 10\^11 GC/g estimated brain weight, single dose of PBGM01 via intra cisterna magna in Late Onset Infantile GM1 Gangliosidosis (Type 2a) and Early Onset Infantile GM1 Gangliosidosis (Type 1)"
62385553|NCT01829542|ACTIVE_COMPARATOR|766 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
61989872|NCT04713475|EXPERIMENTAL|Part 2: Expansion Cohort designed to confirm the safety and efficacy of PBGM01|"Confirmatory Cohorts: Late Onset Infantile GM1 Gangliosidosis (Type 2a) and Early Onset Infantile GM1 Gangliosidosis (Type 1)~Assigned Intervention:~PBGM01 Single dose of PBGM01, via intra cisterna magna Dose to be determined"
61989873|NCT02580357|SHAM_COMPARATOR|Low Level Laser therapy (LLLT) Sham|The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue. The applications were performed by a different operator (CAS) from the one who measured the study parameters. During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications.
61989874|NCT02580357|EXPERIMENTAL|GaAlAs Laser therapy (LLLT) 60 J/cm²|The irradiation was performed with a GaAlAs diode laser that continuously emitted a wavelength of 660 nm with a power of 30 mW. The patients allocated for the group 60 received the following protocol for laser application: Two (2) points of irradiation were performed using a total energy density (fluence) of 60 J/cm2 and a time of 60 seconds (30 J/cm2 per point and an application time of 30 seconds per point). During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications. The power of the equipment was calibrated prior to each application.
62385554|NCT01829542|ACTIVE_COMPARATOR|1466 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
62385555|NCT01829542|ACTIVE_COMPARATOR|1791 mg total blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
61989875|NCT02580357|EXPERIMENTAL|GaAlAs Laser therapy (LLLT) 30 J/cm²|The irradiation was performed with a GaAlAs diode laser that continuously emitted a wavelength of 660 nm with a power of 30 mW. The patients allocated for the group 30 received the following protocol for laser application: Two (2) points of irradiation were performed using a total energy density (fluence) of 30 J/cm2 and a time of 30 seconds (15 J/cm2 per point and an application time of 15 seconds per point). During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications. The power of the equipment was calibrated prior to each application.
62385556|NCT01829542|PLACEBO_COMPARATOR|O mg blueberry polyphenols|Macro- and micronutrient matched control drink
62385557|NCT04851769|EXPERIMENTAL|alirocumab plus statin|Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
62385558|NCT04851769|ACTIVE_COMPARATOR|standard statin therapy|Patients in the standard statin arm will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day. Statin dose escalation or adding concomitant non-statin lipid-lowering therapy could be considered by their responsible physician to achieve an LDL-C target \<100 mg/dL.
62385559|NCT05322759|ACTIVE_COMPARATOR|Aquatic exercises|this group receives sessions for consecutive 8 weeks and 3 days per week. warm up for 10 min, that will include walking in shallow water and stretchings of upper and lower extremities. After that APE for 30 min followed cool down period for 5 min. exercise frequency is 3 sets of each exercise with 15 repetitions.
62558975|NCT05268653|NO_INTERVENTION|Control Group|No attempt will be made
61989876|NCT04888546|OTHER|Anlotinib hydrochloride capsules combined with TQB2450 injection|Anlotinib hydrochloride capsules (10mg po qd, Two weeks off for one week) combined with TQB2450 injection (1200mg ivgtt, q3W)
62558976|NCT03884361|EXPERIMENTAL|Vaginal Microbiome as result of aminocentesis|aginal Microbiome as result of aminocentesis by a blood and a vaginal samples that will taken before and after the aminocentesis
62558977|NCT00920439|EXPERIMENTAL|POLIORIX GROUP|Healthy male or female subjects between, and including, 18 and 24 months of age, received a single booster dose of Poliorix™ vaccine that was administrated into the upper right thigh by intramuscular injection (IM).
62558978|NCT04842071|EXPERIMENTAL|18F-NaF eligible patients|Eligibility for 18F-NaF PET scans is the same than for bone scintigraphy routinely prescribed in the clinic.
61989877|NCT05860283|ACTIVE_COMPARATOR|Core stabilization exercise group|Core muscle activation exercises will be done using the pressure biofeedback unit. The session will include visual, auditory \& tactile biofeedback. Visual monitoring of the pressure gauge by the subjects during the exercise will be allowed and breath holding or compensatory movements will be avoided.
61989878|NCT05860283|ACTIVE_COMPARATOR|Diaphragmatic release group|The subjects will lay supine with relaxed limbs. Positioned at the head of the subjects, there will be manual contact with the pisiform, hypothenar region and the last three fingers bilaterally to the underside of the seventh to tenth rib costal cartilages, with the forearms aligned toward the subject's shoulders. In the inspiratory phase, a gentle pull will be given at the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. During exhalation, a deepened contact will be given towards the inner costal margin, to resist the rebounding movement of the thoracic cage. In the subsequent respiratory cycles, there will be a progressive increase in the depth of contact inside the costal margin.
61989879|NCT05860283|NO_INTERVENTION|Control group|The subjects in this group will receive traditional physical therapy program only.
61989880|NCT01447290||Women being evaluated for preeclampsia|
61989881|NCT05463185|EXPERIMENTAL|stretching exercises|Stretching exercise along with manual lymph drainage
61989882|NCT05463185|EXPERIMENTAL|soft tissue mobilization|soft tissue mobilization along with manual lymph drainage
61989883|NCT05904457|EXPERIMENTAL|1|
62385560|NCT05322759|EXPERIMENTAL|Halliwick exercise programme|this group receives sessions for consecutive 8 weeks and 3 days per week. warm up for 10 min that specifically includes mental adjustments along with walking in shallow side of pool and static stretchings. After that Halliwick exercise programme for 30 min that followed by cool down period for 5 min. exercise frequency is 3 sets of each exercise with 15 repetitions.
62385561|NCT01822912|ACTIVE_COMPARATOR|Heart Failure Disease Management Program|Patients will receive personalized care to include medication titration, daily weights, symptom and activity assessment, documentation of ejection fraction, patient and caregiver education,dietary surveillance, discharge instructions and follow up visit within 7 days of SNF discharge
62385562|NCT01822912|PLACEBO_COMPARATOR|Heart Failure Usual Care|SNF patients with HF will receive usual care
62558979|NCT02401152|PLACEBO_COMPARATOR|Placebo group|Sports drink containing maltodextrin
62558980|NCT02401152|ACTIVE_COMPARATOR|Sports drink 1|Sports drink with a specific source of carbohydrates (CHO).
62558981|NCT02401152|ACTIVE_COMPARATOR|Sports drink 2|Sports drink with a specific source of CHO.
62558982|NCT02677753|ACTIVE_COMPARATOR|Fluoroscopy guided PNE|Fluoroscopy will be utilized to assist with placement and/or confirm correct placement of lead wires.
62558983|NCT02677753|NO_INTERVENTION|PNE without fluoroscopic guidance|No fluoroscopy will be used during or after the placement of the lead wires.
62766936|NCT04641949|ACTIVE_COMPARATOR|Fentanyl|Intravenous fentanyl 50 microgr/ml, XX ml, single dose Inhalation NaCl 9 mg/ml, 3 ml, single dose.
62558984|NCT03469232|EXPERIMENTAL|Huanglian-Jiedu Decoction in acute pericoronitis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
62558985|NCT03469232|EXPERIMENTAL|Huanglian-Jiedu Decoction in recurrent aphthous stomatitis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
62766937|NCT04641949|PLACEBO_COMPARATOR|Placebo|Intravenous NaCl 9 mg/ml, XX ml, single dose. Inhalation NaCl 9 mg/ml, 3 ml, single dose.
62766938|NCT06255067|EXPERIMENTAL|Minocycline hydrochloride with noisome as carrier|"Group I ( Minocycline hydrochloride with noisome carrier)~15 patients will receive the drug ( Minocycline hydrochloride with noisome carrier gel) at intervals 1,3,7\&14 days"
62766939|NCT06255067|ACTIVE_COMPARATOR|Minocycline hydrochoride only|"Group II (Minocycline hydrochloride only)~15 patients will receive the drug (Minocycline hydrochloride only gel) at intervals 1,3,7\&14 days"
62766940|NCT02356887|EXPERIMENTAL|sitting position|The volunteers were kept comfortable in the sitting position. The cricoid cartilage (representing the C6 level) was used as a landmark. A horizontal straight line drawn across the volunteer's neck at the cricoid level and intersecting the IJV on both sides of the neck marked the initial scanning points. The second scanning point was along the IJV at the highest accessible point on the neck. Internal jugular vein cross-sectional area and blood velocity were measured using 2D ultrasound and Doppler (Philips CX50, Andover, MA, USA), respectively, with a 12-3 MHz transducer (Philips L12-3, Andover, MA, USA)
62766941|NCT00424268|ACTIVE_COMPARATOR|Roflumilast|"Roflumilast 500 µg~underlying medication: tiotropium 18 µg, once daily, inhaled"
62766942|NCT00424268|PLACEBO_COMPARATOR|Placebo|"Placebo~underlying medication: tiotropium 18 µg, once daily, inhaled"
62766943|NCT06256146|EXPERIMENTAL|Standard Protocol - High Dose Arm|Subjects will progress through desensitization to a high maintenance dose - 1200 mg of crushed peanut, 200 ml of milk or 1200 mg of egg powder.
62766944|NCT06256146|EXPERIMENTAL|Modified Protocol - Low Dose Arm|Subjects will progress through desensitization to a low maintenance dose - 120 mg of crushed peanut, 50 ml of milk or 300 mg of egg powder.
62766945|NCT06256146|EXPERIMENTAL|Modified Protocol - Cooked/Transformed Allergen Arm|Subjects will begin desensitization with cooked versions of the allergen (muffins in the case of egg and milk) or transformed versions (Bamba puffs for peanut). They will progress up to a full muffin or 4 Bamba puffs (for egg/milk and peanut respectively). Once subjects have reached these doses, they will transition to doses of pure allergen. They will then progress to the same top dose as subjects in the High Dose Arm.
62766946|NCT06133296|ACTIVE_COMPARATOR|Group A (Conventional fixed treatment)|Roth brackets (.018; Gemini Roth System, 3M Unitek, USA) were used for the fixed orthodontic attachment. Tooth surfaces were etched with 35% gel phosphoric acid for 30 seconds and then washed with water for 15 seconds. A primer was applied to the etching surface with the manufacturer's applicator. After an adhesive was applied to the bases of the brackets, the brackets were placed in their appropriate positions. Afterward, LED was irradiated for 20 seconds and 5 seconds for each surface. For leveling after bonding, .012 nickel titanium archwires (3M Unitek Monrovia, CA, USA) were tied with an elastic ligature.
62766947|NCT06133296|ACTIVE_COMPARATOR|Group B (Clear aligner treatment)|Clear aligners were ordered after the recordings were evaluated in the Clincheck program, and the final treatment plan was created. After the clear aligners came from the manufacturer (Align Technology, Santa Clara, CA), the compatibility of the guide aligner with each patient's mouth was checked for attachments. The enamel surfaces on which the attachments will be applied were etching with the same method as in Group A. After an adhesive was condensed into the attachment spaces inside the guide plate, the guide aligner was placed in the correct position in the mouth, and each attachment was applied from the buccal surface with an LED light device for 20 seconds. After the guide plate was removed, the composite residues around the attachments were cleaned, and the first treatment aligner was applied. The individuals were informed that they should use their clear aligner continuously, except during meals, and replace them after 10 days.
62766948|NCT03323671|EXPERIMENTAL|premenstruation group|preemptive mefenamic acid 500mg tablets every 8 hours starting 2 days before anticipated menstruation and during the first 2 days of the cycle
62385563|NCT04390217|EXPERIMENTAL|LB1148|LB1148 contains 7.5 g TXA, polyethylene glycol (PEG), glucose, and electrolytes. A total of 700 mL of LB1148 Active will be administered daily as a split dose (350 mL, every 12 hours) for up to 7 days. LB1148 Active is given as a single bolus, to be delivered orally or enterally via NG/OG tube, and should be fully consumed or delivered within 2 hours of the start of administration.
61989884|NCT03878914|EXPERIMENTAL|Quick responders (Group A)|"Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.~CORTICOSTEROID THERAPY FOR INITIAL EPISODE Group A (Total duration of therapy 8 weeks)~* 60mg/m2/day or 2mg/kg/day (maximum 60mg) day for 2 weeks~* 40mg/m2 or 1.5mg (maximum 40mg) every other day for 2 weeks.~* Wean off in 4 weeks~CORTICOSTEROID THERAPY FOR A RELAPSE~* 60mg/m2/day or 2mg/kg/day (maximum 60mg) until remission~* 40mg/m2 or 1.5mg (maximum 40mg) every other day for one week followed by continued weaning until discontinued in 6-8 weeks."
61989885|NCT03878914|ACTIVE_COMPARATOR|Slow responders (Group B)|"CORTICOSTEROID THERAPY FOR INITIAL EPISODE Group B: (Total duration of therapy ≥ 12 weeks)~* 60mg/m2/day or 2mg/kg/day (maximum 60mg) day for 4 weeks~* 40mg/m2 or 1.5mg (maximum 40mg) every other day for 4 weeks.~* Wean off in 4-6 weeks~CORTICOSTEROID THERAPY FOR A RELAPSE~* 60mg/m2/day or 2mg/kg/day (maximum 60mg) until remission~* 40mg/m2 or 1.5mg (maximum 40mg) every other day for one week followed by continued weaning until discontinued in 6-8 weeks."
61989886|NCT05046041|EXPERIMENTAL|Mifepristone + Misoprostol|200mg mifepristone followed 24-48 h later with 400mcg misoprostol (repeat Q3)
62385564|NCT04390217|PLACEBO_COMPARATOR|Placebo|Placebo contains polyethylene glycol (PEG), glucose, and electrolytes. A total of 700 mL of LB1148 Placebo will be administered daily as a split dose (350 mL, every 12 hours) for up to 7 days. LB1148 Placebo is given as a single bolus, to be delivered orally or enterally via NG/OG tube, and should be fully consumed or delivered within 2 hours of the start of administration.
62385565|NCT02842333|EXPERIMENTAL|Additional biological samples|"Blood samples will be realized at inclusion and 6 months after inclusion (optional).~Peripheral Blood Mononuclear Cells (PBMC) will be collected."
62385566|NCT00741910|EXPERIMENTAL|1|Semapimod 60 mg IV q 6 - 10 weeks
62385567|NCT01362816||Palliative care cancer patients|"Inclusion criteria are:~Patient has a cancer diagnosis (radiological, histological, cytological or operative evidence), local, loco-regional or metastatic disease, defined as a palliative care patient; enrolled in a palliative care programme, age 18 years or older, able to provide written informed consent, able to complete the data collection tool, preferably without help, available for follow up registration"
61989887|NCT04500184||Exercise group|patients who underwent cardiac rehabilitation
61989888|NCT04500184||Control group|patients who did not undergo cardiac rehabilitation
61989889|NCT03407742|EXPERIMENTAL|Intervention|CAPAS Youth Parenting Intervention
61989890|NCT03407742|NO_INTERVENTION|Wait-list control|Participants allocated to this condition were offered the parenting intervention until all T2 assessments of the intervention arm were completed
61989891|NCT03657355|EXPERIMENTAL|50 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
61989892|NCT03657355|EXPERIMENTAL|100 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
61989893|NCT03657355|EXPERIMENTAL|150 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
62385568|NCT02554916||Dual-belt Exercise|The participants assigned to this group will use the dual-belt treadmill 3 times a week for 16 weeks.
62558986|NCT03469232|EXPERIMENTAL|Huanglian-Jiedu Decoction in recurrent herpes simplex labialis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
62766949|NCT03323671|EXPERIMENTAL|menstruation group|mefenamic acid 500mg tablets every 8 hours during the first 2 days of the cycle
62385569|NCT02554916||Treadmill Exercise|The participants assigned to this group will use the treadmill 3 times a week for 16 weeks.
62558987|NCT00596531|ACTIVE_COMPARATOR|A|"Subjects will take acamprosate (Campral) at a dose of 666 mg. three times daily (morning, lunch time, bed time) for 28 days. Only responders will be included in the subsequent double-blind cross over arms after a minimum washout period of 4 weeks.~Subjects will randomly be assigned to Group 1 (A/B) or Group 2 (B/A) after completion of Phase I and its subsequent washout period (Figure 1, periods 1 and 2). Group 1 will receive acamprosate (Campral) at a dose of 666 mg. three times daily for 24 weeks followed by a 4-week washout period"
62766950|NCT05462808|EXPERIMENTAL|Atraumatic Restorative Treatment restorations with high-viscosity glass ionomer cement|Under cotton roll isolation, teeth were restored with EQUIA Forte cement. A layer of EQUIA Forte Coat was applied with a microbrush on surface and then light cured for 20 s
61989894|NCT03657355|ACTIVE_COMPARATOR|150 mg suvorexant|Suvorexant will be administered as tablets for oral use.
61989895|NCT03657355|ACTIVE_COMPARATOR|30 mg zolpidem|Zolpidem will be administered as tablets for oral use.
61989896|NCT03657355|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as tablets for oral use.
61989897|NCT02881645||Best practices|Assessment of critical incidents linked to nursing with a best practices protocol
61989898|NCT02881645||Common practices|Assessment of critical incidents linked to nursing in common practices
61989899|NCT02053181|EXPERIMENTAL|Cadazolid|Single oral dose of 3000 mg.
61989900|NCT01625247|EXPERIMENTAL|1 arm|Patients under LC. Allocated to drain placement . Drainage was removed if the drainage amount was less than 20cc.
62385570|NCT02554916||Usual Care|The participants assigned to this group will not use the treadmills.
62385571|NCT01650610|EXPERIMENTAL|Gait training executive functions tasks|This group will perform a gait training associated with the tasks that require the main executive functions.
62558988|NCT00596531|PLACEBO_COMPARATOR|B|Group 2 will be assigned to the placebo group and take matched placebos for next 24 weeks followed by a 4-week washout period. After the washout period each group will be assigned to the other intervention (acamprosate or placebo) and complete another trial for 24 weeks.
62558989|NCT00595621|ACTIVE_COMPARATOR|MGP-1 ON|Experimental Pacemaker on for 6 weeks
61989901|NCT01625247|ACTIVE_COMPARATOR|2 arm|Patients under LC. Allocation to sham drain,
61989902|NCT02947308||Adolescents with NSSI|12-16 year old females who have a history of non-suicidal self-injury are included in this cohort. No interventions will be administered.
61989903|NCT02947308||Healthy Controls|12-16 year old females with no history of non-suicidal self-injury are included in this cohort.
61989904|NCT02691299|ACTIVE_COMPARATOR|Treatment Arm|All subjects will receive study treatment in 4-week cycles: Fruquintinib, QD, 5mg with best supportive care for 3 consecutive weeks, and then one week off. Tumor assessment will be performed every 4 weeks in the first 2 cycles, and every 8 weeks since the 3rd cycle, until disease progression or death. Subsequent anti-neoplastic treatment and survival status will be followed up after disease progression.
61989905|NCT02691299|PLACEBO_COMPARATOR|Control Arm|All subjects will receive study treatment in 4-week cycles: Placebo, QD, 5mg with best supportive care for 3 consecutive weeks, and then one week off. Tumor assessment will be performed every 4 weeks in the first 2 cycles, and every 8 weeks since the 3rd cycle, until disease progression or death. Subsequent anti-neoplastic treatment and survival status will be followed up after disease
61989906|NCT02598180|EXPERIMENTAL|VergenixTM Flowable Gel|VergenixTM Flowable Gel
61989907|NCT02793518|EXPERIMENTAL|Bipolar Disorder patients|
61989908|NCT02793518|EXPERIMENTAL|Healthy Controls|
61989909|NCT02418195|ACTIVE_COMPARATOR|MDD with recent Suicide Attempt|All subjects with Major Depressive Disorder with a recent Suicide Attempt (in the past 2 weeks) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40 milliliters (mL) over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
62385572|NCT02760589||ACL tear - conservative|conservative treatment
62385573|NCT02760589||ACL tear - ACL reconstruction|reconstruction of the ACL with autologous tendons
62385574|NCT02760589||ACL tear - Internal brace|augmentation of the ruptured ACL with Internal brace
62385575|NCT02760589||healthy subjects|control group of healthy subjects with no previous injury
62558990|NCT00595621|ACTIVE_COMPARATOR|MGP-1 OFF|Experimental Pacemaker on or off for 4 weeks
62766951|NCT05462808|EXPERIMENTAL|restorations with Hall technique|In the Hall technique group, the deposits on the occlusal surface of the teeth were gently removed, SSC (3M ESPE, St. Paul, USA) was placed and were cemented using GIC. The crown was pressed tightly.
62385576|NCT03501394|EXPERIMENTAL|Single Arm|25 patients with pathologically confirmed invasive breast cancer who will undergo neoadjuvant chemotherapy treatment (NACT) and surgery will be recruited. During the study, patients will receive the standard care and the current study will not alter the care plan offered to them. All patients in the single arm will undergo 4 magnetic resonance imaging scan sessions. Histopathological analysis will be performed on the core biopsy and tumour tissue removed in surgery. Health questionnaire will be completed by each patient.
62385577|NCT02798809||GeOrGS cohort|Clinical dental examination of all Children born in 2008 and 2009 in Chivari District (Italy)
62385578|NCT04399434||normal pregnancy|pregnancy with a normal fetal size
62385579|NCT04399434||fetal growth restriction|fetal birth weight is below two standard deviations of the average weight for the same gestational age, or below the 10th percentile of normal weight for the same age
62385580|NCT04399434||fetal macrosomia|fetal birth weight ≥ 4000g
61989910|NCT02418195|ACTIVE_COMPARATOR|MDD with Suicidal Ideation no attempt|All subjects with Major Depressive Disorder with recent Suicidal Ideation (in the past 7 days) without a recent Suicide Attempt (in the past 6 months) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
62385581|NCT04900714|EXPERIMENTAL|Decremental PEEP|Every participant will be exposed to a stepwise decremental PEEP.
62385582|NCT00587340||1|15 subjects with subjective sleep disturbance based on the Pittsburgh Sleep Quality Index
62385583|NCT00587340||2|mild/moderate subjective sleep disturbance (insomnia) based on the Pittsburgh Sleep Quality Index
62385584|NCT00587340||3|severe subjective sleep disturbance (insomnia)based on the Pittsburgh Sleep Quality Index
62385585|NCT04747028||Primary dentition|Children from 4 to 6 years old suffering from malnutrition
62766952|NCT04097496|EXPERIMENTAL|Act Out! Intervention|Eligible classrooms will be randomized to attend a 1-hour ACT OUT! interactive, semi-improvisational psychodrama performance. The ACT OUT! intervention is an established theater program (https://www.claudemcnealproductions.com/act-out-ensemble/). The ACT OUT! production will include three to five vignettes paired with moderated discussions between the audience and the actors, the latter who will remain partly in character for the duration of the intervention. Vignettes will be different for each grade level included in the study (4th, 7th, and 10th). Public documentation of the guidelines for the ACT OUT! intervention will be made available as a supplemental file attached to the primary outcomes paper for the study.
61989911|NCT02418195|ACTIVE_COMPARATOR|MDD without Suicidal Ideation no attempt|All subjects with Major Depressive Disorder without recent Suicidal Ideation (in the past 7 days) without a recent Suicide Attempt (in the past 6 months) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
61989912|NCT02418195|NO_INTERVENTION|Healthy Controls|Healthy Control subjects without a psychiatric diagnosis will have a one-time blood draw to examine miRNAs.
62385586|NCT04747028||Age 13 to 16|Adolecentsfrom 13 to 16 suffering from malnutrition at present time or during their childhood
62385587|NCT05231291||Young Adults|"Skinfold thickness (SFT) at multiple marked sites on biceps, triceps, subscapular and suprailiac areas using a Harpenden Caliper (Baty, UK) for the non-dominant side.~Hand grip strength measurement Jamar Hydraulic Dynamometers (Hydraulic Hand Dynamometer Fabrication Enterprises Inc, NY) was used as the evaluation tool for measuring grip.~The handgrip measurement was carried out as per the recommendations laid by The National Institute of Health Research (NIHR).~The T score for hand grip strength was also calculated. Also the mean predicted handgrip strength for given height was calculated foe the given height Trunk muscle strength testing was done. An analogue hydraulic push-pull dynamometer (Model: FEI-12-0394) was used to evaluate. The trunk extensor and flexor muscle strength was evaluated using and was recorded in pounds (lbs.)."
62385588|NCT04806334|EXPERIMENTAL|4D MRI of pelvis/bladder with genomic analysis of bladder tumor|Patients with sessile appearing bladder masses who are destined to undergo transurethral resection of the bladder tumor (TURBT) and are felt by the treating physician to harbor MIBC will be enrolled. Prior to TURBT, ALL subjects will undergo axial imaging for clinical staging in the form of contrast enhanced MRI of the abdomen and pelvis (standard of care). The pelvic MRI will be multiparametric (mp)-4D MRI incorporating high resolution diffusion weighted imaging (HR-DWI). Both the abdominal and pelvic MRI will have an official interpretation by a radiologist, thus both can be used in the care of the subject. Next, ALL subjects will undergo TURBT at which time, voided urine, blood and fresh frozen bladder tumor will be collected. Follow-up pathology will be collected.
62558991|NCT01629511|EXPERIMENTAL|Treatment (combination chemotherapy, stem cell transplant)|Participants receive gemcitabine IV over 10-25 minutes on days -6 and -4, clofarabine IV over 1 hour and busulfan IV over 3 hours on days -6 to -3. Participants with matched unrelated donors also receive anti-thymocyte globulin IV over 4 hours on days -3 to -1. Starting day -2, participants receive tacrolimus PO daily for up to 6 months. Participants undergo hematopoietic allogeneic stem cell transplant on day 0, then receive methotrexate IV over 15 minutes on days 1, 3, 6 and 11, and filgrastim SC QD beginning 1 week after transplant until blood cell levels return to normal.
62558992|NCT00592306|ACTIVE_COMPARATOR|thymoglobulin (intraoperative)|we plan to blindly randomize these 25 lung transplant patients to intraoperative dosing of thymoglobulin followed by 3 additional postoperative doses (the first of these 3 postoperative doses will be placebo)
62558993|NCT00592306|PLACEBO_COMPARATOR|thymoglobulin (postoperative dosing)|We plan to blindly randomize these 25 lung transplant patients to 3 postoperative doses of thymoglobulin (the intraoperative dose will be placebo)
62558994|NCT00776841|PLACEBO_COMPARATOR|Placebo|Placebo control single dose
62766953|NCT04097496|NO_INTERVENTION|Control|Classrooms randomized to this arm will continue with their school day as normal, except that they will complete the data collection tools.
62766954|NCT01754194||Procedure Type 1|Gastric Sleeve Resection
62766955|NCT01754194||Procedure Type 2|Roux-en-Y Gastric Bypass
62766956|NCT01805544||Rivaroxaban|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
62766957|NCT00700583|EXPERIMENTAL|1|
61989913|NCT02224911||Laser Interstitial Thermal Therapy|This is a minimally invasive procedure for focal treatment of prostate cancer.
62385589|NCT00006242|EXPERIMENTAL|Treatment (BMS-214662)|"Single patient cohorts receive BMS-214662 IV over escalating periods of 2, 4, 8, 16, and 24 hours weekly for 3 weeks followed by 1 week of rest. If no patient experiences DLT, dose escalation proceeds in the single patient cohorts.~Treatment repeats every 4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Individual patient cohorts may increase their duration of BMS-214662 infusion in subsequent courses to the current duration safely reached.~Beginning with the infusion level at which DLT is first encountered by a single patient, cohorts of 3-6 patients receive escalating doses of BMS-214662 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. An additional cohort of 10 patients is treated at the MTD."
62385590|NCT01944462|EXPERIMENTAL|Pharmacist Pneumococcal Vaccine Program (PPVP)|Individuals receiving the PPVP intervention which consists of the educational program delivered on site at the collaborating senior center.
62385591|NCT04899167|EXPERIMENTAL|4 years after kidney transplantation|Patients 4 years after KT (N=10); 5 with estimated (e) glomerular filtration rate (GFR) ≤35 mL/min/1.73m2, and 5 with estimated (e) glomerular filtration rate (GFR)\>35 mL/min/1.73m2.
62385592|NCT04899167|EXPERIMENTAL|7 years after kidney transplantation|Patients 7 years after KT (N=10); 5 patients with eGFR ≤35 mL/min/1.73m2, and 5 with eGFR\>35 mL/min/1.73m2.
62385593|NCT03433599|ACTIVE_COMPARATOR|rAIH + training by research staff|Participants will receive repeated exposure to acute Intermittent Hypoxia (rAIH) and training by research staff.
62385594|NCT03433599|SHAM_COMPARATOR|sham rAIH + training|Participants will sham receive repeated exposure to acute Intermittent Hypoxia (rAIH) and training by the research staff.
61989914|NCT04121260|EXPERIMENTAL|Daratumumab|Participants will receive daratumumab dose 1 subcutaneously (SC) with recombinant human hyaluronidase \[rHuPH20\] 30,000 units \[U\] that is 2,000 U/milliliter (U/mL) SC injection once weekly for the first 8 weeks Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks Cycles 3 to 6 (Days 1 and 15) or the following 16 weeks and then every 4 weeks from Cycle 7 \[Day 1\] in subsequent cycles, until disease progression, unacceptable toxicity, or any other reason for discontinuation. Each cycle is 28 days in duration.
62385595|NCT03466528|ACTIVE_COMPARATOR|Standard treatment - Pabrinex alone|Pabrinex alone
62385596|NCT03466528|ACTIVE_COMPARATOR|Pabrinex + magnesium sulphate|standard treatment and magnesium sulphate
62385597|NCT03466528|EXPERIMENTAL|Magnesium sulphate alone|This group receives the study intervention and delayed Pabrinex
62385598|NCT02804581|EXPERIMENTAL|Gum Arabic|Oral intake of 30 gram of Gum Arabic daily for 12 weeks
62385599|NCT02670395|EXPERIMENTAL|JNJ-54416076|Participants will receive single dose of JNJ-54416076 (in ascending dose) in Part 1 and 2 doses of JNJ-54416076 (one dose in the fasted state and an identical dose in the fed state) in Part 2. The dose selected for Part 2 will be selected based on the preliminary safety and PK data in Part 1.
62385600|NCT02670395|EXPERIMENTAL|Placebo|Participants will receive single dose of placebo in Part 1.
62385601|NCT05167955|EXPERIMENTAL|Experimental Randomized controlled waitlist|n=34 (will receive Mindfulness-based cognitive intervention)
62385602|NCT05167955|OTHER|Waitlist Randomized controlled waitlist|waitlist Randomized controlled waitlist n=34 (will not receive Mindfulness-based cognitive intervention for 1 month)
62385603|NCT02363699|ACTIVE_COMPARATOR|Lidocaine|Group treated with lidocaine solution
62385604|NCT02363699|PLACEBO_COMPARATOR|Placebo|Group treated with saline solution
62385605|NCT02770872||Obese, normal|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2. Observation of SAA on apoB containing lipoproteins
62385606|NCT02770872||Obese, MetS|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2, blood pressure above 135/80, HDL less than 40 mg/dl, triglycerides greater the 150 mg/dl and fasting blood glucose greater than 100 mg/dl but less than 126 mg/dl. Observation of SAA on apoB containing lipoproteins
62385607|NCT02770872||Obese, diabetic|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2 and physician diagnosed diabetes mellitis. Observation of SAA on apoB containing lipoproteins
62385608|NCT00522652|EXPERIMENTAL|Investigational Drug|Dose Escalation
62385609|NCT02908945|EXPERIMENTAL|Group 1|Participants randomized to group 1 will receive a 0.5 mg/kg loading dose of racemic ketamine hydrochloride immediately before induction of anesthesia, followed by a continuous 10 mcg/kg/min infusion throughout maintenance of anesthesia, until procedure end (last suture inserted), up to a maximum cumulative dose of 200 mg. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
62385610|NCT02908945|EXPERIMENTAL|Group 2|Participants randomized to group 2 will receive a 0.25 mg/kg loading dose of racemic ketamine hydrochloride immediately before induction of anesthesia, followed by a continuous 5 mcg/kg/min infusion throughout maintenance of anesthesia, until procedure end (last suture inserted), up to a maximum cumulative dose of 200 mg. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
62385611|NCT02908945|OTHER|Group 3|Participants randomized to the control group will receive an equivalent anesthetic, without the addition of ketamine. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
62385612|NCT00396266|EXPERIMENTAL|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
62558995|NCT00776841|EXPERIMENTAL|Dose 1|Dose 30 mg
62385613|NCT00396266|EXPERIMENTAL|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
62385614|NCT00956046|EXPERIMENTAL|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 Influenza vaccine formulation 1 at Visits 1 and 2; and a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
62558996|NCT00776841|EXPERIMENTAL|Dose 2|Dose 100 mg
62558997|NCT00776841|EXPERIMENTAL|Dose 3|Dose 300 mg
62558998|NCT00776841|EXPERIMENTAL|Dose 4|Dose 900 mg
62558999|NCT00776841|EXPERIMENTAL|Dose 1 repeated|Dose 30 mg for 4 days
62559000|NCT00776841|EXPERIMENTAL|Dose 2 repeated|Dose high for 4 days
62766958|NCT02162212|ACTIVE_COMPARATOR|ADA guideline Instructed|The control intervention will be instruction in basic wellness activities according to the American Diabetes Association guidelines
62385615|NCT00956046|EXPERIMENTAL|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 Influenza vaccine formulation 2 at Visits 1 and 2; and a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
62385616|NCT00956046|EXPERIMENTAL|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Influenza vaccine formulation 3
62385617|NCT02744963|EXPERIMENTAL|Free and convenient medicine access|Free access to a list of essential medicines. Medicines are either mailed to the patient or dispensed at the point of care.
61989915|NCT04706130|OTHER|Arm1: No primaquine|Enrolled patients will only received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days)
62385618|NCT02744963|NO_INTERVENTION|Usual medicine access|Usual access to medicines.
62385619|NCT00504595|EXPERIMENTAL|ACZ885|"Healthy Volunteers: Single administration of 600 mg of ACZ885 (Canakinumab) Intravenous (IV) on Day 1.~Rheumatoid Arthritis (RA) Patients: Dose of 600 mg of ACZ885 (Canakinumab) Intravenous (IV) on Day 1, Day 15, and Day 43."
62385620|NCT00504595|PLACEBO_COMPARATOR|Placebo|"Healthy Volunteers: Single administration of 600 mg of Placebo Intravenous (IV) on Day 1.~Rheumatoid Arthritis (RA) Patients: Dose of 600 mg of Placebo Intravenous (IV) on Day 1, Day 15, and Day 43."
62385621|NCT05228236|EXPERIMENTAL|Plant based protein|
62385622|NCT05228236|EXPERIMENTAL|Whey Protein|
62385623|NCT02381795|EXPERIMENTAL|Nasal Carbon Dioxide|0.17 liters (L) of carbon dioxide (CO2) will be delivered through two 10 second administrations in each nostril, up to 6 times, to treat one attack (total of 1.0 L CO2). Subjects may treat up to three cluster headache attacks during the treatment phase of this study (total of 3.0 L (CO2).
62385624|NCT02145429|EXPERIMENTAL|problem solving therapy + Behavioral Treatment of Insomnia|Problem Solving Therapy + Brief Behavioral Treatment of Insomnia as needed
62559001|NCT03080025|EXPERIMENTAL|CBCT® for Couples|"The CBCT® (Cognitively Based Compassion-Training) for couples (CBCT®-fC) consists of a ten-week training program with a 2h group session weekly and daily home practice based on prerecorded guided mediations (Emory University, Atlanta, USA; Ozawa-de Silva \& Negi, 2013). The ten weeks start with an overview and a take-home ideas for continuing practice. Furthermore the first and the 3rd module will be repeated once resulting in a total of ten weeks. Further couple- and dyadic exercises are added.~It focuses on six essential key parts for the development of compassion:~1. Developing attentional stability and clarity of the mind (Mindfulness)~2. Cultivating insight into the nature of mental experience~3. Cultivating self-compassion~4. Developing impartiality~5. Developing appreciation and affection for others~6. Developing empathy and realizing engaged compassion"
62559002|NCT03080025|NO_INTERVENTION|Treatment as usual (TAU)|"Treatment as usual: Primary care according to guidelines from the S3- and national healthcare guideline Unipolar Depression \[S3-Leitlinie und Nationale VersorgungsLeitlinie (NVL) Unipolare Depression, Ärztliches Zentrum für Qualität in der Medizin\], but excluding current psychotherapy after probatory session."
62559003|NCT02510443||BAY1454032|All subjects who give their consent and meet the eligibility criteria will be scheduled for an insert placement procedure
62559004|NCT05848193|ACTIVE_COMPARATOR|Standard of Care|Patients in the control group will receive standard of care for the treatment of post-concussion symptoms at our Integrated Adult Concussion Clinic
62766959|NCT02162212|EXPERIMENTAL|Optimized Shoulder Movement Program|"The experimental intervention is the Optimized Shoulder Movement Program. Participants will be trained in a progressive home exercise program that includes passive stretching of end range shoulder flexion and external rotation, and active shoulder motion based on the participant's baseline activity count ."
62766960|NCT03344198|EXPERIMENTAL|Firefighter (Veteran) Group|Firefighters with \>10yrs experience. Circuit Training exercise \& Modified Mediterranean diet
61989916|NCT04706130|OTHER|Arm2: Primaquine low dose|Enrolled patients will received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days) and primaquine at 0.25 mg/kg/day for 14 days (starting at day 7)
61989917|NCT04706130|OTHER|Arm3: Primaquine high dose|Enrolled patients will received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days) and primaquine at 0.50 mg/kg/day for 14 days (starting at day 7)
61989918|NCT05541549|PLACEBO_COMPARATOR|Placebo|
61989919|NCT05541549|EXPERIMENTAL|CE-VST01-JC|
61989920|NCT06055855|ACTIVE_COMPARATOR|Traditional Arthrocentesis Group|
61989921|NCT06055855|EXPERIMENTAL|Surgery-Guided Arthrocentesis Group|
61989922|NCT06160466|EXPERIMENTAL|Artificial intelligence arm Patients undergoing colonoscopy with artificial intelligence.|Patients undergoing colonoscopy with artificial intelligence.
61989923|NCT06160466|ACTIVE_COMPARATOR|Conventional Colonoscopy|Standard Colonoscopy with white light
61989924|NCT01827657|EXPERIMENTAL|Part 1 Cohort 1 - Mild hepatic impairment|Subjects with mild hepatic impairment will be enrolled in Cohort 1 and will receive a single dose of 60 mg GSK2336805
61989925|NCT01827657|EXPERIMENTAL|Part 1 Cohort 2 - Moderate hepatic impairment|Subjects with moderate hepatic impairment will be enrolled in Cohort 2 and will receive a single dose of 60 mg GSK2336805
61989926|NCT01827657|EXPERIMENTAL|Part 1 Cohort 3 - Matched healthy volunteers to Cohort 2|Control subjects will be matched for gender, age (+/- 10 years), body mass index (BMI) (+/- 20%), and smoking status to the subjects in the moderate hepatic impairment arm. These healthy volunteers will receive a single dose of 60 mg GSK2336805
61989927|NCT01827657|EXPERIMENTAL|Part 2 Cohort 4 - Severe hepatic impairment|Subjects with severe hepatic impairment will be enrolled in Cohort 2 and will receive a single dose of 60 mg GSK2336805. The decision to move forward into Part 2 (severe hepatic impairment) will be based on a review of the preliminary safety and pharmacokinetic data from subjects with moderate hepatic impairment
62385625|NCT02145429|NO_INTERVENTION|Enhanced Usual Care|Care as usual with scheduled assessments of clinical status
62385626|NCT02008981|ACTIVE_COMPARATOR|Angelica sinensis|Angelica sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
62385627|NCT02008981|ACTIVE_COMPARATOR|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
61989928|NCT01827657|EXPERIMENTAL|Part 2 Cohort 5 - Matched healthy volunteers to Cohort 4|Based on emerging data from Part 1, the sponsor may decide to enroll matched controls to the severe hepatic group (i.e. in case of a change in dose or the demographics of the severe hepatic group are not well matched with the moderate control data). The subjects in this optional control cohort will be matched for gender, age (+/- 10 years), BMI (+/- 20%), and smoking status to the subjects in the severe hepatic impairment category
61989929|NCT03507712|ACTIVE_COMPARATOR|Symmetrical IO weakening.|Same surgery in both eyes
61989930|NCT03507712|ACTIVE_COMPARATOR|Asymmetrical IO weakening.|Different amounts or different surgery in each eye
61989931|NCT02261636||Pentasa|Treatment according to standard clinical practice.
61989932|NCT04444596|OTHER|Swab|Conjunctival swab and nasopharyngeal swab for SARS-COV 2
61989933|NCT01289847|EXPERIMENTAL|Gammaplex|
61989934|NCT05316831|EXPERIMENTAL|Group A|Group A CLL patients: Previously immunized with PCV13, in this study receiving PCV13 followed by PPSV23
61989935|NCT05316831|EXPERIMENTAL|Group B|Group B CLL patients: Previously immunized with PPSV23, in this study receiving PCV13 followed by PCV13
61989936|NCT05316831|ACTIVE_COMPARATOR|Group C|Group C controls: Previously immunized with PCV13, in this study receiving PCV13
61989937|NCT05316831|ACTIVE_COMPARATOR|Group D|Group C controls: Previously immunized with PPPSV23, in this study receiving PCV13
61989938|NCT04694677|ACTIVE_COMPARATOR|women receiving tranexamic acid|
62385628|NCT02008981|ACTIVE_COMPARATOR|Siwu Tang|"TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after."
61989939|NCT04694677|ACTIVE_COMPARATOR|women receiving misoprostol|
61989940|NCT05920421|PLACEBO_COMPARATOR|interscalen group|"(29) patients will receive interscalene block before induction of general anethesia.~patients will receive 30 ml of bupivacaine 0.25 %+250 mg of magnesium sulphate."
61989941|NCT05920421|EXPERIMENTAL|subomohyoid infracavicular group|(29) patients will receive subomohyoid infraclavicular block before induction of general anethesia. patients will receive 30 m lof bupivacaine 0.25 %+250 mg of magnesium sulphate.
61989942|NCT05920421|EXPERIMENTAL|subomohyoid subscapularis group|(29) patients will receive subomohyoid subscapularis block before induction of general anethesia . patients will receive 30 ml of bupivacaine0.25 %+250 mg of magnesium sulphate.
62385629|NCT03188003|EXPERIMENTAL|Stabilization|"This group will undergo 10 Pilates sessions with a focus on lumbo-pelvic stabilization exercises approach.~Intervention administered: Exercise Movement Techniques (Pilates Exercise) based on stabilization"
62559005|NCT05848193|EXPERIMENTAL|mHealth|Patients in the intervention group will use MyHeadHealth - an online application to help in the completion of their treatment plan
62559006|NCT05398328|ACTIVE_COMPARATOR|metal appliance + fixed retainer|fixed metal appliance MBT 0.022'' slot in active phase followed by bonded wire retainer
62559007|NCT05398328|EXPERIMENTAL|esthetic appliance + fixed retainer|fixed ceramic appliance MBT 0.022'' slot in active phase followed by bonded wire retainer
61989943|NCT03330431|EXPERIMENTAL|Experimental group 1 (personal expert)|Participants watch a video of an expert describing the positive effects of Progressive Muscle Relaxation (PMR) with personalized examples and stories before undergoing a PMR session.
61989944|NCT03330431|EXPERIMENTAL|Experimental group 2 (factual expert)|Participants watch a video of an expert describing the positive effects of Progressive Muscle Relaxation (PMR) with factual information (not personal) before undergoing a PMR session.
61989945|NCT03330431|ACTIVE_COMPARATOR|Control group|Participants read a neutral text before undergoing a Progressive Muscle Relaxation (PMR) session.
62385630|NCT03188003|EXPERIMENTAL|Mobilization|"This group will undergo 10 Pilates sessions with a focus on lumbo-pelvic mobilization exercises approach.~Intervention administered: Exercise Movement Techniques (Pilates Exercise) based on mobilization"
62559008|NCT05398328|ACTIVE_COMPARATOR|metal appliance + removable retainer|fixed metal appliance MBT 0.022'' slot followed by removable clear termoplastic retainer
61989946|NCT02486042|ACTIVE_COMPARATOR|Standard of Care (Standard Nutrition)|Infants in this group will receive standard lipids (predominantly Omega-6 fatty acids).
61989947|NCT02486042|EXPERIMENTAL|Omegaven|Infants in this group will receive lipid supplementation with omega-3 fatty acids.
61989948|NCT04366167||Cardiac surgery patients - lockdown 1|Cohort 1 (lockdown 1): Patients undergoing adult cardiac surgery during the Covid-19 pandemic
61989949|NCT04366167||Cardiac surgery patients - lockdown 2|Cohort 2 (lockdown 2): Patients undergoing adult cardiac surgery during the Covid-19 pandemic
61989950|NCT04366167||Cardiac surgery patients - lockdown 3|Cohort 3 (lockdown 3): Patients undergoing adult cardiac surgery during the Covid-19 pandemic
61989951|NCT05705284|EXPERIMENTAL|Patients participating in structured multidisciplinary medication review|Patients participating in structured multidisciplinary medication review
61989952|NCT02063347||Coronary artery disease|With coronary artery disease
61989953|NCT02063347||No coronary artery disease|Without coronary artery disease
61989954|NCT05616858|EXPERIMENTAL|Intervention group|Group with exercise program
61989955|NCT05616858|NO_INTERVENTION|Control group|Group without exercise program
62385631|NCT00078715|EXPERIMENTAL|Yohimbine then Placebo|Participants are randomized to receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep. After 8 days they receive placebo administered over 3 minutes during REM sleep.
62559009|NCT05398328|EXPERIMENTAL|esthetic appliance + removable retainer|fixed ceramic appliance MBT 0.022'' slot followed by removable clear termoplastic retainer
62385632|NCT00078715|EXPERIMENTAL|Placebo then Yohimbine|Participants are randomized to receive placebo administered over 3 minutes during REM sleep. After 8 days they receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
62385633|NCT00469443|EXPERIMENTAL|1|FOLFIRI/Avastin
62385634|NCT00469443|EXPERIMENTAL|2|XELIRI/Avastin
62385635|NCT05892406|ACTIVE_COMPARATOR|Static guide|Prosthetically guided Implant placement utilising a 3D printed static guide based on a digital plan
62385636|NCT05892406|ACTIVE_COMPARATOR|Dynamic navigation|Prosthetically guided Implant placement utilising a dynamic navigation system based on a digital plan
62385637|NCT05892406|EXPERIMENTAL|Robotic system|Prosthetically guided Implant placement utilising robotic surgery based on a digital plan
62385638|NCT01335659||ostial lesion|ostial lesion will be evaluated by IVUS and FFR
62385639|NCT00424463|EXPERIMENTAL|1|
62385640|NCT00424463|PLACEBO_COMPARATOR|2|
62385641|NCT03068182|EXPERIMENTAL|Arm crank Exercise|Sixty-five participated in an arm crank moderate intensity exercise for 40 minutes.
62385642|NCT03068182|EXPERIMENTAL|Treadmill Exercise|Sixty-five participated in a treadmill moderate intensity exercise for 40 minutes.
62385643|NCT05934929|EXPERIMENTAL|circulating tumor DNA detection on operating bed|biological assessment on operating bed to detect residual circulating tumor DNA
62385644|NCT01064973|EXPERIMENTAL|STX209|STX209 (arbaclofen)
62385645|NCT01909635|EXPERIMENTAL|Food Feelings|If you are randomized to this group, you will be asked to think about your feelings of hunger, fullness, and the sensory qualities of the food (such as texture, smell, flavor) as you eat your meal.
62385646|NCT01909635|EXPERIMENTAL|Other Feelings|If you are randomized to this group, you will be asked to think about how hot or cold you feel, and how tired you are feeling as you eat your meal.
62385647|NCT06218238|EXPERIMENTAL|Ossur Power Knee|Subjects will be fitted with the Ossur Power Knee, which has powered flexion and extension.
62385648|NCT06218238|ACTIVE_COMPARATOR|Ossur Rheo XC Knee|Subjects will be fitted with the Ossur Rheo XC Knee, which is a conventional microprocessor-controlled knee joint that modulates the amount of damping during flexion and extension.
62385649|NCT02940158|OTHER|1/2 cup|1/2 cup serving size arm
62385650|NCT02940158|OTHER|1/4 cup|1/4 cup serving size arm
62559010|NCT05317039|EXPERIMENTAL|Group A|Group A will be treated with the buccal plate repositioning technique and grafted with SCPC.
62559011|NCT05317039|ACTIVE_COMPARATOR|Group B|Group B will be similarly managed and grafted using DFDBA
62385651|NCT02403089||neonates|neonates 24-41 weeks gestational age
62385652|NCT02403089||children|hematopoietic stem cell transplant recipient children (\< 18 years old, donor source: cord blood or genoidentical donor)
62385653|NCT03639064|EXPERIMENTAL|CanniMed® Oil 1:20 formulation|∆9-THC: 1.0 mg/mL; CBD: 20.0 mg/mL
62385654|NCT03639064|EXPERIMENTAL|CanniMed® Oil 10:10 formulation|∆9-THC: 9.8 mg/mL; CBD: 9.9 mg/mL
62385655|NCT03639064|EXPERIMENTAL|CanniMed® Oil 18:0 formulation|∆9-THC: 18.3 mg/mL; CBD: 0.2 mg/mL
62385656|NCT03202641|EXPERIMENTAL|PEEP_titration|"There is no randomization in this interventional, crossover, physiological study. All participants will receive the same procedures in the same order. The investigators will compare two PEEPs (PEEPARDSnet vs. PEEPLRM).~Interventions:~1. PEEP ARDSnet: we will select the PEEP based on low PEEP/high FiO2 table (ARDSnet).~2. PEEP LRM: we will perform a lung recruitment maneuver (LRM) and select PEEP based on transpulmonary pressure."
62385657|NCT05237713|OTHER|Canakinumab treatment|200 mg canakinumab subcutaneously every three weeks
62385658|NCT02086760|EXPERIMENTAL|Ultrasonography sensibilized by oral hydratation|Ultrasonography before, 30 min and 90 min following hydratation.
62385659|NCT06356649||Goup 1|Patients extubated after general anesthesia
62766961|NCT03344198|EXPERIMENTAL|Firefighter (Novice) Group|Firefighters with \<10yrs experience. Circuit Training exercise \& Modified Mediterranean diet
62385660|NCT06356649||Group 2|Patients with complications after extubation
62385661|NCT02399189|EXPERIMENTAL|R-MT followed by auto-HSCT|"R-MT followed by auto-HSCT Rituximab 375 mg/m2 d1 MTX 3.5g/m2 d2(0.5g/m2 15min,3g/m2 3h） TMZ 100 mg/m2 d2-6 Q21d\*4cycles~Auto-HSCT conditioning regimen:~BCNU 400mg/m2 d1; Thiotepa 5mg/kg q12h，d2-3"
62385662|NCT02768636|EXPERIMENTAL|Before and after omega-3 used|Before and after omega-3 used
62385663|NCT00592644|EXPERIMENTAL|1|Pulse Dye Laser
62385664|NCT00592644|ACTIVE_COMPARATOR|2|Traditional surgeries
62385665|NCT04880499|EXPERIMENTAL|Intervention (group A)|Patients who are subjected to the intervention, being iron plus other cofactors for hematopoiesis, other than the standard of care.
62385666|NCT04880499|NO_INTERVENTION|Control (group B)|Patients who are not subjected to the intervention and follow the standard of care.
62559012|NCT01963546|OTHER|Intravenous anesthesia|We use total intravenous anesthesia to assess the stress response.
62559013|NCT01963546|OTHER|Intravenous and Inhalation anesthesia|We use intravenous and inhalation anesthesia during the surgery.
62559014|NCT01963546|OTHER|Inhalation anesthesia|We use inhalation anesthesia during the surgery.
62559015|NCT01963546|EXPERIMENTAL|Dexmedetomidine|"the effect of dexmedetomidine on the stress responses generated by patients with diabetic given gastric-bypass surgery : Group A group given the best anesthetic technique from preliminary work + dexmedetomidine Dexmedetomidine as a inducer was given intravenous infusion loading dose 1.0μg/kg for 10min, maintained intravenous infusion by 0.4μg/kg/h.~Group B group given the best anesthesia method from preliminary work(not using dexmedetomidine)."
62559016|NCT05395260|EXPERIMENTAL|FL-101-IV|Open Label Infusion of FL-101 on Day 1 and Day 15
62766962|NCT03344198|EXPERIMENTAL|Control Non-Firefighter Group|Non-Firefighter adults. Circuit Training exercise \& Modified Mediterranean diet
62766963|NCT06505538|EXPERIMENTAL|Intervention|
62766964|NCT06505538|NO_INTERVENTION|Control|
62766965|NCT00997399|EXPERIMENTAL|LBH589|
62766966|NCT00840580|EXPERIMENTAL|Vigamox|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
62766967|NCT00840580|ACTIVE_COMPARATOR|Cravit|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
62766968|NCT04213170|EXPERIMENTAL|Sintilimab and Bevacizumab|Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 every 21 days
62766969|NCT01995955|EXPERIMENTAL|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
62766970|NCT00702494|EXPERIMENTAL|1|Multiple IV doses of TB-403, an antibody directed against PlGF
62766971|NCT06422364|EXPERIMENTAL|Pilot|Weighted wearable blanket, provided by Dreamland Baby Co.
62385667|NCT04030806|EXPERIMENTAL|Intervention group|"All patients will perform 60 minutes of intervention, twice a week, for six weeks. During the intervention, the patient will be positioned seated in a chair with a table in front of him and a mirror (50cm x 50cm) will be placed vertically between his upper extremity.~The patient's paretic upper extremity will be positioned behind the mirror, allowing only the movements of his healthy upper extremity to be visualized. The reflective side of the mirror will be facing the healthy upper extremity , the patient will perform the exercises observing the movements of his healthy upper extremity through the reflection produced by the mirror, interpreting as the movement of his paretic member."
62385668|NCT04030806|SHAM_COMPARATOR|Control group|All patients will perform 60 minutes of intervention, twice a week, for six weeks. The mirror will be placed in the same position as the intervention group. However, the subject will have access to the non-reflective side of the mirror, directly visualizing the movement of his healthy arm. In the control group, the patients will be submitted to the same bimanual activities of the intervention group, but without the reflecting side of the mirror. Thus, the nonreflective side of the mirror will be facing the healthy arm, the patient will perform the same exercises visualizing only the movement of the healthy member.
62385669|NCT00799370|EXPERIMENTAL|1|Early weight bearing: immediate in postoperative
62385670|NCT00799370|EXPERIMENTAL|2|Delayed weight bearing: 2 months after surgery
62385671|NCT04378049|ACTIVE_COMPARATOR|Standard total knee arthroplasty|Participants who are randomized to the control group will undergo TKA according to local standard of care. The choice of implant and use of bone cement will be recorded but left to the surgeon's discretion according to their standard practice.
62385672|NCT04378049|EXPERIMENTAL|Robot-assisted partial knee arthroplasty|Participants with isolated medial or isolated lateral compartment OA who are randomized to the intervention group and have one affected knee compartment will receive a robot-assisted unicompartmental knee arthroplasty (UKA). If the patient has medial or lateral OA plus patellofemoral OA they will receive a bicompartmental knee arthroplasty (BiKA) consisting of a two simultaneous UKAs. The partial knee replacement procedures will be performed using the Mako RIO robotic arm (Stryker) according to the manufacturer's instructions. The choice of implant and use of bone cement will be recorded but will be left to the surgeon's discretion. Surgeons will resurface the patella if the patellar cartilage meets Outerbridge grade 3 or 4 criteria
62385673|NCT01833299|ACTIVE_COMPARATOR|TACE group|Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.
62385674|NCT01833299|EXPERIMENTAL|TACE+sorafinib|TACE+sorafinib
62385675|NCT04084444|EXPERIMENTAL|T8 tablet 0.5mg|Oral T8 tablet with HARRT, 0.5mg, once daily for 48 week
62385676|NCT04084444|EXPERIMENTAL|T8 tablet 1mg|Oral T8 tablet with HARRT, 1mg, once daily for 48 week
62385677|NCT04084444|PLACEBO_COMPARATOR|Placebo|Oral Placebo with HARRT, once daily for 48 week
62385678|NCT05040867|NO_INTERVENTION|Control group (CG)|Participants will continue with their daily life and usual care.
62385679|NCT05040867|EXPERIMENTAL|Traditional periodization exercise group (TEG)|Participants will participate in a physical exercise program with a preplanned intensity progression.
62385680|NCT05040867|EXPERIMENTAL|Heart Rate Variability exercise group (HRVG)|Participants will participate in a physical exercise program guide by participants' daily heart rate variability to plan the intensity progression.
62385681|NCT05774886|EXPERIMENTAL|IMD Placement and Retrieval|"* Participants with confirmed anatomic stage II-III TNBC whose planned treatment includes neoadjuvant systemic therapy with the intention to undergo surgery, including breast and/or axillary surgery, will be selected for study participation.~* Participants will undergo image-guided placement of 2 microdevices within a single lesion.~* Participants will undergo image-guided retrieval of the microdevices (and surrounding tissue) approximately 72 hours after placement.~* Participants will be monitored for safety endpoints and clinical data will be collected for the duration of the study."
62385682|NCT01904760|EXPERIMENTAL|dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
62385683|NCT01904760|PLACEBO_COMPARATOR|control|Drug: Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
62385684|NCT00882544||Diagnosed Pediatric Hydronephrosis|Children diagnosed with hydronephrosis who are to receive robotic pyeloplasty surgery
62385685|NCT03673631||NFHC-O2 Group|NFHC-O2 therapy alone with gas flow at least 40L/min,
62385686|NCT03673631||NIV/Standard-O2 Group|NIV sessions with at least 30% FiO2 and standard oxygen therapy
62385687|NCT03673631||NFHC-O2/NIV Group|combination of NIV sessions and NFHC-O2 therapy,
62385688|NCT02905344||1|Control, no anatomical model used for description
62385689|NCT02905344||2|Anatomical model used for description
62385690|NCT02271620|OTHER|nonallergic rhinitis|nonallergic rhinitis nasal allergen provocation test
62385691|NCT05179564|EXPERIMENTAL|iohexol plasma clearance|"a weight-dependent dose of iohexol will be injected as an intravenous bolus in 100 patients~2,5 -9kg = 1ml; 10-19kg = 2ml; 20-29kg = 3ml; 30-39kg = 4ml; ≥ 40kg = 5ml"
62385692|NCT01539720|EXPERIMENTAL|Levonorgestrel Intrauterine System|Participants randomized to the levonorgestrel IUS will undergo placement at the time of randomization. They will follow-up with a self-administered urine pregnancy test 5-6 weeks following.
62385693|NCT01539720|ACTIVE_COMPARATOR|Ulipristal acetate|Women in this arm will receive the oral Ulipristal acetate (Ella) regimen, which is currently the most effective method of oral emergency contraception.
62385694|NCT04932915|EXPERIMENTAL|UNI91103 intranasal spray 1%|UNI91103 intranasal spray 1%, BID, 10 consecutive days
62385695|NCT04932915|PLACEBO_COMPARATOR|Placebo|Placebo intranasal spray, BID, 10 consecutive days
62385696|NCT04778696|ACTIVE_COMPARATOR|conventional pace mapping|Conventional PVC pace mapping without visual guidance of PASO
62385697|NCT04778696|EXPERIMENTAL|PASO pace mapping|PASO pace mapping with visualisation in CARTO3
62385698|NCT04646720||Neck pain patients|Patients with neck pain evaluated with new technologies and face-to-face
62385699|NCT00159146|ACTIVE_COMPARATOR|A|Venlafaxine and pindolol
62385700|NCT00159146|PLACEBO_COMPARATOR|B|Venlafaxin and placebo
62385701|NCT00681772|EXPERIMENTAL|Arm 1|
62385702|NCT00973466||HIV-infection|All HIV-infected patients attending the Clinic for Infectious Diseases at Berne university hospital, having been sexually active during the past 12 months and having given written informed consent
62385703|NCT05472506|EXPERIMENTAL|Cohort 1|600 mg qd PO IK-175 + nivolumab
62385704|NCT05472506|EXPERIMENTAL|Cohort 2|450 mg q12h PO IK-175 + nivolumab
62385705|NCT01632527|EXPERIMENTAL|HuCNS-SC|HuCNS-SC cells
62385706|NCT00796172|EXPERIMENTAL|1|Medication adherence system (MAS) plus counseling from doctors
62385707|NCT00796172|ACTIVE_COMPARATOR|2|Usual care
62385708|NCT03704233||Cryobiopsy|Transbronchial cryobiopsy is performed in patients with undefined diffuse parenchymal lung diseases, and assess the diagnostic yield and safety.
62385709|NCT01196793||febrile children, age 3 m to 5 y|
62385710|NCT05278611|EXPERIMENTAL|EP-9001A|Dose-escalation trial
62385711|NCT05278611|PLACEBO_COMPARATOR|Placebo|Dose-escalation trial
62385712|NCT03708029|EXPERIMENTAL|Intervention Treatment|Will receive Revita allograft for wound treatment
62385713|NCT03708029|NO_INTERVENTION|Control|Will receive current standard of care for wound treatment
62385714|NCT05853172|EXPERIMENTAL|AK104 plus apatinib, paclitaxel and S-1|AK104 (10mg/kg, iv, Q3W) is combined with apatinib (250mg, po, qd), paclitaxel (non-peritoneal metastasis: 130mg/m2, iv, D1; peritoneal metastasis: 90mg/m2, iv, 40mg/m2, ip, D1) and S-1(60mg, po, bid, D1-D14) for up to 6 cycle for up to 6 cycles.
62385715|NCT02094781|EXPERIMENTAL|Whey protein and creatine supplement|Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
62385716|NCT02094781|ACTIVE_COMPARATOR|Whey protein only supplement|Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
62385717|NCT02094781|PLACEBO_COMPARATOR|Placebo|Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
62385718|NCT01978548|EXPERIMENTAL|JNJ-54861911 10 mg|From Day 1 to Day 28 inclusive, patients will self-administer once daily study drug (JNJ-54861911 or placebo) with a glass of non-carbonated water (approximately 200 mL).
62385719|NCT01978548|EXPERIMENTAL|JNJ-54861911 50 mg|
62385720|NCT01978548|PLACEBO_COMPARATOR|Placebo|Patients will receive matching placebo.
62385721|NCT01192893||OPUS|OPUS is a prospective study of postmenopausal women recruited in the general population between April 1999 and April 2001 from five European centers (Aberdeen (UK), Berlin (Germany), Kiel (Germany), Paris (Hospital Cochin, France), and Sheffield (UK)). Investigations were approved at each institution according to the Declaration of Helsinki. Written consent was obtained from all subjects. Each center recruited approximately 500 postmenopausal women comprising 100 individuals in each 5-yr age band between 55 and 79. Ninety-nine percent of subjects were of white ethnicity.
62385722|NCT01066338||Normal karyotype|The patients were diagnosed as acute myeloid leukemia with normal karyotype.
62385723|NCT06043895|EXPERIMENTAL|EpiFaith CV|The conducting physicians in this group will use EpiFaith CV to localize the central vein and assess if there is arterial puncture
62385724|NCT06043895|ACTIVE_COMPARATOR|Conventional|The conducting physicians in this group will use Raulerson syringe to localize the central vein and assess if there is arterial puncture
62385725|NCT00842504|OTHER|Micafungin|3 mg/kg given once
62385726|NCT00837889||decompensated heart failure patients|
62385727|NCT00837889||chronic heart failure patients|
62385728|NCT00837889||healthy controls|
62385729|NCT03428230|EXPERIMENTAL|30 mg Paracetamol 3% (1 mL)|30 mg Paracetamol 3% (1 mL), solution for injection, single dose by intrathecal injection (IT)
62385730|NCT03428230|EXPERIMENTAL|60 mg Paracetamol 3% (2 mL)|60 mg Paracetamol 3% (2 mL), solution for injection, single dose by intrathecal injection (IT)
62385731|NCT03428230|EXPERIMENTAL|90 mg Paracetamol 3% (3 mL)|90 mg Paracetamol 3% (3 mL), solution for injection, single dose by intrathecal injection (IT)
62385732|NCT03428230|PLACEBO_COMPARATOR|Placebo, 0.9% saline solution|Placebo, 0.9% saline solution (1 mL, 2 mL or 3 mL), solution for injection, single dose by intrathecal injection (IT)
62385733|NCT01521494|EXPERIMENTAL|PA21 750 mg/day|
62385734|NCT01521494|EXPERIMENTAL|PA21 1500 mg/day|
62385735|NCT01521494|EXPERIMENTAL|PA21 2250 mg/day|
62385736|NCT01521494|EXPERIMENTAL|PA21 3000 mg/day|
62385737|NCT01521494|PLACEBO_COMPARATOR|Placebo|
62385738|NCT04061018||High Cholesterol Efflux|Dallas Heart Study participants who are above the sex and ethnicity specific 90th % of cholesterol efflux
62385739|NCT04061018||Low Cholesterol Efflux|Dallas Heart Study participants who are below the sex and ethnicity specific 10th % of cholesterol efflux
62385740|NCT02205229||Patients receiving a topical compounded medication|
62385741|NCT05926011|EXPERIMENTAL|Active RGn600|RGn600 with a 10 Hz-pulsed wave mode light emission
62385742|NCT05926011|SHAM_COMPARATOR|Sham|Inactivated RGn600
61989956|NCT05864911|EXPERIMENTAL|the Gastric Bypass Stent System group|all the participants were implanted with the Gastric Bypass Stent System for 12 weeks and followed up for 24 weeks.
62385743|NCT02752178||DEP+MA+|Incompletely responsive patients (approximately N \~100) who are currently depressed after greater than 6 weeks of treatment with one or more monoaminergic antidepressants
62385744|NCT02752178||DEP-MA+|Responsive patients (approximately N\~50) who are not currently depressed after greater than 6 weeks of treatment with a monoaminergic antidepressant
62385745|NCT02752178||DEP+MA-|Untreated patients (approximately N\~50) who are currently depressed but have not been treated with monoaminergic antidepressants in the previous 6 weeks
62385746|NCT02752178||DEP-MA-|Healthy volunteers (approximately N\~50) who have no personal history of depression requiring treatment with either monoaminergic antidepressants or other clinical interventions including psychotherapy
62385747|NCT04346368|EXPERIMENTAL|Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs)|Conventional treatment plus BM-MSCs
62385748|NCT04346368|PLACEBO_COMPARATOR|Placebo|Conventional treatment plus placebo
62385749|NCT04185194|ACTIVE_COMPARATOR|group A|received especially designed physical therapy program
62385750|NCT04185194|EXPERIMENTAL|group b|received pulsed ultrasound in addition to physical therapy program
62385751|NCT04185194|EXPERIMENTAL|group c|received lidocaine phonophoresis in addition to physical therapy program
62385752|NCT00863031|EXPERIMENTAL|problem-solving therapy|Three sessions of brief problem-solving counselling at week 1, 3 and 5 by a family doctor.
62385753|NCT00863031|PLACEBO_COMPARATOR|viewing video|Three sessions of health education viewing video in groups of 3 to 5 people
62385754|NCT06449456||Patients with Congenital Adrenal Hyperplasia|Patients between the ages of 8-18 years who have been diagnosed with Congenital Adrenal Hyperplasia
62385755|NCT06449456||Healthy Controls|Age and sex matched healthy controls between the ages of 8-18 years
62385756|NCT05869240|EXPERIMENTAL|BPB-101|
62385757|NCT01302535|ACTIVE_COMPARATOR|Yoga group with supervision/trainer|
61989957|NCT02372851|ACTIVE_COMPARATOR|Pureit As+ Filter|Each household will receive one water filter and a replacement battery for free during distribution. The intervention will be distributed door-to-door by the implementation team. Households will be trained on use and maintenance of the device according to the manufacturer's instructions. Households will be advised to drink exclusively from the water filter and to carry water with them if attending school or work. Households will also be advised to clean and cook their rice with filtered water only.
61989958|NCT02372851|NO_INTERVENTION|Control arm|The control arm will be advised to continue with their traditional drinking water and cooking practices. The control arm will receive the intervention at the end of the study period.
62385758|NCT01302535|ACTIVE_COMPARATOR|Yoga at home|
62385759|NCT01302535|NO_INTERVENTION|Control|No changes will be made for the participants in the control group, but they will undergo the same measurements and evaluations as the intervention groups.
62385760|NCT02321163|EXPERIMENTAL|NMES new paradigm|For the NMES new paradigm, A portable electrical stimulator will be used to produce simultaneous stimulation to both the quadriceps and calf muscles. The stimulator delivers a biphasic, asymmetrical square wave at a pulse width of 250 μs and duty cycle 5:10 sec with 2 Hz frequencies of stimulation. To disperse current intensity and enhance the comfort of the stimulation, large rectangular electrodes (80 × 100 mm) will be positioned at the best motor points of the quadriceps and calf muscles. The electrodes will be secured by tight short and sock at the respective positions. The stimulation intensity will be set to just visible muscle contractions. Stimuli will be applied twice a day for 3 h (with a 2 h rest between treatments), 5 days a week for 8 weeks.
62385761|NCT02321163|ACTIVE_COMPARATOR|NMES conventional|For NMES conventional, the experimental protocol will be the conventional electrical stimulation protocol i.e frequency: 50 Hz; intensity: maximum intensity tolerated by the subject; duration: 30 min.
62385762|NCT02321163|SHAM_COMPARATOR|Placebo|For placebo, electrodes will be applied and all conditions will be similar to those in the NMES group, except that the amplitude will be set to 0 mA so that no muscle stimulation occurs.
62385763|NCT03185637||Gastroschisis|All patients presenting primarily to the institution with gastroschisis during the data collection period will be included in the study.
62385764|NCT03185637||Anorectal malformation|All patients presenting primarily to the institution with anorectal malformation during the data collection period will be included in the study.
62385765|NCT03185637||Appendicitis|All patients under 16-years of age presenting primarily to the institution with appendicitis during the data collection period will be included in the study.
62385766|NCT03185637||Intussusception|All patients under 16-years of age presenting primarily to the institution with intussusception during the data collection period will be included in the study.
62385767|NCT03185637||Inguinal hernia|All patients under 16-years of age undergoing surgery for an inguinal hernia at the institution during the data collection period will be included in the study.
62385768|NCT01222767|EXPERIMENTAL|Arm 1|
62385769|NCT02046213|EXPERIMENTAL|E2006|Single oral 10mg dose of 100 uCi \[14C\]E2006
62385770|NCT04439708||Group 1|Patients with choroidal neovascularization in the context of age-related macular degeneration or central serous chorioretinopathy
62385771|NCT04439708||Group 2|Control group : patients without choroidal neovascularization
62385772|NCT03906006|EXPERIMENTAL|ABP-671, Cohort 1-|ABP-671, Cohort 1 participants received 50 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
62385773|NCT03906006|EXPERIMENTAL|ABP-671, Cohort 2-|ABP-671, Cohort 2 participants will receive 0.1 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
62385774|NCT03906006|EXPERIMENTAL|ABP-671, Cohort 3-|ABP-671, Cohort 3 participants will receive 0.5 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
62385775|NCT03906006|EXPERIMENTAL|ABP-671, Cohort 4-|ABP-671, Cohort 4 participants will receive 1.0 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
62385776|NCT05739890||Age >18yrs|The study will compare embryos from \>50 couples and their embryo samples flagged not suitable for transfer from deidentified couples with date of birth required.
62385777|NCT01322711|ACTIVE_COMPARATOR|Atorvastatin|"Each day accordingly to randomization patients allocated to Atorvastatin received a pill of 40 mg of atorvastatin. In diabetic patients the concomitant aspirin treatment include a previous 30 days treatment with 100 mg daily of aspirin.~All patients followed the diet used in the placebo group."
62385778|NCT01322711|PLACEBO_COMPARATOR|Diet|Low-fat diet with mean macronutrient profiles that were close to the present Adult Treatment Panel III guidelines (7% energy from saturated fat and, 200 mg dietary cholesterol per day)
62385779|NCT01772017|EXPERIMENTAL|Device Treatment|Tongue Advancement Retainer Device
62385780|NCT02738073|PLACEBO_COMPARATOR|Control|
62385781|NCT02738073|ACTIVE_COMPARATOR|Interventional|
62385782|NCT01468389|ACTIVE_COMPARATOR|Taxanes or Platinum in combination with Capecitabine|The patients will received chemotherapy combining capecitabine with platinum or taxanes until progression.
62385783|NCT01468389|EXPERIMENTAL|chemotherapy followed by capecitabine alone|The patients who has received 4 cycle chemotherapy combining capecitabine with platinum or taxanes and the result was SD or CR or PR,will be given capecitabine alone until progression.
62385784|NCT03958695|ACTIVE_COMPARATOR|Tunable-tension transobturator tape (TTT)|
62385785|NCT03958695|ACTIVE_COMPARATOR|Transobturator mid-urethral tape (TOT)|
62385786|NCT04477018|EXPERIMENTAL|Iron and Vitamin C|28 mg iron bis-glycinate chelate and 240 mg vitamin C
62385787|NCT04477018|ACTIVE_COMPARATOR|Iron|28 mg iron bis-glycinate chelate
62385788|NCT04477018|PLACEBO_COMPARATOR|Placebo|Matched placebo tablets
62385789|NCT01013636||Anaplasma|
62385790|NCT05972668|EXPERIMENTAL|Intervention Group|Intervention group needs to download the smartphone apps and follow research protocol
62385791|NCT05972668|NO_INTERVENTION|Control group|
62385792|NCT02196389|ACTIVE_COMPARATOR|Nozovent|Nasal Dilator
62385793|NCT02196389|ACTIVE_COMPARATOR|Nasanita|Nasal Dilator
62385794|NCT02196389|ACTIVE_COMPARATOR|Breath Right|Nasal Dilator
62385795|NCT02196389|ACTIVE_COMPARATOR|Airmax|Nasal Dilator
62385796|NCT02481440|EXPERIMENTAL|hUC-MSC Transplantation|Repeated intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration
62385797|NCT04529525|ACTIVE_COMPARATOR|Ivermectin|"The dose of ivermectin in patients who are randomized to the active substance depends on the weight of the patient:~More than 48 kg and less than 80 kg: Two tablets of 6 mg each (12 mg in total) at the time of inclusion and the same dose at 24 hours.~More than 80 kg and less than 110 kg: Three tablets of 6 mg each (18 mg in total) at the time of inclusion and the same dose at 24 hours.~More than 110 Kg: Four tablets of 6 mg each (24 mg in total) at the time of inclusion and the same dose at 24 hours."
62385798|NCT04529525|PLACEBO_COMPARATOR|Placebo|"The dose of placebo in patients who are randomized to the this depends on the weight of the patient:~More than 48 kg and less than 80 kg: Two tablets of 6 mg each (12 mg in total) at the time of inclusion and the same dose at 24 hours.~More than 80 kg and less than 110 kg: Three tablets of 6 mg each (18 mg in total) at the time of inclusion and the same dose at 24 hours.~More than 110 Kg: Four tablets of 6 mg each (24 mg in total) at the time of inclusion and the same dose at 24 hours."
62385799|NCT01985152|EXPERIMENTAL|1.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 8.75mg,orally
62385800|NCT01985152|EXPERIMENTAL|2.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 17.5mg,orally
62385801|NCT01985152|EXPERIMENTAL|3.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 35mg,orally
62385802|NCT01985152|EXPERIMENTAL|4.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 70mg,orally
62385803|NCT01985152|EXPERIMENTAL|5.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 140mg,orally
62385804|NCT01985152|EXPERIMENTAL|6.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 210mg,orally
62385805|NCT01985152|EXPERIMENTAL|7.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 280mg,orally
62385806|NCT01985152|PLACEBO_COMPARATOR|Placebo|Placebo-matching tablets, orally
62385807|NCT02311634|EXPERIMENTAL|Electrical pudendal nerve stimulation|At a frequency of 2.0 Hz and a moderate intensity (25\~35 mA); 60 minutes three times a week for a total of three weeks
62385808|NCT02311634|ACTIVE_COMPARATOR|Transvaginal ES|At a current intensity of \< 60 mA (in 5% increments from 0 mA to the intensity that is sensed without obvious discomfort) and frequencies of 12.5 to 30 Hz, 45 min three times a week for a total of four weeks.
62385809|NCT03715036|NO_INTERVENTION|Fundal height|Patients will have routine fundal height measurement
62385810|NCT03715036|EXPERIMENTAL|Point-of-care US|Patients will receive POC US for DVP and AC.
62385811|NCT03523390|EXPERIMENTAL|Avelumab 3 mg/kg Q2W|
62385812|NCT03523390|EXPERIMENTAL|Avelumab 10 mg/kg Q2W|
62385813|NCT03523390|EXPERIMENTAL|Avelumab 20 mg/kg Q2W|
62385814|NCT03523390|EXPERIMENTAL|Avelumab 10 mg/kg QW|
62385815|NCT05584072||Active pedal plantarflexion (APP) test|
62385816|NCT01853397|EXPERIMENTAL|Treatment at level 1|Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)
62385817|NCT01853397|EXPERIMENTAL|Treatment at level 2|Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)
62385818|NCT01853397|EXPERIMENTAL|Treatment at level 3|Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)
62385819|NCT01853397|ACTIVE_COMPARATOR|Treatment with 3 passes at 60 J/cm2|Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)
62385820|NCT02583399|EXPERIMENTAL|Ibuprofen|Ibuprofen, 10 mg/kg
62385821|NCT04417166|EXPERIMENTAL|Pembrolizumab and Radiotherapy|"Induction Phase:~Standard Involved Field Radiation Therapy (IFRT) and pembrolizumab. Pembrolizumab 200 mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 6 cycles. IFRT will start at first cycle of Pembrolizumab and will be delivered concurrently.~Patients with complete remission (CR), partial response (PR) and stable disease (SD) after Induction Phase will continue with pembrolizumab maintenance.~Maintenance Phase:~Pembrolizumab 200 mg IV will be given over 30 minutes on day 1 of each 21 day cycle up to 34 cycles or until disease progression or unaccepted toxicity"
62385822|NCT01574118|EXPERIMENTAL|Brief Enhanaced Exposure Therapy|"The following interventions are included in this arm:~1. Psycho-education addressing common reactions to trauma~2. Revisiting the Trauma memories~3. Processing the trauma memories~4. In vivo Exposure homework~5. \*Use of a brief pre-exposure trauma memory retrieval trial~6. Exposure to video clips related to the patient's trauma~7. Compound extinction - simultaneously exposing patient to trauma video clips while they listen to their trauma script"
62385823|NCT01574118|ACTIVE_COMPARATOR|Standard Prolonged Exposure Therapy|"The following interventions are included in this arm:~1. Psycho-education addressing common reactions to trauma~2. Revisiting of the Trauma memories~3. Processing the trauma memories~4. Breathing retraining~5. In vivo Exposure homework"
62385824|NCT01574118|NO_INTERVENTION|Delayed Treatment Control|Patients assigned to this arm receive assessment only (Week 0, 3, and 6) prior to receiving standard prolonged exposure therapy using the Foa et al treatment manual.
62385825|NCT01602627|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive Hsp90 inhibitor AUY922 IV over 1 hour on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62385826|NCT00352794|EXPERIMENTAL|Lenalidomide + Prednisone|Lenalidomide oral 10 mg daily/days 1-21 of 28 day cycle. Prednisone starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
62385827|NCT02963194|EXPERIMENTAL|Oxytocin|Oxytoxin nasal spray
62385828|NCT02963194|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray
62385829|NCT02827773|EXPERIMENTAL|Received Talking Pill Bottles|Patients received anti-hypertensives over 90 day period in Talking Pill Bottle which contained summary of pharmacy counselling session.
62385830|NCT02827773|NO_INTERVENTION|Usual Care|Patients received oral summary of pharmacy counselling session.
62385831|NCT03917576|ACTIVE_COMPARATOR|Normoglicamic group|Control normoglycaemic participants
62385832|NCT03917576|ACTIVE_COMPARATOR|Hyperglicaemic group|Control hyperglicaemic group
62385833|NCT03917576|EXPERIMENTAL|Experimental group|Experimental Type 2 Diabetes Mellitus Group
62385834|NCT01402206|OTHER|Structured patient visits|Participants in the intervention group visit their general practitioner at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation.
61989959|NCT03448315|ACTIVE_COMPARATOR|real tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions)
62385835|NCT01402206|OTHER|Treatment as usual|The control group receives treatment as usual by general practitioner (no intervention).
62385836|NCT04779294||Fetus in labour at risk of acedimia|The Group of patients studied are fetuses in labour at risk of hypoxia with internal fetal monitoring and scalp lactate bloodsamples ( standard monitoring).
62385837|NCT04779294||Fetus in labour at risk of acedemia with STAN analysis|Same group of fetuses in labour at risk of hypoxia with internal fetal monitoring and STAN analysis(ST waveform analysis of the fetal electrocardiogram, opened after study inclusion finished)
62385838|NCT03034746|EXPERIMENTAL|Alzheimer's Disease (G1)|(G1) physical activity (PA)
62385839|NCT03034746|EXPERIMENTAL|Alzheimer's Disease (G2)|(G2) cognitive treatment (CT)
62385840|NCT03034746|NO_INTERVENTION|Healthy Old Subjects (G1)|Control group old
62385841|NCT03034746|NO_INTERVENTION|Healthy young Subjects (G2)|Control group young
62385842|NCT02612168|EXPERIMENTAL|All patients|Each patient will have any pigmented lesions (PLs) which are due to be biopsied, two PLs not due for biopsy and one patch of healthy skin photographed. Each will be photographed using three cameras: A standard DSLR and two smartphones with a dermoscopic lens attachment. Photographic images will be analysed by Melanoma Image Analysis Algorithm (MIAA)
62385843|NCT05717413||Patients after arthroplasty of the 1st metatarsophalangeal joint|
62385844|NCT05717413||Patients after arthrodesis of the 1st metatarsophalangeal joint|
62385845|NCT01496924|OTHER|speech therapy group|All dysphagic patients will be submitted to speech therapy
62385846|NCT02220608|EXPERIMENTAL|Arm 1: Dose Level 1 (Bortezomib & G-CSF)|G-CSF will be administered daily for 5 days (Days 1-5). On Day 4 at approximately 1800 hours, bortezomib will be administered. Apheresis will begin on Day 5 either 15 or 18 hours following Day 4 bortezomib dose; 20L of peripheral blood will be processed with a cumulative target collection goal of \> 6.0x106 CD34+cells/kg. If the target collection goal is not met after one apheresis procedures, up to three additional days of G-CSF and apheresis may be repeated.
62385847|NCT02220608|EXPERIMENTAL|Arm 2: Dose Level 2 (Bortezomib & G-CSF)|G-CSF will be administered daily for 5 days (Days 1-5). On Day 4 at approximately 1800 hours, bortezomib will be administered. Apheresis will begin on Day 5 either 15 or 18 hours following Day 4 bortezomib dose; 20L of peripheral blood will be processed with a cumulative target collection goal of \> 6.0x106 CD34+cells/kg. If the target collection goal is not met after one apheresis procedures, up to three additional days of G-CSF and apheresis may be repeated.
62766972|NCT04363047||Healthy Volunteers|"These people will have already provided at least one sample as part of the National Repository Healthy Volunteer Study.~We aim to take blood samples from participants who have recovered from COVID-19 and compare them with blood samples we already have which were taken before the COVID-19 pandemic.~We will need to compare these samples to other samples, so we will also need to blood samples from people who have not had COVID-19 (who have either tested negative or never had any symptoms)."
62766973|NCT04363047||Rheumatoid Arthritis|"These people will have already provided at least one sample as part of the BRAGGSS Study.~We aim to take blood samples from participants who have recovered from COVID-19 and compare them with blood samples we already have which were taken before the COVID-19 pandemic.~We will need to compare these samples to other samples, so we will also need to blood samples from people who have not had COVID-19 (who have either tested negative or never had any symptoms)."
62766974|NCT06507033|EXPERIMENTAL|Intervention Group|This group will be provided with the mobile application and volume measurement device. The planning for hospital visits will be organised at the same frequency in both groups. All individuals will be followed up for three months. The same measurement tools will be applied to both groups before and after the application.
62385848|NCT00516126||Point-of-Care managed|This arm includes all patients in which the hemostatic therapy is guided by POC devices e.g. MULTIPLATE (a platelet function analyzer) or ROTEM (thromboelastometry)
62766975|NCT06507033|NO_INTERVENTION|Control Group|This group will receive routine care at the clinic.The planning for hospital visits will be organised at the same frequency in both groups. All individuals will be followed up for three months. The same measurement tools will be applied to both groups before and after the application.
62385849|NCT00516126||Conventional hemostasis lab managed|This arm includes all patients in which the hemostatic therapy is guided by conventional hemostasis laboratory data e.g. INR, aPTT, fibrinogen concentration, platelet count but no POC devices e.g. MULTIPLATE (a platelet function analyzer) or ROTEM (thromboelastometry)
62385850|NCT04864197|EXPERIMENTAL|prf group|prf membrane placement over implant site for gingival thickening
62385851|NCT04864197|EXPERIMENTAL|control group|no prf placement
62766976|NCT03794453||Stroke patients|
62766977|NCT05226611|EXPERIMENTAL|Tender point treatment with Counterstrain|A tender point was located in the upper trapezius region of the test subject and treated with counterstrain. The side with the highest initial pain level was used as the treatment side. Pain level was measured before and after treatment. The MyotonPRO was also used to measure physiologic parameters of the muscle before and after treatment.
62385852|NCT01203566|ACTIVE_COMPARATOR|Conventional 3-port laparoscopic appendectomy|Laparoscopic appendectomy will be performed with the standard 3-port technique. The laparoscope is introduced via a 10mm subumbilical port. Dissection will be performed with a 5mm LLQ port and a 5mm RLQ port. Exploratory laparoscopy was first carried out to locate the appendix and to rule out other pathologies. The mesoappendix will be divided with the ultrasonic dissector (Sonosurg, Olympus surgical, Tokyo, Japan). The appendix will be ligated between two polydioxanone suture loops. The specimen will be delivered within a plastic bag via the subumbilical port. Purulent fluid will be irrigated and suctioned from the subhepatic space, right lower quadrant and the pelvis if present. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O absorbable subcuticular sutures. A pelvic drain (12Fr) will be inserted in cases of abscesses or gangrene.
62559017|NCT06551532|EXPERIMENTAL|Multicomponent Intervention Group|Soccer players in the intervention group (IG) underwent a multimodal training program comprising 3 sessions per week for 6 weeks. All the soccer players in IG were allowed to continue their usual training (5 sessions per week) and matches (1 per week) at their clubs. The training program comprised both lumbopelvic training (foam rolling, manual therapy, mobility, posture, and strength training) and sprint technique components. The intervention included a total of 18 sessions of approximately 50 minutes each and sessions were supervised by 2 physiotherapists. During the 6 weeks of the intervention, participants performed the multicomponent program 3 times a week. Monday, Wednesday, and Friday were the chosen days for carrying out the training program, as Sunday was usually a game day.
62559018|NCT06551532|NO_INTERVENTION|Control Group|Soccer players in the control group (CG) were requested not to modify their established training routines during the entire 6-week period.
62559019|NCT02426502|EXPERIMENTAL|Conversion to once daily dosing|The conversion to a once daily dosing regimen will be accomplished in three phases (1-conversion to Advagraf; 2-conversion of non-immunosuppressant drugs and; 3-conversion of patients taking twice daily MPA to once daily MPA). No control group.
62766978|NCT06190327|EXPERIMENTAL|blended indoor and outdoor multicomponent structured exercise group|Participants will receive a 16-week blended indoor and outdoor multicomponent structured exercise program, with 2 sessions per week (90 mins/session).
62766979|NCT06190327|ACTIVE_COMPARATOR|indoor-only multicomponent structured exercise group|Participants will receive a 16-week indoor-only multicomponent structured exercise program, with 2 sessions per week (90 mins/session).
62766980|NCT06190327|NO_INTERVENTION|control group|The control group will not receive any intervention during the whole project.
62766981|NCT06353074||study group|The patients who had uterine atony during delivery and to whom Acar's atony suture were performed consisted study group.
61989960|NCT03448315|SHAM_COMPARATOR|sham tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions) but stimulation device is turned off without the participant knowledge
62385853|NCT01203566|ACTIVE_COMPARATOR|LESS appendectomy|Two 5 mm ports and a 10mm port will be inserted through a 13mm transumbilical incision. Exploratory laparoscopy was first carried out to locate the appendix and to rule out other pathologies. Retraction of the appendix would be performed with a flexible curved forceps. The mesoappendix will be divided with the ultrasonic dissector (Sonosurg, Olympus surgical, Tokyo, Japan). The appendix will be ligated between two polydioxanone suture loops. The specimen will be delivered within a plastic bag via the subumbilical port. Purulent fluid will be irrigated and suctioned from the subhepatic space, right lower quadrant and the pelvis if present. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O absorbable subcuticular sutures. A pelvic drain (12Fr) will be inserted in cases of abscesses or gangrene.
61989961|NCT01880112|EXPERIMENTAL|4 gram dose|Pre-operative prophylactic dose of 4 grams of cefazolin
62385854|NCT02438111||age related macular degeneration|metagenome AMD
62385855|NCT02438111||controls|metagenome controls
62385856|NCT02429076|EXPERIMENTAL|Propofol|Subjects in this arm will receive propofol general anesthesia
62385857|NCT02429076|EXPERIMENTAL|Sevoflurane|Subjects in this arm will receive sevoflurane general anesthesia
62385858|NCT06148025|EXPERIMENTAL|Substudy 1 - BCG vaccine, antibiotics and 2nd BCG vaccine|Randomised to receive antibiotics and a BCG vaccine at visit 1 and a second BCG vaccine 6 months later
62385859|NCT06148025|EXPERIMENTAL|Substudy 1 - BCG vaccine, no antibiotics and 2nd BCG vaccine|Randomised to receive no antibiotics and a BCG vaccine at visit 1 and a second BCG vaccine 6 months later
62385860|NCT06148025|EXPERIMENTAL|Substudy 1 - BCG vaccine, antibiotics and placebo vaccine|Randomised to receive antibiotics, a placebo vaccine at visit 1 and a BCG vaccine 6 months later
62385861|NCT06148025|EXPERIMENTAL|Substudy 1 - BCG vaccine, no antibiotics and placebo vaccine|Randomised to receive no antibiotics, a placebo vaccine at visit 1 and a BCG vaccine 6 months later
62385862|NCT06148025|EXPERIMENTAL|Substudy 2 - Yellow Fever vaccine, antibiotics and BCG vaccine|Randomised to receive antibiotics, a BCG vaccine at visit 1 and a Yellow Fever vaccine 3 months later
62385863|NCT06148025|EXPERIMENTAL|Substudy 2 - Yellow Fever vaccine, no antibiotics and BCG vaccine|Randomised to receive no antibiotics, a BCG vaccine at visit 1 and a Yellow Fever vaccine 3 months later
62385864|NCT06148025|EXPERIMENTAL|Substudy 2 - Yellow Fever vaccine, antibiotics and placebo vaccine|Randomised to receive antibiotics, a placebo vaccine at visit 1 and a Yellow Fever vaccine 3 months later
62385865|NCT06148025|EXPERIMENTAL|Substudy 2 - Yellow Fever vaccine, no antibiotics and placebo vaccine|Randomised to receive no antibiotics, a placebo vaccine at visit 1 and a Yellow Fever vaccine 3 months later
61989962|NCT01880112|ACTIVE_COMPARATOR|2 gram dose|Pre-operative prophylactic dose of 2 grams of cefazolin
62385866|NCT01278966|EXPERIMENTAL|The Modified Atkins Diet|Treatment with the Modified Atkins Diet for 6 months
62385867|NCT03713242|EXPERIMENTAL|Group A: ACT-541468 in subjects with mild hepatic impairment|Single oral dose administered on Day 1.
62385868|NCT03713242|EXPERIMENTAL|Group B: ACT-541468 in subj. with moderate hepatic impairment|Single oral dose administered on Day 1.
62385869|NCT03713242|EXPERIMENTAL|Group C: ACT-541468 in subjects with severe hepatic impairment|Single oral dose administered on Day 1.
62385870|NCT03713242|EXPERIMENTAL|Group D: ACT-541468 in healthy subjects.|Single oral dose administered on Day 1.
62385871|NCT05847140||Evusheld exposed pregnancies|A pregnancy is considered exposed to EVUSHELD if 1 of 2 conditions are met: (1) EVUSHELD was received during the 36-week period \[reflective of roughly 3 half-lives of EVUSHELD\] prior to LMP, or (2) EVUSHELD was received on/after LMP during the exposure ascertainment period, which will vary based on the outcome of interest.
62385872|NCT05220020|EXPERIMENTAL|Experimental group|Synchronous treatment group: the first course of TACE treatment was started after 2-3 weeks Lenvatinib treatment.
61989963|NCT02684643|EXPERIMENTAL|enhanced individualised therapy|Patients' dialysis dosage, medication as well as dietary plan will be modified.
61989964|NCT02684643|EXPERIMENTAL|non-enhanced individualised therapy|Patients' medication as well as dietary plan will be modified without alteration of dialysis dosage.
61989965|NCT02684643|EXPERIMENTAL|regular intervention|Phosphate binders and calcitriol will be prescribed and adjusted without altering patients' diet habit.
62385873|NCT05220020|ACTIVE_COMPARATOR|Control group|Sequential treatment group: patients with uncontrolled TACE progression after TACE treatment were sequentially treated with Lenvatinib.
62559020|NCT04332315|ACTIVE_COMPARATOR|VALS|Vaginally asissted laparoscopic sacrocolpopexy
62766982|NCT04791059|EXPERIMENTAL|Combined analgesia group|Patient-controlled analgesia is established with S-ketamine 50 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.
62385874|NCT02424136|OTHER|Entire group|Children aged 2-17 years with suspected peanut allergy who require peanut food challenge to confirm clinical allergy, will be recruited for the study. They will undergo a preceding questionnaire, peanut skin prick testing, spirometry, fraction of exhaled nitric oxide (FeNO) measurement, serum peanut and Ara h2 specific immunoglobulin E (sIgE) antibodies, and collection of blood biomarker prior to food challenge. The primary endpoint will be anaphylaxis at open label peanut challenge, with the primary exposure of interest will be the serum biomarker.
62766983|NCT04791059|PLACEBO_COMPARATOR|Control group|Patient-controlled analgesia is established with sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.
62766984|NCT06232551|EXPERIMENTAL|At-risk patients for which an alert is sent during the intervention phase|Patients found to be at an increased risk for VTE but a low risk for bleeding (based upon eVTE risk assessment), thereby meeting criteria for alerting during the intervention phase
61989966|NCT01623596|EXPERIMENTAL|Fingolimod|
62385875|NCT06070831|EXPERIMENTAL|Inspiratory muscle training group (IMT)|Inspiratory muscle training at 50% of MIP, the training load was set each 2 weeks to keep 50% of MIP.
62385876|NCT06070831|EXPERIMENTAL|Expiratory muscle training group (EMT)|Expiratory muscle training at 50% of MEP, following the same rules as HIT.
62385877|NCT01143818||AndroGel (testosterone gel )1%|AndroGel is topical testosterone gel 1% (1 sachet of 5 g contains 50 mg of testosterone), 1 daily dose.
62385878|NCT01281592|EXPERIMENTAL|LOR-253 HCl|LOR-253 HCl will be given in ascending doses until the maximum administered dose or appropriate target dose is reached. A biomarker study of up to 10 patients will be conducted upon achieving appropriate dose level.
62385879|NCT02798159|EXPERIMENTAL|Part A- Arm 1|Investigational dose = 0.25 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
62385880|NCT02798159|EXPERIMENTAL|Part A- Arm 2|Investigational dose = 0.5 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
62385881|NCT02798159|EXPERIMENTAL|Part A- Arm 3|Investigational dose = 1 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
62385882|NCT02798159|EXPERIMENTAL|Part A- Arm 4|Investigational dose = 1.25 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
62385883|NCT02798159|EXPERIMENTAL|Part B- Arm 1|"Investigational dose = optimal dose in Part A. The drug should not be taken more than one time a day or 3 times a week.~Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month"
62385884|NCT02798159|ACTIVE_COMPARATOR|Part B- Arm 2|Sildenafil Citrate 50 mg on demand The drug should not be taken more than one time a day or 3 times a week. Administered orally once a day, 1 hour before sexual activity, for 1 month
62385885|NCT00496145|EXPERIMENTAL|treatment|Spanish Diabetes Self-Management Program
61989967|NCT01623596|ACTIVE_COMPARATOR|Disease Modifying Therapy|2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)
62385886|NCT00496145|NO_INTERVENTION|control|usual-care control group
62385887|NCT03718728|ACTIVE_COMPARATOR|Standard group|A personalized diet and physical exercise recommendations.
62385888|NCT03718728|EXPERIMENTAL|Mind&Life (standard + intervention) group|A personalized diet and physical exercise recommendations plus the acceptance and mindfulness-based group intervention program.
62559021|NCT04332315|ACTIVE_COMPARATOR|AS|Abdominal Sacrocolpopexy
61989968|NCT04911283||MCs type 1 patients (study group; n=37)|
61989969|NCT04911283||MCs type 2 patients (comparator group; n=44)|
61989970|NCT04911283||healthy controls (n=37)|
61989971|NCT04891900|EXPERIMENTAL|TQB2450 combined with anlotinib, oxaliplatin and capecitabine in the treatment of GC or AEG|In this study, all subjects were treated with TQB2450 (PD-L1 inhibitor) plus anlotinib combined with oxaliplatin and capecitabine, once every 3 weeks, six cycles of chemotherapy with oxaliplatin and capecitabine. Subsequently, TQB2450 (PD-L1 inhibitor) combined with anlotinib was maintained until disease progression, intolerable toxicity, withdrawal of informed consent, loss of follow-up or death, or other circumstances that the researcher judged should stop treatment, whichever occurred first.
62385889|NCT03010358|EXPERIMENTAL|Treatment (entospletinib, obinutuzumab)|Patients receive entospletinib PO either QD or BID on days -7 to -1 (run-in phase) depending on the assigned dose level. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of the first cycle, and on day 1 of subsequent cycles. Treatment with obinutuzumab repeats every 28 days for up to 6 cycles and daily treatment with entospletinib continues every 28 days for up to 12 cycles in the absence of disease progression or unexpected toxicity.
62385890|NCT01442961|ACTIVE_COMPARATOR|laparoscopy|Intervention: Procedure: laparoscopy
62385891|NCT01442961|ACTIVE_COMPARATOR|vaginal|Intervention: Procedure: vaginal
62385892|NCT00982111|EXPERIMENTAL|Necitumumab + Pemetrexed + Cisplatin|Necitumumab + Pemetrexed + Cisplatin
62766985|NCT06232551|ACTIVE_COMPARATOR|At-risk patients during the baseline phase|Patients found to be at an increased risk for VTE but a low risk for bleeding (based upon eVTE risk assessment), and who meet criteria for alerting, but for whom no alert is sent during the baseline phase
62766986|NCT00117689|EXPERIMENTAL|1|Standard (tacrolimus based standard therapy without induction)
62766987|NCT00117689|ACTIVE_COMPARATOR|2 Standard of Care|Thymoglobulin with tacrolimus and corticosteroid sparing maintenance therapy
62766988|NCT00468845|EXPERIMENTAL|1|
62766989|NCT00468845|EXPERIMENTAL|2|
62766990|NCT00468845|PLACEBO_COMPARATOR|3|
62766991|NCT06175351|EXPERIMENTAL|Phase Ib 9MW1911|9MW1911 is administered intravenously in a multiple ascending dose pattern in four dose levels. Each level includes 6 patients.
62766992|NCT06175351|EXPERIMENTAL|Phase IIa 9MW1911|9MW1911 is administered intravenously (two doses selected on phase Ib). Each dose level includes up to 18 patients.
62766993|NCT06175351|PLACEBO_COMPARATOR|Phase Ib Placebo|Placebo is administered intravenously in a multiple ascending dose pattern in four dose levels. Each level includes 2 patients.
62385893|NCT00982111|ACTIVE_COMPARATOR|Pemetrexed + Cisplatin|Pemetrexed + Cisplatin
62385894|NCT01196065|EXPERIMENTAL|Single Arm|
62385895|NCT00758394|PLACEBO_COMPARATOR|Fluoride - A|Fluoride only toothpaste
62385896|NCT00758394|ACTIVE_COMPARATOR|Total + Whitening toothpaste - B|Triclosan/fluoride toothpaste
62385897|NCT00758394|EXPERIMENTAL|Triclosan/fluoride/Amino Acid - C|toothpaste containing amino acid #1
62385898|NCT00758394|EXPERIMENTAL|Triclosan/fluoride/Cavistat -D|toothpaste containing amino acid/bicarbonate
62385899|NCT03315416||NHS Sample|Children diagnosed with speech sound disorder aged 2-5 years
62385900|NCT03672721|EXPERIMENTAL|Arm 1: IA Carbo + radiation|400 mg/m\^2 carbo + 15 Gy
62385901|NCT03672721|EXPERIMENTAL|Arm 2: IA Carbo + radiation|400 mg/m\^2 carbo + 18 Gy
61989972|NCT04829773|EXPERIMENTAL|PK Cohort 1|"Subjects received three single oral doses of palovarotene on Days 1, 6, and 11, separated by 5-day washout periods.~Sequence A-B-C: Subjects received a single oral dose of palovarotene whole capsule under fasting conditions (at least a 10-hour overnight fast); followed by a single oral dose of palovarotene whole capsule 30 minutes after the start of a standardized high-fat, high-caloric breakfast; and then followed by a single oral dose of palovarotene sprinkled on 1 teaspoon of apple sauce, administered 30 minutes after the start of a standardized high-fat, high-caloric breakfast."
61989973|NCT04829773|EXPERIMENTAL|PK Cohort 2|"Subjects received three single oral doses of palovarotene on Days 1, 6, and 11, separated by 5-day washout periods.~Sequence B-C-A: Subjects received a single oral dose of palovarotene whole capsule 30 minutes after the start of a standardized high-fat, high-caloric breakfast; followed by a single oral dose of palovarotene sprinkled on 1 teaspoon of apple sauce, administered 30 minutes after the start of a standardized high-fat, high-caloric breakfast; and then followed by a single oral dose of palovarotene whole capsule under fasting conditions (at least a 10-hour overnight fast)."
62385902|NCT03672721|EXPERIMENTAL|Arm 3: IA Carbo + radiation|400 mg/m\^2 carbo + 20 Gy
62385903|NCT03672721|EXPERIMENTAL|Arm 4: IA Carbo + radiation|400 mg/m\^2 carbo + 25 Gy
62385904|NCT03672721|EXPERIMENTAL|Arm 5: IA Carbo + radiation|400 mg/m\^2 carbo + 30 Gy
62385905|NCT03672721|EXPERIMENTAL|Arm 6: IA Carbo + radiation|400 mg/m\^2 carbo + 35 Gy
62385906|NCT02204267|EXPERIMENTAL|prolonged ECG monitoring|Regular stroke unit treatment and diagnostic procedures according to guidelines and additional prolonged ECG monitoring
62385907|NCT02204267|NO_INTERVENTION|no additional ECG recording|Regular stroke unit treatment and diagnostic procedures according to guidelines
62385908|NCT04695444|ACTIVE_COMPARATOR|conventional PVC tube|When performing nasotracheal intubation, clinicians use the conventional PVC tube.
62385909|NCT04695444|EXPERIMENTAL|PVC tube with rubber suction catheter|When performing nasotracheal intubation, clinicians use the conventional PVC tube + rubber suction catheter.
62385910|NCT04695444|EXPERIMENTAL|velvet soft PVC tube|When performing nasotracheal intubation, clinicians use the velvet soft PVC tube.
62385911|NCT02576951|EXPERIMENTAL|Galcanezumab Solution Formulation-Part A|Galcanezumab solution formulation in a prefilled syringe given SC once.
62385912|NCT02576951|PLACEBO_COMPARATOR|Placebo-Part A|Placebo in a prefilled syringe given SC once.
62385913|NCT02576951|EXPERIMENTAL|Galcanezumab Lyophilized Formulation-Part B|Galcanezumab lyophilized (freeze dried) formulation given SC once.
62385914|NCT02576951|EXPERIMENTAL|Galcanezumab Solution Formulation-Part B|Galcanezumab solution formulation in a prefilled syringe given SC once.
62385915|NCT03098992|ACTIVE_COMPARATOR|Fotona Dynamis Er:YAG Laser System|Active treatment with Fotona Dynamis Er:YAG Laser System
62385916|NCT03098992|SHAM_COMPARATOR|Fotona Dynamis Er:YAG Laser System with Sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
62559022|NCT04413513|EXPERIMENTAL|Integrated Attention Training Program|"The intervention group (I) will receive integrated attention training program (IATP) on a variety of structured attention tasks by an intervention instructor. It is considered to be simple and safe but effective enough for cognitive health promotion."
62385917|NCT03163277|NO_INTERVENTION|Standard of care|Continue current antiretroviral regimen
62385918|NCT03163277|EXPERIMENTAL|Reduced Neurotoxicity Arm|Emtricitabine plus darunavir/cobicistat plus maraviroc
62385919|NCT02581501|EXPERIMENTAL|Gemcitabine, ABRAXANE®, and Xeloda|"Level-1~ABRAXANE® 75 mg/m2 over 30 min Days 5 and 12~GEMCITABINE 600 mg/m2 over 60 min Days 5 and 12.~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day~Level 1~ABRAXANE® 100 mg/m2 over 30 min Days 5 and 12~GEMCITABINE 600 mg/m2 over 60 min Days 5 and 12~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day~Level 2~ABRAXANE® 125 mg/m2 over 30 min Days 5 and 12~GEMCITABINE 600 mg/m2 over 75 min Days 5 and 12~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day~Level 3~ABRAXANE® 125 mg/m2 over 30 min Days 5 and 12~GEMCITABINE 750 mg/m2 over 75 min Days 5 and 12~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day"
62385920|NCT01825759|EXPERIMENTAL|danshen dripping pill|danshen dripping pill 27mg ten pills by mouth every 8 hours for one year
62385921|NCT05327309|ACTIVE_COMPARATOR|Propranolol|propranolol with a mean dose of 2mg/kg/day in 2 divided doses for a period of 6 months
62559023|NCT04413513|PLACEBO_COMPARATOR|Health Education|The control group (C) will receive health educational sessions on health concerns and physical diseases commonly found in old age during the invention period.
62385922|NCT05327309|EXPERIMENTAL|Bleomycin|Bleomycin 15mg diluted in 15 ml of Normal Saline along with a dosage of 0.5 mg/kg for a period of 6 months.
62385923|NCT03797742||NC|Patients without heart failure.
62385924|NCT03797742||DCM|Dilated cardiomyopathy patients.
62385925|NCT03797742||ICM|Ischemic cardiomyopathy patients.
62385926|NCT05442827|EXPERIMENTAL|Treatment group A: SHR7280 tablets|
62385927|NCT05442827|EXPERIMENTAL|Treatment group B:SHR7280 tablets|
62385928|NCT05442827|PLACEBO_COMPARATOR|Treatment group C:Intervention: Drug: PlaceboSHR7280 tablets blank preparation|
62385929|NCT02365311|EXPERIMENTAL|one lung group|
62385930|NCT02150785|EXPERIMENTAL|Adminstering Streptokinase|treatment with 15,000 units/Kg of streptokinase in ischemic stroke patients with symptoms onset for less than 3 hours
62385931|NCT01917799|EXPERIMENTAL|Aspirin|75mg tab of aspirin once daily
62385932|NCT01917799|ACTIVE_COMPARATOR|Aspirin + heparin|75mg tab of aspirin once daily + 0.4 mL/day of injection of low molecular weight heparin
62559024|NCT02790164|EXPERIMENTAL|Rocuronium|Patients will receive a bolus dose of 0.6 mg/kg, then a continuous I.V. infusion of 0.3-0.6 mg/kg/hr as per standard intensive care unit practice.
61989974|NCT04829773|EXPERIMENTAL|PK Cohort 3|"Subjects received three single oral doses of palovarotene on Days 1, 6, and 11, separated by 5-day washout periods.~Sequence C-A-B: Subjects received a single oral dose of palovarotene sprinkled on 1 teaspoon of apple sauce, administered 30 minutes after the start of a standardized high-fat, high-caloric breakfast; followed by a single oral dose of palovarotene whole capsule under fasting conditions (at least a 10-hour overnight fast); and then followed by a single oral dose of palovarotene whole capsule 30 minutes after the start of a standardized high-fat, high-caloric breakfast."
62559025|NCT02790164|PLACEBO_COMPARATOR|Usual Care|Patients will receive 100 mL of normal saline over 5-10 minutes at the beginning of the study in addition to usual care.
62559026|NCT04324424|EXPERIMENTAL|Undialyzed ESRD subjects (P1)|"Part 1: Undialyzed end stage renal disease (ESRD) patients to receive a single dose of HMS5552 ( 25mg ) tablets orally~."
61989975|NCT04829773|EXPERIMENTAL|Drug-Drug interaction (DDI) Cohort|On the morning of Day 1, subjects received a single dose of midazolam 30 minutes after the start of a standardized breakfast. On Day 2 (after the 24-hour midazolam blood draw) through Day 15, subjects received a daily, single dose of palovarotene in the morning 30 minutes after the start of a standardized breakfast. A second dose of midazolam was administered on Day 15 in the morning (immediately following the palovarotene dose) 30 minutes after the start of a standardized breakfast.
62182661|NCT03515200|EXPERIMENTAL|Treatment|"This study will be done in two parts: Part 1: Dose escalation and Part 2: Dose expansion.~In Part 1 - Dose escalation: Patients that lack Ph+ or Ph-like ALL, palbociclib, initially at 50mg/m2/day, 40% of the adult MTD, will be administered on Days 1-5 and 11-15, and escalated based on tolerability. If our highest dosing of 100mg/m2/day is tolerated, we will have a final dose level that receives an additional 10 days of palbociclib (Days 1-5, 11-15, and 21-30).~For patients that are Ph+ or have Ph-like ALL that are also receiving dasatinib or ruxolitinib: palbociclib, initially at 75mg/m2/day, 60% of the adult MTD, will be administered on Days 1-5 and 11-15 and escalated based on tolerability.~In Part 2 - Dose expansion: After determination of dose in Part 1, an additional 10 patients will be enrolled to confirm tolerability."
62385933|NCT06464276||Patients with confirmed Chronic Coronary Syndrome and persistent stable angina.|Patients with confirmed Chronic Coronary Syndrome and persistent stable angina will be observed without any intervention, and the study will follow them for 3 months while they are treated with Trimetazidine 80 mg OD.
62385934|NCT05994664|EXPERIMENTAL|Intervention|Group of up to 20 patients will be randomly allocated into an experimental group at a 1:1 ratio intervention to controls. The experimental group will receive all of the preliminary outcome screening with the additional 10-15 minutes of training and advancement on HeartMath techniques as well as continued written and video reinforcement.
62385935|NCT05994664|PLACEBO_COMPARATOR|Control|Group of up to 20 patients will be randomly allocated into a control group at a 1:1 ratio for intervention to controls. The control group will receive all of the preliminary outcome screening and will have weekly virtual sessions that include the 3-step Protocol HRV assessment. After the CG has completed 8 weeks, they will then have access to materials related to the techniques that were taught to the HMI group to allow for therapeutic equality.
62385936|NCT00303719|EXPERIMENTAL|High Risk Patients|Nonmyeloablative conditioning using fludarabine, cyclophosphamide and low dose Total Body Irradiation with or without anti-thymocyte globulin followed by allogeneic hematopoietic stem cell transplantation, immunosuppressive cyclosporine and mycophenolate mofetil and post-transplant use of bone marrow-stimulating filgrastim.
62385937|NCT00303719|EXPERIMENTAL|Standard Risk Patients|Nonmyeloablative conditioning using fludarabine, cyclophosphamide and low dose Total Body Irradiation with or without anti-thymocyte globulin followed by allogeneic hematopoietic stem cell transplantation, immunosuppressive cyclosporine and mycophenolate mofetil and post-transplant use of bone marrow-stimulating filgrastim.
62385938|NCT03212872|OTHER|Endoscopy|
62385939|NCT03965234|EXPERIMENTAL|Prevention (cisplatin, metastasectomy)|Patients undergo pulmonary suffusion consisting of cisplatin via infusion. Patients the undergo metastasectomy. Beginning 4-8 weeks, patients with unresectable sarcoma may receive chemotherapy.
62385940|NCT01540890||withdrawal|patients who undergo an opioid withdrawal
62559027|NCT04324424|EXPERIMENTAL|Healthy volunteers (H)|"Part 1: Matched healthy volunteers to receive a single dose of HMS5552 ( 25mg ) tablets orally~Matching principle:~H group and P1 group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
62559028|NCT04324424|EXPERIMENTAL|Severe renal impaired subjects (P2)|"Part 2：Severe renal impaired subjects to receive a single dose of HMS5552 ( 25mg ) tablets orally~Matching principle:~P2 group and H group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
62385941|NCT01540890||opioids|patients on opioid medication without withdrawal
62559029|NCT04324424|EXPERIMENTAL|Moderate renal impaired subjects (P3)|"Part 2：Moderate renal impaired subjects to receive a single dose of HMS5552 ( 25mg ) tablets orally~Matching principle:~P3 group and H group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
62559030|NCT04324424|EXPERIMENTAL|Mild renal impaired subjects (P4)|"Part 2：Mild renal impaired subjects to receive a single dose of HMS5552 ( 25mg ) tablets orally~Matching principle:~P4 group and H group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
62559031|NCT02676882|OTHER|EnBrace HR for Prevention of Depressive Relapse (Group 1)|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are not currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are not experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score \</= 10.
62559032|NCT02676882|OTHER|EnBrace HR for Acute Treatment of Major Depression (Group 2)|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score \>/= 15.
62559033|NCT06325826||Group 1|
62385942|NCT01540890||opioid-free|patients with chronic pain without opioid medication
62385943|NCT02400281|EXPERIMENTAL|Arm 1 crenolanib besylate combination|Arm 1 patients will receive crenolanib besylate, combined with standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine, FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin
62385944|NCT02400281|EXPERIMENTAL|Arm 2 crenolanib besylate combination|Arm 2 patients will receive crenolanib besylate and azacytidine.
62385945|NCT05482958||Control: Participants without T2DM|"Participants without T2DM will be recruited and consented through the Courtois Cardiovascular Signature Biorepository protocol, HbA1c % will be measured at baseline from the stored bio-samples collected as a part of the biorepository program. A wearable will be worn for the duration of the clinic appointment.~The participant will then wear the HOP watch for the designated period of time."
62385946|NCT05482958||Case: Patients with T2DM|"Participants with T2DM, their baseline history of T2DM will be determined from chart review and patient history. In patients with T2DM, for the HbA1c % both at baseline and follow-up, the investigators will measure this value as a part of routine standard of care in the DECIDE-CV clinic.~A subset of 20 participants will be given a Polar H10 chest-strap to be worn during the clinic.~Participants will be given a HOP watch to wear in the clinical environment and will be discharged from the clinic to wear the watch for the designated period.~Participants will subsequently wear the watch again, in 3-6 months for the designated period of time."
62385947|NCT04968327|EXPERIMENTAL|Micro-osteoperforations|
62385948|NCT04968327|ACTIVE_COMPARATOR|Canine retraction|
62559034|NCT05641298|ACTIVE_COMPARATOR|ARV-1801(ACG-701) Active Group|ARV-1801(ACG-701) tablets by mouth twice a day for 14 days
62559035|NCT05641298|PLACEBO_COMPARATOR|Placebo Group|Placebo tablets by mouth twice a day for 14 days
62559036|NCT02508623|EXPERIMENTAL|Rifaximin|Rifaximin 550 mg 1 tablet BID for 60 days
62559037|NCT02508623|PLACEBO_COMPARATOR|Placebo|Placebo 1 tablet BID for +60 days
62559038|NCT03248687|EXPERIMENTAL|Home follow up|Patients with a distal radius buckle fracture treated in a removable splint will be provided with discharge instructions and anticipatory guidance without any scheduled physician follow up.
62559039|NCT03248687|ACTIVE_COMPARATOR|Primary Care Physician Follow up|Patients with a distal radius buckle fracture treated in a removable splint will be provided with discharge instructions and anticipatory guidance with scheduled primary care physician follow up at 1-2 weeks post visit to the emergency department.
62559040|NCT06134310|ACTIVE_COMPARATOR|Manual Therapy based Fascial Distortion Model|All participants were given manual therapy based on the Fascial Distortion Model in addition to conventional therapy (Rocabado's 6x6 Exercises and Patient Education). Conventional therapy was implemented as a home program for 8 weeks, while Manual Therapy was conducted for forty-five minutes once a week in a clinical setting.
62559041|NCT06134310|ACTIVE_COMPARATOR|Core Stabilization Training|All participants were given manual therapy based on the Core Stabilization Training in addition to conventional therapy (Rocabado's 6x6 Exercises and Patient Education). Conventional therapy was implemented as a home program for 8 weeks, while Core Stabilization Training was conducted for forty-five minutes once a week in a clinical setting.
62559042|NCT06134310|NO_INTERVENTION|Control|No participant was given any therapy during the study.
62559043|NCT03428243||truSculpt|truSculpt effectiveness after 18 months
62559044|NCT05513482||Cryoballoon pulmonary vein isolation for atrial fibrillation ablation|Diaphragmatic kinetics of participants before and after pulmonary vein isolation will be evaluated with the Tissue Doppler and M Mode Imaging.
62559045|NCT01121614|EXPERIMENTAL|LOTUS|LOTUS ultrasonic instrument
62385949|NCT04703712|ACTIVE_COMPARATOR|Lens extraction combined with goniosynechialysis group|One hundred and fifty-eight patients with advanced angle-closure glaucoma underwent phacoemulsification combined with goniosynechialysis.
62559046|NCT01121614|EXPERIMENTAL|Ethicon Harmonic Scalpel|Ultrasonic instrument
62559047|NCT01121614|EXPERIMENTAL|LigaSure|Bipolar feedback vessel sealing device
62559048|NCT00839488|ACTIVE_COMPARATOR|I|pantoprazole 40 mg iv qd
62559049|NCT00839488|ACTIVE_COMPARATOR|II|famotidine 20 mg q12h
62559050|NCT04037280|EXPERIMENTAL|Isometric strenghtening 1|once a day (1RI): patients in this group will have to play 20 tonic contractions of Pelvic Floor Muscle with a duration of 5 seconds each, performed in supine position), in sitting position and in standing position.
62385950|NCT04703712|ACTIVE_COMPARATOR|Trabeculectomy Group|One hundred and fifty-eight patients with advanced angle-closure glaucoma underwent trabeculectomy.
62385951|NCT03782766|EXPERIMENTAL|piezosurgery|group 1 consisted of 18 molars (13 molars from patients with bilateral first molar extraction space and 5 molars from patients with unilateral first molar extraction space) where piezocesion was performed immediately before molar protraction
62385952|NCT03782766|NO_INTERVENTION|No piezocision|group 2 consisted of 21 molars (13 from patients with bilateral first molar extraction space and 8 molars from patients with unilateral first molar extraction space) where molar protraction was performed with no piezocesion
62385953|NCT03782766|OTHER|Late piezocision|group 3 consisted of 21 molars (group 2 subjects where piezocession was carried on after 3 months of molar protraction with no piezocesion.
62559051|NCT04037280|EXPERIMENTAL|Isometric strenghtening 2|twice a day (2RI): patients in this group will have to play the same typology of exercises in the same way just described (see above), but twice a day (in the morning and in the evening).
62559052|NCT04037280|EXPERIMENTAL|Functional strenghtening 1|once a day (1RF): patients in this group will have to play 10 times the postural passage from supine position to sitting position on a bed and 10 times the postural passage from sitting position to erect position (STS), maintaining the contraction of Pelvic Floor Muscle during the execution of each functional act. In sequence, starting from erect position, they will have to play 10 trunk flexion bending their knees (as to pick up an object on the ground), maintaining the contraction of Pelvic Floor Muscle during the execution of each functional movement.
62766994|NCT06175351|PLACEBO_COMPARATOR|Phase IIa Placebo|Placebo is administered intravenously (two doses selected on phase Ib). Each dose level includes up to 6 patients.
62766995|NCT02805231||primary open-angle glaucoma patients|vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in primary open-angle glaucoma patients.
62766996|NCT02805231||randomly age-matched people|vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in randomly age-matched people.
62766997|NCT04592900|EXPERIMENTAL|the control group|the control group Group 1 the control group received selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and balance training exercises and gait training in open environment.
62766998|NCT04592900|EXPERIMENTAL|the virtual reality group|Group 2 the study group received the same physical therapy program 30 min. plus virtual reality for 30 min
62385954|NCT02795182|OTHER|Zanubrutinib abd Tislelizumab|Based on results of the dose escalation cohorts and the identified recommended Phase 2 dose, all patients will receive zanubrutinib at 160 mg orally twice daily in combination with intravenous infusion of tislelizumab 200mg given every 21 days, to be continued until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination
62766999|NCT04592900|EXPERIMENTAL|the Biodex Balance Training group|Group 3 the study group received the same physical therapy program 30 min. plus virtual reality for 30 min
62767000|NCT00355498||1|Controls
62385955|NCT02195895|EXPERIMENTAL|Alendronate, Calcium, Vitamin D|"Drug: Weekly oral alendronate 70 mg for 12 months~Supplements: 1000 mg Calcium and 1000 IU Vitamin D daily for 12 months"
62385956|NCT02561026|EXPERIMENTAL|FP Transfusion|patients randomized to receive frozen plasma transfusions
62385957|NCT02561026|NO_INTERVENTION|no FP Transfusion|patients not receiving frozen plasma transfusions
62385958|NCT02609529|EXPERIMENTAL|SBI|Entergam 10 g/day PO
62385959|NCT02609529|PLACEBO_COMPARATOR|Placebo|Placebo 10 g/day PO
62385960|NCT04126876|EXPERIMENTAL|Tilsotolimod (IMO-2125)|Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
62385961|NCT04126876|PLACEBO_COMPARATOR|Placebo|Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
62385962|NCT04327245|EXPERIMENTAL|Intervention ingest a 5000 mg of D-tagatose|Intervention: Women with resistance insulin who ingest a 5000 mg of D-tagatose. D-tagatose is a sweetener of natural origin, low in calories (1.5 kcal / g) and with a sweetness power of 0.9.e.
62385963|NCT04327245|NO_INTERVENTION|No Intervention: Intervention ingest a water (control group)|Woman with resistance insulin who ingest a water (control group)
62385964|NCT04327245|EXPERIMENTAL|Intervention ingest a 15,3 mg of stevia|"Intervention: Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet."
62385965|NCT04369742|EXPERIMENTAL|Hydroxychloroquine|
62385966|NCT04369742|PLACEBO_COMPARATOR|Placebo|
62385967|NCT04306835|ACTIVE_COMPARATOR|CPAP + CBT-i|Patients treated simultaneously with CPAP for their OSAS and cognitive behavioral therapy for their insomnia.
62385968|NCT04306835|NO_INTERVENTION|CPAP only|Patients suffering from OSAS and insomnia, but only treated with CPAP.
62385969|NCT01986049|EXPERIMENTAL|Bupivicaine 0.5%|Drug Bupivacaine 0.5%
62385970|NCT01986049|EXPERIMENTAL|Bupivicaine 0.25%|Drug Bupivacaine 0.25%
62385971|NCT01986049|PLACEBO_COMPARATOR|Normal Saline|Saline Normal
62385972|NCT05117580|EXPERIMENTAL|Active group|The active group get telemedicine devices, and lifestyle interventions.
62385973|NCT05117580|NO_INTERVENTION|Comparator Group|The comparator group get the evidence based treatment.
62385974|NCT04005924|NO_INTERVENTION|Control|Bread and sugar-free blackberry jam breakfast
62385975|NCT04005924|EXPERIMENTAL|Low dose|Bread and sugar-free blackberry jam breakfast with 6 g arabinogalactan
62385976|NCT04005924|EXPERIMENTAL|High dose|Bread and sugar-free blackberry jam breakfast with 21 g arabinogalactan
62385977|NCT06286735|ACTIVE_COMPARATOR|Intervention|60 capsules of 500 mg of powdered cinnamomum bark (cinnamomum verum; 40% polyphenols) each. Participants in this group will be instructed to consume two capsules per day, one after lunch and the other after dinner for 3 months.
62385978|NCT06286735|PLACEBO_COMPARATOR|Placebo|60 capsules with 500 mg of corn starch each. Participants in this group will be instructed to consume two capsules per day, one after lunch and the other after dinner for 3 months.
62385979|NCT04841928|NO_INTERVENTION|Waitlist control|Participants randomized to condition 1 are not offered any treatment components immediately upon enrollment, but will be offered a treatment component of own choice at the end of the study. Total number of sessions: 2 (2 contact hours) following study completion.
62385980|NCT04841928|EXPERIMENTAL|Mindful attention|Participants randomized to condition 2 will receive the Mindful attention treatment component. Total number of sessions: 2 (2 contact hours).
62385981|NCT04841928|EXPERIMENTAL|Decentering|Participants randomized to condition 3 will receive the Decentering treatment component. Total number of sessions: 2 (2 contact hours).
62385982|NCT04841928|EXPERIMENTAL|Values and committed action|Participants randomized to condition 4 will receive the Values and committed action treatment component. Total number of sessions: 2 (2 contact hours).
62767001|NCT00355498||2|Mild Cognitive Impairment
62767002|NCT00355498||3|Alzheimer's disease
62767003|NCT00355498||4|FTD
62767004|NCT05513313||Jynneos vaccine with out other vaccines|Allocated to Jynneos without any need for additional indicated/required vaccines intervention. JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection. Administer two doses (0.5 mL each) 4 weeks apart. Each dose (0.5 mL) is supplied in a singledose vial.
62767005|NCT05513313||Jynneos vaccine with other vaccines at dose 1|Allocated to Jynneos with concomitant vaccines given at time of first dose of Jynneos intervention.
62767006|NCT05513313||Jynneos vaccine with other vaccines at dose 2|Allocated to Jynneos with concomitant vaccines given at time of second dose of Jynneos.
62559053|NCT04037280|EXPERIMENTAL|Functional strenghtening 2|twice a day (2RF): patients in this group will have to play the same typology of exercises in the same way just described (see above), but twice a day (in the morning and in the evening).
62559054|NCT03034980||Coronary Artery Disease (CAD) patients|Patients with proven coronary artery disease, who underwent the full cardiac revalidation program at Jessa Hospital from 10-1-2013 till 12-9-2016.
62559055|NCT05610215|EXPERIMENTAL|hybrid ablation|Participants in this group will receive concomitant thoracoscopic epicardial ablation and catheter endocardial ablation
62559056|NCT05610215|ACTIVE_COMPARATOR|catheter ablation|Participants in this group will receive catheter endocardial ablation only
62559057|NCT00610428|PLACEBO_COMPARATOR|Inhaled Placebo|Inhaled Staccato Placebo
62559058|NCT00610428|EXPERIMENTAL|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
62559059|NCT00610428|PLACEBO_COMPARATOR|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
62767007|NCT05824936|EXPERIMENTAL|Pilot study arm for technology-enhanced asthma intervention|All participants will be in the pilot arm for technology-enhanced intervention program.
62559060|NCT05506618|OTHER|Group A: Sample Collection|2x Nasopharyngeal Swab Sample Collection
62559061|NCT05506618|OTHER|Group B: Sample Collection|1x Nasopharyngeal Swab and 2x Nasal Swab Sample Collection
62767008|NCT02876328|EXPERIMENTAL|Ad26.ZEBOV (rHAd26) vaccine + MVA-BN-Filo (MVA) boost|Participants will receive the Ad26.ZEBOV (rHAd26) vaccine at Day 0 followed by an MVA-BN-Filo (MVA) boost at Day 56.
61989976|NCT02658136|OTHER|1 arm study: CCT estimated right ventricular function.|By use of Cardiac computed tomography, the ejection faction of the right ventricle will be visualized and measured in all participants.
61989977|NCT06299774|ACTIVE_COMPARATOR|Usual care|Emergency care in a brick-and-mortar emergency department.
61989978|NCT06299774|EXPERIMENTAL|Emergency care at home|Emergency care in the patient's home.
61989979|NCT04461782|EXPERIMENTAL|Lactobacillus plantarum|"Oral intake 1 cap daily~1E+09 cfu/cap of Lactobacillus plantarum"
61989980|NCT04980677|OTHER|Children|Tangiball (Autism, Neurotypical group) - 20 minute play sessions with digital toy
61989981|NCT05235334|EXPERIMENTAL|Device user|Participant will engage in treatment with the MySOLIUS device, twice per week for 16 weeks
61989982|NCT01964274||Surgical patients|Adult male and female patients undergoing surgery
62559062|NCT05506618|OTHER|Group C: Sample Collection|1x Nasopharyngeal Swab and 2x Nasal Swab Sample Collection for sample pooling
62559063|NCT05506618|OTHER|Group D: Sample Collection|2x Nasal Swab Sample Collection
62559064|NCT02038010|EXPERIMENTAL|Treatment (PI3K inhibitor BYL719, ado-trastuzumab emtansine)|Patients receive PI3K inhibitor BYL719 PO daily on days 1-21 and ado-trastuzumab emtansine IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62559065|NCT06005662|EXPERIMENTAL|High-dose psilocybin + buprenorphine|High-dose psilocybin (30 mg) session following standard-of-care buprenorphine induction
62559066|NCT06005662|ACTIVE_COMPARATOR|Very low-dose psilocybin + buprenorphine|Very low dose psilocybin session (1 mg) following standard-of-care buprenorphine induction
62767009|NCT02876328|PLACEBO_COMPARATOR|Placebo (0.5 mL)|Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.
61989983|NCT00983268|EXPERIMENTAL|Treatment Arm|
61989984|NCT04149600||Bicuspid aortic valve|We wish to investigate the etiology of calcific aortic valve disease, and aortic dilation or aneurysm in patients with a bicuspid aortic valve undergoing aortic valve replacement or aortic surgery.
61989985|NCT04149600||Tricuspid aortic valve|Data and samples will be compared using a control group comprised of patients with a tricuspid aortic valve undergoing aortic surgery.
61989986|NCT00367952|EXPERIMENTAL|ATC 800mg BID|800mg ATC BID
61989987|NCT01340092|ACTIVE_COMPARATOR|Family Navigator|Family navigation
61989988|NCT01340092|NO_INTERVENTION|Standard Care|standard care
61989989|NCT01530295|NO_INTERVENTION|contol|control group
61989990|NCT01530295|OTHER|chemotherapy|neoadjuvant chemotherapy
61989991|NCT06218407|EXPERIMENTAL|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) short-burst paradigm|CBOT consists of repetitive cycles of olfactory stimulation and tasks daily for 14 days.
61989992|NCT06218407|EXPERIMENTAL|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) long-burst paradigm|CBOT consists of repetitive cycles of olfactory stimulation and tasks daily for 14 days.
61989993|NCT06218407|EXPERIMENTAL|CBOT plus (CBOT + beta caryophyllene [BCP])|CBOT device enhanced with BCP
61989994|NCT06218407|SHAM_COMPARATOR|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)|CBOT device without BCP enhancement as control for BCP
61989995|NCT02916563|EXPERIMENTAL|Altitude|Single arm study Blood Glucose Monitoring System Altitude Performance
61989996|NCT01524627|PLACEBO_COMPARATOR|Control Group|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
61989997|NCT01524627|ACTIVE_COMPARATOR|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
61989998|NCT01044602|ACTIVE_COMPARATOR|Best Medical Management|Patients elect to treat obesity and type 2 diabetes mellitus through best medical management.
62559067|NCT02902588|EXPERIMENTAL|ICG washout kinetics assessment|Intravenous administration of 5-10 mg indocyanine green (ICG-PULSION), once per subject
62559068|NCT02902588|OTHER|Pulse oximeter monitor|Monitoring of a person's oxygen saturation (SO2), peripheral oxygen saturation
62559069|NCT02902588|EXPERIMENTAL|Gadolinium washout kinetics assessment|20 mL of gadolinium (Gadovist, Bayer, Germany) injection at 5 mL/s, once per subject
62559070|NCT02851017|EXPERIMENTAL|Exergaming group (XBOX Kinect|Kinect™ exercise group performed sessions on three non-consecutive days per week for 4 weeks (12 sessions in total).
62559071|NCT02851017|EXPERIMENTAL|Traditional gym based exercise group|Traditional gym based (TGB) exercise group performed sessions on three non-consecutive days per week for 4 weeks (12 sessions in total). Those in the TGB group performed exercises that were matched for sequence, intensity, duration and mode of exercise by adopting open and closed kinetic chain movements, in the same range and loading as required in the Kinect™ group.
62559072|NCT03442114|EXPERIMENTAL|Hydroxyurea SDM Toolkit (H-SDM)|During the H-SDM toolkit condition, sites will develop methods for identifying Eligible Patients \& Monitoring Progress, have the opportunity to use Implementation Tools, and will use the Visit Decision Aids. The H-SDM toolkit has four visit decision aids to support parents in their decision about hydroxyurea: pre-visit brochure, in-visit issue card, after-visit booklet and video narratives {videos of parents telling their story about how they made a decision about hydroxyurea).
62559073|NCT03442114|ACTIVE_COMPARATOR|Clinician Pocket Guide|In this condition, sites will provide current guidelines for offering hydroxyurea and use the American Society of Hematology (ASH) pocket guide as a reference. ASH developed 'The Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease' clinician pocket guide based on the National Heart, Lung, and Blood Institute's Evidence Based Management of Sickle Cell Disease: Expert Panel Report, 2014.'
62767010|NCT02876328|EXPERIMENTAL|rVSVΔG-ZEBOV-GP (rVSV) vaccine + placebo boost|Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by a placebo boost at Day 56.
62767011|NCT02876328|EXPERIMENTAL|rVSVΔG-ZEBOV-GP (rVSV) vaccine + rVSV boost|Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by an rVSV boost at Day 56.
62767012|NCT02876328|PLACEBO_COMPARATOR|Placebo (1 mL)|Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.
62767013|NCT03545711|EXPERIMENTAL|Anlotinib plus Irinotecan|
62767014|NCT02400944||patients with bladder cancer|
62767015|NCT04409717||Patients treated for type II endoleaks|Patients treated for type II endoleaks between the 01 January 2008 and the 31 March 2018 in the Cardiovascular and Thoracic Surgery Unit of Dijon Burgundy University Hospital
62767016|NCT01292083|EXPERIMENTAL|Treatment|See Detailed Description
62767017|NCT05149131||mCSPC patients in the province of Alberta|mCSPC patients who initiated and received at least one dose of guideline recommended life-prolonging therapy for mCSPC (docetaxel, abiraterone, enzalutamide, apalutamide, or ADT alone) from 01-Jan-2016 up to 31-Dec-2020 or earlier based on database cutoff, inclusive.
62767018|NCT02525939|ACTIVE_COMPARATOR|Dalcetrapib|"Participants received dalcetrapib 600 mg (two 300 mg tablets) orally once daily.~dalcetrapib: Cholesterol Ester Transfer Protein inhibitor, 300 mg tablets"
62767019|NCT02525939|PLACEBO_COMPARATOR|Placebo|"Participants received dalcetrapib placebo tablets matching dalcetrapib orally once daily.~Placebo: dalcetrapib matching placebo tablets"
62767020|NCT01350115|ACTIVE_COMPARATOR|LDE225|Participants received 400 mg once daily.
62767021|NCT01350115|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo.
62767022|NCT03484364|EXPERIMENTAL|Intervention Group|The ENACTS intervention is four peer-facilitated educational classes delivered over 8 weeks focused on hypertension self-management.
62767023|NCT03484364|NO_INTERVENTION|Waitlist Group|Usual care and $50 in groceries every other week for 8 weeks.
62767024|NCT03484559||1|
62767025|NCT00994591|EXPERIMENTAL|Pharmacokinetic dosing|
62767026|NCT01271257|EXPERIMENTAL|hourly misoprostol|20 microgram misoprostol intake per hour
62767027|NCT01271257|ACTIVE_COMPARATOR|traditional misoprostol|80 microgram misoprostol intake per 4 hours
62767028|NCT03271047|EXPERIMENTAL|Phase 1b / Arm 1A|binimetinib + nivolumab
61989999|NCT01044602|ACTIVE_COMPARATOR|Surgical Treatment|Patients with type 2 diabetes mellitus choice to treat obesity with Roux-en-Y gastric bypass.
62767029|NCT03271047|EXPERIMENTAL|Phase 1b / Arm 1B|binimetinib + nivolumab + ipilimumab
62767030|NCT03271047|EXPERIMENTAL|Phase 2 / Arm 2A|binimetinib + nivolumab
62767031|NCT03271047|EXPERIMENTAL|Phase 2 / Arm 2B|binimetinib + nivolumab + ipilimumab
62767032|NCT05458453|EXPERIMENTAL|Esketamine arm|Self-controlled intravenous analgesia pump was used for continuous injection, and it was prepared according to sufentanil 1.5ug/ml+ esketamine 0.75ug/ml+16mg ondansetron. After the operation, the analgesic pump was connected, and sufentanil 0.1ug/kg/h+ e sketamine 0.05mg/kg/h was pumped continuously for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).
62767033|NCT05458453|NO_INTERVENTION|Sufentanil arm|Continuous pumping with self-controlled intravenous analgesia pump. According to sufentanil 1.5ug/ml+16mg ondansetron. At the end of the operation, connect the analgesic pump, and pump it with sufentanil at 0.1ug/kg/h for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).
62767034|NCT03689244|EXPERIMENTAL|Selexipag DB|During the double blind treatment period, participants in this group will receive selexipag. Each participant will start with one oral tablet of selexipag 200 µg in the evening of Day 1 and will continue with 200 µg twice daily (b.i.d.) on Day 2. If this dose is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg until reaching the individual maximal tolerated dose (iMTD) in the range of 200 to 1600 µg b.i.d. The up-titration period up to Week 12 is followed by a stable maintenance treatment period from Week 12 to Week 26, at the iMTD. After Week 26, further up-titration can be allowed (but not above 1600 µg b.i.d.).
62767035|NCT03689244|PLACEBO_COMPARATOR|Placebo DB|During the double-blind treatment period, participants in this group will receive the oral matching placebo, twice daily. A (mock) up-titration scheme will be followed.
62767036|NCT03689244|EXPERIMENTAL|Selexipag OL|All participants who completed the double-blind treatment period, whether they received placebo or selexipag during the double-blind period, will receive selexipag during the open-label extension period, using the same up-titration schedule as in the double-blind period.
62767037|NCT01522430|EXPERIMENTAL|Renal angiography followed by renal sympathetic denervation|Catheter based therapy for renal denervation using the Simplicity (TM) catheter (Ardian/Medtronic)
62559074|NCT00811044||Entry|This group is just entering the study and will need to be genotyped.
62767038|NCT01522430|SHAM_COMPARATOR|Renal angiography alone|Renal selective angiography using standardized method: Local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
62559075|NCT00811044||Affected|This group has been genotyped and has the gene undergoing study at that time.
62559076|NCT00811044||Control|This group has been genotyped and does not have the gene currently under study.
62559077|NCT03218020||Random Subcohort|Random subcohort (\~10 % of the initial cohort, study has a case-cohort design; details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).
62767039|NCT01459913|EXPERIMENTAL|Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)|Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met rapid viral response (RVR, undetectable Hepatitis C Virus \[HCV\] Ribonucleic Acid \[RNA\] at Week 4) criteria, were randomized in this group, as planned, and did not receive any further treatment.
62767040|NCT01459913|EXPERIMENTAL|Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.
62767041|NCT01459913|EXPERIMENTAL|Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.
62385983|NCT04841928|EXPERIMENTAL|Mindful attention + Decentering|Participants randomized to condition 5 will receive the Mindful attention treatment component and the Decentering treatment component. Total number of sessions: 4 (4 contact hours).
62385984|NCT04841928|EXPERIMENTAL|Mindful attention + Values and committed action|Participants randomized to condition 6 will receive the Mindful attention treatment component and the Values and committed action treatment component. Total number of sessions: 4 (4 contact hours).
62385985|NCT04841928|EXPERIMENTAL|Decentering + Values and committed action|Participants randomized to condition 7 will receive the Decentering treatment component and the Values and committed action treatment component. Total number of sessions: 4 (4 contact hours).
62385986|NCT04841928|EXPERIMENTAL|Mindful attention + Decentering + Value-based action|Participants randomized to condition 8 will receive the Mindful attention treatment component, the Decentering treatment component, and the Values and committed action treatment component. Total number of sessions: 6 (6 contact hours).
62385987|NCT00758316|ACTIVE_COMPARATOR|1|Thoracoscopy with pleurodesis Patients will then undergo standard medical thoracoscopy in the endoscopy center including the use of moderate sedation, prophylactic antibiotics for 1 week and 20F chest tube insertion at the end of the procedure.
62385988|NCT00758316|EXPERIMENTAL|2|Combined thoracoscopy with pleurodesis and pleurx catheter. In the combined procedure group, a PleurxTM tunnelled catheter will be inserted under ultrasound guidance. As this procedure will be done concurrently with thoracoscopy, there is no estimated increase in endoscopy time.
62385989|NCT06008522|EXPERIMENTAL|OCT with IV in colorectal polyps|OCT and FME imaging of Barret and colorectal lesions during endoscopy.
62385990|NCT06103266|EXPERIMENTAL|Rivaroxaban monotherapy|Once daily rivaroxaban 20 mg or 15 mg with reduced kidney function (eGFR 15 - 49 mmol/L) for 6 months in case of percutaneous coronary intervention for stable coronary artery disease or 12 months in case of percutaneous coronary intervention for acute coronary syndrome without concurrent antiplatelet therapy
62385991|NCT01443039|EXPERIMENTAL|phenotypical approach|phenotypical approach
62385992|NCT00381810|EXPERIMENTAL|Rituximab 1000 mg|Participants will receive rituximab 1000 mg intravenously twice, 14 days apart at study entry and again 6 months later. Participants will also receive methylprednisolone 100 or 125 mg IV, acetaminophen 1000 mg orally, and diphenhydramine 50 mg orally prior to study drug infusion.
62385993|NCT03908723|EXPERIMENTAL|all patients in the study|
62767042|NCT01459913|EXPERIMENTAL|Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.
62767043|NCT03762967|EXPERIMENTAL|Lipoaspiration and SVF introduction I.|Patients with azoospermia that introduce with standard treatment and Lipoaspiration and SVF introduction.
62385994|NCT01719718|ACTIVE_COMPARATOR|Closure|
62385995|NCT01719718|SHAM_COMPARATOR|Non-Closure|
62385996|NCT04131504||Phase I - Cross-sectional Study (CD and Suspected IBD)|150 children and young adults who have been previously diagnosed with CD (anti-TNF naïve) or suspected of having IBD (based on clinical symptoms and laboratory testing) who are scheduled for a clinically-indicated colonoscopy are eligible to be enrolled in this cohort.
62385997|NCT04131504||Phase I - Cross-sectional Study (healthy volunteers)|20 healthy controls will be enrolled at Cincinnati Children's Hospital only. Once demographics, past medical/surgical history and biospecimens (blood/stool) are collected, controls will complete participation.
62559078|NCT03218020||Incident CVD Cases|Validated incident cases of myocardial infarction, stroke and CVD death that occured until Dec-31-2009 (details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).
62385998|NCT04131504||Phase II - Longitudinal Study of Participants with CD|70 children and young adults who have been diagnosed with CD (anti-TNF naïve) and are scheduled to receive infliximab (or adalimumab) are eligible to be enrolled in this cohort.
62385999|NCT01287507|PLACEBO_COMPARATOR|Placebo|In born VLBW infants with parental consent form signed will be given oral saline daily as placebo until discharge
62386000|NCT01287507|EXPERIMENTAL|Lactoferrin|In born VLBW infants with parental consent form signed will be given oral bovine lactoferrin daily until discharge
61990000|NCT04799899|EXPERIMENTAL|Virtual MBCT Intervention|Participants will participate in 8 weekly virtual group sessions of MBCT. Participants will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30-60 minutes).
62386001|NCT00286234|PLACEBO_COMPARATOR|1|Dual placebo
62386002|NCT00286234|EXPERIMENTAL|2|niaspan
62386003|NCT00286234|EXPERIMENTAL|3|lovaza
62386004|NCT00286234|EXPERIMENTAL|4|combined therapy
62386005|NCT05416385||Cardiac outpatients|Subjects referred for outpatient stress echocardiogram (SE).
62386006|NCT02215915|EXPERIMENTAL|IVUS guided DES implantation|Stent size and length were selected by online IVUS measurements, and adjunct high-pressure dilation was performed according to the discretion of operators based on the IVUS criteria for stent optimization.
62386007|NCT02215915|ACTIVE_COMPARATOR|Angiography guided DES implantation|Stent size and length were chosen by visual estimation, and adjunct high-pressure dilation was performed if an optimal result was not achieved, which was defined as angiographic residual diameter stenosis 20% and absence of angiographically detected dissection.
62386008|NCT00808184|ACTIVE_COMPARATOR|CPT-11|
61990001|NCT04799899|EXPERIMENTAL|Virtual Health Enhancement Control|Participants will participate in 8 weekly virtual group sessions that focus on cardiac health and depression education. Participants will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30-60 minutes).
61990002|NCT04462809|EXPERIMENTAL|Cohort A, Malignant pleural mesothelioma|Malignant pleural mesothelioma
62386009|NCT05594966||Cerebral Small Vessel Disease|In this group, patients are diagnosed with cerebral small vessel disease preoperatively using multimodal MRI.
62386010|NCT05594966||non-Cerebral Small Vessel Disease|In this group, cerebral small vessel disease is ruled out by preoperative multimodal MRI.
62559079|NCT04279431||SIC Negative|Subjects will include males and females ranging from ages 18 to 85 who are admitted to the ED with a traumatic, closed head injury within 3 days of injury. Subject will undergo site standard clinical ED evaluation and a BrainScope evaluation. The SIC negative group are those patients who obtain a 'Negative' result on the BrainScope One Structural Injury Classifier (SIC) algorithm.
62559080|NCT04279431||SIC Positive/Equivocal|Subjects will include males and females ranging from ages 18 to 85 who are admitted to the ED with a traumatic, closed head injury within 3 days of injury. Subject will undergo site standard clinical ED evaluation and a BrainScope evaluation. The SIC positive group are those patients who obtain a 'Positive' or 'Equivocal' result on the BrainScope One SIC algorithm.
62386011|NCT03822689|ACTIVE_COMPARATOR|Gas flow:2L|use different type ventilator breathing tube as follow Ventilator breathing tube F2220-M: Folding; D: 22mm; L:2.0M Ventilator breathing tube F2216-M: Folding; D: 22mm; L:1.6M Ventilator breathing tube F1520-M: Folding; D: 15mm; L:2.0M Ventilator breathing tube F1516-M: Folding; D: 15mm; L:1.6M Ventilator breathing tube U1016-M: Unfolding; D: 10mm; L:1.6M Ventilator breathing tube U1516-M: Unfolding; D: 15mm; L:1.6M Ventilator breathing tube CA20-.M: Co-axis; L:2.0M Ventilator breathing tube CA16- M: Co-axis; L:1.6M
62386012|NCT03822689|ACTIVE_COMPARATOR|Gas flow:5L|use different type ventilator breathing tube as follow Ventilator breathing tube F2220-M: Folding; D: 22mm; L:2.0M Ventilator breathing tube F2216-M: Folding; D: 22mm; L:1.6M Ventilator breathing tube F1520-M: Folding; D: 15mm; L:2.0M Ventilator breathing tube F1516-M: Folding; D: 15mm; L:1.6M Ventilator breathing tube U1016-M: Unfolding; D: 10mm; L:1.6M Ventilator breathing tube U1516-M: Unfolding; D: 15mm; L:1.6M Ventilator breathing tube CA20-.M: Co-axis; L:2.0M Ventilator breathing tube CA16- M: Co-axis; L:1.6M
62386013|NCT03986671|EXPERIMENTAL|EMG Testing|Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmenbrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
62567675|NCT03162653|ACTIVE_COMPARATOR|Allopurinol|Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
61990003|NCT04462809|EXPERIMENTAL|Cohort B1:Malignant peritoneal mesothelioma non-resected|Malignant peritoneal mesothelioma with non-resected or incompletely resected disease
61990004|NCT04462809|EXPERIMENTAL|Cohort B2:Malignant peritoneal mesothelioma (resected)|Malignant peritoneal mesothelioma with completely resected disease.
62559081|NCT02881398|EXPERIMENTAL|mHealth|Each participant randomized to a mHealth assessment were evaluated with: (1) structural abnormalities with handheld-echocardiography (Vscan®, General Electric Healthcare); (2) vital signs with smartphone-connected oxymetry and blood pressure monitors (iHealthLabs®); (3) functional assessments on a 6-minute walk test with a trial-axial activity monitor (Ozeri®); (4) cardiac rhythm abnormalities with smartphone-connected- iECG (AliveCor®) and; (5)point-of-care testing with fingerstick B-type natriuretic peptide (Alere). All study participants then underwent a comprehensive transthoracic echocardiogram for anatomical assessments of the severity of rheumatic and structural heart disease prior to percutaneous valvuloplasty or a surgical valve replacement.
62559082|NCT02881398|ACTIVE_COMPARATOR|Standard-Care|Each participant randomized to a standard-assessment were evaluated with the resource available at the institution including a physical examination,12 lead-ECG, radiographic, laboratory testing as clinically required. All study participants underwent a comprehensive transthoracic echocardiogram for anatomical assessments of the severity of rheumatic and structural heart disease prior to percutaneous valvuloplasty or a surgical valve replacement.
62559083|NCT01512017|ACTIVE_COMPARATOR|Veloderm|
62386014|NCT00158275|EXPERIMENTAL|Integrated Intervention|Participants will receive cognitive behavioral therapy for back pain and antidepressants and/or problem solving therapy for depression. Study visits will initially occur once a week and then taper to once every 2 weeks for the 6-month duration.
62559084|NCT01512017|PLACEBO_COMPARATOR|Vaseline|
62386015|NCT00158275|NO_INTERVENTION|Standard of Care|Participants will receive care as usual from their health care provider.
62386016|NCT05046418||Hypoallergenic formula containing synbiotics|Infants (aged \<13 months) with cow's milk allergy (CMA) who are prescribed a hypoallergenic formula containing synbiotics as part of usual clinical practice for the dietary management of CMA.
62559085|NCT05860738||As-received NITI archwires|The first group of wires will be investigated in the as-received form (as received from the company without being used clinically).
62386017|NCT06268366|NO_INTERVENTION|Control|Participants in the control group will not receive any exercise interventions. Participants in the control group will receive their individualized corrective exercises program following completion of the research study following the 10 week follow up.
62386018|NCT06268366|EXPERIMENTAL|Exercise Group|Participants in the intervention will be assigned three corrective exercises based on their greatest movement pattern deficit as advised by the Symmio application. Participants in the intervention group will follow the exercise and educational guidance provided by the Symmio application including adjustment of exercises and reviewing educational materials.
61990005|NCT05122065||Asymptomatic/non-HRT|Samples derived from women in menopause who do not self-reportedly experience GSM (Genitourinary Syndrome of Menopause) and who do not take HRT (Hormone Replacement Therapy).
61990006|NCT05122065||Asymptomatic/HRT|Samples derived from women in menopause who do not self-reportedly experience GSM and who take HRT
61990007|NCT05122065||GSM/non-HRT|Samples derived from women in menopause who self-reportedly experience GSM and who do not take HRT
61990008|NCT05122065||GSM/HRT|Samples derived from women in menopause who self-reportedly experience GSM and who take HRT
61990009|NCT05497492|ACTIVE_COMPARATOR|P group|single administration of propofol
61990010|NCT05497492|EXPERIMENTAL|P + S group|administration of propofol and sufentanil in combination
61990011|NCT05497492|EXPERIMENTAL|P + K group|administration of propofol and esketamine in combination
61990012|NCT05497492|EXPERIMENTAL|P + L group|administration of propofol and lidocaine in combination
61990013|NCT05098145|EXPERIMENTAL|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood cells and delivered as a single infusion with a nonmyeloablative conditioning regimen.
61990014|NCT03679871|OTHER|Questionnaire validation|"22-items questionnaire Spiritual Resources and Distress"
61990015|NCT04401696|EXPERIMENTAL|Group A|Use of Bubble CPAP for management of respiratory distress
61990016|NCT04401696|ACTIVE_COMPARATOR|Group B|Use of Oxygen via nasal cannula for respiratory distress
61990017|NCT03678467|EXPERIMENTAL|EB-CMF Implant|Subject receiving EB-CMF implant
62767044|NCT03762967|ACTIVE_COMPARATOR|Standard therapy I.|Patients with azoospermia that introduce with Standard therapy only.
62767045|NCT03762967|EXPERIMENTAL|Lipoaspiration and SVF introduction II|Patients with oligospermia that introduce with standard treatment and Lipoaspiration and SVF introduction.
62767046|NCT03762967|ACTIVE_COMPARATOR|Standard therapy II.|Patients with oligospermia that introduce with Standard therapy only.
62767047|NCT01011972|EXPERIMENTAL|XMT-1107|Dose escalation groups of XMT-1107, I.V. (in the arm) beginning at 6 mg/m\^2, doubling in dose to 24 mg/m\^2, then 40 mg/m\^2, then 60 mg/m\^2, then 80 mg/m\^2 with subsequent doses at 33% of the previous until disease progression or unacceptable side effects are experienced.
62182662|NCT03180554|OTHER|tVNS version 1|Transcutaneous vagus nerve stimulation (tVNS) version 1 will be delivered non-invasively via a portable take-home stimulation device which attaches to the concha of the outer ear. Intensity, pulse duration, and frequency is optimised by the participant. Participants will receive a 15-minute stimulation twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
62386019|NCT06308289|EXPERIMENTAL|Group A|GPRM and ACBT
62559086|NCT05860738||Rapid cycle autoclaved NITI archwires|The second group of archwires will be will be installed in the patients mouth for 4 weeks, and then retrieved, cleaned using ultrasonic cleaner, dried and packaged and finally autoclaved using the rapid cycle (4 mins, 134oC)
62559087|NCT05860738||Universal cycle autoclaved NITI archwires|the third group will be installed in the patients mouth for 4 weeks, and then retrieved, cleaned using ultrasonic cleaner, dried and packaged, the finally autoclaved using the universal cycle (20 mins, 121 oC)
62767048|NCT01694719|EXPERIMENTAL|Behavioral Activation + Cognitive Control Training|Participants will receive 5 sessions of behavioral activation therapy concurrent with 4 sessions of cognitive control training, a computerized intervention which targets cognitive control processes such as working memory and attention.
62559088|NCT03975673|ACTIVE_COMPARATOR|Conventional Total Hip Replacement (cTHR )|"Osteoarthritic patient undergoing the conventional technique~* medializing the hip center of rotation~* obtain a standing acetabular cup position fitting the Lewinneck recommendations (inclination 40°±10°, version 15°±10°)"
62559089|NCT03975673|EXPERIMENTAL|Kinematically Aligned Total Hip Replacement (KATHR )|"Osteoarthritic patient undergoing the kinematically aligned technique~* restoring the acetabular center of rotation~* restoring the constitutional acetabular anteversion by using the transverse acetabular ligament (TAL) as a reference landmark.~* making personalized choice for the hip component design~* considering additional spine surgery based on the assessment of the individual spine-hip relation."
62559090|NCT03859167||Participants with AV block with pacemaker|Participants will have a stress test, and results will be collected and recorded.
62559091|NCT00821743|OTHER|1|The DBS electrodes (model 3389, Medtronic) will be stereotactically implanted bilaterally in the PPN, according to the technique usually used for STN-DBS, and connected to the subcutaneously implanted stimulator (Kinetra, Medtronic).
62767049|NCT01694719|ACTIVE_COMPARATOR|Behavioral Activation Therapy plus Control Task|Participants will receive 5 sessions of behavioral activation therapy and 4 sessions of a non-active, computerized control task.
62767050|NCT05525949|EXPERIMENTAL|VIVID Brain|VIVID Brain, 5 times a week for 12 weeks
62767051|NCT05525949|OTHER|No-treatment Control|No-treatment is administered during control period.
62767052|NCT05025007||Cohort 1|The study cohort will consist of patients with spastic diplegic cerebral palsy who were admitted to our outpatient and inpatient clinics of the Physical Medicine and Rehabilitation Department.
62767053|NCT01536548|EXPERIMENTAL|Skin drawing|
61990018|NCT03202264||TAPERMD|80 Long term care residents on 5 or more medications aged over 70 from 2 long term care facilities
61990019|NCT00783445|EXPERIMENTAL|1|Exercise in a community setting while supervised by a coach
61990020|NCT00783445|ACTIVE_COMPARATOR|2|Self-exercise plan based on an individualized prescription after an initial fitness evaluation
61990021|NCT05595889|EXPERIMENTAL|Surufatinib combined with irinotecan|Surufatinib combined with irinotecan as a second-line treatment for small cell lung cancer
61990022|NCT02539381|OTHER|Gold Standard Assessments|"* Formal perimetry (Goldman or Octopus visual field)~* Albert's visual inattention test~* Star cancellation visual inattention test~* line bisection test~* These are performed as part of the routine assessment in the visual stroke orthoptic clinic and neuro-ophthalmology clinics.~* The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.~* Researcher will record a score (0-10) to quantify the participant's compliance"
61990023|NCT02539381|OTHER|Usual Clinical Screening Practice|"* Visual field assessment to confrontation~* Visual inattention assessment to bilateral stimuli~* The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.~* Researcher will record a score (0-10) to quantify the participant's compliance"
61990024|NCT02539381|OTHER|Stroke Vision App|"* Digital tumbling E visual accuity assessment~* Digital visual field assessment~* Digital line crossing assessment~* Digital shape cancellation assessment~* The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.~* Researcher will record a score (0-10) to quantify the participant's compliance"
62767054|NCT01536548|ACTIVE_COMPARATOR|No skin drawing|
62767055|NCT04366557|EXPERIMENTAL|Body posture correction|Subjects from study group had an education about pelvic floor and additional a six week body posture therapy.
62767056|NCT04366557|OTHER|Without correction of body posture|Subjects form control group had only an education about pelvic floor.
62767057|NCT03458702|EXPERIMENTAL|YogaFit then Quiet Rest|Participants participated in a 30 min YogaFit and then a session of 30 min of Quiet Rest on a separate day.
61990025|NCT05983770|EXPERIMENTAL|Investigative|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
61990026|NCT05983770|ACTIVE_COMPARATOR|Comparator|Tacrolimus administered BID, targeting a whole blood trough concentration of 6-12 ng/mL until Month 6, and 6-8 ng/mL thereafter
61990027|NCT03205059|EXPERIMENTAL|LST MS curriculum+ Bullying/Cyberbullying serious game|
61990028|NCT03205059|ACTIVE_COMPARATOR|LST MS curriculum|
61990029|NCT03883932|EXPERIMENTAL|F3 Program|The F3 group will focus on the fatherhood role each session. The topic of children and parenting will be applied to each of the standard FVEP topics.
61990030|NCT03883932|ACTIVE_COMPARATOR|FVEP Program|A retrospective control group who received the standard FVEP will be included in this arm.
61990031|NCT05346263|EXPERIMENTAL|Intermittent Abdominal Pressure Ventilation|Patients in experimental group will be adapted to Intermittent Abdominal Pressure Ventilation (IAPV). Abdominal ventilation replaces part of usual ventilation (non invasive ventilation with mouthpiece or nasal-pillow)
61990032|NCT05346263|ACTIVE_COMPARATOR|Usual ventilation|Patients in control group continue with usual ventilation (NIV through mouthpiece or nasal-pillow)
61990033|NCT05990400|EXPERIMENTAL|Combination of minoxidil 5% topical and finasteride 0,1% topical group|Combination of minoxidil 5% solutio and finasteride 0,1% solutio which has administered topically
61990034|NCT05990400|ACTIVE_COMPARATOR|Minoxidil 5% topical group|Minoxidil 5% solutio which has administered topically
62559092|NCT04997330|EXPERIMENTAL|Active rTMS|Bilateral high frequency (20Hz) Repetitive Transcranial Magnetic Stimulation (rTMS) over DLPFC
61990035|NCT02132767|ACTIVE_COMPARATOR|Rhythm control|"Rhythm Control in post-operative AF~Amiodarone and/or DC-cardioversion~Amiodarone Initial Dose~* Oral: 400 mg po TID for 3 days is recommended~* For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose~* Oral: at least 200 mg/day to be continued until 60 days after randomization~* If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started~DC-Cardioversion - frequency and duration determined by medical professional as medically needed"
61990036|NCT02132767|ACTIVE_COMPARATOR|Rate control|"Rate Control in post-operative AF~Beta-blocker and/or Calcium channel blockers and/or Digoxin~Dose, frequency and duration determined by medical professional as medically needed"
61990037|NCT01136096|EXPERIMENTAL|Lifestyle counseling|To promote participants' exercise behaviors with individualized home-based exercise program was designed based on the Health Belief Model and Transtheoretical Model
61990038|NCT01136096|OTHER|Control|Received oral instruction and written general education information without individualized exercise program
61990039|NCT05578287|EXPERIMENTAL|Anti-HER2|Disitamab Vedotin (2mg/kg, once every 2 weeks), Tislelizumab (2mg/kg, once every 2 weeks) combined with low-dose capecitabine 0.5g bid chemotherapy and the COX2 inhibitor celecoxib 200mg bid as salvage therapy
61990040|NCT05339451||Severe/Deep infiltrating endometriosis|Endometriosis stage III/IV according to rASRM.
61990041|NCT05339451||Minimal/mild endometriosis|Endometriosis stage I/II according to rASRM
62559093|NCT04997330|PLACEBO_COMPARATOR|Sham rTMS|Sham bilateral high frequency (20Hz) Repetitive Transcranial Magnetic Stimulation (rTMS) over DLPFC
61990042|NCT05339451||Controls|Women operated for other benign gynecological diseases and have no signs of endometriosis perioperatively.
61990043|NCT03062956|EXPERIMENTAL|Single oral dose of MYK-491|single-dose, oral suspension
61990044|NCT03062956|PLACEBO_COMPARATOR|Single oral dose of placebo|single-dose, oral suspension
61990045|NCT05231590|OTHER|Children Aged 5 to <12 Years|
61990046|NCT05231590|OTHER|Children Aged 12 to <18 Years|
62182663|NCT03180554|OTHER|tVNS version 2|Transcutaneous vagus nerve stimulation (tVNS) version 2 will be delivered non-invasively via a portable take-home stimulation device which attaches to the center of the left ear lobe. Intensity, pulse duration, and frequency is optimised by the participant. Participants will receive a 15-minute stimulation twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
62559094|NCT04526028||Palbociclib combined with Fulvestrant|
62559095|NCT04526028||Fulvestrant|
61990047|NCT05231590|OTHER|Adults Aged 18 to 40 Years|
61990048|NCT03725189|EXPERIMENTAL|PPG Group|Testing of PPG device in healthy adult population doing cardiovascular exercise
61990049|NCT04611763|EXPERIMENTAL|Pre FA Group|
61990050|NCT04611763|ACTIVE_COMPARATOR|Post FA Group|
61990051|NCT03488979||Educational Interventional Group|Primary outcome measure: Difference in MOSSAS-3HF score between intervention group and control group, administered 4 weeks after discharge.
61990052|NCT03488979||Attention Control Group|Primary outcome measure: Difference in MOSSAS-3HF score between intervention group and control group, administered 4 weeks after discharge.
61990053|NCT03930446|EXPERIMENTAL|Ethanol|Subjects will receive 4 color-coded beverages in green or blue cups, containing ethanol (0.2 g/kg per dose, total dose 0.8 g/kg).
61990054|NCT03930446|PLACEBO_COMPARATOR|Placebo (Juice)|Subjects will receive 4 color-coded beverages in green or blue cups, containing placebo (Juice).
61990055|NCT01514760|EXPERIMENTAL|Mobile-based Asthma Action Plan|The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts.
62386020|NCT06308289|ACTIVE_COMPARATOR|Group B|Standard Care for COPD (ACBT)
62559096|NCT05383131|EXPERIMENTAL|HEC585 and Pirfenidone|period 1 - Pirfenidone X mg, TID; period 2 - HEC585 X mg, QD; period 3 - Pirfenidone X mg, TID + HEC585 X mg, QD.
61990056|NCT03476083|EXPERIMENTAL|Group A|This is the experimental group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 14-16 and continue until delivery. The mothers will be followed together with their infants until postpartum week 28. Infants will receive hepatitis B vaccine at birth and additional hepatitis B (HBV) vaccine at the age of week 4 and week 24. HBIg will be omitted for the infants in this group.
61990057|NCT03476083|ACTIVE_COMPARATOR|Group B|This is the comparative group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 28 and continue until delivery. Patients in group B will have similar follow-up schedules as those in the experimental group. Infants will receive hepatitis B vaccine plus HBIg at birth and additional hepatitis B vaccine at the age of week 4 and week 24.
61990058|NCT02242708|NO_INTERVENTION|Normal breathing|The control group will do normal breathing.
61990059|NCT02242708|EXPERIMENTAL|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
61990060|NCT05264194|ACTIVE_COMPARATOR|Patients receiving subcuticular suturing|Sutures will be hidden underneath skin
61990061|NCT05264194|ACTIVE_COMPARATOR|Patients receiving transcutaneous suturing|Sutures will be on your skin
61990062|NCT05717010||Group self-retaining retractor|Patients used self-retaining retractor for surgery
61990063|NCT05717010||Group Hand-held retractor|Patients used hand held retractor for surgery
61990064|NCT03645655||hepatoblastoma|The diagnosis of hepatoblastoma is based on enhanced CT scanning and/or histopathology.
61990065|NCT03645655||hepatic hemangioendothelioma|The diagnosis of hepatic hemangioendothelioma is based on enhanced CT scanning and/or histopathology.
61990066|NCT03645655||Healthy control|The healthy control group consist of people undergoing routine medical examination.
61990067|NCT01380184|EXPERIMENTAL|Ridaforolimus 40 mg|In Part 1 (Days 1-19), participants received ridaforolimus (MK-8669) 40 mg via oral enteric-coated tablet on Day 1; followed by no study treatment on Days 2-7; followed by two weekly sequences (Days 8-19) consisting of 5 consecutive days of ridaforolimus 40 mg and 2 consecutive days off study treatment. Following Part 1, participants underwent at least a 2-day study treatment washout prior to starting Part 2. In Part 2, participants received a weekly treatment regimen consisting of 5 consecutive days (Days 1-5) of ridaforolimus 40 mg via oral enteric-coated tablet and 2 consecutive days (Days 6-7) off study treatment. This weekly treatment regimen was repeated every subsequent week for the remainder of participation in Part 2.
61990068|NCT01720914||Critically ill patient|
61990069|NCT02984566|EXPERIMENTAL|SABR with or without KIM|All patients will receive liver SABR. Kilovoltage Intrafraction Monitoring (KIM) tracking will be trialed during mock treatment. If KIM is successful, it will be used throughout treatment. If unsuccessful, cone beam CT will be used instead.
61990070|NCT02776150||MGIT liquid culture+drug sensitivity test|MGIT: The bactec MGIT 960 system is non-radiometric. It uses MGIT media and patented sensors, making efficient use of advanced fluorometric technology, which permits highly accurate detection of O2 consumption without sharps. Automated quality control is performed continuously to ensure precise and reliable operation. Results are provided as positive/negative and numerical growth units.
61990071|NCT02776150||Xpert-MTB/RIF|xpert-MTB/RIF: The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System. A sputum sample is collected from the patient with suspected TB. The sputum is mixed with the reagent that is provided with the assay, and a cartridge containing this mixture is placed in the GeneXpert machine. All processing from this point on is fully automated.The test simultaneously detects Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) in less than 2 hours.
61990072|NCT02776150||probe melting curve detection|Probe-based fluorescence melting curve analysis (FMCA) is a powerful tool for mutation detection based on melting temperature generated by thermal denaturation of the probe-target hybrid, which performed for Mycobacterium tuberculosis's drug resistant monitor. The method was explored two dual-labeled, self-quenched probes, TaqMan and shared-stem molecular beacons, in their ability to conduct FMCA. Both probes could be directly used for FMCA and readily integrated with closed-tube amplicon hybridization under asymmetric PCR conditions. Improved flexibility of FMCA by using these probes was illustrated in three representative applications of FMCA: mutation scanning, mutation identification and mutation genotyping, all of which achieved improved color-multiplexing with easy probe design and versatile probe combination and all were validated with a large number of real clinical samples.
61990073|NCT04985812|EXPERIMENTAL|JNJ-67484703|Participants will receive multiple doses of JNJ-67484703.
61990074|NCT04985812|PLACEBO_COMPARATOR|Placebo|Participants will receive multiple doses of placebo.
61990075|NCT06003010|NO_INTERVENTION|Study group|This group will be given standard pre- and post-surgery movement instructions.
62386021|NCT03381144|EXPERIMENTAL|Part 1: GDC-0334|Participants in up to 7 cohorts will receive single, ascending doses of GDC-0334 under fasting conditions.
62386022|NCT03381144|PLACEBO_COMPARATOR|Part 1: Placebo|Participants in up to 7 cohorts will receive single doses of placebo under fasting conditions.
62386023|NCT03381144|EXPERIMENTAL|Part 2: GDC-0334|Participants in up to 3 cohorts will receive single doses of GDC-0334 under fasting or fed conditions.
62386024|NCT03381144|PLACEBO_COMPARATOR|Part 2: Placebo|Participants in up to 3 cohorts will receive single doses of placebo under fasting or fed conditions.
61990076|NCT06003010|EXPERIMENTAL|Yoga group|This group will be asked to do a 6 week series of yoga videos at home pre- and post-surgery.
61990077|NCT05552872||Pulmonary Infection with DM group|Patients with diabetes and pulmonary infection
61990078|NCT05552872||Pulmonary Infection group|Patients with pulmonary infection while the fasting blood-glucose in the normal range.
61990079|NCT01347541|EXPERIMENTAL|Stepped care|Combination of behavioral therapy and drug therapy
61990080|NCT01347541|ACTIVE_COMPARATOR|Standard care provided to injured trauma survivors|
61990081|NCT01489072|EXPERIMENTAL|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of remifentanil 0.25 mcg/kg before emergence of a desflurane-based anesthesia
62386025|NCT03381144|EXPERIMENTAL|Part 3: GDC-0334|Participants in up to 4 cohorts will receive multiple, ascending doses of GDC-0334 under fasting or fed conditions.
62386026|NCT03381144|PLACEBO_COMPARATOR|Part 3: Placebo|Participants in up to 4 cohorts will receive multiple doses of placebo under fasting or fed conditions.
62559097|NCT05383131|EXPERIMENTAL|HEC585 and Nintedanib|period 1 - Nintedanib X mg, BID; period 2 - HEC585 X mg, QD; period 3 - Nintedanib X mg, BID + HEC585 X mg, QD.
62559098|NCT03631706|EXPERIMENTAL|M7824|
62559099|NCT03631706|ACTIVE_COMPARATOR|Pembrolizumab|
61990082|NCT01489072|ACTIVE_COMPARATOR|Remifentanil 0.5 mcg/kg|Administration of a bolus dose of remifentanil 0.5 mcg/kg before emergence of a desflurane-based anesthesia
61990083|NCT00973479|EXPERIMENTAL|Group I: Placebo + Methotrexate (MTX)|Participants will receive placebo at Weeks 0, 4, 12, and 16. Participants will cross over to golimumab at Week 24, and receive administrations at Weeks 24, 28, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will be eligible for early escape (receive golimumab) at Week 16 if they demonstrate a less than 10 percent improvement in both tender and swollen joint count. These participants will receive golimumab at Weeks 16, 20, and every 8 weeks thereafter.
62386027|NCT03613766|EXPERIMENTAL|Physical activity program|Before 3 to 6 months before the expected date of surgery, the experimental group, performed a 12-week monitored and supervised concurrent exercise program. Before and after of this period, body composition, anthropometric measures, physical fitness, cardiovascular risk, blood samples, Basal Metabolic Rate and health-related quality of life were measured in a laboratory under controlled conditions.
62386028|NCT03613766|NO_INTERVENTION|Habitual care prescription|Before 3 to 6 months before the expected date of surgery, the control group, followed the habitual care prescriptions until the surgery
62386029|NCT02935023|EXPERIMENTAL|CIRT with systemic therapy arm|Carbon ion radiotherapy combined with systemic therapy
62386030|NCT05818215||All participants|Data from electronic medical records of all patients under 16 years of age with medical, surgical and traumatology emergencies attending the paediatric emergency departments during the study period
62386031|NCT03117686||healthy volunteers|10 healthy volunteers climbing Mount Kilimanjaro receiving lung ultrasound
62386032|NCT03117686||patients after lung transplantation|10 patients \> 2years after lung transplantation climbing Mount Kilimanjaro receiving lung ultrasound
62386033|NCT03491527|ACTIVE_COMPARATOR|Conventional Resin Cement|Resin cement without MTA
62386034|NCT03491527|ACTIVE_COMPARATOR|MTA Resin Cement|Resin cement with MTA
62386035|NCT06225830|EXPERIMENTAL|Ekso mediated gait training|"Ekso mediated gait training will take place twice per week for 8 weeks . An Ekso Robotic Eksoskeleton will be used during each treatment session; this device can physically assist leg movements along a customized path or resist or amplify movements the participant makes. Each session will be 60 minutes and will be 3 rounds of 15 minutes of Ekso mediated gait training.~Four (4) study related Assessment sessions will be conducted and include a series of physical tests and a written questionnaire. This will be done at the Evaluation/ 1st visit, then the re-evaluation at visit 9, at discharge or visit 17, and finally at a 3-month follow-up."
62386036|NCT04277429||Normal cardiac function|Normal cardiac function
62386037|NCT04277429||Heart failure with reduced ejection fraction|Heart failure with reduced ejection fraction
62386038|NCT04277429||Heart failure with preserved ejection fraction|Heart failure with preserved ejection fraction
62386039|NCT02178215|PLACEBO_COMPARATOR|Placebo shower gel|•Wash forearm by prepared placebo shower gel twice a day
62386040|NCT02178215|ACTIVE_COMPARATOR|Holly Mangrove Shower Gel|•Wash forearm by Holly Mangrove Showver gel twice a day
62559100|NCT03519412|EXPERIMENTAL|MMR-proficient (MMRp)|MGMT-IHC-negative, MGMT promoter methylation-positive patient population is selected for treatment with temozolomide (induction) orally until disease progression or unacceptable toxicity whichever comes first, followed by pembrolizumab IV if Tumor Mutational Burden post Temozolomide is \> 20 Muts/Mb
61990084|NCT00973479|PLACEBO_COMPARATOR|Group II: Golimumab + Methotrexate (MTX)|Participants will receive golimumab at Weeks 0, 4, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will receive a placebo infusion at Week 16 and Week 24 to maintain the blind.
61990085|NCT02225522|NO_INTERVENTION|Standard Care|Patients in this arm receive standard genetic evaluation without the addition of next generation sequencing for the diagnosis of their presumed genetic condition
62386041|NCT03245372|ACTIVE_COMPARATOR|Standard care|Basic intraoperative hemodynamic objectives
61990086|NCT02225522|EXPERIMENTAL|Rapid whole genome sequencing (StatSeq)|Patients in this arm will receive standard of care genetic evaluation and next generation sequencing of their genome to achieve rapid diagnosis of genetic conditions.
61990087|NCT02589782|EXPERIMENTAL|Regimen 1|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated
61990088|NCT02589782|EXPERIMENTAL|Regimen 2|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
61990089|NCT02589782|EXPERIMENTAL|Regimen 3|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
61990090|NCT02589782|ACTIVE_COMPARATOR|Control Regimen|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
61990091|NCT01283126|EXPERIMENTAL|Euglycemic and hypoglycemic clamp|Subjects will complete clamp study visit.
61990092|NCT03343483|EXPERIMENTAL|Volunteering|Structured social volunteering program providing peer companionship to frail, homebound older adults for at least 16 hours per month for 12 months.
61990093|NCT03343483|ACTIVE_COMPARATOR|Life Review|Self-guided program of life review for 12 months.
61990094|NCT03767920|ACTIVE_COMPARATOR|bupivacaine and dexamethasone|Bilateral TAP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
61990095|NCT03767920|ACTIVE_COMPARATOR|bupivacaine and placebo to dexamethasone|BilateralTAP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
61990096|NCT04759872|EXPERIMENTAL|Metabolic Study Visit|Participants will complete a study visit for metabolic phenotyping and determination of the impact of hyperinsulinemia on outcomes of interest.
61990097|NCT01702701|ACTIVE_COMPARATOR|Montelukast|patients will receive 10 mg po montelukast daily for 12 weeks.
61990098|NCT01702701|ACTIVE_COMPARATOR|Fluticasone|patients will receive 440mcg fluticasone po bid for 12 weeks
61990099|NCT03733171|ACTIVE_COMPARATOR|Platelet rich plasma|endoscopic injection of PRP
62386042|NCT03245372|EXPERIMENTAL|Goal directed therapy|Target value is a cardiac index equal or superior to 2.2 l/min/m2.
62386043|NCT05718011|EXPERIMENTAL|dexmedetomidine|0.5 micrograms/kg
62386044|NCT05718011|ACTIVE_COMPARATOR|ketamine|0.5 milligram/kg
62386045|NCT03941041|EXPERIMENTAL|Prenatal Yoga Practice|Pregnant women participating in a yoga course at least 12 session, each session in duration of 90 minutes.
62386046|NCT03941041|NO_INTERVENTION|Regular Prenatal Care|Pregnant women being treated according to national guidelines
62386047|NCT05572489||patients with cervicogenic headache|visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale
62386048|NCT05572489||healthy controls|visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale
62386049|NCT00106496|EXPERIMENTAL|1A|
62386050|NCT00106496|ACTIVE_COMPARATOR|1B|
62386051|NCT00106496|EXPERIMENTAL|2|Open label
62386052|NCT00106496|EXPERIMENTAL|3A|
62386053|NCT00106496|PLACEBO_COMPARATOR|3B|
62386054|NCT00106496|EXPERIMENTAL|4|Open label
62386055|NCT00050505|EXPERIMENTAL|Cohort C|N=100 to 110 subjects receives 1:10 diluted dose of Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
62386056|NCT00050505|EXPERIMENTAL|Cohort B|N=571 to 581 subjects receives 1:5 diluted dose of Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
62386057|NCT00050505|EXPERIMENTAL|Cohort A|N=226 to 236 subjects receives undiluted dose Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
62386058|NCT03531879||subject with plaques and without plaques|Subject with plaques and without plaques
62386059|NCT04491045|EXPERIMENTAL|Community-Engaged Learning Collaborative (CELC)|The CELC arm is an integration of community engagement and learning collaborative approach which involves province-wide collaborative meetings for commune health stations (6 CHSs for each province) randomized into the CELC implementation condition. CELC CHSs will meet monthly initially for 3 months, followed by bi-monthly meetings for 12 months to engage in continuous quality improvement process, track implementation goals, problem solve implementation barriers, and engage in cross-site learning. This is in addition to usual implementation condition (supervision, workshops, technical assistance, and evidence-based toolkit)
62386060|NCT04491045|EXPERIMENTAL|Enhanced Supervision (ES)|This is an evidence-based training approach which involves 6-9 months of ongoing group supervision support from psychiatric hospital mental health specialist (psychiatrist, psychiatric nurse, or psychologist) for each community health station randomized to the ES condition. Supervision approach is structured and involves observation of sessions, feedback on fidelity and quality. Supervision support will be provided biweekly initially and monthly after completion of one practice case. This is in addition to usual implementation condition (workshops, technical assistance, and evidence-based toolkit)
62386061|NCT04491045|ACTIVE_COMPARATOR|Usual Implementation (UI)|"Usual Implementation (UI) Control intervention that will be enhanced usual implementation and includes hybrid training workshops on basic implementation and training supports for Multicomponent Collaborative Care for Depression program, which is an evidence-based stepped collaborative care intervention for integrating depression care into primary care settings. It consists of six components: routine screening, diagnostic assessment, psychoeducation, antidepressant medication, adherence management, behavior activation therapy.~This implementation and training supports includes a series of online training modules, weekly webinars, and 3 one-day in-person workshops on collaborative care for depression (MCCD), limited technical assistance, and toolkit."
62386062|NCT03719144||Patients|Patients registered on ResearchMatch.org with Atrial Fibrillation as a medical condition; or who participate in afib-related social media platforms and confirm a diagnosis of afib, will be invited to participate in this study. Patients will be consented using an online consent form and then will be asked to complete 1 survey that contains scenarios and ranking questions.
62386063|NCT03719144||Providers|Providers who have contributed at least 25 Atrial Fibrillation patients to the Symphony pharmacy claims dataset will be contacted to participate. Interested providers will be consented using an online consent form and then will be asked to complete 1 survey that contains scenarios and ranking questions.
62386064|NCT03309865|EXPERIMENTAL|Combined diet and vedolizumab|Intervention: vedolizumab injection (300mg, IV infusions at week 0, 2, 6, 14) and concurrently on structured semi-vegetarian diet; Duration of Therapy: 14 weeks
62386065|NCT02473770||Disaster responders|Conducting emergency disaster relief.
62386066|NCT02315859||All patients|All patients
62386067|NCT00483600|EXPERIMENTAL|no arms/one group|
62386068|NCT02475564|PLACEBO_COMPARATOR|placebo|Patients will take once a day a monophasic pill (ethinylestradiol + levonorgestrel) continuously for 42 days with 1 pill of placebo (starch)
62386069|NCT02475564|EXPERIMENTAL|resveratrol|Patients will take once a day a monophasic pill (ethinylestradiol + levonorgestrel) continuously for 42 days with 40mg of resveratrol
62386070|NCT00642343|PLACEBO_COMPARATOR|1|Children with severe to profound deafness that have not received any intervention.
62386071|NCT00642343|ACTIVE_COMPARATOR|2|Children with an unilateral cochlear implant.
62386072|NCT00642343|ACTIVE_COMPARATOR|3|Children with bilateral cochlear implants.
62386073|NCT00642343|ACTIVE_COMPARATOR|4|Children who receive their second implant during the duration of the study.
61990100|NCT03733171|PLACEBO_COMPARATOR|CONTROL GROUP|diluted epinephrine
61990101|NCT02065232||Tilmanocept|Patients will receive technetium-labeled tilmanocept, which is FDA approved for sentinel lymph node mapping in breast cancer.
61990102|NCT02065232||Sulfur Colloid|Patients will receive technetium-labeled sulfur colloid, which is FDA approved for sentinel lymph node mapping in breast cancer.
62182664|NCT03180554|OTHER|MNRB version 1|Motivational nondirective resonance breathing (MNRB) version 1 will be delivered via a take-home guided breathing apparatus. Participants will be guided through a deep breathing session. Participants will practice MNRB version 1 for 15-minutes twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
62386074|NCT01813630|EXPERIMENTAL|DA-3002|0.14 IU (0.045-0.050mg)/kg/day of DA-3002 is injected for 52 weeks by changing injecting areas
61990103|NCT06131008|EXPERIMENTAL|Diastology-Guided Management|Participants in this arm will undergo a focused echocardiogram every 24 hours. The degree of diastolic dysfunction will be reported to the healthcare team. If the degree of diastolic dysfunction is greater than or equal to grade 2, the research team will recommend escalating the diuretic regimen if either (1) urine output is less than 4,000 mL over 24 hours or (2) weight loss is less than 2 kg over 24 hours. If the degree of diastolic dysfunction is grade 1, the research team will recommend transitioning to or discontinuing oral diuresis.
61990104|NCT06131008|ACTIVE_COMPARATOR|Usual Care|Participants in this arm will also undergo a focused echocardiogram every 24 hours. However, the results of these echocardiograms will not be available for clinical decision-making. Instead, participants will receive usual care by the healthcare team without daily hemodynamic parameters from a study echocardiogram.
61990105|NCT02174458||Bariatric Surgery only|Patients after Bariatric Surgery but no secondary reconstructive procedures
61990106|NCT02174458||Body Contouring surgery|Post-bariatric patients and patients with no history of bariatric surgery but after natural weight loss
61990107|NCT04252989||Children with active myopia treated with ATROPINE eye drops|
61990108|NCT02444572|EXPERIMENTAL|ENOXA® group|"Patients under ENOXA® 4000 IU according to randomization:~* Administer ENOXA® 4000 IU (Enoxaparin 4000 IU) per day, regardless of the patient's weight at inclusion~* Start injections 12 hours after the surgical procedure~* Administer ENOXA® subcutaneously~* The administration of ENOXA® should be at the same time on a daily basis for 30 successive days as per the american and french clinical guidelines"
61990109|NCT02444572|ACTIVE_COMPARATOR|LOVENOX® group|"Patients under LOVENOX® 4000 IU according to randomization:~* Administer LOVENOX® 4000 IU (Enoxaparin 4000 IU) per day, regardless of the patient's weight at inclusion~* Start injections 12 hours after the surgical procedure~* Administer LOVENOX® subcutaneously~* The administration of LOVENOX® should be at the same time on a daily basis for 30 successive days as per the american and french clinical guidelines"
61990110|NCT06481527||Children and young people|Children and young people aged 5-15 with or without learning disabilities or autism that are receiving cancer care.
61990111|NCT06481527||Parents|Parents of eligible children and young people aged 5-15 with or without learning disabilities or autism that are receiving cancer care.
61990112|NCT06481527||Healthcare Staff|Healthcare staff that provide cancer care services to children and young people.
61990113|NCT00730782|ACTIVE_COMPARATOR|1|The experimental vaccine PfAMA1 formulated in Alhydrogel
61990114|NCT00730782|ACTIVE_COMPARATOR|2|The experimental vaccine PfAMA1 formulated in Montanide ISA720
62386075|NCT01813630|ACTIVE_COMPARATOR|Genotropin®|0.14 IU (0.045-0.050mg)/kg/day of Genotropin is injected for 52 weeks by changing injecting areas
62386076|NCT03824704|EXPERIMENTAL|Cohort A: Ovarian Cancer Cohort|"Oral rucaparib and Intravenous (IV) nivolumab (combination therapy)~* Cohort A1~* Cohort A2"
62386077|NCT06188403|ACTIVE_COMPARATOR|(group one) will be treated with custom titanium plates and guide to reposition the maxilla|7 patients are included in this arm. Le Fort I osteotomy using CAD CAM surgical guide and 3Dcustomized plate are placed to reposition the maxilla according to the virtual surgical planning.
62386078|NCT06188403|ACTIVE_COMPARATOR|(group 2) will be treated with prebent titanium plates|7 patients are included in this arm. le fort 1 osteotomy using surgical guide and pre-bent stock titanium plates are used after their adaptation on the model of postoperative plan.
62386079|NCT01671176|OTHER|Wide diameter bone anchored implant|Intervention: Implantation of a wide diameter bone anchored auditory implant either 3 or 4 mm in length, into the skull on the side of the ear where intervention is intended in order to restore hearing. In the case of a conductive or mixed hearing loss, that side is chosen. In patients with unilateral, profound sensori-neural hearing loss the implant is implanted on that side but the sound is transmitted to the side with the normal hearing ear via bone conduction stimulation.
62386080|NCT03044730|EXPERIMENTAL|Treatment (pembrolizumab, capecitabine)|Patients receive pembrolizumab IV on day 1 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61990115|NCT00730782|ACTIVE_COMPARATOR|3|The experimental vaccine PfAMA1 formulated in ASO2A
61990116|NCT01356654|SHAM_COMPARATOR|SHAM TDCS|
61990117|NCT01356654|ACTIVE_COMPARATOR|True TDCS|
61990118|NCT03823053|ACTIVE_COMPARATOR|Control Group|The control group will be given home based traditional scoliosis exercise training for 8 weeks, 5 days a week for 30 minutes. The content of the physiotherapy program; posture, interscapular muscle strengthening, stretching and lateral flexion exercises are formed.
61990119|NCT03823053|EXPERIMENTAL|Training Group|"In addition to home based traditional scoliosis exercise, the training group will also receive core stabilization exercise training for 8 weeks, 5 days a week, for 30 minutes. Core stabilization training; exercises for 2 muscle systems that contribute to spinal stability are given. The first one is the local system muscles; multifidus, transversus abdominis, diaphragm and pelvic floor muscles. The second, the global system includes large superficial muscles, such as erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus maximus, and latissimus dorsi."
61990120|NCT04697693|EXPERIMENTAL|Treatment with escitalopram or duloxetine|Participant will be begun on either escitalopram 10mg or duloxetine 30mg. The default medication will be escitalopram. Subjects will begin escitalopram 10mg, continue this dosage for 4 weeks, then if the Hamilton Rating Score for Depression (HRSD) \>7 at Week 4, he/she will have their dosage increased to 20mg for the remainder of the 8 week study. Participants who have not responded to or not tolerated escitalopram in the current depressive episode will be started on duloxetine. They will take 30mg of duloxetine for the first 2 weeks, then, contingent on clinical assessment that the 30mg dose is sufficiently well tolerated, be increased to 60mg for the remaining 6 weeks of the study
62767058|NCT03458702|EXPERIMENTAL|Quiet Rest then YogaFit|Participants participated in a 30 min Quiet Rest session and then a session of 30 min of YogaFit on a separate day.
62767059|NCT04515329|EXPERIMENTAL|Cyclosporine + Artificial Tears|Cyclosporine eye drops twice daily (Treatment) with preservative-free artificial tear drops 4 times a day (Control).
62767060|NCT04515329|OTHER|Artificial Tears|Preservative-free artificial tear drops 4 times a day (Control).
62767061|NCT02329483||High responder infertile patients|Ovarian high responder patients who are being planned for low-dose step-up protocol ovulation induction and intrauterine insemination.
62386081|NCT05613933|EXPERIMENTAL|Intervention arm|In the intervention arm, dentists will receive information on the study 8 weeks before the start of the study and will be invited to consent to participate or to opt out
62767062|NCT02383433|EXPERIMENTAL|Treatment (regorafenib, gemcitabine hydrochloride)|Patients receive regorafenib PO QD on days 1-21 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62767063|NCT06304506|EXPERIMENTAL|Young obese men|BMI \[30, 40\] Age \[18, 35\]
62767064|NCT06304506|EXPERIMENTAL|Young healthy men|BMI \[20, 25\] Age \[18, 35\]
62767065|NCT06304506|EXPERIMENTAL|Old healthy men|BMI \[20, 25\] Age \[60, 75\]
62767066|NCT02012686|PLACEBO_COMPARATOR|Control group|numerical rating scale of TENS non-applied group
62767067|NCT02012686|ACTIVE_COMPARATOR|TENS group|numerical rating scale of TENS applied group
62767068|NCT00259298|EXPERIMENTAL|Teriparatide|Participants receive teriparatide 20 microgram once daily by subcutaneous injection for 18 months followed by 6 months off therapy
62767069|NCT03630744||Adult patients undergoing surgery|Patients over 18 years surgically treated with fluid therapy during the 24 hours of the day study
62767070|NCT05990699|EXPERIMENTAL|Intervention group|"patients will under routine hospital care as well as MBRP. This program consists of eight sessions spanning across four weeks, each focusing on specific techniques and skills to aid in substance use disorder treatment. The first session emphasizes the correlation between the unconscious pilot and substance use, incorporating a corporeal examination technique to promote intentional concentration. The second session focuses on mindfulness to identify stimuli and observe accompanying sentiments, thoughts, and feelings. The third session introduces the ABSTEMIOUS space technique, urging patients to pause, observe their experiences, concentrate on breathing, broaden cognizance, and choose judicious responses in trying or hazardous situations. The remaining sessions address coping mechanisms for relapse risks, taking pragmatic action in high-risk situations, integrating healthy activities into life, and sustaining mindfulness practice through the development of a support network."
62767071|NCT05990699|NO_INTERVENTION|control group|patients with substance use disorder who will be under routine hospital care.
62386082|NCT05613933|NO_INTERVENTION|Control arm|In the clusters randomized to the control arm, no intervention will be performed and no information will be sent to dentists.
62767072|NCT01651390|EXPERIMENTAL|Drug coated balloon|Percutaneous coronary intervention with the Pantera Lux drug coated balloon.
62767073|NCT01651390|ACTIVE_COMPARATOR|Drug eluting stent|Percutaneous coronary intervention with the Orsiro drug eluting stent.
62767074|NCT01504581|EXPERIMENTAL|HM10660A|
62767075|NCT01504581|ACTIVE_COMPARATOR|Pegasys|
62767076|NCT01504581|PLACEBO_COMPARATOR|HM10660A Placebo|
62767077|NCT01028066|ACTIVE_COMPARATOR|Traditional|Traditional nutritional counseling
62767078|NCT01028066|EXPERIMENTAL|Behavioral|Dialogic nutritional counseling
62767079|NCT02609945|EXPERIMENTAL|CVT-427 (zolmitriptan inhalation powder)|"Periods 1-2: Subjects will receive Zomig oral tablet in Period 1 and Zomig nasal spray in Period 2, 1 hour apart.~Periods 3-6: Subjects will receive CVT-427 (dose levels (DL) 1, 2, 3 and 4), administered in ascending order provided that safety and tolerability data are observed to be adequate to allow dose escalation, approximately 24 hours after preceding DL."
62767080|NCT00668590|EXPERIMENTAL|1|
62767081|NCT00668590|ACTIVE_COMPARATOR|2|
62767082|NCT03043677||Non-inflamed|
62767083|NCT03043677||Inflamed ulcerative colitis|
62767084|NCT03043677||inflamed Crohn´s disease|
62767085|NCT04886947|EXPERIMENTAL|stem cell intervention|"Arm A patients who will have surgery with stem cell added.~Arm B only surgery with no stem cell added."
61990121|NCT03095066|PLACEBO_COMPARATOR|Stage 1: Placebo|Participants will receive AVP-786 matching placebo capsules, orally, twice daily (BID) during Weeks 1 to 6 of the Stage 1 treatment period.
61990122|NCT03095066|EXPERIMENTAL|AVP-786|Participants will receive AVP-786-28/4.9 (deudextromethorpan hydrobromide \[d6-DM\] 28 milligrams (mg)/quinidine sulfate \[Q\] 4.9 mg) capsule, along with AVP-786 matching placebo capsule, orally, once daily (QD) during Week 1 followed by AVP-786-28/4.9 capsule, orally, BID during Week 2, and AVP-786-42.63/4.9 (d6-DM 42.63 mg/Q 4.9 mg) capsules (target dose), orally, BID during Weeks 3 to 12 of the treatment period.
62386083|NCT03575975||Mobile-bearing ankle prosthesis user|Users of the Stryker Scandinavian Total Ankle Replacement (STAR) mobile-bearing prosthesis.
62767086|NCT04839848||Permanent suture|Mesh fixation with permanent suture
62386084|NCT03575975||Control|Healthy individual age- and gender-matched to a participant in the mobile-bearing prosthesis user group.
62767087|NCT04839848||Long-term absorbable|Mesh fixation with long-term absorbable suture
62386085|NCT03575975||Fixed-bearing ankle prosthesis user|Users of the INBONE II Total Ankle Replacement fixed-bearing prosthesis.
62386086|NCT03890029|OTHER|Intervention|"Once potential participants have given consent and determined eligible, they will undergo an initial assessment.Pre, post- and follow-up testing. This consists of verbal scales including emotional well-being scales and mental health symptom scales. They will be administered in a group 30-60 minute session. Neuropsychological testing and psychophysiological tests given will require 90 minutes. Neuropsychological testing will be completed at pre and post testing only. In order to ensure unbiased assessment, pre- and post- and follow-up testing will be conducted by individuals blinded to study condition.~Randomization. After pre-testing, all individuals will be randomly assigned to either the active treatment group or minimal attention control condition. After this, intervention participants will meet in small groups of 10 per group for 90 minutes/week over five weeks for resilience training. After five weeks, all participants will be post-tested."
62386087|NCT03890029|OTHER|Control|While intervention participants receive resilience training, the control group will not receive training but will receive minimal attention of a bi-monthly telephone call to indicate to participants that they are still enrolled in the study. A monthly flyer will be mailed to them about wellness and PTSD in recent news coverage. Following completion of an intervention group, participants and controls will be scheduled for post-testing that will be identical to the pre-testing and will occur within two weeks after the final treatment session. After the post-testing and 3-month follow up testing, the controls will be offered the resilience training
62767088|NCT04839848||Short-term absorbable|Mesh fixation with short-term absorbable suture
62767089|NCT04839848||Fibrin glue|Biologic glue/sealant produced from human donor blood
62767090|NCT04839848||Progrip|Pre-fabricated absorbable fixation hooks, integrated in mesh. Progrip is a registered trademark owned by Medtronic
62767091|NCT00567918|EXPERIMENTAL|1|FK506 ophthalmic suspension
62767092|NCT00930436|ACTIVE_COMPARATOR|Saline infusion|Saline will be given as an active control agent to compare with sodium bicarbonate. Each bag of solution will be blinded, and given in the same manner.
62182665|NCT03180554|OTHER|MNRB version 2|Motivational nondirective resonance breathing (MNRB) version 2 will be delivered via a take-home guided breathing apparatus. Participants will be guided through a paced breathing session. Participants will practice MNRB version 2 for 15-minutes twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
62182666|NCT04191148|EXPERIMENTAL|LBP-EC01|crPhage cocktail
62182667|NCT04191148|PLACEBO_COMPARATOR|Placebo|Lactated Ringer's solution, injection, USP
62182668|NCT03389425|EXPERIMENTAL|SIMPLE weightloss group|
62386088|NCT03753867|EXPERIMENTAL|Acitretin treatment|
62386089|NCT04998344|EXPERIMENTAL|Inactivated influenza vaccine group|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
62767093|NCT00930436|EXPERIMENTAL|Sodium Bicarbonate|Infusion of sodium bicarbonate will be given prior to,during and after the contrast agent for a total of 6 to 10 hours
62767094|NCT02423122|EXPERIMENTAL|VX-745 dose 1|Active Group 1: VX-745 40 mg twice daily
62767095|NCT02423122|EXPERIMENTAL|VX-745 dose 2|Active Group 2: VX-745 125 mg twice daily
62767096|NCT04610918||Cases - Pediatric Intestinal Failure Patients|DXA BIA Skin fold measurements Strength tests Physical activity monitoring
62767097|NCT04610918||Controls|BIA Skin fold measurements Strength tests Physical activity monitoring
62767098|NCT05928611|ACTIVE_COMPARATOR|Inferior alveolar nerve block|Using 1.8ml of 4% articaine HCL 1:100,000 epinehrine
62767099|NCT05928611|EXPERIMENTAL|Inferior alveolar nerve block with intraligmentary dexamethasone|Using 1.8ml of 4% articaine HCL 1:100,000 epinehrine for inferior alveolar nerve block and 0.4 mL of 8 mg/ 2mLdexamethasone for intraligmentary injection
62767100|NCT05928611|EXPERIMENTAL|Buccal infiltratation with intraligmentary dexamethasone|Using 1.8ml of 4% articaine HCL 1:100,000 epinehrine for buccal infiltratation and 0.4 mL of 8 mg/ 2mLdexamethasone for intraligmentary injection
62386090|NCT04998344|ACTIVE_COMPARATOR|Inactivated polio vaccine group|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
62386091|NCT01108068|EXPERIMENTAL|Lithium|patients with OPPG will be treated with lithium for 6 months
62386092|NCT01108068|NO_INTERVENTION|Unaffected controls|Family members of patients with OPPG will have DXA and pQCT to compare to OPPG patients. These unaffected participants will not receive lithium.
62559101|NCT03519412|OTHER|MMR-deficient (MMRd)|Patients receive Pembrolizumab (treatment) IV until disease progression or unacceptable toxicity or 35 cycles, whichever comes first
62559102|NCT01254643|EXPERIMENTAL|All Enrolled|9-valent human papillomavirus (9vHPV) L1 VLP vaccine (V503), 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6.
62559103|NCT06314243|EXPERIMENTAL|Pumpkin Seed Oil group|"Group 1 (Pumpkin Seed Oil group): consists of 28 patients who will receive one capsule containing 1010 mg PSO once daily for 12 weeks,  Ronkin®, KMT PHARMA, Egypt. "
62559104|NCT06314243|NO_INTERVENTION|Control group|Group 2 (Control group): consists of 28 patients who will not receive the intervention.
62386093|NCT01520727|EXPERIMENTAL|BIA 9-1067 10 mg|BIA 9-1067 (Opicapone, OPC) - 10 mg
62559105|NCT02446041||ICS/LABA Patients|ICS/LABA Patients following standard of care
62559106|NCT03312244|EXPERIMENTAL|Pyridostigmine|Pyridostigmine 180mg/d slow-release formulation
62559107|NCT03312244|PLACEBO_COMPARATOR|Placebo|Placebo
61990123|NCT03095066|PLACEBO_COMPARATOR|Stage 1: Placebo Non-responders to Stage 2: Placebo|"Participants who will be randomized to receive placebo in Stage 1 and will be classified as non-responders (responders if modified Clinical Global Impression of Severity \[mCGI-S\] score is ≤ 3 at Day 43 and Neuropsychiatric Inventory Clinician (NPI-C)-3 score has decreased by ≥ 25% from baseline. Participants who will not meet these criteria will be considered non-responders) after Week 6 will be re-randomized to continue receiving AVP-786 matching placebo capsules, orally, BID during Weeks 7 to 12 of the Stage 2 treatment period."
61990124|NCT03095066|EXPERIMENTAL|Stage 1: Placebo Non-responders to Stage 2: AVP-786|"Participants who will be randomized randomized to receive placebo in Stage 1 and will be classified as non-responders (responders if mCGI-S score is ≤ 3 at Day 43 and NPI-C-3 score has decreased by ≥ 25% from baseline. Participants who will not meet these criteria will be considered non-responders) after Week 6 will be re-randomized to receive AVP-786 in Stage 2 using the same dose escalation schedule used in Stage 1 i.e., AVP-786-28/4.9 capsule, along with AVP-786 matching placebo capsule, orally, QD during Week 7 followed by AVP-786-28/4.9 capsule, orally, BID during Week 8, and AVP-786-42.63/4.9 capsules, orally, BID, during Weeks 9 to 12 of the Stage 2 treatment period."
61990125|NCT03095066|PLACEBO_COMPARATOR|Stage 1: Placebo Responders to Stage 2: Placebo|"Participants who will be randomized to receive placebo in Stage 1 and will be classified as responders (responders if mCGI-S score is ≤ 3 at Day 43 and NPI-C-3 score has decreased by ≥ 25% from baseline) after Week 6 will be re-randomized to continue receiving AVP-786 matching placebo capsules, orally, BID during Weeks 7 to 12 of the Stage 2 treatment period."
61990126|NCT03095066|EXPERIMENTAL|Stage 1: Placebo Responders to Stage 2: AVP-786|"Participants who will be randomized to receive placebo in Stage 1 and will be classified as responders (responders if mCGI-S score is ≤ 3 at Day 43 and NPI-C-3 score has decreased by ≥ 25% from baseline) after Week 6 will be re-randomized to receive AVP-786 in Stage 2 using the same dose escalation schedule used in Stage 1 i.e., AVP-786-28/4.9 capsule, along with AVP-786 matching placebo capsule, orally, QD during Week 7 followed by AVP-786-28/4.9 capsule, orally, BID during Week 8, and AVP-786-42.63/4.9 capsules, orally, BID, during Weeks 9 to 12 of the Stage 2 treatment period."
61990127|NCT00644969|PLACEBO_COMPARATOR|Placebo Arm|Randomization 2:1 treatment to placebo
61990128|NCT00644969|ACTIVE_COMPARATOR|Treatment Arm|
61990129|NCT00225381||metabolic gas exchange and cardiac output|
61990130|NCT00225381||mass spectrometer and anaerobic metabolism|
61990131|NCT00225381||metaboic gas exchange and type of anesthesia induction|
61990132|NCT00225381||metabolic gas exchange and PEEP|
61990133|NCT00225381||metabolic gas exchange and trendelenburg position|
61990134|NCT00225381||Patients requiring tourniquet during surgery|Patients undergoing orthopaedic surgeries requiring tourniquet intervention. Oxygen consumption and CO2 production were measured before, during and after tourniquet release.
61990135|NCT00225381||Patients prone to metabolic acidosis|Oxygen consumption and CO2 measurements taken during long surgeries prone to metabolic acidosis.
61990136|NCT00105703|OTHER|Arm 1|
61990137|NCT00316199|EXPERIMENTAL|A|
62386094|NCT01520727|EXPERIMENTAL|BIA 9-1067 25 mg|BIA 9-1067 (Opicapone, OPC) - 25 mg
62386095|NCT01520727|EXPERIMENTAL|BIA 9-1067 50 mg|BIA 9-1067 (Opicapone, OPC) - 50 mg
62386096|NCT01520727|EXPERIMENTAL|BIA 9-1067 100 mg|BIA 9-1067 (Opicapone, OPC) - 100 mg
62386097|NCT01520727|EXPERIMENTAL|BIA 9-1067 200 mg|BIA 9-1067 (Opicapone, OPC) - 200 mg
62386098|NCT01520727|EXPERIMENTAL|BIA 9-1067 400 mg|BIA 9-1067 (Opicapone, OPC) - 400 mg
62559108|NCT03599817|EXPERIMENTAL|Healthy lifestyle promotion program|All the participants of the intervention program will be offered group sessions focused on healthy eating, promotion of physical activity and behavioral changes. In this way, the loss of body weight and the increase of physical activity will be promoted. Translating into an improvement in obesity parameters and cardiovascular and metabolic risk factors, to reduce the risk of developing type 2 diabetes.
62559109|NCT03650699|EXPERIMENTAL|Self-Directed Tongue Strengthening Rehab|"8 sessions of self-directed tongue strengthening exercises followed by 8 sessions of electropalatography biofeedback training.~Assessments will be taken during the beginning, middle, and end of each study arm."
62559110|NCT03650699|EXPERIMENTAL|SLP Directed Face-to-Face Rehab|"8 sessions of SLP-directed face-to-face rehabilitation program followed by 8 sessions of electropalatography biofeedback training.~Assessments will be taken during the beginning, middle, and end of each study arm."
62559111|NCT03784638|EXPERIMENTAL|lingually-based triangle flap design|In the experimental group, an incision will be made adjacent to the distal surface of the mandibular second molar, and extended along the sulcus to the distobuccal corner of the mandibular second molar. An oblique vestibular incision will made and extended into the vestibular fornix of the mandible, aligned with the mesiobuccal cusp of the second molar. It was continued posterosuperiorly towards the anterior border of mandibular ramus. The lingually-based triangle flap design will be used.
62767101|NCT03187834|ACTIVE_COMPARATOR|Azithromycin|"Comparison of nasopharyngeal and rectal microbiome in children receiving Azithromycin versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm and treated for 5 days.~Children will receive treatment everyday, once a day as is:~Azithromycin: 10 mg/kg once daily on Day 1, then 5 mg/kg once daily Days 2-5"
62767102|NCT03187834|ACTIVE_COMPARATOR|Amoxicillin|"Comparison of nasopharyngeal and rectal microbiome in children receiving Amoxicillin versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.~Children will receive treatment everyday, twice a day as is:~Amoxicillin: 25 mg/kg/day, divided into twice daily doses for Days 1-5"
62767103|NCT03187834|ACTIVE_COMPARATOR|Cotrimoxazole|"Comparison of nasopharyngeal and rectal microbiome in children receiving Cotri-moxazole versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.~Children will receive treatment everyday, once a day as is:~Co-trimoxazole: 240 mg daily for Days 1-5"
62767104|NCT03187834|PLACEBO_COMPARATOR|Placebo|"Comparison of nasopharyngeal and rectal microbiome in children receiving placebo versus children receiving antibiotics Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.~Children will receive Placebo everyday, once a day."
62386099|NCT01520727|EXPERIMENTAL|BIA 9-1067 800 mg|BIA 9-1067 (Opicapone, OPC) - 800 mg
62767105|NCT01289106|ACTIVE_COMPARATOR|Arm A|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
61990138|NCT01589757|PLACEBO_COMPARATOR|Standard Care|Standard care dietary advice to emphasize high fiber foods with a moderate to high GI
62386100|NCT01520727|EXPERIMENTAL|BIA 9-1067 1200 mg|BIA 9-1067 (Opicapone, OPC) - 1200 mg
62767106|NCT01289106|EXPERIMENTAL|Arm B|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
62767107|NCT01289106|EXPERIMENTAL|Arm C|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
62767108|NCT04932616||Face To Face (Clinic) Group Functional Gait Assessment|"Evaluations to be applied for the cultural adaptation and reliability study of the scale:~Functional Gait Assessment, Timed Up and Go Test, Four-Step Square Test, Timed 25-Foot Walk Test, 12-Item Multiple Sclerosis Walking Scale Berg Balance Scale"
62767109|NCT04932616||Tele- Assessment Group Functional Gait Assessment|"The evaluation to be applied for the tele-evaluation reliability study of the scale:~Functional Gait Assessment"
62767110|NCT05559125|EXPERIMENTAL|STSA-1002 and STSA-1005 dose level 1|
62767111|NCT05559125|EXPERIMENTAL|STSA-1002 and STSA-1005 dose level 2|
62767112|NCT05559125|EXPERIMENTAL|STSA-1002 and STSA-1005 dose level 3|
62767113|NCT05559125|EXPERIMENTAL|STSA-1002 and STSA-1005 dose level 4|
62767114|NCT04447014||Cohort 1|Subjects with confirmed adrenocortical cancer (ACC)
62767115|NCT01944579|EXPERIMENTAL|Control-Blackberry|Participants will receive a controlled diet with the control food (jello) first and then cross over to the controlled diet with blackberries.
62767116|NCT01944579|EXPERIMENTAL|Blackberry-Control|Participants will receive a controlled diet with blackberries first and then cross over to the controlled diet with the control food (jello).
62767117|NCT01498185|EXPERIMENTAL|Arm 1: Dapagliflozin (1 mg)|
61990139|NCT01589757|EXPERIMENTAL|Low GI Diet|Low GI dietary advice in addition to standard care
61990140|NCT05024500|EXPERIMENTAL|ADRSNet protocol|ARDSnet protocol is the current, standard of care for ARDS. Its used by setting PEEP and the fraction of inspired oxygen (FiO2) to achieve the oxygenation goal (SpO2 ≥ 93% - accepting the range of 90-96%)
62386101|NCT01520727|PLACEBO_COMPARATOR|Placebo|Placebo (PLC): single-dose
62767118|NCT01498185|EXPERIMENTAL|Arm 2: Dapagliflozin (2.5 mg)|
62767119|NCT01498185|EXPERIMENTAL|Arm 3: Dapagliflozin (5 mg)|
61990141|NCT05024500|EXPERIMENTAL|Driving Pressure (DP)|setting PEEP after performing a modified alveolar recruitment maneuver followed by a decremental PEEP titration electing the level correspondent to the lowest driving pressure.
62386102|NCT06333535|EXPERIMENTAL|Foot massage group|"Stage 1/Pretest: After the colonoscopy procedure, after the patients regained consciousness in the recovery unit, the Patient Introduction Form, Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were filled out.~2nd Stage/Intervention: The patients were massaged on both feet in accordance with the foot massage instructions.~3rd Stage / 30th minute: Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded. .~4th Stage / 2nd hour: Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded.~5th Stage / 4th Hour Abdominal Pain NRS Scale Form, Abdominal Distension NRS Scale Form and satisfaction (NRS satisfaction) scores were directed to the patients and recorded."
62559112|NCT03784638|PLACEBO_COMPARATOR|buccally based triangle flap design|In the control group, an incision will be made from the anterior border of the mandibular second molar. It will be extended along the sulcus to the distobuccal corner of the second molar crown. The incision will be continuous with vertical incision. The buccally based triangle flap design will be used.
62767120|NCT01498185|EXPERIMENTAL|Arm 4: Dapagliflozin (10 mg)|
62767121|NCT01498185|EXPERIMENTAL|Arm 5: Placebo matching Dapagliflozin|
62767122|NCT03381027|EXPERIMENTAL|Interventional Arm- Baby Massage|Interventional Arm= Baby Massage
62767123|NCT03381027|NO_INTERVENTION|Control Arm- no Baby Massage|Control Arm= no Baby Massage
62767124|NCT03675542|EXPERIMENTAL|Study medication|HSP90 inhibitor (CUDC-305)
62767125|NCT05108597|EXPERIMENTAL|Misoprostol (Study Group)|In study group, 400ug misoprostol will be administered through rectal route, 1 hour before surgery.
62386103|NCT06333535|EXPERIMENTAL|Abdominal massage group|"Stage 1/Pretest: After the colonoscopy procedure, after the patients regained consciousness in the recovery unit, the Patient Introduction Form, Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were filled out.~2nd Stage/Intervention: The patients were massaged in the abdominal area in accordance with the abdominal massage instructions.~3rd Stage / 30th minute: Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded. .~4th Stage / 2nd hour: Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded.~5th Stage / 4th Hour Abdominal Pain NRS Scale Form, Abdominal Distension NRS Scale Form and satisfaction (NRS satisfaction) scores were directed to the patients and recorded."
62386104|NCT06333535|EXPERIMENTAL|Foot and Abdominal massage group|"Stage 1/Pretest: After the colonoscopy procedure, after the patients regained consciousness in the recovery unit, the Patient Introduction Form, Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were filled out.~2nd Stage/Intervention: The patients were massaged in the abdominal area in line with the abdominal massage instructions, and then both feet were massaged in line with the foot massage instructions.~3rd Stage / 30th minute: Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded.~4th Stage / 2nd hour: Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded.~5th Stage / 4th Hour Abdominal Pain NRS Scale Form, Abdominal Distension NRS Scale Form and satisfaction (NRS satisfaction) scores were directed to the patients and recorded."
62386105|NCT06333535|NO_INTERVENTION|Control group|"Stage 1/Pretest: After the colonoscopy procedure, after the patients regained consciousness in the recovery unit, the Patient Introduction Form, Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were filled out.~Stage 2/Attempt: No attempt was made. 3rd Phase / 30th minute: Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded.~4th Stage / 2nd hour: Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded.~5th Stage / 4th Hour Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded."
62386106|NCT04561739|EXPERIMENTAL|Drug-coated balloon|
62386107|NCT04561739|ACTIVE_COMPARATOR|Drug-eluting stent|
61990142|NCT05024500|EXPERIMENTAL|Electrical Impedance Tomography (EIT)|After performing a modified alveolar recruitment maneuver, the PEEP decremental titration guided by the EIT will be set at the level above the intersection of the curves representing relative alveolar overdistention and collapse.
61990143|NCT01454921|EXPERIMENTAL|Intervention I|"Intervention group participants will be enrolled for the duration of one intervention program, which will last approximately 6 months. Each intervention program will consist of two individual and six group intervention sessions with each session lasting approximately 2-3 hours.~Intervention participants will also complete two ACASI assessments (baseline and post-intervention) lasting approximately 1.5-2 hours each."
61990144|NCT01454921|EXPERIMENTAL|Intervention II|"Intervention group participants will be enrolled for the duration of one intervention program, which will last approximately 6 months. Each intervention program will consist of two individual and six group intervention sessions with each session lasting approximately 2-3 hours.~Intervention participants will also complete two ACASI assessments (baseline and post-intervention) lasting approximately 1.5-2 hours each."
61990145|NCT02562651|EXPERIMENTAL|Doxycycline|100 mg of Doxycycline bid for seven days in pts with STEMI underwent PCI (percutaneous coronary intervention) and with current medical therapy
61990146|NCT02562651|ACTIVE_COMPARATOR|Active comparator|Standard care for STEMI
62386108|NCT04427306|EXPERIMENTAL|Treatment (talimogene laherparepvec)|This study all subject get the research treatment drug (talimogene laherparepvec)
62386109|NCT05637749|EXPERIMENTAL|Control|Serious game intervention to be played as is, without facilitation.
62386110|NCT05637749|ACTIVE_COMPARATOR|Intervention|Serious game intervention to be played with facilitator present in game environment.
62386111|NCT02017366|NO_INTERVENTION|Control|Control group = standard of Care regimen: 1000ml = 1000 kCal TPN postop from day 1 until day 7. Oral feeds are started from day 5 onwards if no arguments for clinical leak (cervical anastomosis) or barium swallow is normal. Oral intake consists of regular post gastrectomy diet (building up from fluids over semi-solids to solids) with eventually added high nitrogen energy drinks.
62386112|NCT02017366|ACTIVE_COMPARATOR|Enteral feeding|Treatment group: start jejunostomy feeds from day 1, with target of 1000ml = 1000kCal (= 40cc/hour). To equilibrate energy intake during build up fase, Glucose 20% is given at a total cumulative dose taking into account the dose of j-drip, cumulative not exceeding 40cc/hr. Oral feeds are started at the same time as in the control group (reg. day 5) Jejunostomy feeds are then continued for 6 weeks together with oral intake with a continuous energy administration of 1000kCal, and then stopped. After this time, patients should be on regular full diet in both groups. If failure and step-back needed, temporary switch to Glc 20% is done to maintain fluid and calory administration.
62386113|NCT01808911|ACTIVE_COMPARATOR|Bras A|Steroid 1mg/kg/d and Cyclophosphamide 2mg/kg/d
62767126|NCT05108597|NO_INTERVENTION|No drug|In control group no dose will be administered
62767127|NCT00490022|ACTIVE_COMPARATOR|1|DHT gel (70 mg/day) for one month
62767128|NCT00490022|PLACEBO_COMPARATOR|2|Placebo gel for one month
62182669|NCT03100955|ACTIVE_COMPARATOR|EP chemotherapy|Standard treatment or active comparator group contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide.
61990147|NCT05602415|EXPERIMENTAL|Surgery + Dose Reduced Radiotherapy + Anlotinib|"Surgery would be performed to resect soft tissue sarcoma with as wide margin as possible. Important vessels and nerves should be preserved.~Postoperative radiotherapy would be performed. Postoperative intensity-modulated RT (IMRT) will be performed (50 Gy in 2.0 Gy per fraction).~Anlotinib of 12mg will be administered orally, once daily, 2-days on/1-day off, until disease progression according to RECIST 1.1, death, unacceptable toxicity, or withdrawal of consent for any reasons. A cycle was considered to be 3 weeks. Anlotinib should be started 3-4 weeks after surgery, and continued for 3 months (4 cycles)."
61990148|NCT05200754|EXPERIMENTAL|Convalescent/Vaccine-boosted Plasma|Infusion of plasma on day 1 and 2 (238 - 337 ml anti-SARS-Cov-2 CP/PVP each)
61990149|NCT05200754|NO_INTERVENTION|Standard of Care|No intervention - standard therapy
61990150|NCT05261984|EXPERIMENTAL|Former ICU patients|Research subjects with a prior history of ICU treatment within six months.
62767129|NCT01310023||Static Cohort- closed to enrollment and follow-up|HIV-uninfected children \< 12 years of age at the time of enrollment, born of HIV-infected mothers
61990151|NCT05261984|ACTIVE_COMPARATOR|Age- and sex-matched control group|Research subjects without a prior history of ICU treatment within the last 30 years, age- and sex-matched in a 1:2 ratio to the experimental arm.
61990152|NCT03304847|OTHER|Ablation|Radio-frequency catheter ablation
61990153|NCT04272528|EXPERIMENTAL|experimental group|Nurses provide uniform care to patients according to the quality standards.
61990154|NCT04272528|PLACEBO_COMPARATOR|control group|Nurses provide the routine care to patients.
61990155|NCT01661712|ACTIVE_COMPARATOR|Transcutaneous electrical stimulation|One night of transcutaneous electrical stimulation (electrical current titrated according to skin sensation)
61990156|NCT01661712|SHAM_COMPARATOR|Sham stimulation|One night of sham stimulation (no electrical current)
61990157|NCT04278521|OTHER|Unipolar Depression|Patients diagnosed with unipolar depression.
61990158|NCT05213923|NO_INTERVENTION|Pre-intervention|Patients presenting to the Emergency Department meeting severe sepsis criteria prior to implementation of an ED Sepsis Tracking Sheet
61990159|NCT05213923|EXPERIMENTAL|Post-intervention|Patients presenting to the Emergency Department meeting severe sepsis criteria following implementation of an ED Sepsis Tracking Sheet
61990160|NCT02233322|EXPERIMENTAL|iron supplements|all subjects will receive iron supplementation based on iron levels in blood
61990161|NCT05929183|ACTIVE_COMPARATOR|Repetitive Transcranial magnetic stimulation|
61990162|NCT05929183|SHAM_COMPARATOR|Sham Repetitive Transcranial magnetic stimulation|
61990163|NCT04931433|EXPERIMENTAL|Lignocaine|This arm will receive intravenous Lignocaine bolus and infusion
61990164|NCT04931433|PLACEBO_COMPARATOR|Placebo|This arm will receive Normal saline 0.9% bolus and infusion
61990165|NCT03462550|ACTIVE_COMPARATOR|LMA Supreme|
61990166|NCT03462550|EXPERIMENTAL|LMA Protector|
61990167|NCT01336075|ACTIVE_COMPARATOR|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic radiofrequency ablation
61990168|NCT01336075|ACTIVE_COMPARATOR|Percutaneous ablation|Percutaneous radiofrequency catheter ablation
61990169|NCT04145778||Patient|
61990170|NCT04145778||Control|
61990171|NCT06036576|ACTIVE_COMPARATOR|Thyroid Stimulating Hormone 2.5-4 mU/L|This arm consists of participants who have experienced recurrent pregnancy loss in the first trimester and have TSH levels ranging between 2.5 mU/L and 4 mU/L. These participants will receive levothyroxine treatment of 1.6 micrograms per kg per day
61990172|NCT06036576|ACTIVE_COMPARATOR|Thyroid Stimulating Hormone more than 4 mU/L|This arm consists of participants who have experienced recurrent pregnancy loss in the first trimester and have TSH levels more than 4 mU/L. These participants will receive levothyroxine treatment of 1.6 micrograms per kg per day
61990173|NCT00643422||Observation|
61990174|NCT01052207||Critically Ill Patients|Evaluation of Oxidative Stress, Glucocorticoid Receptor function, and Adrenal Insufficiency amongst critically ill pediatric patients. Serum, and when available endotracheal samples, will be obtained within 24 hours of admission and at 5 days provided patients are 1) still in the PICU and 2) blood draws and endotracheal aspirates are part of their standard of care. Endotracheal aspirates will be sent on day 14, 21, and 28 provided patients are intubated and require suctioning as part of their standard of care.
61990175|NCT01052207||Healthy Controls|Healthy controls will be evaluated and defined as those who do not have any chronic medical condition, are not on steroids (inhaled or oral), and have not received steroids or etomidate in the last month. Given the time and need for multiple lab draws low dose adrenocorticotropin (ACTH) testing will not be done in healthy patients, nor will tracheal aspirate samples be obtained.
61990176|NCT04330560|EXPERIMENTAL|Ex group|Receive CR telerehabilitation (exercise telemonitoring link to the healthcare platform + teleconsultation)
62767130|NCT01310023||Dynamic Cohort|HIV-uninfected children born of HIV-infected mothers enrolled from prior to birth through ≤ 72 hours of age
62767131|NCT01310023||Reference Cohort- closed to enrollment and follow-up|HIV-uninfected children born to a mother HIV uninfected at the time of the child's birth enrolled at 1, 3, 5, or 9 years of age(± 3 months) at the time of the study visit
62767132|NCT01310023||Young Adult Cohort- closed to enrollment and follow-up|Former Dynamic and Static Cohort participants ≥ 18 years of age.
62386114|NCT01808911|EXPERIMENTAL|Bras B|Steroid 1mg/kg/d and Rituximab 375 mg/m2 every week during four weeks
62386115|NCT02950168||Edoxaban|All patients treated with edoxaban with a planned or unplanned diagnostic or interventional procedure
62386116|NCT02679222|EXPERIMENTAL|Supplementation|Protocol involved seven separate but identical metabolic study days for each participant. the test substances were evaluated in random order: vehicle (Control) or 20 mL of the test oils (Coconut oil; tricaprin; tricaprylin; MCT \[tricaprylin/tricaprin\]; coconut oil + MCT \[50:50\]; Coconut oil + tricaprylin \[50:50\]) taken twice, once at breakfast and once at mid-day.
62386117|NCT03647059||LSCM examination|
62386118|NCT00708344|ACTIVE_COMPARATOR|Group 1|Usual elective titration regimen
62559113|NCT00750425|EXPERIMENTAL|1|Cediranib alone, followed by cediranib plus ketoconazole, followed by cediranib alone
62767133|NCT01374659||Study patients|Study patients with histologically proven DTC were studied. All patients had previously undergone total thyroidectomy and more than one session of postoperative RI therapy. After the last RI therapy session, all patients showed increasing pathological Tg levels (Tg \> 9-10 ng/ml) after TSH stimulation (TSH \> 30 mU/l). However, neither tumor recurrence nor metastasis could be detected in any patient by post-therapeutic \[131I\] scanning, neck US, or chest radiography. Patients with obvious cervical pathology or positive fine-needle aspiration cytology (FNAC) were excluded from the study. The work was approved by our Institutional Review Board and written informed consent was obtained from each patient.
62767134|NCT06218706|EXPERIMENTAL|LIFU Treatment|
62767135|NCT06218706|SHAM_COMPARATOR|Sham treatment|
62767136|NCT05302622|OTHER|Group 1|Have surgical experience both laparoscopy and laparotomy and senior resident
62767137|NCT05302622|OTHER|Group 2|Have surgical skills only laparotomic gynecologic procedures and in the middle of his/her residency
62767138|NCT05302622|OTHER|Group 3|Have no surgical experience on gynecologic procedures and newbie residents
62767139|NCT03331783|EXPERIMENTAL|Test of new adhesive strips|"On the peristomal skin 4 different patches are applied to the skin (Standard hydrocolloid adhesive patch; LT-2, LT21 and 33-20. There is a bag welded to each patch. Tthe bag contains real output.~The difference between the four patches is that they are made of four different adhesives.~The primary endpoint is measured after 8 hours and 24 hours."
62767140|NCT00741702|EXPERIMENTAL|Intervention group|A home care nurse followed a predefined treatment algorithm of pharmacologic antihypertensive therapy.
62767141|NCT00741702|NO_INTERVENTION|Control group|Treatment decisions were made by each subject's primary care physician. Participants in this group received usual care.
62386119|NCT00708344|ACTIVE_COMPARATOR|Group 2|Active elective titration regimen
62386120|NCT00229242|ACTIVE_COMPARATOR|1|Diuretic-Based Hypertension Therapy
62386121|NCT00229242|ACTIVE_COMPARATOR|2|Non-Diuretic-Based Hypertension Therapy
62386122|NCT03976882|EXPERIMENTAL|Group A：Hetrombopag|
62386123|NCT03976882|PLACEBO_COMPARATOR|Group B：Placebo|
62386124|NCT04333628|EXPERIMENTAL|low dose chloroquine|oral chloroquine 125mg daily for 7 days (or until the condition worsens, whichever comes first)
62386125|NCT04333628|EXPERIMENTAL|Regular dose chloroquine|oral chloroquine 500 mg twice daily for 7 days (or until the condition worsens, whichever comes first)
62386126|NCT04333628|OTHER|Standard of care|The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.
62386127|NCT03710460|EXPERIMENTAL|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
62386128|NCT03710460|EXPERIMENTAL|Dapagliflozin plus metformin XR|Dapagliflozin plus metformin XR capsules, 10/1000 mg, one per day before breakfast during 12 weeks.
62386129|NCT03710460|EXPERIMENTAL|Metformin XR|Metformin XR capsules, 1000 mg, one per day before breakfast during 12 weeks.
62386130|NCT03171142|ACTIVE_COMPARATOR|Heliox group|receive Helium oxygen mixture 21:79 via nasal cannula 2L/min
62386131|NCT03171142|ACTIVE_COMPARATOR|Air group|receive oxygen 21%via nasal cannula 2L/min
62386132|NCT01711931|ACTIVE_COMPARATOR|Everolimus-eluting bioresorbable vascular scaffold stents|
62386133|NCT01711931|ACTIVE_COMPARATOR|Everolimus-eluting stent|
62767142|NCT01073124|ACTIVE_COMPARATOR|Normal Saline|Normal Saline injected intraarticularly into the knee joint
62767143|NCT01073124|EXPERIMENTAL|Dilute Methylene Blue Dye|1 ml methylene blue dye per 500 ml normal saline injected intraarticularly into the knee
62767144|NCT03283397|EXPERIMENTAL|EK-12|This arm will be treated with 12 mg EK-12 in 2 mL 0.9 % NaCl solution (SC, three times per week) for 144 weeks
62767145|NCT03283397|ACTIVE_COMPARATOR|INF Beta-1a|This arm will be treated with 44 mg INF Beta-1a in 0.5 mL solution (SC, three times per week) for 144 weeks
61990177|NCT04330560|ACTIVE_COMPARATOR|Com group|Receive CR telerehabilitation (exercise self-monitoring + teleconsultation)
62386134|NCT01711931|ACTIVE_COMPARATOR|Biolimus-eluting stent|
62386135|NCT03281239|EXPERIMENTAL|welder/airport agent|No drug and no placebo were used in this study.
62386136|NCT04868513|EXPERIMENTAL|Pregnant women to whom applied silane fluoride|We applied 0.1% silane fluoride (Fluor Protector, Ivoclar Vivadent AG™) as varnish in all teeth on all faces as a promotion strategy on the reduction of S. mutans.
62386137|NCT04868513|EXPERIMENTAL|Pregnant women to whom applied silane fluoride + 1% chlorhexidine|We applied 0.1% silane fluoride (Fluor Protector, Ivoclar Vivadent AG™) and 1% chlorhexidine (Cervitec, Ivoclar Vivadent AG™), both applied as varnish, with a 1 min interval between applications, in all teeth on all faces, using the standardized technique indicated by the manufacturer as a promotion strategy on the reduction of S. mutans.
62559114|NCT01321879|EXPERIMENTAL|Telavancin|10 or 7.5 mg/kg intravenous daily
62559115|NCT02818101|NO_INTERVENTION|Control group|No hypnosis session before the coronary angiography
62559116|NCT02818101|EXPERIMENTAL|Hypnotised group|Hypnosis session before the coronary angiography
62559117|NCT05961956|EXPERIMENTAL|NVDX3 osteogenic implant|
62767146|NCT01972698|EXPERIMENTAL|Self-directed and simulation-assisted training|
62767147|NCT01972698|ACTIVE_COMPARATOR|Traditional apprenticeship training|
62767148|NCT05077358|EXPERIMENTAL|Intracorporeal anastomosis|In this group, the anastomosis is performed inside the abdominal cavity with a laparoscopic technique. Specimen extraction will be done through Pfannenstiel incision or similar incision in lower abdomen.
62767149|NCT05077358|ACTIVE_COMPARATOR|Extracorporeal anastomosis|In this group, the anastomosis is performed by pulling out the bowel through a laparotomy.
61990178|NCT04330560|PLACEBO_COMPARATOR|C group|Standard care - traditional center-based CR
61990179|NCT01859494|EXPERIMENTAL|Users of the Monitoring System|Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.
61990180|NCT05928585|EXPERIMENTAL|MAD HIB210|Increasing doses of HIB210 will be administered for cohorts 1-4 in a multiple ascending dose format
61990181|NCT05928585|PLACEBO_COMPARATOR|MAD Placebo|Placebo will be administered for cohorts 1-4 in a multiple ascending dose format
61990182|NCT04014075|EXPERIMENTAL|All participants|Participants who have centrally confirmed HER2-positive gastric or gastro-esophageal junction cancer will be treated with trastuzumab deruxtecan by intravenous (IV) infusion every 3 weeks, until progression of disease or withdrawal from treatment for other reasons.
61990183|NCT02719132|EXPERIMENTAL|Arm 1|Arm 1 - therapy with dapagliflozin 10 mg once daily in combination with metformin ≤ 1,500 mg (daily dose) for 24 weeks (Treatment Regimen 1) followed by metformin monotherapy with dose titrated up to 2,500 mg/day for further 24 weeks (Treatment Regimen 2)
61990184|NCT02719132|ACTIVE_COMPARATOR|Arm 2|Arm 2 - metformin monotherapy with dose titrated up to 2,500 mg/day for 24 weeks (Treatment Regimen 2) followed by therapy with dapagliflozin 10 mg once daily in combination with metformin ≤ 1,500 mg (daily dose) for further 24 weeks (Treatment Regimen 1)
61990185|NCT03573986|EXPERIMENTAL|Arm A|
61990186|NCT04914390|EXPERIMENTAL|Tislelizumab + Anlotinib + Chemotherapy|Participants receive Tislelizumab every 3 weeks (Q3W) + Anlotinib d1-14 (Q3W) + AT regimen (Q3W) x 6 cycles as neoadjuvant therapy prior to surgery.
61990187|NCT04819555||adult patients with ALS|incident population of ALS patients followed in the FILSLAN centres.
61990188|NCT03136003|EXPERIMENTAL|Arm A: DDAVP followed by exercise|"Intervention #1: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing \<50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: Exercise"
61990189|NCT03136003|ACTIVE_COMPARATOR|Arm B: DDAVP alone|"Intervention #1: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing \<50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: no further intervention (rest)"
61990190|NCT03136003|EXPERIMENTAL|Arm C: Exercise alone|"Intervention #1: Exercise~Intervention #2: no further intervention (rest)"
61990191|NCT03136003|EXPERIMENTAL|ARM D: Exercise followed by DDAVP|"Intervention #1: Exercise~Intervention #2: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing \<50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril)."
61990192|NCT04045496|EXPERIMENTAL|JAB-3312|JAB-3312 will be administered orally once daily in 21 days treatment cycles.
61990193|NCT00859235|ACTIVE_COMPARATOR|1|
61990194|NCT00859235|PLACEBO_COMPARATOR|2. Plain water|
61990195|NCT03121092|NO_INTERVENTION|Discontinue ACEI or ARB|Patients in this group will not take the ACE or ARB 24 hours prior to their procedure.
61990196|NCT03121092|ACTIVE_COMPARATOR|Continue ACEI or ARB|Patients in this group will take an ACE or ARB on the day of surgery.
61990197|NCT00847288|EXPERIMENTAL|Monthly Review Arm|Patients enrolled at centers that are assigned to the monthly review arm will have their device data reviewed monthly
61990198|NCT00847288|ACTIVE_COMPARATOR|Quarterly Review Arm|Patients enrolled at centers that are assigned to the quarterly review arm will have their device data reviewed every 3 months
61990199|NCT03234660|EXPERIMENTAL|Dexmedetomidine|dexmedetomidine infusion
61990200|NCT03234660|PLACEBO_COMPARATOR|control|placebo infusion
61990201|NCT01548131|EXPERIMENTAL|Psychoeducative group therapy|Psychoeducative group therapy
61990202|NCT01548131|NO_INTERVENTION|Control|Women screened for fear of childbirth were taken cared by primary health care nurses and if needed referred to specialized care in hospital
61990203|NCT04991181|EXPERIMENTAL|BIA 5-1058|Capsules; 400 mg; single dose; oral administration.
61990204|NCT03638310|EXPERIMENTAL|ITG (intratympanic gentamicin) group|Patients who underwent prehabituation by gentamicin prior to surgery for vestibular schwannoma. They underwent intratympanic application of gentamicin and microsurgical removal of vest. schwannoma.
61990205|NCT03638310|ACTIVE_COMPARATOR|control group|patients without prehabituation before surgery. They underwent microsurgical removal of vest. schwannoma.
61990206|NCT05928052|EXPERIMENTAL|ARDS cohort|Patient diagnosed with ARDS. Treated daily for 60 minutes with transcutaneous cervical and/or thoracic spinal stimulation
61990207|NCT05928052|EXPERIMENTAL|Surgery Cohort (Active)|Patient undergoing inpatient non-cardiac surgery admitted to the intensive care unit (ICU) after surgery. Treated daily for 60 minutes with transcutaneous cervical and/or thoracic spinal stimulation
61990208|NCT00624806|EXPERIMENTAL|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers
61990209|NCT00624806|ACTIVE_COMPARATOR|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
61990210|NCT03042052||Patients suffering from NDO managed with Botox|"Doses used were 300 units Botox® from January 2001 to January 2011 and 200 units after 2011~Frequency depended on patient's symptoms~Duration was an outcome of the study"
61990211|NCT01335230||10 HIV mono-infected subjects|10 subjects infected with HIV only
61990212|NCT01335230||10 HCV mono-infected subjects|10 subjects infected with HCV only
61990213|NCT01335230||10 HIV/HCV co-infected subjects|10 subjects infected with both HIV and HCV
62767150|NCT04976933||Primary Caregivers|Primary caregivers of children receiving Tacrolimus or cyclosporine immunosuppression for an allogeneic transplant will be introduced to the mHealth adherence app and allowed the opportunity to interact with the app alongside research staff. Following this session primary caregivers are asked to use the app at home until Day 100 or weaning of immunosuppressant, whichever is first.
62767151|NCT05063266|ACTIVE_COMPARATOR|Group A|Deep Breathing exercise
62767152|NCT05063266|EXPERIMENTAL|Group B|Inspiratory Muscle Training
62386138|NCT04868513|NO_INTERVENTION|Children of the pregnant women to whom it was applied silane fluoride|The children not given any intervention, they were only subjected to a microbiological and clinical examination.
62386139|NCT04868513|NO_INTERVENTION|Children of the pregnant women to whom it was applied silane fluoride + 1% chlorhexidine|The children not given any intervention, they were only subjected to a microbiological and clinical examination.
62559118|NCT01823861|EXPERIMENTAL|Mobile phone-based intervention|Standard care plus automated voice message to support post-abortion contraception use every two weeks for total of three months and direct follow up phone call by family planning counsellor depending on response to voice message.
62767153|NCT04485572||Straight Leg Raise test and Bragard test|Patients referred to the radiology department, allocated to undergo MRI scan and neurodynamic tension tests
62767154|NCT04485572||Fajersztajn test (F) and Sicard test (S)|Patients referred to the radiology department, allocated to undergo MRI scan and neurodynamic tension tests
62767155|NCT04485572||Passive Neck Flexion test (PNF)and Kernig test (K)|Patients referred to the radiology department, allocated to undergo MRI scan and neurodynamic tension tests
62767156|NCT04485572||Slump test (ST) and Dejerine triad (DT)|Patients referred to the radiology department, allocated to undergo MRI scan and neurodynamic tension tests
62386140|NCT05837429|EXPERIMENTAL|Low Volume High Intensity Exercise Training|Patients in the intervention group will be given a warm-up phase for 3 minutes at 50% VO2max, 1 minute at 80-100% VO2max and 1 minute at 50% VO2max in 10 cycles, and finally a cool-down phase for 3 minutes at 50% VO2max.
62767157|NCT05556213|ACTIVE_COMPARATOR|Patients|
62767158|NCT05556213|ACTIVE_COMPARATOR|Control|
61990214|NCT01335230||10 control subjects|10 subjects without HIV, HCV, or both
62386141|NCT05837429|ACTIVE_COMPARATOR|Aerobic Exercise|Patients in the control group will be given exercise training on a bicycle ergometer for 5 minutes warm-up phase at 40% of maximal oxygen consumption (VO2max), 20 minutes exercise phase at 60% of VO2max and 5 minutes cool down phase at 40% of VO2max for a total of 30 minutes.
62386142|NCT05465785|EXPERIMENTAL|Pilot batch|Three doses of Recombinant COVID-19 vaccine (Sf9 cell) at the schedule of day 0, 21，42.
62386143|NCT05465785|ACTIVE_COMPARATOR|Commercial batch|Three doses of Recombinant COVID-19 vaccine (Sf9 cell) at the schedule of day 0, 21，42.
62559119|NCT01823861|NO_INTERVENTION|Standard care|Face-to-face post-abortion family planning (PAFP) counselling, follow-up at one or two weeks, clinic phone number, existing 'Hotline' phone number.
62559120|NCT03707405|ACTIVE_COMPARATOR|ROC-sit|Ride-On Cars with Sitting Posture (ROC-sit) The 2-hour training session is composed of a 70-minute driving session and a 40-to-50-minute natural play session, with a 10-mintue break if necessary. The natural play session can be divided into two 20-to-25 sessions depending on the participant's condition. Training will concentrate on building the concept of casual-effect on the switch and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person) in public spaces (e.g., hallways, convenient stores, garden, museum) and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying motor skills for mobility and socialization in natural play session. All the programs will be discussed by the family, the treating therapist and the research team.
61990215|NCT04196946|EXPERIMENTAL|Group I|25 mcg fentanyl intrathecally
62386144|NCT04865016|ACTIVE_COMPARATOR|MIOL Group|30 eyes of 15 cataract patients undergoing cataract surgery were implanted with a low add (+2.75 Diopters \[D\]) bifocal (Tecnis ZKB00; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (MIOL Group).
62386145|NCT04865016|ACTIVE_COMPARATOR|EDOF Group|30 eyes of 15 cataract patients undergoing cataract surgery were implanted with an EDOF (Tecnis Symfony \[ZXR00\]; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (EDOF Group).
62386146|NCT01145833|ACTIVE_COMPARATOR|Immediate treatment group|The immediate treatment group begins the 5-month treatment immediately after baseline assessment.
62386147|NCT01145833|OTHER|Delayed Treatment Group|The delayed treatment group serves as the control group. This group starts treatment 5 months after the baseline assessment. No intervention is involved during this 5-month waiting period. After 5 months, the delayed group is assessed for the second time and then begins the 5-month treatment.
62386148|NCT02183792|EXPERIMENTAL|Tolvaptan|Tolvaptan 30-60mg once daily (with rescue loop diuretic or metolazone)
62386149|NCT02183792|ACTIVE_COMPARATOR|Furosemide|Furosemide continuous infusion 5mg/h with option to titrate (with rescue metolazone)
62386150|NCT01172795||healthy controls|
62386151|NCT01172795||chronic whiplash patients|
62386152|NCT01172795||Fibromyalgia patients|
62386153|NCT04005885|EXPERIMENTAL|somofilcon A then stenfilcon A contact lens|Participants were fitted with comfilcon A lens on a daily wear, reusable basis for 1 month, then randomized to wear somofilcon A daily disposable test lens for 1 week of daily wear and stenfilcon A daily disposable test lens for 1 week of daily wear.
62767159|NCT03109691|ACTIVE_COMPARATOR|group 1|30 patients will receive bupivacaine
62767160|NCT03109691|ACTIVE_COMPARATOR|group 2|30 patients will receive bupivacaine and Dexamethasone. .
62767161|NCT05920473|EXPERIMENTAL|rTMS intervention group|Participants will undergo rTMS treatment using the Magstim Rapid 2 magnetic stimulation device. The coil was placed positioned tangentially on the scalp, targeting the hot spot (thumb movement area) in the ipsilateral cerebral hemisphere. The stimulation protocol will involve 10-Hz stimulation for 2 seconds, followed by a followed by a 10-second rest, which was repeated 50 times. Patients will receive treatment once a day, five days a week (Monday to Friday), for a total of two consecutive weeks.
62767162|NCT05920473|SHAM_COMPARATOR|Sham group|Patients in the sham group underwent sham stimulation using the Magstim Rapid 2 magnetic stimulation device with the same protocol. The coil was positioned to target the same hot spot, with an angulation parallel to the gyrus to the gyrus in order to additionally minimize the rTMS effect.
62559121|NCT03707405|ACTIVE_COMPARATOR|ROC-sit45 and stand25|Ride-On Cars with 45-min Sitting and 25-min Standing Postures (ROC-sit45 and stand25) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute driving session begins with a 45-minute driving with sitting posture and then transfers to the standing posture for driving 25 minutes.
62559122|NCT03707405|ACTIVE_COMPARATOR|ROC-sit25 and stand45|Ride-On Cars with 25-min Sitting and 45-min Standing Postures (ROC-sit25 and stand45) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute driving session begins with a 25-minute driving with sitting posture and then transfers to the standing posture for driving 45 minutes.
62559123|NCT03707405|ACTIVE_COMPARATOR|ROC-stand|Ride-On Cars with Standing Postures (ROC-stand) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute standing session can be divided into two 30-minute sessions with 10-minute break, depending on the child's condition with the standing posture.
62559124|NCT01786993|EXPERIMENTAL|Multi-point pacing arm|MultiPoint Pacing
62559125|NCT01786993|ACTIVE_COMPARATOR|Biventricular arm|Traditional Biventricular Pacing
62559126|NCT02046044|EXPERIMENTAL|Ivabradine|Ivabradine: initial dose of 5 mg b.id. dose up-titration to 7,5 mg b.id. in 2 weeks due to the heart rate and maintaining the last dose during 6 months.
62559127|NCT02046044|EXPERIMENTAL|Digoxin|Digoxin: Digoxin 0,25 mg once a day 5 days per week during 6 months.
62559128|NCT01796678|EXPERIMENTAL|Arginine|100 mg/kg T.I.D 3x a day IV or PO
62559129|NCT01796678|PLACEBO_COMPARATOR|Placebo|Saline or sugar pill
62559130|NCT01818882|ACTIVE_COMPARATOR|Standard care|"Patients randomized to this arm will receive standard care.~Intervention: Standard care."
62559131|NCT01818882|EXPERIMENTAL|Standard care + ultrasound|"Patients randomized to this arm will receive standard care + pleuropulmonary ultrasound.~Intervention: Standard care + ultrasound"
62559132|NCT03691857|OTHER|Acute non-traumatic dyspnea patients|Patients with acute non-traumatic dyspnea managed in the emergency department to assess the diagnostic accuracy of an ultrasound algorithm (EMERALD-US) dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation)
62559133|NCT05736354||BII Subjects|Subjects with breast implants having BII manifestations.
62559134|NCT05736354||Non-BII Subjects|Subjects with breast implants with no reported BII symptoms.
62559135|NCT05736354||Subjects without Breast Implants|Subjects without breast implants.
62559136|NCT06453083|PLACEBO_COMPARATOR|Placebo tablets|Encapsulated placebo tablets per day (dosage for day 1 following the surgery is 32mg, day 2 is 24mg, day 3 is 16mg, day 4 is 12mg, day 5 is 8mg and day 6 is 4mg.)
62559137|NCT06453083|EXPERIMENTAL|Medrol tablets|Encapsulated steroid Medrol tablets (dosage for day 1 following the surgery is 32mg, day 2 is 24mg, day 3 is 16mg, day 4 is 12mg, day 5 is 8mg and day 6 is 4mg)
62559138|NCT01390636||ED-DMT1 and ED/only|Eating Disorder and Type 1 Diabetes and only an Eating Disorder
62559139|NCT00383253|EXPERIMENTAL|10%|
62559140|NCT00383253|EXPERIMENTAL|25%|
62559141|NCT00383253|EXPERIMENTAL|50%|
62559142|NCT00383253|PLACEBO_COMPARATOR|Control|
62559143|NCT03830333|EXPERIMENTAL|Ceftolozane/Tazobactam + Metronidazole|Participants receive ceftolozane/tazobactam 1500 mg (ceftolozane 1000 mg + tazobactam 500 mg) plus metronidazole 500 mg administered as an intravenous (IV) infusion every 8 hours for 4 to 14 days (per protocol, ceftolozane/tazobactam may be adjusted to 500 mg/250 mg if creatinine clearance \[CrCL\] is 30 to ≤50 mL/min)
62559144|NCT03830333|ACTIVE_COMPARATOR|Meropenem + Placebo|Participants receive meropenem 1000 mg plus saline administered as an IV infusion every 8 hours for 4 to 14 days (per protocol, meropenem may be adjusted to every 12 hours if CrCL was 30 to ≤50 mL/min).
62559145|NCT06092801||Individuals suspected of coronary artery disease|Individuals suspected of coronary artery disease and referred for evaluation
62559146|NCT04563663|EXPERIMENTAL|One session|One session of talus posteriorization.
62559147|NCT04563663|EXPERIMENTAL|Two sessions|Two sessions of talus posteriorization.
62559148|NCT04563663|EXPERIMENTAL|Three sessions|Three sessions of talus posteriorization.
62559149|NCT04563663|EXPERIMENTAL|Four sessions|Four sessions of talus posteriorization.
62559150|NCT06076993|EXPERIMENTAL|BodyKind programme group|The intervention group will receive the BodyKind body image programme. The four 50 minute lessons of the BodyKind programme will be delivered by teachers at a rate of 1 lesson per week over four consecutive weeks.
62559151|NCT06076993|NO_INTERVENTION|Waitlist control|The waitlist control group will engage in classes as usual and will receive the BodyKind programme after data is collected.
62559152|NCT05854004|OTHER|Therapeutic Ultrasound|
62559153|NCT05854004|OTHER|Myofascial Release Technique|
62559154|NCT00185289|EXPERIMENTAL|Arm 1|
62559155|NCT04085211||Inflammatory Bowel Disease|Patients with an established diagnosis of ulcerative colitis or Crohn's Disease who require either a flexible sigmoidoscopy or colonoscopy as part of routine care (e.g. surveillance or staging disease activity)
62559156|NCT04085211||Patients with symptoms of gastro-oesophageal reflux disease|Patients with symptoms of gastro-oesophageal reflux disease requiring a gastroscopy as part of routine clinical care.
62559157|NCT04085211||Atrophic gastritis|Patients with known or suspected atrophic gastritis that require a gastroscopy to either confirm the diagnosis or surveillance for pre-cancerous changes.
62559158|NCT04085211||Neuroendocrine Tumours|Patients with an established history of gastric neuroendocrine tumours requiring surveillance
62767163|NCT03690271||Groupe 5-5|"Patients for whom the clinician has prescribed local anesthetics in the epidural:~* fixed dose administered every hour in a systematic way : 5 ml~* dose to be administered every hour by the patient : 5 ml"
62767164|NCT03690271||groupe 6-6|"Patients for whom the clinician has prescribed local anesthetics in the epidural:~* fixed dose administered every hour in a systematic way : 6 ml~* dose to be administered every hour by the patient : 6 ml"
62767165|NCT03690271||groupe 7-7|"Patients for whom the clinician has prescribed local anesthetics in the epidural:~* fixed dose administered every hour in a systematic way :7 ml~* dose to be administered every hour by the patient :7 ml"
62767166|NCT03867019||Subjects with BPPV|"Patients diagnosed with BPPV, who meet the following criteria:~1. Main complain of spinning sensation (Vertigo) when changes are made in head position relative to gravity.~2. Positive Dix-Hallpike / Supine Roll Test, confirmed by presence of nystagmus."
61990216|NCT04196946|EXPERIMENTAL|Group II|250 mcg alfentanil intrathecally
61990217|NCT01839552|EXPERIMENTAL|Fentanyl Citrate Nasal Spray (FCNS)|Treatment for breakthrough pain with Fentanyl Citrate Nasal Spray (FCNS)
62386154|NCT04005885|EXPERIMENTAL|stenfilcon A then somofilcon A contact lens|Participants were fitted with comfilcon A lens on a daily wear, reusable basis for 1 month, then randomized to wear stenfilcon A daily disposable test lens for 1 week of daily wear and somofilcon A daily disposable test lens for 1 week of daily wear.
62767167|NCT03867019||Subjects without BPPV (Control group)|Patients who do not suffer from dizziness / spinning sensation (Vertigo), and do not meet the exclusion criteria in the study.
62767168|NCT01373320|EXPERIMENTAL|Early Intervention|Participants in this group are nested in churches which were randomly assigned to the treatment group.
62767169|NCT01373320|NO_INTERVENTION|Delayed Intervention|Participants in this group are nested in churches which were randomly assigned to the wait-list control group. They receive an educational luncheon focused on stress reduction during the intervention window for the Early Intervention group, and subsequently receive the intervention(s) for their selected target health behaviors at a later date.
61990218|NCT02599155|PLACEBO_COMPARATOR|Crystalloid group|Crystalloid group receive only crystalloid for intravenous volume expansion. The same transfusion protocol is applied in both groups.
61990219|NCT02599155|ACTIVE_COMPARATOR|Colloid group|Colloid group receive colloid preferentially for intravenous volume expansion, until 30 ml/kg. The same transfusion protocol is applied in both groups.
61990220|NCT03772847|EXPERIMENTAL|ginkgolide group|ginkgolide plus alteplase
61990221|NCT03772847|NO_INTERVENTION|control|alteplase
62386155|NCT02808273||Retrospective control|Patients who had received enoxaparine as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
62767170|NCT05473286||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
62767171|NCT02884375||Elderly cancer patient cohort|Patients aged 70 years or older, who had diagnosis of cancer in participating sites (including hematologic malignancies), and referred to a geriatrician for geriatric assessment (GA)
62767172|NCT02519868|EXPERIMENTAL|Experimental arm|Patients will have both interventions: electrical stimulation followed by chemical stimulation
62767173|NCT02231762|EXPERIMENTAL|Lanreotide Autogel 120mg & Temozolomide|"Combination phase for first 6 months: Lanreotide Autogel 120 mg and Temozolomide.~Followed by either 6 months Lanreotide Autogel 120 mg maintenance or 6 months of no treatment."
62767174|NCT02430324||TBI, no cerebral infarction|patients with moderate or severe brain injury that do not develop posttraumatic cerebral infarction
62767175|NCT02430324||TBI, posttraumatic cerebral infarction|patients with moderate or severe brain injury that develops posttraumatic cerebral infarction
62767176|NCT02437604|EXPERIMENTAL|Treatment A|Fp MDPI 200 mcg, 1 inhalation
61990222|NCT01441674|EXPERIMENTAL|Animal Assisted Therapy Visit 1|Standard OT Therapy with Animal Assisted Therapy at Visit 1 and Not at Visit 2
61990223|NCT01441674|EXPERIMENTAL|Animal Assisted Therapy at Visit 2|Standard OT Therapy with Animal Assisted Therapy at Visit 2 and not Visit 1
61990224|NCT01906710|PLACEBO_COMPARATOR|usual care|During admission patients receive standard, non - ward based, pharmaceutical care from a pharmacy team in taking responsibility for the appropriate, safe and cost-effective use of medication from a central hospital pharmacy. The pharmaceutical care consist of daily screening of generated alerts by the Computerized physician order entry (CPOE) system and consultation by phone. Dependent on the local situation the current medication reconciliation process is being performed by nursing and/or medical staff either protocolised or not.
61990225|NCT01906710|ACTIVE_COMPARATOR|integrated medicines management|"integrated medicines management consists of~* patient centred medication reconciliation~* intermediate medication review~* discharge counseling~* transfer of information to primary care"
61990226|NCT00885066|EXPERIMENTAL|gemcitabine, capecitabine, erlotinib|
61990227|NCT01625455|ACTIVE_COMPARATOR|Aprepitant|Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
61990228|NCT01625455|PLACEBO_COMPARATOR|Placebo|Matching placebo will be given in place of aprepitant
62386156|NCT02808273||Prospective Cohort|Patients who will receive bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
62386157|NCT06148181|EXPERIMENTAL|Part 1, ABBV-141 (Intravenous [IV])|Western participants will receive a single IV dose of ABBV-141.
62386158|NCT06148181|PLACEBO_COMPARATOR|Part 1, Placebo for ABBV-141 (IV)|Western participants will receive a single IV dose of placebo for ABBV-141.
62386159|NCT06148181|EXPERIMENTAL|Part 1, ABBV-141 (subcutaneous [SC])|Western participants will receive a single SC dose of ABBV-141.
62386160|NCT06148181|PLACEBO_COMPARATOR|Part 1, Placebo for ABBV-141 (SC)|Western participants will receive a single SC dose of placebo for ABBV-141.
62386161|NCT06148181|EXPERIMENTAL|Part 2, ABBV-141 (IV)|Asian participants will receive a single IV dose of ABBV-141.
62386162|NCT06148181|PLACEBO_COMPARATOR|Part 2, Placebo for ABBV-141 (IV)|Asian participants will receive a single IV dose of placebo for ABBV-141.
62767177|NCT02437604|EXPERIMENTAL|Treatment B|FS MDPI 200/12.5 mcg, 1 inhalation
62767178|NCT02437604|ACTIVE_COMPARATOR|Treatment C|fluticasone propionate (FLOVENT DISKUS) 250 mcg, 2 inhalations
62767179|NCT02437604|ACTIVE_COMPARATOR|Treatment D|fluticasone propionate/salmeterol (ADVAIR DISKUS) 500/50 mcg, 1 inhalation
62386163|NCT06148181|EXPERIMENTAL|Part 2, ABBV-141 (SC)|Asian participants will receive a single SC dose of ABBV-141.
62386164|NCT06148181|PLACEBO_COMPARATOR|Part 2, Placebo for ABBV-141 (SC)|Asian participants will receive a single SC dose of placebo for ABBV-141.
62386165|NCT04923958|EXPERIMENTAL|Evaluation of various novel TB triage and diagnostic tests.|For the novel TB triage and diagnostic tests, the investigators will conduct large-scale evaluation of design-locked tests in a cohort of adults with presumed TB, with nested feasibility/pilot studies of early and late prototype tests. The investigators aim to enroll 300-450 participants per year at each of five enrollment sites for evaluation of various novel TB triage and diagnostic tests and 50 health workers to assess test usability.
62386166|NCT04923958|EXPERIMENTAL|Evaluation of novel rDST assays|Clinicians at participating sites will be asked to refer adult patients with rifampin-resistance identified by routine molecular testing. The investigators aim to enroll 100-200 patients per year at each of three enrollment sites for evaluation of novel rDST assays.
62386167|NCT04627805|NO_INTERVENTION|Phase 2: Usual Care|The investigators will enroll 33 women with SUDs to evaluate baseline family planning discussions and referrals to women's health providers in SUD treatment settings. To establish usual care practice patterns, MyPath will not be administered to this group of participants. Participants will be asked to complete a pre-visit survey, including substance use history and current reproductive health goals, as well as questions about reproductive health knowledge, self-efficacy, and decision conflict. The participants will then attend their scheduled therapy visit with the substance use treatment provider. Following the therapy visit, they will complete the post-visit survey, which will include the same knowledge, efficacy, and decision conflict survey questions as the pre-visit survey. Occurrence of reproductive health discussions, prescriptions or referrals, and satisfaction with reproductive health services will be measured following the visit as well.
62386168|NCT04627805|EXPERIMENTAL|Phase 3: MyPath Pilot|Following completion of the usual care arm, the investogators will enroll a second group of 33 women with SUDs to participate in the MyPath intervention arm. Participants will complete the same pre-visit survey as the usual care group. In addition, they will be provided a website link to navigate through the online MyPath tool. Following completion of MyPath, participants will receive a summary page that they will be encouraged to use as a guide when discussing their reproductive health with their substance use treatment provider at their next scheduled therapy visit. After the visit, they will complete the post-visit survey. In addition to satisfaction with reproductive health services, the intervention group will be asked specific questions about their perception of the MyPath tool.
62386169|NCT00721136|EXPERIMENTAL|1|Moderate risk patients (afib, mechanical aortic valve) randomized to continue coumadin at their usual dose through the procedure.
62386170|NCT00721136|ACTIVE_COMPARATOR|2|Moderate risk patients randomized to hold their coumadin for 4-5 days prior to the procedure (to allow the INR to normalize).
62386171|NCT00721136|EXPERIMENTAL|3|High risk patients (mechanical mitral valve, prior stroke, current deep vein thrombosis, hypercoagulable syndrome) randomized to continue coumadin at the usual dose through the procedure.
62386172|NCT00721136|ACTIVE_COMPARATOR|4|"High risk patients randomized to holding coumadin for 4-5 days and using bridging anticoagulation with heparin while the coumadin is held."
62386173|NCT01547208|EXPERIMENTAL|Group A|Patients will be randomized to a VT ablation procedure immediately after an appropriate ICD shock
62386174|NCT01547208|ACTIVE_COMPARATOR|Group B|Patients will wait until an arrhythmic storm to undergo a VT ablation procedure
62386175|NCT01309581|EXPERIMENTAL|Ketamine|Participants receiving ECT for depression will be randomized 1:1 to either ketamine (experimental condition) or methohexital (standard anesthetic).
62386176|NCT01309581|ACTIVE_COMPARATOR|Methohexital|Participants receiving ECT for depression will be randomized 1:1 to either ketamine (experimental condition) or methohexital (standard anesthetic).
62386177|NCT04995042|EXPERIMENTAL|SHR7280 Does Escalation and Expansion|
61990229|NCT02436421|OTHER|Atrial Fibrillation BPA|The alert will notify providers when patients with atrial fibrillation are not on anticoagulation
61990230|NCT02436421|OTHER|Hypertension BPA|The alert will notify providers when patients have elevated blood pressure
61990231|NCT02436421|OTHER|Atrial Fibrillation and Hypertension BPA|Providers in this arm will receive both alerts
62386178|NCT00963820|EXPERIMENTAL|0.24 mg/m^2|Ixazomib citrate, 0.24 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate
62767180|NCT04867213||SARS-CoV-2 Positive|Clinically tested for SARS-CoV-2 (as completed by standard laboratory testing e.g. RT-PCR) and with a positive result and clinical features in keeping with COVID-19 illness. The investigators aim to collect breath samples within 7 days of symptom onset in 50% of Covid positive patients, with the remaining patients breath samples collected after 7 days of symptoms onset.
62767181|NCT04867213||SARS-CoV-2 Negative|Patients with a negative RT-PCR COVID-19 test and without any clinical features to suggest COVID-19 illness.
62767182|NCT00456599|EXPERIMENTAL|Oxaliplatin & gemcitabine with radiation|This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer.
62767183|NCT04825431|EXPERIMENTAL|TAS-205, [14C]TAS-205|
62767184|NCT02326766|EXPERIMENTAL|KRG|5g Korea red ginseng (KRG)
62767185|NCT02326766|PLACEBO_COMPARATOR|Placebo|5 g placebo (corn starch)
62767186|NCT06522685|EXPERIMENTAL|Left motor cortex targeted anodal transcranial direct current stimulation|Active left motor cortex targeted anodal transcranial direct current stimulation at 2 milliamperes applied for 20 minutes once daily on Monday through Friday for two consecutive weeks.
62767187|NCT06522685|SHAM_COMPARATOR|Left motor cortex targeted sham transcranial direct current stimulation|Active left motor cortex targeted anodal transcranial direct current stimulation at 0 milliamperes applied for 20 minutes once daily on Monday through Friday for two consecutive weeks. The sham consists of a ramp up to 2 mA and immediate ramp down to 0 mA at the beginning of the 20 minute period and a ramp up to 2 mA and immediate ramp down to 0 mA at the end of the 20 minute period.
62767188|NCT06491810||Arm crank exercise|The exercise session will consist of 15 sets of 2 minutes of exercise in arm ergometer with an intensity equivalent to 13-15 on the Borg's perceived exertion scale.
62767189|NCT02636946|ACTIVE_COMPARATOR|SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)|"Primary Eye: Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to three Sham Bimatoprost sustained release (Bim SR) administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.~Contralateral (Other) Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 μg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 μg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants enrolled under Protocol Amendment 2 or later."
62386179|NCT00963820|EXPERIMENTAL|0.48 mg/m^2|Ixazomib citrate, 0.48 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
62386180|NCT00963820|EXPERIMENTAL|0.80 mg/m^2|Ixazomib citrate, 0.80 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
62386181|NCT00963820|EXPERIMENTAL|1.20 mg/m^2|Ixazomib citrate, 1.20 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period.
62386182|NCT00963820|EXPERIMENTAL|1.68 mg/m^2|Ixazomib citrate, 1.68 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
62386183|NCT00963820|EXPERIMENTAL|2.23 mg/m^2|Ixazomib citrate, 2.23 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
62386184|NCT00963820|EXPERIMENTAL|2.97 mg/m^2|Ixazomib citrate, 2.97 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
62386185|NCT00963820|EXPERIMENTAL|3.95 mg/m^2|Ixazomib citrate, 3.95 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
62567676|NCT03162653|PLACEBO_COMPARATOR|Placebo|mannitol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
61990232|NCT02808130||group H|"Group H: normolipidemic+ periodontally healthy individuals The healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
62559159|NCT03797911|EXPERIMENTAL|active resistive capacitive monopolar radiofrequency|"Application of the technique in the intervention group (activated resistive capacitive monopolar radiofrequency therapy): The intervention group will receive the treatment with activated resistive capacitive monopolar radiofrequency system, with the resistive electrode at the minimum intensity, together with the techniques of conventional physiotherapy treatment (trigger point treatment and myofascial techniques according to the location of pain) and pain education.~The patient will be stretched on the stretcher and the session will last 45 minutes, once a week, for 10 sessions. Ass baseline, after half therapy and after 10 weeks therapy."
62567677|NCT05648773|EXPERIMENTAL|Message Only|Email or SMS Booster Vaccination Reminder
62767190|NCT02636946|EXPERIMENTAL|Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)|"Primary Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 μg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 μg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.~Contralateral (Other) Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later."
62767191|NCT03050762||Endocrine Disease Group|"Information from the medical record recorded and entered into a research database.~Starting about 2-3 years after testing and/or diagnosis and/or treatment and continuing for up to 15 years after surgery, research team will contact participant by phone to follow up."
61990233|NCT02808130||Group G|"Group G: normolipidemic + gingivitis individuals the healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
62386186|NCT00963820|EXPERIMENTAL|Relapsed and Refractory (RR)|Ixazomib citrate, 2.97 mg/m\^2 established Maximum Tolerated Dose (MTD), capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
62386187|NCT00963820|EXPERIMENTAL|VELCADE-Relapsed (VR)|Ixazomib citrate, 2.97 mg/m\^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
62386188|NCT00963820|EXPERIMENTAL|PI naïve|Ixazomib citrate, 2.97 mg/m\^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
62386189|NCT00963820|EXPERIMENTAL|Carfilzomib|Ixazomib citrate, 2.97 mg/m\^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
62386190|NCT02599727|EXPERIMENTAL|Active Isometric exercise|Subjects performing the isometric exercises intervention
62386191|NCT02599727|ACTIVE_COMPARATOR|No exercise|Subjects not performing the isometric exercises intervention
62386192|NCT02114528|ACTIVE_COMPARATOR|Anti-arrhythmic drug therapy|Oral and/or intravenous loading doses of Sotalol, mexiletine, procainamide or amiodarone as first line therapy. Drug chosen is preference of the treating physician. May use single or combination of AAD. Loading doses as per standard dosing guidelines for VT. Subjects on amiodarone should receive oral maintenance dose of at least 200 mg/day.
62386193|NCT02114528|ACTIVE_COMPARATOR|Catheter ablation|Ventricular tachycardia (VT) Catheter ablation, using a standardized VT ablation procedure protocol.
62386194|NCT05314530|EXPERIMENTAL|Intervention group|Will receive a rehabilitation intervention
62386195|NCT05314530|ACTIVE_COMPARATOR|Controll|Will receive conventional rehabilitation
62386196|NCT03708042|EXPERIMENTAL|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day.
62386197|NCT03708042|ACTIVE_COMPARATOR|Neoadjuvant Radiochemotherapy|Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
62386198|NCT00917280||Parkinson's Disease|Parkinson Disease participants without dementia
62767192|NCT04526470|EXPERIMENTAL|Alpelisib + Paclitaxel|"Phase IB is planned for a 4-stage dose level and the traditional 3+3 design is applied. The RP2D of alpelisib will be determined based on the MTD and toxicity profiles.~In phase II part, RP2D from the phase IB part will be applied as follows: alpelisib ( ) mg PO bid daily + paclitaxel ( ) mg/m² IV on D1, 8, and 15 every 4 weeks."
62567678|NCT05648773|EXPERIMENTAL|Message + Financial Incentive|Email or SMS Booster Vaccination Reminder + Offer of a financial incentive for getting boosted in the next 2 weeks.
62767193|NCT01660100|ACTIVE_COMPARATOR|Pulmonary vein antrum isolation (PVAI)|Pulmonary vein antrum isolation (PVAI)
62386199|NCT00917280||Control|Non-PD participants, matched for age, education and gender.
62386200|NCT03384394|PLACEBO_COMPARATOR|Conventional oxygen therapy|oxygen by a standard nasal cannula or nonrebreather mask
62386201|NCT03384394|ACTIVE_COMPARATOR|High-flow Nasal Cannula Oxygen Therapy|High-flow Nasal Cannula Oxygen Therapy
62386202|NCT04157907||Patients with borderline personality disorder|Patients with borderline personality disorder included in the MBT program
62386203|NCT00880958|EXPERIMENTAL|1|
62386204|NCT00880958|PLACEBO_COMPARATOR|2|
62767194|NCT01660100|ACTIVE_COMPARATOR|PVAI plus left atrial posterior wall (LAPW) isolation|PVAI plus left atrial posterior wall (LAPW) isolation
62767195|NCT04350060|EXPERIMENTAL|Intervention Group|Subjects with dementia will be living in a retro-fitted room with technological enhancements for a 12 month period.
62767196|NCT04350060|NO_INTERVENTION|Standard of Care Group|
61990234|NCT02808130||Group CP|"Group CP: normolipidemic + generalized chronic periodontitis individuals the healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
61990235|NCT02808130||Group HH|"Group HH: hyperlipidemic + periodontally healthy individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC\>200mg/dl; TG\>200mg/dl; LDL cholesterol \>130 mg/dl; HDL \<35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
62386205|NCT00352027|EXPERIMENTAL|All Participants|Participants receive 12 weeks of Stanford V chemotherapy which includes Adriamycin®, Vinblastine, Nitrogen Mustard (or Cyclophosphamide), Vincristine, Bleomycin, Etoposide, Prednisone, and G-CSF. After completion of 12 weeks of Stanford V chemotherapy, participants receive radiotherapy.
62767197|NCT06182241|EXPERIMENTAL|Participant intervention|The intervention group will likely consist of one to two sessions, conducted in-person, coupled with text- or phone-based client navigation.The intervention group will complete three major assessments: baseline (T1), at the conclusion of the intervention (T2), and a six-month follow-up (T3). Until the follow-up assessment, the interventionist will send participants up to 6 SMS messages (one-way) per month. The content of these messages will be developed collaboratively between the participant and the interventionist during the second session; messages could include reminders about follow-ups and/or prompts to use new skills and resources for navigating specific barriers.
62767198|NCT06182241|NO_INTERVENTION|Treatment as usual|The treatment as usual (TAU) group will receive treatment as usual, including being notified of their abnormal Pap results via SMS and instructed to set up a follow-up appointment, as is typical in routine care. The TAU group will complete the T1 assessment and will complete T2 assessment two-months post-baseline.
61990236|NCT02808130||Group HG|"Group HG: hyperlipidemic + gingivitis individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC\>200mg/dl; TG\>200mg/dl; LDL cholesterol \>130 mg/dl; HDL \<35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
61990237|NCT02808130||group HCP|"Group HCP: hyperlipidemic + generalized chronic periodontitis individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC\>200mg/dl; TG\>200mg/dl; LDL cholesterol \>130 mg/dl; HDL \<35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
61990238|NCT06080386||one group|Patients who had during their care UDFF ultrasound measurements and liver MRI over the study period may be included in this study
61990239|NCT00369551|EXPERIMENTAL|Treatment (paclitaxel, carboplatin, bevacizumab, radiation)|"Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, 36, and 43 and bevacizumab IV over 30-90 minutes on days 1, 15, 29, and 43. Patients also undergo chest radiotherapy 5 days a week for 7 weeks beginning on day 1.~Consolidation therapy: Beginning 4-5 weeks after completion chemoradiotherapy, patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 1 hour followed by bevacizumab IV over 30 minutes. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
61990240|NCT05720156||Case group: History of ASCVD, on high-intensity statins and initiating PCSK9 inhibitor therapy|History of ASCVD, on high-intensity statins and initiating PCSK9 inhibitor therapy
61990241|NCT05720156||Control group: No history of ASCVD, not on statins or initiating PCSK9 inhibitor therapy|No history of ASCVD, not currently on high-intensity statins, other lipid lowering therapy or initiating PCSK9 inhibitor therapy
61990242|NCT04083807|EXPERIMENTAL|TISSEEL Lyo|Applied once intra-operatively to the study suture line using the DUPLOJECT Fibrin Sealant Preparation and Application System.
61990243|NCT04083807|ACTIVE_COMPARATOR|Manual compression with surgical gauze pads|Treated once intraoperatively with manual compression using surgical gauze pads at the study suture line.
61990244|NCT01455012|EXPERIMENTAL|Rotigotine|Rotigotine, optimal dose (minimum dose 1 mg/24 h, maximum dose 3 mg/24 h)
61990245|NCT01455012|PLACEBO_COMPARATOR|Placebo|Placebo
61990246|NCT01817725|EXPERIMENTAL|Engerix-B|Engerix-B (20 μg/ml, GlaxoSmithKline) was administered at 0-2-4-6-8-10-12 months in dosage of 40μg for \>20 years old and 20μg for \< or =20 years old
62386206|NCT03045497|EXPERIMENTAL|Diagnostic (contrast-enhanced ultrasound)|Patients receive perflutren lipid microspheres IV and then undergo contrast-enhanced ultrasound imaging over approximately 1 hour prior to transarterial chemoembolization with drug eluting beads, at 1-2 weeks and 1 month post transarterial chemoembolization with drug eluting beads. Patients also undergo contrast-enhanced MRI at 1 month post-treatment per standard of care.
62386207|NCT02269709|EXPERIMENTAL|ARFI Ultrasound|This study uses ultrasound scanning with acoustic radiation force impulse shear wave velocity imaging to measure pediatric liver fibrosis. Patients will be children who have had the Fontan operation. This is a non-invasive scan that uses sound waves to create images.
62386208|NCT05779280|EXPERIMENTAL|THDA + Acetyl Zingerone|Product will be used twice daily- once in the morning and once in the evening for 8 weeks. Each application will consist of 1-2 pumps (size of quarter) onto the face and neck, until fully absorbed.
62386209|NCT05779280|ACTIVE_COMPARATOR|THDA only|Product will be used twice daily- once in the morning and once in the evening for 8 weeks. Each application will consist of 1-2 pumps (size of quarter) onto the face and neck, until fully absorbed.
62386210|NCT02243904||Lead exposure|
62559160|NCT03797911|PLACEBO_COMPARATOR|Inactive resistive capacitive monopolar radiofrequency|"Application of the technique in the control group (inactivated resistive capacitive monopolar radiofrequency therapy): The control group will receive the treatment with inactivated resistive capacitive monopolar radiofrequency system (placebo), with the resistive electrode at the minimum intensity, together with the techniques of conventional physiotherapy treatment (trigger point treatment and myofascial techniques according to the location of pain) and pain education.~The patient will be stretched on the stretcher and the session will last 45 minutes, once a week, for 10 sessions. Ass baseline, after half therapy and after 10 weeks therapy."
62386211|NCT02599740|PLACEBO_COMPARATOR|Placebo|Rice only
62386212|NCT02599740|ACTIVE_COMPARATOR|Assumed active|Assumed key active consumed with rice
62386213|NCT02599740|ACTIVE_COMPARATOR|Natural fruit extract|Natural fruit extract consumed with rice
62767199|NCT02342379|EXPERIMENTAL|Bevacizumab and TH-302|Patients will be treated with combination of bevacizumab and TH-302.
62386214|NCT00408031|EXPERIMENTAL|1|Randomization to 2 treatment groups. One group receives adjuvant treatment with D-cycloserine, up to 1 g/day. The second group receives adjuvant treatment with placebo, up to 1 g/day.
62386215|NCT04235491||Micra AV leadless pacemaker therapy|All Medicare patients implanted with a Micra AV leadless pacemaker system
62386216|NCT04235491||Dual Chamber Transvenous pacemaker|All Medicare patients implanted with full system (e.g. lead and generator) dual-chamber transvenous pacemakers
62767200|NCT02608307||AYA patients|Adolescence and young adults (AYA) who meet eligibility criteria and consent to participate in the study.
62767201|NCT02608307||Parents of AYA patients|Parents of AYA patients who meet eligibility criteria and consent to participate in the study.
62386217|NCT03727685|NO_INTERVENTION|Usual care|Patients admitted to the hospital will not receive information about Our Care Wishes.
62386218|NCT03727685|ACTIVE_COMPARATOR|Intervention: Our Care Wishes|Patients admitted to the hospital during the intervention phase will receive information from registration representatives regarding Our Care Wishes.
62559161|NCT02585908|NO_INTERVENTION|Experimental Group A(control group)|regular treatment and follow up
62767202|NCT02608307||Health Care Providers (HCPs)|Health care providers who meet eligibility criteria and consent to participate in the study.
62767203|NCT05860491||patients with pre-dialysis hyperkalemia|To investigate the dietary fiber intake of hemodialysis patients with pre-dialysis hyperkalemia. Use a retrospective analysis method. Analyze the relationship between dietary fiber intake and hyperkalemia.
61990247|NCT00521196|NO_INTERVENTION|Baseline- 1 month|Subjects will be asked to maintain a migraine diary in which they will record the onset of each migraine, migraine-associated symptoms, migraine-associated pain, daily average pain, and daily average anxiety.
62386219|NCT02993731|EXPERIMENTAL|Arm 1: Napabucasin plus Nab-paclitaxel with Gemcitabine|Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.
62386220|NCT02993731|ACTIVE_COMPARATOR|Arm 2: Nab-paclitaxel with Gemcitabine|Patients randomized to this arm will receive weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.
62386221|NCT01835964|EXPERIMENTAL|Glucose Variability Observation|The study procedures will start after CGM device training \& practice using the blinded CGM for 2 days and will continue over the course of \~33 days. The study team will collect data about diabetes management including blood glucose data from fingerstick and CGM values along with insulin pump records throughout the 4 week observation period. Insulin sensitivity will be evaluated at home with predetermined meals' carbohydrate count. At the mid-study point glucose variability will be simulated in clinic with a metabolic challenge (liquid mixed meal) followed 4 hours later by the induction of hypoglycemia with an intravenous insulin injection. Insulin sensitivity, as well as glucagon and epinephrine counterregulatory responses will be evaluated to be related to overall Glucose Variability.
62386222|NCT01314885|EXPERIMENTAL|PF-03715455|
62386223|NCT01314885|EXPERIMENTAL|PH-797804|
62386224|NCT01314885|PLACEBO_COMPARATOR|Placebo for PF-03715455|
62386225|NCT01314885|PLACEBO_COMPARATOR|Placebo for PH-797804|
62386226|NCT04335552|ACTIVE_COMPARATOR|Standard of care|
62559162|NCT02585908|EXPERIMENTAL|Experimental Group B|CIK will be used against tumor cells.
62559163|NCT02585908|EXPERIMENTAL|Experimental Group C|γδ T will be used against tumor cells.
62559164|NCT02585908|EXPERIMENTAL|Experimental Group D|CIK and γδ T will be used against tumor cells.
62559165|NCT06043401||healthy volunteers|Age and sex-matched healthy individuals will also be recruited as a control group. They will be scanned three times (baseline, 3-week, and 6-week time points).
62559166|NCT06043401||volunteers with Major Depressive Disorder|20 patients with MDD receiving standard-of-care depression treatment (TMS) at twill be recruited to participate in this observational neuroimaging study. They will be scanned three times (baseline, 3-week, and 6-week time points).
62559167|NCT00634868|SHAM_COMPARATOR|1|The device is emitting a sham light
62559168|NCT00634868|EXPERIMENTAL|2|The device is emitting curative light
62767204|NCT05860491||patients without pre-dialysis hyperkalemia|To investigate the dietary fiber intake of hemodialysis patients without pre-dialysis hyperkalemia. Use a retrospective analysis method. Analyze the relationship between dietary fiber intake and hyperkalemia.
62386227|NCT04335552|EXPERIMENTAL|Standard of care plus hydroxychloroquine|Standard of care plus hydroxychloroquine for 5 days
62386228|NCT04335552|EXPERIMENTAL|Standard of care plus azithromycin|Standard of care plus azithromycin for 5 days
62386229|NCT04335552|EXPERIMENTAL|Standard of care plus hydroxychloroquine plus azithromycin|Standard of care plus hydroxychloroquine plus azithromycin for 5 days
62386230|NCT00468273|EXPERIMENTAL|Intravenous Immune Globulin|Subjects with primary humoral immunodeficiency
62386231|NCT06042764|EXPERIMENTAL|SA55 Injection|Group 1: 300 mg Group 2: 600 mg
62386232|NCT06042764|PLACEBO_COMPARATOR|Placebo|Group 1: 0 mg Group 2: 0 mg
62559169|NCT04736147|EXPERIMENTAL|JNJ-64300535|Participants will receive an electroporation-mediated intramuscular (IM) injection of JNJ-64300535 vaccine.
62559170|NCT01744301||All patients newly prescribed PPI|All patients newly prescribed PPI
62767205|NCT05004506|EXPERIMENTAL|Group A|"Group A patients will receive their treatment at the completion of the case while under general anesthesia. The anesthesia provider will identify the adductor canal using ultrasound guidance and inject 15ccs of 0.5% marcaine with epinephrine around the saphenous nerve.~Group A patients will receive placebo intra-articular and arthroscopic portal site saline injections equal in volume and procedure time point as the treatment in Group B.~At the completion of the case, the patient will be extubated and transferred to the PACU."
62559171|NCT01744301||All patients newly prescribed H2RA|All patients newly prescribed H2RA
62767206|NCT05004506|ACTIVE_COMPARATOR|Group B|"Group B will receive 20ccs of 2% lidocaine with epinephrine as an intra-articular injection. At the completion of the arthroscopic procedure the patient will receive an additional 20ccs of 0.5% marcaine with epinephrine intra-articular injection.~Group B patients will also receive 10ccs of 2% lidocaine with epinephrine injected superficially into each of the arthroscopic portal sites. Group B patients will receive a 15cc saline injection around the saphenous nerve under the same procedure as the adductor canal block for Group A.~At the completion of the case, the patient will be extubated and transferred to the PACU."
62767207|NCT04946617||H group|healthy periodontium, BOP at \\20 % of the sites and no sites with probing depth (PD) \[3 mm and clinical attachment level (CAL) \[2 mm or alveolar bone loss (N = 20, 12 males, 8 females, mean age: 33.38
62767208|NCT04946617||G group|gingivitis, BOP at ≥20 % of the sites and no sites with PD and CAL \[3 mm or bone loss (N = 20, 6 males, 14 females, mean age: 32.35);
62767209|NCT04946617||CP group|chronic periodontitis, ≥4 teeth in each jaw with PD of ≥5 mm, CAL of C4 mm, BOP at \[≥80 % of the proximal sites and radiographic evidence of interproximal bone loss
62386233|NCT00574340|ACTIVE_COMPARATOR|Control study then antecedent hypoglycemia study group|Day 1 euglycemia, day 2 hypoglycemia Hyperinsulinemic Hypoglycemic Clamp: hyperinsulinemic glucose clamp separated by 8 weeks then participants proceeded to antecedent hypoglycemia study Day 1 hypoglycemia, Day 2 hypoglycemia
62386234|NCT00574340|ACTIVE_COMPARATOR|Antecedent Hypoglycemic clamp study|Day 1 hypoglycemia, day 2 hypoglycemia Hyperinsulinemic Hypoglycemic Clamp: hyperinsulinemic glucose clamp separated by 8 weeks then participants proceeded to control study Day 1 euglycemia, Day 2 hypoglycemia
62386235|NCT04451460||Hyponatremia|Hyponatremic small cell cancer patients
62386236|NCT04451460||Normonatremia|Normonatremic small cell cancer patients
62386237|NCT01028131|NO_INTERVENTION|Control|Participants randomized by the computer into this condition will only view the 20-minute video clips of music and tv videos.
62767210|NCT06386861|OTHER|AGPM for English Speakers|Participants identifying as Hispanic, Latino, or Latina whose primary language is English
62386238|NCT01028131|EXPERIMENTAL|Computerized brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model (ask, advise, assess, assist \& arrange) and Motivational Interviewing.
62386239|NCT01028131|EXPERIMENTAL|Contingency Management Alone|Participants randomized by the computer into this condition will view a 20-minute music and tv video clip after completing the brief assessment. The research assistant will then briefly describe the CM process, with some time to discuss questions regarding procedure to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
62386240|NCT01028131|EXPERIMENTAL|Combined Brief Intervention and CM|Combined intervention. Participants in this condition will receive both the brief intervention and the brief description of the CM process.
62559172|NCT03906799|EXPERIMENTAL|Low OMT-28|Verum, low OMT-28
62767211|NCT06386861|OTHER|AGPM for Spanish Speakers|Participants identifying as Hispanic, Latino, or Latina whose primary language is Spanish
62767212|NCT02952105||defibrillation patients|shockable rhythm, defibrillated
62386241|NCT04822389|EXPERIMENTAL|Home-based telerehabilitation exercise|Exercise training is conducted in the patient's home conditions using modern technology to transfer medical data remotely - the participants receive a heart rate monitor and sensor. To know what to do and how to exercise, the first (1-2) exercise training sessions will be controlled by the physiotherapist in a rehabilitation clinic in the hospital, who creates individual exercise training for each patient. The patient's training data will be downloaded and updated regularly via the internet platform and clinicians will evaluate these results and provide patients with telephone feedback.
62559173|NCT03906799|EXPERIMENTAL|Middle OMT-28|Verum, middle OMT-28
62559174|NCT03906799|EXPERIMENTAL|High OMT-28|Verum, high OMT-28
62386242|NCT00281359|EXPERIMENTAL|With heat|heat applied to contracted tissues prior to using the active stretching orthosis.
62559175|NCT03906799|PLACEBO_COMPARATOR|Placebo|Placebo
62559176|NCT01561716|EXPERIMENTAL|Crossover sequence 1|Resting/Wii Fit Free Run/Wii Fit 3 bouts/treadmill
62559177|NCT01561716|EXPERIMENTAL|Crossover sequence 2|Resting/Wii Fit Free Run/treadmill/Wii Fit 3 bouts
62559178|NCT01561716|EXPERIMENTAL|Crossover sequence 3|Resting/Wii Fit 3 bouts/Wii Fit Free Run/treadmill
62386243|NCT00281359|PLACEBO_COMPARATOR|Without heat|No heat applied to the contracted tissues prior to using the stretching orthosis
62386244|NCT04313660|EXPERIMENTAL|Anlotinib In Combination With PD-1/L1 Inhibitor|
62386245|NCT00515021|EXPERIMENTAL|Daytime then nightime dosing|Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 50mg, by mouth, daily, in the evening x 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks.
62386246|NCT00515021|EXPERIMENTAL|Nighttime then daytime dosing|Eplerenone - 50mg, by mouth, daily, in the evening x 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks then patients cross over to 50mg, by mouth, daily, in the morning x 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks.
62559179|NCT01561716|EXPERIMENTAL|Crossover sequence 4|Resting/Wii Fit 3 bouts/treadmill/Wii Fit Free Run
62559180|NCT01561716|EXPERIMENTAL|Crossover sequence 5|Resting/treadmill/Wii Fit Free Run/Wii Fit 3 bouts
62559181|NCT01561716|EXPERIMENTAL|Crossover sequence 6|Resting/treadmill/Wii Fit 3 bouts/Wii Fit Free Run
61990248|NCT00521196|EXPERIMENTAL|tDCS- 1 month|"There will be 10- twenty minute sessions of the tDCS intervention over a four week period. During each tDCS session, two electrodes are placed over selected areas of the brain. 2 mA of direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The subject may feel a slight itching on the scalp. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.~During this phase, participants will continue to maintain their migraine diary. In addition, the pain threshold of patients will be measured at the first, fifth, and tenth sessions via Thermal Sensory Analysis and Von Frey Hair tests."
61990249|NCT00521196|NO_INTERVENTION|Follow Up- 4 months|During the follow up phase, subjects will meet with the study investigators a total of 5 times for follow up monitoring. Participants will continue to maintain their migraine diary during this time.
61990250|NCT00521196|OTHER|Active tDCS- 1 month|Participants randomized to sham tDCS (placebo) will be given the opportunity to receive the active intervention if the intervention is found to be safe and efficacious.
61990251|NCT02290106|EXPERIMENTAL|Pitavastatin|pitavastatin 4mg daily by mouth for 6 months
61990252|NCT02290106|PLACEBO_COMPARATOR|Placebo|Identical placebo 4mg by mouth daily for 6 months
61990253|NCT05398679|ACTIVE_COMPARATOR|OPAT|Patients with infective endocarditis diagnostic, who have completed at least 10 days of intravenous therapy, and/ or seven days in the case of cardiac valvular surgery, and shown good clinical evolution and no clinical or echocardiographic signs of potential bad prognosis will be randomized. If assigned to this arm the patient will recieve parenteral antibiotics until the end of treatment.
61990254|NCT05398679|EXPERIMENTAL|Oral Therapy|Patients with infective endocarditis diagnostic, who have completed at least 10 days of intravenous therapy, and/ or seven days in the case of cardiac valvular surgery, and shown good clinical evolution and no clinical or echocardiographic signs of potential bad prognosis will be randomized. If assigned to this arm the patient will recieve oral antibiotics until the end of treatment.
61990255|NCT03293732|ACTIVE_COMPARATOR|HA antigen only|All subjects in this group received 2 doses of 22.2 μg HA antigens
61990256|NCT03293732|EXPERIMENTAL|7.5 μg of DCB07010|All subjects in this group received 7.5 μg of DCB07010 in 22.2 μg HA antigens twice.
61990257|NCT03293732|EXPERIMENTAL|15 μg of DCB07010|All subjects in this group received 15 μg of DCB07010 in 22.2 μg HA antigens twice.
61990258|NCT03293732|EXPERIMENTAL|30 μg of DCB07010|All subjects in this group received 30 μg of DCB07010 in 22.2 μg HA antigens twice.
61990259|NCT03293732|EXPERIMENTAL|45 μg of DCB07010|All subjects in this group received 45 μg of DCB07010 in 22.2 μg HA antigens twice.
62559182|NCT04328090|EXPERIMENTAL|CDSS-Antimicrobial stewardship|Computer-based, multicomponent intervention targeting on reduction of perioperative antimicrobial use will be delivered to teams in the intervention arm.
62767213|NCT02952105||non defibrillation patients|non-shockable rhythm, non defibrillated
62767214|NCT02492256|ACTIVE_COMPARATOR|PVI group|Conventional PVI by circumferential antral ablation according to standard procedures.
62767215|NCT02492256|EXPERIMENTAL|PVI+GP guided by SUMO technology group|Conventional PVI by circumferential antral ablation according to standard procedures and atrial ganglionated plexi ablation guided by the SUMO technology.
62767216|NCT04515368|EXPERIMENTAL|Fendrix|Fendrix (Hepatitis B surface antigen adjuvanted by AS04C containing 3¬≠O¬≠desacyl¬≠4'¬≠ monophosphoryl lipid A adsorbed on aluminium phosphate, GlaxoSmithKline; 0.5 mL. intramuscular. stat.
61990260|NCT04309656|EXPERIMENTAL|Panel 1: Pretomanid after meal|Each participant will receive four single-dose treatments with a 7-day washout period between each dose. Panel 1 will receive a meal before dosing.
62559183|NCT04328090|NO_INTERVENTION|Standard of care|Teams in the control arm will continue with usual standard clinical care.
62559184|NCT03143283|NO_INTERVENTION|Usual care|Hospital EDs are observed under usual care conditions (families receive usual care at the ED).
62559185|NCT03143283|EXPERIMENTAL|Safety Study Lethal Means Counseling|During the intervention phase, mental health clinicians at EDs of participating hospitals are trained in lethal means counseling and implement the new protocol uniformly with eligible families.
62559186|NCT05754268||Chinese version of Surgical risk Assessment system Group|This group of patients used the Chinese version of the surgical risk assessment system to evaluate the complications.
62559187|NCT01195311|EXPERIMENTAL|INCB024360|
62559188|NCT03818113||HTK-Bretschneider cardioplegic solution|Patients undergoing mitral valve reconstruction via minimal invasive antero- lateral thoracotomy in cardioplegia with HTK-Bretschneider cardioplegic solution
62559189|NCT03818113||St. Thomas cardioplegic solution|Patients undergoing mitral valve reconstruction via minimal invasive antero- lateral thoracotomy in cardioplegia with St. Thomas cardioplegic solution
61990261|NCT04309656|EXPERIMENTAL|Panel 2: Pretomanid after fast|Each participant will receive four single-dose treatments with a 7-day washout period between each dose. Panel 2 will fast before dosing.
61990262|NCT05020340|EXPERIMENTAL|Intervention|External cephalic version
62559190|NCT01482416|EXPERIMENTAL|Estrogen use|climacteric women will use conjugated equine estrogens
62559191|NCT01482416|PLACEBO_COMPARATOR|use of Placebo|climacteric women will use placebo
62559192|NCT06511635||Women between 18 to 40 included in CMVCTORY vaccine trial|Women between 18 to 40 included in CMVCTORY vaccine trial will be included.
62559193|NCT02614924|OTHER|Flexible fibre-optic scope|Randomly allocated to fibreoptic group
62559194|NCT02614924|OTHER|Pentax AWS videolaryngoscope|Randomly allocated Pentax AWS videolaryngoscope
62559195|NCT02719886|EXPERIMENTAL|Fetal growth ultrasound every 2 weeks|Ultrasound to measure fetal growth every 2 weeks (i.e. 28, 30, 32, 34, 36, 38 weeks gestation).
62559196|NCT02719886|ACTIVE_COMPARATOR|Fetal growth ultrasound every 4 weeks|Ultrasound to measure fetal growth every 4 weeks (i.e. 28, 32 and 36 weeks gestation). Usual Care.
62559197|NCT02381847|NO_INTERVENTION|without HIPEC|Patients will be treated with a D2 radical gastrectomy for advanced gastric cancer and postoperative chemotherapy (SOX or XELOX).
62767217|NCT04515368|EXPERIMENTAL|Bexsero|Bexsero (Meningococcal group B subunit / Outer Membrane Vesicles, GlaxoSmithKline); 0.5 mL. intramuscular. stat.
62767218|NCT04515368|EXPERIMENTAL|Fluad|Fluad (split virion inactivated seasonal trivalent influenza vaccine adjuvanted with MF59C, Northern Hemisphere 2016-17, Seqirus Vaccines and Diagnostics) 0.5 mL. intramuscular. stat.
62559198|NCT02381847|EXPERIMENTAL|with HIPEC|"Patients will be treated with a D2 radical gastrectomy for advanced gastric cancer and intraperitoneal chemoperfusion with cisplatin and postoperative chemotherapy as described for the control group.~Cisplatin: 75mg/m2 (max 150mg/m2 max 5L )"
62559199|NCT05163483|EXPERIMENTAL|Tucidinostat (chidamide), PD-1 inhibitor （Toripalimab), Bevacizumab|"Tucidinostat (chidamide), 30mg, po., biw, q3w Toripalimab, 240mg, ivgtt., d1, q3w Bevacizumab, 7.5mg/kg, ivgtt., d1, q3w~approximately 2 years"
62767219|NCT04515368|EXPERIMENTAL|Seasonal Trivalent Influenza Vaccine|Seasonal Trivalent Influenza Vaccine ('ÄòSTIV'Äô, split virion inactivated, Northern Hemisphere 2016-17, Sanofi Pasteur); 0.5 mL. intramuscular. stat.
62559200|NCT04242810|ACTIVE_COMPARATOR|Active rTMS|rTMS applied over memory task-based brain target
61990263|NCT05020340|NO_INTERVENTION|Control|ECV will not be performed.
62386247|NCT04301492|EXPERIMENTAL|Vortioxetine|first visit medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed. After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit (Week 1 - Visit 2) to receive study drug (Brintellix drops 20 mg/ml). All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day. After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day (Visit 3- Phone contact). At Week 4-8-12 (Visits 4-5-6) patients will return to the site to perform all clinical evaluations required and to receive study drug. Visit 7 subjects will return to the site to perform all the assessment required by protocol.
62386248|NCT04134689|ACTIVE_COMPARATOR|DOT Selfie Intervention Arm|"The DOT Selfie Intervention will comprise a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders.~Patients in this arm will receive detailed training (in English or Luganda) on VDOT use prior to starting treatment. Each patient will be required to record and submit daily videos as they self-administer their medication. Patients who successfully submit their videos for seven consecutive days will receive a weekly incentive in the form of social bundles of airtime minutes. A prepaid internet bundle will also be uploaded to each mobile phone weekly to allow for daily video uploads. Additionally, patients will receive text message medication reminders to encourage treatment compliance."
62386249|NCT04134689|ACTIVE_COMPARATOR|In-person DOT Control Arm.|Patients in this arm will be managed according to the usual clinical practice in Uganda i.e. community- or home-based directly observed treatment .Patients in this arm will make prior arrangements with a study nurse to determine a convenient meeting place (e.g. at the patient's work, home etc.) The study nurse will then meet the patient at this location. At each daily meeting, the patient will self-administer the TB drugs as the study nurse directly observes and documents (date, time, drug dosing etc.) At the end of each meeting, the patient and nurse will agree on a convenient meeting place for the next day's dosing. These daily meetings will continue until treatment completion. The study nurse will record patient's medication intake, as well as the time taken to reach the patient, amount of money spent on round-trip transportation, and total amount of time spent during each patient encounter.
62386250|NCT03112343|ACTIVE_COMPARATOR|ICT-based intervention|Subjects in the ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
62386251|NCT03112343|PLACEBO_COMPARATOR|Conventional intervention group|Subjects in the conventional intervention group will only save and send their health information to the server via the personal health record app
62386252|NCT02172820|EXPERIMENTAL|Financial incentives|Participants receive financial incentives for completing exercise sessions.
62386253|NCT02172820|NO_INTERVENTION|Control|Participants receive an equal amount of clinical contact but no financial incentives for completing exercise visits.
62386254|NCT04373616|EXPERIMENTAL|ACI-24|
62386255|NCT04373616|PLACEBO_COMPARATOR|Placebo|
62386256|NCT00299091|NO_INTERVENTION|Control|Efavirenz capsules 600 mg
62386257|NCT00299091|EXPERIMENTAL|Experimental|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
62559201|NCT04242810|PLACEBO_COMPARATOR|Sham rTMS|Sham rTMS applied over memory task-based brain target
61990264|NCT05129488|EXPERIMENTAL|All participants received Biotrue ONEday lenses with and without an alternate packaging solution|Participants were given both Commercially available Biotrue ONEday lenses and Biotrue ONEday Contact Lenses with EPG03 Packaging Solution. Lens material is made from a hydrophilic copolymer of 2- hydroxyethyl methacrylate and N-vinylpyrrolidone and is 78% water by weight when immersed in saline solution. EPG03 Packaging Solution contains a phosphate buffered saline solution containing potassium chloride, poloxamine, poloxamer 181, glycerol (glycerin), erythritol, and polyquaternium-1.
62386258|NCT03702023|ACTIVE_COMPARATOR|Intervention Group|Patients in the intervention group with receive the study medication 1000mg acetaminophen orally one time prior to their scheduled electrophysiology procedure.
62386259|NCT03702023|PLACEBO_COMPARATOR|Placebo Oral Tablet|Patients in the control group will receive a placebo orally one time prior to their scheduled electrophysiology procedure.
62386260|NCT03011606|EXPERIMENTAL|Robotic surgery|Single arm. All Registered patients will undergo robotic surgery
62386261|NCT04840914|EXPERIMENTAL|LY3461767|LY3461767 administered subcutaneously (SC).
62386262|NCT04840914|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously (SC).
62386263|NCT02182505|EXPERIMENTAL|Berodual® Respimat®, low dose|
62386264|NCT02182505|EXPERIMENTAL|Berodual® Respimat®, high dose|
62386265|NCT02182505|ACTIVE_COMPARATOR|Berodual® MDI Aerochamber®|
62559202|NCT00570063|PLACEBO_COMPARATOR|1|PF-02545920 15 mg tablets taken twice a day by mouth for 21 days
62559203|NCT00570063|PLACEBO_COMPARATOR|2|Matching placebo tablets taken twice a day by mouth for 21 days
62567679|NCT05648773|PLACEBO_COMPARATOR|Control|No message or financial incentive
62767220|NCT05524610|NO_INTERVENTION|Pre-Implementation of Routine Sexual Function Screening (Baseline)|This arm will include patients with and surviving cancer who are seen during the Pre-Implementation study period. It will include patients diagnosed prior to age 18 years and 15-24 years old at the time of study. Patients will be approached by research personnel at the end of each visit for participation in a survey. The pre-implementation survey will assess sexual function communication and patient satisfaction. In addition, medical record data abstraction of clinical care related to sexual health and function will be collected.
62559204|NCT03176069|ACTIVE_COMPARATOR|Group A - women diagnosed with vaginismus|"All patients will be submitted to anamnesis, physical examination, examination of the pelvic floor. The algometry will be performed with patient will be lying in a supine position (belly up), with the pelvis in a neutral position, back at 45º and feet supported in stirrups, for the verification the perineal pain threshold.~The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:~Kinesiotherapy Manual therapy Electrotherapy (electric electrostimulation, ultrasound) Behavioral therapy"
62559205|NCT03176069|ACTIVE_COMPARATOR|Group B - women without a diagnosis of vaginismus|All patients will be submitted to anamnesis, physical examination, examination of the pelvic floor. The algometry will be performed with patient will be lying in a supine position (belly up), with the pelvis in a neutral position, back at 45º and feet supported in stirrups, for the verification the perineal pain threshold.
62559206|NCT04935333||Leiomyoma samples|Leiomyoma samples and peripheral blood samples obtained from women between 18 and 80 years with suspected myometrial tumour
62559207|NCT04935333||Leiomyosarcoma samples|Leiomyosarcoma samples and peripheral blood samples obtained from women between 18 and 80 years with suspected myometrial tumour
62559208|NCT04935333||Control samples|Peripheral blood samples obtained from women between 18 and 80 years without suspected myometrial tumour
62559209|NCT06034106|EXPERIMENTAL|Pomegranate (P. granatum) peel compress group|36 g of pomegranate peel powder was given to the patient in a closed container. A teaspoon (approximately 2-3 g) of powder was mixed with water from the storage container and applied to the patient's knee by making a paste, and then the knee was wrapped with a bandage. It was kept for 20 minutes by placing a hot thermophore (approximately 40-45 C) on it. This application was carried out 3 days a week.
62559210|NCT06034106|PLACEBO_COMPARATOR|Hot compress|In the hot compress group, the knee was wrapped with a bandage and the hot thermophor (approximately 40-45 °C) was placed on the knee. The hot thermoform was applied to the patient 3 days a week by keeping it for 20 minutes.
62559211|NCT06034106|NO_INTERVENTION|Control Group|Patients in the control group did not receive any additional intervention.
62559212|NCT04192643|EXPERIMENTAL|TRANEXAMİC ACİD|. 1 gr tranexamic acid in 100 ml salin given in 15 minutes
62559213|NCT04192643|PLACEBO_COMPARATOR|NO TRANEXAMİC ACİD|100 ml salin solution
62559214|NCT01153100|NO_INTERVENTION|Standard insulin drip therapy|Standard insulin drip therapy
62559215|NCT01153100|ACTIVE_COMPARATOR|Insulin drip and glargine|Insulin drip and glargine 0.25 units per kg body weight
62559216|NCT01996930|ACTIVE_COMPARATOR|Haelan tape (steroid impregnated tape)|"Haelan tape, medicated tape for cutaneous use, containing 4mcg Fludroxycortide per centimetre squared.~Maximum daily dosage of 0.1mg = 25cm squared per day. Application = once daily and left in situ for 24 hours Maximum duration of treatment = 28 days"
62386266|NCT04152109|OTHER|Without laying on of hands|The patients will remain in bed supine with blindfolds. A volunteer will move close to the patient with hands behind and mentally repeat the alphabet or do count math during 5 minutes, around 8 weeks.
62386267|NCT04152109|SHAM_COMPARATOR|Laying on of hands with healing intent and without Spiritual connection|Participants included in this subgroup will be exposed to the laying on of hands with healing intent by volunteers. The patients will be blindfold in the supine bed during 5 minutes, 8 weeks.
62386268|NCT04152109|EXPERIMENTAL|"Laying on of hands with healing intent and Spiritual connection by Spiritual Passe"|"The participants will be subjected application of the laying on of hands by the passistas who will give the Spiritist passe. Patients remain in the supine bed blindfolded for 5 minutes, around 8 weeks."
62386269|NCT03310476|EXPERIMENTAL|Baked, consumed chilled potatoes|
62386270|NCT03310476|EXPERIMENTAL|Boiled, consumed hot potatoes|
62386271|NCT05763836|ACTIVE_COMPARATOR|Group Block|Scalp nerve block applied group
62559217|NCT01996930|ACTIVE_COMPARATOR|Silver nitrate|Avoca caustic applicator 95% w/w cutaneous stick Cautery with silver nitrate cutaneous stick undertaken twice weekly Maximum duration of treatment = 28 days
62386272|NCT05763836|EXPERIMENTAL|Group Ibuprofen|Intravenous ibuprofen applied group
62386273|NCT05763836|EXPERIMENTAL|Grup Ibuprofen&Block|Both intravenous ibuprofen and scalp nerve block applied group
62386274|NCT03091920|EXPERIMENTAL|IW-1973 QD/QD|On Days 1-14: IW-1973 40 mg taken once daily (QD) in morning (AM) and placebo taken QD at night (PM).
62386275|NCT03091920|EXPERIMENTAL|IW-1973 BID (Twice Daily)/QD|On Days 1-7: IW-1973 20 mg taken in AM and IW-1973 20 mg taken in PM. On Days 8-14: IW-1973 40 mg taken QD in AM and placebo taken QD in PM.
62559218|NCT03627117|EXPERIMENTAL|Verum/Placebo|This group will start with CBD and after washout will receive placebo.
62559219|NCT03627117|EXPERIMENTAL|Placebo/Verum|This group will start with placebo and will receive CBD after washout.
62386276|NCT03091920|PLACEBO_COMPARATOR|Placebo|On Days 1-14: Placebo taken in AM and in PM.
62386277|NCT05275140|EXPERIMENTAL|Experimental group 1 (adapted taekwondo)|The general structure of the adapted taekwondo will include a 10-min warm-up consisting of joint mobility exercises and low intensity aerobic work, then, for 40-min of the adapted taekwondo (will consist of non-contact activities, distributed in 10-min of basic postures and specific movements with the upper limbs and 20-min of lower limb movements performed individually and in pairs with and without the implementation of taekwondo. In addition, choreographies or forms (sequence of arm and leg movements that simulate an imaginary combat) specific to this modality were adapted to the characteristics of older women for 10-min; and will be developed to finish with the cool down for 10-min through dynamic and static flexibility exercises.
62559220|NCT03629262|EXPERIMENTAL|Dexmedetomidine group|For patients in the dexmedetomidine group, postoperative analgesia is provided in the form of patient-controlled intravenous analgesia. The formula contains a mixture of sufentanil (1.25 ug/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a patient-controlled bolus of 2 ml each time and a lockout interval of 8 minutes.
62559221|NCT03629262|PLACEBO_COMPARATOR|Control group|For patients in the control group, postoperative analgesia is provided in the form of patient-controlled intravenous analgesia. The formula contains a mixture of placebo and sufentanil (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a patient-controlled bolus of 2 ml each time and a lockout interval of 8 minutes.
62767221|NCT05524610|EXPERIMENTAL|Post-Implementation of Routine Sexual Function Screening|This arm will include patients with and surviving cancer who are seen during the Post-Implementation study period, once the routine sexual function screening intervention has been implemented. It will include patients diagnosed prior to age 18 years and 15-24 years old at the time of study. Patients will be approached by research personnel at the end of each visit for participation in a survey. The post-implementation survey will assess sexual function communication and patient satisfaction, as well as measures of acceptability, feasibility, and appropriateness of the intervention. In addition, medical record data abstraction of clinical care related to sexual health and function will be collected.
62767222|NCT03840343|EXPERIMENTAL|Lower Dose MSC|This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Lower Dose.
62767223|NCT03840343|EXPERIMENTAL|Higher Dose MSC|This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Higher Dose
62767224|NCT03722654|EXPERIMENTAL|MTFS|MTFS-I Installation
62767225|NCT03722654|NO_INTERVENTION|Control|
62386278|NCT05275140|ACTIVE_COMPARATOR|Experimental group 2 (multi-component training)|The general structure of the multi-component training will include a 10-min warm-up consisting of joint mobility exercises and low intensity aerobic work, then, for 40-min of the multi-component training (distributed work in a circuit, which includes resistance training focused on the large muscles of the upper limbs and lower limbs combined with exercises aimed at cardiorespiratory fitness, agility and postural control, using elastic bands, poles, 2-kg medicine balls and chairs). The training volume will start (the first 4-weeks) with 3 sets of 10 repetitions per muscular exercise with a 2-min rest period between sets, performing slow movements of two seconds in concentric contraction and four seconds in eccentric contraction. Between weeks 5 to 8, the volume will increase to 4 sets of 10 repetitions per muscular exercise with 2-min of rest between sets.
62386279|NCT05275140|ACTIVE_COMPARATOR|Experimental group 3 (walking program)|The walking program will be distributed in three weekly sessions of 45- to 60-min every other day, for 16-weeks (48 sessions). The general structure of the protocol will include a 5-min warm-up consisting of joint mobility and flexibility exercises. Next, the main part will be developed for 30- to 45-min (increased by 5-min every 4-weeks) consisting of walking on flat ground, touring the jogging circuit that the University has on campus, and ending with 5-min cool down through dynamic and static flexibility exercises.
62386280|NCT05275140|NO_INTERVENTION|Control group|The control group, the individuals will participate in the assessments (initial and final) and will be asked to maintain their usual activities. An undergraduate student (support personnel) will contact the participants by telephone (once a week) to consult them about their health status and monitor their activities. At the end of the intervention period, the control group will be invited to participate in a physical activity program that will be developed at the University based on the results of this project.
62386281|NCT01190280||AC - operation|Patients admitted with acute cholecystitis randomized to operation
62767226|NCT01066351|EXPERIMENTAL|Erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
62386282|NCT01190280||AC - observation|Patients admitted with acute cholecystitis randomized to observation
62767227|NCT01066351|PLACEBO_COMPARATOR|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
62386283|NCT01190280||SGBS - operation|Patients admitted with uncomplicated gallstone disease randomized to operation
62386284|NCT01190280||SGBS - observation|Patients admitted with uncomplicated gallstone disease randomized to observation
62386285|NCT01190280||1983 - stones|Patients that in 1983 were diagnosed with gallstones in a population screening
62386286|NCT01190280||1983 - operation|Patients that were operated for gallstone disease at Haukeland University Hospital, Bergen, Norway, in 1983
62386287|NCT01190280||1983 - controls|Patients that were shown not to have gallstones in a 1983 population screening
62386288|NCT01190280||Gallstone patients|Patients with symptoms from gallstone disease
62386289|NCT06166394||Mepivacaine|Day surgery patients(30 patients); For these patients- Administration of a spinal hypobaric mepivacaine injection
62386290|NCT06166394||Bupivacaine|In-patients(30 patients): For these patients- Administration of a spinal hypobaric bupivacaine injection
62559222|NCT04371289||COVID-19 outpatients|Mild COVID-19 outpatients managed by General Practitioners in Northern Italy (Lombardy)
62559223|NCT04371289||COVID-19 inpatients|Mild, moderate and severe inpatients managed in different Italian Hospitals, mostly in Northern Italy (Lombardy)
62559224|NCT06403176||Minimally conscious state (MCS)|Minimally conscious state (MCS): have reproducible signs of awareness and exhibit fluctuations in consciousness
62767228|NCT06427694||Aldesleukin|Aldesleukin loading dose 1.5 x 10\^6 IU followed by maintenance dose of 1.5 x 10\^6 IU
62767229|NCT06427694||Placebo|Dextrose 5%
62767230|NCT06507839|EXPERIMENTAL|Single Ascending Dose (SAD) THRV-1268|5 dosing cohorts will receive a single oral dose of THRV-1268. The highest dose of THRV-1268 to be administered is 500 mg.
62559225|NCT06403176||Vegetative state (VS)|Vegetative state (VS): can open their eyes and preserve sleep-wake cycles, but unaware of themselves and their surroundings
62559226|NCT06403176||Patients with In-Stent Restenosis|In-Stent Restenosis was defined as greater than 50% within or immediately adjacent (within 5 mm) to the stent implanted that was detected by digital subtraction angiography (DSA).
62559227|NCT06403176||Patients with Non-Restenosis|In-Stent Restenosis was defined as less than 50% within or immediately adjacent (within 5 mm) to the stent implanted that was detected by digital subtraction angiography (DSA).
62559228|NCT02420925|EXPERIMENTAL|Celiac Plexus Block|There is one treatment arm who undergoes celiac plexus block.
62767231|NCT06507839|EXPERIMENTAL|Food Effect THRV-1268|food effect will be integrated into one of the SAD cohorts as a single dose, two-period with at least a 7-day washout, crossover cohort.
62767232|NCT06507839|EXPERIMENTAL|Multiple Ascending Dose (MAD) THRV-1268|3 dosing cohorts will receive THRV-1268 in the morning on Day 1 to Day 7.
62767233|NCT06507839|PLACEBO_COMPARATOR|Single Ascending Dose (SAD) Placebo|5 dosing cohorts will receive a single oral dose of placebo.
62767234|NCT06507839|PLACEBO_COMPARATOR|Food Effect Placebo|Food effect will be integrated into one of the SAD cohorts as a single dose, two-period with at least a 7-day washout, crossover cohort.
62767235|NCT06507839|PLACEBO_COMPARATOR|Multiple Ascending Dose (MAD) Placebo|3 dosing cohorts will receive placebo in the morning from Day 1 to Day 7.
62767236|NCT06187168||intraoperative hypotension|The exposure is intra-operative hypotension during the ERCP procedure (hypotension is defined as a 20% reduction in the mean arterial blood pressure (MAP) or systolic arterial blood pressure (SAP) \< 90 mmHg during CBD manipulation or after obstruction relief). The basal blood pressure (BP) will be the immediate reading before the endoscope insertion while the patient is in his left lateral position.
62767237|NCT06187168||No intraoperative hypotension|Not meeting the above definition of hypotension per our protocol (by timing, threshold, and method).
62386291|NCT04280042||Thoracoscopic surgical ablation|Participants in CASA AF Trial who underwent thoracoscopic surgical ablation to treat their long standing persistent AF will be asked to continue downloading the data from their implanted loop recorder, attend two hospital appointments (at 24 and 36 months post ablation) to complete questionnaires, have an ECG, a blood test and report current medications they use.
62386292|NCT04280042||Cather ablation|Participants in CASA AF Trial who underwent conventional catheter ablation to treat their long standing persistent AF will be asked to continue downloading the data from their implanted loop recorder, attend two hospital appointments (at 24 and 36 months post ablation) to complete questionnaires, have an ECG, a blood test and report current medications they use.
62559229|NCT06214910|OTHER|Investigational: Community-based TB preventive therapy (TPT)|Participants in the community arm will receive a multi-month dispensing packet at enrollment with the complete 3 month supply of TPT (3HP: 3 months of weekly isoniazid and rifapentine).
62559230|NCT06214910|ACTIVE_COMPARATOR|Standard-of-Care Tuberculosis Preventative Therapy (TPT)|Participants in the standard of care arm will receive a referral letter to their local Department of Health (DoH) clinic to continue TPT. They will be instructed to present to the DoH clinic within 2 weeks to receive their continuation doses of TPT per current South African DoH standard of care (refills administered monthly).
62559231|NCT06258083||Systemic right ventricle patients|
62559232|NCT00155311|EXPERIMENTAL|days after treatment|different days after orthodontic treament, samples will be taken.
62767238|NCT00411190|EXPERIMENTAL|Session 1|Subjects will receive 500 mg acetaminophen on Day 1, 400 mg ibuprofen on Day 2, 40 mg atorvastatin on Day 3.
62767239|NCT00411190|EXPERIMENTAL|Session 2|Subjects will be randomized to receive relacatib 60 mg or 120 mg from Day 1-14. On Day 15 subjects will receive 500 mg acetaminophen, 400 mg ibuprofen on Day 16 and 40 mg atorvastatin on Day 17 with usual dose of relacatib.
62767240|NCT02250664|EXPERIMENTAL|0.8 mg nicotine|0.8 mg nicotine very low nicotine content cigarettes
62767241|NCT02250664|EXPERIMENTAL|0.12 mg nicotine|0.12 mg nicotine very low nicotine content cigarettes
62767242|NCT02250664|EXPERIMENTAL|0.03 mg nicotine|0.03 mg nicotine very low nicotine content cigarettes
62767243|NCT01703065|EXPERIMENTAL|Cabozantinib in metastatic CRPC|Metastatic CRPC patients to receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
62559233|NCT03054233|EXPERIMENTAL|Obese|Obese pregnant women received spinal anesthesia using Quincke Needle 25G/27G in crossed leg sitting position for caesarean section
62559234|NCT03054233|EXPERIMENTAL|Non-obese|Non-obese pregnant women received spinal anesthesia using Quincke Needle 25G/27G in crossed leg sitting position for caesarean section
62559235|NCT01795404|EXPERIMENTAL|Inquiry Based Stress Reduction (IBSR) Program|During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts. Through the use of self-inquiry practices participants are taught to increase awareness of their thoughts and feelings, to observe their emotional and physical responses during situations perceived by them as stressful, and allow their mind to return to its true, peaceful, creative nature. Through the process of self-inquiry, participants take an active role in investigating their stressful thoughts, and by this regulating their stress and managing symptoms and emotions, thus enabling them to cope better with the distress related to the possibility of cancer.
62767244|NCT01703065|EXPERIMENTAL|Cabozantinib in non-metastatic CRPC|Non-Metastatic CRPC patients to receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
62767245|NCT03255538|EXPERIMENTAL|DFM: Mean pressure|In this group, deep friction massage will be applied with the mean pressure, previously obtained in a baseline assessment.
61990265|NCT03147547|ACTIVE_COMPARATOR|Promotional Brochure|Participants in this condition received one of the strategies in the Parent Engagement Package: a promotional brochure with information about the parenting intervention being offered at their child's school, the Triple P Positive Parenting Program. This information included the location of meetings, free childcare, topics covered, choice of English or Spanish groups, meeting day and time, and an enrollment form. Parents who returned the enrollment form received a confirmation letter prior to the first parenting program session.
61990266|NCT03147547|EXPERIMENTAL|Parent Engagement Package|Participants in this condition received all engagement strategies in the Parent Engagement Package, which included: 1) the promotional brochure; 2) family testimonial flyer that included photos and quotes from prior participants; 3) teacher endorsement of the Triple P program; 4) provider engagement call to motivate parents to attend; and 5) phone reminders prior to each Triple P session.
61990267|NCT03131440|EXPERIMENTAL|Experimental Condition #1|core, support calls
62767246|NCT03255538|EXPERIMENTAL|DFM: Mean pressure - 25%|In this group, deep friction massage will be applied will less 25% of the pressure previously obtained in a baseline assessment.
61990268|NCT03131440|EXPERIMENTAL|Experimental Condition #2|core, support calls, app+
61990269|NCT03131440|EXPERIMENTAL|Experimental Condition #3|core, support calls, buddy
62767247|NCT03255538|EXPERIMENTAL|DFM: Mean pressure +25%|In this group, deep friction massage will be applied will an increment of 25% of the pressure previously obtained in a baseline assessment.
61990270|NCT03131440|EXPERIMENTAL|Experimental Condition #4|core, support calls, online gym
61990271|NCT03131440|EXPERIMENTAL|Experimental Condition #5|core, support calls, app notifications
61990272|NCT03131440|EXPERIMENTAL|Experimental Condition #6|core, app+
61990273|NCT03131440|EXPERIMENTAL|Experimental Condition #7|core, app+, buddy
61990274|NCT03131440|EXPERIMENTAL|Experimental Condition #8|core, app+, online gym
61990275|NCT03131440|EXPERIMENTAL|Experimental Condition #9|core, app+, app notifications
61990276|NCT03131440|EXPERIMENTAL|Experimental Condition #10|core, buddy
62559236|NCT01795404|NO_INTERVENTION|Control group|Waited-list control
62559237|NCT00607321|EXPERIMENTAL|1|Medtronic Bifurcation Stent System
62559238|NCT02292693|EXPERIMENTAL|intubation with immobilized cervical spine|endotracheal intubation with immobilized cervical spine
62559239|NCT01753570|EXPERIMENTAL|MP-424+RBV+IFN beta, Genotype1|
62559240|NCT01753570|EXPERIMENTAL|RBV+IFN beta, Genotype1|
62559241|NCT01753570|EXPERIMENTAL|MP-424+RBV+IFN beta, Genotype2|
62386293|NCT05315531|EXPERIMENTAL|Water Intake|3-week intervention period during which articipants will be asked to increase their daily plain water consumption to at least 2.5 L/d of water for males and 2L/d for females.
62386294|NCT00558961|EXPERIMENTAL|I|Gleevec Chlorambucil
62386295|NCT03826641|EXPERIMENTAL|Sequence 1|Period 1 : Fasted state + HCP1805, Period 2 : Fasted state + HCP1801
62386296|NCT03826641|EXPERIMENTAL|Sequence 2|Period 1 : Fasted state + HCP1801, Period 2 : Fasted state + HCP1805
62386297|NCT03826641|EXPERIMENTAL|Sequence 3|Period 1 : High fat diet + HCP1805, Period 2 : High fat diet + HCP1801
62386298|NCT03826641|EXPERIMENTAL|Sequence 4|Period 1 : High fat diet + HCP1801, Period 2 : High fat diet + HCP1805
62386299|NCT05263895|ACTIVE_COMPARATOR|Treatment A: PF-0732133/ritonavir|PF-07321332 ritonavir
62386300|NCT05263895|EXPERIMENTAL|Treatment B: PF-07321332/ritonavir|PF-07321332 ritonavir
62386301|NCT05263895|EXPERIMENTAL|Treatment C: PF-07321332/ritonavir|PF-07321332 ritonavir
62386302|NCT05263895|EXPERIMENTAL|Treatment D: PF-07321332/ritonavir|PF-07321332 ritonavir
62386303|NCT05263895|EXPERIMENTAL|Treatment E: PF-07321332|PF-07321332
62386304|NCT03086044|EXPERIMENTAL|HCV NAT Positive Donor|"Intervention: 2 week treatment course with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily~Participants who receive allografts from a donor who is HCV NAT positive will receive treatment with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily, beginning on the day of transplant."
62386305|NCT03086044|EXPERIMENTAL|HCV NAT Negative, HCV Ab Positive Donor|"Intervention: HCV viral load monitoring~Participants who receive allografts from a donor who is HCV Ab positive and NAT negative will have close serial HCV viral load monitoring and will be treated with a direct acting antiviral, 400mg / velpatasvir 100mg daily, for 6 weeks if HCV viremia develops."
62386306|NCT05818176|EXPERIMENTAL|NAVIRFA® Navigation System|
62559242|NCT05058079|ACTIVE_COMPARATOR|Hand-held group|Patients hand will be held by the anesthesia provider during the procedure. A folded blanket will be over the patient's hand during the procedure and the anesthesia provider will have their hand under the folded blanket holding the patient's hand.
62559243|NCT05058079|NO_INTERVENTION|No hand holding group|No physical contact for comfort or reassurance during the procedure. A folded blanket will be over the patient's hand during the procedure and the anesthesia provider will be next to the patient's hand.
62559244|NCT02688543|EXPERIMENTAL|RF treatment|Patients treated with radio frequency of the genicular nerves
62559245|NCT06551207|PLACEBO_COMPARATOR|fuquintinib|
62386307|NCT05818176|ACTIVE_COMPARATOR|ultrasound-guided|
62386308|NCT03853759||Patients with Heart Failure|
62386309|NCT03853759||Healthy İndividuals|
62386310|NCT00852358|EXPERIMENTAL|intrathecal laronidase|The Experimental treatment group will receive study assessments and intrathecal laronidase (1.74 mg laronidase) treatments every 1-3 months beginning at start of study.
62559246|NCT06551207|EXPERIMENTAL|Fuquintinib combined with cardonilizumab and SBRT|
62559247|NCT01455662||all patients after cardiac arrest|
61990277|NCT03131440|EXPERIMENTAL|Experimental Condition #11|core, buddy, online gym
61990278|NCT03131440|EXPERIMENTAL|Experimental Condition #12|core, buddy, app notifications
62559248|NCT06305117|EXPERIMENTAL|Participants|As this is a feasibility study, all patients included in this study will be offered the intervention.
62559249|NCT01068639||A|
62559250|NCT01956578|EXPERIMENTAL|Breathing Exercise Cohort|All patients enrolled will be asked to wear an external respiration band while performing a series of breathing exercises.
62559251|NCT06458517|OTHER|Intraoral PBM|
62559252|NCT06458517|OTHER|Transcutaneous PBM|
61990279|NCT03131440|EXPERIMENTAL|Experimental Condition #13|core, online gym
62386311|NCT00852358|OTHER|Control Group|During the first 11 months, the control group will receive study assessments but will be unblinded with no intrathecal treatment or placebo administered. Beginning at month 12, the control group will receive intrathecal laronidase (1.74 mg) treatment every 3 months (months 12, 15, 18, and 21).
62386312|NCT01444989|EXPERIMENTAL|Patients without actinic keratosis|Patients with out the diagnosis of actinic keratosis will receive the experimental questionnaire.
62386313|NCT01444989|EXPERIMENTAL|Patients with Actinic Keratosis|Patients with the diagnosis of actinic keratosis will receive the experimental questionnaire.
62386314|NCT00673075|ACTIVE_COMPARATOR|1|Encapsulated Nebivolol
62386315|NCT00673075|ACTIVE_COMPARATOR|2|Encapsulated Carvedilol
62386316|NCT04241627|EXPERIMENTAL|Cell Phone Support|An adherence facilitator will deliver Cell Phone Support by daily phone calls Monday through Friday for 12 weeks, to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services.
62559253|NCT04348877|OTHER|Antibody-Rich Plasma|400 millimeter of Antibody-Rich Plasma from COVID-19 recovered patients will be transfused to patients with severe or immediately life-threatening COVID-19
62559254|NCT04240392|EXPERIMENTAL|Collaborative Care (CC)|The CC team includes an obstetrical provider and a nursing case manager. The obstetrician will see all participants, initially to discuss preferences for addiction treatment, buprenorphine, methadone (MAT) or no MAT. The obstetrician will see participants every 1-2 weeks, as needed and will provide prenatal care. The care team will meet at least monthly and review the participants' status. For research purposes, the CM will obtain informed consent, collect and enter results of the urine drug screen (UDS) into a database. At enrollment and at 26 and 34 weeks' gestation the care manager will ask participants to complete an assessment battery of self-reported measures.
62767248|NCT03255538|NO_INTERVENTION|Control session|In this group, the participants will rest for 15 minutes
62767249|NCT03033342|EXPERIMENTAL|Oral single doses of MRX-4|Single escalating oral doses of MRX-4 from 250 mg to 3000 mg
62767250|NCT03033342|EXPERIMENTAL|Oral multiple doses of MRX-4|Twice daily escalating oral doses of MRX-4 for 10 days: 500 mg, 750 mg, 1000 mg, and 1500 mg
61990280|NCT03131440|EXPERIMENTAL|Experimental Condition #14|core, online gym, app notifications
62559255|NCT04240392|ACTIVE_COMPARATOR|Extension for Community Healthcare Outcomes (ECHO)|ECHO is a remote education model that provides mentorship and guided practice and participation in a learning community, via video conferencing. The practice members who participate in ECHO will include obstetricians and nurses as well as other members of the care team who wish to join. Providers are given access to a password-protected website containing the recorded sessions, a discussion board, and resource library. CME credits are available for each session and can motivate providers to attend.
62559256|NCT03617094|EXPERIMENTAL|Early percutaneous vertebroplasty (EPV)|Surgical procedure of percutaneous vertebroplasty.
62559257|NCT03617094|ACTIVE_COMPARATOR|Standard Conservative treatment (CT)|Thoracolumbar corset.
62559258|NCT01780701||High risk prostate cancer patients|Men who have been recently diagnosed with high risk prostate cancer (Gleason score 7 and above) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health \& Science University's Advanced Imaging Research Center.
62559259|NCT01780701||Low risk prostate cancer patients|Men who have been recently diagnosed with low risk prostate cancer (Gleason score 7 \[3+4\] and below) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health \& Science University's Advanced Imaging Research Center.
62767251|NCT03033342|EXPERIMENTAL|MRX-4 co-administered with omeprazole|Impact of concomitant food or omeprazole on the pharmacokinetics of oral MRX-4.
62767252|NCT03033342|PLACEBO_COMPARATOR|Oral single doses of placebo|Single oral doses of placebo to match MRX-4
62767253|NCT03033342|PLACEBO_COMPARATOR|Oral multiple doses of placebo|Multiple oral doses of placebo given twice daily for 10 days to match MRX-4
62559260|NCT01350882|EXPERIMENTAL|A|Patients randomized into the arm blind A. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
62767254|NCT03033342|PLACEBO_COMPARATOR|Placebo co-administered with omeprazole|Oral placebo given on Day 1, Day 7 to match MRX-4 dosing with omeprazole
62767255|NCT04603222|EXPERIMENTAL|Treatment Group|Group treating blepharitis with SUMMIT BRUSH and Ocusoft Lid Scrub Original Foaming Eyelid Cleanser once a day
62767256|NCT04603222|ACTIVE_COMPARATOR|Control Group|Group treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser once a day
62767257|NCT01399203||percutaneous coronary intervention|The investigators reviewed all consecutive patients who were undergoing percutaneous coronary intervention
62767258|NCT03705910|ACTIVE_COMPARATOR|Perceptive Rehabilitation (PR-group)|"This treatment will include small latex cones with different resistance. In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture."
62767259|NCT03705910|ACTIVE_COMPARATOR|Mobilisation Techniques (Mob-group)|"A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point."
61990281|NCT03131440|EXPERIMENTAL|Experimental Condition #15|core, app notifications
61990282|NCT03131440|EXPERIMENTAL|Experimental Condition #16|core, support calls, app+, buddy
61990283|NCT03131440|EXPERIMENTAL|Experimental Condition #17|core, support calls, app+, online gym
61990284|NCT03131440|EXPERIMENTAL|Experimental Condition #18|core, support calls, app+, app notifications
61990285|NCT03131440|EXPERIMENTAL|Experimental Condition #19|core, support calls, buddy, online gym
62767260|NCT03705910|NO_INTERVENTION|Control Group (C-group)|This group will not receive any intervention during this period. C-group will attend assessments.
61990286|NCT03131440|EXPERIMENTAL|Experimental Condition #20|core, support calls, buddy, app notifications
61990287|NCT03131440|EXPERIMENTAL|Experimental Condition #21|core, support calls, online gym, app notifications
61990288|NCT03131440|EXPERIMENTAL|Experimental Condition #22|core, app+, buddy, online gym
61990289|NCT03131440|EXPERIMENTAL|Experimental Condition #23|core, app+, buddy, online gym, app notifications
61990290|NCT03131440|EXPERIMENTAL|Experimental Condition #24|core, support calls, buddy, online gym, app notifications
61990291|NCT03131440|EXPERIMENTAL|Experimental Condition #25|core, buddy, online gym, app notifications
61990292|NCT03131440|EXPERIMENTAL|Experimental Condition #26|core, app+, online gym, app notifications
61990293|NCT03131440|EXPERIMENTAL|Experimental Condition #27|core, support calls, app+, buddy, online gym
61990294|NCT03131440|EXPERIMENTAL|Experimental Condition #28|core, support calls, app+, buddy, app notifications
61990295|NCT03131440|EXPERIMENTAL|Experimental Condition #29|core, support calls, app+, online gym, app notifications
61990296|NCT03131440|EXPERIMENTAL|Experimental Condition #30|core
61990297|NCT03131440|EXPERIMENTAL|Experimental Condition #31|core, app+, buddy, app notifications
61990298|NCT03131440|EXPERIMENTAL|Experimental Condition #32|core, support calls, app+, buddy, online gym, app notifications
61990299|NCT02234375|EXPERIMENTAL|Gadolinium enhancement|Gadolinium enhancement will be performed using intravenous Dotarem\[recommended dose of 0.2 mL/kg (0.1 mmol Gd/kg )\]
62386317|NCT04241627|EXPERIMENTAL|Live Text Support|An adherence facilitator will deliver Live Text Support, Monday through Friday for 12 weeks, to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services.
62767261|NCT02971241|EXPERIMENTAL|Immediate intervention group|"A randomized, waitlist controlled trial with three hundred fifty older adult subjects with type 2 diabetes and 280 young adult subjects will be conducted in Taipei Tzu Chi Hospital and Hualien Tzu Chi Hospital in Taiwan. The patients who are randomized to the immediate intervention group will be assigned to the training course as soon as a course is available.~The intervention is a 12-week program which consists of 8-week training sessions followed by 4-week consultation service for technical support. Both will be provided by the young volunteers with a lead instructor."
62767262|NCT02971241|OTHER|Waitlist control group|The patients randomized to the waitlist control group will need to wait for four months to serve as no intervention control, and then assigned to the training course.
61990300|NCT05334901|EXPERIMENTAL|High intensity light cure|High intensity light curing (2200 mw/cm2)To achieve increased power and a wider spectrum for short exposure time (1 second) to overcome resin composite restoration techniques sensitivity and shorten the clinical procedure
61990301|NCT05334901|ACTIVE_COMPARATOR|Low intensity light cure|Conventional light curing (1200 mw/cm2) for long exposure time (20 seconds) to achieve the slower rate of conversion allowing for a better flow of the material, which decreases contraction stress in the filling material
61990302|NCT04479956|EXPERIMENTAL|Surgical Ligation|Conventional surgical procedures will carried out through a 3-4 cm incision in the groin. The trunk of GSV and the tributaries will be ligated and divided.
62559261|NCT01350882|PLACEBO_COMPARATOR|B|Patients randomized into the arm blind B. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
62559262|NCT02436928|EXPERIMENTAL|AT-501 High Dose vaccine|Inactivated H7N9 High Dose Antigen
62559263|NCT02436928|EXPERIMENTAL|AT-501 High Dose vaccine with Adjuvant|Inactivated H7N9 High Dose Antigen with Adjuvant
62559264|NCT02436928|EXPERIMENTAL|AT-501 Low Dose vaccine|Inactivated H7N9 Low Dose Antigen
62559265|NCT02436928|EXPERIMENTAL|AT-501 Low Dose vaccine with Adjuvant|Inactivated H7N9 Low Dose Antigen with Adjuvant
62559266|NCT01091194|OTHER|Exercise|Interval-based aerobic exercise
62559267|NCT01091194|NO_INTERVENTION|Control|No intervention other than regular follow up hospital visits
61990303|NCT04479956|EXPERIMENTAL|Microwave group|The microwave treating wire (Microwave Intracavity Coagulation System; Shanghai Medical Electronics, Shanghai, China) will be inserted into the GSV until it reached the medial aspect of ankle, guided by a light that illuminated the tip of the wire. Then, GSV will be ablated using pulse mode at 20-30 W. The treating wire will be withdrawn at 2-4 mm/s, with the ablation time lasting 2 s (energy delivery to the GSV was estimated at around 80 J/cm); the treatment parameters will be based on a previous report. Tumescence will be used in all patients with 0.9% saline containing 20 mL 2% lidocaine with 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L 0.9% saline.
61990304|NCT04479956|EXPERIMENTAL|Laser ablation group|"Endovenous Laser Ablation (EVLA) uses a laser Fiber, which is inserted into the abnormal vein via a small skin puncture.using 1470 nm laser and a radial fiber for less discomfort. Two weeks later the branch vessels have reduced in size"
61990305|NCT04479956|EXPERIMENTAL|Radiofrequency ablation group|inserts a small catheter into the diseased vein through a small incision, using ultrasound guidance for an accurate and live view. Consistent and uniform heat is delivered to contract the collagen in the vein walls, causing them to collapse and close. After the vein is closed the treated vein is gradually absorbed into surrounding tissue.
61990306|NCT06386835|EXPERIMENTAL|Collagen Paste|Seton is removed, the fistula tract is de-epithelialised and collagen paste applied.
61990307|NCT06386835|ACTIVE_COMPARATOR|Mucosal Advancement Flap|"The internal opening is excised and is covered with a U-shape rectal mucosal flap"
61990308|NCT04227106|EXPERIMENTAL|EB-101|One-time surgical application of EB-101 on up to 6 chronic, RDEB wounds
61990309|NCT06238076|EXPERIMENTAL|Group experimental|The patients included in the study and admitted in the maxillofacial surgery department for mandibular fibula free flap reconstruction will benefit from a surgery assisted with the universal surgical device FIBUMAND.
61990310|NCT03342742|EXPERIMENTAL|Daily Caloric Restriction|The daily caloric restriction group will be instructed to reduce energy intake by a 34% daily energy deficit from baseline individual weight maintenance energy requirements.
62386318|NCT04241627|ACTIVE_COMPARATOR|Automated Text Reminders|"The comparison condition will include automated text message reminders, using this template: Take \[name of medication\] at \[set time\]. To confirm intake, press REPLY, type CARE 1, and press SEND."
62386319|NCT00551681|ACTIVE_COMPARATOR|1|Epicardial left ventricular lead placement
62386320|NCT00551681|ACTIVE_COMPARATOR|2|transvenous left ventricular lead
62386321|NCT00498784|EXPERIMENTAL|Arm 1|
62386322|NCT00743639|OTHER|1|Interventional
62386323|NCT01117428|EXPERIMENTAL|Sym004|
62386324|NCT00495508|ACTIVE_COMPARATOR|Quinine|
62386325|NCT00495508|ACTIVE_COMPARATOR|Arthemeter lumefantrine|
62767263|NCT04517838||Observational Blood & Tissue Cohort|Patients with stage I-III disease undergo collection of blood samples at baseline, 8 and 16 weeks after starting treatment, and at the time of invasive disease recurrence. Patients with stage IV disease undergo collection of blood samples at baseline, 8 and 16 weeks after starting treatment, and at the time of progressive disease. Patients with stage IV disease with no disease progression ≥ 2 years on the same line of therapy undergo collection of blood samples at baseline, 8 and 16 weeks after starting treatment, and at the time of invasive disease recurrence. For all patients, tissue samples from previous biopsy and/or surgical resection are also collected on study.
62767264|NCT04517838||Observational Tissue-Only Cohort|For patients with stage I-IV disease who received or previously completed anti-HER2 therapy, tissue samples from previous biopsy and/or surgical resection are collected on study.
62767265|NCT03238339||The Portable Home Noninvasive Ventilator treatment group|The patients maintain a stable COPD regimen, and on the basis of conventional home oxygen therapy, a portable, wearable, non-invasive ventilator will be used.
62386326|NCT04902573||Asthma patients|Trimbow pMDI prescribed for maintenance treatment of adult asthma as per the licensed indication.
61990311|NCT03342742|EXPERIMENTAL|Intermittent Fasting|Participants in the intermittent fasting group will be instructed to reduce energy intake to \~20% of estimated energy requirement (delivered as a single meal) three non-consecutive days per week, resulting in a weekly energy deficit of \~34% (similar to the daily caloric restriction group).
62386327|NCT01484522||Group A|Influenza A 2009 Monovalent vaccine
62386328|NCT01484522||Group B|Influenza A 2009 monovalent vaccine
62559268|NCT03926299|EXPERIMENTAL|Laser|dual Fotona laser treatment (Nd:YAG and Er:YAG)
62559269|NCT03926299|ACTIVE_COMPARATOR|Topical steroid|clobetasol propionate 0.05% cream
62559270|NCT01976026|EXPERIMENTAL|Endovascular treatment with flow diversion|"Endovascular treatment with flow diversion, including standard management of thrombo-embolic risk. The goal of the treatment procedure is (as usual) to prevent rebleeding, while keeping treatment-related risks as low as possible.~This trial permits the interventionist or surgeon to use any device, technique or drug judged important to the safety and success of the endovascular or surgical procedure, at his/her discretion at any time during the procedure. It is imperative that the allocated procedure is conducted in the safest possible manner. The interventionist or surgeon may switch to an alternative BST or cross-over to the alternative treatment group, if it is in the best interest of the patient."
62559271|NCT01976026|ACTIVE_COMPARATOR|Best standard therapy|"May be any of the following:~Conservative management when no surgical or endovascular treatment is considered possible or reasonable~Conventional endovascular options including coiling with or without high-porosity stenting, and stent-in stent techniques~Parent vessel occlusion, with or without bypass~Surgical clipping or clip-wrapping (including parent vessel occlusion as a salvage procedure).~Choice of best option is based on the location, anatomy, and particular circumstances, before randomization for this patient's aneurysm.~This trial permits the interventionist or surgeon to use any device, technique or drug judged important to the safety and success of the endovascular or surgical procedure, at his/her discretion at any time during the procedure. The interventionist or surgeon may switch to an alternative BST or cross-over to the alternative treatment group, if it is in the best interest of the patient."
62767266|NCT03238339||Routine home oxygen therapy group|The patient maintained a stable COPD regimen and conventional home oxygen therapy.
62767267|NCT04112979|EXPERIMENTAL|Auditory stimulation 1 (Music)|45 deciBel Sensation Level (dB SL), normalized, high-frequency sampled W.A. Mozart Symphony n°4 in D K19 and n°5 in B-flat K22 (from Mozart Symphonies Vol. I - Adam Fisher, Dacapo Records, Frederiksberg C., Denmark, 2013)
62767268|NCT04112979|EXPERIMENTAL|Auditory stimulation 2 (Mother's lap)|45 dB SL, normalized and filtered, high-frequency sampled heartbeat sound, 75 bpm tempo, looped
62767269|NCT04112979|EXPERIMENTAL|Soundproof earplugs|Disposable foam earplugs with a noise attenuation of at least 30 deciBel (dB)
61990312|NCT04075487|EXPERIMENTAL|User experiences with MEPS-Pain|This is a pilot study to assess user experience with MEPS-Pain App, there is only one arm.
61990313|NCT01957462|EXPERIMENTAL|FirstColplast Test V, Then Coloplast Test X|The subject tests two experimental coloplast products in a randomised order. Coloplast Test product V and after cross over ColoplastTest product X
61990314|NCT01957462|EXPERIMENTAL|First Coloplast Test X, Then Coloplast Test V|The subjects test the two experimental Coloplast products in a randomised order: Coloplast Test product X and after cross over Coloplast Test product V
61990315|NCT04226066|EXPERIMENTAL|T601/T601+5-FC|Part 1: Dose-escalation study of T601 single-dose; Part 2: Dose-escalation study of T601 single-dose combined with 5-FC; Part 3: Dose-escalation study of T601 multiple-dose combined with 5-FC; Part 4: Extended study of T601 multiple-dose combined with 5-FC.
62386329|NCT01484522||Group C|Influenza A 2009 monovalent vaccine
62767270|NCT04112979|NO_INTERVENTION|No stimulation|Current standard of care
61990316|NCT04109664||antral preservation|The patients were grouped according to the distance of gastric division as Antral preservation group (6cm from pylorus)
61990317|NCT04109664||Antral resection|The patients were grouped according to the distance of gastric division as Antral preservation group (2 cm from pylorus)
62386330|NCT02683135|ACTIVE_COMPARATOR|High-carbohydrate diet|
62386331|NCT02683135|EXPERIMENTAL|Low-carbohydrate diet|
62386332|NCT02683135|EXPERIMENTAL|Low-carbohydrate diet with post-meal walking|
62386333|NCT00998933|EXPERIMENTAL|1|
62386334|NCT05311358|EXPERIMENTAL|Normal children|Normal children aged 10-15 years play the game and comment on the satisfaction form
62386335|NCT03862729||Early minimally invasive surgery group|For patients in minimally invasive surgery group, intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
62386336|NCT03862729||conventional treatment group|Eligible patients not accepting early minimally invasive surgery are classified as the conventional treatment group. Conventional treatment includes medical treatment and conventional craniotomy. According to the intention-to-treat principle, patients treated by minimally invasive surgery beyond the 24 hours interval after ICH onset are also classified as conventional treatment group.
62386337|NCT05191615|EXPERIMENTAL|Intervention Group|"The proposed study will be implemented as an intervention study at two levels within the organization, managerial and registered nurses. The intervention comprises three major phases: a pre-intervention phase, an implementation-intervention phase, and a post-intervention phase. The interventions will be provided face-to-face by trained interventionists. At baseline, all participants will complete questionnaires and get labs completed, blood pressure checked, and weight/height measured.~Consists of two main parts. In the first part, both managers and employees will be trained in the principles of SDT and JD-R. For managers, particular attention will be paid to the provision of need support and work values. For employees, particular attention will be paid to employees' opportunities for job crafting and promoting their basic psychological need satisfaction at work."
62559272|NCT03154905||Control|Healthy controls
62559273|NCT03154905||Study group|Patient diagnosed with any disorder of the digestive system (including the alimentary tract, hepatobiliary tree, pancreas, insulin resistance or diabetes, obesity or malnutrition)
62559274|NCT06213077|ACTIVE_COMPARATOR|Nitric Oxide|"Upon enrollment, patients will complete the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey.~Patients will be sent home with instructions to take 2 Berkeley Life capsules once daily (in this case Active NO), in combination with their existing treatment protocol (Tadalafil) and then return on day 60, returning all unused test product.~After 60 days of taking the active ingredient + tadalafil, patients will repeat the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey.~After a 4 week wash out, patients will be crossed over to the placebo group and given the other combination.~After 60 days of both combinations, placebo and active, patients will repeat the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey"
62559275|NCT06213077|PLACEBO_COMPARATOR|Placebo|"Upon enrollment, patients will complete the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey.~Patients will be sent home with instructions to take 2 Berkeley Life capsules once daily (in this case the placebo), in combination with their existing treatment protocol (Tadalafil) and then return on day 60, returning all unused test product.~After 60 days of taking the placebo + tadalafil, patients will repeat the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey.~After a 4 week wash out, patients will be crossed over to the active group and given the other combination.~After 60 days of each combination, placebo and active, patients will repeat the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey"
62559276|NCT04800081|EXPERIMENTAL|Sacubitril/Valsartan|receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan
62559277|NCT04800081|ACTIVE_COMPARATOR|Valsartan|receive once-daily treatment with 80-320 mg of Valsartan
62559278|NCT00683865|ACTIVE_COMPARATOR|Arm 1|
62767271|NCT03773107|EXPERIMENTAL|Phase I|Cohort 1) 5mg ruxolitinib, Cohort 2) 10mg ruxolitinib, Cohort 3) 15mg ruxolitinib
62767272|NCT03773107|OTHER|Phase II|Cohort A) non-responders to Phase I regimen, Cohort B) responders to Phase I regimen
62767273|NCT00779961|EXPERIMENTAL|Group A|Early Cleft Palate Repair (Age group 6-10 months)
62767274|NCT00779961|ACTIVE_COMPARATOR|Group B|Sick Kids Routine cleft palate repair (age group 10-14 months)
62767275|NCT04993729|EXPERIMENTAL|T89 low-dose group|Subjects in this group will take three T89 capsules and one Placebo capsule each time by oral administration three times daily for 5 days.
61990318|NCT01464658|OTHER|panniculectomy|surgical intervention
62386338|NCT05191615|NO_INTERVENTION|Control Group|Participants randomized to the control group will complete the baseline questionnaires and lab tests at baseline and three follow-up times. Lab values will be collected using the current standard of care and American Heart Association (AHA) guidelines (2019).
62559279|NCT00683865|EXPERIMENTAL|Arm 2|
62559280|NCT06416943|EXPERIMENTAL|3D medical education model group|Received a regular learning plus 3D printing model
62559281|NCT05579964|EXPERIMENTAL|DEX Group|Priming Dexmedetomidine 0.5 mcg/kg, Infusion Dexmedetomidine 0.25 mcg/kg/hour
62559282|NCT05579964|PLACEBO_COMPARATOR|Control Group|NaCl 0.9% with adjusted amount and rate same as the DEX group
62559283|NCT00728455|EXPERIMENTAL|A|
62767276|NCT04993729|EXPERIMENTAL|T89 high-dose group|Subjects in this group will take four T89 capsules each time by oral administration three times daily for 5 days.
61990319|NCT00265343|EXPERIMENTAL|1|asenapine
61990320|NCT00265343|ACTIVE_COMPARATOR|2|olanzapine
61990321|NCT04898751||Cutaneous toxicity|Patients who reported a cutaneous immune related adverse event following ICI initiation with appropriate chronology that indicates drug toxicity.
62559284|NCT00728455|EXPERIMENTAL|B|
62559285|NCT00728455|EXPERIMENTAL|C|
62559286|NCT00728455|EXPERIMENTAL|D|
62559287|NCT00728455|EXPERIMENTAL|E|
62559288|NCT01387659|EXPERIMENTAL|Transplant recipients|All subjects receive identical drug treatment
62559289|NCT00931411|EXPERIMENTAL|Formulation 609580 20 then 609209|Formulation 609580 20 cream is applied topically to the entire body twice a day, morning and evening, after bathing for 42 days. This is followed by the same application of formulation 609209 for 2 weeks. Dosage is at the discretion of the parent applying the cream to the child.
62767277|NCT04993729|PLACEBO_COMPARATOR|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will take four placebo capsules each time by oral administration three times daily for 5 days.
62767278|NCT03135925|OTHER|Intervention|Exercise program
62767279|NCT02916147|EXPERIMENTAL|volatile anesthesia|Use 2-3% sevoflurane to maintain the anesthesia during OLV surgery with bispectral index (BIS) 40-60.
62767280|NCT02916147|ACTIVE_COMPARATOR|intravenous anesthesia|Anesthesia was maintained by a continuous infusion of propofol （4-6mg/kg/h）with BIS 40-60.
62767281|NCT01986959|EXPERIMENTAL|Surgery with Periodontal dressing|After the Surgical crown lengthening, the patients were randomly allocated to the periodontal dressing group (PDG) and control group (CG - non-placement of periodontal dressing).
62767282|NCT01986959|OTHER|Surgery without Periodontal dressing|After surgery, the patients were randomly allocated to the periodontal dressing group (PDG) and control group (CG - non-placement of periodontal dressing).
62767283|NCT02124954|EXPERIMENTAL|Digoxin with/without TA-8995|Digoxin with/without TA-8995
62767284|NCT02124954|EXPERIMENTAL|Midazolam with/without TA-8995|Midazolam with/without TA-8995
62767285|NCT03833713|EXPERIMENTAL|SMS Intervention|Once-weekly automated SMS dialogue sessions or micro-interventions and use behavior change techniques including self-monitoring with performance feedback and goal support
62386339|NCT04667585|EXPERIMENTAL|Interim PET-CT with dose de-escalation|Participants will receive an interim PET-CT approximately 2 weeks into radiation therapy.
62386340|NCT04667585|ACTIVE_COMPARATOR|Interim PET-CT with standard radiation|
62386341|NCT00104299|EXPERIMENTAL|Rituximab|
62386342|NCT00104299|ACTIVE_COMPARATOR|Control Group|
62386343|NCT03108989|EXPERIMENTAL|Sugammadex group|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
62386344|NCT03108989|ACTIVE_COMPARATOR|Neostigmine group|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
62386345|NCT00492739|OTHER|Varicella vaccine|2-3 doses of Varicella vaccine to seronegative patients two months apart
62386346|NCT01146158|EXPERIMENTAL|surgery Axillary dissection|surgery Axillary dissection
62386347|NCT00889031||No Treatment|
62386348|NCT04371757|EXPERIMENTAL|Aerobic exercise session|The aerobic exercise session will be performed on a horizontal cycle ergometer. A warm-up will be performed (5 minutes), followed by 40 minutes with moderate intensity (60% HRreserve) and controlled by a heart rate monitor, as well as the subjective effort scale (Borg 6 to 20 points). Blood pressure, heart rate and the Borg scale will be assessed at the beginning of aerobic exercise and every 5 minutes until the end.
62386349|NCT04371757|EXPERIMENTAL|Resistance exercise session|The resistance exercise session will be structured with knee extension, knee flexion, leg pressure and plantar flexion, in a station with guided weights, with 4x12 repetitions and 60% intensity of 1-RM; the cadence will be adjusted to 2:2 (concentric: eccentric) and controlled by a metronome. The rest between sets and exercises will be 90 seconds (total duration: 40 minutes). Blood pressure, heart rate and Borg scale will be recorded at the beginning and at the end of the 4th series of each exercise.
62386350|NCT04371757|EXPERIMENTAL|Combined exercise session|The combined exercise session will be structured with 20 minutes of resistance exercise + 20 minutes of aerobic exercise, as already described, except that the resistance exercises will have 2 sets of each exercise. As with other sessions, blood pressure, heart rate and the Borg scale will be assessed at the beginning and end of the second series of resistance exercise, as well as at the beginning and every 5 minutes of aerobic exercise up to 15 minutes after end of exercises.
62386351|NCT04330794|EXPERIMENTAL|NMFACT|record the caries index using the NMFACT chart
62386352|NCT04330794|ACTIVE_COMPARATOR|DMF index|record the caries index using the DMF chart
62386353|NCT04842942|EXPERIMENTAL|TOETVA|Transoral Endoscopic Thyroidectomy Vestibular Approach
62386354|NCT01386749|NO_INTERVENTION|Control|
62386355|NCT01386749|EXPERIMENTAL|Treatment|receive 6 months LMHFV
62386356|NCT04778722|EXPERIMENTAL|Probiotic group|pilot study with one interventional group
62386357|NCT02776904|OTHER|Healthy athlete|Healthy athletes (14-18 years old) enrolled in sports program in local schools.
62386358|NCT02776904|OTHER|Concussed athletes|Concussed athletes from a sports related injury who are 14-18 years old and referred to a regional sports concussion clinic.
62386359|NCT02194699|EXPERIMENTAL|Tralokinumab|Tralokinumab subcutaneous injection
62767286|NCT03833713|ACTIVE_COMPARATOR|SMS Assessments|Once-weekly SMS assessments related to their target risk behavior without receiving any feedback or goal support
62767287|NCT02223416|EXPERIMENTAL|RGB-10|
62386360|NCT02194699|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection
62386361|NCT01226186|ACTIVE_COMPARATOR|Nurse dispensed oral morphine solution.|
62386362|NCT01226186|ACTIVE_COMPARATOR|Self medicated oral morphine solution.|
62386363|NCT01749930|EXPERIMENTAL|BOL-303259-X|BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
62559290|NCT00931411|ACTIVE_COMPARATOR|Formulation 609209 then 609580 20|Formulation 609209 cream is applied topically to entire body, twice a day, morning and evening, after bathing for 42 days. This is followed by the same application of formulation 609580 20 for 2 weeks. Dosage is at the discretion of the parent applying the cream to the child.
62559291|NCT01547429|EXPERIMENTAL|Intraocular Lens Implantation for the Treatment for Aphakia|Implantation of an Artisan intraocular lens to correct aphakia in Adults. No other information is needed to describe this section
62386364|NCT01749930|ACTIVE_COMPARATOR|Timolol|Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).
62386365|NCT05818202||Stroke patients|The stroke patients who can understand the questionnaires, have only a stroke history, and not have another neurological condition which affect the study.
62386366|NCT05818202||Physiotherapists|Physiotherapists graduated from a university with at least a bachelor degree of physiotherapy and rehabilitation and work in Denizli.
62386367|NCT02530281|EXPERIMENTAL|glycopyrronium|glycopyrronium Topical Wipes
62386368|NCT02530281|PLACEBO_COMPARATOR|Vehicle|glycopyrronium Topical Wipes, Vehicle
62386369|NCT02698176|EXPERIMENTAL|Birabresib 20 mg CRPC Cohort-Part A|Participants in the CRPC cohort in Part A of the study received birabresib 20 mg orally (PO), twice a day (BID), in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
62386370|NCT02698176|EXPERIMENTAL|Birabresib 20 mg NMC Cohort-Part A|Participants in the NMC cohort in Part A of the study received birabresib 20 mg PO, BID, in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
62767288|NCT02223416|ACTIVE_COMPARATOR|Forsteo|
62386371|NCT02698176|EXPERIMENTAL|Birabresib 20 mg TNBC Cohort-Part A|Participants in the TNBC cohort in Part A of the study received birabresib 20 mg PO, BID, in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
62386372|NCT02698176|EXPERIMENTAL|NMC Cohort-Part B|Participants (up to 30) in Part B will receive birabresib at one dose level below the dose currently being administered in Part A of the study. Once the recommended Phase 2 dose (RP2D) from Part A is established, participants in Part B will receive birabresib at the RP2D. Participants will continue receiving birabresib at an assigned/adjusted dose level for continuous cycles up to 24 months.
62386373|NCT05869513|PLACEBO_COMPARATOR|Vegetable oil + Resistance exercise|4g/day vegetable oil and home based resistance exercise for 16 weeks
62386374|NCT05869513|ACTIVE_COMPARATOR|Krill oil + Resistance exercise|4g/day krill oil and home based resistance exercise for 16 weeks
62386375|NCT02443311|EXPERIMENTAL|Group I|Pimecrolimus 1% cream (Elidel, Novartis Pharmaceuticals, East Hanover, NJ)+ custom made hydrophilic Adhesive gel base (Department of Pharmaceutics and Industrial Pharmacy. Faculty of Pharmacy. Ain Shams University) 4 Times/day for 4 weeks
62386376|NCT02443311|ACTIVE_COMPARATOR|Group II|Betamethasone 17-valerate 0.1% cream (Betnovate, GlaxoSmithKline, Cairo, Egypt)+ custom made hydrophilic Adhesive gel base (Department of Pharmaceutics and Industrial Pharmacy. Faculty of Pharmacy. Ain Shams University) 4 Times/day for 4 weeks
62386377|NCT03097666|OTHER|C2 Cryoballoon Swipe Ablation System|C2 Cryoballoon Swipe Ablation System
62386378|NCT03294343|EXPERIMENTAL|HBOCS|For carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome), if they demand for risk-reducing surgeries, counseling, decision-making analysis, then salpingo-oophorectomy only by laparoscopy and long-term follow-up are provided.
62386379|NCT03294343|EXPERIMENTAL|Lynch syndromes|for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11, , if they demand for risk-reducing surgeries, counseling, decision-making analysis, then salpingo-oophorectomy with hysterectomy by laparoscopy and long-term follow-up are provided.
62386380|NCT03294343|OTHER|Refusal to surgery|For carriers with any mutation genes (BRCA1, BRCA2, ATM, BRIP1, RAD51, RAD51C, RAD51D, STK11, MLH1, MSH2, MSH6, PMS2 and EPCAM) but refusal to any risk-reducing surgeries, counseling, decision-making analysis, and then long-term follow-up are provided.
62386381|NCT00461851|EXPERIMENTAL|Chemotherapy plus sorafenib|Gemcitabine 1000 mg/m2 weekly x 2 weeks plus carboplatin AUC (Area under curve) 5 every 3 weeks plus sorafenib x 6 cycles then maintenance sorafenib alone
62386382|NCT01749228|EXPERIMENTAL|Etodolac Capsules USP 300 mg|Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India
62386383|NCT01749228|ACTIVE_COMPARATOR|Etodolac Capsules USP 300mg|Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA
62386384|NCT01920061|EXPERIMENTAL|Arm A|
62386385|NCT01920061|EXPERIMENTAL|Arm B|
62386386|NCT01920061|EXPERIMENTAL|Arm C|
61990322|NCT06256042|ACTIVE_COMPARATOR|Arthrocentesis|Delimitation of a corner-tragus line to mark points A (10mm in front of the tragus and 2mm below the CT line) and B (20mm in front of the tragus and 10mm below the CT line); Local intra- and extra-oral antisepsis with aqueous chlorhexidine 0.12% and 0.2%, respectively; Local anesthesia of the auriculotemporal and intra-capsular nerve with mepivacaine 2% + Epinephrine 1:100,000; Insertion of the first 30x0.8 mm needle at point A and injection of 2-3 mL of Lactated Ringer; Insert the second 30x0.8 mm needle into point B Wash with 100-200mL of Ringer Lactate; Removal of the second needle; Injection of 1mL of 20mg Triamcinolone diluted in 0.9% saline solution (1:1) through the needle at point A.
62386387|NCT01920061|EXPERIMENTAL|Expansion Arm 1|
62386388|NCT01920061|EXPERIMENTAL|Expansion Arm 2|
62386389|NCT01422395|EXPERIMENTAL|freezing|
61990323|NCT06256042|ACTIVE_COMPARATOR|Occlusal splint|A stabilizing maxillary acrylic occlusal splint was made, flat, total and adjusted in central relation (RC).
61990324|NCT02213393|EXPERIMENTAL|Protein enriched products|The intervention group receives protein enriched products (CwC products) in the hospital and receives these also after discharge during 12 weeks.
61990325|NCT02213393|ACTIVE_COMPARATOR|Usual menu|The control group receives the usual protein and energy rich menu in the hospital and receives regular products, no protein enrichment, after discharge during 12 weeks.
62386390|NCT01422395|NO_INTERVENTION|No freezing|
62386391|NCT02058186|ACTIVE_COMPARATOR|Atopic dermatitis patients: Active|Atopic dermatitis patients: age 1-18 years old
62386392|NCT02058186|PLACEBO_COMPARATOR|Atopic dermatitis patients: Placebo|Atopic dermatitis patients: age 1-18 years old
62386393|NCT03272672|EXPERIMENTAL|Braced|Össür Unloading Knee Brace used during walking protocol
62386394|NCT03272672|NO_INTERVENTION|Unbraced|Walking protocol without the use of brace
62386395|NCT05299840|EXPERIMENTAL|Oncogramme group|The oncologist has access to the results of the Oncogramme® Device and decides on the treatment according to the recommendations of the Oncogramme® Device
62386396|NCT05299840|OTHER|Control group|The oncologist does not have access to the results of the Oncogramme® Device and decides on the treatment according to the standard of care.
62559292|NCT02832011|ACTIVE_COMPARATOR|olive oil|After randomization, Investigators will give human milk fortiﬁed with olive oil
62559293|NCT02832011|ACTIVE_COMPARATOR|Eoprotin|After randomization, Human milk fortiﬁed with Eoprotin according to the recommendations of the manufacturer (1g per 30ml milk)
62386397|NCT02243189|EXPERIMENTAL|JNJ-43260295 (Healthy Participants)|Participants will receive a single nasal dose of JNJ-43260295, 6400 microgram, equally spread over the two nostrils.
62386398|NCT02243189|PLACEBO_COMPARATOR|Placebo (Healthy Participants)|Participants will receive a single nasal dose of placebo matching to JNJ-43260295.
62386399|NCT02243189|EXPERIMENTAL|JNJ-43260295 (Asthmatic Participants)|Participants will participate in 3 consecutive treatment periods (Periods 1, 2, and 3). In Period 1, each participant will receive a single nasal dose of JNJ-43260295 without prior nasal allergen challenge. In Period 2, each participant will receive a single nasal dose of JNJ-43260295, preceded by a nasal allergen challenge approximately 15 hours prior to the dosing. In Period 3, each participant will receive single nasal allergen challenge without JNJ-43260295. There will be a washout period of at least 21 days between 3 consecutive treatment periods.
62386400|NCT05706610|EXPERIMENTAL|Tailored Program|8-week tailored program including 4 coach visits and 4 bi-weekly text check-ins
62386401|NCT05706610|OTHER|Feedback Program|8-week feedback program including 8 weekly texts
62559294|NCT01302743|ACTIVE_COMPARATOR|Metformin|oral extended-release Metformin 1000 mg once a day for 90 days
62559295|NCT01302743|EXPERIMENTAL|Cinnamon Bark|Cinnamon Bark 1000 mg once a day for 90 days
62559296|NCT01302743|EXPERIMENTAL|Cinnulin PF|Cinnulin PF 500 mg once a day for 90 days
62559297|NCT04664322||NIV/HFNC|patients receiving non-invasive ventilation than high flow nasal canulae oxygen therapy
62559298|NCT04664322||HFNC/NIV|patients receiving high flow nasal canulae oxygen therapy than non-invasive ventilation
62559299|NCT02841137|EXPERIMENTAL|progesterone 5 mg|progesterone 5 mg tablet
62386402|NCT01048164|ACTIVE_COMPARATOR|10 Massages|This group consists of individuals that wear lead aprons, and they will receive ten, 30-minute scheduled massage appointments during the hours the participant is working in the cardiac lab, over a 10 week period.
62386403|NCT01048164|ACTIVE_COMPARATOR|5 Massages|This group consists of individuals that wear lead aprons, and they will receive five, 30-minute scheduled massage appointments, during the hours the participant is working in the cardiac lab, over a 5 week period. This arm will not receive massages for the first 5 weeks and then will receive their massages during the second 5 week period.
62386404|NCT01048164|NO_INTERVENTION|Control Group|This group will consist of those individuals that wear lead aprons with no desire to participate in the massage study yet are willing to provide information through questionnaires. They will be given the same questionnaire as those in the two massage therapy arms of the study, at the beginning, middle, and end of study.
62386405|NCT06092866|EXPERIMENTAL|Digital triage|Patients are triaged with symptom assessment by a nurse using a digital platform. They are receiving either advice for self-care, referred to other care-level or booked to a digital or physical visit on the primary health care center.
62386406|NCT06092866|ACTIVE_COMPARATOR|Telephone triage|Patients are triaged with symptom assessment by a nurse using tradition telephone. They are receiving either advice for self-care, referred to other care-level or booked to a digital or physical visit on the primary health care center.
62559300|NCT02841137|EXPERIMENTAL|progesterone 10 mg|progesterone 10 mg tablet
62386407|NCT03055806|EXPERIMENTAL|IX-01 1200 mg|1200 mg dose comprising three 400 mg caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
62386408|NCT03055806|PLACEBO_COMPARATOR|Placebo|Three placebo caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
62386409|NCT03055806|EXPERIMENTAL|IX-01 800 mg|800 mg dose comprising two 400 mg caplets and one placebo caplet administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
62559301|NCT02841137|EXPERIMENTAL|progesterone 20 mg|progesterone 20 mg tablet
62767289|NCT01859845|NO_INTERVENTION|Control Study Arm|The control participants will first interact with the simulated melanoma back model to learn clinical unaided visual inspection skills and then view a passive image projected onto a screen for dermoscopy learning. Remediation of inappropriate clinical decisions will be carried out by the research coordinator and is based on predefined feedback consistent across both arms of the study. Along with the projected images, the coordinator will provide each control participant with worksheets for the clinical Asymmetry, Border, Color, Diameter (ABCD) and Dermoscopy 3-point check list. A copy of the completed worksheet will be made at the end of the workshop.
62767290|NCT01859845|EXPERIMENTAL|smartphone|Each participant in the educational intervention arm will have access to a smartphone with a preloaded android software package. The smartphone software allows the participant to visualize a dermoscopic image of the pigmented lesion at the surface of the simulated melanoma model. Participants are given the freedom to navigate through the program via the smartphone to learn at their own pace with reinforcement of correct clinical management decisions and correction of weaknesses. The software content is limited to the dermoscopy information available to the positive control arm through the coordinator and the dermoscopic images projected onto the screen, thus a comparison of retention rates across both arms is possible.
61990326|NCT04552587|EXPERIMENTAL|HEART|Patients and caregivers will complete a HEART visit virtually or in person. The visit includes a needs assessment that generates a tailored care plan with messages, referrals and educational materials for discussion with a nurse. Caregivers will receive brief training about the HEART App and then use the App for 4 weeks with bi-weekly real-time prompts and feedback.
61990327|NCT00721786|EXPERIMENTAL|San Francisco Internet Stop Smoking Site|"UCSF/SFGH Internet Stop Smoking Study site~Internet Stop Smoking site (TC4) with several intervention elements from which the participants may choose as many as they wish~The links (URLs) to register for the study are:~English: www.stopsmoking.ucsf.edu Spanish: www.dejardefumar.ucsf.edu"
61990328|NCT00698581|EXPERIMENTAL|Brivaracetam 50 mg|50 mg/day
62559302|NCT02841137|ACTIVE_COMPARATOR|progesterone 100 mg|progesterone 100 mg capsule
62559303|NCT02603016|EXPERIMENTAL|GLSE compound group|GLSE compound 2g each time by mouth,twice a day for 42 days.
62559304|NCT02603016|EXPERIMENTAL|Maitake mushroom extract compound group|Maitake mushroom extract compound 2 tables each time by mouth,twice a day for 42 days.
62559305|NCT02603016|EXPERIMENTAL|Ginseng compound group|Ginseng compound 2 tables each time by mouth,twice a day for 42 days.
62559306|NCT02603016|NO_INTERVENTION|blank control group|Take nothing.
62386410|NCT03055806|EXPERIMENTAL|IX-01 400 mg|400 mg dose comprising one 400 mg caplet and two placebo caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
62386411|NCT06457529|EXPERIMENTAL|conventional treatment with Prolotherapy|
62386412|NCT06457529|OTHER|Dry Needling and conventional treatment|
62559307|NCT03447639|EXPERIMENTAL|Povidone-Iodine Irrigation|Bladder irrigation with 2% povidine-iodine irrigation immediately prior to catheter removal
62559308|NCT03447639|NO_INTERVENTION|Standard of Care|Catheter removal with no bladder irrigation
62559309|NCT02974686|ACTIVE_COMPARATOR|Interventional (EVR)|Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus
62559310|NCT02974686|ACTIVE_COMPARATOR|Prior Agent (MPA)|Patient will have baseline data collected while on MPA for comparison with EVR
62559311|NCT01733550||Glaucoma patients|Intraocular pressure is measured by Home iCare performed by the study nurse, by the patient it self and by Goldmann applanation tonometry.
62767291|NCT02226549|EXPERIMENTAL|LDV/SOF+VDV|Participants will receive LDV/SOF+VDV for 8 weeks.
62767292|NCT02226549|EXPERIMENTAL|LDV/SOF+VDV+RBV|Participants will receive LDV/SOF+VDV+RBV for 8 weeks.
62559312|NCT04960371||anxiety group|the score of Self-rating Anxiety Scale greater than 50
62559313|NCT04960371||non-anxiety group|the score of Self-rating Anxiety Scale less than 50
62767293|NCT03075124|EXPERIMENTAL|External Counter Pulsation group|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
62767294|NCT03075124|NO_INTERVENTION|Control group|Guideline-driven standard medical treatment
62767295|NCT02003937|EXPERIMENTAL|12 weeks of aerobic conditioning|12 weeks of aerobic conditioning, a total 42 sessions of 30min exercise on a stationary cycle ergometer
62767296|NCT02038660||Patients with coronary artery disease|
62767297|NCT05682989||mesh surgery|Data obtained before the operation
62767298|NCT05682989||Robotic-assisted sacrocolpopexy|Data obtained before the operation
62767299|NCT05682989||a hysterectomy with trans-vaginal mesh repair (Surelift®, Neomedic International, Barcelona, Spain)|Data obtained before the operation
62767300|NCT00624780|EXPERIMENTAL|1|
62767301|NCT00624780|ACTIVE_COMPARATOR|2|
62767302|NCT00624780|EXPERIMENTAL|3|
62767303|NCT00624780|PLACEBO_COMPARATOR|4|
62767304|NCT00846989|EXPERIMENTAL|1|
62767305|NCT00846989|EXPERIMENTAL|2|
62767306|NCT00846989|ACTIVE_COMPARATOR|3|
62767307|NCT04407065|EXPERIMENTAL|Double trigger|GnRH-agonist and HCG are used to trigger ovulation
62767308|NCT04407065|ACTIVE_COMPARATOR|HCG|HCG is used to trigger ovulation
62767309|NCT06507397|ACTIVE_COMPARATOR|Spinal Anesthesia|Patients received 3-ml hyperbaric bupivacaine 0.5% and 25 mcg fentanyl (0.5-ml).
62767310|NCT06507397|EXPERIMENTAL|Dural Puncture Epidural Anesthesia|Patients received 15-ml mixture of bupivacaine 0.25% and 50 mcg fentanyl over 5 minutes , injected in the epidural space by epidural catheter at L3-L4 interspace, a dural puncture was created by the spinal needle. Braun's Espocan® combined spinal epidural kit before insertion of epidural catheter (needle-through-needle technique) but intrathecal medication administration was withheld.
62767311|NCT05271825|EXPERIMENTAL|Broadband amplification|broadband amplification: (125 Hz to 10 kHz)
62386413|NCT02813681|ACTIVE_COMPARATOR|US-epidural SVD|US-epidural SVD group - participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity
62767312|NCT05271825|PLACEBO_COMPARATOR|Band-limited amplification|band-limited amplification (125 Hz to 3-4 kHz)
62767313|NCT01101698|ACTIVE_COMPARATOR|Vitamin K2, calcification score changes, vitamin D|90 μg vitamin K2+10μg cholecalciferol
62767314|NCT01101698|ACTIVE_COMPARATOR|Vitamin D, calcium score changes|10μg cholecalciferol (vitamin D)
62767315|NCT05883046|OTHER|Baseline|The control measurement was made as a baseline measurement without supplementation
62767316|NCT05883046|PLACEBO_COMPARATOR|Placebo|During Placebo conditions, participants consumed 20gr of maltodextrin (European origin, Alfasol®, Kimbiotek, Turkey).
62386414|NCT02813681|SHAM_COMPARATOR|(US sham- epidural SVD)|US sham- epidural SVD group- participants who received US examination process but with the monitor turned off.
62767317|NCT05883046|EXPERIMENTAL|Caffeine|For Caffeine conditions, participants consumed 6 mg/kg of caffeine, obtained from dosing the content of 200 mg capsules (Nature's Supreme® Caffeine)
62767318|NCT05883046|EXPERIMENTAL|NaHCO3|As for NaHCO3 conditions, participants consumed 0.3 g/kg of sodium bicarbonate (Alfasol®, Kimbiotek, Turkey) dissolved in water
62767319|NCT05883046|EXPERIMENTAL|Combined|For the combined condition, (Caf+NaHCO3), 6 mg/kg of caffeine and 0.3 g/kg of sodium bicarbonate per kilogram of body weight of participants were consumed, after being dissolved together in water
62767320|NCT04985539||PD de novo|Observational.
62767321|NCT00600769|OTHER|treatment of MAC and other NTM|Clarithromycin drug given twice daily.
62767322|NCT04941404|EXPERIMENTAL|TQ05105 tablets|Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.
62767323|NCT05953012|EXPERIMENTAL|PART 1- SAD|"The SAD part of the study will be conducted in a step-wise manner for a total of 4 dose levels of PMC-403.~* Dose level 1: 0.7 mg/eye, baseline(Day 0)~* Dose level 2: 2 mg/eye, baseline(Day 0)~* Dose level 3: 3 mg/eye, baseline(Day 0)~* Dose level 4: 4 mg/eye, baseline(Day 0)"
62767324|NCT05953012|EXPERIMENTAL|PART 2- MAD|"Upon the end of the SAD part of the study, the MAD part is planned to be conducted in a step-wise manner for a total of 2 dose levels.~* Dose level 1: 3 mg/eye, baseline(Day 0), Week 4(Day 28), Week 8(Day 56)~* Dose level 2: 4 mg/eye, baseline(Day 0), Week 4(Day 28), Week 8(Day 56)"
62767325|NCT03645304|EXPERIMENTAL|Ropivacaine group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the experimental group, an elastomeric pump filled with local analgesic solution (total volume 100ml) containing 750mg ropivacaine .
62767326|NCT03645304|PLACEBO_COMPARATOR|0.9% Saline group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
61990329|NCT00698581|EXPERIMENTAL|Brivaracetam 100 mg|100 mg/day
62767327|NCT03705975|ACTIVE_COMPARATOR|edit arms|classical physiotherapy and manual treatment. Classical physiotherapy consisting of hotpack and ultrason. Hotpack duration is 20 minutes and ultrason duration is 5 minutes in one session. Manual treatment is consist of scapular mobilization, glenohumeral joint inferior and posterior mobilization. Treatment modality is implemented by physical therapist three times a week for 8 weeks.
62386415|NCT02813681|PLACEBO_COMPARATOR|SVD without an Epidural|Spontaneous vaginal delivery without an Epidural group The purpose of the control group is to serve as a baseline.
62386416|NCT02095444|EXPERIMENTAL|Menstrual blood stem cells|1x10\*7 cells/kg, IV(in the vein) twice a week. Number of course for two weeks.
62386417|NCT04343937||Retrolaminar block|Retrolaminar block for postoperative pain managment in patients undergoing lumbar herniectomy under general anesthesia
62386418|NCT04343937||İntravenous analgesia|İntravenous analgesia for postoperative pain managment in patients undergoing lumbar herniectomy under general anesthesia
62386419|NCT00314028|ACTIVE_COMPARATOR|1|Standard of care treatment
62386420|NCT00314028|EXPERIMENTAL|2|Educational program designed to motivate and provide information on the correct use of condoms
62386421|NCT03722901||Late preterm infants|34 weeks and 0-6 days gestational age
62386422|NCT03722901||Moderate preterm infants|32 weeks and 0-6 days gestational age
62386423|NCT03722901||Reference|Term infants 9m/39-40
62386424|NCT05488873|EXPERIMENTAL|Placebo|Participants will apply 4 mL QD Placebo topical solution
62386425|NCT05488873|EXPERIMENTAL|WST-057 Active|Participants will apply 4 mL QD WST-057 Active topical solution.
62386426|NCT03969589|EXPERIMENTAL|Reproductive Life Planning-Mental Health Intervention|Reproductive Life Planning-Mental Health (RLP-MH) intervention is comprised of two parts: 1) an in-person interactive session in which the participant works with an RLP-MH facilitator to explore pregnancy intentions and RLP goals, consider important factors that impact those goals (e.g. mental health and physical health conditions, psychosocial and lifestyle factors, values, preferences), and identify personal action steps to address RLP goals and 2) a 15-20 minute follow-up session in person or by phone one month later to discuss progress in addressing RLP goals.
62386427|NCT03969589|OTHER|Written materials on Reproductive Life Planning|Participants will receive written materials on reproductive life planning, contraception, and VA resources. Participants will be given the materials and study staff will briefly discuss the content with the participant.
62386428|NCT05785949|EXPERIMENTAL|Microfracture + Chondro-Gide®|Microfracture + Chondro-Gide® bilayer collagen membrane
62386429|NCT05785949|ACTIVE_COMPARATOR|Microfracture|Microfracture
62386430|NCT01522599|ACTIVE_COMPARATOR|ARDS-Net strategy (Control)|
62386431|NCT01522599|EXPERIMENTAL|ECCO2-R with 4 mL/Kg Vt (Treatment)|
62386432|NCT01691937|EXPERIMENTAL|PVB + PCA|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with sufentanil
62386433|NCT01691937|PLACEBO_COMPARATOR|Placebo PVB + PCA|Continuous Paravertebral Block with Saline and Patient-controlled analgesia with sufentanil
62386434|NCT04720027||Closurefast|Patients who were randomised to and underwent radiofrequency ablation using the Closurefast device in the original 3RF Study
62386435|NCT04720027||Radiofrequency Induced Thermal Therapy (RFITT)|Patients who were randomised to and underwent radiofrequency ablation using the RFITT device in the original 3RF Study
62386436|NCT04720027||EndoVenous Radiofrequency (EVRF)|Patients who were randomised to and underwent radiofrequency ablation using the EVRF device in the original 3RF Study
62386437|NCT05860166|EXPERIMENTAL|trial group|The Clinical trial group consists of infants to whom the tests will be applied.
62386438|NCT02907866||Patients undergoing bronchoscopy|All patients presenting for bronchoscopy (These patient are expected to have normal pleural sliding sign identified by ultrasound)
62386439|NCT02907866||Patients with pneumothorax|Patients with pneumothorax requiring chest tube(This group of patient is expected to have residual pneumothorax for identification of absence of lung sliding, B lines and lung point)
62386440|NCT02907866||Patients on mechanical ventilation|Patients with respiratory failure on mechanical ventilation(This group of patient is expected to have alveolo-interstitial findings such as B lines)
62559314|NCT06106204|EXPERIMENTAL|ROAD Home Intervention|Hospitals randomized to receive the ROAD Home Intervention will receive an implementation intervention that includes external facilitation to support them in selecting and implementing evidence-based antibiotic stewardship strategies based on local context and the ROAD Home framework (https://academic.oup.com/cid/article/74/9/1696/6374407).
62767328|NCT03705975|ACTIVE_COMPARATOR|edit arm/intervention cross|classical physiotherapy and proprioceptive neuromusculer fasilitation. Classical physiotherapy consist of hotpack and ultrason. Hotpack duration is 20 minutes and ultrason duration is 5 minutes in one session. Scapular PNF and upper extremity PNF (flexion-abduction-external rotation) pattern. Treatment programme was implemented by physical therapist three times a week for 8 weeks.
61990330|NCT03503903|EXPERIMENTAL|Wet Cupping|One armed self-controlled study. Individuals in this arm will receive three concecutive WCT application
62386441|NCT03049891||Children down-referred from DNH|This group includes children who were transferred from DNH to a study facility. The investigators will first abstract data from the electronic data system 'Tier.net' for these children, which will tell us where they were down-referred. For children who were labeled as down-referred from DNH in Tier.net, data abstraction of the child's clinical data will be conducted at the down-referral site and from the National Health Laboratory Service (NHLS) data.
62386442|NCT03049891||Children LTF from DNH|This group includes children who began ART at DNH and were subsequently LTF. The investigators will first abstract data from the electronic data system 'Tier.net', which will classify them as LTF followed by examination of the the NHLS laboratory data to determine whether these children had received care at another facility since they were LTF.
62386443|NCT03049891||Caregivers of LTF|This group includes the caregivers of a subset of children in the 'LTF from DNH' and 'down-referred from DNH' groups. Among those children down-referred and LTF from DNH, the investigators will use their clinical and laboratory data to determine whether they are still receiving care or not. For children identified as LTF based on their abstracted data will be traced in order to contact their caregivers. If located, caregivers will be interviewed to ascertain if and why these children are no longer in care through a 'Tracing questionnaire'.
62386444|NCT03049891||DNH only|This group includes children who are still in care at DNH, died while in care at DNH, or were transferred to facilities from tier.net will not have any additional information collected other than what is recorded in the Tier.net database.
62386445|NCT02216539|EXPERIMENTAL|Self-hypnosis|Patients trained to self-hypnosis before surgery
62386446|NCT02216539|ACTIVE_COMPARATOR|Usual pain management|Patients receiving the usual post-operative pain management protocols
62767329|NCT05136898|EXPERIMENTAL|UGN-102|Patients will receive 6 once-weekly intravesical instillations of UGN-102 (75 mg mitomycin). Treatment Visit 1 will occur at the investigative site and instillation will be performed by a qualified physician. Treatment Visits 2 to 6 will occur at the patient's home and instillation will be performed by a properly trained and qualified home health professional.
62767330|NCT01186107|EXPERIMENTAL|Endeavor Resolute stent|zotarolimus-eluting stent
62767331|NCT01186107|ACTIVE_COMPARATOR|Cypher stent|sirolimus-eluting stent
62767332|NCT04170829|EXPERIMENTAL|Group 1 (n=6)|will be administered ChAdOx1 MERS: 5 x 109 vp ChAdOx1 MERS
62767333|NCT04170829|EXPERIMENTAL|Group 2 (n=9)|will be administered ChAdOx1 MERS: 2.5 x 1010 vp ChAdOx1 MERS
62767334|NCT04170829|EXPERIMENTAL|Group 3 (n=9)|will be administered ChAdOx1 MERS: 5 x 1010 vp ChAdOx1 MERS
62767335|NCT04835168|EXPERIMENTAL|BT-11 low|Oral
62767336|NCT04835168|EXPERIMENTAL|BT-11 high|Oral
62767337|NCT04835168|PLACEBO_COMPARATOR|Placebo|Oral
62767338|NCT06195995|EXPERIMENTAL|Intervention group for gambling addiction|A 40-minute transcranial alternating current stimulus intervention of real stimulus is conducted twice a day (at least 3 hours apart) for a total of 10 days in the intervention group of gambling addiction.
62767339|NCT04297969||GCK Glow fixation|Patients screened with GoCheck Kids flash concentrated iPhone 7+
62767340|NCT02080260|EXPERIMENTAL|Single Arm|Oral Regorafenib
62767341|NCT00625638|EXPERIMENTAL|Standard Care Only|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
62767342|NCT00625638|EXPERIMENTAL|Standard Care + IVR System|Standard Care + Interactive Voice Response (IVR) System Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes. Phone calls made once daily, each taking about 3-5 minutes to complete.
62767343|NCT04093336|ACTIVE_COMPARATOR|MSCs group|The people in this group will receive intravenous MSCs 2 x 10\^6/kg as a single dose and standardized treatment of acute ischemic stroke.
62767344|NCT04093336|PLACEBO_COMPARATOR|control group|The people in this group will receive placebo and standardized treatment of acute ischemic stroke.
62767345|NCT02398695||Caries Free|Participants who do not have caries (cavities) will have oral samples collected.
62767346|NCT02398695||Caries Active|Participants who do have caries (cavities) will have oral samples collected.
62767347|NCT02846246|EXPERIMENTAL|Intervention|The experimental group will be introduced to a person-centred care model that involves shared decision making where the person with home care service and family together with contact nurse prioritise care content and make rearrangements to make sure the provided home care service maximises health.
62767348|NCT02846246|SHAM_COMPARATOR|Control|A usual care paradigm will guide the control units, i.e. a continuation with practice as usual.
62767349|NCT05538546||Cohort 1|Population: Patients meet Baveno VI criteria (with a liver stiffness \<20kPa and with a platelet count \>150,000) at baseline.
62767350|NCT05538546||Cohort 2|Population: Patients don't meet Baveno VI criteria (with a liver stiffness ≥ 20kPa or with a platelet count ≤150,000) at baseline, but don't have varices requiring treatment (proved by endoscopy at baseline)
62767351|NCT00005976|EXPERIMENTAL|Arm I|"Patients receive carboplatin IV over 30 minutes and pyrazoloacridine IV over 3 hours on day 1. Treatment continues every 28 days in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of carboplatin and pyrazoloacridine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
62767352|NCT00005976|EXPERIMENTAL|Arm II|Patients receive the same treatment as given in study 1. Dose escalation is performed as in study 1 to determine the MTD in patients not receiving concurrent anticonvulsants.
62767353|NCT00005976|EXPERIMENTAL|Arm III|Patients receive the same treatment as given in studies 1 and 2 without dose escalation.
62767354|NCT05002842|EXPERIMENTAL|Immediate Intervention|Those in the immediate intervention arm will begin the LovingKindess Meditation practice upon enrollment.
62767355|NCT05002842|EXPERIMENTAL|Delayed Intervention|Those in the deferred intervention arm will commence the LovingKindness Meditation practice intervention approximately 3 weeks (post 3 -week survey) after enrollment and participate three weeks thereafter.
62767356|NCT01362452|EXPERIMENTAL|Double Umbilical Cord Blood (UCB)|"Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.~Starting dose level of T-cells not to exceed 106/m2.~The investigational component of the treatment plan of this study is the infusion of CD19-specific T cells derived from cord blood (CB) to be infused Day +42 to Day +100 following stem cell transplantation. The transplant component of the treatment plan will include CB transplant regimens that are commonly use for CB transplantation."
62767357|NCT01362452|EXPERIMENTAL|Single Umbilical Cord Blood (UCB)|"Single UCB unit arm does not start enrollment until Dose Level A2 in the double UCB unit arm has been deemed safe.~Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.~Starting dose level of T-cells not to exceed 106/m2.~The investigational component of the treatment plan of this study is the infusion of CD19-specific T cells derived from cord blood (CB) to be infused Day +42 to Day +100 following stem cell transplantation. The transplant component of the treatment plan will include CB transplant regimens that are commonly use for CB transplantation"
62767358|NCT03474211||vaccinated|
62767359|NCT03474211||non vaccinated|
62767360|NCT00769691||Group A|Adult patients undergoing cardiac surgery
62767361|NCT00115895|EXPERIMENTAL|Radioactive iodine 1,1 GBq|Low activity of radioiodine, 1,1 GBq
62767362|NCT00115895|OTHER|Radioactive iodine 3,7 GBq|Routine activity of radioiodine, 3,7 GBq
62767363|NCT04652674|EXPERIMENTAL|Group I|Patients who will undergo telemedicine visit approximately 1 week postoperatively, then an in-person clinic visit approximately 4 weeks postoperatively
62767364|NCT04652674|ACTIVE_COMPARATOR|Group II|Patients who will undergo in-person clinic visit approximately 1 week postoperatively, then a telemedicine visit approximately 4 weeks postoperatively
62767365|NCT04001972|EXPERIMENTAL|Intervention group|Brief advice (AWARD model) + NRT-S + IM Apps and Chatbot
62767366|NCT04001972|ACTIVE_COMPARATOR|Control group|Brief advice (AWARD model) + regular SMS
62767367|NCT02686476|ACTIVE_COMPARATOR|Empagliflozin dose group|Patient Receive Standard of Care with Empagliflozen
62767368|NCT02686476|NO_INTERVENTION|Standard dose group|Standard care for Type 2 Diabetes Mellitus upgraded without Empagliflozin
62767369|NCT00202033|EXPERIMENTAL|1|self monitor blood glucose 3 times a day per usual diabetes class curriculum
62767370|NCT00202033|EXPERIMENTAL|2|only self monitor blood glucose when fasting
62386447|NCT01212666|EXPERIMENTAL|Adductor-Canal-Block, Ropivacain|25 patients. ACB. 30 mL Ropivacain 7,5 mg/mL. Ultrasound-guided application.
62386448|NCT01212666|PLACEBO_COMPARATOR|Adductor Canal Block, Placebo (saline)|25 patients. ACB. 30 mL Saline. Ultrasound-guided application.
62386449|NCT00615420|EXPERIMENTAL|Manuka Honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed
62767371|NCT00202033|EXPERIMENTAL|3|no self monitoring of blood glucose
62767372|NCT04833959|EXPERIMENTAL|89Zr-Panitumumab|Subjects will be injected with 1 mCi (+/- 20%) of 89Zr-panitumumab followed by PET/CT imaging 4-7 days after study drug injection.
62767373|NCT04400604||1: Patients with minimal risk of extensive fibrosis|TE \< 5.8kPa; rule out cut-off value)
62767374|NCT04400604||2: Patients with intermediate risk of fibrosis|
62767375|NCT04400604||Patients with high risk of extensive fibrosis|
62767376|NCT04400604||Patients with compensated cirrhosis biopsy-proven|
62767377|NCT04400604||Patients with a first decompensation|patients with a first decompensation event of cirrhosis after exclusion of HCC.
62386450|NCT00615420|PLACEBO_COMPARATOR|Placebo|Sugar-free placebo gel 5ml 4 times a day, swished and held in mouth for 30 secs then swallowed
62386451|NCT06409442|ACTIVE_COMPARATOR|Control Group (CG) (Standard Physiotherapy Program)|"Patients with subacromial pain syndrome will receive a 6-week treatment program. Patients will be given a treatment program by a physiotherapist three times a week, and on the other days, patients will practice six selected simple exercises at home.~Standard Physiotherapy Program:~The physiotherapy program will be given to all groups in the same way; It consists of patient education, Transcutaneous Electrical Nerve Stimulation (TENS) (20 minutes in each session), cold or hot pack application (15 minutes), mobilization and exercise program.~Mobilization application is as follows:~* Glenohumeral joint posterior glide~* Glenohumeral joint inferior glide~* Acromioclavicular joint inferior glide~* Scapular mobilization~The exercise program is as follows:~* Phase 1 exercises~* Phase 2 exercises~* Phase 3 exercises"
62767378|NCT03475329||adenoidectomy with bilateral partial tonsillectomy|
62386452|NCT06409442|ACTIVE_COMPARATOR|Kinesio Taping Group (KTG) (Standard Physiotherapy Program + Kinesio Taping)|"In the group where kinesio taping will be added to Standard Physiotherapy Program, tape (Kinesio Tex, Standard 5 cm, KT-X-050, Tokyo, Japan) application will be performed by a certified physiotherapist. It will be used for 3 days, and the application will be repeated by the physiotherapist, the next day. Before taping, an allergic reaction test to the tape will be performed, if no allergy will be observed, participants will be taped and the tape maintenance brochure will be giving.~Muscles for inhibition techniques:~* Supraspinatus Muscle~* Deltoid Muscle~* Upper Trapezium Muscle~Muscles for facilitation techniques:~* Serratus Anterior Muscle~* Lower Trapezium Muscle"
62559315|NCT06106204|NO_INTERVENTION|Stewardship as Usual|Hospitals randomized to the control group will continue usual antibiotic stewardship activities. Although control hospitals are part of the HMS collaborative, during the intervention period they will not receive any of the ROAD Home Intervention components including analysis of their baseline data or needs assessment, customized suite of stewardship strategies, supported decision-making in selecting ROAD Home strategies to implement, an implementation blueprint, adaptable stewardship tools, or external facilitation from study investigators.
62767379|NCT03475329||adenoidectomy with complete unilateral tonsillectomy|
62767380|NCT02138240|EXPERIMENTAL|Social network intervention|"Individuals will be recruited and trained to be Peer Educators who will participate in group sessions and then communicate this information with members of participant's social network (Sidekick) and work to make changes to reduce intake of sugar-sweetened beverages. Peer Educators will participate in 6 core group sessions over a 6-week period as well as 3 additional booster sessions over the subsequent 3 months after completing the core curriculum. All sessions will be delivered by a facilitator and assistant facilitator using a guide."
62767381|NCT01561963|EXPERIMENTAL|Apremilast and Rifampin|"Participants received the following 3 treatment regimens:~* A single oral dose of 30 mg apremilast on Day 1 (Period 1);~* A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 (Period 2);~* Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 (Period 3)."
62767382|NCT02120703|ACTIVE_COMPARATOR|gabapentin|
62767383|NCT02120703|ACTIVE_COMPARATOR|Pregabalin|
62767384|NCT03131596|EXPERIMENTAL|IUB dilatation therapy|The patient will have Foley-catheter intrauterine balloon dilatation 2 weeks and 6 weeks after hysteroscopic adhesiolysis. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and third-look hysteroscopy will be carried out 8 weeks after the surgery.
62767385|NCT03131596|NO_INTERVENTION|control group|Patient will not undergo any balloon therapy. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and third-look hysteroscopy will be carried out 8 weeks after the surgery.
62767386|NCT06225271|EXPERIMENTAL|Intervention group|Participants in the intervention group will receive group intervention and individual intervention. Group interventions will include participants' communication meeting and other approach, such as self-management group. They will also receive the combined intervention of physical activity, fruit, and vitamin supplementation 3 times a week for 2 months (the 1st and 6th months).
62767387|NCT06225271|NO_INTERVENTION|Control group|Participants in the control arm will not receive any intervention.
62767388|NCT04272333|EXPERIMENTAL|CIVO Microdose Injection of Motolimod and Nivolumab|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected at least four hours to up to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of motolimod, nivolumab, or motolimod combined with nivolumab. Each microdose is simultaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node.
61990331|NCT01758653||Biorepository|Patients with acute CO poisoning. Blood collection for biorepository only, no study intervention.
62767389|NCT03559699|EXPERIMENTAL|AG-348|Participants received AG-348 tablets, administered orally, at a starting dose of 5 milligrams (mg), twice daily (BID), followed by two sequential dose level increases to 20 mg and 50 mg BID, for a period of 16 weeks in Part 1. This was followed by optimized dose BID, as determined by the investigator in Part 1, for a period of 24 weeks in Part 2.
62767390|NCT03362229|ACTIVE_COMPARATOR|FIXATION|Medial malleolus fixation, with the method of fixation left to the surgeons discretion.
62767391|NCT03362229|ACTIVE_COMPARATOR|NON-FIXATION|A well reduced medial malleolus fracture is then left without fixation ie, non-operative management.
62767392|NCT00180297|EXPERIMENTAL|Mid septal site location|RV lead is placed at mid septum.
62767393|NCT00180297|ACTIVE_COMPARATOR|Apical site location|RV lead is placed in apical position
62767394|NCT00478790|EXPERIMENTAL|1|ologen™ collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy. After operation with ologen™ Collagen Matrix, anti-inflammatory eye-drops will be prescribed
62767395|NCT03503981||Anxiety unit|Patients have anxiety as a primary diagnose. Receive treatment for anxiety (CBT and MCT).
61990332|NCT01425879|EXPERIMENTAL|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62767396|NCT03503981||Eating disorder unit|Patients have eating disorder as primary diagnose. Receive treatment for their eating disorder (CBT and compassion-focused therapy).
62386453|NCT06409442|EXPERIMENTAL|Local Vibration Therapy Group (LVTG) (Standard Physiotherapy Program + Local Vibration Therapy)|In the LVT group, LVT via the Hypervolt™ (HYPERICE Inc, US) vibrating massage device will be added to Standard Physiotherapy Program. This device gives vibration with five different speed settings, vibrating at 3,200 percussions per minute. There are five different head options. The ball head attachment was chosen as it is the least aggressive option and the vibration from the device will be applied to the relevant muscle body. For the facilitator effect, high frequency application will be made to the lower trapezius and serratus anterior muscles. For the inhibitory effect, the upper trapezius, deltoid, pectoralis minor, and supraspinatus muscles will be applied at low frequency. The application will be 5 minutes for each muscle, for a total of 30 minutes. During the application, the speed will be controlled with a metronome, the travel time along the body of the relevant muscle will be 10 seconds, and the return time to the starting point will be 10 seconds.
62386454|NCT05977777|EXPERIMENTAL|Patients|Patients affected by focal pancreatic lesions
62386455|NCT03783221|EXPERIMENTAL|High-fat diet|
62386456|NCT03783221|ACTIVE_COMPARATOR|High-residue diet|
62767397|NCT03503981||Depression unit|Patients have depression as primary disorder. Receive treatment for their depression (Short-term dynamic therapy, existential therapy and relational psychodynamic therapy).
62767398|NCT03503981||Family unit|One of the members of the family has a psychological disorder. The treatment is focused towards the family and family dynamics.
62767399|NCT03503981||Trauma unit|Patients have PTSD and relational trauma as primary diagnosis. Receive stabilizing treatment and exposure therapy.
62767400|NCT06506799|OTHER|intervention|"Data will be collected with the 'Participant Information Form' and the 'Nurses' Knowledge Level, Attitudes and Practices Regarding Physical Restraint Scale', prepared by the researcher in line with the literature and containing the demographic characteristics of the participants.~Intensive care nurses who will participate in the research will be asked to fill out the survey forms with individual consent.~Participant Information Form and Nurses' Knowledge, Attitude and Practice Levels Regarding Physical Restraint Scale will be used as pre-tests. After the pre-test, nurses will be given physical restraint training. The training content was created using the ADDIE model as reference. After the training, the Nurses' Knowledge Level, Attitudes and Practices Regarding Physical Restraint Scale will be used as the final test."
61990333|NCT02295995|EXPERIMENTAL|Physical Activity|Participants randomized to this arm will be enrolled in a 12-week physical activity program.
61990334|NCT02295995|NO_INTERVENTION|Usual Care Wait-List|Participants randomized to this arm will continue to receive usual care services for PTSD through the Veterans Health Administration (VHA) for 12 weeks after which time they will be offered the physical activity program for 12 weeks.
61990335|NCT02812316|EXPERIMENTAL|Scleral lenses|Subjects who meet all eligible requirements for entry into the study will be instructed to insert the Hi-Brite Large Diameter Rigid Gas Permeable contact lens in daily wear basis for clinical evaluation purposes.
62386457|NCT00356434|ACTIVE_COMPARATOR|1|Patients will have the Kendall, A-V foot impulse pump, model 6060 applied to their lower extremities to prevent DVT
62386458|NCT00356434|ACTIVE_COMPARATOR|2|Patients will have the Kendall,sequential compression device, model 9525 applied to the lower extremities to prevent DVT
62386459|NCT01063699|EXPERIMENTAL|Lap Kasai|Patients in this arm had their necessary Kasai procedure in a laparoscopic way.
62386460|NCT00705627|EXPERIMENTAL|B|Drug: cisplatin. Patients in the control arm received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
62386461|NCT01888380|EXPERIMENTAL|Foetuses|"* still birth and termination of pregnancies~* intervention: minimally invasive, virtual autopsy"
62386462|NCT01888380|EXPERIMENTAL|Newborns|"* who died of natural- and non-natural cause~* intervention: minimally invasive, virtual autopsy"
62386463|NCT01888380|EXPERIMENTAL|Children and adolescents|"* who died of natural- and non-natural cause~* intervention: minimally invasive, virtual autopsy"
61990336|NCT02280590|EXPERIMENTAL|Cresnon®|Rosuvastatin 10mg, tablet, q.d.
61990337|NCT02280590|ACTIVE_COMPARATOR|Crestor®|Rosuvastatin 10mg, tablet, q.d.
61990338|NCT01969903|EXPERIMENTAL|No dexmedetomidine injected|Control group in which will be used only lidocaine for brachial plexus block
62767401|NCT06547892|EXPERIMENTAL|Vasopressin|"To dilute vasopressin, an ampoule containing 20 IU/ml (1 ml) of vasopressin will be used, which will be mixed with 100 ml of 0.9% physiological solution, resulting in a solution with a concentration of 0.2 IU/ ml. In this study, both central and peripheral vein infusion will be permitted.~The vasopressin administration protocol will consist of an initial dose of 0.02 IU/min (equivalent to 6 ml/h), which can be increased to 0.03 IU/min (9 ml/h) if the mean arterial pressure (MAP) is less than or equal to 65 mmHg. On the other hand, if MAP exceeds 90 mmHg, the dose can be reduced to 0.01 IU/min (3 ml/h). The minimum period for adjusting the drug dosage should be one hour.~In the event that a MAP exceeds 100 mmHg persists, the dose of the drug can be reduced more quickly or even stopped. The duration of vasopressin therapy will be maintained for 7 days, discharge from the ICU, initiation of renal replacement therapy or until death, whichever occurs first."
61990339|NCT01969903|EXPERIMENTAL|0.3 microgs/kg of dexmedetomidine|Experimental group, in which 0.3 microgs/kg dexmedetomidine will be added to lidocaine for brachial plexus block
61990340|NCT01969903|EXPERIMENTAL|0.6 microgs/kg of dexmedeomidine|Experimental group, in which 0.6 microgs/kg dexmedetomidine will be added to lidocaine for brachial plexus block
61990341|NCT05251376|EXPERIMENTAL|LYN-014 Extended-Release Levomethadone HCl|Extended-release levomethadone HCl 187 mg administered orally once on Day 8 of the study.
61990342|NCT04646499|EXPERIMENTAL|Gamma Stimulation Group|This group will receive gamma stimulation
61990343|NCT02486380|EXPERIMENTAL|Full face/Nasal masks|Toffee Full face/Toffee nasal
62386464|NCT01579383|EXPERIMENTAL|Part A, Cohorts A - H|ALD403/Placebo
62386465|NCT01579383|EXPERIMENTAL|Part A, Cohort I|ALD403/Placebo
61990344|NCT03342664|EXPERIMENTAL|Artemis + Medical Management (MIS)|Minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management
62386466|NCT01579383|EXPERIMENTAL|Part B|ALD403/Placebo/Sumatriptan
62386467|NCT03103464|EXPERIMENTAL|Intervention Group|Patients to receive standard-of-care physical therapy + sit-to-stand therapy using the Movi chair 3x/wk.
62386468|NCT03103464|ACTIVE_COMPARATOR|Control Group|Patients to receive standard-of-care physical therapy 3x/wk.
62767402|NCT06547892|PLACEBO_COMPARATOR|Placebo|Similar to the intervention protocol, but using a placebo composed of 0.9% saline solution.
61990345|NCT03342664|ACTIVE_COMPARATOR|Best Medical Management Alone (MM)|Best medical management alone per standard of care at treating institution
61990346|NCT03265249|EXPERIMENTAL|Group 1|BRIDGE device will be placed prior to start of the surgery with standard of care pain control analgesia
61990347|NCT03265249|NO_INTERVENTION|Group 2|Subjects will receive the standard of care pain control analgesia
61990348|NCT02560337|EXPERIMENTAL|Cabazitaxel|"25 mg/m2 administered as a one hour intravenous infusion on day 1 of a 3-week cycle.~Treatment continues until progression or unacceptable toxicity."
62386469|NCT00416572|EXPERIMENTAL|Education Intervention|Participants attended 4 2-hr education sessions. The overall goal of the sessions was to provide information that would reduce participants' uncertainty about their illness and its treatment, to enhance coping in productive ways with the issues and problems confronting them, and to facilitate communication between the participants and their partners.
62386470|NCT00416572|EXPERIMENTAL|Nutrition Education Intervention|Participants attended 4 2-hr nutrition education sessions. Each session provided information and encouragement on setting and attaining measurable goals for healthy eating and on the benefits of thinking positively about dealing adaptively with problems in life and living a healthy lifestyle.
62386471|NCT00416572|NO_INTERVENTION|Control Condition|Participants received care as usual.
62386472|NCT01160458|EXPERIMENTAL|IMC-A12 Monotherapy in Patients|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
62386473|NCT01506232||ADHD|Youth diagnosed with ADHD.
62386474|NCT01506232||ASD|Youth diagnosed with an Autism Spectrum Disorder (ASD).
62386475|NCT01506232||BPD|Youth diagnosed with Bipolar Disorder.
61990349|NCT00954382||IQ trend|all subjects
61990350|NCT01867450||Biomarker Cross-section|Cross-sectional biomarker study in Chinese diesel workers
61990351|NCT00649896|EXPERIMENTAL|1|Mylan Estradiol Transdermal System 0.025 mg/day
61990352|NCT00649896|ACTIVE_COMPARATOR|2|Climara® Transdermal System 0.025 mg/day
61990353|NCT01602250|PLACEBO_COMPARATOR|levobupivacaine placebo|levobupivacaine placebo
61990354|NCT01602250|EXPERIMENTAL|levobupivacaine Intralipid®|levobupivacaine Intralipid®
61990355|NCT01602250|EXPERIMENTAL|ropivacaine Intralipid®|ropivacaine Intralipid®
61990356|NCT01602250|PLACEBO_COMPARATOR|ropivacaine placebo|ropivacaine placebo
61990357|NCT02846207|EXPERIMENTAL|Yiqi huoxue group|Buyang Huanwu decoction , which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
61990358|NCT02846207|EXPERIMENTAL|Yiqi group|Astragalus 60g. Oral administration, twice one day, for 12weeks.
61990359|NCT02846207|EXPERIMENTAL|Huoxue group|Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
61990360|NCT02846207|PLACEBO_COMPARATOR|placebo group|dextrin, Oral administration, twice one day, for 12weeks.
61990361|NCT03821493|EXPERIMENTAL|PF-06651600 treatment arm|This arm includes two treatment periods. Period 1-Single oral dose of PF-06651600 30 mg as tablets on Day 1 followed by Period 2 in which itraconazole 200 mg (oral solution) is given for 5 days. On Day 4 of Period 2, a single oral dose of PF-06651600 30 mg is given with itraconazole
61990362|NCT02453763||Transcranial direct current stimulation|All participants will receive transcranial direct current stimulation and an magnetic resonance imaging (MRI).
61990363|NCT04098107|EXPERIMENTAL|Throwing Device Phase 1|During Phase 1, subjects that have been recruited, consented, and enrolled will come to the biomechanics laboratory for throwing performance housed at the University of Pennsylvania (Human Motion Laboratory) on the day of their appointment. Subjects will be asked to wear the prototype device during a simulated baseball game (approximately 30-45 pitches), and then will perform a set of other baseball-specific movements while fitted with infrared markers for throwing analysis. This data will be used to develop and refine the algorithm for the prototype.
61990364|NCT05735301|OTHER|Non-Perfusion group|Non-Perfusion group consisted of patients who underwent DWI, FLAIRE, T1, and T2 sequences.The patients in the group whose MR imaging show FVH-DWI mismatch will be perfomed EVT(stent retrievers, contact aspiration, balloon angioplasty, stenting or a combination of these approaches) and best medical treatment; Patients who do not reach FVH-DWI mismatch due to image quality, EVT will be re-judged according to the DAWN criteria, Others will be given best medical treatment）
62767403|NCT02117349|EXPERIMENTAL|Raplixa plus Gelfoam|"During a single predefined surgical procedure, participants receive the assigned treatment on an appropriate target bleeding site (TBS). The treatment is topically applied using 1 of the following 3 methods:~* A thin layer of Raplixa is sprinkled directly from the vial onto the TBS, followed by application of Gelfoam.~* A thin layer of Raplixa is sprayed onto the TBS using the RaplixaSpray device, followed by application of Gelfoam.~* Raplixa is applied onto moistened Gelfoam which is then applied to the TBS.~Manual pressure is applied over the treatments using sterile gauze. The amount of Raplixa and Gelfoam used is at the discretion of the investigator, within the maximum of two 1 gram (g) vials of Raplixa that are permitted for each participant.~Thrombin-containing hemostats included in standard of care at the site are permitted as rescue therapy after the 5-minute time-to-hemostasis (TTH) evaluation."
62767404|NCT02117349|OTHER|Gelfoam Only|"During a single predefined surgical procedure, participants receive the assigned treatment on an appropriate TBS. Gelfoam is cut to the appropriate size and applied topically, according to the manufacturer's package insert, followed by manual pressure using sterile gauze.~Thrombin-containing hemostats included in standard of care at the site are permitted as rescue therapy after the 5-minute TTH evaluation, if necessary."
62767405|NCT00273845|EXPERIMENTAL|1|One session of motivational interviewing
62767406|NCT00273845|EXPERIMENTAL|2|Five sessions of strengths-based case management
62767407|NCT05837858|EXPERIMENTAL|whole grain-wheat flour food, then refined wheat flour food|Participants first received food made by 50 g whole grain wheat flour during breakfast in a fasting state. Standardized meals were provided to the volunteers from the dinner of the day before the intervention day, as well as up to 48 h after the administration of the test food. After a washout period of 5 days, volunteers followed a 2-day restricted diet before the intervention day. Participants then received food made by 50 g refined grain wheat flour in a fasting state.
62767408|NCT05837858|EXPERIMENTAL|refined wheat flour food, then whole grain-wheat flour food|Participants first received food made by 50 g refined grain wheat flour during breakfast in a fasting state. Standardized meals were provided to the volunteers from the dinner of the day before the intervention day, as well as up to 48 h after the administration of the test food. After a washout period of 5 days, volunteers followed a 2-day restricted diet before the intervention day. Participants then received food made by 50 g whole grain wheat flour in a fasting state.
62767409|NCT02981524|EXPERIMENTAL|CY/GVAX with Pembrolizumab|During each 21 day cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 followed by Pembrolizumab at 200mg, the colon cancer vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells for the first 4 cycles of treatment. After cycle 4, cyclophosphamide and GVAX will be administered with every 4th cycle.
62767410|NCT03542435|EXPERIMENTAL|SXC-2023|Dose Escalation
62767411|NCT03542435|PLACEBO_COMPARATOR|Placebo|Dose Escalation
62767412|NCT04386499|EXPERIMENTAL|Resveratrol|A nutraceutical formulation (trade mark Genante) composed of resveratrol, REVIFAST, folic acid, Vitamin D
62767413|NCT04386499|ACTIVE_COMPARATOR|Folic acid|Folic Acid 400 ug
62767414|NCT03859921|EXPERIMENTAL|Dydrogesterone group|Oral dydrogesterone 10mg tds will be given for two weeks from the next day of the LH surge or hCG induced ovulation.
61990365|NCT05735301|OTHER|Perfusion group|The perfusion sequence was examined by the group.The patients in the group whose F-Stroke(Brain Seal Smart Technology) indicate CBV\<70mL,mismatch ratio≥1.8 mismatch Volume\>15ml will be perfomed EVT and then received best medical treatment, others will be given best medical treatment only.
62386476|NCT01506232||Healthy Controls|Youth not diagnosed with any psychiatric/psychological disorder.
62386477|NCT00202267|ACTIVE_COMPARATOR|1|Clients randomized to short-stretch bandaging application
61990366|NCT01938911|EXPERIMENTAL|Hypertensives with oxytocin and social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
61990367|NCT01938911|EXPERIMENTAL|Hypertensives with oxytocin without social support|80 normotensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
62559316|NCT05580874|EXPERIMENTAL|Massage group|"Infants in the massage group received a ten-minute massage once a day, one hour after the morning feeding (between 9.30-11.30 am). Video recordings were made to observe the stress behaviors of the infants before, during and after the massage. Vital signs will be recorded a minute before the starting of the massage, at fifth minutes during the procedure and a minute after the end of the massage, and a video will be recorded during these processes. A saliva cortisol sample will be taken the massage five minutes before and 30 minutes after the massage. The scores given to the Newborn Stress Scale will be evaluated by watching the videos recorded after the procedure by experts in the field."
62559317|NCT05580874|OTHER|Control group|"Infants in the swaddling group will form the control group. The swaddling process will be done one hour after the babies are feding (between 9.30-11.30 am). Before, during and after the swaddling procedure, the video will be recorded to observe the stress behavior of the babies. A minute before swaddling, video recording will start. Infants will be swaddling for ten minutes and video recording will be continue. After this process, a minute video recording will be made while the baby is not swaddling. Vital signs will be recorded one minute before starting the swaddling at fifth minutes during the procedure, and a minute after the swaddling.~A saliva cortisol sample will be taken five minutes before and 30 minutes after the swaddling. The scores given to the Newborn Stress Scale will be evaluated by watching the videos recorded after the procedure by experts in the field."
61990368|NCT01938911|EXPERIMENTAL|Hypertensives without oxytocin with social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
61990369|NCT01938911|PLACEBO_COMPARATOR|Hypertensives without oxytocin or social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
61990370|NCT01938911|EXPERIMENTAL|Normotensives with oxytocin and social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
61990371|NCT01938911|EXPERIMENTAL|Normotensives with oxytocin without social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
62386478|NCT00202267|ACTIVE_COMPARATOR|2|Clients randomized to four-layer bandaging application
62559318|NCT01299103|ACTIVE_COMPARATOR|Single Treatment|Treatment of facial wrinkle with one treatment only
62559319|NCT01299103|ACTIVE_COMPARATOR|Double Treatment|Treatment of facial wrinkle with two treatments
62559320|NCT01299103|ACTIVE_COMPARATOR|Triple treatment|Treatment of facial wrinkle with three treatments
62559321|NCT06025071|EXPERIMENTAL|Colchicine group|Drug: Colchicine; Dosage form: Tablets; Dosage: 0.5mg; Frequency: Once daily; Duration: From randomization to one-year follow-up is completed.
62559322|NCT06025071|NO_INTERVENTION|Control group|No intervention
62559323|NCT00713024||1|Healthy control subjects
62559324|NCT00713024||2|Patients having neuropathic pain
62386479|NCT01952041|EXPERIMENTAL|Device: Smartphone|Participants in the smartphone intervention arm received treatment as usual in addition to receiving a smartphone with the study application. The study application identified relapse risk and prompted the clinical team to provide enhanced services.
62386480|NCT01952041|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as usual included outpatient case management, linkage to services and medication monitoring.
62386481|NCT03143855|EXPERIMENTAL|Lorcaserin|
62386482|NCT03143855|PLACEBO_COMPARATOR|Control Group|
62386483|NCT05140694|EXPERIMENTAL|Empagliflozin|Empagliflozin 10mg p.o. once daily (available to control over \~25mg)
62386484|NCT05140694|EXPERIMENTAL|Dulaglutide|Dulaglutide 0.75mg s.c. once weekly (available to control over \~1.5mg)
62386485|NCT05140694|EXPERIMENTAL|Empagliflozin and Dulagludie|Empagliflozin 10mg p.o. once daily and dulaglutide 0.75mg s.c. once weekly
62386486|NCT04950491|EXPERIMENTAL|Test group (s-CAIS)|The test group workflow used a fully computer-guided implant surgical protocol.
62386487|NCT04950491|OTHER|Control group (CIS)|The control group workflow used a conventional implant surgical protocol.
62386488|NCT01787435||All women exposed to PPI at any time during pregnancy|Exposure to PPI defined as presence of at least one prescription of a PPI any time between last menstrual period and delievry date
62386489|NCT01787435||All women exposed to H2RA at any time during pregnancy|Exposure to H2RA defined as presence of at least one prescription of H2RA any time between last menstrual period and delivery date
62386490|NCT01787435||Pregnant women with no recorded use of acid suppressing drugs|Pregnant women with no recorded use of acid suppressing drugs at any time during pregnancy
62386491|NCT06318000||Persons with visual impairments|Youth aged 7-17 years, male and female, with congenital or acquired visual impairment
62386492|NCT06318000||Able bodied persons|Youth aged 7-17 years, male and female, without impairments
62559325|NCT02352467|EXPERIMENTAL|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
62559326|NCT02352467|NO_INTERVENTION|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
62559327|NCT01383720|EXPERIMENTAL|Lotus Valve System|Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis
62559328|NCT04378972||TREATED GROUP|25 portions of vitreous samples from 25 eyes of patients operated on vitrectomy for complications from diabetic retinopathy, incubated with curcumin, homotaurine and vitamin D3. The substances will be used individually and in triple association, to evaluate a possible synergistic effect on the expression of inflammatory cytokines and endothelial growth factors.
62559329|NCT04378972||CONTROL GROUP|The same fractions of vitreous samples (n = 25) evaluated for the expression of oxidative biomarkers, inflammatory cytokines and metalloproteinases, without prior incubation with the substances of the treated group.
61990372|NCT01938911|EXPERIMENTAL|Normotensives without oxytocin with social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
62559330|NCT02671838|OTHER|Musculoskeletal ultrasound program|Participants will receive the musculoskeletal ultrasound program
62559331|NCT02671838|NO_INTERVENTION|Control|Participants will not be receiving the musculoskeletal ultrasound program.
62559332|NCT05872789|EXPERIMENTAL|Diazepam 1% Oral gel|Patients were treated with Diazepam 1% oral gel.
62559333|NCT05872789|PLACEBO_COMPARATOR|Placebo|Patients treated with a placebo gel control.
62559334|NCT05060536|ACTIVE_COMPARATOR|Removal of infrapatellar fat pad|When patients will have their fat pad removed.
62386493|NCT02363322|ACTIVE_COMPARATOR|A/Current Standard of Care Alone|A/Current Standard of Care Alone: Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting
62386494|NCT02363322|EXPERIMENTAL|B/Current Standard of Care Plus ZMapp|"B/Current Standard of Care Plus ZMapp: ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.~ZMapp 50mg/kg IV administered every third day for 3 infusions."
62386495|NCT05064449|EXPERIMENTAL|Part 1: Soticlestat 300 mg + Itraconazole 200 mg|Soticlestat 300 milligram (mg), tablets, orally, once on Day 1 in Period 1, followed by 4 days washout period, followed by itraconazole 200 mg solution, orally, once daily from Day 1 up to Day 11, further followed by soticlestat 300 mg tablet, orally along with itraconazole 200 mg solution, orally on the morning of Day in Period 2.
62386496|NCT05064449|EXPERIMENTAL|Part 2: Soticlestat 300 mg + Mefenamic Acid 500 mg|Soticlestat 300 mg, tablets, orally, once on Day 1 in Period 1, followed by 4 days washout period, followed by single dose of mefenamic acid 500 mg capsule (first dose only), orally on the morning of Day 1 and 250 mg subsequent doses at every six hours up to Day 7 in Period 2, further followed by soticlestat 300 mg tablet, orally, followed by mefenamic acid 250 mg capsule, orally in morning of Day 2 in Period 2.
62386497|NCT01747733||Endoscopy patients|Patients undergoing endoscopy in the endoscopy unit in HUCH (Helsinki University Central Hospital).
62386498|NCT04572464|EXPERIMENTAL|Experimental|Mindfulness Based Guided Meditation
62386499|NCT06119061|EXPERIMENTAL|Telavancin|Subjects receiving telavancin for pharmacokinetic sampling
62386500|NCT04569890|EXPERIMENTAL|CZP|Certolizumab pegol: subcutaneous CZP at 200mg twice a week.
62559335|NCT05060536|PLACEBO_COMPARATOR|No removal of infrapatellar fat pad|When patients will not have their fat pad removed.
62559336|NCT02289599|EXPERIMENTAL|Part A: 1 mg E2307 (young cohort)|E2307 (1 x 1 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
62386501|NCT04569890|ACTIVE_COMPARATOR|GC+HCQ|"Hydroxychloroquine: HCQ at 200mg daily, and if tolerated, escalated to 400 mg daily.~Glucocorticoid: continuous usage GC at 10mg a day from Week 0 to Week 52.~At 24 week, non-responders (ΔDAS28\<0.6) will switch to the other group. Participants switched to CZP group will taper their dose of GC gradually, if they have an improvement in disease activity (two successive DAS28\<2.6). If participants have a disease flare (increased DAS28\>0.6) during a reduction in corticosteroid dose, then they will resume their previous dose. Weekly step-down GC scheme: 10mg-7.5mg-5mg-2.5mg-0mg."
61990373|NCT01938911|PLACEBO_COMPARATOR|Normotensives without oxytocin or social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
62386502|NCT04768439|EXPERIMENTAL|200 IU/d vitamin D|Patients will receive low-dose vitamin D (200 IU/d)
62386503|NCT04768439|EXPERIMENTAL|1600 IU/d vitamin D|Patients will receive high-dose vitamin D (1600 IU/d)
62386504|NCT01329822|EXPERIMENTAL|Caloric restriction group|CR group were educated by a dietitian to reduce their usual energy intake to 1400 kcal/day (-500 kcal/day, -26% from baseline) for weight reduction and the recommended macronutrient composition was the 50-55% of energy intake as carbohydrate, 15-20% as protein and 20-25% as fat. Daily energy intake and nutrient composition were determined using a computer-aided nutritional analysis program (CAN-Pro 3.0; Korean Nutrition Society, Seoul, South Korea).
62386505|NCT01329822|NO_INTERVENTION|Control group|Control group - ad libitum diet
62386506|NCT05978063|ACTIVE_COMPARATOR|Difelikefalin 2.0 mg tablets|Oral difelikefalin 2.0 mg tablet administered twice daily
62386507|NCT05978063|ACTIVE_COMPARATOR|Difelikefalin 1.0 mg tablets|Oral difelikefalin 1.0 mg tablet administered twice daily
62386508|NCT05978063|ACTIVE_COMPARATOR|Difelikefalin 0.25 mg tablets|Oral difelikefalin 0.25 mg tablet administered twice daily
62386509|NCT05978063|PLACEBO_COMPARATOR|Placebo tablets|Oral placebo tablet administered twice daily
62559337|NCT02289599|EXPERIMENTAL|Part A: 3 mg E2307 (young cohort)|E2307 (3 x 1 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
62559338|NCT02289599|EXPERIMENTAL|Part A: 10 mg E2307 (young cohort)|E2307 (1 x 10 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
62386510|NCT00544674|EXPERIMENTAL|PR104|PR104 will be administered once every 21 days by IV
62386511|NCT03814876|EXPERIMENTAL|SCI intervention|Spinal cord injury intervention group
62386512|NCT03814876|ACTIVE_COMPARATOR|SCI control|Spinal cord injury control
62386513|NCT03814876|EXPERIMENTAL|TBI intervention|Traumatic brain injury intervention group
62559339|NCT02289599|EXPERIMENTAL|Part A: 30 mg E2307 (young cohort)|E2307 (3 x 10 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
62559340|NCT02289599|EXPERIMENTAL|Part A: 100 mg E2307 (young cohort)|E2307 (1 x 100 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
62559341|NCT02289599|EXPERIMENTAL|Part A: 200 mg E2307 (young cohort)|E2307 (2 x 100 mg E2307 capsules) or placebo (2 x 1 E2307 matching placebo capsules)
62559342|NCT02289599|EXPERIMENTAL|Part A: 300 mg E2307 (young cohort)|E2307 (3 x 100 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
62559343|NCT02289599|EXPERIMENTAL|Part B: Elderly cohort|One dose level below MTD from Part A
62559344|NCT04406428|EXPERIMENTAL|NKI followed by EBD|
62559345|NCT04406428|NO_INTERVENTION|Standard EBD|
62559346|NCT01473914|EXPERIMENTAL|Low dose|"Standard renal vitamin plus low dose zinc and selenium plus vitamin E~1 capsule p.o, daily"
62559347|NCT01473914|EXPERIMENTAL|Medium dose|"Standard renal vitamin plus medium doses of zinc and selenium plus vitamin E~1 capsule p.o, daily"
62559348|NCT01473914|ACTIVE_COMPARATOR|Standard treatment|"Standard renal vitamin~1 capsule p.o, daily"
61990374|NCT05138679||Acute lower limb ischemia|Patients with acute lower limb ischemia (older than 18 years)
61990375|NCT01816828|EXPERIMENTAL|Immediate|In the immediate arm, participants will begin the 8 session group motivational interviewing intervention, Gay Poz Sex, within 2 weeks of randomization.
61990376|NCT01816828|ACTIVE_COMPARATOR|Wait List/Standard of Care|Participants in the wait list/standard of care group will be given active referrals to existing community resources available to HIV+ MSM. For ethical reasons, participants randomized to the control group will have the option to attend the Gay Poz Sex program after a 6-month wait period.
61990377|NCT02220244|EXPERIMENTAL|MD1003|MD1003 100mg capsule, 1 capsule TID for 12 months
61990378|NCT02220244|PLACEBO_COMPARATOR|Placebo|Placebo capsule, 1 capsule TID for 6 months, then switch to MD1003 100mg capsule, 1 capsule TID for 6 months
61990379|NCT05939492|NO_INTERVENTION|Standard of Care Control|Participants in this arm will receive the standard of care. For patients with idiopathic chest pain, the standard of care is typically just reassurance of the benign nature of their pain.
61990380|NCT05939492|EXPERIMENTAL|Mindfulness-Based Intervention|Participants in this arm will partake in a 30 day mindfulness-based intervention on the mobile app Headspace.
61990381|NCT02053753|EXPERIMENTAL|Drug Product CP4|Participants received a single dose of 120 mg denosumab manufactured using the new CP4 process subcutaneously on day 1.
61990382|NCT02053753|EXPERIMENTAL|Drug Product CP2|Participants received a single dose of 120 mg denosumab manufactured using the current CP2 process subcutaneously on day 1.
61990383|NCT01094691|EXPERIMENTAL|Renal Allograft Biopsy|Urine left over from clinic visits is analyzed for 'Haufen' by negative staining electron microscopy as a marker of intra-renal polyomavirus nephropathy. Correlate Haufen, urine, and plasma data with the clinical presentation and with renal biopsy findings. Patients with PVN will be approached for study participation in which their routine samples will be monitored until urine is negative for 'Haufen', and a study protocol biopsy will be obtained for confirmation.
61990384|NCT04912934||MetS diagnosis|The research included individuals aged 18 years and older, who were not pregnant or breastfeeding, without any psychological disorder diagnosed by psychiatry, without diagnosis of COVID-19 and not using any psychiatric medications. The MetS group for the research included individuals with metabolic syndrome diagnosis according to IDF-2005 diagnostic criteria.
62559349|NCT03111940|EXPERIMENTAL|PCI optimisation|Post PCI FFR below 0.9
62559350|NCT03111940|NO_INTERVENTION|No PCI optimisation|Post PCI FFR 0.9 or higher
61990385|NCT04912934||non-MetS|The research included individuals aged 18 years and older, who were not pregnant or breastfeeding, without any psychological disorder diagnosed by psychiatry, without diagnosis of COVID-19 and not using any psychiatric medications. The non MetS group in the research included healthy individuals not using any psychiatric medications, without any chronic disorder, and with similar BMI to the individuals in the subject group.
61990386|NCT04557228|PLACEBO_COMPARATOR|Placebo|Study participants will receive 4 weeks of supplementation with 900mg placebo supplements
61990387|NCT04557228|EXPERIMENTAL|Phosphatidylserine Supplementation|Study participants will receive 4 weeks of supplementation with 900mg phosphatidylserine supplements.
61990388|NCT02455271||Participants with insomnia|Participants with insomnia who will receive eszopiclone per approved label.
61990389|NCT03054857|EXPERIMENTAL|Dex group|After skin incision, the Dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
61990390|NCT03054857|PLACEBO_COMPARATOR|Placebo group|The control group received a loading dose and continuous IV infusion of normal saline at the same rate.
62386514|NCT03814876|ACTIVE_COMPARATOR|TBI control|Traumatic brain injury control group
62386515|NCT01641523||Hydroxyapatite Cranioplasty|patient underwent to cranioplasty reconstruction with customized hydroxyapatite prosthesis
62386516|NCT01641523||polymethylmethacrylate|patient underwent to cranioplasty reconstruction with polymethylmethacrylate prosthesis
62386517|NCT01641523||autologous bone|patients underwent to cranioplasty reconstruction by autologous bone repositioning
62386518|NCT01017991|EXPERIMENTAL|Infant formula with probiotic|Infant formula with probiotic for 0 to 12 months of age
62386519|NCT01017991|PLACEBO_COMPARATOR|Standard infant formula|Infant formula for 0 to 12 months of age
62386520|NCT02095028|EXPERIMENTAL|Dietary and lifestyle intervention|Intervention group:Based on standard care,intensive dietary and lifestyle intervention was provided. Initiated from the first trimester to delivery,every 2-4 weeks follow-up
62386521|NCT02095028|NO_INTERVENTION|Standard care group|Standard care group:Participants received one group session in which prenatal general dietary, nutrition guideline, physical activity and recommendation for gestational weight gain introduced by a registered dietitian in 1.5hours.Participants received their regularly scheduled visits without additional dietary and lifestyle follow-up and guidance.
62386522|NCT01791088|EXPERIMENTAL|Treatment (sirolimus)|Patients receive sirolimus PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62386523|NCT01711359|EXPERIMENTAL|Baricitinib + MTX|Baricitinib 4 milligram (mg) administered orally once daily through Week 52. Participants received methotrexate (MTX) orally once weekly with dose ranging from 10 to 20 mg per week through Week 52. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
62386524|NCT01711359|EXPERIMENTAL|Baricitinib|Baricitinib 4 mg administered orally once daily through Week 52. Participants received MTX placebo orally once weekly through Week 52. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
62386525|NCT01711359|ACTIVE_COMPARATOR|MTX|MTX administered orally once weekly with dose ranging from 10 to 20 mg per week through Week 52. Participants also received baricitinib placebo orally once daily. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
62386526|NCT00917007||ABO compatible|
62386527|NCT00917007||ABO incompatible, antiglobulin positive|
62767415|NCT03859921|PLACEBO_COMPARATOR|Placebo group|Placebo will be given given for two weeks from the next day of the LH surge or hCG induced ovulation.
61990391|NCT01237158||healthy controls|
61990392|NCT01237158||bipolar disorder type I|
61990393|NCT00324467|ACTIVE_COMPARATOR|R-CHOP (Negative Mid-Treatment PET Scan)|"All participants will receive 4 cycles of standard dose R-CHOP chemotherapy administered at 3-weekly intervals. Non-progressing participants will undergo a mid-treatment PET scan along with routine restaging investigations after 4 cycles of R-CHOP. Patients with a negative mid-treatment PET scan (no evidence of abnormal 18F-FDG uptake) will complete therapy with two additional cycles of R-CHOP for a total of 6 cycles of chemotherapy. Patients with a mid-treatment PET scan interpreted to be indeterminate or equivocal will be recorded as such, but should be considered negative for the purpose of treatment planning and should not prompt a change in therapy."
61990394|NCT00324467|ACTIVE_COMPARATOR|R-ICE (Positive Mid-Treatment PET Scan|"All participants will receive 4 cycles of standard dose R-CHOP chemotherapy administered at 3-weekly intervals. Non-progressing participants will undergo a mid-treatment PET scan along with routine restaging investigations after 4 cycles of R-CHOP. Patients with a mid-treatment PET scan (abnormal 18F-FDG uptake) will be switched to R-ICE chemotherapy and receive 4 cycles of R-ICE for a total of 8 cycles of chemotherapy.~Following completion of R-ICE chemotherapy, patients will undergo a post-treatment PET scan along with routine restaging investigations. The post-treatment PET scan will be performed between days 28 and 35 following the final cycle of R-ICE. Patients with a negative post-treatment PET scan will undergo no further therapy. Patients with a positive post-treatment PET scan corresponding to persistent abnormalities on CT scan will be considered for radiation therapy to PET positive sites."
61990395|NCT04917055|ACTIVE_COMPARATOR|Active Treatment|Adductor Canal Single Shot with long acting local anesthetic (ropivacaine) plus distal iPACK (between femoral condyles) single shot with long acting local anesthetic (ropivacaine) plus dexamethasone
62386528|NCT00917007||ABO incompatible, antiglobulin negative|
62386529|NCT05384509||Chemotherapy|Cancer Patients underwent chemotherapy
62386530|NCT05384509||Targeted therapy|Patients underwent targeted therapy
62386531|NCT05384509||Immunotherapy|Patients underwent immunotherapy
62386532|NCT05384509||Disease-free|Cancer patients have been disease-free for ≥ 6 months group
62767416|NCT04560894|EXPERIMENTAL|SCT-I10A+SCT510|
62767417|NCT04560894|ACTIVE_COMPARATOR|Sorafenib|
62767418|NCT05545644|EXPERIMENTAL|Brief Family-Involved Treatment for Alcohol Use Disorder (B-FIT_|Up to 3 sessions of family-involved treatment for patients with alcohol use disorder (AUD) and a family member: Session 1; psychoeducation; increasing supportive behaviors, enhancing positive activities. Session 2: Improving communication; recovery contracts. Session 3: Review of session1 \& 2 interventions; continue with communication skills.
61990396|NCT04917055|PLACEBO_COMPARATOR|Placebo|Adductor Canal Single Shot with long acting local anesthetic (ropivacaine) plus iPACK single shot with normal saline
62386533|NCT05291429|ACTIVE_COMPARATOR|VR - coaching arm|30 individuals to be enrolled in the intervention arm that also includes coaching sessions to support and encourage VR use (VR+coaching arm).
61990397|NCT01526889|EXPERIMENTAL|LFG316 -Intravitreal Injection|
61990398|NCT01526889|ACTIVE_COMPARATOR|Conventional Therapy|
61990399|NCT00371254|EXPERIMENTAL|1|
61990400|NCT00371254|EXPERIMENTAL|2|
61990401|NCT02363725|OTHER|Conventionnal treatment|"Optimal conventional treatment used for patients admitted for STEMI (ESC guidelines 2012):~* Double anti-aggregation~* IEC (or sartan) at best tolerated dose~* Beta-blocker at best tolerated dose~* High dose statin (usually atorvastatin 80 mg daily)~* If ventricular dysfunction; inhibitor minérolcorticoïdes (the eplerenone more often)~* Any other treatment will be logged."
61990402|NCT02363725|EXPERIMENTAL|Conventionnal + Colchimax®|Optimal conventional treatment + Colchimax®
61990403|NCT05644704|EXPERIMENTAL|Baseball pitcher training|
61990404|NCT04982055|EXPERIMENTAL|Intravenous group|
61990405|NCT04982055|ACTIVE_COMPARATOR|Subcutaneous group|
61990406|NCT01516944|ACTIVE_COMPARATOR|postoperative chemotherapy,SOX|
61990407|NCT01516944|EXPERIMENTAL|Perioperative chemotherapy,SOX|
62386534|NCT05291429|ACTIVE_COMPARATOR|VR only - no coaching|30 individuals to be enrolled in the intervention arm without coaching (VR arm)
62386535|NCT05291429|NO_INTERVENTION|No intervention - control arm|30 individuals to be enrolled in the control arm with no active intervention (comparator 2; control arm)
62386536|NCT03218943|ACTIVE_COMPARATOR|APRV ventilation|They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours Then, they will return to the initial settings ( PCV ) for 2 hours . then, they will be switched into BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours. Then left for ventilation according to the preference of the physician in charge.
62386537|NCT03218943|ACTIVE_COMPARATOR|BiPAP ventilation|They will start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours. Then, they will return to the initial settings ( PCV ) for 2 hours . then, they will be switched into APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours. Then left for ventilation according to the preference of the physician in charge.
61990408|NCT01516944|EXPERIMENTAL|Perioperative chemotherapy,XELOX|
62386538|NCT01333020|EXPERIMENTAL|transglutaminase cross-linking of emulsion|The impact of enzyme cross linking of the protein stabilising the test emulsion on gastric emptying rate will be assessed. In this crossover study the subjects will also consume ( on a separate day)an emulsion of the same formulation but not cross-linked.
62386539|NCT01740349||30 children with UC|This prospective pilot study of 30 pediatric subjects, that are indicated for standard colonoscopy due to follow-up of ulcerative colitis (UC), examines the Given Diagnostic System and the PillCam Colon Capsule in comparison to standard colonoscopy.
62559351|NCT01383174|EXPERIMENTAL|Peer Support Program|Nuevo Amanecer is the peer support program. Participants receive the peer support program as soon as possible after randomization.
62559352|NCT01383174|NO_INTERVENTION|Wait-list Control|Waits six months, and at the end of the six months is offered the option of participating in the peer support program.
61990409|NCT05837936||Total intravenous anesthesia (TIVA)|TIVA is achieved without inhalational agents and may be performed in cases where patients have an intravenous line in place prior to induction of anesthesia
61990410|NCT05837936||Sevoflurane initiated intravenous anesthesia (SIIVA)|SIIVA is a modification of TIVA in the setting where a patient does not tolerate the insertion of an intravenous line prior to induction of anesthesia. The patient undergoes induction of anesthesia with sevoflurane and transition to Propofol IV anesthesia for maintenance once the intravenous line is in place and discontinues the inhalational agent, sevoflurane.
61990411|NCT01923415||Group 1: SLE|\>=10 participants with systemic lupus erythematosus (SLE)
61990412|NCT01923415||Group 2: DLE|\>=10 participants with discoid lupus erythematosus (DLE)
62559353|NCT02342678|EXPERIMENTAL|Yoga Therapy Group|Participants will take part in twice weekly group yoga classes focusing on selected Iyengar-based yoga techniques as well as practice study-specific yoga techniques at home for at least one hour per week for a total of 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing yoga exercises for at least an hour per week.
62767419|NCT05545644|ACTIVE_COMPARATOR|Treatment as Usual (TAU|Treatment as usual in inpatient AUD rehabilitation program, including daily therapy groups, individual counseling, and health and recreational activities.
61990413|NCT01923415||Group 3: SCLE|\>=10 participants with subacute cutaneous lupus erythematosus (SCLE)
61990414|NCT01167231||Group 1|
61990415|NCT02856633||Vitaliti System|
61990416|NCT06516276|EXPERIMENTAL|MOBILE App|The intervention group will receive standard nutrition, physical exercise, and emotional care recommendations according to scientific evidence and instructions on using the MIO mobile application.
61990417|NCT06516276|NO_INTERVENTION|Control Standard Recommendations|The control group will receive the same recommendations without additional support tools.
61990418|NCT00951028|ACTIVE_COMPARATOR|Enhanced treatment as usual|Participants will receive the life-steps intervention and treatment as usual.
61990419|NCT00951028|EXPERIMENTAL|CBT for adherence and depression (CBT-AD)|Participants will receive the life-steps and CBT-AD interventions.
61990420|NCT00951028|ACTIVE_COMPARATOR|ISP for adherence and depression (ISP-AD)|Participants will receive the life-steps and ISP-AD interventions.
61990421|NCT05542875|EXPERIMENTAL|Group A (Thrust Manipulation)|Participants will be randomly allocated to Group A which will recieve Thrust manipulation treatment in addition to standard treatment protocol. Prone thoracic extension manipulation technique will be applied from T2 - T6 to participants for 4 sessions on alternate days
61990422|NCT05542875|EXPERIMENTAL|Group B (Non-Thrust Manipulation)|Participants will be randomly allocated to group B which, in addition to standard treatment protocol, will recieve Maitland grade III or IV manipulation from T1 to T6. Posterior to anterior glide over spinous process will be maintained for 30 seconds. Participants will recieve 4 sessions on alternate days
62386540|NCT03687229||Patient|"Chronic HCV patients before treatment \& 3 months after starting of treatment. not known to be:~1. Cirrhosis~2. Diabetes Mellitus.~3. Hemochromatosis~4. HBV~5. HIV.~6. Hepatocellular carcinoma (HCC)~7. Chemotherapy~8. Organ transplantation"
62386541|NCT03687229||Control|Apparently healthy individuals
62559354|NCT02342678|EXPERIMENTAL|Physical Conditioning Group|Patricipants will take part in twice weekly group physical conditioning classes and practice stretching exercises at least one hour per week at home for 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing stretching exercises for at least an hour per week.
62559355|NCT03010228|ACTIVE_COMPARATOR|VLA15 12 µg with Alum|VLA15 12 µg (microgram) with Alum has an injection volume of 100 µl (microliter). The amount of Alum per injection is 0.05 mg (milligram).
62559356|NCT03010228|ACTIVE_COMPARATOR|VLA15 12 µg w/o Alum|VLA15 12 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 100 µl (microliter).
61990423|NCT02717481||Patients with known aortic aneurysm|"Patients with known abdominal aortic aneurysm diagnosed in clinical follow-up or after an invasive procedure to repair it.~US-CT Fusion examination"
62386542|NCT04657302|EXPERIMENTAL|R/R DLBCL|Participants will receive a fixed dose of obinutuzumab pre-treatment followed by glofitamab on Cycle 1 Days 8 and 15, then every 3 weeks (Q3W) from Cycles 2-12 (cycle length = 21 days).
62559357|NCT03010228|ACTIVE_COMPARATOR|VLA15 48 µg with Alum|VLA15 48 µg (microgram) with Alum (aluminum hydroxide) has an injection volume of 400 µl (microliter). The amount of Alum per injection is 0.2 mg (milligram).
62559358|NCT03010228|ACTIVE_COMPARATOR|VLA15 48 µg w/o Alum|VLA15 48 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 400 µl (microliter).
62559359|NCT03010228|ACTIVE_COMPARATOR|VLA15 90 µg with Alum|VLA15 90 µg (microgram) with Alum (aluminum hydroxide) has an injection volume of 750 µl (microliter). The amount of Alum per injection is 0.375 mg (milligram).
62559360|NCT03010228|ACTIVE_COMPARATOR|VLA15 90 µg w/o Alum|VLA15 90 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 750 µl (microliter).
62559361|NCT04163614|NO_INTERVENTION|Control|Participants in the control group will have their blood pressure, fluid status, as well as all other aspects of clinical care managed in entirety by their treating nephrologists.
62559362|NCT04163614|EXPERIMENTAL|IBPS (Intradialytic Blood Pressure Slope) Arm|IBPS participants will have their target weight adjusted each month by the study investigator based on recent assessment of intradialytic blood pressure slopes.
62559363|NCT01768377|ACTIVE_COMPARATOR|Intubation with sedation|Sedation with midazolam and analgesia with fentanyl
62559364|NCT01768377|EXPERIMENTAL|Intubation with Nerve block|Laryngeal plus supraglottic plus intratracheal nerve block plus sedation with midazolam
62559365|NCT03936036||2nd generation sulfonylureas|Reference group
62559366|NCT03936036||Linagliptin|Exposure group
62559367|NCT00183547|EXPERIMENTAL|1|"Living in Harmony depression prevention program"
62559368|NCT00183547|ACTIVE_COMPARATOR|2|Depression-prevention education and support
62386543|NCT03851315||LBBAP group|patients received left bundle branch area pacing
62386544|NCT03851315||traditional RVP group|Age and sex-matched patients received traditional right ventricular pacing
62386545|NCT04755751||Pediatric Pompe patients|A retrospective - prospective study evaluating pediatric patients with Pompe before and 2 days after ERT on multiple occasions and different dosing. Evaluation included cardiopulmonary exercise testing (CPET), 6 minute-walking test (6MWT), motor function test (GMFM-88) and self-collected blood samples (on a Guthrie card) for enzyme blood levels.
62386546|NCT04239807|EXPERIMENTAL|Group 1 WBV - training with wbv|"Screening (day -21 until day -7): Subjects will be evaluated according to In- and Exclusion critera~Randomization (day -7): Subjects will be randomized to either Intervention Group (training on wbv platform) or non-Intervention Group (training without wbv).~Introduction Week -1(-7d-d1): All subjects will receive introduction in their training~Month 1:~Day 1: From this day subjects are supposed to start their training accoridng to protocol~Day 2: Telephone Visit~Day 5: Telephone Visit~Day 7: Telephone Visit~Day 10: Telephone Visit~Day 13: Telephone Visit~Day 20: Telephone Visit~Day 27: Telephone Visit~Week 4, Day 28: Study center Visit: 6MWD, QoL-Questionnaire, AEs, re-training~Month 2:~Week 5, Day 34:~Week 6, Day 41:~Week 7, Day 48:~Week 8, Day 55:~Month 3:~Week 9, Day 62:~Week 10, Day 69:~Week 11, Day 76:~Week 12, Day 83: Final Visit"
62559369|NCT01186237|EXPERIMENTAL|Early urinary catheter removal|
62559370|NCT02522689|ACTIVE_COMPARATOR|Ultra-mini PCNL|Endoscopic kidney stone surgery: Patients will undergo ultra-mini percutaneous nephrolithotripsy.
62559371|NCT02522689|ACTIVE_COMPARATOR|Micro PCNL|Endoscopic kidney stone surgery: Patients will undergo micro percutaneous nephrolithotripsy.
62559372|NCT04777227|ACTIVE_COMPARATOR|Debridement|A debridement (procedure involving cleaning and removing all hyperkeratotic tissue) was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr
62559373|NCT04777227|SHAM_COMPARATOR|Debridement with needle insertion|A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.
62559374|NCT04777227|PLACEBO_COMPARATOR|Debridement with physiological water injection|A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The podiatrist pressed completely on the syringe to inject 1 mL of 0.9% sterile sodium chloride water. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.
62559375|NCT04777227|EXPERIMENTAL|Debridement with lidocaine injection|A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The podiatrist pressed completely on the syringe to inject 1 mL of 2% lidocaine solution. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.
62767420|NCT02099201|EXPERIMENTAL|Group A1|Ten subjects will receive ACT-389949 40 mg and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
62767421|NCT02099201|EXPERIMENTAL|Group A2|Ten subjects will receive ACT-389949 (Predicted to be 200 mg) and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
61990424|NCT03904407|EXPERIMENTAL|Probiotic|Lactobacillus probiotic capsules in addition to a routine-care prescribed anticholinergic or beta-3 agonist medication for 4 weeks.
61990425|NCT03904407|PLACEBO_COMPARATOR|Placebo|Matching Lactobacillus probiotic placebo capsules in addition to a routine-care prescribed anticholinergic or beta-3 agonist medication for 4 weeks.
61990426|NCT04254978|EXPERIMENTAL|Bomedemstat|Bomedemstat administered daily for 169 consecutive days
61990427|NCT03035955|ACTIVE_COMPARATOR|Azelaic acid|azelaic acid (Finacea® Gel, 15%) twice daily on either the left side or the right side of the face and no treatment on the other side of the face
61990428|NCT03035955|NO_INTERVENTION|no treatment|no treatment on the other side of the face
61990429|NCT04930679|EXPERIMENTAL|Group I|1 capsule of Andiabet x 3 times/ day . Taken 30 minutes before meals in 28 days
61990430|NCT04930679|EXPERIMENTAL|Group II|2 capsule of Andiabet x 3 times/ day . Taken 30 minutes before meals in 28 days
62559376|NCT06313541|ACTIVE_COMPARATOR|PD-1/PD-L1 inhibitor combined with chemotherapy|
61990431|NCT00963261|EXPERIMENTAL|psycho-oncological intervention|stepped care psycho-oncological intervention
61990432|NCT00963261|NO_INTERVENTION|control group|
61990433|NCT04444609||COVID -19 with chronic lung disease|"Subjects with swab confirmed COVID-19 and underlying chronic lung disease (n=60)~Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia)~Mild/Moderate ( n =30) (absence of severe criteria)"
61990434|NCT04444609||COVID-19 without chronic lung disease|"Subjects with swab confirmed COVID-19 and no chronic lung disease (n=60)~Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia)~Mild/Moderate ( n =30) (absence of severe criteria)"
62386547|NCT04239807|OTHER|Group 2 Control - training without WBV|"Screening (day -21 until day -7): Subjects will be evaluated according to In- and Exclusion critera~Randomization (day -7): Subjects will be randomized to either Intervention Group (training on wbv platform) or non-Intervention Group (training without wbv).~Introduction Week -1(-7d-d1): All subjects will receive introduction in their training~Month 1:~Day 1: From this day subjects are supposed to start their training accoridng to protocol~Day 2: Telephone Visit~Day 5: Telephone Visit~Day 7: Telephone Visit~Day 10: Telephone Visit~Day 13: Telephone Visit~Day 20: Telephone Visit~Day 27: Telephone Visit~Week 4, Day 28: Study center Visit: 6MWD, QoL-Questionnaire, AEs, re-training~Month 2:~Week 5, Day 34:~Week 6, Day 41:~Week 7, Day 48:~Week 8, Day 55:~Month 3:~Week 9, Day 62:~Week 10, Day 69:~Week 11, Day 76:~Week 12, Day 83: Final Visit"
62386548|NCT05734586|OTHER|DYSPHAGING Interventional group|"* Step 1: delivery of the EAT-10 questionnaire for swallowing disorders screening;~* Step 2: in case of EAT≥2 score, immediate implementation of upper airway protection measures in 3 areas:~  1: Postural adjustments; 2 : Hygienic and dietary rules ; 3: Food textures The hypothesis is that allied health professionals in acute geriatric wards, rehabilitation units, and Long Term Care Units are able to implement the current recommendations for screening for sarcopenic dysphagia and to implement preventive measures but in a systematic way.~Patient characteristics will be collected at each site at the end of the study by a clinical research assistant based on their medical records.~At the end of the study, each allied health professionals who has been involved in the care of at least one patient will fill out a satisfaction questionnaire."
62386549|NCT06173726|EXPERIMENTAL|BST02 Injection|
62386550|NCT05862740|EXPERIMENTAL|Laparoscopic debulking surgery - LDS|Primary debulking surgery or Interval debulking surgery performed by laparoscopy (P-LDS and I-LDS)
62559377|NCT06313541|EXPERIMENTAL|Treatment response adapted hybrid radiotherapy plus PD-1/PD-L1 inhibitor and chemotherapy|
62559378|NCT05318027|EXPERIMENTAL|Activity Monitoring and ChatBot|Patients will receive standard of care chemotherapy and radiation therapy regimens, activity monitoring and utilize a ChatBot
62559379|NCT05318027|NO_INTERVENTION|Activity Monitoring without ChatBot|Patients will receive standard of care chemotherapy and radiation therapy regimens, activity monitoring alone
62559380|NCT04820725|EXPERIMENTAL|Study group|Patients whose BASMI score is 2 will be included in the study
61990435|NCT04444609||Chronic Lung disease|"Subjects with chronic lung disease (identified as requiring shielding based on severity) but no COVID-19 (n=80)~* Asthma (defined as severe) - (n=20)~* CF (FEV1% predicted baseline \<50%) - (n=20)~* COPD (FEV1% predicted baseline \<50%) - (n=20)~* Idiopathic Pulmonary Fibrosis (n=20)"
61990436|NCT04444609||Healthy volunteers|Healthy subjects with no COVID-19 (n=30)
61990437|NCT05114135|EXPERIMENTAL|Subject group|undergoing instrumented TLIF with instrumented PLF using investigational product as synthetic bone graft
61990438|NCT04922203|NO_INTERVENTION|Control group|Anesthesiology residents do not receive any in situ simulation sessions during the observation period
61990439|NCT04922203|EXPERIMENTAL|Simulation group|Anesthesiology residents receive in situ simulations sessions during the observation period
61990440|NCT05876273|EXPERIMENTAL|NAP first, then UMPC|Participants will use the Neural Net Artificial Pancreas (NAP) algorithm for 18 hours. Then switch to the University of Virginia Model-Predictive Control (UMPC) for 18 hours.
61990441|NCT05876273|EXPERIMENTAL|UMPC first, then NAP|Participants will use the UMPC for 18 hours, then switch to NAP for 18 hours.
61990442|NCT03889821|ACTIVE_COMPARATOR|Child-focused Treatment|Participants in this group participate in 12 sessions of the Parent-implemented Early Start Denver Model (P-ESDM).
61990443|NCT03889821|EXPERIMENTAL|Child- and Parent-focused Treatment|Participants in this group participate in 12 sessions of the Parent-implemented Early Start Denver Model (P-ESDM). Parents also participate in 6 separate, individual sessions of Mindfulness Based Stress Reduction (MBSR).
61990444|NCT06524310|EXPERIMENTAL|active rTMS group|Male and female ASD individuals aged between 7 and 11 years old who have been diagnosed with ASD on prior clinical assessment using the American Psychiatric Association's DSM-V criteria and corroborated by assessment using the Autism Diagnostic Observation Schedule (ADOS), Childhood Autism Rating Scale (CARS), and The Social Responsiveness Scale (SRS). With normal hearing based on past hearing screens. Participation will be limited to higher functioning (intelligence quotient \[IQ\] \>70) to maximize successful completion of tested paradigms, maintain alertness/attention, furthermore, the ability to follow instructions.
61990445|NCT06524310|NO_INTERVENTION|wait-list-control group|Male and female ASD individuals aged between 7 and 11 years old who have been diagnosed with ASD on prior clinical assessment using the American Psychiatric Association's DSM-V criteria and corroborated by assessment using the Autism Diagnostic Observation Schedule (ADOS), Childhood Autism Rating Scale (CARS), and The Social Responsiveness Scale (SRS). With normal hearing based on past hearing screens. Participation will be limited to higher functioning (intelligence quotient \[IQ\] \>70) to maximize successful completion of tested paradigms, maintain alertness/attention, furthermore, the ability to follow instructions.
61990446|NCT03828812|ACTIVE_COMPARATOR|Breakfast promotion|Receiving the recommendation of daily breakfast
61990447|NCT03828812|ACTIVE_COMPARATOR|Nighttime snack reduction|Receiving the recommendation of reducing nighttime snack frequency
61990448|NCT03828812|EXPERIMENTAL|Breakfast promotion + nighttime snack reduction|Receiving the recommendation of daily breakfast + reducing nighttime snack frequency
61990449|NCT00174915|EXPERIMENTAL|Febuxostat 80 mg QD|
61990450|NCT00174915|EXPERIMENTAL|Febuxostat 120 mg QD|
61990451|NCT00174915|EXPERIMENTAL|Febuxostat 240 mg QD|
61990452|NCT00174915|ACTIVE_COMPARATOR|Allopurinol QD|
61990453|NCT00174915|PLACEBO_COMPARATOR|Placebo QD|
62386551|NCT05862740|ACTIVE_COMPARATOR|Debulking surgery - DS|Primary debulking surgery or Interval debulking surgery performed by/converted to laparotomy (PDS and IDS)
62386552|NCT05103540|EXPERIMENTAL|Intervention|Comprehensive theory-based suicide behavior program
62386553|NCT05103540|NO_INTERVENTION|Control|No intervention will be given to the group
62386554|NCT02216227|EXPERIMENTAL|Surgical Site Infection Checklist|"Patient has a known positive Staph aureus pre-op screening result (MRSA or MSSA):~* ecolonize with intranasal Mupirocin ointment BID x 5 days~* hlorhexidine gluconate (CHG) bathing (daily x 5 days, using wipes or liquid)~* efazolin plus Vancomycin (no Vanco for MSSA positive)~Patient has a known negative Staph aureus pre-op screening result:~* HG bathing (night before \& morning of surgery using wipes or liquid)~* efazolin~Patient was not screened or results are unknown at time of surgery:~* ecolonize with intranasal Mupirocin ointment (start BID x 5 days; discontinue if negative screen)~* HG bathing (start daily bath 5 days before operation if possible; at a minimum bathe the night before \& morning of surgery using wipes or liquid)~* efazolin plus Vancomycin"
62386555|NCT00557362|ACTIVE_COMPARATOR|1|Topical voriconazole with corneal de-epithelialization
62386556|NCT00557362|ACTIVE_COMPARATOR|2|Topical voriconazole without corneal de-epithelialization
62386557|NCT00557362|ACTIVE_COMPARATOR|3|Topical natamycin with corneal de-epithelialization
62386558|NCT00557362|ACTIVE_COMPARATOR|4|Topical natamycin without corneal de-epithelialization
62386559|NCT03604159|EXPERIMENTAL|Buprenorphine Extended-Release|XRB is a 300mg pre-mixed subcutaneous injectable formulation to be administered monthly. XRB is for abdominal subcutaneous injection only. Participants in the XRB treatment arm will be given 1 or more XRB injections prior to release from jail and one more at week 5 post-release, depending on their release date.
62767422|NCT02099201|EXPERIMENTAL|Group A3|Ten subjects will receive ACT-389949 (Predicted to be 800 mg) and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
61990454|NCT02939560|EXPERIMENTAL|rTMS|Participants will receive rTMS sessions according to the study protocol.
61990455|NCT02822989|ACTIVE_COMPARATOR|Vagus Nerve Stimulation|Subjects randomized to this arm will receive transcutaneous vagus nerve stimulation for 5 minutes on 4 consecutive days.
61990456|NCT02822989|SHAM_COMPARATOR|Sham Vagus Nerve Stimulation|Subjects randomized to this arm will receive sham stimulation for 5 minutes for 4 consecutive days.
61990457|NCT00843921|EXPERIMENTAL|Carbaglu|Investigate whether a 3-day treatment with NCG can improve or restore urea genesis capacity in patients with NAGS, CPSI, or OTC deficiency or PA or MMA using surrogate markers: \[13C\] label incorporation into urea and plasma levels of ammonia, urea nitrogen (BUN) and amino acids
61990458|NCT03102931|EXPERIMENTAL|Reduced ROS/RNS content products|Participants will be given and asked to smoke research cigarettes for the first 4 weeks. For the final 4 weeks of the study they will be given and asked to smoke low ROS content cigarettes.
61990459|NCT01457625||liver fat contents|
62386560|NCT03604159|ACTIVE_COMPARATOR|Sublingual Buprenorphine|SLB (SUBOXONE, Zubsolv, or generic tablets) is a daily sublingual film or tablet ranging from 8-24mg/day or equivalent (Zubsolv is dosed 5.7-17.1 mg/day). The film or tablet is placed under the tongue for 5 to 10 minutes until dissolved completely. Participants in the SLB treatment arm will be provided SLB daily by observed dosing in-jail (controlled substances are not self-administered in-jail) and and encouraged to continue SLB treatment in weekly, bi-weekly, or monthly quantities for unobserved, daily, self-administration through week 5. Patients may also elect to obtain SLB care free-of-charge from the Bellevue Hospital Center Addiction Medicine clinic or from non-NYU/Bellevue providers and pharmacies per usual care standards. SLB will not be provided via the study.
62386561|NCT06496698|EXPERIMENTAL|Subcuticular Suture Group|Running subcuticular Vicryl 3-0 sutures will be placed on patients in the experimental group.
62386562|NCT06496698|ACTIVE_COMPARATOR|Simple Interrupted Suture Group|Simple interrupted Monocryl 3-0 sutures will be placed on patients in the control group.
62386563|NCT05523648|EXPERIMENTAL|The control group|The control group was treated with silibinin meglumine tablets and tenofovir
62767423|NCT02099201|EXPERIMENTAL|Group B1|Ten subjects will receive ACT-389949 200 mg and 3 subjects will receive placebo, every 3 days for 13 days (a total of 5 doses), administered orally, in the morning, following an overnight fast.
61990460|NCT01343563|ACTIVE_COMPARATOR|Low frequency to High|For the first six weeks, subjects randomized to this group will receive low frequency stimulation. At the six week point, the low frequency group subjects will be crossed over to high frequency for the remaining six weeks.
61990461|NCT01343563|ACTIVE_COMPARATOR|High frequency|Subjects randomized to this group will receive high frequency stimulation for the entire 12 weeks of the first phase of this study.
62767424|NCT02099201|EXPERIMENTAL|Group B2|Ten subjects will receive ACT-389949 (provisionally 200 mg) and 3 subjects will receive placebo, every 2 days for 9 days (a total of 5 doses), administered orally, in the morning following an overnight fast. The actual dose will depend on the emerging data from Group B1.
61990462|NCT04203628|EXPERIMENTAL|Prospective cohort|"Any child with presumptive TB will be proposed to participate in the study.~If the child is enrolled in the TB-Speed SAM or HIV studies, the study nurse will collect 2 stool samples then collect information about the clinical examination, chest X-ray, HIV-testing and the mycobacterial culture results as soon as they are available, from the data collected in the TB-speed records since all these procedures are already performed in these studies.~For children identified from the routine practice, the nurse will collect 2 respiratory samples (sputum or GA) in consecutive children with presumptive TB to be tested using Ultra as done in routine care, record symptoms and refer the child for clinical exam and for chest X-ray. For the purpose of the study, 2 stool samples will be collected to be tested with Ultra. In addition, for study purpose the two respiratory samples will be tested with Mycobacterial culture as this test is not routinely prescribed for TB diagnosis in the study sites"
61990463|NCT04203628|EXPERIMENTAL|Enrichment cohort|"Any child with presumptive TB and a positive Xpert result from one respiratory sample (NPA, IS or GA) will be proposed to participate in the study.~If the child is enrolled in the TB-Speed SAM or HIV studies, the study nurse will collect 2 stool samples then collect information about the clinical examination, chest X-ray, HIV-testing and the mycobacterial culture results as soon as they are available, from the data collected in the TB-speed records since all these procedures are already performed in these studies~For children identified from the routine care, once enrolled, samples collected as routine practice will be tested with mycobacterial culture in addition to Xpert. If needed an additional respiratory sample will be collected (sputum or GA) and tested with Mycobacterial culture. The nurse will also record symptoms, refer the child for clinical exam and for chest Xray, and collect stool samples. HIV-testing will be offered for children with unknown HIV-status"
61990464|NCT00828191|EXPERIMENTAL|Progesterone SC|
61990465|NCT00828191|ACTIVE_COMPARATOR|Progesterone Tablets|
61990466|NCT01613521|EXPERIMENTAL|DCE-MRI and 18F-FMISO PET|Each patient will undergo three DCE-MRI (dynamic contrast-enhanced MRI) studies: a baseline DCE-MRI within two weeks before chemoradiation; a second DCE-MRI after the second week of treatment (within a week); and a third DCE-MRI three months after treatment. As a pilot study in 10 patients, we will perform 18F-FMISO PET/CT on the same day of a baseline DCE-MRI before chemoradiation. Treatment decisions will not be based on DCE-MRI and 18F-FMISO PET/CT studies.
61990467|NCT02327858|EXPERIMENTAL|Supportive text message group|Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months .
61990468|NCT02327858|NO_INTERVENTION|No supportive text message group|Patients in the control group will only receive a text message once every two weeks thanking them for participating in the study. The aim of this will be to help increase the retention rate for the study.
62386564|NCT05523648|ACTIVE_COMPARATOR|The treatment group|The treatment group was treated with Ganshuang granules combined with silibinin meglumine tablets and tenofovir
61990469|NCT04391387|ACTIVE_COMPARATOR|16-hour prone position|measure vital signs, PaO2/FiO2, driving pressure one hour before prone position and 1-hour, 8-hour, 16-hour after prone position
61990470|NCT04391387|EXPERIMENTAL|24-hour prone position|measure vital signs, PaO2/FiO2, driving pressure one hour before prone position and 1-hour, 8-hour, 16-hour, 24- hour after prone position
62386565|NCT06107387|EXPERIMENTAL|Binge Eating Self-help for Teens|Participants will have 16 guided self-help sessions (4 months; weekly sessions for adolescents with parents joining monthly). Participants will complete daily self-monitoring of eating behaviors (timing of meals and snacks; whether or not a binge occurred) throughout treatment. Treatment sessions involve a self-help component, which includes brief videos that participants watch at home. Treatment sessions also involve a guidance component (brief consultation), which is 15-30 minutes on a secure videoconferencing platform (e.g., Zoom) between the therapist and the participant. These sessions focus on clarifying material, reviewing self-monitoring and looking for patterns, and problem-solving maladaptive thinking patterns and binge behaviors.
61990471|NCT01771146|OTHER|Neoadjuvant FOLFIRINOX Regimen|Single arm, treated with neoadjuvant FOLFIRINOX prior to surgical resection
61990472|NCT04735120|EXPERIMENTAL|Laser to reduce pain intraoperatively and post operatively|Diode lasers are used to assess its efficacy in reducing intraoperative and postoperative pain following root canal treatment in mandibular molar teeth with acute irreversible pulpitis
62559381|NCT04820725|EXPERIMENTAL|Control group|Patients whose BASMI score is 0 and 1 will be included in the study
62559382|NCT00450437|ACTIVE_COMPARATOR|Licensed Meningococcal Vaccine|Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
62559383|NCT00450437|EXPERIMENTAL|Novartis MenACWY Conjugate Vaccine|Novartis meningococcal ACWY conjugate Vaccine
62559384|NCT05951413|EXPERIMENTAL|Sildenafil|patients will be given estradiol in form of Cycloprogynova white pills starting dose is one pill t.i.d may be increased to two pills t.i.d according to endometrial thickness in day 9 measured by vaginal ultrasound and will have will be given sildenafil citrate tablets (50 mg) daily .
62767425|NCT02099201|EXPERIMENTAL|Group C1|10 subjects will receive ACT-389949 and 3 subjects on placebo. The actual dose will depend on the emerging data from the previous groups but will be within the dose range or lower than the dose range tested in Part A. The dosing schedule will be one of those already tested in Part A and/or Part B.
62559385|NCT05951413|PLACEBO_COMPARATOR|control|patients will be given estradiol in form of Cycloprogynova white pills starting dose is one pill t.i.d may be increased to two pills t.i.d according to endometrial thickness in day 9 measured by vaginal ultrasound.
62767426|NCT02099201|EXPERIMENTAL|Group C2|10 subjects will receive ACT-389949 and 3 subjects on placebo. The actual dose will depend on the emerging data from the previous groups but will be within the dose range or lower than the dose range tested in Part A. The dosing schedule will be one of those already tested in Part A and/or Part B.
62767427|NCT03463668||symptomatic non-covered duodenal prosthesis|Any symptomatic duodenal stenosis with symptomatic duodenal duodenal prosthesis between 2010 and 2017.
62386566|NCT02555722|EXPERIMENTAL|fanfilcon A (test)|Subjects will be randomized to wear fanfilcon A lens (test) for one month of daily wear during the study.
62386567|NCT02555722|ACTIVE_COMPARATOR|enfilcon A (control)|Subjects will be randomized to wear enfilcon A lens (control) for one month of daily wear during the study.
62767428|NCT04218071|EXPERIMENTAL|9-ING-41|9-ING-41 is administered by intravenous infusion twice weekly at a dose of 9.3 mg/kg. Cycle duration is 28 days.
61990473|NCT06546904|EXPERIMENTAL|AI group|Group AI used artificial intelligence to empower anesthesia ultrasound assisted simulated PNB operations in 5 areas
61990474|NCT06546904|NO_INTERVENTION|Control group|Control group did not use AI assisted simulated PNB operations in 5 areas
62767429|NCT04218071|EXPERIMENTAL|9-ING-41 plus Ruxolitinib|9-ING-41 9.3 mg/kg will be administered by intravenous infusion twice weekly for cycle durations of 28 days with Ruxolitinib at doses specified in the protocol as appropriate for patient's platelet count.
61990475|NCT01233674||patients referred for standard of care MRI|
61990476|NCT01367574|EXPERIMENTAL|Arm 1|
61990477|NCT01367574|EXPERIMENTAL|Arm 2|
61990478|NCT01367574|EXPERIMENTAL|Arm 3|
61990479|NCT03395158||Prior alert criteria|Patients who activated full, limited or no alert criteria according to the prior alert criteria
61990480|NCT03395158||Present alert criteria|Patients who activated full, limited or no alert criteria according to the present alert criteria
61990481|NCT02723968|OTHER|Continuous glucose monitoring system|OGTT followed by continuous glucose monitoring system and finally IGTT and HbA1C dosage
61990482|NCT06267079|OTHER|study group|"Core stability Exercises. Each participant in the group (A) underwent eighteen sessions of core stability exercises very other day for one and half months, 3 sessions /week, each session for 1hour (30 minutes for core exercises then 30 minutes Selected physical therapy program).~+ Selected physical therapy program."
61990483|NCT06267079|OTHER|control group|Selected physical therapy program. all participants in both groups (A \& B) had three sessions per week for a month and a half, every other day. of Selected physical therapy program which consist of (Exercises for tone modulation, balance, lower limb muscular strengthening, and stretching)
61990484|NCT02360163|ACTIVE_COMPARATOR|Landmark Technique Attempt|Patients will undergo an additonal TLT attempt
61990485|NCT02360163|EXPERIMENTAL|USGPIVA Technique Attempt|Patients will be offered a USGPIVA attempt after two failed attempts using the traditional landmark technique (TLT)
61990486|NCT05606042||IM Implant|Male and female patients who present with a pelvic ring and/or acetabular fracture that has recently undergone surgery to be fixed with a CurvaFix IM Implant.
62386568|NCT02369757|EXPERIMENTAL|Intervention of navigators|Navigators accompany the target population towards OCCS.
62767430|NCT04172168||Heart rupture|Include left ventricular free-wall ruptrue after AMI
62386569|NCT02369757|NO_INTERVENTION|No Intervention|Population is not accompanied by navigators
62386570|NCT04763824|ACTIVE_COMPARATOR|cluster-randomized controlled trial, with delayed start control arm|ECHO education and practice facilitation with plan, do, study, act cycles to improve the delivery of cancer survivorship guideline concordant care.
62559386|NCT05030792|EXPERIMENTAL|ART VR 3 times/week|ART VR practice for 30 minutes, at home, 3 times per week
62767431|NCT04172168||Non heart rupture|AMI with non heart rupture
62767432|NCT01556321|EXPERIMENTAL|Green tea, normal weight|Subjects with a BMI 18.5-25 kg/m2 will receive green tea capsules, which they have to consume daily for a period of twelve weeks
62767433|NCT01556321|PLACEBO_COMPARATOR|Placebo, normal weight|Subjects with a BMI 18.5-25 kg/m2 will receive placebo capsules, which they have to consume daily for a period of twelve weeks
62767434|NCT01556321|EXPERIMENTAL|Green tea, overweight|Subjects with a BMI \>30 kg/m2 will receive green tea capsules, which they have to consume daily for a period of twelve weeks
62767435|NCT01556321|PLACEBO_COMPARATOR|Placebo capsules, obese|Subjects with a BMI \>30 kg/m2 will receive placebo capsules, which they have to consume daily for a period of twelve weeks
62767436|NCT04496661|EXPERIMENTAL|tDCS over M1 and PES|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and PES (20Hz and 330ms) placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area . Duration: 30 minutes.
61990487|NCT04898673|EXPERIMENTAL|CP1000 Sound Processor followed by the CP1110 Sound Processor|All study subjects were provided with a unique identifier. The ones that ended in an odd number were administered the CP1000 Sound Processor followed by the CP1110 Sound Processor.
61990488|NCT04898673|EXPERIMENTAL|CP1110 Sound Processor followed by the CP1000 Sound Processor|All study subjects were provided with a unique identifier. The ones that ended in an even number were administered the CP1110 Sound Processor followed by the CP1000 Sound Processor.
61990489|NCT02007876|EXPERIMENTAL|Mobility and Activity Training|"Pre-operative: Participants will receive weekly sessions of higher level, task-specific transfer training. All MAT participants will learn the GCS set of exercises chosen to activate core muscles and lessen decline in core strength. These sessions will be supplemented by a home-based walking and physical activity enhancement program of the participants' choosing, focusing on attaining a safe community-based rate of perceived exertion. A pedometer and home exercise log will be used to encourage compliance and advance activities.~Post-operative: Participants will be screened by physical therapy for standard physical therapy with focus on early mobilization. The GCS exercises taught pre-operatively will be reinstituted.~Post-discharge/home: Participants will continue the GCS program and begin to return to elements of their pre-operative home-based MAT program. The program physical therapist will call weekly to review progress."
62386571|NCT04763824|EXPERIMENTAL|cluster-randomized controlled trial, intervention|ECHO education and practice facilitation with plan, do, study, act cycles to improve the delivery of cancer survivorship guideline concordant care.
62386572|NCT01406509|EXPERIMENTAL|children aged 2-5 years (1 dose)|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccines of 0.5ml/dose for a person in 20 children aged 2-5 years, on day 0
62386573|NCT01406509|EXPERIMENTAL|children aged 6-23months (2 doses)|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccines of 0.5ml/dose for a person in 20 children aged 6-23 months old, on day 0, 28
62559387|NCT05030792|EXPERIMENTAL|ART VR 4 times/week|ART VR practice for 30 minutes, at home, 4 times per week
62386574|NCT06402240|EXPERIMENTAL|Adjunct Intervention|The intervention is called Pocket Skills 2.0, which is a web-based dialectical behavior therapy skills training (DBT-ST) intervention. The content and material is based on the most recent Linehan (2014) DBT-ST manual. Pocket Skills 2.0 incorporates brief lessons using videos featuring Dr. Linehan herself, exercises involving interaction with the chatbot which allow for text input and selection of responses, and the ability to gain points and unlock additional content which increases user engagement. Pocket Skills is currently the only comprehensive and not-for-profit DBT-ST app available where the effectiveness has been evaluated in at least three research trials.
62386575|NCT01335360||Subjects >80kg|As above
61990490|NCT02007876|NO_INTERVENTION|Normal activity|"Pre-operative: Participants will be given the National Institute on Aging guide to home-based exercise but no further instruction or incentive for walking or physical activity enhancement.~Post-operative: Participants will be screened by in-hospital physical therapy for standard physical therapy with focus on early mobilization. Those who do not receive physical therapy will not be given any additional training, as is standard for reimbursed hospital services.~Post-discharge: Program nurse will call weekly to provide health education but no instruction or incentives for mobility or physical activity enhancement."
61990491|NCT04252755|OTHER|EEG Neurofeedback|Within-subjects sessions of EEG neurofeedback
61990492|NCT00071565||1|475 families with multiple affected family members (phase I) 200 families with multiple affected family members (phase II) 1800 subjects with sporadic intracranial aneurysms
62386576|NCT01335360||Subjects <70kg|As above
62386577|NCT01335360||Subjects 70-80kg|As above
62386578|NCT02343991|EXPERIMENTAL|Transcranial ExAblate|MR Guided Focused Ultrasound
62386579|NCT05286034|EXPERIMENTAL|Intervention group|Women randomized to this group will be sent screening reminder letters to perform HPV self-sampling test, with access to a decision aid tool tailored to those with low education levels. This tool will be available via Chatbot platforms.
62386580|NCT05286034|NO_INTERVENTION|Control group|Women randomized to this group will be sent screening reminder letters to perform HPV self-sampling test (Standard care)
62386581|NCT02727452|EXPERIMENTAL|immediate mother-skin-to-skin contact(SSC)|The immediate mother-SSC begins directly after birth (still during the C-section)
62386582|NCT02727452|ACTIVE_COMPARATOR|immediate father-SSC|The immediate father-SSC begins directly after birth (still during C-section)
62386583|NCT02727452|OTHER|Routine care;mother-SSC after 30 minutes|After birth (still during C-section) the newborn gets routine care of a midwife close to the mother. SSC with mother after 30 minutes
62386584|NCT04736966|EXPERIMENTAL|Guselkumab 30mg|Guselkumab administered by subcutaneous injection at Day 1 and Day 29
62386585|NCT04736966|EXPERIMENTAL|Guselkumab 70 mg|Guselkumab administered by subcutaneous injection at Day 1 and Day 29
62386586|NCT04736966|EXPERIMENTAL|Guselkumab 100mg|Guselkumab administered by subcutaneous injection at Day 1 and Day 29
62386587|NCT03795324|EXPERIMENTAL|Redlove Apple|"Redlove Apple intervention~This product is a biofortified cultivar apple with anthocyanins."
62386588|NCT03795324|EXPERIMENTAL|Green Apple|"Green Apple intervention~This product is a common cultivar apple without anthocyanins."
62386589|NCT03795324|EXPERIMENTAL|Aronia Drink|"Aronia drink intervention~This product is an infusion of aronia fruit extract rich in anthocyanin."
61990493|NCT04484454|EXPERIMENTAL|Omega 3 Oil Supplementation|Following all necessary screening, patients will be provided with the ProdromeNeuro Omega-3 oil supplement and instructed to consume the equivalent of 1 cc of the oil supplement per day for the first month, followed by 2 cc of the supplement/day for the second month, and finally ending with 4 cc/day of the supplement for the third month. Neurocognitive assessment and serology testing will take place at baseline, end of month 1, end of month 2, end of month 3, and one month post intervention-termination.
62386590|NCT04925466|EXPERIMENTAL|Treatment with CPAP at 10cmH2O|Patients with OSA will be treated with CPAP at 10cmH2O during sleep.
62386591|NCT04925466|EXPERIMENTAL|Treatment with CPAP at minimal effective pressure|Patients with OSA will be treated with CPAP at minimal effective pressure derived from manual titration during sleep.
61990494|NCT05818579|EXPERIMENTAL|Virtual reality|The investigators will administer a virtual reality experience programme to promote mental wellbeing of the participants
62386592|NCT02743494|EXPERIMENTAL|Nivolumab|
61990495|NCT05818579|NO_INTERVENTION|Usual care|The investigators will not provide any interventions to the participants.
61990496|NCT01153412|NO_INTERVENTION|Control Group|Control group no intervention
61990497|NCT01153412|EXPERIMENTAL|Osteopathic Manipulative Treatment|Osteopathic Manipulative medicine group
61990498|NCT01275898||Beach chair|Patients scheduled for surgical procedure in beach chair position (Shoulder surgery)
61990499|NCT01275898||Sitting position|Patients scheduled for surgical procedure in sitting position (Neurosurgery)
61990500|NCT01275898||Head down position|Patients scheduled for surgical procedure in head down position (daVinci robotic surgery)
61990501|NCT01275898||Prone position|Patients scheduled for surgical procedure in prone position
61990502|NCT04149951|EXPERIMENTAL|Active|Randomized to active device use plus lifestyle modification (500kcal deficit hypocaloric diet and 150 min of exercise per week for each subject).
62386593|NCT02743494|PLACEBO_COMPARATOR|Placebo|
61990503|NCT04149951|PLACEBO_COMPARATOR|Control|Randomized to sham device use plus lifestyle modification (500kcal deficit hypocaloric diet and 150 min of exercise per week for each subject).
62386594|NCT04205513|NO_INTERVENTION|Control Group|Standard titration management strategy, consisting of regular in-office visits.
62386595|NCT04205513|EXPERIMENTAL|Study Group|Remote titration management strategy, consisting of telephone contacts, which will utilize data from the Medly system.
62386596|NCT05853289|EXPERIMENTAL|Jail staff at pilot jails|Jail staff will be asked to use the implementation resource with guided facilitation to care for pregnant people in and leaving custody.
62386597|NCT04417816|EXPERIMENTAL|Exercise training + adipose tissue cavitation|
62559388|NCT04455867||UHN Toronto Rehab|Participants with prediabetes of T2DM undertaking a 6-month stepped hybrid (home and clinic based) aerobic plus resistance exercise intervention as per the site's standard protocol (Diabetes Exercise and Healthy Lifestyle Program).
62767437|NCT04496661|EXPERIMENTAL|tDCS over DLPFC and PES|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) and PES (20Hz and 330ms) placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area . Duration: 30 minutes.
62559389|NCT04455867||Sunnybrook Health Sciences Centre|Participants with prediabetes or T2DM receiving care from an outpatient service at Sunnybrook Health Sciences Centre.
61990504|NCT05450887|EXPERIMENTAL|OCA 5 mg titrated to 10 mg ± UDCA|"OCA 5 mg once daily for 3 months and then titrating up to 10 mg based on tolerability and response.~Subjects receiving UDCA continued taking UDCA throughout the trial. If the subjects could not tolerate UDCA, they were not treated with UDCA."
61990505|NCT05450887|PLACEBO_COMPARATOR|Placebo ± UDCA|Placebo once daily. Subjects receiving UDCA continued taking UDCA throughout the trial. If the subjects could not tolerate UDCA, they were not treated with UDCA.
61990506|NCT03193411|OTHER|microkeratome group|30 eyes were treated by microkeratome
61990507|NCT03193411|OTHER|femtosecond group|30 eyes were treated by femtosecond laser
61990508|NCT05293756|EXPERIMENTAL|Intervention: OPTIMA-BP Implementation|Participants randomized to OPTIMA-BP intervention for 6 months then observed for a 6 month follow up period
61990509|NCT05293756|NO_INTERVENTION|Waitlist: OPTIMA-BP implementation|Participants randomized to waitlist for 6 months, then offered the OPTIMA-BP intervention for 6 months.
61990510|NCT02180412|EXPERIMENTAL|Panhematin|Panhematin plus glucose
61990511|NCT02180412|PLACEBO_COMPARATOR|Placebo|Placebo (saline) plus glucose
62386598|NCT04417816|SHAM_COMPARATOR|Exercise training + sham procedure|
62386599|NCT06218290|EXPERIMENTAL|All Patients|All patients with chronic kidney disease with hyperphosphatemia
62386600|NCT04465513|ACTIVE_COMPARATOR|Best Standard of Care + CARDIO|Combination of CARDIO and Best Standard of Care
62386601|NCT04465513|PLACEBO_COMPARATOR|Best Standard of Care|Placebo and Best Standard of Care
62386602|NCT04162145|ACTIVE_COMPARATOR|Active Device|Patients in the Active Device arm will receive placement of an active BRIDGE device.
62386603|NCT04162145|SHAM_COMPARATOR|Sham Device|Patients in the Sham Device arm will receive placement of an inactive, or sham, BRIDGE device. The inactive device will be identical in appearance to the active device but will have no electrical current.
62386604|NCT01126528|EXPERIMENTAL|Vitamin D3|Vitamin D3 (cholecalciferol)
62386605|NCT01126528|PLACEBO_COMPARATOR|Control|Placebo control group
62386606|NCT03572101||Calgary Patient Cohort|Patients with advanced colorectal cancer who are recruited from Calgary, Canada before, during, and after an early palliative care pathway becomes the new standard of care in Calgary.
62386607|NCT03572101||Calgary Caregiver Cohort|Caregivers of patients with advanced colorectal cancer who are recruited from Calgary, Canada before, during, and after an early palliative care pathway becomes the new standard of care in Calgary.
62386608|NCT03572101||Edmonton Patient Cohort|Patients with advanced colorectal cancer who are recruited from Edmonton, Canada during the same time period (no palliative care pathway introduced).
62559390|NCT03347110|EXPERIMENTAL|Bimekizumab|Subjects will receive bimekizumab up to 2 years.
62559391|NCT02813915||Use of Cheetah medical NICOM|For those who consent to the study, the Cheetah NICOM will be used to obtain cardiac output, stroke volume, and fluid responsiveness.
62386609|NCT03572101||Edmonton Caregiver Cohort|Caregivers of patients with advanced colorectal cancer who are recruited from Edmonton, Canada during the same time period (no palliative care pathway introduced).
62386610|NCT03309215|EXPERIMENTAL|Patients with nickel allergy|Experimental stimulation with nickel discs
62386611|NCT03309215|EXPERIMENTAL|Persons without nickel allergy|Experimental stimulation with nickel discs
62386612|NCT02683031|NO_INTERVENTION|Without Ca2+ ionophore|Patients with previous incomplete ICSI cycle due to fertilization arrest were counseled to underwent a subsequent conventional ICSI cycle.
62386613|NCT02683031|EXPERIMENTAL|With Ca2+ ionophore|Patients with previous incomplete ICSI cycle due to fertilization arrest were counseled to underwent a subsequent ICSI cycle combined with artificial oocyte activation using Ca2+ ionophore.
62386614|NCT00568399|EXPERIMENTAL|Active Treatment|This is the only arm and involves active treatment with sodium thiosulfate in those subjects with high coronary artery calcium scores.
62386615|NCT03716206|EXPERIMENTAL|exergames group|The exergames intervention is one hour per day, four or five days per week for three weeks.
62386616|NCT03716206|ACTIVE_COMPARATOR|conventional group|The conventional group intervention is one hour per day, four or five days per week for three weeks.
62386617|NCT01265628||Glaucoma|
62386618|NCT01265628||Retinitis pigmentosa (RP)|
62386619|NCT01265628||Anterior Ischemic Optic Neuropathy (AION)|
62386620|NCT01482676||1|controls (normal bladder function)
62559392|NCT02700217|EXPERIMENTAL|Spinal Anaesthesia|2.5ml of heavy 0.5% Bupivacaine, 400mg of Diamorphine (Spinal Anaesthesia) \& IV infusion of Remifentanil 0.2-0.3ug/kg/min, Propofol 2-3mg/kg and 0.2 mg/kg of Cistracurium (General Anaesthesia)
62559393|NCT02700217|ACTIVE_COMPARATOR|Rectus Sheath Injection|50ml of 0.25% I-Bupivacaine max 2mg/kg (IV block Anaesthesia) injected into rectus sheath bilaterally \& IV infusion of Remifentanil 0.2-0.3ug/kg/min, Propofol 2-3mg/kg and 0.2 mg/kg of Cistracurium (General Anaesthesia)
62559394|NCT00578201|EXPERIMENTAL|1|radiochemotherapy,combination Cetuximab-FOLFOX
62559395|NCT00200863|EXPERIMENTAL|1|420 nm light
62559396|NCT00200863|EXPERIMENTAL|2|480 nm
62182670|NCT03100955|EXPERIMENTAL|EP chemotherapy plus apatinib|Apatinib treatment or experimental group contains standard chemotherapy and apatinib, a VEGF tyrosine kinase inhibitor. It contains a platinum drug, a topoisomerase inhibitor and a VEGF-TKI. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI=apatinib, 500 mg, oral daily after chemotherapy, until disease progression or death or un-tolerated toxicites. Used drugs=cisplatinum and etoposide and apatinib.
62182671|NCT00551135|EXPERIMENTAL|3|
62182672|NCT00551135|PLACEBO_COMPARATOR|4|
62386621|NCT01482676||2|acontractile bladder
62386622|NCT01482676||3|overactive bladder
62386623|NCT01482676||4|bladder pain syndrome
62386624|NCT05613244||Patients with Orbital Solitary Fibrous Tumors|
62386625|NCT02602028|EXPERIMENTAL|once daily dosage schema of colchicine|The once daily dosage group was prescribed as once daily at 08:00 a.m. (Total 1mg)
62386626|NCT02602028|EXPERIMENTAL|twice daily dosage schema of colchicine|Twice daily dosage group received the treatment twice daily at 08:00 a.m. and 08:00 p.m. (Total 1mg)
62386627|NCT05677906|ACTIVE_COMPARATOR|Walking only (Step It Up!)|A group-based, weekly walking program (Step It Up) where participants walk for up to 45 minutes.
62386628|NCT05677906|EXPERIMENTAL|Combined (Step It Up! plus Change Club)|A group-based, weekly walking program (Step It Up) where participants walk for up to 45 minutes. Participants also spend 30 minutes each week in a civic engagement program (the Change Club) improving walkability in the community
62386629|NCT00412360|EXPERIMENTAL|Single Cord Blood Transplant|Unrelated donor, single umbilical cord blood unit transplant; conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil
62559397|NCT00200863|EXPERIMENTAL|3|507 nm
62559398|NCT00200863|EXPERIMENTAL|4|555 nm
62559399|NCT00200863|EXPERIMENTAL|5|620 nm
62559400|NCT00200863|EXPERIMENTAL|6|460 nm
62559401|NCT06295172|EXPERIMENTAL|Lafullen15|PCL filler
62559402|NCT06295172|ACTIVE_COMPARATOR|Lafullen|PCL filler
62559403|NCT05140044|ACTIVE_COMPARATOR|Home - Paper Intervention|Older adults who are given a 4-week paper-based balance intervention program. Performed 3days/week for 30min/day over the course of a 4-week period using printed materials with text instruction and images.
62559404|NCT05140044|EXPERIMENTAL|Home - Smartphone Intervention|Older adults who are given a 4-week home-based balance exercise program. Performed 3days/week for 30min/day over the course of a 4-week period using participants' smartphones.
61990512|NCT03854422|ACTIVE_COMPARATOR|Left Position during colonoscopy|Left position, the patient will be in the left-side position during the entire colonoscopy period. If necessary, change of position and pressure will be allowed. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured.Moreover, process recall, sedation amounts and pain scale will be measured after the procedure..During the process, it will be examined whether there is any need for loop formation, repositioning requirement and pressure requirements. The type and amount of anesthetic agent (midazolam) used during the process is paid attention to be equal. All procedures will be done with the same brand device. After the procedure, a mini questionnaire will be applied to the patients for the pain scale.
61990513|NCT03854422|ACTIVE_COMPARATOR|Left Supine Position during colonoscopy|Left Supine position, the patient will be in the left and supine ( after splenic flexura) position during the entire colonoscopy period. If necessary, change of position and pressure will be allowed. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured.
61990514|NCT03854422|ACTIVE_COMPARATOR|Dynamic position during colonoscopy|Dynamic position, the patient will be stared as left position during colonoscopy period. If necessary, change of position and pressure will be allowed at any time. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured..During the process, it will be examined whether there is any need for loop formation, repositioning requirement and pressure requirements. The type and amount of anesthetic agent used during the process is paid attention to be equal. The use of midazolam as an anesthetic agent was planned.All procedures will be done with the same brand device. After the procedure, a mini questionnaire will be applied to the patients for the pain scale.
61990515|NCT03263208|EXPERIMENTAL|CD19 CAR-T|A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
61990516|NCT01187043|EXPERIMENTAL|ARM 1|1 mg Proellex
61990517|NCT01187043|EXPERIMENTAL|ARM 2|3 mg Proellex
61990518|NCT01187043|EXPERIMENTAL|ARM 3|6 mg Proellex
61990519|NCT01187043|EXPERIMENTAL|ARM 4|9 mg Proellex
61990520|NCT01187043|EXPERIMENTAL|ARM 5|12 mg proellex
61990521|NCT05686213|EXPERIMENTAL|combined aerobic exercise + resistance exercise intervention (AE + RE)|Physical exercise during neaodjuvant chemoradiation
61990522|NCT05686213|EXPERIMENTAL|Aerobic exercise prior to daily radiotherapy sessions (ExPR)|Physical exercise during neaodjuvant chemoradiation
62182673|NCT00551135|EXPERIMENTAL|2|
62182674|NCT00551135|EXPERIMENTAL|1|
62386630|NCT00412360|EXPERIMENTAL|Double Cord Blood Transplant|Unrelated donor, double umbilical cord blood unit transplant; Conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil
62386631|NCT04255329|OTHER|Usual reading group|The leader of the activity reads aloud a text to four participants seated around the table. The readen text is a normal, currently used in a everyday life support such as a journal article. Consequently it is not previously adaptated to people with cognitive impairements. After the reading phase, the leader asks the participants the questions about the content.
62386632|NCT04255329|OTHER|Montessori reading roundtable group|The group counts four participants and one activity leader. Each person have the same Montessori reading roundtable book.
62386633|NCT01482338|EXPERIMENTAL|DSG|The low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
61990523|NCT05686213|NO_INTERVENTION|Usual care control (UC)|The control group will receive usual care and will be requested to maintain their usual daily physical activities.
61990524|NCT03295708|EXPERIMENTAL|experimental group|the experimental group will be given 4 fish oil capsules (1g/one capsule)twice daily after two meals at roughly the same time each day,lasting for the first 6 months.fish oil capsule will be provided by the Hunan Kangqi100 Biological Technology Co.Ltd.
61990525|NCT03295708|PLACEBO_COMPARATOR|control group|the control group will be given 4 soybean oil capsules ( placebo capsule,1g/one capsule) twice daily after two meals at roughly the same time each day,lasting for the first 6 months.placebo capsule will be provided by the Hunan Kangqi100 Biological Technology Co.Ltd.The placebo capsule's appearance and flavor are made the exactly the same as the fish oil capsules .
62386634|NCT01482338|ACTIVE_COMPARATOR|DRSP|The other low-dose oral contraceptive pill which consists of 20 microgram ethinyl estradiol and 3 mg drospirenone were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
62386635|NCT02500901|EXPERIMENTAL|Experimental Treatment|Subjects will receive enzalutamide 160 mg/day PO in a 28-day lead-in cycle to assess tolerability. If well-tolerated, cycle 1 of combined enzalutamide and niraparib will commence. Enzalutamide will continue at 160 mg PO daily. Niraparib will be administered in three dose-escalation cohorts of 100mg PO, 200mg PO or 300 mg PO daily. Six subjects will be enrolled at each dose level. Each cycle will be 28 days. Combination treatment will continue until documented progression, unmanageable toxicity, or subject or treating investigator decision to discontinue for any reason.
62386636|NCT06287554||Group A|Group A (n:39) included patients who had been early placed in prone positions within 24 hours of intubation
62386637|NCT06287554||Group B|Group B (n:31) included patients who had not been placed in prone position
62386638|NCT04810429|PLACEBO_COMPARATOR|Placebo|TMJ arthroscopy and Saline solution NaCl 0,9% in 2 syringes with 1 ml each. Injected in Right Masseter (0.5ml), Left Masseter (0.5ml), Right Temporalis (0.5ml) and Left Temporalis (0.5ml).
62386639|NCT04810429|ACTIVE_COMPARATOR|IncobotulinumoxinA|TMJ arthroscopy and Dose of IncobotulinumoxinA to be injected 100 U distributed in 2 syringes with 1 ml each: 25U (0.5ml) in Right Masseter / 25U (0.5ml) in Left Masseter / 25U (0.5ml) in Right Temporalis / 25U in Left Temporalis.
62386640|NCT04774029|EXPERIMENTAL|BVN Block|Patients will receive temporary basivertebral nerve block using lidocaine during the vertebral augmentation procedure for osteoporotic compression fracture.
62386641|NCT03493204|EXPERIMENTAL|Home-delivered, salt restricted|Meal description: salt-restricted (1500 mg to 2000 mg daily), \> 2100 kilocalorie, high protein (\>80 g daily) in addition to receiving standard pamphlet receipt
61990526|NCT03387163||Sacubitril/Valsartan|Chronic systolic heart failure patients newly prescribed in mg. twice daily.
62386642|NCT03493204|ACTIVE_COMPARATOR|Dietary Advice|Standard of care, advice on salt-restriction using standard pamphlet receipt
62386643|NCT03417999|EXPERIMENTAL|Cohort 1|"Cohort 1A:~* Dexmedetomidine 2 μg/kg~* Under general oral endotracheal anesthesia~* 7 subjects age \>2 yo and ≤ 6 yo~* 7 subjects age ≥1 mo and ≤2 yo~Cohort 1B:~* Dexmedetomidine 2 μg/kg~* Under sedation with a natural airway~* 7 subjects age \>2 yo and ≤ 6 yo~* 7 subjects age ≥1 mo and ≤2 yo"
62559405|NCT01585090|EXPERIMENTAL|passive ankle dorsi ﬂexion|doing strengthening exercises of PFM in standing position with passive ankle dorsi ﬂexion (on wooden surface with 15 degree angle)
61990527|NCT03387163||ACEi/ARB|Chronic systolic heart failure patients receiving ACEi/ARB and no s/v
61990528|NCT00772499|EXPERIMENTAL|1|olmesartan medoxomil tablets with added doses of hydrochlorothiazide, amlodipine, or hydralazine, if required to maintain target blood pressure
61990529|NCT00772499|ACTIVE_COMPARATOR|2|Atenolol tablets with added doses of hydrochlorothiazide, amlodipine, or hydralazine, if required to maintain target blood pressure
61990530|NCT05568654|ACTIVE_COMPARATOR|Rapid diagnostic testing (RDT)|Rapid diagnostic testing: Eligible patients at hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT testing. If the patient is not being admitted to the ICU, and the patient has an admitting diagnosis of pneumonia, the form will append orders for viral testing and UAT testing to providers in hospitals randomized to receive it.
62386644|NCT03417999|EXPERIMENTAL|Cohort 2|"* Dexmedetomidine 4 μg/kg~* Under general oral endotracheal anesthesia~* 7 subjects age \>2 yo and ≤ 6 yo"
62386645|NCT05254964|EXPERIMENTAL|Intensive cognitive rehabilitation group|Participants receive intensive cognitive rehabilitation for 20 hours for 4 weeks.
62559406|NCT01585090|EXPERIMENTAL|active ankle plantar ﬂexion with arm up|doing strengthening exercises of PFM in standing position with active ankle plantar ﬂexion with arm up (standing on toe)(n=20) and horizontal standing position
62559407|NCT01585090|NO_INTERVENTION|horizontal standing position|doing strengthening exercises of PFM in standing position with horizontal standing position
62559408|NCT02044263|EXPERIMENTAL|Internet CBT-i|Participants will be instructed on the use of the internet CBT-i (SHUTi) intervention site, then use the program for six weeks.
62559409|NCT02044263|ACTIVE_COMPARATOR|face-to-face CBT-i|4 to 8 sessions of face-to-face CBT-i treatment with one of three clinicians (experienced CBT-i psychiatrists)
62386646|NCT01916733||Lower Extremity Bypass & open AAA|Lower Extremity Bypass (LEB) and open AAA patients will be placed on standard Fletcher Allen Health Care insulin protocol post op
61990531|NCT05568654|ACTIVE_COMPARATOR|Pharmacist-led de-escalation|Pharmacist-led de-escalation: Another CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for \> 48 hours and generate a list for the clinical pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily on weekdays at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. The validated measures of clinical stability in patients with CAP are a) resolved vital sign abnormalities b) normal mental status c) ability to eat. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page.
62386647|NCT01916733||control|patients from the Vascular Study Group of New England centers without a defined program for glucose control after lower extremity bypass and open AAA repair will be used
62386648|NCT02358863|EXPERIMENTAL|Chemotherapy|"Standard chemotherapy doublet based on molecular testing using one of the following interventions:~Modified FOLFOX6 Docetaxel/Capecitabine Cisplatin/Irinotecan Cisplatin/Docetaxel IRI/EPI EPI/Docetaxel Irinotecan/Docetaxel Docetaxel"
62386649|NCT04342572|EXPERIMENTAL|Intra-arterial injections of melphalan|-Participants will receive intra-arterial injections of melphalan Q4W for 3 cycles.
62386650|NCT01747655||Duodopa|Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)
62386651|NCT01747655||Standard of Care|Participants that return to oral or transdermal anti-parkinson's disease medications
62386652|NCT01259388|EXPERIMENTAL|Lithium|"Lithium-treatment phase~Lithium Carbonate: Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time."
62386653|NCT01259388|NO_INTERVENTION|Observation|During observation subjects continue on their standard of care disease modifying agent (or no agent at all if judged not appropriate by the treating physician).
62386654|NCT05331547||BioFreedom BA9 (SS) Ultra DCS|STEMI patients treated with one or several BioFreedom stent(s)
62386655|NCT01783223||Intoxicated patients|patients in the Emergency Department who appear to be intoxicated with ethanol.
61990532|NCT05568654|ACTIVE_COMPARATOR|Rapid diagnostic testing (RDT) and Pharmacist-led de-escalation|"Rapid diagnostic testing: Eligible patients at hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT testing. If the patient is not being admitted to the ICU, and the patient has an admitting diagnosis of pneumonia, the form will append orders for viral testing and UAT testing to providers in hospitals randomized to receive it.~Pharmacist-led de-escalation: Another CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for \>48-hours and generate a list for the clinical pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily on weekdays at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page."
62386656|NCT00339027||Preschool children|Children aged 3-5 years who are enrolled in federally-subsidized early care and education centers in underserved communities in Miami-Dade County
62386657|NCT01891539||doxorubicin|"Day +1:~Lobar Infusion ( lobe with dominant disease) of Doxorubicin preloaded into 2 ml of drug-eluting microspheres.~Second lobar infusion of Doxorubicin preloaded into 2 ml of drug eluting microspheres can be administered at the same time contralaterally or in a further TACE Day +30: The above procedure is repeated. Day +90: In case of response, a third administration following the above procedures will be repeated"
62559410|NCT04840381||Nonagenarians and Centenarians|Nonagenarians and Centenarians borned and living for most of their life in the Abruzzo region.
62386658|NCT00824746|EXPERIMENTAL|Gefitinib retreatment group|Gefitinib retreatment
62386659|NCT02176122|ACTIVE_COMPARATOR|Meropenem|Meropenem 1g adm every 8 hours IV up to study day 4.
62386660|NCT02176122|EXPERIMENTAL|Piperacillin-tazobactam combination product|Piperacillin/tazobactam 4.5g adm every 6 hours IV up to study day 4.
62386661|NCT01849354||Endometriosis patients|Endometriosis patients to be operated in Turku university hospital 2013-2015
62386662|NCT01849354||Control patients|Patients who will be operated because of an adnexal finding other than endometriosis, for example ovarian cyst. Also patients with laparoscopic sterilization will be recruited to the control group.
62386663|NCT01976494|EXPERIMENTAL|domestic PCA equipment|Patient controlled analgesia by the domestic PCA equipment
62386664|NCT01976494|ACTIVE_COMPARATOR|imported PCA equipment|Patient controlled analgesia by imported PCA equipment
62386665|NCT05190406|EXPERIMENTAL|Pulpotomy|complete pulpotomy will be done till the level of root canal orifice.
62559411|NCT05521581|EXPERIMENTAL|intervention|Hand massage will be applied to primiparous mothers who gave birth by cesarean section
62386666|NCT05190406|ACTIVE_COMPARATOR|Root canal treatment|Single visit root canal treatment will be done according to standard protocol.
62386667|NCT05312528||Study Group|Stage 3 and 4 endometriosis patients
62386668|NCT05312528||Control Group|Patients without endometriosis, who required surgery for tubal ligation, benign ovarian cysts or uterine fibroids were included.
62386669|NCT01017289|EXPERIMENTAL|Quantum|In this single arm study, the Quantum nailing system will be used in all patients.
62386670|NCT05547828|OTHER|Tislelizumab combined with chemoradiotherapy|"Tislelizumab: According to the instructions of tislelizumab, 200 mg intravenously on the first day of each cycle, 21 days as a cycle.~Nab-paclitaxel: white purple: 100mg/m2 intravenous infusion on d1.8.15 (during chemotherapy) 100mg/m2 intravenous infusion q3w ╳ 3 cycles (during consolidation therapy) Radiotherapy: 40Gy/20f, 5 times/w, (esophageal primary tumor and metastatic lymph nodes)"
62386671|NCT03803176||Periodontally healthy subjects|Healthy subjects who attended the restorative dental clinic and have clinically healthy gingiva with zero plaque index (PI), gingival index (GI), and CAL (≤3 mm PD). Oral hygeine instructions will be given to these patients.
62559412|NCT05521581|NO_INTERVENTION|control|Routine care will be given to mothers who have given cesarean section and hand massage will not be applied.
62559413|NCT05671341||Parkinson's Patients with Motor Freezing|Individuals with Parkinson's Disease with motor freezing were included in this group.
62386672|NCT03803176||Chronic Periodontitis|Patients with severe Chronic Periodontitis having a pocket depth (PD) of ≥5 mm and a clinical attachment level (CAL) ≥5 mm. Open flap debridement (surgical periodontal therapy) will be carried out for these patients after scaling \& root planing.
62386673|NCT05182034|EXPERIMENTAL|Study Group 1: SMUP-IA-01 (low dose)|Investigational Product - 4.0×10\^6 cells/2 mL of SMUP-IA-01 (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
61990533|NCT05568654|NO_INTERVENTION|Usual care (no intervention)|Usual care
61990534|NCT04865354|OTHER|PRECISION1, then Clariti 1-Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 days in a daily disposable modality.
61990535|NCT04865354|OTHER|Clariti 1-Day, then PRECISION1|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 days in a daily disposable modality.
61990536|NCT03302988|EXPERIMENTAL|Everted closure|Wound eversion will be achieved through buried vertical mattress suture or cuticular suture based on surgeon's preference, either buried vertical mattress suture or cuticular sutures
61990537|NCT03302988|ACTIVE_COMPARATOR|Planar closure|The planar side of the same wond will be closed with traditional buried simple closure and running cuticular sutures
61990538|NCT01708174|EXPERIMENTAL|Sonidegib (LDE225)|600 mg orally for adults and 500 mg/m2 orally for children
61990539|NCT01708174|ACTIVE_COMPARATOR|Temozolamide (TMZ)|150 to 200 mg/m2 for 5 sequential days every 4 weeks according to prescribing information until the study was amended to a single arm study.
61990540|NCT04792632||Intervention|Intervention is the use of Veye Lung Nodules during the reading of the CT scans
61990541|NCT03163745||Asymptomatic spontaneous bacterial peritonitis|"All the included patients will be subjected to:~1. Full medical History and physical examination~2. Laboratory investigations: Complete blood picture , kidney function tests, liver function tests ,prothrombin time and concentration~3. Abdominal Ultrasound~4. Ascitic fluid paracentesis will be done to test for total leucocyte count and polymorphonuclear count , total protein and albumin levels. Testing for cytological analysis and culture will be done."
61990542|NCT06259240|ACTIVE_COMPARATOR|Prone Plank Exercises|Forty two post partum woman will recieve progressive prone plank exercises, three times a week, for eight weeks, and with a moderate hard intensity.
61990543|NCT06259240|SHAM_COMPARATOR|Electrical Stimulation|Forty two post partum woman will recieve electrical stimulation for the rectus abdominis muscle day after day for 8 weeks. The patient position was relaxed in the crook lying position. The session parameters were 30 minutes/session with a low frequency current (50-100Hz).
62386674|NCT05182034|EXPERIMENTAL|Study Group 2:SMUP-IA-01 (mid dose)|Investigational Product - 1.0×10\^7 cells/2 mL of SMUP-IA-01 (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
62559414|NCT05671341||Parkinson's Patients Without Motor Freezing|Individuals with Parkinson's Disease without motor freeze were included in this group.
62559415|NCT04670328||Covid-19 disease severity|Mild, moderate, severe and critical disease
62559416|NCT04395820||Cystic Fibrosis|
61990544|NCT05834517|EXPERIMENTAL|hyaluronic acid/ scaling|topical application of hyaluronic acid after scaling by 1 day
61990545|NCT05834517|EXPERIMENTAL|scaling|scaling only
61990546|NCT02820896|PLACEBO_COMPARATOR|Multiple Dose Placebo IV|Healthy participants or participants with Alzheimer's disease will receive multiple doses of matching placebo IV QW, a total of 4 doses.
61990547|NCT02820896|EXPERIMENTAL|Multiple Dose RO7105705 IV|Healthy participants or participants with Alzheimer's disease will receive multiple doses of RO7105705 IV QW, a total of 4 doses.
61990548|NCT02820896|EXPERIMENTAL|Single Dose RO7105705 SC|Healthy participants will receive a single dose of RO7105705 SC on Day 1.
61990549|NCT02820896|PLACEBO_COMPARATOR|Single dose Placebo IV|Healthy participants will receive a single dose of placebo IV on Day 1.
61990550|NCT02820896|EXPERIMENTAL|Single dose RO7105705 IV|Healthy participants will receive a single dose of RO7105705 IV on Day 1.
61990551|NCT02038582|ACTIVE_COMPARATOR|POC CD4 & Clinic Accompaniment|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and follow up with clinic accompaniment
62559417|NCT04395820||Healthy|
61990552|NCT02038582|ACTIVE_COMPARATOR|POC CD4 & Lay Counselor|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and lay counselor follow up
61990553|NCT02038582|ACTIVE_COMPARATOR|POC CD4 & Clinic Referral|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and referral to clinic
61990554|NCT02038582|ACTIVE_COMPARATOR|CD4 Referral & Clinic Accompaniment|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and follow up with clinic accompaniment
61990555|NCT02038582|ACTIVE_COMPARATOR|CD4 Referral & Lay Counselor|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and lay counselor follow up
62559418|NCT04535141|EXPERIMENTAL|Olanzapine Arm|Olanzapine 5mg tablet with chemotherapy, and 3 days after
61990556|NCT02038582|ACTIVE_COMPARATOR|CD4 Referral & Clinic Referral|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and referral to clinic
61990557|NCT02038582|ACTIVE_COMPARATOR|Circumcision - SMS Reminder|HIV negative uncircumcised males, randomized to SMS reminder for male circumcision
62559419|NCT04535141|PLACEBO_COMPARATOR|Placebo Arm|
62559420|NCT02885779||Patient having an operating indication of adnexa surgery|Patient having an operating indication of adnexa surgery : unilateral or bilateral adnexectomy
62559421|NCT03816423|NO_INTERVENTION|Traditional counseling|Patients will undergo routine prenatal care visit with clinical practicioner only
62559422|NCT03816423|EXPERIMENTAL|video group|"Participants randomized to the intervention group (video education) will view the prenatal screening video How to Decide About Prenatal Genetic Testing, followed by a routine prenatal appointment."
62559423|NCT02236260|ACTIVE_COMPARATOR|Local anesthesia alone|
62559424|NCT02236260|EXPERIMENTAL|Local Anesthesia + Electroacupuncture|
62559425|NCT00352742|EXPERIMENTAL|1|ATN-224 + bortezomib
62386675|NCT05182034|ACTIVE_COMPARATOR|Active Control Group|Investigational Product - 2 ml of 1% sodium hyaluronate (2 ml of sodium chloride injection is administered before administration of 1% sodium hyaluronate)
62386676|NCT04890028|EXPERIMENTAL|F-DOPA PET/CT|Drug: 18 F-DOPA Radiation: F-DOPA PET CT
62386677|NCT02804386|EXPERIMENTAL|treatment|Sofosbuvir, 400 mg OD for 6 months
62386678|NCT02465957|EXPERIMENTAL|aNK (NK-92)|aNK (activated NK-92, formerly Neukoplast)
62386679|NCT02465957|EXPERIMENTAL|aNK (NK-92) + N-803|aNK (activated NK-92, formerly Neukoplast) and N-803
62386680|NCT03525912|EXPERIMENTAL|Ketamine infusion|postoperative pain in adult population after abdominal, thoracic and orthopedic surgery that received adjuvant analgesia with ketamine 0.1mg/kg/h during 24 to 48 hours in postoperative period.
61990558|NCT02038582|ACTIVE_COMPARATOR|Circumcision - Lay Counselor|HIV negative uncircumcised males, randomized to lay counselor follow-up for male circumcision
61990559|NCT02038582|ACTIVE_COMPARATOR|Circumcision - Promotion|HIV negative uncircumcised males, randomized to promotion of male circumcision at the time of HIV testing
62386681|NCT00738322|EXPERIMENTAL|1|
62386682|NCT00738322|PLACEBO_COMPARATOR|2|
62386683|NCT04506073|EXPERIMENTAL|Mesenchymal Stem Cells and Placebo|2 infusions of 10 X 10\^6 MSC/kg and 1 placebo infusion, all doses administered 4 months apart.
62386684|NCT04506073|EXPERIMENTAL|Mesenchymal Stem Cells|3 infusions of 10 X 10\^6 MSC/kg administered every 4 months.
62386685|NCT04506073|PLACEBO_COMPARATOR|Placebo|3 placebo doses administered every 4 months.
62386686|NCT04803656|OTHER|Assesment|Demographic information of all subjects (age, gender, educational status, occupation, body weight, height, body mass index), clinical (diagnosis period) and medical status, personal history and family history, COPD stage, COPD Assessment Test (CAT) score, emergency and hospital admissions numbers in the last 3 months, exacerbation and hospitalization numbers in the last one year were recorded. Respiratory and peripheral muscle strengths are evaluated. Also pulmonary functions test results obtained.
61990560|NCT02038582|ACTIVE_COMPARATOR|POC VL|HIV positive persons on ART, randomized to POC viral load testing
62386687|NCT03949816|EXPERIMENTAL|patient-centered communication style|The patient-centered style is characterized by features such as empathetic communication, open questions, and uses an easily understandable language.
62767438|NCT04496661|SHAM_COMPARATOR|Sham tDCS and PES|Sham tDCS and PES stimulation. Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and PES (20Hz and 330ms) placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. The currents will be turned off automatically after 30 seconds. Duration: 30 minutes.
61990561|NCT02038582|ACTIVE_COMPARATOR|Laboratory based VL assay|HIV positive persons on ART, randomized to laboratory based viral load testing
61990562|NCT04910009|NO_INTERVENTION|Theoretical training group|Students participating in only theoretical training of the privacy education for two 40-minute sessions.
61990563|NCT04910009|EXPERIMENTAL|Digital story and ethical case analysis group|Students participating in 2 sessions of 40-minute theoretical training and then participating in 4 sessions of 60-minute digital story and ethical case analysis preparation and presentation.
61990564|NCT04910009|EXPERIMENTAL|Only ethical case analysis group|Students participating in 2 sessions of 40 minutes of theoretical training and then participating in 4 sessions of 60-minute ethical case analysis preparation and presentation only.
62386688|NCT03949816|EXPERIMENTAL|doctor-centered communication style|The doctor-centered style is defined by an authoritarian and goal-oriented communication. The doctor uses medical terms instead of lay language.
62386689|NCT03949816|ACTIVE_COMPARATOR|information letter|In the active control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
62386690|NCT06234891|ACTIVE_COMPARATOR|Group 1|NSAID
62386691|NCT06234891|ACTIVE_COMPARATOR|Group 2|nsaid and physiotherapy
62386692|NCT03481933|EXPERIMENTAL|1:left-excitatory tDCS|20 SD patients who receive left-excitatory trans cranial stimulation
62386693|NCT03481933|ACTIVE_COMPARATOR|2:right-inhibitory tDCS|20 SD patients who receive right-inhibotory trans cranial stimulation
62767439|NCT02318290||Critically ill patients|Mechanically ventilated critically ill patients receiveing opiates for more than 96 hours will be prospectively followed for the emergence of withdrawal symptoms upon weaning of opiates
61990565|NCT04780763|ACTIVE_COMPARATOR|Arm 1, Test: Fermented milk product containing probiotics L. rhamnosus CNCM I-3690|
61990566|NCT04780763|PLACEBO_COMPARATOR|Arm 2, Control: Milk-based non-fermented dairy product|
61990567|NCT03647228|EXPERIMENTAL|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
61990568|NCT03647228|PLACEBO_COMPARATOR|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
61990569|NCT03691064||LUTATHERA|Treated per labeled LUTATHERA dosing regimen.
62386694|NCT03481933|SHAM_COMPARATOR|3:sham tDCS|20 SD patients who receive sham stimulation
62386695|NCT05573204|ACTIVE_COMPARATOR|Group 1 obeticholic acid group|28 non alcoholic steatohepatitis patients receiving obeticholic acid 10 mg once daily for 6 months duration
62386696|NCT05573204|ACTIVE_COMPARATOR|Group 2 vitamin E group|31 non alcoholic steatohepatitis patients receiving vitamin E 400 mg twice daily for 6 months duration
62386697|NCT00805142|EXPERIMENTAL|Opioid-Naive Participants (Tapentadol PR)|Opioid-naive participants are defined as those who had moderate to severe cancer pain that is not controlled sufficiently with non-opioid medications. Treatment period comprises of Titration and Maintenance period. Titration period (3-14 days) is duration between start of treatment to day before initial dose in the maintenance period. Treatment will be initiated with tapentadol prolonged release (JNS024PR, PR) 25 milligram (mg) oral tablet twice daily. Dose will be increased or decreased as per Investigator's discretion up to Day 14. Maximum dose limit will be 500 mg per day. Participants will then be assigned to the treatment in the maintenance period (15-19 days). The maintenance period is duration between the first dose and the final assessment in the maintenance period. Participants will receive tapentadol PR oral tablet twice daily for 5 days at the same dose used on last day of titration period.
62767440|NCT05116605|EXPERIMENTAL|Photobiomodulation (PBM)|Participants will utilize the NovoTHOR whole body light pod
62386698|NCT00805142|EXPERIMENTAL|Opioid-Switch Participants (Tapentadol PR)|Opioid-switching participants are defined as those who had moderate to severe cancer pain that is controlled sufficiently with opioid therapy. Treatment period comprises of Titration and Maintenance period. Titration period (3-14 days) is duration between start of treatment to day before initial dose in maintenance period. Initial dose of tapentadol PR is selected according to daily dose of opioid (morphine sustained release \[SR\] preparation, oxycodone hydrochloride \[HCl\] SR tablet or fentanyl patch). Equivalent dose of tapentadol PR oral tablet twice daily is given depending on daily dose of opioid at completion of Screening period. Maximum dose limit is 500 mg per day. Participants will then be assigned to treatment in maintenance period (15-19 days). Maintenance period is defined as duration between first dose and final assessment in maintenance period. Participants will receive tapentadol PR oral tablet twice daily for 5 days at same dose used on last day of titration period.
62386699|NCT06170359||Group 1: those who did not take pregabalin (n:45)|
62386700|NCT06170359||Group 2: those who took pregabalin (n:45)|
62386701|NCT00840931|EXPERIMENTAL|Immunotherapy|Participants will take two 5 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Participants will receive 4 treatment cycles with 28 days in each cycle. Those participants showing a clinical response after 4 cycles of treatment may continue to receive lenalidomide as a single agent for additional cycles at the treating Physicians discretion. During each 28 day cycle participants will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
62386702|NCT02918136|EXPERIMENTAL|adipose-derived stem cell injection|ultrasound guided injection of 5cc of adipose-derived stem cells (ADSCs)
62386703|NCT02918136|ACTIVE_COMPARATOR|cortisone injection|ultrasound guided injection of cortisone
62386704|NCT03102073||Radner test|reading speed evaluation
62386705|NCT05340179|ACTIVE_COMPARATOR|Interlaminar cervical epidural steroid injection|
62386706|NCT05340179|EXPERIMENTAL|Cervical selective nerve root block|
62386707|NCT04806165|EXPERIMENTAL|Repeated Administration|
62386708|NCT04806165|EXPERIMENTAL|Personalized Recommendation|
62386709|NCT04806165|EXPERIMENTAL|Motivational Interviewing|
62386710|NCT04806165|EXPERIMENTAL|Core Modules Only|
62386711|NCT04806165|EXPERIMENTAL|Motivational Interviewing, Personalized Recommendation, Repeated Administration|
62386712|NCT04806165|EXPERIMENTAL|Motivational Interviewing, Repeated Administration|
62386713|NCT04806165|EXPERIMENTAL|Motivational Interviewing, Personalized Recommendation|
62386714|NCT04806165|EXPERIMENTAL|Personalized Recommendation, Repeated Administration|
62386715|NCT04806165|EXPERIMENTAL|Psychoeducation|
62386716|NCT04806165|EXPERIMENTAL|Psychoeducation, Repeated Administration|
62386717|NCT04806165|EXPERIMENTAL|Psychoeducation, Personalized Recommendation|
62386718|NCT04806165|EXPERIMENTAL|Psychoeducation, Motivational Interviewing|
62386719|NCT04806165|EXPERIMENTAL|Psychoeducation, Motivational Interviewing, Personalized Recommendation|
62386720|NCT04806165|EXPERIMENTAL|Psychoeducation, Personalized Recommendation, Repeated Administration|
62386721|NCT04806165|EXPERIMENTAL|Psychoeducation, Motivational Interviewing, Repeated Administration|
62386722|NCT04806165|EXPERIMENTAL|Psychoeducation, Motivational Interviewing, Personalized Recommendation, Repeated Administration|
62386723|NCT01087151|ACTIVE_COMPARATOR|A|
62386724|NCT01087151|EXPERIMENTAL|B|
62386725|NCT01087151|EXPERIMENTAL|C|
62386726|NCT01959087|EXPERIMENTAL|1: Single port surgery|Surgery with single port
62386727|NCT01959087|ACTIVE_COMPARATOR|2: Multiport surgery|Surgery with multiport
62386728|NCT05113849|EXPERIMENTAL|Cohort A (Low-dose group)|IN-B009 (Low-dose)
62386729|NCT05113849|EXPERIMENTAL|Cohort B (High-dose group)|IN-B009 (High-dose)
62386730|NCT00935766|PLACEBO_COMPARATOR|Sugar Pill|4 tabs of placebo dependent on randomization
62386731|NCT00935766|ACTIVE_COMPARATOR|Omega 3|omega-3-acid ethyl esters and instructed to take 4 1 mg capsules daily
62386732|NCT01742013|PLACEBO_COMPARATOR|Placebo|NaCl 0.9%, s.c., 4ml (2ml x 2), 3 times per a week, 6 weeks
62386733|NCT01742013|EXPERIMENTAL|GCJBP Laennec Inj.|GCJBP Laennec Injection,s.c., 4ml(2ml x 2)/day, 3 times per a week, 6 weeks
62386734|NCT02705339|EXPERIMENTAL|Arm 1: Rociletinib|"* Rociletinib is an oral drug which will be administered on an outpatient basis at a dose of 500 mg twice per day during each 28-day cycle.~* After completion of cycle 1, patients who tolerate the 500 mg twice per day dose without significant adverse effect may increase dosing to 625 mg twice per day at the discretion of the investigator"
62386735|NCT02511691|OTHER|18F-PSS232|Subjects receive baseline PET with 18F-PSS232 and stimulation PET with 18F-PSS232 after medical challenge with N-acetylcystein
62386736|NCT01454973||Healthy obese individuals|
62386737|NCT01990339||Lansoprazole|Lansoprazole (Takepron), tablets, orally, once daily for up to 8 weeks. Reflux esophagitis: the usual adult dosage is 30 mg of lansoprazole. For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily. Nonerosive gastroesophageal reflux disease: the usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks.
62386738|NCT01811693|EXPERIMENTAL|Dose Tier 1|Glycerly Trinitrate (Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal
62386739|NCT01811693|EXPERIMENTAL|Dose Tier 2|Glycerly Trinitrate (Nitroglycerine) 10mg/24hour (0.4mg/hour) transdermal
62386740|NCT01811693|EXPERIMENTAL|Dose Tier 3|Glycerly Trinitrate (GTN, Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal plus a single metered dose 0.4mg of sublingual GTN
62386741|NCT05909618|EXPERIMENTAL|Cohort 1 metastatic melanoma with brain metastases who failed immunotherapy|The first 3 subjects enrolled to Cohort 1 and Cohort 2 will receive crizanlizumab 5 mg/kg at Cycle 1 Day 1 (C1D1) and C1D15 followed by crizanlizumab 5 mg/kg every 4 weeks until disease progression The subsequent 8 patients will receive crizanlizumab 5 mg/kg at C1D1 and C1D15 followed by 5 mg/kg every 4 weeks plus nivolumab 3mg/kg every 2 weeks until disease progression
62386742|NCT05909618|EXPERIMENTAL|Cohort 2 - Patients with recurrent or progressing GB following radiation and temozolamide.|The first 3 subjects enrolled to Cohort 1 and Cohort 2 will receive crizanlizumab 5 mg/kg at Cycle 1 Day 1 (C1D1) and C1D15 followed by crizanlizumab 5 mg/kg every 4 weeks until disease progression The subsequent 8 patients will receive crizanlizumab 5 mg/kg at C1D1 and C1D15 followed by 5 mg/kg every 4 weeks plus nivolumab 3mg/kg every 2 weeks until disease progression
62182675|NCT02672579||Children 4-7 years|Pediatric subjects between the ages of 4 and 7 who have had pruritus for 6 weeks or longer will complete surveys to assess the severity of pruritus.
62386743|NCT05909618|EXPERIMENTAL|Cohort 3: Patients with newly diagnosed GB|crizanlizumab starting from 4 weeks after completing radiation therapy. The first 2 subjects will receive crizanlizumab 2.5 mg/kg at C1D1 and C1D15 followed by crizanlizumab 5 mg/kg every 4 weeks. The subsequent 6 subjects will receive crizanlizumab 5 mg/kg at C1D1 and C1D15 followed by crizanlizumab every 4 weeks. Treatment will continue for up to 12 months or until disease progression or unacceptable toxicity.
62386744|NCT00598884|EXPERIMENTAL|6-week delay start|This group begins treatment 6 weeks after recruitment and baseline.
62386745|NCT00598884|EXPERIMENTAL|No delay start|This group begins treatment after enrollment and assessment with no wait period.
62386746|NCT06075251|EXPERIMENTAL|I-InTERACT-North|Virtual stepped-care positive parenting program.
62386747|NCT06075251|NO_INTERVENTION|Care as Usual|The CAU group will receive no direct parent treatment other than clinical care provided in cardiac follow-up (i.e., child assessment and consultation), which will be documented at each follow up. At end of trial, participants randomized to CAU will have the option to participate in I-InTERACT-North.
62386748|NCT02929836|ACTIVE_COMPARATOR|PVI+LA linear ablation +CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI, LA linear ablation (roof line and mitral isthmus)and CFAE ablation.
62386749|NCT02929836|ACTIVE_COMPARATOR|PVI+linear ablation +CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI,roof line and mitral isthmus,cavotricuspid isthmus abaltion and CFAE ablation.
62386750|NCT02929836|ACTIVE_COMPARATOR|PVI+CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI and CFAE ablation.
62386751|NCT01865344||Heart surgery|Pain monitoring at different time periods
62386752|NCT00329836||Subjects with cluster headache|Subjects with both episodic and chronic cluster (as defined by the International Headache Society-IHS) were enrolled.
62386753|NCT01652027||Previously Untreated Patients with Hemophilia A|
62386754|NCT01160510||Women undergoing mammography|women undergoing mammography at the UVM Breast Cancer Surveillance Consortium site
62559426|NCT04298944||BeHealthY Cohort|Children from BeHealthY cohort who are obese/overweight but do not have mood disorders are eligible for this study. The children will be given additional questionnaires to assess emotional/behavioral well being.
62559427|NCT04298944||CHAMPION trial Cohort|"Children who are overweight/obese and have severe mental illness, and who have agreed to be contacted for future research.~Tests will be done on all participants which includes cardiovascular assessments, actigraphy, laboratory assessments and emotional/behavioral assessments."
62559428|NCT04298944||Pediatric Medical Psychiatric (PMP) Clinic Cohort|Children from the PMP Clinic who have severe mental illness but healthy weight. Tests will be done on all participants which includes cardiovascular assessments, actigraphy, laboratory assessments and emotional/behavioral assessments.
62386755|NCT04460651|ACTIVE_COMPARATOR|Active treatment|Participants in this arm will receive study medication icosapent ethyl (IPE) with a specific dose scheme.
62386756|NCT04460651|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive Placebo with the same dose scheme as the active comparator:
62386757|NCT04680273|EXPERIMENTAL|Part 1: [14C]-GDC-9545|Participants will be enrolled to receive a single dose of Carbon-14 labelled \[14C\]-GDC-9545.
62386758|NCT04680273|EXPERIMENTAL|Part 2: GDC-9545 Treatment Sequence BCD|Participants will be randomly allocated to one of two treatment sequences (BCD for this arm). In each treatment period, participants will receive a single dose of GDC-9545 in the fasted state in each of three treatment periods. The three treatment periods will be separated by a treatment-free washout between each study drug administration.
62386759|NCT04680273|EXPERIMENTAL|Part 2: GDC-9545 Treatment Sequence BDC|Participants will be randomly allocated to one of two treatment sequences (BDC for this arm). In each treatment period, participants will receive a single dose of GDC-9545 in the fasted state in each of three treatment periods. The three treatment periods will be separated by a treatment-free washout between each study drug administration.
62386760|NCT03066492|ACTIVE_COMPARATOR|Federally Qualified Health Center|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
62386761|NCT03066492|EXPERIMENTAL|Northwestern Follow Up Care Coordination|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
62386762|NCT04228666|EXPERIMENTAL|HB-adMSCs|HB-adMSCs are autologous, adipose-derived mesenchymal stem cells. Four intravenous infusions will be administered on weeks 0, 2, 6, and 8 at a dose of 2 x 10\^8 total HB-adMSC cells.
62559429|NCT03883321||CBSM|Patients included in this group participate in the CBSM program. They attend 10 sessions of stress management according to the CBSM program, 9 take place over 3 months and the tenth session takes place 3 months after the 9th session. The session is composed of relaxation and cognitive and behavioral therapy, which is carried out in groups of 8 to 10 patients
62559430|NCT03883321||Waiting list|"The CBSM group is compared to the waiting list group that does not benefit from the CBSM program. After completing their assessment in the waiting list group, patients in this group will be integrated into the CBSM group but will not be evaluated as such."
62559431|NCT00626353|EXPERIMENTAL|Intervention|Patients treated by an interdisciplinary, intersectoral and interventional team responsible for providing home-based rehabilitation.
62182676|NCT02672579||Children 8-17 years|Pediatric subjects between the ages of 8 and 17 who have had pruritus for 6 weeks or longer will complete surveys to assess the severity of pruritus.
62182677|NCT02672579||Parents|Parents of pediatric subjects between the ages of 4-17 years with chronic pruritus (for 6 weeks or longer) will complete surveys to assess their perception of their child's severity of pruritus.
62559432|NCT00626353|ACTIVE_COMPARATOR|Control|Control patients treated following standard care procedures in our department with no interference from the interventional team.
62559433|NCT03426111|PLACEBO_COMPARATOR|Placebo|Diagnostic upper endoscopy plus lifestyle modification.
61990570|NCT03034720|EXPERIMENTAL|Intervention|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
61990571|NCT03034720|NO_INTERVENTION|Control|Adolescent subjects in the control group will receive care as usual from their health care providers, a standard that is ethically acceptable.
61990572|NCT02836899|PLACEBO_COMPARATOR|Control|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours.
61990573|NCT02836899|EXPERIMENTAL|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
61990574|NCT02901535|ACTIVE_COMPARATOR|Control|Spirometry in baseline Spirometry - 20 weeks
61990575|NCT02901535|EXPERIMENTAL|Intervention|Spirometry in baseline Teleconsultation Telemonitoring Spirometry - 20 weeks
61990576|NCT03095456|EXPERIMENTAL|Revefenacin|Active Revefenacin and placebo (in place of Spiriva Handihaler®)
61990577|NCT03095456|ACTIVE_COMPARATOR|Spiriva Handihaler®|Active Spiriva Handihaler® and placebo (in place of Revefenacin)
61990578|NCT00352846|EXPERIMENTAL|Vitamin D + Calcium Carbonate|Oral Vitamin D 400 mg daily + Calcium 1200 mg daily
61990579|NCT00352846|EXPERIMENTAL|Vitamin D + Calcium Carbonate + Zoledronic Acid|Oral Vitamin D 400 mg daily and Calcium 1200 mg daily; Zoledronic Acid 4 mg/m\^2 intravenous at baseline and 6 months.
61990580|NCT05794178|EXPERIMENTAL|Precision AIM|Education + activity monitor + up to 4 text messages/day, each drawn from one of 3 content libraries and timed based on a person- and context-specific algorithm that will be updated monthly based on incoming data (within a participant-defined availability window)
61990581|NCT05794178|ACTIVE_COMPARATOR|Random AIM|Education + activity monitor + up to 4 text messages/day, each drawn from one of 3 content libraries and timed at random (within a participant-defined availability window).
61990582|NCT05794178|ACTIVE_COMPARATOR|No AIM|Education + activity monitor
61990583|NCT03175328|EXPERIMENTAL|early group|In the early group, continuous renal replacement therapies was started within 8 hours after randomization.
61990584|NCT03175328|EXPERIMENTAL|delayed group|In the delayed group, continuous renal replacement therapies was initiated if at least one of the following criteria was met: KDIGO 3, severe hyperkalemia, pulmonary edema, blood urea nitrogen level higher than 112 mg per deciliter after randomization.
61990585|NCT03522766||Healthy volunteers with no urinary tract infections|people who don't experience urinary tract infections
61990586|NCT03522766||Healthy volunteers with urinary tract infections|people who frequently experience urinary tract infections
61990587|NCT03522766||Intermittent catheter users with neurogenic bladder|
61990588|NCT03522766||Intermittent catheter users with enlarged prostate|
61990589|NCT01885533||Post-radioiodine medication|Anti-thyroid drugs
61990590|NCT01885533||Post-radioiodine medications|anti-thyroid drugs and thyroxine
61990591|NCT01885533||Post-radiodione medication|watchful monitoring
61990592|NCT06265116|ACTIVE_COMPARATOR|Bis-GMA-containing, HEMA-containing, one-step universal adhesive.|Each patient will randomly receive one class II restoration with one of the tested restorative systems
61990593|NCT06265116|ACTIVE_COMPARATOR|Bis-GMA-free, HEMA-containing, one-step universal adhesive|Each patient will randomly receive one class II restoration with one of the tested restorative systems
61990594|NCT06265116|ACTIVE_COMPARATOR|Bis-GMA- free, HEMA-free, acrylic-based one-step universal adhesive|Each patient will randomly receive one class II restoration with one of the tested restorative systems
61990595|NCT06265116|ACTIVE_COMPARATOR|Bis-GMA- containing, HEMA-containing, amide-based one-step universal adhesive|Each patient will randomly receive one class II restoration with one of the tested restorative systems
61990596|NCT03897400||study group|women in reproductive age with crohn's disease
61990597|NCT03897400||control group|women in reproductive age without crohn's disease,
61990598|NCT02515409||CPAP|CPAP, as a first line treatment to OSAS.
61990599|NCT02515409||HHHFNC|Treatment with HHHFNC after CPAP treatment fails.
61990600|NCT03760146|EXPERIMENTAL|60 years and above 20vPnC/Saline|20vPnC and saline
61990601|NCT03760146|ACTIVE_COMPARATOR|60 years and above 13vPnC/PPSV23|13vPnC and PPSV23
61990602|NCT03760146|EXPERIMENTAL|50 through 59 years of age 20vPnC|20vPnC
62559434|NCT03426111|ACTIVE_COMPARATOR|Treatment|Endoscopic gastric tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) plus lifestyle modification.
62559435|NCT01199939|EXPERIMENTAL|ETR + DRV/rtv|Darunavir 800mg once daily orally for 48 weeks,Etravirine 400mg once daily orally for 48 weeks,Ritonavir 100mg once daily orally for 48 weeks
62559436|NCT00596791|OTHER|1 arm|Open-lable study with one arm.
62559437|NCT05717972|EXPERIMENTAL|A Group|
62559438|NCT05717972|OTHER|B Group|Waiting list
62767441|NCT03168100|EXPERIMENTAL|Study Treatment|Elotuzumab (10 mg Days 1 and 15), lenalidomide (15 mg Days 1-21), and dexamethasone (20 mg days 1, 8, 15, and 22) administered in 28-day cycles which will be alternated every 8 weeks with bortezomib (1.0 mg Days 1, 8, and 15), lenalidomide (15 mg Days 1-21), and dexamethasone (20 mg Days 1, 8, 15, and 22)
62386763|NCT04436406|EXPERIMENTAL|Advanced malignant disease (non-small cell lung cancer or malignant melanoma)|"Group 1: Participants with non-small cell lung cancer (NSCLC) as per inclusion/exclusion criteria undergo baseline PD-L1 expression testing by immunohistochemistry and \[99m-Tc\]-anti-PD-L1 single-domain antibody SPECT/CT imaging at 0 and 9 weeks.~FDG-PET/CT is also performed at baseline (0) and first follow-up (9) weeks scans, in addition to standard CT clinical imaging at 0, 9 and 18 weeks.~Group 2: Participants with malignant melanoma (MM) as per inclusion/exclusion criteria undergo baseline PD-L1 expression testing by immunohistochemistry and \[99m-Tc\]-anti-PD-L1 single-domain antibody SPECT/CT imaging at 0 and 12 weeks.~FDG-PET/CT is also performed as standard clinical imaging at baseline (0), first follow-up (12) weeks and 24 weeks."
62386764|NCT00212615|ACTIVE_COMPARATOR|A|Standard XELOX
62386765|NCT00212615|ACTIVE_COMPARATOR|B|Chronomodulated XELOX
62386766|NCT03733704|EXPERIMENTAL|Healthy volunteers|Healthy volunteers
62386767|NCT02026193|EXPERIMENTAL|oocyte vitrification|All retrieved mature oocytes will be vitrified.
62386768|NCT02026193|ACTIVE_COMPARATOR|embryo freezing|All retrieved oocytes will be fertilized, and resulting embryos will be frozen.
62386769|NCT02565303|EXPERIMENTAL|L2-3 intervertebral group|The initial dose of ropivacaine for subarachnoid is chosen as 12 mg in L2-3 intervertebral space group.
62386770|NCT02565303|EXPERIMENTAL|L3-4 intervertebral group|The initial dose of ropivacaine for subarachnoid is chosen as 15 mg in L3-4 group.
62386771|NCT01773057|EXPERIMENTAL|Active decision support|Regular NHGDoc domains plus NHGDoc domain heart failure
62386772|NCT01773057|NO_INTERVENTION|Passive decision support|Regular NHGDoc domains
62386773|NCT01997827|ACTIVE_COMPARATOR|metal-ceramic RBFDP|Treatment with a metal-ceramic RBFDP
62386774|NCT01997827|EXPERIMENTAL|all-ceramic RBFDP|Treatment with an all-ceramic RBFDP
62386775|NCT06118853|NO_INTERVENTION|Group A (control)|Standard treatment for HSCT
62386776|NCT06118853|EXPERIMENTAL|Group B (intervention)|Yoga or gentle massage plus standard treatment for HSCT
62386777|NCT02083822|EXPERIMENTAL|MRI assessment|
62386778|NCT03782389||Elite football players aged 16-40 years|
62386779|NCT00699361|EXPERIMENTAL|1|Measurement before Pantoprazole application
62386780|NCT00699361|EXPERIMENTAL|2|Measurements after Pantoprazole application
62386781|NCT00723515|ACTIVE_COMPARATOR|G1|NaF (sodium fluoride varnish) with 2.26% of fluoride
62386782|NCT00723515|EXPERIMENTAL|G2|NaF (sodium fluoride)2.71% of fluoride plus CaF2 (calcium fluoride)
61990603|NCT03760146|EXPERIMENTAL|18 through 49 years of age 20vPnC|20vPnC
62386783|NCT01483378|OTHER|Subjects who received the vaccine|Patients in this arm were eligible for the herpes zoster vaccine and chose to receive it.
62386784|NCT01483378|NO_INTERVENTION|Subjects who declined the vaccine|
62767442|NCT04063787|EXPERIMENTAL|Fist Assist device (all subjects)|"All study subjects will have Stage 4 or 5 Chronic Kidney Disease (CKD) that requires them to start hemodialysis. In preparation for hemodialysis, they will have an arteriovenous fistula (AVF) procedure which provides access to the veins for dialysis.~This study is testing a device called the Fist Assist to dilate the vein in preparation for dialysis. The device is similar to a blood pressure cuff (worn around the arm and applies pressure). All study participants will wear the Fist Assist twice a day up to three months before their AVF procedure."
61990604|NCT03760146|ACTIVE_COMPARATOR|50 through 59 years of age 13vPnC|13vPnC
62386785|NCT05911893|EXPERIMENTAL|high caloric oral nutritional supplements group|Participants aged 1 to 3 years who are malnourished (underweight and wasting). They will receive nutritional education,dietary instruction and daily high caloric oral nutritional supplements for 12 months.
62386786|NCT05911893|ACTIVE_COMPARATOR|nutritional education and dietary guidance group|Participants aged 1 to 3 years who are malnourished (underweight and wasting). They will receive nutrition education and dietary instruction.
62386787|NCT04981236|ACTIVE_COMPARATOR|Pericapsular nerve group block|Participants receiving pericapsular nerve group block
62386788|NCT04981236|EXPERIMENTAL|Periarticular block|Participants receiving periarticular block
62386789|NCT00364351|ACTIVE_COMPARATOR|1|Erlotinib
62386790|NCT00364351|EXPERIMENTAL|2|Vandetanib
62386791|NCT01939067|OTHER|HHHFNC|"Treatment of respiratory distress by Heated Humidified High Flow Nasal Cannula (HHHFNC).~Escalation of the ventilatory support per protocol and the attending physician."
62386792|NCT01939067|OTHER|NCPAP|"Treatment of respiratory distress by nasal continuous positive airway pressure (NCPAP).~Escalation of the ventilatory support per protocol and the attending physician."
62386793|NCT06447831||Lab testing (study 1)|Two 3-hour laboratory visits (separated by 6 to 18 days) will be conducted. During the first laboratory visit, anthropometric measurements, pulmonary function tests and CPET on a cycle ergometer will be performed. During the second laboratory visit, spirometry will be repeated to ensure stability of the participants health state (particularly relevant for individuals with COPD). Thereafter, the 6MST and 6MWT will be performed in a randomized order, separated by a rest period of at least 30 minutes.
62386794|NCT06447831||At home testing (study 2)|Three 1-hour home visits (separated by 2 to 5 days) will be conducted. The first trial of the 6MST (familiarization trial) will be conducted at the participant's home with the therapist present. The second and third trials of the 6MST will be performed in a randomized order, with either direct (therapist present at the home) or remote (therapist present through videoconferencing software, as in a telerehabilitation setting) monitoring.
62386795|NCT01636050|EXPERIMENTAL|Training group|
61990605|NCT03760146|ACTIVE_COMPARATOR|18 through 49 years of age 13vPnC|13vPnC
61990606|NCT05199454|EXPERIMENTAL|Exercise training|Aerobic exercise training for 12 weeks, 3 times per week, 60 minutes per session.
62386796|NCT01636050|EXPERIMENTAL|Control group|
62386797|NCT05223478|ACTIVE_COMPARATOR|Phentolamine Ophthalmic Solution 0.75%|One drop of study medication in each eye.
62386798|NCT05223478|PLACEBO_COMPARATOR|Phentolamine Ophthalmic Solution Vehicle|One drop of study medication in each eye.
61990607|NCT05199454|NO_INTERVENTION|Control (standards of care)|This arm will receive brochures for healthy lifestyle recommendations. No intervention will be conducted.
61990608|NCT04567875||CRPC patients|CRPC patients without evidence of distant metastasis are eligible
62386799|NCT01051414|EXPERIMENTAL|BMS-790052 + BMS-650032|
62386800|NCT01797302|ACTIVE_COMPARATOR|Vitamin D3 2000 IU|Vitamin D3 2000 IU tablet once daily by mouth for 6 months
62386801|NCT01797302|ACTIVE_COMPARATOR|Vitamin D3 1000 IU|Vitamin D3 1000 IU tablet by mouth once daily for 6 months
62386802|NCT01797302|PLACEBO_COMPARATOR|Vitamin D3 600 IU|Vitamin D3 600 IU tablet by mouth once daily for 6 months
62386803|NCT00464126|ACTIVE_COMPARATOR|Colloid|5% albumin for volume resuscitation
62386804|NCT00464126|PLACEBO_COMPARATOR|Crystalloid|Saline for volume resuscitation
62386805|NCT01871428|EXPERIMENTAL|Aleglitazar|
62386806|NCT01871428|PLACEBO_COMPARATOR|Placebo|
62386807|NCT03914924|ACTIVE_COMPARATOR|Exercise Program|Ex: The participants will be submitted to only a 12-week exercise intervention.
61990609|NCT02953379|EXPERIMENTAL|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
61990610|NCT02953379|ACTIVE_COMPARATOR|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
61990611|NCT01869283|EXPERIMENTAL|Kinesiotherapy group|The volunteer will be subjected to the following protocol: cervical traction, 3 sets of 1 minute, 30-second rest between sets; mobilization grade III postero-anterior on the spines processes of vertebrae C2 to C7, 10 oscillations for each vertebrae; myofascial release of the upper trapezius muscle, 3 sets of 1 minute for each side; static stretching of the upper trapezius muscle, 3 sets of 30 seconds, with an interval of 10 seconds between sets.
61990612|NCT01869283|EXPERIMENTAL|kinesiotherapy + static ultrasound group|Same protocol group kinesiotherapy + ultrasound on the trigger points of the upper trapezius muscle in a static way, with 1 MHz, continuous dose of 1.5 W/cm2, for 1.5 minutes.
61990613|NCT01869283|EXPERIMENTAL|kinesiotherapy + diadynamic currents group|Same protocol group kinesiotherapy + diadynamic currents, with negative electrode (7.0 x 7.0 cm) placed on the myofascial trigger point, while the positive electrode (7.0 x 7.0 cm) is placed between the shoulder blades. Will apply 4 minutes from the biphasic mode (DF) and 6-minute short period (CP), the first of which intesidade the sensory threshold and the second threshold motor, both bearable for the patient.
61990614|NCT01869283|NO_INTERVENTION|Control group|The volunteers of this group will not be subjected to any form of treatment, was evaluated in three stages, as the other groups. It is noteworthy that, after the volunteer's participation, will be offered at the same physical therapy for myofascial pain.
61990615|NCT00142870|PLACEBO_COMPARATOR|A|
61990616|NCT05951530|ACTIVE_COMPARATOR|Traditional physical therapy|This group will receive conventional upper extremity rehabilitation including active and active assisted ROMs and upper extremity stretches for 30 minutes, three to five times a week for 6 weeks.
61990617|NCT05951530|EXPERIMENTAL|The impact of app-based cognitive training|The experimental group received mobile-app-based cognitive training (PEAK) along with conventional upper extremity rehabilitation.
61990618|NCT01980043|OTHER|Rectal Prolapse|endoluminal rectal prolapse repair under sedation and local anesthesia using CO2 colonoscopy to fix the rectum with sutures to the abdominal wall under needlescopic control.
61990619|NCT01508975|EXPERIMENTAL|white rice|White rice
61990620|NCT01508975|EXPERIMENTAL|Brown rice|Brown Rice
61990621|NCT01508975|EXPERIMENTAL|Glucose|Glucose
61990622|NCT06202781||Pre-treatment|Advanced gastric cancer patients prior to receiving combined immunotherapy and chemotherapy
61990623|NCT06202781||Post-treatment|Advanced gastric cancer patients who have received 2 to 8 cycles of combined immunotherapy and chemotherapy
61990624|NCT06202781||Response|Advanced gastric cancer patients who have achieved complete response (CR) or partial response (PR) after receiving combined immunotherapy and chemotherapy
61990625|NCT06202781||Non-response|Advanced gastric cancer patients who have achieved stable disease (SD) or progressive disease (PD) after receiving combined immunotherapy and chemotherapy
61990626|NCT02259309|EXPERIMENTAL|Misoprostol administration - buccal then vaginal|Vaginal or buccal administration
61990627|NCT02259309|EXPERIMENTAL|Misoprostol administration - vaginal then buccal|Vaginal or buccal administration
61990628|NCT00262509|EXPERIMENTAL|Egress Badge Performance|Blind subjects are walked into a building to a specific location, and then are asked to find their way out of the building.
61990629|NCT00262509|NO_INTERVENTION|Baseline Egress Performance|Blind subjects are walked into a building to a particular location and then asked to find their way out of the building.
61990630|NCT00729027|EXPERIMENTAL|25 mg/day AVE5530|
61990631|NCT00729027|EXPERIMENTAL|50 mg/day AVE5530|
61990632|NCT00729027|PLACEBO_COMPARATOR|Placebo|
61990633|NCT05702593|OTHER|Surface EMG Data Collection|For each subject, EMG activity was recorded from the left and right superficial masseter muscles using a multichannel EMG device.The EMG recordings were obtained with three repetitions during mandibular rest, and maximal voluntary isometric contractions (MVIC) in intercuspation (isometry) pre and post-treatment. The EMG data were recorded for 5 seconds, and three trials with 30 seconds of rest between contractions were performed \[Tosato, SENIAM\].
61990634|NCT05702593|OTHER|Pressure pain threshold|The pressure pain threshold was measured using a mechanical pressure algometer (model Baseline® Dolorimeters - Fabrication Enterprises Inc) with a contact head of 1 cm2 area.
61990635|NCT05702593|OTHER|Maximum Active Mouth Opening (MMO)|A tape measure was used to determine the maximum active mouth opening (MMO).
62386808|NCT03914924|EXPERIMENTAL|Exercise and Lifestyle Education Program|ExLE: The participants will be submitted to a 12-week intervention consisting of exercise and education.
62386809|NCT00412425|ACTIVE_COMPARATOR|2 Days Palonosetron|2 Days Palonosetron 0.25 mg intravenous (IV)
62386810|NCT00412425|ACTIVE_COMPARATOR|3 Days Palonosetron|3 Days Palonosetron 0.25 mg IV
62386811|NCT02041533|EXPERIMENTAL|Arm A: Nivolumab subjects|Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
61990636|NCT05702593|OTHER|Hamstring Flexibility|The Maximal Hip Flexion Active Knee Extension (MHFAKE) Test, which is an adapted active knee extension test, was performed to evaluate the hamstring flexibility of the participant.
61990637|NCT05702593|OTHER|Tragus Wall Distance|Tragus wall distance measurement was used to evaluate spinal mobility.
61990638|NCT05702593|EXPERIMENTAL|Static stretching|The participant was positioned supine for static stretching to be applied to the hamstring muscles
61990639|NCT05702593|EXPERIMENTAL|Myofascial Release|For hamstring muscles, the participants were asked to assume a long sitting position on a firm, flat surface with their arms behind their backs and their body weight on their palms.
61990640|NCT03673163|EXPERIMENTAL|Lidocaine|Lidocaine treatment
61990641|NCT03673163|PLACEBO_COMPARATOR|Control|Placebo treatment
61990642|NCT02196792|ACTIVE_COMPARATOR|E-Poly/32 mm|E-Poly polyethylene liner in a titanium cup with a stem with 32 mm cobalt-chromium (CoCr) femoral head.
61990643|NCT02196792|ACTIVE_COMPARATOR|E-Poly/36 mm|E-Poly polyethylene liner in a titanium cup with a stem with 36 mm CoCr femoral head.
61990644|NCT02196792|ACTIVE_COMPARATOR|ArComXL/32 mm|ArComXL polyethylene liner in a titanium cup with a stem with 32 mm CoCr femoral head.
61990645|NCT02196792|ACTIVE_COMPARATOR|ArComXL/36 mm|ArComXL polyethylene liner in a titanium cup with a stem with 36 mm CoCr femoral head.
61990646|NCT02893072|EXPERIMENTAL|Individualized medical nutrition therapy|A comparison of normal lifestyle and medical nutrition therapy after intervention in the same individual
61990647|NCT00433056|EXPERIMENTAL|1|STI
62386812|NCT02041533|ACTIVE_COMPARATOR|Arm B: Investigator's Choice Chemotherapy|"Investigator's Choice Chemotherapy administered in 3-week cycles up to a maximum of 6 cycles of Intravenous injection until disease progression, unacceptable toxicity or completion of the 6 cycles, whichever comes first~Squamous subjects:~* Gemcitabine 1250 mg/mg(2) administered on Day 1 and Day 8 with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle; or~* Gemcitabine 1000 mg/mg(2) administered on Day 1 and Day 8 with Carboplatin (AUC 5) administered on Day 1 of each cycle; or~* Paclitaxel 200 mg/m(2) with Carboplatin (AUC 6) administered on Day 1 of each cycle~Non-Squamous subjects:~* Pemetrexed 500 mg/m(2) with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle~* Pemetrexed 500 mg/m(2) Carboplatin (AUC 6) administered on Day 1 of each cycle~Optional crossover:~* Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent or study closure"
62386813|NCT05011110|EXPERIMENTAL|GraduSOX (left leg) & Sigvaris (right leg)|Half of participants will wear a GraduSOX compression stocking on their left leg whilst wearing a Sigvaris compression stocking on their right leg.
62386814|NCT05011110|EXPERIMENTAL|GraduSOX (right leg) & Sigvaris (left leg)|Half of participants will wear a GraduSOX compression stocking on their right leg whilst wearing a Sigvaris compression stocking on their left leg.
62386815|NCT04094662|EXPERIMENTAL|Mirogabalin|Mirogabalin 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose.
61990648|NCT00433056|ACTIVE_COMPARATOR|2|stable HAART, Any registered regimen containing NRTIs (AZT or D4T or 3TC or TDF or DDI), NNRTIs (EFV or NVP) or PIs (RTV-boosted ATV; IDV; LPV, fosAPV, SQV; unboosted ATV or NFV)is allowed according to international guidelines
61990649|NCT05044455|EXPERIMENTAL|Arm 1: Experimental, intervention|The immediate intervention group will receive an online 9 week CBT intervention led by trained peers who have themselves recovered from postpartum depression. The CBT group will be two hours long, weekly and involves teaching and practice of core CBT skills. Core cognitive skills including thought records and cognitive restructuring are introduced and practiced from week 1. Behavioural techniques are introduced at week 2 and continue throughout the group, including behavioural activation, relaxation techniques, sleep strategies, exercise and goal setting. Each participant will receive a professionally design CBT manual to facilitate learning. Participants in the intervention group may also receive typical care or treatment as usual for new mothers.
61990650|NCT05044455|NO_INTERVENTION|Arm 2: Control Group|The control group will receive treatment as usual (TAU) or typical care available for postpartum depression in participant's home communities, via participant's family doctor, mental health services, midwifery services, etc. Subjects in the control group will receive a list of resources where participants may seek treatment and will receive a monthly email encouraging them to seek treatment if symptoms worsen, including thoughts of self harm or harm to participant's child. Participants will also receive a copy of the Canadian Practice Guidelines for the treatment of PPD.
61990651|NCT02508493||Major Depressive Disorder Population|100 Individuals with DSM-5-defined MDD, aged 18-65
61990652|NCT02508493||Healthy Control Population|100 healthy controls matched on age, sex and years of education
61990653|NCT05563753||ABT in the first week of life|VLBWI with gestational age between 24+0 and 31+6 weeks of gestation with antibiotic treatment in the first week of life
61990654|NCT05563753||no antibiotic therapy (ABT) in the first week of life|VLBWI with gestational age between 24+0 and 31+6 weeks of gestation without antibiotic treatment in the first week of life
61990655|NCT04400838|EXPERIMENTAL|Group 1 a1|Volunteers will receive a single dose ChAdOx1 nCOV19 vaccine, 5x10\^10vp (Abs 260)
61990656|NCT04400838|EXPERIMENTAL|Group 1 a3|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10\^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260) boost, minimum 4 weeks from prime
61990657|NCT04400838|EXPERIMENTAL|Group 1 b1|Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10\^10vp (Abs 260) prime and 2.2x10\^10vp (qPCR) boost (4-6 weeks apart)
61990658|NCT04400838|EXPERIMENTAL|Group 2 a1|Volunteers will receive a single dose ChAdOx1 nCOV19 vaccine, 5x10\^10vp (Abs 260)
62386816|NCT04094662|PLACEBO_COMPARATOR|Placebo|Placebo (14-weeks)
62386817|NCT02737514|ACTIVE_COMPARATOR|air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
62386818|NCT02737514|ACTIVE_COMPARATOR|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy
62386819|NCT02737514|ACTIVE_COMPARATOR|water exchange|Water will be infused and removed during insertion phase of colonoscopy
62386820|NCT04628754|EXPERIMENTAL|Intervention|Resistance exercise and dietary protein guidance
62386821|NCT04628754|NO_INTERVENTION|Control|Usual care
61990659|NCT04400838|EXPERIMENTAL|Group 2 a3|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10\^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260) boost, minimum 4 weeks apart
61990660|NCT04400838|EXPERIMENTAL|Group 2 b1|.Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10\^10vp (Abs 260) prime and 2.2x10\^10vp (qPCR) boost 4-6 weeks apart
61990661|NCT04400838|EXPERIMENTAL|Group 4 a1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10\^10vp (Abs 260)
61990662|NCT04400838|EXPERIMENTAL|Group 4 b1|Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10\^10vp (Abs 260) prime and 2.2x10\^10vp (qPCR) boost 4-6 weeks apart
61990663|NCT04400838|EXPERIMENTAL|Group 4 c1|Volunteers will receive two doses of ChAdOx1 nCOV19 vaccine, 5x10\^10vp (Abs260) prime and 2.2x10\^10vp (qPCR) boost\*, at least 4 weeks apart
61990664|NCT04400838|EXPERIMENTAL|Group 5 a1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10\^10vp, (Abs 260)
61990665|NCT04400838|EXPERIMENTAL|Group 5 a3|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10\^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260) boost, minimum 4 weeks from prime
61990666|NCT04400838|EXPERIMENTAL|Group 5 b1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x1010vp, (qPCR)
61990667|NCT04400838|EXPERIMENTAL|Group 5 c1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10\^10vp, (qPCR)
61990668|NCT04400838|EXPERIMENTAL|Group 5 d1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260)\* 4-6 weeks apart
61990669|NCT04400838|EXPERIMENTAL|Group 5 e1|Two dose ChAdOx1 nCoV-19 0.5mL (Covishield 0.9 x 10\^11 vp/mL), 4-6 weeks apart
61990670|NCT04400838|EXPERIMENTAL|Group 5 f1|Two dose ChAdOx1 nCoV-19 (Covishield 0.9 x 10\^11 vp/mL), 0.25mL prime and 0.5mL boost 4-6 weeks apart
61990671|NCT04400838|EXPERIMENTAL|Group 6 a1|Volunteers will receive a single dose ofChAdOx1 nCoV19 vaccine, 5x1010vp (qPCR)
61990672|NCT04400838|EXPERIMENTAL|Group 6 b1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 5x1010vp (Abs260) prime and 0.5mL (3.5 - 6.5 × 1010 vp, Abs 260)\* boost\* at least 4 weeks apart
61990673|NCT04400838|EXPERIMENTAL|Group 7 a1|Volunteers will receive a single dose ChAdOx1nCOV19 vaccine, 5x10\^10vp (qPCR)
61990674|NCT04400838|EXPERIMENTAL|Group 7 b1|Volunteers will receive two doses of ChAdOx1nCOV19 vaccine, 5x10\^10vp (qPCR)\* 4-6 weeks apart
61990675|NCT04400838|EXPERIMENTAL|Group 8 a1|Volunteers will receive a single dose ChAdOx1nCOV19 vaccine, 5x10\^10vp (qPCR)
61990676|NCT04400838|EXPERIMENTAL|Group 8 b1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260)\* 4-6 weeks apart
61990677|NCT04400838|EXPERIMENTAL|Group 9 a1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260)\* 4-6 weeks apart
61990678|NCT04400838|EXPERIMENTAL|Group 10 a1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260)\* 4-6 weeks apart
61990679|NCT04400838|EXPERIMENTAL|Group 11|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260)\* 4-6 weeks apart
61990680|NCT04400838|EXPERIMENTAL|Group 12|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260)\* 4-6 weeks apart
61990681|NCT04400838|ACTIVE_COMPARATOR|Single dose MenACWY|Groups 1 a2, 2 a2, 4 a2, 5 a2, 5 b2, 5 c2, 6 a2, 7 a2 \& 8 a2 will receive a standard single dose of MenACWY vaccine
61990682|NCT04400838|ACTIVE_COMPARATOR|Two dose MenACWY 4 - 6 weeks|Groups 1 b2, 2 b2, 4 b2, 5 d2, 7 b2, 8 b2, 9 a2 \& 10 a2 will receive two doses of MenACWY 4-6 weeks apart
61990683|NCT04400838|ACTIVE_COMPARATOR|Two dose MenACWY minimum 4 weeks|Groups 1 a4, 2 a4, 4 c2, 5 a4, 6b2 will receive two doses of MenACWY at least 4 weeks apart
61990684|NCT05251220||10 women with objectively confirmed vulvovaginal atrophy|10 women with objectively confirmed vulvovaginal atrophy (genitourinary menopausal syndrome
61990685|NCT05251220||37 women with 1-2 degree prolapse of the vaginal walls combined with stress urinary incontinence|37 women with 1-2 degree prolapse of the vaginal walls combined with stress urinary incontinence
61990686|NCT05251220||7 with vaginal relaxation syndrome|7 with vaginal relaxation syndrome
61990687|NCT05251220||6 with vulvar lichen sclerosus|6 with vulvar lichen sclerosus
61990688|NCT01280552|EXPERIMENTAL|ICT-107|Autologous dendritic cells pulsed with immunogenic peptides from tumor antigens
61990689|NCT01280552|PLACEBO_COMPARATOR|Control|Autologous dendritic cells that have not been pulsed with antigens
61990690|NCT05350033|EXPERIMENTAL|Active-Active|Participants will receive active-tDCS stimulation (anode F4 / cathode F3) at 2 mA during 20 min in Phase 1 (5 sessions, intersession time-24h) and in Phase 2 (5 sessions, intersession time-24h).
61990691|NCT05350033|EXPERIMENTAL|Active-Sham|Participants will receive active-tDCS stimulation (anode F4 / cathode F3) at 2 mA during 20 min in Phase 1 (5 sessions, intersession time-24h), and sham-tDCS at 2 mA (active-stimulation lasting for 1 min) in Phase 2 (5 sessions, intersession time-24h).
61990692|NCT05350033|EXPERIMENTAL|Sham-Active|Participants will receive sham-tDCS stimulation (anode F4 / cathode F3) at 2 mA (active-stimulation lasting for 1 min) in Phase 1 (5 sessions, intersession time-24h), and active-tDCS at 2 mA during 20 min in Phase 2 (5 sessions, intersession time-24h).
61990693|NCT05350033|SHAM_COMPARATOR|Sham-Sham|Participants will receive sham-tDCS stimulation (anode F4 / cathode F3) at 2 mA (active-stimulation lasting for 1 min) in Phase 1 (5 sessions, intersession time-24h), and sham-tDCS at 2 mA (active-stimulation lasting for 1 min) in Phase 2 (5 sessions, intersession time-24h).
61990694|NCT03791216||Psoriasis patients to be treated only topically|
61990695|NCT03791216||Psoriasis patients with moderate-to-severe psoriasis who begin|
61990696|NCT03791216||Age-, sex- and BMI percentile-matched controls|
61990697|NCT03791216||Patients being treated with isotretinoin for acne|
62182678|NCT02672579||Clinicians|Clinicians treating pediatric subjects between the ages of 4-17 years with chronic pruritus (for 6 weeks or longer) will complete surveys to assess their perception of the child's severity of pruritus.
62767443|NCT03161860|EXPERIMENTAL|Personalised citizen assistance|The experimental group will receive the Personalised citizen assistance for social participation (APIC), i.e. weekly 3-hour personalised stimulation sessions by a trained volunteer over 12 months. Sessions will encourage empowerment, gradual mobilisation of personal and environmental resources, and community integration.
62767444|NCT03161860|NO_INTERVENTION|Control group|The control group will receive the publicly-funded universal healthcare services available to all Quebecers.
61990698|NCT06484998|EXPERIMENTAL|low anxiety|"A score was obtained from the MCDASf scale by summing the scores of each question expressed with faces ranging from 1 relaxed, 2 slightly worried, 3 worried, 4 very worried and 5 extremely worried according to the 8 questions. Those with a total score of less than 19 points were included in this group."
61990699|NCT06484998|EXPERIMENTAL|moderate anxiety|"A score was obtained from the MCDASf scale by summing the scores of each question expressed with faces ranging from 1 relaxed, 2 slightly worried, 3 worried, 4 very worried and 5 extremely worried according to the 8 questions. Those with a total score between 19-31 points were included in this group."
61990700|NCT06484998|EXPERIMENTAL|high anxiety|"A score was obtained from the MCDASf scale by summing the scores of each question expressed with faces ranging from 1 relaxed, 2 slightly worried, 3 worried, 4 very worried and 5 extremely worried according to the 8 questions. Those with a total score between 32-40 points were included in this group."
61990701|NCT06304090|EXPERIMENTAL|routine rehabilitation treatment+Stellate ganglion block|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.The experimental group was given Stellate Ganglion Block.
61990702|NCT06304090|PLACEBO_COMPARATOR|routine rehabilitation treatment+Placebo|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.
61990703|NCT03285971|EXPERIMENTAL|CPP Alert Group|Device: Electronic CPP pager alert anesthesia providers will receive a pager alert when CPP decreases below 60 mmHg (median value over 5-minute epochs)
61990704|NCT03285971|NO_INTERVENTION|Control|This arm will not receive the automated pager alerts.
61990705|NCT05268159||Stroke patients|Stroke patients admitted to the Lille Neurological rehabilitation unit after a first-ever hemispheric stroke, assessed at the subacute phase (\< 6months)
61990706|NCT00733746|EXPERIMENTAL|Neoadjuvant therapy + Surgery + Adjuvant therapy|As part of neoadjuvant therapy, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 29, 36, and 43 and oral erlotinib hydrochloride once daily on days 1-43 in the absence of disease progression or unacceptable toxicity. Within 3-6 weeks after completion of neoadjuvant therapy, patients undergo pancreaticoduodenectomy and patients receive gemcitabine hydrochloride and erlotinib hydrochloride as in neoadjuvant therapy within 5-10 weeks post surgery.
62767445|NCT04630717|ACTIVE_COMPARATOR|control group|normal discussion before general anesthesia induction
62767446|NCT04630717|ACTIVE_COMPARATOR|Hypnosis group|hypnosis session before general anesthesia induction
61990707|NCT05624346|EXPERIMENTAL|Experimental Group|After the operation, breathing exercises will be applied to the patients.
62182679|NCT02072421|OTHER|Non-SOS|
62386822|NCT02439424|EXPERIMENTAL|Reactive ATP|"all enrolled subjects will have the Reactive ATP feature in their ICD turned on"
62386823|NCT04328142|EXPERIMENTAL|Qigong|The Qigong experimental group performed the 20 figures to improve health and longevity described by the master of Qigong 'Wang Ziping'. These are based on therapeutic exercises of Traditional Chinese Medicine. They work on breathing, flexibility and balance. Each figure was repeated 6 times. The sessions were administered twice a week during 45 minutes and were guided by a Doctor in Western Medicine who is also qualified as a Doctor of Traditional Chinese Medicine and Qigong teacher.
62559439|NCT03352674|EXPERIMENTAL|Insulin Glargine Ezelin|Drug product Insulin Glargine, Ezelin 100 U/mL (PT Kalbe Farma, Tbk)
62559440|NCT03352674|ACTIVE_COMPARATOR|Insulin Glargine Lantus|Insulin Glargine Pen Injector \[Lantus\]
62767447|NCT03864393|EXPERIMENTAL|Multimodal overground locomotor training|Individuals with Parkinson's Disease that meet the inclusion/exclusion criteria and enrolled in the study will participate in a 12-week multimodal exercise training intervention performed twice per week.
62767448|NCT06013436||Experimental group|Autologous serum tears, twelve times daily（per hour）, 12weeks. 0.05% cyclosporin eye drop, twice times daily, 12weeks.
62767449|NCT02583321|ACTIVE_COMPARATOR|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions
62767450|NCT02583321|EXPERIMENTAL|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
62767451|NCT01939132|EXPERIMENTAL|H.P. Acthar Gel SQ injection|Open-label H.P. Acthar Gel 80 units subcutaneously twice weekly for 12 weeks with a 12 week extension.
62767452|NCT02137187|EXPERIMENTAL|Drug therapy|Control Arm: optimized drug therapy (plus implantable defibrillator (ICD) according to guidelines)
61990708|NCT05624346|NO_INTERVENTION|Control Group|There will be no intervention other than routine nursing care practices in the hospital.
61990709|NCT04152720|ACTIVE_COMPARATOR|Prevention of infection Foley catheter|
61990710|NCT04152720|ACTIVE_COMPARATOR|Conventional Foley catheter|
62767453|NCT02137187|ACTIVE_COMPARATOR|Device: AV junction ablation & CRT|AV junction ablation + CRT (CRT-P or CRT-D according to guidelines) + optimized drug therapy
61990711|NCT01315704||Group 1|Patients with Mild Cognitive Impairment
61990712|NCT01315704||Group 2|Patients with Mild Alzheimer's disease or related disorders
61990713|NCT01315704||Group 3|Patients with Moderate Alzheimer's disease or related disorders
61990714|NCT02912026|EXPERIMENTAL|Intravenous|Intravenous AUC0-infinity
61990715|NCT02912026|EXPERIMENTAL|Oral|Oral AUC0-infinity
61990716|NCT04377360|EXPERIMENTAL|Diffusing Alpha-emitter Radiation Therapy (DaRT)|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. Tumor response to DaRT will be assessed periodically 3 months after removal.
61990717|NCT03349216|EXPERIMENTAL|Intravenous regional Analgesia|in this arm patients will receive intravenous regional anesthesia as infusion of mini dose (that is 1.5 mg/kg ) lidocaine 0.5% and immediately after procedure their torniquettes will be deflated (hence named Rapid MiniBier's block).
61990718|NCT03349216|EXPERIMENTAL|Systemic Analgesia|In this arm patients will receive ketamine 1-2 mg/kg IV slow as a systemic analgesia. ketamine as a PCP derivative has both hypnotic and analgesic effects.
61990719|NCT03745937|EXPERIMENTAL|MEDI0382 Cohort 1|Participants will receive subcutaneous (SC) dose of MEDI0382 uptitrated weekly once daily up to 8 weeks during the up-titration period and thereafter once daily in 3-week treatment extension period (TEP).
61990720|NCT03745937|PLACEBO_COMPARATOR|Placebo Cohort 1|Participants will receive SC dose of placebo matched to MEDI0382 once daily up to 8 weeks during the uptitration period and thereafter once daily through 3 week TEP.
61990721|NCT03745937|EXPERIMENTAL|MEDI0382 Cohort 2|Participants will receive SC dose of MEDI0382 uptitrated weekly once daily up to 8 weeks during the up-titration period and thereafter once daily in 3-week TEP.
61990722|NCT03745937|PLACEBO_COMPARATOR|Placebo Cohort 2|Participants will receive SC dose of placebo matched to MEDI0382 once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
61990723|NCT01852812|EXPERIMENTAL|Montelukast 4 mg OG/1-5 year olds|Participants receive montelukast 4 mg OG in one sachet orally (PO) once daily (QD) at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)
61990724|NCT01852812|EXPERIMENTAL|Montelukast 5 mg CT/6-9 year olds|Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks
61990725|NCT01852812|EXPERIMENTAL|Montelukast 5 mg CT/10-15 year olds|Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks
61990726|NCT03341195|ACTIVE_COMPARATOR|1. One way SMS messages.|Parents/caregiver will receive one way educational/reminder/proactive SMS messages related to routine immunization once a week till 20 weeks of age.
61990727|NCT03341195|ACTIVE_COMPARATOR|2. Two Way SMS messages|Parents/caregiver will receive two way (interactive) educational/reminder/proactive SMS messages related to routine immunization once a week till 20 weeks of age-parents will have the option to reply and receive more information related to immunization through text messages.
61990728|NCT03341195|ACTIVE_COMPARATOR|3. One way automated calls.|Parents/caregiver will receive one way educational/reminder/proactive automated phone call related to routine immunization once a week till 20 weeks of age.
61990729|NCT03341195|ACTIVE_COMPARATOR|4.Two way interactive automated calls|Parents/caregiver will receive two way (interactive) educational/reminder/proactive automated phone call related to routine immunization once a week till 20 weeks of age-parents will have the option to reply and receive more information related to immunization through phone call.
62559441|NCT03498612|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
61990730|NCT03341195|NO_INTERVENTION|5. Control Arm|One time counseling at the baseline survey.
61990731|NCT02345967|EXPERIMENTAL|Study Group|Device: Model 100 Sensor
61990732|NCT00729183|EXPERIMENTAL|Odanacatib 50 mg|Participants receive 50 mg odanacatib and open-label 5600 IU vitamin D3 tablets once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
61990733|NCT00729183|PLACEBO_COMPARATOR|Placebo|Participants receive matching placebo to odanacatib and open-label 5600 IU vitamin D3 once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
61990734|NCT02771483||Suspected GCA (GCA final diagnosis)|
61990735|NCT02771483||Suspected GCA (alternative final diagnosis)|
61990736|NCT03642717||Subjects diagnosed with type 2 diabetes mellitus|
62767454|NCT04287686|EXPERIMENTAL|rhACE2 group|0.4 mg/kg IV BID for 7 days (unblinded) + standard of care
62767455|NCT04287686|NO_INTERVENTION|Control group|Standard of care; no placebo
62767456|NCT02916459|ACTIVE_COMPARATOR|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 21G EBUS-TBNA needle
62182680|NCT03035318|ACTIVE_COMPARATOR|DePuy Global® Anchor Peg Glenoid|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses DePuy Global® Anchor Peg Glenoid Instrumentation to position the glenoid component.
62767457|NCT02916459|EXPERIMENTAL|Flex 19G EBUS-TBNA|Mediastinal and hilar lymph node sampling using the flexible 19G EBUS-TBNA needle
62767458|NCT05291559|EXPERIMENTAL|Enterade (VS001)|237 mL (8 fluid oz) per os, once daily for 14 days
62767459|NCT05291559|PLACEBO_COMPARATOR|Placebo|237 mL (8 fluid oz) per os, once daily for 14 days
62767460|NCT03966677||P-GHR|Patients with persistent severe pain after groin hernia repair.
62767461|NCT03966677||NP-GHR|Patients without pain after groin hernia repair.
62767462|NCT03966677||NP|Healthy non-operated controls
61990737|NCT01541137|ACTIVE_COMPARATOR|diclofenac + IV-PCA|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, intercostal nerve block with 20 ml of 0.5% bupivacaine, IV-PCA programmed with morphine boluses, from the 2nd postoperative morning the patients were given oral diclofenac 75 mg x 2, IV-PCA-morphine was discontinued after removal of pleural drains, and the patients were given oral oxycodone
61990738|NCT01541137|ACTIVE_COMPARATOR|parecoxib/ valdecoxib + IV-PCA|oral valdecoxib 40 mg, a 44-hour iv-infusion parecoxib 80 mg/24h, intercostal nerve block with 20 ml of 0.5% bupivacaine, IV-PCA programmed with morphine, From the 2nd postoperative morning valdecoxib 40 mg x 2, IV-PCA-morphine was discontinued after removal of pleural drains, and the patients were given oral oxycodone
61990739|NCT01541137|ACTIVE_COMPARATOR|patient controlled epidural analgesia|At the induction of anesthesia the PCEA-patients were given IV paracetamol 1g and an epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses, IV paracetamol 1g x 4 for the first 24 hours and thereafter 1g x 3 orally, PCEA was discontinued and paracetamol was replaced with ibuprofen 600 mg x 3 and oral oxycodone
61990740|NCT04927936|ACTIVE_COMPARATOR|Janssen vaccine only|"HCW already vaccinated with Janssen vaccine once. 84 days after the first vaccination, blood samples will be drawn (day =0, baseline) This will be repeated at day 28 (primary endpoint), day 180 and day 365. This arm will have 87 +25% seropositive for SARS-CoV-2 IgG at baseline or loss to follow-up = 108 participants.~In this arm half of the participants will undergo a detailed immunological assessment (n=54 per arm)."
61990741|NCT04927936|EXPERIMENTAL|Janssen vaccine - Janssen vaccine|"HCW already vaccinated with Janssen vaccine once. 84 days after the first vaccination a boost will be given with Janssen vaccine and blood samples will be drawn (day =0, baseline) This will be repeated at day 28 (primary endpoint), day 180 and day 365. This arm will have 87 +25% seropositive for SARS-CoV-2 IgG at baseline or loss to follow-up = 108 participants.~In this arm half of the participants will undergo a detailed immunological assessment (n=54 per arm)."
61990742|NCT04927936|EXPERIMENTAL|Janssen vaccine - Moderna vaccine|"HCW already vaccinated with Janssen vaccine once. 84 days after the first vaccination a boost will be given with Moderna vaccine and blood samples will be drawn (day =0, baseline) This will be repeated at day 28 (primary endpoint), day 180 and day 365. This arm will have 87 +25% seropositive for SARS-CoV-2 IgG at baseline or loss to follow-up = 108 participants.~In this arm half of the participants will undergo a detailed immunological assessment (n=54 per arm)."
61990743|NCT04927936|EXPERIMENTAL|Janssen vaccine - Pfizer vaccine|"HCW already vaccinated with Janssen vaccine once. 84 days after the first vaccination a boost will be given with Pfizer vaccine and blood samples will be drawn (day =0, baseline) This will be repeated at day 28 (primary endpoint), day 180 and day 365. This arm will have 87 +25% seropositive for SARS-CoV-2 IgG at baseline or loss to follow-up = 108 participants.~In this arm half of the participants will undergo a detailed immunological assessment (n=54 per arm)."
61990744|NCT01776788|EXPERIMENTAL|insulin lispro injection, exenatide injection|
61990745|NCT01776788|ACTIVE_COMPARATOR|insulin lispro injection|
61990746|NCT01750164||Invasive breast cancer with metastatic disease|
61990747|NCT01028157|PLACEBO_COMPARATOR|General Health Control|
61990748|NCT01028157|EXPERIMENTAL|HIV Risk Reduction & Relapse Prevention|
61990749|NCT01792947|ACTIVE_COMPARATOR|Diet|Diet 1200 Kcal during 3 months
62386824|NCT04328142|EXPERIMENTAL|Physiotherapy|The physiotherapy experimental group completed an active exercises program guided by a qualified physiotherapist. The exercise programme was based on active shoulder, hips and spine kinesiotherapy. It included a warm up of 3-5 minutes walking, followed by 6 repetitions of shoulder and hip exercises in standing, cervical spine exercises in sitting or standing, according to the comfort of the patient, thoracic and lumbar spine exercises performed in supine on a mat and balance exercises in standing. Stretching exercises were also performed at the end of the session. The exercises were accompanied by gentle breathing coordinated with the movements. The sessions were administered twice a week during 45 minutes.
62767463|NCT02683668|EXPERIMENTAL|Handihaler-Tiotropium 18 mcg untrained|Patients receiving Handihaler who have not been trained (real-life use) for over 3 months on its use. Here the investigators want to see that if patients have on-going symptoms but are on Handihaler-Tiotropium 18mcg what is happening PRIOR to proper inhaler technique training - that is their 'real-life' use of the inhaler - to their lung function (large and small airways) and also symptoms or exercise limitation (determined by CAT score) will already be recorded as entry criteria
62767464|NCT02683668|EXPERIMENTAL|Handihaler-Tiotropium 18 mcg trained|Patients will be trained in their use of Handihaler-Tiotropium and asked to take 18 mcg once daily for 14 days to see if their (i) airway lung function and or (ii) clinical symptoms improve. Here the investigators want to see what happens AFTER proper inhaler technique training on large and small airways lung function and also symptoms or exercise limitation (determined by CAT score)
62767465|NCT02683668|EXPERIMENTAL|Respimat-Tiotropium 5 mcg trained|Patients will be switched to trained Respimat Tiotropium 5 mcg once daily for 14 days to see if their (i) airway lung function and or (ii) clinical symptoms improve. Here the investigators want to see what happens AFTER this efficient device Respimat (trained) compared to PREVIOUS device Handihaler (trained) on large and small airways lung function and also symptoms or exercise limitation (determined by CAT score). The investigators want to see if the properties of the Respimat device with deeper lung deposition (slow velocity and small particles) can improve small airway measures (and indeed large airway measures) that might also be related to an improvement in symptoms.
62767466|NCT05854953|EXPERIMENTAL|Hawley retainers in dry storage condition|Acrylic retainers to be stored in a dry retainer box the entire time when not in use.
61990750|NCT01792947|EXPERIMENTAL|PENS associated to diet|Percutaneous electroneurostimulation of dermatome T6 associated to diet 1200 Kcal
61990751|NCT00817895|EXPERIMENTAL|5-FU+Cisplatin|50 HCC patients will be implanted 600mg sustained released 5-FU and 60mg sustained released cisplatin into liver incisal margin after tumor is resected.
61990752|NCT00817895|ACTIVE_COMPARATOR|5-FU|50 HCC patients will be implanted 600mg sustained released 5-FU into liver incisal margin after tumor is resected.
61990753|NCT00817895|EXPERIMENTAL|control|
61990754|NCT00037921|OTHER|1|
62386825|NCT04328142|NO_INTERVENTION|Control|The control group did not receive any intervention. The participants continued with their routine medical treatment.
62386826|NCT00671190|EXPERIMENTAL|Ramelteon 1 mg QD|
61990755|NCT06468709|ACTIVE_COMPARATOR|Glucocorticoids group|Induction therapy: Prednisone 30mg/d, lasting for 4 weeks, then decreasing by 5mg/d every 2 weeks until maintained at 5mg/d
61990756|NCT06468709|EXPERIMENTAL|Glucocorticoids+MMF group|GC: Induction therapy: 30mg/d, lasting for 4 weeks, then decreasing by 5mg/d every 2 weeks until maintained at 5mg/d. At the initial stage of simultaneous treatment, 1.0g-1.5g MMF combined with GC treatment
61990757|NCT02724904|EXPERIMENTAL|Allogeneic Stem Cell Transplantation|Patients will undergo reduced intensity conditioning (fludarabine and thiotepa) followed by fully matched related or unrelated allogeneic stem cell transplantation. Afterwards, patients will receive standard post-transplant care (Methotrexate).
61990758|NCT06301711|EXPERIMENTAL|Rehabilitation therapy+Stellate ganglion block|"The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)."
61990759|NCT06301711|ACTIVE_COMPARATOR|Rehabilitation therapy|The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
61990760|NCT02367703|EXPERIMENTAL|standard instrument|That is why we propose a randomized comparative study between standard instrument and less than 3 millimeter diameter's instruments to achieve in daily practice laparoscopic hysterectomy
61990761|NCT02367703|OTHER|less than 3 millimeter diameter's instruments|That is why we propose a randomized comparative study between standard instrument and less than 3 millimeter diameter's instruments to achieve in daily practice laparoscopic hysterectomy
61990762|NCT02897674|EXPERIMENTAL|Normal weight|Participants will BMI 18.5-24.9 kg/m2 will consume 20% of their calories from one of the three dietary fats Intervention: palm olei Intervention: interesterified palm olein Intervention: soybean oil
61990763|NCT02897674|EXPERIMENTAL|Overweight|Participants will BMI 25-29.9 kg/m2 will consume 20% of their calories from one of the three dietary fats Intervention: palm olei Intervention: interesterified palm olein Intervention: soybean oil
61990764|NCT00868933|ACTIVE_COMPARATOR|Low glycemic index dietary intervention program|The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
61990765|NCT00868933|PLACEBO_COMPARATOR|Simple lifestyle advice|The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
62559442|NCT06498518|EXPERIMENTAL|IMM-101, Pembrolizumab and Gemcitabine|"IMM-101: will be administered at a dose of 1mg intra-dermal (ID) between 2 to 7 days prior to first cycle of pembrolizumab (MK-3475)/ gemcitabine then 1mg ID on day 8 of cycle 1, 1mg on day 1 of cycle 2, 1mg on day 8 of cycle 3 then 1mg on day 8 of each cycle thereafter.~Pembrolizumab (MK-3475): will be administered at a dose of 200mg by IV infusion every 3 weeks starting from cycle 1, day 1.~Gemcitabine: will be administered at a dose of 1000mg/m2 by IV infusion on day 1 and day 8 of every 3 week-cycle starting from cycle 1, day 1.~Each cycle is 3 weeks"
61990766|NCT05505513|EXPERIMENTAL|Implantation of a percutaneous Utah Slanted Electrode Arrays (pUSEAs)|The arm (s) of the patient which has been amputated. Intervention include insertion of the percutaneous Utah Slanted Electrode Arrays which will interact with nerve endings in order to gain knowledge about device feasibility and nerve stimulation.
61990767|NCT02817165|EXPERIMENTAL|Probiotic (BioK+)|Children will receive 10-40 billion CFUs/day of Bio-K+ (Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2), with dose based on their weight. The product will be administered as a strawberry flavored tub of milk.
61990768|NCT02817165|PLACEBO_COMPARATOR|Placebo|Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.
61990769|NCT01342510|EXPERIMENTAL|Lidocaine|Lidocaine 50 mg in a 10 cc syringe
61990770|NCT01342510|EXPERIMENTAL|Magnesium|Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe
61990771|NCT01342510|EXPERIMENTAL|Lidocaine/Magnesium|Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe
61990772|NCT01342510|PLACEBO_COMPARATOR|Control|0.9% saline in a 10 cc syringe
61990773|NCT02704078|ACTIVE_COMPARATOR|EBUS-TBNA|Mediastinal lymph node aspiration shall be performed transtracheally.
61990774|NCT02704078|EXPERIMENTAL|EUS-B-FNA|Mediastinal lymph node aspiration shall be performed transesophageally
62559443|NCT03757819|EXPERIMENTAL|Before Walking tDCS first then SHAM|To investigate the effects of tDCS applied before walking versus during to evaluate effectiveness of the intervention.
62559444|NCT03757819|EXPERIMENTAL|During Walking tDCS first then SHAM|To investigate the effects of tDCS applied before walking versus during to evaluate effectiveness of the intervention.
62559445|NCT02689765|EXPERIMENTAL|Anthocyanins|Volunteers will be randomised double blinded into 'Anthocyanins' groups(n=60 per group)and given twice daily two capsules of either 80 grams of Anthocyanins, which corresponds a mixture of fresh blue berries and blackcurrants.The total duration of this trial was 24wk.
62559446|NCT02689765|PLACEBO_COMPARATOR|Control|A daily intake of 320mg Placebo to instead of treatment of Anthocyanins.
62559447|NCT04636476|OTHER|Modified Nesbit technique followed by dorsal dartos flap|Modified Nesbit technique to correct penile curvature followed by dorsal dartos flap to correct penile torsion
62559448|NCT04671589|EXPERIMENTAL|Meropenem|Meropenem 1 gram intravenous every 8 hours
62767467|NCT05854953|EXPERIMENTAL|Hawley retainers in wet storage condition|Acrylic retainers to be stored in a glass of clean tap water the entire time when not in use.
61990775|NCT02291055|EXPERIMENTAL|Part A Escalation (Cervical): 1×10^9 CFU ADXS11-001/ 3 mg/kg MEDI4736|Participants with cervical cancer received MEDI4736 3 milligrams per kilogram (mg/kg) intravenous (IV) infusion every 2 weeks (Q2W) at an infusion rate of approximately 60 minutes followed by ADXS11-001 1×10\^9 CFU IV infusion every 4 weeks (Q4W) at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
62182681|NCT03035318|EXPERIMENTAL|DePuy Instrumentation with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses DePuy Global® Anchor Peg Instrumentation with SmartBone™, to position the glenoid component.
62386827|NCT00671190|EXPERIMENTAL|Ramelteon 2 mg QD|
61990776|NCT02291055|EXPERIMENTAL|Part A Escalation (Cervical and Head and Neck): 1×10^9 CFU ADXS11-001/ 10 mg/kg MEDI4736|Participants with cervical cancer and SCCHN received MEDI4736 10 mg/kg IV infusion Q2W at an infusion rate of approximately 60 minutes followed by ADXS11-001 1×10\^9 CFU IV infusion Q4W at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
62767468|NCT05854953|EXPERIMENTAL|Vacuum-formed retainers in dry storage condition|Thermoplastic retainers to be stored in a dry retainer box the entire time when not in use.
62767469|NCT05854953|EXPERIMENTAL|Vacuum-formed retainers in wet storage condition|Thermoplastic retainers to be stored in a glass of clean tap water the entire time when not in use.
62767470|NCT05854953|ACTIVE_COMPARATOR|Baseline characteristics|Newly constructed Hawley retainers and VFRs will be labeled as baseline samples.
62767471|NCT03281551|EXPERIMENTAL|PZ01 CAR-T Cells|This is a phase I study. Patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma are eligible for enrollment.
62767472|NCT04798040|NO_INTERVENTION|Control group|"Routine treatment and nursing care of the clinic will be applied to the patients without any application.~Routine interventions applied to the control group during silicone drain removal in the clinic:~1. The patient will be informed about the procedure.~2. The consent of the patient who agrees to participate in the study will be obtained.~3. The patient will mark the pain he feels due to the silicone drain on the Numeric Rating Scale .~4. The patient will mark the pain again from the Numeric Rating Scale immediately after the procedure.~5. The patient will fill the Numeric Rating Scale 15 minutes after the removal of the silicone drain."
62767473|NCT04798040|EXPERIMENTAL|Cold application group|The patient will mark the pain he feels due to the silicone drain on the Numeric Rating Scale. A gel pad with a temperature of -10 ° C and a homogeneous distribution when cooled will be placed so that the patient is in full contact with the silicone drain.Since the skin temperature must fall below 13.6 ° C for cold application to have a local analgesic effect, the application will be terminated when the patient's skin temperature is 13.6 ° C by measuring every one minute during the cold application and the physician will be informed that the patient is ready.The patient will mark the pain again from the Numeric Rating Scale immediately after the procedure. The patient will fill the Numeric Rating Scale15 minutes after the removal of the silicone drain.
62767474|NCT04798040|EXPERIMENTAL|Lavender oil group|"All patients who accept the study will be tested for lavender oil before the procedure to exclude sensitivity to lavender. Patients in the lavender group will be given oxygen with a lavender oil covered face mask 15 minutes before the silicone drain is removed. Two drops of 2% lavender oil will be applied with a cotton swab inside the oxygen face mask.~The patient will mark the pain he feels due to the silicone drain on the Numeric Rating Scale.The patient will mark the pain again from the Numeric Rating Scale immediately after the procedure.The patient will fill the Numeric Rating Scale 15 minutes after the removal of the silicone drain."
62767475|NCT04798040|EXPERIMENTAL|Oxygen administration|The patient will be informed about the procedure. Consent of the patient who agrees to participate in the study will be obtained. Patients in the oxygen administration group will be given 2 lt/min oxygen with a face mask 15 minutes before the silicone drain is removed. The patient will mark the pain he feels due to the silicone drain on Numeric Rating Scale. The patient will re-mark the pain from Numeric Rating Scale immediately after the procedure. The patient will fill the Numeric Rating Scale 15 minutes after the removal of the silicone drain. Before the procedure, as soon as the procedure is over and 15 minutes after the procedure, the patient's vital signs will be measured.
62767476|NCT05826977|EXPERIMENTAL|CASI-Plus|The CASI-Plus arm involves use of a tablet-based computerized self-interview tool. This mHealth tool supports the initial assisted partner services (APS) encounter (providing information on how APS works, eliciting names of all sexual or injection partners, screening for risk of intimate partner violence \[IPV\], and planning for partner notification), and facilitates case management through partner testing (via repeat follow-up surveys to assess for barriers to notification, interest in provider assistance, IPV, and completion of notification).
61990777|NCT02291055|EXPERIMENTAL|Part A Expansion (Head and Neck): 1×10^9 CFU ADXS11-001/ 10 mg/kg MEDI4736|Participants with SCCHN received MEDI4736 10 mg/kg IV infusion Q2W at an infusion rate of approximately 60 minutes followed by ADXS11-001 1×10\^9 CFU IV infusion Q4W at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
61990778|NCT02291055|EXPERIMENTAL|Part B Expansion (Cervical): 10 mg/kg MEDI4736|Participants with cervical cancer received MEDI4736 10 mg/kg IV infusion Q2W at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
62182682|NCT03035318|EXPERIMENTAL|IRI with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses an Intelligent Reusable Instrumentation (IRI), with a SmartBone™, to position the glenoid component.
62182683|NCT03035318|EXPERIMENTAL|RTI with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses Real Time Instrumentation (RTI), with a SmartBone™, to position the glenoid component.
62559449|NCT04671589|PLACEBO_COMPARATOR|Placebo|Placebo intravenous every 8 hours
61990779|NCT02291055|EXPERIMENTAL|Part B Expansion (Cervical): 1×10^9 CFU ADXS11-001/ 10 mg/kg MEDI4736|Participants with cervical cancer received MEDI4736 10 mg/kg IV infusion Q2W at an infusion rate of approximately 60 minutes followed by ADXS11-001 1×10\^9 CFU IV infusion Q4W at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
61990780|NCT01275274|ACTIVE_COMPARATOR|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone.
61990781|NCT01275274|EXPERIMENTAL|Retinoic acid|Tretinoin in addition to standard of care
61990782|NCT03209063||Group I|195 Patients having history of two or more miscarriages.
61990783|NCT03209063||Group II|90 healthy controls less than 35 years with no history of miscarriage and at least one uncomplicated full-term pregnancy
61990784|NCT03637465|EXPERIMENTAL|Hydrate Philly Intervention|Intervention group that receives hydration station intervention
61990785|NCT03637465|NO_INTERVENTION|Control|Control group that receives no intervention, but observational data is collected; converted to wait-listed intervention status after enrollment and randomization was completed
62559450|NCT01777282|ACTIVE_COMPARATOR|Albiglutide + Sulfonylurea|Albiglutide in combination with background sulfonylurea
61990786|NCT02451410|EXPERIMENTAL|Nutrition and physical activity|This arm includes all preschool classes receiving the educational and behavioral intervention to improve nutrition and physical activity
61990787|NCT06042309|EXPERIMENTAL|NON-SLS, Allergic participants|Participants allergic to thiurams or carbamates assigned to the NON-SLS group.
61990788|NCT06042309|EXPERIMENTAL|NON-SLS, Control participants|Participants not allergic to thiurams or carbamates assigned to the NON-SLS group.
61990789|NCT06042309|EXPERIMENTAL|SLS, Allergic participants|Participants allergic to thiurams or carbamates assigned to the SLS group.
61990790|NCT06042309|EXPERIMENTAL|SLS, Control participants|Participants not allergic to thiurams or carbamates assigned to the SLS group.
61990791|NCT03592147|OTHER|Relaxation|This is a within-subject pilot study, where each participant received, in random order, five different relaxation therapies (Guided Imagery Relaxation Tape, Music Listening, Relaxation Lighting, Meditation and Relaxation Light, and Music and Relaxation Light) and one Control/Silence state spanning across 3-6 weeks.
62559451|NCT01777282|ACTIVE_COMPARATOR|Albiglutide + Biguanide|Albiglutide in combination with background biguanide
62559452|NCT01777282|ACTIVE_COMPARATOR|Albiglutide + Glinide|Albiglutide in combination with background glinide
61990792|NCT03886558|EXPERIMENTAL|Institution Group (n=14)|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months. The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
61990793|NCT03886558|EXPERIMENTAL|Community Group (n=16)|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months. The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
61990794|NCT02799758|EXPERIMENTAL|NK-104-CR|NK-104-CR 8 mg tablet and Placebo (for Livalo® IR 4 mg tablet) orally once daily for 52 weeks.
61990795|NCT02799758|ACTIVE_COMPARATOR|Livalo® IR|Livalo® IR 4 mg tablet and Placebo (for NK-104-CR 8 mg tablet) orally once daily for 52 weeks.
61990796|NCT02859233|NO_INTERVENTION|Control group|Routine advices about the interest of increase fluid after lumbar puncture to prevent PDPH will be transmitted: 2 liters will be provided to be drunk in 2 hours.
61990797|NCT02859233|EXPERIMENTAL|Interventional group|Lack of hyperhydration : no particular advices will be transmitted about the interest of oral hyperhydration. 500 milliliters will be provided in case of thirst, according to patient's convenience.
62182684|NCT03035318|EXPERIMENTAL|IRI with SmartBase|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses an Intelligent Reusable Instrumentation (IRI), with a SmartBase™, to position the glenoid component.
62559453|NCT01777282|ACTIVE_COMPARATOR|Albiglutide + Thiazolidinedione|Albiglutide in combination with background thiazolidinedione
62559454|NCT01777282|ACTIVE_COMPARATOR|Albiglutide + Alpha-glucosidase inhibitor|Albiglutide in combination with background alpha-glucosidase inhibitor
61990798|NCT02620514|NO_INTERVENTION|Health-literacy Assessment|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants with low adherence will continue to one or more intervention groups that address needs based on the results of the survey.
61990799|NCT02620514|EXPERIMENTAL|Health-literacy Assessment + Education and Reminders|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants with then complete a 24-week intervention aimed to improve education about inflammatory bowel disease and scheduled nurse phone call reminders.
61990800|NCT02620514|EXPERIMENTAL|Health-literacy Assessment + Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive education about IBD.
61990801|NCT02620514|EXPERIMENTAL|Health-literacy Assessment + Medication Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive education regarding their medications.
61990802|NCT02620514|EXPERIMENTAL|Health-literacy Assessment + Financial Support|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive financial support for medications.
61990803|NCT05169788|EXPERIMENTAL|regular TOPS group|Patients are required to perform the regular TOPS program, composed of 10 core sessions and other eventual supplementary sessions. In addition, biweekly Google Meet sessions with a cognitive-behavioral psychotherapist are scheduled, with the aim to monitor patients' activities on problem-solving related to the TOPS program contents and the problem solving process in real life. The program has a specific focus on problem-solving, executive functions, behavioral strategies and social skills.
61990804|NCT05169788|ACTIVE_COMPARATOR|modified TOPS group|Patients are required to perform the modified TOPS program, composed of 10 sessions focused only on health and wellness contents. Thus, this program does not include contents on problem-solving, executive functions, behavioral strategies and social skills, representing a low cognitively simulating activity. Biweekly Google Meet sessions with a cognitive-behavioral psychotherapist are scheduled, with the aim of monitoring training adherence and discuss the program's contents.
61990805|NCT04807192|EXPERIMENTAL|Arm 1: SBRT|
61990806|NCT04807192|EXPERIMENTAL|Arm 2: CMP-001 + SBRT|
61990807|NCT03893838||Post refractive surgery without HOA|Patients post refractive surgery that do not complain on the high order aberrations such as glare, halo and starburst.
61990808|NCT03893838||Post refractive surgery with HOA|Patients post refractive surgery that do complain on the high order aberrations such as glare, halo and starburst.
61990809|NCT03893838||Post refractive surgery with rainbow HOA|"Patients post refractive surgery that do complain on:~1. the high order aberrations such as glare, halo and starburst but with the chromatic aureola~2. difficulties working with LCD projectors, monitors, cell phones and tablets"
61990810|NCT01150123|EXPERIMENTAL|5 µg_No Adj|Subjects received either 1 or 2 doses of active vaccine (5 µg) without any adjuvant
61990811|NCT01150123|EXPERIMENTAL|20 µg_No Adj|Subjects received either 1 or 2 doses of active vaccine (20 µg) without any adjuvant.
61990812|NCT01150123|EXPERIMENTAL|5 µg_Alum|Subjects received either 1 or 2 doses of active vaccine (5 µg) with Alum adjuvant.
61990813|NCT01150123|EXPERIMENTAL|20 µg_Alum|Subjects received either 1 or 2 doses of active vaccine (5 µg) with Alum adjuvant.
61990814|NCT01150123|EXPERIMENTAL|5 µg_MF59-H|Subjects received either 1 or 2 doses of active vaccine (5 µg) adjuvanted with 4.87 mg of MF59
61990815|NCT01150123|EXPERIMENTAL|20 µg_MF59-H|Subjects received either 1 or 2 doses of active vaccine (20 µg) adjuvanted with 4.87 mg of MF59
61990816|NCT01150123|EXPERIMENTAL|5 µg_MF59-F|Subjects received either 1 or 2 doses of active vaccine (5 µg) adjuvanted with 9.75 mg of MF59
61990817|NCT01150123|EXPERIMENTAL|20 µg_MF59-F|Subjects received either 1 or 2 doses of active vaccine (20 µg) adjuvanted with 9.75 mg of MF59
61990818|NCT01150123|PLACEBO_COMPARATOR|Placebo|Subjects received 2 injections of placebo administered 1 month apart
61990819|NCT04430777|PLACEBO_COMPARATOR|Placebo group|No use of tranexamic acid. Subcutaneous infiltration of normal saline solution plus 1 mg of epinephrine as required for the procedure.
61990820|NCT04430777|EXPERIMENTAL|Intravenous group|A single dose of 1 gr of tranexamic acid (10 ml) IV, thirty minutes previous to the initiation of the surgery. Subcutaneous infiltration of normal saline solution plus 1 mg of epinephrine as required for the procedure.
61990821|NCT04430777|EXPERIMENTAL|Subcutaneous group|"A single dose of 1 gr of tranexamic acid (10 ml) in the total of the infiltration mixture, as follow:~4 liters of infiltration contents 2.5 ml of tranexamic acid plus 1 mg epinephrine 5 liters of infiltration contents 2 ml of tranexamic acid plus 1 mg epinephrine.~6 liters of infiltration contents 1.6 ml of tranexamic acid plus 1 mg epinephrine."
61990822|NCT03075917|EXPERIMENTAL|Experimental|questionnaire for allergic rhinitis control children from 5 to 11 years old who complete a self questionnaire regarding allergic rhinitis control during the consultation and after 15 days
61990823|NCT03027895|EXPERIMENTAL|Lumen-apposing metal stent(LAMS)|Lumen-apposing metal stent(LAMS) will be deployed by endoscopist under the guidance of EUS
61990824|NCT03027895|ACTIVE_COMPARATOR|Double pigtail plastic stent(DPPS)|Double pigtail plastic stent(DPPS) will be deployed by endoscopist under the guidance of EUS
61990825|NCT01840293||Primary Breast Cancer|
61990826|NCT01840293||Recurrent/Metastatic Breast Cancer|
61990827|NCT02518867|EXPERIMENTAL|high intensity iTBS|high intensity iTBS: 100% of active motor threshold for 3 days.
61990828|NCT02518867|EXPERIMENTAL|low intensity iTBS|low intensity iTBS: 80% of active motor threshold for 3 days.
61990829|NCT02518867|SHAM_COMPARATOR|sham iTBS|sham iTBS for 3 days.
61990830|NCT01066988|OTHER|Right Eye|ORB Ocular Emulsion or SootheXP
61990831|NCT01066988|OTHER|Left Eye|ORB Ocular Emulsion or SootheXP
61990832|NCT02763852|EXPERIMENTAL|BIA 3-202 50 mg|BIA 3-202 single-dose plus 1 tablet of Madopar 125. BIA 3-202 50 mg: 5 tablets of 10 mg. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
61990833|NCT02763852|EXPERIMENTAL|BIA 3-202 100 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 100 mg: 1 tablet of 100 mg + 4 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
61990834|NCT02763852|EXPERIMENTAL|BIA 3-202 200 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 200 mg: 2 tablet of 100 mg + 3 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
61990835|NCT02763852|EXPERIMENTAL|BIA 3-202 300 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 300 mg: 3 tablet of 100 mg + 2 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
61990836|NCT02763852|EXPERIMENTAL|BIA 3-202 400 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 400 mg: 4 tablet of 100 mg + 1 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
61990837|NCT06122142|ACTIVE_COMPARATOR|Study personnel distribution channel|SR product will be delivered by paid study personnel.
61990838|NCT06122142|EXPERIMENTAL|Voucher distribution channel|Voucher which will be used to redeem for SR product(s) on a monthly basis for each head of household.
61990839|NCT06122142|EXPERIMENTAL|Village health team distribution channel|Village health teams will distribute SR products.
61990840|NCT01213979|ACTIVE_COMPARATOR|1000 mg iron isomaltoside 1000 as intravenous infusion|
61990841|NCT01213979|ACTIVE_COMPARATOR|500 mg iron isomaltoside 1000 as bolus injection|
61990842|NCT00885599|EXPERIMENTAL|PERIORINSE|naturopathic remedy
61990843|NCT00885599|ACTIVE_COMPARATOR|CPC|Cepacol, standard anti-bacterial mouthwash
61990844|NCT00885599|ACTIVE_COMPARATOR|Listerine|standard anti-bacterial mouthwash
61990845|NCT00885599|PLACEBO_COMPARATOR|placebo|colored water
61990846|NCT05518968|EXPERIMENTAL|Acceptance and Commitment Therapy|8 weekly coach-guided videoconferencing sessions and the use of a web app based on acceptance and commitment therapy
61990847|NCT06108505|EXPERIMENTAL|Lacticaseibacillus with oats|This group of subjects receives the Lacticaseibacillus with oats.
62767477|NCT05826977|NO_INTERVENTION|Standard of care|"Standard APS services involve:~1) Nurses, social workers or doctors introduce APS services to clients during routine health care visits and complete partner elicitation and intimate partner violence (IPV) screening via in-person counseling.~3) HWs discuss options for partner notification. 4) If index clients opts for a HW to notify the partner, the HW makes multiple contact attempts to contact partners by phone. When index clients return for their regular healthcare services, HW follow up with index clients to check if exposed partners have completed the testing process.~5) If partners have an unknown HIV status, they are encouraged to complete HIV testing.~6) Partners who test negative for HIV are referred to HIV prevention services, while those with confirmed HIV diagnoses are linked to HIV care and treatment."
61990848|NCT06108505|PLACEBO_COMPARATOR|Plain oats|This group of subjects receives plain oats.
61990849|NCT04663581|EXPERIMENTAL|Left Sided Colonoscopy|Left Sided starting position in colonoscopy
61990850|NCT04663581|ACTIVE_COMPARATOR|Right sided Colonoscopy|Right Sided starting position in colonoscopy
61990851|NCT04721912|NO_INTERVENTION|Standard of Care|Subjects in the control group will not receive any Probiotic capsules and will be advised to continue their routine prenatal self-care.
61990852|NCT04721912|EXPERIMENTAL|Probiotic Dietary Supplement|Participants in the intervention group will begin taking oral study Probiotic capsules once daily from time of enrollment/randomization at ≥ 36 weeks gestation until the time of birth. The research staff member will sequentially distribute the pre-labeled bottles of study capsules to the intervention group, one bottle of 30 Florajen Digestion probiotic capsules to women in the intervention group at the time of randomization.
61990853|NCT03486093|EXPERIMENTAL|CVC managed by healthcare workers|Patients with CVC managed by healthcare workers trained/retrained to GAVECELT recommendations.
61990854|NCT03486093|EXPERIMENTAL|CVC managed by healthcare workers plus port protector|Patients with CVC managed by healthcare workers trained/retrained to GAVECELT recommendations with the aid of port protector devices.
61990855|NCT02417688|EXPERIMENTAL|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of 4-8 mCi of Cu\[64\]-25%-CANF-Comb with a mass no more than 100 μgrams followed by PET-MR Imaging
61990856|NCT03357692|EXPERIMENTAL|maxillary total edentulism|all on four implant rehabilitation with trans-sinusal implants
61990857|NCT03096652|ACTIVE_COMPARATOR|Midline approach|Standard midline incision, then optimal debulking (hysterectomy + lymphadenectomy +/- omentectomy).
61990858|NCT03096652|ACTIVE_COMPARATOR|Modified approach|Panniculectomy with vertical incision of the rectus sheath then optimal debulking (hysterectomy + lymphadenectomy +/- omentectomy).
61990859|NCT02902510|EXPERIMENTAL|Experimental|The experimental group is the group that received yoga. The individuals originally assigned to the WLC who completed the yoga intervention AFTER the 8 weeks WLC period also are considered part of the experimental group.
61990860|NCT02902510|NO_INTERVENTION|Wait List Control|There was no intervention during the WLC.
61990861|NCT01816893|SHAM_COMPARATOR|Euglycemic hyperinsulinemic clamp|participant undergoes a euglycemic hyperinsulinemic clamp
61990862|NCT01816893|ACTIVE_COMPARATOR|Hypoglycemic hyperinsulinemic clamp|participant undergoes a hypoglycemic hyperinsulinemic clamp
61990863|NCT06244355||Lung cancer|Metastatic, with complete mutational status, without anterior treatment
61990864|NCT06244355||Chronic obstructive pulmonary disease (COPD)|Diagnosis of post-smoking COPD (without diagnosis of CP)
61990865|NCT06244355||Healthy volunteers|Healthy volunteers (based on biological and clinical data already available from the partner)
62767478|NCT06230978|ACTIVE_COMPARATOR|Standard of care|The first 16 patients will receive standard medication counseling from the pharmacist
62767479|NCT06230978|EXPERIMENTAL|Habit workup arm|The second 16 patients will receive the habit workup in addition to medication counseling
62767480|NCT03393507|EXPERIMENTAL|apatinib combine with chemotherapy|
62767481|NCT03393507|ACTIVE_COMPARATOR|chemotherapy|
62767482|NCT04142151|ACTIVE_COMPARATOR|SanchiTongshu group|"Drug: SanchiTongshu The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.~Drug: Aspirin or Clopidogrel"
62767483|NCT04142151|PLACEBO_COMPARATOR|SanchiTongshu Placebo group|"Drug: placebo of Sanchitongshu The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).~Drug: Aspirin or Clopidogrel"
62767484|NCT01217320|EXPERIMENTAL|creatine supplementation|will receive 5g/d of creatine monohydrate throughout the trial
62767485|NCT01217320|PLACEBO_COMPARATOR|placebo|will receive 5g/d of placebo (dextrose) throughout the trial
62767486|NCT05902481|EXPERIMENTAL|Intervention Group|"Introductory Information Form, Antenatal Breastfeeding Self-Efficacy Scale will be applied as a pre-test after obtaining informed consent from the pregnant women who are between the 6th and 7th weeks of age.~After the pre-test is applied, pregnant women will be given breastfeeding counseling based on mixed reality technology."
62767487|NCT05902481|NO_INTERVENTION|Control Group|"Introductory Information Form, Antenatal Breastfeeding Self-Efficacy Scale will be applied as a pre-test after obtaining informed consent from the pregnant women in the third trimester who agreed to participate in our study and met the inclusion criteria.~After the pre-test is applied, standard breastfeeding counseling will be given to pregnant women with Power Point technique."
62767488|NCT03375372|ACTIVE_COMPARATOR|Group 1 (Treatment Group)|Subjects receive intervention of Scaling and Root Planing (S\&RP) procedure under local anesthesia, plus a specified Oral Hygiene Regimen (OHR)
62767489|NCT03375372|NO_INTERVENTION|Group 2 (Delayed treatment)|Subjects have delayed treatment scaling and root planing procedure and OHR at 36 weeks (Final visit) These subjects are not followed beyond completion of the treatment.
62767490|NCT00131456|ACTIVE_COMPARATOR|Venlafaxine|Venlafaxine
62767491|NCT00131456|PLACEBO_COMPARATOR|Placebo|Placebo
62767492|NCT04123223|EXPERIMENTAL|Restorative CR Intervention|The restorative remediation intervention will consist of a target of 50 hours (5 hours per week, 1 hour per day, over 3 months) of a sequence of computerized cognitive exercises designed to improve cognitive function through repeated drill-and-practice of exercises largely focused on attention, working memory and verbal episodic memory. Cognitive deficits will be directly targeted by these exercises. Exercises will be started at individually determined levels of difficulty at which each client will be successful, e.g., 80% accuracy. Task difficulty will be increased as performance improves.
62767493|NCT04123223|EXPERIMENTAL|Strategy CR Intervention|Participants in this intervention will be treated for 24 hours (2 hours per week, one day per week over 3 months) with Compensatory Cognitive Training (CCT). The therapy targets four cognitive domains: (a) prospective memory, (b) attention and vigilance, (c) learning and memory, and (d) executive function. The program is a group-based intervention that teaches strategies via interactive, game-like activities to maintain interest and enhance motivation and engagement.
62767494|NCT04123223|PLACEBO_COMPARATOR|Computer Games|Three months of 1-hour, 5-times per week, client-selected computer games.
62767495|NCT01362088||CVVH patients|
62559455|NCT05589077|EXPERIMENTAL|Knowledge Assessment and Educational Intervention|All participants will be asked to complete the pre-intervention survey assessing knowledge and confidence of female athlete nutritional concerns. Then participants will engage in an educational intervention on these same topics. Following the intervention, participants will repeat the same survey.
62767496|NCT02844283|EXPERIMENTAL|treatment group|Single dose of Ad-HGF given by investigator via intracoronary injection into infarct-related artery
62767497|NCT02844283|SHAM_COMPARATOR|control group|0.9% sodium chloride (NaCl) injection of same volume given by investigator via intracoronary injection into infarct-related artery
62767498|NCT05110313|EXPERIMENTAL|PSORIASIS TREATMENT|1 syringe containing 1 mL of 100 mg/mL tildrakizumab-asmn. 100mg delivered by subcutaneous injection at weeks 0, 4, 16 and 28. Total of 20 subjects (10 male, 10 female).
61990866|NCT04821206||Cases|Patients with diagnosis of RA, PsA and SpA
61990867|NCT04821206||Controls|Patients with diagnosis of RA, PsA and SpA
61990868|NCT03567837|ACTIVE_COMPARATOR|Obese Metabolically Healthy|Intervention: Oral challenge of Fructose+Glucose Beverage 1:1, 3g/kg
61990869|NCT03567837|EXPERIMENTAL|Obese Pre-diabetes|Intervention: Oral challenge of Fructose+Glucose Beverage 1:1, 3g/kg
62767499|NCT05110313|NO_INTERVENTION|NON-PSORIASIS|No intervention. Total of 10 subjects (5 male, 5 female).
61990870|NCT01254435|ACTIVE_COMPARATOR|'Free' positioning withdrawal|Withdrawal of the colonoscope with the patient positioned at the discretion of the endoscopist
62767500|NCT02749383|EXPERIMENTAL|PAC-14028 cream 0.3%|Twice daily for 4 weeks
62767501|NCT02749383|EXPERIMENTAL|PAC-14028 cream 1.0%|Twice daily for 4 weeks
62767502|NCT02749383|PLACEBO_COMPARATOR|PAC-14028 cream vehicle|Twice daily for 4 weeks
62767503|NCT01340508|EXPERIMENTAL|Intensity modulated Radiotherapy|Intensity modulated radiotherapy, dose escalation, rectal cancer, volumetric modulated arc therapy
62767504|NCT03100214|ACTIVE_COMPARATOR|Control|Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions.
61990871|NCT01254435|EXPERIMENTAL|'Fixed' position withdrawal|Patient positioned in the left lateral position to visualise the caecum, ascending colon and hepatic flexure; supine to visualise the transverse colon; and in the right lateral position to visualise the splenic flexure, descending colon and the sigmoid colon
61990872|NCT04641611|ACTIVE_COMPARATOR|Cavoatrial cannulation|Cannulation of the atrium with 2-stage venous cannula.
61990873|NCT04641611|EXPERIMENTAL|Bicaval cannulation|"Cannulating the superior and inferior vena cavae with separate cannulas, inserted through 2 separate incisions in the right artium going into the superior and inferior vena cavae. No slush added. This technique is used in Right heart procedure (Pulmonic and tricuspid valve) and mitral valve procedures.~This technique is not routinely used in CABG operations."
61990874|NCT03025061||15 children with moderate asthma|Assessment of E-nose measurements: three E-nose measurements on 15 children with moderate asthma (of both sex and 6-11 years old): first measurement, second one after 30 minutes, third one after 7 days. These children attend the outpatient clinic of Pediatric Allergology \& Pulmonology (PAP) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (IBIM CNR).
61990875|NCT03025061||30 healthy children|"Assessment of E-nose measurements: three E-nose measurements on 30 healthy children (of both sex and 6-11 years old): first measurement, second one after 30 minutes, third one after 7 days. These children attend the primary schools involved in the municipal project Educational Pathways (Palermo)."
61990876|NCT00873509|EXPERIMENTAL|1|Buspirone 2.5 mg
61990877|NCT00873509|EXPERIMENTAL|2|Buspirone 5.0 mg
62386828|NCT00671190|EXPERIMENTAL|Ramelteon 4 mg QD|
61990878|NCT00873509|PLACEBO_COMPARATOR|3|Placebo match
61990879|NCT04029714|ACTIVE_COMPARATOR|Arm 1: Current practice for active surveillance|In this arm, patients are monitored according to current practice for active surveillance at the trial centre. Repeat biopsies (and/or other examinations) and initiation of curative treatment are performed according to the urologist's judgement.
61990880|NCT04029714|EXPERIMENTAL|Arm 2: Standardized triggers for treatment|In this arm, patients are monitored according to a standardized active surveillance protocol with specific triggers for treatment. Repeat biopsies and curative treatment are only initiated if/when specific criteria are fulfilled.
61990881|NCT00076687|EXPERIMENTAL|1|
61990882|NCT00076687|EXPERIMENTAL|2|
61990883|NCT00076687|PLACEBO_COMPARATOR|3|
61990884|NCT02037542|EXPERIMENTAL|Diet and Exercise|Prospective, observational, cohort study, with a proposed start date of May 2013 and proposed end date of June 2018. Our goal is to gather data on a total of 200 patients: 100 patients (study group) will be prospectively enrolled, while data on another 100 patients (control) will be accessed through retrospective data collection. Number of patients to be analyzed will depend on enrollment and patient compliance. We would like to enroll the proposed 100 patients in the first 1-3 years of the study (approximately 30 per year).
62386829|NCT00671190|EXPERIMENTAL|Ramelteon 8 mg QD|
62386830|NCT00671190|PLACEBO_COMPARATOR|Placebo QD|
62386831|NCT03508206|EXPERIMENTAL|SBRP arm|Food supplement in hard gelatin capsule form containing a Standardized botanical blend rich in polyphenols (SBRP)
62386832|NCT03508206|PLACEBO_COMPARATOR|Placebo arm|Hard gelatin capsule form containing maltodextrin, with the same appearance as SBRP capsules
62386833|NCT02198911|ACTIVE_COMPARATOR|Order 1|Gum chewing order for sessions, 1-3 respectively: NO GUM, MCC, C
62386834|NCT02198911|ACTIVE_COMPARATOR|Order 2|Gum chewing order for ice-cream sessions, 1-3 respectively: MCC, C, NO GUM
62386835|NCT02198911|ACTIVE_COMPARATOR|Order 3|Gum chewing order for ice-cream sessions, 1-3 respectively: C, NO GUM, MCC
62386836|NCT02327949|EXPERIMENTAL|WP group|WP group:treated with W-Shaped Angular Plate
62386837|NCT02327949|ACTIVE_COMPARATOR|RP group|RP group:treated with Reconstruction Plate
62386838|NCT05867849|EXPERIMENTAL|Cannabidiol|Cannabidiol 200 - 600 mg / day added to current treatment for 6 weeks.
62386839|NCT05867849|PLACEBO_COMPARATOR|Placebo|Placebo added to current treatment for 6 weeks.
62386840|NCT04129931|EXPERIMENTAL|Medium Chain Triglycerides (MCT)|Participants in this arm will receive Medium Chain Triglycerides (MCT) powder packets (10 g each) at each treatment visit at any point in the study. Participants will mix 1-2 packets of MCT supplement powder into liquids or semi-solid food and ingest 3 times a day during the 16-week treatment period. Participants will be randomized to the treatment sequence and will receive either the active MCT or the matching placebo first or vice versa.
62386841|NCT04129931|EXPERIMENTAL|Clazakizumab|Participants randomized to this arm will receive a 12.5 mg dose of Clazakizumab via a subcutaneous injection at every study visit, every 4 weeks, during the 16-week treatment period at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Clazakizumab or the matching placebo first or vice versa.
62386842|NCT04129931|EXPERIMENTAL|Broncho-Vaxom|Participants randomized to this arm will receive 7 mg of Broncho-Vaxom once a day on an empty stomach for the 16-week treatment period duration at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Broncho-Vaxom or the matching placebo first or vice versa.
62386843|NCT04129931|EXPERIMENTAL|Imatinib|At any point in the study, participants randomized to this arm will take two 100 mg Imatinib tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Participants will then take four 100 mg tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Participants will be randomized to the treatment sequence and will receive either the active Imatinib or the matching placebo first or vice versa.
61990885|NCT01995799|EXPERIMENTAL|USPIO timepoint 2-4 days|USPIO given 2-4 days post MI Ferumoxytol enhanced MRI
62386844|NCT04129931|EXPERIMENTAL|Cavosonstat|Participants randomized to this arm will take one 50 mg Cavosonstat capsule orally twice a day for the 16-week treatment period duration at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Cavosonstat or the matching placebo first or vice versa.
62386845|NCT00763373||1|Observation group
62386846|NCT00763373||2|Intervention group
62386847|NCT02694562|EXPERIMENTAL|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg)
62386848|NCT04636333|EXPERIMENTAL|Middle-dose vaccine (18-59 years) & Two dose regimen|Two doses of middle-dose experimental vaccine at the schedule of day 0, 14.
61990886|NCT01995799|EXPERIMENTAL|USPIO timepoint 5-7 days|USPIO given 5-7 days post MI Ferumoxytol enhanced MRI
61990887|NCT01995799|EXPERIMENTAL|USPIO tiempoint 11-21 days|USPIO given 11-21 days post MI Ferumoxytol enhanced MRI
61990888|NCT01035944|EXPERIMENTAL|HemCon Operating Room|The HemCon dressing is the intervention for the HemCon Operating Room arm. The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
61990889|NCT01035944|ACTIVE_COMPARATOR|Control Operating Room|The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
61990890|NCT01035944|EXPERIMENTAL|HemCon Bedside|The intervention for the HemCon Beside arm is the HemCon Dressing. The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
61990891|NCT01035944|ACTIVE_COMPARATOR|Control Bedside.|The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
61990892|NCT03156478|NO_INTERVENTION|Control group|At baseline, individuals in the control group receive digital information package about lifestyle risk factors of type 2 diabetes with recommendations on healthy diet and physical activity in accordance with the Finnish Nutrition Recommendations and the national recommendation for health enhancing physical activity.
61990893|NCT03156478|EXPERIMENTAL|Digital lifestyle intervention group|Participants are instructed to use a digital self-help tool for 12 months. This tool is developed in the StopDia-study to enact positive changes in participant's health behaviour. The digital intervention consists of 2 components which motivate, enable and trigger the participants to improve their health behaviours. B.J. Fogg's Tiny Habits -ideology. The digital intervention is based on the Fogg Behaviour Model (FBM) and the Behaviour Wizard.
61990894|NCT03156478|EXPERIMENTAL|Combined digital and face-to-face lifestyle intervention group|Participants are using the StopDia digital solution tool as described above. In addition, they have six face-to-face group coaching (6-15 participants/group) sessions at local health centers facilitated by trained nurses. The face-to-face group intervention is based on the Self-Determination Theory and theories of self-regulation, and delivered using intrinsic motivational coaching approach designed and tested in the GOAL lifestyle intervention, and further developed in several other studies in Finland and internationally.
61990895|NCT04045678|EXPERIMENTAL|LY03003|
61990896|NCT04045678|PLACEBO_COMPARATOR|Placebo|
61990897|NCT03752307|EXPERIMENTAL|Corticosteroid & Isoxsuprine HCL|Corticosteroid pulse of either daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon for 3 to 5 consecutive days and Isoxsuprine Hydrochloride one 10 mg Capsule 3 times daily for 5 consecutive days
61990898|NCT03752307|PLACEBO_COMPARATOR|Corticosteroid & Placebo|Corticosteroid pulse of either daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon for 3 to 5 consecutive day and placebo one Capsule 3 times daily for 5 consecutive days
61990899|NCT00419198|EXPERIMENTAL|1|Post-conditioning during angioplasty
61990900|NCT00419198|ACTIVE_COMPARATOR|2|standard angioplasty
61990901|NCT03967834|OTHER|Patient with Soft Tissue Sarcoma (Prospective cohort)|
61990902|NCT01459965|ACTIVE_COMPARATOR|10 French Stent|10 French biliary plastic stent
61990903|NCT01459965|ACTIVE_COMPARATOR|11.5 French stent|11.5 French biliary plastic stent
61990904|NCT01492322||Sated and withdrawal group|To determine differences in TRODAT binding to the DAT between a smoker when sated and when in withdrawal
61990905|NCT04754347|NO_INTERVENTION|Control|Routine Colonoscopy
61990906|NCT04754347|EXPERIMENTAL|Experimental|Routine Colonoscopy with the use of Skout
61990907|NCT02801942|EXPERIMENTAL|Healthy subjects|Up to 30 mL of blood sample will be collected from healthy subjects. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, Human Leukocyte antigen D related (HLA-DR) and forkhead box P3 protein also called scurfin (FOXP3).
62767505|NCT03100214|EXPERIMENTAL|Exercise|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
62767506|NCT04304885||Sonication method|The treatment strategies of all patients will be based on the cultural results to be made by the sonication method.
61990908|NCT02801942|EXPERIMENTAL|Subjects with NOT1D|Up to 30 mL of blood sample will be collected from subjects with NOT1D. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, HLA-DR and FOXP3.
61990909|NCT02570061|EXPERIMENTAL|telephone|Information about the Calmette study was given by telephone
61990910|NCT02570061|ACTIVE_COMPARATOR|face-to-face|Information about the Calmette study was given face-to-face at a consultation at the hospital
61990911|NCT03624712||uterine neoplasms|Women with operable and inoperable uterine malignomas (cervical cancer, endometrial cancer, uterine sarcoma)
61990912|NCT00831532|EXPERIMENTAL|Normal|Healthy Volunteers
61990913|NCT00831532|EXPERIMENTAL|Mild Hepatic Impairment|Mild hepatic impairment patients
61990914|NCT00831532|EXPERIMENTAL|Moderate hepatic Impairment|Moderate Hepatic Impairment Patients
61990915|NCT00831532|EXPERIMENTAL|Severe Hepatic Impairment|Severe Hepatic Impairment Patients
61990916|NCT00174655|ACTIVE_COMPARATOR|A1|
61990917|NCT00174655|ACTIVE_COMPARATOR|A2|
61990918|NCT00174655|EXPERIMENTAL|B|
61990919|NCT00174655|EXPERIMENTAL|C|
62559456|NCT05834556|EXPERIMENTAL|Prehabilitation group|Participants will engage in 4 virtual sessions with a physiotherapist, over a 3 week period. They will be prescribed an individual exercise program (based on assessment). Participants will complete the program 3x/week independently and diarize the exercise on provided documents. For participants living within Winnipeg, they will also diarize their accelerometer use/sleeping times during wear.
62559457|NCT04680169|ACTIVE_COMPARATOR|Group A: Bronchoscopic intubation using AuraGain LMA as conduit|A group of 50 patients randomly allocated to bronchoscopic intubation using AuraGain
62559458|NCT04680169|ACTIVE_COMPARATOR|Group B: Bronchoscopic intubation with I-gel SGA as conduit|A group of 50 patients randomly allocated to bronchoscopic intubation using I-gel
62559459|NCT04122521||Glioma|Patients suspected of glioma
62767507|NCT03917069|EXPERIMENTAL|nab-paclitaxel + endostatin+ carboplatin|nab-paclitaxel + endostatin+ carboplatin nab-paclitaxel 260mg/m2, d1 +Carboplatin AUC=5, d1 +endostatin 15mg, d1-14 q28d
62767508|NCT03917069|ACTIVE_COMPARATOR|paclitaxel+carboplatin|paclitaxel+carboplatin paclitaxel 175 mg/m2, d1+ Carboplatin AUC=5, d1 q21d
62559460|NCT03867240|EXPERIMENTAL|Gabapentin|Gabapentin is a common neuropathic medication used in the treatment of chronic pain. Gabapentin will be given preoperative and continued for 5 days postoperatively.
62559461|NCT03867240|PLACEBO_COMPARATOR|Placebo|Control group will receive placebo medication at the same interval with the appropriate number of capsules or liquid for their weight to match the experimental group.
62559462|NCT06196437|EXPERIMENTAL|Acupuncture|Participants will receive acupuncture, five times per day form pre-operation to 3 days after operation. The selected acupoints include RN3,RN4, bilateral ST36,SP6,SP9 and LR3. All acupoints areas have been sterilized before acupuncture. needles (Ф0.30×50mm) will be directly inserted at a depth of 25-30 mm deep. Arrival of Qi by acupuncture and needle retaining for 20 minutes.
62767509|NCT06507124|EXPERIMENTAL|One arm|
62767510|NCT02715726|ACTIVE_COMPARATOR|Ezetimibe 10 mg|Oral ezetimibe 10 mg capsule once daily with or without food for 24 weeks and subcutaneous placebo injection for alirocumab every 2 weeks (Q2W) for 22 weeks added to lipid modifying therapy (LMT).
62767511|NCT02715726|EXPERIMENTAL|Alirocumab 75 mg Q2W/up to 150 mg Q2W|Subcutaneous injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe once daily with or without food added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C level was \>=70 milligrams per deciliter (mg/dL) (1.81 millimoles per liter \[mmol/L\]) at Week 8.
62767512|NCT05833451|EXPERIMENTAL|Reiki|The participants in the Reiki group (n=32) were given Reiki remotely for 60 minutes by two certified practitioners who completed the second level Reiki training with a Master degree Reiki instructor according to the Usui method.
62767513|NCT05833451|NO_INTERVENTION|Control|No intervention was made in the control group (n=32).
62767514|NCT03658070|EXPERIMENTAL|XY0206-12.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：12.5mg;Include single dose treatment and multiple dose phase
62767515|NCT03658070|EXPERIMENTAL|XY0206-25mg|Drug:XY0206;Dosage form:Tablet;Dosage：25mg;Include single dose treatment and multiple dose phase
62767516|NCT03658070|EXPERIMENTAL|XY0206-37.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：37.5mg;Include single dose treatment and multiple dose phase
61990920|NCT01145768|EXPERIMENTAL|1|Each cohort will have 9 volunteers that will receive TC-5214
62559463|NCT06196437|SHAM_COMPARATOR|Sham acupuncture|Participants will receive shame acupuncture, five times per day form pre-operation to 3 days after operation. The selected non-acupoints nearby RN3,RN4, bilateral ST36, SP6,SP9 and LR3, All acupoints areas have been sterilized before acupuncture. needles (Ф0.30×50mm) will be directly inserted at a depth of 5 mm deep. Needle retaining for 20 minutes and without needle manipulation.
62559464|NCT02138877|ACTIVE_COMPARATOR|After coming stent|Dismembered pyeloplasty with insertion of an after coming stent
62559465|NCT02138877|ACTIVE_COMPARATOR|Stentless|Stentless dismembered pyeloplasty
62559466|NCT00991887|NO_INTERVENTION|No Radiation Therapy (XRT)|This group will not receive radiation therapy after surgery.
62559467|NCT00991887|ACTIVE_COMPARATOR|Radiation Therapy (XRT)|Radiotherapy will be administered no later than 72 hours postoperatively.
62559468|NCT06139146|EXPERIMENTAL|Group A Control|A moist heat pack for 15-20 minutes MET of the upper trapezius, levator scapula and pectoral Major muscles Strengthening exercise of deep neck flexors
62559469|NCT06139146|EXPERIMENTAL|Group B Experimental|A moist heat pack for 15-20 minutes Core stability exercises MET of the upper trapezius, levator scapula and pectoral Major muscles Strengthening exercise of deep neck flexors
62559470|NCT06362954||High-Level Spasticity|Hemiparetic stroke patients with spasticity levels 3 and 4 on The Modified Ashworth Scale
62559471|NCT06362954||Low-Level Spasticity|Hemiparetic stroke patients with spasticity levels between 1 and 2 on The Modified Ashworth Scale
62559472|NCT06362954||No Spasticity|Hemiparetic stroke patients with spasticity level 0 on The Modified Ashworth Scale
62559473|NCT00005095||High Risk for Ovarian Cancer|Women who are at increased risk of ovarian cancer based on family or personal medical history who are participating in the Northwestern Ovarian Cancer Early Detection and Prevention Program clinic.
62559474|NCT00005095||Suspected or diagnosed gynecological condition|Women who are planning to undergo surgery for their gynecological condition
62559475|NCT00005095||Control Group|Healthy subjects with no history of cancer and at general risk.
62767517|NCT03658070|EXPERIMENTAL|XY0206-50mg|Drug:XY0206;Dosage form:Tablet;Dosage：50mg;Include single dose treatment and multiple dose phase
62767518|NCT03658070|EXPERIMENTAL|XY0206-75mg|Drug:XY0206;Dosage form:Tablet;Dosage：75mg;Include single dose treatment and multiple dose phase
61990921|NCT01145768|PLACEBO_COMPARATOR|2|Each cohort will have 3 volunteers that will receive placebo
61990922|NCT06159140|EXPERIMENTAL|Healthy subjects|MRI and neuropsychological evaluation
62559476|NCT02165449|EXPERIMENTAL|Ketamine|
62767519|NCT03658070|EXPERIMENTAL|XY0206-100mg|Drug:XY0206;Dosage form:Tablet;Dosage：100mg;Include single dose treatment and multiple dose phase
62767520|NCT05896787|EXPERIMENTAL|AK104 plus nab-paclitaxel and carboplatin|"In the induction period, AK104 (10mg/kg, iv, Q2W) is given for one cycle;~and then AK104 (10mg/kg, iv, Q3W) is combined with nab-paclitaxel (130mg/m2 ivgtt d1，d8, Q3W) and carboplatin ((AUC=5) d1，Q3W) for 2 cycles;~After R0 surgery, AK104 (10mg/kg, iv, Q3W) is given as adjuvant therapy for up to 12 months for those who do not achieve pCR."
61990923|NCT02325336|EXPERIMENTAL|bar-code-assisted administration|during administration rounds, nurses will use the BCMA system to help preventing administration errors
62559477|NCT04293393|ACTIVE_COMPARATOR|Arm A: Doxorubicin plus cyclophosphamide and taxane|"Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.~Approximately duration of 24 weeks (6 months)."
62559478|NCT04293393|EXPERIMENTAL|Arm B: Letrozole plus abemaciclib +/- LHRH|Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- luteinizing hormone-releasing hormone (LHRH) analogs in premenopausal women, up to 12 months, in 28-day cycles.
62559479|NCT05754255|ACTIVE_COMPARATOR|Group A: standard care with a nasal cannula.|Group A will be given the standard nasal cannula during sedation. The cannula prongs will be inserted into the patient's nose to provide oxygen to the patient.
62559480|NCT05754255|ACTIVE_COMPARATOR|Group B: SuperNO2VA™EtCO2|Group B will be given a nasal oxygen to deliver gas, create a seal, and provide positive pressure. The mask will be placed over a patient's nose and connected to either an anesthesia circuit or hyperinflation bag during respiratory, anesthesia, and resuscitation procedures.
61990924|NCT02325336|NO_INTERVENTION|control|during administration rounds, nurses will administer drugs as usual
61990925|NCT01222975|EXPERIMENTAL|1|Risperidone orally disintegrating tablets of Ranbaxy Laboratories, Ltd
62559481|NCT05609513|EXPERIMENTAL|8 HIV clinics randomized to HTN BASIC|The HTN-BASIC intervention will consist of providing consistent access to diagnostic equipment and evidence-based antihypertensive drugs at no cost to the hypertensive patients. Access to a consistent supply of three anti-hypertensive drugs (amlodipine 5, 10mg; valsartan 80, 160mg; and hydrochlorothiazide 12.5, 25mg) will be supplied to each clinic in the trial.
62559482|NCT05609513|EXPERIMENTAL|8 HIV clinics randomized to HTN PLUS|In addition to receiving all the components of HTN-BASIC, HTN-PLUS sites will receive an enhanced, more human-resource intensive package of interventions that have been developed in consultation with key stakeholders during our human-centered design phase. The intervention components will include four broad categories- (1) hypertension training, (2) differentiated service delivery and (3) remote patient monitoring for hypertension and (4) Performance Improvement Program. Uptake of all components will be assessed on a monthly basis during the intervention period. These interventions will by nature cost more, and so cost data will be rigorously collected as well.
62559483|NCT05609513|NO_INTERVENTION|Control Period for all 16 clinics|Outcome data will be collected during the control period prior to intervention roll-out in all 16 clinics.
62559484|NCT01665001|EXPERIMENTAL|Multiagent induction-consolidation|Induction, consolidation, HSCT, maintenance for adults with newly diagnosed precursor lymphoid neoplasms
62559485|NCT06443489|EXPERIMENTAL|SHR-4849|
62386849|NCT04636333|EXPERIMENTAL|Middle-dose vaccine (18-59 years) & Three dose regimen|Three doses of middle-dose experimental vaccine at the schedule of day 0, 14 28.
62559486|NCT03526068|EXPERIMENTAL|SafeZoneUVC|Patients were subjected to 90s UV light therapy of 540 mW/cm2 sessions 2 times a week for 2 weeks for a total of 4 sessions. Pre and post UV light therapy swabs were taken after standard wound irrigation
62767521|NCT05978102|EXPERIMENTAL|STI-7349 alone|Dose escalation and dose expansion for STI-7349 alone,to determine the RP2D and to evaluate the preliminary antitumor activity of STI-7349 in specific solid tumor patients.
62386850|NCT04636333|EXPERIMENTAL|High-dose vaccine (18-59 years) & Two dose regimen|Two doses of high-dose experimental vaccine at the schedule of day 0, 14.
62386851|NCT04636333|EXPERIMENTAL|High-dose vaccine (18-59 years) & Three dose regimen|Two doses of High-dose vaccine at the schedule of day 0, 14, 28.
62559487|NCT01809353|EXPERIMENTAL|Group A: JNJ-54452840 20 mg|Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose.
62559488|NCT01809353|EXPERIMENTAL|Group A: JNJ-54452840 80 mg|Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose.
62559489|NCT01809353|EXPERIMENTAL|Group A: JNJ-54452840 240 mg|Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose.
62559490|NCT01809353|PLACEBO_COMPARATOR|Group A: Placebo|Each participant will receive matching placebo as a single intravenous dose.
62559491|NCT01809353|EXPERIMENTAL|Group B: JNJ-54452840 20 mg|Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose.
62559492|NCT01809353|EXPERIMENTAL|Group B: JNJ-54452840 80 mg|Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose.
62559493|NCT01809353|EXPERIMENTAL|Group B: JNJ-54452840 240 mg|Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose.
62559494|NCT01809353|PLACEBO_COMPARATOR|Group B: Placebo|Each participant will receive matching placebo as a single intravenous dose.
62767522|NCT05978102|EXPERIMENTAL|STl-7349 in combination with Pembrolizumab|Dose escalation and dose expansion for STI-7349 in combination with Pembrolizumab,to determine the RP2D of STI-7349 in combination with Pembrolizumab and to evaluate the preliminary antitumor activity in specific solid tumor patients.
62559495|NCT04526015|EXPERIMENTAL|Ilioinguinal iliohypogastric Block|Each patient will receive spinal anesthesia plus bilateral ultrasound-guided IL/IH nerve block. The abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualized between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side
62559496|NCT04526015|OTHER|Controlled Group|Each patient will receive spinal anesthesia alone with no block.
61990926|NCT01222975|ACTIVE_COMPARATOR|2|Risperdal® M-Tab of Janssen Pharmaceutica Products L.P.
61990927|NCT04382131|EXPERIMENTAL|Hypertonic saline nasal irrigation and gargling|Participants in the intervention arm will be asked to perform hypertonic saline nasal irrigation and gargling up to 12 times daily for a maximum of 14 days or until they report that they feel well.
61990928|NCT04382131|NO_INTERVENTION|Standard Care|Participants in the control arm will be given standard NHS guidance for the management of their symptoms and household hygiene.
62386852|NCT04636333|EXPERIMENTAL|Middle-dose vaccine (> 59 years) & Three dose regimen|Three doses of middle-dose experimental vaccine at the schedule of day 0, 14, 28.
61990929|NCT00511693|EXPERIMENTAL|1|hospitals randomly allocated to receive physician and patient osteoporosis recommendations from the regional coordinator
62386853|NCT04636333|EXPERIMENTAL|High-dose vaccine (> 59 years) & Three dose regimen|Three doses of high-dose experimental vaccine at the schedule of day 0, 14, 28.
62386854|NCT04636333|PLACEBO_COMPARATOR|Middle-dose placebo (18-59 years) & Two dose regimen|Two doses of middle-dose placebo at the schedule of day 0, 14.
62386855|NCT04636333|PLACEBO_COMPARATOR|Middle-dose placebo (18-59 years) & Three dose regimen|Three doses of middle-dose placebo at the schedule of day 0, 14, 28.
62386856|NCT04636333|PLACEBO_COMPARATOR|High-dose placebo (18-59 years) & Two dose regimen|Two doses of high-dose placebo at the schedule of day 0, 14.
62386857|NCT04636333|PLACEBO_COMPARATOR|High-dose placebo (18-59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
62386858|NCT04636333|PLACEBO_COMPARATOR|Middle-dose placebo (> 59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
62386859|NCT04636333|PLACEBO_COMPARATOR|High-dose placebo (> 59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
62386860|NCT03770663|EXPERIMENTAL|European strategy|"3 IV pulses of Methylprednisolone (7.5 mg/kg/day followed by tapering doses of oral Prednisone, started at 1 mg/kg/day from D4 to M12~In association with:~6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day"
62386861|NCT03770663|EXPERIMENTAL|American strategy|"3 IV pulses of Methylprednisolone (7.5 mg/kg/day followed by tapering doses of oral Prednisone, started at 1 mg/kg/day from D4 to M12~In association with:~Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL."
62386862|NCT02492789|EXPERIMENTAL|INCSHR01210|"3 dose levels are designed in this study.3 to 6 patients (traditional 3+3 design) will be enrolled in each dose cohort. INCSHR01210 injection at each dose level is administered every 2 weeks (q2w, except in the first cycle)."
62386863|NCT05043493|ACTIVE_COMPARATOR|Injection (study) group|This group will receive platelet rich plasma (PRP) injection
62386864|NCT05043493|PLACEBO_COMPARATOR|Control group|This group will receive normal saline (NS) injection
62386865|NCT02416466|EXPERIMENTAL|anti-CEA CAR-T cells + Sir-Spheres|Three infusions of gene-modified anti-CEA T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach along with low dose IL-2. A single dose of Sir-Spheres will be given 2 weeks following the final T cell dose.
62386866|NCT05250999|EXPERIMENTAL|Skin stretch sensory stimuli|Skin stretch sensory stimuli along with conventional physiotherapy
62386867|NCT05250999|EXPERIMENTAL|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation along with conventional physiotherapy
62386868|NCT05250999|ACTIVE_COMPARATOR|Control Group|Conventional physiotherapy included balance exercises, static exercise and dynamic exercise.
62386869|NCT03114709|EXPERIMENTAL|Mindful Movement|8, 90-minute, in-person, group sessions over 8 weeks
62386870|NCT03114709|ACTIVE_COMPARATOR|10 Keys to Health & Wellbeing|8, 90-minute, in-person, group sessions over 8 weeks
62386871|NCT01747928|EXPERIMENTAL|Group 1|
62386872|NCT02388750|OTHER|No previous nausea and vomiting|"Palonosetron 0.5 mg oral capsule given for the length of radiation treatment~No previous nausea and vomiting 24 hours prior to radiotherapy"
62386873|NCT02388750|OTHER|Previous nausea and/or vomiting|"Palonosetron 0.5 mg oral capsule given for the length of radiation treatment~Previous nausea and/or vomiting 24 hours prior to radiotherapy"
62386874|NCT01086306||Patients exposed to Saxagliptin|
61990930|NCT00511693|ACTIVE_COMPARATOR|2|hospitals randomly allocated to receive falls prevention advice
62386875|NCT01086306||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
62386876|NCT01192139|EXPERIMENTAL|5 mg saxagliptin + a single 500 mg metformin XR tablet|
62386877|NCT01192139|EXPERIMENTAL|FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fed)|under fed state
62386878|NCT01192139|EXPERIMENTAL|FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fasting)|under fasted state
62386879|NCT05897996|EXPERIMENTAL|creation of vascular access for hemodialysis|creation of vascular access for hemodialysis with percutaneous AVF creation
62386880|NCT05205161|EXPERIMENTAL|Part A (Dose Escalation): Dose Level (DL)-1|Participants with advanced R/R B-NHL will receive AZD0466 on day 1 , day 4, day 8 day 15, day 22 of cycle 1 and day 1, day 8 day 15, day 22 of cycle 2 and beyond until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
62386881|NCT05205161|EXPERIMENTAL|Part A (Dose Escalation): DL1|Participants with advanced R/R B-NHL will receive AZD0466 on day 1 , day 4, day 8 day 15, day 22 of cycle 1 and day 1, day 8 day 15, day 22 of cycle 2 and beyond until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
62386882|NCT05205161|EXPERIMENTAL|Part A (Dose Escalation): DL2|Participants with advanced R/R B-NHL will receive AZD0466 on day 1 , day 4, day 8 day 15, day 22 of cycle 1 and day 1, day 8 day 15, day 22 of cycle 2 and beyond until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
62386883|NCT05205161|EXPERIMENTAL|Part A (Dose Escalation): DL3|Participants with advanced R/R B-NHL will receive AZD0466 on day 1 , day 4, day 8 day 15, day 22 of cycle 1 and day 1, day 8 day 15, day 22 of cycle 2 and beyond until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
62386884|NCT05205161|EXPERIMENTAL|Part A (Dose Escalation): DL4|Participants with advanced R/R B-NHL will receive AZD0466 on day 1 , day 4, day 8 day 15, day 22 of cycle 1 and day 1, day 8 day 15, day 22 of cycle 2 and beyond until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
62559497|NCT01445782|EXPERIMENTAL|1|AZD2115
62559498|NCT01445782|PLACEBO_COMPARATOR|2|Placebo to AZD2115
62559499|NCT03230578||Pharmacists|Actively employed and currently licensed and working in rural counties in New Mexico.
61990931|NCT04588649|OTHER|THK-5351|Name: \[18F\]THK5351，(S)-6-\[(3-Fluoro-2-hydroxy)propoxy\]-2-(2-Methylaminopyrid-5-yl)-quinoline Dosage form: intravenous injection Dose(s): 10mCi Dosing schedule: Visit 2 Mechanism of action (if known): high affinity radiotracer for the tau protein Pharmacological category：Radio pharmaceutical
61990932|NCT04588649|OTHER|AV-45|Name: \[18F\]AV-45, (E)-4-(2-(6-(2-(2-(2-\[18F\]fluoroethoxy) ethoxy) ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine Dosage form: intravenous injection Dose(s): 10mCi Dosing schedule: Visit 2 Mechanism of action (if known): high affinity radiotracer for the β- amyloid protein Pharmacological category：Radio pharmaceutical
61990933|NCT05509699|EXPERIMENTAL|Surufatinib in combination with anti-PD-1/L1 therapy|Surufatinib 250 mg orally once plus anti-PD-1/L1, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.
62559500|NCT03230578||Women|Reproductive age, 18-45 years old from rural counties in New Mexico and who are fluent in English.
62767523|NCT01895244|EXPERIMENTAL|Conditioning with CYC/ antithymocyte globulin (ATG)|Each patient receives stem cell transplantation open label with cluster of differentiation (CD)34 selected stem cells mobilisation and conditioning depending on manifestation If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
62767524|NCT01895244|EXPERIMENTAL|Conditioning with CYC/Thiotepa/ATG|In patients with cardiac manifestations as defined in the protocol the conditioning for stem cell transplantation is changed to Cyclophosphamide (CYC), thiotepa and ATG
62767525|NCT04502121|EXPERIMENTAL|Intervention group (IG)|
61990934|NCT05509699|EXPERIMENTAL|Anti-PD-1/L1 monotherapy|Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy
61990935|NCT01341600|EXPERIMENTAL|Clopidogrel in poor metabolizers|"Healthy subjects who have been genotyped for CYP2C19\*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 poor metabolizers (PM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
62386885|NCT05205161|EXPERIMENTAL|Part B (Dose Expansion): Cohort B1 (R/R MCL)|Participants with advanced R/R MCL will receive AZD0466 at the recommended phase 2 dose (RP2D) until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
61990936|NCT01341600|EXPERIMENTAL|Clopidogrel in intermediate metabolizers|"Healthy subjects who have been genotyped for CYP2C19\*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 intermediate metabolizers (IM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
61990937|NCT01341600|EXPERIMENTAL|Clopidogrel in extensive metabolizers|"Healthy subjects who have been genotyped for CYP2C19\*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 extensive metabolizers (EM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
62386886|NCT05205161|EXPERIMENTAL|Part B (Dose Expansion): Cohort B2 (R/R FL or MZL)|Participants with advanced R/R FL or MZL will receive AZD0466 at the recommended phase 2 dose (RP2D) until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
62386887|NCT05205161|EXPERIMENTAL|Part B (Dose Expansion): Cohort B3 (R/R DLBCL)|Participants with advanced R/R DLBCL will receive AZD0466 at the recommended phase 2 dose (RP2D) until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
62386888|NCT02254694|EXPERIMENTAL|high heeled shoes|see detailed description
62386889|NCT01840566|EXPERIMENTAL|HIGH DOSE CHEMOTHERAPY AND ASCT|This is a phase 1 dose escalation study designed to determine the maximum tolerated dose (MTD) of CAR modified T cells in patients with relapsed and refractory aggressive B-NHL. Three dose levels (5 x 106 19-28z T cells/kg, 1 x 107 19-28z T cells/kg, and 2 x 107 19-28z T cells/kg) are considered for the MTD.
62386890|NCT03399227||Liver transplantation recipients|Venipuncture (6x) Bone mineral density measurement: lumbar spine, hip region (3x) high resolution peripheral quantitative CT: radius, tibia (3x)
62559501|NCT05289505||Prospective phase|This prospective phase involves all patients with an initial HADS score \> 7 and initiating treatment in the radiotherapy department. The treatment sessions will be performed with music, using the MUSIC-CARE device. In the event of technical problems, unavailability of equipment, or the patient's wishes, some radiotherapy sessions may be conducted without music. Nevertheless, a minimum of one weekly session with music is required for the analysis of the study.
62559502|NCT01803698|EXPERIMENTAL|Training in the use of IOM charts|"Training family physicians to regularly refer to the Institute of Medicine guideline trajectories and provide feedback about GWG (training in the use of IOM charts) during routine prenatal visits."
62559503|NCT01803698|NO_INTERVENTION|Usual care|Family physicians providing usual prenatal care.
61990938|NCT01341600|EXPERIMENTAL|Omeprazole/Clopidogrel in PM|PM participants who have completed Arm 1 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
62559504|NCT03238521|ACTIVE_COMPARATOR|classical pedicle finder|Spinal osteosynthesis with classical pedicle finder
62559505|NCT03238521|EXPERIMENTAL|pedicle finder with impedancemetry|Spinal osteosynthesis with pedicle finder with impedancemetry
62767526|NCT04502121|NO_INTERVENTION|Standard of Care (SOC)|
61990939|NCT01341600|EXPERIMENTAL|Omeprazole/Clopidogrel in IM|IM participants who have completed Arm 2 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
61990940|NCT01341600|EXPERIMENTAL|Omeprazole/Clopidogrel in EM|EM participants who have completed Arm 3 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
62559506|NCT01834833|NO_INTERVENTION|Control|usual care without systematic cardiology evaluation between 1 and 2 weeks
62559507|NCT01834833|EXPERIMENTAL|Follow-up|Evaluation by a cardiologist using echocardiography, completed by education of the patient if necessary
62386891|NCT03399227||Control group|Venipuncture (1x) Bone mineral density measurement: lumbar spine, hip region (1x) high resolution peripheral quantitative CT: radius, tibia (1x)
62386892|NCT02616172|EXPERIMENTAL|Autologous bone marrow infusion|One time administration of autologous bone marrow mononuclear cells intravenously, minimum dose of 6 million cells per kg Total nucleated cells.
62559508|NCT02976129|EXPERIMENTAL|V565|V565 three times a day (TID) PO for 6 weeks
62559509|NCT02976129|PLACEBO_COMPARATOR|Placebo|Placebo TID PO for 6 weeks
62559510|NCT04807920|EXPERIMENTAL|Intravesical OnabotulinumtoxinA|The treatment group will receive 100 units of BOTOX® reconstituted in 10mL of injectable preservative-free normal saline at the time of cystoscopy. An injection cystoscopy needle will be set to 3mm and used to inject 0.5mL reconstituted OnabotulinumtoxinA at each injection site, approximately 1cm apart along the posterior bladder wall, for a total of 20 injection sites (4 rows of 5 injection sites). This will be the only treatment.
62559511|NCT04807920|PLACEBO_COMPARATOR|Placebo|Subjects randomized to the placebo group will undergo the same procedure but will only receive 10mL of injectable preservative-free normal saline. This will be the only treatment.
62559512|NCT02291237|EXPERIMENTAL|Eleclazine|Eleclazine 30 mg single loading dose followed by 3 mg daily maintenance dose up until Week 12, then 6 mg daily maintenance dose from Week 12 at least Week 24, followed by eleclazine 6 mg in an open-label extension period.
61990941|NCT00804518|EXPERIMENTAL|Exercise intervention|
62386893|NCT03558503|EXPERIMENTAL|UGN-102|Patients were treated with 6 once-weekly intravesical instillations of UGN-102.
62386894|NCT04144257|EXPERIMENTAL|Subjects diagnosed with Multiple Sclerosis (MS)|We plan to enroll 12 subjects with multiple sclerosis (6 with relapsing multiple sclerosis and 6 with secondary progressive multiple sclerosis).
61990942|NCT02410382|PLACEBO_COMPARATOR|Arm 1 Placebo|Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to placebo bid for 14 days
61990943|NCT02410382|ACTIVE_COMPARATOR|Arm 2 Dexamethasone|Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to dexamethasone 4 mg bid for 14 days
61990944|NCT03161431|EXPERIMENTAL|Monotherapy: SX-682 dose escalation|Escalating oral doses of SX-682 (study drug) of 25, 50, 100, 200 and 400 mg twice-daily (i.e., 50, 100, 200, 400 and 800 mg total each day.
61990945|NCT03161431|EXPERIMENTAL|Combination therapy: SX-682 dose escalation with pembrolizumab|SX-682 will be administrated at the same dose the participant was administered in monotherapy and will be administered in a 6 week cycle that includes 2 i.v. infusions of pembrolizumab on days 1 and 22 of each cycle, for a total of up to 17 cycles. Once the highest safe dose of SX-682 in combination therapy with pembrolizumab is determined, participants will be enrolled in an expansion phase at that SX-682 dose with pembrolizumab combination therapy.
62559513|NCT02291237|EXPERIMENTAL|Placebo|Placebo to match eleclazine until at least Week 24, followed by active eleclazine 6 mg in an open-label extension period.
62559514|NCT02623725|EXPERIMENTAL|CYD Dengue Vaccine Booster Group|Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).
62559515|NCT02623725|EXPERIMENTAL|Placebo Group|Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).
61990946|NCT01757119|EXPERIMENTAL|Drug|
62559516|NCT01433471|EXPERIMENTAL|Trichuris suis ova followed by placebo|Subjects in this arm will receive Trichuris suis ova for 12 weeks, followed by placebo for 12 weeks after crossover
62559517|NCT01433471|ACTIVE_COMPARATOR|Placebo followed by Trichuris Suis Ova|Subjects in this arm will receive placebo for 12 weeks, followed by Trichuris suis ova for 12 weeks after crossover
62559518|NCT01755533|EXPERIMENTAL|Rural curriculum|Receive rural version of curriculum
62559519|NCT01755533|EXPERIMENTAL|Classic curriculum|Receive classic version of curriculum
62559520|NCT01755533|NO_INTERVENTION|Control|Continue normal prevention activities
62767527|NCT03974412|EXPERIMENTAL|All eligible participants|All eligible participants are randomly assigned to one of two interventions- early Head-Up Tilt Table procedure or early Implantable Loop Recorder. The assignment is random and at a 1:1 ratio between the two strategies.
62767528|NCT04313322|EXPERIMENTAL|WJ-MSCs|"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.~WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
62767529|NCT00724113|ACTIVE_COMPARATOR|1|infiltration intra articular
62386895|NCT06481046|EXPERIMENTAL|Treatment Group|Dual injections of PRP - 4 ml injected into each location. The first injection was into the supraspinatus tendon insertion critical zone and bursal area with the patient seated. The second injection was performed with the patient prone into the glenohumeral intra-articular space under the supraspinatus tendon at, or just proximal to, the superior equator of the humeral head.
62386896|NCT03894111||living patients|living patients in intersivecare unit about 28 days
62386897|NCT03894111||deceased patients|deceased patients in intersivecare unit about 28 days
62767530|NCT00724113|EXPERIMENTAL|2|ARTHRO distension plus intensive mobilisation
62767531|NCT04326686|OTHER|N-of-1 study|For 24 weeks, each participant will measure their blood pressure and respond to questionnaires daily, and visit the institute to provide a blood sample every 4 weeks. The study is split into three 8-week phases, the first of which will start when each participant is enrolled. For the first 8-week observation phase (A1) the participant is instructed to continue with their usual diet and exercise habits. For the second 8-week intervention phase (B), the participant will be provided with wholegrains and nuts and recommended to substitute these in place of refined grains and other snacks, respectively. They will also receive dietary advice for following the Dietary Approaches to Stop Hypertension (DASH) diet. For the final 8 week follow-up period (A2), provision of wholegrains and nuts will cease but the participant will continue with measurements at the same frequency as previously.
62767532|NCT06129110|EXPERIMENTAL|Diet Weight Loss|Low calorie meal replacement shakes
61990947|NCT04650477|ACTIVE_COMPARATOR|Fixated in the EP position|Long head of biceps tenodesis was performed for 25 patients whose joints were fixated while forearm in the extension-pronation (EP) position
62767533|NCT06129110|NO_INTERVENTION|Delayed Intervention|Normal feeding
61990948|NCT04650477|NO_INTERVENTION|Fixated in the neutral position|Long head of biceps tenodesis was performed for 25 patients whose joints were fixated while forearm in the neutral position (elbow 90 degrees flexed and hands positioned with the thump pointing up
61990949|NCT02437955|EXPERIMENTAL|FESO4+T|Ferrous sulfate fortified bread with tea
61990950|NCT02437955|EXPERIMENTAL|FESO4+W|Ferrous sulfate fortified bread with water
62386898|NCT01231620|EXPERIMENTAL|Intravenous (IV) Zanamivir 300mg Twice Daily|300mg of IV zanamivir infusion twice daily plus oral oseltamivir placebo twice daily
62386899|NCT01231620|EXPERIMENTAL|Intravenous (IV) Zanamivir 600mg Twice Daily|600mg of IV zanamivir infusion twice daily plus oral oseltamivir placebo twice daily
62386900|NCT01231620|ACTIVE_COMPARATOR|Oral Oseltamivir 75mg Twice Daily|75mg oral oseltamivir twice daily plus intravenous placebo zanamivir twice daily
61990951|NCT02437955|EXPERIMENTAL|FeFu+T|Ferrous fumarate fortified bread with tea
61990952|NCT02437955|EXPERIMENTAL|FeFu+W|Ferrous fumarate fortified bread with water
61990953|NCT03005821|EXPERIMENTAL|pediatric massage|Patients will receive Montmorillonite Powder and racecadotril granules as usual care according to different age or weight. Intravenous infusion, Oral Rehydration Salts (ORS), Zn,and antibiotics will be used if the pediatrician in charge considers necessary. Patients will receive Chinese pediatric massage once per day and for three days continuously. A cloak which can cover the child's hands and upper body will be required to put on, all the manipulations will be done under the cloak. Six acupoints will be adopted,i.e. Neibagua, Dachang,Xiaochang, Banmen, Fu, Tuishang Qijiegu. Each visit, children who are under 2 years old will receive manipulations on Neibagua for 500 times, 300 times for the other 5 acupoints each; if they are from 2-3 years old, the manipulations on Neibagua will be 700 times and 500 times for the other 5 acupoints respectively; while the manipulations on Neibagua will be 1000 times, and 800 times for the other 5 acupoints if the children are from 4-6 years old.
61990954|NCT03005821|SHAM_COMPARATOR|sham massage|Patients will receive the same usual care as the experimental group. For the sham massage, the therapist will use one hand to hold the childrens' hand or just put one hand on childrens' body and the other hand will do the manipulations on the therapist's own hand instead childrens' hand or childrens' body. Patients will be required to put on the same kind of cloak as that for the the experimental group, all the manipulations will be done under the cloak. The manipulation times for each acupoints will be the same as those for experimental group in accordance with different age. The sham massage will be given once per day for 3 days continuously.
61990955|NCT01586819|ACTIVE_COMPARATOR|Botulinum Toxin|The botulinum toxin will be injected into the wrinkles. The injections will take about 10 minutes to complete. Five follow-up visits will be scheduled at 1-7 days, 7-10 days, 2.5-3 weeks, and 12-14 weeks.
61990956|NCT01586819|ACTIVE_COMPARATOR|Chemical Peel Only|"After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water.~Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly."
62386901|NCT04647682||One single group study|Patients aged 75 years and over Hospitalized in a French COVID-19 geriatric unit Positive COVID-19 infection made by Real-time Polymerase Chain Reaction COVID-19 or suspected on thoracic lesions on computerized tomography.
62386902|NCT03470272|EXPERIMENTAL|Active Device|"Active Device: The FB Professional LED red light therapy system~FB Professional is a treatment regime using the FB Professional device for fat removal using red light therapy.~Intervention device: FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs."
62386903|NCT03901742|ACTIVE_COMPARATOR|Standard Enteral Nutrition|Standard Enteral Nutrition: cow's milk based infant formula (Nidina, Nestlé, Barcelona, Spain).
62386904|NCT03901742|ACTIVE_COMPARATOR|Protein-enriched nutrition|Protein-enriched Enteral Nutrition: polymeric infant formula (Infatrini; Nutricia, Madrid, Spain)
62386905|NCT03901742|ACTIVE_COMPARATOR|High Protein-enriched Nutrition|High Protein-enriched Enteral Nutrition: polymeric infant formula (Infatrini; Nutricia, Madrid, Spain) supplemented with 2.6 g of protein/100 mL of formula. The source of the protein supplement would be a nonhydrolyzed protein cow's milk-based formula (Resource Protein Instant; Nestlé, Barcelona, Spain). Final composition 5.1 g/100 mL.
62386906|NCT05685537||Levosimendan - Interventional|Major patients in heart failure with impaired LVEF (\< 40%) who have undergone left heart surgery (coronary artery bypass grafting and/or mitral and/or aortic valve replacement) under extracorporeal circulation between 01/01/2018 and 28/02/2022 at the Nancy University Hospital or at the University Hospital of Rennes, Rouen or Amiens, and who have received Levosimendan preoperatively
62767534|NCT02559661||Medical students|Students with limited knowledge of the anatomy and pathology of the eye.
62767535|NCT02559661||Ophthalmological trainees|The trainees have never done eye surgery but have a better understanding of the eyes pathology and anatomy than the medical students.
62767536|NCT02559661||Vitreoretinal surgeons|The vitreoretinal surgeons knows the eyes anatomy and pathology well and have training and skills in vitreoretinal surgery.
62767537|NCT04494724|EXPERIMENTAL|Clazakizumab|Clazakizumab - 25mg in 50 milliliters (mL) of 0.9% saline, IV infusion over 30 minutes.
61990957|NCT02711423|EXPERIMENTAL|Part I (Dose Escalation): Gantenerumab|Participants will receive a single SC dose of gantenerumab on Day 1.
62559521|NCT02569879||Infants Group|"* All infants ≤12 months of age in Bogota, reported with pertussis disease in the national databases of Bogota, between January 2005 and December 2014.~* All infants ≤12 months of age in Bogota, deceased between January 2005 and December 2014 due to pertussis disease (primary diagnosis), based on death certificate information.~* All infants ≤12 months of age in Bogota, with ALRTI, between January 2005 and December 2014.~* All infants ≤12 months who have received primary pertussis vaccination in Bogota, between January 2005 and December 2014."
61990958|NCT02711423|PLACEBO_COMPARATOR|Part I (Dose Escalation): Placebo|Participants will receive a single SC dose of matching placebo on Day 1.
61990959|NCT02711423|EXPERIMENTAL|Part II (PK Extension): Gantenerumab|Participants will receive a single SC dose of gantenerumab on Day 1. The dose range will be determined by safety and tolerability data collected from Part I.
62386907|NCT05685537||Non Levosimendan - Control|Major patients in heart failure with impaired LVEF (\< 40%) who have undergone left heart surgery (coronary artery bypass grafting and/or mitral and/or aortic valve replacement) under extracorporeal circulation between 01/01/2018 and 28/02/2022 at the Nancy University Hospital or at the University Hospital of Rennes, Rouen or Amiens, and who have not received Levosimendan preoperatively
62386908|NCT00664729|ACTIVE_COMPARATOR|1|Caloric Restriction
62386909|NCT00664729|EXPERIMENTAL|2|Caloric restriction + Moderate-intensity aerobic exercise
62386910|NCT00664729|EXPERIMENTAL|3|Caloric restriction + Vigorous-intensity aerobic exercise
62386911|NCT03581032||A-Active reprogram follwed by sham|This arm will be randomized to have PACING device reprogramming followed by sham reprogramming
62386912|NCT03581032||B-Sham followed by active reprogram|This arm will be randomized to have sham reprogramming followed by active pacing reprogramming
61990960|NCT06142721||ITW Group|3D gait analysis was applied to children with idiopathic toe walking. Static, kinematic and kinetic walking parameters were evaluated.
61990961|NCT06142721||DCP Group|3D gait analysis was applied to diparetic children who were able to walk independently. Static, kinematic and kinetic walking parameters were evaluated.
61990962|NCT06142721||Healthy Group|3D gait analysis was applied to healthy children. Static, kinematic and kinetic walking parameters were evaluated.
62386913|NCT00591786|EXPERIMENTAL|Sugammadex 0.5 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the second twitch (T2) response to Train-of-four (TOF) stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
62767538|NCT04494724|PLACEBO_COMPARATOR|Placebo|Placebo - 50 mL 0.9% saline, IV infusion over 30 minutes.
61990963|NCT04972019|EXPERIMENTAL|Telerehabilitation experimental group|Experimental training will occur in the home. The experimental training will last 8 weeks, each week having up to 4 sessions of therapeutic game play (based on tolerance). Each session will start with vitals being measured and logged. Data will be uploaded on a secure cloud server to which clinicians will have access.
61990964|NCT04972019|SHAM_COMPARATOR|Telerehabilitation control group|Participants will perform web-based game play while wearing sham equipment. Duration of sessions will be fixed and frequency of sessions will equal that of the experimental group training. Over the total training the control group will have an equal duration of training with the experimental group.
62386914|NCT00591786|EXPERIMENTAL|Sugammadex 1.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
62386915|NCT00591786|EXPERIMENTAL|Sugammadex 2.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
62386916|NCT00591786|EXPERIMENTAL|Sugammadex 4.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
62386917|NCT00591786|EXPERIMENTAL|Sugammadex 8.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.8 mg/kg sugammadex was administered IV.
62386918|NCT00591786|EXPERIMENTAL|Sugammadex 0.5 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
62386919|NCT00591786|EXPERIMENTAL|Sugammadex 1.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
61990965|NCT03929848||female|female patient who is scheduled for laryngomicrosurgery
61990966|NCT03929848||male|male patient who is scheduled for laryngomicrosurgery
61990967|NCT03152539|EXPERIMENTAL|Development of MRI protocols|MRI exam to grade differents interventions for future research
61990968|NCT03152539|EXPERIMENTAL|Development of EEG protocols|EEF exam to grade differents interventions for future research
61990969|NCT03152539|EXPERIMENTAL|Development of NIRS protocols|NIRS exam to grade differents interventions for future research
61990970|NCT04430933|EXPERIMENTAL|NC318 + Pemetrexed/Carboplatin|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with pemetrexed/carboplatin
61990971|NCT04430933|EXPERIMENTAL|NC318 + Nab-paclitaxel/carboplatin|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with Nab-paclitaxel/carboplatin
61990972|NCT04430933|EXPERIMENTAL|NC318 + Docetaxel|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with Docetaxel
62386920|NCT00591786|EXPERIMENTAL|Sugammadex 2.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
62386921|NCT00591786|EXPERIMENTAL|Sugammadex 4.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
61990973|NCT00735878|EXPERIMENTAL|ABT-751 100 mg and Carboplatin|100 mg BID ABT-751 orally for 7 days. Carboplatin AUC 4.5 once every 21 days.
61990974|NCT00735878|EXPERIMENTAL|ABT-751 125 mg and Carboplatin|125 mg BID ABT-751orally for 7 days. Carboplatin AUC 4.5 or 6 once every 21 days.
61990975|NCT00735878|EXPERIMENTAL|ABT-751 150 mg and Carboplatin|150 mg BID ABT-751orally for 7 days. Carboplatin AUC 6 once every 21 days.
61990976|NCT02230865||Surgery|Minimally invasive repair of pectus excavatum
61990977|NCT01206179|EXPERIMENTAL|non union|Patients with nonunion fracture of long bones
61990978|NCT03539835|EXPERIMENTAL|Resistance training|
61990979|NCT03539835|ACTIVE_COMPARATOR|Cognitively-based compassion training|
61990980|NCT03329690|EXPERIMENTAL|Parallel: DS-8201a|Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive DS-8201a once every 3 weeks.
62386922|NCT00591786|EXPERIMENTAL|Sugammadex 8.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
62386923|NCT03832712|ACTIVE_COMPARATOR|Surgical|Participants randomized to surgery
62386924|NCT03832712|ACTIVE_COMPARATOR|Medical|Participants randomized to best medical treatment
62386925|NCT04517825||Target Population|HIV positive individuals attending Bugoye ART clinic
62386926|NCT03124329|EXPERIMENTAL|Coronally Advanced Flap|
62386927|NCT03124329|EXPERIMENTAL|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|
62559522|NCT02569879||Pregnant women Group|• Pregnant women will be included in the study to assess the vaccination coverage of Boostrix from March 2013 to December 2014
62767539|NCT03634267|EXPERIMENTAL|Treatment (MRI, internal radiation therapy)|Participants undergo MRI scan during internal radiation therapy applicator placement.
62386928|NCT03124329|EXPERIMENTAL|Intrasulcular tunneling|
62386929|NCT03124329|EXPERIMENTAL|VISTA + Leukocyte-Platelet Rich Fibrin|
62386930|NCT01266811|EXPERIMENTAL|001|Siltuximab Velcade and dexamethasone Given in 21-day treatment cycles Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle Velcade 1.3 mg/m2 IV push on Days 1 4 8 and 11 for Cycles 1-8 and on Days 1 and 8 for Cycles 9 and higher Dexamethasone 20 mg orally on the day of and the day after each Velcade dose
62386931|NCT01266811|OTHER|002|Placebo Velcade and dexamethasone Given in 21-day treatment cycles Placebo as 1-hour IV infusion on Day 1 of every cycle Velcade 1.3 mg/m2 IV push on Days 1 4 8 and 11 for Cycles 1-8 and on Days 1 and 8 for Cycles 9 and higher Dexamethasone 20 mg orally on the day of and the day after each Velcade dose
62386932|NCT02117362|EXPERIMENTAL|Cohort 1|1 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
62386933|NCT02117362|EXPERIMENTAL|Cohort 2|2 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
62386934|NCT02117362|EXPERIMENTAL|Cohort 3|4 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
62386935|NCT02117362|EXPERIMENTAL|Cohort 4|8 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
62767540|NCT01057056|NO_INTERVENTION|control group|control group - receiving standard treatment
62559523|NCT02026401|EXPERIMENTAL|NGM282 Dose 1|NGM282 Dose 1
62559524|NCT02026401|EXPERIMENTAL|NGM282 Dose 2|NGM282 Dose 2
62767541|NCT01300351|EXPERIMENTAL|Fulvestrant 500mg|Fulvestrant 500mg (2 syringes of Fulvestrant 250mg), Fulvestrant 500 mg i.m. every 28 (+/- 3) days plus an additional 500 mg on day 14 (+/-3) of first month only
62767542|NCT01300351|ACTIVE_COMPARATOR|Fulvestrant 250mg|Fulvestrant 250mg (1 syringe of fulvestrant 250mg + 1 syringe matching placebo), Fulvestrant 250 mg and matching placebo i.m. every 28 (+/- 3) days plus an additional 2 placebo syringes on day 14 (+/-3) of first month only
62767543|NCT00340379|ACTIVE_COMPARATOR|Ziprasidone|Subjects in this arm received ziprasidone with a placebo to maintain the blind
61990981|NCT03329690|ACTIVE_COMPARATOR|Parallel: Physician's Choice|Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive monotherapy prescribed by the physician before enrollment.
61990982|NCT03329690|OTHER|Exploratory: Naïve HER2 IHC 2+/ISH-|A maximum of 20 non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every three weeks.
61990983|NCT03329690|OTHER|Exploratory: Naïve HER2 IHC 1+|A maximum of 20 non-randomized patients with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every 3 weeks.
61990984|NCT03103789||GERD patients|Patients who are undergoing standard of care EGD with or without BRAVO pH capsule placement and have been diagnosed with GERD will have mucosal impedance measured by single catheter and balloon assembly.
61990985|NCT03103789||control|Patients who are undergoing standard of care EGD with or without BRAVO pH capsule placement will have mucosal impedance measured by single catheter and balloon assembly.
62182685|NCT04502836|EXPERIMENTAL|preliminary psychological intervention|Participants in this group will receive a psychological intervention providing knowledge and tools for problems solving one hour prior to the ACTH LRH test.
62559525|NCT02026401|PLACEBO_COMPARATOR|Placebo|Placebo
62559526|NCT03477006|EXPERIMENTAL|LTLR-WB|Receiving 2 units of low titer, leucocyte reduced, platelet replete whole blood initiated in the prehospital setting during air medical transport and continued (up to 6 units of whole blood followed by standard component resuscitation) thru the early in-hospital phase of care
62182686|NCT04502836|NO_INTERVENTION|control group|Participants in this group will not receive any psychological intervention prior to the test.
62386936|NCT04006821|EXPERIMENTAL|PD-1 antibody + Apatinib mesylate|Every patient will receive PD-1 antibody 200mg iv every 2 weeks and apatinib 250mg or 500mg (according to the patient's tolerance) orally every day. PD-1 antibody will be administered until disease progression or lasts for two years. Apatinib mesylate will be administered until disease progression.
62386937|NCT01169233|OTHER|Shorter Wavelength (green)|
62386938|NCT01169233|OTHER|Intermediate Wavelength (white w/ green filter)|
62386939|NCT01169233|OTHER|Longer Wavelength (red)|Placebo
62386940|NCT03464929||Airtraq indirect laryngoscopy|Intubation attempts using Airtraq device.
62386941|NCT03464929||King Vision indirect laryngoscopy|Intubation attempts using King Vision device
62386942|NCT03550040|ACTIVE_COMPARATOR|Robot assisted prostatectomy.|Intervention: radical prostatectomy
62386943|NCT03550040|EXPERIMENTAL|3D laparoscopic prostatectomy|Intervention: radical prostatectomy
62386944|NCT02918006|EXPERIMENTAL|Oral Vaccine (VXA-A1.1)|Oral enteric coated vaccine tablets. Placebo (saline solution) IM injection will also be administered in this arm.
62386945|NCT02918006|ACTIVE_COMPARATOR|QIV IM Injection|A commercially available QIV will be administered at the approved dose level as the active comparator. Oral placebo tablets will also be administered in this arm.
62386946|NCT02918006|PLACEBO_COMPARATOR|Oral and IM Placebo|Two forms or placebos (saline IM injection and oral placebo tablets) will be administered in this arm.
62182687|NCT01861639|EXPERIMENTAL|ineffective rTMS - Active TBS - fMRI|
62182688|NCT01861639|EXPERIMENTAL|Effective rTMS - Active TBS - fMRI|
62559527|NCT03477006|NO_INTERVENTION|Standard Care|Receiving standard prehospital air medical care and standard of care component (1:1:1) trauma resuscitation thru the early in-hospital phase of care
61990986|NCT03462316|EXPERIMENTAL|NY-ESO-1 TCR Specific T cell Therapy|NY-ESO-1 TCR specific T cells are prepared by lentiviral infection. Seven days before TCR-T cell reinfusion, the subjects received low-dose cyclophosphamide (15mg/kg/d x 3 days) and low-dose fludarabine (15mg/m2/d x 3 days) lymphocyte clearance. Four days later, TCR-T cells were transfused back (1 x 109-5 x 1010 was administered once or in stages). Then interleukin (IL)-2 subcutaneous injections (250,000 IU/twice/day) will be subcutaneously administered for 14 days concomitantly to each subject within 15-30 minutes after cell reinfusion. If the first three patients had no severe bone marrow suppression side effects (CTCAE was above grade 3) on low-dose lymphocyte clearance therapy, the dosage of cyclophosphamide (20 mg/kg/d x 3 days) and fludarabine (25 mg/m2/d x 3 days) could be increased for follow-up patients.
61990987|NCT04048642|EXPERIMENTAL|DASH diet; plant-based diet; DASH diet|Food is provided: 7 days of an ad libitum DASH diet, followed immediately by 7 days of an ad libitum whole food, plant based diet, followed immediately by 7 days of an ad libitum DASH diet again.
61990988|NCT04318782|EXPERIMENTAL|Thrombectomy|Pharmacodynamic thrombectomy using AngioJet ™ PE Thrombectomy Catheter
61990989|NCT00754754|EXPERIMENTAL|Brain Retraction Monitoring Sensor|
61990990|NCT01261182|EXPERIMENTAL|In School Feeding|
61990991|NCT01261182|EXPERIMENTAL|Take Home Rations|
61990992|NCT01261182|NO_INTERVENTION|Control|
61990993|NCT04606576|PLACEBO_COMPARATOR|Placebo|Fish Oil
61990994|NCT04606576|EXPERIMENTAL|ORMD-0801 QD|8 mg ORMD-0801 administered QD at night
61990995|NCT04606576|EXPERIMENTAL|ORMD-0801 BID|8 mg ORMD-0801 administered at night and in the morning 45 minutes before breakfast.
61990996|NCT00089570|EXPERIMENTAL|Terlipressin|Terlipressin
61990997|NCT00089570|PLACEBO_COMPARATOR|Placebo|Placebo
62767544|NCT00340379|ACTIVE_COMPARATOR|Sertraline/Haloperidol|Subjects in this arm received a combination of sertraline and haloperidol with a placebo to maintain the blind. Sertraline dosage was 150-200mg/day and haloperidol was 6-8mg/day based on tolerance.
62767545|NCT00969072|EXPERIMENTAL|GI198745|
62767546|NCT02194322|EXPERIMENTAL|BIBN 4096 BS - in single rising doses|
62767547|NCT02194322|PLACEBO_COMPARATOR|Placebo|
61990998|NCT05033639|EXPERIMENTAL|Treatment Group|Other than the Standard Management of preterm infant, treatment group A infants will receive 6 mg tablet dissolved in 5 ml breastmilk via oral gastric tube administered once a day at 10 pm.
61990999|NCT05033639|PLACEBO_COMPARATOR|Control Group|Human breast milk 5ml would be used as the placebo in this study. It would be indistinguishable from the treatment group as this will also be the diluent used.
61991000|NCT01758380|EXPERIMENTAL|Vildagliptin + placebo to Gliclazide|Vildagliptin tablets will be given at 50mg twice daily (bid). Placebo to Gliclazide capsules will be given at an equivalent dose to previous sulfonylurea in multiples of 80mg only (80-320 mg/day). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
61991001|NCT01758380|ACTIVE_COMPARATOR|Gliclazide + placebo to Vildagliptin|Gliclazide capsules will be given in multiples of 80 mg (80-320 mg/day) at a dose equivalent to previous sulfonylurea dose, unless at the investigator's discretion it could be up-titrated to the next available dose (if HbA1c is higher than 7.5%). Placebo to Vildagliptin tablets will be given at 50mg twice daily (bid). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
61991002|NCT02134132|ACTIVE_COMPARATOR|platelet rich plasma|The patients with diabetic foot ulcer who receive PG treatment.
62767548|NCT01737294||Treatment with QUTENZA|Patients with Peripheral Neuropathic Pain
61991003|NCT02134132|PLACEBO_COMPARATOR|Placebo|The patients with diabetic foot ulcer who receive placebo.
61991004|NCT05401955|EXPERIMENTAL|Graft versus host disease Group|
61991005|NCT04818190|NO_INTERVENTION|DIEP reconstruction, no neurotization|DIEP reconstruction No sensory neurotization
61991006|NCT04818190|EXPERIMENTAL|DIEP reconstruction, neurotization|DIEP reconstruction With sensory neurotization
61991007|NCT01360658|EXPERIMENTAL|Intravenous immunoglobulins|Intravenous immunoglobulins
61991008|NCT03365310|EXPERIMENTAL|Intervention Group|Participants will receive turmeric and tulsi capsule with milk(100 ml) along with standard of care treatment as determined by research physician...Each participants has to take two capsules of turmeric formula and tulsi twice daily for the study period of 3 months
61991009|NCT03365310|ACTIVE_COMPARATOR|Standard Care Group|Participants will only receive the standard of care treatment as determined by research physician
61991010|NCT06297174|EXPERIMENTAL|Generic Racecadotril 100 mg Capsules|Generic Racecadotril 100 mg Capsules (test drug)
61991011|NCT06297174|ACTIVE_COMPARATOR|HIDRASEC®|HIDRASEC® (Racecadotril 100 mg Capsules (reference drug))
62767549|NCT01158209||Assessed cohort|Subjects attending out-patient health services for gynaecological examination.
62767550|NCT04366375||TLH+BSO|Total Laparoscopic Hysterectomy + Bilateral Salpingo-Oophorectomy N=20
61991012|NCT04706143||Vaccined group by live attenuated or viral vector or mRNA vaccine|Adults between 25-65 years old
61991013|NCT05301088|EXPERIMENTAL|Chocolate Scent|
61991014|NCT05301088|EXPERIMENTAL|Stress Ball|
61991015|NCT05301088|NO_INTERVENTION|Control|
62767551|NCT04366375||TAH + BSO|Total Abdominal Hysterectomy + BSO N=20
62767552|NCT02022241|EXPERIMENTAL|Repeated GnRHa|Patients were triggered with repeated GnRHa
62767553|NCT04679909|EXPERIMENTAL|Single Low Dose AdCOVID|
62767554|NCT04679909|EXPERIMENTAL|Single Medium Dose AdCOVID|
62767555|NCT04679909|EXPERIMENTAL|Single High Dose AdCOVID|
62386947|NCT05032391|EXPERIMENTAL|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Live attenuated bovine-human \[UK\] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is lyophilized and supplied with 2.5 ml of citrate bicarbonate buffer added for reconstitution before oral administration.
62767556|NCT04679909|EXPERIMENTAL|Two Low Doses AdCOVID|
62767557|NCT04679909|EXPERIMENTAL|Two Medium Doses AdCOVID|
62767558|NCT04679909|EXPERIMENTAL|Two High Doses AdCOVID|
62767559|NCT04679909|PLACEBO_COMPARATOR|Single Dose Placebo|
62767560|NCT04679909|PLACEBO_COMPARATOR|Two Dose Placebo|
62767561|NCT02053662||Bladder Cancer Patients|Patients with muscle invasive bladder cancer. A sample collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
62767562|NCT03606772||supracervical hysterectomy|Patients operated abdominal by removal of uterus, with removal of tubes and ovaries and retaining of cervix
62767563|NCT06279702|EXPERIMENTAL|simulation group|"Students will be asked to perform first aid in the First Aid Training for Injuries Serious Game Simulation Scenario without any first aid training and to fill in the data collection tools integrated into the game. Correct approach training to the injured will be given through First Aid in Injuries Training Serious Game Simulation Scenario CORRECT PRACTICES TRAINING integrated into the serious game. Upon completion of the training, the next step will be free work time. Students will be able to play as many games as they want."
62767564|NCT06279702|EXPERIMENTAL|Comic Group|Students will be given First Aid Training in Injuries, prepared in the form of a comic book.
61991016|NCT01825382|NO_INTERVENTION|Accu-chek Meter|Patients receiving the Accu-chek nano meter for use during the study.
61991017|NCT01825382|EXPERIMENTAL|iBGStar meter interventional Arm|Subjects are given iBGstar meter along with iPhone to use as interventional meter.
62386948|NCT05032391|PLACEBO_COMPARATOR|Diluent is a sterile solution (Citrate Bicarbonate Buffer)|Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
61991018|NCT04093388|EXPERIMENTAL|Self-PAP|Each patient will participate in both arms of the study on the day of the clinical examination. This arm includes the self-administered Papanicolaou (Pap) smear. They will be compared to each other for congruence and accuracy.
61991019|NCT04093388|EXPERIMENTAL|Traditional Pap|Each patient will participate in both arms of the study on the day of the clinical examination. This arm includes the traditional, healthcare provider obtained Papanicolaou (Pap) smear specimen. They will be compared to each other for congruence and accuracy.
61991020|NCT00544258|EXPERIMENTAL|1|Two days consecutive days of application of 0.05% PEP005 Topical Gel to a 100cm2 contiguous AK treatment area of the arm.
61991021|NCT06072651|EXPERIMENTAL|Relative Reinforcing Value|The researchers will enroll 120 children from the long-term observational study, NCT06039878.
61991022|NCT02467556|OTHER|intervention|Open label study with psychological intervention and physiotherapy intervention with medication of morphine, memantine for ten weeks (morphine 30mg tbl per day and memantine up to 40mg tbl per day if tolerated).
62182689|NCT01861639|SHAM_COMPARATOR|ineffective rTMS - Sham TBS - fMRI|
62182690|NCT01861639|SHAM_COMPARATOR|Effective rTMS - Sham TBS - fMRI|
62386949|NCT04022109||Gastric cancer patients undergoing surgery|Patients with histologically confirmed gastric cancer (adenocarcinoma) planned for surgical management
62386950|NCT04022109||Gastric cancer patients|Patients with histologically confirmed gastric cancer (adenocarcinoma)
62386951|NCT04022109||Control group patients without gastric cancer|Patients without gastric malignant disease according to data obtained in upper endoscopy
62767565|NCT06279702|NO_INTERVENTION|other|Training will not be provided within the scope of serious games and with comic books.
62767566|NCT03562793|EXPERIMENTAL|COOPERATE Intervention Arm|Intervention patients will focus on 1) goal clarification/prioritization; 2) communication skills. There are 6 total sessions delivered individually over 12 weeks: 4 sessions teaching skills (30 min each) and 2 booster sessions delivered once/month for the next 2 months. Intervention will be delivered by telephone.
62767567|NCT03562793|NO_INTERVENTION|Attention Control Arm|Veterans randomized to the control group will receive phone calls on the same schedule as intervention Veterans. During these phone calls, study staff will ask Veterans a series of questions about their pain, self-management activities, and any changes they have experienced since the last call. These phone calls are designed to control for attention only, and Veterans will not be offered specific information or advice about their pain or its management (with the exception of suggesting a doctor visit if warranted).
62767568|NCT02411786|EXPERIMENTAL|pTVG-AR biweekly|pTVG-AR (dose: 100 µg) alone without rhGM-CSF. Administered at weeks 0, 2, 4, 6, 8, and 10 (biweekly) for 6 doses, then administered at week 12, week 24, week 36, and week 48 (quarterly) for 4 doses, or 10 total doses.
62767569|NCT02411786|EXPERIMENTAL|pTVG-AR staggered biweekly|pTVG-AR (dose: 100 µg) alone without rhGM-CSF. Administered at weeks 0, 2, 12, 14, 24, 26, 36, 38, 48 and 50 (staggered biweekly schedule) for 10 total doses.
62182691|NCT01861639|EXPERIMENTAL|ineffective rTMS - Active TBS - EEG|
62182692|NCT01861639|EXPERIMENTAL|Effective rTMS - Active TBS - EEG|
62182693|NCT01861639|SHAM_COMPARATOR|ineffective rTMS - Sham TBS - EEG|
62767570|NCT02411786|EXPERIMENTAL|pTVG-AR with rhGM-CSF biweekly|pTVG-AR (dose: 100 µg) with rhGM-CSF (200 µg). Administered at weeks 0, 2, 4, 6, 8, and 10 (biweekly) for 6 doses, then administered at week 12, week 24, week 36, and week 48 (quarterly) for 4 doses, or 10 total doses.
61991023|NCT01889784|OTHER|Individuals with diabetes mellitus (phototherapy 150J)|The intervention of this study is phototherapy through light emitting diode (LED) and dose of 150J each muscle. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscles bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
61991024|NCT01889784|OTHER|Health individuals - 150J (phototherapy 150J)|The intervention of this study is phototherapy through light emitting diode (LED) and dose of 150J each muscle. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscle bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
61991025|NCT01889784|OTHER|Individuals with diabetes mellitus (phototherapy 300J)|The intervention of this study is phototherapy through light emitting diode (LED) with 300J. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surale muscles bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
61991026|NCT01889784|OTHER|Health individuals (phototherapy 300J)|The intervention of this study is phototherapy through light emitting diode (LED). The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscle bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
61991027|NCT04458753|EXPERIMENTAL|Lumbar focused + knee focused exercise group|Will receive strengthening of back , abdominal, and quadriceps muscles, and stretching if calf and Hamstring muscles
61991028|NCT04458753|ACTIVE_COMPARATOR|Knee focused exercise group|Will receive strengthening of quadriceps and stretching of calf and Hamstring muscles
61991029|NCT00299260|ACTIVE_COMPARATOR|vaccine|glycoprotein B plus MF59 adjuvant
61991030|NCT00299260|PLACEBO_COMPARATOR|placebo|normal saline
61991031|NCT04419038|ACTIVE_COMPARATOR|conjunctival autografting with MMC|Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).
61991032|NCT04419038|ACTIVE_COMPARATOR|conjunctival autografting augmented with Ologen implantation|Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.
61991033|NCT05192746|EXPERIMENTAL|"group A Control group"|"Twenty two patients will receive conventional treatment hot pack and exercise (control group).~."
61991034|NCT05192746|EXPERIMENTAL|"group BExtracorporeal shock wave group:"|Twenty two patients will receive Radial Extra corporeal Shock Wave Therapy plus conventional treatment hot pack and exercise.
61991035|NCT05192746|EXPERIMENTAL|"Group CHigh power pain threshold ultrasound group:"|Twenty two patients will receive High-Power Pain Threshold Ultrasound therapy plus conventional treatment hot pack and exercise
61991036|NCT03006913|ACTIVE_COMPARATOR|Randomization to counseling: In-person|Behavioral: Comparing genetic counseling modes.
62559528|NCT01480869|ACTIVE_COMPARATOR|Conventional vitamin D and calcium supplementation|Conventional vitamin D and calcium supplementation with 2 daily OROCAL VITAMINE D3® (500 mg calcium/200 IU cholecalciferol) tablets.
62767571|NCT02411786|EXPERIMENTAL|pTVG-AR with rhGM-CSF staggered biweekly|pTVG-AR (dose: 100 µg) with rhGM-CSF (200 µg). Administered at weeks 0, 2, 12, 14, 24, 26, 36, 38, 48 and 50 (staggered biweekly schedule) for 10 total doses.
61991037|NCT03006913|ACTIVE_COMPARATOR|Randomization to counseling: By phone|Behavioral: Comparing genetic counseling modes.
61991038|NCT03006913|ACTIVE_COMPARATOR|Randomization to counseling: By video|Behavioral: Comparing genetic counseling modes.
62386952|NCT04022109||Average risk population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer
61991039|NCT02487212|ACTIVE_COMPARATOR|Laser+Topical corticosteroid|Hypertrophic scars were treated with fractional Erbium: Yttrium aluminium garnet (YAG) (2,940-nm) laser, then 0.05% Clobetasol propionate ointment was immediately applied on the perforated scar on one side
61991040|NCT02487212|PLACEBO_COMPARATOR|Laser+Petrolatum gel|Hypertrophic scars were treated with fractional Erbium: YAG (2,940-nm) laser, then topical petrolatum gel was immediately applied on the perforated scar on the other side
62386953|NCT04022109||Patients with dyspeptic symptoms|Patients with dyspeptic symptoms or other complains being referred for upper endoscopy (Chile)
62386954|NCT01679964|OTHER|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
62386955|NCT04129138||Observational (survey)|Participants complete a survey over 30 minutes.
62386956|NCT00750360|EXPERIMENTAL|Unprimed, > 6 to < 72 Months|Subjects aged \> 6 months to \< 72 months who were previously not vaccinated against influenza (unprimed).
62386957|NCT00750360|EXPERIMENTAL|Unprimed, ≥ 72 to < 108 Months|Subjects aged ≥ 72 months to \< 108 months who were previously not vaccinated against influenza (unprimed).
62386958|NCT00750360|EXPERIMENTAL|Primed, > 6 to < 72 Months|Subjects aged \> 6 months to \< 72 months who previously received a vaccination against influenza (primed).
62767572|NCT04831099|EXPERIMENTAL|Testosterone|Testosterone gel (20 mg/day) for 8 weeks per period.
62767573|NCT04831099|PLACEBO_COMPARATOR|Placebo|Placebo gel (20 mg/day) for 8 weeks per period.
62767574|NCT04039867|EXPERIMENTAL|Oxaliplatin with Gemcitabine|Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
62767575|NCT00697294|EXPERIMENTAL|Supplement|Subjects will serve as their own control in this single-arm protocol. All subjects will receive 400 IU/day of vitamin D as the intervention. Comparisons will be made between Caucasian and Hispanic infants.
61991041|NCT05053529|EXPERIMENTAL|Mirror therapy|Session consist of total 1hour,20 min of passive mobilization, 30 minutes for Movement mirror therapy,10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
62386959|NCT00750360|EXPERIMENTAL|Primed, ≥ 72 to < 108 Months|Subjects aged ≥ 72 months to \< 108 months who previously received a vaccination against influenza (primed).
62386960|NCT00750360|EXPERIMENTAL|Primed, ≥ 108 to < 216 Months|Subjects aged ≥ 108 months to \< 216 months who previously received a vaccination against influenza (primed).
62386961|NCT00750360|EXPERIMENTAL|Primed, ≥ 216 Months|Subjects aged ≥ 216 months who previously received a vaccination against influenza (primed).
62767576|NCT02986932|EXPERIMENTAL|BBB opening|ExAblate focused ultrasound under MRI-guidance delivered through the intact human skull in conjunction with timed intravenous ultrasound contrast agents (Definity®) to temporarily and focally open the BBB.
61991042|NCT05053529|EXPERIMENTAL|Constrained induced movement therapy (CIMT)|Session consist of total 1hour ,20 min of passive mobilization, 30 min session to CIMT and 10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
61991043|NCT05063110|EXPERIMENTAL|Treatment arm|300 mg of ITACITINIB will be administrated per os every day for 30 days, dose with reduction to 200 mg per safety is allowed if AEs are observed or if co-administered a strong CYP3A inhibitor
61991044|NCT03276689|EXPERIMENTAL|Duloxetine|The patients will take 2 tab/d of duloxetine 60mg for 8 weeks. In the first 7 days dose of duloxetine will be 30mg/day in order to lower side effects and improve compliance. For duloxetine, the morning dose will be a sham pill.
62386962|NCT05610228||LLC|
62386963|NCT01642420||Mild cognitive impairment|Patients diagnosed with mild cognitive impairment
62386964|NCT01642420||Alzheimers disease|Patients diagnosed with mild Alzheimers disease
61991045|NCT03276689|EXPERIMENTAL|Pregabaline|The patients will take 2 tab/d of pregabaline 150mg x 2/day for 8 weeks.The initial 7-days dose of pregabaline will 75mg x 2.
62386965|NCT01642420||Healthy control persons|Age matched healthy persons
62386966|NCT01509066|EXPERIMENTAL|Vegan diet|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask participants to keep foods low in fat and low in glycemic index.
61991046|NCT03276689|EXPERIMENTAL|Placebo|The patients will take 2 tab/d placebo for 8 weeks.
61991047|NCT03666923|EXPERIMENTAL|THR-687 dose level 1|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 1
62386967|NCT01509066|ACTIVE_COMPARATOR|Low-calorie|A low-calorie diet contains all food groups. However, participants will be provided with a calorie goal which should promote weight loss.
62386968|NCT05597592|EXPERIMENTAL|Patients with neuromuscular or neurogenerative disease|
62386969|NCT01008098|EXPERIMENTAL|PTSD group|
62386970|NCT00689611|PLACEBO_COMPARATOR|P|Half of patients will receive placebo for 9 weeks.
62386971|NCT00689611|ACTIVE_COMPARATOR|A|Half of patients will receive bupropion for 9 weeks.
62386972|NCT01066624|ACTIVE_COMPARATOR|0.9% Sodium Chloride irrigation solution|Standard of care for prevention and management of oral mucositis (0.9% Sodium Chloride irrigation solution): Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study.
62767577|NCT04988997|ACTIVE_COMPARATOR|Vurolenatide 50 mg/PBO|50 mg biweekly SC administration, PBO alternate weeks
61991048|NCT03666923|EXPERIMENTAL|THR-687 dose level 2|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 2
61991049|NCT03666923|EXPERIMENTAL|THR-687 dose level 3|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 3
61991050|NCT03379649|EXPERIMENTAL|PRP|Patient with recurrent implantation failure who receives intrauterine infusion of platelet rich plasma
61991051|NCT03379649|PLACEBO_COMPARATOR|Placebo|Patient with recurrent implantation failure who receives intrauterine infusion of embryo culture media
61991052|NCT00827255||Patients who received Restasis®|Patients who received Restasis® (cyclosporine ophthalmic emulsion 0.05%)
61991053|NCT04535791|EXPERIMENTAL|cholecalciferol (Vitamin D)|cholecalciferol 4,000 IU orally daily (1 capsule) for 30 days
61991054|NCT04535791|PLACEBO_COMPARATOR|Starch|Starch 500 mg orally daily (1 capsule) for 30 days
62182694|NCT01861639|SHAM_COMPARATOR|Effective rTMS - Sham TBS - EEG|
62182695|NCT00904683|EXPERIMENTAL|LY2062430|
62386973|NCT01066624|ACTIVE_COMPARATOR|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion. After patients are done with the cryotherapy they will follow the standard of care for prevention and management of oral mucositis until the end of the study.
62386974|NCT01066624|ACTIVE_COMPARATOR|Calcium phosphate (Caphosol) mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
61991055|NCT00988507|EXPERIMENTAL|Ferroquine high dose + artesunate|Ferroquine at 6 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
61991056|NCT00988507|EXPERIMENTAL|Ferroquine medium dose + artesunate|Ferroquine at 4 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
61991057|NCT00988507|EXPERIMENTAL|Ferroquine low dose + artesunate|Ferroquine at 2 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
61991058|NCT00988507|EXPERIMENTAL|Ferroquine alone at medium dose|Ferroquine at 4 mg/kg/d OD alone for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
61991059|NCT02181062|EXPERIMENTAL|Walking Intervention|"1. 4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.~2. The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.~3. Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.~4. The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age."
61991060|NCT02181062|NO_INTERVENTION|Wait-list control|After 3 months, participants will be invited to participate in the intervention. No additional measures or outcomes will be recorded.
61991061|NCT03774277|EXPERIMENTAL|Intervention Communities|Packed Promise for a Healthy Heart intervention, free Tribal Wellness Center membership, a Fitbit, and the AYA culturally based mobile walking app.
61991062|NCT03774277|NO_INTERVENTION|Control Communities|Free Tribal Wellness Center membership, Fitbit, and the AYA culturally based mobile walking app
61991063|NCT01385475|EXPERIMENTAL|Control|
61991064|NCT00644293|EXPERIMENTAL|1|
61991065|NCT00644293|EXPERIMENTAL|2|
61991066|NCT02533336|EXPERIMENTAL|DL+LLINs|DL treated with abamectin and fenpyroximate
61991067|NCT02533336|NO_INTERVENTION|LLINs|LLINs only
61991068|NCT01311193|EXPERIMENTAL|light therapy|Morning bright light treatment (at 8000 lux for 40min, daily during 3 weeks)
61991069|NCT05375552|ACTIVE_COMPARATOR|Active transcranial direct current stimulation|Active transcranial direct current stimulation
61991070|NCT05375552|PLACEBO_COMPARATOR|Placebo transcranial direct current stimulation|Placebo transcranial direct current stimulation
61991071|NCT02867540|EXPERIMENTAL|experimental group|Patient's with Crohn's disease who have had ileocolic resection
61991072|NCT00127712|EXPERIMENTAL|Amiodarone|Amiodarone 1050 mg via continuous intravenous infusion for 24 hours followed by 400 mg orally twice daily for 6 days
61991073|NCT00127712|NO_INTERVENTION|No treatment|Patients in this group receive no intervention
61991074|NCT04073758|SHAM_COMPARATOR|Remifentanil group|In both interventional groups, Sevoflurane is used as an inhalational agent, in 0.5-1.5% age-adjusted Minimal Alveolar Concentration (MAC). As explained above, remifentanil is infused with Target Controlled Infusion pump, and concentration is adjusted so that Bispectral index (BIS) is maintained as 40-60, which means that the patients are maintained in general anesthesia. Remifentanil is usually infused with the effect site concentration of 2.0 to 6.0 ng/ml during general anesthesia. If bradycardia or hypotension develops due to remifentanil infusion, the infusion rate could be reduced, or inotropic, vasopressor, anticholinergic agents can be used (ephedrine, atropine, etc.) to correct the side effects of the drug, or the drug infusion can even be ceased. At the end of the surgery when skin closure starts, remifentanil infusion will be stopped.
61991075|NCT04073758|ACTIVE_COMPARATOR|Dexmedetomidine group|In both interventional groups, Sevoflurane is used as an inhalational agent, in 0.5-1.5% age-adjusted MAC (Minimal Alveolar Concentration). As explained above, dexmedetomidine is infused with syringe pump, and concentration is adjusted so that Bispectral index (BIS) is maintained as 40-60, which means that the patients are maintained in general anesthesia. Dexmedetomidine is loaded for 10 minutes in 1mcg/kg, and then infusion rate is set between 0.4 to 0.6mcg/kg/hour for this study. If bradycardia or hypotension develops due to remifentanil infusion, the infusion rate could be reduced, or inotropic, vasopressor, anticholinergic agents can be used (ephedrine, atropine, etc.) to correct the side effects of the drug, or the drug infusion can even be ceased. At the end of the surgery when skin closure starts, dexmedetomidine infusion will be stopped.
61991076|NCT01983579|EXPERIMENTAL|Anti-VEGF substance|At the first study visit patients receive anti-VEGF injection with the standard substance (comparator) and at the second visit with an alternative anti-VEGF substance.
61991077|NCT01983579|EXPERIMENTAL|Sclerotomy occlusion|In the first session patients receive anti-VEGF injection without occlusion of the injection hole, while in the second session no occlusion is done.
61991078|NCT01983579|EXPERIMENTAL|Injection volume|In the first session patients receive anti-VEGF injection with the standard injection volume, while in the second session they receive anti-VEGF injection with a modified injection volume.
62386975|NCT03436576|ACTIVE_COMPARATOR|Autologous Serum 20%|Treatment with Autologous Serum 20% for 2 months
62386976|NCT03436576|ACTIVE_COMPARATOR|Autologous Serum 50%|Treatment with Autologous Serum 50% for 2 months
62182696|NCT00904683|PLACEBO_COMPARATOR|Placebo|
62182697|NCT00500981|EXPERIMENTAL|Intravenous fluid bolus|Administration of 500 ml of 10% pentastarch
62182698|NCT00530998||1|Group #1 NOTES Appendectomy - Transvaginal approach
62182699|NCT00530998||2|Group #2 NOTES Cholecystectomy - Transvaginal approach
62386977|NCT01297621|EXPERIMENTAL|Breast reduction|Breast hypertrophy women allocated to this arm will undergo reduction mammaplasty
62386978|NCT01297621|OTHER|Control|Patients in this arm will be assessed twice, without surgical intervention
62386979|NCT05486715||65 rheumatoid arthritis patient|Vitamin d effect on rheumatoid arthritis activity on 65 rheumatoid arthritis patients and 65 healthy population
62386980|NCT05486715||65 healthy population|Vitamin d effect on rheumatoid arthritis activity on 65 rheumatoid arthritis patients and 65 healthy population
62767578|NCT04988997|ACTIVE_COMPARATOR|Vurolenatide 100 mg/PBO|100 mg biweekly SC administration, PBO alternate weeks
62767579|NCT04988997|ACTIVE_COMPARATOR|Vurolenatide 50/50 mg|50 mg weekly SC administration
62767580|NCT04988997|PLACEBO_COMPARATOR|Placebo|PBO - weekly SC administration
62767581|NCT03851419||People living with HIV|People living with HIV (ART naive or on ART)
61991079|NCT02948491|EXPERIMENTAL|Music therapy|First. Recording of the voice of the mother singing the song to the child. (To choose this option, the song must be sung to the child during pregnancy at least 2 to 3 times per week. Second. The mother's favorite song, obtained externally. (To choose this option, the mother must bring the song that she that she listened to frequently, at least 5 times per week). Third. Pre-determined lullaby. (This option refers only to the lullaby melody or Brahms lullaby, edited to obtain stable volumes and normalization of the audio, with the effect of progressively appearing and fading for the first and last 10 seconds of the intervention with music therapy, so there are no drastic acoustic changes in the intervention. Audacity editing software will be used.)
62386981|NCT03491501||Industrial employees|Ergonomic evaluation using questionnaires in different Industrial settings will be conducted and thus Industrial employees form the included subject group.
62767582|NCT03851419||People not infected with HIV|HIV-negative people. Each participant is matched for age, sex and location to a study participant living with HIV
62767583|NCT01199276|EXPERIMENTAL|Xenon|60%(1MAC)in oxygen (FiO2 = 0.35-0.45)
62767584|NCT01199276|ACTIVE_COMPARATOR|Sevoflurane|1.1-1.4% (1 MAC) in oxygen (FiO2 = 0.35-0.45) and medical air
62767585|NCT00581451|EXPERIMENTAL|A|bifeprunox 25 day
62767586|NCT00581451|EXPERIMENTAL|B|bifeprunox 14 day
62767587|NCT00581451|EXPERIMENTAL|C|bifeprunox 14 day
62386982|NCT00187148|OTHER|1|
62386983|NCT01597921||Breast cancer patient receiving RT|Total dose:2Gy/Fx
62386984|NCT05399823|EXPERIMENTAL|Self Stretching and Kinesio Taping Group|Kinesio taping in addition to self stretching exercises will be given for 15-20 minutes at home or in the office every day for four weeks.
62386985|NCT05399823|SHAM_COMPARATOR|Self Stretching and Sham Taping Group|Sham kinesio taping in addition to self stretching exercises will be given for 15-20 minutes at home or in the office every day for four weeks.
62386986|NCT05399823|ACTIVE_COMPARATOR|Self Stretching Group|A program consisting of stretching exercises for pectoral, erector spinae, latismus dorsi, multifidus, rhomboid and trapezius muscles will be given for 15-20 minutes at home or in the office every day for four weeks.
62386987|NCT02962973|EXPERIMENTAL|Carmat TAH|The surgical intervention takes place through a midsternotomy utilizing cardiopulmonary bypass. The device is then connected via a percutaneous driveline to an external controller and batteries and takes over the circulation.
62767588|NCT00581451|EXPERIMENTAL|D|bifeprunox 9 day
62767589|NCT03876600|EXPERIMENTAL|conventional hospitalization management.|"The patients who are randomized to have a conventional hospitalization for the pacemaker replacement have conventional management.~In this management patient come to hospital one day before this surgical operation and he is operated next day"
62767590|NCT03876600|ACTIVE_COMPARATOR|ambulatory management|"The patients who are randomized to have a ambulatory surgery for the pacemaker replacement have ambulatory management.~In the ambulatory hospitalization patients come to hospital and have a surgical operation the same day"
62767591|NCT03667846|PLACEBO_COMPARATOR|Placebo|Placebo
62767592|NCT03667846|EXPERIMENTAL|Topiramate|Week 0-1: 25 mg qhs Week 1-2: 25 mg qAM, 25 mg qhs Week 2-3: 25 mg qAM, 50 mg qhs Week 3-4: 50 mg qAM, 50 mg qhs Week 4-5: 50 mg qAM, 75 mg qhs Week 5-6: 75 mg qAM, 75 mg qhs Week 6-7: 75 mg qAM, 100 mg qhs Week 7-8: 100 mg qAM, 100 mg qhs Week 8-10: 100 mg qAM, 100 mg qhs Week 10-12: 100 mg qAM, 100 mg qhs Week 12-14: 2-week taper
62767593|NCT02964832|ACTIVE_COMPARATOR|PocketCPR;Grasp method|Subject grasp a smartphone in the hand and compress the chest of manikin.
62767594|NCT02964832|ACTIVE_COMPARATOR|PocketCPR;Armband-in-hand method|Grab the smartphone-contained-armband in hand when performing chest compression
62767595|NCT02964832|ACTIVE_COMPARATOR|PocketCPR;Armband-on-arm method|Fix the smartphone-contained-armband on upperarm when performing chest compression
62767596|NCT04790487|EXPERIMENTAL|Chlorpheniramine|Chlorpheniramine (CPM)
62767597|NCT04790487|PLACEBO_COMPARATOR|Control|Saline
62767598|NCT01646203|EXPERIMENTAL|IMC-TR1|"Part A - Dose Escalation:~Cohort 1A: 1.25 mg/kg, intravenously (IV), every 2 weeks of the 6-week treatment cycle~Cohorts 1B-9: Dose Escalation from 12.5 mg to 1600 mg (flat dose), intravenously (IV), every 2 weeks of the 6-week treatment cycles~Cohorts 10-12: Dose escalation from 800 mg to 1600 mg (flat dose), intravenously (IV), weekly during the 6-week treatment cycles~Part B - Disease Specific Cohort Expansion:~Participants will be enrolled into each of three tumor-specific cohort expansions. Participants will be treated with recommended Phase 2 dose."
62182700|NCT04696133|EXPERIMENTAL|conventional training|children received fine motor exercises
62767599|NCT01571869|EXPERIMENTAL|1 = Tested product|
62767600|NCT01571869|PLACEBO_COMPARATOR|2 = Control product|
62767601|NCT03792152|EXPERIMENTAL|rivaroxaban|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd(15mg If creatinine clearance is between 30-49 ml/min ).
62767602|NCT03792152|ACTIVE_COMPARATOR|Warfarin|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
62767603|NCT01331096||Anesthetic drugs manually administrated|
62767604|NCT01331096||Automated anesthesia delivery system|
61991080|NCT02948491|NO_INTERVENTION|Without sound emission|"The infant does not receive any sound emission because the baffle will be turned off.~One of the three intervention options are chosen. The parents are told that their child may be randomly assigned to either the therapeutic or control group."
61991081|NCT05735223|EXPERIMENTAL|Stretched flaccid penile length (SFPL) following RALP.|Stretched flaccid penile length (SFPL) was measured by a single male assessor at preoperative visit, and at the time of catheter removal (10 days post-surgery).
61991082|NCT01787175|EXPERIMENTAL|Integrated Medication Manager|Experienced providers that participated in the EHR simulations. Half of the providers were assigned to use the new Integrated Medication Manager (intervention) during the simulation. The other half were assigned the VA's CPRS to use (standard EHR). Providers were randomly assigned which system to use.
61991083|NCT01787175|NO_INTERVENTION|Standard EHR|Experienced providers that participated in the EHR simulations. Half of the providers were assigned to use the new Integrated Medication Manager (intervention) during the simulation. The other half were assigned the VA's CPRS to use (standard EHR). Providers were randomly assigned which system to use.
61991084|NCT02863133|EXPERIMENTAL|Easyx Liquid Embolic|embolization of intracranial malformations and fistulas and brain tumours with Easyx Liquid Embolic
61991085|NCT04950569|EXPERIMENTAL|Levosimendan|Receive standard heart failure treatment, plus levosimendan treatment.
61991086|NCT04950569|NO_INTERVENTION|Control|Receive standard heart failure treatment, without levosimendan treatment.
61991087|NCT00763165|ACTIVE_COMPARATOR|A|
61991088|NCT00763165|PLACEBO_COMPARATOR|B|
61991089|NCT02816060|EXPERIMENTAL|neural tensionner exercise|This group will receive a specific tensionner nerve exercise to provide mechanical stress across the median nerve. This technique have two positions, start and end. It consists on going from one to the other position constantly, controlling the speed of the technique to be constant. In the start position, the subject will be supine lying on a couch with the following parameters: contralateral cervical side bending, shoulder depression, shoulder abduction and external rotation to 90°, elbow flexion to 90º, and forearm supination. In the final position, the therapist will perform full elbow extension while maintaining all the joints previously situated as described above until the patients feel tension, then return to the start position.
61991090|NCT02816060|PLACEBO_COMPARATOR|sham neural tensionner exercise|The control group will receive a sham technique (ST) with minimal mechanical stress across the median nerve. Patients will be placed in neutral cervical spine position with no shoulder depression, shoulder abduction and external rotation to 45°, 45° of elbow extension, and forearm pronation.. This technique will be passively repeated from elbow flexion to extension in the same way than the NTE group
61991091|NCT02098590|EXPERIMENTAL|NF54 CPS-immunization challenged by NF135.C10|Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a heterologous malaria challenge infection by exposure to the bites of 5 NF135.C10 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
61991092|NCT02098590|EXPERIMENTAL|NF54 CPS-immunization challenged by NF166.C8|Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a heterologous malaria challenge infection by exposure to the bites of 5 NF166.C8 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
61991093|NCT02098590|OTHER|NF54 CPS-immunization challenged by NF54|\[Negative control group, to assess effectiveness of CPS-immunization.\] Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a homologous malaria challenge infection by exposure to the bites of 5 NF54 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
61991094|NCT02098590|OTHER|Control group challenged by NF135.C10|\[Control group\] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF135.C10 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
61991095|NCT02098590|OTHER|Control group challenged by NF166.C8|\[Control group\] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF166.C8 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
61991096|NCT02098590|OTHER|Control group challenged by NF54|\[Control group\] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF54 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
62386988|NCT01361724|OTHER|One on one with a PT|The participant will work one-on-one with a trained for PT for 3 days a week for four weeks.
62386989|NCT01361724|OTHER|Group exercise class|The participant will be in a group exercise class. That will meet 3 days a week for 4 weeks.
62386990|NCT01361724|OTHER|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
62386991|NCT04778215|EXPERIMENTAL|Intervention group|progressive, 8 week lumbar stabilizing program
62386992|NCT04778215|NO_INTERVENTION|Control group|Continue as usual
62767605|NCT02914561|EXPERIMENTAL|Cohort A: Filgotinib 200 (mg) (Induction Study)|Biologic naïve and biologic experienced participants received filgotinib 200 milligram (mg) with placebo-to-match (PTM) filgotinib 100 mg tablet orally once daily, for a period of 10 weeks.
61991097|NCT01220479|NO_INTERVENTION|Control Healthy|
61991098|NCT01220479|NO_INTERVENTION|Control Diabetic|
61991099|NCT01220479|EXPERIMENTAL|Exercise Diabetic|
61991100|NCT01220479|EXPERIMENTAL|Exercise Healthy|
61991101|NCT03463564|ACTIVE_COMPARATOR|Insulin pump|Insulin Pump with rapid acting insulin analog lispro
62182701|NCT04696133|EXPERIMENTAL|sensory integration training|Children received designed sensory integration program
61991102|NCT03463564|ACTIVE_COMPARATOR|Insulin injections|Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection at bed-time of basal insulin glargine or degludec
61991103|NCT06400433|ACTIVE_COMPARATOR|5 ml of %5 dextrose|"The physical examination, handgrip strength values, two-point discrimination, pain scoring (numeric rating scale), Q-DASH, BCTQ, CTS-6 scores, and ultrasonographically measured median nerve cross-sectional area values of the patients in this group will be evaluated and recorded by the first physician before the treatment and at the second, fourth, and twelfth weeks. The nerve conduction study will be examined by the second physician before the treatment and at the twelfth week.~Patients in this group will be treated with ultrasound-guided median nerve hydrodissection by in-plane technique with 5 ml of %5 dextrose solution."
61991104|NCT06400433|ACTIVE_COMPARATOR|10 ml of %5 dextrose|"The physical examination, handgrip strength values, two-point discrimination, pain scoring (numeric rating scale), Q-DASH, BCTQ, CTS-6 scores, and ultrasonographically measured median nerve cross-sectional area values of the patients in this group will be evaluated and recorded by the first physician before the treatment and at the second, fourth, and twelfth weeks. The nerve conduction study will be examined by the second physician before the treatment and at the twelfth week.~Patients in this group will be treated with ultrasound-guided median nerve hydrodissection by in-plane technique with 10 ml of %5 dextrose solution."
61991105|NCT06400433|ACTIVE_COMPARATOR|2 ml of 8 mg dexamethasone + 3 ml normal saline|"The physical examination, handgrip strength values, two-point discrimination, pain scoring (numeric rating scale), Q-DASH, BCTQ, CTS-6 scores, and ultrasonographically measured median nerve cross-sectional area values of the patients in this group will be evaluated and recorded by the first physician before the treatment and at the second, fourth, and twelfth weeks. The nerve conduction study will be examined by the second physician before the treatment and at the twelfth week.~Patients in this group will be treated with ultrasound-guided median nerve hydrodissection by in-plane technique with 2 ml of 8 mg dexamethasone + 3 ml %0,9 NaCl solution (normal saline)."
61991106|NCT06400433|ACTIVE_COMPARATOR|2 ml of 8 mg dexamethasone + 8 ml normal saline|"The physical examination, handgrip strength values, two-point discrimination, pain scoring (numeric rating scale), Q-DASH, BCTQ, CTS-6 scores, and ultrasonographically measured median nerve cross-sectional area values of the patients in this group will be evaluated and recorded by the first physician before the treatment and at the second, fourth, and twelfth weeks. The nerve conduction study will be examined by the second physician before the treatment and at the twelfth week.~Patients in this group will be treated with ultrasound-guided median nerve hydrodissection by in-plane technique with 2 ml of 8 mg dexamethasone + 8 ml %0,9 NaCl solution (normal saline)."
61991107|NCT01832025|ACTIVE_COMPARATOR|Internal|internal maxillary sinus floor elevation technique with simultaneous implant placement
61991108|NCT01832025|ACTIVE_COMPARATOR|External|external maxillary sinus floor elevation technique with simultaneous implant placement
61991109|NCT02395796|EXPERIMENTAL|Epidural Pressure Waveform|"Study Population:~* Term pregnancy~* in labour~* 18 years of age or older."
61991110|NCT01430013|EXPERIMENTAL|Endostar|CHOPT chemotherapy plus Endostar
61991111|NCT01478321|EXPERIMENTAL|Treatment (radiation, chemotherapy, monoclonal antibody)|"CONCURRENT THERAPY: Patients undergo hypofractionated radiation therapy 5 days a week beginning on day 0. Patients also receive temozolomide PO QD and bevacizumab IV over 30-90 minutes once every 2 weeks beginning on days -3 to 0. Treatment continues for 5 weeks in the absence of disease progression or unacceptable toxicity.~ADJUVANT THERAPY: Beginning 2 weeks after completion of radiation therapy, patients receive temozolomide PO QD for 6 weeks and bevacizumab IV over 30-90 minutes once every 2 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity."
61991112|NCT05542927||Critically ill Acute kidney injury patients|"AKI is defined as any of the following: Increase in SCr by ≥0.3 mg/dl (≥ 26.5 μmol/l) within 48 hours; OR increase in SCr to≥1.5 times baseline, which is known or presumed to have occurred within prior 7 days; OR Urine volume \<0.5 ml/kg/h for 6 hour)~1. Serum chloride, urinary chloride \& serum creatinine will be requested on the first day of admission in ICU~2. Serum chloride \& urinary chloride will be requested every 48 hours in ICU with correlation between urinary chloride concentrations, AKI \& mortality.~3. Serum creatinine will be requested every 24 hours in ICU.~4. Monitoring of Urinary Output every 24 hours.~5. Daily SOFA score."
61991113|NCT03080259|ACTIVE_COMPARATOR|Stimulant Diversion Prevention|Providers will be trained in methods to prevent or decrease the likelihood of stimulant diversion by their adolescent patients (education and counseling, strategies for use by patients and parents, and treatment adjustments).
61991114|NCT03080259|NO_INTERVENTION|Treatment As Usual|Standard clinical care
61991115|NCT04116138|EXPERIMENTAL|Salovum|Salovum®, an egg powder enriched for anti secretory factor.
61991116|NCT05263700|EXPERIMENTAL|68Ga-FAPI-PET/CT|Patients receive 68Ga-FAPI IV then undergo PET/CT.
61991117|NCT02477995|EXPERIMENTAL|DTaP Vaccine A|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
61991118|NCT02477995|ACTIVE_COMPARATOR|DTaP Vaccine B|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B (Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
61991119|NCT05457374|EXPERIMENTAL|Partial hepatectomy+LVD|
62767606|NCT02914561|EXPERIMENTAL|Cohort A: Filgotinib 100 mg (Induction Study)|Biologic naïve and biologic experienced participants received filgotinib 100 mg with PTM filgotinib 200 mg tablet orally once daily, for a period of 10 weeks.
62767607|NCT02914561|PLACEBO_COMPARATOR|Cohort A: Placebo (Induction Study)|Biologic naïve and biologic experienced participants received PTM filgotinib 200 mg and PTM filgotinib 100 mg tablet orally once daily, for a period of 10 weeks.
62767608|NCT02914561|EXPERIMENTAL|Cohort B: Filgotinib 200 mg (Induction Study)|Biologic experienced participants received filgotinib 200 mg with PTM filgotinib 100 mg tablet orally once daily, for a period of 10 weeks.
62767609|NCT02914561|EXPERIMENTAL|Cohort B: Filgotinib 100 mg (Induction Study)|Biologic experienced participants received filgotinib 100 mg with PTM filgotinib 200 mg tablet orally once daily, for a period of 10 weeks.
61991120|NCT05457374|EXPERIMENTAL|Partial hepatectomy+PVE|
62386993|NCT02825745|OTHER|Betashot|"Children:will take Betashot as a proportion of their daily energy requirements calculated from the dietary information obtained during Visit A for up to 12 weeks.~Adults:will introduce Betashot and increase the amount taken in ml incrementally for up to 12 weeks."
61991121|NCT03608774|EXPERIMENTAL|Arm 1|1 gram of Azithromycin (4 capsules of 250 mg) administered orally as a single dose on Day 1, and Doxycycline placebo (1 capsule) administered orally twice daily for 7 days starting on Day 1. N=123
61991122|NCT03608774|EXPERIMENTAL|Arm 2|100 mg of Doxycycline (1 capsule) administered orally twice daily for 7 days starting on Day 1, and Azithromycin placebo (4 capsules) administered orally as a single dose on Day 1. N=123
61991123|NCT04877938|EXPERIMENTAL|Echological Intervention|A starting point for this 'Ecological-Exercise-Intervention'(EEI), would be to limit sitting time to no more than 2 hours/day, and to stand up and move after 30 minutes of continuous sitting. In accordance with several epidemiologic evidences light-intensity activities would be encouraged to substitute sedentary time (e.g., standing up while talking on the telephone, ironing while watching TV). Taking into consideration the guidance provided by ecologic models of health behavior evidences about specific constructs to guide EEI may be derived from behavioral research on physical activity.
61991124|NCT04877938|ACTIVE_COMPARATOR|Standard Physical Activity Intervention|People included in this group will be assigned to a standard physical activity program that will follow the guidelines of the American College of Sport and Medicine. The program will include moderate intensity aerobic and strength training, three times a week for a total amunt of 200 min of physical activity/week.
61991125|NCT04877938|NO_INTERVENTION|Control group|Individuals included in this group will be asked to keep their life style,without taking part in any physical activity program.
61991126|NCT04000204|EXPERIMENTAL|HYAJOINT Plus|
61991127|NCT04000204|ACTIVE_COMPARATOR|Durolane|
61991128|NCT04908670|ACTIVE_COMPARATOR|PNE group|5 minute video :Understanding Pain in less than 5 minutes, and what to do about it! https://www.youtube.com/watch?v=C_3phB93rvI.
61991129|NCT04908670|ACTIVE_COMPARATOR|Manipulation group|PA grade I-II oscillation on C7, T4 and L4
61991130|NCT03759561|ACTIVE_COMPARATOR|Videolaryngoscope group|In the videolaryngoscope group, tracheal intubation was performed using videolaryngoscope under cervical collar application.
61991131|NCT03759561|ACTIVE_COMPARATOR|Fiberoptic bronchoscope group|In the fiberoptic bronchoscope group, tracheal intubation was performed using fiberoptic bronchoscope via oral cavity under cervical collar application.
61991132|NCT01684371||Blue Dotted Elmore Oil|Patients applied the above oil 3 times daily for four weeks and on the fifth week stopped the application completely for the flush out period before switching to Orange Dotted Elmore Oil
61991133|NCT01684371||Orange Dotted Elmore Oil|Patients give this oil applied it three times daily on the affected knees for four weeks and on the fifth week, stopped the application totally for the flush out period before switching to the Blue Dotted Elmore Oil.
61991134|NCT04130243||Congenital Heart disease|In patients with (a history of) pressure- and/or volume loaded right ventricle due to congenital heart disease extra blood will be withdrawn for a blood test; serumbiomarker
61991135|NCT04130243||Pulmonary Arterial Hypertension|In patients with (a history of) pressure- and/or volume loaded right ventricle due to pulmonary arterial hypertension extra blood will be withdrawn for a blood test; serumbiomarker
61991136|NCT04882527|EXPERIMENTAL|anodal stimulation of the rIFL|Anodal stimulation over the right inferior frontal lobe
61991137|NCT04882527|EXPERIMENTAL|cathodal stimulation of the rIFL|Cathodal stimulation over the right inferior frontal lobe
61991138|NCT04882527|EXPERIMENTAL|anodal stimulation of the lIFL|Anodal stimulation over the left inferior frontal lobe
62386994|NCT05883150|EXPERIMENTAL|Nebulized Midazolam|
62386995|NCT05883150|ACTIVE_COMPARATOR|Intranasal Midazolam|
62767610|NCT02914561|PLACEBO_COMPARATOR|Cohort B: Placebo (Induction Study)|Biologic experienced participants received PTM filgotinib 200 mg with PTM filgotinib 100 mg tablet orally once daily, for a period of 10 weeks.
62767611|NCT02914561|EXPERIMENTAL|Filgotinib 200 mg to Filgotinib 200 mg (Maintenance Study)|Participants who received filgotinib 200 mg in induction study and who achieved either clinical remission by PRO2 or endoscopic response at Week 10 were re-randomized to the maintenance study and received filgotinib 200 mg and PTM filgotinib 100 mg tablet orally once daily, up to Week 58.
61991139|NCT04882527|EXPERIMENTAL|cathodal stimulation of the lIFL|Cathodal stimulation over the left inferior frontal lobe
61991140|NCT04882527|EXPERIMENTAL|anodal stimulation of the rSPL|Anodal stimulation over the right superior parietal lobe
61991141|NCT04882527|EXPERIMENTAL|cathodal stimulation of the rSPL|Cathodal stimulation over the right superior parietal lobe
61991142|NCT04882527|SHAM_COMPARATOR|sham stimulation|Sham stimulation over either of the three real stimulation areas
61991143|NCT03293251||uveitic/ POAG|Outcomes, success rates, complications of trabeculectomy with MMC in Uveitic glaucoma
61991144|NCT03293251||POAG|Outcomes, success rates, complications of trabeculectomy with MMC and I stent in this groups
61991145|NCT03506750|EXPERIMENTAL|IVC-1day|patients with proliferative diabetic retinopathy receiving IVC 1 days before surgery
61991146|NCT03506750|EXPERIMENTAL|IVC-2day|patients with proliferative diabetic retinopathy receiving IVC 2 days before surgery
61991147|NCT03506750|EXPERIMENTAL|IVC-3day|patients with proliferative diabetic retinopathy receiving IVC 3 days before surgery
61991148|NCT03506750|EXPERIMENTAL|IVC-4day|patients with proliferative diabetic retinopathy receiving IVC 4 days before surgery
61991149|NCT03506750|EXPERIMENTAL|IVC-5day|patients with proliferative diabetic retinopathy receiving IVC 5 days before surgery
61991150|NCT03506750|EXPERIMENTAL|IVC-6day|patients with proliferative diabetic retinopathy receiving IVC 6 days before surgery
61991151|NCT03506750|EXPERIMENTAL|IVC-7day|patients with proliferative diabetic retinopathy receiving IVC 7 days before surgery
62767612|NCT02914561|EXPERIMENTAL|Filgotinib 200 mg to Placebo (Maintenance Study)|Participants who received filgotinib 200 mg in induction study and who achieved either clinical remission by PRO2 or endoscopic response at Week 10 were re-randomized to the maintenance study and received PTM filgotinib 100 mg and PTM filgotinib 200 mg tablet orally once daily, up to Week 58.
61991152|NCT03506750|SHAM_COMPARATOR|IVC-sham|patients with proliferative diabetic retinopathy receiving sham IVC
61991153|NCT03506750|PLACEBO_COMPARATOR|non-DR|patients with other retinopathy (idiopathic macular hole or epiretinal membrane)
61991154|NCT05067296||Cesarean section niche and patients with abnormal uterine bleeding|Observation by Tvs
61991155|NCT05067296||Abnormal uterine bleeding in patients without Cesarean section niche|Observation by Tvs
61991156|NCT04680689||Fuse-Heart -SG 01|Study subjects with anatomically significant coronary lesions (at least 50% luminal narrowing) on native coronary arteries.
62386996|NCT04225104|EXPERIMENTAL|Yogic breathing intervention|Participants assigned to this group will complete a 20-minute yogic breathing video at least 5 days per week for 4 weeks. All sessions except the initial yogic breathing session will be completed at home. Participants will complete the first session at Texas State under the supervision of the investigative team for familiarization.
62386997|NCT04225104|NO_INTERVENTION|Control|Participants in the control group will be asked to maintain their current daily activities and will be given access to the yogic breathing video once all follow-up testing has been completed at the end of week 4.
62386998|NCT02779621|EXPERIMENTAL|Self-sampling|(Self-collecting a vaginal sample with a swab for HPV testing) Women in the experimental arm will have the option of vaginal self-sampling for HPV testing, in addition to the routine screening test. They can choose one of them.
62767613|NCT02914561|EXPERIMENTAL|Filgotinib 100 mg to Filgotinib 100 mg (Maintenance Study)|Participants who received filgotinib 100 mg in induction study and who achieved either clinical remission by PRO2 or endoscopic response at Week 10 were re-randomized to the maintenance study and received filgotinib 100 mg and PTM filgotinib 200 mg tablet orally once daily, up to Week 58.
62767614|NCT02914561|EXPERIMENTAL|Filgotinib 100 mg to Placebo (Maintenance Study)|Participants who received filgotinib 100 mg in induction study and who achieved either clinical remission by PRO2 or endoscopic response at Week 10 were re-randomized to the maintenance study and received PTM filgotinib 200 mg and PTM filgotinib 100 mg tablet orally once daily, up to Week 58.
62767615|NCT02914561|PLACEBO_COMPARATOR|Placebo to Placebo (Maintenance Study)|Participants who received placebo in induction study and who achieved either clinical remission by PRO2 or endoscopic response at Week 10 were re-randomized to the maintenance study and received PTM filgotinib 100 mg and PTM filgotinib 200 mg tablet orally once daily, up to Week 58.
62767616|NCT04621500|OTHER|Open label|All enrolled subjects will receive vitamin D3 at 4,000 IU daily for approximately one year.
61991157|NCT04680689||Fuse-Heart -SG 02|Study subjects surviving an acute myocardial infarction, revascularized or not.
61991158|NCT03087968|EXPERIMENTAL|GS-4997 + Prednisolone|"GS-4997 + Prednisolone for 28 days~HepQuant SHUNT Test"
61991159|NCT03087968|PLACEBO_COMPARATOR|Prednisolone + Placebo|"Placebo + Prednisolone for 28 days~HepQuant SHUNT Test"
62386999|NCT02779621|ACTIVE_COMPARATOR|Routine smear|(Collection of cervical sample for routine cervical screening) Women in the control arm will only receive the routine cervical screening invitation letter.
62387000|NCT05528965|EXPERIMENTAL|Perpendicular Group|Perpendicular genicular radiofrequency application
62387001|NCT05528965|ACTIVE_COMPARATOR|Parallel Group|Parallel genicular radiofrequency application
62387002|NCT05608824|EXPERIMENTAL|Musculoskeletal injury|Shear wave elastography and microvascular flow imaging.
61991160|NCT01527279|PLACEBO_COMPARATOR|Placebo|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.
61991161|NCT01527279|EXPERIMENTAL|Antazoline|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.
61991162|NCT04049851|EXPERIMENTAL|Moxidectin|
61991163|NCT04049851|ACTIVE_COMPARATOR|Ivermectin|
61991164|NCT02162342||Rehabilitative intervention|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
61991165|NCT04839159|EXPERIMENTAL|SCD Patient|
61991166|NCT02131402|EXPERIMENTAL|enfilcon A / omafilcon A|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
61991167|NCT02131402|ACTIVE_COMPARATOR|enfilcon A / ocufilcon D|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
61991168|NCT02131402|ACTIVE_COMPARATOR|enfilcon A / methafilcon A|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
61991169|NCT02251795|EXPERIMENTAL|Tipranavir/Ritonavir|500 mg Tipranavir / 200 mg Ritonavir 10 days BID
61991170|NCT02251795|ACTIVE_COMPARATOR|Darunavir/Ritonavir|600 mg Darunavir /100 mg Ritonavir 10 days BID
61991171|NCT02251795|ACTIVE_COMPARATOR|Ritonavir|100 mg Ritonavir 10 days BID
62559529|NCT01480869|EXPERIMENTAL|vitamin D supplementation tailored to vitamin D deficiency|"Conventional calcium supplementation with 2 daily OROCAL 500® (500 mg calcium) tablets to suck + vitamin D3 supplementation (UVÉDOSE®, cholecalciferol, 100 000 IU drinkable solution, 2 ml vial) whose schedule of administration depends on vitamin deficiency level:~* 100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25OHD level \< 10 ng/mL~* 100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25OHD level \< 20 ng/mL~* 100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25OHD level \< 30 ng/mL"
62559530|NCT03035188|EXPERIMENTAL|Vismodegib|Continuous once-daily oral dosing of vismodegib at a dosage of 150 mg per administration
61991172|NCT00860782|EXPERIMENTAL|Annual Parent Intervention (API) Group|Participants in this group will receive the parent educational support intervention once a year for 2 years.
62559531|NCT03523520|ACTIVE_COMPARATOR|Methylnaltrexone oral tablets|"Methylnaltrexone oral tablets (total 450 mg) + subcutaneous water injection~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
62559532|NCT03523520|ACTIVE_COMPARATOR|Methylnaltrexone subcutaneous injection|"Methylnaltrexone 12mg subcutaneous injection + sugar placebo tablet~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
62559533|NCT03523520|ACTIVE_COMPARATOR|Naloxegol oral tablets|"Naloxegol oral tablets (total 25 mg) + subcutaneous water injection~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
62559534|NCT02772133||STEMI patients|
62387003|NCT05947968|EXPERIMENTAL|Group A (Scapular PNF)|"will receive scapular proprioceptive neuromuscular facilitation exercise plus conventional treatment of lateral epicondylitis for 12 sessions (3 sessions per week for four weeks).~The conventional treatment of lateral epicondylitis will be:~1. Pulsed ultrasound over the lateral epicondyle for 5 min.~2. Five minutes of deep friction massage. It will be consisted of deep circular motions using the fingertips over the area of maximal tenderness at the lateral epicondyle.~3. Stretching exercise for extensor carpi radialis longus and brevis for 3 repetitions, each repetition will be 45 seconds with 30 seconds' rest.~4. Strengthening exercise for wrist extensors, eccentric exercise for wrist extensors will be as follow: 3 sets, 10 repetitions, 1 min rest interval between each set."
62559535|NCT02772133||Healthy subjects|
62559536|NCT02772133||Unstable angina|
62559537|NCT02445716|ACTIVE_COMPARATOR|Testosterone 500 mcg / Biolipid B2|"The arm, is part of a randomized, double-blind, placebo-controlled, parallel group trial.~The arm have 35 women. It consists of a 12-week treatment phase involving three study visits and one telephone contact at week 7 of the treatment."
62559538|NCT02445716|PLACEBO_COMPARATOR|Placebo|"The arm, is part of a randomized, double-blind, placebo-controlled, parallel group trial.~The arm have 35 women. It consists of a 4-week screening period plus a 12-week treatment phase involving three study visits and one telephone contact at week 7 of the treatment.~Participants will be attended at the Federal University of São Paulo / Post Graduation Program in São Paulo, Brazil for their study visits."
62559539|NCT06155344||Pregnant women included in the VEGALIM project|Pregnant women consulting CEMAFOER (Center for Maternal and Fetal Pathology Screening and Risk Assessment) of Nantes University Hospital for pregnancy monitoring
62559540|NCT03058627|NO_INTERVENTION|TAVI only|TAVI is performed according to current guidelines and the choice of valve prosthesis is at the operators' discretion.
62559541|NCT03058627|EXPERIMENTAL|TAVI + FFR-guided complete revascularization|TAVI is performed according to current guidelines and the choice of transcatheter heart valve is at the operators' discretion. PCI is performed in any suitable lesion with diameter stenosis \> 90% or FFR ≤ 0.80 in vessels ≥ 2.5 mm in diameter .
61991173|NCT00860782|EXPERIMENTAL|Quarterly Parent Intervention (QPI) Group|Participants in this group will receive the parent educational support intervention quarterly (4 times a year) for 2 years.
62559542|NCT06000657|EXPERIMENTAL|Treatment group|Chronic Hepatitis B patients who pretreated with Entecavir
61991174|NCT02200848|EXPERIMENTAL|Lenalidomide, Ibrutinib, Rituximab|Rituximab on day 1, lenalidomide days 1-21 and ibrutinib continuously for 6 cycles or until disease progression or intolerance to the combination. Single agent ibrutinib will then be continued until disease progression or intolerance.
61991175|NCT04664933|EXPERIMENTAL|Intra-arterial administration of 3-n-butylphthalide|Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min.
61991176|NCT03745092|EXPERIMENTAL|NBO group|Between the two time 30min-EEG recordings, the patients in the NBO group would receive NBO (8L/min, via face mask) for 45min.
61991177|NCT03745092|PLACEBO_COMPARATOR|Control group|Between the two time 30min-EEG recordings, the patients in the control group would have a rest (lying, sitting or walking) for 45min.
61991178|NCT06029699|ACTIVE_COMPARATOR|high flow nasal cannula group|patients put on high flow nasal cannula after extubation
61991179|NCT06029699|ACTIVE_COMPARATOR|non invasive positive pressure ventilation group|patients put on non invasive positive pressure ventilation group after extubation
62559543|NCT06000657|ACTIVE_COMPARATOR|Comparator group|Chronic Hepatitis B patients who pretreated with Entecavir
62559544|NCT05435261||Group I|with a score below 14
62559545|NCT05435261||Group II|with a score above 14
62559546|NCT01184651||Girls|Girls with 21-hydroxylase deficiency (21-OHD) congenital adrenal hyperplasia (CAH) ages 10-13
62559547|NCT01184651||Parents|Parent, guardian, or significant caretaker of girls with CAH
62387004|NCT05947968|EXPERIMENTAL|Group B (Shoulder exercises)|"will receive shoulder strengthening exercise plus conventional treatment of lateral epicondylitis for 12 sessions (3 sessions per week for four weeks).~Same conventional treatment in group (A)"
62559548|NCT04241588||3D prostheses users|Children with unilateral congenital upper-limb reductions
62559549|NCT04241588||Typically Developing Children|Age- and sex-matched control group of typically developing children.
62559550|NCT02409927|OTHER|Healthy participant|Each participant undergo 7 metabolic day, separate by at least 3 days, where they received a different dietary supplement on each day: control (no supplement), MCT oil 10g, MCT oil 20g, MCT oil 30g (provided from pure MCT oil), MCT homogenate 10g, MCT homogenate 20g, MCT homogenate 30g (provided by a 10% MCT homogenate emulsion)
62559551|NCT03398564|PLACEBO_COMPARATOR|Group I (Control)|ultrasound guided Bilateral Erector Spinae Plan Block using isotonic saline
61991180|NCT05452395|EXPERIMENTAL|Post-acute care|comprehensive geriatric assessment, and either home-based or hospital-based post-acute care
61991181|NCT05452395|NO_INTERVENTION|control group|comprehensive geriatric assessment only
61991182|NCT02999256|PLACEBO_COMPARATOR|Placebo|"130ml serving twice daily (immediately before breakfast and dinner) for 20 days.~Placebo composition: Water (100ml), Cherry Squash Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml)."
61991183|NCT02999256|EXPERIMENTAL|Montmorency Tart Cherry Juice|"130ml serving twice daily (immediately before breakfast and dinner) for 20 days.~MTCJ Composition: 100ml water and 30ml Montmorency tart cherry concentrate (Cherry Active, Sunbury, UK)."
61991184|NCT05093296|EXPERIMENTAL|Oxytocin + Naltrexone|"All patients will receive 50mg Naltrexone daily (NTX, oral tablet) in the course of standard in-patient treatment. In the experimental group, patients will receive a single dose of 24 I.U. oxytocin nasal spray at two study visits during in-patient treatment:~* Visit 2 - First Application of Oxytocin 40 minutes prior to a combined stress- and alcohol cue-exposure during visit 2~* Visit 3 - Second Application of Oxytocin 40 minutes prior to an fMRI-based assessment of alcohol cue-reactivity"
61991185|NCT05093296|ACTIVE_COMPARATOR|Placebo + Naltrexone|"All patients will receive 50mg Naltrexone daily (NTX, oral tablet) in the course of standard in-patient treatment. In the comparator group, patients will receive a placebo nasal spray (same composition as the verum oxytocin spray except for the active ingredient oxytocin) at two study visits during in-patient treatment:~* Visit 2 - First Application of Placebo 40 minutes prior to a combined stress- and alcohol cue-exposure during visit 2~* Visit 3 - Second Application of Placebo 40 minutes prior to an fMRI-based assessment of alcohol cue-reactivity"
61991186|NCT02945410|EXPERIMENTAL|Caloric Restriction and High Protein|Participants will be calorie restricted to 30 kcal/kg FFM/day and consume 1.7 g protein/kg BW/day.
61991187|NCT02945410|ACTIVE_COMPARATOR|Caloric Restriction and Normal Protein|Participants will be calorie restricted to 30 kcal/kg FFM/day and consume 0.8 g protein/kg BW/day.
61991188|NCT02945410|PLACEBO_COMPARATOR|Energy Balance|Participants will be in energy balance and consume 1.7 g protein/kg BW/day.
62559552|NCT03398564|ACTIVE_COMPARATOR|Group II (ESP)|ultrasound guided Bilateral Erector Spinae Plan Block with bupivacaine 0.25%
62559553|NCT03398564|ACTIVE_COMPARATOR|Group III(OSTAP)|Ultrasound-guided bilateral oblique subcostal TAP block
61991189|NCT01806896|EXPERIMENTAL|20 mg Arm Cohort A|
62767617|NCT05504668|EXPERIMENTAL|Turmeric Brainwave|Turmeric Brainwaves (now Mind Focus) is a proprietorial herbal supplement from Pukka Herbs which contains (inc. mg daily dose when 2 capsules combined); brahmi (320 mg), gotu kola leaf (144 mg), turmeric whole powder (116 mg), reishi full spectrum (116 mg), rosemary (116 mg), cardamom (88 mg), holy basil (86 mg), turmeric Wholistic™ extract (58 mg), green tea (58 mg) and seagreens (58 mg).
61991190|NCT01806896|PLACEBO_COMPARATOR|Placebo Arm Cohort A|
61991191|NCT01806896|EXPERIMENTAL|5 mg Arm Cohort B|
61991192|NCT01806896|PLACEBO_COMPARATOR|Placebo Arm Cohort B|
62387005|NCT03588234||Type 1 diabetes|Individuals with type 1 diabetes (18-29 years old). They must complete a questionnaire. This group has approximately 26 extra questions to respond to compared to controls. The extra questions pertain to their diabetes history as well as their knowledge regarding diabetes.
62559554|NCT01938638|EXPERIMENTAL|BAY1143572 [continuous]|BAY1143572 will be administered from cycle 1, day 1 (C1D1) onwards once daily continuously
62387006|NCT03588234||Matched controls without Type 1 diabetes|Individuals without type 1 diabetes (18-29 years old). They must complete the same questionnaire as the individuals with diabetes (without the diabetes-specific questions).
62387007|NCT06477432|EXPERIMENTAL|mesofiller® mesotox|The investigated product mesofiller® mesotox was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. Both sessions were conducted within 14-day intervals.
62387008|NCT02545504|EXPERIMENTAL|Andecaliximab|Andecaliximab plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by andecaliximab plus LV+5-FU during subsequent cycles
62387009|NCT02545504|PLACEBO_COMPARATOR|Placebo|Placebo plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by placebo plus LV+5-FU during subsequent cycles
62387010|NCT02238509|EXPERIMENTAL|lapatinib and trastuzumab|ARM A: Lapatinib and trastuzumab (experimental arm). Patients with hormone receptor (HR) positive breast cancer will also receive endocrine therapy at the physician's discretion (preferred choice with fulvestrant).
62559555|NCT01938638|EXPERIMENTAL|BAY1143572 [on/off]|BAY1143572 will be administered from C1D1 in a 3 days on/4 days off schedule
62559556|NCT00226577|EXPERIMENTAL|Pre-Surgery Chemotherapy|
62767618|NCT05504668|PLACEBO_COMPARATOR|Placebo|Magnesium Stearate
61991193|NCT05446883|EXPERIMENTAL|QL1706+chemotherapy± bevacizumab|QL1706 (5 mg/kg) + paclitaxel (175 mg/m2) + cisplatin (50 mg/m2)/carboplatin (AUC 5) ± bevacizumab (15 mg/kg)
61991194|NCT05446883|PLACEBO_COMPARATOR|Placebo+chemotherapy± bevacizumab|Placebo + paclitaxel (175 mg/m2) + cisplatin (50 mg/m2)/carboplatin (AUC 5) ± bevacizumab (15 mg/kg)
61991195|NCT02407769|EXPERIMENTAL|Branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during the late evening (after 19:00 hours) daily by two months.
61991196|NCT02407769|SHAM_COMPARATOR|Late evening snack|The patients will eat a snack with similar nutrimental facts that food supplement (480 Kcal, 19g of proteins and they were based in casein and vegetable proteins; 17g of lipids and 63g of carbohydrates) during the late evening (after 19:00 hours) daily by two months.
61991197|NCT04173026|ACTIVE_COMPARATOR|Provider intervention|A web-based application called ProviderMinder has been developed and will be used to alert providers when a patient who has been lost-to-follow-up or has missed their Sickle Stroke Screen (TCD). This will allow providers to follow up with such patients and improve screening rates.
62387011|NCT02238509|EXPERIMENTAL|trastuzumab plus chemotherapy|ARM B: Trastuzumab plus chemotherapy (control arm). Any type of chemotherapy in combination with trastuzumab will be allowed at the physician's discretion.
62387012|NCT05199285|EXPERIMENTAL|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62559557|NCT03236090|ACTIVE_COMPARATOR|Outpatients with refractory ascites|20 consecutive outpatients with cirrhosis and refractory ascites Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
62182702|NCT05700578|EXPERIMENTAL|Safety Behavior Elimination for Traumatic Stress (SBETS)|Web-Based Safety Behavior Elimination for Traumatic Stress Intervention. (1) 30-minute session focused on providing psychoeducation about the nature of posttraumatic stress disorder (PTSD), how trauma-related safety behavior use worsens PTSD, and strategies to reduce or eliminate safety behavior use
62387013|NCT00515866|EXPERIMENTAL|1|Gemcitabine + KU-0059436
62387014|NCT02791841|EXPERIMENTAL|RRT|Rhythmic Reading Training, administered for 13 hours over 9 days (two 45-minute training sessions per day).
62559558|NCT03236090|ACTIVE_COMPARATOR|Patients hospitalized because bacterial infection|30 consecutive patients with cirrhosis and bacterial infections. All patients will receive endovenous antibiotics and, only in the case of patients with SBP, also intravenous albumin Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
62767619|NCT01046240|ACTIVE_COMPARATOR|Intravenous palonosetron|Intravenous palonosetron: control arm (standard treatment)
62387015|NCT02791841|EXPERIMENTAL|VHSS+AVG|Visual Hemispheric-Specific Stimulation + Action Video Games, administered for 13 hours over 9 days (two 45-minute training sessions per day).
62387016|NCT02791841|EXPERIMENTAL|AVG|Action Video Games only, administered for 13 hours over 9 days (two 45-minute training sessions per day).
62387017|NCT04555993|ACTIVE_COMPARATOR|Transversus abdomis plane block|Patients will receive Transversus abdomis plane block
62387018|NCT04555993|EXPERIMENTAL|Erector spinae plane block|Patients will receive Erector spinae plane block.
62387019|NCT03985358|NO_INTERVENTION|Control Group|Patients randomized to the Control Group will not receive opioid counseling and will only receive their standard of care instructions for preoperative and postoperative care.
62387020|NCT03985358|EXPERIMENTAL|Treatment Group|Patients randomized to the Treatment Group will have opioid counseling plus standard of care instructions given by the same counselor (investigator on the study) using the same counseling script at the randomization visit as well as at the visit where they come in for pre-admission testing prior to surgery (as a refresher).
62559559|NCT03295292|SHAM_COMPARATOR|Standard Surgery with Vehicle|After the standard surgical procedure (PRK/PTK or CXL), patients will receive 50uL Fibrin Sealant (sham) without cells.
62559560|NCT03295292|EXPERIMENTAL|Standard Surgery with Stem Cells|After the standard surgical procedure (PRK/PTK or CXL), patients will receive 50uL of a mixture of limbus derived corneal epithelial cells and limbus derived corneal stromal cells in a ratio of 2:1, at a concentration of 50000 cells/uL diluted in the thrombin component of Fibrin Sealant (TISEEL, Baxter).
62182703|NCT05700578|ACTIVE_COMPARATOR|Modifiable Behavior Intervention (MoBI)|Web-Based Modifiable Behavior Intervention. (1) 30-minute session focused on providing psychoeducation about strategies to maintain one's physical and mental health, such as by exercising, maintaining a healthy diet, and managing stress.
62387021|NCT00996385|EXPERIMENTAL|Velcade plus Eloxatin|Six 20-day cycles
62559561|NCT05554601|NO_INTERVENTION|attention control|participants receive a FitBit and set goals but do no other intervention
62387022|NCT04422951|EXPERIMENTAL|Wise interventions plus behavioral Rx|Wise social psychological interventions (growth mindset and values self-affirmation) plus a usual care behavioral intervention for weight control.
62387023|NCT04422951|ACTIVE_COMPARATOR|Education plus behavioral Rx|Health education plus a usual care behavioral intervention for weight control
62387024|NCT02172326|EXPERIMENTAL|Tiotropium inhalation capsules|
62387025|NCT06227689|EXPERIMENTAL|HPV Chatbot Intervention group|In this arm, participants will receive a vaccine chatbot intervention. They will be invited to use the HPV vaccine chatbot online through WeChat or any web browsers, where they can ask any questions related to the HPV vaccine and get immediate answers from the chatbot. The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention.
62387026|NCT06227689|NO_INTERVENTION|Control group|The control group will not use the chatbot during the intervention duration.
62387027|NCT02449694|EXPERIMENTAL|OCS Liver|OCS Liver will be used to preserve the donor liver
62767620|NCT01046240|EXPERIMENTAL|subcutaneous palonosetron|subcutaneous palonosetron
62767621|NCT01510171|ACTIVE_COMPARATOR|Prasugrel loading dose|
62767622|NCT01510171|ACTIVE_COMPARATOR|Ticagrelor Loading dose|
62767623|NCT02042534|EXPERIMENTAL|Rivaroxaban|Rivaroxaban group for 1 month : initial 5 days after randomization rivaroxaban 10mg QD will be administered. Rivaroxaban 20mg QD, but 15mg in case of Cr CL will be administered for remaining 25 days.
62387028|NCT02223533|EXPERIMENTAL|Wound catheter|analgesia with wound catheter after colon surgery
61991198|NCT04173026|ACTIVE_COMPARATOR|Provider and Patient level intervention|A web-based application called ProviderMinder has been developed and will be used to alert providers when a patient who has been lost-to-follow-up or has missed their Sickle Stroke Screen (TCD). This will allow providers to follow up with such patients and improve screening rates. Additionally, sites will have a patient intervention of a single Sickle Stroke Screen coordinator who will interact directly with patients to schedule, reschedule, remind, and follow-up on stroke screening. This person will also act as a point of contact for any educational needs the patient may have. The second patient intervention will include the caregivers own mobile device. When Sickle Stroke Screens are scheduled the coordinator will ensure these appointments are directly put into the caregiver's mobile device calendar acting as an additional reminder for stroke screening.
62182704|NCT01709955|EXPERIMENTAL|Gucomannan|
62182705|NCT01709955|PLACEBO_COMPARATOR|Placebo pill|
62182706|NCT01419977|PLACEBO_COMPARATOR|Placebo|Normal saline solution
62387029|NCT02223533|ACTIVE_COMPARATOR|morphine|analgesia with morphine after colon surgery
62387030|NCT03289676|EXPERIMENTAL|Quitting Smoking Video|This arm will receive a storytelling narrative intervention by watching a video of women living with HIV taking about their success in quitting smoking.
62387031|NCT03289676|ACTIVE_COMPARATOR|HIV Infection Video|This arm will watch an attention-control storytelling narrative intervention by watching a video of women living with HIV taking about their life after the diagnosis of HIV.
62387032|NCT04250142|ACTIVE_COMPARATOR|Conventional Glass Ionomer|Selective removal of carious tissue to soft dentin. Deep carious dentin will be lined by a conventional glass ionomer, followed by a composite resin restoration.
61991199|NCT03779711|EXPERIMENTAL|Treatment|Autologous (self) mononuclear cells derived from umbilical cord blood and that meet all release criteria are injected into the surface of the right heart muscle to achieve the target dose of 1-3 million cells per kilogram body weight . This is a one time treatment at the time of Stage II Glenn surgery .
61991200|NCT03779711|ACTIVE_COMPARATOR|Control|Clinical data will be collected before, during and after the Stage II surgical standard of care procedure. Requires additional imaging studies at 3 months that are not standard of care in addition to some blood tests that would be beyond standard of care. Information will be collected to document the clinical outcomes and will be compared with the information from the group receiving the investigational treatment used in this study.
61991201|NCT01566955|EXPERIMENTAL|transgastric adnexectomy|patients are operated transgastric
61991202|NCT01528072|EXPERIMENTAL|Dynesys System|All patients will receive the Dynesys System and all patients will be compared to historical literature control. Dynesys Spinal System will be used for all subjects.
61991203|NCT03022760|ACTIVE_COMPARATOR|Work-related measures|"* One-day training for GP:s and rehabilitation coordinators~* A treatment protocol which includes contact with the patient's employer~* Clinical support from the Institute of Stress Medicine"
61991204|NCT03022760|NO_INTERVENTION|Treatment as usual|
61991205|NCT00086749||Tamoxifen group|
62387033|NCT04250142|EXPERIMENTAL|Self-etching Adhesive|Selective removal of carious tissue to soft dentin. Deep carious dentin will not be lined and a self-etching adhesive will cover the tissue, followed by a composite resin restoration.
62387034|NCT00391443|EXPERIMENTAL|Bosentan|Subjects receive bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg b.i.d (if body weight \> 40 kg) or bosentan 62.5 mg b.i.d. (if body weight \< 40 kg)
62387035|NCT00391443|PLACEBO_COMPARATOR|Placebo|Subjects receive placebo matching the bosentan treatment regimen
62387036|NCT00579527|EXPERIMENTAL|Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression|Patients with complete DiGeorge Anomaly (cDGA) undergo cultured thymus tissue implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function.
62387037|NCT00579527|EXPERIMENTAL|CTTI with Parathyroid Transplantation w/immunosuppression|Patients with complete DiGeorge Anomaly (cDGA) undergoes cultured thymus tissue thymus implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function. If the patient has hypoparathyroidism, and is eligible, the patient may also receive a parathyroid transplant.
62387038|NCT02862990||Pre menopausal women with breast cancer|Pre menopausal women with breast cancer prior treatment in face of infertility evoked by chemotherapy
62559562|NCT05554601|EXPERIMENTAL|gamification with collaboration|participants receive a FitBit and set goals, then are assigned to a group of other participants who will play a game to gain points based on collaboration with each other
61991206|NCT04988256|ACTIVE_COMPARATOR|Cyclosporine|"All Patients start with 5 mg/kg/day (3 mg/kg/day if renal impairment) PO divided bid for 7 days (or IV if patient is NPO)~1. If complete resolution, stop cyclosporine and monitor closely for relapse~   a. If patient relapses, give 5 (3 if renal impairment) mg/kg/day PO divided bid PO for 7 days~   i. If down-trending, start oral taper regimen~   ii. If not down-trending, switch to steroid arm~2. If \>25% improvement and labs are down-trending, start the oral taper regimen.~3. If 0-25% improvement, give 5 (3 if renal impairment) mg/kg/day PO divided bid for 3 days~   1. If down-trending, start oral taper regimen~  2. If not down-trending, switch to steroid arm~4. If no improvement or up-trending labs at 7 days, switch to steroid arm~Oral Taper Regimen set as 3 mg/kg PO divided bid for 14 days, then 2 mg/kg PO divided bid for 20 days. If renal impairment, oral taper regimen set as 2 mg/kg PO divided bid for 14 days, then 1 mg/kg PO divided bid for 20 days"
61991207|NCT04988256|EXPERIMENTAL|Corticosteroids|"All Patients start with 500 mg IV Methylprednisolone for 3 days~1. If \>25% improvement (must be \>25% in all involved organs), start the taper regimen 2. If 0-25% improvement (in ≥1 involved internal organ), give 500 mg IV Methylprednisolone for 4 days~1. If no improvement, switch to cyclosporine arm of treatment~2. If 0-25% improvement, give 500 mg IV Methylprednisolone for 3 days~i. If labs are down-trending, start the taper regimen~ii. If labs are not down-trending, switch to cyclosporine arm of the study~c. If \>25% improvement, start the taper regimen~Taper Regimen set as:~1. 125 mg IV Methylprednisolone x3 days~2. 1.2 mg/kg PO prednisone x1 week~3. 1 mg/kg PO prednisone x1 week~4. 0.8 mg/kg PO prednisone x1 week~5. 0.6 mg/kg PO prednisone x1 week~6. 0.4 mg/kg PO prednisone x1 week~7. 0.2 mg/kg PO prednisone x1 week~8. 0.1 mg/kg PO prednisone x1 week~9. 0.05 mg/kg PO prednisone x1 week"
61991208|NCT04390594|NO_INTERVENTION|Standard of Care|The Standard of Care is the treatment which is the most adapted to the patient in the clinician's opinion. It could include the combination of Hydroxychloroquine and Azithromycin in the absence of contraindication.
61991209|NCT04390594|EXPERIMENTAL|Standard of Care + Nafamostat mesilate|"* The Standard of Care is the treatment which is the most adapted to the patient in the clinician's opinion. It could include the combination of Hydroxychloroquine and Azithromycin in the absence of contraindication.~* Nafamostat mesilate"
62387039|NCT02961049|ACTIVE_COMPARATOR|Retraction and total-etch|Gingival displacement with a gingival cord (#0, #00 or #000) prior to the restoration. Application of total-etch adhesive system: enamel and dentin etched with 35% phosphoric acid, wash, dry, two layers of primer/bond application with a brush and photoactivated for 20 seconds.
62387040|NCT02961049|ACTIVE_COMPARATOR|No retraction and total-etch|Application of total-etch adhesive system: enamel and dentin etched with 35% phosphoric acid, wash, dry, two layers of primer/bond application with a brush and photoactivated for 20 seconds.
62559563|NCT05554601|EXPERIMENTAL|gamification with competition|participants receive a FitBit and set goals, then are assigned to a group of other participants who will play a game to gain points based on competition with each other
62559564|NCT03433573|EXPERIMENTAL|Intervention|Abbott Sensor Based Glucose Monitoring System
62559565|NCT03657797|EXPERIMENTAL|NCX 470 0.021%|NCX 470 Ophthalmic Solution, 0.021% dosed once daily for 4 weeks
62559566|NCT03657797|EXPERIMENTAL|NCX 470 0.042%|NCX 470 Ophthalmic Solution, 0.042% dosed once daily for 4 weeks
62559567|NCT03657797|EXPERIMENTAL|NCX 470 0.065%|NCX 470 Ophthalmic Solution, 0.065% dosed once daily for 4 weeks
62559568|NCT03657797|ACTIVE_COMPARATOR|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily for 4 weeks
62559569|NCT06206304||Light-eyed females|Blue-green colors were categorized as light
61991210|NCT04944901|EXPERIMENTAL|SB-121|"One dose of SB-121 daily for 28 days according to the treatment group to which they are allocated.~Administration: Oral"
62387041|NCT02961049|ACTIVE_COMPARATOR|Retraction and self-conditioning|Gingival displacement with a gingival cord (#0, #00 or #000) prior to the restoration. Application of self-conditioning adhesive system: selective enamel etched with 35% phosphoric acid, wash, dry, one layer of acid/pirmer on enamel and dentin with a brush, one layer of bond with a brush and photoactivated for 20 seconds.
62387042|NCT02961049|ACTIVE_COMPARATOR|No retraction and self-conditioning|Application of self-conditioning adhesive system: selective enamel etched with 35% phosphoric acid, wash, dry, one layer of acid/pirmer on enamel and dentin with a brush, one layer of bond with a brush and photoactivated for 20 seconds.
62387043|NCT03040063|EXPERIMENTAL|Combined endovascular approach|Combined endovascular approach using covered stent and flexible stent in the popliteal artery
62387044|NCT03040063|EXPERIMENTAL|Standard optimal therapy (OPT)|standard therapy of popliteal artery aneurysm using thrombolysis and surgery
62387045|NCT04126629||Normotensive Group|Subject will be allocated to the experimental group based on the clinical characteristics of their blood pressure. This will be the normotensive group. Every attempt will be made to stratify both groups equally between second and third trimesters.
62387046|NCT04126629||Hypertensive Group|Subject will be allocated to the experimental group based on the clinical characteristics of their blood pressure. This will be the hypertensive group.Every attempt will be made to stratify both groups equally between second and third trimesters.
62387047|NCT03984916|ACTIVE_COMPARATOR|Hesperidin Pharma|500 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R. The approximate particle size is less than 100 µm for the 90% of the extract, and of 10 µm for 10% of the extract.
62387048|NCT03984916|ACTIVE_COMPARATOR|Hesperidin Pharma_M|500 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R. The size of 90% of particles is less than 10 µm.
62387049|NCT03984916|EXPERIMENTAL|Cardiose|500 mg of sweet orange extract with more than 90% of the isomer -S. The size of the 90% of particles is less than 10 µm.
62387050|NCT03243981|EXPERIMENTAL|Open label study-- single arm|All patients will receive Skintyte treatment as well as Skintyte plus broadband light
62387051|NCT03347461|EXPERIMENTAL|Otiprio by surgeon|Otiprio will be administered through the tympanic membrane by the otolaryngologist immediately after tympanostomy placement.
62387052|NCT03347461|ACTIVE_COMPARATOR|Ciprodex by surgeon|Ciprodex drops will be instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery.
62387053|NCT03347461|ACTIVE_COMPARATOR|Ciprodex by surgeon and parent|Ciprodex drops will be instilled by the otolaryngologist into the ear immediately after tympanostomy tube surgery. The parent or guardian will administer Ciprodex drops into the ears twice daily for five days after surgery.
62387054|NCT05931575|EXPERIMENTAL|intervention arm (low dose)|oral Fasudil solution 88 mg/day (2 x 44 mg)
62387055|NCT05931575|EXPERIMENTAL|intervention arm (high dose)|oral Fasudil solution 44 mg/day (2 x 22 mg)
62387056|NCT05931575|PLACEBO_COMPARATOR|Control intervention arm (placebo)|oral placebo solution 2x/day.
61991211|NCT04944901|PLACEBO_COMPARATOR|Placebo|"One dose of placebo daily for 28 days according to the treatment group to which they are allocated.~Administration: Oral"
62387057|NCT04421105|EXPERIMENTAL|Group 1 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
62387058|NCT04421105|EXPERIMENTAL|Group 2 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
62387059|NCT04421105|EXPERIMENTAL|Group 3 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
62387060|NCT04421105|PLACEBO_COMPARATOR|Group 4 N=12|6 doses 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
62387061|NCT01421693|ACTIVE_COMPARATOR|Gatifloxacin|Gatifloxacin 10mg/kg/day for 7 days
62387062|NCT01421693|ACTIVE_COMPARATOR|Ceftriaxone|"* ≥2-\<14 years - 60mg/kg/ once daily for 7 days~* 14 years and older - 2g once daily for 7 days"
62387063|NCT01808027||Acute myocardial infarction|patient with suspected acute coronary syndrome (ACS).
62387064|NCT00999882|EXPERIMENTAL|AZD8055|Dose escalation
62387065|NCT05299112|NO_INTERVENTION|Standard parenteral nutrition|These infants will form the control group and will receive standard parenteral nutrition. They will be sub-stratified into infants \<27 weeks and infants \>27 weeks gestation.
62387066|NCT05299112|EXPERIMENTAL|Arginine supplementation|These infants will form the intervention group and will receive parenteral nutrition with additional arginine (18% of amino acid) for up to 14 days of life. They will be sub-stratified into infants \<27 weeks and infants \>27 weeks gestation.
62387067|NCT03726099|EXPERIMENTAL|14d concomitant therapy|Patients will receive a 14-day concomitant therapy containing esomeprazole, amoxicillin, tetracycline and furazolidone.
61991212|NCT06312878||Included patients|All patients with interrupted IVC with azygous continuation on CT scan.
61991213|NCT02078154||Deep Venous Thrombosis (DVT)|DVT diagnosed by imaging technique with a low or moderate Wells score
61991214|NCT04327999|EXPERIMENTAL|Preservative free artificial tears|Day 1, patients will self-administer artificial tears every 15 minutes for 2 hours followed by every 30 minutes for at least 4 hours or until bedtime at night. On Day 2, patients will self-administer artificial tears every 1 hour for 12 hours. On Day 3, patients will self-administer artificial tears four times that day. On Day 4, patients will self-administer tears twice that day. Patients will be instructed to wear their contact lenses throughout their waking hours.
62182707|NCT01419977|EXPERIMENTAL|Dalteparin|5000 unites subcutaneously, Other Name: Fragmin
62387068|NCT04918524||The Antiphospholipid syndrome (APS)|The cohort includes that patients who meet the proposed Sydney criteria.
62387069|NCT04918524||Undifferentiated connective tissue disease (UCTD)|The cohort includes the patients who are diagnosed with UCTD: at least one presence of auto-antibodies, including antinuclear antibody (ANA), anti-extractable nuclear antigen (ENA) antibodies, anti-doublestranded DNA (ds-DNA) antibody, antiphospholipid antibodies (aPL), and non-criteria aPL (NC-aPL), with at least one symptoms or signs suggesting CTD ,while not fulfilling any classification criteria of a defined CTD.
61991215|NCT00006478|EXPERIMENTAL|Effectiveness of Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation|"Phase II trial to study the effectiveness, safety \& toxicity of vaccine therapy following chemotherapy and peripheral stem cell transplantation in treating patients who have non-Hodgkin's lymphoma.~Vaccinations begin at day 100 or up to 6 months after hematopoietic stem cell transplantation. Participants receive autologous lymphoma-derived idiotype vaccine plus keyhole limpet hemocyanin subcutaneously (SC) on day 1. Sargramostim (GM-CSF) SC is administered on days 1-4. Treatment repeats every 4 weeks for 4 doses, followed 12 weeks later by the fifth and final dose."
61991216|NCT00312494|PLACEBO_COMPARATOR|Placebo|
61991217|NCT00312494|EXPERIMENTAL|Ziprasidone 20-40mg twice a day (BID)|
61991218|NCT00312494|EXPERIMENTAL|Ziprasidone 60-80mg BID|
62387070|NCT02412826||Acute pancreatitis|Patients presenting to the hospital with acute pancreatitis that will receive AbStats sensor
62387071|NCT01797042|ACTIVE_COMPARATOR|Fructose 9%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
61991219|NCT05826899|ACTIVE_COMPARATOR|oat protein-based iron delivery system1|Each subject will complete the six iron absorption studies in which they will receive supplemental iron doses of 4 mg iron from the six products: (i) Fe-oat 1 alone, (ii) Fe-oat 1 with 30 mL acai puree with honey, (iii) Fe-oat 2 alone, (iv) Fe-oat 2 with 30 mL acai puree with honey, (v) FeSO4 alone, (vi) FeSO4 with 30 mL acai puree and honey.
61991220|NCT05826899|ACTIVE_COMPARATOR|oat protein-based iron delivery system2|Each subject will complete the six iron absorption studies in which they will receive supplemental iron doses of 4 mg iron from the six products: (i) Fe-oat 1 alone, (ii) Fe-oat 1 with 30 mL acai puree with honey, (iii) Fe-oat 2 alone, (iv) Fe-oat 2 with 30 mL acai puree with honey, (v) FeSO4 alone, (vi) FeSO4 with 30 mL acai puree and honey.
61991221|NCT05826899|ACTIVE_COMPARATOR|oat protein-based iron delivery system3|Each subject will complete the six iron absorption studies in which they will receive supplemental iron doses of 4 mg iron from the six products: (i) Fe-oat 1 alone, (ii) Fe-oat 1 with 30 mL acai puree with honey, (iii) Fe-oat 2 alone, (iv) Fe-oat 2 with 30 mL acai puree with honey, (v) FeSO4 alone, (vi) FeSO4 with 30 mL acai puree and honey.
61991222|NCT05826899|ACTIVE_COMPARATOR|oat protein-based iron delivery system4|Each subject will complete the six iron absorption studies in which they will receive supplemental iron doses of 4 mg iron from the six products: (i) Fe-oat 1 alone, (ii) Fe-oat 1 with 30 mL acai puree with honey, (iii) Fe-oat 2 alone, (iv) Fe-oat 2 with 30 mL acai puree with honey, (v) FeSO4 alone, (vi) FeSO4 with 30 mL acai puree and honey.
61991223|NCT05826899|ACTIVE_COMPARATOR|oat protein-based iron delivery system5|Each subject will complete the six iron absorption studies in which they will receive supplemental iron doses of 4 mg iron from the six products: (i) Fe-oat 1 alone, (ii) Fe-oat 1 with 30 mL acai puree with honey, (iii) Fe-oat 2 alone, (iv) Fe-oat 2 with 30 mL acai puree with honey, (v) FeSO4 alone, (vi) FeSO4 with 30 mL acai puree and honey.
61991224|NCT05826899|ACTIVE_COMPARATOR|oat protein-based iron delivery system6|Each subject will complete the six iron absorption studies in which they will receive supplemental iron doses of 4 mg iron from the six products: (i) Fe-oat 1 alone, (ii) Fe-oat 1 with 30 mL acai puree with honey, (iii) Fe-oat 2 alone, (iv) Fe-oat 2 with 30 mL acai puree with honey, (v) FeSO4 alone, (vi) FeSO4 with 30 mL acai puree and honey.
61991225|NCT01408121||African-American on clopidogrel|
62387072|NCT01797042|ACTIVE_COMPARATOR|Glucose 9%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
62387073|NCT01797042|ACTIVE_COMPARATOR|High fructose corn syrup 18%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
62387074|NCT01797042|ACTIVE_COMPARATOR|Sucrose 18%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
62387075|NCT02665039|EXPERIMENTAL|Vinflunine + gemcitabine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:~* 280 mg/m2 in patients with GFR 40-60 ml/min~* 250 mg/m2 in patients aged \>80 years and/or GFR 30-40 ml/min~Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2"
62387076|NCT02665039|ACTIVE_COMPARATOR|Carboplatin + gemcitabine|"Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5~Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2"
62387077|NCT00625963||I,A|I=Pulmonary Hypertension Patients A=ILD patients with Pulmonary Hypertension Patients
62387078|NCT00693524|EXPERIMENTAL|1|Tacrolimus + Anti-IL2R AB + Mycophenolate mofetil
62387079|NCT00693524|ACTIVE_COMPARATOR|2|Tacrolimus + Steroid
62387080|NCT03506464|EXPERIMENTAL|plantar fasciitis group|Myofascial release technique
62387081|NCT03506464|NO_INTERVENTION|control group|None of the control group received the treatment
62387082|NCT01085149|EXPERIMENTAL|study group|simvastatin will be inserted to sockets
62387083|NCT01085149|NO_INTERVENTION|control|sockets will be left to healing without material in socket
62559570|NCT06206304||Dark-eyed females|All shades of brown were categorized as dark.
61991226|NCT01408121||African-American on prasugrel|
61991227|NCT01408121||Caucasian on clopidogrel|
61991228|NCT01408121||Caucasian on prasugrel|
61991229|NCT02933177|EXPERIMENTAL|2 months control condition - 4 months chariot-flash|"200 patient , in 15 nursing homes randomly will be exposed two months in the control condition (usual intervention) and 4 months in the experimental condition (chariot-flash intervention). The experimental condition is to propose the chariot-flash in emergency during the emergence or increase of productive symptoms."
62387084|NCT02050256|OTHER|general practioner|
62387085|NCT03899558|EXPERIMENTAL|Intervention|HNHF device (intervention) + usual care
62387086|NCT03899558|NO_INTERVENTION|Control|Usual care alone
62387087|NCT01552408|ACTIVE_COMPARATOR|0.3 mg Ranibizumab|Cohort 1: Subjects will receive 4 IVT of 0.3 mg ranibizumab every 28 days (+/- 7 days), then will be seen monthly (+/- 7 days) \& will receive IVT of 0.3 mg ranibizumab on a pro re nata (PRN) schedule per retreatment criteria.
62559571|NCT03370640|EXPERIMENTAL|SEP-363856 Part 1 Cohort 1|An oral 25 mg dose of SEP 363856 once daily for 3 days, then 50 mg dose of SEP-363856 once daily for 7 days.
62559572|NCT03370640|EXPERIMENTAL|SEP-363856 Part 1 Cohort 2|An oral 50 mg dose of SEP 363856 once daily for 3 days, then 75 mg dose of SEP-363856 once daily for 7 days.
61991230|NCT02933177|EXPERIMENTAL|4 months control condition-2 months chariot flash|200 patient, in 14 other nursing homes will be exposed 4 months in the control condition and 2 months in the experimental condition
61991231|NCT02374879|EXPERIMENTAL|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
61991232|NCT03662984|ACTIVE_COMPARATOR|Ciprofibrate|1dd100mg at breakfast
61991233|NCT03662984|PLACEBO_COMPARATOR|Placebo|1dd0mg at breakfast
61991234|NCT03127657|EXPERIMENTAL|Cock's comb extract 0.01%|25 Patients Cock's comb extract 0.01% Applied topically twice daily for 12 weeks
61991235|NCT00731770|PLACEBO_COMPARATOR|Placebo, then Advair 250- matched|1 puff bid Placebo for two weeks followed by a 4 week washout period with placebo. After the washout period, they then received Advair 250- matched 1 puff bid for two weeks.
61991236|NCT00731770|ACTIVE_COMPARATOR|Advair 250, then Placebo- matched|1 puff bid Advair 250 for two weeks followed by a 4 week washout period with placebo. After the washout period, they then received Placebo- matched 1 puff bid for two weeks.
62387088|NCT01552408|EXPERIMENTAL|Targeted PRP with 0.3 mg Ranibizumab|Cohort 2: Subjects will receive 4 it of 0.3 mg ranibizumab every 28 days (+/- 7 days), then will then be seen monthly (+/- 7 days) \& receive IVT of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at Day 7 they will receive targeted pan-retinal photocoagulation (PRP) based on ultra wide field angiography. Ultra wide field angiography will be performed every 3 months to indicate areas of peripheral ischemia, which will be selectively be treated with PRP at Month 6, Month 18, and Month 25, preserving areas of more perfused retina.
62559573|NCT03370640|EXPERIMENTAL|SEP-363856 Part 2 Cohort 3|An oral 25 mg dose of SEP 363856 once daily for 3 days, 50 mg dose of SEP 363856 once daily for 4 days, and then 75 mg dose of SEP-363856 once daily for 7 days.
61991237|NCT04130295|EXPERIMENTAL|Wearable intensive nerve stimulation|The device will be worn on the upper calf with each session of stimulation lasting 60 minutes after which the device will turn off for 60 minutes before turning back on. Participants will be instructed to wear the device for 5 hours a day in order to receive three one our sessions of stimulation.
61991238|NCT04171037|EXPERIMENTAL|Arm I (oxygen via Optiflow THRIVE)|Patients receive 100% oxygen at a high flow rate via Optiflow THRIVE over 3 minutes prior to anesthetic induction and at a higher flow rate until the end of procedure.
61991239|NCT04171037|ACTIVE_COMPARATOR|Arm II (oxygen via non-rebreather mask)|Patients receive 100% oxygen at a lower flow rate via non-rebreather mask over 3 minutes prior to anesthetic induction and maintain the same flow rate until the end of procedure.
61991240|NCT04078685|ACTIVE_COMPARATOR|CONVENTIONAL group|Patients with supraventricular tachycardia treated with radiofrequency ablation using a standard (non-contact-force sensing) ablation catheter
61991241|NCT04078685|EXPERIMENTAL|CONTACT-FORCE group|Patients with supraventricular tachycardia treated with radiofrequency ablation using a Contact-Force-sensing ablation catheter
61991242|NCT02786628||Solid tumor malignancies|15 patients. Will participate in physical performance testing and patient-generated health data.
61991243|NCT02786628||Hematologic malignancies|15 patients. Will participate in physical performance testing and patient-generated health data.
61991244|NCT02786628||Hematopoietic cell transplantation|15 patients. Will participate in physical performance testing and patient-generated health data.
61991245|NCT01712256|EXPERIMENTAL|Re-boosting with Vacc-4x|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) at day 1 and day 15.
61991246|NCT02284646|EXPERIMENTAL|Personalized physical training|9-week personalized physical training program (ergometric bicycle)
61991247|NCT02284646|NO_INTERVENTION|Information about physical activity|2 sessions of information on physical activity
61991248|NCT02532296|ACTIVE_COMPARATOR|Control|Receive usual hospital discharge, care transition and post-discharge care.
61991249|NCT02532296|EXPERIMENTAL|Transition Coach Intervention|In addition to usual care, the intervention group receives care from a trained Transition Coach to support patients for 30 days after discharge.
61991250|NCT06323460|EXPERIMENTAL|Arm I (reduced > 95% of TTMV, external beam radiotherapy)|"Patients undergo external beam radiotherapy daily for 5 days a week for 4 weeks. Patients also receive cisplatin IV weekly or every 3 weeks or carboplatin/paclitaxel IV weekly at the discretion of treating physician for 4 weeks. Patients undergo blood sample collection for circulating tumor DNA testing at week 4.~Patients with reduced \> 95% of TTMV undergo external beam radiotherapy QD 5 days a week for 5 weeks. Patients also receive cisplatin IV weekly or every 3 weeks or carboplatin/paclitaxel IV weekly at the discretion of treating physician for 5 weeks. Patients also undergo blood sample collection during screening and throughout the trial."
61991251|NCT06323460|ACTIVE_COMPARATOR|Arm II (not reduced > 95% of TTMV, external beam radiotherapy)|"Patients undergo external beam radiotherapy daily for 5 days a week for 4 weeks. Patients also receive cisplatin IV weekly or every 3 weeks or carboplatin/paclitaxel IV weekly at the discretion of treating physician for 4 weeks. Patients undergo blood sample collection for circulating tumor DNA testing at week 4.~Patients without reduced \> 95% of TTMV undergo external beam radiotherapy daily for 5 days a week for 7 weeks. Patients also receive cisplatin IV weekly or every 3 weeks or carboplatin/paclitaxel IV weekly at the discretion of treating physician for 7 weeks. . Patients also undergo blood sample collection during screening and throughout the trial."
61991252|NCT04682626|EXPERIMENTAL|VD3 group|"Dietary Supplement: Soft gelatin capsules each contain 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg once weekly for 8 weeks.~."
61991253|NCT04682626|NO_INTERVENTION|Control group|none has been administered
61991254|NCT03685084|PLACEBO_COMPARATOR|0.9% saline infusion|Saline 0.9% infusion
62182708|NCT00037713|NO_INTERVENTION|1|Best supportive care, but no cancer specific therapy (cytotoxic, radiation or other tumor reductive therapy) can be given until documented progression of disease.
62387089|NCT04467138||Inflammatory bowel disease|Patients with either Crohn's disease (CD, n=22), and Ulcerative colitis (UC, n=19).
62387090|NCT04467138||Chronic intestinal failure|Patients with intestinal failure (CIF, n=20)
62559574|NCT00218712|EXPERIMENTAL|1|Participants will receive personalized cognitive counseling
62559575|NCT00218712|ACTIVE_COMPARATOR|2|Participants will receive standard counseling
62559576|NCT00245518|EXPERIMENTAL|Isoflavone|Isoflavone
62559577|NCT00245518|PLACEBO_COMPARATOR|Placebo|
61991255|NCT03685084|EXPERIMENTAL|AAI101 i.v.|"600 mg, 1g, 2g, 4g, 1g q6h, 2g q6h.~Drug-Drug Interaction:~Sequence 1 = piperacillin 4 g i.v. - AAI101 2 g i.v. - AAI101 2 g + piperacillin 4 g i.v. - cefepime 2 g i.v. - AAI101 2 g + cefepime 2 g i.v.~Sequence 2 = cefepime 2 g i.v. - piperacillin 4 g i.v. - AAI101 2 g + cefepime 2 g i.v. - AAI101 2 g i.v. - AAI101 2 g + piperacillin 4 g i.v."
62767624|NCT02042534|ACTIVE_COMPARATOR|Warfarin|Patients allocated to warfarin receive warfarin plus aspirin 100mg until INR value exceed 1.7 followed by warfarin monotherapy with target INR value of 2.5 \[2.0 - 3.0\].
61991256|NCT03685084|EXPERIMENTAL|Piperacillin i.v.|Piperacillin 3 g
61991257|NCT03685084|EXPERIMENTAL|Cefepime i.v.|Cefepime 1 g
61991258|NCT03823248|EXPERIMENTAL|MoLuoDan and Sanchi powder group|Experiment group: oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day, + oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day, + oral administration of Folic Acid Tablet simulation half a hour after meal for 5 mg each time for 3 times a day. The medication period was 24 weeks.
61991259|NCT03823248|ACTIVE_COMPARATOR|Folic Acid Tablet group|Control group: oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day, + oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day, + oral administration of folic acid tablets half a hour after meal for 5 mg each time for 3 times a day. The medication period was 24 weeks.
61991260|NCT03454984|EXPERIMENTAL|SGI-110|"* SGI 110 (Guadecitabine) will start on day 40, In case the patient is not eligible yet, he should be assessed again each 30 days until day 130, after what, he is not considered eligible for a preventive treatment by SGI.~* Initial dose will be 30/m2/day SQ for 5 days~* total 10 cycles of SGI-110"
62767625|NCT06125691|EXPERIMENTAL|Cohort 1 of ARCT-2138, younger adults|"Dose Level 1 of ARCT-2138 administered through intramuscular injection in the deltoid muscle.~Interventions:~Investigational Vaccine: ARCT-2138"
62767626|NCT06125691|EXPERIMENTAL|Cohort 2 of ARCT-2138, younger adults|"Dose Level 2 of ARCT-2138 administered through intramuscular injection in the deltoid muscle.~Interventions:~Investigational Vaccine: ARCT-2138"
61991261|NCT02410499|PLACEBO_COMPARATOR|Placebo|MLN1202 placebo-matching solution, subcutaneous injection (SC), once, on Day 1 (loading dose), followed by MLN1202 placebo-matching solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
62767627|NCT06125691|EXPERIMENTAL|Cohort 3 of ARCT-2138, younger adults|"Dose Level 3 of ARCT-2138 administered through intramuscular injection in the deltoid muscle.~Interventions:~Investigational Vaccine: ARCT-2138"
62767628|NCT06125691|EXPERIMENTAL|Cohort 4 of ARCT-2138, younger adults|"Dose Level 4 of ARCT-2138 administered through intramuscular injection in the deltoid muscle.~Interventions:~Investigational Vaccine: ARCT-2138"
62767629|NCT06125691|EXPERIMENTAL|Low Dose, younger and older adults|"Low dose level of ARCT-2138 administered through intramuscular injection in the deltoid muscle.~Interventions:~Investigational Vaccine: ARCT-2138"
62767630|NCT06125691|EXPERIMENTAL|Medium Dose, younger and older adults|"Medium dose level of ARCT-2138 administered through intramuscular injection in the deltoid muscle.~Interventions:~Investigational Vaccine: ARCT-2138"
62767631|NCT06125691|EXPERIMENTAL|High Dose, younger and older adults|"High dose level of ARCT-2138 administered through intramuscular injection in the deltoid muscle.~Interventions:~Investigational Vaccine: ARCT-2138"
62767632|NCT06125691|ACTIVE_COMPARATOR|Control Dose, younger adults|"Licensed Quadrivalent Vaccine administered through intramuscular injection in the deltoid muscle.~Interventions:~Control Vaccine: Licensed Quadrivalent Vaccine for younger adults"
62767633|NCT06125691|ACTIVE_COMPARATOR|Control Dose, older adults|"Licensed Quadrivalent Vaccine administered through intramuscular injection in the deltoid muscle.~Interventions:~Control Vaccine: Licensed Quadrivalent Vaccine for older adults"
61991262|NCT02410499|EXPERIMENTAL|MLN1202 75 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 75 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
61991263|NCT02410499|EXPERIMENTAL|MLN1202 105 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 105 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
61991264|NCT02410499|EXPERIMENTAL|MLN1202 150 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 150 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
62767634|NCT03897036|EXPERIMENTAL|CX-4945 28 Day Dose Duration|CX-4945 capsules at 1000mg BID, on Days 1 through 28 of each treatment cycle
62767635|NCT03897036|EXPERIMENTAL|CX-4945 21 Day Dose Duration|CX-4945 capsules at 1000mg BID, on Days 1 through 21 of each treatment cycle
61991265|NCT03170973|EXPERIMENTAL|Comparison of fatty acids before and after exercise|
61991266|NCT03170973|NO_INTERVENTION|Comparison of fatty acids at baseline and 24 hours after|
61991267|NCT01986868|OTHER|Coronary MR Angiography (CMRA)|Coronary MR Angiography(CMRA). A gadolinium-based contrast (Optimark or MultiHance) will be administered as well as a beta blocker which will be assigned based upon heart rate.
61991268|NCT05413252|NO_INTERVENTION|Current Practice|Practices will deliver care as usual and patients at these sites receive standard HTN care delivered.
61991269|NCT05413252|ACTIVE_COMPARATOR|Practice Facilitation|Practices review coaching and support from a trained practice facilitator. This includes 24 site visits in which facilitators meet with staff to work on implementing system changes to improve hypertension management.
61991270|NCT01110746|EXPERIMENTAL|Formulation A|Single Injection
61991271|NCT01110746|EXPERIMENTAL|Formulation B|Single Injection
61991272|NCT06386614|SHAM_COMPARATOR|common group routine training|Conventional rehabilitation
61991273|NCT06386614|EXPERIMENTAL|tDCS group|Conventional rehabilitation plus TDCS treatment
62767636|NCT03897036|EXPERIMENTAL|Expansion CX-4945 Locally Advanced BCC|CX-4945 capsules at 1000mg BID, on the dosing schedule identified during the Phase I treatment duration increment part of the study
62767637|NCT03897036|EXPERIMENTAL|Expansion CX-4945 Metastatic BCC|CX-4945 capsules at 1000mg BID, on the dosing schedule identified during the Phase I treatment duration increment part of the study
62767638|NCT05371041|EXPERIMENTAL|Medtronic Percept Neurostimulator|This is a deep brain stimulator that can also record brain signals and deliver stimulation through a control algorithm based on brain activity.
61991274|NCT06528704|EXPERIMENTAL|Ventilation feedback|First, ventilation without feedback, hereafter ventilation with feedback
61991275|NCT02895958|OTHER|Administration of Zepatier|
61991276|NCT01284283|OTHER|Single|Device: Scandinavian Total Ankle Replacement System (STAR Ankle)
61991277|NCT02932865||MD-TESE (A)|Azoospermic men, MD-TESE operation (standard treatment). Semen sample, serum sample and physical examination with testicular ultrasound.
62387091|NCT05343403||Family Integrated Care|During the intervention period, Family Integrated Care (FICare) will be implemented on the neonatal wards of the participating hospitals. Families that are included during this intervention period will participate in Family Centred Rounds (FCR), while being supported by the principles of FICare. FICare incorporates psychological, educational, communication, and environmental strategies to support parents and to prepare them emotionally, cognitively, and physically to care autonomously for their infant at the time of discharge. In FCR, parents actively participate in the medical rounds and decisions are made based on shared-decision making. Not only are parents informed about the clinical condition of their child, they can ask questions and share their own valuable information on their child. Such information can include the overall wellbeing but also specific medical information.
62387092|NCT05343403||Standard Neonatal Care|In the control period, standard neonatal care (SNC) will be provided. Medical rounds will be held between healthcare professionals, and parents are not (structurally) participating during these rounds. Parents are updated daily by the nurses, and (usually) weekly by their attending physician. Care for the infants is provided mostly by the nurses. Parents usually have (unlimited) access to the ward, but are not supported by the concept of FICare. As such, they do not receive education and are not structurally supported by veteran parents. Healthcare professionals stimulate parents to participate in daily care (such as feedings or skin-to-skin care), but do not receive structural education on how to incorporate parents as equal partners into the care team.
62387093|NCT04069026|EXPERIMENTAL|Dose escalation of BAY2416964|Approximately 8 dose levels of BAY2416964 are planned
62387094|NCT04069026|EXPERIMENTAL|Dose expansion of BAY2416964 in tumor type specific|Patients with NSCLC, HNSCC
62559578|NCT01742312||oesophageal adenocarcinoma|DEXA scan cardio-pulmonary exercise testing (CPEX) muscle biopsy
62559579|NCT00254592|EXPERIMENTAL|AC with GM-CSF and Carboplatin/Nab-Paclitaxel|"Doxorubicin and cyclophosphamide (AC) administered intravenously every 14 days up to a total of 4 cycles, with GM-CSF on days 4-13, depending on tumor response.~Two weeks after the completion of AC, weekly doses of carboplatin/nab-paclitaxel will be given for 3 weeks, followed by 1 week of rest, for a total of 9-12 doses. Subjects who receive 4 cycles of AC will receive 9 doses of nab-paclitaxel and subjects who receive 2 cycles of AC will receive 12 weeks of nab-paclitaxel. In addition, subjects will receive trastuzumab weekly (12-16) doses if they are Her-2 positive and bevacizumab (6-8) doses every 2 weeks if they are Her-2 negative. Each clinic visit will last approximately ½ hour."
62387095|NCT06217926|NO_INTERVENTION|Control Group|"During the pretest of the study, firstly, the 3rd year students of the Faculty of Health Sciences will be informed about the purpose of the study, that their participation in the study is based on the principle of voluntariness, that they can leave the study at any time, and that the study results will be used only for scientific purposes. Then, data collection tools will be applied to students who volunteer to participate in the research.~During the posttest implementation of the study (one week before the final exams), the Personal Information Form, Attitude Scale Towards Artificial Intelligence and Westside Exam Anxiety Scale will be re-administered to the 3rd and 4th year students of the Faculty of Health Sciences."
62387096|NCT06217926|EXPERIMENTAL|Experimental Group|"During the pretest of the study, firstly, the 4th year students of the Faculty of Health Then, data collection tools will be applied to students who volunteer to participate in the research.~Educational content; ChatGPT and Google Bard training for senior students of the Faculty of Health Sciences who volunteered to participate in the study was provided by Dr. Lecturer It will be given by member Yasemin Özyer Güvener. After the training is completed, students will be asked to use generative artificial intelligence for educational purposes.~During the posttest implementation of the study (one week before the final exams), the Personal Information Form, Attitude Scale Towards Artificial Intelligence and Westside Exam Anxiety Scale will be re-administered to the 3rd and 4th year students of the Faculty of Health Sciences."
62387097|NCT03531099|EXPERIMENTAL|HIFU treatment|"65 patients will receive the immediate treatment with focal HIFU in order to destroy the cancer without causing side effects. HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.~Patients randomized in this arm will also have PSA dosage, MRI exam, questionnaires and prostatic biopsies during their follow up."
62559580|NCT03036657|EXPERIMENTAL|Manual Acupuncture|"Device:~Sterile single-use MAC acupuncture needles - 0.22 x 25 mm, TianJin Haing Lim Sou Won Medical Equipment Co, Ltd, South Korea~Used for Intervention:~Manual Acupuncture to PC3, PC5 or HT3, HT4 for 20 min"
62559581|NCT03036657|EXPERIMENTAL|Low-Frequency Electroacupuncture|"Device:~Electrostimulator 6c.Pro, Pantheon Research, Venice, CA~Used for Intervention:~Low-frequency Continuous Electroacupuncture (2Hz) to PC3, PC5 or HT3, HT4 for 20 min"
62559582|NCT03036657|EXPERIMENTAL|High-Frequency Electroacupuncture|"Device:~Electrostimulator 6c.Pro, Pantheon Research, Venice, CA~Used for Intervention:~High-frequency Continuous Electroacupuncture (100 Hz) to PC3, PC5 or HT3, HT4 for 20 min"
61991278|NCT02932865||Subfertile men (B)|Subfertile men receiving medication (standard treatment). Semen sample, serum sample and physical examination with testicular ultrasound.
61991279|NCT02932865||Control (C)|Control group, men scheduled for semen analysis. Semen sample, serum sample and physical examination with testicular ultrasound.
61991280|NCT04851899|EXPERIMENTAL|Low dose Phaeosol group|1 Phaeosol softgel of 440mg/day and 1 placebo softgel of 440mg/day look like softgel of Phaeosol product) + 1 capsule of 440mg/day of natural stimulant
61991281|NCT04851899|EXPERIMENTAL|High dose Phaeosol group|2 Phaeosol softgels of 440mg/day + 1 capsule of 440mg/day of natural stimulant
61991282|NCT04851899|PLACEBO_COMPARATOR|Placebo group|2 placebo softgels of 440mg/day (look like softgel of Phaeosol product) + 1 capsule of 440mg/day containing Microcellulose (look like capsule of natural stimulant)
62767639|NCT04670393|EXPERIMENTAL|FertyBiotic Woman Plus|Participants received FertyBiotic Woman Plus one sachet a day
62767640|NCT04670393|PLACEBO_COMPARATOR|Placebo|Participants received 400 mcg of folic acid once a day
62767641|NCT01929538|ACTIVE_COMPARATOR|Covered biliary metal stent, 12 mm|ERCP and placement of a covered self-expanding biliary metal stent, 12mm in diameter
62767642|NCT01929538|ACTIVE_COMPARATOR|covered Biliary metal stent, 10 mm|ERCP and placement of a covered self-expanding biliary metal stent, 10 mm in diameter
61991283|NCT05081856|EXPERIMENTAL|intervention group|The group mobilized for at least 20 minutes 6 times a day with a modular medical equipment carrying vehicle
62767643|NCT02043119|ACTIVE_COMPARATOR|Breastfeeding Clinic|A breastfeeding clinic that mothers can attend with their infants up to one month post delivery.
62767644|NCT02043119|NO_INTERVENTION|Standard of Care|
62767645|NCT02968914|ACTIVE_COMPARATOR|Benralizumab by Accessorized Pre-Filled Syringe|Drug administration by Accessorized Pre-Filled Syringe. A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
62767646|NCT02968914|OTHER|Benralizumab by Autoinjector|Drug administration by Autoinjector A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
62767647|NCT03522597||Normal weight|Normal weight (BMI) women and their infants
62767648|NCT03522597||Obese|Obese (BMI) women and their infants
62387098|NCT03531099|ACTIVE_COMPARATOR|Active surveillance|"65 patients will be randomized to active surveillance and will have exactly the same follow-up as treated patients excepting the HIFU treatment.~Active surveillance is a therapeutic option that shifts the eventual moment of curative treatment while remaining within a window of curability of the disease.~Patients randomized in this arm will also have PSA dosage, MRI exam, questionnaires and prostatic biopsies during their follow up."
62387099|NCT06250192|EXPERIMENTAL|Intervention with patient-centered virtuel educational tools|Patient randomized to intervention with patient-centered virtuel educational tools based on small videos
62387100|NCT06250192|NO_INTERVENTION|Control: Women were randomized to usal care|Randomized to standard treatment without acces to virutel educational tools
62387101|NCT01787123|PLACEBO_COMPARATOR|Control: standard management|Standard management for patient suffering from aneurysmal subarachnoid haemorrhage
62387102|NCT01787123|ACTIVE_COMPARATOR|Intervention: standard management AND Cerebrolysin|Standard management for aneurysmal subarachnoid hemorrhage and a 14-day administration of intravenous Cerebrolysin
62387103|NCT02994043|ACTIVE_COMPARATOR|MBRP|
62387104|NCT02994043|ACTIVE_COMPARATOR|RP|
62387105|NCT01230021|EXPERIMENTAL|recombinant factor XIII|
62387106|NCT05004363|ACTIVE_COMPARATOR|Lokelma|Lokelma therapy
61991284|NCT05081856|NO_INTERVENTION|control group|The group mobilized for at least 20 minutes 6 times a day with a routin practice
61991285|NCT01769040|EXPERIMENTAL|Rifaximin|Rifaximin tablets for oral ingestion, 550 mg twice daily for 28 days.
61991286|NCT01769040|PLACEBO_COMPARATOR|Placebo tablets|Placebo tablets similar in shape and size to intervention treatment, 1 tablet twice daily for 28 days.
62387107|NCT05004363|PLACEBO_COMPARATOR|Control|Placebo
62387108|NCT00459680|EXPERIMENTAL|Acupuncture|
61991287|NCT05817136||coronary HF aetiology|Patients with coronary HF
61991288|NCT05817136||non-coronary HF aetiology|Patients with non-coronary HF
61991289|NCT00605046|EXPERIMENTAL|Asses [123I] AV151 and SPECT imaging|
62387109|NCT00459680|EXPERIMENTAL|Laser Acupoint|
62767649|NCT03522597||Diabetic|Women with gestational diabetes and their infants
62767650|NCT02699268||Infants (term borns and preterm borns)|Intervention: simultaneous lung function measurement using VoluSense Pediatrics and a mask-based method with an ultrasonic flowmeter (EcoMedics Exhalyzer)
62767651|NCT03159104|EXPERIMENTAL|Tenoten for children|Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
62767652|NCT03159104|PLACEBO_COMPARATOR|Placebo|Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
62767653|NCT05458661|OTHER|recruited patient population|
62767654|NCT06004375|EXPERIMENTAL|intervention group|The intervention group was given a High-Calorie High-Protein + ONS diet containing 4.8 g arginine and 2 g glutamine, namely Neomune 2x 200 cc, purchased from Otsuka Pharmaceutical Co., Ltd
61991290|NCT01261871||Robotic laparoscopic prostatectomy|Patients who are undergoing primary surgical treatment for a diagnosis of prostate operatively will be enrolled. IOP will be measured throughout the case to assess for change. The various techniques employed for a radical prostatectomy will be compared. Patients undergoing RRP (open surgery) will act as controls. Those undergoing LRP (minimally invasive surgery) will be compared with the control group to assess for differences in IOP that may result from the different approaches. three arms will be used for the comparison: open, laparoscopic intraperitoneal approach), and laparoscopic (extraperitoneal approach).
61991291|NCT01093911|EXPERIMENTAL|CDP7657|CDP7657 in dose escalating cohorts
61991292|NCT01093911|PLACEBO_COMPARATOR|Placebo|
61991293|NCT02120794|EXPERIMENTAL|530G insulin pump|Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
61991294|NCT02857478|EXPERIMENTAL|Safety of a Sunscreen product|Sunscreen product safety evaluation under supervised out-door conditions on sport users.
62559583|NCT04753216|EXPERIMENTAL|Treatment (bevacizumab, irinotecan sucrosofate)|Patients receive bevacizumab IV and irinotecan sucrosofate IV over 90 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62559584|NCT06145841||Pathogen metagenomic next-generation sequencing group|This group uses metagenomic next-generation sequencing along with traditional pathogen detection techniques to test for infectious pathogens. The follow-up times are the 1st, 2nd, 3rd, and 4th weeks after being diagnosed with severe pneumonia or sepsis.
62559585|NCT06145841||Conventional pathogen detection group|This group only used conventional pathogen detection methods for the identification of infectious pathogens. Follow-up was conducted at the 1st, 2nd, 3rd, and 4th weeks after the diagnosis of severe pneumonia or sepsis. The conventional means of pathogen detection include, but are not limited to, fungal serology tests, cryptococcal capsular antigen detection, CMV-DNA tests, sputum smear microscopy, gamma interferon release assays, Xpert MTB/RIF, BLAF culture, blood and bone marrow cultures, radiological examinations, and histopathological examinations.
61991295|NCT04990960|ACTIVE_COMPARATOR|Physiotherapist|The Physiotherapist worked on adhered breast scars, stiffness in neck and arm movements and actively worked on AWS cords with gentle extensions and / or energetic detachment maneuvers. No self-treatment methods were offered and required of the subject.
61991296|NCT04990960|EXPERIMENTAL|Self-treatment|The Physiotherapist worked on adhered breast scars, stiffness in neck and arm movements. During each session the patient was also assessed and trained in self-treatment exercises assigned to treat their cords. Subjects were trained to perform self-treatment extension exercises with four exercises selected by the Physiotherapist
61991297|NCT03057938|EXPERIMENTAL|18F-Florbetaben (FBB)|18F-Florbetaben
61991298|NCT06237790||Gene Therapy Group|The study will recruit gene therapy patients who are definitely diagnosed with autosomal recessive deafness 9 (DFNB9).
62387110|NCT05326672|EXPERIMENTAL|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 8 weeks after enrolment.
62387111|NCT05326672|PLACEBO_COMPARATOR|Placebo|Placebo, applied twice daily for 8 weeks after enrolment.
62559586|NCT03011086||oral sub mucous fibrosis|patients suffering with oral sub mucous fibrosis due to gutka/pan chewing confirmed by clinical examination
62559587|NCT03011086||control group|patients having gutka/ pan chewing habit without oral sub mucous fibrosis in oral cavity
62559588|NCT00699816|EXPERIMENTAL|Immunotherapy Group|Adjuvant adoptive immune therapy using a CIK cell agent(Immuncell-LC) 16 times(4 treatments at a frequency of once per week, followed by 4 treatments every 2 weeks, then 4 treatments every 4 weeks, and finally 4 treatments every 8 weeks.
62767655|NCT06004375|ACTIVE_COMPARATOR|control group|the control was administered with a High-Calorie High-Protein diet + ONS hospital standard.
62559589|NCT00699816|NO_INTERVENTION|Control Group|Patients who had undergone curative treatment(surgical resection, radiofrequency ablation\[RFA\], or percutaneous ethanol injection\[PEI\]) for HCC of pretreatment clinical stage I or II according to the American Joint Committee on Cancer staging system(6th edition) based on radiologic imaging studies were eligible for this study with no adjuvant treatment
62559590|NCT01736592|OTHER|Long Term Follow up|Long term follow up in all patients who received SAR422459 in previous study TDU13583
62767656|NCT01490294|EXPERIMENTAL|Gadobutrol 0.01 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.01 mmol/kg body weight (BW) (0.01mL/kg) for stress magnetic resonance imaging (MRI) via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.01 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
61991299|NCT06237790||Cochlear Implant Group|The study will recruit cochlear implant patients with congenital deafness.
61991300|NCT00971347|ACTIVE_COMPARATOR|Nutrition brochure|Control participants will receive only a nutrition brochure, Finding Your Way to a Healthier You, based on a USDHHS/USDA publication, Dietary Guidelines for Americans 2005.
61991301|NCT00971347|EXPERIMENTAL|Chewing gum + nutrition brochure|Participants in the experimental arm will be instructed to incorporate gum chewing in their diet with a goal of at least 90 minutes per day. The schedule is 20 minutes each after breakfast, lunch and dinner plus 10 minutes mid-morning, mid-afternoon and 1 to 2 hours after dinner. Experimental participants also will be told to chew gum instead of unplanned eating in response to hunger, cravings, preoccupation with eating, or negative feelings.
61991302|NCT01002755|EXPERIMENTAL|Treatment (lenalidomide, ofatumumab)|Participants receive ofatumumab IV over 4 hours on days 1, 8, 15, and 22 of course 1, day 1 of courses 2-6, and day 1 of every even course beginning course 8. Beginning day 9 of course 1, participants also receive lenalidomide PO daily. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62387112|NCT01054794|ACTIVE_COMPARATOR|Stimulation ON|
62387113|NCT01054794|SHAM_COMPARATOR|Stimulation OFF|
62767657|NCT01490294|EXPERIMENTAL|Gadobutrol 0.025 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.025 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.025 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
62767658|NCT01490294|EXPERIMENTAL|Gadobutrol 0.05 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.05 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.05 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
61991303|NCT00181961|EXPERIMENTAL|Maca Root 1500mg|Patients receiving 1500mg of maca root
61991304|NCT00181961|EXPERIMENTAL|Maca Root 3000mg|Patients receiving 3000mg of maca root
61991305|NCT02850458||implant retained-overdentures with the attachment of bar|patients treated with implant-retained overdentures,and the attachment is bar
61991306|NCT02850458||implant retained-overdentures with the attachment of magnet|patients treated with implant-retained overdentures,and the attachment is magnet
61991307|NCT05820347|OTHER|Artificial Intelligence Estimation of Muscle Pressure during Mechanical Ventilation|All included subjects will be monitored simultaneously with the esophageal balloon (gold standard) and with the artificial intelligence algorithm integrated in the mechanical ventilator. Electrical Impedance Tomography will be used to monitor ventilatory patterns during different degrees of spontaneous effort. First, a single intravenous bolus of neuromuscular blockade (succinylcholine 1mg/kg or rocuronium 1.2mg/kg) will be performed to measure respiratory system mechanics (compliance and resistance). In cases where rocuronium is used, a single dose of sugammadex 4mg/kg will be administered intravenously to reverse neuromuscular blockade after measuring compliance and resistance. After initiation of spontaneous breathing effort, pressure support will be titrated from 20 cmH2O to 2 cmH2O, in decremental steps during 20 minutes each. After completing titrating of pressure support, the esophageal balloon will be removed.
61991308|NCT01069133|EXPERIMENTAL|Rifaximin|
61991309|NCT01389180|EXPERIMENTAL|BDRC|
61991310|NCT01389180|EXPERIMENTAL|EC|
61991311|NCT01389180|OTHER|TAU|
61991312|NCT01736696|EXPERIMENTAL|5 mg BID|5 mg BID for 13 days and once on Day 14
62387114|NCT03677440|EXPERIMENTAL|Treadmill Walking Exercise Training|"This condition will include 3-months of supervised, progressive light, moderate, and vigorous intensity treadmill walking exercise training based on ACSM guidelines for maximizing adaptations with exercise training. Exercise intensities will be prescribed based on percent oxygen consumption reserve (% VO2R) using values derived from the baseline graded exercise test.~The exercise training itself will be led by trained exercise leaders who are not involved in the collection of outcome assessments. At the outset of each session, participants will be fitted with a Polar HR Monitor (Oy, Finland), and HR will be monitored continuously throughout each session. Each session will begin with a 5-10 min warm-up, followed by the exercise; the target heart rate reserve (HRR) range associated with the VO2R range will be maintained for as long as possible during each exercise period. This will be followed by a 5-10 min cool-down."
62767659|NCT01490294|EXPERIMENTAL|Gadobutrol 0.1 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.1 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.1 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
62767660|NCT05202821|ACTIVE_COMPARATOR|group of 20 participants receiving fluoride varnish|\*Group (I): patients will receive Fluoride varnish ttt.
62767661|NCT05202821|EXPERIMENTAL|group of 20 participants receiving PR-G Barrier coat|\*Group (II): patients will receive PR-G Barrier coat
61991313|NCT01736696|EXPERIMENTAL|10 mg BID|10 mg BID for13 days and once on Day 14\*
62767662|NCT05202821|ACTIVE_COMPARATOR|group of 20 participants receiving MI Paste (CPP-ACP)|\*Group (III): Patients will receive MI Paste (CPP-ACP)
62767663|NCT04317326|EXPERIMENTAL|Life style modification|"Lifestyle modifications group (Control) will consist of a 1,000-calorie/day diet and to maintain proper sleep hygiene and habits (avoid supine decubitus position, maintain regular sleep habits and exercise, not take sedatives, stimulants, alcohol, tobacco or heavy meals within four hours before bedtime). Oxygen therapy can be prescribed by the treating team using standard criteria (awake PaO2 \<55 mmHg or room air oxygen saturation below 88% (Masa JF et al. J Clin Sleep Med. 2016 ;12:1379-88)"
61991314|NCT01736696|EXPERIMENTAL|20 mg BID|20 mg BID for 13 days and once on Day 14
61991315|NCT01736696|EXPERIMENTAL|30 mg BID|30 mg BID for 13 days and once on Day 14
61991316|NCT01736696|EXPERIMENTAL|60 mg QD|60 mg QD for 14 days
61991317|NCT01736696|EXPERIMENTAL|50 mg BID|50 mg BID x 13 days and once on day 14
61991318|NCT04120532|EXPERIMENTAL|Education group|
61991319|NCT04120532|NO_INTERVENTION|Usual care group|
61991320|NCT03569332|EXPERIMENTAL|Test Group|Participants will receive the mobile self-input tool providing alarm on tablet, and their practicing rate will be sent to Nurse's Dashboard.
61991321|NCT03569332|NO_INTERVENTION|Control Group|Participants will receive the mobile self-input tool on tablet (to compare the rate with Test group). But it won't contain alarm function and their practicing rate won't be sent to Nurse's Dashboard, either.
61991322|NCT04384302|EXPERIMENTAL|Visual training|"Pre-specidied visual training methods that use: the Marsden ball, tables that uses green-red visual stimuli, physical reation in response to the visual stimuli that uses the flippers or the preselected distances.~One set of exercises per week was prepared.~Each visual training will last for 15 minutes and should be performed by the participant in their home (using the telemedicine devices to control the conduction of each exercise) 3 times a week."
61991323|NCT01824186|EXPERIMENTAL|SILC|Subjects in this arm were randomized to undergo single-incision laparoscopic cholecystectomy, through a transumbilical incision
61991324|NCT01824186|ACTIVE_COMPARATOR|LC|Subjects in this arm were randomized to undergo conventional 4-port laparoscopic cholecystectomy. Wound sites at umbilicus, right hypocondrium, epigastrium and right flank
61991325|NCT01559012|OTHER|clonidine first - placebo second|in this group patients are treated with transdermal clonidine first for 5 days then switch to placebo for 5 days
61991326|NCT01559012|OTHER|placebo first - clonidine second|in this group patients are treated with placebo first for 5 days then with transdermal clonidine for next 5 days
61991327|NCT01452412|EXPERIMENTAL|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
61991328|NCT01452412|PLACEBO_COMPARATOR|Placebo|placebo dosage/frequency equivalent to sodium bicarbonate
61991329|NCT05255770|EXPERIMENTAL|Test condom A (NRL condom with 5% benzocaine paste)|Following randomisation each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
61991330|NCT05255770|EXPERIMENTAL|Test condom B (NRL condom with 3% benzocaine paste)|Following randomisation each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
61991331|NCT05255770|ACTIVE_COMPARATOR|Control NRL condom|Following randomisation each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
61991332|NCT00112502|ACTIVE_COMPARATOR|Arm I: TMZ|Oral Temozolomide (TMZ) 150 mg/m\^2 once daily on days 1-7 and 15-21.
62387115|NCT03677440|ACTIVE_COMPARATOR|Stretching-and-Toning Exercise Training|The active, non-aerobic exercise condition will involve stretching-and-toning activities using the same frequency and duration of the treadmill walking exercise condition. These activities will be based on a manual provided by the National Multiple Sclerosis Society and sessions will be led by trained exercise leaders who are not involved in the collection of outcome assessments. Activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot. The progression of activities over the 3-month period will involve performing additional exercises and sets along with using progressively thicker elastic resistance bands that provide minimal resistance. Each session is designed to last up to 60 minutes in total. Each session will begin with a warm-up of up to 10 minutes, followed by stretching-and-toning (following the same duration as the treadmill walking exercise training condition) activities, and a cool-down of up to 10 minutes.
62767664|NCT04317326|ACTIVE_COMPARATOR|Life style modificacion and automatic NIV(AVAPS-AE)|Automatic NIV: In addition to lifestyle modification and oxygen (if required), the ventilator will be adjusted to a range of predetermined parameters with the intelligent ventilation mode (pressure of intelligent support with guaranteed volume with automatic backup frequency) with the following adjustment: maximum pressure: 35 cmH2O; respiratory rate: automatic; maximum pressure support: 20 cm H2O; minimum pressure support: 4 cmH2O; maximum EPAP pressure: 15 cmH2O; minimum EPAP pressure: 4 cmH2O; and tidal volume (Vt) based on 8-10 ml/kg of predicted body weight. These parameters may be modified according to patient tolerance or non-compensated leak.
61991333|NCT00112502|EXPERIMENTAL|Arm II: TMZ + Thalidomide|Temozolomide as in arm I and oral Thalidomide (Thal) once daily on days 1-28 (starting dose 200 mg).
61991334|NCT00112502|EXPERIMENTAL|Arm III: TMZ + Isotretinoin|Temozolomide as in Arm I and oral Isotretinoin 40 mg/m\^2 twice daily on days 1-21.
61991335|NCT00112502|EXPERIMENTAL|Arm IV: TMZ + Celecoxib|Temozolomide as in arm I and oral Celecoxib 400 mg twice daily on days 1-28.
61991336|NCT00112502|EXPERIMENTAL|Arm V: TMZ + Thalidomide + Isotretinoin|Temozolomide as in arm I, Thalidomide as in arm II, and Isotretinoin as in arm III.
62387116|NCT06212349|EXPERIMENTAL|Experimental|They will receive therapeutic-educational physiotherapy, which will combine therapeutic exercise with a pain education program,
62387117|NCT06212349|OTHER|Control|They will receive the pain education program.
61991337|NCT00112502|EXPERIMENTAL|Arm VI: TMZ + Thalidomide + Celecoxib|Temozolomide as in Arm I, Thalidomide as in Arm II, and Celecoxib as in Arm IV.
61991338|NCT00112502|EXPERIMENTAL|Arm VII: TMZ + Isotretinoin + Celecoxib|Temozolomide as in Arm I, Isotretinoin as in Arm III, and Celecoxib as in Arm IV.
61991339|NCT00112502|EXPERIMENTAL|Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib|Temozolomide as in Arm I, Thalidomide as in Arm II, Isotretinoin as in Arm III, and Celecoxib as in Arm IV.
61991340|NCT05543486|EXPERIMENTAL|Levitation 2 Tri-Compartment Offloader (TCO) knee brace|Participants in this group are sized and fitted for a Levitation 2 TCO brace and instructed to wear the brace on their affected limb for a total of 3 or more hours per day for 3 months.
61991341|NCT05543486|ACTIVE_COMPARATOR|Knee sleeve|Participants are provided with a off-the-shelf knee sleeve and instructed to wear the sleeve on their affected limb for a total of 3 or more hours per day for 3 months.
61991342|NCT05543486|NO_INTERVENTION|Standard of Care Self-Management|Control group practicing conservative self-management of knee osteoarthritis without using a knee device (e.g., hard brace or sleeve) for 3 months.
61991343|NCT02073279|EXPERIMENTAL|Satralizumab|Participants randomized to this arm for the double-blind period will receive satralizumab monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, up to the end of the study.
61991344|NCT02073279|PLACEBO_COMPARATOR|Placebo|Participants randomized to this arm for the double-blind period will receive placebo monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized.. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, up to the end of the study.
61991345|NCT02255370|EXPERIMENTAL|CURCUMIN|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
61991346|NCT02255370|PLACEBO_COMPARATOR|PLACEBO|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
61991347|NCT05465551|NO_INTERVENTION|Stress Management Toolkit Prototype Development|3-4 qualitative focus groups (n=3-4 dyads/group) will be held to explore experiences, perceptions, preferences, and recommendations of dementia-caring dyads regarding stress, stress management, and key components and features of a stress management toolkit. Eligible tools for the toolkit include low burden, high safety tools (e.g., weighted blankets, robotic pets and baby dolls, guided journals, aromatherapy, bright light therapy devices, massage and acupressure tools).
61991348|NCT05465551|EXPERIMENTAL|Stress Management Toolkit Prototype User Testing|10 dyads will use the toolkit for 2 weeks in their own homes. Feedback on usability, feasibility, and acceptability will be collected through questionnaires and focus groups. Stress-related, participant-reported outcomes (e.g., neuropsychiatric symptoms of dementia, caregiver stress, dyadic relationship strain), and salivary cortisol biospecimens will be collected at baseline and end of week 2, to explore their utility as endpoints in a future pilot study to examine efficacy.
61991349|NCT01972737|EXPERIMENTAL|Ad5-hGCC-PADRE Vaccine|Active vaccine
61991350|NCT05742451|ACTIVE_COMPARATOR|intervention group|The kids yoga was applied to the intervention group for 8 weeks, once a week (8 sessions), 40 minutes per session, by a yoga instructor occupational therapist.
62387118|NCT03270527|EXPERIMENTAL|High SFA diet to low SFA diet|Participants will undergo, sequentially, a high SFA diet (Diet 1) followed by a low SFA diet (Diet 2) for 4 weeks each. Study visits will occur before and after each dietary intervention period. To comply with current UK dietary recommendations, Diets 1 and 2 will both contain \~35% energy from total fat. These diets will be consumed within the homes of free-living participants, by the substitution of \~40g of habitual fat, with either SFA-rich or mono/poly-unsaturated fatty acid-rich (MUFA/PUFA) cooking oils, spreads and snack foods, while maintaining their habitual diet (consistent intake of protein and carbohydrates, including dietary fibre). This will be achieved using a dietary exchange model developed and peer-reviewed for a previous dietary intervention study ('DIVAS') at the University of Reading, U.K.
61991351|NCT05742451|NO_INTERVENTION|Control group|The control group was evaluated at 8-week intervals.
61991352|NCT01249612|PLACEBO_COMPARATOR|Control treatment|Elbow joint icing using two plastic bags with crushed ice
61991353|NCT01249612|ACTIVE_COMPARATOR|Active treatment|Knee joint icing using two plastic bags with crushed ice
61991354|NCT00481546|EXPERIMENTAL|Experimental|All clinical trial subjects received the same vector.
61991355|NCT03397082|EXPERIMENTAL|Lidocaine + Paracervical blockade|5 minutes previous to endouterine manual aspiration, 5mL of lidocaine gel was applied plus standard paracervical blockade.
62387119|NCT01293123|EXPERIMENTAL|Raltegravir|
62387120|NCT01293123|ACTIVE_COMPARATOR|Efavirenz|
62387121|NCT06137235|EXPERIMENTAL|test formula|infant formula and follow-on formula with bioactive ingredients
62387122|NCT06137235|ACTIVE_COMPARATOR|control formula|standard infant formula and follow-on formula
62387123|NCT03893994|EXPERIMENTAL|Stretching group|Posterior shoulder stretching exercises
62387124|NCT03893994|NO_INTERVENTION|Control Group|No exercise will be applied
62387125|NCT01116661|EXPERIMENTAL|ALA for glioma (WHO G1-IV) subjects|Up to 300 patients with diagnosed glioma (WHO G1-IV) eligible for surgery will be entered into the trial and will be given 5-Aminolevulinic Acid (ALA) orally at a dose of 20mg/kg body weight preoperatively
61991356|NCT03397082|PLACEBO_COMPARATOR|Placebo + paracervical blockade|5 minutes previous to endouterine manual aspiration, standard paracervical blockade was applied plus placebo gel (KY).
61991357|NCT00632333|EXPERIMENTAL|1|
61991358|NCT02775344|EXPERIMENTAL|three dimension laparoscopy|This group of patients will have laparoscopic ovarian cystectomy performed using three-dimension laparoscopy. The procedure will be performed in usual manner.
61991359|NCT02775344|NO_INTERVENTION|Two dimension laparoscopy|Two-dimension laparosocpy would be used in this group of patient. The procedure will be performed in usual manner.
61991360|NCT03205618||daclatasvir patients in KSA, UAE, and Qatar|patients treated with daclatasvir-containing regimens in KSA, UAE, and Qatar
61991361|NCT00778700|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle cream, applied topically, once daily from Day 1 to Week 12.
61991362|NCT00778700|EXPERIMENTAL|Ruxolitinib Phosphate 0.5% Cream|Ruxolitinib phosphate 0.5% cream, applied topically, once daily from Day 1 to Week 12.
61991363|NCT00778700|EXPERIMENTAL|Ruxolitinib Phosphate 1.0% Cream|Ruxolitinib phosphate 1.0% cream, applied topically, once daily from Day 1 to Week 12.
61991364|NCT00778700|EXPERIMENTAL|Ruxolitinib Phosphate 1.5% Cream|Ruxolitinib phosphate 1.5% cream, applied topically, once daily from Day 1 to Week 12.
61991365|NCT04306874|EXPERIMENTAL|High Protein Supplement|60 g total protein per day, administered via twice daily ensure max protein shakes
62559591|NCT02018419|EXPERIMENTAL|Dosing Schedule A|"1. the priming step with ID injection of AlloStim on Days 0, 7, and 14;~2. the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 21;~3. the activation step with an IV infusion of AlloStim on Day 28;~4. the booster step with intravenous booster infusion of AlloStim on Days 56 and 84;~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
61991366|NCT04306874|NO_INTERVENTION|Control|No intervention on diet; routine dietary practice
61991367|NCT01810029|EXPERIMENTAL|Cardiac Rehabilitation plus Transcendental Meditation|a standard validated cardiac rehabilitation program plus a standard validated stress reduction component, the Transcendental Meditation program
61991368|NCT01810029|ACTIVE_COMPARATOR|Cardiac Rehabilitation|This control is a standard Cardiac Rehabilitation without a stress reduction technique
62387126|NCT04921111|EXPERIMENTAL|Healthy Women Aged 18 to 26 Years|120 healthy women aged18 to 26 years are in this arm. The first group was 40 subjects to be inoculated with low dose vaccine; After the first low dose group was completed, the safety observation was conducted 7 days after the first dose was completed. If there was no need to suspend / terminate the study, 40 subjects in the group were continued to receive the medium dose vaccine; After the first dose group was completed, the safety observation was 7 days after the first dose was completed. If there was no need to suspend / terminate the test, 40 subjects in the group were inoculated with high dose group. In each dose group SCT1000 : Gardasil®9 : placebo =3:1:1.
62387127|NCT04921111|EXPERIMENTAL|Healthy Women Aged 27 to 45 Years|120 healthy women aged 27 to 45 years are in this arm. The first group was 40 subjects to be inoculated with low dose vaccine; After the first low dose group was completed, the safety observation was conducted 7 days after the first dose was completed. If there was no need to suspend / terminate the study, 40 subjects in the group were continued to receive the medium dose vaccine; After the first dose group was completed, the safety observation was 7 days after the first dose was completed. If there was no need to suspend / terminate the test, 40 subjects in the group were inoculated with high dose group. In each dose group SCT1000 : Gardasil® : placebo =3:1:1.
62387128|NCT02348931|ACTIVE_COMPARATOR|Surgery plus device (Nasella)|Person in need of surgery has cast for one week, then use of customized nasal brace for nose (Nasella) deformities during 8 weeks.
62387129|NCT02348931|EXPERIMENTAL|Surgery, no device thereafter|Person in need of surgery has cast for 1 week; thereafter no use of customized nasal brace (Nasella) .
62559592|NCT02018419|EXPERIMENTAL|Dosing Schedule B|"1. the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;~2. the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14;~3. the activation step with an IV infusion of AlloStim on Day 21;~4. the booster step with intravenous booster infusion of AlloStim on Days 49 and 77.~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
62559593|NCT02018419|EXPERIMENTAL|Dosing Schedule C|"1. the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;~2. the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14, and intra-tumor injection of AlloStim again into the same cryoablated lesion on Day 17;~3. the activation step with an IV infusion of AlloStim on Day 21;~4. the booster step with intravenous infusion of AlloStim on days 49 and 77.~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
62559594|NCT05717569|ACTIVE_COMPARATOR|Group A|Group A: Stoss vitamin D therapy
62559595|NCT05717569|ACTIVE_COMPARATOR|Group B|Group B: Oral vitamin D therapy .
62559596|NCT03692715|EXPERIMENTAL|ciprofloxacin|Single dose oral or intravenous ciprofloxacin prior to shockwave lithotripsy
62559597|NCT03692715|PLACEBO_COMPARATOR|Placebo|identical oral placebo if oral cipro was used, or intravenous saline alone in a blinded fashion if IV cipro was used prior to shockwave lithotripsy.
62767665|NCT04317326|EXPERIMENTAL|Life style modification and titrated NIV(S/T mode)|In-laboratory polysomnographic NIV titration will be performed according to published guidelines (Berry R et al JCSM 2010). In addition to lifestyle modification and oxygen (if required), home NIV therapy with fixed pressures will be started. The ventilator mode will be a bilevel PAP with backup respiratory rate (BIPAP S/T mode). The ventilator adjustment will be firstly performed in awake situation and then during sleep by means of a PSG.
61991369|NCT02761707||Parkinson's Disease|Non-smokers, ages 18-80, diagnosed with Parkinson's Disease. Must be Hoehn and Yahr stage 2 or less with a history of motor symptoms less than two years.
61991370|NCT02761707||Alzheimer's Disease|Non-smokers, ages 18-80, diagnosed with Alzheimer's Disease. Must meet the 2011 National Institute on Aging-Alzheimer's Association and the 1984 National Institute for Neurological and Communicative Disorders and Stroke-Alzheimer's disease and Related Disorders Association criteria for probable AD.
61991371|NCT02761707||Progressive Supranuclear Palsy|Non-smokers, ages 18-80, diagnosed with Progressive Supranuclear Palsy. Must meet the NINDS-SPSP criteria for probable PSP, which requires vertical supranuclear gaze palsy, prominent postural instability, and falls in the first year of onset, as well as a number of other clinical features.
61991372|NCT02761707||Essential Tremor|Non-smokers, ages 18-80, diagnosed with Essential Tremor.
61991373|NCT02761707||Drug-Induced Parkinson's Disease|Non-smokers, ages 18-80, diagnosed with Drug-Induced Parkinson's Disease.
61991374|NCT02761707||Myasthenia Gravis|Non-smokers, ages 18-80, diagnosed with Myasthenia Gravis.
61991375|NCT02761707||Multiple System Atrophy|Non-smokers, ages 18-80, who have been diagnosed with Multiple System Atrophy.
61991376|NCT02761707||Diffuse Lewy Body Disease|Non-smokers, ages 18-80, diagnosed with Diffuse Lewy Body Disease. Must meet the Consensus Criteria for the clinical diagnosis of DLBD.
61991377|NCT02761707||Healthy Controls|Non-smokers, ages 18-80, with no neurodegenerative disease, and no first-degree relatives with a neurodegenerative disease.
61991378|NCT02761707||Spinal Cord Injury|
61991379|NCT02761707||Asymptomatic Relatives|
61991380|NCT01442870|EXPERIMENTAL|Metformin|Metformin
61991381|NCT01442870|NO_INTERVENTION|No metformin|No metformin during primary endpoint assessment period (at least 3 weeks). Patients will subsequently be initiated on metformin.
61991382|NCT00842660|EXPERIMENTAL|Gemzar,survival|
61991383|NCT01865279|EXPERIMENTAL|Trial part 1|
61991384|NCT01865279|ACTIVE_COMPARATOR|Trial part 2|
61991385|NCT00433563|EXPERIMENTAL|Once daily radiotherapy|Once daily radiotherapy
61991386|NCT00433563|ACTIVE_COMPARATOR|Twice daily radiotherapy|Twice daily radiotherapy
62182709|NCT00037713|EXPERIMENTAL|2|"Treatment will consist of 5 vaccinations (each consisting of 8 single intradermal injections) over a period of 10 to 12 weeks unless one of the following occur:~1. intolerable toxicity precluding further treatment progression of disease~2. patient refusal~3. occurrence of pregnancy"
62387130|NCT02348931|ACTIVE_COMPARATOR|Only device (Nasella)|No need for surgery; use of customized nasal brace (Nasella) for nose deformities is made to improve look (cosmetic reason).
62387131|NCT05430230|EXPERIMENTAL|Cross-over Treatment: Initial treatment with naproxen|There will be a 4 period cross-over: 2 weeks of treatment with IP, followed by 2 weeks of washout, and this repeated 3 more times. Treatment will be such that all participants will receive 2 treatment periods with naproxen and 2 treatment periods with placebo. The order of treatment will be randomized and the treatment allocation and IP will be blinded.
62387132|NCT05430230|EXPERIMENTAL|Cross-over Treatment: Initial treatment with placebo|There will be a 4 period cross-over: 2 weeks of treatment with IP, followed by 2 weeks of washout, and this repeated 3 more times. Treatment will be such that all participants will receive 2 treatment periods with naproxen and 2 treatment periods with placebo. The order of treatment will be randomized and the treatment allocation and IP will be blinded.
62387133|NCT00517673|EXPERIMENTAL|GSK945237|Active Study Drug
62387134|NCT00517673|PLACEBO_COMPARATOR|Sugar Pill|Placebo
62387135|NCT03794856||Asthma patients|Asthma patients will undergo behavioral testing and imaging at a single timepoint.
62387136|NCT03794856||Healthy Volunteers|Healthy volunteers will undergo behavioral testing and imaging at a single timepoint.
62387137|NCT03369925|PLACEBO_COMPARATOR|Placebo|
62387138|NCT03369925|EXPERIMENTAL|Cognizin|
62387139|NCT02967042|OTHER|18F-PET-TT|
62387140|NCT03384316|EXPERIMENTAL|1/Arm 1-Dose De-Escalation|Dose De-Escalation
62387141|NCT03384316|EXPERIMENTAL|2/Arm 2 - Dose Expansion|Dose Expansion
62387142|NCT01048736|ACTIVE_COMPARATOR|Exercise|All treatment groups will receive 4d/wk of exercise
62387143|NCT01048736|EXPERIMENTAL|Exercise + Diet (-250 kcal/d deficit)|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; \~4.5 kg weight loss),
62387144|NCT01048736|EXPERIMENTAL|Exercise + Diet (-600 kcal/d deficit)|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; \~10.9 kg weight loss)
62387145|NCT05917002|EXPERIMENTAL|Real TBS to the mPFC|The type of stimulation to be used will be intermittent theta burst (iTBS) stimulation to the mPFC with a figure 8 coil (Coil Cool-B65 A/P). Participants will receive three 3-minute sessions of iTBS (600 pulses; 190s; 120% resting motor threshold) with 10-15-minute breaks in between each session or more per participant preference.
62387146|NCT05917002|SHAM_COMPARATOR|Sham TBS to the mPFC|The MagVenture MagPro system has an integrated, active sham which passes current through two surface electrodes placed on the scalp. The electrodes will be placed on the left frontalis muscle for all sessions. A patient identification card will randomize participants to receive either sham or active stimulation in the first session.This system maintains blinding by a gyroscope in the coil which indicates to the clinical staff whether the coil should be rotated up or down for this participant once the card is entered into the machine. One side of the coil is active, the other is sham. The integrity of the double blind procedure will be assessed by asking the patients and study personnel rate their confidence regarding whether they thought they received real or sham. (Scale 1-10)
62387147|NCT03031873|OTHER|MRI perfusion imaging|"SWAN imaging on the GE 3 T has been attempted but the preliminary evidence suggest that the images are of low resolution and difficult to interpret. Similarly, early experience with TRMRA suggest poor spatial and temporal resolution using the standard out-of-the-box protocols.~Thus, there is a significant opportunity to improve SWAN and TRMRA, to evaluate the evolution of progressive obliteration of the AVM nidus. Specifically, this is attractive for brain AVMs that are treated with radiosurgery as MRI is required for clinical grounds for treatment planning purposes."
62387148|NCT03459794|ACTIVE_COMPARATOR|Ivermectin|Ivermectin will be administered once at 150mcg/kg, orally.
62387149|NCT03459794|PLACEBO_COMPARATOR|Control|An oral placebo will be administered once
62387150|NCT03294798|EXPERIMENTAL|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 600-900μg,once per two weeks.
62387151|NCT03294798|ACTIVE_COMPARATOR|Pegasys|Pegasys 180 mcg, once per week
62387152|NCT01778764||retrospective cohort|retrospective follow-up of patients treated since 2006
62559598|NCT01487967|EXPERIMENTAL|Intervention|Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
62767666|NCT04317326|ACTIVE_COMPARATOR|Life style modification and titrated CPAP|In-laboratory polysomnographic CPAP titration will be performed according to published guidelines (SEPAR guideline or AASM guideline). In addition to lifestyle modification and oxygen (if required), home CPAP therapy at a fixed pressure will be initiated.
62387153|NCT01778764||prospective cohort|patients treated over a 5-year period from January 15, 2013 to December 31, 2017 and followed for at least one year thereafter
62387154|NCT05414422|EXPERIMENTAL|PCN-101 30 mg|PCN-101 30 mg
62387155|NCT05414422|EXPERIMENTAL|PCN-101 60 mg|PCN-101 60 mg
62387156|NCT05414422|PLACEBO_COMPARATOR|Placebo|Placebo
62387157|NCT05937503|EXPERIMENTAL|Manual therapy|Manual therapy group
62387158|NCT05937503|OTHER|Conventional physiotherapy|Conventional physiotherapy group
62387159|NCT05136612|EXPERIMENTAL|control grup|conventional physiotherapy
62387160|NCT05136612|EXPERIMENTAL|intervention group|Armeo spring robotic rehabilitation
62387161|NCT00697424|EXPERIMENTAL|1|All subjects will be placed on continuous positive airway pressure (CPAP) therapy during a full night sleep study or polysomnography (PSG). The subjects will spend 2 hours on sub-therapeutic CPAP 4 cmH2O of pressure and the remainder on there therapeutic pressure. Values reported on the device will be compared to scored values from manual scoring of the sleep study.
62559599|NCT01487967|NO_INTERVENTION|Control|Parents will receive education on ADHD and its treatment, and otherwise receive standard care.
62559600|NCT04376658||Cohort 1 (Coalition I)|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection with up to 4L/minute oxygen supply through nasal catheter.
61991387|NCT00746941|NO_INTERVENTION|Local standard of care|"All participants received local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.~Participants in this treatment arm had the option of adding 250 mg mefloquine by mouth at Week 4 (Day 28) or Week 8 (Day 56) daily for 3 days, and then weekly through Week 24."
61991388|NCT00746941|EXPERIMENTAL|Local standard of care plus mefloquine 250 mg|"All participants received local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.~Participants received 250 mg mefloquine by mouth on Days 0, 1, and 2 and then weekly through Week 24."
62767667|NCT02839239|EXPERIMENTAL|Drops with lactobacilli and vitamin D3|Exclusive breast feeding plus L. rhamnosus 19070-2 and L. reuteri DSM 12246 in a dose of 125 x 106 CFU (both strains) with 1,667 mg fructooligosaccharides and 2,5 mcg (100 IU) vitamin D3 (in sunflower oil) per 6 drops. One dose (6 drops) in the first morning (from 6 AM) breastfeeding, and one dose (6 drops) in one of the evening (6 PM-12 PM) breast feedings for 28 days.
62767668|NCT02839239|PLACEBO_COMPARATOR|Drops with vitamin D3|Exclusive breast feeding plus 2.5 mcg (100 IU) vitamin D3 (in sunflower oil) per 6 drops. One dose (6 drops) in the first morning (from 6 AM) breastfeeding, and one dose (6 drops) in one of the evening (6 PM-12 PM) breast feedings for 28 days.
61991389|NCT01838642|ACTIVE_COMPARATOR|RET mutation positive participants|Rearranged during transfection (RET) mutation positive
62767669|NCT03224091||Patients at Psychiatric Center Ballerup|
61991390|NCT01838642|ACTIVE_COMPARATOR|RET mutation negative participants|Rearranged during transfection (RET) mutation negative
61991391|NCT03322215|EXPERIMENTAL|Palbociclib and fulvestrant|"Combination of palbociclib and fulvestrant~Palbociclib:~125 mg capsule administered orally once daily for 21 consecutive days followed by 7 days off treatment. Dose modification is recommended based on individual safety and tolerability.~Fulvestrant:~500 mg administered intramuscularly on days 1 and 15 of cycle 1, and then on day 1 of each subsequent 28-day cycle."
62559601|NCT04376658||Cohort 2 (Coalition II)|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection needing oxygen supplementation \> 4L/min on nasal catheter or HFNC or NIV or MV or ECMO.
61991392|NCT03322215|ACTIVE_COMPARATOR|Capecitabine|1,000 mg/m2 tablet administered orally twice daily for 2 weeks followed by one week of rest. Depending on adverse reactions, both dose escalation and dose reductions will be performed.
62559602|NCT04376658||Cohort 3 (Coalition III)|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection with moderate or severe ARDS according to the Berlin definition
62559603|NCT04376658||Cohort 4 (Coalition IV)|Adult hospitalized patients with proven SARS-Cov-2 infection and D-dimer above the upper limit of the normal range
62559604|NCT04376658||Cohort 5 (Coalition VI)|Adult hospitalized patients with proven SARS-Cov-2, needing oxygen supplementation to maintain SpO2 \> 93%, and two or more of the following inflammatory tests: D-dimer \> 1,000 ng/mL; C reactive protein (CRP) \> 5 mg/dL; Ferritin \> 300 mg/dL; Lactate dehydrogenase (LDH) \> upper limit of normal
62559605|NCT03855774|OTHER|Polymorphisms|Classification of sleep disorders prevalence through polymorphisms
62559606|NCT01291355|EXPERIMENTAL|Specific maternal position|"women allocated to intervention group will be invited to adopt a posture all fours type:support on the knees, torso tilted forward, back stretched for a minimum of 10 minutes. A cushion is placed between the legs of the woman to limit the cuts. According to Dr de Gasquet, author of the description of this posture, the effect on the variety of presentation would be almost immediate."
62767670|NCT03224091||Healthy Controls|
61991393|NCT05465265|ACTIVE_COMPARATOR|Intervention and control group|To establish the effect of navigation on PrEP uptake, adherence and retention among PWID.
61991394|NCT05465265|PLACEBO_COMPARATOR|Control group|To establish the effect of providing PrEP information through pamphlets on PrEP uptake, adherence and retention among PWID.
62559607|NCT01291355|NO_INTERVENTION|Control|Not specific intervention for this group- Only usual care
62559608|NCT04965311|EXPERIMENTAL|Treatment of POPF (botulinum toxin type A)|Patients receive botulinum toxin type A via endoscopic injection into intraduodenal sphincter of Oddi segment between 7-14 days prior to planned distal pancreas resection.
62559609|NCT03262428||Patients|Patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
62767671|NCT03224091||Healthy Controls recovered from an eating disorder|
62767672|NCT05403697|EXPERIMENTAL|Individualized MAP group|Individualized MAP strategy aimed at achieving a mean arterial pressure within 10% of the reference value (ie, patient's resting MAP measured during the preoperative anesthesiology consultation) during the operating room period and the 24h following surgery in the ICU.
62767673|NCT05403697|NO_INTERVENTION|Control group|Standard management strategy of treating MAP ≥ 65 mmHg, during the operating room period and the 24h following surgery in the ICU. No intervention to actively decrease MAP.
61991395|NCT04434690|EXPERIMENTAL|Simultaneous|2 surgeons will perform simultaneous total knee arthroplasty in this group.
61991396|NCT04434690|ACTIVE_COMPARATOR|Single surgeon bilateral TKA group|One surgeon will perform sequentially tptal knee arthroplasty in this group
62182710|NCT04629443|EXPERIMENTAL|S64315 (also referred as MIK665) with azacitidine|
62182711|NCT02338427|EXPERIMENTAL|proteomic|
62182712|NCT05181397|EXPERIMENTAL|Tocilizumab|Participants in tocilizumab group will receive intravenous 8mg/kg tocilizumab. No Intervention: control, participants in control group will receive regular treatment.
62182713|NCT05181397|NO_INTERVENTION|Control|Participants in control group will receive regular treatment.
62559610|NCT03262428||Caregivers|Caregivers of patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
62559611|NCT03262428||Health care professionals|Health care professionals involved in the care of patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
62559612|NCT05405816|OTHER|after laparoscopic sleeve gastrectomy|Patients who underwent laparoscopic sleeve gastrectomy surgery
62559613|NCT05405816|NO_INTERVENTION|before laparoscopic sleeve gastrectomy surgery|obese patient preparing for laparoscopic sleeve gastrectomy surgery
62559614|NCT02205073|PLACEBO_COMPARATOR|Dosing Period 1|
62559615|NCT02205073|ACTIVE_COMPARATOR|Dosing Period 2|
62767674|NCT00780286|EXPERIMENTAL|1|
62767675|NCT00780286|ACTIVE_COMPARATOR|2|
61991397|NCT03684915|EXPERIMENTAL|rotary files|"1. Pre-operative radiograph showing all roots and their apices.~2. Local anaesthetic (to enable use of rubber dam clamp).~3. Rubber dam isolation.~4. Removal of caries.~5. Removal of roof of pulp chamber.~6. Removal of any remains of coronal pulp tissue with sharp sterile excavator or large bur in slow hand piece.~7. Identify root canals.~8. Irrigate with normal saline (0.9%)~9. Estimate working lengths of root canals keeping 2 mm short of the radiographic apex.~10. Insert rotary files into canals and debride the canals lightly and gently.~11. Irrigate the root canals.~12. Dry canals with pre-measured paper points, keeping 2 mm from root apices.~13. Canals will be dried with paper points, obturated by injecting Metapex. (Meta Biomed - Metapex Root Canal Filling Material)~14. Stainless steel crown will be performed"
61991398|NCT03684915|ACTIVE_COMPARATOR|manual files|All steps as that of intervention group are to be followed except step (j) instead of it; a manual files will be inserted into the canals for debridement lightly and gently
61991399|NCT04220411|EXPERIMENTAL|AR100DP1 (1.25%)_Phase I|Subjects topically apply AR100DP1 twice per day with at least 4 hour interval. The daily dosage of 1.25% AR100DP1 topical administration is 31.25 mg/day (1.25% × 1,250 × 2 = 31.25).
61991400|NCT04220411|EXPERIMENTAL|AR100DP1 (2.5%)_Phase I|Subjects topically apply AR100DP1 twice per day with at least 4 hour interval. The daily dosage of 2.5% AR100DP1 topical administration is 62.5 mg/day (2.5% × 1,250 × 2 = 62.5).
61991401|NCT04220411|EXPERIMENTAL|AR100DP1 (5%)_Phase I|Subjects topically apply AR100DP1 twice per day with at least 4 hour interval. The daily dosage of 5% AR100DP1 topical administration is 125 mg/day (5% × 1,250 × 2 = 125).
61991402|NCT04220411|EXPERIMENTAL|AR100DP1 (5%)_Phase IIa|Subjects topically apply AR100DP1 twice per day with at least 4 hour interval. The daily dosage of 5% AR100DP1 topical administration is 125 mg/day (5% × 1,250 × 2 = 125).
62387162|NCT03996993||Hormone Therapy Cohort|Post-radical prostatectomy patients fitting our inclusion criteria, including rising PSA \> 0.1 ng/ml, a positive SOC Axumin scan, and a patients not having received hormonal therapy for a minimum of 3 months, will receive hormonal therapy in the form of Casodex for 2 weeks, followed by Lupron indefinitely. Patients will then receive serial Axumin scans up to 1 year post-therapy.
61991403|NCT03917420|EXPERIMENTAL|Tenofovir/Emtricitabine|Participants will take 5 once daily doses above noted combination tab at 200mg/300mg before each sampling visit
61991404|NCT03810274||3DV+TPS|This experiment included a total of 300 patients with nasopharyngeal carcinoma, using 3DV + TPS software and imported TPS, domestic TPS, these three sets of TPS delineate bilateral crystal, bilateral optic nerve, bilateral eyeball, bilateral parotid gland, oral cavity, spinal cord There are 12 organs in the brainstem and brain, and the accuracy and speed of the 3 sets of TPS sketches are compared.
62767676|NCT03476161|OTHER|Group 1|"upper left and lower right 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive~upper right and lower left 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive"
62767677|NCT03476161|OTHER|Group 2|"upper right and lower left 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive~upper left and lower right 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive"
62767678|NCT05141656||Single arm|Patients diagnosed as pancreatic tumor will considered to be enrolled regardless of specific pathologic subtypes expect for metastasis of pancreas. Baseline data and treatment information will be collected under fully informed consent.
62767679|NCT00815828|OTHER|1|Group that don't do the resistance exercises
61991405|NCT06136663||Pain-free control subjects|Patients with no postoperative chronic pain after open reduction and internal fixation of lower limb fractures.
61991406|NCT06136663||Patients with chronic postsurgical pain|Patients with postsurgical chronic pain after open reduction and internal fixation of lower limb fractures.
61991407|NCT01886807|OTHER|(DL group)|direct laryngoscopy for nasotracheal intubation without oxygen insufflation
61991408|NCT01886807|OTHER|(DL-O2 Group)|direct laryngoscopy for nasotracheal intubation with oxygen insufflation
62387163|NCT03996993||Salvage Radiotherapy Cohort|Post-radical prostatectomy patients fitting our inclusion criteria, including rising PSA \> 0.1 ng/ml, not concurrently on androgen deprivation therapy (ADT) and/or received ADT in the past 3 months, and a positive SOC Axumin scan, will receive salvage radiation therapy according to the following protocol. External beam radiation therapy will be delivered in the form of high-dose intensity modulated radiation therapy (IMRT). A total prescribed dose of 72 Gy will be delivered in 40 fractions over 8 weeks. For the first 25 fractions, the clinical target volume (CTV) is defined as the residual prostatic bed, plus internal/external iliac nodes. For the subsequent 15 fractions the CTV is defined as the residual prostatic bed plus margin. As part of SOC, the radiation fields will incorporate the Axumin positive areas into treatment planning objectives. Patients will then receive serial Axumin scans up to 1 year post-therapy.
62559616|NCT02205073|EXPERIMENTAL|Dosing Period 3|
62767680|NCT03551665|EXPERIMENTAL|Step training|This group will undergo a baseline control period, as well as an intervention period. As such, they will serve as their own control subjects.
62767681|NCT00556179|EXPERIMENTAL|1|
62767682|NCT04498351|PLACEBO_COMPARATOR|cotrol group|
62767683|NCT04498351|ACTIVE_COMPARATOR|dexmedetomidine group|
62767684|NCT04498351|ACTIVE_COMPARATOR|magnesium sulphate group|
61991409|NCT01886807|EXPERIMENTAL|(VL Group)|nasotracheal intubation using the Truview PCD video laryngoscope
62767685|NCT04498351|ACTIVE_COMPARATOR|dexmedetomidine and magnesium sulphate group|
62767686|NCT02652416|EXPERIMENTAL|SRD part (low dose)|Chinese, Japanese both
62767687|NCT02652416|EXPERIMENTAL|SRD part (medium dose)|Chinese, Japanese both
62767688|NCT02652416|EXPERIMENTAL|SRD part (high dose)|Chinese, Japanese both
62767689|NCT02652416|EXPERIMENTAL|MD part (high dose)|Chinese, Japanese both
61991410|NCT03144882|ACTIVE_COMPARATOR|intervention|the trial group (n =35 )
61991411|NCT03144882|PLACEBO_COMPARATOR|placebo|control group
62767690|NCT02652416|EXPERIMENTAL|Placebo (SRD part)|placebo
62767691|NCT02652416|PLACEBO_COMPARATOR|Placebo (MD part)|placebo
62767692|NCT05065567|ACTIVE_COMPARATOR|haloperidol|these patients will receive 5mg IM haloperidol
62767693|NCT05065567|ACTIVE_COMPARATOR|droperidol|these patients will receive 2.5mg IV droperidol
62767694|NCT05065567|ACTIVE_COMPARATOR|ondansetron|these patients will receive 8mg IV ondansetron
62767695|NCT01256762|EXPERIMENTAL|Imetelstat + Paclitaxel (with or without bevacizumab)|
62559617|NCT01062425|EXPERIMENTAL|Cediranib, TMZ, and RT|Cediranib (3 days) followed by radiation therapy (RT) + daily temozolomide (TMZ) + cediranib followed by cediranib monotherapy (4 weeks) followed by TMZ + cediranib for 12 cycle maximum.
61991412|NCT03125434|EXPERIMENTAL|healthy volunteers|EOS full-spine, MRI, gait analysis
61991413|NCT03330938|EXPERIMENTAL|CBI and Resilience|8 sessions total, once a week, 2 hours long each, consistent of 6 sessions of Cognitive-behavioral Intervention (CBI) plus 2 sessions to improve resilience strengths.
61991414|NCT03330938|ACTIVE_COMPARATOR|Cognitive-behavioral Intervention|8 sessions total, once a week, 2 hours long each. Cognitive-behavioral Intervention (CBI) without resilience strengthening.
62767696|NCT01256762|EXPERIMENTAL|Paclitaxel (with or without bevacizumab) alone|
61991415|NCT04336891||Hypoactive Sexual Desire Disorder|Women with Hypoactive Sexual Desire Disorder (HSDD, n=23)
61991416|NCT04336891||Moderate to severe VVA|Women with dyspareunia due to moderate to severe vulvovaginal atrophy (VVA) (n=12)
61991417|NCT04336891||Mild to moderate VVA|Women with dyspareunia due to mild to moderate VVA (n=37)
61991418|NCT04336891||HSDD + VVA|Women with HSDD reporting also significant dyspareunia due to moderate to severe VVA (n=9).
61991419|NCT05612685|EXPERIMENTAL|Intervention|This arm will receive a healthcare provider referral to a tax filing app
61991420|NCT03220217|EXPERIMENTAL|5-20μg/40-80 MBq, 30-45μg/100-140 MBq|Subjects will receive a first intravenous (i.v.) injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 40 to 80 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 100 to 140 MBq.
62767697|NCT04334213|EXPERIMENTAL|Sequence 1|"Period 1: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days.~Period 2: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets)."
62767698|NCT04334213|EXPERIMENTAL|Sequence 2|Period 1: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets). Period 2: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days
62767699|NCT04334213|EXPERIMENTAL|Sequence 3|Period 1: D745, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D745: 1 tablet, D150: 2 tablets). Period 2: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets).
61991421|NCT03220217|EXPERIMENTAL|5-20μg/100-140 MBq, 30-45μg/160-200 MBq|Subjects will receive a first i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 100 to 140 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 160 to 200 MBq.
61991422|NCT03220217|EXPERIMENTAL|5-20μg/160-200 MBq, 30-45μg/40-80 MBq|Subjects will receive a first i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 160 to 200 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 40 to 80 MBq.
61991423|NCT05735561||Proximal Humerus Fracture Anterior Dislocation|The study doesn't provide any intervention. This group is defined as having a dislocation that is anterior to the glenoid.
62559618|NCT01062425|ACTIVE_COMPARATOR|Placebo, TMZ, and RT|Placebo (3 days) followed by radiation therapy (RT) + daily temozolomide (TMZ) + placebo followed by placebo monotherapy (4 weeks) followed by TMZ + placebo for 12 cycle maximum.
62559619|NCT03975894|EXPERIMENTAL|Intervention|Regular prophylactic blood transfusion given every 6-10 weeks during pregnancy to maintain a HbS% of \<30%.
62767700|NCT04334213|EXPERIMENTAL|Sequence 4|Period 1: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets). Period 2: D745, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D745: 1 tablet, D150: 2 tablets).
62767701|NCT02413801||Psoriasis|Individuals with psoriasis
62767702|NCT02413801||Healthy|Individuals that are healthy
61991424|NCT05735561||Proximal Humerus Fracture Posterior Dislocation|The study doesn't provide any intervention. This group is defined as having a dislocation that is posterior to the glenoid.
61991425|NCT05735561||Proximal Humerus Fracture Varus Dislocation|The study doesn't provide any intervention. This group is defined as having a dislocation that is in varus compared to the glenoid.
61991426|NCT05735561||Proximal Humerus Fracture Valgus Dislocation|The study doesn't provide any intervention. This group is defined as having a dislocation that is in valgus compared to the gelnoid.
61991427|NCT02479711|EXPERIMENTAL|composite restoration|lower permanent molar with an approximal and /or occlusal carious lesion will be restored with Tetric EvoCeram Bulk Fill composite
62559620|NCT03975894|NO_INTERVENTION|Control|Symptom directed blood transfusion during pregnancy.
62559621|NCT06346301|EXPERIMENTAL|Imagery Rescripting|"Baseline consists of a random assigned period of 3-8 weeks with measurements and no intervention.~Intervention consists of a maximum of 12 sessions of imagery rescripting, provided twice-weekly.~Post treatment follow up consists of 6 weeks with only measurements and no intervention."
62559622|NCT02385474|EXPERIMENTAL|38% SDF semi-annual|semi-annual application of 38% SDF
62767703|NCT06237803||Subjects with MGUS, SMM, MM, PCL|"Subjects with Monoclonal Gammopathy of Undetermined Significance (MGUS), smouldering Multiple Myeloma (SMM), Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)~Timepoints and samples to be collected are the following:~* bone marrow aspirate, bone marrow biopsy, EMD biopsy, peripheral blood and serum at baseline;~* bone marrow aspirate, bone marrow biopsy, peripheral blood and serum pre-maintenance in TE patients or after 1 year of therapy in Non-Transplant-Eligible (NTE) patients;~* bone marrow aspirate, bone marrow biopsy, peripheral blood and serum during maintenance therapy and only if performed as SOC;~* bone marrow aspirate, bone marrow biopsy, EMD biopsy peripheral blood and serum at 1st and later PD."
62767704|NCT02976103|OTHER|Standard Care|-Standard Care pain medicine/management will be given
62767705|NCT02976103|EXPERIMENTAL|JACKI® RECOVERY JACKET + Standard Care|"* Patient will be encouraged to use the Jacki Recovery Jacket at home~* Patient will be taught how to tuck the drainage tubes in the jacket pocket~* Patient will be taught how to un-tuck the drainage tubes from jacket pocket~* Standard care pain medicine/management will be given"
61991428|NCT02479711|ACTIVE_COMPARATOR|glass ionomer cement|lower permanent molar with an approximal and /or occlusal carious lesion will be restored with the glass ionomer restoration, Equia
61991429|NCT02669368|ACTIVE_COMPARATOR|Standard dose Rocuronium|Pretreatment of saline 100ml then giving Rocuronium 0.6 mg/kg at induction of anesthesia.
61991430|NCT02669368|ACTIVE_COMPARATOR|Low dose Rocuronium|Pretreatment of saline 100ml then giving Rocuronium 0.45 mg/kg at induction of anesthesia.
61991431|NCT02669368|ACTIVE_COMPARATOR|Low dose Rocuronium + Magnesium Sulfate|Pretreatment of Magnesium sulfate 30 mg/kg then giving Rocuronium 0.45 mg/kg at induction of anesthesia.
61991432|NCT02998801|PLACEBO_COMPARATOR|Watch video using IPAD|Patient will watch the educational video using an IPAD
61991433|NCT02998801|ACTIVE_COMPARATOR|Watch video using VR goggles|Patient will watch the educational video using VR goggles
61991434|NCT02942355|EXPERIMENTAL|Cohort A: First-line therapy|Anastrozole by mouth daily and palbociclib by mouth Days 1-21 on a 28 day cycle
61991435|NCT02942355|EXPERIMENTAL|Cohort B: Maintenance therapy|Anastrozole by mouth daily and palbociclib by mouth Days 1-21 on a 28 day cycle
61991436|NCT03179150||Oncological patients with extra-thoracic cancer|Patients enrolled into the study performed CT either for staging, restaging or follow-up of extrathoracic malignancies.
61991437|NCT04961034|OTHER|classic KPE|the classic management of biliary atresia as described
62559623|NCT02385474|EXPERIMENTAL|38% SDF annual|annual application of 38% SDF
62767706|NCT00581360|OTHER|Bortezomib + Doxorubicin|Patients with incurable adenoid cystic carcinoma of the head and neck who receive doxorubicin and bortezomib
61991438|NCT04961034|OTHER|modified KPE|we added 2 sutures posterior, one on each side and two anterior. this will hang the jejunal loop to promote tension free anastomosis
61991439|NCT02514356|ACTIVE_COMPARATOR|Own adherence|Participants in this group receive a weekly message by SMS. They receive the intervention 'Behavioral: Own Adherence'.
62387164|NCT02612558|EXPERIMENTAL|Fostamatinib 150 mg|Fostamatinib 150 mg bid (morning and evening) over the course of 24 weeks
62559624|NCT02385474|ACTIVE_COMPARATOR|12% SDF semi-annual|semi-annual application of 12% SDF
62767707|NCT04170270|EXPERIMENTAL|oral omeprazole|oral omeprazole in bleeding peptic ulcer after endoscopic therapy 40 mg twice daily for 72 hours
62767708|NCT04170270|ACTIVE_COMPARATOR|intravenous omeprazole|intravenous omeprazole in bleeding peptic ulcer after endoscopic therapy as continuous infusion at rate of 8 mg/hour for 72 hours
62767709|NCT05262686|EXPERIMENTAL|belimumab plus low dose IL-2|"10mg/kg belimumab was intravenously injected to patients with systemic lupus erythematosus every month for 24 weeks.~Interleukine-2 was first added to the original treatment for systemic lupus erythematosus with 1 million IU qod for 12 weeks, injected subcutaneously at the outer side of upper arm, abdomen and thigh, then the same dose of IL-2 was injected once a week for 12 weeks subcutaneously."
61991440|NCT02514356|ACTIVE_COMPARATOR|Own and group level adherence|Participants in this group receive a weekly message by SMS. They receive the intervention 'Behavioral: Own and Group Adherence'.
61991441|NCT02159664|EXPERIMENTAL|didgeridoo practice|
61991442|NCT04085198|ACTIVE_COMPARATOR|No-touch technique with the application of light physics rules|This procedure will be performed by the gynecologists who are familiar to the rules of the 'lights physics' and are currently 'lights physics' rules in their clinical practice. The brightness or darkness of the tissue which reflects the distance between the light source and the surrounding tissue will be used to find the correct route from the vagina introitus to the uterine cavity.
61991443|NCT04085198|PLACEBO_COMPARATOR|Control|Patients in this arm of the study protocol will receive standard hysteroscopy with 'no-touch' technique without the utilization of the 'lights physics' rules. The gynecologist performing this procedure will find their route from the vagina introitus to the uterine cavity by the identification of the anatomical structures on their way.
61991444|NCT02862431|EXPERIMENTAL|Cohort 1 (JNJ-64565111 2.5 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 2.5 Nanomole Per Kilogram (nmol/kg) JNJ-64565111 or placebo.
61991445|NCT02862431|EXPERIMENTAL|Cohort 2 (JNJ-64565111 3 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 3.0 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
62182714|NCT05096078|ACTIVE_COMPARATOR|Diet Group|Individuals will receive only dietary treatment that the dietitian deems appropriate for 6 weeks.
62387165|NCT04509206|EXPERIMENTAL|Intervention|Subjects will undergo four nutritional educational classes, lasting 1 hour long, conducted over a two month period. These classes will occur on zoom and subjects will be located in their home.
62559625|NCT02385474|ACTIVE_COMPARATOR|12% SDF annual|annual application of 12% SDF
62559626|NCT00942084|ACTIVE_COMPARATOR|Protocol V2&up-Grp1-Acyclo10 mg/kg IVq12|Gestational Age 23-29 weeks Postnatal Age \< 14 days Dosage 10 mg/kg IV q12 Number of Infants 8
62559627|NCT00942084|ACTIVE_COMPARATOR|Protocol V2&up-Grp2_Acyclo20 mg/kg IVq12|Gestational Age 23-29 weeks Postnatal Age 14-44 days Dosage 20 mg/kg IV q12 Number of Infants 8
62559628|NCT00942084|ACTIVE_COMPARATOR|Protocol V2&up-Grp3-Acyclo20 mg/kg IVq8|Gestational Age 30-34 weeks Postnatal Age \<45 days Dosage 20 mg/kg IV q8 Number of Infants 4
62767710|NCT05262686|ACTIVE_COMPARATOR|belimumab|10mg/kg belimumab was administrated to patients with systemic lupus erythematosus for at least 24 weeks, intravenously injected every month.
62767711|NCT05262686|ACTIVE_COMPARATOR|low dose IL-2|The first stage: interleukine-2 was added to the original treatment for systemic lupus erythematosus with 1 million IU qod for 12 weeks, injected subcutaneously at the outer side of upper arm, abdomen and thigh; The second stage: 1 million IU IL-2 was injected once a week for 12 weeks subcutaneously.
62767712|NCT05334420|EXPERIMENTAL|Healthy Dads Healthy Kids|A group-based lifestyle behavioral program for Hispanic fathers and children
62767713|NCT05334420|OTHER|Standard of care control|National guidelines and recommendations for healthy eating, physical activity and weight loss.
62767714|NCT00278330|EXPERIMENTAL|Arm I|Patients will receive a 1-hour infusion of flavopiridol on 5 days in week 1 and vorinostat by mouth three times a day in weeks 1 and 2. Treatment may repeat every 3 weeks for as long as benefit is shown.
62767715|NCT04878536|PLACEBO_COMPARATOR|Placebo drink|
62767716|NCT04878536|EXPERIMENTAL|Collagen drink|
61991446|NCT02862431|EXPERIMENTAL|Cohort 3 (JNJ-64565111 3.5 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 3.5 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
61991447|NCT02862431|EXPERIMENTAL|Cohort 4 (JNJ-64565111 Repeat or Lower Dose or Placebo)|Participants in ratio of 3:1 will receive a dose of JNJ-64565111 or placebo that would be a repeat or lower dose level previously assessed as well-tolerated.
61991448|NCT04838249||Female Control|"n = 20; Inclusion criteria~informed consent, if \<18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m² Exclusion criteria severe medical impairments (e.g., uncontrolled cardiovascular disease, severe heart failure, uncontrolled hypertension, cerebral insult, active malign disease, etc.) only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan (i.e., presence of metal in body, tattoos in head/neck region, claustrophobia etc.)"
61991449|NCT04838249||Male Control|"n = 20; Inclusion criteria~informed consent, if \<18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m² Exclusion criteria severe medical impairments (e.g., uncontrolled cardiovascular disease, severe heart failure, uncontrolled hypertension, cerebral insult, active malign disease, etc.) only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan (i.e., presence of metal in body, tattoos in head/neck region, claustrophobia etc.)"
61991450|NCT04838249||Female cross-sex hormone therapy|"n = 20; Inclusion criteria~transsexual patients undergoing cross-sex hormone therapy informed consent, if \<18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m²~Exclusion criteria~severe medical impairments (e.g., uncontrolled cardiovascular disease, etc.) self-initiated cross-sex hormone therapy before study start only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan"
62559629|NCT00942084|OTHER|Protocol V1-Grps1-4-Acyclo 500 mg/m2 IVq8h|All patients in protocol V1 were to be dosed with 500 mg/m2 IV q8h. Protocol V1 Group 1: Gestational Age: 23-29 Weeks; PNA: \<14 days; Protocol V1 Group 2: Gestational Age: 30-42 Weeks; PNA: \<14 days; Protocol V1 Group 3: Gestational Age: 23-29 Weeks; PNA: 14-60 days; Protocol V1 Group 4: Gestational Age: 30-42 Weeks; PNA: 14-60 days
62559630|NCT00503698|EXPERIMENTAL|Somatropin|Somatropin once daily from week 0 to end of trial
62767717|NCT05086055||Stroke patients|Stroke patients admitted to the stroke unit, St Olav´s hospital, Trondheim, Norway, without previous stroke, neurological disease or central nervous system (CNS) trauma, will be eligible for inclusion into the study. The planned cohort size is 135 patients.
62767718|NCT05086055||healthy volunteers|Age and gender matched controls without previous CNS disease or trauma are eligible for inclusion into the study. Estimated cohort size is 45 individuals. Volunteers will be recruited through announcement in local newspaper.
62767719|NCT06529848|ACTIVE_COMPARATOR|Exercise|The exercise intervention consists of supervised training 40-50 minutes x 3 weekly for 12 weeks.
62767720|NCT06529848|NO_INTERVENTION|Control|The participants who are randomized to the no-training group will be offered exercise train-ing after the intervention is completed. Participants will be encouraged to not change their lifestyle or medication throughout the study period.
62767721|NCT04098978|EXPERIMENTAL|Pharmacist Drug Therapy Management|
62767722|NCT00473525|PLACEBO_COMPARATOR|Placebo|
62767723|NCT00473525|EXPERIMENTAL|PF-00734200 10 mg QD|
61991451|NCT04838249||Male cross-sex hormone therapy|"n = 20; Inclusion criteria~transsexual patients undergoing cross-sex hormone therapy informed consent, if \<18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m²~Exclusion criteria~severe medical impairments (e.g., uncontrolled cardiovascular disease, etc.) self-initiated cross-sex hormone therapy before study start only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan"
61991452|NCT04259957||Clinician using Virtual Reality in Pain Management Program|Clinicians who have used immersive virtual reality as part of Pain Management program group.
61991453|NCT01068509|EXPERIMENTAL|Non-randomized Cvac|Participants received 6-8 intradermal injections of Cvac at 4 sites along both upper arms and both thighs. The 6-8 injections contained \~ 60 × 10\^6 dendritic cells. Following evaluation after the first dose, participants received additional injections as described for the randomized Cvac group below.
62559631|NCT00503698|PLACEBO_COMPARATOR|Placebo|Placebo once daily to end of trial
62559632|NCT04810208|EXPERIMENTAL|NZ-DTX Depot|
62767724|NCT00473525|EXPERIMENTAL|PF-00734200 20 mg QD|
62767725|NCT00473525|EXPERIMENTAL|PF-00734200 5 mg QD|
62767726|NCT00473525|EXPERIMENTAL|PF-00734200 2 mg QD|
62767727|NCT01167166|EXPERIMENTAL|rigosertib|Patients will receive 2400 mg dose of rigosertib as a intravenous continuous infusion over 24 hours for 72 to 120 consecutive hours every 2 weeks for the first 4 weeks then will receive oral rigosertib at a 560 mg twice-daily dose as capsules taken continuously.
62767728|NCT06419816||Patients with type 2 diabetes|"mobile application WellCheck use"
62767729|NCT04072107|EXPERIMENTAL|Arm I|Patients receive GP IC + IMRT concurrent with cisplatin chemotherapy + capecitabine AC. All patients will receive concurrent cisplatin (100 mg/m2) every 3 weeks, in a total of three cycles. All patients will receive low-dose metronomic capecitabine (650 mg/m2 bid, oral, d1-21, q3w) until disease progression, or intolerable toxicity or 6 months.
62767730|NCT04072107|EXPERIMENTAL|Arm II|Patients receive GP IC + IMRT concurrent with cisplatin chemotherapy and anti-PD-1 therapy (sintilimab) + anti-PD-1 therapy (sintilimab) AC. All patients will receive concurrent cisplatin (100 mg/m2) and sintilimab (200 mg, IV drop 30-60 min) every 3 weeks in a total of three cycles. All patients will receive adjuvant anti-PD-1 therapy (sintilimab, 200 mg, IV drop 30-60 min, q3w) in a total of nine cycles until disease progression, or intolerable toxicity or 6 months.
62767731|NCT04794764|EXPERIMENTAL|McGrath MAC|First pass success rate using the McGrath Mac
62767732|NCT04794764|EXPERIMENTAL|Macintosh Laryngoscope|First pass success rate using the Macintosh laryngoscope
62767733|NCT05874349||Cohort 1: Crohn's disease|Patients with CD diagnosed according to the criteria of the ECCO guidelines. For the histological and lymphocyte subpopulation analysis of duodenal samples, all patients with CD who required an endoscopic examination during the disease have been prospectively included. All the recorded variables were registered at the moment of the endoscopy.
61991454|NCT01068509|EXPERIMENTAL|Randomized Cvac|Participants received 6-8 intradermal injections of Cvac at 4 sites along both upper arms and both thighs every 4 weeks for 24 weeks (7 doses at Weeks 8, 12, 16, 20, 24, 28, and 32), and then every 8 weeks for 24 weeks (3 doses at Weeks 40, 48, and 56). The 6-8 injections contained \~ 60 × 10\^6 dendritic cells.
61991455|NCT01068509|NO_INTERVENTION|Observational standard of care|Participants in this group did not receive any treatment during the study.
62559633|NCT00004919|EXPERIMENTAL|Treatment (cisplatin, irinotecan, amifostine)|"Treatment A: Patients receive cisplatin IV over 1 hour followed immediately by irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Courses repeat every 6 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.~Treatment B: Patients receive therapy as in treatment A. In addition, amifostine IV is administered over 15 minutes immediately before cisplatin."
61991456|NCT00821470|EXPERIMENTAL|bone marrow graft group|core decompression + bone marrow implantation into the necrotic lesion
61991457|NCT00821470|ACTIVE_COMPARATOR|control|core decompression
61991458|NCT01413360|EXPERIMENTAL|HD Vitamin C|High dose vitamin C
61991459|NCT00896558|EXPERIMENTAL|Cohort A|A single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
61991460|NCT00896558|EXPERIMENTAL|Cohort B|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
61991461|NCT00896558|EXPERIMENTAL|Cohort C|Subjects in the probe cohort will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12. All subjects will receive a single dose of midazolam alone on Day -1, and co-administered with the morning dose of GSK1322322/placebo on Day 1 and Day 12.
61991462|NCT00896558|EXPERIMENTAL|Cohort D|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
62559634|NCT02101125|EXPERIMENTAL|BMS-986020 + Rosuvastatin (Treatment A, B and C)|"Cohort 1: Rosuvastatin Tablet Single dose and BMS- 986020 orally on specific days~Cohort 2 (Administered 4 hrs, after the morning dose of BMS-986020): Rosuvastatin Tablet Single dose and BMS- 986020 orally on specific days"
62559635|NCT01103180|EXPERIMENTAL|Escitalopram|10-20 mg of escitalopram for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
62559636|NCT01103180|PLACEBO_COMPARATOR|Placebo|Inert placebo (sugar pill) taken daily for eight weeks
62559637|NCT04717752|EXPERIMENTAL|Double trigger unit|HCG: 6000IU (Ovidrel: 250ug) + GnRH-a (Troprilin) 0.2mg
62559638|NCT04717752|SHAM_COMPARATOR|HCG trigger unit|HCG: 6000IU (Ovidrel: 250ug)
62767734|NCT05874349||Cohort 2: Control groups|Two groups are included: 1) Disease control: Patients with celiac disease diagnosed according to the Catassi and Fasano criteria and 2) Healthy control subjects. For the histological and lymphocyte subpopulation analysis of duodenal samples, patients with celiac disease were prospectively included to undergone gastroscopy, before starting gluten-free diet. Control subjects were patients referred for upper endoscopy due to digestive symptoms that have normal appearing mucosa both at endoscopic and histological assessment (Marsh 0, \<25 intraepithelial lymphocytes). Serological markers of celiac disease were negative and they have no signs of inflammatory bowel diseases.
62767735|NCT02506660|ACTIVE_COMPARATOR|Intravenous dexamethasone|Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
61991463|NCT00896558|EXPERIMENTAL|Cohort E|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
61991464|NCT00581568|EXPERIMENTAL|Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
62767736|NCT02506660|EXPERIMENTAL|Perineural dexamethasone|Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
61991465|NCT04338295|EXPERIMENTAL|Microneedling|Participants with Alopecia Areata will receive microneedling with a tattoo machine.
61991466|NCT00772356|EXPERIMENTAL|A|
61991467|NCT00772356|ACTIVE_COMPARATOR|B|
61991468|NCT03849885|NO_INTERVENTION|Standard Skin Prep|"Patients will undergo a skin cleansing protocols using 4% Chlorhexidine gluconate (CHG) cloths.~After the skin prep, three 3-mm punch (Acu-Punch, Acuderm, Fort Lauderdale, FL) skin biopsies will performed for both an anterior-based hypothetical incision, and for a more lateral/posterior incision, for a total of 6 biopsies taken per subject."
61991469|NCT03849885|EXPERIMENTAL|Experimental Skin Prep with BPO|"Patients will undergo a skin cleansing protocols using 4% Chlorhexidine gluconate (CHG) cloths.~Following the CHG wipes, patients will be prepped with 5% BPO gel applied directly to the biopsy site.~After the skin prep, three 3-mm punch (Acu-Punch, Acuderm, Fort Lauderdale, FL) skin biopsies will performed for both an anterior-based hypothetical incision, and for a more lateral/posterior incision, for a total of 6 biopsies taken per subject."
61991470|NCT02070835|EXPERIMENTAL|autologous skin cell|autologous skin cell with skin graft
61991471|NCT02070835|ACTIVE_COMPARATOR|skin graft|split-thickness skin graft as control group
61991472|NCT00978068|ACTIVE_COMPARATOR|Lopinavir/ritonavir (LPV/r) +2 NRTI|Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
61991473|NCT00978068|ACTIVE_COMPARATOR|Nevirapine (NVP) or Efavirenz (EFV) +2 NRTI|Nevirapine (NVP) or Efavirenz (EFV) +2 nucleoside reverse transcriptase inhibitor (NRTI)
62559639|NCT01987778|EXPERIMENTAL|Resistance training|The resistance training will be supervised and individualized by an experienced physiotherapist. First the relative load will be lighter during three weeks, thereafter the intensity and load will be increased over another 12 weeks.
61991474|NCT06224842|EXPERIMENTAL|mitoxantrone liposome and azacitidine treatment|In the dose escalation phase, the mitoxantrone liposome will start at a dose of 16 mg/m\^2 on day1 via intravenous infusion, combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days). Three predetermined dose groups for mitoxantrone liposome are 16, 18, and 20 mg/m\^2. In the dose expansion phase, 10-20 cases will be included with the mitoxantrone liposome injection at the recommended phase II dose (RP2D) based on the results of the dose escalation phase.
61991475|NCT06140095|EXPERIMENTAL|Full group|"Evolocumab 140 mg subcutaneously. Två months later, repetitive doses of atorvastatin 40 mg once daily.~After continued atorvastatin, evolocumab 140 mg is added subcutaneously."
61991476|NCT01496092|EXPERIMENTAL|Keto Acid supplemented with usual protein diet|
61991477|NCT01496092|NO_INTERVENTION|usual protein diet|
62387166|NCT01924793|EXPERIMENTAL|Formulation of DAS181-F02 Dry Powder in Bulk|"The DAS181-F02 nebulized formulation includes 10mL of normal saline to prepare a liquid solution referred to as DAS181-F02 nebulized.~Dry Powder Inhaled Dose:~Non-ventilated subjects, capable of using a cyclohaler, will be treated by Dry Powder Inhalation. Each subject will receive a targeted daily dose of 10mg for 7 days for a total of 70mg of DAS181-F02. If a subject requires ventilation, the subject will be allowed to continue dosing following the Nebulized formulation instruction."
62387167|NCT01924793|EXPERIMENTAL|Nebulized Formulation Inhaled Dose|"Subjects unable to use the Dry Powder Inhaler (as determined by site Investigator) on continuous positive airway pressure (CPAP), Bi-level positive airway pressure (BIPAP) or requiring mechanical ventilation will be treated by Nebulized formulation. The subject will remain on the nebulized formulation for the duration of the study regardless of ventilation status. DAS-F02 10 mg will be utilized to prepare the nebulized solution per the Study Reference Manual.~Multiple methods (T piece, face mask, direct to ET tube) will be allowed for the nebulized dose administration. Detailed specification for nebulized dose administration will be defined in the Study Reference Manual."
61991478|NCT03327610|NO_INTERVENTION|BASELINE|The subjects were kept in their current ventilatory mode.
61991479|NCT03327610|EXPERIMENTAL|VC-CMV20|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow of 20Lpm.
61991480|NCT03327610|EXPERIMENTAL|VC-CMV50|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow of 50Lpm.
62767737|NCT06135363|EXPERIMENTAL|Multiple doses SC1011 300mg（A1）|Drug: SC1011 tablet, SC1011-matching placebo tablet; Treatment: Food intake prior to dosing
62767738|NCT06135363|EXPERIMENTAL|Multiple doses SC1011 400mg（A2）|Drug: SC1011 tablet; Treatment: Food intake prior to dosing
62767739|NCT02126072|EXPERIMENTAL|Alcohol|The study is a randomized single blinded trial in cross over design. Subjects are randomized to drink alcohol in one session and water in another session.
61991481|NCT03327610|EXPERIMENTAL|PC-CMV1|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1) with an inspiratory time of 1 second.
61991482|NCT03327610|EXPERIMENTAL|PC-CMV3|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1) with an inspiratory time of 3 seconds.
61991483|NCT03327610|EXPERIMENTAL|PSV10|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV) with a cycling off of 10% of peak inspiratory flow.
62387168|NCT03432819|EXPERIMENTAL|Siempre Seguiré|We will conduct a small randomized controlled trial (RCT), testing study protocols and materials, the acceptability of randomization, and overall program feasibility. The pilot will help to identify logistical considerations; assess whether the program is acceptable and understandable LMSM; and collect initial data on how successfully the program motivates change in coping and adherence. It will allow us to estimate expected attrition and response rates, and to perform preliminary power analyses in preparation for a fully powered RCT.
62559640|NCT01987778|NO_INTERVENTION|Control group|No intervention for 15 weeks but the same registrations, diaries and forms as the intervention group. The control group will however be omitted from muscle strength testing.
62767740|NCT02126072|ACTIVE_COMPARATOR|Water|Water in the same volume as the volunteer would have to drink in wine according to the protocol.
62767741|NCT04979403|ACTIVE_COMPARATOR|Usual care in physiotherapy|The usual care group will receive interventions recommended by clinical guidelines: education on the nature of LBP, advice to stay active and to continue usual activities, specific exercise programs combined with orthopedic manual therapy.
62767742|NCT04979403|EXPERIMENTAL|Psychologically-informed physiotherapy intervention|The psychologically-informed physiotherapy group will receive the control intervention enhanced with specific interventions targeting psychosocial factors (e.g., positive reinforcement, mindfulness-based stress reduction, diaphragmatic breathing, graded exposure). Most of these techniques are efficient to mitigate the impact of psychological factors such as anxiety and fear of movement. To standardize the psychologically-informed physiotherapy approach, physiotherapists will receive a two-day training course by a physiotherapist expert with this approach in chronic pain conditions (Alain Gaumond).
61991484|NCT03327610|EXPERIMENTAL|PSV25|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV) with a cycling off of 25% of peak inspiratory flow.
62387169|NCT03432819|NO_INTERVENTION|Control|Control participants will not be randomized to receive the intervention and will receive standard of care during the intervention period. We will offer the program to any interested control participants shortly after the 6-month follow-up surveys are completed.
62387170|NCT00724789||Observational Cohort|Subjects with an ongoing pregnancy after controlled ovarian stimulations with recombinant follicle stimulating hormone/ganirelix followed by in vitro fertilization or intra cytoplasmatic sperm injection.
61991485|NCT01616485|EXPERIMENTAL|Treatment A|TA-1790 + glyceryl trinitrate
62387171|NCT00724789||Historical Controls|Subjects with an ongoing pregnancy after controlled ovarian stimulations with recombinant follicle stimulating hormone in a long protocol with a gonadotropin releasing hormone agonist followed by IVF or ICSI
62387172|NCT03389659|EXPERIMENTAL|Vitamin D3 group|vitamin D3 2000IU (400IU\*5pills） po. qd continue to disease progression plus XELOX (oxaliplatin 130mg/m2 d1; capecitabine 1000mg/m2 bid po. d1-14; q3w) or mFOLFOX (oxaliplatin 85mg/m2，d1; leucovorin 400mg/m2，d1；5-fluorouracil 400mg/m2，d1; 5-fluorouracil 2400mg/m2 continue 46h, q2w)
62387173|NCT03389659|PLACEBO_COMPARATOR|control group|placebo 5 pills po. qd continue to disease progression plus XELOX (oxaliplatin 130mg/m2 d1; capecitabine 1000mg/m2 bid po. d1-14; q3w) or mFOLFOX (oxaliplatin 85mg/m2，d1; leucovorin 400mg/m2，d1；5-fluorouracil 400mg/m2，d1; 5-fluorouracil 2400mg/m2 continue 46h, q2w)
62387174|NCT03776331||Myeloma Patients|
62387175|NCT03776331||Controll group|
62387176|NCT02749643|EXPERIMENTAL|Vibrotactile feedback|Vibrotactile system - comprises of force sensors, attached to the fingertips of the prosthetic hand, and a set of 8 vibration actuators attached to a fabric arm cuff. When the subject applies force on the sensors with his prosthetic hand, he receives a vibration on the skin of his arm. The sensors and actuators are connected to an electronic control board, which transforms the resistance from the sensors to an electric signal that activates the vibration actuators.
62387177|NCT05230992|EXPERIMENTAL|Cryoprobes First|Use of cryoprobes and then conventional forceps during the same operating time.
62387178|NCT05230992|EXPERIMENTAL|Cryoprobes Second|Use of conventional forceps and then cryoprobes during the same operating time.
62387179|NCT02337855|EXPERIMENTAL|Group A|N=10 subjects will receive single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113
62387180|NCT02337855|EXPERIMENTAL|Group B|N=10 subjects will receive single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
62387181|NCT02337855|PLACEBO_COMPARATOR|Group C|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
62387182|NCT02337855|EXPERIMENTAL|Group D|N=10 subjects will receive single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113
62387183|NCT02337855|EXPERIMENTAL|Group E|N=10 subjects will receive single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
62387184|NCT02337855|PLACEBO_COMPARATOR|Group F|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
62387185|NCT02337855|EXPERIMENTAL|Group G|N=10 subjects will receive single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113
61991486|NCT01616485|ACTIVE_COMPARATOR|Treatment B|sildenafil citrate + glyceryl trinitrate
61991487|NCT01616485|PLACEBO_COMPARATOR|Treatment C|placebo + glyceryl trinitrate
61991488|NCT06483035|EXPERIMENTAL|Intensive Visual Stimulation (IVS)|"Treatment is performed by an IVS trained physiotherapists. Patients receive maximum 16 treatments over 2 months. In addition, all participants will undergo a baseline, an endpoint and a 2-month follow-up examination conducted by a physiotherapist. The treatment is individually adapted to the level of motor control in the phantom arm/leg and pain level of the individual participant.~An IVS treatment session consists of 8-10 different exercises with 8-10 reps of each exercise for the phantom arm/phantom leg with appropriate progression and adjustments.~In addition to IVS, all participants in the experimental group continues their routine medical care"
61991489|NCT06483035|ACTIVE_COMPARATOR|Usual Care|All participants randomized to the control group undergo the same baseline, endpoint, and follow-up examinations as the experimental group. This group continues with their routine medical care offered by their own doctor during the study period.The participants shall not start mirror therapy or IVS therapy during this period
62387186|NCT02337855|EXPERIMENTAL|Group H|N=10 subjects will receive single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
62387187|NCT02337855|PLACEBO_COMPARATOR|Group I|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
62387188|NCT04963738|EXPERIMENTAL|Group 1: JNJ-73763989|Participants with moderate renal impairment will receive a single subcutaneous (SC) injection of JNJ-73763989 on Day 1.
62387189|NCT04963738|EXPERIMENTAL|Group 2: JNJ-73763989|Participants with severe renal impairment or end-stage renal disease (ESRD) will receive a single SC injection of JNJ-73763989 on Day 1.
62387190|NCT04963738|EXPERIMENTAL|Group 3: JNJ-73763989|Participants with normal renal function will receive a single SC injection of JNJ-73763989 on Day 1.
62387191|NCT04327505|EXPERIMENTAL|Hyperbaric oxygen|Hyperbaric oxygen 1,6-2.4 Bar for 30-60 minutes (compression/decompression time, according to local routines) in addition to best practice
62387192|NCT04327505|NO_INTERVENTION|Control|Best practice
62387193|NCT00560872|OTHER|1|conventional ablation with manual catheter navigation
62387194|NCT00560872|ACTIVE_COMPARATOR|2|ablation with remote magnetic catheter navigation
62387195|NCT01378156|EXPERIMENTAL|JS7 plasmid DNA and MVA62B vaccines|All subjects receive JS7 plasmid DNA (at 1 and 9 weeks) and MVA62B vaccines (17 and 25 weeks), followed (in 2 months after last vaccination) by a 12-week treatment interruption phase. Subjects reinstitute therapy after the treatment interruption and are followed for 6 months.
62387196|NCT01362062||RA Cohort|Participants with active RA who had an inadequate clinical response to current non-biologic disease modifying anti-rheumatoid drug (DMARD) and/or anti-tumor necrosis factor (anti-TNF) therapy being treated with tocilizumab according to the routine clinical practice and in line with prescribing information will be observed for a total duration of 12 months.
62387197|NCT06028893|EXPERIMENTAL|Study group|All subjects will perform heart rhythm measurements with both diagnostic tests.
62387198|NCT01920087|EXPERIMENTAL|ATNC05|Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.
62387199|NCT01920087|PLACEBO_COMPARATOR|Placebo|Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.
62387200|NCT02925780|EXPERIMENTAL|Resin infiltration|"The labial surface of fluorosed teeth (upper front teeth) that are selected for this group will be treated using the resin infiltrant Icon (DMG, Germany). This is a minimally invasive treatment to improve the aesthetics by masking the white spots."
62387201|NCT02925780|ACTIVE_COMPARATOR|Microabrasion|"The labial surface of fluorosed teeth (upper front teeth) that are selected for this group will be treated by microabrasion using the microabrasive material Opalustre (Ultradent, USA). This is a minimally invasive treatment to improve the aesthetics by masking the white spots."
62387202|NCT04269629||patients with a history of an anaphylactic sting reaction|At Visit 1, patients will be included after carefully reviewing all inclusion and exclusion criteria. All data concerning the index sting, laboratory parameters like immunoglobulin E (IgE) and tryptase levels and skin test results will be recorded as well as the concomitant diseases and medication. Visit 2 will be performed after VIT updosing is finished. At this Visit data concerning the immunotherapy - premedication, preparation, updosing protocol, the outcome of possible large, local reactions (LLR) and systemic reactions (SR) and changes in diseases and medication will be recorded. One year after reaching the maintenance dose, Visit 3 will be performed. At this Visit data concerning the maintenance phase like premedication and possible side effects will be recorded as well as the outcome of insect stings.
62387203|NCT01716585|EXPERIMENTAL|ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62387204|NCT01716585|EXPERIMENTAL|Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62387205|NCT03596307|EXPERIMENTAL|Ashwagandha extract|180 mg Shoden once daily before breakfast for 2 days in Acute Phase and 16 days in Short Term Phase.
62387206|NCT03596307|PLACEBO_COMPARATOR|Placebo|180 mg identical placebo once daily before breakfast for 2 days in Acute Phase and 16 days in Short Term Phase.
62387207|NCT04096781|EXPERIMENTAL|Shared Decision Making Tool (SDMT)|
62387208|NCT04096781|ACTIVE_COMPARATOR|Usual Care|
62387209|NCT01363973|EXPERIMENTAL|Sensory stimulation|Transcutaneous electrical stimulation at 75% of motor threshold
62387210|NCT01363973|EXPERIMENTAL|Motor stimulation|Transcutaneous electrical stimulation at motor threshold
62387211|NCT03769753|EXPERIMENTAL|intraoperative use of IRE|Patients with intraoperatively determined advanced unresectable PHC will be treated with IRE during the same surgical exploration session (N=20). Electrodes will be placed using ultrasound guidance. All electrodes will be placed by hepatopancreatobiliary surgeons with experience using IRE.
62387212|NCT00841854|ACTIVE_COMPARATOR|PBMT7|pantoprazole 40mg bid, bismuth 300mg qid, metronidazole 500mg tid,tetracycline 500mg qid for 7 days
62387213|NCT00841854|ACTIVE_COMPARATOR|PBMT14|pantoprazole 40mg bid, bismuth 300mg qid, metronidazole 500mg tid,tetracycline 500mg qid for 14 days
62387214|NCT03960294|EXPERIMENTAL|DOZE Users|Adolescents and young adults (AYAs) using DOZE for sleep disturbance.
62387215|NCT01515813|EXPERIMENTAL|Arm A: Pravastatin sodium alone for 24 weeks|One 40 mg tablet of Pravastatin sodium taken orally once daily for 24 weeks starting at week 0 and ending at week 24.
62387216|NCT01515813|EXPERIMENTAL|Arm B: EFV/FTC/TDF plus Pravastatin sodium at week 13|EFV/FTC/TDF once daily for 24 weeks starting at week 0 and ending at week 24 plus pravastatin sodium (80 mg)once daily for 12 weeks starting at week 13 ending at week 24.
62387217|NCT01515813|EXPERIMENTAL|Arm C: Pravastatin sodium + EFV/FTC/TDF for 24 weeks|Participants will be administered Pravastatin sodium once daily for 24 weeks starting at week 0 and ending at week 24 plus EFV/FTC/TDF once daily for 24 weeks starting week 0 and ending at week 24.
62387218|NCT05007912||Orvil Group|Group that used the Orvil (circular stapler) for esophagojejunostomy
62387219|NCT05007912||Linear Group|Group that used the linear stapler for esophagojejunostomy
62387220|NCT04960332|NO_INTERVENTION|Standard treatment|Group A: Standard wound closure with staples and conventional wound dressing.
62559641|NCT06570694|EXPERIMENTAL|Intervention Group 1: Concurrent Therapist Support|Participants will receive the four-week intervention via the mobile application. This will be supplemented with asynchronous written support from a CBT practitioner (qualified or after the second year of their training) via WhatsApp and will be available twice a week to relevant participants at specific times predetermined by the therapist. Participants will be available to utilise this support but will not be directed to do so. Participants in this condition will, as part of their use of the application, participate in providing daily sampling, which includes emotion valuation questions.
62767743|NCT03974204|EXPERIMENTAL|Cerebrospinal fluid and Blood sample collection|"Collection of cerebrospinal fluid and blood samples:~* At initial diagnostic assessment;~* 1 month and 3 months after initial diagnostic assessment, for patients classified possible, probable or confirmed according to EANO-ESMO classification, leading to specific leptomeningeal metastase treatment;~* In case of symptoms leading to leptomeningeal metastase suspicion and at least 3 months after diagnostic assessment, for patients classified lack of evidence according to EANO-ESMO classification."
62387221|NCT04960332|EXPERIMENTAL|Prevena|Group B: Wound closure with staples and Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System).
61991490|NCT02731872|EXPERIMENTAL|High Flow humidification system|In addition to their usual oxygen apparatuses, the treatment group will have an Airvo humidifier system installed in the home. The supplied oxygen flow will be entrained along with room air through the Airvo humidification system. this combined respiratory gas will then be warmed and humidified and delivered to the patient via a nasal cannula. The total respiratory gas flow rate will be between 20-25 l/min, depending on participant´s preference. Then the oxygen fraction is adjusted until the subjects target oxygen saturation levels are achieved.
61991491|NCT02731872|NO_INTERVENTION|Standard oxygen therapy|The control group will continue receiving the standard oxygen therapy prescribed by the department
61991492|NCT04694313|EXPERIMENTAL|OPM|Two types of measurement will be compared (SQUID and OPM) with the reference that constitutes the in-depth recordings (Stereotactic-EEG or SEEG) used to precisely define the region of the brain to be resected in order to cure epileptic patients of their seizures.
62387222|NCT01683058|EXPERIMENTAL|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg once monthly (every 28 days) for 24 weeks
61991493|NCT04164979|EXPERIMENTAL|Cabozantinib and Pembrolizumab|Subjects receive Cabozantinib 40mg PO daily on days 1-21 and Pembrolizumab 200mg IV on day 1 every 21 days.
62559642|NCT06570694|EXPERIMENTAL|Intervention Group 2: No Concurrent Therapist Support|Participants will receive the four-week intervention via the mobile application. No concurrent therapist support will be provided in this group. Participants in this condition will, as part of their use of the application, participate in providing daily sampling, which includes emotion valuation questions.
62767744|NCT03951909|EXPERIMENTAL|Active intervention|Either Physiotherapy activity and awareness intervention (PAAI) or Teaching recovery techniques (TRT)
62767745|NCT03951909|EXPERIMENTAL|Waiting list|The same interventions as above will be hold for waiting lists participants, but after 6 to 8 weeks
61991494|NCT06126757|EXPERIMENTAL|PelviSense-assisted pelvic floor muscle training group|Women assigned to the experimental group will perform pelvic floor muscle training exercises with the wearable PelviSense device sensor to the perineal region.
62387223|NCT03024944|EXPERIMENTAL|Brain Imaging with 18F-THK-5351|This group consists of 30 adult subjects: 10 with Type 2 diabetes, 10 with pre-diabetes, and 10 with normal glucose tolerance. Each subject will receive a baseline scan and a follow-up PET scan with 18F-THK-5351.
62767746|NCT04425785|EXPERIMENTAL|Physical Exercise Group|A structured exercise program for 12 weeks
62387224|NCT05610865|ACTIVE_COMPARATOR|Control; Standard-of-care management|Saline dressing will be done as a routine care management.
62387225|NCT05610865|EXPERIMENTAL|Only PRP injection|Only PRP will be injected at the wound site.
62559643|NCT06570694|NO_INTERVENTION|Partial Intervention|Partial intervention group: This group will not receive the four-week mobile intervention, but will participate in providing daily sampling (via web-based form), which includes emotion valuation questions.
62767747|NCT04425785|EXPERIMENTAL|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy for 12 weeks
62767748|NCT04425785|NO_INTERVENTION|Standard Clinical Care|Standard Clinical Care
62767749|NCT03821623|EXPERIMENTAL|Nicotinamide riboside|Subjects will take 500 mg of the vitamin B3-precursor, nicotinamide riboside (NIAGEN) twice per day (1,000 mg per day total) for 3 months.
62767750|NCT03821623|PLACEBO_COMPARATOR|Placebo|Subjects will take placebo pills twice a day for 3 months.
62767751|NCT02720640|EXPERIMENTAL|Implant 'on' vs implant 'off'|Intra-individual comparison of implant 'on' vs implant 'off'
62767752|NCT01484379|EXPERIMENTAL|unilateral neck exploration|unilateral neck exploration of elderly with primary hyperparathyroidism
62767753|NCT01063842|EXPERIMENTAL|001|tramadol hydrochloride / acetaminophen and placebo 1 tablet of tramadol/acetaminophen in the morning 1 tablet of placebo in the afternoon and evening for 3 days then 1 tablet of tramadol/acetaminophen in the morning evening and 1 tablet of placebo in the afternoon for 4 days then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
62767754|NCT01063842|ACTIVE_COMPARATOR|002|tramadol hydrochloride /acetaminophen 1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
62767755|NCT03931915|EXPERIMENTAL|TAK-385|TAK-385 40 mg administered orally once daily before breakfast + Leuprorelin placebo administered subcutaneously once every 4 weeks
62767756|NCT03931915|ACTIVE_COMPARATOR|Leuprorelin acetate|TAK-385 placebo administered orally once daily before breakfast + Leuprorelin acetate 1.88 mg / 3.75 mg administered subcutaneously once every 4 weeks
62767757|NCT05440448|EXPERIMENTAL|Patch-free occlusion therapy|
62767758|NCT05440448|ACTIVE_COMPARATOR|Standard-of-care patching with an adhesive patch|
62767759|NCT02142036|EXPERIMENTAL|ATI based targeted therapy.|EMA-approved ATI based targeted therapy. Patients will receive therapy based on molecular aberrations identified in the metastatic lesion.
61991495|NCT06126757|ACTIVE_COMPARATOR|Pelvic floor muscle exercise (training) without the Pelvisense device|Women assigned to the unassisted PFMT group will perform the exercise without the PelviSense device.
61991496|NCT01971853|PLACEBO_COMPARATOR|oral placebo|an Ibuprofen and Acetaminophen Placebo will be added to a Demerol-Vistaril regimen
61991497|NCT01971853|ACTIVE_COMPARATOR|Oral Analgesics|5 mg/kg ibuprofen + 15 mg/kg acetaminophen will be added to a Demerol-Vistaril regimen
61991498|NCT04829487|EXPERIMENTAL|Vitamin D|Vitamin D 50,000 IU orally weekly for 8 weeks
61991499|NCT04829487|PLACEBO_COMPARATOR|Placebo|Placebo capsules orally weekly for 8 weeks
61991500|NCT03946735|EXPERIMENTAL|Intervention study|Cognitive Behavioural Therapy for social anxiety
61991501|NCT03946735|EXPERIMENTAL|Social anxiety|
61991502|NCT01650207|EXPERIMENTAL|EA group|To acupuncture the Juanyu (Li15) \& Jugu (Li16) with sensation of de-qi, and then give 50 Hz electrical stimulation for 20 minutes.
62387226|NCT05610865|EXPERIMENTAL|PRP + SVF injection|SVF pellet mixed with PRP will be injected at the wound site after adjusting number of cells.
62767760|NCT05700253|EXPERIMENTAL|Cooled Radiofrequency Ablation|Relieves pain by blocking pain signals via the deactivation of nerve structures using radiofrequency energy.
62767761|NCT05700253|ACTIVE_COMPARATOR|Hyaluronic Acid Injection|Injection of hyaluronic acid into the affected knee provides lubrication and shock absorption.
62559644|NCT06570694|NO_INTERVENTION|Control|Control group: This group will not receive the four-week mobile intervention, but will participate in providing daily sampling (via web-based form) - this does not include emotion valuation questions.
62767762|NCT00690170|ACTIVE_COMPARATOR|Ketamine and Nicotine|"* 0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~* 13.5 µg/kg of nicotine IV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"
61991503|NCT01650207|EXPERIMENTAL|TENS group|The electrical patches were placed on the Juanyu (Li15) \& Jugu (Li16) or Juanyu (Li15), Quchi (Li11), Shousanli (Li10) \& Hegu (Li4), connected to a TENS apparatus and then give 50 Hz electrical stimulation for 20 minutes.
62387227|NCT05610865|EXPERIMENTAL|PRP + ASCs injection|Cultured ASCs mixed with PRP will be injected at the wound site after adjusting number of cells.
62387228|NCT02517502|EXPERIMENTAL|DHA|Participants will be asked to take four 400 mg (1600 mg; 1.6 grams) capsules of DHA daily. Participants will start taking capsules before the start of and for the duration of their neoadjuvant chemotherapy.
61991504|NCT01650207|SHAM_COMPARATOR|sham-acupuncutre|The Park's Sham Device were placed on the Juanyu (Li15) \& Jugu (Li16).
62387229|NCT02517502|PLACEBO_COMPARATOR|Placebo|Participants will be asked to take four 400 mg (1600 mg; 1.6 grams) capsules of a matched placebo daily. Participants will start taking capsules before the start of and for the duration of their neoadjuvant chemotherapy.
62387230|NCT01385098|EXPERIMENTAL|Vitamin D3 and Calcium|Dietary supplement of vitamin D3 and calcium
62387231|NCT04509024|EXPERIMENTAL|Incidental training|Participants undergo novel non-linguistic incidental category learning training.
62387232|NCT04509024|EXPERIMENTAL|Explicit training|Participants undergo traditional explicit language learning.
62387233|NCT04509024|NO_INTERVENTION|No training|Participants do not undergo any training.
62387234|NCT04509024|EXPERIMENTAL|Classroom training|Participants take part in structured classroom learning.
62387235|NCT04509024|EXPERIMENTAL|Classroom and incidental training|Participants take part in structured classroom learning and incidental learning.
62387236|NCT04509024|EXPERIMENTAL|Classroom and explicit training|Participants take part in structured classroom learning and explicit learning.
62387237|NCT01083615|EXPERIMENTAL|Custirsen|"Study treatment starts with a Loading Dose Period (1 week) during which 3 infusions of custirsen will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel (75 mg/m2 total dose) or cabazitaxel (25 mg/m2 total dose) on a 21-day cycle with weekly custirsen infusions (640 mg total dose) on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.~Participants will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol."
62387238|NCT01083615|PLACEBO_COMPARATOR|Placebo|"Study treatment starts with a Loading Dose Period (1 week) during which 3 infusions of placebo (isotonic, 0.9% sodium chloride) will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel (75 mg/m2 total dose) or cabazitaxel (25 mg/m2 total dose) on a 21-day cycle with weekly placebo infusions on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.~Participants will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol."
62387239|NCT00561964|EXPERIMENTAL|1|
62387240|NCT00561964|PLACEBO_COMPARATOR|2|
61991505|NCT01498952|EXPERIMENTAL|Phase 1b Cohort A|Participants will receive MEDI-573 10 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
62387241|NCT05094258|ACTIVE_COMPARATOR|mobile insert|Unicondylar knee arthroplasty with mobile insert was applied to 30 patients determined by randomization. The patients were followed for 1 year.
62387242|NCT05094258|ACTIVE_COMPARATOR|fixed insert|Unicondylar knee arthroplasty with fixed insert was applied to 30 patients determined by randomization. The patients were followed for 1 year.
62387243|NCT06330727|ACTIVE_COMPARATOR|Coffee capsule|participants in this arm ingest coffee capsules with 1.8g instant black coffee powder twice daily with breakfast and lunch.
62387244|NCT06330727|PLACEBO_COMPARATOR|Placebo|participants in this arm consume cornstarch capsules (without coffee) twice daily with breakfast and lunch.
62387245|NCT01513460|EXPERIMENTAL|NVA237 + Fluticasone/Salmeterol (Flu/Sal)|NVA237 50 µg once daily (NVA237 + Tiotropium placebo + Flu/Sal). NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI) o.d. plus Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
62387246|NCT01513460|ACTIVE_COMPARATOR|Tiotropium + Flu/Sal|Tiotropium 18µg once daily (NVA237 placebo + Tiotropium + Flu/Sal). Tiotropium 18 μg o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
62559645|NCT02959125|EXPERIMENTAL|Intervention|"Intervention~* NutFish based supplementation for 60 days~* Multiple micro nutrient for 60 days~* Health education in pregnancy class"
62559646|NCT02959125|ACTIVE_COMPARATOR|Control|"Control~* Government food supplementation for 60 days~* Iron Folic acid for 60 days~* Health education in pregnancy class"
62559647|NCT03307252|EXPERIMENTAL|Treatment Reference 1|
62559648|NCT03307252|EXPERIMENTAL|Treatment Reference 2|
62559649|NCT03307252|EXPERIMENTAL|Treatment Reference 3|
62559650|NCT03307252|EXPERIMENTAL|Treatment 1|
62767763|NCT00690170|PLACEBO_COMPARATOR|Placebo Comparator|-Placebo administration: Normal saline (sodium chloride 0.9%)over 95 minutes
62767764|NCT00690170|ACTIVE_COMPARATOR|Ketamine and Placebo|"Ketamine administration: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes~Placebo administration: Normal saline (sodium chloride 0.9%)over 94 minutes"
61991506|NCT01498952|EXPERIMENTAL|Phase 1b Cohort B|Participants will receive MEDI-573 45 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
61991507|NCT01498952|EXPERIMENTAL|Phase 1b Cohort C|Participants will receive MEDI-573 30 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
61991508|NCT01498952|EXPERIMENTAL|Phase 2 Arm 1|Participants will receive recommended dose of MEDI-573 from Phase 1b IV on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
61991509|NCT01498952|ACTIVE_COMPARATOR|Phase 2 Arm 2|Participants will receive sorafenib 400 mg orally twice daily until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
62387247|NCT01513460|PLACEBO_COMPARATOR|Flu/Sal|Placebo (NVA237 placebo + Tiotropium placebo + Flu/Sal). Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
62387248|NCT00283062|EXPERIMENTAL|Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)|Participants administered docetaxel every three weeks (q3w) for 6 cycles in combination with leuprolide acetate every 3 months for 18 months immediately following prostatectomy.
62387249|NCT00283062|ACTIVE_COMPARATOR|Leuprolide Acetate - Immediate Treatment (I-HT)|Participants administered leuprolide acetate every 3 months for 18 months immediately following prostatectomy.
62387250|NCT00283062|EXPERIMENTAL|Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)|Participants in whom treatment was deferred from randomization until first progression - i.e. PSA progression and/or radiologically or histologically documented progression. Participants were treated with docetaxel every three weeks (q3w) for 6 cycles in combination with leuprolide acetate every 3 months for 18 months.
62387251|NCT00283062|ACTIVE_COMPARATOR|Leuprolide Acetate - Deferred Treatment (D-HT)|Participants in whom treatment was deferred from randomization until first progression - i.e. PSA progression and/or radiologically or histologically documented progression. Participants were treated with with leuprolide acetate every 3 months for 18 months.
62387252|NCT05713929|ACTIVE_COMPARATOR|Recruitment maneuver (RM) group 1|
62387253|NCT05713929|ACTIVE_COMPARATOR|Reverse Trend (REV TREND) group 2|
62387254|NCT05814406|EXPERIMENTAL|JW0201+C2202+C2204|Experimental group, Treatment period for 24 weeks
62387255|NCT05814406|PLACEBO_COMPARATOR|C2202+C2204|Placebo group, Treatment period for 24 weeks
62387256|NCT04654819|NO_INTERVENTION|Control group|This group made anesthesia application on patients without training on simulators.
62387257|NCT04654819|EXPERIMENTAL|Study group|This group made anesthesia application on patients after training on simulators.
62387258|NCT01663155||all enrolled subjects|Intervention is chest x-ray and CT scan. The chest x-ray image is read first without computer aided detection (CAD) and then a second time with computer aided detection (CAD) the CT scan is read by one reader. Subjects are asked to contribute breath and blood samples.
62387259|NCT03359382|NO_INTERVENTION|control|
62387260|NCT03359382|EXPERIMENTAL|exercise|
62387261|NCT04951882|PLACEBO_COMPARATOR|hUC-MSCs treatment|Patients of acute lung injury will be treated by suspention of hUC-MSCs and albumin combined with standard therapies.
62387262|NCT04951882|NO_INTERVENTION|non-cell therapy|Patients of acute lung injury will be treated by vehicle (albumin) combined with standard therapies.
62387263|NCT02300922|EXPERIMENTAL|several cohorts|"All patients will receive 3 injections of TF2 (the first: 14 mg/m², the second and the third:75 mg/m²). One day after each injection of TF2, the patient will receive a radiolabelled peptide (IMP-288) with Yttrium for therapeutic injectionThe First cohort will receive 555 MBq/m2 X 2 of 90-Y-IMP-288.:~All patient will receive 180 MBq of 111-In-IMP-288 for dosimetry analysis"
62559651|NCT03307252|EXPERIMENTAL|Treatment 2|
62559652|NCT03307252|EXPERIMENTAL|Treatment 3|
62559653|NCT03307252|EXPERIMENTAL|Treatment 4|
62559654|NCT03307252|EXPERIMENTAL|Treatment 5|
62559655|NCT03307252|EXPERIMENTAL|Treatment 6|
62559656|NCT03766295|EXPERIMENTAL|Masitinib & gemcitabine|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
62559657|NCT03766295|ACTIVE_COMPARATOR|Placebo & gemcitabine|Participants receive matching placebo, given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
62559658|NCT02613247|EXPERIMENTAL|Immediate-start group|Hylan G-F 20 6 mL intra-articular knee injection
62387264|NCT02772042|EXPERIMENTAL|Intervention Group|Investigators will performed traction manipulation of those articulations of upper cervical spine with indication for this treatment. Before manipulation soft tissue techniques will be applied in order to prepare the joint. After manipulation the patient rest in supine position. The intervention will have a duration of 10 minutes.
61991510|NCT06078033|EXPERIMENTAL|Intervention: Mobilization with movement (MWM)|The MWM technique was performed by asking patients to perform their painful movement (flexion, extension...). If pain was not reproduced, a combination of movements (flexion + rotation...) was performed. The most painful vertebral level was also evaluated with passive accessory vertebral movements. Then, with the patient in a seated position on a stretcher with the feet supported and a belt around the waist, the therapist performed a sustained glide over the targeted vertebra (spinous process) with the force and direction that relieved pain to the lowest level and asked the patient to perform his previous painful movement, as described by Mulligan. Three sets of 10 repetitions were performed, with 1-2 minutes rest between sets.
62387265|NCT02772042|OTHER|Control Group|The patient of the control group maintain the supine position for 10 minutes.
61991511|NCT06078033|SHAM_COMPARATOR|Control: Sham mobilization with movement|Patients allocated to sham group received same evaluation and treatment process. However, only manual contact was performed over the spinous process of the targeted vertebra, without the sustained glide and without applying any force. Three sets of 10 repetitions were performed, with 1-2 minutes rest between sets.
61991512|NCT01978028|ACTIVE_COMPARATOR|ferric carboxymaltose|ferric carboxymaltose
61991513|NCT01978028|PLACEBO_COMPARATOR|placebo|placebo
62387266|NCT01071772|EXPERIMENTAL|euglycemia|
61991514|NCT00702403|EXPERIMENTAL|Treatment (prophylactic inhibition of BCR-ABL tyrosine kinase)|"Beginning after engraftment and blood count recovery (21 to 28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate PO QD until day 80 and then nilotinib PO BID on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO BID beginning after engraftment and blood count recovery until day 445.~Treatment continues in the absence of disease progression or unacceptable toxicity."
61991515|NCT01886183|EXPERIMENTAL|Virtual Reality Training|The virtual reality training will be done by experimental group with ten games of Nintendo Wii Fit.
61991516|NCT01886183|ACTIVE_COMPARATOR|Control group: Physical Therapy|The Control Group will be trained by conventional Physical Therapy exercises.
61991517|NCT03244865||Pregnant Females|"All patients admitted to the Labor \& Delivery Suite at UF Health, will be eligible for inclusion in the study except minors and those unable to consent for themselves.~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus. No longitudinal follow-up is planned or indicated."
61991518|NCT03141281|EXPERIMENTAL|BrainHQ|Participants will be provided with a laptop computer and enrolled in a commercial web-based cognitive training program, BrainHQ, trained on how to access it, and instructed to complete a fixed number of sessions in 20 hours.
62387267|NCT01071772|EXPERIMENTAL|hyperglycemia|
62387268|NCT01626599|OTHER|Assess product useability|All subjects participate in the same arm. This arm completes the primary objective of product usability.
62387269|NCT06202313|EXPERIMENTAL|Cadonilimab + Eribulin|Participants receive Cadonilimab 10mg/kg IV on Day 1 of each 21-day cycle PLUS Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
61991519|NCT03141281|EXPERIMENTAL|Rise of Nations|Participants will be provided with a laptop computer with the Rise of Nations video game, be trained in game play, and instructed to play the game for 20 hours
61991520|NCT03141281|EXPERIMENTAL|IADL training|Participants will be enrolled in American Association of Retired Persons' web-based driver training course, trained on how to access it, and asked to complete the course, estimated to take approximately 6-8 hours. They will also be provided with web-based access to a finance and fraud avoidance training tutorial, instructed on how to access it, and be asked to complete the course, estimated to take approximately 5-7 hours. The two courses combined are estimated to take about 15 hours.
61991521|NCT03141281|ACTIVE_COMPARATOR|Active Control|Participants will be provided with a laptop computer and asked to complete 20 hr of training with Sudoku, crossword puzzles, and word search
62387270|NCT06202313|ACTIVE_COMPARATOR|Eribulin|Participants receive Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
62387271|NCT03756805|ACTIVE_COMPARATOR|Group 1 (CPAP)|Patient, who are receiving a CPAP
62387272|NCT03756805|EXPERIMENTAL|Group 2 (UAS)|Patient, who are receiving a device for upper airway stimulation
62387273|NCT04045431|EXPERIMENTAL|PAAG-OA|Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)
62387274|NCT04045431|ACTIVE_COMPARATOR|Synvisc-One|Intra-articular injection with Synvisc-One (hyaluronic acid)
62387275|NCT04226365|EXPERIMENTAL|Experimental|10mg capsule once daily for 4 weeks of nortriptyline
62387276|NCT04226365|PLACEBO_COMPARATOR|Control|10mg capsule once daily for 4 weeks of Thick-It filler
62387277|NCT04993144|ACTIVE_COMPARATOR|Active|"Participants received the real intervention of TBS (cTBS 600) over the left dorsolateral prefrontal cortex for 8 weeks (2 days/week).~\*cTBS = continuous theta burst stimulation"
62387278|NCT04993144|SHAM_COMPARATOR|Sham|Participants received the sham intervention of TBS (coil tilted one-wing 90° off the head) over the left dorsolateral prefrontal cortex for 8 weeks (2 days/week).
62387279|NCT04993144|NO_INTERVENTION|Normal control|No intervention.
62559659|NCT02613247|OTHER|Delayed-start group|Washout control group which then becomes an experimental group (Hylan G-F 20 6 mL intra-articular knee injection) at 6 weeks post-enrolment
62559660|NCT04731727|EXPERIMENTAL|Cross linking treatment for corneal thinning|Cornea will be saturated with Vitamin B2 (Riboflavin) and then treated with 365 nm wavelength ultra violet light.
62767765|NCT00690170|ACTIVE_COMPARATOR|Nicotine and Placebo|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg)IV (in the arm), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
62767766|NCT06329882|ACTIVE_COMPARATOR|control group|patients were on sitagliptin 100mg /day monotherapy
61991522|NCT06428227||Heart failure patients with inspiratory muscle weakness|Exercise capacity (6 minute walking test), pulmonary function (spirometry), respiratory muscle strength (mouth pressure device), peripheral muscle strength (hand-held dynometer), dyspnea (The Modified Medical Research Council (MMRC) dyspnea scale), fatigue (Fatigue Severity Scale), quality of life (The Short Form 36 (SF-36) questionnaire), physical activity level (The International Physical Activity Questionnaire) were evaluated.
61991523|NCT06428227||Heart failure patients without inspiratory muscle weakness|Exercise capacity (6 minute walking test), pulmonary function (spirometry), respiratory muscle strength (mouth pressure device), peripheral muscle strength (hand-held dynometer), dyspnea (The Modified Medical Research Council (MMRC) dyspnea scale), fatigue (Fatigue Severity Scale), quality of life (The Short Form 36 (SF-36) questionnaire), physical activity level (The International Physical Activity Questionnaire) were evaluated.
61991524|NCT06428227||Healthy controls|Exercise capacity (6 minute walking test), pulmonary function (spirometry), respiratory muscle strength (mouth pressure device), peripheral muscle strength (hand-held dynometer), dyspnea (The Modified Medical Research Council (MMRC) dyspnea scale), fatigue (Fatigue Severity Scale), quality of life (The Short Form 36 (SF-36) questionnaire), physical activity level (The International Physical Activity Questionnaire) were evaluated.
62559661|NCT02367469||Brain Tumors|Patients with newly diagnosed or recurrent brain tumors will be studied.
61991525|NCT01865903||Cohort 1|All with diagnose of NSCLC in Oslo during 6 months
62767767|NCT06329882|ACTIVE_COMPARATOR|Comparative group|patients were on sitagliptin 100mg /day monotherapy plus doxycycline 100 mg
61991526|NCT01865903||Cohort 2|All NSCLC in Ulleval university hospital whom are in need of palliative chemotherapy
62767768|NCT02867774|EXPERIMENTAL|Intervention|This pilot study will enroll 25 women age 18-65 with greater than six months of noncyclic pelvic pain. Subjects will participate in an 8-week physical activity program specifically designed for patients with chronic pain and supervised by personal trainers and exercise physiologists in a rehab-focused, medically-based fitness center. Subjects will complete web-based assessment tools at the start of the program, immediately after completion of the 8-week program and four weeks after the conclusion of the program (at the 12-week time point).
62767769|NCT02801760||Subjects Currently or Previously Enrolled in ATN 110/ATN 113|Younger and older YMSM and transgender women who have sex with men, ages 15 through 22 years, inclusive, at the time of consent into the ATN 110 or ATN 113 study.
61991527|NCT03526458|ACTIVE_COMPARATOR|Holmium:YAG laser: 0.2J&15Hz|Patients are assigned to treat stones with 0.2J\&15Hz of the holmium laser.
61991528|NCT03526458|EXPERIMENTAL|Holmium:YAG laser: 0.8J&15Hz|Patients are assigned to treat stones with 0.8J\&15Hz of the holmium laser.
61991529|NCT03291210|EXPERIMENTAL|Normoxemia|Patients randomized to the normoxemia group receives inspired oxygen fraction of 0.3 from initiation of induction of anesthesia to the end of the procedure.
62767770|NCT02801760||Sub-Sample of Subjects to Complete Qualitative Interview|A sub-sample of subjects who completed the web-based survey and indicated willingness to complete the qualitative interview.
62767771|NCT00139256|EXPERIMENTAL|Betamethasone|Betamethasone injection
62767772|NCT00139256|PLACEBO_COMPARATOR|Placebo|Placebo injection
61991530|NCT03291210|ACTIVE_COMPARATOR|Hyperoxemia|Patients randomized to the hyperoxemia group receives inspired oxygen fraction of 0.8 from initiation of induction of anesthesia to the end of the procedure.
61991531|NCT05111691|EXPERIMENTAL|Dry needling|"Two needles will be inserted on or near the most tender point of the low back. Two additional needles will be inserted on the opposite side at the level of the most tender point regardless of unilateral or bilateral low back pain (LBP). After piercing the skin, the needle will be directed toward the spinous process in a slight inferior-medial angle (approximately 20-30°). Once the needle is inserted, the treating investigator will use a ultrasound scanner to visualize the needle placement and to confirm that needle has reached the deeper layer of the lumbar multifidus (LM) muscle.~Once the needle placement is confirmed, it will be pulled slightly in and out within the muscle and redirected in small angles for 10 seconds after insertion. The needles will stay (in situ) in the LM for approximately 10 minutes after the insertion and then will be withdrawn."
61991532|NCT03390881|EXPERIMENTAL|Fasting condition|Effects of cumulated negative energy balance (fasting over 480 min) on breath acetone changes
61991533|NCT03390881|ACTIVE_COMPARATOR|Sugar condition|Effects of sugar consumption on breath acetone changes
61991534|NCT03390881|ACTIVE_COMPARATOR|Fat condition|Effects of fat consumption on breath acetone changes
61991535|NCT00798369|EXPERIMENTAL|Canakinumab 10 mg|Canakinumab 10 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
61991536|NCT00798369|EXPERIMENTAL|Canakinumab 25 mg|Canakinumab 25 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
61991537|NCT00798369|EXPERIMENTAL|Canakinumab 50 mg|Canakinumab 50 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
61991538|NCT00798369|EXPERIMENTAL|Canakinumab 90 mg|Canakinumab 90 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
61991539|NCT00798369|EXPERIMENTAL|Canakinumab 150 mg|Canakinumab 150 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
62387280|NCT01143116|EXPERIMENTAL|Catheter A|"Catheterization with Catheter A, which releases silver ions into the urethra and urinary bladder upon catheterization,.~After activation in the wetting solution the coating retains water creating a smooth liquid surface around the catheter.The products are intended for single use. No additional lubricant were used.~The subject will be treated with investigational products during 24 hours. During this period the subject will be catheterized with the study catheter at six occasions (every 4 hours)."
62387281|NCT01143116|EXPERIMENTAL|Catheter B|"Catheterization with Catheter B, which releases both silver ions and degradable silver particles.. After activation in the wetting solution the coating retains water creating a smooth liquid surface around the catheter.The products are intended for single use. No additional lubricant were used.~The subject will be treated with investigational products during 24 hours. During this period the subject will be catheterized with the study catheter at six occasions (every 4 hours)."
62387282|NCT03789864|OTHER|Individuals undergoing SOC Gemcitabine Treatment for mycosis fungoides (MF) T-cell lymphoma|Standard of Care (SOC) treatment with gemcitabine in this setting is 1200 mg/m2 as a 30 minute infusion given intravenously on days 1, 8, and 15 of every 28-day treatment cycle. Standard dose reductions are expected in patients experiencing unacceptable toxic effects of treatment. All subjects will undergo standardized staging tests, with tumor stage defined according to established guidelines. For this study, three 6-mm x 4-mm dermal punch biopsies from one or more target lesions will be collected prior to treatment initiation and submitted for Biodynamic imaging (BDI). All patients will be considered off-study after completing cycle 2.
62387283|NCT03513835||Mitochondrial myopathy|
62387284|NCT03513835||Healthy controls|
62387285|NCT00422955|EXPERIMENTAL|Arm 1|
62387286|NCT06172205|EXPERIMENTAL|Infusional FOLFOX|Infusional mFOLFOX7 plus Camrelizumab and apatinib
62387287|NCT06172205|ACTIVE_COMPARATOR|HAIC-FOLFOX|HAIC-FOLFOX plus Camrelizumab and apatinib
62387288|NCT04998058|PLACEBO_COMPARATOR|Control (conventional graft procedure), bone substitute and saline solution.|one randomly assigned maxillary sinus grafted internally defined as control (bone substitute + saline solution) per subject.
62767773|NCT03873506|EXPERIMENTAL|Mesenchymal Stem Cell|A single intravenous transplantation of Mesenchymal Stem Cell (Dose A - 1 million cells per kg, Dose B - 5 million cells per kg)
62767774|NCT02066415|PLACEBO_COMPARATOR|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection.
62387289|NCT04998058|EXPERIMENTAL|Test (modified graft), bone substitute and concentrated culture medium (CM)|one randomly assigned maxillary sinus grafted internally defined as test (bone substitute + concentrated culture medium) per subject.
62387290|NCT02394457|EXPERIMENTAL|Intravenous Cosyntropin Group A|Cosyntropin 500 mcg in 1000cc Normal Saline
62387291|NCT02394457|ACTIVE_COMPARATOR|Epidural Blood Patch Group B|Epidural Blood Patch and I000cc Normal Saline
62387292|NCT05489276|EXPERIMENTAL|TQB2825 injection|TQB2825 injection is given intravenously every 2 weeks, and every 4 weeks (28 days) as a treatment cycle, with the longest treatment duration not exceeding 2 years.
62387293|NCT01482598|ACTIVE_COMPARATOR|Optimal Remote Care|Patient follow up is performed through remote care, remote alerts on CRT-D device data are transmitted daily to the hospital, remote follow up is scheduled every 6 months, hospital in clinic follow up is scheduled at 12 months after implant.
61991540|NCT00798369|ACTIVE_COMPARATOR|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg intramuscularly (i.m) once. The i.m. injection was recommended to be administered deeply into the gluteal muscle. Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
61991541|NCT02918149|OTHER|Palpation Landmark Technique LP|Traditional landmark palpation technique will be used to perform LP
61991542|NCT02918149|EXPERIMENTAL|Ultrasound-Assisted Technique LP|Bedside ultrasonography exam will be used for identification of anatomic landmarks before performing LP
61991543|NCT05930730|EXPERIMENTAL|Comvigen (Bivalent, ChulaCov19 BNA159.2)|
61991544|NCT05930730|ACTIVE_COMPARATOR|BIVALENT Pfizer/BNT vaccine|
61991545|NCT04568590|EXPERIMENTAL|Vaccine Hesitant|Subjects who consent to this study and deemed vaccine hesitant, they will receive an educational intervention.
61991546|NCT01811927|EXPERIMENTAL|PRO-Kinetic Energy Stent|PRO-Kinetic Energy Stent
61991547|NCT06427356|EXPERIMENTAL|Interdisciplinary Team|Participants complete surveys, meet with five pain specialists to develop individualized treatment plans based on whole health, receive monthly coaching calls for five months, then meet with the pain specialists once more for a 6-month follow-up appointment and complete surveys.
61991548|NCT06427356|NO_INTERVENTION|Waitlist Control|Participants complete surveys but do not engage with the pain specialists for 6 months.
62767775|NCT02066415|EXPERIMENTAL|Erenumab 70 mg|Participants received 70 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
62767776|NCT02066415|PLACEBO_COMPARATOR|Erenumab 140 mg|Participants received 140 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
62387294|NCT01482598|NO_INTERVENTION|Optimal Standard Care|Patient standard in clinic visits are performed every 6 months.
61991549|NCT01262482|EXPERIMENTAL|Oxaliplatin + Sorafenib|
62767777|NCT04149678|EXPERIMENTAL|Treatment Group A - Ozanimod|Subjects will receive a single oral dose of ozanimod 0.46 mg
61991550|NCT02970279|EXPERIMENTAL|Enhanced Behavioural Activation Groups|"Behavioural activation group (BAG) psychotherapy delivered with two embedded treatment augmentations;~1. Implementation intentions~2. Dose-response psychoeducation"
62387295|NCT05862675||experimental group|meeting the specific diagnostic criteria for acute Lung Injury
62387296|NCT05862675||control group|Healthy children
62387297|NCT05207371|EXPERIMENTAL|GAIA-102 alone|GAIA-102: 1 vial (2 x 10\^8 cells) / dose at a fixed dose, 1 to 3 doses / week for 3 consecutive weeks.
62387298|NCT05207371|EXPERIMENTAL|GAIA-102 with Pembrolizumab|"GAIA-102: 1 vial (2 x 10\^8 cells) / dose at a fixed dose, 1 to 3 doses / week for 3 consecutive weeks.~Pembrolizumab：200 mg Administer on Day 1."
62387299|NCT04097925|EXPERIMENTAL|Doravirine + Descovy® TAF/FTC|Doravirine (MK-1439) 100 mg administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) co-formulated as single tablet (Descovy® TAF/FTC 25/200 mg) and administered orally once daily during 16 weeks
62387300|NCT01488994|EXPERIMENTAL|BAX326 < 6 years of age|
62387301|NCT01488994|EXPERIMENTAL|BAX326 6 to <12 years of age|
62387302|NCT02183220|EXPERIMENTAL|Metamizol high & Placebo|
62387303|NCT02183220|EXPERIMENTAL|Metamizol low & Placebo|
62387304|NCT02183220|ACTIVE_COMPARATOR|Acetylsalicylic acid & Placebo|
62387305|NCT02183220|PLACEBO_COMPARATOR|Placebo|
62387306|NCT03525613|EXPERIMENTAL|APL-2 15mg 0.1 mL Monthly for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month
62387307|NCT03525613|EXPERIMENTAL|APL-2 15mg 0.1 mL EOM for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month
61991551|NCT04976842|ACTIVE_COMPARATOR|Opioid-free anesthesia|Opioid free anesthesia protocol for urological procedurs
61991552|NCT04976842|ACTIVE_COMPARATOR|Opioid-based anesthesia|Opioid based anesthesia protocol for urological procedures
61991553|NCT01064492|EXPERIMENTAL|ABC, ACB, BAC, BCA, CAB, and CBA|
61991554|NCT03792672|EXPERIMENTAL|TAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg|TAK-653 6 milligram (mg) high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 milligram per kilogram (mg/kg), intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
61991555|NCT03792672|EXPERIMENTAL|TAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kg|TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
61991556|NCT03792672|EXPERIMENTAL|TAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kg|TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
62387308|NCT03525613|EXPERIMENTAL|Sham Procedure Monthly for 24 months|Sham Procedure monthly for 24 months
62387309|NCT03525613|EXPERIMENTAL|Sham Procedure Every Other Month for 24 months|Sham Procedure every other month for 24 months
62767778|NCT04149678|EXPERIMENTAL|Treatment Group B - Ozanimod plus Cyclosporine|Subjects will receive a single oral dose of ozanimod 0.46 mg plus a single oral dose of cyclosporine 600 mg
62767779|NCT01685983|EXPERIMENTAL|Abiraterone actetate and Prednisolone|
62767780|NCT05997576|EXPERIMENTAL|TG103 22.5 mg|Administered subcutaneously once every week for 52 weeks. Doses gradually increased to 22.5 mg.
62767781|NCT05997576|PLACEBO_COMPARATOR|Placebo|Administered subcutaneously once every week for 52 weeks.
62559662|NCT03304405||Gait Analysis|All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
62559663|NCT01381965|ACTIVE_COMPARATOR|Eyes with macular hole|
62559664|NCT03667040|NO_INTERVENTION|Control Group|75 participants will take part in three visits (baseline, 30days and 60days)
62559665|NCT03667040|ACTIVE_COMPARATOR|Intervention|75 participants will take complete a baseline visit and then participate in the intervention. They will use the application, the JOOL app for 30 days. Then complete surveys at 30days and 60days after the interventions
62559666|NCT01838369|EXPERIMENTAL|BI-505|
62559667|NCT03093259|EXPERIMENTAL|ABX464 Treatment Arm|Subjects will receive 50 mg of ABX464 orally once daily for 56 days.
62559668|NCT03093259|PLACEBO_COMPARATOR|ABX464 matching placebo Treatment Arm|Subjects will receive 50 mg of ABX464 matching Placebo orally once daily for 56 days.
62559669|NCT02162277||Osteoporosis diagnostic kit|
62387310|NCT03343990||group A|Interlocking multi-twisted wires techniqe in sternal closure
62559670|NCT04290364||Prospective cohort|Patients newly diagnosed with pancreatic cancer included in the prospective part of the study
62559671|NCT04290364||Retrospective cohort|Patients diagnosed with pancreatic cancer before early palliative care was introduced (historical control patients)
62559672|NCT01735461|EXPERIMENTAL|Dietary supplement|Calcium Carbonate
62559673|NCT02767167|ACTIVE_COMPARATOR|Milk treatment group|Semi-skimmed cow's milk + normal diet for 12 weeks
62387311|NCT03343990||group B|Eight Figure techniqe in sternal closure
62559674|NCT02767167|NO_INTERVENTION|Control group|Normal diet for 12 weeks
62559675|NCT05782933|EXPERIMENTAL|Rituximab|Patients received rituximab 100 and 500 mg of intravenous medication on days 1 and 2, respectively. If proteinuria was reduced from baseline by no more than 25% at 3 months, cyclosporine was administered. In addition, CD19+ B-cell count was monitored every 3 months, and another rituximab 100 and 500 mg will be administered if CD19+ B-cell count \>5 cells/mL.
62559676|NCT05782933|ACTIVE_COMPARATOR|Modified Ponticelli regimen|Patients received corticosteroids at months 1, 3, and 5 (methylprednisolone 0.5 g at days 1, 2, and 3, then prednisone 0.5 mg/kg/d from day-4 to day-30). At months 2, 4, and 6, patients received cyclophosphamide adjusted for age and renal function (1.0-2.0 mg/kg/day for 30 days, maximum dose 100 mg/d).
62387312|NCT03922919|ACTIVE_COMPARATOR|Cefotaxime or ceftriaxone group|free use of cefotaxime or ceftriaxone by the investigator
62559677|NCT04647084|EXPERIMENTAL|Intradermal Lidocaine 2%|
62559678|NCT04647084|EXPERIMENTAL|Buzzy|
62559679|NCT04821076|ACTIVE_COMPARATOR|Energy balance|
62559680|NCT04821076|EXPERIMENTAL|Energy restriction|
62559681|NCT04821076|ACTIVE_COMPARATOR|Energy balance + exercise|
62559682|NCT04821076|EXPERIMENTAL|Energy restriction + exercise|
62559683|NCT04427761||pancreatic cancer health-illness transition|In this prospective longitudinal correlational study, a convenience sample of patients with pancreatic cancer receiving chemotherapy will be asked to report on their health-illness transition experiences and their level of distress.
62387313|NCT03922919|EXPERIMENTAL|Cefotaxim group|Systematic use of cefotaxime
62387314|NCT02822274|EXPERIMENTAL|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62559684|NCT02345980|ACTIVE_COMPARATOR|Sildenafil|Patient in this arm will receive sildenafil citrate 50 mg tablet once daily after ureteral stent fixation.
62559685|NCT02345980|PLACEBO_COMPARATOR|Placebo|Patient in this arm will receive placebo daily after ureteral stent fixation.
62559686|NCT03820128|ACTIVE_COMPARATOR|Very early refeeding|"Very early diet intervention: refeeding within 24 hours from the hospital admission.~Participants will be encouraged to start eating immediately after the time of admission. They will be able to choose the meal from the list with no amount or calories restriction.They will be asked to conduct the daily diet diary - time of feeding, quality and quantity of the foods ingested. Laboratory tests will be performed at the study entry, on the day of 3 and 5 of hospitalization and on the day of discharge."
62559687|NCT03820128|ACTIVE_COMPARATOR|Early refeeding|"Early diet intervention: refeeding after 24 hours from the hospital admission .~During the first 24 hours after admission participants will be on fluid only (orally and/or intravenously). Later on they will be encouraged to start eating. They will be able to choose the meal from the list with no amount or calories restriction.They will be asked to conduct the daily diet diary - time of feeding, quality and quantity of the foods ingested. Laboratory tests will be performed at the study entry, on the day of 3 and 5 of hospitalization and on the day of discharge."
62559688|NCT04482764|OTHER|cyanotic breath holding spells|drug, valproic acid: 5mg/kg/d for 6 months
62559689|NCT02005289|EXPERIMENTAL|Cohorts 1-3Treatment (MOR00208, lenalidomide)|Patients receive anti-CD19 monoclonal antibody MOR00208 IV over 2 hours on day 1 (days 1, 2, 8, 15, and 22 of course 1 only) and lenalidomide PO daily on days 1-28 (days 9-28 of course 1 only). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Correlative studies will be collected for this trial and will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.
62387315|NCT01535638|ACTIVE_COMPARATOR|BI 207127 NA TFII medium dose|Film-coated tablet for oral administration
62387316|NCT01535638|ACTIVE_COMPARATOR|BI 207127 NA FF medium dose|Film-coated tablet for oral administration
62387317|NCT01535638|ACTIVE_COMPARATOR|BI 207127 NA FF modified medium dose|Film-coated tablet for oral administration
62387318|NCT00890851|OTHER|Procedure TUNA|
62387319|NCT00527722|EXPERIMENTAL|Pleural Plug|Experimental lung plug after the lung biopsy.
62387320|NCT00527722|ACTIVE_COMPARATOR|No Pleural Plug|The standard lung biopsy without placement of the plug.
62559690|NCT02005289|EXPERIMENTAL|Cohort 4 Treatment (MOR00208, ibrutinib)|Patients receive anti-CD19 monoclonal antibody MOR00208 IV over 2 hours on day 1 (days 1, 2, 8, 15, and 22 of course 1 only) and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Correlative studies will be collected for this trial and will focus on the effects of MOR00208 alone and in combination with ibrutinib on immune effector cell number and function.
62559691|NCT03209271|EXPERIMENTAL|Body temperature fluid|500ml Ringers Acetate infused over 15 minutes warmed to 38°C
62559692|NCT03209271|ACTIVE_COMPARATOR|Room temperature fluid|500ml Ringers Acetate infused over 15 minutes cooled to 22°C
62559693|NCT05203770||CBP+mOUD|Chronic Back pain participants taking opioids and classified in the opioid misuse disorder group
61991557|NCT03792672|EXPERIMENTAL|TAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kg|TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
61991558|NCT03792672|EXPERIMENTAL|Placebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kg|TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
61991559|NCT03792672|EXPERIMENTAL|Placebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kg|TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
62767782|NCT05996042|OTHER|Time-restricted diet group|Subjects in this group were given a limited diet every Tuesday, Thursday and Saturday. They were only allowed to eat from 7am to 3pm on the same day, and only allowed to drink purified water during other periods, namely an 8-hour eating window and a 16-hour fasting period
62387321|NCT03244189|EXPERIMENTAL|Intervention|"Participants in the intervention arm will receive an individualized fluid prescription, which will be the additional volume of fluid intake needed to maintain a study-specified urine output. This fluid will be consumed from and measured by a smart water bottle. The intervention arm also includes a behavioral program that consists of financial incentives and structured problem solving (SPS) to maintain the recommended fluid intake."
62387322|NCT03244189|NO_INTERVENTION|Control|"Participants in the control arm will receive standard care instructions according to American Urological Association (AUA) guidelines to increase overall fluid consumption to achieve study-specified urine output. They will also receive a smart water bottle with capability to self-monitor their fluid intake."
62387323|NCT04785781|OTHER|no mask|individuals perform cardiopulmonary test via cycle ergometer without mask till voluntary exhaustion
62387324|NCT04785781|OTHER|surgical mask|individuals perform cardiopulmonary test via cycle ergometer with surgical mask till voluntary exhaustion
62559694|NCT05203770||CBP+O|Chronic Back pain participants taking opioids and without opioid misuse disorder group
62767783|NCT05996042|OTHER|Multimode aerobics group|Subjects in this group performed multi-mode aerobic exercise from 6:00 PM to 7:00 PM on Monday, Wednesday and Friday under the unified guidance of the physical education teacher of the Health Science Center in the gymnasium and sports field of Peking University Health Science Center, including aerobics, yoga and comprehensive physical training
62767784|NCT05996042|EXPERIMENTAL|A combination of time-restricted diet and multimodal aerobic exercise|Subjects in this group received the same time-limited dietary intervention every Tuesday, Thursday and Saturday according to the above requirements of the single time-limited dietary group, and the same multi-mode aerobic exercise intervention every Monday, Wednesday and Friday according to the above requirements of the single multi-mode aerobic exercise group.
61991560|NCT05039710|EXPERIMENTAL|Cohort 1: JNJ-75220795 or Placebo|Participants will receive single subcutaneous (SC) dose of JNJ-75220795 Dose 1 or matching placebo on Day 1 in Cohort 1.
61991561|NCT05039710|EXPERIMENTAL|Cohort 2: JNJ-75220795 or Placebo|Participants will receive single SC dose of JNJ-75220795 Dose 2 or matching placebo on Day 1 in Cohort 2.
62387325|NCT04785781|OTHER|N95/fpp2|individuals perform cardiopulmonary test via cycle ergometer with N95 mask till voluntary exhaustion
62387326|NCT04301349|EXPERIMENTAL|vaginal dinoprostone|vaginal dinoprostone 6 mg (two tablets) 3 hours prior to IUD insertion
62387327|NCT04301349|ACTIVE_COMPARATOR|vaginal misoprostol|vaginal misoprostol 400 mcg (two tablets) 3 hours prior to IUD insertion
62559695|NCT05203770||CBP-O|Chronic Back pain participants not taking opioids
62559696|NCT05203770||Healthy Controls|Healthy control without pain or taking opioids.
62559697|NCT02284477|EXPERIMENTAL|non- PVC containing packing materials|Participants will be provided food for lunch and dinner with 360mL apple juice which was stored in glass bottle for 24 hours in 4 ℃. After 1 week, participant will cross over to other intervention.
62559698|NCT02284477|EXPERIMENTAL|PVC containing packing materials|Participants will be provided food for lunch and dinner with 360mL apple juice which was stored in PVC blood bag for 24 hours in 4 ℃. After 1 week, participant will cross over to other intervention.
62767785|NCT05810714|ACTIVE_COMPARATOR|Arm I (FIT, usual care)|Participants receive the FIT kit and usual care on study.
62767786|NCT05810714|EXPERIMENTAL|Arm II (FIT, audio brochure, reminder)|Participants receive the FIT kit with an audio brochure, disposable gloves and stool collection device, and scheduled reminder on study.
62767787|NCT05810714|EXPERIMENTAL|Arm III (FIT, video brochure, reminder)|Participants receive the FIT kit with a video brochure, disposable gloves and stool collection device, and scheduled reminder on study.
62767788|NCT01534949|EXPERIMENTAL|CT-P10|rituximab
62387328|NCT04301349|PLACEBO_COMPARATOR|placebo|two tablets of placebo similar in shape ,color, odor to the study drugs
62767789|NCT05705661|NO_INTERVENTION|The control group (I)|The control group (I): The participants will follow the traditional pulmonary rehabilitation program including (active cycle of breathing technique, breathing control, deep breathing exercises, huffing). The session duration will be between 30 min twice/day for 15 days as guided by subject fatigue and comfort. (According to Borg scale of dyspnea for monitoring).
61991562|NCT01596348||RA patients|Patients with Rheumatoid Arthritis
61991563|NCT03054662|EXPERIMENTAL|Patients with Haemophilia|Male patients with severe and moderate haemophilia A and B in Ivory Coast
61991564|NCT03054662|EXPERIMENTAL|Carriers for Haemophilia|Carriers for severe and moderate haemophilia A and B in Ivory Coast
61991565|NCT06340438|OTHER|Histamine application|In the first session, the subjects will fill some questionnaires. After that, a squared area of 4x4 cm will be selected at the center of each middle forearm of the subject and cowage or histamine will be applied for 10 minutes, during which the pain/itch following the cowhage/histamine application will be monitored with a VAS scale. After the itch-induction, the subjects will fill in other questionnaire. In second session, the subjects will fill some questionnaires. After that, a squared area of 4x4 cm will be selected at the center of each middle forearm of the subject and cowage or histamine will be applied for 10 minutes, during which the pain/itch following the cowhage/histamine application will be monitored with a VAS scale. After the itch-induction, the subjects will fill out other questionnaires. The order will be randomized, so if the subjects were given the cowhage in the first session, they will receive the histamine application in the second session, and vice versa.
61991566|NCT06340438|OTHER|Cowhage application|In the first session, the subjects will fill some questionnaires. After that, a squared area of 4x4 cm will be selected at the center of each middle forearm of the subject and cowage or histamine will be applied for 10 minutes, during which the pain/itch following the cowhage/histamine application will be monitored with a VAS scale. After the itch-induction, the subjects will fill in other questionnaire. In second session, the subjects will fill some questionnaires. After that, a squared area of 4x4 cm will be selected at the center of each middle forearm of the subject and cowage or histamine will be applied for 10 minutes, during which the pain/itch following the cowhage/histamine application will be monitored with a VAS scale. After the itch-induction, the subjects will fill out other questionnaires. The order will be randomized, so if the subjects were given the cowhage in the first session, they will receive the histamine application in the second session, and vice versa.
61991567|NCT04526483|EXPERIMENTAL|laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D|
61991568|NCT03616288|PLACEBO_COMPARATOR|Negative Control|placebo; 0 mg thiamine
62767790|NCT05705661|ACTIVE_COMPARATOR|The study group (II)|The study group (II): The participants will receive active cycle of breathing technique, breathing control, deep breathing exercises (15 min) in addition to (HFCWO); the patient position will be in a semi-recline position, with wrapped vest around the chest. The (HFCWO) protocol included 3-5 cycles, with a pressure range of +10 to +40 IP cmH2O and will be adjusted according to the patient age, number of secretions, tolerance of patients, and chest auscultation every session. The numbers of total sets will be 3-5 with a duration of 15 min, daily, for two sessions / day , time range according to the ability of the patient. (Çelik et al., 2021).
62387329|NCT04812457|EXPERIMENTAL|Physiological cures using pure hyaluronic acid (Hialucic®)|After the intervention of unilateral onychocryptosis, the partial matricectomy technique with phenol / alcohol,next to an ointment with hyaluronic acid (hyalucic ®) will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding
62767791|NCT05207163|EXPERIMENTAL|Received CME|
62387330|NCT04812457|ACTIVE_COMPARATOR|Control group using traditional cure (Betadine Gel).|After the intervention of unilateral onychocryptosis, the partial matricectomy technique with phenol / alcohol,next to Povidone Iodine Gel (Betadine Gel®) will be applied following the same procedure.
62387331|NCT00991913||Delirium|Delirium was determined by CAM-ICU
62387332|NCT00991913||no Delirium|no Delirium was determined by CAM-ICU
62767792|NCT05207163|NO_INTERVENTION|Not received CME|
62767793|NCT04788771|SHAM_COMPARATOR|Tracheal intubation in laparoscopic extraperitoneal hernia repair|Tracheal intubation in laparoscopic extraperitoneal hernia repair
62767794|NCT04788771|ACTIVE_COMPARATOR|laryngeal mask airway in laparoscopic extraperitoneal hernia repair|laryngeal mask airway in laparoscopic extraperitoneal hernia repair
62767795|NCT04783857|ACTIVE_COMPARATOR|Group 1|Participants in this group will receive progesterone
62767796|NCT04783857|NO_INTERVENTION|Group 2|Participants in this group will not receive progesterone
62767797|NCT03353766|EXPERIMENTAL|Early crossbite correction|Early crossbite correction with Q-H Device
62767798|NCT03353766|NO_INTERVENTION|Crossbite correction in mixed dentition|Later crossbite correction, during mixed dentition
61991569|NCT03616288|EXPERIMENTAL|EAR Group|1.2 mg thiamine as thiamine hydrochloride
61991570|NCT03616288|EXPERIMENTAL|Double EAR Group|2.4 mg thiamine as thiamine hydrochloride
61991571|NCT03616288|EXPERIMENTAL|Positive Control|10 mg thiamine as thiamine hydrochloride
61991572|NCT01266213|EXPERIMENTAL|Fulvestrant plus Goserelin|
61991573|NCT01266213|EXPERIMENTAL|Anastrozole plus Goserelin|
61991574|NCT01266213|ACTIVE_COMPARATOR|Goserelin alone|
62387333|NCT00902473|EXPERIMENTAL|1|25 mg Topiramate tablets of Ranbaxy Laboratories, Ltd
62387334|NCT00902473|ACTIVE_COMPARATOR|2|(Topamax®) 25 mg Topiramate tablets of Ortho-McNeil Pharmaceutical, Inc. New jersey 08869
62387335|NCT05204901|EXPERIMENTAL|Magnetic tracking|This is the only arm of the study. All 12 participants will undergo the insertion of the magnetic-tipped guidewire into their nasogastric tube after its correct placement is confirmed by chest X-ray.
62387336|NCT00640900|EXPERIMENTAL|Commercial program at center|
62387337|NCT00640900|EXPERIMENTAL|Commercial program over the telephone|
62387338|NCT00640900|OTHER|Usual care|Weight loss counseling
61991575|NCT04069156|PLACEBO_COMPARATOR|Placebo Arm|LVAD Patients on the placebo arm will be given placebo medication
61991576|NCT04069156|ACTIVE_COMPARATOR|Active Arm|LVAD Patients on the active arm will be given 100mg Aspirin
61991577|NCT04783805||Spontaneous HSIL regression|Patients that have spontaneous regression of HSIL throughout follow-up. Patients in this group will be further classified into 3 subgroups: total resolution (no colposcopic lesion, normal pathology by biopsy and cytology, and negative HPV for the HPV type initially detected); partial resolution (regression of colposcopic lesion, negative cytology and biopsies, but persistence of the initial hrHPV detected); and lesion regression (HSIL no longer detected, but persistent LSIL in either cytology, histology or colposcopy).
61991578|NCT04783805||Conization|Women who have cervical conization for any reason during follow-up. Patients in this group will be further classified according to indication criteria: failure to meet criteria for conservative management or persistence of HSIL after 24 months of follow-up.
61991579|NCT03465878|EXPERIMENTAL|LY900014-Part A|Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014.
61991580|NCT03465878|ACTIVE_COMPARATOR|Humalog (Insulin Lispro)-Part A|Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL of Humalog.
61991581|NCT03465878|EXPERIMENTAL|LY900014-Part B|Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the continuous subcutaneous insulin infusion (CSII) pump.
61991582|NCT03465878|ACTIVE_COMPARATOR|Humalog (Insulin Lispro)-Part B|Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.
61991583|NCT02727920|EXPERIMENTAL|Experimental|drink containing pyridoxine, folate; B12); taurine, choline, glucuronic acid; tyrosine, phenylalanine\*, malic acid, and caffeine administered one time.
61991584|NCT02727920|PLACEBO_COMPARATOR|Placebo drink|Placebo drink administered one time.
61991585|NCT01177540|EXPERIMENTAL|Arm A|
61991586|NCT01177540|EXPERIMENTAL|Arm B|
61991587|NCT01363596||Natural Procreative Technology (NPT)|Patients who are treated or who consider being treated with Natural Procreative Technology (NPT) for infertility or history of spontaneous abortion.
61991588|NCT02381912||Hematuria - NMIBC|Primary hematuria due to NMIBC.
61991589|NCT02381912||Hematuria - other cause|Other non-malignant cause of hematuria.
61991590|NCT02208609|EXPERIMENTAL|Maize Tortillas with 20% Amaranth|Children in this arm were fed maize tortillas fortified with 20% amaranth
61991591|NCT02208609|EXPERIMENTAL|Maize Tortillas without 20% Amaranth|Children in this arm were fed maize tortillas without amaranth
61991592|NCT00702117|ACTIVE_COMPARATOR|A|IV flecainide in atrial fibrillation
62387339|NCT04030351|EXPERIMENTAL|dried fruit|100 g per day of dried fruit
62559699|NCT02284477|NO_INTERVENTION|Only lunch and dinner|Participant received food for lunch and dinner After 1 week, participant get over to each experimental arms.
62559700|NCT06269991||bow category|the athletes using recurve bow or compound bow will investigating.
61991593|NCT00702117|EXPERIMENTAL|B|IV ajmaline in atrial fibrillation
61991594|NCT00702117|ACTIVE_COMPARATOR|c|iv procainamide in ventricular tachycardia
61991595|NCT00702117|EXPERIMENTAL|d|iv ajmaline in ventricular tachycardia
61991596|NCT00702117|ACTIVE_COMPARATOR|e|iv flecainide in diagnosis of Brugada Sd
61991597|NCT00702117|EXPERIMENTAL|f|iv ajmaline in diagnosis of Brugada Sd
61991598|NCT00199290|PLACEBO_COMPARATOR|P|
61991599|NCT00199290|EXPERIMENTAL|L|low dose (0.2 %)
61991600|NCT00199290|EXPERIMENTAL|M|medium dose (0.3 %)
62387340|NCT04030351|NO_INTERVENTION|no dried fruit|no intervention to be given
62387341|NCT03474380|EXPERIMENTAL|Intervention|"Implementation of iHI-FIVES program~Intervention: Behavioral: iHI-FIVES"
62387342|NCT03474380|NO_INTERVENTION|Usual Care|Pre-implementation before iHI-FIVES program
62387343|NCT00470223|EXPERIMENTAL|Chemotherapy + zoledronic acid|
62387344|NCT00470223|ACTIVE_COMPARATOR|chemotherapy|
61991601|NCT00199290|EXPERIMENTAL|H|high dose (0.4 %)
61991602|NCT06376240|EXPERIMENTAL|Treatment order AB|Treatment with A (either pyridoxamine or placebo) in period 1 followed by treatment with B (either pyridoxamine or placebo) in period 2.
61991603|NCT06376240|EXPERIMENTAL|Treatment order BA|Treatment with B (either pyridoxamine or placebo) in period 1 followed by treatment with A (either pyridoxamine or placebo) in period 2.
61991604|NCT04425746|EXPERIMENTAL|Afamelanotide|Subjects visited the clinic on Day 0 (administration of afamelanotide implant and porfimer sodium), Day 2 (photodynamic therapy), and Days 20 and 90 for assessments of adverse events, concomitant medication and the results of evaluation of phototoxicity.
61991605|NCT04425746|PLACEBO_COMPARATOR|Placebo|Subjects visited the clinic on Day 0 (administration of placebo implant and porfimer sodium), Day 2 (photodynamic therapy), and Days 20 and 90 for assessments of adverse events, concomitant medication and the results of evaluation of phototoxicity.
61991606|NCT06338592|NO_INTERVENTION|Study 1 (Study of Patients with Uncertain LCS Eligibility) Control Arm|In Study 1 (Study of Patients with Uncertain LCS Eligibility), patients allocated to the control arm will not be exposed to the project intervention unless their EHR data change during the trial so that they have documented LCS eligibility. In these rare cases, these patients will be exposed to the intervention provided to patients in the control arm of Study 2 but will not be considered participants in Study 2.
62387345|NCT01594424|EXPERIMENTAL|IVIG + Tocilizumab|
62387346|NCT00656981|EXPERIMENTAL|Arm 1|
62387347|NCT00656981|PLACEBO_COMPARATOR|Arm 2|
62387348|NCT01301534||T-Con|1. Nurse initiated Telephone Consult (T-Con)
62387349|NCT01301534||Mail-Out|2. Mail-0ut Letter to the patient
62387350|NCT01301534||Education|3. Provider, Nurse and Technician Education with point-of-care patient referrals , Exam Room Flyer
61991607|NCT06338592|EXPERIMENTAL|Study 1 (Study of Patients with Uncertain LCS Eligibility) Intervention Arm|Patients allocated to the intervention arm of Study 1 will be exposed to the MyLungHealth intervention in addition to usual care. The Study 1 MyLungHealth eligibility questionnaires will consist of pre-visit smoking history questions asked through the EHR patient portal to increase the identification of screening-eligible patients (Figure 2). Patients will be prompted to engage in the intervention through pre-visit questionnaires for primary care visits administered up to 7 days prior to the visits. These questions will ask about the patients' smoking history and determine whether patients meet LCS eligibility criteria. Study 1 patients who meet LCS eligibility criteria will be offered the intervention provided to patients in the intervention arm of Study 2 immediately after confirming eligibility but will not be considered participants in Study 2.
61991608|NCT06338592|ACTIVE_COMPARATOR|Study 2 (Study of Patients with Documented LCS Eligibility) Control Arm|In Study 2 (Study of Patients with Documented LCS Eligibility), patients allocated to the control arm will be exposed to the DecisionPrecision+ intervention because DecisionPrecision+ intervention automatically identifies patients with documented LCS eligibility in the EHR. The DecisionPrecision+ intervention is designed to promote LCS and LCS SDM; the intervention consists of provider-facing EHR preventive care reminders, a provider-facing EHR SDM tool, and simple patient-facing preventive care reminders (only available at UUH). Simple patient-facing preventive care reminders will be available at UUH, but not NYU, because NYU does not use this type of reminders.
62387351|NCT01301534||Control group|4. Control group (i.e. usual care)
62387352|NCT02686957||women closed|"This cohort will include women who underwent repair for obstetric fistula at three fistula repair hospitals in Guinea and who had a closed fistula at hospital discharge.~no intervention will be done."
62387353|NCT03224442|EXPERIMENTAL|PRF with immediate implants|Immediate implants placed and covered with two prf layers
62387354|NCT03224442|ACTIVE_COMPARATOR|palatal pedicle graft|immediate implant placement followed by soft tissue augmentation by oalatal pedicle graft
62387355|NCT02509195|EXPERIMENTAL|Switch to Triumeq|HIV-1 infected subjects currently receiving stable antiretroviral therapy switch their treatment to abacavir/lamivudine/dolutegravir (Triumeq).
62387356|NCT03204136||tarcolimus|refractory inflammatory bowel disease patents who used tarcolimus to induce and maintain remission
62387357|NCT03204136||methotrexate|refractory inflammatory bowel disease patents who used methotrexate to induce and maintain remission
62387358|NCT02256956|ACTIVE_COMPARATOR|Amitriptyline first, Placebo second|Amitriptyline first, Placebo second
62387359|NCT02256956|ACTIVE_COMPARATOR|Placebo first, Amitriptyline second|Placebo first, Amitriptyline second
62387360|NCT05341609|EXPERIMENTAL|JT001(VV116)|Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
62387361|NCT05341609|ACTIVE_COMPARATOR|Paxlovid|Day 1\~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days
62387362|NCT02238392|ACTIVE_COMPARATOR|Group A|Adenosine testing after PVI and elimination of dormant conduction
62387363|NCT02238392|ACTIVE_COMPARATOR|Group B - Termination of AF|Termination of atrial fibrillation by catheter ablation
62387364|NCT03757026|ACTIVE_COMPARATOR|Conventional Physical Therapy|"20-22 participants randomly assigned to receive 10 sessions of balance training. Conventional balance training group (PT) will receive individualized standard of care physical therapy with the goal of improving balance and mobility during sessions 3 through 12. The only instructions to the PT are that the focus of the course of care should be on balance and mobility and that there should be 10 sessions total. The first visit will include an initial evaluation and limited treatment. While the remaining 9 sessions will consist of 45 minutes of PT treatment."
62387365|NCT03757026|EXPERIMENTAL|Slip training|20-22 participants randomly assigned to 1 session of slip training and 9 sessions of accompanied walking. Reactive slip training group (Slip) will complete a standing slip session using the current protocol of scaling slip distance and force to each individual and modulating the slip intensity across the session based on subject responses. Initial perturbation intensity (percent body weight and slip distance) will be based on the participant's miniBEST score and each subsequent perturbation intensity will be determined based on their response to the previous perturbations. The remaining nine intervention sessions will consist of accompanied walking for up to 45 minutes. Participants will walk at a comfortable pace while accompanied by a researcher around Cleveland State.
62387366|NCT03757026|EXPERIMENTAL|Harnessed gaming|20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
62387367|NCT00540228|EXPERIMENTAL|GSK1247446A 1 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62387368|NCT00540228|EXPERIMENTAL|GSK1247446A 2 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62387369|NCT00540228|EXPERIMENTAL|GSK1247446A 3 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62387370|NCT00540228|EXPERIMENTAL|GSK1247446A 4 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62559701|NCT05339633|OTHER|Single Dose|All study subjects will receive a a single oral dose of radiolabeled microtracer of D-0502 following an overnight fast
62559702|NCT02300064|EXPERIMENTAL|Healthy volunteers|Healthy volunteers will undergo one or more exercise interventions: knee-extensor exercise test; exercise test with restricting/releasing blood flow; exercise test with variable oxygen concentration and MRI; or exercise test with oral antioxidant or placebo cocktail.
62767799|NCT05558462|EXPERIMENTAL|RT-sequence|Group 1 (12 volunteers, RT sequence) will take 4 tablets of XC8, 10 mg, in Period 1 and 1 tablet of XC8, 40 mg, in Period 2
61991609|NCT06338592|EXPERIMENTAL|Study 2 (Study of Patients with Documented LCS Eligibility) Intervention Arm|Patients allocated to the intervention arm will be offered the MyLungHealth education tool in addition to the DecisionPrecision+ intervention. The pre-visit questionnaire will directly invite patients to use the MyLungHealth education app, rather than first asking about smoking history to confirm eligibility. When patients affirm in the patient portal that they were able to successfully open the MyLungHealth education tool, their providers will be notified of their potential interest in LCS through a passive (non-interruptive) prompt in the EHR.
62387371|NCT00540228|ACTIVE_COMPARATOR|Fluarix Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62387372|NCT00087685|EXPERIMENTAL|RAD001|RAD001 10 mg by mouth Daily
62387373|NCT05275309|EXPERIMENTAL|Children <= 1 years old|Pediatric patients \<= 1 years old of age scheduled for surgery in the prone position
62387374|NCT00577421|EXPERIMENTAL|1|5 mg/day risedronate
62387375|NCT04539444|EXPERIMENTAL|CD19/22 CART cells combined with PD-1 inhibitors|Patients will receive PD-1 inhibitor on the first day after CART cell infusion
62387376|NCT01454531|EXPERIMENTAL|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
62387377|NCT04408716|EXPERIMENTAL|Ablation Index Guided High-Power Short-Duration Group|For patients assigned to undergo AF ablation with ablation index guided high-power short-duration strategy, point-by-point circumferential pulmonary vein ablation will be performed using the advanced STSF catheter under ablation index guided high power short duration strategy (Radiofrequency energy is set up at a power of 50 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 20 mL/min; Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
62387378|NCT04408716|ACTIVE_COMPARATOR|Standard Radiofrequency Ablation Group|For patients assigned to undergo AF ablation with standard radiofrequency ablation group, point-by-point circumferential pulmonary vein ablation will be performed using the ST catheter under standard radiofrequency ablation settings (Radiofrequency energy is set up at a power of 30 to 35 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 17 to 30 mL/min. Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
62387379|NCT02546739|EXPERIMENTAL|Experimental: 1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
62387380|NCT02546739|EXPERIMENTAL|Experimental: 2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
62387381|NCT02546739|EXPERIMENTAL|Experimental: 3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
62387382|NCT01701531|EXPERIMENTAL|RBCPF|Treatment intervention arm
62387383|NCT00582842||1|Men with prostate cancer
62387384|NCT00582842||2|Men with prostate cancer
62387385|NCT02608099|ACTIVE_COMPARATOR|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
62387386|NCT02608099|EXPERIMENTAL|Uninterrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
62387387|NCT01537458||Isolated TI repair|Patients that underwent isolated tricuspid valve repair
62387388|NCT00764530|EXPERIMENTAL|Investigational|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell.
62387389|NCT00764530|ACTIVE_COMPARATOR|Control Device|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head.
62387390|NCT01455064||Type 1 or 2 diabetes, MDI or pump|
62387391|NCT00141297|EXPERIMENTAL|PD-0332991|
62387392|NCT03070054|NO_INTERVENTION|Control|non-LIA group prior to surgery
62387393|NCT03070054|EXPERIMENTAL|Treatment|Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
62387394|NCT02677506|EXPERIMENTAL|Supraclavicular|Supraclavicular brachial plexus block will be done.
62387395|NCT02677506|ACTIVE_COMPARATOR|Infraclavicular|Infraclavicular brachial plexus block block will be done.
62387396|NCT02855996|EXPERIMENTAL|Intervention|"Fathers will be randomly assigned to participate in the Fathers in Action/Padres Activos (FA/PA) intervention program to support fathers' healthy relationships with their children and support their co-parenting skills."
62387397|NCT02855996|NO_INTERVENTION|Control|"Fathers waitlisted for participation in the Fathers in Action/Padres Activos (FA/PA) program."
62387398|NCT04168775|OTHER|Home PIFR monitoring|Measurement of PIFR using the InCheck Dial® device and quantification of respiratory symptoms and COPD exacerbations using standardized questionnaires in the patient's home setting and during research visits in the clinic setting
62387399|NCT00864656||1|Patients submitted to application of 1 drop of 10% phenylephrine
62387400|NCT00864656||2|Patients submitted to application of 2 drops of 10% phenylephrine
62387401|NCT00864656||3|Patients submitted to application of 4 drops of 10% phenylephrine
62387402|NCT01191190|EXPERIMENTAL|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered.~Each patient may receive 3 cycles of treatment in the absence of progressive disease or significant toxicity."
62387403|NCT02517606|EXPERIMENTAL|Conventional physical therapy plus HPCS|Conventional physical therapy (Combination of manual therapy techniques and exercises for spinal segmental stabilization) plus the addition of hip posterolateral complex strengthening (HPCS)
62387404|NCT02517606|ACTIVE_COMPARATOR|Conventional physical therapy|Conventional physical therapy (Combination of manual therapy techniques and exercises for spinal segmental stabilization)
62767800|NCT05558462|EXPERIMENTAL|TR-sequence|Group 2 (12 volunteers, sequence TR) will take 1 tablet of XC8, 40 mg, in Period 1 and 4 tablets of XC8, 10 mg, in Period 2.
62387405|NCT00374452|EXPERIMENTAL|ATHENA-CDS-HTN plus Guideline Link|ATHENA-CDS-HTN plus Guideline Link. ATHENA-CDS-HTN display on the cover sheet of electronic health record, plus link to the guidelines
62387406|NCT00374452|OTHER|Guideline Link Only|Guideline Link Only. Link to The Seventh Report of the Joint National Committee on Prevention Detection and Treatment of High Blood Pressure (JNC7) and to VA-Department of Defense (DoD) hypertension guidelines
61991610|NCT00275951|EXPERIMENTAL|Cetuximab Plus P-HDFL|Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
62387407|NCT02952027|EXPERIMENTAL|Bell On|Subjects in the Bell On arm will receive a timer where the alarm will sound every hour.
61991611|NCT03413059|ACTIVE_COMPARATOR|morphine sulfate group|patients in this arm will receive : morphine dose 0.1mg /kg with 9 ml of 0.25 % bupivacaine with through epidural catheter on admission Then continuous epidural infusion of bupivacaine (0.1 mg.kg-1.h) 1st 72 hours
61991612|NCT03413059|ACTIVE_COMPARATOR|triamcinolone acetonide group|patients in this arm will receive will receive a mixture of 9 ml of 0.125 % bupivacaine with 80mg of triamcinolone ( 10 ml total volume) through epidural catheter on admission
61991613|NCT00355186|NO_INTERVENTION|Control|
61991614|NCT00355186|EXPERIMENTAL|Early|
61991615|NCT00355186|EXPERIMENTAL|Late|
62559703|NCT02300064|EXPERIMENTAL|COPD patients|Patients with Chronic Obstructive Pulmonary Disease (COPD) will undergo one or more exercise interventions: knee-extensor exercise test; exercise test with restricting/releasing blood flow; exercise test with variable oxygen concentration and MRI; or exercise test with oral antioxidant or placebo cocktail.
62559704|NCT06110273|ACTIVE_COMPARATOR|m-Health Control|This arm receives a digital fitness tracker, digital scale, and basic information about behavioral approaches for weight gain prevention.
62559705|NCT06110273|EXPERIMENTAL|Fit for Duty Mobile|This arm receives a digital fitness tracker; digital scale; smartphone app which delivers a behavioral weight gain prevention intervention; and periodic coaching calls.
62559706|NCT03261414|EXPERIMENTAL|With preoperative hypnosis|standard care plus hypnosis followed by administration of propofol for anesthesia induction
62559707|NCT03261414|ACTIVE_COMPARATOR|Without preoperative hypnosis|standard care without preoperative hypnosis followed by administration of propofol for anesthesia induction
62559708|NCT05444452|EXPERIMENTAL|GENOSS stent arm|Coronary lesions of the subjects this arm will be treated with GENOSS stent when in need of stent implantation
62559709|NCT05444452|ACTIVE_COMPARATOR|XIENCE stent arm|Coronary lesions of the subjects this arm will be treated with Xience stent when in need of stent implantation
62559710|NCT05368324|EXPERIMENTAL|CogFun-RV|It consists of 12 sessions, each lasting 75 minutes for each children. Parallel parents will participate in the parental guidance and psychoeducation program with one of the two therapists assigned to the child.
61991616|NCT04128163|EXPERIMENTAL|QL1206|"QL1206 injection (60mg:1ml) by subcutaneous injectionevery 6 month for two times.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
61991617|NCT04128163|PLACEBO_COMPARATOR|Placebo|"placebo injection (1ml) by subcutaneous injectionevery 6 month for two times.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
61991618|NCT03196011|ACTIVE_COMPARATOR|TKR with mechanical alignment|TKR implanted using traditional alignment methods
61991619|NCT03196011|EXPERIMENTAL|TKR using alternative alignment method|TKR implanted using alternative alignment methods
61991620|NCT04384965|EXPERIMENTAL|Accelerated iTBS|In the acute treatment phase, treatment will occur 8 times daily (50 min pause between treatments) on weekdays, until symptom remission is achieved (HRSD-24 score \< to 10) or a maximum of 10 working days of daily treatment. In the tapering phase, treatments will be reduced to 2 treatment days per week for 2 weeks and then 1 treatment day per week for 2 weeks (4 weeks total). Patients will then enter the symptom-based relapse prevention phase including virtual check-in with study staff and a treatment schedule based on symptom level according to a modified relapse prevention algorithm that has been developed to prevent relapse after a successful course of ECT (known as the STABLE algorithm). The relapse prevention phase will last a maximum of 6 months.
61991621|NCT03263416|EXPERIMENTAL|Arm A|
62387408|NCT02952027|PLACEBO_COMPARATOR|Bell Off|Subjects in the Bell Off arm will receive a timer where the alarm will not sound, but still record incentive spirometer usage
62387409|NCT05445869|EXPERIMENTAL|EVO Sleep and Snore Device|Participants will be provided with a custom EVO Sleep and Snore Device
62387410|NCT05007236|EXPERIMENTAL|RP7214 + Standard of care (SOC)|
62387411|NCT05007236|PLACEBO_COMPARATOR|Placebo + Standard of care (SOC)|
62387412|NCT01064518|ACTIVE_COMPARATOR|Dose A|RT001 Topical Gel
62559711|NCT05368324|OTHER|Control group on waiting list|After 6 months, the participants of the control group on the waiting list will be invited to participate if the results of the analysis show positive effects of the intervention.
62559712|NCT03120182|ACTIVE_COMPARATOR|Aspirin Arm|The patients will receive acetylsalicylic acid (100mg once a day, orally) for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization
62559713|NCT03120182|PLACEBO_COMPARATOR|Placebo Arm|The patients will receive placebo oral tablets for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization
62559714|NCT01690117|EXPERIMENTAL|GE-REACH-program|GE-REACH-program
62559715|NCT01690117|NO_INTERVENTION|control group|usual care
62559716|NCT01236716|EXPERIMENTAL|Albumin paclitaxel plus carboplatin|Treatment of Albumin paclitaxel plus carboplatin
62559717|NCT01236716|ACTIVE_COMPARATOR|Gemcitabine plus carboplatin|Treatment of Gemcitabine plus carboplatin
62767801|NCT05996809||Patients who underwent an index gynecologic surgery|The population will consist of patients who underwent an index gynecologic surgery (performed at least 2 years prior to the start of the study) during which COSEAL was used
61991622|NCT03263416|OTHER|Arm B|Standard
61991623|NCT02519712|EXPERIMENTAL|Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells|This is a single center trial to assess the feasibility of standard induction chemotherapy followed by a single dose of unmanipulated G-PBSC for the treatment of elderly patients with newly diagnosed AML.
61991624|NCT05096936|EXPERIMENTAL|Pilates PBMT|This group will receive training in the Pilates method associated with the effective application of photobiomodulation.
62559718|NCT02977715|EXPERIMENTAL|Intervention (Liquid Formulation)|Up to 1000 male and female healthcare personnel ages 18 years and older in Tshuapa Province in The Democratic Republic of Congo at risk for mpox will receive two doses of attenuated live virus smallpox vaccine (JYNNEOS liquid formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 10\^8 Tissue Culture Infectious Dose 50 \[TCID50\] per 0.5 mL). A subset of participants will receive a booster dose.
62387413|NCT01064518|PLACEBO_COMPARATOR|Dose B|Placebo Comparator
62559719|NCT02977715|EXPERIMENTAL|Intervention (Lyophilized Formulation)|Up to 600 male and female healthcare personnel ages 18 years and older in Tshuapa Province in The Democratic Republic of Congo at risk for mpox will receive two doses of attenuated live virus smallpox vaccine (JYNNEOS lyophilized formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 10\^8 Tissue Culture Infectious Dose 50 \[TCID50\] per 0.5 mL). A subset of participants will receive a booster dose.
62559720|NCT02977715|EXPERIMENTAL|Single booster dose (Liquid Formulation)|Up to 400 male and female healthcare personnel ages 18 years and older who received primary vaccination as a previous study participant
62559721|NCT02398266|EXPERIMENTAL|Healthy subjects|Intervention: administration of ultrasound contrast agent (drug) to assess muscle perfusion. Normal healthy subjects (n=10) will be used for optimization of dose and acoustic settings for performing real-time contrast ultrasound perfusion imaging of the limb.
62559722|NCT02398266|EXPERIMENTAL|Patients with PAD and ABI 0.4-0.6|Intervention: administration of ultrasound contrast agent (drug) to assess muscle perfusion. Patients with moderate to severe PAD (ABI 0.4 to 0.6) will be evaluated with contrast ultrasound perfusion imaging using methods optimized in the first Arm to determine whether symptoms better correlate with perfusion imaging than other measures of PAD severity.
61991625|NCT05096936|EXPERIMENTAL|Pilates|This group will receive training in the Pilates method associated with the not effective (placebo) application of photobiomodulation.
61991626|NCT05096936|PLACEBO_COMPARATOR|PBMT|This group will receive effective application of photobiomodulation and will not perform the pilates method training
62559723|NCT02398266|EXPERIMENTAL|Patients with PAD Undergoing Revascularization|Intervention: administration of ultrasound contrast agent (drug) to assess change in muscle perfusion produced by revascularization (surgical or percutaneous procedure). Patients with symptomatic PAD will be evaluated with contrast ultrasound perfusion imaging using methods optimized in the first Arm before and within 1 month of revascularization to determine whether improvement in symptoms correlate with perfusion imaging data.
61991627|NCT01885312|ACTIVE_COMPARATOR|Tailored not adaptive based Intervention|Tailored Text Messaging - not adaptive in the moment and once a day intervention to reduce problem drinking
62559724|NCT01133730|EXPERIMENTAL|Active treatment group|Ultrasound-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine
62559725|NCT01133730|PLACEBO_COMPARATOR|Placebo arm|Ultrasound-guided TFP block with 20ml of 5% dextrose solution
62559726|NCT04867005|ACTIVE_COMPARATOR|Online traininig group. A|This arm included 5 primary care teams, that carried out a 10 hours online course.
62559727|NCT04867005|EXPERIMENTAL|online and face-to-face training group. B|This arm included 5 primary care teams, that carried out a 10 hours online course plus a 6h hours face-to-face course
62559728|NCT04924192|EXPERIMENTAL|TQB3616 capsules+Anlotinib hydrochloride capsules|TQB3616 capsules 120/150/180mg orally on an empty stomach, once a day for 21 consective days as a treatment cycle;Anlotinib hydrochloride capsules 12mg, once a day for 2 consecutive weeks and stop for 1 week.
62559729|NCT04924192|EXPERIMENTAL|TQB3616 capsules +Irinotecan Hydrochloride for Injection|TQB3616 capsules 120/150/180mg orally on an empty stomach, once a day for 28 consecutive days as a treatment cycle. Irinotecan Hydrochloride Injection 100 mg/m2 intravenous infusion on D1、D8 and D15, a total of 4-6 cycles.
62559730|NCT02658253|EXPERIMENTAL|Group A1:Primvac 20 µg +alhydrogel|"Group A1: 3 European volunteers 0.5 ml intramuscular injection: 20 µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56"
62559731|NCT02658253|EXPERIMENTAL|Group A2:Primvac 20 µg +GLA-SE|Group A2: 3 European volunteers 0.5 ml intramuscular injection:20 µg Primvac+ 2.5 µg GLA-SE Vaccination schedule: D0, D28 and D56
62559732|NCT02658253|EXPERIMENTAL|Group B1:Primvac 50 µg +alhydrogel|"Group B1: 6 European volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56"
61991628|NCT01885312|OTHER|Ecological Momentary Assessment|Mobile Assessment only
61991629|NCT01885312|EXPERIMENTAL|Tailored Adaptive Text Messaging|Tailored Adaptive Text Messaging intervention to reduce problem drinking
61991630|NCT01885312|ACTIVE_COMPARATOR|Consequence based text messaging|Consequence based Text Messaging intervention to reduce problem drinking
61991631|NCT02313025|EXPERIMENTAL|Speech sound intervention|This group receives a speech sound and phonemic awareness intervention for four months.
61991632|NCT02313025|ACTIVE_COMPARATOR|World-project|This group receives the WORLD intervention for four months.
61991633|NCT01065519|ACTIVE_COMPARATOR|1|drug-eluting stent
61991634|NCT01065519|ACTIVE_COMPARATOR|2|Biolimus A9-eluting Biomatrix stent
61991635|NCT04307628|ACTIVE_COMPARATOR|Walnut|Eat 2 ounces of walnuts provided by the study. Eating any other nuts is to be avoided. Background diet will be low in polyphenols.
61991636|NCT04307628|PLACEBO_COMPARATOR|Nut-Free|Eating any other nuts is to be avoided. Background diet will be low in polyphenols.
61991637|NCT03303404|EXPERIMENTAL|Ambulatory (24-hour) Blood Pressure|
61991638|NCT02679859|EXPERIMENTAL|B-type natriuretic guided medical therapy optimisation|B-type natriuretic guided medical therapy optimisation
61991639|NCT02679859|NO_INTERVENTION|Normal medical management|
61991640|NCT02853240|EXPERIMENTAL|Children with spastic CP receiving toxin injections|Children with spastic cerebral palsy receiving toxin injections
62387414|NCT05875909|EXPERIMENTAL|corneal flap transplantation|Patients with macular holes underwent a 25-gauge, 3-port pars plana vitrectomy . Fluid-air exchange was performed in patients with pathologic myopia suffering from macular holes with retinal detachment. We used a flute needle to drain the subretinal fluid. A corneal flap was obtained by small incision lenticule extraction (SMILE). Stripping pliers were applied to spread corneal flap over the macular hole. A drop of fresh autologous whole blood was dripped over the corneal flap to immobilise it. The vitreous cavity was filled with 14% perfluoropropane (C3F8) for macular holes with retinal detachment . The surgical incision was self-closed or sutured with a 6-0 polyglactin 910 suture . The patients were instructed to maintain a prone position for 2 weeks postoperatively.
61991641|NCT03891654|EXPERIMENTAL|Dynamic Contrast Enhanced Computed Tomography|DCE-CT, also known as perfusion CT, is a functional imaging modality that uses repeated computed tomography imaging after injection of an iodine based contrast agent.
61991642|NCT02293070|EXPERIMENTAL|Repeat Cardiac MRI Post Cryoablation|All subjects in this study receive a follow up delayed enhanced cardiac MRI 2-6 weeks after they undergo a cryoablation procedure.
61991643|NCT02155023|EXPERIMENTAL|Insulin dosing and glucose sensors|To test the glucose sensors different levels of glycemia are needed. To provoke different glycemic levels the following intervention will be performed: Lunch (with fast glucose absorption characteristics) will be served. Up to 30 minutes after the usual insulin dosing time, the subjects will take his/her lunch dose of insulin adjusted to the chosen lunch plus additional approximately 25% (in the range of 0-50% according to the discretion of the Investigator) of insulin - in order to provoke moderate postprandial hypoglycaemia with glucose values \< 70 mg/dl.
61991644|NCT00718328|EXPERIMENTAL|I|Simvastatin Group
61991645|NCT00718328|PLACEBO_COMPARATOR|II|Placebo Group
61991646|NCT00080743|ACTIVE_COMPARATOR|Tamoxifen|Tamoxifen 20 mg po once daily
61991647|NCT00080743|PLACEBO_COMPARATOR|Placebo|Placebo comparator one tablet po once daily
61991648|NCT03721419|EXPERIMENTAL|High Flow High Humidity device|High Flow High Humidity device arm subjects will be placed on a High Flow Airvo device post tracheostomy with oxygen bled into system which maintains a safe level of patient blood oxygen. This device has its own flow generator built in.
61991649|NCT03721419|ACTIVE_COMPARATOR|Low Flow High Humidity Device|Low Flow High Humidity device arm patients will be placed on a Low Flow device post tracheostomy with oxygen bled into system which maintains a safe level of patient blood oxygen.
61991650|NCT05413135|EXPERIMENTAL|ARO-APOC3|1 dose of ARO-APOC3 by subcutaneous (sc) injection every 3 or 6 months
62387415|NCT05162534||Patients needing IoC|"Patients needing IoC can be recognized by the acronym IoCp"
62387416|NCT05162534||30-day deceased patients|"Patient died after a period of observation of 30 days are presented with the acronyms 30-ddp (30-day deceased patients)"
62387417|NCT05162534||did not undergo IoC|"Patients did not undergo IoC, we chose the acronym nIoCp."
62387418|NCT05162534||30-day survived patients|"Patient survived after a period of observation of 30 days are presented with the acronyms 30-dsp (30-day survived patients)"
62559733|NCT02658253|EXPERIMENTAL|Group B2:Primvac 50 µg +GLA-SE|Group B2: 6 European volunteers 0.5 ml intramuscular injection:50 µg Primvac+ 2.5 µg GLA-SE Vaccination schedule: D0, D28 and D56
61991651|NCT00496847|EXPERIMENTAL|Drug Group|PERIOGEN
61991652|NCT00496847|ACTIVE_COMPARATOR|Control group|Beta TCP alone
61991653|NCT03733821||CUD patients on HF-rTMS treatment|Patients fulfilling the Diagnostic and Statistical Manual of Mental Disorders - 5 (DSM 5) criteria for Cocaine Use Disorder undergoing a High Frequency rTMS protocol stimulating over the left dorsolateral prefrontal cortex (DLPFC).
61991654|NCT02567006|ACTIVE_COMPARATOR|Short Message Service (SMS) group|Receiving SMS message reminders 1 week before scheduled vaccination
61991655|NCT02567006|PLACEBO_COMPARATOR|Usual care|Not receiving SMS messages
61991656|NCT04525950|EXPERIMENTAL|Navio|Using the new technology during surgery
61991657|NCT04525950|ACTIVE_COMPARATOR|Conventional|Using the conventional surgical instruments
61991658|NCT03581656|EXPERIMENTAL|Arm|The ChordArt System is intended for chordal replacement in patients with mitral valve insufficiency due to leaflet prolapse or flail delivered through a catheter based technology for mitral chordal replacement via a small incision in the thorax.
62387419|NCT02359500|EXPERIMENTAL|68Ga-DOTATOC PET|patients with known or suspected somatostatin receptor positive neuroendocrine tumors (NETs)
62387420|NCT04594473|NO_INTERVENTION|Standard of Care (SOC)|Participants randomized to SOC will be instructed to continue their typical lifestyle activity.
62559734|NCT02658253|EXPERIMENTAL|Group C1:Primvac 50 µg +alhydrogel|"Group C1: 10 African volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56"
61991659|NCT05568784||Healthy Participants|Patients without pre-existing lower extremity injury that may inhibit response to testing
61991660|NCT05568784||Participants with Knee Arthroscopy|Patients who have recently suffered knee injury that required arthroscopic surgery
61991661|NCT05683119|EXPERIMENTAL|EUM Group|"Participants must: have menstrual cycle lengths ≥ 21 days and ≤ 35 days resulting in 9 or more consecutive periods per year; provide evidence of a luteinising hormone (LH) surge; demonstrate the required hormonal profile as defined below; and have not used any type of hormonal contraceptives (HC) for a minimum of 3 months, but ideally 6 months, prior to enrolment.~Phase 1- Indicated by the onset of bleeding until day 5 Oestrogen and progesterone levels are low~Phase 2- Oestrogen higher than during phase 1 and 3 Progesterone higher than during phase 1, but lower than 6.36 nmol·L-1 Must be followed by a positive luteinising hormone surge~Phase 3- +7 days after ovulation has been confirmed Oestrogen higher than phase 1, but lower than phase 2 Progesterone \>16 nmol·L-1"
62387421|NCT04594473|EXPERIMENTAL|Comprehensive Oncology Rehabilitation and Exercise (CORE) Program|Participants randomized to CORE will be instructed to follow the clinical algorithm for this study. An in-clinic assessment consisting of two questionnaires will be used to identify the appropriate pathway for triage. Participants will be triaged into one of three pathways: Physical Medicine \& Rehabilitation, Personal Optimism With Exercise Recovery, or Exercise Self-Management.
62387422|NCT05091840||patients requiring intubation at birth and subsequent surfactant administration|
62387423|NCT05091840||patients who receive surfactant by LISA|
62387424|NCT04071028|ACTIVE_COMPARATOR|Footbath group|"All the participants were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, the participants in the footbath group received legs soaking from the heel to the Sanyinjiao (SP6) acupoint (above the ankle) 24 in 42 ℃ water with air bubbles and vibration given to the soles for 20 minutes,"
62387425|NCT04071028|NO_INTERVENTION|Control group|"All the participants were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, whereas the participants in the control group kept on sitting quietly without legs soaking during the additional 20-minute period."
62387426|NCT00101790|ACTIVE_COMPARATOR|1|
62559735|NCT02658253|EXPERIMENTAL|Group C2: Primvac 50 µg +GLA-SE|"Group C2: 10 African volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 2.5 µg GLA-SE~Vaccination schedule: D0, D28 and D56"
61991662|NCT05683119|EXPERIMENTAL|OCP Group|"Participants must: have been taking their OCP ≥ 3 months prior to recruitment; be taking a combined, monophasic, second generation OCP; and demonstrate the correct hormonal profile as defined below.~Pill-taking phase- Indicated by the 21 consecutive pill-taking days Oestrogen and progesterone levels are low; ≤ phase 1 of the menstrual cycle~Pill-free phase- Indicated by the 7 consecutive pill-free days Oestrogen and progesterone levels may begin to rise in comparison with the pill-taking phase"
61991663|NCT01080898||DMLA patients|patients \> 50 years with suspicion of choroidal neo-vessels complicating age related macular degeneration (DMLA)
61991664|NCT03938194|EXPERIMENTAL|Aquablation|Surgery of benign prostatic hyperplasia by waterjet ablation
61991665|NCT04190082||Group Control|Group who maintains deep sedation using the University of Michigan sedation scale (UMSS) score.
61991666|NCT04190082||Group BIS|Group who maintain deep sedation using Bispectral Index (BIS) score.
61991667|NCT00116831|ACTIVE_COMPARATOR|Glipizide|oral anti-diabetic medication
61991668|NCT00116831|EXPERIMENTAL|rosiglitazone maleate|oral anti-diabetic medication
61991669|NCT02466555|EXPERIMENTAL|Music Therapy Group|Music therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Music therapy is an established health profession in which music is used within a therapeutic relationship to address physical, emotional, cognitive, and social needs of individuals (American Music Therapy Association \[AMTA\], 2013, para 1 and 2).
61991670|NCT05912699|EXPERIMENTAL|Intervention Group (SlimBiotic Postbiotic)|Participants will take 1 serving (1 capsule) per day.
61991671|NCT05912699|PLACEBO_COMPARATOR|Placebo Group|Participants will take 1 serving (1 capsule) per day.
61991672|NCT00655967|EXPERIMENTAL|1|Acamprosate(Campral)
61991673|NCT01663415|EXPERIMENTAL|Enzalutamide|
61991674|NCT04248933|EXPERIMENTAL|"Peer-Delivered Behavioral Activation (Peer Activate)"|"Participants received a peer recovery specialist-delivered behavioral activation (BA) intervention (Peer Activate) to address barriers to retention in methadone treatment and increase substance-free, positive reinforcement to support retention."
62767802|NCT05733728||Uveal Melanoma|
61991675|NCT01203592|EXPERIMENTAL|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
61991676|NCT05629013|NO_INTERVENTION|Child Family Team (CFT) as Usual|The CFT is a family meeting model that is an existing mechanism being implemented systemwide in San Diego County Child Welfare Services (CWS). Each child or youth is required to have a CFT meeting within sixty days of entering the CWS to identify areas of behavioral, emotional, or social needs, and to complete an initial case Action Plan.
61991677|NCT05629013|EXPERIMENTAL|Child Family Team (CFT) with After Action Review (AAR)|CFT is being augmented with the after-action review.
61991678|NCT05324540|EXPERIMENTAL|Cool therapy|A chilled instrument that has been chilled to a proscribed temperature will be applied to the oblique sinus. The instrument may be applied for up to 3 minutes per application and up to 3 times per patient.
61991679|NCT02478242|ACTIVE_COMPARATOR|Nafamostat mesilate group|Nafamostat mesilate was used for maintenance anticoagulation during continuous renal replacement therapy.
61991680|NCT02478242|PLACEBO_COMPARATOR|No anticoagulation group|Normal saline was used for maintenance anticoagulation during continuous renal replacement therapy.
61991681|NCT00748215|EXPERIMENTAL|Arm I: CASAD|Oral calcium aluminosilicate anti-diarrheal (CASAD) 4 times daily for 6 weeks in the absence of disease progression or unacceptable toxicity. Participants who develop grade 3 or 4 diarrhea may receive CASAD for an additional 6 weeks.
61991682|NCT00748215|PLACEBO_COMPARATOR|Arm II: Placebo|Oral placebo 4 times daily for 6 weeks in the absence of disease progression or unacceptable toxicity. Participants who develop grade 3 or 4 diarrhea may then receive CASAD for 6 weeks.
61991683|NCT03620565||Laparoscopic sacrocolpopexy(LSC)|Patients who prefer to accept laparoscopic sacrocolpopexy after hysterectomy. For patients who has desire of uterine-preservation,laparoscopic sacrocervicopexy or sacrohysteropexy is carried.
61991684|NCT03620565||Reconstruction with transvaginal mesh(TVM)|Patients who undertake pelvic reconstruction with tran-vaginal mesh(commercial mesh kits or self-cut synthesized mesh).
61991685|NCT03620565||Reconstruction with native tissue(NT)|Patients who prefer to accept reconstruction with native tissue,mainly including high uterosacral ligament suspension, sacrospinous ligament fixation,ischial spinous fascia fixation,the Lefort operation.
61991686|NCT03620565||Tension-free vaginal tape surgery(TVT)|Patients who undertake anti-incontinence surgeries(tension-free vaginal tape procedure).
62559736|NCT02658253|PLACEBO_COMPARATOR|Group C3: Placebo|"Group C3: 5 African volunteers 0.5 ml intramuscular injection: NaCl 0.9% (placebo)~Vaccination schedule: D0, D28 and D56"
62559737|NCT02658253|EXPERIMENTAL|Group D1:Primvac 100 µg +alhydrogel|"Group D1: 10 African volunteers 0.6 ml intramuscular injection: 100µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56"
62767803|NCT06466993|EXPERIMENTAL|Intervention|Relaxing breathing occuring during rotation of OSCE station
62767804|NCT06466993|ACTIVE_COMPARATOR|Control|Free time during rotation of OSCE station
61991687|NCT00040885|EXPERIMENTAL|infliximab + docetaxel|"Patients receive infliximab IV over 2 hours once weekly on weeks 1, 3, and 5 of the first course and once weekly on weeks 1 and 5 of all subsequent courses and docetaxel IV over 1 hour (immediately after completion of infliximab infusion once weekly on weeks 1-6 of each course.~Treatment repeats every 8 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life, fatigue, appetite/anorexia, cachexia, and weight are assessed at baseline, weekly on weeks 1-8, and then monthly for the remainder of study treatment.~Patients are followed every 6 months for 5 years."
61991688|NCT00040885|ACTIVE_COMPARATOR|placebo + docetaxel|"Patients receive docetaxel IV over 1 hour (immediately after completion of infliximab infusion once weekly on weeks 1-6 of each course. Patients receive placebo IV over 2 hours once weekly on weeks 1, 3, and 5 of the first course and once weekly on weeks 1 and 5 of all subsequent courses.~Treatment repeats every 8 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life, fatigue, appetite/anorexia, cachexia, and weight are assessed at baseline, weekly on weeks 1-8, and then monthly for the remainder of study treatment.~Patients are followed every 6 months for 5 years."
61991689|NCT00263068|EXPERIMENTAL|1|Up to 6.75 mg/day (optimal dosing)
61991690|NCT01276093|EXPERIMENTAL|PVI ablation|Pulmonary Vein Ablation
61991691|NCT01276093|ACTIVE_COMPARATOR|Amiodarone medical treatment|Amiodarone medical treatment
61991692|NCT04146064||Validation cohort: NSCLC|"Patients with advanced/metastatic NSCLC planned for IO-treatment in one of the following categories~* Pembrolizumab monotherapy first-line~* Pembrolizumab or nivolumab monotherapy in second or later line"
61991693|NCT04146064||Cohort 1: NSCLC|Patients with advanced/metastatic NSCLC planned for Pembrolizumab-chemotherapy combination therapy first-line
61991694|NCT04146064||Cohort 2: Melanoma|"Patients with advanced/metastatic melanoma planned for IO-treatment in one of the following categories~* Nivolumab/ipilimumab combination treatment 1L~* Pembrolizumab or nivolumab monotherapy treatment 1L~* Ipilimumab monotherapy 2L"
61991695|NCT04146064||Cohort 3: Mixed solid tumor cohort|Patients with advanced/metastatic solid tumors such as Head\&Neck tumors, kidney cancer and urothelial cancer planned for IO-treatment
61991696|NCT04146064||Cohort 4: NSCLC|Patients with advanced/metastatic NSCLC planned for treatment with Chemotherapy-only (either platinum-based combination treatment or docetaxel monotherapy)
61991697|NCT05993611|EXPERIMENTAL|Treatment (CD6-CAR Treg, tafasitamab)|Donors undergo leukapheresis over 2-4 hours for collection of PBMSc and the manufacturing of CD6-CAR Treg cells over 2 weeks. Patients then receive CD6-CAR Treg intravenously on day 0. Patients may also receive ablation tafasitamab IV post Treg cell infusion on days 1, 4, 8, 15, 22 for 1 cycle. If ablation is not complete by day 28, patients may receive an additional 1-2 cycles per investigator's discretion. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO, CT, and x-ray imaging during screening and as clinically indicated. Patients undergo blood specimen collection on study and during follow-up. Patients may undergo a biopsy on study as well as a lumbar puncture and MRI/CT as clinically indicated on study.
61991698|NCT05439408|EXPERIMENTAL|XS004 - Period 1|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 100 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel and in accordance with the randomization schedule.
61991699|NCT05439408|ACTIVE_COMPARATOR|SPRYCEL - Period 1|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 140 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel, and in accordance with the randomization schedule.
61991700|NCT05439408|EXPERIMENTAL|XS004 - Period 2|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 100 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel and in accordance with the randomization schedule.
61991701|NCT05439408|ACTIVE_COMPARATOR|SPRYCEL - Period 2|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 140 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel, and in accordance with the randomization schedule.
61991702|NCT05439408|EXPERIMENTAL|XS004 - Period 3|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 100 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel and in accordance with the randomization schedule.
61991703|NCT05439408|ACTIVE_COMPARATOR|SPRYCEL - Period 3|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 140 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel, and in accordance with the randomization schedule.
61991704|NCT05439408|EXPERIMENTAL|XS004 - Period 4|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 100 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel and in accordance with the randomization schedule.
61991705|NCT05439408|ACTIVE_COMPARATOR|SPRYCEL - Period 4|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 140 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel, and in accordance with the randomization schedule.
61991706|NCT06372288|EXPERIMENTAL|Transcranial Magnetic Stimulation (TMS)|This arm receives the TMS treatments.
61991707|NCT06372288|SHAM_COMPARATOR|Sham-TMS|This arm receives sham TMS treatments.
61991708|NCT02182362|EXPERIMENTAL|BI 201335 NA in rising doses|single dose of BI 201335 NA on day 1, multiple dosing days 4-24
61991709|NCT02182362|PLACEBO_COMPARATOR|Placebo|
61991710|NCT02182362|EXPERIMENTAL|BI 201335 NA|highest tolerated dose of BI 201335 on day 1-28 in patients with Gilbert's syndrome
62559738|NCT02658253|EXPERIMENTAL|Group D2: Primvac 100 µg +GLA-SE|"Group D2: 10 African volunteers 0.6 ml intramuscular injection: 100 µg Primvac+ 2.56 µg GLA-SE~Vaccination schedule: D0, D28 and D56"
62559739|NCT02658253|PLACEBO_COMPARATOR|Group D3: placebo|"Group D3: 5 African volunteers 0.6 ml intramuscular injection: NaCl 0.9% (placebo)~Vaccination schedule: D0, D28 and D56"
61991711|NCT02236429|EXPERIMENTAL|recurrent bacterial vaginitis|
61991712|NCT01411163|EXPERIMENTAL|Creatine|
61991713|NCT06544811|ACTIVE_COMPARATOR|Tailored|Tailored texting program for quit smoking
61991714|NCT06544811|PLACEBO_COMPARATOR|Standard|Standard texting program for quit smoking
61991715|NCT06436846||Cohort 1|The entire study is a singular cohort of patients with retroperitoneal liposarcoma (index or recurrent) who undergo surgical resection of their tumor.
61991716|NCT05768152|EXPERIMENTAL|Repeated low-level red-light (RLRL) therapy|single vision spectacles \& RLRL
61991717|NCT02456610|EXPERIMENTAL|Infusion of CMV/EBV specific CTLs|Repetitive CTLs infusion to treat CMV/EBV activation and infection
61991718|NCT02511470|OTHER|CPR with metronome on|Participants will perform two minutes of uninterrupted chest compressions on a pediatric manikin with the metronome on. Data for compression rate and depth will be collected during this time interval.
61991719|NCT02511470|OTHER|CPR with metronome off|Participants will perform two minutes of uninterrupted chest compressions on a pediatric manikin with the metronome off. Data for compression rate and depth will be collected during this time interval.
61991720|NCT05064956|EXPERIMENTAL|Ad26.ZEBOV|Ad26.ZEBOV will be given as a booster dose to all participants approximately 4 years after administration of the 2-dose Ebola regimen, Ad26.ZEBOV/MVA-BN-Filo, as part of the parent trial VAC52150EBL2002.
61991721|NCT05595317|EXPERIMENTAL|Study group|Traditional physiotherapy + A non-immersive virtual reality game will be played to provide treatment for lower limbs.
61991722|NCT05595317|SHAM_COMPARATOR|Sham-controlled group|Traditional physiotherapy + A sham non-immersive virtual reality game will be played but not provides treatment for lower limbs.
61991723|NCT03379207||"Community Acquired Pneumonia group"|"Participants admitted to Intensive Care Unit (ICU) of University Hospital of Tours (France) for Community Acquired Pneumonia.~Interventions:~* Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose, at inclusion, day 1, 7, and every week during ICU stay Tracheal Aspirates for research purpose: only for mechanically ventilated participants, at inclusion, day 1, 7, and and every week during ICU stay~* Surplus of Broncho-alveolar lavage fluid: only if performed for diagnosis purpose by the treating investigator (indication left at his discretion)"
61991724|NCT03379207||"Control group"|"Participants admitted to Intensive Care Unit of University Hospital of Tours (France) for whom invasive mechanical ventilation is required for an estimated duration of at least 48h, without diagnosis of pneumonia or shock.~Interventions:~* Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose, at inclusion, day 3, 8, and 15 during ICU stay Tracheal Aspirates for research purpose: at inclusion, day 3, 8, and 15 during invasive mechanical ventilation period,~* Surplus of Broncho-alveolar lavage fluid: only if performed for diagnosis purpose by the treating investigator (indication left at his discretion)"
62767805|NCT04682990|EXPERIMENTAL|Pulmonary TB|"This arm will enroll 80-100 patients older than 18 years old, from the Center of Respiratory Diseases in Douala, with pulmonary TB proved by TB LAMP test.~Interventions:~1. They will be asked to perform a breath exhalation with a nose clamp.~2. Medical History: Symptom based Survey, Physical Exam,and HIV status.~Other interventions:~* Sputum samples for Ziehl Neelsen smear or Culture in L-J or GeneXpert MTB/RIF;~* Chest X-ray Follow Up 5 days after beginning of Tx Follow Up 15 days after beginning of Tx Follow Up 30 days after beginning of Tx"
61991725|NCT03088176|EXPERIMENTAL|Combination|"Talimogene laherperepvec intratumoral injection up to 4ml of 10\^6 PFU/mL on Day 1, followed by up to 4mL of 10\^8 PFU/mL 3 weeks later, followed by every 2 weeks thereafter for up to two years.~Dabrafenib 150mg orally twice daily for up to two years Trametinib 2mg orally once daily for up to two years"
61991726|NCT02231346||chronic obstructive pulmonary disease patients|
62559740|NCT01276340||1|women with urinary incontinence
62767806|NCT04682990|ACTIVE_COMPARATOR|Non Pulmonary TB|"This arm will enroll 50-100 patients older than 18 years old, from the Center of Respiratory Diseases in Douala, with Negative pulmonary TB status proved by TB LAMP test. These Negative TB patients can be healthy controls or TB suspects.~Interventions:~They will be asked to perform a breath exhalation with a nose clamp. Medical History: Symptom based Survey, and HIV status.~Other interventions:~* Sputum samples for Ziehl Neelsen smear or Culture in L-J GeneXpert MTB/RIF;~* Chest X-ray."
62767807|NCT02424292||Physical activity|Physical activity in a personalised program
62767808|NCT05463068|EXPERIMENTAL|Lot 1|1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 1.
62767809|NCT05463068|EXPERIMENTAL|Lot 2|1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 1.
62767810|NCT05463068|EXPERIMENTAL|Lot 3|1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 1.
61991727|NCT03803280||Traditional care|Patients with major abdominal surgery without before a enhanced recovery program was stablished
61991728|NCT03803280||ERAS care|Patients with major abdominal surgery within a enhanced recovery program was stablished
61991729|NCT06370156||Group A : (Adalimumab therapy)|"About 30 patients suffering from Plaque Psoriasis and will take Adalimumab therapy orally.~Correlation between serum\& TWEAK levels and Psoriasis Area and Severity Index (PASI) score and the ACR score pre and post Adalimumab therapy"
61991730|NCT06370156||Group B : (methotrexate therapy)|"About 30 patients suffering from Psoriatic arthritis and will take methotrexate therapy orally.~Correlation between serum\& TWEAK levels and Psoriasis Area and Severity Index (PASI) score and the ACR score pre and post methotrexate therapy"
61991731|NCT06370156||Group C: (control Group):|About 40 healthy individuals selected as control group as related to age, sex ,BMI matching with healthy individuals
61991732|NCT00696137|EXPERIMENTAL|BEMA Fentanyl|BEMA Fentanyl
61991733|NCT02029651|EXPERIMENTAL|E-glove system|E-glove rehabilitation system for upper extremity
61991734|NCT02029651|ACTIVE_COMPARATOR|Conventional occupational therapy|conventional occupational therapy
61991735|NCT01417481|ACTIVE_COMPARATOR|Glycine|Patients will receive a daily oral supplement of 0.5 g/kg glycine dissolved in water.
62559741|NCT05370625|EXPERIMENTAL|Totum-854|2.65-g dose of Totum-854 dietary supplement, a mix of 6 plant extracts. Five capsules per day to consume orally in two intakes Other names: active product
62559742|NCT05370625|PLACEBO_COMPARATOR|Placebo|Five capsules per day to consume orally in two intakes
62559743|NCT00631046|EXPERIMENTAL|Fish Oil|containing n-3 LCPUFA
61991736|NCT01417481|PLACEBO_COMPARATOR|Placebo|Patients will receive a daily supplement of 0.5 g/kg sugar glass dissolved in water.
61991737|NCT00880347|OTHER|Alzheimer's Disease|Group of patients clinically diagnosed with probable AD
61991738|NCT00880347|OTHER|Non-AD dementia|Group of patients clinically diagnosed with one of the 5 most frequent non-AD dementia : vascular dementia, mixed dementia, frontotemporal dementia, Lewy bodies dementia, Parkinson's disease dementia.
61991739|NCT00880347|OTHER|control subjects|Group of control subjects without any clinical cognitive impairment.
61991740|NCT04352751|EXPERIMENTAL|Single Arm|"Intervention: Convalescent plasma (Frozen Solution for infusion) obtained from COVID-19 recovered patients.~The dosage depends upon the clinical situation and underlying disorder. Children: 15 ml/kg over 4-6 hours once in patients under 35 kg body weight. Adults: maximum 450 - 500 ml over 4-6 hours once in all adults patients."
61991741|NCT02090517|ACTIVE_COMPARATOR|Pulsed Dye Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with pulsed dye laser.
61991742|NCT02090517|ACTIVE_COMPARATOR|Long Pulsed Alexandrite Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with long pulsed alexandrite laser.
61991743|NCT02090517|ACTIVE_COMPARATOR|Pulsed Dye Laser Plus Nd:YAG Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with pulsed dye laser plus Nd:YAG laser.
62387427|NCT05408676|EXPERIMENTAL|Group Acu|"a surface electrode was applied in the induction room to the P6 acupoint on the dominant upper extremity, located ∼4 cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode on the opposing dorsal aspect of the forearm. When the patient enters the operating room， an investigator connected the device to both electrodes with electrical wires, set initial electric stimulating current at 1 mA with the frequency at 2 Hz(square-wave pulses of 0.2 ms), gradually increased the current intensity until the patient felt pain or reached the discomfort threshold (ranging from 6 to 20 mA), and maintained the stimulation until end of operation.~At the start of skin closure, saline (3 ml) was administered i.v."
61991744|NCT02090517|ACTIVE_COMPARATOR|Electrodesiccation|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with electrodesiccation.
61991745|NCT02090517|NO_INTERVENTION|No Treatment|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will receive no treatment.
61991746|NCT03639766|EXPERIMENTAL|Abobotulinum toxin A|Injection of 300 units of abobotulinum toxin A in 10 ml of non-bacteriostatic normal saline to chosen hand.
61991747|NCT03639766|PLACEBO_COMPARATOR|Saline solution|Injection of 10 ml of non-bacteriostatic normal saline to chosen hand.
62559744|NCT00631046|PLACEBO_COMPARATOR|Sunflower oil|containing n-6 PUFA
62559745|NCT03130972||developmental delay|Children who visited tertiary rehabilitation clinic for delayed motor development were all included.
61991748|NCT02474095|EXPERIMENTAL|Arm I (ALTENS QIW)|Patients undergo ALTENS delivered via the Codetron machine QIW for 6 weeks in the absence of disease progression or unacceptable toxicity.
61991749|NCT02474095|ACTIVE_COMPARATOR|Arm II (ALTENS BIW)|Patients undergo ALTENS delivered via the Codetron machine BIW for 12 weeks in the absence of disease progression or unacceptable toxicity.
61991750|NCT01267396|EXPERIMENTAL|Sertraline Hydrochloride tablets 100 mg|Sertraline Hydrochloride tablets 100 mg of Dr.Reddy's Laboratories Limited
61991751|NCT01267396|ACTIVE_COMPARATOR|Zoloft 100 mg Tablets|Zoloft 100 mg Tablets of Pfizer
62387428|NCT05408676|SHAM_COMPARATOR|Group Gra|"Group Gra receive the same protocol but silicone covers were attached to both electrodesin to achieve an inert control.~At the start of skin closure, granisetron (3 mg; Group Trp) was administered i.v."
62559746|NCT04090125|EXPERIMENTAL|Physical Activity and Symmetry (PAS) Intervention|Participants assigned to the PAS intervention will receive 4 sessions on balance training and physical activity coaching delivered by a physical therapist, in addition to their usual post-TKA physical therapy (PT) care.
62559747|NCT04090125|PLACEBO_COMPARATOR|Attention Control|Participants assigned to the ATT group will receive usual post-TKA physical therapy (PT) care, followed by two additional sessions with their physical therapist.
61991752|NCT03615807|EXPERIMENTAL|Short antibiotic arm|10 days for soft tissue infections 3 weeks for osteomyelitis
61991753|NCT03615807|ACTIVE_COMPARATOR|Standard antibiotic arm|20 days for soft tissue infections 6 weeks for osteomyelitis
61991754|NCT03552575|EXPERIMENTAL|Sacubitril/valsartan|24mg/26mg (dose level 1), 49mg/51mg (dose level 2) and 97mg/103mg (dose level 3) twice daily
61991755|NCT03552575|EXPERIMENTAL|Valsartan|40mg (dose level 1), 80mg (dose level 2) and 160mg (dose level 3) twice daily.
61991756|NCT00803881||CF patients of all age groups|Longitudinal prospective assessment of upper and lower airway colonization in all patients attended in the Jena University CF centre
61991757|NCT01995695|EXPERIMENTAL|Group 1: One Vaccine Dose and One Booster Vaccine Dose|Participants will receive one dose of live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine at study entry. They will then receive one dose of inactivated subvirion H7N9 influenza vaccine on Day 98.
61991758|NCT01995695|EXPERIMENTAL|Group 2: Two Vaccine Doses and One Booster Vaccine Dose|Participants will receive two doses of live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine: one dose at study entry and one dose on Day 28. They will then receive one dose of inactivated subvirion H7N9 influenza vaccine on Day 98.
62387429|NCT05408676|SHAM_COMPARATOR|Group Dxm|"Group Dxm receive the same protocol but silicone covers were attached to both electrodesin to achieve an inert control.~At the start of skin closure, saline (3 ml) was administered i.v."
61991759|NCT02522390||Nutrition Researcher Cohort|This cohort study is an observational, one-group study. The intervention consists of research activities that participants are asked to perform throughout the cohort, including the use of do-it-yourself devices, filling out online-questionnaires and sample collection with supplied kits for the analysis of various health parameters. The frequency with which participants are asked to measure these health parameters varies, ranging from once to weekly.
61991760|NCT02661360|EXPERIMENTAL|Starting condition of swaddled|
61991761|NCT02661360|EXPERIMENTAL|Starting Condition of Unswaddled|
62559748|NCT06196892|PLACEBO_COMPARATOR|Placebo group|one sachet per day, with maltodextrin
62559749|NCT06196892|EXPERIMENTAL|Probiotic group|one sachet per day, with BBr60 and maltodextrin
62559750|NCT00542633|EXPERIMENTAL|A|VIAject™
62559751|NCT00542633|ACTIVE_COMPARATOR|B|Regular Human Insulin
61991762|NCT03231787|EXPERIMENTAL|Experimental group|"In this group the platelet aggregability will be evaluated and if it is normal, the surgery will be performed within 24-48 hours.~If it is not normal, the evaluation of platelet aggregability will be repeated daily until the third day or until it is normalized if it is earlier.~If at the third day is not normalized, it will proceed as with the control group, which will take into account the safety time of the drug."
61991763|NCT03231787|NO_INTERVENTION|Control group|The control group will wait for the safety time of the drug according to the usual practice of the center.
61991764|NCT05345639|EXPERIMENTAL|TTP group (= Transversus Thoracic Plane block = Deep PIP = Deep parasternal intercostal plane block)|At the end of the surgery, realisation of a bilateral transverse thoracic block. (20ml of Naropeine 0.2%, each side) Followed by standard analgesic treatment.
61991765|NCT05345639|EXPERIMENTAL|PSB group (=ParaSternal Block = Superficial PIP = Superficial parasternal intercostal plane block)|"At the end of the surgery, realisation of a bilateral parasternal block (20ml of Naropeine 0.2%, each side).~Followed by standard analgesic treatment."
62559752|NCT00695344|EXPERIMENTAL|1|Everolimus 2 times per day + cyclosporin low dose +/- steroids
62559753|NCT00695344|ACTIVE_COMPARATOR|2|Cyclosporin + azathioprine or mofetil mycophenolate +/- steroids (the same treatment that patient had before the study).
61991766|NCT05345639|SHAM_COMPARATOR|Control group|Standard analgesic treatment alone (without LRA) .
61991767|NCT03000699|EXPERIMENTAL|Cognitive Bias Modification|64 training paragraphs, approximately 10-20 seconds each, digitally recorded and presented stereophonically through headphones, delivered over the course of one week.
61991768|NCT03000699|NO_INTERVENTION|Assessment-Only Control|No training will be provided.
61991769|NCT04631679||Group A: anemic patients with iron treatment|For Group A anemic patients (hemoglobin levels below 13g/dL in men and 12g/dL in women) with iron deficiency (transferrin saturation below 20% or ferritin serum level below 300μg/L) are screened in the Anesthesia pre-assessment clinic 1-4 days prior to cardiosurgical procedure (valve repair/implementation, aortocoronary bypass or a combination of both) and are treated with a single intravenous dose of 500 milligrams of ferric carboxymaltose in 100ml 0,9% sodium chloride solution as iron supplementation directly (FerInject® 50 mg/ml, 10 ml, Vifor Pharma Group, Switzerland).
61991770|NCT04631679||Group B: non-anemic patients without iron treatment|For Group B, non-anemic patients (hemoglobin levels above 13g/dL in men and 12g/dL in women) without iron deficiency (transferrin saturation above 20%, ferritin serum levels above 300μg/L) are screened in the Anesthesia pre-assessment clinic 1-4 days prior to cardiosurgical procedure (valve repair/implementation, aortocoronary bypass or both combined) and are not treated with iron supplementation.
61991771|NCT02576028|OTHER|standard treathment|two sessions of 45 minutes of active exercises for 10 days
61991772|NCT02576028|EXPERIMENTAL|FM associated to standard treathment|the same intervention of CG except on days 2 and 7 where one session treatment was replaced with a FM treatment.
61991773|NCT06361823|EXPERIMENTAL|Semaglutide|Expanding on the usual treatment regimen, Semaglutide is administered through a subcutaneous injection once weekly over a period of 3 months. Initially, the dose is 0.25 mg for the first month, then increased to 0.5 mg for patients who could tolerate it in the second month, and finally raised to 1.0 mg for patients who still tolerated it in the third month.
61991774|NCT06361823|ACTIVE_COMPARATOR|Usual treatment|Usual treatment refers to the 2018 consensus guidelines on the management of IIH.
61991775|NCT04338438|EXPERIMENTAL|Apatinib Mesylate tablets combined with S-1 capsules|single arm trial: apatinib 500 mg once daily, across entire cycle and S-1 60 mg twice daily, on the first 14 days of a 21-day cycle. Medication was continued until the disease progression, withdrawal requirement, or intolerable adverse events
61991776|NCT04059146|EXPERIMENTAL|Pain Education + Exercise|"The goals of the pain education intervention are for patients to 1) address fear of movement and pain catastrophizing specific to AT, 2) learn about the neurophysiology of pain, 3) develop coping skills, and 4) promote exercise participation through pacing. This program enables patients to have a conceptual change in their understanding of what causes pain, gain greater control over the psychological aspects of pain, and reduce the perceived threat of chronic pain.~All participants will receive the same progressive Achilles tendon loading exercise program."
62559754|NCT01881477|EXPERIMENTAL|kinetics modalities|passive movements active movements assisted movements resisted movements
62559755|NCT00535210|OTHER|1|
62559756|NCT00535210|OTHER|2|
62767811|NCT00459537|EXPERIMENTAL|Terbinafine|10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.
62767812|NCT00459537|ACTIVE_COMPARATOR|Amorolfine|5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.
62559757|NCT01057511|ACTIVE_COMPARATOR|progesterone|Each subject in this group will be give progesterone oil 20mg via intramuscular route once a day for 7 days totally
62767813|NCT04400578|EXPERIMENTAL|TRICIN|"If a patient is eligible~1. local anesthesia with Xylocain 10% with a pump spray for a period of 10 seconds- one time application~2. Procain 2%: local anesthesia with a swab for a period of 10 seconds- one time application~3. Trichloroacetic acid TCA 85% 1-2 ml with soaked swab for max. 2 minutes -one time application"
62559758|NCT01057511|EXPERIMENTAL|Crinone 8%|Each subjects in this group will be given Crinone 8% 90mg via vaginal route once a day for 7 days totally.
62559759|NCT00282646|ACTIVE_COMPARATOR|1|intraarterial application of bone marrow mononuclear cells
62559760|NCT00282646|PLACEBO_COMPARATOR|2|intraarterial application of placebo
62559761|NCT00347646|EXPERIMENTAL|Plasmin|Human-derived plasmin reconstituted with sterile sodium chloride for intravitreal injection.
62767814|NCT00801047|EXPERIMENTAL|1|Epidural group
62767815|NCT00801047|ACTIVE_COMPARATOR|2|Remifentanil iv PCA
62767816|NCT02816203|EXPERIMENTAL|Primary Hemostatic Intra-Uterine suction cup|Patients who present primary postpartum hemorrhage requiring administration of Nalador and the suction cup placed in the uterine cavity
62767817|NCT06217419|NO_INTERVENTION|Trial 1 - control group|On site visit every 3 months as for SoC
62767818|NCT06217419|NO_INTERVENTION|Trial 1 - PROMs + spirometer group|On site visit every 6 months. Monthly remote PROMs evaluation + portable spirometer measurement to remotely monitor the disease.
62767819|NCT06217419|NO_INTERVENTION|Trial 2 - control group|Monthly on site visit and paper PROMs.
61991777|NCT04059146|ACTIVE_COMPARATOR|Standard Education + Exercise|"The comparison group will be given education based on standard of care resources that primarily utilize a biomedical model, which assumes that AT pain is primarily caused by tissue damage.~All participants will receive the same progressive Achilles tendon loading exercise program."
62387430|NCT04395924||Pregnant women COVID-19 positive by RT-PCR|Pregnant women COVID-19 positive by RT-PCR on nasopharyngeal swabs and/or by serology or with previous history of SARS-Cov-2 positive during the pregnancy coming to the maternity to deliver
62387431|NCT01032057|ACTIVE_COMPARATOR|Gemcitabine|GEMCAP induction chemotherapy (28 day cycle of IV gemcitabine 1000mg/m2 day 1, 8,15 and capecitabine 830mg/m2 bd for 21 days po) followed by gemcitabine 300mg/m2 weekly (IV) + 50.4Gy radiation over five and half weeks (1.8Gy per fraction, Monday-Friday)
62387432|NCT01032057|ACTIVE_COMPARATOR|chemoradiotherpay with capecitabine|GEMCAP induction chemotherapy (28 day cycle of IV gemcitabine 1000mg/m2 day 1, 8,15 and capecitabine 830mg/m2 bd for 21 days po), followed by capecitabine 830mg/m2 bd (po, Mon-Fri) + 50.4Gy radiation over five and half weeks (1.8Gy per fraction, Monday-Friday)
62387433|NCT02280382|OTHER|Femmeze®|Femmeze® will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
62387434|NCT01333865|EXPERIMENTAL|Memantine (Namenda) Treatment|
62387435|NCT04945239|EXPERIMENTAL|Amplification of Positivity Training (6 Sessions)|
62387436|NCT04945239|ACTIVE_COMPARATOR|Stress Management Training (6 Sessions)|
62387437|NCT05434728||Hypermobile EDS|Individuals with a confirmed diagnosis of hypermobile EDS
62387438|NCT05434728||Classical EDS|Individuals with a confirmed diagnosis of classical EDS
62387439|NCT05434728||Vascular EDS|Individuals with a confirmed diagnosis of vascular EDS
62387440|NCT03838692|EXPERIMENTAL|Ponatinib Arm|Ponatinib tablets will be taken by mouth, continuously, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment can be taken with water, with or without food, at approximately the same time each day.
62387441|NCT03238209|EXPERIMENTAL|Exercise testing|The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
62387442|NCT05280223|ACTIVE_COMPARATOR|Dexmeditomidine group|injection of 1 microgram/kg dexmedetomidine + 10 cc saline injection nearby median nerve as hydrodissection
62387443|NCT05280223|ACTIVE_COMPARATOR|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
62387444|NCT02117024|EXPERIMENTAL|Viagenpumatucel-L Plus Metronomic Cyclophosphamide|Viagenpumatucel-L (HS-110) given as 1\*10\^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.
62387445|NCT02117024|ACTIVE_COMPARATOR|Chemotherapy Alone|Patients will be treated with a physician's choice regimen until progression.
62387446|NCT05956223|EXPERIMENTAL|Experimental: Virtual Reality & Movement Monitoring|Participants will don the equipment used to measure their tremor and replicate a series of standardized movements to measure their tremor, in and out of the VR platform.
62387447|NCT06188039|EXPERIMENTAL|Patients undergoing open aortic surgery with sinus rhythm|Arm to validate SVC-CI during open aortic surgery with special focus of predicting FR during aortic cross clamping (n=50).
62387448|NCT06188039|EXPERIMENTAL|Patients undergoing laparotomy and high PEEP|Arm designed to validate SVC-CI during laparotomy, ventilated with high PEEP levels (8-10cmH2O). PEEP will be raised transiently during measurements (n=50).
61991778|NCT00680082||1|Patients to whom a statin was initiated or switched between 3 and 6 months before consultation
61991779|NCT00510354|EXPERIMENTAL|RAD001 + Imatinib|
61991780|NCT03811795|OTHER|Arm 1-Repeat Cryoballoon Ablation|Subjects will be randomized to repeat cryoballoon ablation.
61991781|NCT03811795|OTHER|Arm 2-Radiofrequency Ablation|Participants will have radiofrequency ablation guided by high-fidelity mapping (Rhythmia) following an initial cryoballoon ablation.
62387449|NCT06188039|ACTIVE_COMPARATOR|Patients undergoing laparotomy with standard ventilatory settings|Arm designed as an active comparator with standard (protective) ventilatory settings (n=50). Tidal volumes (Vt) will be set for 8ml/kg.
62387450|NCT01991431||TAVI|All Patients undergoing transaortic transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve with the Ascendra+ Delivery-System in participating sites
62387451|NCT01420523|EXPERIMENTAL|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
62387452|NCT02862028|EXPERIMENTAL|HerinCAR-PD1 cells|Patients will receive 3 cycles of HerinCAR-PD1 cells treatment.
62387453|NCT03213106|EXPERIMENTAL|Transcranial Magnetic Stimulation (TMS) Stimulation|All patients will receive 5 sessions of active TMS stimulation.
61991782|NCT02032147||NGF group|This group will be treated with NGF 18u daily for 60 days.
61991783|NCT02032147||control group|"this group will receive conservative therapy such as hyperbaric therapy or corticosteroids therapy or wait and see policy"
62387454|NCT03213106|SHAM_COMPARATOR|Sham Stimulation|All patients will receive 5 sessions of active TMS stimulation
62387455|NCT05968196||FTC|Follicular thyroid carcinoma
62387456|NCT05968196||HCC|Hurthle cell carcinoma
62387457|NCT04459858||rotator cuff lesion|patients treated for traumatic or degenerative rotator cuff lesion
62387458|NCT04656769||PERI group|
62387459|NCT04656769||EV group|
62387460|NCT00103207|EXPERIMENTAL|Cetuximab|Cetuximab was given as a weekly intravenous (IV) infusion (over 60 minutes) at 250 mg/m2 from week 2 onwards after an initial loading dose of 400 mg/m2 (over 120 minutes) on week 1 until disease progression or unacceptable toxicity. The infusion rate of cetuximab could not exceed 5 mL/min. Each cycle will be 28 days in length. To prevent a hypersensitivity reaction, all patients were premedicated with diphenhydramine hydrochloride 50 mg (or an equivalent antihistamine) by IV (over 30-60 minutes) prior to the first dose of cetuximab. Premedication might be administered prior to subsequent doses, but at the investigator's discretion, the dose of diphenhydramine (or a similar agent) was reduced.
61991784|NCT04459117|ACTIVE_COMPARATOR|Acetaminophen|The active product is a 10 ml polyethylene ampoule of acetaminophen containing 100 mg of acetaminophen, solution for infusion, B BRAUN.
62767820|NCT06217419|NO_INTERVENTION|Trial 2- Social Network Chatbot|PROM answered remotely weekly + monthly on site, first by themselves with the aid of Chatbot on the electronic forms and then under direct supervision of the clinicians.
61991785|NCT04459117|PLACEBO_COMPARATOR|NaCL 0.9%|The placebo product is a polyethylene ampoule of 10ml of NaCL 0.9%, B BRAUN. Polyethylene ampoule of active and placebo products are with the same appearance, in accordance with Good Manufacturing Practices Drugs for Clinical Trials.
61991786|NCT06114758||control group - group 1|"1. Patients' postoperative 1st, 2nd, and 6th-hour vital signs (pulse rate, systolic and diastolic blood pressure, temperature, oxygen saturation).~2. Shock indices.~3. Hemogram and hematocrit values at 6-24 hours postoperatively.~4. Duration of the surgery.~5. Adverse effects experienced by the patients.~6. Additional treatments administered.~7. Whether blood transfusion was performed or not."
61991787|NCT06114758||intraoperatively admistiration of tranexamic acid (1 gram intravenous) - group 2|"1. Patients' postoperative 1st, 2nd, and 6th-hour vital signs (pulse rate, systolic and diastolic blood pressure, temperature, oxygen saturation).~2. Shock indices.~3. Hemogram and hematocrit values at 6-24 hours postoperatively.~4. Duration of the surgery.~5. Adverse effects experienced by the patients.~6. Additional treatments administered.~7. Whether blood transfusion was performed or not."
62387461|NCT02650518|NO_INTERVENTION|Control|Subject receives the standard of care that is provided by the primary team taking up his/her case.
62387462|NCT02650518|EXPERIMENTAL|Catheter change+Short-course Antibiotics|
62387463|NCT05238246|SHAM_COMPARATOR|Standard treatment group|Dental treatment was carried out with tell-show-do technique as a behavioural guidance technique.
62387464|NCT05238246|EXPERIMENTAL|Robot group|The robot group (RG) were treated with the robot accompaniment
62387465|NCT05724641|EXPERIMENTAL|Healthy Volunteers|N = 10, who do not use contact lenses or eye glasses and have a recent evaluation of vision 10/10 ta participate in the repeatability study.
62387466|NCT05724641|EXPERIMENTAL|Chronic|N = 30 (10 patients with thyroid associated orbitopathy (TAO), 10 patients with inflammatory optic neuropathy (ION), 10 patients with ischemic neuropathy), all chronic patients followed in ophthalmology consultation, enlightened volunteers ta participate in the study, and presenting a decrease in residual visual acuity entering the TAO, inflammatory or ischemic frameworks.
62387467|NCT05724641|EXPERIMENTAL|Acute|N = 30 (10 patients with TAO, 10 patients with ION, 10 patients with ischemic neuropathy) all patients seen in the acute phase in ophthalmology consultation who will accept participation in the study, knowing the constraint of repeating the examination in the chronic phase.
62387468|NCT03366935|EXPERIMENTAL|EPL and CEI|Those with receive a standard epidural (EPL) and continuous epidural infusion(CEI) + patient-controlled epidural analgesia (PCEA)
62387469|NCT03366935|ACTIVE_COMPARATOR|DPE and CEI|Those with receive a dural puncture labor epidural (DPE) and continuous epidural infusion(CEI) + patient-controlled epidural analgesia (PCEA)
62387470|NCT03366935|ACTIVE_COMPARATOR|DPE and PIEB|Those with receive a dural puncture labor epidural (DPE) and programmed intermittent epidural boluses(PIEB) + patient-controlled epidural analgesia (PCEA)
62387471|NCT05810324|EXPERIMENTAL|18F-FAPI|Experimental: Experimental: 18F-FAPI Each subject receive a single intravenous injection of 18F-FAPI, and undergo PET/CT imaging within the specificed time.
62387472|NCT04711954||ATHENA|Cohort of people living with HIV in the Netherlands
62387473|NCT04711954||LUKCY|Cohort of people living with HIV in the Lviv area, Ukraine
62387474|NCT02146352|EXPERIMENTAL|Treatment|AXIOS Stent with Electrocautery Enhanced Delivery System
62387475|NCT01388114|EXPERIMENTAL|Electrosensing antibody probing system (e- Ab sensing)|
62387476|NCT03336307||Patients with Parkinson's disease|"All participants could walk independently without walking devices. All patients were taking oral administrations of levodopa (18 patients), dopamine agonists (5 patients), or both (13 patients) and were recorded in on phase. Medication was kept constant throughout the trial, and all interventions were performed at the same time of day for each patient during ON phase.~Severity of parkinsonism was evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS-II and III) and the Hoehn and Yahr staging system.~All patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease"
62387477|NCT03615586|ACTIVE_COMPARATOR|With Chaperone|Female patients examined by male physicians in the presence of a female (nurse) chaperone. The intervention consists of the presence of a female chaperone.
62767821|NCT06217419|NO_INTERVENTION|Trial 2- Phonebot|PROM answered remotely weekly + monthly at hospital, first by themselves with the aid of Phonebot on the electronic forms and then under direct supervision of the clinicians.
61991788|NCT06114758||intraoperatively admistiration of prostoglandin f2 alfa (cytotec 400 microgram rectal)- group 2|"1. Patients' postoperative 1st, 2nd, and 6th-hour vital signs (pulse rate, systolic and diastolic blood pressure, temperature, oxygen saturation).~2. Shock indices.~3. Hemogram and hematocrit values at 6-24 hours postoperatively.~4. Duration of the surgery.~5. Adverse effects experienced by the patients.~6. Additional treatments administered.~7. Whether blood transfusion was performed or not."
62387478|NCT03615586|ACTIVE_COMPARATOR|Without Chaperone|Female patients examined by male physicians without a chaperone. The intervention is the absence of a female chaperone.
62387479|NCT05608122||unstable intracranial aneurysms|Unstable intracranial aneurysms are defined as the intracranial aneurysms that grows or ruptures.
62387480|NCT05608122||stable intracranial aneurysms|Stable intracranial aneurysms are defined as the intracranial aneurysms that have no significant morphological changes.
62387481|NCT03770078|EXPERIMENTAL|Study period|First the subjects will use the comparator (SenSura Mio) and then the test products (Test Product A)
62387482|NCT01497899|EXPERIMENTAL|E/C/F/TAF|E/C/F/TAF plus E/C/F/TDF placebo for at least 48 weeks
62387483|NCT01497899|ACTIVE_COMPARATOR|E/C/F/TDF|E/C/F/TDF plus E/C/F/TAF placebo for at least 48 weeks
62767822|NCT06217419|NO_INTERVENTION|Trial 2 - Mobile app|PROM answered remotely weekly + monthly at hospital, first by themselves with the aid of Mobile app on the electronic forms and then under direct supervision of the clinicians.
62767823|NCT06217419|NO_INTERVENTION|Trial 3 - asthma + CRSwNP Spirometer|Airflow monitoring recorded remotely with Spirometer every 2 weeks + on site visit every 2 month to compare wearable device with the standard one.
62767824|NCT06217419|EXPERIMENTAL|Trial 3 - asthma + CRSwNP RFID|Airflow monitoring with RFID (daily) + on site visit every 2 months to compare wearable device with the standard one.
61991789|NCT00685243|ACTIVE_COMPARATOR|Fraxel|Fraxel laser treatment
62767825|NCT06351709|EXPERIMENTAL|Hot Pack Group|Hot pack application was applied to the participants in the hot group to warm the extremities locally after the pre-tests were completed. For the application of hotpack, which is a superficial and moist temperature agent, a Chattanooga ® brand hotpack pad (DJO Global, Chattanooga; CA, USA) with 10 slices and a size of 28 cm x 39 cm was used. The hotpack pad was taken with the help of tongs from the Chattanooga ® brand hot pack boiler (DJO Global, Chattanooga; CA, USA) at 80° temperature and wrapped in a total of 5 layers with the help of 2 towels. A hotpackpad was placed on each knee of the participant. Hotpack pads were applied for 15 minutes in total.
61991790|NCT00685243|ACTIVE_COMPARATOR|PDL|Pulsed dye laser treatment
61991791|NCT02146638|ACTIVE_COMPARATOR|Morphine|Patients received morphine 0.02 mg/Kg/h infused at 2 ml/h for 24 hours. The infusion contained morphine and saline.
61991792|NCT02146638|EXPERIMENTAL|Fentanyl|Patients received Fentanyl 0.3 mcg/Kg/h infused at 2 ml/h for 24 hours. The infusion contained morphine and saline.
61991793|NCT06281041||Antiplatelet agents|Among patients with intermediate coronary artery stenosis (50-70% diameter stenosis by quantitative coronary angiography) but who did not undergo PCI based on negative FFR, those who were taking antiplatelet agents (aspirin or clopidogrel) are classified into this group.
61991794|NCT06281041||No antiplatelet agents|Among patients with intermediate coronary artery stenosis (50-70% diameter stenosis by quantitative coronary angiography) but who did not undergo PCI based on negative FFR, those who were not taking antiplatelet agents (aspirin or clopidogrel) are classified into this group.
61991795|NCT03647540|EXPERIMENTAL|Group F|Group F received endoscopic submucosal injection of indocyanine green (ICG) 2 hours before operation, followed by fluorescent laparoscopic radical gastrectomy. All specimens were grouped for lymph node collection, and the postoperative management was unified according to enhanced recovery after surgery (ERAS). All basic clinical and pathological data were statistically analyzed
61991796|NCT03647540|ACTIVE_COMPARATOR|Group L|Group L received traditional laparoscopic radical gastrectomy. All specimens were grouped for lymph node collection, and the postoperative management was unified according to enhanced recovery after surgery (ERAS). All basic clinical and pathological data were statistically analyzed
61991797|NCT04585087|EXPERIMENTAL|Healthy adult men|"Participants will initially be seen for a pre-study assessment (2 hours). They will then be studied for up to 6 times (6 different levels of threonine intake). Each set of experiments will be 9-days in length. During the first 2 days, a pre-adaptation (milkshake) diet will be consumed. For the remaining 7 days, a protein liquid drink and protein-free cookies will be consumed. All of the diets will be provided by the investigators.~During each 9-day experiment, participants are expected to come to the Clinical Research Centre at the Hospital for Sick Children for breath and urine collection (5 hours total for each visit)"
61991798|NCT01210365|EXPERIMENTAL|furosemide (40 mg) +amiloride (10 mg)|One group of patients will receive furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow the tablet in whole form on an empty stomach with some liquid.
62767826|NCT06351709|EXPERIMENTAL|Cold Pack Group|For participants in the cold group, MSD ® brand cold pack gel (MVS Inmotion, MSD cold pack; Weftdijk 1502830, Belgium), 15 cm x 25 cm in size, was used to cool the extremities locally. The cold pack gel, kept in the freezer, was wrapped in a paper towel and placed on the knee area. Cold pack was applied to both knees for a total of 15 minutes.
61991799|NCT01210365|ACTIVE_COMPARATOR|Lasix ®|One group of patients will receive Lasix® (furosemide 40 mg). For treatment, the patient will swallow the tablet in whole form on an empty stomach with some liquid.
61991800|NCT01050985|EXPERIMENTAL|temsirolimus and capecitabine|Treatment with the combination of temsirolimus and capecitabine
62387484|NCT01497899|EXPERIMENTAL|E/C/F/TAF Open-Label|"Following study unblinding, participants from the E/C/F/TAF and E/C/F/TDF arms may have the option to receive E/C/F/TAF during an open-label extension phase.~Also, participants who are actively participating in a Gilead-sponsored study of cobicistat-boosted darunavir plus nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) who have reached the protocol-defined secondary endpoint (Week 48) and remain virologically suppressed are eligible to participate and receive E/C/F/TAF in this open-label extension phase."
62767827|NCT06351709|EXPERIMENTAL|Stretching Group|Static stretching technique was applied to the quadriceps and hamstring muscle groups in both the dominant and non-dominant extremities of the participants in the stretching group. All stretches were performed twice for 20 seconds with a 3-second rest.
62767828|NCT06351709|NO_INTERVENTION|Control Group|No intervention was applied to the control group.
62767829|NCT05640609|EXPERIMENTAL|Capeox regimen combined with Sintilimab and Bevacizumab|Capeox regimen combined with Sintilimab and Bevacizumab
62387485|NCT01917565||Airtraq laryngoscope group|The patients who will be intubated by using Airtraq laryngoscope
62767830|NCT03263780|EXPERIMENTAL|18F-Fluciclovine|10mCi +/-20% 18F-fluciclovine injection
62767831|NCT00810940|ACTIVE_COMPARATOR|1|Control: Standard treatment for severe head trauma including mannitol
62767832|NCT00810940|EXPERIMENTAL|2|Study drug plus standard treatment
62767833|NCT04539860||Healthy Controls|Blood pressure measurements by standard assessment methods and Transdermal Optical Imaging
62767834|NCT04539860||Patients|Blood pressure measurements by standard assessment methods and Transdermal Optical Imaging
62387486|NCT01917565||Macintosh laryngoscope group|The patients who will be intubated by using Macintosh laryngoscope
62387487|NCT01917565||Fiberoptic bronchoscope group|The patients who will be intubated by using Fiberoptic bronchoscope
62387488|NCT04302363||Control Group|Healthy controls must be 18-75 years old with no tumors and no history of cancer.
62767835|NCT02410265|EXPERIMENTAL|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
62767836|NCT02410265|EXPERIMENTAL|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
61991801|NCT06300164|EXPERIMENTAL|People with celiac disease who eat cookies with unripe carob - Experimental Group|"Individuals with celiac disease who met the inclusion criteria and participated in the study will divided into two groups by Specialist OrhN SEZGİN, and they will be asked to consume the cookies produced (in the preliminary study) produced as a standard (n=15) and with the addition of unripe carob (n=15) for eight weeks.~The individuals participating in the study will be asked not to change their eating habits, physical activity habits, and drug treatments during the study period. Each individual participating in the study will be provided with the required amount of cookie during the study and will be contacted weekly by Ecem GÜLÜŞEN, a dietitian, to verify whether they consume cookies regularly."
61991802|NCT06300164|NO_INTERVENTION|No intervention - Control Group|Individuals with celiac disease will not eat unripe carob cookie
61991803|NCT03257631|EXPERIMENTAL|Pomalidomide|Pomalidomide will administered at a starting dose of 2.6 m2/day. Pomalidomide will be provided as either a capsule (0.5 mg, 1 mg, 2 mg, 3 mg or 4 mg) or as an oral suspension (2 mg/mL).
61991804|NCT01381133|EXPERIMENTAL|CBOP without ACC|
61991805|NCT01381133|EXPERIMENTAL|CBOP with ACC|
61991806|NCT01381133|EXPERIMENTAL|MET/CBT 7 without ACC|
61991807|NCT01381133|EXPERIMENTAL|MET/CBT 7 with ACC|
61991808|NCT04380987||Predicovid|
61991809|NCT05047081|EXPERIMENTAL|College Workshop Arm|Intervention
61991810|NCT05047081|PLACEBO_COMPARATOR|Placebo|Placebo
61991811|NCT02474108|PLACEBO_COMPARATOR|without prevention|isolated mitral valve replacement or reconstruction, implantation of cardiac monitor
61991812|NCT02474108|ACTIVE_COMPARATOR|group of prevention|"mitral valve replacement or reconstruction with surgical prevention of AF (concomitant ablation of the left atrium) and implantation of cardiac monitor.~Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe."
61991813|NCT03034785|NO_INTERVENTION|Group 1|Term
61991814|NCT03034785|NO_INTERVENTION|Group 2|Preterm
61991815|NCT03034785|EXPERIMENTAL|Group 3|Term
61991816|NCT03034785|EXPERIMENTAL|Group 4|Preterm
62387489|NCT04302363||Test Group|Inclusion criteria in the experimental group are age 18-75 years old, colonoscopy revealing colon or rectal tumor, biopsy-confirmed adenocarcinoma or adenoma, no chemotherapy or surgery, and no history of other cancer. Both groups must be able to understand and be willing to sign informed consent.
62387490|NCT05789823|EXPERIMENTAL|Ischemic post-conditioning group|Mechanical thrombectomy combined with ischemic post-conditioning
62387491|NCT05789823|SHAM_COMPARATOR|Control group|Mechanical thrombectomy alone
62767837|NCT02410265|NO_INTERVENTION|Delayed Program|Subject assigned to this arm will receive one of the online programs in 9 months.
62767838|NCT01278589|EXPERIMENTAL|• Plantago asiatica L. extract 5g|
61991817|NCT01749579|EXPERIMENTAL|Propofol|The patients will receive propofol for sedation in addition to fentanyl
62387492|NCT03310879|EXPERIMENTAL|Participants with CCND1, CCND2, or CCND3|"* Abemaciclib will be administered orally on a daily basis~* Dosage will be determine by the PI"
62387493|NCT03310879|EXPERIMENTAL|Participants with CDK4 or CDK6|"* Abemaciclib will be administered orally on a daily basis~* Dosage will be determine by the PI"
62387494|NCT02115620|EXPERIMENTAL|Telemedicine|Patients will be followed using frequent communication of symptom status and physiologic data and remote consultations with Heart Failure specialists.
62767839|NCT01278589|EXPERIMENTAL|Plantago asiatica L. extract 10g|
62767840|NCT01278589|EXPERIMENTAL|Plantago asiatica L. extract 20g|
62767841|NCT01278589|PLACEBO_COMPARATOR|Placebo|
62767842|NCT01756118|EXPERIMENTAL|BEZ235|
62767843|NCT04459975||AKI (-)|patients treated in ICU for COVID-19 infection and without occurrence of AKI (define as creatinine \> 1,5x baseline according with KDIGO guidelines)
62767844|NCT04459975||AKI (+)|"patient treated in ICU for COVID-19 infection and with occurrence of AKI among which:~• Severe AKI patients (define as creatinine \> 3x baseline or need for renal replacement therapy according with KDIGO guidelines) who will participate to biocollection and to post-mortem biopsy (if death)."
62767845|NCT02042313|ACTIVE_COMPARATOR|Epidural|Epidural catheters will be applied at the T6-8 level prior to the induction. 6 ml of 2% xylocaine with 1 in 200,000 epinephrine administered before surgery. During the surgery, 2% xylocaine with 1 in 200,000 epinephrine infusion will be administered at a rate of 2-10 ml/hour adjusted according to patient's blood pressure. After surgery, 0.125% levobupivacaine with 2.5μg fentanyl and 1 in 400,000 epinephrine will be given at a rate of 0.10-0.15 ml kg-1 h-1 (0.5 h lock and 2 ml bolus) through a patient-controlled infusion pump.
61991818|NCT01749579|ACTIVE_COMPARATOR|Midazolam|The patients will receive midazolam for sedation in addition to fentanyl
61991819|NCT05507983|EXPERIMENTAL|Tranexamic acid arm|"Tranexamic acid 1500 mg dissolved in 100 ml sodium chloride, once, directly after anesthetizing the participant.~In participants with renal insufficiency (creatinine \>120 umol/L) the dose will be reduced to 1000 mg."
61991820|NCT05507983|PLACEBO_COMPARATOR|Placebo arm|100ml sodium chloride 0.9%, once, directly after anesthetizing the participant.
61991821|NCT04374890|EXPERIMENTAL|Experimental|
61991822|NCT02504567|OTHER|Laser ablation|Ablation with laser catheter
61991823|NCT02504567|OTHER|RF ablation|Ablation with RF catheter
61991824|NCT03624660|EXPERIMENTAL|HR-A (High-risk A)|"* Prostate and proximal seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 78 cobalt gray equivalent.~* Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent."
61991825|NCT03624660|EXPERIMENTAL|HR-B (High-risk B)|"* Prostate, proximal seminal vesicles, and pelvic nodes: 2 cobalt gray equivalent per fraction to a total does of 46 cobalt gray equivalent.~* Prostate and proximal seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 32 cobalt gray equivalent.~* Entire uninvolved seminal vesicle when part of the seminal vesicle is involved with tumor: 2 cobalt gray equivalent per fraction to a total dose of 78 cobalt gray equivalent.~* Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent."
62387495|NCT05202249|EXPERIMENTAL|muscle layer fixation group|
62387496|NCT05202249|NO_INTERVENTION|conventional skin fixation group|
61991826|NCT01599273|EXPERIMENTAL|Triam inj|
61991827|NCT01599273|NO_INTERVENTION|observation group|
61991828|NCT00176592|ACTIVE_COMPARATOR|Betaseron|Betaseron 250 micrograms SQ every other day and Triple-Dose Gadolinium at each MRI
62387497|NCT04759391|EXPERIMENTAL|Exercise group|Lifestyle recommendations as well as digital pelvic floor muscle training to the exercise group
62387498|NCT04759391|ACTIVE_COMPARATOR|Control group|Lifestyle recommendations will be given to the control group
62387499|NCT00668876|ACTIVE_COMPARATOR|1|Group A: perioperative immunonutrition
62387500|NCT00668876|ACTIVE_COMPARATOR|2|Group B: postoperative immunonutrition
61991829|NCT00176592|ACTIVE_COMPARATOR|Copaxone|Copaxone 20 mg daily SQ and Triple-Dose Gadolinium at each MRI
61991830|NCT04457609|PLACEBO_COMPARATOR|Control Group|Patients receive standardized treatment, consisting of Oseltamivir and Azithromycin
62387501|NCT00668876|ACTIVE_COMPARATOR|3|Group C: control
61991831|NCT04457609|EXPERIMENTAL|Experiment Group|Patients receive intravenous infusion of 1x10\^6 unit of umbilical-cord derived mesenchymal stem cells (UC-MSCs)/kgBW in 100 cc of 0.9% NaCl for 1 hour, in addition to standardized treatment
61991832|NCT04153500|NO_INTERVENTION|Traditional Methodology|A professor/lecturer of anatomy will carry out the session in the control group. The traditional (40 minutes total) will consist of 30 minutes of lecture (75% out of the total time), where female pelvic floor will be presented throughout theory and images. In the 2nd part, during 10 min (25%), participants will review anatomical drawings /atlases.
61991833|NCT04153500|EXPERIMENTAL|Pelvic+ method|The second researcher will carry out the session in the intervention group. The interventional session (40 minutes total) will consist of two parts: The 1st one is a lecture of 10 minutes (25% out of the total time) on female pelvic floor anatomy. In the 2nd part, during 30 min (75%), participants, in small groups of 4 people, will assemble the female pelvic floor interactive model, following the indications suggested by the second researcher. Pelvic+ is supported by an assembling manual that participants will be allowed to use.
62387502|NCT02723474|OTHER|MRI at baseline and over time|Patients with chronic lung disease will undergo pulmonary function tests, hyperpolarized Helium and or Xenon MRI at each visit.
62387503|NCT01375491|EXPERIMENTAL|Doxycycline|Participants with DM2 receiving doxycycline 100mg BID
62387504|NCT01375491|PLACEBO_COMPARATOR|Placebo|Pills prepared identical to doxycycline.
62387505|NCT04171752|EXPERIMENTAL|Young Adults|Single oral dose of elafibranor 120mg
62387506|NCT04171752|EXPERIMENTAL|Elderly|Single oral dose of elafibranor 120mg
62387507|NCT01619436|ACTIVE_COMPARATOR|clonidine|clonidine 2 mg/kg IV
62387508|NCT01619436|PLACEBO_COMPARATOR|ringer lactato 1 ml|Ringer lactato 1 ml IV as Placebo
62387509|NCT01567254|EXPERIMENTAL|guided imaginary|7 children receiving auditory guided imagery disk
62387510|NCT01567254|ACTIVE_COMPARATOR|music|6 children receiving music disk
62387511|NCT05814107|EXPERIMENTAL|CT-996|Capsule of CT-996 intervention
62387512|NCT05814107|PLACEBO_COMPARATOR|Placebo|Capsule of placebo matching CT-996 dose
62387513|NCT05234762|EXPERIMENTAL|ES-481|Week 1 - 25 mg qd (2 x 25 mg capsule in the mornings Days 1 to 7 in Treatment Period 1 and Days 44 to 50 in Treatment Period 2) Week 2 - 50 mg bid (2 x 25 mg capsule in the mornings and 2 x 25 mg capsules in the evening on Days 8 to 14 in Treatment Period 1 and Days 51 to 57 in Treatment Period 2) Week 3 - 75 mg bid (2 x 25 mg capsule in the mornings and 2 x 25 mg capsules in the evening on Days 15 to 21 in Treatment Period 1 and Days 58 to 64 in Treatment Period 2) Week 4 - 75 mg bid (2 x 25 mg capsule in the mornings and 2 x 25 mg capsules in the evening on Days 22 to 28 in Treatment Period 1 and Days 65 to 71 in Treatment Period 2)
62387514|NCT05234762|PLACEBO_COMPARATOR|Placebo|Placebo will be dosed at the same quantity and frequency as ES-481 just as Placebo HPMC capsules
62387515|NCT00384969|EXPERIMENTAL|1|RAD001 and Sorafenib
62387516|NCT02538705|EXPERIMENTAL|Neovasculgen|
61991834|NCT04094467|EXPERIMENTAL|Study group|"the antagonist protocol group where they will do intra-cytoplasmic injection using classical antagonist protocol"
61991835|NCT04094467|ACTIVE_COMPARATOR|control group|"agonist stop/antagonist protocol group where they will receive mid luteal agonist in the preceding intra-cytoplasmic injection cycle before starting classical antagonist protocol"
62387517|NCT03579004|EXPERIMENTAL|Trimodality approach|"2 cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/м2 iv day 1, cisplatin 75 mg/м2 iv day 1, fluorouracil 750 mg/m2/day continuous infusion, day 1-4 every 3 weeks). 3-4 weeks later - preoperative chemoradiotherapy (paclitaxel 50 mg/m2 + cisplatin 20 mg/m2 weekly + radiotherapy 44 Gray (Gy) for 4 weeks).~4-6 weeks after completion of chemoradiation patients undergo Ivor Lewis esophagogastrectomy."
62387518|NCT04643769|EXPERIMENTAL|25 mg ORIN1001 (Active)|25 mg ORIN1001
62387519|NCT04643769|EXPERIMENTAL|50 mg ORIN1001 (active)|50 mg ORIN1001
62387520|NCT04643769|EXPERIMENTAL|100 mg ORIN1001 (active)|100 mg ORIN1001
62387521|NCT04643769|PLACEBO_COMPARATOR|Placebo - 25 mg|Placebo comparator for ORIN1001 at 25 mg
61991836|NCT02444091|EXPERIMENTAL|Cyclophosphamide|Cyclophosphamide, intravenous infusions four weeks apart. Six infusions in total. First infusion: 600 mg/m2. Infusions 2 to 6: 700 mg/m2
61991837|NCT05150535|ACTIVE_COMPARATOR|Hypofractionation control arm|Patients who will receive 40 Gy in 15 fractions to the entire breast or chest wall over three weeks and have had breast conservation surgery (BCS) or oncoplastic breast surgery(OBS) will receive an additional boost to the tumour site if and will receive sequential dose 12GY\\4 fractions or SIB 8GY 15 fractions. The supraclavicular fossa will be treated in patients with node-positive disease or those who had received neoadjuvant chemotherapy . The IMLN will be irradiated in N2and N3 at first presentation.
62387522|NCT04643769|PLACEBO_COMPARATOR|Placebo - 50 mg|Placebo comparator for ORIN1001 at 50 mg
62387523|NCT04643769|PLACEBO_COMPARATOR|Placebo - 100 mg|Placebo comparator for ORIN1001 at 100 mg
62387524|NCT02073149|ACTIVE_COMPARATOR|Low-dose iron as NaFeEDTA|Daily point-of-care fortification of (complementary) foods with 3 mg iron as NaFeEDTA.
61991838|NCT05150535|EXPERIMENTAL|. Ultrahypofractionation experimental arm|Patients who will receive 26 Gy in 5 fractions to the entire breast and or chest wall for one week only. The volume of this arm will be the same as the volume of the control arm as regard axillary nodes, supraclavicular and IMLN. Patients who have had breast conservation or oncoplastic breast surgery(OBS) will be given a boost. If a boost is given, SIB of 6 Gy in 5 fractions will be used (or a sequential boost of 12GY\\4 fractions).
61991839|NCT04129788|EXPERIMENTAL|bisacodyl|bisacodyl 5mg tablet, once a day on three consecutive days
61991840|NCT04129788|PLACEBO_COMPARATOR|placebo|tablet, once a day on three consecutive days
61991841|NCT03051542|EXPERIMENTAL|NK/T-cell lymphoma patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
61991842|NCT06040021||EOCRC|Patients aged\<50 with colorectal cancer between 2008 and 2018 in Fudan university Shanghai cancer center.
61991843|NCT06040021||IOCRC|Patients aged between 50 to 70 with colorectal cancer between 2008 and 2018 in Fudan university Shanghai cancer center.
61991844|NCT06040021||LOCRC|Patients aged between≥70 with colorectal cancer between 2008 and 2018 in Fudan university Shanghai cancer center.
61991845|NCT01892696|OTHER|mechanically ventilated patients|"patients admitted to a 18-bed medical surgical intensive care unit of the military hospital of Tunisia and were mechanically ventilated fully adapted to their ventilator and in sinus rhythm.~intervention:varying inspiratory flow waveforms"
61991846|NCT06255951|EXPERIMENTAL|Itraconazole|Itraconazole
61991847|NCT06255951|EXPERIMENTAL|Rifampicin|Rifampicin
61991848|NCT02492529|OTHER|Healthy volunteers|"60 old healthy volunteers (aged 25-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~* Neuropsychological tests~* Experimental procedure"
61991849|NCT02492529|EXPERIMENTAL|Patients with early Alzheimer disease|"20 patients (aged 60-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~* Neuropsychological tests~* Experimental procedure~* A cranial MRI"
61991850|NCT02492529|EXPERIMENTAL|Old healthy volunteers|"20 healthy volunteers (aged 60-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~* Neuropsychological tests~* Experimental procedure~* A cranial MRI"
61991851|NCT04113499|ACTIVE_COMPARATOR|Direct Endoscopic Necrosectomy|The subject will have endoscopic drainage and necrosectomy at the time of the index intervention.
61991852|NCT04113499|ACTIVE_COMPARATOR|Step-up Endoscopic Interventions|The subject will only have endoscopic drainage of the pancreatic necrotic collection at the time of index intervention.
61991853|NCT04361162|EXPERIMENTAL|Nivolumab + Ipilimumab + Radiation|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits, (Study cycles are 6 weeks.)~* Nivolumab via iv, at predetermined dose every 2 weeks for duration of study.~* Ipilimumab via iv at a predetermined dose on day 1 of 4 study cycles.~* Radiation treatments will be administered every other weekday or 2 days during week 1 of cycle 1."
61991854|NCT05305872|EXPERIMENTAL|Treatment group|Gandouling
62387525|NCT02073149|ACTIVE_COMPARATOR|Conventional dose iron as ferrous salt|Daily point-of-care fortification of (complementary) foods with 12.5 mg iron as encapsulated ferrous fumarate.
62387526|NCT02073149|PLACEBO_COMPARATOR|Placebo|Daily point-of-care fortification of (complementary) foods with placebo.
62387527|NCT00431132|EXPERIMENTAL|Vagifem® 10 mcg|One 10 mcg (microgram) vaginal tablet of intravaginal estradiol (Vagifem®) once daily for two weeks followed by one 10 mcg vaginal tablet twice weekly for 50 weeks
62387528|NCT02159911||200 mcg misoprostol|Misoprostol administered orally one hour before surgery
62387529|NCT02159911||400 mcg misoprostol|Misoprostol administered orally one hour before surgery
61991855|NCT05305872|PLACEBO_COMPARATOR|Control group|Zinc gluconate
61991856|NCT00944151|PLACEBO_COMPARATOR|Single injection with Saline infused TAP catheter|Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given normal saline in infusion pump, attached to catheter.
61991857|NCT00944151|ACTIVE_COMPARATOR|Single injection with Ropivicaine infused TAP catheter|Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given 0.2% ropivicaine in infusion pump, attached to catheter
61991858|NCT04941508|EXPERIMENTAL|Mother's recorded voice|Children will be exposed to the mother's voice.
61991859|NCT04941508|EXPERIMENTAL|Dexmedetomidine IV|Children will be given dexmedetomidine injection.
61991860|NCT04941508|PLACEBO_COMPARATOR|Saline placebo IV|Children will be given normal saline.
61991861|NCT01514968|EXPERIMENTAL|DNV/r+cyclosporine|
61991862|NCT01514968|ACTIVE_COMPARATOR|cyclosporine|
61991863|NCT01514968|ACTIVE_COMPARATOR|danoprevir+ritonavir|
61991864|NCT02925546|EXPERIMENTAL|GSK2798745 ABCD treatment sequence|Subjects will be given 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
62387530|NCT02134340|EXPERIMENTAL|[I-124]-CPD-1028 PET/CT|"Administration of \[I-124\]-CPD-1028 Injection followed by a maximum of 3 PET/CT imaging sessions.~A pre-targeting dose of CPD-1061 may be given prior to injection of \[I-124\]-CPD-1028."
62387531|NCT00444639|EXPERIMENTAL|1|triptorelin 11.25mg given 12 weekly by subcutaneous formulation
62387532|NCT00444639|ACTIVE_COMPARATOR|2|triptorelin 11.25mg given 12 weekly by intramuscular injection
62387533|NCT06492421|EXPERIMENTAL|Group 1: IT injection of double ICIs|Neoadjuvant therapy: intra-tumor injection of double ICIs only.
62387534|NCT06492421|EXPERIMENTAL|Group 2: IT injection of double ICIs and chemodrug|Neoadjuvant therapy: intra-tumor injection of double ICIs and chemodrug.
62387535|NCT06492421|EXPERIMENTAL|Group 3: IT injection of double ICIs and chemodrug plus bevacizumab|Neoadjuvant therapy: intra-tumor injection of double ICIs and chemodrug plus bevacizumab.
62387536|NCT03334994|ACTIVE_COMPARATOR|Control group: immediate implant alone|Patient will be treated with immediate implant alone.
62387537|NCT03334994|ACTIVE_COMPARATOR|(Group A) immediate implant alone|Patient will be treated with immediate implant alone.
61991865|NCT02925546|EXPERIMENTAL|GSK2798745 CABD treatment sequence|Subjects will be given 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
61991866|NCT02925546|EXPERIMENTAL|GSK2798745 ACBD treatment sequence|Subjects will be given 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
61991867|NCT02925546|EXPERIMENTAL|GSK2798745 BACD treatment sequence|Subjects will be given 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
61991868|NCT02925546|EXPERIMENTAL|GSK2798745 BCAD treatment sequence|Subjects will be given 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
61991869|NCT02925546|EXPERIMENTAL|GSK2798745 CBAD treatment sequence|Subjects will be given 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
61991870|NCT01264458||Traumatic Injury|Trauma patients arriving at Saint Mary's Emergency Department
61991871|NCT01264458||Control group|
61991872|NCT00656630|ACTIVE_COMPARATOR|1|Acamprosate
61991873|NCT00656630|ACTIVE_COMPARATOR|2|Naltrexone
61991874|NCT00656630|PLACEBO_COMPARATOR|3|
61991875|NCT01925404|EXPERIMENTAL|Frequent User Arm|Park users will be able to earn rewards or prizes by coming more frequently to the park
62767846|NCT02042313|EXPERIMENTAL|combined PVB TAP|"Paravertebral catheterization into the paravertebral region ipsilateral to the VATS incision as described by Murata at the level of T7-8 will be performed. 10 ml of 2% xylocaine with 1 in 200,000 epinephrine to initiate analgesia. During the surgery, 2% xylocaine with 1 in 200,000 epinephrine infusion will be administered at a rate of 2-10 ml/hour adjusted according to patient's blood pressure. After the surgery, 0.125% levobupivacaine with 2.5μg fentanyl and 1 in 400,000 epinephrine will be administered at the rate of 0.10-0.15 ml kg-1 h-1 (0.5 h lock and 2 ml bolus) through a patient-controlled infusion pump.~Ultrasound-guided (USG) subcostal TAP block will be performed at the end of surgery. Fifteen milliliters of 0.5% levobupivacaine with 1 in 400,000 epinephrine will be injected in incremental doses on each side of the abdomen."
61991876|NCT01925404|EXPERIMENTAL|Free Physical Activity Classes/programs|We will offer at least 100 free physical activity classes at the park
61991877|NCT01925404|EXPERIMENTAL|Combined arm|We will offer free classes and the frequent user program at the park
61991878|NCT01925404|NO_INTERVENTION|Control|Business as usual, no special physical activity programs offered
61991879|NCT01380743|EXPERIMENTAL|Cohort 1, Duvoglustat 50 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 50 milligram (mg) oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
61991880|NCT01380743|EXPERIMENTAL|Cohort 2, Duvoglustat 100 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 100 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
62767847|NCT01242566|EXPERIMENTAL|temozolomide|Administration of temozolomide 150-200 mg/m2/day for 5 consecutive days every 4 weeks for a maximum of 12 cycles or until disease progression or prohibited toxicity
62767848|NCT01426308||Method Comparison Group|The method comparison group will consist of de-identified, leftover DNA samples from patients referred for post-natal cytogenetic testing.
62767849|NCT01426308||Clinical Specificity Group|The clinical specificity group will consist of de-identified, leftover DNA samples from non-phenotypic patients, or patients not referred for post-natal cytogenetic testing.
61991881|NCT01380743|EXPERIMENTAL|Cohort 3, Duvoglustat 250 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 250 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
61991882|NCT01380743|EXPERIMENTAL|Cohort 4, Duvoglustat 600 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 600 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
61991883|NCT01542216|PLACEBO_COMPARATOR|Yoga and Stretching Group|Patients undergo yoga and stretching exercises
61991884|NCT01542216|ACTIVE_COMPARATOR|Nutrition and Exercise Group|Patients are provided with nutrition, cardiovascular exercise and strength exercise consultations
61991885|NCT02759666|EXPERIMENTAL|SHR3162|"3 to 6 participants (traditional 3+3 design) will be enrolled in 6 dose levels. SHR3162 was administered once daily in dose levels 1 and 2 and will be administered twice daily in dose levels 3 to 6."
62767850|NCT03919227|EXPERIMENTAL|Group 1: empty bladder|In group 1, investigator empty the bladder of urine with a catheter before inserting UAS.
61991886|NCT00624533|ACTIVE_COMPARATOR|A|Primary Health Care Conventional Physiotherapy Treatment (based in electrotherapy)
61991887|NCT00624533|EXPERIMENTAL|B|Group B was treated with the GDS Method (muscular and articular chains physiotherapy method)
61991888|NCT05010889||Achalasia patients|Patients schedule to undergo POEM for treatment of symptomatic achalasia. The diagnosis of achalasia was based on high resolution manometry, barium esophagram, and upper endoscopy.
61991889|NCT04952870||COVID-19 group|Perinatal COVID-19 infection group, including newborns born from COVID-19 infected mothers and newborns with postnatal COVID-19 infections;
61991890|NCT04952870||NO group|Newborns admitted in NICU and receiving inhaled NO for respiratory failure
61991891|NCT04952870||Control group|Newborns admitted in NICU for respiratory failure not receiving iNO and not infected with COVID-19;
61991892|NCT01874496|EXPERIMENTAL|GDS, meal|GDS, meal
61991893|NCT01874496|EXPERIMENTAL|GDS, no meal|GDS, no meal
62559762|NCT05011838|EXPERIMENTAL|A multi-component intervention to improve hypertension care and control|The intervention will be implemented in Commune 2. It will integrate activities related to 1) Health services redesign, 2) Clinical staff training and 3) Patient and community engagement. The intervention activities will be implemented by health services staff with technical assistance from the investigation team.
62559763|NCT05011838|NO_INTERVENTION|Routine Care|The Commune 6 was selected as control area, where routine care will be delivered.
62559764|NCT06286501|EXPERIMENTAL|Study group|Standard, personalized oral hygiene and Lumoral Treatment home-use
62559765|NCT06286501|ACTIVE_COMPARATOR|Control group|Standard, personalized oral hygiene
62559766|NCT06067841|EXPERIMENTAL|Administration of BMS-986460|
62559767|NCT03754010|PLACEBO_COMPARATOR|Scaling and root planning (SRP)|Under local anesthesia, full-mouth SRP was performed within 24 h in a single or two sessions using ultrasonic and hand instruments (Gracey, Hu-Friedy, Chicago, IL, USA) by a single investigator (DA). Immediately after the SRP, HA gel (Gengigel, Hyaluronic acid, gingival gel, Ricefarma S.R.L, Italy) or mouthrinse was performed according to the groups' procedure. In Group 1, the periodontal sulcus was irrigated with saline solution after SRP.
62559768|NCT03754010|EXPERIMENTAL|Hyaluronic acid gel (HA) and SRP|Group 2, after SRP was performed and irrigated with saline the area was dried with a soft air and, then, a gel containing HA was applied intrasulcular.
62559769|NCT03754010|EXPERIMENTAL|HA mouthrinse and SRP|In Group 3, HA hydrogel mouthrinse (Gengigel, Hyaluronic acid, Hydrogel moutrinse for gums, Ricefarma S.R.L, Italy) were used as an irrigator after SRP.
62767851|NCT03919227|ACTIVE_COMPARATOR|Group 2: natural state of bladder|In group 2, investigator does not interfere with the filling degree of bladder before inserting UAS.
62767852|NCT01330654|ACTIVE_COMPARATOR|Beta blocker|These patients will be randomized to receive a standard dose of metoprolol (50mg) starting two weeks prior to surgery
62767853|NCT01330654|NO_INTERVENTION|Control|This arm will receive no additional treatment prior to surgery
62767854|NCT03645317|OTHER|Single arm|Blood samples (FBC, lipids, cholesterol, troponin, CRP, BNP) Cardiac imaging (cardiac CT, cardiac ultrasound, 12-lead ECG)
62767855|NCT01354704|ACTIVE_COMPARATOR|lovenox|patient under lovenox 4000 IU
62767856|NCT01354704|ACTIVE_COMPARATOR|enoxa|patients under Enoxa 4000 IU
61991894|NCT01874496|ACTIVE_COMPARATOR|control, no meal|control, no meal
61991895|NCT01874496|ACTIVE_COMPARATOR|control, meal|control, meal
62767857|NCT01354704|NO_INTERVENTION|total knee replacement|patients undergoing total knee replacement
62767858|NCT01354704|NO_INTERVENTION|total hip replacement|patient undergoing total knee replacement
62767859|NCT05490966|EXPERIMENTAL|Isometric fatigue|Fatiguing intermittent isometric exertions of trunk extensor muscles will be performed.
62767860|NCT01305655|EXPERIMENTAL|Glucarpidase arm|In the NOPHO ALL-2008 protocol patients with delayed methotrexate elimination (DME) in high-dose methotrexate treatments should be given Glucarpidase (50 ie/kg) with-in 60 hours from start of the methotrexate treatment.
62767861|NCT00402493|ACTIVE_COMPARATOR|Latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
62767862|NCT00402493|ACTIVE_COMPARATOR|Brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
61991896|NCT04608500|EXPERIMENTAL|FMX103 1.5%|Participants will apply the assigned FMX103 minocycline foam 1.5% topically once daily for 12 weeks as directed.
61991897|NCT04608500|PLACEBO_COMPARATOR|Vehicle foam|Participants will apply the assigned vehicle foam topically once daily for 12 weeks as directed.
61991898|NCT01840774|ACTIVE_COMPARATOR|Low-dose pain medication|80min IV infusion of a low-dose pain medication
61991899|NCT01840774|PLACEBO_COMPARATOR|saline placebo|80min IV infusion of a saline placebo
61991900|NCT04695860|EXPERIMENTAL|Open label Burosumab|Burosumab Q4W, 1mg/kg body weight s.c.
61991901|NCT00930995|ACTIVE_COMPARATOR|A|
61991902|NCT00930995|PLACEBO_COMPARATOR|B|
61991903|NCT02692092||Total Arthroplasty Patients|Any patient who has received a total hip or total knee arthroplasty at a healtheast acute care hospital.
62387538|NCT04980300|EXPERIMENTAL|Expanded Intervention|Virtual consultation sessions with a physical therapist, focusing on lower extremity strengthening exercises, physical activity (i.e., walking), and education about knee osteoarthritis.
61991904|NCT06443762|EXPERIMENTAL|Experimental group patients who underwent PET scanning with injection probes|\[68Ga\] MDM2/MDMX Peptide PET/CT Imaging: Patients are intravenously injected with prepared and quality-assured \[68Ga\] MDM2/MDMX Peptide (0.05-0.1 mCi/kg). Imaging is performed 40 minutes to 1 hour post-injection using either the United Imaging uEXPLORER 2m PET/CT or Siemens Biograph m-CT flow PET/CT for whole-body scans, extending from the top of the head to the feet. In cases where conventional imaging reveals indeterminate lesions, delayed imaging is conducted for further differentiation. The patient is positioned supine with calm respiration. The imaging conditions for the head and torso remain as described above. Data are reconstructed using the OSEM method to produce coronal, sagittal, and axial PET and PET/CT fusion images.
61991905|NCT03336216|ACTIVE_COMPARATOR|Arm A|"Investigator choice of chemotherapy:~Gemcitabine/Nab-Paclitaxel (Abraxane®) or 5-Fluorouracil/Leucovorin/Irinotecan Liposome (ONIVYDE)"
61991906|NCT03336216|EXPERIMENTAL|Arm B|Cabiralizumab Q2W + Nivolumab Q4W
61991907|NCT03336216|EXPERIMENTAL|Arm C|Cabiralizumab Q2W + Nivolumab Q4W and Gemcitabine + Nab-Paclitaxel (Abraxane®) D1, 8 and 15 Q4W
61991908|NCT03336216|EXPERIMENTAL|Arm D|Cabiralizumab Q2W + Nivolumab Q4W and Oxaliplatin/5-Flurouracil/Leucovorin (FOLFOX) Q2W
61991909|NCT03562039|EXPERIMENTAL|M-MIST (group A)|M-MIST(incomplete granulation tissue removal)
61991910|NCT03562039|ACTIVE_COMPARATOR|M-MIST (group B)|conventional M-MIST.
61991911|NCT05828251|EXPERIMENTAL|Combined Phako-Vitrectomy for FTMH|Study 1: Patient randomized to this arm will receive a combined phako-vitrectomy within two weeks from referall day.
61991912|NCT05828251|ACTIVE_COMPARATOR|Sequential phako and vitrectomy for FTMH|Study 1: Patients randomized to this arm will receive a standard phacoemulsification as soon as possible. About four weeks after phacoemulsification a vitrectomy is performed.
62387539|NCT04980300|ACTIVE_COMPARATOR|Brief Intervention|Web-based resources on knee osteoarthritis, including an overview of knee osteoarthritis, brief anatomy of the knee and how that is related to pain, different types of arthritis pain and how to manage it, and how to be active with arthritis.
62387540|NCT05653115||Bariatric surgery|Individuals with morbid obesity and clinically relevant portal hypertension undergoing bariatric surgery
62387541|NCT05243199|EXPERIMENTAL|Sacubitril/Valsartan|The initial dose of 50mg Qd was increased to 50mg Bid after 1 week and maintained to 100mg Bid after 2 weeks if the patient could tolerate it
61991913|NCT05828251|OTHER|Longstanding FTMH|Study 2: Patients with symptomduration of 3-12 months will be included in this part of the study in a prospective design.
62387542|NCT05243199|ACTIVE_COMPARATOR|Irbesartan|the maximum tolerated dose of irbesartan was administered
62387543|NCT03950505|EXPERIMENTAL|1|Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
62387544|NCT00331058|OTHER|healthy volunteers|control group not receiving prednisolone
62387545|NCT00331058|OTHER|asthmatic volunteers|receive prednisolone for 14-16 days
62387546|NCT04748159|EXPERIMENTAL|Infants in prone position|The purpose of this intervention study is to evaluate short-term effects (within one hour) of prone positioning on vital signs in infants under 12 months of age with acute RSV bronchiolitis.
62387547|NCT03810599|OTHER|Early cardiac rehabilitation|Single Group: 5 week cardiac rehabilitation programme. Pre-post comparison.
62387548|NCT04470960|EXPERIMENTAL|participating community centers|Training course for the community center health coordinators Professional guidance for the CC health coordinators
62387549|NCT00760994|EXPERIMENTAL|1 - Experiential Accepatance|Experiential acceptance
62387550|NCT00760994|ACTIVE_COMPARATOR|2 - Cognitive Restructuring|Cognitive restructuring
62387551|NCT00760994|PLACEBO_COMPARATOR|3 - Control|No-intervention control: Nutrition information
62387552|NCT00060333|EXPERIMENTAL|Treatment (adjuvant radiation therapy)|Within 8 weeks after surgical resection, patients undergo radiation therapy twice weekly over approximately 2.5 weeks for a total of 5 fractions in the absence of disease progression or unacceptable toxicity.
61991914|NCT04475588|EXPERIMENTAL|Arm A - Itolizumab + BSC|
62387553|NCT02461342||Dr.Tang's research group|Dr.Tang's research group for genetic, environment and its interaction analysis of human complex disease
62387554|NCT03956459|OTHER|Patients with a cancer|
62387555|NCT00754312|EXPERIMENTAL|1|ER positive
61991915|NCT04475588|ACTIVE_COMPARATOR|Arm B - Best supportive care (BSC)|
62387556|NCT00754312|EXPERIMENTAL|2|ER negative and/or PR negative histology
62387557|NCT00754312|EXPERIMENTAL|3|triple negative histology (for ER, PR, HER-2)
62387558|NCT05673057|EXPERIMENTAL|Dose escalation|
62387559|NCT05673057|EXPERIMENTAL|Dose expansion|
62387560|NCT06247462|EXPERIMENTAL|Ibuprofen|600 mg of Ibuprofen was ingested 12- and 1-hour prior to exercise.
62387561|NCT06247462|PLACEBO_COMPARATOR|Placebo (Corn Starch)|600 mg of corn starch was ingested 12- and 1-hour prior to exercise.
62387562|NCT01913275|ACTIVE_COMPARATOR|endoscopic stenting|endoscopic stenting to reduce preoperative jaundice
62387563|NCT01913275|ACTIVE_COMPARATOR|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
62387564|NCT01817218|EXPERIMENTAL|PRP (Platelet Rich Plasma)|PRP treatment of vascular ulcers one a week PRP: a volume of 9-30 ml of blood will be collected from the patient (depending of the size of their ulcer) in sterile 4.5-ml tubes containing 3.8% sodium citrate, which will bind to the calcium ions, preventing clot formation we will add 50 μl of CaCl2 per ml liquid plasma. The extraction of the PRP fraction by sticking with a syringe and the adding of CaCl2 should be performed under sterile conditions.
62387565|NCT01817218|ACTIVE_COMPARATOR|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
62559770|NCT03754010|EXPERIMENTAL|HA mouthrinse+gel and SRP|In Group 4, after SRP was performed, the sulcus was irrigated with HA hydrogel mouthrinse and, then, intrasulculary HA gingival gel was applied.
61991916|NCT06034613|EXPERIMENTAL|mindfulness intervention group|provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
61991917|NCT03023033|EXPERIMENTAL|Clinic group 1|Clinics using SMS health promotion and reminder messages (mhealth messaging)
61991918|NCT03023033|EXPERIMENTAL|Clinic group 2|Clinics using SMS health promotion and reminder messages + Clinics providing payment scaled to reflect typical transport costs to facility (transport payments)
61991919|NCT03023033|NO_INTERVENTION|Clinic group 3|Services provided under the Ministry of Health standard care
62559771|NCT02690831|ACTIVE_COMPARATOR|Inspiratory Muscle training (IMT)|"The IMT program consisted of supervised and domiciliary exercises:~1. - The supervised exercises was performed in the presence of physiotherapist. This consisted of 30 min 2 days for 6 weeks using the threshold device (Powerbreathe classic level 1, Gaiam Ltd; Southam, Warwickshire, UK). This program involve 5 sets of 5 repetitions with 30 seconds rest between each one. The load of the training was distributed as follow:~   * First week: 30% Maximum Inspiratory Pressure (MIP)~  * Second week: 40% MIP~  * Third week: 50% MIP~  * Fourth week: 50% MIP~  * Fifth week: 60% MIP~  * Sixth week: 60% MIP~2. - The domiciliary exercises consisted of Yoga Breathing Exercises (Pranayama) that combines the inspiration and expiration through one or both nostrils, and requires the activation of chest and abdomen."
62767863|NCT00402493|ACTIVE_COMPARATOR|ibuprofen|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
61991920|NCT06537349|EXPERIMENTAL|DQS group|Participants in DQS group will be administered one drop of 3% DQS (Diquas, Santen Pharmaceutical Co.,Ltd., Osaka, Japan) six times per day for 4 weeks
61991921|NCT03639337|EXPERIMENTAL|Allergic Children|"Allergic children to milk or egg, aged between 10 and 14 months, confirmed by double-blind oral provocation test against placebo.~Intervention: 30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63"
61991922|NCT03639337|NO_INTERVENTION|Not confirmed Allergic Children|Sensible children to milk or egg, aged between 10 and 14 months, not confirmed by double-blind oral provocation test against placebo.
61991923|NCT03639337|NO_INTERVENTION|Controls|Healthy controls ages between 10 and 14 months
61991924|NCT04073381|EXPERIMENTAL|Prehabiliation Program|100 subjects between the ages of 18 and 90, who have GI cancer and will undergo surgery will be recruited for this study ad participate in the prescribed prehabilitation exercise and nutrition program.
61991925|NCT02495311||Women with uterine myoma|Women with uterine myoma
61991926|NCT02495311||Women with adenomyosis|Women with adenomyosis
61991927|NCT02495311||Women without uterine myoma or adenomyosis|Control group
62767864|NCT02528357|EXPERIMENTAL|Part 1A: GSK3174998 Monotherapy- Dose escalation|Participants will receive GSK3174998 intravenously (IV) (dose range 0.003 to 10.0 milligram per kilogram \[mg/kg\]) every 3 weeks (Q3W) for up to 2 years or 35 cycles, whichever comes first.
61991928|NCT02572466||ESRD group|"1. Aged 18 years or older.~2. was diagnosed as End-stage renal disease for more than one year.~3. Attend hemodialysis 3 times a week consistently for more than 6 months.~4. Hemodialysis with Kt/V \> 1.2~5. No urine output or is less than 500 ml per day.~6. No symptoms of myocardial infarction Or were hospitalized with the similar diagnosis during the two weeks."
61991929|NCT02572466||Control group|"1. Aged 18 years or older.~2. without kidney disease (eGFR \> 60 ml/min/1.73m2)"
61991930|NCT02046148|EXPERIMENTAL|GBS Group|Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Group B Streptococcus (GBS) trivalent vaccine, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).
61991931|NCT02046148|ACTIVE_COMPARATOR|Placebo Group|Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Placebo, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).
62387566|NCT04287673|EXPERIMENTAL|RIST-UR|"Group having performed the rehabilitation involving strongly the trunk for the first 3 months and then having performed its usual rehabilitation for the last 3 months.~Before and after each 3-months period, an evaluation of the postural control of the trunk (using the Trunk Control Measurement Scale and a dynamic posturography on an unstable sitting device) and a clinical gait analysis were performed."
62767865|NCT02528357|EXPERIMENTAL|Part 2A: GSK3174998+ pembrolizumab - Dose escalation|Participants will receive GSK3174998 IV (dose range 0.003 to 10.0 mg/kg) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for up to 2 years or 35 cycles, whichever comes first.
61991932|NCT02113956|EXPERIMENTAL|Guy2Guy (G2G)|G2G is a 6-week HIV prevention program delivered daily via text messaging to 14-18 year old males who self-identify as gay, bisexual, and/or queer. In addition to program content, participants are paired with another participant (i.e., a Text Buddy) with whom they can text throughout the program to provide support; and an on-demand advice line, G2Genie, which shares information about condoms, sex, relationships, and the lesbian, gay, bisexual, transgender (LGBT) community.
61991933|NCT02113956|NO_INTERVENTION|Healthy Lifestyle Control|The attention-matched control arm message content consists of information publicly available online related to living a healthy lifestyle. Content discussed includes: STD information, nutrition and sleep hygiene, self-esteem and body image, bullying, and drugs and alcohol. The control arm is 6-weeks in length (Week 6 is a review booster) and is delivered via text messaging. Messages are didactic and not tailored to user sexual experience. Additionally, the Text Buddy and G2Genie intervention program components are not available.
61991934|NCT00975533|EXPERIMENTAL|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM. The device is intended to improve glycemic control and induce weight loss.
61991935|NCT00975533|ACTIVE_COMPARATOR|Control|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
61991936|NCT05972538|ACTIVE_COMPARATOR|Group I|patients received ball and socket retained mandibular implant overdentures restoring complete edentulous mandible.
61991937|NCT05972538|EXPERIMENTAL|Group II|patients received cement retained mandibular implant overdentures restoring complete edentulous mandible.
61991938|NCT05952622|NO_INTERVENTION|Standard rehabilitation protocol|Standard rehabilitation after surgical treatment consisting of initial immobilization followed by physiotherapy.
61991939|NCT05952622|ACTIVE_COMPARATOR|Rehabilitation protocol with CPM|Additional treatment of patients with continuous passive motion after initial immobilization for 6 weeks.
61991940|NCT02079688|EXPERIMENTAL|SB011, 2 % (Water/Oil/Water) emulsion of hgd40|"All patients will perform treatment with formulation SB011 containing 2 % hgd40 and the active ingredient-free vehicle. The comparison of the IMPs will be performed intraindividually.~Comparison and random assignment of treatments to two distinct treatment areas (area 1, area 2).~IMP SB011: Topical application of approximately 5 mg/cm2 (250 μl) per treatment area (50 cm2) twice daily on 14 consecutive days, one single last application at the site on Day 15 (29 treatments) daily dosage: Approximately 10 mg hgd40 total dosage: Approximately 145 mg hgd40"
61991941|NCT02079688|PLACEBO_COMPARATOR|Multiple W/O/W formulation, active ingredient-free vehicle|"All patients will perform treatment with formulation SB011 containing 2 % hgd40 and the active ingredient-free vehicle. The comparison of the IMPs will be performed intraindividually.~Comparison and random assignment of treatments to two distinct treatment areas (Area 1, Area 2).~Vehicle: Topical application of approximately 5 mg/cm2 (250 μl) per treatment area (50 cm2) twice daily on 14 consecutive days, one single last application at the site on Day 15 (29 treatments)"
61991942|NCT05965856|EXPERIMENTAL|BL-B01D1 + SI-B003|Participants receive SI-B003 or BL-B01D1+SI-B003 dual therapy in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
61991943|NCT01074164|PLACEBO_COMPARATOR|Control group|This group of subjects will serve as the control group and will follow a standard-of-care treatment regimen for AD, including the use of moisturizers and topical corticosteroids.
61991944|NCT01074164|EXPERIMENTAL|Accu-patch pellet|This group of subjects will follow a standard-of-care treatment regimen for AD, including the use of moisturizers and topical corticosteroids. Additionally, they will use a titanium pellet (accu-patch pellet) to self-apply pressure at the LI11 acupuncture pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times weekly for 1 month.
61991945|NCT06284785||Obese patients|Obese patients with T2D and hyperfiltration that will undergo bariatric surgery
61991946|NCT06284785||Healthy controls|Healthy, lean controls with BMI 20-25
61991947|NCT04922918|EXPERIMENTAL|Probiotic arm|Administration of Ligilactobacillus salivarius MP101 (\>9 log10cfu, daily) for 4 months
61991948|NCT05277246|ACTIVE_COMPARATOR|1% NaOCIL|2 ml of 1% NaOCl solution will be used as irrigation solution at every file change during root canal preperation .2 ml dental injector and 27 gauge thickness dental needle tip will be used for irrigation . The tip of the cannula will be adjusted to reach two-thirds of the working length.
61991949|NCT05277246|ACTIVE_COMPARATOR|2.5% NaOCI|2 ml of 2.5% NaOCl solution will be used as irrigation solution at every file change during root canal preperation .2 ml dental injector and 27 gauge thickness dental needle tip will be used for irrigation . The tip of the cannula will be adjusted to reach two-thirds of the working length.
62387567|NCT04287673|EXPERIMENTAL|UR-RIST|"Group having performed its usual rehabilitation for the first 3 months and then having performed the rehabilitation involving strongly the trunk for the last 3 months.~Before and after each 3-months period, an evaluation of the postural control of the trunk (using the Trunk Control Measurement Scale and a dynamic posturography on an unstable sitting device) and a clinical gait analysis were performed."
62387568|NCT04287673|NO_INTERVENTION|Typically Developing children|Typically developing children who served as a control group in the first assessment (Trunk Control Measurement Scale, dynamic posturography on an unstable sitting device, clinical gait analysis)
62567680|NCT02060058|EXPERIMENTAL|Patients with 32 week therapy|"For non-cirrhotic patients whose response of previous HCV therapy with PEG-IFN/RBV were relapse or partial response, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 (boceprevir+ PEG-IFN/RBV). If HCV RNA is undetectable during 8-24 weeks, boceprevir+PEG-IFN/RBV triple therapy will be administered from week 5 to week 32.~Dosage of drugs: Boceprevir 800mg tid po, PegIntron 1.5 mcg/kg im QW, and Ribavirin 800 to 1400 mg/day PO divided BID Regimen adjusted according to body weight.~Stop trial intervention for patients with 32 week therapy: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm A)."
62387569|NCT02748018|EXPERIMENTAL|Hybrid Closed Loop Arm|The HCL Arm will use the MiniMed System (i.e., using Auto Mode) for 6 months during the study period.
62387570|NCT02748018|ACTIVE_COMPARATOR|Control Arm|The Control Arm will use individual subject's current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump). Each cohort (CSII, MDI, or SAP) will be used as the control arm to be compared to the experimental arm (HCL).
61991950|NCT05277246|ACTIVE_COMPARATOR|5.25% NaOCI|2 ml of 5.25% NaOCl solution will be used as irrigation solution at every file change during root canal preperation .2 ml dental injector and 27 gauge thickness dental needle tip will be used for irrigation . The tip of the cannula will be adjusted to reach two-thirds of the working length.
61991951|NCT01271868|EXPERIMENTAL|IB1001|
61991952|NCT06109584|ACTIVE_COMPARATOR|CVC location with Rx|After placement of the CVC we will perform the X-ray and subsequent verification of the correct location. Simultaneously, a stopwatch will be started to calculate the time interval until the interpretation of the X-ray by the anesthesiologist.
62387571|NCT00650689|EXPERIMENTAL|Ezetimibe + Atorvastatin|
61991953|NCT06109584|ACTIVE_COMPARATOR|CVC location with echocardiography|Cardiac ultrasound will be performed to visualize the correct position of the CVC tip, and the time until the interpretation of the ultrasound results will also be monitored.
61991954|NCT02699203|EXPERIMENTAL|High-carbohydrate meal|High carbohydrate breakfast meal consisting of oatmeal and berries.
61991955|NCT02699203|EXPERIMENTAL|Low-carbohydrate meal|Low carbohydrate breakfast meal consisting of eggs and avocado.
61991956|NCT03462238|OTHER|Kidney transplant patients|Group of renal transplant patients for 24 months
61991957|NCT03462238|OTHER|Dialysis patients|Group of dialysis patients for 24 months
61991958|NCT01083095|ACTIVE_COMPARATOR|3 +/- 1 bite|Volunteers were exposed to mosquito biting for 10 min
61991959|NCT01083095|ACTIVE_COMPARATOR|6 +/- 1 bite|Volunteers were exposed to mosquito biting for 10 min
61991960|NCT01083095|ACTIVE_COMPARATOR|9 +/- 1 bite|Volunteers were exposed to mosquito biting for 15 min
61991961|NCT01049321|EXPERIMENTAL|DASH diet|DASH: Dietary approaches to stop hypertension eating plan
61991962|NCT01049321|PLACEBO_COMPARATOR|Diabetic diet|Diabetic diet: a usual diabetic diet
61991963|NCT02952014|EXPERIMENTAL|C4 Extreme|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 10 mg synephrine, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
61991964|NCT02952014|ACTIVE_COMPARATOR|C4 Extreme (without Advantra Z)|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
61991965|NCT02952014|PLACEBO_COMPARATOR|Placebo|One dose of flavored placebo (powder mixed with water)
62387572|NCT00650689|ACTIVE_COMPARATOR|Atorvastatin|
62387573|NCT06186674||normal|normal persons
62767866|NCT02528357|EXPERIMENTAL|Part 2B: GSK3174998+ pembrolizumab - Cohort expansion|Participants will receive GSK3174998 IV (at one dose level shown to be tolerable in dose escalation of part 2A) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for 2 years or 35 cycles, whichever comes first.
62767867|NCT01883648|EXPERIMENTAL|Coconut Oil Beverage|The treatment will consist of a 1.25 oz serving size taken orally, two times daily by subjects. This treatment arm will last 3 months.
61991966|NCT00729339|ACTIVE_COMPARATOR|1|lansoprazole plus mosapride for the first month, and followed by lansoprazole plus placebo for the second month
61991967|NCT00729339|ACTIVE_COMPARATOR|2|lansoprazole plus placebo for the first month, and lansoprazole plus mosapride for the second month
61991968|NCT02180334|EXPERIMENTAL|Mosapride|"* Mosapride citrate 5 mg (Gasmotin®): 1 tablet (5 mg) will be administered 1 hour before MMTT.~* Linagliptin 5 mg (Trajenta®): 1 tablet (5 mg) per day should be taken for 7 days during run-in period. 1 tablet (5 mg) will be administered 1 hour before MMTT.~* Acetaminophen 500 mg (Tylenol®): 3 tablets (1500 mg) will be administered at once with the mixed meal for calculating gastric emptying time."
61991969|NCT02180334|PLACEBO_COMPARATOR|Control|"* Placebo drug: 1 tablet will be administered 1 hour before MMTT.~* Linagliptin 5 mg (Trajenta®): 1 tablet (5 mg) per day should be taken for 7 days during run-in period. 1 tablet (5 mg) will be administered 1 hour before MMTT.~* Acetaminophen 500 mg (Tylenol®): 3 tablets (1500 mg) will be administered at once with the mixed meal for calculating gastric emptying time."
61991970|NCT04079478||AI|Artificial Intelligence colonoscopy
61991971|NCT04079478||Control|White light colonoscopy
61991972|NCT03001258||PO (program organizers)|"PO (program organizers): Employed by Brac as field level organizers. A two day presbyopia screening training were provided.~A total of eight POs organized eye camps in two sub districts. POs were responsible for identifying the presbyopia patients through screening and SS assisted in organizing and mobilizing the community people for the eye camps, and glass sale (on the spot). Four camps were organized per day for five days by four POs in each sub-district. Thus a total of 40 eye camps were held in two sub districts by eight POs."
61991973|NCT03001258||USS (Upgraded Shashthya Shebika)|"USS (Upgraded Shashthya Shebika): A new caddre of community health workers of Brac. A two day presbyopia screening training were provided.~In this arm, 20 USSs were assigned in two upazillas to run the two camp-day i.e. screening patients and selling glasses during the total 40 eye camps."
61991974|NCT03001258||SS (Shashthya Shebika)|"SS: Community health workers of Brac. A two day presbyopia screening training were provided.~In this arm, the SS, undertook the screening of potential presbyopia cases. A total of 27 SS organized 25 eye camps in eight days in two upazilas."
61991975|NCT03037528|EXPERIMENTAL|Positive Affect, Mindfulness, Tracking|Participants will receive information about positive affect and mindfulness, in addition to being asked to actively track what they eat and receiving the core program
61991976|NCT03037528|EXPERIMENTAL|Mindfulness, Tracking|Participants will receive information about mindfulness, be asked to actively track what they eat, and receive the core program.
61991977|NCT03037528|EXPERIMENTAL|Positive Affect, Tracking|Participants will receive information about positive affect, be asked to actively track what they eat, and receive the core program.
61991978|NCT03037528|EXPERIMENTAL|Tracking|Participants will be asked to actively track what they eat in addition to receiving the core program.
61991979|NCT03037528|EXPERIMENTAL|Positive Affect, Mindfulness|Participants will receive information about positive affect and mindfulness in addition to the core program.
61991980|NCT03037528|EXPERIMENTAL|Positive Affect|Participants will receive information about positive affect in addition to the core program.
61991981|NCT03037528|EXPERIMENTAL|Mindfulness|Participants will receive information about mindfulness in addition to the core program.
62387574|NCT06186674||low back pain|patients with low back pain
62387575|NCT02584660|EXPERIMENTAL|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food, for approximately 69 days for a total treatment duration of 90 days.
62387576|NCT02584660|EXPERIMENTAL|local Standard-of-care|Participants will receive local Standard-of-care as per local protocol and defined by the medical team caring for the participant.
62387577|NCT05157178|EXPERIMENTAL|4 week interval|Administration of two doses of the Covid-19 (recombinante) vaccine, with a 4 week interval between the two doses.
61991982|NCT03037528|EXPERIMENTAL|No Extras|Participants will receive the core program.
61991983|NCT03899948|EXPERIMENTAL|Teacher Anxiety Program for Elementary Students (TAPES)|Teachers in the experimental condition attend a 6-hour training on the TAPES program. The teachers learn to implement a brief intervention (5 meetings) with the student and his or her parent, utilize classroom anxiety-reduction strategies, and apply relationship enhancement strategies to improve the relationship with the target student and parents.
61991984|NCT03899948|ACTIVE_COMPARATOR|Teacher Anxiety Training (TAT)|Teachers in this condition receive training about childhood anxiety and classroom anxiety-reduction strategies using a 3-hour typical teacher professional development training format.
61991985|NCT01395329|ACTIVE_COMPARATOR|Nebivolol|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of Nebivolol. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of nebivolol.
61991986|NCT01395329|ACTIVE_COMPARATOR|Metoprolol|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of Metoprolol. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of Metoprolol.
61991987|NCT01395329|PLACEBO_COMPARATOR|Placebo|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of placebo. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of placebo.
61991988|NCT05687435|EXPERIMENTAL|Changyanning group|Changyanning tablet: Each tablet weighs 0.42g and is taken orally, 4 tablets once and 3 times a day.The course of treatment was 8 weeks.
61991989|NCT05687435|PLACEBO_COMPARATOR|Placebo group|Changyanning tablet placebo: Each tablet weighs 0.42g and is taken orally, 4 tablets once and 3 times a day.The course of treatment was 8 weeks.
61991990|NCT03921931|EXPERIMENTAL|healthy volunteers|light stimulation
61991991|NCT03921931|EXPERIMENTAL|primary open angle glaucoma patients|light stimulation
61991992|NCT03921931|EXPERIMENTAL|age-related macular degeneration patients|light stimulation
61991993|NCT03546751|EXPERIMENTAL|CPAP|This arm will consist of patients with obstructive sleep apnea who will be asked to use CPAP nightly to treat their OSA for six months
61991994|NCT03546751|ACTIVE_COMPARATOR|Diet and Exercise|This arm will consist of patients with obstructive sleep apnea who will be asked to engage in dietary management and regular exercise for six months.
61991995|NCT03943563|OTHER|single cohort|"There is only one cohort where each patient experiment the classic sequences as the standard of care and the DIXON sequences for the study."
61991996|NCT02276872|EXPERIMENTAL|Cohort 1 (Transitioning from Parental)|Transitioned from IV or SC Remodulin to oral treprostinil
61991997|NCT02276872|EXPERIMENTAL|Cohort 2 (Transitioning from Inhaled)|Transitioned from inhaled prostacyclin to oral treprostinil
61991998|NCT02276872|EXPERIMENTAL|Cohort 3 (Add-on to Current PAH Therapy)|Treated with oral treprostinil as a de novo add-on to current PAH therapy
61991999|NCT05492669|EXPERIMENTAL|Lidocaine group|General anesthesia is induced in the lidocaine group with intravenous lidocaine 1.5mg/kg for ten minutes, followed by continuous injection of lidocaine 1.5mg/kg.h. At the end of the operation, the patient controlled intravenous analgesia with lidocaine is used, and the dose of lidocaine is 30mg/kg(no more than 2000mg at most).
61992000|NCT05492669|PLACEBO_COMPARATOR|Conventional analgesia group|The lidocaine is replaced by identical volumes and rates of 0.9% saline. At the end of the operation, the patient controlled intravenous analgesia without lidocaine is used.
61992001|NCT02071355|EXPERIMENTAL|Group 1|Participants will receive 100 mg TMC435 once daily for 7 days.
62559772|NCT02690831|EXPERIMENTAL|IMT + Manual Therapy and Motor Control Exercise|"The protocol for this group is identical to the previous group with the sole difference that is added a manual therapy (MT) and a motor control exercises (MCE). The MT protocol was performed for 15min, whereas the MCE was 10min. Below it described both protocols:~1. - MT:~   * Upper cervical region mobilization in flexion~  * Lower cervical postero-anterior mobilization + maintained traction~  * Costovertebral joint postero-anterior mobilization~  * Thrust dorsal~  * Cervical postero-anterior mobilization~2. - MCE:~   * Isometric contraction of the deep neck flexors.~  * Isometric contraction of the neck extensors.~  * Neural self-mobilization.~  * Cervical retraction with theraband.~  * Sphinx.~  * Scapular adduction exercises in prone.~  * Scapular adduction exercises in sitting position with theraband."
61992002|NCT02071355|EXPERIMENTAL|Group 2|Participants will receive 150 mg TMC435 once daily for 7 days.
61992003|NCT02212587|EXPERIMENTAL|TOBI Podhaler|
61992004|NCT02245789|ACTIVE_COMPARATOR|Macintosh laryngoscope|Tracheal intubation will be performed using a Macintosh laryngoscope. All patients will received propofol and remifentanil anesthesia.
61992005|NCT02245789|EXPERIMENTAL|McGrath Mac videolaryngoscope|Tracheal intubation will be performed using a McGrath Mac videolaryngoscope. All patients will received propofol and remifentanil anesthesia.
61992006|NCT05603923|ACTIVE_COMPARATOR|Group 1: Lumen Coached Group|Participants in this group will attend an Intervention Orientation session to receive the Coach Lumen tutorial, a study iPad, and a Lumen Intervention Workbook. They will complete 8 PST sessions with Coach Lumen using their study assigned iPad at home over 12 weeks. The first 4 sessions occur weekly and then the last 4 occur every other week. Participants will receive automated reminders on the day before and on the day of their scheduled session, and have the opportunity to reschedule sessions through the iPad. Participants will work with Coach Lumen to learn problem-solving skills to address current life challenges, plan activities, and complete home activities. Participants will also complete surveys before and after each PST session: a mood assessment survey before and a user experience survey after. At the end of study, Participants may be invited to provide their perspective regarding their Lumen use experience.
62387578|NCT05157178|EXPERIMENTAL|8 week interval|Administration of two doses of the Covid-19 (recombinante) vaccine, with a 8 week interval between the two doses.
61992007|NCT05603923|ACTIVE_COMPARATOR|Group 2: Human Coached Group|Participants in this group will receive a study iPad and Human-Coached Intervention Workbook and will complete the first of 8 PST sessions in person with a trained health coach. Participants' first PST session will be in person for approximately 1 hour. Participants will complete the remaining sessions remotely via Zoom (or by phone, if necessary) using their study iPad. The first 4 sessions occur weekly and then the last 4 occur every other week. Participants will receive automated reminder notifications on the day before and on the day of their scheduled session, and have the opportunity to reschedule sessions with their coach. Participants will also complete a mood assessment survey at the beginning of each PST session. Participants will work with their health coach to learn problem-solving skills to address current life challenges, plan activities, and complete home activities.
61992008|NCT05603923|PLACEBO_COMPARATOR|Group 3: Optional (Delayed) Lumen Coached Group|Participants assigned to this group can choose to attend a Lumen Orientation session to receive training and a study iPad to complete 8 PST sessions with Coach Lumen after their follow-up assessment at 18 weeks. They will receive 8 Sunday mood assessment surveys to complete (4 every Sunday and then 4 every other Sunday).
61992009|NCT01485562|ACTIVE_COMPARATOR|Misoprostol|women who experience a PPH will be randomized to receive 800 misoprostol (four tablets of 200 mcg administered sublingually)
61992010|NCT01485562|PLACEBO_COMPARATOR|placebo|women who experience a PPH will be randomized to receive 4 placebo tablets administered sublingually
61992011|NCT02107599|EXPERIMENTAL|Physician Readers|Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir(18F) as part of this study.
62767868|NCT01883648|PLACEBO_COMPARATOR|Placebo Beverage|The treatment will consist of a 1.25 oz serving size taken orally, two times daily by subjects.This will similar in look and taste but not have the same ingredients of the actual coconut oil beverage. This treatment arm will last 3 months.
61992012|NCT05310110|EXPERIMENTAL|10% lidocaine spray and cisatracurium group|The subjects received laryngeal local anesthetics (10% lidocaine spray), intravenous cisatracurium 0.12 mg/kg, and propofol before laryngeal mask airway placement. The predetermined dosage of propofol for the first subject is 1 mg/kg.
61992013|NCT05310110|EXPERIMENTAL|10% lidocaine spray and placebo of cisatracurium group|The subjects received laryngeal local anesthetics (10% lidocaine spray), intravenous normal saline as a substitute for cisatracurium, and propofol before laryngeal mask airway placement. The predetermined dosage of propofol for the first subject is 1.25 mg/kg.
61992014|NCT05310110|EXPERIMENTAL|Placebo of lidocaine spray and cisatracurium group|The subjects received normal saline spray as a substitute for laryngeal local anesthetics (10% lidocaine spray), intravenous cisatracurium 0.12 mg/kg, and propofol before laryngeal mask airway placement. The predetermined dosage of propofol for the first subject is 1 mg/kg.
61992015|NCT05310110|PLACEBO_COMPARATOR|Placebo group|The subjects received normal saline spray as a substitute for laryngeal local anesthetics (10% lidocaine spray), intravenous normal saline as a substitute for cisatracurium, and propofol before laryngeal mask airway placement. The predetermined dosage of propofol for the first subject is 2 mg/kg.
61992016|NCT05628077||PAIN|
61992017|NCT05628077||NO PAIN|
61992018|NCT06372847|OTHER|Receiving hypoglossal nerve stimulation (HNS)|All included patients will be part of this arm. Patients who are eligible for HNS-therapy for obstructive sleep apnea (OSA) will be invited to participate in the study. Data from the baseline PSG and baseline DISE as part of the standard pathway for HNS-eligibility will be accessed and collected. All patients will undergo HNS-implantation and receive HNS-therapy as part of the standard pathway. After one year of treatment, information from the one-year follow-up PSG as part of the standard pathway will be collected. Furthermore, patients will undergo an additional one-year follow-up DISE.
61992019|NCT05795426||Female volleyball players|Female volleyball players were included in the first group.
61992020|NCT05795426||Male volleyball players|Male volleyball players are included in the second group
61992021|NCT03664752|EXPERIMENTAL|IDP-120 Gel|IDP-120 Gel, once-daily application
61992022|NCT03664752|PLACEBO_COMPARATOR|IDP-120 vehicle gel|IDP-120 vehicle gel, once daily application
61992023|NCT02417012|EXPERIMENTAL|U-TURN intervention|"The intervention group will receive an intensive lifestyle intervention including partly supervised aerobic and strength exercise, diet plans and counseling by clinical dietitians. All exercise will be supervised initially and the supervision will be reduced gradually across the 12-month intervention. Additionally, the participants will be offered educational classes on implementation of a healthy lifestyle and diabetes education and support by trained nurses.~Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines."
61992024|NCT02417012|ACTIVE_COMPARATOR|Standard care|"The reference group will receive diabetes education and support by trained nurses.~Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines."
61992025|NCT02251951|EXPERIMENTAL|nab-Paclitaxel|Abraxane
61992026|NCT05442528||Experimental: FIX replacement therapy.|Subject's previous treatment plan will be followed
61992027|NCT03046199|NO_INTERVENTION|Control|
61992028|NCT03046199|EXPERIMENTAL|Questionnaire|
61992029|NCT03046199|EXPERIMENTAL|Coordination|
61992030|NCT03046199|EXPERIMENTAL|Questionnaire + coordination|
61992031|NCT01575184|EXPERIMENTAL|Shoulder traction|The ultrasonographic measurements with shoulder traction
62767869|NCT03546218|EXPERIMENTAL|Smartphone Application (SPSRS)|Participants watch motion picture using an application that displays positive-word stimuli.
62767870|NCT03546218|ACTIVE_COMPARATOR|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
62767871|NCT03759964|ACTIVE_COMPARATOR|Ferric Carboxymaltose group|Ferric carboxymaltose group will receive 1g of Ferric carboxymaltose at day 1 following cardiac surgery
61992032|NCT01575184|ACTIVE_COMPARATOR|No traction|The ultrasonographic measurements without shoulder traction
61992033|NCT02932904|EXPERIMENTAL|Vortioxetine 10 mg|Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
62387579|NCT05157178|ACTIVE_COMPARATOR|12 week interval|Administration of two doses of the Covid-19 (recombinante) vaccine, with a 12 week interval between the two doses.
62387580|NCT00556283|EXPERIMENTAL|1|STARR
62387581|NCT00556283|ACTIVE_COMPARATOR|2|Biofeedback
62387582|NCT03163290|EXPERIMENTAL|Posterolateral Hip Complex Exercises|The intervention protocol will be composed of: Heating, lower limb stretching, strengthening the quadriceps, and hip abductors, lateral rotators and extensors. Posterolateral Hip Complex Exercises add extension knee in open kinetic chain, squat , abduction exercise, Clam exercise and external rotation exercise. Physiotherapy treatment sessions will last for an average of one hour, twice a week, for a period of six weeks.
62387583|NCT03163290|ACTIVE_COMPARATOR|Anteromedial Hip Complex Exercises|The intervention protocol will be composed of: Heating, lower limb stretching, strengthening the quadriceps, and hip aductors, medial rotators and flexors. Anteromedial Hip Complex Exercises add extension knee in open kinetic chain, squat ,hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise. Physiotherapy treatment sessions will last for an average of one hour, twice a week, for a period of six weeks.
62767872|NCT03759964|PLACEBO_COMPARATOR|Placebo group|Placebo group will receive 100 mL of IV isotonic serum saline at day 1 following cardiac surgery
62767873|NCT05661266||Single cohort of MS patients with EDSS 0-8.0|Confirmed diagnosis of MS with an EDSS score ranging from 0 and 8.0.
61992034|NCT02932904|EXPERIMENTAL|Vortioxetine 20 mg|Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 1 week followed by vortioxetine 20 mg, overencapsulated tablets, orally, once daily from Week 2, up to 4 weeks.
62767874|NCT02641522|EXPERIMENTAL|Post-Infusion|Single infusion of siltuximab (11 mg/kg)
62767875|NCT00936078||Non-donors/controls|Healthy normotensive people who have not donated a kidney including relatives or friends of the donor, or candidates who were ineligible to donate due to blood group or cross-match incompatibility. These non-donor/controls must meet all screening criteria (same as standard criteria donors).
62767876|NCT00936078||Living Kidney Donors|"Living kidney donors who went on to donate their kidney. All donors were recruited and are divided into 2 groups:~1. Standard criteria donors (meet all screening criteria)~2. Expanded-criteria donors (did not meet one or more of the screening criteria)~Expanded criteria donors will be examined in a separate protocol and analysis."
62767877|NCT04667416|NO_INTERVENTION|Standard of Care (SOC)|Participants will receive SOC for chronic ulcers of the lower extremities.
62767878|NCT04667416|EXPERIMENTAL|PalinGen Flow Treatment plus SOC|Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.
62767879|NCT01035346|EXPERIMENTAL|A|
62767880|NCT01035346|PLACEBO_COMPARATOR|B|
62767881|NCT04660721|EXPERIMENTAL|sFilm-FS|
62767882|NCT04660721|ACTIVE_COMPARATOR|TACHOSIL®|
62767883|NCT04323293|EXPERIMENTAL|CPM - Cold Water Bath|
62767884|NCT04323293|SHAM_COMPARATOR|CPM - SHAM|
61992035|NCT02932904|ACTIVE_COMPARATOR|Paroxetine 20 mg|Paroxetine 20 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
61992036|NCT02932904|PLACEBO_COMPARATOR|Placebo|Vortioxetine placebo matching-capsules, orally, once daily for up to 5 weeks.
61992037|NCT04344314|OTHER|Small gauge arm|2 PIVCs of same gauge (22G) and different lengths
61992038|NCT04344314|OTHER|Large gauge arm|2 PIVCs of same gauge (20G) and different lengths
61992039|NCT01166828|EXPERIMENTAL|1|The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
61992040|NCT01166828|ACTIVE_COMPARATOR|2|TAC participants will have six phone contacts every other week for three months.
61992041|NCT01120613|EXPERIMENTAL|chronotherapy|Patients identified with Nocturnal Hypertension, will have one of the blood pressure medications switched from daytime dosing to nighttime dosing
61992042|NCT01388075|EXPERIMENTAL|Rifampicin|Consecutive treatments with rifampicin and placebo
61992043|NCT05836207|EXPERIMENTAL|Abstinence-focused Contingency Management (CM)|Youths receive 12 weeks of outpatient abstinence-focused CM consisting of providing incentives for cannabis abstinence, based on twice-weekly rapid test urinalysis.
62387584|NCT04047342||Standard welcome email|The standard welcome email mentions the benefits of enrollment (maintaining good health and saving money on insurance premiums), the average premium savings, the ease of the registration process, and the deadline for registering and having health measures on file, plus it provides registration steps and hyperlinks for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location.
62387585|NCT04047342||Loss frame email|"The loss frame email recommends that GHP members not throw away a precise dollar amount in savings (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action.~This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction."
61992044|NCT05836207|ACTIVE_COMPARATOR|Cognitive Behavioural Therapy (CBT)|Youths receive 12 weeks of outpatient usual care CBT consisting of once-weekly 60-minute sessions according to the standard CBT youth protocol by a trained psychologist.
61992045|NCT01652664|EXPERIMENTAL|Travoprost|Travoprost 0.004% PQ ophthalmic solution, 1 drop administered in each eye in the evening with travoprost vehicle administered once daily in the morning for 3 months
61992046|NCT01652664|ACTIVE_COMPARATOR|Timolol|Timolol, 0.5% or 0.25% ophthalmic solution, 1 drop administered in each eye twice daily (once in the morning and once in the evening) for 3 months
61992047|NCT00006294||Chlorthalidone|Participants will take chlorthalidone at recommended doses to control hypertension
61992048|NCT00006294||Amlodipine|Participants will take Amlodipine at recommended doses to control hypertension
61992049|NCT00006294||Lisinopril|Participants will take Lisinopril at recommended doses to control hypertension
61992050|NCT00006294||Doxazosin|Participants will take Doxazosin at recommended doses to control hypertension
61992051|NCT05378620|OTHER|Project Dulce + Dulce Digital|Patients will participate in a peer-led group diabetes self-management education and support program and receive ongoing support via text messages designed to improve knowledge, health beliefs, self-management behaviors and clinical outcomes.
61992052|NCT04172441|EXPERIMENTAL|dasiglucagon first then placebo|48 hours of dasiglucagon subcutaneous (sc) infusion starting at 10 µg/hour with crossover to 48 hours placebo sc infusion (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
61992053|NCT04172441|EXPERIMENTAL|placebo first then dasiglucagon|48 hours of placebo sc infusion with crossover to 48 hours dasiglucagon sc infusion starting at 10 µg/hour (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
62387586|NCT00917553|EXPERIMENTAL|doxycycline monohydrate|
61992054|NCT01609920|EXPERIMENTAL|Gadofosveset MRL|
61992055|NCT04287504||Yeast, control|Women negative for vulvovaginal candidosis on Gram stain smear.
61992056|NCT04287504||Yeast, study group|Women positive for vulvovaginal candidosis on Gram stain smear.
62387587|NCT00917553|PLACEBO_COMPARATOR|Placebo|Placebo
62767885|NCT01573481|ACTIVE_COMPARATOR|Pressure support ventilation|"Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure support ventilation mode. The level of the pressure support is the same as the previous day.~During the day (9 AM to 10 PM), patients are ventilated with pressure support ventilation (the level of pressure support is progressively decreased)."
61992057|NCT04287504||Bacterial vaginosis, control|Women negative for bacterial vaginosis on Gram stain smear.
61992058|NCT04287504||Bacterial vaginosis, study group|Women positive for bacterial vaginosis on Gram stain smear.
61992059|NCT05216874|EXPERIMENTAL|Occlusal stabilization splint|Skeletal class III laterognathia surgery patients who has occlusal stabilization splint thearapy for at least 2 mounths before surgery
61992060|NCT05216874|NO_INTERVENTION|Control|Skeletal class III laterognathia surgery patients did not have occlusal stabilization splint thearapy
61992061|NCT05066971|EXPERIMENTAL|Participants in gradual self-adjustment rate control medication|Patients receive a weekly simplified version of the information transmitted by the HM system. In the first 3 months, using that information, the physician changes or not the rate control medication posology (i.e. if the mean heart rate is 60bpm, betablocker dose is cut to half, and another heart rate evaluation is done a week later, and if heart rate is now 120bpm the dose is increased to a 3/4 of the initial dose, and so on). After those three initial months where physician guide titration, the patient is allowed to make self-adjustment of their medication accordingly to the information received (i.e. increasing or decreasing their rate control medication depending on heart rates and activity hours per day.
61992062|NCT01571206|ACTIVE_COMPARATOR|CT-P13|infliximab
62387588|NCT01567280||Controlled patients|Asthmatic patients with controlled asthma (according to ACQ score)
62387589|NCT01567280||Partly controlled/Uncontrolled patients|Patients with partly controlled or uncontrolled asthma (according to ACQ score)
61992063|NCT03146442|ACTIVE_COMPARATOR|Normal Protein (NP) Breakfast|The participants in the NP Breakfast group will be provided with NP Breakfasts to consume, at home, between 6:00-9:00 am each day over the 6-month intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The energy content of the breakfast meals is \~18% of daily energy intake estimated from the energy expenditure equations specific for adolescents ages 13-19y. The NP breakfasts will be 11% protein (10g protein), 63% CHO, and 26% fat. The types of protein incorporated within the NP and HP meals will include a combination of animal (egg, dairy, animal tissue) and plant-based proteins (soy, pea, gluten). An 8-d breakfast rotation will occur throughout the 6 months.
61992064|NCT03146442|EXPERIMENTAL|High Protein (HP) Breakfast|The participants in the HP Breakfast group will be provided with HP Breakfasts to consume, at home, between 6:00-9:00 am each day over the 6-month intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The energy content of the breakfast meals is \~18% of daily energy intake estimated from the energy expenditure equations specific for adolescents ages 13-19y. The HP breakfasts will be 34% protein (30g protein), 40% CHO, and 26% fat. The types of protein incorporated within the HP and HP meals will include a combination of animal (egg, dairy, animal tissue) and plant-based proteins (soy, pea, gluten). An 8-d breakfast rotation will occur throughout the 6 months.
61992065|NCT03146442|PLACEBO_COMPARATOR|Breakfast Skipping (BS)|The participants in the BS group will continue to skip breakfast each day over the 6-month intervention. They will have nothing to eat or drink (besides water) until 11 am.
61992066|NCT03827278|EXPERIMENTAL|HIV Negative Host talaromyces using Voriconazole|Voriconazole On the first day, 6 mg/kg bid was given, and then 4 mg/kg bid was given intravenously for 6 days, and then oral voriconazole 200 mg bid was administered to maintain treatment for at least 6 months.
61992067|NCT03827278|EXPERIMENTAL|HIV Negative talaromyces AMB Sequential Itraconazole|Amphotericin B (AMB) sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until cluster of differentiation 4 (CD4+ T) cells are greater than 100 cells/L for at least 6 months
61992068|NCT03531216|ACTIVE_COMPARATOR|Topical application of rosemary oil|Rosemary essential oil (10% )
61992069|NCT03531216|PLACEBO_COMPARATOR|Placebo|Pharmaceutical quality olive oil
62387590|NCT05502276|ACTIVE_COMPARATOR|Endoscopic Submucosal Dissection (ESD)|The Endoscopic Submucosal Dissection (ESD) procedures will be performed with the devices commonly used at the Services of Endoscopy of the Centers participating in the study. There are several models of knives on the market, produced by different companies, all considered equally effective by international guidelines.
62387591|NCT05502276|EXPERIMENTAL|Endoscopic Full-Thickness Resection (EFTR)|"The FTRD® (Full Thickness Resection Device; Ovesco Endoscopy, Tübingen, Germany) is the only over-the-scope device designed to undergo Endoscopic Full-Thickness Resection (EFTR) using a clip-and-cut technique. It consists of a 14 mm modified over-the-scope-clip (OTSC) mounted on the outside of a 23 mm cap, which has a preloaded 13 mm monofilament loop at the end. This device received the CE mark for the lower digestive tract in September 2014 and its efficacy and safety have been evaluated in preclinical studies and clinical trials."
62387592|NCT06366035|NO_INTERVENTION|Treatment as Usual (TAU)|Mothers receiving treatment as usual (TAU) at the postpartum health care facilities according to standard guideline from period of delivery up to 6 weeks postpartum
62567681|NCT02060058|EXPERIMENTAL|Patients with 48 weeks therapy|"For non-cirrhotic patients whose response of previous HCV therapy with PEG-IFN/RBV were relapse or partial response, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 (boceprevir+ PEG-IFN/RBV). If HCV RNA is detectable at week 8 and undetectable at week 24, boceprevir+ PEG-IFN/RBV triple therapy will be administered from week 5 to week 32, followed by additional 12 weeks of PEG-IFN/RBV therapy.~Dosage of drugs: as Patients with 32 week therapy Stop trial intervention for patients with 48 weeks therapy: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm B)."
62767886|NCT01573481|ACTIVE_COMPARATOR|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate \> or equal to 12 breath per min). During the day (9 AM to 10 PM), patients are ventilated with pressure support ventilation (the level of pressure support is progressively decreased).
62767887|NCT02578342||Healthy volunteers|healthy volunteer between age of 20 to 55 will undergo MRI examination.
62767888|NCT02578342||ADHD subjects without medication|Medication-naive subjects with ADHD (20-55 years) will undergo MRI examination.
62767889|NCT02578342||ADHD subjects with medication|Subjects with ADHD (20-55 years), under medication will undergo MRI examination.
61992070|NCT01005004|EXPERIMENTAL|HuCNS-SC cells|Intracerebral implantation of HuCNS-SC via direct injection during surgery
61992071|NCT03806920|ACTIVE_COMPARATOR|Intervention A|"Nutritional intervention in healthy subjects and T2DM subjects:~Accompanying a carbohydrate based breakfast, participants ingest either 50 g sucrose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
62387593|NCT06366035|EXPERIMENTAL|Treatment as Usual & LoVE4MUM phone application|Mothers receiving treatment as usual (TAU) and LoVE4MUM phone application from period of delivery up to 6 weeks postpartum
62387594|NCT04606810|ACTIVE_COMPARATOR|Arm1, Participants received the multidisciplinary educational intervention at baseline|Participants in arm1 received the usual care plus the multidisciplinary educational intervention consisting of an educational DVD followed by a teleconference at baseline.
62387595|NCT04606810|OTHER|Arm2, Participants in arm2 received the educational intervention after 3 months|Participants in group 2 first received usual care, and after 3 months were offered the multidisciplinary educational intervention.
62387596|NCT01914042|EXPERIMENTAL|Morphine|Morphine in changing dosages (range between 10-60 mg twice a day). Opioid titration proceeds as follows: starting at an oral dose of 10 mg twice per day, followed every 5 days by a dose increase of 10 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 120 mg per day had been reached.
62387597|NCT01914042|ACTIVE_COMPARATOR|Milnacipran|Milnacipran (Ixel)- a serotonin-norepinephrine reuptake inhibitor (SNRI), will be administrated in changing dosages (range between 12.5-75 mg twice daily). SNRI titration proceeds as follows: starting at an oral dose of 12.5 mg twice per day, followed every 5 days by a dose increase of 12.5 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 150 mg per day had been reached.
62387598|NCT01230489|NO_INTERVENTION|Standard Care|This group will undergo the current standard of care for post operative exit sites at the involved institutions. This group will act as the control or the group to which the interventional group will be compared too.
62387599|NCT01230489|EXPERIMENTAL|MediHoney|This study group will have the dry 2 x 2 dressing replaced with a honey 2 x 2 dressing. Additionally all indentations in the exit site wound will be filled with honey ointment prior to the application of the dressing.
62387600|NCT00499733|EXPERIMENTAL|Intervention|Participant will receive one time intravenous infusion of cyclophosphamide three days after scheduled cryoablation surgery.
62387601|NCT05916794|EXPERIMENTAL|: Modified Cervical Retraction Exercises (MCRE)|The patient is in sitting OR standing position and faces the physical therapist. The MCRE program consisted of alternating head positions. Hold each position for 20 sec with 8 to 10 repetitions
62387602|NCT05916794|EXPERIMENTAL|Motor Control therapeutic exercise(MCTE)|The MCTE will used is based on retraining the cervical muscles and included four exercises
62387603|NCT00986817|EXPERIMENTAL|Terlipressin|
62387604|NCT00986817|PLACEBO_COMPARATOR|Placebo|
62387605|NCT01005875|EXPERIMENTAL|Radiation followed by Sorafenib|Radiation therapy, stereotactic body radiation therapy followed by Sorafenib
62387606|NCT05273203|EXPERIMENTAL|Control|No intervention. Participated only in measurements at baseline and at 6 months.
62387607|NCT05273203|EXPERIMENTAL|FIM-1|Participated in a supervised 6 months football training program once per week and in measurements at baseline and at 6 months.
62387608|NCT05273203|EXPERIMENTAL|FIM-2|Participated in a supervised 6 months football training program twice per week and in measurements at baseline and at 6 months.
62387609|NCT05273203|EXPERIMENTAL|FIM-3|Participated in a supervised 6 months football training program thrice per week and in measurements at baseline and at 6 months.
62387610|NCT03797391|EXPERIMENTAL|Dose Escalation-Part 1, Expansion-Part 2|"In part 1, escalating dose cohort, patients will receive intravenous infusions of EMB-01 weekly (QW). The duration of each treatment cycle is 28 days (4 weeks). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at the recommended Phase II dose (RP2D) regimen(s) once weekly. The duration of each treatment cycle is 28 days (4 weeks)."
62387611|NCT04787146||Patients|"From Monday to Friday, the study will be offered to patients selected consecutively and who have fallen within the previous 24 hours (between 7.55 a.m. the day before and 7.55 a.m. the next day).~After delivery of the written information note to the patient, the investigating physician answers the patient's questions and accepts his non-objection. The patient should be given sufficient time to think things through to make the decision to participate in the study.~Its non-opposition will be traced in the computerized medical file created on the day of its inclusion in the protocol. Each patient participating in the study retains the possibility of participating simultaneously in another research. No exclusion period is provided for in the protocol."
62387612|NCT05870891|EXPERIMENTAL|Peanut Butter Cereal|Consumption of Peanut Butter Cereal
62387613|NCT05870891|EXPERIMENTAL|Cinnamon Almond Cereal|Consumption of Cinnamon Almond Cereal
62387614|NCT05870891|EXPERIMENTAL|Sriracha Crisps|Consumption of Sriracha Crisps
61992072|NCT03806920|ACTIVE_COMPARATOR|Intervention B|"Nutritional intervention in healthy subjects and T2DM subjects:~Accompanying a carbohydrate based breakfast, participants ingest either 50 g palatinose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
61992073|NCT03806920|ACTIVE_COMPARATOR|Intervention C|"Nutritional intervention in healthy subjects:~Accompanying a protein-based breakfast, participants ingest either 50 g sucrose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
61992074|NCT03806920|ACTIVE_COMPARATOR|Intervention D|"Nutritional intervention in healthy subjects:~Accompanying a protein-based breakfast, participants ingest either 50 g isomaltulose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
61992075|NCT04174911|EXPERIMENTAL|BOL-DP-o-08|BOL-DP-o-08
61992076|NCT04174911|PLACEBO_COMPARATOR|Placebo|Placebo
61992077|NCT01743287|EXPERIMENTAL|Imotun capsule|Imotun capsule: 300.03mg/cap, orally, 1 capsule once a day during 24 weeks
61992078|NCT01743287|PLACEBO_COMPARATOR|Imotun capsule placebo|Imotun capsule Placebo: Placebo 1 capsule once a day during 24 weeks
61992079|NCT06396832||Patients undergoing gastric sleeve surgery with omentopexy|Omentopexy aims to prevent or reverse sleeve gastrectomy complications, but it is not a standardized technique by itself, with more than 5 descriptions of it. Among the authors who have presented their technique are Sharma, Batman, Pilone, Abou Ashour, Nosrati, and Labib. It consists of fixing the remnant stomach with the gastrosplenic and gastrophrenic ligaments to stabilize the posterior aspect of the stomach and prevent gastric torsion, a functional cause of stenosis
61992080|NCT06396832||Patients undergoing conventional sleeve gastrectomy|The procedure is associated with other complications, some of which are believed to be related to loss of fixation of the stomach to the greater omentum. Among the main ones is nausea, exacerbation or onset of symptoms due to reflux, as well as intolerance to certain foods and regurgitation
61992081|NCT01777204||Tacrolimus|Influence of tacrolimus on gastrointestinal transit and motility in renal transplant recipients.
61992082|NCT01777204||Cyclosporine|Influence of cyclosporine on gastrointestinal transit and motility in renal transplant recipients.
61992083|NCT01777204||Mycophenolate mofetil|Influence of mycophenolate mofetil on gastrointestinal transit and motility in renal transplant recipients.
61992084|NCT01777204||Mycophenolate sodium|Influence of mycophenolate sodium on gastrointestinal transit and motility in renal transplant recipients.
61992085|NCT01777204||Everolimus|Influence of everolimus on gastrointestinal transit and motility in renal transplant recipients.
61992086|NCT01777204||Sirolimus|influence of sirolimus on gastrointestinal transit and motility in renal transplant recipients.
61992087|NCT01777204||Without immunosuppression|Gastrointestinal transit and motility in healthy volunteers.
61992088|NCT00802412|OTHER|Topiramate|The subjects for the proposed study will be 180 currently smoking, treatment-seeking male veterans with alcohol and nicotine dependence. Ninety subjects will be randomized to the topiramate arm and 90 subjects will be randomized to the placebo group.
61992089|NCT00802412|PLACEBO_COMPARATOR|Placebo|90 participants, will receive matching placebo
61992090|NCT05296785|OTHER|Participants|patients undergoes intramedullary nail with Limb Reconstruction System
61992091|NCT04241497|EXPERIMENTAL|Patients with Pulmonary Arterial Hypertension|12 weeks home-based rehabilitation
61992092|NCT04932785|ACTIVE_COMPARATOR|Regular Diet|Patient randomized to regular diet will begin with a regular diet.
61992093|NCT04932785|ACTIVE_COMPARATOR|Clear Liquid Diet|Patient randomized to clear liquid diet will begin with a clear liquid diet.
61992094|NCT00642668|EXPERIMENTAL|Methoxy Polyethylene Glycol-Epoetin Beta|Participants received methoxy polyethylene glycol-epoetin beta treatment monthly for 36 weeks with an efficacy evaluation period (EEP) during weeks 29-36 and followed by a 4 week follow-up period.
61992095|NCT02541071|EXPERIMENTAL|Yohimbine and Stress Film|Administration of 10mg yohimbine before the trauma film.
61992096|NCT02541071|EXPERIMENTAL|Placebo and Stress Film|Administration of placebo before the trauma film.
62387615|NCT05870891|EXPERIMENTAL|Cheddar Crisps|Consumption of Cheddar Crisps
62387616|NCT05870891|EXPERIMENTAL|Almond Blueberry Butter Bar|Consumption of Almond Blueberry Butter Bar
62387617|NCT05870891|EXPERIMENTAL|Peanut Butter and Dark Chocolate Bar|Consumption of Peanut Butter and Dark Chocolate Bar
62387618|NCT05870891|EXPERIMENTAL|Almond Dark Chocolate Bar|Consumption of Almond Dark Chocolate Bar
62387619|NCT05870891|EXPERIMENTAL|White Bread 5 g available carbohydrate|Consumption of white bread containing 5 g available carbohydrate
62387620|NCT05870891|ACTIVE_COMPARATOR|White Bread 20 g available carbohydrate|Consumption of white bread containing 20 g available carbohydrate
62559773|NCT01987440|EXPERIMENTAL|Lubricating Gel|The speculum was warmed, and patients were informed about what was going to happen. The labia were spread from below to introduce the speculum, which was inserted at a 45-degree angle pointing downward then rotated horizontally as the insertion continued. A VAS score (insertion) was obtained at this point. Next, the bill of the speculum was opened up until the vaginal cuff could be seen, and the speculum was secured by turning the thumbnut. A second VAS score (dilation) was recorded. During speculum examination, cervical smear with cervical brush was obtained for pathologic assessment if necessary. The speculum was withdrawn slightly, which allowed the bill to close together, and at this stage (extraction) the final VAS score was obtained. In the gel group , a doctor placed 6,5 mL mL sterile lubricating gel on the top and bottom blades of the speculum. Length of the vagina was measured by the index finger.
61992097|NCT02541071|EXPERIMENTAL|Clonidine and Stress Film|Administration of 0.15mg clonidine before the trauma film.
61992098|NCT03935633|EXPERIMENTAL|First Dosage|The dose of CN128 is 20 mg/kg bw， bid.
61992099|NCT03935633|EXPERIMENTAL|Second Dosage|The dose of CN128 is 15 mg/kg bw， bid.
61992100|NCT02723149|EXPERIMENTAL|Approach Avoidance Training Condition|The AAT group will push away the joystick from marijuana pictures 90% of the trials and pull towards the marijuana pictures 10% of the trials.
61992101|NCT02723149|SHAM_COMPARATOR|Sham Condition|The sham group will undergo the same procedures, except the ratio for marijuana pictures will be 50% push and 50% pull.
61992102|NCT03780842|EXPERIMENTAL|Invasive NAVA ventilation|A titration protocol will be used for changing NAVA levels in intubated newborns
61992103|NCT03780842|EXPERIMENTAL|Non-invasive NAVA ventilation|A titration protocol will be used for changing NAVA levels in newborns with non-invasive NAVA ventilation (= with a nasal interface).
61992104|NCT02621814|EXPERIMENTAL|Experimental 1|Formula feeding
61992105|NCT02621814|EXPERIMENTAL|Experimental 2|Formula feeding
61992106|NCT00903617|EXPERIMENTAL|Part A Treatment A|5 mg of GSK256073
61992107|NCT00903617|EXPERIMENTAL|Part A Treatment B|50 mg of GSK256073
61992108|NCT00903617|EXPERIMENTAL|Part A Treatment C|150 mg of GSK256073
61992109|NCT00903617|PLACEBO_COMPARATOR|Part A Treatment D|placebo
61992110|NCT00903617|PLACEBO_COMPARATOR|Part B Treatment A|placebo
61992111|NCT00903617|ACTIVE_COMPARATOR|Part B Treatment B|1500 mg Niaspan
61992112|NCT00903617|EXPERIMENTAL|Part B Treatment C|x mg dose of GSK256073 based on data from Part A
61992113|NCT00903617|EXPERIMENTAL|Part B Treatment D|optional dose of GSK256073 based on data from Part A
61992114|NCT02855749|NO_INTERVENTION|landmark group|percutaneous tracheostomy with traditional landmark technique
61992115|NCT02855749|ACTIVE_COMPARATOR|ultrasound-guided long axis group|percutaneous tracheostomy will be implemented In the real-time ultrasound-guided in plane technique
61992116|NCT02855749|ACTIVE_COMPARATOR|ultrasound-guided short axis group|percutaneous tracheostomy will be implemented In the real-time ultrasound-guided out of plane technique
61992117|NCT00699556|EXPERIMENTAL|patch+spray|Within subject design. All volunteers complete two laboratory sessions. In one session they receive nicotine patch + nicotine nasal spray.
61992118|NCT00699556|PLACEBO_COMPARATOR|patch+placebo spray|Within subject design. All volunteers complete two laboratory sessions. In one session they receive nicotine patch + placebo nicotine nasal spray.
61992119|NCT05277844|ACTIVE_COMPARATOR|Arm 1: Continuation of TKI therapy alone|Patients in this arm will continue to receive standard treatment of TKI alone
61992120|NCT05277844|EXPERIMENTAL|Arm 2: Continuation of TKI therapy + Local Consolidative Radiation therapy to 1-5 sites|Patients will receive local consolidate radiation therapy to all oligo-metastatic sites plus radiation therapy to primary disease in addition to TKI
62387621|NCT01866839|EXPERIMENTAL|CD34+ cell positively selected graft stem cell recipient|Recipients received a myeloablative conditioning regimen of cyclophosphamide (120 mg/kg total), fludarabine (125 mg/m2 total) and total body irradiation (1200 cGy with lung shielding to 600 cGy), followed by an infusion of a stem cell product selected for CD34+ progenitors using the Miltenyi CliniMACS® system. Older subjects will receive a lower dose of irradiation (800 or 600 cGy based on age) to reduce the regimen intensity.
62387622|NCT03497975|EXPERIMENTAL|Active|162 mg nalbuphine ER tablets, BID
62387623|NCT03497975|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets
62387624|NCT03497975|EXPERIMENTAL|Open Label Extension|162 mg nalbuphine ER tablets, BID
62387625|NCT01294761|EXPERIMENTAL|Raltegravir, Darunavir/r|"An arm to change the regimen from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD~to: Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID"
61992121|NCT05180136|EXPERIMENTAL|Rice bran extract group|This group takes rice bran extract for 8 weeks.
62387626|NCT01294761|NO_INTERVENTION|Tenofovir, Emtricitabine, Lopinavir/r|An arm continuing on the same regimen before the randomization as Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD
62387627|NCT05464849||Resistant hypertension|Patients presenting with resistant hypertension
61992122|NCT05180136|PLACEBO_COMPARATOR|Control group|This group takes a placebo for 8 weeks.
61992123|NCT03501095||patients|patients who must undergo general and/or urology surgery of an elective type
61992124|NCT04906785|EXPERIMENTAL|Sequence1|"1. Period 1: Reference drug(D744)~2. Period 2: Test drug(CKD-385)"
61992125|NCT04906785|EXPERIMENTAL|Sequence2|"1. Period 1: Test drug(CKD-385)~2. Period 2: Reference drug(D744)"
62387628|NCT05464849||non-resistant hypertension|Patients presenting with non-resistant hypertension
62387629|NCT05464849||normotensive subjects|control group including normotensive volunteers
62387630|NCT00211692|ACTIVE_COMPARATOR|Group A consensus interferon+rbv 52 wks|Daily CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given 52 weeks (group A)
62387631|NCT00211692|EXPERIMENTAL|Group B CIFN variable duration|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for 52-72 weeks (from time of viral response +48 weeks) (group B)
62387632|NCT04166136|ACTIVE_COMPARATOR|Usual Treatment Group|This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
62559774|NCT01987440|PLACEBO_COMPARATOR|water|A VAS score (insertion) was obtained at this point. Next, the bill of the speculum was opened up until the vaginal cuff could be seen, and the speculum was secured by turning the thumbnut. A second VAS score (dilation) was recorded. During speculum examination, cervical smear with cervical brush was obtained for pathologic assessment if necessary. The speculum was withdrawn slightly, which allowed the bill to close together, and at this stage (extraction) the final VAS score was obtained. In the water group the speculum's top and bottom blades were moistened with 6,5 mL tap water previously loaded into a syringe kept at room temperature.After the speculum examination, pelvic examination was performed and length of the vagina (defined as distance from vaginal cuff to vaginal apex) was measured by the index finger.
61992126|NCT01076504|EXPERIMENTAL|Amrubicin/Carboplatin with Pegfilgrastim|Systemic therapy
61992127|NCT01785576|EXPERIMENTAL|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
61992128|NCT01785576|NO_INTERVENTION|Treatment as Usual|The treatment as usual group will complete all assessements and will not receive the psychosocial couple based intervention.
61992129|NCT05588102|EXPERIMENTAL|Selective Serotonin Reuptake Inhibitor（SSRIs）combined with Electronic cognitive training|SSRIs（Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）combined with Electronic cognitive training (60min, once a day)
61992130|NCT05588102|PLACEBO_COMPARATOR|SSRIs antidepressants combined with blank control Electronic training for 52 weeks|SSRIs drug treatment （Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）combined with the blank control Electronic training(subjects were allowed to use electronic products to browse the web and watch the news for 1 hours every day)
61992131|NCT01388842|PLACEBO_COMPARATOR|Placebo|Controls will receive small pulses of placebo study drug via the INOpulse delivery system. Oxygen saturation will be maintained above 94% by adding oxygen to inspired gas via a loose fitting mask when necessary.
61992132|NCT01388842|EXPERIMENTAL|inhaled nitric oxide|Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air using an INOpulse delivery system for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days. Oxygen saturation will be maintained above 94% by adding oxygen to inspired gas via a loose fitting mask when necessary.
62559775|NCT01416636|ACTIVE_COMPARATOR|Treprostinil sodium low dose - Arm I|"Arm I (low dose):~Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and was kept stable for another 12 weeks.~Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3.~This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump."
61992133|NCT01883427|PLACEBO_COMPARATOR|Placebo: Saline+glucose nasal spray|Subjects received nasal spray containing both saline+glucose twice daily for 3 months
61992134|NCT01883427|ACTIVE_COMPARATOR|Nasal spray with glucose oxidase+glucose|Nasal spray in a bag-on-valve device with 50U/ml containing both glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.
61992135|NCT01341561||weaning patients|
61992136|NCT05038995||Cow milk elimination group|The CME children will be eligible for the study if they (1) had a diagnosis of CMA by OFC, except children with known anaphylaxis (2) those on a CME diet or a specialized infant formula for at least three months (3) had reintroduced cow's milk for at least three months ago. Children who excluded other foods in addition to cows' milk in the first four years of life for ≥ three months and who currently introduced these foods for at least ≥ three months will be also enrolled in the CME group.
61992137|NCT05038995||Healthy group|Healthy children will ve eligible for the study if they (1) did not have CMA and other allergic diseases (2) who had never been on a diet throughout their lives.
61992138|NCT03392116|EXPERIMENTAL|Part A: NGM120|Single Dose
61992139|NCT03392116|PLACEBO_COMPARATOR|Part A: Placebo|Single Dose
61992140|NCT03392116|EXPERIMENTAL|Part B: NGM120|Multiple Dose
61992141|NCT03392116|PLACEBO_COMPARATOR|Part B: Placebo|Multiple Dose
61992142|NCT03981081|EXPERIMENTAL|eosinophil-guided group|patients will receive prednisone at a dose of 1mg/kg/day for up to 5 days or during the hospital stay if less than 5 days, only if the eosinophil count is\> 2%
61992143|NCT03981081|ACTIVE_COMPARATOR|control group|a treatment based on prednisone at a daily dose of 1 mg/kg will be routinely administered for a maximum of 5 days, or during the hospital stay, if it is less than 5 days
61992144|NCT03184051||Ultrasound assessment|All subject of the study have a knee osteoarthritis (OA) and are going to have a total arthroplasty. Diagnostic performance of ultrasonography is evaluated on ex vivo cartilage samples (2 samples per patient are selected with different stage of OA : 1 with early stage and 1 with advanced stage).
61992145|NCT04750837|ACTIVE_COMPARATOR|Platelet rich plasma group|chronic diabetic foot ulcer was treated by platelet rich plasma
61992146|NCT04750837|SHAM_COMPARATOR|conventional dressing group|chronic diabetic foot ulcer was treated by conventional dressing
61992147|NCT03818165|EXPERIMENTAL|CAR2 Anti-CEA CAR-T cell|3 doses of CAR2 Anti-CEA CAR-T cells for each cycle; up to 3 additional cycles received per investigator discretion
61992148|NCT05300490||Knee infiltration|Patients requiring prednisolone knee infiltration as part of routine medical management
61992149|NCT04098276|EXPERIMENTAL|Online weWomen Intervention|For first stage randomization, women in the intervention group receive the online safety planning intervention informed by culturally specific danger assessment (DA) tool.
61992150|NCT04098276|NO_INTERVENTION|Online usual care or no treatment control|Women in the control group receive the non-DA informed usual safety planning resources modeled on national and state domestic violence online resources, but not provided with immediate and visual feedback to their level of danger or a tailored safety planning.
61992151|NCT04098276|EXPERIMENTAL|WeWomen Plus Text messaging only|For second stage randomization, the text messaging intervention will follow-up with non-responder group of immigrant women (those who did not improve in intervention or control arms above) on their enactment of tailored (tailored to the DA Score and priorities) safety plan provided in the online weWomen intervention or non-tailored (standard list of resources) safety recommendations provided in the usual care control arm
61992152|NCT04098276|EXPERIMENTAL|WeWomen Plus Text messaging and phone|Second stage randomization will involve both text (described above) and phone calls for non-responder group of women in intervention or control arm. The phone calls will draw from motivational interviewing adapted for abused women, solution focused therapy and a strengths perspective to discuss women's safety concerns and other needs, and strategies to strengthen social support networks
61992153|NCT02453958|EXPERIMENTAL|mTBI-diagnosed group|Subjects diagnosed with mTBI were assessed with a multi-modal assessment system.
61992154|NCT02453958|EXPERIMENTAL|non mTBI-diagnosed group|Non-concussed subjects were assessed with a multi-modal assessment system.
61992155|NCT01108536|EXPERIMENTAL|adaptive trans-tibial socket|subjects are fitted with experimental sockets.
61992156|NCT01076712|EXPERIMENTAL|Physiotherapy Interventions|Physiotherapy Interventions including strengthening exercise, balance training, gait training with visual cue, gait training with treadmill.
61992157|NCT01076712|OTHER|Education|Education
61992158|NCT00297037|ACTIVE_COMPARATOR|1|"During the 6-week double-blind phase, all patients will be randomly assigned to receive either pimecrolimus 1% cream or its vehicle twice daily with occlusion on the affected areas. Topical application of pimecrolimus1% cream for oral erosive lichen planus for a duration of 6 weeks; ¼ gram of cream will be applied to each of the 2 sides of the mouth BID with a 2x2 gauze."
61992159|NCT00297037|PLACEBO_COMPARATOR|2|"During the 6-week double-blind phase, all patients will be randomly assigned to receive either pimecrolimus 1% cream or its vehicle twice daily with occlusion on the affected areas. Topical application of pimecrolimus1% cream for oral erosive lichen planus for a duration of 6 weeks; ¼ gram of cream will be applied to each of the 2 sides of the mouth BID with a 2x2 gauze."
61992160|NCT01894152||XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
61992161|NCT02477501|ACTIVE_COMPARATOR|Ephedrine|A continuous Ephedrine infusion at 10 mcg/kg/min
61992162|NCT02477501|ACTIVE_COMPARATOR|Norepinephrine|A continuous Norepinephrine infusion at 0.1 mcg/kg/min
61992163|NCT05871359|ACTIVE_COMPARATOR|tDCS group|transcranial Direct Current Stimulation group (tDCS group) : patients carry out activities in Dual Task associated with tDCS real.
61992164|NCT05871359|SHAM_COMPARATOR|Sham group|Sham group: patients carry out activities in Dual Task associated with tDCS sham.
61992165|NCT05773547||Professional|Two investigators who have performed over 200 MSOT measurements.
61992166|NCT05773547||Trainee-personal teaching|Trainees are defined as who haven't performed any MSOT measurement. In this cohort, one trainee received a personal teaching from one professional.
61992167|NCT05773547||Trainee-video|Trainees are defined as who haven't performed any MSOT measurement. In this cohort, one trainee received instruction from video.
61992168|NCT05773547||Trainee-instruction in paperform|Trainees are defined as who haven't performed any MSOT measurement. In this cohort, one trainee received instruction in paperform.
61992169|NCT03187457|OTHER|Treatment group|Metronidazole 400 mg 3 times daily for 5 days for Bacterial Vaginosis (BV) infection
62387633|NCT04166136|ACTIVE_COMPARATOR|Transition from the Rearfoot to the Forefoot and Midfoot|"Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. The participants will receive verbal command Try to touch first with the middle region of the foot on the treadmill. In the last four sessions, feedback will be gradually removed. At the end of each session, participants will be asked a question about the naturalness of running the new foot touch pattern on the ground. A scale from 0 to 10 will be used, where 0 means very difficult to perform and 10 indicates easy pattern. The perception of pain will also be evaluated with the numerical scale of pain of 11 points (0 to 10), where 0 means no pain and 10 the greatest pain possible."
62387634|NCT04166136|ACTIVE_COMPARATOR|Muscle Strengthening Group|The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
62559776|NCT01416636|EXPERIMENTAL|Treprostinil sodium high dose - Arm II|"Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and kept stable for another 12 weeks.~Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3.~This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump."
61992170|NCT03187457|OTHER|Control group|Healthy women without Bacterial Vaginosis and without treatment
61992171|NCT01512953|NO_INTERVENTION|no PPI|Patients, stratified according to the genetic stratum, will be randomized not to take any PPI on top of clopidogrel
61992172|NCT01512953|EXPERIMENTAL|PPI|Patients stratified to the genetic stratum will be randomized to take PPI on top of clopidogrel
61992173|NCT05638685||Dutch-speaking people living or working in Belgium|Every participant was asked to complete a questionnaire about the impact of a COVID-19 infection and/or the impact of lockdown measures as a result of the COVID-19 pandemic on fatigue and musculoskeletal complaints.
61992174|NCT05936866|EXPERIMENTAL|Pelvic floor stretching|Pelvic floor stretching exercises
61992175|NCT05936866|ACTIVE_COMPARATOR|Pelvic floor strengthening|Pelvic floor strengthening Exercises
61992176|NCT06038201|EXPERIMENTAL|EUS-GBD with stone clearance|Patients \>18-year-old with a diagnosis of gallstones by abdominal ultrasound, will be randomly allocated to EUS-guided GBD with electrocautery-enhanced lumen-apposing metal stent (LAMS) (Boston Scientific, Marlborough, MA, EEUU) with stone clearance.
61992177|NCT06038201|ACTIVE_COMPARATOR|Elective laparoscopic cholecystectomy|Patients \>18-year-old with a diagnosis of gallstones by abdominal ultrasound are randomly allocated to elective laparoscopic cholecystectomy and laparoscopic biliary exploration.
61992178|NCT02803307|EXPERIMENTAL|6 mg TLC599|6 mg DSP with 50 μmol PL
61992179|NCT02803307|EXPERIMENTAL|12 mg TLC599|12 mg DSP with 100 μmol PL
61992180|NCT04733651|ACTIVE_COMPARATOR|Control arm|In this arm subjects will receive the hospital COVID-19 standard care
62767890|NCT02546960|EXPERIMENTAL|ExPEC4V (4 : 4 : 4 : 4)|Participants will be stratified according to their age in 2 groups \>=18 to \<50 years and \>=50 years. Part 1: In age group \>= 18 to \<50 years, participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in microgram \[mcg\]) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in \>=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V (4:4:4:4) or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
61992181|NCT04733651|EXPERIMENTAL|Isoquercetin arm|In this arm subjects will receive the hospital COVID-19 standard care + Isoquercetin
61992182|NCT00624494|ACTIVE_COMPARATOR|Conventional monitoring|hemodynamic monitoring - conventional monitoring
62387635|NCT03377985|ACTIVE_COMPARATOR|axillary brachial plexus block group|Patients placed in the supine position with arm to be blocked abducted and externally rotated. After sterilization of the axilla ultrasound device with high frequency of 8-12 MHZ, linear transducer was put parallel to the anterior axillary fold at axilla to identify the axillary artery, lateral, medial and posterior cords of the brachial plexus in relation to the axillary artery. Lidocaine 1% was infiltrated subcutaneously 1 cm lateral to the probe, 7-10 ml of bupivacaine 0.5% was injected around each cord of the brachial plexus
62559777|NCT04990453|OTHER|RPD frameworks fabricated from PEEK material|14 patients received extracoronal precision attachment RPD frameworks fabricated from PEEK material using milling machine (CAD/CAM technology)
62559778|NCT04990453|OTHER|RPD frameworks fabricated from Co-Cr|14 patients received extracoronal precision attachment RPD frameworks fabricated from Co-Cr material using casting machine
62559779|NCT04185155|EXPERIMENTAL|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
61992183|NCT00624494|ACTIVE_COMPARATOR|Advanced monitoring|hemodynamic monitoring - advanced monitoring
61992184|NCT04644614|ACTIVE_COMPARATOR|Group 1: Magnetic Stimulation|Patients will be instructed to sit in a magnetic coil chair. Magnetic flux is generated in this field. This current stimulates the nerve or muscle of the pelvic floor. To administer MS, a stimulation amplitude of 200 μs and a repetition of 10 Hz for 10 minutes, 2 minutes rest in between, 50 Hz for 10 minutes (20 minutes total), 5 seconds on / 5 seconds off, in accordance with device literature will be adjusted to produce maximum stimuli with the cycle. During each treatment session, the device will be adjusted to receive patients the current intensity gradually increasing, reaching the maximum stimulation intensity.
61992185|NCT04644614|SHAM_COMPARATOR|Group 2: Sham Magnetic Stimulation|"The Sham MS treatment program will be the same as active MS in terms of duration, frequency, current duration, current intensity and general patient experience. The same magnetic chair will be used for both groups. Sham therapy application will be applied by the coordinator of the study by placing a thin deflector lead / aluminum coated plate on the magnetic coil of the magnetic chair that prevents the magnetic flux from penetrating into the patient.~During both applications, the patients will be exposed to the same sound, vibration sensation and lighting of the device."
62559780|NCT04185155|PLACEBO_COMPARATOR|Attention placebo|Smartphone activity for same amount of time.
62559781|NCT02566772|EXPERIMENTAL|TAS3681|All participants will receive TAS3681 in 28-day cycles. The Escalation phase includes participants who have progressed after abiraterone, enzalutamide and chemotherapy. Eleven dose escalation cohorts are planned, one of which includes a preliminary assessment of food effect. The MTD/recommended dose for further development will be used for participants in the Expansion Phase. The Expansion Phase will enroll participants who have progressed after abiraterone or enzalutamide with chemotherapy consisting of no more than 2 prior taxane-based therapies (Group A) or without any chemotherapy (Group B). Participants receive TAS3681 until discontinuation criteria are met.
62559782|NCT05383495|EXPERIMENTAL|Intranasal dexmedetomidine|IN dexmedetomidine 3 mcg/kg \[100 mcg/mL (max 200 mcg or 2 mL)\]
62559783|NCT05383495|EXPERIMENTAL|Intranasal midazolam|IN midazolam 0.4 mg/kg \[5 mg/mL (max 10 mg or 2 mL)\]
62559784|NCT05383495|EXPERIMENTAL|Inhaled nitrous oxide|50% N2O in 50% oxygen by face mask or on-demand system
62559785|NCT00029003|EXPERIMENTAL|Treatment (gefitinib)|Patients receive oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
62559786|NCT05757128|EXPERIMENTAL|treatment arm|The single treatment arm will be administered optimal health program (OHP) intervention.
61992186|NCT03770650|EXPERIMENTAL|IVUS-guided DK crush stenting|"In the IVUS-guided DK crush stenting group, IVUS will be before side branch stenting, after rewiring side branch, after 1st kissing balloon inflation, after rewiring side branch, after 2nd kissing balloon inflation.~For LM bifurcation lesions involving ostial LAD and LCX: minimum stent are (MSA) should be ≥10mm2 (LM), 7 mm2 (LAD), and 6 mm2 (LCX), with stent expansion index ≥90% (CSA≥90% of distal reference lumen area in LCX) and symmetry index \>0.8.~For non-LM bifurcation lesion involving the MSA should be ≥6 mm2 in the main vessel; and the MSA in the ostial side branch should be ≥5 mm2 and ≥90% of distal reference lumen area; and symmetry index should be \>0.8."
61992187|NCT03770650|ACTIVE_COMPARATOR|Angiography-guided DK crush stenting|In the Angiography-guided DK crush stenting group, stent diameter and length will be selected by visual estimation with a stent/artery ratio of 1.1:1.0. Post-dilation with a noncompliant balloon (balloon/stent diameter=1.0:1.0) inflated at \>18 atm will be performed for all lesions. Angiographic success is defined as Thrombolysis In Myocardial Infarction (TIMI) grade 3, residual stenosis \<20%, and the absence of ≥Type B dissection.
61992188|NCT03229265|EXPERIMENTAL|Patiromer|
61992189|NCT05174910|ACTIVE_COMPARATOR|With Obsidian ASG|Anastomosis treatment using standard procedure and Obsidian ASG
61992190|NCT05174910|NO_INTERVENTION|Without Obsidian ASG|Anastomosis treatment using standard procedure
61992191|NCT01936116|EXPERIMENTAL|patients with intrauterine balloon catheter placement|In this group, during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
61992192|NCT01936116|ACTIVE_COMPARATOR|patients with intracervical balloon catheter placement|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
61992193|NCT05409872|EXPERIMENTAL|Combination of Epigallocatechin gallate, vitamin D, vitamin B6, and D-Chiro-inositol|The subject takes a combination of 333.35 mg of green tea extract (150 mg of Epigallocatechin gallate), 25 mg of D-Chiro-inositol, 25 mcg of Vitamin D, and 5 mg of Vitamin B6 twice a day for three months.
61992194|NCT05409872|PLACEBO_COMPARATOR|Placebo|The subject takes the placebo twice a day for three months
61992195|NCT03031808|OTHER|Lidocaine spray|Endotracheal lidocaine spray prior to intubation
61992196|NCT03031808|OTHER|Muscle relaxant|Muscle relaxant prior to intubation
61992197|NCT03031808|OTHER|No Muscle relaxant, no Lidocaine|'No Muscle relaxant, no Lidocaine Control group
61992198|NCT02086669|EXPERIMENTAL|Pneumatic dilatation|Repetitive pneumatic dilatation as the initial treatment followed by repetitive dilatation in case of dysphagia recurrence.
61992199|NCT02086669|ACTIVE_COMPARATOR|Surgical myotomy|Laparoscopic myotomy and subsequent follow up.
61992200|NCT01241903|EXPERIMENTAL|Crestor|
61992201|NCT01241903|PLACEBO_COMPARATOR|sugar pill|
62559787|NCT03937362||Clinical Response Evaluation|"Patients with operable esophageal squamous cell carcinoma who are planned to undergo neoadjuvant chemoradiotherapy according to the CROSS regimen (intravenous carboplatin AUC 2 mg/mL/min and intravenous paclitaxel 50 mg/m2 on days 1, 8, 15, 22 and 29 with concurrent 41.4 Gy radiotherapy given in 23 fractions of 1.8 Gy on 5 days per week) followed by surgery.~Patients will undergo a first clinical response evaluation (CRE-1) 4-6 week after completion of nCRT. In patients without histological evidence of residual tumor surgery will be postponed another 6 weeks. A second clinical response evaluation (CRE-2) will be performed 10-12 weeks after completion of nCRT. Immediately after CRE-2 all patients without evidence of distant metastases will undergo esophagectomy."
61992202|NCT05360953|EXPERIMENTAL|Arm Clonidine|
61992203|NCT05360953|EXPERIMENTAL|Arm Doxazosin|
61992204|NCT05360953|PLACEBO_COMPARATOR|Placebo|
61992205|NCT03732885|EXPERIMENTAL|densah burs drilling group|maxillary sinus floor elevation during implant placement using Densah burs
61992206|NCT03732885|EXPERIMENTAL|Summers osteotomes|maxillary sinus floor elevation during implant placement using Summer's Osteotomes
61992207|NCT02141997|ACTIVE_COMPARATOR|Adalimumab 40 mg EOW|Adalimumab 40 mg every other week (EOW) for 11 weeks.
61992208|NCT02141997|EXPERIMENTAL|ABT-122 60 mg EOW|ABT-122 60 mg every other week (EOW) for 11 weeks.
61992209|NCT02141997|EXPERIMENTAL|ABT-122 120 mg EOW|ABT-122 120 mg every other week (EOW) for 11 weeks.
61992210|NCT02141997|EXPERIMENTAL|ABT-122 120 mg EW|ABT-122 120 mg every week (EW) for 11 weeks.
61992211|NCT05683288|EXPERIMENTAL|IASTM|"EYYDM will be applied to the upper trapezius and sternocleideomastoid muscles of the participants for 90 seconds, with a frequency of 60 beats per minute. The instruments will be applied to the soft tissue at 30º-60º angles with multidirectional strokes (stroking) movements."
61992212|NCT05683288|EXPERIMENTAL|Myofascial Release|Basic movements will be used in the rectus capitis, sternocleidomastoideus, hyoid region and upper trapezius regions within the scope of myofascial release application. The application will take 3 minutes for each region.
61992213|NCT05683288|EXPERIMENTAL|Control|It will include 250W infrared application on the cervical region from 50cm away for 15 minutes and TENS application for 20 minutes at 80Hz frequency with 150ms current transit time, home exercise program.
61992214|NCT06352450|EXPERIMENTAL|Active isolated stretching (AIS)|
61992215|NCT06352450|EXPERIMENTAL|Myofascial release (MFR)|
61992216|NCT00965822|ACTIVE_COMPARATOR|1|
61992217|NCT00965822|PLACEBO_COMPARATOR|2|
61992218|NCT02599753|EXPERIMENTAL|18F-DTBZ for Parkinson's Disease|The participants qualify for the study will return to the clinic at a later date and will have catheter(s) placed for i.v. administration of 18F- DTBZ for injection. The participants will receive a single i.v. bolus of 18F- DTBZ, followed by brain PET imaging of 10 minutes duration, approximately 80 minutes post-dose injection. Vital signs will be obtained prior to and immediately after the administration of 18F- DTBZ, and at the completion of the imaging session. Adverse events will be continuously monitored during the imaging session. The participants experience any adverse event will not be discharged until the event has resolved or stabilized.
61992219|NCT01214707||Exercise protocol|No arms are required for this study as all subjects complete the entire protocol
61992220|NCT03790527|EXPERIMENTAL|CBM training|"participants have to complete the picture assessment task ; Approach-avoidance Task(AAT) and cue-induced task in the fMRI；data on game-craving level, game hours, the ability of self-control and emotion regulation are also collected.~Half of the participants will be random-assigned into the CBM training group; Each participant will do these task twice( e.g. Before training and after training)"
61992221|NCT03790527|SHAM_COMPARATOR|Sham training|"participants have to complete the picture assessment task ; Approach-avoidance Task(AAT) and cue-induced task in the fMRI；data on game-craving level, game hours, the ability of self-control and emotion regulation are also collected.~Half of the participants will be random-assigned into the sham training group; Each participant will do these task twice( e.g. Before training and after training)"
61992222|NCT02253212|EXPERIMENTAL|SonoCloud + carboplatin|SonoCloud : dose escalation Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC
61992223|NCT01044082|EXPERIMENTAL|controlled cord traction|Controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs.
61992224|NCT01044082|ACTIVE_COMPARATOR|clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
61992225|NCT02843035|EXPERIMENTAL|Open label (OL) venglustat|Administered once a day orally for up to approximately 8.7 years. Patients will continue their usual dose of Cerezyme during Part 1, Part 2 and Part 3. There is no administration of Cerezyme in Part 4 unless administrated as rescue treatment.
61992226|NCT01617057|EXPERIMENTAL|Skelid|tiludronic acid
61992227|NCT01617057|PLACEBO_COMPARATOR|Control|Placebo
61992228|NCT05392361|ACTIVE_COMPARATOR|control group|conservative management for spinal stenosis
61992229|NCT05392361|EXPERIMENTAL|baclofen group|conservative management for spinal stenosis plus baclofen treatment
61992230|NCT03467087|EXPERIMENTAL|Electrical muscle stimulation|Electrical muscle stimulation is administered on both thighs and upper arms using a Myopuls 2000D device. Pre-set training time is 30 minutes per day (15 minutes for thighs and 15 minutes for upper arms) for at least 5 days a week.
61992231|NCT02361710||vitamin D deficient patients|Serum 25- (hydroxide) OH Vitamin D levels \<20ng/L undergoing Frozen embryo transfer (Vitamin D levels are measured on the day of embryo transfer)
61992232|NCT02361710||vitamin D sufficient patients|Serum 25- (hydroxide) OH Vitamin D levels \>20ng/L undergoing Frozen embryo transfer (Vitamin D levels are measured on the day of embryo transfer)
61992233|NCT01296295|EXPERIMENTAL|Spirometry and lifestyle counseling|Intervention group: The intervention is to give brief structured smoking cessation advice combined with a detailed and structured discussion of the spirometric results.
61992234|NCT01296295|NO_INTERVENTION|Lifestyle counseling|No intervention group: the patients of the control group will receive a brief structured smoking cessation advice.
61992235|NCT04909775|EXPERIMENTAL|Arm 1|Patients will receive 4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before cystectomy discussion. The patients reach clinical complete remission will receive tislelizumab maintenance therapy for a year or 13 cycles.
61992236|NCT04078828|ACTIVE_COMPARATOR|PR|
61992237|NCT04078828|ACTIVE_COMPARATOR|Non-PR|
61992238|NCT00862173||Patients with NSCLC with CNS Metastasis|Patients who developed CNS metastasis of NSCLC during the treatment.
61992239|NCT00862173||Patients with NSCLC without CNS Metastasis|Patients with NSCLC that does not develop CNS metastasis during the treatment.
61992240|NCT05453942|EXPERIMENTAL|SAR441566|Repeated dose of SAR441566 administered twice a day (BID) for 4 weeks under fed conditions
62387636|NCT03377985|ACTIVE_COMPARATOR|supraclavicular brachial plexus block group|patients placed in the supine position with the head of the bed elevated 30 degrees and patient's head turned away from the side to be blocked after skin disinfection, ultrasound device was put transversely parallel to and above the middle third of the clavicle, the probe was tilted till identification of the subclavian artery, 1st rib, pleura and brachial plexus lateral to the subclavian artery and above the 1st rib. Lidocaine 1% was infiltrated subcutaneously 1 cm lateral to the lateral side of the probe. A needle was inserted in plane 1 cm lateral to the probe when adjacent to brachial plexus 25 ml of bubivacaine 0.5% was injected around the brachial plexus
62559788|NCT00768586||1|Extreme premature infants under the 28th week of gestation.
62559789|NCT00697632|EXPERIMENTAL|1|
61992241|NCT05453942|PLACEBO_COMPARATOR|Placebo|Repeated dose of matching placebo administered twice a day (BID) for 4 weeks under fed condition
61992242|NCT02445690||Clinical remission without inflammation|Patients with Crohn's disease in clinical remission and no inflammation in the colonoscopy
61992243|NCT02445690||Clinical remission with inflammation|Patients with Crohn's disease in clinical remission and active inflammation in the colonoscopy
62559790|NCT00673699||A|Seventy dyspeptic consecutive patients that going upper gastrointestinal endoscopy
62559791|NCT03926429||Patient with reactive arthritis|
61992244|NCT04850014||Poisoned patients|All subjects with paracetamolemia in the context of paracetamol poisoning
61992245|NCT04850014||Control group|Acetaminophen-poisoned patient being non-obese
61992246|NCT05117411||Patients group|Subjects over 18 years that after cataract surgery, showed pseudophakic cystoid macula edema.
61992247|NCT05117411||Control Group|Normal subjects over 18 years that did not show pseudophakic cystoid macula edema.
62559792|NCT02521883|ACTIVE_COMPARATOR|Device: Sooma tDCS|The active group will receive active Sooma tDCS treatment for the first three weeks followed by maintenance treatments at weeks 5 and 6.
61992248|NCT01139736|EXPERIMENTAL|Probiotics|IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks. VSL#3 was selected for use in this study because (a) it contains three different Bifidobacteria strains (in addition to lactobacilli and streptococci) and the limited evidence available Bifidobacteria as the most effective probiotics in IBS .
62559793|NCT02521883|PLACEBO_COMPARATOR|Device: Sham tDCS|The placebo group will receive sham tDCS treatment for the first three weeks followed by sham maintenance treatments at weeks 5 and 6.
62559794|NCT02023983|EXPERIMENTAL|Early discharge|
61992249|NCT06253065||Patients undergoing PLND|Patients (will) undergo radical prostatectomy and pelvic lymph node dissection
61992250|NCT01104636||Single group prospective treatment cohort (varenicline)|
61992251|NCT05514158|EXPERIMENTAL|RC48 combind with RC98|
62387637|NCT01299636|EXPERIMENTAL|PM060184|
62387638|NCT00005089|EXPERIMENTAL|CHOP + Rituximab + RT|3 21-day cycles of CHOP (cyclophosphamide 750 mg/m\^2, doxorubicin 50 mg/m\^2, vincristine 1.4 mg/m\^2, prednisone 100 mg x 5 days) + Rituximab 375 mg/m\^2 (x 2 days for cycle 1, x 3 days for cycles 2-3). RT 4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
61992252|NCT04720196|EXPERIMENTAL|Active repetitive transcranial magnetic stimulation|10 hertz (Hz) rTMS will be administered over the primary motor area. Therapy will include 5 daily sessions (on consecutive week days). In every sessions 1500 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
61992253|NCT04720196|SHAM_COMPARATOR|Sham repetitive transcranial magnetic stimulation|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
61992254|NCT02431754|EXPERIMENTAL|Tadalafil|"5 milligrams (mg) tadalafil administered once daily orally for 8 weeks in one of two treatment periods.~0.2 mg tamulosin once daily or 4 mg silodosin twice daily.~Participants will remain on stable dose of alpha1 blocker through both treatment periods."
62387639|NCT03178591|ACTIVE_COMPARATOR|vildagliptin|Vildagliptin is a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) Dose of Vildagliptin is 50 mg once or twice daily.
62559795|NCT02023983|ACTIVE_COMPARATOR|Standard discharge|
62559796|NCT01983267|ACTIVE_COMPARATOR|cannabis|Patient using cannabis during chemotherapy treatment
61992255|NCT02431754|PLACEBO_COMPARATOR|Placebo|"Placebo administered once daily orally for 8 weeks in one of two treatment periods.~0.2 mg tamulosin once daily or 4 mg silodosin twice daily.~Participants will remain on stable dose of alpha1 blocker through both treatment periods."
62767891|NCT02546960|EXPERIMENTAL|ExPEC4V (4 : 4 : 4 : 8)|Participants will be stratified according to their age in 2 groups \>=18 to \<50 years and \>=50 years. Part 1: In age group \>= 18 to \<50 years, participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in \>=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses (4 : 4 : 4 : 8/8 : 8 : 8 : 8) of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
61992256|NCT02316483||Group I: T2D and Charcot foot|Individuals with confirmed diagnosis of type 2 diabetes, using the American Diabetes Association guidelines and confirmed diagnosis of Charcot foot, based on clinical and radiological evidence of Charcot foot.
61992257|NCT02316483||Group II: T2D neuropathy, no charcot|Individuals with type 2 diabetes and presence of neuropathy but the absence of Charcot foot.
61992258|NCT02316483||Group III: Control, non-diabetic|Individuals without history of type 2 diabetes.
61992259|NCT01742338|ACTIVE_COMPARATOR|Low Dose Corticosteroids|"10 mg IV q8hrs x 3 days\*, then prednisone 40 mg PO daily x 4 days, then prednisone 30 mg daily x 1 day, then prednisone 20 mg daily x 1 day, then prednisone 10 mg daily x 1 day, then stop.~\*If patient unable to receive IV medications, will give prednisone 20 mg PO bid for the first 3 days."
61992260|NCT01742338|EXPERIMENTAL|High Dose Corticosteroids|Methylprednisolone 40 mg IV q8hrs x 3 days\*, then prednisone 80 mg PO daily x 4 days, then prednisone 60 mg daily x 1 day, then prednisone 40 mg daily x 1 day, then prednisone 20 mg daily x 1 day, then stop. \*If patient unable to receive IV medications, will give prednisone 40 mg PO bid for the first 3 days.
61992261|NCT01163409|EXPERIMENTAL|acupuncture|will be made with classic acupuncture needling in traditional points, surpassing the skin
61992262|NCT01163409|EXPERIMENTAL|sham acupuncture|sham acupuncture will be done through a needle and a plastic device attached to skin in traditional acupuncture points.
61992263|NCT01163409|EXPERIMENTAL|exercise training resistance and aerobic|Aerobic exercise for 1 hour and resistance exercises for major muscle groups.
61992264|NCT01163409|NO_INTERVENTION|healthy lifestyle|Group 4 - will be the control group who receive follow-up and recommendation for physical activity, but without any intervention supervised.
61992265|NCT01148602|NO_INTERVENTION|'Off Clock'|"Stopwatch timers will NOT be used for off clock weeks, so patients presenting with hyperacute stroke will be managed normally without the visual timer."
62559797|NCT01983267|NO_INTERVENTION|control|Patients under chemotherapy treatment
62559798|NCT01769248|ACTIVE_COMPARATOR|Fine needle aspiration|fine needle aspiration
61992266|NCT01148602|ACTIVE_COMPARATOR|"'On Clock"|"LED stopwatch-clock timers will be posted for all patients presenting during ON clock weeks. All patients presenting with hyperacute stroke will be managed normally with the addition of a visual stopwatch timer."
62559799|NCT01769248|ACTIVE_COMPARATOR|Fine needle biopsy|Fine needle biopsy
62387640|NCT03178591|ACTIVE_COMPARATOR|Dapagliflozin|Dapagliflozin is a sodium glucose cotransporter-2 (SGLT-2 inhibitor) Dose of Dapagliflozin is 10 mg once daily.
62387641|NCT01880320|EXPERIMENTAL|CD0271 0.3% /CD1579 2.5% Gel|active arm
62387642|NCT01880320|ACTIVE_COMPARATOR|CD0271 0.1% / CD1579 2.5%|Comparator arm
62387643|NCT01880320|PLACEBO_COMPARATOR|Topical Gel Vehicle|Placebo arm
62387644|NCT02700932|EXPERIMENTAL|PicoWay laser treatment|3 wavelength tattoo treatment with picosecond laser (PicoWay)
62387645|NCT01831570|OTHER|symptomatic and radiographic hand osteoarthritis|Patients above 35-years old with symptomatic and radiographic hand osteoarthritis
62387646|NCT03962127||First time ischemic stroke|Patients with a first event of ischemic stroke admitted to hospitals in Central Norway.
62387647|NCT01183299|ACTIVE_COMPARATOR|High salt intake|
62387648|NCT01183299|PLACEBO_COMPARATOR|Low salt intake|
62387649|NCT00001151|EXPERIMENTAL|Drug treatment|1,25-Dihydroxycholecalciferol 5 ug orally per day for 2 years
62387650|NCT06292026|EXPERIMENTAL|Treatment with ProgenaMatrix|application of ProgenaMatrix daily for 12 weeks
62559800|NCT00469430|NO_INTERVENTION|Op|traditional surgery
62559801|NCT00469430|EXPERIMENTAL|Ab|antibiotic treatment
61992267|NCT03656419|EXPERIMENTAL|aPDT group|For photodynamic therapy will be used an equipment developed for this project with emission of red LED (660nm) and tip of 2.84 cm² .One session of the Chimiolux® photosensitizing aPDT will be performed, at a concentration of 0.005%, to be applied enough to cover the middle third and back of the tongue for 2 minutes for incubation. Four points will be irradiated with a distance of 1cm between the points, considering the scattering halo and the effectiveness of aPDT. The LED apparatus will be previously calibrated with wavelength 660 nm, with energy of 72 J, power of 800 mW for 90 seconds per point, creep of 282mW / cm².
61992268|NCT03656419|ACTIVE_COMPARATOR|Tongue Scraper|Tongue scraper 10 times in the tongue, from the back to the front.
61992269|NCT03656419|EXPERIMENTAL|aPDT and tongue scraper|Tongue scraper 10 times in the tongue, from the back to the front. For aPDT will be used an equipment developed for this project with emission of red LED (660nm) and tip of 2.84 cm² . One session of the Chimiolux® photosensitizing aPDT will be performed, at a concentration of 0.005%, to be applied enough to cover the middle third and back of the tongue for 2 minutes for incubation. Four points will be irradiated with a distance of 1cm between the points. Based on previous studies carried out with the aPDT for the treatment of halitosis the apparatus will be previously calibrated with wavelength 660 nm, with energy of 72 J, power of 800 mW for 90 seconds per point, creep of 282mW / cm².
61992270|NCT01478126|EXPERIMENTAL|Glutamine|Intravenous glutamine infusion perioperatively and 24 hours after surgery
61992271|NCT01478126|PLACEBO_COMPARATOR|Placebo|
61992272|NCT02518477|EXPERIMENTAL|exercise group|"The first 20 weeks, twice-weekly 60 minute session of physical exercise supervised by the research assistant and once weekly home exercise programme is offered. The exercise intervention will consist of stretching, scar tissue mobilization and resistance exercises.~For the following 32 weeks a home-training manual specifying three times weekly training is provided. At week 26 an individual booster session will be offered. In the case of lymphedema, referral to trained lymphedema physiotherapist for evaluation of appropriate intervention is made."
61992273|NCT02518477|NO_INTERVENTION|usual care control group|Receives all standard care offered from the operating hospital and rehabilitation in the municipality.
61992274|NCT03087656|ACTIVE_COMPARATOR|Antibiotic arm|The drugs ceftriaxone and levofloxacin will be administered to patients in the antibiotic arm.
62387651|NCT00623350|ACTIVE_COMPARATOR|1|Acute Stroke Telephone consult for the decision of tPA within 3 hours of symptoms onset.
62387652|NCT00623350|ACTIVE_COMPARATOR|2|Acute Stroke consult via audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
62387653|NCT02122965|EXPERIMENTAL|Pharmacist-led medication review|Pharmacist-led medication review in the ED
62387654|NCT02122965|NO_INTERVENTION|Usual care|Usual care includes nurse-led medication reconciliation.
62387655|NCT02536209|EXPERIMENTAL|Regimen 1|Period 1: MT-8554 low dose, Period 2: MT-8554 high dose, Period 3: Placebo and Period 4: Oxycodone hydrochloride, respectively single dosing
62387656|NCT02536209|EXPERIMENTAL|Regimen 2|Period 1: MT-8554 high dose, Period 2: Oxycodone hydrochloride, Period 3: MT-8554 low dose and Period 4: Placebo, respectively single dosing
62559802|NCT01436240||Spanish-speaking Latino participants|The investigators will conduct up to two rounds of PRO-CTCAE (patient-reported outcome- Common Terminology Criteria for Adverse Events) version questionnaire administration followed by cognitive interviews in Spanish-speaking Latino patients who are receiving cancer treatment or who have completed treatment for cancer within the past six months at one of the participating sites.
62559803|NCT05354037|ACTIVE_COMPARATOR|Group A|EMD + M-MIST approach
61992275|NCT03087656|NO_INTERVENTION|No Antibiotic arm|No prophylactic antibiotics will be administered.
61992276|NCT03571919|PLACEBO_COMPARATOR|Control|Will receive normal saline bolus and infusion and have sham lab draws every 8 hours.
61992277|NCT03571919|ACTIVE_COMPARATOR|Lidocaine|Will receive lidocaine bolus and infusion and have lidocaine lab draws every 8 hours.
61992278|NCT05584696|EXPERIMENTAL|Green Light Exposure Group|"When patients enter the clinic, toss a coin to determine which group they will belong to. Before the patient puts on the green glasses, the anxiety level is measured with the help of VAS. Then the patient is seated in the dental unit and green glasses will be put on. After 10 minutes the anxiety level will be measured again with the help of VAS.~The level of pain felt during surgery was determined by VAS. All operations will be performed by a single experienced surgeon. Since the patients enter the clinic, their heart rate, oxygen saturation and blood pressure will be measured continuously."
61992279|NCT05584696|PLACEBO_COMPARATOR|Control Group|"When patients enter the clinic, toss a coin to determine which group they will belong to. Before the patient puts on transparent glasses, the anxiety level is measured with the help of VAS. Then the patient is seated in the dental unit and transparent glasses will be put on. After 10 minutes the anxiety level will be measured again with the help of VAS.~The level of pain felt during surgery was determined by VAS. All operations will be performed by a single experienced surgeon. Since the patients enter the clinic, their heart rate, oxygen saturation and blood pressure will be measured continuously."
62387657|NCT02536209|EXPERIMENTAL|Regimen 3|Period 1: Placebo, Period 2: MT-8554 low dose, Period 3: Oxycodone hydrochloride and Period 4: MT-8554 high dose, respectively single dosing
62387658|NCT02536209|EXPERIMENTAL|Regimen 4|Period 1: Oxycodone hydrochloride, Period 2: Placebo, Period 3: MT-8554 high dose and Period 4: MT-8554 low dose, respectively single dosing
62387659|NCT04252872|EXPERIMENTAL|Sequence A|"Period 1 : HCP0605+HGP1405~Period 2 : HCP1401"
62387660|NCT04252872|EXPERIMENTAL|Sequence B|"Period 1 : HCP1401~Period 2 : HCP0605+HGP1405"
62387661|NCT00386152|EXPERIMENTAL|epoetin alfa (120,000 Units)|epoetin alfa (PROCRIT) 120,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
62387662|NCT00386152|EXPERIMENTAL|epoetin alfa (80,000 Units)|epoetin alfa (PROCRIT) 80,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
62387663|NCT00386152|ACTIVE_COMPARATOR|darbepoetin alfa (500 mcg)|darbepoetin alfa (ARANESP) 500 mcg injected subcutaneously the skin once every 3 weeks for up to 13 weeks
62387664|NCT02728804||Health Services Research (questionnaire administration)|Patients complete questionnaires (including the Baseline, Financial/Employment Impact, Insurance Impact, Quality of Life, and Treatment Perceptions questionnaires) over 30-60 minutes at baseline and at 3, 6, 9, and 12 months. Caregivers complete questionnaires over 30-60 minutes at baseline and at 6 and 12 months.
62559804|NCT05354037|EXPERIMENTAL|Group B|EMD with flapless approach
62767892|NCT02546960|EXPERIMENTAL|ExPEC4V (8 : 8 : 8 : 8)|Participants will be stratified according to their age in 2 groups \>=18 to \<50 years and \>=50 years. Part 1: In age group \>= 18 to \<50 years, participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in \>=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses (4 : 4 : 4 : 8/8 : 8 : 8 : 8) of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
61992280|NCT06003556|EXPERIMENTAL|PSMA PET|"These patients will have been diagnosed with unilateral prostate cancer by standard of care diagnostic tests deemed eligible and interested in focal therapy. These patients will be randomized to undergo a single \[18\]F-PSMA-1007 PET/CT or PET/MRI scan prior to focal therapy. If they are diagnosed with bilateral disease, they will be ineligible for focal therapy and be referred for radical therapy. Those with unilateral disease will then proceed to focal therapy. They will then receive PSMA PET, MRI, and combined targeted and systematic biopsy 12 months after ablation~Intravenous bolus injection of 4 MBq/kg +/- 10% of \[18\]F-PSMA-1007, up to a maximum of 400 MBq."
62767893|NCT02546960|EXPERIMENTAL|ExPEC4V (8 : 8 : 8 : 16)|Participants will be stratified according to their age in 2 groups \>=18 to \<50 years and \>=50 years. Part 1: In age group \>= 18 to \<50 years, participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in \>=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses (8 : 8 : 8 : 16/16 : 16 : 16 : 16) of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
62387665|NCT04854603|EXPERIMENTAL|Chocolate milk with a regular added sugar content|Dairy product with a regular sugar content
61992281|NCT06003556|NO_INTERVENTION|No Additional Imaging|"These patients will have been diagnosed with unilateral prostate cancer by standard of care diagnostic tests deemed eligible and interested in focal therapy. These patients will undergo no further testing and will undergo focal therapy.~They will then receive PSMA PET, MRI, and combined targeted and systematic biopsy 12 months after ablation.~Intravenous bolus injection of 4 MBq/kg +/- 10% of \[18\]F-PSMA-1007, up to a maximum of 400 MBq."
61992282|NCT02844296|EXPERIMENTAL|exercise group|"A free handgrip (strength 15 kg) will be given to the subject and some short-bout exercise will be introduced to the subjects for reliving the cravings for smoking through a short video. After the video, the counselor will install a smartphone application which is about exercise in the subject's mobile phone to set up exercise reminder schedule for 4 weeks. 20-30 reminders on exercise and quitting tips via the App for 4 weeks. Subjects will be requested o record a daily diary on smoking.~A leaflet with exercise instruction and motivation messages based on the Health Action Process Approach (HAPA) will be given to the participant. 2-month, 6 -month and 12-month telephone interview will be conducted. Biochemical validation will be conducted at 6-month follow up. And hand grip strength will be measured the next time when the participant comes back to CISI."
62387666|NCT04854603|EXPERIMENTAL|Chocolate milk with a reduced added sugar content|Dairy product with a reduced sugar content
62387667|NCT04854603|EXPERIMENTAL|Yogurt with a regular added sugar content|Dairy product with a regular sugar content
62387668|NCT04854603|EXPERIMENTAL|Yogurt with a reduced added sugar content|Dairy product with a reduced sugar content
62387669|NCT04854603|EXPERIMENTAL|Energy-free control|Potable water
62387670|NCT05798299|EXPERIMENTAL|UP-C/C|UP-C/C intervention - 15 weekly sessions for children; 3 group sessions for parents; 1 family meeting before exposure sessions.
62387671|NCT05798299|ACTIVE_COMPARATOR|Coping Cat, Group Format|Coping Cat in group format intervention - 16 weekly sessions for children; 2 individual sessions for parents.
62387672|NCT03988465||Cardiac Surgery Patients|Patients undergoing cardiopulmonary bypass surgery, including placement of a ventricular access device.
62387673|NCT01048827|EXPERIMENTAL|experimental|dose-escalation Busulfan
62387674|NCT00694239|NO_INTERVENTION|B|Standard Care
62387675|NCT00694239|EXPERIMENTAL|A|Risk Assessment plus standard care
62559805|NCT03160378|EXPERIMENTAL|Intervention|The participants in the intervention group will receive treatment as usual + 10 sessions of organizational skills training
61992283|NCT02844296|EXPERIMENTAL|diet group|"Subjects will view a short video on healthy diet only. After the video, the counselor will also install another smartphone application which is about healthy diet in the subject's mobile phone to set up healthy die reminder schedule for 4 weeks.~A leaflet on healthy diet will be given to the subjects, and 20-30 reminders on healthy diet and quitting tips via the App for 4 weeks.2-,6- and 12-month telephone interview will be conducted. Biochemical validation will be conducted at 6-month follow up. And hand grip strength will be measured the next time when the participant comes back to CISI."
61992284|NCT01972269|ACTIVE_COMPARATOR|bupivacaine-fentanyl 4|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 4mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
61992285|NCT01972269|ACTIVE_COMPARATOR|bupivacaine-fentanyl 6|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 6mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
61992286|NCT01972269|ACTIVE_COMPARATOR|bupivacaine-fentanyl 8|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 8mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
61992287|NCT01972269|ACTIVE_COMPARATOR|bupivacaine-fentanyl 10|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 10mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
61992288|NCT01972269|ACTIVE_COMPARATOR|bupivacaine-fentanyl 12|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 12mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
61992289|NCT01972269|ACTIVE_COMPARATOR|bupivacaine-fentanyl 14|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 14mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
61992290|NCT01972269|ACTIVE_COMPARATOR|bupivacaine-fentanyl 16|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 16mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
61992291|NCT01972269|ACTIVE_COMPARATOR|lidocaine 4|Test dose: 3mL of 2% lidocaine. Loading dose: 4mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
61992292|NCT01972269|ACTIVE_COMPARATOR|lidocaine 6|Test dose: 3mL of 2% lidocaine. Loading dose: 6mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
61992293|NCT01972269|ACTIVE_COMPARATOR|lidocaine 8|Test dose: 3mL of 2% lidocaine. Loading dose: 8mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
61992294|NCT01972269|ACTIVE_COMPARATOR|lidocaine 10|Test dose: 3mL of 2% lidocaine. Loading dose: 10mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
62387676|NCT01097057|EXPERIMENTAL|Treatment (rituximab, etoposide, carboplatin, ifosfamide)|Patients receive rituximab IV on day 1, etoposide IV on days 2-4, carboplatin IV on day 3, and ifosfamide IV on day 3 over 24 hours. Patients also receive G-CSF SC once daily beginning on day 6 and continuing until apheresis is completed and plerixafor SC once daily for up to 4 days beginning 24 hours after recovery from nadir and continuing until apheresis is completed. Patients may undergo up to 4 apheresis procedures until the optimal number of CD34+ cells are collected.
62387677|NCT05133102||Control|Patients who have undergone an endoscopy within the last three years and have never been diagnosed with Barrett's esophagus.
62387678|NCT05133102||Barrett's Esophagus|Patients who have undergone an endoscopy within the last three years and have histologically confirmed Barrett's esophagus. BE segment must be M\>1cm, and has not be treated with endoscopic eradication therapy (focal mucosal resection without subsequent eradication therapy is allowed).
61992295|NCT01972269|ACTIVE_COMPARATOR|lidocaine 12|Test dose: 3mL of 2% lidocaine. Loading dose: 12mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
61992296|NCT01972269|ACTIVE_COMPARATOR|lidocaine 14|Test dose: 3mL of 2% lidocaine. Loading dose: 14mL of 0.125% bupivacaine-fentanyl 5mcg/mL
61992297|NCT01972269|ACTIVE_COMPARATOR|lidocaine 16|Test dose: 3mL of 2% lidocaine. Loading dose: 16mL of 0.125% bupivacaine-fentanyl 5mcg/mL
61992298|NCT04562896|NO_INTERVENTION|No Device|Participants will be evaluated without a CDO.
61992299|NCT04562896|EXPERIMENTAL|CDO-A|The first design variant will be designated CDO-A
61992300|NCT04562896|EXPERIMENTAL|CDO-B|The second design variant will be designated CDO-B
61992301|NCT04562896|EXPERIMENTAL|CDO-C|The third design variant will be designated CDO-C
61992302|NCT03496688|ACTIVE_COMPARATOR|bone substitute material MCBA|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using mineralized sol-vent-dehydrated bone allograft material.
61992303|NCT03496688|ACTIVE_COMPARATOR|bone substitute material FDBA|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using freeze-dried mineralized bone allograft material.
61992304|NCT03496688|ACTIVE_COMPARATOR|bone substitute material ABB|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using anorganic bovine bone material.
61992305|NCT03496688|ACTIVE_COMPARATOR|bone substitute material EB|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using equine-derived bone material.
62387679|NCT03472339|EXPERIMENTAL|Group A|diclofenac sodium75 mg, intravenously, once
62387680|NCT03472339|ACTIVE_COMPARATOR|Group B|diclofenac sodium 100 mg, orally, once
62559806|NCT03160378|OTHER|Control|Control participants will receive treatment as usual.
62559807|NCT03000231||Healthy Controls|Matched by age, race, gender and BMI to adrenal insufficiency subjects
62559808|NCT03000231||Adrenal Insufficiency Patients|Eligible patients will have either primary adrenal insufficiency or secondary adrenal insufficiency and will be age 18 and older.
61992306|NCT03496688|ACTIVE_COMPARATOR|bone substitute material HA-β-TCP 30/70|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using synthetic micromacroporous bi-phasic calcium-phosphate block consisting of 70% beta-tricalcium phosphate and 30% hy-droxyapatite material.
61992307|NCT03496688|ACTIVE_COMPARATOR|bone substitute material BC|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using bioapatite-collagen material.
62387681|NCT04514705|EXPERIMENTAL|Intervention Group|The exercises performed will attend the musculoskeletal dimension of the body, which includes the muscular strength / endurance indexes, which is part of the functional-motor dimension of physical fitness related to health. The protocol will be applied in the form of sessions lasting approximately 50 minutes, performed three times a week on alternate days, for a period of 6 weeks, totaling 20 sessions. For aerobic exercises, a treadmill will be used and for anaerobic exercises, four exercises involving muscle mobility / strength in upper and lower limbs will be performed at weight training station.
62387682|NCT03693391|EXPERIMENTAL|Cohort 1: JNJ-64140284|Participants in cohort 1 will receive single oral dose of JNJ-64140284 at a starting dose of 0.5 milligram (mg) under fasted conditions. The dose levels of JNJ-64140284 will be escalated sequentially based on the decisions of an independent Data Review Committee (iDRC), the clinical team and the investigator. First 3 participants will also receive an intravenous (IV) bolus injection of \[18F\]JNJ-64511070 at a dose of 185 megaBecquerel (MBq). Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent positron emission tomography-computed tomography (PET-CT) scan.
61992308|NCT02220270||patient with PDA or ASD|
61992309|NCT05718232|EXPERIMENTAL|SBRT+TACE+Lenvatinib|Patients in SBRT+TACE+Lenvatinib group will take oral lenvatinib within 3 days of randomization and receive TACE 1 day after oral administration of lenvatinib. SBRT will begin within 3 weeks after the first TACE.
61992310|NCT05718232|ACTIVE_COMPARATOR|Lenvatinib|Patients in Lenvatinib group will take oral lenvatinib alone.
61992311|NCT02488681|EXPERIMENTAL|Micra Pacemaker Implant|Micra Pacemaker Implant
61992312|NCT02416427|EXPERIMENTAL|Arm A|Atorvastatin 80 mg/day for 3 weeks
61992313|NCT02416427|NO_INTERVENTION|Arm B|Observation
61992314|NCT02578927|EXPERIMENTAL|GT+Ex|Ingestion of one dose of 2 g of green tea (GT) ingested at 10 minutes after the period of rest. After the Ingestion, the volunteers practice aerobic exercise (EX) in treadmill.
61992315|NCT02578927|PLACEBO_COMPARATOR|PL+Ex|Ingestion of one dose 2 g of placebo (PL) ingested at 10 minutes after the period of rest. After the Ingestion, the volunteers practice aerobic exercise (EX) in treadmill.
61992316|NCT02578927|ACTIVE_COMPARATOR|Green Tea|Ingestion of one dose 2g of green tea (GT) at 10 minutes after the period of rest. In this section the volunteers does not practice aerobic exercise.
61992317|NCT04874974|EXPERIMENTAL|Metacognitive and Defusion Training|All participating patients are allocated to the same five-week experimental group therapy, which consists of three different modules (Module I: Psychoeducation on cognitive processes and rational of the therapy - week 1; Module II: Metacognition - week 2+3; Module III: Cognitive Defusion - week 4+5). Group therapy will start with a psychoeducation session of 60 minutes in the first week and will then take place twice a week with each session lasting 60 minutes.
61992318|NCT02229942|EXPERIMENTAL|Rituximab|Rituximab induction (two infusions two weeks apart) and maintenance (infusions at 3, 6, 9 and 12 months)
62387683|NCT03693391|EXPERIMENTAL|Cohort 2: JNJ-64140284|Participants in cohort 2 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of \[18F\]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
61992319|NCT02229942|PLACEBO_COMPARATOR|Placebo|Saline (with added albumin), two infusions two weeks apart, followed by infusions at 3, 6, 9 and 12 months.
61992320|NCT05699083|OTHER|Patients with BMI between 30-34.5 kg/m2|Patients with BMI between 30-34.5 kg/m2 will be administered a body image/self-esteem questionnaire pre-operatively and at 1 month, 3 months, 6 months and 12 months post-operatively.
61992321|NCT00615056|ACTIVE_COMPARATOR|B|Bevacizumab (avastin)
61992322|NCT00615056|EXPERIMENTAL|C|AG-013736 (axitinib)
61992323|NCT00615056|EXPERIMENTAL|A|AG-013736 (axitinib)
62387684|NCT03693391|EXPERIMENTAL|Cohort 3: JNJ-64140284|Participants in cohort 3 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of \[18F\]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
62387685|NCT03693391|EXPERIMENTAL|Cohort 4: JNJ-64140284|Participants in cohort 4 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of \[18F\]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
62559809|NCT02348736|EXPERIMENTAL|SensaScope|Time for tracheal intubation with the SensaScope
61992324|NCT00615056|ACTIVE_COMPARATOR|D|bevacizumab (avastin)
61992325|NCT00858442|EXPERIMENTAL|With PRP|Each patient received a single dose of 5cc PRP before the graft.
61992326|NCT00858442|NO_INTERVENTION|Without PRP|Control patients did not receive any intervention before the graft.
61992327|NCT03247166|EXPERIMENTAL|Lower Back and Leg Pain Patients|Patients suffering from lower back and leg pain resulting in degenerative spondylolisthesis and/or spinal stenosis will undergo treatment using the TOPS™ System
61992328|NCT02063737|SHAM_COMPARATOR|Control Group|The control group will receive text-message assessments only at the start, during, and end of shift. These queries will attempt to capture the worker's self-reported sleepiness, fatigue, and occurrence of work-related injury during shift work.
61992329|NCT02063737|EXPERIMENTAL|Intervention Group|The intervention group will receive the same text-message assessments as the control group. In addition, these subjects will receive text-message interventions for high level fatigue for reducing fatigue and sleepiness during shift work if they report a high-level of fatigue or sleepiness at the start or during their shift. These subjects will then receive additional text message queries at the end of their shifts to determine if they adopted a strategy for reducing perceived sleepiness or fatigue.
61992330|NCT01881659||Women attending cervical screening|Women aged 30-64 years who signed informed consent and comply with inclusion and exclusion criteria.
61992331|NCT02504697||Longitudinal Cohort|For this longitudinal screening cohort, we will enroll 800 participants who currently or historically smoked and who have a 10 year Bach risk model of lung cancer \> 2.5% (5). We will include participants 50 to 79 years old, with ≥10 cigarettes/day for current smokers, or ≥20 pack years for former smoker who quit 20 years ago or less. In order to further enrich for lung cancer risk, participants also will have COPD/emphysema or at least one first-degree relative with a diagnosis of lung cancer. We will exclude patients previously diagnosed with lung cancer. These patients will be followed for a total of 4 years with annual follow-up visits. Biosamples from airway and blood and images will be collected.
61992332|NCT02103283|EXPERIMENTAL|Teprotumumab|Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
61992333|NCT05284838|EXPERIMENTAL|Error Management Training (Difficult)|Participants receive the learning strategy Error Management Training and encounter difficult questions.
61992334|NCT05284838|EXPERIMENTAL|Error Management Training (Easy)|Participants receive the learning strategy Error Management Training and encounter easy questions.
61992335|NCT05284838|ACTIVE_COMPARATOR|Error Avoidance Training|Participants receive the learning strategy Error Avoidance Training.
61992336|NCT04536727|EXPERIMENTAL|Intervention|The 8-week intervention will consist of the Fit \& Strong! program adapted to address the impact of exercise on enhancing positive affect and reducing negative affect and depressive symptoms. Exercise classes will meet three times per week for 90 minutes per session for eight weeks. Each class is divided into 60 minutes of strength training, flexibility, and cardiovascular exercise and 30 minutes of group education/discussion, which has been adapted to include affect-oriented content.
61992337|NCT04536727|PLACEBO_COMPARATOR|Wait list|Participants randomized to the wait list group, receive the 8-week Fit \& Strong! intervention after the intervention group has completed it.
61992338|NCT02008448|ACTIVE_COMPARATOR|PVI+LL|Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.
61992339|NCT02008448|ACTIVE_COMPARATOR|PVI+LL+BT injection|"Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.~Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster)."
61992340|NCT04779255|EXPERIMENTAL|Tumescent anesthesia|Patient who will receive tumescent anesthesia as analgesic treatment
61992341|NCT04779255|ACTIVE_COMPARATOR|Painkillers and cold water|Patient who will receive painkillers 1 hour before photodynamic therapy and cold water during session as analgesic treatment
61992342|NCT05372692|EXPERIMENTAL|Single-arm open clinical study|After blood collection from qualified subjects, lymphocytes will be pretreated，the subjects will then be treated with CAR T cells.
61992343|NCT01613781|ACTIVE_COMPARATOR|T1/Tc amplitude-guided group|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
61992344|NCT01613781|ACTIVE_COMPARATOR|TOF count-guided group|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
61992345|NCT03500133|EXPERIMENTAL|Group A|"Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.~No radiotherapy if CR at the end of chemotherapy."
61992346|NCT03500133|EXPERIMENTAL|Group B|"Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.~No radiotherapy if CR at the end of chemotherapy"
61992347|NCT03500133|EXPERIMENTAL|Group B2|"Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
61992348|NCT03500133|EXPERIMENTAL|Group C|"Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.~No radiotherapy if CR at the end of chemotherapy."
61992349|NCT03500133|EXPERIMENTAL|Group D|"Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
61992350|NCT03500133|EXPERIMENTAL|Group E|"High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.~No radiotherapy if CR at the end of chemotherapy"
61992351|NCT03500133|EXPERIMENTAL|Group F|"High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
62559810|NCT02348736|EXPERIMENTAL|McGrath Series 5|Time for tracheal intubation with the McGrath Series 5
61992352|NCT02234921|EXPERIMENTAL|DRibble Vaccine|Patients will receive cyclophosphamide 3 days prior to the first of 9 planned DRibble vaccine injections. Imiquimod will be applied following 6 injections. Patients will receive 2 HPV vaccinations (Human papillomavirus).
61992353|NCT05352828|EXPERIMENTAL|Nivolumab and CD30.CAR-T|Study treatment will include 4 cycles of nivolumab and a single CD30.CAR-T infusion (preceded by lymphodepletion chemotherapy of Fludarabine and Bendamustine).
61992354|NCT01039896|EXPERIMENTAL|Group1|SLM0807
61992355|NCT01039896|EXPERIMENTAL|Group2|SLM0807 and HKB0701
61992356|NCT02603042||Observation|Patients with Hypophosphatasia disease or high-grade suspicion for Hypophosphatasia disease
61992357|NCT02138461||bimatoprost|These patients take bimatoprost topically for glaucoma.
61992358|NCT02138461||latanoprost group|These patients take latanoprost topically for glaucoma.
61992359|NCT02396836|ACTIVE_COMPARATOR|6 step hand hygiene technique|Hand decontamination with alcohol hand rub using the World Health Organisations 6 step technique
61992360|NCT02396836|EXPERIMENTAL|3 step hand hygiene technique|Hand decontamination with alcohol hand rub using the 3 step technique
61992361|NCT03960151|EXPERIMENTAL|Rolapitant|Rolapitant plus Olanzapine, Palonosetron, and Dexamethasone
61992362|NCT04640519|EXPERIMENTAL|TASC Intervention|TASC patients will receive a BP monitoring kit and electronic tablet and tailored infographics, and attend 5 telehealth visits over 3 months, including primary care nurse practitioner, pharmacy and stroke neurologist.
61992363|NCT04640519|ACTIVE_COMPARATOR|TASC Control|Usual care patients will be seen by a primary care nurse practitioner and a stroke neurologist.
61992364|NCT04706845||1|No evident disease
61992365|NCT04706845||2|Metastatic Disease; Watchful Waiting: Tumors bearing NOTCH Mutation
61992366|NCT04706845||3|Metastatic Disease; Watchful Waiting: Tumors bearing Notch Wild Type
61992367|NCT04706845||4|Progressive Disease: Tumors bearing NOTCH Mutation
62387686|NCT06444724|NO_INTERVENTION|Control group|Patients in the control group received verbal instructions for bowel preparation before endoscopy from the endoscopy nurse, along with pamphlets containing relevant information. This instructional material encompassed details regarding a purgative regimen, instructions on its administration, dietary restrictions preceding colonoscopy, and medication adjustments necessary for some patients.
61992368|NCT04706845||5|Progressive Disease: Tumors bearing Notch Wild Type
61992369|NCT04147065|EXPERIMENTAL|7-day triple therapy and 7-day bismuth quadruple therapy|7-day triple therapy is consisted of proton pump inhibitor (PPI), amoxicillin and clarithromycin for seven days 7-day bismuth quadruple therapy is consisted of PPI, bismuth, tetracycline, metronidazole for seven days
61992370|NCT04147065|ACTIVE_COMPARATOR|14-day triple therapy and 14-day bismuth quadruple therapy|14-day triple therapy is consisted of PPI, amoxicillin and clarithromycin for fourteen days 14-day bismuth quadruple therapy is consisted of PPI, bismuth, tetracycline, metronidazole for fourteen days
61992371|NCT02910167||Men with spasmodic syndromes|Men with any type of gastrointestinal, hepato-biliary, urinary or genital spasmodic syndromes
61992372|NCT02910167||Women with spasmodic syndromes|Women with any type of gastrointestinal, hepato-biliary, urinary or genital spasmodic syndromes
61992373|NCT03393156|EXPERIMENTAL|Internet-based metracognitive therapy|"The internet-based metacognitive therapy group receives a ten-week long treatment, which is based on the book Metacognitive therapy for depression and anxiety by Adrian Wells (2011)."
61992374|NCT03393156|NO_INTERVENTION|Wait-list|When the active treatment groups have finished treatment (W11), the WL group will be able to start active treatment and be assessed at post-treatment, 6 and 12 months later using the same questionnaires as the treatment group.
62387687|NCT06444724|ACTIVE_COMPARATOR|Application group|Patients in the application group will be communicated via Line applications (APP group) with guidance on preparation before colonoscopy through video media.
62559811|NCT04154683|EXPERIMENTAL|group using Cellvizio® optical biopsy|
61992375|NCT04592965|EXPERIMENTAL|Clinical and neuropsychological examinations|Participants will be assessed by means of validated and lab-tailored clinical scales, alongside with semi-structured interviews, to assess the status of the disease (PD), amongst others, such as cognitive capabilities.
61992376|NCT04592965|EXPERIMENTAL|Robot induced PH, through sensorimotor stimulation|Participants will manipulate a patented robotic system designed to induce the PH and other accompanying bodily illusions. At the end, participants will report on various subjective experiences, by answering a structured questionnaire.
61992377|NCT04592965|EXPERIMENTAL|Resting-state fMRI acquistion|We will acquire resting-state data in the MRI scanner for all the participants. Respiration and heart beat rate data will also be acquired.
61992378|NCT04592965|EXPERIMENTAL|Robot induced PH, through sensorimotor stimulation (MRI)|All healthy participants, and all patients who are deemed capable of performing the robotic manipulation task in the MRI scanner, will take part on this arm. Participants will perform a robotic manipulation task, with a patented robotic system, capable of inducing the PH and other accompanying bodily illusions in the MRI scanner. At the end participants will report on the various subjective experiences, by answering a structured questionnaire.
61992379|NCT05172661|EXPERIMENTAL|Integrated training model|"Participants in this group will accept postural and cognitive training at the same time, e.g. naming animals while standing on the foam.~Each training session will last for 70 minutes, twice a week, and 12 sessions in total."
61992380|NCT05172661|EXPERIMENTAL|Consecutive training model|"Participants in this group will accept postural and cognitive training separately and for identical durations (both 30 minutes).~Each training session will last for 70 minutes, twice a week, and 12 sessions in total."
61992381|NCT04047264|EXPERIMENTAL|Basic Science (microdialysis)|Patients undergo microdialysis over 30 minutes during standard of care biopsy or resection.
61992382|NCT03642392||Tendinopathy|Athletes with unilateral tendinopathy
61992383|NCT04859868|EXPERIMENTAL|Galvanic Vestibular Stimulation During the Entire Session|Subjects given Galvanic Vestibular Stimulation (GVS) to mitigate motion sickness in the rotating chair turning stimulation ON from beginning.
61992384|NCT04859868|NO_INTERVENTION|No Galvanic Vestibular Stimulation|Subjects were not given Galvanic Vestibular Stimulation (GVS) to mitigate motion sickness in the rotating chair turning stimulation entire session.
61992385|NCT04859868|EXPERIMENTAL|Galvanic Vestibular Stimulation Starting From Mid-session|Subjects given Galvanic Vestibular Stimulation (GVS) to mitigate motion sickness in the rotating chair turning stimulation ON from the middle of the session.
61992386|NCT05617768||• Cardiac anesthesiologists • Cardiac intensivists • Cardiothoracic surgeons|"* Anesthesia department, Cairo university hospitals, kasr al-ainy.~* Cardiothoracic thoracic surgery department, Cairo university hospitals, kasr al-ainy.~* Anesthesia department, National Heart Institute.~* Cardiothoracic surgery department, National Heart Institute."
61992387|NCT03042390||DArunavir/cobicistat|Patients starting treatment with a regimen containing Darunavir / cobicistat for at least 24 weeks
61992388|NCT05902039||CADASIL patients|"Inclusion Criteria:~1. Patients with CADASIL confirmed by gene or/and skin biopsy.~2. The age range is 20-70 years old.~3. There is no contraindication to MRI examination, and the informed consent is signed.~exclusion criteria：~1. Combined with definite cerebrovascular disease, or combined with brain tumor, brain trauma and other causes of brain diseases.~2. CADASIL is not confirmed.~3. There are contraindications to examination or refusal to sign the informed consent."
61992389|NCT05902039||Healthy controls|"Inclusion Criteria:~1. The age range is 20-70 years old.~2. There is no contraindication to MRI examination, and the informed consent is signed.~exclusion criteria：~1. Combined with definite cerebrovascular disease, or combined with brain tumor, brain trauma and other causes of brain diseases.~2. There are contraindications to examination or refusal to sign the informed consent."
61992390|NCT01051128|EXPERIMENTAL|Spasticity. Baclofen|This study is a non-randomized, open-label, multi-center study of the Prometra Programmable Implantable Pump System in the administration of Lioresal® intrathecal (baclofen) in patients suffering from severe muscle spasticity of spinal origin.
61992391|NCT00817167|EXPERIMENTAL|inReach (A)|Bronchoscopy procedure is planned using inReach planning software
61992392|NCT00817167|ACTIVE_COMPARATOR|Control (B)|Bronchoscopy procedure is planned using standard CT viewer software
61992393|NCT02063516|EXPERIMENTAL|Guardian|Device: Guardian Laryngeal Mask
61992394|NCT02063516|EXPERIMENTAL|Proseal|Device:Proseal Laryngeal Mask Airway
61992395|NCT01506518||Duchenne muscular dystrophy and age 5-6 years|Boys diagnosed with Duchenne muscular dystrophy and age 5-6 years at enrollment.
62387688|NCT06323629|EXPERIMENTAL|Adaptive recursive self-feedback procedure|Using a tablet, participants listen to speech playback of their response to a prompt and self-correct/minimize their speech errors in a subsequent attempt. This process is looped multiple times per prompt. It adapts across narrative prompts with low and high complexities.
62387689|NCT06323629|EXPERIMENTAL|Non-adaptive recursive self-feedback procedure|Using a tablet, participants listen to speech playback of their response to a prompt and self-correct/minimize their speech errors in a subsequent attempt. This process is looped multiple times per prompt. However, it only uses narrative prompts with high complexity.
61992396|NCT01506518||Duchenne muscular dystrophy and age 7-8 years|Boys diagnosed with Duchenne muscular dystrophy and age 7-8 years at enrollment.
61992397|NCT01506518||Duchenne muscular dystrophy and age 9-10 years|Boys diagnosed with Duchenne muscular dystrophy and age 9-10 years at enrollment.
61992398|NCT01506518||No known neuromuscular disorders and age 5-14 years|Volunteer boys ages 5-14 years with no known neuromuscular disorders to serve as controls.
61992399|NCT05591014|EXPERIMENTAL|Software Tutorial|Participants will be asked to interpret a series of ROTEM studies before and after a tutorial on a novel ROTEM interpretation software.
61992400|NCT03476304|EXPERIMENTAL|Semi-direct composite endocrown restorations|
61992401|NCT03476304|ACTIVE_COMPARATOR|Post retained direct composite restoration|
61992402|NCT03476304|ACTIVE_COMPARATOR|Post retained ceramic restoration|
61992403|NCT05263154|EXPERIMENTAL|Goal directed low oxygen|Oxygen given at low concentrations following goals of oxygen saturation during and after anesthesia
61992404|NCT05263154|ACTIVE_COMPARATOR|High oxygen|Oxygen given as traditionally including high concentrations
61992405|NCT04356963|EXPERIMENTAL|All patients|All patients were intended to engage in three different 20-30 min sessions run by research coordinators and spaced a minimum of 4 hours apart to allow for washout of effects, including 1) a commercially available, immersive VR environment, theBlu (WEVR, Inc, Venice, California, USA) delivered via Oculus Rift (Oculus VR, Irvine, California, USA) headset (VR Blu), 2) a non-immersive two-dimensional mimic delivered via a tablet computer (Tablet Blu), and 3) a VR control session delivered via a content-less Oculus Rift headset (VR Blank). The three sessions were run by research coordinators and spaced a minimum of 4 hours apart. The intervention order was counterbalanced using a randomized sequence generator.
61992406|NCT02140658|ACTIVE_COMPARATOR|multiple health education interventions|The first group will receive health education manuals and Digital Video Disc (DVD) during hospitalization and regular health education messages during 6 months after discharge.
61992407|NCT02140658|PLACEBO_COMPARATOR|conventional health education|The second group will receive conventional health education during hospitalization except health education manuals, regular health education messages and Digital Video Disc (DVD)
61992408|NCT01317238|EXPERIMENTAL|CJ Vaccination arm|healthy vaccinia-experienced volunteers who received CJ smallpox vaccine
61992409|NCT02319005|ACTIVE_COMPARATOR|Revusiran (ALN-TTRSC)|administered by subcutaneous (SC) injection
61992410|NCT02319005|PLACEBO_COMPARATOR|Sterile Normal Saline (0.9% NaCl)|administered by subcutaneous (SC) injection
61992411|NCT05102110||Non-small cell lung cancer|A cohort of patients with known NSCLC who are assessed.
61992412|NCT05102110||Pancreatic cancer|A cohort of patients with known pancreatic adenocarcinoma who are assessed.
61992413|NCT05102110||Urothelial cancers|A cohort of patients with known uroepithelial cancers who are assessed.
61992414|NCT05102110||Colorectal cacncers|A cohort of patients with known colorectal cancers have been added to the study following methodology change in analysis techniques.
61992415|NCT03510156|EXPERIMENTAL|Treatment|
61992416|NCT03510156|NO_INTERVENTION|Observation|
61992417|NCT02187588|EXPERIMENTAL|Eschscholtzia Californica - low dose|
61992418|NCT02187588|EXPERIMENTAL|Eschscholtzia Californica - high dose|
61992419|NCT02187588|ACTIVE_COMPARATOR|Ibuprofen|
61992420|NCT02187588|PLACEBO_COMPARATOR|Placebo|
62387690|NCT02180854|EXPERIMENTAL|Intervention (8 hours)|EWS every 8 hours
62387691|NCT02180854|ACTIVE_COMPARATOR|Control (12 hours)|EWS every 12 hours
62387692|NCT01825811|EXPERIMENTAL|TissueGene-C (Low dose)|TissueGene-C (1.0 x 10\^6 cells per cm\^2 of the cartilage defect) combined with fibrin-glue
62387693|NCT01825811|EXPERIMENTAL|Experimental: TissueGene-C (High dose)|TissueGene-C (3.0 x 10\^6 cells per cm\^2 of the cartilage defect) combined with fibrin-glue
62387694|NCT05878340|EXPERIMENTAL|Miffy intervention|story of miffy, rewards based on colour they ate
62387695|NCT05878340|ACTIVE_COMPARATOR|Reward intervetion|no story, rewards not assigned to colours
62387696|NCT05878340|NO_INTERVENTION|Control|no story, no rewards
62387697|NCT00830479|ACTIVE_COMPARATOR|Open Surgery|
61992421|NCT05348382|EXPERIMENTAL|Intradermal acupuncture group|Points around the herpes zoster sites (about 1 cm peripherally) are selected for intradermal acupuncture (IDA) encircled needling. Meanwhile, intradermal acupuncture is also performed in Ashi acupoints in the distribution area of herpes zoster.
61992422|NCT05348382|SHAM_COMPARATOR|Sham intradermal acupuncture group|Sham intradermal acupuncture will be implemented in the same acupoints as the intradermal acupuncture group using pseudo-intradermal needling.
61992423|NCT04190134|EXPERIMENTAL|Immediate Robot|One month after study entry, participants will receive the robot at home for two months, followed by a three month observation period without the robot.
61992424|NCT04190134|ACTIVE_COMPARATOR|Delayed/Waitlist Robot|Three months after study entry, participants will receive the robot at home for three months.
61992425|NCT02142127|EXPERIMENTAL|14C-labelled GFT505 120 mg|
61992426|NCT05915767|EXPERIMENTAL|olive leaf tea|SIBO diagnosed individuals in this group will receive olive leaf tea orally, twice a day after meals for 8 weeks.
61992427|NCT05915767|NO_INTERVENTION|Control group|SIBO diagnosed individuals in this group will not receive olive leaf tea or any intervention for 8 weeks.
61992428|NCT01373749|EXPERIMENTAL|NOS|NO inhalation was performed in the first stage(\<48h) of PPHN, NO inhalation was replaced by sildenafil in the second stage(\>48h).
61992429|NCT01373749|PLACEBO_COMPARATOR|NO|NO inhalation was performed during the whole treatment procedure of PPHN. There is no other methods given to treat PPHN during the therapy course.
61992430|NCT02689258|EXPERIMENTAL|Part A, Cohort A: HTX-011A|HTX- 011A (bupivacaine/meloxicam), 200 mg/6 mg via injection
61992431|NCT02689258|PLACEBO_COMPARATOR|Parts A and B, Cohort B: Saline Placebo|Saline placebo via injection
61992432|NCT02689258|EXPERIMENTAL|Part A, Cohort C: HTX-011B|HTX- 011B (bupivacaine/meloxicam), 200 mg/6 mg via injection
61992433|NCT02689258|EXPERIMENTAL|Part A, Cohort D: HTX-011B|HTX- 011B (bupivacaine/meloxicam), 400 mg/12 mg via injection
61992434|NCT02689258|EXPERIMENTAL|Part A, Cohort E: HTX-011B|HTX- 011B (bupivacaine/meloxicam), 400 mg/12 mg via combination
61992435|NCT02689258|EXPERIMENTAL|Part A, Cohort F: HTX-011B|HTX- 011B (bupivacaine/meloxicam), 600 mg/18 mg via injection
61992436|NCT02689258|EXPERIMENTAL|Part B, Cohort A: HTX-002|HTX-002, 400 mg via combination
61992437|NCT02689258|EXPERIMENTAL|Part C, Cohort A: HTX-011B|HTX-011B (bupivacaine/meloxicam), 400 mg/12 mg via instillation
61992438|NCT02689258|EXPERIMENTAL|Part C, Cohort B: HTX-011B|HTX-011B (bupivacaine/meloxicam), 400 mg/12 mg via combination
61992439|NCT02689258|EXPERIMENTAL|Part C, Cohort C: HTX-011B|HTX-011B (bupivacaine/meloxicam), 300 mg/9 mg via combination
61992440|NCT02689258|ACTIVE_COMPARATOR|Part C, Cohort D: Bupivacaine HCI|Bupivacaine HCl, 100 mg via injection
61992441|NCT02689258|PLACEBO_COMPARATOR|Part C, Cohort E: Saline Placebo|Saline placebo via injection
61992442|NCT05698966|ACTIVE_COMPARATOR|betamethasone 12 mg|3 mg betamethasone sodium phosphate and 3 mg betamethasone acetate per milliliter. The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later
61992443|NCT05698966|EXPERIMENTAL|betamethasone 3 mg|3 mg betamethasone sodium phosphate and 3 mg betamethasone acetate per milliliter. The first dose of study drug medication will be administered at randomization as 0.5 ml injection; the next dose of 0.5 ml will be administered 24 hours later
61992444|NCT03146988|EXPERIMENTAL|RGB-02 6 mg SC (test product)|
61992445|NCT03146988|ACTIVE_COMPARATOR|Neulasta®|
61992446|NCT00891137|EXPERIMENTAL|Group A|Low dose, single donor CLT-008 (human myeloid progenitor cells)
61992447|NCT00891137|EXPERIMENTAL|Group B|Low dose, multiple donor CLT-008 (human myeloid progenitor cells)
61992448|NCT00891137|EXPERIMENTAL|Group C|Intermediate dose, multiple donor CLT-008 (human myeloid progenitor cells)
61992449|NCT00891137|EXPERIMENTAL|Group D|High dose, multiple donor CLT-008 (human myeloid progenitor cells)
61992450|NCT05993065||polycythemia vera|All patients aged 18 years and older who were newly diagnosed to have polycythemia vera between September 2014 and November 2022 at Sohag university hospital, department of internal medicine, hematology unit and hematology outpatient clinic.
61992451|NCT05993065||secondary erythrocytosis|Patients with secondary erythrocytosis will be included as controls and will be recruited from Sohag university hospital especially internal medicine department and chest department. Patients of chronic respiratory failure, congenital heart diseases, polycystic kidney and other causes recruited in this study to be compared to PV group as regards Hematocrit to Hemoglobin Ratio and Red Blood Cell Distribution Width
61992452|NCT05017610|EXPERIMENTAL|Treatment (methimazole, lomustine, liothyronine)|See Outline in Detailed Description.
61992453|NCT02858219|EXPERIMENTAL|Botulinum toxin|"Injection of 50 units (50U) botulinum toxin type A (powder), reconstituted in 1 mL physiologic saline solution in each perineal muscle (100 units in total).~First injection at day 1 and. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale)."
61992454|NCT02858219|PLACEBO_COMPARATOR|Saline solution|Injection of 1 mL physiologic saline solution in each perineal muscle. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale).
61992455|NCT01243359|EXPERIMENTAL|Treatment (sunitinib malate, bevacizumab)|Patients receive sunitinib malate PO on days 1-28 and bevacizumab IV over 30-90 minutes on day 29. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
61992456|NCT01068938||open angle glaucoma, glaucoma suspects|risk of progression, Latanoprost monotherapy
61992457|NCT06546254|EXPERIMENTAL|1% lidocaine paracervical injection|10 cc 1% lidocaine with epinephrine paracervical injection
61992458|NCT06546254|PLACEBO_COMPARATOR|normal saline paracervical injection|10 cc normal saline paracervical injection
61992459|NCT06546254|SHAM_COMPARATOR|control|gently tapping the cervicovaginal junction with a capped needle
61992460|NCT03469479|EXPERIMENTAL|Resection plus HAIC with FOLFOX|Patients receive 4 times of neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX and hepatic resection
61992461|NCT03469479|ACTIVE_COMPARATOR|Resection|Patients receive hepatic resection without neoadjuvant hepatic arterial infusion chemotherapy
61992462|NCT04738110||KCH patients|75 high grade glioma patients from KCH
61992463|NCT04738110||NHNN patients|75 high grade glioma patients from NHNN
61992464|NCT02050282|NO_INTERVENTION|Business as usual|Triage and treatment based on routine clinical assessment as usual
61992465|NCT02050282|EXPERIMENTAL|Supplementary NT-proBNP measurement|Triage and treatment based on routine clinical assessment supplemented with measurement of NT-proBNP
61992466|NCT00531232|EXPERIMENTAL|Clofarabine 55 mg/day|Participants received Clofarabine 55 mg/day orally for 5 consecutive days of each 28-day treatment cycle until disease progression or death, whichever comes first (maximum study duration: up to 4 years).
61992467|NCT00531232|EXPERIMENTAL|Clofarabine 35 mg/day|Participants received Clofarabine 35 mg/day orally for 5 consecutive days of each 28-day treatment cycle until disease progression or death, whichever comes first (maximum study duration: up to 4 years).
61992468|NCT00531232|EXPERIMENTAL|Clofarabine 25 mg/day|Participants received Clofarabine 25 mg/day orally for 5 consecutive days of each 28-day treatment cycle until disease progression or death, whichever comes first (maximum study duration: up to 4 years).
61992469|NCT00925418|NO_INTERVENTION|Without Glove|Patients do not use frozen glove during chemotherapy with Taxotere®
61992470|NCT00925418|EXPERIMENTAL|With Glove|Patients use frozen glove during chemotherapy with Taxotere®
61992471|NCT05813158|ACTIVE_COMPARATOR|Group 1|Patients will preoperatively receive low concentration-high volume U/S ESP block, and then the patient will be transferred to the operating room one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline}, for each patient.
61992472|NCT05813158|ACTIVE_COMPARATOR|Group 2|Patients will preoperatively receive high concentration-low volume U/S ESP block block, and then the patient will be transferred to the operating room one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% }, for each patien).
61992473|NCT03689166|ACTIVE_COMPARATOR|Probiotics group|Probiotic drug
61992474|NCT03689166|PLACEBO_COMPARATOR|Control group|This group will receive placebo
61992475|NCT03496142|ACTIVE_COMPARATOR|Transperineal prostate biopsy|Patient will have a transperineal prostate biopsy.
61992476|NCT03496142|ACTIVE_COMPARATOR|Transrectal prostate biopsy|Patient will have a transrectal prostate biopsy.
61992477|NCT05202847|EXPERIMENTAL|pulsed radiofrequency ablation to modified points group|pulsed radiofrequency ablation aimed at the adjusted target point of Park et al. under C-arm guidance
61992478|NCT05202847|ACTIVE_COMPARATOR|pulsed radiofrequency ablation to conventional points group|pulsed radiofrequency ablation aimed at conventional target point under C-arm guidance
61992479|NCT06383663|EXPERIMENTAL|Supraclavicular lymph node dissection combined with radiotherapy|Breast cancer patients with ipsilateral supraclavicular lymph node metastases receive standard radiotherapy after supraclavicular lymph node dissection.
61992480|NCT06383663|PLACEBO_COMPARATOR|radiotherapy|Breast cancer patients with ipsilateral supraclavicular lymph node metastases receive only standard radiotherapy.
61992481|NCT01903304|EXPERIMENTAL|olive oil|intervention with olive oil for 3 months
61992482|NCT01903304|PLACEBO_COMPARATOR|Placebo|Intervention with placebo for 3 months
61992483|NCT04882007|EXPERIMENTAL|OSE-127 High dose induction phase|OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 3 total infusions, weeks 0, 2, and 6
61992484|NCT04882007|EXPERIMENTAL|OSE-127 Low dose induction phase|OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 3 total infusions, weeks 0, 2, and 6
61992485|NCT04882007|PLACEBO_COMPARATOR|Placebo induction phase|Normal saline intravenous infusion 3 total infusions, weeks 0, 2, and 6
61992486|NCT04882007|EXPERIMENTAL|OSE-127 High dose optional extension phase|OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 7 total infusions, weeks 10, 14, 18, 22, 26, 30, and 34
61992487|NCT05930665|EXPERIMENTAL|Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin|Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin for 4 to 6 cycles, followed by Maintenance with Cadonilimab and Bevacizumab
61992488|NCT04016545||Treated patients|
61992489|NCT02753699|EXPERIMENTAL|From Study 2210|All participants enrolled from CDEB025A2210 (n=164) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
61992490|NCT02753699|EXPERIMENTAL|From Study 2301|All participants enrolled from CDEB025A2301 (n=397) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
62387698|NCT00830479|ACTIVE_COMPARATOR|Endoscopic Surgery|
61992491|NCT02753699|EXPERIMENTAL|From Study 2211|All participants enrolled from CDEB025A2211 (n=162) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
61992492|NCT00776646|EXPERIMENTAL|1|hydrochlorothiazide 50 mg tablet
61992493|NCT00776646|ACTIVE_COMPARATOR|2|hydrochlorothiazide 50 mg tablet
62387699|NCT02139709|EXPERIMENTAL|Ganglioside|1.0 gram ZETA dairy lipid powder (Fonterra NZ)
62387700|NCT02139709|PLACEBO_COMPARATOR|Placebo|1.0 gram milk fat fraction void of ganglioside
62387701|NCT00636233||Anencephaly|Fetuses with anencephaly, parents and siblings
62387702|NCT02229513|NO_INTERVENTION|Control|Normal cesarean technique.
61992494|NCT04130399|EXPERIMENTAL|Preoperative Chemotherapy + SBRT|"Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines.~After 6 cycles of neoadjuvant therapy are completed, patients will undergo imaging with pancreatic protocol CT and PET-MRI to assess disease status . Patients without evidence of disease progression at the end of 6 cycles of neoadjuvant treatment will proceed to SBRT followed by surgical resection.~Following surgery, patients will receive an additional 6 cycles of FOLFIRINOX chemotherapy."
61992495|NCT02586896|EXPERIMENTAL|Strengths-based Case Management (SBCM)|The structure of SBCM follows the widely accepted functions of case management-assessment, planning, linking, monitoring and advocacy-and the theory-driven gestalt of the strengths perspective. Strengths-based principles include an emphasis on client strengths, teaching clients a method for setting and completing goals, and development of a strong working alliance.
61992496|NCT02586896|ACTIVE_COMPARATOR|Screening, Assessment and Referral (SAR)|Following randomization, participants in the SAR condition will be provided with minimal scripted feedback to let them know that their assessment indicates substance dependence, and given a recommendation to seek treatment.
61992497|NCT00741481||1|all study population
61992498|NCT02124863|EXPERIMENTAL|Intrapulmonary Percussive Ventilation|number of refluxes during 20 min of IPV ( rate : 300/min, p = 10cmH2O) at least 120 min after feeding
61992499|NCT06197594|EXPERIMENTAL|Proprioceptive neuromuscular facilitation techniques|"GROUP A (experimental group)~PNF based exercises for trunk control duration 45 min 5 session/week for 6 weeks; Resist person concentric contraction while move in sitting .Resist eccentric control as th lie down. Balance using stabilizing reversals or rhythmic stabilization .Resist shoulder pelvis ,head.Trunk exercises dynamic reversals and combination of isotonic to increase trunk strength and coordination .Resist at scapula and lifting combinations for irradiation. Trunk flexion and extension. Reaching forward and to side with return,for this hip flexion, extension ,lateral motion and rotation with the trunk remaining stable Bridging exercises Lower trunk rotation .Weight shifting in long leg sitting"
61992500|NCT06197594|ACTIVE_COMPARATOR|Rebound Therapy|"Rebound Therapy lying down on trampoline bouncing created.10 times.Hip kneeling bounce and Standing bouncing with physio balls .Jump on trampoline. Learning front drops, seat drops for 5 minutes.~Resist person concentric contraction while move into sitting .Resist eccentric control as they lie down. Balance using stabilizing reversals to increase trunk stability .Resist shoulder pelvis, head.Trunk exercises: use dynamic reversals and combination of isotonic to increase trunk strength and coordination .Resist at scapula and lifting combination for irradiation. Trunk flexion and extension. Reaching forward and to side with return,for this hip flexion , extension ,lateral motion and rotation with trunk remaining stable Bridging exercises Lower trunk rotation .Weight shifting in long leg sitting"
61992501|NCT00575055|EXPERIMENTAL|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
61992502|NCT00575055|PLACEBO_COMPARATOR|Placebo Dose|infusion every 13 weeks for a total of 6 infusions.
61992503|NCT00575055|EXPERIMENTAL|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions.
61992504|NCT00648596|PLACEBO_COMPARATOR|Arm 2|
61992505|NCT00648596|ACTIVE_COMPARATOR|Arm 1|
61992506|NCT05403879|EXPERIMENTAL|cases undergoing fixation of fractured greater tuberosity|
61992507|NCT05111977|EXPERIMENTAL|Capsule stimulation|Participants in this arm will receive gastric stimulation via the Vibrant capsule
61992508|NCT05111977|PLACEBO_COMPARATOR|Placebo stimulation|Participants in this arm will receive no gastric stimulation via a placebo capsule
61992509|NCT05744349|EXPERIMENTAL|Study group|Patients who are younger than the age of 10 years old from both genders and suffering from displaced fractures of shaft both bone of the forearm
61992510|NCT04414709|EXPERIMENTAL|Two short implants|DENTIUM superline implant fixture is characterized by sandblasted with large grits and acid etched surface treatment (S.L.A). SLA surface allows good bone-implant contact with good clinical performance, maintaining crestal bone margin. Short Implants of 7.0 mm length and 4.5 mm diameter are to be used. The Short Implants are characterized by 1.5mm supra-bony smooth collar, and 5.5mm infra-bony surface treated double threaded titanium.
61992511|NCT04414709|ACTIVE_COMPARATOR|Single short implant|DENTIUM superline implant fixture is characterized by sandblasted with large grits and acid etched surface treatment (S.L.A). SLA surface allows good bone-implant contact with good clinical performance, maintaining crestal bone margin. Short Implants of 7.0 mm length and 4.5 mm diameter are to be used. The Short Implants are characterized by 1.5mm supra-bony smooth collar, and 5.5mm infra-bony surface treated double threaded titanium.
61992512|NCT05096507||Study group|People age 65 years and older undergoing primary hip fracture surgery
61992513|NCT05252039|EXPERIMENTAL|Goals in Focus Therapy|Participants in this arm will receive 24 weekly sessions with Goals in Focus therapy (GiF) over 6 months.
61992514|NCT05252039|NO_INTERVENTION|Waitlist Control|Participants in this arm will not receive any psychological treatment for 6 months. After 6-months, they will receive 24 sessions of Goals in Focus Therapy.
61992515|NCT01113879|EXPERIMENTAL|Aphasia therapy with an exercise adjuvant|"Aphasia therapy for anomia: The treatment is a traditional lexical/semantic stimulation approach during which subjects will attempt to name drawings of objects.~Aerobic exercise: An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate."
61992516|NCT01113879|PLACEBO_COMPARATOR|Aphasia therapy with a stretching adjuvant|"Aphasia therapy for anomia: The treatment is a traditional lexical/semantic stimulation approach during which subjects will attempt to name drawings of objects.~Stretching: Stretching will occur for 50 minutes a day, three days/week for 12 weeks."
61992517|NCT02869490||Patients with cervical cancer diagnosis|
61992518|NCT01814735|EXPERIMENTAL|Brown rice|Brown Rice
61992519|NCT01814735|ACTIVE_COMPARATOR|White rice|White rice
61992520|NCT03669120|ACTIVE_COMPARATOR|Arm I (mainstream instructional care)|Participants receive mainstream instructional care including brief advice on how to quit smoking, 10-week supply of NRT in the form of nicotine patches, and intensive print materials to promote smoking cessation.
62559812|NCT01342471|ACTIVE_COMPARATOR|30-min walk|"Instructed to use brisk walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Participants were permitted to exercise in one long bout (30 min) or divide the exercise into multiple bouts as long as the bout length was 10 min or greater."
61992521|NCT03669120|EXPERIMENTAL|Arm II (tailored intensive care)|Participants receive tailored intensive care including brief advice on how to quit smoking, NRT, and intensive print materials to promote smoking cessation as in Arm I. Participants also receive individualized text based messages to promote smoking cessation for 6 months.
62767894|NCT02546960|EXPERIMENTAL|ExPEC4V (16 : 16 : 16 : 16)|Participants will be stratified according to their age in 2 groups \>=18 to \<50 years and \>=50 years. Part 1: In age group \>= 18 to \<50 years, participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in \>=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses (8 : 8 : 8 : 16/16 : 16 : 16 : 16) of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
61992522|NCT01871610|EXPERIMENTAL|Alzheimer disease after mild traumatic brain injury|Based on the TBI registry databank, to recruit patients 1, 5, 10, 15 years after mTBI for cognitive evaluatio
61992523|NCT01871610|EXPERIMENTAL|mild traumatic brain injury without Alzheimer disease|To recruit patients 1, 5, 10, 15 years after mTBI with or without cognitive impairment and age-gender-matched controls (a total of 3 groups) for amyloid- positron emission tomography (A-PET)
61992524|NCT01871610|EXPERIMENTAL|Normal control|People aged 30 or older without mTBI or AD
61992525|NCT03924258|EXPERIMENTAL|HEART FAILURE|Patients with Heart Failure diagnosis
61992526|NCT02717988|EXPERIMENTAL|SKI-O-703 50 mg|SKI-O-703 capsule (2x25 mg)
61992527|NCT02717988|EXPERIMENTAL|SKI-O-703 100 mg|SKI-O-703 capsule (4x25 mg)
61992528|NCT02717988|EXPERIMENTAL|SKI-O-703 200 mg|SKI-O-703 capsule (1x200 mg)
61992529|NCT02717988|EXPERIMENTAL|SKI-O-703 400 mg|SKI-O-703 capsule (2x200 mg)
61992530|NCT02717988|EXPERIMENTAL|SKI-O-703 600 mg|SKI-O-703 capsule (3x200 mg)
61992531|NCT02717988|EXPERIMENTAL|SKI-O-703 800 mg|SKI-O-703 capsule (4x200 mg)
61992532|NCT02717988|PLACEBO_COMPARATOR|Placebo|Placebo capsule
61992533|NCT04020133|ACTIVE_COMPARATOR|the control group|this group will receive post-operative saphenous nerve block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg.
61992534|NCT04020133|ACTIVE_COMPARATOR|the intervention group|this group will receive popliteal plexus block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg in addition to standard saphenous nerve block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg.
61992535|NCT01862887|EXPERIMENTAL|PH-797804|Subjects will receive a single 24 mg dose in the fed state
61992536|NCT01862887|EXPERIMENTAL|Moxifloxacin|Subjects will receive a single 400 mg dose in the fed state
62767895|NCT02546960|PLACEBO_COMPARATOR|Placebo|Participants will be stratified according to their age in 2 groups \>= 18 to \<50 years and \>=50 years. Part 1: Participants will receive matching placebo to ExPEC4V as an intramuscular injection into the deltoid muscle. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe and well tolerated based on the review of safety data through Day 8 by the IDMC.
61992537|NCT01862887|EXPERIMENTAL|Placebo|Subjects will receive a single placebo dose
61992538|NCT04006665||Lung Ultrasonography prior to docking Robotic arms|Base line Lung ultrasonography will be performed in three basal zones for Right and Left lung -Post intubation and prior to docking robotic arms .
61992539|NCT04006665||Lung Ultrasonography after removal of robotic arms|Lung Ultrasonography will be performed to assess degree of atelectasis after removal of robotic arms and before extubation in three basal zones for Right and Left lung .
61992540|NCT03022292|EXPERIMENTAL|IAI Treatment|Intravitreal injection of aflibercept 2 mg/0.05 ml at baseline, week 4, week 8, week 16, week 24, week 36, and week 48. Additional injections can be administered during the remaining visits on an as needed basis per Primary Investigator (PI) discretion based on the presence of any intraretinal or subretinal fluid on OCT, heme visualized on examination, reduction of BCVA by 5 or more ETDRS letters, or evidence of either increased area, density, or activity of the brush border of the neovascularization on OCT-angiography. There will be a minimum of 21 days between subsequent injections. Each subject will therefore receive a minimum of 7 injections and up to a maximum of 13 injections throughout the study period.
61992541|NCT04564612|EXPERIMENTAL|Part 1|Participants will receive single oral dose of BIIB091 on Day 1 of each study period, in fasted state, for up to 5 periods. There will be a minimum 7-day washout between Day 1 of each study period.
61992542|NCT04564612|EXPERIMENTAL|Part 1B|Participants will be randomized to receive single oral or 2 oral doses for divided daily doses of BIIB091 on Day 1 of Period 1, in fasted state or single oral dose of BIIB091 on Day 1 of Period 1, in fed state. Participants will receive single oral dose of BIIB091 on Day 1 of Period 2, in fasted state. Participants will receive single or two divided oral dose(s) of BIIB091 on Day 1 of Periods 3 and 4, in fasted or fed state. There will be a minimum 7-day washout between Day 1 of each study period.
61992543|NCT04564612|EXPERIMENTAL|Part 2|Participants will receive single oral dose of BIIB091 on Day (D) 1 of Period (P) 1 in fasted/fed state; then itraconazole 100 milligram (mg) capsules (cap), orally, twice daily (BID) for 1 day (D -4) of P2, in fed state; then itraconazole 100 mg cap, orally, once daily (QD) for 2 days (D -3, -2) of P2, in fed state; then itraconazole 100 mg cap, orally, QD for 1 day (D -1) of P2, in fasted/fed state; then combination of itraconazole 100 mg cap, orally and BIIB091, orally on 5th day (D 1) of P2, in fasted/fed state; then itraconazole 100 mg cap, orally on 6th day (D 2) of P2, in fed state; then rabeprazole 20 mg tablets (tab), orally, BID for 3 days (D -3, -2, and -1) of P3 in fed state; then combination of rabeprazole 20 mg tab, orally and BIIB091, orally, on 4th day (D 1) of P3 in fasted/fed state. Minimum 7-day washout between dose of BIIB091 in P1 and 1st dose of itraconazole in P2; minimum 10-day washout between final dose of itraconazole in P2 and 1st dose of rabeprazole in P3.
62767896|NCT04932291|EXPERIMENTAL|vafidemstat 1.2mg|Vafidemstat is administered as capsules.
62767897|NCT04932291|PLACEBO_COMPARATOR|placebo|Placebo is administered as capsules.
62767898|NCT04179513|EXPERIMENTAL|GB224 10mg|GB224 10mg
62767899|NCT04179513|EXPERIMENTAL|GB224 20mg|GB224 20mg
62767900|NCT02858752|EXPERIMENTAL|Healthy Children|Memory and Attention in healthy children will be assessed non-invasively through behavioral and electrophysiological measures while participants will perform passive or active computer task involving auditory and/or visual perception.
62767901|NCT03149003|EXPERIMENTAL|Arm 1: DSP-7888 Dosing Emulsion plus Bevacizumab|
61992544|NCT04564612|EXPERIMENTAL|Part 3|Participants will receive BIIB091, orally, QD or BID for at least 7 days in fasted or fed state.
61992545|NCT02442778|PLACEBO_COMPARATOR|Placebo|Participants were administered AVP-786 matching placebo capsules, orally, twice daily (BID) for up to 12 weeks.
61992546|NCT02442778|EXPERIMENTAL|AVP-786-28|Participants were administered AVP-786-18 capsule, orally, once daily (QD) along with AVP-786 matching placebo capsule, orally, QD during Week 1 followed by AVP-786-18 capsules, orally, BID during Weeks 2, 3 and AVP-786-28 capsules, orally, BID during Weeks 4 to 12.
62767902|NCT03149003|ACTIVE_COMPARATOR|Arm 2: Bevacizumab|
61992547|NCT02442778|EXPERIMENTAL|AVP-786-42.63|Participants were administered AVP-786-28 capsules, orally, QD along with AVP-786 matching placebo capsule, orally, QD during Week 1 followed by AVP-786-28 capsules, orally, BID during Weeks 2, 3, and AVP-786-42.63 capsules, orally, BID during Weeks 4 to 12.
61992548|NCT04049942|EXPERIMENTAL|Prehabilitation group|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization(whey protein supplement), and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence). Patients are advised to record daily exercises and adherence to nutritional, psychological and other recommendations. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
61992549|NCT04049942|EXPERIMENTAL|Aerobic training group|Aerobic training strategy includes the same guided individualized moderate aerobic exercise as the multimodal prehabilitation group, as well as the conventional guidance. Patients are advised to record daily exercises. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
61992550|NCT04602637||P1|
61992551|NCT04602637||P2|
61992552|NCT04602637||P3|
61992553|NCT02599181|EXPERIMENTAL|WITH-Group: alcoholic skin disinfection|In the WITH-group, the skin is disinfected with an aerosolized alcoholic solution propanol-biphenol: Kodan, Schülke \& Mayr, Zurich, Switzerland prior to perineural catheter removal.
61992554|NCT02599181|NO_INTERVENTION|WITHOUT: no alcoholic skin desinfection|"In the WITHOUT-group, the skin is NOT disinfected prior to perineural catheter removal."
61992555|NCT06088433|EXPERIMENTAL|SAPT|Ticagrelor SAPT 90mgBID for 1 month, followed by 60mgBID
61992556|NCT06088433|ACTIVE_COMPARATOR|DAPT|Aspirin 100mgQD+Clopidogrel 75mgQD for 1 month, followed by clopidogrel 75mgQD
61992557|NCT03795675|EXPERIMENTAL|Meniere's Disease/Vestibular Schwannoma|Individuals diagnosed with Meniere's disease and undergoing labyrinthectomy or diagnosed with vestibular schwannoma and undergoing surgical excision via translabyrinthine approach for treatment will receive cochlear implant at the time of surgery.
61992558|NCT03913091|EXPERIMENTAL|20 mL 0.5% Bupivacaine HCL|
61992559|NCT03913091|EXPERIMENTAL|Interscalene nerve block with Liposomal + Bupivacaine 0.5%|Administered in an Interscalene block for TSA
61992560|NCT05019924|ACTIVE_COMPARATOR|Intervention arm|Dietary supplement
61992561|NCT05019924|NO_INTERVENTION|Control arm|No intervention given
61992562|NCT01015586|EXPERIMENTAL|Lamotrigine|Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks
61992563|NCT01015586|PLACEBO_COMPARATOR|Placebo|Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks
61992564|NCT02860715|EXPERIMENTAL|Cohort 1|GX-I7 SC 20㎍/㎏ (8 subjects) / Placebo (2 subjects)
61992565|NCT02860715|EXPERIMENTAL|Cohort 2|GX-I7 SC 60㎍/㎏ (8 subjects) / Placebo (2 subjects)
61992566|NCT02860715|EXPERIMENTAL|Cohort 3|GX-I7 IM 60㎍/㎏ (8 subjects) / Placebo (2 subjects)
61992567|NCT01274403|EXPERIMENTAL|Melphalan, prednisone plus Thalidomide|
61992568|NCT01274403|ACTIVE_COMPARATOR|Melphalan and Prednisone|
61992569|NCT06122090|EXPERIMENTAL|Treatment|Bimatoprost will be delivered to the scars using laser-assisted drug delivery in this arm
62767903|NCT05956509|EXPERIMENTAL|Part 1: ABBV-950 Dose A|Participants will receive ABBV-Dose A on Day 1.
62767904|NCT05956509|PLACEBO_COMPARATOR|Part 1: Placebo for ABBV-950 Dose A|Participants will receive placebo for ABBV-950 on Day 1.
62767905|NCT05956509|EXPERIMENTAL|Part 1: ABBV-950 Dose B|Participants will receive ABBV-950 Dose B on Day 1.
62767906|NCT05956509|PLACEBO_COMPARATOR|Part 1: Placebo for ABBV-950 Dose B|Participants will receive placebo for ABBV-950 on Day 1.
62767907|NCT05956509|EXPERIMENTAL|Part 1: ABBV-950 Dose C|Participants will receive ABBV-950 Dose C on Day 1.
61992570|NCT06122090|SHAM_COMPARATOR|Control|Saline control will be delivered to the scars using laser-assisted drug delivery in this arm
61992571|NCT05580341|EXPERIMENTAL|Zerun HPV-9|Subjects receive 3 doses of Zerun HPV-9 vaccine
61992572|NCT05580341|ACTIVE_COMPARATOR|GARDASIL®9|Subjects receive 3 doses of GARDASIL®9
62767908|NCT05956509|PLACEBO_COMPARATOR|Part 1: Placebo for ABBV-950 Dose C|Participants will receive placebo for ABBV-950 on Day 1.
62767909|NCT05956509|ACTIVE_COMPARATOR|Part 2: BOTOX Dose A|Participants will receive BOTOX Dose A on Day 1.
62767910|NCT05956509|EXPERIMENTAL|Part 2: ABBV-950 Dose A|Participants will receive ABBV-950 Dose A on Day 1.
62767911|NCT05956509|EXPERIMENTAL|Part 2: ABBV-950 Dose B|Participants will receive ABBV-950 Dose B on Day 1.
62767912|NCT05956509|EXPERIMENTAL|Part 2: ABBV-950 Dose C|Participants will receive ABBV-950 Dose C on Day 1.
62767913|NCT05956509|PLACEBO_COMPARATOR|Part 2: Placebo for ABBV-950|Participants will receive placebo for ABBV-950 on Day 1.
62767914|NCT00412074|ACTIVE_COMPARATOR|Control 400 IU vitamin D3|400 IU vitamin D3/day given to lactating women and 400 IU vitamin D3/day given as oral supplement to infant in dyad
62767915|NCT00412074|EXPERIMENTAL|2400 IU vitamin D3 (cholecalciferol)|2400 IU vitamin D3 given to lactating mother: 400 IU vitamin D3 from a prenatal vitamin and 2000 IU vitamin D3 and 0 IU vitamin D3 (placebo) given to her breastfeeding infant
62387703|NCT02229513|EXPERIMENTAL|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
62387704|NCT01212627|EXPERIMENTAL|Ridaforolimus|Ridaforolimus: 20mg Daily, 5 days each week, on a 28 day cycle until progression
62387705|NCT03036891|EXPERIMENTAL|Study Group|Naloxegol 25 mg, oral tablet, daily for 4 weeks
62387706|NCT03036891|PLACEBO_COMPARATOR|Placebo Control|Placebo Oral Tablet, 25 mg, oral tablet, daily for 4 weeks
62387707|NCT02033824|OTHER|Group 1 Control|Will receive only traditional craniectomy
62387708|NCT02033824|EXPERIMENTAL|Group 2 Treatment dHACM|Will receive craniectomy, but with the addition of a piece of dHACM placed over any dural defect or dural closure.
62387709|NCT01568957|EXPERIMENTAL|Dual-task gait training|Gait training with simultaneous performance of cognitive tasks for 75% of training session.
62387710|NCT01568957|ACTIVE_COMPARATOR|Single-task gait training|Gait training (without simultaneous cognitive task performance)
62387711|NCT04582695|ACTIVE_COMPARATOR|Written Exposure Therapy|
62387712|NCT04582695|EXPERIMENTAL|Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder|
62387713|NCT04282343|OTHER|Arm I- Usual care|Patients receive usual care consisting of general cancer treatment information on a sheet of paper before attending video-recorded meetings with their oncologist to discuss treatment plans.
62387714|NCT04282343|OTHER|Arm II - DISCO app|Patients use the DISCO education and communication app before attending video-recorded meetings with their oncologist to discuss treatment plans.
62387715|NCT02245295||EBUS-TBNA|EBUS-TBNA for enlarged mediastinal/hilar lymph nodes
62387716|NCT06322511|EXPERIMENTAL|Intervention group|These families receive Dialogical family guidance, including six meetings (during 3 months) within the intervention manual proceedings. Parents fill the questionnaires before and after the intervention.
62387717|NCT06322511|NO_INTERVENTION|comparative group|"These families (parents in the family) give responses how they manage in ordinary life with their child with neurodevelopmental disorders.~These families do not receive the intervention."
62387718|NCT02483715|EXPERIMENTAL|High-dose dual therapy|group A-high-dose dual therapy ( rabeprazole 20 mg, tablet, qid + amoxicillin 750 mg, capsule, qid for 14 days)
62387719|NCT02483715|ACTIVE_COMPARATOR|Bismuth-containing quadruple therapy|group B-bismuth-containing quadruple therapy (rabeprazole 20 mg, tablet, bid + tripotassium dicitrate bismuthate 300 mg, tablet, qid + metronidazole 250 mg, tablet, qid + tetracycline 500 mg qid, capsule, for 10 days)
62387720|NCT02966912|EXPERIMENTAL|Magnesium|20 participants will be treated with 400 mg of Magnesium Oxide twice daily
62387721|NCT02966912|ACTIVE_COMPARATOR|Comparator|20 participants will receive no treatment
62387722|NCT01344213|ACTIVE_COMPARATOR|Pregabalin|Oral single-dose of pregabalin (150 mg) and 1 capsule of placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
62387723|NCT01344213|ACTIVE_COMPARATOR|Celecoxib|Oral single-dose of celecoxib (400 mg) and 1 capsule of placebo (C) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
62387724|NCT01344213|ACTIVE_COMPARATOR|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
62559813|NCT01342471|EXPERIMENTAL|TV commercial stepping|"Instructed to stand and briskly step in place, or briskly walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Rather than exercising continuously for at least 10-minute bouts, participants performed multiple (\~9 or 10), short (\~3-5 min) bouts, conveniently incorporated into their daily TV viewing time."
62387725|NCT01344213|PLACEBO_COMPARATOR|Placebo|Oral single-dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
62387726|NCT01896596|ACTIVE_COMPARATOR|Menjugate|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with Menjugate (at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
62387727|NCT01896596|ACTIVE_COMPARATOR|Menitorix|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with Menitorix (at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
62387728|NCT01896596|ACTIVE_COMPARATOR|NeisVac-C|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with NeisVac-C(at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
62387729|NCT01999205|EXPERIMENTAL|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees
62559814|NCT03063008|OTHER|Lumbar fusion with PEEK cage|Control arm
62387730|NCT04730739|EXPERIMENTAL|FastFrame External Fixation System - Knee Spanning or Damage Control Kit|The patient must have been treated with either Knee Spanning or Damage Control FastFrame External Fixation System.
62559815|NCT03063008|OTHER|Lumbar fusion with TiPEEK cage|Study arm
62559816|NCT00122382|ACTIVE_COMPARATOR|ABA + MTX|abatacept 10 mg/kg intravenous (IV) + methotrexate
62559817|NCT00122382|ACTIVE_COMPARATOR|Placebo (PLA) + MTX|placebo IV + methotrexate
62559818|NCT04430062||Covid-19 patients operated (February 21st -April 10th)|
62559819|NCT04845867||Measurement and digital documentation|continuous measurement and digital documentation with alarms and display off
62559820|NCT03103438|EXPERIMENTAL|Cohort 1|his cohort includes one subject who will receive the maximum safe starting dose of BCD-089 (0.06 mg/kg) subcutaneously. If the dose limitating toxicity occurs within the first seven days after injection the study will be stopped. If there is no DLT within mentioned above period then Cohort no.2 is included.
62567682|NCT02060058|EXPERIMENTAL|Null responder or cirrhotic patients|"For null responder or cirrhotic patients, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 to 48.~Dosage of drugs: as Patients with 32 week therapy Stop trial intervention for for null responder or cirrhotic patients: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm C)."
62387731|NCT03845842|ACTIVE_COMPARATOR|Control (volitional help sheet)|"Participants read a brief statement designed to encourage them to reduce their cannabis use (We want you to plan to reduce your cannabis use). Participants are presented with a table with two columns and twenty rows. Twenty 'high risk' situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to use cannabis and identifying ways to overcome those temptations had been shown to help people change their behaviour and are asked to tick critical situations/appropriate responses that might be useful to them."
62387732|NCT03845842|EXPERIMENTAL|Intervention (volitional help sheet)|"Participants read a brief statement designed to encourage them to reduce their cannabis use (We want you to plan to reduce your cannabis use). Participants are presented with a table with two columns and twenty rows. Twenty 'high risk' situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to use cannabis and identifying ways to overcome those temptations had been shown to help people change their behaviour. Implementation intentions are formed by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
62387733|NCT02134912|EXPERIMENTAL|Arm I (crizotinib, pemetrexed disodium)|Patients receive crizotinib PO BID on days 1-21 and pemetrexed disodium IV over 10 minutes on day 1.
62387734|NCT02134912|EXPERIMENTAL|Arm II (pemetrexed disodium)|ARM II: Patients receive pemetrexed disodium IV over 10 minutes on day 1. Upon disease progression or symptomatic deterioration, patients may crossover to Arm I.
62387735|NCT02350660|EXPERIMENTAL|Cow's milk for alpha-gal allergics|daily consumption of cow's milk
62387736|NCT02350660|EXPERIMENTAL|Peanut powder|peanut oral immunotherapy
62387737|NCT00372905|EXPERIMENTAL|bortezomib, Ibritumomab tiuxetan, rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
62387738|NCT00312390|OTHER|Healthy Control Subjects|
62559821|NCT03103438|EXPERIMENTAL|Cohort 2|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 0.3 mg/kg.If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no.3 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 3.
62559822|NCT03103438|EXPERIMENTAL|Cohort 3|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 0.625 mg/kg.If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 4 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 4.
62567683|NCT05270577|EXPERIMENTAL|Prehabilitation|Prehabilitation with physical exercise, psychological support, nutritional support and smoking/alchohol stop
62767916|NCT00412074|EXPERIMENTAL|6400 IU vitamin D3 (cholecalciferol)|6400 IU vitamin D3 given to lactating mother: 400 IU vitamin D3 from a prenatal vitamin and 6000 IU vitamin D3 and 0 IU vitamin D3 (placebo) given to her breastfeeding infant
62767917|NCT04708132|ACTIVE_COMPARATOR|screw retained restorations|
62767918|NCT04708132|OTHER|implant-retained ball overdentures|
62767919|NCT00002514|EXPERIMENTAL|Transplant|Allogeneic (if donor) or Autologous (if no donor) bone marrow transplant
62767920|NCT00002514|ACTIVE_COMPARATOR|Conventional Consolidation/Maintenance|Consolidation/Maintenance Therapy
62767921|NCT04710914|EXPERIMENTAL|sedation by inhaled isoflurane|sedation by midazolam with the MIRUS device
62767922|NCT04710914|ACTIVE_COMPARATOR|sedation with intravenous midazolam|continuation of sedation with intravenous midazolam
62767923|NCT04832945||Ivermectin Group|Healthcare personnel receiving Ivermectin weekly PrEP
62767924|NCT04832945||Control Group|Healthcare personnel not receiving Ivermectin
62387739|NCT00312390|OTHER|Subjects with amblyopia|
62387740|NCT05230693|EXPERIMENTAL|SPARC Group|
62387741|NCT05230693|ACTIVE_COMPARATOR|Enhanced Standard Care Control Group|
62387742|NCT05916534|EXPERIMENTAL|WeCAB Intervention|
62387743|NCT05916534|NO_INTERVENTION|Usual Care|
62387744|NCT00041119|ACTIVE_COMPARATOR|Arm I (CA for 4 courses)|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62387745|NCT00041119|EXPERIMENTAL|Arm II (CA for 6 courses [closed to accrual 12/15/2007])|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62767925|NCT00876785|ACTIVE_COMPARATOR|1|Reference wheat bread breakfast
61992573|NCT03419728|EXPERIMENTAL|Healthy Families, Healthy Futures|Family coaches meet with participating pregnant and parenting females, the woman's partner, and the child. Visit frequency varies from once per week to once per month, depending on the length of time in the program, the client's needs, and the accomplishment of program milestones. In the short term, the program seeks to increase the use of Long-Acting Reversible Contraception (LARC), enhance family functioning including improving father involvement, and to meet the baby's child development needs. In the long term, the program aims to delay subsequent pregnancies, ensure positive child development, and increase parents' self-sufficiency.
61992574|NCT03419728|NO_INTERVENTION|Control group|"No active treatment for control group. Control group has access to business as usual services in community."
61992575|NCT02507635|NO_INTERVENTION|healthy volunteers|healthy volunteers
61992576|NCT02507635|ACTIVE_COMPARATOR|Desloratadine|patients with allergic rhinitis under treatment with Desloratadine 5 mg/day, 4 weeks
61992577|NCT02507635|ACTIVE_COMPARATOR|Levocetirizine|patients with allergic rhinitis under treatment with Levocetirizine 5 mg/day, 4 weeks
61992578|NCT02876900|EXPERIMENTAL|Low dose Asenapine maleate patch|Low dose asenapine maleate, transdermal patches will be compared against placebo patches.
61992579|NCT02876900|EXPERIMENTAL|High dose asenapine maleate patch|High dose asenapine maleate, transdermal patches will be compared against placebo patches.
61992580|NCT02876900|PLACEBO_COMPARATOR|Placebo transdermal patch|Low dose or high dose asenapine maleate transdermal patch will be compared against placebo patches
61992581|NCT02134873|ACTIVE_COMPARATOR|0.1ml 24% sucrose concurrent opioids|0.1ml 24% sucrose concurrent opioids
61992582|NCT02134873|ACTIVE_COMPARATOR|0.5ml 24% sucrose concurrent opioids|0.5ml 24% sucrose concurrent opioids
61992583|NCT02134873|ACTIVE_COMPARATOR|1.0ml 24% sucrose concurrent opioids|1.0ml 24% sucrose concurrent opioids
61992584|NCT02134873|ACTIVE_COMPARATOR|0.1ml 24% sucrose no opioids|0.1ml 24% sucrose no opioids
61992585|NCT02134873|ACTIVE_COMPARATOR|0.5ml 24% sucrose no opioids|0.5ml 24% sucrose no opioids
62387746|NCT00041119|EXPERIMENTAL|Arm III (paclitaxel for 4 courses)|Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62567684|NCT05270577|ACTIVE_COMPARATOR|Standard care|Standard preoperative recomendations
61992586|NCT02134873|ACTIVE_COMPARATOR|1.0ml 24% sucrose no opioids|1.0ml 24% sucrose no opioids
61992587|NCT05276245|EXPERIMENTAL|Program Group|This structured protocol was a 10-day nature-based program with high level of nature engagement and involvement of multiple sensory processes. The program was held in lunch breaks between 12:00 noon and 2:00 p.m. Each session consisted of 30 minutes in the Eco Garden of The Education University of Hong Kong. Activities of this program included walking, ecological photography, sketching butterflies, planting vegetables, drinking herbal tea, observing birds, and taking a nap in nature. Each activity corresponded to specific sensory pathways. For example, butterfly sketching is focused on the use of visual sense, whereas drinking herbal tea involved sense of taste, smell, and touch. Trainers with master's degrees in environmental education and rich experience in guiding ecological tours provided instructions and guidance to participants during the activities. Participants were also asked to pay attention to their surroundings and focus on their five senses during participation.
61992588|NCT05276245|NO_INTERVENTION|Waitlist control group|Participants who were randomly assigned to the waitlist control group were instructed to spend their usual half-hour lunch break in the office for consecutive 10 weekdays. Also, the waitlist control group was told to wait for at least three months before they took part in the structured protocol of nature contact.
61992589|NCT04037319||Main cohort|Will undergo surgery for colorectal cancer with curative intent as planned by local cancer multidisciplinary team.
61992590|NCT00805428||2|control group
61992591|NCT00805428||patients with UC|patients with UC, without corticosteroid or immunosuppressive therapy
61992592|NCT02106728|EXPERIMENTAL|Multi-Family Therapy|Multi-family group therapy involving eight to ten families who meet as a group with two therapists for a duration of 8, 1.5h sessions.
61992593|NCT02106728|ACTIVE_COMPARATOR|Supportive Family Therapy|Family supportive counseling consists of people with eating disorders and their family members meeting with a family therapist. This is treatment as usual in the Eating Disorders Program at University Health Network.
61992594|NCT04390581|EXPERIMENTAL|Juvéderm® VOLIFT with Lidocaine|All participants to be injected with Juvéderm® VOLIFT with Lidocaine in both hands no more than 6ml total per both hands. Optional touch-up will be done on Day 30 according to aesthetic results.
61992595|NCT01238614|EXPERIMENTAL|PSF-JIT|Mothers in this arm receive prescreening questions and clinicians receive just-in-time handouts to aid in diagnosis.
61992596|NCT01238614|EXPERIMENTAL|PSF|Mothers in this arm receive screening questions on the prescreener form
61992597|NCT01238614|PLACEBO_COMPARATOR|Control|Mothers in this arm receive no maternal depression CHICA additional care
61992598|NCT01716013|EXPERIMENTAL|BondEase|Topical Skin Adhesive
61992599|NCT01716013|ACTIVE_COMPARATOR|CWCD|Conventional Wound Closure Devices (CWCD) including: sutures, staples, or adhesive strips
61992600|NCT00291668|EXPERIMENTAL|Certolizumab pegol 200 mg|Subjects received one subcutaneous (sc) injection of 200 mg CZP and one injection of Placebo to maintain the study blind on Weeks 0 (first dose), 2 and 4.
61992601|NCT00291668|EXPERIMENTAL|Certolizumab pegol 400 mg|Subjects received two subcutaneous (sc) injections of 200 mg CZP on Weeks 0 (first dose), 2 and 4.
61992602|NCT00291668|PLACEBO_COMPARATOR|Placebo|Subjects received two subcutaneous (sc) injections of Placebo on Weeks 0 (first dose), 2 and 4.
61992603|NCT04112017|EXPERIMENTAL|YVOIRE Y-Solution 360|Maximum 5 ml including touch-up
62387747|NCT00041119|EXPERIMENTAL|Arm IV (paclitaxel for 6 courses [closed 12/15/2007])|Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62567685|NCT01253629|EXPERIMENTAL|25 mg bid AFQ056|1 capsule of 25 mg and 1 capsule of placebo per intake
62567686|NCT01253629|EXPERIMENTAL|50 mg bid AFQ056|2 capsules of 25 mg per intake
62767926|NCT00876785|EXPERIMENTAL|2|Rye bread breakfast
62767927|NCT04465565|EXPERIMENTAL|Intravenous fluid administration|This arm will include 20 children who received Testoviron or Estrofem prior to the the stimulation test and 40 children who did not receive preparation prior to the stimulation test. Participants in this arm will be treated with I. V of 9%NORMAL SALINE (0. 20cc /Kg) administrated over 60 minutes. The fluids treatment will be initiated 90 minutes after the stimulation test will begin
61992604|NCT04112017|NO_INTERVENTION|No-treatment|No-treatment. At 12 weeks after the assessment, treatment maximum 5 ml including touch-up
61992605|NCT02758392|EXPERIMENTAL|Dose 1: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 0.1 milligram/kilogram (mg/kg) or Placebo Intravenously (IV) on Day 1.
62387748|NCT03814642|ACTIVE_COMPARATOR|Clopidogrel 75 mg|Oral administration of clopidogrel 75 mg tablet once daily for 7 days
62387749|NCT03814642|EXPERIMENTAL|Clopidogrel 75 mg + Tegoprazan 50 mg|Oral administration of clopidogrel 75 mg tablet and tegoprazan 50 mg tablet once daily for 7 days
62387750|NCT03814642|EXPERIMENTAL|Clopidogrel 75 mg + Esomeprazole 20 mg|Oral administration of clopidogrel 75 mg tablet and esomeprazole 20 mg tablet once daily for 7 days
62387751|NCT05013476|ACTIVE_COMPARATOR|In-Person ultrasound participants|In-Person ultrasound participant's will receive ultrasound training that is guided by online modules (identical to virtual) with trained faculty in the same room with a ration of 4 students to 1 instructor.
62767928|NCT04465565|NO_INTERVENTION|Control Group|This arm will include 20 children who received Testoviron or Estrofem prior to the the stimulation test and 40 children who did not receive preparation prior to the stimulation test. Participants in this arm will not receive fluids intravenously during the stimulation test, unless it will be required due to safety reasons
62767929|NCT01697150|EXPERIMENTAL|Control to Range Testing|Subjects will spend two nights in a non hospital setting while the DiAs Diabetes Assistant Wearable Artificial Pancreas Platform is remotely monitored from an adjacent room. DiAs Diabetes Assistant Wearable Artificial Pancreas Platform is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
62767930|NCT03022500|EXPERIMENTAL|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
61992606|NCT02758392|EXPERIMENTAL|Dose 2: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 0.3 mg/kg or Placebo IV on Day 1.
61992607|NCT02758392|EXPERIMENTAL|Dose 3: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 1 mg/kg or Placebo IV on Day 1.
61992608|NCT02758392|EXPERIMENTAL|Dose 4: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 3 mg/kg or Placebo IV on Day 1.
61992609|NCT02758392|EXPERIMENTAL|Dose 5: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 10 mg/kg or Placebo IV on Day 1.
61992610|NCT02758392|EXPERIMENTAL|Dose 6: JNJ-61178104 OR Placebo SC|Participants will receive either JNJ-61178104 1 mg/kg or Placebo Subcutaneously (SC) on Day 1.
62168268|NCT05823051|NO_INTERVENTION|Routine Care|"The control group will receive routine care in the obstetric ward. A pre-test will be conducted using the Google Survey form. Personal Information Form, Sudden Infant Death Syndrome Knowledge Level Assessment Form (Pre-Test) and General Self-Efficacy Scale will be completed at this stage.~The mothers in the control group will receive the training included in clinical routine care. The mothers in this group will not receive any planned structured training by the researchers during the study. The mothers in the control group will be administered the Sudden Infant Death Syndrome Knowledge Level Assessment Data Form and the General Self-Efficacy Scale with the Google survey that will be sent to their phones 1 month after the pre-test application. After the completion of the study, the control group will receive the same intervention (VASIDS-TP) as the intervention group."
62387752|NCT05013476|ACTIVE_COMPARATOR|Virtual ultrasound participants|Virtual ultrasound participants will receive ultrasound training that is guided by online modules (identical to in-person) with trained faculty present in a private zoom classroom. Faculty will be rotating between breakout rooms and will share the same ratio of participants to staff.
62387753|NCT01513824|ACTIVE_COMPARATOR|stress management, acupressure|bio feedback guided stress management by daily measurement of pressure pain sensitivity followed by acupressure´for 3 months
62387754|NCT01513824|NO_INTERVENTION|bio feedback guided, stress management|control without treatment
62387755|NCT04930627|EXPERIMENTAL|oral administration of Empagliflozin|
62387756|NCT03520842|EXPERIMENTAL|Treatment (regorafenib, methotrexate)|Participants receive regorafenib PO QD on days 1-21, and methotrexate PO twice weekly with 2-3 days apart on a 3 week on/ 1 week off cycle. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62387757|NCT03949894|EXPERIMENTAL|tolvaptan|
62387758|NCT00815373|ACTIVE_COMPARATOR|1|Cosopt\* b. i. d. (dosed morning and bedtime) will be administered topically
62387759|NCT00815373|ACTIVE_COMPARATOR|2|Xalacom\* q.d.(dosed bedtime) and placebo vehicle q.d. (dosed morning) topically in the other group
62387760|NCT01393561|EXPERIMENTAL|Group 1|Fixed dose combination of brompheniramine + phenylephrine.
62387761|NCT01393561|PLACEBO_COMPARATOR|Group 2|Placebo
62387762|NCT01012700|NO_INTERVENTION|intranasal or IV|Each study group consists of 12 volunteers randomized in a 2:1 ratio to receive poly ICLC or placebo: in group 1, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, subcutaneously; and in group 2, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, intranasally. A total of up to 24 volunteers will be enrolled in the study.
62567687|NCT01253629|EXPERIMENTAL|100 mg bid AFQ056|1 capsule of 100 mg and 1 capsule of placebo per intake
62567688|NCT01253629|PLACEBO_COMPARATOR|Placebo|2 capsules of placebo per intake
62767931|NCT00771797|EXPERIMENTAL|1|Treatement with low dose flavanoids over 60 days
61992611|NCT01542385|ACTIVE_COMPARATOR|Immediate stenting|the stent selection (bare metal vs drug eluting) and implantation will be performed as recommended by current practice guidelines.
61992612|NCT01542385|EXPERIMENTAL|Delayed stenting|participants randomised to delayed stenting will be treated with GPIIb-IIIa inhibitors for 12-18 hours after reperfusion followed by anticoagulation for until the control angiogram, expected no sooner than 18-24 hours after the index reperfusion.
61992613|NCT04707261|EXPERIMENTAL|Dapagliflozin|Dapagliflozin with standard-of-care therapies for heart failure, including sacubitril/valsartan or ACEI/ARB, beta-blocker, MRA, ICD and CRT
61992614|NCT04707261|PLACEBO_COMPARATOR|Placebo|Standard-of-care therapies for heart failure, including sacubitril/valsartan or ACEI/ARB, beta-blocker, MRA, ICD and CRT
62387763|NCT01012700|ACTIVE_COMPARATOR|Hiltonol (poly ICLC)|Each study group consists of 12 volunteers randomized in a 2:1 ratio to receive poly ICLC or placebo: in group 1, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, subcutaneously; and in group 2, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, intranasally. A total of up to 24 volunteers will be enrolled in the study.
62387764|NCT03240003|EXPERIMENTAL|GC-MRT|Group 1 will receive a 4-week (8-sessions) course of standard GC-MRT
62387765|NCT03240003|ACTIVE_COMPARATOR|non-GC-MRT|Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
62387766|NCT03240003|EXPERIMENTAL|GC-MRT-modified|Group 3 will receive a 4-week (8-sessions) course of modified GC-MRT.
62767932|NCT00771797|EXPERIMENTAL|2|Treatment with high dose flavanoids over 60 days
61992615|NCT02922270||Patients|Who have received PD as renal replacement therapy (RRT) over a period of 20 years.
61992616|NCT05434806|EXPERIMENTAL|Post menomausal women (PMW)|40g/day of Jarlsberg cheese will be given three PMW's in the first designlevel. Based on the change in serum osteocalcin level after 4 weeks, the daily Jarlsberg cheese dose for five new PMWs in the second designlevel will be calculated. The results obtained by these five will be used to calculate the dose for seven new PMWs in the third design level.
61992617|NCT05434806|EXPERIMENTAL|Men passed the age of 65 years|40g/day of Jarlsberg cheese will be given three men in the first designlevel. Based on the change in serum osteocalcin level after 4 weeks, the daily Jarlsberg cheese dose for five new men in the second designlevel will be calculated. The results obtained by these five will be used to calculate the dose for seven new men in the third design level.
61992618|NCT01484574|EXPERIMENTAL|Low dose|Stempeucel - CLI will be administered at the lowest dose
61992619|NCT01484574|EXPERIMENTAL|Intermediate dose|Stempeucel - CLI will be administered at intermediate dose
62767933|NCT02907749|ACTIVE_COMPARATOR|Carvedilol|Carvedilol starts at 6.25mg/d and increases to 12.5mg/d in next week as a maintainence dose
62767934|NCT02907749|EXPERIMENTAL|Spironolactone and carvedilol|"1. Carvedilol starts at 6.25mg/d and increases to 12.5mg/d in next week as a maintainence dose~2. Spironolactone is added after carvedilol being tolerated, which starts with 20mg/d and increases to 40mg/d as a maintainence dose"
61992620|NCT01484574|NO_INTERVENTION|Control arm|Standard protocol of care alone
61992621|NCT02818777|EXPERIMENTAL|cannabidiol|"GWP42003-P oral solution, is purified cannabidiol (purity of ≥98%, 100 mg/ml cannabidiol in sesame oil with anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring).~Started at 5 mg/kg/day and is increased by 2.5-5 mg/kg at 3-5 day intervals to a target dose of 20 mg/kg/day."
61992622|NCT04329312||Pulmonary arterial hypertension (PAH)|The patients with PAH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
61992623|NCT04329312||PH due to left-heart disease (PH-LHD)|The patients with PH-LHD received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
62767935|NCT05804149|EXPERIMENTAL|study group|"Each patient in the study group will be instructed about the beneficial effect of the acupuncture.~* Each woman in the study group will assume side lying position with uncovered treatment area,~* thyroxine tablets (levothyroxine) (1tablet per day) describe by the physician. Levothyroxine is usually taken 30-60 minutes before breakfast, or four hours after food, as certain substance such as food and calcium can inhabit the absorption of levothyroxine.~* low caloric diet regime consisting of 1200 to 800Kcal/ day for 4 months.~* Fine sterile needles will be used with a size 0.25x25mm. They will be inserted to various depths (2-5 cm) at acupoints points on the body according to site and fat deposition. 16 needles will be used in the treatment"
61992624|NCT04329312||Chronic thromboembolic pulmonary hypertension (CTEPH)|The patients with CTEPH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
61992625|NCT04329312||PH due to emphysema (PH-LD-Emphys)|The patients with PH-LD-Emphys received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
61992626|NCT04329312||PH due to lung fibrosis (PH-LD-Fibr)|The patients with PH-LD-Fibr received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
61992627|NCT04329312||PH due to combined emphysema and fibrosis (PH-LD-CPFE)|The patients with PH-LD-CPFE received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
61992628|NCT04329312||No PH|The patients without PH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
61992629|NCT03371901|EXPERIMENTAL|Physical therapy with BFR-LLST|
62387767|NCT05284383|EXPERIMENTAL|Open-label counterconditioning|Closed-label conditioning followed by open-label counterconditioning, using moderately painful stimuli (during conditioning) and non-painful stimuli (during counterconditioning), combined with closed-label nocebo suggestions and open-label nocebo reduction suggestions
62387768|NCT05284383|EXPERIMENTAL|Closed-label counterconditioning|Closed-label conditioning followed by closed-label counterconditioning, using moderately painful stimuli (during conditioning) and non-painful stimuli (during counterconditioning), combined with closed-label nocebo suggestions and closed-label nocebo reduction suggestions
62387769|NCT05284383|ACTIVE_COMPARATOR|Closed-label extinction|Closed-label conditioning followed by closed-label extinction, using moderately painful stimuli (during conditioning) and slightly-painful stimuli (during extinction), combined with closed-label nocebo suggestions during conditioning and no/neutral suggestions during extinction
62567689|NCT01826331|NO_INTERVENTION|Control Group|Participants will be incentivized for assessments only
62767936|NCT05804149|OTHER|control group|Each woman in both groups (control and study) will receive thyroxine tablets (levothyroxine) (1tablet per day) describe by the physician. Levothyroxine is usually taken 30-60 minutes before breakfast, or four hours after food, as certain substance such as food and calcium can inhabit the absorption of levothyroxine Each woman in both groups will follow a low caloric diet regime consisting of 1200 to 800Kcal/ day for 4 months. The regime will start with 1200 Kcal for the first month and 1100 for the second month then 900 Kcal for the third month until reach 800 Kcal in fourth month.
62767937|NCT03675516||Rheumatoid arthritis cases|New onset cases of rheumatoid arthritis
61992630|NCT06030778||intervention group|The descriptive characteristics form and the attitude scale of healthcare professionals towards their patients with chronic pain were administered to 205 students from the departments of medicine, physical therapy and rehabilitation, and nursing who agreed to participate in the study. The attitude scale of the health professionals towards their chronic pain patients was applied to 29 randomly selected students among these 205 students 15 days later.
62387770|NCT00952133|EXPERIMENTAL|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery.
62387771|NCT00952133|PLACEBO_COMPARATOR|Palonosetron only|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Intravenous Palonosetron and Saline solution
62387772|NCT01388205|EXPERIMENTAL|Family-based Intervention Arm|
62387773|NCT01388205|NO_INTERVENTION|Control|
61992631|NCT04527861|EXPERIMENTAL|Single-incision Laparoscopic Surgery|Patients with colorectal cancer undergo single-incision laparoscopic surgery.
61992632|NCT04527861|ACTIVE_COMPARATOR|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（3\~5 ports）.
61992633|NCT01212575||300 patients|Female or male aged 18-65 years with a diagnosis of schizophrenia having received at least one dose of Seroquel XR or Seroquel IR during January - March 2010
61992634|NCT05462028|NO_INTERVENTION|control group|Only received conventional therapy comprised of standardized treatment and regular rehabilitation (i.e., postural training, facilitation techniques, stretching exercise, and strengthening exercise) prescribed by a rehabilitation physician and performed at 3 to 6 days after admission for five 60-minute sessions per week by the physical, occupational, and speech therapists in the rehabilitation center of the medical center.
61992635|NCT05462028|PLACEBO_COMPARATOR|exercise group|The exercise group will receive extra 5 days of 30-minute lower-limb ergometer exercise training in addition to the conventional therapy.
62387774|NCT02816255|PLACEBO_COMPARATOR|Full Face Mask with same CPAP Pressure|After the two week period all will switch to a full face mask with half using the same CPAP pressure.
62767938|NCT03675516||Controls|Age, gender and primary care practice-matched controls
62767939|NCT04023123||Anterior Cornea Striae|Eyes with anterior cornea striae present
62767940|NCT04023123||Hypotony Maculopathy|Eyes with hypotony maculopathy present
61992636|NCT05462028|SHAM_COMPARATOR|wearable leg vibration training group|The wearable leg vibration training group will receive extra 5 days of 30-minute wearable leg vibration of lower limbs combined with 30-minute lower-limb ergometer exercise training at post-vibration session, in addition to the conventional therapy.
62387775|NCT02816255|ACTIVE_COMPARATOR|Full Face Mask with new Pressure|After the two week period all will switch to a full face mask with half using with a new cpap pressure derived from our formula.
62767941|NCT04023123||Hypotony only|Eyes with intraocular pressure less than 10 without cornea striae and/or maculopathy
62387776|NCT00962780|EXPERIMENTAL|1|3 doses of 13vPnC and 1 dose of 23vPS, each dose given approximately 1 month apart
62387777|NCT03026764|EXPERIMENTAL|Outpatient|Patients in the outpatient group (same day discharge following THA) are discharged the same day following surgery. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
62387778|NCT03026764|ACTIVE_COMPARATOR|Inpatient|Patients in the inpatient group (following day discharge following THA) stay in the hospital overnight and then are discharged home the next day. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
62387779|NCT02795871|EXPERIMENTAL|Group D+ 1|Girls and boys at risk of CAH treated in utero by Dexamethasone but unaffected.
62387780|NCT02795871|EXPERIMENTAL|Group D+ 2|Girls and boys affected by CAH and treated in utero by Dexamethasone.
62387781|NCT02795871|ACTIVE_COMPARATOR|: Group D - 1|Girls and boys not affected by CAH and not treated in utero by Dexamethasone.
62387782|NCT02795871|ACTIVE_COMPARATOR|Group D - 2|Girls and boys affected by CAH and not treated in utero by Dexamethasone.
62387783|NCT02795871|OTHER|Group D - 3|Girls and boys enrolled in school closed to Lyon
62387784|NCT02935010|EXPERIMENTAL|Tailored therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole 20mg bid and two sensitive ones of amoxicillin,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.
62387785|NCT02935010|ACTIVE_COMPARATOR|Empiric therapy|give esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, amoxicillin 1000mg tid and metronidazole 400mg tid for 14 days
62387786|NCT04384952|EXPERIMENTAL|Parent-administered reading therapy.|Parent-administered reading therapy program: 15min each day, 5 days a week during 6 weeks during the summer break. Repeated reading with feedback from the parent and time control.
62387787|NCT04384952|ACTIVE_COMPARATOR|Dyslexic's Holliday Workbook.|Use of a special Dys holiday book, no parent-guided training.
62387788|NCT00872586|EXPERIMENTAL|1|Olmesartan medoxomil and hydrochlorothiazide
62387789|NCT00872586|ACTIVE_COMPARATOR|2|olmesartan medoxomil
62387790|NCT02020811|EXPERIMENTAL|sentinel arm|all patients will be recieving Iv therapy by using the sentinel controller, a device that is mounted on the IV administration set.
62767942|NCT02792998|EXPERIMENTAL|IW-1701|IW-1701 tablets administered orally in multiple ascending dose.
62767943|NCT02792998|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets administered orally.
62387791|NCT02251782||Epi proColon Group|Subjects assigned to the Epi proColon Group will be offered the Epi proColon test for colorectal cancer screening.
62387792|NCT02251782||FIT Group|Subjects in the FIT Group will be offered a fecal immunochemical test (FIT test) for colorectal cancer screening.
62387793|NCT02251782||Usual Care Group|For the purpose of comparison to usual care, participating health systems will build an anonymized group of patients meeting study eligibility criteria, who do not participate in the study. This group will serve as a passive control and their CRC screening activity will be monitored via Medical Record.
62387794|NCT01567046||Correlative studies|Archived DNA tissue samples are analyzed for frequency of genetic mutations, including SNPs, SNVs, and small deletions and/or insertions, by PCR and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.
62387795|NCT02590627|ACTIVE_COMPARATOR|A|Artemether-lumefantrine
62387796|NCT02590627|EXPERIMENTAL|B|Dihydroartemisinin-piperaquine
62387797|NCT00455780|EXPERIMENTAL|MR-/REDE-|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy for weight loss maintenance.
62387798|NCT00455780|EXPERIMENTAL|MR+/REDE-|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy and use of meal replacements for weight loss maintenance.
62387799|NCT00455780|EXPERIMENTAL|MR-/REDE+|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy as well as Reduced Energy Density Education for weight loss maintenance.
62387800|NCT00455780|EXPERIMENTAL|MR+/REDE+|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy, as well as Reduced Energy Density Education and continued meal replacement use, for weight loss maintenance.
62387801|NCT05638529|EXPERIMENTAL|Treatment Arm- Group A|A subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of hCG (Pregnyl 1,500 IU).
62387802|NCT05638529|PLACEBO_COMPARATOR|Control Arm- Group B|A subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of normal saline (1.5 mL) (sham-placebo).
62387803|NCT03602911|OTHER|Proof of Concept|The isotope 68Ga, available as NETSPOT and 18F-FDG-PET/CT per established protocol will both be administered
62567690|NCT01826331|EXPERIMENTAL|Incentives for Participation|Participants will be incentivized for each assessment and for each smoking cessation session they complete
62767944|NCT04602026|EXPERIMENTAL|Arm I (physical therapy consultation, exercise intervention)|Patients undergo a physical therapy consultation and complete home exercises 3 days per week.
62767945|NCT04602026|ACTIVE_COMPARATOR|Arm II (best practice)|Patients receive standard of care.
62767946|NCT05027685||Renal Denervation Treatment|Patients candidate for treatment or already treated within 6 months prior to consent, as per the sites normal practice with the commercially available Paradise Ultrasound Renal Denervation System, will be enrolled in this single arm registry.
62387804|NCT02812550|OTHER|full-spectrum colonoscopy|Colonoscopy is performed with a full-spectrum colonoscopy (330º angle of view)
62387805|NCT02812550|OTHER|standar forward-viewing colonoscopy|Colonoscopy is performed with standar forward-viewing colonoscopy (170º angle of view)
62387806|NCT03452059|EXPERIMENTAL|AiLegs/AiWalker|use of lower extremity rehabilitation training robot assisted walking (including AiLegs, AiWalker)
62387807|NCT03452059|ACTIVE_COMPARATOR|HKAFO/RGO|use hip and knee ankle foot orthosis (HKAFO) assisted walking
62387808|NCT02683330|EXPERIMENTAL|Mindfulness-based intervention (MBI)|Participants randomly assigned to the MBI group will receive 8 sessions over an 8-week period. The sessions will last 1 hour and will be held via video-conference through Skype, an online application.
62387809|NCT02683330|NO_INTERVENTION|Wait-list control (WLC)|Participants randomly assigned to the WLC group will be discouraged from any new mindfulness related activities during the trial. The WLC group will be offered the opportunity to take part in the MBI at the end of the 20-week follow-up.
62387810|NCT04306627|ACTIVE_COMPARATOR|Perindopril/Amlodipine arm|"Patients will be preliminary screened before 7-10 days for clinical and laboratory examination to meet eligibility criteria for inclusion in study.~Perindopril+amlodipine combination doses will be up titrated over two weeks in case of need to control adequate arterial blood pressure \< 140/90. The 4 doses combinations and their adjustments will be made by investigating physician according to guideline based treatment of arterial hypertension and dyslipidemia."
62387811|NCT04306627|ACTIVE_COMPARATOR|Perindopril/Amlodipine/Atorvastatin arm|Subjects should not previously be on statin therapy and subjects who needs to be will start atorvastatin in combination treatment pill . We will study the effects of 6-month treatment with perindopril +amlodipin+atorvastatin combination on plasma concentrations of total cholesterol and LDL cholesterol.
62387812|NCT05761158||patient|patients answer the same questionnaire whether they have frontal alopecia or lichen planus pilaris
62767947|NCT00286221|EXPERIMENTAL|Supratentorial PCA fentanyl|
62767948|NCT00286221|ACTIVE_COMPARATOR|Supratentorial PRN fentanyl|
62387813|NCT03710343|EXPERIMENTAL|Metformin|Metformin oral tablet will be taken by mouth or through a gastrostomy tube, once or twice a day for 16 weeks.
62387814|NCT00743626|OTHER|1|Healthy patients screened for cervical cancer
62387815|NCT01844310|ACTIVE_COMPARATOR|RAL +TDF+ LPV/r|Arm A: RAL +TDF+ KELETRA(LPV/r) Group A will be assigned with RAL+TDF+LPV/r.
62567691|NCT01826331|EXPERIMENTAL|Incentives for Cessation|Participants will be incentivized for each assessment and biochemically confirmed abstinence at 12 and 24 months
62767949|NCT00286221|EXPERIMENTAL|Infratentorial PCA fentanyl|
62567692|NCT01641458|EXPERIMENTAL|fluoropyrimidine-based chemotherapy|DPYD-genotype and TDM-driven dosing of 5FU/Capecitabine
62767950|NCT00286221|ACTIVE_COMPARATOR|Infratentorial PRN fentanyl|
62767951|NCT03916016|EXPERIMENTAL|Intervention Group|The intervention group received enhanced integrated behavioral health care.
62767952|NCT03916016|ACTIVE_COMPARATOR|Control Group|The control group received care as usual only.
62767953|NCT04142190||ELONVA|Patients stimulated with Elonva
62767954|NCT04142190||PUREGON|Patients stimulated with Puregon
62767955|NCT04036994|ACTIVE_COMPARATOR|Experimental: Treatment group|
62767956|NCT04036994|NO_INTERVENTION|Control group (no intervention)|
62767957|NCT05742165|EXPERIMENTAL|Time-Restricted Eating - 6 Hours (TRE6)|Participants will be instructed to consume all daily food and beverages during their allotted 6-hour time period.
62767958|NCT05742165|EXPERIMENTAL|Time-Restricted Eating - 10 Hours (TRE10)|Participants will be instructed to consume all daily food and beverages during their allotted 10-hour time period.
62767959|NCT01584635|EXPERIMENTAL|Peroral Endoscopic Myotomy (POEM)|Peroral Endoscopic Myotomy- a less invasive treatment for patients with Achalasia
62767960|NCT03930875||Control - No Obstructive Sleep Apnea with Aspirin|"The control group consist of patients with a negative diagnosis of OSA (based on a negative home sleep apnea test (REI) \< 5 and attended sleep study, AHI \< 5; or attended NPSG with an AHI \< 5) and the patient is taking aspirin at a dose of 81 mg/day for at least a week prior to inclusion.~After obtaining written informed consent, approximately 6 ml of blood was collected via venipuncture."
62767961|NCT03930875||Arm 1- Obstructive Sleep Apnea with CPAP therapy and Aspirin|"Arm 1 consist of patients with a diagnosis of OSA (based on home or attended sleep study) with an REI/AHI \> 15 with or without symptoms or REI/AHI \> 5 with symptoms of sleep apnea in a patient 18-85 years old, CPAP has been started within the last 2 years, and patient is taking aspirin at a dose of 81mg/day for at least a week, last dose taken within 24 hours prior to enrollment.~After obtaining written informed consent, approximately 6 ml of blood was collected via venipuncture."
62767962|NCT03930875||Arm 2 -Obstructive Sleep Apnea with no CPAP & Aspirin|"Arm 2 consist of patients with a diagnosis of OSA (based on home or attended sleep study) with an REI/AHI \> 15 with or without symptoms or REI/AHI \> 5 with symptoms of sleep apnea in a patient 18-85 years old and patient is taking aspirin at a dose of 81mg/day for at least a week, last dose taken within 24 hours prior to enrollment.~After obtaining written informed consent, approximately 6 ml of blood was collected via venipuncture."
62767963|NCT02383602||Retention strategies|In addition to telephone call(s) made within 1 week prior to scheduled visit, participants will receive at least biweekly communications from the study staff in order to establish and maintain a good relationship between participants and study sites. These communications will make use of various social networking tools (for example, Grindr, LINE and/or WhatsApp and/or SMS and/or Facebook and/or electronic mail).
62767964|NCT06234436|EXPERIMENTAL|Plasma exchange|1-20 plasma exchanges.
62767965|NCT03121170|EXPERIMENTAL|ESWT during PD|For women with primary dysmenorrhea, they have new devise Extracorporeal Shock Wave Therapy to treat. The dose is 15 hertz, 1.8-2.2bar and total 5000 frequencies approximately. The time is menstrual cycle first one and third day, and the therapy divide into two times.
62387816|NCT01844310|ACTIVE_COMPARATOR|3TC+ TDF+LPV/r|Arm B: 3TC+ TDF+KELETRA(LPV/r) Group B will be assigned with 3TC+TDF+LPV/r
62767966|NCT03121170|EXPERIMENTAL|ESWT before PD|For women with primary dysmenorrhea, they have new devise Extracorporeal Shock Wave Therapy to treat. The dose is 15 hertz, 1.8-2.2 bar and total 5000 frequencies approximately. The time start from the 5th and 7th day before the estimated first day of menstrual cycle and all therapy time consuming need 15 minutes.
62767967|NCT03121170|PLACEBO_COMPARATOR|hot compress paste|In hot compress paste group , the women with primary dysmenorrhea stick the hot compress paste on their belly autonomously.
62767968|NCT03191877|EXPERIMENTAL|COFFEE|they will start to drink coffee 6 hours postoperative for maximum 3 doses (100ml), 8 hours apart, diet will start after 1st audible bowel sound.
62767969|NCT03191877|ACTIVE_COMPARATOR|oral fluid|"they will drink plain fluid (water) 6 hours postoperative. Diet will start after 1st audible bowel sound.~Women in this group will not receive either coffee."
62767970|NCT03191877|NO_INTERVENTION|control|the control group and they will be NPO for 24 hours on IV fluid (3 LITRES/24 HOURS). Diet will start after 1st audible bowel sound
62387817|NCT04899752|EXPERIMENTAL|Traditional OPCR|Those who are in the traditional group will discuss topics like medication adherence, physical activity questions, or eating habits without a clear from of autonomy or nonautonomy basis as is currently completed in OPCR. This will occur in a face to face format.
62387818|NCT04899752|EXPERIMENTAL|OPCR + MI|The MI group will be consistent with the spirit of MI and utilize a high autonomy communication style to provide support for behavior change across multiple behaviors. This will occur in a face to face format.
62387819|NCT04899752|EXPERIMENTAL|OPCR + Clinician centered|The OPCR + CC group will participate in low-autonomy face to face interviews. Meaning the communication style will be clinician centered, providing goals to the participants without valuing their input.
62387820|NCT04524130|EXPERIMENTAL|Lidocaine and Ketamine|Participants in this arm will receive intra-operative lidocaine and ketamine infusion as adjunctive drugs for pain control. All medication is dosed based on calculated lean body weight (LBW) by Janmahasatian formula.
62559823|NCT03103438|EXPERIMENTAL|Cohort 4|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 1.0 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 5 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 5.
62387821|NCT04524130|ACTIVE_COMPARATOR|Lidocaine|Participants in this arm will receive only intra-operative ketamine infusion as adjunctive drugs for pain control. All medication is dosed based on calculated lean body weight (LBW) by Janmahasatian formula.
62168269|NCT06492057|EXPERIMENTAL|EMS (electromyostimulation) participants|Healthy Astronauts that perform EMS-assisted inflight exercise onboard the International Space Station
61992637|NCT05462028|EXPERIMENTAL|lower-extremity weight bearing vibration training group|The lower-extremity weight bearing vibration training group will receive extra 5 days of 30-minute lower-extremity weight bearing vibration combined with30-minute lower-limb ergometer exercise training at post-vibration session, in addition to the conventional therapy.
61992638|NCT03911440|ACTIVE_COMPARATOR|Azithromycin|Azithromycin (10mg/kg/day) is given to children with mycoplasma pneumonia for 3 days.
62387822|NCT04524130|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive normal saline, same volume as lidocaine and ketamine.
61992639|NCT03911440|EXPERIMENTAL|Doxycycline|Doxycycline (2-4mg/kg/day) is given to children with mycoplasma pneumonia for 5-10 days.
61992640|NCT02076828|EXPERIMENTAL|Fe-OH-PM (Santafer® sp.)(Group II)|The patients in Group II were treated with Fe-OH-PM (Santafer® sp.), 6 mg/kg/day orally.
61992641|NCT02076828|EXPERIMENTAL|Fe-Zn (Ferro Zinc® sp.)(Group III)|The patients in Group III were treated with Fe-Zn (Ferro Zinc® sp.), 6 mg/kg/day orally
61992642|NCT02076828|EXPERIMENTAL|Fe-S (Ferro Sanol® sp.)(Group I)|The patients in Group I were treated with Ferro Sanol® sp., 6 mg/kg/day orally
61992643|NCT01611987|EXPERIMENTAL|MSTEP|The MSTEP program is a 6 day tailored exercise program. It includes flexibility, aerobic, peripheral strengthening, core and balance training, power and speed training and push days.
61992644|NCT01611987|ACTIVE_COMPARATOR|General guideline approach|The general Guideline approach is the general guidelines that are recommended for people with MS by the Canadian Society Exercise Physiology.
61992645|NCT01644175|PLACEBO_COMPARATOR|Placebo Q2W|Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 52 weeks.
61992646|NCT01644175|EXPERIMENTAL|Alirocumab|Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
61992647|NCT05040581|EXPERIMENTAL|Experimental Group - 1 Day CBT|"The intervention is a 6-hour long CBT-based workshop. Cognitive behavioural therapy is a structured psychotherapy based on the cognitive theory of depression that posits that negative thoughts about the self, others and the future can lead to and perpetuate depressed mood states. CBT equips participants with skills that enable them to identify and modify distortions in their thinking that lead to depressed mood and maladaptive behavioural responses.~The intervention will be delivered in in modules and contain content on PPD etiology (with a focus on modifiable risk factors), the development of cognitive skills including cognitive restructuring, behavioural skills such as problem solving, sleep strategies, behavioural activation, assertiveness, and self-care, and the final module will involve goal setting and action planning."
61992648|NCT02372669|EXPERIMENTAL|Chitosan|Enrolled participants presenting with traumatic sensory nerve lesions of the hand without defect zone that were randomized to primary microsurgical repair with the additional use of a chitosan nerve tube.
61992649|NCT02372669|ACTIVE_COMPARATOR|Gold standard alone|Enrolled participants presenting with traumatic sensory nerve lesions of the hand without defect zone that were randomized to primary microsurgical repair without the additional use of a chitosan nerve tube.
61992650|NCT01859507|EXPERIMENTAL|BOTOX group|Injection of BOTOX in the perineal muscles in resistant cases of vaginismus. Proper informed consent forms will be signed. The injection procedure is done under local anesthesia for most of our patients. We followed up the patient by phone calls for possible adverse effects following the procedure for 4 days.The patient is then instructed to attend dilatation sessions twice weekly in the clinic, in the presence of the husband, for 3-4 weeks. We use silicone dilators, of ascending sizes, covered by lubricated condoms. In the initial phase of the dilatation procedure we start each session with the appropriate size of the dilator according to the capacity of the introitus and the degree of vaginismus, and thereafter increase the size gradually.
62168270|NCT01442623|ACTIVE_COMPARATOR|Conventional Vestibular Rehabilitation|Six week program of conventional vestibular rehabilitation.
62168271|NCT01442623|EXPERIMENTAL|Nintendo Wii Vestibular Rehabilitation|Six week program of vestibular rehabilitation using the Nintendo Wii Fit Plus.
62387823|NCT00114894|EXPERIMENTAL|Safe Sea|
62387824|NCT00114894|SHAM_COMPARATOR|Placebo|Coppertone® SPF15 (Schering-Plough)
62387825|NCT01244971|ACTIVE_COMPARATOR|Acarbose|
62387826|NCT01244971|ACTIVE_COMPARATOR|Exercise|
62387827|NCT01244971|EXPERIMENTAL|Exercise + Acarbose|
62559824|NCT03103438|EXPERIMENTAL|Cohort 5|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 1.6 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 6 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 6.
62567693|NCT05688566|EXPERIMENTAL|zero condition|Then the pedal angle is the angle between the lowest pedal position and the floor. The zero condition is 0 ˚of pedal angle.Participants were asked to step with the consistent cadence at 60 steps/ min by the metronome.Three successful trials will be collected for each condition. Fifteen seconds of data will be collected for each trial.
62387828|NCT03136029|EXPERIMENTAL|Oral AOx|8 week oral antioxidant treatment
62387829|NCT03136029|PLACEBO_COMPARATOR|Oral AOx (placebo)|Placebo for arm 1
62387830|NCT03136029|EXPERIMENTAL|Oral BH4|8 week oral tetrahydrobiopterin treatment
62387831|NCT03136029|PLACEBO_COMPARATOR|Oral BH4 (placebo)|Placebo for arm 3
62387832|NCT03136029|EXPERIMENTAL|Ex training|8-week knee-extensor exercise training program
62387833|NCT03136029|SHAM_COMPARATOR|Ex training (attn con)|Attention control for arm 5
62387834|NCT01756209|ACTIVE_COMPARATOR|Acetaminophen|Acetaminophen 15 mg/kg oral single dose (n=40)
62387835|NCT01756209|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 10 mg/kg oral single dose (n=40)
62387836|NCT01756209|EXPERIMENTAL|Acetaminophen + magnesium 400 mg|Acetaminophen 15 mg/kg oral single dose (n=40) + magnesium 400 mg
62387837|NCT01756209|EXPERIMENTAL|ibuprofen + magnesium 400 mg|ibuprofen 10 mg/kg oral single dose (n=40) + magnesium 400 mg
62387838|NCT00784836|EXPERIMENTAL|Avonex|Avonex 30 mcg given subcutaneously, once weekly, for 18 months.
61992651|NCT02159521|EXPERIMENTAL|EkoSonic® Endovascular System|Thrombolytic infusion (Alteplase), at an infusion rate of 0.5-1.0 milligrams/hour (mg/hr) will be delivered to the participants with chronic lower extremity venous obstruction after DVT and PTS through the EkoSonic® Endovascular System for at least 12 hours and overnight as needed up to a maximum of 48 hrs. The alteplase dose could be adjusted per investigator discretion, but not to be exceeded 1 mg/hr or a total dose of 48 mg.
61992652|NCT04346472||Gliomes de grade II initial|Gliomes de grade II initial
61992653|NCT02780804|EXPERIMENTAL|Treatment (entinostat)|Patients receive entinostat PO on days 1, 8, 15, and 22. Cycles repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
61992654|NCT01041872|ACTIVE_COMPARATOR|Propofol Astrazeneca|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
61992655|NCT01041872|EXPERIMENTAL|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
62559825|NCT03103438|EXPERIMENTAL|Cohort 6|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 2.2 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 7 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 7.
62559826|NCT03103438|EXPERIMENTAL|Cohort 7|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 2.9 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level.
62559827|NCT03710408|EXPERIMENTAL|Subcutaneous hydration|
62559828|NCT03710408|ACTIVE_COMPARATOR|Intravenous hydration|
62559829|NCT02691923|ACTIVE_COMPARATOR|Fluorescein|Fluorescein administered IV at 5mg/kg approximately 30 minutes prior to the beginning of the tumor resection. A second injection may occur if the fluorescein fluorescence is dissipated substantially during the course of the procedure.
62559830|NCT02691923|EXPERIMENTAL|Fluorescein + ALA|"Fluorescein administered IV at 5mg/kg approximately 30 minutes prior to the beginning of the tumor resection. A second injection may occur if the fluorescein fluorescence is dissipated substantially during the course of the procedure.~ALA administered orally at 20mg/kg approximately 3 hours before surgery."
62559831|NCT06575205|EXPERIMENTAL|Video|An original brief 3 to 5 minute educational video, covering themes such as: defining OTC NSAIDs and their uses, potential harms of NSAIDs, and broad general alternatives. Will involve suggestion to speak to their healthcare provider.
62767971|NCT04118569|EXPERIMENTAL|Narrative Intervention Group|Patients in the narrative intervention group will participate in an interview and the resulting narrative will be uploaded to the electronic medical record. This group will also complete outcome measures (questionnaires) and exit interview.
61992656|NCT01041872|EXPERIMENTAL|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
61992657|NCT01041872|EXPERIMENTAL|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
61992658|NCT01041872|EXPERIMENTAL|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
61992659|NCT01041872|EXPERIMENTAL|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
62559832|NCT06575205|NO_INTERVENTION|Control|A static image of a standardized FDA warning label for OTC NSAIDs covering themes such as: uses of OTC NSAIDs, potential harms of NSAIDs, and suggestion to speak to their healthcare provider.
61992660|NCT05667623|EXPERIMENTAL|1% OPA-15406 Ointment|The 1% formulation of OPA-15406 ointment will be administered twice-daily (approximately 12 hours apart between morning and night administration) for 4 weeks/24 weeks. The amount of IMP (g) per dose is 10 g/m2 BSA and calculated.
61992661|NCT05667623|PLACEBO_COMPARATOR|0% OPA-15406 Vehicle|The vehicle of OPA-15406 vehicle will be administered twice-daily (approximately 12 hours apart between morning and night administration) for 4 weeks/24 weeks. The amount of IMP (g) per dose is 10 g/m2 BSA and calculated.
62559833|NCT03492515|EXPERIMENTAL|experimental group|Accepting the treatment of rhTPO according platelet and bleeding condition
62767972|NCT04118569|NO_INTERVENTION|Usual Care Group|Patients in the usual care group will complete outcome measures (questionnaires) and exit interview only.
62767973|NCT01656629|ACTIVE_COMPARATOR|teriparatide|teriparatide 20 mcg sq for 3 months
62387839|NCT06077682|ACTIVE_COMPARATOR|Cyclopentolate arm|"To study the effect of cyclopentolate 1% for cycloplegic refractions in pediatric populations with ET:~Firstly, we instilled an anesthetic drop into patients' eyes. Secondly, 2 drops of cyclopentolate 1% (cyclogel) 5 minutes apart were instilled. Autorefraction was taken at 60 minutes after first drop instillation. Primary outcome: spherical equivalent (SE) of cycloplegic refraction at 60 minutes."
62767974|NCT01656629|ACTIVE_COMPARATOR|Alendronate|70 mg po weekly for 3 months
62767975|NCT01656629|ACTIVE_COMPARATOR|calcium and vitamin D|calcium 630 mg vitamin D 500 units daily for 3 months
62767976|NCT02610244|NO_INTERVENTION|Treatment As Usual|Standard treatment as usual as directed by the physician.
62767977|NCT02610244|EXPERIMENTAL|Modified Cogmed Training|10 weeks of computerized training (3x weekly for 35-minutes each session) that targets thinking skills that are often impaired in individuals diagnosed with ADHD.
62767978|NCT05674253|ACTIVE_COMPARATOR|Dexmedetomidine + Hydrocortisone group|Patients will receive dexmedetomidine 0.7 ɥg/kg/hr IV infusion before aortic cross-clamping, and will be continued intra-operatively and in ICU till weaning from mechanical ventilation Patients also will also receive Hydrocortisone 100 mg intravenous (IV) before aortic cross-clamping then 100 mg every 8 hours after surgery which will be continued for 48 hours .
62767979|NCT05674253|NO_INTERVENTION|Standard group|Patients will not receive dexmedetomidine nor Hydrocortisone and will receive the standard management
62767980|NCT06414161|EXPERIMENTAL|Intervention group:|patients in test group will topically apply 20 ml (green tea plus peppermint) (1:1) to the oral mucosa. They will be instructed to keep green tea plus peppermint for at least 5 min duration and then to spit it out. They will be advised to rinse 20 mL of green tea plus peppermint in the same manner before sleeping from fourth week of radiotherapy to three months after radiotherapy.
62387840|NCT06077682|ACTIVE_COMPARATOR|Tropicamide arm|"To study the effect of tropicamide 1% for cycloplegic refractions in pediatric populations with ET:~Firstly, we instilled an anesthetic drop into patients' eyes. Secondly, 2 drops of tropicamide 1% (mydriacil) 5 minutes apart were instilled. Autorefraction was taken at 30 minutes after first drop instillation. Primary outcome: spherical equivalent (SE) of cycloplegic refraction at 30 minutes."
62767981|NCT06414161|PLACEBO_COMPARATOR|Control group|Patients in the control arm will topically apply 20 mL of 0.9% of saline 15 min before and after radiotherapy. They will be advised to rinse saline. They will be instructed to keep saline for at least 5 min duration and then to spit it out. They will be advised to rinse 20 mL of saline in the same manner before sleeping from fourth week of radiotherapy to three months after radiotherapy.
62767982|NCT04349033|EXPERIMENTAL|Emotional Disclosure and Brain Education|Patients are interviewed about stress and other emotional issues and are educated about how emotions and the brain influence pain.
62767983|NCT04349033|ACTIVE_COMPARATOR|Emotional Disclosure only|Patients are interviewed about stress and other emotional issues only.
62387841|NCT03763942|EXPERIMENTAL|HealthMindr App|Participants in the intervention arm will receive access to all HealthMindr app capabilities. The app information will cover the importance of testing, links to HIV prevention resources, resources to locate HIV testing and PrEP services, the Substance Abuse and Mental Health Services Administration (SAMHSA) substance abuse treatment resource locator, and other prevention information specific to their area.
62387842|NCT03763942|PLACEBO_COMPARATOR|Control App|Participants in the control arm will be directed to download a study app that allows study staff to interact with them.
62387843|NCT00918905|EXPERIMENTAL|1 Telemonitor|Within 24 hours after the patient was discharged the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with a doctor. The patient was planned to have the equipment for approximately one week and had at least one follow-up phone call within the four weeks period. Telemonitoring video conferences could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period of time (hot-line).
62387844|NCT00918905|NO_INTERVENTION|Control group|No tele-monitor at home. The COPD patients discharged after an acute exacerbation living outside Svendborg or Faaborg-Midtfyn municipalities in the recruiting area were included in the control group and assigned to conventional care.
62767984|NCT04349033|PLACEBO_COMPARATOR|Pain Information Control|Patients are interviewed about their pain history and experience.
62767985|NCT06394453|NO_INTERVENTION|control group|Control group will be unfed orally during 72 hours of therapeutic hypothermia. The group will be receiving parenteral nutrition (PN) from day one onwards. Parenteral nutrition will be defined as receiving any type of nutrient solution in any volume through any route of administration (peripheral venous cannula, central venous catheter, or umbilical catheter).
61992662|NCT02127359||Lung/Colon Adenocarcinomas|Metastatic lung and colon adenocarcinomas
61992663|NCT06274541||Patients with HGSEC|
61992664|NCT01549964|EXPERIMENTAL|Fasiglifam (TAK-875) 25 mg|Fasiglifam 25 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
61992665|NCT01549964|EXPERIMENTAL|Fasiglifam (TAK-875) 50 mg|Fasiglifam 50 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
62387845|NCT06425185||Cross-sectional study group|"The study group consists of 30 subjects who are free from any specific medical condition or injury affecting the lower extremities. These subjects are physically active individuals without any known musculoskeletal disorders or impairments. They all will be assessed in the same way.~Data collection will take place during single-leg stance on the BB in its different configurations and on the floor. Three attempts of 20 seconds each will be recorded for each condition. The subjects will perform these exercises under the guidance of a trained physiotherapist."
61992666|NCT01549964|ACTIVE_COMPARATOR|Sitagliptin 100 mg|Sitagliptin 100 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. TAK-875 placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
61992667|NCT01549964|PLACEBO_COMPARATOR|Placebo|Fasiglifam (TAK-875) placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
61992668|NCT04426565|OTHER|the motivational enhancement interview|The motivational enhancement interview is a counseling approach developed in part by clinical psychologists William R. Miller and Stephen Rollnick. It is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence.
61992669|NCT04426565|OTHER|the individual psychotherapy|The individual psychotherapy is the use of psychological methods, particularly when based on regular personal interaction with adults, to help a person change behavior and overcome problems in desired ways. Psychotherapy aims to improve an individual's well-being and mental health, to resolve or mitigate troublesome behaviors, beliefs, compulsions, thoughts, or emotions, and to improve relationships and social skills.
61992670|NCT04426565|OTHER|the group psychotherapy|The group psychotherapy is a form of psychotherapy in which one or more therapists treat a small group of clients together as a group. The term can legitimately refer to any form of psychotherapy when delivered in a group format, including Art therapy, cognitive behavioural therapy or interpersonal therapy, but it is usually applied to psychodynamic group therapy where the group context and group process is explicitly utilised as a mechanism of change by developing, exploring and examining interpersonal relationships within the group.
61992671|NCT04426565|OTHER|the family therapy|The family therapy is is a branch of psychotherapy that works with families and couples in intimate relationships to nurture change and development. It tends to view change in terms of the systems of interaction between family members.
61992672|NCT02665208|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Participants will receive informational pamphlets and information for a 1800 quit line, and a prescription for a nicotine replacement therapy (NRT) for 7 Days
61992673|NCT02665208|ACTIVE_COMPARATOR|Nicotine Replacement Therapies|Participants will receive a prescription for a nicotine replacement therapy (NRT) for 7 Days.
62387846|NCT05901142|EXPERIMENTAL|Exercise-based multi-phasic, multi-modal intervention|An exercise-based multi-phasic (pre-surgery and post-surgery) and multi-modal (exercise, targeted physiotherapy, dietary advice, and psychological coping and behaviour change) intervention
62767986|NCT06394453|EXPERIMENTAL|experimental group|"Experimental group will start receiving enteral feeding at 10 ml/kg/day during first day of TH, 20 ml/kg/day during second day and 30 ml/kg/day during third day.~Additionally will be receiving parenteral nutrition (PN) from day one onwards. Parenteral nutrition will be defined as receiving any type of nutrient solution in any volume through any route of administration (peripheral venous cannula, central venous catheter, or umbilical catheter). As the volume of enteral feeding will be increased, the volume of PN will be decreased gradually."
62387847|NCT03607435|EXPERIMENTAL|Test Article Scanning|Spectroscopy for Analyte Quantification
62387848|NCT05784558||UroLift System|Therapy to be treatment with the UroLift System.
62387849|NCT05784558||Watchful Waiting or BPH Medications|Subjects for whom the physician decides the best course of therapy to be either watchful waiting or new or continuing BPH medications.
62559834|NCT03492515|ACTIVE_COMPARATOR|non-administered group|No rhTPO will be used. If necessary, the patients will be given transfusion of platelets according to the their conditions.
62559835|NCT03492515|NO_INTERVENTION|healthy control group|Healthy pregnant women and no use of any medicine。
62559836|NCT05810532|ACTIVE_COMPARATOR|4H group|fasting more than 4 hours before sedation
62767987|NCT04069923|EXPERIMENTAL|Treatment (OsteoCrete)|Participants receive OsteoCrete intraoperatively to fill voids that occur in bones during surgery or to augment screw fixation.
62559837|NCT05810532|EXPERIMENTAL|1H group|oral hydration (water) is allowed 1 hour before sedation, while other food must be fasted more than 4 hours before sedation
62559838|NCT01290588||Children of Caucasian descent|Healthy children of Caucasian descent.
62559839|NCT01290588||Adults of Caucasian descent|Healthy adult eyes of Caucasian descent.
62767988|NCT01872442|EXPERIMENTAL|Dasatinib|Dasatinib,Bristol Myers Squibb
62387850|NCT05784558||Other Surgical Intervention|Physician decides the best course of therapy to be a surgical intervention other than the UroLift System.
62387851|NCT04589221||Degree of food processing and food texture|"Processed vs unprocessed foods based on NOVA classification~Soft and hard foods manipulated by cooking method"
62387852|NCT01611558|EXPERIMENTAL|Arm: Ipilimumab, 10 mg/kg|Participants received 10 mg/kg of ipilimumab administered intravenously once every 3 weeks for 4 doses (Induction Phase). Then, once every 12 weeks (Maintenance Phase), until disease progression or unacceptable toxicity occurs.
61992674|NCT02665208|ACTIVE_COMPARATOR|Text Message Intervention|Participants will receive up to 5 messages a day with message content informed by principles of cognitive behavioral therapy using software developed and maintained by the National Cancer Institute.
61992675|NCT03897452|EXPERIMENTAL|Fentanyl for procedural pain|"A dose of Fentanyl 5 microgram/ml, 0.5 microgram/kg (anticipated medium pain) or 2 microgram/kg (anticipated strong pain) will be given prior to a painful procedure during NICU-care. Repeated doses or complementary analgesics will be administered according to pain assessment and clinical judgement.~This is not an RCT with several arms."
61992676|NCT06186778|ACTIVE_COMPARATOR|conventional colonoscopy group|It starts from the rectum and progresses forward to the cecum, with observations made during withdrawal: from the cecum, ascending colon, transverse colon, descending colon, and sigmoid colon to the rectum.
61992677|NCT06186778|EXPERIMENTAL|secondary colonoscopy group|After the routine colonoscopy, a repeat colonoscopy of the sigmoid colon is performed
62387853|NCT01227161||ultrasonography children|American Society of Anesthesiologists (ASA) I-II children between the age 0-7, undergoing elective urological surgery, such as inguinal hernia repair, orchiopexy, ureteroneocystostomy
62387854|NCT01337440|ACTIVE_COMPARATOR|UDCA pretreatment|"Ursodeoxycholic Acid (UDCA) for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
62387855|NCT01337440|ACTIVE_COMPARATOR|Sitagliptin pretreatment|"Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
62387856|NCT02189239|ACTIVE_COMPARATOR|Zeller Entspannung film coated tablets|Relaxing film coated tablets, 570 mg (Zeller Entspannung Filmtabletten), 3x1 tablet per day for the first three days (morning, midday, evening), at day four 2x1 tablet (morning, midday) preferably during meals with a glass of water.
62387857|NCT02189239|PLACEBO_COMPARATOR|Placebo tablets|Placebo medication is identical in presentation, color and shape, 3x1 tablet per day for the first three days (morning, midday, evening), at day four 2x1 tablet (morning, midday) during meals with a glass of water.
62387858|NCT02189239|SHAM_COMPARATOR|No Treatment|No medication intake.
62767989|NCT01872442|EXPERIMENTAL|Peg-Interferon alpha2b|Peg-Interferon alpha2b (Peg-IFN α2b), Merck
62767990|NCT01180517|ACTIVE_COMPARATOR|Drug Eluting Balloon|
62767991|NCT01180517|ACTIVE_COMPARATOR|Plain Old Balloon Angioplasty (POBA)|
62767992|NCT02196428|OTHER|Telemonitoring and Teleconsultation|
62767993|NCT02712424|ACTIVE_COMPARATOR|DAR-901|0.1 mL intradermal injection of 1 mg DAR-901
62767994|NCT02712424|PLACEBO_COMPARATOR|Placebo|0.1 mL intradermal injection of sterile saline for human use
62767995|NCT03698565|EXPERIMENTAL|PPI and ANI measurements|"The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes."
61992678|NCT06321133|EXPERIMENTAL|Immediate ending|High flow is ended immediately
62387859|NCT04004026||Multiple sclerosis patient|First day, first evaluator will perform all tests, and second day, second evaluator will perform 3 m backwards walk test.
62559840|NCT01290588||Children of African-American descent|Healthy children of African-American descent.
62559841|NCT01290588||Adults of African-American descent|Healthy adults of African-American descent.
61992679|NCT06321133|ACTIVE_COMPARATOR|Weaning|High flow is ended by gradually reducing the flow rate
61992680|NCT05540834|EXPERIMENTAL|VET guided tPA administration + standard care|Actilyse (tPA) will be administered as a 2-hour bolus then low dose infusion over 24 hours (safety and dose-finding stage) and 72 hours (randomised stage). Regular monitoring of the coagulation status and lysis time using VET will enable increases or decreases/cessation of the dose. Prophylactic low molecular weight heparin will continue throughout.
61992681|NCT05540834|NO_INTERVENTION|Standard care|Patients will receive standard care for their condition including prophylactic low molecular weight heparin. Coagulation status and lysis time monitoring with VET will occur at the same times as the experimental arm.
61992682|NCT01500707|EXPERIMENTAL|SCH 900800|Participants receiving a single dose of SCH 900800
62387860|NCT03011164||WV 1|The condition of this group will be set as participants walking at 3.5km/h
62387861|NCT03011164||WV 2|The condition of this group will be set as participants walking at 4.0km/h
62559842|NCT01853215|EXPERIMENTAL|Sternal intraosseous vascular access|Sternal intraosseous vascular access using T.A.L.O.N. Intraosseous System.
62387862|NCT03011164||RV 1|The condition of this group will be set as participants running at 3.5km/h
62767996|NCT01875718|ACTIVE_COMPARATOR|UC1010 low dose|
62767997|NCT01875718|ACTIVE_COMPARATOR|UC1010 high dose|
62767998|NCT01875718|PLACEBO_COMPARATOR|Vehicle|
62767999|NCT05501314|EXPERIMENTAL|Early discharge with remote home monitoring.|"* Patients are discharged early~* Patients receive remote home monitoring using a wearable sensor and a smartphone app.~* Patients fill in a satisfaction questionnaire"
62768000|NCT03613467||VATS lobectomy|Pathologic N2 NSCLC patients who received lobectomy by video-assisted thoracoscopic surgery
62768001|NCT03613467||Thoracotomy lobectomy|Pathologic N2 NSCLC patients who received lobectomy by thoracotomy
62768002|NCT00187187|ACTIVE_COMPARATOR|Implantable Defibrillator (ICD) VVI-40|The DAVID II Clinical Study evaluates the hypothesis that, in patients needing an ICD but without overt indications for pacing, AAI pacing with maximal concomitant drug therapy (AAI-70)will not increase the rate of the combined endpoint of mortality or hospitalization for new or worsened heart failure, compared to patients with ventricular backup pacing (VVI-40).
61992683|NCT04800003||Dry human mandibles, selected for evaluation|51 dry mandibles with posterior region endetulism and sufficient bone integrity to make the necessary measurements were evaluated. CBCT images of the 51 dry human mandibles included in the study were obtained using the Planmeca Promex-3D (Helsinki, Finland) device in our faculty Dentomaxillofacial Radiology department. Gonial angle was measured on CBCT images as the angle between the tangent line drawn posterior to the border of the ramus of the mandible and the tangent line drawn to the lower border of the mandible. While determining the depth of the submandibular fossa, a line was drawn to connect the most dislocated upper and lower points on the inner surface of the mandible in the coronal plane sections obtained with CBCT, and the length of the line drawn at a right angle from the deepest point of the fossa to this line was measured as the depth of the submandibular fossa.
61992684|NCT02631863|EXPERIMENTAL|ALA|Patients will receive 3 topical treatments of aminolaevulinic acid 500mg
61992685|NCT02631863|PLACEBO_COMPARATOR|Placebo|Patients will receive 3 topical treatments of placebo 500mg
61992686|NCT01900028|EXPERIMENTAL|Olaparib alone, olaparib+itraconozole|Sequential treatments of olaparib alone followed by olaparib+itraconazole, with a washout period in between.
61992687|NCT04659746|NO_INTERVENTION|Control|Participants allocated to the control group will receive the routine care and follow-up for chronic patients in Pandemic situation at Hospital Regional de Encarnación (Encarnación, Paraguay), according to epidemiological surveillance and preventive isolation management protocol released by the Ministry of Health of Paraguay (URL: https://www.mspbs.gov.py/dependencias/portal/adjunto/c1c79a-ProtocoloVigilanciaEpidemiolgica.pdf)
61992688|NCT04659746|EXPERIMENTAL|Intervention|"Participants allocated to the intervention group will follow the same routine care as the control group. Additionally, they will receive access to the MejoraCare app.~The MejoraCare app delivers the following functionalities:~* Remote symptoms monitoring through an electronic Patient Reported Outcome (ePRO)~* Patient empowerment through personalized educational resources promoting healthy lifestyles"
61992689|NCT00357188|ACTIVE_COMPARATOR|A|
61992690|NCT00357188|ACTIVE_COMPARATOR|B|
61992691|NCT01347138|EXPERIMENTAL|case management|case management regulary
61992692|NCT01347138|NO_INTERVENTION|Control|usual care
61992693|NCT00128921|EXPERIMENTAL|Velcade, Cohort A|Treatment: 1.3 mg/m\^2
61992694|NCT00128921|EXPERIMENTAL|Velcade, Cohort B|Treatment: 1.0 mg/m\^2
61992695|NCT00128921|EXPERIMENTAL|Velcade, Cohort C|Treatment: 0.7 mg/m\^2
61992696|NCT02488603|EXPERIMENTAL|Decision aids|
62387863|NCT03011164||RV 2|The condition of this group will be set as participants running at 4.0km/h
62387864|NCT02143427|EXPERIMENTAL|Social Skills Training|Social Skills Training child-focused and subsequent social competence training which combines patient- and parent-/teacher and peer-focused interventions
61992697|NCT02488603|NO_INTERVENTION|usual care|
61992698|NCT05129878|EXPERIMENTAL|Test group 1|patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive scaling and oral hygiene instructions (OHI)
61992699|NCT05129878|EXPERIMENTAL|Test group 2|patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive oral hygiene instructions only
61992700|NCT05129878|ACTIVE_COMPARATOR|Control Group|Systemically Healthy (age and BMI matched) females with gingivitis will receive with OHI and scaling.
61992701|NCT04156568|EXPERIMENTAL|6INH Group|10mg/kg 6INH were used in this group.
61992702|NCT04156568|EXPERIMENTAL|3INH+RFT group|3INH+RFTwere used in this grroup.
61992703|NCT04924036|OTHER|Glycopyrronium Cloths then Placebo|Participants that are randomized to Glycopyrronium cloths for 4 weeks, then 2 week wash out, then cross over to placebo cloths for 4 weeks.
61992704|NCT04924036|OTHER|Placebo then Glycopyrronium Cloths|Participants that are randomized to placebo cloths for 4 weeks, then 2 week wash out, then cross over to Glycopyrronium cloths for 4 weeks.
62387865|NCT02143427|ACTIVE_COMPARATOR|Treatment Program with techniques to activate resources|Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training child-focused
62387866|NCT05640141||Control|Control group composed of 80 healthy aged volunteers.
62387867|NCT05640141||Motoric Cognitive Syndrom|MCR group composed of 80 MCR participants.
62387868|NCT05751915||PET CAV 0|Normal perfusion with normal global stress (\> 1.7 mL/min/g)
62387869|NCT05751915||PET CAV 1|Normal perfusion with abnormal global stress MBF (\<1.7 mL/min/g and ejection fraction \>45%) OR Single vessel perfusion defect with normal global stress MBF.
62387870|NCT05751915||PET CAV 2/3|Normal perfusion with abnormal global stress MBF (\<1.7 mL/min/g) and ejection fraction \< 45% OR Single vessel perfusion defect with abnormal global stress MBF (\<1.7 mL/min/g) OR Multivessel perfusion defects v
62387871|NCT02860676|EXPERIMENTAL|Cirmtuzumab|
62387872|NCT01408862||controls|Healthy volunteers will be asked to donor a 10-80 ml blood through a venous puncture
62387873|NCT02303730|EXPERIMENTAL|Exenatide|Exenatide 5 ug twice daily 1 hour before meal subcutaneously for 4 weeks, then add to 10 ug twice daily 1 hour before meal subcutaneously for another 20 weeks
62387874|NCT02303730|ACTIVE_COMPARATOR|Insulin glargine|Insulin glargine subcutaneously, once daily, for 24 weeks
62387875|NCT05441124|EXPERIMENTAL|Mindfullness Based Stress Reduction|Mindfullness Based Stress Reduction (MBSR) therapy
62387876|NCT05441124|NO_INTERVENTION|Control|Control
62559843|NCT02864576|EXPERIMENTAL|Cognitive Remediation_Aerobic Exercise|"Cognitive Remediation:~12 weeks of systematic cognitive training (REHACOP), performed 3 days per week in a 90-minutes-long sessions.~Aerobic Exercise:~12 weeks of systematic aerobic exercise program, performed 3 days per week, lasting 40 minutes."
62387877|NCT06376201|EXPERIMENTAL|Amphotericin B cholesterol-sulfate complex (ABCD)|"Investigational drug: Amphotericin B cholesterol-sulfate complex (ABCD) at the same time as a treatment for underlying disease.~Dosage: According to the patient's condition and the investigator's judgment, the initial dose of ABCD can be 0.5-1.0mg/kg/d, and the dose can be increased daily according to the situation, and the therapeutic dose can be increased to 3.0-4.0mg/kg/d on the third day.~Course of treatment: ≥ 14 days (whether to continue to receive trial drug treatment after 14 days is decided by the investigator according to the patient's condition)."
62387878|NCT04120025|NO_INTERVENTION|Control Group|Subject will continue standard of care for GERD symptoms
62559844|NCT02864576|ACTIVE_COMPARATOR|Cognitive Remediation_Health Promotion|"Cognitive Remediation:~12 weeks of systematic cognitive training (REHACOP), performed 3 days per week in a 90-minutes-long sessions.~Health Promotion:~12 weeks of health promotion sessions, performed 3 days per week, lasting 40 minutes each."
62559845|NCT02069639||no treatment|
62559846|NCT05144529|ACTIVE_COMPARATOR|Ipilimumab/nivolumab|Subjects receive ipilimumab 1 mg/kg IV every 6 weeks and nivolumab 240 mg IV every 2 weeks.
62559847|NCT05144529|EXPERIMENTAL|ipilimumab/nivolumab/evolucumab|Subjects receive ipilimumab 1 mg/kg IV every 6 weeks and nivolumab 240 mg IV every 2 weeks plus evolocumab 140 mg SC every 2 weeks
62559848|NCT01274702|EXPERIMENTAL|Visual Reconstitution Therapy|
62559849|NCT01274702|ACTIVE_COMPARATOR|Saccadic Eye Movement Training|
62559850|NCT04061174|EXPERIMENTAL|Shoulder stabilization exercise and office exercise training|Shoulder stabilization exercises will be given to the experimental group participants individually during 8 weeks. Exercises will be done 3 times a week and each exercise will be performed with 10 repetitions, 3 sets and 60-90 seconds rest between sets. Also experimental group participants will do office exercise training that given to other group participants.
62559851|NCT04061174|EXPERIMENTAL|Office exercise training|"Office-based stretching exercises will be given to other group 3 sets will be applied by waiting 15 seconds for increasing range of motion of back, shoulder and neck joints.~In addition, isometric exercises and scapula stabilization exercises will be given to strengthen the shoulder muscles and participants will do these exercises 3 times a week and once a day in 10 repetitions (10-15 seconds) and 3 sets. Each set will be given a rest of 60-90 seconds. Total time will be 10-15 minutes.Office exercise training will last a total of 8 weeks."
62768003|NCT00187187|ACTIVE_COMPARATOR|Implantable Defibrillator (ICD) AAI-70|The DAVID II Clinical Study evaluates the hypothesis that, in patients needing an ICD but without overt indications for pacing, AAI pacing with maximal concomitant drug therapy (AAI-70)will not increase the rate of the combined endpoint of mortality or hospitalization for new or worsened heart failure, compared to patients with ventricular backup pacing (VVI-40).
62768004|NCT02008357|EXPERIMENTAL|Solanezumab/Solanezumab|"Participants received 400 milligram (mg) solanezumab followed by 800 mg solanezumab and then 1600 milligram solanezumab administered intravenously (IV) every 4 weeks (Q4W) for approximately 240 weeks in double-blind placebo-controlled period.~Participants begin open label extension and received 1600 mg solanezumab Q4W for 204 weeks (from week 240 to week 444)."
62768005|NCT02008357|PLACEBO_COMPARATOR|Placebo/Solanezumab|"Participants received placebo administered IV Q4W for approximately 240 weeks in double-blind period.~Participants begin open label extension period and received 1600 mg solanezumab Q4W for 204 weeks (from week 240 to week 444)."
62768006|NCT03891628|EXPERIMENTAL|Modified ABC|Modified Attachment and Biobehavioral Catch-Up (14 session in-home intervention with parents and infants present) and Safe Environment for Every Kid (1 to 2 in-home resource visits)
62768007|NCT03891628|ACTIVE_COMPARATOR|Modified DEF|Modified Developmental Education for Families (14 session in-home intervention with parents and infants present) and Safe Environment for Every Kid (1 to 2 in-home resource visits)
62387879|NCT04120025|EXPERIMENTAL|Treatment Group|Subjects will continue with usual care but will also receive diaphragm training (belly breathing) instructions using verbal, visual and tactile cues for proper contraction of the diaphragm as a home program
62768008|NCT04408768||Normal RBS|Normal RBS on ICU admission and controlled blood sugar within 24 hours
62768009|NCT04408768||High RBS|High RBS on ICU admission and uncontrolled blood sugar during first 24 hours
62387880|NCT01485289||Investigational Stabilimax|
62387881|NCT01485289||Control, Posterolateral Fusion|
62768010|NCT05741047|ACTIVE_COMPARATOR|a2 Group|The group consuming a2Milk skim milk powder (1L) containing A2 β-casein only
62768011|NCT05741047|PLACEBO_COMPARATOR|Control Group|The group consuming Yili skim milk powder (1L) containing A1 and A2 β-caseins
62768012|NCT02779504||Agluna treated METS|Patient implanted with Agluna treated METS
62387882|NCT01982942|EXPERIMENTAL|ibudilast|Subjects will receive up to 100 mg/d ibudilast for 96 weeks.
62387883|NCT01982942|PLACEBO_COMPARATOR|Placebo Oral Capsule|Subjects will receive placebo for 96 weeks.
62387884|NCT05712174|EXPERIMENTAL|[18]F-PSMA-1007 PET/CT or PET/MRI|All participants will undergo a single \[18\]F-PSMA-1007 PET/CT or PET/MRI scan. Intravenous bolus injection of 4 MBq/kg +/- 10% of \[18\]F-PSMA-1007, up to a maximum of 400 MBq.
62387885|NCT00958230|EXPERIMENTAL|dCell Vascular Patch|This Xenograft device is manufactured from Porcine Pericardium Tissue which has been decellularised leaving a scaffold style structure for ingrowth of human endothelial cells after placement into the operative site.
62387886|NCT03264976||Group 1|Patients without DR. Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years.
62768013|NCT02779504||Untreated METS|Patient implanted with untreated METS
62768014|NCT03167320||LOVIC|Irish patients with low Von Willebrand levels will be have both venous blood sampling and a bleeding score administered at study entry. A DDAVP (1-desamino-8-D-arginine vasopressin) fall off study was organised for those patients in the cohort with no previous fall offs available and no contraindications to DDAVP.
62768015|NCT06358404|OTHER|Intervention|Peer coaches will deliver the PeersCOG intervention to participants.
62768016|NCT02220114|OTHER|Vigabatrin: Vigabatrin new ST formulation then Sabril®|"Sabril®: sachet for oral solution 500 mg, 50 to 100mg/Kg/day, twice a day, 14 days.~Vigabatrin new ST formulation: Soluble tablets 100 or 500 mg, 50 to 100mg/Kg/day, twice a day, 12 weeks."
62387887|NCT03264976||Group 2|"Patients with mild non-proliferative DR (NPDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years."
62387888|NCT03264976||Group 3|"Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years."
62387889|NCT03264976||Group 4|"Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years."
62387890|NCT03264976||Group 5|"Proliferative DR (PDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years."
62387891|NCT05535452|PLACEBO_COMPARATOR|Group control|Patients will receive applications with the LED board turned off without light activation. Applications will be performed within 1 hour after radiotherapy, three times a week, by a trained team, consisting of physical therapists and physical therapy students, and the application time will be the same as in the intervention group. Women will be instructed to maintain specific home exercises for the upper limbs, which are part of the routine of the physiotherapy sector since the first postoperative day at the HCIII/INCA, in addition to their usual physical activities.
62387892|NCT05535452|EXPERIMENTAL|Intervention group|At the beginning of radiotherapy treatment, all HCIII/INCA patients are instructed by the nursing team in this sector to use the DNA® ointment provided at the institution and to take proper skin care. Patients identified by the nursing staff with some degree of radiodermatitis undergo treatment with silver sulfadiazine and, if necessary, radiotherapy can be interrupted so that the skin regenerates.
62387893|NCT05768360|EXPERIMENTAL|Drug cocktail/Savolitinib + Drug cocktail|Subjects will receive two different interventions in two periods (Periods 1 and 2). In Period 1, the subjects will receive a single-dose of Drug cocktail components (digoxin Dose B, furosemide Dose C, metformin hydrochloride Dose D, and rosuvastatin Dose E). During Period 2, the subjects will receive savolitinib dose A in combination with the Drug cocktail components.
62387894|NCT00426842|EXPERIMENTAL|Arm 1|Blood pressure response during HUT following administration of Midodrine Hydrochloride compared with no drug.
62387895|NCT01165515||Healthy young females|20 healthy females, aged between 18 and 35 years
62387896|NCT01165515||Healthy young males|20 healthy males, aged between 18 and 35 years
62387897|NCT01165515||Healthy elderly smokers|20 healthy smokers, aged between 45 and 75 years
62387898|NCT01165515||Healthy elderly non-smokers|20 healthy non-smokers, aged between 45 and 75 years
62387899|NCT01165515||Healthy young female smokers|20 healthy female smokers, aged between 18 and 35 years
62387900|NCT01165515||Healthy young male smokers|20 healthy male smokers, aged between 18 and 35 years
62387901|NCT01165515||Healthy postmenopausal women|20 healthy postmenopausal women
62387902|NCT01165515||Female CMP Patients|20 female patients suffering from cardiomyopathy (ischemic or dilating)
62387903|NCT01165515||Male CMP Patients|20 male patients suffering from cardiomyopathy (ischemic or dilating)
62387904|NCT01165515||Female CHD patients|30 female patients suffering from cardiac heart disease, before aorto-coronary bypass surgery (and after)
62387905|NCT01165515||Male CHD Patients|30 male patients suffering from cardiac heart disease, before aorto-coronary bypass surgery (and after)
62387906|NCT01165515||male athlets|20 male athlets
62387907|NCT01165515||female athlets|20 female athlets
62387908|NCT05815004|EXPERIMENTAL|AVR-RD-02 Arm|Participants will have been on a stable prescribed ERT dose for at least 6 consecutive months at the time of Screening and willing to remain on the same ERT dose until 2 weeks prior to gene therapy infusion.
62387909|NCT05815004|ACTIVE_COMPARATOR|ERT Control Arm|"Participants on stable prescribed ERT dose for at least 6 consecutive months at the time of Screening.~Participants will have the opportunity to receive a gene therapy infusion of AVR-RD-02 after week 52 of Part 1."
62387910|NCT00570089|EXPERIMENTAL|Study Drug Ranexa, Then Placebo|"Participants first received study drug Ranexa, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.~After a washout period of 2 weeks, they then received Placebo tablet (matching Ranexa tablet)."
62768017|NCT00637572|EXPERIMENTAL|Megestrol acetate oral suspension nanocrystal dispersion|Megestrol acetate oral suspension nanocrystal dispersion formulation 115 mg/mL
62768018|NCT00637572|ACTIVE_COMPARATOR|Megestrol acetate oral suspension micronized formulation|Megestrol acetate oral suspension micronized formulation 60 mg/mL
61992705|NCT01297907||Crohn's Patients|Random Crohn's Disease Patients that can perform Methacholine Challenge Test (MCT)
61992706|NCT01297907||Negative MCT|Patients evaluated for functional cough who had negative Methacholine Challenge Test (MCT)
61992707|NCT01894789|EXPERIMENTAL|stable CAD management|Experimental: Ticagrelor (BrilintaTM) 90 mg tablet by mouth twice a day
62387911|NCT00570089|EXPERIMENTAL|Placebo, Then Study Drug Ranexa(Ranolazine)|"Participants first received Placebo tablet (matching Ranexa tablet) for two weeks.~After washout period of 2 weeks, they then received Ranexa 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval."
62559852|NCT02308930|EXPERIMENTAL|Vitamins + DHA supplement|2 x 400 mg capsules per day orally for 6 months, each capsule providing 154μg Vitamin A, 2.36μg Vitamin D, 0.4mg Vitamin E and 375mg algal oil (containing 150mg DHA).
62559853|NCT02308930|OTHER|Vitamins supplement|2 x 400 mg capsules per day orally for 6 months, each capsule providing 154μg Vitamin A, 2.36μg Vitamin D, 0.4mg Vitamin E and 375mg corn oil (free of omega-3 fatty acids).
62559854|NCT05346198|EXPERIMENTAL|Subjects will receive CART-BCMA|"Biological: CART-BCMA Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CART-BCMA.~During CART-BCMA production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CART-BCMA product, subjects will receive treatment with CART-BCMA therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of CART-BCMA administered by intravenous (IV) injection."
62559855|NCT04633005|EXPERIMENTAL|Polypill Arm|Patients will be randomized to receiving a fixed-dose polypill in addition to other guideline-directed medical therapies prescribed by their physician. Polypill formulations will include metoprolol succinate (a beta-blocker), empagliflozin (an SGLT2-inhibitor), and spironolactone (a mineralocorticoid antagonist). Three dose formulations of the pill, varied in metoprolol succinate dose, will be available for up-titration of the beta-blocker dose per ACC/AHA/HFSA guidelines.
62768019|NCT03766269|OTHER|Baseline Opioid|One of Seven existing Baseline Opioid subgroups (Hydrocodone, Oxycodone, Morphine, Hydromorphone, Buprenorphine, Tramadol) coadministered with intervention drug, Dronabinol.
62768020|NCT04626960||Patient|OAB patients
62387912|NCT01140646|EXPERIMENTAL|Arm I|The first week of the study is a baseline week where data are being collected but study agent is not being taken. Patients then receive oral s-adenosyl-L-methionine, 400 mg, once daily on days 8-14 and twice daily on days 15-49 in the absence of unacceptable toxicity.
62387913|NCT01226758|EXPERIMENTAL|FLU-v with adjuvant|
62387914|NCT01226758|PLACEBO_COMPARATOR|Placebo|Adjuvant only placebo
62768021|NCT04626960||Control|Healthy
62768022|NCT02989805|ACTIVE_COMPARATOR|Professional Care Manager|Each participating site will have a nurse or social worker to provide care management. Training activities will include modules for each of the key domains covered in the intervention: shared decision making, action planning; motivational interviewing; and mental health as a cornerstone of recovery, working effectively within the mental health system; and self-care and stress management.
62387915|NCT06201585|EXPERIMENTAL|Single-port robot-assisted gastrectomy|SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)
62387916|NCT01453439|EXPERIMENTAL|Cognitive Behavioral Therapy|Group receiving Cognitive-Behavioral Therapy
62387917|NCT01453439|ACTIVE_COMPARATOR|Supportive Psychotherapy|Group receiving Supportive Psychotherapy
62387918|NCT01914536||Pompe patients|Adult onset pompe patients being or not treated with enzyme therapy replacement
62387919|NCT03223649|EXPERIMENTAL|Sedentary|(Control intervention) Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
62387920|NCT03223649|EXPERIMENTAL|Walking bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
62387921|NCT03824756|EXPERIMENTAL|NGO supported GMP program|Intervention: NGO supported GMP program Site: Community clinic Duration: 12 months Study participants: 6-12 months aged children living within community clinic catchment area
61992708|NCT01894789|ACTIVE_COMPARATOR|CAD comparison group|Active comparator: clopidogrel 75 mg plus placebo tablet by mouth twice a day.
61992709|NCT03466476|EXPERIMENTAL|Wearable Technology Group|Patients in this arm will be provided with their own Consensus TracPatch wearable device postoperatively and instructed on its use for six weeks.
62768023|NCT02989805|EXPERIMENTAL|Peer Specialist Care Manager|Each participating site will have a peer specialist to provide care management. Peer specialists will have a minimum of a high school education, a history of a mental illness, be self-described as 'in recovery,' and have reliable transportation to the study site. All certified peer specialists will receive training in a curriculum that supports identifying and pursuing goals for recovery; developing and documenting recovery-focused treatment plans; and supporting linkages with community-based services. Peers learn to help other individuals with mental health conditions to facilitate mental health dialogues; explore mental health choices and options; identify and work with a clinician; and obtain access to community health supports.
62768024|NCT00316524|EXPERIMENTAL|GP 1: two x 1x10E08 TCID, MVA-BN® s.c., vaccinia naive|vaccinia naive subjects receiving two subcutanenous vaccinations with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID)
62768025|NCT00316524|EXPERIMENTAL|GP 2: 1x10E08 TCID, MVA-BN®, 1x Placebo, s.c., vaccinia naive|vaccinica naive subjects receiving one vaccination with 0.5ml MVA-BN® IMVAMUNE(1x10E08 TCID), followed by one vaccination Placebo (0.5ml Tris Buffer)
62387922|NCT03824756|ACTIVE_COMPARATOR|Non-supported GMP program|Comparison: Non-supported GMP program Site: Community clinic Duration: 12 months Study participants: 6-12 months aged children living within community clinic catchment area
62387923|NCT04873609|NO_INTERVENTION|No primary care provider (PCP) appointment, No patient outreach|400 patients that did not have an upcoming PCP appointment in 6 months were randomly assigned to control group and did not receive a patient portal message with order for HCV antibody screening
61992710|NCT03466476|NO_INTERVENTION|Current Standard of Care Group|Patients in this arm will not be provided with any wearable device. Participants will be evaluated as part of the study for a total of six weeks.
62387924|NCT04873609|ACTIVE_COMPARATOR|No PCP appointment, Patient outreach|400 patients that did not have an upcoming PCP appointment in 6 months were randomly assigned to receive a patient portal message with order for HCV antibody screening
62387925|NCT04873609|NO_INTERVENTION|PCP appointment, No patient outreach|400 patients that had an upcoming PCP appointment in 6 months were randomly assigned to control group and did not receive a patient portal message with order for HCV antibody screening
62387926|NCT04873609|ACTIVE_COMPARATOR|PCP appointment, Patient outreach|400 patients that had an upcoming PCP appointment in 6 months were randomly assigned to receive a patient portal message with order for HCV antibody screening
62387927|NCT01709240|EXPERIMENTAL|BioWeld1 System|
62387928|NCT03724799|EXPERIMENTAL|single arm|Intravenous low level laser therapy
62387929|NCT02179216|ACTIVE_COMPARATOR|Hydration|•Group 1: First day, Orthostatic Hypotension test after hydration by three large glasses of clear liquid (33cl). Second day, Orthostatic Hypotension test with venous contention in the morning.
62387930|NCT02179216|ACTIVE_COMPARATOR|Venous contention|•Group 2: First day, Orthostatic Hypotension test after implementation of venous contention in the morning. Second day, Orthostatic Hypotension test after hydration by three large glasses of clear liquid (33cl).
62387931|NCT01357928||Healthy Volunteers|
62387932|NCT04796454|ACTIVE_COMPARATOR|CisGem/GemOx|"Cisplatin/Gemcitabine (3-week cycle):~* Cisplatin IV 25 mg/m² d1 and day8~* Gemcitabine 1000 mg/m² d1 and d8~This treatment regimen will be given until documented disease progression, unacceptable toxicity, or patient refusal, for a maximum of 2 years.~In case of unacceptable toxicity the CisGem regimen can also be switched to a GemOx regimen (4-week cycle):~* Oxaliplatin IV 100 mg/m² d1 and day15~* Gemcitabine 1000 mg/m² d1 and d15"
62387933|NCT04796454|EXPERIMENTAL|PamTMZ|"Pamiparib + temozolomide (4-week cycle):~Pamiparib 60 mg PO twice a day d1-d28 Temozolomide 60 mg PO daily d1-d7~This treatment regimen will be given until documented disease progression, unacceptable toxicity, or patient refusal, for a maximum of 2 years."
61992711|NCT02771990|SHAM_COMPARATOR|sham tDCS|10 sessions sham transcranial direct current stimulation (tDCS)
62387934|NCT00061828||Biliary Atresia|Infants presenting with cholestasis who are diagnosed with biliary atresia.
61992712|NCT02771990|EXPERIMENTAL|active tDCS|10 sessions active transcranial direct current stimulation (tDCS)
62387935|NCT00061828||Non-Biliary Atresia|Infants presenting with cholestasis without a diagnosis of biliary atresia.
62387936|NCT06326658|EXPERIMENTAL|Bufei Yishen Prescription|Bufei Yishen formula consists of Radix Panax Ginseng 6g, Radix Astragali 15g, Cornu Cervi Pantotrichum 12g, Fructus Lycii 12g, Fructus Schisandrae Chinensis 9g, Fructus Epimedium Brevicornum 9g, Fructus Pelargonium Chinense 9g, Radix Paeoniae Lactiflorae 9g, Rhizoma Dillonis 9g, Fructus Ziziphiroxylon 9g, Fructus Schisandrae Chinense 15g, Pericarpium Citriodora 9g
62387937|NCT06326658|PLACEBO_COMPARATOR|Bufei Yishen Prescription placebo|Bufei Yishen Prescription placebo is prepared by adding 5% of the drug on the basis of dextrin and bitter agent, and its appearance, weight, color and smell are consistent with Chinese medicine granules.
62387938|NCT01089075|PLACEBO_COMPARATOR|placebo/20 mg hydrocortisone|Order of study treatment: 7 days placebo followed by 7 days 20 mg hydrocortisone
62387939|NCT01089075|ACTIVE_COMPARATOR|20 mg hydrocortisone/placebo|Order of study treatment: 7 days 20 mg hydrocortisone followed by 7 days placebo
61992713|NCT00265512|ACTIVE_COMPARATOR|Telephone Case Monitoring Aftercare|Telephone Case Monitoring Aftercare
61992714|NCT00265512|ACTIVE_COMPARATOR|Continuing Care as Usual|Continuing Care as Usual
61992715|NCT01701115|EXPERIMENTAL|Low Dose (20 mL) Local Anesthetic|Intervention to be administered is a total volume of 20 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine.
62387940|NCT00784680|ACTIVE_COMPARATOR|1|Arimidex 1mg + Nolvadex placebo
62387941|NCT00784680|ACTIVE_COMPARATOR|2|Arimidex placebo + Nolvadex 20mg
62387942|NCT00784680|ACTIVE_COMPARATOR|3|Arimidex 1mg + Nolvadex 20mg
62387943|NCT05838586|EXPERIMENTAL|CON|Control group
62387944|NCT05838586|EXPERIMENTAL|Break|
62387945|NCT05838586|EXPERIMENTAL|BOUT|
62387946|NCT02217176||endotracheal intubation|
62387947|NCT02217176||laryngeal mask airway|
62559856|NCT04633005|ACTIVE_COMPARATOR|Control Arm|Patients will receive GDMT as usually prescribed by their provider. All of the individual components will be available at low- or no-cost to participants as individual pill formulations.
61992716|NCT01701115|ACTIVE_COMPARATOR|Control Dose (40 mL) Local Anesthetic|Intervention to be administered is a total volume of 40 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine
61992717|NCT03559712|EXPERIMENTAL|Telemedicine|Participants in this arm will be treated by the trained primary health care physicians in the primary health care centers, who will be having weekly supervisions with the specialists for case management.
61992718|NCT03559712|NO_INTERVENTION|Control|Participants in this arm will experience treatment as usual, which means referral to a specialist.
61992719|NCT03314727|NO_INTERVENTION|Control group|Drink 200 ml soup with no added salt
61992720|NCT03314727|EXPERIMENTAL|High salt (NaCl) intake|Group 2: Drink 200 ml soup with 3 g added salt Group 3: Drink 200 ml soup with 3 g added salt plus 500 ml water Group 4: Drink 200 ml soup with 3 g added salt plus 750 ml water
62559857|NCT05173181|OTHER|Adult with fracture distal ulna|
62559858|NCT01349192|EXPERIMENTAL|Treatment|Subjects are treated with two oral antibiotics, topical antibiotics, and are instructed to use environmental decontamination techniques.
62768026|NCT00316524|PLACEBO_COMPARATOR|GP 3: two x Placebo, s.c., vaccinia naive|vaccinia naive subjects, receiving two subcutaneous vaccinations with Placebo (0.5ml Tris Buffer).
62768027|NCT00316524|EXPERIMENTAL|GP 4: 1x10E08 TCID, MVA-BN®, s.c., vaccinia experienced|vaccinia experienced subjects, receiving one subcutaneous vaccination with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID).
61992721|NCT03877627|NO_INTERVENTION|Negative 1|Patients in this arm will not undergo Pelvic and Peritoneal Lymphadenectomy.
62387948|NCT04613076|EXPERIMENTAL|"Me cuido y me siento mejor"|Patients in the primary care clinics assigned to the intervention will receive eight sessions of a computer-assisted, psycho-educational intervention delivered by trained therapists; structured telephone calls by social worker to monitor clinical progress and treatment adherence; usual medical care for chronic diseases; and access to the project's website, which will be populated with information about the project's aims, the research team, and contact data, along with educational material related to depression, diabetes and hypertension, and healthy lifestyles. Study therapists will receive biweekly and monthly supervision by psychologist and psychiatrist, respectively. A monthly meeting will be held between the PCC team and a member of the research team to ensure continuity of care.
62387949|NCT04613076|ACTIVE_COMPARATOR|Enhanced Usual Treatment|The patients in the primary care clinics assigned to the comparator will receive the usual treatment for depression and their physical conditions -all the guaranteed interventions for people with depression, hypertension, and/or diabetes in primary care, according to the Clinical Guidelines for the Treatment of Depression- and their associated basket of health benefits included in the Regime of Explicit Health Care Guarantees. They will have access to the project's website, which will be populated with information about the project's aims, the research team, and contact data, along with educational material related to depression, diabetes and hypertension, and healthy lifestyles.
62387950|NCT01986166|EXPERIMENTAL|MEHD7945A + Cobimetinib - Stage 1|Patients will receive MEHD7945A 1100 milligrams (mg) intravenous (IV) infusion every 2 weeks (q2w) in combination with cobimetinib. Cobimetinib will be administered at a starting dose of 80 mg oral tablet q2w. Cobimetinib doses will be escalated to establish maximum tolerated dose (MTD) of MEHD7945A+cobimetinib combination for Stage 2.
62768028|NCT05107583|EXPERIMENTAL|Low-Carbohydrate Pre-Exercise Meal|Participants will consume a low-carbohydrate (\<10% carbohydrate) lunch meal at 13:30 - 2.5 hours prior to commencing exercise at 16:00.
62387951|NCT01986166|EXPERIMENTAL|MEHD7945A + Cobimetinib - Stage 2 (CRC)|CRC patients will receive MEHD7945A in combination with cobimetinib until disease progression or unacceptable toxicity. The doses and schedule of the combination treatment will be according to the MTD established in Stage 1.
61992722|NCT03877627|EXPERIMENTAL|Negative 2|Patients in this arm will undergo Pelvic and Peritoneal Lymphadenectomy.
62387952|NCT01986166|EXPERIMENTAL|MEHD7945A + Cobimetinib - Stage 2 (NSCLC)|NSCLC patients will receive MEHD7945A in combination with cobimetinib until disease progression or unacceptable toxicity. The doses and schedule of the combination treatment will be according to the MTD established in Stage 1.
62387953|NCT03676712|EXPERIMENTAL|scoliosis patients|scoliosis patients who have cobb angle over 20 degree wear scoliosis brace for six months
62559859|NCT01349192|NO_INTERVENTION|Observational|Subjects are tracked and not treated for their MRSA. If the subject reaches a protocol defined exacerbation within the first 28 days then they will be treated per choice of their primary Pulmonologist.
62559860|NCT02353286|EXPERIMENTAL|Post-cholecystecomy bile leak|Endoscopic insertion of biodegradable biliary stent
62768029|NCT05107583|EXPERIMENTAL|High-Carbohydrate Pre-Exercise Meal|Participants will consume a high-carbohydrate (\~2.2 g/kg carbohydrate) lunch meal at 13:30 - 2.5 hours prior to commencing exercise at 16:00.
62768030|NCT05107583|EXPERIMENTAL|Fasted Exercise|Participants will skip lunch, and continue fasting since breakfast (08:00) before commencing exercise at 16:00. Therefore, exercise will commence after an 8 hour period of fasting.
62768031|NCT02580513|NO_INTERVENTION|Control|3 days with normal circadian alignment.
62768032|NCT02580513|EXPERIMENTAL|Circadian Misalignment|3.5 days in which the subjects will undergo a maximal circadian misalignment of 12 hours by means of a midday nap during the second day, and a subsequent start of a new normal wake period, shifted 12 hours.
62768033|NCT01475162|EXPERIMENTAL|Tocilizumab|"Drug: Tocilizumab~Other Names:~Actemra~Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response."
62768034|NCT02392403|EXPERIMENTAL|Nucleus CI532 cochlear implant|
62768035|NCT03094559|EXPERIMENTAL|FlowMet device|This is a feasibility study
62768036|NCT04240314|EXPERIMENTAL|Cohort 1 (Minimal Efficacious Dose)|The Minimal Effective Dose (MED) will be delivered.
62768037|NCT02619721|EXPERIMENTAL|Sacral Neuromodulation is on|Sacral Neuromodulation is on as soon as implantation
62768038|NCT02619721|PLACEBO_COMPARATOR|Sacral Neuromodulation is off|Sacral Neuromodulation is off after implantation
62768039|NCT05235919|EXPERIMENTAL|repetitive transcranial magnetic stimulation (rTMS)|Participants will receive 15 rTMS sessions for 3 weeks.
62768040|NCT05235919|SHAM_COMPARATOR|Sham|Participants will receive 15 sessions of sham stimulation for 3 weeks.
61992723|NCT01124604|EXPERIMENTAL|Tapentadol Hydrochloride|
62768041|NCT01462890|OTHER|Control Arm|Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 16 cycles.
61992724|NCT01124604|PLACEBO_COMPARATOR|Placebo|
61992725|NCT01571895|EXPERIMENTAL|DF2156A 150 mg|150 mg capsule twice a day (every 12 h) for a maximum of 14 days
61992726|NCT01909908|EXPERIMENTAL|ECM in Saline|
61992727|NCT01909908|ACTIVE_COMPARATOR|Blood Products|
61992728|NCT01909908|EXPERIMENTAL|ECM in Blood Products|
61992729|NCT00732810|EXPERIMENTAL|Breast cancer randomized to SCH 727965|
61992730|NCT00732810|ACTIVE_COMPARATOR|Breast cancer randomized to capecitabine|
62559861|NCT02353286|EXPERIMENTAL|Benign biliary stricture|Endoscopic insertion of biodegradable biliary stent
62559862|NCT00837837|EXPERIMENTAL|Chlorpheniramine|Chlorpheniramine dose by body weight.
62559863|NCT00959478|EXPERIMENTAL|Educational tool & Carbon Monoxide Alarm|"Parents will be randomly assigned into a control and intervention group. Both groups will complete a computer based survey at enrollment and at their home visits occuring two weeks and approximately six months following enrollment. Participants will be given the following materials at enrollment.~Intervention:~* Fast Facts about Carbon Monoxide Educational Tool~* Kidde Nighthawk Carbon Monoxide Alarm~Control:~- Central Ohio Poison Control Center Flyer"
62559864|NCT05723094|EXPERIMENTAL|Retention Laser Group (LG)|Before the orthodontic retention phase, the Ga-Al-As diode laser(Ilase, USA) was applied to the experimental group.
62559865|NCT05723094|PLACEBO_COMPARATOR|Retention Control Group (CG)|Before the orthodontic retention phase, those who did not apply the Ga-Al-As diode laser (Ilase, USA) were the control group.
62559866|NCT02579473|EXPERIMENTAL|Cohort 0|"Subjects in Cohort 0 will receive a single subcutaneous injection of 20 mg SER-214, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
62559867|NCT02579473|EXPERIMENTAL|Cohort 1|"Subjects in Cohort 1 will receive a single SC injection of 50 mg SER-214 at the beginning of each week for two consecutive weeks, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
62559868|NCT02579473|EXPERIMENTAL|Cohort 2|"Subjects in Cohort 2 will receive a single SC injection of 50 mg SER-214 at the beginning of week one, followed by a weekly SC injection of 100 mg SER-214 for two consecutive weeks, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
62559869|NCT02579473|EXPERIMENTAL|Cohort 3|"Subjects in Cohort 3 will receive a single SC injection of 50 mg SER-214 at the beginning of week one, followed by a single SC injection of 100 mg SER-214 at the beginning of week two, followed by a single SC injection of 200 mg SER-214 for two consecutive weeks, followed by a two week wash-out period, to determine PK and terminal wash-out PK of rotigotine and pro-drug SER-214."
62559870|NCT01588067||Medical|Patients treated for PAD medically or with exercise therapy
62559871|NCT01588067||Endovascular|Patients with PAD treated with endovascular therapy
62559872|NCT01588067||Surgery|Patients with PAD treated with surgery
62768042|NCT01462890|EXPERIMENTAL|Research Arm|Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 38 cycles.
62768043|NCT02391532|ACTIVE_COMPARATOR|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA lozenges twice daily for 12 weeks
62768044|NCT02391532|PLACEBO_COMPARATOR|Placebo|Placebo lozenges twice daily for 12 weeks
62768045|NCT01238978|EXPERIMENTAL|Vildagliptin|
62559873|NCT01075789|PLACEBO_COMPARATOR|Placebo|This arm will include children aged 6 years of age and older seen at the Royal Children's Hospital who are having an NGT inserted for a clinical indication and who have never experienced an NGT insertion before. These children will be randomised to be in this placebo arm or the treatment arm in a 1:1 ratio. The placebo for swallowing is a viscous, coloured, sucrose-flavoured gel designed to match the appearance of the treatment lignocaine gel to be swallowed by the treatment arm, and normal saline will be delivered to the nasal turbinates and nasopharynx in a similar way to atomised xylocaine in the treatment arm.
62559874|NCT01075789|ACTIVE_COMPARATOR|Lignocaine|This arm will include children aged 6 years of age and older seen at the Royal Children's Hospital who are having an NGT inserted for a clinical indication and who have never experienced an NGT insertion before. These children will be randomised to be in this treatment placebo arm or the treatment arm in a 1:1 ratio. The children in the treatment arm will receive xylocaine viscous 2% to swallow, and atomised 10% xylocaine to the nasal turbinates and nasopharynx.
62559875|NCT01075789|ACTIVE_COMPARATOR|Pre/post intervention evaluation group|This is a contemporaneous arm of children aged 6 years of age and older requiring nasogastric intubation for a clinical reason, who have previously had a nasogastric tube inserted. These children will be ask to rate by recall their previous NGT intubation on a VAS pain scale, and then will perform a post-procedure VAS pain assessment.
62559876|NCT01845441|EXPERIMENTAL|Dexmedetomidine arm|Precedex will be started after randomization/prior to catheterization and will be stopped at the end of the procedure. It will be used for an average of 90 minutes and will be used as a continuous intravenous infusion started at 0.3 mcg/kg/hour. If HR \> 80 and BP \> 120/70, a full loading dose (1.0 mcg/kg/hour) will be administered over 10 minutes. If HR is 60 - 80 or systolic BP is 90 - 120, or age \> 65 years, a reduced loading dose of 0.5 mcg/kg will be given over 10 minutes. If no volume overload history, 500mL of colloid (hespan or albumin) will be bolused with 0.2mg of glycopyrrolate. Every 10 minutes, Precedex will be titrated by 0.1 mcg/kg/hour to achieve and maintain RASS of 0 to -1.
62768046|NCT01238978|ACTIVE_COMPARATOR|other Oral Antidiabetic Drug in a different therapeutic class|
62768047|NCT05686096|EXPERIMENTAL|MYK-224|
62768048|NCT04489121|EXPERIMENTAL|omalizumab preseasonal treatment|For patients in the Omalizumab group, subcutaneous injections of Omalizumab based on the specific participant's weight and serum total IgE was performed 2 weeks prior the anticipated pollen season. Rescue medication could be used during pollen seasons.
62768049|NCT04489121|NO_INTERVENTION|control|No preseasonal treatment was performed. Rescue medication could be used during pollen seasons.
62768050|NCT03952715|EXPERIMENTAL|Evoked pain training|
62768051|NCT03952715|EXPERIMENTAL|Control|
62768052|NCT02645435|ACTIVE_COMPARATOR|Hip direct anterior approach|Patients with hip arthritis
62768053|NCT02645435|ACTIVE_COMPARATOR|Lateral hip approach|Patients with hip arthritis
62768054|NCT04761484|EXPERIMENTAL|Intervention|Insertion of peripheral venous catheter on admission to the NICU
62768055|NCT04761484|NO_INTERVENTION|Control|Insertion of and umbilical venous catheter on admission
62559877|NCT01845441|ACTIVE_COMPARATOR|Control arm|Our usual standard of care is to attempt the intervention without sedation. As per attending physician discretion, Fentanyl (50mcg) and/or Midazolam (0.5 mg) intravenous boluses will be used to control aggressive patient movement that adversely affects the technical capacity of the procedure. The boluses will be repeated at interval of 10 minutes, as necessary. Control arm patients will receive a normal saline placebo drip for the purposes of ensuring patient assessor blindness.
61992731|NCT00732810|EXPERIMENTAL|SCH 727965 in breast cancer after progression on capecitabine|
62768056|NCT00439452|ACTIVE_COMPARATOR|Telemedicine-Based Collaborative Care|Telemedicine-Based Collaborative Care - Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
62768057|NCT00439452|ACTIVE_COMPARATOR|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
62768058|NCT02092402|PLACEBO_COMPARATOR|Fecal transplantation of own stool|Autologous fecal transplantation (own stool)
61992732|NCT00732810|EXPERIMENTAL|NSCLC randomized to SCH 727965|Note: Enrollment of participants with NSCLC was completed per protocol as of 26 JAN 2010
61992733|NCT00732810|ACTIVE_COMPARATOR|NSCLC randomized to erlotinib|Note: Enrollment of participants with NSCLC was completed per protocol as of 26 JAN 2010
62768059|NCT02092402|EXPERIMENTAL|Fecal transplantation (stool from donor)|Allogeneic fecal transplantation (from donor)
61992734|NCT00732810|EXPERIMENTAL|SCH 727965 in NSCLC after progression on erlotinib|Note: Crossover to SCH 727965 after progression on erlotinib was completed per protocol as of 26 JAN 2010
61992735|NCT05777031|EXPERIMENTAL|Collagenase Clostridium Histolyticum (CCH) Group|There will be 8 total treatments. These will follow the manufacturer protocol of 2 injections 24-72 hours apart (one cycle), followed by a 6-week break. This will total a maximum of 4 cycles.
61992736|NCT05963087|EXPERIMENTAL|Advanced CRC|Patients with BRAF Mutated Advanced CRC were given Cetuximab in Combination With Dabrafenib and Tislelizumab
61992737|NCT04975555|EXPERIMENTAL|Siltuximab|Patients who experience CRS/ICANS will receive this treatment
61992738|NCT01909349|NO_INTERVENTION|Control Group|Control Group will gain access to the intervention after the intervention group has finished the program (\>8 weeks after signing up)
61992739|NCT01909349|EXPERIMENTAL|Intervention Group I|Self-regulation support Behavior sequence: Physical activity, then fruit \& vegetable intake
61992740|NCT04398069|NO_INTERVENTION|Standard Group|standard hemodynamic goals and catecholamin infusion to achieve: mean arterial pressure \> or equal to 65 mmHg and diastolic arterial pressure \> ou equal to 50 mmHg within the first 60 minutes.
62559878|NCT03733769|EXPERIMENTAL|TQL group|transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery
61992741|NCT04398069|EXPERIMENTAL|personalized hemodynamic goals Group|Personalized hemodynamic goals and catecholamin infusion to achieve normal cerebral perfusion assessed by transcranial doppler: PI \< 1,2.
61992742|NCT04477343|EXPERIMENTAL|Experimental: SX-682 and Nivolumab|"SX-682 Dose: 25, 50, 100, 200, 400mg BID taken as an oral pill~Nivolumab Dose: 240mg, every 2 weeks via intravenous infusion"
62768060|NCT00636012|EXPERIMENTAL|1|verum acupuncture
62768061|NCT00636012|SHAM_COMPARATOR|2|sham acupuncture
61992743|NCT00987116|ACTIVE_COMPARATOR|Starting dose Prednisone Azathioprine|Classical Strategy
62768062|NCT01307293|EXPERIMENTAL|Cognitive Behavior Therapy|6-12 sessions of Cognitive Behavior Therapy to address PTSD symptoms and parenting issues related to premature infants.
61992744|NCT00987116|ACTIVE_COMPARATOR|Starting dose Prednisone - Azathioprine|Rapid strategy
61992745|NCT05868070|NO_INTERVENTION|Conventional rehabilitation|Conventional rehabilitation corresponds to general rehabilitation for critically ill patients and is mainly performed according to functional mobility with a range of motion. This includes Lying without contractures, turning self, sitting balance, sitting at the edge, standing and transfer, assisted gait, and gait endurance.
61992746|NCT05868070|EXPERIMENTAL|Conventional rehabilitation plus multimodal exercise|Conventional rehabilitation corresponds to general rehabilitation for critically ill patients and is mainly performed according to functional mobility with a range of motion. This includes Lying without contractures, turning self, sitting balance, sitting at the edge, standing and transfer, assisted gait, and gait endurance. Patients in the intervention group additionally receive multimodal exercise using the in-bed cycle/stepper.
61992747|NCT00099125|EXPERIMENTAL|RT with chemotherapy + post-radiation chemotherapy|Radiation therapy (RT) with concurrent chemotherapy + post-radiation chemotherapy
61992748|NCT01999595|EXPERIMENTAL|High frequency TENS with large pads|"TENS=transcutaneous electrical nerve stimulation~High frequency TENS was a 80 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 10 cm~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
61992749|NCT01999595|EXPERIMENTAL|Low frequency TENS with large pads|"TENS=transcutaneous electrical nerve stimulation~Low frequency TENS was a 3 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 10 cm~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
61992750|NCT01999595|EXPERIMENTAL|High frequency TENS with small pads|"TENS=transcutaneous electrical nerve stimulation~High frequency TENS was a 80 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 2.5 cm~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
61992751|NCT01999595|EXPERIMENTAL|Low frequency TENS with small pads|"TENS=transcutaneous electrical nerve stimulation~Low frequency TENS was a 3 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 2.5 cm~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
62768063|NCT01307293|NO_INTERVENTION|Placebo comparison|Education regarding NICU parenting issues.
61992752|NCT01999595|PLACEBO_COMPARATOR|Control TENS|"TENS=transcutaneous electrical nerve stimulation~Control TENS was the application of electrical stimulation via skin with no current"
61992753|NCT01999595|SHAM_COMPARATOR|Sham TENS|"TENS=transcutaneous electrical nerve stimulation~Sham TENS was the application of electrical stimulation via skin with no current on the participant, who was told that the TENS was turn-on whether you feel it or not"
62387954|NCT04851522|EXPERIMENTAL|Di-Dak-Sol + White Petrolatum|"Participants will receive Di-Dak-Sol (dilute bleach compresses) prior to receiving radiation. This will continue throughout their radiation therapy and for one week after.~Participants will also be asked to apply white petrolatum ointment 2x daily throughout treatment: once after radiation and once in the evening.~Participants will be provided with a log and asked to document information (dates/times of application) about the study treatment ."
62387955|NCT01425242|EXPERIMENTAL|Aliskiren|Half of all subjects with mild to moderate hypertension and a small abdominal aortic aneurysm are treated with aliskiren, combined with hydrochlorothiazide if hypertension cannot be treated sufficiently with aliskiren monotherapy
62387956|NCT01425242|ACTIVE_COMPARATOR|Amlodipine|Half of all subjects with mild to moderate hypertension and a small abdominal aortic aneurysm are treated with amlodipine, combined with hydrochlorothiazide if hypertension cannot be treated sufficiently with amlodipine monotherapy
62559879|NCT00459563|PLACEBO_COMPARATOR|Placebo|
62559880|NCT00459563|ACTIVE_COMPARATOR|Cholecalciferol|Cholecalciferol
62559881|NCT00459563|ACTIVE_COMPARATOR|Calcitriol|Calcitriol
62768064|NCT06412952|EXPERIMENTAL|68Ga-RM26, PET/CT|Inject 68Ga-Pentixafor and then perform PET/CT scan.
62768065|NCT00277394|EXPERIMENTAL|innohep®|innohep® 175 anti-Xa IU/kg once daily
61992754|NCT03167879|EXPERIMENTAL|SCC1--high intensity supervision|Integration of safer conception counseling into family planning services, with intensive training and supervision
61992755|NCT03167879|EXPERIMENTAL|SCC2-- low intensity supervision|Integration of safer conception counseling into family planning services, with less intensive training and supervision that mimics Ministry of Health approach
61992756|NCT03167879|NO_INTERVENTION|Usual care family planning services|Family planning services that are currently available as part of usual care, which focus almost solely on contraception and pregnancy prevention
61992757|NCT05719012|EXPERIMENTAL|UC-MSCs|UC-MSCs
61992758|NCT05719012|PLACEBO_COMPARATOR|Placebo|0.9% Normal Saline
61992759|NCT05215743|EXPERIMENTAL|Combined antioxidant therapy (CAT)|Intravenous administration of deferoxamine, n-acetylcysteine, and ascorbate over 90 minutes.
62387957|NCT01353976|EXPERIMENTAL|Econazole Nitrate Foam 1%|Study medication
62387958|NCT01353976|PLACEBO_COMPARATOR|Vehicle Foam|Placebo medication
62387959|NCT04939064||ART Infertile|Women that are part of a couple diagnosed with unexplained infertility that conceived on the first embryo transfer (ET) attempt
62387960|NCT04939064||Early Implantation Failure (EIF)|Infertility defined by a failure to conceive after: a) three or more failed transfers of high-quality blastocyst(s) (grade 3BB or higher); or b) two or more transfers of euploid blastocyst
62387961|NCT04939064||Early Pregnancy Failure (EPF)|defined by two or more biochemical pregnancies after transfer of a high-quality or euploid blastocyst with a positive hCG 12 days after ET but without subsequent clinical signs of pregnancy
62387962|NCT04939064||Normal Fertile|Women with proven parity based on spontaneous conception without fertility treatment or prior diagnosis of infertility, normal uncomplicated pregnancy, birth of at least one healthy baby
62387963|NCT04939064||Recurrent Pregnancy Loss (RPL)|defined as the loss of two or more pregnancies after transfer of a high-quality or euploid blastocyst with a positive HCG 12 days after ET and subsequent clinical signs of pregnancy
62559882|NCT02826629|OTHER|Schizophrenia|40 patients with diagnosis of schizophrenia (25 medicated - 15 non-medicated)
62559883|NCT02826629|OTHER|Healthy sibling|25 healthy siblings
62559884|NCT02826629|OTHER|Ultra high risk for developing Schizophrenia|15 patients with ultra high risk for developing Schizophrenia
62559885|NCT02826629|OTHER|Controls|-25 age and gender-matched healthy controls
62559886|NCT03194919|EXPERIMENTAL|Negotiating quit date|Endre: a digital smoking cessation counsellor
62559887|NCT03194919|ACTIVE_COMPARATOR|Preset quit date|Endre: a digital smoking cessation counsellor
62768066|NCT00277394|ACTIVE_COMPARATOR|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
62768067|NCT02036762|ACTIVE_COMPARATOR|Treatment Group|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
62768068|NCT02036762|SHAM_COMPARATOR|Control Group|The control group received stretching exercises in the fist and ankle muscles and treadmill exercises
62768069|NCT01467388||phacic|Study patients who still have their own ocular lens
62768070|NCT01467388||pseudophacic|Study patients who have an intraocular lens after cataract surgery
62768071|NCT06141837||Included|Patient hospitalized between 01/03/20 and 31/05/21 in an intensive care unit of the Nancy University Hospital for at less 48 h for COVID-19 acute respiratory distress syndrome and presenting a positive sample for P. aeruginosa during his stay in the intensive care unit.
61992760|NCT05215743|PLACEBO_COMPARATOR|Placebo|Intravenous administration of NaCl 0.9% over 90 minutes
62559888|NCT00764205||Study Group|Troponin measured prior to hospital arrival
62559889|NCT00764205||Control Group|Patients transported to hospital without troponin measurements enroute
62559890|NCT03613181|EXPERIMENTAL|ANG1005|ANG1005 Investigational Drug
62559891|NCT03613181|ACTIVE_COMPARATOR|Physician's Best Choice|One of the protocol specified Physician's Best Choice therapies, assigned by the Investigator prior to randomization: capecitabine or eribulin or high-dose intravenous (IV) methotrexate.
62559892|NCT02436343||obese pregnant women|"pregnant women wit body mass index more than or equal to 30 kg/m2 will be subjected to four serial echocardiograms in the 3 trimesters of pregnancy and in the postpartum state.~Height, weight, systolic and diastolic blood pressures will be measured at each echocardiographic evaluation."
61992761|NCT05516082|EXPERIMENTAL|Lens A|All participants wore Lens A for 15 minutes (Period 1)
61992762|NCT05516082|EXPERIMENTAL|Lens B|All participants wore Lens B for 15 minutes (Period 2)
62559893|NCT02436343||lean pregnant women|"pregnant women wit body mass index less than or equal to 25kg/m2 will be subjected to four serial echocardiograms in the 3 trimesters of pregnancy and in the postpartum state.~Height, weight, systolic and diastolic blood pressures will be measured at each echocardiographic evaluation."
61992763|NCT01453244||SVR group|A patients who achieved SVR (sustained virologic response)
62387964|NCT02768428|EXPERIMENTAL|Video-Audio Media|watching the entire video in 15 mins
62387965|NCT02768428|NO_INTERVENTION|Handbooks|study the hand book in 15 mins
62387966|NCT06404476|EXPERIMENTAL|Healthy Periodontium|Full-mouth clinical periodontal measurements recorded and saliva obtained.
62387967|NCT06404476|EXPERIMENTAL|Gingivitis|Full-mouth clinical periodontal measurements recorded and saliva obtained.
62387968|NCT06404476|EXPERIMENTAL|Periodontitis|Full-mouth clinical periodontal measurements recorded and saliva obtained.
62387969|NCT01070381|OTHER|nelfilcon A / ocufilcon D|Nelfilcon A contact lenses worn first, with ocufilcon D contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
62768072|NCT04433013|EXPERIMENTAL|Treatment group|
61992764|NCT01453244||non-SVR group|A patients who not achieved SVR (sustained virologic response)
61992765|NCT00546611|ACTIVE_COMPARATOR|1|Three day application of 0.05% PEP005 Topical Gel to one or two common warts located on the hand.
61992766|NCT01957748|NO_INTERVENTION|Standard of Care (SoC)|Subjects randomized to the Standard of Care Arm will receive their HIV clinic's current standard of care retention services.
61992767|NCT01957748|ACTIVE_COMPARATOR|SoC + ALERT Intervention|Subjects randomized into the ALERT Enhanced Retention Intervention Arm will receive SoC at the HIV clinic where subjects are seen. In addition to SoC, the Intervention arm will receive aggressive engagement efforts by the ALERT specialist to ensure visit continuity and retention into care. The ALERT specialist will also administer an education intervention consisting of 5 retention modules designed to improve HIV knowledge and self-efficacy, and will also monitor health care visits and intervene via methods to track, find, and re-engage patients during the study.
62387970|NCT01070381|OTHER|ocufilcon D / nelfilcon A|Ocufilcon D contact lenses worn first, with nelfilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
62387971|NCT00842829|EXPERIMENTAL|FBT 100 mcg|During the Titration Period, participants took fentanyl buccal tables (FBT) with a starting dose of 100 mcg until they reached an effective dose, with a maximum dose of 800 mcg and a maximum timeframe of 7 days. Participants who reached an effective dose entered the Open-label Treatment Period, whose length depended on how long was needed to treat up to 8 episodes of breakthrough pain (BTP) with FBT (maximum of 8 days). The length of the Continuation Period (when applicable) varied from country to country, up to until FBT was commercially available in that country.
62559894|NCT03569410|ACTIVE_COMPARATOR|Supplement Group|The protein supplement group was instructed by their dietician in how many protein supplements to consume in addition to their natural food intake in order to reach their goal protein intake.
62559895|NCT03569410|EXPERIMENTAL|Natural Food Group|The Natural food group was instructed by their dietician in how much additional protein rich foods to eat in order to reach their goal protein intake.
62559896|NCT01946828|EXPERIMENTAL|FIM|safety and efficacy of the FIM when exposed to a large and varied population of patients and users and operated according to its instructions for use
62559897|NCT03627975|NO_INTERVENTION|Conservative treatment|Conservative treatment. The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, the prevention and treatment of secondary epilepsy, the control of intracranial hypertension(including the application of mannitol and glycerol fructose, etc.), and the corresponding symptomatic and neurotrophic treatment. Non-specific treatment is mainly deal with intracranial hematoma, including intraventricular drainage, intracranial hematoma evacuation, and ventriculoperitoneal shunt.
62559898|NCT03627975|EXPERIMENTAL|Indirect vascular reconstruction surgery|Indirect vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) is performed. The surgery is performed according to the procedures described by Matsushima.
62768073|NCT04433013|PLACEBO_COMPARATOR|Control group|
62768074|NCT03166111|EXPERIMENTAL|lidocaine group|lidocaine in-situ gel inserted vaginally
62768075|NCT03166111|PLACEBO_COMPARATOR|placebo group|placebo gel inserted vaginally
62768076|NCT01797380|PLACEBO_COMPARATOR|Sugar Pill|Placebo
61992768|NCT04014257|EXPERIMENTAL|NOV1601(CHC2014)|a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A(TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
61992769|NCT01577667|NO_INTERVENTION|Conventional ventilation|Usual ventilation is administered according to the protocols implemented in the unit
62168272|NCT04836234|EXPERIMENTAL|intervention group|Participants will receive Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum. They will be instructed to chew the gum for pain relief after the separator and initial arch wire placement if required. Chew the gums for 10-12 minutes and as much as they want whenever they feel discomfort or pain. They are free to take any medication when necessary and respond to the questionnaires on the amount of chewing gum and analgesics used.
62387972|NCT00842829|ACTIVE_COMPARATOR|FBT 200 mcg|During the Titration Period, participants took fentanyl buccal tables (FBT) with a starting dose of 200 mcg until they reached an effective dose, with a maximum dose of 800 mcg and a maximum timeframe of 7 days. Participants who reached an effective dose entered the Open-label Treatment Period, whose length depended on how long was needed to treat up to 8 episodes of breakthrough pain (BTP) with FBT (maximum of 8 days). The length of the Continuation Period (when applicable) varied from country to country, up to until FBT was commercially available in that country.
62387973|NCT03589794|EXPERIMENTAL|Group 1|10 subjects receive 10 mcg rCSP + AP 10-602 \[GLA-LSQ\] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85.
62387974|NCT03589794|EXPERIMENTAL|Group 2|10 subjects receive 30 mcg rCSP + AP 10-602 \[GLA-LSQ\] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85.
62559899|NCT03627975|EXPERIMENTAL|direct vascular reconstruction surgery|Direct vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) bypass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And if necessary, the STA may not be preserved. The bone flap should be large enough to select the right recipient blood vessel.
62559900|NCT01417793|EXPERIMENTAL|Smoking Cessation Program|
62559901|NCT01910493|ACTIVE_COMPARATOR|ART no SMS reminders|control group
62559902|NCT01910493|ACTIVE_COMPARATOR|PMTCT no SMS reminders|control group
62559903|NCT01910493|EXPERIMENTAL|SMS reminders to PMTCT cohort|experimental group
62559904|NCT01910493|EXPERIMENTAL|SMS reminders to ART cohort|experimental group
62559905|NCT01750801|ACTIVE_COMPARATOR|Propolis|alcohol-free mouthwash containing 5% green propolis (MGP 5%) on the control of plaque and gingivitis.
62559906|NCT01750801|ACTIVE_COMPARATOR|chlorhexidine|chlorhexidine used on the control of plaque and gingivitis.
62559907|NCT00897650||Lung cancer|Patients with a diagnosis of invasive lung cancer.
62559908|NCT02286713|ACTIVE_COMPARATOR|Patient Decision Aid|Decision Aid study materials including video mailed to participant with 1-week, 3-month, and 6-month Follow-up Assessments
62559909|NCT02286713|ACTIVE_COMPARATOR|Standard Educational Information|Study materials including education booklet mailed to participant with 1-week, 3-month, and 6-month Follow-up Assessments
62559910|NCT04629040|EXPERIMENTAL|Intervention|
62559911|NCT04629040|PLACEBO_COMPARATOR|Control|
62559912|NCT01169350|EXPERIMENTAL|Diagnostic (18F FDG and 18F FMISO PET/CT)|Patients undergo 18F FDG and 18F FMISO PET/CT scans before starting neoadjuvant chemotherapy (without or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy.
62559913|NCT05577559|ACTIVE_COMPARATOR|Superficial cervical group|patients will receive bilateral ultrasound guided intermediate cervical plexus block using 15 ml of bupivacaine 0.25% for each side.
62768077|NCT01797380|ACTIVE_COMPARATOR|Active Drug|Escitalopram tablet, 10mg, daily, 9 weeks.
62768078|NCT01389323|EXPERIMENTAL|Arm 1: Daclatasvir + Peg-Interferon Alfa-2a + Ribavirin|
62768079|NCT04214639|EXPERIMENTAL|IDP-126 Gel|
62768080|NCT04214639|PLACEBO_COMPARATOR|IDP-126 Vehicle Gel|
62768081|NCT00635089|OTHER|Open-Label Reslizumab|Open-label reslizumab intravenous (IV) infusion at an initial dose of 1 mg/kg monthly
62387975|NCT03589794|EXPERIMENTAL|Group 3|10 subjects receive 30 mcg rCSP intramuscularly (IM) on days 1, 29 and 85.
62559914|NCT05577559|ACTIVE_COMPARATOR|Erector spinae group|patients will receive bilateral ultrasound guided cervical erector spinae plane block using 15 ml of bupivacaine 0.25% for each side at the level of C6.
62559915|NCT03646383|EXPERIMENTAL|Treatment with radiofrequency|Treatment of symptomatic benign nodules with radiofrequency ablation as an alternative to surgical treatment
62559916|NCT04720105|EXPERIMENTAL|Participants with plaque type psoriasis|Participants with plaque type psoriasis to be treated with Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion) to be applied thinly once a day on the affected areas of hands and/or feet.
62559917|NCT00402077|EXPERIMENTAL|1|
62559918|NCT00402077|EXPERIMENTAL|2|
62559919|NCT00402077|EXPERIMENTAL|3|
62559920|NCT00402077|PLACEBO_COMPARATOR|4|
62559921|NCT02545582||Therapy|Heart failure patients implanted with the VITARIA system
62559922|NCT00273182||Cohort|Patients implanted with InSync Model 8040, InSync III Model 8042 , or Medtronic CRT-D system. A total of 1999 subjects were enrolled in the study. Of them, 1738 had successful post market implants of InSync Model 8040 (601 subjects), InSync III Model 8042 (512 subjects) and CRT-D devices (625 subjects). The rest 262 subjects came from two pre-market studies: the MIRACLE study added 141 subjects to InSync Model 8040, and the InSync III study added 121 subjects to the InSync III Model 8042. A total of 1014 subjects completed the study through 36 month follow up. Follow-up of 1000 subjects was required by the FDA to satisfy the conditions of approval.
62559923|NCT04573322|EXPERIMENTAL|Lead-in 0.25 mg/kg|0.25 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
62387976|NCT03589794|EXPERIMENTAL|Group 4|9 subjects receive 60 mcg rCSP + AP 10-602 \[GLA-LSQ\] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1 and 85. Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
62387977|NCT03589794|EXPERIMENTAL|Group 4B|10 subjects receive 60 mcg rCSP + AP 10-602 \[GLA-LSQ\] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85. Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
62559924|NCT04573322|EXPERIMENTAL|Lead-in 0.50 mg/kg|0.50 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
62559925|NCT04573322|EXPERIMENTAL|Lead-in 1.0 mg/kg|1.0 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
62559926|NCT04573322|EXPERIMENTAL|Lead-in 1.5 mg/kg|1.5 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
62768082|NCT01013415|EXPERIMENTAL|ARM 1|Arm I (N=5) received antiretroviral therapy (ART) plus low dose IL-2 (1.2 million units/m2) subcutaneously daily for 56 days
62768083|NCT01013415|EXPERIMENTAL|ARM 2|Arm 2 (N=5) received ART plus a single infusion of approximately 5 to 11 billion CD4-zeta gene modified T cells.
62768084|NCT01013415|EXPERIMENTAL|ARM 3|Arm 3 (n=5) received ART plus IL-2 (1.2 million units/m2) and a single infusion of approximately 5 to 11 billion CD4-zeta gene modified T cells.
62768085|NCT02059954|ACTIVE_COMPARATOR|Vaginal hysterectomy|Vaginal hysterectomy
62768086|NCT02059954|ACTIVE_COMPARATOR|Total laparoscopic hysterectomy|Laparoscopic hysterectomy
62768087|NCT03625583||chronic myeloid leukaemia|chronic myeloid leukaemia diagnosed from 2007 - 2017
62768088|NCT05937594||Infants exposed to in utero opiates|Infants that meet IRB-approved inclusion/exclusion criteria.
62768089|NCT04367597|EXPERIMENTAL|Active NMES|
62768090|NCT04367597|SHAM_COMPARATOR|Modified NMES sham|
61992770|NCT01577667|EXPERIMENTAL|Intellivent|"Intellivent is a ventilatory mode included in ventilator S1, Hamilton Medical. Intervention: the patient is ventilated with the same ventilator than in the conventionnal group; but the ASV-Intellivent ventilation has to be activated via a dedicated key on the ventilator screen.~IntelliVent® activation requires selecting the kind of patient: ARDS, COPD and whether hemodynamic instability exists.~The initial settings are IntelliVent® by default settings (% MV: 110%, PEEP: 5 cm H2O, FiO2: 60% - 100% in case of ARDS).~Therefore modification of these various parameters is automatic. FiO2 and PEP are modified according to SpO2; %MV according to EtCO2."
62168273|NCT04836234|NO_INTERVENTION|Control group|Participants will not receive any prescription after the separators and initial arch wires placement. They will be specifically asked not to chew chewing gum. As in the intervention group, they can take any medication when they feel necessary and respond to the questionnaires on the amount of analgesics used.
62559927|NCT04573322|EXPERIMENTAL|Randomized Active TSC|TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days
62559928|NCT04573322|PLACEBO_COMPARATOR|Randomized Placebo|Normal Saline, in an equivalent volume by participant body weight, administered via IV bolus every 6 hours for up to 15 days
62559929|NCT06331325|EXPERIMENTAL|Frenotomy procedure|Two C-shaped partial thickness incisions are performed on the two sides of the frenum leaving the underlying periosteum intact. Relocation of the muscle attachment is performed by blunt dissection using a mucoperiosteal elevator. Undermining or separation of the epithelium from the underlying lip mucosa is then performed by blunt dissection to facilitate tension-free suturing. The epithelium is then sutured to the underlying periosteum using three interrupted periosteal sutures and is left to heal by secondary intention.
62387978|NCT03589794|EXPERIMENTAL|Group 5|10 subjects receive 10 mcg or 30 mcg rCSP + AP 10-602 \[GLA-LSQ\] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85 if immunogenicity analysis conducted 28 days post-2nd dose in Groups 1, 2, and 3 show promise (at least fourfold increase in geometric mean anti-CSP antibody or geometric mean anti-CSP titer of 20). Otherwise, subjects will receive 60 mcg rCSP + AP 10-602 \[GLA-LSQ\] (5 mcg GLA - 2 mcg LSQ). Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
62559930|NCT06331325|ACTIVE_COMPARATOR|Frenectomy procedure|Frenectomy group (Control): Two full-thickness incisions are performed apical and coronal to the frenum attachment and extending down to and including the periosteum. Complete excision of all muscle tissues is ensured and then both epithelial edges are approximated using single interrupted sutures achieving primary closure.
62559931|NCT03608163|NO_INTERVENTION|No intervention (Susceptibility to HAAF evaluation)|Susceptibility to HAAF evaluation: No intervention medication will be given during episodes of hypoglycemia.
62768091|NCT03561701|EXPERIMENTAL|Oteseconazole (VT-1161) 150mg capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
62768092|NCT03561701|PLACEBO_COMPARATOR|Placebo capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
62768093|NCT02668029|EXPERIMENTAL|oxygen|oxygen administered through a nasal cannula at a personalized, fixed flow
62768094|NCT02668029|PLACEBO_COMPARATOR|medical air|Medical air administered through a nasal cannula at the same flow
62768095|NCT05736003|EXPERIMENTAL|Prolonged laparoscpic cholecystectomy|Patients received laparoscopic cholecystectomy for acute cholecystitis after 27 hours of symptoms
62768096|NCT05736003|ACTIVE_COMPARATOR|Delayed laparoscpic cholecystectomy|Patients received laparoscopic cholecystectomy for acute cholecystitis after 6 weeks of symptoms
62768097|NCT04082780|EXPERIMENTAL|Rifamycin|Rifamycin-SV MMX 600 mg PO two times a day (1200 mg) for 30 days
62768098|NCT04082780|PLACEBO_COMPARATOR|Placebo|Placebo PO two times a day for 30 days
62168274|NCT05549479|EXPERIMENTAL|Intervention Group (AgeMatchPLUS).|
62168275|NCT05549479|ACTIVE_COMPARATOR|Control Condition (AgeMatch):|
62168276|NCT04265742|EXPERIMENTAL|Group A. Normal BMD, no fracture|Post-menopausal women with normal bone density (BMD t-score \>-1.5) and no history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
62387979|NCT03589794|OTHER|Group 6|6 subjects receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain.
62387980|NCT01935622|EXPERIMENTAL|Doxycycline 100 mg|Doxycycline 100 mg twice daily for 14 days
62387981|NCT01935622|EXPERIMENTAL|Doxycycline 20 mg|Doxycycline 20 mg twice daily for 14 days
62387982|NCT01935622|PLACEBO_COMPARATOR|Placebo|Placebo
62387983|NCT06419062||People with COPD|The study population for this research consists of individuals diagnosed with COPD (Chronic Obstructive Pulmonary Disease) who have a history of exacerbation-induced hospitalization within the one-year period preceding recruitment.
62387984|NCT01427855|EXPERIMENTAL|High Saturated Fat Red Meat Diet|
62387985|NCT01427855|EXPERIMENTAL|High Saturated Fat White Meat Diet|
62768099|NCT05716243|ACTIVE_COMPARATOR|Group A|Group A will receive a standard intraoperative analgesia protocol
62768100|NCT05716243|EXPERIMENTAL|Group B|Group B will receive a NOL-guided analgesia protocol
62559932|NCT03608163|EXPERIMENTAL|Naloxone|Naloxone evaluation: Intranasal naloxone (4 mg NARCAN Nasal Spray) via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Intranasal naloxone (4 mg NARCAN Nasal Spray) will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
62768101|NCT01806649|EXPERIMENTAL|BKM120|BKM120, starting at 100 mg oral once daily
62768102|NCT01468636|ACTIVE_COMPARATOR|Oral Zinc|
62768103|NCT01468636|PLACEBO_COMPARATOR|Placebo|
62768104|NCT01606787|EXPERIMENTAL|mannitol arm|This study is a prospective randomized double blind placebo controlled trial comparing renal function outcomes in patients undergoing partial nephrectomy for renal tumors. Patients will be randomized in 1:1 fashion to receive mannitol or saline provided intravenously within 30 minutes prior to renal vascular clamping for performing partial nephrectomy.
62768105|NCT01606787|PLACEBO_COMPARATOR|placebo arm|This study is a prospective randomized double blind placebo controlled trial comparing renal function outcomes in patients undergoing partial nephrectomy for renal tumors. Patients will be randomized in 1:1 fashion to receive mannitol or saline provided intravenously within 30 minutes prior to renal vascular clamping for performing partial nephrectomy.
62768106|NCT04176120|EXPERIMENTAL|TTAX01|TTAX01 plus standard care
62768107|NCT04176120|OTHER|Control|Standard Care alone
62768108|NCT05190055|EXPERIMENTAL|Minimally invasive spinal fusion surgery|A filler tube with an integrated threaded rod, which can be connected to a surgical drill, was used for rapid and continuous graft filling.
62768109|NCT05190055|ACTIVE_COMPARATOR|traditional spinal fusion surgery|Bone substitutes were filled in the disc space manually using a bone grafting funnel.
62768110|NCT01394887|ACTIVE_COMPARATOR|metformin group|this group received 850 mg metformin twice daily, along with recommended diet and exercise
62768111|NCT01394887|PLACEBO_COMPARATOR|placebo group|This group received 850 mg of placebo twice daily, along with a recommended regimen of diet and exercise
62768112|NCT04809974|PLACEBO_COMPARATOR|Placebo|Placebo: 40 participants will take placebo in the form of a capsule.
62768113|NCT04809974|EXPERIMENTAL|Niagen|Supplement: 60 participants will take Niagen 2000mg in the form of capsules daily.
62559933|NCT03608163|PLACEBO_COMPARATOR|Placebo (for Naloxone)|Naloxone evaluation: Placebo (for naloxone) nasal spray via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Placebo (for naloxone) nasal spray will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
62559934|NCT03608163|EXPERIMENTAL|Naloxone + diazoxide|Naloxone/Diazoxide evaluation: Up to 7 mg/kg oral diazoxide 3 hours before the first hypoglycemic episode. Intranasal naloxone (4 mg NARCAN Nasal Spray) via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Intranasal naloxone (4 mg NARCAN Nasal Spray) will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
62567694|NCT05688566|ACTIVE_COMPARATOR|eversion codition|Then the pedal angle is the angle between the lowest pedal position and the floor. The eversion condition is -10 ˚of pedal angle.Participants were asked to step with the consistent cadence at 60 steps/ min by the metronome.Three successful trials will be collected for each condition. Fifteen seconds of data will be collected for each trial.
62768114|NCT01743404|ACTIVE_COMPARATOR|Inflaminat|Inflaminat 500 mg tablet by mouth three times a day
62768115|NCT01743404|PLACEBO_COMPARATOR|Sugar pill|Placebo 500 mg tablet by mouth three times a day
62768116|NCT03211013|EXPERIMENTAL|Immediate Oxytocin|Participants randomly assigned to this arm will receive OT nasal spray (24 IU) at laboratory visit 1 and placebo nasal spray at visit 2. The order will be masked for participants and study staff.
62768117|NCT03211013|PLACEBO_COMPARATOR|Delayed Oxytocin|Participants randomly assigned to this arm will receive placebo nasal spray at laboratory visit 1 and OT nasal spray (24 IU) at visit 2. The order will be masked for participants and study staff.
62768118|NCT04474041|EXPERIMENTAL|Visual Acuity with a Hand-held Device Supported by Mobile App.|The Insight will be compared to a standard ETDRS eyechart
62768119|NCT01926769|EXPERIMENTAL|FOLFOX6+Metformin/FOFIRI+Metformin|
62768120|NCT02191839|ACTIVE_COMPARATOR|alpha 1 antitrypsin|patients receive 4 grams of IV alpha 1 antitrypsin preoperatively
62168277|NCT04265742|EXPERIMENTAL|Group B. Normal BMD, with fracture|Post-menopausal women with normal bone density (BMD T-score \>-1.5) with history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
62387986|NCT01427855|EXPERIMENTAL|High Saturated Fat Non-Meat Diet|
62768121|NCT02191839|PLACEBO_COMPARATOR|placebo|10 patients will randomely receive placebo
62768122|NCT03230292|EXPERIMENTAL|Cohort 1|Subjects in this cohort will receive dose 1 every four weeks (Q4W) subcutaneously (sc) during the 48-week open-label Treatment Period. There will be an option to increase the dose to dose 2 Q4W at the discretion of the Investigator if the subject's Psoriasis Area and Severity Index (PASI) response is \>=50% to \<75% reduction from the Baseline of PS0016 at Week 12 or later. If the subject's disease is adequately controlled on dose 2 Q4W, they may return to dose 1 Q4W at the discretion of the Investigator.
62768123|NCT02108691|EXPERIMENTAL|Glycin max(L.) Merr. pell extract|
62768124|NCT02108691|PLACEBO_COMPARATOR|Placebo|
62768125|NCT03364413||Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).
62768126|NCT04356794|EXPERIMENTAL|Medical electroacupuncture(EA)|EA were treated for 4 weeks, 3 times per week.
62768127|NCT04356794|SHAM_COMPARATOR|Sham electroacupuncture|"Sham acupuncture was performed without stimulation and manipulation to avoid eliciting De Qi sensations.It were treated for 4 weeks, 3 times per week."
62768128|NCT05932602||Aveir DR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention is required in this study.
62559935|NCT03608163|ACTIVE_COMPARATOR|Diazoxide + placebo (for naloxone)|Naloxone/Diazoxide evaluation: Up to 7 mg/kg oral diazoxide 3 hours before the first hypoglycemic episode. Placebo (for naloxone) nasal spray via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Placebo (for naloxone) nasal spray will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
62559936|NCT03608163|ACTIVE_COMPARATOR|Naloxone + placebo (for diazoxide)|Naloxone/Diazoxide evaluation: Oral placebo (for diazoxide) 3 hours before the first hypoglycemic episode. Intranasal naloxone (4 mg NARCAN Nasal Spray) via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Intranasal naloxone (4 mg NARCAN Nasal Spray) will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
62559937|NCT03608163|PLACEBO_COMPARATOR|Placebo (for naloxone) + placebo (for diazoxide)|Naloxone/Diazoxide evaluation: Oral placebo (for diazoxide) 3 hours before the first hypoglycemic episode. Placebo (for naloxone) nasal spray via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Placebo (for naloxone) nasal spray will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
62559938|NCT01368653|ACTIVE_COMPARATOR|Standard treatment|In this arm, smokers receive a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling sessions to help them quit smoking
62559939|NCT01368653|EXPERIMENTAL|Standard treatment+practice quitting|In this arm, participants receive standard treatment (a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling session) and an experimental treatment that involves practice quitting 7 times prior to a target quit date (for 4-12 hours per day) and returning to smoking by puffing smoke without inhaling.
62559940|NCT01368653|EXPERIMENTAL|Very low nicotine cigarettes|In this condition, smokers from both the Standard treatment and the Standard treatment+practice quitting arms who have smoked in the last 7-days at a 4-week post-target-smoking-cessation-date follow-up interview may be randomly assigned to this group. Those assigned to this group will receive a 6-week supply of cigarettes that contain tobacco with very low levels of nicotine (in regular or menthol flavors) to smoke instead of regular cigarettes containing nicotine. This treatment is designed to help people stop smoking after slipping (returning to smoking) during an attempt to stop smoking
62559941|NCT01368653|NO_INTERVENTION|Advice and encouragement only|In this condition, smokers from both the Standard treatment and the Standard treatment+practice quitting arms who have smoked in the last 7-days at a 4-week post-target-smoking-cessation-date follow-up interview may be randomly assigned to this condition. Those in this arm will receive advice and encouragement to try to stop smoking again after they have slipped (returned to smoking) during a stop smoking attempt.
62559942|NCT05552820|EXPERIMENTAL|Verum Electroacupuncture|Verum electroacupuncture treatment will be given 3 times a week, at least 1 day apart , for consecutive 4 weeks with a 24-week follow-up. Each session lasts for 30 min.
62559943|NCT05552820|SHAM_COMPARATOR|Sham Electroacupuncture|Sham electroacupuncture on non-acupoints plus non-penetrating plus no electrical stimulation will be given 3 times a week, at least 1 day apart , for consecutive 4 weeks with a 24-week follow-up. Each session lasts for 30 min.
62559944|NCT02475473|EXPERIMENTAL|Intervention|"The acute intervention will consist of 1 session of training following the program:~Resistance Training Exercises. Each participant in the intervention group will perform resistance-training exercises in the form of a circuit. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Initial intensity 6-7 of RPE and ending the set at 9-10. Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round."
62559945|NCT02475473|NO_INTERVENTION|Control|Control
62768129|NCT05932602||Dual Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a dual-chamber transvenous pacemaker as a comparator to the Aveir DR LP system study arm. No device intervention is required in this study.
62768130|NCT01808885|EXPERIMENTAL|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
62768131|NCT01808885|PLACEBO_COMPARATOR|placebo|placebo (3 soft capsules, od) will be administered orally for 6 months
62768132|NCT00895687|EXPERIMENTAL|Erlotinib + Bortezomib|Up to 4 dose levels of study drug combination tested with 3-6 participants enrolled at each dose level. Erlotinib beginning dose of 150 mg taken by mouth daily for 21-day cycle. Bortezomib beginning dose of 1. mg/m\^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
62768133|NCT05094817||Access to Computer|Participants completing the BHA should be at least somewhat comfortable or very comfortable with using a computer and mouse and should use a computer at least once a week.
62768134|NCT05094817||No Access to Computer|Since participants in previous studies on cognitive screening are usually more educated individuals with higher income, participants who do not have proficiency/or access to a computer will be asked to complete some questionnaires to determine any sociodemographic or baseline differences between patients who are able to complete BHA vs. those who are not able to complete BHA.
62168278|NCT04265742|EXPERIMENTAL|Group C. osteoporotic, no fracture|Post-menopausal women with low bone density (BMD T-score \<-2.5) and no history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
62168279|NCT04265742|EXPERIMENTAL|Group D. osteoporotic, with fracture|Post-menopausal women with low bone density (BMD T-score \<-2.5) with history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
62768135|NCT00721175|EXPERIMENTAL|SEMS|self-expandable metal stent group
62768136|NCT00721175|ACTIVE_COMPARATOR|PS|plastic stent group
62768137|NCT03189121||Healthy Volunteers|20 overweight and obese adult men
62768138|NCT05793034|OTHER|Biological biomarker assessment|FFPE tumor tissue will be processed with a number of molecular biology techniques
62768139|NCT03033563||Testicular tissue versus ejaculate|Evaluation of ICSI outcome.
62387987|NCT01427855|EXPERIMENTAL|Low Saturated Fat Red Meat Diet|
62559946|NCT05410665||Sepsis group|Adult septic patients admitted into the intensive care unit (ICU) of Nanjing First Hospital. The diagnostic criteria for sepsis were in accordance with the surviving sepsis guidelines.
62559947|NCT05410665||Control group|Baseline data (including age, sex, body-mass index, disease severity scores) matched adult non-septic critical patients in our ICU.
62559948|NCT02003404||Control Abdominal Skin|Apply SoftFlex (standard wear commercial skin barrier), FlexWear (standard wear commercial skin barrier), and FlexTend (extended wear commercial skin barrier), material to non-peristomal abdominal skin.
62768140|NCT05156268|EXPERIMENTAL|Pembrolizumab with Olaparib|Eligible patients will receive olaparib in combination with pembrolizumab. Olaparib will be administered orally at 300 mg every 12 hours. Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.
62768141|NCT03274804|EXPERIMENTAL|Single arm, prospective, open-label trial|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22) together with maraviroc administered perorally on day 1 to 21 of each cycle (d1-21; qd22).
62768142|NCT02076906|EXPERIMENTAL|MR-HIFU|Magnetic Resonance High Intensity Focused Ultrasound (MR-HIFU) ablative therapy for children with recurrent or relapsed solid tumors.
62768143|NCT00254683|EXPERIMENTAL|PET/CT|Single arm study evaluating the use of PET/CT to assess rectal cancer response to neoadjuvant therapy
62768144|NCT00454649|EXPERIMENTAL|Axitinib [AG-013736] + chemotherapy combination|"The following separate groups were included:~axitinib~1. plus carboplatin/paclitaxel in three different schedules~2. plus paclitaxel~3. plus docetaxel/carboplatin~4. plus docetaxel~5. plus capecitabine~6. plus gemcitabine/cisplatin~7. plus pemetrexed/cisplatin"
62768145|NCT05619640||Group 1|The study group divided into 3 groups according to COVID-19 WHO Clinical progression scale: Uninfected; No viral RNA detected
62768146|NCT05619640||Group 2|The study group divided into 3 groups according to COVID-19 WHO Clinical progression scale: Ambulatory mild disease Viral RNA detected but asymptomatic course, Symptomatic but not given any medication and Symptomatic given medication
62768147|NCT05619640||Group 3|The study group divided into 3 groups according to COVID-19 WHO Clinical progression scale: Hospitalized moderate disease Hospitalized but no oxygen therapy and Hospitalized and given oxygen by mask or nasal cannula
62768148|NCT05485142|EXPERIMENTAL|overactive bladder|Overactive bladder
62768149|NCT05485142|EXPERIMENTAL|Underactive bladder|Underactive bladder
62768150|NCT06384664|ACTIVE_COMPARATOR|Intercostal nerve block|Standard of care
62768151|NCT06384664|EXPERIMENTAL|Cryoablation|Cryoablation is a procedure that is used to freeze and burn away tissue cells via a device called a cryosphere which emits a freezing gas.
62768152|NCT03423524|EXPERIMENTAL|Arm: Investigational Device|"Implantation of monofocal intraocular lens (IOL) Micropure 1.2.3. consisting of hydrophobic material"
62768153|NCT04487561|OTHER|aspirative drainage|Drainage is the usual treatment after axillary lymphadenectoma for breast cancer
62768154|NCT04487561|ACTIVE_COMPARATOR|Hemopatch|The hemopatch group will be the group without drainage and with a product patch
62768155|NCT02049619|NO_INTERVENTION|Control|Following endotracheal intubation, no pharyngeal pack was inserted into the hypopharynx.
62387988|NCT01427855|EXPERIMENTAL|Low Saturated Fat White Meat Diet|
62768156|NCT02049619|EXPERIMENTAL|pharyngeal pack|Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
62768157|NCT01020903|ACTIVE_COMPARATOR|Aprepitant|
62768158|NCT01020903|PLACEBO_COMPARATOR|Placebo|
62768159|NCT01014455|EXPERIMENTAL|CO reminder|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
62768160|NCT01014455|PLACEBO_COMPARATOR|no CO reminder|a brief intervention that recommends fasting but does not mention that CO will be checked
62768161|NCT00905203|EXPERIMENTAL|1|moderate exercise training (three times/ week including one home-based training and two supervised training)
62768162|NCT00905203|EXPERIMENTAL|2|intensive exercise training (four times/ week including one home-based training and three supervised training)
62768163|NCT02142881|EXPERIMENTAL|Antihypertensive medication intensification|
62768164|NCT02142881|OTHER|Usual care|
62768165|NCT00693472|EXPERIMENTAL|Part 1: Preladenant|Preladenant 25 mg every 12 hours for 13 days
62768166|NCT00693472|PLACEBO_COMPARATOR|Part 1: Placebo|Placebo every 12 hours for 13 days
62768167|NCT00693472|EXPERIMENTAL|Part 2: Preladenant|Preladenant 25 mg every 12 hours for 13 days
62387989|NCT01427855|EXPERIMENTAL|Low Saturated Fat Non-Meat Diet|
62387990|NCT04193228||People with distal hereditary motor neuropathy|This is a single arm, feasibility study
62387991|NCT01759095|NO_INTERVENTION|Control|At hospital discharge, patients of the control group will receive usual care at their community pharmacy.
62387992|NCT01759095|EXPERIMENTAL|Electronic Multidrug Blister Pack|
62387993|NCT01728194|EXPERIMENTAL|Escitalopram|Target dose 20mg for 12 weeks
62387994|NCT01728194|OTHER|Control|Non-psychiatric comparison participants.
62387995|NCT05047601|EXPERIMENTAL|PF-07321332/ritonavir (5 days)|Participants will receive PF-07321332/ritonavir every 12 hours from Day 1 through Day 5 followed by Placebo every 12 hours from Day 6 through Day 10
62387996|NCT05047601|EXPERIMENTAL|PF-07321332/ritonavir (10-Day)|Participants will receive PF-07321332/ritonavir every 12 hours from Day 1 through Day 10.
62387997|NCT05047601|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo every 12 hours from Day 1 through Day 10.
62387998|NCT03576456|ACTIVE_COMPARATOR|Alprazolam|Patients receive alprazolam 0.5 mg 1 hour prior to coronary angiography.
62387999|NCT03576456|PLACEBO_COMPARATOR|Placebo Oral Tablet|Patients receive placebo 1 hour prior to coronary angiography.
62388000|NCT04824118||Group 1: Gestation less than 10 weeks|Blood tests and urine sample at baseline and 10-14 days after mifepristone administration
62388001|NCT04824118||Group 2: Gestation 10-14 weeks|Blood tests and urine sample at baseline and 10-14 days after mifepristone administration
61992771|NCT02018458|EXPERIMENTAL|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
62388002|NCT04824118||Group 3: Gestation 14-20 weeks|Blood tests and urine sample at baseline and 10-14 days after mifepristone administration
62388003|NCT04824118||Group 4: Non-pregnant controls|Blood tests at baseline only.
62388004|NCT01756482|EXPERIMENTAL|GS-5806|GS-5806, powder for oral solution
62388005|NCT01756482|PLACEBO_COMPARATOR|Sugar powder for oral solution in juice|Sugar powder for oral solution
62388006|NCT04669106||Healthy group|90 research subjects coming from mothers who had healthy children
62388007|NCT04669106||Stunting group|90 research subjects came from mothers who had stunted children or other nutritional disorders
62559949|NCT02003404||Peristomal Abdominal Skin|Apply SoftFlex, FlexWear and FlexTend barrier material to peristomal abdominal skin.
61992772|NCT02018458|EXPERIMENTAL|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
61992773|NCT04328974||the lumbar CSF drainage group|We named the patients treated with the protocol and the lumbar CSF drainage as the lumbar CSF drainage group.
62559950|NCT00908570|EXPERIMENTAL|1Topical estriol cream|
62768168|NCT00693472|ACTIVE_COMPARATOR|Part 2: Standard of Care|Anticholinergic agents or Propranolol as standard-of-care dosing regimen (supplied by the study site)
62768169|NCT03266172|EXPERIMENTAL|Subjects in Part A|Subjects in Part A will receive GSK2982772 MR (Period 1, 2, 4, 5 and 6) and GSK2982772 IR (Period 3)
62768170|NCT03266172|EXPERIMENTAL|Subjects in Part B|Subjects in Part B will receive GSK2982772 MR
62768171|NCT03266172|EXPERIMENTAL|Subjects in Part C|Subjects in Part C will receive GSK2982772 MR (Period 1, 3, 4, 5 and 6) and GSK2982772 IR (Period 2)
61992774|NCT06207539|OTHER|Group 1|"Intramuscular administration of 20 milligrams hyoscine N-butyl bromide under the generic name of buscopan ampoule produced by Sanofi company, plus misoprostol under the generic name of misotac tablets, each of wich is 200 micrograms produced by Sigma company, approximately 400 micrograms (2 tablets) given by a member of the study team according to FIGO guidelines for use of misoprostol 2019 and to have a halved dose to 200 micrograms if patient with history of one or two cesarean section.~Misoprostol only will be repeated every 4 hours for maximum 5 doses."
62388008|NCT03651011|ACTIVE_COMPARATOR|Aflibercept + Navigated laser|Patients will receive intravitreal aflibercept at M0, M1 and M2 (loading phase) and in addition receive navigated retinal laser photocoagulation at M3. Patients will receive aflibercept according to pro re nata regimen from M3-M12.
62388009|NCT03651011|ACTIVE_COMPARATOR|Aflibercept only|Patients will receive intravitreal aflibercept at M0, M1 and M2 (loading phase). Patients will receive aflibercept according to pro re nata regimen from M3-M12.
62388010|NCT03006952|ACTIVE_COMPARATOR|pentoxifylline & losartan|pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
62388011|NCT03006952|ACTIVE_COMPARATOR|Losartan|losartan arm took 100mg losartan daily for 12 weeks.
62388012|NCT02499380||Treatment|Patients treated with PneumRx Coil System
62388013|NCT03602521|EXPERIMENTAL|BPD|Blood sample After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of patients with a BPD
62388014|NCT03602521|ACTIVE_COMPARATOR|HC|Blood sample After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of healthy controls (HC) patients .without any history of psychopathology
62559951|NCT00908570|PLACEBO_COMPARATOR|2Placebo cream|
62559952|NCT05989464||Human Papilloma Virus (HPV) Self swab|Enrolled participants will be instructed to perform a self swab for genital Human Papilloma Virus (HPV) infection. Additionally, a short survey will be administered to collect demographic information, evaluate knowledge of HPV/cervical cancer, and assess acceptability of HPV self swab.
62559953|NCT03258411|ACTIVE_COMPARATOR|Haas group (H)|Rapid Expansion of palatal suture device: tooth-tissue supported expander (Haas (H)).
62559954|NCT03258411|ACTIVE_COMPARATOR|Hyrax (Hx)|Rapid Expansion of palatal suture device: tooth anchored expander (Hyrax (Hx)).
62559955|NCT03258411|ACTIVE_COMPARATOR|Miniscrew-supported (MHx)|Rapid Expansion of palatal suture device: bone anchored expander (Temporary anchorage devices(miniscrew)-supported (MHx))
62768172|NCT05440136|EXPERIMENTAL|LY3462817 - SC|LY3462817 administered subcutaneously (SC)
62559956|NCT01550237|EXPERIMENTAL|radiotherapy daily reduced|radiotherapy, with daily CT position verification and reduced safety margins
62559957|NCT01550237|ACTIVE_COMPARATOR|radiotherapy weekly standard|radiotherapy, with weekly orthogonal position verification and standard safety margins
62559958|NCT01558960|EXPERIMENTAL|IVit Treatment group|Intravitreal injections of Melphalan
62559959|NCT00955617|EXPERIMENTAL|Dotarem / Gadovist|Contrast-enhanced MRA - Imaging examination contrast enhanced-MRA first with Dotarem in period 1 then with Gadovist in period 2
62559960|NCT00955617|EXPERIMENTAL|Gadovist / Dotarem|Contrast-enhanced MRA - Imaging examination contrast enhanced-MRA first with Gadovist in period 1 then with Dotarem in period 2
62559961|NCT02526667|EXPERIMENTAL|Chlorhexidine Gluconate Cloth|2% CHG, single application
62768173|NCT05440136|EXPERIMENTAL|LY3462817 - IV|LY3462817 administered intravenously (IV)
62768174|NCT05440136|PLACEBO_COMPARATOR|Placebo - SC|Placebo administered SC
62768175|NCT05440136|PLACEBO_COMPARATOR|Placebo - IV|Placebo administered IV
62768176|NCT03082014|ACTIVE_COMPARATOR|Arm A|Amlodipine for 4 weeks, Losartan for 4 weeks, Atenolol for 4 weeks.
62768177|NCT03082014|ACTIVE_COMPARATOR|Arm B|Atenolol for 4 weeks, Amlodipine for 4 weeks, Losartan for 4 weeks.
62768178|NCT03082014|ACTIVE_COMPARATOR|Arm C|Losartan for 4 weeks, Atenolol for 4 weeks, Amlodipine for 4 weeks.
62768179|NCT03374202|EXPERIMENTAL|Group 1: AAV8-VRC07 (5 x 10^10 vg/kg IM)|AAV8-VRC07 (5 x 10\^10 vg/kg) administered by intramuscular (IM) injection (Day 0)
62768180|NCT03374202|EXPERIMENTAL|Group 2: AAV8-VRC07 (5 x 10^11 vg/kg IM)|AAV8-VRC07 (5 x 10\^11 vg/kg) administered by IM injection (Day 0)
62768181|NCT03374202|EXPERIMENTAL|Group 3: AAV8-VRC07 (2.5 x 10^12 vg/kg IM)|AAV8-VRC07 (2.5 x 10\^12 vg/kg) administered by IM injection (Day 0)
62768182|NCT01181024|EXPERIMENTAL|A: HV ascending dose|
62768183|NCT01181024|EXPERIMENTAL|B: HV food effect|
62768184|NCT01181024|EXPERIMENTAL|C: Hepatitis C|
62768185|NCT06470750||Observational group 1|Participants take part in a focus group or complete questionnaires and may take part in an interview on study.
62768186|NCT06470750||Observational group 2|Participants complete questionnaires throughout the study.
62768187|NCT01256021|EXPERIMENTAL|Treatment Group 1|Meditoxin
62768188|NCT04821323|EXPERIMENTAL|Indomethacin Challenge|Participants will receive challenge agent as two single oral doses of Indomethacin, one on Day -1 and one on Day 1. In addition, participants will receive lactulose-mannitol solution on Day -4 (baseline) and on Day 1 (post Indomethacin challenge).
62768189|NCT06301139|EXPERIMENTAL|Goat milk-based formula|goat milk-based infant formula (GMF)
62768190|NCT06301139|PLACEBO_COMPARATOR|Cow's milk-based formula|cow's milk-based infant formula supplemented with probiotics (CMFp)
62768191|NCT02564328|ACTIVE_COMPARATOR|Intravenous stem cell transplantation|Intravenous transplantation of autologous bone marrow mesenchymal stem cell plus conventional treatment include rehabilitation
62768192|NCT02564328|NO_INTERVENTION|Conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
62768193|NCT00840060|EXPERIMENTAL|AMALS|Addressing multiple aspects of language simultaneously
62768194|NCT00840060|EXPERIMENTAL|DTA|Discrete Trial Approach
62768195|NCT05558215|EXPERIMENTAL|Remote Otago Exercise Program|Individuals with dementia will participate in Otago Exercise Program in their home using video recordings and with safety oversight by their trained care partners.
62768196|NCT01600053|EXPERIMENTAL|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles
62768197|NCT04454645|EXPERIMENTAL|Modified ABC|12-session home visiting intervention designed to increase parental sensitivity and nurturance and decrease parental frightening behavior.
62768198|NCT04454645|ACTIVE_COMPARATOR|Modified DEF|12-session home visiting intervention designed to increase parental playful interactions that stimulate infant cognitive and motor development
62768199|NCT01576185||Observational (xenograft models)|Human acute myeloid leukemia cells are injected into NSG mice. Mice are then treated with sorafenib or quizartinib via gavage once daily for 28 days. Peripheral blood and tissue samples are collected biweekly or weekly and analyzed for the presence of human CD45+ and CD33+ cells by quantitative flow cytometry.
62768200|NCT01287195|EXPERIMENTAL|Oral OKT3|Participants with ulcerative colitis will receive Oral OKT3 given with Omeprazole once daily for 30 days.
62768201|NCT02220751|PLACEBO_COMPARATOR|chronic periodontitis|Non-surgical periodontal therapy.
62768202|NCT02220751|ACTIVE_COMPARATOR|Chronic periodontitis + type 2 diabetes|Non-surgical periodontal therapy + systemic doxycycline non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before first scaling and root planning session.
62768203|NCT02220751|NO_INTERVENTION|Control|Periodontal- and systemically healthy patients were included as control group.
62768204|NCT02751528|EXPERIMENTAL|ETBX-021|Ad5 \[E1-, E2b-\]-HER2/neu Vaccine, Suspension for Injection
62768205|NCT06053736|EXPERIMENTAL|REVIVE™ Toric Soft Contact Lenses|
62768206|NCT01709201|NO_INTERVENTION|Treatment as Usual|Those in the Treatment as Usual group will not receive the brief intervention for substance use but will receive a brief health education brochure.
62768207|NCT01709201|EXPERIMENTAL|Brief Intervention|Those in the Brief Intervention group will receive a brief motivational intervention aimed at encouraging the participant to decrease their substance use.
62559962|NCT02526667|PLACEBO_COMPARATOR|Vehicle Cloth|Excipients on cloth
62768208|NCT02776592|EXPERIMENTAL|Experimental|A cow's milk-based formula with added nutrients
62768209|NCT02776592|ACTIVE_COMPARATOR|Control|A cow's milk-based formula
62768210|NCT02420548|ACTIVE_COMPARATOR|Services as Usual|Participants continue with any services they may be receiving outside of the study.
62768211|NCT02420548|EXPERIMENTAL|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
62768212|NCT00667654|EXPERIMENTAL|100-200 µg CNTX-4975|single dose
62768213|NCT00667654|EXPERIMENTAL|300-425 µg CNTX-4975|Total dose delivered as two separate lower doses
62559963|NCT02526667|ACTIVE_COMPARATOR|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
62559964|NCT02163044||Statin|Patients on statin treatment
62559965|NCT06582654||Pre-adolescent group|Defined as girls between 9 and 14 years old, who are vaccinated against HPV with either the Cervarix, Gardasil or Gardasil9 vaccine and are not yet menstruating (pre-menarche).
62559966|NCT06582654||Ovulatory group|Defined as women between 18 and 30 years old, who are vaccinated against HPV with either the Cervarix, Gardasil or Gardasil9 vaccine and are not using any hormone- or ovulation-influencing contraceptives that impact hormonal levels during the menstrual cycle.
62388015|NCT05992051|EXPERIMENTAL|online exercise therapy|"The participants had weekly online exercise meetings with the physiotherapist in a group of 3-5 participants using online meeting app. Then the participants performed the remaining two sessions of exercises themselves weekly. All the participants of the experimental group received a package of exercise pamphlet and a video disc containing 17-minute exercise demonstrations by the physiotherapist.~At baseline, the suitable elastic bands (Thera-band®) for performing the exercises were selected by testing the 15 repetitions maximum (15RM) of the Modified Brügger's Exercise (MBE) and the Modified Proprioceptive Neuromuscular Facilitation Diagonal Flexion Exercise (MPNFDFE) for the participants of both the experimental group and control group.~Participants performed the following exercises three times a week for six weeks at home:~A. Warm-up exercises B. Cranio-cervical flexion exercises C. Strength-endurance exercises D. Scapular stabilization exercises E. Stretching exercises"
62768214|NCT00667654|EXPERIMENTAL|600-700 µg CNTX-4975|Total dose delivered as two separate lower doses
62768215|NCT00667654|EXPERIMENTAL|800 µg CNTX-4975|Total dose delivered as two separate lower doses
62768216|NCT00667654|EXPERIMENTAL|900-1000 µg CNTX-4975|Total dose delivered as two separate lower doses
62768217|NCT02323152|EXPERIMENTAL|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
62768218|NCT02323152|ACTIVE_COMPARATOR|Control group|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment.
62768219|NCT02533726|EXPERIMENTAL|Treatment - Optimal Turning|All patients will have a sensor applied. Patients within this arm will receive care from nurses who have access to a User Dashboard that provides visual advisories for patient turning, based on data obtained from a wearable patient sensor (Leaf Healthcare, Inc.).
62768220|NCT02533726|ACTIVE_COMPARATOR|Control - Standard Care|All patients will have a sensor applied. Patients within this arm will receive care from nurses who DO NOT have access to a User Dashboard that provides visual advisories for patient turning. Instead, these patients will receive standard care practices, patient turning initiated by nurses as necessary.
62768221|NCT04464824||patient over 75 years of age with an emergency room visit|Patients over 75 years of age, with a visit to the emergency department between April 1, 2019 and September 30, 2019, with a non-hospitalization at the end of their visit to the emergency department.
62768222|NCT00330668|EXPERIMENTAL|All rhIGF-1 Subjects|"All subjects entering MS306 began recombinant human insulin-like growth factor-1 (rhIGF-1) twice a day (BID) treatment. Each subject treated in MS301 had an MS306 starting dose that was based on their dose at the completion of MS301 (i.e. subcutaneous injections of rhIGF-1 at 40, 80, or 120 micrograms \[μg\]/ kilogram \[kg\] BID).~MS301 untreated control subjects were randomised in MS306 in a 1:1 ratio to a dose of either 80 or 120 μg/kg rhIGF-1 BID.~Following Protocol Amendment 1, all subjects received either 80 or 120 μg/kg rhIGF-1 BID until the implementation of Protocol Amendment 2.~Following Protocol Amendment 2, all subjects were first switched to receive subcutaneous injections of 160 μg/kg rhIGF-1 once a day (QD), followed by individual dose-escalation first to 200 μg/kg rhIGF-1 QD and subsequently to a targeted maximum dose of 240 μg/kg rhIGF-1 QD. Subjects were treated QD until the early termination of the study."
62768223|NCT01888419|NO_INTERVENTION|No active treatment|Clinical follow-up, no active intervention.
62768224|NCT01888419|EXPERIMENTAL|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site.
62768225|NCT00800410|NO_INTERVENTION|Information on community resources|Participants received information about free and publicly available community resources on healthy lifestyle activities
62768226|NCT00800410|EXPERIMENTAL|Community Health Worker services|
62768227|NCT02876874||the patients group|0.1ml, 5mg/ml indocyanine green(ICG) will be injected subcutaneously to aid visualization in NIR
62768228|NCT02876874||the health group|0.1ml, 5mg/ml indocyanine green(ICG) will be injected subcutaneously to aid visualization in NIR
62388016|NCT05992051|ACTIVE_COMPARATOR|conventional exercise therapy|"Participants in the control group completed the same exercise program three times a week for six weeks with face-to-face mode delivery by physiotherapists.~At baseline, the suitable elastic bands (Thera-band®) for performing the exercises were selected by testing the 15 repetitions maximum (15RM) of the Modified Brügger's Exercise (MBE) and the Modified Proprioceptive Neuromuscular Facilitation Diagonal Flexion Exercise (MPNFDFE) for the participants of both the experimental group and control group.~Participants performed the following exercises three times a week for six weeks in a group of 3-5 participants in the laboratory of the Sport Medicine and Rehabilitation School of the Beijing Sport University:~A. Warm-up exercises B. Cranio-cervical flexion exercises C. Strength-endurance exercises D. Scapular stabilization exercises E. Stretching exercises"
62388017|NCT02017769||CIDP - treated|Patients diagnosed with CIDP and fulfilling the criteria by EFNS and PNS and in maintenance treatment with subcutaneous immunoglobulin
62768229|NCT04966923||Breast Cancer and documented pathogenic variant TP53|Documented pathogenic or likely pathogenic variants of TP53 were identified using blood DNA colection and localized breast cancer diagnosis by histological confirmation. All patients met Revised Chompret criteria or Li Fraumeni like syndrome or family member of carrier TP53
61992775|NCT06207539|OTHER|Group 2|"Administration of misoprostol under generic name of misotac tablets each one is 200 micrograms produced by Sigma company, about 400 micrograms (2 tablets) given by a member of the study team according to FIGO guidelines use of misoprostol 2019 and to have a halved dose if patient with history of one or two cesarean sections.~Misoprostol only will be repeated every 4 hours for maximum 5 doses."
62388018|NCT02017769||Healthy controls|Healthy, gender and age matched controls
62388019|NCT02017769||CIDP - untreated|Patients newly diagnosed with CIDP and untreated are treated with immunoglobulin and re-examined after 4 months of treatment
62388020|NCT04576962||Children aged 14 years or younger|All children in Indiana aged 14 years and younger who received the first dose of HPV vaccine during the 2017 and 2018 calendar years. This is a non-interventional study, with data to be analyzed at the county level only.
62388021|NCT05459428||Confocal laser endomicroscopy scoring of the extent of intestinal metaplasia|Get pictures and Videos from gastric antrum body and angle by confocal laser endomicroscopy in order to calculate the CGGIM score.
62768230|NCT04966923||Breast Cancer and no documented pathogenic variants in genetic test|Control group with localized breast cancer and no pathogenic variants documented in a genetic test
62388022|NCT05459428||Artificial intelligence scoring of the extent of intestinal metaplasia|Get pictures and Videos from gastric antrum body and angle by Artificial intelligence in order to calculate the CGGIM score.
62388023|NCT02274987|EXPERIMENTAL|Treatment|The treatment plan for each patient is individualized and different depending on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
62388024|NCT04737551||No adjuvant treatment|Pancreatic cancer patients who received surgery without subsequent adjuvant treatment.
62388025|NCT04737551||Adjuvant chemotherapy|Pancreatic cancer patients who received surgery and only adjuvant chemotherapy.
62388026|NCT04737551||Adjuvant chemoradiotherapy|Pancreatic cancer patients who received surgery and only adjuvant chemoradiotherapy.
62768231|NCT02699372|PLACEBO_COMPARATOR|Placebo|Healthy volunteers will receive the placebo equivalent to RO6889450 as oral capsules.
62388027|NCT04737551||Adjuvant chemoradiotherapy + adjuvant chemotherapy|Pancreatic cancer patients who received surgery and both adjuvant chemoradiotherapy and chemotherapy.
62388028|NCT06309368|ACTIVE_COMPARATOR|Primary Closure with 0.1% Betaine/0.1% Polyhexanide Wound Irrigation|The ostomy wound will be irrigated with 0.1% Betaine/0.1% Polyhexanide wound irrigation, then closed completely with sutures.
62388029|NCT06309368|ACTIVE_COMPARATOR|Secondary Closure with Pursestring|The ostomy wound will be partially closed using the Pursestring method.
62388030|NCT00169273|ACTIVE_COMPARATOR|Weight loss only intervention|Structured group weight loss intervention
62768232|NCT02699372|EXPERIMENTAL|RO6889450: Part 1 Single Ascending Dose (SAD)|Participants will undergo a series of screening visits prior to treatment and 4 weeks follow-up. Healthy volunteers will be enrolled in up to 7 dose groups (5 milligram \[mg\] to 450 mg) and will receive single oral dose of RO6889450 in the morning of the Day 1.
62768233|NCT02699372|EXPERIMENTAL|RO6889450: Part 2 Multiple Ascending Dose (MAD)|The starting dose for Part 2 MAD will be determined by analysis of safety and pharmacokinetic data of Part 1 SAD. All participants will receive RO6889450 orally for 14 days.
62768234|NCT05856097|EXPERIMENTAL|kinesio taping with diaphragmatic breathing|kinesio taping application with diaphragmatic breathing
62768235|NCT05856097|ACTIVE_COMPARATOR|kinesio taping without diaphragmatic breathing|kinesio taping application without diaphragmatic breathing
61992776|NCT00719004|EXPERIMENTAL|Normals|Normal volunteers having Ultrasound scan of foot.
61992777|NCT00181207|EXPERIMENTAL|Active|Pneumatic Compression Device used twice daily for 20 minutes each time for 12 weeks
62388031|NCT00169273|EXPERIMENTAL|Combined intervention|Structured group program for weight loss and depression
62388032|NCT03459976||2 groups|control group case group
62388033|NCT03550508|EXPERIMENTAL|Anti-RANKL Monoclonal Antibody|Anti-RANKL Monoclonal Antibody is to be injected subcutaneously 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg or 3.0 mg/kg.
62388034|NCT05238324|EXPERIMENTAL|HMI-203 Low Dose Level Cohort 1|
62768236|NCT04311398||Respiratory infection group|Patients went to fever clinic with respiratory infectious symptoms in Huashan Hospital affiliated to Fudan University
62768237|NCT02371200||Brain Sentinel Seizure Detection and Warning System|This study will compare accuracy of seizure detection by the study device to simultaneously collected data of seizure detection by video EEG.
62768238|NCT05707481|NO_INTERVENTION|Control group (Usual Standard Care)|"Control group patient will undergo routine care by their physician and nurses. However, the investigator will only provide basic counseling regarding drug prescribed during discharge to the patients. In another term Usual care will be provided to the patients"
62768239|NCT05707481|OTHER|Intervention Group (Clinical Pharmacist-led educational Intervention)|In addition to routine care by physician and nurses, Patients in interventional group will receive two consecutive face to face interview and counseling of 20-40 minutes during the baseline period and the first follow-up period at 3-month by clinical pharmacist. Teaching and counseling session involves information on various non-pharmacological and pharmacological disease management strategies.
62768240|NCT02584361|ACTIVE_COMPARATOR|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
62768241|NCT02584361|ACTIVE_COMPARATOR|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA)
62768242|NCT01499394||Normal|"Donor samples reflective of a normal non-disease state"
62768243|NCT01499394||Disease state or condition|Donor samples reflective of a known disease state or condition
62388035|NCT05238324|EXPERIMENTAL|HMI-203 Intermediate Dose Level Cohort 2|
62388036|NCT05238324|EXPERIMENTAL|HMI-203 High Dose Level Cohort 3|
62388037|NCT04306003|EXPERIMENTAL|Enhanced Recovery After Surgery (ERAS) pathway|"Preop~1. Diet: Solids until midnight before surgery with a carbohydrate rich drink before midnight and 3-hours prior to surgery.~2. Analgesia: Acetaminophen 975mg \& Celecoxib 400mg administered PO 1-hour before surgery.~Intraop~1. Hypothermia prevention: Forced-air warming units and core temperature monitoring.~2. Fluid management: Euvolemic fluid management with balanced crystalloid solution.~3. Analgesia: 0.25% bupivacaine block of intercostal nerves and rectus sheath by the surgical team. Additional IV analgesia by anesthesiologist with the goal to minimize opioids.~4. PONV prophylaxis: Ondansetron 4-8mg IV during emergence.~Postop~1. Diet: Clear fluids immediately post-op. Saline lock and advance to DAT on POD#1.~2. Analgesia: Routine administration of Acetaminophen 975mg PO q6h \& Celecoxib 200mg PO q12h. Opioids used as breakthrough analgesia only. No PCA.~3. Early mobilization: Mobilization within the first 24 hours after surgery with assistance."
62388038|NCT04306003|ACTIVE_COMPARATOR|Standard Perioperative Care|Patients in the control arm received routine perioperative care as determined by respective surgeons participating in the study.
62388039|NCT02957500|EXPERIMENTAL|Mediclore®|adhesion barrier Mediclore 5cc, to apply medical device fully around intrauterine surgery area
62388040|NCT02957500|NO_INTERVENTION|No treatment|standard treatment for surgery
62768244|NCT03323736|OTHER|Pivotal Cohort|Active Tymbion iontophoresis and tube insertion using the Tube Delivery System in-office.
62768245|NCT03323736|OTHER|Office Lead-In Cohort|Active Tymbion iontophoresis and tube insertion using the Tube Delivery System in-office. Physician initial in-office iontophoresis and tube insertion procedures (minimum of 2 subjects per investigator).
62768246|NCT03323736|OTHER|OR Lead-In Cohort|Tubes insertion using the Tube Delivery System in the operating room (OR). Physician initial tube insertion procedures in the OR (minimum of 2 subjects per investigator).
62388041|NCT03812198|ACTIVE_COMPARATOR|Group 1-1|Part 1: Subjects will receive 3 doses of LEO 32731 in different formulations, as follows (1 dose per formulation/treatment period): LEO 32731 modified release tablet; LEO 32731 blend, hard capsule; LEO 32731 API hard capsule (reference formulation).
62388042|NCT03812198|ACTIVE_COMPARATOR|Group 1-2|Part 1: Subjects will receive 3 doses of LEO 32731 in different formulations, as follows (1 dose per formulation/treatment period): LEO 32731 soft capsule; LEO 32731 gastro-resistant capsule; LEO 32731 API hard capsule (reference formulation).
62388043|NCT03812198|EXPERIMENTAL|Group 2-1|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.~The formulation depends on the outcome of Part 1."
62388044|NCT03812198|EXPERIMENTAL|Group 2-2|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.~The formulation depends on the outcome of Part 1."
62388045|NCT03812198|EXPERIMENTAL|Group 2-3|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.~The formulation depends on the outcome of Part 1."
62388046|NCT03812198|PLACEBO_COMPARATOR|Group 3-1|Subjects will be dosed twice daily from Days 1-17 (morning dose only on Day 17) with LEO 32731 or placebo. The formulation depends on the outcome of Part 2.
62768247|NCT02461316||Combination Treatment in Chronic Lymphocytic Leukemia (CLL)|All participants receiving combination treatment in Chronic Lymphocytic Leukemia (CLL)
62768248|NCT05480449|EXPERIMENTAL|Dose Escalation Arm|"The phase 1 dose escalation portion of the trial will use a standard 3+3 design to establish the recommended phase 2 dose of huCART19 cells in patients with subjects with prior treatment with CD19-directed CAR T cells. Two dose escalations of huCART19 are planned for the dose escalation phase."
62388047|NCT03812198|PLACEBO_COMPARATOR|Group 3-2|Subjects will be dosed twice daily from Days 1-17 (morning dose only on Day 17) with LEO 32731 or placebo. The formulation depends on the outcome of Part 2.
62388048|NCT04044625|EXPERIMENTAL|High-intensity NPPV|The patients will receive high-intensity noninvasive positive pressure ventilation.
62768249|NCT05480449|EXPERIMENTAL|Dose Expansion Arms|"If at least one dose level of the dose escalation phase is determined to be safe, the phase 2b dose expansion phase of the trial will be opened to enrollment. Subjects will receive the highest dose of huCART19 cells that were determined to be safe in the dose escalation part of the trial. 2 cohorts are planned:~* Cohort A (relapsed/refractory, CAR T cell naïve)~* Cohort B (prior treatment with CD19-directed CAR T cells)"
61992778|NCT00181207|PLACEBO_COMPARATOR|Sham|Device looked and sounded like a pneumatic compression device, but was not inflating nor deflating.
61992779|NCT01755923|EXPERIMENTAL|Gefitinib|Gefitinib (Iressa) 250mg once per day until progression disease or intolerant side effects
62768250|NCT01700465||Hemodialysis|Patients undergoing hemodialysis
62768251|NCT01827332|ACTIVE_COMPARATOR|Oxytocin|intranasal administration
62768252|NCT01827332|PLACEBO_COMPARATOR|Saline|intranasal administration
62768253|NCT00007644|OTHER|Radical Prostatectomy|Surgical removal of the prostate
62768254|NCT00007644|NO_INTERVENTION|Watchful Waiting|Closely watching, waiting and treating symptoms if and when cancer progresses
62768255|NCT02201836|ACTIVE_COMPARATOR|One time music therapy session|One time music therapy session which consists of music meditation, including as assessment/evaluation of confined body breathing function as expressed through drawing and coloring post music imagery session. This is followed by an entrainment wind playing/breath expansion music therapy intervention. At the end of the session, the subjects are given a donated wind instrument for play at home.
62768256|NCT02201836|ACTIVE_COMPARATOR|Weekly group music therapy intervention|The weekly group music therapy intervention consists of children and teens using guided visualization and expressing their fears and or fantasies related to breathing with one another. This is followed by creative music improvisations with part-playing on flutes, slide whistles, recorders and melodicas.
62768257|NCT02201836|NO_INTERVENTION|Control|
62768258|NCT00127335|PLACEBO_COMPARATOR|1|
62768259|NCT00127335|ACTIVE_COMPARATOR|2|statin administration
62388049|NCT04044625|ACTIVE_COMPARATOR|Low-intensity NPPV|The patients will receive low-intensity noninvasive positive pressure ventilation.
62768260|NCT05551624|EXPERIMENTAL|Atorvastatin + N-acetylcysteine|Patients included in the study received an oral treatment of Atorvastatin 40 mg daily and N-acetylcysteine 400 mg every 8 hours, for at least 1 month (up to 12 months)
62768261|NCT05614284|EXPERIMENTAL|Virtuous|Virtuous +/- Local Bone
62768262|NCT05614284|ACTIVE_COMPARATOR|Autograft|Autograft +/- Allograft Chips
62768263|NCT04293367|EXPERIMENTAL|Exercise|14 African American Women with obesity will be randomly assigned to the 14-week high intensity interval training program
62768264|NCT04293367|NO_INTERVENTION|Control|14 African American Women with obesity will be randomly assigned to serve as a reference group, i.e. follow the same protocol as the experimental group, however, they will not undergo exercise training
62768265|NCT02358915|EXPERIMENTAL|Peri-auricular muscles voluntary contraction training paradigm|The whole training paradigm consists of two steps. At the first step of training, the electrical stimulation (FastStart neuromuscular electrical stimulator) will be applied to facilitate the voluntary contractions of the ear muscles, and the motion of the outer ear in two directions (up/down, forward/backward) will be videotaped and played back to the participants so that they can get real-time visual feedback about their ear movement. At the second step of training, surface EMG electrodes will be placed on the skin around participants' ears. During the training, they are required to move a cursor to a specific target that will randomly appear on the computer screen. The cursor will be controlled by the electrical signal from the contraction of their bilateral peri-auricular muscles. In the computer game, contraction of the left ear muscles will move the cursor to the left side and contraction of your right ear muscles will move the cursor to the right side.
61992780|NCT01755923|ACTIVE_COMPARATOR|Docetaxel|Docetaxel 75mg/m2,d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
61992781|NCT02750891|EXPERIMENTAL|DSP-7888|
62388050|NCT02452034|EXPERIMENTAL|3.5 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 3.5 mg/kg by intravenous (IV) solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by powder for oral suspension (PFS) for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
61992782|NCT06083350|EXPERIMENTAL|Yeast beta-glucan|Yeast beta-glucan capsules, 250mg，taken with meals, two capsules twice a day
62768266|NCT02338375|EXPERIMENTAL|Cartistem|For control group patients currently standard treatment of arthroscopic curettage and microfracture is performed, and for study group patients allogenic umbilical cord blood-derived mesenchymal stem cell product(Cartistem®) is added on the lesion after above mentioned procedure.
61992783|NCT06083350|PLACEBO_COMPARATOR|Starch|Starch capsule, 250mg, taken with meals, two capsules twice a day
61992784|NCT01531387|NO_INTERVENTION|Standard Therapy: Observation|Half of the subjects will be randomized to clinical observation only, which includes monthly visits with clinical evaluations, laboratory tests, and TCD endpoint examinations
61992785|NCT01531387|EXPERIMENTAL|Hydroxyurea|Half of the subjects will be randomized to hydroxyurea, taken as capsules (300 mg, 400 mg, or 500 mg), or as a liquid formulation (100 mg/mL). Hydroxyurea will be administered once daily by mouth. Subjects will be monitored monthly with clinical evaluations, laboratory tests, and TCD endpoint examinations.
61992786|NCT02978742|EXPERIMENTAL|Coached Recovery Record App|Participants will complete the 8-week adaptive Recovery Record app program and will be linked with a healthcare professional who will provide standardized coaching, in the way of feedback and support to participants for the duration of the program.
62768267|NCT02338375|ACTIVE_COMPARATOR|standard treatment|standard treatment of arthroscopic curettage and microfracture for osteochondral lesion of talus
62768268|NCT03551756||Heart Failure & Coronary Artery Disease|Biomarker assessment in adults with decompensated heart failure and significant underlying coronary artery disease
62768269|NCT03551756||Healthy Adult|Biomarker assessment in 20 healthy age-matched subjects
62768270|NCT04588090|EXPERIMENTAL|Experimental group|The concurrent 3 weeks treatment group（external radiation plus intraluminal after-loading irradiation+concurrent platinum-containing 3 weeks chemotherapy）
62768271|NCT04588090|PLACEBO_COMPARATOR|Standard chemoradiation group|Standard chemoradiation（external radiation plus intraluminal after-loading irradiation+concurrent platinum-containing weekly chemotherapy）
62559967|NCT06582654||Ovulation-influencing contraceptive group|Defined as women between 18 and 30 years old, who are vaccinated against HPV with either the Cervarix, Gardasil or Gardasil9 vaccine and are using ovulation-influencing contraceptives that impact hormonal levels during the menstrual cycle (including oral contraceptives, hormonal ring, contraceptive injection, contraceptive patch, hormonal implant).
61992787|NCT02978742|ACTIVE_COMPARATOR|Uncoached Recovery Record App|Participants will complete the 8-week adaptive Recovery Record app program on their own (i.e., without a coach providing feedback and support).
61992788|NCT06414174|ACTIVE_COMPARATOR|Very preterm neonates or birth weight < 1500 gram receiving split septum needleless connector|Very preterm neonates or birth weight \< 1500 gram who needs central line access will use split septum mechanism for their needleless connector
61992789|NCT06414174|ACTIVE_COMPARATOR|Very preterm neonates or birth weight < 1500 gram receiving mechanical valve needleless connector|Very preterm neonates or birth weight \< 1500 gram who needs central line access will use mechanical valve for their needleless connector
61992790|NCT00563953|EXPERIMENTAL|1|Primary chemotherapy regimen consisting of four cycles of pegylated-liposomal doxorubicine at 35 mg/m² IV plus CPM 600 mg/m² on Day 1 every 4 weeks followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
61992791|NCT03741036|ACTIVE_COMPARATOR|autogenous bone graft as a space filling material|Autogenous bone from sub mental bone had been grafted in jumping gap between implant and freshely extracted socket
61992792|NCT03741036|ACTIVE_COMPARATOR|deproteinized bovine as a space filling material|Granules of deproteinized bovine bone of 0.25-1.0 mm diameter were used to fill the remaining defect when the distance of the defect wall to the implant surface was \> 3 mm.
61992793|NCT03741036|ACTIVE_COMPARATOR|nano-hydroxyapatite alloplast as a space filling material|The patient was treated using alloplast material mixed with a nano-bone graft to fill gap between implant and freshely extracted socket
62388051|NCT02452034|EXPERIMENTAL|4.5 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
62768272|NCT03696095|ACTIVE_COMPARATOR|Continous infusion ropivacaine|Continuous infusion via peri-neural femoral nerve catheter of Ropivacaine Hcl 0.2% Inj Bag 200Ml (CI mode) at rate of 6ml/h + patient controlled bolus of 3ml ...
62768273|NCT03696095|EXPERIMENTAL|PIB ropivacaine|Programmed intermittent bolus of Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode) : 6ml each 60min + patient controlled bolus 3ml ...
62768274|NCT05435066||Arm 1 - cancer group|Arm 1 - newly diagnosed cancer subjects
62768275|NCT05435066||Arm 2 - non cancer group|Arm 2 - non-cancer subjects (Not currently enrolling in this arm)
61992794|NCT03045965|EXPERIMENTAL|Salpingectomy|Concomitant salpingectomy at the time of hysterectomy for a benign reason
61992795|NCT03045965|NO_INTERVENTION|No salpingectomy|No salpingectomy at the time of hysterectomy for a benign reason
61992796|NCT05278429|ACTIVE_COMPARATOR|Myosuit arm|Patients perform exercise training with the Myosuit
61992797|NCT05278429|OTHER|Control arm|Patients perform exercise training without the Myosuit
61992798|NCT03434041|EXPERIMENTAL|Intranasal Esketamine plus Oral Antidepressant|Eligible participants will self-administer esketamine (56 mg or 84 mg) intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Treatment Phase. All participants will start at a dose of 56 milligram (mg) on Day 1. The dose may be increased to 84 mg or maintained at 56 mg per investigator's discretion. In addition, participants will simultaneously initiate a new, open-label 1 of 4 oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine extended release \[XR\]) on Day 1 that will be continued for the duration of the 4-week Double-Blind Treatment Phase.
61992799|NCT03434041|ACTIVE_COMPARATOR|Oral Antidepressant plus Intranasal Placebo|Eligible Participants will self-administer matching placebo intranasally twice per week for 4 weeks in Double-Blind Treatment Phase. In addition, participants will simultaneously initiate a new, open-label oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Treatment Phase.
61992800|NCT00453999|EXPERIMENTAL|Arm 1: Peramivir 200 mg|Peramivir 200 mg administered intravenously once daily for 5 days (5 doses)
62388052|NCT02452034|EXPERIMENTAL|3.5 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 3.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
62388053|NCT02452034|EXPERIMENTAL|4.5 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
62388054|NCT02452034|EXPERIMENTAL|6 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
62388055|NCT02452034|EXPERIMENTAL|6 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
62768276|NCT03668158||recurrent HCC|recurrent HCC after LT
62768277|NCT03668158||non-recurrent HCC|non- recurrent HCC after LT
62768278|NCT06506539|NO_INTERVENTION|scaling and root planning only|
62768279|NCT06506539|ACTIVE_COMPARATOR|scaling and root planning+planenta extract gel group|
62768280|NCT06337578||Patients with amyotrophic lateral sclerosis (ALS)|Individuals having been received a clinical diagnosis of amyotrophic lateral sclerosis according to current diagnostic criteria
62768281|NCT06337578||Patients with Alzheimer's disease (AD)|Individuals having been received a neurochemical and/or aclinical diagnosis of Alzheimer's according to current diagnostic criteria
62768282|NCT06337578||Patients with Lewy body dementia (LBD)|Individuals having been received a clinical diagnosis of Lewy body dementia according to current diagnostic criteria
61992801|NCT00453999|EXPERIMENTAL|Arm 2: Peramivir 400 mg|Peramivir 400 mg administered intravenously once daily for 5 days (5 doses)
61992802|NCT00453999|EXPERIMENTAL|Arm 3: Oseltamivir|Oseltamivir 75 mg oral suspension administered orally twice daily for 5 days (10 doses)
61992803|NCT02302651|OTHER|Osteoid Osteoma|MR guided High Intensity focused ultrasound
61992804|NCT03898349|NO_INTERVENTION|Non-Texters|"Patients did not receive the automated text messaging system Annie"
61992805|NCT03898349|ACTIVE_COMPARATOR|Texters|Patients received the Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
61992806|NCT05805761|EXPERIMENTAL|Conventional Treatment Group|Participants in this group will receive the conventional treatment for the removal of dental biofilm (prophylaxis with bicarbonate jet).
62388056|NCT03146195||POP|Female patients with pelvic organ prolapse,such as: cystocele, uterine prolapse, the vault prolapse, rectal prolapse ,undergo pelvic floor reconstruction surgery.Before and after sugery,take dynamic magnetic resonance imaging scan.
61992807|NCT05805761|EXPERIMENTAL|aPDT + Conventional Treatment Group|Participants in this group will receive both the antimicrobial photodynamic therapy and the conventional treatment (prophylaxis with bicarbonate jet) for the removal of dental biofilm.
61992808|NCT05464654|EXPERIMENTAL|Polynucleotide vaginal suppositories|"In this arm 72 first-time participants of the peri-postmenopause and bone metabolism clinic of the Regional Hospital October 1st  of ISSSTE Mexico, were randomly enrolled to be treated with local salmon polydeoxyribonucleotide (PDRN) therapy."
61992809|NCT05464654|ACTIVE_COMPARATOR|Conjugated estrogens cream|"In this arm 64 first-time participants of the peri-postmenopause and bone metabolism clinic of the Regional Hospital October 1st  of ISSSTE Mexico, were randomly enrolled to be treated with the gold-standard treatment with local estrogen-based hormone therapy."
61992810|NCT02138903||ZEEP and tubing-spontaneous ventilation|Prospective clinical study in ICU with ventilated patients eligible to weaning trials of mechanical ventilation (ZEEP and tubing-spontaneous ventilation) comparing hemodynamic and cardiac effects evaluated by trans-thoracic echocardiography.
62559968|NCT06582654||Non-ovulation-influencing contraceptive group|Defined as women between 18 and 30 years old, who are vaccinated against HPV with either the Cervarix, Gardasil or Gardasil9 vaccine and are using contraceptives that do not affect ovulation (i.e. intrauterine devices).
61992811|NCT02138903||trans-thoracic echocardiography|Prospective clinical study in ICU with ventilated patients eligible to weaning trials of mechanical ventilation (ZEEP and tubing-spontaneous ventilation) comparing hemodynamic and cardiac effects evaluated by trans-thoracic echocardiography.
62388057|NCT03146195||Non-POP|Females with normal pelvic floor support,don't need pelvic floor reconstruction surgery,only take once dynamic magnetic resonance imaging scan.
62388058|NCT03934333|EXPERIMENTAL|A/B (BDA MDI/Pulmicort)|For each participant, the BDA MDI/Pulmicort Flexhaler DPI will be administered as a single dose (2 inhalations) on Day 1 of the respective treatment period per the assigned treatment sequence. The IMP will be administered in the morning, at approximately the same time of day throughout the study (±30 minutes).
62768283|NCT06337578||Patients with frontotemporal dementia (FTD)|Individuals having been received a clinical diagnosis of frontotemporal dementia (i.e., behavioural variant-frontotemporal dementia; semantic dementia; progressive non-fluent aphasia) according to current diagnostic criteria
62559969|NCT06582654||Post-menopausal group|Defined as fully vaccinated women between 50 and 70 years old, who are vaccinated against HPV with either the Cervarix, Gardasil or Gardasil9 vaccine and have had no menses for at least one year.
62559970|NCT06582654||Male group|Defined as fully vaccinated men between 18 and 30 years old, who are vaccinated against HPV with either the Cervarix, Gardasil or Gardasil9 vaccine.
62559971|NCT04358081|EXPERIMENTAL|Arm 1: hydroxychloroquine + aithromycin placebo|Hydroxychloroquine 600mg o.d. as loading dose (Day 1) +followed by 200mg t.i.d was initiated within 8-12 hours of the loading dose (not to exceed 12 hours) Azithromycin (AZT) placebo o.d.
62768284|NCT06337578||Patients with chronic cerebrovascular disorders (CVD)|Individuals with mild cognitive impairment/dementia and neuroradiological evidence of chronic cerebrovascular diseases
62768285|NCT06337578||Normotypical individuals (NI)|Individuals without brain disorders
62768286|NCT02626975||ACL reconstruction ballooning|"ACL reconstruction with short hamstring tendon autograft~* arm ballooning~* arm no ballooning"
62768287|NCT03684694|EXPERIMENTAL|Phase 1: Dose-Escalation of ADCT-402|A standard 3+3 dose escalation design will be used. The dose-limiting toxicity (DLT) period will be the 21 days following the first dose of ibrutinib. The dose escalation cohort will receive loncastuximab tesirine for Cycle 1 and 2 (3 weeks each) with concurrent ibrutinib (concomitant therapy) daily. Participants may continue to receive ibrutinib therapy up to 1 year after Cycle 1 Day 1 (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered intravenously (IV).
62768288|NCT03684694|EXPERIMENTAL|Phase 2: MTD or RP2D of ADCT-402 in Non-GCB DLBCL|Participants with non-germinal center B-cell diffuse large B-cell lymphoma (Non-GCB DLBCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered IV.
62768289|NCT03684694|EXPERIMENTAL|Phase 2: MTD or RP2D of ADCT-402 in GCB DLBCL|Participants with germinal center B-cell diffuse large B-cell lymphoma (GCB DLBCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered IV.
62768290|NCT03684694|EXPERIMENTAL|Phase 2: MTD or RP2D of ADCT-402 in MCL|Participants with mantle cell lymphoma (MCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered IV.
62768291|NCT04453176||"operating block admission on foot"|Patient going to the oparating block on foot
62388059|NCT03934333|EXPERIMENTAL|B/A (Pulmicort/ BDA MDI)|For each participant, the Pulmicort Flexhaler DPI / BDA MDI will be administered as a single dose (2 inhalations) on Day 1 of the respective treatment period per the assigned treatment sequence. The IMP should be administered in the morning, at approximately the same time of day throughout the study (±30 minutes).
62559972|NCT04358081|EXPERIMENTAL|Arm 2: hydroxychloroquine + azithromycin|Hydroxychloroquine 600 mg o.d. as a loading dose (Day 1) followed by 200 mg t.i.d. was initiated within 8-12 hours of the loading dose (not to exceed 12 hours) Azithromycin: 500 mg as a loading dose (Day 1) followed by 250 mg o.d. Day 2 - Day 5
62559973|NCT04358081|PLACEBO_COMPARATOR|Arm 3: hydroxychloroquine placebo + azithromycin placebo|Hydroxychloroquine placebo o.d. (day 1) followed by hydroxychloroquine placebo t.i.d Azythromycin placebo o.d.
62559974|NCT03751176|EXPERIMENTAL|FOLFIRI + panitumumab|"Patients received panitumumab plus FOLFIRI in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:~* Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy~* FOLFIRI:~* Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1~* Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1~* 5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
62559975|NCT03751176|ACTIVE_COMPARATOR|FOLFIRI|"Patients received FOLFIRI in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:~* Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1~* Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1~* 5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
62559976|NCT00882518|EXPERIMENTAL|1-Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)|Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) extended-release (300 mg/1st day, 600 mg/2nd day, 400 or 600 or 800 mg/3-42 day)
62559977|NCT00882518|ACTIVE_COMPARATOR|2-Chlorpromazine|Chlorpromazine (50 or 100 mg/1st day; 100-200 mg/2nd day; 150-300 mg/3rd day; 200-400 mg/4th day; 300 or 400 or 500 or 600 mg/5-42 days)
62559978|NCT03246451|PLACEBO_COMPARATOR|Placebo|Placebo, oral tablet in 14 days and in liquid meal.
62559979|NCT03246451|EXPERIMENTAL|Metformin|Metformin, oral tablet 2-4 x 500 mg in 14 days and in liquid meal.
62768292|NCT04453176||standard operating block admission|Patient going to the operating room in a conventional way (stretcher)
61992812|NCT01936935|EXPERIMENTAL|Low-fat dairy|3 servings/d of low-fat dairy
62388060|NCT03927703|EXPERIMENTAL|SB206 12%|SB206 12% topically once daily
62388061|NCT03927703|PLACEBO_COMPARATOR|Placebo Comparator|Placebo topically once daily
62388062|NCT04541394|EXPERIMENTAL|MolecuLight group|Patients with infected wounds received MolecuLight photography during debridement operation to evaluate the adequacy of remission of infected biofilm and facilitate wound healing
62388063|NCT04541394|NO_INTERVENTION|Control group|Patients with infected wounds received debridement operation by surgeon's clinical experiences to decide the extension of wounds
62388064|NCT00636116|EXPERIMENTAL|Group 1|Anavip with Anavip Maintenance Therapy
62559980|NCT03246451|EXPERIMENTAL|Saline|Saline infusion (9mg/mL) on experimental days
62388065|NCT00636116|EXPERIMENTAL|Group 2|Anavip with Placebo Maintenance Therapy
62388066|NCT00636116|ACTIVE_COMPARATOR|Group 3|CroFab with CroFab Maintenance Therapy
62559981|NCT03246451|EXPERIMENTAL|Exendin(9-39)|Exendin(9-39) infusion. GLP-1 receptor antagonist used as a study tool on experimental days.
62559982|NCT04135937|EXPERIMENTAL|MESH|Mobile Evidence-Based Smoking Cessation for Veterans Living with HIV is an intervention that is tailored for participants. It can include cognitive behavioral therapy, relapse-prevention text messaging, and/or pharmacotherapy with nicotine replacement therapy, bupropion, or varenicline.
62559983|NCT01477346|OTHER|Nurse intervention|Nurse led package of care based on current recommended best practice.
62559984|NCT01477346|OTHER|Standard care|Continuing standard general practitioner led care
62559985|NCT02273388|EXPERIMENTAL|12 mg BI 6727|
62768293|NCT01855152|EXPERIMENTAL|Optimised WHELD intervention|The optimised WHELD intervention combining person centred care, promoting person centred activities and interactions and provide care home staff and general practitioners with updated knowledge regarding the optimal use of psychotropic medications for persons with dementia in care homes, is more effective in improving the quality of life and mental health, than usual care for people with dementia living in nursing homes.
62768294|NCT01855152|EXPERIMENTAL|Treatment as usual|Treatments delivered as usual
62768295|NCT00582738|ACTIVE_COMPARATOR|CsA-TAC|Continuation of current immunosuppressive regimen (continuation of Calcineurin Inhibitor \[CNI\] with or without Enteric-coated mycophenolate sodium (myfortic) or mycophenolate mofetil(Cellcept)\[MPA\], with or without steroids) / no everolimus introduction.
62768296|NCT00582738|EXPERIMENTAL|everolimus|Initiation of everolimus with discontinuation of CNI/MPA, with or without steroids.
61992813|NCT01936935|PLACEBO_COMPARATOR|Sugar-sweetened beverages|3 servings/d of sugar-sweetened foods
61992814|NCT02017314|ACTIVE_COMPARATOR|Group 5|Patients with BMI \> 50
61992815|NCT02017314|ACTIVE_COMPARATOR|Group IV|Patients with BMI between 40 and 49.9
61992816|NCT02017314|ACTIVE_COMPARATOR|Group III|Patients with BMI between 35 and 39.9
61992817|NCT02017314|ACTIVE_COMPARATOR|Group II|patients with BMI between 30 and 34.9
61992818|NCT02017314|ACTIVE_COMPARATOR|Group I|Patients with BMI \<30
62388067|NCT03145584|ACTIVE_COMPARATOR|Continuous Adductor Canal Saphenous Catheter|Participants in this group were randomly allocated to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A PERINEURAL CATHETER WAS INSERTED IMMEDIATELY AFTER INJECTION OF THE INITIAL BOLUS OF LOCAL ANAESTHETIC. THE CATHETER WAS CONNECTED TO A PAJUNK FUSERPUMP CONTAINING 350 ML OF 0.15625% BUPIVACAINE AND INFUSED AT 8ML/HR.
62559986|NCT02273388|EXPERIMENTAL|24 mg BI 6727|
62559987|NCT02273388|EXPERIMENTAL|48 mg BI 6727|
62559988|NCT02273388|EXPERIMENTAL|75 mg BI 6727|
62559989|NCT02273388|EXPERIMENTAL|125 mg BI 6727|
62559990|NCT02273388|EXPERIMENTAL|200 mg BI 6727|
61992819|NCT03412084|EXPERIMENTAL|Stand up intervention|four week behavioral intervention based on self-regulation theory which is designed to facilitate the development of action plans to break up prolonged sitting
61992820|NCT03412084|NO_INTERVENTION|Control|No behavioral intervention - the control group will go about their daily life, but come in for assessments at the same time points as the intervention group
62388068|NCT03145584|SHAM_COMPARATOR|Single Shot Adductor Canal Saphenous Block|Participants in this group were randomly allocated NOT to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A SHAM CATHETER WAS PLACED ON THE SURFACE OF THE LEG AND COVERED BY AN OPAQUE DRESSING TO CONCEAL THE INSERTION SITE. ALL PATIENTS HAD THE PROXIMAL END OF THEIR CATHETER ATTACHED TO PORTABLE ELASTOMERIC PUMPS (PAJUNK FUSERPUMP 350 ML) CONCEALED IN OPAQUE BAGS TO PREVENT PATIENTS AND ASSESSORS FROM DETERMINING WHICH PUMPS WERE ACTUALLY FUNCTIONING. THESE PUMPS FUNCTION WITHOUT A MOTOR AND SO MAKE NO SOUND.
62559991|NCT02273388|EXPERIMENTAL|300 mg BI 6727|
61992821|NCT03561415|EXPERIMENTAL|Universal posaconazole prophylaxis|Universal posaconazole prophylaxis: All patients will start posaconazole modified release tablet (300mg daily ) between Day 4 and Day 14 post lung or heart-lung transplantation for 3 months.
61992822|NCT03561415|EXPERIMENTAL|Pre-emptive posaconazole therapy|Pre-emptive posaconazole therapy: Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease and given for 3 months.
61992823|NCT06169280|EXPERIMENTAL|NSC-CRAd-S-pk7|NSC-CRAd-S-pk7 1·50 x 10⁸ NSCs loaded with1·875 x viral particles administered intra-tumorally on Day 0 and Day 15, then every 4 weeks for up to 6 total doses.
61992824|NCT06169280|EXPERIMENTAL|NSC-CRAd-S-pk7 + N-acetylcysteine amide (NACA)|NSC-CRAd-S-pk7 1·50 x 10⁸ NSCs loaded with 1·875 x viral particles administered intra-tumorally on Day 0 and Day 15, then every 4 weeks for up to 6 total doses. In addition, N-acetylcysteine amide (NACA) 600 mg oral, is taken daily from registration to just prior to dose 2 of NSC-CRAd-S-pk7.
61992825|NCT00313612|EXPERIMENTAL|Treatment (oxaliplatin plus topotecan)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.
61992826|NCT02791620|EXPERIMENTAL|A nanofractional radiofrequency device|
61992827|NCT02391103|EXPERIMENTAL|NMES group|Anterior muscles of both thighs were electrically stimulated twice a day (2×30 minutes of NMES with a break of at least 30 minutes between both sessions) 7 days a week during the entire ICU stay but no longer than 14 days, starting on postoperative day 1. Highest tolerable intensity was applied.
62388069|NCT02736487|ACTIVE_COMPARATOR|Group A: True-Washout-Sham|Subjects in group A receives true air filtration intervention, then at least two weeks of washout period, followed by sham air filtration intervention.
62388070|NCT02736487|ACTIVE_COMPARATOR|Group B: Sham-Washout-True|Subjects in group B receives sham air filtration intervention, then at least two weeks of washout period, followed by true air filtration intervention.
62388071|NCT05512273|EXPERIMENTAL|Study|
61992828|NCT02391103|SHAM_COMPARATOR|Control group|In the control group, the electrodes were applied, connected to the stimulator, but no electricity was delivered.
61992829|NCT03278964|ACTIVE_COMPARATOR|Antro-ethmoidal technique|Patients in the inactive phase of Graves orbitopathy will be submitted to orbital decompression by antro-ethmoidal technique.
61992830|NCT03278964|EXPERIMENTAL|Lateral wall technique|Patients in the inactive phase of Graves orbitopathy will be submitted to orbital decompression by lateral wall technique.
61992831|NCT06363565|EXPERIMENTAL|supplementation of compound nutrients|Folic acid, vitamin B6, vitamin B12, and betaine are provided as a 1.0g tablet. the tablet is orally taken twice a day, two tablets at a time 12 weeks.
62388072|NCT05512273|ACTIVE_COMPARATOR|Control|
62388073|NCT03673150||women with breast cancer|women who gave birth in 2002/2005 with cord blood collection and developed invasive or non-invasive breast cancer in the following years (2005- O6/2018) to the exclusion of another cancer.
62388074|NCT03673150||women without breast cancer|Controls will be obtained by matching by date of delivery, location, age (woman's date of birth), parity at the time of cord collection and not having had breast cancer
62388075|NCT03313440|EXPERIMENTAL|high fibre|A 10 day increase in daily wheat fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
62388076|NCT03313440|EXPERIMENTAL|low fibre|A 10 day control intervention with no additional wheat fibre. Products are provided in boxes that must be consumed each day during the intervention.
62388077|NCT04060706||Prostate Cancer|Adults suitable for radical image-guided radiotherapy for their Prostate cancer, approximately 170 patients Components from RTOG, LENT SOM(A), RMH symptom scale and UCLA PCI (prostate cancer index) questionnaires will be used.
62559992|NCT02273388|EXPERIMENTAL|300 mg BI 6727 1h2h|Infusion over 1 hour (1h) in course 1 and over 2 hours (2h) in course 2.
61992832|NCT06363565|PLACEBO_COMPARATOR|placebo control|The placebo is an excipient and the color, flavor, shape, taste, and weight are same with the tablet of folic acid, vitamin B6, vitamin B12, and betaine supplement.
62559993|NCT02273388|EXPERIMENTAL|300 mg BI 6727 2h1h|Infusion over 2 hours (2h) in course 1 and over 1 hours (1h) in course 2.
62559994|NCT02273388|EXPERIMENTAL|350 mg BI 6727|
62559995|NCT02273388|EXPERIMENTAL|400 mg BI 6727|
62559996|NCT02273388|EXPERIMENTAL|450 mg BI 6727|
61992833|NCT03375541|NO_INTERVENTION|Control|Natural discussion of disease modifier selection conducted without augmentation by risk aversion calculator
61992834|NCT03375541|EXPERIMENTAL|Calculator|Natural discussion of disease modifier selection conducted with augmentation by risk aversion calculator
61992835|NCT03414463|EXPERIMENTAL|TREAT|A 4-week one-to-one intervention between the clinical RA (cRA) and participant. Comprised of eight sessions, it involves psycho-educational lessons and skill-building exercises to achieve objectives based on the characteristics of alexithymia.
61992836|NCT03414463|EXPERIMENTAL|Waitlist Control|After Time 1 testing in Week 1, participants randomized to WLC will not receive any treatment during Weeks 2-5. The only staff interaction during this no treatment time period will be to schedule Time 2 testing appointment for week 6. After Time 2 testing, WLC will receive TREAT (weeks 14-17), followed up with testing.
62388078|NCT04060706||Head & Neck Cancer|Adults suitable for radical image-guided radiotherapy for their Head \& Neck cancer, approximately 140 patients. Components from CTCAE v3, LENT SOM(A), EORTC QLQ H+N35 \& Modified xerostomia questionnaires will be used.
61992837|NCT02417051|EXPERIMENTAL|Resiliency Training|Intervention: Disaster Worker Resiliency Training (DWRT) Program.
61992838|NCT02417051|NO_INTERVENTION|Waitlist|Waitlist control: Participants to be offered the program after completion of the trial.
61992839|NCT01308450||Single Arm, Non ADHD Control Group|Single site, single visit study. Subjects will be administered Standard Rating Scales (Defined) and the Quotient ADHD System Test (Adolescent and Adult Version). Subject's assessed to be Non-ADHD will be eligible to have their Quotient tests added to the Quotient Adolescent and Adult Normative Database.
62559997|NCT00834691||1|Patients with anemia and systolic heart failure
62559998|NCT00834691||2|Patients with systolic heart failure but without anemia
61992840|NCT01164449|EXPERIMENTAL|1|Space TGC system with incorporated eMPC advised insulin titration to establish glycaemic control
61992841|NCT00573755|EXPERIMENTAL|Arm I|Patients receive oral sorafenib tosylate twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
61992842|NCT00573755|ACTIVE_COMPARATOR|Arm II|Patients receive oral placebo twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62559999|NCT00834691||3|Patients with at least moderate chronic renal failure, with or without anemia and without systolic heart failure.
61992843|NCT01561352|EXPERIMENTAL|Factor VII|
61992844|NCT04903327|EXPERIMENTAL|COVI-MSC|Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4
61992845|NCT04903327|PLACEBO_COMPARATOR|Placebo|Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4
61992846|NCT06097208||Intervention Group|Children who attended kindergartens actively delivering a community-based health promotion and obesity prevention intervention
61992847|NCT06097208||No-intervention Group|Children who attended usual care kindergartens
62388079|NCT04060706||Central Nervous System Tumours|Adults suitable for radical image-guided radiotherapy for their CNS tumour, as many patients recruited as possible. Components from RTOG, LENT SOM(A), Folstein mini mental state examination \& Generalised activites of daily living scale (G-ADL) questionnaires will be used.
62388080|NCT04060706||Lung Cancer|Adults suitable for radical image-guided radiotherapy for their Lung cancer, as many patients recruited as possible. Components from RTOG \& LENT SOM(A) questionnaires will be used.
62388081|NCT06205459|EXPERIMENTAL|intervention|deep marginal acquisition using thermacut bur from dentsply
62388082|NCT06205459|ACTIVE_COMPARATOR|control|functional crown lengthening
62388083|NCT01434498|ACTIVE_COMPARATOR|Arm 1|GS-5885, GS-9451, tegobuvir (GS-9190), and Copegus® for 24 weeks
61992848|NCT02331225||Systemic sclerosis, no pulmonary hypertension|This group will be systemic sclerosis patients without pulmonary hypertension
61992849|NCT02331225||Systemic sclerosis/pulmonary hypertension|This group will be systemic sclerosis patients with pulmonary hypertension
61992850|NCT02331225||Healthy controls|These will be healthy age- and sex-matched controls
61992851|NCT04248595|EXPERIMENTAL|Azacitidine plus HAG|"Patients of de novo or relapsed AML(age≥60y or ineligibility to receive intensive chemotherapy) will receive AZA+HAG (homoharringtonie, cytarabine, G-CSF) regiment as induction therapy. After complete remission(CR), the AZA+HAG regimen was further given 4-6 cycles and followed by azacitidine maintenance or until the disease progresses.~AZA -Azacitidine HAG -Homoharringtonie, Cytarabine, G-CSF"
62560000|NCT01007305|EXPERIMENTAL|Bilateral salpingo-oophorectomy|Removal of both ovaries and fallopian tubes at the time of hysterectomy for benign conditions.
62560001|NCT01007305|ACTIVE_COMPARATOR|Ovarian conservation|No ovaries or fallopian tubes removed at the time of hysterectomy for benign conditions.
62560002|NCT01483703||Diagnostic tool|Laser Speckle Imaging of Critical Care Neonates
61992852|NCT04248595|EXPERIMENTAL|Azacitidine plus HIA|"Patients of de novo or relapsed AML(age\<60y or eligible for intensive chemotherapy) will receive AZA +HIA(homoharringtonie, Idarubicin, cytarabine) regiments as introduction therapy. After CR, post-remission therapy will follow with NCCN guidelines.~AZA -Azacitidine HIA -Homoharringtonie, Cytarabine, Idarubicin"
62388084|NCT01434498|ACTIVE_COMPARATOR|Arm 2|GS-5885, GS-9451, tegobuvir (GS-9190), and a placebo matching ribavirin for 24 weeks
62388085|NCT01434498|ACTIVE_COMPARATOR|Arm 3|GS-5885, GS-9451, a placebo matching tegobuvir, and Copegus® for 24 weeks
62388086|NCT02113891|EXPERIMENTAL|Eculizumab|Eculizumab will be given in addition to standard immunosuppression regimen (tacrolimus, mycophenalte mofeti, prednisone)
62388087|NCT00750074||1|"During volume assist-control ventilation, a 0.4 second end-inspiratory pause will be set and the following pressures measured: peak pressure; plateau pressure; and PEEP. The following ventilator settings will be recorded: inspiratory flow; expired tidal volume; and rate. The presence or absence of autoPEEP will be noted.~During pressure-control ventilation, the flow versus time waveform will be printed from the ventilator using a conventional computer printer for later analysis. The following ventilator settings will be recorded: inspiratory pressure; PEEP; and expired tidal volume."
62388088|NCT06093321|EXPERIMENTAL|SYB PDO Thread|PDO Thread
62388089|NCT06093321|ACTIVE_COMPARATOR|MINT lift®|PDO Thread
62388090|NCT05707403|EXPERIMENTAL|Test treatment (T) followed by Reference treatment (R)|
62560003|NCT06582004|PLACEBO_COMPARATOR|Placebo|use vaginal hyaluronic acid gel as placebo
62560004|NCT06582004|EXPERIMENTAL|CH2 vaginal gel|use CH2 vaginal gel as intervention The usage frequency is 2 units per week, with a 3-day interval between each unit, for a total duration of 24 weeks
62560005|NCT02126514|EXPERIMENTAL|AZD3293|7 subjects will receive AZD3293
62560006|NCT02009189|PLACEBO_COMPARATOR|Control|Saline flush
62560007|NCT02009189|ACTIVE_COMPARATOR|2% Taurolidine lock|Catheter lock with 2% Taurolidine
62560008|NCT02009189|ACTIVE_COMPARATOR|1.35% Taurolidine with citrate|Catheter lock with 1.35% Taurolidine + citrate
62560009|NCT05241340|EXPERIMENTAL|Open arm|All patients will receive study interventions (sasanlimab and SBRT) and standard-of-care radical cystectomy.
61992853|NCT04248595|EXPERIMENTAL|Azacitidine plus HDA|"Patients of de novo or relapsed AML(age\<60y or eligible for intensive chemotherapy) will receive AZA +HDA(homoharringtonie, daunorubicin, cytarabine) regiments as introduction therapy., After CR, post-remission therapy will follow with NCCN guidelines.~AZA -Azacitidine HDA -Homoharringtonie, Cytarabine, Daunorubicin"
62388091|NCT04781946|EXPERIMENTAL|Treatment Arm|Endoscopic pneumatic balloon dilation (PBD), gastric peroral endoscopic myotomy (G-POEM) and Roux-en-Y gastric bypass (RYGB) will be used for the management of post-LSG GSS using a predefined treatment algorithm.
62388092|NCT05692427|OTHER|Cryotherapy|Cryotherapy on granuloma pyogenicum
62388093|NCT00842010||Hyperglycemic without previous DM diagnosis|Patients with hyperglycemia, without previous diagnosis of diabetes
62388094|NCT00842010||Previous diagnosis of DM|Patients that have previous diagnosis of Diabetes Mellitus
62388095|NCT00842010||No previous DM diagnosis and no hyperglycemia|Patient with NO previous diagnosis of diabetes, and no hyperglycemia
62560010|NCT04711993|NO_INTERVENTION|Control group|No application will be made to the control group. However, these patients will be included in the exercise program they want after the 8-week treatment period is completed.
62768297|NCT01850043||Military Conscripts|A term of whole military conscripts per year in one Reserve Force Battalion. Military conscripts gather from all around area in Korea randomly
62768298|NCT00049595|ACTIVE_COMPARATOR|ABVD|8 cycles of ABVD
62768299|NCT00049595|EXPERIMENTAL|BEACOPP|4 cycles of BEACOPP Escalated + 4 cycles of BEACOPP Baseline
62388096|NCT01907750|ACTIVE_COMPARATOR|Transanastomotic tube|use of transanastomotic tube.
62388097|NCT01907750|ACTIVE_COMPARATOR|Transcystic tube|use of transcystic tube to drain bile duct
62560011|NCT04711993|EXPERIMENTAL|Aerobic exercise group|Patients in the aerobic exercise group will exercise under the supervision of the therapist.
62560012|NCT04711993|EXPERIMENTAL|Stretching exercise group|Patients in the stretching-mobility exercise group will do stretching exercises under the supervision of the therapist
62560013|NCT01153815|PLACEBO_COMPARATOR|placebo|Sodium chloride
62560014|NCT01153815|EXPERIMENTAL|GSK1358820(Botulinum Toxin Type A)|"GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)"
62560015|NCT03440229|NO_INTERVENTION|Emuslfier-free diet|This is western style diet prepared without any emulsifiers. Emulsifier free brownies and sorbet are provided daily.
62768300|NCT04721340||Test Group|people with multiple sclerosis
62768301|NCT04721340||Control Group|healthy volunteers
62768302|NCT01965899|EXPERIMENTAL|Insertable Cardiac Monitor Implant|
62768303|NCT05998135|EXPERIMENTAL|Treatment (atovaquone)|Patients receive atovaquone PO on study. Patients also undergo CT and biopsy or paracentesis throughout the study.
62768304|NCT04110470|ACTIVE_COMPARATOR|Control Group|Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.
62768305|NCT04110470|EXPERIMENTAL|Treatment Group|These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
61992854|NCT03464006|EXPERIMENTAL|Online Support Module|Patients in the online support module group will receive a tablet which has the developed peripheral arterial disease platform installed on it. The platform helps the patient to monitor factors related to their peripheral arterial disease such as exercise, smoking, and diet and helps them to track and modify these behaviours.
61992855|NCT03464006|ACTIVE_COMPARATOR|Standard of Care|Patients in this arm will receive the standard of care as provided by the institution.
61992856|NCT00117559|EXPERIMENTAL|TEL-CBT|Telehealth, problem solving based treatment provided over the telephone
62388098|NCT02365961|EXPERIMENTAL|FI Block|Fascia iliaca block consisting of up to 60 mL of 0.35% ropivicaine at a dose of 3 mg/kg (with adjuvants of 100 mcg clonidine \[per 60 mL\] and epinephrine 1:400,000)
62388099|NCT02365961|ACTIVE_COMPARATOR|Local Injection|Local anesthetic in the hip joint consisting of 30cc of 0.5% Noropin
62388100|NCT02709239|ACTIVE_COMPARATOR|DHA 200mg|Participants will receive 200mg DHA to take per day. Participants will be asked to take four capsules containing 50mg DHA each.
62388101|NCT02709239|EXPERIMENTAL|DHA 800mg|Participants will receive 800mg DHA to take per day. Participants will be asked to take four capsules containing 200mg DHA each.
62388102|NCT04588298|EXPERIMENTAL|Stage 1: AZD9833 Dose A|Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 1 of the study.
62388103|NCT04588298|EXPERIMENTAL|Stage 1: AZD9833 Dose B|Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 1 of the study.
61992857|NCT00117559|NO_INTERVENTION|Treatment as Ususal|Control group, no treatment provided
61992858|NCT05993676|SHAM_COMPARATOR|Control|The control group received an app containing only signposting information about a range of statutory and third sector organisations that focused on veterans' mental health.
62388104|NCT04588298|EXPERIMENTAL|Stage 2: AZD9833 Dose A|Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 2 of the study.
62388105|NCT04588298|EXPERIMENTAL|Stage 2: AZD9833 Dose B|Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 2 of the study.
62388106|NCT04588298|EXPERIMENTAL|Stage 2: AZD9833 Dose C|Post-menopausal participants will receive once daily oral dose C of AZD9833 in stage 2 of the study.
62388107|NCT04588298|EXPERIMENTAL|Stage 3: AZD9833 Dose A|Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 3 of the study.
62388108|NCT04588298|EXPERIMENTAL|Stage 3: AZD9833: Dose B|Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 3 of the study.
62388109|NCT04613687|EXPERIMENTAL|URGOBD001|Compression bandage
62388110|NCT03515031|EXPERIMENTAL|High Flow Nasal Cannula Oxygenation|High Flow Nasal Cannula Oxygenation with a minimum flow ≥ 60L / min, and an FiO2 such as to maintain a SpO2 ≥ 92% for at least 48 hours until clinical stability
62388111|NCT03515031|ACTIVE_COMPARATOR|Venturi Mask Oxygenation|Venturi Mask Oxygenation, with an FiO2 such as to maintain an SpO2 ≥ 92% for at least 48 hours until clinical stability
62388112|NCT05810415||Renin group and lactate group|Renin group and lactate group
62388113|NCT04984252|ACTIVE_COMPARATOR|Only Active components|15 minutes, once
62388114|NCT04984252|SHAM_COMPARATOR|Inactive components|15 minutes, once
62768306|NCT00599690|EXPERIMENTAL|A|Epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
62768307|NCT03541460||Older Cohort|Demographic, health and functional data will be collected from subjects 95 years and older by means of a structured interview. Blood will be collected for laboratory and genetic testing.
61992859|NCT05993676|ACTIVE_COMPARATOR|Intervention|"The intervention group will receive a 'full' version of the app over the 1month trial period. The app consists of five core elements:~1. Personas developed as an aide to the provision of psycho-education on how mental health difficulties might look in real life and to help participants identify symptoms of mental health difficulties in themselves.~2. Daily life goals employing behavioural activation principles to encourage users to set a series of small tasks to help them achieve larger goals in different areas of their life e.g. work, family, physical health.~3. Self-help tools to provide participants with a range of resources that they can use independently to help them manage symptoms of mental ill-health they may be experiencing.~4. Tracking tools to allow users to monitor their own mental health and to see their progress across the elements of the app.~5. A schedule of daily notifications to encourage participants to continue to engage with the app."
62768308|NCT03541460||Younger Controls|Demographic, health and functional data will be collected from the children of the older subjects and other aged-matched controls by means of a structured interview. Blood will be collected for laboratory and genetic testing.
61992860|NCT03025828|EXPERIMENTAL|Acthar|Acthar will be administered subcutaneously (SC) 80 units for the first week and then 80 units twice weekly
61992861|NCT02811224||Ovarian Cancer|
61992862|NCT02811224||Benign Neoplasm|
61992863|NCT00603746|EXPERIMENTAL|GW685698X|GW685698X
62388115|NCT04984252|PLACEBO_COMPARATOR|Distraction group|15 minutes, once
62388116|NCT00572858||Premenopausal women|Female patients who have undergone coronary angiography and are under the age of 55
62388117|NCT05539742|ACTIVE_COMPARATOR|Coconut oil|The coconut oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits. Each participant will have ten minutes to consume biscuits with 250 ml of water. No other food will be consumed during the study period (6 hours). After that, participants will be allowed an ad libitum intake of standard meals. Each meal will be weighed before and after it is consumed, with the amount of food ingested being calculated. Then the participants will take the other treatment after a 1-week washout interval.
62560016|NCT03440229|EXPERIMENTAL|Emulsifier-containing diet|This is a western style diet prepared without any emulsifiers with the exception of the CMC that is included in brownies and sorbet that are provided daily.
62768309|NCT03563508||CBCT of Egyptian subpopulation|Cone-beam computed tomography (CBCT) of a sample of Egyptian subpopulation containing maxillary premolars for image assessment.
62768310|NCT01395277|EXPERIMENTAL|High Flavanol first then Low Flavanol|"The measurements will be made on all study participants on two separate occasions; 1) before and 2 hours following consumption of a beverage with high flavanol content and 2) before and 2 hours following consumption of a beverage with low flavanol content."
62768311|NCT01395277|EXPERIMENTAL|Low Flavanol first then High Flavanol|"The measurements will be made on all study participants on two separate occasions; 1) before and 2 hours following consumption of a beverage with low flavanol content and 2) before and 2 hours following consumption of a beverage with high flavanol content."
62768312|NCT01713556|EXPERIMENTAL|Propranolol + reactivation|they have a script-driven mental imagery of the traumatic event white drug
62768313|NCT01713556|PLACEBO_COMPARATOR|Placebo + reactivation|They have a script-driven mental imagery of the traumatic event with placebo
62768314|NCT01504347|EXPERIMENTAL|Primary vaccination in seronegative subjects|
62768315|NCT01504347|EXPERIMENTAL|Booster vaccination in seronegative subjects|
62388118|NCT05539742|ACTIVE_COMPARATOR|Palm oil|The palm oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits. Each participant will have ten minutes to consume biscuits with 250 ml of water. No other food will be consumed during the study period (6 hours). After that, participants will be allowed an ad libitum intake of standard meals. Each meal will be weighed before and after it is consumed, with the amount of food ingested being calculated. Then the participants will take the other treatment after a 1-week washout interval.
62388119|NCT03232151|EXPERIMENTAL|C-ARM CBCT|A C-arm CBCT evaluation with SMART RECON novel software for the rapid assessment of time-resolved CT angiogram and CT perfusion.
62388120|NCT01475227|EXPERIMENTAL|Arm A- early Solvazinc group|Zinc sulphate 125mg (1 Solvazinc tablet) once daily orally after dissolution in water, day 2 to day 15
61992864|NCT00811577|EXPERIMENTAL|AZX100-placebo|Three trocar sites designated as anterior, lateral and posterior were randomized on each patient to receive one low dose of AZX100 3 mg/linear cm, one high dose of AZX100 10 mg/linear cm, or placebo (saline).
61992865|NCT00811577|PLACEBO_COMPARATOR|Placebo-only|Three trocar sites on each patient received one dose of placebo (saline).
61992866|NCT05433779|EXPERIMENTAL|Neosense Umbilical Catheter|
61992867|NCT02653651|ACTIVE_COMPARATOR|Ketamine|Ketamine infused at 0.1 mg/kg/hour
62768316|NCT01504347|EXPERIMENTAL|Primary + booster vacc. (seronegative + seropositive subjects)|
61992868|NCT02653651|EXPERIMENTAL|Lidocaine|Lidocaine infused at 1 mg/kg/hour
61992869|NCT02653651|PLACEBO_COMPARATOR|Placebo|An equal volume of saline
61992870|NCT05563064|EXPERIMENTAL|Karika Syrup|Karika syrup has been used to treat thrombocytopenia
61992871|NCT01948739|EXPERIMENTAL|BMI control of MAHI Exo-II|MAHI EXO-II exoskeleton augmented with BMI system will be used to actively include the patient in the control loop, thereby making the therapy 'active' and engaging patients with various impairment severity in rehabilitation tasks. Patients will receive longitudinal training with the BMI-robotic interface for 3-4 sessions per week, over a period of 3 months.
62560017|NCT02763046|EXPERIMENTAL|Secukinumab - delayed NSAID tapering|"Induction with secukinumab 150 mg s.c. once per week (Week 0, 1, 2, 3 and 4) followed by maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 8, 12, 16 and 20), with intermittent placebo injections at Week 5, 6, 7, 17, 18 and 19 to maintain the blind.~NSAID tapering allowed from Week 4 (delayed tapering)."
62768317|NCT02439567|EXPERIMENTAL|Patients|Treatment with new oral antiviral drugs for HCV infection, Fibroscan: Liver and Spleen elastography
62768318|NCT00709878||L|Patients treated with lapatinib who developed skin toxicities and have been biopsied for skin rash.
62388121|NCT01475227|EXPERIMENTAL|Arm B- late Solvazinc group|Zinc sulphate 125mg (1 Solvazinc tablet) once daily orally after dissolution in water, day 15 to day 28
62768319|NCT00709878||C|Patients treated with cetuximab who developed skin toxicities and have been biopsied for skin rash.
62388122|NCT05798286|EXPERIMENTAL|QUANTRA group|"Adult subjects (18 years-old or older) undergoing double-lung transplantation: transfusion algorithm based on whole blood viscoelastic test with Quantra® + standard coagulation test. These samples are collected at five standard surgical time points:~* on arrival at the hospital on the day of surgery,~* after first pulmonary artery clamping,~* after first graft implantation,~* after second graft implantation,~* at end-surgery status."
62388123|NCT05798286|ACTIVE_COMPARATOR|Control group|"Adult subjects (18 years-old or older) undergoing double-lung transplantation: standard transfusion algorithm based on standard practice and coagulation test. These samples are collected at five standard surgical time points:~* on arrival at the hospital on the day of surgery,~* after first pulmonary artery clamping,~* after first graft implantation,~* after second graft implantation,~* at end-surgery status."
62768320|NCT00709878||P|Patients treated with panitumumab who developed skin toxicities and have been biopsied for skin rash.
62388124|NCT02657109|ACTIVE_COMPARATOR|Control|Participants are submitted to cardiac rehabilitation protocol of the hospital where it will be conducted the study, which consists in respiratory exercises of 3 series Inspirations Maximum Sustained for 10 reps, 3 sets of 20 repetitions metabolic exercises with dorsiflexion and plantar flexion and ankle and wrist extension and fingers of the upper limbs. Assessment of heart rate varibility and oxidative stress carried out before the heart valve replacement surgery , the first day of postoperative and on the fifth postoperative day
62388125|NCT02657109|ACTIVE_COMPARATOR|Early mobilization|Participants performed exercise in cycle ergometer of lower Limbs, pedaling for 20 consecutive minutes at a moderate level with Heart Rate Assessment and the Borg scale to evaluate the Voluntary Comfort. Assessment of heart rate varibility and oxidative stress carried out before the heart valve replacement surgery , the first day of oepratório post and on the fifth postoperative day
62388126|NCT00380601|EXPERIMENTAL|1|
62388127|NCT02218346|ACTIVE_COMPARATOR|Treatment A (unfed)|Treatment A: Single oral dose of AG-221 mesylate at Hour 0 on Day 1, following a 10-hour overnight fast.
62388128|NCT02218346|ACTIVE_COMPARATOR|Treatment B (fed)|Treatment B: Single oral dose of AG-221 mesylate at Hour 0 on Day 1, 30 minutes after the start of a high-fat breakfast.
62388129|NCT03519815|ACTIVE_COMPARATOR|Ectoin Eye Spray|"Eye Spray to be applied 3 times per day for the duration of 10 +/-3 days Ectoin® Eye Spray - Colloidal (EES09; bitop AG) - CE marked medical device~Ingredients: Ectoin®, Soy-Lecithin, Vitamin A, Vitamin E, water, physiological buffer system Indication: to treat mild to moderate dry eye disease"
62388130|NCT03519815|ACTIVE_COMPARATOR|Liponit Eye Spray|"Eye Spray to be applied 3 times per day for the duration of 10 +/-3 days~Liposomal eye spray: Tears Again® (TA, Optima Medical Swiss AG) - CE marked medical device Ingredients: Soy-Lecithin, Sodium Chloride, Ethanol, Phenoxyethanol, Vitamin A-Palmitate, Vitamin E, Aqua purificata Indication: to treat mild to moderate dry eye disease"
62388131|NCT05151952||Cancer patients receiving proton radiation therapy|Cancer patients receiving proton radiation therapy, Registry of cancer patients who receive proton radiation therapy to crack disease and toxicity outcomes.
62388132|NCT01098435|EXPERIMENTAL|RDC-0313 (ALKS 33)|2-capsules taken orally
62388133|NCT01098435|PLACEBO_COMPARATOR|Placebo|2-capsules taken orally
62388134|NCT05003687|EXPERIMENTAL|Part A: Single Dose of Lu AG06474 or Placebo|Participants will receive single oral dose of Lu AG06474 or placebo.
62388135|NCT05003687|EXPERIMENTAL|Part B: Repeated Dose of Lu AG06474 and Food Interaction|"Participants will receive a single oral dose of Lu AG06474 in each dosing period (Period 1, 2, and 3) in the following sequence:~Sequence B1: Fed - Fasting- Fasting~Sequence B2: Fasting- Fed - Fasting~Sequence B3: Fasting- Fasting - Fed"
62388136|NCT00990522|EXPERIMENTAL|debridement|monthly vs weekly debridement
62388137|NCT04419558|EXPERIMENTAL|Pamrevlumab|"Treatment phase: Pamrevlumab 30 mg/kg administered by IV infusion, every 3 weeks, for a total of up to 17 infusions over 48 weeks.~Open-label extension phase: Pamrevlumab 30 mg/kg administered by intravenous infusion, every 3 weeks for up to 48 weeks"
62388138|NCT04419558|EXPERIMENTAL|Placebo|Pamrevlumab-matching placebo administered by IV infusion every 3 weeks for a total of up to 17 infusions over 48 weeks
62388139|NCT05964296|EXPERIMENTAL|Application group|Patients randomized to the digital application arm will benefit from treatment as usual and will have access to the MAURISSE application, allowing them to communicate with the healthcare team using a messaging system, to report and follow substance use, to access a To-do list, to access personal multimedia contents helping with the treatment, to report a feeling of boredom (these moments presenting a risk of relapse) and finally to access a list of propositions in order to fight this feeling
62388140|NCT05964296|ACTIVE_COMPARATOR|Standard-of-care group|These patients will benefit from the usual care within the center (appointments with doctors; regular follow-up meetings with nurses, psychologists, social workers, therapeutic groups depending on the evaluation).
62768321|NCT00709878||E|Patients treated with erlotinib who developed skin toxicities and have been biopsied for a skin rash.
62768322|NCT01114360|ACTIVE_COMPARATOR|Melatonin|African-American subjects with mild to moderate essential hypertension will be given 8mg time release melatonin for 4 weeks. (either before or after placebo exposure).
62768323|NCT01114360|PLACEBO_COMPARATOR|Placebo|African-American subjects with mild to moderate essential hypertension will be given placebo for 4 weeks (either before or after exposure to melatonin)
62768324|NCT04008511|EXPERIMENTAL|Phase Ib: Regorafenib plus XELOX|"Phase Ib followed a Modified toxicity probability interval (mTPI) design to determine the maximum administered dose (MAD), there are 3 dose levels, and the dose level started from Group A:~Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX. (Regorafenib qd po for 14 days, every 3 weeks; XELOX: Oxaliplatin 130 mg/m2 IV, day 1, Capecitabine 1000 mg/m2 bid po for 14 days)"
62768325|NCT04008511|EXPERIMENTAL|Phase II: Regorafenib plus XELOX|Regorafenib MAD qd po for 14 days, every 3 weeks, Oxaliplatin 130 mg/m2 IV on day 1, Capecitabine 1000 mg/m2 bid po for 14 days.
62768326|NCT04008511|ACTIVE_COMPARATOR|Phase II: XELOX|Oxaliplatin 130 mg/m2 IV on day 1, Capecitabine 1000 mg/m2 bid po for 14 days.
61992872|NCT00378066|ACTIVE_COMPARATOR|Bevacizumab|Bevacizumab, capecitabine and oxaliplatin for metastatic colorectal cancer, 1st line treatment
61992873|NCT02918851|EXPERIMENTAL|7-day old RBCs|Transfusion of 7-day stored red blood cells: Subjects will be transfused with their own 7-day old red blood cells
61992874|NCT02918851|EXPERIMENTAL|28-day old RBCs|Transfusion of 28-day stored red blood cells: Subjects will be transfused with their own 28-day old red blood cells
61992875|NCT02918851|EXPERIMENTAL|42-day old RBCs|Transfusion of 42-day stored red blood cells: Subjects will be transfused with their own 42-day old red blood cells
62388141|NCT02519127|EXPERIMENTAL|Low glycaemic load diet|Subjects will be following a low glycaemic load diet, typically high in polyphenols, proteins, vegetables, pulses, fibres and nuts, and low in glycemic carbohydrates, for six continuous weeks.
62388142|NCT02519127|EXPERIMENTAL|Western diet|Subjects will be following a western diet, typically high in saturated fat, refined sugars and salt, and low in fruit and vegetables and fibers, for six continuous weeks.
62560018|NCT02763046|EXPERIMENTAL|Secukinumab - early NSAID tapering|"Placebo at weeks 0, 1, 2, 3 to maintain the blind; followed by induction with secukinumab 150 mg s.c. once per week (Week 4, 5, 6, 7, 8) and maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 12, 16 and 20), with intermittent placebo injections at Week 17, 18 and 19 to maintain the blind.~NSAID tapering allowed from Week 4 (early tapering)."
62560019|NCT02763046|PLACEBO_COMPARATOR|Placebo|"Placebo s.c. at Week 0, 1, 2, 3, 4, 5, 6, 7, 8 and 12. After the Week 16 assessments of the secondary endpoint had been performed, these patients received weekly doses of secukinumab 150 mg s.c. (Week 16, 17, 18, 19 and 20).~NSAID tapering allowed from Week 4."
62560020|NCT04504968|EXPERIMENTAL|Intervention group|Multimodal intervention:
62560021|NCT04504968|PLACEBO_COMPARATOR|Usual care group|Usual care group
62560022|NCT03359850|EXPERIMENTAL|Normal hepatic function (Group 1):|To evaluate the pharmocokinetics and safety of niraparib
62560023|NCT03359850|EXPERIMENTAL|Moderate hepatic impairment (Group 2):|To evaluate the pharmocokinetics and safety of niraparib
62560024|NCT06468592|EXPERIMENTAL|Tilted implants|The tilted implants are inserted palatally into the maxillary sinus
62560025|NCT06468592|ACTIVE_COMPARATOR|Straight implants|The implants inserted into the maxillary sinus in an axial direction
62560026|NCT03173209|OTHER|school professional development|Professional development in Calm Moments Cards program. Occupational therapists used lecture and coaching to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
62768327|NCT00262847|ACTIVE_COMPARATOR|Arm I (placebo, paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Beginning in course 2, patients also receive placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive placebo alone IV over 30-90 minutes on day 1. Treatment with placebo repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
61992876|NCT05369858|EXPERIMENTAL|[14C] SKLB1028|Eligible healthy male subjects received a single oral 150 mg (radioactivity of 120µCi) dose of \[14C\] SKLB1028
62168280|NCT00317135|EXPERIMENTAL|Hib-MenAC Lot 1 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 1 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
62560027|NCT01506505|EXPERIMENTAL|Polypill in the morning|Cardiovascular agents in a polypill used from 05.00-11.00 in the morning (acetylsalicylic acid 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg)
62768328|NCT00262847|EXPERIMENTAL|Arm II (placebo, paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel and carboplatin as in arm I. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive placebo alone IV over 30-90 minutes on day 1. Treatment with placebo repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
62388143|NCT06085404|OTHER|Interventional|
62388144|NCT03602209|EXPERIMENTAL|4 weeks of treatment|
62388145|NCT03602209|ACTIVE_COMPARATOR|6 weeks of treatment|
62388146|NCT03220594||Hypogastric artery ligation (HAL)|Patients who underwent only hypogastric artery ligation performed during the delivery of their babies. Six months after the operation they will evaluated for their ovarian reserve via hormones and astral follicle count (AFC)
62388147|NCT03220594||HAL and hysterectomy|Patients who underwent both hypogastric artery ligation and hysterectomy performed during the delivery of their babies. Six months after the operation they will evaluated for their ovarian reserve via hormones and astral follicle count (AFC)
61992877|NCT04820790|EXPERIMENTAL|Experimental Group 1|The efficiency of the mobile app in the follow-up of patients with home oxygen will be evaluated during 3 months
61992878|NCT04820790|NO_INTERVENTION|Intervention Group 2:|Regular monitoring of the home oxygen without mobile app during 3 months
61992879|NCT03468907|EXPERIMENTAL|Early cessation|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. Antiviral therapy was discontinued in intrapartum.
62168281|NCT00317135|EXPERIMENTAL|Hib-MenAC Lot 2 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 2 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
62388148|NCT03220594||Postpartum|Postpartum control group constituted of patients delivered baby without any complication and evaluated 6 months later.
62388149|NCT01365104|EXPERIMENTAL|Healthy young|Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.
62388150|NCT01365104|EXPERIMENTAL|healthy old|Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.
62388151|NCT02424708|PLACEBO_COMPARATOR|Placebo|The study medication is packaged in sterile 1 ml pre-filled syringes, containing saline, which will be delivered intranasally.
62388152|NCT02424708|ACTIVE_COMPARATOR|Reduced Glutathione 100mg|The study medication is packaged in sterile 1 ml pre-filled syringes, containing 100 mg/ml of reduced glutathione (GSH), which will be delivered intranasally.
62388153|NCT02424708|ACTIVE_COMPARATOR|Reduced Glutathione 200mg|The study medication is packaged in sterile 1 ml pre-filled syringes, containing 200 mg/ml of reduced glutathione (GSH), which will be delivered intranasally.
62388154|NCT00298766|EXPERIMENTAL|1|VELCADE
62388155|NCT03334682|EXPERIMENTAL|spironolactone|Spironolactone ARROW ® 75 mg, 150mg, orally, once a day during all the trial (12 months: 6 months on double-blinded spironolactone then 6 months on open-label spironolactone), + topical therapy during all the trial (benzoyl peroxide 5%)
62388156|NCT03334682|ACTIVE_COMPARATOR|doxycycline|(Doxycycline Sandoz 100 mg), 100mg/day during 3 months followed by placebo during 3 months, on double-blinded + topical therapy during all the trial (benzoyl peroxide 5%
62388157|NCT02899026|EXPERIMENTAL|Part A: Sirukumab 100 mg SC + prednisone (6-week taper)|Eligible subjects will receive blinded Sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) for 52 weeks plus a 6-week oral prednisone taper regimen
62388158|NCT02899026|EXPERIMENTAL|Part A: Sirukumab 50 mg SC + prednisone (6-week taper)|Eligible subjects will receive blinded Sirukumab 50 mg SC q4w (with placebo SC injections q2w between sirukumab injections) for 52 weeks plus a 6-week oral prednisone taper regimen
62388159|NCT02899026|PLACEBO_COMPARATOR|Part A: Placebo SC + prednisone (52 week taper)|Eligible subjects will receive blinded placebo SC q2w for 52 weeks plus a blinded 52-week oral prednisone taper
62388160|NCT00600639|EXPERIMENTAL|1|non-invasive ventilation with BiPAP Vision or another ICU ventilator with NIV option
62388161|NCT00600639|ACTIVE_COMPARATOR|2|standard therapy + oxygen
62388162|NCT03490123|EXPERIMENTAL|Intervention|"Repeated total community treatment, TCT with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single dose every 6 months, for 12 months (3 doses).~Study interventions are:~R1-Total community treatment with azithromycin, R2-Total community treatment with azithromycin, R3-Total community treatment with azithromycin."
62388163|NCT03490123|ACTIVE_COMPARATOR|Control|"Single total community treatment, TCT, with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single, at month 0 (1 dose); followed by two total targeted treatment, TTT, with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single, at months 6 and 12.~Study interventions are:~R1-Total community treatment with azithromycin, R2-Total targeted treatment with azithromycin, R3-Total targeted treatment with azithromycin."
62560028|NCT01506505|EXPERIMENTAL|Polypill in the evening|Cardiovascular agents in a polypill used from 18.00-00.00 in the evening (acetylsalicylic acid 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg)
62768329|NCT00262847|EXPERIMENTAL|Arm III (paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel and carboplatin as in arm I. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive bevacizumab alone IV over 30-90 minutes on day 1. Treatment with bevacizumab repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
62768330|NCT05236712|EXPERIMENTAL|Mobile health|Participants will receive access to a mobile app installed on their device and will be asked to use the app at least once a week
62768331|NCT05236712|NO_INTERVENTION|Usual care|Participants will receive information on public online resources
62768332|NCT02204852|EXPERIMENTAL|Iloprost+eptifibatide|Co-administration of 1 ng/kg/min Ilomedin® and 0.5 µg/kg/min Integrilin® as 48h continuous i.v infusions
62768333|NCT02204852|PLACEBO_COMPARATOR|Saline|Double dummy 0.9% saline as 48h continuous i.v infusion
62768334|NCT00803972|EXPERIMENTAL|Stage 1: 3 U insulin plus rHuPH20|Participants will receive 3 Units (U) of regular insulin (100 U/milliliter \[mL\]), coadministered with sequential concentrations of 0, 1.25, 5, 10, 20, and 80 micrograms (μg)/mL recombinant human hyaluronidase (rHuPH20).
62768335|NCT00803972|EXPERIMENTAL|Stage 1: 12 U insulin plus rHuPH20|Participants will receive 12 U of regular insulin (100 U/mL), coadministered with sequential concentrations of 0, 1.25, 5, 10, 20, and 80 μg/mL rHuPH20.
62768336|NCT00803972|EXPERIMENTAL|Stage 2: insulin plus rHuPH20|Participants will receive 6, 12, and 24 U regular insulin (100 U/mL) in a randomly assigned order, with each insulin dose administered once with and once without 5 μg/mL rHuPH20.
62768337|NCT00803972|EXPERIMENTAL|Stage 3: 1.5 U insulin lispro plus rHuPH20|Participants will receive 1.5 U of insulin lispro (50 U/mL), coadministered with sequential concentrations of 0, 0.0625, 0.3125, 1.25, 5, and 20 μg/mL rHuPH20.
62768338|NCT00803972|EXPERIMENTAL|Stage 3: 6 U insulin lispro plus rHuPH20|Participants will receive 6 U of insulin lispro (50 U/mL), coadministered with sequential concentrations of 0, 0.0625, 0.3125, 1.25, 5, and 20 μg/mL rHuPH20.
62560029|NCT01506505|ACTIVE_COMPARATOR|Individual agents of the polypill)|"Cardiovascular agents in as acetylsalicylic acid 75 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg used 05.00-11.00 in the morning.~Simvastatin 40 mg used 18.00-00.00 in the evening."
62388164|NCT01562327||Tocilizumab|Participants with moderate to severe rheumatoid arthritis (RA) received Tocilizumab according to individualized physician-prescribed regimens.
62560030|NCT03648099|EXPERIMENTAL|Labor Dance and music groups|"1. Labor Dance; The pregnant women performed labor dance when the cervical dilatation reached 4-5 cm. The dance was performed in the company of music played through headphones.~2. The pregnant women listened to music for 30 minutes when the cervical dilatation reached 4-5 cm. They took any position they wanted while listening to music."
62560031|NCT03648099|NO_INTERVENTION|Control group|The control group: No intervention was made to relieve the labor pain and reduce the fear of childbirth in the control group of the study. They were administered routine hospital applications.
62560032|NCT00289848|EXPERIMENTAL|1|sitagliptin 100 mg
62388165|NCT00784316|ACTIVE_COMPARATOR|metoprolol|
62388166|NCT00784316|ACTIVE_COMPARATOR|amiodarone|
62560033|NCT00289848|PLACEBO_COMPARATOR|2|placebo
62560034|NCT05081037|EXPERIMENTAL|Wearable Care Group|This group will receive both a continous glucose monitoring sensor and an exercise tracker to be worn for at least 2 weeks at each study visit timepoint.
62560035|NCT05081037|NO_INTERVENTION|Scheduled Care Group|This group will receive standard medical care with dietary and nutritional advice alone.
62560036|NCT01432067|OTHER|Adaptated physical activity|Physical activity advices adaptated to physical status of patients
62560037|NCT01432067|OTHER|Standard physical activity|Daily physical activities based on a standard guide
62560038|NCT04857528||Retrospective (Participants Who Have Already Been Treated for HPV-Related Cancer Before Study)|This group will use medical records from participants who have already received chemoradiation for their HPV-related anal or cervical cancer at a time before this study started. Because they have already received treatment, these participants will provide previous blood/tumor tissue samples that contain detectable HPV DNA as well as at least one post-treatment sample that their doctor collected before the study. Data from these previously collected samples will be compared to current samples from participants who are actively enrolled in this study in present day (chart review).
62388167|NCT01227694|EXPERIMENTAL|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias Avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
61992880|NCT03468907|EXPERIMENTAL|Late cessation|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. After delivery, mothers ceased antiviral treatment at postpartum 6 weeks.
61992881|NCT03468907|NO_INTERVENTION|Control|Eligible patients who refused antiviral therapy but consented to the study were assigned to the control arm.
61992882|NCT05128175|EXPERIMENTAL|25 mg /100 mg treatment A group|Treatment A: carbidopa/levodopa (25 mg /100 mg)
61992883|NCT05128175|EXPERIMENTAL|25 mg /150 mg treatment B group|Treatment B: carbidopa/levodopa (25 mg/150mg)
61992884|NCT05128175|EXPERIMENTAL|25 mg /150 mg treatment C group|Treatment C: carbidopa/levodopa (25 mg /150 mg)
62560039|NCT04857528||Prospective (Participants Who Will Receive Radiation Treatment for HPV-Related Cancer During Study)|This group is for participants who plan to receive radiation treatment (with or without chemotherapy) for their HPV-related anal or cervical cancer during the time this study will be conducted. Participants in this group will sign a consent form allowing researchers to collect their blood samples and analyze/compare them to the samples from the retrospective group of participants.
62560040|NCT05486039||Normal Posture|
62768339|NCT00803972|EXPERIMENTAL|Stage 4: 95 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 95 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
61992885|NCT05128175|EXPERIMENTAL|25 mg /150 mg treatment D group|Treatment D: carbidopa/levodopa (25 mg /150 mg)
61992886|NCT05128175|PLACEBO_COMPARATOR|25 mg /100 mg placebo group|Treatment E(Reference): Carbidopa and Levodopa tablets (a generic version of Sinemet® IR) 25 mg/100 mg
61992887|NCT00624962|OTHER|Correlative/Supportive Care|
61992888|NCT02529137||Surgical pathology cases|Cases will be selected from the sites Laboratory Information Systems using the in- and exclusion criteria.
61992889|NCT03510117|OTHER|Mindfulness|Mindfulness
61992890|NCT01867593|EXPERIMENTAL|C-11 methionine PET|C-11 methionine PET pre and post radiation
62560041|NCT05486039||Lordotic Posture|
61992891|NCT00783029||Healthy Subjects|Healthy participants between the ages of 21 and 65 years old.
61992892|NCT03606954|ACTIVE_COMPARATOR|Combination topical corticosteroid|"The combination topical corticosteroid will be applied to specific and marked sites on the forearms (on the flexor side of the forearm- 5\*5 cm with a distance of 3 cm) - two sites on both forearms of every subject (4 sites in total). The nature of this application method will enable the measurement of the level of potency of each drug, in a manner that is comparative, neutralizing thus the influence of inter-subject variability.~The drugs will be topically applied (50 microliter on each site) for 16 hours, utilizing an occlusive dressing bandage such as Tegaderm. The vasoconstriction test will be preformed both before and after drug application. The vasoconstriction in each subject will be graded on the Olsen scale"
62388168|NCT04948840|OTHER|Group A|Patients with early grade ≥2 radio-induced epidermis Intervention : blood sample
62560042|NCT05486039||Sway Back Posture|
62560043|NCT05486039||Hypolordotic Back Posture|
61992893|NCT03606954|ACTIVE_COMPARATOR|Non-combination topical corticosteroid|"The non-combination topical corticosteroid will be applied to specific and marked sites on the forearms (on the flexor side of the forearm- 5\*5 cm with a distance of 3 cm) - two sites on both forearms of every subject (4 sites in total). The nature of this application method will enable the measurement of the level of potency of each drug, in a manner that is comparative, neutralizing thus the influence of inter-subject variability.~The drugs will be topically applied (50 microliter on each site) for 16 hours, utilizing an occlusive dressing bandage such as Tegaderm. The vasoconstriction test will be preformed both before and after drug application. The vasoconstriction in each subject will be graded on the Olsen scale"
61992894|NCT00641095|EXPERIMENTAL|Fludarabine/Cyclophosphamide/Rituximab|"Fludarabine 40mgs/m2 oral days 1-3 Cyclophosphamide 250mgs/m2 oral days 1-3 Rituximab 375mgs/m2 day 1 iv infusion~Every 28 days"
62560044|NCT05486039||Head Anterior Tilt Posture|
62560045|NCT05486039||Scoliotic Posture|
62560046|NCT05486039||Kyphotic Posture|
62560047|NCT03875508|EXPERIMENTAL|Risankizumab|Risankizumab solution (150 mg/mL) for injection; self-administered subcutaneously via a pre-filled autoinjector at Weeks 0, 4, 16, and 28
62768340|NCT00803972|EXPERIMENTAL|Stage 4: 50 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 50 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
62768341|NCT00803972|EXPERIMENTAL|Stage 4: 25 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 25 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
62768342|NCT05059964|EXPERIMENTAL|Circuit Training program|circuit training for 4 weeks
61992895|NCT00641095|ACTIVE_COMPARATOR|Fludarabine/Cyclophosphamide|"Fludarabine 40mgs/m2 oral days 1-3 Cyclophosphamide 250mgs/m2 oral days 1-3~Every 28 days"
61992896|NCT00959842|EXPERIMENTAL|Lovaza|Lovaza was given as the only agent; there was no comparator agent or arm
62388169|NCT04948840|OTHER|Group B|Patients with early grade 0-1 radiation-induced epidermis Intervention : blood sample
61992897|NCT02117375|EXPERIMENTAL|Patients with multiple sclerosis|80 patients / clinical Follow-up at M0, M6, M12, M18, M24, M30, M36, M42, M48, M54 and M60 / spinal cord MRI follow-up at M0, M12, M24, M36 and M60 / brain MRI follow-up at M0, M12, M24, M36 and M60
62388170|NCT04948840|NO_INTERVENTION|Group C|Patients with late pathologic radio-induced fibrosis (more than 6 months after the end of radiotherapy), grade CTCAE v4.0 ≥ 3 No intervention : Blood sample already collected from another study and patients agree to use their blood sample for another research
62388171|NCT04948840|NO_INTERVENTION|Group D|Patients without late pathologic radio-induced fibrosis of grade CTCAE v4.0 ≤ 1 (follow-up after RT ≥4 years) No intervention : Blood sample already collected from another study and patients agree to use their blood sample for another research
62388172|NCT04948840|NO_INTERVENTION|Group E|Control group : patients over 18 who have given their consent to the Blood Establishment for the use of their samples for research purposes.
62388173|NCT06106399|ACTIVE_COMPARATOR|WALLANT (group 1)|wide awake local anesthesia and no tourniquet (WALLANT)
62388174|NCT06106399|ACTIVE_COMPARATOR|CPB (group 2)|clavipectoral fascia plane block combined with superficial cervical plexus block (CPB)
62388175|NCT01371721|EXPERIMENTAL|Desvenlafaxine Succinate Sustained-Release|
62388176|NCT03655951|EXPERIMENTAL|Resource 1|Web-based resource on adolescent sexual health
62388177|NCT03655951|ACTIVE_COMPARATOR|Resource 2|Alternate web-based resource on adolescent sexual health
62388178|NCT04335227|EXPERIMENTAL|Yoga therapy group|Structured yoga therapy program for 60 minutes six days per week for 12 weeks and nutritional management uniquely prepared by dietitian
62388179|NCT04335227|EXPERIMENTAL|Aerobic exercise group|Aerobic training of moderate intensity for 30-60 minutes six days per week for 12 weeks and nutritional management uniquely prepared by dietitian
62388180|NCT04335227|EXPERIMENTAL|Combined yoga therapy and aerobic exercise group|Combined yoga therapy for three days and vigorous aerobic exercise program for three days with nutritional management uniquely prepared by dietitian
62388181|NCT04335227|ACTIVE_COMPARATOR|Control group|Nutritional management uniquely prepared by dietitian
62388182|NCT04622878|OTHER|acute lower limb ischemia patients|patients with no palpable pulsations or audible signals in the lower limb
62388183|NCT05321264|EXPERIMENTAL|Intervention|The intervention is defined as educational support (improving the knowledge of the disease, identification of risks and consequences), behavioral support (promoting skills related to personal, home, and environmental self-care) and attitudinal support (reflecting on benefits and risks).
62388184|NCT05321264|NO_INTERVENTION|Control|Control group will receive the usual strategy of a health service provider institution.
62388185|NCT04846634|EXPERIMENTAL|neoadjuvant Penpulimab + chemotherapy followed by adjuvant Penpulimab|
62560048|NCT03104192|ACTIVE_COMPARATOR|Develop & Refine MOWI w/o Amulet (2A)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults without the use of Amulet technology.
62388186|NCT04846634|EXPERIMENTAL|neoadjuvant Penpulimab + chemotherapy + Anlotinib followed by adjuvant Penpulimab + Anlotinib.|
62388187|NCT04846634|EXPERIMENTAL|neoadjuvant Penpulimab + Anlotinib followed by adjuvant Penpulimab + Anlotinib.|
61992898|NCT02117375|EXPERIMENTAL|Healthy volunteers|20 healthy volunteers (stability of spinal cord imaging) / spinal cord MRI follow-up at M0 and M24
62388188|NCT04843527|ACTIVE_COMPARATOR|FreeStyle Libre|Subjects will be randomized to use the FreeStyle Libre Flash Glucose Monitoring System to manage their diabetes.
62388189|NCT04843527|ACTIVE_COMPARATOR|FreeStyle Libre plus food logging|Subjects will be randomized to use the FreeStyle Libre Flash Glucose Monitoring System and a food logging smartphone application to manage their diabetes.
62388190|NCT00980850|EXPERIMENTAL|Groups A1 and A2|Baxter vaccine
62388191|NCT00980850|EXPERIMENTAL|Groups B1 and B2|GSK vaccine
62388192|NCT03140150|EXPERIMENTAL|Active Group|A single visit 1 to 3 months after implantation then followed by the attending cardiologist.
62388193|NCT03140150|OTHER|Control Group|A first visit 1 to 3 months after implantation and then every 6 months or every year according to the recommendations of pacemaker follow-up (ie 2 or 4 systematic visits during the follow-up of 2 years).
62388194|NCT01547494|PLACEBO_COMPARATOR|Dietary Supplement|
62388195|NCT01547494|EXPERIMENTAL|Vegan Diet|
62560049|NCT03104192|EXPERIMENTAL|MOWI Weight Loss Maintenance|Evaluate the feasibility, acceptability, and potential effectiveness of an 8-session, tri-weekly, psychosocial skills group intervention to support weight loss maintenance post-MOWI.
62560050|NCT03104192|ACTIVE_COMPARATOR|Develop & Refine MOWI w Fitbit (2B)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults with the use of Fitbit technology.
61992899|NCT02869594||Patients with prostate cancer diagnosis|
61992900|NCT00962104|EXPERIMENTAL|Atomoxetine|
62388196|NCT05852964||Control|Healthy 13 female 14 male subjects
62388197|NCT05852964||Transplantation Patients|10 female, 17 male subjects
62388198|NCT01372020|SHAM_COMPARATOR|control group|
62388199|NCT01372020|EXPERIMENTAL|neuromuscular electrical therapy|
62388200|NCT03958149|OTHER|Spinal collar|Participants will undergo MRI scans in and out a spinal collar to assess whether the measurements of angulation of the C-spine change whilst wearing a spinal collar.
62388201|NCT01734967|EXPERIMENTAL|needle based CLE & EUS-FNA|The study will prospectively include patients referred to our department for EUS and EUS-FNA of suspected pancreatic masses during a 12 months period. The indication for this investigation will be based on the patient's clinical history and previous imaging studies (abdominal ultrasound, CT scan, MRI).
62388202|NCT01466972|EXPERIMENTAL|Pazopanib in combination with a NSAI|Non-randomized, open label
62388203|NCT01688362|EXPERIMENTAL|platelet-rich plasma protein (PRP)|Subjects in this group will receive 2 injections with PRP. Each injection separated by two weeks.
62388204|NCT01688362|ACTIVE_COMPARATOR|Corticosteroid|Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later.
62388205|NCT00350610|ACTIVE_COMPARATOR|1|Standard treatment as usual (TAU) in a community based clinic consisting of individual and group therapy sessions and regular urine monitoring.
62560051|NCT03104192|ACTIVE_COMPARATOR|Develop & Refine MOWI w Fitbit/Protein (2P)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults with the use of Fitbit technology augmented by whey protein.
62768343|NCT05059964|ACTIVE_COMPARATOR|Continuous aerobic exercise Group|aerobic exercise for 4 weeks
62768344|NCT05620953||SARI case|
62768345|NCT02915185|EXPERIMENTAL|strength training intervention|Strength training of the affected upper limb in chronic stroke survivors
62768346|NCT02915185|EXPERIMENTAL|direct-current brain stimulation (tDCS)|tDCS real of sham will be applied during each session of the strength training intervention
62768347|NCT04438460|EXPERIMENTAL|Patient group|150 children aged 1 month to 12 years with multi-visceral failure syndrome within 48 hours of hospitalization in pediatric resuscitation will be included in this study
62768348|NCT04438460|OTHER|Control group|60 children aged 1 month to 12 years hospitalized for simple elective surgery will be included in this study
62768349|NCT02539511|EXPERIMENTAL|CI-581a+MET|Administration of CI-581a during wk 2 at 0.71 mg/kg in the context of a 5 wk course of MET
62768350|NCT02539511|ACTIVE_COMPARATOR|CI-581b+MET|Administration of CI-581b during wk 2 at 0.025 mg/kg in the context of a 5 wk course of MET
62768351|NCT02074813|NO_INTERVENTION|Standard|conventional pulmonary rehabilitation
62768352|NCT02074813|EXPERIMENTAL|Inspiratory muscle training|Inspiratory muscle training associated with a conventional pulmonary rehabilitation
62388206|NCT00350610|EXPERIMENTAL|2|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping cocaine use and increasing coping skills twice weekly for 8 weeks.
62768353|NCT06198855||Hypertension Diagnosis|Subject need 24-h BP monitor for hypertension diagnosis
62768354|NCT06198855||hypertension control evaluation|Patients need 24-h BP monitor for assessment hypertension control
62388207|NCT01493024|PLACEBO_COMPARATOR|Placebo|Placebo (silicified microcrystalline cellulose) randomized to mimic escalating doses of experimental drug administered three times daily (TID) with meals.
62388208|NCT01493024|EXPERIMENTAL|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated, microporous zirconium silicate, an oral sorbent) administered 3 times daily (tid) with meals.
62388209|NCT01945229||Hyperthyroid patients|Patients with hyperthyroidism admitted for treatment with radioiodine or antithyroid drugs
62768355|NCT00832052|EXPERIMENTAL|Cohort 1|Subjects will be randomized to receive either experimental drug (n=6) or placebo (n=2).
62768356|NCT00832052|EXPERIMENTAL|Cohort 2|Subjects will be randomized to receive either experimental drug (n=6) or placebo (n=2).
62768357|NCT00832052|EXPERIMENTAL|Cohort 3a|Subjects will be randomized to receive either experimental drug (n=3) or placebo (n=1).
62768358|NCT00832052|EXPERIMENTAL|Cohort 3b|Subjects will be randomized to receive either experimental drug (n=3) or placebo (n=1).
62768359|NCT00832052|EXPERIMENTAL|Cohort 4|
62768360|NCT02067494|EXPERIMENTAL|Myofascial Soft Tissue Release|"* Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.~* Myofascial release assisted the paravertebral fascia."
62388210|NCT04920305|EXPERIMENTAL|Phosphatidylserine group|subjects in the treatment group oral the PS (600mg/d, q.d.) for 6 months.
62560052|NCT05878275|NO_INTERVENTION|Usual Care Group Receiving an Informational Tummy Time Brochure|Usual care group will receive a brochure on the importance of tummy time and limiting baby gear.
62768361|NCT02067494|ACTIVE_COMPARATOR|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
62768362|NCT00882739|OTHER|no pre-treatment|No pre-treatment at first medical contact - Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
62768363|NCT00882739|EXPERIMENTAL|600 mg loading dose|600 mg clopidogrel loading dose at first medical contact
62768364|NCT00882739|EXPERIMENTAL|900 mg loading dose|900 mg clopidogrel loading dose at first medical contact
62388211|NCT04920305|PLACEBO_COMPARATOR|Bean powder group|Subjects in the control group were given a placebo, which was the same shape of bean powder(600mg/d, q.d.) for 6 months.
62768365|NCT05160818|ACTIVE_COMPARATOR|Arm A: HSFRT|Hypofractionated stereotactic radiotherapy to the resection cavity, dose prescription: 6-7 x 5 Gy
62768366|NCT05160818|ACTIVE_COMPARATOR|Arm B: SRS|Single fraction stereotactic radiotherapy to the resection cavity, dose prescription: 1 x 12-20 Gy
62768367|NCT02380898|EXPERIMENTAL|Ketorolac|
62768368|NCT02380898|PLACEBO_COMPARATOR|Normal saline 0.9%|
61992901|NCT00962104|PLACEBO_COMPARATOR|Placebo|
62768369|NCT05996029|EXPERIMENTAL|Intervention group|"Intensive intervention package Quit with Love (1 month)~1. Cognitive-behavioral (CBT) smoking cessation intervention~2. ACT cessation intervention with positive thinking~3. Online group smoking cessation intervention through live streaming~Quit Assistant intelligent support platform (3 months)~1. Quit smoking punch card toolkit~2. Machine learning algorithm-driven cessation assistance practice service"
62768370|NCT05996029|NO_INTERVENTION|control group|Reduced functionality of the Love Quit applet Only a simple smoking punch card support function, mainly used to assist subjects to quit smoking on their own and collect follow-up information
62768371|NCT01950091|EXPERIMENTAL|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
62768372|NCT01950091|ACTIVE_COMPARATOR|Alternative website control|Intervention is a Menu of links to 4 popular Websites offering back pain education
62768373|NCT01950091|NO_INTERVENTION|Usual care control group|No contact; Control group
62768374|NCT01885910|EXPERIMENTAL|doxy + aczone|Subjects will start treatment with doxycycline 100mg once daily and Aczone 5% gel applied to the face twice daily and those who improve significantly are continued on Aczone gel alone to see if it can maintain therapeutic response
62768375|NCT01905969||Biomarker positive|NF-kB(+)/JNK(-) in curatively removed specimens
62768376|NCT01905969||Biomarker negative|NF-kB(-)/JNK(+) in curatively removed specimens
62768377|NCT01399008|EXPERIMENTAL|Arhalofenate 400 mg|Arhalofenate 400 mg plus allopurinol 300 mg
62768378|NCT01399008|EXPERIMENTAL|Arhalofenate 600 mg|Arhalofenate 600 mg plus allopurinol 300 mg
62768379|NCT01399008|ACTIVE_COMPARATOR|Allopurinol|Placebo plus Allopurinol 300 mg
62768380|NCT03400631|EXPERIMENTAL|Dextrose 0. Aspiration 1 week.|Dextrose injection given at time 0, at 1 week aspiration only, and then open label injection of dextrose at 0, 1, 2, 3, 4, 5, and 6 months.
62768381|NCT03400631|EXPERIMENTAL|Aspiration 0. Dextrose 1 week.|Aspiration only at time 0. Dextrose injection given at 1 week, and then open label injection of dextrose at 0, 1, 2, 3, 4, 5, and 6 months.
61992902|NCT01251380|EXPERIMENTAL|Dysport|Dysport was injected into either one or both lower limbs in up to 4 cycles of treatment, a minimum of 12 weeks apart and up to a maximum of 40 weeks apart. Doses varied from 5 Units (U)/Kg to 20 U/kg for one leg, or from 10 U/Kg to 30 U/kg for two legs, with a maximum dose of no more than 30 U/Kg overall, or 1000 U, whichever was reached first.
62388212|NCT00495794|EXPERIMENTAL|Pharmacist management|Eligible patients assigned to - adherence counseling and medication management delivered by a clinical pharmacist trained in behavioral counseling approaches (motivational interviewing)
62388213|NCT00495794|NO_INTERVENTION|Usual care|Eligible patients receive usual care
62768382|NCT03147794|EXPERIMENTAL|FES using MyndMove Technology|This is the only arm of the study. Participants will be provided with the FES intervention as part of the protocol.
62768383|NCT04753021|EXPERIMENTAL|Exercise|Progressive exercise training
62768384|NCT04795700|EXPERIMENTAL|The intervention group|Patients in the intervention group receiving the 8 weeks MSC intervention sessions.
62768385|NCT04795700|NO_INTERVENTION|The control group|No interventions except conventional care were performed for the control group.
62768386|NCT05330858|EXPERIMENTAL|ESK-001 Liquid|ESK-001 administered as an oral liquid
62768387|NCT05330858|EXPERIMENTAL|ESK-001 Tablet Fasted|ESK-001 administered as an oral tablet in the fasted state
62768388|NCT05330858|EXPERIMENTAL|ESK-001 Tablet Fed|ESK-001 administered as an oral tablet in the fed state
62768389|NCT05330858|EXPERIMENTAL|ESK-001 and Rabeprazole|ESK-001 administered as an oral tablet with rabeprazole
62768390|NCT01719003|EXPERIMENTAL|Empagliflozin low dose qd|Empagliflozin low dose once daily
62768391|NCT01719003|EXPERIMENTAL|Empagliflozin high dose qd|Empagliflozin high dose once daily
62768392|NCT01719003|EXPERIMENTAL|OL empa high dose + met 1000 mg bid|Open label empagliflozin high dose split twice daily + metformin 1000 mg twice daily - Patients are no longer enrolled into this arm because of change in the inclusion criteria in protocol version 2.0 all patients are now enrolled into remaining double-blind arms. Patients already enrolled in the open-label arm according to protocol version 1.0 can complete the study.
62768393|NCT01719003|EXPERIMENTAL|Empagliflozin low dose + met 500 mg bid|Empagliflozin low dose split twice daily + metformin 500 mg twice daily
62768394|NCT01719003|EXPERIMENTAL|Empagliflozin low dose + met 1000 mg bid|Empagliflozin low dose split twice daily + metformin 1000 mg twice daily
62768395|NCT01719003|EXPERIMENTAL|Empagliflozin high dose + met 500 mg bid|Empagliflozin high dose split twice daily + metformin 500 mg twice daily
62768396|NCT01719003|EXPERIMENTAL|Empagliflozin high dose + met 1000mg bid|Empagliflozin high dose split twice daily + metformin 1000 mg twice daily
61992903|NCT02641379|EXPERIMENTAL|PEG-IFN 24 weeks|Participants will receive PEG-IFN (180 microgram \[mcg\]), subcutaneously (sc), once weekly for 24 weeks and Ribavirin 1000-1200 milligram per day (mg/day) (\<75 kilogram (kg); \>75 kg) for 24 weeks.
61992904|NCT02641379|EXPERIMENTAL|PEG-IFN 24/72 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (\<75kg; \>75 kg) till week 24; if patient is still HCV RNA positive. Treatment will be stopped if participant is HCV RNA negative at week 24 -treatment with PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (\<75kg; \>75 kg) till week 72
61992905|NCT02641379|EXPERIMENTAL|PEG-IFN 48 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly for 48 weeks and Ribavirin 1000-1200 mg/day (\<75kg; \>75 kg) for 48 weeks.
62768397|NCT01719003|EXPERIMENTAL|Metformin 500 mg bid|Metformin 500 mg twice daily
62768398|NCT01719003|EXPERIMENTAL|Metformin 1000 mg bid|Metformin 1000 mg twice daily
62768399|NCT00384982|EXPERIMENTAL|A, B, C, D|Early or late; percutaneous intracoronary or combined (intramyocardial and intracoronary) administration of BM-MNCs
62768400|NCT01739543|EXPERIMENTAL|Investigational|Subject receives Hem-Avert Device.
62768401|NCT01739543|NO_INTERVENTION|Control|Subject does not receive Hem-Avert Device.
62768402|NCT03155308||Polyp group|Consecutive adult patients between 18 and 80 years of age, referred for elective outpatient colonoscopy and in whom polypectomy or biopsy is perform will be enrolled to be evaluated using Pentax chromoendoscopy (i-scan and Optical Enhancement)
62768403|NCT04294914|ACTIVE_COMPARATOR|Fibromyalgia|Individuals with fibromyalgia.
62768404|NCT04294914|EXPERIMENTAL|Healthy controls|Healthy, pain-free individuals
62768405|NCT03527719|EXPERIMENTAL|Experimental Group|Village-doctor-led multifaceted intervention
62768406|NCT03527719|NO_INTERVENTION|Control Group|Village doctors in usual care group will not receive hypertension management training or support. However, they will be trained in standardized BP measurement. Participants in control group will receive their usual care from village doctors or primary care physicians in township hospitals
62768407|NCT02499692|EXPERIMENTAL|SYNERGYTM Coronary Stent System|Device:SYNERGY MONORAIL Everolimus-Eluting Platinum Chromium Coronary Stent System
62768408|NCT05485883|EXPERIMENTAL|Advanced Renal Cell|Patients will receive treatment with Tislelizumab every 3 weeks,and take Lenvatinib 8mg every day
62768409|NCT02258529|EXPERIMENTAL|Idelalisib + rituximab|Idelalisib + rituximab for up to 104 weeks
62388214|NCT02241460|ACTIVE_COMPARATOR|Promescent Lidocaine Spray|Double-Blind Treatment Period: 3 cycles (3 weeks each); 1 week wash-out between each cycle Open-Label Treatment Period: 4 cycles (1 week each); no wash-out
62388215|NCT02241460|PLACEBO_COMPARATOR|Placebo|Double-Blind Treatment Period: 3 cycles (3 weeks each); 1 week wash-out between each cycle Open-Label Treatment Period: 4 cycles (1 week each); no wash-out
62388216|NCT04849429|PLACEBO_COMPARATOR|Placebo|Placebo (trigger point injection under C-arm)
62388217|NCT04849429|EXPERIMENTAL|Platelet rich plasma (PRP) with exosomes|PRP with exosomes at the center of the nucleus pulposus (2ml)
62388218|NCT02337075|EXPERIMENTAL|Now Group - PATH Program|The Now Group will receive the PATH program. They will participate in a brief education session, use a wearable physical activity tracker, and physical activity mentoring by an Activity Mentors. In Month 1 and 2, participants will meet with their Activity Mentor once every 2 weeks to review their physical activity status, activity goals, and the health programs available at the Centre. In Month 3 and 4, they will continue to use physical activity tracker but will no longer have regular meetings with the Activity Mentor.
62388219|NCT02337075|ACTIVE_COMPARATOR|Later Group|The Later Group will receive the PATH program in Month 1-2. Intervention will be provided two months later (i.e., Month 3 and 4).
62388220|NCT03104686|ACTIVE_COMPARATOR|Bread|Bread (50g available carbohydrate, 109 g) eaten with 500 mL of water
62768410|NCT01146288|EXPERIMENTAL|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.
62388221|NCT03104686|EXPERIMENTAL|Short pasta (dry)|Cooked penne (142 g; 71 g uncooked) eaten with 500 mL of water
62388222|NCT03104686|EXPERIMENTAL|Long pasta (dry)|Cooked spaghetti (142 g; 71 g uncooked) eaten with 500 mL of water
62560053|NCT05878275|EXPERIMENTAL|Parent Informational Session|Parental education session that includes information and a video on avoiding screen time in the first two years of life, the importance and benefits of infants being exposed to tummy time, varying play positions and limiting time in baby gear. Additional information will be provided on the importance of implementing tummy time during the first month of life as well as different ways to implement tummy time and how to increase infant tolerance to tummy time. Parents in the Parent Informational Session can request a Zoom consultation with the Principal Investigator if the parents have questions or need guidance with implementing tummy time.
62768411|NCT01146288|EXPERIMENTAL|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.
62768412|NCT04845139|EXPERIMENTAL|Nivolumab administration|Nivolumab administration Q2W by intraventricular injection through Ommaya reservoir
62768413|NCT06081192|EXPERIMENTAL|One-piece titanium-zirconium mini implants|Six one-piece titanium-zirconium mini implants (Straumann® Mini Implant System, Institut Straumann AG, Switzerland) in the edentulous maxilla, using a partially-guided insertion protocol.
62768414|NCT06194071||Patients with Traumatic Brain Injury|Patients with all types of TBI will be recruited (mild, moderate and severe). They mus accept participation in the prolonged follow-up (up to 18 months after the accident). Relatives will also accept to participate. Patients will undergo routine care regarding TBI in our institution. Only the prolonged follow-up and monitoring is proposed which combines remote questionnaire completion, and on-site visits at 3 time-points (6, 12 and 18 months). No on-site visit is proposed for relatives who will fill out questionnaires. However, they may accompany patients during on-sites visits.
62768415|NCT04608162|ACTIVE_COMPARATOR|Group I|Group one received PEMF and exercise (PEMF+EX)
62768416|NCT04608162|PLACEBO_COMPARATOR|Group II|Group two received placebo PEMF and exercise (PPEMF+EX)
62768417|NCT04608162|ACTIVE_COMPARATOR|Group III|Group three will be treated by PEMF alone (PEMF)
62768418|NCT04983797|EXPERIMENTAL|OPTRELL Mapping Catheter|Participants diagnosed with cardiac arrhythmias who are scheduled to have a clinically-indicated catheter mapping and ablation procedure of arrhythmia management for Atrial and ventricular procedures will be using multi-electrode OPTRELL mapping catheter.
62768419|NCT02917915|EXPERIMENTAL|New Canadian Standardized PR|"* Education Content: exercise, living well with chronic lung disease, breathing management, conserving energy, pulmonary medications, inhaler devices, integrating exercise in your life, management of respiratory infections, management of aggravating environmental factors, management of stress \& anxiety, nutrition, leisure \& travel, getting a good night's sleep, enjoying intimacy, living in a smoke-free environment, integrating long-term oxygen into your life, keeping a healthy lifestyle.~* Delivery style: During group sessions patients engage in active, participatory-based learning of program content. Workbooks are available. During one-on-one interactions motivational communication style (asking for permission before providing information, using open questions, etc.) is used."
61992906|NCT02641379|EXPERIMENTAL|PEG-IFN 72 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly for 72 weeks and Ribavirin 1000-1200 mg/day (\<75 kg; \> 75 kg) for 72 weeks.
61992907|NCT03471533|EXPERIMENTAL|Ëxperimental|"Consumption during 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.~Two capsules a day will be consumed thirty minutes before breakfast for 84 days."
61992908|NCT03471533|PLACEBO_COMPARATOR|Placebo|Consumption during 84 days of saccharose. Two capsules a day will be consumed thirty minutes before breakfast for 84 days.
61992909|NCT03439371|EXPERIMENTAL|HLA-mismatched micro-transplantation|HLA-mismatched micro-transplantation
62388223|NCT03104686|ACTIVE_COMPARATOR|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
62388224|NCT01284127||Deferiprone|All patients must have MRI evidence of superficial siderosis and be treated with deferiprone according to standard of care guidelines.
62388225|NCT03374228|EXPERIMENTAL|BMS-986205|Single oral dose of BMS-986205 tablet on the morning of Day 1 followed by a 15-minute infusion of \[13C\]BMS-986205 solution for intravenous administration starting 01:45 hours after the oral dose administration
62388226|NCT02638285|EXPERIMENTAL|HCG group|HCG group
62388227|NCT02638285|EXPERIMENTAL|LH group|LH group
62388228|NCT02638285|EXPERIMENTAL|clomiphene citrate|clomiphene citrate
62768420|NCT02917915|ACTIVE_COMPARATOR|Traditional PR|"* Education Content: Exercise, anatomy, pulmonary diseases, healthier breathing, pulmonary medications, pulmonary devices, exercise action plan, allergies \& pulmonary function tests, health and air quality, healthier eating, travel, stress management \& relaxation, tips to remember/summary of content.~* Delivery style: During group sessions, patients engage in passive learning of program content delivered in a lecture-style approach. Patients also receive one-on-one education regarding: dyspnea management/pacing, inhaler technique, exercise maintenance."
62388229|NCT05153252|EXPERIMENTAL|Morning Exercise (AM)|Participants in this group will be prescribed morning aerobic exercise.
62388230|NCT05153252|EXPERIMENTAL|Evening Exercise (PM)|Participants in this group will be prescribed evening aerobic exercise.
62388231|NCT00626327|EXPERIMENTAL|MenACWY-CRM+ MMRV|
62388232|NCT00626327|ACTIVE_COMPARATOR|MMRV|
62560054|NCT01200446|PLACEBO_COMPARATOR|Placebo Docosahexaenoic Acid (DHA)|Eight subjects will take 8 placebo DHA capsules per day for 3 weeks.
62560055|NCT01200446|EXPERIMENTAL|Active Docosahexaenoic Acid (DHA)|Eight subjects will take 8 active DHA capsules per day for 3 weeks.
62560056|NCT01813617||Recent onset polymyositis and dermatomyositis|Patients in this cohort was diagnosed with polymyositis or dermatomyositis during 2003-2010 and was treated with corticosteroids and other immunosuppressive agents according to standard care. They were all diagnosed and treated at the Rheumatology Clinic, Karolinska University Hospital.
62560057|NCT02452606|EXPERIMENTAL|Stalevo®|Participants who are assigned to Stalevo Arm will take Stalevo® at bedtime for 3 month.
62388233|NCT00626327|EXPERIMENTAL|MenACWY-CRM|
62768421|NCT02105545|EXPERIMENTAL|Cancer Treatment Options|Blood samples and, for some patients, buccal (mouth cell) samples will be collected at diagnosis and/or relapse. Solid tumor samples will be collected in the normal course of treatment, from biopsy, blood or other specimens. For blood-based cancers such as leukemia, blood and bone marrow specimens will be collected before treatment begins, on day 29 and possibly at a later time point if relapse occurs.
62768422|NCT05616585|EXPERIMENTAL|Pharmacokinetic|Single Day Intervention of 10 test foods
62768423|NCT05616585|EXPERIMENTAL|Dose Response|Six day, 3 level (zero, medium, high dose) controlled feeding study
62768424|NCT02871089|EXPERIMENTAL|24/7 Closed loop delivery|Unsupervised home use of day and night automated closed-loop insulin delivery system FlorenceM (Medtronic 640G insulin pump, guardian 3 CGM and Android smartphone) of CamAPS FX (Dana insulin pump, Dexcom G6 CGM and App on Android smartphone) until 24 months after diagnosis
62768425|NCT02871089|ACTIVE_COMPARATOR|Multiple Daily Injections|Participants will apply standard insulin therapy using multiple daily injections via insulin pens during the 24 months control period
61992910|NCT03532620|EXPERIMENTAL|pitavastatin|Pitavastatin Calcium + lifestyle modification
61992911|NCT03532620|ACTIVE_COMPARATOR|atorvastatin|Atorvastatin Calcium + lifestyle modification
62560058|NCT04751812|ACTIVE_COMPARATOR|High-pain Standard of care|Patients grading pain associated with venous cannulation \>=2.0 allocated to standard treatment.
62560059|NCT04751812|EXPERIMENTAL|High-pain Multimodal anesthesia with opioids|Patients grading pain associated with venous cannulation \>2.0 allocated to extra treatment.
61992912|NCT03974815|EXPERIMENTAL|ACTIVE|Active stimulation (tDCS) will be used in the dose of 2mA /30 min per day, for 6weeks. (minimum 5 times per week)(total of 30\~42 sessions)
62388234|NCT06454227|ACTIVE_COMPARATOR|Subcutan lavage|Subcutaneous washing with antiseptic solution: Chlorhexidine gluconate 0.2%
62388235|NCT06454227|PLACEBO_COMPARATOR|no lavage|No subcutaneous washing
62388236|NCT01398631||Study Group|All included patients presented with chest pain at the emergency room within the inclusion period.
62388237|NCT01903096|EXPERIMENTAL|Cognitive Behavioral Treatment (CBT)|Cognitive Behavioral Treatment. Seven 90-minute sessions of group treatment along 24 weeks.
62388238|NCT01903096|ACTIVE_COMPARATOR|Treatment-As-Usual (TAU)|Primary Care Treatment As Usual
62388239|NCT05910489||Control|"Biomonitoring studies to detect MNPLs in biological samples and study of health effects.~Determination of MNPLs levels, genotoxic damage, and immunological effects"
62388240|NCT05910489||Greenhouse workers|"Biomonitoring studies to detect MNPLs in biological samples and study of health effects.~Determination of MNPLs levels, genotoxic damage, and immunological effects"
62388241|NCT05290389||Physicians|All Emergency Medicine physicians and Interventional Cardiologists involved in STEMI care in the Hamilton Niagara Haldimand Brant Local Health area will be eligible for participation in this study.
62388242|NCT03654638|EXPERIMENTAL|Arm I Soy Bread Intervention|Men who are scheduled to begin androgen deprivation therapy for prostate cancer will begin an intervention to consume 2 slices of soy bread daily for approximately 20 weeks. Blood, urine and toxicity data will be collected at regularly scheduled medical oncology visits.
62388243|NCT03654638|ACTIVE_COMPARATOR|Arm II Wheat Bread Intervention|Men who are scheduled to begin androgen deprivation therapy for prostate cancer will begin an intervention to consume 2 slices of wheat bread for approximately 20 weeks. Blood, urine and toxicity data will be collected at regularly scheduled medical oncology visits.
62388244|NCT05161949||group 1|200 patients with suspected ovarian cancer
62560060|NCT04751812|ACTIVE_COMPARATOR|Low-pain Standard of care|Patients grading pain associated with venous cannulation to \<2.0 allocated to standard treatment.
62560061|NCT04751812|EXPERIMENTAL|Low-pain opioid-free|Patient grading pain associated with venous cannualation to \<2.0 allocated to opioid-free anesthesia.
62560062|NCT02764255||embryoscope group|cases with embryos continuously monitored by the embryoscope followed by embryo selection based on a multivariable model
62560063|NCT02764255||control group|cases with embyos cultured in the standard incubator and evaluated only by morphology
62560064|NCT04823325||Surgery patients|Otherwise healthy patients with Skeletal Class III problem
61992913|NCT03974815|SHAM_COMPARATOR|SHAM|Sham stimulation (tDCS) will be used in the dose of 0mA /30 min per day, for 6weeks. (minimum 5 times per week)(total of 30\~42 sessions)
61992914|NCT03726008|EXPERIMENTAL|Experimental group|The experimental group will receive the perinatal health promotion program and regular prenatal care
62388245|NCT05161949||group 2|40 non oncological patients of witch 20 with endometriosis
62388246|NCT04627389|EXPERIMENTAL|study arm|20 patients with a unilateral cleft lip will be repaired with orbicularis oris muscle Z-plasty modification of modified Millard technique
62388247|NCT04627389|ACTIVE_COMPARATOR|controlled arm|20 patients with a unilateral cleft lip will be repaired with modified Millard technique
62388248|NCT00702949|EXPERIMENTAL|Pregabalin75|Patients receive 75 mg of oral pregabalin twice daily for 6 weeks.
62388249|NCT00702949|EXPERIMENTAL|Pregabalin150|Patients receive 150 mg of oral pregabalin twice daily for 6 weeks.
62388250|NCT00702949|PLACEBO_COMPARATOR|Placebo|Patients receive oral placebo twice daily for 6 weeks.
62388251|NCT04063059|ACTIVE_COMPARATOR|Intervention|Subjects will be randomized to the program intervention which is a female-specific, culturally relevant, self-regulation based in-person group sessions and telephone counseling intervention designed for African American women who are overweight or obese.
62388252|NCT04063059|NO_INTERVENTION|Control|Usual care
62388253|NCT01967082|EXPERIMENTAL|Prevention (focus group, APPSPIRE app, survey)|Participants attend an audio-taped focus group over 1 hour and are given the APPSPIRE app. After 1 and 4 months of using the app, participants complete a telephone survey over 1 hour to discuss how they liked the app and its usefulness.
62388254|NCT02384629|EXPERIMENTAL|AXXESS stent1|AXXESS stent (OCT-guided)
62388255|NCT02384629|EXPERIMENTAL|Conventional DES1|Conventional DES (Biomatrix flex stent, OCT-guided)
62388256|NCT02384629|ACTIVE_COMPARATOR|AXXESS stent2|AXXESS stent (Angio-guided)
62388257|NCT02384629|ACTIVE_COMPARATOR|Conventional DES2|Conventional DES (Biomatrix flex stent, Angio-guided)
62388258|NCT02063906||Breast cancer stage I-III|who received curative surgery for stage I-III breast cancer and had available data on immunohistochemistry profiles including hormone receptor status (HR) status, human epidermal growth factor receptor 2 (HER2) status, and Ki 67 staining at Samsung Medical Center from January 2004 to September 2008.
62388259|NCT05791487|EXPERIMENTAL|Ulcerative colitis Exclusion Diet + Partial enteral nutrition|Participants in Group 1 will receive the UCED combined with partial enteral nutrition (PEN) using a novel nutritional formula for 6 weeks (diet phase 1) that will add to oral budesonide 9 mg topical therapy for 6 weeks and will follow diet + PEN (phase 2: wk6-wk12) and diet phase 3 for 24 weeks.
62560065|NCT03364101|EXPERIMENTAL|PowerOff|PowerOff is a nutraceutical and a blend of nine ingredients for sleep, including: melatonin; California Poppy; L-Cystine; Glycine; and Magnolia Officinalis
62560066|NCT03364101|PLACEBO_COMPARATOR|Placebo|The placebo pill will be manufactured at the same facility and appear identical in all aspects. However, the control agent will feature non-active ingredients with regards to sleep.Capsules will be instructed to commence on day 7 of the study after baseline appointment
62388260|NCT05791487|ACTIVE_COMPARATOR|Free diet|Participants in Group 2 will receive oral budesonide 9 mg topical therapy alone for 6 weeks with no dietary intervention
61992915|NCT03726008|NO_INTERVENTION|Control group|The control group will receive the regular perinatal care
62388261|NCT04930133||Cohort A|T790M+ patients sequentially treated with osimertinib in cohort A
62768426|NCT02990507|EXPERIMENTAL|AVEED|AVEED is composed of arm and leg cranks that can be used independently or together with a virtual exercise environment (VEE). Participants rotate arm and/or leg cranks under 4 conditions for 5 min each with a 5 min rest between: 1) Arm rotation with VEE, while sitting or standing (AVEED: Arm rotation, video display); 2) Arm rotation without VEE, while sitting or standing (AVEED: Arm rotation, without video display); 3) Leg rotation with arm-energy input to assist the legs with VEE, while sitting (AVEED: Leg rotation, arm-energy input, video display); 4) Leg rotation with arm-energy input to assist the legs without VEE, while sitting (AVEED: Leg rotation, arm-energy input, without video display). VEE controlled with voice commands, leaning, or keyboard buttons.
62388262|NCT04930133||Cohort B|T790M- patients treated with chemotherapy or other treatments in cohort B
62388263|NCT04930133||Cohort C|patients with unknown mutation status in cohort C
62388264|NCT04930133||Cohort D|Cohort D included patients who were still ongoing with afatinib.
62388265|NCT05804344|EXPERIMENTAL|Anodal speech motor tDCS (Anode: C5; Cathode: Fp2)|Speech motor learning task performed with the stimulation condition in the arm title.
62388266|NCT05804344|ACTIVE_COMPARATOR|Cathodal speech motor tDCS (Anode: Fp2; Cathode: C5)|Speech motor learning task performed with the stimulation condition in the arm title.
62560067|NCT04242277||WF-OCT imaging of excised breast lumpectomy tissue|Excised lumpectomy tissue from all consented patients will be imaged on an investigational OCT-based device. No clinical decisions will be made based on the images acquired.
62560068|NCT02260661|EXPERIMENTAL|Part A|AZD8835 single agent dose escalation
62560069|NCT02260661|EXPERIMENTAL|Part B|Following the single agent dose escalation (Part A), additional patients with mutations in the PIK3CA gene will be enrolled to a single agent dose expansion phase at the MTD or recommended phase II dose (RP2D) at the selected dose schedule (as appropriate) to explore further the safety, tolerability, pharmacokinetics and biological activity at the selected dose (Part B). Part B will include patients with ER+/HER2 negative breast cancer whose tumours have a mutation of the PIK3CA gene and patients with any solid tumours which have a mutation of the PIK3CA gene.
62560070|NCT02260661|EXPERIMENTAL|Part C|AZD8835 in combination with fulvestrant dose escalation
62560071|NCT02260661|EXPERIMENTAL|Part D|Following the combination dose escalation segment of the study (Part C), additional postmenopausal patients with ER+/HER negative breast cancer and mutations of the PIK3CA gene will be enrolled to a AZD8835 and fulvestrant combination dose expansion phase at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) (as appropriate) to explore further the safety, tolerability, pharmacokinetics and biological activity at the selected dose (Part D).
62560072|NCT03134248|EXPERIMENTAL|MyDay Toric|Participants were randomized to wear a new pair of MyDay Toric lenses each day for one week during the cross over study
62560073|NCT03134248|ACTIVE_COMPARATOR|1-Day Acuvue Moist for Astigmatism|Participants were randomized to wear a new pair of 1-Day Acuvue Moist Toric lenses each day for one week during the cross over study
62560074|NCT03134248|ACTIVE_COMPARATOR|Dailies Aquacomfort Plus Toric|Participants were randomized to wear a new pair of Dailies Aquacomfort Plus Toric lenses each day for one week during the cross over study
62560075|NCT03857477||Stage 1|Caucasian men aged 55-69 to undergo genetic SNP profiling.
62560076|NCT03857477||Stage 2|Men from Stage 1 identified as having a higher genetic risk score (top 10%) for prostate cancer will be offered an MRI scan, prostate biopsy and prostate cancer screening.
62560077|NCT02905058|EXPERIMENTAL|Ketoprofen|women will take one tablet 150 mg one hour before the procedure
62560078|NCT02905058|PLACEBO_COMPARATOR|Placebo|women will take one placebo tablet one hour before the procedure
62388267|NCT05804344|ACTIVE_COMPARATOR|Anodal IFG tDCS (Anode: F3; Cathode: Fp2)|Speech motor learning task performed with the stimulation condition in the arm title.
62388268|NCT05804344|ACTIVE_COMPARATOR|Cathodal IFG tDCS (Cathode: F3; Anode: Fp2)|Speech motor learning task performed with the stimulation condition in the arm title.
62388269|NCT05804344|SHAM_COMPARATOR|Sham tDCS|Speech motor learning task performed with the stimulation condition in the arm title.
62388270|NCT00158301|EXPERIMENTAL|1|Continuation phase cognitive behavioral therapy and drug therapy for 6 more months following acute treatment response
62388271|NCT00158301|ACTIVE_COMPARATOR|2|Continuation phase drug therapy only for 6 more months following acute treatment response
62560079|NCT03037593|EXPERIMENTAL|Intervention|4000 IU vitamin D3 +prenatal vitamin
62560080|NCT03037593|NO_INTERVENTION|Control|standard prenatal vitamin
62560081|NCT02892045||MMG versus Mindray NMT|24 patients where Mindray NMT is monitoring one hand versus Mechanomyograph on the other hand accessible in supine position, alternately right and left hands monitoring neuromuscular block of rocuronium neuromuscular blocking agent 0.6 mg/kg.
62560082|NCT02892045||TOFWatch versus Mindray NMT|24 patients where Mindray NMT is monitoring one hand versus TOF-Watch Acceleromyograph on the other hand accessible in supine position, alternately right and left hands monitoring neuromuscular block of rocuronium neuromuscular blocking agent 0.6 mg/kg
62560083|NCT04593615|EXPERIMENTAL|Group A|Laparoscopic gastrectomy Group with the use of near-infrared imaging (ICG group)
62560084|NCT04593615|PLACEBO_COMPARATOR|Group B|Laparoscopic gastrectomy Group without the use of near-infrared imaging (Non-ICG group)
62560085|NCT05840055|EXPERIMENTAL|Acceptance and Commitment Therapy|
62560086|NCT03504319||Lean Group|Pre-pregnancy BMI between 18.5 and 24.9 kg/m2
62560087|NCT03504319||Obese Group|Pre-pregnancy BMI ≥30 kg/m2
62560088|NCT04382729|EXPERIMENTAL|NMES Group|
62560089|NCT04382729|ACTIVE_COMPARATOR|Control Group|
61992916|NCT01860456||CML Imatinib/Nilotinib|Patients affected by chronic myeloid leukemia and treated with imatinib or nilotinib
62388272|NCT04694079|EXPERIMENTAL|Group 1, CMR-guided VT ablation|"Patients randomized to Group 1, will undergo CMR-guided VT ablation. LGE-CMR data obtained by 1,5 or 3 T CMR and multi-detector cardiac tomography (MDCT) data obtained using a 128 slice CT scanner will be processed with ADAS-VT software (Galgo Medical, Barcelona, Spain).~Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation."
62388273|NCT04694079|EXPERIMENTAL|Group 2, CMR-aided VT ablation|"Patients randomized to Group 2, will undergo CMR-aided VT ablation. LGE-CMR data obtained by 1,5 or 3 T CMR and multi-detector cardiac tomography (MDCT) data obtained using a 128 slice CT scanner will be processed with ADAS-VT software (Galgo Medical, Barcelona, Spain).~Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation."
62388274|NCT04694079|ACTIVE_COMPARATOR|Group 3, Electroanatomical guided ablation|Patients assigned to Group 3, will not undergo LGE-CMR. Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation.
62388275|NCT05891457|EXPERIMENTAL|Malnourished children|"* Severe Stunting (length/height-for-age Z-scores \<-3SD)~* Severe Acute Malnutrition (weight-for-length/height Z-scores \<-3SD, and/or mid-upper-arm circumference \<11.5 cm, with or without nutritional edema)~* Wasting (weight-for-length/height Z-scores\<-3SD)"
62388276|NCT00245726|ACTIVE_COMPARATOR|1|Passive (Motor Assist) Cycle
62388277|NCT00245726|ACTIVE_COMPARATOR|2|
62388278|NCT00245726|EXPERIMENTAL|3|
62388279|NCT02051257|EXPERIMENTAL|Arm 1 (autologous TCM-enriched T cells)|Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TCM-enriched T cells IV over 10 minutes on day 2 or 3 following HSCT.
62388280|NCT02051257|EXPERIMENTAL|Arm 2 (autologous TN/MEM-enriched T cells)|Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TN/MEM-enriched T cells IV over 10 minutes on day 2 or 3 following HSCT.
62560090|NCT03266146|EXPERIMENTAL|36 Weeks Methylprednisolone|Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA). Participants will then be followed for 24 weeks.
62560091|NCT03266146|EXPERIMENTAL|48 Weeks Methylprednisolone|Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in glucocorticoid 48 weeks of treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA). Participants will then be followed for 24 weeks.
62560092|NCT01269918|ACTIVE_COMPARATOR|Remifentanil|Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
62560093|NCT01269918|ACTIVE_COMPARATOR|Dexmedetomidine|a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
62560094|NCT03309761||Patients aged 55-60|
62560095|NCT04686955|EXPERIMENTAL|Group A|Group A will receive Xiao-Xian-Gui-Fu-Tang three times per day for 6 weeks, then entry 2 weeks wash-out period. Then switch to receive the placebo for another 6 weeks. Post-follow-up will be 4 weeks later.
62560096|NCT04686955|PLACEBO_COMPARATOR|Group B|Group B will receive a placebo three times per day for 6 weeks, then entry 2 weeks wash-out period. Then switch to receive the Xiao-Xian-Gui-Fu-Tang for another 6 weeks. Post-follow-up will be 4 weeks later.
62560097|NCT02303457|EXPERIMENTAL|CO2 laser surgery|CO2 Laser surgery for T1N0 Glottic Squamous Cell Carcinoma With Anterior Commissure Involved. All patients, under general anesthesia, underwent endoscopic excision of the lesion using a carbon dioxide (CO2) laser (Sharplan 100) coupled with a microscope (Zeiss) set to an output power of between 5 and 12 W in superpulse mode. The lesion's resection was accomplished in a radical fashion, with a free margin of 2 mm. For lesions which involved the anterior commissure, the excision plane always uncovered the cartilage.
62560098|NCT02303457|OTHER|Open surgery|"Open Surgery for T1N0 Glottic Squamous Cell Carcinoma With Anterior Commissure Involved.~open surgery :Frontolateral Vertical Partial Laryngectomy or laryngofissure with cordectomy was accomplished in a radical fashion, with a free margin of 2 mm."
62560099|NCT04827693||Immediate|implants are placed immediately after tooth extraction
62560100|NCT04827693||Delayed|implants are placed months after the tooth has been extracted
62560101|NCT05719428|EXPERIMENTAL|DRUID|Patients NGS profile will be analysed with DRUID system to generate recommendations based on predicted efficacy. Patients with available archival tissue will have gene expression analysis performed to optimise DRUID recommendation. Patients will subsequently receive single agent therapy based on DRUID recommendations and criteria for therapy choice.
62560102|NCT01138202|EXPERIMENTAL|1|boosted LPV/r 400/100 mg BID + 2 NRTI
62560103|NCT01138202|EXPERIMENTAL|2|boosted LPV/r 600/150 mg BID + 2 NRTI
62560104|NCT03076632|ACTIVE_COMPARATOR|Non-disabled volunteers|"Volunteers without neurological injury.~Interventions:~* Cervical plus transcranial stimulation~* Cervical stimulation plus hand/wrist exercise~* Electromyographic (EMG)-triggered (closed-loop) stimulation"
61992917|NCT03858946|SHAM_COMPARATOR|Simple trapeziectomy|Simple trapeziectomy with two sham incisions for primary thumb carpometacarpal osteoarthritis
62388281|NCT01049789|ACTIVE_COMPARATOR|TAU|Sites participating in Phase I and Phase II will be randomized to implement this treatment method or the other treatment method. All ATN 080 participants at a site randomized to implement TAU will receive that treatment method.
62560105|NCT03076632|ACTIVE_COMPARATOR|Spinal cord injury|"Volunteers with motor-incomplete cervical spinal cord injury.~Interventions:~* Cervical plus transcranial stimulation~* Cervical stimulation plus hand/wrist exercise~* Electromyographic (EMG)-triggered (closed-loop) stimulation"
61992918|NCT03858946|EXPERIMENTAL|Weilby|Ligament reconstruction interpositions arthroplasty modo Weilby for primary thumb carpometacarpal osteoarthritis
61992919|NCT03050619||New users of Empagliflozin|New users of empagliflozin
61992920|NCT03050619||New users of Other SGLT2 inhibitors|New users of other SGLT2 inhibitors
62560106|NCT03076632|ACTIVE_COMPARATOR|Amyotrophic lateral sclerosis|"Volunteers with amyotrophic lateral sclerosis.~Interventions:~* Cervical plus transcranial stimulation~* Cervical stimulation plus hand/wrist exercise~* Electromyographic (EMG)-triggered (closed-loop) stimulation"
62560107|NCT05294679|PLACEBO_COMPARATOR|Propofol group|"The initial dose of propofol was 2mg/kg, and the intravenous infusion time was 30s. Within 1 minute (inclusive) of the end of the initial dose: if the subject has achieved sufficient sedation (MOAA/S score =0), the colonoscopy will commence. If subjects' MOAA/S score ≥ 1 point, additional administration of cyclopofol will be allowed 1 minute after the end of the initial dose. If the MOAA/S score was 0 after 3 consecutive times of addition, sedation failure was determined, and the study was recorded and quit. The drug was given according to clinical needs and the examination was completed. Maintenance of sedation after colonoscopy: In order to maintain a certain degree of sedation after colonoscopy (MOAA/S score ≤1 point), the evaluator decides when to administer additional drugs.~Additional administration of propofol: The additional dose was 0.5mg/kg/ time, and intravenous bolus was administered."
62560108|NCT05294679|EXPERIMENTAL|Ciprofol ground|"The initial dose of ciprofol was 0.4mg/kg, and the intravenous infusion time was 30s. Within 1 minute (inclusive) of the end of the initial dose: if the subject has achieved sufficient sedation (MOAA/S score =0), the colonoscopy will begin; If subjects' MOAA/S score ≥ 1 point, additional administration of ciprofol will be allowed 1 minute after the end of the initial dose. If the MOAA/S score was 0 after 3 consecutive times of addition, sedation failure was determined, and the study was recorded and quit. The drug was given according to clinical needs and the examination was completed. Maintenance of sedation after colonoscopy: In order to maintain a certain degree of sedation after colonoscopy (MOAA/S score ≤1 point), the evaluator decides when to administer additional drugs.~Ciprofol supplemental administration: the supplemental dose was 0.1mg/kg/ time, and intravenous bolus was administered."
62560109|NCT00764881|EXPERIMENTAL|EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)|Daily oral administration of one capsule BAY86-5027 \[estradiol valerate (EV) / dienogest (DNG)\] for 28 days per cycle in the sequential 4-phasic regimen for 6 treatment cycles.
62560110|NCT00764881|ACTIVE_COMPARATOR|EE/LNG (Microgynon) + Placebo|Daily oral administration of one capsule ethinylestradiol (EE) / levonorgestrel (LNG) for 21 days, followed by 1 capsule placebo for 7 days (28 days total per cycle) for 6 treatment cycles.
62560111|NCT03604224||Canagliflozin Containing Treatment Regimens|No intervention will be administered as a part of this study. Participants with type 2 diabetes mellitus (T2DM) who were initiated on canagliflozin 300 milligram (mg) treatment 12 weeks back and meeting the inclusion criteria will be observed.
62560112|NCT01766076|EXPERIMENTAL|atorvastatin, Lipitor®|"Intervention is be atorvastatin, Lipitor® (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.~Peripheral blood mononuclear cells (PBMC) will be collected for immune activation assays using flowcytometry"
62560113|NCT01766076|PLACEBO_COMPARATOR|Placebo|Intervention for the placebo comparator arm is Placebo 2 tablets daily for 12 weeks PBMC will be collected for immune activation assays using flowcytometry
62560114|NCT06139822|EXPERIMENTAL|Experimental Group|"hamstring stretching, cold pack, stretching, strengthening of plantar fascia and calf muscles.~. Hamstring stretching will be used as an intervention protocol along with conventional physical therapy. Treatment protocol will be followed for thrice a week for 2 weeks. The session will be of approximately 20 minutes. Patient will be in supine lying, passively increase hip flexion while keeping the back straight, and the knee in the extended position from the start to the end of the stretching while the ankle will be in a neutral position~a 30-second rest period will be recommended between stretching repetitions. For each stretching repetition, the individual had to achieve a position of mild discomfort (not pain) which will sustain for 30 seconds."
62768427|NCT04732104|EXPERIMENTAL|intranasal spray anesthesia|intranasal lidocaine lidocaine 4% topical
62768428|NCT04732104|ACTIVE_COMPARATOR|injectable local anesthesia|gold standard infiltration local anesthesia (2% lidocaine with 1:100,000 epinephrine)
62768429|NCT05514249|EXPERIMENTAL|Single patient|Single dose of CRD-TMH-001 administered by IV
61992921|NCT03050619||New users of Other non-insulin GLDs|New users of other non-insulin GLDs
62768430|NCT03661086|ACTIVE_COMPARATOR|O2matic|Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation
62768431|NCT03661086|NO_INTERVENTION|Manual|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously.
62768432|NCT06060860|ACTIVE_COMPARATOR|Cognitive-Behavioral Therapy (CBT)|The arm receives the Unified Protocol (UP), a modular transdiagnostic CBT treatment that uses a parsimonious approach to treatment by addressing common emotion-related mechanisms underlying both anxiety and depression.
61992922|NCT06083506|OTHER|NOVALOC TiN|Each subject will receive 4 implants. Implants will be placed flapless using a guided surgical protocol and will be immediately loaded by means of a NOVALOC TiN retained maxillary overdenture.
61992923|NCT03079323|EXPERIMENTAL|PART-trial|External beam radiotherapy
61992924|NCT04534764|EXPERIMENTAL|TEST/CONTROL|Eligible subjects that are habitual soft contact lens wearers will be randomized into lens wear sequence (Test/Control)
61992925|NCT04534764|EXPERIMENTAL|CONTROL/TEST|Eligible subjects that are habitual soft contact lens wearers will be randomized into lens wear sequence (Control/Test)
61992926|NCT02710890|EXPERIMENTAL|Lacosamide|Up to 2 age-based Cohorts with Cohort 1 including at least 40 subjects who are \>=8 to \<17 years. For Cohort 2 every attempt will be made to enroll 20 subjects \>= 4 to \< 8 years of age, 12 subjects \>= 2 to \< 4 years of age and 12 subjects \>= 1 month to \< 2 years of age. A Data Monitoring Committee (DMC) will review the safety and tolerability data for each Cohort to make the following recommendations: the progression of the current Cohort, including intravenous (iv) infusion durations to be evaluated, and progression to initiate enrollment in the next Cohort (Cohort 2).
61992927|NCT05762146|EXPERIMENTAL|Riociguat +Propylthiouracil +Perphenazine|"Triple combination therapy group:~○ each patient in this group will receive two doses (8 +/- 2 hours between doses) of orally administered combination therapy of riociguat, propylthiouracil, and perphenazine, in addition to standard of care."
62560115|NCT06139822|ACTIVE_COMPARATOR|Control Group|"Cold pack, stretching, strengthening of plantar fascia and calf muscles~Control group included Cold pack for 7 to 10 mins. Followed by stretching of plantar fascia through:~* toe stretches to stretch the plantar fascia.~* towel to stretch the bottom of foot (towel scrunches)~* calf muscles stretching~After stretching exercises strengthening is performed by the following:~* towel curls~* heel raise Patients performed 2 sets, each repetition lasting 30 seconds, 2 times a day for each exercise."
62560116|NCT04234308|EXPERIMENTAL|Polyglycolic Acid Absorbable suture|Periodontal and periimplant flaps closed with at least one suture with Polyglycolic Acid Absorbable suture, synthetic, 4-0. (TAGUM®).
62560117|NCT04234308|EXPERIMENTAL|Chromic Gut Absorbable suture|Periodontal and periimplant flaps closed with at least one suture with Chromic Gut Absorbable suture, natural, 4-0. (TAGUM®)
62560118|NCT04234308|EXPERIMENTAL|ePTFE Non absorbable suture|Periodontal and periimplant flaps closed with at least one suture with ePTFE Non absorbable suture, synthetic, 4-0. (TAGUM®)
62560119|NCT04234308|EXPERIMENTAL|Nylon Non absorbable sutures|Periodontal and periimplant flaps closed with at least one suture with Nylon Non absorbable sutures, synthetic, 4-0. (TAGUM®)
62560120|NCT05821816|EXPERIMENTAL|Experimental Group|Standard rehabilitative treatment for stroke + tDCS
61992928|NCT05762146|NO_INTERVENTION|standard of care|Control group: each patient in this group will receive only standard of care
61992929|NCT03762382|EXPERIMENTAL|TFV/LNG IVR (10mg/20μg) (Continuous)|Tenofovir/Levonorgestrel Intravaginal Ring
62388282|NCT01049789|EXPERIMENTAL|COMB|Sites participating in Phase I and Phase II will be randomized to implement this treatment method or the other treatment method. All ATN 080 participants at a site randomized to implement COMB will receive that treatment method.
62388283|NCT02406599|OTHER|SOC + Device|The surgeon will perform routine standard of care lumpectomy with adjunctive MarginProbe device use on the main ex-vivo lumpectomy specimen.
62560121|NCT05821816|ACTIVE_COMPARATOR|Control Group|Only standard rehabilitative treatment for stroke
62560122|NCT06100523|EXPERIMENTAL|Arm A (interventional)|Analysis of the responses to the self-administered questionnaires with, if necessary, protocol interview concerning environmental and occupational factors, which will determine the consultations to be planned for their follow-up by the platform
62560123|NCT06100523|ACTIVE_COMPARATOR|Arm B (standard management)|Care path according to the usual modalities of the assisted reproductive treatment (ART) center
62560124|NCT03405831|ACTIVE_COMPARATOR|Ivabradine|Study participants in this arm will receive ivabradin 5 mg bid for a period of 12 weeks.
62560125|NCT03405831|PLACEBO_COMPARATOR|Placebo|Study participants in this arm will receive placebo bid for a period of 12 weeks.
62560126|NCT03402295|ACTIVE_COMPARATOR|Vcd- (Bortezomibe, cyclophosphamide and dexamethasone)|"Intervention - Bortezomib 1.3mg/m2 Intra venous or Subcutaneous once a week (D1-8-15-22) 35days cycle Intervention- Dexamethasone 40mg once a week for four weeks orally or Intravenously- total dose per cycle was 160mg.~Intervention- Cyclophosphamide 900-2000mg- intravenously or orally- total dose monthly Total of four cycles"
61992930|NCT03762382|EXPERIMENTAL|TFV IVR (10mg) (Continuous)|Tenofovir Intravaginal Ring
61992931|NCT03762382|PLACEBO_COMPARATOR|Placebo IVR (Non-eluting)|Placebo Intravaginal Ring
61992932|NCT03232385|EXPERIMENTAL|MR-US Fusion Arm|Clear Guide SCENERGY, MR-US
61992933|NCT03232385|ACTIVE_COMPARATOR|EM Fusion or No Fusion Arm|
61992934|NCT04794790|NO_INTERVENTION|Standard Dose|Standard dose induction Visit 1 Day 1 (intake/baseline) Participants will commence induction with a dose of 4mg if COWS is above 7. If COWS is below 7, participant will be instructed to return the next day, so that COWS can be above 7 to start the study.
61992935|NCT04794790|EXPERIMENTAL|Macro or High Dose|Macro or High Dosing Visit 1 Day 1 (intake/baseline) Participants will commence induction with a dose of 4mg if COWS is above 7. If COWS is below 7, participant will be instructed to return the next day, so that COWS can be above 7 to start the study. (These participants can still be in the study and will only have to re-do a baseline COW's on the day they come back to the clinic, which will then be considered their day 1).
62388284|NCT02406599|OTHER|SOC + Additional Inspection|The surgeon will perform routine standard of care lumpectomy with additional inspection on the main ex-vivo lumpectomy specimen.
62388285|NCT05080686|EXPERIMENTAL|ThoraxBelt (Inpatients)|Received ThoraxBelt after the surgery in addition to oral analgesics. Standard care for pain management will be the same as the Standard Care Arm (Inpatients).
62388286|NCT05080686|NO_INTERVENTION|Standard Care (Inpatients)|Standard Care with IV PCA and on-request oral painkiller.
62388287|NCT05080686|EXPERIMENTAL|ThoraxBelt (Outpatients)|Received ThoraxBelt at the emergency room in addition to oral analgesics. Standard care for pain management will be the same as the Standard Care Arm (Outpatients).
62388288|NCT05080686|NO_INTERVENTION|Standard Care (Outpatients)|Standard Care and on-request oral painkiller.
62388289|NCT01226602|EXPERIMENTAL|1|Adenosinladder; Ticagrelor (180 mg), Adenosinladder ; Theophylline (5 mg/kg), Adenosinladder
62388290|NCT01226602|PLACEBO_COMPARATOR|2|Adenosinladder; Placebo, Adenosinladder; Theophylline (5 mg/kg), Adenosinladder
61992936|NCT04794790|EXPERIMENTAL|Micro or Low Dose|Micro or Low Dose Visit 1 Day 1 (intake/baseline) Participants will commence induction with a dose of 4mg if COWS is above 7. If COWS is below 7, participant will be instructed to return the next day, so that COWS can be above 7 to start the study. (These participants can still be in the study and will only have to re-do a baseline COW's on the day they come back to the clinic, which will then be considered their day 1).
61992937|NCT00239707|EXPERIMENTAL|Infusion 1|Normal Saline
61992938|NCT00239707|PLACEBO_COMPARATOR|Infusion 2|GIP or modified GIP
62388291|NCT00526227|EXPERIMENTAL|Secura ICD implant|Secura ICD device implanted
62388292|NCT03861832|EXPERIMENTAL|Nutraceutical, KB220Z|A nutraceutical pill containing pro-dopamine precursors
62388293|NCT03861832|PLACEBO_COMPARATOR|Placebo|A placebo that looks the same and is in a similar bottle
62388294|NCT02872090|EXPERIMENTAL|Arm 1|The patients receive once a week during 4 weeks, in the order: indacaterol, tiotropium, glycopyrronium and placebo
62388295|NCT02872090|EXPERIMENTAL|Arm 2|The patients receive once a week during 4 weeks, in the order: tiotropium, glycopyrronium, placebo and indacaterol
62388296|NCT02872090|EXPERIMENTAL|Arm 3|The patients receive once a week during 4 weeks, in the order: glycopyrronium, placebo, indacaterol and tiotropium,
62388297|NCT02872090|EXPERIMENTAL|Arm 4|The patients receive once a week during 4 weeks, in the order: placebo, indacaterol and tiotropium and glycopyrronium
62388298|NCT03973827|EXPERIMENTAL|Low dose|3 patients receiving low dose
62168282|NCT00317135|EXPERIMENTAL|Hib-MenAC Lot 3 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 3 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
62388299|NCT03973827|EXPERIMENTAL|Medium dose|3 patients receiving medium dose
62388300|NCT03973827|EXPERIMENTAL|High dose|3 patients receiving high dose
62388301|NCT03973827|SHAM_COMPARATOR|Control|6 patients
62388302|NCT06077409|ACTIVE_COMPARATOR|Gentle Human Touch Group|After the mother is dressed in a clean apron, she will be provided to wash and disinfect her hands and heat her hand temperature with a non-contact fire meter device until the measurement value is 34 ºC.Jul. The mother, who was previously informed about the method, will place the fingertips and palm of one hand above the eyebrow line so that it touches the baby's crown part, while placing the other hand on the lower abdomen surrounding the baby's waist and hips (Figure 1). The GHT application will be started 5 minutes before the blood collection procedure, it will be continued during the blood collection procedure and until 5 minutes after the end of the blood collection procedure.
62388303|NCT06077409|ACTIVE_COMPARATOR|Skin to Skin Group|"The temperature of the environment where skin to skin will be carried out will be adjusted between 22-26 degrees C. The mother will be allowed to disinfect her hands and warm them until her hand temperature is at least 34 C. Only the baby's diaper, hat and socks will be left behind, and the baby will be placed face down on the mother's chest, with its head upright and its legs under the breasts in a frog position. The baby's face will be turned towards the mother and eye contact will be made. The baby will be in an upright position between the mother's breasts and skin to skin with the mother.~Skin-to-skin contact will begin 5 minutes before blood collection, continue throughout the procedure, and skin to skin will continue until 5 minutes after the procedure."
62388304|NCT06077409|NO_INTERVENTION|Control Group|The standard procedure of the clinic was applied to preterm infants in the control group. In the standart prosedure of the clinic, the mother was with her baby in the blood collection room and did not perform any procedure.
62388305|NCT04244227|EXPERIMENTAL|Active treatment|Participants will self-administer treatment with the Empower device at the active treatment anatomic location once daily for three weeks. Participants will complete daily and weekly surveys to evaluate the effects of the Empower active treatment.
62560127|NCT03402295|ACTIVE_COMPARATOR|Ctd- Cyclophosphamide, thalidomide and dexamethasone|"Intervention- Cyclophosphamide 900-2000mg intravenously or orally total dose monthly Intervention- Thalidomide 100-200mg orally- daily dose Intervention -Dexamethasone 40mg once a week for four weeks each month- total dose per cycle was 160mg Total of four cycles (cycles of 28 each one)~28 days each cycles- total of four cycles"
61992939|NCT00239707|PLACEBO_COMPARATOR|Infusion 3|GIP or modified GIP, opposite of Infusion 2
61992940|NCT00368264|EXPERIMENTAL|1|azathioprine plus 4 infusions of infliximab (5 mg/kg)
61992941|NCT00368264|PLACEBO_COMPARATOR|2|azathioprine plus 4 placebo infusions
61992942|NCT05080452||ACNES patients|Patients referred to ultrasound-guided treatment for abdominal wall pain caused by ACNES
61992943|NCT05080452||LUCNES patients|Patients referred to ultrasound-guided treatment for lower back pain caused by LUCNES
61992944|NCT01674231|ACTIVE_COMPARATOR|Grape|Grapes in the form of a Freeze-dried Whole Grape Powder. 60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
61992945|NCT01674231|PLACEBO_COMPARATOR|Sugar|Grape Powder Placebo. 60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
61992946|NCT01160068|EXPERIMENTAL|Metformin|Metformin Hydrochloride 1000 mg tablets of Dr. Reddy's Laboratories Limited
61992947|NCT01160068|ACTIVE_COMPARATOR|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
61992948|NCT00924872|EXPERIMENTAL|intervention|receive wheelchair skills training
61992949|NCT00924872|NO_INTERVENTION|control|no formalized wheelchair skills training provided
61992950|NCT03384121|EXPERIMENTAL|Rifampin|All subjects
61992951|NCT04620083|NO_INTERVENTION|Control Group|For the control group, the participants received conventional therapy which included group activities for reality orientation, reminiscence therapy and activities organized by occupational therapists one hour a day, five days a week.
62388306|NCT04244227|SHAM_COMPARATOR|Sham treatment|Participants will self-administer treatment with the Empower device at the sham treatment anatomic location once daily for three weeks. Participants will complete daily and weekly surveys to evaluate the effects of the Empower sham treatment.
62388307|NCT01496781|EXPERIMENTAL|EndoClot|This arm is designed to observe if the Endoclot treatment can achieve comparable hemostasis efficacy compared with hemoclip.
62388308|NCT01496781|ACTIVE_COMPARATOR|Hemoclip|This arm is used as a control treatment group to compare with Endoclot treatment.
61992952|NCT04620083|EXPERIMENTAL|Experimental 3-day Normal Group|In addition to conventional therapy, the participants in this experimental groups also joined the integrative learning program for 3 days per week.
61992953|NCT04620083|EXPERIMENTAL|Experimental 5-day Intensive Group|In addition to conventional therapy, the participants in this experimental groups also joined the integrative learning program for 5 days per week. For consistency, Day 1 and 3 of the 3-day protocol were replicated as Day 4 and Day 5 of the 5-day protocol.
61992954|NCT03073590|EXPERIMENTAL|Intervention with lunch|Intervention factory with hot lunch program A. Nutritionally enhanced lunch meal program B. Once weekly iron/folate supplement C. Behavior change communications program
61992955|NCT03073590|ACTIVE_COMPARATOR|Control with lunch|Control factory with lunch program A. Regular lunch meal program B. Behavior change communications program
61992956|NCT03073590|EXPERIMENTAL|Intervention without lunch|Intervention factory without lunch program A. Twice weekly provision of iron/folate supplements B. Enhanced behavior change communications program
62168283|NCT00317135|ACTIVE_COMPARATOR|Hiberix Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB vaccine mixed extemporaneously with conjugate vaccine Hiberix at 2, 4 and 6 months of age as intramuscular injection in the anterolateral part of the thigh.
62388309|NCT02949544|OTHER|water immersion|patients with heart failure will be immersed to the neck for 15 minutes
62388310|NCT04264260|EXPERIMENTAL|colchicine group|The participants will receive colchicine starting from 2 tablets after meal twice per day (total 2 mg). The dose will be adjusted ranging from total minimum 1.5 mg to maximum 3 mg per day based on the condition and tolerance of the participant. One cycle of treatment is defined as 4 days treatment and 3 days off. The participants will receive repeated cycles till the participants quit the trial.
62560128|NCT03383965|EXPERIMENTAL|ICAR30 T cells|anti-CD30 CAR-T cells. Patients receive ICAR30 T cells infusion.
62768433|NCT06060860|ACTIVE_COMPARATOR|Mindfulness-Based Cognitive Therapy (MBCT)|Mindfulness-Based Cognitive Therapy (MBCT) is an empirically supported treatment that focuses on non-judgmental acceptance of present moment experiences and emotions. MBCT was adapted from Mindfulness-Based Stress Reduction (MBSR) to focus on improving mental health more specifically in individuals with depression and other psychiatric conditions.
62768434|NCT01012752|ACTIVE_COMPARATOR|modified allergen extract|
62768435|NCT01012752|PLACEBO_COMPARATOR|Placebo|
62768436|NCT02881528|EXPERIMENTAL|Metformin Hydrochloride|"Metformin Hydrochloride Ph Eur oral solution (100mg/1ml) Starting Dose 10mg/Kg body weight once daily for 2 weeks, increasing to 10mg/Kg body weight twice daily if tolerated, increasing to target dose of 20mg/Kg body weight twice daily (max 1000mg twice daily) at Month 1 (4 weeks post randomization).~Down-titration to 10mg/kg twice daily if target dose not tolerated. Stage 1: Dosing for up to 15 months (option to extend to Stage 2: 36 months)"
62768437|NCT02881528|PLACEBO_COMPARATOR|Placebo|"Placebo (100mg/1ml) Starting Dose 10mg/Kg body weight once daily for 2 weeks, increasing to 10mg/Kg body weight twice daily if tolerated, increasing to target dose of 20mg/Kg body weight twice daily (max 1000mg twice daily) at Month 1 (4 weeks post randomization).~Down-titration to 10mg/kg twice daily if target dose not tolerated. Stage 1: Dosing for up to 15 months (option to extend to Stage 2: 36 months)"
61992957|NCT03073590|ACTIVE_COMPARATOR|Control without lunch|Control factory without lunch program A. Behavior change communications program
61992958|NCT03463889|EXPERIMENTAL|Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)|Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.
61992959|NCT04667039|EXPERIMENTAL|GNR-067|Ranibizumab
61992960|NCT04667039|ACTIVE_COMPARATOR|Lucentis®|Ranibizumab
61992961|NCT02848677|ACTIVE_COMPARATOR|intervention group|Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.
61992962|NCT02848677|SHAM_COMPARATOR|control group|usual care of hypertensive patients.
61992963|NCT01452464||MenACYW-CRM vaccinated adolescents|All adolescent recipients of MenACYW-CRM vaccines during the study period. Among these, adolescents who have additionally experienced an event of interest within the 1-year observation period following vaccination will be included in the self-controlled case series.
61992964|NCT02476968|OTHER|Olaparib|Open Label Drug
61992965|NCT04762134|EXPERIMENTAL|STI PrEP arm|doxycycline capsules 100mg orally daily for 12 months. Though the usual treatment dose of doxycycline is 100mg twice daily
61992966|NCT04762134|EXPERIMENTAL|STI PEP arm|doxycycline 200mg orally once within 24-72 hours following each sexual encounter deemed at risk (i.e. condomless anal or oral sex), to a maximum of six pills (i.e. 600 mg total) per week
61992967|NCT05517499|EXPERIMENTAL|Group A (Dexamethasone Group),|Group A (Case Group) was given dexamethasone i.e., 0.2 mg per kg per day every 12 hours for 7 days intravenously. All treatment strategies were same in both groups but steroid was given to group A
61992968|NCT05517499|NO_INTERVENTION|Group B (Control Group)|Group B (Control group), received routine treatment.No dexamethasone
61992969|NCT05486221||Cryptogenic stroke patients|Patients with an acute ischemic stroke of cryptogenic origin with a previous negative work-up that includes: blood analysis, brain CT / MRI, angio-TC / angio-MRI, brain vessel ultrasound, ECG, 24h ECG-holter, echocardiography).
61992970|NCT01124643|EXPERIMENTAL|Replagal 0.2 mg/kg EOW|Intravenous, 0.2mg/kg EOW
61992971|NCT05096416|NO_INTERVENTION|Control arm|Patients in this arm will have standard of care where they will be annulated by the palpation method by the dialysis technician and nurse.
61992972|NCT05096416|EXPERIMENTAL|Intervention arm|Patients in this arm will have a three-dimensional (3D) printed vascular access model to assist the dialysis technician and nurse in cannulation.
62388311|NCT03866824|EXPERIMENTAL|PRP group|
62388312|NCT03866824|ACTIVE_COMPARATOR|reference treatment|
62560129|NCT05828498||grup 1|patients who were on a diet and had a Mediterranean Diet Adherence Scale ≥7 were included in the diet group
62560130|NCT05828498||grup 2|As the control group (group 2), 64 patients participated in the study.
62560131|NCT02368990||NSCLC T790M positive|NSCLC patients who have had 1st line treatment with an approved EGFR targeted TKI, who are known to be T790M mutation positive and who have been prescribed platinum based doublet chemotherapy (pemetrexed + cisplatin/carboplatin) as a 2nd line treatment as part of their standard care.
62560132|NCT04658966||cases|Women with a history of pre-eclampsia
62560133|NCT04658966||controls|Women with no history of hypertensive disorder during pregnancy
62768438|NCT00106574|EXPERIMENTAL|1|
62768439|NCT00106574|PLACEBO_COMPARATOR|2|
61992973|NCT04222712|EXPERIMENTAL|TRS01 low dose|
61992974|NCT04222712|EXPERIMENTAL|TRS01 high dose|
62768440|NCT00215514|EXPERIMENTAL|ECF followed by 5-FU/RT followed by ECF|
62768441|NCT01915823|ACTIVE_COMPARATOR|Dymista|"(azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137mcg/50mcg: Mode of Administration: Topical/intranasal spray~Dose: 548 mcg azelastine hydrochloride / 200 mcg fluticasone propionate, total daily dose Regimen: 1 spray per nostril twice daily"
61992975|NCT00449644|EXPERIMENTAL|TMC207 Stage 1|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 weeks in addition to Background Regimen (BR) for multi-drug resistant tuberculosis (MDR-TB).
61992976|NCT00449644|PLACEBO_COMPARATOR|Placebo Stage 1|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 weeks in addition to BR for MDR-TB.
61992977|NCT00449644|EXPERIMENTAL|TMC207 Stage 2|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 22 weeks in addition to BR for MDR-TB.
61992978|NCT00449644|PLACEBO_COMPARATOR|Placebo Stage 2|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 22 weeks in addition to BR for MDR-TB.
61992979|NCT03984786|EXPERIMENTAL|ICBT for alcohol misuse: Assessment Interview/Guidance|"In this arm, an interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization during the initial telephone screen, where the interviewer will use the AUD section from SCID-5.~Participants randomized to this arm will then receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse with guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT."
61992980|NCT03984786|EXPERIMENTAL|ICBT for alcohol misuse: Assessment Interview/No Guidance|"In this arm, an interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization during the initial telephone screen, where the interviewer will use the AUD section from SCID-5.~Participants randomized to this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no guidance from a health educator will be provided. Clients will be monitored by providing brief measures on alcohol and depression each week. However, clients will only be contacted if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms of depression and suicidal ideation)."
61992981|NCT03984786|EXPERIMENTAL|ICBT alcohol misuse: No Assessment Interview/Guidance|"The client will not receive any assessment interview during the telephone screen.~Participants randomized to this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse with guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT."
62168284|NCT04073849|ACTIVE_COMPARATOR|Cohort A|EPOGEN® (epoetin alfa) Study Drug Epoetin Alfa (EPOGEN®) 40 IU / kg dose during boosting phase, delivered s.c.; 8 injections 900 IU dose during microdosing, delivered i.v.; 6 injections
62168285|NCT04073849|SHAM_COMPARATOR|Cohort B|Saline 40 IU / kg dose during boosting phase, delivered s.c.; 8 injections 900 IU dose during microdosing, delivered i.v.; 6 injections
62560134|NCT03849924|EXPERIMENTAL|Self-affirmation|Participants assigned to the self-affirmation intervention condition will undergo a self-affirmation intervention in the form of a questionnaire at time point one (one week after the intervention). This is a brief intervention that involves forming self-affirming implementation intentions. Implementation intentions are formulated plans that encourage one to link critical situations with appropriate behavioural responses. In this study participants are encouraged to write out the stem and their response to the stem from the four options.
62560135|NCT03849924|EXPERIMENTAL|Self-affirmation 'booster'|Participants assigned to this condition will undergo the self-affirmation intervention described above twice, in comparison to just once, in the form of a questionnaire at time points one (one week after the intervention) and two (two weeks after the intervention).
62560136|NCT03849924|NO_INTERVENTION|Control|Participants assigned to the control condition will not undergo a self-affirmation intervention. Instead they will still complete the same questionnaire as participants in the intervention conditions but without the self-affirmation intervention included (normally included on the last page of the questionnaire).
62560137|NCT02657486|EXPERIMENTAL|BGJ398|BGJ398 will be administered at a dose of 125 mg orally once daily on a three weeks on, one week off schedule.
62560138|NCT02090088||All Subjects|All Subjects
62560139|NCT06147882|ACTIVE_COMPARATOR|Psychoeducation Group|The group of patients who are given psychoeducation program
62768442|NCT01915823|PLACEBO_COMPARATOR|Dymista vehicle|Dose: vehicle only Regimen: 1 spray per nostril twice daily
62168286|NCT04263558|ACTIVE_COMPARATOR|LHF|Long intervention (16 sessions) High parental involvement (5 sessions) Feedback
62168287|NCT04263558|ACTIVE_COMPARATOR|LHN|Long intervention (16 sessions) High parental involvement (5 sessions)
62168288|NCT04263558|ACTIVE_COMPARATOR|LLF|Long intervention (16 sessions) Low parental involvement (Brochure) Feedback
62560140|NCT06147882|NO_INTERVENTION|Control Group|The group of patients who are not given psychoeducation program
62560141|NCT01451450|EXPERIMENTAL|QGE031 A|
62560142|NCT01451450|EXPERIMENTAL|QGE031 B|
62560143|NCT01451450|EXPERIMENTAL|QGE031 C|
62560144|NCT01451450|EXPERIMENTAL|QGE031 D|
62768443|NCT02678884|EXPERIMENTAL|HNSCC Patients receiving RT|
62388313|NCT03918356|EXPERIMENTAL|Inclusion Body Myositis patients|Subjects with clinically or clinico-pathologically defined IBM will be included in this study. Patients with consistent clinical and laboratory features including ages 18 to 80 years, duration of symptoms\> 12 months, serum creatine kinases (CK) no greater than 15 times upper limit of normal, prominent weakness of quadriceps and/or finger flexor weakness\>shoulder abduction weakness along with some characteristic histopathological findings of endomysial inflammatory infiltrate, rimmed vacuoles and protein accumulation or 15-18 nm filaments will be considered as clinically or clinicopathologically defined IBM as proposed by the European Neuromuscular Center (ENMC IBM working group, 2013).
62560145|NCT01451450|PLACEBO_COMPARATOR|Placebo A|
62560146|NCT01451450|PLACEBO_COMPARATOR|Placebo B|
62560147|NCT01451450|PLACEBO_COMPARATOR|Placebo C|
62560148|NCT01451450|PLACEBO_COMPARATOR|Placebo D|
62560149|NCT00124189|OTHER|open label|Sequential dose cohort, open label, escalation trial evaluating one infusion duration of 2 hours
62768444|NCT01029444|EXPERIMENTAL|Insulin|Brittle diabetic patients or patients with uncontrolled blood sugars will complete blood sugar diaries weekly and have hemoglobin A1c lab tests performed quarterly to evaluate progress in stabilizing blood sugars.
61992982|NCT03984786|EXPERIMENTAL|ICBT for alcohol misuse: No Assessment Interview/No Guidance|"The client will not receive any assessment interview during the telephone screen.~Participants randomized to this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no guidance from a health educator will be provided. Clients will be monitored by providing brief measures on alcohol and depression each week. However, clients will only be contacted if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms of depression and suicidal ideation)."
61992983|NCT00749320|OTHER|ASL MRI|ASL MRI performed at different time intervals on participants receiving sunitnib or pazopanib for treating RCC
61992984|NCT04407130|ACTIVE_COMPARATOR|Tab Ivermectin +Cap Doxycycline|"200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)~+ Placebo one tablet D2-5"
61992985|NCT04407130|ACTIVE_COMPARATOR|Tab Ivermectin|"Ivermectin - 200 mcg/kg (12 mg tablet) once per day D1-D5~+ Placebo two tablets D1 followed by Placebo one tablet D2-5"
61992986|NCT04407130|PLACEBO_COMPARATOR|Placebo|"Drug: Placebo~3 Placebo tablets D1 followed by 2 tablets D2-5"
62768445|NCT02313883|PLACEBO_COMPARATOR|SRP only|Scaling and root planing only
61992987|NCT06050551|EXPERIMENTAL|14-Fr pigtail catheter after uniportal VATS|smaller catheter used after uniportal VATS
61992988|NCT06050551|OTHER|20-Fr chest tube after uniportal VATS|routine management after uniportal VATS
61992989|NCT03237728|EXPERIMENTAL|0.06mg/kg,KB and Placebo|Group A:0.06mg/kg,Q8h,Day1-Day7
61992990|NCT03237728|EXPERIMENTAL|0.12mg/kg,KB|Group B:0.12mg/kg,Q8h,Day1-Day7
61992991|NCT03237728|EXPERIMENTAL|0.24mg/kg,KB|Group C:0.24mg/kg,Q8h,Day1-Day7
61992992|NCT03237728|EXPERIMENTAL|Placebos|Group D:Placebos,Q8h,Day1-Day7
61992993|NCT05148481|EXPERIMENTAL|BIIB104: Dose 1|Japanese and non-Japanese participants will receive BIIB104, Dose 1, oral capsule, BID, from Day 1 through Day 9 with an additional dose on Day 10.
61992994|NCT05148481|EXPERIMENTAL|BIIB104: Dose 2|Japanese and non-Japanese participants will receive BIIB104, Dose 2, oral capsule, BID, from Day 1 through Day 9 with an additional dose on Day 10.
61992995|NCT05148481|PLACEBO_COMPARATOR|Placebo|Japanese and non-Japanese participants will receive BIIB104-matching placebo, oral capsule, BID, from Day 1 through Day 9 with an additional dose on Day 10.
61992996|NCT03357484|EXPERIMENTAL|L-PRF|Third molar extraction sockets were filled with two leukocyte- and platelet rich fibrin (L-PRF) clots
61992997|NCT03357484|ACTIVE_COMPARATOR|Blood clot|Third molar extraction sockets allowed to form a natural blood clot and undergo natural healing
62168289|NCT04263558|ACTIVE_COMPARATOR|LLN|Long intervention (16 sessions) Low parental involvement (Brochure)
62168290|NCT04263558|ACTIVE_COMPARATOR|SHF|Short intervention (8 sessions, group) and 8 sessions web-based High parental involvement (5 sessions) Feedback
62168291|NCT04263558|ACTIVE_COMPARATOR|SHN|Short intervention (8 sessions, group) and 8 sessions web-based High parental involvement (5 sessions)
62168292|NCT04263558|ACTIVE_COMPARATOR|SLF|Short intervention (8 sessions, group) and 8 sessions web-based Low parental involvement (Brochure) Feedback
62768446|NCT02313883|PLACEBO_COMPARATOR|SRP and Placebo|Scaling and root planing followed by placebo drug administration
62768447|NCT02313883|EXPERIMENTAL|SRP and 0.3% PerioSept(r)|Scaling and root planing followed by 0.3% PerioSept(r) drug administration
62768448|NCT02313883|EXPERIMENTAL|SRP and 1 % PerioSept(r)|Scaling and root planing followed by 1% PerioSept(r) drug administration
62768449|NCT02313883|EXPERIMENTAL|SRP and 3% PerioSept(r)|Scaling and root planing followed by 3% PerioSept(r) drug administration
62168293|NCT04263558|ACTIVE_COMPARATOR|SLN|Short intervention (8 sessions, group) and 8 sessions web-based Low parental involvement (Brochure)
62567695|NCT05688566|ACTIVE_COMPARATOR|inversion condition|Then the pedal angle is the angle between the lowest pedal position and the floor. The inversion condition is +10 ˚of pedal angle.Participants were asked to step with the consistent cadence at 60 steps/ min by the metronome.Three successful trials will be collected for each condition. Fifteen seconds of data will be collected for each trial.
62768450|NCT05951712|PLACEBO_COMPARATOR|No Intervention|"In this arm, the participants will receive placebo ( 100 ml water) 10-30 minutes before the procedure under the supervision of a trained nurse. All patients will be given standard recommendations before the procedure: at least 8 hours of liquid and solid fasting.~During endoscopy, mucosal visibility will be evaluated in 6 segments (gastric antrum, lower gastric body, upper gastric body, fundus, first and second part of duodenum), using a scale ranging from 1 to 4 points: (1) no adherent mucus in the gastric mucosa examined; (2) a small amount of mucus in the gastric mucosa examined that does not hinder vision; (3) a large amount of mucus in the gastric mucosa examination, which can be washed thoroughly with \<50 mL of water; (4) a large amount of mucus in the gastric mucosa examined which requires ≥50 mL of water for washing."
62768451|NCT05951712|EXPERIMENTAL|Simethicone 150 mg|"In this arm, the participants will receive 150 mg simethicone dissolved in 100 ml water 10-30 minutes before the procedure under the supervision of a trained nurse.All patients will be given standard recommendations before the procedure: at least 8 hours of liquid and solid fasting.~During endoscopy, mucosal visibility will be evaluated in 6 segments (gastric antrum, lower gastric body, upper gastric body, fundus, first and second part of duodenum), using a scale ranging from 1 to 4 points:(1) no adherent mucus in the gastric mucosa examined; (2) a small amount of mucus in the gastric mucosa examined that does not hinder vision; (3) a large amount of mucus in the gastric mucosa examination, which can be washed thoroughly with \<50 mL of water; (4) a large amount of mucus in the gastric mucosa examined which requires ≥50 mL of water for washing."
62768452|NCT05951712|EXPERIMENTAL|N Acetyl cysteine 600 mg|"In this arm the participants will receive 600 mg N-acetyl cysteine dissolved in 100 ml water 10-30 minutes before the procedure under the supervision of a trained nurse.All patients will be given standard recommendations before the procedure: at least 8 hours of liquid and solid fasting.~During endoscopy, mucosal visibility will be evaluated in 6 segments(gastric antrum, lower gastric body, upper gastric body, fundus, first and second part of duodenum), using a scale ranging from 1 to 4 points:(1) no adherent mucus in the gastric mucosa examined; (2) a small amount of mucus in the gastric mucosa examined that does not hinder vision; (3) a large amount of mucus in the gastric mucosa examination, which can be washed thoroughly with \<50 mL of water; (4) a large amount of mucus in the gastric mucosa examined which requires ≥50 mL of water for washing."
62768453|NCT05951712|EXPERIMENTAL|Simethicone (150 mg) plus N Acetyl cysteine 600 mg combination|"In this arm, the participants will receive 150 mg simethicone and N-acetyl cysteine dissolved in 100 ml water 10-30 minutes before the procedure under the supervision of a trained nurse.All patients will be given standard recommendations before the procedure: at least 8 hours of liquid and solid fasting.~During endoscopy, mucosal visibility will be evaluated in 6 segments (gastric antrum, lower gastric body, upper gastric body, fundus, first and second part of duodenum), using a scale ranging from 1 to 4 points:(1) no adherent mucus in the gastric mucosa examined; (2) a small amount of mucus in the gastric mucosa examined that does not hinder vision; (3) a large amount of mucus in the gastric mucosa examination, which can be washed thoroughly with \<50 mL of water; (4) a large amount of mucus in the gastric mucosa examined which requires ≥50 mL of water for washing."
62768454|NCT02476123|EXPERIMENTAL|Mogamulizumab+Nivolumab|"During parts 1 and 2, Mogamulizumab and Nivolumab are administered at appropriate intervals.~Part 1 (Dose Escalation Part) During Cohort 1 to 2, Mogamulizumab and Nivolumab are administered in combination.~Part 2 (Expansion Part) Patients will be treated with maximum tolerated dose established in the dose escalation part for each combination."
62768455|NCT02179541||Group 1|All Group 1 patients were diagnosed with OME, diagnoses made by endoscopic-otoscopic examination findings and type-B tympanograms. They were all scheduled for ventilation tube insertion. Diagnosis of OME was confirmed during this surgery. All patients were examined by 4 mm 0-degree Storz endoscope and light source. The Adobe Photoshop Elements 7.0 program was used for RGB measurements. Viscosity was measured by the Brookfield DV-II+ProCP Viscometer.
62768456|NCT02179541||Group 2|Children in Group 2 had totally normal tympanic membranes and type A tympanograms. They had no hearing loss, Eustachian tube dysfunction, or any other ear-related problem, and were included in the study as healthy controls. Excluded from the study were patients presenting with acute otitis media, tympanosclerotic plaques, mental retardation, and children who were difficult to cooperate with. All subjects were examined by 4 mm 0-degree Storz endoscope and light source. The Adobe Photoshop Elements 7.0 program was used for RGB measurements.
62768457|NCT02179541||Group 1a|To determine whether higher or lower viscosity of an effusion impacted RGB values, the patient group was subdivided into two subgroups according to viscosity level. Patients with an effusion below the mean viscosity value of 450 cP (centipoise) were assigned to Group 1a.
62768458|NCT02179541||Group 1b|To determine whether higher or lower viscosity of an effusion impacted RGB values, the patient group was subdivided into two subgroups according to viscosity level. Patients with an effusion above the mean viscosity value of 450 cP (centipoise) were assigned to Group 1b.
62768459|NCT04274803|EXPERIMENTAL|Intralipid group|the patients will receive the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily. In addition intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.
62768460|NCT04274803|ACTIVE_COMPARATOR|Standard care group|the patients will receive the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.
62168294|NCT00774306|ACTIVE_COMPARATOR|1|Participants randomized to Group 1 will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
62168295|NCT00774306|ACTIVE_COMPARATOR|2|Participants randomized to Group 2 will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses or in a once-daily extended release formulation.
62168296|NCT00774306|ACTIVE_COMPARATOR|3|Participants randomized to Group 3 will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
62567696|NCT00687726|EXPERIMENTAL|G1|Standing balance and mini squat training
61992998|NCT01904604|PLACEBO_COMPARATOR|Placebo Patch|Subjects apply placebo Viaskin® patch daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an oral food challenge (OFC) and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC crossover to active treatment (using the same 21-day graduated dosing period used in the blinded phase) and dose with a high-dose DBV712 Viaskin® patch containing 250 μg peanut protein for a total active treatment period of 30 months (130 weeks).
62388314|NCT03918356|EXPERIMENTAL|Idiopathic Inflammatory Myopathies patients|Subjects with more than 2 of the following criteria, symmetric proximal weakness, elevated CK, electromyography (EMG) suggesting myositis, muscles biopsy showing inflammatory changes, and typical skin rashes of dermatomyositis (DM) will be recruited as dermatomyositis and polymyositis (DM/PM) based on Bohan and Peter criteria.
62388315|NCT03918356|PLACEBO_COMPARATOR|control|Healthy controls without any known neuromuscular disorders and no family history of Amyotrophic lateral sclerosis (ALS) will be recruited for the study.
62388316|NCT01442142|EXPERIMENTAL|Appetitie Awareness|"Parents and kids assigned to this group with learn about appetite awareness and to appropriately respond to their hunger meter."
62388317|NCT01442142|EXPERIMENTAL|Cue Reactivity and Sensitivity Training|Parents and kids in this group learn about how external cues can lead to overeating and how to better respond to these cues.
62388318|NCT01442142|EXPERIMENTAL|Combined CAAT/CRST|In this 14 week intervention combining Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST), parents and kids learn about both internal hunger cues and external cues that can cause one to overeat. Skills to learn the internal hunger cues and better responses to external cues are taught.
62388319|NCT01442142|NO_INTERVENTION|Control|Between baseline and the post-intervention data collection point, no intervention is given. Participants are given a take home binder of intervention materials at that second data collection point; they have the option of reviewing the material prior to the final follow-up data collection point.
62388320|NCT00836199|PLACEBO_COMPARATOR|Placebo vaccine|
62388321|NCT00836199|EXPERIMENTAL|NicVAX vaccine|
62388322|NCT01807442|OTHER|Optimal adherence|"Participants receive the qualitative interview and adherence intervention.~This arm includes participants with scores of greater than or equal to 15 on the Medical Outcomes Study Specific Adherence Scale. This scale ranges from a score of 3 (extremely low adherence to health behaviors) to a score of 18 (extremely high adherence to health behaviors). A score of greater than or equal to 15 suggests optimal adherence to health behaviors."
62388323|NCT01807442|OTHER|Sub-optimal adherence|"Participants receive the qualitative interview and adherence intervention.~This arm includes participants with scores of less than 15 on the Medical Outcomes Study Specific Adherence Scale. This scale ranges from a score of 3 (extremely low adherence to health behaviors) to a score of 18 (extremely high adherence to health behaviors). A score of less than 15 suggests sub-optimal adherence to health behaviors."
62388324|NCT02857049|EXPERIMENTAL|Geriatric patients administered with ONS|Oral nutritional supplements (ONS) degustation
62388325|NCT02917161|EXPERIMENTAL|Prostatic Artery Embolization (PAE)|PAE is performed 6weeks before RALP
62388326|NCT01446744|ACTIVE_COMPARATOR|Standard arm|Standard of care, palliative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
61992999|NCT01904604|EXPERIMENTAL|100 µg Peanut Patch|Subjects apply low-dose DBV712 Viaskin® patch containing 100 micrograms (μg) peanut protein daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an OFC and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC crossover to active treatment (using same 21-day graduated dosing period used in blinded phase for subjects 4-\<6 years old at enrollment or who had Grade 2 reaction or higher within previous 2 months) and dose with a high-dose DBV712 Viaskin® patch containing 250 μg peanut protein for a total active treatment period of 30 months (130 weeks).
62168297|NCT00774306|NO_INTERVENTION|4|Participants randomized to Group 4 will receive no drug intervention.
62168298|NCT01697592|EXPERIMENTAL|Omarigliptin 25 mg/Sulfonylureas (SUs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of SUs throughout the duration of the study.
62388327|NCT01446744|EXPERIMENTAL|Stereotactic arm|Stereotactic ablative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
62388328|NCT04416074|EXPERIMENTAL|Group psychotherapy group|Students will be intervened by an online 5-week professional identity group psychotherapy.
62388329|NCT04416074|OTHER|Controlled message push group|Students will receive online messages of self-care knowledge forward by researchers.
62388330|NCT02249377|EXPERIMENTAL|Platelets-Rich-Plasma Group|Patients will be asked to stop taking any type of anti-inflammatory medication from 7 days before the procedure to 2 weeks after and fasting for 3 hours before the procedure. At the moment of the procedure, the radiology team will draw 60ml of venous blood from the patient, the blood will be processed with different components of the PRP kit and centrifuged in the SmartPrep PRP machine, to obtain the PRP. The patient is then scanned prone using a linear 14 or 9 megahertz (MHz) transducer. A 20 Gauge spinal needle is usually employed for purposes of aspiration. Sterile saline will be used to confirm needle placement in the cyst in lieu of lidocaine and then inject the PRP by the radiologist.
62388331|NCT02249377|ACTIVE_COMPARATOR|Corticosteroid group:|Patients will be asked to stop taking any kind of anti-inflammatory medication from 7 days before the procedure to 2 weeks after but fasting in this group won't be required. An ultrasound guided aspiration and triamcinolone (40 mg) diluted with lidocaine without epinephrine and ropivacaine will be used to anesthetize the tissues down to the cyst (including within the cyst for steroid injections). A compression bandage will be placed locally for 7 days. Investigators will monitor any side effect from the injection and treat the patients per standard care - this can include prescription of analgesics.
62388332|NCT00954356|EXPERIMENTAL|XPF-001|
62768461|NCT05661045||Group DA|In the Group (DA), the standard consisting of electrocardiogram(ECG), peripheral oxygen saturation (Spo2), and non-invasive blood pressure will be monitored.Prior to induction, the first blood sample (To) will be taken for analysis. After induction of anesthesia with propofol and rocuronium, he will be intubated.Anesthesia will be maintained with desflurane (MAC:1), oxygen (50%), air (50%). After a high flow phase of 4 l/min for 10 min, the fresh gas flow will be reduced to 0.6 L/min and fentanyl,rocuronium will be administered intermittently. Patients will be ventilated with a ventilator at a constant tidal volume (kg x 6 mL) and respiratory rate (12/min). At the 1st hour of low flow anesthesia maintenance, a second blood sample (T1) will be taken for analysis. Patients will be awakened at the end of the case. After the recovery room, it will be transferred to the relevant service. A third blood sample (T2) will be taken at the postoperative 24th hour in the service for analysis.
62768462|NCT05661045||Group NA|In the Group (NA),the standard consisting of electrocardiogram(ECG), peripheral oxygen saturation (Spo2),non-invasive blood pressure will be monitored.Prior to induction, the first blood sample (To) will be taken for analysis.After induction of anesthesia with propofol and rocuronium, patients will be intubated. Anesthesia will be maintained with desflurane (MAC:1), oxygen (50%), air (50%). After a high flow phase of 4 l/min for 10 min, the fresh gas flow will be reduced to 2.0 L/min and fentanyl, rocuronium will be administered intermittently. Patients will be ventilated with a ventilator at a constant tidal volume (kg x 6 mL) and respiratory rate (12/min). A second blood sample (T1) will be taken for analysis at the 1st hour of normal flow anesthesia maintenance. Patients will be awakened at the end of the case. After the recovery room, it will be transferred to the relevant service. A third blood sample (T2) will be taken at the postoperative 24th hour in the service for analysis
61993000|NCT01904604|EXPERIMENTAL|250 µg Peanut Patch|Subjects apply high-dose DBV712 Viaskin® patch containing 250 micrograms (μg) peanut protein daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an OFC and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC continue active treatment with a high-dose DBV712 Viaskin® patch for a total active treatment period of 30 months (130 weeks).
62768463|NCT03529110|EXPERIMENTAL|Trastuzumab deruxtecan (T-DXd)|Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DXd as a sterile intravenous (IV) solution at a dose of 5.4 mg/kg every 3 weeks (Q3W).
61993001|NCT01514396|EXPERIMENTAL|Surgical Glue|Surgiseal
61993002|NCT00311896|EXPERIMENTAL|Bemiparin|
61993003|NCT00311896|PLACEBO_COMPARATOR|Placebo|
61993004|NCT06045091|EXPERIMENTAL|Human BCMA Targeted CAR-NK Cells Injection|Two doses on Day 0 and Day 7. 1.5×10\^8 CAR+NK cells/dose, 3.0×10\^8 CAR+NK cells/dose or 6.0×10\^8 CAR+NK cells/dose
61993005|NCT02276612|EXPERIMENTAL|E/C/F/TAF|"Treatment-experienced participants will receive open-label E/C/F/TAF for up to 48 weeks.~After completion of 48 weeks of treatment, all eligible participants will be given the option to participate in an open-label extension phase to receive E/C/F/TAF until a) the participant turns 18 years old and E/C/F/TAF is commercially available for use in adults in the country the participant is enrolled, or b) E/C/F/TAF becomes commercially available for use in the participant's current age group in the country the participant is enrolled, or c) E/C/F/TAF becomes accessible to participants through an access program, or d) Gilead Sciences elects to terminate development of E/C/F/TAF in the applicable country."
61993006|NCT05739851|EXPERIMENTAL|Sequence A(Before→ After)|
61993007|NCT05739851|EXPERIMENTAL|Sequence B(After→ Before)|
61993008|NCT04091503|ACTIVE_COMPARATOR|Intranasal Modified Temozolomide 75 mg/M2 per day|75 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
61993009|NCT04091503|ACTIVE_COMPARATOR|Intranasal Modified Temozolomide 150 mg/M2 per day|150 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
61993010|NCT04091503|ACTIVE_COMPARATOR|Intranasal Modified Temozolomide 200 mg/M2 per day|200 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
61993011|NCT00916474||Cohort A|Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time
62388333|NCT00954356|PLACEBO_COMPARATOR|Placebo|
62388334|NCT02200549|EXPERIMENTAL|Control group|Neither cycle training nor inspiratory muscle training.
61993012|NCT00916474||Cohort B|Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time
61993013|NCT05408416|ACTIVE_COMPARATOR|preoperative group|PDR patients who received ranibizumab injection (0.5mg/0.05ml) 3-5 days before vitrectomy were assigned to preoperative group
62388335|NCT02200549|EXPERIMENTAL|Cycle training group|A 30-minute cycling training session is performed 3 days a week using calibrated cycle ergometer.
62388336|NCT02200549|EXPERIMENTAL|Combined group|A 30-minute Combined training session is performed 3 days a week using calibrated cycle ergometer and threshold loading device.
62388337|NCT05381272||Cases|Infants born before 34 weeks of gestational age (WGA) with severe and early antenatal diagnosed intra uterine growth restriction
62388338|NCT05381272||Controls|infants born before 34 WGA at the same period, with no IUGR, apparied on sex and gestationnal age
62567697|NCT00687726|ACTIVE_COMPARATOR|G2|Isometric knee extension exercise
61993014|NCT05408416|EXPERIMENTAL|intraoperative group|PDR patients who received ranibizumab injection (0.5mg/0.05ml) at the end of vitrectomy were assigned to intraoperative group
61993015|NCT02680639|ACTIVE_COMPARATOR|optimal EPAP determination|On the BiPAP Synchrony ventilator the EPAP (and IPAP) will be automatically adjusted by the ventilator to find optimal EPAP that abolishes EFL. Peak-to-Peak pressure oscillations will be set at 2.5 cmH2O (centimeters of water)
61993016|NCT02680639|EXPERIMENTAL|Optimized EPAP w/ no peak-to-peak|On the BiPAP Synchrony ventilator the EPAP (and IPAP) will be set at optimal pressure as determined by the Auto EPAP. Peak-to-Peak pressure oscillations will be set at 0 cmH2O (centimeters of water)
61993017|NCT02680639|EXPERIMENTAL|Optimized EPAP w/ max peak-to-peak|On the BiPAP Synchrony ventilator EPAP (and IPAP) will be set at optimal pressure as determined by the Auto EPAP. Peak-to-Peak pressure oscillations will be set at 5 cmH2O (centimeters of water)
61993018|NCT02680639|EXPERIMENTAL|non-optimized EPAP w/ no peak-to-peak|On the BiPAP Synchrony ventilator EPAP will be set at 4 cmH2O and IPAP will be set at 10 cmH2O (centimeters of water). Peak-to-Peak pressure oscillations will be set at 0 cmH2O (centimeters of water).
62388339|NCT06358261|ACTIVE_COMPARATOR|Intervention Arm (DPACT)|In this arm, patients will have at least 2 visits with the participants primary care doctor. Before each visit, participants will complete a patient activation survey. Results of the survey will be shared with the primary care doctor and entered into the medical record so that the Diabetes Prevention Patient Activation Clinical Decision Support Tool can be used by the participants doctor during the visit to discuss lifestyle management.
62388340|NCT06358261|NO_INTERVENTION|Control Arm (Usual Care)|Patients in the control arm will follow the same visit schedule as the intervention arm. At the beginning of the study, participants will receive a handout on pre-diabetes which will include information on lifestyle changes and the benefits of joining a Diabetes Prevention Program. Before each visit, participants will complete a patient activation survey but the results will not be shared with the participants primary care doctor
62388341|NCT05560412|EXPERIMENTAL|Zein nanocapsules|Subjects will consume daily a powder dissolved in water with nanoencapsulated zein
62388342|NCT05560412|PLACEBO_COMPARATOR|control|Subjects will consume daily a powder dissolved in water with zein
62388343|NCT01234558|PLACEBO_COMPARATOR|Normal Saline|IV placebo
62388344|NCT01234558|EXPERIMENTAL|GLYX-13, 1 mg/kg|
62388345|NCT01234558|EXPERIMENTAL|GLYX-13, 5 mg/kg|
62388346|NCT01234558|EXPERIMENTAL|GLYX-13, 10 mg/kg|
62388347|NCT02155660|EXPERIMENTAL|Benralizumab Arm A|Benralizumab administered subcutaneously
62388348|NCT02155660|EXPERIMENTAL|Benralizumab Arm B|Benralizumab administered subcutaneously
62388349|NCT02155660|EXPERIMENTAL|Benralizumab Arm C|Benralizumab administered subcutaneously
62560150|NCT02748746|EXPERIMENTAL|Surgery no Lymphedema|The inclusion criteria for involving the first group is surgery time. No one will be involved into the first group if surgery was applied 18 months ago before enrollment to this study. Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum. Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
62560151|NCT02748746|EXPERIMENTAL|Surgery having Lymphedema|The second group will contain patients who had breast cancer surgery and having upper extremity lymphedema.Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio Impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum.Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
62768464|NCT03529110|ACTIVE_COMPARATOR|Ado-trastuzumab emtansine (T-DM1)|Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DM1 in accordance with the approved label.
61993019|NCT00892567|EXPERIMENTAL|9 Peptide Vaccine|
61993020|NCT03224702|EXPERIMENTAL|M6495|
61993021|NCT03224702|PLACEBO_COMPARATOR|Placebo|
61993022|NCT03858491|EXPERIMENTAL|Cobicistat|Cobicistat will serve as experimental drugs, and will be added to the regular treatment with osimertinib. Combination-treatment will be started at 150 milligram cobicistat, and can be increased to a maximum daily dose of 600 milligram cobicistat (four times 150 milligram).
61993023|NCT01750580|EXPERIMENTAL|Arm 1: Lirilumab + Ipilimumab|Lirilumab and Ipilimumab on specific days
61993024|NCT04738773|ACTIVE_COMPARATOR|Patients receiving Naltrexone|
61993025|NCT04738773|PLACEBO_COMPARATOR|Patients receiving Placebo|
61993026|NCT03480997|EXPERIMENTAL|albuterol sulfate 100 mcg|albuterol sulfate 100 mcg Test MDI
62168299|NCT01697592|EXPERIMENTAL|Omarigliptin 25 mg/Glinides (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of glinides throughout the duration of the study.
62388350|NCT02155660|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously
62388351|NCT02558595|EXPERIMENTAL|Niacinamide|Participants will be asked to take niacinamide at a dose of 30 mg/kg/d orally.
61993027|NCT03480997|ACTIVE_COMPARATOR|albuterol sulfate 200 mcg|albuterol sulfate 200 mcg Reference MDI
62388352|NCT02558595|PLACEBO_COMPARATOR|Placebo|Participants will be asked to take a placebo pill at a dose of 30 mg/kg/d orally.
62388353|NCT03216564|EXPERIMENTAL|Intervention Group|Participants are treated with angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) AND active vitamin D (Calcitriol) 0.25 micrograms orally per day for 26 weeks.
62388354|NCT03216564|NO_INTERVENTION|Usual Care|Participants are treated with ACEI/ARB alone for 26 weeks.
62388355|NCT03547882||Other|Target interviewees will be primary care providers at six facilities and their staff (e.g., nurse care managers).
62388356|NCT03547882||Patients|Ten interviews were conducted with VA patients receiving ORT.
62388357|NCT00701181|ACTIVE_COMPARATOR|Laser|This is a procedure - not a drug intervention.
62388358|NCT00701181|EXPERIMENTAL|PF-04523655 (High)|
62388359|NCT00701181|EXPERIMENTAL|PF-04523655 middle|
62388360|NCT00701181|EXPERIMENTAL|PF-04523655 low|
62388361|NCT03536689|EXPERIMENTAL|Upright maternal position change|The participant will be measured by ultrasonograhy for amniotic fluid index in supine position before maternal position change, then she will do the upright position for 5 minute. After 5 minute of upright position , she will lie down in supine position and she will be measured by ultrasonograhy for amniotic fluid index after upright position.
62388362|NCT03536689|EXPERIMENTAL|Left lateral decubitus maternal position change|the participant will be measured by ultrasonograhy for amniotic fluid index in supine position before maternal position change, then she will do the left lateral decubitus position for 5 minutes. After 5 minutes of left lateral decubitus position , she will lie down in supine position and she will be measured by ultrasonograhy for amniotic fluid index after left lateral decubitus position.
62388363|NCT01966952||Resistant Hypertension|Resistant hypertension as described as; patients with uncontrolled hypertension on 3 or more antihypertensive medications with no secondary causes for hypertension (i.e. hyperaldosteronism, renal artery stenosis)
62768465|NCT02877498|EXPERIMENTAL|Adaptive support ventilation|adaptive support ventilation mode during invasive mechanical ventilation
62768466|NCT02877498|ACTIVE_COMPARATOR|Volume controlled ventilation|Volume controlled ventilation during invasive mechanical ventilation
62168300|NCT01697592|EXPERIMENTAL|Omarigliptin 25 mg/biguanides (BGs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of BGs throughout the duration of the study.
62567698|NCT02252224||T2DM patients treated with Forxiga|Korean patients who are at least 18 years old, diagnosed with type2 diabetes and treated with Forxiga according to the approved lable
62388364|NCT03440606|EXPERIMENTAL|MCAT Supervision Group|The 6-week 3-hour Mindful-Compassion Art Therapy (MCAT) supervision will include intervention elements of brief psycho-education, weekly mindfulness mediation that serve as a foundation to foster creative art making, reflective writing, group sharing and discussion.
62388365|NCT03440606|EXPERIMENTAL|Waitlist Control Group|Those assigned to the waitlist control group will not receive Mindful-Compassion Art Therapy (MCAT) supervision until approximately 1.5 month later; equivalent intervention and assessment procedures will be administered.
62388366|NCT00129220|EXPERIMENTAL|Olanzapine|olanzapine: 5 to 20 mg per day for 6 weeks
62388367|NCT00129220|ACTIVE_COMPARATOR|Haloperidol|haloperidol: 2.5 to 10 mg per day for 6 weeks
62768467|NCT01122108|ACTIVE_COMPARATOR|Cholestyramine 12 grams|Cholestyramine 12 grams
62768468|NCT01122108|ACTIVE_COMPARATOR|Colesevelam HCl|Colesevelam HCl, 4 grams
62768469|NCT02530996|EXPERIMENTAL|Placebo before BH4|Six SSc received oral placebo 10 mg/kg and had flow mediated dilatation measured. After a five day washout they crossed over to oral BH4 10 mg/kg and had flow mediated dilatation measured. Blood samples were obtained from these SSc patients and assessed for oxidative stress.
62768470|NCT02530996|EXPERIMENTAL|BH4 before Placebo|Six SSc received oral BH4 10 mg/kg and had flow mediated dilatation measured. After a five day washout they crossed over to oral placebo 10 mg/kg and had flow mediated dilatation measured. Blood samples were obtained from these SSc patients and assessed for oxidative stress.
61993028|NCT03480997|EXPERIMENTAL|albuterol sulfate and ipratropium bromide|albuterol sulfate 100 mcg and ipratropium bromide 20 mcg Test MDI
61993029|NCT01119989|NO_INTERVENTION|weight maintenance diet|
61993030|NCT01119989|PLACEBO_COMPARATOR|weight maintenance + fructose|
61993031|NCT01119989|EXPERIMENTAL|weight maintenance diet + fructose and amino-acid|
61993032|NCT02290821|EXPERIMENTAL|diclofenac sodium gel 1%|diclofenac sodium gel 1%
61993033|NCT02290821|PLACEBO_COMPARATOR|Placebo|Placebo
61993034|NCT05228392|EXPERIMENTAL|lullaby group|For two weeks and 30 minutes every day at home, the lullaby group (LG) only listened to the lullaby record selected by the researcher
61993035|NCT05228392|EXPERIMENTAL|multi music group|For two weeks and 30 minutes every day at home, the multi-music group (MG) listened to self-selected music from different records presented to them by the researcher.
61993036|NCT05228392|NO_INTERVENTION|control group|The control group (CG) only received routine care. This group do not listened to music.
61993037|NCT04602858|EXPERIMENTAL|Reactive Balance Training|"Participants randomised to the intervention group will initially undertake 3 x 40 min training sessions of reactive balance training over 3 weeks followed by 3-monthly retraining sessions at 3, 6 and 9 months, and final assessment at month 12.~During the training, participants will be exposed to unpredictable slips and trips whilst they are walking on the Trip and Slip Walkway (Okubo et al. 2019). They will be required to consistently walk at their normal walking pace using our gait regulation protocol (i.e. individually adjusted stepping tiles and metronome). Each training session will involve up to 30 trips and slips which progress in unpredictability.~Participants will also receive a Staying active and on your feet fall prevention booklet containing guidance regarding fall risk factors including exercise, diet, vision, footwear, medications and home safety."
61993038|NCT04602858|ACTIVE_COMPARATOR|Control|"After exposing the control group to one trip and one slip at baseline, participants will then be provided with the Staying active and on your feet fall prevention booklet, an educational booklet providing guidance on fall risk factors including exercise, diet, vision, footwear, medications and home safety. The control group will then return for a reassessment after 12 months."
61993039|NCT01025427|EXPERIMENTAL|Elite controller|Sixteen controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
61993040|NCT04079153|ACTIVE_COMPARATOR|25% of maximal mandibular advancement|25% of maximal mandibular advancement of individual protrusion range
61993041|NCT04079153|ACTIVE_COMPARATOR|50% of maximal mandibular advancement|50% of maximal mandibular advancement of individual protrusion range
62768471|NCT05746936||Obese patients underwent laparoscopic gastric bypass|
62768472|NCT05746936||obese patients underwent robotic gastric bypass|
61993042|NCT02357940|EXPERIMENTAL|Adult Tolerance Assessment|Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
61993043|NCT02357940|EXPERIMENTAL|Baby (infants, toddlers, young children) Tolerance Assessment|Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
61993044|NCT00954642|EXPERIMENTAL|A|
61993045|NCT00954642|EXPERIMENTAL|B|
61993046|NCT02935790|EXPERIMENTAL|ACY-241 combo with Ipi and Nivo|ACY-241 in Combination with Ipilimumab and Nivolumab
61993047|NCT04626869|ACTIVE_COMPARATOR|Interscalene block|"patients will be placed in a semi-sitting position with their heads facing the opposite side. Linear ultrasound probe (GE Loqic P9 7-15 MHz) to detect the brachial plexus. At the cervical level 5-6, the posterior brachial plexus will be approached as in-plane from the posterior with the needle (Contiplex C, Braun) through the catheter. The nerve structure will be confirmed with stimulation in the upper extremity muscles with a nerve stimulator and 5 ml 0.5% Bupivacaine will be injected."
62768473|NCT03623178||Assertive Community Treatment|"patients with DSM-5 Diagnosis of SUD and one of the following criteria (1) present important functional difficulties, in at least one of the following areas: everyday life activities and maintaining a supportive social network, for minimum two years.~or (2) difficulties to attend their health care appointments, during the last 3 months."
61993048|NCT04626869|ACTIVE_COMPARATOR|Anterior suprascapular nerve block|"patients will be placed in a semi-sitting position with their heads facing the opposite side. Linear ultrasound probe (GE Loqic P9 7-15 MHz) will be placed in the suprascapular region in a coronal oblique manner. The omohyoid muscle, under it the suprascapular nerve, the brachial plexus and the subclavian artery will be identified. The suprascapular nerve will be approached from the posterior as in-plane with a needle (Contiplex C, Braun) through the catheter. The nerve structure will be confirmed by stimulation in the supraspinous muscle with a nerve stimulator and 5 ml 0.5% Bupivacaine will be injected."
61993049|NCT05585970|ACTIVE_COMPARATOR|healthy Control individuals|
61993050|NCT05585970|ACTIVE_COMPARATOR|CKD patients|
61993051|NCT05585970|ACTIVE_COMPARATOR|ESRD on regular hemodialysis|
61993052|NCT00280579||Cases|Cases would have had their blood cyanide concentration measured
62168301|NCT01697592|EXPERIMENTAL|Omarigliptin 25 mg/Thiazolidinediones (TZDs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of TZDs throughout the duration of the study.
62768474|NCT03623178||Treatment As Usual|patients with DSM-5 Diagnosis of SUD which do not respond to ACT inclusion criteria
61993053|NCT02386696|EXPERIMENTAL|Ultrasound findings|"Thoracic ultrasound examinations in the following conditions:~1. Apnea;~2. Spontaneous regular breathing;~3. Valsalva maneuver, during which each subject will be asked for performing three forced expirations with closed glottis after one forced inspiration;~4. Muller maneuver, during which each subject will be asked for performing three forced inspirations after one forced expiration;~5. Hyperventilation."
62388368|NCT00129220|PLACEBO_COMPARATOR|Placebo|placebo for 3 weeks, then olanzapine 5 to 20 mg per day for 3 weeks
61993054|NCT02184221|EXPERIMENTAL|High frequency stimulation|alpha burst, 8\~12Hz, run 2 seconds, rest 8 seconds, lasts 20 minutes each time
62388369|NCT01028794|EXPERIMENTAL|autologous bone marrow mononuclear cell|On day 7-10 after stroke, patient has 25ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.
62388370|NCT01028794|EXPERIMENTAL|autologous bone marrow mononuclear cells|On day 7-10 after stroke, patient has 50ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.
62388371|NCT00072215|EXPERIMENTAL|Regimen A: TIP|
62388372|NCT00072215|EXPERIMENTAL|Regimen B: VeIP|
62388373|NCT05836428||Persistent post-COVID-19 headache|post-COVID-19 patients with persistent headache
62388374|NCT05836428||controls|Mild Neuro-COVID-19 patients without persistent headache and other neurological diseases
62560152|NCT02748746|ACTIVE_COMPARATOR|Healthy Women|The third group will contain healthy women. Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio Impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum.Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
62768475|NCT05618093|EXPERIMENTAL|Patients diagnosed with PAH or CTEPH|Patients with a confirmed diagnosis or suspected diagnosis of pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) prior to initiation or change in therapy.
62768476|NCT04031872|EXPERIMENTAL|TGF-beta activated colorectal cancer|TGF-beta activated advanced colorectal cancer with LY3200882 and capecitabine
61993055|NCT02184221|ACTIVE_COMPARATOR|Low frequency stimulation|0.5Hz, run 0.5 seconds, rest 1.5 seconds, lasts 20 minutes each time
61993056|NCT01176227|PLACEBO_COMPARATOR|Kyodophilus matching placebo capsules|
61993057|NCT01176227|ACTIVE_COMPARATOR|Kyodophilus multi strain probiotic capsules|
62388375|NCT01156246|EXPERIMENTAL|1|Dapagliflozin/metformin tablet, high fat, high calorie breakfast day 1, visit 2, 7-14 days wash-out, Dapagliflozin/metformin tablet, fasting conditions day 1, visit 3.
62388376|NCT01156246|EXPERIMENTAL|2|Dapagliflozin/metformin tablet, fasting conditions day 1, visit 2, 7-14 days wash-out, Dapagliflozin/metformin tablet, high fat, high calorie breakfast day 1, visit 3.
62388377|NCT02036567||surgical patients|no interventions, observational study
62388378|NCT02036567||laboring women|no interventions, observational study
62388379|NCT02036567||volunteers|pain induction by noxious heat stimulation, measurement of pain by device and documentation of pain reported by subjects
62388380|NCT05342376|ACTIVE_COMPARATOR|Dexmedetomidine|This is group D, which will receive 10 micro-gram Dexmeditomidine diluted in 02 ml normal saline to be administered intravenously in 10 minutes after umbilical cord is clamped..
62388381|NCT05342376|ACTIVE_COMPARATOR|Saline|This group S will receive 02 ml normal saline intravenously as placebo in 10 minutes after umbilical cord is clamped..
62388382|NCT04414150|EXPERIMENTAL|SHR-1802|
62388383|NCT04998175|EXPERIMENTAL|iNPH cohort|The patients diagnosed of iNPH.
62388384|NCT03467035||desaturation|"ΔSpO2 \>10% or lowest SpO2\<90 during baseline six minute walk test~Check serum level of inflammasone, such as IL-1beta, TGF-beta TRT-PCR for PBMC"
62768477|NCT06164288|EXPERIMENTAL|hAESCs injection|Intravenous reinfusion of human amniotic epithelial cell injection, the number of injections is single
62768478|NCT04845191|EXPERIMENTAL|Experimental: Cohort 1: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous|Cohort 1 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous on Day 1
62768479|NCT04845191|EXPERIMENTAL|Experimental: Cohort 2: hAd5-S-Fusion+N-ETSD Subcutaneous and Oral|Cohort 2 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Oral on Day 1
62388385|NCT03467035||non-desaturation|"ΔSpO2 \<10% and lowest SpO2\>90 during baseline six minute walk test~Check serum level of inflammasone, such as IL-1beta, TGF-beta TRT-PCR for PBMC"
61993058|NCT00884299|NO_INTERVENTION|1|Free diet
61993059|NCT00884299|EXPERIMENTAL|Diet rich in antioxidants|Diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients in this arm will be seen regularly in the outpatient clinic where there will be informed for the potential beneficial effects of fruits and vegetables in health status by two members of the study team (attending physician and specialist nurse). At baseline and at each visit it is clearly explained to them that the dietary goal is to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the 3-year study period.
61993060|NCT02891707|ACTIVE_COMPARATOR|Control Group|The investigators will recruit 20 healthy subjects at Walter Reed National Military Medical Center (WRNMMC) with the goal of consenting and enrolling 15 healthy subjects to assess the reliability and validity the wearable Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD) system.
61993061|NCT02891707|ACTIVE_COMPARATOR|Amputee Group|The investigators will recruit a total of 130 subjects (65 at WRNMMC and 65 at the Miami VA) with the goal of consenting and enrolling 100 subjects (50 and WRNMMC and 50 at the Miami VA) with lower limb amputation to utilize the ReLOAD system.
61993062|NCT06362135|EXPERIMENTAL|Virtual home visit|to evaluate the effectiveness of virtual home visits in terms of time, cost and caregiver competence
61993063|NCT06362135|ACTIVE_COMPARATOR|Home visit|to evaluate the effectiveness of home visits in terms of time, cost and caregiver competence
62388386|NCT01678469|OTHER|blood sample|
62388387|NCT01265511|PLACEBO_COMPARATOR|Placebo|Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
62388388|NCT01265511|ACTIVE_COMPARATOR|SCY-635 600 mg|SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
62388389|NCT00877929|EXPERIMENTAL|Telmisartan 80 / Amlodipine 10|Telmisartan 80 / Amlodipine 5 for two weeks, then forced titration to Telmisartan 80 / Amlodipine 10 Fixed Dose Combination
62388390|NCT00877929|ACTIVE_COMPARATOR|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
62388391|NCT01741285|ACTIVE_COMPARATOR|Fluticasone|Two weeks treatment with HFA-Fluticasone 250 microgram twice daily
62388392|NCT01741285|ACTIVE_COMPARATOR|Clenil|Two weeks treatment with HFA-Clenil 200 microgram 2 inhalations twice daily.
62388393|NCT01741285|EXPERIMENTAL|QVAR|Two weeks treatment with QVAR 2 times 100 microgram twice daily
62388394|NCT05601271|PLACEBO_COMPARATOR|Placebo|pills exactly as the drug will be delivered to participants. Instructions will be made to take the pill once a day.
62388395|NCT05601271|ACTIVE_COMPARATOR|Allopurinol|pills exactly as the placebo will be delivered to participants. Instructions will be made to take the pill once a day.
62388396|NCT04314258|EXPERIMENTAL|Drinking Moringa oleifera tea|The experimental group will drink twice daily 2 tea bags of Moringa oleifera tea (Kanhye brand) infused in 200 ml of hot water (during 5 minutes) for a period of 4 weeks. The locally available Moringa tea with the international certification by ECOCERT France will be used in this study.
62388397|NCT04314258|NO_INTERVENTION|Drinking plain water|The control group will receive instructions to consume 200 ml of plain water twice daily for a period of 4 weeks.
62388398|NCT05970159||Hypoalbuminemia group|Patients with hepatocellular carcinoma whose preoperative serum albumin concentration are \< 36g/L.
62388399|NCT05970159||Normal group|Patients with hepatocellular carcinoma whose preoperative serum albumin concentration are ≥ 36g/L.
62388400|NCT00074789|EXPERIMENTAL|1|Participants will receive home-based interpersonal depression treatment for 26 weeks
62388401|NCT00074789|ACTIVE_COMPARATOR|2|Participants will receive attention control/usual care for 26 weeks
61993064|NCT02872779|EXPERIMENTAL|Patients Treated for Metastatic Colorectal cancer|Blood sampling for free mutant DNA analysis for Patients Treated for Metastatic Colorectal cancer
62388402|NCT03935945|EXPERIMENTAL|Personalized Feedback Intervention (PFI)|Participants in the intervention group will receive a computerized personalized feedback intervention (PFI) lasting approximately 20-30 minutes.
62388403|NCT03935945|NO_INTERVENTION|Attention-Control|Attention control information will be comparable in focus on health-related behaviors (e.g., nutrition, exercise). We will use behaviors in the attention control feedback that are not associated with study outcomes. Attention control feedback will have text and graphs that are similar in appearance and length (i.e., 20-30 minutes) to intervention feedback.
62388404|NCT04778111||Patients with exclusion|
62768480|NCT05204056|EXPERIMENTAL|Group A|Twenty patients who were given intraoperative joint cavity infusion therapy using 20ml tranexamic and 40ml iced normal saline.
61993065|NCT01734564|EXPERIMENTAL|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
61993066|NCT01734564|EXPERIMENTAL|Hiltonol, dendritic cells and radiation|Hiltonol, dendritic cells and radiation.
61993067|NCT06460896|OTHER|Patients eligible for bypass bariatric surgery and treated for metabolic syndrome|6 samples will be taken on the same day (T0, i.e. just before taking the drug, then T30 minutes, T1h, T2h, T4h, T7h after taking the drug).
62388405|NCT04778111||Control|
62388406|NCT02488265|EXPERIMENTAL|Motor training|Balance training, Screening to prevent falls
62388407|NCT02488265|EXPERIMENTAL|Balance RhytmicalTraining|Balance training, Screening to prevent falls
62388408|NCT04927585|EXPERIMENTAL|Group 1 (Treatment): DNA Vaccine + Protein Vaccine/GLA-SE|Participants will receive 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0, and Months 3, 6, and 12.
62388409|NCT04927585|PLACEBO_COMPARATOR|Group 1 (Control)|"Participants will receive placebo at Day 0, Months 3, 6, and 12.~Interventions:"
62388410|NCT04927585|EXPERIMENTAL|Group 2 (Treatment): Admixture of DNA Vaccine and Protein Vaccine|Participants will receive admixture of 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine (no adjuvant) at Day 0, and Months 1, 3, 6, and 8.
62388411|NCT04927585|PLACEBO_COMPARATOR|Group 2 (Control)|"Participants will receive placebo at Day 0, and Months 1, 3, 6, and 8.~Interventions:"
62388412|NCT03067701|EXPERIMENTAL|Carbon Monoxide Inhalation|In healthy young adults 18-39 years of age, The Investigator will determine if intermittent inhalation a 0.1% CO, from a 1-liter bag once every minute for 30-40 minutes, at a level that approaches the CO boost with hookah smoking, augments endothelial function, thus implicating CO as the major endothelial vasodilator substance in hookah smoke.
62388413|NCT00052494|EXPERIMENTAL|STI-571 with cisplatin and irinotecan|
62388414|NCT04554888|EXPERIMENTAL|Doxepin Application|During the session each forearm of the subject will be divided into four squared areas (2.5x2.5 cm), see Figure 4. Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours 48. At the end of the pre-treatment period, the patches will be removed and the skin will be cleaned with alcohol.
62388415|NCT04554888|EXPERIMENTAL|Itch Induction|After Doxepin removal, Then tests with papain, cowhage, histamine or vehicle will be conducted. Each substance will be randomly applied in two areas, one pretreated with doxepin and one with no pre-treatment.
62388416|NCT02699489|EXPERIMENTAL|Laparoscopic donor nephrectomy arm|This group will undergo laparoscopic donor nephrectomy
62388417|NCT02699489|ACTIVE_COMPARATOR|Open donor nephrectomy arm|This group will undergo open donor nephrectomy
62388418|NCT02643316|ACTIVE_COMPARATOR|Same day 4 L preparation of PEG|Receive 1 gallon (4 L) of Polyethylene Glycol (PEG) preparation on the morning of the colonoscopy.
62388419|NCT02643316|ACTIVE_COMPARATOR|Split dose 4 L preparation of of the PEG|Receive the split-dose regimen. Will take half (2 L) of the PEG preparation the evening before colonoscopy and half (2 L) of the PEG preparation on the morning of the procedure.
62388420|NCT00273715|NO_INTERVENTION|Staples|
62388421|NCT00551629|EXPERIMENTAL|AR51 (12, 10)|Participants were vaccinated with 0.5 ml of AR51 (12, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
62560153|NCT00581750||LCIS diagnosis|Patient with LCIS diagnosis
62768481|NCT05204056|EXPERIMENTAL|Group B|Twenty patients who were given 20ml of iced normal saline, 20ml of iced cocktail and 20ml of tranexamic
62768482|NCT05204056|ACTIVE_COMPARATOR|Control group|Twenty patients were given joint cavity infusion therapy with 20ml tranexamic only as the control group
62388422|NCT00551629|EXPERIMENTAL|PR51 (3, 10)|Participants were vaccinated with 0.5 ml of PR51 (3, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
62388423|NCT00551629|EXPERIMENTAL|PR51 (6, 10)|Participants were vaccinated with 0.5 ml of PR51 (6, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
62388424|NCT00551629|EXPERIMENTAL|PR51 (6, 15)|Participants were vaccinated with 0.5 ml of PR51 (6, 15) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
62388425|NCT06341738|EXPERIMENTAL|DIgital Education Group|The intervention group will receive information on HPV and the HPV vaccine from an 8-minute video in front of the class, two electronic reminder messages send to participant before the vaccination events
62388426|NCT06341738|ACTIVE_COMPARATOR|Usual Information Service Group|the control group will only receive the usual information service from staff
62388427|NCT05730049|EXPERIMENTAL|Active taVNS|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA. Pulse width will be set at 100μs and frequency will be set at 25Hz as performed in a previous protocol in stroke patients. Stimulation will be applied for a duration of 1 hour.
62388428|NCT05730049|SHAM_COMPARATOR|Sham taVNS|The control group will receive the same stimulation parameters but will have the earpiece placed in the sham position such that stimulation is applied to the earlobe and does not activate the vagus nerve.
62388429|NCT04176016|EXPERIMENTAL|Single Study Arm, no competitor|
62768483|NCT04463849|EXPERIMENTAL|COVID-19 positive patients|Patients will be enrolled in hospital for confirmed COVID-19 infection (with reverse transcriptase-polymerase chain reaction on the airway swab) but with normal basal glucose and no previous history of diabetes or impaired fasting glucose or impaired tolerance glucose. Patients will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.
62768484|NCT04463849|OTHER|Healthy volunteers|Healthy volunteers, not affected by COVID-19 and with no previous history of diabetes or impaired fasting glucose or impaired glucose tolerance will be enrolled. Healthy volunteers will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.
62768485|NCT04463849|OTHER|Type 2 diabetes patients|Patients with established Type 2 diabetes, not affects by COVID-19. Patients will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.
62768486|NCT00721539|OTHER|Transoral Robotic Surgery|Pilot study; single arm - use of da Vinci Surgical Robot Platform to access neoplastic disease of the upper aerodigestive tract.
62768487|NCT00259727||1|
62768488|NCT04185415|EXPERIMENTAL|bepranemab|Subjects will be randomized to receive bepranemab.
62768489|NCT04185415|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to receive Placebo.
62768490|NCT05620784|EXPERIMENTAL|Loop Diuretic (Furosemide)|This group of patients will receive 20mg of IV furosemide during the morcellation phase of their HoLEP.
62768491|NCT05620784|NO_INTERVENTION|Control|This group of patients will not receive 20mg of IV furosemide during the morcellation phase of their HoLEP.
62768492|NCT00870194|EXPERIMENTAL|1|
62768493|NCT00870194|PLACEBO_COMPARATOR|2|
62768494|NCT01771614|EXPERIMENTAL|Normoglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
62768495|NCT01771614|EXPERIMENTAL|Steady-State Hyperglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. During this time, steady-state hyperglycemia (\~10 mM) will be induced experimentally via a variable-rate intravenous infusion of 20% dextrose. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
62388430|NCT01854918|ACTIVE_COMPARATOR|Standard of Care|Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 48, participants began treatment with evolocumab at a dose of either 140 mg every 2 weeks (Q2W) or 420 mg every month (QM), based on participant choice, for approximately 2 years during the all-investigational product \[all-IP\] period.
62388431|NCT01854918|EXPERIMENTAL|Evolocumab + Standard of Care|Participants received subcutaneous evolocumab plus standard of care during the first year of the study (SOC-controlled period) and for approximately 2 years during the all-IP period. Evolocumab was administered at a dose of 140 mg every 2 weeks (Q2W) or 420 mg every month (QM) based on participant choice.
62768496|NCT01771614|EXPERIMENTAL|Fluctuating Hyperglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. During this time, fluctuating hyperglycemia (\~8-15 mM) will be induced by intravenously injecting 0.15 g/kg boluses of 20% dextrose every 30 minutes. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
62768497|NCT05296980|EXPERIMENTAL|REMINDER program online|The REMINDER program in this arm will be delivered by videoconferencing. It will integrate 20 sessions (with approximate length of 45-60 min), therapist-mediated, carried out twice a week, over a period of 12 weeks. Psychoeducation sessions and part of the reminiscence and memory strategies training sessions will be facilitated in groups, as means to promote social support and modeling, and the remaining will be individual sessions. Several activities aimed to promote personal development and definition and achievement of meaningful goals will be included in the program, and the program will be manualized to facilitate its future dissemination and implementation
62768498|NCT05296980|EXPERIMENTAL|REMINDER program face-to-face|The REMINDER program in this arm will be delivered face to face. It will integrate 20 sessions (with approximate length of 45-60 min), therapist-mediated, carried out twice a week, over a period of 12 weeks. Psychoeducation sessions and part of the reminiscence and memory strategies training sessions will be facilitated in groups, as means to promote social support and modeling, and the remaining will be individual sessions. Several activities aimed to promote personal development and definition and achievement of meaningful goals will be included in the program, and the program will be manualized to facilitate its future dissemination and implementation
62768499|NCT05296980|SHAM_COMPARATOR|Brain psychoeducation program|The control condition will have the same length as the experimental harms, including 20 psychoeducation sessions, with information regarding dementia modifiable risk factors, information on healthy lifestyles, and brain health promotion.
62768500|NCT00558532||Surgical|Those subjects undergoing bariatric surgery or abdominal surgery following a previous bariatric surgery.
62768501|NCT00558532||Control|Volunteers who have dietary habits similar to the subjects.
62768502|NCT02086201|ACTIVE_COMPARATOR|Problem Solving Therapy|Problem solving therapy is an evidence based psychotherapy for depression, with 30 years of research supporting its efficacy. PST focuses on the patients themselves and helps them develop skills in identifying, prioritizing, and solving problems, and thereby creates a sense of empowerment.
62388432|NCT03490734|ACTIVE_COMPARATOR|Beverage A (Sweetened)|"One quarter of the group to receive black cherry and orange flavored beverage with added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a water solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
62388433|NCT03490734|ACTIVE_COMPARATOR|Beverage B (Sweetened)|"One quarter of the group to receive strawberry kiwi \& lemonade flavored beverage with added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a water solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
62388434|NCT03490734|ACTIVE_COMPARATOR|Beverage A (Unsweetened)|"One quarter of the group to receive black cherry and orange flavored beverage no added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a water solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
62768503|NCT02086201|EXPERIMENTAL|Engage|"Engage utilizes reward exposure consisting of the reintroduction of activities that patients once found rewarding and enjoyed, but have abandoned after they developed depression. Engage uses basic problem solving through which patients learn how to form action plans for pursuing rewarding activities of their choice."
62768504|NCT01862835|EXPERIMENTAL|Degarelix/Te/placebo/ placebo|Degarelix 80 mg (given as two s.c. injections of 60 mg) once \[called day 1\]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral placebo once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
62768505|NCT01862835|EXPERIMENTAL|degarelix/Te/anastrozole/ placebo|degarelix 80 mg (given as two s.c. injections of 60 mg) once \[called day 1\]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral anastrozole 2.0 mg once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
62768506|NCT01862835|EXPERIMENTAL|degarelix/Te/ anastrozole/E2 patch|degarelix 80 mg (given as two s.c. injections of 60 mg) once \[called day 1\]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral anastrozole 2.0 mg once daily x 22 days; and an E2 patch calibrated to deliver 0.05 mg/day E2 beginning on day 1 and changed every 3 days through day 22.
62768507|NCT01862835|EXPERIMENTAL|degarelix/ placebo/placebo/no patch|degarelix 80 mg (given as two s.c. injections of 60 mg) once \[called day 1\]; placebo i.m. given on day 1, 8 and 15; Oral placebo once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
62768508|NCT01264614|EXPERIMENTAL|Early stage dementia|Individuals with early stage dementia who attended a Adult Day Care Program at least twice a week. Participants engaged in a strengthening exercise program three to five times per week for 10 weeks.
62768509|NCT01264614|ACTIVE_COMPARATOR|Normative older adults|Normative older adults with no known neurological condition. Participants engaged in a strengthening exercise program three to five times per week for 10 weeks.
62388435|NCT03490734|ACTIVE_COMPARATOR|Beverage B (Unsweetened)|"One quarter of the group to receive strawberry kiwi \& lemonade flavored beverage no added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a water solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
62388436|NCT03677752|EXPERIMENTAL|GP_Posit|Participants allocated to this arm will receive the GP_Posit intervention.
61993068|NCT05322174|EXPERIMENTAL|Baby Sleep|Those randomized to this intervention group will receive an interactive online intervention focused on promoting infant sleep. This will include membership in a private Facebook group with support provided in the group, including weekly resources in the form of videos and tip sheets. To supplement this, they will also receive items meant to help with sleep (ex. sleep sack, baby sleep book).
61993069|NCT05322174|ACTIVE_COMPARATOR|Baby Care|The active control condition will parallel the intervention, but will be focused on general baby care and not sleep. Participants will be added to a private Facebook group in which general baby care information will be shared (e.g., bathing, play) and will receive items to help with general baby care (e.g., baby care kit with items such as nail clippers and comb; general baby care book). Topics related to sleep and feeding will not be highlighted in this group.
62388437|NCT03677752|NO_INTERVENTION|Control|Participants in the control arm will receive usual care.
62388438|NCT01974414|ACTIVE_COMPARATOR|cedar honey|The two study groups were provided with standard treatment(dexamethasone and Fluconazole).The Case group(A) received cedar honey, 20 ml 3 times daily by swish and swallow technique, in addition to the standard treatment .
61993070|NCT05165212|EXPERIMENTAL|Patients receiving one dose of amoxicillin.|Patients receiving one dose of amoxicillin and then observed for one hour for signs/symptoms off allergic reaction.
62388439|NCT01974414|NO_INTERVENTION|control group|the control group (B) only received standard treatment(Dexametazone and Fluconazole).
62388440|NCT04135599|ACTIVE_COMPARATOR|real tDCS|Participants received 1.5mA tDCS for 20 minutes in 10 consecutive days.
62388441|NCT04135599|SHAM_COMPARATOR|sham tDCS|Participants received sham tDCS for 20 minutes in 10 consecutive days.
62388442|NCT04390334|EXPERIMENTAL|Treatment A: Daridorexant|Single dose of 50 mg daridorexant
62388443|NCT04390334|EXPERIMENTAL|Treatment B: Famotidine & daridorexant|Single dose of 40 mg famotidine followed 3 h later by a single dose of 50 mg daridorexant
62768510|NCT04454736|EXPERIMENTAL|SBGmentdis|Children and adolescents with mental disorders at the Department of Child and Adolescents Psychiatry in Salzburg, Austria
62768511|NCT04454736|EXPERIMENTAL|SBGhealthy|Healthy children and adolescents from schools in Salzburg, Austria
61993071|NCT05312229|EXPERIMENTAL|Replicating Effective Programs (REP)|A stakeholder-informed training and technical assistance implementation strategy
62388444|NCT04390334|EXPERIMENTAL|Treatment C: Efavirenz|600 mg efavirenz once daily in the evening from Day 5 to Day 14
61993072|NCT05312229|ACTIVE_COMPARATOR|REP + External Facilitation (Enhanced REP)|REP plus site specific weekly facilitation to support CTI implementation.
61993073|NCT05312229|NO_INTERVENTION|Control Group|No CTI implementation
62168302|NCT01697592|EXPERIMENTAL|Omarigliptin 25 mg/α-GIs (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of α-glucosidase (α-GIs) inhibitors throughout the duration of the study.
62168303|NCT01697592|PLACEBO_COMPARATOR|Placebo/SUs (Phase A) → Omarigliptin 25 mg/SUs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of SUs throughout the duration of the study.
62388445|NCT04390334|EXPERIMENTAL|Treatment D: Daridorexant & efavirenz|Single dose of 50 mg daridorexant in the morning of Day 15 followed by a single dose of 600 mg efavirenz in the evening of Days 15 and 16
62388446|NCT01201902|EXPERIMENTAL|Group 1 : Low dose with adjuvant|Group 1: 18 \~ 64 years old subjects
62388447|NCT01201902|EXPERIMENTAL|Group 1: High dose with adjuvant|Group 1: 18 \~ 64 years old subjects
62768512|NCT04454736|EXPERIMENTAL|VIEhealthy|Members from the Vienna Boys Choir, Austria
62768513|NCT01702168||CBT Training|
62768514|NCT01189305|EXPERIMENTAL|Behavioral Couples Therapy|
62388448|NCT01201902|ACTIVE_COMPARATOR|Group1 : Plain vaccine|Group 1: 18 \~ 64 years old subjects
62388449|NCT01201902|EXPERIMENTAL|Group 2 : Low dose with adjuvant|Group 2: greater than or equal to 65 years of age
62388450|NCT01201902|EXPERIMENTAL|Group 2 : high dose with adjuvant|Group 2: greater than or equal to 65 years of age
62388451|NCT04786899||Hispanic/Latino patients undergoing cardiothoracic surgery|Observational study of patients scheduled for cardiothoracic surgery as part of standard of care. Patients will be followed up to 30 days prior to surgery and up to 7 days after surgery or hospital discharge, whichever is sooner. Patients preoperative sleep patterns and postoperative delirium will be followed.
62388452|NCT06089226||Assessment Group|
62388453|NCT01623492||diagnosis of Eisenmenger Syndrome|subjects with diagnosis of Eisenmenger Syndrome
62388454|NCT00792922|ACTIVE_COMPARATOR|≥90% coverage with azithromycin target|Selected communities will receive mass treatment annually for three years.
62388455|NCT00792922|ACTIVE_COMPARATOR|80%-89% coverage with azithromycin target|Selected communities will receive mass treatment annually for three years.
62388456|NCT00792922|ACTIVE_COMPARATOR|≥90% coverage with azithromycin , treatment based|"Treatment to be administered at baseline then continued yearly if trachoma prevalence is greater than 5%~In Niger, treatment will be every 6-months for children ages twelve and under."
62560154|NCT02192463|EXPERIMENTAL|Nevirapine (NVP) ER 300 mg (KCR 20%) Medium Release|
62560155|NCT02192463|EXPERIMENTAL|NVP ER 300 mg (KCR 25%) Medium Release|
62768515|NCT01189305|EXPERIMENTAL|Individual Drug Counseling|
62768516|NCT04871594|EXPERIMENTAL|Nivolumab monotherapy|Day 1: nivolumab 240 mg Day 22: nivolumab 240 mg Day 43: nivolumab 240 mg
62768517|NCT01513681|EXPERIMENTAL|Lamotrigine Tablets 200 mg|Lamotrigine Tablets 200 mg of Dr. Reddy's Laboratories Limited
61993074|NCT06308068|EXPERIMENTAL|Generic diacerein 50 mg capsule|Each subject will receive a single dose of generic diacerein 50 mg capsule, EIDAR, as a test formulation (T), or a single dose of diacerein 50 mg capsule, with 240±2 mL of ambient temperature drinking water at 30 minutes after the start of standardized HFHC breakfast. Investigational product will be provided to subject in stainless steel cup and subject will be dosed without touching the tablet. This activity will be followed by a mouth check using a tongue depressor and a flashlight to assess the compliance of dosing. The formulations will be given in a crossover fashion as per the randomization schedule. The dosing processes will be conducted under normal light condition.
62388457|NCT00792922|ACTIVE_COMPARATOR|80%-89% coverage with azithromycin : treatment based|"Treatment to be administered at baseline then continued yearly if trachoma prevalence is greater than 5%~In Niger, treatment will be every 6-months for children ages twelve and under."
62388458|NCT04982276|EXPERIMENTAL|AK109 combined with chemotherapy|AK109 combined with paclitaxel, iv, every 3 weeks
62560156|NCT02192463|EXPERIMENTAL|NVP ER 300 mg (KCR 30%) Slow Release|
62560157|NCT02192463|EXPERIMENTAL|NVP ER 400 mg (KCR 25%) Medium Release|
62388459|NCT04982276|EXPERIMENTAL|AK104 and AK109 combined with chemotherapy|AK104 combined with AK109 and paclitaxel, iv, every 3 weeks
62388460|NCT01165268|ACTIVE_COMPARATOR|Dapagliflozin (T2DM)|
62388461|NCT01165268|ACTIVE_COMPARATOR|Dapagliflozin (Healthy Subjects)|
62388462|NCT01926366|EXPERIMENTAL|Experimental: AZD6423|Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo.
62388463|NCT01926366|PLACEBO_COMPARATOR|Placebo to match AZD6423|Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo.
62388464|NCT01647477|ACTIVE_COMPARATOR|questionnaires|4 questionnaires to answer at baseline 45 minutes approx.
62388465|NCT01647477|EXPERIMENTAL|interview|semi directive interview 105 patients
62388466|NCT00420823|PLACEBO_COMPARATOR|Placebo pill|4 placebo pills daily for 3 months
62388467|NCT00420823|EXPERIMENTAL|Taurine 4g|Taurine 4g daily comprising four 1g pills
62560158|NCT02192463|EXPERIMENTAL|NVP ER 300 mg (KCR 40%) Slow Release|
62560159|NCT02192463|EXPERIMENTAL|NVP ER 300 mg (ECR 20%) Fast Release|
62560160|NCT02192463|EXPERIMENTAL|NVP ER 400 mg (KCR 20%) Medium Release|
62768518|NCT01513681|ACTIVE_COMPARATOR|Lamictal® 200 mg Tablets|Lamictal® 200 mg Tablets of GlaxoSmithKline Inc
62168304|NCT01697592|PLACEBO_COMPARATOR|Placebo/Glinides (Phase A) → Omarigliptin 25 mg/Gln. (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of glinides throughout the duration of the study.
62768519|NCT01292564|ACTIVE_COMPARATOR|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
62388468|NCT02883010|EXPERIMENTAL|PICO|Single use NPWT (PICO Softport V1.6)
62388469|NCT02883010|OTHER|Standard care|Gauze dressing, Film dressing, foam dressing, skin glue, no dressing
62388470|NCT05752591||Enrolled patients with DM|
62388471|NCT02164890|OTHER|Pharmacokinetics of micafungin|
62388472|NCT04020224|EXPERIMENTAL|Treatment with pathogen reduced whole blood|Subjects will receive one amustaline/GSH treated whole blood product.
62388473|NCT04020224|ACTIVE_COMPARATOR|Treatment with Standard of Care|Subjects will receive the Standard of Care (SOC), either one red blood cell (RBC) component or one whole blood product
62388474|NCT05831956||Collagen group /Control group|"Patients who received collagen patches on the anastomotic site during colectomy were allocated to the collagen group.~Patients without collagen patches on the anastomotic site during colectomy were allocated to the control group."
62388475|NCT03080389||Extended urine culture|Each patient will be their own control and two specimens will be obtained from each participant. The first will be a catheterized urine sample to be sent for routine culture and the second will be collected from the same catheterized specimen and sent for extended culture.
62388476|NCT01761682||Ph-ALL|Diagnosed as ALL with Philadelphia-negative
62388477|NCT01761682||Ph+ALL|Diagnosed as ALL with Philadelphia-positive (including biphenotypic acute leukemia with Philadelphia-positive)
62388478|NCT01761682||Other ALL|Diagnosed as ALL of other type, including Burkitt leukemia
62388479|NCT03884868|NO_INTERVENTION|Control group|Regular nursing visit: 1. Explanation of the meaning of a positive result in the FIT. 2. Explanation of the need to perform a colonoscopy with sedation. 3. Anamnesis. 4. Agreement of the day and hour to perform the colonoscopy. 5. Explanation of the diet and delivery of preparation for the preparation of the colon.
62560161|NCT02192463|EXPERIMENTAL|NVP ER 400 mg (KCR 30%) Slow Release|
62560162|NCT02192463|EXPERIMENTAL|NVP ER 400 mg (KCR 40%) Slow Release|
62560163|NCT02192463|EXPERIMENTAL|NVP ER 400 mg (ECR 20%) Fast Release|
62560164|NCT02192463|ACTIVE_COMPARATOR|Nevirapine IR 1 tablet|
62560165|NCT02192463|ACTIVE_COMPARATOR|Nevirapine IR 2 tablets|
62560166|NCT00948272|EXPERIMENTAL|VRVg Group|
62560167|NCT00948272|ACTIVE_COMPARATOR|Verorab Group|
62560168|NCT06510699|EXPERIMENTAL|Precision Care|Voriconazole dosing will be initiated using current standard care dosing. Samples for TDM and genotype testing will be collected. Based on the results of these tests on Day 5, 8, 14, and up to day 30 ( ± 1 day) patients will be evaluated for dose adjustment using dosing software that includes patient data including TDM and genotype data.
62768520|NCT01292564|PLACEBO_COMPARATOR|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
62560169|NCT06510699|NO_INTERVENTION|Standard Care|Current standard of care at trial-site institutions uses weight-based (mg/kg) initial dosing of voriconazole, with dose adjustment based on standard therapeutic drug monitoring (TDM) results of measured voriconazole concentrations and based on clinical judgement.
62560170|NCT05425212|EXPERIMENTAL|Functional activation with kinesio tapping|given 5 cm wide kinesio tape at tibialis anterior and gastrocnemius to facilitate dorsiflexion of the ankle and inhibit planter flexion simultaneously along with conventional treatment.
61993075|NCT06308068|ACTIVE_COMPARATOR|Diacerein 50 mg capsule, ARTRODAR®|Each subject will receive a single dose of generic diacerein 50 mg capsule, , ARTRODAR®, as a reference formulation (R), with 240±2 mL of ambient temperature drinking water at 30 minutes after the start of standardized HFHC breakfast. Investigational product will be provided to subject in stainless steel cup and subject will be dosed without touching the tablet. This activity will be followed by a mouth check using a tongue depressor and a flashlight to assess the compliance of dosing. The formulations will be given in a crossover fashion as per the randomization schedule. The dosing processes will be conducted under normal light condition
61993076|NCT03794037|ACTIVE_COMPARATOR|control|dydrgesterone 10 mg( tab)/12hs/14 days
61993077|NCT03794037|EXPERIMENTAL|study|montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days
61993078|NCT05935007||Interventions|"Device: Aveir DR Leadless Pacemaker System~This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention will be conducted in this study."
61993079|NCT04991571|EXPERIMENTAL|Part 1|Participants will be administered with zibotentan once daily for 5 days.
61993080|NCT04991571|EXPERIMENTAL|Part 2: Treatment Sequence ABC|Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment A; Treatment B; Treatment C) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.
61993081|NCT04991571|EXPERIMENTAL|Part 2: Treatment Sequence BCA|Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment B; Treatment C; Treatment A) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.
61993082|NCT04991571|EXPERIMENTAL|Part 2: Treatment Sequence CAB|Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment C; Treatment A; Treatment B) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.
61993083|NCT01492452|NO_INTERVENTION|guidelines|22 parents in the intervention group were randomized and received standardized guidelines for nursing:The guidelines took around an hour and involved pre-operative care such as bathing with detergent solution, pre-anesthetic administration (as prescribed), preoperative fasting (as prescribed), clothing, hygiene care and nail oral. They were also provided information on the endotracheal tube, tubes, catheters, epicardial pacemaker wires and electrodes to be used in the perioperative period and which remain for some period after surgery, as well as possible complications.
61993084|NCT05682131|PLACEBO_COMPARATOR|Control group|Oral placebo was added to conventional chemotherapy
61993085|NCT05682131|EXPERIMENTAL|Experimental Group|Oral RIF was added to conventional chemotherapy
61993086|NCT04104009|EXPERIMENTAL|Interventional group|"In the exam group there will be group training for four meetings of one hour each.~After completing the training program with the test group, a break of 5 weeks will follow, during which a new test and control group will be formed. The procedure will be carried out until the estimated sample size (99 subjects per group) is met."
61993087|NCT04104009|ACTIVE_COMPARATOR|Control group|In the control group there will not be any group training.
61993088|NCT06488482|ACTIVE_COMPARATOR|12 months of immunotherapy|Standard immunotherapy (adjuvant +/- neoadjuvant), currently monotherapy with PD-1 inhibitor administered intravenously for 12 months.
62560171|NCT05425212|ACTIVE_COMPARATOR|Conventional physical therapy|strengthening and stretching, combined with Ankle ranges and Hip strengthening. (6) The exercises performed will be Calf stretches, Heel and Toe raises, Hip marching in sitting/standing; Heel walk; Pebble picking; Single leg standing; and Ankle range of motions
62560172|NCT02736552|EXPERIMENTAL|S-1 for 6 months|S-1 80-120mg daily for 14 days in 3 weeks for totally 6 months after D2 resection
62768521|NCT02845531|EXPERIMENTAL|ICD implantation and optimal medical therapy|
62768522|NCT02845531|ACTIVE_COMPARATOR|optimal medical therapy|
62388480|NCT03884868|EXPERIMENTAL|Intervention group|In addition of the regular nursing visit: the nurse will use iconographies specially designed to communicate the risk of the different possible diagnoses and the complications of the colonoscopy. Because the risks are different according to sex and age, specific iconographies will be developed from the data available in the first screening round.
62388481|NCT03873259|EXPERIMENTAL|Treatment Group|Subjects in this arm receive the 10-minute burst wave lithotripsy intervention dose during their standard-of-care lithotripsy procedure.
62768523|NCT01443130|EXPERIMENTAL|Chloroquine IPT|300 subjects to receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) will be administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.
61993089|NCT06488482|EXPERIMENTAL|6 months of immunotherapy|Standard immunotherapy (adjuvant +/- neoadjuvant), currently PD-1 inhibitor administered intravenously for 6 months.
61993090|NCT00733863|EXPERIMENTAL|1|
61993091|NCT00733863|PLACEBO_COMPARATOR|2|
61993092|NCT06427278||Patient group|A total of 60 primary CRC treatment-naïve Egyptian patients admitted to the Dar Al Shefa Hospital, Cairo, Egypt, were enrolled in the study.
61993093|NCT06427278||Healthy Control|30 age-matched and sex-matched apparently healthy volunteers, not receiving any medications or suffering from any disease, age range 30-60 years, were included as controls, male-to-female 1:1 (15/15). Control subjects were recruited randomly during routine check-up examinations for themselves or during blood donation.
61993094|NCT00506155|EXPERIMENTAL|Neoadjuvant Chemotherapy with M-VAC + Avastin|Avastin 10 mg/kg by vein over 90 minutes. Cisplatin 70 mg/m\^2 by vein over 4 hours. Doxorubicin 30 mg/m\^2 by vein over 15 minutes. Methotrexate 30 mg/m\^2 by vein over 30 minutes. Vinblastine Sulfate 3 mg/m\^2 by vein over 30 minutes.
62388482|NCT03341728|EXPERIMENTAL|Intervention, then Control|Older adults will walk during exposure to optical flow perturbations
62388483|NCT03341728|EXPERIMENTAL|Control, then Intervention|Older adults will walk normally (without optical flow perturbations)
62388484|NCT03162302||Healthy Subjects|Healthy volunteers will undergo 60 minute non-contrast enhanced Magnetic Resonance Imaging (MRI) of the abdomen using novel imaging sequences.
62388485|NCT03162302||Clinical Patients|Patients in whom an MRI is indicated for their disease condition will undergo the clinical scan, followed by up to 30 minutes non-contrast enhanced Magnetic Resonance Imaging (MRI) of the abdomen using novel imaging sequences. Clinical patients may also elect to undergo a research only scan of approximately one hour.
62388486|NCT05001672|EXPERIMENTAL|TAF arm|"54 patients will be randomized into TAF arm\*. TAF 25 mg QD will be initiated 7 days before bDMARDs, and continued for up to 144-weeks.~\*for patients received rituximab (anti-CD20 monoclonal antibody) will be enrolled into TAF arm, and TAF 25 mg QD will be initiated 7 days before rituximab, and continued for up to 144-weeks. Max 20 rituximab patients will be recruited."
62560173|NCT02736552|ACTIVE_COMPARATOR|S-1 for 1 year|S-1 80-120mg daily for 14 days in 3 weeks for totally 1 year after D2 resection
62560174|NCT05286177|EXPERIMENTAL|Volume-based EN|Volume-based EN algorithm arm.
62560175|NCT05286177|ACTIVE_COMPARATOR|Rate-based EN|Rate-based EN algorithm (standard of care).
62560176|NCT05804214||Infants who started feeding with the product at ≤ 4 months of age|Infants who started feeding with the product at ≤ 4 months of age, either supplemental to breastfeeding or as sole source of feeding
62560177|NCT04882813||Dapagliflozin|Exposure group
62560178|NCT04882813||Sitagliptin|Reference group
62560179|NCT01959633|EXPERIMENTAL|Vemurafenib+Cobimetinib + Peg-interferon|Vemurafenib 960 mg b.i.d. + Cobimetinib 60 mg o.d.(21 days on followed by 7 days off) + Peg-interferon 1/2/3 micrograms/Kg once weekly
62560180|NCT05976880|ACTIVE_COMPARATOR|Conventional treatment of isometric hand grip training exercises|In control group, conventional treatment perform by using isometric hand grip training exercises (putty grip and squeeze exercise, thumb pinch z strengthening exercises, isometric Hooks exercises, rubber band abduction and c thumb exercises) for 3times a week in one month.
62560181|NCT05976880|EXPERIMENTAL|Conventional treatment along with power ball training|In experimental group, 3sessions per week and total 12 training sessions in a month will be perform. In this session, conventional treatment perform with power ball exercise should be done for 3 minutes in a day, where power ball can initially alleviate the pain, then make them feel strong and in the end persons feel strengthen with pain free movements. Before start training with a power ball, hand held dynamometer will use prior to the first session, on 7th session of training and after 12th training session. So that changes in hand grip strength can be measured by dynamometer.
62560182|NCT02735902|EXPERIMENTAL|vitamin K antagonist or Direct oral anticoagulant treatment|"In this group, patients will receive monotherapy via anticoagulant (AVK or DOAC) excepted rivaroxaban; this treatment given corresponds to the anticoagulant treatment the patient was receiving before surgery. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient.~Intervention: anticoagulant"
62560183|NCT02735902|ACTIVE_COMPARATOR|vitamin K antagonist or Direct oral anticoagulant + Aspirin|"In this group, patients will receive combination therapy via anticoagulant (AVK or DOAC) and aspirin, whose daily dose is between 75 mg and 100 mg; the anticoagulant treatment administered corresponds to the anticoagulant treatment the patient was receiving before the procedure, monitored and adapted according to current recommendations. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient.~Intervention: anticoagulant Intervention: Aspirin"
61993095|NCT06025630|EXPERIMENTAL|Endoplasmic Reticulum Stress Inhibition|
61993096|NCT06025630|PLACEBO_COMPARATOR|Placebo|
61993097|NCT05712408|EXPERIMENTAL|Diet Intervention|8 week non-restrictive diet program
61993098|NCT03728894|ACTIVE_COMPARATOR|A: Midazolam-hydroxyzine with 100% O2|Midazolam-hydroxyzine with 100% O2 was administrated to 30 children. Drug: Oral Medication (midazolam 7.5 mg and hydroxyzine 10 mg) and Inhalation Gas 100% O2 Patients were randomly assigned to received one of two regimens (A,B) in across over design, Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
62168305|NCT01697592|PLACEBO_COMPARATOR|Placebo/BGs (Phase A) → Omarigliptin 25 mg/BGs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of BGs throughout the duration of the study.
61993099|NCT03728894|EXPERIMENTAL|Midazolam-hydroxyzine with 50% N2O/ O2|children received Midazolam-hydroxyzine with 50% N2O/O2, one tablet of oral midazolam 7.5 mg and one tablet of hydroxyzine 10 mg with 50% N2O/O2. Drug: Oral Medication and Inhalation Gas Patients were randomly assigned to received one of two regimens (A,B) in across over design, Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
61993100|NCT02852096|EXPERIMENTAL|Dual or Multiple Paraffin Blocks|Assessing Her2/neu Expression in Gastric Cancer with Dual or Multiple Tumor Tissue Paraffin Blocks
61993101|NCT02852096|ACTIVE_COMPARATOR|One Paraffin Blocks|Assessing Her2/neu Expression in Gastric Cancer with One Tumor Tissue Paraffin Blocks
61993102|NCT00344773|EXPERIMENTAL|Gefitinib|Gefitinib 250mg tablet once daily
61993103|NCT04710706|ACTIVE_COMPARATOR|Water-alone colonoscopy (water exchange technique)|During water-alone colonoscopy, gas insufflation (air or CO2) is not allowed during the insertion of the colonoscope to the caecum. Instead, water is used to facilitate the passage of the scope to the caecum. On withdrawal, CO2 is permitted.
61993104|NCT04710706|ACTIVE_COMPARATOR|Water-CO2 hybrid colonoscopy (modified water immersion technique)|During water-CO2 hybrid colonoscopy, the operator has access to both water and CO2. In the left colon, predominately water is used to navigate the sigmoid. Once the splenic flexure is reached, a combination of water and CO2 is used to reach the caecum. On withdrawal, CO2 is permitted.
62560184|NCT03732664|OTHER|Single arm|
62560185|NCT04066452||Single-group studies|"Patients will be informed about the study and their written informed consent will be requested.~Once included in the study:~* A series of clinical, analytical and echocardiographic parameters will be collected and measured~* Will be performed:~  * Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP)~ * Analytical to rule out monoclonal protein:~    * Proteinogram and serum immunoglobulins.~   * Light chains free in serum -Freelite-~   * Immunofixation in serum and urine.~* The number of readmissions, emergency visits and mortality in the following 12 months will be recorded to compare the readmission and mortality rates in one year of patients with and without CA.~* The prescribed pre- and post-diagnostic treatments will be described, according to clinical practice (without intervention).~* No intervention, whether diagnostic or follow-up, that is not the usual clinical practice will be applied to patients."
62560186|NCT03983980|EXPERIMENTAL|Tapinarof (DMVT-505) Cream Group|Tapinarof cream, 1%, applied once daily
62560187|NCT03983980|PLACEBO_COMPARATOR|Vehicle Cream Group|Vehicle cream applied once daily
62560188|NCT00459355|EXPERIMENTAL|Home Safety Toolkit|Intervention group receives home safety tool-kit with education and self-efficacy materials to promote competence to make home safety modifications.
62560189|NCT00459355|NO_INTERVENTION|Conventional Safety Checklist|Comparison group received a conventional home safety checklist
62388487|NCT05001672|OTHER|Observation arm|54 patients will be randomized into observation arm initially. These patients will be closely monitored their HBV status (including qHBsAg and HBV DNA) for 48 weeks. TAF 25 mg QD will be initiated for 144 weeks in the presence of HBV reactivation, or after 48 weeks of observation.
62388488|NCT00719693|EXPERIMENTAL|A|ABT-143 under low-fat meal condition
62388489|NCT00719693|EXPERIMENTAL|B|ABT-143 under fasting meal condition
62388490|NCT01760356||Healthy Volunteers No treatment|This is set as reference a cohort of untreated healthy volunteers, over which will be measured the biomarkers to determine the baseline. Implies PBMC ex-vivo exposure to Tacrolimus prior all cell incubations to study ex-vivo PD in stimulated conditions with mitogens to identify potential genetic sources of interindividual variability in physiological conditions Number proposed 30.
62388491|NCT01760356||Liver Transplant Patients on Tacrolimus|"To explore PD/PG/PK relationships of TAC residual PD activities ex-vivo in stimulated and non-stimulated conditions in liver recipients.~The number proposed is 50."
62560190|NCT06195137|EXPERIMENTAL|Caffeine group|Burning mouth syndrome (BMS) patients in Caffeine group were provided with BMS disease explanation and psychological counseling. Then they were told to drink instant coffee containing 120-150 mg of the active ingredient caffeine (2 bags of Nescafe Black Coffee, 1.8g each) at a certain point in time from 8:00 to 12:00 every day, for 2 consecutive weeks.
62560191|NCT06195137|ACTIVE_COMPARATOR|Alpha Lipoic Acid (ALA) group|Burning mouth syndrome (BMS) patients in the ALA group were provided with BMS disease explanation and psychological counseling. Then they took α-lipoic acid (ALA) 3 times a day, after meals, 200 mg each time, for 2 consecutive weeks.
62768524|NCT01443130|EXPERIMENTAL|Chloroquine Prophylaxis|300 subjects to receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week.
61993105|NCT03463746|EXPERIMENTAL|Experimental group (EG)|Subacute stroke patients will get standard individual physical therapy 2x/week, 45min and electromechanical-assisted gait training on LYRA® gait trainer 3x/week, 45min.
61993106|NCT03463746|ACTIVE_COMPARATOR|Comparator group (CG)|The CG will get standard individual physical therapy 5x/week, 45min without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
61993107|NCT06041412||DPN group|Patients with type 2 diabetic peripheral neuropathy were categorized into the DPN group
62560192|NCT06195137|NO_INTERVENTION|Control gruop|Without intervention treatment, we provided BMS patients in Control group with disease explanation and psychological counseling for patients.
62560193|NCT02044380|EXPERIMENTAL|Afatinib|patient to receive a tablet containing 40 mg afatinib once a day, with the option to reduce the dose to 30 or 20 mg/day, based on individual tolerability
62768525|NCT01443130|ACTIVE_COMPARATOR|SP IPT|300 subjects to receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.
62768526|NCT00568113|EXPERIMENTAL|NAC group|NAC given plus 17Oh progesterone caproate
62768527|NCT00568113|ACTIVE_COMPARATOR|Progesterone group|17 OH progesterone caproate
62768528|NCT03636607|EXPERIMENTAL|Non-metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
62768529|NCT03636607|EXPERIMENTAL|Metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
62768530|NCT03294629|NO_INTERVENTION|APAP begins without SensAwake|Patients will receive CPAP treatment without SensAwake™ activation for two weeks, then crossed-over to CPAP treatment with SensAwake™ activation for additional two weeks.
62768531|NCT03294629|EXPERIMENTAL|APAP begins with SensAwake|"Patients will receive CPAP treatment with SensAwake™ activation for two weeks, then crossed-over to CPAP treatment without SensAwake™ activation for additional two weeks.~SensAwake™ modification: SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep."
62768532|NCT02413411|EXPERIMENTAL|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
62768533|NCT02413411|ACTIVE_COMPARATOR|Attention Control|Patients randomized to the attention control arm will receive an educational program (an NIH-developed booklet) that summarizes how to live with knee OA but does not specifically mention joint replacement. This booklet provides examples of exercises one could do to improve pain and reduce stiffness from knee OA.
62768534|NCT01095354||Asthma Patients|Spirometry. Bronchodilator with Salbutamol. Induced sputum in \> 10 years of age using Sodium Chloride Inhalation. Multiple Breath Washout (MBW).
62768535|NCT05768243|EXPERIMENTAL|Treated with hyaluronic acid + SRP|After scaling and root planing, hyaluronic acid (GENGIGEL®) will be applied in the following forms (one ml of 0.8% HA was injected subgingivally once every four weeks), topically (0.2 ml of 0.8% HA applied by the patient twice daily for the following 14 days after the subgingival application).
62768536|NCT05768243|EXPERIMENTAL|Treated with red i-PRF + SRP|The red i-PRF will be injected into the pocket at the point of interdental space after SRP. Moreover, to control bleeding due to the needle tip after the procedure, a saline-soaked sponge will be placed between the lip and the gingiva and removed after 15 minutes. A total of four sessions of i-PRF will be administered to patients at a ten-day interval.
62768537|NCT05768243|NO_INTERVENTION|Scaling and root planing only|no adjunctive treatment will be done to scaling and root planing
61993108|NCT06041412||Diabetic group|patients with type 2 diabetes mellitus but not with DPN were distributed into the Diabetic group.
62388492|NCT01760356||Waiting List for Liver Transplantation|"To study the ex-vivo PD response to TAC in stimulated and non-stimulated conditions and the potential genetic sources of PD variability in pathological conditions.~The number proposed is 12."
62388493|NCT01760356||Liver Transplant Patients on Cyclosporine|"To explore PD/PG/PK relationships of CsA residual PD activities ex-vivo in stimulated and non-stimulated conditions in liver recipients.~The number proposed is 10."
62560194|NCT05285423|EXPERIMENTAL|Prolene suture technique.|The Group of Patients who were offered Vocal Cord Lateralization with prolene suture technique.
62768538|NCT05986903||HLA-DQA1*05 variant carriers|
62768539|NCT05986903||HLA-DQA1*05 non-carriers|
62768540|NCT02320344|EXPERIMENTAL|Partners in Care|
62768541|NCT05895539|NO_INTERVENTION|Control|Did not receive the tool
62768542|NCT05895539|EXPERIMENTAL|Intervention|Did receive the tool
62768543|NCT05491746|EXPERIMENTAL|Eye4|This is the arm with the Eyedaptic Device
62768544|NCT05491746|PLACEBO_COMPARATOR|Baseline|This is the placebo arm with the best correction the subject has
62768545|NCT02538133|EXPERIMENTAL|99mTc-Exametazime (HMPAO)-labeled leucocytes|
62768546|NCT05250791|ACTIVE_COMPARATOR|lidocaine|An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.
62768547|NCT05250791|PLACEBO_COMPARATOR|0.9% sterile Sodium Chloride solution for injection|An equivalent infusion rate (ml) of placebo will be administered following the induction of anaesthesia over 20 minutes followed by hourly equivalent intravenous infusion in ml/hr of placebo with a maximum rate of 6mls/hr (equivalent of 120mg/hour for lidocaine) for 24 hours.
61993109|NCT06041412||control group|The other individuals without type 2 diabetes mellitus were selected as the control group
61993110|NCT00690391||Surgical observation|patients with cancer in a palliative setting and in need of surgical interventions
61993111|NCT02712944|ACTIVE_COMPARATOR|Testosterone|Testosterone intramuscular every 2 weeks
61993112|NCT02712944|PLACEBO_COMPARATOR|Saline|Saline intramuscular every 2 weeks
61993113|NCT03215329||CPAP30|Alveolar recruitment maneuver with a continuous positive airway pressure (CPAP) at 30 cmH2O during 30 seconds
62388494|NCT01760356||Longitudinal Cohort|"Patients form the waiting list for liver transplantation will be enrolled and monitored at different times after transplantation to study the relationships between TAC PD and the clinical responses.~The number proposed is 20."
62388495|NCT01638546|EXPERIMENTAL|Arm I (veliparib and temozolomide)|Patients receive veliparib PO BID on days 1-7 and temozolomide PO on days 1-5.
62388496|NCT01638546|ACTIVE_COMPARATOR|Arm II (placebo and temozolomide)|Patients receive placebo PO BID on days 1-7 and temozolomide as in Arm I.
62560195|NCT04637503|EXPERIMENTAL|effectiveness of CAR-T cells targeting GD2, PSMA and CD276|Gene-modified T cells are designed to kill tumor cells through specific recognition of GD2, PSMA and CD276. This study will evaluate the side effects and effective doses of GD2, PSMA and CD276 CAR-T cells in treating refractory and recurrent NB
62560196|NCT03905798||Lorazepam|Patients administered Lorazepam in accordance with the indication (for Status Epilepticus, SE) and have no history of using this drug
62560197|NCT06265454|ACTIVE_COMPARATOR|myopic children atropine 0.05%|they will receive topical atropine 0.05% for 12 weeks and all investigations will be done before administration of atropine (baseline assessment), then after 1 month, 2 months, 3 months.
62560198|NCT06265454|ACTIVE_COMPARATOR|myopic children atropine 0.01%|they will receive topical atropine 0.01% for 12 weeks and all investigations will be done before administration of atropine (baseline assessment), then after 1 month, 2 months, 3 months.
62560199|NCT06265454|PLACEBO_COMPARATOR|myopic children placebo|they will receive placebo for 12 weeks and all investigations will be done before administration of placebo (baseline assessment), then after 1 month, 2 months, 3 months.
62560200|NCT02817763|ACTIVE_COMPARATOR|Connective tissue graft (CTG)|After local anesthesia, the surgical procedure performed was the trapezoidal-type of Coronally advanced flap (CAF). After the flap was raised, the exposed root surface was gently scaled and planed until it became smooth. Afterward, a thin and small connective tissue graft that was sutured over the root surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
62560201|NCT02817763|EXPERIMENTAL|CTG plus resin composite restoration|After local anesthesia, a sterile rubber dam was placed to isolate the operative field and the coronal zone of the non-carious cervical lesion restoration was performed with a nanocomposite resin, following the manufacturer's instructions. The apical margin of the restoration was place 1 millimeter beyond to the cemento-enamel junction estimation. In the next session, the surgical procedure performed was the trapezoidal-type of CAF. After the trapezoidal-type of CAF flap was raised, a thin and small connective tissue graft that was sutured over the restoration surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
62560202|NCT03866577|EXPERIMENTAL|Part A|Healthy volunteers will receive a single ascending dose of M254 or placebo
62560203|NCT03866577|EXPERIMENTAL|Part B|Immune thrombocytopenic purpura (ITP) patients will receive a single ascending dose of M254 followed by IVIg
62768548|NCT02880995|EXPERIMENTAL|patient group|"* 50 Drug-naïve patients with first episode psychosis (We anticipate the non-responder rate will be 30% of the patients)~  1. Drug-naïve~ 2. Diagnosed as first episode psychosis~ 3. The total score of PANSS\>70~ 4. No co-morbid psychiatric illness (including drug dependence/abuse)~* They will also undergo PET scan at the baseline. And the investigators are going to determine treatment response after 6 weeks of treatment with amisulpride. Also they should complete clinical scales at 0, 2, 4, 6, and 8 week."
62388497|NCT04197999|EXPERIMENTAL|Single Ascending Dose followed by Multiple Doses|Up to 3 single ascending doses of GMI-1359 followed by the highest tolerated dose given for 3 consecutive days.
62388498|NCT05465850|ACTIVE_COMPARATOR|Filtek Z350XT|
62388499|NCT05465850|EXPERIMENTAL|Essentia universal shade, GC composite|
62388500|NCT05465850|EXPERIMENTAL|Omnichroma composite|
62388501|NCT00242658|EXPERIMENTAL|Tailored Physical Activity Intervention Group|Four feedback reports aimed to increase physical activity.
62388502|NCT00242658|NO_INTERVENTION|No Tailored Physical Activity Intervention Group|General reports on preventive screening based on responses to preventive screening questions.
62560204|NCT03866577|EXPERIMENTAL|Part C|ITP patients will receive a single dose of M254 or IVIg, followed by a single dose of the other drug approximately 28 days later
62560205|NCT03866577|EXPERIMENTAL|Part D|ITP patients will receive repeated doses of M254
62560206|NCT02433132|OTHER|Diagnostic test|Diagnostic test will be perform on cell from nasal brushing
62560207|NCT04805905||Skin graft|
62560208|NCT04805905||Local flap|
62560209|NCT01008566|EXPERIMENTAL|Treatment (cixutumumab, sorafenib tosylate)|Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22 and oral sorafenib tosylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62560210|NCT01403402||Congenital Muscle Disease|The congenital muscle diseases include congenital muscular dystrophy, congenital myopathy, congenital myasthenic syndrome and bridge into the limb girdle/late onset spectrum. For data collection and analysis, subtype specific reports will be generated. True incidence of the congenital muscle diseases is unknown.
62768549|NCT02880995|OTHER|healthy control group|"* 12 healthy volunteers~  1. No history of psychiatric disorder (including drug dependence/abuse)~ 2. No history of physical illness~ 3. No contra-indication to scanning~* They will also undergo PET scan at the baseline"
62768550|NCT01459367|EXPERIMENTAL|TAK-438 10 mg QD|
62388503|NCT05280691|OTHER|Family Support Intervention|Families in the intervention group receive the Family Support Intervention in addition to usual care
62388504|NCT05280691|NO_INTERVENTION|Usual Care|Families in the control group will receive usual care.
62388505|NCT01979029|EXPERIMENTAL|preserving the left colic artery|We preserve the left colic artery and resect the No. 253 lymph node during the rectal surgery.
62388506|NCT01979029|EXPERIMENTAL|not preserving the left colic artery|We preserve the high ligation of the inferior mesenteric artery during the rectal surgery.
62768551|NCT01459367|EXPERIMENTAL|TAK-438 20 mg QD|
62388507|NCT05771246||Case group|Patients with third molar agenesis.
62388508|NCT05771246||Control group|Patients with the presence of all third molars.
62388509|NCT04621825|EXPERIMENTAL|Assigned intervention|"ActivHeal Silicone PHMB Adhesive and Non Adhesive Foam.~Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with ActivHeal Silicone PHMB Adhesive and Non Adhesive Foam."
62388510|NCT00166504|EXPERIMENTAL|Vytorin|Ezetimibe 10 mg/Simvastatin 20 mg
62388511|NCT00166504|ACTIVE_COMPARATOR|Atorvastatin|Atorvastatin 10 mg
62388512|NCT04118127|EXPERIMENTAL|2mg conventional tablet, once-weekly tablets|
62388513|NCT04853069|ACTIVE_COMPARATOR|Oestrogen Therapy|Patients will receive standard care + transdermal 17ß-estradiol gel (3 mg) for ten days.
62388514|NCT04853069|NO_INTERVENTION|Control Group|Patients will receive only standard care.
62388515|NCT01522391|PLACEBO_COMPARATOR|Placebo for DPK-060 ointment|
62388516|NCT01522391|EXPERIMENTAL|DPK-060 1% ointment|
62560211|NCT03286153|EXPERIMENTAL|Ideal Body Weight First|Randomized to receive factor product based on ideal body weight first
62560212|NCT03286153|EXPERIMENTAL|Actual Body Weight First|Randomized to receive factor product based on actual body weight first
62768552|NCT01459367|ACTIVE_COMPARATOR|Lansoprazole 15 mg QD|
62768553|NCT04485195|ACTIVE_COMPARATOR|Vernakalant|Patients randomized to this arm will receive an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump.82 For patients ≤ 100 kg the infusion is prepared by adding 25 mL of BRINAVESS 20 mg/mL to 100 mL of diluent creating a total volume of 125 mL at a concentration of 4 mg/mL. For patients \> 100 kg the infusion is prepared by adding 30 mL of BRINAVESS 20 mg/mL to 120 mL of diluent creating a total volume of 150 mL at a concentration of 4 mg/mL. For patients weighing ≥ 113 kg, the maximum initial dose is 339 mg (84.7 mL of 4 mg/mL solution).
62768554|NCT04485195|ACTIVE_COMPARATOR|Procainamide|Patients randomized to this arm will receive a continuous infusion of IV procainamide with a dose of 15 mg/kg in 500 mL of normal saline given over 60 minutes (maximum dose 1,500 mg), by a pre-programmed pump. While the CAEP Best Practices Checklist suggests an infusion time of 30-60 minutes, we believe that a 60-minute period will avoid some adverse events.
61993114|NCT03215329||PEEPsteps|Alveolar recruitment maneuver with a stepwise increase and decrease in positive end expiratory pressure from 5 to 20 cmH2O.
61993115|NCT02338869|EXPERIMENTAL|Dialogue-based psychosocial intervention|Participants receive six individual meetings with trained health care professional in additional to usual rehabilitation and care. Dialogues focus on individual psychosocial challenges and needs and provide emotional and informational support to encourage and facilitate coping.
61993116|NCT02338869|NO_INTERVENTION|Usual care Control group|Participants receive usual rehabilitation and care.
62768555|NCT01278316|EXPERIMENTAL|Cognitive training|Cognitive Intervention Tasks Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
62768556|NCT01278316|ACTIVE_COMPARATOR|Control|The control group will perform computerized tasks that utilize cognitive performance, but were not systematically developed to improve cognitive performance.
61993117|NCT01115595|ACTIVE_COMPARATOR|Intervention|injection by Mite extract with standard allergic medication (oral antihistamine and/or topical nasal steroid)
61993118|NCT01115595|OTHER|Control Group|Injection by buffer solution WITH standard allergic medication (oral antihistamine and/or topical nasal steroid
62388517|NCT01970384|EXPERIMENTAL|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
62388518|NCT01970384|SHAM_COMPARATOR|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
62388519|NCT01019733|EXPERIMENTAL|Patients|Children whom will receive intrathecal autologous stem cells
62388520|NCT03900182|ACTIVE_COMPARATOR|HBO treated group|Patients in the treated group were evaluated three - at baseline, after 6 weeks of HBOT and after 6 weeks of neuropsychological treatment or no treatment.
62388521|NCT03900182|SHAM_COMPARATOR|crossover group|Patients in the crossover group were evaluated three times: baseline, after 6 weeks control period of no treatment, and after subsequent 6 weeks of HBOT
62768557|NCT05500300|EXPERIMENTAL|Neo-Russian Electrical Stimulation|"Subjects will receive Neo-Russian electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, a fatigue will be done with this type of current."
61993119|NCT03012113|OTHER|Short term mild cooling|Subjects will undergo a short term mild cooling protocol consisting of personalized water cooling method for approximately 2 hours.
61993120|NCT03012113|ACTIVE_COMPARATOR|Mirabegron|Subjects will receive one dosage of 200 mg Mirabegron (Astellas Pharma).
61993121|NCT03012113|PLACEBO_COMPARATOR|Placebo|Subjects will receive one dosage of Placebo, which is packed and labeled to mach the active compound.
61993122|NCT06330922||Group 1: healthy individuals (cross-sectional study)|Typically developed adolescents and young adults will be recruited and measured once within the cross-sectional study.
61993123|NCT06330922||Group 2: mildly affected individuals with cerebral palsy (cross-sectional study)|Mildly affected adolescents and young adults will be recruited and measured once within the cross-sectional study.
61993124|NCT06330922||Group 3: moderately and severely affected individuals with cerebral palsy (cross-sectional study)|"The results of the baseline assessment (T0) of the adolescents and young adults with moderate to severe cerebral palsy will be compared with group 1 and group 2.~After the baseline assessment (T0) also used for the group comparison (see description above), group 3 enters a 12-week control period following daily routines. After the 12 weeks, the individuals will be assessed (T1) and will then start with the 12-week cardiorespiratory fitness training. The final assessment (T2) will terminate study participation of group 3."
61993125|NCT03777293|EXPERIMENTAL|training cohort|ultrasound viscoelasticity
61993126|NCT03777293|OTHER|testing cohort|ultrasound viscoelasticity
61993127|NCT01649375|EXPERIMENTAL|Secukinumab 75 mg|Secukinumab 75 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks.
62388522|NCT02404324|EXPERIMENTAL|spectacles|"Esotropia is treated by full optical correction (spectacles prescription) in all children with refractive errors. Special attention is paid to astigmatism up to 0.5 Dptr.~Intervention: Prescription of spectacles"
62560213|NCT04057742||Group A|30 participants with a positive virtual crossmatch (VXM) at the time of transplant will be monitored for 12 months and undergo protocol biopsies on months 3 and 12 to detect subclinical rejection. Participants may also undergo clinically indicated biopsies for suspicion of rejection. AlloSure, AlloMap, immune cell phenotypes, and inflammatory cytokines will be measured at baseline (within 48 hours of transplant), 3 weeks, 6 weeks, 3 months (Standard of Care (SOC) biopsy), 6 months, 12 months (SOC biopsy), and additionally at the time of any indication biopsy (5-7 time points/participant). Participants in this group will be monitored for 12 months. Participants will be offered the option of donating either 22.5 mL of blood (Allosure+AlloMap+cytokines) or 52.5 mL of blood (Allosure+AlloMap+cytokines+immune cell phenotyping) at each visit. Participants may change their donation volume from 22.5 mL to 52.5 mL at any point during the study.
62560214|NCT04057742||Group B|24 participants with De novo donor specific antibodies (dnDSA) will undergo a SOC biopsy within approximately three months to determine the incidence of Active Antibody Mediated Rejection (AMR). Immune cell phenotyping, AlloSure, and AlloMap will be measured at the time of the SOC biopsy (1 timepoint/patient). This is a single-time point study, unless participants are diagnosed with AMR and require treatment. In this case, they would be enrolled in group C (see below).
62560215|NCT04057742||Group C|15 additional participants with the diagnosis of Chronic Active Antibody Mediated Rejection (cAMR) will undergo standard of care therapy and be monitored for treatment response with a follow-up biopsy at three months. Immune cell phenotyping, AlloSure, and AlloMap will be used at baseline (prior to index biopsy) and 3 month (follow-up surveillance biopsy) (2 timepoints/participant). Participants in this group will be monitored per SOC for three months (time between the two biopsies).
62560216|NCT00755742|EXPERIMENTAL|Group 1 - Viremic / Non-cirrhotic|13 obese and insulin resistant, non-cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with chronic hepatitis C (HCV RNA positive) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who are naive to antiviral therapy, relapsed or not responded to antiviral therapy.
62560217|NCT00755742|ACTIVE_COMPARATOR|Group 2 - Non-viremic / Non-cirrhotic|13 obese and insulin resistant, non-cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with cured chronic hepatitis C (HCV RNA negative) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who have cleared hepatitis C virus with previous antiviral therapy.
62560218|NCT00755742|EXPERIMENTAL|Group 3 - Viremic / Cirrhotic|13 obese and insulin resistant, cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with chronic hepatitis C (HCV RNA positive) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who are naive to antiviral therapy, relapsed or not responded to antiviral therapy.
62560219|NCT00755742|ACTIVE_COMPARATOR|Group 4 - Non-viremic / Cirrhotic|13 obese and insulin resistant, cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with cured chronic hepatitis C (HCV RNA negative) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who have cleared hepatitis C virus with previous antiviral therapy
62560220|NCT00987337|EXPERIMENTAL|Arm A|"Filibuvir 300 mg BID + pegIFN/RBV x 24 weeks (subjects with undetectable HCV RNA at week 4)~- or - Filibuvir 300 mg BID + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks (subjects with detectable HCV RNA at week 4)"
62560221|NCT00987337|EXPERIMENTAL|Arm B|"Filibuvir 600 mg BID + pegIFN/RBV x 24 weeks (subjects with undetectable HCV RNA at week 4)~- or - Filibuvir 600 mg BID + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks (subjects with detectable HCV RNA at week 4)"
62560222|NCT00987337|PLACEBO_COMPARATOR|Arm C|Placebo + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks
62560223|NCT01452243|EXPERIMENTAL|Calcium and vitamin D|The pharmacological intervention will be the daily administration of chewable tablets containing vitamin D and calcium.
62560224|NCT03746847||Patients with Suspected Cardiac Sarcoidosis|patients with biopsy proven or suspected sarcoidosis (based on standard clinical imaging findings).
62567699|NCT01870973|EXPERIMENTAL|root canal treatment|root canal treatment, anesthesia with 2% lidocaine with 1:100,000 epinephrine, pain medication (1000 mg acetaminophen and 600 mg ibuprofen every 6 hours)five day supply, antibiotic (500 mg penicillin, if allergic 300 mg clindamycin)
61993128|NCT01649375|EXPERIMENTAL|Secukinumab 150 mg|Secukinumab 150 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks
61993129|NCT01649375|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks
61993130|NCT05721274|EXPERIMENTAL|Intervention|"The study will adopt a pretest/post-test quasi-experimental design. The approach of the proposed project is to implement a participatory community engagement and demand creation strategy with trust-building community mobilization and a conditional community-based incentive scheme to reduce the refusals to vaccination and improve polio immunization coverage in intervention UCs. Clusters will be formed on a population of 1500-2000 in each intervention UC. Committees would be formed with approximately 5-7 prominent members of the community.~Intervention Non-cash, incentives would be given and decided with consensus by UC committees and aim to improve infrastructure linked to health including water and sanitation and toilets in the community."
62388523|NCT05706831|EXPERIMENTAL|Group 1|Group 1 will receive tEs combined with music stimulation for 2 weeks, 1 week of wash out, then sham stimulation combined with noise (placebo) for other 2 weeks.
62388524|NCT05706831|EXPERIMENTAL|Group 2|Group 2 will receive sham stimulation and noise (placebo) for the first 2 weeks, then 1 week wash out, and finally tEs and music stimulation for other 2 weeks.
62388525|NCT05706831|EXPERIMENTAL|Group 3|Group 3 will receive only music stimulation and sham stimulation for 2 weeks, 1 week of wash out, then sham stimulation and noise (placebo) for another 2 weeks.
62388526|NCT03661658|ACTIVE_COMPARATOR|Inferior alveolar nerve lateralization with implant placement|
62388527|NCT03661658|EXPERIMENTAL|Using short dental implant with atrophic mandible|
62388528|NCT06196372|EXPERIMENTAL|Experimental: Intervention|An online mindfulness nursing support program (MenoMind) was applied to this group for 8 weeks and lasting an average of 50 minutes.
62768558|NCT05500300|EXPERIMENTAL|Aussie Electrical Stimulation|"Subjects will receive Aussie electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, a fatigue will be done with this type of current."
62768559|NCT05500300|EXPERIMENTAL|RBS Electrical Stimulation|"Subjects will receive RBS electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, a fatigue will be done with this type of current."
62388529|NCT06196372|NO_INTERVENTION|Control|The control group received no intervention and the women were left to routine clinical care.
62560225|NCT05659199|EXPERIMENTAL|extracorporeal shockwave therapy|extracorporeal shockwave group: Patients will be treated with extracorporeal shockwave therapy (ESWT) with bladder lithotomy position, twice a week for 4 weeks, 3,000 individually with a maximum total energy flow density of 0.25 mJ/mm2, rate 3Hz each time. Extracorporeal shockwave (RUIDI.SWT001, Shenzhen, China) can provide a kind of physical spark wave energy, that will be delivered by the probe. The water sac probe will be moved slowly over the groin, perineum and crura of the penis.
62560226|NCT05659199|EXPERIMENTAL|myofascial release therapy|myofascial release group: Based on the palpation findings, pressure was applied at 1 kg/cm2 (within the patient's tolerable range depending on the individual) to the points where patients had a VAS pain score of 4 or more during palpation. Intermittent pressure will be applied for 180-210s at the tenderness until the muscle relaxed.
62560227|NCT05659199|EXPERIMENTAL|extracorporeal shockwave combined with myofascial release therapy|Combined therapy group: On top of the routine palpation, the combined intervention group will be then treated with extracorporeal shockwave and myofascial release therapy in identical format as that in the intervention A and B
62560228|NCT02773147|EXPERIMENTAL|Triobe|Cyanocobalamin 0,5 mg. Daily for 24 months. Folate 0,8 mg. Daily for 24 months. Pyridoxine 3,0 mg. Daily for 24 months.
62560229|NCT02773147|NO_INTERVENTION|Control|
62560230|NCT02922920|EXPERIMENTAL|Tart cherry juice|Participants consumed 16 fl. oz of tart cherry juice daily for 12 weeks.
62560231|NCT02922920|PLACEBO_COMPARATOR|Placebo juice|Participants consumed 16 fl. oz of placebo daily for 12 weeks.
62560232|NCT05927012|EXPERIMENTAL|Part 1 (Initial Titration Strategy)|KER-047(30 mg, 60mg or 80mg) oral tablet daily (or every other day) for up to 24 weeks.
62768560|NCT05500300|EXPERIMENTAL|RBS-IPI Electrical Stimulation|"Subjects will receive RBS-IPI electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, a fatigue will be done with this type of current."
62768561|NCT05500300|EXPERIMENTAL|HIFEM|"Subjects will receive HIFEM electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, a fatigue will be done with this type of current."
62768562|NCT04077372|EXPERIMENTAL|Serious illness conversation guide (SICG)|"Patients have serious illness conversation within 3 wks of randomization and every 3 months thereafter."
62388530|NCT05042531|EXPERIMENTAL|experimental group|Patients with intermediate and high risk AML were negative for minimal residual disease after intensive induction and consolidation chemotherapy,the patients were randomly divided into two groups, and one group was given azacitidine(75mg/m2, per day on day 1-7\]. Dasatinib 100 mg p.o. qd was administered on days 1-28 of each consolidation cycle.
62388531|NCT05042531|ACTIVE_COMPARATOR|control group|Patients with intermediate and high risk AML were negative for minimal residual disease after intensive induction and consolidation chemotherapy,the patients were randomly divided into two groups, and the other group was given azacitidine(75mg/m2, per day on day 1-7)on days 1-28 of each consolidation cycle.
62560233|NCT05927012|EXPERIMENTAL|Part 2 (Cohort Expansion or Alternate Titration Strategy)|The starting dose regimen and titration schedule of KER-047 oral tablet will be based on the SRC (Safety Review Committee) recommendation from Part 1.
62560234|NCT00129389|ACTIVE_COMPARATOR|Arm A: FAC|FAC X 6 The standard arm consisted of six cycles of FAC (fluorouracil 500 mg/m2, doxorubicin 50mg/m2, and cyclophosphamide 500mg/m2) administered once every 3 weeks.
62560235|NCT00129389|EXPERIMENTAL|Arm B: FAC-wP|FAC X 4 + 8 weekly Paclitaxel (wP) Patients in the experimental arm received four cycles of the FAC regimen followed by eight weekly administrations of paclitaxel (100mg/m2 per dose)
62560236|NCT02923232|EXPERIMENTAL|Accommodative contact lens|The accommodative contact lens is composed of traditional hydrogel lens material but has an internal cavity to allow lens deformation that increases its refractive power at an downward angle.
62560237|NCT04937413|EXPERIMENTAL|Single dose of evolocumab|420 mg of evolocumab subcutaneous injection 7-14 days before scheduled surgery for malignant glioma
62560238|NCT03514459|NO_INTERVENTION|Control|Control clinics: Clinics randomized to the control arm will continue usual procedures. Periodic evaluation of cervical cancer screening rates will be examined every 3 months using FP register data.
62768563|NCT04077372|ACTIVE_COMPARATOR|Conversations by treating team|Patients have conversations as determined by treating team (but not using SICG tool).
62560239|NCT03514459|EXPERIMENTAL|Intervention with SAIA|Clinics randomized to the intervention arm will be introduced to the five steps of SAIA by study staff. The cascade analysis will be performed within the FP clinic to identify drop-offs in cervical cancer screening and referrals, using an Excel-based tool adapted from previous SAIA trials. Flow mapping performed by clinic and study staff will describe the cervical cancer screening process including who the client interacts with, timing of these interactions, any cervical cancer screening performed, and any referrals made. Initial drafts will be reviewed together with clinic and study stuff to ensure adequate and complete representations of processes. Study staff will work with clinic staff to identify bottlenecks in the process and potential solutions to improve flow. Proposed solutions will be implemented, and the process will be examined again to determine the effect of the implemented changes. The cycle will be repeated approximately every 6-8 weeks during the RCT.
62388532|NCT02275052|EXPERIMENTAL|UMEC/VI 62.5/25mcg|Participants will self-administer blinded UMEC/VI (62.5 mcg/25 mcg) each morning (once daily) as one inhalation from the double-blind DPI in one of the 2 treatment periods of 12 weeks. The treatment periods will be separated by a wash out period of 12-17 days.
62388533|NCT02275052|EXPERIMENTAL|Placebo|Participants will self-administer blinded placebo each morning (once daily) as one inhalation from the double-blind DPI in one of the 2 treatment periods of 12 weeks. The treatment periods will be separated by a wash out period of 12-17 days
62560240|NCT04727385|EXPERIMENTAL|single-arm of 3 cohorts|"These patients will be sequentially recruited in 3 cohorts :~* One disc level cohort: 5 patients with only one disc to be treated; First enrolled cohort with 48 weeks of follow-up (9 visits V1-V9)~* Two disc level cohort: 5 patients with 2 discs to be treated; Second enrolled cohort with 36 weeks of follow-up (8 visits, same visits except for V9)~* One or two disc level cohort: 10 patients with 1 or 2 discs to be treated; Third enrolled cohort with 24 weeks of follow-up (6 visits, V1 to 7 except for V4)"
62560241|NCT05352230|ACTIVE_COMPARATOR|Continue Glucose Monitoring (CGM)|External diabetes device glucose sensor that measures interstitial glucose levels every minute
62560242|NCT05352230|OTHER|Glucometer|Device that measures capillary blood glucose levels
62560243|NCT01431079|EXPERIMENTAL|Health belief model based education|This experimental arm will provide an educational intervention designed to modify constructs of health belief model regarding HPV vaccine acceptability.
62560244|NCT01431079|ACTIVE_COMPARATOR|Knowledge-based education|This comparison arm will provide education based on knowledge regarding HPV vaccine acceptability.
62560245|NCT01608100|EXPERIMENTAL|ARCHITECT STAT High Sensitive Troponin I Assay testing|All subjects will have their blood tested by the investigational ARCHITECT STAT High SensitiveTroponin I assay.
62560246|NCT04827095|EXPERIMENTAL|Web-Based Support and Education Program 1|The support and education program involves 6 weeks of web-based classes (75-90 minutes per class) given once per week with weekly homework assignments of approximately one hour per week.
62560247|NCT04827095|EXPERIMENTAL|Web-Based Education and Support Program 2|The support and education program involves 6 weeks of web-based classes (75-90 minutes per class) given once per week with weekly homework assignments of approximately one hour per week.
62560248|NCT05362071|EXPERIMENTAL|Remote Exercise Group|Participants will practice physical exercises twice a week, remotely and under the supervision of an exercise professional, for 12 weeks.
62560249|NCT05362071|OTHER|Group control|Participants will receive a booklet with recommendations for physical activity from the physical activity guide for the Brazilian population.
62388534|NCT02389868|EXPERIMENTAL|Lovastatin|
62388535|NCT01060410||Cyclophosphamide,low dose,continuous|
62560250|NCT02123784||Rotator cuff tear|Patients which demonstrate a full-thickness tear of the rotator cuff tendon and meet the inclusion criteria.
62768564|NCT04475484||School-age children|School-age children from primary school to high school (about age 6 to 18) in the Academy of Lyon
61993131|NCT05721274|NO_INTERVENTION|Control arm|This would be the standard of care
62388536|NCT05527418|EXPERIMENTAL|Dasatinib|Dasatinib monotherapy (70 mg/day) will be given for 4 weeks. Antiretroviral therapy (ART) based on unboosted integrase inhibitors will be initiated at week 4 (S4) and dasatinib will be continued with ART until week 12.
62388537|NCT05527418|PLACEBO_COMPARATOR|Placebo|Placebo monotherapy will be given for 4 weeks. Antiretroviral therapy (ART) based on unboosted integrase inhibitors will be initiated at week 4 (S4) and placebo will be continued with ART until week 12.
62388538|NCT02132312|EXPERIMENTAL|OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
62388539|NCT02132312|ACTIVE_COMPARATOR|Phenylephrine HCl|Phenylephrine diluted in balanced salt solution (BSS) and administered as irrigation solution
62388540|NCT04160494|EXPERIMENTAL|D2C7-IT (6920 ng/mL) + Atezolizumab|Single D2C7-IT convection-enhanced delivery (CED) infusion (6920 ng/mL) plus atezolizumab (1200 mg) intravenous (IV) infusions every three weeks for up to two years
62388541|NCT04160494|EXPERIMENTAL|D2C7-IT (4613.2 ng/mL) + Atezolizumab|Single D2C7-IT convection-enhanced delivery (CED) infusion (4613.2 ng/mL) plus atezolizumab (1200 mg) intravenous (IV) infusions every three weeks for up to two years
62388542|NCT04264611|EXPERIMENTAL|Short Foot Exercise Group|The group that received the short foot exercise
62388543|NCT04264611|EXPERIMENTAL|Towel Curl Exercise Group|The group that received the towel curl exercise
62388544|NCT04264611|NO_INTERVENTION|Control Group|The group that received no exercise
61993132|NCT02342483|ACTIVE_COMPARATOR|1g|METHYLSULFONYLMETHANE
61993133|NCT02342483|ACTIVE_COMPARATOR|3g|METHYLSULFONYLMETHANE
61993134|NCT02342483|ACTIVE_COMPARATOR|6g|METHYLSULFONYLMETHANE
61993135|NCT00106782|OTHER|1|Real TEP
61993136|NCT00106782|OTHER|2|Sham Stimulation
62388545|NCT05393986|EXPERIMENTAL|Experimental: CAR-CLDN18.2 T-Cells (CT048)|The subjects will be initially enrolled in the lymphodepletion cohort. Subsequent subjects will be enrolled in the non-lymphodepletion cohort after reviewing the data in the lymphodepletion cohort.
62388546|NCT06462391|OTHER|single arm (open label)|all participants will be in pilot psychotherapy group
61993137|NCT03237767|EXPERIMENTAL|Moderate vs. High-intensity exercise (randomised)|Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (MIE completed first)
61993138|NCT03237767|EXPERIMENTAL|High-intensity vs. Moderate intensity exercise (randomised)|Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (HIIE completed first)
61993139|NCT03766854|EXPERIMENTAL|Insulin 287 followed by insulin glargine U100|"Run-in period (2 days to 7 weeks): The basal insulin glargine dose for each subject will be established and optimised.~After run-in, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic (PK) sampling where subjects are treated with once daily (OD) insulin glargine.~After insulin 287 treatment, participants will receive insulin glargine U100 OD for 2 weeks."
61993140|NCT03766854|EXPERIMENTAL|Insulin glargine U100 followed by insulin 287|"Run-in period (2 days to 7 weeks): The basal insulin glargine dose for each subject will be established and optimised.~After run-in, participants will receive insulin glargine U100 OD for 2 weeks followed by 1-14 days (at least 1 day is mandatory) of continued insulin glargine treatment.~After insulin glargine treatment, participants will receive insulin 287 OW for 8 weeks and subsequent 4 weeks of terminal PK sampling."
61993141|NCT01462357|EXPERIMENTAL|Cervarix 2 dose Group|Subjects who received 2 doses of Cervarix vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
61993142|NCT01462357|EXPERIMENTAL|Gardasil 2 dose Group|Subjects who received 2 doses of Gardasil vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
61993143|NCT01462357|EXPERIMENTAL|Gardasil 3 dose Group|Subjects who received 3 doses of Gardasil vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
61993144|NCT00048542|EXPERIMENTAL|Double-Blind Adalimumab + MTX|Subjects who were inadequate responders to MTX and were adalimumab responders during the Open-Label Lead-In (OL-LI) phase received adalimumab plus concomitant MTX during the Double-Blind Phase. MTX-treated inadequate responders must have had active disease on MTX treatment for at least 3 months prior to screening.
62388547|NCT01404689|EXPERIMENTAL|Midazolam-Meperidine-Dexmedetomidine|midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and dexmedetomidine 1μg/Kg•hr infusion (30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)
62768565|NCT01983124|EXPERIMENTAL|Fotemustine + Vemurafenib|Fotemustine 100 mg/m2 q21 + Vemurafenib gelatin capsules supplied as 240-mg strengths. Vemurafenib will be administered continuous oral dosing at 960 mg twice daily or dose administered at time of disease progression with Vemurafenib previous treatment.
62388548|NCT01404689|SHAM_COMPARATOR|Midazolam-Meperidine|midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and placebo(saline) infusion(30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)
62388549|NCT06173973|ACTIVE_COMPARATOR|Ketone Supplement|Ketone Supplement drink with 10 g ketones three times daily for five days.
62388550|NCT06173973|PLACEBO_COMPARATOR|Placebo Beverage|Matching Placebo drink three times daily for five days
62388551|NCT04977778|ACTIVE_COMPARATOR|Fatty Acids Compounds (FAG)|Individuals taking FAG mouthwash
62388552|NCT04977778|ACTIVE_COMPARATOR|Stannous Fluoride (SF)|Individuals taking SF mouthwash
62388553|NCT06137027|ACTIVE_COMPARATOR|Cannabidiol Oil|Cannabidiol oil 5.5mg, equivalent to 10 drops
62388554|NCT06137027|PLACEBO_COMPARATOR|Placebo|Peppermint oil, 10 drops
62560251|NCT05405751|EXPERIMENTAL|Patients received BIKTARVY (BIC/FTC/TAF)|"The patient enrolled in the study and access HIV consulting will start treatment with BIKTARVY the same day of the inclusion. The medication will provided by the sponsor and it will be dispensed by pharmacy service.~The delivery of medication to the patient can be delegated by a member of investigator staff who pick up the mediaction from pharmacy service to be delivered to the patient. The patient can pick up the medication directly from the pharmacy service. It will be recorded the face to face on delegated dispensing.~The deliver of medication will be bi-monthly and 2 bottles of tablets will be dispensed. The patients will receive a BIC/FTC/TAF single oral dose per day for 12 months."
62388555|NCT01732380|ACTIVE_COMPARATOR|Radiotherapy|Radiotherapy 2.0Gy/day, 5 times/week,6 weeks In Subjects With Inoperable esophageal cancer
62388556|NCT01732380|EXPERIMENTAL|Raltitrexed/Oxaliplatin Plus Radiotherapy|Raltitrexed 2.5mg/㎡ d1,Oxaliplatin 100mg/㎡ d1,q21d Plus Radiotherapy 2.0Gy/day, 5 times/week,6 weeks In Subjects With Inoperable esophageal cancer
62768566|NCT05592496|ACTIVE_COMPARATOR|Block group|Patients after laparotomic gastrectomy and musculus rectus sheath block and continuous analgesia with 0,125% bupivacaine solution for 72h
62768567|NCT05592496|PLACEBO_COMPARATOR|Control group|"Patients after laparotomic gastrectomy, musculus rectus sheath block and induction of 0,9% NaCl Solution by using easy pump system for 72 h"
62768568|NCT06120101|EXPERIMENTAL|Experimental|Reflexology will be applied in a total of 3 sessions and the final test will be applied to the patients by phone 24 hours after the last reflexology application. At the end of the study, 3 reflexology sessions and 2 test measurements will be performed on the experimental group. Each reflexology session takes approximately 30-40 minutes. Sessions will be performed in a private room within the neurology clinic, on ergonomic and repositionable beds. Each session started with the right foot and will continue with the left foot. Primary relaxation techniques will be applied to both feet, followed by reflexology techniques to all system organs.
62768569|NCT06120101|NO_INTERVENTION|Control|No application will be applied to the control group.
62768570|NCT00175409|ACTIVE_COMPARATOR|1|Infants will be randomized to two interventions which will take place during two separate blood collections that are required for clinical management. For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
62388557|NCT01736176|EXPERIMENTAL|Levodopa-Carbidopa Intestinal Gel|"Participants had the PEG-J tube placement procedure performed on Study Day 1 and, at the discretion of the investigator, began initiation and titration of LCIG infusion. Dosing was determined individually. The starting total daily dose of LCIG was based solely on the daily dose of the oral levodopa taken immediately prior to Study Day 1 and was adjusted to obtain the optimal clinical response for the individual participant.~Participants received treatment for up to 60 weeks; participants who completed their Week 60 visit before LCIG was commercially available had the option to extend their LCIG therapy, if in the opinion of the investigator, the participant would benefit from continued LCIG treatment."
62560252|NCT02333058|EXPERIMENTAL|Treosulfan|"Treosulfan dose per day is to be calculated by using BSA. One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.~Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.~Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2."
62560253|NCT00204490|EXPERIMENTAL|1|soy isoflavones
62560254|NCT00204490|PLACEBO_COMPARATOR|2|carbohydrates (maltodextrin)
62560255|NCT06168461|PLACEBO_COMPARATOR|placebo|placebo pill taken once daily at bedtime for 12 weeks
62560256|NCT06168461|EXPERIMENTAL|aspirin|162mg aspirin taken once daily at bedtime for 12 weeks
62388558|NCT03556644|OTHER|Single arm study|70 patients with coronary artery disease will have CTCA imaging and 3 vessel intravascular imaging with NIRS-IVUS during percutaneous coronary intervention and the obtained imaging data will be used to assess the efficacy of CTCA in detecting plaque morphology and shear stress distribution.
62560257|NCT05592171|OTHER|Occlusafe assisted MWA+ DEB-TACE|
62560258|NCT05592171|OTHER|Occlusafe assisted MWA|
62560259|NCT05592171|OTHER|MWA+ DEB-TACE|
62560260|NCT02336321|EXPERIMENTAL|BNCI hand-exoskeleton|Hand motor function before, during and after application of the device
62560261|NCT04818125|OTHER|Patients with breast cancer|
62560262|NCT02090725|EXPERIMENTAL|3-4 Diaminopyridine (DAP)|
62560263|NCT00995124|EXPERIMENTAL|NeutraLice Lotion|Single application of head lice product.
61993145|NCT00048542|PLACEBO_COMPARATOR|Double-Blind Placebo + MTX|Subjects who were inadequate responders to MTX and were adalimumab responders during the Open-Label Lead-In (OL-LI) phase received placebo plus concomitant MTX during the Double-Blind Phase. MTX-treated inadequate responders must have had active disease on MTX treatment for at least 3 months prior to screening.
61993146|NCT00048542|EXPERIMENTAL|Double-Blind Adalimumab|Subjects in the non-methotrexate (MTX) stratum who were either naïve to MTX or withdrawn from MTX at least 2 weeks prior to study drug administration, and were adalimumab responders during the OL-LI phase, received adalimumab, but no concomitant MTX treatment, during the Double-Blind Phase.
62560264|NCT00995124|EXPERIMENTAL|NeutraLice Advance|single application of head lice product
62560265|NCT00995124|ACTIVE_COMPARATOR|Moov Head Lice Solution|Single application for head lice with 10 min application time.
62560266|NCT04098341|OTHER|Screening|All eligible migrants will be offered opt-out IGRA blood test to screen for for latent Tuberculosis infection
62560267|NCT00115076|EXPERIMENTAL|psoriasis|moderate to severe plaque psoriasis
62560268|NCT03991234|EXPERIMENTAL|Coordinated Reading and Math Intervention|Coordinated intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction addressing similar skills as those addressed in the reading intervention arm \& similar skills as the math intervention arm.
62388559|NCT03223129|OTHER|Patients with normal glucose tolerance|"Patients included in this arm will have a plasma glucose below 140 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
62388560|NCT03223129|OTHER|Patients with impaired glucose tolerance|"Patients included in this arm will have a plasma glucose between 140 mg/dl to 199 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
62388561|NCT03223129|OTHER|Patients with type 2 diabetes mellitus|"Patients included in this arm will have a plasma glucose above 200 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
62388562|NCT03479424||Training Set|n = 333
62388563|NCT03479424||Validation Set|n = 167
62388564|NCT01493362||1|Participants with Bulimia Nervosa
62388565|NCT01493362||2|Participants who are healthy controls
62388566|NCT03920046||Effects of passive smoking on children|The prevalence of laryngospasm in sedation applied to endoscopic intervention whose parents smoking.
62388567|NCT00983827|EXPERIMENTAL|Aquatic treadmill training|Aquatic treadmill training (ATT) is a pool-based treadmill training that combines the three concepts of unweighting the body, treadmill training, and the resistance effects of water into one modality.
62560269|NCT03991234|ACTIVE_COMPARATOR|Reading Intervention|Reading intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction designed to build skill on letter-sound associations, decoding, sight words, \& contextualized reading.
62560270|NCT03991234|ACTIVE_COMPARATOR|Math Intervention|Math intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction on number knowledge, counting strategies, and arithmetic skill.
62560271|NCT03991234|NO_INTERVENTION|Business-as-usual Control|Participation in the school's typical reading and math classroom instruction and, if designated by the school, its supplemental program.
62388568|NCT02827747|PLACEBO_COMPARATOR|Placebo with Dietary Sources of Vitamins|Persons assigned to placebo, who obtain Vitamins A, C, E and Glutathione from dietary sources alone, and have not been on oral RDA supplementation, in the 1 month leading up the time of enrollment and throughout the study period.
61993147|NCT00048542|PLACEBO_COMPARATOR|Double-Blind Placebo|Subjects in the non-methotrexate (MTX) stratum who were either naïve to MTX or withdrawn from MTX at least 2 weeks prior to study drug administration, and were adalimumab responders during the OL-LI phase, received placebo, but no concomitant MTX treatment, during the Double-Blind Phase.
61993148|NCT00048542|EXPERIMENTAL|OLE BSA Adalimumab + MTX|All subjects received subcutaneous injections of 24 mg adalimumab per square meter of body surface area (BSA) up to a maximum of 40 mg total body dose every other week (eow), concomitantly with MTX treatment, during the Open-Label Extension (OLE) BSA Phase of the study.
62388569|NCT02827747|ACTIVE_COMPARATOR|Antioxidants(Vitamins A,C,E) plus GSH, plus Centrum|Persons assigned to the study medication, and are continuing the take an oral RDA supplementation, in the form of Centrum.
62560272|NCT01161511|EXPERIMENTAL|1|XmAb5574
62388570|NCT02827747|ACTIVE_COMPARATOR|Antioxidants (Vitamins A,C, E) plus GSH|Persons assigned to the study medication alone, without oral RDA supplementation in the 1 month leading up the time of enrollment and throughout the study period.
62388571|NCT02827747|ACTIVE_COMPARATOR|Placebo plus Centrum|Persons assigned to placebo, who have been on oral RDA supplementation, who would continue to do so throughout the study.
62560273|NCT00646490||A|patients with parapneumonic pleural effusion due to community acquired pneumonia
62560274|NCT00646490||B|patients with pleural effusion of other etiologies
62560275|NCT03808181|OTHER|Active treatment with ChloraSolv|Single arm
62560276|NCT04939298|EXPERIMENTAL|Patients under mechanical ventilation|Ultrasound evaluation of the variation of thickness of abdominal muscles after 7 days of mechanical ventilation
62560277|NCT06052293|EXPERIMENTAL|ANG003 Dose Level 1|Single administration starting dose contains lipase, protease and amylase.
62560278|NCT06052293|EXPERIMENTAL|ANG003 Dose Level 2|Single administration dose contains 2x lipase, 2x protease and 2x amylase starting dose.
61993149|NCT00048542|EXPERIMENTAL|OLE BSA Adalimumab|All subjects received subcutaneous injections of 24 mg adalimumab per square meter of body surface area (BSA) up to a maximum of 40 mg total body dose every other week (eow), but not MTX treatment, during the Open-Label Extension (OLE) BSA Phase of the study.
61993150|NCT00048542|EXPERIMENTAL|OLE FD Adalimumab + MTX|Subjects received adalimumab concomitantly with MTX treatment during the Open-Label Extension (OLE) Fixed Dose (FD) Phase of the study in which only body weight (not BSA) determined dosing; subjects weighing less than 30 kg were dosed with 20 mg of adalimumab SC eow, and subjects weighing 30 kg or more were dosed with 40 mg of adalimumab SC eow.
61993151|NCT00048542|EXPERIMENTAL|OLE FD Adalimumab|Subjects received placebo without concomitant MTX treatment during the Open-Label Extension (OLE) Fixed Dose (FD) Phase of the study in which only body weight (not BSA) determined dosing; subjects weighing less than 30 kg were dosed with 20 mg of adalimumab SC eow, and subjects weighing 30 kg or more were dosed with 40 mg of adalimumab SC eow.
61993152|NCT05223855|ACTIVE_COMPARATOR|Intervention group|The intervention group receives intervention for 8 weeks
62768571|NCT00175409|ACTIVE_COMPARATOR|2|Infants will be randomized to two interventions which will take place during two separate blood collections that are required for clinical management. For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
61993153|NCT05223855|NO_INTERVENTION|control group|The control group receives usual care for 8 weeks and is then offered participation in a de-stress class for 8 weeks.
62388572|NCT05034029|EXPERIMENTAL|Metformin|Metformin hydrochloride sustained release tablet will administer orally in escalating doses to reduce side-effects and maintain masking: 0.5 g/day for the first two weeks, 1 g/day for the next 2 weeks, and then 2 g/day until the end of the study if tolerated. If the subject cannot tolerate the maximum dose (2 g/day), take their maximum tolerable dose. In case of adverse reaction, the researchers can determine whether the subject needs to reduce or stop the drug based on their discretion.
62388573|NCT05034029|PLACEBO_COMPARATOR|Placebo|Placebo will administer the same as the experimental drug.
62388574|NCT02063958|EXPERIMENTAL|SNX-5422|Open-label administration of SNX-5422 capsules dosed in the morning once every other day (qod) for 21 days (11 doses), followed by a 7 day drug free period. Dose escalation will be based on safety defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level. Dose escalation will not exceed a dose of 100 mg/m2 SNX-5422 qod even if the MTD has not been identified. Subjects will receive daily oral everolimus in the PM about the same time every day for 28 days.
62388575|NCT02330731|OTHER|N-butyl-2-cyanoacrylate|injection sclerotherapy for gastric varices
62388576|NCT02330731|OTHER|iso-amyl-2-cyanoacrylate|injection sclerotherapy for gastric varices
62388577|NCT02330731|OTHER|72% chromated glycerin|injection sclerotherapy for gastric varices
62388578|NCT01434927||Colonoscopy outpatients|All patients referred to our Unit to undergo colonoscopy for any indication
62388579|NCT03775733|EXPERIMENTAL|Hydrolysed red ginseng extract|Hydrolysed red ginseng extract 2.4g/day for 12 weeks
62388580|NCT03775733|PLACEBO_COMPARATOR|Placebo|Placebo for 12 weeks
62388581|NCT02303535||Congenital|"All patients with congential and acquired heart disease treated by cardiac surgery and therapeutic cardiac catheterisations procedures .~For acquired heart disease, the audit covers all arrhythmias \& cardiomyopathies in patients less than 16 years old only.~For congenital heart disease, the audit collects data on both children and adult patients."
62768572|NCT00853840|EXPERIMENTAL|1.|Maraviroc + Vardenafil
62388582|NCT02478736||delirium group|the patients with delirum after on-pump cardiac surgery
62388583|NCT02478736||no delirium group|the patients without delirum after on-pump cardiac surgery
62388584|NCT04168359|EXPERIMENTAL|Semi-barbed Sutures Localization Group|Patients with pulmonary nodules requiring CT-guided puncture positioning before thoracoscopic surgery
62388585|NCT01719627|EXPERIMENTAL|MVC 300 mg|MVC 300 mg in unique dose
62388586|NCT01719627|ACTIVE_COMPARATOR|TVD 300/200 QD|TVD 300/200 QD during 7 days.
62388587|NCT01719627|EXPERIMENTAL|Maraviroc 600mg|MVC 600mg in unique dose
62388588|NCT04121637|EXPERIMENTAL|Aerobic exercise+Frenkel coordination Study group|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. There will be a 1 minute break between each exercise set. Following this, an aerobic exercise of 30 minutes will be performed on the bicycle ergometer with electronic brake. Subjects will be advised not to do any exercise two days before or on that day and to eat only a light meal at least two hours before the test. The intensity of the exercise will be adjusted based on maximum oxygen consumption (VO2 max) specific to each individual.
62768573|NCT00853840|PLACEBO_COMPARATOR|2.|Maraviroc + Placebo
62388589|NCT04121637|ACTIVE_COMPARATOR|Frenkel coordination exercise group - Control group|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. There will be a 1 minute break between each exercise set.
62560279|NCT06052293|EXPERIMENTAL|ANG003 Dose Level 3|Single administration dose contains 4x lipase, 2x protease and 2x amylase starting dose.
62768574|NCT01860898|OTHER|Skin Biopsy|
62768575|NCT01389999||Chronic back pain patients|Patients who have had back pain for at least three months.
62768576|NCT03386734|EXPERIMENTAL|SLN biopsy only|Sentinel lymph node (SLN) biopsy only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
62768577|NCT03386734|ACTIVE_COMPARATOR|SLN biopsy + PLN dissection|SLN biopsy + full pelvic lymph node dissection (PLN) will be performed. The radical hysterectomy or trachelectomy will be done.
62768578|NCT04911179|EXPERIMENTAL|Combined multicomponent physical exercise and cognitive stimulation (Vivfrail-Cog)|"The supervised multicomponent exercise training program (resistance, endurance, balance and flexibility) will be comprised of upper and lower body exercises tailored to the individual's functional capacity. Subjects will be encouraged at performing strength and endurance exercise at a moderate intensity. Exercise will progress in terms of intensity and difficulty upon individual adaptation.~The cognitive intervention will include the performance of different exercises with pencil and paper in order to train different cognitive areas, especially the executive functions."
62768579|NCT04911179|NO_INTERVENTION|Usual care|The usual care group will receive normal outpatient care (including the evidence-based Otago exercise program).
61993154|NCT03023865|EXPERIMENTAL|Staged stress function|A preoperative staged stress function procedure for elongation of the proximal and distal segments to achieve utilizing the native esophagus to establish esophageal continuity
61993155|NCT05830474|EXPERIMENTAL|Test group (group T)|lung isolation was performed with visual double-lumen bronchial catheter, andcontinuous airway monitoring and intervention were performed
61993156|NCT05830474|NO_INTERVENTION|Control group (group C)|lung isolation was performed with visual double-lumen bronchial catheter, and only intra-airway video was performed without monitoring
61993157|NCT02510378|EXPERIMENTAL|Short course radiotherapy|"Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.~After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy."
62560280|NCT06052293|EXPERIMENTAL|ANG003 Dose Level 4|Single administration dose contains 6x lipase, 3x protease and 3x amylase starting dose.
62560281|NCT05934630||Stratum 1: Medulloblastoma|Participants in Arm 1 must have diagnosis of Medulloblastoma. All children and adolescent/young adult (AYA) patients \<= 21 years of age are eligible. AYA patients \< 40 are eligible with a primary brain tumor entity more common in children than adults.
62768580|NCT02822300|EXPERIMENTAL|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
61993158|NCT03199027|NO_INTERVENTION|Clinic-based Care|Clinic-based care is the current Standard-of-Care whereby newly initiated ART patients attend the ART clinic.
62388590|NCT06131294|EXPERIMENTAL|Expermental Fluoride Application|The two-step system, consisting of Component A (ammonium fluoride solution) and Component B (calcium fluoride application), will be applied once on the white spot lesions one.
62388591|NCT06131294|ACTIVE_COMPARATOR|Fluor Protector S|The ammonium fluoride gel will be applied once on the white spot lesions.
62388592|NCT06261216||wild-type transthyretin amyloid cardiomyopathy|
62388593|NCT06261216||heart failure with preserved ejection fraction|
61993159|NCT03199027|EXPERIMENTAL|Adherence Club Care|Adherence club care involves referral to community-based ART services in the form of Adherence clubs, which are led by community health workers and supported by ART clinic nurses.
62388594|NCT06261216||heart failure with reduced ejection fraction|ischemic or inflammatory origin
62768581|NCT00499746|ACTIVE_COMPARATOR|Tramadol|oral dose, once per day
62768582|NCT00499746|PLACEBO_COMPARATOR|Placebo|oral dose, once per day
62560282|NCT05934630||Stratum 2: High-grade Glioma (IDH-wildtype) or Diffuse Intrinsic Pontine Glioma|Participants in Arm 2 must have diagnosis of High-grade Glioma (IDH-wildtype) or Diffuse Intrinsic Pontine Glioma (DIPG). All children and adolescent/young adult (AYA) patients \<= 21 years of age are eligible. AYA patients \< 40 are eligible with a primary brain tumor entity more common in children than adults. DIPG patients must meet clinical and imaging requirements for DIPG diagnosis. Patients with newly diagnosed DIPGs, defined as tumors with a pontine epicenter and diffuse involvement of 2/5 or more of the pons, are eligible without histologic confirmation. Patients with brainstem tumors that do not meet these criteria or not considered to be typical intrinsic pontine gliomas will only be eligible for Stratum 2 if the tumors have been biopsied and are proven to be an anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma, anaplastic mixed glioma or fibrillary astrocytoma.
62388595|NCT06261216||healthy controls|
62388596|NCT01586013|EXPERIMENTAL|propofol infusion|Healthy adults scheduled for elective surgery will receive a computer controlled infusion until obtain the loss of counsiousness (BIS \<50). After stoping the infusion we observe the emergency of anesthesia and the correspondant BIS curve. Using the complete loss and recovery curve of BIS we can describe the course of the effect of the drug. Venous sample will be taken during the study to evaluate the pharmacokinetic performance of the model.
62560283|NCT05934630||Stratum 3: Low-grade Glioma (IDH-wildtype)|Participants in Arm 3 must have diagnosis of Low-grade Glioma (IDH-wildtype). All children and adolescent/young adult (AYA) patients =\< 21 years of age are eligible. AYA patients \< 40 are eligible with a primary brain tumor entity more common in children than adults.
62560284|NCT05934630||Stratum 4: Diffuse Leptomeningeal Glioneuronal Tumor|Participants in Arm 4 must have diagnosis of Diffuse Leptomeningeal Glioneuronal Tumor. All children and adolescent/young adult (AYA) patients =\< 21 years of age are eligible. AYA patients \< 40 are eligible with a primary brain tumor entity more common in children than adults.
62560285|NCT05934630||Stratum 5: Pineoblastoma|Participants in Arm 5 must have diagnosis of Pineoblastoma. All children and adolescent/young adult (AYA) patients =\< 21 years of age are eligible. AYA patients \< 40 are eligible with a primary brain tumor entity more common in children than adults.
62560286|NCT05934630||Stratum 6: All other eligible primary brain tumor types|Participants in Arm 6 must have diagnosis of all other eligible primary brain tumor types. All children and adolescent/young adult (AYA) patients =\< 21 years of age are eligible. AYA patients \< 40 are eligible with a primary brain tumor entity more common in children than adults.
62560287|NCT05761314|EXPERIMENTAL|Case group|To report the prevalence of solid tumors in a monocentric cohort of individuals with RASopathies
62560288|NCT04444024||NTC/-HTN group|Patients with TC \< 5.18 mmol/l, systolic blood pressure \<130 mmHg and diastolic blood pressure \<80 mmHg belong to normal TC/ none hypertension(NTC/-HTN) group.
62560289|NCT04444024||NTC/+HTN group|Patients with TC \< 5.18 mmol/l, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg belong to normal TC/ hypertension(NTC/+HTN) group.
62560290|NCT04444024||BHTC/-HTN group|Patients whose TC is 5.18 ≤ TC \< 6.19 mmol/l, systolic blood pressure \<130 mmHg and diastolic blood pressure \<80 mmHg belong to borderline-high TC/ none hypertension (BHTC/-HTN) group.
62560291|NCT04444024||BHTC/+HTN group|Patients whose TC is 5.18 ≤ TC \< 6.19 mmol/l, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg belong to borderline-high TC/ hypertension (BHTC/+HTN) group.
62560292|NCT04444024||HTC/-HTN group|Patients with TC ≥6.19 mmol/l, systolic blood pressure \<130 mmHg and diastolic blood pressure \<80 mmHg belong to high TC/ none hypertension(HTC/-HTN) group.
62388597|NCT02936206|EXPERIMENTAL|Fulvestrant|750 mg injection in 3 divided doses
62388598|NCT02936206|ACTIVE_COMPARATOR|Tamoxifen|20mg orally
62388599|NCT00038116|ACTIVE_COMPARATOR|embryonic dopamine cell implant surgery|embryonic dopamine cell implant surgery
62388600|NCT00038116|PLACEBO_COMPARATOR|sham surgery|sham surgery (placebo)
62388601|NCT01976403|EXPERIMENTAL|Pain booklet|
62388602|NCT01976403|NO_INTERVENTION|standard care|
62560293|NCT04444024||HTC/+HTN group|Patients with TC ≥6.19 mmol/l, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥ 80 mmHg belong to high TC/ hypertension(HTC/+HTN) group.
62388603|NCT02723539|EXPERIMENTAL|MBN-101|MBN-101: a suspension of 150, 375, or 600 microgram (µg)/milliliter (mL) (w:v) BisEDT drug particles in suspension in 3% methylcellulose / 0.5% polysorbate 80 / 10 millimole (mM) sodium chloride / 10 mM sodium phosphate.
62388604|NCT02723539|PLACEBO_COMPARATOR|Vehicle|MBN-101 diluent (placebo): 3% methylcellulose / 0.5% polysorbate 80 / 10 mM sodium chloride / 10 mM sodium phosphate
62388605|NCT05342727|ACTIVE_COMPARATOR|tDCS group|The tDCS arm receives two real (or active) stimulation at 2 mA and 3 mA intensities and one placebo electrical stimulation for 20 minutes.
62388606|NCT05342727|ACTIVE_COMPARATOR|tACS group|The tACS arm receives two real (or active) stimulation at 8 Hz and 40 Hz frequencies and one placebo alternating electrical stimulation for 20 minutes.
62567700|NCT01870973|ACTIVE_COMPARATOR|no root canal treatment|no root canal treatment, anesthesia with 2% lidocaine with 1:100,000 epinephrine, pain medication (1000 mg acetaminophen and 600 mg ibuprofen every 6 hours)five day supply, antibiotic (500 mg penicillin if allergic 300 mg clindamycin)
62567701|NCT02263430|EXPERIMENTAL|Deep Brain Stimulation|Stimulation is on.
62567702|NCT02263430|SHAM_COMPARATOR|Placebo|Stimulation is off.
61993160|NCT01527292|ACTIVE_COMPARATOR|Control Group|Baseline Assessments and followup assessments are the same for both arms. Control group Intervention: Stereotactic Radiation Therapy only
61993161|NCT01527292|EXPERIMENTAL|Treatment Group|SRT with Vertebral Augmentation Procedure Baseline Assessments and followup assessments are the same for both arms. Treatment group Intervention: Stereotactic Radiation Therapy with Vertebral Augmentation Procedure
61993162|NCT02189564|ACTIVE_COMPARATOR|Intrinsic reward|Feedback about good performance
61993163|NCT02189564|EXPERIMENTAL|Intrinsic and extrinsic reward|Feedback about good performance + money
61993164|NCT02189564|EXPERIMENTAL|Intrinsic reward (average performance)|Feedback about random selection of trials
61993165|NCT03873987|ACTIVE_COMPARATOR|Current Formulation of Oritavancin|Three single-use vials, each containing 400 mg (1200 mg total) of oritavancin diphosphate (as the free base) and the inactive component mannitol. Oritavancin vials will be reconstituted with SWFI and further diluted in D5W for a total volume of 1000 mL and infused intravenously over 3 hours.
61993166|NCT03873987|EXPERIMENTAL|Kimyrsa|A single vial containing 1200 mg of oritavancin, HPβCD, and mannitol. Kimyrsa vials will be reconstituted with SWFI and further diluted with 0.9% sodium chloride for a total volume of 250 mL and infused intravenously over 1 hour.
61993167|NCT01475630|OTHER|control|information, avoiding parafunctions
61993168|NCT01475630|EXPERIMENTAL|physical therapy|mobilisation, exercises ,..
61993169|NCT05344898|EXPERIMENTAL|Subscap Tenotomy|The subscapularis tendon is not repaired.
61993170|NCT05344898|EXPERIMENTAL|Subscap Repair|The subscapularis tendon is repaired.
62388607|NCT05107700|EXPERIMENTAL|Start with: Stay at altitude 2500 m above sea level (high altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.
62560294|NCT06430164|EXPERIMENTAL|Gait with functional electrical stimulation|"Participants will participate in 2 to 5 sessions over 2-8 weeks. Each session will comprise gait or stepping practice on a treadmill with functional electrical stimulation, and non-invasive measurement of neural circuit excitability.~Participants will complete multiple 30-second to 4-minute bouts of walking on the treadmill or overground at speeds ranging from self-selected to fast speeds (faster than comfortable self-selected speed), with rest breaks between bouts. For gait training, participants may complete up to six 6-minute bouts of walking with rest breaks between bouts (30-36 minutes walking)."
62567703|NCT06181214|PLACEBO_COMPARATOR|Placebo|Maltodextrin + Flavoring
61993171|NCT04774978|EXPERIMENTAL|Cardiac output measurements|Cardiac output will be measured using TTE continuously with ProbeFix
62388608|NCT05107700|PLACEBO_COMPARATOR|Start with: Stay at altitude 470 m above sea level (low altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m as comparator.
62388609|NCT05807646|EXPERIMENTAL|Vein ligation first|During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric vein ligated first.
62567704|NCT06181214|EXPERIMENTAL|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
61993172|NCT04382248|EXPERIMENTAL|Interventional Group|An app for tracking medications, receiving personal coaching and educational material
61993173|NCT04382248|ACTIVE_COMPARATOR|Control Group|An app for tracking medications
61993174|NCT00353405|EXPERIMENTAL|1|Participants receiving social skills training and mass media messages
61993175|NCT00353405|EXPERIMENTAL|2|Participants receiving social skills training and no mass media messages
61993176|NCT00353405|EXPERIMENTAL|3|Participants receiving mass media messages and no social skills training
61993177|NCT00353405|EXPERIMENTAL|4|Participants receiving no social skills training and no mass media messages
61993178|NCT06193746||study group|wear the laser watch on wrist 3times/weak up to 30 minute for 12 weeks ,
61993179|NCT06193746||control group|taking advises only
61993180|NCT05415696|OTHER|Prostatic artery embolization (PAE)|Study participants will be treated with a single PAE procedure performed with Embosphere microspheres.
61993181|NCT00665600|EXPERIMENTAL|1|Levalbuterol 0.63 mg TID
62388610|NCT05807646|ACTIVE_COMPARATOR|Artery ligation first|During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric artery ligated first.
62388611|NCT05961761|EXPERIMENTAL|Propranolol + pembrolizumab|pembrolizumab 2 mg/kg every 3 weeks and propranolol 40 mg x2 daily until progression, unacceptable toxicity or patient withdrawal for a maximum of two years.
62388612|NCT03725904|EXPERIMENTAL|IVF/FET|
62567705|NCT05337280|EXPERIMENTAL|Imagio OA/US|Imagio OA/US Imaging
61993182|NCT00665600|EXPERIMENTAL|2|Levalbuterol 1.25 mg TID
61993183|NCT00665600|ACTIVE_COMPARATOR|3|Racemic Albuterol 2.5 mg TID
61993184|NCT00665600|PLACEBO_COMPARATOR|4|Placebo TID
61993185|NCT01398956|EXPERIMENTAL|Levetiracetam|Twice daily (morning and evening) orally
61993186|NCT01430481|ACTIVE_COMPARATOR|Standard Rosehip Powder (A)|6 capsules of standardized hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
61993187|NCT01430481|EXPERIMENTAL|New rosehip formulation (B)|6 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
61993188|NCT01430481|EXPERIMENTAL|New rosehip formulation in half dose (C)|3 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
61993189|NCT03057028|EXPERIMENTAL|anakinra|Patients will be treated with anakinra, injected SQ daily in a dose of 100mg for 14 days. Before and after this intervention, patients will undergo cardiopulmonary exercise testing (as well as echocardiography, EKG analysis, and serologic analysis). Subjects will be assessed for changes in exercise capacity, as determined by peak oxygen uptake and ventilatory efficiency to CO2 production slope.
61993190|NCT03340337|EXPERIMENTAL|Neo-Russian Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive Neo-Russian electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, the fatigue will be measured with this type of current."
61993191|NCT03340337|EXPERIMENTAL|Aussie Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive Aussie electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, the fatigue will be measured with this type of current."
61993192|NCT03340337|EXPERIMENTAL|RBS Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive RBS electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, the fatigue will be measured with this type of current."
61993193|NCT03662542|EXPERIMENTAL|Combination Therapy|Participants will receive guselkumab Dose 1 as intravenous (IV) infusion and Dose 2 as subcutaneous (SC) injection; and golimumab Dose 1 and Dose 2 as SC injection and placebo to maintain the blind.
61993194|NCT03662542|EXPERIMENTAL|Monotherapy: Guselkumab|Participants will receive guselkumab Dose 1 as IV infusion, Dose 2 as SC injection and placebo to maintain the blind.
61993195|NCT03662542|ACTIVE_COMPARATOR|Monotherapy: Golimumab|Participants will receive golimumab Dose 1 and Dose 2 as SC injection and placebo to maintain the blind.
61993196|NCT05826782|ACTIVE_COMPARATOR|A|The treated group
61993197|NCT05826782|PLACEBO_COMPARATOR|B|The placebo group
61993198|NCT02307851|EXPERIMENTAL|Group A|Quadrivalent VLP vaccine, low dose, intramuscular injection (0.5mL)
61993199|NCT02307851|EXPERIMENTAL|Group B|Quadrivalent VLP vaccine, high dose, intramuscular injection (0.5mL)
61993200|NCT02307851|EXPERIMENTAL|Group C|Quadrivalent VLP vaccine, medium dose, intramuscular injection (0.5mL)
61993201|NCT02307851|ACTIVE_COMPARATOR|Group D|Comparator TIV, intramuscular injection (0.5mL)
61993202|NCT06481306|EXPERIMENTAL|Cohort A Part 1|
61993203|NCT06481306|EXPERIMENTAL|Cohort A Part 2|
61993204|NCT06481306|EXPERIMENTAL|Cohort A Part 3|
61993205|NCT06481306|EXPERIMENTAL|Cohort B Part 1|
62388613|NCT04139161|EXPERIMENTAL|Q-Factor Intervention|Participants will progress through three increasing Q-Factors for each cycling workrate; Q-Factor 1 (Q1, 192mm), Q2 (234mm), Q3 (276mm). After completing bouts of all three Q-Factors for a given workrate, workrate will be increased by 20 Watts and bouts at each Q-Factor will be repeated.
62388614|NCT03804138||Patient|patient with COPD
62388615|NCT03804138||control group|patient without COPD
62388616|NCT02924311||Previously treated patient|Already treated with any other treatment such as an anti-VEGF agent (other than IVT aflibercept), macular laser photocoagulation (laser), intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
62388617|NCT02924311||Naïve patient|Not previously treated with an anti-VEGF agent, macular laser photocoagulation (laser) or intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
62388618|NCT02924311||Entire study population|Already treated patient with any other treatment such as an anti-VEGF agent (other than intravitreal aflibercept), macular laser photocoagulation, intravitreal steroid injection and initiating treatment with intravitreal aflibercept and not previously treated patients with an anti-VEGF agent, macular laser photocoagulation or intravitreal steroids injection and initiating treatment with intravitreal aflibercept
62388619|NCT04169126|EXPERIMENTAL|F-18-PMPBB3|F-18-PMPBB3 imaging
61993206|NCT06481306|EXPERIMENTAL|Cohort B Part 2|
61993207|NCT01932827||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is a online consumer monitor panel which answers surveys every 8-10 weeks about diet and health.
61993208|NCT04684147|EXPERIMENTAL|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
61993209|NCT06244862|EXPERIMENTAL|Interventional medicinal product|
61993210|NCT00235872|EXPERIMENTAL|Adalimumab 40 mg every other week (eow)|
61993211|NCT04504383|EXPERIMENTAL|PN-943 450 mg BID|Oral administration of PN-943 450 mg BID
61993212|NCT04504383|EXPERIMENTAL|PN-943 150 mg BID|Oral administration of PN-943 150 mg BID
61993213|NCT04504383|PLACEBO_COMPARATOR|Placebo BID|Oral administration of matching placebo
61993214|NCT05262634||study group: iron deficiency|Pregnant women with a documented iron deficiency in the first trimester
62388620|NCT04741022||CAD with OSA|coronary artery disease with Obstructive sleep apnea
62388621|NCT04741022||CAD without OSA|coronary artery disease without Obstructive sleep apnea
62388622|NCT04500626|EXPERIMENTAL|HBOT|These patients will receive hyperbaric oxygen therapy (HBOT) in addition to usual treatment for COVID-19. HBOT sessions will be 75 minutes in length at a pressure of 2.0 ATA.
61993215|NCT05262634||control group: normal iron status|Pregnant women with normal hematological parameters and iron status in the first trimester
61993216|NCT04990752||The ulinastatin group|In the ulinastatin group, ulinastatin was used for inflammation management and organ protection early before ECMO was started. The recommended dosage of ulinastatin is 300,000 IU, q8h (Continuous administration for more than 5 days).
61993217|NCT04990752||The control group|In the control group, patients were treated with conventional treatment without ulinastatin.
61993218|NCT05533853|ACTIVE_COMPARATOR|Traditional exercise|The exercise group will receive a posture corrective exercise program in the form of two strengthening(deep cervical flexors and shoulder retractors)and two stretching (cervical extensors and pectoral muscles) exercises. The exercise program will be done according to Harman et al.'s protocol and based on Kendall et al.'s approach.
61993219|NCT05533853|EXPERIMENTAL|Denneroll extension traction|Denneroll extension traction. Participants in the intervention group will receive the Denneroll cervical orthotic . In the current study, Denneroll cervical traction will be used to restore the normal cervical alignment. . We will follow previously published protocols and procedures for application of this orthotic. The Denneroll orthotic will be performed in the physiotherapy clinic setting. The participants will be instructed to lie supine on the floor, in a straightened position, with their arms gently folded across their stomach.
61993220|NCT01068457||PTPS|Patients with pain after VATS
61993221|NCT01068457||Pain free|Patients reporting no pain late after VAT
61993222|NCT02033421||Pharmacokinetics Beta-lactam antibiotics|Patients with infective endocarditis treated with Beta-lactam antibiotics
61993223|NCT04959838|EXPERIMENTAL|Ophthalmology physicians and residents|"Ophthalmology physicians and residents will be followed during 34h, from 8 am to 6 pm the following day,in five different conditions:~* Control day (no work)~* Typical working day~* Working day + one night shift~* Emergency working day + two consecutive night shifts~* Night shift."
61993224|NCT01966965|EXPERIMENTAL|PIOLIN®|PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
61993225|NCT01966965|ACTIVE_COMPARATOR|NEDAX|FOLLOWING THE LEAFLET TREATMENT
62388623|NCT04500626|NO_INTERVENTION|Control|These patients will receive usual treatment for COVID-19, including oxygenation at normal atmospheric pressure (normobaric oxygenation).
62388624|NCT04542525|EXPERIMENTAL|PanOptix Toric Trifocal IOL|ACRYSOF IQ PanOptix Toric Trifocal IOL Model TFNT20 implanted in the capsular bag in the posterior chamber following cataract surgery. At least one eye will be implanted.
61993226|NCT04358887|EXPERIMENTAL|periapical surgery with piezo.|After flap reflection bone and root end cutting are done with US6 piezoelectric surgical insert
61993227|NCT04358887|ACTIVE_COMPARATOR|Periapical surgery with bur.|After flap reflection bone and root end cutting are done with surgical bur.
62388625|NCT05359575|EXPERIMENTAL|"Audio recording with instructional flashcard with cervical-collar (audio kit) - 1 month follow-up"|MP3 audio files for each of 6 steps (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application, used for c-collar application attempt. Participants repeat the c-collar application with the audio kit at 1 month follow-up.
62560295|NCT06430164|EXPERIMENTAL|Gait without functional electrical stimulation|"Participants will participate in 2 to 5 sessions over 2-8 weeks. Each session will comprise gait or stepping practice on a treadmill without functional electrical stimulation, and non-invasive measurement of neural circuit excitability.~Participants will complete multiple 30-second to 4-minute bouts of walking on the treadmill or overground at speeds ranging from self-selected to fast speeds (faster than comfortable self-selected speed), with rest breaks between bouts. For gait training, participants may complete up to six 6-minute bouts of walking with rest breaks between bouts (30-36 minutes walking)."
62388626|NCT05359575|EXPERIMENTAL|Instructional flashcard with cervical-collar - 1 month follow-up|Instructional flashcard with seven pictures corresponding to 6 steps of c-collar application, used for c-collar application attempt. Participants repeat the c-collar application with the instructional flashcard at 1 month follow-up.
62388627|NCT05359575|EXPERIMENTAL|In-person training with cervical-collar - 1 month follow-up|10 minutes of a Lay First Responder (LFR) spinal immobilization course (extracted from the current LFR Level 1 trauma course) are used for instruction for c-collar application attempt. Participants repeat the c-collar application without any POC instruction or re-training at 1 month follow-up.
62388628|NCT05359575|NO_INTERVENTION|Control group with no in-person training and no access to POC instruction - 1 month follow-up|There is no in-person training or point-of-care (POC) instructional interventions for this group for c-collar application attempt. Participants repeat the c-collar application without any in-person training or POC instructional interventions at 1 month follow-up.
62388629|NCT05359575|EXPERIMENTAL|"Audio recording with instructional flashcard with cervical-collar (audio kit) - 2 Months follow-up"|MP3 audio files for each of 6 steps (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application, used for c-collar application attempt. Participants repeat the c-collar application with the audio kit at 2 months follow-up.
62560296|NCT06430164|EXPERIMENTAL|Paired stimulation of the cortex and peripheral nervous system|Participants will participate in a single session of peripheral electrical stimulation paired with cortical stimulation pulses (i.e. paired associative stimulation(PAS)) on somatosensory, spinal-reflex, and corticospinal neurophysiology.
62560297|NCT01257269||1|Patients with confirmed hereditary TTP due to congenital ADAMTS13 deficiency
62560298|NCT01257269||2|Family members of patients with confirmed hereditary TTP
62560299|NCT03035591|EXPERIMENTAL|ODM-207|Escalating doses of ODM-207
62560300|NCT02621866|EXPERIMENTAL|Active|UVA irradiation.
61993228|NCT04988217|EXPERIMENTAL|Part 1a: Interferon alpha 2b 2.5 MIU|Nebulized interferon alpha 2b 2.5 MIU every 12 hours during 10 days (20 doses total)
62560301|NCT02621866|SHAM_COMPARATOR|Sham UVA irradiation|
62560302|NCT03055624|EXPERIMENTAL|Prostate artery embolization|Single arm study of patients undergoing the prostate artery embolization procedure with Embosphere particles.
62560303|NCT04055740|EXPERIMENTAL|IVUS imaging|IVUS imaging will be used each patient undergoing transvenous lead extraction to visualize ILA
61993229|NCT04988217|EXPERIMENTAL|Part 1b: Interferon alpha 2b 5 MIU|Nebulized interferon alpha 2b 5 MIU every 12 hours during 10 days (20 doses total)
62560304|NCT03485144|EXPERIMENTAL|TV003|Live Attenuated Virus Vaccine-TetraVax-DV
62560305|NCT03485144|PLACEBO_COMPARATOR|Placebo for TV003|Placebo
62560306|NCT01105897||Surgically treated endometriosis patients|Women scheduled for operation on suspected endometriosis in two study hospitals specialized in the surgical treatment of endometriosis between January 2005 - December 2007 (Päijät-Häme Central Hospital) and January 2008 - December 2008 (Helsinki University Hospital).
61993230|NCT04988217|PLACEBO_COMPARATOR|Part 1: Placebo|Nebulized placebo every 12 hours during 10 days (20 doses total)
61993231|NCT04988217|EXPERIMENTAL|Part 2: Interferon alpha 2b 5 MIU (or maximum tolerated dose from part 1)|Nebulized interferon alpha 2b 5 MIU (or maximum tolerated dose from part 1) every 12 hours during 10 days (20 doses total)
61993232|NCT04988217|PLACEBO_COMPARATOR|Part 2: Placebo|Nebulized placebo every 12 hours during 10 days (20 doses total)
61993233|NCT01100242|EXPERIMENTAL|Arm 1: VELCADE and Sorafenib|Patients will be given VELCADE® (bortezomib) 1mg/m2 intravenously on days 1,4,8 \& 11 and sorafenib at a dosage of 200 mg orally twice per day. One full course is comprised of 21 days.
61993234|NCT03238911|EXPERIMENTAL|Iron isomaltoside/ferric derisomaltose|Administered IV
62567706|NCT01063192|ACTIVE_COMPARATOR|Gemcitabine|Arm 1: Gemcitabine alone
61993235|NCT03238911|ACTIVE_COMPARATOR|Ferric carboxymaltose|Administered IV
61993236|NCT02493738|EXPERIMENTAL|Lozanoc 50mg|Lozanoc 50mg, oral administration
61993237|NCT02493738|ACTIVE_COMPARATOR|Sporanox 100mg|Sporanox 100mg, oral administration
61993238|NCT01250587|EXPERIMENTAL|PDC31|
61993239|NCT06438042||Patients in nursing homes or long-stay geriatrics department|
61993240|NCT02400723|EXPERIMENTAL|BREATHE|Four weeks of DVD-delivered behavioral intervention. Intervention consists of diaphragmatic breathing and progressive muscle relaxation.
61993241|NCT02400723|PLACEBO_COMPARATOR|Psychoeducation|Four weeks of DVD-delivered psychoeducation as an attention placebo control.
61993242|NCT01083212|EXPERIMENTAL|1|Gemfibrozil day 1-5 + AZD1656 day 4, 1 week without, Placebo day 1-5 + AZD1656 day 4
61993243|NCT01083212|EXPERIMENTAL|2|Placebo day 1-5 + AZD1656 day 4, 1 week without, Gemfibrozil day 1-5 + AZD1656 day 4
61993244|NCT03519568|EXPERIMENTAL|Combination inoculation group|GroupⅠ: HepB:3 and EV71 were injected at 6 months old, EV71 second dose was injected at 7 months old GroupⅡ: MPSV-A:1 and EV71 were injected at 6 months old, EV71 second dose was injected at 7 months old, MPSV-A:1 second dose was injected at 9 months old GroupⅢ: MR and EV71 were injected at 8 months old, EV71 second dose was injected at 9 months old GroupⅣ: JE-Land EV71 were injected at 8 months old, EV71 second dose was injected at 9 months old
61993245|NCT03519568|ACTIVE_COMPARATOR|Separate inoculation control group|GroupⅠ: HepB:3 third dose was injected at 6 months old GroupⅡ: MPSV-A:1 was injected at 6 months old, then MPSV-A:1 second dose was injected at 9 months old GroupⅢ: MR was injected at 8 months old GroupⅣ: JE-L was injected at 8 months old
61993246|NCT03519568|ACTIVE_COMPARATOR|EV71 inoculation control group|GroupⅠ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅡ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅢ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅣ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old
61993247|NCT00621881|EXPERIMENTAL|1|750 mg naproxcinod
62560307|NCT06447532||Group I: Breast cancer|All the participants involved in our study are women who are diagnosed breast cancer and treated with surgery or neoadjuvant chemotherapy from January 1st 2013 to December 31st 2018.
61993248|NCT01814254||Receiving hemodialysis|
61993249|NCT04656210||Group 1: MD type 1 normal|patients with type 1 myotonic dystrophy with normal carbohydrate tolerance
61993250|NCT04656210||Group 2: MD type 1 Diabetes|"patients with type 1 myotonic dystrophy with diabetes. Patients with carbohydrate intolerance (pre-diabetes) who became diabetic at 3 years of age will be divided into Group 2."
61993251|NCT02280135|EXPERIMENTAL|Intravitreal injection of Autologous bone marrow Stem Cell|"Patients included in the trial will receive a pars plana intravitreal injection of autologous mononuclear cells (MNC) of bone marrow (BM) in one eye (experimental group A or group). The eye in which autologous BM MNCs were injected will be determined randomly.~The average dose will be 30 million of cells (5-60 million) diluted in 0.1 ml. of saline."
61993252|NCT02280135|PLACEBO_COMPARATOR|Subconjunctival injection of saline|Patients included in the trial will receive a subconjunctival injection of 0.1 ml of saline (SF) (placebo) in the fellow eye (group B or control group). In this way the patient will receive an injection in the control eye but avoid the risks of intraocular injection.
61993253|NCT03561493|EXPERIMENTAL|zumba exercise group|Participants will engage in 16 classes of 60-minute Zumba® fitness for two consecutive menstrual cycles (an 8-week period, twice weekly). Each class was one h in length and a recovery period of at least 48 h was taken between classes.
61993254|NCT03561493|NO_INTERVENTION|non zumba exercise group|The participants in the control group did not receive any intervention.
61993255|NCT03488316|ACTIVE_COMPARATOR|Calcium Hydroxide temporary filling material|Temporary filling with Ca(OH)2
61993256|NCT03488316|ACTIVE_COMPARATOR|MTA temporary filling material|Temporary filling with MTA
62388630|NCT05359575|EXPERIMENTAL|Instructional flashcard with cervical-collar - 2 months follow-up|Instructional flashcard with seven pictures corresponding to 6 steps of c-collar application, used for c-collar application attempt. Participants repeat the c-collar application with the instructional flashcard at 2 months follow-up.
62388631|NCT05359575|EXPERIMENTAL|In-person training with cervical-collar - 2 months follow-up|10 minutes of a Lay First Responder (LFR) spinal immobilization course (extracted from the current LFR Level 1 trauma course) are used for instruction for c-collar application attempt. Participants repeat the c-collar application without any POC instruction or re-training at 2 months follow-up.
62388632|NCT05359575|NO_INTERVENTION|Control group with no in-person training and no access to POC instruction - 2 months follow-up|There is no in-person training or POC instructional interventions for this group for c-collar application attempt. Participants repeat the c-collar application without any in-person training or POC instructional interventions at 2 months follow-up.
62388633|NCT05359575|EXPERIMENTAL|Audio recording with instructional flashcard (version 1) with cervical-collar - no follow-up|"Prior to randomization to 1 or 2 month follow up, these participants served as an initial cohort of participants who were not assigned to any longitudinal follow-up date so that the POC instructional flashcard could first be piloted to receive feedback for instructional flashcard revision prior to launching the trial after participants expressed concern about ambiguity in the instructional flashcard. Data from these participants is not considered part of the trial for any analytic purposes. Revisions to the instructional flashcard were made."
61993257|NCT02786485|EXPERIMENTAL|Rivogenlecleucel & Rimiducid|"All subjects will receive 3 courses of rivogenlecleucel (BPX-501 T cells) infusions at 30 day intervals with 2 escalating dose levels (DL). DL1 on Day 0 and DL2 on Days 30 and 60.~Escalating doses of rimiducid (AP1903) (0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after rivogenlecleucel infusion."
62560308|NCT04933344||patients having had BJI or PJI treated with daptomycin|patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia or elevation of CPK
62560309|NCT05579431|EXPERIMENTAL|Part A|Participants grouped in different cohorts will receive a single ascending dose of VX-634.
62560310|NCT05579431|PLACEBO_COMPARATOR|Placebo Part A|Participants will be randomized to receive placebo matched to VX-634.
62560311|NCT05579431|EXPERIMENTAL|Part B|Participants grouped in different cohorts will receive multiple doses of VX-634.The dose levels will be determined based on the data from Part A.
62768583|NCT00499746|ACTIVE_COMPARATOR|hydromorphone|oral dose, once per day
61993258|NCT06528392|EXPERIMENTAL|subcutaneous Efgartigimod-hyaluronidase (EFG)|Participants with GAD65-antibody positive SPS will be given subcutaneous Efgartigimod-hyaluronidase (EFG).
61993259|NCT06496841||Transnasal sphenopalatine ganglion block group|transnasal administration of lidocaine to the sphenopalatine ganglion
61993260|NCT06496841||Ultrasound-guided suprazygomatic sphenopalatine ganglion block group|ultrasound-guided suprazygomatic approach
61993261|NCT03444974|ACTIVE_COMPARATOR|Patient therapy group|"* Adolescents with substance use disorders~* Receiving an adapted treatment according to the MATRIX-A therapy"
62560312|NCT05579431|PLACEBO_COMPARATOR|Placebo Part B|Participants will be randomized to receive placebo matched to VX-634.
62768584|NCT00499746|ACTIVE_COMPARATOR|methylphenidate|oral dose, once per day
62768585|NCT05245214||Patients with disc herniation|Having only disc degeneration and not having any other neurological or orthopedic disease. Patients who had previous spinal surgery, patients with lumbar scoliosis, spondylolisthesis or structural defect in the sacrum were excluded from the study.
62560313|NCT03203967|EXPERIMENTAL|Epidural morphine|"1. Epidural morphine (2 mg morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.~2. Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.~3. Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h."
62560314|NCT03203967|PLACEBO_COMPARATOR|Epidural placebo|"1. Epidural placebo (5 ml normal saline) is administered through the epidural catheter at the end of surgery.~2. Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.~3. Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h."
62560315|NCT00738179|EXPERIMENTAL|1|CPAP plus standard care of cardiovascular risk factors
62560316|NCT00738179|ACTIVE_COMPARATOR|2|Standard care alone
62768586|NCT05245214||Patient in control group|Patients without disc herniation, severe disc degeneration and spondylolisthesis were included in the control group.
62768587|NCT04118790||Minor Stroke patients|"* Clinical Assessment~* MRI scan session"
61993262|NCT03444974|ACTIVE_COMPARATOR|Parental therapy group|"* Parents of adolescents with substance use disorders~* Receiving an adapted treatment according to the MATRIX-A therapy"
61993263|NCT03444974|NO_INTERVENTION|Patient waiting list group|"* Adolescents with substance use disorders~* On the waiting list for receiving a MATRIX-A therapy"
61993264|NCT03444974|NO_INTERVENTION|Parental waiting list group|"* Parents of adolescents with substance use disorders~* On the waiting list for receiving a MATRIX-A therapy"
61993265|NCT03444974|NO_INTERVENTION|control group|"* Adolescents with no history of substance use disorders~* no other intake of psychotropic substances such as psychotropic medication"
61993266|NCT01566448|EXPERIMENTAL|Ketamine|Ketamine oral mouthwash 20mg/5ml swish and spit four times daily
61993267|NCT01726738|EXPERIMENTAL|BRAF (dabrafenib) and MEK (trametinib) inhibitors|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
61993268|NCT05811546||H. pylori Gastritis specimens|
61993269|NCT05811546||Non-H. pylori Gastritis specimens|
61993270|NCT05811546||Gastric carcinoma specimens|
61993271|NCT00793338|EXPERIMENTAL|Sildenafil|All patients will receive open-label treatment with sildenafil.
62560317|NCT04478929||gastroscopy clinic patients|NBT gastroscopy clinic invited participants. Patients are already due to attend the clinic, and we are inviting them to share their gastroscopy data with our research study.
62560318|NCT05385653|EXPERIMENTAL|patients with bulimia or binge eating disorder|patients with bulimia or binge eating disorder
62768588|NCT04118790||TIA patients|"* Clinical Assessment~* MRI scan session"
62768589|NCT04118790||Healthy Controls|* MRI scan session
62768590|NCT04295863|EXPERIMENTAL|standard interval dosing|
62768591|NCT04295863|EXPERIMENTAL|extended interval dosing|
62768592|NCT04527627|EXPERIMENTAL|Experimental Group (EG)|The nursing empowerment intervention will be administered in the experimental group
62768593|NCT04527627|NO_INTERVENTION|Control Group (CG)|The nursing empowerment intervention will not be administered in the control group
62768594|NCT02406443|EXPERIMENTAL|Experimental arm|sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
62768595|NCT02406443|PLACEBO_COMPARATOR|Placebo arm|placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
61993272|NCT03864315|EXPERIMENTAL|Vitiligo|30 Patients with Vitiligo
61993273|NCT01121692|EXPERIMENTAL|VCT/Women's CoOp|
62560319|NCT05385653|OTHER|control|paired healthy controls
62560320|NCT04088812|PLACEBO_COMPARATOR|Placebo meat derivative + Placebo satiating compound|60 g Placebo meat derivative 25 g Placebo satiating compound
62560321|NCT04088812|EXPERIMENTAL|Placebo meat derivative + Satiating compound|60 g Placebo meat derivative 25 g Satiating compound
62560322|NCT04088812|EXPERIMENTAL|Experimental meat derivative + Placebo satiating control|60 g Experimental meat derivative 25 g Placebo satiating compound
62560323|NCT04678518|ACTIVE_COMPARATOR|SIRS|Patients will be grouped according to the presence or absence of SIRS criteria into group I (SIRS)
62768596|NCT05829863|EXPERIMENTAL|Message exposure|Participants will all be exposed to anti-vaping PSAs utilizing cognitive, emotional, and social appeals, aiming to persuade them to reduce or quit using e-cigarettes.
62560324|NCT04678518|PLACEBO_COMPARATOR|NON-SIRS|Patients will be grouped according to the presence or absence of SIRS criteria into group II (Non-SIRS)
62768597|NCT03839758|ACTIVE_COMPARATOR|TSA Standard|This group will include patients schedule for a total shoulder arthroplasty. Glenoid preparation will be done following surgeon evaluation of the 2D CT scan with the institution software. Generic guides included in the regular instrumentation set will be used
62768598|NCT03839758|ACTIVE_COMPARATOR|RTSA standard|This group will include patients schedule for a reverse total shoulder arthroplasty. Glenoid preparation will be done following surgeon evaluation of the 2D CT scan with the institution software. Generic guides included in the regular instrumentation set will be used
62768599|NCT03839758|EXPERIMENTAL|TSA blueprint|This group will include patients schedule for a total shoulder arthroplasty. Glenoid preparation will be done using the personalized guide provided by Wright-Tornier. This guide will be ordered after CT-scan measurement, using Blueprint software prior to surgery.
61993274|NCT01121692|EXPERIMENTAL|Women's CoOp/Men's CoOp|
61993275|NCT01121692|EXPERIMENTAL|Couples CoOp|
61993276|NCT05379439|EXPERIMENTAL|Intervention|Intervention families will participate in the Structured Family Deliberation that includes a clinician-led review of a web-based decisional aid.
61993277|NCT05379439|NO_INTERVENTION|Control|Control families will undergo the standard decisional process for home ventilation and will also review the web-based decisional aid independently.
62388634|NCT05359575|EXPERIMENTAL|Instructional flashcard (version 1) with cervical-collar - no follow-up|"Prior to randomization to 1 or 2 month follow up, these participants served as an initial cohort of participants who were not assigned to any longitudinal follow-up date so that the POC instructional flashcard could first be piloted to receive feedback for instructional flashcard revision prior to launching the trial after participants expressed concern about ambiguity in the instructional flashcard. Data from these participants is not considered part of the trial for any analytic purposes. Revisions to the instructional flashcard were made."
62388635|NCT04832633|EXPERIMENTAL|test bolus(TB) I|We use the TB method with biphasic injection, followed by the saline flush. Initially, we inject the 10 ml of test contrast media with a velocity of 3ml/s and apply the ROI at the bifurcation of PA and descending aorta at the same level. The dynamic curve demonstrates the time to peak enhancement of P second and A second. The first phase of contrast media injection uses a velocity of 2ml/s and the volume of contrast is measured as 2ml/s multiply (A-P) second. The second phase of contrast media injection uses a velocity of 3ml/s and the volume of contrast media is 70ml minus the amount of first phase injection. The total volume of the contrast media is 80ml, including the 10ml for pre-diagnostic test bolus images. We performed the saline flush following the administration of the contrast media with 20 ml normal saline. The start time of the diagnostic scan is at the A second.
62388636|NCT04832633|EXPERIMENTAL|test bolus(TB) II|This group is similar to the TB I. However, we use the lesser contrast media in the second phase of injection. The second phase of contrast media injection is applied with a velocity of 3ml/s and the volume of the contrast media is 60ml minus the amount of first phase injection. The total volume of the contrast media is 70 ml, also including the 10ml for pre-diagnostic test bolus images. The following saline flush uses 30 ml of normal saline. The start time of the diagnostic scan is at the A second as well.
62388637|NCT04832633|EXPERIMENTAL|bolus-tracking(BT) I|Initially, 10ml of test contrast media was administrated but no calculation was performed for these pre-diagnostic test bolus images in this group. Unlike the TB method, we use 10 seconds as the fixed interval of (A-P) in this group. The first phase of contrast media injection uses a velocity of 2ml/s and thus the volume of contrast is 20ml. The second phase of contrast media injection is administered with a velocity of 3ml/s and the volume of the contrast media is 70ml minus 20ml. The total volume of the contrast media is 80 ml. The following saline flush uses 20 ml of normal saline. The tracking scan started after contrast injection was initiated for 15 seconds. The ROI is placed in the descending aorta at the same level of PA bifurcation and the diagnostic CT scan is triggered when the density in the ROI achieves the baseline density plus 150HU.
62560325|NCT05362604||prenatal|patients affected by confirmed fetal esophageal, duodenal or intestinal atresia and followed in our high-risk pregnancy unit, and scheduled for delivery between 38 and 39 weeks in our tertiary center, regardless of the patient's place of residence
62560326|NCT05362604||postnatal|patients with unsuspected fetal atresia who delivered in their local hospitals: their newborns were transferred to our tertiary hospital within 24 hours and the mother had the option to be also transferred in order to follow her baby.
62560327|NCT01357499||control group|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg but without inflating the cuff and without stimulating the muscle. Now 25 minutes will have to pass by before beginning the coronary angioplasty.
62768600|NCT03839758|EXPERIMENTAL|RTSA blueprint|This group will include patients schedule for a reverse total shoulder arthroplasty. Glenoid preparation will be done using the personalized guide provided by Wright-Tornier. This guide will be ordered after CT-scan measurement, using Blueprint software prior to surgery.
61993278|NCT00506090|EXPERIMENTAL|A|pulsed dye laser and dynamic cooling device at 3 weeks intervals
61993279|NCT00506090|ACTIVE_COMPARATOR|B|pulsed dye laser and dynamic cooling device at 6 weeks intervals
61993280|NCT00506090|SHAM_COMPARATOR|C|dynamic cooling device
61993281|NCT01169506|EXPERIMENTAL|COPD patients and healthy individuals|
61993282|NCT00943228|EXPERIMENTAL|mycophenolate mofetil|mycophenolate mofetil 2000mg BID (4g/day) for 14 days, followed by mycophenolate 1000mg BID (2g/day) thereafter
61993283|NCT05838131|EXPERIMENTAL|CAR-T cells Infusion|Biological: CART cells chimeric antigen receptor T cells
61993284|NCT01030562||Alternate Arm|Subjects who meet eligibility requirements but do not fit into any of the primary experimental arms.
61993285|NCT01030562||Control Arm|Subjects with an on-time interval between Dose 1 and 2 and an on-time interval between Dose 2 and 3.
61993286|NCT01030562||Experimental/Primary Arm 1|This primary arm will consist of subjects receiving the second dose on time/third dose substantially late.
61993287|NCT01030562||Experimental/Primary Arm 2|This primary arm will consist of subjects receiving the second dose substantially late/third dose on time.
61993288|NCT01030562||Experimental/Primary Arm 3|This primary arm will consist of subjects receiving the second dose substantially late/third dose substantially late.
61993289|NCT02600637|EXPERIMENTAL|MBSR|Mindfulness-based Stress Reduction program
61993290|NCT02600637|ACTIVE_COMPARATOR|Education|Educational group program
61993291|NCT01667978|EXPERIMENTAL|PI|Study group with PI: atazanavir ritonavir
61993292|NCT01667978|PLACEBO_COMPARATOR|Control|o PI therapy, control group
61993293|NCT03398720|EXPERIMENTAL|Cohort 1|One participant will receive HTI-1066 at the starting dose.
61993294|NCT03398720|EXPERIMENTAL|Cohort 2|Participants will receive HTI-1066 at dose level 2.
61993295|NCT03398720|EXPERIMENTAL|Cohort 3|Participants will receive HTI-1066 at dose level 3.
61993296|NCT03398720|EXPERIMENTAL|Cohort 4|Participants will receive HTI-1066 at dose level 4.
61993297|NCT02361255||Drug-induced parkinsonism|subjects with drug-induced parkinsonism
61993298|NCT02361255||antipsychotic treated non-parkinsonian control|subjects treated with antipsychotic but without parkinsonism
61993299|NCT00593307|EXPERIMENTAL|Low GI|low GI breakfast
61993300|NCT00593307|EXPERIMENTAL|Low GI -low carb|Low GI and Low carb breakfast
61993301|NCT00593307|EXPERIMENTAL|High GI|High GI breakfast
61993302|NCT00593307|EXPERIMENTAL|High GI Low Carb|high GI low carb breakfast
61993303|NCT00281203||healthy smokers|Must be free of serious diseases that might make it dangerous to undergo bronchoscopy.
61993304|NCT03488212|ACTIVE_COMPARATOR|Basic Implementation Intervention|
61993305|NCT03488212|EXPERIMENTAL|Enhanced Implementation Intervention|
61993306|NCT03488212|ACTIVE_COMPARATOR|Online Treatment; Control Maintenance Intervention|
62388638|NCT04832633|EXPERIMENTAL|bolus-tracking(BT) II|This group is similar to the BT I. The first phase of injection is the same as the BT I group. We use lesser contrast media in the second phase of contrast injection. The second phase of contrast media injection is applied with a velocity of 3ml/s and the volume of the contrast media is 60ml minus 20ml. The total volume of the contrast media is 70 ml, including the 10ml for pre-diagnostic test bolus images. The following saline flush uses 30 ml of normal saline. The protocol for triggering diagnostic CT scan is the same as that in BT I.
62388639|NCT05858645|EXPERIMENTAL|deucravacitinib treatment|treatment with deucravacitinib for 6 months
62388640|NCT03362827||Chronic low back pain patients|People must have experienced low back pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
62388641|NCT03362827||Subjects without chronic low back pain|Participants must not have presented episodes of low back pain for more than 7 days in the last 12 months.
61993307|NCT03488212|EXPERIMENTAL|Online Treatment; Monthly Lessons & Feedback for Maintenance|
61993308|NCT03488212|EXPERIMENTAL|Online Treatment; Refresher Courses for Maintenance|
61993309|NCT05017194|EXPERIMENTAL|Emodepside 5 mg|
61993310|NCT05017194|EXPERIMENTAL|Emodepside 10 mg|
61993311|NCT05017194|EXPERIMENTAL|Emodepside 15 mg|
61993312|NCT05017194|EXPERIMENTAL|Emodepside 20 mg|
61993313|NCT05017194|EXPERIMENTAL|Emodepside 25 mg|
61993314|NCT05017194|EXPERIMENTAL|Emodepside 30 mg|
61993315|NCT05017194|ACTIVE_COMPARATOR|Albendazole|
61993316|NCT05017194|PLACEBO_COMPARATOR|Placebo|
61993317|NCT06225726||Experimental : Urothelial bladder tumour|Patient with an indication of transurethral resection of the bladder. Following the Urology consultation, the patient will be called for a trans-urethral bladder resection within 1 month. The patient will be admitted to the Urology Department of the Tours University Hospital the previous day.
61993318|NCT06327399|ACTIVE_COMPARATOR|Group A|patients will receive Dexmedetomidine infusion dose of 1 mcg/kg over 10 min.
61993319|NCT06327399|ACTIVE_COMPARATOR|Group B|patients will receive Dexmedetomidine bolus dose of 0.3 mcg/kg over 60 seconds.
61993320|NCT03729336|EXPERIMENTAL|PEEZY specimen|All subjects will use PEEZY to give a urine specimen.
61993321|NCT03729336|PLACEBO_COMPARATOR|CATHETER specimen|All subjects will use CATHETER (performed by their clinician) to give a urine specimen, following PEEZY use.
61993322|NCT03987893|EXPERIMENTAL|PEG+Lactulose|this arm will recieve PEG3350 in addition to standard of care
61993323|NCT03987893|ACTIVE_COMPARATOR|Lactulose alone|this arm will recieve only standard of care for management of hepatic encephlaopathy with ACLF
61993324|NCT02666183|EXPERIMENTAL|Closer|"The full intervention (Closer) is a tested intervention that uses videoconferencing technology (WebEx) for delivery and delivers the highest dose of the intervention. This arm of the intervention will deliver personalized information to the DCG (aimed at enhancing self-efficacy) and emotional support via nurse coaching as well as the opportunity for the DCG to talk with the oncologist and patient in real time during a minimum of four patient-oncologist office visits over a 4-month period (at least once/month). For patients who have more than one oncologist-patient meeting/month, the study will use the videoconference technology to allow the DCG to join as many of the join in as many of the oncologist-patient office visits as desired."
61993325|NCT02666183|ACTIVE_COMPARATOR|Video-C Only|"This arm will involve the delivery of information solely via the use of videoconference technology during the patient-oncologist-DCG visit. There is always the possibility that the DCG will receive emotional support from the oncologist during the office visit (as would potentially occur during a face-to-face meeting) - but this will not be delivered systematically as in the Closer intervention. As with the Closer intervention, the DCG will be able to participate in the patient-oncologist visit in real time during a minimum of four office visits over the 4-month study period (total dose \~5 hours). The procedure for these meetings will be the same as outlined for Closer but will not involve having the nurse involved in the videoconference sessions with the oncologist, patient, and DCG."
62388642|NCT06157411|EXPERIMENTAL|Mindful Eating Intervention (AC group)|"* Mindful eating program: Two sub-groups of 14 participants will follow the program for 8 consecutive weeks.~* Follow-up group session: The two groups of 14 participants will each attend a follow-up group session.~* 3 visits with a doctor: The 28 participants will have a pre-intervention visit, a post-intervention visit, and a final visit 3 months after the program.~* Focus groups: The two groups of 14 participants will be divided into two (N=7, x4) for a focus group session."
62768601|NCT03128190|NO_INTERVENTION|Control group|In the control period, patients were given intravenous fluids at the discretion of the anesthesiologist based on institutional protocol using 250ml of crystalloids or 100ml of colloids based on central venous pressure (CVP) and mean arterial pressure (MAP) measurements. The aim was to keep the CVP ≥ 8mmHg and MAP ≥ 65mmHg. Fluid boluses were administered up to a total of 1000ml, if patients did not attain a MAP of \>65 mmHg, a vasopressor drug was administered.
61993326|NCT02666183|ACTIVE_COMPARATOR|Web-Only|"This group will be provided access to a website that will provide the following major links: a) Caregiving Resources (links to National Family Caregiver Association, etc.), b)Resources for DCGs (links to the Caregiving from a Distance, etc.), c) Cancer Information (links to National Cancer Institute, etc.). DCGs will be told that the study team will track usage of the website in order to assess which areas of the website are used most frequently. Any questions or concerns regarding use of the website can be sent online to the study's technical site, and the support staff will respond within 24 hours. As is current practice, DCGs can call an oncology nurse or oncologist to ask specific questions. Web-Only will deliver the lowest dose of the intervention."
61993327|NCT02143908|PLACEBO_COMPARATOR|placebo supplementation|2000 mg placebo tablets/day
61993328|NCT02143908|ACTIVE_COMPARATOR|Supplementation|lysine 2000 mg tablets/day supplementation
61993329|NCT01450410|ACTIVE_COMPARATOR|Nicotinic Acid|
61993330|NCT01450410|PLACEBO_COMPARATOR|Placebo|
61993331|NCT05810090||TKA (Total Knee Arthroplasty)|Patients did total knee arthroplasty in our hospital.
61993332|NCT01334203|EXPERIMENTAL|Ranolazine|
61993333|NCT01334203|PLACEBO_COMPARATOR|Placebo|
61993334|NCT00877695|EXPERIMENTAL|Motive8 2 Change FtF|This arm of the motivational enhancement intervention (MEI) will be delivered face to face (FtF) using a real-time, dynamic implementation approach. The intervention consisted of 2 sessions lasting approximately 60 to 90 minutes. The sessions focused on increasing participants' awareness of the multiple influences on behaviors from self, family, culture and community and how these influences impact the way we think and behave including sexually. Through a series of exercises the participant develops strategies for understanding and managing his own triggers that helps them to make healthy life choices. Both Motiv8 2Change arms used the exact same intervention, with the exception that one was delivered face to face and the other through the internet.
61993335|NCT00877695|EXPERIMENTAL|Motive8 2Change -Internet|This arm of the motivational enhancement intervention (MEI) will be delivered via the Internet face to face (FtF) using a real-time, dynamic implementation approach.The intervention consisted of 2 sessions lasting approximately 60 to 90 minutes. The sessions focused on increasing participants' awareness of the multiple influences on behaviors from self, family, culture and community and how these influences impact the way we think and behave including sexually. Through a series of exercises the participant develops strategies for understanding and managing his own triggers that helps them to make healthy life choices. Both Motiv8 2Change arms used the exact same intervention, with the exception that one was delivered face to face and the other through the internet.
61993336|NCT00877695|NO_INTERVENTION|delayed|
61993337|NCT00877695|ACTIVE_COMPARATOR|Motiv8 2Change Careers|Comparable in number of sessions and duration to the experimental arms, but focused on resume development and interviewing skills. This arm consisted of 2 sessions. In the first session participants reviewed different career choices and created a winning resume. The second session focused on job interviewing skills. It included role plays with feedback. It also contains ethically mandated information regarding HIV prevention. It was delivered on line by a trained facilitator.
61993338|NCT00244712|EXPERIMENTAL|ABC/3TC|The intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo +lopinavir/ritonavir.
61993339|NCT00244712|ACTIVE_COMPARATOR|TDF/FTC|The intervention is a regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
61993340|NCT01658423||Junior high school student|All subjects participated in measurements of body composition, muscle strength and motor fitness
61993341|NCT06045234|EXPERIMENTAL|Pesticide measurement|
62388643|NCT06157411|ACTIVE_COMPARATOR|Conventional Dietetic Intervention (DC group)|"* Therapeutic education program (ETP): The 28 participants will follow the ETP program Obesity: living better, balancing my weight.~* Follow-up group session: The 28 participants will have an individual follow-up session in the form of a final Shared Educational Assessment.~* 3 visits with a doctor: The 28 participants will have a pre-intervention visit, a post-intervention visit, and a final visit 3 months after the program."
61993342|NCT06115265|EXPERIMENTAL|KDDP|KDDP - Participants enrolled in the KDDP arm will be placed on a traditional ketogenic diet (\<20 grams of carbohydrate/day).
61993343|NCT06115265|EXPERIMENTAL|NDPP|NDPP - Participants enrolled in the NDPP arm will be placed on a low fat diet.
62168306|NCT01697592|PLACEBO_COMPARATOR|Placebo/TZDs (Phase A) → Omarigliptin 25 mg/TZDs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of TZDs throughout the duration of the study.
62388644|NCT06300866|EXPERIMENTAL|Group I|toothpaste brushing 2x daily morning \& evening for 2 minutes
62388645|NCT06300866|ACTIVE_COMPARATOR|Group II|toothpaste brushing 2x daily morning \& evening for 2 minutes
62560328|NCT01357499||intervention group 1|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. There will be no electrical muscle stimulation in this group.
62567707|NCT01063192|ACTIVE_COMPARATOR|GOFL|Arm 2: GOFL (Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
62567708|NCT01862926|EXPERIMENTAL|Rituximab|1g given at baseline and two weeks.
62768602|NCT03128190|EXPERIMENTAL|PPV group|intraoperative fluid management was titrated to maintain PPV\< 10%. fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
61993344|NCT05700552|EXPERIMENTAL|Intervention Group|In the intervention group, after cesarean delivery in the operating room, maternal vital signs and the newborn's 1st and 5th minute Apgar Score will be evaluated. After the newborn baby is aspirated if necessary, dried with a green cover under the radiant warmer, tied the diaper, and put on a hat, the newborn with an Apgar Score ≥7 and vital signs stable will be wrapped in pre-warmed operating room covers. After providing a suitable environment, the newborn whose body temperature is stabilized will be placed in the prone position without any covering and clothing on the chest area of the mother, and the ALPS value will be applied for about 3 minutes due to the application of hospital procedures, the intramuscular injection will be applied and the ALPS score will be evaluated again after the injection.
61993345|NCT05700552|NO_INTERVENTION|Control group|The routine procedure of the institution where the study will be performed will be applied to the newborn baby after cesarean section in the control group. Within the scope of this procedure, after the baby is born, the umbilical cord is cut, mouth and nose aspiration is performed under the radiant heater in the operating room, they are dried, and the Apgar Score is evaluated at the 1st and 5th minutes by the midwife. The newborn is wrapped in pre-heated operating room covers, and after being shown to the mother, anthropometric measurements (height, body weight, head circumference) are taken and taken to the delivery room for the administration of vitamin K, hepatitis B vaccine, and the first examination of the baby. The first ALPS value will be recorded in the delivery room in the baby care area, the intramuscular injection will be applied and the ALPS score will be evaluated again after the injection.
61993346|NCT03356249||Sepsis Group|Patients (n=500) with suspected or proven sepsis or septic shock (according to the Sepsis-3 definitions).
61993347|NCT03364296|OTHER|Patients hospitalized for stroke|
61993348|NCT01856790|EXPERIMENTAL|Closed Loop Insulin Delivery|"Each participant recruited into the study will undergo two inpatient closed loop admissions.~The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback.~Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.~Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy."
61993349|NCT00449956|EXPERIMENTAL|1|combination of dorzolamide hydrochloride and timolol maleate
61993350|NCT00449956|ACTIVE_COMPARATOR|2|Concomitant use of dorzolamide hydrochloride and timolol maleate
61993351|NCT00449956|ACTIVE_COMPARATOR|3|timolol maleate
61993352|NCT06350175|ACTIVE_COMPARATOR|Nicotine Replacement Therapy (NRT)|Subject provided with a 2-week supply of NRT and a West Virginia Quit Line (WV QL) fact sheet/contact information.
61993353|NCT06350175|OTHER|Control Non NRT Therapy|Subject will be provided with a box/bag containing a WV QL fact sheet/contact information.
61993354|NCT05804383|EXPERIMENTAL|50 mg active|BMS-984923 50 mg in healthy participants
61993355|NCT05804383|PLACEBO_COMPARATOR|50 mg Placebo|Placebo 50 mg in healthy participants
62560329|NCT01357499||intervention group 2|A Blood pressure cuff and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle
61993356|NCT05804383|EXPERIMENTAL|100 mg Active|BMS-984923 100 mg in healthy participants
61993357|NCT05804383|PLACEBO_COMPARATOR|100 mg Placebo|Placebo 100 mg in healthy participants
61993358|NCT05804383|EXPERIMENTAL|100 mg Active 20d|BMS-984923 100 mg in healthy participants 20 days
61993359|NCT05804383|PLACEBO_COMPARATOR|100 mg Placebo 20d|Placebo 100 mg in healthy participants 20 days
62388646|NCT03070262|EXPERIMENTAL|CA group|caffeic acid (300mg, tid, po) continue given until progression of disease or death, or patients are unable to bear the side effects
62388647|NCT03070262|PLACEBO_COMPARATOR|placebo group|the same shape placebo tablets continue given until progression of disease or death, or patients are unable to bear the side effects
62388648|NCT04271189|EXPERIMENTAL|POLYCHEM|Metformin (extended release), Pioglitazone, Sitagliptin and Empaglifozin.
62567709|NCT01862926|ACTIVE_COMPARATOR|Cyclophosphamide|Intravenous dose of 600 mg/m2 body surface area. 6 doses given 4 weekly.
62567710|NCT00475488|OTHER|Group 1|Radial Artery versus Right Internal Thoracic Artery when used as a coronary conduit in patients undergoing multi-vessel coronary artery bypass grafting.
61993360|NCT05804383|EXPERIMENTAL|150 mg Active 20d|BMS-984923 150 mg in healthy participants 20 days
62388649|NCT04271189|ACTIVE_COMPARATOR|STANDARD CARE|Standard of care according to the local health service.
62388650|NCT03798366|EXPERIMENTAL|GLPG1690 600 mg|Participants received GLPG1690 600 milligrams (mg), orally once daily for 24 weeks.
62388651|NCT03798366|PLACEBO_COMPARATOR|Placebo|Participants received GLPG1690 matching placebo, orally once daily for 24 weeks.
62388652|NCT02138552|ACTIVE_COMPARATOR|OCT 0.1% vs. Placebo|0.1 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
62567711|NCT00475488|OTHER|Group 2|Radial Artery versus Saphenous Vein when used as a coronary conduit in patients undergoing multi-vessel coronary artery bypass grafting.
62567712|NCT01035294|EXPERIMENTAL|mindfulness based intervention|
62567713|NCT01035294|ACTIVE_COMPARATOR|usual care (UC)|
61993361|NCT05804383|PLACEBO_COMPARATOR|150 mg Placebo 20d|Placebo 150 mg in healthy participants 20 days
61993362|NCT05804383|EXPERIMENTAL|50 mg Active-AD|BMS-984923 50 mg
61993363|NCT05804383|EXPERIMENTAL|100 mg Active-AD|BMS-984923 100 mg
61993364|NCT05804383|PLACEBO_COMPARATOR|Placebo-AD|Placebo matching
61993365|NCT06168487|EXPERIMENTAL|Cohort 1: Telmisartan Alone|Patients will receive telmisartan alone.
62388653|NCT02138552|ACTIVE_COMPARATOR|OCT 0.15% vs. Placebo|0.15 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
62388654|NCT02138552|ACTIVE_COMPARATOR|OCT 2.0% vs. Placebo|0.2 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
62388655|NCT02579889|EXPERIMENTAL|Active group - CLS ON|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON; Intervention: DDD+CLS
62388656|NCT02579889|ACTIVE_COMPARATOR|Control group - CLS OFF|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
61993366|NCT06168487|EXPERIMENTAL|Cohort 2: Telmisartan + Standard of Care Regimen|Patients will receive telmisartan with cabazitaxel or docetaxel without abiraterone), or telmisartan with docetaxal with abirateron or olaparib or rucaparib, or talazoparib plus enzalutamide.
61993367|NCT06212219|ACTIVE_COMPARATOR|Standard Neurofeedback Procedure|"The standard NF (sensory feedback) will consist of motor imagery tasks, that is to say that the patient will have to imagine themselves carrying out movements, without real motor execution.~Two types of movements will be alternately requested: a complete sustained extension of the fingers of the paralyzed hand, a global movement of the arm (e.g. opening of the elbow) of the paralyzed arm."
61993368|NCT06212219|EXPERIMENTAL|Personalized Neurofeedback Procedure|Personalized NF will consist of adding to these motor imagery tasks, personalized aspects depending on the patient's profile, for example in terms of level of support and emotional support (addition of a relaxation exercise using an audio recording at the start of training - and in the middle of training if necessary, adding the presence of a virtual companion to provide social presence and emotional support, depending on the user's performance and progress) , of the virtual environment.
61993369|NCT01172951|ACTIVE_COMPARATOR|OGTT-OGTT-Physical tests|2 successive Oral Glucose Tolerance Tests followed by a physical tests session
61993370|NCT01172951|ACTIVE_COMPARATOR|OLTT-OLTT-Physical tests|2 successive Oral Lipid Tolerance Tests followed by a physical test session
62388657|NCT03370133|EXPERIMENTAL|Bimekizumab cohort|Subjects will receive bimekizumab for 52 weeks.
62768603|NCT02643823|EXPERIMENTAL|hUC-MSC + DMARDs|Patients will be treated in combination with hUC-MSC and DMARDs with a 12 months follow-up.
62768604|NCT02643823|ACTIVE_COMPARATOR|DMARDs|Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs) with a 12 months follow-up.
62768605|NCT01852279|EXPERIMENTAL|Active muscle stimulation|Muscle stimulation delivered by Brain Computer Interface
62768606|NCT01852279|ACTIVE_COMPARATOR|Passive muscle stimulation|FES will be delivered by therapist
62768607|NCT01249456||Femara(Letrozole)|
61993371|NCT01172951|ACTIVE_COMPARATOR|OGTT-OLTT-Physical tests|Oral glucose tolerance test followed by an oral lipid tolerance test (or vice-versa) followed by a physical tests session
61993372|NCT02755376|ACTIVE_COMPARATOR|ACL reconstruction only|only ACL reconstruction without any injection
61993373|NCT02755376|EXPERIMENTAL|ACL reconstruction + Cartistem(TM)|ACL reconstruction and concomitant Cartistem(TM) injection which is human cord blood derived mesenchymal stem cell under arthroscopy.
61993374|NCT02755376|EXPERIMENTAL|ACL reconstruction + Hyaluronic acid|ACL reconstruction and concomitant hyaluronic acid injection under arthroscopy
61993375|NCT02506335|OTHER|Hep quant cholate testing|diagnostic measure of liver function
61993376|NCT04693390|EXPERIMENTAL|Acupuncture|The acupuncture will be applied at points LI4, ST36, HT7, in association with auriculotherapy point Master Cerebral, immediately after induction of anesthesia for 20 minutes
61993377|NCT04693390|NO_INTERVENTION|Standard care group|The patients will follow the standard procedure
61993378|NCT05751330|EXPERIMENTAL|patients affected by Cardioinhibitory Neurocardiogenic Syncope|
61993379|NCT04649164|OTHER|Focus group participants|"Subjects participating in focus groups will be either:~1. caregiver mentees in our previous peer mentoring study~2. peer mentors and completed 16 weeks of mentoring in our previous peer mentoring study~3. current family caregivers of community-dwelling LBD patients in the Chicago area.~The investigators will conduct virtual focus groups using a password-protected videoconference platform. The informed consent process will take place online prior to the focus group. Focus groups will be led by a qualified neuropsychologist using open-ended questions. The aim of these groups is to revise and improve upon our previous peer mentor program's curriculum. Participants will be presented with the previous program's curriculum and a variety of proposed educational resources for inclusion in the revised curriculum. The investigators will obtain participants' feedback. Focus groups will be recorded and transcribed."
62388658|NCT03370133|ACTIVE_COMPARATOR|Ustekinumab cohort|Subjects will receive ustekinumab (dose 1 or dose 2 depending on subjects weight) for 52 weeks. Placebo will be administered at pre-specified time points to maintain the blinding.
62388659|NCT03370133|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo up to week 16 and bimekizumab starting at week 16 through week 52.
61993380|NCT04649164|OTHER|Peer mentors|Mentors will attend one 6-7 hour virtual training session. Study expectations and logistics will be reviewed with each potential mentor prior to the training session via phone. Informed consent process will take place online via REDCap prior to the training session. Baseline data will be collected via online surveys. Next, mentors will receive training regarding topics including active listening, mentoring, goal-and boundary-setting, an overview of LBD, risk factors for hospitalization, impact on caregiver, practical approaches to symptom management, and caregiving issues. The study team will present the PERSEVERE curriculum and accompanying handbook. The team will solicit questions and lead roleplay conversations. Finally mentors will complete post-training assessments. Once all caregiver mentees (Arm 3) are recruited, the mentors will contact their mentees once weekly by phone for 16 weeks to deliver the PERSEVERE curriculum.
62388660|NCT03627442|ACTIVE_COMPARATOR|Mastectomy with PhotonBlade|Patients undergoing double mastectomy with immediate reconstruction with expanders. One breast will be randomly selected to be operated with PhotonBlade
62388661|NCT03627442|ACTIVE_COMPARATOR|Mastectomy with Bovie|Patients undergoing double mastectomy with immediate reconstruction with expanders. One breast will be randomly selected to be operated with Bovie.
62388662|NCT04102124|EXPERIMENTAL|SHR3680+SHR3162|Participants will receive SHR3680 combined with SHR3162 orally
62768608|NCT04808193|EXPERIMENTAL|Brugada Survey|Survey will be answered by all participants
62768609|NCT01893359|EXPERIMENTAL|LASIK followed by Cross-linking (Continuous Wave)|Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 2 minutes continuous UVA.
62768610|NCT01893359|EXPERIMENTAL|LASIK followed by Cross-linking (Pulsed)|Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off.
62768611|NCT01893359|PLACEBO_COMPARATOR|LASIK Only|Eyes assigned to this arm will receive standard LASIK with no cross-linking.
62768612|NCT05932264|EXPERIMENTAL|Cohort 1: Apatinib + Fluzoparib|
62388663|NCT04102124|EXPERIMENTAL|SHR3680+SHR3162(Placebo)|Participants will receive SHR3680 combined with SHR3162(Placebo) orally
62768613|NCT05932264|EXPERIMENTAL|Cohort 2: Apatinib + Fluzoparib + Adebrelimab|
61993381|NCT04649164|EXPERIMENTAL|Caregiver mentees|Once Aim 2 is complete and mentors have been trained, caregiver mentees will be matched with mentors by relationship to LBD patient, then by sex and age, as much as possible. The study team will contact mentees once a match is available for them. The mentee will complete baseline primary and secondary outcome assessments online via REDCap, including: mastery and loneliness scales, Short Zarit Burden Interview, Hospital Anxiety and Depression Scale. The team will provide the mentor's contact information and send the PERSEVERE handbook. Mentoring pairs will begin the 16-week peer mentor program. Pairs will be expected to speak for \>15-30 minutes weekly, and to review that week's PERSEVERE topics in the handbook before or during each call to facilitate meaningful conversations. Mentors and mentees will complete online study diaries every 2 weeks. Upon completion of the 16-week mentor program, mentors and mentees will be sent a link to complete postmentoring assessments online.
61993382|NCT02597556|ACTIVE_COMPARATOR|Albendazole|Albendazole will be administered as a single 400mg chewable tablet at 0, 3, 6, 9, and 12 months.
62388664|NCT04102124|PLACEBO_COMPARATOR|SHR3680(Placebo)+SHR3162(Placebo)|Participants will receive SHR3680(Placebo) combined with SHR3162(Placebo) orally
62388665|NCT06113276||tidal hyperinflation|As the study aim to identify whether tidal hyperinflation is an independent predictor for ARDS mortality, and as this variable will be entered as a quantitative predictor in the multivariate model, the study encompass a single group of patient (i.e. all included patients)
62388666|NCT04984629|EXPERIMENTAL|HYDRAFIL Implant|Polymer Implant of HYDRAFIL into a one or two lumbar intervertebral discs
62388667|NCT00107536|EXPERIMENTAL|Arm I|Patients receive oral lapatinib ditosylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62388668|NCT01409642|ACTIVE_COMPARATOR|Individual Child CBT|12 sessions of individual child-focused cognitive behavior therapy with a parent component
62388669|NCT01409642|EXPERIMENTAL|Positive Family Interaction Therapy|12 sessions of standard individual child CBT plus six sessions of positive family interaction therapy (PFIT)
62388670|NCT02636049|EXPERIMENTAL|Treatment Period: 6 mg Triferic IV over 3 hours|Each subject will receive a single 6 mg dose of Triferic administered as a continuous intravenous infusion over 3 hours on Day 2. The Triferic IV dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 0.020 mg/mL. Administration of 300 mL IV at 100 mL/hr for 3 hours results in delivery of 6 mg of Triferic iron.
62388671|NCT02636049|EXPERIMENTAL|Treatment Period: 35 micrograms/kg IV push|Each subject will receive Triferic as 35 µg/kg body weight IV push over 30-60 seconds on Day 3. The Triferic IV push dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 35 µg Triferic iron/kg body weight per subject in 4.5 mL.
62388672|NCT03498911|ACTIVE_COMPARATOR|envelope Coronally Advanced Flap (eCAF)|A mucogingival surgery where an envelope flap is coronally advanced and sutured to cover the mucosal recession
62388673|NCT03498911|EXPERIMENTAL|Modified Tunnel Technique (MTT)|A mucogingival surgery where the gingiva is released without reflecting a flap (as described for tunnel techniques) and then coronally advanced and sutured to cover the mucosal recession
62388674|NCT05771974|EXPERIMENTAL|Compression therapy using surgical gloves|Study participants wear two-layer of normal-sized surgical gloves on both hands during chemotherapy infusion
62388675|NCT05771974|NO_INTERVENTION|Control|No intervention is provided on both hands.
62388676|NCT03351582|EXPERIMENTAL|Grief and Communication One Session|Group one will meet with a family therapist for one 90 minute session where the main focus will be on providing psychoeducation on grief and communication to both children and parents. This arm receives only the first session of the grief and communication family intervention.
62388677|NCT03351582|EXPERIMENTAL|Grief and Communication Three Sessions|Thie Group will receive all three sessions of the grief and communication family intervention.
62388678|NCT03351582|NO_INTERVENTION|Control|Group three will be the control group and will not receive the grief and communication family intervention.
62388679|NCT03021733||Non-operative|Patients whom elected non-operative treatment
62388680|NCT03021733||Operative|Patients whom elected operative treatment
62768614|NCT06116695|EXPERIMENTAL|human-treated dentin matrix|drug: Human-treated dentin matrix young permanent molars treated with human-treated dentin matrix
62768615|NCT06116695|PLACEBO_COMPARATOR|mineral tri oxide aggregate|Drug: Mineral Trioxide Aggregate young permanent molars treated with Mineral Trioxide Aggregate mineral trioxide aggregate was used as control
62768616|NCT03463395|NO_INTERVENTION|Standard of Care|Group A will receive standard of care
62567714|NCT04762160|EXPERIMENTAL|Tazmetostat in combination with rituximab|Tazemetostat 800 mg BID is administered daily starting on Cycle 1 Day 1 (C1D1). Tazemetostat will be administered from C1D1 to the end of Cycle 24, for 24 months of therapy or until disease progression, unacceptable toxicity, or withdrawal of consent. Rituximab will be administered by either subcutaneous injection or IV infusion according to the regional product prescribing information, labeling and institutional guidelines. Rituximab will be administered at a dose of 375 mg/m2 on Day 1, 8, 15, and 22 of Cycle 1, and then on Day 1 of Cycles 3 through 6, accounting for an additional 4 doses, i.e., a total of 8 doses of rituximab in 6 cycles.
62768617|NCT03463395|EXPERIMENTAL|Reza band use|Group B will receive standard care plus the Reza band (worn as recommended by the manufacturer)
62768618|NCT03118830|ACTIVE_COMPARATOR|Long GnRH agonist|daily SC injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium \< 5 mm and low E2 \< 50 and LH \< 5IU/l with either HMG or rFSH in a starting dose of 150-300 IU/day
62768619|NCT03118830|ACTIVE_COMPARATOR|GnRH antagonist|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l. Daily sc rFSH injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done
62768620|NCT04419480|EXPERIMENTAL|CardioMEMS Implant Group|Following enrollment, patients randomized 1:1 to post-discharge implantation of the CardioMEMS device will receive that device ≤14 days following discharge from the index hospitalization for Cardiogenic Shock, in addition to local standard of care medical therapy.
62768621|NCT04419480|NO_INTERVENTION|Non-CardioMEMS Implant Group|Following enrollment, patients randomized 1:1 to post-discharge standard of care will be treated according to local standard of care medical therapy following their index hospitalization for Cardiogenic Shock.
61993383|NCT02597556|PLACEBO_COMPARATOR|Placebo|Matching Placebo will be administered as a single chewable tablet at 0, 3, 6, and 9 months. At month 12, all participants will receive a single 400mg Albendazole tablet.
61993384|NCT05372796|EXPERIMENTAL|Control Group|participants were given home exercise (once a day for 5 weeks)
61993385|NCT05372796|EXPERIMENTAL|IASTM (instrument-assisted soft tissue mobilization)|IASTM was applied to the patients (M. Sternocleidomastoideus, M. Trapezius, M. Paraspinales and M. Levator Scapula) in the IASTM group twice a week for 5 weeks.
61993386|NCT05372796|EXPERIMENTAL|OTES (Occipital Transcutenous Electric Stimulation)|Participants in the OTES group were treated with a Chattanooga direct Tens device (DJO UK Ltd, Guildford Surrey, United Kingdom) 3 times a week for 5 weeks. Four self-adhesive 40\*40 mm sized electrodes were attached to the occipital region of the patients bilaterally, covering the occipital nerves. The current intensity was adjusted according to the patient. The current intensity started from 0 mA and the current intensity was increased one by one every 30 seconds, the patient was allowed to tolerate the current by giving current without muscle twitching or harmful stimulation. The current frequency was determined as 2/100 Hz. Square waves at 2 Hz were applied for 3 seconds followed by an automatic shift to 100 Hz for another 3 seconds.
61993387|NCT02886390|EXPERIMENTAL|RIC group|The upper limb ischemic conditioning is composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 2 hours after r-tPA thrombolytic therapy. In addition, all participants receive a standard clinical therapy.
62388681|NCT02137902|EXPERIMENTAL|Tobacco/Physical Activity Intervention|Includes a psychosocial component that utilizes a counselor-facing computer-assisted intervention with tailored counseling feedback focused on increasing intrinsic motivation, goal setting for tobacco and physical activity, adherence with nicotine replacement therapy, and self-monitoring with a pedometer-based walking program. The intervention will provide 12 weeks of nicotine replacement therapy for participants.
62768622|NCT04064346|EXPERIMENTAL|Lixivaptan|Lixivaptan capsules, 100-200 mg twice a day (BID)
61993388|NCT02886390|NO_INTERVENTION|Control group|The participants received r-tPA thrombolytic therapy after diagnosed ischemic stroke. In addition, all participants receive a standard clinical therapy.
61993389|NCT04157595|EXPERIMENTAL|Participating Couples|Reproductive Genetic Carrier Screening
61993390|NCT01536431|EXPERIMENTAL|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
62768623|NCT04064346|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules BID
62768624|NCT02285530|EXPERIMENTAL|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.~docetaxel:75mg/m2 cisplatin:75 mg/m2 5-Fu:750 mg/m2/day"
62768625|NCT02285530|OTHER|surgery group|Radical resection of the primary lesion and full neck,radiotherapy was arranged 4 to 6 weeks after surgery
62768626|NCT02222090||patients who have been prescribed warfarin|
62768627|NCT02222090||patients who have been prescribed apixaba|
61993391|NCT01536431|ACTIVE_COMPARATOR|Pro insulin peptide & saline|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
61993392|NCT01536431|PLACEBO_COMPARATOR|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls)
61993393|NCT04427969||EPP|patients who applied early awake prone position for treatment with conventional oxygen supply
61993394|NCT04427969||non-EPP|patient who only get conventional oxygen therapy as respiratory supply
62560330|NCT03627546|EXPERIMENTAL|Rapid Treatment with sofosbuvir/velpatasvir (Intervention arm)|"The intervention arm receives same-day medical evaluation and treatment for hepatitis C. They receive medical evaluation, laboratory assessment , baseline questionnaire/interview, and distribution of a medication (sofosbuvir/velpatasvir) starter pack on the day of enrollment. Participants who are HCV RNA negative are followed separately and do not receive intervention. Other participants start medications and receive weekly text messages during treatment to record adherence. They have follow up visits for laboratory tests, medication distribution, and counseling for prevention of reinfection. They have HCV testing at end of treatment and 12 weeks post treatment, and at 48 weeks to assess for reinfection. Each study visit will include a brief questionnaire and qualitative interview."
62560331|NCT03627546|ACTIVE_COMPARATOR|Usual Care (Control arm)|Participants in the control arm will be provided facilitated referral to community HCV providers by an on-site care coordinator already facilitating care at the community site. HCV RNA negative participants will be called to inform them of these results, and then followed separately. HCV RNA positive participants will be asked during the semi-structured interviews as at 12, 24, 36 and 48 week if they engaged in HCV treatment to assess whether their HCV referral has been filled, and to record their current HCV treatment status. They will also receive repeat HCV RNA testing at week 12, 24, and 48. Participants that have started treatment will be asked to sign consent for release of medical records pertaining to HCV-related laboratory testing to determine achievement of treatment response.
62560332|NCT03627546|NO_INTERVENTION|HCV RNA negative|Participants assigned to either group who were found to be HCV RNA-negative at entry. They are not eligible for treatment and thus not part of the analysis. They were asked to return the treatment starter pack. They are followed with HCV RNA measured at Week 24 and 48.
62560333|NCT01388959|EXPERIMENTAL|Single arm|
62560334|NCT06347224|OTHER|male group|Male Group: In this study, the male group consists of 200 healthy adult men selected from hospital radiology archive records, who have undergone pelvic computed tomography (CT) scans for various reasons. These individuals were chosen excluding those with pelvic fractures, anatomical abnormalities, or severe osteoporosis. The age range of the male group is between 18 and 65 years, with a median age of approximately 39.4 years. Analyses conducted on the male group focus on concepts such as the Both Column Fixation Corridor (BCFC) and Both Column Screws (BCS), evaluating the feasibility, gender-specific anatomical differences, and potential advantages of this new fixation technique.
62567715|NCT05032027|EXPERIMENTAL|Probiotic group|Probiotic( recieving Probiotic at the first day of chemoradiotherapy daily)with radiotherapy and Chemotherapy Intervention
61993395|NCT05522413||Health Status|normal examination in recent six months and not fit inclusion criteria of suboptimal health status.
61993396|NCT05522413||Suboptimal health Status|(A) Sub-Health Questionnaire (SHSQ-25) ≧35 points (B) Resting blood pressure 120-139/80-89 mmHg measured more than 3 times a week (C) The PSQI score of the sleep questionnaire on the first test is greater than 5 points (D) Body mass index (BMI): 24\~29 Kg/m2
62388682|NCT02137902|EXPERIMENTAL|Diet plus BP/CHOL Intervention|Consists of a psychosocial component that includes counselor-facing computer-assisted intervention with tailored counseling feedback focused on increasing intrinsic motivation, goal setting for managing hypertension and hypercholesterolemia, and adherence with antihypertensives and statins with supportive dietary changes. The intervention provides a cookbook of heart healthy regional recipes and medication bag for storing medications.
62388683|NCT02802527|OTHER|Bronchoscopy Guided|Percutaneous tracheostomy will be guided by bronchoscopy. Initially, the tube will be placed according to the desired height observed by the bronchoscope, phase two will be tracheal perforation by a needle under trans illumination and real-time view on the income of the needle and the passage of the guide wire.
62388684|NCT02802527|OTHER|Direct Laryngoscopy|Performing percutaneous tracheostomy by placing the tube higher up, near the vocal cords by direct laryngoscopy. In the second stage tracheal perforation by a needle will be carried out by palpation of the anatomical placement of the neck.
62388685|NCT02519777|PLACEBO_COMPARATOR|Arm A: Placebo MVC and placebo DTG|In addition to their existing ART regimens, participants in Arm A received placebo for MVC and placebo for DTG.
62388686|NCT02519777|EXPERIMENTAL|Arm B: DTG and placebo MVC|In addition to their existing ART regimens, participants in Arm B received DTG and placebo for MVC.
62388687|NCT02519777|EXPERIMENTAL|Arm C: MVC and DTG|In addition to their existing ART regimens, participants in Arm C received MVC and DTG
62388688|NCT04515589||Main study cohort|The main study cohort in this single-arm cohort is 250 adults with rheumatoid arthritis
61993397|NCT01246947|ACTIVE_COMPARATOR|Mitral surgery alone|Mitral valve surgery randomization for no repair of the moderate tricuspid regurgitation
61993398|NCT01246947|ACTIVE_COMPARATOR|Mitral surgery w/Tricuspid valve repair|Mitral valve surgery with randomization to repair the moderate tricuspid regurgitation
61993399|NCT06304142|EXPERIMENTAL|Rehabilitation therapy+Stellate ganglion block|The study lasts 10 days for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. Based on this, the patients in the experimental group are provided with Stellate Ganglion Block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day.
62388689|NCT03397095|EXPERIMENTAL|CSWT+BMMSCs|Patients in CSWT+BMMSCs group will receive a 3-month cardiac shock wave therapy and then a total of 1 million/kg BMMSCs will be infused using the stop-flow technique through an over-the-wire balloon catheter positioned in a coronary artery or bypass graft supplying the targeting viable myocardium.
62388690|NCT03397095|SHAM_COMPARATOR|CSWT+Sham operation|Placebo group will receive a 3-month CSWT and a sham procedure.
62388691|NCT00723489|EXPERIMENTAL|YFV-17D (Right Deltoid)|Participants will be randomized within each atopic dermatitis (AD) severity subgroup or as non-atopic controls to either subcutaneous (SC) or transcutaneous (TC) vaccine administration. In this arm, participants will receive a standard vaccine dose (5.5x10\^4 Plaque Forming Units) of YFV-17D administered subcutaneously in the right deltoid and placebo vaccination transcutaneously (then covered with a semi-occlusive dressing) in the left deltoid. The site pharmacist will maintain the blind and an unblinded (i.e., masked) site coordinator will administer assigned treatment: investigators, participants and assessors remain blinded to treatment assignments throughout the duration of the trial.
62560335|NCT06347224|OTHER|female group|Female Group: Similarly, the female group comprises 200 healthy adult women who have had pelvic CT scans for any reason, selected from hospital radiology archives. Like the male group, these individuals meet the specific criteria set for the study. The age range for the female group is also between 18 and 65 years, with a median age comparable to that of the male group. The analysis of the female group centers on the feasibility of applying BCFC and BCS, taking into account the unique anatomical structures of the female pelvis and their implications for surgical planning. The work on this group aims to enhance the understanding of gender-specific anatomical variations and integrate this knowledge into surgical practices.
62560336|NCT04074187|EXPERIMENTAL|Caplacizumab|Eligible study participants will receive caplacizumab in addition to standard of care such as daily plasma exchange (PE) and corticosteroid treatment (mandatory), immunosuppressive treatment (if needed)
62560337|NCT05050812|EXPERIMENTAL|Grounded|All participants will sleep on a grounding mat for at least six hours per 24-hour period.
62560338|NCT01880892|EXPERIMENTAL|Post cricopharyngeal myotomy|Subjects scheduled to undergo an endoscopic criocopharyngeal myotomy, which is the standard treatment for a Zenker's diverticulum, will have levels of laryngopharyngeal reflux measured after the procedure.
62560339|NCT02552446||All patients|All ICU patients mechanically ventilated staying more than 72 hours were included and indirect calorimetry was performed and compared to predictive energy expenditure formulas using different body weights.
62560340|NCT03196583|EXPERIMENTAL|Single-arm study|Velo-Lingual Bite (BVL)
62560341|NCT04196569||trifocal intraocular lens|
62560342|NCT03640312|EXPERIMENTAL|QUARTET LDQT|Patients randomized to the intervention arm will take a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.
62560343|NCT03640312|ACTIVE_COMPARATOR|Candesartan|Patients randomized to the comparison arm will take a once daily 8mg candesartan.
62560344|NCT02928289|ACTIVE_COMPARATOR|VISCO360 ab interno canaloplasty surgery|Subjects randomized to this arm will undergo a surgical procedure in which the VISCO360 Viscosurgical System will be used to microcatheterize and viscodilate Schlemm's canal (i.e., canaloplasty).
62560345|NCT02928289|ACTIVE_COMPARATOR|Selective Laser Trabeculoplasty (SLT)|Subjects randomized to this arm will undergo the SLT procedure.
62560346|NCT03902665|EXPERIMENTAL|Allogeneic hematopoietic stem cell transplantation|Day -6, -5 Thiotepa 5 mg/kg/day . Day -4 to -3 Busulfan i. v 3,2 mg/kg/day and fludarabine i.v. 50 mg/m2 /day Day -2 fludarabine i.v. 50 mg/m2 Day -1 Rest Day 0 Begin cyclosporine; Infusion of T cell replete bone marrow transplant Day 1 Begin mycophenolate mofetil Day 3 and 5 Cyclophosphamide 50 mg/kg IV and Mesna Day 6 G-colony stimulating factor
62768628|NCT06507527||Outpatients over 70 years of age referred to the Digestive Endoscopy Unit|Collection of variables: demographic variables, comorbidity, frailty (specific questionnaires), digestive endoscopy (upper and/or lower), possible complications related to the endoscopic process and the profitability and impact of the endoscopy.
62768629|NCT04591925|EXPERIMENTAL|"Investigative Device - SteadiSet™ device with coil-reinforced soft polymer indwelling cannula"|Participants are randomized into the investigational device (SteadiSet™) insulin infusion set group and then switched to a Commercially available infusion set (using a soft Teflon indwelling cannula) group. At the Day of Insertion (Day 0) clinic visit, study participants will insert (under supervision) the investigational infusion set. Upon completion of a wear period (after 14 days or sooner, in the event that infusion set change out has occurred), participants will be asked to insert a new set at home and thus start the next 14-day wear period. After two periods participants will return to the study site to cross over into the last two periods with the Control device infusion set. A total of four infusion sets will be studied in each participant, two Investigational Device infusion sets and two commercially available Teflon infusion sets.
62388692|NCT00723489|EXPERIMENTAL|YFV-17D (Left Deltoid)|Participants will be randomized within each atopic dermatitis (AD) severity subgroup or as non-atopic controls to either subcutaneous (SC) or transcutaneous (TC) vaccination. In this arm, participants will receive YFV-17D vaccination (1x10\^3 Plaque Forming Units) by transcutaneous administration (then covered with a semi-occlusive dressing to optimize YFV-17D absorption) in the left deltoid and placebo by subcutaneous administration in the right deltoid. The site pharmacist will maintain the blind and an unblinded (i.e., masked) site coordinator will administered treatment: investigators, participants and assessors remain blinded to treatment assignments throughout the duration of the trial.
62388693|NCT01029691|EXPERIMENTAL|Positive Airway Pressure (compliant)|This arm was women who used auto-titrating positive airway pressure (APAP) for at least 4 hours per night
62388694|NCT01029691|NO_INTERVENTION|Standard care|
62388695|NCT01029691|EXPERIMENTAL|Positive Airway Pressure (non-compliant)|No one was assigned to this arm, but for results data quality purposes, women assigned to PAP who were explicitly non-compliant (used less than 4 hours per night), were analyzed separately from women who were compliant with the PAP assignment.
62388696|NCT03349840|ACTIVE_COMPARATOR|Insulin glargine U100|Intervention: half of the subjects will be randomised to insulin glargine U100 basal insulin treatment (or continued on glargine if already treated) that will be administered daily in the evening
61993400|NCT06304142|PLACEBO_COMPARATOR|Rehabilitation therapy+placebo block|The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. This group will be additionally provided with placebo block without any drugs.
61993401|NCT02622828|OTHER|Behavioural|Participant-identified community based activity
61993402|NCT02550496|EXPERIMENTAL|tinea capitis|
61993403|NCT02993003|OTHER|Children between 7 months and 12 months|nasopharyngeal probe will be marked with indelible ink from 2-10 cm in 1-cm increments and inserted 10 cm
61993404|NCT02993003|OTHER|children between 1 and 5 years|nasopharyngeal probe will be marked with indelible ink from 2-15 cm in 1.5-cm increments and inserted 10 cm
61993405|NCT02993003|OTHER|children between 6 and 12 years|a nasopharyngeal probe will be marked with indelible ink from 2 to 20 cm at 2 cm increments from its tip, and inserted 20 cm
61993406|NCT05620576|EXPERIMENTAL|45 mg LY3857210|Participants received 45 milligram (mg) of LY3857210 orally once daily for up to 8 weeks.
62388697|NCT03349840|ACTIVE_COMPARATOR|insulin degludec U100|Intervention: half of the subjects will be randomised to insulin degludec U100 basal insulin treatment that will be administered daily in the evening
62388698|NCT04805606|EXPERIMENTAL|Sequence 1|CKD-843 A - 27mg, Single Dose
62388699|NCT04805606|EXPERIMENTAL|Sequence 2|CKD-843 A - 45mg, Single Dose
62388700|NCT04805606|EXPERIMENTAL|Sequence 3|CKD-843 A - 56mg, Single Dose
62388701|NCT04805606|EXPERIMENTAL|Sequence 4|CKD-843 B - 45mg, Single Dose
62388702|NCT04805606|ACTIVE_COMPARATOR|Sequence 5|CKD-843-R
62388703|NCT04778995|EXPERIMENTAL|Manager nurses (Experimental group)|Manager nurses who participated in the structured training program based on qualitative data. Web based training program was the intervention for this group.
62560347|NCT01487525|PLACEBO_COMPARATOR|PBFR-|double leg press without application of partial blood flow restriction to the upper leg
62560348|NCT01487525|EXPERIMENTAL|PBFR+|double leg press with application of partial blood flow restriction to the upper leg
62560349|NCT01288807|EXPERIMENTAL|Treatment|Titrated Milnacipram doses
62560350|NCT01622647|ACTIVE_COMPARATOR|NCPAP Group|Group of patients that do receive NCPAP treatment
62560351|NCT01622647|NO_INTERVENTION|No NCPAP|subjects will not receive NCPAP
62560352|NCT05819970|EXPERIMENTAL|Allium sativum oil (Experimental-Group A)|Premade Allium sativum oil (Garlic oil) (Mohammad and Baroudi, 2015b) will be used in this research (SAC group of companies-9001:2015 certified; Registration # PAK17.1724-U; NTN # 0299739-8, Karachi, Pakistan
62567716|NCT05032027|NO_INTERVENTION|placebo group|placebo( one times a day)with radiotherapy and Chemotherapy Intervention
62567717|NCT05032027|NO_INTERVENTION|healthy control group|healthy control group
62567718|NCT05577988|NO_INTERVENTION|Control arm|Standard of Care : Systematic de-escalation to a high potency antiplatelet single therapy
62567719|NCT05577988|OTHER|Intervention arm|single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.
61993407|NCT05620576|PLACEBO_COMPARATOR|Placebo|Participants received placebo orally once daily for up to 8 weeks.
62560353|NCT05819970|EXPERIMENTAL|Turmeric gel (Experimental-Group B)|Turmeric gel will be self-prepared at the Institute of Microbiology and Molecular Genetics, Punjab University, Lahore. 2kgs of Turmeric rhizomes were purchased from a local market in Lahore and verified by a taxonomist, Botany Department, Government College University, Lahore (voucher number: GC.Herb.Bot.3693). Approximately 170g powder along with 550ml distilled water will be taken in a Soxhlet extractor for 96 hours and then filtered repeatedly through Whatman No.1 filter paper. The obtained filtrate will then be mixed with 6% Sodium Carboxy-Methyl Cellulose (NaCMC) (Genevex Chem, Hyderabad, India) to form gel. Four Vitamin C grounded tablets (Wilson's Vitamin C, Wilson's Healthcare, Islamabad, Pakistan) and twelve Vitamin E capsules (Evion, Martin Dow pharmaceuticals, Ltd. Karachi, Pak) will then be added in 100g of gel as antioxidants.
62388704|NCT04778995|NO_INTERVENTION|Manager nurses (Control group)|Manager nurses who were not included to the structured training program based on qualitative data. No intervention was performed for this group.
62388705|NCT00186121|EXPERIMENTAL|Anastrozole + Goserelin|Participants received goserelin 3.6 mg subcutaneously monthly. Beginning on Day 22 after the first dose of goserelin, participants began taking anastrozole 1 mg orally daily. No dose attenuation or escalation was allowed for either goserelin or anastrozole.
62560354|NCT02492373|ACTIVE_COMPARATOR|laser+steroid 2 days before and after laser|Before lentigines' treatment with Qs Nd:YAG 532 nm laser, topical 0.05% Clobetasol propionate ointment was applied 2 days on the lesion. Then applied 2 days after the treatment.
62388706|NCT04749303|ACTIVE_COMPARATOR|Large screen|This is a high definition screen which gives a 76cm height and 67cm width (area: 5092cm2) endoscopic image.
62388707|NCT04749303|NO_INTERVENTION|Standard screen|This is a high definition screen which gives a 37.5cm height and 32.5cm width (area: 1218.75cm2) endoscopic image.
62388708|NCT04305158|EXPERIMENTAL|Nitrous Oxide|Patient receiving Nitrous Oxide are evaluated for success of the procedure
62560355|NCT02492373|OTHER|laser+steroid 2 days after laser|Controlled side. Applied topical 0.05% Clobetasol propionate ointment only 2 days after the laser treatment
62560356|NCT01568567|ACTIVE_COMPARATOR|Double dose|One stick pack with active ingredients contains 1.0 g contains 75% GOS (galactooligosaccharide), 25% L-Rhamnose, 1x108 live bacteria (CFU) Lactobacillus reuteri and silicon dioxide
62560357|NCT01568567|ACTIVE_COMPARATOR|Single dose|One stick pack with active ingredients contains 1.0 g contains 75% GOS (galactooligosaccharide), 25% L-Rhamnose, 1x108 live bacteria (CFU) Lactobacillus reuteri and silicon dioxide
62388709|NCT04305158|ACTIVE_COMPARATOR|IV Sedation group|In this group a combination of Midazolam and Fentanyl is used per endoscopic discretion
62388710|NCT00465894|ACTIVE_COMPARATOR|Extended Release Tolterodine LA|An anti-muscarinic drug that is used for symptomatic treatment of urinary incontinence.
62388711|NCT00465894|ACTIVE_COMPARATOR|Intra Vaginal Estradiol Cream|For topical application to the vaginal area to treat symptoms of urgency or irritation with urination.
62560358|NCT01568567|PLACEBO_COMPARATOR|Placebo|One stick pack with placebo contains 1.0 g maltodextrin and silicon dioxide
62560359|NCT02142790|EXPERIMENTAL|paclitaxel liposome injection weekly|paclitaxel liposome injection 100mg/m2 administered by intravenous on day1 and day8 of a 21-day cycle for at least 4cycles or till progression or intolerable
62560360|NCT02142790|EXPERIMENTAL|paclitaxel liposome injection every 3 weeks|paclitaxel liposome injection 175mg/m2 administered by intravenous on day1 of a 21-day cycle for at least 4cycles or till progression or intolerable
62560361|NCT00897715|ACTIVE_COMPARATOR|Interleukin-1 receptor antagonist|active drug
62560362|NCT00897715|PLACEBO_COMPARATOR|Placebo|matching placebo
61993408|NCT01200628||Road traffic accident victims|Cohort of patients hospitalized in surgical department after a motor vehicle accident less than 2 weeks
61993409|NCT02888548|EXPERIMENTAL|Arm cross over 1|botulinum toxins alone then botulinum toxins + orthos
61993410|NCT02888548|EXPERIMENTAL|Arm cross over 2|botulinum toxins + orthosis then botulinum toxins alone
61993411|NCT00934739|NO_INTERVENTION|Control|Standard postoperative concurrent chemoradiotherapy
62560363|NCT01622673|EXPERIMENTAL|RAL, TUMS+RAL, MINTOX+RAL, MINTOX Before RAL, MINTOX After RAL|Participants received Raltegravir in treatment period 1, followed by TUMS® + Raltegravir in treatment period 2, followed by MINTOX® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours After Raltegravir in treatment period 5. There was a 2-day washout between treatment periods.
61993412|NCT00934739|EXPERIMENTAL|Thalidomide, Celebrex|Adjuvant anti-angiogenesis therapy
61993413|NCT00934739|ACTIVE_COMPARATOR|Cyclophosphamide, Dexamethasone|Adjuvant anti-angiogenesis therapy
61993414|NCT04497779||Screening (biospecimen collection, medical record review, CCP)|"PROSPECTIVE CCP DONORS: Participants undergo collection of blood and/or nasopharyngeal swabs at the time of screening. Participants' medical records are reviewed.~CONVALESCENT BLOOD DONORS WHO CHOOSE NOT TO DONATE CCP: Participants undergo collection of blood sample at the time of screening. Participants' medical records are reviewed.~CCP RECIPIENTS: Patients undergo collection of blood samples at baseline, 12-24 hours after each CCP infusion, and 7 days after last CCP infusion. Patients' medical records are reviewed."
61993415|NCT05622279|EXPERIMENTAL|percutaneous tenotomy + PRP|There will be a single arm receiving the treatment being evaluated
61993416|NCT05723016||AMH < 0.5 ng/ml|
61993417|NCT05723016||AMH 0.5-0.99 ng/ml|
61993418|NCT05723016||AMH 1.0-1.49 ng/ml|
61993419|NCT05723016||AMH 1.5-1.99 ng/ml|
61993420|NCT05723016||AMH 2.0-4.99 ng/ml|
62560364|NCT01622673|EXPERIMENTAL|TUMS+RAL, MINTOX+RAL, RAL, MINTOX Before RAL, MINTOX After RAL|Participants received TUMS® + Raltegravir in treatment period 1, followed by MINTOX® + Raltegravir in treatment period 2, followed by Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
62560365|NCT01622673|EXPERIMENTAL|MINTOX+RAL, RAL, TUMS+RAL, MINTOX Before RAL, MINTOX After RAL|Participants received MINTOX® + Raltegravir in treatment period 1, followed by Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
62560366|NCT01622673|EXPERIMENTAL|RAL, MINTOX+RAL, TUMS+RAL, MINTOX After RAL, MINTOX Before RAL|Participants received Raltegravir in treatment period 1, followed by MINTOX® + Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
62560367|NCT01622673|EXPERIMENTAL|TUMS+RAL, RAL, MINTOX+RAL, MINTOX After RAL, MINTOX Before RAL|Participants received TUMS® + Raltegravir in treatment period 1, followed by Raltegravir in treatment period 2, followed by MINTOX® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
62560368|NCT01622673|EXPERIMENTAL|MINTOX+RAL, TUMS+RAL, RAL, MINTOX After RAL, MINTOX Before RAL|Participants received MINTOX® + Raltegravir in treatment period 1, followed by TUMS® + Raltegravir in treatment period 2, followed by Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
61993421|NCT05723016||AMH > 5.0 ng/ml|
61993422|NCT04785274||SpHb|
61993423|NCT04785274||Control|
61993424|NCT01024907|EXPERIMENTAL|Arm I|Patients undergo proton beam radiation therapy for 6 weeks in the absence of disease progression or unacceptable toxicity.
61993425|NCT03695731|EXPERIMENTAL|Patients without Neuropathy|activation of cold induced brown adipose tissue
62388712|NCT05232903|EXPERIMENTAL|Group 1 SVF dose 0.5 x 10^6/kg Intravenous infusion (IV)|Intravenous infusion of stromal vascular fraction (SVF) dose 0.5 x 10\^6/kg for 5 participants within 1 month after neurosurgical intracerebral hemorrhage (ICH) evacuation.
62388713|NCT05232903|EXPERIMENTAL|Group 2 SVF dose 1.0 x 10^6/kg Intravenous infusion (IV)|Intravenous infusion of stromal vascular fraction (SVF) dose 1.0 x 10\^6/kg for next 5 participants within 1 month after neurosurgical intracerebral hemorrhage (ICH) evacuation.
62388714|NCT05232903|EXPERIMENTAL|Group 3 SVF dose 1.5 x 10^6/kg Intravenous infusion (IV)|Intravenous infusion of SVF stromal vascular fraction (SVF) dose 1.5 x 10\^6/kg for final 5 participants within 1 month after neurosurgical intracerebral hemorrhage (ICH) evacuation.
62388715|NCT03060109||Suspected traumatic brain injury|
61993426|NCT03695731|EXPERIMENTAL|Patients with Neuropathy|activation of cold induced brown adipose tissue
61993427|NCT00914810|EXPERIMENTAL|Vitamin D|Cholecalciferol (2000 I.U. daily)
61993428|NCT00914810|PLACEBO_COMPARATOR|Placebo|Placebo capsule (sugar pill daily)
61993429|NCT05970315|EXPERIMENTAL|PPC|
61993430|NCT05970315|ACTIVE_COMPARATOR|Usual Care|
61993431|NCT04437966|EXPERIMENTAL|Self-management Group|"The intervention consists of three levels - (1) chronic disease self-management workshops, (2) distribution of and teaching on the use of medication pill boxes and (3) use of social media (WhatsApp version 2.0) to encourage medication adherence.~We combine the Stanford Chronic Disease Self-Management Curriculum, add medication adherence tools and social media use to develop a novel intervention aimed at better blood pressure control. The CDSMP focuses on enhancing skills through problem solving and brainstorming activities. In the workshop we discuss: blood pressure control, finding and affording healthy foods, label reading, physical activity, planning a healthy plate, making traditional foods healthy and portion control. Pill boxes will be distributed to all individuals in the intervention group. Post workshop, participants will be sent twice weekly reminders to use their high blood pressure medications via the social media tool WhatsApp. These will be sent for one month."
61993432|NCT04437966|NO_INTERVENTION|Usual care group|Controls will receive educational material at baseline and one didactic session (on importance of medication adherence to hypertension control) lasting 1 hour delivered by a health care professional.
61993433|NCT05471050|EXPERIMENTAL|tacrolimus and Danazol|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
61993434|NCT05471050|ACTIVE_COMPARATOR|Danazol|Danazol is given at 200mg bid for 12 weeks.
62388716|NCT03104361|EXPERIMENTAL|Platelet-rich plasma treatment arm|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
62560369|NCT04898686|ACTIVE_COMPARATOR|Probiotic group|daily use of a probiotic chewable for 8 weeks
61993435|NCT04995016|EXPERIMENTAL|Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma|Neoadjuvant pembrolizumab plus axitinib
61993436|NCT00319826||1|Subjects with Staphylococcus Bacteremia
61993437|NCT00319826||2|Healthy (Non-infected) Control Subjects in the Nasal Carriage Group
61993438|NCT00550095|EXPERIMENTAL|1|valsartan
61993439|NCT02578784|PLACEBO_COMPARATOR|POBA-after-Cutting Balloon|After cutting balloon angioplasty, subsequent angioplasty is performed using a standard, non-coated balloon (plain old balloon, POBA).
61993440|NCT02578784|ACTIVE_COMPARATOR|DCB-after-Cutting Balloon|After cutting balloon angioplasty, subsequent angioplasty is performed using a drug-coated balloon (DCB)
61993441|NCT01391481|EXPERIMENTAL|Perfluorocarbon|
61993442|NCT01391481|PLACEBO_COMPARATOR|Sterile Water for Injection|
62388717|NCT03909035|EXPERIMENTAL|Medication therapy management|Medication therapy management by the community pharmacist in collaboration with the General Practitioners to the Optimizations of Prescriptions
62388718|NCT03909035|NO_INTERVENTION|Usual pharmaceutical care|Usual pharmaceutical care provided by the community pharmacist (first level pharmaceutical analysis of the prescriptions)
62388719|NCT06056245||Study group|Patients with chronic kidney disease (CKD) over 18 years old undergoing surgery using general anesthesia with subsequent use of intravenous patient-controlled analgesia (IV-PCA) of methadone.
62388720|NCT06048627|ACTIVE_COMPARATOR|Mouthwash Test|
62768630|NCT04591925|ACTIVE_COMPARATOR|Commercially available Insulin Infusion device using a soft Teflon indwelling cannula|Participants are randomized into the Commercially available insulin infusion set (using a soft Teflon indwelling cannula) group and then switched to Investigative Device infusion set (SteadiSet™) group. At the Day of Insertion (Day 0) clinic visit, study participants will insert (under supervision) the Control infusion set. Upon completion of a wear period (after 14 days or sooner, in the event that infusion set change out has occurred), participants will be asked to insert a new set at home and thus start the next 14-day wear period. After two periods participants will return to the study site to cross over into the last two periods with the Investigational Device infusion set. A total of four infusion sets will be studied in each participant, two Investigational Device infusion sets and two commercially available Teflon infusion sets.
62768631|NCT01840254|EXPERIMENTAL|dexmedetomidine|addition of dexmedetomidine to fentanyl-based intravenous patient controlled analgesia (PCA)
62768632|NCT01840254|PLACEBO_COMPARATOR|normal saline|normal saline as a placebo
61993443|NCT05256121|NO_INTERVENTION|control|At 6 months and 12months the study team will communicate with the participants by phone to inquire about risk factors data, propose alternative activities, and provide positive reinforcement and feedback
61993444|NCT05256121|EXPERIMENTAL|intervention|"At baseline, participants in the intervention group will be asked to fill a daily risk-factor diaries (Risk factors log using the REDCap (Research Electronic Data Capture) software's survey).~In the Risk factors log, participants will need to answer shortly questions about their specific unbalanced risk factor.~In addition, during the 18-months intervention period, the study team will communicate with the participants' every 3-4 weeks by phone. Before each phone call, participants' Risk factors log data since previous phone call will be analyzed. The team will propose alternative activities, and provide positive reinforcement and feedback."
61993445|NCT00264641|EXPERIMENTAL|High RAS activity|10 healthy men were characterized by having high basal RAS activity.
61993446|NCT00264641|EXPERIMENTAL|Low RAS activity|10 healthy men were characterized by having either a low basal RAS activity.
61993447|NCT03558815||Adults with mild, moderate, severe or profound ID|Adults with mild, moderate, severe or profound ID in contact with either a sheltered workshop and/ or sheltered living Institution in Saxony.
61993448|NCT01212718|ACTIVE_COMPARATOR|5-FU|FUFA 5-flurouracil and folinic acid control
61993449|NCT01212718|ACTIVE_COMPARATOR|Folfiri|5-fluouracil and folinic acid in combination with irinotecan (Folfiri) systemic chemotherapy intensified treatment arm
61993450|NCT00273572|ACTIVE_COMPARATOR|Moderate lifestyle intervention|Moderate lifestyle intervention including two group sessions and one individual counselling session with a nutritionist, at recruitment. Individual sessions with a nutritionist after 6 and 12 months on follow-up.
61993451|NCT00273572|EXPERIMENTAL|Intensive lifestyle intervention|Intensive lifestyle intervention, including bi-monthly group sessions with a physical activity instructor; a monthly group session with a nutritionist, and a monthly individual session with a nutritionist.
61993452|NCT05625035|EXPERIMENTAL|Lianhua Qingwen plus conventional therapy|
61993453|NCT05625035|NO_INTERVENTION|Conventional therapy|
61993454|NCT02626143|EXPERIMENTAL|Investigational nutrient-rich whey protein formula|
61993455|NCT02626143|ACTIVE_COMPARATOR|Cow's milk based formula|
62388721|NCT06048627|EXPERIMENTAL|Mouthwash Experimental|
62388722|NCT03121625|EXPERIMENTAL|Autologous CAR-T cells|Patients will be be treated with autologous CAR-T cells.
62388723|NCT02307331|OTHER|Optivac and E1|Sirius stem used with Optivac mixed cement - Exceed Cup - E1 PE
62388724|NCT02307331|OTHER|Optivac and Arcom|Sirius stem used with Optivac mixed cement - Exceed Cup - Arcom PE
62768633|NCT03063190|PLACEBO_COMPARATOR|Hyperparathyroidism_0|Chronic Kidney Disease patients with parathyroid hormone higher than 300pg/ml
61993456|NCT02626143|NO_INTERVENTION|Breast milk|
62388725|NCT02307331|OTHER|Optipac and E1|Sirius stem used with Optipac mixed cement - Exceed Cup - E1 PE
62388726|NCT02307331|OTHER|Optipac and Arcom|Sirius stem used with Optipac mixed cement - Exceed Cup - Arcom PE
62560370|NCT04898686|PLACEBO_COMPARATOR|Placebo group|daily use of the placebo chewable for 8 weeks
62768634|NCT03063190|ACTIVE_COMPARATOR|Hyperparathyroidism_1|Chronic Kidney Disease patients with parathyroid hormone higher than 300pg/ml
61993457|NCT03451877|ACTIVE_COMPARATOR|Study group|Children with cycloplegia refractive error more than -6 D TGFB1 AND LAMA1 GENE POLYMORPHISMS were examined
61993458|NCT03451877|OTHER|Control group|Emmetropic children TGFB1 AND LAMA1 GENE POLYMORPHISMS were examined
61993459|NCT00218673|EXPERIMENTAL|experimental|social network
61993460|NCT00218673|NO_INTERVENTION|control|testing and counseling
61993461|NCT06404151||Obese Patients|60 patients with ASA I-III, of both genders, between 18-75 years of age, with a BMI of 40\>30 kg m2 and intubated under general anesthesia
61993462|NCT03951246|EXPERIMENTAL|Training Group|"Training Group recieved cognitive and Motor training included 6 sessions using the following training devices.~* Dynavision D2 ® (USA) (https://products.dynavisioninternational.com/products/d2) presents a panel with 64 bulbs which take the form of five circles. The task of a participant is to press the bulb that is glowing as quick as possible. In the trial 8 modes will be used; they have different instructions which are aimed at visual-motor co-ordination, processing speed, inhibition, and shifting.~* Fitlight Trainer ® (Canada) (https://www.fitlighttraining.com) consists of 7 clickers, and the tasks are similar to Dynavision ones.~* NeuroTracker ® (Canada) (https://neurotracker.net) includes a task of multiple object training for working memory and attention enhancement."
61993463|NCT03951246|NO_INTERVENTION|Control Group|Control Group didn't recieved any cognitive and motor training. They visited swimming pool and physical therapy.
61993464|NCT04653779|EXPERIMENTAL|Group A|Patients receive Evogliptin 5mg/Metformin 1000mg once a day
61993465|NCT02519920|EXPERIMENTAL|group 1|This group patients were given dosages of fluorescein sodium 0.01ml/kg intravenous administration.
61993466|NCT02519920|EXPERIMENTAL|group 2|This group patients were given dosages of fluorescein sodium 0.02ml/kg intravenous administration.
62768635|NCT03063190|PLACEBO_COMPARATOR|Adynamic_0|Chronic Kidney Disease patients with parathyroid hormone lower than 150pg/ml
61993467|NCT02519920|EXPERIMENTAL|group 3|This group patients were given dosages of fluorescein sodium 0.05ml/kg intravenous administration.
61993468|NCT02519920|ACTIVE_COMPARATOR|group 4|This group patients were given dosages of fluorescein sodium 0.1ml/kg intravenous administration.
61993469|NCT04566419|ACTIVE_COMPARATOR|Control group|Oxygen delivered by Venturi Mask
61993470|NCT04566419|EXPERIMENTAL|HFNC - high flow nasal cannulae|Oxygen delivered by high flow nasal cannula (HFNC) 60 l/min
61993471|NCT03034954|ACTIVE_COMPARATOR|Active HD-tDCS|"Participants will receive real HD-tDCS (3 milliamps for 20 minutes) for a single session."
61993472|NCT03034954|SHAM_COMPARATOR|Sham HD-tDCS|Participants will undergo the exact same procedures as the active group but will receive sham stimulation for a single session.
61993473|NCT01553006|ACTIVE_COMPARATOR|cefditoren pivoxil|cefditoren 10 mg/kg/day for 14 days
61993474|NCT01553006|ACTIVE_COMPARATOR|cefditoren pivoxil high dose|cefditoren 20 MKD were used to compare efficacy of treatment.
62768636|NCT03063190|ACTIVE_COMPARATOR|Adynamic_1|Chronic Kidney Disease patients with parathyroid hormone lower than 150pg/ml
62768637|NCT01767272|OTHER|fexofenadine 60 mg|First dose strength
61993475|NCT02889640|NO_INTERVENTION|Control group|These youth will receive standard mathematics instruction and support (including possibly other tutoring interventions), but not the daily, intensive, during-the-school-day math tutoring provided by SAGA.
61993476|NCT02889640|EXPERIMENTAL|Scale-up SAGA math tutoring|These youth will receive intensive, daily mathematics tutoring, and students will be paired with scale-up tutors. Tutors will be hired using the randomization process, and will be randomly assigned to youth.
61993477|NCT02889640|EXPERIMENTAL|Standard SAGA math tutoring|These youth will receive intensive, daily mathematics tutoring, and students will be paired with tutors hired via SAGA's standard process, which does not involve randomization. Tutors will be randomly assigned to youth.
61993478|NCT01909037|EXPERIMENTAL|Flexofytol (bio-optimized curcumin)|
61993479|NCT03373383|EXPERIMENTAL|Padsevonil dosing regimen 1|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
62768638|NCT01767272|OTHER|fexofenadine 120 mg|Second dose strength
62768639|NCT01767272|OTHER|fexofenadine 180 mg|Third dose strength
61993480|NCT03373383|EXPERIMENTAL|Padsevonil dosing regimen 2|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
61993481|NCT03373383|EXPERIMENTAL|Padsevonil dosing regimen 3|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
61993482|NCT03373383|EXPERIMENTAL|Padsevonil dosing regimen 4|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
61993483|NCT03373383|PLACEBO_COMPARATOR|Placebo|Subjects randomized to the placebo group will receive a combination of several Placebo tablets to maintain the blinding.
61993484|NCT03801564|EXPERIMENTAL|Platelet Rich Plasma Group (PRP)|Platelet Rich Plasma Treatment Group (PRP): The blood is drawn from the antecubital vein to the 10cc line of EasyPRP syringe consisted 1.5ml of anticoagulant. The syringe is centrifuged at a rate of 1200 g for 2 minutes. Then the syringe is rotated and the lower chamber filled with erythrocytes is discharged. The connector is inverted and the air gap is discharged. The injector is again centrifuged at 1200G for 10 minutes. Then the injector is rotated in the direction of the arrow, the lower stopper is removed. The application injector of 3cc with connector is placed in the EasyPRP injector. 1 ml of the PRP containing Buffycoat is separated for content analysis, the remaining 2 ml of the string is injected. Injection is repeated one month interval
61993485|NCT03801564|EXPERIMENTAL|Hyaluronic acid Group (HA)|Hyaluronic Acid Treatment Group (HA): 2 ml HA (32mg / ml) containing 1.6% sodium hyaluronate is injected intraarticular. The molecular weight is 800 - 1200 K Dalton. The viscosity is 20 pascal / s. The pH of the product is 7-7.5.Injection is repeated one month interval.
62768640|NCT01767272|OTHER|fexofenadine 240 mg|Fourth dose strength
62768641|NCT01767272|OTHER|fexofenadine 360 mg|Fifth dose strength
62768642|NCT01425671||Schizophrenic patients, family members|Schizophrenia Spectrum Disorder Patients
62768643|NCT01425671||Controls|Normal controls
62768644|NCT03924921|EXPERIMENTAL|autogenic training|Autogenic training
62388727|NCT04826315|EXPERIMENTAL|Patient Caregiver Dyad|Participants who are 65 years or older with cancer and mild cognitive impairment with their caregiver.
62560371|NCT04587154|EXPERIMENTAL|Intervention Group|This arm will follow a low-fat vegan diet in addition to 1/2 a cup of cooked soybeans each day for the duration of the study. They will also weigh themselves each week, and report weight and hot flash frequency/severity weekly.
62560372|NCT04587154|NO_INTERVENTION|Control Group|This arm will not change their diet for the duration of the study. They will also weigh themselves each week and report weight and hot flash frequency/severity weekly.
62560373|NCT01560975|EXPERIMENTAL|Sensimed Triggerfish|
62388728|NCT02948452||Anorexia|fMRI: reward task, anxiety provocation
62388729|NCT02948452||Mild anxiety comparison group|fMRI: reward task, anxiety provocation
62388730|NCT00665002|EXPERIMENTAL|WT-1 Analog Peptide Vaccine|Participants received 6 bi-weekly vaccinations over 10 weeks. WT-1 vaccine was given with Montanide. Participants also received an injection of Sargramostim (GM-CSF) two days before each vaccination and again on the day of the WT-1 injection at the same spot.
62388731|NCT04590976||Healthcare Professionals (n = 5)|Intervention: Single, Semi-Structure Interview to identify and define the key attributes associated with treatment options that would warrant trade-off evaluation. These will be used to create the first version of the questionnaire
62388732|NCT04590976||Stage 1 (n = 5)|Intervention: Single, Semi-Structure Interview to identify and define the key attributes associated with treatment options that would warrant trade-off evaluation. These will be used to create the first version of the questionnaire
62388733|NCT04590976||Stage 2 (n = 10)|"Intervention: Single, Think Aloud Interview Interview. These will be analysed using an inductive thematic analysis by at least two researchers. Common themes will be extracted by researchers individually and then discussed and agreed."
62388734|NCT04590976||Stage 3 (n = 300)|Intervention: Single, Discrete Choice Experiment Questionnaire at Enrollment Visit
62388735|NCT01090167|EXPERIMENTAL|Clofarabine|
61993486|NCT01438320|EXPERIMENTAL|Quercetin|Quercetin is a bioflavonoid.
62388736|NCT01475214|ACTIVE_COMPARATOR|potassium bicarbonate low dose|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
62388737|NCT01475214|ACTIVE_COMPARATOR|potassium bicarbonate higher dose|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
62388738|NCT01475214|PLACEBO_COMPARATOR|placebo|microcrystalline cellulose
62388739|NCT02514889|ACTIVE_COMPARATOR|Calorie-counting|Intervention protocol adapted from Diabetes Prevention Program lifestyle change intervention.
62388740|NCT02514889|EXPERIMENTAL|MyPlate|Intervention protocol adapted from Dietary Approaches to Stop Hypertension dietary pattern.
62388741|NCT06296602|EXPERIMENTAL|ANAPreP-HPV|"A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections.~A questionnaire will be completed by the doctor to record the data of interest."
62388742|NCT04196244|EXPERIMENTAL|Abdominal or body CT with intravenous contrast|Abdominal or body CT with intravenous contrast
62560374|NCT00955929|EXPERIMENTAL|PRN Sildenafil|Placebo QHS (blinded) and sildenafil 100mgs (open-label) as required for sexual relations. The placebo will be omitted on nights that 100mgs is used. Placebo will start within 24-48 hours post-surgery.
62560375|NCT00955929|EXPERIMENTAL|Nightly Sildenafil Arm|Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery.
62560376|NCT00955929|EXPERIMENTAL|Combination Therapy Arm|Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL), at initial dose of 5 units (0.05ml) will be given; the first 2 injections will be done in the MSKCC urology outpatient clinic (if needed, the investigator can determine appropriate amount of injections for patient training).
62560377|NCT04363580||Patients|Children consulting for an assessment of central auditory skills
62560378|NCT01706406|EXPERIMENTAL|1 treatment|"Women randomized into the treatment group will undergo pre-treatment testing (questionnaires and physiological assessment)within 14 days of beginning treatment"
62560379|NCT01706406|OTHER|2 waitlist|"Women randomized to the waitlist group will undergo initial testing (questionnaires and physiological testing) and receive no treatment until the next scheduled group (4 months). They will undergo pretreatment testing and treatment on the same schedule as women in the treatment group."
61993487|NCT05706688||Regional anesthesia|4,152 patients undergoing elective carotid endarterectomy under regional anesthesia
61993488|NCT05706688||General anesthesia|4,152 matched controls undergoing elective carotid endarterectomy under general anesthesia
61993489|NCT03102281||recurrent group|Patients who had recurrent common bile duct stones.
62388743|NCT04196244|ACTIVE_COMPARATOR|Abdominal or body CT without intravenous contrast (native CT)|Abdominal or body CT without intravenous contrast (native CT)
62560380|NCT04991246|EXPERIMENTAL|Students, teachers,administrative staff from the medical school of Paris-Saclay University|Students,teachers,administrative staff from the medical school of Paris-Saclay University
62768645|NCT03924921|EXPERIMENTAL|wait list|usual care for 6 months Autogenic training after 6 months
61993490|NCT03102281||control group|Patients who had not recurrent common bile duct stones.
62388744|NCT03977363||Anticoagulated patients|Patients receiving anticoagulation treatment
62388745|NCT02242305|EXPERIMENTAL|Hyoscine Butylbromide - Tablet|
62388746|NCT02242305|ACTIVE_COMPARATOR|Hyoscine Butylbromide - Capsule|
62388747|NCT06313242|ACTIVE_COMPARATOR|Laxatives arm|Normal diet 1 day before the test, fasting and laxatives from 20:00 pm. The laxatives, Polyethylene Glycol Electrolytes Powder (II), should be prepared as a solution and taken as 2000 ml the night before the test and 1000 ml the following morning, within 2 hours and 1 hour, respectively.
62388748|NCT06313242|EXPERIMENTAL|Low residue diet arm|Low residue diet 1 day before the test, fasting from 20:00 pm.
62388749|NCT06313242|EXPERIMENTAL|Normal diet arm|Normal diet 1 day before the test, fasting from 20:00 pm.
62388750|NCT01219686|EXPERIMENTAL|escitalopram 20mg + pindolol 15mg|Days 1-2: escitalopram 10 mg + placebo, days 3-42: escitalopram 20mg + placebo Days 1-14: pindolol 15 mg, days 15-17: pindolol 7.5 mg
62388751|NCT01219686|ACTIVE_COMPARATOR|Escitalopram 30 mg|Days 1-2: escitalopram 10 mg+ placebo, days 3-4 escitalopram 20 mg + placebo, days 5-42: escitalopram 30mg+ placebo
62388752|NCT01219686|ACTIVE_COMPARATOR|escitalopram 20 mg|days 1-2: escitalopram 10 mg+ placebo, days 3-42: escitalopram 20 mg + placebo
62388753|NCT02471625||Traumatic Brain Injury|Men and women ages 18-65 with suspected acute head trauma within 24-72hrs. of presentation, scoring a 3-15 on initial evaluation on GCS scale.
62388754|NCT02471625||Control|Men and women ages 18-65 with no history of head trauma and a score of 15 on the GCS scale.
62388755|NCT04855474|EXPERIMENTAL|Low Protein|0.2 g/kg/day of protein provided as crystalline amino acid made after egg protein.
62388756|NCT04855474|EXPERIMENTAL|Moderate Protein|1.2g/kg/day of protein provided as crystalline amino acid made after egg protein.
62388757|NCT04855474|EXPERIMENTAL|High Protein|2.0 g/kg/day of protein provided as crystalline amino acid made after egg protein.
61993491|NCT01740596|EXPERIMENTAL|C-Pulse® System|C-Pulse® System Counterpulsation
61993492|NCT01740596|NO_INTERVENTION|Control Arm|Optimal Medical Therapy
61993493|NCT00571506|EXPERIMENTAL|1|Rosiglitazone 4 mg by mouth daily
62388758|NCT02286622|EXPERIMENTAL|Renal Impairment|Eight (8) subjects with ESRD on HD will receive one 18 mg dose of deflazacort.
62388759|NCT02286622|EXPERIMENTAL|Healthy Volunteers|Eight (8) healthy subjects with estimated creatinine clearance (CLcr) ≥ 90 mL/min. Subjects will be matched for age \[± 15 years\], BMI \[± 15 %\], and gender \[1:1\] to the subjects in the ESRD cohort. Subjects will receive one 18 mg dose of deflazacort.
62388760|NCT00417248|EXPERIMENTAL|Investigational Treatment|Cisplatin/Etoposide/Radiotherapy followed by Sorafenib in patients with inoperable stage III non-small cell lung cancer
62388761|NCT05139550|EXPERIMENTAL|Smartphone Rehabilitation Application|"Upper Limb Exercise Protocol:~Passive Exercises ROMs for shoulder, ROMs for elbow, ROMs for wrist,fingers and thumb~Active/Assisted Exercises bilateral shoulder flexion with both hands interlocked, Elbow pronation and supination, Wrist flexion and extension with the help of unaffected hand, Forearm to box, Extend elbow (side), Hand to box (front)~Functional Activities Lift can, Lift pencil, Lift paper clip, Stack checkers, Flip cards, Fold towel, drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, combing their hair, Eating with affected hand, opening and closing jars"
62388762|NCT04794530|ACTIVE_COMPARATOR|cocoa flavanols|
62388763|NCT04794530|PLACEBO_COMPARATOR|placebo|
62388764|NCT05032196|EXPERIMENTAL|WVE-003 (Dose A) or placebo|
62388765|NCT05032196|EXPERIMENTAL|WVE-003 (Dose B) or placebo|
62388766|NCT05032196|EXPERIMENTAL|WVE-003 (Dose C) or placebo|
62388767|NCT02781662|NO_INTERVENTION|Control|No Intervention; Control Arm: Receives Written Medication Information
62388768|NCT02781662|EXPERIMENTAL|Intervention|Behavioral: Pharmacist Home-Visit
62560381|NCT04159389|NO_INTERVENTION|traditional teaching|theoretical courses and procedural simulation on airway management during rapid sequence induction
62560382|NCT04159389|EXPERIMENTAL|Mental visualization|traditional teaching completed by mental visualization : theoretical courses and procedural simulation on airway management during rapid sequence induction + mental visualization (theoretical courses, audioguide for individual practice and experience sharing session)
62768646|NCT00500760|EXPERIMENTAL|Panitumumab Plus Chemoradiation|Participants received standard radiation therapy for 7 weeks and cisplatin 75 mg/m\^2 and panitumumab 9 mg/kg on Days 1, 22 and 43.
61993494|NCT00571506|ACTIVE_COMPARATOR|2|Pioglitazone 30 mg by mouth daily
61993495|NCT02051530|EXPERIMENTAL|tryptophan depletion first day|tryptophan depletion on the first day. on the other day participants receive placebo.
61993496|NCT02051530|EXPERIMENTAL|tryptophan depletion on day 2|tryptophan depletion on the second day. on the first day participants receive placebo.
62388769|NCT01884935|EXPERIMENTAL|Natalizumab|300 mg intravenously (IV) every 4 weeks
62388770|NCT03725709||All patients|spinal anesthesia
62388771|NCT00548366|EXPERIMENTAL|1|4 gram sodium diet
62388772|NCT00548366|ACTIVE_COMPARATOR|2|2 gram sodium diet
62388773|NCT01480193|ACTIVE_COMPARATOR|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
62560383|NCT05830786|EXPERIMENTAL|Immersive virtual reality (IVR) group|The experimental group will experience various surgical training modules using immersive virtual reality.
62560384|NCT05830786|ACTIVE_COMPARATOR|Traditional hands on orthopaedic workshop group|Hands-on orthopaedic workshop sessions (including arthroscopy simulators, cadaveric models, and Sawbones®) in differing orthopaedic subspecialties (including sports, arthroplasty, and spine surgery).
62768647|NCT00500760|ACTIVE_COMPARATOR|Chemoradiotherapy Alone|Participants received standard radiation therapy for 7 weeks and cisplatin 100 mg/m\^2 on Days 1, 22, and 43.
61993497|NCT03394768||NICOM Cheetah®|Patients will be treated as per department protocols and no additional intervention will be performed. Each patient will have an arterial catheter inserted as per our usual practice. All patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The NICOM CO monitor involves the application of non-invasive sensor strips. In this study, it will be applied to patients receiving the FloTrac (standard of care), on top of the standard care of monitoring with Flotrac.
61993498|NCT03394768||FloTrac®|Same patient population as the NICOM Cheetah® group as described above as all patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The FloTrac CO monitor is the current standard of care for cardiac output monitoring in the SICU of CGH. All patients deemed to require cardiac output monitoring will receive the FloTrac (as per departmental practice).
62388774|NCT01480193|EXPERIMENTAL|Integrative Medicine Therapies and SBE|2 Sound Based and Educational Sessions 3 Cognitive Based Therapy Sessions 9 Telephonic Health Coaching Sessions 5 Acupuncture Sessions Group-Based 8 week Mindfulness Based Stress Reduction
62388775|NCT03306849||Regular menstrual cycles|Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days). Recruitment will be targeted such that equal numbers of lean (BMI \<25kg/m2) and overweight or obese (BMI \>24.9kg/m2) participate.
62768648|NCT03562416|EXPERIMENTAL|Nintedanib|Nintedanib 150 mg tablet by mouth twice daily for 24 months.
62768649|NCT03562416|PLACEBO_COMPARATOR|Placebo|Placebo tablet by mouth twice daily for 24 months
62768650|NCT02587546|EXPERIMENTAL|laryngeal carcinoma|patients with T1-T2 (some T3) laryngeal carcinoma will undergo treatment using thulium contact laser surgery - tumour resection
62768651|NCT02587546|EXPERIMENTAL|bilateral vocal cord paralysis|patients with bilateral vocal cord paralysis treated with partial arytenoidectomy will be treated using thulium laser surgery and laterofixation
62768652|NCT02587546|EXPERIMENTAL|subglottic stenosis|patients with subglottic stenosis treated endoscopically (incisions and dilatation) will be treated with thulium laser surgery
62768653|NCT00858663|EXPERIMENTAL|Chemoradiation|"* IMRT, 1 fraction/day, over approximately 33 treatment days~* RAD001 per oral or PEG, per dose escalation scheme (Days 1 - 42)~* Cisplatin IV weekly, per dose escalation scheme (Days 1, 8, 15, 22, 29, 36)"
62768654|NCT03333317|EXPERIMENTAL|Regimen A (Low-Dose Lumicitabine)|Participants will receive a single 40 milligram per kilogram (mg/kg) loading dose (LD) (Dose 1) followed by nine 20 mg/kg maintenance doses (MDs) (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.
61993499|NCT02357147|EXPERIMENTAL|Arm 1|"Combination Phase - Amatuximab + Pemetrexed and Cisplatin~Maintenance Phase - Amatuximab"
61993500|NCT02357147|EXPERIMENTAL|Arm 2|"Combination Phase - Placebo + Pemetrexed and Cisplatin~Maintenance Phase - Placebo"
61993501|NCT05839210|EXPERIMENTAL|LIFE-L Group|Participants already undergoing chemotherapy treatment as per standard of care for 6 cycles will meet weekly via phone for 30-45 minutes with a health coach that will provide education on a Mediterranean diet and an exercise program.
62388776|NCT03306849||Normoandrogenic anovulation|Women will be assigned to this category if they do not have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (\<21 days or \>35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted such that equal numbers of lean (BMI \<25kg/m2) and overweight or obese (BMI \>24.9kg/m2) participate.
62388777|NCT03306849||Hyperandrogenic anovulation|Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (\<21 days or \>35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted such that equal numbers of lean (BMI \<25kg/m2) and overweight or obese (BMI \>24.9kg/m2) participate.
62388778|NCT00106626|EXPERIMENTAL|1|vorinostat (Suberoylanilide Hydroxamic Acid \[SAHA\])
62388779|NCT00014560|EXPERIMENTAL|Single arm|Antibody
62560385|NCT03726372|EXPERIMENTAL|deep neuromuscular blockade|Rocuronium, a neuromuscular blocking agent will be given by continuous infusion at a dose that reaction to train of four (TOF) stimulation is depressed to zero
62560386|NCT03726372|EXPERIMENTAL|moderate neuromuscular blockade|Rocuronium, a neuromuscular blocking agent will be given at a dose by intermittent injection that reaction to train of four (TOF) stimulation is kept 1 to 2
62768655|NCT03333317|EXPERIMENTAL|Regimen B (High-Dose Lumicitabine)|Participants will receive a single 60 mg/kg LD (Dose 1) followed by nine 40 mg/kg MDs (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.
62768656|NCT03333317|PLACEBO_COMPARATOR|Regimen C (Placebo)|Participants will receive either a single 40 mg/kg placebo LD (Dose 1) followed by nine 20 mg/kg maintenance dose (MDs) (Doses 2 to 10) of placebo twice daily or single 60 mg/kg placebo LD (Dose 1) followed by nine 40 mg/kg placebo MDs (Doses 2 to 10), twice daily up to Day 5/6.
62768657|NCT01439126|ACTIVE_COMPARATOR|Subjects on KAPVAY™ (clonidine hydrochloride)|Subjects in the KAPVAY™ arm receive their optimal dose of KAPVAY™ for the 26-week randomized-withdrawal period (Period 3)
62768658|NCT01439126|PLACEBO_COMPARATOR|Subjects on Placebo|Subjects in placebo arm tapered off optimal dose of KAPVAY™ (ie, Period 2 Maintenance Dose) at weekly intervals in decrements of 0.1 mg/day until reaching dose of 0 mg/day; subjects then receive only placebo for the rest of the study
62768659|NCT03048591|EXPERIMENTAL|Electroacupuncture group|
62768660|NCT03048591|NO_INTERVENTION|control group|
62768661|NCT03218579|NO_INTERVENTION|No intervention|No intervention after antibiotic treatment.
62768662|NCT03218579|ACTIVE_COMPARATOR|Probiotic microbiome rehabilitation|Probiotic treatment after antibiotic treatment.
62388780|NCT00892879|EXPERIMENTAL|1|Single port laparoscopic device
62388781|NCT00892879|ACTIVE_COMPARATOR|2|Four-port laparoscopic device
62560387|NCT05274178|EXPERIMENTAL|Naive listeners|"Participants who have never worn a hearing aid before. This group will be tested with both sets of devices, those labeled as OTC and those labeled as Prescriptive"
62560388|NCT05274178|EXPERIMENTAL|Experienced users|"Participants who have at least six months experience wearing hearing aids. This group will be tested with both sets of devices, those labeled as OTC, and those labeled as Prescriptive"
62768663|NCT03218579|ACTIVE_COMPARATOR|Bacteriotherapy microbiome rehabilitation|Bacteriotherapy after antibiotic treatment.
62560389|NCT03825354|EXPERIMENTAL|Brief Intervention and contact (BIC)|Brief education about suicidal behaviour and follow up contacts for 6 months in addition to treatment as usual. follow up will occur at the following time points post discharge: weeks 1, 2, 4, 6, 8, 12, 16 and 20. this will occur in addition to treatment as usual.
62560390|NCT03825354|NO_INTERVENTION|control|control will continue treatment as usual which is whatever the clinical team decides upon post discharge. data will be collected on repeated suicidal behaviour through medical records with consent.
62560391|NCT05587010||Foot drop|Participants living with foot drop in either foot. Orthotic support devices will be compared within this cohort to assess their impact on gait biomechanics and clinical outcomes
61993502|NCT05839210|OTHER|Control Group|Participants in this group already undergoing 6 cycles of chemotherapy will receive study materials and two 30-45 minutes health coaching sessions four weeks post- intervention.
61993503|NCT03774940|EXPERIMENTAL|fever|patients that have fever after PNL
62560392|NCT04018378|EXPERIMENTAL|RT|"period 1: HGP1604 1mg (reference drug, R) will be administered once orally.~period 2: HIP1502 1mg (test drug, T) will be administered once orally after 14 days of the washout period."
62768664|NCT02151331|EXPERIMENTAL|REP + EF|Replication Effective Programs (REP) augmented with External Facilitation (EF)
61993504|NCT03774940|ACTIVE_COMPARATOR|No fever|Patients without fever after PNL
62560393|NCT04018378|EXPERIMENTAL|TR|"period 1: HIP1502 1mg (test drug, T) will be administered once orally.~period 2: HGP1604 1mg (reference drug, R) will be administered once orally after 14 days of the washout period."
62560394|NCT05899777|EXPERIMENTAL|Treatment group|After proficiently mastering the complete set of Yizhi Baduanjin, the practice group is required to practice sitting posture of YizhiBaduanjin twice a day and standing posture of YizhiBaduanjin once every two days.
62560395|NCT05899777|NO_INTERVENTION|control group|The control group is a waiting control group, and after 24 weeks, they will continue to learn the Yizhi Baduanjin.
62560396|NCT02380612|EXPERIMENTAL|All Participants (within patient control)|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
61993505|NCT01378793|NO_INTERVENTION|Standard of Care|Participants will be asked to continue doing whatever their healthcare providers advise for their insomnia, but not to start any new treatments during the study. They will also be given a sleep hygiene handout as a standard of care. After six weeks, they will be reassessed and then provided the opportunity to engage in the web-based acupressure intervention.
61993506|NCT01378793|ACTIVE_COMPARATOR|Relaxation Acupressure|In addition to being given a sleep hygiene handout as a standard of care, participants will be asked to apply pressure on each of following points (bilaterally where indicated). There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes done once daily.
62560397|NCT02843321|EXPERIMENTAL|T-cell infusion|Infusion of donor-derived T cells. Non randomised, prevention study arm
62560398|NCT00489866|EXPERIMENTAL|Aripiprazole|
62560399|NCT00489866|PLACEBO_COMPARATOR|Placebo|
62560400|NCT01207687|EXPERIMENTAL|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes once every 3 weeks. Courses repeat every 6 weeks for up to 48 weeks in the absence of disease progression or unacceptable toxicity.
62560401|NCT05074368|ACTIVE_COMPARATOR|Heterologous ChAdOx1-nCov-19 vaccination - 8 weeks apart|Astra-Zeneca vaccine 0.5 mL/dose
62560402|NCT05074368|ACTIVE_COMPARATOR|mRNA-1273 Vaccination and Heterologous ChAdOx1-nCov-19 vaccination- 8 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
62560403|NCT05074368|ACTIVE_COMPARATOR|Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination- 4 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
62560404|NCT05074368|ACTIVE_COMPARATOR|The mRNA-1273 Vaccination- 4 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose
62768665|NCT02151331|EXPERIMENTAL|REP + EF/IF|Replicating Effective Programs (REP) augmented with External and Internal Facilitation (EF + IF)
62768666|NCT04480034||Group Pisa|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UOC Chirurgia Bariatrica, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy (Head Prof. Marco Anselmino) will be collected in a prospective database, to monitor the postoperative course.
62768667|NCT04480034||Group Padova|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UOSD Week Surgery, Azienda Ospedaliera, Università di Padova, Italy (Head Dr. Mirto Foletto) will be collected in a prospective database, to monitor the postoperative course.
62560405|NCT05074368|ACTIVE_COMPARATOR|Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination-12 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
62560406|NCT01022476|EXPERIMENTAL|Raltegravir potassium|raltegravir 400 mg twice a day
62560407|NCT00134823|EXPERIMENTAL|dosing decision support|weight based dosing decision support
62560408|NCT00134823|NO_INTERVENTION|no decision support|no weight based dosing decision support
62560409|NCT02656303|EXPERIMENTAL|Parent Study Arm B|Participants from Arm B of the parent trial (UTX-TGR-304) received ublituximab, 150 milligrams (mg), intravenously (IV), on Day 1, 750 mg on Day 2, followed by 900 mg on Days 8 and 15 of Cycle 1 (cycle length=28 days), Day 1 of Cycles 2-6, and once every 3 months thereafter, along with umbralisib, 800 mg, orally, once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 78 months.
61993507|NCT01378793|ACTIVE_COMPARATOR|Stimulating Acupressure|In addition to being given a sleep hygiene handout as a standard of care, participants will be asked to apply pressure on each of following points (bilaterally where indicated). There are 6 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 10 points to stimulate. Each of the 10 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 30 minutes done once daily.
61993508|NCT01784783|EXPERIMENTAL|HOPE Intervention|"Pregnant women and their male partners will receive home-based couple HIV testing and counseling and partner education 1-2 weeks after enrollment. The intervention will include educational messages concerning socio-behavioral, condom-based, and treatment-oriented approaches to prevention of horizontal and vertical HIV transmission, based on the status of each of the partners. The couple will also be educated about the importance of facility delivery, exclusive breastfeeding, family planning, and post-partum contraception.~During the HOPE Intervention, the purpose and design of the study will be explained to male partners. Men will be asked to provide written informed consent for study participation. Provided they consent, men will complete a questionnaire asking for sociodemographic characteristics, medical and sexual history, behavioral data and information on prior HIV testing and counseling."
61993509|NCT01784783|EXPERIMENTAL|INVITE Intervention|Pregnant women will be tested and encouraged to bring their male partners to the antenatal clinic for testing. Women will receive a clinic invitation to give to their male partners to attend the next visit for couple HIV counseling and testing. The couples will also be offered the relevant components of the intervention at the final study visit, 6 months postpartum.
61993510|NCT02048553|EXPERIMENTAL|Tablet-guided|Guide-assisted ventriculostomy.
61993511|NCT02048553|EXPERIMENTAL|Freehand|standard ventriculostomy.
61993512|NCT03228004|EXPERIMENTAL|Intervention Group|Participants will be provided with training on how to upload glucose data via GLOOKO and will receive reminders to upload glucose data on a biweekly basis between clinic visits.
61993513|NCT02558790|EXPERIMENTAL|L-Threonic Acid Magnesium Salt (L-TAMS)|Subjects received open label L-Threonic acid Magnesium salt for 12 weeks. Subjects took MMFS202 (6-hour release) and MMFS302 (12-hour release) by mouth each day, up to three times a day.
61993514|NCT00177892|EXPERIMENTAL|1|non-OSAH/overweight individuals with the Metabolic Syndrome
61993515|NCT00177892|EXPERIMENTAL|2|non-OSAH/overweight individuals without Metabolic Syndrome
62560410|NCT02656303|EXPERIMENTAL|Parent Study Arm C|Participants from Arm C of the parent trial (UTX-TGR-304) received ublituximab, 900 mg, IV, on Day 1 of Cycles 1-6 (cycle length=28 days), and once every 3 months thereafter, along with umbralisib, 800 mg, orally, once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 78 months.
61993516|NCT00177892|ACTIVE_COMPARATOR|3|non-OSAH/normal weight without Metabolic Syndrome
61993517|NCT00177892|EXPERIMENTAL|4|OSAH patients with chronic positive airway pressure therapy
62388782|NCT04446273|EXPERIMENTAL|PRI group|The PRI and DRI groups will receive an equal amount of treatment time, comprising 1.5 hours per day, 3 days per week, for 6 weeks. The PRI protocol provides robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist).
62388783|NCT04446273|ACTIVE_COMPARATOR|DRI group|The PRI and DRI groups will receive an equal amount of treatment time, comprising 1.5 hours per day, 3 days per week, for 6 weeks. The DRI protocol provides robotic training for 45 minutes and impairment-oriented training for 45 minutes. The DRI group will start from the Bi-Manu-Track distal mode (i.e., wrist) and then the Bi-Manu-Track proximal mode (i.e., forearm).
61993518|NCT00177892|EXPERIMENTAL|5|OSAH patients without chronic positive airway pressure therapy
61993519|NCT04027738|EXPERIMENTAL|PRP injection|The patients received a single 3-ml injection of PRP.
61993520|NCT02552316|OTHER|NB-UVB Phototherapy|NB-UVB phototherapy is a therapy which uses ultraviolet B (UVB) light directed at the skin. This type of light therapy is given through the use of phototherapy booths which contain fluorescent tubes that emit UVB light. Booths used for phototherapy look similar to commercial tanning booths. NB-UVB phototherapy affects psoriasis by causing changes to the cells of the skin and producing a local effect by reducing the number of certain types of skin cells which have an impact on psoriasis formation.
62560411|NCT02656303|EXPERIMENTAL|Parent Study Arm D|Participants from Arm D of the parent trial (UTX-TGR-304) received ublituximab, 150 mg, IV, on Day 1, 750 mg on Day 2, followed by 900 mg on Days 8 and 15 of Cycle 1 (cycle length=28 days), Day 1 of Cycles 2-6, and once every 3 months thereafter, along with umbralisib, 800 mg, orally, once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 78 months.
61993521|NCT04843709|EXPERIMENTAL|MRG004A|All patients in Part A (dose escalation) and Part B (dose expansion) will be administrated MRG004A on Day 1 of every 3 weeks (21-day cycle).
61993522|NCT04488965|EXPERIMENTAL|Autologous neural cell ecosystems - ANCE|The patient will undergo first surgery under general anesthesia for the collection of the cortical biopsy (5x5x5 mm biopsy of non-dominant frontal cortex). After the production of ANCE from the cortical biopsy, which last 8 to 12 weeks, the patient will undergo a second neurosurgery, for the stereotaxic reimplantation of ANCE under general anesthesia.
61993523|NCT05289609||Prospective Cohort|Liver Transplant Recipients from High-volume centers (i.e., performing \>= 65 LTs per year)
62388784|NCT02026427||Drotaverine|40 mg of drotaverine hydrochloride administered intramuscularly just after the proper level of spinal anesthesia was achieved.
62567720|NCT00314340|ACTIVE_COMPARATOR|extended-release morphine|"Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity~On one of three study dates, subjects received ER morphine tablets, 45 mg (Mallinckrodt Pharmaceuticals, St. Louis, MO). The dose of ER morphine sulfate (45 mg) was selected because of its approximate equianalgesic effect to the dose of hydrocodone-acetaminophen (30/925 mg)."
61993524|NCT05289609||Retrospective Cohort|Liver Transplant Recipients from Low-to-medium volume centers (i.e., performing \<65 LTs per year) and High-volume centers
61993525|NCT00855491|EXPERIMENTAL|1. MYOPIA|axial length \> 26.00 mm
61993526|NCT00855491|ACTIVE_COMPARATOR|2. Emmetropia|emmetropic eyes- eyes with an axial length of 21.00 to 23.99 mm
61993527|NCT03439969|NO_INTERVENTION|Control|Dental appointment, one hour and included activities that are normally part of a SPT (Suportive Periodontal Treatment) consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback considered crucial to the accomplishment of long term behavior change. Moreover, special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation) in order to focus patients´ attention on the varied facets of oral health care and increase their perception of the treatment needs. In this group, the device SOPROCARE® by Acteon and Text Messages were not used.
61993528|NCT03439969|EXPERIMENTAL|Intra Oral Camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback. Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.
61993529|NCT03439969|EXPERIMENTAL|Mobile Text Messages|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback.. Participants in the SMS group further received a total of 16 messages (SMS). One per week.
61993530|NCT03439969|EXPERIMENTAL|Intra Oral Camera and Text Messages|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback. Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.Participants also received SMS a total of 16 messages (SMS). One per week.
61993531|NCT00640705|ACTIVE_COMPARATOR|A|Topical diclofenac sodium patch
61993532|NCT00640705|PLACEBO_COMPARATOR|B|Topical patch identical in appearance to active comparator, except without diclofenac sodium
61993533|NCT06061393|ACTIVE_COMPARATOR|venofer|Women with iron def. anemia aith hemoglobin level \<9 gr/dl who will be traeted with venofer
61993534|NCT06061393|ACTIVE_COMPARATOR|Ferinject|Women with iron def. anemia aith hemoglobin level \<9 gr/dl who will be traeted with ferinject
61993535|NCT02140437|EXPERIMENTAL|Fulvestrant and anastrozole|Anastrozole 1 mg PO QD Fulvestrant 500mg IM d1,15, 29 and 4 weeks after
61993536|NCT02140437|ACTIVE_COMPARATOR|Anastrozole|Anastrozole 1 mg PO QD
62388785|NCT02026427||Control|Without intramuscular administration of drotaverine hydrochloride.
62388786|NCT03144596|EXPERIMENTAL|Alfuzosin Hydrochloride|Alfuzosin hydrochloride 10 mg tablet by mouth, every 24 hours for 3 months
62388787|NCT03144596|ACTIVE_COMPARATOR|Tamsulosin Hydrochloride|Tamsulosin hydrochloride 0.4 mg tablet by mouth, every 24 hours for 3 months
62388788|NCT01442545|EXPERIMENTAL|001|
62388789|NCT01380847||Renal allograft nephropathy|To evaluate urine from KTRs during the first year post-transplantation to assess whether mRNA levels of genes involved in EMT/fibrogenesis can diagnose and predict CAN, and identify patients at risk of chronic allograft dysfunction
62388790|NCT04149210|EXPERIMENTAL|fluorometholone|Fluorometholone 0.1% eyedrops, one drop twice daily for four weeks
62388791|NCT04149210|PLACEBO_COMPARATOR|Artificial Tears|one drop two times daily for four weeks
62388792|NCT05366881||Cases|Cases will include participants with newly diagnosed, treatment-naive cancer at the time of enrollment.
62388793|NCT05366881||Controls|Controls will include participants without known cancer at the time of enrollment.
62388794|NCT04843228|EXPERIMENTAL|Active Cognitive Bias Modification Group|This group of participants will receive 4 sessions of CBM targeting their interpretation biases for perfectionism and intolerance to uncertainty.
62388795|NCT04843228|PLACEBO_COMPARATOR|Placebo-Control Cognitive Bias Modification Group|This group of participants will receive 4 sessions of inactive CBM.
62768668|NCT04480034||Group Bologna|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit Chirurgia Bariatrica, Azienda Ospedaliera Universitaria di Bologna, Italy (Head Dr. Paolo Bernante) will be collected in a prospective database, to monitor the postoperative course.
61993537|NCT01275495|EXPERIMENTAL|Telephone Assessment and Skill-Building Kit (TASK II)|The TASK II group will fill out a checklist about their needs and concerns, and will receive written tip sheets by mail that address the needs and concerns that they feel are most important. A nurse will call by telephone (lasting about 30 minutes or less) once a week for a total of 8 weeks, with another call at 12 weeks, to provide more information, answer questions, and to discuss more written tip sheets based on the caregiver's needs and concerns.
61993538|NCT01275495|ACTIVE_COMPARATOR|Information, Support, and Referral (ISR)|The ISR group will receive existing educational materials about stroke and caregiving developed by the American Stroke Association and weekly telephone calls by a nurse (lasting about 30 minutes or less) for a total of 8 weeks, with another call at 12 weeks.
61993539|NCT03947749||Patients with HICMP|Patients with PROMIS Pain Interference-6b scores one standard deviation above the national average will be categorized into this group.
61993540|NCT03947749||Patients without HICMP|Patients without PROMIS Pain Interference-6b scores one standard deviation above the national average will be categorized will be categorized into this group.
61993541|NCT03947749||Patients at risk for opioid abuse or misuse|The Opioid Risk Tool and PROMIS Short Form v1.0-Prescription Pain Medication Misuse will be used to categorize patients at risk.
61993542|NCT03947749||Patients not at risk for opioid abuse or misuse|The Opioid Risk Tool and PROMIS Short Form v1.0-Prescription Pain Medication Misuse will be used to categorize patients at risk.
62388796|NCT03181776|EXPERIMENTAL|left lateral tilting arm|all patients will be put in three angles of left lateral tilt in randomized order (supine position - left lateral tilting in 15 degrees - and left lateral tilting in 30 degrees) and the hemodynamic data will be compared in the three angles.
62388797|NCT02122302|EXPERIMENTAL|Web-based health assessment|
62388798|NCT02288663|OTHER|Freage group|only one group in this trial. All the participants will follow all the listed interventions.
62560412|NCT02597764|ACTIVE_COMPARATOR|Standard Urotherapy (SU)|Standard Urotherapy (SU): A non-invasive therapy combining cognitive, behavioral and physical therapy. The study team will explain the problem to the children and their parents and educate them on the following: proper voiding mechanics, sitting, standing positions, how and when to void, techniques on relaxing pelvic floor muscles, and avoiding straining. An assessment of bowel habits will be done and their diet and drinking/voiding habits will be modified to maintain proper hydration with timed voiding. Voiding diaries will be provided for the assessment of the bladder and bowel habits.
62560413|NCT02597764|EXPERIMENTAL|Standard Urotherapy (SU) + Diaphragmatic Beathing (DB)|"Standard Urotherapy (SU) with the addition of Diaphragmatic Breathing (DB):~A non-invasive breathing technique that is performed by a marked expansion of the abdomen (contracting diaphragm) rather than chest cavity during inspiration and tightening of the stomach muscles during expiration. Participants will lie on their back on a flat surface. Head is supported with a pillow and knees are bent forward supported by another pillow. Participants will place one hand on chest and the other on the abdomen, then start inhalation by moving their abdomen out against their hand, breathing in through their nose while keeping their chest and the other hand as still as possible. During expiration, the participants will tighten their abdominal muscles by forcing them inward and breathe out through pursed lips while keeping the hand on the chest as still as possible. Participants will be asked to perform this exercise for 10 minutes 3 times daily for 3 months."
62560414|NCT03359148||Disposable ventilator system|The experimental study group will be assigned to a disposable ventilator system combined with an auto-filled heated humidifier (HH), a closed suction catheter, and a closed aerosol therapy procedure with a valved T-adaptor.
62768669|NCT04480034||Group Bergamo|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UOC Chirurgia Generale e Oncologica, Policlinico San Marco di Zingonia, Bergamo, Italy (Head Prof. Stefano Olmi) will be collected in a prospective database, to monitor the postoperative course.
61993543|NCT06366880|EXPERIMENTAL|Parenteral nutrition cycling|
62388799|NCT03270631|NO_INTERVENTION|Control|Multidisciplinary rehabilitation, no interventions
62768670|NCT04480034||Group Tor Vergata|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit U.O.S.D. Chirurgia Mininvasiva e dell'Apparato Digerente, Università Tor Vergata, Rome, Italy (Head Prof. Paolo Gentileschi) will be collected in a prospective database, to monitor the postoperative course.
62768671|NCT04480034||Group Torino|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit Dipartimento di Scienze Chirurgiche, Azienda Ospedaliera Universitaria Citta della Salute e della Scienza, Università di Torino, Italy (Head Prof. Mario Morino) will be collected in a prospective database, to monitor the postoperative course.
61993544|NCT06366880|NO_INTERVENTION|Continuous parenteral nutrition|
61993545|NCT01845285||aortic valve disease|aortic valve replacement
61993546|NCT00937417|EXPERIMENTAL|Arm 1|vandetanib and docetaxel
61993547|NCT05090761|ACTIVE_COMPARATOR|SAPB|40 Patients - Patients will receive 30 mL of 0.25% bupivacaine injected below the serratus anterior muscle in the caudal direction using ultrasound guidance.
61993548|NCT05090761|ACTIVE_COMPARATOR|SAPB with Mg|40 Patients - Patients will receive 30 mL of 0.25% bupivacaine with 150 mg of Mg injected below the serratus anterior muscle in the caudal direction using ultrasound guidance.
62388800|NCT03270631|EXPERIMENTAL|FM and MCE|Subjects will have 4-5 times of fascial manipulation (FM) treatment and 4-6 times movement control exercises (MCE) at home to be done based on movement control testing (MCT). Both are given in 3 month period.
62388801|NCT03270631|OTHER|FM and sham-MCE|FM 4-5 times in 3 months and 4 general exercise prescription.
62388802|NCT03270631|OTHER|MCE and sham-FM|Sham-FM 4 times in 3 months including trigger point treatment in before decided points and 4-6 times MCE prescription and home exercises.
62388803|NCT03270631|SHAM_COMPARATOR|Sham-MCE and sham-FM|4 general practice guiding and Sham-FM 4 times in 3 months including trigger point treatment in before decided points.
62388804|NCT05953896|EXPERIMENTAL|Hyaluronic acid gel|will include 10 patients undergoing non invasive reconstruction of interdental papilla using injectable Hyaluronic acid gel
62388805|NCT05953896|ACTIVE_COMPARATOR|Multilayer L-PRF|will include 10 patients undergoing minimally invasive surgery for reconstruction of interdental papilla using multilayer L-PRF membranes
62388806|NCT05188560|EXPERIMENTAL|AOT+MI|participants who, in addiction to standard rehabilitation program after surgery, underwent a single pre-operative training session of action observation therapy associated with motor imagery.
62388807|NCT05188560|NO_INTERVENTION|Control group|Participants who was not subjected to any pre-operative activity. They received standard rehabilitation program after surgery too.
62388808|NCT04879576|EXPERIMENTAL|Treatment Group|
62388809|NCT04879576|NO_INTERVENTION|Control Group|
62388810|NCT02354599|EXPERIMENTAL|Cohort 1: MT203 80 mg|Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
62388811|NCT02354599|PLACEBO_COMPARATOR|Cohort 1: MT203 80 mg matching placebo|Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
62388812|NCT02354599|EXPERIMENTAL|Cohort 2: MT203 150 mg|Six Japanese participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
62388813|NCT02354599|PLACEBO_COMPARATOR|Cohort 2: MT203 150 mg matching placebo|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
62388814|NCT02354599|EXPERIMENTAL|Cohort 3: MT203 300 mg|Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
62388815|NCT02354599|PLACEBO_COMPARATOR|Cohort 3: MT203 300 mg matching placebo|Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
62388816|NCT02354599|EXPERIMENTAL|Cohort 4: MT203 150 mg|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
62388817|NCT02354599|PLACEBO_COMPARATOR|Cohort 4: MT203 150 mg matching placebo|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously
62388818|NCT02349841|EXPERIMENTAL|Meropenem;amoxycillin/clavulanic acid|Meropenem 2g will be administered intravenously 8-hourly; plus amoxycillin/CA 500mg/125mg will be administered orally 8-hourly for 14 days
62388819|NCT02349841|EXPERIMENTAL|Faropenem; amoxycillin/CA|Faropenem 600mg will be administered orally 8-hourly; plus amoxycillin/CA 500mg/125mg will be administered orally 8-hourly for 14 days
62768672|NCT04480034||Group Milano|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UO di Chirurgia Bariatrica, Humanitas Research Hospital, Rozzano, Milano, Italy (Head Dr. Giuseppe Marinari) will be collected in a prospective database, to monitor the postoperative course.
62388820|NCT02349841|ACTIVE_COMPARATOR|Rifafour e-275|Rifafour e-275 will be administered orally once daily for 14 days as per South African National TB Treatment Guidelines
62388821|NCT04293081|ACTIVE_COMPARATOR|chlorpheniramine maleate group|A total of 45 adult patients undergoing FESS procedure for sinusitis with postoperative nasal packing. Written informed consent will be obtained from all patients before randomization. Patients will be assigned to chlorepheniramine maleate group (A)
62388822|NCT04293081|PLACEBO_COMPARATOR|placebo group|A total of 45 adult patients undergoing FESS procedure for sinusitis with postoperative nasal packing. Written informed consent will be obtained from all patients before randomization. Patients will be assigned to placebo group (A)
62388823|NCT01941160|EXPERIMENTAL|Amoxicillin/Clavulanic Acid and Lacidofil® STRONG|Participants are provided in double blinded fashion Lacidofil® STRONG to take with antibiotics
62388824|NCT01941160|PLACEBO_COMPARATOR|Placebo|Participants are provided in double blinded fashion placebo to take with antibiotics
62388825|NCT06006676|EXPERIMENTAL|Near Apnoeic Ventilation|Near Apnoeic ventilation (with a respiratory rate of 2 breaths per minute, plateau pressure of 30cmH20 and PEEP set according to the mean airway pressure being delivered during mechanical ventilation prior to randomisation) for a 72 hour period following randomisation
62388826|NCT06006676|ACTIVE_COMPARATOR|Standard Care|Standard care for patient on ECMO as per consultant with respiratory rate of 15-30, PEEP of 10cmH20 or more and Plateau pressure of 25cmH20 or less for a 72 hour period following randomisation
62388827|NCT00271362|ACTIVE_COMPARATOR|1|comparing 2 surgical procedures
62388828|NCT02974673|EXPERIMENTAL|Ejaculatory test|Measures of sphincter pressures during ejaculation
62388829|NCT04665492||SCI with CNP|People with subacute spinal cord injury and no chronic pain
62388830|NCT04665492||SCI no CNP|People with subacute spinal cord injury with central neuropathic pain
62560415|NCT03359148||Conventional reused ventilator system|According to clinical commonly used system, the control study group will be assigned to use with conventional reused ventilator system, combined with a manually filled HH, an open suction catheter, and a conventional aerosol therapy procedure.
62388831|NCT04665492||Able bodied|Able bodied people with no chronic pain
62388832|NCT06205212|ACTIVE_COMPARATOR|facemask|preoxygenation using a conventional facemask
62388833|NCT06205212|EXPERIMENTAL|high-flow nasal oxygen|preoxygenation using high-flow nasal cannula oxygen
62388834|NCT03689114|EXPERIMENTAL|Low dose|Dosage is in mg: low dose carbamazepine, 300 ; low dose levetiracetam, 500; low dose valproate, 300; low dose zonisamide, 150; low dose oxcarbazepine, 600; low dose topiramate, 100; low dose lamotrigine, 100; low dose gabapentin, 450. Study drugs are in form of tablets for daily administration. Study drug administration duration is 12 months. The choice of the drug is left to the caring physician's discretion but it must be limited to the AEDs marketed for monotherapy use. All the study drugs will be used according to the respective SPCs, which will be sent by the promoter to all the study investigators.
62388835|NCT03689114|ACTIVE_COMPARATOR|Standard dose|Dosage is in mg: standard dose carbamazepine 600; standard dose levetiracetam 1000; standard dose valproate, 600; standard dose zonisamide 300; standard dose oxcarbazepine 1200; standard dose topiramate, 200; standard dose lamotrigine, 200; standard dose gabapentin 900. Study drugs are in form of tablets for daily administration. Study drug administration duration is 12 months. The choice of the drug is left to the caring physician's discretion but it must be limited to the AEDs marketed for monotherapy use. All the study drugs will be used according to the respective SPCs, which will be sent by the promoter to all the study investigators.
62388836|NCT02430298|PLACEBO_COMPARATOR|Matched placebo|Drug: match placebo Drug: placebo suspension gargle for 2 minutes before radiation 15 minutes and placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
62388837|NCT02430298|ACTIVE_COMPARATOR|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
62388838|NCT01486979|EXPERIMENTAL|Low dose|
62388839|NCT01486979|ACTIVE_COMPARATOR|High dose|
62388840|NCT04542863|EXPERIMENTAL|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo 18F-DX600 PET/CT scans.
62388841|NCT02230644|EXPERIMENTAL|Audio enhanced|Enhanced Clinical Environment: participants wait for their operation in the enhanced audio-visual booth.
62388842|NCT02230644|ACTIVE_COMPARATOR|Other distraction method|Participants wait for their operation in a booth with another distraction such as the news on television
62388843|NCT02230644|NO_INTERVENTION|Ordinary|Participants wait for their operation in an ordinary, unenhanced booth
62388844|NCT02058966|PLACEBO_COMPARATOR|Placebo followed by Placebo|Subjects will receive placebo, then one hour later, placebo
62388845|NCT02058966|EXPERIMENTAL|Placebo followed by Methamphetamine|Subjects will receive placebo, then one hour later, methamphetamine
62388846|NCT02058966|EXPERIMENTAL|Entacapone followed by Placebo|Subjects will receive entacapone, then one hour later, placebo
62388847|NCT02058966|EXPERIMENTAL|Entacapone followed by Methamphetamine|Subjects will receive entacapone, then one hour later, methamphetamine
62388848|NCT01721213||Patients using Trobalt™|Use of Trobalt™ current use or at least one prescription filled within the previous three months.
62388849|NCT01721213||Physicians prescribing AEDs|Physicians (neurologists) who prescribed AEDs at least once in the three months prior to the survey.
62388850|NCT01721213||Physicians Prescribing Trobalt™|Physicians (neurologists) who have had experience of prescribing Trobalt™ specifically, from among those who have prescribed AEDs at least once in the three months prior to the survey.
62560416|NCT03110237|ACTIVE_COMPARATOR|Control Balance Training (BT) class|Group based circuit training class, 30 minute session, twice a week for three weeks
62388851|NCT03514394|ACTIVE_COMPARATOR|Usual Care|Usual care administered for depression at clinic.
62388852|NCT03514394|EXPERIMENTAL|Modified Behavioral Activation (Task Sharing)|This intervention will be a modification of Behavioral Activation (BA), which is a behavioral intervention that identifies work, social, health, or family activities that patients have stopped engaging in because of their mood. Specifically, we will introduce a Task Sharing modification, which will allow clinicians and care managers to more efficiently share the tasks involved in BA. These modifications will be based on clinician and care manager feedback from Phases 1 and 2 of this study.
62388853|NCT04384276|EXPERIMENTAL|Prospective Weigh Easy|"Patients enrolled onto this arm of the study will use the Weigh Easy system for weight tracking in the first three months of life. Weights will be measured in home using the Weigh Easy scale and transmitted to the study team via the Weigh Easy eClipboard message. A notification scheme will be activated for weights found to have plateaued or decreased to ensure that the infant's standard of care nutritionist and provider are able to follow up and recommend additional interventions to counteract the weight change.~After three months, families will complete a satisfaction survey to determine if the Weigh Easy system was preferable or if there are any improvements that could be made.~All other aspects of the patients' care will follow the standard of care for cleft and craniofacial diagnoses and will be guided by the nutritionists specializing in cleft and craniofacial care."
62388854|NCT04384276|OTHER|Retrospective Control Arm|Patients enrolled onto the control arm will have retrospectively presented to the Cleft and Craniofacial Clinic from January 1, 2016 to December 31, 2018 as infants. These patients were treated with the standard of care for cleft and craniofacial diagnoses and were followed by the nutritionists specializing in cleft and craniofacial care.
62560417|NCT03110237|EXPERIMENTAL|Fallproof Balance Training (BT) class|Group based balance training class based on the FallProof(TM) approach, 30 minute session , twice a week for three weeks
62560418|NCT05514015|EXPERIMENTAL|Intervention arm|rituximab combined with corticosteroids treatment group
62560419|NCT05514015|ACTIVE_COMPARATOR|Control arm|Rituximab monotherapy treatment
62560420|NCT01149863|EXPERIMENTAL|Plerixafor 17 hours prior to apheresis|Dosing of plerixafor will occur at 3PM (1500 hours).
62388855|NCT03327740||Subjects on DTG based ARV with ABC|These are subjects who begin a DTG based ARV regimen that includes ABC
62768673|NCT04480034||Group Rome|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UOC Chirurgia Generale \& Bariatric Center of Excellence IFSO-EC, University La Sapienza of Rome, Italy (Head Prof. Gianfranco Silecchia) will be collected in a prospective database, to monitor the postoperative course.
62768674|NCT02297165|EXPERIMENTAL|Program|olfactory stimulation program
62388856|NCT03327740||Subjects that start DTG based ARV regimen but without ABC|These are subjects who begin a DTG-based ARV regimen that does not contain ABC
62768675|NCT02297165|NO_INTERVENTION|Control|normal follow-up
62388857|NCT03327740||Subjects on other integrase inhibitor based regimen with ABC|These are subjects who begin other integrase inhibitor based regimens (RAL and EGV) that contains ABC
62768676|NCT00952614|EXPERIMENTAL|Retisert for Retinal Vein Occlusion|0.59 mg Fluocinolone Acetonide (Retisert implant) for Retinal Vein Occlusion
62388858|NCT03327740||Subjects on other integrase inhibitor based regimen but no ABC|These are subjects that start non-ABC containing RAL or EGV based regimens
62388859|NCT03327740||Subjects that start any other DTG based ARV regimen|These are subjects who begin any other DTG based ARV regimen that will include DTG as monotherapy or two-drug regimens
62388860|NCT04059328||Physicians in Haiti|7 OBGYN physicians underwent a laparoscopic training and simulation course and then were proctored as they performed 3 in vivo cases using a check list to help the participants remember all the steps of laparoscopic set-up.
62388861|NCT01369394|EXPERIMENTAL|Tailored information|Individuals assigned to the experimental group will receive individually-tailored educational messages.
62768677|NCT02308488|EXPERIMENTAL|Radiation Therapy|
62388862|NCT01369394|ACTIVE_COMPARATOR|Untailored information|Individuals assigned to the control group will receive generic, untailored educational messages.
62388863|NCT05620160|EXPERIMENTAL|RAY1216|Participants received 400mg RAY1216 tablet orally three times daily for 5 days.
62388864|NCT05620160|PLACEBO_COMPARATOR|Placebo|Participants received 400mg placebo orally three times daily for 5 days.
62388865|NCT01799291|OTHER|Treatment: Decision Making Tutorial|A brief presentation on mood disorders (i.e., Control condition) combined with the intervention (i.e., Treatment condition): a 20-minute training on decision-making errors and cognitive de-biasing strategies.
62388866|NCT01799291|NO_INTERVENTION|Control|A brief presentation about mood disorders.
62388867|NCT00012870|OTHER|Arm 1|
62388868|NCT04273620|EXPERIMENTAL|Intervention-Control (IC)|In the Intervention-Control (IC) arm, patients will first receive the intervention (OKS-READ) containing 15 individual therapy sessions within a maximum time period of 28 days. Afterwards they will receive the control therapy (again 15 sessions within max. 28 days).
62388869|NCT04273620|ACTIVE_COMPARATOR|Control-Intervention (CI)|In the Control-Intervention (CI) arm, patients will first receive the control therapy (15 sessions within max. 28 days), followed by the intervention phase (15 therapy sessions OKS-READ within a maximum time period of 28 days).
62388870|NCT00495274|EXPERIMENTAL|Healthy male subjects|In Part A each subject will participate in six sessions and will be administered, in randomized order, single doses of five new formulations (formulation B, C, D, E and F) of SB-649868 30 milligrams (mg), in fasted state and a single dose of the original formulation (formulation A), after a standard Food and Drug Administration (FDA) High-Fat breakfast. All dosing sessions will be separated by a washout session of at least 5 ± 2 days after each dose. In Part B a single dose of the selected SB-649868 30 mg formulation will be administered after a standard FDA High-Fat breakfast.
62388871|NCT03807336|EXPERIMENTAL|Experiential Condition|This group will receive an experiential version of the program Emotion-Focused Skills Training for Parents, meaning they will engage in tasks that are supposed to activate the parents emotional system, providing them with a deeper sense of understanding towards their child.
62388872|NCT03807336|ACTIVE_COMPARATOR|Psychoeducational version|This group will receive a non-experiential, psychoeducational version of the program Emotion-Focused Skills Training for Parents, meaning they will not engage in tasks that are meant to activate the parents emotional system.
62560421|NCT03859427|ACTIVE_COMPARATOR|Carfilzomib once-weekly|Carfilzomib, lenalidomide, dexamethasone (KRd) regimen using once-weekly carfilzomib 56 mg/m2
62560422|NCT03859427|ACTIVE_COMPARATOR|Carfilzomib twice-weekly|Carfilzomib, lenalidomide, dexamethasone (KRd) regimen using twice-weekly carfilzomib 27 mg/m2
62768678|NCT04649047|EXPERIMENTAL|Intervention|All participants will be assigned to the experimental group and receive a 3-weekly intervention via web and individual health coaching. The educational topics cover stress management, healthy eating, and physical activity
62768679|NCT03315377|ACTIVE_COMPARATOR|Lunate-Capitate Fusion (LCF)|Operation with a Lunate-Capitate Fusion (LCF) for SLAC or SNAC arthritis.
62768680|NCT03315377|ACTIVE_COMPARATOR|Four Corner Fusion (4CF)|Operation with a Four Corner Fusion (4CF) for SLAC or SNAC arthritis
62768681|NCT00980304|EXPERIMENTAL|Rituximab in combination with ICE as salvage therapy|
62388873|NCT03385395|EXPERIMENTAL|OctaAlpha1|
62388874|NCT03385395|ACTIVE_COMPARATOR|Glassia®|
62388875|NCT02160743|EXPERIMENTAL|CJ-30056 20mg/500mg|fasting, fed
62560423|NCT03342378||Oropharynx Cancer Patients|Patients with OPSCC will be treated with comprehensive head and neck RT to 70 Gy in 33 fractions with concurrent weekly cisplatin at 40 mg/m2 and at the University of Wisconsin.
62560424|NCT05533619||AKI Group|
62768682|NCT01188057|EXPERIMENTAL|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, single dose
62560425|NCT05533619||Non-AKI Group|
62768683|NCT01188057|ACTIVE_COMPARATOR|NIRAVAM TM|NIRAVAM TM 2 mg orally disintegrating tablets, single dose
62768684|NCT00846716|EXPERIMENTAL|Pioglitazone add on to SU or biguanide|
62768685|NCT00846716|ACTIVE_COMPARATOR|SU or Biguanide|
62768686|NCT05546255|EXPERIMENTAL|Eribulin Combined With Lobaplatin|Eribulin 1.4mg/m2 d1 Lobaplatin 25g/m2 d1 / q14d
62768687|NCT01940393|ACTIVE_COMPARATOR|Cetirizine|Cetirizine
62768688|NCT01940393|ACTIVE_COMPARATOR|Desloratadine|desloratadine
62768689|NCT01940393|ACTIVE_COMPARATOR|Fexofenadine|Fexofenadine
62768690|NCT01940393|ACTIVE_COMPARATOR|Ebastine|ebastine
61993549|NCT05090761|ACTIVE_COMPARATOR|SAPB with Mg and Buprenorphine|40 Patients - Patients will receive 30 mL of 0.25% bupivacaine with 150 mg of Mg and 300 mcg of buprenorphine injected below the serratus anterior muscle in the caudal direction using ultrasound guidance.
61993550|NCT04372602|EXPERIMENTAL|Duvelisib|-Duvelisib 25 mg twice daily for up to 10 days.
62768691|NCT01940393|ACTIVE_COMPARATOR|Bilastine|bilastine
61993551|NCT04372602|SHAM_COMPARATOR|Placebo|-Placebo 25 mg twice daily for up to 10 days.
61993552|NCT05420246||These cases were given the treatment regimen including Ainuovirine|These cases were given the regimen including Ainuovirine (150mg, oral,qd)
61993553|NCT05400616|EXPERIMENTAL|Intervention|For each nostril, the donated nasal wash sample is quiesced to 15 mls with saline Nasal Microbiota Transplant therapy.
61993554|NCT05400616|PLACEBO_COMPARATOR|Control|For each nostril, 15 mls of saline will be used as the placebo therapy.
61993555|NCT00113659|ACTIVE_COMPARATOR|1|Participants in this arm will receive Lactobacillus GG.
62560426|NCT01709500|EXPERIMENTAL|Alirocumab 75 mg/up to 150 mg|Alirocumab 75 mg every two weeks (Q2W) added to stable dose of statin with or without LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL at Week 8.
62560427|NCT01709500|PLACEBO_COMPARATOR|Placebo|Placebo matched to alirocumab SC injection for 78-week treatment duration.
62560428|NCT04176250|EXPERIMENTAL|TBA-7371 100 mg QD|
62560429|NCT04176250|EXPERIMENTAL|TBA-7371 100 mg BID|
61993556|NCT00113659|PLACEBO_COMPARATOR|2|Participants in this arm will receive a placebo.
61993557|NCT00868712||1|Warfarin use \< 6 months
61993558|NCT00868712||2|Warfarin use 6-24 months
61993559|NCT00868712||3|Warfarin use \>24 months
61993560|NCT05311371|EXPERIMENTAL|Breathing exercise group|"The researcher will collect the data using Patient Information Form, Rhodes Index of Nausea, Vomiting and Retching Scale, Patient Diary for determining the number of nausea, vomiting, and retching episodes and the hours of breathing exercise of the patient, and Daily Nutritional Consumption Amount Form through face-to-face interview technique on the first day and for 14 days.~During chemotherapy and stem cell transplantation, antiemetic treatment included in the treatment protocol will be applied to the patients.~The patients will train about the application of breathing exercise by the researcher. They will be asked to do this breathing exercise with the guideline for at least 5 min in case of sensation of nausea and vomiting for 14 days."
61993561|NCT05311371|OTHER|Control group|"The researcher will collect the data using Patient Information Form, Rhodes Index of Nausea, Vomiting and Retching Scale, Patient Diary for determining the number of nausea, vomiting, and retching episodes and the hours of breathing exercise of the patient, and Daily Nutritional Consumption Amount Form through face-to-face interview technique on the first day. The researcher will continue to fill out Rhodes Index of Nausea, Vomiting and Retching Scale, Patient Diary for determining the number of nausea, vomiting, and retching episodes and the hours of breathing exercise of the patient, and Daily Nutritional Consumption Amount Form for 14 days.~During chemotherapy and stem cell transplantation, antiemetic treatment included in the treatment protocol will be applied to the patients."
61993562|NCT01467999|EXPERIMENTAL|Guanfacine|Guanfacine, 4mg given once daily
61993563|NCT04953533||patients with gout|"1. age:year of 25\~60;~2. consistent with the 2015 ACR gout diagnostic criteria ,and serum uric acid \>420umol/L;~3. The patient are willing to take part in our study."
61993564|NCT04953533||patients with hyperuricemia|"1. age:year of 25\~60;~2. A medical record in our hospital showed that the person is healthy, without key disease;~3. serum uric acid \>420umol/L without gout flares."
61993565|NCT04953533||healthy controls|"1. age:year of 25\~60;~2. A medical record in our hospital showed that the person is healthy, without key disease;~3. serum uric acid ≤420umol/L."
61993566|NCT04916795|EXPERIMENTAL|Vupanorsen 80 milligram (mg)|Participants will receive one, 0.8 milliliter (mL) subcutaneous injection with vupanorsen 100 mg/mL solution
61993567|NCT04916795|EXPERIMENTAL|Vupanorsen 160 milligram (mg)|Participants will receive two, 0.8 mL subcutaneous injections with vupanorsen 100 mg/mL solution
61993568|NCT06219460|EXPERIMENTAL|Cuffed face amsk|Ventilation using cuffed face mask
61993569|NCT06219460|EXPERIMENTAL|Uncuffed face mask|Ventilation using uncuffed face mask
61993570|NCT03491618|ACTIVE_COMPARATOR|PARALLEL|Thick canulae (18 gauge) placed parallel to Medial Branch under fluoroscopy.
61993571|NCT03491618|ACTIVE_COMPARATOR|PERPENDICULAR|Thin canulae (22 gauge) placed perpendicular to Medial Branch under fluoroscopy.
62388876|NCT02160743|EXPERIMENTAL|group 2|fed, fasting
62388877|NCT03288558|EXPERIMENTAL|Intervention Group|Subjects randomized to the intervention group will receive a comprehensive perioperative mechanical ventilation strategy that includes a bundle of protective settings (use of PEEP, recruitment maneuvers and continuation of mechanical ventilation during CPB).
62560430|NCT04176250|EXPERIMENTAL|TBA-7371 200 mg QD|
62560431|NCT04176250|EXPERIMENTAL|TBA-7371 100 mg TID|
62560432|NCT04176250|EXPERIMENTAL|TBA-7371 400 mg QD|
62560433|NCT04176250|ACTIVE_COMPARATOR|HRZE|
62560434|NCT02315911|NO_INTERVENTION|expectancy for mild-moderate OSA|6 months expectancy
62560435|NCT02315911|EXPERIMENTAL|ATE for mild-moderate OSA|adeno-tonsillectomy
62560436|NCT02315911|EXPERIMENTAL|ATE for severe OSA|adeno-tonsillectomy
62560437|NCT02315911|EXPERIMENTAL|APP for severe OSA|adeno-pharyngoplasty
62560438|NCT06394310|EXPERIMENTAL|Dry needling|Participants will complete three sessions of dry needling through three weeks (one session per each week)
62560439|NCT06394310|SHAM_COMPARATOR|Sham DN|Participants randomized to the control group will be receiving sham needling
62560440|NCT06583174||breastfeeding mothers|breastfeeding mothers
62560441|NCT01316081|EXPERIMENTAL|Antioxidant Group|500mg Vitamin C 400 I.E. Vitamin E 50 mcg Selenium
62560442|NCT01316081|PLACEBO_COMPARATOR|Placebo Group|identical appearing placebo supplements
62768692|NCT03123042|EXPERIMENTAL|Sentinel basin dissection|Intervention: Sentinel basin dissection
62768693|NCT05238259|OTHER|kinesiotaping|Kinesio tape is the name of an adhesive tape created by Kenzo Kase in Japan in 1973. Kinesiotaping is latex-free with 100% cotton fibers that has no pharmaceutical effect, designed to mimic the elasticity properties of the muscle, skin, and fascia. These properties make it resistant and wearable for a long period, in general, 3 to 5 days at a time; it is even water resistant.
62768694|NCT05238259|OTHER|wrist wheel|Wrist wheel is a therapy aid that exercises muscles in the wrist, forearm and shoulder. It utilizes exercises known as pronation and supination moving from pronation to supination exercises is made easy because of the wheel. It allows the patient to easily roll wrist back and forth focusing on the wrist and arm
61993572|NCT00165425|EXPERIMENTAL|Cardiac screening|"Interventions:~Participants will~* meet with study cardiologist~* undergo cardiac risk factors screening~* undergo resting and stress echocardiogram (echo and stress echo)"
62388878|NCT03288558|NO_INTERVENTION|Control Group|Subjects randomized to the control group will receive mechanical ventilation according to the current usual care.
62388879|NCT00085189|EXPERIMENTAL|Cohort I (melanoma peptide vaccine, Montanide ISA-51)|Patients receive multi-epitope peptide melanoma peptide vaccine with incomplete Freund's adjuvant and agatolimod sodium SC at 0, 2, 4, 6, 8, 10, 14, 18, 22, 26, 38, and 50 weeks and then every six months for two years for up to 16 vaccinations in the absence of disease progression or unacceptable toxicity.
62388880|NCT00085189|EXPERIMENTAL|Cohort II (melanoma peptide vaccine, Montanide ISA 51 VG)|Patients receive multi-epitope peptide melanoma peptide vaccine with Montanide ISA 51 VG and agatolimod sodium SC at 0, 2, 4, 6, 8, 10, 14, 18, 22, 26, 38, and 50 weeks and then every six months for two years for up to 16 vaccinations in the absence of disease progression or unacceptable toxicity.
62560443|NCT03856411|EXPERIMENTAL|Group TORIPALIMAB combined with standard chemotherapy|
62560444|NCT03856411|PLACEBO_COMPARATOR|Group Placebo combined with standard chemotherapy|
62560445|NCT03957044|EXPERIMENTAL|sensory integration group|This group was given the education of sensory integration with vestibular education.
62560446|NCT03957044|NO_INTERVENTION|Control group|The control group was given the education of sensory integration without vestibular education.
62560447|NCT04878029|EXPERIMENTAL|Treatment (cabozantinib, enfortumab vedotin)|Patients receive cabozantinib PO QD on days 1-28 and enfortumab vedotin IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62560448|NCT04072081|EXPERIMENTAL|Drug-coated ballon|Treatment of in suit coronary lesions with drug-coated balloon
62560449|NCT04072081|ACTIVE_COMPARATOR|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting stent
62560450|NCT03572686|SHAM_COMPARATOR|Group Ropivacaine High (RH)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.5% 20ml + N/S 1.6mL.
62560451|NCT03572686|PLACEBO_COMPARATOR|Group Ropivacaine Low (RL)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.25% 20ml + N/S 1.6mL.
62560452|NCT03572686|EXPERIMENTAL|Group Ropivacaine Low + Dexamethasone (RLD)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.25% 20ml + Dexamethasone 8mg (1.6mL).
62768695|NCT03254355|EXPERIMENTAL|Multimodal physiotherapy|12 weeks of weekly multimodal physiotherapy treatments
61993573|NCT00733044|EXPERIMENTAL|Specialized Care|Stepped-care cognitive behavioural approach with elements from tinnitus retraining therapy
61993574|NCT00733044|ACTIVE_COMPARATOR|Usual Care|Audiological diagnostics and intervention and, if necessary, one or more consultations with a social worker with a maximum of ten one hour session
61993575|NCT04342104||NIV|Patients on Bilevel NIV
61993576|NCT04342104||CPAP|Patients on CPAP
61993577|NCT01371097|NO_INTERVENTION|Control Group|
61993578|NCT01371097|EXPERIMENTAL|Treatment group|
62388881|NCT01262040|EXPERIMENTAL|pts having a thorascopic, laparoscopic or robotic procedure|The procedure will begin with washings (peritoneal) and two assessments of the extent of peritoneal disease. First, a four quadrant inspection of the peritoneal cavity under white light, this is the standard of care assessment. Then, a repeat four quadrant inspection of the peritoneal cavity under NBI will be done, this is the only experimental component of the design. White light imaging will always be done first, followed by NBI. For those patients scheduled for thorascopic procedures: The procedure will begin with sampling of pleural effusions when clinically indicated. Then there will be two assessments of the pleural surfaces. First, an inspection of the pleural cavity under white light, this is the standard of care assessment. Then, a repeat inspection under NBI, this is the only experimental component of the design. White light imaging will always be done first, followed by NBI.
62560453|NCT01708577|EXPERIMENTAL|IPANEMA validation without water intake|The one group is restricted to the water intake during the Indoor phase during testing the IPANEMA measurement system. The other group is not restricted to the water intake.
62560454|NCT01708577|EXPERIMENTAL|IPANEMA validation with water intake|The one group is restricted to the water intake during the Indoor phase, the other group is not restricted to the water intake.
62560455|NCT05383183|EXPERIMENTAL|Choline Alfoscerate 1,200mg + Donepezil 5mg or 10mg|Oral administration of choline alfoscerate 400mg TID, donepezil QD (evening) for 48 weeks, no dosage change during trial period
62560456|NCT05383183|PLACEBO_COMPARATOR|Placebo + Donepezil 5mg or 10mg|Oral administration of placebo TID, donepezil QD (evening) for 48 weeks, no dosage change during trial period
62560457|NCT04495829||Phorcides|Both eyes of subjects eligible for Contoura(R) topography-guided ablation with the Wavelight excimer laser, with surgery planned using Phorcides software.
62560458|NCT02005380||Text-based Task|This group is required to do the text-based task
62560459|NCT02005380||Graphic-based Task|This group is required to do the graphic-based task
62560460|NCT01894919|EXPERIMENTAL|2H3H511_V|In the parent study V72_28 (NCT01339923), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.
62560461|NCT01894919|NO_INTERVENTION|2H3H511_NV|In the parent study V72_28 (NCT01339923), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
62560462|NCT01894919|EXPERIMENTAL|3H5_11_V|In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.
62768696|NCT03254355|NO_INTERVENTION|Waiting-list control group|12 weeks of weekly full-body relaxation massage
62768697|NCT04353882||patients with tumor recurrence|
62768698|NCT04353882||patients with-out tumor recurrence|
62388882|NCT05261321|ACTIVE_COMPARATOR|Cannabis oil with a high ratio of THC to CBD|Participants will be given a single dose of oral cannabis oil containing 5mg THC and 0.17mg CBD.
62388883|NCT05261321|ACTIVE_COMPARATOR|Cannabis oil with a high ratio of CBD to THC|Participants will be given a single dose of oral cannabis oil containing 5mg THC and 25mg CBD.
62388884|NCT05261321|PLACEBO_COMPARATOR|Placebo|Participants will be given a single dose of 1 mL placebo (carrier oil with botanical terpenes) via oral route of administration.
62388885|NCT03023436|EXPERIMENTAL|CRS + HIPEC + Systemic Chemotherapy|"Cytoreductive surgery(CRS) followed by Hyperthermic Intraperitoneal Chemotherapy(HIPEC) and systemic chemotherapy will be performed for the treatment of patients assigned to this group.~CF regimens or other first line regimens based on Fluoropyrimidine and Cisplatin according to the National Comprehensive Cancer Network（NCCN） Guidelines （Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial."
62388886|NCT06496399|EXPERIMENTAL|trial|psychoeducation
62388887|NCT06496399|NO_INTERVENTION|control|standart care
62388888|NCT03757702||Fibromiyalgia group|women with FMS between 18-65 years of age and being volunteered.
62388889|NCT03757702||Healthy group|healthy women and being volunteereed
62388890|NCT02612194|EXPERIMENTAL|Cohort 1|c-MET high (\> 50%), RON null (0-9%)
62388891|NCT02612194|EXPERIMENTAL|Cohort 2|c-MET + (10-100%), RON + (10-100%)
62388892|NCT02612194|EXPERIMENTAL|Cohort 3|c-MET null (0-9%), RON + (10-100%)
62388893|NCT01289730|EXPERIMENTAL|Etanercept 25 mg|Etanercept 25 mg subcutaneously twice a week
62388894|NCT02444611|ACTIVE_COMPARATOR|Group 1|BCG vaccine, 0,05ml intradermally at birth
62388895|NCT02444611|ACTIVE_COMPARATOR|Group 2|BCG vaccine, 0,05ml intradermally at birth Hepatitis B vaccine, 5 micrograms, intramuscularly at birth
62560463|NCT01894919|NO_INTERVENTION|3H5_11_NV|In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
62560464|NCT01894919|EXPERIMENTAL|68_11_V|In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.
62560465|NCT01894919|NO_INTERVENTION|68_11_NV|In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
62388896|NCT02444611|ACTIVE_COMPARATOR|Group 3|Hepatitis B vaccine, 5 micrograms, intramuscularly at birth
62388897|NCT02444611|NO_INTERVENTION|Group 4|No birth vaccines
62388898|NCT01404884|EXPERIMENTAL|SUPRACOR|Treatment arm consisting of patients with history of myopia or myopic astigmatism who are also diagnosed with presbyopia.
62388899|NCT05568251|ACTIVE_COMPARATOR|Active tDCS combined with Cognitive Training|
62560466|NCT01894919|EXPERIMENTAL|02_2_5_V|In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.
62560467|NCT01894919|NO_INTERVENTION|02_2_5_NV|In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.
61993579|NCT02286193||Patients presenting to Community Resource Specialist (CRS)|Primary care patients who are referred or self-refer to the CRS for education and linkage to community resources that can help support health goals
61993580|NCT04483024|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62388900|NCT05568251|SHAM_COMPARATOR|Sham tDCS combined with Cognitive Training|
62388901|NCT02811367|EXPERIMENTAL|HPV self-test|Women will perform the HPV self-test.
62560468|NCT01894919|EXPERIMENTAL|02_6_10_V|In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.
62768699|NCT03372005|EXPERIMENTAL|Floorball|The subjects in this group are set to play floorball three times pr. week for 39 weeks.
61993581|NCT04483024|ACTIVE_COMPARATOR|Glucosamine|Glucosamine hydrochloride
61993582|NCT04483024|EXPERIMENTAL|Collagen hydrolysate|2g of hydrolyzed collagen II
62388902|NCT01230827|EXPERIMENTAL|CNTO 148 (Golimumab)|All patients will receive golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 12. Patients who have a clinical response at Week 16 and who are randomly allocated to golimumab, will receive 30 mg per square meter every 4 weeks through Week 48. Patients will continue to receive golimumab 30 mg per square meter after Week 48 in a long-term extension until Week 248. All patients will receive their fixed dose of commercial methotrexate throughout the study duration.
62560469|NCT01894919|NO_INTERVENTION|02_6_10_NV|In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.
62560470|NCT01894919|EXPERIMENTAL|NAIVE 123|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
62560471|NCT01894919|EXPERIMENTAL|NAIVE_4A|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
62560472|NCT01894919|EXPERIMENTAL|NAIVE_4B|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
62560473|NCT02555579|EXPERIMENTAL|Dietary Protein Counting & Free Fruits & Vegetables|Subjects will be educated on new simplified diet approach and phenylalanine levels will be monitored for 1 year, and will be compared to 12 months prior to study enrollment
62560474|NCT00584324|EXPERIMENTAL|Bispectral Index (BIS) 40|Target BIS 40
62560475|NCT00584324|EXPERIMENTAL|Bispectral Index (BIS) 60|Target BIS 60
62560476|NCT05359263|EXPERIMENTAL|Dapagliflozin 10 mg once daily|
62768700|NCT03372005|NO_INTERVENTION|Control|This group functions as a control group, that will continue the normal lifestyle throughout the study.
62768701|NCT05069324||Acromegaly patients not adequately controlled by any kind of SSAs monotherapy|Acromegaly patients not adequately controlled by any kind of SSAs monotherapy, requiring PEG in combination with SSAs or PEG monotherapy
62768702|NCT05069324||Acromegaly patients adequately controlled by medical treatment|Acromegaly patients adequately controlled by medical treatment, by any kind of SSAs or by PEG
61993583|NCT04483024|EXPERIMENTAL|Collagen hydrolysate + chicken extract|2g of hydrolyzed collagen II with chicken extract
61993584|NCT05022758||Participants treated with rivaroxaban|NVAF patients who were OAC-naïve (Have no record of Oral anticoagulation \[OAC\] therapy use in the January 2013 to December 2014) and newly initiated on rivaroxaban (defined as the index date) during the enrollment period from January 2015 to December 2017.
61993585|NCT05022758||Participants treated with warfarin|NVAF patients who were OAC-naïve (Have no record of Oral anticoagulation \[OAC\] therapy use in the January 2013 to December 2014) and newly initiated on warfarin (defined as the index date) during the enrollment period from January 2015 to December 2017.
61993586|NCT01391975|EXPERIMENTAL|Surveillance and proactive intervention|
61993587|NCT01391975|NO_INTERVENTION|Control and reactive intervention|
61993588|NCT06063486|EXPERIMENTAL|Arm I (C3 Complex/Bioperine)|Patients receive C3 complex/Bioperine PO BID for 12 months in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy at baseline and follow up, and collection of blood samples throughout the trial.
61993589|NCT06063486|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID for 12 months in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy at baseline and follow up, and collection of blood samples throughout the trial.
61993590|NCT00189228|EXPERIMENTAL|xolair|This is a single arm, parallel study examining differences of therapeutic outcomes of Xolair. Xolair is being examined as an intervention that might change the outcome of immunization.
61993591|NCT01865162|EXPERIMENTAL|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
62768703|NCT05069324||Healthy controls|Healthy volunteers matched with patients for age and sex
62768704|NCT02203955|ACTIVE_COMPARATOR|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally per day for 12 months
62768705|NCT02203955|PLACEBO_COMPARATOR|Maltodextrin|4 chews (maltodextrin) daily for 12 months
61993592|NCT05133999||Preterm infants|infants born at \<31 week's post-menstrual age (PMA) or ≤1250g of birth weight
61993593|NCT06495918|EXPERIMENTAL|OTX-TKI Re-dose|
61993594|NCT06495918|ACTIVE_COMPARATOR|Aflibercept 2mg on label|
61993595|NCT06495918|OTHER|Aflibercept 8mg high dose|
61993596|NCT01720433|EXPERIMENTAL|intervention|In the intervention group, in addition to the above, the patient was placed in the Trendelenburg position (30°) and a pulmonary recruitment maneuver utilized, consisting of two manual inflations to a maximum pressure of 60 cm H2O. This was performed by the Anaesthetist, who held each positive pressure inflation for five seconds, with the valves on the operative ports fully open.
61993597|NCT01720433|NO_INTERVENTION|control arm|In the control group residual carbon dioxide pneumo-peritoneum was evacuated at the end of the procedure by passively allowing the abdomen to decompress by opening the operative ports.
61993598|NCT03255343|EXPERIMENTAL|IMDENDRIM|
61993599|NCT05546684|EXPERIMENTAL|foot bath|Individuals who apply to the urology service for TURP or TURM will be informed about the study 1 day before the surgery, and the questions in the patient introduction form will be asked to the patients who declared that they agreed to participate in the study in written and verbal form. On the morning of the surgery, the RCSQ will be applied to the patients to determine the preoperative sleep quality, and the Patient follow-up form will be applied to determine the confounding factors that may affect the sleep. The patient's feet will be kept in the footbath device for ten minutes. After the foot bath, the patient's feet will be completely dried with a towel and the existing socks and anti-embolic socks will be put on again. On the morning of the 1st postoperative day, the patient will be asked the questions in the RCSQ and the follow-up form, and the data collection process of the study will be terminated.
61993600|NCT05546684|NO_INTERVENTION|Control Group|After informing the individuals who applied to the urology service for TURP or TURM about the study, the researcher will receive their informed consent in written form. The information required for the study of the patients in the control group 1 day before the operation will be recorded in the Patient Information Form by the service nurse. On the morning of the surgery, the RCSQ will be applied to the patients to determine the preoperative sleep quality and the Patient follow-up form will be applied to determine the confounding factors that may affect sleep. In the morning of the first day after the surgery, the RCSQ will be applied to the patients to determine the sleep quality on the postoperative day 0, and the Patient follow-up form will be applied to determine other possible factors that may affect sleep, and the data collection process of the study will be terminated. No foot bath application will be in question for the patients in the control group.
61993601|NCT05360563|EXPERIMENTAL|Physical training group|In addition to receive regular medical care, the physical training group will participate in a tailored home-based exercise program (remotely supervised by healthcare professionals).
61993602|NCT05360563|NO_INTERVENTION|Control group|The control group will receive regular medical care.
62560477|NCT05359263|PLACEBO_COMPARATOR|Placebo once daily|
62768706|NCT05556538||Those who had TFESI and whose subcutaneous fat index was above the cut-off value|Those who are above the subcutaneous fat index cut-off values (9.4 mm in men, 8.45 mm in women) will be included in this group.
62768707|NCT05556538||Those who had TFESI and whose subcutaneous fat index was below the cut-off value|Those who are below the subcutaneous fat index cut-off values (9.4 mm in men, 8.45 mm in women) will be included in this group.
62768708|NCT02240316||Follicular NHL Cohort|
62768709|NCT02240316||DLBCL Cohort|
62768710|NCT02791412||unprotected left main|undergone percutaneous coronary intervention or coronary artery bypass graft
62768711|NCT02918708|ACTIVE_COMPARATOR|group 2 (Synflorix then Prevenar13)|PCV10 given at 2 and 4 months of age, PCV13 given at 12 months of age
62768712|NCT02918708|ACTIVE_COMPARATOR|group 1 (Prevenar13 only)|PCV13 given at 2,4 and 13 months of age
62768713|NCT04052776|ACTIVE_COMPARATOR|Buspirone|40mg
62768714|NCT04052776|ACTIVE_COMPARATOR|Levodopa-Carbidopa|400mg/100mg
62768715|NCT04052776|ACTIVE_COMPARATOR|Buspirone + Levodopa-Carbidopa|40mg + 400mg/100mg
62768716|NCT04052776|PLACEBO_COMPARATOR|Placebo|Mannitol pill
62768717|NCT03090347|EXPERIMENTAL|High-sugar diet|Participants will be asked to consume a relatively low-fat, high-carbohydrate eucaloric diet enriched in free-sugars (20% total energy).
62768718|NCT04454541|ACTIVE_COMPARATOR|Greater occipital nerve block with ultrasound|A-Greater occipital nerve block The ultrasound-guided GONB was performed to more accurately locate the nerve. The patient was asked to lie prone on the table. To locate the nerve, we searched for the occipital artery in the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp was cleaned with iodine. After that, the skin was sterilized, and the probe was sheathed in a sterile plastic package GONB was performed by applying the injection to the medial of the artery. A 22-gauge needle was advanced beneath the lateral border of the probe using real-time ultrasound guidance and an in-plane technique. In all patients the occipital nerve was seen medial to the artery. The injected side was determined by the patients' clinical symptoms and according to the painful side reported in their headache diaries. The patients were required to lie down for 30 minutes after the injection to avoid dizziness.
62768719|NCT04454541|EXPERIMENTAL|Multifidus cervicis plane block with ultrasound guided|Patients placed in a lateral position with their affected side upwards. Several gel cushions were placed under their head, neck, and arm to put the neck in a stable and slightly anterior flexion position spinal level was determined by identifying the transverse process of the seventh and sixth cervical vertebrae (C7 and C6). The seventh cervical transverse process (C7) differs from the levels above by having a rudimentary anterior tubercle and a prominent posterior tubercle. After aseptic preparation of the injection area, lidocaine 1% was used to anesthetize the skin. Under continuous ultrasound guidance, the needle (22-G, 0.7 mm × 60 mm, Plexufx, B-BRAUN, Tokyo, Japan) was introduced in-plane through the skin and advanced into the fascial plane between the multifidus cervicis and semispinalis cervicis muscles for the MCP block.
62768720|NCT04597671|EXPERIMENTAL|Arm A|Durvalumab with low-dose PCI
62768721|NCT04597671|ACTIVE_COMPARATOR|Arm B|Durvalumab with observation
62768722|NCT04287088|NO_INTERVENTION|Control|After IMPROD bpMRI all men undergo prostate biopsies. In men with Likert scores of 1-2, TRUS guided systematic biopsies are performed. In men with Likert 3-5 score, in addition to systematic biopsies, two targeted biopsies are taken from each lesion (up to two lesions).
62768723|NCT04287088|EXPERIMENTAL|Intervention|After IMPROD bpMRI prostate biopsies are performed according to shared decision-making by the treating urologist and the patient. If biopsies are to be performed, in men with IMPROD bpMRI likert scores of 1-2, 12-core systematic TRUS guided biopsies are performed and in men with Likert 3-5 score lesions systematic biopsies are performed and two targeted biopsies are taken from each lesion (up to two lesions). If biopsies are not performed, men are referred for a PSA follow-up.
61993603|NCT02596854|EXPERIMENTAL|Neurological MRI|Images acquired for post processing with synthetic software. This is a crossover design where all subjects receive the same imaging scan, and comparison is done between the raw conventional scan and post-processed images using the research software.
62560478|NCT06318520|EXPERIMENTAL|Arm 1|Calcium silicate based resin cement
62560479|NCT06318520|EXPERIMENTAL|Arm 2|Resin modified glass ionomer cement
62768724|NCT02144831|ACTIVE_COMPARATOR|anti-thrombotic treatment|10 days of ASA (75-325 mg) + Clopidogrel (75mg) anti-thrombotic treatment
62768725|NCT02144831|ACTIVE_COMPARATOR|anti-thrombotic|30 days of ASA (75-325 mg) + Clopidogrel (75mg) anti-thrombotic treatment
62768726|NCT01621867|ACTIVE_COMPARATOR|pGM169/GL67A (CFTR Gene/Lipid Vector)|
62560480|NCT03224312||Primary aldosteronism|screened, confirmed and subtyped according to the guidelines.
62768727|NCT01621867|PLACEBO_COMPARATOR|Placebo|
61993604|NCT03198377|EXPERIMENTAL|TENS: Randomized frequency modulation|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
62768728|NCT05208775|EXPERIMENTAL|PDT group|After enrollment, patients were injected with photosensitizer at a dose of 2mg/kg, and received photodynamic irradiation 48 hours later.
62768729|NCT05208775|ACTIVE_COMPARATOR|ESD group|Patients received standard ESD treatment after enrollment
61993605|NCT03198377|EXPERIMENTAL|TENS: Scan 6/6 of frequency modulation|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
61993606|NCT03198377|EXPERIMENTAL|TENS: Fixed frequency|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
61993607|NCT03198377|SHAM_COMPARATOR|TENS: Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
62560481|NCT03224312||Essential hypertension|screened for PA and excluded the diagnosis of PA as well as other secondary hypertesion
62560482|NCT02021981||Observational Group 1|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
62560483|NCT02021981||Observation Group 2|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
62560484|NCT02021981||Observation Group 3|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
62560485|NCT02021981||Observation Group 4|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
62768730|NCT00777699|EXPERIMENTAL|1|
61993608|NCT03893552|EXPERIMENTAL|Patient with sleep disordered breathing symptoms|Patients referring to the clinic of sleep disorders will be asked to participate in this study. A negative expiratory pressure will be applied via a cough-assist attached to a facial mask.
61993609|NCT06071455|EXPERIMENTAL|Platelet-rich Fibrin|A 20 ml blood sample will be drawn from the median cubital vein into a PRF tube. Centrifugation will be done at 700 rpm for 3 minutes and the liquid of PRF will be suctioned out using a separate syringe. PRF will be injected distal to the canine on the experimental side three times; at the beginning of canine retraction (T0), 1 month after the start of canine retraction (T1), and 2 months after the start of canine retraction (T2).
62388903|NCT01230827|PLACEBO_COMPARATOR|Placebo|All patients will receive golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 12. Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive placebo every 4 weeks through Week 48. However, patients receiving placebo and who will have lack/loss of clinical response will be eligible to receive golimumab 30 mg per square meter every 4 weeks through Week 48. At Week 48, patients do not have a clinical response will begin to receive golimumab 30 mg per square meter in a long-term extension until Week 248 and patients who have a clinical response will be discontinued from the study. All patients will receive their fixed dose of commercial methotrexate throughout the study duration.
62768731|NCT04152213|EXPERIMENTAL|Low GI diet group|"The components of the Low GI diet group include:~(1) A one-off, 60-minute, face-to-face, educational session conducted by the research nurse for GI knowledge input. (2) An informational booklet will be given out during the education session. (3) Three follow-up telephone calls of fifteen minutes will be conducted by the research nurse at the 2nd, 5th , and 8th weeks after completing the face-to-face education session."
62388904|NCT03570476|EXPERIMENTAL|Treatment (olaparib, radical prostatectomy)|Participants receive olaparib orally twice daily for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.
62388905|NCT02081664|OTHER|Lifestyle intervention|life-style oriented group program together with an individualized treatment program using therapies out of the spectrum of Complementary and Alternative Medicine (CAM)
62388906|NCT05150925|EXPERIMENTAL|Immediate mobilization after distal radius fracture treated with volar locking plate|
62388907|NCT05150925|ACTIVE_COMPARATOR|2 weeks cast immobilization after distal radius fracture treated with volar locking plate|
62560486|NCT02021981||Observation Group 5|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
62560487|NCT02021981||Observation Group 6|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
62560488|NCT02021981||Observation Group 7|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
62768732|NCT04152213|PLACEBO_COMPARATOR|Control group|"The components of the control group include:~(1) Pamphlets from the Department of Health about obesity and a balanced diet based on the food pyramid will be distributed. (2)Three follow-up telephone calls of fifteen minutes will be conducted by the research nurse at the 2nd, 5th , and 8th weeks after receiving the pamphlets."
61993610|NCT06071455|EXPERIMENTAL|Vitamin D3|Subjects will receive vitamin Dꝫ injection distal to the canine on the experimental side three times; at the beginning of canine retraction (T0), 1 month after the start of canine retraction (T1), and 2 months after the start of canine retraction (T2).
61993611|NCT03932396||Single group of subjects who fulfill the inclusion criteria|All the population condemned to a non-custodial sentence that is presented in the Service of Management of Penalties and Alternative Measures of the Center of Social Insertion (CIS) José Hierro CP Dueso during the study period (March 2019 and March 2021) , with ages between 18 and 79 years (approximately 1000 people / year) and willing to participate (signs the IC).
61993612|NCT04931056||Facial Plating|Patients undergoing surgical procedures for facial reconstruction for whom Biomet Microfixation titanium plates (or Ti mini plates) were utilized for the repair.
61993613|NCT04931056||Mandibular Plating|Patients undergoing surgical procedures for mandibular reconstruction, including TMJ, for whom Biomet Microfixation titanium plates (or Ti mini plates) were utilized for the repair.
61993614|NCT04931056||HTR-PEKK (midface)|Patients undergoing surgical procedures for midface reconstruction using custom-made prostheses manufactured on PEEK material.
62388908|NCT03495999||Normouricemia|Serum uric of 7mg/dl or less in men or 6mg/dl or less in women
62388909|NCT03495999||Hyperuricemia|Serum uric of 7mg/dl or more in men or 6mg/dl or more in women
62388910|NCT05661500|EXPERIMENTAL|Creative Darama Group|"Postmortem care content including The concept of death, Postmortem Care, Postmortem Care and Postmortem Care Practices will be given to the students in the Creative Darama group in six sessions consisting of the preparation/warm-up, animation and evaluation stages of creative drama."
62388911|NCT05661500|ACTIVE_COMPARATOR|Classical Education Group|"Theoretical training titled Post-Death Care and The Concept of Death, Post-Death Changes, Post-Death Care and Post-Death Care Practices will be conveyed to the students in the classical education group by the researcher using the method of direct expression. After the theoretical training, the students will be taken to the application laboratory and post-mortem care applications will be explained with the demonstration method."
62560489|NCT02021981||Observation Group 8|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
62768733|NCT03204890|EXPERIMENTAL|TPTNS|Transcutaneous Posterior Tibial Nerve Stimulation
62768734|NCT02952560||High resolution CT Scan of the head and neck|Patients scheduled for high resolution computerized tomography (CT scan) of the head and neck as part of their medical investigation of thyroid or laryngeal disorders will be recruited for this study.
62768735|NCT05116696||Chronic limb-threatening ischemia (CLTI) group|All CLTI patients presenting with wound, ischemia, foot infection (WIfI) stage IV disease consecutively treated at one institution
62768736|NCT05116696||Colorectal liver metastases (CRLM) group|All CRLM patients presenting with wound, ischemia, foot infection (WIfI) with stage IV disease consecutively treated at one institution
62768737|NCT05052619|EXPERIMENTAL|Preventive use of advanced antibiotics group|Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
62768738|NCT05052619|OTHER|Routine group|Treat patients in this group with routine preventive usage of antibiocs: Cefmetazole 1g q12h, in postoperative days 1-3.
62768739|NCT04836988||Digitally delivered osteoarthritis treatment|Participants enrolled in the digitally delivered osteoarthritis managament program (Joint Academy register)
62768740|NCT04836988||Face-to-face delivered osteoarthritis treatment|Participants enrolled in the face-to-face delivered osteoarthritis managament program (BOA-register)
62768741|NCT05539209|ACTIVE_COMPARATOR|The Standard Helpline Care (SC) group|The SC group will receive standard Oklahoma Smoking Cessation Helpline care AND complete daily check-ins and weekly surveys for 27 weeks.
62768742|NCT05539209|ACTIVE_COMPARATOR|OKquit group|The OKquit group will receive SC plus daily check-ins and weekly surveys for 27 weeks. In addition, the OKquit group will receive tailored smoking cessation messages in the smartphone application following completion of each survey. Further, the OKquit group will have access to on-demand smoking cessation content through the app.
62768743|NCT01027260|ACTIVE_COMPARATOR|Itopride 50 mg|
62768744|NCT01027260|ACTIVE_COMPARATOR|Itopride 100 mg|
62768745|NCT01027260|PLACEBO_COMPARATOR|Placebo|
62768746|NCT06040281|EXPERIMENTAL|Intervention|App-assisted three-week comprehensive rehabilitation individual support in nutrition and exercise
62768747|NCT06040281|ACTIVE_COMPARATOR|Control|usual care App-assisted
62768748|NCT04590209|EXPERIMENTAL|Acrosyndrome|"The blood sample, skin biopsy and other biological samples will be taken from patients~The precise description of the semiology of skin lesions, their topography, as well as the analysis of the entire skin integument and mucous, cardiac and pulmonary auscultation and neurological examination will be done as required."
62768749|NCT00096018|EXPERIMENTAL|Dose escalation|Thalidomide (100 mg/day, 200 mg/day, or 300 mg/day) on Day 1 followed by Fludarabine 25 mg/m2/day for 5 days starting on Day 7 (cycle = 28 days
62768750|NCT01039298|ACTIVE_COMPARATOR|A|"All subjects in this study will receive surgery to treat their oral lesions. The margins (or boundaries) of the tissue to be removed during surgery will be defined by 2 different procedures (or study arms) in the operating room.~The Control arm. Surgical boundaries for oral lesions will be defined under regular white light."
62768751|NCT01039298|EXPERIMENTAL|B|"All subjects in this study will receive surgery to treat their oral lesions. The margins (or boundaries) of the tissue to be removed during surgery will be defined by 2 different procedures (or study arms) in the operating room.~The FV arm (experimental arm). Surgical boundaries for oral lesions will be defined by FV."
61993615|NCT03621228|EXPERIMENTAL|MindfulGarden|Standard care + exposure to an interactive digital device
61993616|NCT03621228|NO_INTERVENTION|Control|Standard care only
62388912|NCT06145269|ACTIVE_COMPARATOR|New oral anticoagulant (rivaroxaban)|We will use (rivaroxaban) 15 mg oral tablets twice a day, After 21 days: Should transition to 20 mg orally once a day untill we complete 6 months from the starting the treatment.
62388913|NCT06145269|ACTIVE_COMPARATOR|Marevan (warfarin)|Initiate warfarin on day 1 or 2 of parenteral anticoagulation therapy (eg, LMWH or unfractionated heparin) Overlap warfarin and parenteral anticoagulant for at least 5 days until desired INR (\>2.0) maintained for 24 hours, then discontinue parenteral therapy and continue only with (warfarin) tablets 5 mg/day for 6 months.
62768752|NCT01268215|EXPERIMENTAL|A (two study drugs group)|The standard management + two study drugs (endotracheal instillation of a mixture containing budesonide and Infasurf)
62768753|NCT01268215|ACTIVE_COMPARATOR|B (one study drug group)|The standard management + one study drug (endotracheal instillation of Infasurf only).
62768754|NCT01268215|SHAM_COMPARATOR|C (no study drug group)|The standard management only.
62768755|NCT04772144|EXPERIMENTAL|Intervention group|
62768756|NCT04772144|NO_INTERVENTION|Control group|
62768757|NCT00514020|EXPERIMENTAL|Treatment|
62768758|NCT05389215|EXPERIMENTAL|DWN12088 Xmg Tablet (BID)|PRS inhibitor
62768759|NCT05389215|PLACEBO_COMPARATOR|Placebo 0mg Tablet (BID)|Placebo
62768760|NCT01650415|EXPERIMENTAL|Erythropoietin and Rehabilitation|recombinant human erythropoietin injection and active rehabilitation
62768761|NCT01650415|PLACEBO_COMPARATOR|Placebo and Rehabilitation|Placebo erythropoietin and rehabilitation
62768762|NCT04248894|EXPERIMENTAL|High-intensity interval training (HIIT)|High-intensity interval training (HIIT) = the exercise of high intensity perform on a cycle ergometer, three times per week for 12 weeks, and training sessions were matched for energy expenditure (i.e., an isocaloric energy expenditure of 200 Kcal/session). The intensity of the HIIT session was established based on the HR and workload levels corresponding to 5% above the respiratory compensation point.
62768763|NCT04248894|EXPERIMENTAL|Moderate-intensity continuous training (MICT)|Moderate-intensity continuous training (MICT) = the exercise of moderate intensity perform on a cycle ergometer, three times per week for 12 weeks, and training sessions were matched for energy expenditure (i.e., an isocaloric energy expenditure of 200 Kcal/session). The intensity of the MICT session was established based on the HR and workload levels corresponding to anaerobic threshold and respiratory compensation point
62768764|NCT04248894|SHAM_COMPARATOR|No training|The patients are instructed to avoid any regular exercise program or any non-supervised exercise protocol during the study.
62768765|NCT00002807|NO_INTERVENTION|Observation|
62768766|NCT00002807|EXPERIMENTAL|Radiation|Post-operative pelvic radiation therapy (45 Gy in 25 fractions over 5 weeks)
62768767|NCT00775333||1|Patients with diabetes and carpal tunnel syndrome
62768768|NCT00775333||2|Non-diabetic patients with carpal tunnel syndrome
62768769|NCT05330793|OTHER|: Oral probiotic lozenges + placebo toothpaste (toothpaste without ADP-1)|1 active oral probiotic with placebo toothpaste
62768770|NCT05330793|ACTIVE_COMPARATOR|Oral probiotic lozenges + toothpaste with ADP-1|Oral probiotic and ADP1 toothpaste
62388914|NCT04073680|EXPERIMENTAL|Serabelisib|"Part 1 is dose escalation of Serabelisib Cohort 1 = 600mg; Cohort 2 = 900mg; Cohort 3 = 1200mg~Part 2 is expansion of mutational cohorts with selected dose as follows:~Cohort 4 = PIK3CA-mutated breast cancer; Cohort 5 = PIK3CA-mutated Non breast cancer; Cohort 6 = KRAS mutated"
62388915|NCT00638651|ACTIVE_COMPARATOR|1|The tattoo will be treated with laser and imiquimod 5% cream
62388916|NCT00638651|PLACEBO_COMPARATOR|2|The tattoo will be treated with laser and placebo topical cream
62388917|NCT05151549|EXPERIMENTAL|Camrelizumab , Cisplatin or Carboplatin|Participants will be given intravenous administration of Camrelizumab (200mg) ,Cisplatin(40mg/m²) or Carboplatin(AUC 2) and Radiotherapy. After completing 17 cycles of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until one year.
62388918|NCT02793531|EXPERIMENTAL|Healthy matched controls|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
62388919|NCT02793531|EXPERIMENTAL|Cancer subjects|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
62388920|NCT03289442|EXPERIMENTAL|supine position group|
62388921|NCT03289442|NO_INTERVENTION|left lateral position|
62388922|NCT06017349|EXPERIMENTAL|Non-invasive glucose meter|The noninvasive glucose meter was entrained on the finger, Glucose concentration levels were measured by measuring physiological parameters related to metabolic heat and local oxygen supply.
62388923|NCT06017349|ACTIVE_COMPARATOR|Accu-Chek Guide blood glucose meter|Being used for quantitative determination of blood glucose concentration in fresh capillary whole blood taken from fingers.
62388924|NCT06017349|ACTIVE_COMPARATOR|EKF Biosen C-Line|Using the hexosyl enzymatic method to detect plasma glucose values
62388925|NCT03955731|OTHER|Single study arm|STEMI Patients treated with Magmaris resorbable magnesium scaffold
62388926|NCT00270816|EXPERIMENTAL|interferon beta cyclical administration|Interferon ß-1b Treatment by Cyclical Administration
62388927|NCT00270816|ACTIVE_COMPARATOR|Interferon ß-1b Treatment|Interferon ß-1b Treatment
62388928|NCT01017211|EXPERIMENTAL|auricular acupuncture protocol|
62388929|NCT01017211|SHAM_COMPARATOR|sham auricular acupuncture|
62388930|NCT02528461||Sofosbuvir|"All patients receiving Sofosbuvir based treatment regimes during the study period will be included in the study.~All patients will receive all interventions (galactose elimination capacity test, gastroscopy, fibroscan), except liver biopsy which the patients may decline to participate in without affecting the participation in the rest of the study. If varices are found during the gastroscopy a liver vein catheterization will be performed."
62768771|NCT05330793|PLACEBO_COMPARATOR|Placebo lozenges (lozenges without oral probiotics) + placebo toothpaste (toothpaste without ADP-1)|Placebo without oral probiotics or ADP1 toothpaste
62388931|NCT04449185|EXPERIMENTAL|HP eradication group|"HP eradication group~Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days"
62388932|NCT00720291|ACTIVE_COMPARATOR|Metronidazole|Subjects who are randomly assigned to receive metronidazole 500 mg po for a period of 7 days following diagnosis of asymptomatic BV.
62388933|NCT00720291|PLACEBO_COMPARATOR|Placebo|Subjects who are randomly assigned to receive a placebo for a period of 7 days following the diagnosis of asymptomatic BV.
62388934|NCT01500538|EXPERIMENTAL|Eltrombopag and vorinostat combination therapy|Daily oral intake of 400mg vorinostat if necessary with combination therapy eltrombopag commencing at 50mg per day increasing to a maximum of 200mg per day
62388935|NCT05217004|EXPERIMENTAL|Dementia Talk|Participants in this group will be asked to use the mobile app Dementia Talk over a 2-week period.
62768772|NCT02554214|EXPERIMENTAL|Glafkos device|
62388936|NCT05217004|EXPERIMENTAL|CLEAR Dementia Care|Participants in this group will be asked to use the mobile app CLEAR Dementia Care over a 2-week period.
62388937|NCT05217004|NO_INTERVENTION|Waitlist Control Group|Participants in this group will not use any of the apps.
62388938|NCT00207363|EXPERIMENTAL|Initial induction therapy|Receive Peg Intron 3.0mcg/kg/wk for 12 weeks followed by Peg Intron 1.5 mcg/kg/wk for 36 weeks
62388939|NCT00207363|ACTIVE_COMPARATOR|Standard of Care|Peg Inter 1.5mcg/kg/wk for 48 weeks
62388940|NCT03410641||Diet and antismoking advice|Dietary and antismoking advice, aiming to reduce participant's risk of cardiovascular diseases
62768773|NCT04986280||Single Arm|Arm 1 - All patients will undergo PET/CT with 18F-PSMA-1007
62768774|NCT05386212||control|regular nursing care instructions
62388941|NCT03410641||Control|No intervention
62388942|NCT01593800|EXPERIMENTAL|open label probiotics|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
62388943|NCT02265575|EXPERIMENTAL|hyaluronic acid|Rehydration using hyaluronidase-assisted subcutaneous infusion
62768775|NCT05386212||Expirement|web app healthcare instructions for relieving back pain
62768776|NCT02412709|EXPERIMENTAL|Parent Performing ECG (PPE)|Parent Performing ECG (PPE) Group--When the baby is 2 weeks old, research staff will contact interested parents to schedule a home visit. During the visit, a research assistant will provide the parents with a kit that includes the QTScreen system and instructions. The parents will perform an ECG on their child using the QTScreen and instructions. If after attempting the ECG on their own parents encounter problems, parents can ask the research assistant for assistance.
62768777|NCT02412709|ACTIVE_COMPARATOR|Staff Performing ECG (SPE)|Staff Performing ECG (SPE) Group--When the baby is 2-4 weeks of age, research staff will contact the family to schedule a home visit. The QTScreen test will be done by a research assistant.
62768778|NCT01904656|EXPERIMENTAL|Arm I|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
62560490|NCT02021981||Observation Group 9|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
62560491|NCT02021981||Observation Group 10|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
62768779|NCT01904656|ACTIVE_COMPARATOR|Arm II|"Participants are exposed to a Healthy Eating Peaches!- media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
62768780|NCT06242223|ACTIVE_COMPARATOR|Multimodal HIIT|multimodal HIIT protocol followed by sprinting
62388944|NCT02587845|ACTIVE_COMPARATOR|IV group|Intravenous tranexamic acid injection Group IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
62388945|NCT02587845|EXPERIMENTAL|Topical group|Intra-articular tranexamic acid injection Group Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
62560492|NCT01878357|EXPERIMENTAL|DHP monthly|Three mass screening and selective treatment using dihydroartemisinin-piperaquine and primaquine i.e. on month 1 (MST1), month 2 (MST2), and month 3 (MST3) with an interval of 6 weeks between each MST
62560493|NCT01878357|EXPERIMENTAL|DHP bi-monthly|Two mass screenings and selective treatment using dihydroartemisinin-piperaquine and primaquine i.e. on month 1 (MST1) and month 3 (MST3) with an interval of 3 months.
62388946|NCT03000920|NO_INTERVENTION|1_Control|Classic screening invitation strategy with at least an invitation mail and then one or two reminder by mail if necessary.
62388947|NCT03000920|EXPERIMENTAL|2_SMS Reminder 1|Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
62560494|NCT01878357|NO_INTERVENTION|Arm 3|Without MST
62560495|NCT00499005|ACTIVE_COMPARATOR|Primi|
62560496|NCT00499005|ACTIVE_COMPARATOR|Multi|
62560497|NCT00613769|ACTIVE_COMPARATOR|ordinary per operative prophylaxis|cefuroxime(1500mg) i.v.+ metronidazole (1500mg)i.v.given at the time point of induction of anesthesia
62560498|NCT00613769|EXPERIMENTAL|Per oral alternative|Trimethoprim-sulfamethoxazole(160mg/800mg)p.o.+metronidazole (1200mg)p.o.given 06.00 am on the day of operation
62560499|NCT03982732||Women vaccinated at less than 24 weeks|Women receiving a pertussis containing vaccine at less than 24 weeks
62560500|NCT03982732||Women vaccinated at 24-27+6 weeks|Women receiving a pertussis containing vaccine at 24-27+6 weeks
62560501|NCT03982732||Women vaccinated at 28-31+6 weeks|Women receiving a pertussis containing vaccine at 28-31+6 weeks
62388948|NCT03000920|EXPERIMENTAL|3_SMS before invitation|One SMS a few days before the Invitation by mail and then one or two reminder(s) by mail if necessary.
62560502|NCT00794768|EXPERIMENTAL|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
62560503|NCT00794768|EXPERIMENTAL|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
62768781|NCT06242223|EXPERIMENTAL|conventional HIIT|Conventional protocol with 4-5 repetitions of 40 seconds maximum running
62388949|NCT03000920|EXPERIMENTAL|4_SMS before invitation + SMS Reminder 1|One SMS a few days before the Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
62560504|NCT01332487||Early initiation of 5ARI therapy|Patients starting 5ARI therapy within 30 days of initiating AB therapy
62388950|NCT04589260|EXPERIMENTAL|TD-1058|"Part A (SAD): 6 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive a single dose of TD-1058~Part B (MAD): 6 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive multiple dose of TD-1058~Part C (IPF subjects): 8 out of 12 subjects per cohort (up to 2 cohorts) will be randomized to receive multiple dose of TD-1058~Part D (Healthy Subjects): 6 subjects (1 cohort) will receive a single dose of TD-1058. After receipt of initial dose, subjects will recieve infusion of radiolabeled TD-1058 microtracer."
62560505|NCT01332487||Delayed initiation of 5ARI therapy|Patients starting 5ARI therapy more than 30 days but less than 6 months from the initiation of AB therapy
62560506|NCT05981690|EXPERIMENTAL|Therapist guided, parent-led CBT for preadolescent children with OCD|6 to 8 sessions of therapist guided, parent-led CBT for preadolescent children with OCD
62560507|NCT03028428|EXPERIMENTAL|Placenta Derived Mesenchymal Stem Cell|Placenta Derived Mesenchymal Stem Cell administered into the knee joint once
62560508|NCT03028428|ACTIVE_COMPARATOR|sodium hyaluronate|Sodium hyaluronate administered into the knee joint once
62560509|NCT04305132||Depression|Subjects with depression treated with electroconvulsive therapy
62560510|NCT04305132||Healthy|Healthy subjects
62560511|NCT05832203|EXPERIMENTAL|Intervention|90 overweight/obese adults will be given counseling on planetary health diet, calorie restriction diet, and healthy lifestyle materials through a mobile app within 6 months
62768782|NCT00054691|EXPERIMENTAL|Iressa (ZD1839)|Iressa (ZD1839) 250 mg by mouth daily.
61993617|NCT06249282|EXPERIMENTAL|Treatment (carfilzomib, sotorasib)|Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 of each cycle and sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO at screening and undergo CT or MRI and collection of blood samples at screening and on study. Patients may undergo optional biopsies on study.
62768783|NCT03757754|EXPERIMENTAL|HPPH 2.5 mg/m2|HPPH 2.5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
62768784|NCT03757754|EXPERIMENTAL|HPPH 3 mg/m2|HPPH 3 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
62768785|NCT03757754|EXPERIMENTAL|HPPH 3.5 mg/m2|HPPH 3.5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
62768786|NCT03757754|EXPERIMENTAL|HPPH 4 mg/m2|HPPH 4 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
62388951|NCT04589260|PLACEBO_COMPARATOR|Placebo|"Part A (SAD): 2 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive a single dose of placebo~Part B (MAD): 2 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive multiple dose of placebo~Part C (IPF subjects): 4 out of 12 subjects per cohort (up to 2 cohorts) will be randomized to receive multiple dose of placebo"
62388952|NCT02662374|ACTIVE_COMPARATOR|Control|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid
62560512|NCT05832203|PLACEBO_COMPARATOR|Control|90 overweight/obese adults will be given counseling on balanced nutrition diet, calorie restriction diet, and healthy lifestyle materials through a mobile app within 6 months
62560513|NCT02642172|EXPERIMENTAL|ITF (Inulin/OFS 75/25)|16 gram/day of ITF (Inulin/OFS 75/25)
62560514|NCT02642172|PLACEBO_COMPARATOR|placebo|16 gram/day of maltodextrin (placebo)
62560515|NCT02201004|EXPERIMENTAL|tofogliflozin|Tofogliflozin administered once daily for 52 weeks. Insulin administered as base treatment.
62560516|NCT02201004|PLACEBO_COMPARATOR|placebo|Placebo administered once daily for 16 weeks. After 16-weeks, Tofogliflozin administered once daily for 36 weeks. Insulin administered as base treatment.
62560517|NCT02565680|PLACEBO_COMPARATOR|placebo|tablets of Xyzall 5mg/ day during 5 days + placebo 40mg/ day during 4 days
62768787|NCT03757754|EXPERIMENTAL|HPPH 5 mg/m2|HPPH 5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
62768788|NCT03757754|EXPERIMENTAL|HPPH 6 mg/m2|HPPH 6 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
62768789|NCT05407415|EXPERIMENTAL|Kardia Mobile Group|"The intervention arm will be given a KardiaMobile device synched to their smartphone at the time of enrollment. They will be instructed on proper device procedure and will use the device with the onset of potential AF-related symptoms or when requested to do so by their healthcare provider.~The device ECG recordings will be transmitted to participants physicians through MyChart who will incorporate this information into the patient's treatment as indicated.~Healthcare utilization will be assessed by having the participants in both groups complete a questionnaire asking how many times they used their KardiaMobile device (if randomized to this group) and how many office appointments, emergency department visits, and hospital admissions they had within that six-month period."
61993618|NCT03714048||Perioperative|
62560518|NCT02565680|EXPERIMENTAL|prednisone|tablets of Xyzall 5 mg/j during 5 days + prednisone 40 mg/ day during 4 days
62560519|NCT04575337||AD group|Dementia is diagnosed according to the 2011 NIA-AA criteria.
62768790|NCT05407415|NO_INTERVENTION|Standard of Care Group|"The standard of care group will follow their routine care for their atrial fibrillation.~Healthcare utilization will be assessed by having the participants in both groups complete a questionnaire asking how many times they used their KardiaMobile device (if randomized to this group) and how many office appointments, emergency department visits, and hospital admissions they had within that six-month period."
61993619|NCT03714048||Cardiogenic shock minus arrest|
62560520|NCT04575337||MCI group|aMCI diagnosed according to the criteria of 2004 Peterson.
62560521|NCT04575337||pre-MCI group|β-Amyloid positive or APOE ε4 carrier or complains of cognitive impairment; not up to MCI or cognitive impairment.
61993620|NCT03714048||Cardiogenic shock plus arrest|
62388953|NCT02662374|EXPERIMENTAL|Group 1|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid Extra soft toothbrush, brushing with saline bd
62388954|NCT02662374|EXPERIMENTAL|Group 2|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid Supersaturated Calcium Phosphate Spray, 5ml qid
62388955|NCT00464841|EXPERIMENTAL|1|Tsui test for combined spinal-epidural
62388956|NCT00464841|EXPERIMENTAL|2|Tsui test for intrathecal catheter
62560522|NCT04575337||Other neurodegenerative diseases|Frontotemporal Dementia; or Parkinson's disease
62560523|NCT04575337||Cognitive normal group|Individuals are with normal cognitive function and ≥ 60 years old.
62560524|NCT02873793||7/8 cases pure seminomas|
61993621|NCT03714048||Preventive|
61993622|NCT00543764||Pre pathway|Pre pathway
61993623|NCT00543764||Post pathway|Post pathway
61993624|NCT03667352|EXPERIMENTAL|Scalp & TAP Block (Group T)|Group T received 0.2% Ropivacaine + clonidine 1µg/kg mixture, for ipsilateral scalp block (10ml),TAP block under USG guidance (20ml) and intravenous saline 0.1ml/kg/hr (sham infusion) for continuous infusion.
61993625|NCT03667352|ACTIVE_COMPARATOR|Intravenous Fentanyl (Group C)|Group C received saline, for ipsilateral scalp block (10ml) and TAP block under USG guidance (20ml) and I.V fentanyl 1 µg/kg/hr as analgesic.
61993626|NCT02242851||Hypertensive patients|
61993627|NCT06458894|OTHER|There were no interventions|Give guidance on respiratory function exercise
61993628|NCT06458894|OTHER|Prerehabilitation|Give guidance on respiratory function exercise
62560525|NCT02873793||5 cases of non-seminoma|
61993629|NCT00066066|PLACEBO_COMPARATOR|Scaling and root planing alone|Full mouth scaling and root planing (SRP) alone plus a placebo pill taken twice daily for 2 weeks.
61993630|NCT00066066|ACTIVE_COMPARATOR|SRP + Metronidazole|Full mouth Scaling and Root Planing plus Metronidazole (MET) 250 mg tid x 14 days
62388957|NCT05223374||Assess the time to diagnosis from initial concern by EAC utilizing Canvas Dx|Time from initial concern to diagnosis when using Canvas Dx as part of the diagnostic process (Reported time to diagnosis)
62388958|NCT03860181|ACTIVE_COMPARATOR|Traditional Dermabond + subcuticular sutures - Surgeon 1|Subcuticular sutures with traditional Dermabond applied to incision.
62388959|NCT03860181|ACTIVE_COMPARATOR|Metal staples - Surgeon 2|Metal staples
62388960|NCT03860181|EXPERIMENTAL|Dermabond PRINEO - Surgeon 1|Dermabond PRINEO System
62388961|NCT03860181|EXPERIMENTAL|Dermabond PRINEO - Surgeon 2|Dermabond PRINEO System
62388962|NCT01464073|ACTIVE_COMPARATOR|arm 3 : Good Medical Practices|physical exercise at home monitored by telephone (achieving a minimum of 30 minutes per day)
62388963|NCT01464073|ACTIVE_COMPARATOR|arm 2 : 60% VO2peak|physical exercise at the intensity of 60% of VO2 peak. 4 times a week. duration will be adjusted for arm 1 and arm 2 have the same total energy expenditure by session.
62388964|NCT01464073|EXPERIMENTAL|arm 1 : LIPOXmax|physical exercise at the LIPOXmax intensity during 60 minutes. 4 times a week
62388965|NCT05539040|EXPERIMENTAL|Intervention|Right atrial GP ablation in addition to pulmonary vein isolation
62388966|NCT05539040|ACTIVE_COMPARATOR|Control|PVI alone with no GP mapping or ablation
62388967|NCT04245813|EXPERIMENTAL|Intervention|"Consists of 3 interdisciplinary educational sessions and Face-to-face with a fortnightly telephone follow-up and text messages. Each session will be directed by medical staff (cardiologist and / or physiatrist) and supported by other health professionals (physical therapist, occupational therapist, nutritionist and psychologist). The educational sessions, include the topics knowledge of the disease, recognition of alarm signs, pharmacological treatment, healthy lifestyle habits, mental health and regular aerobic exercise; The entire educational component will be based on the Colombian clinical practice guide for the prevention, diagnosis, treatment and rehabilitation of heart failure."
62388968|NCT04245813|NO_INTERVENTION|Control|Once the patient ends phase II of the cardiac rehabilitation program, he/she will receive the usual care, which consists of a 5-minute educational intervention by a physiatrist at the end of the functional test, where recommendations are given on healthy lifestyle habits, adherence to pharmacological treatment and regular aerobic exercise. This educational intervention will be performed after each of the functional tests (at the end of phase II of the program and during the follow-up of patients at months 1, 3, 6 and 12 during Phase III of the program) performing 5 educational interventions in total .
62388969|NCT01592773|EXPERIMENTAL|Memantine|"To maintain the blind of the preceding study, patients who participated in MEM-MD-68 (NCT01592747) began this study with 6 weeks of double blind dosing during which all patients were either titrated to or remained on their maximum target dosages. This was followed by up-to 42 weeks of open-label dosing.~Patients who took open-label memantine in study MEM-MD-67 (NCT01999894) or MEM-MD-91(NCT01592786), received up to 48 weeks of open-label memantine at their maximum tolerated weight based target dosage."
62388970|NCT00863434|EXPERIMENTAL|Treatment (colony stimulating factor and chemotherapy)|Patients receive G-CSF SC QD on days 1-5 and clofarabine IV over 1 hour and cytarabine IV on days 2-5. Beginning approximately 1 month later, patients may receive one additional course of treatment in the absence of disease progression or unacceptable toxicity.
62388971|NCT03402308|EXPERIMENTAL|Schisandra chinensis extract group|This group takes Schisandra chinensis extract for 12 weeks
62388972|NCT03402308|PLACEBO_COMPARATOR|Placebo group|This group takes placebo for 12 weeks
62388973|NCT05823155|EXPERIMENTAL|Detailed penicillin allergy evaluation during pre-operative care|This group will undergo a detailed penicillin allergy evaluation performed by an Infectious Diseases specialist. Patients with negative result in skin test and oral provocation test will have their prior labelled penicillin allergy removed from electronic health record, and an additional entry documenting the negative allergy evaluation will be added. A letter signed by an infectious disease specialist documenting the allergy evaluation results will also be given to patients.
62388974|NCT05823155|NO_INTERVENTION|Standard pre-operative care|This group will receive standard perioperative care. The choice of antibiotics during the perioperative period will be decided by surgical team.
62388975|NCT03763292|EXPERIMENTAL|Information brochure|Intervention: The parents are given a specific information brochure that describes the procedures that the child is going through during anesthesia when it has been decided that the child is going to have the surgery.
61993631|NCT00066066|ACTIVE_COMPARATOR|SRP + MET + Amoxicillin + Doxycycline|Full mouth Scaling and Root Planing plus Metronidazole (MET) 250 mg tid x 14 d and Amoxicillin (AMOX) 500 mg tid for 14 days and local drug delivery of Doxycycline (TET LDD) in pockets \>4mm
62388976|NCT03763292|NO_INTERVENTION|Information as usual|Information as usual, i.e. oral information about the procedures to parents when they arrive at the hospital with the child that is going to have the surgery.
62388977|NCT05370235|EXPERIMENTAL|Afamelanotide|
62388978|NCT04193982|EXPERIMENTAL|Saraglitazar|Patients will receive Saraglitazar 4 mg once daily for 6 months
62388979|NCT04193982|EXPERIMENTAL|Vitamin E|Patients will receive Vitamin E 400mg twice daily for 6 months
62388980|NCT04193982|EXPERIMENTAL|Combination|Patients will receive combination of Saraglitazar 4 mg once daily and Vitamin E 400mg twice daily for 6 months
61993632|NCT04656132|EXPERIMENTAL|Participants with cardiovascular disease or cardiovascular disease risk factors|Population We will recruit 59 males and females age \> 18 being seen in the NYU Langone Center for Prevention of Cardiovascular Disease (4F). Participants have cardiovascular disease or cardiovascular disease risk factors.
61993633|NCT03317171|EXPERIMENTAL|Treated group|oral administration of flavonoids, DHA and EPA, once a day for 24 weeks.
61993634|NCT03317171|PLACEBO_COMPARATOR|Placebo group|oral administration of placebo compound, once a day for 24 weeks.
61993635|NCT04280367||Comparator group|Specific learning disorders group
62560526|NCT02873793||3 cases of composite tumours seminoma/non-seminoma.|
62768791|NCT00773890|EXPERIMENTAL|TRF-1101|Daily treatment with TRF-1101
61993636|NCT04280367||neuro-developmental complexed group|Group of neuro-developmental complexe of learning
61993637|NCT04280367||Complexed with anxiety|Disorders in learning with anxiety
61993638|NCT01446965|EXPERIMENTAL|Wearable defibrillator|subjects in the Device Group will receive a LifeVest® wearable cardioverter-defibrillator (manufacturer: ZOLL Medical Corporation) plus guideline-directed medical therapy for post-myocardial infarction patients
61993639|NCT01446965|NO_INTERVENTION|Conventional treatment|subjects in the Control Group will only receive guideline-directed medical therapy for post-myocardial infarction patients
61993640|NCT04797260|EXPERIMENTAL|Gene therapy|In this arm, 10 patients will be included for gene therarpy
61993641|NCT01946399|OTHER|Ozurdex implant|Intravitreal injection of Ozurdex implant
61993642|NCT05847530|EXPERIMENTAL|Group A|This group is Potenza treatments only.
62560527|NCT03289091|EXPERIMENTAL|water-based continuous aerobic training|Participants who will be randomized for the intervention in the continuous aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle. In the first mesocycle (weeks 1-4), participants will carry out three 4-minute series of each exercise whose intensity corresponds to the Rating of Perceived Exertion (RPE) 13. In the second mesocycle (weeks 5-8), participants will perform four 3-minute series of each exercise corresponding to RPE 14. In the third mesocycle, participants will perform six 2-minute series of each exercise at intensity corresponding to RPE 15 from weeks 9-10, whereas intensity corresponding to RPE 16 will be experienced from weeks 11-12.
61993643|NCT05847530|EXPERIMENTAL|Group B|This group is Potenza and Icon treatments.
62560528|NCT03289091|EXPERIMENTAL|water-based interval aerobic training|Participants who will be randomized for the intervention in the interval aerobic training group will carry out exercises which associate effort phases, at higher intensity and recovery phases, at lower intensity, with no interval for exercise change. Intensity will be increased every mesocycle. The first mesocycle (weeks 1-4) comprises three 4-minute series of each exercise whose intensity corresponds to the RPE 16 for 2 minutes and RPE 11 for 2 minutes. The second mesocycle (weeks 5-8) includes four 3-minute series of each exercise whose intensity corresponds to the RPE 17 for 1.5 minutes and RPE 11 for 2 minutes. The third mesocycle (weeks 9-12) comprises six 2-minute series of each exercise whose intensity corresponds to the RPE 18 for 1 minute and RPE 11 for 1 minute.
62560529|NCT02298127|EXPERIMENTAL|Shenmen, mouth, lung & stomach|Participants in this group will receive 4 weekly treatment sessions of auricular acupressure via the shenmen, mouth, lung and stomach.
62560530|NCT02298127|EXPERIMENTAL|Subcortex,endocrine&sympathetic systems|Participants in this group will receive 4 weekly treatment sessions of auricular acupressure via the subcortex, endocrine and sympathetic systems.
62560531|NCT02298127|SHAM_COMPARATOR|Elbow, shoulder & knee|Participants in this group will receive 4 weekly treatment sessions of sham-controlled acupressure on the elbow, shoulder and knee acupoints on the auricle that is non-specific to smoking cessation.
62560532|NCT02963779|EXPERIMENTAL|LY2775240 (Part A)|Escalating oral doses of LY2775240 administered in healthy participants
61993644|NCT02806050|EXPERIMENTAL|Palbociclib and FES PET|To evaluate whether low uptake on FES-PET at baseline is related to non-response to letrozole plus palbociclib treatment.
61993645|NCT00969787|EXPERIMENTAL|DWP05195|
61993646|NCT03161483|EXPERIMENTAL|CC-220 0.45 mg QD Placebo Controlled Phase|"* At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.45 mg once daily (QD)~* At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.45 mg once daily (QD)~* Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
61993647|NCT03161483|EXPERIMENTAL|C-220 0.3 mg QD Placebo Controlled Phase|"* At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.3 mg once daily (QD)~* At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.30 mg once daily (QD)~* Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
61993648|NCT03161483|EXPERIMENTAL|CC-220 0.15 mg QD Placebo Controlled Phase|"* At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.15 mg once daily (QD)~* At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.15 mg once daily (QD)~* Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
61993649|NCT03161483|PLACEBO_COMPARATOR|Placebo|Weeks 0 to 24: CC-220 Placebo Controlled Phase: placebo once daily (QD)
61993650|NCT05640570|EXPERIMENTAL|The individualized Jade Wind-Barrier Herbal Tea Bag (JWBT) arm|
61993651|NCT05640570|NO_INTERVENTION|Control arm|
62560533|NCT02963779|EXPERIMENTAL|LY2775240 (Part B)|Oral dose of LY2775240 in healthy participants
62560534|NCT02963779|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered orally in healthy participants
62560535|NCT02963779|ACTIVE_COMPARATOR|Apremilast (Part B)|Oral dose of apremilast in healthy participants
62560536|NCT05457504|EXPERIMENTAL|Experimental|
62560537|NCT05457504|PLACEBO_COMPARATOR|Usual Care|
61993652|NCT04274647|EXPERIMENTAL|Device and Control|"NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.~Positive control: 0.4% sodium lauryl sulfate (SLS) Dose. 0.2ml"
61993653|NCT05026684|EXPERIMENTAL|Experimental group|Personalized cost information group.
62560538|NCT00208442|ACTIVE_COMPARATOR|Marathon™|Moderately cross-linked polyethylene liner in a modular acetabular component
61993654|NCT00952107|EXPERIMENTAL|Imaging system operation|
61993655|NCT01476943||Patient treated with Belatacept at the time of transplantation|Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with Belatacept at the time of transplantation
62560539|NCT00208442|ACTIVE_COMPARATOR|Enduron™|Standard UHMWPE polyethylene liner in a modular acetabular component
62567721|NCT00314340|ACTIVE_COMPARATOR|hydrocodone|"Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity~On the day of the study session, patients received hydrocodone 30 mg plus N-acetyl-para-aminophenol 975 mg (APAP;Qualitest Pharmaceuticals Inc, Huntsville, AL)."
61993656|NCT01476943||Patient treated with CNI at the time of transplantation|Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with a Calcineurin inhibitor (CNI) based regimen at the time of transplantation
61993657|NCT05385419|OTHER|Patients subjected for bronchoscopy or medical thoracoscopy|Bronchoscopic and thoracoscopic biopsies will be sent for both frozen section and permenant paraffin section
62560540|NCT05359744|EXPERIMENTAL|Elite cyclists, male|Bicycle ergometer-based exercise testing. 15 min aerobic warm-up phase (2 W/kg) followed by a standardized but individualized ramp-bicycle ergometer protocol to reach maximal exercise capacity after 8 - 12 minutes. The exclusively aerobic energy supply during warm-up will be assessed by constant respiratory quotient and constant arterial lactate concentration (\<0.5 mmol in the last 5 min). During exercise, respiratory gas exchange, heart rate, blood pressure, ECG and ratings of perceived exertion will be continuously monitored. Venous blood specimens will be collected before exercise (baseline), at the end of the warm-up as well as 2 min, 10 min, and 30 min in recovery.
62560541|NCT05359744|EXPERIMENTAL|Recreational athletes, male|Bicycle ergometer-based exercise testing. 15 min aerobic warm-up phase (1 W/kg) followed by a standardized but individualized ramp-bicycle ergometer protocol to reach maximal exercise capacity after 8 - 12 minutes. The exclusively aerobic energy supply during warm-up will be assessed by constant respiratory quotient and constant arterial lactate concentration (\<0.5 mmol in the last 5 min). During exercise, respiratory gas exchange, heart rate, blood pressure, ECG and ratings of perceived exertion will be continuously monitored. Venous blood specimens will be collected before exercise (baseline), at the end of the warm-up as well as 2 min, 10 min, and 30 min in recovery.
62560542|NCT05359744|EXPERIMENTAL|Recreational athletes, female|Bicycle ergometer-based exercise testing. 15 min aerobic warm-up phase (1 W/kg) followed by a standardized but individualized ramp-bicycle ergometer protocol to reach maximal exercise capacity after 8 - 12 minutes. The exclusively aerobic energy supply during warm-up will be assessed by constant respiratory quotient and constant arterial lactate concentration (\<0.5 mmol in the last 5 min). During exercise, respiratory gas exchange, heart rate, blood pressure, ECG and ratings of perceived exertion will be continuously monitored. Venous blood specimens will be collected before exercise (baseline), at the end of the warm-up as well as 2 min, 10 min, and 30 min in recovery.
62560543|NCT05359744|NO_INTERVENTION|Control, male|Venous blood specimens will be collected at the same time points in the absence of exercise.
61993658|NCT05947136|EXPERIMENTAL|Intervention group|For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective), specific and proactive referrals will be made systematically after each detection visit according to the level of risk, estimated on the basis of decision trees (management guide) and via the dedicated PASCA network of healthcare professionals, to initiate early treatment and follow-up where necessary.
62560544|NCT05354167|EXPERIMENTAL|muscle energy technique|the subject to sit comfortably and then stabilize the subject's distal humerus with one hand, then the forearm was supinated with the therapist another hand until resistance appeared. Holding the position the subject was asked to slowly pronate the forearm that is Isometric contraction against resistance for a period of 6-10 seconds with inhale and exhale, followed by slightly increasing supination until resistance was met once again. After 5 seconds of relaxation, the procedure was repeated 5 times during a single treatment session.
62560545|NCT05354167|EXPERIMENTAL|oscillating manual energy therapy|It is also known as V-spread .The subject was asked to sit on a chair with the affected painful arm resting on the treatment table. Tender points were palpated. Then the therapist places the index and middle fingers of one hand in a V-shape around the tender point and placed the index finger of the other hand in the medial side of the elbow, diagonally across the located tender point. Gentle pressure was applied a few times using fingertips to the tissues alternatively from the medial and lateral sides to start the oscillations. On the initiation of oscillations, the application of pressure should be stopped and allow the oscillations to continue between the two points of contact on the subject's elbow. This technique was repeated until there were no tender points on palpation. The duration varied from 30 seconds to 2 minutes.
62560546|NCT00720213|ACTIVE_COMPARATOR|Respironics BiPAP autoSV2, Then Respironics BiPAP autoSV3|Participants will be randomized to receive Respironics BiPAP autoSV2 first and Respironics BiPAP autoSV3 second.
62560547|NCT00720213|EXPERIMENTAL|Respironics BiPAP autoSV3, then Respironics BiPAP autoSV2|Participants will be randomized to receive Respironics BiPAP autoSV3 first and Respironics BiPAP autoSV2.
62560548|NCT02254382|EXPERIMENTAL|Adaptive servo ventilation (ASV)|This group will receive ventilation therapy (AutoSet CS, ASV device)
62560549|NCT03671161|EXPERIMENTAL|Patients with poorly controlled diabetes type 1|Adults with type 1 diabetes, HbA1c \>9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day swithced to Insulin Pump and flash glucose monitoring
62560550|NCT01307332|EXPERIMENTAL|MabCampath-1h|Single arm, single cohort study, all subjects will be dosed with alemtuzumab.
62768792|NCT00773890|PLACEBO_COMPARATOR|Placebo|Daily treatment with placebo
62768793|NCT05570071|EXPERIMENTAL|vaginal radiofrequency|vaginal radiofrequency therapy 4 times
62768794|NCT05570071|ACTIVE_COMPARATOR|electromyography biofeedback|electromyography combined with biofeedback therapy 15 times
61993659|NCT05947136|ACTIVE_COMPARATOR|Control group|For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective): all the data from each detection visit will be sent to the referring forwarded to the referring onco-haematologists, so that they can initiate their own management.
61993660|NCT05528237|EXPERIMENTAL|HPV self-sampling|Participants will be offered self-collection kits for HPV-based cervical cancer screening.
61993661|NCT02264002|EXPERIMENTAL|Cilobradine low dose 1|
61993662|NCT02264002|EXPERIMENTAL|Cilobradine low dose 2|
61993663|NCT02264002|EXPERIMENTAL|Cilobradine medium dose|
61993664|NCT02264002|EXPERIMENTAL|Cilobradine high dose 1|
61993665|NCT02264002|EXPERIMENTAL|Cilobradine high dose 2|
61993666|NCT02264002|ACTIVE_COMPARATOR|Metoprolol succinate|1 tablet on day 1, day 2 followed by two tablets from day 3 to day 14
61993667|NCT02264002|PLACEBO_COMPARATOR|Placebo|
61993668|NCT05613621||training cohort|Consisting of 4 sub-groups: HBV (+) steatosis (+), HBV (-) steatosis (+), HBV (+) steatosis (-) and HBV (-) steatosis (-). HBV (+) is defined as either: (a) HBsAg (+) or (b) HBsAg (-) anti-HBc (+) and HBV DNA detectable in blood or tumor tissue. Steatosis is defined by histology. We will enroll 400 patients who had sufficient tissue for testing in the training cohort.
61993669|NCT05613621||validation cohort|For the validation cohort, the clinical and pathological information will be obtained retrospectively by TCOG and will take 6 months to identify eligible patients for the 4 sub-groups listed above.
61993670|NCT00443586|ACTIVE_COMPARATOR|Developmental Screening|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age.
61993671|NCT00443586|ACTIVE_COMPARATOR|Screening plus Transportation|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two).
61993672|NCT00443586|ACTIVE_COMPARATOR|Screening, Transport, Prenatal Visits|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy.
61993673|NCT00443586|EXPERIMENTAL|Screen, Transport, Prenatal/Inf Visits|Participants received regular sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy and through child age two.
62388981|NCT04193982|ACTIVE_COMPARATOR|Lifestyle|Patients will follow instruction from dietician and life style changes advise as per protocol including targeting 7 to 10percent weight loss in 6 months
62388982|NCT04450394|EXPERIMENTAL|LY3209590 Algorithm 1 (Paper)|Algorithm 1 is a paper-based algorithm where dose adjustments were manually determined by the investigator based on fasting glucose and hypoglycemia data. LY3209590 was provided in a 20 milligram (mg) vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by subcutaneous (SC) injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of \<=100 milligrams per deciliter (mg/dL).
62560551|NCT04846400|EXPERIMENTAL|ssNPA|self-supporting nasopharyngeal airway to be used nightly for approximately 8 weeks.
62560552|NCT02441010|NO_INTERVENTION|Group 1|Participants without suboptimal health status are randomly grouped into the group without monitor (Group 1) and the monitor group (Group 2 or Group 3). Thus, no monitoring or intervention technologies are used in Group 1.
61993674|NCT04305795|OTHER|Cohort 1- 1L HNSCC|Recurrent locally advanced and/or metastatic head and neck squamous cell carcinoma
62388983|NCT04450394|EXPERIMENTAL|LY3209590 Algorithm 2 (Digital)|"Algorithm 2 is a computer-based algorithm to determine dose adjustments. LY3209590 was provided in a 20 mg vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by SC injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of \<=100 mg/dL.~As per protocol amendment (d) approved on 28-Oct-2020, this arm was terminated during the early enrollment phase due to technical issues with data entry."
62388984|NCT04450394|ACTIVE_COMPARATOR|Insulin Degludec|Insulin degludec was provided as 100 units/milliliter (U/mL) in a prefilled pen. Participants received individually adjusted doses once daily by SC injection with a starting dose of 10 units, during the 26-week treatment period, to achieve target fasting blood glucose of \<=100 mg/dL.
62388985|NCT03637959|EXPERIMENTAL|Mechanical Vibrations with Ultrasound Shear Wave Imaging|Subjects that are scheduled to undergo a clinical indicated Magnetic Resonance Elastography (MRE) will also have mechanical vibrations ultrasound shear wave imaging to measure liver stiffness
62560553|NCT02441010|SHAM_COMPARATOR|Group 2|Group 2 are participants without metabolic abnormality in the monitor group. Group 2 use the monitoring device with three months.
62560554|NCT02441010|SHAM_COMPARATOR|Group 3|Group 3 are participants with metabolic abnormality in the monitor group. Group 3 use the monitoring device and the health information push technology with three months.
62560555|NCT02441010|ACTIVE_COMPARATOR|Group 4|All of participants with suboptimal health status use the monitoring device with three months, and are randomly grouped into the non-intervention group (Group 4 or Group 5) and the intervention group using the meridian therapy instrument (Group 6 or Group 7). Group 4 are participants without metabolic abnormality in the non-intervention group. No intervention technologies are used in Group 4.
62560556|NCT02441010|ACTIVE_COMPARATOR|Group 5|Group 5 are participants with metabolic abnormality in the non-intervention group. Group 5 use the health information push technology with three months.
62768795|NCT04496375||Institut Paoli Calmettes Outpatients|Patients with a solid tumor or an hematologic malignancy who will attend an appointement at IPC Outpatients clinic
61993675|NCT04305795|OTHER|Cohort 2- 1L cuSCC|Locally advanced or metastatic cutaneous squamous cell carcinoma
61993676|NCT04305795|OTHER|Cohort 3- 2L cuSCC|Locally advanced or metastatic cutaneous squamous cell carcinoma
61993677|NCT06118112||Persons with- long-covid|Women and men diagnosed with persistent COVID according to WHO (World HEalth Organization) criteria: persistent symptoms three months after the acute manifestations of COVID-19 and lasting at least two months and cannot be explained by an alternative diagnosis.
61993678|NCT03588221|OTHER|Six-step hand hygiene technique with application time of 30|
61993679|NCT03588221|OTHER|Six-step hand hygiene technique with application time of 15|
61993680|NCT03588221|OTHER|Three-step hand hygiene technique with application time of 3|
61993681|NCT03588221|OTHER|Three-step hand hygiene technique with application time of 1|
61993682|NCT03947151|OTHER|one arm|one arm
61993683|NCT02596646|ACTIVE_COMPARATOR|Group A|Early Precut
61993684|NCT02596646|ACTIVE_COMPARATOR|Group B|Prolonged cannulation attempts
61993685|NCT01982253|PLACEBO_COMPARATOR|Placebo|Fasiglifam placebo-matching tablets, orally, twice daily for up to 12 weeks.
61993686|NCT01982253|EXPERIMENTAL|Fasiglifam 25 mg BID|Fasiglifam 25 mg tablets, orally, twice daily (BID) for up to 12 weeks.
61993687|NCT01982253|EXPERIMENTAL|Fasiglifam 50 mg QD +Placebo QD|Fasiglifam 50 mg tablets, orally once daily (QD) and fasiglifam placebo-matching tablets, orally, once daily for up to 12 weeks.
61993688|NCT02678676||Pioglitazone|Participants who previously received pioglitazone in the PROactive study (NCT00174993).
62388986|NCT01695499||Immunosuppressed ICU Patients with lung infiltrates|Immunosuppressed ICU Patients with lung infiltrates
62388987|NCT01695499||Control Group|BAL and blood aliquots of 20 immunocompetent pts (suffering from lung diseases) will be collected and tested identically as a control population.
62388988|NCT01876056|EXPERIMENTAL|Brief CaCBTp|The experimental group will receive brief for of Culturally adapted CBT for psychossis
61993689|NCT02678676||Placebo|Participants who previously received Pioglitazone-matching placebo in the PROactive study (NCT00174993).
62388989|NCT01876056|NO_INTERVENTION|Treatment As Usual|Treatment as usual means seeing a mental health professional and taking the prescribed anti psychotics and being cared by family members
62388990|NCT04717154|EXPERIMENTAL|Treatment arm|"Combinatory regimen of nivolumab 3mg/kg and ipilimumab 1mg/kg, followed by nivolumab 480mg flat dose (Q4w) to up to one year.~This regimen will be given to participants in both cohort 1 and 2."
62388991|NCT03373006|EXPERIMENTAL|Men with Gleason Score 7 prostate cancer|Men seeking focal therapy for Gleason Score 7 prostate cancer will receive Axumin PET/CT imaging to detect metastasis which will result in exclusion from laser focal therapy.
62388992|NCT06111729|EXPERIMENTAL|HabitAware Participants|Patients will be asked to wear the HabitAwareness bracelet for 12 weeks. The bracelet provides the attention stimulus of gentle vibration when the motion of nail biting is sensed.
62560557|NCT02441010|EXPERIMENTAL|Group 6|Group 6 are participants without metabolic abnormality in the intervention group. Group 6 use the meridian therapy instrument with two weeks. If the suboptimal health status is not improved, then the meridian therapy instrument will continue to be used with an interval of one week.
61993690|NCT04578249|PLACEBO_COMPARATOR|Clear goggles|Patients recovering from CABG, AVR, MVR, CABG AVR, CABG MVR, or SAH surgery will be given clear goggles to wear at nighttime.
61993691|NCT04578249|EXPERIMENTAL|Blue-light blocking goggles|Patients recovering from CABG, AVR, MVR, CABG AVR, CABG MVR, or SAH surgery will be given blue-light blocking goggles to wear at nighttime.
61993692|NCT02865915|PLACEBO_COMPARATOR|Placebo|Plain, round, biconvex, white film-coated tablets that appear identical to MLE4901 tablets
61993693|NCT02865915|EXPERIMENTAL|MLE4901|Plain, round, biconvex, white film-coated tablets administered twice per day
61993694|NCT01677091|ACTIVE_COMPARATOR|Control group|This group will benefit from conventional rehabilitation
62560558|NCT02441010|EXPERIMENTAL|Group 7|Group 7 are participants with metabolic abnormality in the intervention group. Group 7 use the health information push technology with three months and the meridian therapy instrument with two weeks. Similar with Group 6, if the suboptimal health status is not improved after the treatment of the meridian therapy instrument, then the instrument will continue to be used with an interval of one week.
62560559|NCT06581744|EXPERIMENTAL|hyperaldosteronism|Intravenous inject 18F-Pentixather，perform PET/CT imaging at the designated time
62560560|NCT03916718||Dementia|The target population includes patients seen at Ochsner Clinic Foundation, \>=55 years old, diagnosed with dementia, and meeting other inclusion/exclusion criteria. this study will recruit subjects identified as high utilizers of the Ochsner System. This will be defined by \>= 2 ED visits, \>= 2 Hospitalizations, or some combination prior to baseline. We will co-variate by insurance plan.
62560561|NCT04099745|EXPERIMENTAL|CGM（continuous glucose monitoring）|Each diabetic patient received three CGM tests within 14 days of FGM monitoring, on days 1-3, 6-9 and 12-14, respectively.
62560562|NCT04099745|EXPERIMENTAL|FGM（Flash glucose monitoring）|Each diabetic patient received one FGM test for 14 days.
62560563|NCT04359394||PP patients|patients with active PP
62560564|NCT01025882|EXPERIMENTAL|Regimen 1|Patients undergo a single fraction of margin-intensive stereotactic body radiotherapy (SBRT) on day 1. Patients undergo pancreatoduodenectomy between days 15-43.
61993695|NCT01677091|EXPERIMENTAL|Cervical vibration|This group will benefit from a daily 20 minutes session, with vibration of neck muscles during 10 minutes
61993696|NCT01677091|EXPERIMENTAL|Prism adaptation|This group will benefit from a daily 20 minutes session, with prism adaptation during 10 minutes
62560565|NCT01025882|EXPERIMENTAL|Regimen 2|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Patients undergo a single fraction of SBRT between days 21-28 followed by pancreatoduodenectomy between days 35-63.
62560566|NCT04229862|EXPERIMENTAL|Evaluation with 14 cm high pillow|When inserting laryngeal mask airway, head elevation is performed using a 14 cm high pillow.
62560567|NCT04229862|ACTIVE_COMPARATOR|Evaluation with 7 cm high pillow|When inserting laryngeal mask airway, head elevation is performed using a 7 cm high pillow.
62560568|NCT03304691||Bandiagara, Mali|Children of both sexes between 6 months and 10 years of age.
62388993|NCT03679572|EXPERIMENTAL|Robot assisted partial nephrectomy super-selective clamping|The Da Vinci robot (device) allows to use near-infrared fluorescence in order to clamp precisely the branches of the vascularization for the partial nephrectomy. The healthy parenchyma ischemia is avoided.
62560569|NCT03304691||Yirimadio, Bamako, Mali|Children and adults of both sexes 6 months and older.
62768796|NCT00754091|EXPERIMENTAL|1|
62388994|NCT03679572|ACTIVE_COMPARATOR|Robot assisted partial nephrectomy with renal artery clamping|The partial nephrectomy with robotic assistance is performed using a renal artery. It's the conventional method.
62388995|NCT01673373|EXPERIMENTAL|iCAST RX™ Stent Systen|All enrolled subjects will receive the iCAST RX™ Stent System
62388996|NCT00551200|ACTIVE_COMPARATOR|BUPHENYL® to HPN-100 vs. HPN-100|Buphenyl treatment for one week was followed by dose escalation to HPN-100. Dose of Buphenyl was gradually decreased while HPN-100 dose was gradually increased until subject reached dosing of 100% HPN-100. HPN-100 at 100% of the dose was given for 1 week before subject was switched back to original Buphenyl treatment.
62388997|NCT00735839|EXPERIMENTAL|V710|V710 vaccination (60 mcg) single dose on Day 1
62388998|NCT00735839|PLACEBO_COMPARATOR|Placebo|Placebo single dose on Day 1
62388999|NCT05365256|ACTIVE_COMPARATOR|Standard time occupation of treatment period|habitual distraction of patients during chemotherapy sessions authorized as part of routine care (doing nothing, discussion, reading, games, etc.).
61993697|NCT01677091|EXPERIMENTAL|Cervical vibration + Prism adaptation|This group will receive a daily 30 minutes session, with cervical vibration during 10 minutes + prism adaptation during 10 minutes
61993698|NCT00162565|EXPERIMENTAL|1|bbloquant treatment
61993699|NCT04877275|EXPERIMENTAL|Arm I: Selinexor+Pegylated liposomal doxorubicin +Dexamethasone|Arm I is given XDd regimen (ATG-010(Selinexor) 80mg/d QW, Pegylated liposomal doxorubicin 25mg/m2, d1and Dexamethasone 40mg/d QW) in approximately 25 subjects. 4 weeks per cycle and include a total of 12 cycles.
62768797|NCT01763294|ACTIVE_COMPARATOR|Nicolet Endeavor CR: 30min|Apply 1 session of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
62768798|NCT01763294|ACTIVE_COMPARATOR|Nicolet Endeavor CR: 60min|Apply 1 session of 2 milliampere intensity for 60 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
62768799|NCT01763294|ACTIVE_COMPARATOR|Nicolet Endeavor CR: 30min for 3 days|Apply 3 sessions of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
62768800|NCT01763294|ACTIVE_COMPARATOR|Nicolet Endeavor CR: 30min for 5 days|Apply 5 sessions of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
62389000|NCT05365256|EXPERIMENTAL|time occupation of treatment period by virtual reality|Use of virtual reality as a distraction during chemotherapy sessions. A virtual reality headset will be worn for 15 minutes per hour of treatment (with a maximum of three sessions per cycle of chemotherapy)
62560570|NCT04753008|EXPERIMENTAL|Dopamine group|Cardiac surgery patients receiving dopamine to support their cardiac function (as part of the routine post-operative care).
62560571|NCT04753008|NO_INTERVENTION|Control group|Cardiac surgery patients receiving no positive inotrope drug.
62560572|NCT03997812|EXPERIMENTAL|VVZ-149 Injections|
62560573|NCT03997812|PLACEBO_COMPARATOR|Placebo|
62560574|NCT03839420|EXPERIMENTAL|CZM IOL|
62560575|NCT03839420|ACTIVE_COMPARATOR|Competitor IOL|
62560576|NCT03485560|EXPERIMENTAL|internvention of Chrinic skin conditions|All cases of chronic skin conditions will be included to measure the effect on the 3 of them and whihc one will respond to the treatment better
62560577|NCT06581393|EXPERIMENTAL|Professional Care in an In-Center Hemodialysis Setting|Hemodialysis using the Moda-flx Hemodialysis System
62560578|NCT05066425|EXPERIMENTAL|Soluble Corn Fiber|22g Soluble Corn Fiber/day for 4 weeks
62560579|NCT05066425|PLACEBO_COMPARATOR|Maltodextrin|22g Maltodextrin/day for 4 weeks
62560580|NCT04744025|EXPERIMENTAL|Microfluidics|Half of participants eggs will be injected with sperm processed using a microfluidics chamber.
62560581|NCT04744025|ACTIVE_COMPARATOR|Density gradient centrifugation|Half of participants eggs will be injected with sperm processed using a density gradient centrifugation (the standard method).
62560582|NCT03739281|OTHER|Nuclear medicine imaging|Patients undergo nuclear medicine imaging with PET/MR and PET/CT.
62560583|NCT03164876|EXPERIMENTAL|Dose AUT00206 800 mg BD|AUT00206 800mg twice daily for 28 days
62560584|NCT03164876|PLACEBO_COMPARATOR|Placebo|Placebo to match AUT00206 twice daily for 28 days
62560585|NCT05264662|ACTIVE_COMPARATOR|Open label Adacel|"Tdap (Adacel) ADACEL (0,5 ml) should be administered as an injection by the intramuscular route.~Re-dosing with ADACEL can be used to boost immunity to diphtheria, tetanus and pertussis at 5- to 10-year intervals.~ADACEL may be administered to pregnant women during the second and third trimester to provide passive protection to infants against pertussis."
62560586|NCT05264662|NO_INTERVENTION|control|Infants born to unvaccinated mothers.
62560587|NCT01946750|EXPERIMENTAL|Case|Hospitalized patient with clinical signs of Clostridium Difficile Infection and specific detection in stools of Clostridium Difficile toxins
62560588|NCT01946750|OTHER|Non-diarrheal control|Hospitalized patient and asymptomatic carrier of Clostridium Difficile
62560589|NCT01899339||pulmonary embolism|patients with submassive pulmonary embolism
62560590|NCT00731835|NO_INTERVENTION|Group I|1. Wound Care (group 1)--Best standard wound care with aggressive debridement
62560591|NCT00731835|ACTIVE_COMPARATOR|Group 2|"2. Endovascular Intervention + Wound Care (group 2)--Best standard wound care in combination with endovascular revascularization~Endovascular revascularization is the intervention"
62560592|NCT02070965|EXPERIMENTAL|DFD01 Spray Group 1|DFD01 Spray, bid, 28 days
62560593|NCT02070965|ACTIVE_COMPARATOR|Comp01 Lotion|Comp01 Lotion, bid, 14 days
62560594|NCT02070965|EXPERIMENTAL|DFD01 Spray Group 2|DFD01 Spray, bid, 14 days
62560595|NCT05051852||Women with low-grade squamous intraepithelial lesion (LSIL) in cervix|In the enrollment, women whose cervical histopathological results have been diagnosed as low-grade squamous intraepithelial lesion (LSIL) for the last 3 months with abnormal results will be included in this study. All participants will be followed up three times, at 6 months,12 months and 24 months.
62567722|NCT00314340|PLACEBO_COMPARATOR|placebo|Subjects received a placebo pill if randomized to this arm. Both opioid medications and the placebo were administered in identical capsules.
62768801|NCT01763294|PLACEBO_COMPARATOR|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
62768802|NCT06038994||Patients with acute myocardial infarction who experienced CAG|Patients with acute myocardial infarction who experienced coronary angiography
61993700|NCT04877275|EXPERIMENTAL|Arm II: Selinexor+Cyclophosphamide+Dexamethasone|Arm II is given XCd regimen (ATG-010 100mg/d QW, Cyclophosphamide 300mg/m2, d1and Dexamethasone 40mg/d QW). 4 weeks per cycle and include a total of 12 cycles.
61993701|NCT03583996|EXPERIMENTAL|Open Label|All subjects receive HepQuant SHUNT Liver Diagnostic Test within 42 days of the scheduled EGD. Test includes 20mg of 13C Cholate mixed with Albumin via IV push, and 40mg of d4 Cholate mixed with juice orally, both doses given simultaneously one time.
61993702|NCT06342843|ACTIVE_COMPARATOR|Posterolateral approach (PLA)|THA by using the posterolateral approach
61993703|NCT06342843|ACTIVE_COMPARATOR|Direct superior approach (DSA)|THA using the direct superior approach
61993704|NCT00902564|EXPERIMENTAL|Escitalopram|
61993705|NCT03610243|EXPERIMENTAL|Self-administered acupressure|"The proposed self-administered acupressure intervention is patient-centered comprising four pre-selected acupoints that should be applied pressure on by all patients and a list of additional acupoints from which patients can choose two for self-administration according to the personalized recommendations of trainers. In this way, each patient will receive an individualized protocol (four pre-selected and two self-selected acupoints).~The intervention consists of: individual participant training (Two 2-hour one-on-one training sessions in week 1), self-practice (15 minutes of self-administered acupressure twice a day), and follow-up visits (a 1-hour follow-up visit at weeks 2, 3, and 4)."
62389001|NCT03092141|ACTIVE_COMPARATOR|Patients|Patients will be submitted to physical training (12-weeks, twice/week)
62389002|NCT03092141|ACTIVE_COMPARATOR|Control group|Healthy individuals will be submitted to physical training (12-weeks, twice/week)
62389003|NCT02055976|EXPERIMENTAL|Population A|A total of 9 groups in two population. Population A comprises hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a stable dose of atorvastatin. A subject who is receiving a stable dose of atorvastatin will be randomized into one out of 5 dose groups.
62389004|NCT02055976|EXPERIMENTAL|Population B|A total of 9 groups in two population. Population B comprises hypercholesterolemic Japanese subjects who are naïve for a treatment by lipid lowering drug and whose fasting LDL-cholesterol is not controlled. A subject who is treatment naïve will be randomized into one out of 4 dose groups.
62560596|NCT04696224|ACTIVE_COMPARATOR|INTRAVENOUS|30 patients who will receive 15mg / kg of TXA intravenous in 100ml salina solution (0,9%), after anesthetic induction and before incising the skin (administered in 10 minutes). For masking purposes, these patients will also receive at the end of the surgery, and before performing the plan closure, a compress soaked in 80ml of saline solution (0.9%), which will fill all the plans of the incision, and will be kept for 5 minutes.
62389005|NCT03480360|OTHER|Johns Hopkins' conditioning regimen|Cyclophosphamide, fludarabine, total body irradiation, immune suppression including tacrolimus and cellcept, Granulocyte colony-stimulating factor (G-CSF), and peripheral blood transplant
62389006|NCT00969462|NO_INTERVENTION|Doxorubicin|Single arm
62389007|NCT00003389|EXPERIMENTAL|Arm A (ABVD)|Arm A (ABVD): Patients receive doxorubicin (25 mg/m²), bleomycin (10 u/m²), vinblastine (6 mg/m²), and dacarbazine (375 mg/m²) intravenously (IV) on days 1 and 15. Courses repeat every 28 days. Patients are restaged after 4 courses. Patients who are in complete remission receive 2 additional courses. Patients with a partial response or less are evaluated after 6 courses, and if there is an ongoing response, patients may receive 2 additional courses for a total of 8. If no ongoing response is observed, patients are removed from the study. All patients with massive mediastinal disease, regardless of stage, receive radiotherapy 2-3 weeks after completion of chemotherapy.
62389008|NCT00003389|ACTIVE_COMPARATOR|Arm B (Stanford V)|Arm B (Stanford V): Patients receive Stanford V chemotherapy comprising doxorubicin (25 mg/m²) and vinblastine (6 mg/m²) IV on day 1 of weeks 1, 3, 5, 7, 9, and 11; vincristine (1.4 mg/m²) and bleomycin (5 u/m²) IV on day 1 of weeks 2, 4, 6, 8, 10, and 12; mechlorethamine (6 mg/m²) IV on day 1 of weeks 1, 5, and 9 (if mechlorethamine is unavailable, may substitute with cyclophosphamide \[375 mg/m²\] IV); etoposide (60 mg/m²) IV on days 1 and 2 of weeks 3, 7, and 11; and oral prednisone (40 mg/m²) every other day of weeks 1-9 followed by a taper. All patients with bulky disease receive radiotherapy 2-3 weeks after completion of chemotherapy.
62389009|NCT00754273||1|PAL samples collected for pneumonia evaluation
62389010|NCT05987709|OTHER|Guardant Shield Blood Test|Patients will have the Guardant Shield blood test for colorectal cancer screening.
62389011|NCT05987709|NO_INTERVENTION|Standard of Care|Patients will have standard of care, which is a reminder to do their FIT test for colorectal cancer screening
62389012|NCT02260609|OTHER|Open-Label|Grafix®: Cryopreserved Placental Membrane
62389013|NCT02896959|EXPERIMENTAL|25mmHg pressure|Pump pressure of 25mmHg during rotator cuff repair
62389014|NCT02896959|EXPERIMENTAL|45mmHg pressure|Pump pressure of 45mmHg during rotator cuff repair
62560597|NCT04696224|ACTIVE_COMPARATOR|LOCAL|30 patients who, at the end of the surgery, and before the suture in layers, will receive a compress soaked in a solution of 1.5 g of tranexamic acid (six ampoules of Transamin®, Zydus Nikkho) diluted in 50 ml of saline solution (0.9 %) (total volume of 80ml), which will fill all the plans of the incision and will be maintained for 5 minutes. For masking purposes, these patients will also receive 100ml of saline solution (0.9%) after anesthetic induction and before incising the skin.
62560598|NCT04696224|PLACEBO_COMPARATOR|PLACEBO|30 patients who will not receive the TXA, but will receive a 100ml intravenous saline solution 0,9% after anesthetic induction and before incising the skin (such as group 1) and a compress soaked in saline solution as used in group 2.
62768803|NCT03434314|EXPERIMENTAL|MISACE arm|"Minimally-Invasive Segmental Artery Coil-Embolization~MISACE procedure prior to aneurysm repair~segmental arteries are occluded with coils or plugs in one to three MISACE sessions (staged procedure)"
62560599|NCT01797874|EXPERIMENTAL|Pazopanib|pazopanib maintenance after 4 cycles of etoposide/platinum in SCLC
62560600|NCT01797874|PLACEBO_COMPARATOR|placebo|placebo after 4 cycles of etoposide/platinum chemotherapy in SCLC
61993706|NCT03610243|NO_INTERVENTION|Wait-list control|The wait-list control group will be contacted in the third week to attend a health talk unrelated to symptom management.
61993707|NCT06021561||Multiple sclerosis group|Multiple sclerosis patients registered in Varazdin General Hospital from 1 January 2017 - 31 December 2022
61993708|NCT00682188|EXPERIMENTAL|CI|Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)
61993709|NCT00682188|ACTIVE_COMPARATOR|II|Six individual sessions with the school nurse over 2 months to check weight and behavior changes and provide a series of six pamphlets on weight and weight management
61993710|NCT01959152|EXPERIMENTAL|HiRes90K™ Advantage Cochlear Implant|HiRes90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with a moderate level of hearing loss in the low frequencies and severe-to-profound hearing loss in the mid-to-high frequencies.
62389015|NCT02896959|EXPERIMENTAL|65mmHg pressure|Pump pressure of 65mmHg during rotator cuff repair
61993711|NCT03067805|EXPERIMENTAL|Oxytocin|Oxytocin nasal spray
61993712|NCT03067805|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray
61993713|NCT05292560|EXPERIMENTAL|Positive psychology app|
61993714|NCT05292560|OTHER|Waiting list|
61993715|NCT00864747|EXPERIMENTAL|A|Propranolol Hydrochloride Extended Release Capsules 160 mg, single dose
62560601|NCT05889650|EXPERIMENTAL|1st stage - prophylactic|External lumbar drainage @15mmHg if intracranial pressure is not raised on admission
62560602|NCT05889650|EXPERIMENTAL|2nd stage - treatment|External lumbar drainage @20mmHg if / when intracranial pressure \>20mmHg and tier 1 therapies cannot achieve ICP\<20mmHg
62560603|NCT05889650|NO_INTERVENTION|Usual treatment|Usual treatment as per SIBICC algorithm
62560604|NCT04430959|EXPERIMENTAL|Candesartan first then Placebo|4 weeks of candesartan with crossover to the other.
61993716|NCT00864747|ACTIVE_COMPARATOR|B|INDERAL® LA 160 mg Capsules, single dose
61993717|NCT03669835|EXPERIMENTAL|Dietary supplement and standard therapy.|Participants will take a supplement of 1 sachet (20 mg) 3 times/day accompanied with the standard therapy for 1 month.
61993718|NCT03669835|OTHER|Standard therapy only.|Patients would be given standard treatment for 1 month.
61993719|NCT01895738|EXPERIMENTAL|WrapAround Care|Participants randomized to the intervention arm will be met in the emergency department by a support worker who has lived experience. They will start to build a relationship with the participant at that time (i.e. during the teachable moment) and will work with the participant for approximately one year, delivering WrapAround Care. Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
61993720|NCT01895738|NO_INTERVENTION|Standard of Care|Standard of Care is typically a sheet of community resources potentially handed out by the emergency physician, nurse or social worker.
61993721|NCT04657497|EXPERIMENTAL|FOY-305 group|Camostat Mesilate tablets 600 mg will be orally administered 4 times daily, before breakfast, before lunch, before evening meal, and at bedtime. The treatment period is up to 14 days.
62560605|NCT04430959|PLACEBO_COMPARATOR|Placebo first then Candesartan|4 weeks of placebo with crossover to the other.
61993722|NCT04657497|PLACEBO_COMPARATOR|Placebo group|Placebo tablets will be orally administered 4 times daily, before breakfast, before lunch, before evening meal, and at bedtime. The treatment period is up to 14 days.
61993723|NCT06394869|EXPERIMENTAL|Test Arm|The site will receive the Cxbladder Detect+ result and the urologist study investigator discuss it with the patient before making a shared decision whether or not to proceed with cystoscopy.
61993724|NCT06394869|NO_INTERVENTION|Control arm|Neither the site nor the patient will receive the Cxbladder Detect+ result. The decision whether or not to proceed with cystoscopy will be made following standard of care.
61993725|NCT05210686|EXPERIMENTAL|subgingival re-instrumentation + gel containing PDRN and HA|subgingival re-instrumentation + gel containing PDRN and HA
61993726|NCT05210686|ACTIVE_COMPARATOR|subgingival re-instrumentation|subgingival re-instrumentation
61993727|NCT02061969|ACTIVE_COMPARATOR|Insulin glargine|Insulin glargine starting at 0.1 unit/kg/day added to ongoing metformin if the patient is already on it. The duration will be for a 6-month period.
61993728|NCT02061969|EXPERIMENTAL|linagliptin|Oral linagliptin 5mg once daily added to ongoing metformin if the patient is already on it. The duration will be for a 6-month period.
61993729|NCT00779103|EXPERIMENTAL|Histrelin Subcutaneous Implant (50 mg)|Subcutaneous implant designed to deliver histrelin continously for 12 months.
61993730|NCT03048396|EXPERIMENTAL|Uterus transplantation|
61993731|NCT05159245|EXPERIMENTAL|Alectinib|For patients with a molecular tumor profile that can potentially be targeted by alectinib.
61993732|NCT05159245|EXPERIMENTAL|Cobimetinib|For patients with a molecular tumor profile that can potentially be targeted by cobimetinib.
61993733|NCT05159245|EXPERIMENTAL|Vismodegib|For patients with a molecular tumor profile that can potentially be targeted by vismodegib.
61993734|NCT05159245|EXPERIMENTAL|Trastuzumab+Pertuzumab|For patients with a molecular tumor profile that can potentially be targeted by trastuzumab+pertuzuma combination.
61993735|NCT05159245|EXPERIMENTAL|Entrectinib|For patients with a molecular tumor profile that can potentially be targeted by entrectinib.
61993736|NCT05159245|EXPERIMENTAL|Atezolizumab|For patients with a molecular tumor profile that can potentially be targeted by atezolizumab.
61993737|NCT05159245|EXPERIMENTAL|Vemurafenib|For patients with a molecular tumor profile that can potentially be targeted by vemurafenib.
62560606|NCT00651833|EXPERIMENTAL|1|All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. Patient will also receive cisplatin, 75 mg/m2 as a 1- to 3-hour infusion on Day 1 of each cycle.
62560607|NCT05032300|ACTIVE_COMPARATOR|focused shockwave therapy|Patients will receive 6 sessions of focused shockwave therapy.
62560608|NCT05032300|ACTIVE_COMPARATOR|control|Patients in the control group will be treated using the home therapy protocol only.
62389016|NCT04547452|EXPERIMENTAL|Sintilimab Combined with SBRT|"Patients will be randomly placed in either of the two arms. Participants enrolled in this arm treated to a total dose of 35-80Gy in 5-8 fractions with stereotactic radiotherapy to a liver or lung or any metastatic lesion. The choice of radiation dose will be at the discretion of the treating radiation oncologist.~Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year."
62389017|NCT04547452|ACTIVE_COMPARATOR|Sintilimab|Participants enrolled in this arm treated with sintilimab administered intravenously at 200 mg every 3 weeks for up to 1 year.
62389018|NCT05980494|EXPERIMENTAL|Scanning group|Lung ultrasound (LUS), Inferior vena cava ultrasound (IVC US) and pulse pressure variation (PPV) will be done to every patient in the study.
62389019|NCT03807258|EXPERIMENTAL|COPD patients group|COPD patients undergoing transcranial magnetic stimulation (TMS) evaluations.
62389020|NCT03807258|ACTIVE_COMPARATOR|Controls group|Healthy matched controls undergoing transcranial magnetic stimulation (TMS) evaluations.
62389021|NCT00628680|EXPERIMENTAL|AAT-023 (Zuragen Arm)|Active experimental consisting of AAT-023 (Zuragen)solution
62389022|NCT00628680|ACTIVE_COMPARATOR|Heparin|5000 units diluted with normal saline to the exact catheter lumen volume
62389023|NCT04383041||Patients with Type 2 Diabetes|Patients with Metformin containing prescription drugs will be eligible for participation and consecutively invited to study participation in their pharmacy.
62389024|NCT03244111|ACTIVE_COMPARATOR|Healthy Cognition|The intervention will be carried out as described in the study details using the simple memory tool. The group with healthy cognition may perform better on tasks since they have a higher level of cognition.
62389025|NCT03244111|ACTIVE_COMPARATOR|MCI|The intervention will be carried out as described in the study details using the simple memory tool. The group with MCI may have a lower level of performance on tasks since they have a lower level of cognition. Some tasks may take longer for the participant or need more explanation from the researcher (e.g., explanation of a question).
62389026|NCT01511211|EXPERIMENTAL|Ropivacaine + Dexamethasone Combination|
62560609|NCT01381211|ACTIVE_COMPARATOR|Yttrium-90 radioembolization (90Y-RE)|
62768804|NCT03434314|NO_INTERVENTION|control arm|receives treatment of aneurysm as usual: open surgical repair or endovascular repair without MISACE
61993738|NCT05159245|EXPERIMENTAL|Regorafenib|For patients with a molecular tumor profile that can potentially be targeted by regorafenib.
61993739|NCT05159245|EXPERIMENTAL|Apalutamide|For patients with a molecular tumor profile that can potentially be targeted by apalutamide.
62389027|NCT01511211|ACTIVE_COMPARATOR|Ropivacaine-Only Block|
62389028|NCT04253652||Oral iron|These patients will have diagnosed with iron deficiency anaemia and been prescribed oral iron supplements as part of their treatment from their doctor. This will be in accordance with the NICE guidelines; 200mg capsules containing 65mg elemental iron, 2-3 times a day for a period of atleast 1 month.
62389029|NCT04253652||Intravenous iron|These patients will have diagnosed with iron deficiency anaemia and been prescribed intravenous iron as part of their treatment from their doctor. Participants will receive an infusion of either 1000mg or 1500mg
62389030|NCT02665273|EXPERIMENTAL|Greater occipital nerve block|Bilateral greater occipital nerve block with 3cc of 0.5% bupivacaine, delivered using fan technique
62389031|NCT02665273|SHAM_COMPARATOR|Sham|Bilateral intradermal injection of 0.5cc of 0.5% bupivacaine, delivered superficially to the area overlying the greater occipital nerve
62389032|NCT01634087|EXPERIMENTAL|100 mg QD Itacitinib|
62389033|NCT01634087|EXPERIMENTAL|100 mg QD Placebo|
62389034|NCT01634087|EXPERIMENTAL|200 mg QD Itacitinib|
62389035|NCT01634087|EXPERIMENTAL|200 mg QD Placebo|
62389036|NCT01634087|EXPERIMENTAL|200 mg BID Itacitinib|
61993740|NCT05159245|EXPERIMENTAL|Abemaciclib|For patients with a molecular tumor profile that can potentially be targeted by abemaciclib.
61993741|NCT05159245|EXPERIMENTAL|Tepotinib|For patients with a molecular tumor profile that can potentially be targeted by tepotinib.
62389037|NCT01634087|EXPERIMENTAL|200 mg BID Placebo|
62389038|NCT01634087|EXPERIMENTAL|600 mg once a day Itacitinib|
62389039|NCT01634087|EXPERIMENTAL|600 mg once a day Placebo|
62389040|NCT00531466|ACTIVE_COMPARATOR|1|
62389041|NCT00531466|PLACEBO_COMPARATOR|2|
62389042|NCT01004159|EXPERIMENTAL|cetuximab with irinotecan|
62768805|NCT03963102|ACTIVE_COMPARATOR|Control Group 3 hours|Application of Ameluz for 3 hours.
61993742|NCT05159245|EXPERIMENTAL|Dabrafenib|For patients with a molecular tumor profile that can potentially be targeted by dabrafenib.
61993743|NCT05159245|EXPERIMENTAL|Trametinib|For patients with a molecular tumor profile that can potentially be targeted by trametinib.
62389043|NCT03859115|ACTIVE_COMPARATOR|preanesthesia-TENS|Patients in preanesthesia-TENS group receive TENS for 30 minutes at one arm before anesthesia.
62389044|NCT03859115|SHAM_COMPARATOR|preanesthesia-sham|Patients in preanesthesia-sham group receive sham stimulation for 30 minutes at one arm before anesthesia.
62389045|NCT03859115|EXPERIMENTAL|sevoflurane-TENS|Patients in sevoflurane-TENS group receive TENS for 30 minutes at one arm under sevoflurane anesthesia.
62389046|NCT03859115|ACTIVE_COMPARATOR|sevoflurane-sham|Patients in sevoflurane-sham group receive sham stimulation for 30 minutes at one arm under sevoflurane anesthesia.
61993744|NCT05159245|EXPERIMENTAL|Dabrafenib+Trametinib|For patients with a molecular tumor profile that can potentially be targeted by dabrafenib+trametinib combination.
62389047|NCT03859115|EXPERIMENTAL|propofol-TENS|Patients in propofol-TENS group receive TENS for 30 minutes at one arm under propofol anesthesia.
62389048|NCT03859115|ACTIVE_COMPARATOR|propofol-sham|Patients in propofol-sham group receive sham stimulation for 30 minutes at one arm under propofol anesthesia.
62560610|NCT01381211|ACTIVE_COMPARATOR|Transarterial chemoembolization with drug eluting beads|Transarterial chemoembolization is performed with drug eluting beads, polyvinyl alcohol-based microspheres (DC Beads, Biocompatibles) loaded with the chemotherapeutic agent doxorubicin.
62560611|NCT04252651||Blood Draw|This study will involve blood draws to test for specific cytokines
62768806|NCT03963102|EXPERIMENTAL|Trial Group 4 hours|Application of Ameluz for 4 hours.
62768807|NCT03052556|OTHER|Cohort of women with cystic fibrosis|Includable patients are adult women, transplanted or not, followed at Lyon CRCM (Centre de Ressources et de Compétences de la Mucoviscidose).
62768808|NCT01348555|EXPERIMENTAL|V0162|
62389049|NCT01296321|EXPERIMENTAL|Tailored Internet-delivered CBT|Behavioral: Tailored Internet-delivered CBT
62389050|NCT01296321|ACTIVE_COMPARATOR|Waitlist|Waitlist.
62389051|NCT05671029|EXPERIMENTAL|Group 1|"Subjects (32 male and female subjects) receive 400 mg pritelivir on Day 1, 100 mg pritelivir from Day 2 to 6 and 400 mg pritelivir from Day 7 to 16.~Furthermore, these subjects receive 400mg moxifloxacin matching placebo on the Days 2 and 17."
62389052|NCT05671029|EXPERIMENTAL|Group 2a|"Subjects (16 male and female subjects) receive 400 mg pritelivir matching placebo on Day 1, 100mg pritelivir matching placebo from Day 2 to Day 16.~Furthermore, these subjects receive 400 mg moxifloxacin on Day 2 and 400 mg moxifloxacin matching placebo on Day 17."
62560612|NCT00432926|EXPERIMENTAL|1|Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
62768809|NCT01348555|PLACEBO_COMPARATOR|Placebo|
62768810|NCT02246608|ACTIVE_COMPARATOR|Routine NPWT Standard of Care|Prior to applying and activating the Negative Pressure Wound Treatment (NPWT) pump, standard of care dressing will be placed.
62768811|NCT02246608|EXPERIMENTAL|NPWT Standard of Care plus Oasis wound product|Prior to applying and activating the Negative Pressure Wound Treatment (NPWT) pump, Oasis wound product will be applied in addition to standard of care dressing.
62768812|NCT00413010|PLACEBO_COMPARATOR|Arm 2|
62768813|NCT00413010|EXPERIMENTAL|Arm 1|
62768814|NCT04764344|EXPERIMENTAL|Haloperidol|2.5 mg of IV haloperidol diluted to a final concentration of 5 mL with 0.9% sodium chloride
62768815|NCT04764344|ACTIVE_COMPARATOR|Ondansetron|4 mg of IV ondansetron diluted to a final concentration of 5 mL with 0.9% sodium chloride
62768816|NCT03445390|EXPERIMENTAL|Acetaminophen First|Patients in this group are presenting for 2 surgeries and will be administered intravenous acetaminophen in one surgery and placebo in the other. Patients in this group will be randomized to receive acetaminophen first.
62768817|NCT03445390|EXPERIMENTAL|Placebo First|Patients in this group are presenting for 2 surgeries and will be administered intravenous acetaminophen in one surgery and placebo in the other. Patients in this group will be randomized to receive placebo first.
62768818|NCT02274545|EXPERIMENTAL|H7N9 live attenuated vaccine & inactivated subvirion H7N9 vac.|Participants will receive one dose of the H7N9 vaccine at Days 0 and 28. They will receive one dose of the inactivated subvirion H7N9 vaccine on Day 98.
62768819|NCT00409344|PLACEBO_COMPARATOR|1|Normal Saline
62768820|NCT00409344|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine is a highly specific a2 agonist with prominent central nervous system and cardiovascular effects. A postoperative sedative-hypnotic agent for intensive care patients for use up to 24 hours.
62768821|NCT00199888|EXPERIMENTAL|124I-cG250|Patients who were scheduled for surgical resection of renal masses received a single intravenous (IV) dose of 10 mg of 5 milliCurie (mCi) /10 mg 124I-cG250. Patients underwent Positron-Emission Tomography/Computed Tomography (PET/CT) imaging of the whole body on at least 2 occasions: once following injection and once immediately prior to surgical resection. Patients were scheduled for surgical resection of their renal masses on day 8.
62768822|NCT00710385|ACTIVE_COMPARATOR|Heroin|Heroin 25 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
62768823|NCT00710385|ACTIVE_COMPARATOR|Naloxone|Naloxone (NAL) .4 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
62768824|NCT00710385|EXPERIMENTAL|Low Bup Dose|Combined dosing groups of (4 mg and 8mg of Buprenorphine) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
62768825|NCT00710385|EXPERIMENTAL|Low Bup/Nal Dose|Combined dosing groups of (4/1 mg and 8/2mg of Buprenorphine + Naloxone) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
62389053|NCT05671029|EXPERIMENTAL|Group 2b|"Subjects (16 male and female subjects) receive 400 mg pritelivir placebo on Day 1, 100mg pritelivir placebo from Day 2 to Day 16.~Furthermore, these subjects receive 400 mg moxifloxacin matching placebo on Day 2 and 400 mg moxifloxacin on Day 17."
62389054|NCT04777422|EXPERIMENTAL|Interventional|Defibrotide 6.25 mg/kg IV q6h
62768826|NCT00710385|EXPERIMENTAL|High Bup Dose|Combined dosing groups of (8mg and 16mg of Bup) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
62768827|NCT00710385|EXPERIMENTAL|High Bup/Nal Dose|Combined dosing groups of (8/2mg and 16/4mg of Buprenorphine + Naloxone) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
62389055|NCT01823991|EXPERIMENTAL|COGNUTRIN (VITABLUE and n-3 fatty acids)|Participants will be provided with two bottles containing Lovaza and VitaBlue. Participants will be asked to take 1 tablet of Lovaza two times a day and 1 tablet of VitaBlue three times a day.
62389056|NCT01823991|PLACEBO_COMPARATOR|Placebo Administration|Participants will be provided with two bottles containing placebo. Participants will be asked to take 1 tablet of one placebo two times a day and 1 tablet of other placebo three times a day.
62389057|NCT01897779|EXPERIMENTAL|Single and multiple dose of RPX7009|Single and multiple dose of RPX7009
61993745|NCT05159245|EXPERIMENTAL|Pemigatinib|For patients with a molecular tumor profile that can potentially be targeted by pemigatinib.
61993746|NCT04334499||Age Related Macular Degeneration|Subjects with Age Related Macular Degeneration upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
62389058|NCT01897779|EXPERIMENTAL|Single and multiple dose of RPX2014|Single and multiple dose of RPX2014
62389059|NCT01897779|PLACEBO_COMPARATOR|Normal Saline|Single and multiple dose of normal saline
62389060|NCT01897779|EXPERIMENTAL|Combination RPX7009 and RPX2014|Single and Multiple dose of Combination RPX7009 and RPX2014
62389061|NCT01279421|EXPERIMENTAL|Social Network HIV Testing|Participants in this arm will be recruited through social networks and will receive an HIV test.
62389062|NCT01279421|EXPERIMENTAL|Peer Network Intervention|Eight (8) current or former crack users will be recruited to facilitate small networks of crack users in a three-day intervention. They will also facilitate monthly meetings open to all community members regarding HIV prevention and interpersonal violence.
62389063|NCT02911324|EXPERIMENTAL|Nabilone|Will receive nabilone at 1 mg daily (BID) over 4 weeks.
62389064|NCT02911324|EXPERIMENTAL|Nabilone and EX/RP|Will receive nabilone at 1 mg daily (BID) plus therapist-guided Exposure and Response Prevention Therapy during 4 weeks.
62389065|NCT01180829|NO_INTERVENTION|Control condition|No interventions text messages sent
62389066|NCT01180829|EXPERIMENTAL|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking
62560613|NCT00432926|EXPERIMENTAL|2|Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
62560614|NCT00432926|ACTIVE_COMPARATOR|3|An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
62560615|NCT04522440|EXPERIMENTAL|Inpatients in hospice Ward|Inpatients in hospice Ward with pain control problems
62560616|NCT03452670|EXPERIMENTAL|Active Group|Participants in this group will use a contemplative wellness application for 8 weeks.
62560617|NCT03452670|OTHER|Waitlist Group|The waitlist group will receive no intervention during the study but will be able to use the wellness application after completion of the study.
62560618|NCT01863667|EXPERIMENTAL|Omarigliptin|Participants receive an omarigliptin (MK-3102) 25 mg capsule once weekly and glimepiride placebo tablet(s) once daily, for 54 weeks.
62560619|NCT01863667|ACTIVE_COMPARATOR|Glimepiride|Participants receive glimepiride 1 mg and/or 2 mg tablet(s) (maximum dose 6 mg/day) once daily and an omarigliptin placebo capsule once weekly, for 54 weeks.
62560620|NCT02735759|OTHER|Healthy Volunteers|This cohort will consist of ten healthy volunteers. The photoacoustic flow cytometry device will be used to establish device settings. The intervention with the subject will include the PAFC device to establish appropriate device settings.
62560621|NCT02735759|OTHER|Venous Thromboembolism|This cohort will consist of ten patients with newly diagnosed, non-life threatening acute venous thromboembolism. The intervention with the subjects is to perform the photoacoustic flow cytometry device to detect circulating emboli in vivo in patients with venous thromboembolism at diagnosis, during and after anticoagulation therapy.
62560622|NCT04851977|EXPERIMENTAL|Cohort 1: low dose|IM injection on Day 0 (12 active, 3 placebo); with follow up at 7 days ± 1 day post vaccination and at Day 30 ± 5 days and a final follow up/end of study (EOS) teleconference assessment at Day 60 ± 5 days.
62560623|NCT04851977|PLACEBO_COMPARATOR|Cohort 2: low dose|IM injection on Day 0 and at Day 30 (12 active, 3 placebo) with follow up at 7 days post vaccination (Day 7 ± 1 day and Day 37 ± 1 day) and Day 60 ± 5 days and a final follow up/ EOS teleconference assessment at Day 90 ± 5 days.
62560624|NCT04851977|EXPERIMENTAL|Cohort 3: high dose|IM injection on Day 0 (12 active, 3 placebo); with follow up at 7 days ± 1 day post vaccination and at Day 30 ± 5 days and a final follow up/end of study (EOS) teleconference assessment at Day 60 ± 5 days.
62560625|NCT04851977|PLACEBO_COMPARATOR|Cohort 4: high dose|IM injection on Day 0 (12 active, 3 placebo); with follow up at 7 days ± 1 day post vaccination and at Day 30 ± 5 days and a final follow up/end of study (EOS) teleconference assessment at Day 60 ± 5 days.
62560626|NCT04601766|EXPERIMENTAL|Group A|
62768828|NCT00710385|PLACEBO_COMPARATOR|Placebo|Intravenous placebo (PCB) administration. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
62560627|NCT04601766|EXPERIMENTAL|Group B|
62560628|NCT03582462|EXPERIMENTAL|IONIS FXI-LRx|Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection.
62560629|NCT03582462|PLACEBO_COMPARATOR|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator.
62768829|NCT04024423||Related M. abscess isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
62389067|NCT01180829|EXPERIMENTAL|Consciousness raising text message|A series of 12 text messages, each of which contains text designed to get the person to think about his or her drinking
62560630|NCT05460767|EXPERIMENTAL|IBI363|Single arm
62560631|NCT03125967|ACTIVE_COMPARATOR|Blue Light|Blue light exposure (Philips GoLite Blu HF3429/60) administered daily for 25 minutes between 8:00AM and 9:00AM
62560632|NCT03125967|PLACEBO_COMPARATOR|Red Light|Red light exposure (Philips LivingColor Aura 70998/60/48) administered daily for 25 minutes between 8:00AM and 9:00AM
62560633|NCT01675934|ACTIVE_COMPARATOR|Adult colonoscope|Use of the adult colonoscope.
62768830|NCT04024423||Unrelated M. abscessus isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
62389068|NCT02144662|EXPERIMENTAL|Ranibizumab|Ranibizumab
62560634|NCT01675934|ACTIVE_COMPARATOR|Pediatric colonoscope|Use of the pediatric colonoscope.
62560635|NCT02060331||Pelvic Organ Prolapse with Nocturia|Pelvic Organ Prolapse with Nocturia
62560636|NCT06079411|ACTIVE_COMPARATOR|TAU|"the treatment as usual (TAU; i.e., visuospatial paper and pencil stimulation) will consist of paper and pencil exercises used in clinical routine of 8 sessions of 30/40 minutes 3 times a week."
62560637|NCT06079411|EXPERIMENTAL|VR non-embodied|the non-embodied spatial training will consist of egocentric and allocentric spatial memory training with passive navigation of 8 sessions of 30/40 minutes 3 times a week.
62560638|NCT06079411|EXPERIMENTAL|VR embodied|the embodied spatial training will consist of egocentric and allocentric spatial memory training with active navigation of 8 sessions of 30/40 minutes 3 times a week.
62560639|NCT05120986||IND/GLY/MF with sensor|Patients prescribed with indacaterol acetate, glycopyrronium bromide and mometasone furoate with sensor
62560640|NCT05120986||IND/GLY/MF without sensor|Patients prescribed with indacaterol acetate, glycopyrronium bromide and mometasone furoate without sensor
62389069|NCT06334380|ACTIVE_COMPARATOR|Control Group: Virtual Reality Modules Only|Participants will have access to the prehabilitation (preoperative) and rehabilitation (postoperative) virtual reality physical therapy modules.
62389070|NCT06334380|EXPERIMENTAL|Intervention Group: Virtual Reality Modules + Live Physical Therapist Support|"Participants will have access to prehabilitation and rehabilitation virtual reality physical therapy modules in addition to zoom office hours with the physical therapist so that they may ask questions."
62389071|NCT02527291||Study Group|"The Study group will comprise of seropositive CMV patients undergoing cardiothorathic surgery and having a complicated postoperative course.~In addition to the routine blood work which includes: CBC, chemistry and INR, blood work for CMV PCR will be done three times: at enrollment, follow up 1 (7 days post operation) and follow up 2 (14 days post operation).~Blood work for Interleukin28 (IL28) will be done at enrollment. All visits include data collection from computerized medical records."
62389072|NCT02527291||Control Group 1|"The first control group will be comprised of patients who are seropositive CMV undergoing cardiothorathic surgery and having a normal postoperative course.~In addition to the routine blood work which includes: CBC, chemistry and INR, blood work for CMV PCR will be done two times: at enrollment and follow up 1 (7 days after discharge).~Blood work for Interleukin28 (IL28) will be done at enrollment. All visits include data collection from computerized medical records."
62389073|NCT02527291||Control Group 2|"The second control group will include seronegative patients for CMV undergoing cardiothorathic surgery with complicated and uncomplicated post-operative course.~Blood work for CMV PCR and IL28 will be done at enrollment. All other visits include data collection from computerized medical records only."
62389074|NCT03439007||Hypotensive|A group of pediatric patients who showed hypotension during induction of anesthesia
62768831|NCT04024423||Related M. avium isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
62768832|NCT04024423||Unrelated M. avium isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
61993747|NCT04334499||Glaucoma|Subjects with Glaucoma upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
62389075|NCT03439007||Normotensive|A group of pediatric patients who did not show hypotension during induction of anesthesia
62389076|NCT03421899||Genetic Parkinson's group|Those participants with Parkinson's disease and a genetic mutation known to cause or increase risk of Parkinson's disease (e.g. Parkin, PINK1, GBA or LRRK2)
62389077|NCT03421899||Idiopathic Parkinson's group|Those participants with Parkinson's disease but without a known genetic mutation known to cause or increase risk of Parkinson's disease
62389078|NCT03421899||Healthy control group|Those participants unaffected by Parkinson's disease
62389079|NCT03024151|ACTIVE_COMPARATOR|T4/T3 combination replacement|Comthyroid
62389080|NCT03024151|ACTIVE_COMPARATOR|T4 mono replacement|Synthroid
62560641|NCT03591874|EXPERIMENTAL|OCU-300|Brimonidine Tartrate Nanoemulsion Eye Drops 0.18% given 2 times a day for 12 weeks.
62768833|NCT04024423||Related M. intracellulare isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
62768834|NCT04024423||Unrelated M. intracellulare isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
62768835|NCT00671450||Group 1|Participants will be patients diagnosed with PTSD but with no history of TBI. Participants must be between the ages of 19 and 39. Participants must be compentent to sign a consent form and be willing ot participate in a vision screening.
61993748|NCT04334499||Diabetic Retinopathy|Subjects with Diabetic Retinopathy upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
61993749|NCT04334499||Ocular Trauma|Subjects with Ocular Trauma upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
61993750|NCT04334499||Control|Subjects with no ocular disease or trauma comorbidities upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
62389081|NCT05905692|EXPERIMENTAL|L carnitine group|patients will take L carnitine (20 mg/kg/day) 3 times per week (on the same days of the dialysis session, 30 minutes before the session)
62389082|NCT05905692|PLACEBO_COMPARATOR|Placebo group|patients will take placebo 3 times per week (on the same days of the dialysis session, 30 minutes before the session)
62389083|NCT00620815|EXPERIMENTAL|T/P-A|One dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Aflunov (A) on day 22
62389084|NCT00620815|EXPERIMENTAL|A/P-T|One dose of the Aflunov (A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Tetravalent influenza vaccine (T) on day 22.
62389085|NCT00620815|ACTIVE_COMPARATOR|A/S-A|One dose of Aflunov (A) and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed Aflunov (A) on day 22.
62389086|NCT00620815|EXPERIMENTAL|T/P-A (V2 blood draw)|One dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by a blood draw at visit 2 (V2) prior to Aflunov (A) vaccination on day 22.
62560642|NCT03591874|PLACEBO_COMPARATOR|Placebos|Placebo - Ophthalmic buffered saline Eye Drops given 2 times a day for 12 weeks.
62560643|NCT01023009||eye occlusion|
62560644|NCT03388151|ACTIVE_COMPARATOR|Midazolam|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation
62560645|NCT03388151|ACTIVE_COMPARATOR|Propofol|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation
62560646|NCT04019977|EXPERIMENTAL|Nurse Home Visiting Group|This group will be offered services from the nurse home visiting program.
61993751|NCT01928862|EXPERIMENTAL|Prepopik® ½ Sachet x 2 (9-12 years)|Prepopik® ½ Sachet x 2 (9-12 years)
62768836|NCT03518346|EXPERIMENTAL|Virtual Reality Group|Participants may be randomized to the virtual reality, VR, group or the standard of care group. For the VR group, we are using the Samsung VR Go (VR head set), Samsung S7 (phone) and programmed distraction (Spaceburgers, Pebbles the Penguin, and/or Happy Place). Spaceburgers and Pebbles the Penguin were designed by the Department of Anesthesiology at Lucile Packard Children's Hospital Stanford through the Stanford Chariot Program (Childhood Anxiety Reduction Through Innovation and Technology). Happy Place is a nongame immersive experience that will be offered to children uninterested in the previously mentioned game. Happy Place was designed by a Swedish Pharmacy Chain, Apotek Hjartat, aimed to distract patients from their pain with a peaceful, interactive environment. Each of the video games runs for the length of time needed to complete the venipuncture.
62768837|NCT03518346|ACTIVE_COMPARATOR|Standard of Care Group|Participants may be randomized to the virtual reality, VR, group or the standard of care group. The standard of care group will use various distractions. Distraction tools include books and movies using a wall mounted TV as standard practice.
61993752|NCT01928862|EXPERIMENTAL|Prepopik® 1 Sachet x 2 (9-12 years)|Prepopik® 1 Sachet x 2 (9-12 years)
62768838|NCT04004403|EXPERIMENTAL|Alternate day fasting|"These participants will consume 600 kcal on the fast day and eat ad libitum at home on alternating feed days."
62768839|NCT04004403|EXPERIMENTAL|Exercise|These participants will participate in a supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.
62768840|NCT04004403|EXPERIMENTAL|Combination alternate day fasting plus exercise|"These participants will consume 600 kcal on the fast day and eat ad libitum at home on alternating feed days. They will also participate in a supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax."
61993753|NCT01928862|ACTIVE_COMPARATOR|Oral polyethylene glycol (PEG) based preparation (9-12 years)|Local standard of care
61993754|NCT01928862|EXPERIMENTAL|Prepopik® 1 Sachet x 2 (13-16 years)|Prepopik® 1 Sachet x 2 (13-16 years)
62389087|NCT00620815|EXPERIMENTAL|A/P-T (V2 blood draw)|One dose of the Aflunov(A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by additional blood draw at visit 2 (V2) prior to the Tetravalent influenza vaccination (T) on day 22.
62768841|NCT04004403|NO_INTERVENTION|Control|Controls will be instructed to maintain their weight throughout the trial, and not to change eating or physical activity habits.
62768842|NCT06130982|EXPERIMENTAL|EG1:Health Qigong·Yijinjing|HQ·Yijinjing includes the following 10 movements:Wei Tuo Presenting the Stick1-3,Picking the star and Embracing the Moon,Hauling Nine Cattle's Tails Inversely,Pushing out the Palms Like Birds Extending the wings,Nine Ghosts Pulling Horse Blade Technique,Three Trays Falling Down,Black Dragon Streching out the Claws,Crouched Tiger,Pouncing on Its Prey,Bowing Posture,Hips Hanging.
62768843|NCT06130982|EXPERIMENTAL|EG2:Health Qigong·Wuqinxi|HQ·Wuqinxi includes the following 10 movements:Tiger Lifting,Tiger Pouncing,Deer Wrestling,Deer Dashing,Bear Lumbering,Bear Swaying,Monkey Hooking,Monkey Picking,Crane Stretching,Crane Flying.
62768844|NCT06130982|EXPERIMENTAL|EG3:Health Qigong·Baduanjin|HQ·Baduanjin includes the following 8 movements:Supperting the Palms to the Sky to Regulate Qi of Sanjiao,Forward Lunge on the Right and Left Like Shooting an Eagle,Lifting One Arm to Regulate the Functions of Spleen and Stomach,Looking Backward to Treat Strain and Impairments,Swaying the Head and the Bottoms to Clear the Heat of Heart,Hands Grabbing Toes to Strengthen the Kidney and the Waist,Clenching Fists with Wild Eyes Glowering to Increase Strength,Raising and Lowering the Heels 7times to Alleviate Diseases.
61993755|NCT01928862|ACTIVE_COMPARATOR|Oral polyethylene glycol (PEG) based preparation (13-16 years)|Local standard of care
61993756|NCT02734810|EXPERIMENTAL|Part A|Liprotamase Powder for Oral Solution in Subjects aged ≥7 years of age
62389088|NCT00620815|ACTIVE_COMPARATOR|A/S-A (V2 blood draw)|One dose of Aflunov (A)and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed by an additional blood draw at visit 2 (V2) prior to Aflunov (A) vaccination on day 22.
62389089|NCT05032131|EXPERIMENTAL|Experimental|"Group 1:~Patients treated by sirolimus since at least 6 months (but still disabled)~Group 2:~Patients currently (for at least 3 months) without specific treatment for inclusion myositis"
62560647|NCT04019977|NO_INTERVENTION|Non-intervention Group|This group will not be offered services from the nurse home visiting program.
61993757|NCT02734810|EXPERIMENTAL|Part B|Liprotamase Powder for Oral Solution in Subjects aged 28 days to \<7 years
61993758|NCT05347316|EXPERIMENTAL|Colchicine|0.5 mg of colchicine daily for 12 months
61993759|NCT05347316|NO_INTERVENTION|Placebo|Follow-up for 12 months
61993760|NCT01251588||MACI|autologous cultured chondrocytes on porcine collagen membrane implant received in previous MACI00206 study
61993761|NCT01251588||Microfracture|Microfracture treatment received in previous MACI00206 study
61993762|NCT01461772|EXPERIMENTAL|CCRT weekly carboplatin|Concurrent chemoradiation therapy with weekly carboplatin
61993763|NCT01461772|ACTIVE_COMPARATOR|CCRT weekly cisplatin|Concurrent chemoradiation therapy with weekly cisplatin
61993764|NCT06250062|EXPERIMENTAL|Placebo（JS005）|
61993765|NCT06250062|EXPERIMENTAL|Recombinant humanized IL-17A Monoclonal Antibody（JS005）150mg|
61993766|NCT06250062|EXPERIMENTAL|Recombinant humanized IL-17A Monoclonal Antibody（JS005）300mg|
61993767|NCT02260284|EXPERIMENTAL|Yaotong points acupuncture|patients under the treatment of Yaotong ponts penetration mode
61993768|NCT02260284|ACTIVE_COMPARATOR|standardized acupuncture|patients under the treatment of standardized acupuncture
61993769|NCT02260284|OTHER|the usual care|In the usual care group, participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS)).
61993770|NCT06072937|EXPERIMENTAL|IntelliStent Arm|Single Arm Safety and Effectiveness of the IntelliStent System
61993771|NCT00004888|EXPERIMENTAL|Arm I (combination chemotherapy)|"Patients receive doxorubicin hydrochloride liposome IV over 30 minutes followed by docetaxel IV over 1 hour. Treatment is repeated every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.~Patients may receive maintenance therapy of docetaxel IV over 1 hour either weekly or every 3 weeks. Maintenance continues in the absence of disease progression or unacceptable toxicity."
62768845|NCT06130982|OTHER|CG:Walking|The control group underwent walking exercise, with a walking speed of 1.0 ± 0.2m/s based on age characteristics and human dynamic stability.
62768846|NCT02861911|SHAM_COMPARATOR|Control group|The current intensity is generally defined between the sensory and motor threshold (patients feel the power but no visible muscle contraction will be obtained).
62768847|NCT02861911|ACTIVE_COMPARATOR|Active NMES group|Tthe current intensity must always meet and exceed the motor threshold (patients feel the current and quadriceps muscle will contract a visible and quantifiable if possible).
62768848|NCT00947414|ACTIVE_COMPARATOR|Shockwave plus strength training|6 sessions of extracorporeal shock wave plus daily gluteal strength exercises
62768849|NCT00947414|SHAM_COMPARATOR|Sham extracorporeal shock wave plus gluteal strength exercise|SHAM extracorporeal shock wave plus gluteal strength exercise
62768850|NCT05301036|EXPERIMENTAL|Active stimulation|Personalized low-intensity transcranial focused ultrasound stimulation of deep brain target (subgenual cingulate or alternative targets)
62768851|NCT05301036|SHAM_COMPARATOR|Sham stimulation|Personalized low-intensity transcranial focused ultrasound stimulation of lateral ventricle
61993772|NCT00004888|EXPERIMENTAL|Arm II (combination chemotherapy, trastuzumab)|"Patients receive trastuzumab IV over 90 minutes on day 1, with subsequent doses over 30 minutes. Patients receive doxorubicin HCl liposome IV over 30 minutes followed by docetaxel IV over 1 hour on day 2 of course 1, followed by subsequent doses on day 1 of each course. Antibody therapy continues weekly and chemotherapy every 3 weeks for 8 courses.~Patients may receive maintenance therapy of trastuzumab IV over 30 minutes weekly followed by docetaxel IV over 1 hour weekly or every 3 weeks. Maintenance continues in the absence of disease progression or unacceptable toxicity."
61993773|NCT02871739|EXPERIMENTAL|DA viewing with SPI Feedback|Group 1 receives three decision aids and feedback on their standardized patient (SPI) interaction rating their shared decision making skills and highlighting opportunities for improvement.
61993774|NCT02871739|EXPERIMENTAL|DA viewing with no SPI Feedback|Group 2 receives three decision aids. This group does not receive any feedback from the SPI.
62560648|NCT01631760||MicroRNA ages 5-12 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
62768852|NCT06508359|EXPERIMENTAL|Prophylactic norepinephrine group|A maintenance dose of norepinephrine (0.05 ug/kg/min) infusion simultaneous with spinal anesthesia. The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62560649|NCT01631760||MicroRNA ages 13-55 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
62768853|NCT06508359|EXPERIMENTAL|Prophylactic phenylephrine group|A maintenance dose of phenylephrine (0.625 ug/kg/min) infusion simultaneous with spinal anesthesia. The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62768854|NCT06508359|ACTIVE_COMPARATOR|Rescue norepinephrine group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery. Spinal anesthesia-induced hypotension is managed by administering a 6 μg intravenous bolus of norepinephrine.
62768855|NCT06508359|ACTIVE_COMPARATOR|Rescue phenylephrine group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery. Spinal anesthesia-induced hypotension is managed by administering a 75 μg intravenous bolus of phenylephrine.
62768856|NCT04132635|EXPERIMENTAL|artificial dermis with growth factor|
61993775|NCT02871739|EXPERIMENTAL|Webinar with SPI Feedback|Group 3 receives an online, interactive webinar that focuses on SDM skills in clinical encounters and feedback on their standardized patient (SPI) interaction rating their shared decision making skills and highlighting opportunities for improvement.
61993776|NCT02871739|EXPERIMENTAL|Webinar with no SPI Feedback|Group 4 receives an online, interactive webinar that focuses on SDM skills in clinical encounters. This group does not receive any feedback from the SPI.
61993777|NCT00314236|EXPERIMENTAL|Microfracture with BST-CarGel|BST-CarGel applied to a Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle
61993778|NCT00314236|ACTIVE_COMPARATOR|Microfracture without BST-CarGel|Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle
62560650|NCT01631760||MicroRNA ages 56-85 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
62560651|NCT02764892|EXPERIMENTAL|V81444|Single oral dose of V81444
62768857|NCT04132635|EXPERIMENTAL|artificial dermis only|
62768858|NCT03103035|EXPERIMENTAL|Exposition to a healthy eating blog|Participants randomised to this arm are exposed to one blog post each week for a period of 6 months.
62768859|NCT03103035|NO_INTERVENTION|No exposition to a healthy eating blog|Participants randomised to this arm do not have exposure to the blog.
62768860|NCT00508612|ACTIVE_COMPARATOR|1|The 12-lesson Williams LifeSkills anger and stress management workshop (WLS) enhances awareness of thoughts and feelings in stressful situations, and provides training in evaluation, deflection, problem-solving, assertion, saying no, speaking, listening, empathy, and emphasizing positives.
62768861|NCT00508612|PLACEBO_COMPARATOR|2|Control group (will attend regular high school classes)
62768862|NCT05751148|ACTIVE_COMPARATOR|Group 1: Hyperbaric Bupivacaine|
62768863|NCT05751148|ACTIVE_COMPARATOR|Group 2: Hyperbaric Prilocaine|
62768864|NCT02090790|ACTIVE_COMPARATOR|iv dexamethasone|perioperative 2ml 8 mg ıv dexamethasone
61993779|NCT01865981||Hereditary VF|Patients with hereditary ventricular fibrillation, negative for known mutations
61993780|NCT01865981||Brugada|Patients suffering from Brugada syndrome
61993781|NCT03500146||Normal sexual function|Patients with an overall FSFI score equal to or above 26.5 will be in the normal sexual function group. Patients in both groups will be treated with an overactive bladder treatment, either anticholinergics, beta-agonists or PTNS.
61993782|NCT03500146||Low sexual function|Female sexual dysfunction is defined as an overall FSFI score below 26.5, patients meeting this criteria will be in the low sexual function group. Patients in both groups will be treated with an overactive bladder treatment, either anticholinergics, beta-agonists or PTNS.
61993783|NCT01054638||HIV infected patients: HAART naive or experienced|Patients with a claims diagnosis of HIV infection (HIV, AIDS, or ARC) in the NHI or Impact Databases, according to either of the 3-digit International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes 042 HIV disease and V08 Asymptomatic HIV infection status
61993784|NCT01054638||Patients with HIV infection HAART naïve|A naïve subcohort of patients consisting of HAART initiators. Among the primary cohort, we will exclude patients with a dispensing for any HAART in the 6-month baseline period prior to the cohort entry date.
61993785|NCT01787578|EXPERIMENTAL|Sobetirome|Subjects will receive oral doses of sobetirome. All subjects will start with a 50 mcg dose, once-daily for 14 days. If this dose proves safe and well tolerated, subjects will receive a 100 mcg dose once-daily for an additional 14 days.
61993786|NCT01182493|EXPERIMENTAL|Insulin Pump Treatment|Patients will get an insulin pump
61993787|NCT01182493|NO_INTERVENTION|Insulin treatment with MDI|patients treated with Multiple Daily Injections (MDI); basal/bolus therapy with rapid- and long-acting analogs with at least 3 injections per day
61993788|NCT01582997|EXPERIMENTAL|Dose Escalation Part|Dose escalation will be conducted to assess safety, tolerability, single and repeat dose PK profile and preliminary efficacy of GSK2118436 . The dose may be escalated to the overseas recommended phase III dose.
62560652|NCT01735084|EXPERIMENTAL|Prevenar13|The booster dose of Prevenar13 is 0.5 mL given intramuscularly only, with care to avoid injection into or near nerves and blood vessels. The preferred sites are anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in young children.
61993789|NCT04092166|NO_INTERVENTION|Controlled|Participants will have no intervention.
61993790|NCT04092166|OTHER|Cardiac Rehab Exercise: Stationary Bike|Participants will use a stationary bike machine that also engages the arms and use . This will be performed for 6 minutes, 3 times a week for a total of 8 weeks).
61993791|NCT04377282|EXPERIMENTAL|Buckwheat|Cooked buckwheat
62560653|NCT01735084|EXPERIMENTAL|Synflorix|The booster vaccination schedule consists of one dose of 0.5 ml with an interval of at least 1 month between doses.
62560654|NCT01593397|EXPERIMENTAL|Propofol and Fentanyl administration|Propofol and Fentanyl will be administered to all subjects. All subjects will have blood drawn to determine pharmacokinetic variables. Processed EEG will be used to determine pharmacodynamics. Plasma samples will be used to ascertain adiponectin levels and for DNA sampling for analysis of adiponectin single nucleotide polymorphisms.
61993792|NCT04377282|EXPERIMENTAL|Couscous|Cooked couscous
61993793|NCT04377282|EXPERIMENTAL|Water|Potable water
61993794|NCT02876965|ACTIVE_COMPARATOR|Physical Exercise|Aerobic physical exercise protocol of moderate intensity, for 12 weeks, 3 sessions per week, about 12 minutes. Physical activity chosen will be pedaling on a static bike.
61993795|NCT02876965|EXPERIMENTAL|Muscle Stretching|Stretching program on the main muscle groups of the body, for 12 weeks, 1sessions per week, about 45 minutes.
61993796|NCT02419118|EXPERIMENTAL|Dara len dex|Daratumumab in combination with lenalidomide and dexamethasone
61993797|NCT02419118|ACTIVE_COMPARATOR|Len dex|Lenalidomide in combination with dexamethasone
61993798|NCT02187328|EXPERIMENTAL|Grapefruit juice|12.5 OZ Grapefruit juice: Subject will ingest grapefruit juice 12.5 OZ twice on the day of their scheduled laboratory visit. Once in the morning and once in the afternoon prior to their evening visit
61993799|NCT02187328|PLACEBO_COMPARATOR|Apple juice|10.5 OZ Apple juice: Subject will ingest apple juice 10.5 OZ twice on the day of their scheduled laboratory visit. Once in the morning and once in the afternoon 3 hours prior to their evening visit.
61993800|NCT02886377||NMOSD-ON|NMOSD-ON included patients who met the established diagnostic criteria for NMO or NMOSD published by Wingerchuk et al,with AQP4 seropositive according to the results of the AQP4-Ab test.
61993801|NCT02886377||MS-ON|MS-ON group patients included typical acute demyelinating ON with brain lesions fulfilling the revised McDonald criteria or clinical isolate syndrome (CIS), with AQP4 seronegative according to the results of the AQP4-Ab test.
61993802|NCT02886377||Healthy controls|Age- and gender- matched healthy controls.
61993803|NCT01667640|ACTIVE_COMPARATOR|whole brain irradiation|whole brain irradiation with 40 Gy, with fixation mask, radiation of the entire brain, skull base and meninges
61993804|NCT01667640|EXPERIMENTAL|sector irradiation|irradiation of the resection margin plus 5 mm safety margin with 30 Gy in 5 fractions
61993805|NCT01770288|EXPERIMENTAL|Anaerobic Performance|
62560655|NCT02515331|EXPERIMENTAL|LHW090 100 mg|LHW090 100 mg once daily for 28 days
62560656|NCT02515331|EXPERIMENTAL|LHW090 200 mg|LHW090 200 mg once daily for 28 days
61993806|NCT00882258|EXPERIMENTAL|12.5 mg Proellex|Proellex 12.5 mg daily
62560657|NCT02515331|PLACEBO_COMPARATOR|Placebo|Matching placebo to LHW090 oral dose for 28 days
62560658|NCT01031329||Complicated Acute otitis media Group|"This group was divided into 3 sub-groups.~* One sub-group includes treatment failure subjects who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment or reappearance of symptoms within 10 days following the end of antibiotic treatment.~* The second sub-group includes subjects with recurrent acute otitis media, who have had new episodes of acute otitis media within the past 6 months or the fourth (or greater) new episode within the past year.~* The third sub-group includes subjects with spontaneous otorrhoea if perforation has occurred \< 24 hours prior to the visit."
62560659|NCT03439241|EXPERIMENTAL|Silent arm|The participants test the new Coloplast ostomy device use the product as they usually would.
62560660|NCT03439241|EXPERIMENTAL|Active arm|The participants test the tnew Coloplast ostomy device and are guided by the measuring device
62560661|NCT01110018|ACTIVE_COMPARATOR|Period 1|20μg intravenous infusion administered over 30 minutes
62560662|NCT01110018|ACTIVE_COMPARATOR|Period 2|1000μg Oral dose
61993807|NCT00882258|EXPERIMENTAL|25 mg Proellex daily|Proellex 25 mg
61993808|NCT00882258|PLACEBO_COMPARATOR|Placebo|Placebo daily
61993809|NCT03880851|OTHER|Hypofractionated image-guided radiotherapy|"Hypofractionated image-guided radiotherapy IGRT to a total dose of 60 Gy (20 fractions) is performed.~Weekly MRI are used to estimate volume/deformation changes of OAR and target volume.~Intervention: In case of a significant change of target volume or OARs (threshold based) the radiation treatment plan is adapted on individual MR-anatomy."
62560663|NCT01110018|ACTIVE_COMPARATOR|Period 3|50μg Intravenous infusion administered over 30 minutes
61993810|NCT05407246|ACTIVE_COMPARATOR|Hemay005 75mg BID group|75mg BID of Hemay005; daily oral administrtion for 16 weeks
61993811|NCT05407246|ACTIVE_COMPARATOR|Hemay005 60mg BID group|60mg BID of Hemay005; daily oral administrtion for 16 weeks
61993812|NCT05407246|PLACEBO_COMPARATOR|placebo group|Placebo of Hemay005; daily oral administrtion for 16 weeks
62389090|NCT05521828|OTHER|Follitropin delta and dydrogesterone (treatment A followed by treatment B)|"Treatment A: Ovarian stimulation is started with daily subcutaneous injections of Follitropin delta (Rekovelle) 12 mcg/daily from day 2 of the follicular phase onwards. Dydrogesterone (Duphaston) 20mg/day will be initiated on stimulation day 7 until the criteria for oocyte trigger are achieved.~Treatment B: From day 20 of the menstrual cycle onwards, daily subcutaneous injections of Follitropin delta (Rekovelle) 12 mcg/daily will be administered. Dydrogesterone (Duphaston) 20mg/day will be initiated on stimulation day 7 or when serum LH \> 10 IU/L until day of trigger.~For both treatment (A and B) oocyte maturation trigger will be planned when transvaginal ultrasound shows at least 3 follicles \>20mm in diameter with a single subcutaneous injection of GnRH agonist (Gonapeptyl 0.2 mg). Oocyte retrieval will be performed 36 hours after trigger. The retrieved cumulus oocyte complexes will be counted, denuded and the number of mature oocytes evaluated."
62560664|NCT01110018|ACTIVE_COMPARATOR|Period 4|1000μg Inhaled dose
62560665|NCT01110018|ACTIVE_COMPARATOR|Period 5|100μg Intravenous infusion administered over 30 minutes
62560666|NCT03159390|EXPERIMENTAL|phenylacetate salt of ornithine|There are 4 study days of approximately 10 hours. Amino acid tracers (e.g., OP, PHE, TYR) will be provided via IV. The dosage of OP provided in this study 6 g in a period of 6 hours. 2 muscle biopsies will be completed on 2 of the study days.
62560667|NCT04795037|EXPERIMENTAL|CU06-1004 for SAD|"* Fifty-six (56) healthy subjects are planned to be enrolled in 7 cohorts~* 6 of out 8 subjects per cohort will be randomized to receive CU06-1004"
62560668|NCT04795037|PLACEBO_COMPARATOR|Placebo for SAD|"* Fifty-six (56) healthy subjects are planned to be enrolled in 7 cohorts~* 2 of out 8 subjects per cohort will be randomized to receive placebo"
62560669|NCT04795037|EXPERIMENTAL|CU06-1004 for MAD|"* Twenty-four (24) healthy subjects are planned to be enrolled in 3 cohorts~* 6 of out 8 subjects per cohort will be randomized to receive CU06-1004"
62560670|NCT04795037|PLACEBO_COMPARATOR|Placebo for MAD|"* Twenty-four (24) healthy subjects are planned to be enrolled in 3 cohorts~* 2 of out 8 subjects per cohort will be randomized to receive placebo"
62560671|NCT05271175|EXPERIMENTAL|Active TMS & Neutral videos|Received active iTBS stimulation while watching neutral videos
62768865|NCT02090790|ACTIVE_COMPARATOR|femoral dexamethasone|femoral block was performed postoperative 30 ml 0,5 % bupivacaine added 2 ml 8 mg dexamethasone
61993813|NCT05776654||COPD cohort|Patients with COPD currently experiencing and receiving treatment for an exacerbation.
62560672|NCT05271175|EXPERIMENTAL|Active TMS & Smoking videos|Received active iTBS stimulation while watching smoking-related videos
62560673|NCT05271175|SHAM_COMPARATOR|Sham TMS & Smoking videos|Received sham stimulation while watching smoking-related videos
62560674|NCT00692692|EXPERIMENTAL|DermaMatrix|experimental group with DermaMatrix acellular dermis over tissue expanders in addition to skin/soft tissue and muscle to allow for more natural appearing breast and prevention of complications
62560675|NCT00692692|ACTIVE_COMPARATOR|Standard of care|standard of care using skin/soft tissue and muscle coverage of tissue expander for breast reconstruction after mastectomy without acellular dermal matrix
62567723|NCT03588910|ACTIVE_COMPARATOR|Number of oxycodone tablets typically prescribed|Participants will receive a prescription for 10 tablets of 5 mg oxycodone (1 tablet every 6 hours as needed) as well as 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed) and 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed).
62768866|NCT02090790|PLACEBO_COMPARATOR|serum physiologic|
61993814|NCT04277754||two-year-old children with typical development|
61993815|NCT01498640|EXPERIMENTAL|XIAFLEX/XIAPEX MP Joint|Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the metacarpophalangeal (MP) joint cord
61993816|NCT01498640|EXPERIMENTAL|XIAFLEX/XIAPEX PIP Joint|Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the proximal interphalangeal (PIP) joint cord
61993817|NCT05766332||Observational (clinical evaluation, record review)|Patients undergo a clinical evaluation consisting of a six-minute walk test, hand grip strength test, and gait speed test on study. Patients' medical records are also reviewed for a year on study.
61993818|NCT02418858|ACTIVE_COMPARATOR|Awake DBS Surgery|"Deep brain stimulation surgery: Essential tremor patients undergoing traditional awake DBS surgery utilizing microelectrode recordings and intraoperative stimulation."
61993819|NCT02418858|ACTIVE_COMPARATOR|Asleep DBS Surgery|Deep brain stimulation surgery: Essential tremor patients undergoing DBS surgery under general anesthesia utilizing intraoperative imaging to verify the stereotactic accuracy of DBS electrode placement at the time of surgery.
61993820|NCT05086796|ACTIVE_COMPARATOR|Substance Use Treatment and Recovery Team (START)|The intervention is administered to participants in this arm. Participants in this arm will work with the Substance Use Treatment and Recovery Team (START), a collaborative care team for inpatients with opioid use disorder.
61993821|NCT05086796|NO_INTERVENTION|Usual Care|Usual care for people with opioid use disorder.
61993822|NCT06060626|ACTIVE_COMPARATOR|Propofol|Patients in whom only propofol will be administered during sedation. Intermittent boluses of propofol titrated to moderate level of sedation.
61993823|NCT06060626|ACTIVE_COMPARATOR|Fentanyl|"Patients in whom combination of propofol and fentanyl will be administered during sedation.~Fentanyl 1 ug/kg bolus 3 minutes before induction + Propofol intermittent boluses titrated to moderate level of sedation."
61993824|NCT04210752|EXPERIMENTAL|Treatment 1 (EG-HZ-001)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of administration: Intramuscular injection"
62768867|NCT06508476|EXPERIMENTAL|Amnion chorion allograft|participants will receive amnion chorion with coronally advanced flap
61993825|NCT04210752|EXPERIMENTAL|Treatment 2 (EG-HZ-002)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of administration: Intramuscular injection"
61993826|NCT04210752|EXPERIMENTAL|Treatment 3 (EG-HZ-003)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of administration: Intramuscular injection"
61993827|NCT04210752|EXPERIMENTAL|Treatment 4 (EG-HZ-004)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of administration: Intramuscular injection"
61993828|NCT04210752|EXPERIMENTAL|Treatment 5 (Shingrix)|"Shingrix~Suspension for injection supplied as a single dose vial of lyophilised VZVgE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. After reconstitution, a single dose of ShingrixTM is 0.5 mL.~Route of Administration: Intramuscular injection"
61993829|NCT02357069|EXPERIMENTAL|LBEC0101|Etanercept
62768868|NCT06508476|ACTIVE_COMPARATOR|Connective tissue graft|participants will receive connective tissue graft with coronally advanced flap
62768869|NCT04542720||Observational: Decompression|Eligible patients may have a preference for the surgical procedure they wish to have. In these instances, they may choose to undergo a decompression alone or a decompression with extension of fusion. These patients are eligible for the study and will be enrolled under observational arms. This arm refers to the decompression alone observational study arm.
61993830|NCT02357069|ACTIVE_COMPARATOR|Enbrel|Etanercept
61993831|NCT03422120||Healthy Donors|Healthy patients, without a diagnosis of cancer and age\>40. The Natural Killer Cell Activity Assay (NKA) will be measured with a blood test.
61993832|NCT03422120||Colorectal Cancer Surgery Patients|Patients \>40 years of age with a histologically confirmed diagnosis of primary colorectal cancer and a planned surgical resection of the primary tumour. The Natural Killer Cell Activity Assay (NKA) will be measured at various perioperative time points with a blood test.
61993833|NCT02701972|EXPERIMENTAL|Control and Test|Pre-implantation and Post-implantation of BACE device
61993834|NCT04301765|EXPERIMENTAL|testosterone 1.62% gel|Testosterone 1.62% gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.
61993835|NCT04301765|PLACEBO_COMPARATOR|placebo gel|The placebo gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.
61993836|NCT04031833|EXPERIMENTAL|Phase 1a single ascending dose study|Phase IA will consist of a single ascending dose study in 9 participants to test three doses to determine the max tolerated dose.
61993837|NCT04031833|EXPERIMENTAL|Phase 1b multiple day dosing|9 subjects will receive the Phase Ia 100% tolerated MAT2203 dose for 7 days.
61993838|NCT04031833|EXPERIMENTAL|Phase 2 safety and tolerability|Safety, tolerability, and microbiologic efficacy of MAT2203 among HIV-infected patients with cryptococcal meningitis compared with standard IV AMB.
62768870|NCT04542720||Observational: Extension Fusion|Eligible patients may have a preference for the surgical procedure they wish to have. In these instances, they may choose to undergo a decompression alone or a decompression with extension of fusion. These patients are eligible for the study and will be enrolled under observational arms. This arm refers to the decompression with extension of fusion observational study arm.
61993839|NCT06062966|EXPERIMENTAL|Treatment arm|
61993840|NCT04328831|OTHER|IBI322|Single arm
61993841|NCT02515942|EXPERIMENTAL|CLG561|CLG561 10 mg, one IVT injection every 28 days for a total of 12 injections
61993842|NCT02515942|EXPERIMENTAL|CLG561+LFG316|CLG561 5mg + LFG316 5 mg, one IVT injection every 28 days for a total of 12 injections
61993843|NCT02515942|SHAM_COMPARATOR|Sham Injection|One sham injection every 28 days for total of 12 sham injections
61993844|NCT04052542|ACTIVE_COMPARATOR|Traditional online continuing education|
61993845|NCT04052542|ACTIVE_COMPARATOR|Interprofessional education|
61993846|NCT04052542|ACTIVE_COMPARATOR|Just-in-time education|
61993847|NCT01112631||Stage II patients post surgery|Stage II patients treated with surgery alone
61993848|NCT01112631||Stage III patients post surgery|Stage III patients treated with surgery and PORT
61993849|NCT01583972|EXPERIMENTAL|Vitamin A|50,000 IU vitamin A in edible oil
62768871|NCT00596583|ACTIVE_COMPARATOR|High Dose|
62768872|NCT00596583|ACTIVE_COMPARATOR|Low Dose|
62560676|NCT04991441|EXPERIMENTAL|Control|Participants will follow their usual or normal diet for 5 months (CON) followed by an Controlled Dietary Sodium Restriction (INT) diet for 2 months. During the sodium restricted diet, participants will be provided with 2 meals and snacks daily, for 30 days (Month 5 - days 1-30) and 1 meal and snacks daily, for 30 days (Month 6 - days 31-60). These meals should meet the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDQOI) guidelines for energy and protein (30-35 kcal/kg \& 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (\<2,000g/day) and will be ordered and delivered through momsmeals.com
62560677|NCT04991441|EXPERIMENTAL|Intervention|Participants will be provided with 2 meals and snacks daily, for 30 days (days 1-30) and 1 meal and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg \& 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (\<2,000g/day) and will be ordered and delivered through momsmeals.com
62768873|NCT04955418|ACTIVE_COMPARATOR|Epi-no Group|The study group was evaluated before the intervention (between 30 and 32 weeks) and 6 months after delivery.From the 34th week onwards, they performed 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device. The pregnant woman was placed in the supine position and EPI-NO® was inserted into vaginal canal. After the introduction of the deflated tube, it was minimally inflated until the perception in the vaginal canal. The first 5 minutes were for perception of the pelvic floor with 10 contractions and relaxation of the perineum in order to maintain muscle strength. After 15 minutes for stretching the perineum, the device was gradually inflated and always respecting the pregnant woman's tolerance. After a total of 20 minutes, the pregnant woman was asked to relax the pelvic floor in order for the inflated device to gently exit her vaginal cavity. The perimeter was measured using a tape measure in its largest diameter.
62560678|NCT00743925|ACTIVE_COMPARATOR|1|A-002 (500 mg QD) plus Atorvastatin (80 mg QD)
62768874|NCT04955418|PLACEBO_COMPARATOR|Control Group|The control group was evaluated only once, six month after delivery.
61993850|NCT01583972|PLACEBO_COMPARATOR|Placebo|edible oil used as diluent for vitamin A
61993851|NCT02629692|EXPERIMENTAL|Vodobatinib (K0706) capsules|
62768875|NCT02488746||EFTR-GERDX|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
62768876|NCT05977452||patients with PICC placement|
61993852|NCT03533387|EXPERIMENTAL|Extended-release formulation 1 (ER1)|50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.
61993853|NCT03533387|EXPERIMENTAL|Extended-release formulation 2 (ER2)|50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.
61993854|NCT03533387|ACTIVE_COMPARATOR|Intermediate-release formulation (IR)|10mg MN-166 capsule. This formulation is typically given two or three times daily, hence, the label of intermediate-release.
61993855|NCT03435965||PPROM from 20- less than 28 weeks|pregnant ladies with PROM from 20 - 28 weeks
62389091|NCT05521828|OTHER|Follitropin delta and dydrogesterone (treatment B followed by treatment A)|"Treatment B: From day 20 of the menstrual cycle onwards, daily subcutaneous injections of Follitropin delta (Rekovelle) 12 mcg/daily will be administered. Dydrogesterone (Duphaston) 20mg/day will be initiated on stimulation day 7 or when serum LH \> 10 IU/L until day of trigger.~Treatment A: Ovarian stimulation is started with daily subcutaneous injections of Follitropin delta12 mcg/daily (Rekovelle) from day 2 of the follicular phase onwards. Dydrogesterone (Duphaston) 20mg/day will be initiated on stimulation day 7 until the criteria for oocyte trigger are achieved.~For both treatment (B and A) oocyte maturation trigger will be planned when transvaginal ultrasound shows at least 3 follicles \>20mm in diameter with a single subcutaneous injection of GnRH agonist (Gonapeptyl 0.2 mg). Oocyte retrieval will be performed 36 hours after trigger. The retrieved cumulus oocyte complexes will be counted, denuded and the number of mature oocytes evaluated."
61993856|NCT03435965||PROM from more than 28 weeks - less than 37 weeks|pregnant ladies with PROM from more than 28- less than37 weeks
61993857|NCT03435965||control group pregnant ladies in labour after 37 weeks|control group pregnant ladies in labour after 37 weeks with rupture of membrane in labour or in cs
61993858|NCT00621218|ACTIVE_COMPARATOR|1|
61993859|NCT00621218|PLACEBO_COMPARATOR|2|
61993860|NCT05769959|EXPERIMENTAL|Part I Single Participant Cohort RO7515629 Dose Escalation|Participants will receive a fixed dose of RO7515629 intravenously as a single agent on cycle 0 day -7 and 7 days later on cycle 1 day 1 followed by every three-week dosing frequency. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.
61993861|NCT05769959|EXPERIMENTAL|Part II Multiple Participant Cohort RO7515629 Dose Escalation|Participants will receive RO7515629 intravenously, as a single agent on cycle 0 day -7 and 7 days later on cycle 1 day 1 followed by every three-week dosing frequency. In case of toxicity, step up dosing (single or double) may be implemented. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.
62389092|NCT02651038|EXPERIMENTAL|Micafungin|Micafungin is administered per clinical need and the pharmacokinetic parameters are analyzed
62389093|NCT00160147|EXPERIMENTAL|1|
62389094|NCT00160147|PLACEBO_COMPARATOR|2|
62389095|NCT02883894||bullous pemphigoid|Patients with bullous pemphigoid.
62389096|NCT06321796|EXPERIMENTAL|Group A: Treatment|"Part 1: Blinded Treatment (14 weeks)~Vancomycin, Magnesium Citrate, Antacid, MTP-101P"
62389097|NCT06321796|PLACEBO_COMPARATOR|Group B: Placebo|"Part 1: Blinded Placebo (14 weeks)~Placebo Vancomycin, Real Magnesium Citrate, Real Antacid, Placebo MTP-101P"
62389098|NCT00741624|EXPERIMENTAL|1|bilateral post refractive surgery subject
62389099|NCT02815982|EXPERIMENTAL|NOURISH-T|"The intervention aims to increase caregivers' self-efficacy for behavioral change, and facilitate an authoritarian approach to parenting. Behavioral strategies such as self-monitoring, contingency management, and stimulus control are integrated in these sessions. Further, because participatory experiences enhance overall intervention efficacy, these activities are incorporated throughout, including self-assessments, discussions and experiential activities. Homework is assigned between sessions so skills can be practiced. We also focus on the caregivers' relationship with everyone in the family, not just the identified patient or overweight child."
62560679|NCT00743925|PLACEBO_COMPARATOR|2|Matching Placebo tablets plus Atorvastatin (80 mg QD)
62389100|NCT02815982|ACTIVE_COMPARATOR|Enhanced Usual Care|Caregivers randomized to the EUC will attend assessment sessions and an initial session moderated by an independent interventionist. The session addresses the role of diet and exercise in pediatric overweight. In addition, EUC caregivers receive nationally available print or web-based brochures on pediatric overweight on 2 occasions during the study so that similar (but not as intensive) information is provided in the intervention and EUC arms of the study. Participants also receive a booster phone call 2 months after the end of the intervention period.
62389101|NCT01075022|EXPERIMENTAL|Vitamin D|
62389102|NCT01075022|PLACEBO_COMPARATOR|Placebo|
62389103|NCT00508118|EXPERIMENTAL|1|Nicardipine
62560680|NCT00659711|ACTIVE_COMPARATOR|Januvia 100mg|The first group will be started on 100 mg sitagliptin daily for 12 weeks
62560681|NCT00659711|PLACEBO_COMPARATOR|placebo|will be placed on a placebo for 12 weeks.
62560682|NCT03468218|EXPERIMENTAL|Treatment (pembrolizumab, cabozantinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and cabozantinib PO QD on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62560683|NCT00893880|EXPERIMENTAL|1|(1) 30min treatment
62560684|NCT00893880|EXPERIMENTAL|2|(1) 60min treatment
62560685|NCT00893880|EXPERIMENTAL|3|(2) 30min treatments over two consecutive days.
62560686|NCT00893880|EXPERIMENTAL|4|(2) 60min treatments over two consecutive days.
62560687|NCT00942357|EXPERIMENTAL|Arm I (cisplatin, radiation therapy, paclitaxel, carboplatin)|Patients receive cisplatin IV on days 1 and 29. Patients also undergo radiation therapy QD, 5 days a week, for 5-6 weeks. Some patients may then undergo brachytherapy over 2-3 weeks. Beginning within 8 weeks after completion of chemoradiotherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62389104|NCT00508118|PLACEBO_COMPARATOR|2|0.9% saline
62389105|NCT03259607|EXPERIMENTAL|Treatment A|Nicorette Extra Mint 2 mg Gum
62389106|NCT03259607|ACTIVE_COMPARATOR|Treatment B|Nicorette Mint 2 mg Gum
62560688|NCT00942357|ACTIVE_COMPARATOR|Arm II (paclitaxel and carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62560689|NCT02010957|EXPERIMENTAL|FDG positron emission tomography and Iodometomidate imaging|Combined FDG PET and Iodometomidate imaging prior adrenal surgery of uncertain adrenal neoplasms
62560690|NCT06033937||Migraine Medication Group|
62560691|NCT06033937||PFO Occlusion Group|
62560692|NCT01352195|ACTIVE_COMPARATOR|Usual Care (UC)|This condition will comprise a single, high quality booklet that is currently in dissemination: NCI's Clearing the Air (NCI, 2003).
62560693|NCT01352195|ACTIVE_COMPARATOR|Standard Repeated Mailings (Stand-RM)|Stand-RM will be the same 8 Forever Free booklets (edited for cessation) distributed over 12 months as in our preliminary studies.
62560694|NCT01352195|ACTIVE_COMPARATOR|Intensive Repeated Mailings (Inten-RM)|Inten-RM will add two additional booklets to extend the intervention out to 18 months, plus additional monthly contacts.
62560695|NCT01252095|EXPERIMENTAL|PG545|
62560696|NCT00655993|PLACEBO_COMPARATOR|1|placebo drug
62560697|NCT00655993|ACTIVE_COMPARATOR|2|simvastatin
62560698|NCT03796325||Depression|patients characterize with morbid obesity or obesity type 2 with co-morbidities and depression
62389107|NCT03259607|EXPERIMENTAL|Treatment C|Nicorette Extra Mint 4 mg Gum
62389108|NCT03259607|ACTIVE_COMPARATOR|Treatment D|Nicorette Mint 4 mg Gum
62389109|NCT02468076|EXPERIMENTAL|Radiofrequency ablation (StarMed)|Radiofrequency ablation catheter
62389110|NCT06210828|EXPERIMENTAL|Telerehabilitation Group|A telerehabilitation group participates in two weekly exercise sessions over a 12-week period at home. These sessions, led by a physical therapist through two-way communication, focus on lower extremity strengthening and balance exercises. In addition to the guided sessions, participants are encouraged to perform self-directed exercises one day per week.
62560699|NCT03796325||No-depression|patients characterize with morbid obesity or obesity type 2 with co-morbidities without depression
62560700|NCT03074578|EXPERIMENTAL|Night-time desensitization|Watching a video containing verbal and visual violence in the evening, and again in the next morning
62560701|NCT03074578|SHAM_COMPARATOR|Daytime desensitization|Watching a video containing verbal and visual non-violence in the morning, and then again the evening of the same day
62560702|NCT04537884|EXPERIMENTAL|Treatment with UBX1325|UBX1325, single intravitreal injection, ascending dose
62560703|NCT04977011|EXPERIMENTAL|experimental group|30 minutes music intervention for 3 days on bedside
62560704|NCT04977011|NO_INTERVENTION|control group|usually care
62567724|NCT03588910|EXPERIMENTAL|Half the number of oxycodone tablets typically prescribed|Participants will receive 5 tablets of 5mg oxycodone as well as 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed) and 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed).
62768877|NCT05342337|EXPERIMENTAL|Telerehabilitation Group|"The Telerehabilitation program includes a Biopsychosocial Exercise Therapy (BETY) approach.~BETY approach includes patient education on pain, functional body stabilization exercises (mind-body information management), dance therapy authentic movement (emotion-state information management), and sexual information management."
61993862|NCT05769959|EXPERIMENTAL|Part III Multiple Participant Cohort RO7515629 Dose Expansion|Participants with selected solid tumors will receive a selected dose of RO7515629 intravenously as a single agent based on the recommended dose sequence for expansion (RDE) and dosing regimen selected from Part I and Part II. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.
61993863|NCT02653742|EXPERIMENTAL|Ketorolac|Ketorolac 1mg/kg sublingual, in the form of Ketorolac Tromethamine solution for intravenous/intramuscular use.
61993864|NCT02653742|EXPERIMENTAL|Fentanyl|Fentanyl 2mcg/kg intranasal, in the form of Fentanyl Citrate solution for intravenous/intramuscular use.
61993865|NCT02653742|EXPERIMENTAL|Ketorolac and Fentanyl|Ketorolac 1mg/kg sublingual, in the form of Ketorolac Tromethamine solution for intravenous/intramuscular use and Fentanyl 2mcg/kg intranasal, in the form of Fentanyl Citrate solution for intravenous/intramuscular use.
61993866|NCT01976832|EXPERIMENTAL|Music with movement|Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-weeks music with movement (MWM) intervention protocol.
61993867|NCT01976832|ACTIVE_COMPARATOR|Social interaction|"The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.~The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period."
61993868|NCT03239470|EXPERIMENTAL|Cohort 1: 1.0 x 10^8 PolyTregs|A single intravenous infusion of 1.0 x 10\^8 PolyTregs will be administered.
61993869|NCT03239470|EXPERIMENTAL|Cohort 2: 2.5x10^8 PolyTregs|A single intravenous infusion of 2.5x10\^8 PolyTregs will be administered.
61993870|NCT02685631||Observational/data registry collection|Patients receiving Yttrium-90 resin microspheres as part of care
61993871|NCT02782416|NO_INTERVENTION|Waiting for renal transplant_no screening of LTBI|patients with renal failure and are waiting for renal transplant We do routine examination but no LTBI check
61993872|NCT02782416|PLACEBO_COMPARATOR|Not waiting for renal transplant|Dialysis patients who are not waiting for renal transplant
61993873|NCT02782416|OTHER|Status post renal transplant|patients who have received renal transplant
62560705|NCT05869591|EXPERIMENTAL|Cirrhotic patients with Child A or B under apixaban|"Twenty non-anticoagulated patients with Child A or B liver cirrhosis will receive a therapeutic dose of apixaban (Eliquis®) for 7 consecutive days.~Blood samples will be collected just before and after apixban intake at day 1 and 3. Another blood samples are collected at day 8 and at day 9.~In vivo thrombin generation parameters (F1+2, TAT, fibrin monomers, D-dimers), ex vivo thrombin generation parameters \[ST Genesia (Drugscreen)\], as well as peak and trough apixaban levels will be measured."
62560706|NCT05869591|EXPERIMENTAL|Cirrrhotic patients with Child A or B under edoxaban|"Twenty non-anticoagulated patients with Child A or B liver cirrhosis will receive a therapeutic dose of edoxaban (Lixiana®) for 7 consecutive days.~Blood samples will be collected just before and after edoxaban intake at day 1 and 3. Another blood samples are collected at day 8 and at day 9.~In vivo thrombin generation parameters (F1+2, TAT, fibrin monomers, D-dimers), ex vivo thrombin generation parameters \[ST Genesia (Drugscreen)\], as well as peak and trough edoxaban levels will be measured."
61993874|NCT02782416|EXPERIMENTAL|Waiting for renal transplant_ screening of LTBI|patients with renal failure and are waiting for renal transplant We do routine examination in addition to LTBI check
61993875|NCT02801318|OTHER|Polysomnography|
61993876|NCT04434885||Psoriatic arthritis|Patients diagnosed with PsA and fulfilling the classification criteria for PsA with symptom duration of up to 10 years and not receiving biological or targeted synthetic disease modifying antirheumatic drugs (b or tsDMARDs).
61993877|NCT04929652|EXPERIMENTAL|Advanced CRC|Patients with Advanced CRC were given Surufatinib Combine With Immunotherapy and Chemotherapy.
61993878|NCT02174835|EXPERIMENTAL|Cohort A - Period 1|Twice daily dosing orally for 7 days
61993879|NCT02174835|ACTIVE_COMPARATOR|Cohort A - Period 2|Twice daily dosing orally for 7 days
61993880|NCT02174835|EXPERIMENTAL|Cohort A - Period 3|Twice daily dosing orally for 7 days
61993881|NCT02174835|EXPERIMENTAL|Cohort B - Period 1|Twice daily dosing orally for 7 days
61993882|NCT02174835|ACTIVE_COMPARATOR|Cohort B - Period 2|Twice daily dosing orally for 7 days
61993883|NCT02174835|EXPERIMENTAL|Cohort B - Period 3|Twice daily dosing orally for 7 days
62389111|NCT06210828|ACTIVE_COMPARATOR|Control Group|"* Receive fall prevention exercise brochure that includes instructions on how to perform the exercises, the recommended repetition and number of sets.~* Participants are suggested to perform self-directed exercises three day per week."
62389112|NCT03486067|EXPERIMENTAL|Administration of CC-93269|
62389113|NCT02408016|EXPERIMENTAL|Arm I, Stage I (T lymphocytes, cyclophosphamide, IL-2)|Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on days 0 and 14, cyclophosphamide IV on days 11 and 12, and aldesleukin SC BID for 14 days. Patients who have received radiation to the chest/lung tissue may receive gene-transduced T lymphocytes 90 days after completion of radiation.
62389114|NCT02408016|EXPERIMENTAL|Arm I, Stage II (T lymphocytes, cyclophosphamide, IL-2)|Patients receive cyclophosphamide IV on days -3 and -2, autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on day 0, and aldesleukin SC BID for 14 days.
62389115|NCT02408016|EXPERIMENTAL|Arm II (T lymphocytes, IL-2, surgery)|Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV between 24-96 hours after the last dose of chemotherapy and receive aldesleukin SC BID for 14 days. Patients then undergo surgery within 3-4 weeks after the T-cell infusion.
62389116|NCT00709813|NO_INTERVENTION|1|
62389117|NCT00709813|EXPERIMENTAL|2|
62389118|NCT02896972|ACTIVE_COMPARATOR|Inverted ILM flap group|Eyes underwent vitrectomy with inverted internal limiting membrane technique
62389119|NCT02896972|ACTIVE_COMPARATOR|ILM peeling group|Eyes underwent vitrectomy with internal limiting membrane peeling
62389120|NCT04130360|EXPERIMENTAL|Problem-solving|
62560707|NCT03805412|ACTIVE_COMPARATOR|DEXCOM G6 RT-CGM|These participants will wear blinded continuous glucose monitoring for 10 days at baseline and 14 weeks. They will also complete real-time continuous glucose monitoring (RT-CGM) for 10 days at 2 weeks and 6 weeks. They will receive Nutrition and exercise counseling at week 2 and 6. They will also receive additional training on continuous glucose monitoring.
62560708|NCT03805412|NO_INTERVENTION|Blinded CGM|These participants will have blinded continuous glucose monitoring(CGM) at the baseline and last 14 weeks. They will not wear continuous glucose monitoring at the interim appointments. They will receive 2 session of nutrition and exercise counseling at week 2 and 6.
62560709|NCT00815880|EXPERIMENTAL|Implantable Counterpulsation Therapy|The primary study population will include 20 patients enrolled and implanted with C-Pulse. This expansion protocol will allow up to 40 patients to be enrolled and implanted. Patients that meet eligibility will be enrolled and implanted into the treatment arm of the study. These patients will receive the C-Pulse System Implant as intervention therapy. There is not a control arm in this feasibility study.
62560710|NCT00653627|EXPERIMENTAL|A|Study of BCG quantification and immunogenicity 2 weeks after BCG vaccination
62560711|NCT00653627|EXPERIMENTAL|B|Study of BCG quantification and immunogenicity 4 weeks after BCG vaccination
62560712|NCT06581419|EXPERIMENTAL|phase I|Dose escalation (Phase I): 14 to 48 subjects with advanced malignancies are planned to be enrolled to initially investigate the safety and tolerability of IAP0971 and to determine the MTD based on the frequency of DLT in each dose arm.The starting dose of IAP0971 for injection is 0.0005 mg/kg, with a preset maximum escalation dose of 18.0 mg/kg, administered once every 3 weeks.
62560713|NCT06581419|EXPERIMENTAL|phase II|Dose Extension (Phase II) : Phase II will use an open-label, non-randomized, single-arm, multicenter design. Under the RP2D dose determined in Phase I, 20-30 untreated patients with advanced or metastatic non-small cell lung cancer, who are driver gene negative and PD-L1 positive (TPS ≥ 50%), will be enrolled. The drug IAP0971 is administered once every 3 weeks, and every 3 weeks is 1 cycle
62560714|NCT05154175||Ottobock helmet|Infants treated with an Ottobock helmet
62768878|NCT05342337|ACTIVE_COMPARATOR|Control Group|The control group participants include those who do not want to receive exercise treatment with telerehabilitation and take their routine medications during the 12 weeks period.
62389121|NCT04130360|NO_INTERVENTION|Control|
62389122|NCT01652651|EXPERIMENTAL|Psychological Intervention|
62389123|NCT02139891|EXPERIMENTAL|"MultiPoint Pacing On"|Patients will be randomized to the MPP-ON Arm vs MPP-OFF in in crossover fashion with 3 months in each period.
62389124|NCT02139891|ACTIVE_COMPARATOR|"MultiPoint Pacing Off"|Patients will be randomized to the MPP-OFF arm vs MPP-ON in crossover fashion with 3 months in each period.
62389125|NCT01226134|EXPERIMENTAL|1.Itopride Group|The itopride group will receive itopride 150mg per day(50mg TDS)for four weeks
62389126|NCT01226134|PLACEBO_COMPARATOR|2.Control placebo group|The control group will receive placebo tablets for four weeks
62389127|NCT06249074|EXPERIMENTAL|Gluten|Gluten group received gluten in gastrosoluble capsules - 2 g of gluten in 3 capsules daily for 4 weeks (week 5 to week 8).
62389128|NCT06249074|PLACEBO_COMPARATOR|Placebo|Placebo group received rice starch in gastrosoluble capsules - 3 capsules daily for 4 weeks (week 5 to week 8).
62389129|NCT01005355|EXPERIMENTAL|IMC-1121B|Participants receiving IMC-1121B intravenously
62389130|NCT03151928||women presenting with vaginitis symptoms|"Women with vaginitis seeking routine care will be approached to have five additional swabs collected during their pelvic exam~* vaginal swab for qualitative PCR using the BD Max Vaginal Panel on the automated BDMAX System~* Vaginal smear for evaluation with Gram's stain and Nuget's criteria~* Vaginal swab for yeast culture~* Vaginal swab for Trichomonas vaginalis NAAT~* Vaginal swab for discrepant analysis testing"
62389131|NCT02785588|OTHER|3.0 T Neonatal MRI scanner|All subjects who participate in this study will be scanned using the 3.0 T Neonatal MRI scanner.
62560715|NCT06377774||DPMAS therapy group|This is a prosepctive, sigle-arm and muticenter study. The study will enroll ACLF patients which receive the DPMAS therpay during hospitalization.
62567725|NCT01868737|EXPERIMENTAL|HIV exposed infants|Probiotic: L. rhamnosus GG (0.35 x 109 colony-forming units \[CFU\]) and B. infantis (0.35 x 109 CFU) daily
62768879|NCT06102772||Adebrelimab, Fruquintinib combined with paclitaxel|Fruquintinib 4mg d1-14, q3w Paclitaxel 150mg/m2, d1, q3w / Albumin paclitaxel 125mg/m2, d1, d8, q3w PD-L1 antibody (Adebrelimab) 20 mg/kg, d1, q3w
62768880|NCT01282294||ETN PROtect|There is only 1 cohort in this case series
62768881|NCT05055882||children and adult diagnosed with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital|children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital
62768882|NCT02210091|EXPERIMENTAL|<6 years old|
62768883|NCT02210091|EXPERIMENTAL|≥6 to <12 years|
62389132|NCT02195349|EXPERIMENTAL|Healthy Subjects (no DTH)|One subject will be dosed with GSK2831781 (0.0003 mg/kg) and one with placebo. Depending on the safety data obtained for 28 days post dose along with the available PK data, a dose escalation may be done to the next planned dose (0.0015 , 0.0075, 0.04, 0.15 mg/kg). In case safety findings are noted then the cohort may be expanded to a maximum cohort size of 6:3 (GSK2831781: placebo) or the escalation will be stopped.
62768884|NCT02834286|EXPERIMENTAL|Rituximab, eltrombopag and dexamethasone|Each patient will receive Rituximab 100 mg weekly days 1, 7, 14, 21 Eltrombopag 50 mg PO days 1-28 Dexamethasone 40 mg IV/PO days 1-4
62768885|NCT00842101||pressure monitor|Tibial Fracture
62389133|NCT02195349|EXPERIMENTAL|Healthy Subjects (DTH)|Sentinel subjects (one dosed with GSK2831781 (0.0003 mg/kg) and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 1 placebo subject will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). After reviewing the safety data for 28 days the healthy subjects (DTH) will be escalated to the planned dose of GSK2831781 (0.0075, 0.04, 0.15 mg/kg) in 6:3 ratio with placebo.
62768886|NCT01433302||Punch Biopsy|
62768887|NCT03505736||Diagnostic (stress test)|Within 2 years of initiating anti-estrogen therapy or 2 years after completing chemotherapy, participants undergo a stress test which consists of receiving adenosine IV over 1-5 minutes or regadenoson IV over 2 minutes and then undergoing CMR imaging over 45-60 minutes at baseline, and again 3-6 months later.
62768888|NCT00031564|EXPERIMENTAL|Vaccine Therapy With Interleukin-2|At approximately 3-6 weeks after surgery, patients receive B7-1 gene-modified autologous tumor cell vaccine subcutaneously (SC) once on days 1, 29, and 57. At 6 weeks after the first vaccination, patients receive interleukin-2 (IL-2) SC five days a week for 6 weeks (days 43-82). Patients with stable or responding disease after day 106 may receive additional vaccinations in the absence of disease progression or unacceptable toxicity.
62768889|NCT06295705|EXPERIMENTAL|Hip-Hop Dance|The program will be a 7-week occupational therapy led dance program utilizing hip-hop dance as an intervention. Subjects with ASD will dance for 1 time a week for 60 minutes, ending with a dance showcase on the final week.
62768890|NCT00774020|EXPERIMENTAL|1|
61993884|NCT05132764|EXPERIMENTAL|MOPs group|Orthodontic treatment will be started in all subjects using fixed preadusted edgewise appliance (0.022-in MBT prescription, Ortho Organizers, Inc. USA).Local anesthesia will be given in lower arch .Two points for screw insertion will be demarcated on buccal mucosa, in each interdental segment using a calibrated periodontal probe. Orthodontic miniscrew (AbsoAnchor, Korea) of 1.3 mm diameter will be used for MOPs to the depth of 2-3 mm into the buccal cortical bone. An endodontic rubber stopper will be set for required / optimal depth on miniscrew and MOPs will be performed. After the intervention, the patients will be instructed for maintaining good oral hygiene and to take analgesics, such as acetaminophen, only if necessary.
62389134|NCT02195349|EXPERIMENTAL|Subjects with Psoriasis|Sentinel subjects (one dosed with GSK2831781 and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 2 placebo subjects will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). All subsequent cohorts do not require stratification for pre-existing ADAs. After reviewing the safety data for 28 days for minimum of 8 out of 9 subjects within the cohort and all subjects have completed dosing and the inpatient monitoring until Day 4, the subjects with psoriasis will be escalated to the planned dose of GSK2831781 (1.5 and 5 mg/kg) in 6:3 ratio with placebo.
62768891|NCT03968783|EXPERIMENTAL|Monofilament suture|continuous double-layer unlocked suturing with 1.0 monofilament synthetic absorbable suture
62768892|NCT03968783|ACTIVE_COMPARATOR|Multifilament suture|continuous double-layer unlocked suturing with 1.0 multifilament synthetic absorbable suture
62768893|NCT03612843||Dry needle|Dry needling is provided as a part of a comprehensive treatment program by a physical therapist. The patient and the therapist will record any adverse events that occur.
62768894|NCT00766974|ACTIVE_COMPARATOR|1|Anti-embolism Knee High compression stocking
62768895|NCT00766974|ACTIVE_COMPARATOR|2|20-30mmHg Knee High Jobst Compression Stocking
62560716|NCT02596360|EXPERIMENTAL|Dextromethorphan|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
62560717|NCT02596360|PLACEBO_COMPARATOR|Placebo|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
62560718|NCT06582355|EXPERIMENTAL|Neurofeedback|Four weekly MRI sessions where they will learn to upregulate the activity of the putamen during motor imagery via fMRI neurofeedback.
62768896|NCT04314219|EXPERIMENTAL|Arm 1: Intervention|Peripheral blood matched related donor HCT, using myeloablative conditioning regimen (IV Busulfan/IV Fludarabine for AML, IV VP16/TBI for ALL) HCT with cyclophosphamide, and oral tacrolimus (or another calcineurin inhibitor if intolerant for tacrolimus) for GVHD prophylaxis. Cyclophosphamide will be given at a dose of 50 mg/kg/day IV on Day +3 and Day +5 post stem cell infusion (only 2 doses).
62768897|NCT04314219|ACTIVE_COMPARATOR|Arm 2: Standard of Care|Peripheral blood matched related donor HCT, using myeloablative conditioning regimen (IV Busulfan/IV Fludarabine for AML, IV VP16/TBI for ALL) HCT with methotrexate, and oral tacrolimus (or another calcineurin inhibitor if intolerant for tacrolimus) for GVHD prophylaxis
62768898|NCT04589143|EXPERIMENTAL|Experience group|In this group,participants take agomelatine at a dose of 25-50 mg/d for 8 weeks.
62768899|NCT04589143|PLACEBO_COMPARATOR|Contral group|In this group,participants take a placebo at a dose of 25-50 mg/d for 8 weeks.
62768900|NCT01968057|EXPERIMENTAL|Baricitinib|Single oral dose of 4 milligrams (mg) baricitinib on Day 1
62768901|NCT01968057|EXPERIMENTAL|Baricitinib + Ciclosporin|Single oral dose of 4 mg baricitinib co-administered with a single oral dose of 600 mg ciclosporin on Day 4
62768902|NCT04050267|PLACEBO_COMPARATOR|Control group - air|Breathing air with 21 % of oxygen (0% nitrous oxide). Performing cognitive tests as per protocol.
62389135|NCT02075580|EXPERIMENTAL|psychological support|Arm A will undergo psychological support and standard care prior and post TIVAD (Totally Implantable Venous Access Devices) insertion Arm B will undergo standard care prior and post TIVAD insertion
62389136|NCT02075580|NO_INTERVENTION|standard care|this arm does not receive psychological support before and after Totally Implantable Venous Access Devices positioning
62389137|NCT06000891|ACTIVE_COMPARATOR|ZP7570|ZP7570 for subcutaneous once-weekly injection.
62389138|NCT06000891|PLACEBO_COMPARATOR|Placebo|Placebo for subcutaneous once-weekly injection. Corresponding volume matching active treatment
62389139|NCT02745093|EXPERIMENTAL|64-84 days gestational age|Women whose pregnancies are estimated to have a gestational age of 64-84 days will receive 200 µg mifepristone followed by misoprostol 24-48 hours later.
62389140|NCT02745093|NO_INTERVENTION|57-63 days gestational age|Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range: 200 µg mifepristone administered orally in the clinic on Day 1 then 800 μg misoprostol administered sublingually 24-48 hours later at home with a subsequent dose of 400 μg misoprostol sublingually 6 hours later if she has not expelled the pregnancy).
62389141|NCT05805332||pulmonary rehabilitation|
62389142|NCT02600715|EXPERIMENTAL|Active B&O suppository of belladonna|Receive the B\&O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
62389143|NCT02600715|PLACEBO_COMPARATOR|Placebo suppository|Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
62389144|NCT05191927||female group|all are female
62389145|NCT05191927||male group|all are male
62389146|NCT01295073|ACTIVE_COMPARATOR|A|Oral Trientine 1500mg x 1 week before cataract surgery and 3 days post surgery
62560719|NCT06582355|ACTIVE_COMPARATOR|Kinesthetic imagery|Four weekly MRI sessions with motor imagery without fMRI neurofeedback.
62560720|NCT02727803|EXPERIMENTAL|Myeloablative regimen 1|"Patients receive anti-thymocyte globulin IV over 4 hours on days -9 and -8, fludarabine phosphate IV over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3 hours on days -7 to -4. Patients undergo TBI on day -3.~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
62560721|NCT02727803|EXPERIMENTAL|Non-myeloablative regimen 2|"Patients with CD20 positive malignancies receive rituximab IV over 6 hours on day -9. Patients receive anti-thymocyte globulin IV over 4 hours on days -8 and -7, fludarabine phosphate IV over 1 hour on days -6 to -3, and cyclophosphamide IV over 3 hours on day -6 and undergo TBI on day -1 at the discretion of the investigator(s).~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
62560722|NCT02727803|EXPERIMENTAL|Reduced intensity regimen 3|"Patients receive anti-thymocyte globulin IV over 4 hours on days -7 and -6, fludarabine phosphate IV over 1 hour on days -5 to -2, and melphalan IV over 30 minutes on day -2.~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
62560723|NCT02607046|EXPERIMENTAL|Exercise|Exercise Training
61993885|NCT05132764|NO_INTERVENTION|Control group|Orthodontic treatment will be started in all subjects using fixed preadusted edgewise appliance (0.022-in MBT prescription, Ortho Organizers, Inc. USA).The control group will receive no MOPs at the alignment stage.
61993886|NCT02865031|EXPERIMENTAL|Decorin|Intravitreal injection of 200-400 ug of Decorin.
62389147|NCT01295073|PLACEBO_COMPARATOR|B|Oral Placebo x 1 week before cataract surgery and 3 days post surgery
62389148|NCT05725837|PLACEBO_COMPARATOR|Placebo|40mg, single dose a day, by mouth or enteric tube
62389149|NCT05725837|EXPERIMENTAL|Paroxetine|40mg, single dose a day, by mouth or enteric tube
62389150|NCT05384873|EXPERIMENTAL|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Oral Impact®). The intervention will start approximately two weeks before anticancer treatment initiation and will continue up to first disease re-assessment (12-14 weeks) and prolonged according to patient's needs
62560724|NCT02607046|EXPERIMENTAL|NMES|Neuromuscular Electrical Stimulation
62560725|NCT00634036|ACTIVE_COMPARATOR|1|
62560726|NCT00634036|PLACEBO_COMPARATOR|2|
62567726|NCT01868737|PLACEBO_COMPARATOR|HIV- exposed infants|MCT oil
61993887|NCT03072966|EXPERIMENTAL|Distress screening group|Physical activities will be monitored by wearable device. Patient-reported outcomes including distress, depression, physical activities and quality of life are going to be collected by questionnaires based on smartphone application and paper. The algorithm of distress screening will be developed with the analysis of patterns of physical activities.
62768903|NCT04050267|EXPERIMENTAL|Intervention Group - 5% nitrous oxide|Breathing 5% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
62768904|NCT04050267|EXPERIMENTAL|Intervention Group - 7% nitrous oxide|Breathing 7% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
62768905|NCT04050267|EXPERIMENTAL|Intervention Group - 10% nitrous oxide|Breathing 10% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
62768906|NCT04050267|EXPERIMENTAL|Intervention Group - 12% nitrous oxide|Breathing 12% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
61993888|NCT05511142|EXPERIMENTAL|Classic Peyton's Four-Step Approach|Students followed offline training session of endotracheal intubation and mask ventilation procedural skills
61993889|NCT05511142|EXPERIMENTAL|Modified Peyton's Four-Step Approach|Students followed online training session of endotracheal intubation and mask ventilation procedural skills
62768907|NCT04050267|EXPERIMENTAL|Intervention Group - 15% nitrous oxide|Breathing 15% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
62768908|NCT04050267|EXPERIMENTAL|Intervention Group - 20% nitrous oxide|Breathing 20% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
61993890|NCT04903405||Sepsis|
61993891|NCT05077943|ACTIVE_COMPARATOR|No Breathing Exercise|Patients will do the second phase of cardiac rehabilitation for minimum 5 times per week, 30 minutes each time, in 3 months without being supervised
61993892|NCT05077943|EXPERIMENTAL|With Breathing Exercise|Patients will do the second phase of cardiac rehabilitation for minimum 5 times per week, 30 minutes each time and breathing and chest mobilization exercise for 3 times per week. They will be supervised through online meetings.
62389151|NCT05384873|ACTIVE_COMPARATOR|Control dietary intervention|Patients will receive nutritional counseling as standard of care. Nutritional counseling may comprise the use of oral nutritional supplements (ONS), which are usually prescribed when patients are unable to maintain satisfactory spontaneous food intake (less than 50% of the requirement for more than one week or only 50-75% of the requirement for more than two weeks). Therefore, in this arm the use of isonitrogenous standard blend ONS will be considered according to the regular assessment of food intake.
62389152|NCT02386605|EXPERIMENTAL|Treatment|Motivational Interviewing Treatment group
62389153|NCT02386605|ACTIVE_COMPARATOR|Control|Relaxation Skills Training group
62768909|NCT05471180|PLACEBO_COMPARATOR|Control group|Control group (n=39) - 3M Cavilon ® protective spray film + simulation of the use of laser (placebo) - after cleaning the skin, the pain scale will be applied and after application of FBM in the same points of the group that will undergo irradiation. To mimic the action of the laser, the BIP noise will be recorded and its activation will be done by the nursing employee who provides the care, after simulating the use of the laser, the use of the 3M Cavilon ® protective spray film will be applied. The application of the laser will be immediate in 8 points of the perineum region in the areas that present lesions, these applications will occur 1 x a day every 24 hours for three consecutive days. Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film. A photographic record of the lesion will be made on days 0 and 3 of treatment and after 2 days after treatment to monitor the recovery of the IAD
61993893|NCT05525845|OTHER|Food-Print Main Arm|Functional Magnetic Resonance Imaging (pCASL-MRI) after Caloric and Volumetric stimulus in lean patients will be performed on all patients in the study
61993894|NCT05725512|EXPERIMENTAL|Prednisolone|Prednisolone tablets (20 mg daily for 6 weeks, 10 mg daily for 1 week, 5 mg daily for 1 week)
61993895|NCT05725512|PLACEBO_COMPARATOR|Placebo|Identical placebo tablets for 8 weeks
61993896|NCT02265055|ACTIVE_COMPARATOR|transfer early cleavage embryos (EC)|transfer early cleavage embryos
61993897|NCT02265055|ACTIVE_COMPARATOR|transfer non early cleavage embryo (NEC)|transfer non early cleavage embryos
61993898|NCT01188408|EXPERIMENTAL|Liposome Entrapped Docetaxel (LE-DT)|Disease status and tumor responses/progression is assessed in accordance to the RECIST guideline
61993899|NCT05159895|EXPERIMENTAL|[14C]-DZD9008|A Single dose of \[14C\]-DZD9008
61993900|NCT03075670|EXPERIMENTAL|N9-GP|
62389154|NCT01329991|ACTIVE_COMPARATOR|oral dose of 200 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
62389155|NCT01329991|ACTIVE_COMPARATOR|oral dose of 400 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
62389156|NCT01329991|ACTIVE_COMPARATOR|oral dose of 800 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
62768910|NCT05471180|EXPERIMENTAL|Experimental group|Experimental group (n= 39) 3M Cavilon ® protective spray film + FBM - skin cleaning and pain scale application will be performed and after laser application in 8 points of the affected perineum region, these applications will occur 1 x a day every 24 hours for three days. Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film. The photographic record of the lesion will be performed on days 0 and 3, 5 and 7 days of treatment. To monitor the participants and observe the recovery and obtainment of skin healing. It will be used the Globaid tool that will be applied in both groups.
61993901|NCT03075670|ACTIVE_COMPARATOR|ALPROLIX®|
62389157|NCT01329991|ACTIVE_COMPARATOR|oral dose of PLX5622-dose to be determined|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
62389158|NCT01329991|PLACEBO_COMPARATOR|Placebo Comparator|2 patients per cohort will be randomly assigned to take placebo. 8 patients total will be randomized to take placebo in this study.
62389159|NCT01721668|EXPERIMENTAL|MSR - Music Supported Rehabilitation|Behavioral: Music Supported Rehabilitation
62389160|NCT01721668|ACTIVE_COMPARATOR|CU/ET|Experimental: CU/ET (Conventional Upper Extremity Therapy)
62389161|NCT02715115|EXPERIMENTAL|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
62389162|NCT02715115|PLACEBO_COMPARATOR|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water for Injection
62389163|NCT03243201|EXPERIMENTAL|Colloidal Silver|The colloidal silver arm will administer intranasal colloidal silver, 2 sprays each nostril twice daily, for a total volume of 0.8ml per day (8 mcg of silver per day), for 28 days.
62389164|NCT03243201|PLACEBO_COMPARATOR|Purified Water|The placebo arm will administer intranasal purified water, 2 sprays each nostril twice daily, for a total volume of 0.8ml per day, for 28 days.
62389165|NCT04824092|EXPERIMENTAL|Tafasitamab plus lenalidomide in addition to R-CHOP|"Patients will receive tafasitamab plus lenalidomide in addition to R-CHOP for six 21-day cycles:~Tafasitamab dose: 12 mg/kg body weight. Each 21-day cycle (cycles 1-6) will comprise of a tafasitamab IV infusion on Day 1, Day 8 and Day 15.~Lenalidomide dose: 25 mg as a starting dose per os (orally) once per day on Days 1-10 of each 21-day cycle~R-CHOP dose: Rituximab (or locally approved biosimilar) 375 mg/m2, IV Day 1 of every 21-day cycle; Cyclophosphamide 750 mg/m2, IV Day 1 of 21-day cycle; Doxorubicin 50 mg/m2, IV Day 1 of 21-day cycle; Vincristine 1.4 mg/m2 (max 2 mg) IV Day 1 of 21-day cycle; Prednisone/prednisolone 100 mg/day, per os, Day 1-5 of every 21-day cycle"
62389166|NCT04824092|PLACEBO_COMPARATOR|Tafasitamab placebo plus lenalidomide placebo in addition to R-CHOP|"Patients will receive tafasitamab placebo plus lenalidomide placebo in addition to R-CHOP for six 21-day cycles:~Tafasitamab placebo: 0.9% saline solution Days 1, 8 and 15 of each 21-day cycle~Lenalidomide placebo: Days 1-10 of each 21-day cycle~R-CHOP dose: Rituximab (or locally approved biosimilar) 375 mg/m2, IV Day 1 of every 21-day cycle; Cyclophosphamide 750 mg/m2, IV Day 1 of 21-day cycle; Doxorubicin 50 mg/m2, IV Day 1 of 21-day cycle; Vincristine 1.4 mg/m2 (max 2 mg) IV Day 1 of 21-day cycle; Prednisone/prednisolone 100 mg/day, per os, Day 1-5 of every 21-day cycle"
62389167|NCT02400268|EXPERIMENTAL|7 days course of antibiotic treatment|Accepted antibiotic indicated for enterobacteriaceae infections, according to sensibility test performed and daily practice protocols or local guidelines.
62389168|NCT02400268|ACTIVE_COMPARATOR|14 days course of antibiotic treatment|Accepted antibiotic indicated for enterobacteriaceae infections, according to sensibility test performed and daily practice protocols or local guidelines.
62389169|NCT00851721|EXPERIMENTAL|Prophylaxis arm|
62389170|NCT00851721|ACTIVE_COMPARATOR|On-demand arm|
62768911|NCT03462953|PLACEBO_COMPARATOR|individuals with healthy gingiva|Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls.
62768912|NCT03462953|PLACEBO_COMPARATOR|periodontally diseased individuals|Gingival tissue samples will be harvested during periodontal surgery and extraction of the periodontally hopeless tooth for the periodontitis patients.
62768913|NCT05898230||Subjects who have been implanted with the Carbomedics OptiForm Mitral Heart Valve|Mitral Valve Replacement with Carbomedics OptiForm Mitral Heart Valve
61993902|NCT05659173||1- normotensive women|Women with vitamin D deficiency and normotensive during pregnancy
62389171|NCT06482957||Observational|Patients monitor physical activity, sedentary behavior, heart rate and sleep wearing a FitBit device, undergo blood urine, stool and/or saliva sample collection, complete surveys and have medical records reviewed throughout study.
62389172|NCT04184674|OTHER|Acute Respiratory Distress Syndrome|Children of more than one month of age and adults hospitalized in Intensive Care Unit for Acute Respiratory Distress Syndrome.
62389173|NCT04838678|EXPERIMENTAL|Healthy Control|Healthy age matched controls with no history of cardiovascular disease and normal bodyweight
62389174|NCT04838678|EXPERIMENTAL|Hypertensive|Hypertensive adults who are not obese
62389175|NCT04838678|EXPERIMENTAL|Obese|Obese adults who are not hypertensive
62389176|NCT04838678|EXPERIMENTAL|Obese-hypertensive|Obese adults who are being treated for hypertension
62389177|NCT02102776|ACTIVE_COMPARATOR|MMC after pterygium excision|Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision. The conjunctival defect will be left bare without graft.
62389178|NCT02102776|ACTIVE_COMPARATOR|AMT after Pterygium Excision|Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision. No mitomycin C will be applied.
62768914|NCT00937755||olanzapine|olanzapine 10-20 mg/day
62768915|NCT00937755||quetiapine|quetiapine 300-600 mg/day
62768916|NCT00937755||risperidone|risperidone monotherapy, 2-4 mg/day
62768917|NCT04246814|PLACEBO_COMPARATOR|CC + dressing|The group will receive placebo LASER application associated with Helianthus annuus oil dressing.
62768918|NCT04246814|ACTIVE_COMPARATOR|LG1 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 10 J/cm² associated with Helianthus annuus oil dressing.
62389179|NCT02102776|ACTIVE_COMPARATOR|CAG after Pterygium Excision|A conjunctival autograft will be harvested from the superior side of the operating eye's bulbar conjunctiva. Then the graft will be sutured to cover the conjunctival defect after pterygium excision. No mitomycin C will be applied.
62389180|NCT02587780||Inactive|people who perform \< 30mins.day physical activity at a 'moderate' level of intensity.
62389181|NCT02587780||Active|people who perform 30mins-60 mins.day of physical activity at a 'moderate' level of intensity.
62389182|NCT02587780||Very active|People who perform \> 60 mins.day of physical activity at a \>moderate level of intensity.
62389183|NCT06345287|EXPERIMENTAL|clinical complete response|radiotherapy 60Gy + concurrent chemotherapy + immunotherapy maintenance
62389184|NCT06345287|EXPERIMENTAL|deep partial response|radiotherapy 66Gy + concurrent chemotherapy + immunotherapy maintenance
62389185|NCT06345287|EXPERIMENTAL|non-deep partial response|radiotherapy 70Gy+ concurrent chemotherapy + immunotherapy maintenance
62389186|NCT00100542||1|All HIV infected and uninfected participants and their caregivers.
62389187|NCT01957904|OTHER|ArterX Surgical Sealant|
62389188|NCT04021342|ACTIVE_COMPARATOR|Montmorency tart cherry concentrate|Participants will consume 30 ml of Montmorency tart cherry concentrate (MC) concentrate (King Orchard farms, USA) twice daily, once in the morning and again in the evening. According to the manufacturer each 30 ml dose of MC is estimated to be equivalent to approximately 90 whole cherries (equating to \~180 cherries per day).
62389189|NCT04021342|PLACEBO_COMPARATOR|Isocaloric cherry flavoured placebo|The PLA is prepared by mixing by mixing unsweetened black cherry flavoured Kool-Aid (Kraft Foods, United States), dextrose, fructose with water to best match the calorie content of the MC concentrate. Additional lemon juice, for tartness, and artificial food colouring is added so the final product had a similar visual properties to the active comparator.
62560727|NCT04298398|EXPERIMENTAL|Mindfulness (MBCT)|Group therapy based on Mindfulness Based-Cognitive Therapy (MBCT).
62768919|NCT04246814|ACTIVE_COMPARATOR|LG2 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 8 J/cm² associated with Helianthus annuus oil dressing.
61993903|NCT05659173||2- women with hypertensive disorder in pregnancy|Women with Vitamin D deficiency and hypertensive disorder in pregnancy
61993904|NCT05619276|ACTIVE_COMPARATOR|Standard serving utensil toolkit|Participants will self-serve and condiment a cold meal in the laboratory using standard kitchen utensils, including 2 nylon serving spoons and a simple glass oil dispenser. Participants will complete an eye-tracking test before eating, and will fill in questionnaires and provide blood samples during and after the meal. At 2h post-meal, they will complete a computerized memory reconstruction task related to the meal. After leaving the laboratory participants will keep a food diary, and will complete an on-line learning test before bedtime.
62560728|NCT04298398|EXPERIMENTAL|Emotion Focused Therapy (EFT-CR)|Group therapy based on Emotion Focused Therapy for Cancer Recovery (EFT-CR).
62567727|NCT01868737|PLACEBO_COMPARATOR|HIV-unexposed infants|MCT oil
62768920|NCT04246814|ACTIVE_COMPARATOR|LG3 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 4 J/cm² associated with Helianthus annuus oil dressing.
62768921|NCT01751776|PLACEBO_COMPARATOR|Part 1, Placebo BI 655064 80/120mg (HV)|Part 1, Healthy volunteers (HV): Placebo matching BI 655064 80 or 120 milligram (mg) injected subcutaneous on days 1, 8, 15, and 22 (once weekly, for 4 weeks) followed by 6 weeks follow-up period.
62768922|NCT01751776|PLACEBO_COMPARATOR|Part 1, Placebo BI 655064 180/240mg (HV)|Part 1, Healthy volunteers (HV): Placebo matching BI 655064 180 or 240 mg injected subcutaneous on days 1, 8, 15, and 22 (once weekly, for 4 weeks) followed by 6 weeks (180mg dosing group) or 8 weeks (240mg dosing group) follow-up period.
62389190|NCT00508001|PLACEBO_COMPARATOR|1|Best Supportive Care + Placebo
62389191|NCT00508001|EXPERIMENTAL|2|Best Supportive Care + ZD6474 100 mg
62389192|NCT00508001|EXPERIMENTAL|3|Best Supportive Care + ZD6474 300 mg
62389193|NCT04027504|EXPERIMENTAL|Fitabisc|Participants receiving fitabisc preoperatively
62389194|NCT02846337|EXPERIMENTAL|ULTRAFILTRATION|The ultrafiltration sodium-overload extraction will be chosen by the patient nephrologist and the patient himself (according to his comorbidities) among the following one: peritoneal dialysis (at least a daily contact), hemodialysis (\>1 session per week) or isolated ultrafiltration (\>1 session per week). Ultrafiltration technique could change throughout the care
62389195|NCT02846337|OTHER|ENHANCED MEDICAL TREATMENT|"The control group called enhanced medical treatment will not benefit of ultrafiltration (except refractory pulmonary edema, or terminal kidney failure requiring extra renal depuration). These situations will not be considered as protocol violation, because they are scientifically indicated for extra renal depuration."
62389196|NCT00461552|ACTIVE_COMPARATOR|Leptin|Leptin weight and gender based dose, sub-cutaneous, twice daily. Leptin versus placebo for entire 6 months double-blind.
62389197|NCT00461552|PLACEBO_COMPARATOR|Placebo|Placebo , sub-Q injection twice daily.
62389198|NCT03427203|EXPERIMENTAL|Arm 1|"The subjects test the products in the following order~SenSura Mio (comparator) Coloplast Ostomy device 1 Coloplast Ostomy device 2 Coloplast Ostomy device 3"
62389199|NCT03427203|EXPERIMENTAL|Arm 2|"The subjects test the products in the following order~SenSura Mio (comparator) Coloplast Ostomy device 1 Coloplast Ostomy device 3 Coloplast Ostomy device2"
62389200|NCT01417949|ACTIVE_COMPARATOR|Immediate arm|Immediate arm: ART should be initiated as soon as possible but no later than 3 days after initiation of OI treatment.
62389201|NCT01417949|ACTIVE_COMPARATOR|Deferred arm|Deferred arm: ART should be initiated after the completion of OI treatment which is achieved at the earliest at day 21 for PCP and at day 28 for TE. ART should be initiated no later than 6 weeks after initiation of OI treatment.
62389202|NCT01414686|EXPERIMENTAL|Immediate Treatment Group|
62389203|NCT01414686|NO_INTERVENTION|Delayed Treatment Group|
62389204|NCT02774499|EXPERIMENTAL|Methadone|Methadone 0.3 mg/kg (to a maximum of 30 mg) will be given to the patient preoperatively.
62768923|NCT01751776|EXPERIMENTAL|Part 1, BI 655064 80mg (HV)|Part 1, Healthy volunteers (HV): 80 mg of BI 655064 injected subcutaneous on days 1, 8, 15, and 22 (once weekly, for 4 weeks) followed by 6 weeks follow-up period.
62768924|NCT01751776|EXPERIMENTAL|Part 1, BI 655064 120mg (HV)|Part 1, Healthy volunteers (HV): 120 mg of BI 655064 injected subcutaneous on days 1, 8, 15, and 22 (once weekly, for 4 weeks) followed by 6 weeks follow-up period.
62389205|NCT02774499|PLACEBO_COMPARATOR|Placebo|Equivalent volume (5mL) of syrup will be given to the patient preoperatively.
62560729|NCT04298398|OTHER|Control Group|Treatment as Usual is the condition in which participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral and intervention for people identified with significant distress difficulties.
62560730|NCT02047695||Migraine with aura|Participants with migraine with aura (cases), their co-twins, and unrelated migraine-free twins (controls)
62560731|NCT01368497|EXPERIMENTAL|Entecavir and peginterferon|Entecavir for 8 weeks followed by 40 weeks of both entecavir and peginterferon
62560732|NCT00446693|EXPERIMENTAL|I|Use of EndoFast Reliant System
62560733|NCT06461806|EXPERIMENTAL|Plant-based pea/lupine protein supplement|
62768925|NCT01751776|EXPERIMENTAL|Part 1, BI 655064 180mg (HV)|Part 1, Healthy volunteers (HV): 180 mg of BI 655064 injected subcutaneous on days 1, 8, 15, and 22 (once weekly, for 4 weeks) followed by 6 weeks follow-up period.
62560734|NCT06461806|EXPERIMENTAL|Animal-based whey protein supplement|
62560735|NCT05418842|EXPERIMENTAL|Prehabilitation Group|In addition to standard medical care, the prehabilitation group will have three supervised exercise training sessions per week from diagnosis to start of radiotherapy (pre-treatment phase).
62560736|NCT05418842|NO_INTERVENTION|Control Group|The control group will receive the standard medical care.
62560737|NCT05459961|ACTIVE_COMPARATOR|active|oral spermidine supplement
62560738|NCT05459961|NO_INTERVENTION|placebo|matching placebo
62560739|NCT02542007|EXPERIMENTAL|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
62560740|NCT02542007|ACTIVE_COMPARATOR|Nano Polymer-free sirolimus-eluting stent system|The Nano polymer-free sirolimus-eluting stent produced by LePu medical.
62560741|NCT00521105|NO_INTERVENTION|1|Participants will be seen every 3-4 months with a physician-only visit alternating with a multidisciplinary visit (MD, RN and RD). This is the current standard of practice.
62560742|NCT00521105|EXPERIMENTAL|2|Participants will be seen every 3-4 months with a phone contact, with the diabetes nurse educator, alternating with a multidisciplinary visit (MD, RN and RD).
62560743|NCT00218595|EXPERIMENTAL|DBT|
62560744|NCT00218595|ACTIVE_COMPARATOR|I/GDC|
62560745|NCT03196453|ACTIVE_COMPARATOR|Probiotic|Lactobacillus rhamnosus GG
62560746|NCT03196453|ACTIVE_COMPARATOR|Probiotic and protein|Lactobacillus rhamnosus GG and whey protein isolate
62560747|NCT03196453|PLACEBO_COMPARATOR|Placebo|Placebo
62560748|NCT02960009|EXPERIMENTAL|Anode HD-tDCS|The center anode is fixed on the ipsilesional primary motor cortex and the 4 surrounding cathode electrodes will be placed about 6 cm to the center.
62768926|NCT01751776|EXPERIMENTAL|Part 1, BI 655064 240mg (HV)|Part 1, Healthy volunteers (HV): 240mg of BI 655064 injected subcutaneous on days 1, 8, 15, and 22 (once weekly, for 4 weeks) followed by 8 weeks follow-up period.
62768927|NCT01751776|PLACEBO_COMPARATOR|Part 2, Placebo BI 655064 120mg (RA)|Part 2, patients with Rheumatoid arthritis (RA) who had prior inadequate response to Methotrexat (MTX) therapy: Placebo matching BI 655064 120 milligram (mg) injected subcutaneous on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 (once weekly for 12 weeks) followed by 8 weeks follow-up period.
62389206|NCT03374059|EXPERIMENTAL|Exercise|Exercise group received a home exercise program treatment for 4 weeks including isometric exercises for neck muscles and postural correction exercises for neck region.
62389207|NCT03374059|EXPERIMENTAL|Exercise and Life modification|This group received life modification suggestions additional to home exercise treatment program for 4 weeks.
62389208|NCT03374059|NO_INTERVENTION|Control Group|Control group did not receive any treatments
62389209|NCT04938882|PLACEBO_COMPARATOR|Normal saline in transversus abdominis plane block|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
62389210|NCT04938882|ACTIVE_COMPARATOR|Ropivacaine in transversus abdominis plane block|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
62389211|NCT04938882|ACTIVE_COMPARATOR|Compound lidocaine at low-concentration in transversus abdominis plane block|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
62560749|NCT02960009|EXPERIMENTAL|Cathode HD-tDCS|The center cathode is fixed on the contralesional primary motor cortex and the 4 surrounding anode electrodes will be placed about 6 cm to the center.
62560750|NCT02960009|PLACEBO_COMPARATOR|Sham HD-tDCS|The center anode is fixed on the ipsilesional primary motor cortex and the 4 surrounding cathode electrodes will be placed about 6 cm to the center.
62560751|NCT01930682|EXPERIMENTAL|Early post-fibrinolytic catheterisation|For STEMI Patients, alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.Early routine catheterization after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
62560752|NCT01930682|OTHER|Primary PCI|For STEMI Patients,primary PCI is performed without fibrinolytic therapy.
62560753|NCT04416282|EXPERIMENTAL|Terlipressin + Albumin|Injection terlipressin 2 mg/24 hours infusion + i/v albumin 1g/Kg/day
62560754|NCT04416282|ACTIVE_COMPARATOR|Albumin|i/v albumin 1g/Kg/day for next 36 hours f/b inj terlipressin 2mg/24 hours
62560755|NCT04629495|ACTIVE_COMPARATOR|RAPA (rapamycin) treatment group|Subjects will receive active drug
61993905|NCT05619276|EXPERIMENTAL|Optimised portion-control toolkit|Participants will self-serve and condiment a cold meal in the laboratory using an optimised portion control toolkit. This toolkit will include two calibrated serving spoons, one for vegetables (slotted) and one for starch (solid), and a calibrated oil dispenser. Both spoons have a volume capacity of 155 ml with a 121 ml mark. The oil dispenser has a volume capacity of 250ml and allows pre-portioning of the oil via a sucking device in amounts ranging from 5-20 millilitres, 1-3 teaspoons or 0.5 to 1 tablespoon, prior to serving. Participants will complete an eye-tracking test before eating, and will fill in questionnaires and provide blood samples during and after the meal. At 2h post-meal, they will complete a computerized memory reconstruction task related to the meal. After leaving the laboratory participants will keep a food diary, and will complete an on-line learning test before bedtime.
62768928|NCT01751776|EXPERIMENTAL|Part 2, BI 655064 120mg (RA)|Part 2, patients with RA who had prior inadequate response to MTX therapy: 120 milligram (mg) of BI 655064 injected subcutaneous on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 (once weekly for 12 weeks) followed by 8 weeks follow-up period.
62768929|NCT04212013|EXPERIMENTAL|Ibrutinib/Rituximab|All subjects meeting eligibility criteria will receive rituximab: 375 mg/m\^2 on days 1, 8, 15 and 22 on cycle 1.
62389212|NCT04938882|ACTIVE_COMPARATOR|Compound lidocaine at high-concentration in transversus abdominis plane block|Before the induction of anesthesia, 0.6% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
62560756|NCT04629495|PLACEBO_COMPARATOR|Placebo group|Subjects will receive placebo
62560757|NCT01163838|PLACEBO_COMPARATOR|Placebo|
62560758|NCT01163838|EXPERIMENTAL|RN316: 1 mg/kg every 2 weeks|
62560759|NCT01163838|EXPERIMENTAL|RN316: 2 mg/kg every 4 weeks|
62768930|NCT04212013|PLACEBO_COMPARATOR|Ibrutinib/Placebo|Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis. Placebo capsules will be similarly dosed at 4 capsules daily.
61993906|NCT03047109|ACTIVE_COMPARATOR|Group P|Patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
61993907|NCT03047109|ACTIVE_COMPARATOR|Group E|Patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
61993908|NCT03088254|EXPERIMENTAL|Group I|Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin 20 mg for 8 weeks
61993909|NCT03088254|ACTIVE_COMPARATOR|Group II|Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo for 8 weeks
61993910|NCT03088254|ACTIVE_COMPARATOR|Group III|Treatment of Telmisartan 80 mg, Amodipine placebo, Rosuvastatin 20 mg for 8 weeks
61993911|NCT03782428|ACTIVE_COMPARATOR|Probiotic group|27 participants received probiotics twice daily for six months
62389213|NCT01074060|EXPERIMENTAL|Arm I|"MOBILIZATION: Patients receive cyclophosphamide IV. Patients also receive filgrastim subcutaneously (SC) daily beginning approximately 24 hours later.~TREATMENT/APHERESIS: Beginning 10 days after cyclophosphamide, patients receive plerixafor IV over 30 minutes followed by filgrastim SC on each day of apheresis."
62389214|NCT05899946|OTHER|pre- and post-educational group|This project will deliver an integrated program by nursing students with robots to clarify the misunderstanding about cannabis among parents and their children in Hong Kong
62389215|NCT05568966|EXPERIMENTAL|Blood Draw|"Venous blood draw up to 24mL and/or 6 capillary fingersticks~Interventions:~Diagnostic Test: Venepuncture Diagnostic Test: Fingerstick"
62560760|NCT01163838|EXPERIMENTAL|RN316: 4 mg/kg every 4 weeks|
62389216|NCT06199791|EXPERIMENTAL|Lamotrigine 100 mg oral tablet|Test
62560761|NCT01163838|EXPERIMENTAL|RN316: 4 mg/kg every 8 weeks|
62560762|NCT01163838|EXPERIMENTAL|RN316: 8 mg/kg every 8 weeks|
62560763|NCT01163838|EXPERIMENTAL|RN316: 12 mg/kg every 8 weeks|
62560764|NCT05920304|EXPERIMENTAL|virtual Hospital at Home (vHaH)|Participants are transferred home for telemedicine supported home-based admission.
62768931|NCT03208439|EXPERIMENTAL|EMG-driven NMES|subjects will receive EMG-driven NMES cycling exercise.
62389217|NCT06199791|ACTIVE_COMPARATOR|Lamictal 100 mg oral tablet|Reference
62389218|NCT06365840|EXPERIMENTAL|IMC-001|
62389219|NCT06221085||normal BMI|30 female students who have normal BMI \<25kg/m2.
62389220|NCT06221085||overweight|30 female students who are overweight and their BMI 25 - 30 kg/m2
62560765|NCT05920304|NO_INTERVENTION|Continued conventional hospitalisation|Participants will follow a conventional hospital admission.
62560766|NCT03746132|ACTIVE_COMPARATOR|Transdermal Continuous Oxygen Therapy|Subjects who satisfy the inclusion/exclusion conditions will be randomly assigned to the Treatment arm which provides Transdermal Continuous Oxygen Treatment (TCOT) (as delivered by EPIFLO device), in addition to standard of care for the surgical wound
62768932|NCT03208439|PLACEBO_COMPARATOR|passive pre-programmed NMES|subjects will receive passive pre-programmed NMES during cycling exercise.
61993912|NCT03782428|PLACEBO_COMPARATOR|Placebo group|25 participants received placebo twice daily for six months
61993913|NCT00853554|EXPERIMENTAL|A|Hydromorphone Hydrochloride tablet 8 mg
61993914|NCT00853554|ACTIVE_COMPARATOR|B|Dilaudid® tablet 8 mg
61993915|NCT01853033|EXPERIMENTAL|Group 1|Randomized 6 drug/2 placebo by group
61993916|NCT01853033|EXPERIMENTAL|Group 2|Randomized 6 drug/2 placebo by group
62389221|NCT06221085||obese|30 female students who are obese and their BMI \> 30 kg/m2.
62560767|NCT03746132|NO_INTERVENTION|Control|Subjects who satisfy the inclusion/exclusion conditions will be randomly assigned to the control arm which provides standard of care for the surgical wound.
62560768|NCT01279824|ACTIVE_COMPARATOR|Usual Care|Patients will receive behavioral swallowing therapy comprising combination's of treatment strategies / exercises chosen from an approved hierarchy. This formulation of treatment will be designed and applied by the treating clinician.The treatment will be provided daily for a one-hour over a consecutive 3-week period.
62560769|NCT01279824|PLACEBO_COMPARATOR|sham NMES|Patients will receive behavioral swallowing therapy comprising combinations of treatment strategies / exercises chosen from an approved hierarchy with the addition of non stimulating electrodes. A faux NMES device will be utilized with an active current display and non stimulating electrodes. The treatment will be provided daily for a one-hour over a consecutive 3-week period.
62768933|NCT01958853|EXPERIMENTAL|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from the NeuroPoint device
62768934|NCT01290900|EXPERIMENTAL|CXL104|2000 mg NXL104 + 1500 mg Ceftaroline (IV)
61993917|NCT01853033|EXPERIMENTAL|Group 3|Randomized 6 drug/2 placebo by group
62389222|NCT03458468|EXPERIMENTAL|Group A|Tranexamic Acid 1g IV
62389223|NCT03458468|PLACEBO_COMPARATOR|Group B|Saline injection
62389224|NCT01191359|ACTIVE_COMPARATOR|sublingual administration|oral immunotherapy with drops applied once daily by single dose containers (200 STU per dose)
62389225|NCT01191359|ACTIVE_COMPARATOR|vestibular administration|oral immunotherapy with drops applied by single dose containers (200 STU per dose)
62560770|NCT01279824|EXPERIMENTAL|NMES therapy|Patients will receive a protocol of standardized behavioral swallowing intervention combined with NMES. This formulation of treatment will be prescribed from a standard protocol and will be applied daily for one-hour over a consecutive 3-week period.
62560771|NCT01737047||HIV positive over 50 years of age|"All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.~Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn"
62560772|NCT01737047||HIV positive under the age of 50|"All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.~Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn"
62560773|NCT01737047||HIV negative over the age of 50|All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.
62389226|NCT06148805|EXPERIMENTAL|Pilates Group|"fifteen patients diagnosed with shoulder rotator cuff tendinopathy for at least 3 months randomly selected from ministry of health units will receive Pilates exercises program additional to traditional (RCT) physical therapy program containing Hot-Pack (HP), Therapeutic Ultrasound (US) and upper extremity strengthening and stretching exercise program)~* The assessment of pain intensity was carried out by visual analog scale~* The assessment of pain threshold was carried out by pressure algometer.~* The assessment of lateral rotation strength and abduction strength were carried out by hand heled dynamometer.~* The assessment of shoulder function was carried out by Arabic version of the Disability of the Arm, Shoulder and Hand (DASH-Arabic)~* The assessment of the functional exercise performance was carried out by Six-min walk test"
62389227|NCT06148805|EXPERIMENTAL|diaphragmatic Group|"fifteen patients diagnosed with shoulder rotator cuff tendinopathy for at least 3 months randomly selected from ministry of health units will receive diaphragm manual therapy techniques and traditional rotator cuff tendinopathy physical therapy program containing Hot-Pack (HP), Therapeutic Ultrasound (US) and upper extremity strengthening and stretching exercise program)~* The assessment of pain intensity was carried out by visual analog scale~* The assessment of pain threshold was carried out by pressure algometer.~* The assessment of lateral rotation strength and abduction strength were carried out by hand heled dynamometer.~* The assessment of shoulder function was carried out by Arabic version of the Disability of the Arm, Shoulder and Hand (DASH-Arabic)~* The assessment of the functional exercise performance was carried out by Six-min walk test"
62560774|NCT00886080|EXPERIMENTAL|Add-on arrhythmia surgery|"Adjuvant anti-arrhythmic surgery consists of a beating heart epicardial box isolation of all pulmonary veins using microwave energy (Flex 4 or Flex 10 ablation probes and Microwave generator by Guidant/Afix, Fremont, CA, USA). The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. In addition excision or exclusion of the left atrial appendage is performed in both the treated as the control group."
62560775|NCT02952144|EXPERIMENTAL|Lixelle® treatment|2 years of Lixelle® treatment in the patients with dialysis related amyloidosis (DRA)
62560776|NCT02952144|NO_INTERVENTION|natural history|2 years of natural history in the patients with dialysis related amyloidosis (DRA)
62389228|NCT06148805|ACTIVE_COMPARATOR|traditional Group|"fifteen patients diagnosed with shoulder rotator cuff tendinopathy for at least 3 months randomly selected from ministry of health units will receive 15 received traditional rotator cuff tendinopathy physical therapy program containing Hot-Pack (HP), Therapeutic Ultrasound (US) and upper extremity strengthening and stretching exercise program)~* The assessment of pain intensity was carried out by visual analog scale~* The assessment of pain threshold was carried out by pressure algometer.~* The assessment of lateral rotation strength and abduction strength were carried out by hand heled dynamometer.~* The assessment of shoulder function was carried out by Arabic version of the Disability of the Arm, Shoulder and Hand (DASH-Arabic)~* The assessment of the functional exercise performance was carried out by Six-min walk test"
62560777|NCT02045446|ACTIVE_COMPARATOR|Maintenance chemotherapy|FDA approved drugs for the study population: Bevacizumab, Docetaxel, Erlotinib, Gemcitabine, Pemetrexed
62560778|NCT02045446|EXPERIMENTAL|Stereotactic Body Radiation Therapy|consolidative Stereotactic Body Radiation Therapy (SBRT) plus maintenance chemotherapy
62560779|NCT02248844||Botulinum Toxin Type A|Subjects who receive botulinum toxin Type A injected into crow's feet line areas per clinical practice.
62560780|NCT04237376||Treatment Arm A: CHB Mothers treated with TAF during Pregnancy|120 pregnant women with double positive HBsAg and HBeAg and HBV DNA levels ≥ 2 × 10\^6 IU/mL were recruited from all four treatment centers. Mothers were enrolled and observed from gestational week 24-28 until postpartum week 28, and treated with TAF (25mg oral daily) from gestational week 28 until delivery (if the liver function is significantly abnormal after delivery, that is, ALT ≥ 5 × Upper Limit of Normal (ULN), the oral antiviral drug can be continued according to the wishes of the pregnant woman and the test results). All babies were given 3 HBV vaccines (0, 1, 6) and 1 routine Hepatitis B immunoglobin (HBIG) after birth. All babies were followed up to 2 years. According to the mother's wishes, if the mother agrees to collect breast milk and determine TAF concentration, breast milk was collected every day, and continuously collected 5-7 days for TAF concentration measurement. The time of last TAF dose taken as well as the time between milk collection and delivery was recorded.
61993918|NCT02323854|OTHER|Ablation and Surgical Resection|Ablation of lung tumor; followed by surgical resection of the ablation zone.
62389229|NCT06148805|EXPERIMENTAL|pilates and diaphragmatic Group|"fifteen patients diagnosed with shoulder rotator cuff tendinopathy for at least 3 months randomly selected from ministry of health units will receive diaphragm manual therapy, Pilates exercises program and traditional rotator cuff tendinopathy physical therapy program containing Hot-Pack (HP), Therapeutic Ultrasound (US) and upper extremity strengthening and stretching exercise program)~* The assessment of pain intensity was carried out by visual analog scale~* The assessment of pain threshold was carried out by pressure algometer.~* The assessment of lateral rotation strength and abduction strength were carried out by hand heled dynamometer.~* The assessment of shoulder function was carried out by Arabic version of the Disability of the Arm, Shoulder and Hand (DASH-Arabic)~* The assessment of the functional exercise performance was carried out by Six-min walk test"
62389230|NCT02409017|ACTIVE_COMPARATOR|Protocol A|Our current standard during labor
62389231|NCT02409017|ACTIVE_COMPARATOR|Protocol B|Another commonly accepted alternative for insulin drip management during labor
62389232|NCT04104399|EXPERIMENTAL|XC101-D13H|single dose
62389233|NCT04104399|PLACEBO_COMPARATOR|Placebo|single dose
62560781|NCT04237376||Comparative Arm C: CHB Pregnant Mothers|This arm C consists of 360 cases of pregnant women with HBsAg and HBeAg double-positive, and HBV DNA level ≥ 2 × 10\^6 IU/mL. The mothers in this historical cohort did not receive any antiviral treatment during their pregnancy. All cases of pregnant mothers in this arm were extracted from the four treatment centers involved in this study: Beijing You'an Hospital, Capital Medical University, Fourth Hospital Affiliated to Harbin Medical University, Third Hospital of Qinhuangdao, and Tongliao Infectious Disease Hospital. All babies received 3 doses of HBV vaccine (0, 1, 6) and 1 dose of HBIG after birth.
62560782|NCT04237376||Comparative Arm B: CHB Pregnant Mothers treated with TDF|This retrospective cohort arm B consists of 120 cases of pregnant women with double-positive HBsAg and HBeAg and HBV DNA levels ≥ 2 × 10\^6 IU/mL. All cases of pregnant mothers in this arm were extracted from the four treatment centers involved in this study: Beijing You'an Hospital, Capital Medical University, Fourth Hospital Affiliated to Harbin Medical University, Third Hospital of Qinhuangdao, and Tongliao Infectious Disease Hospital. Pregnant mothers were treated with TDF (300mg oral daily) starting from gestational week 28 and discontinued the drug at delivery. All babies received 3 doses of HBV vaccine (0, 1, 6) and 1 dose of HBIG after birth.
62389234|NCT06336109|EXPERIMENTAL|Experimental Knee Pain and Shoulder Pain|"Injection to the infrapatellar fat pad. Will always be administered first.~Injection to the deltoid muscle. Will always be administered last."
62389235|NCT03389490|EXPERIMENTAL|Active|Insulin glargine 300U/ml
62389236|NCT03389490|ACTIVE_COMPARATOR|Control|Neutral Protamine Hagedorn insulin
62389237|NCT01142960|ACTIVE_COMPARATOR|Placebo|Starch
62389238|NCT01142960|EXPERIMENTAL|Lycium Barbarum|Lycium Barbarum supplement
62389239|NCT01135368|EXPERIMENTAL|Lansoprazole|"Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.~Depending on response, dosage could then be decreased to 15 mg, once daily, or increased to 30 mg, twice daily for up to 4 years and 10 months."
62560783|NCT05059613|EXPERIMENTAL|probiotics group|Use thalidomide in combination with probiotics during radiotherapy and chemotherapy
62560784|NCT05059613|NO_INTERVENTION|thalidomide group|Thalidomide is used only during radiotherapy and chemotherapy
62768935|NCT01290900|EXPERIMENTAL|CAZ104|Placebo Infusion (saline) + 2000 mg NXL104 + 3000 mg Ceftazidime (IV)
62768936|NCT01290900|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin 400mg (1 tablet)
62768937|NCT01290900|PLACEBO_COMPARATOR|Placebo|Placebo Infusion (saline)
62768938|NCT05400629|EXPERIMENTAL|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises will be perform between 6 and 8 maximal repetitions.
62768939|NCT05325294|EXPERIMENTAL|MiniMed 780G System Utilizing Insulin Lyumjev®|Subjects with insulin-requiring type 1 diabetes age 7-80 using the MiniMed 780G system with Insulin Lyumjev® for a period of three months.
62768940|NCT04222855|EXPERIMENTAL|Diltiazem|Postpartum patients were administered (60 mg) orally every 8 hours with diltiazem (tables).
62768941|NCT04222855|ACTIVE_COMPARATOR|Nifedipine|Postpartum patients were administered (10 mg) orally every 8 hours with nifedipine (capsule).
62768942|NCT04927793|EXPERIMENTAL|Single arm EDP-938|
62768943|NCT06507852||Overall Cohort|Adult patients with ASCVD and hypercholesterolemia, ASCVD-RE with hypercholesterolemia, or FH, who were prescribed inclisiran in a real-world setting as per clinical practice and according to the label in Austria.
62768944|NCT02546089|ACTIVE_COMPARATOR|intervention group|"local anaesthetic - lidocaine 1%, dry needling, autologous blood injection,~+ structured rehab programme"
62768945|NCT02546089|PLACEBO_COMPARATOR|control group|"local anaesthetic - lidocaine 1%, dry needling,~+ structured rehab programme"
62768946|NCT05332093||Local cutaneous leishmaniasis patients group (LCL)|local cutaneous leishmaniasis patients
62768947|NCT05332093||Mucocutaneous leishmaniasis patients group (MCL)|mucocutaneous leishmaniasis patients
62768948|NCT05332093||Diffuse cutaneous leishmaniasis patients group (DCL)|diffuse cutaneous leishmaniasis patients
62768949|NCT05332093||Healthy control patients group Ethiopia (HC - Ethiopia)|healthy control patients undergoing elective surgery in Northern Ethiopia
62768950|NCT05332093||Healthy control patients group Belgium (HC - Belgium)|healthy control patients undergoing plastic surgery in Belgium
62768951|NCT03974737||Adolescents with POTS|"Adolescents with Postural Orthostatic Tachycardia Syndrome (POTS) who meet diagnostic criteria for an orthostatic heart rate increase of \>30, between ages 12-21 are eligible for this group. They will have a urine specific gravity conducted at the beginning of the clinic visit to assess hydration status. If urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.~Interventions performed:~* Urine specific gravity measurement~* CRI measurements, orthostatic vitals measurements~* Survey administration"
62768952|NCT03974737||Adolescents without POTS, Control Group|"Adolescents without Postural Orthostatic Tachycardia Syndrome (POTS) between ages 12-21 are eligible for this group. This group of subjects will have a urine specific gravity conducted at the beginning of the clinic visit to assess hydration status. If the urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and their urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.~Interventions performed:~* Urine specific gravity measurement~* CRI measurements, orthostatic vitals measurements~* Survey administration"
62768953|NCT03974737||Adolescents diagnosed with POTS who do not meet HR|"Adolescents diagnosed with Postural Orthostatic Tachycardia Syndrome (POTS) between ages 12-21, who do not meet diagnostic heart rate criteria, are eligible for this group. This group of subjects will have a urine specific gravity conducted at beginning of the clinic visit to assess hydration status. If the urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.~Interventions performed:~* Urine specific gravity measurement~* CRI measurements, orthostatic vitals measurements~* Survey administration"
62768954|NCT04064645|EXPERIMENTAL|Respiratory rate accuracy measurement|
62768955|NCT04847557|EXPERIMENTAL|Tirzepatide|Tirzepatide administered subcutaneously (SC)
62768956|NCT04847557|PLACEBO_COMPARATOR|Placebo|Placebo administered SC
62768957|NCT01806064|EXPERIMENTAL|TRC105 and Axitinib|Patients randomized to receive TRC105 at 3 mg/kg on day 1, 7 mg/kg on day 4, and 10 mg/kg on day 8 and weekly thereafter in combination with axitinib 5 mg twice daily
62768958|NCT01806064|ACTIVE_COMPARATOR|Axitinib|Patients randomized to receive axitinib 5 mg twice daily
62560785|NCT05059613|NO_INTERVENTION|healthy control group|healthy control group
62567728|NCT01868737|EXPERIMENTAL|HIV-unexposed|Probiotic: L. rhamnosus GG (0.35 x 109 colony-forming units \[CFU\]) and B. infantis (0.35 x 109 CFU) daily
62768959|NCT01448005||wearable defibrillator use|subjects will use a wearable defibrillator
62768960|NCT04334564|ACTIVE_COMPARATOR|Test team|Patients were treated with ginkgo biloba capsule regularly. Take 2 capsules 3 times a day, orally
62768961|NCT04334564|PLACEBO_COMPARATOR|Control group|Patients were treated with placebo regularly.Take 2 capsules 3 times a day, orally
62768962|NCT05489900|NO_INTERVENTION|0.9% Saline Infusion|The placebo group will receive 0.9% saline infusion at the same rates as the intervention group.
62768963|NCT05489900|EXPERIMENTAL|Dexmedetomidine Infusion|Dexmedetomidine will be used in the intervention group as follows: beginning in anesthetic induction after obtaining venous access at 1mcg/kg/h for 20 minutes, followed by 0.2 - 0.5 mcg/kg/h until the end of the surgery.
62768964|NCT03957941|EXPERIMENTAL|FamilyLink Pumping|Pump three times while away from infant, while watching baby via FamilyLink.
62567729|NCT01420068||All patients|All patients previously treated with study medication in the CSPP100A2365 and CSPP100A2365E1 studies.
61993919|NCT00581776|EXPERIMENTAL|VCR-CVAD with rituximab maintenance|Induction chemotherapy with Bortezomib, cyclophosphamide, rituximab, vincristine, doxorubicin, and dexamethasone. Subjects will receive 6 cycles of induction chemotherapy, of 21 days each. After completing induction, subjects will receive rituximab consolidation (4 weeks), and then rituximab maintenance therapy for up to 5 years.
61993920|NCT01851720|ACTIVE_COMPARATOR|Control group / Standard of Care|"* IV fentanyl bolus 25-50 mcg every 1-2 hrs as needed for pain~* (Bolus dose can be titrated up in 25 mcg increments if necessary)~* Maximum dose of 100 mcg/hr"
62560786|NCT04020887|NO_INTERVENTION|Observation Phase|In the first three months of this proof-of-concept study, a telemedicine center for the PACU will monitor patients assigned to PACU bays. Both telemedicine center clinicians and nurses caring for patients in these PACU bays will independently record information on patient physiological derangements, treatable symptoms, situations requiring urgent medical intervention, and discharge readiness (based on the modified Aldrete scale). During this phase of the study, clinicians in the telemedicine center will not communicate with clinicians in the PACU (nurses or physicians), unless there was a patient safety event.
62560787|NCT04020887|EXPERIMENTAL|Interaction Phase|In the three months following the observation phase, clinicians in the telemedicine center will interact with clinicians and patients in the two designated PACU bays using audio-visual technology. The clinicians in the telemedicine center will continue to document information on physiological derangements, treatable symptoms, situations requiring urgent medical intervention, and discharge readiness.
62560788|NCT01662492|EXPERIMENTAL|Botulinum toxin type A Dose 1|Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.
62560789|NCT01662492|EXPERIMENTAL|Botulinum toxin type A Dose 2|Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.
62560790|NCT01662492|PLACEBO_COMPARATOR|Placebo (Normal Saline)|Placebo (Normal Saline) intramuscular injections into specified muscles.
62560791|NCT01129557|ACTIVE_COMPARATOR|Tekturna|Tekturna (Aliskiren), a direct renin inhibitor (DRI) 300 mg by mouth once daily for 9 months
62560792|NCT01129557|ACTIVE_COMPARATOR|Diovan|Diovan (Valsartan), an angiotensin receptor blocker (ARB) 320 mg by mouth once daily for 9 months
62560793|NCT01129557|ACTIVE_COMPARATOR|Tekturna & Diovan|Tekturna (Aliskiren), a direct renin inhibitor (DRI) 150 mg by mouth once daily \& Diovan (Valsartan), an angiotensin receptor (ARB) 160 mg by mouth once daily for 9 months
62560794|NCT03817125|PLACEBO_COMPARATOR|SER-401 Matching Placebo/ Nivolumab|Participants will undergo a 4-day lead-in pretreatment with antibiotic placebo, then matching placebo for SER-401 and nivolumab (480 mg) treatment.
62560795|NCT03817125|EXPERIMENTAL|SER-401/ Nivolumab|Participants will undergo a 4-day lead-in pretreatment with antibiotic (vancomycin) to prime the gut microbiome for engraftment of the oral microbiome study intervention, then SER-401 and nivolumab treatment.
62560796|NCT03093142|EXPERIMENTAL|tDCS & neurofeedback|30 minutes tDCS \& 30 minutes neurofeedback
62560797|NCT03093142|ACTIVE_COMPARATOR|real neurofeedback|30 minutes real neurofeedback.
62560798|NCT03093142|SHAM_COMPARATOR|sham neurofeedback|30 minutes sham neurofeedback.
62560799|NCT05487950|EXPERIMENTAL|experimental group|Patients in the Rivaroxaban group will receive Rivaroxaban at the dose of 15 mg once daily ((or 10 mg if renal insufficiency) during 2 years.
62560800|NCT05487950|NO_INTERVENTION|group control|Patients in the control group will be followed according to the standard of care (SOC) chosen by the investigator during 2 years. Additions or changes to SOC are allowed during the patient participation in the study based on patient status and evolution (with the exception of the use of anticoagulant therapy).
62560801|NCT04965597|EXPERIMENTAL|Treatment (conditioning regimen; transplant; GVHD prophylaxis)|"CONDITIONING REGIMEN: Patients receive treosulfan IV over 120 minutes on days -6 to -4, fludarabine phosphate IV over 60 minutes on days -6 to -2, and rATG IV over 4-6 hours on days -4 to -2.~TRANSPLANTATION: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously beginning on day -2 and a taper beginning on day 180. Patients may also receive tacrolimus PO. Patients also receive methotrexate IV on days 1, 3, 6, and 11.~Patients undergo ECHO or MUGA as well as possible x-ray or CT at baseline and undergo bone marrow biopsy and aspiration at baseline and follow up. Patients also undergo blood sample collection throughout the trial."
62560802|NCT04658134|EXPERIMENTAL|Glycine supplementation|Glycine supplementation
62560803|NCT01785082|EXPERIMENTAL|LiMAx-group|Intravenous pre- and post-surgical injection of 0.4% 13-C-Methacetin solution. Dosage is adapted due to body weight (2 mg/kg). A LiMAx-test of \>150 µg/kg/h would correspond to a general ward indication.
62560804|NCT01785082|NO_INTERVENTION|control group|Control group without intervention. Post-surgical management as defined prior to surgery following well-established clinical standards.
62768965|NCT03957941|ACTIVE_COMPARATOR|Standard Pumping|Pump three times while away from infant, not watching baby via FamilyLink.
62768966|NCT01147900|EXPERIMENTAL|Boostrix-REF Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, reference formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
62560805|NCT06053346|EXPERIMENTAL|Pay For Performance (PFP)|Participants receive a tailored mix of assertive case management, crisis intervention, substance use counseling, mental health treatment, peer support, skill-building and care coordination, among other services delivered by a provider agency contracted by Santa Clara County. Individual and organizational performance incentives relative to traditional contracted service arrangements were also included. Specifically, the agreement between the contracted provider and the County included an agreed schedule of financial rewards and penalties for the contracted provider based on whether its enrollees utilized more or less care than had a historical cohort of patients enrolled before the program began.
61993921|NCT01851720|ACTIVE_COMPARATOR|Low dose IV fentanyl PCA|"* Initially: 10 mcg demand dose every 12 minutes~* No initial bolus and no continuous infusion~* Demand dose increased 10 mcg every 12 minutes if necessary~* Maximum dose of 100 mcg/hr"
61993922|NCT00283933|EXPERIMENTAL|Migalastat|Migalastat 150 milligrams (mg) was administered orally QOD during the 24-week treatment period and then during the optional 24-week extension period.
61993923|NCT04924829||Tocilizumab|Group that received tocilizumab (8mg/kg, maximum dose 800 mg, only once) while being admitted with severe COVID-19 pneumonia.
61993924|NCT04924829||Non-tocilizumab|Group that did not receive tocilizumab but share the same indication according to the elegibility criteria for it as the tocilizumab group while admitted with severe COVID-19 pneumonia.
61993925|NCT03690388|EXPERIMENTAL|Cabozantinib|cabozantinib (60 mg) once daily orally (qd)
61993926|NCT03690388|PLACEBO_COMPARATOR|Placebo|placebo once daily orally (qd)
61993927|NCT03843879|ACTIVE_COMPARATOR|TAP Block|Single-injection transversus abdominis plane block
61993928|NCT03843879|ACTIVE_COMPARATOR|IV Lidocaine|Continuous intravenous lidocaine infusion
61993929|NCT02527954||Infertile with Y-chromosome deletions|"No intervention will be performed.~Couples whose infertile men has a Y-chromosome microdeletion (detected in blood cells by Polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 1)"
61993930|NCT02527954||Infertile without Y-chromosome deletions|"No intervention will be performed.~Couples whose infertile men has not any Y-chromosome microdeletion (detected in blood cells by polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 2)"
61993931|NCT01364428|EXPERIMENTAL|IDeg 200 U/mL|
61993932|NCT01364428|EXPERIMENTAL|IDeg 100 U/mL|
62389240|NCT02671786|EXPERIMENTAL|Intervention Arm|"Intervention area: Provision of community based health care to severely malnourished children 6 months age in 16 tribal villages by trained semi-literate village health workers.~1. Treatment of severely malnourished children through MAHAN RUTF \& MAHAN Vit-Min mix~2. Growth monitoring of all children below the age of 5 years~3. Treatment of associated diseases like Diarrhea, Pneumonia, Malaria, etc.~4. Management of resistant or relapsed severely malnourished cases by pediatrician.~5. Intensive behavior change communication of parents of children below the age of 5 years for proper nutrition.~Dose: 46 gms of proteins/kg/day \& 100170 calories/kg/day with gradual escalation with micro nutrient supplementation Route: Oral Frequency: 4 times a day Duration: 12 weeks"
62389241|NCT02671786|NO_INTERVENTION|Control Arm|Control area: In control area, the V.H.W. and supervisor records weight of all under 5 children. They also collect data related to birth, deaths and verbal autopsy.
62389242|NCT05079100|ACTIVE_COMPARATOR|group of intervention (counseling)|the group will receive the contraception counseling
62389243|NCT05079100|NO_INTERVENTION|group of control (no counseling)|this group will not receive any counseling
62389244|NCT04438642|OTHER|conventional ceramic onlay with shoulder finishline|tooth that need ceramic onlay restoration, a conventional cavity will be prepared with shoulder finishline.
62560806|NCT06053346|ACTIVE_COMPARATOR|Usual Care (UC)|Participants receive the usual array of mental health and psychosocial services offered by Santa Clara County.
62560807|NCT01372618|EXPERIMENTAL|SOM 230/Pasireotide|Treatment with SOM230 600mcg twice daily for 20 days.
61993933|NCT05282719|EXPERIMENTAL|Treatment regime|On day 1 of each cycle, decitabine 75 mg/m2 will be given subcutaneously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 14 day cycle is finished.
62560808|NCT03695900|OTHER|Targeting SpO2 at 93-95% followed by targeting at 90-92%|FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours, followed by FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours.
61993934|NCT01791738|EXPERIMENTAL|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
61993935|NCT01791738|NO_INTERVENTION|Standard total hip arthroplasty|Each surgeon will use their standard methods of pre-operative planning using pre-operative x-rays, and complete the procedure using standard surgical instruments for total hip arthroplasty.
61993936|NCT02768675|EXPERIMENTAL|LOADPRO arm|Participants will temporarily receive a LOADPRO device affixed to kyphotic corrective rods. The device will not be implanted and will be removed prior to surgery closure.
61993937|NCT05764187|EXPERIMENTAL|Ceramic orthodontic brackets|Patients bonded with ceramic brackets for orthodontic treatment
61993938|NCT05764187|ACTIVE_COMPARATOR|Metal orthodontic brackets|Patients bonded with metal brackets for orthodontic treatment
61993939|NCT04095507|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
61993940|NCT04865237|EXPERIMENTAL|Healthy Volunteers|SARS-CoV-2, intranasally, (1x10\^1 TCID50, 1x10\^2 TCID50 and 1x10\^3 TCID50 or higher, as necessary)
61993941|NCT01440738|EXPERIMENTAL|health workshops|Health promotion group intervention
61993942|NCT01440738|NO_INTERVENTION|comparison group|usual care
61993943|NCT03301194||RAMP-HT patients|HT patients who have enrolled into the RAMP-HT between 1 October 2011 and 31 March 2012 and fulfilled the inclusion criteria and without any exclusion criteria
61993944|NCT03301194||Usual care patients|HT patients receiving usual care in GOPCs who have never enrolled into RAMP-HT on or before 31 March 2017 and fulfilled the inclusion criteria and without any exclusion criteria
62389245|NCT04438642|EXPERIMENTAL|conservative ceramic onlay preparation buttjoint with bevel|tooth that need ceramic onlay restoration, a conservative cavity will be prepared with butt joint with bevel finishline.
62389246|NCT04340167|EXPERIMENTAL|Autologous humanized anti-CD22 CAR-T treatment|
62768967|NCT01147900|EXPERIMENTAL|Boostrix-US Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, United States(US)-marketed formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, US-marketed formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
61993945|NCT00451035|EXPERIMENTAL|Panobinostat (LBH589)|Participants were administered panobinostat 20 milligram (mg) orally once a day (OD) three times a week as part of a 4 week (28 day) treatment cycle. Panobinostat were administered at the same time each morning with 8oz/240 milliliter (ml) of water after a fasting period of at least two hours (water was allowed). Participants could continue treatment until they experienced unacceptable toxicity or disease progression.
62389247|NCT02572492|EXPERIMENTAL|Carfilzomib/dexamethasone maintenance|Carfilzomib/dexamethasone maintenance after salvage HDT
62389248|NCT02572492|SHAM_COMPARATOR|Observation without maintenance|Observation without maintenance after salvage HDT
62389249|NCT05782660|EXPERIMENTAL|Treatment Group|Participants in the treatment group received up to $400 per month.
62768968|NCT01147900|EXPERIMENTAL|Boostrix-INV Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, investigational formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
62768969|NCT01978626|EXPERIMENTAL|Smart phone Apps|"1. 1st year: Electronic sleep diary module: an app with electronic sleep diary and message reminder~2. 2nd year: Social persuasion system module: an app of smart phone that encourages participants with each others~3. 3rd year: Tai-chi module: a multi-media oriented app that helps participants practice Tai-Chi"
61993946|NCT05783635|EXPERIMENTAL|Enhanced Usual Care then Usual Surgical Care|Randomized two times (2 possible randomization groups each time). Responder to Enhanced Usual Care
61993947|NCT05783635|EXPERIMENTAL|Enhanced Usual Care then Post-operative Health Coaching|Randomized two times (2 possible randomization groups each time). Responder to Enhanced Usual Care
61993948|NCT05783635|EXPERIMENTAL|Enhanced Usual Care then On-Track|Randomized two times (2 possible randomization groups each time). Non-responder to Enhanced Usual Care
61993949|NCT05783635|EXPERIMENTAL|Enhanced Usual Care then Combine (Postoperative Health Coaching + On-track)|Randomized two times (2 possible randomization groups each time). Non-responder to Enhanced Usual Care
61993950|NCT05783635|OTHER|Enhanced Usual Care alone|Only completed first randomization. Study withdrawal prior to re-randomization
61993951|NCT05783635|EXPERIMENTAL|Preoperative Virtual Health Coaching then Usual Surgical Care|Randomized two times (2 possible randomization groups each time). Responder to Preoperative Virtual Health Coaching
61993952|NCT05783635|EXPERIMENTAL|Preoperative Virtual Health Coaching then Postoperative Virtual Health Coaching|Randomized two times (2 possible randomization groups each time). Responder to Preoperative Virtual Health Coaching
61993953|NCT05783635|EXPERIMENTAL|Preoperative Virtual Health Coaching then On-Track|Randomized two times (2 possible randomization groups each time). Non-responder to Preoperative Virtual Health Coaching
62560809|NCT03695900|OTHER|Targeting SpO2 at 90-92% followed by targeting at 93-95%|FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours, followed by FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours.
61993954|NCT05783635|EXPERIMENTAL|Preoperative Virtual Health Coaching then Combine (Postoperative Virtual Health Coaching + On-track)|Randomized two times (2 possible randomization groups each time). Non-responder to Preoperative Virtual Health Coaching
61993955|NCT05783635|OTHER|Preoperative Virtual Health Coaching only|Only completed first randomization. Study withdrawal prior to re-randomization.
61993956|NCT01835743|ACTIVE_COMPARATOR|Erchonia HPS Laser|The Erchonia HPS Laser contains 3 independent diodes mounted in scanner devices and positioned equidistant from each other and titled at a 30 degree angle. Each scanner emits 17 milliwatts (mW), 635 nm of red laser light.
61993957|NCT01835743|PLACEBO_COMPARATOR|Placebo Laser|The Placebo Laser is identical in appearance and operation to the Erchonia HPS Laser but does not emit any therapeutic light.
61993958|NCT05102188||African American adults with poor sleep|Individuals with self-identified poor sleep quality and/or quantity
62389250|NCT05782660|ACTIVE_COMPARATOR|Control Group|Participants in the control group did not receive monthly cash benefits.
62560810|NCT03689829|EXPERIMENTAL|MOR106 Single Dose A, i.v. infusion, Part 1|A single dose of MOR106 will be administered by i.v. infusion.
62560811|NCT03689829|EXPERIMENTAL|MOR106 Single Dose B, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
62560812|NCT03689829|EXPERIMENTAL|MOR106 Single Dose C, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
62389251|NCT00733096|EXPERIMENTAL|1|Epidural etanercept 4 mg, two doses 2 weeks apart
62389252|NCT00733096|ACTIVE_COMPARATOR|2|Epidural methylprednisolone 60 mg, two doses 2 weeks apart
62389253|NCT00733096|PLACEBO_COMPARATOR|3|Epidural saline, two doses 2 weeks apart
62389254|NCT02432027|EXPERIMENTAL|IMP 1|C-82 Topical Gel, 1%
62389255|NCT02432027|PLACEBO_COMPARATOR|IMP 2|C-82 Topical Gel, placebo
62389256|NCT02432027|ACTIVE_COMPARATOR|IMP 3|Daivonex cream
62389257|NCT02432027|ACTIVE_COMPARATOR|IMP 4|Diprosis gel
62389258|NCT04051320|EXPERIMENTAL|Hormone Sensitive Women (HS+)|Participants will take leuprolide acetate (lupron) via intramuscular injection, for 2 months. Participants will take 2 mg of estradiol twice daily and 200 mg of progesterone twice daily for 2 weeks.
62389259|NCT04051320|EXPERIMENTAL|Hormone Insensitive Women (HS-)|Participants will take leuprolide acetate (lupron) via intramuscular injection, for 2 months. Participants will take 2 mg of estradiol twice daily and 200 mg of progesterone twice daily for 2 weeks.
62389260|NCT02206958|OTHER|No treatment control group|No treatment control group
61993959|NCT03873870|EXPERIMENTAL|68Ga -DOTATATE PET scan|Single arm study.
62560813|NCT03689829|EXPERIMENTAL|MOR106 Single Dose D, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
62560814|NCT03689829|EXPERIMENTAL|MOR106 Repeated Doses E, s.c. injection, Part 2|Repeated doses of MOR106 will be administered by s.c. injection with a loading dose on the first day of administration.
62560815|NCT03689829|PLACEBO_COMPARATOR|Placebo s.c.injection, Part 2|Corresponding Placebo will be administered by s.c. injection.
62560816|NCT03689829|EXPERIMENTAL|MOR106 Repeated Doses F, s.c. injection, Part 3|Repeated doses of MOR106 will be administered by s.c. injection with a loading dose on the first day of administration.
62560817|NCT03689829|PLACEBO_COMPARATOR|Placebo s.c.injection, Part 3|Corresponding Placebo will be administered by s.c. injection.
62560818|NCT01928264|EXPERIMENTAL|Physical activity|Physical activity group program over 12 weeks; 1 hour sessions, 2 times a week
62560819|NCT01928264|NO_INTERVENTION|Leisure time activities|Predominantly sedentary leisure time group activities, like playing board games, doing handicrafts, etc.; 12 weeks, 1 hour sessions, 2 times a week
62768970|NCT01978626|ACTIVE_COMPARATOR|Control|"1. 1st year: traditional paper-pencil diary~2. 2nd year: no social persuasion is given beyond sessions~3. 3rd year: Tai-chi teaching by Digital Video Disc only"
61993960|NCT02381418|EXPERIMENTAL|1|"Trivalent influenza subunit vaccine Influvac. 3x 15mcg Hemagglutinin Antigen (HA) per 0.5 ml,trivalent one injection at Day 1 "
61993961|NCT01224639|EXPERIMENTAL|Group 1: Low Dose; SC|TDV-1: 8 x 10\^3 Plaque Forming Units (PFU), TDV-2: 5 x 10\^3 PFU, TDV-3: 1 x 10\^4 PFU, TDV-4: 2 x 10\^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.
61993962|NCT01224639|EXPERIMENTAL|Group 2: Low Dose; ID|TDV-1: 8 x 10\^3 PFU, TDV-2: 5 x 10\^3 PFU, TDV-3: 1 x 10\^4 PFU, TDV-4: 2 x 10\^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.
61993963|NCT01224639|EXPERIMENTAL|Group 3: High Dose; SC|TDV-1: 2 x 10\^4 PFU, TDV-2: 5 x 10\^4 PFU, TDV-3: 1 x 10\^5 PFU, TDV-4: 3 x 10\^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.
61993964|NCT01224639|EXPERIMENTAL|Group 4: High Dose; ID|TDV-1: 2 x 10\^4 PFU, TDV-2: 5 x 10\^4 PFU, TDV-3: 1 x 10\^5 PFU, TDV-4: 3 x 10\^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.
61993965|NCT01224639|PLACEBO_COMPARATOR|Placebo (SC)|Phosphate buffered saline administered subcutaneously in a volume of 0.5 mL.
61993966|NCT01224639|PLACEBO_COMPARATOR|Placebo (ID)|Phosphate buffered saline administered intradermally in a dose volume of 0.1 mL.
61993967|NCT02574871||Single Group|Psychological and biological data collection
61993968|NCT04943731|OTHER|Provox Life™|"Phase 1: Provox Life™. Like-for-like transition from Provox (or other brand) to Provox Life™ under guidance from Speech Pathologist who will assess when the participant is ready to commence the 6 week study observation period.~Phase 2: Provox Life™ with Day/Night regimen. Establishment of optimal day/night routine under guidance of Speech Pathologist who will assess when the participant is ready to commence the 6 week observation period."
61993969|NCT06244264|EXPERIMENTAL|Autoblood transfusion + leukocyte filter group|In our department open surgery is considered as the standard procedure. The patients underwent open surgery, with autologous blood transfusion combined with a leukocyte filter. Blood transfusion based on bleeding during surgery.
61993970|NCT06244264|NO_INTERVENTION|Allogeneic blood transfusion group|In our department open surgery is considered as the standard procedure. The patients receives open surgery with allogeneic blood transfusion. Blood transfusion based on bleeding during surgery.
62389261|NCT02206958|EXPERIMENTAL|Behavioral Urinary Incontinence Treatment|12 week program combining behavioral treatments for urinary incontinence and physical activity
62389262|NCT05021159||Methotrexate Group|20 acute lymphocytic leukemia patients receiving MTX treatment (3- 5 mg/ cm2)
62389263|NCT05021159||Healthy control group|20 healthy pediatric subjects not receiving any treatment
62389264|NCT05899127|EXPERIMENTAL|Lidocaine|Lidocaine will be injected intravenously at 1.5mg/kg during anesthesia induction and intravenously pumped at 1.5mg/kg/h during anesthesia induction.
62389265|NCT05899127|PLACEBO_COMPARATOR|Control group|Normal saline will be injected intravenously at 1.5mg/kg during the induction period and intravenously pumped at 1.5mg/kg/h during the induction period.
62389266|NCT05076981||Pure Natural Cycle|"* Transvaginal ultrasound (TVUS) on day 2/3 of cycle + hormones FSH, LH, E2, P4 (IVF1)~* TVUS day 9-10 of cycle to identify dominant follicle.~* Blood test for IVF1 every 24h until identification of the LH surge.~* The LH surge will be diagnosed when the concentration rises by 180% above the latest serum value available in that patient and continued to rise thereafter (Fatemi et al, 2010).~* Once the LH rise is detected, blood test for IVF1 to be performed after 2h, and then every 12h after LH rise for 2 days.~* During luteal phase, IVF1 day 7 after LH rise and day 14 after LH rise."
62389267|NCT05076981||Modified Natural Cycle|"* Transvaginal ultrasound (TVUS) on day 2/3 of cycle + hormones FSH, LH, E2, P4 (IVF1)~* TVUS day 9-10 of cycle to identify dominant follicle.~* Once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously. IVF1 to be performed just before the rhCG-administration.~* IVF1 2h after rhCG.~* IVF1 every 12h for 2 days after rhCG.~* During luteal phase, IVF1 day 7 after rhCG and day 14 after rhCG."
62389268|NCT02561572|EXPERIMENTAL|Intervention|Acupuncture at the Yintang point for 30 minutes.
62389269|NCT02561572|NO_INTERVENTION|Control|No intervention for 30 minutes.
62389270|NCT03953794||Patients with inflammatory bowel disease|"Patients who have...~1. a diagnosis of ulcerative colitis or Crohn's disease as confirmed by a clinician~2. experienced a flare within the past 24 months as determined by a clinician~3. had quiescent disease for at least 3 months as determined by a clinician"
62389271|NCT04862689|EXPERIMENTAL|Experimental|Adult subjects clinically indicated for non-emergent percutaneous coronary intervention (PCI) as a stand-alone procedure or following non-emergent diagnostic angiography performed during the same procedure that, in the physician's estimation, requires prolonged balloon inflation with distal perfusion.
62389272|NCT05848128|EXPERIMENTAL|5% Tavilermide ophthalmic solution|
62389273|NCT05848128|PLACEBO_COMPARATOR|Vehicle ophthalmic solution|
62560820|NCT03700060||General Practice|Volunteering General Practices who registers contacts from nursing homes on residents with suspected UTI
61993971|NCT02676531|EXPERIMENTAL|Walking Meditation|"Walking Meditation program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking while listening to the sound Budd and Dha and squeeze rubber balls according to the sound in order to practice mindfulness while walking. In phase 1 (week 1-6), Walking Meditation will be conducted at initial moderate intensity (41-50% heart rate reserve) 3 sets, 10 minutes per set and rest 3 minutes between set In phase 2 (week 7-12), the training intensity will be increased to ultimate moderate intensity (51-60% heart rate reserve) 3 sets, 15 minutes per set and rest 3 minutes between set. In both phases of the training, the frequency of Walking Meditation training is three times a week."
61993972|NCT02676531|NO_INTERVENTION|No Walking meditation|keep regular activities, sedentary life style.
62389274|NCT06154044|EXPERIMENTAL|Treatment Arm|After successful LVAD implantation, patients will be enrolled and followed for 2 months to allow for postoperative rehabilitation and heart failure medical therapy and LVAD support optimization. All patients will then undergo autologous CD34+ cell therapy which will be delivered via intracoronary route. All patients will be followed for 6 months after cell therapy. At baseline, and at 1, 3 and 6 months after cell therapy, we will perform comprehensive clinical evaluation. Clinical, biochemical, biomarker-related, imaging and myocardial histology data will be transferred to a secured central database.
62389275|NCT02409966|ACTIVE_COMPARATOR|Quadrant-wise scaling|Patients underwent quadrant scaling under local anesthesia in four weekly sections.
62389276|NCT02409966|EXPERIMENTAL|Full-mouth 24-hour scaling|Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours.
62560821|NCT05411185||the plateau group|People travelling from the plains to areas at altitudes of 3800 meters
62560822|NCT05411185||the plain group|People staying in the plains throughout the whole test
62560823|NCT04433208|EXPERIMENTAL|Cohort 1 (PPI + probiotic)|Subjects in Cohort 1 will take a PPI and a probiotic orally once daily on Days 1-7. Subjects will mix the probiotic in an aqueous diluent supplied by the pharmacy and ingest between 1-2 hours after taking a PPI.
62560824|NCT04433208|EXPERIMENTAL|Cohort 2 (Complex oligosaccharide + PPI)|Subjects in Cohort 2 will take the complex oligosaccharide orally twice daily on Days 1-14. On Days 1-7, the first dose of the complex oligosaccharide will be taken between 1-2 hours after taking a PPI. On Days 8-14, subjects will not take a PPI prior to the complex oligosaccharide.
62560825|NCT04433208|EXPERIMENTAL|Cohort 3-6 (Complex oligosaccharide + PPI +probiotic)|Subjects in Cohort 3, 4, and 6 will take a complex oligosaccharide orally twice daily (doses will vary per cohort) on Days 1-14 in combination with a probiotic orally once daily on Days 1-7. Cohort 5 will undergo the same dosing regimen a second time on days 29-43
62560826|NCT00162981|EXPERIMENTAL|Clobazam Low Dose|
62560827|NCT00162981|EXPERIMENTAL|Clobazam High Dose|
62560828|NCT01228682||Patients who are treated with Samsca.|
62560829|NCT02234908|EXPERIMENTAL|Contacts|Contacts are the household contacts of confirmed TB and drug-resistant TB patients.
62560830|NCT02234908|OTHER|Index|Index subjects are confirmed TB and drug-resistant TB patients who distribute referral cards to their household contacts.
62560831|NCT06262763|EXPERIMENTAL|Group (A)|Laser with traditional exercises
62560832|NCT06262763|PLACEBO_COMPARATOR|Group (B)|Placebo LASER with traditional exercises
62560833|NCT00413699|EXPERIMENTAL|Open-Label Active Treatment Enrolled from Phase 2|Patients enrolling from Phase 2 studies
62560834|NCT00413699|EXPERIMENTAL|Open-Label Active Treatment Enrolled from Phase 3|Patients enrolling from Phase 3 studies
61993973|NCT03549702|ACTIVE_COMPARATOR|Povidone irrigation Group|Includes the 100 women who will undergo elective caesarian section with subcutaneous tissue irrigation with Povidone iodine 1% solution.
61993974|NCT03549702|NO_INTERVENTION|Control Group|Includes the 100 women who will undergo elective caesarian section without subcutaneous tissue irrigation with Povidone iodine 1% solution.
62389277|NCT05454696|EXPERIMENTAL|Exercise Group|The exercise group will follow the online clinical mat pilates exercises (via Zoom application) accompanied by a physiotherapist.
62560835|NCT01425489||Observation|Patients with Krabbe Disease
62560836|NCT03802526|EXPERIMENTAL|NVP-1805-R1|"Drug: NVP-1805-R1~1 tablet, oral dosing"
62560837|NCT03802526|EXPERIMENTAL|NVP-1805-R2|"Drug: NVP-1805-R2~1 tablet, oral dosing"
62560838|NCT03802526|EXPERIMENTAL|NVP-1805-R1 and NVP-1805-R2|Drug: NVP-1801-R1 1 tablet and NVP-1801-R2 1 tablet co-administration(oral dosing)
62560839|NCT03340597|EXPERIMENTAL|A1; F901318 (10 days)|F901318 : 10 days dosing orally
62560840|NCT03340597|EXPERIMENTAL|A2; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
62560841|NCT03340597|EXPERIMENTAL|A3; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
62560842|NCT03340597|EXPERIMENTAL|A4; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
62560843|NCT01446302|ACTIVE_COMPARATOR|Double meal on a HD day|A standardized meal is served 1 h after start of HD and 1 h after end of HD
62560844|NCT01446302|NO_INTERVENTION|Single meal on a HD day|A standardized meal is served 1 h after start of HD. After the meal participants fast for 9 h (6 h after end of HD).
62560845|NCT01446302|NO_INTERVENTION|Single meal on a non-HD day|A standardized meal is served 1 h after study start. After the meal participants fast for 9 h.
62560846|NCT01446302|NO_INTERVENTION|Single meal (healthy controls)|A standardized meal is served 1 h after study start. After the meal participants fast for 9 h.
62560847|NCT04505670|EXPERIMENTAL|Donepezil and Topical Zinc Oxide|donepezil 5mg daily and topical zinc oxide 20% three times daily
62560848|NCT04505670|PLACEBO_COMPARATOR|Placebo and Topical Zinc Oxide|Placebo daily and topical zinc oxide 20% three times daily
62560849|NCT01293916|ACTIVE_COMPARATOR|Double leg spica cast|The current accepted treatment is the double leg spica cast in the treatment of pediatric diaphyseal femur fractures.
62560850|NCT01293916|EXPERIMENTAL|Single leg spica casts|The study group is the single leg spica cast group
62560851|NCT03718988|EXPERIMENTAL|Meat Phase first|Participants will be asked to consume traditional meat products for 8 weeks, then switch to plant-based meat alternative products for another 8 weeks.
62560852|NCT03718988|EXPERIMENTAL|Plant Alternative Phase first|Participants will be asked to consume plant-based meat alternative products for 8 weeks, then switch to traditional meat products for another 8 weeks.
62768971|NCT01105455|PLACEBO_COMPARATOR|High fiber|High fiber carbohydrate foods with a high / medium glycemic index. Whole wheat bread and/or brown rice are provided to subjects if they wish. Subjects are provided with a list of other recommended carbohydrate foods.
61993975|NCT01889680|ACTIVE_COMPARATOR|Arm 1: 5-FU + LV|Patients receive mFOLFOX6 plus ziv-aflibercept every 14 days for 6 cycles (induction regimen), followed by 5-FU/LV every 14 days until disease progression (continuation regimen)
61993976|NCT01889680|EXPERIMENTAL|Arm 2: 5-FU + LV + ziv-aflibercept|Patients receive mFOLFOX6 plus ziv-aflibercept every 14 days for 6 cycles (induction regimen), followed by 5-FU/LV plus ziv-aflibercept every 14 days until disease progression (continuation regimen)
61993977|NCT00922766||1.0|
61993978|NCT03250546|EXPERIMENTAL|Haplo-identical group|
61993979|NCT03250546|ACTIVE_COMPARATOR|HLA-9/10 MMUD group|
61993980|NCT03325686|EXPERIMENTAL|vitamin D supplement|D
62768972|NCT01105455|ACTIVE_COMPARATOR|Low GI|Carbohydrate foods with a low glycemic index. Low GI rice and whole grain bread provided to subjects if they wish. Subjects are provided with a list of recommended foods.
62389278|NCT05454696|ACTIVE_COMPARATOR|Control Group|The control group will receive online (via Zoom application) physical activity counselling by the physiotherapist only once.
62389279|NCT04322799|EXPERIMENTAL|Acetabular cup HXLPE (Intervention)|Randomization to HXLPE acetabular component.
62389280|NCT04322799|EXPERIMENTAL|Acetabular cup Conventional PE (control)|Randomization to Coventional PE as control group
62389281|NCT04331314|EXPERIMENTAL|SYMBIOS®|Sinus augmentation with SYMBIOS® Biphasic Bone Graft Material
62389282|NCT04331314|ACTIVE_COMPARATOR|Algipore®|Sinus augmentation with Algipore® Bone Substitution Material
62389283|NCT04279509|EXPERIMENTAL|Cancer patient|Histological or cytological diagnosis of head and neck squamous cell carcinoma (HNSCC), colorectal, breast or epithelial ovarian cancer.
62389284|NCT01365195|PLACEBO_COMPARATOR|Control|"Loading and Infusion:~Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate"
62389285|NCT01365195|ACTIVE_COMPARATOR|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
62389286|NCT01365195|ACTIVE_COMPARATOR|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
62389287|NCT02114905|EXPERIMENTAL|OTs Trained and Deliver CBIT|CBIT certified clinicians will train OTs in delivering CBIT to affected youth. OTs will be supervised in the practice of CBIT with youth in the New York City and Birmingham areas. Pre- and post-treatment assessment measures will be collected from 16 families (8 from each site) to evaluate intervention acceptability, feasibility, and fidelity. Patient and parent satisfaction of CBIT-OT will also be documented.
62389288|NCT02594280||Selective Laser Trabeculoplasty (SLT)SLT|Monitor glaucoma patients that are scheduled to be treated with Selective Laser Trabeculoplasty (SLT) with VEP/PERG. The treatment is not dependent on the study.
62389289|NCT02594280||Trabecular stent bypass microsurgery|Monitor glaucoma patients that are scheduled to be treated with trabecular stent bypass microsurgery with VEP/PERG.The treatment is not dependent on the study.
62389290|NCT03136809|EXPERIMENTAL|Cu(II)ATSM|Cu(II)ATSM administered once daily
62389291|NCT02843113|EXPERIMENTAL|4 Your Child Program|Program integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
62389292|NCT02843113|EXPERIMENTAL|4 Your Child + Case Management|Participants assigned to treatment group that includes case management will receive an initial assessment to determine their strengths and needs. The participant will then work collaboratively with their case manager to connect to community resources to meet his needs. To do so, the case manager will meet with the participant using the following schedule: Months 1-2: intervention in the form of weekly face-to-face meeting with a case manager, plus a weekly phone call from a case manager; Months 3-4: intervention in the form of face-to-face meeting every other week, plus a weekly phone call; Months 5-6: intervention in the form of face-to-face meeting once a month, plus a weekly phone call.
62567730|NCT02174263|EXPERIMENTAL|Supportive care (tocilizumab)|Patients receive tocilizumab IV over 1 hour every 2 weeks for 12 weeks (weeks 1, 3, 5, 7, 9, and 11) and then every 4 weeks for 12 weeks (weeks 13, 17, and 21).
62768973|NCT03678831||Arthritic patients with knee prosthetic replace|Arthritic post-menopausal patients with knee prosthetic replacement Each patient is her own control since the two cell types are compared within the same patient The main criteria is based on a comparison of two cell types from the same patient. The secondary criteria are based on a comparison of cell types according to a grouping of patients according to different metabolic parameters.
62768974|NCT03328923|EXPERIMENTAL|500mg brown seaweed powder|2 x 250mg capsules InSea2® (brown seaweed powder)
62768975|NCT03328923|PLACEBO_COMPARATOR|Placebo|2 x capsules microcrystalline cellulose (bulking agent) (0mg InSea2®)
61993981|NCT03325686|PLACEBO_COMPARATOR|control|P
61993982|NCT05553015||PH Patients receiving treprostinil sodium treatment|Patients with pulmonary hypertension receiving treprostinil sodium treatment
61993983|NCT06343064|EXPERIMENTAL|Phase Ib:Vebreltinib 100mg/150mg/200mg BID + PLB1004 80mg/160mg QD|In the dose-escalation and dose-expansion phase, patients received oral Vebreltinib 100mg/150mg/200mg BID plus PLB1004 80mg/160mg once daily.
61993984|NCT06343064|EXPERIMENTAL|Phase II:Cohort 1|In phase II-Cohort 1:Failed first-generation or second-generation EGFR inhibitors, negative T790M mutation and c-Met amplification(GCN≥6).Patients received oral Vebreltinib（RP2D）plus PLB1004 （RP2D）.
61993985|NCT06343064|EXPERIMENTAL|Phase II:Cohort 2|In phase II-Cohort 2 :Failed third-generation EGFR inhibitors, c-Met amplification(GCN≥6).Patients received oral Vebreltinib（RP2D）plus PLB1004 （RP2D）.
61993986|NCT06343064|EXPERIMENTAL|Phase II:Cohort 3|In phase II-Cohort 3 :Failed first-generation or second-generation EGFR inhibitors, c-Met over expression.Patients received oral Vebreltinib（RP2D）plus PLB1004 （RP2D）.
61993987|NCT02883296|EXPERIMENTAL|Patients with perianal fistulizing Crohn's disease|
61993988|NCT01716728|NO_INTERVENTION|Enzyme analysis|Patients invited for evaluation will undergo lysosomal acid lipase enzyme analysis
61993989|NCT00405548|ACTIVE_COMPARATOR|BNP (nesiritide)|BNP 10 micrograms/Kg twice per day given subcutaneously for 12 weeks
61993990|NCT00405548|PLACEBO_COMPARATOR|Placebo|Saline solution given subcutaneously twice per day for 12 weeks (packaged to match active comparator)
61993991|NCT03282292|EXPERIMENTAL|Jugular|CVC insertion in the left or right internal jugular vein
62560853|NCT03660930|EXPERIMENTAL|Treatment (ABI-009, pazopanib)|Participants receive nab-sirolimus intravenously (IV) on days 1 and 8 or day 1 only and pazopanib hydrochloride orally (PO) daily on days 1-21. Cycles repeat every 21 days until unequivocal clinical disease progression, unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at the patient's discretion.
62560854|NCT00991393||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
61993992|NCT03282292|ACTIVE_COMPARATOR|Femoral|CVC insertion in the right or left femoral vein
62560855|NCT03067727|EXPERIMENTAL|Dinoprostone vaginal insert|
62560856|NCT03067727|PLACEBO_COMPARATOR|Placebo|
61993993|NCT04152889|EXPERIMENTAL|Camrelizumab+chemotherapy|
62389293|NCT02843113|NO_INTERVENTION|Waiting list control|Individuals who are randomly assigned to this condition will receive no treatment for a period of months in parallel with the experimental intervention conditions. Data will be gathered from them, and they will be randomly assigned to a treatment condition when possible.
62560857|NCT01234350||FIRMAGON|
62560858|NCT01234350||GnRH Agonist|
62389294|NCT00757159|EXPERIMENTAL|1|
62560859|NCT01136941|EXPERIMENTAL|Treatment|Research participants will be administered Zileuton according to the dose escalation/de-escalation schema provided in the protocol.
62560860|NCT03942757||observation before educational program|100 preterm infant medical records will be studied in a first part of this observational study
62560861|NCT03942757||Observation after educational program|An educational program will be implemented in the unit after this first period. 100 preterm infant will be included in a second part of this observational study.
62560862|NCT03413462|ACTIVE_COMPARATOR|HS-25|20mg, QD, 12 weeks
62560863|NCT03413462|PLACEBO_COMPARATOR|Placebo of HS-25|20mg, QD, 12 weeks
62560864|NCT00397462|NO_INTERVENTION|Control|No change to usual behavior
62560865|NCT00397462|EXPERIMENTAL|Low dose|Request that calf muscle pump stimulation be used less than four hours per day
62560866|NCT00397462|EXPERIMENTAL|High dose|Request that calf muscle pump stimulation be used at least four hours per day
62560867|NCT04881474|ACTIVE_COMPARATOR|ibuprofen and paracetamol|
62560868|NCT04881474|ACTIVE_COMPARATOR|paracetamol only|
62560869|NCT02771977|NO_INTERVENTION|Usual Care|No alert will be fired.
62560870|NCT02771977|EXPERIMENTAL|Drug-specific alert|A drug-specific AKI alert, including information about the drug of interest as well as the presence of AKI will be fired.
62560871|NCT05172206|ACTIVE_COMPARATOR|Symptom-focused Rehabilitation|Patients in this arm will be referred to a 3-week inpatient comprehensive rehabilitation program. Initially, patients will be classified into one out of three clusters namely: Cluster A (Fatigue), Cluster B (cognition), or Cluster C (physical). The content of the rehabilitation program will be individually adapted according to the patient's most relevant symptom cluster.
62560872|NCT05172206|OTHER|Usual Care|Patients in this arm do not receive any intervention beyond usual care during the study phase. However, all patients in this group will get the opportunity to also receive a rehabilitation program after the study phase.
62560873|NCT03273101|EXPERIMENTAL|Intervention group|The sit-to-stand training is assisted by mechanical device
62389295|NCT00757159|ACTIVE_COMPARATOR|2|
62560874|NCT03273101|ACTIVE_COMPARATOR|Control group|The sit-to-stand training is assisted by manual device
62560875|NCT01965860|EXPERIMENTAL|PROSPECT|the trainee will study four modules of E-learning (basic endovascular skills module, iliac artery module, superficial femoral artery module and postoperative care module). After studying each module the trainee will complete a Multiple Choice Questionnaire and perform a simple and a complex exercise on the simulator.
61993994|NCT00922883|EXPERIMENTAL|Eltrombopag|Eltrombopag (Promacta): Subjects commenced eltrombopag at a dose of 50 mg, which was increased by 25 mg every 2 weeks if the platelet count had not increased by 20 × 103/µL, to a maximum dose of 150 mg.
61993995|NCT03155009|EXPERIMENTAL|Alectinib|600 mg orally twice daily (BID) for up to 2 years
61993996|NCT04100707|EXPERIMENTAL|Operated|Genicular block will aply to the patients with knee pain who was operated before
61993997|NCT04100707|SHAM_COMPARATOR|Nonoperated|Genicular block will aply to the patients with knee pain who wasn't operated before
61993998|NCT02265822|EXPERIMENTAL|melatonin|0.5 mg/kg (max 20 mg) oral melatonin premedication will be administered approximately 40 min before the induction of general anaesthesia with propofol. The melatonin will be prepared in a fixed volume of 5 ml adding water in a syringe without needle.
61993999|NCT02265822|ACTIVE_COMPARATOR|midazolam|0.5 mg/kg (max 20 mg) oral midazolam premedication will be administered approximately 40 min before the induction of general anaesthesia with propofol. The melatonin will be prepared in a fixed volume of 5 ml adding 5% dextrose in a syringe without needle.
62389296|NCT06082011||RWS study for SP Gynecological Surgeries|da Vinci SP Surgical System(SP1098)
62389297|NCT01577446|EXPERIMENTAL|CRT|The CRT group undergoes implantation of a CRT defibrillator
62389298|NCT01577446|NO_INTERVENTION|no-CRT|The no-CRT group receives a dual-chamber defibrillator
62560876|NCT01965860|NO_INTERVENTION|CONTROL|The trainee will continue clinical education without additional curriculum, but will be allowed to study independently.
62560877|NCT01965860|EXPERIMENTAL|E-LEARNING|the trainee will study four modules of E-learning (basic endovascular skills module, iliac artery module, superficial femoral artery module and postoperative care module). After studying each module the trainee will complete a Multiple Choice Questionnaire, no simulation.
62560878|NCT01502319||All subjects|Group/Cohort label is not applicable to this umbrella protocol. The Consortium funds specific research teams who will determine the number of group(s)/cohort(s) relevant to their study.
62560879|NCT04956744|EXPERIMENTAL|Low Dose|Low dose of cells/kg of intravenous (IV) IMS001 as a single dose infusion on Day 1.
62560880|NCT04956744|EXPERIMENTAL|High Dose|High dose of cells/kg of intravenous (IV) IMS001 as a single dose infusion on Day 1.
62560881|NCT04956744|EXPERIMENTAL|Optional Dose|High dose of cells/kg of intravenous (IV) IMS001 as a single dose infusion on Day 1 and at Month 6.
62560882|NCT04118387|ACTIVE_COMPARATOR|acetazolamide|To determine the effect of dampening chemoreceptor sensitivity AND decreasing plant gain. The investigators hypothesize that combined therapy with PAP, acetazolamide and oxygen will be superior to PAP plus each intervention alone or placebo in reducing CAHI and the CO2 reserve during sleep in Veterans with CSA.
62560883|NCT04118387|ACTIVE_COMPARATOR|zolpidem|To determine the effect of decreasing respiratory-related arousals on the propensity to develop central apnea. The investigators hypothesize that administration of PAP and zolpidem, will decrease respiratory-related arousals, CAHI and the CO2 reserve during sleep in Veterans with CSA compared to PAP plus placebo.
62560884|NCT04118387|ACTIVE_COMPARATOR|buspirone|To determine the effect of augmenting serotonin A1 receptor activity on breathing during sleep. The investigators hypothesize that administration of PAP and buspirone, a serotonin A1 receptor agonist; will reduce the propensity to central apnea during sleep in Veterans with CSA compared to PAP plus placebo.
61994000|NCT02174848|EXPERIMENTAL|Deferiprone|All patients will receive deferiprone oral solution.
61994001|NCT01820416|EXPERIMENTAL|Low-Level Laser Therapy|Low-level laser applied for approximately 4 minutes to the area around the pinna, the back of the neck, and the top of the head.
62560885|NCT03655171||H&Y 0|"Age-matched non-disease population, or prodromal Parkinson's patients with no noticeable motor symptoms.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
62768976|NCT02966015|EXPERIMENTAL|Testing the new Coloplast Test catheter|The subjects used the new Coloplast Test catheter for 1 week
62768977|NCT02223481|EXPERIMENTAL|Terbogrel low dose|
61994002|NCT01820416|PLACEBO_COMPARATOR|Disabled Laser|Low-level laser device with laser diodes disabled. Also applied for approximately 4 minutes to the area around the pinna, the back of the neck, and the top of the head.
61994003|NCT01820416|NO_INTERVENTION|Control|Visit laboratory using same schedule as experiment and placebo. No Low-level laser or any treatment applied. Used to assess normal test-retest variability.
61994004|NCT04362631||Adults|Adults 18 years or older
62768978|NCT02223481|EXPERIMENTAL|Terbogrel high dose|
61994005|NCT04721249|ACTIVE_COMPARATOR|Verum|
62389299|NCT03580707|ACTIVE_COMPARATOR|Part 1|Compare rapidity of CNS effects of levetiracetam (LEV) \& brivaracetam (BRV) within same pt-(randomized, two-way crossover, dbl-blind in total 16 pts w/epilepsy. Pt 1: IV infusion over 15 min BRV will also be administered as 15-min.infusion. BRV vs LEV in randomized double blinded, crossover fashion.
62389300|NCT03580707|ACTIVE_COMPARATOR|Part 2|Pt 2 Op I:Assuming statistically signify. diff. in rapidity of CNS action has been observed from an analysis of data set in Pt 1,will proceed w/ Pt 2Opt I. Levetiracetam (LEV) or brivaracetam (BRV administered in randomized, two-way crossover, dbl-blind design as IV infusion over 5 min. to another cohort of 8 pts w/photosensitive epilepsy OR Pt 2,Opt II: Assuming no statistically signif. diff. in rapidity of CNS action has been observed from an analysis of data set in Pt 1, will proceed w/Pt 2,Opt II. LEV or BRV will be administered, in randomized, two-way crossover, dbl-blind design as IV infusion over again 15 min. to another cohort of 8 pts w/ photosensitive epilepsy. LEV will be given as 500 mg dose \& BRV as 25 mg dose. BRV vs LEV in randomized double blinded, crossover fashion.
62389301|NCT01305616|ACTIVE_COMPARATOR|Group 1, glaucoma and cataract|Group1 were those patients with visually significant cataract (less than grade 2) and mild to moderate open angle glaucoma
62768979|NCT02223481|PLACEBO_COMPARATOR|Placebo|
62768980|NCT05449275|EXPERIMENTAL|Faradic current|This study will use the faradic current for treating foot drop. In Group A 15 number of patient with foot drop will get the 40 minutes of session with the frequency of 50-100hz alternative three days / week for 25 weeks
62768981|NCT05449275|EXPERIMENTAL|Ankle foot orthosis|Group B will get the treatment by Ankle foot orthosis.In group B 15 patients with foot drop will get the session alternative three days/week for 25 weeks. All participants have to use Ankle foot orthosis on a daily basis and patients have to walk for 10 minutes without walking aid.
62768982|NCT01076621||A|
62768983|NCT00279812|PLACEBO_COMPARATOR|Placebo|Placebo
61994006|NCT04721249|PLACEBO_COMPARATOR|Placebo|
62768984|NCT00279812|EXPERIMENTAL|50ug selenium enriched yeast|50ug/d selenium enriched yeast (containing 60% selenomethionine)
62768985|NCT00279812|EXPERIMENTAL|100ug selenium enriched yeast|100ug/d selenium enriched yeast (containing 60% selenomethionine)
62768986|NCT00279812|EXPERIMENTAL|200ug selenium enriched yeast|200ug/d selenium enriched yeast (containing 60% selenomethionine)
62768987|NCT00279812|EXPERIMENTAL|Control onion|3 meals/wk containing un-enriched onions equivalent to 4ug/d Se
62768988|NCT00279812|EXPERIMENTAL|Enriched onion|3 meals/wk containing enriched onions equivalent to 50ug/d Se
61994007|NCT01926080|OTHER|DVD Intervention Arm|Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU- Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
61994008|NCT01926080|NO_INTERVENTION|Standard Bereavement Care|Those randomized to control group (no DVD) Standard Bereavement Care Arm receive the bereavement materials given to families as standard-practice of care in the NICU at SLCH following the death of an infant
61994009|NCT03317431||ventilation|patients undergoing selective operation with general anesthesia(GA) and mechanical ventilation(MV)
61994010|NCT04115943|EXPERIMENTAL|Experimental Group|The experimental group (EG) will be submitted to a clinical method considered the gold standard for the treatment of neck pain together with a tongue muscle release protocol.
61994011|NCT04115943|ACTIVE_COMPARATOR|Control Group|The control group (CG) will only receive the gold standard method for the treatment of neck pain.
62768989|NCT01399268|EXPERIMENTAL|Steroid|Hydrocortisone 100 mg IV Q 8hrs x3
62768990|NCT01399268|PLACEBO_COMPARATOR|Control|Saline IV Q8hr x3
62768991|NCT01872299||Control|Healthy control subjects
62768992|NCT01872299||Heart failure without co-morbidities|Patients with a clinical diagnosis of chronic heart failure without co-morbidities
62768993|NCT01872299||Heart failure with co-morbidities|Patients with a clinical diagnosis of chronic heart failure with co-morbidities
62768994|NCT01872299||Type 2 diabetes mellitus|Patients with type 2 diabetes mellitus and without heart failure
62768995|NCT00025155|EXPERIMENTAL|Treatment (ixabepilone)|Patients receive ixabepilone IV over 1 hour. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 2 additional courses after achieving CR.
62560886|NCT03655171||H&Y 1|"Hoehn and Yahr disability stage was 1: Unilateral involvement only usually with minimal or no functional disability.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
62389302|NCT01305616|SHAM_COMPARATOR|Group2, cataract patients|This group included those patients with visually significant cataract and normal other eye examination.
62560887|NCT03655171||H&Y 2|"Hoehn and Yahr disability stage was 2: Bilateral or midline involvement without impairment of balance.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
62560888|NCT03655171||H&Y 3|"Hoehn and Yahr disability stage was 3: Bilateral disease: mild to moderate disability with impaired postural reflexes; physically independent.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
62560889|NCT03655171||H&Y 4|"Hoehn and Yahr disability stage was 4: Severely disabling disease; still able to walk or stand unassisted.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
62560890|NCT02453932|EXPERIMENTAL|Tianzhi granule|Tianzhi granule and placebo identified to donepezil
62560891|NCT02453932|ACTIVE_COMPARATOR|Donepezil|Donepezil and placebo identified to Tianzhi granule
62560892|NCT02453932|PLACEBO_COMPARATOR|Placebo|Placebo identified toTianzhi granule and placebo identified to donepezil
62560893|NCT03585023||Spontaneous miscarriage|The study group will be recruited at admission for uterine cavity revision planned for spontaneous abortion.
62560894|NCT03585023||Voluntary pregnancy interruption|The control group will be recruited at admission for uterine cavity revision planned for voluntary pregnancy interruption.
62560895|NCT00920868|EXPERIMENTAL|Dasatinib 50mg|Cohort 1
62560896|NCT04649008|EXPERIMENTAL|Epilepsy patient volunteers|Patients recruited for the study with intractable epilepsy who are anticipated to undergo epilepsy surgery
62560897|NCT03807427|EXPERIMENTAL|READY-Nepal|Skills groups based on dialectical behavior therapy principles delivered over 10-12 weeks in a classroom format.
62560898|NCT03807427|NO_INTERVENTION|Waitlist Control|Adolescent participants assigned to the control condition will be placed on a waitlist for future enrollment in READY-Nepal. After primary data collection has ceased, those assigned to the control arm will receive the identical READY-Nepal intervention delivered in the experimental condition.
62560899|NCT05382273||Use of T-Break Guide: None|Participants who reported not using the T-Break Guide (intervention)
62560900|NCT05382273||Use of T-Break Guide: Some|"Participants who reported using the T-Break Guide some"
62560901|NCT05382273||Use of T-Break Guide: A lot|"Participants who reported using the T-Break Guide a lot"
62560902|NCT04773340||DBT intervention|Adaptation of Dialectical Behavior Therapy designed for repeat criminal offenders at high risk of reoffense.
62560903|NCT02548143|EXPERIMENTAL|Coagulation Factor VIIa (Recombinant)|A dose of 75 μg/kg (minor surgery or invasive procedure) or 200 μg/kg (major surgery or major invasive procedure) of LR769 will be administered as an initial intravenous (IV) bolus dose of LR769 within ≤2 minutes before the surgical incision or start of the invasive procedure. For both minor and major procedures, the initial dose will be followed by repeated administration of 75 µg/kg of LR769 every 2 hours (±5 minutes) for the first 48 hours after completion of the procedure and then as per the dosing schedules in the protocol for major or minor surgeries or invasive procedures. The minimum duration of LR769 treatment for major procedures will be 5 days, and for minor procedures 2 days except for certain procedures that may not require this duration of treatment.
62560904|NCT01329055||Hemodialysis patients|
62560905|NCT05430373|OTHER|GT101 treatment group|Autologous tumor infiltrating lymphocyte injection
62567731|NCT02560922|EXPERIMENTAL|Pain Coping Skills Training|This group will take part in an 11-week pain coping skills training (CST) intervention.
62560906|NCT03749876|ACTIVE_COMPARATOR|Study Group 1|Study Group 1 will begin the first treatment period with the provided Unfiltered Cigarettes intervention for two weeks, followed by a three-week wash-out period, before switching to the provided Filtered Cigarette intervention for two weeks.
62560907|NCT03749876|EXPERIMENTAL|Study Group 2|Study Group 2 will begin the first treatment period with the provided Filtered Cigarettes intervention for two weeks, followed by a three-week wash-out period, before switching to the provided Unfiltered Cigarette intervention for two weeks.
62560908|NCT03098212|EXPERIMENTAL|Aromatherapy|Receive essential oil diffuse by Aroma diffuser during labor. Pain score and dose of analgesics drug are recorded
62560909|NCT03098212|NO_INTERVENTION|Non-aromatherapy|This group receive pain control by standard of care without essential oil (aromatherapy)
62768996|NCT02314364|EXPERIMENTAL|Stereotactic body radiation therapy (SBRT) with protons or photons|"* SBRT dosage determined by treating physician~* Patients will continue to receive standard of care (SOC) tyrosine kinase inhibitors (TKI) in the intervals between SBRT courses, as well as after the completion of SBRT~* If there is more than one active site of cancer, additional site(s) will be treated with stereotactic treatment courses. The total duration of SBRT courses (from the first day of any SBRT course to the last day of any SBRT course) will not exceed 4 months."
62560910|NCT01856725|ACTIVE_COMPARATOR|MultiPoint Pacing programming based on hemodynamics|"CRT device implant with MultiPoint Pacing~Hemodynamic measurements for CRT device programming"
62560911|NCT01856725|EXPERIMENTAL|MultiPoint Pacing programming without hemodynamics|"CRT device implant with MultiPoint Pacing~CRT device programming without hemodynamics"
62560912|NCT05899738|EXPERIMENTAL|Iberdomide Powder (Fasted), followed by Iberdomide Capsule (Fasted)|
62560913|NCT05899738|EXPERIMENTAL|Iberdomide Capsule (Fasted), followed by Iberdomide Powder (Fasted)|
62560914|NCT05899738|EXPERIMENTAL|Iberdomide Powder (Fasted), followed by Iberdomide Powder (Fed)|
62560915|NCT05899738|EXPERIMENTAL|Iberdomide Powder (Fed), followed by Iberdomide Powder (Fasted)|
62389303|NCT04927858||Population 1|Patients ≥ 18 years old on 31st of December 2017 with Type 2 Diabetes Mellitus (T2DM) who were alive on 31st of December 2017 and had at least one registration in the Swedish National Diabetes Registry (NDR) between 1996 - 2017.
62560916|NCT02135523|EXPERIMENTAL|single arm: involved-field radiation therapy group|
62560917|NCT03771092|EXPERIMENTAL|Patients with non-severe anemia treated with SunActive®Fe|Patients with non-severe anemia Hb\> 10 g/dl (Hb \<12 g/dl for women and Hb \<13 g/dl for men), treated with SunActive®Fe micronized
62560918|NCT03771092|EXPERIMENTAL|Patients with non-severe anemia treated with Lipofer®|Patients with non-severe anemia Hb\> 10 g/dl (Hb \<12 g/dl for women and Hb \<13 g/dl for men), treated with Lipofer®
62560919|NCT03771092|EXPERIMENTAL|Patients with severe anemia with Lipofer®|Patients with severe anemia (Hb \<10 g/dl) treated respectively with Lipofer®
62768997|NCT02248740|ACTIVE_COMPARATOR|Radiofrequency Ablation|"Device: ClosureFast radiofrequency catheter (VNUS Medical Technologies Inc, San Jose, CA).~Patients will have the intervention, ablation of the incompetent small saphenous vein, using this device."
62768998|NCT02248740|ACTIVE_COMPARATOR|Laser Ablation|"Device: EVLT 980nm diode laser system (Angiodynamics, Queensbury, NY).~Patients will have the intervention, ablation of the incompetent small saphenous vein, using this device."
62768999|NCT01487993|ACTIVE_COMPARATOR|Metformin|Metformin with lifestyle intervention during 18 months
62389304|NCT04927858||Population 2|Population 2 is a sub-population of population 1. Patients with Type 2 Diabetes Mellitus (T2DM) who were initiated on Empagliflozin between 1st of January 2015 and 31st of December 2017, who had at least one registration in the Swedish National Diabetes Register (NDR).
62389305|NCT02663024|EXPERIMENTAL|Arm 1|0.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
62389306|NCT02663024|EXPERIMENTAL|Arm 2|1.0 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
62560920|NCT03771092|EXPERIMENTAL|Patients with severe anemia with SunActive®Fe|Patients with severe anemia (Hb \<10 g/dl) treated respectively with SunActive®Fe micronized
62560921|NCT03771092|EXPERIMENTAL|Patients with severe anemia with intravenous ferric gluconate|Patients with severe anemia (Hb \<10 g/dl) treated respectively with intravenous ferric gluconate according to departmental protocols
62560922|NCT00944099|EXPERIMENTAL|Grazing|participants will be given an eating frequency prescription to eat every 2 to 3 hours
62560923|NCT00944099|EXPERIMENTAL|Three Meals|participants will be given an eating frequency prescription of eating 3 meals per day
62769000|NCT01487993|PLACEBO_COMPARATOR|Placebo|Placebo and lifestyle intervention during 18 months
62769001|NCT01207245|ACTIVE_COMPARATOR|Morning dose of tobramycin|Administration of tobramycin once daily dose in the morning
62560924|NCT06354881||Lacunar Stroke Syndrome Patients|Patients who have been diagnosed with lacunar stroke syndrome. This is a non-intervention study so no intervention will be given. However, the investigators will observe the changes in cerebral haemodynamics of this group before and after they have been given medications to help control hypertension and/or diabetes which are common risk factors of lacunar stroke syndrome.
62560925|NCT03004651||Obese Patients|Power Doppler ultrasound on obese patients with PR comparating with a clinical evaluation (swollen joint count (SJC) as componant of SDAI)
62769002|NCT01207245|ACTIVE_COMPARATOR|Evening tobramycin|Evening dose of tobramycin once daily
62769003|NCT02753634|EXPERIMENTAL|Square-stepping exercise Intervention|Participant attend sessions 2 times per week for 24-weeks at a community location. An instructor demonstrated increasingly difficulty walking or stepping patterns across a gridded mat and participants are asked to try and remember and repeat the patterns. Social engagement is encouraged.
62769004|NCT02753634|NO_INTERVENTION|Usual care wait-list control group|This group will be invited to participate in square-stepping exercise after final assessments are completed.
62769005|NCT00820404|EXPERIMENTAL|1|BLI-489
62389307|NCT02663024|EXPERIMENTAL|Arm 3|1.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
62560926|NCT03004651||Non obese patients|Power Doppler ultrasound on non obese patients with PR comparating with a clinical evaluation (swollen joint count (SJC) as componant of SDAI)
62560927|NCT02655614|EXPERIMENTAL|SAD Stage: GDC-0134|Participants in multiple cohorts and treatment periods will receive single doses of GDC-0134 oral capsules under fed/fasting conditions. To study the effect of proton pump inhibitor (PPI) medication rabeprazole on PK properties of GDC-0134, few participants may receive rabeprazole 20 milligrams (mg).
62560928|NCT02655614|PLACEBO_COMPARATOR|SAD Stage: Placebo|Participants in multiple cohorts and treatment periods will receive placebo matching to GDC-0134 under fed/fasting conditions. Few participants may receive rabeprazole 20 mg.
62560929|NCT02655614|EXPERIMENTAL|MAD Stage: GDC-0134|Participants will receive multiple doses of GDC-0134 for 28 days. To study the interactions between GDC-0134 and other drugs, some participants may receive single doses of midazolam and caffeine at various time points.
62560930|NCT02655614|PLACEBO_COMPARATOR|MAD Stage: Placebo|Participants will receive placebo matching to GDC-0134 for 28 days. To study the interactions between GDC-0134 and other drugs, some participants may receive single doses of midazolam and caffeine at various time points.
62560931|NCT02655614|OTHER|Open-Label Safety Expansion (OSE)|Participants will receive GDC-0134 at a dose determined by the corresponding MAD cohort.
62560932|NCT06257654||singel|
62560933|NCT03194828|ACTIVE_COMPARATOR|Monitoring only|Patients in this arm will be given a real-time medication use monitor to use in dispensing their topical glaucoma medication for 3 months
62560934|NCT03194828|EXPERIMENTAL|Monitoring and reminder|Patients in this arm will be given a real-time medication use monitor to use in dispensing their topical glaucoma medication for 3 months and will receive an automated reminder (text or voice) when a missed dose is determined by the device's system
62560935|NCT00139451|ACTIVE_COMPARATOR|Nutrition and Growth Hormone|
62560936|NCT00139451|ACTIVE_COMPARATOR|Observation and Growth Hormone|
62389308|NCT02663024|ACTIVE_COMPARATOR|Arm 4|0.5mg/kg, iv, weekly infusion of idursulfase for 24 weeks
62389309|NCT02576106|EXPERIMENTAL|Cryoablation|Cryoablation of the tumor followed by a lumpectomy as practiced in standard care
62389310|NCT04035408||All subjects|All the enrolled subjects will be considered for the assessment of the primary and secondary outcomes.
62389311|NCT03718624|EXPERIMENTAL|paclitaxel,apatinib and S-1|
62389312|NCT05707364||Practices Engaged for Pre-Visit Lab Clinic Workflow|Providers and patients/ at the designated practice sites
62389313|NCT02778594|PLACEBO_COMPARATOR|Placebo|Placebo (4 tablets) Simultaneously with the placebo dose, subjects were administered 1 capsule of Madopar® HBS 125
62389314|NCT02778594|EXPERIMENTAL|Nebicapone 50 mg|Nebicapone 50 mg (1 tablet of 50 mg plus 3 tablets of placebo). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
62389315|NCT02778594|EXPERIMENTAL|Nebicapone 100 mg|Nebicapone 100 mg (2 tablets of 50 mg plus 2 tablets of placebo). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
62389316|NCT02778594|EXPERIMENTAL|Nebicapone 200 mg|Nebicapone 200 mg (4 tablets of 50 mg). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
62389317|NCT00787280|EXPERIMENTAL|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
62389318|NCT00787280|EXPERIMENTAL|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
62389319|NCT01359319|EXPERIMENTAL|650 mg (single dose only)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
62389320|NCT01359319|EXPERIMENTAL|1,950 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
62389321|NCT01359319|EXPERIMENTAL|2,925 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
62389322|NCT01359319|EXPERIMENTAL|4,875 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
62389323|NCT01359319|EXPERIMENTAL|6,000 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
62560937|NCT02004418|EXPERIMENTAL|C-Choline PET Scans|Radioactive doses of 11C-Choline: 400 MBq ± 10% per injection, pre-radiation treatment and following treatment at 3 and 6 months
62560938|NCT04748640|EXPERIMENTAL|Treatment group|Participants will undergo a thalamotomy contralateral to their previous treatment with Gamma Knife using a frame-based, Gamma Knife Perfexion or Icon unit (Elekta, Stockholm, Sweden).
62560939|NCT00517881|EXPERIMENTAL|C.E.R.A.|
62560940|NCT02633007|EXPERIMENTAL|CVT-301 then Placebo (AB)|All subjects will receive both CVT-301 and placebo in two dosing periods separated by one day. Subjects will be randomized 1:1 into sequence AB or BA \[CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)\] and they will start pre-treatment of carbidopa (as Lodosyn®) administered every 8 hours until the completion of all study treatments.
62560941|NCT02633007|EXPERIMENTAL|Placebo then CVT-301 (BA)|All subjects will receive both CVT-301 and placebo in two dosing periods separated by one day. Subjects will be randomized 1:1 into sequence AB or BA \[CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)\] and they will start pre-treatment of carbidopa (as Lodosyn®) administered every 8 hours until the completion of all study treatments.
62567732|NCT02560922|NO_INTERVENTION|Wait list Control|The other group will be the wait list group and will receive the pain CST program after completing all follow-up study measures.
62769006|NCT00820404|PLACEBO_COMPARATOR|2|Placebo
62769007|NCT01143987|EXPERIMENTAL|Cinacalcet|Oral cinacalcet
62389324|NCT03171688||Modeling|It is the cohort that will be used for selecting risk factors and models for predicting postoperative nausea and vomiting.
62560942|NCT03361306|EXPERIMENTAL|KRd-Elotuzumab|"Induction (4 28-day cycles):~Carfilzomib (IV) @ 20 mg/m\^2, Day 1 of Cycle 1; @ 56 mg/m\^2, Day 8,15 of Cycle 1; @ 56 mg/m\^2, Day 1,8,15 of Cycles 2-4~Lenalidomide (Oral) @ 25 mg, once daily at bedtime on Days 1-21 of each cycle (Cycles 1-4)~Dexamethasone @ 28 mg orally OR 8 mg IV, once weekly on Day 1,8,15,22 of Cycles 1-2; @28 mg orally OR 8 mg IV on Day 1 of Cycles 3-4~Elotuzumab (IV) @ 10 mg/kg, once weekly on Day 1,8,15,22 of Cycles 1-2; @ 20 mg/kg on Day 1 of Cycles 3-4~Maintenance (28-day cycles):~Elotuzumab (IV) @ 20 mg/kg, Day 1 of each cycle (Cycles 1-n)~Lenalidomide (Oral) @ 15 mg (or last tolerated dose if \<15 mg), once daily at bedtime on Days 1-21 of each cycle (Cycles 1-n)"
62560943|NCT04030299|EXPERIMENTAL|OTC Group|In this group, the over-the-counter fitting will be used to provide hearing aids.
62560944|NCT02499731|EXPERIMENTAL|Strong Hearts, Healthy Communities|Full Intervention participants will meet twice per week for one hour each time, for approximately 6 months plus monthly community meetings and events. Participants will learn and practice good nutrition and physical activity for improved individual, family and community health.
62560945|NCT02499731|EXPERIMENTAL|Strong Hearts, Healthy Women|Strong Hearts, Healthy Women minimum intervention participants meet once per month for an hour each time for 6 months. Participants will learn and discuss techniques and strategies to improve personal health.
62560946|NCT01111773|EXPERIMENTAL|Heated Lidocaine and Tetracaine Patch|
62560947|NCT01227473|EXPERIMENTAL|mindfulness prediabetes education group|The mindfulness-based diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the mindfulness-based diabetes prevention group, the instruction will be enhanced with instruction in mindfulness.
62560948|NCT01227473|ACTIVE_COMPARATOR|conventional prediabetes education group|The conventional diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the conventional diabetes prevention group, the instruction will be enhanced with group exercises and discussions.
62560949|NCT05806385|NO_INTERVENTION|Standard of Care Arm:|Control arm: Stage I/II TNBC patients will receive neoadjuvant chemotherapy followed by lumpectomy/mastectomy with sentinel node biopsy +/- axillary dissection.
62560950|NCT05806385|EXPERIMENTAL|Intervention 1|Cryoablation Alone Arm: Intervention with cryoablation alone followed by neoadjuvant chemotherapy followed by lumpectomy/mastectomy with sentinel node biopsy +/- axillary dissection.
62560951|NCT05806385|EXPERIMENTAL|Intervention 2|Cryoablation + PD1 Inhibitor Arm: Intervention with cryoablation + Pembrolizumab followed by neoadjuvant chemotherapy followed by lumpectomy/mastectomy with sentinel node biopsy +/- axillary dissection.
62560952|NCT03699332|EXPERIMENTAL|Intraoperative multi-modality imaging|Patients receive a single intravenous dose of Indium-111-DOTA-Labetuzumab-IRDye800CW. At day 4 or 5 after antibody injection a SPECT/CT scan will be acquired. At day 6 or 7 standard of care cytoreductive surgery will be performed. This will be extended with the use of dual-modality imaging.
62560953|NCT03214224|EXPERIMENTAL|remote PFT (rPFT) validation|Subjects in this arm perform both standard and remote PFT assessments in order to validate the procedure.
62560954|NCT02885220|ACTIVE_COMPARATOR|Conventional Program|The aim of our study is to determine if a goal directed program improves weight loss outcomes after sleeve gastrectomy. In the conventional weight loss program, patients will only be given their ideal weight to strive toward after surgery. Routine dietary and physiotherapy/exercise counseling are provided and patients would be educated on their ideal weights based on a BMI of 23. The target weight loss over a 12 month period would be 100% excess weight loss.
62389325|NCT03171688||Validation|It is the cohort that will be used for validation of risk factors and models selected in the modeling group.
62389326|NCT05741528|EXPERIMENTAL|SEP-363856|
62389327|NCT01965691|EXPERIMENTAL|Protein intake|Protein intake- Dietary supplement
62389328|NCT02897830|EXPERIMENTAL|Study treatment|Ixazomib, Lenalidomide, Dexamethasone Induction and extended Consolidation followed by Lenalidomide Maintenance
62389329|NCT04656262|EXPERIMENTAL|Metronomic cyclophosphamide|Cyclophosphamide 50 mg daily per os continuously; Patients will be visited for re-cycling every three weeks. Metronomic cyclophosphamide will be taken in the morning along with a full glass of water.
62769008|NCT04736615|EXPERIMENTAL|Intervention community|Households will be randomly allocated to the intervention every 1-2 months over the12 month intervention
62389330|NCT04656262|ACTIVE_COMPARATOR|Doxorubicin|Doxorubicin 60 mg/mq i.v. in 10 minutes, day 1; to be repeated every three weeks up to a maximum of 6 cycles.
62389331|NCT03757936|EXPERIMENTAL|HLX04+HLX10|HLX10, at three dose levels (1, 3, 10 mg/kg), to be intravenously injected once every two weeks; HLX04, at a fixed dose of 5 mg/kg, intravenously injected once every two weeks; Study drugs given in combination for up to 2 years or until the disease gets worse, whichever comes first.
62389332|NCT01549327|ACTIVE_COMPARATOR|Routine Care|Participants who are randomized to the active comparator arm will receive routine care, which is the care routinely provided to the participant's patient population at the study centre.
62389333|NCT01549327|EXPERIMENTAL|Routine Care plus OIN|OIN (Oncology Interactive Navigator) is the intervention. Participants who are randomized to routine care plus OIN will receive routine care and have unlimited access to the website for the study duration.
62389334|NCT03773510|ACTIVE_COMPARATOR|Trabectedin continuation|All the patients who will complete 6 cycles of trabectedin without disease progression, will continue trabectedin until progressive disease, unacceptable toxicity, patient or investigator decision
62389335|NCT03773510|EXPERIMENTAL|Trabectedin discontinuation|"All the patients who will complete 6 cycles of trabectedin without disease progression , will discontinue trabectedin.~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin."
62389336|NCT03917394||rHuEPO monotherapy group|rHuEPO was administrated during hospitalization period.
62560955|NCT02885220|EXPERIMENTAL|Goal Directed Program|For the goal directed program, patients would be given an additional sheet to show expected weight loss goals to strive towards at each consultation after surgery (3, 6, 9 and 12 months post operation). Bariatric patients in this modified program will be counselled prior to laparoscopic sleeve gastrectomy (LSG) and EWL (excess weight loss) targets will be set for patients to achieve at fixed intervals post LSG. These targets are charted in a graph, with the patient's actual weight charted on the graph at each clinic consultation, providing a strong visual aid counselling and motivation.
62769009|NCT02469415|EXPERIMENTAL|Pacritinib + Azacitidine or Decitabine|"Part 1: Pacritinib 200 mg taken by mouth twice daily. Study cycles administered every 28 days.~Part 2: After 4 cycles of treatment, Pacritinib combined with 5-azacitidine or Decitabine. Pacritinib decreased to 200 mg in morning and 100 mg in evening for first cycle of combined therapy with Pacritinib increased to 200 mg twice a day on subsequent cycles of combined therapy. Those with disease progression prior to 4 cycles of Pacritinib may initiate Pacritinib + HMA study portion prior to completion of 4 cycles. Starting dose of either 5-azacitidine 75 mg/m2 by vein (IV) or Decitabine 20 mg/m2 IVon Days 1 - 5 of Cycles 5 and beyond."
62769010|NCT02072525|EXPERIMENTAL|Mtdap1 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
62769011|NCT02072525|EXPERIMENTAL|Mtdap2 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
62769012|NCT02072525|EXPERIMENTAL|Mtdap3 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
62769013|NCT02072525|EXPERIMENTAL|Pneum1 Group|Subjects will receive a dose of Pneumovax 23.
62769014|NCT02072525|EXPERIMENTAL|Pneum2 Group|Subjects will receive a dose of Pneumovax 23.
62769015|NCT02072525|EXPERIMENTAL|Pneum 3 Group|Subjects will receive a dose of Pneumovax 23.
62769016|NCT02072525|EXPERIMENTAL|Prev1 Group|Subjects will receive a dose of Prevnar 13.
62560956|NCT03896022|ACTIVE_COMPARATOR|Auriculotherapy - Acupressure with Gold Beads|A designated trained auriculotherapy provider will place gold beads at five acupoints on each ear (10 points total). The beads are affixed with a small round adhesive disk. The beads will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
62769017|NCT02072525|EXPERIMENTAL|Prev2 Group|Subjects will receive a dose of Prevnar 13.
62769018|NCT02072525|EXPERIMENTAL|Prev3 Group|Subjects will receive a dose of Prevnar 13.
62769019|NCT04059107|EXPERIMENTAL|Prosthetic Device|3D Printed Myoelectric Prosthetic Device
62769020|NCT03622320||Vitiligo patients|Vitiligo patients (100 NSV and 50 segmental) who will be further classified according to age of onset and blood sample will be taken
62769021|NCT03622320||controls|Matching will be done taking into consideration age, sex, education and socio economic status, blood sample will be taken
62769022|NCT05995041|EXPERIMENTAL|Multiple universal CAR T cells to treat AML|
62769023|NCT04534348||Control|All central-line-associated blood stream infections (CLABSI) diagnosed during the year previous the implementation of 70% isopropyl alcohol-impregnated Curos catheter caps
62769024|NCT04534348||CUROS|All central-line-associated blood stream infections (CLABSI) diagnosed during the year after the implementation of 70% isopropyl alcohol-impregnated Curos catheter caps
62769025|NCT03241004|EXPERIMENTAL|Intensive Care Unit|"Patients will be induced in a standard fashion using intravenous (IV) anesthetics. A continuous administration of propofol will be used for maintenance of anesthesia.~Baseline EEG readings will be established for 30 minutes, then EEG data will be recorded and a sleep mask applied to the patient for one hour. After one hour, eye masks will be removed for an hour and reapplied after another hour. During the hour that the mask is off, 2 hours into sedation, EEG data will again be recorded."
62769026|NCT03241004|EXPERIMENTAL|Operating Room|"Patients will be induced in a standard fashion using intravenous (IV) anesthetics. A continuous administration of propofol and inhalational anesthetics will be used for maintenance of anesthesia.~Baseline EEG readings will be established for 30 minutes, then EEG data will be recorded and a sleep mask applied to the patient for one hour. After one hour, eye masks will be removed for an hour and reapplied after another hour. During the hour that the mask is off, 2 hours into sedation, EEG data will again be recorded."
62769027|NCT03867682|EXPERIMENTAL|Phase I and Phase II|"Lintuzumab-Ac225 administered on Day 5 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review).~Venetoclax taken on Days 1-21 of each cycle for up to 12 cycles.~Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery."
62769028|NCT05952401|ACTIVE_COMPARATOR|Usual Care|Patients will receive general brief advice about smoking cessation at patient tobacco treatment needs assessment then receive the intervention at 3 months.
62168307|NCT01697592|PLACEBO_COMPARATOR|Placebo/α-GIs (Phase A) → Omarigliptin 25 mg/α-GIs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of α-GIs inhibitors throughout the duration of the study.
62389337|NCT03917394||iron sucrose monotherapy group|Iron sucrose was administrated during hospitalization period.
62389338|NCT03917394||rHuEPO combined with iron sucrose group|rHuEPO combined with iron sucrose was administrated during hospitalization period.
62389339|NCT03917394||control group|Subjects didn't be administrated with rHuEPO and/or iron sucrose during hospitalization period.
62560957|NCT03896022|ACTIVE_COMPARATOR|Auriculotherapy - Acupuncture with Pyonex Needles|A designated trained auriculotherapy provider will place 1.2mm (Pyonex) needles at five acupoints on each ear (10 points total). The needles are affixed with a small round adhesive disk. The needles will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
62769029|NCT05952401|EXPERIMENTAL|"Nudges to Quit"|Patients will receive a multilevel intervention that includes reminders to care team to increase tobacco treatment engagement.
62168308|NCT02959255|ACTIVE_COMPARATOR|10-day concomitant PAMC|40mg esomeprazole twice daily, 500mg clarithromycin twice daily, 1gr amoxicillin twice daily, and 500mg metronidazole twice daily for 10 days
62560958|NCT03896022|SHAM_COMPARATOR|Placebo Group|A designated trained auriculotherapy provider will place adhesive disks at five acupoints on each ear (10 points total). The disks resemble those used with the active treatments. The disks will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
62560959|NCT06177873|EXPERIMENTAL|intervention group|Hot water foot bath will applied to intervention group.
62769030|NCT03795090|ACTIVE_COMPARATOR|Regular Patient privacy curtain|Control arm is a regular patient privacy curtain, washed and dried in hospital laundry using commercially available sodium hypochlorite and hydrogen peroxide.
62168309|NCT02959255|ACTIVE_COMPARATOR|14-day concomitant PAMC|(40mg esomeprazole twice daily, 500mg clarithromycin twice daily, 1gr amoxicillin twice daily, and 500mg metronidazole twice daily for 14 days.
62389340|NCT04966442|EXPERIMENTAL|GrandAides|Patients randomized to this arm of the trial received access to a specially trained GrandAide to work as a credible messenger community health worker. This GrandAide received 6 weeks of education around congestive heart failure to support the patient in the outpatient setting.
62389341|NCT04966442|NO_INTERVENTION|Standard of Care|This arm served as the control and included standard of care outpatient support for patients with heart failure.This support was done telephonically.
62389342|NCT04818034|EXPERIMENTAL|Study Drug|The study drug Dapagliflozin
62389343|NCT05910242|ACTIVE_COMPARATOR|RIC group|Patients are treated with remote ischemic conditioning (RIC).
62389344|NCT05910242|SHAM_COMPARATOR|Sham RIC group|Patients are treated with sham remote ischemic conditioning (sham-RIC).
62389345|NCT00933816|EXPERIMENTAL|Sorafenib with Low-dose FP|
62389346|NCT05049915|EXPERIMENTAL|Masquelet technique: bioactive glass|
62389347|NCT05049915|ACTIVE_COMPARATOR|Masquelet technique: RIA + TCP|
62389348|NCT02010489|NO_INTERVENTION|Control|Following randomization, the control group will receive usual preoperative care consisting of two to four multidisciplinary visits over six months. During this time, patients will be provided with exercise counseling through the team kinesiologist. They will complete a behavior modification program called Craving ChangeTM and must achieve usual goals of lifestyle and dietary modification, along with modest weight loss of approximately 5%, in order to be scheduled for surgery. Patients will also complete a liquid diet consisting of 900 calories per day for two weeks prior to their procedure in order to reduce intra-abdominal obesity and facilitate the procedure.
62389349|NCT02010489|OTHER|12 Week Exercise Program|The intervention group will undergo standard pre-operative care and will also be enrolled in a 12-week exercise program at the Reh-Fit Centre in Winnipeg. The Reh-Fit Centre is a non-profit organization with the mission to enhance the health and wellbeing of its members and the community by providing innovative health and fitness services. The intervention will be offered at no cost to the patient. It will involve regular supervised exercise sessions at the Reh-fit centre three times per week. Most patients will complete the intervention prior to commencing the liquid diet but will otherwise discontinue the program while on the diet two weeks prior to surgery.
62389350|NCT00931515|EXPERIMENTAL|NuBac|NuBac device implanted at the L4/5 level
62389351|NCT00931515|ACTIVE_COMPARATOR|Prodisc-L|Prodisc-L implanted at the L4/5 level.
62389352|NCT01353521|EXPERIMENTAL|Contrast-enhanced ultrasound|
62389353|NCT00408408|ACTIVE_COMPARATOR|Arm 1A: Docetaxel then AC|Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
62389354|NCT00408408|EXPERIMENTAL|Arm 1B Docetaxel + Bev then AC + Bev|Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
62560960|NCT06177873|NO_INTERVENTION|control group|Patients in the control group will not have a hot water foot bath and the scales will be applied at the same hours as the patients in the experimental group.
62560961|NCT05507814|EXPERIMENTAL|Episodic Future Thinking (EFT)|Participants will generate positive future events they are looking forward to at several time points in the future (e.g., 2 weeks, 1 month, 3 months, 1 year, and 5 years). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions. This intervention will be tested in both the presence and absence of stress probes.
61994012|NCT05276492|EXPERIMENTAL|Group 1: Dose Regimen 1|"You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive:~- Abiraterone 500 mg and prednisone 5mg with a low-fat meal every other day.~You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log.~You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary."
61994013|NCT05276492|EXPERIMENTAL|Group 2: Dose Regimen 2|"You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive:~- Abiraterone 500 mg and prednisone 5mg with a low-fat meal on day 1, day 3, day 5 of every week~You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log.~You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary."
61994014|NCT05276492|EXPERIMENTAL|Group 3: Dose Regimen 3|"You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive:~- Abiraterone 500 mg and prednisone 5mg with a low-fat meal on day 1 and day 4 of every week~You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log.~You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary."
61994015|NCT05276492|EXPERIMENTAL|Group 4: Dose Regimen 4|"You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive:~- Abiraterone 500 mg and prednisone 5mg with a low-fat meal on day 1 of every week~You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log.~You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary."
61994016|NCT01834807||Cohort|
61994017|NCT01340157|EXPERIMENTAL|Fasting|Treatment A: 1200mg fexinidazole administered in fasting conditions by oral route
61994018|NCT01340157|EXPERIMENTAL|Meal 1: Plumpy Nuts|Treatment B: 1200mg fexinidazole administered in fed conditions (meal 1) by oral route
61994019|NCT01340157|EXPERIMENTAL|Meal 2: Rice + beans|Treatment B: 1200mg fexinidazole administered in fed conditions (meal 2) by oral route
61994020|NCT03044132|EXPERIMENTAL|DermACELL AWM|Human acellular dermal matrix (ADM) recovered from human donors, decellularized, provided with at least 97% DNA removal, terminally sterilized in its final package, and ready to use.
61994021|NCT05844852|OTHER|OCT|Device: P200TE The P200TE provides OCT imaging including retina topography and ONH (optic nerve head) scans.
62168310|NCT05561296|OTHER|Astigmatism correction with iris registration guided corneal relaxing incisions|This sub-group will include patients who will undergo femtosecond laser-assisted cataract surgery (Catalys) and astigmatism correction using corneal relaxing incisions and implantation of EyHance IOL. The alignment would be guided by preoperatively obtained iris registration using Cassini Ambient.
62389355|NCT00408408|EXPERIMENTAL|Arm 2A: Docetaxel + Capecitabine then AC|Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
62560962|NCT05507814|SHAM_COMPARATOR|Control Episodic Thinking (CET)|Participants will generate positive recent past events that have happened to them at several time points in the previous day (e.g., 7pm-10pm, 4pm-7pm, 1pm-4pm, 10am-1pm, and 7am-10am). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions. This intervention will be tested in both the presence and absence of stress probes.
62560963|NCT04746287|EXPERIMENTAL|Part A|Single dose administration
62560964|NCT04746287|EXPERIMENTAL|Part B|Multiple dose administration (food Effect)
62560965|NCT04746287|EXPERIMENTAL|Part C|Multiple dose administration
62560966|NCT04746287|PLACEBO_COMPARATOR|Placebo|Matching placebo
62560967|NCT02554682|OTHER|Sexual Health|Parents of teens between the ages of 14 and 15 will review psychoeducational workbooks related to sexual health at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 4 to 5 months post baseline we will collect data to assess the efficacy of the study materials.
62560968|NCT02554682|OTHER|Alcohol Prevention|Parents of teens between the ages of 14 and 15 will review psychoeducational workbooks related to alcohol prevention at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 4 to 5 months post baseline we will collect data to assess the efficacy of the study materials.
62560969|NCT02554682|NO_INTERVENTION|Sexual Health & Alcohol Control Group|Parents of teens between the ages of 14 and 15 will receive their usual care at their well-child visit appointment with their primary care giver (baseline) and then at 4 to 5 months post baseline we will collect data. At the end of the post data collection, the control group will get all of the study materials from both the sexual health and alcohol prevention groups.
62560970|NCT02554682|OTHER|Teen Driving|Parents of teens between the ages of 16 and 17 who are planning on having the medical certification for the permit application completed and plan on taking their driving permit test in the next 8 weeks will review psychoeducational workbooks related to teen driving at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 6 months post baseline we will collect data to assess the effectiveness of the study materials.
62560971|NCT02554682|NO_INTERVENTION|Teen Driving Control|Parents of teens between the ages of 16 and 17 who are planning on having the medical certification for the permit application completed and plan on taking their driving permit test in the next 8 weeks will receive their usual care at their well-child visit appointment with their primary care giver (baseline) and then at 6 months post baseline we will collect data. At the end of the post data collection, the control group will get all of the study materials from the teen driving group.
61994022|NCT05850169|EXPERIMENTAL|intervention group|"After completion of the initial assessments, the intervention group received 3 sessions per week of creative dance training for 4 weeks (12 sessions), with each session lasting approximately 40 minutes. The creative dance training took place in a 40-square-metre mirrored hall with a tatami mat on the floor. The training was conducted individually for each child in the IG. Different children's songs were selected for each session in harmony with the rhythm of the dance movements. In each session, 10 minutes of warm-up movements and 20 minutes of creative dance training were conducted, accompanied by songs. Meanwhile, materials such as spiky and heavy balls, ribbons, rhythm sticks and holihop were included in the application.~The creative dance training was planned by diversifying the 8 movement models (breath, tactile, core-distal, head-tail, upper-lower, body side, cross lateral and vestibular) of Brain Dance, which is a part of creative dance (Gilbert, 2002,2015)."
61994023|NCT05850169|NO_INTERVENTION|Control group|
62560972|NCT04110015||Neurology patients|Any patients with neurological disorders
62560973|NCT04110015||Glaucoma patients|Any patients with chronic open angle and chronic angle closure glaucoma of all stages
62560974|NCT04110015||Retina patients|Any patients with known retinal conditions
62560975|NCT02641327||Internal ward|Patients hospitalized in Internal Medicine unit with unstable blood pressure that need regulation/ stabilization of their blood pressure (e.g., CHF, post surgical, hypotension or Hypertension patients, patients with kidney failure, heart disease, stroke)
62560976|NCT02641327||ICU|Patients hospitalized in intensive care with arterial line that allow continuous blood pressure measurement
62560977|NCT01139775|EXPERIMENTAL|Phase 1: LY2603618 130 to 275 mg|"Cycle 1-2 (21-day cycle):~Day 1: pemetrexed 500 milligrams per meter square (mg/m\^2) + cisplatin 75 mg/m\^2~Day 2: LY2603618 at 130-275 milligrams (mg)~After 2 cycles, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
61994024|NCT01517516||Functional Pain Conditions and Inflammatory bowel disease|Cyclical Vomiting Syndrome, Irritable Bowel Syndrome, Inflammatory Bowel disease (Ulcerative colitis and Crohns)and Vulvodynia (vestibulodynia)
61994025|NCT01517516||Inflammatory Bowel Disease|Subjects diagnosed with Crohn's Disease or Ulcerative Colitis.
62560978|NCT01139775|EXPERIMENTAL|Phase 2: Pemetrexed + Cisplatin + LY2603618|"Cycles 1-4 (21-day cycle):~Before 25 Oct 2012:~Day 1: pemetrexed 500 mg/m\^2 + cisplatin 75 mg/m\^2~Day 2: LY2603618 dose from phase 1 portion of trial~After 25 Oct 2012:~Day 1: pemetrexed 500 mg/m\^2 + cisplatin 75 mg/m\^2~After 4 cycles, participants may continue on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion is met.~Maintenance Therapy Experimental Arm (every 21 days):~Before 25 Oct 2012:~Day 1: pemetrexed 500 mg/m\^2~Day 2: LY2603618 dose determined from phase 1~After 25 Oct 2012:~Day 1: pemetrexed 500 mg/m\^2~If, as of 25 Oct 2012, participant was in maintenance therapy and randomized to the experimental arm, the participant is eligible to continue with pemetrexed (Day 1)/LY2603618 (Day 2) therapy if the investigator deems it is in the best interest of the participant and the participant consents."
62389356|NCT00408408|EXPERIMENTAL|Arm 2B: Docetaxel + Cape + Bev then AC + Bev|Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
62560979|NCT01139775|ACTIVE_COMPARATOR|Phase 2: Pemetrexed + Cisplatin|"Cycle 1-4 (21-day cycle):~Day 1: pemetrexed 500 mg/m\^2 + cisplatin 75 mg/m\^2~After 4 cycles, participants may continue on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion is met.~Maintenance Therapy Comparator Arm: Phase 2 (every 21 days):~Day 1: pemetrexed 500 mg/m\^2"
62560980|NCT06563453|SHAM_COMPARATOR|sham stimulation|Two inactive electrodes (anodes and cathodes) - placed over Medial frontal lobe and Inferior parietal lobe. The flow of current discontinues after 20 seconds, the stimulation continues.
62560981|NCT06563453|EXPERIMENTAL|frontal stimulation|"One active electrode (anode and cathode) - placed over Medial frontal lobe, one inactive electrode (anode and cathode) - placed over Inferior parietal lobe.~Current intensity - 2 (milliamperes) mA, frequency: theta 4.51 Hz, stimulation time: 20 minutes"
62560982|NCT06563453|EXPERIMENTAL|frontoparietal stimulation|"One active electrode (anode and cathode) - placed over Medial frontal lobe, another active electrode (anode and cathode) - placed over Inferior parietal lobe.~Current intensity - 2 mA, frequency: theta 4.51 Hz in-phase, stimulation time: 20 minutes"
61994026|NCT02164227|EXPERIMENTAL|respiratory pattern|Deep and slow inspiration is used in the initial and active stages, at which time the contractions vary from uncomfortable to strong, lumbosacral pain and cervical dilation may occur between 3 and 8 cm in this case the mother is driven to inspire slowly and the level of inspiratory reserve volume followed by slow exhalation to functional residual capacity; Sigh with post-expiratory pause that corresponds to a small spontaneous exhalation to relax occurs in tidal volume; Expiratory delay that corresponds to a prolonged propelled with the lips during the lull and expiration in the expiration time that corresponds to a slow inspiration followed by two or three puffs with the short lips will be used propelled.
62389357|NCT00408408|EXPERIMENTAL|Arm 3A: Docetaxel + Gem then AC|Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
62389358|NCT00408408|EXPERIMENTAL|Arm 3B: Docetaxel + Gem + Bev then AC + Bev|Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
62389359|NCT02396680||TR006 Subjects|Subjects that have previously been randomised into study TR006
62389360|NCT03443921|EXPERIMENTAL|Surgery Group|In Surgery Group, an artery divestment combined pancreatectomy will be performed if no pre-operative contra-indication or intra-operative metastasis were revealed. Post-operative adjuvant chemotherapies were prescribed according to performance status.
62389361|NCT03443921|ACTIVE_COMPARATOR|NeoChemo Group|In NeoChemo (Neoadjuvant Chemotherapy) Group, neoadjuvant chemotherapy will be utilized. After 2 circles of neoadjuvant chemotherapies, patients will be reevaluated and curative operation would be attempted if without disease progression.
62389362|NCT05109949|EXPERIMENTAL|Dapagliflozin 10 mg|Dapagliflozin is an oral medication used to treat Type 2 diabetes. It belongs to a sodium-glucose cotransporter 2 (SGLT2) inhibitors.
62389363|NCT05109949|EXPERIMENTAL|Empagliflozin 25 mg|Empagliflozin is an oral medication used to treat Type 2 diabetes. It belongs to sodium-glucose cotransporter 2 (SGLT2) inhibitors.
62389364|NCT05109949|PLACEBO_COMPARATOR|Placebo|Calcinated magnesium is a white powdery compound, MgO, used in pharmaceuticals as binder.
62389365|NCT05689229|ACTIVE_COMPARATOR|Colistin IV|
62389366|NCT05689229|ACTIVE_COMPARATOR|Colistin Aerosolized|
62389367|NCT05689229|NO_INTERVENTION|Control|
62389368|NCT00765726|OTHER|Moroctocog alfa(AF-CC)|
62389369|NCT06399458||1. group|Patients with lymphedema in the lower extremity
62389370|NCT06399458||2. group|Patients with lymphedema or no edema in the lower extremities
62389371|NCT02155166|ACTIVE_COMPARATOR|intracervical anesthesia|Intracervical anesthesia with lidocaine 2%
62560983|NCT02323412|EXPERIMENTAL|Amoxicillin|Amoxicillin (Amoksicillintrihydrat) tablets 750 mg 1x3 for 100 days (oral intake). The tablets will be encapsulated in Capsugel DB-caps AAel Swedish orange.
62560984|NCT02323412|PLACEBO_COMPARATOR|Placebo|Placebo capsules for 100 days of daily (1x3), oral intake. The placebo tablets will also be encapsulated in Capsugel DB-caps AAel Swedish orange.
62560985|NCT02747108|EXPERIMENTAL|Blood Test Group|Patients will complete an HbA1c test and then receive brief counseling and written information about their test result based on the American Diabetes Association and National Diabetes Prevention Program guidelines.
62389372|NCT02155166|ACTIVE_COMPARATOR|ibuprofen|ibuprofen 400 mg
62560986|NCT02747108|ACTIVE_COMPARATOR|Brochure Group (usual care)|Patients will not complete an HbA1c test and will instead receive brief counseling and written information about recommended screenings and immunizations.
62389373|NCT04156984|OTHER|Study arm|Subjects treated with optimized dose of golimumab, irrespective of weight: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 100 mg sc q4 weeks. In case of disease flare: discontinuation of drug.
62769031|NCT03795090|EXPERIMENTAL|Antimicrobial Coated Curtains|Treatment arm is an antimicrobial coated curtains, which is obtained by dipping the hospital laundered curtains into the antimicrobial coating. The curtains are then dried and provided to the nursing/supporting staff.
62769032|NCT03394690|ACTIVE_COMPARATOR|green coffe|green coffe 2 capsuls of green coffe
62560987|NCT05557929||Hemodialysis patients|The present study will comparatively evaluate a series of parameters (measured with cardiopulmonary exercise testing, spirometry, heart ultrasound, lung ultrasound and bioelectrical impedance analysis) in end-stage kidney disease patients undergoing hemodialysis between the end of the long and the end of the short interdialytic interval. The primary aim of the study is the evaluation of cardiorespiratory fitness - cardiovascular reserve assessed with cardiopulmonary exercise testing at these time points.
62769033|NCT03394690|PLACEBO_COMPARATOR|control|2 capsuls of placebo
62769034|NCT01297400|EXPERIMENTAL|Investigational Drug, MW-III|Investigational Drug, MW-III
62769035|NCT01297400|ACTIVE_COMPARATOR|Standard of care|Silvadene® Cream 1% \[Silver Sulfadiazine\]
62769036|NCT01729494|EXPERIMENTAL|Group A|Alemtuzumab + belatacept + mycophenolate mofetil /Enteric coated mycophenolate sodium + early cessation of steroids
62769037|NCT01729494|EXPERIMENTAL|Group B|Rabbit antithymocyte globulin + belatacept + mycophenolate mofetil /Enteric coated (EC) mycophenolate sodium + early cessation of steroids
62769038|NCT01729494|ACTIVE_COMPARATOR|Group C|Rabbit antithymocyte globulin + tacrolimus + mycophenolate mofetil /Enteric coated (EC) mycophenolate sodium + early cessation of steroids
62769039|NCT04046172|EXPERIMENTAL|test group|intensive periodontal treatment (IPT)
62769040|NCT04046172|SHAM_COMPARATOR|control group|Control periodontal treatment (CPT)
62769041|NCT01956370|EXPERIMENTAL|PrePex™ device|Intervention 'PrePex™ device for adult male circumcision
62560988|NCT05557929||Controls without CKD|Controls without CKD will be evaluated with cardiopulmonary exercise testing, spirometry, heart ultrasound, lung ultrasound and bioelectrical impedance analysis at one time point (baseline visit)
62560989|NCT04024670|ACTIVE_COMPARATOR|Patients on a high-risk obstetrics unit with an anticipated stay of two or more weeks|patients in this group will receive twice weekly sewing and embroidery interactions with a professional artist in residence.
62560990|NCT04024670|ACTIVE_COMPARATOR|Patients on a bone marrow transplant unit with an anticipated stay of two or more weeks|patients in this group will receive twice weekly visits with a professional storyteller.
62769042|NCT01956370|ACTIVE_COMPARATOR|Surgical|Adult male surgical circumcision
62769043|NCT05338203|EXPERIMENTAL|experimental group (tandem breastfeeding)|mother mılk wıll collected from these mother and they wıll be analyzed
62560991|NCT04024670|NO_INTERVENTION|HRO Standard of Care|SOC
62560992|NCT04024670|NO_INTERVENTION|BMT Standard of Care|SOC
62560993|NCT01119859|EXPERIMENTAL|Tocilizumab 8 mg/kg|Patients received 6 infusions of tocilizumab 8 mg/kg intravenously every 4 weeks and 12 injections of placebo to adalimumab subcutaneously every 2 weeks.
62769044|NCT05338203|NO_INTERVENTION|control group ( non-tandem breastfeeding)|mother mılk wıll collected from these mother and they wıll be analyzed
62769045|NCT01051401|EXPERIMENTAL|Arm I (rosuvastatin)|Patients receive rosuvastatin PO once daily for 3 months in the absence of disease progression or unacceptable toxicity.
62769046|NCT01051401|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO once daily for 3 months in the absence of disease progression or unacceptable toxicity.
62769047|NCT06088160||Direct Anterior|This group will consist of people undergoing elective unilateral THA for OA using the Direct Anterior surgical approach
62769048|NCT06088160||Direct Lateral|This group will consist of people undergoing elective unilateral THA for OA using the Direct Lateral surgical approach
62769049|NCT02064972||Patients undergoing allo-HSCT, who manifest GvHD.|Patients undergoing allo-HSCT, that manifest GvHD. Patients undergoing allo-HSCT will have CEC count performed at the following timepoints: T1 (baseline), T2 (pre-transplant), T3 (engraftment), T4 (GvHD onset) and T5 (post-GvHD). All patients will also be checked for CEC at day + 28.
62769050|NCT05693454|PLACEBO_COMPARATOR|Control|local wound infiltration at the end of spine surgery with NaCl
62769051|NCT05693454|ACTIVE_COMPARATOR|Arm I|local wound infiltration at the end of spine surgery with Ropivacain
62769052|NCT05693454|ACTIVE_COMPARATOR|Arm II|local wound infiltration at the end of spine surgery with a combination of Levobupivacaine and Tramadol
62769053|NCT03233438|ACTIVE_COMPARATOR|New Critical Pathway|The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
62769054|NCT03233438|ACTIVE_COMPARATOR|Usual Care|Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
62769055|NCT04578925|EXPERIMENTAL|Happy, Healthy, Loved|"Both parents will complete surveys on a tablet during the postpartum hospital stay. Surveys cover three topic areas related to breast-feeding; modeling and feedback, partner support, and stress coping. For the next 6 weeks participants' will receive 4 personalized text messages per week based on their tablet survey responses. Participants will be asked one yes/no question each week (still breastfeeding? Text Y for yes, N for no). Once a no response has been received from a participant, all remaining text messages will emphasize coping and partner support rather than breastfeeding."
61994027|NCT02164227|NO_INTERVENTION|Control|Follows the service routine
61994028|NCT00880529|EXPERIMENTAL|ON-Q|Subcutaneous bupivicaine administration and IV opioid medication if necessary
62769056|NCT04578925|NO_INTERVENTION|Control|Control group participants will complete surveys on a tablet during the postpartum hospital stay. Surveys cover three topic areas related to breast-feeding; modeling and feedback, partner support, and stress coping. The control group participants will be sent 4 text messages per week for the first 6 weeks, but the content of the texts will be non-breastfeeding related. The content will instead summarize infant development facts.
61994029|NCT00880529|ACTIVE_COMPARATOR|IV opioids alone|Standard therapy with IV opioid administration
62769057|NCT02940782|EXPERIMENTAL|Reciproc single file system|It is a reciprocating NiTi file used for instrumentation of root canals in endodontic treatment
62769058|NCT02940782|ACTIVE_COMPARATOR|One Shape single file system|It is a rotary NiTi file used for instrumentation of root canals in endodontic treatment
61994030|NCT05091268|EXPERIMENTAL|Exercise group|"All participants will attend a four-hour pain education session including gynecologist, psychologist, sexologist, and physiotherapist at Akershus University Hospital.~The education will be held twice, with half of the participants at the time. The training group will then attend a 60 minutes weekly group training session led by a physiotherapist with specialist training in women's health, over a period of four months. In addition, participants will perform a progressive home exercise program performed daily over the same period. The focus will be general strength training using own body weight and cardiovascular fitness (walking, low-impact aerobic exercise), stretching, and relaxation."
61994031|NCT05091268|NO_INTERVENTION|Pain education group|No further follow-up
61994032|NCT03422393|EXPERIMENTAL|venetoclax with high-dose ibrutinib|venetoclax with high-dose ibrutinib for the treatment of patients with chronic lymphocytic leukemia with progressive disease on single agent ibrutinib.
61994033|NCT03425929|ACTIVE_COMPARATOR|Oxytocin (6 days)|Intranasal administration, 24 international units (IU) oxytocin for three days after the first trauma movie exposure and three days after the second trauma movie exposure (24 IU per day)
61994034|NCT03425929|ACTIVE_COMPARATOR|Oxytocin (3 days)|Intranasal administration, 24 international units (IU) oxytocin for three days after the first trauma movie exposure (24 IU per day) and placebo nasal spray for three days after the second trauma movie exposure
61994035|NCT03425929|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray for six days
61994036|NCT04998591|EXPERIMENTAL|Fasting group|Participants will be councelled and accompanied to follow a fasting regime of 7 days in an outpatient setting under medical supervision.
61994037|NCT04998591|NO_INTERVENTION|Waiting list|This group maintains their individual diet during the whole time of the study. In case that the first cycle of In-Vitro-Fertilization fails, they are offered a fasting intervention before a next cycle.
62769059|NCT05374187|EXPERIMENTAL|Active eTNS|Following screening and determination of eligibility , participants at baseline are randomized to receive 4 weeks nightly treatment with active eTNS. Positive responders will be invited to participate in a 12-month open-label continuation phase.
61994038|NCT01203072|EXPERIMENTAL|DU-176b 5 mg|
61994039|NCT01203072|EXPERIMENTAL|DU-176b 15 mg|
61994040|NCT01203072|EXPERIMENTAL|DU-176b 30 mg|
61994041|NCT01203072|EXPERIMENTAL|DU-176b 60 mg|
61994042|NCT01203072|PLACEBO_COMPARATOR|Placebo|
61994043|NCT01215227|EXPERIMENTAL|Preladenant 2 mg|Participants who received preladenant 2 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 2 mg in this extension study. Participants will receive preladenant 2 mg taken orally twice daily (BID): one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
61994044|NCT01215227|EXPERIMENTAL|Preladenant 5 mg|Participants who received preladenant 5 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 5 mg in this extension study. Participants will receive preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
62389374|NCT04156984|OTHER|Control arm|"Subjects treated according to current European Label (2019) based on body weight:~1. \<80kg: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 50 mg sc q4wk. In case of disease flare (defined as PRO-2 ≥1): dose optimization to 100 mg sc q4wk starting at week 6 or at any time during first year.~2. ≥80kg: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 100 mg sc q4wk. In case of disease flare (defined as PRO-2 ≥1): discontinuation of drug."
62389375|NCT06198946|OTHER|control group|Provide participants with routine rehabilitation treatment
62389376|NCT06198946|OTHER|observation group|Participants received EDP treatment on the basis of conventional rehabilitation treatment
62560994|NCT01119859|ACTIVE_COMPARATOR|Adalimumab 40 mg|Patients received 12 injections of adalimumab 40 mg subcutaneously every 2 weeks and 6 infusions of placebo to tocilizumab intravenously every 4 weeks.
62560995|NCT05302817|EXPERIMENTAL|Standard-of-care Radiation Therapy for lung cancer using HXe MRI for diagnosis.|Patients with non-small cell lung cancer scheduled for radiation therapy will be voluntarily enrolled in this study, where they will have their lung ventilation and function imaged with hyperpolarized xenon MRI. The 3D HXe images will be used in determining a functional lung avoidance treatment map. However, for this part of the study, subjects will still follow the standard-of-care radiation treatment plan. At 6-month follow up the subjects will be imaged again with HXe to assess lung ventilation and function post-RT compared to baseline (pre-RT). Additionally, standard-of-care lung testing (DLCO, PFT) and quality-of-life questionnaires will be assessed at several time points during the study.
61994045|NCT01215227|EXPERIMENTAL|Preladenant 5 mg (on placebo in parent study)|Participants who received placebo to preladenant tablet in parent study NCT01155466 or NCT01227265 will receive preladenant 5 mg in this extension study. Participants will receive preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
62560996|NCT05302817|EXPERIMENTAL|Guided Radiation Therapy for lung cancer using HXe MRI for functional lung avoidance and diagnosis.|Patients with non-small cell lung cancer scheduled for radiation therapy will be voluntarily enrolled in this study. They will have their lung ventilation and function imaged with hyperpolarized xenon MRI. The 3D HXe images will be used in determining a functional lung avoidance treatment map. Patients will follow radiation therapy optimized for functional lung avoidance. At 6-month follow up the subjects will be imaged again with HXe to assess lung ventilation and function post-RT compared to baseline (pre-RT). Additionally, standard-of-care lung testing (DLCO, PFT) and quality-of-life questionnaires will be assessed at several time points during the study.
61994046|NCT01215227|EXPERIMENTAL|Preladenant 10 mg|Participants who received preladenant 10 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 10 mg in this extension study. Participants will receive preladenant 10 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
61994047|NCT01215227|ACTIVE_COMPARATOR|Rasagiline 1 mg|Participants who received rasagiline 1 mg in parent study NCT01155466 or NCT01227265 will continue to receive rasagiline 1 mg in this extension study. Participants will receive rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.
61994048|NCT01215227|ACTIVE_COMPARATOR|Rasagiline 1 mg (on placebo in parent study)|Participants who received placebo to rasagiline capsule in parent study NCT01155466 or NCT01227265 will receive rasagiline 1 mg in this extension study. Participants will receive rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.
61994049|NCT04480255|ACTIVE_COMPARATOR|Group 1: Standard of Care|Parents of infants born from date July 2020-December 2020
62389377|NCT04456114|EXPERIMENTAL|Acid etched brackets|Stainless steel bracket base etched with 10% Hydrofluoric acid for 1 minute
62389378|NCT04456114|ACTIVE_COMPARATOR|Sandblasted brackets|Stainless steel bracket sandblasted base
62389379|NCT04981886|EXPERIMENTAL|Group 1: Normal tension glaucoma subjects with thin corneas|NTG subjects with CCT ≤ 540 nm will be randomized to receive either netarsudil or bimatoprost.
62389380|NCT04981886|EXPERIMENTAL|Group 2: Normal tension glaucoma subjects with thick corneas|NTG subjects with CCT \> 540 nm will be randomized to receive either netarsudil or bimatoprost.
62389381|NCT03637504|EXPERIMENTAL|Interventional|web-based, mobile medication management application \[MedActionPlan® (MAP) and continued use of eTrack nebulizer +/- AdhereTech pill bottles as measures of adherence
62389382|NCT03637504|NO_INTERVENTION|Control|usual care and continued use of eTrack nebulizer +/- AdhereTech pill bottles as measures of adherence
62389383|NCT03637504|OTHER|Optional Extension|web-based, mobile medication management application \[MedActionPlan® (MAP)\]
61994050|NCT04480255|ACTIVE_COMPARATOR|Group 2: NICU2HOME+ app|Parents of infants born from mid Jan 2021-May2021
62389384|NCT00348686|EXPERIMENTAL|Candesartan|Subjects were treated for 24 weeks with Candesartan 16mg once daily as initial dose. Subjects were modified investigational product dose to Candesartan 32mg, Candesartan 32mg + Felodipine 5mg, Candesartan 32mg + Felodipine 10mg, sequentially according to their blood pressures.
62389385|NCT06518330||Patients presenting a possible drug-induced adverse effects|Drug: search for methylphenidate intake
62389386|NCT02667262||Extended Release and/or Long-Acting Opioids|
62389387|NCT04850066|EXPERIMENTAL|Equine-assisted intervention|Brief program (3 sessions)
62389388|NCT04850066|NO_INTERVENTION|Control|Standard care with treatments as usual
62389389|NCT01047631|EXPERIMENTAL|Functional circuit training and lifestyle counseling|
62389390|NCT01047631|ACTIVE_COMPARATOR|Health education and independent walking|
62389391|NCT05553886|EXPERIMENTAL|S086 piece|Sacubitril alisartan calcium tablets,60mg,120mg,180mg,240mg
62389392|NCT05553886|ACTIVE_COMPARATOR|Sacubitril valsartan sodium tablets|Sacubitril valsartan sodium tablets,50mg,100mg
62389393|NCT01990001|EXPERIMENTAL|Office enrollment in the online contraceptive reminder system|Members of this arm were enrolled in the reminder system during their visit.
62567733|NCT04185220|EXPERIMENTAL|1- Experimental Treatment: Dose Escalation|Interleukin-15 (IL-15) by continuous intravenous (CIV) infusion at escalating doses of 2 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 6 cycles) with mogamulizumab by intravenous (IV) infusion at a dose of 1 mg/kgdays 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle to determine MTD.
61994051|NCT02404350|EXPERIMENTAL|Secukinumab 150 mg load (Group 1)|"Secukinumab 150 mg sc injection every week for 4 weeks followed by Secukinumab 150 mg every 4 weeks until week 100~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks until week 100"
62560997|NCT03534687|EXPERIMENTAL|Aerobic Exercise Group|Aerobic Exercise (AE) subjects will come in for supervised, aerobic exercise training sessions 5 days a week for 12 weeks. Training will progress from 55% VO2max for week 1 (40 min session), to 60-65% VO2max for week 2 (50 min session), to \~70% VO2max for all other weeks (50 min session). Subjects will perform a warm-up and cool down (\~5 min each) that includes stretching exercises. Subjects will wear heart rate monitors during each training session to provide feedback of target heart rate. Intensity, duration, resting and exercise heart rates, and blood pressures will be recorded for each session. Follow-up VO2max tests will be performed at weeks 4 and 8 to monitor progress and adjust AE training intensity.
62560998|NCT03534687|NO_INTERVENTION|Control Group|During the 12 week control period, subjects are to maintain their normal, daily-living activities. Control group participants will be given the option to enroll in the AE training group after completion of the original Control group trial period.
62769060|NCT05374187|SHAM_COMPARATOR|Sham eTNS|Following screening and determination of eligibility, participants at baseline are randomize to receive 4 weeks nightly treatment with sham eTNS. At conclusion of the double-blind phase, participants randomized to sham will be provided an opportunity to receive an additional 4 weeks nightly treatment with active eTNS. Positive responders to active eTNS will be invited to participate in a 12-month open-label continuation phase.
61994052|NCT02404350|EXPERIMENTAL|Secukinumab 150 mg no load (Group 2)|"Secukinumab 150 mg sc injection every 4 weeks until week 100~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
61994053|NCT02404350|EXPERIMENTAL|Secukinumab 300 mg load (Group 3)|Secukinumab 300 mg sc injection every week for 4 weeks followed by Secukinumab 300 mg every 4 weeks until week 100
62168311|NCT05561296|OTHER|Astigmatism correction with iris registration guided implantation of toric IOLs|This sub-group will include patients who will undergo femtosecond laser-assisted cataract surgery (Catalys) and astigmatism correction with the implantation of EyHance toric II IOLs. The alignment would be guided by preoperatively obtained iris registration using Cassini Ambient.
62389394|NCT01990001|NO_INTERVENTION|Control|Members in the control group were not enrolled in the reminder system
62560999|NCT04747158|EXPERIMENTAL|Convalescent plasma|COVID-19 convalescent plasma
62561000|NCT02626091|EXPERIMENTAL|Perfusion evaluation of anastomosis|During left-sided colonic resections, anastomosis perfusion will be estimated by the visual appreciation of the surgeon and the ICG fluorescence-based enhanced reality. These two approaches will be compared.
62561001|NCT05584618|EXPERIMENTAL|intervention|The women allocated in experimental group will be given antenatal education for 6 weeks
62561002|NCT05584618|NO_INTERVENTION|control|The women allocated for the control group will receive prenatal care services routinely provided at the outpatient clinics of the same hospital
62561003|NCT02631642|EXPERIMENTAL|HMPL-689|Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.
62561004|NCT02631642|PLACEBO_COMPARATOR|HMPL-689 placebo|Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.
62561005|NCT03901794||With Clear Sight|record and observe the data including SVI, CI, SVR with clearSight during hemodialysis
62561006|NCT04321746|ACTIVE_COMPARATOR|Ketamine|
62561007|NCT04321746|PLACEBO_COMPARATOR|Control|
62561008|NCT00594867|ACTIVE_COMPARATOR|1|Acetaminophen - 4 grams per day + Placebo
62561009|NCT00594867|ACTIVE_COMPARATOR|2|Aspirin - 325 mg per day + Placebo
62561010|NCT00594867|EXPERIMENTAL|3|Acetaminophen 4 gram per day + Aspirin 325 mg per day
62561011|NCT00478062|EXPERIMENTAL|Cell vaccine after initial therapy for Hodgkin lymphoma|Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.
62561012|NCT06497608||scRNA_DR|Patients with proliferative diabetic retinopathy who underwent prosthetic eye implantation.
62561013|NCT06497608||scRNA_normal|Body donors without history of diabetic retinopathy
62561014|NCT06497608||Validate_DR|Patients with proliferative diabetic retinopathy (PDR) who underwent vitrectomy surgery
62561015|NCT06497608||Validate_normal|Patients who underwent vitrectomy surgery for macular hole (MH) and did not have diabetic retinopathy (DR)
62769061|NCT04887389|EXPERIMENTAL|Group of • Nano Silver Fluoride varnish ( NSF)|"Selected children will be divided randomly into three groups:~Group 1: Children receiving Nano Silver Fluoride varnish (NSF) (n =50)."
62389395|NCT03494764|ACTIVE_COMPARATOR|5 Days Hyperbaric Therapy|Patients will be enrolled and follow an identical medical treatment algorithm. At day 3 responders (based on partial Mayo score) will be re-randomized in a 1:1 fashion to complete 5 total days of HBOT (1 session per day) or to stop after 3 days of HBOT. Non-responders will be entered into an open label arm to complete 5 total days of HBOT.
62561016|NCT02681861|EXPERIMENTAL|Part 1: ASP6294 Single Ascending Intravenous Doses|A dose escalation design will be implemented. Successive cohorts of patients (8 participants/cohort) will each be started on a fixed dose of ASP6294 or Placebo intravenously. If no dose limiting toxicities are observed escalation to the next higher dose is planned approximately every 3 weeks. Within the planned dose range, a dose lower than the next planned dose may be tested, or a dose level may be repeated, depending on emerging safety, tolerability and/or other relevant data, such as available pharmacokinetic and pharmacodynamic data of previous dose levels.
62389396|NCT03494764|ACTIVE_COMPARATOR|3 Days Hyperbaric Therapy|Patients will be enrolled and follow an identical medical treatment algorithm. At day 3 responders (based on partial Mayo score) will be re-randomized in a 1:1 fashion to complete 5 total days of HBOT (1 session per day) or to stop after 3 days of HBOT. Non-responders will be entered into an open label arm to complete 5 total days of HBOT.
62389397|NCT04484610|EXPERIMENTAL|Appropriate Opioid Quantities|Pharmacists in the intervention regions are invited to complete an eLearning program to promote the practice change intervention of assessing and dispensing appropriate quantities of opioids prescribed for acute pain.
62561017|NCT02681861|EXPERIMENTAL|Part 2: ASP6294 Single Ascending Subcutaneous Doses|A dose escalation design will be implemented. Successive cohorts of patients (8 participants/cohort) will each be started on a fixed dose of ASP6294 or Placebo subcutaneously. The subcutaneous cohorts may be done in parallel with part 1, using doses which have been proven to be safe and tolerable. Within the planned dose range, a dose lower than the next planned dose may be tested, or a dose level may be repeated, depending on emerging safety, tolerability and/or other relevant data, such as available pharmacokinetic and pharmacodynamic data of previous dose levels.
62561018|NCT01701011|EXPERIMENTAL|PRCI-monitoring|Coping intervention, Daily Record Keeping, Questionnaires
62561019|NCT01701011|NO_INTERVENTION|Routine care control|Questionnaires
62561020|NCT01701011|NO_INTERVENTION|Monitoring control|DRK and Questionnaires
62389398|NCT04484610|NO_INTERVENTION|Usual Practice|Pharmacists in the comparison regions are not targeted for the practice change intervention (they are not invited nor provided access to the eLearning program).
62389399|NCT03336164|EXPERIMENTAL|Front-of-pack labelling Nutri-Score|"Introduction of the Nutri-Score front-of-pack nutrition label on every food and beverage sold in the same campus university restaurant after the control period without food labelling.~The implementation of the label is accompanied by a communication campaign towards students in the form of posters and leaflets."
62389400|NCT03114475|EXPERIMENTAL|CO2 Laser Irradiation|This group of patients will be treated by splitting the dental arches into four quadrants: upper right, upper left, lower right and lower left. Two quadrants will receive the CO2 laser irradiation whereas the remaining two quadrants will receive no treatment (i.e. the placebo light).
62561021|NCT01827111|EXPERIMENTAL|ABI-007 + Ipilimumab|Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. Ipilimumab 3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses. Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
62561022|NCT00711087|PLACEBO_COMPARATOR|ARM 2|Subjects randomized to receive placebo (saline) sham saline injections on Days 0 and 90.
62561023|NCT00711087|ACTIVE_COMPARATOR|ARM 1|Subjects randomized to receive 100 units BOTOX-A injections on Days 0 and 90.
62561024|NCT01228058||Adult trauma patients|Patients admitted to the emergency department (ED) as the highest level of acuity following a traumatic injury at three Level 1 trauma centers in the United States (UT Houston, UC San Francisco, Oregon Health Center).
62561025|NCT05098717||UIP patients|Patients with pulmonary fibrosis and UIP pattern undergoing mechanical ventilation for acute respiratory failure
62769062|NCT04887389|EXPERIMENTAL|group of Nano hydroxyapatite varnish (n-HAP)|Group 2 Children receiving Nano-hydroxyapatite varnish (n = 50)
62389401|NCT03114475|PLACEBO_COMPARATOR|Placebo|A placebo light will be used as if the patient is irradiated with the laser beam.
62389402|NCT05245240|EXPERIMENTAL|Severe OSA group|Dietary and physical activity intervention
62389403|NCT05245240|EXPERIMENTAL|Mild OSA group|Dietary and physical activity intervention
62389404|NCT00876759|ACTIVE_COMPARATOR|WBRT|standard WBRT to a total dose of 30 Gy in 10 fractions
62389405|NCT00876759|EXPERIMENTAL|WBRT with simulatneous boost|The experimental group will be treated with helical tomotherapy giving 3 Gy per fraction to the whole brain up to a total dose of 30 Gy in 10 fractions and raising the prescribed dose to the brain metastases to 5 Gy per fraction. The dose fall off to the normal brain should be as steep as possible around each brain metastasis. The optic chiasm and the optic nerves should not receive more than 3.5 Gy per fraction.
62389406|NCT06028763|EXPERIMENTAL|Group 1 (main)|Treatment consists of 2 stages. 1 stage starts with lipoaspiration of subcutaneous adipose tissue from patients. This tissue will then undergo Mesenchymal Stem Cells (MSC) isolation, cultivation and become a biocomposite hydrogel with growth factors. The 2 stage involves ankle joint arthroscopy using the hydrogel for cartilage therapy. To ensure proper hydrogel fixation, we'll clean cartilage remnants, remove fibrous tissue, and create 10mm deep, 2.5mm diameter microperforations. Cartilage donor site prep during arthroscopy will remove non-viable tissue and establish communication with underlying bone marrow. After stopping bleeding, heparin-conjugated fibrin hydrogel with MSCs and growth factors (TGF-β1 and BMP-4) will be implanted using epinephrine-soaked gauze. Hydrogel gels in 3-5 mins. Ankle joint movement tests will confirm successful implantation. Joint stability, articular congruence, and joint condition will be inspected.
62389407|NCT06028763|ACTIVE_COMPARATOR|Group 2 (control)|Patients from control group will undergo arthroscopic debridement of the joint with microfracturing (traditional method of treatment).
62389408|NCT01381601||Severe adverse event claims in subjects with metastatic RCC|Presence or absence of common severe treatment related adverse events (based on existence of claims) in patients with metastatic RCC. Common severe adverse event defined as Grade 3 or higher with \>=5% frequency of occurence as reported in product label.
62561026|NCT05098717||ARDS patients|Patients with ARDS undergoing mechanical ventilation for acute respiratory failure
62561027|NCT06525350|EXPERIMENTAL|Glumetinib tablets+HB1801 combination treatment arm|Glumetinib tablets RP2D PO QD, HB1801 RP2D iv Q3W until a treatment discontinuation criterion is met.
62561028|NCT06525350|EXPERIMENTAL|Glumetinib tablets monotherapy arm|Glumetinib tablets RP2D PO QD until a treatment discontinuation criterion is met.
62389409|NCT04420390|EXPERIMENTAL|Radiotherapy|
62561029|NCT06525350|ACTIVE_COMPARATOR|Docetaxel monotherapy arm|Docetaxel 75mg/m\^2 iv Q3W until a treatment discontinuation criterion is met.
62561030|NCT01578239|EXPERIMENTAL|177Lu-DOTA0-Tyr3-Octreotate|"* 30 mg Octreotide LAR treatment for symptom control continued until the end of study, unless the participant progressed or died.~* Treatment consisted of a cumulative administered radioactivity of 29.6 Giga Becquerel (GBq) (800 mCi) 177Lu-DOTA0-Tyr3-Octreotate: Four administrations of 7.4 GBq (200 mCi).~* Concomitant amino acids were given with each administration for kidney protection.~* 177Lu-DOTA0-Tyr3-Octreotate was administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.~* In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections were allowed."
62561031|NCT01578239|ACTIVE_COMPARATOR|Octreotide LAR|"* 60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.~* In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections were allowed."
62769063|NCT04887389|EXPERIMENTAL|group of Sodium Fluoride Varnish (NaF)|Group 3: Children receiving Sodium Fluoride Varnish (n = 50)
62769064|NCT06198335|ACTIVE_COMPARATOR|Group M-TAPA (Modified Perichondral Approach Thoracoabdominal Nerve block group)|Patients will be performed to block at the end of the surgery. Patients will be administered paracetamol 1 gr (PERFALGAN® ) IV every 8 hours in the postoperative period.. If the patient's NRS score is ≥ 4 0,5 mg/kg IV meperidine (Aldolan ampul 100 mg/2 ml) will be administered.
62769065|NCT06198335|ACTIVE_COMPARATOR|Group TAP (Transversus Abdominal Plane block group)|Patients will be performed to block at the end of the surgery. Patients will be administered paracetamol 1 gr (PERFALGAN® ) IV every 8 hours in the postoperative period.. If the patient's NRS score is ≥ 4 0,5 mg/kg IV meperidine (Aldolan ampul 100 mg/2 ml) will be administered.
62769066|NCT01142024|PLACEBO_COMPARATOR|saline|saline hydration
62769067|NCT01142024|EXPERIMENTAL|Glutathione|
62769068|NCT04718168|EXPERIMENTAL|Ventral/Incisional Hernia - Preperitoneal ENFORM Biomaterial|
62769069|NCT04718168|EXPERIMENTAL|Ventral/Incisional Hernia - Intraperitoneal ENFORM Biomaterial|
62769070|NCT04718168|EXPERIMENTAL|Hiatal/Diaphragmatic Hernia - Preperitoneal ENFORM Biomaterial|
62769071|NCT04718168|EXPERIMENTAL|Hiatal/Diaphragmatic Hernia-Intraperitoneal ENFORM Biomaterial|
62769072|NCT01321203||Group-A, use of air;|
62769073|NCT01321203||Group-B use of CO2|
62769074|NCT01384032|EXPERIMENTAL|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
61994054|NCT02404350|PLACEBO_COMPARATOR|Placebo arm 1 (Group 4)|"Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders will be switched to Secukinumab either 150 or 300 mg sc injection every four weeks until week 100. Responders at week 16 continued receiving placebo until week 24, then were switched to secukinumab 150 or 300 mg sc injection every 4 weeks until week 100. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
62168312|NCT00522678|EXPERIMENTAL|Cohort A|In Cohort A, subjects will be randomized (3:1) to receive once daily doses of GW685698X 400 microgram (mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
62389410|NCT03241485|PLACEBO_COMPARATOR|Placebo|60 patients will be randomly assigned to this arm. The patients in this arm will receive intrathecal saline.
62389411|NCT03241485|ACTIVE_COMPARATOR|Intrathecal morphine|60 patients will be randomly assigned to this arm. The patients in this arm will receive intrathecal morphine.
62561032|NCT04220515|EXPERIMENTAL|Inactivated Poliomyelitis Vaccine Made From Sabin Strain|Primary 3-dose of sIPV and booster 1 dose of sIPV
62769075|NCT01384032|EXPERIMENTAL|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
62769076|NCT01384032|EXPERIMENTAL|High saturated fat plus DHA diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
62769077|NCT03883113|EXPERIMENTAL|MVA-NP+M1 & H3N2 Challenge Virus|Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10\^6 TCID50/ml)
62769078|NCT03883113|PLACEBO_COMPARATOR|Saline Placebo & H3N2 Challenge Virus|Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10\^6 TCID50/ml)
62769079|NCT02176603||Patients with Phenylketonuria|Patients with Phenylketonuria due to phenylalanine hydroxylase deficiency
62769080|NCT02176603||Control group|Control group of healthy volunteers
62561033|NCT06582953|OTHER|Patients, family members and healthcare providers|Patients that experience violent injuries or are high risk of violence between ages of 15-35 and treated at MUSC Charleston will be enrolled. The hospital violence intervention program is incorporated into regular care of patients, and they may opt to receive services from the program (TTVIP) if they qualify and opt to participate. There is no randomization or assignment. Investigators will assess outcomes of these patients and outcomes will be assessed for between group differences between those that receive services from the program and those that do not. Patient family members and healthcare providers that care for patients will be included and are exposed to the regular healthcare and services provided to patients.
62769081|NCT05779904||Stunted (Case)|In the case group, stunted children (\<-2SD) (n=150) will be recruited.
62769082|NCT05779904||Non-stunted (Control)|In the control group, non-stunted children (\>-1SD) (n=150) will be recruited.
62769083|NCT01548742|EXPERIMENTAL|Arm 1: Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR)
62769084|NCT01548742|ACTIVE_COMPARATOR|Arm 2: Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT)
62769085|NCT02099305|EXPERIMENTAL|Intervention|Receive Adolescent Depression Awareness Program (ADAP) intervention
62769086|NCT02099305|NO_INTERVENTION|Wait list control|no intervention
62769087|NCT06213779||One group|This is a prospective observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
62769088|NCT04830124|EXPERIMENTAL|Advanced Cutaneous Melanoma Subcutaneous Dosing (Cohort 1)|Patients with unresectable and/or metastatic cutaneous melanoma
62769089|NCT04830124|EXPERIMENTAL|Advanced mucosal melanoma with IV Dosing (Cohort 2)|Patients with unresectable and/or metastatic mucosal melanoma
62389412|NCT04330586|EXPERIMENTAL|Ciclesonide|Ciclesonide 320ug oral inhalation q12h for 14 days
62389413|NCT04330586|NO_INTERVENTION|Control|Standard care without ciclesonide
62389414|NCT00578331|EXPERIMENTAL|Olopatadine 0.6% Nasal Spray|2 sprays each nostril twice daily
62561034|NCT05335486|EXPERIMENTAL|RELEARN - Intervention|"Intervention group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines.~In addition, intervention group participants will be asked to attend eight sessions of RELEARN neurofeedback with an approximate duration of 45 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention"
62561035|NCT05335486|ACTIVE_COMPARATOR|Standard care control|Standard Care control. Control group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines. During standard care, the control group participants will be asked to attend eight control sessions with no RELEARN intervention with an approximate duration of 5 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention
62561036|NCT01915030|EXPERIMENTAL|High protein diet|High protein diet during caloric restriction
62561037|NCT01915030|PLACEBO_COMPARATOR|Standard protein diet|Standard protein diet during caloric restriction
62561038|NCT06225791|NO_INTERVENTION|Standard MMS delivery with two 90-count bottles|Pregnant women are provided with two 90-count bottles of MMS at two different time points during pregnancy, along with standard MMS delivery strategy (MMS orientation only). (1 sub-district within each of the 13 districts with high- or moderate-intensity evaluation).
62561039|NCT06225791|ACTIVE_COMPARATOR|Enhanced MMS delivery with two 90-count bottles|Pregnant women are provided with two 90-count bottles of MMS at two different time points during pregnancy, along with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC). (1 sub-district within each of the 13 districts with high- or moderate-intensity evaluation).
62561040|NCT06225791|ACTIVE_COMPARATOR|Enhanced MMS delivery with one 180-count bottle|Pregnant women are provided with one 180-count bottle of MMS along with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 with MMS orientation with expanded BCC). (1 sub-district with each of the 13 districts with high- or moderate-intensity evaluation).
62561041|NCT01774760|EXPERIMENTAL|Patients with stage III-IV head and neck cancer|18F-EF5 PET/CT scan
62561042|NCT03591848|EXPERIMENTAL|DECISIF|Exposed to an online support decision tool, in addition of the standard oral information
62561043|NCT03591848|ACTIVE_COMPARATOR|IRIS|Exposed to a standard oral information
62561044|NCT04650269|EXPERIMENTAL|Rapid ART group|Patients will receive HIV care including Biktarvy for 6 months at the syringe services program followed by 6 months of standard of care at a traditional clinic.
62561045|NCT02339168|EXPERIMENTAL|enzalutamide and metformin hydrochloride|Patients receive enzalutamide PO QD and metformin hydrochloride PO BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62561046|NCT02360241|EXPERIMENTAL|Robot|A robot will be used and it's position will be evaluated
62561047|NCT04666948|ACTIVE_COMPARATOR|Standard of Care Vancomycin treatment|Vancomycin standard-of-care dosing and therapeutic drug monitoring, according to institutional guidelines during 30 day study period
62561048|NCT04666948|EXPERIMENTAL|vancomycin model-informed precision dosing|Area Under the Concentration (AUC)-time curve/MIC-based model-informed precision dosing of vancomycin using a CE labelled dosing calculator during 30 day study period
62561049|NCT05915247|PLACEBO_COMPARATOR|Placebo (Part 1)|Corresponding volumes of placebo solution according to the dosing cohort administered as a s.c. injection.
62561050|NCT05915247|ACTIVE_COMPARATOR|HER-096 (Part 1)|Single ascending doses of HER-096 up to six dosing cohorts administered as a s.c. injection.
62561051|NCT05915247|ACTIVE_COMPARATOR|HER-096 (Part 2)|A single dose of HER-096 will be administered as a s.c. injection.
62769090|NCT04830124|EXPERIMENTAL|Advanced Cutaneous Melanoma with Less Frequent IV Dosing (Cohort 3)|Patients with unresectable and/or metastatic cutaneous melanoma
62389415|NCT00578331|PLACEBO_COMPARATOR|Placebo Nasal Spray|2 sprays each nostril twice daily
62389416|NCT03977376|EXPERIMENTAL|Intervention|Valuation instruments were two validated scales: ESAS y HADS. Experimental nursing instrument: Guide of hosting.
62561052|NCT02462590|ACTIVE_COMPARATOR|Lactobacillus rhamnosus GG|Patients allocated to the intervention group will receive 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule suspended in tap water, administered through a nasogastric (or orogastric) or nasoduodenal (or oroduodenal) tube twice daily while patients are in the ICU. The first dose will be within 72 hours of intubation. Patients in the ICU who await discharge and can swallow pills will take the capsules orally.
62561053|NCT02462590|PLACEBO_COMPARATOR|Placebo|Patients allocated to the placebo group will receive a capsule identical in appearance to the L. rhamnosus GG capsule, but containing microcrystalline cellulose. The placebo will also be suspended in tap water and similarly administered twice a day. When suspended in water, the placebo has identical appearance and consistency as the probiotic. The placebo will be prepared by the manufacturer of L. rhamnosus GG, Culturelle, and has been used successfully in a recent RCT in the ICU population \[Morrow 2010\]. This has also been used successfully in the PROSPECT Pilot Trial.
62561054|NCT02284776|NO_INTERVENTION|Témoin|No treatment.
62389417|NCT03977376|NO_INTERVENTION|Control|Valuation instruments were two validated scales: ESAS y HADS. Without Guide of hosting.
62389418|NCT04552821||Control|Non-sepsis and non-ARDS adults receiving mechanical ventilation
62389419|NCT04552821||Sepsis complicated with mild ARDS|Patients who meet the criteria of sepsis-3, and also meet the criteria of Berlin diagnostic for mild ARDS
62561055|NCT02284776|EXPERIMENTAL|Action|People in hydrotherapeutic cure are following a program of Therapeutic Education. This program includes dietary advice, physical activities, behavior advice in order to change the lifestyle of the obese people.
62561056|NCT04121559|EXPERIMENTAL|Intervention|A\&T intervention areas: adolescent-nutrition-focused behavior change interventions delivered through government primary schools and communities
62561057|NCT04121559|NO_INTERVENTION|Control|Comparison areas: standard activities at government primary schools
62561058|NCT02162056|EXPERIMENTAL|use of bioresorbable vascular scaffolds|Implantation of bioresorbable vascular scaffold for coronary artery disease.
62561059|NCT01936844|EXPERIMENTAL|Anakinra (short)|Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14
62561060|NCT01936844|PLACEBO_COMPARATOR|Placebo|Placebo injections twice daily for the first 3 days then once daily for days 4-14.
61994055|NCT02404350|PLACEBO_COMPARATOR|Placebo arm 2 (Group 4)|"Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders were switched to Secukinumab either 150 or 300 mg sc injection every four weeks until week 100. Responders at week 16 continued receiving placebo until week 24, then were switched to secukinumab 150 or 300 mg sc injection every 4 weeks until week 100. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
62561061|NCT04133701|EXPERIMENTAL|Time-Restricted Feeding|"Control (Baseline): Blood pressure and neurovascular control will be measured.~Post-Intervention: Blood pressure and neurovascular control will be measured."
62561062|NCT03113812|EXPERIMENTAL|ABvac40|
62561063|NCT03113812|PLACEBO_COMPARATOR|Placebo|
62561064|NCT02600975|ACTIVE_COMPARATOR|Group 1|10µg of R21 with AS01B on days 0, 28, and 56.
62561065|NCT02600975|ACTIVE_COMPARATOR|Group 2|50µg of R21 with AS01B on days 0, 28, and 56.
62561066|NCT01938092|ACTIVE_COMPARATOR|Diazepam|Participated will be instructed to insert one 10mg tablet vaginally 1-2 times per day as needed for pain.
62561067|NCT01938092|PLACEBO_COMPARATOR|Placebo|Participated will be instructed to insert one 10mg tablet vaginally 1-2 times per day as needed for pain.
62561068|NCT00364767|EXPERIMENTAL|A|Whiskey (32 gram of alcohol/day)
62561069|NCT00364767|PLACEBO_COMPARATOR|B|Water (0 gram alcohol/day)
62561070|NCT02084862|EXPERIMENTAL|Ultrasound|Ultrasound guided percutaneous tracheostomy
62561071|NCT02084862|ACTIVE_COMPARATOR|Bronchoscopy|Bronchoscopy guided percutaneous tracheostomy
62561072|NCT04078594|EXPERIMENTAL|Experimental wards|Active sepsis e-alert
61994056|NCT05913895|EXPERIMENTAL|hydrogen water|At the end of cancer treatment (chemotherapy, radiotherapy, or Chemoradiotherapy), a hydrogen water gargle (dissolved for 12 hours or longer) was administered by the investigator or a researcher every Monday through Friday. The changes in six scales described above were tracked in the experimental and control groups on days 1 (T1), 3 (T2), 7 (T3), and 14 (T4) after the end of treatment.
61994057|NCT05913895|PLACEBO_COMPARATOR|boiled water|At the end of cancer treatment (chemotherapy, radiotherapy, or Chemoradiotherapy),boiled water gargle was administered by the investigator or a researcher every Monday through Friday. The changes in six scales described above were tracked in the experimental and control groups on days 1 (T1), 3 (T2), 7 (T3), and 14 (T4) after the end of treatment.
62561073|NCT04078594|NO_INTERVENTION|Contol wards|"Masked sepsis e-alert.~The wards will have masked sepsis e-alert."
62561074|NCT03852654|EXPERIMENTAL|treatment|
62561075|NCT03847025||Lead extraction|Patients undergoing clinically indicated lead extraction procedures.
62561076|NCT00731354|ACTIVE_COMPARATOR|SAL|Each patient will have Suction Assisted Lipoplasty procedure on one side of the body (this will be considered the control side)
62561077|NCT00731354|ACTIVE_COMPARATOR|VAL|Each patient will have VASER- assisted lipoplasty on the opposite side of the body. This will be the comparison side.
62561078|NCT03304925|EXPERIMENTAL|Fat Reduction|The treatments are designed to see if the fat can be reduced in the flanks with a new applicator design.
62561079|NCT02508337|EXPERIMENTAL|XG-102|sterile ophthalmic solution for sub-conjunctival injection
62561080|NCT02508337|PLACEBO_COMPARATOR|placebo|sterile ophthalmic solution for sub-conjunctival injection
62561081|NCT04509076|EXPERIMENTAL|PrEP iT! (plus usual PrEP care)|The PrEP iT! intervention is a mobile-optimized website with components tailored for young men who have sex with men on PrEP.
62561082|NCT04509076|PLACEBO_COMPARATOR|Usual PrEP care only|Clinic visits every 3 months in the initial period following PrEP initiation, including HIV/STI screening and laboratory toxicity testing
62561083|NCT01228201|EXPERIMENTAL|Aerboic interval training|
62561084|NCT01228201|ACTIVE_COMPARATOR|Moderate continuous training|
62561085|NCT06368492|EXPERIMENTAL|Patient group|Each participant will receive 2 different doses of psilocybin (5mg and 10mg) and a matching placebo on three separate occasions.
62561086|NCT03945305|ACTIVE_COMPARATOR|RIC group|Patients are treated with previous antihypertensive treatment plus remote ischemic conditioning.
62561087|NCT03945305|OTHER|Control group|Patients are only treated with previous antihypertensive treatment.
62561088|NCT04386850|EXPERIMENTAL|Treatment|Infected patients with acute respiratory tract infection symptoms (e.g. fever, cough, dyspnea) with no other etiology that fully explains the clinical presentation accompanied by chest computed tomography (CT) scan findings compatible with Covid-19 or with a COVID-19 positive test by the polymerase chain reaction (PCR)
62561089|NCT04386850|EXPERIMENTAL|Prevention|This arm of study includes the health care providers and hospital workers with a negative test for COVID-19 and a close patient relative with a negative test for COVID-19 who lives with the infected patients.
62561090|NCT04069650||None-malnutrition|normal nutritionnal status
62561091|NCT04069650||Malnutrition|"* weight loss was superior to 5% in the past month;~* a weight loss was superior to 10% in the past 6 months;~* a BMI was inferior to 18,5 kg/m² (if age inferior to 70 years old) or inferior to 21 kg/m² (if age superior to \> 70 years old) - a serum albumin level inferior to 30g/L (if age inferior to 70 years old) or inferior to \<35g/L (if age superior to 70 years old)."
62561092|NCT00639301||1|Long term survivors of retinoblastoma
62561093|NCT05652673|EXPERIMENTAL|Early discontinuation of nivolumab|
62561094|NCT03175536||HDHP with PDL|Enrollees switched from a health savings account (HSA)-eligible high-deductible health plan (HDHP) without a preventive drug list (PDL) to a HSA-HDHP with a PDL
62561095|NCT03175536||HDHP without PDL|Enrollees who stayed in a HSA-HDHP without a PDL.
62561096|NCT03175536||traditional plan|Enrollees who remained in a traditional health plan with a deductible \< $500
62561097|NCT04460911||PAL + FUL|Patients who initiated palbociclib-fulvestrant combination therapy as first-line or beyond therapy in the advanced or metastatic setting.
62561098|NCT00308204|EXPERIMENTAL|Raptiva|raptiva injection
62561099|NCT02473627|EXPERIMENTAL|Period 1|Period 1 Day 1: single oral dose of 2.5 mg midazolam hydrochloride Day 2: single oral cocktail dose of 20 mg omeprazole, 15 mg pioglitazone hydrochloride, 500 mg tolbutamide and 150 mg bupropion
61994058|NCT04619524|EXPERIMENTAL|A: Patients undergo cycle with the transfer of fresh embryos|In study group A the cervical mucus will be collected from patients undergoing the in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI)/embryo transfer (ET) cycle with the transfer of fresh embryos.
61994059|NCT04619524|EXPERIMENTAL|B: Patients undergo cycle with the transfer of frozen embryos|In study group B cervical mucus will be sampled from patients undergoing treatment cycles with the transfer of cryopreserved embryos.
61994060|NCT05540964||Single group|Study participants will be taken off antiretroviral therapy and blood samples will be collected during each clinic visit.
61994061|NCT05791474|EXPERIMENTAL|ATI-2231 monotherapy dose escalation|"* Patients will receive single agent ATI-2231 at assigned dose levels (n=3-6 per dose level). Starting dose of 20 mg by mouth twice per day.~* Each cycle is 21 days"
61994062|NCT06163248|EXPERIMENTAL|Chrono nutrition|"1. During the 6-month period, participants will be asked to fast for 12 hours each day. During the fasting period, they may consume non-caloric beverages such as plain water, coffee, or unsweetened tea.~2. The total daily calorie intake will be calculated using indirect calorimetry, considering the participant's current weight, age, sex, and physical activity level. 500 calories will be subtracted from the total calorie amount.~3. The dietary plan will have the following macronutrient distribution: 40% carbohydrates (\<10% simple carbohydrates), 20% protein, and 40% fats (6-11% polyunsaturated, 15-20% monounsaturated, and \<10% saturated).~4. The plan will consist of 3 meals and breakfast will account for 40% of the total calories.~5. During dinner, only 10% of the total grams of carbohydrates will be included.~6. The order of food consumption should be as follows: 1) vegetables, 2) proteins, 3) complex carbohydrates, and 4) simple carbohydrates (fruits)."
61994063|NCT06163248|ACTIVE_COMPARATOR|Standard|"1. The total daily calorie intake will be calculated using indirect calorimetry, considering the participant's current weight, age, sex, and physical activity level. 500 calories will be subtracted from the total calorie amount.~2. The dietary plan will have the following macronutrient distribution: 40% carbohydrates (\<10% simple carbohydrates), 20% protein, and 40% fats (6-11% polyunsaturated, 15-20% monounsaturated, and \<10% saturated).~3. The plan will consist of 3 meals with an isocaloric distribution, with each meal containing 33% of the total calories."
61994064|NCT01527188|EXPERIMENTAL|100IR|
61994065|NCT01527188|EXPERIMENTAL|300IR|
61994066|NCT01527188|EXPERIMENTAL|500IR|
61994067|NCT01527188|PLACEBO_COMPARATOR|Placebo|
61994068|NCT04724954|EXPERIMENTAL|Rehabilitation Therapy on Experimental Robotic Table and standard of care|"10 elderly 5 days or more post-CVA admitted to Kessler Institute for Rehabilitation/Kessler Foundation) for inpatient rehabilitation will be recruited for experimental group.~The investigators will also recruit the 10 caregivers of the experimental subjects. Both experimental and control groups will undergo standardized evaluations for motor function/impairment, cognition and emotive states."
62389420|NCT04552821||Sepsis complicated with moderate/severe ARDS|Patients who meet the criteria of sepsis-3, and also meet the criteria of Berlin diagnostic for moderate/severe ARDS
62389421|NCT05578040|EXPERIMENTAL|Group A: Left AH13 acupoint (left cervical vertebra)|Participants received sham auricular acupressure by adhesive patches without Vaccaria seed at the left auricular cervical vertebra acupoint and auricular acupressure Vaccaria seed at the left auricular cervical vertebra acupoint after 1 week. At each time, the skin surface temperature of the neck area will be recorded.
62561100|NCT02473627|EXPERIMENTAL|Period 2|"Period 2 Days 1 through 12 repeated doses of 400 mg DS-1971a administered orally bid .~On the days listed below, each probe substrate(s) will be coadministered with the morning dose of DS 1971a:~Day 8: single oral dose of 2.5 mg midazolam hydrochloride Day 9: single oral cocktail dose of 20 mg omeprazole, 15 mg pioglitazone hydrochloride, 500 mg tolbutamide and 150 mg bupropion"
62561101|NCT03807570|EXPERIMENTAL|Morus Alba L. extract|Morus Alba L. extract 30 ml/day for 12 weeks
62561102|NCT03807570|PLACEBO_COMPARATOR|Placebo|Placebo 30 ml/day for 12 weeks
62561103|NCT05839444|ACTIVE_COMPARATOR|BioPB-01|2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner.
62561104|NCT05839444|PLACEBO_COMPARATOR|Placebo|2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner.
62561105|NCT02673177|EXPERIMENTAL|Robot-assisted total mesorectal excision|Robot-assisted total mesorectal excision (RTME) for rectal cancer. Two different RTME procedures were chose to personalized patients. Generally, when the tumor located within 5-15cm from the anal verge, low anterior resection (LAR) was employed, and tumor located below 5cm, abdominoperineal resection (APR) was applied usually.
62561106|NCT02673177|ACTIVE_COMPARATOR|Laparoscopic total mesorectal excision|Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer was performed. The Urinary, sexual function and sphincter- preservation outcomes were evaluated.
62561107|NCT05474014|ACTIVE_COMPARATOR|superior trunk block|"Ultrasound guided superior trunk block with 10 ml % 0.25 bupivacaine~+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA (patient-controlled analgesia): 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg."
62561108|NCT05474014|ACTIVE_COMPARATOR|tramadol|400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA (patient-controlled analgesia): 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
62567734|NCT04185220|EXPERIMENTAL|2- Experimental Treatment: Dose Expansion|Interleukin-15 (IL-15) by continuous intravenous (CIV) infusion at the maximum tolerated dose (MTD) on days 1- 5 of each 28-day cycle (max 6 cycles) with mogamulizumab by intravenous (IV) infusion at a dose of 1 mg/kgdays 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle.
62389422|NCT05578040|EXPERIMENTAL|Group B: RIght AH13 acupoint (right cervical vertebra)|Participants received sham auricular acupressure by adhesive patches without Vaccaria seed at the right auricular cervical vertebra acupoint - and auricular acupressure Vaccaria seed at the right auricular cervical vertebra acupoint after 1 week. At each time, the skin surface temperature in the neck area will be recorded.
62389423|NCT04001426|EXPERIMENTAL|Monitoring during activation of the FemPulse System|Subjects will undergo non-invasive monitoring during activation of the FemPulse System.
62389424|NCT05686668||AASP|
62389425|NCT04429269||mammography and ultrasound|mammography and ultrasound screening
62567735|NCT04987320|EXPERIMENTAL|Olpasiran Dose A|Participants will be administered Olpasiran dose A as a subcutaneous injection.
61994069|NCT04724954|SHAM_COMPARATOR|Rehabilitation Therapy as part of Standard of Care|"10 elderly 5 days or more post-CVA admitted to Kessler Institute for Rehabilitation/Kessler Foundation) for inpatient rehabilitation will be recruited as a control group.~The investigators will also recruit the 10 caregivers of the control subjects. Both experimental and control groups will undergo standardized evaluations for motor function/impairment, cognition and emotive states."
62389426|NCT01038609|PLACEBO_COMPARATOR|Placebo|1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release) plus 1 placebo capsule (for morphine extended release), administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
62389427|NCT01038609|ACTIVE_COMPARATOR|Acetaminophen|1 dose of 1 placebo capsule (for morphine extended release) plus 1 acetaminophen tablet, administered once every 12 hours, and 1 dose of 1 acetaminophen tablet, administered once every 6 hours (for a total of 8 doses).
62389428|NCT01038609|ACTIVE_COMPARATOR|Morphine Extended Release|1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release) plus 1 morphine extended release capsule, administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
62389429|NCT01038609|ACTIVE_COMPARATOR|Morphine Extended Release / Acetaminophen|1 dose of 1 morphine extended release capsule plus 1 acetaminophen tablet, administered once every 12 hours, and 1 dose of 1 acetaminophen tablet, administered once every 6 hours (for a total of 8 doses).
62389430|NCT01038609|EXPERIMENTAL|Hydrocodone/Acetaminophen Extended Release|1 dose of 1 hydrocodone/acetaminophen extended release tablet plus 1 placebo capsule (for morphine extended release), administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
62389431|NCT05354115|OTHER|Sampling|"Every second participant will be instructed to blow their nose. Study personnel will then collect one nasal swab from both nostrils and two NP swabs, one from each nostril from each participant.~Nasal samples must always be collected prior to the Nasopharyngeal sampling. A minimum of 90 Flu A positive subjects, a minimum of 90 Flu B positive subjects and a minimum of 100 SARS-CoV-2 positive subjects will be enrolled. In addition, a minimum of 385 negative subjects will be enrolled."
62389432|NCT01597076|EXPERIMENTAL|60-240 mL/day|60 -240 mL/day dose group
62389433|NCT06412965||Rimegepant|Cohort of patients treated with rimegepant
62389434|NCT06412965||Triptans|Cohort of patients treated with triptans
62389435|NCT00635804|EXPERIMENTAL|Pt 1: MK-3281 100 mg BID (Panel A)|Healthy male participants in this Part I serial panel receive 100 mg MK-3281 orally twice daily (BID) for 10 consecutive days for a total daily dose administered of 200 mg. The evening (PM) dose of MK-3281 was not administered on Day 10.
62389436|NCT00635804|EXPERIMENTAL|Pt 1: MK-3281 200 mg BID (Panel B)|Healthy male participants in this Part I serial panel receive 200 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 400 mg. The PM dose of MK-3281 was not administered on Day 10.
62389437|NCT00635804|EXPERIMENTAL|Pt 1: MK-3281 400 mg BID (Panel C)|Healthy male participants in this Part I serial panel receive 400 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 800 mg. The PM dose of MK-3281 was not administered on Day 10.
62389438|NCT00635804|EXPERIMENTAL|Pt 1: MK-3281 800 mg BID (Panel D)|Healthy male participants in this Part I serial panel receive 800 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 10.
62389439|NCT00635804|EXPERIMENTAL|Pt 2: MK-3281 800 mg BID (Panel E)|Genotype (GT)1 HCV-infected male participants in this Part II serial panel receive 800 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 7.
62389440|NCT00635804|EXPERIMENTAL|Pt 2: MK-3281 800 mg BID (Panel F)|GT1a/GT1-nontypeable/GT3/GT1b HCV-infected male participants in this Part II serial panel receive 800 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 7.
62389441|NCT00635804|EXPERIMENTAL|Pt 2: MK-3281 1200 mg BID (Panel G)|GT1a (and/or GT1 nontypeable) and GT1b HCV-infected male participants in this Part II serial panel receive 1200 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 2400 mg. The PM dose of MK-3281 was not administered on Day 7.
62567736|NCT04987320|EXPERIMENTAL|Olpasiran Dose B|Participants will be administered Olpasiran dose B as a subcutaneous injection.
61994070|NCT02311491|EXPERIMENTAL|Ceramic Coated Orthodontic Archwire|Ceramic coated orthodontic archwires will be evaluated in a limited clinical study at the university of North Carolina to test their efficacy in early and intermediate stages of tooth straightening in orthodontic patients.
61994071|NCT02311491|NO_INTERVENTION|Control|The patients will receive the ordinary archwires. There is no intervention to the standard treatment.
61994072|NCT02439320|EXPERIMENTAL|Lasmiditan 100 mg|Oral tablet. Lasmiditan 100 mg plus placebo (to match 200 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
62389442|NCT00635804|PLACEBO_COMPARATOR|Placebo|Participants receive dose-matched placebo to MK-3281 orally BID for 7 or 10 consecutive days depending on randomization. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
62389443|NCT03955211|EXPERIMENTAL|Treatment Group 1|A single dose of HTX-011 administered via instillation into the surgical site.
62389444|NCT03955211|EXPERIMENTAL|Treatment Group 2|A single dose of HTX-011 administered via instillation into the surgical site and a scheduled non-opioid multimodal analgesic (MMA) regimen.
62389445|NCT01558206||Patients with impression of PTE|Those with signs and symptoms in favor of pulmonary thromboembolism.
62389446|NCT03843567|PLACEBO_COMPARATOR|Didactic Training|Training will be conducted in a classroom for those participants randomised to receive didactic training, with training provided via a PowerPoint (Microsoft Inc., Redmond, Washington, USA) presentation by an expert endoscopist. An endoscopist with extensive experience in optical characterisation using virtual chromoendoscopy reviewed all teaching material.
62567737|NCT00471224||Patients who have received drug.|Patients who have received drug.
62567738|NCT05759741|EXPERIMENTAL|MIYAIRI 588 group|4 tablets of MIYAIRI 588 were inserted into distal ileostomy once a week for 6 months.
62567739|NCT05759741|NO_INTERVENTION|control group|The anastomosis stoma was followed up monthly in the outpatient department
62567740|NCT02062060|ACTIVE_COMPARATOR|Abametapir Lotion 0.74% w/w|Single topical treatment administered to scalp and hair for 10 minutes. Applied at home by subject/caregiver.
62389447|NCT03843567|ACTIVE_COMPARATOR|Computer-based self-training|Participants randomised to the computer-based self-learning group will be given the same PowerPoint presentation as the didactic group and completed the training in a separate room. Participants completed training without feedback interaction.
62389448|NCT01767844|EXPERIMENTAL|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
62389449|NCT01767844|PLACEBO_COMPARATOR|Fruit powder drink|A regular fruit flavoured powder that has no benefits
62389450|NCT00513331||Algorithm #1|Patients without visable lesions
62389451|NCT00513331||Algorithm #2|Patients with a visable lesion that is less than 1cm
62389452|NCT00513331||Algorithm #3|Patients with a visable lesion greater than 1cm
62389453|NCT03434860|ACTIVE_COMPARATOR|probiotic|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day.
62389454|NCT03434860|PLACEBO_COMPARATOR|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day.
62389455|NCT01410331|EXPERIMENTAL|Cohort 1|Subjects will be randomized to receive either 4 mg of JVS-100 or placebo over 8 injections.
62389456|NCT01410331|EXPERIMENTAL|Cohort 2|Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 8 injections.
62389457|NCT01410331|EXPERIMENTAL|Cohort 3|Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 16 injections.
62389458|NCT01410331|EXPERIMENTAL|Cohort 4|Subjects will be randomized to receive either 16 mg of JVS-100 or placebo over 16 injections.
62389459|NCT05445999|EXPERIMENTAL|tES treatment|The stimulation type is cathode direct current stimulation and alternating current stimulation. The maximum stimulation current of a single channel is not more than 3mA. The frequency of electrical stimulation was 0-10Hz; DLPFC was preferentially selected for electrical stimulation, and other candidate brain regions were: orbitofrontal cortex premotor cortex, motor cortex, sensorimotor cortex, auditory cortex, posterior parietal cortex, and cerebellar cortex. The brain state changes caused by each stimulus parameter combination were compared with sleep state to determine the optimal stimulus parameters. Each cycle of stimulation was 2 weeks, once a night on weekdays, a total of 10 times
62389460|NCT01066819||Cohort|Participants chronically infected with the hepatitis C virus including genotypes 1 to 6.
62389461|NCT02719028|PLACEBO_COMPARATOR|Placebo|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C \> 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
62389462|NCT02719028|EXPERIMENTAL|Antroquinonol 50 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C \> 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
62389463|NCT02719028|EXPERIMENTAL|Antroquinonol 100 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C \> 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
62389464|NCT02719028|EXPERIMENTAL|Antroquinonol 150 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C \> 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
62389465|NCT02180035|EXPERIMENTAL|Symbiotic & Nutritional intervention|Symbiotic (dietary fibers + probiotic bacteria) 6g sachet twice daily for 6 months, dietary prescription and nutritional counseling
62389466|NCT02180035|PLACEBO_COMPARATOR|Maltodextrin & Nutritional intervention|Maltodextrin (placebo for symbiotic) 6g sachet twice daily for 6 months, dietary intervention and nutritional counseling.
62389467|NCT01302340|ACTIVE_COMPARATOR|Delta-THC|THC will be administered twice daily during three consecutive days per treatment block(0.75 or 1.5 mg twice daily)
62389468|NCT01302340|PLACEBO_COMPARATOR|placebo|Placebo will be administered twice daily during three consecutive days per treatment block.
62389469|NCT04071899||Patients|patients with RBD
62389470|NCT04071899||Bedpartners|Subjects which are the bedpartners of patients with RBD
62389471|NCT03463720||Extremity wound|Patients with extremity wounds. Infected and not infected patients will be compared.
62389472|NCT04256642|ACTIVE_COMPARATOR|Intrathecal morphine|
62389473|NCT04256642|EXPERIMENTAL|Erector Spinae Plane Block|
62389474|NCT05551195|OTHER|WB001 with adjunctive Treatment as Usual|Participants randomized to the WB001 + TAU group will be asked to download and use the study application.
62389475|NCT05551195|OTHER|Educational Control (ED001) with adjunctive Treatment as Usual|Participants randomized to the ED001 + TAU group will be asked to download and use the study application.
62389476|NCT00535236|EXPERIMENTAL|Autologous HCT-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
62389477|NCT00535236|PLACEBO_COMPARATOR|Autologous HCT-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
62389478|NCT00535236|EXPERIMENTAL|Allogeneic HCT-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
62389479|NCT00535236|PLACEBO_COMPARATOR|Allogeneic HCT-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
62567741|NCT02062060|PLACEBO_COMPARATOR|Vehicle Lotion|Single topical treatment administered to scalp and hair for 10 minutes. Applied at home by subject/caregiver.
61994073|NCT02439320|EXPERIMENTAL|Lasmiditan 200 mg|Oral tablet. Lasmiditan 200 mg plus placebo (to match 100 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
62561109|NCT03101631|EXPERIMENTAL|CASE ARM|"This is a three cohorts arm with intervention (CGA):~* Nutritional Assessment: Mini Nutritional Assessment (MNA)~* Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.~* Cognitive Assessment: Mini-Mental State Examination (MMSE-30)~* Psychological status: Geriatric Depression Scale (GDS)~* Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)~* Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)~* Age~* Haemoglobin~* Creatinine Clearance (CrCl)~* Presence of Geriatric Syndromes"
62561110|NCT03101631|NO_INTERVENTION|CONTROL ARM|This is a three cohorts arm with no intervention
62561111|NCT05227391|EXPERIMENTAL|Letrozole-stimulated group|
62561112|NCT05227391|ACTIVE_COMPARATOR|Hormone replacement treatment group|
62561113|NCT01028963|PLACEBO_COMPARATOR|Placebo|
61994074|NCT02439320|PLACEBO_COMPARATOR|Placebo|Oral tablet. Placebo tablets match lasmiditan 100 mg and lasmiditan 200 mg. One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
62561114|NCT01028963|ACTIVE_COMPARATOR|Active control|
62561115|NCT01028963|EXPERIMENTAL|Active Study Medication (Group C)|CCX140-B
62561116|NCT01028963|EXPERIMENTAL|Active Study Medication (Group D)|CCX140-B
62561117|NCT03908996|EXPERIMENTAL|Profile by Sanford|All enrolled subjects are assigned to participate in the Profile by Sanford weight management program for a period of 12 months..Subjects will follow the Profile program and will be provided a nutritional plan which includes consuming Profile nutritional supplements and other food items. Subjects will work with a Profile lifestyle coach to develop a personalized nutrition plan, discuss their activity, and lifestyle behavior. Subjects on this research study will follow the Profile by Sanford weight loss and management plan as all Profile members. All enrolled subjects will collect and return a fecal specimen prior to beginning the Profile by Sanford weight management plan and again after 6 months of participation.
62561118|NCT00134680|EXPERIMENTAL|Letrozole & Trastuzumab|Letrozole 2.5 mg tablets daily and Trastuzumab 2 mg/kg by IV weekly
62561119|NCT01362335||patients, that are having a routine surgical procedure.|
62561120|NCT02946476||HFrEF|patients with heart failure and reduced ejection fraction
62561121|NCT02946476||HFpEF|patients with heart failure and preserved ejection fraction
62561122|NCT04357769||Patients|Individuals aged 18-70 years with a diagnosis of severe mental disorder (schizophrenia or psychosis spectrum disorder; bipolar disorder; major depressive disorder) who were in a condition of psychopathological compensation, had their last clinical evaluation at the University of Naples Federico II outpatient unit of Psychiatry during January-February 2020, were not positive or suspected positive for COVID-19, and were under strict quarantine
62561123|NCT04357769||Controls (General Population)|Individuals aged 18-70 years who had not a psychiatric condition nor were positive or suspected positive for COVID-19 and were under strict quarantine (e.g. not getting out for work)
62389480|NCT00535236|EXPERIMENTAL|STM-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
62389481|NCT00535236|PLACEBO_COMPARATOR|STM-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
62561124|NCT04357769||First-degree Relatives|Individuals aged 18-70 years who were first-degree relatives and caregivers of an individual included in the Patients group, who had not a psychiatric condition nor were positive or suspected positive for COVID-19 and were under strict quarantine
62561125|NCT05479786||Ectopic pregnancy|Women with diagnosed tubal ectopic pregnancy
62561126|NCT04310202||Single-arm|In this single-arm study, the only interventions compared to routine clinical practice are the completion of two patient questionnaires (APHAB and GBI) and additional follow-up visits after surgery.
62561127|NCT06490848|ACTIVE_COMPARATOR|Transradial approach group|The diagnostic angiography was performed by radial approach.
62561128|NCT06490848|ACTIVE_COMPARATOR|Trasfemoral approach group|The diagnostic angiography was performed by femoral approach.
62561129|NCT03288155|EXPERIMENTAL|Flavonoid rich cocoa|Dark cocoa beverage rich in flavonoids
62561130|NCT03288155|PLACEBO_COMPARATOR|Low flavonoid cocoa|A control cocoa beverage low inn flavonoids
62561131|NCT01753999|ACTIVE_COMPARATOR|Standard CPAP|Use of a standard CPAP (continuous positive airway pressure) device with constant pressure for 4 weeks to improve breathing during sleep
61994075|NCT05604768||Normal parturient group|20 normal parturients who had undergone antenatal examination and delivery in Beijing Ditan Hospital were fully informed of the risks and volunteered to join the study and signed the informed consent form.
61994076|NCT05604768||Pregnant women with threatened premature delivery group|20 pregnant women with threatened preterm labor who had undergone antenatal examination and delivery in Beijing Ditan Hospital were fully informed of the risks and volunteered to join the study and signed the informed consent form.
62168313|NCT00522678|EXPERIMENTAL|Cohort B|In Cohort B, subjects will be randomized (3:1) to receive once daily doses of GW685698X (600 mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
62561132|NCT01753999|ACTIVE_COMPARATOR|CPAP - Flex|Use of CPAP-Flex (continuous positive airway pressure) device with decreased pressure during expiration for 4 weeks to improve breathing during sleep
62561133|NCT01839708|EXPERIMENTAL|Lifestyle Counseling|Intervention group: in addition to usual WIC care, watch the DVDs at home, complete action plan worksheets, call in to moderated (MI) group discussions.
62561134|NCT01839708|NO_INTERVENTION|No Lifestyle Counseling|Comparison group: usual WIC care; read printed materials at home
62769091|NCT04830124|EXPERIMENTAL|Advanced Cutaneous Melanoma with Less Frequent IV Nemvaleukin Dosing + Pembrolizumab (Cohort 4)|Patients with unresectable and/or metastatic cutaneous melanoma. Patients must not have received prior systemic anticancer therapy for unresectable or metastatic melanoma. Prior adjuvant and/or neoadjuvant PD-\[L\]1 treatments are allowed if there is at least 6 months between the last dose and date of recurrence.
62561135|NCT02266784|EXPERIMENTAL|Contingency Management (CM)|ADHD (N=20) \& CTRL (N=20). Participants will earn compensation, based upon smoking abstinence via a Contingency Management (CM) system. This level of compensation will increase by the same amount each visit based upon abstinence. In addition, escalating bonus payments will be available for evidence of continued abstinence. The first 10 visits will be daily weekdays. The following 9 visits will be over three weeks. The final 3 treatment visits will occur weekly. The 2nd \& 3rd type visits CM payments will be based upon monitoring participants' cotinine levels. A missed visit or elevated CO level will lead to 1) no CM payment for that day; 2) resetting the contingencies such that the next CO sample that is below the criterion will result in payment equal to the first day. If there is a lapse, participants' contingencies will be reinstated at their previous highest level post 3 abstinent days. Also follow-up visits at 3 and 6 months.
62561136|NCT02266784|OTHER|Treatment as Usual|ADHD (N=20). Transdermal nicotine skin patches (i.e. Habitrol) will be used along with supportive counseling in the treatment as usual groups. Visit schedules will coincide with the visit schedules for the CM groups (daily visits for 1st 2 weeks, 3X weekly visits for weeks 3-5, 1x weekly visit for weeks 6-8). A standard regimen of nicotine replacement with which the study team has experience will be used: four weeks of 21 mg/d beginning on the QD, two weeks of 14 mg/d and two weeks of 7 mg/d. Also follow-up visits at 3 and 6 months.
62561137|NCT01629628|EXPERIMENTAL|Adalimumab|
62561138|NCT01629628|ACTIVE_COMPARATOR|6-mercaptopurine|
62561139|NCT03427242|EXPERIMENTAL|treatment arm|oral apatinib
62561140|NCT05550233|EXPERIMENTAL|DCB treatment|drug-coated balloon in PCI
62561141|NCT05550233|OTHER|DES treatment|drug-eluted stent in PCI
62561142|NCT02347813|OTHER|Delayed Intervention|After enrollment, subjects will be observed for 24 weeks for skin cancer tumors. Tumors will be appropriately treated as per standard of care. Then they will begin the pioglitazone regimen for 24 more weeks, during which time skin cancer tumors will be observed and appropriately treated as per standard of care.
62769092|NCT03662659|EXPERIMENTAL|BMS-986213 + investigator's choice chemotherapy|BMS-986213 + XELOX or BMS-986213 + FOLFOX or BMS-986213 + SOX
62769093|NCT03662659|EXPERIMENTAL|Nivolumab + investigator's choice chemotherapy|Nivolumab + XELOX or Nivolumab + FOLFOX or Nivolumab + SOX
61994077|NCT01828372|OTHER|additional blood withdrawals|"Theoretical anyone with taking a drug of interest (see list of substances and metabolites of interest) can join this trial. But we turn mainly our attention to patient groups who are excluded in modern drug approval studies."
62389482|NCT00535236|EXPERIMENTAL|HM-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
62389483|NCT00535236|PLACEBO_COMPARATOR|HM-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
62389484|NCT00535236|EXPERIMENTAL|HIV-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
62389485|NCT00535236|PLACEBO_COMPARATOR|HIV-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
62389486|NCT01677520||18-30 yrs, 31-50 yrs, 51-70 yrs|No intervention
62389487|NCT04312958||Trauma patients|Trauma patients experiencing traumatic injuries requiring a full trauma team response.
62389488|NCT04312958||Liver transplant patients|Patients undergoing liver transplant surgery.
62389489|NCT04153799|EXPERIMENTAL|EGFR CAR-T|Group: 3 dose levels
62769094|NCT02763436|NO_INTERVENTION|"Group immediate cord clamping (ICC)"|The cord will be clamped within the first minute after birth, afterwards the newborn will be placed on the mothers chest/abdomen. This corresponds to the present routine approach in Graz.
61994078|NCT05050058||Neonates born to diabetic mothers|
62389490|NCT00529594|PLACEBO_COMPARATOR|Control Group|Patients who received placebo
62389491|NCT00529594|ACTIVE_COMPARATOR|Treatment Group|Patients who received etoricoxib 120 mg
62389492|NCT05419596||Major Urologic Surgery Group|Elder patients who undergo major urologic surgery will be investigated for the change in genomic protein that are related to cognition. These proteins are APOE, phosphatidyl-inositol-binding clathrin assembly protein, CR1 (complement receptor 1) , ATP-binding cassette transporter, IL6, Triggering receptor expressed on myeloid cells2 (TREM2)
62389493|NCT03293706|ACTIVE_COMPARATOR|CHO Control 1 Glucose|25 g glucose
62389494|NCT03293706|ACTIVE_COMPARATOR|CHO Control 2 Glucose|25 g glucose
62389495|NCT03293706|EXPERIMENTAL|CHO Experimental 1 Slowly Digested|25 g slowly-digested carbohydrate blend
62389496|NCT03293706|EXPERIMENTAL|CHO Experimental 2 Digestion Resistant|25 g digestion-resistant carbohydrate blend
62389497|NCT03293706|EXPERIMENTAL|CHO Experimental 3 Low Sugar|25 g low sugar carbohydrate blend
62389498|NCT03293706|EXPERIMENTAL|CHO Experimental 4 Maltodextrin|25 g maltodextrin
62389499|NCT04645628|EXPERIMENTAL|All subjects will have an MRI examination|
62389500|NCT03026556||Dabigatran vs. Rivaroxaban|OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, rivaroxaban (new oral anticoagulant or NOAC).
62769095|NCT02763436|ACTIVE_COMPARATOR|"Group physiological based cord clamping (PBCC)"|"The newborn will be placed on mother's chest/abdomen with intact cord. After the newborn has established stable breathing efforts (continuous regular breathing pattern and SpO2 values \>25th percentile from Dawson et al reference range for oxygen saturation -minute 2\>58%, minute 3\>67%, minute 4\>76%) the cord is clamped. This will need 2 - 4 minutes."
62769096|NCT01299402|EXPERIMENTAL|Soulera Herbal Blend|
61994079|NCT05050058||Neonates born to non-diabetic mothers (control)|
62561143|NCT02347813|OTHER|Immediate Intervention|Subjects will begin the 24 week pioglitazone regimen immediately after enrollment, during which time skin cancer tumors will be observed and appropriately treated as per standard of care. After 24 weeks of drug, subjects will be observed for 24 weeks for skin cancer tumors. Tumors will be appropriately treated as per standard of care.
62561144|NCT00929370|EXPERIMENTAL|GSK1018921|Glycine Transporter-1 inhibitor to modulate the NMDA receptor.
62561145|NCT02191774||Gestational length up to 63 days|Medical abortion at home using 200 mg of Mifepristone orally at the clinic followed by 0.8 mg Cytotec vaginally at home 48 hours later
62561146|NCT02191774||Gestational length 64-70 days|Medical abortion at home using 200 mg of Mifepristone orally at the clinic followed by 0.8 mg Cytotec vaginally at home 48 hours later
61994080|NCT00733109|ACTIVE_COMPARATOR|excision of the lesion|
62561147|NCT03514732|EXPERIMENTAL|Novanuit® Triple Action|2 capsules of Novanuit® Triple Action once daily for 2 weeks, 30 minutes to 1 hour before bedtime.
62561148|NCT03525704|EXPERIMENTAL|Saline Solution Enriched|Saline Solution enriched with electrolytes and PH balanced to mimic normal tears
62561149|NCT03525704|ACTIVE_COMPARATOR|Saline Rinse Solution|Saline Solution .9% NaCL
62561150|NCT03606343|EXPERIMENTAL|Open Trial|Group based treatment targeting academic executive functioning skills such as organization, planning, and study skills. Likely to be 7 90-minute sessions attended weekly by parents and teens
62561151|NCT04153461|ACTIVE_COMPARATOR|MINI-PERCUTANEOUS NEPHROLITHOTOMY|MINIPERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 15 FR, LASER DUSTING OF THE STONE, NEPHROSTOMY TUBE 12 FIXATION
62561152|NCT04153461|ACTIVE_COMPARATOR|STANDARD PERCUTANEOUS NEPHROLITHOTOMY|PERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 24 FR, ULTRASOUND OR LITHOCLAST DISINTEGRATION OF THE STONE AND FORCEPS EXTRACTION OF THE FRAGMENTS, NEPHROSTOMY TUBE 22 FIXATION
62561153|NCT01131169|EXPERIMENTAL|relapsed multiple myeloma|This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma.
62561154|NCT01131169|EXPERIMENTAL|high-risk multiple myeloma|This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma.
62561155|NCT03694509|EXPERIMENTAL|Breakfast tea with full fat milk|Black breakfast tea (200ml) with full fat milk (50ml) - The volume of milk added to the tea is at the discretion of the patient but the remaining milk must be consumed afterwards.
62561156|NCT03694509|ACTIVE_COMPARATOR|Water|Water 250ml
62561157|NCT01831635||Myeloproliferative neoplasm case|"Patients with Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) will be recruited based on the WHO diagnostic criteria.~Exclusion Criteria~* younger than 18 years old.~* where the clinician/General Practitioner (GP) does not provide consent.~* incapable of giving informed consent.~* physically or cognitively incapable of completing the questionnaire.~* too ill to participate.~We will assess whether a pen (branded, non-branded or none), a £10 cheque and/or a charity branded trolley token will affect uptake rates in the study."
62561158|NCT01831635||General Practice Control|"GP controls will be randomly selected and frequency matched to the distribution of cases by 5-year age band, geographic location (Belfast and Southampton) and gender.~The following patient groups will be excluded. Those:~* younger than 18 years old.~* where the clinician/GP does not provide consent.~* incapable of giving informed consent.~* physically or cognitively incapable of completing the questionnaire.~* too ill to participate.~We will assess whether a pen (branded, non-branded or none), a £10 cheque (at study completion) and/or a charity branded trolley token will affect uptake rates in the study."
61994081|NCT00733109|NO_INTERVENTION|espontaneous regression|
61994082|NCT05678556|EXPERIMENTAL|Experimental Arm|all2GETHER is an HIV prevention and relationship education program designed for young MSM. all2GEHTER consists of 3 online didactic skills modules and 2 videoconference-based skills coaching sessions The 3 online modules focus on developmental skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
62389501|NCT03026556||Dabigatran vs. Apixaban|OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, or apixaban (new oral anticoagulant or NOAC).
62561159|NCT01831635||Non-blood relative or family Control|"Recruitment of 100 non-blood relative/friend controls will be undertaken by asking cases to pass on a flyer to up to 2 or 3 non-blood relatives/friends aged 18 years or older.~We will assess whether a pen (branded, non-branded or none) and/or a £10 cheque (at study completion) will affect uptake rates in the study. Only a limited number of trolley tokens were available so not assessed in this group."
62769097|NCT01299402|PLACEBO_COMPARATOR|Placebo Blend|
62168314|NCT00522678|EXPERIMENTAL|Cohort C|InIn Cohort C, subjects will be randomized (3:1) to receive once daily doses of GW685698X (800 mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
62561160|NCT03380065|ACTIVE_COMPARATOR|Late deflation of TR band|"1. first 3ml of air removed from the TR band after TWO hour of sheath removal. Then, 3ml of air removed every 15minutes.~2. Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 3ml of air is pushed back into the device until bleeding stops. Then wait for another 15minutes for the next deflation."
62561161|NCT03380065|ACTIVE_COMPARATOR|Early deflation of TR band|"1. First 2ml of air is removed from the TR band ONE hour after sheath removal. Then, 2ml of air is removed every 30minutes.~2. Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then push the 2ml of air back into the device until bleeding stops. Then wait for another 30minutes for the next deflation."
62561162|NCT02051582||Surgeons using fluoroscopy with laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
62561163|NCT02051582||Surgeons using fluoroscopy without laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
62561164|NCT06254443|OTHER|Oral PEG group|Following the administration protocol recommended by the Chinese expert consensus for PEG, a 3 L PEG regimen is employed. The regimen involves segmented intake, with 1 L taken 10-12 hours before the intestinal examination and an additional 2 L taken 4-6 hours before the examination on the day of the procedure.
62561165|NCT06254443|OTHER|Enema group|Enema is administered using either normal saline or 1% soapy water for cleansing until the effluent is clear of fecal debris, or until a total volume of 3000 ml of enema solution has been administered. The enema should be initiated 4-6 hours before colonoscopy, with the dosage and frequency of incremental enemas determined based on the patient's tolerance. The final enema administration should be completed no later than 10 minutes before the scheduled colonoscopy.
62561166|NCT02252835|EXPERIMENTAL|Arhalofenate with febuxostat (PK cohort)|
62561167|NCT02252835|EXPERIMENTAL|Arhalofenate with febuxostat (non-PK cohort)|
62561168|NCT03645473|EXPERIMENTAL|Monarch device settings assessment group|"Patients with cystic fibrosis who have experience with the Monarch Airway Clearance System will be enrolled in the study.~The duration of subject participation is approximately 4 - 6 hours during 1 study visit. Each subject will receive therapy with The Monarch® System at multiple frequency and intensity combinations as defined in the Study procedures."
62561169|NCT02111798|PLACEBO_COMPARATOR|Placebo/Abstinence Initiation|In week 2 participants will randomly assigned to receive twice daily capsules filled with placebo powder. At the end of week 6, participants who did not provide \>/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
62561170|NCT02111798|ACTIVE_COMPARATOR|Bupropion XL/Abstinence Initiation|In week 2 participants will randomly assigned to receive bupropion 150mg capsules filled with placebo powder. At the end of week 6, participants who did not provide \>/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
62561171|NCT02111798|PLACEBO_COMPARATOR|Placebo/Relapse Prevention|In week 2 participants will randomly assigned to receive twice daily capsules filled with placebo powder. At the end of week 6, participants who did provide \>/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
62561172|NCT02111798|ACTIVE_COMPARATOR|Bupropion XL/Relapse Prevention|In week 2 participants will randomly assigned to receive bupropion 150mg capsules filled with placebo powder. At the end of week 6, participants who did provide \>/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
62561173|NCT05452460|EXPERIMENTAL|Mindfulness training group|Participants in the mindfulness training (MT) group will engage in a 60-min session of mindfulness program per week for 8 weeks.
62561174|NCT05452460|NO_INTERVENTION|Waitlist control group|Participants in the waitlist control group will be required to maintain regular life and routine training. Once the participants in control group finished the whole experiment, they will be invited to participate in the MBPP program for eight weeks.
62561175|NCT04745533||SARS-CoV2 contacts|Subjects considered close contacts of COVID-19 patients according to the definition of the Ministry of Health in the health area of Cáceres.
62561176|NCT02185196|ACTIVE_COMPARATOR|Vitamin D3|Vitamin D3, Doses form: 20,000 IU vitamin D3 in children \<6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days.
62561177|NCT02185196|PLACEBO_COMPARATOR|Miglyol-oil|20,000 IU Miglyol-oil in children \<6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days.
61994083|NCT05678556|NO_INTERVENTION|Control Arm|Participants will receive no intervention, but have access to HIV prevention resources from the CDC website and national databases. We will also assess exposure to other interventions that may be naturally occurring in participants' local context, which can be used to describe the sample and as a covariate (as necessary).
61994084|NCT06539117|EXPERIMENTAL|EARLY FEEDING GROUP|In this group, participants were encouraged to commence oral sips of 150 millilitres of water from 6 hours post-caesarean delivery by the staff nurse. Thereafter, they were given semi-solid diet (250 milliliter of pap) from the 12th hour, and subsequently solid diet (a plate of well- cooked rice) by the trained nursing staff.
61994085|NCT06539117|ACTIVE_COMPARATOR|TRADITIONAL FEEDING GROUP|Participants in this group were managed traditionally by restricting commencement of oral fluid intake until after 24 hours. They were allowed intake of oral sips of 150 millilitres of water after 24 hours post-caesarean section, thereafter, 250 millilitres of pap and subsequently solid diet (a plate of well-cooked rice)
62168315|NCT01516502|ACTIVE_COMPARATOR|laser to acupoint|
62389502|NCT01832753|PLACEBO_COMPARATOR|Treatment Phase: Months 6-18|"Subject who are found to have SCH at the 6-month visit will be randomized to receive either levothyroxine or placebo during months 6-12. Levothyroxine dose will be between 0.5 - 1 mcg/kg/day. There will be 1 blood draw visit at month 7.5 (6 weeks after randomization) and 1 study visit at month 12 that will provide the opportunity for dose adjustments if needed.~From months 12-18, all subjects will receive levothyroxine. Levothyroxine dose will be between 0.5 - 1 mcg/kg/day. There will be one blood draw visit at month 13.5 that will provide the opportunity for dose adjustments if needed."
62389503|NCT01832753|NO_INTERVENTION|Observation Phase: Months 0-6|"Subjects will be observed for the first 6 months of the study to ensure that the subclinical hypothyroidism is persistent. Subjects who do not have SCH at 6 months will not proceed to the treatment phase.~Subjects that have TSH \>10 mIU/L during the 6 month Observational Phase will not be considered subclinical and will not qualify to continue the study. They will be referred to an endocrinologist for treatment."
62769098|NCT02455076|ACTIVE_COMPARATOR|Exenatide inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels \> 140 mg/dL per the sliding scale.
62769099|NCT02455076|ACTIVE_COMPARATOR|Exenatide plus glargine insulin inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide twice daily and glargine once daily. Glargine insulin will be given once daily at the same time. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels \> 140 mg/dL per the sliding scale.
62769100|NCT02455076|ACTIVE_COMPARATOR|Basal bolus regimen inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive the Basal Bolus Regimen with Glargine and Rapid-Acting Insulin Analogs. Patients treated with insulin previously will receive 80% of total home daily insulin dose as the basal bolus. Half of the total daily dose will be given as glargine and half as rapid-acting insulin analogs. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels \> 140 mg/dL per the sliding scale.
62389504|NCT05872243|EXPERIMENTAL|WMN group|Active rTMS will be delivered to the tailored stimulation site within the working memory network.
62389505|NCT05872243|EXPERIMENTAL|DMN group|Active rTMS will be delivered to the tailored stimulation site within the default mode network.
62389506|NCT05872243|SHAM_COMPARATOR|sham WMN group|Sham rTMS will be delivered to the tailored stimulation site within the working memory network.
62769101|NCT02455076|ACTIVE_COMPARATOR|Exenatide outpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels \> 140 mg/dL per the sliding scale.
62769102|NCT02455076|ACTIVE_COMPARATOR|Insulin Only|Patients with Type 2 Diabetes will be treated with Insulin only
62769103|NCT01589913|EXPERIMENTAL|Treatment as usual plus remote care|"The same treatment as described under treatment as usual plus participation in the intervention ICD-Forum."
62769104|NCT01589913|NO_INTERVENTION|Treatment as usual|Standard information provided by hospitals on ICD-technology as well as consequences of ICD-implantation plus medical aftercare including cardiology appointments at 1, 3, and 6 months, and one year after ICD-implantation.
62769105|NCT02482402|EXPERIMENTAL|Inhaled Iloprost|2 inhalations per day of 2.5 µg Iloprost \[Ventavis®\] per inhalation to a maximum of 6 inhalations per day of 5 µg Iloprost per inhalation (total daily dose 5 - 30 µg) will be performed according to each patient's health condition.
62769106|NCT02482402|PLACEBO_COMPARATOR|Placebo inhaled|2 to a maximum of 6 inhalations per day of placebo solution (PLA) will be performed. Study medication will be inhaled using the portable, hand-held I-Neb AAD vibrating mesh technology nebulizer system.
62769107|NCT01119677|EXPERIMENTAL|Group 1|No dose titration
62769108|NCT01119677|EXPERIMENTAL|Group 2|Fast dose titration
62769109|NCT01119677|EXPERIMENTAL|Group 3|Slow dose titration
62168316|NCT01516502|SHAM_COMPARATOR|sham laser to acupoint|
62389507|NCT05872243|SHAM_COMPARATOR|sham DMN group|Sham rTMS will be delivered to the tailored stimulation site within the default mode network.
62389508|NCT00634933|EXPERIMENTAL|Arm 1|Consists of Arms 1a and 1b
62389509|NCT00634933|EXPERIMENTAL|Arm 2|Consists of Arms 2a and 2b
62389510|NCT00634933|PLACEBO_COMPARATOR|Arm 3|Consists of Arms 3a and 3b.
62389511|NCT03863964|ACTIVE_COMPARATOR|plasma TXA and ROTEM test at 3 minutes|Blood test
62389512|NCT03863964|ACTIVE_COMPARATOR|plasma TXA and ROTEM test at 7 minutes|Blood test
62389513|NCT03863964|ACTIVE_COMPARATOR|plasma TXA and ROTEM test at 15 minutes|Blood test
62389514|NCT03863964|ACTIVE_COMPARATOR|plasma TXA and ROTEM test at 30 minutes|Blood test
62389515|NCT03863964|ACTIVE_COMPARATOR|plasma TXA and ROTEM test at 1 hour|Blood test
62389516|NCT03863964|ACTIVE_COMPARATOR|plasma TXA and ROTEM test at 1.5 hours|Blood test
62389517|NCT03863964|ACTIVE_COMPARATOR|plasma TXA and ROTEM test at 2 hours|Blood test
62389518|NCT03863964|ACTIVE_COMPARATOR|plasma TXA and ROTEM test at 2.5 hours|Blood test
62389519|NCT03863964|ACTIVE_COMPARATOR|plasma TXA and ROTEM test at 3 hours|Blood test
62389520|NCT03863964|ACTIVE_COMPARATOR|plasma TXA and ROTEM test at 3.5 hours|Blood test
62389521|NCT03863964|ACTIVE_COMPARATOR|plasma TXA and ROTEM test at 4 hours|Blood test
62389522|NCT03863964|ACTIVE_COMPARATOR|plasma TXA and ROTEM test at 4.5 hours|Blood test
62389523|NCT03863964|ACTIVE_COMPARATOR|plasma TXA and ROTEM test at 5 hours|Blood test
62389524|NCT02533011||24 Hours|HBP lab test performed 24 hours after meeting sepsis inclusion criteria.
62389525|NCT02533011||48 Hours|HBP lab test performed 48 hours after meeting sepsis inclusion criteria.
62389526|NCT02533011||72 Hours|HBP lab test performed 72 hours after meeting sepsis inclusion criteria.
62389527|NCT03083613|EXPERIMENTAL|Raltitrexed and Paclitaxel|"All patients receive the combination therapy of Raltitrexed and Paclitaxel for a maximum of 6 cycles~Raltitrexed:3mg/m2,d1 Paclitaxel:80mg/m2,d1,d8,~Eery 3 weeks"
62389528|NCT02364362|EXPERIMENTAL|Famitinib + docetaxel|Low, medium and high dose of famitinib and 60 mg/m\^2 docetaxel every 3 weeks
62389529|NCT04220645|ACTIVE_COMPARATOR|Standard of care|Hospitalised patients with hep C are referred to the outpatient clinic at the medical department following discharge.
62561178|NCT05800470|EXPERIMENTAL|Neurofeedback combined with MI (NFB-MI)|"Participants in both NFB-MI and MI groups will receive a total of 12 sessions of training in 3 weeks. At the first, 4th and 8th session, NFB-MI group will receive fNIRS-based neurofeedback during MI training in lab setting. Prior to each NFB-MI session during lab visit, participants will watch a video of a person executing balance tasks and walking in different environments. The explicit instruction will be given by the researcher. One trial of MI training consists of 30 seconds of imagery tasks and 20 seconds of rest, and the trial will be repeated 12 times. The training will take approximately 10 minutes. Visual feedback with a thermometer based on the changes of HbO concentration will be displayed on the screen during NFB-MI training.~In each training session, actual balance and gait tasks will be practiced for 20 min. The difficulty of the tasks will be modified individually for each participant."
62769110|NCT05948618|EXPERIMENTAL|Embodied Conversational Agent|The ECA systems compromises 1) a smartphone based ECA patient interface; 2) clinician authoring tool, to enable new measurement systems to be rapidly configured 3) clinician and patient data visualizations; and 4) a central server with relation database, administrative user interfaces and ability to send asynchronous notifications to users' smartphones.
62769111|NCT05948618|ACTIVE_COMPARATOR|RedCap Survey|An internet-based measure will use PROMIS Profile measures which will include depression, anxiety, fatigue, pain intensity and interference, sleep disturbance, physical function and satisfaction with social role
62769112|NCT02272179|EXPERIMENTAL|ASAP Treatment and Brite|Participants in the experimental arm received the ASAP treatment, during their transition from inpatient to outpatient care, as well as the Brite app for distress tolerance/emotion regulation and safety planning.
62769113|NCT02272179|ACTIVE_COMPARATOR|Treatment as Usual|Participants in this grouping were studied as they proceed from inpatient to outpatient care, per usual treatment protocols at each site. Participants completed paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
62769114|NCT02342080|EXPERIMENTAL|Interventional group|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period. For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
62389530|NCT04220645|EXPERIMENTAL|Opportunistic treatment|Hospitalised patients with hep C are opportunistically and immediately treated when hospitalized for acute care in psychiatric, addiction treatment or somatic wards
62389531|NCT02557828|ACTIVE_COMPARATOR|palpation|participants who are randomized to have radial arterial cannulation via palpation technique
62389532|NCT02557828|ACTIVE_COMPARATOR|ultrasound|participants who are randomized to have radial arterial cannulation via a new ultrasound technique
62389533|NCT00864968|EXPERIMENTAL|A|Nabumetone 750 mg tablets, single dose
62389534|NCT00864968|ACTIVE_COMPARATOR|B|Nabumetone 750 mg tablets, single dose
62389535|NCT02902406||normal oral mucosa|
62389536|NCT02902406||oral precancerous lesion or oral cancer|
62389537|NCT03891199|NO_INTERVENTION|Control|Traditional THA.
62389538|NCT03891199|ACTIVE_COMPARATOR|Intervention|Robotic-arm assisted THA.
62389539|NCT05023239|SHAM_COMPARATOR|control group|patients will receive sham block by 10 ml of normal saline (5 mL in each side) as a control.
62389540|NCT05023239|EXPERIMENTAL|UG-SZM Group|The patients will be receive bilateral Ultrasound-Guided Suprazygomatic Maxillary (UG-SZM) Nerve Blocks 10 mL of a local anesthetic mixture composed of 0.25% plain bupivacaine
62389541|NCT02825589|EXPERIMENTAL|BIA-guided|Assessment of target dry weight guided by using bioelectrical impedance analysis (BIA).
62389542|NCT02825589|NO_INTERVENTION|Standard clinical guided|Assessment of target dry weight guided by clinical evaluation eg. jugular venous pressure, blood pressure, edema etc.
62389543|NCT03872739|EXPERIMENTAL|distilled water|Oral distilled water at the rate of 3 mL/kg/h rate during undergoing enhanced computed tomography examination before 1-2 and after 4-6 hours
62389544|NCT03872739|PLACEBO_COMPARATOR|Saline|intravenous saline hydration at the rate of 1 mL/kg/h rate during undergoing enhanced computed tomography examination before and after 12 hours
62389545|NCT01842282|EXPERIMENTAL|Amlexanox|
62389546|NCT00149227|ACTIVE_COMPARATOR|Non-ARB|'Non-ARB' was defined as Conventional anti-hypertensive treatment except for ARB and ACEIs
62389547|NCT00149227|EXPERIMENTAL|Valsartan|Valsartan add-on treatment
62389548|NCT03489460|ACTIVE_COMPARATOR|Receive sleep health messages + GAD|Procedures will be delivered to users of the GAD, individuals who have opted in via their smartphone application, to receive messages about various areas of health.
62389549|NCT03489460|ACTIVE_COMPARATOR|Sleep message No GAD|For two weeks participants agree to receive sleep health messages and wear the GAD
62769115|NCT02496923|EXPERIMENTAL|High flow nasal oxygen therapy (Optiflow™)|In patients randomised to receive high flow nasal oxygen therapy (HFNO) the gas flow through the HFNO will be calculated for each patient, based on their body characteristics, and comfort level. The standard starting flow rate will be 30 L/min, and this will be adjusted up or down between a range of 20-50 L/min with the aim of achieving both patient comfort and a respiratory rate of less than 16 breaths per minute.
62389550|NCT01503567||Subjects 6 to 18 years old without inhibitors|
62389551|NCT01503567||Subjects 6 to 18 years old with inhibitors|
62389552|NCT01503567||Subjects above18 years old without inhibitors|
62389553|NCT01503567||Subjects above 18 years old with inhibitors|
62389554|NCT04600115|EXPERIMENTAL|MRI vs.PET with/without Cardiac disease|Adenosine Regadenoson O-15 Labeled radioactive water MRI PET Imaging
62389555|NCT01488175|ACTIVE_COMPARATOR|with tourniquet|
62389556|NCT01488175|PLACEBO_COMPARATOR|without tourniquet|
62389557|NCT04048434|NO_INTERVENTION|Standard of care (SOC)|
62389558|NCT04048434|EXPERIMENTAL|Cyotosorb|
62389559|NCT06303011|EXPERIMENTAL|Group: A|TENS on sacral areas with Abdominal Massage
62389560|NCT06303011|ACTIVE_COMPARATOR|Group: B|TENS on para sacral area with Abdominal Massage
61994086|NCT05768477||Chronic pain patients|Chronic pain patients with a dominant nociceptive pain mechanism, a dominant neuropathic pain mechanism and a dominant nociplastic pain mechanism. They will receive different treatments: Consultations, Interventions (injections, denervations...), Baxter therapy and interdisciplinary treatment.
61994087|NCT05798416|ACTIVE_COMPARATOR|Exercise under inhalation of CO2|Subjects will perform shuttle walk test under inhalation of low concentration of CO2 supplied by a novel device at high altitude.
61994088|NCT05798416|PLACEBO_COMPARATOR|Exercise under inhalation of ambient air|Subjects will perform shuttle walk test under inhalation of ambient air at high altitude.
62389561|NCT05767437|EXPERIMENTAL|Abdominal drawing-in maneuver exercise, afterward Sham therapy(conventional physiotherapy)|Participants first received Abdominal drawing-in maneuver exercise 2 times a week for 4 weeks. Each session is 40 minutes for additional 10 min with conventional therapy. Afterward a washout period of one month, they then received sham therapy (conventional therapy_release pain or upper limb mobilization) 2 times a week for 4 weeks. Each session is 40 minutes.
62769116|NCT02496923|ACTIVE_COMPARATOR|Standard oxygen therapy (Hudson face mask or nasal prongs)|Patients randomised to receive standard oxygen therapy will be fitted with a soft face mask or nasal prongs, and the oxygen flow titrated to provide pulse oxygen saturation of at least 95% (93% for those at risk of hypercapnic respiratory failure such as confirmed COPD patients and morbidly obese patients). The standard oxygen therapy group will have their oxygen gas flow reduced to the minimum level which provides saturations of at least 95% (93% for those at risk of hypercapnic respiratory failure such as patients with confirmed COPD and morbidly obese patients).
62769117|NCT05690750||Case|Cirrhosis with GAVE
62769118|NCT05690750||Control|Cirrhosis without GAVE
62769119|NCT04569994|EXPERIMENTAL|Part 1|Healthy volunteers will receive either NNC0363-0845 or placebo
62389562|NCT05767437|EXPERIMENTAL|Sham therapy(conventional physiotherapy), afterward Abdominal drawing-in maneuver exercise|Participants first received sham therapy(release pain or upper limb mobilization)2 times a week for 4 weeks. Each session is 40 minutes. Afterward a washout period of one month, they then received Abdominal drawing-in maneuver exercise 2 times a week for 4 weeks. Each session is 40 minutes for additional 10 min with conventional therapy
62389563|NCT01508182|EXPERIMENTAL|Treatment Sequence AB|Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 1 followed by Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between Treatment Periods.
62389564|NCT01508182|EXPERIMENTAL|Treatment Sequence BA|Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 1 followed by Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between Treatment Periods.
62389565|NCT05973825|EXPERIMENTAL|Immuno-virological evaluation of persons living with HIV|Leucapheresis will be performed in HIV positive people making white blood cells available for in depth virological and immunological evaluation
62389566|NCT00430703|EXPERIMENTAL|1|Patients with severe traumatic brain injury
62389567|NCT00430703|EXPERIMENTAL|2|Healthy volunteers
62389568|NCT03273933|ACTIVE_COMPARATOR|10 children with DragONE only|
62769120|NCT04569994|EXPERIMENTAL|Part 2|Participants with T1D will receive either NNC0363-0845 or insulin degludec
62769121|NCT04569994|EXPERIMENTAL|Part 3|Participants with T1D will receive NNC0363-0845
62769122|NCT03813381|EXPERIMENTAL|Intervention Arm (IA)|Patients randomized in the Intervention Arm (IA) will be given personalized diet based on calorie and protein restriction. Calorie restriction will be up to 600 kcal below patients' energy requirements and the amount of protein will be 0.8g of protein/Kg body weight mostly form plant-origin food.
62769123|NCT03813381|NO_INTERVENTION|Control Arm (CA)|Participants in the CA will be given information about the importance of a healthy lifestyle in reducing the risk of cancer and will receive a leaflet based on WCRF/AICR recommendations.
62769124|NCT01936493||Females with uterine fibroids|Participants will be females age of 18 or older who have be diagnosed with uterine leiomyoma. Study Subjects will be asked if mothers or siblings also have diagnosis of uterine leoimyoma (either past or present diagnosis) and these family members will be invited to participate in this trial. All participants will provide blood samples for serum aliquots for hormonal analysis and genomic DNA analysis, and will answer a baseline genetic epidemiology questionnaire.
62769125|NCT02786680|EXPERIMENTAL|stroop test in condition DBS off|Condition 1 : On Med /Off Stim
61994089|NCT01063764|EXPERIMENTAL|Levetiracetam|Open-label, single-arm
61994090|NCT04189458|EXPERIMENTAL|Multimodal exercise program|The experimental group intervention will attend the multimodal exercise program. The program integrates 3 sessions / week of 60 minutes on alternated days. The multimodal exercise program includes exercises promoting simultaneous motor and cognitive stimulation.
62389569|NCT03273933|EXPERIMENTAL|10 children with DragONE and SmartOne|
62389570|NCT05196074||Acute hypoxemic respiratory failure patients on VV-ECMO|
62389571|NCT04209140||bipolar I disorders who initiate lithium treatment|
62769126|NCT02786680|ACTIVE_COMPARATOR|stroop test in condition DBS on|Condition 2 : On Med /On Stim
62769127|NCT05703594|OTHER|Dokuz Eylul University|Dokuz Eylul University Clinic
61994091|NCT04189458|NO_INTERVENTION|Control Group|Usual care. After the study, it will be offered the opportunity to integrate a similar exercise program for the control group (CG) participants.
62389572|NCT01049360|EXPERIMENTAL|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID)
62389573|NCT01049360|EXPERIMENTAL|Aclidinium 400 μg / formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID)
62769128|NCT04375176||Tested positive for SARS-CoV-2|"Patients, tested positive for SARS-CoV-2, will be recruited in E.R. of the Ospedale Di Circolo - ASST Settelaghi Teaching Hospital in Varese."
62769129|NCT02995551|EXPERIMENTAL|Arthroscopy|Arthroscopic meniscal repair or resection will be conducted at the discretion of the operating surgeon (this cannot be determined before the surgeon has visual confirmation about the exact knee pathology and extend of the meniscal tear by scope).
62769130|NCT02995551|ACTIVE_COMPARATOR|Exercise and Education|Patients allocated to exercise therapy and education will participate in a 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear. Furthermore, they will participate in a patient education program developed through interviews with pilot study participants, from our experiences from the Good Life with osteoArthritis in Denmark (GLA:D) program for patients with knee and hip pain. Both the exercise and education will take place in a number of private physiotherapy clinics associated with the GLA:D program, specifically trained to supervise and lead the treatment in this study.
62769131|NCT04056780||Septic group|The septic group will be considered as patients that fulfill the 2018 ICM definition of PJI.
62769132|NCT04056780||Aseptic group|The aseptic group will be considered as patients that don't fulfill the 2018 ICM definition of PJI.
61994092|NCT01814306|ACTIVE_COMPARATOR|Supreme|Supreme LMA
62389574|NCT01049360|EXPERIMENTAL|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID)
62389575|NCT01049360|ACTIVE_COMPARATOR|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily
62561179|NCT05800470|ACTIVE_COMPARATOR|Motor imagery|"Participants in both NFB-MI and MI groups will receive a total of 12 sessions of training in 3 weeks. At the first, 4th and 8th session, MI group will practice kinesthetic MI under supervision in lab setting. Prior to each NFB-MI session during lab visit, participants will watch a video of a person executing balance tasks and walking in different environments. The explicit instruction will be given by the researcher. One trial of MI training consists of 30 seconds of imagery tasks and 20 seconds of rest, and the trial will be repeated 12 times. The training will take approximately 10 minutes.~In each training session, actual balance and gait tasks will be practiced for 20 min. The difficulty of the tasks will be modified individually for each participant. The researcher will ensure the safety of executing each task during lab visit. Participants will be asked to practice at home and be checked by the daily phone call."
62561180|NCT02534051|ACTIVE_COMPARATOR|Clinical care pathway|The intervention is the clinical care pathway designed by investigators, informed by the national guideline co-authored by one of the team, and supplemented by the review of the literature
62561181|NCT02534051|NO_INTERVENTION|Usual Care|The control group will receive the usual prenatal care.
62561182|NCT00595894||1 CLEAR participants - African Americans with early rheumatoid arthritis|CLEAR enrollees include African American patients with early rheumatoid arthritis, as defined using ACR criteria
62769133|NCT02450968|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone 4 mg capsules, twice per day, orally
62769134|NCT02450968|PLACEBO_COMPARATOR|Placebo|Placebo capsules twice per day, orally
62769135|NCT02679365|EXPERIMENTAL|group a|This arm will have lower segment cesarean section done with double locking technique for closure of Rectus Sheath.
62389576|NCT01049360|PLACEBO_COMPARATOR|Placebo|Placebo twice-daily
62769136|NCT02679365|ACTIVE_COMPARATOR|group b|This arm will have lower segment cesarean section done with continuous non-locking technique for closure of rectus sheath.
62769137|NCT05219019||PD patients who have elected DBS|Ten individuals with moderate to advanced Parkinson's disease who have elected to undergo deep brain stimulation (DBS) of the subthalamic nucleus (STN) or internal globus pallidus (GPi) as standard of care for management of Parkinson's disease tremor and/or motor complications
62561183|NCT00595894||2 VARA participants - male veterans with established rheumatoid arthritis|VARA enrollees will include male veterans with established RA diagnosed using ACR criteria
62561184|NCT03440242||JJVC Contact Lens (Asymptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the JJVC Contact Lens arm based on their habitual lenses and then stratified to an Asymptomatic group based on wear time responses during the baseline assessment.
62561185|NCT03440242||JJVC Contact Lens (Symptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the JJVC Contact Lens arm based on their habitual lenses and then stratified to a Symptomatic group based on wear time responses during the baseline assessment.
62561186|NCT03440242||Marketed Contact Lens (Asymptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the Marketed Contact Lens arm based on their habitual lenses and then stratified to an Asymptomatic group based on wear time responses during the baseline assessment.
62561187|NCT03440242||Marketed Contact Lens (Symptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the Marketed Contact Lens arm based on their habitual lenses and then stratified to a Symptomatic group based on wear time responses during the baseline assessment.
61994093|NCT01814306|ACTIVE_COMPARATOR|Proseal|Proseal LMA
61994094|NCT01463371|NO_INTERVENTION|Control|without azithromycin
61994095|NCT01463371|ACTIVE_COMPARATOR|azithromycin|treatment with azithromycin during three months
61994096|NCT00605774|EXPERIMENTAL|1|Hyperinsulinemic euglycemic glucose clamps x 2 on Day 1 Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion on Day 2
61994097|NCT00605774|EXPERIMENTAL|2|Day 1 euglycemic exercise period x 2 Day 2 hyperinsulinemic euglycemic glucose clamp with epinephrine infusion
62168317|NCT01516502|ACTIVE_COMPARATOR|laser to trigger point|
62389577|NCT01494909|EXPERIMENTAL|Ensure plus|Ensure sip feeds during 6 hours. After 2 hours pancreatic intake
62389578|NCT05389761|EXPERIMENTAL|Enzyme DAO administration|DAO enzyme supplementation for 6 months
62389579|NCT05389761|PLACEBO_COMPARATOR|Placebo administration|Placebo supplementation for 6 months
62389580|NCT03802331|EXPERIMENTAL|Test Treatment|fed
62389581|NCT03802331|EXPERIMENTAL|Reference Treatment|fasted
61994098|NCT03462212|OTHER|Standard treatment|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d 1 q 21 for 6 cycles + Bevacizumab 15 mg/kg d 1 q 21 days for 22 cycles (in combination and maintenance)
62389582|NCT04854122|EXPERIMENTAL|Combined exercise intervention Down syndrome|The exercise intervention will last 12 weeks and will consist of a supervised combined aerobic and resistance training program with a frequency of 3 days/week.In the exercise sessions, the participant will work with the trainer on their strength, balance and aerobic endurance. Each session consists of 10 min of strength exercises (Foundational Exercise), 10 min of Hip Strengthening, 10 min of Vestibular and Balance Exercise, and 20 min of Aerobic Exercise, and starts with a warming up and ends with stretching/cooling down. Each new exercise will be introduced in easy steps and practiced until the participant is comfortable executing it.
62769138|NCT06380127|EXPERIMENTAL|Exercise|Progressive concurrent exercise training
62769139|NCT06380127|NO_INTERVENTION|Usual Care|The usual care
62769140|NCT04375397|EXPERIMENTAL|Ibrutinib 420 mg + SOC|420 mg ibrutinib administered once daily as three hard gelatin capsules (140 mg each) with approximately 240 mL of water for up to 28 days and supportive care (standard-of-care, SOC)
62769141|NCT04375397|PLACEBO_COMPARATOR|Placebo + SOC|Three hard gelatin placebo capsules administered once daily with approximately 240 mL of water for up to 28 days and supportive care (standard-of-care, SOC)
62769142|NCT04664582|EXPERIMENTAL|Sentinel Lymph Node Biopsy|Lymphoscintigraphy will be ordered alongside usual pre-operative investigations. Intra-operatively, the excision of the primary tumor will be done with the aim of histologically clear margins and appropriate closure as per routine practice at the operating surgeon's discretion. The patients are injected with technicium 99 pre-operatively and a sentinel lymph node biopsy will be performed with a handheld gamma probe.
62769143|NCT04664582|NO_INTERVENTION|Standard of Care|These patients will be treated with standard of care, which is wide local excision of the primary tumor without performance of sentinel lymph node biopsy, if not indicated.
62769144|NCT00875940||Group 1|Patients having both Tc-99m perfusion scan and echocardiogram.
62769145|NCT02097342|EXPERIMENTAL|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
62769146|NCT02097342|PLACEBO_COMPARATOR|Placebo|Tablet Placebo per oral, once daily will be given to 10 patients for 6 months
62769147|NCT02097342|ACTIVE_COMPARATOR|Voglibose|Tablet Voglibose (0.2mg) per oral, thrice daily (with meals) will be given to 10 patients for 6 months
62769148|NCT03255759|ACTIVE_COMPARATOR|Molecular dx arm|Positive blood cultures are tested using a molecular ID system in addition to the standard of care (biochemical identification)
62769149|NCT03255759|NO_INTERVENTION|Standard of care arm|Positive blood cultures are treated as per normal lab protocol (biochemical identification)
62769150|NCT05740319|EXPERIMENTAL|FMT|Participants will be given FMT through oral capsules or nasojejunal tube once a month for three months.
62769151|NCT00130923|EXPERIMENTAL|Risperidone Long Acting|Risperidone Long Acting; aka Risperdal Consta; injectable form
62769152|NCT00130923|ACTIVE_COMPARATOR|Oral Risperidone|Oral Risperidone; aka Risperdal; oral form
62769153|NCT01369680|EXPERIMENTAL|Ketamine 0.25 mg/kg/dose|The first three subjects were administered 0.25 mg/kg/dose oral ketamine.
62769154|NCT01369680|EXPERIMENTAL|Ketamine 0.5 mg/kg/dose|The second group of three subjects were administered 0.5 mg/kg/dose oral ketamine.
62769155|NCT01369680|EXPERIMENTAL|Ketamine 1 mg/kg/dose|The third group of three subjects were administered 1 mg/kg/dose oral ketamine.
62769156|NCT01369680|EXPERIMENTAL|Ketamine 1.5 mg/kg/dose|The fourth group of three subjects were administered 1.5 mg/kg/dose oral ketamine.
62769157|NCT06171074|EXPERIMENTAL|CM310|CM310, Subcutaneous injection
62769158|NCT01913704|PLACEBO_COMPARATOR|Placebo device|"The placebo comparator is a placebo version of the active device which is a system to deliver oxygen from an oxygen generator topically to the wound bed via a proprietary device.~The device will be applied to the wound and attached to the placebo oxygen generator and the generator switched on at the time of enrolment. Secondary dressings will then be applied. The device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
62769159|NCT01913704|ACTIVE_COMPARATOR|NatroxTM Device|"A system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM oxygen delivery device will be applied to the wound and attached to the NatroxTM oxygen generator which will be switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
62769160|NCT01496105|ACTIVE_COMPARATOR|lidocaine spray 10%|
62769161|NCT01496105|PLACEBO_COMPARATOR|Saline|
61994099|NCT03462212|EXPERIMENTAL|Carboplatin + Paclitaxel + Bevacizumab + Rucaparib|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d1 q 21 days for 6 cycles + Bevacizumab 15 mg/kg d1 q 21 for 22 cycles (in combination and maintenance) + Rucaparib at the dose defined by the Phase I study continuously for 2 years (Rucaparib only in maintenance)
61994100|NCT03462212|EXPERIMENTAL|Carboplatin + Paclitaxel + Rucaparib|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d1 q 21 days for 6 cycles + Rucaparib 600 mg BID continuously for 2 years (Rucaparib only as maintenance).
62389583|NCT04854122|SHAM_COMPARATOR|Usual care Down Syndrome|The control condition consists of usual activities.
62769162|NCT04645745|EXPERIMENTAL|myo-inositol plus alpha-lactalbumin|Patients were treated with 2 g myo-inositol, 50 mg alpha-LA and 200 mcg of Folic Acid twice a day for 6 months. Controls were the same patients at baseline (t0)
62769163|NCT02140541||Blood eosinophil count ≤ 400/µl|
62769164|NCT02140541||Blood eosinophil count > 400/µl|
62769165|NCT01659255|EXPERIMENTAL|Tirabrutinib 20 mg Once Daily (CLL)|Participants with relapsed/refractory chronic lymphocytic leukaemia (CLL) received tirabrutinib 20 mg once daily.
62561188|NCT04633317|EXPERIMENTAL|Group A Regimen|Randomized 80 subjects diagnosed with pneumonia of carbapenem-resistant gram negative bacteria will received inhaled colistimethate sodium generated by a pneumatic nebulizer or a vibrating mesh nebulizer every 12 hours for 7-10 days
61994101|NCT04884711||Interviews: Older people living at the Leach Court (Brighton, UK).|Older adults who will be enrolled at the Leach Court (Brighton, UK) as a part of the INNOVATEDIGNITY project will be involved in 1:1 open ended interviews.
62389584|NCT04854122|NO_INTERVENTION|Reference group without Down syndrome|This reference group of age- and sex-matched inactive individuals without Down syndrome will undergo the same baseline testing as the other groups but without intervention or post-intervention measures.
62389585|NCT05652361|EXPERIMENTAL|Additional visualisation of surgical assistance during surgery|
62389586|NCT05855382||COVID-19|Adults with at least one positive SARS-CoV-2 RT-qPCR test
62389587|NCT03820388|EXPERIMENTAL|Propofol Group|Propofol 2 mg/kg
62389588|NCT03820388|EXPERIMENTAL|Etomidate Group|Etomidate 0.3 mg/kg
62389589|NCT03820388|EXPERIMENTAL|Propofol plus Etomidate Group|Propofol 1 mg/kg plus Etomidate 0.15 mg/kg
62561189|NCT04633317|NO_INTERVENTION|Group B Regimen|Randomized 40 subjects diagnosed with pneumonia of carbapenem-resistant gram negative bacteria will received inhaled colistimethate sodium intravenous every 12 hours for 7-10 days
62561190|NCT01637116||autoimmune chronic spontaneous urticaria|Patients with chronic spontaneous urticaria with a positive ASST, who also test positive in a cell activating assay (BHRA OR CD 63 activation of healthy donor basophils) and who exhibit anti-FcεRI and/or anti-IgE autoantibodies (=autoimmune chronic spontaneous urticaria).
62561191|NCT01637116||autoreactive, non-autoimmune chronic spontaneous urticaria|Patients with chronic spontaneous urticaria with a positive ASST, who test negative in cell activation assay or who do not exhibit anti-FcεRI or anti-IgE autoantibodies (=autoreactive, non-autoimmune chronic spontaneous urticaria)
62561192|NCT01637116||non-autoreactive chronic spontaneous urticaria|Patients with chronic spontaneous urticaria and a negative ASST (= non-autoreactive chronic spontaneous urticaria)
62561193|NCT04806737|ACTIVE_COMPARATOR|IMP|Teriflunomide 14 mg tablets, first 7 days 5 tablets once pr day, thereafter 1 pr day for another 6 days.
62561194|NCT04806737|PLACEBO_COMPARATOR|Placebo|Sham tablets
62561195|NCT05495945|EXPERIMENTAL|Dorsolateral prefrontal cortex (DLPFC)|
62561196|NCT05495945|EXPERIMENTAL|Anterior insula cortex (AIC)|
62561197|NCT05495945|EXPERIMENTAL|Central thalamus (CT)|
62561198|NCT05495945|ACTIVE_COMPARATOR|Sham control|
62561199|NCT05664360||ED patients|
61994102|NCT04884711||Focus Group Discussions: Older People Living at the Leach Court (Brighton, UK)|10 older people who have previously participated in the interview stage will be involved in two focus group discussions in a group of 5 participants each to co-design digital health technologies that are 'dignity' sensitive and aims to resolve the barriers older people face in technology adoption.
61994103|NCT04381845|OTHER|psychiatric patient|patients who are hospitalized in psychiatric department
62168318|NCT01516502|SHAM_COMPARATOR|sham laser to trigger point|
62389590|NCT02185040|EXPERIMENTAL|CC-220 0.3mg Every Other Day (QOD)|Part 1: CC-220 0.3mg capsules by mouth every other day (QOD)
62389591|NCT02185040|EXPERIMENTAL|CC-220 0.3mg Every Day (QD)|"* Part 1: CC-220 0.3mg capsules by mouth every day (QD)~* ATEP: CC-220 0.3 mg capsules by mouth every day (QD)"
62389592|NCT02185040|EXPERIMENTAL|CC-220 0.6mg/0.3mg alternating dose QD|"* Part 1: CC-220 0.6 mg and 0.3mg capsules PO on alternating days~* ATEP:CC-220 0.6 mg and 0.3 mg capsules PO on alternating days"
62389593|NCT02185040|EXPERIMENTAL|CC-220 0.6mg QD|Part 1: CC-220 0.6mg capsules by mouth QD
62389594|NCT02185040|PLACEBO_COMPARATOR|Placebo QD|Part 1: Identically matching placebo capsules PO QD
62389595|NCT03674645|EXPERIMENTAL|MRI|MRI exam performed on 200 healthy volunteers
62389596|NCT05199389|EXPERIMENTAL|PBM1 group|The patients allocated to the first PBM-group will receive six PBM sessions of 6 J/cm² over three weeks (2x/week).
62389597|NCT05199389|EXPERIMENTAL|PBM2 group|The patients allocated to the first PBM-group will receive six PBM sessions of 8 J/cm² over three weeks (2x/week).
62561200|NCT03649672|EXPERIMENTAL|Awake calibration|The dominant arm of the patient
62561201|NCT03649672|ACTIVE_COMPARATOR|Asleep calibration|The non dominant arm of the patient
62561202|NCT04775160|NO_INTERVENTION|Control group|The control group will be monitored using smartphone-based active and passive Ecological Momentary Assessment through the MEmind and eB2 mobile applications, and will receive treatment as usual, which will consist of psychiatric follow-up (scheduled appointments with their psychiatrist) in an outpatient Secondary Suicide Prevention Programme, with predetermined clinical reviews according to the Brief Intervention Contact recommendations (1, 2, 4, 7 and 11 weeks, and 4, 6, 9 and 12 months)
62561203|NCT04775160|EXPERIMENTAL|Intervention group|The intervention group will receive an Ecological Momentary Intervention called SmartSafe, will be monitored using smartphone-based active and passive Ecological Momentary Assessment through the MEmind and eB2 mobile applications, and their treatment as usual, which will consist of psychiatric follow-up (scheduled appointments with their psychiatrist) in an outpatient Secondary Suicide Prevention Programme, with predetermined clinical reviews according to the Brief Intervention Contact recommendations (1, 2, 4, 7 and 11 weeks, and 4, 6, 9 and 12 months)
62561204|NCT01161069|ACTIVE_COMPARATOR|PF-03049423|Cohorts 1 through 3 were healthy young adult volunteers; cohorts 4 and 5 were healthy elderly adult volunteers
62561205|NCT01161069|PLACEBO_COMPARATOR|Drug|Placebo in oral solution, given once daily for 14 days
62561206|NCT04584801||COPD Patients|"Development Phase Any adult (≥18 years old) who has been diagnosed with COPD guide GOLD criteria (FEV1/FVC ratio post bronchodilator \<0.70)~* Cohort A (N=50): COPD stage 1~* Cohort B (N=50): COPD stage 2~* Cohort C (N=50): COPD stage 3~* Cohort D (N=50): COPD stage 4"
62561207|NCT04584801||Healthy Smoker Subjects|• Cohort E (N=50): Healthy Smokers (≥35 years old, current or ex-smoker with a history of ≥10 pack-years (20 cigarettes smoked per day for 1 year)
62168319|NCT00871143|EXPERIMENTAL|CBT specific for BDD|This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.
62389598|NCT01731951|EXPERIMENTAL|Arm A: Imetelstat 9.4 mg/kg (Myelofibrosis [MF])|Participants with MF regardless of spliceosome mutation status or presence of ring sideroblasts received imetelstat 9.4 milligram per kilogram (mg/kg), intravenously (IV) as 2-hour infusion on Day 1 of each 21-day cycle in Core Phase up to 9 cycles. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
62389599|NCT01731951|EXPERIMENTAL|Arm B: Imetelstat 9.4 mg/kg as Induction + Maintenance (MF)|Participants with MF regardless of spliceosome mutation status or presence of ring sideroblasts received imetelstat 9.4 mg/kg, IV as 2-hour infusion on Days 1, 8, and 15 of 21-day cycle in Cycle 1 followed by 9.4 mg/kg on Day 1 of each 21-day cycle up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
62389600|NCT01731951|EXPERIMENTAL|Arm D: Imetelstat 9.4 mg/kg (Blast-phase MF/Acute Myeloid Leukemia)|Participants with blast-phase myelofibrosis/acute myeloid leukemia (MF/AML) received imetelstat 9.4 mg/kg, IV as 2-hour infusion weekly on Days 1, 8, 15, 22 of a 28-day cycle up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
62389601|NCT01731951|EXPERIMENTAL|Arm E: Imetelstat 7.5 - 9.4 mg/kg (MF [with Spliceosome Mutation or Ring Sideroblasts])|Participants with MF and spliceosome mutations or ring sideroblasts present received 2 cycles (Cycles 1-2) of imetelstat 7.5 mg/kg, IV as 2-hour infusion on Day 1 of a 28-day cycle followed by maintenance therapy with the same regimen or the possibility of dose escalation to imetelstat 9.4 mg/kg weekly if response to the initial dose was insufficient up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
62389602|NCT01731951|EXPERIMENTAL|Arm F: Imetelstat 7.5 - 9.4 mg/kg (MF [without spliceosome mutation and ring sideroblasts])|Participants with MF without spliceosome mutations or ring sideroblasts present received 2 cycles (Cycles 1-2) of imetelstat 9.4 mg/kg, IV as 2-hour infusion on Day 1 of a 28-day cycle followed by maintenance therapy with the same regimen or imetelstat 7.5 mg/kg twice weekly on Days 1, 3 for 2 cycles of 28-day cycle (Cycles 3-4) followed by imetelstat 7.5 mg/kg 3-times-weekly on Days 1, 3, 5 of Cycles 5 and beyond of 28-day cycle up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
62389603|NCT01731951|EXPERIMENTAL|Arm G: Imetelstat 7.5 - 9.4 mg/kg (MDS/MPN or MDS with Spliceosome Mutations or Ring Sideroblasts)|Participants with either myelodysplastic syndromes/ myeloproliferative neoplasm (MDS/MPN) or MDS and spliceosome mutations or ring sideroblasts present received 2 cycles of 28-day cycle (Cycles 1-2) of imetelstat 7.5 mg/kg, IV as 2-hour infusion on Day 1 of a 28-day cycle followed by maintenance therapy with the same regimen or the possibility of dose escalation to imetelstat 9.4 mg/kg weekly if response to the initial dose was insufficient up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
62389604|NCT05430724|ACTIVE_COMPARATOR|Grup E|Patients given esmolol infusion
62389605|NCT05430724|ACTIVE_COMPARATOR|Grup N|Patients given nicardipine infusion
62389606|NCT00701064|EXPERIMENTAL|Bright Light Exposure|Bright Light (30 min/day)
62389607|NCT00701064|PLACEBO_COMPARATOR|Negative Ion Generator|Negative Ion Generator (30 min/day)
62389608|NCT05986409|EXPERIMENTAL|opaque black tape covering part of the light source|10 wards were randomly selected as the intervention group (opaque black tape covering part of the light source).
62389609|NCT05986409|NO_INTERVENTION|no intervention|another 10 wards were selected as the control group (no intervention)
62389610|NCT04058860|OTHER|Study Patients|Patients undergoing open heart surgery with minimal invasive extracorporeal circulation (MiECC) according to accepted indications
62389611|NCT03054311|EXPERIMENTAL|Lifestyle Matters intervention|
62389612|NCT01820169|EXPERIMENTAL|Single arm|
62769166|NCT01659255|EXPERIMENTAL|Tirabrutinib 40 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 40 mg once daily.
62769167|NCT01659255|EXPERIMENTAL|Tirabrutinib 80 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily.
62769168|NCT01659255|EXPERIMENTAL|Tirabrutinib 160 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily.
62769169|NCT01659255|EXPERIMENTAL|Tirabrutinib 320 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily.
62769170|NCT01659255|EXPERIMENTAL|Tirabrutinib 400 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily.
62769171|NCT01659255|EXPERIMENTAL|Tirabrutinib 500 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily.
62769172|NCT01659255|EXPERIMENTAL|Tirabrutinib 600 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily.
62389613|NCT06204003|EXPERIMENTAL|Dose Escalation|When participants start the CBD, they will be started on a low dose of CBD, beginning at 5 mg CBD/kg body mass, and then increased by 5 mg/kg every 2-weeks until 30 mg CBD/kg body mass is taken.
62389614|NCT01726309||Stage IV CRC|
62389615|NCT01726309||Stage IV NSCLC|
62389616|NCT02427412|ACTIVE_COMPARATOR|IA Tranexamic acid + IV Tranexamic Acid|3 gram of Tranexamic acid diluted into 30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.
62389617|NCT02427412|PLACEBO_COMPARATOR|IA Saline Water + IV tranexamic Acid|30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.
62389618|NCT01503528|ACTIVE_COMPARATOR|Motor Sparing Nerve Block|Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
62389619|NCT01503528|EXPERIMENTAL|Peri-Articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by peri-articular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
62389620|NCT04553796||diabetic participants|HBA1C : 6.5% or higher Fasting Plasma Glucose : 126 mg/dl or higher Oral Glucose Tolerance Test : 200 mg/dl or higher Random Plasma Glucose Test : greater than or equal to 200 mg/dl
62561208|NCT05341219|EXPERIMENTAL|light needle therapy|The study participants will receive 12 sessions of light needle therapy within 4 weeks using a gallium aluminum arsenide Physiolaser olympic (maximal power, 60mW; wavelength, 655 nm; area of probe, 0.008 cm2; power density, 7.5 W/cm2; pulsed-wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). Those in the experimental group received a total 135 J of energy delivered from 6 light needles being placed between LU7 and LU9. The light needle therapy was applied to each point for 15 min.
62561209|NCT05341219|SHAM_COMPARATOR|sham light needle therapy|The study participants will receive 12 sessions of sham light needle therapy, without any laser output (no stimulation), within 4 weeks using a gallium aluminum arsenide Physiolaser olympic. Those in the control group received 0 J of energy delivered from 6 light needles being placed between LU7 and LU9 for 15 min.
62561210|NCT03995641|NO_INTERVENTION|Surgery Alone|Patient will receive sacrospinous ligament suspension surgery without any additional interventions
62561211|NCT03995641|EXPERIMENTAL|Surgery Plus Trigger Point Injection|Patient will have sacrospinous ligament suspension procedure with addition of a trigger point injection (9cc of 0.5% marcaine and 1 cc kenalog) over area of suture placement
62769173|NCT01659255|EXPERIMENTAL|Tirabrutinib 300 mg Twice Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily.
62769174|NCT01659255|EXPERIMENTAL|Tirabrutinib 20 mg Once Daily (NHL)|Participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) received tirabrutinib 20 mg once daily.
62769175|NCT01659255|EXPERIMENTAL|Tirabrutinib 40 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 40 mg once daily.
62769176|NCT01659255|EXPERIMENTAL|Tirabrutinib 80 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 80 mg once daily.
62389621|NCT04553796||prediabetic participants|HBA1C : 5.7% to 6.4% Fasting Plasma Glucose : 100 mg/dl to 125 mg/dl Oral Glucose Tolerance Test : 140 mg/dl to 199 mg/dl
62389622|NCT04553796||non diabetic participants|HBA1C : less than 5.7% Fasting Plasma Glucose : less than 100 mg/dl Oral Glucose Tolerance Test : less than 140 mg/dl
62389623|NCT02127970|EXPERIMENTAL|Single-Dose Dalbavancin|Single-dose of dalbavancin 1500 mg intravenous (IV) infusion over 30 minutes on Day 1 followed by dalbavancin-matching placebo IV infusion over 30 minutes on Day 8 for participants with creatinine clearance (CrCl) ≥30 mL/min or with CrCl \<30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl \<30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin dose was 1000 mg.
62389624|NCT02127970|EXPERIMENTAL|Two-Dose Dalbavancin|Two-dose regimen of dalbavancin 1000 mg IV infusion over 30 minutes on Day 1 followed by 500 mg IV infusion over 30 minutes on Day 8 for participants with CrCl ≥30 mL/min or with CrCl \<30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl \<30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin doses were 750 mg on Day 1 and 375 mg on Day 8.
62769177|NCT01659255|EXPERIMENTAL|Tirabrutinib 160 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 160 mg once daily.
62769178|NCT01659255|EXPERIMENTAL|Tirabrutinib 320 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily.
61994104|NCT00129129|EXPERIMENTAL|MenHibrix Group|Subjects in the Group were followed during the entire study period, from Day 0 up to study end 6 months post fourth dose vaccinationDuring Primary Phase (Study 101858), subjects in this group, aged 6-12 weeks at enrolment, received 3 doses of Menhibrix™ co-administered with Pediarix™ and Prevnar™ (at Day 0 and Months 2 and 4). During Fourth-Dose Phase (Study 102015), subjects primed with 3 doses of Menhibrix™ during the Primary Phase received one dose of Menhibrix™ and one concomitant dose of Prevnar™ at Month 10-13. During Primary Phase, Menhibrix™ was administered intramuscularly (IM) in the right upper thigh, and Pediarix™ and Prevnar™ IM in the left upper and lower thighs, respectively. During Fourth-Dose Phase, Menhibrix™ was administered by the same route and at the same site as during Primary Phase, and Prevnar™ was administered IM in the left upper thigh.
61994105|NCT00129129|ACTIVE_COMPARATOR|ActHIB Group|During Primary Phase (Study 101858), subjects in this group, aged 6-12 weeks at enrolment, received 3 doses of ActHIB™ vaccine co-administered with the Pediarix™ and Prevnar™ vaccines (at Day 0 and Months 2 and 4). Subjects in this Group were followed from Day 0 up to Month 10-13 solely. During Fourth-Dose Phase (Study 102015), these subjects were followed as subjects either in the ActHIB/MenHibrix Group or in the ActHIB/ActHIB Group, receiving then one dose of either Menhibrix™ or ActHIB™ concomitantly with one dose of Prevnar™. During Primary Phase, ActHIB™ was administered intramuscularly (IM) in the right upper thigh, and the Pediarix™ and Prevnar™ vaccines IM in the left upper and lower thighs, respectively.
61994106|NCT00129129|ACTIVE_COMPARATOR|Menomune Group|Subjects in the Group were followed solely during the period of Primary Phase (Study 101858), up to Month 10. Subjects in the Group, aged 3-5 years at enrolment, received one dose of Menomune™ at Day 0. Menomune™ was administered subcutaneously in the left deltoid region.
62561212|NCT00450879|EXPERIMENTAL|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD for 12-20 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgical resection of tumor between days 13 and 21 (24 hours after completion of pazopanib hydrochloride).
62561213|NCT06208917|EXPERIMENTAL|oral soluble film of ondansetron combined with dexamethasone|"Participants received the first dose of ondansetron oral soluble film (age-based adjustment) 30 minutes before chemotherapy and equal doses were given 4 hours and 8 hours after the first dose for whom younger than 12 years old while the others should be given 8h hours after the first dose.~Ondansetron oral soluble film was administered continuously for two days after chemotherapy according to the administration regimen on the day of chemotherapy. Dexamethasone (based on body surface area) iv/po twice daily from day 1 of chemotherapy until 2 days after completion of chemotherapy."
62561214|NCT06208917|ACTIVE_COMPARATOR|ondansetron intravenously combined with dexamethasone|"Participants received the first dose of ondansetron intravenously (weight-based adjustment) 30 minutes before chemotherapy and equal doses were given 4 hours and 8 hours after the first dose.~Ondansetron (po) was given for next continuously two days in the same dose and frequency of administration. Dexamethasone (based on body surface area) iv/po twice daily from day 1 of chemotherapy until 2 days after completion of chemotherapy."
62561215|NCT04054765|EXPERIMENTAL|Teens in the Invite Only VR videogame|155 adolescents playing the Invite Only VR intervention
62561216|NCT04054765|OTHER|Teens receive treatment as usual|132 adolescents receive treatment as usual, which includes regular instruction in health class regarding the dangers of e-cigarettes
62561217|NCT02034929|ACTIVE_COMPARATOR|Endocuff-assisted colonoscopy|Endocuff-assisted colonoscopy
62561218|NCT02034929|ACTIVE_COMPARATOR|Standard colonoscopy|Standard Colonoscopy
61994107|NCT00129129|EXPERIMENTAL|ActHIB/Menhibrix Group|Subjects in the Group were followed solely during the period of the Fourth-Dose Phase of the study (Study 102015), from Month 10-13 to Month 11-14. Subjects in this Group had been primed with ActHIB™ during Primary Phase (study 101858) and received at Month 10-13 a fourth dose of Menhibrix™ and a concomitant fourth dose of Prevnar™. Menhibrix™ and Prevnar™ were administered intramuscularly in the right and left upper thighs, respectively.
62389625|NCT05882487|EXPERIMENTAL|KL002 injection solution|single dose, neurosurgically infused, bilaterally into the striatum
62561219|NCT01366924|NO_INTERVENTION|Muscle protein turnover and intracellular signaling at rest|Muscle protein turnover and intracellular signaling are measured at rest for comparison to post-exercise muscle metabolism.
62561220|NCT01366924|ACTIVE_COMPARATOR|Muscle metabolism after endurance exercise|Post-exercise muscle protein metabolism was measured to determine if endurance exercise affects muscle metabolism compared to rest.
62561221|NCT01366924|EXPERIMENTAL|Muscle Metabolism after endurance exercise|Muscle metabolism response to endurance exercise with essential amino acid supplementation
62561222|NCT01366924|EXPERIMENTAL|Muscle anabolism after endurance exercise|Muscle anabolism after endurance exercise with essential amino acid supplementation.
62561223|NCT00740636|EXPERIMENTAL|75 mg/m2/day Temozolomide|75 mg/m2/day Temozolomide for 21 days (7 days off treatment). 28 day cycles.
62561224|NCT00740636|EXPERIMENTAL|200 mg/m2/day Temozolomide|200 mg/m2/day Temozolomide for 5 days (23 days off treatment). 28 day cycles.
62561225|NCT01761903||Primary Focal Dystonia|Volunteers with primary focal dystonia
62561226|NCT01761903||Healthy Controls|'Healthy' volunteers, consisting of people of the same age as the PFD volunteers, w/o a diagnosis of PFD.
62561227|NCT03380429|EXPERIMENTAL|Data on Maintenance use supplied to Subject and HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensor attached to RELVAR/BREO ELLIPTA will be fed back to the subject via an app on smart phone and to the subject's HCP via an online dashboard.
62769179|NCT01659255|EXPERIMENTAL|Tirabrutinib 480 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily.
62769180|NCT01659255|EXPERIMENTAL|Tirabrutinib 600 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily.
62769181|NCT01659255|EXPERIMENTAL|Tirabrutinib 240 mg Twice Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 240 mg twice daily.
61994108|NCT00129129|EXPERIMENTAL|ActHIB/ActHIB Group|Subjects in the Group were followed solely during the period of the Fourth-Dose Phase of the study (Study 102015), from Month 10-13 to Month 11-14. Subjects in this Group had been primed with ActHIB™ during Primary Phase of the study (study 101858) and received at Month 10-13 a fourth dose of ActHIB™ and a concomitant fourth dose of Prevnar™. ActHIB™ and Prevnar™ were administered intramuscularly in the right and left upper thighs, respectively.
62769182|NCT00024011|EXPERIMENTAL|Treatment (bortezomib)|Patients receive PS-341 IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62769183|NCT00996346|EXPERIMENTAL|Irinotecan&Temsirolimus:Arm 1, Level 1|"Arm 1, Level 1: Irinotecan intravenously at 80 mg/m2 + Temsirolimus intravenously at 15 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
62769184|NCT00996346|EXPERIMENTAL|Irinotecan&Temsirolimus:Arm 1, Level 2|"Arm 1, Level 2: Irinotecan intravenously at 80 mg/m2 + Temsirolimus intravenously at 20 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
62769185|NCT00996346|EXPERIMENTAL|Irinotecan&Temsirolimus:Arm 2, Level 1|"Arm 1, Level 2: Irinotecan intravenously at 50 mg/m2 + Temsirolimus intravenously at 25 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
62769186|NCT01804166|OTHER|IBD patients with HSTCL|Subjects with Inflammatory Bowel Disease with a diagnosis of Hepatosplenic T-cell lymphoma
62769187|NCT04363450|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine loading dose will be given as 400mg for two doses 12 hours apart. This will then be followed by maintenance dosing of 200mg twice weekly for the remainder of the trial.
62769188|NCT04363450|PLACEBO_COMPARATOR|Placebo|An identical placebo will be administered on an identical dosing interval and frequency.
62769189|NCT03648216|EXPERIMENTAL|Intervention Group|The intervention group will receive a pedometer and HAPA behavioural counseling with the aim of limiting their daily step count to \<5000 steps per day, over a one week period. Counseling strategies will be grounded in the HAPA model - specifically, creating an action plan and coping strategies for maximizing their daily sedentary behaviour and minimizing steps taken. Strategies may include: driving to locations more often, refraining from physical activity as much as possible, and/or completing tasks in sedentary postures.
62769190|NCT03648216|NO_INTERVENTION|Control Group|The control group will not receive any behavioural intervention or instruction.
62769191|NCT06526156||Hypobaric L5-S1 Spinal Anesthesia|Will receive a dose of hypobaric (0.33%) bupivacaine, administered at the L5-S1 space.
62769192|NCT02638155||Food Addiction Group|Those participants identified as having food addiction by the Yale Food Addiction Scale.
62769193|NCT02638155||No Food Addiction Group|Those participants with no identified food addiction
61994109|NCT03168464|EXPERIMENTAL|Immunotherapy + Radiation|Non-ablative radiotherapy (6GyX5) is directed to one lesion during a first immunotherapy treatment with Ipilimumab 3 mg/kg (± 24hrs from first RT dose). On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
62561228|NCT03380429|EXPERIMENTAL|Data on Maintenance use supplied to Subject|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensor attached to RELVAR/BREO ELLIPTA will be fed back to the subject via an app on smart phone.
61994110|NCT02067377|PLACEBO_COMPARATOR|inactive powder substance|inactive powder substance by mouth twice a day for 6 months
61994111|NCT02067377|EXPERIMENTAL|serum bovine immunoglobulin (SBI) medical food|SBI medical food 5 gr powder substance by mouth twice a day for 6 months
62389626|NCT06479577|EXPERIMENTAL|ultrasound|therapeutic ultrasound 1MHZ continuous mode for 20 minutes
62561229|NCT03380429|EXPERIMENTAL|Data on Maintenance and Rescue use supplied to Subject and HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensors attached to RELVAR/BREO ELLIPTA and salbutamol MDI will be fed back to both subject and HCP. The data will be fed back to the subject through an app and to HCP through an online dashboard.
62769194|NCT03228485||MyBPH Care|All patients enrolled in this study.
62769195|NCT05455801|EXPERIMENTAL|negative wound therapy group|those who receive negative pressure therapy
62769196|NCT05455801|NO_INTERVENTION|conventional dressing group|those patients who heal with conventional dressing, therefore negative pressure therapy is not applied
62389627|NCT06479577|ACTIVE_COMPARATOR|high intensity laser therapy|approximately 905 nm super pulsed laser
62389628|NCT04586920|EXPERIMENTAL|LY3509754 - Part A|Escalating doses of LY3509754 administered orally
62389629|NCT04586920|PLACEBO_COMPARATOR|Placebo - Part A|Placebo administered orally
62389630|NCT04586920|EXPERIMENTAL|LY3509754 plus Itraconazole - Part B|LY3509754 and Itraconazole administered orally
62389631|NCT04586920|PLACEBO_COMPARATOR|Placebo plus Itraconazole - Part B|Placebo and Itraconazole administered orally
62389632|NCT04586920|EXPERIMENTAL|LY3509754 plus Midazolam - Part C|Multiple doses of LY3509754 administered orally. Some participants will also receive midazolam orally.
62389633|NCT04586920|PLACEBO_COMPARATOR|Placebo plus Midazolam - Part C|Multiple doses of placebo administered orally. Some participants will also receive midazolam orally.
62389634|NCT04586920|EXPERIMENTAL|LY3509754 (Japanese) - Part D|Multiple doses of LY3509754 administered orally to Japanese participants
62561230|NCT03380429|EXPERIMENTAL|Data on Maintenance and Rescue use supplied to Subject|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensors attached to RELVAR/BREO ELLIPTA and salbutamol MDI will be fed back to subject through an app.
62561231|NCT03380429|ACTIVE_COMPARATOR|No data supplied to Subject or HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Subjects will be provided with a home hub through which their data will be uploaded during the study but the subjects and their HCP will not be able to view the data.
62561232|NCT05415176|EXPERIMENTAL|Taurine and Exercise (Tau+Exe)|Individuals who will receive 3g of taurine supplementation combined with physical training in the period of 16 weeks
62561233|NCT05415176|EXPERIMENTAL|Taurine (Tau)|Individuals who will receive 3g of taurine supplementation
62769197|NCT02163213|OTHER|Serum Bovine Immunoglobulin|"Serum-Derived Bovine Immunoglobulin (SBI) 5.0 g by mouth twice daily;~Effects of SBI will be compared with observations and measurements performed at baseline PRIOR to starting the SBI treatment"
62769198|NCT01123473|EXPERIMENTAL|Lapatinib|Chemotherapy + lapatinib
62389635|NCT04586920|PLACEBO_COMPARATOR|Placebo (Japanese) - Part D|Placebo administered orally to Japanese participants
62389636|NCT01921842|EXPERIMENTAL|Nutrition and Physical Activity Training|NAP-SACC Child Care Wellness program administered in year 1 of study
62389637|NCT01921842|OTHER|Delayed Intervention Group|NAP-SACC Child Care Wellness Program is administered in year 2 of study.
62389638|NCT00788801|EXPERIMENTAL|Baseline|
62389639|NCT00788801|EXPERIMENTAL|ABT-614 Low Dose|
62389640|NCT00788801|EXPERIMENTAL|ABT-614 High Dose|
62561234|NCT05415176|EXPERIMENTAL|Exercise (Exe)|Individuals who will perform a physical training and receive a placebo supplementation in the period of 16 weeks
62561235|NCT05415176|PLACEBO_COMPARATOR|Placebo (Cont)|Individuals who will receive a placebo supplementation in the period of 16 weeks
62561236|NCT05377749|EXPERIMENTAL|FACT intervention|Families Addressing Cancer Together (FACT) intervention plus questionnaires
62769199|NCT01123473|PLACEBO_COMPARATOR|Placebo|Chemotherapy + placebo
62769200|NCT00915148||Ultrasound examination|Women with prolonged Labour; Primi gravidae, single pregnancy, \>37 weeks, fetus alive, cephalic presentation.
62769201|NCT00975143|EXPERIMENTAL|CIP-Isotretinoin|
62389641|NCT03559595|EXPERIMENTAL|Intervention group|All study participants will be exposed to the intervention
62389642|NCT04424589|EXPERIMENTAL|Myofascial release|"Myofascial release or induction (MFR) is a widely used manual therapy treatment involving specifically guided, low-load, long-lasting mechanical forces to manipulate the myofascial complex, aimed at restoring optimal length, decreasing pain, and improving function. Manual therapists often use their hands using their knuckles, elbows, or other instrumental tools to slowly penetrate the layers of the fascia, using applied pressure with a few kilograms of force that can strain the restricted fascia, this implies a guided gentle stretch.~The experimental group will receive 1 examination session and 6 myofascial release sessions carried out by a physiotherapist specialized in orthopedic manual therapy, superficial and deep techniques will be applied in the cervical region, for the spinal at the level of the quadratus lumborum, sacroiliac region and upper trapezius. 2 sessions per week over the course of 3 weeks."
62389643|NCT04424589|SHAM_COMPARATOR|Sham Therapy|The control group will receive 1 examination session and 6 simulated myofascial releasesessions, where a physiotherapist will apparently apply the same techniques and maneuvers of myofascial release, however, they will not follow the basic principles of technique execution, which does a procedure with a placebo effect.
62389644|NCT03896334|EXPERIMENTAL|Isometric handgrip training|All participants that will be assigned to supervised isometric handgrip training will train three times per week, during 24 weeks. They will perform a bout of isometric handgrip exercise: four sets of 2-min of isometric contractions (using alternate hands) at 30% of maximal voluntary contraction.
62561237|NCT05377749|NO_INTERVENTION|Wait-list control condition|Participants assigned to the waitlist control condition only complete questionnaires during the study period. After they have completed their 6-week study activities, they will receive access to the FACT intervention.
62561238|NCT00777387|ACTIVE_COMPARATOR|1|slow-freeze
62561239|NCT00777387|ACTIVE_COMPARATOR|2|vitrification
62561240|NCT01435850|SHAM_COMPARATOR|HIP STEM SL PLUS|study group
62561241|NCT01435850|ACTIVE_COMPARATOR|HIP STEM SL PLUS MIA|control group
62561242|NCT04010565|EXPERIMENTAL|Extract of aged black garlic|Participants will consume a tablet of 550 mg daily with 250 mg of aged black garlic extract and 300 mg of excipients (microcrystaline cellulose 90 mg; dicalcium phosphate 157 mg; crosscamellose sodium 10 mg; magnesium stearate 7 mg; sodium alignate 3.06 mg; stearic acid 0.03 mg; oleic acid 1.54 mg; medium chain triglycerides 2.80 mg; ethylcellulose 13.17 mg; hydroxypropylcellulose 4.86 mg; hydroxypropylmethylcellulose 4.86 mg; talcum 2.88 mg; titanium dioxide 1.80 mg; vanilla aroma 1.00 mg) .
62769202|NCT00975143|ACTIVE_COMPARATOR|Isotretinoin|
62769203|NCT02653716|ACTIVE_COMPARATOR|Case Management|CM
62769204|NCT02653716|EXPERIMENTAL|New Orleans Intervention Model|NIM
62769205|NCT03085472||benigh hematoma|Patients with novel imaging markers or clinical features suggestive of a relatively benigh hematoma (less likely to expand and have a relatively good outcome).
62561243|NCT04010565|PLACEBO_COMPARATOR|Placebo|Participants will consume a tablet of 550 mg daily with 550 mg of excipients (microcrystaline cellulose 342.5 mg; dicalcium phosphate 154.5 mg; crosscamellose sodium 10 mg; magnesium stearate 7 mg; sodium alignate 3.06 mg; stearic acid 0.03 mg; oleic acid 1.54 mg; medium chain triglycerides 2.80 mg; ethylcellulose 13.17 mg; hydroxypropylcellulose 4.86 mg; hydroxypropylmethylcellulose 4.86 mg; talcum 2.88 mg; titanium dioxide 1.80 mg; vanilla aroma 1.00 mg).
62561244|NCT05583435|EXPERIMENTAL|One-on-one professional coaching|"One-on-one professional coaching (N=30). Six one-on-one coaching sessions via Zoom with one of two private professional coaches every other week for 3-4 months.~The professional coaching method includes (but will not be limited to) the following themes: optimizing meaning and engagement in work, building social support and community, improving work efficiency, addressing workload and boundary setting, enhancing communication, and building leadership skills, pursuing hobbies and creation/innovation, and promoting self-compassion and self-care (with a focus on physical and mental health).~Coach-guided activities/behavioral interventions are included with coaching sessions. These activities are reviewed with participants throughout the 3-4 month period and include, but are not limited to: Wheel of Life, visioning exercise, one page miracle: core values, purpose, and goals, buckets and mental models."
62561245|NCT05583435|EXPERIMENTAL|Small-group professional coaching with coach-guided activities/behavioral internventions|"Coach-facilitated small group professional coaching sessions and coach-guided activities/behavioral interventions (N=30). Six small-group coaching sessions via Zoom with one of two private professional coaches and three physician participants in each group, every other week for 3-4 months.~The professional coaching method is similar to those receiving 1:1 professional coaching. The primary difference in this intervention group is that coaching sessions will be group-based with 3 physician participants."
62389645|NCT03896334|SHAM_COMPARATOR|Control group|All participants randomized to control group will realize stretching and relaxation exercises, three times per week, during 24 weeks.
62389646|NCT03444389||Study group|Patients with hemorrhoids
62389647|NCT03444389||Control group|Healthy participants without hemorrhoids
62389648|NCT01475812||COPD hyperinflation|
62389649|NCT04180891||successful test|Students that have successfully passed the test procedure (directly with written exam or after written and oral interviews) and that can enter one of the four medical courses of health studies (medicine, pharmacy, dentistry, midwifery).
62389650|NCT04180891||failed test|Students that have failed to enter one of the four medical courses of health studies (medicine, pharmacy, dentistry, midwifery) after the selection procedure.
62389651|NCT01977573|EXPERIMENTAL|GSK1278863|Subjects will be administered GSK1278863 QD. Starting dose will be based on data from previous studies with GSK1278863 and dose-response modelling, as well as Baseline Hgb concentration. After 4 Week of fixed dose period, dose may be adjusted to achieve Hgb 9.0 to 10.5 g/dL
62389652|NCT01977573|OTHER|Control|All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered.
62389653|NCT04718376|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection|Subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles.
62769206|NCT03085472||malignant hematoma|Patients with novel imaging markers or clinical features suggestive of a relatively bad hematoma (more likely to expand and have a relatively poor outcome).
62769207|NCT01977690|NO_INTERVENTION|Standard Management|Patients wore no brace.
62769208|NCT01977690|EXPERIMENTAL|Clavicle Brace Wearing|Patient has to wear clavicle brace for one month.
61994112|NCT02067377|EXPERIMENTAL|serum bovine immunoglobulin (SBI) medicalfood|SBI medical food 10 gr powder substance by mouth twice a day for 6 months
61994113|NCT01209442|EXPERIMENTAL|RT with Temozolomide and Bevacizumab|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily TMZ at 75 mg/m2 qd concurrent with IMRT (including weekends and holidays). Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Day 1 and the 1st Fx of IMRT must start on the same day. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab therapy, patients will have a brain MRI and if there is no evidence of disease progression, patients will receive 6 cycles of Bevacizumab and TMZ. Beginning a minimum of 28 days after the last radiation treatment the bevacizumab will be dosed at 10 mg/kg on day 1 and day 15 of each cycle. TMZ will be given at 150-200 mg/m2 qd on days 1-5 of each cycle. Each cycle is 28 days.
61994114|NCT04681482||Apixaban Group|The cohort prescribed apixaban and diagnosed with Atrial Fibrillation
62389654|NCT05121129|EXPERIMENTAL|iTBS|Subjects suffering of MDD assigned to start the trial by 25 sessions of iTBS applied in left DLPFC
62389655|NCT01621516||Healthy controls|10 healthy volunteers
62389656|NCT01621516||Solitary small bowel transplant patients|3
62389657|NCT01621516||Liver/small bowel transplant patients|3
61994115|NCT04681482||Warfarin Group|patients prescribed warfarin only diagnosed with Atrial Fibrillation.
61994116|NCT06481540|EXPERIMENTAL|Expiratory muscle strength training + SpiroGym application|The experimental arm will undergo 8 weeks of expiratory muscle strength training coupled with SpiroGym app.
61994117|NCT06481540|ACTIVE_COMPARATOR|Expiratory muscle strength training|The experimental arm will undergo 8 weeks of expiratory muscle strength training.
62389658|NCT02493075|EXPERIMENTAL|CF guided group|Ablation will be performed with smart-touch catheter.The operator will kown the real-time contact force (CF), ablation time, FTI, etc during the procedure.
62389659|NCT02493075|ACTIVE_COMPARATOR|Usual ablation group|Although we use the same catheter,operator will be blinded to CF data during the procedure.
62389660|NCT05864105|EXPERIMENTAL|PM8002+FOLFOX-4|PM8002 20mg/kg Q2W day 1: oxaliplatin \[85 mg/m2, 2-h infusion\] plus leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]; day 2: leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]
62389661|NCT03474991|ACTIVE_COMPARATOR|Celestamine® N 0.5|oral betamethasone solution, once daily for two consecutive days at 0.1-0.2 mg/kg
62389662|NCT03474991|PLACEBO_COMPARATOR|Placebo|oral placebo matched to the product described above
62769209|NCT01953900|EXPERIMENTAL|GD2 T cells plus VZV vaccine|In this study we will be administering from 1 x 10\^6 to 1 x 10\^9 transduced autologous VZV-specific CTLs, derived from VZV-specific memory T cells, so there will be no risk of alloreactivity. 6.1.1 Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m2/day followed by Fludarabine 30 mg/m2/day.
62769210|NCT04981028||Patients with acute episode of thrombotic thrombocytopenic purpura (TTP)|Any adult patients with a suspected diagnosis of TTP (defined by low platelets and anaemia with evidence of red cell breakdown) and confirmed by a low ADAMTS13 enzyme level \<10%
62769211|NCT04981028||Healthy volunteers|Non-blood relative / friend / carer
62769212|NCT04981028||Patients with known diagnosis of TTP|Any adult patients with a previously confirmed diagnosis of TTP (more than 12 months ago) based on an ADAMTS13 enzyme level \<10% at initial diagnosis
62769213|NCT05883618||Radiologically confirmed traumatic spine injury|
62769214|NCT04731532|ACTIVE_COMPARATOR|Classical respiratory physiotherapy application|Patient positions, postural drainage application tapping and trifled
62769215|NCT04731532|ACTIVE_COMPARATOR|classical respiratory physiotherapy with thoracic vibration|Thoracic Vibration: The physiotherapist places his hands open with his / her fingers on the front and side walls of the patient's chest when the elbow is at 5-10 degrees of flexion. The elbow expands the patient's chest with vibrations. Exercise can be repeated 5-10 times a day+Patient positions, postural drainage application tapping and trifled
62769216|NCT05242094|ACTIVE_COMPARATOR|Group 1|Traditional Pulmonary Rehabilitation
62769217|NCT05242094|EXPERIMENTAL|Group 2|Pulmonary Rehabilitation in Virtual Reality
62769218|NCT04385225|OTHER|Healthy controls|Age-matched controls with normal hearing or mild sensorineural hearing loss: 40 decibel or less in better hearing ear, and normal vestibular function
61994118|NCT02093598|EXPERIMENTAL|Temsirolimus|25 mg administered intravenously, infused over a 30- to 60-minute period once weekly for 28 days (Total doses: 4 doses).
62769219|NCT04385225|OTHER|Moderate Sensorineural hearing loss|Moderate Sensorineural hearing loss: 41-60 decibel in the better hearing ear
62769220|NCT04385225|OTHER|Severe Sensorineural hearing loss|Severe Sensorineural hearing loss: 61-80 decibel in the better hearing ear
61994119|NCT03828799|EXPERIMENTAL|Folfirinox-R|Folfirinox + regorafenib
61994120|NCT02482025|NO_INTERVENTION|Usual care|Usual care delivered at VA Boston
62769221|NCT04385225|OTHER|Bilateral Vestibulopathy|Bilateral vestibulopathy: half with normal hearing, half with severe to profound sensorineural hearing loss
62769222|NCT04385225|OTHER|Mild Cognitive Impairment|Mild Cognitive Impairment
62769223|NCT04385225|OTHER|Alzheimer's Disease|Alzheimer's Disease
62769224|NCT02721108|EXPERIMENTAL|Mindfulness: Group A|Using a 60-day mindfulness instruction meditation app: 60 days of 10 and 20 minute long app modules with a spoken guide to mindfulness meditation, to be used once a day, including modules on the basics of mindfulness and a module targeted to pain, which can re-revisited until the end of the study
62769225|NCT02721108|ACTIVE_COMPARATOR|Relaxation: Group B|Using comparison relaxation app with a series of non-meditative progressive muscle relaxation instructions: 60 days of 10 and 20 minute long app modules to be used once per day with spoken words and relaxing sounds, which can re-revisited until the end of the study
62769226|NCT02721108|NO_INTERVENTION|Treatment as usual: Group C|No app: treatment as usual (watch and wait, medication and/or surgery) to investigate if any app intervention makes a difference to wellbeing and to ascertain dropout rates for the full-scale trial in patients who perceive that they are getting no intervention.
62769227|NCT02544373|ACTIVE_COMPARATOR|Immediate PAP therapy (Group 1)|Subjects will receive PAP treatment for OSA as soon as possible after baseline PSG and repeat baseline cognitive testing 3 months after initiation of PAP therapy. PAP therapy is considered standard clinical care for OSA. It involves wearing an apparatus that includes a hose and a mask (that covers the nose, or nose and mouth), connected to a small machine that blows air into the airway during sleep. The degree of air pressure given depends on your apnea severity, and the supplied air pressure can be continuous or change with your breathing pattern (bilevel).
62769228|NCT02544373|OTHER|Standard Care PAP therapy (Group 2)|Subjects will delay PAP treatment for 3 months following their baseline sleep study, and repeat their baseline cognitive testing prior to PAP treatment for sleep apnea. PAP therapy is considered standard clinical care for OSA. It involves wearing an apparatus that includes a hose and a mask (that covers the nose, or nose and mouth), connected to a small machine that blows air into the airway during sleep. The degree of air pressure given depends on your apnea severity, and the supplied air pressure can be continuous or change with your breathing pattern (bilevel).
62769229|NCT06273046|EXPERIMENTAL|Biofeedback|
62769230|NCT06273046|PLACEBO_COMPARATOR|Placebo|
62769231|NCT00576576|EXPERIMENTAL|A|All patients in this arm are given atorvastatin therapy.
62769232|NCT00201123|PLACEBO_COMPARATOR|Standard Treatment|Isoniazid, Rifampin, Pyrazinamide Anti-Tuberculous Therapy
62769233|NCT00201123|EXPERIMENTAL|Aerosol Interferon-gamma|Aerosol Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide
61994121|NCT02482025|ACTIVE_COMPARATOR|SMMRT|Receives Usual Care PLUS SMMRT Intervention
61994122|NCT00542581|EXPERIMENTAL|The Acrysof toric SN60T3 IOL|Multifocal Intraocular Lens
61994123|NCT03898596|OTHER|ECG Monitoring|ECG readings will be collected for neonatal patients who require or currently have UVC
62389663|NCT05288439|EXPERIMENTAL|patients|A full neurocognitive battery with quality-of-life assessment will be conducted and an rs-fcMRI sequence will be added to the brain MRI performed as standard of care follow-up between 3-5 months post-PBRT.
62769234|NCT00201123|EXPERIMENTAL|Subcutaneous Interferon-Gamma|Subcutaneous Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide
62389664|NCT05288439|EXPERIMENTAL|healthy matched controls|Healthy participants will be asked to complete the MRI scan and undergo neurocognitive assessment.
62389665|NCT04939441|EXPERIMENTAL|TAF group|TAF \[Vemlidy® 25mg QD\] monotherapy
62769235|NCT03125811|ACTIVE_COMPARATOR|Inhaled Isopropyl Alcohol (IPA)|Inhaled Isopropyl Alcohol (alcohol prep pad)
61994124|NCT03442738||Group I Endocuff group|Group I Endocuff cap use
61994125|NCT03442738||Group II standard colonoscope|Group II standard colonoscope, no further device used
62389666|NCT04795752|EXPERIMENTAL|TearCare Group (Study Device)|
62389667|NCT04795752|ACTIVE_COMPARATOR|Restasis Group (Control)|
62769236|NCT03125811|OTHER|Oral Dissolvable Tablet Zofran (OZ)|4 mg Oral Dissolvable Tablet Zofran (ondansetron)
62769237|NCT01057524|ACTIVE_COMPARATOR|Usual Airway Clearance Technique|Two self administered treatment sessions a day and two treatments a day assisted by a Physiotherapist both using the patient's usual airway clearance method.
62769238|NCT01057524|EXPERIMENTAL|High Frequency Chest Wall Oscillation (HFCWO)|Two self administered treatments a day using HFCWO and two treatment sessions a day assisted by a Physiotherapist using their 'usual' airway clearance method.
62769239|NCT01908088|EXPERIMENTAL|fibroblast transplant|Transplantation of autologous cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hand deformity
62769240|NCT05827601||Avian Influenza Outbreak Farms|People involved in outbreak management, ranging from poultry farm owners and their family to inspectors through veterinarians and cullers/cleaners, will be invited to take part in the study at the earliest step possible after outbreak detection. Self sampling by nasopharyngeal swab will be requested every 2 days during 2 weeks.
62769241|NCT05827601||Poultry Farm Sentinel Network|"People working in poultry farms and in contact with animals will be invited to join the cohort. Self sampling by nasopharyngeal swab will be requested every 2 weeks for the whole duration of the study.~anticipated: 15"
62769242|NCT05827601||Wild bird/life Rehabilitation Centre Sentinel Network|"People working in wild bird/life rehabilitation centers and in contact with animals will be invited to join the cohort. Self sampling by nasopharyngeal swab will be requested every 2 weeks for the whole duration of the study.~anticipated: 25"
62769243|NCT05827601||Pig Industry Veterinarian Sentinel Network|"Veterinarians working in the pig industry and in contact with animals will be invited to join the cohort. Self sampling by nasopharyngeal swab will be requested every 2 weeks for the whole duration of the study.~anticipated: 15"
62769244|NCT04969315|EXPERIMENTAL|Multiple Ascending Dose|3+3 Dose escalation until MTD and/or R2PD of TT-10 is determined
62769245|NCT01092793|ACTIVE_COMPARATOR|Krill|
62769246|NCT01092793|ACTIVE_COMPARATOR|Fish oil|
62769247|NCT01092793|NO_INTERVENTION|Control|
62389668|NCT06041594|EXPERIMENTAL|Laguna Thrombectomy System|
62389669|NCT05794334|EXPERIMENTAL|Low Dye Taping|: There were 20 patients in group A which received the low dye taping technique. Low-dye is a classic taping method to reduces strain from plantar fascia and provide medial ankle arch support. If properly applied, reduces subtalar joint motion, pain, excessive pronation. Hence, it can be used in the treatment of ankle and foot.
62389670|NCT05794334|EXPERIMENTAL|Robert Debre Method|This second group also contains 20 participents.French functional method is similar to the Ponseti method. In this technique, the patient undergoes 30-minute daily session for 2 weeks and then twice a week until achieving foot correction. It consists of stretching of triceps surae to improve tibio-talar joint function. daily manipulations of the newborn's foot, stimulation and strenghtening of the muscles around the foot (particularly the peroneal muscles) and temporary immobilization of the foot with elastic and nonelastic adhesive taping so that the reduction achieved by.
62389671|NCT00003855|EXPERIMENTAL|Surgery + radiotherapy|"Patients undergo axillary lymph node dissection involving removal of at least level I and II nodes, followed by whole-breast radiotherapy (exclusive of a third supraclavicular field) 5 days a week for a maximum of 7 weeks. Patients may receive adjuvant systemic therapy at the discretion of the treating physician.~Patients are followed up at 30 days, at 6, 12, 18, 30, and 36 months, and then annually for a total of 10 years."
62389672|NCT00003855|ACTIVE_COMPARATOR|Radiotherapy|"Patients undergo breast radiotherapy only. Patients may receive adjuvant systemic therapy at the discretion of the treating physician.~Patients are followed up at 30 days, at 6, 12, 18, 30, and 36 months, and then annually for a total of 10 years."
62389673|NCT01467817|EXPERIMENTAL|Lifestyle Intervention|This arm will test the combination of 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
62389674|NCT01467817|PLACEBO_COMPARATOR|Exercise Control|This arm will test the benefits of exercise alone while controlling for investigator contact.
62389675|NCT05543980|SHAM_COMPARATOR|Sham control|Participants will be provided a leg heat therapy system and will be instructed to apply the therapy daily (90 min/day) for 12 consecutive weeks. The water heater will circulate water at 33ºC.
62769248|NCT04934436|EXPERIMENTAL|Intervention Group|According to their chronotype, the intervention group will then be given sleeping glasses and earplugs at night for those who are in the morning type, and till afternoon during the day for those who are in the evening type. Moreover, patients in the intervention group will be given 5000 Lux daylight during the time they are awake depending on their circadian rhythms. An Android smartwatch will be used to determine patients' sleeping and waking up times, sleep quality and sleep depth. Nursing care will also be provided when patients are awake per their chronotype. Before the study, intensive care nurses will be trained to provide appropriate care according to the circadian rhythm and chronotype to have consistency in the care. Patients will be observed for three days and during this time cortisone and melatonin levels will be checked in both control and intervention groups. At the end of the third day, surveys will be conducted once again with both groups.
62769249|NCT04934436|NO_INTERVENTION|Control Group|All surveys that will be used in the study will be applied to both groups during the first and last interviews. The control group will not have any interventions, only the standard ICU care to be provided.
62769250|NCT00758589|EXPERIMENTAL|AZD1981 50 mg|AZD1981 50 mg Twice Daily (Bid)
62769251|NCT00758589|PLACEBO_COMPARATOR|Placebo|Placebo
62769252|NCT00758589|EXPERIMENTAL|AZD1981 400 mg|AZD1981 400 mg Twice Daily (Bid)
62769253|NCT00758589|EXPERIMENTAL|AZD1981 1000 mg|AZD1981 1000 mg Twice Daily (Bid)
62769254|NCT03699137||Cases with confirmed ACS|Cases with confirmed diagnosis of acute coronary syndrome in the MINAP database (national registry of ACS patients). No interventions apply to this group as this is an observational study.
61994126|NCT03905785|EXPERIMENTAL|Parenting Intervention Group(Samarthan)|Parenting intervention was designed as group program, training parents in cognitive-behavioural techniques for managing child's difficult behaviour and issues. Program was focused on parent-child problem solving method and positive interaction.
62389676|NCT05543980|EXPERIMENTAL|Heat therapy|Participants will be provided a leg heat therapy system and will be instructed to apply the therapy daily (90 min/day) for 12 consecutive weeks. The water heater will circulate water at 42ºC.
62389677|NCT02090699||Myocardial Iron Overload|chronic blood transfusion related myocardial iron overload
61994127|NCT03905785|NO_INTERVENTION|Wait list Control group|wait list control group was given no intervention for the trial period. They were offered sam intervention after the intervention was completed in experimental group.
61994128|NCT01746212||Degenerative Disc Disease|Patients diagnosed with degenerative disc disease, meeting all eligibility requirements (please refer to inclusion/exclusion criteria), will be asked to participate in this study. A one-level or two-level anterior lumbar interbody fusion surgery using InQu Bone Graft Extender and Substitute, mixed with BMAC (bone marrow aspirate concentrate) as autograft, with Synthes Spinal Instrumentation will be recommended to the patient. If patients elect to proceed with surgery using the prescribed surgical components, they will be offered enrollment into the study. If the patient opts to use a different bone graft, or other spinal instrumentation, then the patient will not meet all inclusion criteria and will not be offered the opportunity to enroll in this study.
61994129|NCT01175733|EXPERIMENTAL|Panitumumab|
61994130|NCT03762655|EXPERIMENTAL|Neuro-Spinal Scaffold Arm|Subjects in the Scaffold Arm will have the Scaffold implantation immediately following standard of care open spine surgery.
61994131|NCT03762655|NO_INTERVENTION|Comparator Arm|Subjects in the Comparator Arm will have standard of care open spine surgery and will not receive the Scaffold.
61994132|NCT01516957|EXPERIMENTAL|AMG 827 140|140 mg AMG 827
61994133|NCT01516957|PLACEBO_COMPARATOR|Placebo SC|Placebo
61994134|NCT01516957|EXPERIMENTAL|AMG 827 280|280 mg AMG 827
61994135|NCT01516957|EXPERIMENTAL|AMG 827 210|AMG 827 SC 210 mg
61994136|NCT01675882|EXPERIMENTAL|Viaskin Peanut 50 mcg|
61994137|NCT01675882|EXPERIMENTAL|Viaskin Peanut 100 mcg|
61994138|NCT01675882|EXPERIMENTAL|Viaskin Peanut 250 mcg|
61994139|NCT01675882|PLACEBO_COMPARATOR|Viaskin Placebo|
61994140|NCT05375734|EXPERIMENTAL|treatment group|Tislelizumab combined with Anlotinib Tislelizumab：200 mg，ivgtt，d1，Q3W Anlotinib： 10mg P.O d1-d14, Q3W
61994141|NCT03145896|ACTIVE_COMPARATOR|IBD patients with Vitamin D treatment|
62567742|NCT02721277|EXPERIMENTAL|SMOFlipid|Subjects with cholestasis will receive 3 G/kg/day of intravenous SMOFlipid daily until parenteral nutrition (PN) is discontinued. In addition, the following monitoring for effects of SMOFlipid will be performed: total days of parenteral nutrition, maximum conjugated bilirubin, time to resolution of bilirubin, time to liver transplant, time to death, positive blood cultures, rates of increase in weight, length, and head circumference, time dependent changes in liver function tests, including triglycerides, and length of hospital stay.
62769255|NCT03699137||EMS personnel|Emergency Medical Service (EMS) personnel will take part in the focus group. No intervention applies to this group in this qualitative component of the study.
62769256|NCT05086510|ACTIVE_COMPARATOR|Sinus Rhythm|This group will undergo mapping during sinus rhythm to identify and ablate late potentials that may be incriminated in the tachycardia circuit.
61994142|NCT03145896|NO_INTERVENTION|IBD patients with no Vitamin D treatment|
61994143|NCT05677620||Group A - Pharyngeal Computed Tomography Group|22 randomly selected patients with mild to moderate obstructive sleep apnea will undergo pharyngeal CT with cephalometry and with registration in maximum comfortable protrusion (MCP)
61994144|NCT05677620||Group B - Drug-Induced Sleep Endoscopy Group|22 randomly selected patients with mild to moderate obstructive sleep apnea will undergo Drug-induced sleep endoscopy with registration in maximum comfortable protrusion (MCP)
61994145|NCT05677620||Group C - Pharyngeal Computed Tomography and Drug-Induced Sleep Endoscopy Group|22 randomly selected patients with mild to moderate obstructive sleep apnea will undergo a pharyngeal computed tomography + Drug-induced sleep endoscopy with registration in maximum comfortable protrusion (MCP)
61994146|NCT04133493|PLACEBO_COMPARATOR|Standard of Care Group|Fibracol Dressing covered with gauze and wrapped with kerlix and wrap. Change 3Xper week
61994147|NCT04133493|ACTIVE_COMPARATOR|Intervention Group|Kerecis affixed with steri-strips, cover with gauze and change one per week .
61994148|NCT01183169|EXPERIMENTAL|Treatment A: ALV 600 mg QD|Alisporivir (ALV) 600 mg once daily (QD) with Peginterferon alfa-2a (PEG) and Ribavirin (RBV) for up to 48 weeks
61994149|NCT01183169|EXPERIMENTAL|Treatment B: ALV 800 mg QD|Alisporivir (ALV) 800 mg QD with PEG and RBV for up to 48 weeks
61994150|NCT01183169|EXPERIMENTAL|Treatment C1: ALV Placebo - 600 mg QD|ALV Placebo with PEG and RBV for up to 48 weeks; participants not achieving complete early virologic response (cEVR) after 12 weeks of treatment may switch to active ALV 600 mg QD with PEG and RBV.
61994151|NCT01183169|EXPERIMENTAL|Treatment C2: ALV Placebo - 400 mg BID|ALV Placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR after 12 weeks of treatment may switch to active ALV 400 mg twice daily (BID) with PEG and RBV.
61994152|NCT01183169|EXPERIMENTAL|Treatment D: ALV 400 mg BID|Alisporivir (ALV) 400 mg twice daily BID with PEG and RBV for up to 48 weeks
61994153|NCT03903627|EXPERIMENTAL|Verbal instruction|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:~(1) contract your pelvic floor - all sphincters; (2) contract your anus; (3) contract your pelvic floor as if you're trying to stop urinating.~Those who will not be able to contract will be taught by the ultrasound as a biofeedback."
61994154|NCT00339326||Cases with Kaposi's Sarcoma|Cases with Kaposi's Sarcoma from Southern Italy.
61994155|NCT00339326||Controls without KS|Controls from Southern Italy.
61994156|NCT01998451|EXPERIMENTAL|Double sphincter group|patients from double sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
61994157|NCT01998451|OTHER|general gallbladder sphincter group|patients from general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
62168320|NCT00871143|ACTIVE_COMPARATOR|Non Specific CBT|Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
62168321|NCT01243398|EXPERIMENTAL|Gefitinib 500mg once daily|Gefitinib 500mg once daily
62567743|NCT00746148|EXPERIMENTAL|1|Reflexology
62567744|NCT00746148|NO_INTERVENTION|2|No intervention
62769257|NCT05086510|ACTIVE_COMPARATOR|Right ventricular extrastimulus pacing group|This group will undergo mapping during right ventricular single extrastimulus pacing to identify and thus ablate potentials that might have been masked during sinus rhythm.
62769258|NCT06113575|EXPERIMENTAL|Scheduled Treatment Arm|5 day treatment course, 36 total treatments and clinical assessments.
61994158|NCT04783506||Suicidal Behavior|Adolescents who have suicidal behavior, which for this study, is defined by a recent (within 3 months of enrollment) suicide attempt or suicidal ideation warranting urgent evaluation.
61994159|NCT04783506||At Risk for Mood Disorders|Adolescents at risk for mood disorders, which for this study, is defined by either personal history of anxiety disorder or substance use disorder or a history of trauma, or a first degree relative with a history of a mood disorder or suicidal history.
62769259|NCT01233388||Text message surveillance|enroll for text message surveillance
61994160|NCT04783506||Healthy Control|Healthy adolescents with no lifetime history of any psychiatric or substance use disorders or a history of trauma. Additionally, no first-degree family member with a history of a mood disorder or suicidal history.
61994161|NCT05243095|EXPERIMENTAL|Cognitive training group|The training group received 20 minutes of cognitive training every day for 8 weeks
62389678|NCT02090699||Healthy Volunteers|age matched healthy volunteers
62769260|NCT02602665|EXPERIMENTAL|Shallow catheter tip placement|Patients randomized to shallow tip placement will have the tip of the catheter placed approximately one vertebral body above to even with the carina.
62769261|NCT02602665|EXPERIMENTAL|Deep catheter tip placement|Patients randomized to deep tip placement will have the tip of the catheter placed 1.5 to 2.5 vertebral bodies below the carina.
62769262|NCT05216055|EXPERIMENTAL|Investigational Arm|"The study drug volume, concentration, and dose of treatment arm #1 selected is based on the Principal Investigator's prior experience recommendations by the Food Drug Administration (FDA), and evidence based on prior literature. The final concentration of ropivacaine is 0.375% and final volume of the mixture is 60mL.~1. Ropivacaine 0.5% HCl, 40 mL (5 mg per mL) (200 mg)~2. Dexmedetomidine HCl, 0.50 ml (100 ug per mL) (50 ug)~3. Dexamethasone sodium phosphate, 1 mL (10 mg per mL) (10 mg)~4. Normal saline 0.9%, 18.5mL"
62389679|NCT01349881|PLACEBO_COMPARATOR|eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets, PO, daily for 3 years. Sulindac placebo, 1 tablet, PO, daily for 3 years.
62769263|NCT05216055|ACTIVE_COMPARATOR|Liposomal Bupivacaine (Exparel)|"The study drug for patients in the treatment arm #2 will be a mixture of liposomal bupivacaine and bupivacaine 0.25% as follows:~1. Liposomal bupivacaine, 20 mL (13.3 mg/ml) (266 mg)~2. Normal saline 0.9%, 40mL The total volume to be injected in each patient will be 60 mL (see below for different treatment arms)."
62769264|NCT02337725|EXPERIMENTAL|TVP-1012 1 mg|For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of TVP-1012 1 mg orally, once daily before or after breakfast.
62567745|NCT06577909|EXPERIMENTAL|The combination group|Prednisone 20mg per day×4 weeks and IVIg 400mg/kg per day（≤20g per day）×5 days
62769265|NCT02337725|PLACEBO_COMPARATOR|Placebo|For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of placebo orally, once daily before or after breakfast.
62769266|NCT00368121|EXPERIMENTAL|Cetuximab + Dexamethasone|
62769267|NCT02108665|OTHER|Radiographic hysterosalpingography|Realisation in first: radiographic hysterosalpingographyresonance then imaging hysterosalpingography
62769268|NCT02108665|OTHER|Magnetic resonance imaging hysterosalpingography|Realisation in first : magnetic resonance imaging hysterosalpingography then a radiographic hysterosalpingography
62769269|NCT01731093|EXPERIMENTAL|AT-001|AT-001
62769270|NCT01731093|PLACEBO_COMPARATOR|Placebo|Matching placebo.
62769271|NCT00778570||ASA|Participants treated for Excimer laser vision correction using Advanced Surface Ablation (ASA).
62769272|NCT00778570||LASIK|Participants treated for Excimer laser vision correction using Laser-Assisted In Situ Keratomileusis (LASIK)
62769273|NCT00798317|EXPERIMENTAL|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
62769274|NCT00798317|PLACEBO_COMPARATOR|Placebo|Intravitreal injection of placebo
62769275|NCT04936347|EXPERIMENTAL|Cold knife|The interference of the experimental group is to perform intrauterine adhesiolysis with scissors
62769276|NCT04936347|OTHER|Hot knife|The interference of the control group is to perform intrauterine adhesiolysis with bipolar electric needle electrode, part of the scar tissue removed by electronic loop when it is necessary.
61994162|NCT05243095|NO_INTERVENTION|Control group|No training was applied to the control group.
61994163|NCT02110316|OTHER|Bioavailability|1 arm, different dosage form
61994164|NCT04860102|EXPERIMENTAL|hands on|Hands-on was defined as involving one hand on the fetal head, applying pressure to control expulsion, with the other hand applying pressure on the maternal perineum
61994165|NCT04860102|NO_INTERVENTION|hands off|standard of care
61994166|NCT02052921|ACTIVE_COMPARATOR|Rectal resection|Surgical rectal resection
61994167|NCT02052921|EXPERIMENTAL|Observation|Conservative approach
61994168|NCT03216447|EXPERIMENTAL|Experimental Arm|Switch from Prograf to Advagraf on POD 15
61994169|NCT03216447|ACTIVE_COMPARATOR|Control Arm|Continue Prograf treatment
61994170|NCT02996864|EXPERIMENTAL|Healthy Detours App|Participants will be encouraged to use the Healthy Detours app daily to track food, physical activity, and sleep.
61994171|NCT02996864|PLACEBO_COMPARATOR|Fat Secret App|Participants will be encouraged to use the FatSecret application daily to track food and physical activity.
62389680|NCT01349881|EXPERIMENTAL|Eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo one tablet PO daily for 3 years.
62389681|NCT01349881|EXPERIMENTAL|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
62769277|NCT05647668|ACTIVE_COMPARATOR|laparoscopic Nissen fundoplication|Creation of a 360° fundoplication wrap over a 30-Fr intra-esophageal bougie.
62769278|NCT05647668|ACTIVE_COMPARATOR|laparoscopic Toupet fundoplication|Creation of a 270° fundoplication wrap over a 30-Fr intra-esophageal bougie.
62561246|NCT05583435|EXPERIMENTAL|Delayed-entry group (placebo then one-on-one professional coaching)|"Delayed-Entry Group 3 (N=30). No intervention during the 90 day study period. Note: once participation in the pilot study has been completed for Groups 1 and 2, physicians participating in Group 3 will be offered to participate in six one-on-one sessions with a private professional coach over a 3 month period.~The professional coaching method includes (but will not be limited to) the following themes: optimizing meaning and engagement in work, building social support and community, improving work efficiency, addressing workload and boundary setting, enhancing communication, and building leadership skills, pursuing hobbies and creation/innovation, and promoting self-compassion and self-care (with a focus on physical and mental health)."
62561247|NCT00435331|EXPERIMENTAL|1|Open Label
62561248|NCT02016534|EXPERIMENTAL|Single arm|AMG 337 Monotherapy
62561249|NCT01365871|ACTIVE_COMPARATOR|basal injection|basal injection of anesthetics
62561250|NCT01365871|ACTIVE_COMPARATOR|basal + apical injection|basal + apical injection of anesthetics
62561251|NCT00800267|EXPERIMENTAL|Fixed combination of latanoprost 0.005% and timolol 0.5%|
62561252|NCT00800267|ACTIVE_COMPARATOR|latanoprost 0.005%|
62561253|NCT00800267|ACTIVE_COMPARATOR|Timolol - 0.5%|
62561254|NCT04421599|EXPERIMENTAL|Experimental Group A|Experimental Group A who were administered intramuscular injection during which aspiration lasted for 5-10 seconds.
62769279|NCT01477008|EXPERIMENTAL|BiCRI|BiPhasic Cartilage Repair Implant
62561255|NCT04421599|NO_INTERVENTION|Control Group|Control Group who were administered intramuscular injection during which aspiration lasted for 1-2 seconds.
62769280|NCT01477008|ACTIVE_COMPARATOR|Marrow Stimulation|Microfracture or Subchondral Drilling
62769281|NCT04199819|OTHER|HBsAg-negative recipients|Recipients who are HBsAg-negative will undergo a panel of test to detect HBV viral markers. In addition, real-time PCR will be used to determine the presence of intrahepatic HBV DNA and cccDNA on the explant histology. Patients with evidence of OBI, as characterized by any one positive biomarker (serum HBV DNA, serum HBV RNA, serum HBcrAg, intrahepatic HBV DNA, intrahepatic cccDNA) in either the donor or recipient, will be commenced on life-long oral nucleos(t)ide analog therapy as part of their routine antiviral prophylaxis. For those without evidence of OBI, that is, negative for all biomarkers, no antiviral prophylaxis will be given.
62561256|NCT04421599|EXPERIMENTAL|Experimental Group B|Experimental Group B who were not administered aspiration during IM injection.
62561257|NCT00708461|EXPERIMENTAL|Worksite Environmental Intervention|Changes to healthy food availability, physical activity opportunities and promotion, body weight scale access, and media enhancements to target weight gain prevention
62561258|NCT00708461|NO_INTERVENTION|No-contact control|No-treatment control condition. Worksites were offered program materials upon completion of programs at intervention sites.
62561259|NCT04113161|ACTIVE_COMPARATOR|Standard Care|Standard care will consist of 1) community-based screening and referral and 2) monthly contacts by a case manager, who will track attendance in mental health services and provide referrals upon request.
62561260|NCT04113161|EXPERIMENTAL|Child Behavioral Health Navigators (cbhN)|CbhNs will engage in a series of face to face and phone contacts with families to coordinate needed appointments at mental health care sites, as well as a range of human service support organizations (e.g. housing, food, financial, legal assistance). Over time, contact may decrease as the youth/family make ongoing connection with mental health care and other resources. However, over the course of the study (twelve months), twice per month check-ins will be routine between cbhNs and families. In addition, the cbhN will be expected to actively engage with the range of service providers and mental health resources as needed and preferred by the family. These contacts include telephone linkage calls, in-person advocacy meetings and at time, accompanying the youth and families to meetings at each organization.
62561261|NCT01459133|EXPERIMENTAL|Technosphere® Insulin Inhalation System|Single Site, Single Subject use of Technosphere® Insulin Inhalation System
62561262|NCT06545851|EXPERIMENTAL|Excercise Training Order A and B|The first series of five exercise trainings (A) involves supplemental oxygen therapy, with automatically titrated oxygen flow rates to maintain an oxygen saturation of 90-94% (A). The second series of five exercise trainings employs supplemental oxygen therapy with constant flow rates (B), as prescribed.
62769282|NCT03224065|NO_INTERVENTION|Recommended therapy group|Guideline recommended regimen for treatment, regardless of antibiotic resistant genotype test results
62769283|NCT03224065|EXPERIMENTAL|Optimized therapy group|Optimized therapy based on antibiotic resistant genotype test results
62769284|NCT01092962|EXPERIMENTAL|Mycophenolate mofetil|Mycophenolate mofetil
62769285|NCT01092962|ACTIVE_COMPARATOR|Cyclophosphamide|Cumulative dose of 148mg/kg of cyclophosphamide in 84 days (2mg/kg/day during 12 weeks)
62769286|NCT03984487|EXPERIMENTAL|STRW|Participants will receive the daily living skills intervention, Surviving and Thriving in the Real World (STRW).
62769287|NCT03984487|ACTIVE_COMPARATOR|PEERS|Participants will receive a social skills intervention, Program for the Education and Enrichment of Relational Skills (PEERS).
62769288|NCT02698371|ACTIVE_COMPARATOR|FBDC-SE (G1; Control)|Futurabond DC (single dose blister) will be applied as thickness to the enamel/dentine and rub into the tooth surface for 20s; FBDC drying layer for at least 5s with an air syringe; This adhesive layer will be light-cured with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2, during 20s.
62769289|NCT02698371|ACTIVE_COMPARATOR|FBDC-SE-EE (G2; Control )|Etch with 36% phosphoric acid, during 30s in enamel structures. Remove the 36% phosphoric acid with water during 1 minute. The remove of water excess will be done with weak air spray, not to dry the dentine completely. The dentine surface must slightly remain wet. Application of Futurabond DC (FBDC) as self-etch mode simultaneously in dentin and enamel, and the light-cured (LED light; 1000mW/cm2), during 20s.
61994172|NCT04196933|EXPERIMENTAL|Normal Controls|"normal control subjects - no history of neurologic or inner ear disease~The investigators will characterize vestibular spatial and temporal precision by calculating perceptual thresholds and reaction times for vestibular (yaw rotation, ytranslation) stimuli in normal subjects over a wide age range. Vestibular-visual temporal binding is then performed on each subject and the relationship between the principal parameters (vestibular perceptual thresholds \[inversely related to spatial precision\], vestibular reaction time variability \[inverse of temporal precision\], and the PSS and TBW from the temporal binding paradigm) will be examined. The investigators will collect qualitative assessments of dizziness/disbalance (DHI: dizziness handicap index) and quantitative measurements of balance and vestibular function (FGA: functional gait analysis, postural sway, and standard rotational testing - VOR gain, time constant, asymmetry)."
62389682|NCT01349881|EXPERIMENTAL|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
62389683|NCT02681094|ACTIVE_COMPARATOR|Saxagliptin+Dapagliflozin+Metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin
62561263|NCT06545851|EXPERIMENTAL|Excercise Training Order B and A|The first series of five exercise trainings employs supplemental oxygen therapy with constant flow rates (B), as prescribed.The second five series of five exercise trainings involves supplemental oxygen therapy, with automatically titrated oxygen flow rates to maintain an oxygen saturation of 90-94% (A).
62769290|NCT02698371|OTHER|FBU-ER (G3)|FuturabondU® (FBU) apply in enamel and dentin as etch-and-rinse (ER) mode. Etching of the dental hard tissue phosphoric acid (15s in dentin and 30s in enamel) and then rinse with water for 1 min. Dry off excess moisture with a gentle stream of air. Activating FBU SingleDose. FBU adhesive will be homogeneously applied to all cavity surfaces and rub in for 20s using the Single Tim; This adhesive layer will be light-cured with a light emitting diode unit, with an intensity of 1000mW/cm2 during 20s.
62769291|NCT02698371|OTHER|FBU-SE (G4)|FuturabondU® (FBU) apply in enamel and dentin as SE mode. Activating FBU SingleDose. FBU adhesive will be homogeneously apply to all cavity surfaces and rub in for 20 s using the Single Tim; Dry off the adhesive layer with dry, oil-free air for at least 5 s in order to remove any solvents. This adhesive layer will be light-cured with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2, during 20 seconds.
62769292|NCT02698371|OTHER|ADU-ER (G5)|Adhese®Universal (ADU) apply by etch-and-rinse (ER) mode. Etching of the dental hard tissue phosphoric acid (15 seconds in dentin and 30 seconds in enamel); Etch agent rinse with water for 1 minute. Dry off excess moisture with a gentle stream of air. Keep dentin dry, do not over dry; Adhesive ADU will be scrubbed into the tooth surface (enamel and dentin) for at least 20 seconds. Adhesive will be dispersed with compressed air until a glossy, immobile film layer results.Light-curing for 10 s with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2 for 20s.
62168322|NCT01243398|PLACEBO_COMPARATOR|Placebo|Gefitinib 500mg once daily
62389684|NCT02681094|ACTIVE_COMPARATOR|Dapagliflozin+Saxagliptin placebo+Metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Dapagliflozin and Saxagliptin Placebo
62389685|NCT02681094|ACTIVE_COMPARATOR|Saxagliptin+Dapagliflozin placebo+metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin placebo
62389686|NCT04974853|EXPERIMENTAL|Ayurveda Formulation|Patients with hypercholesterolemia treated with Ayurveda formulation, Cardio-Complement
62769293|NCT02698371|OTHER|ADU-SE (G6)|Adhese®Universal (ADU)apply by self-etch (SE) mode. Starting with the enamel, thoroughly coat the tooth surfaces (enamel and dentin) to be treated with ADU; Adhesive will be scrubbed into the tooth surface for at least 20 seconds. Adhesive will be dispersed with compressed air until a glossy, immobile film layer results.Light-curing for 20 s with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2.
62769294|NCT00507273||GIST|Patients diagnosed with a gastrointestinal stromal tumor (GIST)
62769295|NCT02965690|ACTIVE_COMPARATOR|Zimmer Biomet NexGen CR|Patients receive a Zimmer Biomet NexGen Total Knee Replacement
62769296|NCT02965690|ACTIVE_COMPARATOR|Medacta International GMK Sphere|Patients receive a Medacta International, GMK Sphere Total Knee Replacement
62769297|NCT01182311||Controls|Never received HBV vaccine and never had HBV
62769298|NCT01182311||HIV vaccinated >= 10 years|Well compensated HIV disease, vaccinated HBV \>= 10 years ago
62769299|NCT01182311||Spontaneously recovered >= 10 years|Spintaneously recovered from acute HBV \>= 10 years ago
62769300|NCT01182311||Vaccinated >= 20 years|Vaccinated against HBV \>= 20 years ago
62769301|NCT01182311||Vaccinated 10 < 15 years|Vaccinated against HBV 10 \< 15 years ago
61994173|NCT04196933|EXPERIMENTAL|Central Vestibular Dysfunction|"Migraine and Vestibular Migraine patients~The investigators intend to evaluate vestibular (yaw rotation or y-translation) - visual temporal binding in people with a wide range of motion sickness sensitivities (as quantified with standard questionnaires), including normal subjects, people with migraine and with vestibular migraine. The investigators will use our standard adaption method to narrow the TBW in these subjects, and will also employ PSS adaptation if a consistent pattern emerges that relates MS sensitivity to the PSS. The investigators will induce motion sickness using a pseudo-Coriolis task (so susceptibility can be quantified pre and post training)."
61994174|NCT04196933|EXPERIMENTAL|Peripheral Vestibular Dysfunction|"Vestibular Schwannoma patients~The basic approach is to characterize the precision of their vestibular information (perceptual thresholds for spatial precision, reaction times for temporal precision), and their temporal binding characteristics for vestibular (yaw rotation or y-translation)-visual inputs, in three states: pre-op, sub-acute post-op (2-6 weeks), and chronic post-op (6 months+). At each state the investigators will also assess the quality of their vestibular-mediated behaviors through questionnaires (e.g. DHI), postural sway, functional gait analysis, and standard rotational testing (VOR gain, time constant, and asymmetry)."
62769302|NCT01182311||Vaccinated 15 < 20 years|Vaccinated against HBV 15 \< 20 years ago
61994175|NCT04196933|EXPERIMENTAL|Implant Subjects|"Cochlear Implant (CI)/Vestibular Implant (VI) patients~A causative role for vestibular precision in temporal binding will be investigated in the VI patients, since the noise characteristics of the vestibular channel will be varied and to determine how this affects thresholds and temporal binding. As part of a second aim, the investigators will use VI and CI prosthetic signals in patients who have never received them together to see how the brain process sensory cues to which it is essentially naïve. Finally, after the acute experiments the investigators will provide 8 hours of 'physiologic' VI and CI stimulation by turning both implants on, sound modulates activity in the CI as usual, and angular head motion modulates activity in the VI while the subject actively explores the hospital environment."
61994176|NCT00578175|EXPERIMENTAL|Group A|Subjects received refrigerator-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation A) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
62769303|NCT00865085|EXPERIMENTAL|A|Citalopram HBr 40 mg tablets, single dose
62561264|NCT02802410|EXPERIMENTAL|IQ-Tape|IQ-application on leg muscles muscles
62561265|NCT02802410|EXPERIMENTAL|Kinesiotape|Kinesiotape application on leg muscles
62561266|NCT02802410|EXPERIMENTAL|No-Tape|No-Tape on leg muscles
62769304|NCT00865085|ACTIVE_COMPARATOR|B|CelexaTM 40 mg tablets, single dose
62769305|NCT05628207||4 hospitals using CDS TBI|healthcare system leveraging the rigorous approach, SCALED (SCaling AcceptabLE cDs), to guide CDS scaling across the system in VTE prevention.
62769306|NCT05628207||3 hospitals not using CDS TBI (control)|healthcare system not leveraging the rigorous approach, SCALED (SCaling AcceptabLE cDs), to guide CDS scaling across the system in VTE prevention.
62769307|NCT00308074|EXPERIMENTAL|Aripiprazole|aripiprazole monotherapy, begun at 2.5 mg or 5.0 mg based on clinical impression and severity of aggression and agitation. Dose to be adjusted in not more than 5 mg increments, weekly. The lowest effective dose will be used up to a maximum daily dose of 20 mg.
62769308|NCT02481713|EXPERIMENTAL|MI condition|motivational interview condition
62769309|NCT02481713|SHAM_COMPARATOR|CI condition|learning style interview condition
62769310|NCT01622907||Pts Symptomatic Recurrent Persistent AF|Patients with Symptomatic Recurrent Persistent AF or Long standing AF,for \> 1-year \< 5 years duration
62769311|NCT02752464|EXPERIMENTAL|Feedback report plus peer counseling|Feedback report plus peer counseling Participants receive 12 sessions of behavioral counseling and a brief printed feedback report
62769312|NCT02752464|ACTIVE_COMPARATOR|Feedback report|Feedback report Participants receive a brief printed feedback report
62769313|NCT05701891|EXPERIMENTAL|Physiotherapy with integrated VR|Our intervention will be a 12-week personalised, VR-integrated physiotherapy intervention in which a selection of existing VR modules developed by our partners (i.e. Reducept and SyncVR) will be integrated into physiotherapy treatment. The following VR modules will be used: education (Reducept), relaxation and distraction (SyncVR Relax \& Distract), activation (SyncVR Fit). Patients will use the Pico Neo 3 VR headset at the physiotherapy practice and at home 5 days a week for 10-30 minutes. In addition, physiotherapists will help patients transition from movements performed in a VR context to daily activities without VR.
62769314|NCT05701891|ACTIVE_COMPARATOR|Physiotherapy (usual care)|The control condition is usual physiotherapy care for 12 weeks.
61994177|NCT00578175|EXPERIMENTAL|Group B|Subjects received freezer-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation B) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
61994178|NCT00578175|ACTIVE_COMPARATOR|Group C|Subjects received ProQuad® co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
61994179|NCT06216431||Emergency call center workers|This group will consist of individuals working as operators at Izmir 112 Emergency Call Center.
61994180|NCT06216431||Office workers|This group will consist of office workers who work actively at a desk.
61994181|NCT01106209||Prematurely born infants in the NICU|Preterm infant patients delivered at UUMC and hospitalized in the NICU who are ≤1500 grams or \<30 weeks gestational age at birth
61994182|NCT01106209||Healthy term infants|Term infants delivered at UUMC without complication, either via cesarean section or vaginal delivery
61994183|NCT01106209||Infants having surgery at <1 year old|Infants admitted to the PCMC same-day surgery unit in preparation for elective surgery within the first year of life
61994184|NCT02659020|EXPERIMENTAL|Phase 1b: Cohort 1 - 15 mg/kg Olaratumab + Gemcitabine + Docetaxel|Participants received intravenous infusions of olaratumab 15 milligrams per kilogram (mg/kg) on days 1, 8 plus gemcitabine 900 milligrams per meter square (mg/m\^2) on days 1, 8 plus docetaxel 75 mg/m\^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met.
61994185|NCT02659020|EXPERIMENTAL|Phase 1b: Cohort 2 overall - 20 mg/kg Olaratumab + Gemcitabine + Docetaxel|Participants received intravenous infusions of olaratumab 20 mg/kg on days 1, 8 in combination with gemcitabine 900 mg/m\^2 on days 1, 8 and docetaxel 75 mg/m\^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met (cohort 2). Following a protocol amendment, additional participants were enrolled into this group to confirm the safety of the 20 mg/kg dose level prior to opening the Phase 2 (cohort 2 expansion).
61994186|NCT02659020|EXPERIMENTAL|Phase 2: Olaratumab + Gemcitabine + Docetaxel|Participants received intravenous infusions of olaratumab loading dose 20 mg/kg on days 1, 8 of cycle 1 followed by 15 mg/kg on days 1, 8 of all subsequent cycles in combination with gemcitabine 900 mg/m\^2 on days 1, 8 and docetaxel 75 mg/m\^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met. This cohort is a combination of participants who never received olaratumab (olaratumab-naive) and who received commercially available olaratumab (olaratumab pre-treated) prior to enrollment.
61994187|NCT02659020|PLACEBO_COMPARATOR|Phase 2: Placebo + Gemcitabine + Docetaxel|Participants received intravenous infusions of placebo on days 1, 8 in combination with gemcitabine 900 mg/m\^2 on days 1, 8 and docetaxel 75 mg/m\^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met. This cohort is a combination of participants who never received olaratumab (olaratumab-naive) and who received commercially available olaratumab (olaratumab pre-treated) prior to enrollment.
61994188|NCT05687279|EXPERIMENTAL|RSVt Vaccine Group|2 intranasal administrations (56 days apart) of the RSVt vaccine at D01 and D57
61994189|NCT05687279|PLACEBO_COMPARATOR|Control Group|2 intranasal administrations (56 days apart) of the placebo at D01 and D57
61994190|NCT00586183|EXPERIMENTAL|1|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
61994191|NCT04093778|EXPERIMENTAL|SDA intervention|Low dose high frequency training of all health workers in maternity and pediatric ward and dissemination of a Safe Delivery Application
61994192|NCT06456281||Cancer arm|Participants with new diagnosis of pancreatic cancer.
61994193|NCT06456281||Precancerous lesions arm|Participants with precancerous lesions.
61994194|NCT06456281||Healthy individuals arm|Healthy individuals without findings of clinical significance during routine health checkups.
61994195|NCT01988142|EXPERIMENTAL|SCI|
61994196|NCT05128851|ACTIVE_COMPARATOR|High Tibial Osteotomy and arthroscopy|High Tibial Osteotomy with arthroscopically treatment of intraarticular lesions.
61994197|NCT05128851|SHAM_COMPARATOR|High Tibial Osteotomy|Descending High Tibial Osteotomy with arthroscopy without treatment of intraarticular lesions.
61994198|NCT05128851|ACTIVE_COMPARATOR|High Tibial Osteotomy, arthroscopy and microfractures|High Tibial Osteotomy with arthroscopically treatment of intraarticular lesions and microfracture.
61994199|NCT01500642|ACTIVE_COMPARATOR|sublingual immunotherapy|15 patients treated with sublingual immunotherapy (SLIT One, ALK Abello) administered at standard dose (200 STU / dose) from June to August 2001
61994200|NCT01500642|ACTIVE_COMPARATOR|vestibular immunotherapy|15 patients treated with vestibular immunotherapy (SLIT One, ALK Abello) administered at standard dose (200 STU / dose) from June to August 2001
61994201|NCT01500642|ACTIVE_COMPARATOR|sublingual doubled immunotherapy|15 patients treated with sublingual immunotherapy (SLIT One, ALK Abello) administered at doubled dose (400 STU / dose) from June to August 2001
61994202|NCT01667666|EXPERIMENTAL|Nebulized HTS|The first 5 patients will receive 3% Nebulized hypertonic saline, the second 5 patients will receive 4.5% Nebulized hypertonic saline, the third group 6% Nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% Nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
61994203|NCT00615277|ACTIVE_COMPARATOR|1|1: omega-3 fatty acid supplement
61994204|NCT00615277|PLACEBO_COMPARATOR|2|2: olive oil
61994205|NCT01794091|EXPERIMENTAL|Eplerenone|In a subgroup of 50 patients, 25 will be randomized to eplerenone to assess effects on fibrotic index pre- and post-6 months of therapy.
61994206|NCT01794091|PLACEBO_COMPARATOR|Sugar pill|
61994207|NCT01637740||eyes with pseudoexfoliation syndrome|cataract myopic eyes with pseudoexfoliation syndrome
61994208|NCT01637740||eyes without pseudoexfoliation syndrome|cataract myopic eyes without pseudoexfoliation syndrome
61994209|NCT02028988|EXPERIMENTAL|Enzalutamide with External Beam Radiation|"Enzalutamide~40 mg orally 4x daily for 6 (28 day +/-3 days) cycles.~External Beam Radiation Therapy (EBRT) - 7-10 weeks after beginning Enzalutamide~75.6 to 79.2 Gy in 1.8 Gy fractions for up to 11 weeks.~\*Patients that are unable to complete enzalutamide therapy will still be treated with EBRT"
62561267|NCT02653625|EXPERIMENTAL|Cenicriviroc 150 mg|One tablet of Cenicriviroc 150 mg once daily with food in the morning for 24 weeks.
61994210|NCT04523233||Neural tube defects (NTDs)|NTDs are a group of birth defects in which an opening in the spine or cranium remains from early in human development. Neural tube defects may be diagnosed during the ultrasound scan that is carried out around week 12 of the pregnancy or, more likely, during the anomaly scan that is carried out at around weeks 19 to 20.
62389687|NCT05308420|ACTIVE_COMPARATOR|PENG block|"Patients scheduled for primary total hip arthroplasty after receiving spinal anesthesia will undergo pericapsular nerve group (PENG) block.~Postoperative multimodal analgesia with paracetamol, etoricoxib and oxycodone"
62561268|NCT03309137|EXPERIMENTAL|Antiseptic device|Patients who are randomized to receive the device will receive Chlorhexidine at a dose of 0.24-0.42 mg/installation into all intravenous lines. The intervention will be administered every 24 hrs and as needed for as long as the intravenous is in place
62567746|NCT06577909|ACTIVE_COMPARATOR|The prednisone group|Prednisone 20mg per day×4 weeks
62567747|NCT00428246|ACTIVE_COMPARATOR|1|1 mcg paricalcitol
61994211|NCT04523233||Control group|The control group will be included pregnant women with healthy fetuses (n = 70), who were matched for gestational weeks and maternal age and underwent amniocentesis because of age-related risk or increased risk in the triple test.
61994212|NCT05812014|EXPERIMENTAL|Study Vaccine Group|
61994213|NCT05812014|PLACEBO_COMPARATOR|Control Group|
61994214|NCT00666757|EXPERIMENTAL|duloxetine|study drug
61994215|NCT00666757|ACTIVE_COMPARATOR|citalopram|
61994216|NCT00666757|ACTIVE_COMPARATOR|fluoxetine|
61994217|NCT00666757|ACTIVE_COMPARATOR|paroxetine|
61994218|NCT00666757|ACTIVE_COMPARATOR|sertraline|
61994219|NCT03272919|EXPERIMENTAL|Arm 1: Investigational INF|Intraneural Facilitation (INF) treatment is an effective way to restore blood flow to damaged nerves as neuropathy is strongly impacted by reduced blood flow.
61994220|NCT03272919|OTHER|Arm 2: Standardized muscle stretching and strengthen|subjects will receive a standardized program of muscle stretching and strengthening exercise twice a week for six weeks under the supervision of treating physical therapist
61994221|NCT06003530|EXPERIMENTAL|Low dose hOMSC200|Administration of low dose hOMSC200 in addition to routine standard of care
61994222|NCT06003530|EXPERIMENTAL|High dose hOMSC200|Administration of high dose hOMSC200 in addition to routine standard of care
61994223|NCT06003530|PLACEBO_COMPARATOR|Placebo|Administration of placebo in addition to routine standard of care
61994224|NCT01018199|EXPERIMENTAL|Group 1- C-reactive protein (CRP) guided antibiotic therapy|Intervention on antibiotic therapy will be based on circulating RCP levels
61994225|NCT01018199|ACTIVE_COMPARATOR|Group 2 - procalcitonin (PCT) guided antibiotic therapy|Intervention on antibiotic therapy will be based on circulating PCT levels
61994226|NCT02663635|OTHER|Single Arm|
61994227|NCT02122536|ACTIVE_COMPARATOR|Xeomin right side; Xeomin to left side of face|Patients were randomized as to which side of the face was treated with Xeomin.
61994228|NCT02122536|ACTIVE_COMPARATOR|Botox right side; Botox to left side|Patients were randomized as to which side of the face was treated with Botox.
61994229|NCT03427359|EXPERIMENTAL|experimental arm|Induction chemotherapy: capecitabine tablet 1000mg/m2 po bid from day1 to 14,cisplatin injection 80mg/m2 iv day1,every 3 weeks for a total of 3 cycles. Then followed by concurrent chemoradiotherapy with cisplatin injection 100mg/m2 iv every 3 weeks for a total of 2 cycles.
61994230|NCT05697887|EXPERIMENTAL|The feasibility of the ketogenic diet|The purpose of this study was to verify the feasibility of the ketogenic diet in children with refractory epilepsies followed at a pediatric center in South Vietnam. The patient was considered feasible if he (or she) did not have the contra-indication for the ketogenic diet
61994231|NCT05697887|EXPERIMENTAL|the tolerability of the ketogenic diet|The purpose of this study was to verify the tolerability of the ketogenic diet in children with refractory epilepsies followed at a pediatric center in South Vietnam. The patient was considered tolerant if he (or she) did not have any side effects caused by the ketogenic diet
61994232|NCT05697887|EXPERIMENTAL|the efficacy of the ketogenic diet|The purpose of this study was to verify the efficacy of the ketogenic diet in children with refractory epilepsies followed at a pediatric center in South Vietnam. Patients were considered responders when a 50% seizure frequency was reached.
61994233|NCT03227887|ACTIVE_COMPARATOR|Good chewing ability|
61994234|NCT03227887|EXPERIMENTAL|Impaired chewing ability|
62168323|NCT03238326|EXPERIMENTAL|Rollover & De-Novo|1-4 mg/day; Start at 0.5 mg/day, titrate and maintain between 1mg/day to max of 4 mg/day
62168324|NCT03968744|EXPERIMENTAL|Safinamide|PO treatment: 2 weeks of treatment at dose 50 mg/day followed by 10 weeks at 100 mg/day
62168325|NCT06084260|ACTIVE_COMPARATOR|Self-compassion group|Group meetings using a self-compassion approach related to body dissatisfaction and eating issues.
62389688|NCT05308420|ACTIVE_COMPARATOR|Intrathecal morphine|"Patients scheduled for primary total hip arthroplasty will receive spinal anesthesia with local anesthetic and morphine administered intrathecally. After onset of spinal anesthesia a sham PENG block will be performed.~Postoperative multimodal analgesia with paracetamol, etoricoxib and oxycodone."
62389689|NCT05850637|EXPERIMENTAL|Single Arm Ultra-hypofractionated|5 fractions of 5.7 Gy every other day in the breast or chest wall region, with or without the inclusion of regional lymph node drainage chains
62389690|NCT05221658|EXPERIMENTAL|Arm A|As first-line therapy
62389691|NCT05221658|EXPERIMENTAL|Arm B1|EGFR H score ≥ 200, as third-line or above therapy
62389692|NCT05221658|EXPERIMENTAL|Arm B2|EGFR H score \<200, as third-line or above therapy
62389693|NCT03049189|EXPERIMENTAL|177Lu-edotreotide PRRT|"177Lu-edotreotide (177Lu-DOTATOC)~A maximum of four cycles of 7.5 ± 0.7 GBq (gigabequerel) 177Lu-edotreotide, each.~Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 4 cycles, 90 days apart (total duration: 270 days/9 months)"
61994235|NCT05404061|NO_INTERVENTION|Gut hormone secretion study|"This will be a retrospective study of participants who have undergone bariatric surgery. On the day of the visit participants will undergo comprehensive physiological profiling which will include the following tests:~* Body weight and bioelectrical impedance analysis~* Mixed Meal Tolerance Test. This will be analysed for metabolites including gut hormones, insulin, glucose, bile acids and their sub-fractions, fibroblast-growth factors, lipids and immune profiles.~* Resting Energy Expenditure and Diet Induced Thermogenesis assessed via Indirect Calorimetry~* Metabolomic and Metagenomic Assessment"
61994236|NCT05404061|PLACEBO_COMPARATOR|Gut hormone sensitivity study|This will be a single blinded study with participants attending three visits. Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM). This will not only allow us to acclimatise the study volunteer to the study visits, but also allow us to test for subject tolerability of the gut hormones. Occasionally some volunteers are more sensitive to the gut hormone infusion and the doses needs to be titrated down. The doses used will be established doses of the gut hormones infused previously and which have been shown to be safe and tolerated, and to reduce appetite (In house data).
61994237|NCT05404061|NO_INTERVENTION|Prospective assessment of gut hormone response pre and post-surgery|"This will be a prospective study assessing the gut hormone response pre and post bariatric surgery.~On the day of the visit participants will undergo comprehensive physiological profiling which will include the following tests:~* Body weight and bioelectrical impedance analysis~* Mixed Meal Tolerance Test. This will be analysed for metabolites including gut hormones, insulin, glucose, bile acids and their sub-fractions, fibroblast-growth factors, lipids and immune profiles.~* Resting Energy Expenditure and Diet Induced Thermogenesis assessed via Indirect Calorimetry~* Metabolomic and Metagenomic Assessment"
61994238|NCT04389125|EXPERIMENTAL|Improvement of Blood Flow group|One packet once a day, after breakfast (1.5 g/day, 1.5 g/day as an Angelica Gigas Nakai and Allium Cepa L.Extract Mixtures)
61994239|NCT04389125|PLACEBO_COMPARATOR|Placebo group|One packet once a day, after breakfast (1.5 g/day)
61994240|NCT00382811|EXPERIMENTAL|1|Daily Phenoxodiol + weekly carboplatin
61994241|NCT00382811|ACTIVE_COMPARATOR|2|Daily phenoxodiol placebo + weekly carboplatin
61994242|NCT01452308|EXPERIMENTAL|Cohort 1|Participants will receive simtuzumab at a dose of 10 mg/kg by intravenous (IV) infusion every other week for a total of 3 infusions.
61994243|NCT01452308|EXPERIMENTAL|Cohort 2|Participants will receive simtuzumab IV every other week for a total of 3 infusions. The dose will depend on the safety and tolerability of simtuzumab seen in Cohort 1 but will not exceed 20 mg/kg.
61994244|NCT01056809|ACTIVE_COMPARATOR|Traditional strategy|First resection of the primary colorectal tumour, then treatment of metastases with chemotherapy and if possible surgery.
61994245|NCT01056809|ACTIVE_COMPARATOR|Alternative strategy|First treatment of metastases with chemotherapy and if possible surgery, later resection of primary colorectal tumour if hope for cure or if symptoms develope that necessitates treatment
61994246|NCT01188603|EXPERIMENTAL|flibanserin|flibanserin 100 mg dose every evening
61994247|NCT01894269|EXPERIMENTAL|Anti-viral treatment|Oral antiviral drugs will be commenced after TACE. That is: Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
61994248|NCT01894269|NO_INTERVENTION|Control|No anti-viral therapy after TACE.
62389694|NCT03049189|ACTIVE_COMPARATOR|Everolimus|"Everolimus (Afinitor ®)~Doses: 10 mg/d Route of administration: Oral Duration of treatment: Continuous daily treatment until diagnosis of progression or End of Study (EOS)"
62389695|NCT01612494|PLACEBO_COMPARATOR|Normal Saline|
62389696|NCT01612494|EXPERIMENTAL|Hypertonic Saline|
62389697|NCT06207864|EXPERIMENTAL|Category 1 (biospecimens, surveys, interviews)|Cancer patients and survivors undergo collection of tissue, blood, saliva, and stool samples on study for genomic sequencing and microbiome analysis. Cancer patients and survivors also complete surveys and interviews on study pre and post intervention.
62389698|NCT05429528|NO_INTERVENTION|Control Arm (Arm 1)|Participants will experience a default version of NUSMart which replicates the traditional shopping experience of online grocery stores with no FOP labels.
62389699|NCT05429528|EXPERIMENTAL|Implicit Tax Arm (Arm 2)|Similar to Arm 1 except that an implicit tax is levied on qualifying beverages.
62389700|NCT05429528|EXPERIMENTAL|Explicit Tiered Tax Arm (Arm 3)|Similar to Arm 1 except that an explicit tiered tax is levied on qualifying food and beverage products.
62769315|NCT05451355|ACTIVE_COMPARATOR|Control Group|Participants receive a link to review an educational webpage (e.g., the AAP Firearm Storage Web Page)
62389701|NCT06305793|EXPERIMENTAL|IVIG + Coordinated Care|IVIG (Gamunex); 2g /kg monthly for 9 months (36 weeks)
62769316|NCT05451355|EXPERIMENTAL|Intervention Group|Participants receive the newly developed prototype (e.g., the Family Safety Check In)
61994249|NCT01272830|EXPERIMENTAL|oral Apatone®B|An amalgam of Vitamins C \& K3
61994250|NCT01272830|PLACEBO_COMPARATOR|Placebo|Oral capsule of similar appearance and taste without Apatone®B
61994251|NCT01302574|PLACEBO_COMPARATOR|mixed liquid meal|500 mL mixed liquid meal + 50 mg 13C-sodium-acetate
61994252|NCT01302574|ACTIVE_COMPARATOR|mixed liquid meal + lactisole|500 mL mixed liquid meal + 50 mg 13C-sodium-acetate + 450 ppm lactisole
61994253|NCT05695716|EXPERIMENTAL|CSI pVAD System|clinical use of the CSI pVAD System during high risk percutaneous coronary interventions (HR-PCI)
62168326|NCT06084260|ACTIVE_COMPARATOR|Diet group|Group meetings using a restricted diet approach related to body dissatisfaction and eating issues.
62389702|NCT06305793|EXPERIMENTAL|IVIG Placebo + Coordinated Care|Saline: Same dosage as IVIG; monthly for 9 months (36 weeks)
62389703|NCT06305793|EXPERIMENTAL|IVIG + Usual Care|IVIG (Gamunex); 2g /kg monthly for 9 months (36 weeks)
62389704|NCT06305793|EXPERIMENTAL|IVIG Placebo + Usual Care|Saline: Same dosage as IVIG; monthly for 9 months (36 weeks)
62389705|NCT04325490|EXPERIMENTAL|Liquid powder|Liquid powder containing tapioca starch stimutex AS, aloe barbadensis, rose hip oil and allantoin on the selected intertrigo area.
62769317|NCT05044624|OTHER|Margin, Tumor-Free|
62389706|NCT04325490|ACTIVE_COMPARATOR|Hydrocortisone|1% hydrocortisone cream
61994254|NCT01852266|EXPERIMENTAL|RSV cps2 Vaccine|Participants will receive one dose of the RSV cps2 vaccine administered as nose drops at study entry.
61994255|NCT01852266|PLACEBO_COMPARATOR|Placebo|Participants will receive one dose of placebo administered as nose drops at study entry.
61994256|NCT03266120|ACTIVE_COMPARATOR|Art Intervention|Participants randomly assigned to this arm will receive a hands-on art intervention that will consist of twice weekly group sessions of approximately 60 minutes each in duration that will take place indoors over a period of four weeks for a total of eight art sessions. Participants will complete sets of self-report psychometric assessments and blood pressure and heart rate will be monitored before, during, and following the conclusion of the intervention.
61994257|NCT03266120|EXPERIMENTAL|Gardening Intervention|Participants randomly assigned to this arm will receive a hands-on gardening intervention that will consist of twice weekly group sessions of approximately 60 minutes each in duration that will take place in a greenhouse over a period of four weeks for a total of eight gardening sessions. Participants will complete sets of self-report psychometric assessments and blood pressure and heart rate will be monitored before, during, and following the conclusion of the intervention.
61994258|NCT05400928|EXPERIMENTAL|Three-dimensional Directed Pulsed Field Ablation|Paroxysmal atrial fibrillation will be ablated with ring-shaped pulsed field ablation catheter directed by integrated three-dimensional mapping system
61994259|NCT03091608||The individuals taking XLGB Granule|The overall individuals taking XLGB Granule with recommended dosage and achieving the inclusion criteria.
61994260|NCT00980395|EXPERIMENTAL|VCR (Velcade, Cladribine and Rituximab)|"* Rituximab 375 mg/m2 IV day1~* Cladribine 4 mg/m2 IV over 2 hours days 1-5~* Bortezomib 1.3 mg/m2 IV days 1 and 4~* Repeat every 28 days for a maximum of 6 cycles"
61994261|NCT01449526|EXPERIMENTAL|B&L Investigational Contact Lens|The Bausch + Lomb investigational silicone hydrogel contact lens
61994262|NCT01449526|ACTIVE_COMPARATOR|B&L PureVision Contact Lens|The Bausch + Lomb PureVision silicone hydrogel contact lens
61994263|NCT06353490|OTHER|Subjects: 0 up to 1 year|"Collecting temperatures using the Geon Digital, Infrared Ear and Infrared Forehead thermometer"
61994264|NCT06353490|OTHER|Subjects: Older than 1 year and younger than 5 years|"Collecting temperatures using the Geon Digital, Infrared Ear and Infrared Forehead thermometer"
61994265|NCT06353490|OTHER|Subjects: Older than 5 years|"Collecting temperatures using the Geon Digital, Infrared Ear and Infrared Forehead thermometer"
61994266|NCT00907374|ACTIVE_COMPARATOR|Low dose inhibition of RAS|Standard low dose inhibition of the RAS with 10 mg of benazepril orally daily to treat microalbuminuria
62389707|NCT01071902|EXPERIMENTAL|Moxidex|Moxidex otic solution
62769318|NCT02782026|EXPERIMENTAL|idiopathic PAH|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
62389708|NCT01071902|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin otic solution
62561269|NCT03309137|NO_INTERVENTION|Routine Care|Patients who are randomized to routine care (no device, no intervention) will receive normal saline flush as per standard ICU care.
62561270|NCT01334229|EXPERIMENTAL|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
62561271|NCT01334229|PLACEBO_COMPARATOR|Placebo|Placebo for 6 weeks
62769319|NCT02782026|EXPERIMENTAL|heritable PAH with BMPR2 mutation|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
62561272|NCT04850339|ACTIVE_COMPARATOR|ANXV single dose|ANXV in a single ascending dose pattern in four dose levels.
62561273|NCT04850339|PLACEBO_COMPARATOR|Placebo single dose|Placebo in a single ascending dose pattern in four dose levels.
62561274|NCT04850339|ACTIVE_COMPARATOR|ANXV multiple dose|ANXV in a multiple ascending dose pattern in three dose levels.
62561275|NCT04850339|PLACEBO_COMPARATOR|Placebo multiple dose|Placebo in a multiple ascending dose pattern in four dose levels.
61994267|NCT00907374|EXPERIMENTAL|Agressive inhibition of the RAS|40-80 mg benazepril plus 25-100 mg losartan both orally once or twice daily
61994268|NCT06105385|EXPERIMENTAL|First|Suboccipital Myofascial Release Technique will be applied to this group first. After the intervention in this group is completed, the transition to the other crossover group will be made.
61994269|NCT06105385|EXPERIMENTAL|Second|"Once the intervention to the first group is completed, the second intervention Suboccipital Myofascial Release Technique will be applied to this group."
62389709|NCT01071902|PLACEBO_COMPARATOR|Vehicle|Vehicle
62389710|NCT02473029||Cases|Patients admitted to a tertiary hospital, with a clinical suspicion of Horton disease
62389711|NCT03943524|NO_INTERVENTION|DrApp Without Interax-AI|There are approximately 100 outpatients in whom the indications were registered through the use of DrApp, before the implementation of the drug interactions detection module.
62389712|NCT03943524|EXPERIMENTAL|DrApp With Interax-AI|"There are approximately 100 outpatients in whom the indications were registered through the use of DrApp, AFTER the implementation of the drug interactions detection module (Interax-AI).~Intervention: Device: Medication Interaction System of Dr App (Interax-AI)"
62561276|NCT00047450|PLACEBO_COMPARATOR|1|Participants will take placebo
62561277|NCT00047450|ACTIVE_COMPARATOR|2|Participants will take citalopram (Celexa)
62561278|NCT05562570|EXPERIMENTAL|Physical activity intervention coupled with standard post-cancer directed treatment care group|
62561279|NCT05562570|OTHER|Standard post-cancer directed treatment care control group|
62561280|NCT04138901|EXPERIMENTAL|Group T|Patients receiving bilateral subcostal TAP block.
62561281|NCT04138901|NO_INTERVENTION|Group C|Patients not receiving bilateral subcostal TAP block.
62769320|NCT02782026|EXPERIMENTAL|chronic thromboembolic PH|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
62769321|NCT02782026|EXPERIMENTAL|Controls|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
62769322|NCT00957333||case|ketamine + Cystitis
62769323|NCT02395198||HCV negative or in HCV treatment at T1|This group will be followed up at T2
62769324|NCT03756831|ACTIVE_COMPARATOR|Group I (normal subjects)|30 individuals (15 male, and 15 female students) with (BMI\<25 kg//m\^2)). Core Stability Assessment will be performed for them using Prokin system.
62769325|NCT03756831|ACTIVE_COMPARATOR|Group II (overweight subjects)|30 individuals (15 male, and 15 female students) with (BMI, 25-30 kg//m\^2)). Core Stability Assessment will be performed for them using Prokin system.
62561282|NCT01641640|EXPERIMENTAL|Sofosbuvir+PEG+RBV|
62561283|NCT06207721|EXPERIMENTAL|Control group (A)|conventional treatment by diet regimen and laxatives
62561284|NCT06207721|EXPERIMENTAL|study Group (B)|physical therapy program in addition to conventional treatment by diet regimen and laxatives
62561285|NCT02312167|EXPERIMENTAL|confocal laser endomicroscopy|confocal laser endomicroscopy : 10 to 15 minutes endomicroscopy procedure to obtain real time microscopical images of healthy and malignant tissue of the targeted organs
62561286|NCT03531775|OTHER|Upright MRI|All participants will be scanned using an upright MRI in seated/standing position and supine position. They will also be scanned supine using a conventional MRI.
62561287|NCT01295749|ACTIVE_COMPARATOR|ventilation by laryngeal tube|ventilation by laryngeal tube and continuous chest compression
62561288|NCT01295749|SHAM_COMPARATOR|ventilation by bag valve mask|ventilation by bag valve mask and interrupted chest compression
62561289|NCT06305806|EXPERIMENTAL|Ivabradine + Coordinated Care|"The starting dose will be 5 mg twice a day, and the dose will be modified if needed at the 1 month clinic visit. At this visit, HR will be measured and the dose will be modified as applicable. The maximum dose will be 7.5 mg twice daily if HR is ˃ 90 bpm.~The table below provides the dosing of ivabradine based on HR.~Supine Resting HR 60-80 2.5 mg BID Supine Resting HR \>80 5 mg BID Supine Resting HR \>90 7.5 mg BID~\*Resting HR should be measured 5 minutes after lying down"
62561290|NCT06305806|EXPERIMENTAL|Ivabradine Placebo + Coordinated Care|
62561291|NCT06305806|EXPERIMENTAL|Ivabradine + Usual Care|"The starting dose will be 5 mg twice a day, and the dose will be modified if needed at the 1 month clinic visit. At this visit, HR will be measured and the dose will be modified as applicable. The maximum dose will be 7.5 mg twice daily if HR is ˃ 90 bpm.~The table below provides the dosing of ivabradine based on HR.~Supine Resting HR 60-80 2.5 mg BID Supine Resting HR \>80 5 mg BID Supine Resting HR \>90 7.5 mg BID~\*Resting HR should be measured 5 minutes after lying down"
62561292|NCT06305806|EXPERIMENTAL|Ivabradine Placebo + Usual Care|
62561293|NCT02584101|EXPERIMENTAL|ACT|ACT therapy
62561294|NCT02584101|ACTIVE_COMPARATOR|Enhanced Treatment as Usual|Group support
62769326|NCT03756831|ACTIVE_COMPARATOR|Group III (obese subjects)|30 individuals (15 male, and 15 female students) (BMI\>30 kg//m\^2)). Core Stability Assessment will be performed for them using Prokin system.
62769327|NCT05363540|ACTIVE_COMPARATOR|Pre-incisional parasternal block|ultrasound guided parasternal intercostal block will be administrated before surgical incision.
61994270|NCT04407910|EXPERIMENTAL|Air-powder polishing device|
61994271|NCT04407910|EXPERIMENTAL|Rubber-cup+paste|
61994272|NCT03578081|EXPERIMENTAL|Arm I (fosaprepitant dimeglumine, olanzapine)|Patients receive palonosetron hydrochloride IV over 30 seconds or ondansetron hydrochloride IV over 2-5 minutes or PO on day 1, dexamethasone PO on days 1-4, fosaprepitant dimeglumine IV over 20-30 minutes on day 1, and olanzapine PO on days 1-4. Treatment may repeat every 4 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
61994273|NCT03578081|ACTIVE_COMPARATOR|Arm II (placebo, olanzapine)|Patients receive palonosetron hydrochloride IV over 30 seconds or ondansetron hydrochloride IV over 2-5 minutes or PO on day 1, dexamethasone PO on days 1-4, placebo IV over 20-30 minutes on day 1, and olanzapine PO on days 1-4. Treatment (with no placebo) may repeat every 4 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
61994274|NCT04434131|EXPERIMENTAL|Convalescent Plasma|The investigational product is anti-SARS-CoV-2 convalescent plasma obtained from former patients identified as having recovered from COVID-19 and obtained by Vitalant from local and national donors following national blood donation guidelines. All subjects receive the convalescent plasma.
61994275|NCT03348696|ACTIVE_COMPARATOR|dexamethasone tapering dose|standard dexamethasone pre-medication (8mg B.I.D x 3 days commencing the day before chemotherapy) then 4mg 1x/d for 2 days followed by 2mg 1x/d for 2 days
61994276|NCT03348696|ACTIVE_COMPARATOR|dexamethasone physician choice|standard dexamethasone pre-medication (i.e. 8mg B.I.D x 3 days commencing the day before chemotherapy) then physician choice interventions
61994277|NCT00398853|EXPERIMENTAL|Chromium Picolinate|Chromium
61994278|NCT00398853|OTHER|Placebo|Placebo
61994279|NCT05677542||Axial Spondyloarthritis Patients|Patients with Axial Spondyloarthritis
61994280|NCT05677542||Psoriatic Arthritis Patients|Patients with Psoriatic Arthritis
62561295|NCT04337398|EXPERIMENTAL|Wearables|Adults with several mental illness
62561296|NCT04337398|EXPERIMENTAL|Wearables and exergames|Adults with several mental illness
62561297|NCT06266325||Derivation|Individuals whose randomly selected assessment was done between April 1, 2010 and March 31, 2018, in whom model will be developed
61994281|NCT01540058|EXPERIMENTAL|test-guided strategy|"Treatment considered as the standard at the time of patient inclusion based on the primary cancer suspected by the BioTheranostics Cancer Type ID test molecular analysis"
61994282|NCT01540058|ACTIVE_COMPARATOR|Empiric strategy|Gemcitabine/Cisplatin
61994283|NCT03712033||TEC4Home Stroke Cohort|"All participants or caregiver involved will be instructed to measure BP per the TEC4Home BP Telemonitoring Protocol. Participants will measure their BP daily, 4x/day, for the first week. After the first week, all weekly BP measurements will be done 3 days/week with 4 measurements a day. All readings must be taken before administration of antihypertensive medications, twice in the morning, 5 minutes apart and twice in the evening, 5 minutes apart.~The TEC4Home telemonitoring nurse will review the BP measurements and contact the participant on a weekly basis until the end of the 6-month monitoring period. The telemonitoring nurse will adjust the antihypertensive medication doses as per the TEC4Home Stroke - Hypertension Management Algorithm."
62561298|NCT06266325||Validation|Individuals whose randomly selected assessment was done between April 1, 2018 and March 31, 2020, in whom model's performance will be assessed
62567748|NCT00428246|ACTIVE_COMPARATOR|2|2 mcg paricalcitol
62567749|NCT00428246|PLACEBO_COMPARATOR|3|Placebo
62567750|NCT00634361|EXPERIMENTAL|A|
61994284|NCT01938274|EXPERIMENTAL|Educational intervention|Patients in this group will receive a brief educational intervention to assist them in setting the appropriate expectations for leisure activity after surgery with respect to the type, amount, intensity, and duration of activity.
61994285|NCT01938274|NO_INTERVENTION|Control group|No intervention will be received. Patients will receive a written version of the education intervention at the end of the study.
61994286|NCT04968899|EXPERIMENTAL|Experimental group|Oral dexamethasone (Neofordex®) 40 mg (Day1 to Day 4), ± an additional 4-days cycle of dexamethasone between days 10 and 21
62561299|NCT02134431||HIV positive|HIV-positive subjects ages 10-14 years old and 18-21 years old taking tenofovir in their antiretroviral regimen.HIV positive subjects will undergo lower endoscopy (specifically either flexible sigmoidoscopy or colonoscopy) with biopsies to obtain colorectal tissue samples. HIV-1 levels and tenofovir levels in tissue will be measured.
62561300|NCT02134431||HIV negative|HIV-negative subjects ages 10-14 years old and 18-21 years old. HIV negative subjects will undergo lower endoscopy (specifically either flexible sigmoidoscopy or colonoscopy) with biopsies to obtain colorectal tissue samples. These tissue samples will be pretreated with tenofovir and challenged with laboratory HIV-1.
62561301|NCT05702333||Vasoactive-inotropic drug use (VASO+)|All patients treated with vasoactive-inotropic drugs (epinephrine, norepinephrine, dobutamine, dopamine, and levosimendan) after 12 hours after Intensive Care Unit Admission were retrospectively classified in the VASO + cohort.
62561302|NCT05702333||No vasoactive-inotropic drug (VASO -)|Patients treated with vasoactive-inotropic drugs (epinephrine, norepinephrine, dobutamine, dopamine, and levosimendan) in the first 12 hours after Intensive Care Unit Admission (ICU) or patients never treated with such drugs in ICU were retrospectively classified in the VASO - cohort.
62561303|NCT03051451|ACTIVE_COMPARATOR|combination metformin hydrochloride/ fluoxetine 500/20 mg|"Dosage: The dose will depend on the period of treatment in which the patient is:~* Single dose treatment (from visit 2 (from day 0 to day 30 ± 7), the patient will take 1 metformin hydrochloride tablet 500 mg / fluoxetine 20 mg and 1 placebo tablet , every 24 hours in the morning for 30 days).~* Treatment at double dose (from visit 3 and until visit 8), the patient will take 2 tablets of metformin hydrochloride 500 mg / fluoxetine 20 mg and 2 tablets of Placebo, every 24 hours in the morning for 150 days)."
62561304|NCT03051451|ACTIVE_COMPARATOR|combination metformin hydrochloride/ fluoxetine 1000/20mg|"Dosage: The dose will depend on the period of treatment in which the patient is:~* Single dose treatment (from visit 2 (from day 0 to day 30 ± 7), the patient will take 1 metformin hydrochloride tablet 850 mg / fluoxetine 20 mg and 1 placebo tablet , every 24 hours in the morning for 30 days).~* Treatment at double dose (from visit 3 and until visit 8), the patient will take 2 tablets of metformin hydrochloride 850 mg / fluoxetine 20 mg and 2 tablets of Placebo, every 24 hours in the morning for 150 days)."
62561305|NCT03051451|PLACEBO_COMPARATOR|Placebo Oral Tablet|Placebo
61994287|NCT04968899|ACTIVE_COMPARATOR|Control|IVIg (1g/kg D1-D2) plus prednisone (1 mg/kg/day x 21 days (3 weeks))
62561306|NCT00663936|EXPERIMENTAL|1|T-817MA once daily
62561307|NCT00663936|PLACEBO_COMPARATOR|2|Placebo once daily
61994288|NCT01180309||lingual frenum alterations|individuals each one with their phonological system complete
61994289|NCT05953662|EXPERIMENTAL|Reduced-port laparoscopic surgery|locations of trocars: A 10mm trocar is placed in the supraumbilical or subumbilicus as an observation port, and the surgeon inserts a 10mm trocar and a 5mm trocar on the ipsilateral side of the patient according to the intraoperative situation, as the main operation port and the secondary operation port, and the positions of the trocars follow the principle that the lesion is located at the triangular apex of the two trocars.
62561308|NCT05089383||combined progesterone group|patients will receive vaginal plus subcutaneous or per os progesterone
62561309|NCT05089383||Vaginal progesterone group|patients will receive vaginal progesterone
62561310|NCT02890173|EXPERIMENTAL|CS-3150 2.5 mg|CS-3150 2.5 mg, orally, once daily after breakfast for 12 weeks
62561311|NCT02890173|EXPERIMENTAL|CS-3150 5.0 mg|CS-3150 5 mg, orally, once daily after breakfast for 12 weeks
62561312|NCT02890173|ACTIVE_COMPARATOR|Eplerenone|Eplerenone 50 mg, orally, once daily after breakfast for 12 weeks
62561313|NCT05214625||Gastroenterology patients|"Patient receiving an endoscopic procedure because of regular care will be considered eligible for inclusion. Patients receive an endoscopic procedure in the context of the Dutch national screening program, because of gastrointestinal symptoms, or because of follow-up of previously diagnosed bowel diseases.~Patients will be asked to complete a questionnaire concerning AI. No intervention will be administered."
62561314|NCT05214625||Gastroenterology physicians|"GI physicians (both gastroenterologists and gastroenterology fellows), participating in a yearly gastroenterology and hepatology training day, will be asked for their participation in this study.~Physician will be asked to complete a questionnaire concerning AI. No intervention will be administered."
62561315|NCT04588701||persons with anal fistulas|all persons with anal fistulas treated by a single surgeon over 22 years
62561316|NCT00882752||Ulcerative colitius|The method used to identify the microbes in the sample was chosen because it had the potential to provide more exhaustive identification of the bacteria present in the sample as compared to culturing methodology.
61994290|NCT05953662|ACTIVE_COMPARATOR|conventional laparoscopic surgery|locations of trocars: A 10mm trocar is placed in the supraumbilicus or subumbilicus as an observation port, and the surgeon inserts a 10mm trocar and a 5mm trocar in a suitable position according to the intraoperative situation as the main operation port and the secondary operation port. The assistant places two 5mm trocars in the appropriate position as the assistant operation port.
61994291|NCT03240133|EXPERIMENTAL|Part1: BCX7353 750 mg|
61994292|NCT03240133|EXPERIMENTAL|Part 2: BCX7353 500 mg|
61994293|NCT03240133|EXPERIMENTAL|Part 3: BCX7353 250 mg|
61994294|NCT03240133|PLACEBO_COMPARATOR|Parts 1, 2 and 3: placebo|
61994295|NCT00834210|ACTIVE_COMPARATOR|1|Dapsone Gel 5% and Tazarotene Cream 0.1%
61994296|NCT00834210|ACTIVE_COMPARATOR|2|Tazarotene Cream 0.1%
61994297|NCT04563091|EXPERIMENTAL|Interventional group|"The study population will consist of 6 evaluable, outpatient patients with chronic kidney failure who need to perform hemodialysis thrice weekly for their survival.~In the case of drop out of a patient will be enrolled another patient to arrive at 6 patients evaluable both at the end of Period A and at the end of Period B of the study"
61994298|NCT04145258|OTHER|WHO TBM treatment + placebo|"* Inclusion (D-0) to end of Week-8 (W-8): isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin~* W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
61994299|NCT04145258|OTHER|WHO TBM treatment + aspirin|"* Inclusion (D-0) to end of Week-8 (W-8): isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + aspirin 200 mg/d~* W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
61994300|NCT04145258|OTHER|Intensified TBM treatment + placebo|"* Inclusion (D-0) to end of Week-8 (W-8): high dose rifampicin (35 mg/kg/d) + high dose linezolid (1200 mg/d from D-0 to end of W-4, then 600 mg/d from W-5 to W-8) + isoniazid 5 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin~* W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
61994301|NCT04145258|OTHER|Intensified TBM treatment + aspirin|"* Inclusion (D-0) to end of Week-8 (W-8): high dose rifampicin (35 mg/kg/d) + high dose linezolid (1200 mg/d from D-0 to end of W-4, then 600 mg/d from W-5 to W-8) + isoniazid 5 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + aspirin 200 mg/d~* W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
61994302|NCT04126395||Controls|"This groups consists of children now aged 6-12y:~* Without a medical diagnosis possibly influencing motor development~* Without motor problems (M-ABC-2 and DCD-Q)~* Without social reponsiveness problems (SRS-2)"
61994303|NCT04126395||Developmental Coordination Disorder|"This groups consists of children now aged 6-12y:~* With a multidisciplinary diagnosis of DCD~* With motor problems (M-ABC-2 and DCD-Q)"
61994304|NCT04126395||Developmental Coordination Disorder + Autism Spectrum Disorder|"This groups consists of children now aged 6-12y:~* With a multidisciplinary diagnosis of DCD~* With motor problems (M-ABC-2 and DCD-Q)~* With social responsiveness problems (SRS-2)"
61994305|NCT01023581|PLACEBO_COMPARATOR|Placebo|Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
62561317|NCT03243110||Asthmatics requiring breathing test|"Participants must have had a diagnosis of asthma by a physician. The participant must have had a self-reported health care interaction related to asthma (physician visit, ED visit, hospitalization) in the past 5 years.~Participants must be 1 to 85 years old."
62561318|NCT05653479|EXPERIMENTAL|Treatment Group 1|Single subcutaneous injection of a low dose of UPB-101 (formerly ASP7266) in 8 Japanese participants
62561319|NCT05653479|EXPERIMENTAL|Treatment Group 2|Single subcutaneous injection of a medium dose of UPB-101 (formerly ASP7266) in 8 Japanese participants
62769328|NCT05363540|ACTIVE_COMPARATOR|Post-incisional parasternal block|under direct vision parasternal intercostal block will be administrated after surgical incision and before closure of the sternum.
62769329|NCT01397604|NO_INTERVENTION|Saline Placebo|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects."
62561320|NCT05653479|EXPERIMENTAL|Treatment Group 3|Single subcutaneous injection of a high dose of UPB-101 (formerly ASP7266) in 8 Japanese participants
62561321|NCT05653479|EXPERIMENTAL|Treatment Group 4|Single subcutaneous injection of a high dose of UPB-101 (formerly ASP7266) in 8 Non-Japanese Non-East Asian participants
62769330|NCT01397604|PLACEBO_COMPARATOR|SE Vehicle|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~The SE (squalene) vehicle contains the oil emulsion in which the GLA-SE is solubilized."
61994306|NCT01023581|EXPERIMENTAL|Alogliptin 25 QD|Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
61994307|NCT01023581|EXPERIMENTAL|Alogliptin 12.5 BID|Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
61994308|NCT01023581|ACTIVE_COMPARATOR|Metformin 500 BID|Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.
61994309|NCT01023581|ACTIVE_COMPARATOR|Metformin 1000 BID|Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.
61994310|NCT01023581|EXPERIMENTAL|Alogliptin 12.5 BID + Metformin 500 BID|Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.
61994311|NCT01023581|EXPERIMENTAL|Alogliptin 12.5 BID + Metformin 1000 BID|Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.
61994312|NCT02051036|EXPERIMENTAL|Moxibustion|A series of moxibustion sessions within four weeks from the baseline with concurrent conventional medications for BPH.
61994313|NCT02051036|NO_INTERVENTION|Waiting|Participants who will be allocated to waitlist will receive no moxibustion treatments throughout the 4 weeks while receiving other conventional managements for BPH. After 4 weeks, if participants choose to try the moxibustion treatment, the active acupuncture treatment will be provided for 4 weeks (2 sessions/week).
61994314|NCT02889094||HIV-HBV co-infected individuals|No interventions will be administered. Individuals will be undergoing routine care.
61994315|NCT02120976|EXPERIMENTAL|Dose 1 JTT-252 or Placebo|Tablets, single dose in fasted condition
62389713|NCT03682926|EXPERIMENTAL|electrostimulation individualized|Selective electrostimulation for tonic fiber, phasic fiber FIa and FIIb and different stimulus times. Muscle fibers (Tonic) with a frequency of 20Hz, pulse width (t) of 700μs to 1ms, time of rise and fall of the wave of 1.0 seconds, duration of contraction and repetition was based on the perineal evaluation But the resting time was twice as long as sustained. For the IIa (phasic) fibers the frequency was 50 Hz with a pulse width of 400μs to 500μs, for 3 seconds of sustentation and 6 seconds of relaxation, time of rise of 0,5 seconds and 0,5 seconds of descent. E for type IIb (phasic) fibers, 80 Hz frequency, pulse width 250μs to 400μs, 1 second contraction for 3 seconds rest and 0.2 seconds rise and fall time.
62389714|NCT03682926|ACTIVE_COMPARATOR|electrostimulation with fixed protocol|Intervention -Electro-stimulate all fibers with a single electrical parameter. Pulse width 700μs, rise and fall time of 2 seconds each, sustain time of 4 seconds and rest 8 seconds for 20 minutes, the intensity will be modulated, as in the previous group by patient tolerance in milliamperes.
62389715|NCT03946072|ACTIVE_COMPARATOR|Transseptal Group|Transseptal Aortic Approach Catheter Ablation Procedure
62389716|NCT03946072|ACTIVE_COMPARATOR|Retrograde Group|Retrograde Aortic Approach Catheter Ablation Procedure
62389717|NCT03417102|ACTIVE_COMPARATOR|Bypassing Agents (BPA) On-demand|Participants received On-demand BPAs (use of these agents, as needed, for episodic bleeding episodes, and not on a regular regimen intended to prevent spontaneous bleeding) per Investigator discretion from Day 1 for treatment of breakthrough bleeding episodes, up to a total of 9 months.
62389718|NCT03417102|EXPERIMENTAL|Fitusiran 80 mg Prophylaxis|Participants received Fitusiran 80 mg subcutaneously (SC) as prophylaxis once monthly from Day 1, along with the on-demand BPAs (per investigator's discretion and within bleeding dosing guidelines) for treatment of breakthrough bleeding episodes, up to a total of 9 months.
61994316|NCT02120976|EXPERIMENTAL|Dose 2 JTT-252 or Placebo|Tablets, single dose in fasted condition
61994317|NCT02120976|EXPERIMENTAL|Dose 3 JTT-252 or Placebo|Tablets, single dose in fasted condition
61994318|NCT02120976|EXPERIMENTAL|Dose 4 JTT-252 or Placebo|Tablets, single dose in fasted condition
61994319|NCT02120976|EXPERIMENTAL|Dose 5 JTT-252 or Placebo|Tablets, single dose in fasted condition
61994320|NCT02120976|EXPERIMENTAL|Dose 6 JTT-252 or Placebo|Tablets, single dose in fasted condition
61994321|NCT02120976|EXPERIMENTAL|Dose 7 JTT-252 or Placebo|Tablets, single dose in fasted condition
61994322|NCT02120976|EXPERIMENTAL|Dose 8 JTT-252|Tablets, single dose in fed condition
62389719|NCT01667731|EXPERIMENTAL|SOF+RBV 12 Weeks (GT 2/3, TN)|Treatment-naive (TN) participants coinfected with HIV-1 and genotype (GT) 2 or genotype 3 HCV infection will receive SOF+RBV for 12 weeks.
62389720|NCT01667731|EXPERIMENTAL|SOF+RBV 24 Weeks (GT 2/3, TE)|Treatment-experienced (TE) participants coinfected with HIV-1 and genotype 2 or genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
61994323|NCT02120976|EXPERIMENTAL|Dose 9 JTT-252|Tablets, single dose in fasted condition
61994324|NCT00913744|EXPERIMENTAL|Ocriplasmin|
61994325|NCT00913744|SHAM_COMPARATOR|Sham injection|
61994326|NCT06158191|EXPERIMENTAL|Intervention group|Lifestyle modification program focused on physical activity and diet. Diet recommendations in line with the AHA's guidelines focusing on foods rather than nutrients. Emphasis will be placed on awareness of the risk of overeating associated with the consumption of energy-dense foods (fat, added sugar or both). Dieticians will closely interact with participants and will not recommend a daily energy deficit greater than 500 kcal. Participants will have constant access to the dieticians and bi-monthly appointment will be required for the first year of the study to tailor recommendations to the participants. The physical activity/exercise component will be under the supervision of a kinesiologist and will aim at 160 minutes per week of moderate intensity endurance-exercise (mainly brisk walking) tailored to the participants' preferences and habits. Following the first year, participants will meet a dietician and a kinesiologist every month for the next two years (maintenance period).
61994327|NCT06158191|NO_INTERVENTION|Control group|Usual behavior
61994328|NCT04836299|EXPERIMENTAL|Ivermectin|Participants will receive a single 600 µg / kg dose of ivermectin.
62389721|NCT01667731|EXPERIMENTAL|SOF+RBV 24 Weeks (GT 1, TN)|Treatment-naive (TN) participants coinfected with HIV-1 and genotype 1 HCV infection will receive SOF+RBV for 24 weeks.
62389722|NCT03550976|EXPERIMENTAL|High risk intervention group|
62561322|NCT05132062||Patients with CA-AKI occurrence|Occurrence of CA-AKI as defined by the Acute Kidney Injury Network definition
61994329|NCT04836299|PLACEBO_COMPARATOR|Placebo Comparator|Participants will receive a single dose of placebo.
61994330|NCT01930292|EXPERIMENTAL|Part A: Debio 1143|Eligible participants receive Part A: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle according to dose escalation rules (in combination with Paclitaxel and Carboplatin standard of care)
61994331|NCT01930292|EXPERIMENTAL|Part B: Lung Cancer|Participants with Lung Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
62389723|NCT03550976|NO_INTERVENTION|High risk control group|Dietary evaluation and body composition analysis at 12 and 28 weeks of pregnancy. Receive routine obstetric examinations and routine health education which includes proper diet and exercise advice.Collect birth outcomes.
62389724|NCT03550976|NO_INTERVENTION|Low risk control group|Dietary evaluation and body composition analysis at 12 and 28 weeks of pregnancy. Receive routine obstetric examinations and routine health education which includes proper diet and exercise advice.Collect birth outcomes.
62389725|NCT02609087|EXPERIMENTAL|Sevoflurane|adjust the end-tidal sevoflurane (sevofran inhaler, Hana pharmacy, Korea) concentration maintaining the 40 \~ 50 BIS (bispectral index) with 3 ng/ml of remifentanil using TCI (target controlled infusion) pump
62389726|NCT02609087|EXPERIMENTAL|Propofol|adjust propofol (FRESOFOL MCT INJ 2% (vial), Fresinus Kabi Korea) concentration maintaining the 40 \~ 50 BIS (bispectral index) with 3 ng/ml of remifentanil using TCI (target controlled infusion) pump
62389727|NCT04629105|ACTIVE_COMPARATOR|Cohort 1 (SARS-CoV-2): Arm 1 (LMSCs)|Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 1: 25 subjects treated with up to 3 doses of 100 million LMSCs.
62389728|NCT04629105|PLACEBO_COMPARATOR|Cohort (SARS-CoV-2): Arm 2 (Placebo)|Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 2: 10 subjects treated with up to 3 doses of Placebo.
62389729|NCT04629105|ACTIVE_COMPARATOR|Cohort 2 (Flu): Arm 3 (LMSCs)|Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 3: 25 subjects treated with up to 3 doses of 100 million LMSCs.
62389730|NCT04629105|PLACEBO_COMPARATOR|Cohort 2 (Flu): Arm 4 (Placebo)|Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 4: 10 subjects treated with up to 3 doses of Placebo.
62389731|NCT00266331|ACTIVE_COMPARATOR|Group A, RayGel Topical Cream|RayGel Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
62389732|NCT00266331|PLACEBO_COMPARATOR|Arm B Placebo Topical Cream|Placebo Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
62389733|NCT02801487|EXPERIMENTAL|CIRT with concurrent chemo arm|Treated with carcon ion radiotherapy along with concurrent chemotherapy (Cisplatin 40mg/m\^2, weekly).
62389734|NCT02777294|EXPERIMENTAL|Online intervention|Therapist-facilitated, cognitive behavioral therapy
62389735|NCT02777294|ACTIVE_COMPARATOR|Psycho-educational website|Self-help, psycho-educational website
62389736|NCT01168297||Maycoba residents|Pima and non-Pima Mexicans from the village of Maycoba
62389737|NCT03529552|EXPERIMENTAL|Patients with anterior cruciate ligament rupture|
62389738|NCT05135494|EXPERIMENTAL|Experimental Group|Experimental Group: Inspiratory Muscle Training + rehabilitation program
62389739|NCT05135494|OTHER|Control Group|Control Group: rehabilitation program
62389740|NCT00862927||Cue reactivity in virtual reality|Breath Scan + Saliva Sample + Questionnaires + View Virtual Reality Scenes
62389741|NCT02774824||CABG patients from protocol 003-03|"Patients who will agree to be followed for an additional 9 months, which include:~2 phone calls at 6 and 9 months after coronary artery bypass graft surgery~1 clinic visit at 12 months after coronary artery bypass graft surgery ( 64-slice or better MDCT angiography)"
62389742|NCT03145207|OTHER|name brand patch|name brand lidocaine patch
62389743|NCT03145207|OTHER|generic patch|generic lidocaine patch
62389744|NCT03145207|OTHER|name brand patch-early|name brand lidocaine patch-early
62389745|NCT03145207|OTHER|name brand patch-late|name brand lidocaine patch-late
61994332|NCT01930292|EXPERIMENTAL|Part B: Ovarian Cancer|Participants with Ovarian Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
62389746|NCT03145207|OTHER|generic patch-early|generic lidocaine patch-early
62389747|NCT03145207|OTHER|generic patch-late|generic lidocaine patch-late
62389748|NCT03145207|OTHER|both patches|brand name and generic lidocaine patch
62389749|NCT05732740|EXPERIMENTAL|Treatment|Participants will participant in 9 weekly group-based sessions
62389750|NCT00612573|EXPERIMENTAL|Doxycyline 0.6 mg/kg/day|Doxycycline dosed at 40 mg/day to subjects of appropriate weights
62389751|NCT00612573|EXPERIMENTAL|Doxycycline 1.2 mg/kg/day|Doxycycline dosed at 80 mg/day to subjects of appropriate weights
62389752|NCT00612573|EXPERIMENTAL|Doxycycline 2.4 mg/kg/day|Doxycycline dosed at 160 mg/day to subjects of appropriate weights
62389753|NCT00612573|PLACEBO_COMPARATOR|Placebo|
62389754|NCT01078389|EXPERIMENTAL|Febuxostat 40 mg or 80 mg|Febuxostat 40 mg or 80 mg (based on serum urate levels at Day 14), capsules, orally, once daily for up to 24 Months.
62561323|NCT05132062||Patients without CA-AKI occurrence|No occurrence of CA-AKI as defined by the Acute Kidney Injury Network definition
62769331|NCT01397604|ACTIVE_COMPARATOR|GLA-AF|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~GLA-AF contains the study drug in an aqueous solution."
62769332|NCT01397604|ACTIVE_COMPARATOR|GLA-SE|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~GLA-SE contains the study drug in a squalene oil emulsion."
62769333|NCT05069753|ACTIVE_COMPARATOR|Immediate sequential bilateral cataract surgery (ISBCS)|
62389755|NCT01078389|PLACEBO_COMPARATOR|Placebo|Febuxostat placebo-matching capsules, orally, once daily for up to 24 Months.
62769334|NCT05069753|ACTIVE_COMPARATOR|Delayed sequential bilateral cataract surgery (DSBCS)|
62769335|NCT04901091||study group№ 1|patients who have left ventricular aneurysm without thrombosis
62769336|NCT04901091||study group№ 2|patients who have left ventricular aneurysm with thrombosis
61994333|NCT01930292|EXPERIMENTAL|Part B: Breast Cancer|Participants with Breast Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
62389756|NCT06382415||Patients operated on rectal cancer|Patients operated on rectal cancer, included in two compulsory audits of the Catalan Cancer registry and in the Catalan Infection Surveillance Program, who suffered an organ-space surgical infection.
62389757|NCT04856293|EXPERIMENTAL|Three Period Treatment Sequence|Participants will receive a single 250 mg crizotinib dose of the formulated capsule(FC) formulation, a single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial, and a single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules)
62769337|NCT04901091||control group|patients who have not left ventricular aneurysm
62769338|NCT04147936|ACTIVE_COMPARATOR|AXA1665 29.4g|Dietary Supplement: AXA1665 Amino acids, food study
62769339|NCT04147936|ACTIVE_COMPARATOR|AXA1665 53.9 g|Dietary Supplement: AXA1665 Amino acids, food study
62769340|NCT04147936|PLACEBO_COMPARATOR|Placebo 29.4 g|Dietary Supplement: Placebo
62769341|NCT03166644|EXPERIMENTAL|Control Group|Patients with major abdominal surgery
62769342|NCT03166644|EXPERIMENTAL|Intervention Group|Patients with standard practice
62769343|NCT00259688|NO_INTERVENTION|1|Women with gestational hypertension
62769344|NCT00259688|NO_INTERVENTION|2|Women with uncomplicated pregnancies
62769345|NCT00259688|NO_INTERVENTION|3|Re-test of women one to two years post-partum.
61994334|NCT03137888|EXPERIMENTAL|sMRI-Guided RT with TMZ|Patients undergo spectroscopic magnetic resonance imaging-guided dose-escalated radiation therapy daily for the first 5 days of every week (Monday - Friday) over 6 weeks. Patients also receive standard of care temozolomide PO daily during radiation therapy for up to 42 days.
62389758|NCT04856293|EXPERIMENTAL|Two Period Treatment Sequence|Participants will receive a single 250 mg crizotinib dose of the formulated capsule(FC) formulation, a single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial
62389759|NCT03878706||GLP1 and SGLT2i group|60 patients treated with a combination of liraglutide and empagliflozin. All subjects will undergo an echocardiographic study in order to estimate GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx, SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of sublingual vessels using Sideview Darkfield Imaging (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx. Oxidative stress markers, vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, thrombomodulin, nitrites and nitrates, N-terminal pro B-type natriuretic peptide (NT-proBNP), growth differentiation factor (GDF)-15, mitochondrial-derived peptide-c (MOTS-c), blood glucose, glycosylated hemoglobin (HbA1c) and a full lipidemic profile will be measured before and at 6 and 12 months of treatment.
62389760|NCT03878706||GLP1 group|60 patients treated with liraglutide. All subjects will undergo an echocardiographic study in order to estimate GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx, SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of sublingual vessels using Sideview Darkfield Imaging (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx. Oxidative stress markers, vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, thrombomodulin, nitrites and nitrates, N-terminal pro B-type natriuretic peptide (NT-proBNP), growth differentiation factor (GDF)-15, mitochondrial-derived peptide-c (MOTS-c), blood glucose, glycosylated hemoglobin (HbA1c) and a full lipidemic profile will be measured before and at 6 and 12 months of treatment.
62769346|NCT04893499|EXPERIMENTAL|Low-dose mastic group|This arm will consume 600 mL of a sparkling water enriched with Chios mastic per day for a 3-month period.
62389761|NCT03878706||SGLT2i group|60 patients treated with empagliflozin. All subjects will undergo an echocardiographic study in order to estimate GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx, SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of sublingual vessels using Sideview Darkfield Imaging (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx. Oxidative stress markers, vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, thrombomodulin, nitrites and nitrates, N-terminal pro B-type natriuretic peptide (NT-proBNP), growth differentiation factor (GDF)-15, mitochondrial-derived peptide-c (MOTS-c), blood glucose, glycosylated hemoglobin (HbA1c) and a full lipidemic profile will be measured before and at 6 and 12 months of treatment.
61994335|NCT05861791|EXPERIMENTAL|opioid group|IV-PCA consisted of fentanyl
61994336|NCT05861791|ACTIVE_COMPARATOR|non-opioid group|IV-PCA consisted of ketorolac and nefopam
61994337|NCT05279586|ACTIVE_COMPARATOR|patients that will receive lactulose|Cirrhotic patients who were recovered from HE will be randomized into lactulose group receiving 30-60 ml of lactulose orally in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
62561324|NCT06119776||Study|Patients who underwent Whipple over the splenic artery (WOTSA) as a treatment for PDAC
62561325|NCT06119776||Control|Patients who underwent total pancreatectomy (TP) as a treatment for PDAC
62561326|NCT01982682|EXPERIMENTAL|Treatment (TBI, DLI, cyclophosphamide, CD34+ donor HSCT)|"CONDITIONING REGIMEN: Patients undergo TBI BID on days -10 to -8, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANT: Patients undergo CD34+ (cluster of differentiation 34+) selected allogeneic HSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning by day 42, and mycophenolate mofetil IV BID on days -1 to 28."
62561327|NCT04760899|ACTIVE_COMPARATOR|Active Group|This group will receive the active form of tDCS. The tDCS will be administered with the anode over the right lobule of the cerebellum, and the cathode over the left lobule of the cerebellum. Stimulation will be administered for a twenty minute period that does not include the 30 second ramp up at the beginning and end of the stimulation.
62769347|NCT04893499|PLACEBO_COMPARATOR|Low-dose control group|This arm will consume 600 mL of a standard sparkling water per day for a 3-month period.
62769348|NCT04893499|EXPERIMENTAL|High-dose mastic group|This arm will consume 600 mL of a sparkling fruit juice enriched with Chios mastic per day for a 3-month period.
62769349|NCT04893499|PLACEBO_COMPARATOR|High-dose control group|This arm will consume 600 mL of a standard sparkling fruit juice per day for a 3-month period.
62769350|NCT05563467|EXPERIMENTAL|Pembrolizumab Treatment|
61994338|NCT05279586|ACTIVE_COMPARATOR|patients that will receive colistin|colistin group receiving colistin sulfate 1.5 million I.U. tablet orally twice
61994339|NCT00363454|EXPERIMENTAL|Dose Escalation|Phase I: Triciribine Phosphate Monohydrate
62769351|NCT01221194|ACTIVE_COMPARATOR|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
61994340|NCT02583932|EXPERIMENTAL|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis. The MMi consists of 3-4 weekly sessions of 30-90 min each with an intervener (psychologist, social worker, or nurse) who provides the necessary ingredients to foster a good therapeutic alliance (i.e., trust, warmth, empathy, neutrality, and authenticity), encourages self-exploration and systematically addresses different levels of meaning (i.e., situational, global, existential, historical).
62561328|NCT04760899|SHAM_COMPARATOR|Sham Group|This group will receive the sham form of tDCS. The electrodes will be placed in the same montage as in the Active group, however the stimulation parameters are different. For this group, the stimulation will be ramped up to the target intensity over thirty seconds at the beginning, then immediately ramp down over thirty seconds. The stimulation will then remain off for the next twenty minutes. After twenty minutes the stimulation will ramp up to the target intensity and then back down over thirty seconds.
61994341|NCT02583932|PLACEBO_COMPARATOR|Empathic Visitor (EV)|Empathic visitors will meet with patients over 3-4 weekly sessions of 30-90 minutes as in the experimental group. They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic listener will be specifically instructed to avoid initiating discussions about meaning (e.g., perspective-taking, how the patient interprets his/her feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present). If the patient initiates discussions about these topics, the visitor will simply listen without further intervening.
61994342|NCT02583932|NO_INTERVENTION|Usual Care Control Group|Treatment as usual in tertiary care hospital, typically medically-focused. All participants will be free to use hospital- or community-based supports, which will be tracked in all groups throughout the study by questionnaire and through a chart review. Both recruiting centres include well established psychosocial oncology services including psychiatrists, psychologists and social workers.
61994343|NCT03646110|EXPERIMENTAL|single-incision MIE|Esophageal cancer patients received single-incision Minimally invasive esophagectomy
62561329|NCT04760899|NO_INTERVENTION|Healthy Controls|These will be age and sex-matched healthy controls who only come in for the baseline visit in order to provide comparative values with which to confirm adequate impairment in our diseased population.
62561330|NCT02942017|PLACEBO_COMPARATOR|Placebo|Participants received an infusion rate equivalent to the 90 micrograms per kilogram per hour (μg/kg/h) group.
62561331|NCT02942017|EXPERIMENTAL|SAGE-547 90 μg/kg/h|Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).
62561332|NCT01518322||FeNO|All subjects will have their Fractional Exhaled Nitric Oxide (FeNO) measured with the NIOX MINO® device according to instructions for NO measurements.
62561333|NCT00537173||Arm 1|Paclitaxel 90 mg/m2 IV D1, 8, and 15 + Avastin 10 mg/kg IV, day 1 and 15
62561334|NCT01744769||Hypothyroidism for RAI|The group of patients who experience hypothyroidism after thyroid hormone withdrawal for radioactive iodine(RAI) therapy
61994344|NCT03646110|ACTIVE_COMPARATOR|multi-incision MIE|Esophageal cancer patients received multi-incision Minimally invasive esophagectomy
62561335|NCT00865761|EXPERIMENTAL|A|Alprazolam 3 mg Extended Release Tablets, single dose
62561336|NCT00865761|ACTIVE_COMPARATOR|B|XANAX XR® 3 mg tablets, single dose
62561337|NCT03876951|EXPERIMENTAL|vacuum-assisted biopsy|Patients will be submitted to percutaneous vacuum-assisted biopsy (VAB), followed by breast surgery
62561338|NCT01472861|PLACEBO_COMPARATOR|No AECC|Routine procedures without AECC
62561339|NCT01472861|EXPERIMENTAL|AECC|Endometrial biopsy and Autologous endometrial coculture
62561340|NCT03047187||ACLR patients|anterior cruciate ligament reconstruction patients
62567751|NCT06198153|ACTIVE_COMPARATOR|Stationary Cycling|This group will receive stationary cycling for 6 weeks.
62567752|NCT06198153|EXPERIMENTAL|Progressive Functional Training|This group will receive Progressive Functional Training programs for 6 weeks.
62567753|NCT01496677|EXPERIMENTAL|Elderly subjects (65 or older)|
62769352|NCT01221194|ACTIVE_COMPARATOR|PFC Stockings|The stocking therapy group will be given PFC shear reducing stockings to wear.
62769353|NCT01537055|EXPERIMENTAL|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy
62769354|NCT01537055|ACTIVE_COMPARATOR|levofloxacin-based triple therapy|levofloxacin-based triple therapy for 10 days
62769355|NCT04714021|EXPERIMENTAL|Single steep arm- CO2 insufflation|PEG will be performed by single step technique and CO2 will be insufflated during the endoscopy
62769356|NCT04714021|ACTIVE_COMPARATOR|Single steep arm- air insufflation|PEG will be performed by single step technique and air will be insufflated during the endoscopy
62769357|NCT04714021|EXPERIMENTAL|Pull technique arm- CO2 insufflation|PEG will be performed by pull technique and CO2 will be insufflated during the endoscopy
62769358|NCT04714021|ACTIVE_COMPARATOR|Pull technique arm- air insufflation|PEG will be performed by pull technique and air will be insufflated during the endoscopy
62769359|NCT05046691|EXPERIMENTAL|Intervention group|8-week .b Foundations course
62769360|NCT05046691|NO_INTERVENTION|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after their counterparts in experimental group completed the intervention.
62769361|NCT01595594|ACTIVE_COMPARATOR|Systemic Doxycycline|
62769362|NCT01595594|EXPERIMENTAL|aPDT+ Placebo|
62769363|NCT06275308|EXPERIMENTAL|Observational Group|Manipulation of end tidal carbon dioxide in subjects
62769364|NCT05908968|EXPERIMENTAL|Drinking ELO water|Drinking 1.5 litres of ELO water daily
62769365|NCT03262116|EXPERIMENTAL|Bionic Pancreas - Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
62769366|NCT03262116|EXPERIMENTAL|Bionic Pancreas - Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
62769367|NCT03262116|EXPERIMENTAL|Bionic Pancreas - BC222 insulin lispro|Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
62769368|NCT02784600||Partial or full-thickness rotator cuff tear|Rotation Medical bioinductive implant
62168327|NCT05311774|EXPERIMENTAL|•tramadol and duloxetine|patients will receive tramadol 50 mg twice daily, titration will be done every 3days until 2 weeks, maximum dose will be 400mg daily and will receive duloxetine 30mg daily fixed dose in combination with tramadol. Investigators will follow up the patients for 3 months
62561341|NCT05410249||Patients with primary ITP|Patients with primary ITP and aged 18 and older will be included in the study. Patients under 18 and those with proven secondary ITP \[as cases initiated by or associated with infections due to human immunodeficiency virus (HIV-associated), hepatitis B virus, or hepatitis C virus-associated secondary ITP\] will be excluded. Moreover, patients with accompanying autoimmune disorders such as systemic lupus erythematosus (SLE) and patients of malignancies were excluded.
62769369|NCT01345383||Current smokers|
62769370|NCT00663845|EXPERIMENTAL|Arm 1|
62769371|NCT00663845|PLACEBO_COMPARATOR|Arm 2|
62769372|NCT06103994|EXPERIMENTAL|Intervention|Multistrain probiotic
62168328|NCT05311774|ACTIVE_COMPARATOR|tramadol and placebo|patients will receive tramadol 50 mg twice daily, titration will be done every 3days until 2 weeks, maximum dose will be 400mg daily and will receive placebo drug once daily in combination with tramadol. Investigators will follow up the patients for 3 months
62769373|NCT06103994|PLACEBO_COMPARATOR|Placebo|Placebo
62769374|NCT02476136||Placebo group|Patients participating in one of the included randomized controlled trials, assigned to the placebo group
62769375|NCT02476136||Intervention group|Patients participating in one of the included randomized controlled trials, assigned to the investigational antidepressant (paroxetine, duloxetine or fluoxetine) or active comparator (venlafaxine) group.
62769376|NCT05085912|EXPERIMENTAL|Group A|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation
62769377|NCT05085912|ACTIVE_COMPARATOR|Group B|Circumferential pulmonary vein isolation + linear ablation + posterior wall box isolation
62769378|NCT05085912|ACTIVE_COMPARATOR|Group C|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion
62769379|NCT02102152|ACTIVE_COMPARATOR|TOBI / Placebo|TOBI / Placebo.
62769380|NCT02102152|ACTIVE_COMPARATOR|Placebo / TOBI|Placebo / TOBI
62769381|NCT00313976|EXPERIMENTAL|Arm 1|
62769382|NCT00313976|EXPERIMENTAL|Arm 2|
62769383|NCT06088836|EXPERIMENTAL|Group I (Retrolaminar block group)|Patients received ultrasound guided Retrolaminar block bolus dose of 20 ml 0.25% bupivacaine then continuous infusion at a rate of 0.1 mL/kg/hr. for 4 days
62769384|NCT06088836|EXPERIMENTAL|Group II (Erector spinae plane block group)|Patients received ultrasound guided Erector spinae plane block bolus dose of 20 ml 0.25% bupivacaine then continuous infusion at a rate of 0.1 mL/kg/hr. for 4 days
62769385|NCT00906958|EXPERIMENTAL|Nexus Flow Generator|Participants were randomised to Nexus Flow Generator group for one night.
62769386|NCT00906958|ACTIVE_COMPARATOR|VPAP Flow Generator 25|Participants were randomised to VPAP Flow Generator 25 group for one night.
62769387|NCT06198088|EXPERIMENTAL|experimental group|The patient in the experiment group will PNF techniques (hold relax) the participants who were assigned for post traumatic stiffness of the elbow with baseline treatment (heating pad), stretching applied for 30 sec then relaxation time 10 sec, 5 repetition were given in a session for 5 days a week for 4 weeks.
62561342|NCT05410249||normal individuals|The control group will be age-matched and sex-matched normal healthy volunteers.
62561343|NCT05881629|EXPERIMENTAL|Side-lying peanut ball group|Participants randomized to this group will be asked to adopt a side-lying, lateral position on the ipsilateral side of the fetal spine. A peanut ball will be positioned between the participant's legs while in this position. They will be asked to maintain this position for 60 minutes.
62769388|NCT06198088|OTHER|control group|exercise therapy range of motion, stretching and strengthening were applied with heating pad as baseline treatment. 5 repetition were given in a session for 5 days a week for 4 week.
62769389|NCT02187315|EXPERIMENTAL|Melodie group|Induction chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy
62769390|NCT02187315|OTHER|Routine-chemotherapy group|Induction chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
62769391|NCT03344263|EXPERIMENTAL|tests of attentional performance|
61994345|NCT02735161|EXPERIMENTAL|Exercise training|"Four exercise training sessions. Two endurance training sessions, one with high intensity interval training and one session of moderate intensity of longer duration. Two strength training session; one with high load and few repetitions and one with low load and many repetitions.~Fatigue and lactate will be measured before, after and 24 hours post-exercise. Trainings sessions will be randomized."
61994346|NCT04935021|EXPERIMENTAL|ATTR-CM|Patients or Gene carrier
62389762|NCT03878706||Control group|60 patients treated with insulin and metformin.All subjects will undergo an echocardiographic study in order to estimate GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx, SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using Sideview Darkfield Imaging (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx. Oxidative stress markers, vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, thrombomodulin, nitrites and nitrates, N-terminal pro B-type natriuretic peptide (NT-proBNP), growth differentiation factor (GDF)-15, mitochondrial-derived peptide-c (MOTS-c), blood glucose, glycosylated hemoglobin (HbA1c) and a full lipidemic profile will be measured before and at 6 and 12 months of treatment.
62389763|NCT02373176|EXPERIMENTAL|[14C] PRC-4016 (Icosabutate)|Investigational medicinal product (IMP), \[14C\] PRC-4016 (Icosabutate) solution (600 mg in 2 mL, 200.0 μCi \[7.4 MBq\]). The radiochemical purity of \[14C\]PRC-4016 will be at least 97%.
62389764|NCT04531436|EXPERIMENTAL|Intervention|Brief mindful eating intervention
62561344|NCT05881629|PLACEBO_COMPARATOR|Control group|Participants randomized to this group will be able to adopt any position of their choosing during the 60-minute study period. They will not be able to use a peanut ball during this time.
62561345|NCT00256178|EXPERIMENTAL|Lapaquistat Acetate 50 mg QD + Simvastatin|
62561346|NCT00256178|EXPERIMENTAL|Lapaquistat Acetate 100 mg QD + Simvastatin|
62561347|NCT00256178|ACTIVE_COMPARATOR|Simvastatin|
61994347|NCT04263974|EXPERIMENTAL|Smartphone Application|"A protocol of exercises and general recommendations based on the current scientific evidence will be provided through a smartphone application. A follow-up of the use of the application will be carried out. The treatment protocol will last 6 months, during which a minimum of 4 weekly sessions of exercises will be carried out at home.~Each pathology will have an unique program of exercises and recommendations."
61994348|NCT04263974|ACTIVE_COMPARATOR|Conventional Treatment|Those in this group will received the conventional treatment protocol provided within the Andalusian Public Health System. This will consist on the delivery of an exercise program and recommendations using a sheet of paper. Participants will be told to perform the exercises during 6 months, with minimum of 4 weekly sessions of exercise that will be carried out at home.
61994349|NCT03072485|OTHER|Sirolimus, metformin, diclofenac|First five enrolled participants
62561348|NCT01417871||case goup|Lifestyle counseling, ABC program
62561349|NCT01417871||control group|usual care
62561350|NCT04382547|EXPERIMENTAL|mesenchymal stem cells|Patients with Covid-19 associated pneumonia receiving standard treatment and allogenic pooled olfactory mucosa-derived mesenchymal stem cells
61994350|NCT03072485|OTHER|Metformin, diclofenac|Sixth to tenth enrolled participants
62561351|NCT04382547|ACTIVE_COMPARATOR|control|Patients with Covid-19 associated pneumonia receiving standard treatment
62561352|NCT06349525|EXPERIMENTAL|4 implants overdenture with telescopic|Completely edentulous maxillary arch treated with 4 implants overdenture
62561353|NCT06349525|ACTIVE_COMPARATOR|4 implant supported overdenture with Locator|Completely edentulous maxillary arch treated with 4 implant supported overdenture
62561354|NCT03600389|EXPERIMENTAL|Intervention Arm (Implementing Patient Priorities Care)|Aligning healthcare recommendations to achieve patients' specific health outcome goals within the context of what patients are willing and able to do.
62561355|NCT03600389|NO_INTERVENTION|Control Arm (Not Implementing Patient Priorities Care)|Routine Care
62567754|NCT01496677|EXPERIMENTAL|Younger adults (18-45 years old)|
62769392|NCT02395211|ACTIVE_COMPARATOR|Usual Physiotherapy|
62769393|NCT02395211|EXPERIMENTAL|Gloreha device|
62769394|NCT01930890|EXPERIMENTAL|BIIB023 3 mg/kg|Participants will receive BIIB023 3 mg/kg IV every 4 weeks through Week 100 plus background therapy including oral steroids (prednisone or equivalent) and mycophenolate mofetil (MMF).
62769395|NCT01930890|EXPERIMENTAL|BIIB023 20 mg/kg|Participants will receive BIIB023 20 mg/kg IV every 4 weeks through Week 100 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
62769396|NCT02584920|EXPERIMENTAL|HLX01|375mg/m2 iv single dose
62769397|NCT02584920|ACTIVE_COMPARATOR|Rituximab|375mg/m2 iv single dose
62769398|NCT01293981||Lumbar Degenerative Disc Disease|
61994351|NCT02813603||Study Product (19-gauge)|After randomization, the subject undergo EBUS-TBNA either with the 19-gauge needle or the 22-gauge needle
61994352|NCT02813603||Control Intervention (22-gauge)|After randomization, the subject undergo EBUS-TBNA either with the 19-gauge needle or the 22-gauge needle
62769399|NCT05040906|EXPERIMENTAL|H02+ Chemotherapy|Participants received six cycles of H02(375 mg/m2) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone/prednisolone(CHOP) chemotherapy(21-day cycles).
62389765|NCT05621109|EXPERIMENTAL|Intervention|Rapid moderate weight loss (approximately 10% of body weight at baseline over 8-10 weeks or BMI 23 kg/m\^2 is achieved) by very low-calorie diet (VLCD), reintroduction (4 weeks), weight loss maintenance until pregnancy (up to 12 months), and a high protein, high fiber diet during pregnancy (n=120 females/couples).
62389766|NCT05621109|NO_INTERVENTION|Standard of care|The control group will not receive any dietary advice prior to pregnancy. During pregnancy control subjects will receive dietary advice similar to the intervention group, i.e. a high protein, high fiber diet (n=120 females/couples).
62561356|NCT04460872|EXPERIMENTAL|testosterone enanthate|Testosterone enanthate via i.m. injection (100 mg/week)
62389767|NCT05376163||Individuals with headache|Individuals with headaches caused by neck problems
62389768|NCT02790320||Patients with locally recurrent or metastatic breast cancer|Patients received 1.4 mg/m2 eribulin, administered intravenously on day 1 and 8 of each 21 day cycle until disease progression or unmanageable toxicity, per routine clinical practice.
62389769|NCT01996956|OTHER|Volume loading|
62389770|NCT04579458||COVID-19 Positive|COVID-19 positive in nasopharyngeal swabs and tears or saliva.
62389771|NCT02809872||Study Group|Study Group with Pleural effusion for any cause and receiving chest CT scan and thoracic Ultrasounds.
62389772|NCT03033290|EXPERIMENTAL|Bu-Zhong-Yi-Qi-Tang (BZYQT)|capsule of BZYQT, 4gm tid, 12gm a day for 2 months
62769400|NCT05040906|ACTIVE_COMPARATOR|Rituxan+Chemotherapy|Participants received six cycles of Rituxan combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles).
62168329|NCT06072833|EXPERIMENTAL|Patient Financial Education / Navigation|Individuals who screen positive will all move forward to receive the intervention. This intervention includes partnering with community-based organizations to deliver financial education, connection to resources, and counseling tailored to individual patients and spouses for 6-months.
62389773|NCT03033290|PLACEBO_COMPARATOR|placebo control|similar placebo capsule 4gm tid, 12gm a day for 2 months
62389774|NCT05115812||RAT|patients having undergone robotic-assisted RAT procedure
62389775|NCT04858516|EXPERIMENTAL|Neoadjuvant treatment with palbociclib and exemestane plus trastuzumab and pyrotinib|
62389776|NCT00483431|PLACEBO_COMPARATOR|PLACEBO|MK7 dosage 0 mcg, 4 capsules, orally, daily for 12 weeks.
62389777|NCT00483431|ACTIVE_COMPARATOR|MK7_10|MK7 dosage 10 mcg, 1 capsule of 10 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
62561357|NCT04460872|EXPERIMENTAL|locomotor training, testosterone enanthate|Treadmill and overground walking training and testosterone enanthate via i.m. injection (100 mg/week)
62561358|NCT04460872|NO_INTERVENTION|non-interventional control|Non-interventional control group
62561359|NCT05263908||PAXLOVID PACK|Subjects administered PAXLOVID PACK
62561360|NCT01522911|OTHER|atrial and brain natriuretic peptide|Impact on atrial an brain natriuretic peptide secretion after percutaneous left atrial appendage closure
61994353|NCT02253810|EXPERIMENTAL|Tranexamic Acid|Patients randomized to this arm will receive standard dosing of tranexamic acid intraoperatively.
61994354|NCT02253810|PLACEBO_COMPARATOR|Placebo|Patients randomized to this arm will receive normal saline solution, instead of tranexamic acid, intraoperatively.
62389778|NCT00483431|ACTIVE_COMPARATOR|MK7_20|MK7 dosage 20 mcg, 2 capsules of 10 mcg and 2 placebo-capsules, orally, daily for 12 weeks.
62389779|NCT00483431|ACTIVE_COMPARATOR|MK7_45|MK7 dosage 45 mcg, 1 capsules of 45 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
62389780|NCT00483431|ACTIVE_COMPARATOR|MK7_90|MK7 dosage 90 mcg, 2 capsules of 45 mcg and 2 placebo-capsules, orally, daily for 12 weeks.
62389781|NCT00483431|ACTIVE_COMPARATOR|MK7_180|MK7 dosage 180 mcg, 4 capsules of 45 mcg, orally, daily for 12 weeks.
62389782|NCT00483431|ACTIVE_COMPARATOR|MK7_360|MK7 dosage 360 mcg, 1 capsule of 360 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
62389783|NCT01248923|EXPERIMENTAL|ARRY-520 (Schedule 1) + bortezomib + G-CSF|
62389784|NCT01248923|EXPERIMENTAL|ARRY-520 (Schedule 1) + bortezomib + dexamethasone + G-CSF|
62389785|NCT01248923|EXPERIMENTAL|ARRY-520 (Schedule 2) + bortezomib + dexamethasone + G-CSF|
62389786|NCT03942536||MNH Emergency Cohort|Participants will be either patients who have experienced a critical pregnancy-related, obstetric, or neonatal health emergency.
62389787|NCT03942536||Birth Planning cohort|Pregnant women who complete an initial Birth Plan through the HN program within Mfangano Island East and South Sub-locations.
62389788|NCT05208749|ACTIVE_COMPARATOR|Rotablation|Use of rotational atherectomy first-line if NC balloon does not fully open
62389789|NCT05208749|ACTIVE_COMPARATOR|Shockwave IVL|Use of Shockwave IVLS first-line if NC balloon does not fully open
62389790|NCT01754142||Type 2 diabetes mellitus subjects initiating Kombiglyze XR|Patients with diagnosis of type 2 diabetes mellitus initiating Kombiglyze XR treatment within the approved indications will be enrolled
62561361|NCT03154541|EXPERIMENTAL|Non Cystic Fibrosis (CF) cohort|"The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. No prescription is necessary. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline."
62389791|NCT03278834|EXPERIMENTAL|Intervention Group|"Neuromuscular muscle stimulation machine - Muscle stimulation machine to be used on glutes and abductors on disuse atrophy setting.~Twice per day for 45 minutes.~Exercise - Home exercises programme once per day with 10 exercises."
62389792|NCT03278834|PLACEBO_COMPARATOR|Placebo Group|"Neuromuscular muscle stimulation- Muscle stimulation machine to be used on glutes and abductors on TENS setting. Twice per day for 45 minutes.~Exercise - Home exercises programme once per day with 10 exercises."
62561362|NCT03154541|EXPERIMENTAL|Cystic Fibrosis (CF) cohort|The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse.
62769401|NCT05332418|EXPERIMENTAL|study group|the study group received the same exercise training program in addition to electromagnetic field therapy, three times per week for four weeks
62769402|NCT05332418|EXPERIMENTAL|control group|the control group which received the selected exercise program
62769403|NCT04252495|EXPERIMENTAL|Subjects with moderate hepatic impairment (Group 1)|
61994355|NCT01253252|EXPERIMENTAL|Specific procedure|"A \[18F\] Fluorodeoxyglucose PET Scan Imaging will be added to their conventional follow up (CT scan, usual blood sampling, ECG...) i.e. within one month before endovascular surgery (inclusion visit), at one month and 6 month of follow-up.~Furthermore, blood sampling for biological investigations (biological markers of the inflammation, proteolysis and coagulation potentially related to morphology and evolution of AAA) will be done."
61994356|NCT01120756|EXPERIMENTAL|Goal-oriented attentional self-regulation training|Goal-oriented attentional self-regulation training (GOALS).
61994357|NCT01120756|ACTIVE_COMPARATOR|Brain Health Education|Brain Health Education (EDU)
61994358|NCT03160053|EXPERIMENTAL|Treatment Group|Keloids that were randomized to the treatment group, were exposed to Narrowband-UVB (NB-UVB). Targeted UVB will be delivered to the keloid for up to 16 weeks using the Lumera UVB light phototherapy device (Daavlin, Bryan Ohio, USA).The affected skin will be irradiated using a hand-held fiber optic cable with an adjustable aperture.
61994359|NCT03160053|NO_INTERVENTION|Control Group|Keloids that were randomized to a non treatment group, were not exposed to the NB-UVB light.
61994360|NCT06423911|OTHER|Part A, RCT, olverembatinib arm and bosutinib arm|Randomized controlled part that is designed to compare the efficacy and safety of olverembatinib (investigational arm) versus bosutinib (control arm) in patients with CML-CP, previously treated with at least two TKIs
61994361|NCT06423911|OTHER|Part B, SAT, olverembatinib arm|To evaluate the efficacy and safety of olverembatinib in the CML-CP patients with T315I mutation previously
61994362|NCT05543512|EXPERIMENTAL|Individualized Diet Elimination Therapy|Subjects in this arm will be assigned an allergen-specific immune signature-directed diet to follow for 8 weeks
61994363|NCT05543512|PLACEBO_COMPARATOR|Sham Diet Elimination Therapy|Subjects in this arm will be assigned a sham diet to follow for 8 weeks
61994364|NCT01988116|EXPERIMENTAL|Oral Calcitriol|Oral Calcitriol 0.5 mcg once daily for 6 weeks
61994365|NCT01988116|PLACEBO_COMPARATOR|Placebo Arm|Placebo capsule 1 Capsule once daily for 6 weeks
61994366|NCT03591237|EXPERIMENTAL|MBCT|As patients with significant pain are identified and accept the offer of receiving 'Mindfulness-Based Cognitive Therapy' (MBCT) for pain, they will be consecutively included in groups of 12-20 participants. The patients will participate in eight weekly two hour group sessions and will be asked to do an additional 45 minutes of daily training at home.
61994367|NCT04846725||Retrievable Inferior Vena Cava Filters (IVCF)|The population study includes patients with a Retrievable Inferior Vena Cava Filters (IVCF) inserted between April 2012 and November 2019. Follow up data is collected up to July 2020.
61994368|NCT03530579|EXPERIMENTAL|Group 1|Participants will receive 6 two and a half hour educational group trainings over the course of 6 months.
62389793|NCT01591577|EXPERIMENTAL|Lapatinib/Temozolomide/radiation|Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
62389794|NCT01810081||cholecystectomy|cholecystectomy group: H.Pylori infection in gall bladder
62561363|NCT01545648|EXPERIMENTAL|denosumab|"Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection"
62561364|NCT00733005|EXPERIMENTAL|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
62561365|NCT00733005|PLACEBO_COMPARATOR|Arm 2|Matching placebo nasal spray
62561366|NCT01060241|EXPERIMENTAL|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
61994369|NCT03530579|ACTIVE_COMPARATOR|Group 2|A community health worker will answer your questions about diabetes and refer participant if you need one.
61994370|NCT03225911|EXPERIMENTAL|Insole group|This group will be treated via using lateral wedge insole. lateral wedge insole is an insole with higher lateral side than medial side. This insole is inserted in the participant shoes.
61994371|NCT03225911|EXPERIMENTAL|Sleeve group|This group will be treated via using simple knee sleeve. Simple knee sleeve is a knee support which has no metal support. This sleeve is wrapped around each participant knee.
61994372|NCT03225911|EXPERIMENTAL|insole + sleeve group|this group will have treated via using the later wedge insole and the sleeve together as combined treatment. lateral wedge insole is an insole with higher lateral side than medial side. This insole is inserted in the participant shoes. Simple knee sleeve is a knee support which has no metal support. This sleeve is wrapped around each participant knee.
61994373|NCT05326165|EXPERIMENTAL|Compression therapy|"Participants will receive a ready to wear compression sleeve and glove with embedded sensor.~Compression sleeve will be set to 20-30mm Hg pressure with instructions to wear for 12 hours a day for four consecutive weeks.~Participants will also receive a journal to record usage and standard of care post-operative lymphedema monitoring and education and asked to fill out questionnaires."
61994374|NCT02403245|EXPERIMENTAL|Psychosocial stimulation|One session of a social stimulation
61994375|NCT02403245|NO_INTERVENTION|Control group|Residents are in a social controlled condition but without direct stimulation.
61994376|NCT00258076|EXPERIMENTAL|001|EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE
61994377|NCT00138437||Leprosy Patients (Group 1)|All leprosy patients
61994378|NCT00138437||Household Contacts (Group 2)|Household contacts with known contact with leprosy patients
61994379|NCT00138437||Healthy Individuals (Group 3)|Healthy persons with no known contact with leprosy patients
61994380|NCT03173716|ACTIVE_COMPARATOR|Intervention Group|DEFINITY contrast will be prepared according to package insert instructions. A dose of 1.5 mL activated DEFINITY diluted in 28.5 of preservative free saline to constitute a total volume of 30 mL will be infused at a rate of 90-120 mL/hr (1.5-2.0 mL/min). RTMPE will be performed.
61994381|NCT03173716|NO_INTERVENTION|Control Arm|Echocardiograms will be performed without the use of DEFINITY contrast/RTMPE.
61994382|NCT06310850|PLACEBO_COMPARATOR|Group Placebo|intravenous placebo
61994383|NCT06310850|ACTIVE_COMPARATOR|Group Ketamine|intravenous ketamine 0.15 mg kg-1
61994384|NCT02105337||tegaderm placement|all pts will have tegaderm placed prior to goggles for VEP
62561367|NCT01060241|NO_INTERVENTION|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
62561368|NCT03936010||DPP4i|Reference group
62561369|NCT03936010||Canagliflozin|Exposure group
61994385|NCT02523846|ACTIVE_COMPARATOR|Background morphine infusion to IV-PCA Morphine|Calculate based on patient's age, in mg/hour
62561370|NCT03336736||Pulmonary Sarcoidosis|"Self-reported and self-referred self-reported medically diagnosed pulmonary sarcoidosis.~Exercise capacity and function will be assessed."
61994386|NCT02523846|EXPERIMENTAL|Patient re-education to IV-PCA Morphine|Using patient information leaflet
62389795|NCT03077399|EXPERIMENTAL|stroke|stroke patients, application of SCALA
62389796|NCT03077399|EXPERIMENTAL|control|Healthy individuals (patients without stroke), application of SCALA
62389797|NCT01968473|EXPERIMENTAL|NMES Device comfort|NMES Device comfort, establishing Sensory, Motor and Pain thresholds. Max Pain tolerance is also established.
62389798|NCT05135637||Kharotabad 1 - Intervention Union Council (UC)|UC where all interventions (mobile health services, community mobilization, private practitioner engagement and test of Sehat Nishani app) will take place, and the UC will undergo a baseline, midline and endline survey.
62389799|NCT05135637||Ward 11 - Control UC|UC where no interventions will be done but the UC will undergo a baseline, midline and endline survey.
62389800|NCT05135637||Bhana Mari - Intervention UC|UC where all interventions (mobile health services, community mobilization, private practitioner engagement and test of Sehat Nishani app) will take place, and the UC will undergo a baseline, midline and endline survey.
62389801|NCT05135637||Sheikh Junaidabad - Control UC|UC where no interventions will be done but the UC will undergo a baseline, midline and endline survey.
62389802|NCT05135637||Bakhmal Ahmedzai - Intervention UC|UC where all interventions (mobile health services, community mobilization, private practitioner engagement and test of Sehat Nishani app) will take place, and the UC will undergo a baseline, midline and endline survey.
62389803|NCT05135637||Pahar Khel Thal|UC where no interventions will be done but the UC will undergo a baseline, midline and endline survey.
62389804|NCT01298661|OTHER|Healthy Young Subjects|Subjects apparently healthy, with age of 18 to 27 years old.
62389805|NCT01298661|OTHER|Healthy Elderly subjects|Subjects apparently healthy, with age of 60 to 75 years old.
62389806|NCT01298661|OTHER|COPD Patients|Patients with clinical and spirometric diagnosis of COPD
62389807|NCT01018069|ACTIVE_COMPARATOR|AEG35156|Patient receive AEG35156 prior to chemotherapy
62389808|NCT01018069|SHAM_COMPARATOR|Control|Patients receive chemotherapy only
62389809|NCT06428929|NO_INTERVENTION|Control|"Infants in the control group received standard care, with no pharmacological or non-pharmacological methods used to reduce pain, except for allowing the parents to be present. Parents and nurses observed the infant's behavior during and immediately after the procedure to assess pain and stress. After the procedure, they were asked to mark the maximum pain and stress experienced by the baby on the ALPS-Neo pain and stress rating scale. This assessment was done immediately after the needle was removed and a tampon was placed to stop the bleeding, approximately one minute after the procedure."
61994387|NCT04398758|EXPERIMENTAL|Treatment group|"Children of the treatment group receive the cream SanaCutan Basiscreme. The cream's main ingredients are white soft paraffin and liquid paraffin and it is already approved for the treatment of several skin diseases due to its skin care effect."
61994388|NCT04398758|NO_INTERVENTION|Control group|Children of the control group should avoid regular skincare applications. Skincare is not prohibited, however, it is recommended to use products only in urgent cases.
62389810|NCT06428929|EXPERIMENTAL|Intervention|Before the procedure, the researcher informed the parents of the newborns in the musical and lighted baby crib mobile group about the study procedure and purpose. The mobile was fixed 60 cm above the newborn's eye level to prevent contamination and trauma. After obtaining written consent, the researcher collected data using the 'Newborn Information Form' through face-to-face interviews. Once the form was completed, the mobile was activated. One minute later, the nurse performed the blood draw. Parents and nurses observed the infant's behavior during and immediately after the procedure to assess pain and stress. They were then asked to mark the maximum pain and stress experienced by the baby on the ALPS-Neo pain and stress rating scale.
62389811|NCT02230501|EXPERIMENTAL|moderate diet regimen|"Week 1-4: replacement of breakfast and dinner with 1g PRMR /kg normal weight (=height in cm-100), a protein-rich lunch was allowed Week 5-12: replacement of dinner~For this arm a local subgroup (n=55) and a nation-wide subgroup (n=100) is planned."
62389812|NCT02230501|EXPERIMENTAL|stringent diet regimen|"Week 1: replacement of 3 main meals by 1g PRMR / kg normal weight (=height in cm - 100) Week 2-4: replacement of breakfast and dinner, a protein-rich lunch was allowed Week 5-12: replacement of dinner~For this arm a local subgroup (n=55) and a nation-wide subgroup (n=100) is planned."
62561371|NCT03336736||Control|Healthy age-matched control group with no known lung disease. Exercise capacity and function will be assessed.
61994389|NCT01913366|EXPERIMENTAL|CM-PST|If you are assigned to CM-PST, you will be working with the same care manager from your introductory session. The care manager will continue to work with you on your problem-solving plan. Additionally, you will receive case management services.
61994390|NCT01913366|EXPERIMENTAL|SG-PST|If you are assigned to SG-PST, you will continue to work on your problem-solving plan, using the self-guided materials provided to you during the introductory session. Additionally, you will be partnered with a senior peer counselor who will support you in your SG-PST efforts.
62168330|NCT05300217|EXPERIMENTAL|Intervention Group 1 - Strategies for promoting mental health|Exposure to information about strategies for promoting mental health
62168331|NCT05300217|EXPERIMENTAL|Intervention Group 2 - General information about depression|Exposure to general information about depression
62389813|NCT02793115|EXPERIMENTAL|Arm 1|Disclosure Letter-RISKS
62389814|NCT02793115|EXPERIMENTAL|Arm 2|Disclosure Letter-BENEFITS
62389815|NCT02793115|EXPERIMENTAL|Arm 3|Disclosure Letter-RISKS AND BENEFITS
62389816|NCT02793115|EXPERIMENTAL|Arm 4|Disclosure Letter-NO RISKS OR BENEFITS
62389817|NCT02793115|PLACEBO_COMPARATOR|Arm 5|Letter-APPOINTMENT REMINDER
62389818|NCT01509651|EXPERIMENTAL|Sugammadex|
62389819|NCT02892357|EXPERIMENTAL|Treatment group|Participants in this group take the herbal compound of Jianpi Qinghua granules and half-dose omeprazole tablet.Jianpi Qinghua granule:one bag after 1 hour of breakfast and supper(twice a day) for 4 weeks.Half-dose omeprazole tablet:1 tablet of real omeprazole (10mg) and 1 tablet of Sham(10mg),once a day before breakfast for 4 weeks.
62769404|NCT04252495|EXPERIMENTAL|Healthy subjects (Group 2)|
62769405|NCT00514228|EXPERIMENTAL|Continuous sunitinib treatment|
61994391|NCT04122859|ACTIVE_COMPARATOR|Zip Skin Closure Device|The device is a class IIa device as per Annex II of the MDD 93/42EEC, as amended by Directive 2007/47/EEC. A CE-mark was affixed in 2014. The Zip device adheres to the skin adjacent to an incision or laceration by use of pressure-sensitive skin adhesives. A combination of acrylic and hydrocolloid adhesives is used to provide a skin-friendly environment while providing the necessary tack to maintain skin adhesion during a maximum wear time of 14 days. In addition to the pressure-sensitive adhesives, the device's closure and force distribution components are made up of polyurethane monofilm, polyethylene tape, polyester and nylon.
61994392|NCT04122859|ACTIVE_COMPARATOR|Standard of Care Sutures|Conventional sutures used for laceration repair
61994393|NCT00594061|EXPERIMENTAL|A|There is no arm to this study--(each participant serves ashis or her own control). Blinding or masking procedures are not included in the design, as it is not possible to conceal the presence or absence of a cochlear implant from device recipients and/or clinical investigators.
61994394|NCT00394212|EXPERIMENTAL|1|Transoral suturing of the dilated gastrojejunostomy
61994395|NCT00394212|SHAM_COMPARATOR|2|Sham Endoscopy (suturing not performed)
61994396|NCT00694369|EXPERIMENTAL|1|etoricoxib 90 mg
61994397|NCT00694369|EXPERIMENTAL|2|etoricoxib 120 mg
61994398|NCT00694369|ACTIVE_COMPARATOR|3|ibuprofen 2400 mg
61994399|NCT00694369|ACTIVE_COMPARATOR|4|acetaminophen 2400 mg/codeine 240 mg
61994400|NCT00694369|PLACEBO_COMPARATOR|5|Matching Placebo
61994401|NCT03090100|EXPERIMENTAL|Group I: Guselkumab Plus Placebo|Participants will receive 1 injection of active guselkumab and 1 injection of placebo when guselkumab is scheduled to be administered (Weeks 0, 4, 12, 20, 28, 36, and 44) or 2 injections of placebo when no guselkumab is scheduled to be administered (Weeks 1, 2, 3, 8, 16, 24, 32, and 40). Placebo injections will be administered to maintain the blind.
61994402|NCT03090100|ACTIVE_COMPARATOR|Group II: Secukinumab|Participants will receive 2 injections of active secukinumab subcutaneously (SC) at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
61994403|NCT01718756|PLACEBO_COMPARATOR|Placebo|The placebo group received 12 hourly boluses of 0.9% saline, followed by a constant infusion for 48 hrs after surgery.
61994404|NCT01718756|ACTIVE_COMPARATOR|Scheduled|They received a 12 hourly boluses of lornoxicam followed by a constant infusion of 0.9% saline, for 48 hrs after surgery
62389820|NCT02892357|ACTIVE_COMPARATOR|Control group|Participants in this group take the sham herbal granules twice a day as treatment group and two pieces of real omeprazole tablet(10mg each) once a day before breakfast for 4 weeks.
62389821|NCT02090140|EXPERIMENTAL|ADSC Application|Patients undergo an arthroscopic surgical procedure, ADSC application, followed by physical therapy.
62389822|NCT02090140|ACTIVE_COMPARATOR|Microfracture Arm|Patients undergo an arthroscopic surgical procedure, microfracture, followed by physical therapy.
62389823|NCT03230240||HIPEC|Patients with carcinomatosis or other peritoneal surface malignancy
62389824|NCT04418752|OTHER|Psychological therapy|Narrative Exposure Therapy will be delivered to all participants in the study except carer participants recruited to complete informant measures.
61994405|NCT01718756|ACTIVE_COMPARATOR|Continuous infusion|They received boluses of lornoxicam 0.8 mg/mL before induction of anaesthesia followed by a 12 hourly boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery.
61994406|NCT03160833|EXPERIMENTAL|HMPL-453|Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE (high-density polyethylene) bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, until disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 50, 100, 200, 300, 400, and 500 mg/day
61994407|NCT03979638|EXPERIMENTAL|BLU-5937 oral tablet BID|Randomized crossover design of 4 different doses (25, 50, 100, 200 mg BID) of BLU-5937 tablets to be administered orally BID
61994408|NCT03979638|PLACEBO_COMPARATOR|Placebo oral tablet BID|Randomized crossover design of matching placebo tablets to be administered orally BID
61994409|NCT04916730|PLACEBO_COMPARATOR|Standard of Care (SOC)|Participants will receive standard of care nutritional behavioral counseling and will be required to log their caloric intake through the use of a smartphone app.
61994410|NCT04916730|EXPERIMENTAL|TRE + SOC|Participants in this arm will receive standard of care nutritional behavioral counseling and will implement a daily, self-selected, 10-hour window within which they must consume all calories. They will also be required to log their caloric intake through the use of a smartphone app
62389825|NCT04937127||Experimental Group|The experimental group will be made up of patients from nursing homes whose carers have received I-Learn training.
62567755|NCT05732571|ACTIVE_COMPARATOR|Breathing Techniques Intervention|A 12 session/six week, twice a week online group-based intervention based on breathing techniques including yoga practice directed by a specialist. Each group will aim for between 3- 6 participants.
61994411|NCT02609334|PLACEBO_COMPARATOR|Placebo|Matching placebo tables are given as a single dose
61994412|NCT02609334|ACTIVE_COMPARATOR|CRD007 Low dose|"Low dose of CRD007 (pemirolast sodium) given as a single dose"
61994413|NCT02609334|ACTIVE_COMPARATOR|CRD007 High dose|"High dose CRD007 (pemirolast sodium) given as a single dose"
61994414|NCT00500292|PLACEBO_COMPARATOR|1|FOLFOX + Placebo vandetanib
61994415|NCT00500292|EXPERIMENTAL|2|FOLFOX + low dose vandetanib
62389826|NCT04937127||Control Group|The control group will consist of nursing homes patients whose caregivers have not received I-Learn training and will continue their usual care, regardless of the practices already implemented.
62389827|NCT05745415||pancreatic cancer patients|
62389828|NCT03995199||Furlow group|All cleft palate patients surgically treated with a modified Furlow technique since January 2012
62769406|NCT00987701|ACTIVE_COMPARATOR|Crystalloid resuscitation|Crystalloid (Ringer's lactate) will be delivered before (15min) or after (15min) neuraxial anesthesia
62769407|NCT00987701|ACTIVE_COMPARATOR|Colloid resuscitation|Colloid (6% hydroxyethyl starch ) will be delivered before (15min) or after (15min) neuraxial anesthesia
62561372|NCT02913911|EXPERIMENTAL|Feedback|Subjects will be trained using the sit-to-stand weight-taking machine. Prior to the training, subjects sit in a standard sitting position. Then they will be instructed to take most of their body-weight onto the legs while they standing up where the light bars will be gradually lightened from the red, yellow and green zones according to the level of LLL. Then they stand up, hold a standing position for 3-5 seconds and sit-down with always maximize their body-weight onto their legs during performing the task in which the green zone will always be lightened.
62561373|NCT02913911|SHAM_COMPARATOR|No feedback|Subjects will be trained using the same instruction and protocol as the experimental group, but without the provision of external feedback.
62561374|NCT02771067|EXPERIMENTAL|Pulse pressure variation|Pulse pressure variation will be recorded via an arterial catheter after anesthetic induction, before pneumoperitoneum, after pneumoperitoneum, before infusion of 6% hydroxyethyl starch, and after infusion of 6% hydroxyethyl starch. Stroke volume will be also measured to differentiate the fluid responders.
62561375|NCT04879992|ACTIVE_COMPARATOR|Tetracycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 300mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid
62561376|NCT04879992|EXPERIMENTAL|rifabutin triple therapy|Esomeprazole 20mg bid, amoxicillin 1000mg bid, rifabutin 150mg bid
62769408|NCT01081639|EXPERIMENTAL|Gonal-f|
62769409|NCT01081639|ACTIVE_COMPARATOR|Puregon|
62561377|NCT05129501|EXPERIMENTAL|Treatment: Tiwahe Wicaghwicayapi|Part 1: Conduct informed consent process, perform baseline assessments (time 1 survey) Part 2: Complete the program over 7 weeks, fidelity checking during program Part 3: Takes survey immediately after program (time 2 survey) Part 4: Time 3 survey six months after Time 2 survey
62389829|NCT03995199||Furlow + Sommerlad group|All cleft palate patients surgically treated with a modified Furlow technique in combination with an intravelar veloplasty by Sommerlad
62389830|NCT04870294|ACTIVE_COMPARATOR|Teeth treated with composite resin, control group|The teeth grouped in group R were treated with composite resin restoration without liner material, considered a control group.
62389831|NCT04870294|EXPERIMENTAL|Teeth treated with lining, pulp wall with PBS DTA® cement and composite resin restoration|The teeth grouped in group D received PBS CIMMO DTA® as indirect capping material of the cavity, followed by restoration of composite resin.
62769410|NCT00081211|EXPERIMENTAL|Treatment (PV701)|Patients receive intratumoral PV701 once weekly for 3 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of PV701 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 6 evaluable patients are treated at that dose.
62389832|NCT02785094||A|Group of High Education level
62389833|NCT02785094||B|Group of Low/Non Education level
62561378|NCT05129501|NO_INTERVENTION|Wait List Control: Tiwahe Wicaghwicayapi|"Part 1: Conduct informed consent process, perform baseline assessments (time 1 survey) Part 2: Waitlist with access to resources while treatment group completes program Part 3: Takes survey immediately after experimental group completes program (time 2 survey) Part 4: Time 3 survey six months after Time 2 survey~\*Complete program"
62561379|NCT05063422|EXPERIMENTAL|Mild Resorption of mandibular ridge|Loss of upto 1/3 of original vertical height
62769411|NCT05957614|EXPERIMENTAL|Traditional Rehabilitation Protocol|
62769412|NCT05957614|ACTIVE_COMPARATOR|Acupuncture-assisted Rehabilitation Protocol|
62389834|NCT02785094||C|Group has Accessibility to Social Media
62389835|NCT02785094||D|Group has not Accessibility to Social Media
62389836|NCT04421430|EXPERIMENTAL|Distraction cards group|Distraction cards was applied to the children in this group during the venipuncture procedure.
62389837|NCT04421430|EXPERIMENTAL|Virtual reality group|Virtual reality intervention was applied to the children in this group during the venipuncture procedure.
62389838|NCT04421430|EXPERIMENTAL|Buzzy® group|Buzzy® was applied to the children in this group during the venipuncture procedure.
62561380|NCT05063422|EXPERIMENTAL|Moderate Resorption of mandibular ridge|2. Moderate Resorption: Loss of upto 1/3 to 2/3 of original vertical height
62561381|NCT05063422|EXPERIMENTAL|Severe Resorption of mandibular ridge|3. Severe Resorption: Loss of 2/3 or more of original vertical height
62389839|NCT04421430|NO_INTERVENTION|Control group|The control group received the routine venipuncture procedure and did not receive any other non-pharmacological intervention.
62389840|NCT02030795|ACTIVE_COMPARATOR|Disconnection group|The single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse.
62561382|NCT02302417|OTHER|All Subjects|Approximately 1000 subjects with clinical diagnoses of asthma and/or COPD or clinical presentations suggestive of either or both will be included. Subjects will undergo spirometry assessments and also will be asked a series of questions by a qualified health care practitioner using a questionnaire containing 41 questions concerning their respiratory condition.
62561383|NCT04899674|EXPERIMENTAL|Bupropion (Reference, R) - BI 1358894 + Bupropion (Test, T)|
62561384|NCT01707173|OTHER|Standard Education|Control group participants will receive standard educational materials published by the CDC or American Academy of Pediatrics as an intervention along with a generic infant safety DVD
62561385|NCT01707173|EXPERIMENTAL|Tailored education|Parents/caregivers will receive educational materials tailored to their specific beliefs and barriers about infant supine sleep along with a DVD detailing standard guidelines along with specific solutions and facilitators to infant supine sleep as the intervention.
62561386|NCT03835923|EXPERIMENTAL|lifestyle intervention|Telemedicine-supported lifestyle intervention trough individual structured exercise training (endurance and strength training), increase in daily physical activity, and individual nutritional recommendations
62389841|NCT02030795|ACTIVE_COMPARATOR|Bronchial Suction group|The suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
62561387|NCT03835923|ACTIVE_COMPARATOR|usual care|general exercise and nutritional recommendations according to current guidelines
62389842|NCT04196231|ACTIVE_COMPARATOR|FR insulin/GLP-1RA|Patients in this arm will receive one of these fixed ratio combo of insulin and GLP-1RAs, according to the current clinical practice and the drugs' data sheet: IDegLira or IGlarLixi
62561388|NCT02330497|EXPERIMENTAL|Radiofrequency|Procedure/Surgery Thermal Radiofrequency Ablation under endoscopic ultrasonography guidance of the pancreatic neuro endocrine tumor or mucinous cyst.
62561389|NCT00626002|EXPERIMENTAL|1|
62389843|NCT04196231|ACTIVE_COMPARATOR|Insulin/SGLT-2i|Patients in this arm will receive the basal insulin used before the randomization and one of these SGLT-2i according to the current clinical practice and the drugs' data sheet: canagliflozin, dapagliflozin or empagliflozin.
62561390|NCT03257540||Small Bone Intramedullary Nail|All study participants
62389844|NCT04196231|ACTIVE_COMPARATOR|Basal Bolus|Patients in this arm will receive a basal insulin (glargine, glargine-300 or degludec) at bed-time plus 3 injections of a short-acting insulin analogue (aspart, lispro or glulisine) before meals
62389845|NCT00667381|NO_INTERVENTION|Control|The combination of anatomic landmarks and fluoroscopic localization of the femoral head will be used to guide femoral arterial access.
62389846|NCT00667381|EXPERIMENTAL|Ultrasound|Patients randomized to Ultrasound will have anatomic landmarks checked and real-time ultrasound guidance to aid femoral arterial access.
62389847|NCT03943602|EXPERIMENTAL|Cabozantinib|Cabozantinib will be administered orally at a dose of 60 mg/day continuously until 28 days prior to planned surgery or at time of the evidence of disease progression or onset of unacceptable toxicity.
62561391|NCT00856492|EXPERIMENTAL|Arm 1|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 and bevacizumab IV over 30- to 90-minutes on day 1 of weeks 1-12. Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 14, 16, 18, 20, 22, and 24.
62561392|NCT00856492|ACTIVE_COMPARATOR|Arm 2|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 of weeks 1-12, and then receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 14, 16, 18, 20, 22, and 24.
62561393|NCT00856492|ACTIVE_COMPARATOR|Arm 3|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 1, 3, 5, 7, 9, and 11, and then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 of weeks 14-25.
62561394|NCT01825473|EXPERIMENTAL|Erythromycin|50 mg/kg/day divided every 6 hours oral for 7 days
62561395|NCT01825473|PLACEBO_COMPARATOR|Placebo|Dextrose 5 Water (D5W) equal amount as experimental every 6 hours oral for 7 days
62561396|NCT01516281||mTBI|Historical cohort of subjects seen in the emergency rooms of NorthShore University HealthSystem with ICD-9 diagnoses of mild or moderate traumatic brain injury during the years 2006-2011 (7,122 subjects). 100 mTBI+ subjects are randomly selected for clinical assessment and DaTscan.
62561397|NCT01516281||mTBI-|Historical cohort of subjects seen in the emergency rooms of NorthShore University HealthSystem with ICD-9 diagnoses of disorders other than mild or moderate traumatic brain injury during the years 2006-2011 (7,122 subjects). 100 mTBI- subjects are randomly selected for clinical assessment and DaTscan.
62561398|NCT01226160|EXPERIMENTAL|Face-down posturing group|Postoperative face-down positioning for 10 days after surgery.
62561399|NCT01226160|ACTIVE_COMPARATOR|Non-posturing group|avoid a face-up position for 10 days after surgery
62561400|NCT05001893||The use of a mixture of BonAlive® putty and autologous bone|A retrospective case-controlled study will be created to compare the use of a mixture of BonAlive® putty and autologous bone to autologous bone alone for clinical safety and efficacy.
62561401|NCT03481972|EXPERIMENTAL|Doxy/TUDCA|"doxycicline (100 mg / BID)~tauroursodeoxycholic acid (250 mg / TID)"
62561402|NCT03481972|ACTIVE_COMPARATOR|Standard of care|Standard of care therapies.
62561403|NCT00180661||Severe Asthma|Patients under Steps 4/5 of Asthma Treatment - SIGN/BTS Guidelines
62561404|NCT00180661||Moderate Asthma|Asthma patients on steps 2/3 of Asthma treatment according to SIGN/BTS Guidelines
62561405|NCT00180661||Mild Asthma|Asthma patients on steps 1 of asthma treatment (steroid naive).
61994416|NCT00500292|EXPERIMENTAL|3|FOLFOX + high dose vandetanib
61994417|NCT05767632|ACTIVE_COMPARATOR|R reference (first dose)|Reference drugs (Vesicare \& Betmiga)
61994418|NCT05767632|EXPERIMENTAL|T test|Test drug (Mirfenacin MR)
61994419|NCT05767632|ACTIVE_COMPARATOR|R reference (second dose)|Reference drugs (Vesicare \& Betmiga)
61994420|NCT01299922|EXPERIMENTAL|cyclosporine+mycophenolic acid+prednison|Triple therapy
62389848|NCT01966367|EXPERIMENTAL|CliniMACS PLUS followed by chemotherapy|"Patients will receive a pre-transplant conditioning regimen of Busulfan Fludarabine and Alemtuzumab. For patients with pre-transplant hepatic dysfunction, Melphalan will be substituted for the Busulfan. For patients receiving a second transplant or a boost, pre-transplant conditioning based on the clinical condition of the patient will be determined by the Principal Investigator and the patient's bone marrow transplantation (BMT) physician. The donor peripheral blood stem cells will undergo CD34+ selection (Biological/Vaccine: CD34 Stem Cell Selection Therapy). The CliniMACS (PLUS) Reagent System will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD)."
62561406|NCT04842331|EXPERIMENTAL|RESP301 + Standard of Care (SOC)|"Treatment arm will receive the study drug RESP301 alongside standard of care (SOC).~RESP301 will be administered for a period of 7 days (i.e. 21 doses) to both index cases and their household members in the treatment arm. Participants will be given the first dose under medical supervision and self-administer at home the remaining 20 doses.~RESP301 is a formulation consisting of 3 agents currently used in clinical practice: mannitol, sodium nitrite and citric acid."
62561407|NCT04842331|ACTIVE_COMPARATOR|Standard of Care (SOC)|SOC
62561408|NCT02215655|ACTIVE_COMPARATOR|Motivational interviewing|Motivational interviewing counselling will be administered to the subjects
62561409|NCT02215655|NO_INTERVENTION|No intervention: control group|No motivational interviewing counselling will be administered to the subjects
62561410|NCT04394403|EXPERIMENTAL|immediate guided self-help|In this condition, individuals will be given access to material and exercises based on CBT to reduce their stress
62561411|NCT04394403|NO_INTERVENTION|waitlist|Individuals in this condition will wait 6 weeks before they are provided access to the guided self-help program
62561412|NCT02655913|EXPERIMENTAL|vitamin C+ mEHT+ supportive care|"Patients will be allocated into 3 Vitamin C infusion dosage groups:~1g/kg.d,1.2g/kg.d,1.5g/kg.d;3 times a week for 8 weeks(25 infusions);concurrent with Modulated Electro-Hyperthermia (mEHT): 150W x 60 min/session,3 times a week for 8 weeks (25 sessions);together with supportive care."
62561413|NCT02655913|PLACEBO_COMPARATOR|Supportive care|Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
62561414|NCT04719442|EXPERIMENTAL|BHF-LC|To test an innovative implementation strategy, four communities will be assigned to pilot test the packaged PWMI and training materials when coupled with a learning collaborative facilitation strategy and sustainability action planning process to support PWMI adoption, implementation, and sustainability (BHF-LC).
62561415|NCT04719442|ACTIVE_COMPARATOR|BHF-Program Only|Four other communities will be assigned to receive the packaged PWMI and training program only.
62561416|NCT03938883|EXPERIMENTAL|Ocular Bandage Gel (OBG)|Cross-linked Hyaluronic Acid 0.75%, regulated through CDRH (device). EyeGate Ocular Bandage Gel will be applied topically to both eyes (OU) four times a day. Ocular Bandage Gel use is discontinued once complete re-epithelialization has occurred in that eye.
61994421|NCT01299922|ACTIVE_COMPARATOR|mycophenolic acid + prednison|Mycophenolic acid+prednison 106 weeks
61994422|NCT02164799||Shock|Patients found to have persistent hypotension after resuscitation or vasopressor requirement
62389849|NCT04187612||Total body water measurement|Total body water will be measured using Bioelectrical Impedance Analysis (BIA).
62389850|NCT00485615|EXPERIMENTAL|1|OMEGA 3
61994423|NCT02164799||Pre-shock|Patients with markedly abnormal vital signs (Heart Rate (HR)\>130, Respiratory Rate (RR)\>24, Shock Index \>1, Lactate \> 4.0mmol/L, or Systolic Blood Pressure (SBP) \<90mm/hg) without shock, as defined previously.
61994424|NCT02319538|NO_INTERVENTION|Non-surgical treatment only|Control arm. This arm receives standard medical hormone treatment (Thyroxine substitution) only and no surgical intervention.
61994425|NCT02319538|ACTIVE_COMPARATOR|Total thyroidectomy performed|Surgical arm.The approach for total thyroidectomy will be a complete removal of all visible, and immunological active thyroid tissue with a high accuracy, with a special focus on three sites; 1) The angle where the recurrent laryngeal nerve enters the cricothyroid membrane, 2) The pyramidal lobe and 3) The hilus where the superior vessels are entering the field. Standard Thyroxine supplementation maintained as in the control group.
61994426|NCT05134207|EXPERIMENTAL|oral carbohydrate solution|Oral carbohydrate solution was given orally to the experimental group as 800 ml at 24:00 the night before the surgery and 400 ml at 06:00 2 hours before the intervention.
61994427|NCT05134207|NO_INTERVENTION|control|From 24:00 on the night before the surgical intervention, food and water intake was prohibited for the patients in the control group.
61994428|NCT05888129||locally advanced pancreatic cancer|"Locally advanced pancreatic cancer (LA-PC) is classified according to the National Comprehansive Cancer Networks (NCCN) guidelines.~Patients with the above conditions underwent surgery after neoadjuvant chemotherapy."
62389851|NCT01636076|EXPERIMENTAL|QMF149|QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device
62561417|NCT03938883|OTHER|Bandage Contact Lens (BCL)|standard-of-care post-operative intervention following PRK. BCL (Acuvue® Oasys plano lens) applied OU. Bandage contact lens use is discontinued once complete re-epithelialization has occurred in that eye.
62561418|NCT01961986|ACTIVE_COMPARATOR|TSR: traditional subscap release|"TSR - traditional subscapularis release approach~Subscapularis tendon release technique TSR"
62561419|NCT01961986|EXPERIMENTAL|TSR: rotator cuff sparing|Rotator cuff sparing technique TSR
62389852|NCT01636076|ACTIVE_COMPARATOR|Salmeterol xinafoate/fluticasone propionate|Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®
62561420|NCT02401269|EXPERIMENTAL|Aspirin|Aspirin 325mg daily
62561421|NCT02401269|PLACEBO_COMPARATOR|Placebo|Placebo
62561422|NCT03213808||respiratory allergies|respiratory allergies (asthma, rhinitis)
62561423|NCT03213808||skin allergies|skin allergies (dermatitis, urticarial, angioedema)
62561424|NCT03213808||anaphylaxis|anaphylaxis
62561425|NCT03213808||gastrointestinal allergic conditions|gastrointestinal allergic conditions
62561426|NCT03213808||ocular allergies|ocular allergies (conjunctivitis)
62561427|NCT00314327|EXPERIMENTAL|long-acting injectable risperidone|One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.
62561428|NCT01921608|EXPERIMENTAL|PrePex™ device|Adult male circumcision by the PrePex™ device
61994429|NCT05888129||borderline resectable pancreatic cancer|"Borderline resectable pancreatic cancer (BR-PC) is classified according to the NCCN guidelines.~Patients with the above conditions underwent surgery after neoadjuvant chemotherapy."
62561429|NCT00569972|EXPERIMENTAL|15 mg PD 0200390|
62561430|NCT00569972|EXPERIMENTAL|30 mg PD 0200390|
61994430|NCT05888129||resectable pancreatic cancer|"Resectable pancreatic cancer (PC) is classified according to the NCCN guidelines.~There are no arterial and venous contact with tumor Patients with the above conditions underwent upfront surgery"
62561431|NCT00569972|EXPERIMENTAL|45 mg PD 0200390|
62561432|NCT00569972|EXPERIMENTAL|60 mg PD 0200390|
62561433|NCT00569972|EXPERIMENTAL|Placebo PD 0200390|
62389853|NCT02074059|EXPERIMENTAL|Aerosolized lucinactant (25 mg/kg)|25 mg total phospholipids (TPL)/kg: Lucinactant for inhalation with nCPAP
62561434|NCT04719572|OTHER|Basic treatment group|elemental calcium 600mg/ day + vitamin D 1000IU/day
62561435|NCT04719572|ACTIVE_COMPARATOR|Basic treatment+ anti-osteoporosis drug group|alendronate(70mg/week), zoledronate(5mg 1/ year), tripopeptide(20ug 1/day), denosumab(120mg/month), activated vitamin D(0.25ug 1/day), menatetrenone(15mg tid) according to the patient's condition
61994431|NCT05151211||Validity and Reliability Group|In order to evaluate the usability of the 1 MSTS, the validity and reliability of the test will be examined. In order to determine its validity in assessing physical capacity, the correlation of 1 minute sit up and 6 MWT and quadriceps muscle strength; In order to determine its validity in the evaluation of effort-induced desaturation, the correlation between the change in oxygen saturation and heart rate parameters before and after the 6 MWT and the change before and after the 1 MSTS test will be examined. In order to determine the reliability of the 1 MSTS, a re-test will be performed and 1 MSTS will be applied again after 1 week and the intraclass correlation coefficient will be checked.
62561436|NCT04719572|OTHER|Basic treatment + non-drug treatment group|diet, exercise, rehabilitation therapy
62561437|NCT04085237|EXPERIMENTAL|Ultrasound-guided continuous ESP block with opioid PCA|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T7/T8 spinous process. The patient's skin will be anesthetized with 2% lidocaine. A Contiplex Echo ultra 360 18G needle with 20G × 55 cm Contiplex Echo catheter will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% ropivacaine with 5mcg/mL of epinephrine will be injected in 5-mL aliquots through the needle (maximum of 3mg/kg) followed by insertion of the echo catheter system under direct vision 2-3 cm beyond the needle tip.
62561438|NCT04085237|SHAM_COMPARATOR|Ultrasound-guided sham block and catheter with opioid PCA|The exact same procedure as the experimental group will be followed, substituting saline for local anesthetic at the same amounts and rate. As with the ESP group, the patients will have PCA initiated postoperatively in the PACU at the same doses.
62769413|NCT02049138|EXPERIMENTAL|Upadacitinib|"Participants received treatment with upadacitinib for up to 312 weeks. The starting dose was 6 mg twice a day (BID). Participants who did not achieve a 20% improvement from RCT Baseline in both Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 6 or Week 12 were up-titrated to 12 mg BID. From January 2017 participants were transitioned to a once-daily (QD) regimen of upadacitinib, either 15 mg QD (participants who were taking 6 mg BID) or 30 mg QD (participants taking 12 mg BID). Starting with Protocol Amendment 5 participants receiving 30 mg QD upadacitinib had the option to decrease the dose to 15 mg QD at the investigator's discretion.~A subset of participants who opted-in to the vaccine substudy received a single-dose of 0.5 mL intramuscular injection of pneumococcal 13-valent conjugate vaccine (PCV-13)."
62769414|NCT01669213|ACTIVE_COMPARATOR|ramosetron 0.3 mg|preparation of ramosetron 0.3 mg
62561439|NCT00950118||Congenital Diaphragmatic Hernia (CDH)|Humans affected with congenital diaphragmatic hernia (CDH)
62769415|NCT01669213|ACTIVE_COMPARATOR|ondansetron 8 mg|preparation of ondansetron 8mg
62769416|NCT01669213|ACTIVE_COMPARATOR|ondansetron 4 mg|preparation of ondansetron 4mg
62769417|NCT01669213|PLACEBO_COMPARATOR|non 5-HT3 receptor antagonist|preparation of normal saline 5 ml
62769418|NCT05108805|EXPERIMENTAL|YESCARTA in the Outpatient Setting|Participants will receive YESCARTA therapy in the outpatient setting
62769419|NCT02454153|ACTIVE_COMPARATOR|REMStar Positive Airway Pressure|Positive pressure therapy is the standard of care for managing obstructive sleep apnea.
62769420|NCT02454153|OTHER|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
62769421|NCT01008462|EXPERIMENTAL|Treatment (autologous HCT, donor HCT)|See Detailed Description
62769422|NCT01378611|PLACEBO_COMPARATOR|active control group|The active control group is stimulated with: Output current 0.25 milliampere, Pulse width 0.1 milliseconds, Frequency 1 Hz, Duty cycle: 14 sec on 60 min off (duty cycle \<0.5%)
62769423|NCT01378611|EXPERIMENTAL|treatment group|The high stimulation group is stimulated with output current 0.25 milliampere, Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off in the treatment group the current was stepwise increased with two week intervals to the maximally tolerated output current (maximum 1.75 mA).
62769424|NCT00645905|ACTIVE_COMPARATOR|A|
62769425|NCT00645905|PLACEBO_COMPARATOR|B|
62561440|NCT00950118||Unaffected|Healthy family members of individuals affected with congenital diaphragmatic hernia (CDH)
62567756|NCT05732571|NO_INTERVENTION|Usual Care|A six week non-intervention (usual care) period will be recruited to, allowing a comparison to the intervention.
62769426|NCT00841932||Fractional Flow Reserve|Patients with suspected coronary artery disease undergoing FFR to assess physiological significance of stenosis
62769427|NCT00733057|EXPERIMENTAL|1|Minocycline treatment
62389854|NCT02074059|EXPERIMENTAL|Aerosolized lucinactant (50 mg/kg)|50 mg TPL/kg: Lucinactant for inhalation with nCPAP
62389855|NCT02074059|EXPERIMENTAL|Aerosolized lucinactant (75 mg/kg)|75 mg TPL/kg: Lucinactant for inhalation with nCPAP
62389856|NCT02074059|EXPERIMENTAL|Aerosolized lucinactant (100 mg/kg)|100 mg TPL/kg: Lucinactant for inhalation with nCPAP; repeat dosing possible if criteria met.
62769428|NCT00733057|PLACEBO_COMPARATOR|2|Placebo
62769429|NCT06098664||Low score group (DNN-score = 0 - 10%)|The inclusions will be stratified to the deep neural network (DNN) score. The study will enrol 20 patients in each group.
62769430|NCT06098664||Medium score group (DNN-score = 10 - 50%)|The inclusions will be stratified to the deep neural network (DNN) score. The study will enrol 20 patients in each group.
62769431|NCT06098664||High score group (DNN-score = 50 - 100%)|The inclusions will be stratified to the deep neural network (DNN) score. The study will enrol 20 patients in each group.
62769432|NCT01347255|EXPERIMENTAL|LEO 90100 cutaneous spray ointment|LEO 90100 cutaneous spray, ointment, is a new product containing calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate).
61994432|NCT04355000|ACTIVE_COMPARATOR|Hall Technique|In Hall Technique, SS Crown will be cemented on primary carious molar which satisfy the inclusion criterion without any carious removal, without any tooth preperation, without any local anaesthesia.
61994433|NCT04355000|ACTIVE_COMPARATOR|RMGIC restoration|In RMGIC(Vitremer) filling, carious lesion will be completely removed from primary molars using air rotor and local anaesthesia according to need and filled with vitremer rmgic material.
61994434|NCT04553432|EXPERIMENTAL|Omnigen + OmniLenz|Omnigen amniotic membrane 17mm disk with 6mm central aperture place under 18mm OmniLenz bandage contact lens
61994435|NCT04553432|ACTIVE_COMPARATOR|OmniLenz|Bandage contact lens alone
61994436|NCT00314574|EXPERIMENTAL|Xolair|"The subcutaneous dose of Xolair administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.~Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.~Participants were permitted to use albuterol as rescue medicine throughout the study."
61994437|NCT00314574|PLACEBO_COMPARATOR|placebo|"The subcutaneous dose of placebo administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.~Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.~Participants were permitted to use albuterol as rescue medicine throughout the study."
61994438|NCT03881137|EXPERIMENTAL|Intervention|Geriatric assessment with management
62389857|NCT02074059|EXPERIMENTAL|Aerosolized lucinactant (150 mg/kg)|150 mg TPL/kg: Lucinactant for inhalation with nCPAP; repeat dosing possible if criteria met.
62561441|NCT03280238|EXPERIMENTAL|Experiment|"* Individualized painful electrical stimuli, Surpass LT stimulator (EMS Biomedical, Korneuburg, Austria) with a bipolar felt pad electrode~* Measurement of pupil diameter, Algiscan® (iDMed, Marseille, France)~* Measurement of Analgesia Nociception Index, PhysioDoloris® (MetroDoloris, Lille, France)"
62561442|NCT00728234||1|all infants born below 30 weeks gestational age at the medical university vienna within the study period (01/2000 - 12/2002)
62561443|NCT03717155|EXPERIMENTAL|Avelumab and Cetuximab|Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.
62769433|NCT01347255|ACTIVE_COMPARATOR|LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone|Vehicle cutaneous spray, ointment, with betamethasone 0.5 mg/g (as dipropionate)
62389858|NCT02074059|ACTIVE_COMPARATOR|nCPAP alone|nCPAP therapy alone
62389859|NCT03266159|EXPERIMENTAL|Part 1: Subjects receiving GSK525762 + trametinib|Eligible subjects will receive doses of GSK525762 with a starting dose of 40 milligrams (mg), or 60 mg in combination with trametinib with a starting dose of 1 mg or 1.5 mg or 2 mg, administered orally once daily. Dose escalation will continue until the maximally-tolerated dose combination (MTC) is reached. Once the MTC is reached, subjects will be enrolled in expansion cohort and will receive a fixed dose combination.
62389860|NCT03266159|EXPERIMENTAL|Part 2: Subjects with SCLC receiving GSK525762+ trametinib|Eligible subjects with small cell lung cancer (SCLC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
62389861|NCT03266159|EXPERIMENTAL|Part 2: Subjects with RMCRC receiving GSK525762+ trametini|Eligible subjects with Ras-mutated colorectal cancer (RMCRC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
62769434|NCT01347255|PLACEBO_COMPARATOR|LEO 90100 Cutaneous Spray, Ointment, Vehicle|LEO 90100 vehicle served as a negative control for the two cutaneous spray ointments with active ingredients.
61994439|NCT03881137|NO_INTERVENTION|Control|Patients receiving supportive care and follow up according to routine practice
61994440|NCT06428604||GRUP W|patient group given only 5 ml kg-1 oral water 3 hours before the surgery,
62389862|NCT03266159|EXPERIMENTAL|Part 2: Subjects with RMNSCLC receiving GSK525762+ trametinib|Eligible subjects with Ras-mutated non small cell lung cancer (RMNSCLC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
62561444|NCT00894972|ACTIVE_COMPARATOR|1|General exercise. Participants in this group will perform aerobic exercise, range of motion exercise and general strengthening exercise.
62561445|NCT00894972|EXPERIMENTAL|2|Specific exercise. Participants in this group will perform aerobic exercise, range of motion exercise, and specific motor control exercises.
62769435|NCT01347255|ACTIVE_COMPARATOR|Daivobet® Ointment|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
62769436|NCT05597072|EXPERIMENTAL|Intervention|In the evening before an elective surgery the sterile surgical goods will be prepared under calm circumstances with only 2 persons in the OR (intervention). Thereafter, the sterile goods will be protected with sterile covers and time pending surgery will be approximately 12 hours (intervention).
61994441|NCT06428604||GRUP C|Patient group given 5 ml kg-1 clear carbohydrate-rich liquid orally 3 hours before surgery
61994442|NCT02094001|EXPERIMENTAL|Riociguat therapy|After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
61994443|NCT05083988|EXPERIMENTAL|audiovisual distraction|
62561446|NCT03160937|EXPERIMENTAL|Manual therapy Foam|The subjects included rolled the foam roller down their quadriceps using short kneading-like motions until it was just above their patellae, and then rolled it back to its initial position in one fluid motion. The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets
62769437|NCT05597072|ACTIVE_COMPARATOR|Control|The control is to prepare the sterile goods in the morning with more people in the OR (approximately 4-5 persons).
61994444|NCT05083988|EXPERIMENTAL|audiodistraction|
61994445|NCT04537858|EXPERIMENTAL|Virtual reality therapy first|Subjects with COVID-19 who will start the first day of the protocol with Virtual Reality tasks in the morning and then in the second period, in the afternoon, will perform the conventional exercises (n = 25)
61994446|NCT04537858|EXPERIMENTAL|Conventional therapy first|Subjects with COVID-19 who will start the first day with conventional exercises in the morning and in the second period, in the afternoon, will perform activity with virtual reality (n = 25).
61994447|NCT01965288|EXPERIMENTAL|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating the schedule for the second pair without a washout period.
61994448|NCT01965288|ACTIVE_COMPARATOR|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating the schedule for the second pair without a washout period.
61994449|NCT03562819||NSCLC|Non-small cell lung cancer
61994450|NCT06266455|ACTIVE_COMPARATOR|Standardized Fortification|"All study participants will undergo feed advancement and fortification with liquid, bovine-based human milk fortifier (HMF) to an assumed human milk content of 24kcal/oz per the Children's National Hospital NICU standardized clinical feeding protocol. The same milk fortification recipes are utilized for mother's own milk (MOM) and donor human milk (DHM). Each infant's growth trajectory is monitored (weight, length, and head circumference) with dietary modifications performed as needed based on growth parameters.~Growth failure is defined as a decline in weight-for-age z-score by greater than 1 standard deviation (\>1 SD) beginning 1 week after reaching goal fortified feeds. For infants who demonstrate growth failure, Step 1 will be to add medium chain triglyceride (MCT) oil. If growth remains sub-optimal, Step 2 will be to add liquid protein."
61994451|NCT06266455|EXPERIMENTAL|Adjustable|"Adjustable fortification will begin 1 week after tolerating goal feeds of standardized fortification. Blood urea nitrogen (BUN) level as a marker of protein metabolism will be measured weekly, and supplementation with liquid protein will be adjusted as necessary to maintain a goal BUN level between 9-14mmol/dL, up to a maximum assumed protein intake of 4.5 g/kg/day. Liquid protein supplementation will be modified as follows:~* BUN Level \<9 mmol/dL: Increase by 0.5g/kg/day~* BUN Level 9-14 mmol/dL: No change~* BUN Level \>14 mmol/dL: Decrease by 0.25g/kg/day~* BUN Level \>20 mmol/dL: Hold for 1 week and re-assess~Growth failure is defined as a decline in weight-for-age z-score by \>1 SD beginning 1 week after achieving BUN within goal range from adjustable fortification. For infants who demonstrate growth failure, MCT oil will be added and increased weekly as needed."
61994452|NCT06266455|EXPERIMENTAL|Targeted|"Targeted fortification will begin 1 week after tolerating goal feeds of standardized fortification. Additional supplementation with liquid protein and/or MCT oil will be provided based on twice weekly milk analysis using a mid-infrared human milk analyzer in order to meet macronutrient (carbohydrate, protein, lipid) and energy intake goals per pediatric nutrition guidelines (protein 4-4.5g/kg/day, fat 6-8g/kg/day, energy 120-130kcal/kg/day).~Growth failure is defined as a decline in weight-for-age z-score by \>1 SD beginning 1 week after receiving macronutrient and energy intake within goal range from targeted fortification. For infants with growth failure, total energy intake will be increased with additional protein and/or MCT oil supplementation. Energy intake may be increased weekly as needed."
61994453|NCT03758742|EXPERIMENTAL|High-Fruit Diet|Whole fruit-rich diet (\~50% of calories from whole fruit)
61994454|NCT02321462|EXPERIMENTAL|Eziclen|
62389863|NCT03266159|EXPERIMENTAL|Part 2: Subjects with RMPAC receiving GSK525762+ trametinib|Eligible subjects with Ras-mutated pancreatic adenocarcinoma (RMPAC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
62389864|NCT03266159|EXPERIMENTAL|Part 2: Subjects with RAST receiving GSK525762+ trametinib|Eligible subjects with Ras-pathway activated solid tumors (RAST) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
62389865|NCT00453635|EXPERIMENTAL|1|Docetaxel + Carboplatin + Herceptin (D/Carbo/Her)
62769438|NCT03331822|EXPERIMENTAL|Light|High illuminance ,white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux.
62769439|NCT03331822|NO_INTERVENTION|No Light|Ambient, standard white fluorescent environmental light will serve as control.
62769440|NCT01330966|EXPERIMENTAL|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
62769441|NCT02235103||Clinical Pregnancy|Patients who are clinically pregnant after first treatment cycle with intra-uterine insemination.
62769442|NCT02235103||No Clinical Pregnancy|Patients who are not clinically pregnant after first treatment cycle with intra-uterine insemination.
62769443|NCT01146964|EXPERIMENTAL|Phacoemulsification, Safety, Efficacy|
62769444|NCT01146964|EXPERIMENTAL|MSSICS, Safety, Efficacy|
62769445|NCT04473365||Without parasite|For secondary outcome: effect of co-infection with parasite on COVID-19 severity Group 1 will constitute those without parasite co-infection
62389866|NCT00453635|EXPERIMENTAL|2|Vinorelbine + Herceptin (VHer)
62389867|NCT00612456|EXPERIMENTAL|Arm 1|Pazopanib eye drops formulation 5 mg/mL daily for 28 days
62389868|NCT00612456|EXPERIMENTAL|Arm 2|Pazopanib eye drop formulation 5mg/mL TID for 28 days
62769446|NCT04473365||With parasite|For secondary outcome: effect of co-infection with parasite on COVID-19 severity Group 2 will constitute those with parasite co-infection
62389869|NCT00612456|EXPERIMENTAL|Arm 3|Pazopanib eye drop formulation 2mg/mL TID for 28 days
62389870|NCT01105429|ACTIVE_COMPARATOR|BMS-820132 (0.3 mg) or Placebo|
62389871|NCT01105429|ACTIVE_COMPARATOR|BMS-820132 (1.0 mg) or Placebo|
62389872|NCT01105429|ACTIVE_COMPARATOR|BMS-820132 (3 mg) or Placebo|
62389873|NCT01105429|ACTIVE_COMPARATOR|BMS-820132 (10 mg) or Placebo|
62389874|NCT01105429|ACTIVE_COMPARATOR|BMS-820132 (30 mg) or Placebo|
62389875|NCT01105429|ACTIVE_COMPARATOR|BMS-820132 (75 mg) or Placebo|
62769447|NCT01107938|EXPERIMENTAL|10 mg ilaprazole|
62769448|NCT01107938|EXPERIMENTAL|15 mg ilaprazole|
62769449|NCT01107938|ACTIVE_COMPARATOR|40 mg esomeprazole|
62389876|NCT01105429|ACTIVE_COMPARATOR|BMS-820132 (150 mg) or Placebo|
61994455|NCT02321462|ACTIVE_COMPARATOR|Fortrans®|
61994456|NCT05581316|EXPERIMENTAL|patients who use peripheral venous catheters|Patients' procalcitonin, thrombocyte, and leukocyte levels were assessed every other day for 4 weeks, beginning on the first day they were admitted to the burn center. The above examinations at the Laboratories of the December 25th State Hospital, Ministry of Health of the Republic of Turkey, were retrieved retrospectively from the hospital database
61994457|NCT05581316|EXPERIMENTAL|patients who use venous catheters|Patients' procalcitonin, thrombocyte, and leukocyte levels were assessed every other day for 4 weeks, beginning on the first day they were admitted to the burn center. The above examinations at the Laboratories of the December 25th State Hospital, Ministry of Health of the Republic of Turkey, were retrieved retrospectively from the hospital database
62561447|NCT03160937|ACTIVE_COMPARATOR|Manual therapy Nerve|The subjects was positioned lying on his/her side with a pillow underside leg (without fully flexing it) and the cervical and thoracic spines flexed. The investigator flex the knee and the hip extended and then put it back to its initial position in one fluid motion. The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets
62561448|NCT02509819|EXPERIMENTAL|Military Performance Lab testing|Subjects who use IDEOs will come to the Military Performance Lab for one test session during which they will walk in standardized shoes with six different foam heel wedges (Heel Cushion Material Bulk (foam) from Kingsley Manufacturing Company) in random order. Control data will also be collected on able-bodied individuals. Control subjects will also come to the MPL for one test session in which they will walk using the same standardized shoes. For all subjects, biomechanical gait data will be collected as the subjects walk along a walkway in the MPL. This data will be used to calculate roll-over shape, instantaneous radius of curvature, COP velocity, and ankle moment.
61994458|NCT03999892|EXPERIMENTAL|Pilot weight management module|Consumers with serious mental illness who attend a psychiatric rehabilitation program will participate in a pilot of modules of a group-based diet and physical activity program. Staff/ peer leaders a psychiatric rehabilitation program will observe sessions.
61994459|NCT04951934|EXPERIMENTAL|EmoLED Group|The EmoLED Group will undergo treatment with EmoLED twice a week for 5 consecutive weeks. The therapy, in this case, in addition to the standard treatment, will also include a treatment with the EmoLED device.
61994460|NCT04951934|ACTIVE_COMPARATOR|Control Group|The Control Group will follow the standard treatment indicated.
61994461|NCT00744575||1|Chronic Back Pain
61994462|NCT00744575||2|Healthy Sex \& Age Matched Controls
61994463|NCT02151526|EXPERIMENTAL|LentiGlobin BB305 Drug Product|Following myeloablative conditioning with IV busulfan for 4 consecutive days (dose may be adjusted as per protocol) and subsequent daily monitoring of busulfan levels for confirmation of adequate washout, a single dose cluster of differentiation (CD) 34+ cells/kg LentiGlobin BB305 Drug Product was administered to participants by IV infusion.
61994464|NCT04055597|EXPERIMENTAL|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot
61994465|NCT04055597|SHAM_COMPARATOR|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot
61994466|NCT06297707|EXPERIMENTAL|experimental group|aquatic high intensity resistive training
62561449|NCT03379402||Adult patients presenting with sepsis|Adult patients, both males and females, presenting with sepsis will be approached for participation in the study.
62561450|NCT03082859|EXPERIMENTAL|Reduced-exertion high-intensity interval training|Cycling Exercise. 2 x 20-sec sprints.
61994467|NCT06297707|ACTIVE_COMPARATOR|control group|usual care
62561451|NCT03082859|EXPERIMENTAL|High Intensity Interval Training (HIT)|Cycling Exercise. 10 x 1 min at approx 85% peak power output (Wmax)
61994468|NCT01483105|EXPERIMENTAL|DVD self-hypnosis|This group will receive standard care, and parents/children in this group will receive in the mail a set of questionnaires and the DVD self-hypnosis training program. Parents will be asked to review these materials and practice the training at home with their children for one week leading up to the procedure Parents will also be asked to try to use these techniques with their child during his or her upcoming VCUG procedure.
62561452|NCT03082859|EXPERIMENTAL|Moderate Intensity Continuous Exercise|Cycling exercise. 30 min at 50% peak power output (Wmax)
62561453|NCT03082859|NO_INTERVENTION|Sedentary (no exercise)|No exercise. Rest.
62769450|NCT05883358||Kratom withdrawal|Kratom withdrawal syndrome patients, undergoing withdrawal therapy. On alternate weeks, each patient receives rotational treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch.
61994469|NCT01483105|NO_INTERVENTION|Standard care|Children in this arm will receive standard care and parents/children will be mailed a set of questionnaires to complete before and after your child's upcoming VCUG.
61994470|NCT04884685|EXPERIMENTAL|Experimental Group|Participant will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine . Vaccine will given by intramuscular injection on day 0 and day 28.
61994471|NCT04884685|PLACEBO_COMPARATOR|Control Group|Placebo will receive two doses of placebo. The placebo will given by intramuscular injection on day 0 and day 28.
61994472|NCT03610932|EXPERIMENTAL|Vitamin C|Participants will ingest 3 (500 mg) capsules of Vitamin C each day for 2 weeks.
61994473|NCT03610932|ACTIVE_COMPARATOR|Placebo|Participants will ingest a matched capsule for size and color to the Vitamin C supplement.
61994474|NCT02509065|ACTIVE_COMPARATOR|Usual Care|Comparator week to all closed-loop control, utilizing usual diabetes care and the subject's own insulin pump.
61994475|NCT02509065|EXPERIMENTAL|145 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 145 mg/dl and using only an insulin pump.
61994476|NCT02509065|EXPERIMENTAL|130 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is for subjects with type 1 diabetes only. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
62168332|NCT05999513|EXPERIMENTAL|Casdatifan - Sequence ABC|Participants will sequentially receive casdatifan capsules fasted (Treatment A), followed by casdatifan tablets fasted (Treatment B), followed by casdatifan tablets fed (Treatment C)
62389877|NCT01105429|ACTIVE_COMPARATOR|BMS-820132 (300 mg) or Placebo|
62389878|NCT01105429|ACTIVE_COMPARATOR|BMS-820132 (TBD) or Placebo|
61994477|NCT02509065|EXPERIMENTAL|130 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
61994478|NCT02509065|EXPERIMENTAL|115 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 115 mg/dl using both an insulin and a glucagon pump.
61994479|NCT02509065|EXPERIMENTAL|100 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 100 mg/dl using both an insulin and a glucagon pump.
61994480|NCT02509065|EXPERIMENTAL|110 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
61994481|NCT02509065|EXPERIMENTAL|110 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
61994482|NCT02509065|EXPERIMENTAL|120 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 120 mg/dl and using only an insulin pump.
61994483|NCT00132418|PLACEBO_COMPARATOR|Placebo|placebo
61994484|NCT00132418|EXPERIMENTAL|Enbrel|Enbrel
61994485|NCT00558103|ACTIVE_COMPARATOR|arm 1|Lapatinib
61994486|NCT00558103|ACTIVE_COMPARATOR|arm2|Pazopanib monotherapy (open label)
61994487|NCT00558103|EXPERIMENTAL|arm3|Lapatinib+ pazopanib
61994488|NCT03365596||Subacute stroke|
62389879|NCT05723172|ACTIVE_COMPARATOR|active tACS|40 mins tACS for 10 consecutive daily sessions
62389880|NCT05723172|SHAM_COMPARATOR|sham tACS|40 mins sham tACS for 10 consecutive daily sessions
61994489|NCT02903186|EXPERIMENTAL|Nutrition messages|The intervention will focus on reinforcing the WIC breastfeeding messages, preventing overfeeding (i.e. using spoon to feed baby, not adding baby food or cereal to bottle, not placing their babies to sleep with a bottle, feeding their babies without distractions, etc), delaying introduction of solid foods, and delaying and reducing baby juice consumption. Constructs in the transtheoretical model such as self-efficacy and decisional balance will be used to address key determinants of behavior change to ensure relevance to the audience, and will target individuals both at the earlier and later stages of change. The messages are written at a grade 5 level in Spanish (PR site) and English (Hawaii site) and will be sent on different days and times of the week.
61994490|NCT02903186|ACTIVE_COMPARATOR|General health messages|The control group will receive weekly SMS about general infant's health issues, such as placing the infant on his/her back to sleep, the timeline for immunizations, the proper use of car seats, asthma and other respiratory conditions common among small children, and other health information relevant to infants. The investigators will follow the same protocol (schedule, length, language, etc.) as for the intervention messages.
61994491|NCT01992731|ACTIVE_COMPARATOR|IUI group|"Group 1: Patients undergo a standard treatment with 3 consecutive gonadotrophin stimulated IUI cycles Intervention: treatment choice and drug:(Follitropine Bèta, Puregon, MSD).~vs."
61994492|NCT01992731|ACTIVE_COMPARATOR|IVF/ICSI arm|"Group 2: 1 Patients start immediately with IVF/ICSI instead of IUI. A standard antagonist protocol with treatment with a recombinant FSH (Follitropine Bèta, Puregon, MSD) is used.~Intervention: treatment choice and drug: recombinant FSH (Follitropine Bèta, Puregon,"
62389881|NCT03648047|EXPERIMENTAL|Experimental group|Patients in this group will receive a mixed home-based rehabilitation program consisting of face-to-face sessions with a Physical Therapist (with decreasing periodicity depending on program stage) as well as sessions performed with a digital kinematic biofeedback system.
62389882|NCT03648047|ACTIVE_COMPARATOR|Conventional rehabilitation|Patients in this group will receive a home-based rehabilitation program consisting of face-to-face sessions with a Physical Therapist 3 times per week, for 1 hour. Patients will also be instructed to perform additional unsupervised sessions in at least two other days of the week. Compliance to these additional sessions is not mandatory, but patients will be asked to fill in a diary regarding these extra-sessions.
62389883|NCT00417911|ACTIVE_COMPARATOR|No treatment|
62389884|NCT00417911|EXPERIMENTAL|Bortezomib consolidation|Bortezomib consolidation : 20 injections starting 3 months after ASCT
62389885|NCT05698342||Melasma mMASI 7|Female patients with melasma mMASI at least 7
61994493|NCT04200807||Healthy preterm neonate|Neonate 26 weeks to 36 weeks + 6 days of gestation, without congenital heart defects and/or hemodynamically significant fetal circulation, any respiratory therapy, nor need of supplemental oxygen. Subjects had no clinically and laboratory-identified infections.
61994494|NCT04200807||Healthy term neonate|Neonate from 37 weeks of gestation, without congenital heart defects and/or hemodynamically significant fetal circulation, any respiratory therapy, nor need of supplemental oxygen. Subjects had no clinically and laboratory-identified infections.
61994495|NCT04200807||Sick neonate|Neonate of any gestation, without congenital heart defects, with clinically and laboratory-identified infection.
61994496|NCT05728346|EXPERIMENTAL|single-arm|
61994497|NCT00563238|NO_INTERVENTION|Control|
61994498|NCT00563238|ACTIVE_COMPARATOR|Metoprolol|
62389886|NCT00303290|EXPERIMENTAL|PEG-Intron + ARA-C|Peg Interferon Alpha 2b (Peg Intron) 4.5 micrograms/kg once a week. ARA-C 10 mg under the skin daily.
62389887|NCT06076863|EXPERIMENTAL|Pharmacist Care|Pharmacists on a regional team will manage requests for Paxlovid placed by patients via e-visits using a standard protocol.
62389888|NCT06076863|ACTIVE_COMPARATOR|Adult and Family Medicine Physician Pool Care|Adult and family medicine physicians serving in pools will manage requests for Paxlovid placed by patients via e-visits using a standard protocol.
62389889|NCT01245296|OTHER|Early cord clamping (ECC)|Early cord clamping consisted of early (\< 10 s) clamping of the umbilical cord and obtaining blood gas samples after clamping.
61994499|NCT00909948|ACTIVE_COMPARATOR|Fludarabine|The patients in this cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
61994500|NCT00909948|ACTIVE_COMPARATOR|TBI only|Patients will be given 200 centiGray (cGy) total body irradiation (TBI) in one fraction. TBI will be given on day 0, 4 to 6 hours prior to HCT.
62168333|NCT05999513|EXPERIMENTAL|Casdatifan - Sequence BCA|Participants will sequentially receive Treatment B, followed by Treatment C, then Treatment A
62168334|NCT05999513|EXPERIMENTAL|Casdatifan - Sequence CAB|Participants will sequentially receive Treatment C, followed by Treatment A, then Treatment B
62168335|NCT01393262||Healthy Escort|
62168336|NCT01393262||Hand Service patient|
62168337|NCT03483597||rheumatologists|Inclusion criteria: Registered rheumatoid specialist physicians subordinated to the 12 designated hospitals The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in rheumatologists.
62168338|NCT03483597||patients|Inclusion criteria: Aged over 18, confirming RA for more than 6 months Exclusion criteria. Patients with Chinese reading comprehension barriers (unable to complete the questionnaire independently), without any RA treatment The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in patients.
62168339|NCT03792035|EXPERIMENTAL|Experimental group|First time given 8 capsules of Tongxinluo, then given 4 capsules of Tongxinluo, tid, po.Dosage form: capsule;Dose: 0.26g/capsule;Duration:1 year
62168340|NCT03792035|PLACEBO_COMPARATOR|Control group|First time given 8 capsules of placebo, then given 4 capsules of placebo, tid, po.Dosage form: capsule;Dose: 0.26g/capsule;Duration:1 year
62168341|NCT05388864|EXPERIMENTAL|Three-Tier Model|130 children with ACEs who received well-child care by a trained provider will be enrolled in this group.
62168342|NCT05388864|NO_INTERVENTION|Comparison Group|80 children without ACEs who received usual well-child care will be enrolled in this group.
62769451|NCT05054543|EXPERIMENTAL|Uproleselan|Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Uproleselan in combination with HiDAC/IDAC during consolidation
61994501|NCT03503721|EXPERIMENTAL|BipolEP|includes all patients undergoing BipolEP surgery
62168343|NCT05388864|NO_INTERVENTION|Control Group|130 children with ACEs who received usual well-child care will be enrolled in this group.
62168344|NCT01588847|EXPERIMENTAL|Regional anesthesia|
62168345|NCT01588847|ACTIVE_COMPARATOR|General anesthesia|
62168346|NCT01979120||only 1 cohort!|All patients already got an ICD implanted which includes an algorithm for screening of sleep-disordered breathing and will be examined by an portable polygraphy monitor in order to compare the Apnea-Hypopnea-Index.
62168347|NCT05880771|EXPERIMENTAL|Immediate implant placement with buccal gap grafted with Allograft|Following tooth extraction immediate implant will be placed in the palatal bone and the buccal gap between the implant and the buccal bone will be grafted with Allograft
62168348|NCT05880771|EXPERIMENTAL|Immediate implant placement with buccal gap grafted with Xenograft|Following tooth extraction immediate implant will be placed in the palatal bone and the buccal gap between the implant and the buccal bone will be grafted with Xenograft
62168349|NCT01103141|ACTIVE_COMPARATOR|Micropuncture|
62168350|NCT01103141|ACTIVE_COMPARATOR|Standard|
62168351|NCT02991781|EXPERIMENTAL|COPD Patients|"C.O.P.D. patients: Presence of a post-bronchodilator forced expiratory volume at one second (FEV1) / forced vital capacity (FVC) \< 0.70 with symptoms as dyspnea, chronic cough, chronic sputum production~Biofeedback and Neurofeedback Training~Varenicline use for smoking cessation~Passive Control"
62168352|NCT02991781|EXPERIMENTAL|Asthma Patients|"Asthma patients: Presence of 2 or more of symptoms of airflow obstruction (cough, wheezing, dyspnea). Airflow obstruction at least partially reversible demonstrated by spirometry with FEV1 increased by \>12% following b2 agonist inhalation) or evidence of bronchial hyperresponsiveness by metacholine provocation test (demonstrated by provocative concentration causing a 20% fall (PC20) \<8 mg or mannitol provocation test (with FEV1 decrease of 15%)~Biofeedback and Neurofeedback Training~Varenicline use for smoking cessation~Passive Control"
62168353|NCT02991781|EXPERIMENTAL|Smokers|"Smokers will consist of a group of patients that are under the age of 35, unemployed and healthy according to a standard clinical evaluation.~Biofeedback and Neurofeedback Training~Varenicline use for smoking cessation~Sham Neurofeedback~Passive Control"
62168354|NCT02127645|EXPERIMENTAL|Early Rectal Cancer|patients with T1 - T2, N0, G1-2 rectal cancer
62168355|NCT05827809|EXPERIMENTAL|Unified Protocol (UP-C/A) for children and youth with anxiety disorders and/or depression|A within group design where one clinical manualised intervention, the Unified protocol based on the third-wave of Cognitive Behavior Therapy (CBT), is offered in a 11 session group format to children and adolescents. Parent training is at the same time also offered in a group format. Therapists are trained in the method and receive regular supervision adhering to the evidence-based manual. The group treatment and parent training is delivered face-to- face.
62168356|NCT01174875||Pregnant mothers, infants and children|Women in their early pregnancy who are attending the first trimester antenatal ultrasound scan at the public maternity units at KK Women's and Children's Hospital (KKH) and National University Hospital (NUH). Only women age 18 years and above who are Singapore Citizens or Singapore Permanent Residents. Participants have to intend to eventually deliver in NUH or KKH and to reside in Singapore for the next 5 years. Willingness to donate cord, cord blood and placenta. The fetus should be racially homogenous with both sets of grandparents of the same ethnicity. Babies born from these mothers will be followed up until the child is at least 14 years of age.
62168357|NCT02181400|ACTIVE_COMPARATOR|NIR Laser Treatment 25 miiliwatts (mW)/cm2 dose|The Ellex Integre NIR (near Infrared Light) Laser dose of 25 milliwats(mW)/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
62389890|NCT01245296|OTHER|Delayed cord clamping (DCC)|Delayed cord clamping consisted of delayed (\> 180 s) clamping of the umbilical cord and obtaining blood gas samples before clamping (within 30 seconds).
61994502|NCT03503721|ACTIVE_COMPARATOR|TURP|includes all patients undergoing TURP surgery
62168358|NCT02181400|ACTIVE_COMPARATOR|NIR laser treatment 100mW/cm2 dose|The Ellex Integre NIR Laser dose of 100 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
62168359|NCT02181400|ACTIVE_COMPARATOR|NIR laser treatment 200mW/cm2 dose|The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
62168360|NCT05113212|ACTIVE_COMPARATOR|Control arm|patients aﬀected by macular pucker or macular hole, whose internal limiting membrane peeling is performed using a traditional optical microscope (Leica F40)
62168361|NCT05113212|EXPERIMENTAL|Experimental arm|patients aﬀected by macular pucker or macular hole whose internal limiting membrane peeling is performed by 3D heads-up microscopy system (NGenuity 3D)
62168362|NCT02089984|EXPERIMENTAL|Internet-Based Training|On-line tutorial followed by live remote training via videoconferencing
62389891|NCT01809158|ACTIVE_COMPARATOR|minocycline|Subjects randomized to the minocycline group will take 2 tablets per day, each 100mg of minocycline, for a total daily dose of 200mg of minocycline.
62389892|NCT01809158|PLACEBO_COMPARATOR|placebo|Subjects randomized to the placebo group will take 2 tablets of placebo (matched for minocycline) per day.
62561454|NCT05308511|EXPERIMENTAL|Swallowing order I|First swallow the trial device(PC-I) for examination, and then swallow the comparator device(COLON2) for examination at an interval of 2h.
62561455|NCT05308511|EXPERIMENTAL|Swallowing order II|First swallow the comparator device(COLON2) for examination, and then swallow the trial device(PC-I) for examination at an interval of 2h.
62389893|NCT01399931||Early-stage Hodgkin Lymphoma Patients|Early-stage Hodgkin Lymphoma (HL) patients presenting bulky nodal lesions treated with ABVD and consolidation radiotherapy
62389894|NCT01712763|EXPERIMENTAL|Degarelix|180 women will be treated with degarelix 120mg in one administration
62389895|NCT01712763|ACTIVE_COMPARATOR|leuprolide acetate 11.25 mg/ml|180 women will be treated with leuprolide acetate 11.25 mg/ml only once covering three months
62561456|NCT00879255|EXPERIMENTAL|Videoteleconferencing CPT|"The experimental arm is the group condition that received the CPT treatment via videoteleconferencing modality as compared to the experimental condition which is via face-to-face traditional modality.~Cognitive Processing Therapy Group Videoteleconference is delivered to male combat veterans who have been diagnosed with PTSD, through videoteleconference."
62561457|NCT00879255|ACTIVE_COMPARATOR|Face-to-Face CPT|"The control arm is the group condition that received the CPT treatment via face-to-face traditional modality as compared to the experimental condition which is via videoteleconferencing modality.~Cognitive Processing Therapy Group In-Person is delivered to male combat veterans who have been diagnosed with PTSD, in-person, rather than through videoteleconference."
62561458|NCT02090972||Patients with fracture|"* fracture within the last 14 days~* no other fractures within the last 6 month~* patients \>60 years"
62561459|NCT02090972||Control Patients|"* patients hospitalized for an internal reason~* no other fractures within the last 6 month~* patients \>60 years"
62561460|NCT03687320|EXPERIMENTAL|Standard and B-Cure Pro|Subjects from the Standard and B-Cure Pro group will receive standard care and in addition will self-treat at home daily with the B-Cure device.
62561461|NCT03687320|SHAM_COMPARATOR|Standard and Sham|Subjects from the Standard and sham group will receive standard care and in addition will self-treat at home daily with the sham B-Cure device.
62561462|NCT03807544|EXPERIMENTAL|TENS treatment arm|This study is a usability study, where all subjects will receive the same experimental treatment for their single visit.
62168363|NCT05024396|EXPERIMENTAL|maximum jump height|Two visits will take place 1-2 weeks apart. At the first visit, participants will complete 2x3 single-leg countermovement jumps measured by two subjects each. At the second visit, three jumps are completed measured by the first test subject.
62168364|NCT00119795|ACTIVE_COMPARATOR|Health education control|This is an education program for older adults entitles, successful aging.
62168365|NCT00119795|EXPERIMENTAL|Exercise Only|Structured exercise 150 min/wk
62168366|NCT00119795|EXPERIMENTAL|Weight Loss|Behavioral weight loss; goal of 7%
62168367|NCT01381614||Occurance of severe adverse event claims in subjects|Presence or absence of common severe treatment related adverse events (based on existence of claims) in patients with metastatic RCC. Common severe adverse event defined as Grade 3 or higher with \>=5% frequency of occurance as reported in product label.
62168368|NCT00161434|EXPERIMENTAL|1|
62168369|NCT00161434|PLACEBO_COMPARATOR|2|
62168370|NCT05469867|EXPERIMENTAL|Corneat EverPatch - Synthetic Tissue Substitute for Covering Ophthalmic Implants|
62168371|NCT04299971|ACTIVE_COMPARATOR|methotrexate|This group of 38 TAK cases are prescribed with methotrexate tablets (Dose: 15.0 mg. qw. p.o.) for 24 weeks.
62168372|NCT04299971|EXPERIMENTAL|Tofacitinib|This group of 38 TAK cases are prescribed with tofacitinib tablets (Dose: 5.0 mg. bid. p.o.) for 24 weeks.
62769452|NCT05054543|PLACEBO_COMPARATOR|Placebo (Saline, 0.9% Sodium Chloride)|Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Placebo in combination with HiDAC/IDAC during consolidation
62769453|NCT03474198|ACTIVE_COMPARATOR|Standard TB Management Strategy|Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol, then 16 weeks rifampicin, isoniazid only
62561463|NCT00576719|EXPERIMENTAL|1|Participants will receive intensive cognitive behavioral therapy treatment without parent involvement
62769454|NCT03474198|EXPERIMENTAL|TRUNCATE-TB Management Strategy using Regimen B|"TRUNCATE-TB Management Strategy: 8 weeks\* of initial treatment using Regimen B; close monitoring after treatment completion; treatment of relapse with 24 weeks of standard treatment.~\*If persistent symptoms and positive smear at week 8, extend to 12 weeks of treatment using Regimen B; if persistent symptoms and positive smear at week 12, switch to standard treatment regimen and extend to 24 weeks of treatment.~Regimen B: Rifampicin (35mg/kg), isoniazid, pyrazinamide, ethambutol, linezolid"
62769455|NCT03474198|EXPERIMENTAL|TRUNCATE-TB Management Strategy using Regimen C|"TRUNCATE-TB Management Strategy as described above, using Regimen C in place of B.~Regimen C: Rifampicin (35mg/kg), isoniazid, pyrazinamide, ethambutol, clofazimine"
62769456|NCT03474198|EXPERIMENTAL|TRUNCATE-TB Management Strategy using Regimen D|"TRUNCATE-TB Management Strategy as described above, using Regimen D in place of B.~Regimen D: Rifapentine, isoniazid, pyrazinamide, linezolid, levofloxacin"
62561464|NCT00576719|EXPERIMENTAL|2|Participants will receive intensive cognitive behavioral therapy treatment with parent involvement
62561465|NCT00576719|PLACEBO_COMPARATOR|3|Waitlist control group
62561466|NCT02902523|ACTIVE_COMPARATOR|Viread ® tablet 300mg|Tenofovir disoproxil fumarate
62561467|NCT02902523|EXPERIMENTAL|HUG116 tablet 245mg|Tenofovir disoproxil
62769457|NCT03474198|EXPERIMENTAL|TRUNCATE-TB Management Strategy using Regimen E|"TRUNCATE-TB Management Strategy as described above, using Regimen E in place of B.~Regimen E: Isoniazid, pyrazinamide, ethambutol, linezolid, bedaquiline"
62561468|NCT03198962||Groups A|At each visit, a series of self-administered questionnaires will be used to collect demographic, sexual behavioral risk and drug use data. HIV testing, risk reduction counseling, condoms \& lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-negative participants will be actively offered to visit the clinic for pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP) or STI services and encouraged to visit the clinic outside of the scheduled visits for these services whenever they feel needed. Adherence to PrEP, PEP, STI treatment will be evaluated in those who are prescribed these medications. Among HIV seroconverters, drug use patterns will be longitudinally monitored prior to and after HIV diagnosis. HIV seroconverters at month 6 or month 12 will be transferred to groups C, D dependent on drug use history.
62769458|NCT05481099|EXPERIMENTAL|Intervention|Cognitive-behavioural-based intervention combined with mindfulness, psychoeducation, and relaxation techniques
62769459|NCT05481099|NO_INTERVENTION|Control|Care as usual
62769460|NCT02017522|EXPERIMENTAL|11C-PBR PET|"Subjects will have a blood sample drawn to evaluate the presence of a specific genetic variation which would prevent the new type of imaging test we are evaluating from working and we will test the inflammatory cells in the blood for the same purpose.~All participants who proceed will have to return on at least one additional day to undergo a positron emission tomography (PET) scan similar to the scan your doctor ordered. we will use 11C-PBR28 as the radiotracer. This study will evaluate whether 11C-PBR28 can show areas of inflammation due to cardiac sarcoidosis. On either the same day or a different day, you will also undergo a cardiac MRI."
62769461|NCT04902664|EXPERIMENTAL|Intervention Arm|Intervention arm physicians will receive an email with feedback on how they compare to their peers in aggregate on test ordering during annual physicals, along with physician-facing education materials. This email will be sent before each patient study visit for all patients in the study. Participating patients of intervention arm physicians will receive patient education materials one to two days before their study visit.
62769462|NCT04902664|PLACEBO_COMPARATOR|Control Arm|Control arm physicians receive an email with information on the general visit preparation tips that their patients will receive. Participating patients of control arm physicians will receive general visit preparation tips one to two days before their study visit.
62769463|NCT00844259||Research Group|15 children with Down syndrome, observed in two interaction conditions: playing with their therapist (A) and playing with their caregiver (B).
62769464|NCT01627444|EXPERIMENTAL|ear acupuncture|
62769465|NCT01627444|PLACEBO_COMPARATOR|Placebo acupuncture|No needle insertion, only stickers on acupuncture points.
62769466|NCT04254029|EXPERIMENTAL|Non-randomized single-arm of MOROLSTEVER1|"Non-randomized single-arm clinical trial with a before and after design. The study population consisted on all type 2 diabetes mellitus (T2DM) patients with a target population of T2DM patients with HbA1c between 42 to 64mmol/mol (6-8%) with no change in anti-diabetic treatment during the last three months, previous the study.~The intervention consisted of a daily consummation of 425 ml of drink containing the extracts of 1,38mg of leaves extracts of moringa oleifera and 23,46 mg of stevia rebaudiana Bertoni leaves extracts lasting 45 days."
62769467|NCT00940485|EXPERIMENTAL|Peginterferon alfa-2a + entecavir|Participants received PEGASYS® (peginterferon alfa-2a)180 micrograms (mcg) subcutaneously once weekly for 48 weeks, plus entecavir 0.5 milligram (mg) orally once daily for 8 weeks.
62769468|NCT00940485|ACTIVE_COMPARATOR|Entecavir|Participants received entecavir 0.5 mg orally once daily for 48 weeks.
62389896|NCT01243047|ACTIVE_COMPARATOR|Arm A|Continuous erlotinib administration (21-day cycle). Erlotinib dose given at 100mg daily
62389897|NCT01243047|ACTIVE_COMPARATOR|Arm B|Intermittent erlotinib administration (21-day cycle). Erlotinib dose given at 150mg.
62389898|NCT03907072|EXPERIMENTAL|WVE-210201 (3 mg/kg)|Weekly IV administrations of WVE-210210 at 3 mg/kg
62389899|NCT03907072|EXPERIMENTAL|WVE-210201 (4.5 mg/kg)|Weekly IV administrations of WVE-210210 at 4.5 mg/kg
62389900|NCT03907072|PLACEBO_COMPARATOR|Placebo|Weekly IV administrations of phosphate buffered saline solution visually identical in appearance to WVE-21021
62389901|NCT04033328|EXPERIMENTAL|Dose Escalation|ORIC-101 dosed orally, once per day in combination with enzalutamide (160 mg) of each 28-day cycle.
62389902|NCT04033328|EXPERIMENTAL|Dose Expansion|RP2D dose
62389903|NCT00483067|EXPERIMENTAL|2-CdA + Ara-C + G-CSF|2-CdA 12 mg/m\^2/day by vein (IV) Continuous Infusion and Ara-C 1 gm/m\^2/day IV for 5 Days with G-CSF 5 mcg/kg/day subcutaneously starting Day 9
62389904|NCT05138731||Stable angina (SA)|Typical chronic exersive angina pectoris attacks, lasting several minutes to more than 10 minutes, 3-5 minutes in most cases, generally not more than 30 minutes. The pain disappeared after rest or taking nitrates, and the pain degree, frequency, duration, nature and inducing factors did not change in the last 1-3 months.
62389905|NCT05138731||Unstable angina (UA）|Including resting angina (attack at rest, the duration is usually \>20 minutes), primary angina (usually the first symptoms within 1-2 months, very light physical activity can be induced, at least CCSIII level), worsening angina (angina gradually increases on the basis of relatively stable labor angina. More severe pain, longer or more frequent pain, at least grade I increase according to THE CCS classification, at least GRADE II CCSI). TNI was negative, routine electrocardiogram may have transient ST segment depression, T wave low flat or inverted.
62389906|NCT05138731||Acute non-ST-segment elevation myocardial infarction （NSTEMI）|Patients with elevated troponin accompanied by one or more of the following conditions: electrocardiogram showed new ST segment depression or T wave flatness or inversion; Persistent ischemic chest pain; Echocardiography showed abnormal segmental ventricular wall activity. Abnormal coronary angiography.
62389907|NCT05138731||Acute ST-segment elevation myocardial infarction （STEMI）|Troponin was elevated, and ECG showed ST segment arcuate back elevation, accompanied by one or more of the following conditions: persistent ischemic chest pain; Echocardiography showed segmental abnormal ventricular wall activity; Abnormal coronary angiography.
62389908|NCT05138731||normal coronary artery （NCA）|symptoms of chest pain and no stenosis in coronary arteries (such as myocardial bridging, reflux esophagitis, intercostals neuralgia, cervical spondylopathy, and unexplained chest pain)
62389909|NCT05138731||nonobstructive coronary atherosclerosis （NOCA）|stenosis \< 50% in coronary arteries
62389910|NCT05138731||healthy volunteers|Healthy control subjects who had no significant systemic diseases (e.g. ischemic heart disease, hypertension,diabetes,cancer, pulmonary disease, or infectious diseases) were recruited from Physical Examination Center of Ningxia Medical University General Hospital
62389911|NCT02741336|EXPERIMENTAL|CBT-I Intervention|For those randomized to the CBT-I group, the therapist will initiate telephone-delivered cognitive-behavioral therapy within 2 weeks of baseline assessment. Participants will complete 4 telephone sessions over a period of 8 weeks. Sessions last approximately 45 minutes. CBT-I is a short-term, focused psychotherapy that is action-oriented, practical, rational, and helps the patient gain independence and effectiveness in dealing with real-life issues. Techniques utilized in CBT-I include psychoeducation, sleep hygiene, cognitive restructuring, stimulus control, sleep restriction, and relaxation training.
62389912|NCT02741336|ACTIVE_COMPARATOR|Self-Monitoring Control Group|Individuals randomized to the self-monitoring control group will be asked to complete a weeklong sleep diary every other week for 8 weeks. The sleep diary will inquire about (1) the time of getting into bed; (2) the time at which the individual attempted to fall asleep; (3) sleep onset latency; (4) number of awakenings; (5) duration of awakenings; (6) time of final awakening; (7) final rise time; (8) perceived sleep quality (rated via Likert scale); and (9) an additional space for open-ended comments from the respondent. The control condition is designed to increase self-monitoring, which has been demonstrated to be an effective means of inducing change for various health behaviors such as diet and exercise.
62389913|NCT05499208|EXPERIMENTAL|Giving side position with patient turning and movement system|On the day she was admitted to the clinic, the pregnant woman was taken to the room with the turning and movement system, the system was introduced and the personal information form was filled. When she came to the clinic from the operating room, the puerperant was placed on the bed with the turning and motion system (side position) and a follow-up form for LATCH, GKO and Lactogenesis Free symptoms was filled in the first three breastfeedings. Before discharge, LATCH, GCS, and Lactogenesis symptoms follow-up forms were filled in the last three breastfeedings. WHO was filled 1-2 hours before discharge. On the 3rd and 4th days after discharge, the lactogenesis symptoms follow-up form was filled by phone.
62769469|NCT00069992|EXPERIMENTAL|Submyeloablative Allogeneic Stem Cell Transplant|Total Body Irradiation Fludarabine Campath 1H
62168373|NCT03653689|ACTIVE_COMPARATOR|FODMAPs|Dietary supplement: FODMAPs 50 grams three servings per day for seven days.
62168374|NCT03653689|ACTIVE_COMPARATOR|Gluten|Dietary supplement: Gluten 17.3 grams three servings per day for seven days.
62168375|NCT03653689|PLACEBO_COMPARATOR|Placebo|Dietary supplement: Placebo rice porrige three servings per day for seven days.
61994503|NCT02694146|EXPERIMENTAL|PRP (platelet rich plasma)|"37 patients with coxarthrosis are treated with 6ml of PRP (platelet rich plasma), obtained from blood extracted from patients in the 20 minutes prior to infiltration thereof.~For PRP administration:~* The injection should be performed at room temperature.~* The administration should be carried out under aseptic conditions.~* The patient will be placed in the supine position and the administration will be performed by an anterolateral approach.~* The PRP is injected into the synovial space."
61994504|NCT02694146|ACTIVE_COMPARATOR|Hylan G-F 20 (Synvisc-One ®)|"37 patients with coxarthrosis are treated with a pre-filled syringe of hyaluronic acid 60mg / 6ml (Synvisc-One ®).~It is necessary to remove synovial fluid before injecting Hylan G-F 20.~* The injection should be performed at room temperature.~* The administration should be carried out under aseptic conditions.~* The patient will be placed in the supine position and the administration will be performed by an anterolateral approach.~* The Hylan G-F 20 is injected into the synovial space.~* After injecting Hylan G-F 20 the patient should stand 5 minutes."
61994505|NCT04287738|EXPERIMENTAL|Navigated Care|Telephone-based collaborative dementia care navigation
61994506|NCT04287738|NO_INTERVENTION|Survey of Care|Control group that will receive usual care and undergo the same regular assessments as patients enrolled in Navigated Care
62389914|NCT05499208|NO_INTERVENTION|Control: Assigned Interventions standard care group|routine maintenance of the hospital
62389915|NCT01059955|EXPERIMENTAL|Active treatment at day 0 and day 7|"Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and one at Day 7.~The three iontophoresis doses are:~1. Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA~2. Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA~3. Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA"
62389916|NCT01059955|ACTIVE_COMPARATOR|Active Treatment at Day 0, Sham Treatment at Day 7|"Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and a sham treatment Day 7.~The three iontophoresis doses are:~1. Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA~2. Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA~3. Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA"
62561469|NCT03198962||Groups C|At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms \& lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18.
62168376|NCT05599230||CF patients before (3 days) and during (14 days) ETI treatment|"Patients over 12 years old and eligible will start ETI treatment ( current standart treatment).~* Morning: Elexacaftor 100 mg, Tezacaftor 50 mg, Ivacaftor 75 mg, 2 tablets~* Evening: Ivacaftor 150 mg"
62389917|NCT00361504|EXPERIMENTAL|Tapentadol (CG5503)|Tapentadol (CG5503) extended release (ER) 100 to 250 mg twice daily (BID) for up to one year.
62389918|NCT00361504|ACTIVE_COMPARATOR|Oxycodone|Oxycodone controlled release (CR) 20 to 50 mg twice daily (BID) for up to one year.
62389919|NCT04602468|OTHER|Standard group|The standard testing group will be available for both age cohorts with sites having a predefined recruitment cap for each testing group. The standard testing will involve the following assessments; sweat chloride, LCI, height/weight/BMI, FEV1, airway sampling (micro), FeNO, liver function testing, liver ultrasound, liver examination, stool collection, blood collection, abdominal symptom score, CFQ-R, pharmacy records medication pick up rate, adherence questionnaires, MEMs caps and antibiotic use.
62561470|NCT03198962||Group B|At each visit, a series of self-administered questionnaires will be used to collect demographic, sexual behavioral risk and drug use data. HIV testing, risk reduction counseling, condoms \& lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18.
62561471|NCT03198962||Group D|At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms \& lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-positive participants, if they have not yet started ART, will be referred to preferred hospitals to receive ART regardless of CD4 count according to the 2014 National Guidelines. Drug use patterns will be longitudinally monitored prior to and after ART initiation.
62168377|NCT02956915||patients with severe symptomatic aortic stenosis|Stable patients with severe symptomatic aortic stenosis undergoing planned Transfemoral Transcatheter aortic valve implantation with the SAPIEN-3 prosthesis will be included. TF-TAVI will be done using a minimalist approach of local anesthesia and conscious sedation.
62168378|NCT05361083|EXPERIMENTAL|First-in-man investigastion of [18F]CETO|"15 patients were investigated with PET/CT after injection of 2,5 MBq/kg \[18F\]CETO. 5 healthy volunteers were investigated twice (Test-retest), with approximately 2 weeks in-between each PET/CT investigation, after injection of 1,3 MBq/kg \[18F\]CETO. Arterial blood samples were taken as well as urinary sampels.~3 out of 5 healthy volunteers were also investigated twice with PET/CT after injection of 13,2 MBq/kg \[15O\]water, performed before the \[18F\]CETO PET/CT."
62561472|NCT06181773|EXPERIMENTAL|EPO Feeding program + Usual care (intervention group)|Participants in the intervention group will receive the EPO Feeding program and usual care. EPO Feeding program includes four, weekly group training sessions for parents of preschool children (aged 2-6) led by healthcare professionals. The intervention incorporates lessons and information (i.e., slide shows and handouts), group discussions, motivational interviewing, and other supplementary materials (e.g., stories, key messages, and educational videos) to improve parents' knowledge, skills, and behaviors regarding feeding preschool children. After each module, homework activities will be assigned to participants to help reinforce their knowledge, skills, and behaviors. The motivational interviewing will be conducted by healthcare professionals to provide individual support. Moreover, a WeChat group will be set up to facilitate parental involvement, learning, and communication.
62561473|NCT06181773|NO_INTERVENTION|Usual care (control group)|Parents involved in the control group will receive usual care, which is the printed materials of child health-related dietary recommendations published by the Chinese government/Nutrition Society. These materials will also be distributed to the participants in the intervention group. After the final data collection at one-month follow-up, participants from this control group will be offered the complete material package of the EPO Feeding program, their child's weight status measured at the final time point and provided access to pre-recorded modules by healthcare professionals as a incentive.
62561474|NCT00708890|EXPERIMENTAL|Intervention group|
62561475|NCT00708890|NO_INTERVENTION|Control group|Will only get a standard information about TSG group (information about meeting etc.)
62561476|NCT02052024|ACTIVE_COMPARATOR|Botox|Treatment group will receive 100 units of BOTOX and will receive 1-3 injections per muscle at each visit.
62561477|NCT02052024|ACTIVE_COMPARATOR|MYOBLOC|Treatment group will receive 5,000 units of MYOBLOC and will receive 1-3 injections per muscle at each visit.
62561478|NCT04871360|EXPERIMENTAL|Citrulline group|Group of adolescents supplemented orally with 6 g / day of pure L-citrulline in capsules. The dose will be met by taking four (3 g) capsules in the morning before the first meal and four capsules (3 g) in the evening after the last meal.
62561479|NCT04871360|PLACEBO_COMPARATOR|Placebo group|Group of adolescents supplemented with placebo (carboxymethyl cellulose). The indication for taking will be the same as in the experimental group, four capsules in the morning before the first meal and four capsules at night, after the last meal.
62561480|NCT01653535|EXPERIMENTAL|Fast Track Eligible|"Participants in the Experimental group received the Fast Track intervention. Intervention included school-based curriculum attended by high-risk children, parents, program staff, and occasionally teachers, home visiting, the the in-class PATHS prevention program."
62561481|NCT01653535|NO_INTERVENTION|Control Group|Participants in the Control group were not eligible to receive the Fast Track intervention. These children received other services as usual, and served as the randomized comparison group for examining Fast Track program impacts
62561482|NCT05211570|EXPERIMENTAL|AB8939|AB8939 administered as a single agent
62561483|NCT05211570|EXPERIMENTAL|AB8939 plus azacitidine|AB8939 administered in combination with azacitidine
62561484|NCT05670808|EXPERIMENTAL|Epinephrine 1:200,000|In this group participants will receive the epinephrine concentration of 1:200,000 in normal saline
62561485|NCT05670808|EXPERIMENTAL|Epinephrine 1:400,000|In this group participants will receive the epinephrine concentration of 1:400,000 in normal saline
62769470|NCT06182696|EXPERIMENTAL|OriCAR-017 ( GPCRC5D-directed chimeric antigen receptor modified T cells )|"Phase I (Dose-Escalation) The subjects enrolled will be sequentially assigned to the corresponding dose level to determin the RP2D. The dose-escalation part of the study will adopt the the standard 3+3 design, wherein 3 dose levels are planned to be evaluated.~Phase I (Dose-Expansion) After determining the RP2D, one of the dose levels will be selected for further evaluation during the dose-expansion part. Up to 10 to 15 additional subjects who are diagnosed with relapsed/refractory MM will be enrolled to further explore the anti-tumor activity of Ori-CAR-017.~Phase II The Phase II part of the study will be initiated at the RP2D of OriCAR-017 which will be selected based on the clinical data obtained during the Phase I part of the study."
62769471|NCT05019989|EXPERIMENTAL|Intervention group: on diet and physical activity|"Individual advice on diet and on physical activity Kitchen courses to teach basic Mediterranean and macrobiotic recipes (two 1-day course plus ten 3-h courses associated with common dinner) (15-20 participants at a time) Fortnightly common lunch or dinner (50-60 participant at a time) Basic gymnastic course (twelve - monthly- 2-hour courses)~* Study newsletter, with scientific information, kitchen recipes, study facilities~* Periodic conferences on diet and health~* Periodic reinforcement meetings with common meals, gymnastic sessions, and dancing, after the first year~* Periodic body weight assessment (weekly self-measurement and monthly measurement at the study center)~* Discounted rate for advanced kitchen courses~* Psychological support groups"
62561486|NCT05670808|PLACEBO_COMPARATOR|Placebo|In this group participants will receive only 10 ml of normal saline (control group)
62561487|NCT01015534|EXPERIMENTAL|Whole brain irradiation plus Temozolomide|Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks, and a fixed dose of oral Temozolomide, 1h before each fraction of whole brain irradiation, 200 mg on Monday, Wednesday, Friday; 300 mg on Tuesday, and Thursday. Without adjuvant cycles of Temozolomide.
62561488|NCT01015534|ACTIVE_COMPARATOR|Whole brain irradiation|Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks
62561489|NCT03727074|EXPERIMENTAL|5-FU Cream|topical cream
62561490|NCT03727074|ACTIVE_COMPARATOR|Efudex®|topical cream
61994507|NCT02838264|EXPERIMENTAL|Cohort 1|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
61994508|NCT02838264|EXPERIMENTAL|Cohort 2|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
62168379|NCT00765921|EXPERIMENTAL|1.0 mg ranibizumab|1.0 mg intravitreal injection given bi-monthly for 22 months
62561491|NCT03727074|PLACEBO_COMPARATOR|Vehicle|topical cream
62561492|NCT03198442|EXPERIMENTAL|Breast PET|PET imaging of breast with patient in prone position.
61994509|NCT02838264|EXPERIMENTAL|Cohort 3|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
62769472|NCT05019989|EXPERIMENTAL|Control group: only public recommendations on lifestyle|"1. Invitation leaflet, explaining the rationale of the study and including basic life-style recommendations, based on the 1997 World Cancer Research Fund recommendations (to be updated in 2007) and the Italian National Institute of Nutrition food pyramid.~2. Dissemination of the information on the study by media~3. Yearly follow-up questionnaire on breast events and dietary and physical activity chang"
62769473|NCT06257836||MPFL reconstruction with quadriceps graft|Children with medial patellofemoral reconstruction operated with epiphyses sparing quadriceps technique from 2016-2022.
62769474|NCT06257836||Healthy Cohort|A healthy cohort matched on age (+/- 2 years) and gender
62561493|NCT03521388|EXPERIMENTAL|Intervention group|"The intervention consists of an Internet-based program. The program will last 3 months, with subsequent monthly reinforcement sessions for other 3 months.~The program is stepped, so that the more depressive symptomatology the more intensive program and consists of more components.~The students will interact with the program via a monitoring and feedback e-mail with 3 questions of the PHQ--9- adolescent version (1st, 2nd \& 9th question) that they will receive every 2 weeks and a Website that will allow them to access to psycho-educational videos and information. There will also in the Website sections that will provide emergency information, the possibility of a contact via e-mail, and group chats. Adolescents with more depressive symptoms or suicidal risk will be invited to participate in an online counselling appointment or a face to face assessment with a mental health professional of the program."
62561494|NCT03521388|OTHER|Control group|The comparison group will receive general psychoeducation of depression in adolescents and will be on the waiting list to receive the intervention in the event that its efficacy is demonstrated.
62561495|NCT06323837|EXPERIMENTAL|MZP+TAU|Mirtazapine + Treatment as Usual
62561496|NCT06323837|PLACEBO_COMPARATOR|PLO+TAU|Placebo + Treatment as Usual
62561497|NCT06439160||anorexia nervosa/AN|"Individuals of both biological sexes affected by AN who will take part in the multidisciplinary inpatient intensive rehabilitation treatment as offered by the U.O. dei Disturbi del Comportamento Alimentare, San Giuseppe Hospital, Piancavallo (VCO), Italy.~Inclusion Criteria:~i) age between 18 and 65 years old; ii) diagnosis of AN, as per DSM V criteria (APA, 2013); iii) BMI ≤ 17 Kg/m2; iv) adherence to the rehabilitation program, meaning participating at the 75% of the proposed activities.~Exclusion criteria:~i) presence of other pathologies not associated with AN (i.e., neurodegenerative diseases); ii) severe psychopathologies other than AN (i.e., schizophrenia); iii) spontaneous dropout from the multidisciplinary inpatient intensive rehabilitation treatment."
62561498|NCT05725941|ACTIVE_COMPARATOR|Control Group|"Individuals who will participate in the control group will receive a traditional functional exercise training protocol (conventional physiotherapy program) for one hour. It will focus on the enhancement of muscle strength, joint range of motion, arm \&hand activities, and daily living functions of the affected upper limbs.~The treatment, for the control group, will be conducted over a period of 4 successive weeks, with 3 sessions per week."
62561499|NCT05725941|EXPERIMENTAL|Experimental Group|"Participants in the experimental group will receive the conventional treatment program similar to that will be provided to the control group. The treatment, for the experimental group, will be conducted over a period of 4 successive weeks, with 3 sessions per week.~Moreover, they will ¬wear an upper limb spiral strapping system with a hand splint 8 hours daily/ 6 days per week."
62769475|NCT03139799|EXPERIMENTAL|Puzzle Video Game Intervention|Group T will first receive the experimental and then the control intervention (T-C) In phase I both groups take a baseline measurement (pre-test), then group T is given the casual puzzle game task (experimental intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the the experimental intervention group T now serves as control. After phase II (16 weeks) both groups are post-tested again.
62561500|NCT04962295||Cerebral Small Vessel Diseases group|CSVD patients
62561501|NCT02364765|OTHER|Orthognatic surgery|Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour.
62769476|NCT03139799|ACTIVE_COMPARATOR|Tablet Newspaper Reading Intervention|Group C will first receive the the control intervention and then experimental and (C-T). In phase I both groups take a baseline measurement (pre-test), then group C is performing the newspaper reading task (control intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the control group C is given the experimental intervention (casual puzzle game task). After phase II (16 weeks) both groups are post-tested again.
62769477|NCT02759315|EXPERIMENTAL|GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT1 Arm is sub-divided into GT1a and GT1b Arms. GT1a Arm will enroll approximately 35 participants including up to 10 participants who are compensated cirrhotics and GT1b Arm will enroll approximately 15 participants including up to 5 participants who are compensated cirrhotics.
62769478|NCT02759315|EXPERIMENTAL|GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT2 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
62769479|NCT02759315|EXPERIMENTAL|GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT3 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
62168380|NCT00765921|EXPERIMENTAL|0.5 mg ranibizumab|0.5 mg intravitreal injection given bi-monthly for 22 months
62769480|NCT02759315|EXPERIMENTAL|GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT4 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
62561502|NCT04314037|EXPERIMENTAL|Sequence 1 (T1-R1-T2-R2)|Participants will receive first dose of Cesol on Day 1 in treatment period 1 followed by first dose of Biltricide on Day 8 in treatment period 2 followed by second dose of Cesol on Day 15 in treatment period 3 followed by second dose of Biltricide on Day 22 in treatment period 4. A washout period of 7 days will be maintained between 4 treatment periods.
62168381|NCT02511847|OTHER|single-arm|"Drug: Afatinib (single group assignment)~1. First phase: Afatinib montherapy~2. The following phases: combination with oral afatinib and weekly paclitaxel in a 3-weekly course for total of four courses."
62389920|NCT04602468|OTHER|Advanced group|In addition to all elements of the standard testing group, the advanced testing group will undergo: Ultra-low dose spirometry-controlled CT scanning, sputum collection and nasal lavage collection. This will be available for both age cohorts with sites having a predefined recruitment cap for each testing group.
62389921|NCT04415749|EXPERIMENTAL|NasoShield One Dose in Position 1|NasoShield on Day 1 and saline placebo on Day 29 in position 1 (Group 1)
62389922|NCT04415749|PLACEBO_COMPARATOR|Placebo in Position 1|Saline placebo on Day 1 and saline placebo on Day 29 in position 1 (Group 1)
62769481|NCT02759315|EXPERIMENTAL|GT5: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT5 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.
62769482|NCT02759315|EXPERIMENTAL|GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT6 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.
62769483|NCT03130452|ACTIVE_COMPARATOR|concomitant group|lansoprazole 30 mg tablet, amoxicillin 1.0 g tablet, metronidazole 500 mg tablet and clarithromycin 500 mg tablet by mouth every 12 hours for 2 weeks, regardless of 23S ribosomal RNA point mutation.
62769484|NCT03130452|EXPERIMENTAL|tailored treatment group I|23S ribosomal RNA point mutation negative, lansoprazole 30 mg, amoxicillin 1.0 g, and clarithromycin 500 mg were administered twice a day for 2 weeks.
62769485|NCT03130452|EXPERIMENTAL|tailored treatment group II|23S ribosomal RNA point mutation positive, lansoprazole 30 mg, amoxicillin 1.0 g and metronidazole 500 mg For 2 weeks.
62769486|NCT03105648||thyroid cancer|
62769487|NCT03105648||benign thyroid nodules|
62769488|NCT04191785|EXPERIMENTAL|plasmatic NGAL and MRI|
62769489|NCT02048410|ACTIVE_COMPARATOR|diet plus Lactobacillus paracasei B21060|low saturated fats diet plus the symbiotic (2.5×109cfu, bid)
62769490|NCT02048410|PLACEBO_COMPARATOR|low saturated fats diet|low saturated fats diet
61994510|NCT02838264|EXPERIMENTAL|Cohort 4|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive the highest safe dose (mg) of PF-06463922 as a single-dose Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
62168382|NCT03959930|EXPERIMENTAL|Interventional arm|Total and segmental body fluid volumes (total water, extracellular water and interstitial water) will be measured by Segmental Bioelectrical Impedance Spectroscopy (as per manufacturer instructions of use). Areas with most significant oedema and skin in a suitable condition shall be selected for the TFR application. Moisture Meter shall be used at the selected site to measure the skin water content at 4 depths (0.5mm, 1.5mm, 2.5mm and 5mm).
62389923|NCT04415749|EXPERIMENTAL|NasoShield Two Doses in Position 2|NasoShield on Day 1 and Day 29 in position 2 (Group 2)
62769491|NCT02191605|EXPERIMENTAL|electronic SBIRT (eSBIRT)|Participants in this condition will receive empathic exploration of their thoughts regarding marijuana use, provision of information on possible consequences of marijuana use during pregnancy and potential benefits of changing use (with permission), normed feedback, use of Motivational Interviewing techniques to elicit their own reasons for change, video testimonials modeling successful change, and information on change methods with optional goal setting.
62769492|NCT02191605|EXPERIMENTAL|Tailored texting|Participants in this condition will chose the frequency and time of text messages that will continue until childbirth or the participant opts out. The text messages will be a mix of marijuana targeted content (without directly referring to marijuana in a way that implies use by the participant) and general content related to healthy pregnancy; using appropriate humor and tips for community resources. Tailoring will focus on gestational age, self-efficacy, and social support.
62769493|NCT02191605|EXPERIMENTAL|eSBIRT & texting|Participants in this arm will receive both the computerized intervention and tailored text messaging intervention as described in the eSBIRT and Tailored texting arms.
62769494|NCT02191605|NO_INTERVENTION|Assessment only|Participants in the arm will participant in screening and the baseline assessment conducted on the computer only. They will not receive an intervention.
62769495|NCT02191605|NO_INTERVENTION|Screening only|Participants in this arm of the study will only answer the screening questions and will not be asked the baseline assessment or participate in an intervention.
62769496|NCT02599623|EXPERIMENTAL|Local anesthesia|Patient operated in local anesthesia, with a mesh repair in Lichtenstein if no bowel necrosis existed.
62769497|NCT02599623|ACTIVE_COMPARATOR|General anesthesia|Patient operated in general anesthesia, with a mesh repair in Lichtenstein if no bowel necrosis existed.
62769498|NCT02642965|EXPERIMENTAL|Treatment (CPX-351 and FLAG)|"COURSE 1: Patients receive cytarabine IT on day 0 and at day 28-30 or up to 7 days prior to day 1 of course 2, and liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5. Patients with CNS1 receive no further CNS-directed therapy in course 1. Patients with CNS2 disease may receive additional 4-6 doses of cytarabine IT twice weekly starting 48 hours after the third dose of liposome-encapsulated daunorubicin-cytarabine until CNS is clear at the discretion of the investigator. Patients meeting criteria for CR, CRp, and CRi may proceed to course 2.~COURSE 2: Patients receive filgrastim on days 1-5 and then on day 15 until blood count recovery, and fludarabine phosphate IV over 30 minutes and high-dose cytarabine IV over 1-3 hours QD on days 1-5."
62769499|NCT00185601|OTHER|on-line self management intervention|
62769500|NCT00185601|NO_INTERVENTION|usual care control group|
62769501|NCT00185601|EXPERIMENTAL|on-line self management intervention with email reinforcement|
62769502|NCT01325714|EXPERIMENTAL|Arm 1: PAVeD Intervention|In the experimental arm, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
62769503|NCT01325714|ACTIVE_COMPARATOR|Arm 2: Enhanced Usual Care|In the comparison arm, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.
62769504|NCT01407796|EXPERIMENTAL|Endotoxin and [18F](+/-)NOS|All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation. They will also be imaged before and after endotoxin instillation with the novel PET tracer F-18 (+/-) NOS
62769505|NCT05118802||Observational (interview, survey)|"Part I: Patients and clinicians attend semi-structured interviews over 20-30 minutes or cognitive interviews over 60 minutes in support of survey refinement.~Part II: Patients complete survey over 15 minutes."
62769506|NCT00547040||A|incident renal transplant patients
62769507|NCT02515201|ACTIVE_COMPARATOR|Taurolidine|Taurolidine be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Taurolidine infusion will be used TaurolockTM with ampoule presentation containing 3 ml.
61994511|NCT02271191|ACTIVE_COMPARATOR|Nicardipine and Remifentanil|intravenous nicardipine and remifentanil during deliberate hypotension
62389924|NCT04415749|PLACEBO_COMPARATOR|Placebo in Position 2|Saline placebo on Day 1 and Day 29 in position 2 (Group 2)
62769508|NCT02515201|ACTIVE_COMPARATOR|Heparin|Heparin be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Heparin infusion will be used with heparin solution contain 50 International Unit (UI)/ml.
62769509|NCT04445623|ACTIVE_COMPARATOR|prasugrel hydrochloride|film-coated tablets of prasugrel hydrochloride (10 mg daily dose after loading dose of 60 mg)
62769510|NCT04445623|PLACEBO_COMPARATOR|placebo|film-coated tablets of placebo (10 mg daily dose after loading dose of 60 mg)
62769511|NCT04798209|EXPERIMENTAL|Part A (single ascending dose) Dose A1|Single dose A1 of ACT-777991.
62769512|NCT04798209|EXPERIMENTAL|Part A (single ascending dose arm) Dose A2|Single dose A2 of ACT-777991.
62769513|NCT04798209|EXPERIMENTAL|Part A (single ascending dose arm) Dose A3|Single dose A3 of ACT-777991.
62769514|NCT04798209|EXPERIMENTAL|Part A (single ascending dose arm) Dose A4|Single dose A4 of ACT-777991 under fasted and fed conditions, separated by at least 14 days.
62769515|NCT04798209|EXPERIMENTAL|Part A (single ascending dose arm) Dose A5|Single dose A5 of ACT-777991.
62769516|NCT04798209|EXPERIMENTAL|Part A (single ascending dose arm) Dose A6|Single dose A6 of ACT-777991.
62769517|NCT04798209|EXPERIMENTAL|Part A (single ascending dose arm) Dose A7|Single dose A7 of ACT-777991.
62769518|NCT04798209|EXPERIMENTAL|Part A (single ascending dose arm) Dose A8|Single dose A8 of ACT-777991.
62769519|NCT04798209|EXPERIMENTAL|Part B (multiple ascending dose) Dose B1|Multiple doses B1 of ACT-777991.
62769520|NCT04798209|EXPERIMENTAL|Part B (multiple ascending dose) Dose B2|Multiple doses B2 of ACT-777991.
62769521|NCT04798209|EXPERIMENTAL|Part B (multiple ascending dose) Dose B3|Multiple doses B3 of ACT-777991.
61994512|NCT02271191|PLACEBO_COMPARATOR|Remifentanil|intravenous remifentanil during deliberate hypotension
62389925|NCT04415749|EXPERIMENTAL|NasoShield Two Doses in Position 3|NasoShield on Day 1 and Day 29 in position 3 (Group 3)
62389926|NCT04415749|PLACEBO_COMPARATOR|Placebo in Position 3|Saline placebo on Day 1 and Day 29 in position 3 (Group 3)
62561503|NCT04314037|EXPERIMENTAL|Sequence 2 (R1-T1-R2-T2)|Participants will receive first dose of Biltricide on Day 1 in treatment period 1 followed by first dose of Cesol on Day 8 in treatment period 2 followed by second dose of Biltricide on Day 15 in treatment period 3 followed by second dose of Cesol on Day 22 in treatment period 4. A washout period of 7 days will be maintained between 4 treatment periods.
62561504|NCT03981107|EXPERIMENTAL|Chest Compression Only CPR (CO-CPR)|Instructions from a dispatcher at the dispatch center to trained bystanders to perform CO-CPR with chest compressions only.
62561505|NCT03981107|ACTIVE_COMPARATOR|Standard CPR (S-CPR)|Instructions from a dispatcher at the dispatch center to trained bystanders to perform S-CPR with chest compressions and rescue breaths in a 30:2 ratio.
62561506|NCT04688437||Patients with degenerative scoliosis|
62561507|NCT04904211|EXPERIMENTAL|Feasiblity and Safety|All eligible patients will be assigned to this arm
62561508|NCT00380874|EXPERIMENTAL|1|flexible dosing
62561509|NCT00380874|PLACEBO_COMPARATOR|2|
62561510|NCT00682786|EXPERIMENTAL|Good Risk (Thymidylate Synthase (TYMS)*2/*2, *2/*3, *2/*4)|"Radiation 45 Gy in 25 fractions to the pelvis.~5FU CIVI 225 mg/m2/day by CIVI during radiation~Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable."
62561511|NCT00682786|EXPERIMENTAL|Poor Risk (Thymidylate Synthase (TYMS)*3/*3, *3/*4)|"Radiation 45 Gy in 25 fractions to the pelvis.~5FU CIVI 225 mg/m2/day by CIVI during radiation~Irinotecan 50 mg/m2 IV weekly for 5 doses.~Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable."
62561512|NCT05669950|EXPERIMENTAL|Lu AG13909|Participants in Part A will receive multiple intravenous (IV) doses of Lu AG13909 per a prespecified dosing schedule. After data from Part A has shown that a pharmacologically relevant dose level is safe and tolerable, participants in Part B will then receive multiple IV doses of Lu AG13909 per a prespecified dosing schedule.
62561513|NCT03630497|EXPERIMENTAL|Period 1 Single Dose SD1 (first dose)|"Period 1 Group SD1 a single IV infusion of first single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
62561514|NCT03630497|EXPERIMENTAL|Period 1 Single Dose SD2 (second dose)|"Period 1 Group SD2 a single IV infusion of second single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
62561515|NCT03630497|EXPERIMENTAL|Period 1 Single Dose SD3 (third dose)|"Period 1 Group SD3 a single IV infusion of third single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
62561516|NCT03630497|EXPERIMENTAL|Period 1 Single Dose SD4 (fourth dose)|"Period 1 Group SD4 a single IV infusion of fourth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
62561517|NCT03630497|EXPERIMENTAL|Period 2 Single Dose SD1 (fifth dose)|"Period 2 Group SD1 a single IV infusion of fifth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
62168383|NCT03623399|NO_INTERVENTION|15 mmhg-15mmhg|Abdominal entrance pressure will be set to 15 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 15 mmhg.
62168384|NCT03623399|OTHER|15 mmhg-12 mmhg|"Abdominal entrance pressure will be set to 15 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 12 mmhg.~Low gas pressure laparoscopy"
62561518|NCT03630497|EXPERIMENTAL|Period 2 Single Dose SD2 (sixth dose)|"Period 2 Group SD2 a single IV infusion of sixth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
62561519|NCT03630497|EXPERIMENTAL|Period 2 Single Dose SD3 (seventh dose)|"Period 2 Group SD3 a single IV infusion of seventh single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
62561520|NCT03630497|EXPERIMENTAL|Period 2 Single Dose SD4 (Optional)|"(Optional) Period 2 Group SD4 a single IV infusion of eighth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
62561521|NCT03630497|EXPERIMENTAL|Multiple Dose MD1|"MD1 once daily IV infusions of first multiple dose BN201 (n=6) or placebo (n=2) for 5 consecutive days~Comparison of BN201 treatment with Placebo"
62561522|NCT03630497|EXPERIMENTAL|Multiple Dose MD2|"MD2 once daily IV infusions of second multiple dose BN201 (n=6) or placebo (n=2) for 5 consecutive days~Comparison of BN201 treatment with Placebo"
62561523|NCT02265094|EXPERIMENTAL|Patients|Electroencephalography and neuropsychological tests in children with autism
62561524|NCT02265094|EXPERIMENTAL|Control|Electroencephalography and neuropsychological tests in children without autism
62561525|NCT02329028||Prehospital mini-EEG|Feasibility of prehospital EEG device in unconscious patients.
61994513|NCT06182644|EXPERIMENTAL|Positron-labeled FAPI PET/CT|Imaging was performed 60 minutes after injection of 5mci Positron-labeled FAPI tracer
62168385|NCT03623399|OTHER|12 mmhg-12 mmhg|"Abdominal entrance pressure will be set to 12 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 12 mmhg.~Low gas pressure laparoscopy"
62168386|NCT01949649|ACTIVE_COMPARATOR|Peer-Led Group Intervention|In the Peer-Led Group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique the thin-ideal ideal during 4 1-hr sessions and in homework activities which are led by peer leaders.
62168387|NCT01949649|ACTIVE_COMPARATOR|Clinician-Led Group Intervention|In the Clinician-Led Group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique the thin-ideal ideal during 4 1-hr sessions and in homework activities which are led by University clinicians.
62389927|NCT05500742|ACTIVE_COMPARATOR|Coenzyme Q10 + Selenium|Coenzyme Q10 100 mg bid + Selenium 100 mcg with the evening meal
62389928|NCT05500742|ACTIVE_COMPARATOR|Resveratrol + TA-65|Resveratrol 350 mg bid + TA-65 MD 100 U with the evening meal
62561526|NCT01185327||Study|Infants to Israeli Ethiopian-origin Mothers
62561527|NCT01185327||Control|Infants to Israeli non-Ethiopian-origin mothers
62561528|NCT02352571|EXPERIMENTAL|Single group assignment|GC1118 recombinant human anti-EGFR antibody
62561529|NCT00116779|EXPERIMENTAL|Degarelix 60mg|Initial dose of 200 milligrams (40 milligrams per milliliter) of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams (20 milligrams per milliliter) of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.
62561530|NCT00116779|EXPERIMENTAL|Degarelix 80mg|Initial dose of 200 milligrams (40 milligrams per milliliter) of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams (20 milligrams per milliliter) of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.
62561531|NCT05266053|EXPERIMENTAL|Treatment Group|This group will have a PICO negative pressure wound treatment device applied to their surgical wound site.
62561532|NCT05266053|OTHER|Control Group|Standard Intervention. This group will have a standard wound dressing (gauze, bandage) applied to their surgical wound site.
62561533|NCT03539302|EXPERIMENTAL|Repeat dose inhaled flecainide acetate|"One 120 mg dose of flecainide acetate inhalation solution will be administered via two oral inhalations of 3.5 minutes. There will be a 1 minute break between the two inhalations. A single nebulizer will be used.~A subset of enrolled patients will be included in a sub-study in which a Hand Held ECHO device at bedside will be used to confirm eligibility by verifying absence of structural heart disease. Once eligibility is confirmed the treatment for this subset of patients will be the same as described above; one 120 mg dose of flecainide acetate inhalation solution will be administered via two oral inhalations of 3.5 minutes. There will be a 1 minute break between the two inhalations. A single nebulizer will be used."
62561534|NCT03839628|EXPERIMENTAL|Reduced Physical Activity|Participants will reduce their physical activity levels for 2-weeks by approximately 75% of their baseline level of physical activity
62389929|NCT05500742|PLACEBO_COMPARATOR|Placebo|Placebo-1 bid + Placebo-2 with the evening meal
62389930|NCT05033106|ACTIVE_COMPARATOR|Eyes with IVI bevacizumab|0.625 mg/0.025 mL bevacizumab is injected into the vitreous cavity of the left eye
62561535|NCT03376893||SCA with overt stroke|Participants have sickle cell disease and a history of overt stroke.
62561536|NCT03376893||SCA with silent stroke|Participants have sickle cell disease and a history of silent stroke.
62561537|NCT03376893||SCA with no stroke|Participants have sickle cell disease and no history of stroke.
62561538|NCT06320340|ACTIVE_COMPARATOR|Group I|
62561539|NCT06320340|EXPERIMENTAL|Group II|
62561540|NCT04700241|ACTIVE_COMPARATOR|Potassium nitrate|During this experimental day, men will receive 10 mmol of potassium nitrate
62561541|NCT04700241|PLACEBO_COMPARATOR|Placebo|During this experimental day, men will receive an isomolar dose of potassium chloride
62389931|NCT05033106|ACTIVE_COMPARATOR|Eyes with IVI ranibizumab|A dose of 0.25 mg/0.025 mL ranibizumab (Lucentis) is injected in the right eye of the infant
62389932|NCT03181139||pre-ERAS|Patients cared for prior to the implementation of the Enhanced Recovery after surgery for total mastectomy pathway
62389933|NCT03181139||post-ERAS|patients cared for after the implementation of the Enhanced Recovery after surgery for total mastectomy pathway. Pathway included preoperative acetaminophen and gabapentin, Pec blocks, multimodal analgesia postoperatively and aggressive PONV treatment.
62561542|NCT03466450|EXPERIMENTAL|Glasdegib and Temozolomide Oral Capsule|"During Phase Ib, Four to six weeks after surgical diagnosis, concurrent with radiotherapy (STUPP) + temozolomide (75mg/m2/day for 42 days) + PF-04449913 (Glasdegib) (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered.~During Phase II, Radiation therapy, temozolomide and glasdegib will be administered. This last, as the dose that have been selected previously, based on the Phase Ib results. Glasdegib ( PF-04449913) recommended dose until progresion of disease, unacceptable toxicity, non-compliance, consent withdrawal up to 2 years."
62561543|NCT05125471|EXPERIMENTAL|Investigational Drug|Cobimetinib will be administered at a maximal dose of 60 mg daily for 21 days on, then 7 days off, in a 28-Day treatment cycle for 12 cycles (approximately 12 months). Cobimetinib should be taken once daily at approximately the same time each day, and no later than 4 hours after the scheduled time. Cobimetinib can be taken with or without a meal. Cobimetinib tablets should never be chewed, cut, or crushed. Therapy may continue for up to 12 cycles provided the subject meets the criteria for starting subsequent cycles and does not meet any of the criteria for cobimetinib discontinuation. At least 7 days off cobimetinib (within +7 days) is required prior to starting a new treatment cycle.
62561544|NCT05417841|EXPERIMENTAL|IDegAsp group|IDegAsp twice daily
62561545|NCT05417841|ACTIVE_COMPARATOR|IDegAsp + IAsp group|IDegAsp once daily plus IAsp twice daily
62561546|NCT05179889|EXPERIMENTAL|Arm A|mFOLFIRINOX
62561547|NCT05179889|ACTIVE_COMPARATOR|Arm B|mFOLFOX 6
62769522|NCT04798209|EXPERIMENTAL|Part B (multiple ascending dose) Dose B4|Multiple doses B4 of ACT-777991.
62769523|NCT04798209|EXPERIMENTAL|Part B (multiple ascending dose) Dose B5|Multiple doses B5 of ACT-777991.
62389934|NCT03578211|EXPERIMENTAL|DAs group|Shared decision making using decision aids
62389935|NCT03578211|NO_INTERVENTION|Control group|Standard oral explanation guided with booklets
62561548|NCT02200055|EXPERIMENTAL|Bioimpedance Assessment|"The only group will be those patients having major intra-abdominal surgical procedures.~Each patient involved in the study will be evaluated with a bioimpedance monitor ('Bodystat Quadscan 4000') to assess total body water, estimated body water, and intravascular body water volume preoperatively, postoperatively, and daily during the postoperative recovery period.~Bioimpedance Assessment"
62561549|NCT00422916|EXPERIMENTAL|intervention arm|Lifestyle Intervention based on Nutrition Treatment, exercise Treatment and behavorial treatment
62561550|NCT00422916|NO_INTERVENTION|waiting list|waiting 6 months for Intervention without any intervention
62561551|NCT05442229||Normally developing child|Normal development is defined as children without intellectual development disorders, developmental speech or language disorders, ASD (autism spectrum disorder), and ADHD (attention deficit hyperactivity disorder).
62561552|NCT05442229||Abnormally developed child|Abnormal development is defined as that hospital visits of children were professionally assessed for MR (mental retardation), ASD (autism spectrum disorder), and ADHD (attention deficit hyperactivity disorder). Diagnostic criteria were all referred to Diagnostic and Statistical Manual of Mental Disorders，DSM-5.
62561553|NCT05628610|EXPERIMENTAL|Tislelizumab combined with radiotherapy|
62561554|NCT05628610|EXPERIMENTAL|Tislelizumab combined with chemotherapy|
62561555|NCT02246400|ACTIVE_COMPARATOR|Delayed Intervention|Usual care for first three months. Initiation of the eCMP after the 3-month time point.
62561556|NCT02246400|EXPERIMENTAL|Immediate Intervention|Initiation of the eCMP immediately upon completion of baseline data collection and randomization
62561557|NCT04648267|ACTIVE_COMPARATOR|Control group|Patients who have the cast and bolster on for standard 5 days after their radial forearm free flap and 7 days after their fibula free falp
62561558|NCT04648267|EXPERIMENTAL|Experimental group|Patients who have the cast and bolster on for 10-14 days
62561559|NCT06377124|EXPERIMENTAL|The 3S intervention group|Receive information and support on self-management of lung cancer
62561560|NCT06377124|PLACEBO_COMPARATOR|The GH information group|Receive general health information such as sleep hygiene, environmental hygiene, etc.
62561561|NCT02492828||Patients for filled prescriptions for apixaban|
62561562|NCT02492828||Patients for filled prescriptions for warfarin|
62561563|NCT01992172|ACTIVE_COMPARATOR|Photocil for Atopic Dermatitis|Active Drug - Photocil for Atopic Dermatitis
62561564|NCT01992172|PLACEBO_COMPARATOR|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
62561565|NCT00287586|ACTIVE_COMPARATOR|Testosterone|Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
62561566|NCT00287586|PLACEBO_COMPARATOR|Placebo|Participants received placebo-matching testosterone gel daily for 3 years.
62561567|NCT02242253|EXPERIMENTAL|Tiotropium+salmeterol QD|free combination of tiotropium and salmeterol
62561568|NCT02242253|ACTIVE_COMPARATOR|Tiotropium+salmeterol BID|free combination of tiotropium and salmeterol
62561569|NCT02242253|ACTIVE_COMPARATOR|Tiotropium QD|
61994514|NCT00116558|EXPERIMENTAL|Early NIPPV Intervention|Participants with \>80% predicted forced vital capacity (FVC).
62561570|NCT02242253|ACTIVE_COMPARATOR|Salmeterol BID|
62561571|NCT05699343|EXPERIMENTAL|Bone grafting with collagen membrane|This arm will receive surgical intervention involving placement of a bone xenograft subsitute (InterOss Collagen) into the peri-implant bone defect with a collagen membrane (InterCollagen Guide) placed over the bone graft.
62561572|NCT05699343|ACTIVE_COMPARATOR|Bone grafting without collagen membrane|This arm will receive surgical intervention involving placement of a bone xenograft subsitute (InterOss Collagen) into the peri-implant bone defect with no collagen membrane placed over the graft.
62561573|NCT04636788|OTHER|pancreatic cancer group|"pancreatic cancer, anticipated participants: 68~other pancreatic lesions including MCN, SCN, IPMN, SPN without malignant pathological finding chronic pancreatitis cholangiocarcinoma healthy control anticipated participants: 34"
62561574|NCT06381206|EXPERIMENTAL|case group|patients who had given silodosin
62561575|NCT06381206|NO_INTERVENTION|Control group|patients who had not given silodosin
62561576|NCT01357837|PLACEBO_COMPARATOR|Matching Placebo|Once daily oral administration of matching placebo for 4 weeks.
62561577|NCT01357837|EXPERIMENTAL|75 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
62561578|NCT01357837|EXPERIMENTAL|200 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
62561579|NCT01357837|EXPERIMENTAL|400 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
62561580|NCT02382042|ACTIVE_COMPARATOR|Intensive Referral Intervention|
62561581|NCT02382042|NO_INTERVENTION|Standard Care|
62561582|NCT05807490|EXPERIMENTAL|PF-07328948 and Placebo (Cohort 1)|Dose level 1: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
62561583|NCT05807490|EXPERIMENTAL|PF-07328948 and Placebo (Cohort 2)|Dose level 2: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
61994515|NCT00116558|ACTIVE_COMPARATOR|Standard of Care NIPPV|Participants with 50-74% predicted forced vital capacity (FVC).
62561584|NCT05807490|EXPERIMENTAL|PF-07328948 and Placebo (Cohort 3)|Dose level 3: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
62561585|NCT05807490|EXPERIMENTAL|PF-07328948 and Placebo (Cohort 4)|Dose level 4: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
62561586|NCT05807490|EXPERIMENTAL|PF-07328948 and Placebo (Cohort 5)|Dose level 5: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
62769524|NCT04798209|EXPERIMENTAL|Part A (single ascending dose) Absolute Bioavailability|Single dose of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from A4 to A8.
61994516|NCT00116558|ACTIVE_COMPARATOR|Standard of Care NIPPV and Nutritional Monitoring|Participants with 50-95% forced vital capacity (FVC), and normal or impaired amyotrophic lateral sclerosis functional rating scale (ALSFRS) scores. Participants in this group will receive standard of care NIPPV therapy but will also undergo detailed analysis of nutritional status.
61994517|NCT04264468||response group and the non-response group|Received neoadjuvant chemotherapy according to the routine clinical diagnosis and treatment, and evaluated the clinical efficacy once every two cycles of chemotherapy. According to the clinical efficacy, the patients were divided into the neoadjuvant chemotherapy response group and the non-response group (evaluation standard RECIST1.1).
61994518|NCT02614911||Sick patients|Biological sampling of blood for all patients. Biological sampling of saliva, biopsies (skin and endoscopic), feces, for some patients
61994519|NCT02614911||Healthy relatives|Biological sampling of blood for all healthy relatives
61994520|NCT01554618|EXPERIMENTAL|EQW|Exenatide once weekly
61994521|NCT01554618|PLACEBO_COMPARATOR|Placebo|Placebo once weekly
61994522|NCT05016388|EXPERIMENTAL|Collaborative Multidimensional Model (CMD)|The teams in the CMD group will be composed each of at least a MD, a psychologist, and a social worker. The teams will receive the CMD training and the CMD will be installed in the primary health care (PHC) center. Then, the participants with depression who enter treatment for depression in their respective PHC center, will be enrolled and evaluated by an external team, blind to the interventions at the beginning, three and six months after.
61994523|NCT05016388|OTHER|Standard Model (SM)|The teams in the SM group will be composed each of at least a MD, a psychologist, and a social worker. The teams will receive the SM training and the SM will be set in the primary health care (PHC) center. Then, the participants with depression who enter treatment for depression in their respective PHC center, will be enrolled and evaluated by an external team, blind to the interventions at the beginning, three and six months after.
61994524|NCT02206412||HMGB1 group|
61994525|NCT01687491|ACTIVE_COMPARATOR|Enoxa|ENOXA® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours
61994526|NCT01687491|ACTIVE_COMPARATOR|Lovenox|LOVENOX® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours
62168388|NCT01949649|ACTIVE_COMPARATOR|Internet-Based Intervention|The Internet-Based Intervention consists of 6 40-min modules involving user-driven self-education activities and games (e.g., role-plays), writing/video contests, and off-line exercises designed to induce dissonance regarding pursuit of the thin-ideal, mirroring activities from the group Body Project.
62561587|NCT05807490|EXPERIMENTAL|PF-07328948 and Placebo (Cohort 10)|Optional cohort - Multiple dose administration of PF-07328948 and placebo over 14 days in healthy Japanese participants; 5 participants will receive PF-07328948 and 1 will receive placebo
61994527|NCT06155591|NO_INTERVENTION|Control Group|Usual care of complex and pluripathological chronic patients (CPCP)
61994528|NCT06155591|EXPERIMENTAL|Experimental Group|Usual care of CPCP + Community Nurse Case Manager (CNCM) standardized protocol
62561588|NCT05807490|EXPERIMENTAL|PF-07328948 and Placebo (Cohort 7)|Dose level 7: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
62769525|NCT04798209|EXPERIMENTAL|Part B (multiple ascending dose) ADME|Multiple doses of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from B1 to B5.
62769526|NCT03869333|EXPERIMENTAL|Invaplex[AR-Detox] 2.5 μg|Participants received an intramuscular injection of 2.5 μg Invaplex\[AR-DETOX\] vaccine on Days 1, 22, and 43.
62769527|NCT03869333|EXPERIMENTAL|Invaplex[AR-Detox] 10 μg|Participants received an intramuscular injection of 10 μg Invaplex\[AR-DETOX\] vaccine on Days 1, 22, and 43.
62561589|NCT05807490|EXPERIMENTAL|PF-07328948 and Placebo (Cohort 8)|Optional cohort - Dose level TBD. Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
62561590|NCT05807490|EXPERIMENTAL|PF-07328948 oral tablet and oral suspension (Cohort 11)|Assessment of relative bioavailability PF-07328948 oral tablet compared to PF-07328948 oral suspension under fed and fasted condition; 12 participants will be enrolled, and 6 participants randomized to 1 of 2 sequences
62561591|NCT05807490|EXPERIMENTAL|PF-07328948 and Placebo (Cohort 6)|Dose level 6: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
62561592|NCT05807490|EXPERIMENTAL|PF-07328948 and Placebo (Cohort 9)|Optional cohort - Dose level TBD. Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
62561593|NCT00665405||PN|Control - Induced or natural labor under anesthesia
62561594|NCT00665405||PC|Case - Cesarean section under anesthesia
62561595|NCT03694080|EXPERIMENTAL|Calcium Electroporation treatment|Calcium electroporation for colorectal cancer as a preoperative treatment before elective surgery.
62561596|NCT00017810|EXPERIMENTAL|Condition 1: Dietary Intervention|Patients will receive behavioral dietary intervention using normal foods.
62561597|NCT00017810|ACTIVE_COMPARATOR|Condition 2 (Control): HIV Self-Care|Patients will receive HIV self-care information, and be given the dietary intervention at the completion of the last study session (post study).
62561598|NCT01676207||1|CAD
62561599|NCT01676207||2|no CAD
62561600|NCT05116501|EXPERIMENTAL|low VWF|In patients with low VWF levels, whole-exome sequencing will be performed to identity possible variants in the VWF gene or other genes that are associated with reduced VWF plasma levels. Furthermore, a correlation study between variants identified and the bleeding symptoms of patients will be performed.
62561601|NCT05116501|OTHER|Healthy controls|In healthy controls, the investigators will analyze the whole-exome sequencing to include the variants that are either not present in healthy controls or are present but with a significantly lower frequency than the patients.
62561602|NCT05374655|EXPERIMENTAL|Preoperative blood glucose control|Under the guidance of endocrinologists, the patient's hypoglycemic strategy is formulated, follow-up guidance is guided by the patient to take the drug, the HbA1c level is reviewed after 6 weeks, the preoperative HbA1c \< 7.5% is performed surgically, and if it is still above the standard, the hypoglycemic therapy is continued, during which the patient is administered according to the corresponding heart disease type.
62561603|NCT05374655|NO_INTERVENTION|Preoperative blood glucose uncontrol|Patients included in this group ≥ 7.5% preoperative HbA1c and underwent surgery directly
62561604|NCT05674032||Cases|In-patients with AP or cUTI admitted for treatment to the hospital.
62561605|NCT05674032||Control group 1|Out-patients seeking treatment for uncomplicated acute cystitis.
62561606|NCT05674032||Control group 2|In-patients admitted to the ward without signs and symptoms of a urinary tract infection and with a negative urine culture result.
62561607|NCT05392842|PLACEBO_COMPARATOR|Placebo group|plain mucoadhesive fast dissolving film
62561608|NCT05392842|EXPERIMENTAL|Treated group|Corchorus Olitorius Buccal Films
62561609|NCT05961696|EXPERIMENTAL|Mosunetuzumab|Participants will be assigned to a dose level of mosunetuzumab based on when the participants join this study. Up to 2 dose levels of mosunetuzumab will be tested. The first group of participants will receive the lowest dose level. A second group will receive a higher dose than the group before it, if no intolerable side effects were seen.
62769528|NCT03869333|EXPERIMENTAL|Invaplex[AR-Detox] 25 μg|Participants received an intramuscular injection of 25 μg Invaplex\[AR-DETOX\] vaccine on Days 1, 22, and 43.
62769529|NCT03869333|PLACEBO_COMPARATOR|Placebo|Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.
62769530|NCT02421926||IDEAL-E observational group|Subjects who were newly diagnosed as chronic phase chronic myelogenous leukemia, were enrolled to 'IDEAL' study, finished the total study period of 'IDEAL' study or were dropped during the study period.
62561610|NCT04263311|EXPERIMENTAL|Community Health Workers (CHW) treatment group|Once recruited and consented, surveys will be administered and collected at baseline and 6 months in person or by a study coordinator within two weeks of completion of the CHW coaching component of the intervention. Participants enrolled in the intervention will receive monthly text and phone call reminders. in addition, multiple sessions will be hosted at varying times/days of the week to accommodate schedules of both working individuals and at-home caretakers. Finally, small incentives will be provided at each session to encourage ongoing attendance, and a cash raffle prize will be distributed at program completion for individuals who attend all five sessions.
62561611|NCT04263311|NO_INTERVENTION|Control group|Control participants will be offered the health education sessions as a point of service and not for research purposes
62561612|NCT00993538|EXPERIMENTAL|1|
62769531|NCT02428413|ACTIVE_COMPARATOR|Standard oxygen mask|Standard face mask to provide supplemental oxygen
62561613|NCT00856882|EXPERIMENTAL|soy protein and isoflavones|
62561614|NCT00856882|EXPERIMENTAL|milk protein and isoflavones|
62561615|NCT00856882|PLACEBO_COMPARATOR|milk protein only|
62769532|NCT02428413|ACTIVE_COMPARATOR|ISO-Gard Mask|Face mask to scavenge waste anesthetic gases from patient during recovery from general anesthesia and to provide supplemental oxygen.
62769533|NCT00478309|NO_INTERVENTION|Arm I|Participants receive standard primary care.
62769534|NCT00478309|EXPERIMENTAL|Arm II|Participants receive standard primary care followed by the Genetic Epidemiology and Risk Assessment (GERA) intervention. Participants also participate in a discussion session regarding the GERA including the rationale behind methylenetetrahydrofolate reductase mutation detection and folate assessment and its relationship to colorectal cancer risk.
62769535|NCT00444977|EXPERIMENTAL|Case-management linkage intervention|"The intervention represents a brief, real world intervention that could easily be adopted by HIV care clinics to facilitate linkage and increase use of oral services by their HIV+ patients (if shown to be effective). We are seeking to compare this intervention to usual practice in these clinics."
62769536|NCT00444977|NO_INTERVENTION|Standard of Care|Subjects will receive standard of care services.
62561616|NCT05895448|EXPERIMENTAL|PWID (people who inject drugs)|velpatasvir (100 mg) and sofosbuvir (400 mg) once daily for 12 weeks (brand or branded generic) in subjects who had used intravenous drugs at least once in preceding six months.
61994529|NCT03246113|EXPERIMENTAL|Cannabis + Chemoradiation|Patients will receive a cannabis strain with high cannabidiol (4.8%) and low Delta-9-THC (3.23%). Patients will smoke the cannabis over a 2 hour session (from 0.5 - 2.0 cannabis cigarettes) before receiving chemoradiation therapy with radiation and concurrent temozolomide.
62561617|NCT05895448|ACTIVE_COMPARATOR|Non-PWID|velpatasvir (100 mg) and sofosbuvir (400 mg) once daily for 12 weeks (brand or branded generic) in subjects who had NOT used intravenous drugs at least once in preceding six months, but were treated concurrently in the same hepatology referral clinics.
62561618|NCT01370629||All participants|Participants treated with vernakalant IV in acute care and inpatient hospital settings
62561619|NCT00663793|EXPERIMENTAL|Oral testosterone|"(Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by immediate release T 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
62561620|NCT00663793|EXPERIMENTAL|Finasteride plus Oral Testosterone|"(Day -2 to Day 12) 1 mg Finasteride PO once daily for 14 days total. (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by immediate release T 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
62561621|NCT01422213|PLACEBO_COMPARATOR|Placebo|
62561622|NCT01422213|EXPERIMENTAL|Vortioxetine 10 mg|
62561623|NCT01422213|EXPERIMENTAL|Vortioxetine 20 mg|
62561624|NCT03919656|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10 mg daily (orally)
62561625|NCT03919656|PLACEBO_COMPARATOR|Placebo|Matching placebo for dapagliflozin daily (orally). Does not contain active ingredient
62769537|NCT03730545|EXPERIMENTAL|EIN group|Enteral formula including not only basic energy components, but also immune components such as omega-3 fatty acids, glutamine (Gln), arginine (Arg), and nucleotide.
62769538|NCT03730545|ACTIVE_COMPARATOR|SEN group|Enteral formula including only basic energy components.
62769539|NCT01480011|EXPERIMENTAL|lactobacillus lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
62769540|NCT04773990|OTHER|Experimental Group|Group (A) twenty-five patients will receive biodex balance training
62769541|NCT04773990|OTHER|Controlled Group|twenty-five patients will receive a physical therapy exercise protocol
62769542|NCT03522831|ACTIVE_COMPARATOR|Salbutamol meter-dose inhaler|Inhalation of 400 μg salbutamol
62769543|NCT03522831|PLACEBO_COMPARATOR|Placebo meter-dose inhaler|Inhalation of 400 μg placebo
62561626|NCT04010851|EXPERIMENTAL|Peer co-led educational group|The intervention delivered in a group format is added to treatment as usual. After the parents participate in the one day-intervention, they can continue in self-help groups, which meet once a week for a 2-hour evening session. User representatives lead these weekly self-help groups, which do not require user-fees and aim to offer practical tools, support and information to increase the parent's skills, knowledge and confidence.
62561627|NCT04010851|OTHER|Control group|The control goup will receive treatment as usual.
62168389|NCT01949649|ACTIVE_COMPARATOR|Education Video|The Education Video describes eating disorders, their adverse effects, and the need for treatment, which is key information to provide to young women at elevated risk for eating disorders due to body dissatisfaction.
62168390|NCT02066961||Cohort 1|Subjects with biochemical failure experience after primary treatment and have high-risk disease
62168391|NCT02066961||Cohort 2|Subjects with a medical diagnosis of castration-resistant prostate cancer
62168392|NCT02066961||Cohort 3|Subjects with an initial diagnosis of metastatic prostate cancer
62168393|NCT01107249|OTHER|BS Ultraflex or Wallstent stents|All subjects receive a stent of surgeons choice from selected stents.
62168394|NCT03433378|ACTIVE_COMPARATOR|Tretinoin cream, 0.05%|Apply once a day application, under at-home use conditions.
62168395|NCT03433378|ACTIVE_COMPARATOR|RETIN-A® (tretinoin) cream, 0.05%|Apply once a day application, under at-home use conditions.
62168396|NCT03433378|PLACEBO_COMPARATOR|Vehicle of the test product|Apply once a day application, under at-home use conditions.
62389936|NCT02174406||women scheduled for breast screening|"Each patient will have the following:~* Screening whole breast ultrasound~* DBT (Full field digital mammography + tomosynthesis views in the CC and MLO projections). The only change in patient management will be the addition of digital breast tomosynthesis views in patients scheduled for FFDM alone. DBT is currently clinically approved and being offered on a voluntary basis to patients scheduled for FFDM."
62389937|NCT05512039|ACTIVE_COMPARATOR|Botox: Standard dose|The standard dose of 100 units of botox will be injected into the bladder.
62389938|NCT05512039|EXPERIMENTAL|Botox: Low dose|A lower dose of 50 units of botox will be injected into the bladder.
62389939|NCT05246735|OTHER|MR-guided NIR|"Women with breast abnormalities will undergo an optical exam (NIR) in combination with MRI where the NIR light imaging system illuminates the breast from multiple positions covering the area of interest.~A total of 60 women will be evaluated: 20 with breast abnormalities receiving gadolinium (Gd) contrast enhancement, 20 with breast abnormalities receiving both Gd-contrast enhancement and indocyanine green (ICG) contrast enhancement, and 20 healthy volunteers not receiving any contrast agents."
62389940|NCT03191604||Endoscopists familiar with EET|Physicians familiar with conducting endoscopic eradication therapy.
62389941|NCT02365246|EXPERIMENTAL|immunoadsorption group|All patients will be treated with 10 immunoadsorptions with an IgE-specific adsorption column :
62389942|NCT04274972||Pancreaticoduodenectomy patients|All patients, affected by a resectable PDAC of the head of the pancreas, visited at the Department of Pancreatic Surgery of Verona, will be enrolled. All the patients must be scheduled for an elective PD. The oral and rectal microbiome samples will be collected preoperatively. The PDAC tissue from the surgical specimen, the intestinal mucosal tissue from the enteric side of the pancreatic anastomosis, and the bile sample will be collected intraoperatively. On the 30th postoperative day, the oral and rectal samples will be repeated.
62389943|NCT03942991|ACTIVE_COMPARATOR|2% Mepecaine-L|infiltration injection of 2% Mepivacaine
62389944|NCT03942991|EXPERIMENTAL|4% Artpharmadent|infiltration injection of 4% Articaine
62389945|NCT05302999|EXPERIMENTAL|Low dose|600mg treatment group will receive 2 capsules of gabapentin by mouth 3 times per day for 90 days.
62389946|NCT05302999|EXPERIMENTAL|Medium dose|1800 mg treatment groups will receive 2 capsules of gabapentin by mouth 3 times per day for 90 days.
62389947|NCT05302999|PLACEBO_COMPARATOR|Control|The control group will receive 2 placebo capsules of inert cellulose by mouth 3 times per day for 90 days.
62561628|NCT01595880|EXPERIMENTAL|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg
62561629|NCT01595880|EXPERIMENTAL|C|Combination of gemigliptin50mg/metformin HCl extended release 500mg
62561630|NCT02769507|EXPERIMENTAL|real tDCS|DC Stimulator PLUS (NeuroConn) The real tDCS condition comprises two daily sessions of 20 min tDCS, separated by a minimum break of 3h, for five consecutive days. Anodal and cathodal tDCS will be applied with 2mA to the left dorsolateral prefrontal cortex (a point midway between F3 and FP1) and the left peri-Sylvian region (a point midway between T3 and P3), respectively. Electrode size is 7cm x 5cm.
62561631|NCT02769507|SHAM_COMPARATOR|sham tDCS|"DC Stimulator PLUS (NeuroConn) The sham condition is identical to the real tDCS condition except that after 40s of tDCS stimulation is going to be reduced to a small pulse every 550msec (110 μA over 15 msec) through the remainder of the 20 minute period."
62561632|NCT02620995|EXPERIMENTAL|hypertensive patients|Hypertensive patients will receive a single oral dose of sildenafil citrate (100 mg) - acute protocol - and a chronic 30-day treatment with sildenafil citrate (50 mg twice daily) - chronic protocol. Penile and systemic microvascular function will be evaluated before and one hour after acute sildenafil administration and in the end of each treatment period.
62168397|NCT00840918|ACTIVE_COMPARATOR|1|Intravenous Lidocaine group
62168398|NCT00840918|PLACEBO_COMPARATOR|Placebo|Intravenous placebo Group - Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
62168399|NCT00443599|EXPERIMENTAL|Insulin|Insulin was infused to target a blood glucose concentration of 80-110 mg/dL
62168400|NCT00443599|ACTIVE_COMPARATOR|Usual Care|Insulin was infused according to the discretion of the treating clinical team.
62168401|NCT04694300|EXPERIMENTAL|Naproxen sodium|Naproxen sodium 440 mg followed by naproxen sodium 220 mg q 8h (max 660 mg/day)
62168402|NCT04694300|ACTIVE_COMPARATOR|Acetaminophen|Acetaminophen 1000 mg followed by acetaminophen 1000 mg q 6h (max 3000 mg/day according to Tylenol package insert)
62168403|NCT04293341|EXPERIMENTAL|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
62561633|NCT02620995|SHAM_COMPARATOR|comparator group|Normotensive individuals age-matched to the hypertensive patients will receive only a single dose of sildenafil citrate (100 mg) - acute protocol. Penile and systemic microvascular function will be evaluated before and one hour after sildenafil administration.
61994530|NCT05179421|EXPERIMENTAL|First infusion day low dose oxytocin, Second infusion day high dose oxytocin|On the first oxytocin study day, participants will receive a 10 minute IV infusion of saline then one hour later will receive a 10 minute infusion of oxytocin 1.3 micrograms. On the second study day they will receive a 10 minute IV infusion of oxytocin 0.3 micrograms then one hour later will receive a 10 minute infusion of oxytocin 7 micrograms.
62561634|NCT03678246|EXPERIMENTAL|LSFOI (Ramped)|LSFOI (Ramped)
62561635|NCT03678246|ACTIVE_COMPARATOR|LSFOI (Supine)|LSFOI (Supine)
62389948|NCT03656315|OTHER|Airway assessment|All patients recruited will be entered into this arm of the study. Airway assessment including Ultrasound scan will be performed
62389949|NCT05994105|NO_INTERVENTION|Control Group|individuals who will not receive the management plan
62389950|NCT05994105|EXPERIMENTAL|Experimental Group|Individuals who will receive therapy
62389951|NCT02600195|EXPERIMENTAL|EPIQ sites|Use Evidence-based Practice for Improving Quality (EPIQ) method to develop and implement evidence-based practice changes to reduce hospital-acquired infection
62389952|NCT02600195|NO_INTERVENTION|Control sites|Continue current practices
62389953|NCT01632345|EXPERIMENTAL|Doravirine 25 mg|Doravirine 25 mg + TRUVADA® Participants in this arm will receive doravirine 25 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
62389954|NCT01632345|EXPERIMENTAL|Doravirine 50 mg|Doravirine 50 mg + TRUVADA® Participants in this arm will receive doravirine 50 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
62389955|NCT01632345|EXPERIMENTAL|Doravirine 100 mg|Doravirine 100 mg + TRUVADA® Participants in this arm will receive doravirine 100 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
62389956|NCT01632345|EXPERIMENTAL|Doravirine 200 mg|Doravirine 200 mg + TRUVADA® Participants in this arm will receive doravirine 200 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
62389957|NCT01632345|ACTIVE_COMPARATOR|Efavirenz|Efavirenz + TRUVADA® Participants in this arm will receive efavirenz in Part I and in Part II. These participants also receive placebo that matches doravirine.
62389958|NCT00795717|ACTIVE_COMPARATOR|Lovaza|Lovaza, dietary counseling
62389959|NCT00795717|PLACEBO_COMPARATOR|Placebo|Placebo, dietary counseling
62389960|NCT03395613|NO_INTERVENTION|Standard management|Standard sterile gauze dressing on surgical groin wound.
62389961|NCT03395613|EXPERIMENTAL|NPWT management|Negative Pressure Wound Therapy dressing on surgical groin wound.
62389962|NCT05939336|EXPERIMENTAL|Mannooligosaccharides|Mannooligosaccharides yeast extract
62389963|NCT02915133||MF-MB|Consecutive participants with high myopic foveoschisis are scheduled to macular buckling (MB) surgery.
62389964|NCT00027846|NO_INTERVENTION|GTR1 Differentiated Histology Supratentorial (Group 1)|Patients undergo observation.
62561636|NCT05662371|PLACEBO_COMPARATOR|Standard Clinical Care Group|Hemodynamic changes outside of the normal range i.e., hypertension (systolic blood pressure greater than 140 mm Hg), tachycardia (heart rate greater than 90 min-1) and hypotension (mean arterial pressure less than 60 mm Hg) will be first assessed using the guidance of Bispectral index and Train of four monitors. Sufentanil in doses of 2.5 to 5 mcg (maximum of 0.6-1.2 mic/kg for the entire surgery) is administered if the Bispectral index and Train of four monitor values are within normal range and if required vasopressor infusion is used. Vasoconstrictors may be given as a continuous infusion of norepinephrine, or bolus doses of ephedrine or phenylephrine. Only when blood pressure remains, low additional crystalloids will be given. Finally, in case of bradycardia (heart rate less than 30 min-1), atropine may be given
62168404|NCT04293341|ACTIVE_COMPARATOR|Disorder Specific Therapies|To provide an evidence-based comparison for the TBT condition, DSTs will be used that are matched to the participant's most severe diagnosis, based upon the average of the ADIS interference and distress scores. If the scores are equivalent for two or more diagnoses, participants will be asked to list which diagnosis/symptoms that they find most impairing. DSTs will be included for each of the three targeted diagnoses, including PTSD (CPT for PTSD), PD/AG (CBT for PD/AG), and MDD (CBT for MDD). Each of these DSTs have published manuals for administration and have received extensive support in the literature (Barlow, 2014).
62168405|NCT05857618||Patients who have undergone exposer to General Anesthesia|Patients who have undergone general anesthesia at the University of Chicago Medical Center more than 20 times or patients who have general anesthesia 5 or fewer times in the past.
62168406|NCT03036124|EXPERIMENTAL|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
62168407|NCT03036124|PLACEBO_COMPARATOR|Placebo|Placebo matching dapagliflozin.
62168408|NCT05915884||Type 2 diabetic patients using SGLT-2 inhibitors|The data of all patients who applied to Samsun Training and Research Hospital Internal Medicine outpatient clinic for 12 months in 2022 and were started on SGLT-2 inhibitor will be examined. According to the inclusion and exclusion criteria, the patients will be evaluated and the data of the patients admitted to the study will be analyzed. The triglyceride glucose index of the patients before starting the SGLT-2 treatment and the triglyceride glucose index at the end of 3 months of treatment will be calculated by the researchers using the data in the system. No additional blood tests or laboratory analyses will be performed on the patients.
62168409|NCT01611532||Acute pancreatitis|All adult patients (\>18y.o.) requiring admission for acute pancreatitis (amylase \>3 times the upper limit of normal and typical symptoms of abdominal pain and vomiting)
62168410|NCT00688051|EXPERIMENTAL|1|
62168411|NCT04245878||intensive care unit inpatient|Inpatient intubated resuscitation patient with a scheduled extubation
62168412|NCT01580735|EXPERIMENTAL|ARQ 197|
62168413|NCT05610254|ACTIVE_COMPARATOR|Cold-Warm|Trial day 1: Participants receive Ringer's lactate cold (15°C, 59°F), Trial day 2: Participants receive Ringer's lactate at body temperature (37°C, 98.6°F)
62168414|NCT05610254|ACTIVE_COMPARATOR|Warm-Cold|Trial day 1: Participants receive Ringer's lactate at body temperature (37°C, 98.6°F) Trial day 2: Participants receive Ringer's lactate cold (15°C, 59°F),
62561637|NCT05662371|EXPERIMENTAL|Nociception Level-guided Analgesia Group|In the nociception level-guided group, sufentanil will be administered to maintain a nociception level value between 10 and 25. In case the nociception level values rise greater than 25 for more than 60 s, additional 2.5 microgram sufentanil (if nociception level increase remained less than 45) or 5 micrograms (if nociception level increase greater than 45). Atropine will be administered when heart rate decreases less than 30 min-1. Because the nociception level may be sensitive to such medication, nociception level values will then not used for at least 5 min to guide analgesia, with the exception of norepinephrine as this drug will be given as continuous infusion
62561638|NCT04274933|EXPERIMENTAL|Dose Escalation: Venetoclax and Capecitabine|Venetoclax at various doses will be administered in combination with capecitabine until a recommended dose is determined.
62561639|NCT04274933|EXPERIMENTAL|Dose Expansion: Venetoclax and Capecitabine|Venetoclax at the dose identified in Dose Escalation administered in combination with capecitabine.
62168415|NCT05102760|ACTIVE_COMPARATOR|Fascia Iliaca Compartment|Fascial Iliaca block (FIC) (40mL of Bupivacaine 0.25%) for patients with hip fractures in the ED
62561640|NCT01731639|EXPERIMENTAL|MSOME|The samples will be evaluated under high magnification
62561641|NCT03472014|EXPERIMENTAL|IMVAMUNE®|Two subcutaneous vaccinations with 0.5 mL IMVAMUNE® vaccine administered at a 4 week intervals
62561642|NCT06121323|ACTIVE_COMPARATOR|Lactate infusion|All participants will be randomized to first receive a three-hour intravenous infusion with either a racemic (D/L) mixture of sodium lactate or intravenous isotonic sodium chloride placebo. All participants will then cross over to the converse infusion on the same day.
62561643|NCT06121323|ACTIVE_COMPARATOR|Lactate ingestion|All participants will be randomized to first receive either an orally administered racemic (D/L) mixture of sodium lactate or isocaloric, isovolumic oral placebo (maltodextrin). The oral dose of lactate will be equal to the intravenous dose. All participants will be studied for three hours and then cross over to receive the converse oral administration following additional three hours of observation time on the same day.
62561644|NCT03285347|EXPERIMENTAL|Brain+ Evolution|"Intervention: Training with computer-based programme Brain+ Evolution for 8 weeks, receiving follow-ups every second week.~Computer-based cognitive training."
62561645|NCT03285347|EXPERIMENTAL|Scientific Brain Training PRO|"Intervention: Training with computer-based programme Scientific Brain Training PRO for 8 weeks, receiving follow-ups every second week.~Computer-based cognitive training."
62561646|NCT03285347|NO_INTERVENTION|Control group|This Group receives no intervention except for the same amount of follow-ups as the two training Groups. This is done to ensure that an effect of training is not aqtually due to the follow-up's with a professional.
62561647|NCT06520618|EXPERIMENTAL|Experimental Group|
62168416|NCT05102760|ACTIVE_COMPARATOR|PENG Block|Pericapsular Nerve Group (PENG) Block (20mL of Bupivacaine 0.50%)
62561648|NCT06520618|ACTIVE_COMPARATOR|Control Group|
62168417|NCT03856814||Patients with varicose veins|Patients with varicose veins, indicative for treatment with EndoVenous Laser Ablation (EVLA) using the ELVeS® Radial® 2ring slim fiber or Surgery (ligation/stripping) according to the standard of care of the participating investigators.
62168418|NCT00341016||Cohort of Chernobyl cleanup workers (liquidators) in Ukraine|Cases with leukemia and related diseases, and matched controls in the cohort
61994531|NCT05179421|EXPERIMENTAL|First infusion day high dose oxytocin, Second infusion day low dose oxytocin|On the first oxytocin study day, participants will receive a 10 minute IV infusion of oxytocin 0.3 micrograms then one hour later will receive a 10 minute infusion of oxytocin 7 micrograms. On the second study day they will receive a 10 minute IV infusion of saline then one hour later will receive a 10 minute infusion of oxytocin 1.3 micrograms.
62168419|NCT05552014|ACTIVE_COMPARATOR|Natural Psychotherapy|Intervention using natural psychotherapy for OCD patients for two to three hours once a week for eight weeks
62168420|NCT05552014|PLACEBO_COMPARATOR|Mental Health Education|Mental health education was given to another group of OCD patients for two hours once a week for eight weeks
62168421|NCT06223958|EXPERIMENTAL|OTX-TKI (axitinib implant)|
62168422|NCT06223958|OTHER|Control|
62168423|NCT04390971|EXPERIMENTAL|ET-01|BCL11A Enhancer modified Autologous Hematopoietic Stem Cells.
62561649|NCT05164692|PLACEBO_COMPARATOR|Control|"Control group receives the routine treatment and uses 0.9% NaCl physiological saline:~Routine treatment is as follows:~* Oral administrative drugs: antipyretic paracetamol (Efferegant®️); anti-inflammatory corticosteroid methylprednisolon; antibiotics e.g. ampicillin and sulbactam complex (Ama-power®️), tobramycin (Medphatobra®️), or cefotaxim (Goldcefo®️), based on the results of antibiotic susceptibility test.~* Aerosol therapy: bronchodilator e.g. salbutamol (Ventolin ®️inhaler) or budesonide (Pulmicort ®️Respules)."
62561650|NCT05164692|EXPERIMENTAL|Navax|"Navax group receives the routine treatment and uses NaCl 0.9% plus B. subtilis and B. clausii at 5 billions CFU/5 mL (LiveSpo®️ Navax):~Routine treatment is as follows:~* Oral administrative drugs: antipyretic paracetamol (Efferegant®️); anti-inflammatory corticosteroid methylprednisolon; antibiotics e.g. ampicillin and sulbactam complex (Ama-power®️), tobramycin (Medphatobra®️), or cefotaxim (Goldcefo®️), based on the results of antibiotic susceptibility test.~* Aerosol therapy: bronchodilator e.g. salbutamol (Ventolin ®️inhaler) or budesonide (Pulmicort ®️Respules)."
62561651|NCT04558073|EXPERIMENTAL|Body Project (BP)|The BP intervention includes four one-hour sessions given over a month by two facilitators. The sessions will be held on a collaborative platform in groups of six people.
62561652|NCT04558073|EXPERIMENTAL|Healthy Weight Program (HW)|The HW intervention includes four one-hour sessions given over a month by two facilitators. The sessions will be held on a collaborative platform in groups of six people.
62561653|NCT04558073|NO_INTERVENTION|Waiting-list (WL)|The waiting list will consist of two assessments each separated by a one-month interval. Following this waiting time, participants will receive the BP intervention.
62561654|NCT05774067|ACTIVE_COMPARATOR|control|
62561655|NCT05774067|ACTIVE_COMPARATOR|noradrenaline|
62168424|NCT05952583||sFGR cohort|Monochorionic diamniotic twin pregnancies complicated by sFGR (diagnosed before 28 weeks of gestational age)
62168425|NCT06402851|ACTIVE_COMPARATOR|Warfarin|Full-dose anticoagulation with adjusted dose (target INR 2.0-3.0) warfarin.
62168426|NCT06402851|EXPERIMENTAL|Edoxaban|Dose will be based on label from Brazil considering adjustment for low CrCl, that is, 30 mg QD.
62168427|NCT06402851|NO_INTERVENTION|No anticoagulation|No oral anticoagulation should be used
62168428|NCT06647368|EXPERIMENTAL|PET with 18-FDG|
62168429|NCT01026883|OTHER|Healthy subjects|Hematocrit level of each subject will be assessed by two different techniques
62561656|NCT05774067|ACTIVE_COMPARATOR|glypressin|
62561657|NCT01832064|EXPERIMENTAL|Mailed Chronic Disease Self-Management|Mailed Chronic Disease Self-Management Program: self management information and self assessment
62561658|NCT00962819||cross-sectional|College-aged students who were immunized with MMR.
62168430|NCT06269887||Male|Hand preference was evaluated with the Edinburgh Hand Preference Questionnaire, grip muscle strength with the Jamar dynamometer, dexterity with the Purdue Pegboard Test, and proprioception as joint position sense with the inclinometer.
62168431|NCT06269887||Female|Hand preference was evaluated with the Edinburgh Hand Preference Questionnaire, grip muscle strength with the Jamar dynamometer, dexterity with the Purdue Pegboard Test, and proprioception as joint position sense with the inclinometer.
62168432|NCT03366233|EXPERIMENTAL|Mentally fatiguing task|A modified Stroop task of 90 min, partitioned in 8 blocks of 252 stimuli, will be used as mentally fatiguing task.
62168433|NCT03366233|PLACEBO_COMPARATOR|Control task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial for 90 min.
62168434|NCT05756348|OTHER|receives both product|all participants receive both products under evaluation.
62168435|NCT00485914|EXPERIMENTAL|On-site work evaluation|Participants will receive one-to-one contact with an occupational therapist and an individualized work plan
62168436|NCT00485914|ACTIVE_COMPARATOR|Educational material|Participants will receive educational materials to develop strategies to compensate for limitations caused by their condition
62168437|NCT02502851|ACTIVE_COMPARATOR|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy followed by implantation of the ORSIRO sirolimus-eluting stent
62168438|NCT02502851|ACTIVE_COMPARATOR|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloon followed by implantation of the ORSIRO sirolimus-eluting stent
62389965|NCT00027846|EXPERIMENTAL|Radiation (Group 2)|Supratentorial Anaplastic Ependymoma (GTR1, GTR2, NTR) and Anaplastic or Differentiated Infratentorial Ependymoma (GTR1, GTR2, NTR) and Supratentorial Differentiated Ependymoma(GTR2, NTR). Patients undergo conformal radiation therapy to the brain once daily 5 days a week for 6-6½ weeks.
62561659|NCT04949217|EXPERIMENTAL|Inlay Bristow Group|Inlay Bristow procedure
62561660|NCT04949217|ACTIVE_COMPARATOR|Onlay Bristow Group|Onlay Bristow procedure
62561661|NCT04343040|EXPERIMENTAL|perioperative glucose intake|glucose intolerant patients with perioperative glucose (carbohydrate supplement (Preload™) intake before Gastric By-Pass or Sleeve Gastrectomy.
62389966|NCT00027846|EXPERIMENTAL|Sub-Total Resection Any Histology or Location (STR) (Group 3)|Patients receive an initial course of chemotherapy comprising vincristine sulfate IV on days 1 and 8, carboplatin IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on days 1 and 2. Patients also receive filgrastim (G-CSF) subcutaneously or IV beginning on day 3 and continuing until blood counts recover. Patients then receive a second course of chemotherapy comprising vincristine sulfate IV on days 1 and 8, carboplatin IV over 1 hour on day 1, and oral etoposide on days 1-21. After completion of chemotherapy, patients are evaluated for second therapeutic conventional surgery. Patients who have unresectable disease undergo conformal radiation therapy. Patients who have resectable disease undergo second surgery followed by conformal radiotherapy.
62389967|NCT06482905|EXPERIMENTAL|Cohort A Single delivery route|Administration of TX103 via intraventricular(ICV) on Days 1 and 8 in a 21-day treatment cycle.
62389968|NCT06482905|EXPERIMENTAL|Cohort B Dual delivery route|Administration of TX103 on Day 1 via intracavitary (ICT) and on Day 8 via intraventricular(ICV) in a 21-day treatment cycle.
62389969|NCT00958399|PLACEBO_COMPARATOR|No fiber|No fiber added to study products
62769544|NCT05027984|EXPERIMENTAL|Intermediate lesion OCT-based management|"At OCT analysis, lesion features prompting intervention instead of conservative approach will be the following:~1. FCT \<75 µm, plus at least 2 of 3 other OCT criteria of plaque vulnerability (i.e., MLA \<3.5 mm2, lipid arc with circumferential extension \>180°, and the presence of macrophages).~2. The presence of intracoronary thrombus at a non-culprit site, irrespective of the presence of other vulnerability criteria, may prompt treatment with DES, at the operator's discretion.~All lesions fulfilling these interventional criteria will be treated with an OCT guided DES implantation in order to achieve an optimal stent implantation.~In presence of a MLA \<2.0 mm2, best cut-off showing correlation with fractional-flow reserve positive functional (FFR) assessment, clinical decision whether to treat the lesion will be based on FFR assessment irrespective of the presence of other criteria of vulnerability. Alternatively authors will have the option to treat the lesion with a DES."
62389970|NCT00958399|EXPERIMENTAL|Resistant Starch|Muffins, cereal, and bars made with a resistant starch
62389971|NCT00958399|EXPERIMENTAL|Resistant starch + soluble fiber|Muffins, cereal, and bars made with a mixture of resistant starch and a soluble fiber
62389972|NCT00958399|EXPERIMENTAL|Fiber made from corn starch|Muffins, cereal, and bars made with novel corn fiber
62389973|NCT00958399|EXPERIMENTAL|Fiber made from corn starch + soluble fiber|Muffins, cereal, and bars made with a mixture of novel corn fiber and a soluble fiber
62561662|NCT04343040|SHAM_COMPARATOR|6 hours of preoperative fasting|glucose intolerant patients receiving 6 hours of preoperative fasting before Gastric By-Pass or Sleeve Gastrectomy.
62561663|NCT02816736|ACTIVE_COMPARATOR|LCZ696 (Entresto) + placebo|LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks
62561664|NCT02816736|ACTIVE_COMPARATOR|valsartan + placebo|valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks
62389974|NCT05078268|EXPERIMENTAL|Combined group|Participants in combined group will receive both HRV biofeedback training and self-help CBT-I concurrently.
62561665|NCT03023072||Phase 1|Subjects will use the incontinence pad with incontinence detection notifications turned on
62168439|NCT06255899|ACTIVE_COMPARATOR|Education|All participants will attend an educational training session on the team's Injury Prevention Program (IPP), which will be performed prior to practices and matches throughout the season. All team members, coaching staff, and medical staff will attend the educational session. This session will be administered during the pre-season training period, will last 60-90 minutes, and include a didactic component and a practical component in which all athletes on the team will receive instruction on how to properly perform each component of the IPP program. and have an opportunity to practice performing the IPP on the field. This is an evidence-based program that will be provided to all lacrosse athletes regardless of participation in the research study.
62168440|NCT06255899|EXPERIMENTAL|Individualized Feedback + Education|After completing the Education Program, participants assigned to the individualized feedback group will perform the IPP during a strength and conditioning session while a research team member records their performance on a laboratory video camera. The video will be analyzed to identify errors and compensations with movements and a plan for a feedback session to correct movements will be developed. The feedback session will include showing the athlete their video, identifying the error or compensation, and providing verbal, tactile, and visual feedback to correct the error or compensation. Two additional feedback sessions will be scheduled at regular intervals during the season.
62168441|NCT00316589|EXPERIMENTAL|Healthy subjects|Control group with and without a history of previous smallpox vaccination IMVAMUNE (MVA-BN)
62168442|NCT00316589|EXPERIMENTAL|HIV-infected, vaccinia-naive|Subjects without a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)
62168443|NCT00316589|EXPERIMENTAL|HIV-infected, vaccinia-experienced|Subjects with a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)
62168444|NCT03237598||male|young (≥18 and ≤45), adult (45\~60), and old (\>60) , n=1960
62168445|NCT03237598||female|young (≥18 and ≤45), adult (45\~60), and old (\>60) , n=2348
62168446|NCT04044352|EXPERIMENTAL|Group 1|2 mL (approximately 5x10\^6/mL tissue culture infective dose (TCID50)) of influenza A/Bethesda/MM2/H1N1challenge virus administered intranasally via a sprayer on Day 1. N=80.
62168447|NCT05872620|EXPERIMENTAL|Orforglipron Dose 1|Participants will receive orforglipron administered orally.
62168448|NCT05872620|EXPERIMENTAL|Orforglipron Dose 2|Participants will receive orforglipron administered orally.
62168449|NCT05872620|EXPERIMENTAL|Orforglipron Dose 3|Participants will receive orforglipron administered orally.
61994532|NCT03981133|EXPERIMENTAL|A: unrestricted pacifier|recommendation to offer a pacifier at the facility providing maternity and newborn services the first days of life
62168450|NCT05872620|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo
62168451|NCT05164133|EXPERIMENTAL|All Participants|Participants who are hospitalized with COVID-19 and who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation will receive a single dose of TCZ on Day 1, with the option to receive a second dose 8-24 hours later if clinically indicated.
62168452|NCT02103816|EXPERIMENTAL|SmartLipo Triplex laser system along with the SideLaze800 hand|
62168453|NCT05394467||Lipedema|Women with diagnosed lipedema
62168454|NCT05216952|EXPERIMENTAL|UPA 90mg|Participants receive ulipristal acetate 90mg PO followed by self-administration of misoprostol 800mcg vaginally 6 to 18 hours following ulipristal acetate administration.
62168455|NCT06552910||Group/Cohort 1|Label: Peripheral Nerve Block Description: Injection of anesthetic near specific nerves to block sensation in a particular area of the body.
62168456|NCT06453161||Cohort|Adults patients with pre-operative simplified predictive risk index for renal replacement therapy after cardiac surgery ≥2, with cardiac surgery performed in Louis Pradel Hospital between 08/2022 and 02/2024.
62389975|NCT05078268|ACTIVE_COMPARATOR|Self-help CBT-I only group|Participants in self-help CBT-I only group will receive self-help CBT-I only.
62389976|NCT04887012|EXPERIMENTAL|CAR-NK019|All subjects were intravenously administrated with CAR-NK019
61994533|NCT03981133|ACTIVE_COMPARATOR|restricted pacifierr|recommendation not to offer a pacifier to normal new born infant at the maternity thre first days of live
61994534|NCT02363465||Participants aged 18-30 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 18-30 years.~aimed number: 12 male \& 12 female maximum number: 15 male \& 15 female"
62168457|NCT01022671|EXPERIMENTAL|Belotecan|Single arm
62389977|NCT04647929|EXPERIMENTAL|PRESERFLO MicroShunt|Patients will undergo Santen PRESERFLO MicroShunt implantation with intraoperative use of Mitomycin C 0.2mg/ml for 2 minutes.
62389978|NCT04647929|ACTIVE_COMPARATOR|Trabeculectomy|Patients will undergo trabeculectomy with intraoperative use of Mitomycin C 0.2mg/ml for 2 minutes.
62389979|NCT01522963|EXPERIMENTAL|Nicotine Lozenge Immediately Prior to Stress task|Subjects will receive the nicotine lozenge immediately prior to the stress task at one laboratory session and after the stress task at the other laboratory session
62389980|NCT01522963|EXPERIMENTAL|Nicotine lozenge 10 Minutes prior to Stress task|Subjects will receive the nicotine lozenge after the stress task during one laboratory session and immediately prior to the stress task at the other laboratory session
62389981|NCT01522963|EXPERIMENTAL|Nicotine lozenge 20 minutes prior to Stress task|Subjects will receive the nicotine lozenge after the stress task during one laboratory session and 10 minutes prior to the stress task at the other laboratory session
61994535|NCT02363465||Participants aged 31-40 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 31-40 years.~aimed number: 12 male \& 12 female maximum number: 15 male \& 15 female"
61994536|NCT02363465||Participants aged 41-50 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 41-50 years.~aimed number: 12 male \& 12 female maximum number: 15 male \& 15 female"
61994537|NCT02363465||Participants aged 51-65 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 51-65 years.~aimed number: 12 male \& 12 female maximum number: 15 male \& 15 female"
62168458|NCT06621875||Dynapenia Group|Those with no decrease in muscle mass but decreased muscle strength and/or performance will be included in the 'dynapenia group'.
62168459|NCT06621875||Control Group|Those with no decrease in muscle mass, muscle function and performance will be included in the 'control group'.
62168460|NCT02625168|EXPERIMENTAL|Afatinib|Afatinib 30 or 40 or 50mg daily orally after study recruitment until radiologically documented disease progression, intolerable side effects as judged by investigators or patient withdrawal.
62168461|NCT02625168|EXPERIMENTAL|Erlotinib|Erlotinib 150mg daily until radiologically documented disease progression, intolerable side effects as judged by investigators or patient withdrawal.
62168462|NCT03453177|NO_INTERVENTION|Standard of Care|ampicillin 50mg/kg twice daily and gentamicin \[3mg/kg for babies \<2kg or 5mg/kg for babies \>2kg\] once daily for 7 days, as per Kenyan guidelines).
62168463|NCT03453177|EXPERIMENTAL|Standard of Care plus Fosfomycin|Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).
62168464|NCT02433392|EXPERIMENTAL|CM-BC2|Patients diagnosed with recurrent, surgically resectable glioblastoma multiforme will receive up to 75 mg irinotecan delivered by drug-eluting beads (CM-BC2).
62168465|NCT01289197|NO_INTERVENTION|No Feedback or services offered.|The Family Check-Up is not offered.
62168466|NCT01289197|OTHER|Intervention|Family Check Up is offered.
62168467|NCT05729347|EXPERIMENTAL|Virtual Reality|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
62561666|NCT03023072||Phase 2|Subjects will use the incontinence pad with incontinence notification turned off
62561667|NCT03257280|EXPERIMENTAL|Early oral nutrition|An early oral nutrition with supplements and increased progressively according to an established schedule, start 48 hours after total gastrectomy.
62561668|NCT03257280|NO_INTERVENTION|control group|In our center, the classical postoperative management consisted in one week period of non oral intake and total parenteral nutrition. At the 7 day, an oral contrast image is performed to prove the correct function of the anastomosis, in witch case, a three days progressive oral diet is begin.
62168468|NCT05729347|NO_INTERVENTION|Control|No intervention (i.e. virtual reality headset) will be applied to the participant.
62168469|NCT05512910|EXPERIMENTAL|Treatment group|Patients randomized to the treatment group will receive oral minocycline in addition to endovascular treatment and other standard medical. The first dose of minocycline will be administered 200 mg orally prior to successful reperfusion, followed by 100 mg every 12 hours times for a total of 5 days. If vomiting occurs within half an hour of the first dose, the clinician should assess the necessary of re-administering 100mg based on the severity of vomiting. If the patient is considered to be at any risk for aspiration or is unable to swallow based on swallowing evaluation, study drug will be oral via feeding tube.
62168470|NCT05512910|NO_INTERVENTION|Control group|Patients randomized to the control group will receive endovascular treatment and other standard treatment, without minocycline treatment.
62168471|NCT01295775|ACTIVE_COMPARATOR|Sulodexide group|50 mg of sulodexide a day will be administered by oral route (1+1 capsule/day) for 360 days
62168472|NCT01295775|PLACEBO_COMPARATOR|Placebo group|Sulodexide placebo will be administered at the same schedule (1+1 capsule/day) and for the same lengths of time (for 360 days) as Sulodexide group
62168473|NCT00659971|EXPERIMENTAL|1|PAC113 0,15% mouthrinse
62389982|NCT01522963|EXPERIMENTAL|Nicotine Lozenge 30 minutes prior to stress taks|Subjects will receive the nicotine lozenge 10 minutes prior to the stress task during one laboratory session and after the stress task at the other laboratory session
62168474|NCT00659971|EXPERIMENTAL|2|PAC113 0,075% mouthrinse
62168475|NCT00659971|EXPERIMENTAL|3|PAC113 0,0375% mouthrinse
62168476|NCT00659971|ACTIVE_COMPARATOR|4|Nystatin suspension
62561669|NCT03866213||Quantitative Measurement of Bilirubin|Bilirubin content of the neonate will be measured by the following: BiliSpec, laboratory spectophotometric bilirubinometer (Reichert UNISTAT), and transcutaneous bilirubinometer. The infant may or may not be receiving phototherapy treatment at the time of sample measurement.
62561670|NCT05360810|ACTIVE_COMPARATOR|Wei Nasal Jet Tube Group (Group W)|After induction of anesthesia, the Wei Nasal Jet Tube was placed in the patients.
62561671|NCT05360810|ACTIVE_COMPARATOR|Gastro-Laryngeal Tube Group (Group G)|After the induction of anesthesia, the Gastro Laryngeal Tube was placed in the patients.
62561672|NCT00007631|ACTIVE_COMPARATOR|1|Topical Tretinoin
62561673|NCT00007631|PLACEBO_COMPARATOR|2|Placebo
62389983|NCT05722418|EXPERIMENTAL|CB-011|"* Part A Escalation with CB-011 in ascending doses using a traditional 3+3 design.~* Part B Expansion. Up to 30 participants will be enrolled to receive CB-011 at the RDE/MTD and/or RP2D determined in Plan A"
62389984|NCT03268603|EXPERIMENTAL|Mesenchymal Stromal Cells|Autologous Adipose-derived Mesenchymal Stromal Cells (aaMSCs) will be administered intrathecally at a single dose in a volume of 5-10 mL, all patients will receive 5 x 10\^7 intrathecal aaMSCs at the first injection (Visit 4). Subsequent doses may be reduced to 1 x 10\^7 or increased to 1 x 10\^8, based on Dose Modification Rules.
62389985|NCT04873323|EXPERIMENTAL|TS-142 10 mg|TS-142 therapeutic dose oral tablet (low dose)
62389986|NCT04873323|EXPERIMENTAL|TS-142 30 mg|Description: TS-142 supratherapeutic dose oral tablet (high dose)
62561674|NCT04999059||Participants with Fabry Disease|This is a long-term follow-up study of participants who previously received AVR-RD-01 (single dose administration) in the AVRO-RD-01-201 treatment study. No investigational product will be administered in this study.
62561675|NCT01004354|EXPERIMENTAL|Vitamin D|
62561676|NCT02813408||Participants with Prostate Cancer (abiraterone acetate)|Participants with metastatic castration resistant prostate cancer (mCRPC) will receive abiraterone acetate at the discretion of his treating physician.
62389987|NCT04873323|EXPERIMENTAL|Moxifloxacin 400 mg|Moxifloxacin tablet
62389988|NCT04873323|EXPERIMENTAL|Placebo|Placebo oral tablet
62389989|NCT01813136|ACTIVE_COMPARATOR|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
62561677|NCT02813408||Participants with Prostate Cancer (enzalutamide)|Participants with metastatic castration resistant prostate cancer (mCRPC) will receive enzalutamide at the discretion of his treating physician.
62168477|NCT06115642|EXPERIMENTAL|HLX43 group|Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
62168478|NCT06434571|EXPERIMENTAL|Telehealth cognitive behavioral therapy for insomnia (tCBT-I)|1x/week, 6-week 45-60 min one-one-one manualized program via video conferencing (HIPAA-compliant Zoom) with a trained research assistant that includes time in bed restriction, stimulus control, relaxation strategies, cognitive restructuring, and sleep health promotion education.
62389990|NCT01813136|EXPERIMENTAL|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression"
62389991|NCT05381740|EXPERIMENTAL|cHMC rTMS + Upper Limb Training Training|Real Repetitive Transcranial Magnetic Stimulation given to facilitate the Contralesional Higher Motor Cortices+ Upper Limb Training
62389992|NCT05381740|SHAM_COMPARATOR|Sham rTMS + Upper Limb Training Training|Sham Repetitive Transcranial Magnetic Stimulation over Contralesional Higher Motor Cortices+ Upper Limb Training
62389993|NCT02409576|EXPERIMENTAL|Expanded, activated NK Cells(NKEXPSARC)|Intravenous infusion of expanded, activated NK Cells Donor cell will be expanded and activated in the cGMP compliant TECT lab for 10 to 12 days prior to infusion into the patient.
62561678|NCT03987282|ACTIVE_COMPARATOR|Enhanced usual care (EUC)|The EUC consists of provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
62561679|NCT03987282|EXPERIMENTAL|Fully Implemented Seek-Test-Treat-Retain (FI-STTR) model|The FI-STTR care model will include the usual care supplemented by continuing education and coaching of medical staff at HIV/AIDS and MMT clinics and by provision of additional peer-based counseling intervention
62561680|NCT01779440|OTHER|Electronic Decision Support System|The Electronic Decision Support System is a web-based computer program designed to motivate, educate, and engage people with severe mental illness into evidence-based smoking cessation treatment.
62561681|NCT01779440|PLACEBO_COMPARATOR|Control Computer Program|A computer program aimed to educate people about smoking cessation treatment.
62561682|NCT04542473|ACTIVE_COMPARATOR|Pancreatic Enzymes (PE)|"Pancreatic enzymes formulated as 5000 IE lipase, 3600 IE amylase and 200 IE protease per 100 mg of granules, packaged as sachets. The target dose is 3000 IU lipase/kg, twice daily (1440 IU/kg amylase/80 IU/kg protease), which is the dose used for children with cystic fibrosis and exocrine pancreas insufficiency. For oedematous malnutrition, weight for dosing is reduced by 10%. To be prescribed following enrolment and given just prior to or during a feed. Prescription will follow weight bands to allow a lower range of 2000 IU/kg/day and upper range of 4000 IU/kg/day:~Weight from Weight to Dose Dose Upper range Lower range (Kg) (Kg) (sachets) (IU Lipase) (IU/kg/dose) (IU Lipase)~---------------------------------------------------------------------------------------------------------- 2.50 4.99 2 10000 4000 2000 5.00 7.49 4 20000 4000 2670 7.50 9.99 6 30000 4000 3000 10.0 15.0 8 40000 4000 2667"
62168479|NCT06434571|EXPERIMENTAL|Web-based cognitive behavioral therapy for insomnia (wCBT-I)|The Go!ToSleep online program is a 6-week interactive, web-based program that delivers typical CBT-I treatment techniques of stimulus control, sleep restriction, behavioral modifications, relaxation techniques and cognitive restructuring with daily lessons (41 lessons in total)
62168480|NCT06434571|OTHER|Treatment as usual (TAU)|The treatment as usual comparison group will be encouraged to continue with their usual care recommended by their physician and their usual activities and sleep habits during the period between baseline and 6-month reassessment.
62168481|NCT01651416|ACTIVE_COMPARATOR|HMM using short-acting ACT|Home management of malaria using Artemether-lumefantrine combination (a short-acting ACT) for treatment in children with malaria diagnosed using RDTs
62769545|NCT05027984|ACTIVE_COMPARATOR|Intermediate lesion physiology-based management|The iFR/FFR/RFR measurements will be obtained using a coronary-pressure guidewire. For FFR, hyperemia will be induced with the administration of intravenous adenosine, in accordance with the clinical practice at each participating center. Lesion features prompting intervention instead of conservative medical approach will be the following: iFR ≤0.89, or FFR ≤0.80.(32) All lesions fulfilling these interventional criteria will be treated with an FFR guided DES implantation. PCI will be performed with the aim of achieving a post-stenting FFR ≥0.90 (i.e. optimal FFR result). If post-stenting FFR was \<0.90 a further post-dilation of the stent could be performed and if FFR remained at \<0.90, a pullback of the wire to identify another possible pressure drop and/or a subsequent stent implantation at least 5 mm from the stent will be performed according to physician's preference.
62769546|NCT01877889|EXPERIMENTAL|Part 1: Cana|Each volunteer will receive 300 mg of canagliflozin once daily for 4 days.
62168482|NCT01651416|EXPERIMENTAL|HMM using short-acting ACT plus SMC|Home management of malaria using using Artemether-lumefantrine combination (a short-acting ACT) for treatment in children with malaria diagnosed using RDTs plus seasonal malaria chemoprevention with Amodiaquine plus sulphadoxine-pyrimethamine combination.
62168483|NCT01651416|EXPERIMENTAL|HMM using a long-acting ACT|Home management of malaria using Dihydroartemisinin Piperaquine combination (a long-acting ACT) for treatment in children with malaria diagnosed using RDTs
62168484|NCT05530460|EXPERIMENTAL|OCT Imaging|
62389994|NCT03871803|ACTIVE_COMPARATOR|Arm A|"Controlled Withdrawal of Beta-blockers and Cardiopulmonary Exercise Testing (CPET) Patient will be assessed for chronotr0pic incompetence by CPET. If the patient exhibits chronotropic incompetence, we will reduce half dose of previous beta-blocker.~A cardiologist will evaluate clinically the the patient and the heart rate in 3 days. If clinical and heart rate stability (below 90 bpm), the patients will withdraw the beta-blocker and will be assessed by CPET at 15-day.~After second CPET, the patient will introduce the half-dose of beta-blocker and will be evaluated in 3 days. If clinical stability, the patient will introduce the previous dose of beta-blocker A third CPET will be performed at 15-day"
62389995|NCT03871803|ACTIVE_COMPARATOR|Arm B|"Cardiopulmonary Exercise Testing (CPET) and Controlled Withdrawal of Beta-blockers Patient will be assessed for chronotropic incompetence by CPET.If the patient exhibits chronotropic incompetence, a cardiologist will evaluate clinically the patient and the heart rate in 3 days and will be assessed by CPET at 15-day.~After second CPET, the patient will reduce half dose of previous beta-blocker. A cardiologist will evaluate clinically the the patient and the heart rate in 3 days. If clinical and heart rate stability (below 90 bpm), the patients will withdraw the beta-blocker and will be assessed by CPET at 15-day."
62168485|NCT01641289|EXPERIMENTAL|Paracetamol|"\>50kg: Paracetamol 1gm PO/NG q6hourly for 72 hours and febrile for 24 hours (maximum total dose 4g/24 hours) plus intravenous Artesunate~\<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72 hours and febrile for 24 hours (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate"
62389996|NCT00963742|EXPERIMENTAL|Lenstec Softec HD IOL implantation|390 eyes of 390 study subjects all receiving the investigational IOL; IOL implanted after surgical removal of cataract
62769547|NCT01877889|EXPERIMENTAL|Part 2: Sequence 1 (Dapa/Cana)|Each volunteer will receive 10 mg of dapagliflozin once daily for 4 days (treatment period 1) followed by 300 mg of canagliflozin once daily for 4 days (treatment period 2). Each treatment period will be separated by a 12- to 14-day washout period (with no medication).
61994538|NCT06416696|EXPERIMENTAL|Toripalimab combined with Chemoradiotherapy followed by Toripalimab maintenance therapy|Toripalimab combined with Chemoradiotherapy followed by Toripalimab maintenance therapy for High-risk Locally Advanced Cervical Cancer
61994539|NCT05403242|EXPERIMENTAL|RC48-ADC Combined With S-1|
61994540|NCT01794052|EXPERIMENTAL|DSS enabled health care delivery model|Evidence based, DSS enabled, health care delivery model
61994541|NCT00647127|ACTIVE_COMPARATOR|Buprenorphine|
62389997|NCT02529358|EXPERIMENTAL|EG stand|Standardized text messages
62561683|NCT04542473|PLACEBO_COMPARATOR|Placebo-PE|"Oral/enteral placebo matching active Pancreatic Enzymes (PE). Dose presentation in whole sachets of 100mg of granules. For oedematous malnutrition, weight for dosing is reduced by a pragmatic 10%. To be prescribed following enrolment and given just prior to or during a feed. Prescription will follow weight bands:~Weight from Weight to Dose Dose Upper range Lower range (Kg) (Kg) (sachets) (IU Lipase) (IU/kg/dose) (IU Lipase)~----------------------------------------------------------------------------------------------------------------------------------------- 2.50 4.99 2 Nil Nil Nil 5.00 7.49 4 Nil Nil Nil 7.50 9.99 6 Nil Nil Nil 10.0 15.0 8 Nil Nil Nil"
62561684|NCT04542473|ACTIVE_COMPARATOR|Ursodeoxycholic acid (UA)|The dose of ursodeoxycholic acid will be given at 10 mg/kg twice per day just prior to or during a feed, using a suspension of 50 mg/ml = 0.2 ml/kg. For oedematous malnutrition participants, weight is pragmatically reduced by 10%. To be prescribed and given following enrolment.
62561685|NCT04542473|PLACEBO_COMPARATOR|Placebo-UA|The dose of placebo will be given twice per day just prior to or during a feed at 0.2 ml/kg. To be prescribed and given following enrolment.
62769548|NCT01877889|EXPERIMENTAL|Part 2: Sequence 2 (Cana/Dapa)|Each volunteer will receive 300 mg of canagliflozin once daily for 4 days (treatment period 1) followed by 10 mg of dapagliflozin once daily for 4 days (treatment period 2). Each treatment period will be separated by a 12- to 14-day washout period.
62769549|NCT00710242|EXPERIMENTAL|1|DF01
62769550|NCT00710242|PLACEBO_COMPARATOR|2|
62389998|NCT02529358|EXPERIMENTAL|EG ind|Personalized text messages
62389999|NCT02529358|OTHER|Control|Standardized text messages after 10 weeks
62390000|NCT04307264||Overall eligible participants|Eligible participants will receive standard esophagogasrtoduodendoscopy, liver stiffness measurement and serological examination (platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, Prothrombin time, albumin).
62561686|NCT01113723|OTHER|CMAC Device|CMAC Intubating device time to achieve successful tracheal intubation.
62561687|NCT01113723|ACTIVE_COMPARATOR|Fiberoptic bronchoscope|Fiberoptic bronchoscope Intubating device time to achieve successful tracheal intubation.
62769551|NCT00050674|EXPERIMENTAL|Filgrastim-SD/01|6 mg SC, Day 9, 24 hours after the end of the chemotherapy infusion
62769552|NCT00771121|ACTIVE_COMPARATOR|new emulsion|
62769553|NCT00771121|PLACEBO_COMPARATOR|new emulsion placebo|
62769554|NCT02545816|OTHER|study group|Patients (age ≥ 18 years) admitted to the ICU with an acute neurological insult which will be sedated/ventilated (Glasgow Coma Scale (GCS) ≤ 8).
62769555|NCT00238459||Recently infected patients|Cohort 1)Patients elcted to be immediately treated with licensed drugs:21 patients Cohort 2) Or to delay treatment until clinically indicated:16 patieints
62769556|NCT00238459||A vaccine,HIV-1 immunogen was not provided for evaluation|In the intial design, acandiate HIV vaccine was to be evaluated, but in August 2007 the manufacturer refused to provide vaccine to allow this study to evaluate the effect of a vaccine on control of HIV. Therefore the study became an observational study of the effects of early versus delayed initiation of antiretrovral therapy on the preservation of anti-HIV immune responses and the ability of patients to control virus after a closely monitored discontinuation of therapy.
62769557|NCT00921310|EXPERIMENTAL|Phase I Dose Level 1 (pemetrexed + temsirolimus)|"-Dose Level 1~* Pemetrexed 500mg/m\^2 intravenous (IV) on Day 1 of each 21 day cycle~* Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle"
61994542|NCT00647127|ACTIVE_COMPARATOR|Fentanyl|
61994543|NCT00647127|PLACEBO_COMPARATOR|Placebo|
62390001|NCT04613804|EXPERIMENTAL|Toripalimab group|Toripalimab 240mg ivgtt Q21d
62390002|NCT01317368|ACTIVE_COMPARATOR|TAP block|"TAP block with Ropivacaine~Wound infiltration with Saline"
62390003|NCT01317368|ACTIVE_COMPARATOR|Wound infiltration|"TAP block with Saline.~Wound infiltration with Ropivacaine."
62390004|NCT01317368|PLACEBO_COMPARATOR|Placebo|"TAP block with Saline.~Wound infiltration with Saline."
62390005|NCT06016166|EXPERIMENTAL|Eye mask users|The eyes of the patients will be defined as the intervention
62390006|NCT06016166|NO_INTERVENTION|Non eye mask users|The eyes of the patients will be defined as the controls
62168486|NCT01641289|ACTIVE_COMPARATOR|No Paracetamol|"No paracetamol + Intravenous Artesunate~* If temperature \> 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
62168487|NCT06302010|NO_INTERVENTION|Control Group|Pregnant women in the control group will not receive any intervention other than routine hospital care during the NST procedure.
62168488|NCT06302010|EXPERIMENTAL|Intervention Group|Pregnant women in the intervention group will be explained how to use the stress ball before NST. Pregnant women will be asked to demonstrate using a stress ball, and it will be verified that they can use it correctly. Pregnant women will be told to squeeze the ball once and release it after counting to three, to inhale each time they press the ball, to exhale when they relax their grip, and to focus only on the ball. Pregnant women will be instructed to continue this practice throughout the NST procedure (approximately 20 minutes). In addition, stress balls used in the hospital environment to minimize contamination will be disinfected with disposable asepsis wipes before being given to pregnant women.
62168489|NCT05044078|EXPERIMENTAL|Group 1 (Autogenic Inhibition)|Autogenic Inhibition (5 reps, 10-sec hold, 5-sec rest in between each rep, 1 set, in all sessions) will be provided with the Conventional therapy including neck Isometric strengthening exercise (Neck Flexion, Extension, Both sides Rotation, and Neck Bending with each 5 rep, 10-sec hold, 1 set, in all sessions), Maitland Central posterio-anterior glide (Grade 1 and 2, 30 rep, 3 sets, in all sessions) and hot pack (10 minutes in all sessions on the back of the neck)
62168490|NCT05044078|ACTIVE_COMPARATOR|Group 2 (Reciprocal Inhibition)|Reciprocal Inhibition (5 reps, 10-sec hold, 5-sec rest in between each rep, 1 set, in all sessions) will be provided with the with same Conventional therapy as in group 1 .
62168491|NCT01150500|EXPERIMENTAL|Drug Eluting Stent|Up to two lesions in two separate target vessels may be treated under this protocol. The lesions should be amenable to treatment with at least one 2.25 mm stent, a second lesion could be treated with any stent from 2.25 to 3.5 mm.
62168492|NCT03915002||Patients|"Steatohepatitis:~1. Alcoholic Steatohepatitis and Alcoholic liver disease~2. Nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)"
62168493|NCT03915002||Disease control|Patients 18 years or older with a diagnosis of cholestatic liver diseases (primary biliary cholangitis or primary sclerosing cholangitis) or hepatotropic virus (hepatitis C or B virus), according to the current international guidelines.
62168494|NCT03915002||Control subjects|"Patients over 18 years old without a diagnosis of liver disease that for any other reason (i.e candidate to liver donor, patients with liver metastasis that require surgery, patients with any type of benign liver tumor or HCC in a healthy liver).~Patient over 18 years old with a documented alcoholic used disorder in their clinical records and without any evidence of liver disease."
62168495|NCT06344949|EXPERIMENTAL|Ciprofol Group|
62168496|NCT06344949|ACTIVE_COMPARATOR|Propofol Group|
62168497|NCT06170983|EXPERIMENTAL|Pilot Cohort for Skin Inflammation|Testing skin inflammation
62168498|NCT06170983|EXPERIMENTAL|Azithromycin and Artificial Skin Inflammation|Investigating tissue PK of Azithromycin in artificially inflamed tissue
62168499|NCT06170983|EXPERIMENTAL|Azithromycin and Skin Infection|Investigating tissue PK of Azithromycin in actually infected tissue
62168500|NCT03087851|ACTIVE_COMPARATOR|6-month group|Zoledronic acid will be administered at study day 0. If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered.
61994544|NCT02705677||Rett syndrome|This is a biobanking project for individuals with mutations in MECP2 or meeting diagnostic criteria for classic (typical) or variant (atypical) Rett syndrome in order to identify other genetic factors such as X-chromosome inactivation or genetic background that may explain the variations noted in these individuals, including those with the same MECP2 mutation. No interventions are anticipated.
62168501|NCT03087851|ACTIVE_COMPARATOR|9-months group|"Zoledronic acid will be administered depending on increase in s-CTX (above 1.26 ug/l) or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 3.~If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered."
62168502|NCT03087851|ACTIVE_COMPARATOR|Observation group|"Zoledronic acid will be administered depending on increase in s-CTX (above 1.26 ug/l), decrease in BMD (more than 5% at any site), or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 6.~If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered."
62168503|NCT06279780|EXPERIMENTAL|Very low-calorie diet Intervention|
62168504|NCT04143737|OTHER|Intervention|38 women participated in the intervention group which was located in a community center in Zur-Baher neighborhood. The intervention consisted of 20 weekly sessions on nutrition, physical activity, stress management skills, and self-monitoring. All taught by professional facilitators (nutritionists, exercise trainers, health coaches, and psychotherapists). Baseline data was collected
61994545|NCT02705677||MECP2 Duplication disorder|This is a biobanking project for individuals with MECP2 duplications to understand the difference in the size of the duplication and the potential impact of other genes in the duplicated segment. No interventions are anticipated.
62561688|NCT00837148|EXPERIMENTAL|Sorafenib and Dacarbazine|This study is an open label, single arm, Simon two stage, phase 2 trial of continuous, daily oral sorafenib, with intravenous dacarbazine administered every three weeks for patients with synovial sarcoma, leiomyosarcoma and malignant peripheral nerve sheath tumor.
61994546|NCT02705677||Rett-related disorders: CDKL5, FOXG1|This is a biobanking project for individuals with mutations in MECP2, CDKL5, and FOXG1 to understand the interplay of mutations in these individuals and the resultant phenotypic expression; for example, individuals with mutations in MECP2 but not meeting diagnostic criteria for Rett syndrome or individuals with mutations in CDKL5 or FOXG1 who may or may not meet diagnostic criteria for atypical Rett syndrome. No interventions are anticipated.
61994547|NCT03547388|EXPERIMENTAL|Single Arm|Additional application of weekly moderate whole-body hyperthermia concurrent to re-irradiation plus chemotherapy
61994548|NCT03411876|EXPERIMENTAL|First ESWT with Oxymizer, second ESWT with CNC|Patients in this study arm first perform the first endurance shuttle walk test (ESWT) with the Oxymizer and the second ESWT with a conventional nasal cannula (CNC).
61994549|NCT03411876|EXPERIMENTAL|First ESWT with CNC, second ESWT with Oxymizer|Patients in this study arm first perform the first endurance shuttle walk test (ESWT) with the CNC and the second ESWT with the Oxymizer.
61994550|NCT03634787||Acute pancreatitis|First time acute pancreatitis. No later than 2 days since the clinical symptoms started.
61994551|NCT03634787||Healthy|No major systemic illness
61994552|NCT04512248|EXPERIMENTAL|Quit and Stay Quit Monday Model|
61994553|NCT04512248|NO_INTERVENTION|Usual Care|
61994554|NCT06065826||subjects with myogenic TMD|"Subjects diagnosed as myogenic TMD according to the presence of trigger points in masseter, temporalis, upper trapezius and C5-C6 articular pillars Subjects are heavy smartphones users, using the SAS-SV, the cuffof value for males is 31 and for females is 33.~Subjects have forward head posture assessed by CVA \<49.9 degrees"
61994555|NCT06065826||subjects without myogenic TMD|"Subjects are heavy smartphones users, using the SAS-SV, the cuffof value for males is 31 and for females is 33.~Subjects have forward head posture assessed by CVA \<49.9 degrees"
61994556|NCT04470999|EXPERIMENTAL|Single arm|Venous blood and apheresis collection will be conducted
62168505|NCT04143737|NO_INTERVENTION|Control|22 women participated in the control group. They were recruited from a community center in the old city of Jerusalem and did not receive any intervention. Baseline data was collected.
62168506|NCT04284774|EXPERIMENTAL|Treatment (tipifarnib)|Patients receive tipifarnib PO or via nasogastric or gastric tube BID on days 1-7 and 15-21. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo tumor disease evaluation with PET scan, CT scan, MRI, or MIBG scintigraphy throughout the trial. Patients may undergo bone marrow aspiration or biopsy at baseline, or if there is suspicion of bone marrow metastasis, or when a complete or partial response is identified, or if there is disease progression in the marrow suspected. Patients may undergo blood specimen collections throughout the trial.
62561689|NCT03322202|EXPERIMENTAL|Motivational Interviewing|Physical and Occupational Therapists will have 16 hours of training in Motivational Interviewing and use these techniques during sessions with patients.
62769558|NCT00921310|EXPERIMENTAL|Phase I Dose Level -1 (pemetrexed + temsirolimus)|"* Pemetrexed (375 mg/m\^2) IV on Day 1 of each 21 day cycle~* Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle"
62769559|NCT00921310|EXPERIMENTAL|Phase 2 (pemetrexed + temsirolimus)|"* Phase 2 dose will be the maximum tolerated dose found in the Phase I portion of the study.~* Pemetrexed (375 mg/m\^2) IV on Day 1 of each 21 day cycle~* Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle"
61994557|NCT05269693|EXPERIMENTAL|the Brief Hope Intervention group|The BHI consisted of 4 one-on-one sessions: 2 (1 hr) face- to-face sessions, and 2 (30 min) telephone follow-up sessions in-between.
61994558|NCT05269693|NO_INTERVENTION|wait-listed control group|Usual community care
61994559|NCT05316012|EXPERIMENTAL|Residents|"5 residents - fase 1 Intervention device: smart diaper (diaper, sensor and strips, without alerting system).~15 residents -fase 2, of which 5 residents of study phase 1 Intervention device: smart diaper (diaper, sensor and strips, with alerting system)"
62168507|NCT05115136|EXPERIMENTAL|Doxepin|25mg PO one time
62561690|NCT03322202|NO_INTERVENTION|Control|Therapists will not participate in additional training.
62769560|NCT04610736|EXPERIMENTAL|Single arm|Temozolomide 40 mg/ml, Oral suspension
62769561|NCT00689754|ACTIVE_COMPARATOR|NGA|Patients will receive the standard of care to proceed with nasogastric tube placement, aspiration and lavage up to 1L of normal saline
62769562|NCT00689754|NO_INTERVENTION|NO NGA|Patient presenting with Upper GI hemorrhage going straight to endoscopy.
61994560|NCT06298175|EXPERIMENTAL|Intervention Group|The study group received 8 weeks of self-management training. Reflections, prepared using Power Point, were used in all sessions. The study employed various methods, including the question-answer and audio-visual methods, as well as performance feedback when necessary during the sessions. Final evaluations were conducted for both groups after eight weeks.
61994561|NCT06298175|ACTIVE_COMPARATOR|Control Group|The control group was informed about self-management for 1 week. General information was given about approaches to improving self-management. Final evaluations were conducted for both groups after eight weeks.
62168508|NCT05115136|ACTIVE_COMPARATOR|Diphenhydramine|50mg PO one time
62168509|NCT03390270||Patients with NSTEMI|All patients admitted to Duke University Hospital with an NSTEMI
62168510|NCT01372826|EXPERIMENTAL|NKTR118 Group1|Normal Renal Function
62168511|NCT01372826|EXPERIMENTAL|NKTR118 Group 2|Moderate Renal Function
62168512|NCT01372826|EXPERIMENTAL|NKTR118 Group 3|Severe Renal Impairment
62390007|NCT00211536|EXPERIMENTAL|MiniMed Implantable insulin Pump (MIP)|The experimental group will receive intraperitoneally (IP) delivered insulin via the Medtronic MiniMed Implantable Pump (MIP). At the time of implant, the pump will be filled with Aventis HOE21PH U400 insulin and the subject will be treated with this insulin for the first 180 days post implant. During the refill procedure performed 180 days post implant, any insulin remaining in the pump will be removed and the pump will be refilled with Medtronic MiniMed Implantable Pump Human Recombinant Insulin.
62390008|NCT00211536|NO_INTERVENTION|Subcutaneous insulin arm (SC)|The control group will remain on their current pre-study subcutaneous insulin therapy of either Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII - external insulin pump). The SC group will not be restricted to the type of insulin used, or be required to change or modify their current diabetes therapy for the purpose of the study.
62390009|NCT02184520|ACTIVE_COMPARATOR|TRANSITION|Stabilization System
62390010|NCT02184520|ACTIVE_COMPARATOR|REVERE|Stabilization System
62769563|NCT04055454|EXPERIMENTAL|MV-LASV low dose: treatment group A|In total 24 participants will receive two low dose treatments with MV-LASV on day 0 and 28.
62769564|NCT04055454|EXPERIMENTAL|MV-LASV high dose: treatment group B|In total 24 participants will receive two high dose treatments with MV-LASV on day 0 and 28.
62769565|NCT04055454|PLACEBO_COMPARATOR|Placebo: treatment group C|In total 12 participants will receive placebo treatment on day 0 and 28.
62769566|NCT00457223|EXPERIMENTAL|1Fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®)
62769567|NCT00457223|ACTIVE_COMPARATOR|2 Suture|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using continuous suture with nylon 10-0
62769568|NCT02282904|EXPERIMENTAL|CGD Recipient|CGD patients that will undergo haplo transplantation with post-transplant cyclophosphamide as described
62769569|NCT00624416|OTHER|Prednisolone and Isoproteronol Together|Beta-adrenergic agonists and corticosteroid
62769570|NCT01077089||Transported TBI patients|Traumatically brain injured patients undergoing in-hospital transport.
62769571|NCT06391853|EXPERIMENTAL|Intranasal Insulin then Placebo|"First day , participant will receive Intranasal Insulin (100IU insulin/ml) 2 spray representing 0.8 ml in each nostril to achieve 1.6 ml (total dose =160UI)~Second day participant will receive Placebo Intranasal , witch is saline solution (Nacl 0.9%). 2 spray representing 0.8 ml in each nostril to achieve 1.6 ml"
62769572|NCT06391853|ACTIVE_COMPARATOR|Placebo then Intranasal Insulin|"First day ,participant will receive Placebo Intranasal , witch is saline solution (Nacl 0.9%). 2 spray representing 0.8 ml in each nostril to achieve 1.6 ml~Second day, participant will receive Intranasal Insulin (100IU insulin/ml) 2 spray representing 0.8 ml in each nostril to achieve 1.6 ml (total dose =160UI)"
62168513|NCT01372826|EXPERIMENTAL|NKTR118 Group 4|End-Stage Renal Disease
62168514|NCT06646978||Patients with chronic myeloid leukaemia included in the French imatinib-based SPIRIT trial|
62168515|NCT05401201|EXPERIMENTAL|Study group|Subjects in the study group will use the Lumoral device five to seven times a week according to the verbal and written instructions provided to them. In addition, they will brush their teeth twice daily in their customary manner while using the provided sonic toothbrush and regular toothpaste.
62390011|NCT03341091|EXPERIMENTAL|Tai-chi group|"16-week 10-step simplified Tai-chi programme.~Two 1-hour sessions of centre-based Tai-chi training and a minimum of three 30-minute Tai-chi sessions at home on a weekly basis."
62390012|NCT03341091|NO_INTERVENTION|Control group|"Group recreational activities and continue their usual lifestyles and levels of physical activity as usual for 16 weeks.~Two 1-hour sessions of group recreational activities on a weekly basis."
62390013|NCT01735552||Infants requiring PRBCs|Premature infants who require PRBCs for anemia that is not related to sepsis, surgery, NEC or immunologic abnormalities.
62168516|NCT05401201|ACTIVE_COMPARATOR|Control group|Subjects in the control group will brush their teeth in their customary manner twice daily while using the provided sonic toothbrush and regular toothpaste. They will not receive any additional intervention.
62168517|NCT00374673|EXPERIMENTAL|transcranial magnetic stimulation|repetitive transcranial magnetic stimulation of the motor cortex
62168518|NCT00374673|SHAM_COMPARATOR|placebo stimulation|repetitive placebo stimulation of the motor cortex
62168519|NCT04016571||Adults with Cystic Fibrosis|"All Adults with a confirmed diagnosis of Cystic Fibrosis being admitted for Intra-Venous Antibiotic Treatment of a Pulmonary Exacerbation~This study is observational so no intervention will be carried out."
62390014|NCT00824759|PLACEBO_COMPARATOR|placebo|
62390015|NCT00824759|ACTIVE_COMPARATOR|oxygen|
62390016|NCT01682694|EXPERIMENTAL|Glucosamine and Chondroitin|Glucosamine and Chondroitin
62390017|NCT01682694|PLACEBO_COMPARATOR|Placebo|Inactive ingredients
62168520|NCT03824353|EXPERIMENTAL|Social Intelligence Training|The social intelligence training is delivered online to individuals in midlife (ages 40 and older). This is the sole active treatment condition within this RCT.
62168521|NCT03824353|PLACEBO_COMPARATOR|Attention Control|The attention control condition, known as The Healthy Living program provides information about different aspects of health.
62168522|NCT05969119|EXPERIMENTAL|Pyridostigmine|Parturients with postoperative PDPH and a VAS score of ≥5 will receive either 60 mg oral Pyridostigmine every 6 hours.
62561691|NCT02851628|EXPERIMENTAL|Alternative sizing model trial mask|In this arm participants who are randomized to the alternative sizing model based mask will be given the alternative sizing model based mask to use in home for the duration of this arm.
62561692|NCT02851628|ACTIVE_COMPARATOR|Prototype Full Face Mask (PFFM)|In this arm, participants who are randomized to the PFFM will be given the PFFM to use in-home for the duration of this arm.
62168523|NCT05969119|PLACEBO_COMPARATOR|Placebo|Parturients with postoperative PDPH and a VAS score of ≥5 will receive placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
62168524|NCT05607732|EXPERIMENTAL|MyCog Paradigm|The MyCog paradigm establishes a protocol for implementing our self-administered assessment in the clinic whenever a patient or involved family member reports a concern. The MyCog test can be completed either in the exam room or the waiting room. The MyCog app, on an iPad, can be readily linked to the electronic health record, so once the two tests are completed, results are securely transmitted and will populate within discrete, fields that can be queried found in the patient record; specifically: 1) in a screening tab, under 'cognitive abilities', 2) a flow sheet to capture trend with future repeated tests - informing physicians of a patient's relative vs. normative cognitive decline. Both a binary, objective classification of 'impairment detected or suspected' or 'no impairment detected' will populate in the record, as well as a summary score to further guide the clinician by clarifying the extent to which a patient's performance falls outside a normal threshold.
62390018|NCT03198585|ACTIVE_COMPARATOR|Empagliflozin 10 mg|
62390019|NCT03198585|PLACEBO_COMPARATOR|Placebo|
62769573|NCT02517671|OTHER|EECP Treatment|35 one hour (1hr) sessions of Enhanced External Counterpulsation (EECP).
62769574|NCT01638104|EXPERIMENTAL|ANX-042: 0.001 mcg/kg/min (with low sodium diet)|0.001 dose unit equal to 1 millionth of a gram of an ANX-042 preparation / 1 kilogram of body mass administered / unit of time equal to 1 minute(mcg/kg/min), w/ diet restricted to 2.5 grams (gm) per day sodium (Na+) and 2.1 liters (L) fluid total daily intake
62769575|NCT01638104|EXPERIMENTAL|ANX-042: 0.001 mcg/kg/min|0.001 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
62390020|NCT06221722||Refractory constipation: fluoxetine sensitive|"Functional constipation patients maintained at least 3 months of continuous regular therapy with ineffective treatment. The treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.~After 3 months of regular treatment, patients received fluoxetine therapy for 4-week with effective treatment of constipation symptoms."
62390021|NCT06221722||Refractory constipation: fluoxetine insensitive|"Functional constipation patients maintained at least 3 months of continuous regular therapy with ineffective treatment. The treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.~After 3 months of regular treatment, patients received fluoxetine therapy for 4-week with ineffective treatment of constipation symptoms."
62390022|NCT06221722||Non-refractory constipation|Functional constipation patients maintained at least 3 months of continuous regular therapy with effective treatment. The treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.
62390023|NCT06221722||Health Control|Volunteers without symptoms of constipation
62390024|NCT05331144|EXPERIMENTAL|Intensive Treatment (IT)|Lowering SBP \< 120 mmHG
62390025|NCT05331144|ACTIVE_COMPARATOR|Usual Care (UC)|Participants will follow their PCP's recommendations for BP control
62390026|NCT01465984|EXPERIMENTAL|IV Paracetamol|
62390027|NCT01465984|ACTIVE_COMPARATOR|IV Morphine Sulfate|
62390028|NCT00224952||Patients receiving Carbamazepine or Valproic Acid|
62390029|NCT06152367|EXPERIMENTAL|TAPCells|Patients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination.
62390030|NCT06167031|EXPERIMENTAL|Chatbot-facilitated Group|
62561693|NCT05021900|EXPERIMENTAL|Tenalisib 800 mg BID|Single agent at a dose of 800 mg BID
62561694|NCT05021900|EXPERIMENTAL|Tenalisib 1200 mg BID|Single agent at a dose of 1200 mg BID
62769576|NCT01638104|EXPERIMENTAL|ANX-042: 0.003 mcg/kg/min (low sodium diet)|0.003 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
62769577|NCT01638104|EXPERIMENTAL|ANX-042: 0.003 mcg/kg/min|0.003 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
62769578|NCT01638104|EXPERIMENTAL|ANX-042: 0.0065 mcg/kg/min (low sodium diet)|0.0065 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
62769579|NCT01638104|EXPERIMENTAL|ANX-042: 0.01 mcg/kg/min (low sodium diet)|0.01 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
62561695|NCT05828381|EXPERIMENTAL|Envafolimab combination with Abraxane and cisplatin|Arm description：Envafolimab:300mg,sc,d1,q3w; for a total of 2 cycles. Chemotherapy： Abraxane + Cisplatin Abraxane :100mg/m2,ivgtt, D1、D8,q3w ,for a total of 2 cycles. Cisplatin : 75 mg/m 2 vigtt D1 , q3w , for a total of 2 cycles.
62390031|NCT06167031|ACTIVE_COMPARATOR|Controlled Group|
62182715|NCT05096078|EXPERIMENTAL|Exercise Group|In addition to the 6-week diet program that the dietitian deems appropriate, a circuit exercise program will be applied for 6 weeks. The circuit exercise program will consist of a medium-intensity circuit training for 50 minutes, 3 days a week, detailing the main muscle groups of the patients (chest, back, biceps, triceps, deltoid, quadriceps, thigh and calf muscles). Exercise intensity will be monitored using Borg's scale of perceived exertion, with a target intensity of 12 to 14. 8 exercises will be given in a continuous, circuit-type manner with short 1-minute rests.
62390032|NCT02013999|EXPERIMENTAL|Virtual reality program|mobile device for virtual reality program
62390033|NCT02013999|ACTIVE_COMPARATOR|Control|standard occupuational therapy
62390034|NCT03161184|ACTIVE_COMPARATOR|Control (paper based)|"Women received prenatal household visits from CHWs who were trained on the Tanzania Ministry of Health and Social Welfare's National integrated Maternal, Newborn and Child Health (i-MNCH) paper-based protocols, i.e. received intervention SUSTAIN Paperbased training of CHW (SOC)"
62390035|NCT03161184|EXPERIMENTAL|Intervention (Smart phone assisted)|"Women received prenatal household visits from CHWs trained on the following:~A) National i-MNCH programme; and B) Smartphone-assisted counseling protocol: a smartphone application designed to assist with identification of danger signs during pregnancy, referral to health facilities, and MNCH counseling~, i.e. received intervention SUSTAIN Smartphone training of CHW (SP+)"
62390036|NCT05281146|ACTIVE_COMPARATOR|chickpea and peanuts biscuits dependent group|children aged 8- 12 years attending the village school. This group received one daily pack of three fortified biscuits as snakes between breakfast and lunch on daily basis for four months.
62390037|NCT05281146|ACTIVE_COMPARATOR|The chickpea and crushed peanut biscuits non-dependent group|Matched age and sex children attending the same village school. This group did not receive the fortified biscuits but received their ordinary usual breakfasts or snacks for four months.
62390038|NCT00977366|ACTIVE_COMPARATOR|Hydrochloric acid infusion|
62390039|NCT00977366|PLACEBO_COMPARATOR|Saline|
62390040|NCT03765554|EXPERIMENTAL|PF-06700841: IR followed by MR|Participants receive PF-06700841 Immediate release tablets (IR) followed by PF-06700841 Modified release tablets (MR)
61994562|NCT01087047||Physiological modifications|Pregnant women who attend the routine ultrasound control in our institution before 14 weeks of pregnancy
61994563|NCT01087047||MRI and acoustic|Women undergoing an MRI for obstetrical purpose
61994564|NCT01998048|ACTIVE_COMPARATOR|Latarjet|60 patients treated with open Latarjet operation
61994565|NCT01998048|ACTIVE_COMPARATOR|Bankart|60 patients treated with arthroscopic Bankart operation
62390041|NCT03765554|EXPERIMENTAL|PF-06700841: MR followed by IR|Participants receive PF-06700841 Modified release tablets (MR) followed by PF-06700841 Immediate release tablets (IR)
62390042|NCT05152836|EXPERIMENTAL|Vibrotactile stimulation atdifferent settings|All participants receive vibrotactile stimulation at three different stimulation settings as well as one sham condition. Specifically, stimulation is applied at (1) brief bursts of 80Hz that occur at the individual tremor frequency, (2) 80Hz bursts at tremor frequency\*1.5, and (3) continuous stimulation at 80Hz. The sham condition does not involve any stimulation. All of the stimulations will be applied under three different contextual manipulations: during rest, posture and cognitive coactivation (serial subtraction task). Within each context, stimulation/sham conditions are applied in random order.
62390043|NCT01979692|EXPERIMENTAL|One arm ; CLM use in TTNB|"1. to determine the feasibility of using the CLM in performing TTNB of thoracic and mediastinal lesions~2. to obtain imaging criteria for distinguishing viable from non viable (necrotic) tissue and normal versus abnormal (inflammatory/malignant) lesions. On site rapid cytological examination (ROSE) will be the standard of biopsy quality.~3. the results will be compared to historic data of standard biopsies as to yield and quality of sampling"
62390044|NCT05403775|EXPERIMENTAL|3D printing guide plate group|3D-printed customized guide plate will be used to guide the puncture in TFESI combined with dorsal root ganglion PRF.
62390045|NCT05403775|ACTIVE_COMPARATOR|Conventional guidance group|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy.
62769580|NCT01638104|EXPERIMENTAL|ANX-042: 0.01 mcg/kg/min|0.01 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
62561696|NCT03866889|EXPERIMENTAL|Strength|Maximum strength protocol based on a Maximum Repetition (1RM). The aim of the application of the training is to produce an increase in strength based on training with high loads (80% 1RM), individually and covering the muscles of the lower extremity (quadriceps, hamstrings, gluteus maximus).
62168525|NCT05607732|NO_INTERVENTION|Usual Care Arm|At Oak Street Health, cognitive assessments included when concerns are reported by patients or family members, if a clinician suspects a concern, or during Annual Wellness Visits (AWVs) are limited to the Mini-Cog©, and are variably administered, particularly outside of AWVs. Oak Street practices vary by clinician in terms of making referrals, how results are documented, what diagnosis code, placement in problem list or visit diagnosis, and any follow-up plans. While we will not make any explicit recommendations to usual care practices regarding their use of a cognitive assessment, we will ensure that 1) any chosen test is linked to a data field that can be queried in the EHR, and 2) providers receive a compiled list of local medical and non-medical referrals for any detected cases of CI. The Alzheimer's Association recommendations for early detection efforts among primary care practices will be provided to each clinical leadership.
62168526|NCT01621321|EXPERIMENTAL|Steroid group|
62168527|NCT01621321|EXPERIMENTAL|Voriconazole group|
62561697|NCT03866889|ACTIVE_COMPARATOR|Normal activity|The subjects included in the control group will perform the same physical activity to improve the strenght until the beginning of the study. The exercises will be done in the same conditions and with the same period (4 days / week)
62561698|NCT04466280|ACTIVE_COMPARATOR|Control Group|Participants in this group use personal protective equipment in the face of patients with COVID-19
62561699|NCT04466280|EXPERIMENTAL|Intervention Group 1|In this group, participants will receive 200 mg of hydroxychloroquine tablets daily in addition to personal protective equipment.
62561700|NCT04466280|EXPERIMENTAL|Intervention Group 2|In this group, participants, while observing and using complete personal protective equipment, will apply a thin layer of Dentol gel to the vestibular area of the mouth daily, every 6 to 8 hours.
62561701|NCT02603289||Teen|\< 17 years of age
62561702|NCT02603289||Adult|17 years of age or older
62769581|NCT01638104|EXPERIMENTAL|ANX-042: 0.03 mcg/kg/min|0.03 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
62168528|NCT03074097|ACTIVE_COMPARATOR|Rectus Sheath|Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
62168529|NCT03074097|NO_INTERVENTION|Control|Control group: the patients did not receive any intervention after anaesthesia induction.
62769582|NCT01638104|EXPERIMENTAL|ANX-042: 0.1 mcg/kg/min|0.1 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
62769583|NCT01638104|EXPERIMENTAL|ANX-042: 0.3 mcg/kg/min|0.3 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
62168530|NCT02415335|PLACEBO_COMPARATOR|Placebo|Injection of 2 ml isotonic NaCl intravenously minimum 30 minutes preoperative.
62168531|NCT02415335|EXPERIMENTAL|dexamethasone|Injection of 2 ml 4 mg/ml dexamethasone phosphate intravenously minimum 30 minutes preoperative.
62168532|NCT06246227||High Risk Melanoma Patients|Patients followed-up for Melanoma, Clinical Stages IIB - III and Resected Stage IV
62168533|NCT03138616|EXPERIMENTAL|vitamin D intervention group(NGR)|"normal glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~took 1600 units of vitamin D daily for nine months and meanwhile receive lifestyle intervention."
62561703|NCT02603289||Adult with Primer Aligners|17 years of age or older This group will get Primer Aligners
62561704|NCT02721342||Ramipril, Irbesartan and Atorvastin treatment|A multidrug approach, including Angiotensin II Converting Enzyme (ACE) inhibitor, Ramipril, and Angiotensin II Receptor Blocker (ARB), Irbesartan, and Atorvastin will be done. Treatment doses of drugs will be up-titrated gradually considering the tolerability.
62561705|NCT01942993|EXPERIMENTAL|Vemurafenib|960 mg (four tablets of 240 mg each) of vemurafenib PO BID
62561706|NCT05138861|EXPERIMENTAL|TP-03 (Lotilaner Ophthalmic Solution), 0.25%|TP-03, topical ocular administration in healthy adults. Single and multiple doses for 42 days.
62561707|NCT02012322|OTHER|Placebo vs. Q10 100mg vs. Q10 300mg|
62561708|NCT02012322|OTHER|Placebo vs. Q10 300mg vs. Q10 100mg|
62561709|NCT02012322|OTHER|Q10 100mg vs. Placebo vs. Q10 300mg|
62561710|NCT02012322|OTHER|Q10 100mg vs. Q10 300mg vs. Placebo|
62561711|NCT02012322|OTHER|Q10 300mg vs. Placebo vs. Q10 100mg|
62561712|NCT02012322|OTHER|Q10 300mg vs. Q10 100mg vs. Placebo|
62769584|NCT01638104|PLACEBO_COMPARATOR|Placebo (low sodium diet)|Placebo and diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
62769585|NCT01638104|PLACEBO_COMPARATOR|Placebo|Placebo and diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
62561713|NCT05327400||pancreatic cancer patients|pathologically confirmed pancreatic cancer patients
62769586|NCT04689152|NO_INTERVENTION|Control group|Best Supportive care
62769587|NCT04689152|EXPERIMENTAL|Injection group: Cellgram-LC|Within 1 month after extracting bone marrow, directly inject 7X10\^7 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery.
62769588|NCT05527886|EXPERIMENTAL|Group 1|Randomized AAROM, Slow Load, or Plyometric intervention
62769589|NCT05527886|EXPERIMENTAL|Group 2|Randomized AAROM, Slow Load, or Plyometric intervention
62390046|NCT05943548|EXPERIMENTAL|Omuyambi Traditional Healer (TH) Intervention|The traditional healer (TH) clusters randomized to the intervention arm will refer consented people living with HIV to a predetermined government-run HIV clinic for the provision of care. The patients that are in this arm will receive, adherence support for PLWH using a TH-tailored curriculum as an adjunct to clinic-based HIV care. These participants will also receive one-on-one counselling to improve self-efficacy, be provided social support, and will work with THs to develop individualized adherence strategies.
62390047|NCT05943548|PLACEBO_COMPARATOR|Control Arm|The traditional healer (TH) clusters randomized to the control arm will refer consented people living with HIV to a predetermined government-run clinic for the provision of care. The patients in this arm will receive no additional linkage or psychosocial support.
62390048|NCT03061617|OTHER|volume controlled ventilation (VCV)|VCV mode, tide volume 6ml/kg, f 12-14, set fixed tide volume for each breath
62390049|NCT03061617|EXPERIMENTAL|pressure controlled ventilation (PCV)|PCV mode, pressure is adjusted to achieve tide volume 6ml/kg, f 12-14
62390050|NCT00561028||1|ST-elevation acute myocardial infarction.
62390051|NCT00561028||2|high-risk unstable angina or non-ST-elevation myocardial infarction.
62390052|NCT00561028||3|known coronary artery disease, either asymptomatic or with stable angina.
62390053|NCT00561028||4|blood donors without known coronary artery disease.
62390054|NCT04067076||Students of IEMS of Mexico City|Students currently enrolled in the academic year 2019-2020 from the 24 IEMS centers of Mexico City
62390055|NCT02508012|EXPERIMENTAL|Immuno monitoring|in case of loss of response, the clinician uses immunomonitoring data to adapt the treatment following a treatment algorithm.
62390056|NCT02508012|NO_INTERVENTION|No immuno monitoring|in case of loss of response, immunomonitoring data are not transmit to the clinician who adapts the treatment with classical biological informations.
62390057|NCT01654224|ACTIVE_COMPARATOR|High Dose Inactivated Influenza Vaccine|For HDIV,0.5 ml of high dose inactivated influenza vaccine consisting of a total of 180mcg (60 mcg each strain) of influenza virus hemagglutinin
62390058|NCT01654224|ACTIVE_COMPARATOR|Standard Dose Inactivated Influenza Vaccine|For SDIV, 0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg of each strain) of influenza virus hemagglutinin
62390059|NCT00768365||group 1|patients with adrenal incidentaloma
62390060|NCT00768365||group 2|Thirty-five subjects comparable for sex, age, and BMI were enrolled as a control group (group 2).
62390061|NCT00768365||group 3|The other control group (group 3) of 35 healthy individuals matched for sex, age, BMI, metabolic syndrome criteria, cardiovascular risk parameters, menopausal status, smoking status, consumption of alcohol, usage of antihypertensive drugs, insulin or oral hypoglycaemic agents to perform a 1:1 case-control analysis.
62390062|NCT05505487|NO_INTERVENTION|control group|Implement routine nursing such as: routine oral nursing, tracheostomy, dressing change, sputum suction nursing, oral education, etc.
62390063|NCT05505487|EXPERIMENTAL|intervention group|Implement comprehensive nursing models such as: admission risk assessment, personalized oral care based on beck oral score, aspiration prevention, airway care, diversified health education
62390064|NCT03815201|PLACEBO_COMPARATOR|Group 1|exercise training program: 2 non-consecutive days per week during 12 weeks plus placebo ingestion post-training
62390065|NCT03815201|ACTIVE_COMPARATOR|Group 2|exercise training program: 2 non-consecutive days per week during 12 weeks plus leucine-enriched protein supplementation post-training
62390066|NCT01724021|EXPERIMENTAL|Arm A|Participants in Arm A received one cycle of rituximab 375 mg/m\^2 intravenously (IV), then three cycles of rituximab 1400mg subcutaneously (SC), followed by four cycles of rituximab 375 mg/m\^2 IV in combination with a standard chemotherapy of cyclophosphamide, hydroxydaunorubicin, Oncovin, prednisone/prednisolone (CHOP), cyclophosphamide, vincristine, prednisone/prednisolone (CVP), or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
62390067|NCT01724021|EXPERIMENTAL|Arm B|Participants in Arm B received four cycles of rituximab 375 mg/m\^2 IV followed by four cycles of rituximab 1400mg SC in combination with a standard chemotherapy of CHOP, CVP, or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
62390068|NCT01763099|EXPERIMENTAL|Mesenchymal stem cells|Mesenchymal stem cells group refers to treatment with mesenchymal stem cells (1×10\^6 cells/kg, intravenously)
62390069|NCT01763099|EXPERIMENTAL|Mesenchymal stem cells and cord blood|Mesenchymal stem cells and cord blood group refers to treatment with mesenchymal stem cells (at a dose of 1×10\^6 cells/kg) and cord blood
62390070|NCT03379324|ACTIVE_COMPARATOR|Superiority of augmented repairs|Assess pain, function, and structural integrity of the rotator cuff at 3 months, 6 months, 1 year, and 2 years post-operation
62390071|NCT03379324|ACTIVE_COMPARATOR|Fat degeneration of supraspinatus muscle|MRI assessment the quantity and disposition of fat within the supraspinatus muscle body compared to pre-operation MRI, at 1 year and 2 years post-operation
62390072|NCT02769689|EXPERIMENTAL|Methylprednisolone|The primary purpose of this protocol is to investigate the impact of high dose of oral methylprednisolone, given once a month during the washout period between NTZ and Fingolimod (FTY).
62390073|NCT02769689|PLACEBO_COMPARATOR|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
62168534|NCT03138616|NO_INTERVENTION|control group(NGR)|"normal glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~only receive lifestyle intervention."
62168535|NCT03138616|EXPERIMENTAL|vitamin D intervention group(IGR)|"impaired glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~took 1600 units of vitamin D daily for nine months and meanwhile receive lifestyle intervention."
62168536|NCT03138616|NO_INTERVENTION|control group(IGR)|"impaired glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~only receive lifestyle intervention."
62561714|NCT05327400||healthy people|people without no neoplastic lesions and other organic diseases
62561715|NCT03526328||DCLK1 post BE treatment|Effects of EMR and RFA on the expression of putative stem cell biomarkers and correlate them with serum/plasma protein expression and disease progression and/or recurrence (Barrett's esophagus/ esophageal adenocarcinoma)
62561716|NCT05494996||Questionnaires assessed partners|"1. ≥18 years old;~2. Participants who are married or in a romantic relationship;~3. Be able to read and communicate in Chinese."
62561717|NCT02041819|EXPERIMENTAL|Nimotuzumab nab-paclitaxel cisplatin|"Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22.~Nab-paclitaxel: 125mg/m2,IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
62561718|NCT03142477|OTHER|Control|Control group patients will not receive any interventions with therapeutic touch. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
62168537|NCT05001815|EXPERIMENTAL|Continuous subcutaneous insulin infusion (CSII)|Patients with indications will receive continuous subcutaneous insulin infusion (CSII) treatment achieved by patch insulin pump devices.
62168538|NCT05001815|ACTIVE_COMPARATOR|Multiple daily insulin injection (MDI)|Patients with indications will receive traditional multiple daily insulin injection (MDI) treatment.
62168539|NCT04349124|OTHER|Treatment Group|The treatment group will be provided with month supply of 30mg tablets of nifedipine extended release prior to discharge from the delivery admission. Dose increases in clinic will be at the discretion of providers, however a treatment algorithm will be provided for guidance.Treatment group will be given a home blood pressure cuff prior to discharge with instructions for use. They will also be scheduled for a 1 week blood pressure check and 4 week postpartum clinic appointment which standard for these patients outside of this proposal.
62390074|NCT06010264|EXPERIMENTAL|Kinesiotaping group|Kinesiotaping + Standard Physiotherapy Program
62390075|NCT06010264|ACTIVE_COMPARATOR|Control group|Standard Physiotherapy Program
62390076|NCT06010264|SHAM_COMPARATOR|Shamtape Group|Shamtaping + Standard Physiotherapy Program
62390077|NCT04043676|EXPERIMENTAL|Ponatinib Treatment|Patients will be treated with 15 mg/day of ponatinib during 48 weeks. If a patient maintains MR4 throughout the 48 weeks, he/she will be eligible to start the ponatinib TFR phase. If a patient has confirmed loss of MR4 (two consecutive BCR-ABL \> 0.01% IS) or loss of MMR (no confirmation needed), he/she will not be eligible for the TFR phase. Instead, he/she will restart imatinib treatment.
62182716|NCT03272529||Patient-specific simulated rehearsals|Participants recruited to this cohort will complete just-in-time simulation, i.e., practice a short time prior to the live event using hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. This is in addition to standard prerequisite simulation training.
62390078|NCT01397409|EXPERIMENTAL|Stage 1: AGN-150998 4.2 mg|Stage 1: AGN-150998 4.2.mg given as a single intravitreal injection.
62390079|NCT01397409|EXPERIMENTAL|Stage 1: AGN-150998 3.0 mg|Stage 1: AGN-150998 3.0 mg given as a single intravitreal injection.
62390080|NCT01397409|EXPERIMENTAL|Stage 1: AGN-150998 2.0 mg|Stage 1: AGN-150998 2.0 mg given as a single intravitreal injection.
62390081|NCT01397409|EXPERIMENTAL|Stage 1: AGN-150998 1.0 mg|Stage 1: AGN-150998 1.0 mg given as a single intravitreal injection.
62561719|NCT03142477|PLACEBO_COMPARATOR|Placebo|Placebo patients group patients will receive the therapeutic touch intervention by a graduate student without any therapeutic touch training. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
62561720|NCT03142477|EXPERIMENTAL|Treatment|Treatment patients group patients will receive the therapeutic touch interventions with a trained therapeutic touch professional. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
62561721|NCT05714592|EXPERIMENTAL|Optical genome mapping|
62561722|NCT00089804|ACTIVE_COMPARATOR|1|300 mg (three 2 mL vials of abetimus sodium plus six 2 mL vials of normal saline) administered i.v (in the vien) weekly
62561723|NCT00089804|ACTIVE_COMPARATOR|2|900 mg (nine 2 mL vials of abetimus sodium) administered i.v. (in the vein) weekly
62168540|NCT04349124|NO_INTERVENTION|Control Group|The control group will not receive any medications at discharge. Providers will be instructed to only prescribe new blood pressure medication at subsequent postpartum visits if the blood pressure is in the severe range (\>/=160/110). The control group will be given a home blood pressure cuff prior to discharge with instructions for use. They will also be scheduled for a 1 week blood pressure check and 4 week postpartum clinic appointment which standard for these patients outside of this proposal.
62561724|NCT00089804|PLACEBO_COMPARATOR|3|A volume of 18 mL (Nine 2 mL vials) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly
62168541|NCT05168696|EXPERIMENTAL|Virtual Reality in Women with Breast Cancer|It is planned to pre-test, wear virtual reality glasses and post-test before chemotherapy for breast cancer women who will receive adjuvant treatment for the first time, who agree to participate in the study. This follow-up will be done 3 more times, and each cure will be followed for 4 cures. It will be ensured that the patients fill out the State Anxiety Scale and Cancer Fatigue Scale as a pre-test and post-test. After the chemotherapy infusion starts, the patient will listen and watch the relaxing beach and nature content with 360 degrees for 30 minutes with virtual reality glasses attached to the patient.
62168542|NCT05168696|NO_INTERVENTION|Standard Care in Women with Breast Cancer|Women with breast cancer who will receive adjuvant treatment for the first time, who agree to participate in the study, will be pre-tested before chemotherapy and a post-test will be performed 30 minutes after the start of chemotherapy treatment by the nurse. This follow-up will be done 3 more times, and each cure will be followed for 4 cures. It will be ensured that the patients fill out the State Anxiety Scale and Cancer Fatigue Scale as a pre-test and post-test.
62168543|NCT02000232||Diagnosis with Gout and use of colchicine|Observational study age 18+
62168544|NCT05555849||Study group, Newly retired elite athletes|Elite athletes at the time of retirement of professional career. Reinvestigated after three months and thereafter yearly.
62561725|NCT03412721|EXPERIMENTAL|Laser analgesia|Procedure: Laser analgesic procedure Performing protocol for pre-emptive laser analgesia with Er:YAG laser (Litetouch, Syneron) switched on.
62561726|NCT03412721|PLACEBO_COMPARATOR|Placebo analgesia|Procedure: Placebo analgesic procedure Performing imitation of laser analgesic protocol with Er:YAG laser (Litetouch, Syneron) switched off - no pulse energy applied.
62561727|NCT02789774|EXPERIMENTAL|Surgical treatment|Stabilization of odontoid fracture with posterior fusion C1-C2
62561728|NCT02789774|ACTIVE_COMPARATOR|Conservative treatment|External stabilization of odontoid fracture with a rigid cervical collar for 3 months.
62561729|NCT04492982|ACTIVE_COMPARATOR|Yoga|60 minute sessions of guided yoga in small group format
62561730|NCT04492982|ACTIVE_COMPARATOR|Distress Tolerance|60 minutes sessions of guided didactic distress tolerance skill building in small group format
62168545|NCT06378918|EXPERIMENTAL|puncture/aspiration|The puncture is then carried out using a 16 gauge needle. Antibiotic coverage will be offered.
62561731|NCT04492982|NO_INTERVENTION|Treatment as Usual|Those recruited through Student Health and Wellness will complete the university standard BASICS intervention.
62561732|NCT01880866|EXPERIMENTAL|(-)-Epicatechin|A single dose of 100mg or 200mg (-)-Epicatechin to be administered orally
62561733|NCT06382818|OTHER|COHORT A|In this cohort, the patients with low risk of recurrence and a low risk of breast toxicity
62168546|NCT06378918|ACTIVE_COMPARATOR|abscess incision|The incision is made in the operating room under general or local anesthesia. The intervention is carried out on an outpatient basis but if necessary, short-term hospitalization is carried out. Daily drying is then carried out with nursing care at home until healing.
62168547|NCT06546566|EXPERIMENTAL|Experimental Group|Patients in the experimental group will receive video game-based breathing exercises training for 8 weeks, 5 days a week, 30 minutes a day. The exercise program will consist of 5 breathing games included in the BreathingLabs game kit and each game will be performed in 2 sets of 10 repetitions. In addition to video game-based breathing exercises, coughing techniques and relaxation techniques will be taught and physical activity recommendations will be given.
62561734|NCT06382818|OTHER|COHORT B|"For this cohort, patients with low risk of recurrence and a high risk of breast toxicity, will receive breast radiotherapy according to the investigator's decision among:~* External partial VMAT: 40 Gy in 15 fractions to the partial breast only (tumorectomy bed).~* Exclusive Brachytherapy: 30.1 Gy in 7 fractions or 32.0 Gy in 8 fractions of high-dose-rate brachytherapy in 5 days or as 50 Gy of pulsed-dose-rate brachytherapy over 5 treatment days.~* Whole Breast Normo fractionated IMRT with Fixed Field IMRT Technique: 50 Gy in 25 daily fractions over 5 weeks +/- Sequential (+ 16 Gy/8fr) or SIB (60 Gy/25 fr) treatment for boost if applicable."
62561735|NCT06382818|OTHER|COHORT C|"For this cohort, patients with high risk of recurrence and a low risk of breast toxicity, will receive whole breast and nodes Hypofractionated VMAT and a localized simultaneous boost according to the HypoG01 schema protocol:~VMAT Technique, 42.3 Gy in 18 fractions on all target volume on 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fractions)."
62561736|NCT06382818|OTHER|COHORT D|"For this cohort, patients with high risk of recurrence and a high risk of breast toxicity, will receive breast radiotherapy based on available clinical trials:~- Whole Breast and Nodes Hypofractionated VMAT with adaptive treatment (margin reduction): HypoG01 Schema with VMAT Technique, 42.3 Gy in 18 fractions on all target volume over 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fr) In case of patient refusal or technique unavailable, a standard treatment available in the center for this indication will be delivered."
62390082|NCT01397409|EXPERIMENTAL|Stage 2: AGN-150998 4.2 mg|Stage 2: AGN-150998 4,2 mg (highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
62390083|NCT01397409|EXPERIMENTAL|Stage 2: AGN-150998 3.0 mg|Stage 2: AGN-150998 3.0 mg (one dose below highest tolerated dose) from Stage 1 given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
62561737|NCT03203473|EXPERIMENTAL|Overall cohort: Initial Primary Treatment with Nivolumab (induction phase)|"* Therapy with nivolumab IV every 2 weeks~* Serial imaging assessments every 8 weeks~* After confirmatory scans, patients are assigned to Arm A or Arm B."
62561738|NCT03203473|EXPERIMENTAL|Arm A: Observation Arm (for patients with persistent response to induction nivolumab)|"Patients with persistent response (complete or partial response) to induction nivolumab are assigned to Arm A (Observation Arm).~* Patients discontinued nivolumab after allocation to Arm A.~* Serial imaging assessments every 8 weeks.~* If scans persistently show PR/CR, patients remained on observation.~* If progressive disease develops, therapy with nivolumab (480 mg IV every 4 weeks) will be resumed.~* If there is subsequent progression on nivolumab monotherapy, ipilimumab (1 mg/kg IV every 3 weeks x 2 doses) is added.~* If progression after nivolumab + ipilimumab, therapy discontinued. If SD/PR/CR, nivolumab is continued until progression."
62561739|NCT03203473|EXPERIMENTAL|Arm B: Nivolumab+Ipilimumab then nivolumab alone (for patients with SD/PD to induction nivolumab)|"Patients with confirmed SD/PD to induction nivolumab are allocated to Arm B (Combination Therapy Arm).~* In combination therapy, patients received nivolumab 3 mg/kg and ipilimumab 1 mg/kg intravenously every 3 weeks for two doses.~* After then nivolumab will be continued at 480 mg IV every 4 weeks until disease progression.~* Arm B patients undergo imaging at 12 weeks and then every 8 weeks."
62561740|NCT01656460|EXPERIMENTAL|Stereotactic radiation Arm 1|"Dose Levels/total Dose~1 16 Gy"
62561741|NCT01656460|EXPERIMENTAL|Stereotactic radiation Arm 2|2 20 Gy
62561742|NCT01656460|EXPERIMENTAL|Stereotactic radiation Arm 3|3 24 Gy
62561743|NCT01656460|EXPERIMENTAL|Stereotactic radiation Arm 4|4 28 Gy
62561744|NCT00810212|ACTIVE_COMPARATOR|1|Autograft
62561745|NCT00810212|EXPERIMENTAL|2|Low Dose MPCs
62561746|NCT00810212|EXPERIMENTAL|3|Medium Dose MPCs
62561747|NCT00810212|EXPERIMENTAL|4|High Dose MPCs
62561748|NCT00979654|EXPERIMENTAL|Sifalimumab (MEDI-545) 500 or 600 milligram (mg)|All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
62561749|NCT02767557|EXPERIMENTAL|Tocilizumab & Gemcitabine and nab-Paclitaxel|"Tocilizumab:~8 mg/kg given I. V. on day 1 over 60 minutes every 28 day cycle.~Gemcitabine:~1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.~Nab-Paclitaxel:~125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle."
62561750|NCT02767557|ACTIVE_COMPARATOR|Gemcitabine and nab-Paclitaxel|"Gemcitabine:~1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.~Nab-Paclitaxel:~125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle."
62561751|NCT03558581|NO_INTERVENTION|Control|Patients have not received any special intervention, the follow up care was the standard care for the specific clinic
62561752|NCT03558581|EXPERIMENTAL|Intervention|After initial allocation the select patient received six educational interventions selected from Nursing Intervention Classification (NIC)
62561753|NCT01714830|SHAM_COMPARATOR|sham group|the same protocol is applied but with the probe being turned off.
62561754|NCT01714830|SHAM_COMPARATOR|treatment group|patients will be treated by ESWT once a week for 4 weeks
62561755|NCT04735510|OTHER|Single arm|This is a single arm study in which all subjects will receive study medication.
62561756|NCT06494475|EXPERIMENTAL|Group 1 (coadministration [CA] Group/1 upper limb)|Participants will receive a single placebo dose on Day 1. They will then receive two doses of the GBS-NN/NN2 vaccine on Days 29 and 57, respectively. The second dose on Day 57 will be administered in combination with the Tdap vaccine, with both injections given in the same upper limb.
62561757|NCT06494475|EXPERIMENTAL|Group 2 (CA Group/2 upper limbs)|Participants will receive a single placebo dose on Day 1 and two doses of the GBS NN/NN2 vaccine on Days 29 and 57, respectively. The second dose on Day 57 will be administered in combination with the Tdap vaccine, with the GBS-NN/NN2 injection in one upper limb and the Tdap injection in the other upper limb.
62561758|NCT06494475|EXPERIMENTAL|Group 3 (non-coadministration [NCA] Group/1 upper limb)|Participants will receive two doses of the GBS NN/NN2 vaccine on Days 1 and 29, respectively. On Day 57, they will receive a single dose of the Tdap vaccine administered in combination with a placebo, with both injections (Tdap and placebo) given in the same upper limb.
62769590|NCT05527886|EXPERIMENTAL|Group 3|Randomized AAROM, Slow Load, or Plyometric intervention
62769591|NCT03234231|NO_INTERVENTION|Control Group|This group receive nothing during the study period.
61994566|NCT01100099|EXPERIMENTAL|Gluten challenge.|Diagnosis of celiac disease. Before and after a gluten challenge small bowel biopsies will be taken, and blood samples will be drawn for tetramer staining of gluten specific T cells.
62390084|NCT01397409|ACTIVE_COMPARATOR|Stage 2: ranibizumab 0.5 mg|Stage 2: ranibizumab 0.5 mg given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
62561759|NCT06494475|EXPERIMENTAL|Group 4 (NCA Group/2 upper limbs)|Participants will receive two doses of the GBS-NN/NN2 vaccine on Days 1 and 29, respectively. On Day 57, they will receive a single dose of the Tdap vaccine, administered in combination with a placebo. The Tdap vaccine will be injected in one upper limb and the placebo in the other upper limb.
62561760|NCT03507868||Group 1|Periodontally healthy individuals
62561761|NCT03507868||Group 2|Chronic periodontitis patients
62769592|NCT03234231|EXPERIMENTAL|Intervention Group|A 3-month supervised tooth brushing programme will be provided to the students. An oral health education talk with written material delivered to the carers and the students
62561762|NCT04390776|EXPERIMENTAL|Treatment Sequence 1|PF-06651600 100 mg Tablets (fasted, Period 1), followed by Capsules (fasted, Period 2), and followed by Capsules (fed, Period 3).
62561763|NCT04390776|EXPERIMENTAL|Treatment Sequence 2|PF-06651600 100 mg Capsules (fasted, Period 1), followed by Tablets (fasted, Period 2), and followed by Capsules (fed, Period 3).
62561764|NCT04390776|EXPERIMENTAL|Treatment Sequence 3|PF-06651600 100 mg Tablets (fasted, Period 1), followed by Capsules (fasted, Period 2).
62168548|NCT06546566|ACTIVE_COMPARATOR|Control Group|Patients in the control group will receive home-based conventional breathing exercises training for 8 weeks, 5 days a week, 30 minutes a day. Breathing exercises will be given 2 times a day, 5 repetitions, 2 sets. In addition to home-based conventional breathing exercises, coughing techniques and relaxation techniques will be taught and physical activity recommendations will be given.
62168549|NCT01383616|ACTIVE_COMPARATOR|Unipedicular kyphoplasty|Balloon kyphoplasty achieves reduction of the vertebral compression fracture using a balloon tamp inserted into the vertebral body by a transpedicular approach, followed by fixation of the fracture fragments with polymethylmethacrylate (PMMA) bone cement. In this arm only vertebral body pedicle was entered to deliver bone cement.
62168550|NCT01383616|ACTIVE_COMPARATOR|Bipedicular Kyphoplasty group|Balloon kyphoplasty achieves reduction of the vertebral compression fracture using a balloon tamp inserted into the vertebral body by a transpedicular approach, followed by fixation of the fracture fragments with polymethylmethacrylate (PMMA) bone cement. In this arm two pedicles were entered to deliver bone cement.
62168551|NCT00737997|PLACEBO_COMPARATOR|1|
62561765|NCT04390776|EXPERIMENTAL|Treatment Sequence 4|PF-06651600 100 mg Capsules (fasted, Period 1), followed by Tablets (fasted, Period 2).
62561766|NCT03393923|NO_INTERVENTION|Control Group|Patient will undergo gait analysis
62561767|NCT03393923|EXPERIMENTAL|Experimental group|Patient will undergo gait analysis with use of anterior wedge
62561768|NCT01375062|NO_INTERVENTION|tissue from biopsies|
62561769|NCT00616265|NO_INTERVENTION|B|Group B. Only Usual Control
61994567|NCT04118309|EXPERIMENTAL|High-intensity interval training|Three sessions of high-intensity interval training per week for nine weeks. Following a three minute warm up, a session contained twenty minutes of alternating between a sprint (80% of maximum workload, 90-95% of maximum heart rate) and active rest (30% of maximum workload) at a one minute to one minute ratio. Every session ended with a two and a half minute cool down.
62168552|NCT00737997|EXPERIMENTAL|2|
62561770|NCT00616265|EXPERIMENTAL|A|Group A: Cpap treatment plus Usual control
62561771|NCT02738918|EXPERIMENTAL|Nulojix|
62561772|NCT05674539|ACTIVE_COMPARATOR|fludarabine and busulfan|fludarabine (30 mg/m\^2/day, days -6 to days -2, the total dase is 150 mg/m\^2) and busulfan (3.2 mg/kg/day, days -3 to days -2, the total dose is 6.4 mg/kg)
62561773|NCT05674539|EXPERIMENTAL|fludarabine and melphalan|fludarabine (30 mg/m\^2/day, days -6 to days -2, the total dose is 150 mg/m\^2) and melphalan (70 mg/m\^2/day, days -3 to days -2, the total dose is 140 mg/m\^2)
62561774|NCT01628731|ACTIVE_COMPARATOR|furosemide|furosemide, 0.2 mg/kg/h up to 0.8 mg/kg/h for 72 hours
62769593|NCT02881619|PLACEBO_COMPARATOR|Placebo|Placebo - (inert content)
62769594|NCT02881619|EXPERIMENTAL|Experimental -|400 mg of NAISE etodolac
62769595|NCT00343382|EXPERIMENTAL|Arm I|Patients receive oral pilocarpine hydrochloride once a day for 3 days, twice a day for 3 days, three times a day for 3 days, and then 4 times a day for up to 6 weeks in the absence of unacceptable toxicity.
62769596|NCT00343382|EXPERIMENTAL|Arm II|Patients receive oral pilocarpine hydrochloride once a day for 3 days and then twice a day for up to 6 weeks in the absence of unacceptable toxicity.
62168553|NCT00562484|EXPERIMENTAL|1|
62168554|NCT00562484|OTHER|2|
62168555|NCT05456308|EXPERIMENTAL|Pressure (30 centimeters), Duration (1 minute), Number of times done (1)|
62168556|NCT05456308|EXPERIMENTAL|Pressure (30 centimeters), Duration (2 minute), Number of times done (1)|
62561775|NCT01628731|ACTIVE_COMPARATOR|ethacryinic acid|ethacrynic acid, 0.2 mg/kg/h up to 0.8 mg/kg/h for 72 hours
62561776|NCT02125682|ACTIVE_COMPARATOR|low dose|patients receiving 10 mg of atorvastatin daily
62561777|NCT02125682|ACTIVE_COMPARATOR|High dose|Patients receiving 80 mg of atorvastatin daily
62561778|NCT04377204|ACTIVE_COMPARATOR|Lidocaine Group|Local injection of 1% lidocaine with 1:100,000 epinephrine one time pre-operatively prior to general anesthesia
62561779|NCT04377204|ACTIVE_COMPARATOR|Lidocaine with Bupivacaine|Local injection of 1% lidocaine with 1:100,000 epinephrine mixed 1:1 with 0.5% marcaine bupivacaine with 1:200,000 epinephrine, one time pre-operatively prior to general anesthesia
62561780|NCT04623619|EXPERIMENTAL|Acetyl L-Carnitine|Acetyl L-Carnitine
62561781|NCT04623619|NO_INTERVENTION|Standard of care|Standard of care
62561782|NCT01894386|EXPERIMENTAL|Sequence 1|Subjects will receive treatment A, B, C, D in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
62561783|NCT01894386|EXPERIMENTAL|Sequence 2|Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
62168557|NCT05456308|EXPERIMENTAL|Pressure (30 centimeters), Duration (1 minute), Number of times done (2)|
62168558|NCT05456308|EXPERIMENTAL|Pressure (80 centimeters), Duration (1 minute), Number of times done (1)|
62561784|NCT01894386|EXPERIMENTAL|Sequence 3|Subjects will receive treatment C, A, D, B in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
62561785|NCT01894386|EXPERIMENTAL|Sequence 4|Subjects will receive treatment D, C, B, A in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment C, A, D, B in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
62769597|NCT00343382|PLACEBO_COMPARATOR|Arm III|Patients receive oral placebo once a day for 3 days, twice a day for 3 days, three times a day for 3 days, and then 4 times a day for up to 6 weeks in the absence of unacceptable toxicity.
62390085|NCT01397409|EXPERIMENTAL|Stage 3: AGN-150998 2.0 mg|Stage 3: AGN-150998 2.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.
62390086|NCT01397409|EXPERIMENTAL|Stage 3: AGN-150998 1.0 mg|Stage 3: AGN-150998 1.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.
62390087|NCT01397409|ACTIVE_COMPARATOR|Stage 3: ranibizumab 0.5 mg|Stage 3: ranibizumab 0.5 mg given as intravitreal injections every 4 weeks for 16 weeks.
62390088|NCT05879848|EXPERIMENTAL|Experimental analgesic treatment (VR)|Achieved active labor and regular contractions (\>= 4 contractions in 10 minutes), patients are given the virtual reality scenario synchronized with the uterine contractions , and no other alternative analgesia is provided, except for the midwife's support.
62390089|NCT05879848|NO_INTERVENTION|Standard Care (non-VR)|Patients in active labour. undergo standard care (only midwife's support, no analgesia)
62390090|NCT05240573|EXPERIMENTAL|SKI App|
62390091|NCT05240573|ACTIVE_COMPARATOR|CMUH Dialysis Care App|
62390092|NCT01389310||HIV-infected children <18 yrs old - exposed to Atazanavir|
62390093|NCT04568382|EXPERIMENTAL|Intervention|Enhanced PVP
62769598|NCT00343382|PLACEBO_COMPARATOR|Arm IV|Patients receive oral placebo once a day for 3 days and then twice a day for up to 6 weeks in the absence of unacceptable toxicity.
62769599|NCT06422585||Femoral Nerve Block + IPACK Block|After adequate venous access has been obtained, spinal anesthesia with Levobupivacaine will be performed. After which antalgic Femoral Nerve Block and IPACK Block will be performed.
62168559|NCT05456308|EXPERIMENTAL|Pressure (80 centimeters), Duration (2 minute), Number of times done (1)|
62168560|NCT05456308|EXPERIMENTAL|Pressure (80 centimeters), Duration (1 minute), Number of times done (2)|
62168561|NCT05456308|EXPERIMENTAL|Pressure (30 centimeters), Duration (2 minute), Number of times done (2)|
62168562|NCT05456308|EXPERIMENTAL|Pressure (80 centimeters), Duration (2 minute), Number of times done (2)|
62168563|NCT04127019|EXPERIMENTAL|TC*6|6 cycles of (Docetaxel 75mg/m2 ivgtt d1+ Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) .
62390094|NCT04568382|ACTIVE_COMPARATOR|Standard|Standard PVP
62390095|NCT02151045|ACTIVE_COMPARATOR|Non target epidural infiltration at L3-L4 stage|"In this control arm, there are patients with a non target posterior epidural space infiltration of corticoids done at L3-L4 stage on scan control.~These patients must have a discal hernia confirmed by scanner or RMI"
62390096|NCT02151045|EXPERIMENTAL|Epidural infiltration on contact of disco radicular conflict|"In this experimental arm, there are patients with an epidural infiltration of corticoids done in lateral on contact of disco radicular conflict on scan control.~These patients must have a discal hernia confirmed by scanner or RMI"
62390097|NCT01790451|ACTIVE_COMPARATOR|peripheral ablation|an ablation of the peripheral area of the prostate
62390098|NCT01790451|ACTIVE_COMPARATOR|More central ablation|an ablation, more centrally, in proximity of the urethra
62390099|NCT00580827|PLACEBO_COMPARATOR|placebo disulfiram|placebo disulfiram (0 mg/day)
62390100|NCT00580827|EXPERIMENTAL|disulfiram 62.5|disulfiram at 62.5 mg/day
62390101|NCT00580827|EXPERIMENTAL|disulfiram 125|disulfiram at 125 mg/day
62390102|NCT00580827|EXPERIMENTAL|disulfiram 250|disulfiram at 250 mg/day
62390103|NCT02412241|OTHER|LEF Measures|"PATIENT-REPORTED OUTCOME MEASURE: Validity of LSIDS-H\&N will be assessed using 6 forms (e.g., Vanderbilt Head and Neck Symptom Survey (v2.0); Neck Disability Index; and Hospital Anxiety and Depression Scale).~CLINICIAN-REPORTED OUTCOME MEASURES: External LEF will be assessed using HN-LEF Grading Criteria, CTCAE (v4.03), and digital photos of the head and neck. Internal LEF will be scored using Modified Patterson Scale through an endoscopic exam. Both external/internal measures are re-assessed for intrarater and interrater reliability.~OBJECTIVE/TECHNICAL MEASURES: Patients undergo CT scans and ultrasound exams with results re-scored for intrarater and interrater reliability."
62390104|NCT03732040|SHAM_COMPARATOR|standerd preventive measures|tooth brushing twice daily with fluoride tooth paste and dental flossing and mouthwash
62390105|NCT03732040|EXPERIMENTAL|miswak stick|use of miswak stick twice daily
62390106|NCT03732040|EXPERIMENTAL|Use of Miswak plus tooth brushing and tooth paste|use of miswak stick and tooth brush with fluoride toothpaste twice daily
62390107|NCT01192581|NO_INTERVENTION|control|routine treatment for brain hypoperfusion
62561786|NCT05071599|EXPERIMENTAL|Twin arch brackets|the malocclusion for this group will be treated using fixed appliance which utilize twin arch brackets system.
62561787|NCT05071599|EXPERIMENTAL|Conventional brackets|"the malocclusion for this group will be treated using fixed appliance which utilize conventional pre-adjusted edgewise brackets system."
62561788|NCT03973606|NO_INTERVENTION|Arab Women health literacy focus groups|Arab women in East Jerusalem will be part of focus groups. During the focus groups, a set of pre-prepared questions will be presented to the participants. The focus groups will be recorded and analyzed verbatim.
62561789|NCT03973606|EXPERIMENTAL|Health literacy workshop|Women from East-Jerusalem and other Arab communities in Israel will be invited to participate in a 4-sessions workshop designed to improve health literacy, self-efficacy when interacting with their physician and increase their cardiovascular health knowledge.
62561790|NCT03065855|EXPERIMENTAL|Early removal group|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 2 days following surgery.
62561791|NCT03065855|ACTIVE_COMPARATOR|Normal removal group|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
62561792|NCT03456102|OTHER|Pravastatin 80 mg|Pravastatin 80 mg, isoniazid 300 mg, rifampin 450 mg (weight \<50 kg) or 600 mg (weight \>50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 2 will only be recruited if pravastatin 40 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
62561793|NCT03456102|OTHER|Pravastatin 120 mg|Pravastatin 120 mg, isoniazid 300 mg, rifampin 450 mg (weight \<50 kg) or 600 mg (weight \>50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 3 will only be recruited if pravastatin 80 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
62390108|NCT01192581|EXPERIMENTAL|Vuloven1|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
62561794|NCT03456102|OTHER|Pravastatin 160 mg|Pravastatin 160 mg, isoniazid 300 mg, rifampin 450 mg (weight \<50 kg) or 600 mg (weight \>50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 4 will only be recruited if pravastatin 120 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
62561795|NCT03456102|OTHER|Pravastatin 40 mg|Pravastatin 40 mg, isoniazid 300 mg, rifampin 450 mg (weight \<50 kg) or 600 mg (weight \>50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days
62561796|NCT03006601|PLACEBO_COMPARATOR|Placebo group|After enrollment, patients will be randomized into either treatment group or placebo group. Patients will receive placebo procedure which were designed to look like real vergence/accommodative therapy procedures yet not stimulate vergence, accommodation, of fine saccadic eye movement skills beyond normal daily visual activities. Office-based procedures (60 minutes per visit, one time per week, 12 weeks) and home procedures (15 minutes each time, five times per week, 12 weeks) will be provided to patients.
62561797|NCT03006601|EXPERIMENTAL|Treatment group|After enrollment, patients will be randomized into either treatment group or placebo group. Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 12 weeks) and home reinforcement (15 minutes each time, five times per week, 12 weeks) will be provided to patients of treatment group.
62168564|NCT04127019|EXPERIMENTAL|CEF*3-T*3|3 cycles of CEF (Epirubicin 100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
62390109|NCT01192581|EXPERIMENTAL|Vuloven2|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
62168565|NCT04127019|EXPERIMENTAL|EC*4-wP*12|4 cycles of EC (Epirubicin 90 mg/m2 ivgtt d1+Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) followed by 4 cycles of Paclitaxel (Paclitaxel 80mg/m2, ivgtt d1,8,15, 21days per cycle).
62561798|NCT02442947|EXPERIMENTAL|Research arm|"1. 1 day which will include: physician examination,ECG,anthropometric measurements and Vo2max test.~2. 6 acclimatization days carried out by a standard protocol including a daily 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade \& 40% HR) and when dressed in shorts.At the sixth day, the subjects will be dressed in a standard work uniform as a baseline exposure. Core (rectal) and skin temperature and heart rate will be monitored continuously.~3. 4 experiment days carried out by the following protocol: 2 hour walk on a treadmill (5 Km/h,2% incline) under heavy heat stress conditions (30 deg. centigrade,60% RH) and when dressed each time with different clothing out of 4 options:~   1. NBC protective garment (charcoal base).~  2. combat garment.~  3. 2 different types of work uniforms. physiological stress will be examined based on rectal temperature and heart rate measurements."
62168566|NCT01568112|EXPERIMENTAL|BG00012|Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA placebo during the first 4 weeks.
62168567|NCT01568112|PLACEBO_COMPARATOR|Placebo|Participants received BG00012 placebo for 8 weeks and premedication with ASA placebo during the first 4 weeks.
62168568|NCT01568112|EXPERIMENTAL|BG00012 + ASA|Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA during the first 4 weeks.
62561799|NCT00637845|EXPERIMENTAL|1|40mg once daily
62561800|NCT00637845|ACTIVE_COMPARATOR|2|30mg twice daily
62561801|NCT05754905||Normal hip joint|The normal side of patients with hip joint disease
62561802|NCT05754905||Abnormal hip joint|The abnormal side of patients with hip joint disease
62561803|NCT05564156|NO_INTERVENTION|Control Group|In the control group; No intervention will be made by the investigators in this group. The participant will take standard treatment. Participant's length of stay in hospital, suitability of antibiotics used, development of microbial resistance, Antibiotic related nephrotoxicity due to infection, mortality data due to infection will be recorded, hospitalization will be questioned within 30 days after the patient is discharged, and a drug consensus report will be created, drug-related problems will be determined, and a pharmacoeconomic evaluation of all possible outcomes will be made. Evaluations will be recorded, but the investigators will take no action.
62561804|NCT05564156|EXPERIMENTAL|Intervention Group|"In the intervention group; The participant will take standard treatment and the clinical pharmacist services such as drug reconciliation by the investigators, medication review (Identification of drug-related problems, detection of possible unsuitable drugs), quality of life measurement, antibiotic selection, drug suitability, dose and route of administration advice, and concomitant medications are included. Suggestions will be made by the investigators to physicians about the solution to drug-related problems.~Participants' length of hospital stay, suitability of antibiotics, development of microbial resistance, antibiotic-related nephrotoxicity due to infection, and mortality numbers due to infection will be recorded, hospitalization will be questioned within 30 days after discharge. The investigators will create a drug consensus report, drug-related problems will be determined, and a pharmacoeconomic evaluation of all possible outcomes will be accomplished by investigators."
62561805|NCT01395147|EXPERIMENTAL|Lu AA21004 group|
62561806|NCT04812444|EXPERIMENTAL|Zylox Peripheral Venous Stent Implantation|Percutaneous stent placement in the iliofemoral veins
62561807|NCT04812444|ACTIVE_COMPARATOR|Zilver Vena Venous Stent Implantation|Percutaneous stent placement in the iliofemoral veins
62561808|NCT03671967|EXPERIMENTAL|piperacillin tazobactam|
62168569|NCT01568112|EXPERIMENTAL|BG00012 Slow Titration|Participants received BG00012 for 8 weeks (120 mg once daily \[QD\] during Week 1, 120 mg BID during Week 2, 240 mg AM/120mg PM during Week 3, and 240 mg BID during Week 4, and 240 mg BID during Weeks 5 to 8) and premedication with ASA placebo during the first 4 weeks.
62561809|NCT03671967|ACTIVE_COMPARATOR|meropenem|
62561810|NCT00671112|EXPERIMENTAL|Everolimus and Bortezomib|Patients will receive a combination of Everolimus by mouth and Bortezomib intravenously for a 21 day cycle.
61994568|NCT04118309|PLACEBO_COMPARATOR|Placebo exercise group|No changes in physical activity behaviour occurred (already engaging in less than 150 minutes per week, instructed to maintain their current inactivity). They were told they needed to stay inactive since they were part of an 'acute' exercise group, aiming to see how long the effects of their baseline maximal exercise test would last. Thus, the cover story gave them the impression they were also in an exercise group, as oppose to a non-exercise control group.
62561811|NCT02563054|ACTIVE_COMPARATOR|5-Fluorouracil + Cisplatin|Participants will receive 5-FU in combination with cisplatin upto disease progression.
62561812|NCT02563054|EXPERIMENTAL|Capecitabine + Cisplatin|Participants will receive capecitabine in combination with cisplatin upto disease progression.
62561813|NCT05549843|EXPERIMENTAL|Hemophilia group|"Intervention protocol:~* Preparatory work: active mobilizations with the patient supine.~* Global passive mobilization of the forefoot and midfoot.~* Calcaneocuboid mobilization, functional and structural work of said joint.~* Astragaloscaphoid mobilization, functional and structural work of said joint.~* Talar manipulation dorsally.~* Manipulation-tibial displacement:~* Tibiotarsal decompression: 2 very gentle high-speed and short-course tibial-tarsal manipulations.~* Plantar fascia induction for foot captors of the plantar fascia.~* Tibiotarsal sustained traction technique (unwinding)~* Sural triceps induction technique:"
62168570|NCT06501885|EXPERIMENTAL|Ethnodrama Audience Members|
62561814|NCT02672917|EXPERIMENTAL|Group A|MVT-5873 monotherapy dose escalation, initial to MTD
62561815|NCT02672917|EXPERIMENTAL|Group B|MVT-5873 is administered in Group B every 1 week in combination with gemcitabine and nab-paclitaxel
61994569|NCT01779193|EXPERIMENTAL|latic acid bacteria and cranberry|oral latic acid bacteria and cranberry capsule (dose of 2 \* 10\^9 cfu per capsule), one pill daily
61994570|NCT01779193|ACTIVE_COMPARATOR|cranberry|oral cranberry capsule without lactic acid bacteria, one pill daily
62168571|NCT00443755|ACTIVE_COMPARATOR|Insulin Sensitizer Therapy|Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily.
62168572|NCT00443755|PLACEBO_COMPARATOR|Placebo|Placebo tablets were used to match the active comparator drugs and dosing regimen.
62168573|NCT01521221|EXPERIMENTAL|Patients|Patients with autonomic failure.
62168574|NCT01521221|EXPERIMENTAL|Healthy subjects|Control group
62390110|NCT01192581|EXPERIMENTAL|Vuloven3|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
62390111|NCT03730987|EXPERIMENTAL|HoMBRES Intervention Group - Father|Four sessions (2 sessions per week, approximately 1.5 hours each) with the fathers, in which facilitators conduct educational sessions; During the period of social distancing, interventions were remotely facilitated via a well-tested video platform accessible by a link sent to the participants' telephone, computer, tablet or IPad (approximately 1.5 hours each session. Intervention videos were followed up with a telephone call to respond to any questions participants may have had about the sessions and clarify (if needed) the material covered in the videos via telephone or videoconferences. Only fathers were included in this group.
62390112|NCT03730987|ACTIVE_COMPARATOR|Diabetes Prevention Intervention Group - Father|One session of 1.5 hours held once per week. Session content will focus on the importance of physical activity, healthy eating, and maintaining a healthy weight. Only fathers were included in this group.
62390113|NCT03730987|NO_INTERVENTION|HoMBRES Intervention Group - Adolescent|The adolescent received no intervention.
62561816|NCT02672917|EXPERIMENTAL|Group C|MVT-5873 is administered in Group C every 4 weeks by intravenous infusion following a lead in dose. Each cycle is 28 days. During dose escalation, doses of MVT-5873 will be increased to define the MTD. Up to 30 patients will be treated at the RP2D.
62561817|NCT02672917|EXPERIMENTAL|Group D|MVT-5873 is administered in Group D every 2 weeks by intravenous infusion following a lead in dose. During dose escalation, doses of MVT-5873 will be increased to defined the MTD. Up to 30 patients will be treated at the RP2D.
62769600|NCT06422585||Saphenous (Adductor Canal) Block + IPACK Block|After adequate venous access has been obtained, spinal anesthesia with Levobupivacaine will be performed. After which Saphenous and IPACK Block will be performed.
62168575|NCT01910740|EXPERIMENTAL|Enhanced Physical Activity|Participants in the Enhanced Physical Activity group will receive a program of enhanced physical activity in addition to the usual care.
62168576|NCT01910740|ACTIVE_COMPARATOR|Usual Care|The Usual Care group will receive usual therapy provided by a multidisciplinary team and social interaction.
62390114|NCT03730987|NO_INTERVENTION|Diabetes Prevention Intervention Group - Adolescent|The adolescent received no intervention.
62390115|NCT04694820|EXPERIMENTAL|Text message intervention|Six month text message intervention
62390116|NCT05262842|EXPERIMENTAL|JS001+IMP4297|
62390117|NCT01273207|EXPERIMENTAL|Inhaled Cyclosporine in HSCT Participants|Hemopoietic Stem Cell transplant (HSCT) subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) at maximum tolerated dose not exceeding 300 mg administered three times per week
62390118|NCT03188991|EXPERIMENTAL|Dose Escalation: NanoPac® 6 mg/mL|Single intracystic injection of NanoPac® at a dose of 6 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
62769601|NCT06422585||Dual Subsartorial Block|After adequate venous access has been obtained, spinal anesthesia with Levobupivacaine will be performed. After which Dual Subsartorial Block will be performed.
62769602|NCT05453695|EXPERIMENTAL|Intravenous DNase I|"We will enroll up to 36 Participants; each is receiving repeated unit doses of DNase I, BID, delivered by IV infusion over 3 or 7 consecutive days (12 +/- 1 hour apart) according to the following dose-escalation schedule with up to 6 Participants per dose panel.~* Panel 1: 25 µg/kg, BID for 3 days (cumulative dose: 150 µg/kg)~* Panel 2: 25 µg/kg, BID for 7 days (cumulative dose: 350 µg/kg)~* Panel 3: 125 µg/kg, BID for 3 days (cumulative dose: 750 µg/kg)~* Panel 4: 125 µg/kg, BID for 7 days (cumulative dose: 1750 µg/kg)"
62769603|NCT05453695|NO_INTERVENTION|Control|We will also enroll 12 septic Participants who do not receive intravenous DNase I (as Comparator Group). These patients will be recruited contemporaneously based on the same inclusion and exclusion criteria.
62769604|NCT01744314|EXPERIMENTAL|drug|The treatment arm will receive 21 days of Indomethacin and Pantoprazole (gastrointestinal protective agent). The patients will receive Indomethacin 25mg three times a day and Pantoprozole 40mg once a day.
62769605|NCT01744314|PLACEBO_COMPARATOR|placebo|The placebo group will receive microcrystalline cellulose powder tablets to be taken as a control. The placebo will be dosed at the same intervals and duration as the treatment arm in this study.
62769606|NCT00267150|EXPERIMENTAL|1|
62769607|NCT02855944|EXPERIMENTAL|Rucaparib|"Drug: Oral rucaparib~600 mg BID (twice a day)~Other Names:~* CO-338~* PF 01367338~* AG 14699~* Rubraca"
62769608|NCT02855944|ACTIVE_COMPARATOR|Chemotherapy|"Monotherapy platinum (cisplatin or carboplatin) or platinum-based doublet chemotherapy (carboplatin/paclitaxel, carboplatin/gemcitabine, or cisplatin/gemcitabine administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.~Single agent paclitaxel will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision."
62769609|NCT03973905||Pertussis Case Group|"Infant subjects of at least 2 days old and less than (\<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility).~This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa."
62168577|NCT00276783|EXPERIMENTAL|Treatment Arm|Pemetrexed 900 mg/m2 every 21 days until disease progression.
62168578|NCT02502487|PLACEBO_COMPARATOR|Tetracaine gel group|Dorsal penile nerve block with saline and tetracaine gel into urethra before rigid cystoscopy
62168579|NCT02502487|EXPERIMENTAL|Dorsal penile nerve block group|Dorsal penile nerve block with ropivacaine and plain lubricating gel into urethra before rigid cystoscopy
62168580|NCT02502487|EXPERIMENTAL|Combination group|Dorsal penile nerve block with ropivacaine and tetracaine gel into urethra before rigid cystoscopy
62168581|NCT01370564|OTHER|Daily diuretic adjustment|Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
62168582|NCT03810638||Heart Failure Patients|All Heart Failure Patients seen at 3 major academic medical centers.
62390119|NCT03188991|EXPERIMENTAL|Dose Escalation: NanoPac® 10 mg/mL|Single intracystic injection of NanoPac® at a dose of 10 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
62390120|NCT03188991|EXPERIMENTAL|Dose Escalation: NanoPac® 15 mg/mL|Single intracystic injection of NanoPac® at a dose of 15 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
62390121|NCT03188991|EXPERIMENTAL|Second Phase: NanoPac® at Best Dose|Intracystic injection of NanoPac®. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® injections, with the second injection administered 12 weeks after the first injection.
62390122|NCT00411229|ACTIVE_COMPARATOR|1|Capecitabine + Oxalipatin
62390123|NCT00411229|NO_INTERVENTION|2|
62390124|NCT02297620||Suglat group|
62168583|NCT02150109|EXPERIMENTAL|Persons With Diabetes|Untrained subjects WITH Diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System).
62168584|NCT02150109|EXPERIMENTAL|Persons With and Without Diabetes|Untrained subjects WITH/WITHOUT Diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System).
61994571|NCT01779193|PLACEBO_COMPARATOR|placebo|placebo without lactic acid bacteria and cranberry, one pill daily
62390125|NCT00989417|ACTIVE_COMPARATOR|CONTROL Group - Without Home Monitoring|Patients receiving the standard of care. Due to safety concerns, the patients are followed every 6 months after a first follow-up, which is performed between 1 and 3 months after implantation.
62390126|NCT00989417|EXPERIMENTAL|ACTIVE GROUP With Home Monitoring|After a first follow-up (between 1 and 3 months after implantation), the patients are followed one time per year. Within this period, the additional ICD follow-up or therapeutic intervention will be primarily triggered on cardio-reports reception, Data/IEGM-online analysis on internet site or patient/physician call.
62390127|NCT01200251|EXPERIMENTAL|Bimatoprost treated eyelid|one eyelid of the patient was randomized to the treatment arm and given the gel to use
62390128|NCT01200251|NO_INTERVENTION|control arm - no gel|the other fellow eyelid of the patient did not receive any treatment until month 4 and the patient crossed over to treating both eyelids
62390129|NCT00686894|EXPERIMENTAL|Infliximab 5 mg/kg|Infliximab infusions: 5 mg/kg at weeks 0, 2, and 6.
62390130|NCT00219531||control|subjects with no irritable bowel syndrome or gastrointestinal complaints and regular menstrual cycle.
62390131|NCT00219531||IBS|women with IBS symptoms and normal menstrual cycle.
62390132|NCT05647889|EXPERIMENTAL|Jet lidocaine group|Jet lidocaine will be applied before PVC and PVC will be performed 3 minutes later.
62390133|NCT05647889|EXPERIMENTAL|Ice group|Ice will be applied for 1 minute before PVC, and then PVC will be performed.
62390134|NCT05647889|ACTIVE_COMPARATOR|Control group|Standard PVC procedure will be applied
62390135|NCT05630742||Interstitial Cystitis|patients with an existing diagnosis of BPS/IC. BPS/IC was confirmed by reviewing medical record.
62390136|NCT05630742||control group|patients with chronic non-neoplastic pain, suffering from fibromyalgia or other types of chronic pain (chronic arthralgia or lower back pain).
62769610|NCT03973905||Control Group|"Infant subjects of at least 2 days old and less than (\<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant).~This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa."
62390137|NCT05747170|EXPERIMENTAL|Group natural_neutral_chemical|"The recruited subjects (DoC patients and healthy subjects) will be evaluated inside a quiet, well-ventilated room and will be subjected to olfactory stimulation using odors with different characteristics a natural type odor, e.g., mint, a chemical type odor, e.g., gasoline, and a neutral type odor, e.g., water.~Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.~The sequence of odor administration will be: natural odor (mint) for 5 minutes, neutral odor (water) for 5 minutes, chemical odor (gasoline) for 5 minutes."
62561818|NCT02672917|EXPERIMENTAL|Group E - metastatic|MVT-5873 is administered in combination with mFOLFIRINOX every 2 weeks. Both MVT-5873 and mFOLFIRINOX will be administered by intravenous infusion. During dose escalation, doses of MVT-5873, will be increased to define the MTD in combination with mFOLFIRINOX. mFOLFIRINOX will be administered according to institutional standards in compliance with the package insert for each drug. Up to 30 patients will be treated at the RP2D.
62769611|NCT00664326|EXPERIMENTAL|Regorafenib (Stivarga, BAY73-4506)|Participants received Regorafenib 160 mg per os (po) every day (qd) for 3 weeks on 1 week off of every 4 week cycle
62769612|NCT06256718|OTHER|Health services research (PC TEACH)|Primary practice providers sites receive PC TEACH over 3.5 hours for 12 months
61994572|NCT06404827|EXPERIMENTAL|Intervention group (Horseback riding simulator+Routine physiotherapy)|Horseback riding simulator (HRS) will be applied in addition to routine Physiotherapy and Rehabilitation. This group will receive 20 minutes of routine physiotherapy training and 20 minutes of HRS application in addition to 2 sessions per week for 8 weeks.
61994573|NCT06404827|ACTIVE_COMPARATOR|Control group (Routine physiotherapy)|Routine physiotherapy training will be applied within a specific programme for 40 minutes in 2 sessions per week for 8 weeks.
61994574|NCT03719313|EXPERIMENTAL|Group 1|Lonafarnib 50 mg BID + Ritonavir 100 mg BID
62168585|NCT06472960|EXPERIMENTAL|Moderate-intensity cycling|Moderate-intensity cycling on Ergoline Ergoselect 100
62168586|NCT06472960|EXPERIMENTAL|Vigorous-intensity cycling|Vigorous-intensity cycling on Ergoline Ergoselect 100
62168587|NCT06472960|EXPERIMENTAL|Uninterrupted sitting|Uninterrupted sitting in a quiet room
62168588|NCT00147745|EXPERIMENTAL|1|colesevelam 3.8g administered daily for 12 weeks
62168589|NCT00147745|PLACEBO_COMPARATOR|2|Colesevelam matching placebo for 12 weeks
62168590|NCT00147745|ACTIVE_COMPARATOR|3|open-label Insulin Glargine for 12 weeks
62168591|NCT02519270|EXPERIMENTAL|Dose Escalation Stage/ Expansion Stage|"The Dose-Escalation Stage will employ a modified 3 + 3 cohort design, subjects will receive up to 26 doses of IGN002.~In the Expansion Stage, subjects will receive up to 24 doses of IGN002 at the maximum tolerated dose administered weekly in three 8-week cycles."
62168592|NCT01896921|EXPERIMENTAL|Maraviroc + Raltegravir or Dolutegravir|Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks
62168593|NCT06646354|EXPERIMENTAL|HODO-2224-1+HODO-2224-2+HODO-2224-4|Oral tablet, QD
62168594|NCT06646354|ACTIVE_COMPARATOR|HODO-2224-1+HODO-2224-4+HODO-2224-5|Oral tablet, QD
62168595|NCT06646354|ACTIVE_COMPARATOR|HODO-2224-2+HODO-2224-3+HODO-2224-6|Oral tablet, QD
62561819|NCT02672917|EXPERIMENTAL|Group F - adjuvant|MVT-5873 is administered in combination with mFOLFIRINOX every 2 weeks. Both MVT-5873 and mFOLFIRINOX will be administered by intravenous infusion. During dose escalation, doses of MVT-5873, will be increased to define the MTD in combination with mFOLFIRINOX. mFOLFIRINOX will be administered according to institutional standards in compliance with the package insert for each drug. Up to 30 patients will be treated at the RP2D.
62168596|NCT04286893||TAVI group|Consecutive patients undergoing TAVI
62168597|NCT00092456|EXPERIMENTAL|RotaTeq™ Lot 1|\~8.81 X 10\^7 IU/Dose of RotaTeq™
62168598|NCT00092456|EXPERIMENTAL|RotaTeq™ Lot 2|\~8.01 X 10\^7 IU/Dose of RotaTeq™
62561820|NCT00786786||1|Spinal Cord Injury
62561821|NCT03076892|ACTIVE_COMPARATOR|Conventional PDT|Aktilite® Galderma
62561822|NCT03076892|EXPERIMENTAL|PHOS ISTOS PDT|Light Emitting textile device
62168599|NCT00092456|EXPERIMENTAL|RotaTeq™ Lot 3|\~6.91 X 10\^7 IU/Dose of RotaTeq™
61994575|NCT03719313|EXPERIMENTAL|Group 2|Lonafarnib 50 mg BID + Ritonavir 100 mg BID + PEG IFN alfa-2a 180 mcg QW
61994576|NCT03719313|ACTIVE_COMPARATOR|Group 3|placebo Lonafarnib + placebo Ritonavir + PEG IFN-alfa-2a 180 mcg QW
62561823|NCT05561387|ACTIVE_COMPARATOR|Arm I (VRd-Lite)|"INDUCTION CYCLES 1-9: Patients receive bortezomib SC on days 1, 8, 15, and 22 of each cycle, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CYCLES 10+: Patients receive lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
61994577|NCT03719313|PLACEBO_COMPARATOR|Group 4|placebo Lonafarnib + placebo Ritonavir
61994578|NCT00762398||Adult patient undergoing a surgery|Adult patient undergoing a surgery in the supine position and require an arterial line for anesthesia/surgery purposes
62168600|NCT00092456|PLACEBO_COMPARATOR|Placebo|
62168601|NCT05933083|ACTIVE_COMPARATOR|In-person cardiac rehabilitation|Participants will participate in 12-week in-person cardiac rehabilitation as delivered at the site where they are enrolled. The typical course is 36 sessions of group exercise, health education, and counseling over 12 weeks.
62168602|NCT05933083|ACTIVE_COMPARATOR|Telehealth cardiac rehabilitation|Participants will participate in 12-week telehealth cardiac rehabilitation. The program will follow the same core components as in-person cardiac rehabilitation, but in-person supervised exercise will not be required. The core element of telehealth cardiac rehabilitation is 12 weekly individual telehealth sessions between the patient and cardiac rehabilitation provider.
62168603|NCT03029234|EXPERIMENTAL|Carfilzomib with Dexamethasone|"Participants will receive carfilzomib administered by intravenous (IV) infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter).~Participants will also receive 20 mg dexamethasone IV or orally on days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle.~Participants will receive treatment until disease progression, unacceptable toxicity, initiation of new antimyeloma therapy, withdrawal of consent, non-compliance, or intercurrent illness or worsening of a chronic condition, whichever occurs first."
62561824|NCT05561387|EXPERIMENTAL|Arm II (DRd-R)|"INDUCTION CYCLES 1-9: Patients receive daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CYCLES 10+: Patients receive lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62769613|NCT06316973|EXPERIMENTAL|CS-1103 Single dose of CS-1103 Injection|CS-1103 for injection
62769614|NCT06316973|PLACEBO_COMPARATOR|Placebo|Sterile saline for injection
62769615|NCT05613582|EXPERIMENTAL|Primary Motor Cortex (M1)|Subjects were randomly assigned to receive tDCS stimulation at the primary motor cortex (M1)
62769616|NCT05613582|EXPERIMENTAL|Primary Sensory Cortex (S1)|Subjects were randomly assigned to receive tDCS stimulation at the primary sensory cortex (S1)
61994579|NCT03318991|ACTIVE_COMPARATOR|GreenLight laser|180W Greenlight laser is used for vaporesection of the prostate.
62561825|NCT05561387|EXPERIMENTAL|Arm III (DRd-DR):|"INDUCTION CYCLES 1-9: Patients receive daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CYCLES 10+: Patients receive daratumumab and hyaluronidase-fihj SC on day 1 of each cycle and lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
61994580|NCT03318991|ACTIVE_COMPARATOR|Thulium laser|200W Thulium laser is used for enucleation of the prostate.
62561826|NCT02727478|EXPERIMENTAL|Balance training group|1 hour group balance training twice weekly for 10 weeks, as well as perform a home exercise program.
62561827|NCT02727478|NO_INTERVENTION|Control group|Subjects in this group will receive no intervention and will be advised to continue their normal level of exercise throughout the intervention period.
62769617|NCT05613582|EXPERIMENTAL|Dorsolateral Prefrontal Cortex (DLPFC)|Subjects were randomly assigned to receive tDCS stimulation at the dorsolateral prefrontal cortex (DLPFC)
61994581|NCT01727141|EXPERIMENTAL|QVA149|27.5/12.5 ug twice daily (b.i.d.) via Single Dose Dry Powder Inhaler (SDDPI)
61994582|NCT01727141|ACTIVE_COMPARATOR|QAB149|27.5 ug b.i.d.
61994583|NCT01727141|ACTIVE_COMPARATOR|NVA237|12.5 ug b.i.d.
61994584|NCT01727141|PLACEBO_COMPARATOR|Placebo|b.i.d
61994585|NCT03773731|EXPERIMENTAL|High intensity interval training|"3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks:~* 5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test~* 30 minutes: intensive cycling bouts of 60s interspersed with 60s of recovery intervals. Power output will be 90% (week 1-6) or 95% (week 7-12) of the maximal power output of the exercise test during the intensive cycling bouts. During recovery intervals, subjects will pedal with a power output of 30% (week 1-6) or 35% (week 7-12) of the maximal power output of the exercise test.~* 10 minutes with 30% of maximal power output."
61994586|NCT03773731|ACTIVE_COMPARATOR|Moderate intensity continuous training|"3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks:~* 5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test~* 30 minutes: Continuous training with 60% (week 1-6) or 65% (week 7-12) of maximal power output~* 10 minutes with 30% of maximal power output."
61994587|NCT05110911||Healthcare Workers|"Eligible participants will be recruited from 1 of 6 participating hospitals in Australia and will meet the following criteria: personnel (including staff, honorary staff, students and volunteers) located at a participating hospital or healthcare service at the time of recruitment who would be eligible for the hospital's free vaccination programme; be aged ≥18 years old and ≤60 years old; have a mobile phone that can receive and send SMS messages; willing and able to provide blood samples; available for follow-up over the next 7 months; able and willing to complete the informed consent process.~There are no restrictions on the type of healthcare worker (HCW) that can be recruited into the study in terms of their job role. HCW will be any hospital staff, including clinical, research, administrative and support staff."
61994588|NCT00366990|ACTIVE_COMPARATOR|weight loss and sodium intake reduction|Behavioral and weight loss intervention, including a low sodium diet. Study goals are a 10% weight loss, 200 minutes of moderate physical activity a week, such as walking, and a 50% reduction in sodium intake.
61994589|NCT00366990|PLACEBO_COMPARATOR|weight loss and normal sodium intake|Behavioral and weight loss intervention, with regular sodium intake. Study goals are a 10% weight loss, 200 minutes of moderate physical activity a week, such as walking.
61994590|NCT02261376|EXPERIMENTAL|Caucasian men, aged 18-55 years|
61994591|NCT02261376|EXPERIMENTAL|Caucasian men, aged 65 years or older|
61994592|NCT02261376|EXPERIMENTAL|Japanese men, aged 18-55 years|
61994593|NCT02261376|EXPERIMENTAL|Caucasian women, aged 18-55 years|
61994594|NCT05662579|EXPERIMENTAL|hip exercises|"PHASE I: (sessions 1 to 4)~1. Active exercise without weight support (standing) for abductors, adductors, hip flexors and extensors~2. Hip extension exercise in 4 supports~3. Hip abduction exercise in 4 supports (hydrant)~4. Oyster Exercise~5. Hip abduction exercise in lateral decubitus~6. Hip extension exercise in ventral decubitus~PHASE II: (sessions 5 to 8)~1. Hip abduction exercise in lateral decubitus~2. Progressive resistance exercise for abductors, adductors, flexors and hip extensors with standing theraband~3. Side walk with theraband positioned at the ankle joint~4. Squat exercise~5. Advance exercise~6. Step down exercise"
62168604|NCT04124016|EXPERIMENTAL|Inulin|Inulin_ extract of chicory fermentable fiber
62168605|NCT04124016|EXPERIMENTAL|green tea extract|green tea extract_rich in tri-hydroxylated flavan-3-ol monomers (1 mmol of PVL precursor)
62561828|NCT02729298|EXPERIMENTAL|Advanced Solid Tumors|"Phase 1a Single daily dose of TP-0903 by oral administration on Days 1-21 of a 28 day cycle~AND~Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle."
62390138|NCT05747170|EXPERIMENTAL|Group chemical:neutral_natural|"The recruited subjects (DoC patients and healthy subjects) will be evaluated inside a quiet, well-ventilated room and will be subjected to olfactory stimulation using odors with different characteristics a natural type odor, e.g., mint, a chemical type odor, e.g., gasoline, and a neutral type odor, e.g., water.~Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.~The sequence of odor administration will be: chemical odor (gasoline) for 5 minutes, neutral odor (water) for 5 minutes, natural odor (mint) for 5 minutes."
62390139|NCT00817752|EXPERIMENTAL|1|Receives Ashwagandha herb.
62390140|NCT02406131|NO_INTERVENTION|Control Group:|This group will be getting all the routine work up including Duplex scan . we will add request for inflammatory and coagulation markers in their blood samples before and after intervention . The pre-op blood sample will be collected within the 24 hours before intervention and the post intervention in the 24 hrs after (second RIPC window). The repeated duplex scan will be schedule after 6 months.
62390141|NCT02406131|ACTIVE_COMPARATOR|RIPC Group|Remote Ischemic Preconditioning Group (RIPC):This group will have all the tests as for the control group with the additional component will be preconditioning. One hour prior to procedure candidates in this group will have structured intermittent periods of induced remote ischaemic preconditioning using standard blood pressure cuffs. The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles, which needs 40 minutes.
62390142|NCT04515849|EXPERIMENTAL|Cotadutide 100 micrograms|Cotadutide 100 micrograms administered subcutaneously
62561829|NCT02729298|EXPERIMENTAL|EGFR+ NSCLC|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
62561830|NCT02729298|EXPERIMENTAL|BRAF-, KRAS-, or NRAS-Mutated CRC|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
62561831|NCT02729298|EXPERIMENTAL|Persistent/Recurrent Ovarian Cancer|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
62390143|NCT04515849|EXPERIMENTAL|Cotadutide 300 micrograms|Cotadutide 300 micrograms administered subcutaneously
62561832|NCT02729298|EXPERIMENTAL|BRAF-Mutated Melanoma|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
62561833|NCT02264769|ACTIVE_COMPARATOR|Carbetocin 20mcg|Patient is given carbetocin 20 mcg intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
62561834|NCT02264769|ACTIVE_COMPARATOR|Carbetocin 100mcg|Patient is given carbetocin 100 mcg intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
62561835|NCT01116167|EXPERIMENTAL|Letrozole -Berberine|
62561836|NCT01116167|ACTIVE_COMPARATOR|Letrozole|
62561837|NCT01116167|ACTIVE_COMPARATOR|Berberine|
62390144|NCT04515849|EXPERIMENTAL|Cotadutide 600 micrograms|Cotadutide 600 micrograms administered subcutaneously
62390145|NCT04515849|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously
62561838|NCT04827823||Group 1- Amalgam restorations|Multi-surface amalgam restorations performed by dental students and are in function for about 5 years.
62561839|NCT04827823||Group 2- Composite restorations|Multi-surface composite restorations performed by dental students and are in function for about 5 years.
62561840|NCT06187129||diabetic children and adolescent with type 1 diabetes|nerve ultrasound and nerve conduction study
62561841|NCT06187129||healthy age matched group|nerve ultrasound
62561842|NCT05966584|EXPERIMENTAL|Benralizumab and PI3K inhibition (alpelisib)|Patients will receive fulvestrant or AIs and PI3K inhibition (alpelisib) per SOC (fulvestrant on days 1, 15, 29 and monthly thereafter; Ais on a daily continuous basis). Participants will receive one injection of benralizumab 30mg subcutaneously on day -1.
62561843|NCT04220788|EXPERIMENTAL|Enhanced pharmacist service|The advanced care group will be undergo a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA) with the pharmacist
62561844|NCT04220788|ACTIVE_COMPARATOR|Usual care|Patients in the usual care arm will receive their usual care which they will obtain care from their doctor,nurse and pharmacist where appropriate
62561845|NCT00529373|EXPERIMENTAL|Odanacatib|Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly for 5 years. Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.
62561846|NCT00529373|PLACEBO_COMPARATOR|Placebo|Participants receive blinded placebo to 50 mg of odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly for 5 years. Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.
62561847|NCT03943693|ACTIVE_COMPARATOR|Single Shock Group|Patients randomized to single shock will then be treated initially with a 200 Joule shock through the antero-posterior pads only.
62168606|NCT04124016|EXPERIMENTAL|grape seed|grape seed extract - rich in di-hydroxylated flavan-3-ol monomers (1 mmol of PVL precursors)
62168607|NCT04124016|EXPERIMENTAL|grape seed exctract|grape seed extract - rich in di-hydroxylated flavan-3-ol oligomers (1 mmol of PVL precursors)
62168608|NCT03326193|EXPERIMENTAL|Participants receiving niraparib+ bevacizumab|Participants will be administered bevacizumab 15 milligram per kilogram (mg/kg) via a 30 minute (min) intravenous (IV) infusion on Day 1 of each 21-day cycle. Niraparib will be administered orally once a day continuously throughout each 21-day cycle (84-day cycle after amendment 2). On Day 1 of each cycle, niraparib will be administered upon completion of bevacizumab infusion. The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count.
62390146|NCT04515849|ACTIVE_COMPARATOR|Semaglutide|Semaglutide 1.0 miligrams administered subcutaneously
62390147|NCT01011959|ACTIVE_COMPARATOR|1|dose 1 vs. placebo
62390148|NCT01011959|ACTIVE_COMPARATOR|2|dose 2 vs. placebo
62561848|NCT03943693|ACTIVE_COMPARATOR|Double Shock Group|Patients randomized to the dual shock group will have two near-simultaneous 200-Joule shocks delivered through the two sets of pads (antero-posterior position and right infraclavicular-axillary position). The first of these shocks will be synchronized.
62561849|NCT02841839|EXPERIMENTAL|2-step system|Subjects are to brush with 2-step system for 4 weeks; stannous fluoride
61994595|NCT05662579|EXPERIMENTAL|hip + core exercises|"In addition to all the exercises in the hip exercise group, this group will do:~PHASE I: (sessions 1 to 4)~1. Exercise for contraction of the transversus abdominais in the supine position~2. Bridge exercise~3. Plank exercise PHASE II: (sessions 5 to 8)~1. Unilateral bridge exercise 2. Plank exercise with hip extension 3. Lateral plank exercise"
61994596|NCT01878539|EXPERIMENTAL|Health Center training|The intervention will consist of a patient training programme involving the provision of information and practical training concerning their condition and its treatment, as well as how to use a portable blood coagulation monitoring device and adjust their anticoagulant dose.
61994597|NCT01306370|EXPERIMENTAL|Tranexamic acid|Tranexamic acid is a synthetic derivative of the amino acid lysine. It inhibits fibrinolysis by blocking the lysine binding sites on plasminogen and facilitates the coagulation process.
61994598|NCT01306370|EXPERIMENTAL|Fibrin glue BSTC|It is homologous fibrin glue from a single blood donor.
61994599|NCT01306370|EXPERIMENTAL|Tissucol|It is fibrin glue commercialized from multiple donors.
61994600|NCT01306370|OTHER|Habitual haemostasis|Electrocoagulation of blood vessels was performed during surgery in all patients (routine hemostasis)
62168609|NCT02701595|EXPERIMENTAL|Oral switch treatment|Oral switch to amoxicillin
62168610|NCT02701595|ACTIVE_COMPARATOR|Conventional IV treatment according to european guidelines|Conventional IV treatment of streptococci/enterococci IE (European guidelines 2015)
62168611|NCT06559098|EXPERIMENTAL|Stimulation|Patients who were previously enrolled in a vibrotactile study meant to reduce symptoms associated with Parkinson's disease will be enrolled in the study and will be asked to stimulate with the Stanford Coordinated Reset(CR) glove in sessions that last 2 hours. Sessions may be daily or a few times weekly depending on the needs of the patient.
62168612|NCT03785210|EXPERIMENTAL|1/Arm 1 - Nivolumab, Tadalafil and Oral Vancomycin|Nivolumab, tadalafil and oral vancomycin
62390149|NCT01011959|ACTIVE_COMPARATOR|3|dose 3 vs. placebo
62390150|NCT01011959|ACTIVE_COMPARATOR|4|dose 4 vs. placebo
62390151|NCT01011959|ACTIVE_COMPARATOR|5|dose 5 vs. placebo
62390152|NCT01011959|ACTIVE_COMPARATOR|6|dose 6 vs. placebo
62390153|NCT04691518|ACTIVE_COMPARATOR|Acute Intermittent Hypoxia (AIH)|Undergoing Acute Intermittent Hypoxia sessions
62390154|NCT04691518|PLACEBO_COMPARATOR|Sham AIH|Undergoing Sham AIH sessions
62390155|NCT02254876|ACTIVE_COMPARATOR|Standard physical therapy program|Standard physical therapy program is delivered for four rehabilitation sessions for a period of about 45 minutes each.
62390156|NCT02254876|EXPERIMENTAL|NeuroMuscular Taping (NMT)|"NeuroMuscular Taping is delivered in addiction to the Standard Treatment for four rehabilitation sessions. The sessions were spaced apart about five days to ensure the optimum adhesion of the NMT."
62390157|NCT01091116|EXPERIMENTAL|Double dose MEN16132 0.125 mg|Intra-articular administration of two 0.125 mg doses of MEN16132 at 2-week interval.
62390158|NCT01091116|EXPERIMENTAL|Double dose MEN16132 0.25 mg|Intra-articular administration of two 0.25 mg doses of MEN16132 at 2-week interval.
62390159|NCT01091116|EXPERIMENTAL|Double dose MEN16132 0.5 mg|Intra-articular administration of two 0.5 mg doses of MEN16132 at 2-week interval.
62390160|NCT01091116|EXPERIMENTAL|Single dose MEN16132 0.5 mg|Intra-articular administration of one 0.5 mg dose of MEN16132 followed by one intra-articular injection of placebo at 2-week interval.
62390161|NCT01091116|PLACEBO_COMPARATOR|Placebo|Intra-articular administration of two doses of Placebo at 2-week interval.
62390162|NCT05157009|OTHER|Immediate implant placement without reconstruction|Immediate implant placement after tooth extraction
62769618|NCT05613582|SHAM_COMPARATOR|Sham|The sham intervention procedure was carried out similarly to the experimental group, but in the following group, the device would only conduct electric current in the first and last 30 seconds of the intervention.
62390163|NCT05157009|OTHER|Immediate implant placement with reconstruction|Immediate implant placement and simultaneous bone reconstruction after tooth extraction
62390164|NCT03595072||Stimulation|patient ECOG recordings during active VNS stimulation
62390165|NCT03595072||interstimulation|the same patient ECOG during inter-stimulation periods
62390166|NCT04277286||Experimental group|Patients transferred to adult service according to the Transend transition program (between September 2016 and January 2018)
62561850|NCT06115135|EXPERIMENTAL|open-label|"This is a Phase 2, multicenter, open-label study evaluating the safety and efficacy of venetoclax in combination with isatuximab and dexamethasone among RRMM patients who show the t(11;14) marker and currently show PD and have received at least 3 prior lines of therapy for multiple myeloma. All subjects in Dose Level 0 will receive 1) venetoclax, PO, at 400 mg every day (QD) on Days 1-28 of a 28-day cycle, 2) dexamethasone 40 mg IV, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle where day 8 and 22 doses may be administered PO; and 3) isatuximab 10mg/kg, IV, on Days 1, 8, 15, and 22 of the first 28-day cycle, and then Days 1 and 15 during subsequent 28-day cycles.~The primary safety analysis will focus on determining the DLTs for the study regimen, and occurrence of AEs throughout the study."
62561851|NCT02883972|EXPERIMENTAL|Intervention letter and reminder|Behavioural insights informed invitation letter and SMS/email reminder message
62561852|NCT02883972|EXPERIMENTAL|Intervention letter|Behavioural insights informed invitation letter only
62561853|NCT02883972|EXPERIMENTAL|Control letter and reminder|Control invitation letter and SMS/email reminder message
62561854|NCT02883972|ACTIVE_COMPARATOR|Control letter|Control invitation letter only
62561855|NCT02696343|EXPERIMENTAL|EPI experimental|Preterm infants randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
62561856|NCT02696343|SHAM_COMPARATOR|EPI control|Preterm infants randomized to receive the Sham (blind pacifier) during tube feedings.
62561857|NCT03330561|EXPERIMENTAL|PRS-343|
62168613|NCT00666991|EXPERIMENTAL|Nanotax, 50 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 50 mg/m2 once every 28 days until progression or unacceptable toxicity
62390167|NCT04277286||Control group|Patients transferred to adult service without a transition program, in the same center, before the implementation of Transend (between January 2015 and September 2016)
62390168|NCT03303131||Period A|Children discharged as recovered from September 2007 to March 2009 with at least 15% of their weight at admission
62390169|NCT03303131||Period B|Children discharged as recovered from April 2009 to December 2011 with Children discharged as recovered from September 2007-March 2009 with MUAC ≥ 124 mm
62390170|NCT01948544||chronic obstructive pulmonary disease|"* More than 12 million adults are diagnosed with COPD~* COPD is the 4th leading cause of death in the U.S.~* Breathing difficulty is the major reason patients seek medical attention~* COPD patients requiring hospitalization were associated with higher costs~* Oximetry is an important tool for assessing need for Long-term oxygen therapy~* LTOT has been proven to improve survival and quality of life~* Patients will be provided a lightweight portable oxygen concentrator to:~  1. support increased activity~ 2. improve quality of life~ 3. increase functional capacity"
62390171|NCT06337656|EXPERIMENTAL|Galileo Intervention|
62390172|NCT06337656|NO_INTERVENTION|Galileo Control|
62390173|NCT03851302|EXPERIMENTAL|Active RIC + isometric hand exercise|Subjects will receive an active remote ischemic conditioning (200mmHg cuff pressure) before an active isometric hand exercise.
62390174|NCT03851302|SHAM_COMPARATOR|Sham RIC + isometric hand exercise|Subjects will receive an sham remote ischemic conditioning (10 mmHg below the subjects' diastolic blood pressure) before an active isometric hand exercise.
62561858|NCT06211309|ACTIVE_COMPARATOR|co.mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
62561859|NCT06211309|PLACEBO_COMPARATOR|Kin mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
62561860|NCT06211309|PLACEBO_COMPARATOR|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
62561861|NCT01341275|EXPERIMENTAL|birth, lower dose booster|Adolescents who received their first dose of hepatitis B vaccine at or before day 7 of life who received a 10 ug dose of hepatitis B vaccine as a booster
62561862|NCT01341275|EXPERIMENTAL|birth, higher dose booster|Adolescents who received their first dose of hepatitis B vaccine at or before day 7 of life who received a 20 ug dose of hepatitis B vaccine as a booster
62561863|NCT01341275|EXPERIMENTAL|4 weeks, lower dose booster|Adolescents who received their first dose of hepatitis B vaccine at or after 4 weeks of life who received a 10 ug dose of hepatitis B vaccine as a booster
62561864|NCT01341275|EXPERIMENTAL|4 weeks, higher dose booster|Adolescents who received their first dose of hepatitis B vaccine at or after 4 weeks of life who received a 20 ug dose of hepatitis B vaccine as a booster
62561865|NCT04319471|EXPERIMENTAL|Sufficient Chemotherapy Combine With Maintenance Chemotherapy|Patients with oligometastatic Nasopharyngeal Carcinoma was given S-1 40-60mg bid d1-14, q4w, oral maintenance chemotherapy for 1 year or capecitabine 2500mg/m2/d twice daily oral d1-14, q4w after receiving sufficient chemotherapy and consolidative local therapy
62561866|NCT00221338|EXPERIMENTAL|Gabapentin|Double blind, placebo controlled
62561867|NCT00221338|PLACEBO_COMPARATOR|Placebo|Double blind
62561868|NCT02832232|EXPERIMENTAL|Mobilization Group|translational dorsal glide mobilization technique grade III and Protocolized Physiotherapy
62561869|NCT02832232|EXPERIMENTAL|Maintained pressure Group|pressure maintained suboccipital inhibition technique and Protocolized Physiotherapy
62168614|NCT00666991|EXPERIMENTAL|Nanotax, 82.5 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 82.5 mg/m2 once every 28 days until progression or unacceptable toxicity
62168615|NCT00666991|EXPERIMENTAL|Nanotax, 125 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 125 mg/m2 once every 28 days until progression or unacceptable toxicity
62168616|NCT00666991|EXPERIMENTAL|Nanotax, 175 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 175 mg/m2 once every 28 days until progression or unacceptable toxicity
62390175|NCT00982800|PLACEBO_COMPARATOR|Placebo Sugar Pill|"Patients are stratified based on their initial pain score in the recovery room. patients with a pain numeric rating scale of greater than or equal to 7/10 are stratified to the high group. then randomized to receive gabapentin 200 mg tid x 9 doses, or placebo x 9 doses. Patients with a pain score equal to or less than 6/10 are stratified to the low group, then randomized to receive gabapentin 200mg tid x 9 doses or placebo x 9 doses.~All patients receive Acetaminophen 1gm every 6 hours for 3 days, Celecoxib 400mg as a loading dose then 200mg twice a day for 3 days. Patients also receive patient controlled analgesia (PCA) of hydromorphone for 24 hrs, then are transitioned to oxycodone 5-15 mg every 2 hours as needed."
62390176|NCT00982800|ACTIVE_COMPARATOR|Gabapentin 200 mg tid x 9 doses|
62390177|NCT06021912||ITA GROUP|Patients with asthma or allergic rhinitis who have received allergen immunotherapy (ITA).
62561870|NCT02832232|OTHER|Control Group|Protocolized Physiotherapy
62561871|NCT05230381|ACTIVE_COMPARATOR|Continous infusion group|Infusion with 20mg/kg tranexamic acid and 5mg/kg/h tranexamic acid.
62561872|NCT05230381|ACTIVE_COMPARATOR|Single infusion group|Infusion with 20mg/kg tranexamic acid and same volume 0.9% saline.
62561873|NCT05230381|PLACEBO_COMPARATOR|Placebo group|Infusion with same volume of 0.9% saline.
62561874|NCT04705792|EXPERIMENTAL|Physical activity|The program comprises the practice of resistance exercises for the main muscular groups, with free weights and with their own body weight against the action of gravity, the proposal consists of 3 weekly sessions, for 12 consecutive weeks.
62561875|NCT01026753|NO_INTERVENTION|FOBT by laboratory requisition or directly by PCP|The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit.
62561876|NCT01026753|EXPERIMENTAL|FOBT by lab req. or directly from PCP + study magnet|The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit. The family physician provides each patient with a study magnet containing a PHCC telephone number and study specific website address.
62561877|NCT03578224|EXPERIMENTAL|Diagnostic (EUS, FNA, perflubutane microbubble)|Participants undergo standard of care unenhanced endoscopic ultrasound (EUS) and fine needle aspiration (FNA) of identified lymph nodes. Participants then receive perflubutane microbubble peri- or intratumorally and undergo contrast-enhanced EUS followed by FNA of identified lymph nodes.
62561878|NCT02639845||Patients Prescribed Eye Drops|Patients who are scheduled to receive prescription eye drops due to complications such as cataract surgery, glaucoma, retina surgery, or eye-related condition.
62561879|NCT05510037||HER2-0|
62561880|NCT05510037||HER2-LOW|
62561881|NCT05510037||HER2-POSITIVE|
62561882|NCT04704310|EXPERIMENTAL|Intervention Group|Individuals acting as own control. Looking at changes pre and post intervention
62168617|NCT00666991|EXPERIMENTAL|Nanotax, 225 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 225 mg/m2 once every 28 days until progression or unacceptable toxicity
62168618|NCT00666991|EXPERIMENTAL|Nanotax 275 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 275 mg/m2 once every 28 days until progression or unacceptable toxicity
62168619|NCT04390451|EXPERIMENTAL|Whole Health STEPS|Participants will immediately receive Whole Health STEPS.
62168620|NCT04390451|OTHER|Waitlist|Participants will receive Whole Health STEPS after a defined waiting period.
62168621|NCT01961804|OTHER|Actual recommendations|Current guidelines recommend to perform a CT scan and realise the anticoagulation reversion only in case of intracranial bleeding diagnosed.
62390178|NCT06021912||STANDARD TREATMENT|patients with asthma or allergic rhinitis who have received standard allergen treatment.
62390179|NCT03029494|EXPERIMENTAL|Treatment 1: stabilization splint, placebo oral tablet|stabilization splint during night and 1 placebo oral tablet daily, for 6 months
62390180|NCT03029494|ACTIVE_COMPARATOR|Treatment 2: placebo splint, vitamin C|placebo splint during night and 1000 mg Vitamin C tablet daily, for 6 months
62390181|NCT03029494|NO_INTERVENTION|Control group|determination of oxidative stress biomarkers and cortisol in saliva of healthy control subjects
62390182|NCT06026137|EXPERIMENTAL|eFisioTrack Group|"Use of the eFisioTrack platform in the experimental group to perform active exercises as part of their shoulder rehabilitation. These will. bee performed independently by each patient in a hospital room, using the efisioTrack system without supervision by the physiotherapist.~The subjects will be previously instructed in the use of the system in two 20-minute sessions. The type of exercise and its parameters will be chosen and progressed considering the functional status of the patient and being similar to those executed under the physiotherapist's supervision."
62390183|NCT06026137|ACTIVE_COMPARATOR|Excercises Group|Patients who performed the exercise program supervised by the physical physiotherapist in a hospital room.
62390184|NCT02372539||Non-diabetes|Patients without diabetes will serve as the control group
62561883|NCT03077477|PLACEBO_COMPARATOR|SAD|"Cohort will have a total 6 subjects: SAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate);~SAD cohorts are defined as follows:~* Cohort 1: One placebo and one AMXT 1501 dicaprate subject will be treated as sentinel subjects receiving one tablet each of their assigned treatment. Assuming no intolerance is noted after at least 3 days, the remaining cohort subjects (placebo, 1 subject and AMXT 1501 dicaprate, 3 subjects) will be treated.~* Cohort 2: 2 subjects 2 placebo each and 4 subjects 2 AMXT 1501 dicaprate tablets each~* Cohort 3: 2 subjects 4 placebos each and 4 subjects 4 AMXT 1501 dicaprate tablets each~* Cohort 4: 2 subjects 8 placebos each and 4 subjects 8 AMXT 1501 dicaprate tablets each"
62561884|NCT03077477|PLACEBO_COMPARATOR|MAD|"Each cohort will have a total 6 subjects: MAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate); MAD cohorts will receive dosing once daily for 14 consecutive days. Dosing will be contingent on adequate tolerance in Cohorts 1-5.~* Cohort 6: 2 subjects 2 placebos each; 4 subjects 2 AMXT 1501 dicaprate tablets each~* Cohort 7: 2 subjects 4 placebos each; 4 subjects 4 AMXT 1501 dicaprate tablets each~* Cohort 8: 2 subjects 8 placebos each; 4 subjects 8 AMXT 1501 dicaprate tablets each"
62390185|NCT02372539||Diabetes|Patients with diabetes will be further stratified based upon antihyperglycemic medications (insulin versus oral medications)
62390186|NCT06187519|EXPERIMENTAL|Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch|15 patients with gout will be invited to participate in a standardized meal at the UCLA Human Nutrition Center and a 7-day community follow up for the measurement of uric acid (and other metabolites) using our Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch.
62390187|NCT02119780|EXPERIMENTAL|YVOIRE® contour|
62390188|NCT02119780|ACTIVE_COMPARATOR|Restylane SubQ™|
62390189|NCT04126759|EXPERIMENTAL|Protocol 1|The subjects enrolled in this protocol will dedicate 33 days of home-based measurement and two days for in-clinic measurements. For reference measurements, subjects will be equipped with a BG-meter (Contour Next One, Ascenia). Optical measurements are collected with the IMD. Each day of measurements consists of four sessions each comprising two capillary blood glucose measurement with a BG-meter and two IMD measurements. IMD measurements will be performed using the thenar of the right hand of the subject.
62390190|NCT05352451|EXPERIMENTAL|Intervention Arm - coaching sessions|Intervention group, will be asked to complete the surveys before and after attending coaching sessions. The two interviews each lasting for about one hour and will be done in-person or through video-conferencing meeting (depending on which is more convenient for you) with a study team member
62390191|NCT05352451|ACTIVE_COMPARATOR|Control Arm - interview|"Will be asked to complete the same surveys at appropriate time after meeting with the research assistant. Be asked to complete brief questionnaire about the understanding of the illness.~All individual interviews, patient and caregiver coaching, and caregiver support sessions will be audio recorded. The recorders are password protected and the audio files will be saved securely. Only authorized study team members can access the recordings to evaluate how well the answers to survey questions are logged and how well the coaching/support content is delivered by the study team member."
62390192|NCT01790633|ACTIVE_COMPARATOR|Standard testing with ELISA|HBV, HCV, and HIV infection status determined by enzyme-linked immuno-assay (ELISA).
62390193|NCT01790633|EXPERIMENTAL|Rapid testing|HBV, HCV, and HIV infection status determined by a rapid test
62390194|NCT03187314|EXPERIMENTAL|Experimental Group|Radiation to 60 Gy, 5 x per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
62390195|NCT05779410|EXPERIMENTAL|Vitamin D group|
62390196|NCT05779410|PLACEBO_COMPARATOR|Placebo group|
62390197|NCT04434703|ACTIVE_COMPARATOR|Platelet rich fibrin (PRF)|Platelet rich fibrin is the secoond generation of platelet concentrates which is an autogenous biomaterial that is prepared from the patient's own blood
62390198|NCT04434703|EXPERIMENTAL|Advanced platelet rich fibrin (A-PRF)|Advanced platelet rich fibrin is the last modification of PRF which is expected to contain a relatively greater number of white blood cellsand growth factors
62390199|NCT04434703|PLACEBO_COMPARATOR|blood clot|normal healing of the wound without adding any biomaterial
62390200|NCT00266799|EXPERIMENTAL|Pegylated liposomal doxorubicin|
62390201|NCT00266799|ACTIVE_COMPARATOR|Capecitabine|
62390202|NCT01288742|EXPERIMENTAL|001|TMC435 One 150-mg capsule once daily for 7 days (Trts B and D).
62390203|NCT01288742|EXPERIMENTAL|002|Digoxin One 0.25-mg tablet for 1 day (Trt A)
62390204|NCT01288742|EXPERIMENTAL|003|Digoxin One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
62390205|NCT01288742|EXPERIMENTAL|004|Rosuvastatin One 10-mg tablet for 1 day (Trt C).
62390206|NCT01288742|EXPERIMENTAL|005|Rosuvastatin One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
62390207|NCT03302923|EXPERIMENTAL|Brisk walking 1|1 time a week of 9 months brisk walking
62390208|NCT03302923|EXPERIMENTAL|Brisk walking 3|3 times a week of 9 months brisk walking
62390209|NCT03302923|NO_INTERVENTION|Control group|No brisk walking session
62390210|NCT00453349|EXPERIMENTAL|Moxifloxacin|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
62390211|NCT00453349|ACTIVE_COMPARATOR|Levofloxacin plus Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
62390212|NCT04726943|EXPERIMENTAL|RF Energy|RF delivery targeting the atrial side of a significant residual leak in patients with acute and chronic evidence of incomplete percutaneous LAA occlusion
62390213|NCT06241144|EXPERIMENTAL|Intervention|
62390214|NCT06241144|NO_INTERVENTION|Control|
62390215|NCT03804476|EXPERIMENTAL|AER-271|The experimental drug AER-271 will be administered in this Arm. In Part A single ascending doses will be administered by IV bolus infusion of AER-271 formulated in phosphate buffered normal saline over a 30-min period. In Part B multiple ascending doses of AER-271 will be administered by IV 30-min bolus infusion BID for 72 hours. AER-271 will also be administered as an initial bolus dose over 30-min then continuous infusion over 72 hours.
62390216|NCT03804476|PLACEBO_COMPARATOR|Placebo|A placebo control will be administered in this Arm. In Part A phosphate buffered normal saline will be administered over a 30-min period. In Part B multiple doses of phosphate buffered normal saline will be administered by IV 30-min bolus infusion BID for 72 hours. This placebo will also be administered as an initial bolus dose over 30-min then continuous infusion over 72 hours. In both Parts, the volume of placebo administered will be the same as the Experimental Arm.
62390217|NCT06098001|ACTIVE_COMPARATOR|Low dose fiber|Dose esacalation design
62561885|NCT03077477|ACTIVE_COMPARATOR|FE|"Each cohort will have a total 6 subjects: FE crossover (6 subjects receiving active AMXT 1501 dicaprate).~FE Crossover:~• Cohort 5: 6 new subjects will be randomized to a fed (n=3 standard meal) or fasted (n=3) group and administered the highest dose of AMXT 1501 dicaprate tolerated by previous cohorts. First dose and accompanying assessments will be referred to as Period 1. Subjects will then crossover to the opposite diet plan (fed or fasted) and receive a second administration of study treatment at the same dose level. The second dose and assessments are referred to as Period 2. There will be a 7-day washout between doses administered in Periods 1 and 2."
62168622|NCT01961804|EXPERIMENTAL|Preventive reversion|Realise a preventive reversion before performing any CT scan.
62390218|NCT06098001|ACTIVE_COMPARATOR|High dose of fiber|Dose escalation design which is one arm with low and followed by high dose
62390219|NCT04974294|ACTIVE_COMPARATOR|PPV23|
62390220|NCT04974294|ACTIVE_COMPARATOR|PCV13|
62390221|NCT04974294|PLACEBO_COMPARATOR|Saline placebo|
62390222|NCT02646501|EXPERIMENTAL|group A+PSGB|(Antiarrhythmic drug + percutaneous stellate ganglion block) group
62390223|NCT02646501|ACTIVE_COMPARATOR|group A|Antiarrhythmic drug group
62390224|NCT01621659|EXPERIMENTAL|multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
62390225|NCT01621659|NO_INTERVENTION|Observational arm|Participants randomized to observational arm will receive usual care.
62390226|NCT02219750|ACTIVE_COMPARATOR|Preprandial premix therapy|switch twice-daily insulin Preprandial premix therapy mean that transition of advance insulin based on the basal insulin daily total dose at study entry divided into two equal dose of preprandial NovoMix 30. Patient discontinued all pre-study oral antidiabetic drug(OAD), including sulfonylureas, glinides, Thiazolidinedione(TZD) and Dipeptidyl peptidase-4(DPP-4) inhibitor but left metformin alone
62390227|NCT02219750|ACTIVE_COMPARATOR|Basal-plus insulin|switch twice-daily insulin Basal-plus insulin consisted of continued previous basal insulin and add-on once-daily insulin aspart(NovoRapid) before breakfast. The starting dose of insulin aspart was 4 unit(U) before breakfast and continued under previous basal insulin dose.
62390228|NCT00389922|EXPERIMENTAL|A (Daily Dosing)|"Oral lapatinib given daily for 28 days plus IV vinorelbine given weekly (3 out of 4 weeks)~Cohorts of 3-6 patients receive escalating doses of lapatinib ditosylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during course 1. At least 6 patients are treated at the MTD. Once the MTD of lapatinib has been determined, patients may be accrued to group B or to a separate pharmacokinetics cohort in group A."
62168623|NCT05944133||Patients enrolled|Patients who are enrolled on health plans during active MOUD treatment.
62390229|NCT00389922|EXPERIMENTAL|B (Intermittent Dosing)|"Oral lapatinib given days 2-5, 9-12 and 16-25 plus IV vinorelbine given weekly (3 out of 4 weeks)~Cohorts of 3-6 patients receive escalating doses of lapatinib ditosylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during course 1. At least 6 patients are treated at the MTD. Once the MTD of lapatinib has been determined, patients may be accrued to group B or to a separate pharmacokinetics cohort in group A."
62390230|NCT01724749||Healthy control subjects|"1. Age: 21 - 80 years~2. No prior history or symptoms of cardiovascular disease~The investigators aim to include equal numbers of females and males. Furthermore, the investigators aim to include patients in six different age strata: 21-30, 31-40, 41-50, 51-60, 61-70, 71-80."
62561886|NCT04396808|ACTIVE_COMPARATOR|Standard of care (no pre-treatment genomics testing)|Provider will discuss askMUSIC results with patient prior to deciding on a management strategy (standard of care).
62168624|NCT05944133||Patients who disenrolled|Patients who disenrolled from health plans during active MOUD treatment.
62168625|NCT02368691|EXPERIMENTAL|GTx-024|GTx-024 capsules, 18 mg PO once-daily for up to 12 months
62168626|NCT01819428|EXPERIMENTAL|NOV120101 (Poziotinib)|Single arm study with NOV120101(poziotinib)12mg PO daily administration
62168627|NCT05285878|PLACEBO_COMPARATOR|Placebo|Participants will take a placebo capsule daily for 3 months. Placebo will be methylcellulose encapsulated into an opaque closed gelatin capsule for blinding. Capsules will be placed in a labeled bottle, with the contents only identifiable by a code on the package label and only the compounding pharmacy and the unblinded pharmacist at Houston Methodist Investigational Drug Service will know the code definition.
62390231|NCT01724749||Subjects with cardiovascular disease|"1. Age: 21 - 80 years~2. HeartSCORE \> 0%~3. Symptoms of angina pectoris~The investigators aim to include equal numbers of females and males. Furthermore, the investigators aim to include patients in six different age strata: 21-30, 31-40, 41-50, 51-60, 61-70, 71-80. Also, the investigators aim to include patients in 3 strata of HeartSCORE risk: low risk (1-4%), mild risk (5-9%) and high risk (\> 9%)"
62390232|NCT05493579|EXPERIMENTAL|Complete denture then complete implant supported overdenture|
62390233|NCT01619631|EXPERIMENTAL|12-week Tai Chi intervention|
62390234|NCT01619631|ACTIVE_COMPARATOR|Education control group|After 24 weeks, and upon completion of the study, each participant will be offered twelve weeks of Tai Chi twice weekly.
62390235|NCT01619631|NO_INTERVENTION|Waitlist control group|The waitlist control will not receive any intervention during the duration of the study. After 24 weeks, and upon completion of the study, each participant will be offered twelve weeks of Tai Chi twice weekly.
62390236|NCT04470362|PLACEBO_COMPARATOR|Control group|The control group will receive an isokinetic strengthening program for the quadriceps muscles. Twenty-four strengthening session will be performed using an isokinetic device. The exercise program begins with 60% of the mean peak torque, and the patient reaches this intensity by auditory biofeedback. An increasing dose program will be used in the first 5 sessions (1 set to 5 sets), and a dose of 6 sets will be applied from the sixth to twenty-fourth sessions, with the density rising from 60% to 80% of the mean peak torque according to the patient tolerance. Each set consisted of 5 repetitions of concentric (Con/Ecc) contraction in angular velocities of 30°/second and 120°/second for extensors. This program accomplished significant results in increasing quadriceps power and strength.
62168628|NCT05285878|ACTIVE_COMPARATOR|Fingolimod|Participants will take a 0.5 mg fingolimod capsule each day for 3 months. The fingolimod capsule will be placed inside an opaque closed gelatin capsule without transformation of the manufacteror's fingolimod capsule. The fingolimod blinded product and the placebo capsule will be identical in size, color, appearance, and weight.
62168629|NCT01099813||Inpatients assessed for critical care|Patients admitted to Critical Care Units participating in the ICNARC CMP programme who have been assessed at any time on a ward prior to ICU admission by a critical care decision maker (e.g. the CCOT or any member of the medical staff on duty for the unit)
62390237|NCT04470362|EXPERIMENTAL|Study group|"* Participants in the study group will perform the same exercise parameters used in the control group but in a different manner.~* The isokinetic exercise will be done with a closed eye to improve the proprioception function. This exercise will be performed for 6 sets.~* Additional training will be performed by the application of three vibrators above and on both sides of the knee joint to improve the function of the Pacinian and Meissner corpuscles which is one of the included receptors in the sensation of the fatigue."
62561887|NCT04396808|ACTIVE_COMPARATOR|Standard of care + pre-treatment genomics testing|Provider will discuss askMUSIC and Gene Expression Classifier (GEC) results with patient prior to deciding on a cancer management strategy. Patients' biopsy tissue will be analyzed using one of the following GECs: Decipher, Prolaris or Oncotype Dx.
61994601|NCT00747435|EXPERIMENTAL|Original Audiological Criteria|"Inclusion Criteria:~Pure-tone air-conduction threshold levels shall fall at or within the levels listed in the following chart.~Frequency (Hz): 250 500 750 1000 1500 2000 4000 8000 Lower Limit: 10 10 10 60 60 70 70 70 Upper Limit: 65 65 75 \*110+ \*110+\*110+ \*110+ \*90+~Minimal benefit from optimally fit hearing aid/s, preferably bilateral, with monosyllabic word scores in quiet of ≤50% in the best-aided condition."
62168630|NCT01856647||lean (BMI≤ 24.9 Kg/m2)|Adipose tissue biopsy (fat biopsy) in 9 lean (BMI≤ 24.9 Kg/m2)
62168631|NCT01856647||obese (BMI= 30-40 Kg/m2)|9 obese (BMI= 30-40 Kg/m2)
62168632|NCT01856647||psoriatic lean|9 psoriatic lean
62168633|NCT01856647||psoriatic obese|9 psoriatic obese
62182717|NCT03272529||Idealized simulated rehearsals|Participants recruited to this cohort will complete just-in-time simulation, i.e., practice a short time prior to the live event using hydrogel models that incorporate the necessary anatomy, physiology, and pathology of an ideal training case. This is in addition to standard prerequisite simulation training.
62390238|NCT02138864|EXPERIMENTAL|18F-FP-(+)-DTBZ only|PET tracer: 18F-FP-(+)-DTBZ
62390239|NCT04284579|EXPERIMENTAL|time for cannulation|intravenous cannulation after sevoflurane induction
62390240|NCT02838186|ACTIVE_COMPARATOR|right colon in retroflexion|"* polyp/adenoma detection~* feasibility"
62390241|NCT02838186|ACTIVE_COMPARATOR|right colon in forward view|polyp/adenoma detection
62390242|NCT02828982|EXPERIMENTAL|Powered Ankle Prosthesis|In this condition, the participant is fitted with a powered prosthetic ankle by a certified prosthetist. The ankle is the BiOM which is manufactured by Bionx (which used to be named iWalk). This device was given 510(K) Exempt status by the FDA under (regulation number: 890.3500). Participants will wear the device for 2 weeks.
62390243|NCT02828982|SHAM_COMPARATOR|Dynamic Response Foot|In this arm, participants will wear their clinically prescribed dynamic response foot. This period is 2 weeks long.
62390244|NCT00669240||1. Non-interventional|Patients prescribed varenicline in a non interventional manner.
62168634|NCT02509754|EXPERIMENTAL|Atrial fibrillation catheter ablation|Atrial fibrillation (AF) catheter ablation is performed following each Center's common practice. Activated clotting time (ACT) is maintained above 350 seconds. The left atrium (LA) is accessed by transseptal puncture or through a patent foramen ovale. A multipolar catheter and an irrigated-tip ablation catheter are inserted into the LA and a 3-dimensional reconstruction of the LA and pulmonary veins (PVs) ostia is performed. The mainstay is to obtain a complete antral PVs isolation, defined by complete elimination of PVs potentials. PVs isolation may be accompanied by the creation of linear lesions (roof line, left isthmus) or ablation of complex fractioned atrial electrograms. Patients are discharged on oral anticoagulation and optimal medical therapy. Each center will evaluate patients for ICD implantation; a loop recorder may be implanted if within routine clinical practice.
62168635|NCT02509754|EXPERIMENTAL|Rate control arm|Patients randomized to rate control only arm will undergo ICD implantation and optimization of the rate control therapy. In case of uncontrolled ventricular rate at 24-h ECG Holter, defined as a mean resting heart rate higher than 90 bpm, patients will receive atrioventricular (AV) node ablation and resyncronization therapy (CRT-D) implantation, performed following common practice at each Center. In case of failure or technical difficulties of the transvenous approach, epicardial screw-in or steroid-eluting passive lead is implanted via a limited thoracotomy. Transcatheter AV node ablation is performed as follows: a non-irrigated tip ablation catheter is introduced on the right side of the interatrial septum and ablation performed on the fast pathway region or the smallest His bundle signal. The goal of the procedure is AV modulation below 30 bpm or complete AV block.
62168636|NCT01181206|ACTIVE_COMPARATOR|Arm 1|
62168637|NCT01181206|ACTIVE_COMPARATOR|Arm 2|
62168638|NCT04348383|EXPERIMENTAL|Defibrotide + standard therapy|Defibrotide + standard therapy
62168639|NCT04348383|PLACEBO_COMPARATOR|Placebo|Placebo + standard therapy
62168640|NCT01798238|PLACEBO_COMPARATOR|Placebo group|
62168641|NCT01798238|EXPERIMENTAL|MP-513 group|
62168642|NCT05432583|EXPERIMENTAL|Part A - BNT163|Escalating dose levels
62390245|NCT01942564||Case Subjects|"1. Age 18 years or older~2. Had a head injury that occurred at least 6 months prior to entering study~3. Have found lights more bothersome since injury"
62168643|NCT05432583|PLACEBO_COMPARATOR|Part A - Placebo|Isotonic NaCl solution (0.9%)
62168644|NCT05432583|EXPERIMENTAL|Part B - BNT163 Dose 1|
62168645|NCT05432583|EXPERIMENTAL|Part B - BNT163 Dose 2|
62561888|NCT01859338||MRI, CBCT, FBCT|Patients undergo MRI and fan beam CT (FBCT) at baseline, within the first 3 weeks of radiotherapy and between week 4 and 6 of radiotherapy. Patients with lung cancer may undergo 4D cone beam x-ray CT (CBCT) on the same day as the second and third MRI and FBCT.
62561889|NCT01861743|EXPERIMENTAL|Multimodal analgesia|multiple analgesic medications utilized in a synergistic manner to control pain while minimizing side-effects of individual drugs due to decreased doses. This includes pre-operative patient education, intra-operative pain management and post-operative pain protocols.
62168646|NCT05432583|EXPERIMENTAL|Part C - BNT163|One fix dose level of BNT163
62168647|NCT05432583|PLACEBO_COMPARATOR|Part C - Placebo|Isotonic NaCl solution (0.9%)
62561890|NCT01861743|ACTIVE_COMPARATOR|Patient Controlled analgesia|Pain management using patient controlled narcotic analgesia.
62561891|NCT04383548|EXPERIMENTAL|Hyper immunoglobulins have anti-Corona VS2 immunoglobulin|safe purified hyper immunoglobulins containing anti-Corona VS2 immunoglobulins from plasma collected from COVID19 convalescent patients
62561892|NCT03915132|EXPERIMENTAL|VMAT plus Nimotuzumab|Patients receive Nimotuzumab weekly during radiotherapy .
62390246|NCT01942564||Control Subjects|"1. Age 18 years or older~2. Have not had a previous head injury~3. Have had a full eye examination at Ohio State University College of Optometry during last 6 months."
62561893|NCT05421819|ACTIVE_COMPARATOR|Calcium and vitamin D supplement|In this arm, 50 women will receive calcium and vitamin D supplement once per day.
62561894|NCT05421819|ACTIVE_COMPARATOR|Calcium, vitamin D and prebiotic supplement|In this arm, 50 women will receive calcium, vitamin D and prebiotic supplement once per day.
62168648|NCT00699829||1|Mohs' micrographic surgery (MMS)
62168649|NCT00699829||2|Conventional surgery
62168650|NCT03759132|EXPERIMENTAL|Anodal tDCS|"Bihemispheric tDCS applied over primary motor cortex.~Dose: 2mA, 20 minutes"
62168651|NCT03759132|SHAM_COMPARATOR|Sham tDCS|"Bihemispheric tDCS applied over primary motor cortex.~Dose: 2mA, 20 minutes (30s ON)"
62561895|NCT05421819|ACTIVE_COMPARATOR|Calcium, vitamin D, prebiotic and flavonoid supplement|In this arm, 50 women will receive calcium, vitamin D, prebiotic and flavonoid supplement once per day.
62168652|NCT03603223|EXPERIMENTAL|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
62168653|NCT03609671|EXPERIMENTAL|Standard of Care + Intervention (Individualized Therapy)|Intervention (individualized therapy) plus Standard of Care, and the completion of a psychological questionnaire at chemotherapy start and at the end, approximately four to six months later.
62168654|NCT03609671|OTHER|Control Group: Standard of Care|Standard of Care plus the completion of a psychological questionnaire at the beginning of the chemotherapy and at the end, approximately four to six months later.
62168655|NCT05742256|EXPERIMENTAL|Test group 1(OCA group)|
62168656|NCT05742256|EXPERIMENTAL|Test group 2(OCB group)|
62168657|NCT05742256|ACTIVE_COMPARATOR|Control group(SF group)|
62168658|NCT02394171|EXPERIMENTAL|Physical Activity|Women completed a physical activity group cohesion intervention which included six content intensive intervention sessions over a 24 week period that focused on specific group dynamics team building strategies to increase physical activity. A small team structure was used for peer problem solving and support throughout the intervention. Teams were given weekly physical activity goals, with slowly increasing weekly minutes milestones to gradually meet recommended amounts of physical activity. Sessions included brief instructions, team-based activities, and discussion with the entire group lead by a trained health educator. The intervention sessions ended with the health educator leading the teams in a brisk 15-minute walk.
62390247|NCT05892094|EXPERIMENTAL|Exercise Group|Participants will participate in a 12-week full-body resistance and aerobic exercise program. It will include full body resistance exercises two days a week and aerobic exercise program three days a week. For aerobic exercise, participants will be asked to do brisk walking 3 days a week. Participants will be called regularly to monitor their participation in the aerobic exercise program. Resistance exercises sessions will be supervised by a physical therapist. Each resistance training session will include five minutes of warm-up, forty minutes of resistance training and five minutes of cool-down. Resistance exercises will consist of weight-bearing exercises performed with the participant's own body weight. Participants in the exercise group will complete the questionnaires at baseline and after 12 weeks at the end of the intervention.
62390248|NCT05892094|NO_INTERVENTION|Control Group|Participants in the control group were instructed not to change their physical activity habits during 15 weeks and to avoid any other treatment for vasomotor symptoms. Participants in the control group will complete the questionnaires at baseline and after 12 weeks.
62390249|NCT04008160||healthy persons|
62390250|NCT04008160||individuals with paraplegia|
62390251|NCT01047215|ACTIVE_COMPARATOR|Aripipazole|Heart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication
62390252|NCT01047215|ACTIVE_COMPARATOR|Quetiapine|Heart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication
62168659|NCT02394171|ACTIVE_COMPARATOR|Fruit and Vegetable|Women completed a fruit and vegetable group cohesion intervention which involved six content intensive intervention sessions over a 24 week period that focused on specific group dynamics team building strategies to increase fruit and vegetable consumption. A small team structure was used for peer problem solving and support throughout. Teams were given weekly fruit and vegetable consumption goals at each session, with slowly increasing weekly servings milestones to gradually meet recommended amounts of fruit and vegetable consumption. Sessions included brief instructions, team-based activities, and discussion with the entire group lead by a trained health educator. The intervention sessions ended with the health educator leading the teams in a fruit and vegetable taste test.
62168660|NCT01193283|EXPERIMENTAL|SAA hematologic response|Treatment-naive severe aplastic anemia patients will receive a low dose of cyclophosphamide (120mg/kg) and low dose cyclosporine ( target therapeutic level of 100-200 micrograms per liter). Cyclophosphamide will be given once daily for 4 doses. Cyclosporine will be started after cyclophosphamide completion, cyclosporine will be given twice daily. The dosing will be modified to attain the therapeutic level.
62168661|NCT02636751|EXPERIMENTAL|In-person prehabilitation group|The participants in this group will receive a 12-week rehabilitation program (2x/week) including, education, stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities, in addition to walking aid adjustment. General information about pain control, such as ice application and medication usage will also be provided
62168662|NCT02636751|EXPERIMENTAL|Tele-prehabilitation group|The participants in this group will receive a 12-week rehabilitation program (2x/week) including, education, stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities, in addition to walking aid adjustment using a telecommunication software (Reacts®, Facetime® or Skype®). General information about pain control, such as ice application and medication usage will also be provided.
62390253|NCT01645215|EXPERIMENTAL|Fruquintinib capsule|cohort 1: fruquintinb continuous oral dosing (1mg once a day) cohort 2: fruquintinb continuous oral dosing (2mg once a day) cohort 3: fruquintinb continuous oral dosing (4mg once a day) cohort 4: fruquintinb continuous oral dosing (6mg once a day) cohort 5: fruquintinb continuous oral dosing (5mg once a day) cohort 6: fruquintinb oral dosing, 3 weeks on/1 week off (5mg once a day) cohort 7: fruquintinb oral dosing, 3 weeks on/1 week off (6mg once a day)
62390254|NCT03658213|EXPERIMENTAL|ZOLADEX 10.8 mg depot group|• ZOLADEX 10.8 mg depot group: subcutaneous depot injection once every 12 weeks
62390255|NCT03658213|ACTIVE_COMPARATOR|ZOLADEX 3.6 mg depot group|• ZOLADEX 3.6 mg depot group: subcutaneous depot injection once every 4 weeks
62390256|NCT04324983|OTHER|Biomarker|This single-arm study is a Phase I study to exploratively identify potential biomarkers in patients with early prostate cancer relapse and limited metastases in PSMA-PET, who need further assistance in treatment decisions (for or against local treatment options).
62390257|NCT04704869|EXPERIMENTAL|Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood)|Cryoprecipitate will be given in addition to the standard of care massive transfusion protocol products, which include red blood cells, plasma, platelets and whole blood. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).
62561896|NCT02598635|EXPERIMENTAL|Cholecalciferol|A capsule of pulverized cholecalciferol 4800 U will be administered once a day for 16 weeks. At serum calcium levels \> 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels \> 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to \< 10.6 mg/dL and/or \<7.1 mg/dL respectively.
62390258|NCT04704869|ACTIVE_COMPARATOR|Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood)|Only standard of care massive transfusion protocol products will be given, including red blood cells, plasma, platelets, and whole blood.
62390259|NCT01868126|EXPERIMENTAL|Group 1: DE-117 ophthalmic solution|One drop DE-117 Low Dose in each eye daily for 28 days
62390260|NCT01868126|EXPERIMENTAL|Group 2: DE-117 ophthalmic solution|One drop DE-117 Low Middle Dose in each eye daily for 28 days
62390261|NCT01868126|EXPERIMENTAL|Group 3: DE-117 ophthalmic solution|One drop DE-117 High Middle Dose in each eye daily for 28 days
62390262|NCT01868126|EXPERIMENTAL|Group 4: DE-117 ophthalmic solution|One drop DE-117 High Dose in each eye daily for 28 days
62561897|NCT02598635|PLACEBO_COMPARATOR|Placebo|An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks. At serum calcium levels \> 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels \> 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to \< 10.6 mg/dL and/or \<7.1 mg/dL respectively.
62561898|NCT01941615|EXPERIMENTAL|BI 207127 + faldaprevir + Microgynon|Period A: Microgynon®; Period B: Microgynon® + FDV + BI 207127
62561899|NCT06144138|EXPERIMENTAL|Breathing Exercises followed by Meditation|Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Participants will receive three weekly online instructions (90 minutes each) by trained instructors in addition to standard care. Weekly 60 minutes follow-ups will include 10 minutes of breathing exercises followed by 33 minutes of guided meditation practice, and then focus on participants' experiences with breathing exercise followed by meditation during the week, additional observations, and a review of relevant knowledge to support their home practice.
62769619|NCT04033874|EXPERIMENTAL|Kangaroo care|"Heel stick procedure will be performed during kangaroo care.~During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
62769620|NCT04033874|EXPERIMENTAL|Mother's lap|"Heel stick procedure will be performed during newborns who are holding on their mother's lap.~During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
62168663|NCT02636751|ACTIVE_COMPARATOR|Usual care group|The participants in this group will be provided with the hospital's usual documentation before total joint arthroplasties, consisting of information regarding the pre- and post-surgery course and medication.
62168664|NCT02062671|EXPERIMENTAL|immediate renal denervation|immediate renal denervation
62390263|NCT01868126|ACTIVE_COMPARATOR|latanoprost ophthalmic solution|One drop latanoprost 0.005% in each eye daily for 28 days
62561900|NCT06144138|NO_INTERVENTION|Treatment as Usual|The usual standard of care for patients with glaucoma includes starting them on first line of drugs. Participants will be initiated and maintained on appropriate dosages of such medications as part of standard of care. The usual standard of care also includes an ophthalmic examination measuring best-corrected Snellen VA and pinhole acuities and a follow-up visit once a year.
62561901|NCT04699929|EXPERIMENTAL|Intervention/treatment|All subject will receive YH001 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
62561902|NCT01144611|ACTIVE_COMPARATOR|bIAP|intravenous as a bolus of bIAP (alkaline phosphatase, 1000 IU) just prior to surgery followed by a 40 IU/kg bIAP infusion during the first 8 hours post surgery.
62168665|NCT02062671|ACTIVE_COMPARATOR|delayed renal denervation|delayed renal denervation
62390264|NCT01868126|PLACEBO_COMPARATOR|placebo (vehicle of DE-117) ophthalmic solution|One drop DE-117 vehicle in each eye once daily for 28 days
62390265|NCT02487576|OTHER|Carbohydrate-rich_Fat-rich (HC_HF)|Isocaloric carbohydrate-rich meals in the morning (06.00 am - 01.30 pm) and isocaloric fat-rich meals in the evening (04.30 pm - 10.00 pm) for 4 weeks
62390266|NCT02487576|OTHER|Fat-rich_Carbohydrate-rich (HF_HC)|Isocaloric fat-rich meals in the morning (06.00 am - 01.30 pm) and isocaloric carbohydrate-rich meals in the evening (04.30 pm - 10.00 pm) for 4 weeks
62168666|NCT00749671|ACTIVE_COMPARATOR|ICD testing BIS|Bispectral Index Monitoring will be used to assess adequacy of moderate sedation during DFT.
62168667|NCT00749671|ACTIVE_COMPARATOR|ICD testing Ramsey|Ramsey Sedation Scale will be used to assess adequacy of moderate sedation during DFT
62390267|NCT01922869|EXPERIMENTAL|COB mixture|One time ingestion of flavonoid mixture from chocolate (80 g), orange juice (500 ml)and blackberries (160 g), also known as the 'COB mixture' providing approximately 640 mg of flavan-3-ols, 390 mg of anthocyanins and 342 mg of flavanones respectively.
62390268|NCT01828346|EXPERIMENTAL|Treatment|5-Azacitidine plus birinapant
62390269|NCT01598831|ACTIVE_COMPARATOR|ART-123|
62390270|NCT01598831|PLACEBO_COMPARATOR|Placebo|
62561903|NCT01144611|PLACEBO_COMPARATOR|placebo|intravenous as a bolus just prior to surgery followed by an infusion during the first 8 hours post surgery.
62168668|NCT01001637|ACTIVE_COMPARATOR|curcumin|
62390271|NCT03035175|EXPERIMENTAL|Video Laryngoscopy Group|Subjects enrolled in this arm received real-time guidance from a supervisor utilizing the screen of the video laryngoscope while the subjects performed direct neonatal intubations in the NICU.
62390272|NCT03035175|ACTIVE_COMPARATOR|Traditional Laryngoscopy Group|Subjects enrolled in this arm, received traditional guidance while they performed direct neonatal intubations in the NICU.
62390273|NCT01909492||Group 1|Group 1 will consist of 10 subjects with suspected MS, who have had a clinical attack within the last 12 weeks, have at least one gadolinium-enhancing lesion on brain or spinal cord MRI taken within the prior 4 weeks, and for which they have not received any immunomodulating or immunosuppressant medication. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
62390274|NCT01909492||Group 2|Group 2 will consist of 10 subjects with clinically stable definite MS, with no evidence of clinical relapse for at least the past 12 weeks, and have no gadolinium enhancing lesions on MRI in the prior 4 weeks. These subjects will fulfill the Revised (2010) McDonald's Criteria for the Diagnosis of MS. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
62390275|NCT01909492||Group 3|Group 3 will consist of 10 subjects without evidence of inflammatory systemic or inflammatory central nervous system disease, who require CSF removal for some other cause, such treatment of benign intracranial hypertension or as part of the procedure for insertion of an intrathecal medication delivery system. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
62390276|NCT00468013|EXPERIMENTAL|1|Computer-based exercises to be executed at home.
62390277|NCT00468013|SHAM_COMPARATOR|2|Computer-based exercises to be executed at home.
62561904|NCT03166722|EXPERIMENTAL|Study group: Invos 5100|"Supplemental oxygen support and respiratory/circulatory support is guided by cerebral regional tissue oxygenation (crSO2) measured with near-infrared spectroscopy (INVOS 5100 ), in addition to the SpO2/HR (oxygen saturation/heart rate) monitoring according to routine."
62561905|NCT03166722|ACTIVE_COMPARATOR|Control group: Routine care|Supplemental oxygen support and respiratory/circulatory support is guided by SpO2/HR monitoring according to routine - The resuscitation team is blinded to the crSO2 monitoring.
62561906|NCT01924689|EXPERIMENTAL|Clostridium novyi-NT spores|
62561907|NCT01436097|ACTIVE_COMPARATOR|Usual Care arm|Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
62168669|NCT01001637|PLACEBO_COMPARATOR|placebo|
62168670|NCT02721628|EXPERIMENTAL|Epi-keratoplasty Group|Epi-keratoplasty Group: Reversible keratoplasty performed with only the removal of corneal epithelium of the host cornea. A donor graft is transplanted on the recipients' eye locating on the Bowman's layer.
62168671|NCT02721628|ACTIVE_COMPARATOR|Collagen Cross-Linking Group|Collagen Cross-Linking: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes
62390278|NCT00740116|ACTIVE_COMPARATOR|The Tranexamic acid group|The group of women receiving Tranexamic acid intravenously immediately before the surgery
62390279|NCT00740116|PLACEBO_COMPARATOR|The placebo group|The group of women receiving saline solution (0.9% NaCl) intravenously immediately before the surgery
62390280|NCT01343940|EXPERIMENTAL|Dulce family partner intervention|"Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services."
62390281|NCT01343940|ACTIVE_COMPARATOR|Safety intervention|Participating family is assigned a safety specialist who will provide the parent with guidance, equipment and instruction to reduce risk of newborn injury during transport (car seat) and while sleeping (Pack-and-Play).
62390282|NCT02344758|EXPERIMENTAL|Celiac adult|Patient \>16 years, initially diagnosed based on the detection of IgA anti-endomysial and anti-tissue transglutaminase antibodies in serum and confirmed by a small intestinal biopsy, on a GFD for \>2 years
62168672|NCT00762502|ACTIVE_COMPARATOR|senofilcon A toric bilaterally|senofilcon A lenses worn daily bilaterally (in both eyes) for 3 months, replaced weekly.
62168673|NCT00762502|ACTIVE_COMPARATOR|balafilcon A toric bilaterally|balafilcon A lenses worn daily bilaterally (in both eyes) for 3 months, replaced weekly.
62168674|NCT00762502|ACTIVE_COMPARATOR|senofilcon A/balafilcon A contralaterally|senofilcon A lens worn in one eye and balafilcon A lens worn in the other eye (contralaterally), daily for 3 months, replaced weekly.
62168675|NCT05045638|EXPERIMENTAL|Rosuvastatin alone|
62168676|NCT05045638|EXPERIMENTAL|Rosuvastatin + sotorasib|
62168677|NCT01289158||non-classical CMAMMA, classical CMAMMA|
62168678|NCT01678781||One patient group|Patients suffering from irritable bowel syndrome
62168679|NCT03788421|ACTIVE_COMPARATOR|Study group|Women undergoing elective bilateral salpingectomy during cesarean section with LIGASURE.
62168680|NCT03788421|ACTIVE_COMPARATOR|Control group|Women undergoing elective bilateral salpingectomy during cesarean section with traditional step by step clamping and suturing.
62168681|NCT05167734|NO_INTERVENTION|Control (Standard of Care) Group|Subjects will receive standard clinical care for the treatment of anemia while in the ICU.
62390283|NCT02344758|EXPERIMENTAL|Celiac child|Patient \<16 years, initially diagnosed based on the detection of IgA anti-endomysial and anti-tissue transglutaminase antibodies in serum and confirmed by a small intestinal biopsy, on a GFD for \>2 years
62769621|NCT04033874|EXPERIMENTAL|White noise|"Heel stick procedure will be performed during newborns listened to white noise.~For the white noise; the track named do not cry your baby, pt. 2 will be played in Orhan Osman's Colic album. The white noise level will be adjusted to an average of 55 decibels. During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
62769622|NCT04033874|EXPERIMENTAL|Ambient sound|"Heel stick procedure will be performed during newborns listened to ambient sound.~During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
62769623|NCT00780273|EXPERIMENTAL|Ankylos dental implants.|"3 Ankylos dental implants placed in platform switch configuration on one side of the mandible in support of a fixed restoration.~A total number of 19 subjects participated in this randomized, split mouth, masked, prospective, open, comparison, monocenter study. Participants were subjects with an edentulous mandible who recieved 3 implants on each side which were splinted for the delivery of a fixed prosthesis."
62168682|NCT05167734|EXPERIMENTAL|Anemia Treatment Bundle|The intervention arm is multi-faceted with 3 primary components: 1) Optimized phlebotomy, defined by minimal volume draws and closed-loop blood sampling, all performed by a dedicated phlebotomy team independent from the treatment team; 2) Decision support aids, including visual and electronic alerts reminding the care team to minimize non-essential laboratory testing and mitigate patient-specific bleeding risk; and 3) Pharmacologic anemia treatment with a single dose of IV iron and/or subcutaneous erythropoietin (given immediately following enrollment) targeted to 2 broad groups: 1) anemias responsive to iron supplementation alone (i.e. acute blood loss, iron deficiency) and 2) anemias requiring erythropoietic stimulation (e.g. anemia of inflammation, anemia of renal disease).
62168683|NCT01907971||Ebstein anomaly|Patients with Ebstein anomaly
62168684|NCT00527696|ACTIVE_COMPARATOR|TVT SECURE|sling
62168685|NCT00527696|ACTIVE_COMPARATOR|TVT O|sling
62168686|NCT02744898|EXPERIMENTAL|Carboplatin AUC and Abraxane 100mg/m2|
62168687|NCT04783987||Healthy Control Group|Walking Assessments will be practised under dual and single task conditions.
62168688|NCT04783987||Case Group|Walking Assessments will be practised under dual and single task conditions.
62168689|NCT02259569|EXPERIMENTAL|PCV group|After insertion of I-gel, mechanical ventilation of the lungs was commenced. Mechanical ventilator was set to obtain a tidal volume of 8ml/kg in pressure-controlled mode.
62168690|NCT02259569|ACTIVE_COMPARATOR|VCV group|After insertion of I-gel, mechanical ventilation of the lungs was commenced. Mechanical ventilator was set to obtain a tidal volume of 8ml/kg in volume-controlled mode.
62168691|NCT03184519|EXPERIMENTAL|All patients|Patients will undergo 3 blood samples after IVF-ET (pregnancy test) to determine pregnancy.
62168692|NCT03199170|SHAM_COMPARATOR|Intrathecal morphine|Intrathecal morphine 0.2 mg, 0.9%NSS each side
62390284|NCT02344758|ACTIVE_COMPARATOR|Healthy adult|Healthy individual \> 16 years. Exclusion criteria: the presence of family history of CD, digestive disease symptoms, known medical disease, use of prescription medications, and use of antibiotics and probiotics in the previous 2 months to the inclusion in the study.
62168693|NCT03199170|EXPERIMENTAL|Intrathecal morphine with bilateral Quadratus Lumborum Block|Intrathecal morphine 0.2 mg, 0.25%Bupivacaine 25 ml each side
62390285|NCT02344758|ACTIVE_COMPARATOR|Healthy child|Healthy individual \< 16 years. Exclusion criteria: the presence of family history of CD, digestive disease symptoms, known medical disease, use of prescription medications, and use of antibiotics and probiotics in the previous 2 months to the inclusion in the study.
62390286|NCT01689831|EXPERIMENTAL|Aplisol, potency determination|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.
62390287|NCT01689831|ACTIVE_COMPARATOR|Reference standard PPD-S2, reference|Reactivity of Aplisol compared to reference standard PPD-S2.
62390288|NCT02501486|OTHER|ACTH stimulation test|this is a single arm study. An ACTH-stimulation test will be done
62390289|NCT01061762|EXPERIMENTAL|Low Literacy Adherence Counseling|3-counseling sessions for medication adherence improvement tailored for people with poor literacy
62390290|NCT01061762|ACTIVE_COMPARATOR|Standard Adherence Counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
62561908|NCT01436097|EXPERIMENTAL|Information provision intervention|Participants in the Information provision group will receive the same care as those in the Usual Care arm. In addition, the Information provision group participants will receive weekly reminders about the benefits of eating five servings of fruits and vegetables a day and their Way to Health portal will provide graphical depictions of their produce purchase proportions through information from their Price Plus card. This data will be available to them throughout the entire intervention.
62561909|NCT01436097|EXPERIMENTAL|Information provision + flat incentive|Participants assigned to the Information provision + flat group will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the Information provision arm.
62561910|NCT01436097|EXPERIMENTAL|Information provision + tiered incentive|In addition to receiving all features of the Information provision treatment the participants assigned to the Information provision + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption. In this arm, the more participants spend on produce the more money they can earn back.
62561911|NCT02827461||MZ|Monozygotic twins
62561912|NCT02827461||DZ|Dizygotic twins
61994602|NCT00747435|EXPERIMENTAL|Expanded Audiological Criteria|"Pure-tone air-conduction threshold levels shall fall at or within the levels listed in the following chart.~Frequency (Hz): 250 500 750 1000 1500 2000 4000 8000 Lower Limit: 10 10 10 60 60 70 70 70 Upper Limit: 65 65 75 \*110+ \*110+\*110+ \*110+ \*90+~Minimal benefit from optimally fit hearing aid/s, preferably bilateral, with monosyllabic word scores in quiet of ≤50% in the best-aided condition.~Study Arm 2 candidates are those who meet the inclusion criteria listed above with the exception that:~In the ear to be implanted, the pure-tone air conduction threshold(s) at 250, 500, and/or 750 Hz will be greater than or equal to 0 dB HL and less than 10 dB HL, and/or In the ear to be implanted, the pure-tone air conduction threshold(s) at 1000 and/or 1500 Hz will be greater than or equal to 0 dB HL and less than 60 dB HL and/or In their best-aided condition, they score 51-60% on monosyllabic word scores."
61994603|NCT05866861|EXPERIMENTAL|CUG252|CUG252 or placebo will be administered to participants in a 3:1 ratio.
61994604|NCT05866861|PLACEBO_COMPARATOR|Placebo|CUG252 or placebo will be administered to participants in a 3:1 ratio.
61994605|NCT00663052|EXPERIMENTAL|Group A|A
61994606|NCT00663052|EXPERIMENTAL|Group B|B
61994607|NCT06357611|PLACEBO_COMPARATOR|Control Group|After completing an individual questionnaire and giving informed consent, a placebo technique was performed, consisting only of contact in the area of the participant's shoulders.
61994608|NCT06357611|EXPERIMENTAL|Experimental group MET|After completing an individual questionnaire and giving informed consent, the muscle energy technique was performed on the dominant hamstring muscle.
61994609|NCT06357611|EXPERIMENTAL|Experimental group CV-4 and MET|After completing an individual questionnaire and giving informed consent, the 4th ventricle technique (CV-4) was performed, followed by the muscle energy technique on the dominant hamstring muscle.
61994610|NCT03659305|EXPERIMENTAL|RPH-001|Humanized recombinant monoclonal anti-VEGF antibody. 5 mg/kg single intravenous infusion (for no less than 90 minutes)
61994611|NCT03659305|ACTIVE_COMPARATOR|Avastin|Humanized recombinant monoclonal anti-VEGF antibody. 5 mg/kg single intravenous infusion (for no less than 90 minutes)
61994612|NCT04589676|ACTIVE_COMPARATOR|Personal recruitment|Participants in this training condition will receive recruitment messages that appeal to their personal sense of identity (e.g., you could be a hero if you get trained with naloxone).
61994613|NCT04589676|EXPERIMENTAL|Online training|Participants in this training condition will receive recruitment messages that appeal to their communal sense of identity (e.g., your family and friends will thank you for getting trained with naloxone).
62168694|NCT03199170|EXPERIMENTAL|Bilateral Quadratus Lumborum Block|No intrathecal morphine, 0.25%Bupivacaine 25 ml each side
62168695|NCT06416111|ACTIVE_COMPARATOR|Local group(Group L)|"Local infiltrative anesthesia will be applied with 15 ml 2% prilocaine for Local group patients.Before surgery, NIRS probes will be placed on the hypothenar ,antecubital regions of both hands and arms .The peripheral regional oxygen saturation values will be recorded preoperatively and every 5 minutes during the operation.~Surgeon and patient satisfaction will be evaluated by 5 Point Likert Scale (worst: 1 point, best: 5 points) at the end of the surgery."
62390291|NCT01061762|ACTIVE_COMPARATOR|Health Counseling Comparison|3-sessions of health improvement counseling.
62390292|NCT04443855|ACTIVE_COMPARATOR|Water quality|90 clusters, approx. 720 newborns
62390293|NCT04443855|ACTIVE_COMPARATOR|Sanitation|90 clusters, approx. 720 newborns
62390294|NCT04443855|ACTIVE_COMPARATOR|Hand washing|90 clusters, approx. 720 newborns
62390295|NCT04443855|ACTIVE_COMPARATOR|Combined WASH|90 clusters, approx. 720 newborns
62390296|NCT04443855|ACTIVE_COMPARATOR|Nutrition|90 clusters, approx. 720 newborns
62390297|NCT04443855|ACTIVE_COMPARATOR|Nutrition+ Combined WASH|90 clusters, approx. 720 newborns
62390298|NCT04443855|NO_INTERVENTION|Non-intervention|180 clusters, approx. 1,440 newborns
62561913|NCT01654640|EXPERIMENTAL|Metformin group|Metformin 500mg 1 tablet p.o. bid
62561914|NCT01654640|PLACEBO_COMPARATOR|Placebo group|1 tablet p.o. bid
62769624|NCT00780273|ACTIVE_COMPARATOR|3i Prevail dental implants.|"Three 3i Prevail dental implants placed on the opposite side of the mandible from the Ankylos implants in support of fixed dental restoration.~After a baseline phase of 1 month the mandible sides of subjects were randomly assigned to one of the 2 parallel treatment groups: one side received ANKYLOS plus implants. The contralateral sde recieved Certain PREVAIL Implants. Abutments were installed and loaded immediately by a fixed temporary bridge. After 3 months the final prosthesis was incorporated."
62769625|NCT02303860|EXPERIMENTAL|Panel 1|Adaptive design: Each subject will receive MR A or MR B formulation of ORM-12741 or a combination of these once or twice daily for one week either combined with IR formulation or not.
62769626|NCT02303860|EXPERIMENTAL|Panel 2|Adaptive design: Each subject will receive MR A or MR B formulation of ORM-12741 or a combination of these once or twice daily for one week either combined with IR formulation or not.
62769627|NCT04758520|EXPERIMENTAL|Experimental|"Six subjects are involved in a single session of upper limb robotic-assisted therapy lasting about 3 hours and including:~* passive mobilization of patient's upper arm along elementary shoulder movements:shoulder flexion/extension, adduction/ abduction in the frontal plane, horizontal adduction/ abduction, intra/extrarotation (Passive Mode);~* passive mobilization of patient's upper arm along complex trajectories recorded from manual mobilization of the therapist (Learn\&Replay Mode);~* active mobilization, performed by the patient during rehabilitative functional tasks, relying only on gravity and friction compensations and tuneable assistance from the exoskeleton (Transparency Mode)."
62769628|NCT06516744|EXPERIMENTAL|Bye Bye Bloat Capsules|Participants will take 2 Bye Bye Bloat capsules immediately after eating (when they feel full and bloated) at least 3 times a week. They may also take the product during times of hormonal bloating. The study will last for 4 weeks, with questionnaires and waist measurements completed at Baseline, first use, Week 2, and Week 4.
62769629|NCT04367467||Individuals with solid tumors receiving PARPi|"Kidney function will be assessed by serum creatinine, serum cystatin C, and urine creatinine clearance calculation for patients who opt-in to 24 hour urine collection.~These laboratory measures will be completed by patients at the following time points:~* Timepoint A: Baseline (prior to PARP inhibitor initiation, at the time of standard of care clinical testing)~* Timepoint B: On-treatment (within 3-9 weeks of PARP inhibitor initiation, at the time of standard of care clinical testing)~* Timepoint C: Post-treatment (within 4 weeks of PARP inhibitor discontinuation, only for those patients with clinically significant changes in GFR based on serum creatinine, cystatin C, or 24 hour urinalysis at Timepoint B"
62769630|NCT02621073|ACTIVE_COMPARATOR|VeraFlo with Prontosan|V.A.C. VeraFlo™ Therapy, the only NPWT system with an instillation feature which allows solution to dwell in the wound for thorough contact with the wound bed. The solution being instilled is Prontosan: Unlike other antiseptics, the antimicrobial efficacy of Prontosan® is not impaired in human wound fluid, human tissue or by high loads of blood or albumin. Furthermore, Prontosan® blocks the microbial attachment to surfaces and has been shown to effectively remove biofilms in vitro and in vivo (Hubner et al 2010).
62769631|NCT02621073|ACTIVE_COMPARATOR|V.A.C Ulta System|The V.A.C.Ulta™ Therapy System is an integrated wound therapy system that provides NPWT (negative pressure wound therapy), without instillation.
62769632|NCT03495271||Hemodialysis Patients|"Inclusion Criteria:~* Patient's undergoing hemodialysis.~* Male and female of any race~* 18 years/ older.~Those with dysphagia were excluded.~In both participant groups, before each tasting protocol commences, sterile cotton dental rolls will be placed in the participant's mouth. This will be used to collect a saliva sample and determine salivary flow.~Tasting Protocol: The hemodialysis patients will taste each solutions twice, both before and after their dialysis session. An sensory questionnaire and an open ended comment box will be given for participants to type in other words to describe the sensations.~In dialysis patients only, blood will be drawn pre and post dialysis for serum ion concentrations."
62769633|NCT03495271||Healthy Controls|"Inclusion Criteria~* No tongue, lip, or cheek piercings~* Over 18 years of age~* Normal taste and smell function~* No known issues with salivation or dry mouth~* Willing to comply with study protocol (taste samples and provide saliva)~The above protocol will be mimicked in the healthy control group. The only difference is that instead of a pre/post dialysis tastings, the control population will have a 2-4 hour gap in between tastings in order to follow the approximate time-frame of the dialysis patients. Finally they will not be required to provide blood samples."
62390299|NCT04681469|EXPERIMENTAL|Single Arm Treatment|"For all patient's population:~* Niraparib 200 mg/day: day -49 to day -21;~* Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.~If no clinical evidence of disease progression:~* Niraparib 200 mg/day: day -21 to day -7~* Dostarlimab 500 mg iv: day -7~* Radiological assessment (day -1, ± 3 days),~* Surgery (original margin) at day 0 (±3 days)~* Standard postoperative (chemo)radiotherapy according to pathologic report;~* Maintenance Niraparib, 200 mg/day for 6 months~* Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months."
62390300|NCT01177943|EXPERIMENTAL|Atomoxetine Oral Solution|
62390301|NCT01177943|ACTIVE_COMPARATOR|Atomoxetine Capsule Formulation|
62390302|NCT05579938|ACTIVE_COMPARATOR|Verum Lozenges|Active enzyme-containing lozenges to be consumed 5 times per day for 4 days
62390303|NCT05579938|PLACEBO_COMPARATOR|Identical Placebo Lozenges|Placebo lozenges to be consumed 5 times per day for 4 days
62390304|NCT02332616|ACTIVE_COMPARATOR|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
62390305|NCT02332616|PLACEBO_COMPARATOR|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
62390306|NCT01026558|ACTIVE_COMPARATOR|Ceftobiprole (not morbidly obese subjects)|Ceftobiprole 500 mg single-dose over 2 hours.
62390307|NCT01026558|EXPERIMENTAL|Ceftobiprole (morbidly obese subjects)|Ceftobiprole 500 mg single-dose over 2 hours.
62769634|NCT03928626|ACTIVE_COMPARATOR|CRAVING REGULATION|"In the CRAVING REGULATION condition, participants will first read a brief essay about the adverse consequences of drinking alcohol. Then, participants may complete a comprehension check consisting of questions to ensure that they understood and encoded the content of the essays. Participants will be trained to use the information to inform the strategy they will use in the regulation of craving training (ROC-T). A single trial in the regulation of craving training will have two possible instructions: (a) STRATEGY: implement the strategy (bring to mind the negative facts from the essay) and (b) LOOK: to merely observe the image and allow natural responses to come. Participants will follow the instructions; followed by an alcohol-related picture, a brief delay, and will then rate their craving. Participants will then be instructed to use this strategy in daily life situations when they might drink."
62561915|NCT02353182|EXPERIMENTAL|Active open label single arm|"Dexmedetomidine- remifentanil- caudal based anaesthetic for lower abdominal/lower extremity surgery.~Dexmedetomidine (Precedex): loading dose: 1 mcg/kg over 10 minutes. Infusion: Start 1 mcg/kg/hr; titrate up or down within 50% of starting doses as needed~Remifentanil (Ultiva): loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed~Caudal- Bupivacaine (Marcaine) 0.175%-0.25% or Ropivacaine (Naropin) 0.2% with dose at discretion of anaesthetist"
62561916|NCT05590611|PLACEBO_COMPARATOR|Brown Bread|
62561917|NCT05590611|ACTIVE_COMPARATOR|Wholemeal Sourdough Bread|
62561918|NCT00498147||ADEC <6months|Patients new to the ADEC program who will be provided the ADEC interventions (prospective study)
62769635|NCT03928626|PLACEBO_COMPARATOR|CONTROL (NO REGULATION)|In the CONTROL condition, participants will first read a brief essay about a non-alcohol-related topic (e.g., color perception). Then, participants will complete a comprehension check consisting of questions to ensure that they understood and encoded the content of the essays. Participants will view images of objects that are unrelated to alcohol. Furthermore, participants in the control condition will not practice any strategy in the regulation of craving task (ROC-T). That is, in the CONTROL condition, participants would merely observe the image and allow natural responses to come (i.e., LOOK instruction) and rate how colorful is each item (this controls for task time and experiment setting).
62769636|NCT05742204||Lung cancer group|Patients age over 18, with confirmed diagnosis of lung cancer.
61994614|NCT03283020|ACTIVE_COMPARATOR|RemifentanilMNTX|Volunteers are given an intravenous infusion with remifentanil, with an effect-site target concentration of 3 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
61994615|NCT03283020|ACTIVE_COMPARATOR|PlaceboMNTX|Volunteers are given an intravenous infusion with saline 0,9%. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
61994616|NCT00736801|EXPERIMENTAL|A|Treatment with Salmeterol for 2 weeks, followed by a treatment with Salmeterol and Fluticasone for 2 weeks.
62390308|NCT02458989|ACTIVE_COMPARATOR|Scalpel|Use of a scalpel as a first incision during thyroid operation.
62390309|NCT02458989|EXPERIMENTAL|Electrocautery|Use of an electrocautery as a first incision during thyroid operation.
62390310|NCT03937739||Group 1: Case group,|The patients who admitted to the general surgery for operation with inguinal hernia were the case group of this study.
62390311|NCT03937739||Group 2: Control group,|The patients who were admitted to the same hospital with such as eye, ear/nose/throat, dermatologic diseases or elective surgeries and did not have any inguinal hernia complaints, constipation and other chronic disease which could increase the intra abdominal pressure selected as control group.
62390312|NCT05440227|EXPERIMENTAL|PG2 treatment group|500 mg PG2 injection will be administered to this group once per week for 8 weeks.
62390313|NCT05440227|EXPERIMENTAL|Placebo-controlled group|Placebo injection will be administered to this group once per week for 8 weeks.
62390314|NCT05058066|ACTIVE_COMPARATOR|Control implant loaded at 6 weeks post-surgery|The control implant included the previous generation as-machined titanium Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm conically shaped abutment.
62561919|NCT00498147||ADEC >6months|Patients who have been with the ADEC program as early as 2002 (coincides with ADEC's EMR initiation date) who continue to be provided the ADEC interventions (combined retrospective/prospective study)
62390315|NCT05058066|EXPERIMENTAL|Test implant loaded at 6 weeks post-surgery|The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment.
62390316|NCT05058066|EXPERIMENTAL|Test implant loaded at 3 weeks post-surgery|The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment.
62390317|NCT05768776||HoLEP patients without MOSESTM 2.0 effect (open label)|control retrospective open label
62390318|NCT05768776||HoLEP patients with MOSESTM 2.0 effect (open label)|prospective open label
62390319|NCT01237665|EXPERIMENTAL|IXO regimen|single-group
62561920|NCT05712499|EXPERIMENTAL|Mindfulness-based psychoeducation program|The group in which the mindfulness-based psychoeducation program was applied.
62561921|NCT05712499|ACTIVE_COMPARATOR|control group|The group in which no intervention was made and only the pre-test and post-test were applied for comparison.
62769637|NCT05742204||Control group|Non-cancer patients including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.
61994617|NCT02670044|EXPERIMENTAL|Dose Escalation: Arm A (Venetoclax 400mg + Cobi 40mg)|Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 40mg daily on Days 1-21 of each 28-day treatment cycle.
61994618|NCT02670044|EXPERIMENTAL|Dose Escalation: Arm A (Venetoclax 600mg + Cobi 40mg)|Participants received Venetoclax 600mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 40mg daily on Days 1-21 of each 28-day treatment cycle.
61994619|NCT02670044|EXPERIMENTAL|Dose Escalation: Arm A (Venetoclax 800mg + Cobi 40mg)|Participants received Venetoclax 800mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 40mg daily on Days 1-21 of each 28-day treatment cycle.
62390320|NCT00598585|EXPERIMENTAL|sidenafil|sidenafil
62390321|NCT00598585|PLACEBO_COMPARATOR|placebo|placebo
62390322|NCT04900961|ACTIVE_COMPARATOR|Intervention|A personalised, resistance-based exercise intervention for patients during the convalescence phase in-hospital through to 3-months post-discharge, a duration reflecting chronic, maintenance treatment studies. To maximise enrolment of eligible patients, the intervention may be initiated in-hospital or in the community post-discharge. Resistance bands may be used according to the exercise guideline.
62390323|NCT04900961|NO_INTERVENTION|Control|Standard of care treatment
62390324|NCT04880148|EXPERIMENTAL|Thyme and Honey-based oral spray|Thyme and Honey-based oral spray
62561922|NCT02810457|EXPERIMENTAL|FKB238 / paclitaxel / carboplatin|"Drug: FKB238:~15 mg/kg IV infusion on Day 1 of each 21-day cycle.~Drug: Paclitaxel:~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.~Drug: Carboplatin:~Area Under Curve (AUC) = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles."
62561923|NCT02810457|ACTIVE_COMPARATOR|Avastin / paclitaxel / carboplatin|"Drug: Avastin:~15 mg/kg IV infusion on Day 1 of each 21-day cycle.~Drug: Paclitaxel:~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.~Drug: Carboplatin:~AUC = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles."
62561924|NCT04784091|EXPERIMENTAL|Active|TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days
62561925|NCT04784091|PLACEBO_COMPARATOR|Control|Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days
62561926|NCT04765930|ACTIVE_COMPARATOR|PRP Injection|Half of the face
62561927|NCT04765930|PLACEBO_COMPARATOR|Saline injection|Other half of the face
62769638|NCT02900755|EXPERIMENTAL|Epilepsy|Epilepsy patients (focal onset seizure with or without secondary generalization)
62769639|NCT03568955||Swiss Bereaved|Adults from the Swiss population who have lost a loved one at least 6 months to 10 years prior to testing
62769640|NCT03568955||Japanese Bereaved|Adults from the Japanese population who have lost a loved one at least 6 months to 10 years prior to testing
62769641|NCT03568955||Chinese Bereaved|Adults from the Chinese population who have lost a loved one at least 6 months to 10 years prior to testing
62769642|NCT05223387|EXPERIMENTAL|Study Group|Anthogyr Axiom TL REG and corresponding Multi-Unit abutments
62769643|NCT05223387|ACTIVE_COMPARATOR|Control Group|Anthogyr Axiom BL REG and corresponding Multi-Unit abutment
62769644|NCT05918627|EXPERIMENTAL|Dose level 1|Single Oral Doses of 20 mg SLx-2119 or placebo on Day 1
62769645|NCT05918627|EXPERIMENTAL|Dose level 2|Single Oral Doses of 40 mg SLx-2119 or placebo on Day 1
62769646|NCT05918627|EXPERIMENTAL|Dose level 3|Single Oral Doses of 80 mg SLx-2119 or placebo on Day 1
62769647|NCT05918627|EXPERIMENTAL|Dose level 4|Single Oral Doses of 160 mg SLx-2119 or placebo on Day 1
62769648|NCT05918627|EXPERIMENTAL|Dose level 5|Single Oral Doses of 320 mg SLx-2119 or placebo on Day 1
62769649|NCT05918627|EXPERIMENTAL|Dose level 6|Single Oral Doses of 640 mg SLx-2119 or placebo on Day 1
62769650|NCT02795312|EXPERIMENTAL|Smoking Cessation Training Program|Participants will take part in a 9-week Smoking Cessation Program class curriculum consisting of weekly 2.5 hour classes and complete pre and post questionnaires
62769651|NCT02479776|ACTIVE_COMPARATOR|Stem cell injection|Stem cells are injected and patients crossed over to placebo at 6 months
62561928|NCT05825638||Continuous training session|
62769652|NCT02479776|PLACEBO_COMPARATOR|saline injection|saline is injected and patients crossed over to active arm at 6 months
61994620|NCT02670044|EXPERIMENTAL|Dose Escalation: Arm A (Venetoclax 400mg + Cobi 60mg)|Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 60mg daily on Days 1-21 of each 28-day treatment cycle.
62168696|NCT06416111|ACTIVE_COMPARATOR|Block group(Group B)|"For Block group patients, 30 ml 0.25% bupivacaine will be applied with Infraclavicular approach around brachial plexus with inplane technique.The effect of the peripheral nerve block will be evaluated with 10-minute intervals until regional anesthesia is achieved.Sensory block will be evaluated with the Pinprick Test and motor block with the Modified Bromage Scale. Before surgery, NIRS probes will be placed on the hypothenar ,antecubital regions of both hands and arms .The peripheral regional oxygen saturation values will be recorded preoperatively and every 5 minutes during the operation.~Surgeon and patient satisfaction will be evaluated by 5 Point Likert Scale (worst: 1 point, best: 5 points) at the end of the surgery."
62390325|NCT04880148|PLACEBO_COMPARATOR|Placebo oral spray|Placebo oral spray
62390326|NCT04929782|ACTIVE_COMPARATOR|Resin-based sealant|A dental isolation device was used (Mr. Thisty One Step, Zirc Dental, Buffalo, MN, USA) and the treatments were conducted by one operator according to following steps; Group 1: Etching with 37% phosphoric acid for 30 s (i-GEL N, i-dental, Lithuania), rinsing for 30 s with air-water spray and drying with oil-free air for 15 s, resin sealant (Conceal F, SDI, Australia) application into the occlusal and buccal/palatal pits and fissures with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20s on each surface.
62390327|NCT04929782|ACTIVE_COMPARATOR|Giomer sealant|Group 2: Self-etch primer (BeautiSealant Primer, Shofu, Japan) application to the occlusal and buccal/palatal pits and fissures with fine microbrush and waiting for 5 s, homogenizing the bond layer with gentle air stream for 5 s, giomer sealant application (BeautiSealant Paste, Shofu, Japan) with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20 s on each surface.
62390328|NCT06320223||Prostate cancer patients with PSMA PET|"Inclusion:~* Adult patients with~* biopsy/histo proven prostate cancer who~* underwent PSMA PET (any type)~* for staging or re-staging at any stage and who~* have at least 3-year overall survival follow-up data available will be included consecutively.~Exclusion:~* Patients with neuroendocrine prostate cancer~* Patients with metastasized or disseminated malignancy other than prostate cancer."
62390329|NCT04536181|PLACEBO_COMPARATOR|3 months group|Subjects will receive 12-weeks of placebo following randomization
62390330|NCT04536181|EXPERIMENTAL|6 months group|12 Weeks of Prednisolone Therapy Subjects will add an additional 12 weeks of Prednisolone to follow pre-randomization standard of care prednisolone.
62390331|NCT04354870|EXPERIMENTAL|HCQ Group|Approximately 300 Health Care Workers (HCW) who choose to be provided HCQ
62390332|NCT04354870|NO_INTERVENTION|Control Group|approximately 50 HCW who choose not to be provided HCQ
62390333|NCT02493101||Chronic kidney disease|Patients with lupus nephritis and IgA nephropathy
62390334|NCT02493101||Control|Healthy controls
62390335|NCT05330195|EXPERIMENTAL|Treatment Group|Home exercise program Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week. Also, aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 40 minutes total duration consisting of 5 min warm up and 5 min cool down period to children in treatment group
62390336|NCT05330195|ACTIVE_COMPARATOR|Control Group|Home Based Exercise Group Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do this program for 3-5 days a week.
62390337|NCT03942029|EXPERIMENTAL|Cohort 1 Part A - LY3154207 Capsule|LY3154207 capsule (reference) administered orally, once.
62390338|NCT03942029|EXPERIMENTAL|Cohort 1 Part A - LY3154207 Tablet|LY3154207 tablet (test) administered orally, once.
62561929|NCT05825638||Interval Training session|
62561930|NCT02222922|EXPERIMENTAL|PF-06647020 Q3W|Investigational drug infused over 60 minutes once every 21 days.
62561931|NCT02222922|EXPERIMENTAL|Drug-drug interaction (DDI)|PF-06647020 combined with fluconazole
62390339|NCT03942029|EXPERIMENTAL|Cohort 1 Part B LY3154207 (Dose 1) + Fluconazole|LY3154207 (dose 1) administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.
62561932|NCT02222922|EXPERIMENTAL|PF-06647020 Q2W|Investigational drug infused over 60 minutes once every 14 days (28 day cycle)
62561933|NCT02222922|EXPERIMENTAL|PF-06647020 combined with Avelumab|PF-06647020 combined with Avelumab administered by infusion
62561934|NCT05988827|EXPERIMENTAL|NGenuity|NGenuity allowing a reduced light intensity to 15% during cataract surgery
62561935|NCT05988827|NO_INTERVENTION|SOM|microscope without NGenuity with light intensity of 60%, similar to a Standad Operating Microscope (SOM)
62561936|NCT01615367|EXPERIMENTAL|NEW Tx|25 people will be randomized to NEW Tx, a weekly individualized psychotherapy. Therapy is 20 weeks long.
62561937|NCT01615367|ACTIVE_COMPARATOR|Treatment as usual (TAU)|25 people will be randomized to TAU and will meet with their psychiatrist as often as clinically needed over the 20 week study duration.
62561938|NCT02720666|EXPERIMENTAL|Group A:K-001 2700mg/d (1350mg BID)|K-001 1350mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
62561939|NCT02720666|EXPERIMENTAL|Group B: K-001 3240mg/d (1620mg BID)|K-001 1620mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
62561940|NCT02720666|EXPERIMENTAL|Group C: K-001 3780mg/d (1890mg BID)|K-001 1890mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
62769653|NCT06286826||Patients with oesophageal atresia minithoracotomy|Patients with oesophageal atresia who underwent a minithoracotomy between 2011-2021
62769654|NCT06286826||Patients with oesophageal atresia postero-lateral thoracotomy|Patients with oesophageal atresia who underwent a postero-lateral thoracotomy between 2011-2021
62168697|NCT02507297|EXPERIMENTAL|PAP Group|Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly
62168698|NCT02507297|NO_INTERVENTION|TAU Group|Treatment as usual through obstetrics
62168699|NCT02720978|EXPERIMENTAL|Intravenous oxytocin|"Women that arrive to women's ER and diagnosed with rupture of membranes in week 34+0 and onward, are not in active labor and with Bishop score lower than 7.~Those who agreed to participate in the study after signing an informed consent form will undergo the following steps:~1. Verification rupture of membranes and gestational age.~2. Choosing the treatment group Intravenous oxytocin from red envelope, randomly.~3. Collecting basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~4. Induction according to departmental protocol of each delivery way.~5. Data collecting after the delivery."
62168700|NCT02720978|EXPERIMENTAL|vaginal prostaglandin|"Women that arrive to women's ER and diagnosed with rupture of membranes in week 34+0 and onward, are not in active labor and with Bishop score lower than 7.~Those who agreed to participate in the study after signing an informed consent form will undergo the following steps:~1. Verification rupture of membranes and gestational age.~2. Choosing the treatment group vaginal prostaglandin from red envelope, randomly.~3. Collecting basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~4. Induction according to departmental protocol of each delivery way.~5. Data collecting after the delivery."
62168701|NCT03185910|EXPERIMENTAL|MBCP education|The intervention includes 3-hour classes per week during the duration of eight weeks and a 7- hour silent meditation practice as well.
62168702|NCT03185910|PLACEBO_COMPARATOR|Hospital-based antenatal education|Hospital-based antenatal education program will be held 2 hrs once a month for 2 months.
62168703|NCT05174988|EXPERIMENTAL|Angle stitch|"If the allocation corresponds to Angle stitch, surgeon will use 0 polyglactin 910 suture on a tapered needle to place figure of 8 sutures on both (left and right) apexes. Knot tying technique (intra-corporeal vs extracorporeal) will be up to surgeon preference. After this is completed, barbed suture will be used to re-approximate the remainder of the vaginal cuff from right to left, backtracking once at the end for reinforcement."
62168704|NCT05174988|NO_INTERVENTION|control|"If the subject's group corresponds to Control group, the surgeon will re-approximate the cuff in a standard fashion, using a running-barbed suture (2-0 V-LOC 90 with tapered needle), starting at the right apex, moving towards the left, and then back-tracking once to further reinforce the closure."
62168705|NCT01219972||Allografted patients|"* All consecutive patients who underwent an allogeneic blood stem cells transplantation performed at saint Louis hospital during the study recruitment period~* if alive at 100 days post-transplant~* and who gave informed consent"
62168706|NCT02683317|EXPERIMENTAL|DHA group|Experimental group will receive 75 mg of docosahexaenoic acid per kilo of baseline weight in one dose per day, administered by enteral feeding throughout 14 days.
62168707|NCT02683317|SHAM_COMPARATOR|Control group|"Control group will receive sunflower oil, the excipient of the DHA in our intervention.~They will receive it once a day, administered by enteral feeding throughout 14 days."
62168708|NCT02787135|ACTIVE_COMPARATOR|CBTd-E|Experimental: emotion-oriented Cognitive Behavior Therapy focused on delusions for patients with schizophrenia-spectrum disorders and delusions. The therapeutical intervention follows a treatment-manual consisting of two modules. Patients work on two modules every week for 25 weeks in a row. Module I comprises psychoeducation on emotions, training radical acceptance of emotions and mindfulness, cognitive and behavioral strategies in order to change negative emotions and in order to foster positive emotions and suggestions for life-style changes (positive activities, sports, stress reduction). In the second module, the focus is on self-acceptance. Patients receive psychoeducation on self-acceptance and learn strategies in order to reduce negative self-schema and foster positive self-schema.
62561941|NCT02720666|EXPERIMENTAL|Group D: K-001 4320mg/d (2160mg BID)|K-001 2160mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
62561942|NCT02570789|EXPERIMENTAL|patients with sunitinib or pazopanib|This will be a non-randomized, proof-of-concept, prospective, longitudinal, multi-center study in patients with metastatic clear cell renal cell carcinoma with good or intermediate risk (based on MSKCC criteria) treated with sunitinib or pazopanib in first line.
62561943|NCT02780037|EXPERIMENTAL|Prevention|Regulatory frame: prevention
62769655|NCT02510183|ACTIVE_COMPARATOR|Acupressure Wrist Band|Patient receive preoperative education a day before surgery, education for acupressure application on the day of surgery, an acupressure wrist band is applied on P6 acupoint in both wrist an hour before surgery
62769656|NCT02510183|PLACEBO_COMPARATOR|Placebo Wrist Band|Patient receive preoperative education a day before surgery, an placebo acupressure wrist band is applied in both wrist an hour before surgery
62561944|NCT02780037|EXPERIMENTAL|Promotion|Regulatory frame: promotion
62561945|NCT02780037|SHAM_COMPARATOR|Neutral|Regulatory frame: not implied
62561946|NCT03723850|EXPERIMENTAL|Older, active tDCS, dlPFC|"Older adults (ages 60-75) randomized to this arm will receive 2 sessions of active tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex. One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).~2."
62561947|NCT03723850|SHAM_COMPARATOR|Older, sham tDCS, dlPFC|Older adults (ages 60-75) randomized to this arm will receive 2 sessions of sham tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex. One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
62168709|NCT02787135|PLACEBO_COMPARATOR|Treatment as Usual|Patients who are randomized and assigned to the Wait-list receive treatment as usual (regular visits to a physicist every third month and antipsychotic medication). After six month the waiting list patients receive the treatment specified above.
62168710|NCT02488070|EXPERIMENTAL|Diagnostic (68Ga-PSMA PET/CT or PET/MRI)|Patients receive gallium Ga 68-labeled PSMA ligand Glu-urea-Lys(Ahx) IV and then undergo PET/CT or PET/MRI approximately 45-60 minutes later.
62168711|NCT00904384||HIV+|Patients with HIV infection living in the Autonomous Community of the Balearic Islands (CAIB), Spain
62168712|NCT00904384||Reference group|Same determinations as in HIV+ cases will be obtained in the control group of COPD patients without HIV infection as part of the study PAC-EPOC (FIS 05/2082)
62168713|NCT05008315|EXPERIMENTAL|deep and superficial tissue mobilization group|include deep and superficial tissue mobilization
62168714|NCT05008315|ACTIVE_COMPARATOR|superficial tissue mobilization group|superficial tissue mobilization
62390340|NCT03942029|EXPERIMENTAL|Cohort 1 Part B - Placebo + Fluconazole|Placebo administered alone, orally, once. Fluconazole administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.
62390341|NCT03942029|EXPERIMENTAL|Cohort 2 - LY3154207 (Dose 2) + Fluconazole|LY3154207 (dose 2) administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.
62561948|NCT03723850|EXPERIMENTAL|Younger, active tDCS, dlPFC|Younger adults (ages 18-30) randomized to this arm will receive 2 sessions of active tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex. One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
62561949|NCT03723850|SHAM_COMPARATOR|Younger, sham tDCS, dlPFC/parietal|Younger adults (ages 18-30) randomized to this arm will receive 2 sessions of sham tDCS stimulation (Soterix Medical) delivered to either the left dorsolateral prefrontal cortex (area F3 using the 10-20 EEG system, n = 25), or the left parietal cortex (area P5 using the 10-20 EEG system, n = 25). One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
62561950|NCT03723850|ACTIVE_COMPARATOR|Younger, active tDCS, parietal cortex|Younger adults (ages 18-30) randomized to this arm will receive 2 sessions of active tDCS stimulation (Soterix Medical) delivered to the left parietal cortex (area P5 using the 10-20 EEG system). One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
62561951|NCT05748743|EXPERIMENTAL|Glove change group|The surgical gloves were changed prior to closure of the peritoneum or closure of the abdominal fascia
62769657|NCT02510183|NO_INTERVENTION|Control Grup Without Band|Patient receive preoperative education a day before surgery, and patient are only visited an hour before surgery
62769658|NCT06507670||Esophageal foreign body/impaction (suspected)|
62769659|NCT06507670||Control (No symptoms of esophageal foreign body/impaction)|
62769660|NCT02880813|EXPERIMENTAL|Gastric|gastric infusion
62769661|NCT02880813|EXPERIMENTAL|Duodenal|Duodenal infusion
62769662|NCT03689712|EXPERIMENTAL|GC4419 (avasopasem manganese) 90 mg|
62168715|NCT05008315|PLACEBO_COMPARATOR|control group|Sham (very light hand touch on the same location as the other two groups but without any treatment intention)
62168716|NCT05008315|OTHER|vaginal delivery group|education session
62168717|NCT03494907|EXPERIMENTAL|Seltorexant (Low and high dose)|Participants will receive seltorexant tablets orally in 2 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
62168718|NCT03494907|EXPERIMENTAL|Moxifloxacin|Participants will receive moxifloxacin tablets orally in 1 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
62168719|NCT03494907|EXPERIMENTAL|Placebo Matched to Seltorexant|Participants will receive seltorexant placebo tablets orally in 3 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
62390342|NCT03942029|EXPERIMENTAL|Cohort 2 - Placebo + Fluconazole|Placebo administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.
62390343|NCT03942029|EXPERIMENTAL|Cohort 3 - LY3154207 + Fluconazole|LY3154207 (dose 2) administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.
62769663|NCT03689712|PLACEBO_COMPARATOR|Placebo|
62769664|NCT00967161|EXPERIMENTAL|Evolution Medial Pivot Knee|20 Patients will receive the EMP Knee Implant
62769665|NCT00967161|ACTIVE_COMPARATOR|Triathlon PS Knee|20 Patients will receive the Triathlon PS Knee
62769666|NCT03947970|EXPERIMENTAL|[14C] CR845|Subjects will receive a single dose of \[14C\] CR845 IV solution administered as an IV bolus on Day 1.
62769667|NCT01824706||craniectomy|craniectomy
62769668|NCT02138695||Yonsei AF Cohort|Patients with atrial fibrillation who undergoing catheter ablation of atrial fibrillation
62769669|NCT03233295|EXPERIMENTAL|Vitamin D deficiency|
62769670|NCT04315636|EXPERIMENTAL|Surfactant nebulisation|The experimental group will receive a positive end-expiratory pressure (PEEP, +/- noninvasive positive pressure ventilation) and nebulised surfactant via a customised vibrating membrane nebuliser. Nebulisation will commence with the first application of a PEEP and will continue for a maximum of 30 minutes.
62168720|NCT03494907|EXPERIMENTAL|Placebo Matched to Moxifloxacin|Participants will receive moxifloxacin placebo tablets orally in 3 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
62168721|NCT03223935|ACTIVE_COMPARATOR|Roasted snacks|Corn nuts
62168722|NCT03223935|EXPERIMENTAL|Roasted chickpeas|Chickpeas
62168723|NCT03223935|EXPERIMENTAL|Roasted yellow peas|Yellow peas
62168724|NCT03223935|EXPERIMENTAL|Roasted pinto beans|Pinto beans
62168725|NCT03223935|EXPERIMENTAL|Roasted soybeans|Soybeans
62168726|NCT03223935|EXPERIMENTAL|Roasted almonds|Almonds
62168727|NCT04919044|EXPERIMENTAL|Motor Imagery|The participants were instructed to imagine and visualize to straighten both knees with eyes closed. You have to see and feel only what you would see and feel if you had to perform the action to straighten both of your knees in sitting position. Imagine the movement using the most comfortable way for you, and make sure not to contract your muscles.
62561952|NCT05748743|NO_INTERVENTION|Usual care group|The surgical gloves were not changed before abdominal closure
61994621|NCT02670044|EXPERIMENTAL|Dose Escalation: Arm B (Venetoclax 400mg + Ida 200mg)|Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 200mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.
62168728|NCT04919044|NO_INTERVENTION|Control|No intervention provided.
62390344|NCT03942029|EXPERIMENTAL|Cohort 3 - Placebo + Fluconazole|Placebo administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.
62390345|NCT01116895|ACTIVE_COMPARATOR|LEO 22811 0.5 mg|LEO 22811 0.5 mg: Oral solution
62390346|NCT01116895|ACTIVE_COMPARATOR|LEO 22811 1.5 mg|LEO 22811 1.5 mg: Oral solution
62390347|NCT01116895|ACTIVE_COMPARATOR|LEO 22811 3.0 mg|LEO 22811 3.0 mg: Oral solution
62390348|NCT01116895|PLACEBO_COMPARATOR|Placebo|Placebo: Oral solution
62390349|NCT00740766|EXPERIMENTAL|Monitored|
62390350|NCT00740766|NO_INTERVENTION|Unmonitored|
62561953|NCT02686307||ICD Implant|All patients receiving a dual chamber ICD
62561954|NCT03977467|EXPERIMENTAL|Arm A (Chemo + Atezolizumab)|In Arm A, patients with NSCLC will receive chemotherapy plus atezolizumab at a flat dose of 1200 mg intravenously (IV) every 3 weeks. Standard of care chemotherapy is defined as a platinum-doublet therapy (or triplet if bevacizumab is used) of the Investigator's choice.
61994622|NCT02670044|EXPERIMENTAL|Dose Escalation: Arm B (Venetoclax 600mg + Ida 150mg)|Participants received Venetoclax 600mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 150mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.
62168729|NCT02413502|EXPERIMENTAL|Bacillus Calmette-Guérin (BCG)|Tice brand BCG used to vaccinate BCG-Naïve adults.
62168730|NCT04675086|EXPERIMENTAL|Aralast NP + Antiviral Treatment + Standard of Care|"The investigational product is alpha1-proteinase inhibitor, administered as a loading dose of 120mg/kg/body weight intravenous infusion on the first day, and then 60mg/kg/BW intravenous infusion on Days 3, 5, 7 and 9. Booster infusion of 120 mg/kg/BWon Day 17.~The Antiviral treatment is Remdesivir. For patients not requiring invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days. Recommended dosage in adults and pediatric patients 12 years of age and older and weighing at least 40 kg: a single loading dose of Remdesivir 200 mg on Day 1 followed by once-daily maintenance doses of Remdesivir 100 mg from Day 2 infused over 30 to 120 minutes~Standard of Care treatments are at the investigator's discretion based on best practices."
62182718|NCT03272529||Standard simulation|Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in this group in addition to the standard.
62390351|NCT04437524|ACTIVE_COMPARATOR|balance-proprioception exercises group|balance-proprioception exercises group
62390352|NCT04437524|ACTIVE_COMPARATOR|aerobic exercises group|aerobic exercises group
62390353|NCT05895591|EXPERIMENTAL|Treated Group|all subjects will apply the study product
62390354|NCT00365872|EXPERIMENTAL|EBRT + DC Injection + Resection|Single Arm: EBRT + DC Injection + Resection. Prior to the fourth DC Injection, participants were assigned to 3 cohorts as outlined in that intervention.
62390355|NCT04212221|EXPERIMENTAL|MGD013|MGD013 monotherapy dose escalation and expansion
62390356|NCT04212221|EXPERIMENTAL|MGD013+Brivanib Alaninate|MGD013+Brivanib Alaninate dose escalation and expansion
62390357|NCT02004457|EXPERIMENTAL|Acceptance-based behavior therapy (ABBT)|ABBT will consist of 2 sessions. The first session will be used to introduce the concept of acceptance and its possible benefits in the context of life values and patient-identified barriers to care engagement. Following a discussion of life values will be a discussion of which, if any, of these values are currently misaligned with the participant's HIV self-care. At the second session, acceptance-based coping skills will be practiced and a behavioral plan will be developed to targets barriers identified in the first session. These discussions will help the participant clarify how best to align their values with decisions on how to manage his/her HIV (e.g. when and how to disclose, what to expect at appointments).
62390358|NCT02004457|PLACEBO_COMPARATOR|Treatment-as-usual (TAU)|TAU will consist of the standard sessions all individuals receive as they enter HIV care and attend their first follow-up visit to review lab results. TAU includes identification of environmental barriers to care, assessment of needs for additional care and corresponding referrals (i.e., for depression, substance abuse), and recommendations to attend HIV support groups.
62390359|NCT05021731|ACTIVE_COMPARATOR|3-month Isoniazid plus Rifampicin|Daily isoniazid 300 mg plus rifampicin 600 mg for three months
62390360|NCT05021731|EXPERIMENTAL|3-month Isoniazid plus Rifapentine|Weekly isoniazid 900 mg plus rifapentine 900 mg for 12 weeks
62390361|NCT05021731|EXPERIMENTAL|4-month Rifampicin|Daily rifampicin 600 mg for four months
62390362|NCT01480401|EXPERIMENTAL|low-sodium diet|(1500 mg daily)
62390363|NCT01480401|NO_INTERVENTION|moderate-sodium diet|sodium (100 mmol or 2300 mg daily; Usual Care)
62390364|NCT05936827||athletic group|Moderate to high PA levels according to IPAQ.
62390365|NCT05936827||non-athletic group|Low levels of PA according to IPAQ.
62168731|NCT04675086|ACTIVE_COMPARATOR|Antiviral Treatment + Standard of Care|"The Antiviral treatment is Remdesivir. For patients not requiring invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days. Recommended dosage in adults and pediatric patients 12 years of age and older and weighing at least 40 kg: a single loading dose of Remdesivir 200 mg on Day 1 followed by once-daily maintenance doses of Remdesivir 100 mg from Day 2 infused over 30 to 120 minutes~Standard of Care treatments are at the investigator's discretion based on best practices."
61994623|NCT02670044|EXPERIMENTAL|Dose Escalation: Arm B (Venetoclax 600mg + Ida 200mg)|Participants received Venetoclax 600mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 200mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.
62390366|NCT00976521|EXPERIMENTAL|Local infusion, thrombus aspiration|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter following thrombus aspiration.
62561955|NCT03977467|EXPERIMENTAL|Arm B (Atezolizumab and Tiragolumab)|In Arm B, patients with advanced solid tumors will be treated with atezolizumab at a flat dose of 1200 mg IV every 3 weeks in combination with tiragolumab at a flat dose of 600 mg IV every 3 weeks until progression or unacceptable toxicity.
62561956|NCT05471999|OTHER|Patients with SBP|
62561957|NCT04571372||Patients with severe aortic stenosis or severe aortic regurgitation|Patients with severe aortic stenosis or severe aortic regurgitation
62561958|NCT00012792|OTHER|Arm 1|
62561959|NCT01693016|OTHER|inhalation group|20 children Taking blood samples and SpHb-measurement was made under inhalational anesthesia
62561960|NCT01693016|OTHER|non-inhalational|40 children Taking blood samples and SpHb measurements in awake and spontaneous breathing children.
62561961|NCT06469554|NO_INTERVENTION|Usual Care Group|Participants randomly assigned to this group will receive standard hospital care, which may include physical rehabilitation if deemed necessary by the clinical staff.
62168732|NCT05225285|EXPERIMENTAL|VACC|This group will receive the inactivated Coronavac/Butantan vaccine.
62390367|NCT00976521|EXPERIMENTAL|Local infusion, no aspiration|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter and no aspiration
62390368|NCT00976521|ACTIVE_COMPARATOR|No local infusion, thrombus aspiration|No local infusion of abciximab, thrombus aspiration.
62168733|NCT05225285|ACTIVE_COMPARATOR|BNTC|This group will receive the immunizing BNT162b2 (Pfizer).
62168734|NCT05225285|ACTIVE_COMPARATOR|ADU|This group of adults participants will receive the inactivated Coronavac/Butantan vaccine.
62390369|NCT00976521|ACTIVE_COMPARATOR|No local infusion, no aspiration|No local infusion abciximab and no thrombus aspiration
62561962|NCT06469554|EXPERIMENTAL|Intervention group|Participants in this group will receive a Multicomponent Exercise Program (MEP) or with virtual reality added
62561963|NCT02143128|EXPERIMENTAL|Efficacy Safety Score|Patients assessed using the ESS
62561964|NCT02143128|ACTIVE_COMPARATOR|Verbal Numeric Rating Scale|Patients assessed using VNRS
62561965|NCT02143128|NO_INTERVENTION|Control|Regular follow up
62561966|NCT02869243|EXPERIMENTAL|hrBMP4|Intra-tumour and interstitial convection enhanced delivery (CED) as a continuous infusion via intracranial catheters of hrBMP4 solution and gadolinium
62561967|NCT03126773||BAY86-4891|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Angeliq Micro is indicated are fit for participation in this non-interventional study.
62561968|NCT06513078|EXPERIMENTAL|Static cupping|"Negative pressure was created inside 4 plastic cups (2 diameter) placed on the gastrocnemius by drawing out air with two full pumps via a manual suction tool and participants laid in the prone position for 10 minutes while the cups stayed attached to the skin. Cups were attached to the skin with adhesive tape."
62561969|NCT06513078|SHAM_COMPARATOR|Static sham cupping|"Negative pressure was created inside 4 plastic cups (2 diameter) placed on the gastrocnemius by drawing out air with two full pumps via a manual suction tool and participants laid in the prone position for 10 minutes while the cups stayed attached to the skin. Cups were attached to the skin with adhesive tape. However, the sham cups had a small hole in them which allowed pressure to leak out."
62561970|NCT06513078|EXPERIMENTAL|Dynamic cupping|"Negative pressure was created inside 4 plastic cups (2 diameter) placed on the gastrocnemius by drawing out air with two full pumps via a manual suction tool and participants laid in the prone position for 5 minutes while the cups stayed attached to the skin. Participants then completed two sets of 10 full range ankle pumps with a rest period of 30 seconds between sets (approximately 2 minutes). For the remaining 3 minutes, participants remained still in the prone position with the cups remaining attached. Cups were attached to the skin with adhesive tape."
62561971|NCT06513078|SHAM_COMPARATOR|Dynamic sham cupping|"Negative pressure was created inside 4 plastic cups (2 diameter) placed on the gastrocnemius by drawing out air with two full pumps via a manual suction tool and participants laid in the prone position for 5 minutes while the cups stayed attached to the skin. Participants then completed two sets of 10 full range ankle pumps with a rest period of 30 seconds between sets (approximately 2 minutes). For the remaining 3 minutes, participants remained still in the prone position with the cups remaining attached. Cups were attached to the skin with adhesive tape. However, the sham cups had a small hole in them which allowed pressure to leak out."
62168735|NCT05928858|EXPERIMENTAL|Premixed Bio-ceramic MTA|Partial caries removal will be carried out then Premixed Bio-ceramic MTA will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
62168736|NCT05928858|ACTIVE_COMPARATOR|Calcium hydroxide|Partial caries removal will be carried out then calcium hydroxide will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
62390370|NCT02432924|EXPERIMENTAL|Feedback Group|Participants randomised into the intervention group will be invited to return to the university for a one-off 60 minute set-up session once their physical activity monitor has been returned and processed. Within this session the participant will be given detailed instructions on how to use and wear the activity monitor and real time display and upload their data to and navigate the multidimensional feedback web platform (See materials section for details). They will also be introduced to the concept of goal setting and talked through the different aspects of the instantaneous feedback display and how that might benefit them. Following this visit the participant will be given licence to wear and use the physical activity monitoring devices for a 6-week period and encouraged to self-monitor their behaviour using the combined instantaneous and multidimensional feedback.
62390371|NCT02432924|NO_INTERVENTION|Waiting List Control Group|Participants who have been randomised into the control arm will be put on a 3 month waiting list to receive the intervention described above. They will still attend assessment visits at week 6 and week 12 while they are not receiving any advice or feedback. Following their 12 week assessment, participants in the control arm will be invited to attend the same 60 minute set-up session as received by the intervention group and then provided with the armband monitor and display to then receive the intervention in full. No further post-intervention or follow-up assessments will be taken from these participants.
62561972|NCT01170988|OTHER|surgical procedure|T-graft bypass or conventional bypass
62168737|NCT01388621|EXPERIMENTAL|Experimental arm (A):|"Caelyx 30 mg/m² d1 Carboplatin AUC 5 d1 Panitumumab 6 mg/kg/KG d1 + 15 q4w until progressive disease or for a max. of 6 cycles~OR~Gemcitabine 1000 mg/m² d1 + 8 Carboplatin AUC 4 d1 Panitumumab 9 mg/kg/KG d1 q3w until progressive disease or for a max. of 6 cycles~The backbone chemotherapy (Caelyx or Gemcitabine-based) is specified by the investigator before randomization of a patient."
62390372|NCT04449016|EXPERIMENTAL|Caucasian|Participants performed 9 sessions of HIIT over 3 weeks, utilizing progressive overload by increasing the number of bouts by 1 each week. They started with 8 bouts on week 1, 9 bouts on week 2, and 10 bouts on week 3.
62390373|NCT04449016|EXPERIMENTAL|Hispanic|Participants performed 9 sessions of HIIT over 3 weeks, utilizing progressive overload by increasing the number of bouts by 1 each week. They started with 8 bouts on week 1, 9 bouts on week 2, and 10 bouts on week 3.
62390374|NCT03762785|ACTIVE_COMPARATOR|nebulized dexmedetomidine 2ug/kg|inhalation of dexmedetomidine in the dose of 2ug/kg by nebulization
62390375|NCT03762785|ACTIVE_COMPARATOR|nebulized dexmedetomidine 3ug/kg|inhalation of dexmedetomidine in the dose of 3ug/kg by nebulization
62168738|NCT01388621|ACTIVE_COMPARATOR|Standard arm (B):|"Caelyx 30 mg/m² d1 Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles~OR~Gemcitabine 1000 mg/m² d1 + 8 Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles~The backbone chemotherapy (Caelyx or Gemcitabine-based) is specified by the investigator before randomization of a patient."
62390376|NCT01475513|ACTIVE_COMPARATOR|African-American women|African-American women
62390377|NCT01475513|ACTIVE_COMPARATOR|Caucasian women|Caucasian women
62390378|NCT03367091|EXPERIMENTAL|Ekso GT gait training|"Participants will be measured during three Ekso GT gait trainings:~* 20-minute Ekso GT gait training with high swing assistance~* 20-minute Ekso GT gait training with neutral swing assistance~* 20-minute Ekso GT gait training with high swing resistance.~Each training will be performed on a separate day in a randomized order (within one week and controlled for time of day)."
62390379|NCT00838422||FD-OCT, ORA, USP|
62390380|NCT01334138|EXPERIMENTAL|4-week diet, low in sodium|The study subjects go on a 4-week diet, low in sodium.
62769671|NCT04315636|NO_INTERVENTION|Standard care|The control group will receive standard care (PEEP, +/- noninvasive positive pressure ventilation, without surfactant nebulisation).
62769672|NCT04221191||Standard of Care (SoC) Group|SoC neurologists will include and follow-up all study participants who receive DMF according to their standard of care practice (non-coached participants).
62168739|NCT04475497|EXPERIMENTAL|Blood mangement group|The intervention will include pre-surgical optimization blood management referral based on pre-operative Hgb levels \<11.0 g/dL. Treatment will include PO iron, IV iron, B12 or folate per blood management algorithm.
62168740|NCT04475497|ACTIVE_COMPARATOR|Usual care|Usual care per surgeon preference can include iron by mouth or no iron therapy.
62168741|NCT05110651|ACTIVE_COMPARATOR|Hydroxychloroquine|Oral hydroxychloroquine 200mg once daily
62168742|NCT05110651|NO_INTERVENTION|No treatment|No treatment
62168743|NCT03304730||facet inflammatory signs|patients with facet inflammatory signs identified on MRI
62390381|NCT01933542|ACTIVE_COMPARATOR|Chlorzoxazone|"* Oral administration of chlorzoxazone 500 mg (two 250 mg tablets)~* Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~* Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed"
62390382|NCT01933542|PLACEBO_COMPARATOR|Placebo|"* Oral administration of two placebo tablets~* Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~* Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed"
62769673|NCT04221191||OroSEP PSP (OPSP) Group|OPSP neurologists will include and follow-up all study participants who receive DMF according to their standard of care practice and the OroSEP PSP (coached participants).
62769674|NCT03353103|ACTIVE_COMPARATOR|symptomatic|
62769675|NCT03353103|ACTIVE_COMPARATOR|asymptomatic|
62168744|NCT03304730||no facet inflammatory signs|patients without facet inflammatory signs identified on MRI
62168745|NCT02246387||Manchester Operation|Manchester Operation: Native tissue repair
61994624|NCT02670044|EXPERIMENTAL|Dose Escalation: Arm B (Venetoclax 400mg + Ida 400mg)|Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 400mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.
62168746|NCT01380964||DMD patients|DMD Patients
62168747|NCT01380964||Control patients|Control patients
62168748|NCT01498523|EXPERIMENTAL|raw camel milk|
62168749|NCT01498523|EXPERIMENTAL|camel milk powder solution|
62168750|NCT01498523|ACTIVE_COMPARATOR|raw cow milk|
62390383|NCT01834040|OTHER|intralesional and Intravenous|Intralesional/ Intravenous of Autologous Stem cells.
62390384|NCT05215106|EXPERIMENTAL|Durvalumab|All patients enrolled in the study will receive 2 administrations of durvalumab 10mg/kg monotherapy before any standard treatment.
62390385|NCT03016260||Infliximab (Remicade®)|
62390386|NCT03016260||Adalimumab (Humira®)|
62390387|NCT03016260||Etanercept (Enbrel®)|
62390388|NCT03016260||Golimumab (Simponi®)|
62168751|NCT01498523|ACTIVE_COMPARATOR|Glucose solution|
62168752|NCT06330857|EXPERIMENTAL|Surgical intervention|Operated with the intervention, ie vaginorectopexy
62168753|NCT04559516|EXPERIMENTAL|Mobile application-based home exercise intervention|"The exercise program will be administered over 12 weeks through the Ethica mobile app. Participants will perform exercise sessions at home guided by instructional video accessed via Ethica, six days per week. The program will include a combination of education, endurance, strength, and respiratory muscle training.~The Ethica mobile app will provide a daily alert and a daily exercise video. There will be background monitoring of step counts and actigraphy will be monitored for one week intervals at baseline, at week six, and at week twelve."
62168754|NCT04559516|ACTIVE_COMPARATOR|Standard care|No supervised exercise session will be performed. Symptoms and quality of life will be monitored in the same manner as the intervention group, and participants will receive the same educational message alerts through the Ethica app as the exercise intervention group.
62168755|NCT00662883|EXPERIMENTAL|A|"* PMI-150 (intranasal ketamine HCl), day 1~* mometasone furoate, days 2-15~* PMI-150 (intranasal ketamine HCl), day 15"
62168756|NCT00762723|EXPERIMENTAL|Group 1|Trinica Anterior Lumbar Plate System with fixed screws only
62390389|NCT03016260||Certolizumab Pegol (Cimzia®)|
62390390|NCT03016260||Infliximab biosimilar (Remsima®/ Inflectra®)|
62168757|NCT00762723|EXPERIMENTAL|Group 2|Trinica Anterior Lumbar Plate System with variable screws only
62168758|NCT00762723|EXPERIMENTAL|Group 3|Trinica Anterior Lumbar Plate with hybrid screw configuration (2 fixed-angle screws with 2 variable-angle screws).
62168759|NCT05664009|EXPERIMENTAL|Redsenol-1 Plus|Participants will be instructed to take two (2) capsules, three (3) times a day in the morning, at noon and in the evening (before going to bed), for a total of 6 capsules a day, with food for 12 weeks. If a dose is missed participants are instructed to take the missed dose as soon as possible.
62390391|NCT03016260||Etanercept biosimilar (Benepali®)|
62390392|NCT03016260||Infliximab biosimilar (Flixabi®)|
62390393|NCT03235245|ACTIVE_COMPARATOR|ARM A: Nivolumab + Ipilimumab|nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression. Then treatment will be left at the investigator choice and continued until the 2nd progression.
62168760|NCT05664009|PLACEBO_COMPARATOR|Placebo|Participants will be instructed to take two (2) capsules, three (3) times a day in the morning, at noon and in the evening (before going to bed), for a total of 6 capsules a day, with food for 12 weeks. If a dose is missed participants are instructed to take the missed dose as soon as possible.
62168761|NCT04554316|ACTIVE_COMPARATOR|Parallel placement|Steri-strips will be placed in-line (parallel) with the surgical incision.
62168762|NCT04554316|ACTIVE_COMPARATOR|Perpendicular placement|Steri-strips will be placed perpendicular to the surgical incision.
62168763|NCT03398434|EXPERIMENTAL|MAA868 low dose regimen|patients receive dose monthly.
62168764|NCT03398434|EXPERIMENTAL|MAA868 middle dose regimen|patients receive dose monthly.
62168765|NCT03398434|EXPERIMENTAL|MAA868 high dose regimen|patients receive dose monthly.
62168766|NCT03398434|ACTIVE_COMPARATOR|Apixaban|Apixaban 5 mg b.i.d
62168767|NCT03227432|EXPERIMENTAL|Nivolumab + Elotuzumab|"* 22 patients will be entered, If \> 4 patients achieve at least a partial response (PR) within 4 cycles an additional 18 patients will be treated.~* Nivolumab will be administered intravenously twice per cycle for cycle 1-4~* Nivolumab will be administered intravenously once per cycle for cycle 5~* Elotuzumab will be administered intravenously 4 times per cycle for cycle 1-2~* Elotuzumab will be administered intravenously twice per cycle for cycle 3-4~* Elotuzumab will be administered intravenously once per cycle for cycle 5"
62390394|NCT03235245|EXPERIMENTAL|ARM B: Encorafenib + Binimetinib + Nivolumab + Ipilimumab|encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks followed, after a week of pause, by nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections, followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression. Then patients will be rechallenged with encorafenib 450 mg QD + binimetinib 45 mg BID orally continuously until the 2nd progression.
62390395|NCT02582008|EXPERIMENTAL|Arm A (bupropion hydrochloride)|Patients receive bupropion hydrochloride PO for 3 days and then BID for up to 1 year post RT/CRT.
62390396|NCT02582008|ACTIVE_COMPARATOR|Arm B (varenicline, NRT)|Patients receive smoking cessation treatment tailored to individual smokers based on preference, smoking history and contra-indications. Patients are given the choice of one of the NCCN-recommended first-line pharmacotherapy options for smoking cessation comprised of varenicline PO daily for 1 week and then BID for 12 weeks or combination of nicotine patch and acute NRT for 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Treatment with varenicline or NRT can be extended up to 6 months to 1 year as needed.
62561973|NCT02933164|EXPERIMENTAL|Arms|Evaluation of the effectiveness of modified Sensor designs on the longevity (up to 180 days) of the Senseonics Continuous Glucose Monitoring (CGM) System. The investigation will also evaluate safety of the Senseonics CGM System usage, while in the clinic and during home use.
62561974|NCT02931864|NO_INTERVENTION|Usual care group|Usual care is meant the routine medical and health care services at the hospital.
62168768|NCT03227432|EXPERIMENTAL|Nivolumab+Elotuzumab+Pomalidomide+Dexamethasone|"* Nivolumab will be administered intravenously twice per cycle for cycle 1-4~* Nivolumab will be administered intravenously once per cycle for cycle 5~* Elotuzumab will be administered intravenously 4 times per cycle for cycle 1-2~* Elotuzumab will be administered intravenously twice per cycle for cycle 3-4~* Elotuzumab will be administered intravenously once per cycle for cycle 5~* Pomalidomide will be administered for 21 days per cycle~* Dexamethasone will be administered weekly"
62168769|NCT02149576|ACTIVE_COMPARATOR|LDCT Surveillance Program Group|This cohort will follow a strict schedule of Low Dose Computed Tomography Imaging scans and clinical visits 3, 6, and 12 months after surgery. At each encounter, a history, physical examination, and review of the LDCT results will be performed. Patients with normal clinical and imaging findings will proceed to the next scheduled clinical encounter. Patients with abnormal findings will be managed according to predetermined algorithms.
62168770|NCT02149576|OTHER|Historical Control Group|The control group will be a retrospective cohort taken from 1-year before the implementation of the LDCT surveillance program. The post-operative follow-up of these participants was not standardized, but rather left up to the discretion of the individual surgeons, and involved chest radiograph imaging as opposed to Low Dose Computed Tomography.
62168771|NCT05285345||Pre-Guideline Implementation|Participants in this group will be recruited during the first 3 months of the study and the time will be used for baseline data collection with existing standards of care around discharge practices of infants with BPD
62561975|NCT02931864|EXPERIMENTAL|Experimental group|Five weekly sessions of online symptom management + mindfulness training programme + usual care
62561976|NCT02931864|ACTIVE_COMPARATOR|Comparison group 1|Five weekly sessions of online symptom management programme + usual care
62561977|NCT02931864|ACTIVE_COMPARATOR|Comparison group 2|Five weekly sessions of online mindfulness training programme and usual care
62561978|NCT01219816|EXPERIMENTAL|Patients under 60 years|Hyper CVAD regimen + Epratuzumab (Cyclophosphamide Vincristine Doxorubicin Dexamethasone)
62561979|NCT01219816|EXPERIMENTAL|Patients older than 60 years or < =60 years|Vincristine + Aracytine + Dexamethasone
62561980|NCT05882825||Patients admitted to the physical medicine and rehabilitation outpatient clinic.|Patients admitted to the physical medicine and rehabilitation outpatient clinic and gave consent to participate.
62561981|NCT00918866|EXPERIMENTAL|Low Pulmonary Arterial Pressure|Subjects with pulmonary arterial pressure (PAP) of \< or = to 35 mmHg.
62561982|NCT00918866|EXPERIMENTAL|Elevated Pulmonary Arterial Pressure|Subjects with a PAP of \> or = to 35 mmHg.
62561983|NCT00935116|ACTIVE_COMPARATOR|etoricoxib|"G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery"
62168772|NCT05285345||Post-Guideline Implementation|After 3 months, the discharge bundle developed from consensus from the Delphi process will be introduced to both NICUs using Quality Improvement principles. Participants will be recruited after the introduction of the discharge bundle.
62561984|NCT04757974|EXPERIMENTAL|Part 1: Treatment sequence ABC|Participants will receive FTR 3×200 mg ER tablets (Treatment A) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 2 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 3.
62561985|NCT04757974|EXPERIMENTAL|Part 1: Treatment sequence BCA|Participants will receive FTR 3×200 mg ER tablets (Treatment B) in Period 1 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 3.
62561986|NCT04757974|EXPERIMENTAL|Part 1: Treatment sequence CAB|Participants will receive FTR 600 mg ER tablet in Period 1 (Treatment C, reference) followed by FTR 3×200 mg ER tablets (Treatment A) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 3.
62168773|NCT00347425|OTHER|A|
62390397|NCT04302311|ACTIVE_COMPARATOR|Standard of Care|Holter monitoring
62390398|NCT04302311|ACTIVE_COMPARATOR|Enhanced Monitoring|Kardia/AliveCor monitoring with additional Holter monitoring as needed
62390399|NCT00805194|EXPERIMENTAL|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
62390400|NCT00805194|PLACEBO_COMPARATOR|Placebo plus docetaxel|Placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
62390401|NCT01028859|EXPERIMENTAL|CKD-516 inj|
62390402|NCT02539680|EXPERIMENTAL|normal renal function|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
62390403|NCT02539680|EXPERIMENTAL|CKD stage 3-5 (not on dialysis)|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
62390404|NCT02539680|EXPERIMENTAL|on dialysis|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
62390405|NCT05836688|EXPERIMENTAL|Goal-Focused Emotion-Regulation Therapy (GET)|A novel behavioral intervention to enhance self-regulation through improved goal navigation skills, improved sense of purpose, and better ability to regulate emotional responses in young adults with testicular cancer.
62390406|NCT05836688|ACTIVE_COMPARATOR|Individual Supportive Listening|Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience.
62390407|NCT04361695|ACTIVE_COMPARATOR|Ketoprophenum|A tablet with 10 mg Ketoprophenum is taken per os 2 hours before surgery
62561987|NCT04757974|EXPERIMENTAL|Part 1: Treatment sequence ACB|Participants will receive FTR 3×200 mg ER tablets (Treatment A) in Period 1 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 3.
62168774|NCT00347425|OTHER|B|
61994625|NCT02670044|EXPERIMENTAL|Dose Optimisation: Arm B (Ven 600mg (Day 1 to 21) + Ida 150mg)|Participants received Venetoclax 600mg daily on Days 1-21 of each 28 day treatment cycle and Idasanutlin 150mg daily on Days 1-5 of each 28 day treatment cycle.
62390408|NCT04361695|PLACEBO_COMPARATOR|Placebo|A tablet containing starch is taken per os 2 hours before surgery
62390409|NCT03635645|EXPERIMENTAL|Retinal stimulation|Alternative stimulus patterns will be tested (vs. baseline). The intervention is the alternative stimulus pattern. The intervention will be tested only in the clinic vs. baseline. The subject will go home with baseline settings. The two alternative stimulus patterns to be tested are asymmetric waveforms and bipolar stimulus.
62390410|NCT00816712|ACTIVE_COMPARATOR|A|Testosterone - 300 mg IM
62390411|NCT00816712|ACTIVE_COMPARATOR|B|Testosterone - 100 mg IM
62390412|NCT00816712|PLACEBO_COMPARATOR|C|Placebo - IM
62390413|NCT02280265|EXPERIMENTAL|ADVATE|The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight every 48 ± 6 hours) with Recombinant Human Coagulation Factor VIII for injection(ADVATE) for 1 year. Subjects must be prescribed ADVATE by the treating physician. Data will be collected over a period of 2 years from the time of study enrollment. Study visits are to coincide with routinely rescheduled and emergency visits. Available data from these visits shall be transcribed onto the case report forms (CRFs).
62390414|NCT06393205|EXPERIMENTAL|the Naso-Esophageal Tube Feeding group|The patients will be given Naso-Esophageal Tube Feeding and routine treatment, for 15 days.
61994626|NCT02635464|EXPERIMENTAL|hUC-MSCs+Injectable collagen scaffold+CABG|
62390415|NCT06393205|ACTIVE_COMPARATOR|The Nasogastric Tube Feeding group|The patients will be given Nasogastric Tube Feeding and routine treatment, for 15 days.
62561988|NCT04757974|EXPERIMENTAL|Part 1: Treatment sequence BAC|Participants will receive FTR 3×200 mg ER tablets (Treatment B) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 2 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 3.
62561989|NCT04757974|EXPERIMENTAL|Part 1: Treatment sequence CBA|Participants will receive FTR 600 mg ER tablet (Treatment C, reference) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 3.
61994627|NCT02635464|ACTIVE_COMPARATOR|hUC-MSCs+CABG|
61994628|NCT02635464|ACTIVE_COMPARATOR|CABG|
61994629|NCT01485211|EXPERIMENTAL|crosslinking with hypoosmolar riboflavin|Riboflavin and UVA-induced corneal cross-linking increases the stability of keratoconic corneas. The current inclusion criteria require a minimum stromal thickness of 400 µm. Hypo-osmolar riboflavin solution increases the stromal thickness before CXL in cases with preoperatively thin corneas.
61994630|NCT03127891|EXPERIMENTAL|pranayama yoga|yoga breathing exercise
61994631|NCT03127891|PLACEBO_COMPARATOR|control group|no intervention
61994632|NCT05627882||Standard ERCP|Patients undergoing ERCP with standard side viewing scope
61994633|NCT00624676|EXPERIMENTAL|A|LHA formulation
61994634|NCT00624676|ACTIVE_COMPARATOR|B|5% benzoyl peroxide
61994635|NCT04796246|EXPERIMENTAL|Leap Motion Controller|Intervention Group: which will receive treatment with Leap Motion Controller
61994636|NCT04796246|ACTIVE_COMPARATOR|Conventional Physiotherapy|Control Group: who will receive treatment with conventional physiotherapy.
61994637|NCT04298996||study group (passive smoking children)|examining for caries prevalence and taking saliva samples to determine oxidative stress markers TAS and TOS
61994638|NCT04298996||control group|examining for caries prevalence and taking saliva samples to determine oxidative stress markers TAS and TOS
61994639|NCT03302728|EXPERIMENTAL|Lenalidomide & brentuximab vedotin|Brentuximab vedotin 1.8mg/Kg Lenalidomide 15 mg
61994640|NCT01672476|PLACEBO_COMPARATOR|Placebo|1 capsule/day of placebo will be orally administered for the study period (8 weeks)
61994641|NCT01672476|ACTIVE_COMPARATOR|Valsartan 80mg|(As reference group) 80mg/day of Valsartan will be orally administered for the study period (8 weeks)
61994642|NCT01672476|EXPERIMENTAL|Fimasartan 30mg|30mg/day of Fimasartan will be orally administered for the study period (8 weeks)
62168775|NCT01014663|ACTIVE_COMPARATOR|Therapeutic Exercise|
62168776|NCT01014663|ACTIVE_COMPARATOR|Non-Contact Boxing Training|
62168777|NCT03937596|EXPERIMENTAL|D-Cycloserine|Participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine daily (Monday-Friday) for the first 2 weeks of rTMS treatment (10 sessions), followed by 2 weeks of rTMS without adjunctive medication.
62182719|NCT05771025|EXPERIMENTAL|Hepatectomy group|Patients in the hepatectomy group receive hepatectomy, which could be combined with radiotherapy and chemotherapy for the primary tumor during the perioperative period.
62168778|NCT03937596|PLACEBO_COMPARATOR|Placebo|Participants will orally ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for the first 2 weeks of rTMS treatment (10 sessions), followed by 2 weeks of rTMS without adjunctive medication.
62168779|NCT04385849|EXPERIMENTAL|Experimental Arm|N-803 Recombinant human super agonist interleukin-15 (IL-15) complex
62168780|NCT04385849|PLACEBO_COMPARATOR|Placebo Arm|Sterile saline solution
62168781|NCT01099150|EXPERIMENTAL|42 healthy volunteers - crossover|"Acute consumption of three interventions (60 g dark chocolate enriched in flavan-3-ols, 60 g standard dark chocolate, or 60 g white chocolate) on three separate days (at least 2 weeks apart) in random order.~Post-prandial measurements at t = 0 h, t = 2 h and t = 6 h."
62168782|NCT03038152|EXPERIMENTAL|Diagnostic (Magseed marker)|Patients receive the Magseed marker via ultrasound guided injection into the previously clipped lymph node or within perinodal tissue =\< 3mm from the clipped node. Patients then undergo axillary lymph node localization and targeted dissection within 30 days.
62168783|NCT06116942|EXPERIMENTAL|Active stimulation - Placebo stimulation|Participants will undergo a 2 intervention periods. The first intervention period will consist of a 2-week course of rTMS followed by BCI-mediated training. This intervention will be succeeded by a 4-week washout period to mitigate any carry-over effects. The second intervention period will entail 2 weeks of sham rTMS followed by BCI-mediated training.
62168784|NCT06116942|EXPERIMENTAL|Placebo stimulation - Active stimulation|Participants will undergo the same interventions as the first arm but delivered in inverse order. The first intervention period will consist of 2 weeks of sham rTMS followed by BCI-mediated training. The second intervention period will entail 2 weeks of rTMS prior to BCI-mediated training and will start after a 4-weeks washout period.
62168785|NCT00393198|EXPERIMENTAL|Arm 1|
62561990|NCT04757974|EXPERIMENTAL|Part 2: Treatment sequence DE|Participants will receive the selected low-dose formulation of FTR 3 × 200 mg ER tablets in a fasted state (Treatment D) in Period 1 and following a high fat high calorie meal (Treatment E) in Period 2.
61994643|NCT03576248|EXPERIMENTAL|In-phase 6 Hz prefronto-parietal tACS|6 Hz stimulation (1000 μA) with transcranial Alternative Current Stimulation (tACS) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3 of the 10-20 international scalp EEG system, with a return electrode in Cz) for 20 minutes. The phase difference between the two stimulation sites will be 0°.
61994644|NCT03576248|SHAM_COMPARATOR|Sham prefronto-parietal tACS|The same stimulation as in in-phase transcranial Alternative Current Stimulation tACS (6 Hz F3 and P3 stimulation with 0° phase difference) will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation. The whole session duration is 20 minutes.
61994645|NCT03576248|EXPERIMENTAL|2 mA left prefrontal tDCS|2000 μA anodal transcranial Direct Current Stimulation (tDCS) will be applied over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system with a right supraorbital return electrode (Fp2 of the 10-20 international scalp EEG system) during 20 minutes.
62168786|NCT00393198|PLACEBO_COMPARATOR|Arm 2|
62168787|NCT00393198|ACTIVE_COMPARATOR|Arm 3|
62168788|NCT04171258|EXPERIMENTAL|Botulax®|
62168789|NCT04171258|ACTIVE_COMPARATOR|Botox®|
62168790|NCT01407302||LMA group|patients undergoing general anesthesia with LMA insertion
62168791|NCT01407302||E-tube group|patients undergoing general anesthesia with e-tube
62168792|NCT03779126|EXPERIMENTAL|Active comparator|Low frequency electrical stimulation for 60 minutes, three times a week during 60 days.
62168793|NCT03779126|EXPERIMENTAL|Other|High frequency electrical stimulation for 60 minutes, three times a week during 60 days.
62168794|NCT03779126|EXPERIMENTAL|Experimental group|Low and High frequency electrical stimulation for 60 minutes, three times a week during 60 days.
62168795|NCT03779126|PLACEBO_COMPARATOR|Placebo|Placebo electrical stimulation for 60 minutes, three times a week during 60 days. In the intervention groups will be used highest intensity tolerated by the individual, and in the sham will be maintained the minimum intensity after beginning of the perception of the electric current
62168796|NCT05996458||group one|The screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori (HP) antigen test, ring finger protein 180 (RNF180) and SEPTIN9 gene methylation test, and investigation of risk factors, including past disease history, alcohol drinking history, smoking history, tea drinking history, family history of cancer, marital and reproductive status, and dietary habits.
62168797|NCT05996458||Group one's control（Spouse or sibling of group one )|Only the risk factors will be investigated
62168798|NCT05996458||group two|The screening population will undergo investigation of risk factors, a fecal occult blood test (FIT), and a stool test for Helicobacter pylori (HP) antigen. If a stool occult blood test or H. pylori antigen is positive after testing, RNF180 and SEPTIN9 gene methylation testing will be scheduled. If the gene methylation test is positive, a colonoscopy will be scheduled.
62168799|NCT05996458||group two's control（Spouse or sibling of group two)|Only the risk factors will be investigated
62168800|NCT04027491|EXPERIMENTAL|Virtual reality intervention|"Participant undergo 12 treatment sessions, during a 4-week period (3 sessions per week).~Each intervention session lasts 45 minutes."
62168801|NCT04027491|NO_INTERVENTION|Observational|Participant undergo a 4 weeks observational period. No intervention are performed.
62168802|NCT04658537|ACTIVE_COMPARATOR|Standard Arm|8 Gy / 1 Fraction
62168803|NCT04658537|EXPERIMENTAL|Single Fraction Dose Escalation|8Gy Planning Target Volume / 12Gy Clinical Target Volume +/- 14Gy Gross Tumour Volume / 1 fraction
62168804|NCT01513447|ACTIVE_COMPARATOR|Sterile Water Injection|"In the sitting position, study subjects will receive a total of 0.4 mL of study drug via four intracutaneous injections: bilateral injections at the posterior superior iliac spine and bilateral injections at 1 cm medial and 1-2 cm inferior to the first point."
62168805|NCT01513447|PLACEBO_COMPARATOR|Normal Saline Injection|"In the sitting position, study subjects will receive a total of 0.4 mL of study drug via four intracutaneous injections: bilateral injections at the posterior superior iliac spine and bilateral injections at 1 cm medial and 1-2 cm inferior to the first point."
62168806|NCT01032200|EXPERIMENTAL|Arm I - Armodafinil|Patients receive oral armodafinil once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.
62168807|NCT01032200|PLACEBO_COMPARATOR|Arm II - Placebo|Patients receive oral placebo once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.
62168808|NCT05202327|PLACEBO_COMPARATOR|Placebo|Two placebo capsules thrice daily for 56 days (8 weeks).
62168809|NCT05202327|EXPERIMENTAL|Low-dose|One placebo capsule and 1 PDC-1421 Capsule, thrice daily for 56 days (8 weeks).
62168810|NCT05202327|EXPERIMENTAL|High-dose|Two PDC-1421 Capsules thrice daily for 56 days (8 weeks).
62168811|NCT00871455|EXPERIMENTAL|1|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
62168812|NCT01100593|ACTIVE_COMPARATOR|1.75 inch catheter length|Length of catheter to be used
62168813|NCT01100593|ACTIVE_COMPARATOR|2.5 inch catheter length|length of catheter to be used
62168814|NCT04528147|EXPERIMENTAL|Yi Jin Jing Tiger Roaring Speech Rehabilitation|Yi Jin Jing tiger roaring speech rehabilitation with real-time feedback technique Duration: Each time requires an hour of training; Frequency: three times a week, 4 weeks in total.
62168815|NCT04528147|EXPERIMENTAL|Conventional Speech Rehabilitation|"Patients will receive speech rehabilitation recommended by The Parkinson's Foundation.~Duration: Each time requires an hour of training; Frequency: three times a week, 4 weeks in total."
62168816|NCT00262769|EXPERIMENTAL|A - Gemcitabine|Gemcitabine alone
62168817|NCT00262769|EXPERIMENTAL|B - Gemcitabine and Cisplatin|Gemcitabine and Cisplatin
62168818|NCT00748358|EXPERIMENTAL|drug|drug
62168819|NCT03770299|EXPERIMENTAL|Arm A|Nivolumab + SOC (chemotherapy in eligible participants or observation)
62168820|NCT03770299|ACTIVE_COMPARATOR|Arm B|SOC (chemotherapy in eligible participants or observation)
62168821|NCT04440579|ACTIVE_COMPARATOR|Standard Cystoscopy|Patients will undergo a standard of care cystoscopy
62168822|NCT04440579|EXPERIMENTAL|PTNS and Cystoscopy|Patients will undergo PTNS while undergoing cystoscopy
62168823|NCT04440579|SHAM_COMPARATOR|Sham PTN and Cystoscopy|Patients will undergo a sham PTNS procedure while undergoing cystoscopy
62168824|NCT00629161|EXPERIMENTAL|A|
62168825|NCT00629161|PLACEBO_COMPARATOR|B|
62168826|NCT05946447|EXPERIMENTAL|Gastric Ultrasound|Ultrasound measurements of the antrum will be recorded.
62168827|NCT03206489|EXPERIMENTAL|nHFOV|noninvasive high-frequency ventilation (nHFOV) is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
62168828|NCT03206489|ACTIVE_COMPARATOR|nCPAP|nasal continuous positive airway pressure (nCPAP) is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
62168829|NCT02556918|EXPERIMENTAL|Sitagliptin|"Subjects undergoing cardiac surgery with type 2 diabetes (T2D) will be randomized to receive one tablet of sitagliptin once a day.Subjects with stress hyperglycemia (defined as a blood glucose (BG) greater than 180 mg/dL) in the intensive care unit (ICU) will continue to receive sitagliptin and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.~Interventions:~Drug: Sitagliptin Drug: Regular Human Insulin Drug: Insulin glargine Drug: Supplemental insulin (Insulin lispro) Drug: Supplemental insulin (Insulin aspart)"
62182720|NCT02937896|EXPERIMENTAL|Ketorolac|30mg ketorolac administrated intravenous and 4 puffs nasal Normal Saline.
62168830|NCT02556918|PLACEBO_COMPARATOR|Placebo|"Subjects undergoing cardiac surgery with type 2 diabetes will be randomized to receive one tablet of placebo once a day.Subjects with stress hyperglycemia (defined as a blood glucose (BG) greater than 180 mg/dL) in the intensive care unit (ICU) will continue to receive a placebo and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.~Interventions:~Drug: Placebo Drug: Regular Human Insulin Drug: Insulin glargine Drug: Supplemental insulin (Insulin lispro) Drug: Supplemental insulin (Insulin aspart)"
62168831|NCT01486277|EXPERIMENTAL|Quisinostat|Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
62168832|NCT00187122|OTHER|1|See Detailed Description section for description of treatment plan.
62561991|NCT04757974|EXPERIMENTAL|Part 2: Treatment sequence ED|Participants will receive the selected low-dose formulation of FTR 3 × 200 mg ER tablets following a high fat high calorie meal (Treatment E) in Period 1 and in a fasted state (Treatment D) in Period 2.
62168833|NCT04927559||Observational (survey)|Patients complete a survey over 5-10 minutes about their understanding of radiation therapy.
62168834|NCT04092699|OTHER|patient|CBCT Dicom file of patient has been scanned will be used for measurements of maxillary sinus volume by different software
62168835|NCT04092699|OTHER|skulls|CBCT Dicom file of patient has been scanned will be used for measurements of maxillary sinus volume by different software
62168836|NCT04523571|EXPERIMENTAL|Low-dose, 18-55 years of age|
62168837|NCT04523571|EXPERIMENTAL|High-dose, 18-55 years of age|
62168838|NCT04523571|PLACEBO_COMPARATOR|Placebo, 18-55 years of age|
62390416|NCT00749489|EXPERIMENTAL|Femoral Nerve Block|Intervention patients will have a continuous fascia iliaca blocks placed by a regional anesthesiologist 24 hours after the initial single injection femoral nerve block or at the time of surgery.
62390417|NCT00749489|NO_INTERVENTION|No Intervention|No intervention
62390418|NCT02690506|PLACEBO_COMPARATOR|Group C|Oral placebo pill was administered 2 hours before anesthesia
62390419|NCT02690506|ACTIVE_COMPARATOR|Group P|Oral pregabalin 150 mg was administered 2 hours before anesthesia
62390420|NCT01107483||AC group|asymptomatic carriers
62390421|NCT01107483||CH group|patients with chronic hepatitis
62168839|NCT04523571|EXPERIMENTAL|Low-dose, 65-85 years of age|
62168840|NCT04523571|EXPERIMENTAL|High-dose, 65-85 years of age|
62168841|NCT04523571|PLACEBO_COMPARATOR|Placebo, 65-85 years of age|
62168842|NCT05640947|EXPERIMENTAL|LAMS gastro-gastrostomy|
62168843|NCT05400226|EXPERIMENTAL|0.32mg/kg VGT-309|Single arm in an open label study
62168844|NCT06645834|OTHER|Treatment|Subjects will start using the Smart MDI system consisting of the InPen™ System and Simplera™ System.
62168845|NCT06645834|NO_INTERVENTION|Control|None -Subjects will continue their own MDI therapy
62168846|NCT00647283|EXPERIMENTAL|1|Stable liver transplant recipients fulfilling inclusion criteria.
62168847|NCT00598637|ACTIVE_COMPARATOR|EES|Everolimus-eluting stent (Xience)
62390422|NCT01107483||HC group|patients with hepatic cirrhosis
62390423|NCT01107483||ACLF group|patients with acute on chronic liver failure
62390424|NCT01107483||healthy control|healthy volunteers
62561992|NCT01267019|EXPERIMENTAL|Arm 1: vivo augmentation|social cognitive training with in vivo augmentation
62561993|NCT01267019|ACTIVE_COMPARATOR|Arm 2: social cognitive|social cognitive training
62561994|NCT01267019|ACTIVE_COMPARATOR|Arm 3: non-social skills|non-social skills training
62168848|NCT00598637|EXPERIMENTAL|ZES|Zotarolimus-eluting stent (Endeavor Resolute)
62168849|NCT06570434|EXPERIMENTAL|Dose 1|Low dose
62168850|NCT06570434|EXPERIMENTAL|Dose 2|Middle dose
62168851|NCT06570434|EXPERIMENTAL|Dose 3|High Dose
62168852|NCT00778141|EXPERIMENTAL|1|metformin HC1 750 mg extended-release tablets
62168853|NCT00778141|ACTIVE_COMPARATOR|2|Glucophage® XR 750 mg tablets
62168854|NCT02194777|EXPERIMENTAL|BIBN 4096 BS - in single rising doses|
62168855|NCT02194777|PLACEBO_COMPARATOR|Placebo|
62168856|NCT03715413|OTHER|Tamoxifen group|they was received Tamoxifen 10 mg daily.
62168857|NCT03715413|ACTIVE_COMPARATOR|Tamoxifen and pulsed radiofrequency group|they was received Tamoxifen 10 mg daily and pulsed radiofrequency of 2nd , 3rd and 4th thoracic dorsal root ganglia.
62168858|NCT02251405|PLACEBO_COMPARATOR|One big bag, no stainless container|No stainless container
62390425|NCT02141594||Early glaucoma|The study group consisted of consecutive unilateral glaucoma patients, categorized as early stage by Hodapp-Anderson-Parrish classification.
62390426|NCT02141594||Normal subjects|Normal control subjects had a normal ocular examination, Intraocular pressure (IOP) \<22 mmHg, no past history of high IOP, no family history of glaucoma, normal optic disc morphology and visual field in both eyes. One eye of control subject was randomly selected.
62390427|NCT03555227|ACTIVE_COMPARATOR|Group X|"PECS group~USG PECS2 with Drug A (active) Wound infiltration with Drug P (placebo)"
62390428|NCT03555227|ACTIVE_COMPARATOR|Group Y|"LA (local anaesthetic) infiltration group~USG PECS2 with Drug P (placebo) Wound infiltration with Drug A (active)"
62390429|NCT04594616|EXPERIMENTAL|Smartphone-delivered CBT for MDD|8-week Smartphone delivered CBT for MDD.
62390430|NCT04594616|OTHER|8 Week Waitlist Control|8-week waitlist control. (Note: participants will be crossed over to 8-week Smartphone-delivered CBT for MDD following the 8-week waitlist control).
62390431|NCT02622217|EXPERIMENTAL|Sleep deprived|Participants undergo a simulation session after an on call night
62390432|NCT02622217|NO_INTERVENTION|Rested|Participants undergo a simulation session after a night of normal sleep at home
62390433|NCT01402882|EXPERIMENTAL|Tranexamic acid|
62390434|NCT01402882|PLACEBO_COMPARATOR|Placebo|(Sodium Chloride 0.9%)
62561995|NCT02251093|EXPERIMENTAL|Lcr Regenerans|
62561996|NCT02251093|PLACEBO_COMPARATOR|Placebo|
62168859|NCT02251405|ACTIVE_COMPARATOR|One big bag with two stainless containers|Two stainless containers
62561997|NCT04032015|ACTIVE_COMPARATOR|rTMS treatment|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered using neuro-navigation based on participants' own MRI images. Daily treatment regiments will last 30 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
62168860|NCT02815618||Infants delivered by elective caesarean|Infants to be measured immediately after birth and on their second day of life.
62168861|NCT02815618||Infants on mechanical ventilation|Infants to be measured while changing ventilator settings to normalize arterial pCO2.
62168862|NCT02815618||Infants on ventilatory support|Infants to be measured for 24 hours continuously to assess user-friendliness and loss of signal.
62168863|NCT01502787|ACTIVE_COMPARATOR|Initial treatment with metoprolol|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
62168864|NCT01502787|ACTIVE_COMPARATOR|Initial treatment with nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
62168865|NCT02243436|EXPERIMENTAL|BV-ESHAP|"1. - 3 cycles every 21 days:~   * Brentuximab Vedotin, on day 1 (BV will be administered at three different doses 0.9mg/kg, 1.2mg/kg, 1.8mg/kg)~  * Etoposide 40 mg/m2/day, on days 1 to 4~  * Soludomerin (methylprednisolone) 250 mg/day, on days 1 to 4~  * Cisplatin 25 mg/m2/day, on days 1 to 4~  * Ara C (cytarabine) 2 g/m2, on day 5~2. - A fourth dose of BV will be given 21 days after the third BV dose during the evaluation of response before the transplant.~3. - Autologous peripheral blood stem cell transplant~4. - A fifth dose of BV (1.8mg/kg) will be given on between day 28 and 35 post-transplant, followed by two additional doses (1.8mg/kg) every 3 weeks, to complete a total of 7 BV infusions."
62390435|NCT02240901|EXPERIMENTAL|Laryngeal mask airway|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
62390436|NCT02240901|EXPERIMENTAL|Endotracheal intubation group（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
62390437|NCT03470506||Ischemic stroke|Diagnosed with an ischemic stroke by a Neurologist
62390438|NCT02760420|EXPERIMENTAL|Placebo|250 mg of placebo (dispersible tablet) DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age)
62390439|NCT02760420|ACTIVE_COMPARATOR|3 Days|250 mg amoxicillin (dispersible tablet) DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age)
62390440|NCT04058782||Patients with myocardial|
62390441|NCT04951726|ACTIVE_COMPARATOR|IV push|2 mg slow intravenous injection over five minutes repeated q12hr until resolution for up to 24 hours. (4 mg total in 24 hours)
62390442|NCT04951726|EXPERIMENTAL|subcutaneous|1.0 mg subcutaneous repeated q8hr until resolution for up to 24 hours (3.0 mg total in 24 hours)
62390443|NCT03651960|EXPERIMENTAL|Robot|ROBOT PROTOTYPE
62390444|NCT00948389|ACTIVE_COMPARATOR|Dasatinib|
62390445|NCT00948389|ACTIVE_COMPARATOR|Lomustine|
62168866|NCT05885464|EXPERIMENTAL|Fludarabine, cyclophosphamide and alemtuzumab|Lymphodepletion regimen including fludarabine, cyclophosphamide and alemtuzumab
62168867|NCT05885464|EXPERIMENTAL|Fludarabine, cyclophosphamide without alemtuzumab|Lymphodepletion regimen without Alz but consisting of the same dose of Flu/Cy as in the other arm
62168868|NCT00472069|EXPERIMENTAL|A|transplantation of the squeletic muscular cells
62390446|NCT00578006|EXPERIMENTAL|A|If you are in group A, the investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
62561998|NCT04032015|SHAM_COMPARATOR|Sham treatment|"Sham rTMS will be delivered for 20 sessions over 4 weeks. To maximize sham validity, both 1) a direction-sensor TMS coil will alert the operators to flip the coil if the wrong side is being used, and 2) low-intensity 10Hz electrical stimulation will be applied to scalp electrodes under the coil for sham and placed but not activated in the active arm. The rTMS coil will be positioned using neuro-navigation based on participants' own MRI images, mimicking active rTMS treatment. Daily treatment regiments will last 30 minutes and sham rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the sham rTMS sessions for adverse events and/or side effects.~Upon completing the 20 sham sessions, participants are unblinded and offered 20 treatments of active rTMS. The open-label treatment would follow the active rTMS treatment protocol."
62168869|NCT04910061|EXPERIMENTAL|NMN-C|Healthy individuals receiving NMN-C
62168870|NCT03711825|EXPERIMENTAL|Sentinel/Main|Sentinel dosing of two subjects in clinic of LYN-057 (50 mg), followed by Main, i.e. remaining 6 subjects, for total of 8 subjects doses; followed by imaging assessment (MRI/abdominal U/S)
62168871|NCT03401411|EXPERIMENTAL|Standard SCCMP|Health care provider completes triage survey of 15 fictional patient case scenarios using the standard SCCMP to prioritize each for admission.
62168872|NCT03401411|EXPERIMENTAL|SCCMP + Algorithm-based Triage Tool|Health care provider completes triage survey of 15 fictional patient case scenarios using SCCMP in addition to a newly designed flowchart-based triage guide to prioritize each for admission.
62168873|NCT00084409|EXPERIMENTAL|Arm I|Patients receive oral iloprost twice daily for 6 months in the absence of unacceptable toxicity.
62390447|NCT00578006|EXPERIMENTAL|B|If you are in group B, the investigators will provide you with access to the STAR website using a computer in the waiting area, into which you can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy. The investigators may also provide you with a website address so that you can access STAR from home (or any other location) to report your symptoms at any time.
62390448|NCT03654963|NO_INTERVENTION|Control|Patients of the control group will not receive the best possible medication history with medication reconciliation at admission. The standard physician-acquired medication history will be performed as usual.
62561999|NCT05477069|EXPERIMENTAL|First intervention group|The volunteer ingests the medical device which passes through the body for a period of 12 to 24 hours. Capsules are collected and analysis on intestinal fluid and faeces are performed
62562000|NCT02462603|EXPERIMENTAL|PTC589|Participants with Parkinson's disease (idiopathic and mitochondrial genetic subtype participants) will receive PTC589 at a dose of 500 milligrams (mg) (2 tablets of 250 mg each) orally twice daily (BID) for up to 3 months unless discontinued for safety or tolerability issues.
62562001|NCT04162743|ACTIVE_COMPARATOR|Trazodone|take trazodone 100mg hs
62562002|NCT04162743|PLACEBO_COMPARATOR|Placebo|take placebo pill hs
62562003|NCT00586703|EXPERIMENTAL|NK-CD56|NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors
62168874|NCT00084409|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo twice daily for 6 months in the absence of unacceptable toxicity.
62168875|NCT03158519|EXPERIMENTAL|iMETX intervention|Individualized exercise recommendation
62168876|NCT01257048|PLACEBO_COMPARATOR|1|Single Dose evaluation placebo (V5)
62168877|NCT01257048|ACTIVE_COMPARATOR|2|Single Dose evaluation formoterol (V5)
62168878|NCT05819983|ACTIVE_COMPARATOR|Oral ivermectin 3 dosages and placebo|"Twenty patients will be administered randomly oral ivermectin 200µg/kg BW on days 1, 2, and 8 and also placebo cream on days 1 and 8~Placebo cream: Cream base"
62168879|NCT05819983|ACTIVE_COMPARATOR|Oral ivermectin 2 dosages and placebo|"Twenty patients will be administered randomly oral ivermectin 200µg/kg BW on days 1 and 8 and also oral placebo on day 2, placebo cream on days 1 and 8~Placebo cream: Cream base"
62168880|NCT05819983|ACTIVE_COMPARATOR|Permethrin 5% cream 2 applications and placebo|"Twenty patients will be administered randomly permethrin 5% cream on days 1 and 8 and also oral placebo on days 1, 2, and 8~Placebo: vitamin B complex"
62168881|NCT03024593|EXPERIMENTAL|Searching condition|To simulate participants' natural behavior they are requested to search online for personally relevant health or illness information in their usual manner. By doing so their attentional focus lies on the searching process and the information they obtain.
62168882|NCT03024593|NO_INTERVENTION|Waiting condition (i.e. non- searching, no distraction)|Participants are requested to do nothing and not to distract themselves by reading or using their smartphone for instance. By doing so, it is expected that their attentional focus lies on their induced worries and symptoms.
62168883|NCT05044065|EXPERIMENTAL|Exercise group|The experimental group will in addition to standard care receive supervised and home-based exercise training program with a specific focus to induce metabolic stress (blood flow restriction exercise), and protein supplementation to ensure adequate protein intake.
62168884|NCT05044065|NO_INTERVENTION|Usual care|The control group will in addition to standard care receive protein supplementation to ensure adequate protein intake.
62168885|NCT01074099|ACTIVE_COMPARATOR|Control|CABG only
62168886|NCT01074099|EXPERIMENTAL|BMAC enhanced CABG|Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery
62168887|NCT02746237|EXPERIMENTAL|KAR5585|KAR5585 Capsules
62168888|NCT02746237|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62168889|NCT02278133|EXPERIMENTAL|WNT974, LGX818 and cetuximab combo|Phase l: Dose Escalation phase; Phase ll: SIngle group assessing the triple combination of WNT974, LGX818 and cetuximab
62562004|NCT06150586||Preterm infants with minimal gestational age of 27 weeks requiring LISA|LISA will be preformed according to our local standard protocol while measuring skin conductance via a specific monitor. At the same time a video is recorded for later unblinded and blinded N-PASS assessment.
62562005|NCT04355078|EXPERIMENTAL|Neuromuscular Training|The rehabilitation program starts two months after surgery, 45 minutes daily session, 3 times a week for 6 weeks. The involved leg is used if nothing else is stated that includes Walking on a treadmill, Squatting exercises, Single leg stance exercise Balance reach leg and arm exercises, Lunge exercises: anterior, lateral and posterior, Step-up and step down exercises, Single leg standing on balance mat, appropriate knee and hip position, Backwards and sideways walking for 5 steps on each side 1, 1 leg and 2 leg Wobble board Exercise and progress after every two weeks
62562006|NCT04355078|EXPERIMENTAL|Strength Training|The rehabilitation program starts two months after surgery, 45 minutes daily session, 3 times a week for 6 weeks that includes straight leg raising exercises, Supine position-isometric quadriceps contraction, Supine position-knee flexion and extension ROM exercises, the heel in contact with the bench during the ROM, Prone position-straight leg raising exercises, Prone position-knee flexion \& Extension ROM exercises, Stationary biking-before reaching 100 degrees of flexion(Progression: stair climbing and strength exercises), Standing-full weight-bearing, controlled balance double-limb support during parallel and diagonal stance, controlled knee extension, emphasis on full knee extension in weight-bearing position 3 10 reps Standing heel rising exercises both legs and one leg, 1 leg and 2 leg Wobble board Exercise, Step Up and down low height, Squatting exercises without bars/weight, Hamstrings, hip adductor and abductor strengthening exercises and progress after every two weeks
62562007|NCT01087918|EXPERIMENTAL|First RAGT, then strength training|16 sessions of 45 minutes of robot-assisted gait training 4 times a week in first intervention period and 16 sessions of 45 minutes of strength training 4 times a week in second intervention period.
62562008|NCT01087918|EXPERIMENTAL|First strength training, then RAGT|16 sessions of 45 minutes of strength training 4 times a week in first intervention period and 16 sessions of 45 minutes of robot-assisted gait training 4 times a week in second intervention period.
62562009|NCT01741038|EXPERIMENTAL|AlloStim® treatment|The treatment schedule includes: (1) the priming step with two ID AlloStim® injections (Days 0 and 3), an additional two ID injections followed by IV infusion of AlloStim® (Days 7 and 10); (2) the vaccination step with cryoablation of a single metastatic lesion followed by injection of AlloStim® into the ablated tumor and IV infusion of AlloStim® on protocol day 14, followed by IV infusion of AlloStim® on Day 17 (3) the activation step with an IV study drug infusion on Day 21 and (4) the booster step with IV booster infusions of AlloStim® on days 49 and 77. Additional booster infusions can be administered monthly at the discretion of the Investigator.
62562010|NCT01741038|OTHER|Physician's Choice (PC)|All subjects will be assigned Physician's Choice (PC) therapy. PC can consist of best supportive care (BSC) or any US-FDA-approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated.
62168890|NCT05179096|EXPERIMENTAL|Mindfulness|Participants in the experimental group will undergo an 8-week mindfulness training program with weekly 60-minute group sessions
62390449|NCT03654963|EXPERIMENTAL|Medication reconciliation|The pharmacy assistant will obtain the best possible medication history by compiling a comprehensive list of the medications the patient is taking. To confirm the accuracy of the history, the pharmacy assistant will use at least two sources of information, one of which being, when possible, the interview with the patient and/or family members. The clinical pharmacist will reconcile the best possible medication history with prescribed medicines and, to resolve unclear or ambiguous discrepancies between the two lists and/or to propose any adaptations of the pharmacotherapy, the clinical pharmacist will refer to the medical doctor. The medical doctor will decide potential changes in pharmacotherapy and communicate them to the patient.
62390450|NCT00733122|EXPERIMENTAL|A|GARDASIL, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
62390451|NCT04802226|EXPERIMENTAL|optimized self-exclusion procedure A|optimized self-exclusion procedure including content optimization with brief intervention, normative feedback, motivational approach, a personal story of a peer who had a positive experience using the tool, re-contact before the end of the self-exclusion period to propose an extension of the period outside the gambling plateform
62390452|NCT04802226|OTHER|standard self-exclusion B|standard self-exclusion with a single neutral notification email
62168891|NCT05179096|NO_INTERVENTION|Control|The control group will follow routine daily school activities
62168892|NCT00459433|EXPERIMENTAL|1|psychosocial intervention
62168893|NCT00459433|ACTIVE_COMPARATOR|2|Usual care
62168894|NCT00588991|EXPERIMENTAL|Treatment (veliparib, topotecan hydrochloride, carboplatin)|Patients receive veliparib orally twice daily on days 1-8, 1-14, or 1-21 and topotecan hydrochloride with or without carboplatin IV continuously over 120 hours on days 3-7. Treatment repeats every 28-63 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62390453|NCT03328325|EXPERIMENTAL|Arm 1|0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240
61994646|NCT03576248|SHAM_COMPARATOR|Sham left prefrontal tDCS|The same stimulation as active transcranial Direct Current Stimulation (tDCS) (anodal F3 and return in Fp2) will start at 2 mA intensity for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation. The whole session duration is 20 minutes.
62168895|NCT03087461|EXPERIMENTAL|Intervention Group|"The intervention group will receive a multi-component KT intervention. This will include exercise and self-management components.~The exercise intervention will involve a moderate intensity aerobic exercise program, using recumbent bikes, delivered within the cancer institution. Participants will take part in the 30-minute sessions 8 times. The intervention will be supervised by a physiotherapist (PT) educated in cancer rehabilitation.~The SM component will include educational modules created by a PT. Participants will view these 30 minute modules prior to each exercise intervention, over the same 8 sessions."
62168896|NCT03087461|NO_INTERVENTION|Usual Care|Control group receiving usual care (no exercise or self-management education within the institution).
62182721|NCT02937896|ACTIVE_COMPARATOR|Desmopressin|40 microgram nasal desmopressin administrated and 1cc Normal Saline intravenous
62562011|NCT02550561|EXPERIMENTAL|Posterior Tibial Nerve Stimulation|PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots. If benefits are obtained, 12 weeks of treatment is followed by spaced maintenance sessions at timing of provider and patient discretion.
62562012|NCT06292039|EXPERIMENTAL|Injury Thrivorship Pathway|Enrollment in the human-centered injury thrivorship pathway.
62562013|NCT01583140|EXPERIMENTAL|Exercise Intervention|Culturally-modified, individually tailored physical activity print materials
62390454|NCT03547219|EXPERIMENTAL|Escitalopram|Participants with depression were treated with escitalopram(ranging from 5mg to 30mg) for 8 weeks. Escitalopram was initiated at 5mg for 1 week, followed by an increase to 10mg at week 2. After week 2, doses of escitalopram were titrated according to symptoms and adverse effects. Specific, indicated psychotherapy for depression was not allowed during the study.
62390455|NCT04430491||Training dataset|No interventions
62390456|NCT04430491||Validation dataset|No interventions
62390457|NCT01359865|NO_INTERVENTION|Lumbar plexus Block|This group will recieve pre-operative lumbar plexus block plus general anesthesia
62390458|NCT05411731|ACTIVE_COMPARATOR|Conventional physical therapy treatment|Patients in this group will receive conventional physical therapy i.e. stretching, strengthening exercises, Aeroplan positioning
62390459|NCT05411731|EXPERIMENTAL|Constraint induced movement therapy|patients of this group will receive the same treatment along with constraint induced movement therapy
62390460|NCT02416375||Observation|Adult Cystic Fibrosis patients
62390461|NCT05471453|SHAM_COMPARATOR|DHEA group|75 mg DHEA supplementation per day for 3 months before IVF
62390462|NCT05471453|EXPERIMENTAL|DHEA+CoQ10+Tocotrienol group|75 mg DHEA supplementation + 30 mg CoQ10 + 300 mg Tocotrienol per day for 3 months before IVF
62390463|NCT05471453|NO_INTERVENTION|Control group|No supplementation before IVF
62390464|NCT01741610|PLACEBO_COMPARATOR|No coloading (Group E)|Placebo comparator
62390465|NCT01741610|ACTIVE_COMPARATOR|Cristalloid (Lactated Ringer) Coloading|Cristalloid (Lactated Ringer's) Coloading (Group L)
62390466|NCT01741610|ACTIVE_COMPARATOR|Colloid (HES) coloading|Colloid (HES) coloading (Group C)
62390467|NCT03600311|PLACEBO_COMPARATOR|Energy Balance|Participants will be in energy balance and consume 1.2 g/kg BW protein. They will be provided 30 g of maltodextrin following exercise.
62562014|NCT01583140|ACTIVE_COMPARATOR|Control|Bilingual health education booklets
62562015|NCT02123264|ACTIVE_COMPARATOR|Zoledronic acid|Zoledronic acid: 5 mg/year x 2 years
62562016|NCT02123264|NO_INTERVENTION|No intervention|No intervention
62562017|NCT04125147|EXPERIMENTAL|Montage Bone Hemostat|Use of Montage Settable Resorbable Hemostatic bone putty on the cut surfaces of bleeding bone at the osteotomy site
62390468|NCT03600311|ACTIVE_COMPARATOR|Caloric Restriction and CHO Supp|Participants will be calorie restricted to 15 kcal/kg FFM/day and consume 1.2 g/kg BW protein. They will be provided 30 g of maltodextrin following exercise.
62562018|NCT04125147|NO_INTERVENTION|Standard of Care: No bone hemostat|Use of no bone hemostat on the cut surfaces of bleeding bone at the osteotomy site
62390469|NCT03600311|EXPERIMENTAL|Caloric Restriction and PRO Supp|Participants will be calorie restricted to 15 kcal/kg FFM/day and consume 1.2 g/kg BW protein. They will be provided 30 g of whey protein following exercise.
62390470|NCT00836342||Previous history of SCC|Participants had previous history of SCC
62390471|NCT00836342||Previous history of BCC|Participants had previous history of BCC
62390472|NCT00836342||Control|Participants had no previous history of squamous cell carcinoma or basal cell carcinoma
62390473|NCT00945945|EXPERIMENTAL|DLX30-PLA|Per the protocol, patients randomized to the duloxetine group were to receive duloxetine for the entire 13-week acute treatment period. Patients were to start at a 30 mg daily (QD) dose of duloxetine for 1 week, then increase to 60 mg QD of duloxetine for the following 12 weeks. However, due to a study drug labeling error, patients randomized to this group received 30 mg of duloxetine for the initial 1-week, but received placebo instead of receiving 60 mg QD of duloxetine for the next 12 weeks. The resulting unintended, mixed treatment group was labeled as DLX30-PLA throughout this document. Per protocol, the last week of the study (week 14) was intended to be a 1-week taper period. Patients in this treatment group were to receive 30 mg QD of duloxetine during that week, and that did occur per protocol.
62390474|NCT00945945|PLACEBO_COMPARATOR|PLA-DLX60|Per the protocol, patients randomized to the placebo group were to receive placebo for the entire 13-week acute treatment period. Patients were to start on placebo for the first week, then continue on placebo for the following 12 weeks. However, due to a study drug labeling error, patients in this group received placebo for the initial 1-week, but received 60 mg QD of duloxetine instead of receiving placebo for the next 12 weeks. The resulting unintended, mixed treatment group was labeled as PLA-DLX60 throughout this document. Per protocol, the last week of the study (week 14) was intended to be a 1-week taper period. Patients in this treatment group were to receive placebo that week, and that did occur per protocol.
62390475|NCT05476965|EXPERIMENTAL|Arm 1|De-escalation radiation following induction therapy and surgery Drug: Cisplatinum Drug: Paclitaxel Drug: Sintilimab Surgery: Surgery Radiation: De-escalation radiotherapy
62390476|NCT05476965|ACTIVE_COMPARATOR|Arm 2|Arm 2 Standard radiation following induction therapy and surgery Drug: Cisplatinum Drug: Paclitaxel Drug: Sintilimab Surgery: Surgery Radiation: Standard radiotherapy
62390477|NCT02127580||with BAV|Patients undergoing TA-TAVI WITH predilation of the AV (Group A)
62390478|NCT02127580||without BAV|Patients undergoing TA-TAVI WITHOUT predilation of the AV
62390479|NCT05763030|EXPERIMENTAL|Intervention|Parent questionnaires and sleep characteristics of children (actigraphy and parent report) will be collected at three-time points- Time 1, 2, and 3. Time 1 is the first Baseline Data Collection for the Control Group and Intervention Group, and these data will be collected before the intervention group starts the 3-week intervention. Between Time 1 and Time 2, the Intervention Group will receive the 3-week intervention at the childcare center.
62390480|NCT05763030|NO_INTERVENTION|Control|The control arm will not receive the intervention. They will be assessed at time 1 and again at 2, following the completion of intervention in the intervention arm
62390481|NCT03061864|NO_INTERVENTION|Standard Counseling|Patients at risk of delivery between 20 and 25+6 weeks gestation will receive the normal counseling from Ob/gyn and Neonatology.
62390482|NCT03061864|EXPERIMENTAL|Periviable Birth Plan|Patients at risk of delivery between 20 and 25+6 weeks gestation will receive the normal counseling from Ob/gyn and Neonatology with completion of the written periviable birth plan.
62390483|NCT04862273||Native T1 CMR|Diagnostic accuracy of native T1 CMR and ATTR probability estimator are tested against the reference methods (99mTc-DPD scintigraphy, laboratory screening for multiple myeloma / AL amyloidosis; or cardiac biopsy, if noninvasive evaluation is inconclusive)
62390484|NCT01490385|ACTIVE_COMPARATOR|LED Phototherapy|LED phototherapy will be delivered transdermally via an extra-oral device and in a split mouth manner (half of the dental arch).
62390485|NCT01490385|NO_INTERVENTION|Control: conventional orthodontic tooth movement|
62390486|NCT00913731||psychotic patients|psychotic patients, acute ward, symptom rating scale.
62390487|NCT02921594|ACTIVE_COMPARATOR|Total knee arthroplasty with Vanguard XP|The new Vanguard XP Total knee arthroplasty system is a further development of the Vanguard TKA. The new Vanguard XP system both cruciate ligaments are preserved.
62390488|NCT02921594|ACTIVE_COMPARATOR|Total knee arthroplasty with Vanguard CR|Total knee arthroplasty system without preservation of the anterior cruciate ligament
62168897|NCT03388021|EXPERIMENTAL|routine use of completion angiography after thromboembolectomy|"this group will undergo surgical revascularization followed by routine completion angiography assisted with one of these adjuvant techniques as:~1. Thromboembolectomy under fluoroscopic guidance using Fogarty over the wire~2. Balloon angioplasty and/or stenting~3. Intraarterial thrombolysis~Aiming to correct any residual angiographic lesion as:~1. Residual thrombus~2. Retained embolus~3. Atheromatous plaque"
62562019|NCT05576688|EXPERIMENTAL|Alzheimer's disease|People with Alzheimer's disease who were diagnosed with Alzheimer's disease according to NINCDS/ARDRA diagnostic criteria by a neurologist and whose cognitive level was between 18-23 points according to Mini Mental State Examination.
62562020|NCT05576688|NO_INTERVENTION|Healthy older adults|33 healthy older adults with matching ages and gender.
62562021|NCT03644641|EXPERIMENTAL|Desflurane Group|Induction and anesthesia will be held by using desflurane
62390489|NCT05498207|NO_INTERVENTION|No Intervention|Participants will complete assessments at baseline, 3 months, 6 months, 9 months and 12 months. (this includes specimen collections, interviews, and surveys). Participants will also be asked to wear a Fitbit for 12 months.
62390490|NCT05498207|EXPERIMENTAL|Maya mobile app|Maya mobile app- CBT based self-help app
62562022|NCT03644641|EXPERIMENTAL|Propofol Group|Induction and anesthesia will be held by using target-control anesthesia with propofol
62562023|NCT03564119|EXPERIMENTAL|S5G4T-1|Participants will topically apply S5G4T-1 cream, once daily to face for 12 weeks.
62562024|NCT03564119|PLACEBO_COMPARATOR|S5G4T-2 Vehicle Cream|Participants will topically apply S5G4T-2 vehicle cream, once daily to face for 12 weeks.
62562025|NCT06118476|EXPERIMENTAL|Group trained with 3D animation|The experimental group was followed by training with 3D animation videos every week.
62562026|NCT06118476|NO_INTERVENTION|Control group|Lessons were taught with traditional learning method.
61994647|NCT04428892|EXPERIMENTAL|Clinical Simulation|The group denominated SP received a teaching strategy based on a class session with simulated practice for decision-making in clinical skills when caring for a person with LBP. Each session lasted approximately 120 minutes, and the clinical case used for the SP sessions was subjected to face validity with experts in the area of study.
61994648|NCT04428892|ACTIVE_COMPARATOR|Conventional Pedagogical strategy|"received a class session based on a role playing simulation strategy, structured for the same purpose established in the SP group. This session lasted approximately 120 minutes, and the learning environment was the classroom in which students assumed different roles to act out; some of them acted as people with LBP and others as physiotherapists"
61994649|NCT04010942|ACTIVE_COMPARATOR|Vitamin D|"Group V : number of 60 women will receive 100000 IU Cholecalciferol Intramuscular every month + 2000 mg Metformin (oral: 2 tablets 1000 per day) for 5 months .~-after two months from the start:~Clomiphene citrate 100mg (2 tablets clomid 50mg each per day,from 2nd to 6th day of the cycle ) will be added every month starting from the 3rd month to the 5th month ."
61994650|NCT04010942|PLACEBO_COMPARATOR|Control|"Group C: number of 60 patients will receive Metformin 2000mg (oral: 2 tablets1000 mg per day) for months .~-after two months from the start:~Clomiphene citrate 100mg (2 tablets clomid 50mg each per day, from 2nd to 6th day of the cycle ) will be added every month starting from the 3rd month to the 5th month ."
61994651|NCT03439566||Total hip arthroplasty|No intervention will take place. Only registration and data collection of patient´s care and treatment will take place. There will be no changes in patient´s treatment.
61994652|NCT00889954|EXPERIMENTAL|TGFBeta resistant HER2/EBV-CTLs|"The following dose levels will be evaluated:~Dose Level 1: 1 x 10\^4 cells/m\^2~Dose Level 2: 3 x 10\^4 cells/m\^2~Dose Level 5: 1 x 10\^6 cells/m\^2~Dose Level 6: 3 x 10\^6 cells/m\^2~Dose Level 7: 1 x 10\^7 cells/m\^2~Dose Level 8: 3 x 10\^7 cells/m\^2~Dose Level 9:1 x 10\^8 cells/m\^2"
62562027|NCT06407323|EXPERIMENTAL|Personalized vibration therapy powered by AI|
62562028|NCT06407323|OTHER|physical therapy treatment|
62562029|NCT02695446|OTHER|Oral ER Minocycline - Up to 2mg/kg|Oral extended release minocycline - up to 2mg/kg once a day for 30 days.
62562030|NCT05524389|EXPERIMENTAL|Molecular classification based treatment|"Establishment of molecular-clinicopathological classification to make adjuvant treatment decisions: observation for favourable group; vaginal brachytherapy(VBT) for intermediate group; external beam radiotherapy(EBRT) for unfavourable group.~Molecular-clinicopathological classification strategy：Favourable group：POLE-mutated. CTNNB1(wide-type)with IA (G1-3) or IB(G1-2)and LVSI(lymph-vascular space invasion) focal/-.~Intermediate group：MMRD and LVSI focal/-. CTNNB1(wide-type) and IB(G3) or II with LVSI focal/-. CTNNB1-mutated and IA(G1-3) or IB (G1-2) with LVSI focal/-.~Unfavourable group: TP53 mutation. CTNNB1-mutated and IB (G3) or II. Substantial LVSI."
61994653|NCT02984358|PLACEBO_COMPARATOR|Animal protein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by animal products (meat and fish).
61994654|NCT02984358|ACTIVE_COMPARATOR|Low-nucleotide mycoprotein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by nucleotide-depleted mycoprotein products (commercial Quorn products).
61994655|NCT02984358|ACTIVE_COMPARATOR|High-nucleotide mycoprotein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by nucleotide-rich mycoprotein products.
61994656|NCT01350128|EXPERIMENTAL|PT001 MDI (Dose 1)|PT001 MDI
61994657|NCT01350128|EXPERIMENTAL|PT001 MDI (Dose 2)|PT001 MDI
61994658|NCT01350128|EXPERIMENTAL|PT001 MDI (Dose 3)|PT001 MDI
61994659|NCT01350128|EXPERIMENTAL|PT001 MDI (Dose 4)|PT001 MDI
61994660|NCT01350128|ACTIVE_COMPARATOR|Ipratropium Bromide HFA Inhalation Aerosol|Ipratropium Bromide HFA Inhalation Aerosol
61994661|NCT01350128|PLACEBO_COMPARATOR|Placebo MDI|PT001 Placebo MDI
61994662|NCT05422781|EXPERIMENTAL|Participants With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)|Eight participants with MCC (\> 1.0 years since definitive treatment or participants who had recurrence \>2 years since evidence of disease) and NEAD
62168898|NCT03388021|ACTIVE_COMPARATOR|if the results were not satisfactory intraoperatively as fail|this group will undergo surgical thromboembolectomy. if the results were not satisfactory intraoperatively as failure to advance the Fogarty catheter or to get satisfactory inflow or backflow or Extraction of intimal fragments.patient will undergo diagnostic angiography and endovascular or surgical intervention according to result of diagnostic angiography.
62390491|NCT06227429||Full Analysis Set (FAS)|The Full Analysis Set (FAS) will include all patients with a confirmed HT-1 diagnosis on Nitisinone treatment in routine clinical care, who provide signed informed consent. Patients must be either on treatment with Nitisinone at study entry or they must have been prescribed Nitisinone at enrollment. No specific exclusion criteria from the analysis set will be applied. The FAS will be used for all analyses.
62390492|NCT01031368|EXPERIMENTAL|Treatment (chemotherapy, G-CSF, cord blood infusion)|"INDUCTION THERAPY: Patients receive clofarabine IV over 1 hour and cytarabine hydrochloride IV over 2 hours on days 1-5. Patients receive an infusion of non-HLA matched ex vivo expanded cord blood progenitors on day 6. G-CSF is administered SC on days 0-5 and from day 7 until blood counts recover. Treatment modifications may apply according to response.~CONSOLIDATION THERAPY: Patients receive clofarabine IV over 1 hour and cytarabine hydrochloride IV over 2 hours on days 1-5. Patients also receive G-CSF SC beginning on day 0 and continuing until blood counts recover."
62390493|NCT03439319|ACTIVE_COMPARATOR|MyndMove® therapy|Non-invasive Functional Electrical Stimulation (FES) technique with surface electrodes to stimulate from 3 to 8 muscles to create purposeful movements in one or both hands/arms
62562031|NCT05524389|ACTIVE_COMPARATOR|Conventional risk stratification based treatment|"Adjuvant vaginal brachytherapy alone for intermediate risk patients (IA G1-2 with LVSI present or age\>60, IA G3 or IB G1-2 regardless of LVSI status).~EBRT for high-intermediate risk (stage I B with G3, or stage II)"
62562032|NCT03083327|ACTIVE_COMPARATOR|Standard Care|The control group in this study is pragmatic standard nutrition care. Currently after a bone marrow transplant in Australia, patients are normally fed orally for as long as possible. If oral intake fails to provide sufficient calories for a period of two to three days, enteral or parenteral nutrition may be provided.
62562033|NCT03083327|ACTIVE_COMPARATOR|Early supplemental parenteral nutrition|"Supplemental prophylactic early parenteral nutrition will be commenced 1 day prior to conditioning chemoradiotherapy in patients who are not already malnourished. Supplemental parenteral nutrition continues throughout conditioning chemoradiotherapy and stem cell transplant.~The dose of supplemental parenteral nutrition will be dependent on the total calories also received from oral and/or enteral nutrition intake."
62769676|NCT05277038||Clonidine vs Zopiclone for insomnia|Consecutive adult patients who underwent pain management at a Canadian pain clinic. The patients were subsequently prescribed and provided zopiclone 3.75mg tablet (1-2 tablets per dose), and clonidine 0.1mg tablet (1-2 tablets per dose). They were advised to take either clonidine or zopiclone on alternate nights. For each medication, they alternated the doses of 1 tablet or 2 tablets at subsequent nightly administrations. The four possible medication doses were zopiclone 3.75mg, zopiclone 7.5mg, clonidine 0.1mg, and clonidine 0.2mg; as shown on the sleep diary in Figure 1. The recommended orders of treatment were zopiclone 7.5mg, clonidine 0.1mg, zopiclone 3.75mg, clonidine 0.2mg; or clonidine 0.2mg, zopiclone 3.75mg, clonidine 0.1mg, zopiclone 7.5mg. Each patient participated in the study treatment and completed the sleep diary for 3 continuous weeks. Therefore, each of the four medication doses was used five times by each patient.
62769677|NCT02520921|ACTIVE_COMPARATOR|Arm 1 : Novel strategy|enteric coated aspirin 100 mg in the morning and 100 mg in the evening
62769678|NCT02520921|ACTIVE_COMPARATOR|Arm 2 : Conventional strategy|enteric coated aspirin 100 mg in the morning
62769679|NCT04464525|EXPERIMENTAL|Omecamtiv mecarbil|All subjects will be assigned to OM
62769680|NCT06172400|ACTIVE_COMPARATOR|Touniquet|Local injection of Mepivacaine (10 mg/ml) approximately 10 ml in the incisional area at least 10 minutes before surgery start. Use of a forearm tourniquet at the pressure of 250 mmHg.
62769681|NCT06172400|EXPERIMENTAL|Adrenaline|Local injection of Mepivacaine (10 mg/ml) and adrenaline (5 mcg/ml) approximately 10 ml in the incisional area at least 10 minutes before surgery start. Forearm tourniquet applied but not inflated.
62769682|NCT02478450|EXPERIMENTAL|Cohort 1|Unilateral lumbar surgical transplantation of Q-Cells dose level 1
62769683|NCT02478450|EXPERIMENTAL|Cohort 2|Unilateral cervical surgical transplantation of Q-Cells dose level 1
62769684|NCT02478450|EXPERIMENTAL|Cohort 3|Unilateral cervical surgical transplantation of Q-Cells dose level 2
61994663|NCT00870363|ACTIVE_COMPARATOR|1|maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
62390494|NCT03439319|ACTIVE_COMPARATOR|Intensive Conventional therapy|Using Conventional therapy which focuses exclusively on the purposeful movements in one or both hands/arms
62562034|NCT05568069|EXPERIMENTAL|Intervention|ICD or CRTD fitted
62562035|NCT05568069|NO_INTERVENTION|Control|No ICD fitted (with Implantable Loop Recorder) or Cardiac Resynchronisation Therapy Pacemaker (CRTP)
62562036|NCT05568069|NO_INTERVENTION|Registry|Usual medical care
62769685|NCT02478450|EXPERIMENTAL|Cohort 4|Unilateral cervical surgical transplantation of Q-Cells dose level 3
62769686|NCT02478450|EXPERIMENTAL|Cohort 5|Unilateral cervical surgical transplantation of Q-Cells dose level 4
62769687|NCT02478450|EXPERIMENTAL|Cohort 6|Unilateral cervical surgical transplantation of Q-Cells dose level 5
62769688|NCT06503120|EXPERIMENTAL|Mediterranean-diet intervention group|"Dietitian-guided Nutritionist Education Process:~1. Conduct online educational sessions at Weeks 0, 3, 6, and 9, lasting 10 to 15 minutes each.~2. The ultimate goal is to increase the MEDAS score by more than five points within 12 weeks.~3. After the initial education session, provide participants with a common Q and A sheet, online, based on the dietary advice given. Investigators also provide education materials, a food-group list specifying preferred choices and approximate numbers and size of servings to consume per day."
62769689|NCT06503120|ACTIVE_COMPARATOR|Standard care group|A 10-minute talk on the epidemiology of MASLD and balanced diet, resembling routine clinical practice.
62769690|NCT02570880|EXPERIMENTAL|Bread sample vs. glucose solution|glycemic index
62769691|NCT03600454|EXPERIMENTAL|Hip surgery: spinal anesthesia|Patients scheduled to undergo elective total hip arthroplasty will receive spinal anesthesia in combination with monitored anesthesia care (MAC).
62562037|NCT00006105|EXPERIMENTAL|Administration of Cisplatin, Gemcitabine, and Amifostine|Subjects receive the study drug combination in 29-day cycles. Gemcitabine (1000 mg/m2) is given by IV infusion on Days 1, 8, and 15 of each cycle. Cisplatin (70 mg/m2) is given by IV infusion on Day 1 of each cycle. Immediately prior to each cisplatin infusion amifostine (910 mg/m2) will be given by IV infusion.
62562038|NCT00578045|EXPERIMENTAL|1|Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
62168899|NCT03662854|EXPERIMENTAL|Hair Stimulating Complex|Hair Stimulating Complex (HSC) is derivative of hypoxia-induced multipotent cell conditioned media enriched for certain key growth factors
62168900|NCT03662854|PLACEBO_COMPARATOR|Phosphate Buffered Saline|Phosphate Buffered Saline
62168901|NCT02029521|EXPERIMENTAL|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg.
62390495|NCT05884606|EXPERIMENTAL|non-randomized, pilot study|"This study is a prospective, non-randomized, pilot study to test the impact of the Allurion Digital Behaviour Change Intervention in participants who have been treated with the Allurion Gastric Balloon System. The study consists of the following segments:~* Screening and enrolment period (prior to or day of Allurion Gastric Balloon System treatment)~* All participants will take part in the Allurion DBCI for 6 months following study enrolment~* All participants will complete a 6-month follow-up assessment after completion of the Allurion DBCI"
62562039|NCT00663416|EXPERIMENTAL|1|
62562040|NCT00663416|PLACEBO_COMPARATOR|2|
62562041|NCT03691519|PLACEBO_COMPARATOR|Placebo|"During the 18 months placebo-controlled period, participants will ask to consume 3 identical 1g vegetarian control capsules (containing a 1:1 ratio of corn oil and soy oil) per day. During the following 18-month open-label extension period, placebo subjects are switched to active treatment.~36 months consisting of a 18-month placebo-controlled period followed by a 18-month open-label extension period wherein all participants will receive active treatment"
62562042|NCT03691519|EXPERIMENTAL|Omega-3 treatment|During the entire length of the study (that is, both the placebo-controlled and open-label extension periods), participants in the intervention (Omega-3 treatment) arm will ask to consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day).
62562043|NCT05864248|EXPERIMENTAL|HRPCI patients|Patients undergoing non-emergent, high-risk percutaneous coronary interventions.
62168902|NCT02029521|PLACEBO_COMPARATOR|Placebo Calcium Citrate|The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
62562044|NCT01772589|ACTIVE_COMPARATOR|New saw blade|New saw blade
62562045|NCT01772589|ACTIVE_COMPARATOR|Reprocessed saw blade|Reprocessed saw blade
62769692|NCT03600454|EXPERIMENTAL|Hip surgery: general anesthesia|Patients scheduled to undergo elective total hip arthroplasty will receive general anesthesia
62562046|NCT04781426||HIV-negative MSM/TG|Oral pre-exposure prophylaxis (PrEP) will be offered to HIV negative MSM, TG identified to be at substantial risk for HIV infection and those motivated to take daily PrEP.
62168903|NCT02133066|ACTIVE_COMPARATOR|US-Assisted site marking for Lumbar Punctures (LP)|Mindray M7 Ultrasound marking
62168904|NCT02133066|PLACEBO_COMPARATOR|Routine lumbar puncture|"These patients will receive no ultrasound-assisted site marking prior to lumbar puncture; The patients will simply have a standard-of-care spinal tap performed by the clinician"
62168905|NCT03994900|EXPERIMENTAL|Blood sampling for HbNO assessment|
62390496|NCT01861587|EXPERIMENTAL|Real tDCS:Active Comparator|For Real tDCS, stimulation will be delivered in 20-minute-sessions using 2mA current. The anode will be placed over left BA9 or the motor cortex corresponding with the painful area (if applicable). The cathode will be placed over right BA43 (for GI pain) or right BA9 (located via the international 10-20 EEG system).
62390497|NCT01861587|EXPERIMENTAL|Sham tDCS: Sham Comparator|For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
62390498|NCT04440176|EXPERIMENTAL|Group 1 (MenABCWY 0-, 12-months)|MenABCWY administered at Month 0 and Month 12
62390499|NCT04440176|EXPERIMENTAL|Group 2 (MenABCWY 0-, 36-months)|MenABCWY administered at Month 0 and Month 36
62390500|NCT00336960|EXPERIMENTAL|treatment intervention|
62390501|NCT02666079|EXPERIMENTAL|Treatment arm|Wide local excision (WLE) for breast cancer with intra-operative use of the LightPath® Imaging System.
62390502|NCT02718365|EXPERIMENTAL|Group A|Wedge resection
62390503|NCT02718365|ACTIVE_COMPARATOR|Group B|Segmentectomy
62390504|NCT00545584|EXPERIMENTAL|Sitagliptin with Standard of Care|Subjects received sitagliptin 100 mg once daily for 26 Weeks, and: No specific intervention (standard recommendation) on physical exercise and diet.
62390505|NCT00545584|EXPERIMENTAL|Sitagliptin with Diet Advice|"Subjects received sitagliptin 100 mg once daily for 26 Weeks,~and:~Intervention on diet which includes advice on diet with a leaflet and a diary"
62390506|NCT00545584|EXPERIMENTAL|Sitagliptin with Diet and Physical Activity Advice|"Subjects received sitagliptin 100 mg once daily for 26 Weeks,~and:~Intervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week."
62390507|NCT04882579|EXPERIMENTAL|PoCUS group|Patients allocated to the PoCUS investigation arm will receive an ultrasound investigation resulting in either confirmation or dismissal of pulmonary embolism suspicion or requiring CTPA or VQ
62390508|NCT04882579|NO_INTERVENTION|Control group|Patients allocated to the control group will continue with CTPA or VQ without PoCUS investigation
62390509|NCT02003287|EXPERIMENTAL|FEES|Swallowing evaluation with the Fiberoptic Endoscopic Evaluation of Swallowing
62390510|NCT02003287|ACTIVE_COMPARATOR|VFSS|Swallowing evaluation with the Videofluoroscopic Swallowing Study
62390511|NCT03119428|EXPERIMENTAL|OMP-313M32|Intravenous (in the vein) infusions of OMP-313M32 as a single agent
62562047|NCT02320305|EXPERIMENTAL|Arm I (MART-1 antigen and TLR4 antagonist GLA-SE)|Patients receive MART-1 antigen and TLR4 antagonist GLA-SE IM on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62769693|NCT03600454|EXPERIMENTAL|Colectomy: general anesthesia and epidural analgesia|Patients scheduled to undergo elective laparoscopic hemicolectomy will receive general anesthesia combined with epidural analgesia (EA).
62769694|NCT03600454|EXPERIMENTAL|Colectomy: general anesthesia|Patients will receive general anesthesia.
62168906|NCT05820087|EXPERIMENTAL|HistoSonics Edison System|
62168907|NCT03586752|EXPERIMENTAL|On-line group|On-line program course
62168908|NCT03586752|ACTIVE_COMPARATOR|Standard group|Standard program course
62168909|NCT04895202||Siponimod|Patients administered Siponimod as per Swiss label
62168910|NCT02711553|EXPERIMENTAL|8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received 8 mg/kg ramucirumab plus 25 mg/square meter (mg/m²) cisplatin and 1000 mg/m² gemcitabine intravenously (IV) on days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for ramucirumab therapy).
62390512|NCT03119428|EXPERIMENTAL|OMP-313M32 and Nivolumab|Intravenous (in the vein) infusions of OMP-313M32 in combination with nivolumab
62390513|NCT00391911|ACTIVE_COMPARATOR|NAC and CRRT|N-Acetylcysteine and CRRT Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label,
62390514|NCT00391911|OTHER|NAC and non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
62769695|NCT03322813|EXPERIMENTAL|ExAblate 4000 - Type 2|ExAblate BBBD
62562048|NCT02320305|EXPERIMENTAL|Arm II (MART-1 antigen)|Patients receive MART-1 antigen IM on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62390515|NCT00391911|OTHER|Placebo and CRRT|Patients are assigned to placebo treatment and CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT is open label.
62562049|NCT01058473||Sickle Cell Disease|
62562050|NCT00015964|EXPERIMENTAL|Daily administration of ZD1839|
62769696|NCT05575908|EXPERIMENTAL|Digital expert team|The participants allocated to this arm will receive personalized advice from an expert team. The participants will have one video meeting with the team and receive a written report.
62769697|NCT05575908|NO_INTERVENTION|Treatment as usual|The participants will answer a digital questionnaire and will get normal follow-up from his/her general practitioner and labor- and welfare administration (NAV).
62390516|NCT00391911|OTHER|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. This is the standard of care arm. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
62390517|NCT01072227||Single Group|
62390518|NCT00208702|EXPERIMENTAL|sertraline + triiodothyronine|
62390519|NCT00208702|PLACEBO_COMPARATOR|sertraline + placebo|
62390520|NCT04568265|EXPERIMENTAL|APG-1387 12 mg combined with entecavir 0.5 mg|
62390521|NCT04568265|EXPERIMENTAL|APG-1387 20 mg combined with entecavir 0.5 mg|
62769698|NCT02699190||Prospective Study Cohort|This cohort comprises recently identified individuals for whom a clinical decision has been made to pursue whole genome sequencing (WGS) as a first-line diagnostic test. The cohort also includes each subject's biological parents.
62769699|NCT02699190||Historical Study Cohort|This cohort comprises approximately 50 historical controls who received either whole genome sequencing (WGS) or standard diagnostic testing as part of their participation in a previous version of this protocol, which used a randomized controlled design to assess diagnostic efficacy of WGS. This cohort is closed to new enrollment, and exists for statistical analysis purposes only.
62769700|NCT01732913|EXPERIMENTAL|Rituximab + idelalisib|Participants will receive rituximab + idelalisib.
61994664|NCT00870363|ACTIVE_COMPARATOR|2|maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
62390522|NCT04568265|EXPERIMENTAL|APG-1387 30 mg combined with entecavir 0.5 mg|
62390523|NCT04568265|EXPERIMENTAL|entecavir 0.5 mg|
62390524|NCT00787527|EXPERIMENTAL|Zolinza + CHOP|Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
62390525|NCT01668017|EXPERIMENTAL|Part 1: Pimasertib 30mg in Solid Tumor|
62390526|NCT01668017|EXPERIMENTAL|Part 1: Pimasertib 45 mg in Solid Tumor|
62390527|NCT01668017|EXPERIMENTAL|Part 1: Pimasertib 60 mg in Solid Tumor|
62390528|NCT01668017|EXPERIMENTAL|Part 1: Pimasertib 30 mg in Hepatocellular Carcinoma (HCC)|
62390529|NCT01668017|EXPERIMENTAL|Part 1: Pimasertib 45 mg in HCC|
62562051|NCT03870815||CABG|Patients with CAD who undergoing CABG
62562052|NCT03870815||PCI|Patients with CAD who undergoing PCI with DES
62562053|NCT03970577|EXPERIMENTAL|Rituximab treatment|Two injections of Rituximab (375mg/m2) separated by one week (one at time of randomization and the other one week after) and definitive withdrawal of steroid at the time of second injection of Rituximab (for a total steroids exposure of 9 weeks)
62562054|NCT03970577|ACTIVE_COMPARATOR|Oral steroid treatment|"The patients will continue exclusive oral steroid treatment, that will be progressively tapered, for a total of 24 weeks (by taking into account the initial oral steroid therapy administered during 8 weeks and the oral steroid treatment given after randomization).~Each patient will be followed up until 18 months after randomization. The patient will have study visits at inclusion, 4 weeks and 8 weeks after inclusion. At the time of randomization, patients who will have reached CR of MCNS will be allocated in test or control group and will be followed up similarly: visits at 1, 4, 16, 24 weeks, 12 and 18 months after randomization."
62562055|NCT02389478|EXPERIMENTAL|colostrums|Oropharyngeal administration of colostrums, every 4 hours，continue for 7days
62562056|NCT02389478|OTHER|Normal saline|Oropharyngeal administration of Normal saline,every 4 hours，continue for 7days
62562057|NCT03514524|EXPERIMENTAL|healthy ageing|
61994665|NCT00870363|ACTIVE_COMPARATOR|3|efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
61994666|NCT00870363|NO_INTERVENTION|4|HIV-negative
61994667|NCT01728025|EXPERIMENTAL|Ranolazine|Ranolazine 500-1000 mg twice a day as tolerated
62390530|NCT01672827|EXPERIMENTAL|[18F]Flutemetamol|
62390531|NCT01144897|EXPERIMENTAL|PET Acetate Imaging with Docetaxel|"PET-acetate as an intermediate endpoint in the assessment of response of patients undergoing docetaxel for hormone refractory prostate cancer (HRPC).~Subjects will be treated with docetaxel, 75 mg/m2 every 21 days until disease progression or unacceptable toxicity occurs. Subjects will have two PET acetate scans - one prior to beginning chemotherapy and one approximately 8-9 weeks after chemotherapy has begun."
62390532|NCT03331393||RA patients treated with Abatacept|Treated with Abatacept as a first-line biologic
62390533|NCT03331393||RA patients treated with TNFi|Treated with Tumor necrosis factor inhibitor (TNFi) as a first-line biologic
62390534|NCT02968277|EXPERIMENTAL|Started with Forearm Support Walker (LW Upright)|Data collection began with participants using the LifeWalker Upright Walker then using the two remaining walkers in a randomized order
62562058|NCT03514524|EXPERIMENTAL|TBI|
62562059|NCT03514524|EXPERIMENTAL|CTE|
62562060|NCT03514524|EXPERIMENTAL|Ischemic stroke|
62562061|NCT03514524|EXPERIMENTAL|aMCI and MBI|
62562062|NCT06303804|EXPERIMENTAL|Educational videos arm|
62562063|NCT02925962|EXPERIMENTAL|Clinical Decision Support System (CDSS)|"PCPs get a notice the CKD Clinical Decision Support System (CDSS) is available.~CDSS overview:~* The study MDs order CKD triple marker tests~* Patients will go to the lab as per usual clinical care~* Lab results are returned to PCPs clinical results folder as per usual clinical workflow with information about CKD and link to KDIGO guidelines~* Results will also be sent to the Study MD's for monitoring~* At the patient's next visit, if the labs are completed, the full CDSS launches for the PCP~* If the labs are not completed by the next visit, a Best Practice Alert (BPA) will launch for the PCP notifying them that the labs have been ordered, but the patient hasn't done them yet"
62562064|NCT02925962|EXPERIMENTAL|Clinic Decision Sup System + Pharmacist|"The Clinical Decision Support System + Pharmacist follow-up call extends beyond the CDSS alone.~CDSS Plus overview:~* At the visit in which the CDSS launches, the PCP will hand a study card with pharmacist information to their patient notifying them that a pharmacist will be calling to follow-up after the visit~* The pharmacist will use MyChart and/or phone calls to schedule a follow-up call within two weeks of the visit~* On the follow-up phone call, the pharmacist will discuss understanding of CKD, medication review and adherence assessment, home BP checks, and the importance of NSAID avoidance~* A second follow-up call will only be scheduled if the patient is non-adherent with their medications and makes an active plan for adherence with the pharmacist, or if the patient requests an additional call from the pharmacist"
62168911|NCT02711553|PLACEBO_COMPARATOR|Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received placebo (indistinguishable and equivalent volume to ramucirumab) plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for placebo therapy).
62390535|NCT02968277|EXPERIMENTAL|Standard Rollator Walker (Control)|Data collection began with participants using a conventional standard rollator (SR) walker then using the two remaining walkers in a randomized order
62562065|NCT02925962|NO_INTERVENTION|Usual Care|Patients continue to receive usual care by their provider.
62562066|NCT02391922|NO_INTERVENTION|No first aid course, No dipatch instruction|Participants' first aid skills are tested in two scenarios without prior first aid course and no dispatch instructions during the scenarios
62562067|NCT02391922|ACTIVE_COMPARATOR|First aid course, No dispatch instructions|Participants' first aid skills are tested in two scenarios 4 to 5 months after receiving a first aid course and no dispatch instructions during the scenarios
62562068|NCT02391922|ACTIVE_COMPARATOR|First aid course, dispatch instructions|Participants' first aid skills are tested in two scenarios 4 to 5 months after receiving a first aid course and they are given instructions from emergency dispatch by phone during the test scenarios
62562069|NCT02391922|ACTIVE_COMPARATOR|No first aid course, dispatch instructions|Participants' first aid skills are tested in two scenarios without prior first aid course, and they are given instructions from emergency dispatch by phone during the test scenarios
62562070|NCT03017768|ACTIVE_COMPARATOR|Acute tryptophan depletion|Administration of an amino acid mixture consisting of 15 amino acids, (4.1g L-alanine, 2.4g glycine, 2.4g L-histidine, 6.0g L-isoleucine, 10.1g L-leucine, 6.7g L-lysine, 4.3g L-phenylalanine, 9.2g L-proline, 5.2g L-serine, 4.3g L-threonine, 5.2g L-tyrosine, 6.7g L-valine, 3.7g L-argine, 2.0g L-cysteine, 3.0g L-methionine) lacking tryptophan to investigate the effect of tryptophan depletion on esophageal sensitivity
62562071|NCT03017768|PLACEBO_COMPARATOR|Placebo|Administration of an amino acid mixture consisting of 15 amino acids, (4.1g L-alanine, 2.4g glycine, 2.4g L-histidine, 6.0g L-isoleucine, 10.1g L-leucine, 6.7g L-lysine, 4.3g L-phenylalanine, 9.2g L-proline, 5.2g L-serine, 4.3g L-threonine, 5.2g L-tyrosine, 6.7g L-valine, 3.7g L-argine, 2.0g L-cysteine, 3.0g L-methionine and 3.0g L-trypyophan). Since this amino-acid mixture contains tryptophan it is used as the placebo arm of this cross-over study
62562072|NCT03253614||Exposed group|250 children aged 6-15 years exposed to gentamicin in the neonatal period
62562073|NCT03253614||Control group|25 healthy children aged 6-15 years NOT exposed to gentamicin in the neonatal period
62562074|NCT03830489|EXPERIMENTAL|Large volume based preparation|This strategy will consist of split dose 4 L polyethylene glycol plus 10 mg bisacodyl plus 3 days of fiber-free diet.
62562075|NCT03830489|ACTIVE_COMPARATOR|Low volume based preparation|This strategy will consist of split dose 2 L polyethylene glycol plus Ascorbic acid plus 1 day of fiber-free diet
62562076|NCT05032781|EXPERIMENTAL|Intra-arterial neuroprotective substances|"Cold saline, minocycline, and magnesium sulfate to be infused intra-arterially immediately after thrombectomy via the internal carotid artery. A dose escalation design will be used, as described above in Study Description."
62390536|NCT02968277|EXPERIMENTAL|Predicate Device (PD)|Data collection began with participants using their own rollator walkers then using the two remaining walkers in a randomized order
62562077|NCT03775616|EXPERIMENTAL|Supportive (financial navigation program)|Participants receive financial navigation program intervention consisting of a financial navigation video, monthly one-one financial counselling session, monthly phone or email consultation with patient navigators for 6 months and complete surveys at baseline, 3, 6, and 12 months.
62562078|NCT03468660|EXPERIMENTAL|Experimental group|Auditory training with feedback
62562079|NCT03468660|NO_INTERVENTION|Passive control group|Pre-post testing only; no training
62562080|NCT03468660|ACTIVE_COMPARATOR|Active Control group|Listening task with no feeback
62562081|NCT05543616|EXPERIMENTAL|3 microgram dose, 6 Months to <2 Years (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and approximately 6-months post-Dose 3
62390537|NCT00699582|EXPERIMENTAL|1|
62562082|NCT05543616|EXPERIMENTAL|6 microgram dose, 6 Months to <2 Years (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and approximately 6-months post-Dose 3
62562083|NCT05543616|EXPERIMENTAL|10 microgram dose, 6 Months to <2 Years (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and approximately 6-months post-Dose 3
62562084|NCT05543616|EXPERIMENTAL|Selected dose, 6 Months to <2 Years (Substudy A, Phase 2/3, Group 1) - 0/8 week schedule|Injection in the muscle at 0- and 8-weeks
62562085|NCT05543616|EXPERIMENTAL|Selected dose, 6 Months to <2 Years (Substudy A, Phase 2/3, Group 2) - 0/8 week schedule|Injection in the muscle at 0- and 8-weeks
62390538|NCT00699582|EXPERIMENTAL|2|
62390539|NCT00699582|PLACEBO_COMPARATOR|3|
62390540|NCT03390049|ACTIVE_COMPARATOR|Fractional CO2 Laser Treatment|Fractional CO2 laser will be applied to the entire vestibule, anteriorly to the fourchette, and laterally to the labia majora. This takes approximately 5 minutes to complete. A treatment cycle will consist of three laser sessions separated by 6 weeks +/- 1 week. The procedures will take place in the outpatient clinic. EMLA cream will be applied to the introitus for 20 minutes and wiped clean and dried prior to each laser session. Subjects will be advised to avoid intercourse for at least 3 days after each laser session because a mild inflammatory reaction may last up to 48 hours after a laser session. Topical lidocaine 5% ointment may be used for any vulvar discomfort post-procedure.
62390541|NCT03390049|SHAM_COMPARATOR|Sham Laser Treatment|A treatment cycle will consist of three laser sessions separated by 6 weeks +/- 1 week. The procedures will take place in the outpatient clinic. Subjects assigned to sham laser will undergo the same pre-treatment with EMLA cream and will receive the same post-treatment instructions as the fractional CO2 laser subjects.
62390542|NCT04071249||Control|Patients who use symptomatic medication as therapy for their allergic rhinoconjuntivitis as recommended by their physician
62390543|NCT04041648|PLACEBO_COMPARATOR|placebo|placebo group
62390544|NCT04041648|EXPERIMENTAL|L606 Liposomal inhalation solution|Liposomal inhalation solution
62390545|NCT00916903||1|Patients with genetic condition being studied.
62390546|NCT00916903||2|Matched controls
62390547|NCT02201199|ACTIVE_COMPARATOR|insulin glargine U100|1 single dose
62390548|NCT02201199|EXPERIMENTAL|insulin glargine U200|1 single dose
62390549|NCT02201199|EXPERIMENTAL|insulin glargine U500|1 single dose
62390550|NCT04227561|ACTIVE_COMPARATOR|Pudendal nerve block|Neurostimulation-guided pudendal nerve block
62390551|NCT04227561|ACTIVE_COMPARATOR|Penile nerve block|Ultrasound-guided penile nerve block
62562086|NCT05543616|EXPERIMENTAL|3 microgram dose, 6 Months to <4 Years 6 Months (Substudy B, Group 1)|Injection in the muscle, 2 doses 2 months apart
62562087|NCT05543616|EXPERIMENTAL|3 microgram dose, 6 Months to <5 Years (Substudy B, Group 2)|Injection in the muscle, 1 dose
62562088|NCT05543616|EXPERIMENTAL|3 microgram dose, 6 Months to <5 Years (Substudy B, Group 3)|Injection in the muscle, 1 dose
61994668|NCT05107258||Subjects Symptomatic for COVID-19|"Subjects must present with 1 or more of the following signs or symptoms:~1. Fever~2. Cough~3. Shortness of Breath~4. Difficulty Breathing~5. Muscle Pain~6. Headache~7. Sore Throat~8. Chills~9. New Loss of Taste or Smell~10. Congestion~11. Runny Nose~12. Diarrhea~13. Nausea or vomiting 2. Subjects must have experienced symptom onset within the previous 10 days"
62390552|NCT02792569|EXPERIMENTAL|Biopsy at Right side|Biopsy of ovarian cortical tissue (50% right side)
62390553|NCT02792569|EXPERIMENTAL|Biopsy at Left side|Biopsy of ovarian cortical tissue (50% left side)
62390554|NCT04952792|EXPERIMENTAL|Apixaban|Apixaban treatment, oral, 2.5 mg/12h, 28 days
62390555|NCT03266211||Patients|People older than 65 years in the Auvergne-Rhônes-Alpes region who are consulting their general practitioner.
62390556|NCT03266211||General practitioner|General practitioner of the Auvergne-Rhônes-Alpes region
62390557|NCT05423847||Benin1|Benin urban recruitment site National teaching hospital for tuberculosis, outpatient emergency department
62562089|NCT05543616|EXPERIMENTAL|6 microgram dose, 6 Months to <2 Years (Substudy C, Phase 1)|Injection in the muscle, 1 dose
62769701|NCT01732913|PLACEBO_COMPARATOR|Rituximab + Placebo|Participants will receive rituximab + placebo. Following confirmation of iNHL disease progression by the independent review committee and unblinding, participants may be eligible to receive open-label idelalisib 150 mg twice daily.
62562090|NCT05543616|EXPERIMENTAL|10 microgram dose, 6 Months to <2 Years (Substudy C, Phase 1)|Injection in the muscle, 1 dose
62562091|NCT05543616|EXPERIMENTAL|10 microgram dose, 5 to <12 Years (Substudy D, Group 1)|Injection in the muscle, 1 dose
62390558|NCT05423847||Mali1|Mali urban recruitment site University Hospital Bamako, outpatient emergency department
62562092|NCT05543616|EXPERIMENTAL|10 microgram dose, 5 to <12 Years (Substudy D, Group 2)|Injection in the muscle, 1 dose
62562093|NCT05543616|EXPERIMENTAL|10 microgram dose, 5 to <12 Years (Substudy D, Group 3)|Injection in the muscle, 1 dose
62562094|NCT05543616|EXPERIMENTAL|3 microgram dose, 2 Years to <4 years 3 months (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and approximately 6-months post-Dose 3
62562095|NCT05543616|EXPERIMENTAL|6 microgram dose, 2 Years to <4 years 3 months (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and approximately 6-months post-Dose 3
62562096|NCT05543616|EXPERIMENTAL|10 microgram dose, 2 Years to <4 years 3 months (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and approximately 6-months post-Dose 3
62562097|NCT05543616|EXPERIMENTAL|6 microgram dose, 2 Years to <5 Years (Substudy C, Phase 1)|Injection in the muscle, 1 dose
62562098|NCT05543616|EXPERIMENTAL|10 microgram dose, 2 Years to <5 Years (Substudy C, Phase 1)|Injection in the muscle, 1 dose
62769702|NCT01731067|ACTIVE_COMPARATOR|CYP1A2, 2B6, 2C9, 2C19, 3A4 inhibitors|Oral intake of fluvoxamine (50 mg per day during 2 days) and voriconazole (400 mg) before oral intake of the cocktail probe drugs
62769703|NCT01731067|ACTIVE_COMPARATOR|CYP2D6 and P-gp inhibitor|Oral intake of quinidine (200 mg) before oral intake of the cocktail probe drugs
62769704|NCT01731067|ACTIVE_COMPARATOR|CYPs and P-gp inducer|Oral intake of rifampicin (600 mg per day during 7 days) before oral intake of the cocktail probe drugs
62769705|NCT01731067|EXPERIMENTAL|Probe cocktail alone|"Oral intake of the cocktail probe drugs :~* bupropion 25 mg~* flurbiprofen 25 mg~* omeprazole 5 mg~* dextromethorphan 5 mg~* midazolam 1 mg~* fexofenadine 25mg~* Caffeine (a cup of coffee)"
62562099|NCT05543616|EXPERIMENTAL|3 microgram dose, 6 Months to <2 Years (Substudy A, Phase 2/3, Group 3) - 0/3/11 week schedule|Injection in the muscle at 0-, 3-, and 11-weeks
62562100|NCT05543616|EXPERIMENTAL|Selected dose, 2 to <5 Years (Substudy A, Phase 2/3, Group 4) - Single dose|Injection in the muscle, 1 dose
62562101|NCT05543616|EXPERIMENTAL|Selected dose, 2 to <5 Years (Substudy A, Phase 2/3, Group 5) - Single dose|Injection in the muscle, 1 dose
62769706|NCT01009749|EXPERIMENTAL|MESA|
62769707|NCT01009749|ACTIVE_COMPARATOR|MESH|
62769708|NCT02334488|ACTIVE_COMPARATOR|Everolimus-Tacrolimus|"* Tacrolimus (Prograf®) started at 0,1 mg/kg/day since Day0, then adapted to C0 concentration (4-7 ng/ml),~* Everolimus (Certican®) started within 24h after reperfusion, to be adapted to C0 concentration (3-8 ng/ml)."
62390559|NCT05423847||South-Africa1|South-Africa rural recruitment site 1 Tintswalo hospital, outpatient emergency department
62390560|NCT05423847||South-Africa2|South-Africa rural recruitment site 2 Zithulele hospital, outpatient emergency department
62390561|NCT01495741||Asenapine|Participants prescribed asenapine
62390562|NCT01495741||Risperidone Comparator|Participants prescribed risperidone
62390563|NCT01495741||Olanzapine Comparator|Participants prescribed olanzapine
62562102|NCT05543616|EXPERIMENTAL|3 microgram dose, 2 Years to <5 Years (Substudy E, Group 1)|Injection in the muscle, 1 dose
62562103|NCT05543616|EXPERIMENTAL|10 microgram dose, 5 Years to <12 Years (Substudy E, Group 2)|Injection in the muscle, 1 dose
62562104|NCT05935228|OTHER|The control group|"The control group will consist of patients included in phase 1. These are the patients from the before phase, i.e. before the implementation of the Difficult Intravenous Access Scale."
62562105|NCT05935228|EXPERIMENTAL|The experimental group|"The experimental group will consist of the patients included in phase 3. These are the patients from the after phases i.e after the implementation of the algorithm."
62562106|NCT00300235||1|200 subjects ages 5 to 9.9 years with a diagnosis of HbSS/HbSβ0
62562107|NCT00300235||2|400 subjects ages 10 to 14.9 years with a diagnosis of HbSS/HbSβ0
62562108|NCT00300235||3|400 subjects ages 15 to 24.9 years with a diagnosis of HbSS/HbSβ0
62562109|NCT00300235||4|400 subjects over the age of 25 with a diagnosis of HbSS/HbSβ0
62562110|NCT00300235||5|250 subjects age 15 and older with a diagnosis of HbSC or HbSβ+
62562111|NCT01901640|EXPERIMENTAL|DA-8159|Udenafil(The study had one arm.)
62562112|NCT04468425|EXPERIMENTAL|Pharmacokinetic Study|"Period 1 (Day 1) and 2 (Day 8 - Day 21) separated by 7-day washout period. Period 1: A single 5 mg tofacitinib tablet will be administered orally on Day 1.~Period 2: Repeat dosing of Tofacitinib Citrate Topical Gel 3.2% to approximately 10% BSA in the morning of Day 8 and twice daily from Day 9 to Day 20 with the last dose in the morning of Day 21."
62769709|NCT02334488|EXPERIMENTAL|Everolimus-Mycophenolate sodium|"* Everolimus (Certican®) started within 24h after reperfusion, to be adapted to C0 concentration (3-8 ng/ml),~* Tacrolimus (Prograg®) started at 0,1 mg/kg/day from J0 then to be adapted to C0 concentration (4-7 ng/ml), then replacement by mycophenolate sodium (Myfortic®) at M3 (3 months visit) started at 1440 mg/day."
62390564|NCT04329273|EXPERIMENTAL|Training group|"For the balance exercise the participants will perform one-legged stance of certain duration, on a stable surface.~For the sliding leg curl exercise the participants lay supine on a mat, wearing only socks in order to create a slippery surface between their heels and the gym floor. The player begins by extending the hip and having the working leg on knee flexion. The contralateral limb is on hip flexion and knee flexion. The base of support is the shoulder blades, the elbows and the heel of the working leg. After assuming this position, the player begins to extend the knee, as slowly as possible, resisting the low friction properties of the ground.~The core stability program consists of front plank, side planks, supine bridge, leg lowering and superman exercise. These exercises will be performed at the end of the training session, in contrast to the balance and hamstring exercises which will be executed before the training session."
62390565|NCT04329273|NO_INTERVENTION|Control group|The participants in this group will follow only the usual training program
62390566|NCT05374070|ACTIVE_COMPARATOR|Streptococcus salivarius K12|Streptococcus salivarius K12 (Dose 1: 1 Billion colony forming units /g)
62390567|NCT05374070|ACTIVE_COMPARATOR|Streptococcus salivarius K12 with a prebiotic included|Streptococcus salivarius K12 (Dose 1: 1 Billion colony forming units /g)
62390568|NCT05374070|ACTIVE_COMPARATOR|Streptococcus salivarius M18|Streptococcus salivarius M18 (Dose 1: 1 Billion colony forming units /g)
62390569|NCT05374070|ACTIVE_COMPARATOR|Streptococcus salivarius M18 with a prebiotic included|Streptococcus salivarius M18 (Dose 1: 1 Billion colony forming units /g)
62390570|NCT03279731|ACTIVE_COMPARATOR|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg via subcutaneous injection. Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
62390571|NCT03279731|PLACEBO_COMPARATOR|Placebo|Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg of placebo via subcutaneous injection. The placebo will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.The inactive ingredients include: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection.
62390572|NCT04041401||Children and their Caregivers|Children following discharge from PICU and their caregivers receiving a storybook intervention.
62390573|NCT04490902|ACTIVE_COMPARATOR|Single graft corneal transplantation|Limbal transplantation combined with central penetrating keratoplasty from single donors.
62390574|NCT04490902|EXPERIMENTAL|Dual graft corneal transplantation|Limbal transplantation combined with central penetrating keratoplasty from different donors.
62390575|NCT03907085|ACTIVE_COMPARATOR|High intensity laser therapy (HILT) + exercise|Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist.
62390576|NCT03907085|PLACEBO_COMPARATOR|Placebo HILT + exercise|Placebo therapy was applied in five sessions a week for three weeks, with a total of 15 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist.
62390577|NCT01142362|EXPERIMENTAL|0.6mg of DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 0.6 mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
62390578|NCT01142362|EXPERIMENTAL|2mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 2mg of DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
62390579|NCT01142362|EXPERIMENTAL|6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 6 mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
62390580|NCT02089165|EXPERIMENTAL|Krill oil|The interventions are administered in the randomized order.
62390581|NCT02089165|EXPERIMENTAL|Krill meal|The interventions are administered in the randomized order.
62390582|NCT02089165|ACTIVE_COMPARATOR|Fish oil|The interventions are administered in the randomized order.
62390583|NCT05699382|ACTIVE_COMPARATOR|a study group (SG) in which participants practiced mindfulness through the application for 6 weeks|a study group (SG) in which participants practiced mindfulness through the application for 6 weeks
62390584|NCT05699382|NO_INTERVENTION|control group|Waiting for the intervention
62562113|NCT06326346|EXPERIMENTAL|Oral Paclitaxel (Liporaxel)|Liporaxel 200mg/m2 twice daily orally on day 1, 8, and 15 every 4 weeks (1 cycle = 4 weeks)
62562114|NCT00468819|EXPERIMENTAL|Gadobutrol (Gadavist, BAY86-4875) - age 2 to 6 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
62562115|NCT00468819|EXPERIMENTAL|Gadobutrol (Gadavist, BAY86-4875) - age 7 to 11 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
62562116|NCT00468819|EXPERIMENTAL|Gadobutrol (Gadavist, BAY86-4875) - age 12 to 17 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
62769710|NCT02704689|EXPERIMENTAL|AccuLIF|
62769711|NCT03547934|EXPERIMENTAL|Treatment Group|Treatment with the investigated device - High Intensity Focused ElectroMagnetic System
62168912|NCT02711553|EXPERIMENTAL|80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received 80 mg merestinib orally each day, plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on Days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for merestinib therapy).
62562117|NCT00468819|EXPERIMENTAL|Gadobutrol (Gadavist, BAY86-4875) - age 2 to 17 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
62562118|NCT00970346|EXPERIMENTAL|Inhaled OligoG CF-5/20|
62562119|NCT02105467|EXPERIMENTAL|Immediate Treatment Group|Participants received blinded grazoprevir 100 mg / elbasvir 50 mg fixed-dose combination (FDC) tablet orally once daily for 12 weeks followed by a 24-week follow-up period
62769712|NCT04799691||Invasive strategy group|Patients admitted in ICU with Covid-19 related pneumonia during COVID19 first period.
62168913|NCT02711553|PLACEBO_COMPARATOR|Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received placebo (indistinguishable to merestinib) orally each day, plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on Days 1 and 8, every 21 days. Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for placebo therapy).
62168914|NCT00999271||Healthy subjects|30 healthy subjects without family history of diabetes or gastrointestinal disease, a normal oral glucose tolerance test (OGTT) and no intake of medicine
62168915|NCT02160834|EXPERIMENTAL|B-MOBILE smartphone-based intervention (3-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
62168916|NCT02160834|EXPERIMENTAL|B-MOBILE Smartphone-Based Intervention (6-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
62168917|NCT02160834|NO_INTERVENTION|Control|
62168918|NCT01802476|OTHER|Fixed Sequence Crossover Arm|This study arm consists of a fixed sequence crossover where study subjects will receive Treatment A and following a washout of no less than 10 days will then receive Treatment B. The drug class is a CDK4/6 inhibitor.
62168919|NCT02156999|EXPERIMENTAL|Osteoporosis|
62769713|NCT04799691||Non-invasive strategy group|Patients admitted in ICU with Covid-19 related pneumonia during COVID19 second period.
62769714|NCT03399656|PLACEBO_COMPARATOR|Placebo|4 placebo tablets
62769715|NCT03399656|ACTIVE_COMPARATOR|Low Dose Avmacol|2 tablets Avmacol and 2 placebo tablets
62168920|NCT04783519|EXPERIMENTAL|BASICS + SLEEP|The BASICS + SLEEP intervention will integrate BASICS feedback and the Motivational Interviewing (MI) process described in the BASICS arm with Brief Behavioral Therapy for Insomnia (BBTI) content and materials. The BASICS + SLEEP intervention will be implemented in 2 sessions of 45-75 minutes and 2 telephone booster sessions. We will follow BBTI procedures, including provision of a physiological rationale for insomnia and the importance of behavioral strategies to regulate sleep; introduction of sleep hygiene; discussion of factors that can impede duration and quality of sleep; introduction of sleep restriction and stimulus control strategies and negotiation of an initial sleep restriction schedule; and follow-up evaluation of success and continued refinement to achieve sleep efficiency goals. Booster contacts serve as opportunities to adjust the sleep restriction schedule, problem-solve challenges, and further build motivation.
62390585|NCT03102164||cardiac rehabilitation|patients undergoing cardiologic rehabilitation according to the protocol used routinely at the Military Hospital in Wroclaw.The protocol of rehabilitation, adjusted to clinical status, individual needs and physical capability of the patient, includes gradually increasing level of physical exercise. Upon achieving relative stabilization of clinical status and excluding absolute contraindications to physical exercise, usually on the 2nd or 3rd day of hospitalization, the cardiologic rehabilitation is ordered by a physician in charge. The rehabilitation protocol comprises respiratory, assisted, active dynamic,and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase;they are conducted in a lying, sitting, or standing position.
62562120|NCT02105467|PLACEBO_COMPARATOR|Deferred Treatment Group|Participants received blinded placebo tablet orally once daily for 12 weeks; after a 4-week unblinding/washout period participants received open label grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks. Follow-up was continued for an additional 24 weeks.
62562121|NCT05206123||Adolescents with perinatal acquired HIV infection|group of Adolescents with perinatal acquired HIV infection
62562122|NCT05605418|EXPERIMENTAL|CHESS intervention|Physicians and patients at the intervention group will receive training and support on the use of the multi-faceted CHESS system.
62769716|NCT03399656|ACTIVE_COMPARATOR|High Dose Avmacol|4 Avmacol tablets
62769717|NCT02058719||Cohort A1|HIV positive smokers
62769718|NCT02058719||Cohort A2|HIV positive non-smokers
62769719|NCT02058719||Cohort A3|HIV negative smokers
62769720|NCT02058719||Cohort A4|HIV negative non-smokers
62769721|NCT02058719||Cohort B1|HIV positive with COPD
62562123|NCT05605418|NO_INTERVENTION|Control|After site randomization, physicians at the control sites will manage their patients by usual care at hypertension clinics.
62562124|NCT01589458|PLACEBO_COMPARATOR|Non-fluoride toothpaste|
62562125|NCT01589458|EXPERIMENTAL|NaF/SiO2 toothpaste|
62562126|NCT01589458|EXPERIMENTAL|MFP/CaCO3 toothpaste|
62562127|NCT02863796|EXPERIMENTAL|Single arm|This prospective, multi-center, single arm study is designed to evaluate the safety and feasibility of the WhiteSwell System in the reduction of interstitial fluid overload in patients with acutely decompensated heart failure (ADHF)
62562128|NCT02282540|EXPERIMENTAL|Iodixanol to the Eustachian tube|Iodixanol contrast medium diluted with NaCl to 20% into the tympanostomy tube while the patient lies on his / her back with the head slightly turned to the opposite side. After 10 minutes the CT examination will be conducted using 200 mA and 120 kV.
62562129|NCT03321682|EXPERIMENTAL|Functional Training|Patients in the functional training group, in addition to maintaining their usual care, will perform functional training including exercises for core strength, power training, knee dominance, hip dominance, horizontal pressure, vertical pressure, horizontal pull and vertical pull, using unstable surfaces.
62562130|NCT03321682|ACTIVE_COMPARATOR|Strength Training|These group, in addition to maintaining their usual care, will perform the exercise protocol as recommended by the American Heart Association.
62562131|NCT05505591||High bleeding risk|Patients treated with cangrelor who met the Academic Research Consortium (ARC) definition of high bleeding risk (HBR)
62182722|NCT04199455|EXPERIMENTAL|Integrative Treatment Group|Patients randomly assigned to the intervention group will receive EPACH and NQABC Chinese herbal compound granules, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.
62390586|NCT03102164||Controls|patients treated using standard pharmacotherapy within Center for Heart Disease, Military Clinical Hospital in Wroclaw.
62182723|NCT04199455|PLACEBO_COMPARATOR|Control Group|Patients randomly assigned to the control group will receive recipe simulators as placebo, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.
62390587|NCT03672474|EXPERIMENTAL|Photobiomodulation REGEnLIFE RGn530 device group|
62390588|NCT03672474|SHAM_COMPARATOR|Sham REGEnLIFE RGn530 device group|
62390589|NCT01241643|EXPERIMENTAL|CYT107|repeated cycles of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
62390590|NCT01241643|NO_INTERVENTION|Control|Control arm with possible CYT107 injection after 12 months of study participation
62390591|NCT05798559|EXPERIMENTAL|Intervention Group|"* Sleep Training will be applied.~* With the training, examples will be presented to mothers that they can apply in their daily lives.~* 1 month will be followed"
62390592|NCT05798559|NO_INTERVENTION|Control Group|"No training will be provided~note: Sleep Training will be given after the study is completed so that the control group is not victimized."
62390593|NCT03507049|ACTIVE_COMPARATOR|Intervention group|The intervention Group receives operation with SI-joint arthrodesis with the iFuse implant. The patient undergoes full anesthesia. The procedure starts with an approximately 5cm long skin incision over the posterolateral aspect of the pelvis. A guide-pin is inserted over the sacroiliac joint at the desired entry-point, verified by fluoroscopy. The surgeons drills and boraches over the pin and the ifuse implant is inserted. This is repeated for a total of three implants. The wound is closed with non-resorbable suture. An injection of the SIJ with local anesthetic is performed under guidance of fluoroscopy at the time of the procedure.
62390594|NCT03507049|SHAM_COMPARATOR|Sham group|"The sham operation will consist of the surgeon making the same skin incision as for an iFuse procedure, although nothing more, and then closing the wound.~The patients undergoing a sham operation will be under general anesthesia for a random time of 20-40minutes in order to keep the two procedures as similar as possible.~An injection of the SIJ with local anesthetic is performed under guidance of fluoroscopy at the time of the procedure."
62562132|NCT05505591||Non-high bleeding risk|Patients treated with cangrelor who did not meet the Academic Research Consortium (ARC) definition of high bleeding risk (HBR)
62562133|NCT04390607||Subjects undergoing revision joint surgery|
62562134|NCT03808948|EXPERIMENTAL|All Patients|VFI dose: 47 mg / 3 mL Number of doses: 2 Route of administration: intravenous
62562135|NCT00459862|EXPERIMENTAL|Arm I|Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
62562136|NCT06463990||Study group|women with macrosomic newborns
62562137|NCT06463990||Control group|women with non-macrosomic newborns
62562138|NCT00697463|EXPERIMENTAL|Women with Idiopathic osteoporosis (IOP)|Each subject will receive 20 micrograms of Teriparatide (PTH 1-34) subcutaneously daily for 18 -24 months
62769722|NCT02058719||Cohort B2|HIV positive without COPD (non-COPD)
62769723|NCT02058719||Cohort B3|HIV negative with COPD
62769724|NCT05106010||Usual Activity|Participants continued with usual activity, not participating in any yoga intervention for 12 weeks
62769725|NCT05106010||Balance Flow Yoga|Community hatha yoga flow class, 75 minutes duration, twice per week for 12 weeks
62769726|NCT06546488||Subject population|All subjects who meet the inclusion/exclusion criteria for the trial.
62769727|NCT02107157|EXPERIMENTAL|755nm Alexandrite laser with cap array|
62168921|NCT04783519|ACTIVE_COMPARATOR|BASICS|The BASICS condition will meet for 2 sessions of 45-75 minutes. Content depends on the degree to which participants discuss the feedback, have questions, and/or explore behavior change options. Therapists review feedback components with participants, eliciting personally relevant reasons to change as domains are explored. When the participant is ambivalent about change, therapists work with them to explore and resolve that ambivalence. The method is non-confrontational and utilizes exploration of personalized graphic feedback (i.e., frequency, quantity, and peak use alongside perceived and actual norms for alcohol/MJ use) to increase motivation for change by highlighting ways alcohol and/or marijuana use could be incongruent with goals or values. Beliefs, expectations, and motives for use are discussed as are strategies to minimize risks and consequences. Booster sessions address questions and problem-solve challenges that have arisen since the session.
62182724|NCT05195892|EXPERIMENTAL|Sequence 1|Participants will receive a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 2 and a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 3.
62390595|NCT03507049|OTHER|Functional MRI study|The Swedish patients will also undergo quantitative sensory testing at inclusion and at 6 month follow-up. At the same time they will undergo a cerebral MRI and a Functional MRI looking at activation of the CNS from pain in the sacroiliac joints induced by one leg lift. The purpose of this study is to look at contributing factors in treatment response. One hopes to map which CNS mechanisms are involved in causing the chronic pain these patients experience as well as how they respond to treatment.
62390596|NCT04896606|EXPERIMENTAL|SARS-CoV-2 CTLS + Standard of Care|Patients will get family donor derived SARS-CoV-2 cytotoxic t-lymphocytes up to 5 times every 2 weeks along with Standard of care of COVID-19.
62390597|NCT04896606|ACTIVE_COMPARATOR|Standard of Care Only|Patients will NOT received COVID CTLs but will get standard of care.
62390598|NCT04915742|EXPERIMENTAL|exercises and thetahealing|
62390599|NCT04915742|ACTIVE_COMPARATOR|exercises|
62390600|NCT06262009||household|House Members (adults and minors) from 175 households owning a dog
62390601|NCT04054050|EXPERIMENTAL|Light therapy|Participants receive one hour of morning (within 9:00am-11:00am) and afternoon/evening (within 5:00pm-7:00pm).
62390602|NCT01812564|PLACEBO_COMPARATOR|PPP|"Placebo: Platelet Poor Plasma~Under sterile conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PPP each, administered by a sports medicine physician (total 3 cc PPP).~Following the completion of the injections (treatment or control) physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
62390603|NCT01812564|ACTIVE_COMPARATOR|PRP|"Biological: Platelet Rich Plasma~Under sterile ultrasound conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PRP each, administered by a sports medicine physician (total 3 cc PRP).~Following the completion of the injections (treatment or control) physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
62390604|NCT01812564|NO_INTERVENTION|Physiotherapy|"These patients will not receive an injection.~Following the inclusion physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
62390605|NCT01932671||SMART|The SMART (Second Manifestation of ARTerial disease) cohort comprises patients at high-risk for or who have clinically manifest cardiovascular disease, including transient ischemic attack, cerebrovascular disease, peripheral artery disease, aneurysma aorta abdominalis, myocardial infarction, coronary ischemia for which coronary intervention is required, renal artery stenosis, diabetes mellitus, hyperlipidemia, hypertension, patients diagnosed with human immunodeficiency virus, pre-eclampsia, HELLP syndrome, abruption placentae and Intrauterine growth restriction in medical history. Participants are re-invited after 4 years for a second screening. This screening is performed to study the progression of atherosclerosis and evaluate the effects of the advice of the multidisciplinary team.
62390606|NCT03778476|EXPERIMENTAL|Isometric Exercise|Participants will perform a submaximal voluntary contraction of the quadriceps muscle to task failure.
62390607|NCT03778476|NO_INTERVENTION|Quiet Rest|Participants will sit quietly for a period of time that mimics the exercise.
62390608|NCT04454632|EXPERIMENTAL|Mirror therapy group|The number of participants in this group is anticipated to be 12. In addition to basic treatment, the mirror therapy group bilateral exercised with the affected arm behind the mirror for 10 minutes after every session. Participants in this group perform three exercises as glenohumeral flexion, abduction, and rotation.
62390609|NCT04454632|EXPERIMENTAL|Visual feedback group|The number of participants in this group is anticipated to be 12. In addition to basic treatment, the visual feedback group bilateral exercised by seeing both arms in the mirror for 10 minutes after every session. Participants in this group perform three exercises as glenohumeral flexion, abduction, and rotation while seeing both arms in the mirror.
62390610|NCT04454632|NO_INTERVENTION|Control group|The number of participants in this group is anticipated to be 12. In addition to basic treatment, the control group bilateral exercised without a mirror for 10 minutes after every session. Participants in this group perform three exercises as glenohumeral flexion, abduction, and rotation while seeing both arms in the mirror.
62562139|NCT01242293|ACTIVE_COMPARATOR|0.9% Saline with glucose 5%|rate of infusion is 125cc/h
62562140|NCT01242293|ACTIVE_COMPARATOR|Ringer lactate|rate of infusion is 250cc/h
62562141|NCT01242293|ACTIVE_COMPARATOR|Ringer lactate - Controls|rate of infusion is 125cc/h
62562142|NCT02633293|EXPERIMENTAL|Inhaled Treprostinil|Open-label access
62168922|NCT04783519|NO_INTERVENTION|Assessment Only Control|Participants in Assessment Only Control (AOC) condition will complete all assessments (including survey, daily, actigraphy) at the same time as participants in the 2 active interventions. AOC will also attend an in-person meeting to verify identity, provide rationale for daily monitoring, control for time/attention, and participants in all conditions including AOC will receive referrals for community services to address alcohol and MJ use, sleep, and other mental health concerns. No participants will be deprived of services; use of outside services will be tracked to assist with interpretation of outcomes. AOC condition will be offered BASICS + SLEEP after 3-month follow-up.
62168923|NCT03143634|EXPERIMENTAL|The Modular Protocol for Mental Health|"The Modular Protocol for Mental Health (Psychological Therapy) will last up to 18 regular weekly face-to-face sessions. Treatment follows a standard structured treatment session as per Cognitive Behavioural Therapy. The MPMH Treatment Manual was written by clinical psychologists. The selection and ordering of the modules for treatment will be delivered and determined by the Trial Clinical Psychologist in collaboration with the service-user. The treatment modules include:~M1. Getting Acquainted M2. Understanding Emotions M3. Managing and Tolerating Emotions M4. Behavioural activation M5. Tackling Avoidance M6. Tackling Unhelpful Thoughts M7. Tackling Unhelpful Habits M8. Overcoming Repetitive Thinking M9. Managing Upsetting Memories and Images M10. Relapse Prevention and Future Orientation"
62168924|NCT03143634|PLACEBO_COMPARATOR|Treatment-as-usual|For Treatment-as-usual (Psychological Therapy), clinicians will be asked to provide whatever treatment they deem appropriate, including psychological services, medication and referral to other services. TAU will be delivered by high-intensity therapists or clinical psychologists.
62562143|NCT03012997|ACTIVE_COMPARATOR|Active Comparator: 40% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen 40% during the induction, surgery and in Postoperative care unit.
62168925|NCT01578278|EXPERIMENTAL|Bepotastine besilate formulation|Nasal Spray
62562144|NCT03012997|ACTIVE_COMPARATOR|Active Comparator: 100% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen during 100% induction and with 60-70% ( determined according to the arterial blood gas sample results) during surgery and in Postoperative care unit.
62562145|NCT03004274|ACTIVE_COMPARATOR|Running sutures|Deep layers will be closed using running sutures
62562146|NCT03004274|EXPERIMENTAL|Interrupted sutures|Deep layers will be closed using interrupted sutures
62168926|NCT01578278|EXPERIMENTAL|Fluticasone propionate|Nasal Spray
62168927|NCT01578278|EXPERIMENTAL|Bepotastine besilate-fluticasone propionate|Nasal Spray
62168928|NCT01578278|PLACEBO_COMPARATOR|Placebo Comparator|Nasal Spray
62168929|NCT01984853||OBSERVATIONAL REGISTRY|Individuals presenting with signs and/or symptoms of Acute Coronary Syndrome at the Henry Ford Hospital Emergency Department (ED).
62562147|NCT03202082|EXPERIMENTAL|Neuropsychological testing|Participants from this group will be administered a neuropsychological battery in addition to the initial and follow-up surveys
62168930|NCT04388917||Clip Group|Use of Hemo-lock hemostatic clips during tumor resection to prevent bleeding
62168931|NCT04388917||No Clip group|No Hemo-lock hemostatic clips used during tumor resection
62390611|NCT02695758|ACTIVE_COMPARATOR|interscalene brachial plexus block|Direct interscalene nerve block injection via brachial plexus
62562148|NCT03202082|NO_INTERVENTION|Treatment as usual|Participants from this group will be administered the initial and follow-up survey.
62562149|NCT02483676|EXPERIMENTAL|Treadmill+anklebot|This group will receive gait training on a treadmill while wearing the anklebot with the adaptive control system.
62562150|NCT02483676|ACTIVE_COMPARATOR|Treadmill only|This group will receive gait training on a treadmill, without use of the anklebot.
62562151|NCT05820204|EXPERIMENTAL|Pain reprocessing therapy (PRT)|"PRT has 5 components: 1) education about the origin of pain in the brain, its reversibility, and the pain-fear cycle; 2) reinforcing education using personal biography; 3) somatic tracking of pain through mindfulness and reappraisal of pain sensations as non-dangerous; 4) lowering the level of personal threat that may trigger pain sensation; and 5) inducing positive affect in periods of pain. Patients will attend 1 assessment and education telehealth session with a physician followed by 8, 50-minute, therapist-led sessions. Pacing will be flexible, ranging from 5-12 weeks, to increase accessibility. Treatment will be provided by experienced PRT clinicians. All PRT sessions will be remotely-delivered."
62562152|NCT05820204|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|CBT-CP, considered the leading psychological treatment for chronic pain, is a structured, time-limited intervention that aims to teach patients how to better manage chronic pain and improve their quality of life. Participants will receive 9, 50-minute sessions of CBT-CP over 5 - 12 weeks. The VA CBT-CP protocol contains an initial orientation involving education and familiarization with the CBT-CP approach to chronic pain. The protocol then includes sessions that focus on topics such as exercise, relaxation, pleasant activities, cognitive coping, and sleep. All CBT-CP sessions will be remotely-delivered.
62562153|NCT05820204|ACTIVE_COMPARATOR|Usual Care|Participants will be asked to continue whatever they are already doing to care for their back pain. Length of the usual care condition will be 5 weeks, the expected mean completion time of the PRT and CBT arms, and may be adjusted at mid-enrollment to match treatment arm length more closely.
62390612|NCT02695758|ACTIVE_COMPARATOR|Bupivacaine extended-release liposome injection|Infiltration of local anesthetic/analgesic, Bupivacaine extended-release liposome injection (Exparel) + Diluted in 40cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues.
62390613|NCT04703959||glaucomatous subjects (50)|"Subjects included in the MARS database of CHU Grenoble-Alpes with available polysomnographic data and with the following ophthalmological characteristics:~* increase in intraocular pressure (IOP before treatment greater than 21 mmHg) with characteristic alterations of the optic nerve (pathological papillary excavation, papillary pallor, papillary atrophy) with corresponding alterations and characteristics of the visual field. The visual field should be considered reliable (European criteria (European Glaucoma Society, 1999).~* Patients whose age is greater than or equal to 18 years~* Male or female patients~* Patients not objecting to the study~* Affiliation to a social security scheme or beneficiary of such a scheme"
62390614|NCT04703959||non glaucomatous subjects (100)|"Subjects included in the MARS database of CHU Grenoble-Alpes with available polysomnographic data and with the following ophthalmological characteristics:~* no known ophthalmological pathologies, with an ophthalmological examination on telephone examination - in the 2 years preceding the polysomnographic examination - normal apart from minor refractive disorders (myopia with spherical equivalent less than -6 diopters or hyperopia with spherical equivalent less than 3 diopters).~* Patients whose age is greater than or equal to 18 years~* Male or female patients~* Patients not objecting to the study~* Affiliation to a social security scheme or beneficiary of such a scheme"
62390615|NCT06431139|EXPERIMENTAL|INSPIRE group|Intervention group. Daily intensive sit-to-stand exercises following a described algorithm and utilising motor-relearning principles of feedback to increase the participant's motivation. This exercise is an addition to standard care.
62562154|NCT06035692|EXPERIMENTAL|Brachial plexus block group（BPB）|All patients received receive Ultrasound-guided BPB with 0.15% ropivacaine 20ml 30min before surgery
62562155|NCT06035692|NO_INTERVENTION|Control group （Control）|All patients received receive Ultrasound-guided BPB with normal saline 20ml 30min before surgery
62562156|NCT05479825|EXPERIMENTAL|inflation- deflation line combined with ICG fluorography|Identification of the intersegmental plane using inflation- deflation line combined with ICG fluorography under the status of tubeless
62562157|NCT02031861|EXPERIMENTAL|nifedipine CR tablets (Xin Ran)|Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 12-week treatment period.
62562158|NCT02031861|ACTIVE_COMPARATOR|nifedipine CR tablets (Adalat)|Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 12-week treatment period.
62562159|NCT03509064||1: Patients with small fiber neuropathy|patients with Sjogren syndrome have a definite small fiber neuropathy
62562160|NCT03509064||2: Patients without peripheral neuropathy|patients with Sjogren syndrome without signs of peripheral neuropathy (small or large fiber)
62562161|NCT02783924|ACTIVE_COMPARATOR|Cholecalciferol|Vitamin d (as a 20.000 IU capsule) will be given i a dose of 40.000 IU per week for two months
62562162|NCT02783924|PLACEBO_COMPARATOR|Placebo|two capsules (identical looking to the vitamin D capsules) will be given per week for two months
62562163|NCT03678610|EXPERIMENTAL|ICSI medium supplemented with Ionomycin and Latrunculin A|
62562164|NCT03678610|NO_INTERVENTION|ICSI medium as it is|
62562165|NCT03349021|EXPERIMENTAL|Bougiecap|Treatment with Bougiecap instead of Savary Bougie
62168932|NCT05788081|EXPERIMENTAL|Arm A- Golcadomide + Rituximab|Rituximab 375mg/m2 IV infusion Q4W + golcadomide 0.4mg po D1-D14 of each cycle for 8 cycles, followed by Rituximab 375mg/m2 IV infusion Q12W in participants with CR/PR at end of induction
62168933|NCT05788081|EXPERIMENTAL|Arm B- Nivolumab + golcadomide + Rituximab|Nivolumab 480mg IV infusion Q4W, Rituximab 375mg/m2 IV infusion Q4W and golcadomide 0.4mg po D1-D14 of each cycle for 8 cycles, followed by Rituximab 375mg/m2 IV infusion Q12W in participants with CR/PR at end of induction
62390616|NCT06431139|NO_INTERVENTION|Standard care group|Treatment in this group will be standard care interventions performed at the rehabilitation department.
62562166|NCT04099472|PLACEBO_COMPARATOR|Control Group|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission. The intervention group will also receive the same pamphlet.
62562167|NCT04099472|EXPERIMENTAL|Intervention Group|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission. Additionally, they will receive delirium education on prevention and management of delirium.
62562168|NCT02092870|EXPERIMENTAL|Treatment of Chronic Wound|Patients will receive a single treatment with ASCs in the form of multiple injections of cells within and immediately surrounding the wound. Cells will be delivered using a 1 cc syringe with an appropriate gauge and length needle. Each injection will have a volume less than 250 micro-liters. The number of injections will be determined by the surgeon as a function of total wound volume.
62562169|NCT03402061||Community living seniors|Approximately 50 seniors will taste test each nutrient enhanced recipe and determine acceptability and palatability.
62562170|NCT03402061||LTC cognitively well|Approximately 15 seniors living in long term care who do not have cognitive impairment will taste test each nutrient enhanced recipe and determine acceptability and palatability.
62562171|NCT03402061||LTC persons living with dementia|Approximately 15 seniors living in long term care with cognitive impairment will taste test each nutrient enhanced recipe and determine acceptability and palatability.
62562172|NCT00968747|EXPERIMENTAL|Fasting (Healthy).|Participants will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily and two fat samples will be obtained by a trained surgeon. (We are no longer recruiting for Study Arm A).
62562173|NCT00968747|EXPERIMENTAL|Fasting (NAFLD)|Participants with liver-biopsy diagnosed non-alcoholic fatty liver disease (NAFLD) will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily, and participants will have an MRI before and after the fast.
62562174|NCT00968747|EXPERIMENTAL|Hypocaloric diet (NAFLD)|Participants will follow a low-calorie diet until they lose 3-5% of their body weight. Participants will have weekly outpatient visits at Beth Israel Deaconess Medical Center in Boston, MA for weight measurements. Participants will have blood drawn before and after the diet. Participants will also have an MRI before and after the diet.
62168934|NCT02790047|ACTIVE_COMPARATOR|Home-base exercise|"Patients will receive intervention as following~1. A home-base exercise program~2. Health education~3. Breathing strategies for self secretion clearance~4. The medication following the COPD GOLD guidelines (2015)"
62168935|NCT02790047|EXPERIMENTAL|Home-base exercise with a PEP mask|"Patients will receive intervention as following~1. A home-base exercise program with using a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise~2. Health education~3. Breathing strategies for self secretion clearance~4. The medication following the COPD GOLD guidelines (2015)"
62168936|NCT03168009|EXPERIMENTAL|Bariatric Surgery|Patients will undergo either Omega Loop Gastric Bypass or Sleeve Gastrectomy. The decision which type of surgery will be performed, will by made by the surgeon and the patient based on clinical considerations and the patient's wishes.
62562175|NCT00968747|EXPERIMENTAL|Oral carbohydrate challenge|Participants will fast for 16 hours overnight then ingest drinks containing fructose, glucose or a mixture of fructose and glucose. Blood will be drawn postprandially at specified timepoints for up to 5 hours
62562176|NCT00349973|EXPERIMENTAL|1|Dipyridamole
62769728|NCT02488642|EXPERIMENTAL|isosorbide dinitrate-oxytocin|"Preinduction with isosorbide dinitrate gel solution (80 mg/1.5 mL) were administered in the posterior fornix every 3 hours. Once a Bishop score of over 7 was reached, oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.~If the cervical conditions (\<7 Bishop Score) did not change after the treatment application, a new dose, without exceeding 4 doses, to facilitate cervical ripening."
62769729|NCT02488642|PLACEBO_COMPARATOR|misoprostol-oxytocin|"Preinduction with misoprostol gel solution (100 mcg/1.5 mL) were administered in the posterior fornix every 3 hours. Once a Bishop score of over 7 was reached, oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.~If the cervical conditions (\<7 Bishop score) did not change after the treatment application, participants received a new dose, without exceeding 4 doses, to facilitate cervical ripening."
62769730|NCT00480259|ACTIVE_COMPARATOR|Standard Nutrition|
62769731|NCT00480259|EXPERIMENTAL|Hyperprotein Nutrition|
62769732|NCT06454149||MALT lymphoma|Patients who were newly diagnosed as gastric MALT lymphoma
62769733|NCT06454149||Control group|"Patients who underwent~1. diagnosed upper endoscopy for dyspepsia and had chronic gastritis,~2. therapeutic upper endoscopy for gastric hyperplastic polyps, or~3. screening upper endoscopy without any symptoms."
62562177|NCT00349973|ACTIVE_COMPARATOR|2|Olanzapine
62562178|NCT03961737|EXPERIMENTAL|prostatic explants|A first series of biopsies will be performed during the procedure to place the gold grains prior to radiotherapy. Explants will be performed from these biopsies. Half of these explants will be irradiated with a research irradiator at a dose of 2 Gy then placed for 24 hours in an appropriate culture medium. The other half will be directly cultured for 24 hours. After 24 hours of incubation, half of the irradiated explants and half of the explants will be used to study the transcriptome. The tissues will be stored in RNAlater solution and then frozen at -80°C. The remaining half explants will be used for immunohistochemical analysis. Two years after the end of radiotherapy, a new series of biopsies will be performed for research, in order to verify histologically the effectiveness of radiotherapy.
62168937|NCT01613183|EXPERIMENTAL|Chinese Medicine group|Chinese Medicine prescription of one of three prestigious Chinese medicine clinicians
62168938|NCT01613183|PLACEBO_COMPARATOR|placebo group|
62168939|NCT00734851|EXPERIMENTAL|Multimodality|4 cycles of 70 mg/m2 Docetaxel + 37.5 mg daily Sunitinib for 14 days followed by a 7 day break for 3 cycles + external beam radiotherapy to 66 Gray over 6-7 weeks
62562179|NCT00972374|EXPERIMENTAL|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
62562180|NCT00972374|EXPERIMENTAL|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
62168940|NCT04923230|EXPERIMENTAL|CAP Intervention|CAP is a parent-focused intervention being developed to help parents in states with legalized medical marijuana to address adolescent marijuana use. The proposed intervention will address the effects of marijuana on adolescent behavioral health, brain development, and social functioning and enhance parent motivation to use CAP concepts. Guided by formative research, CAP will build skills and provide strategies to: (1) restrict adolescent exposure to cannabis products and parent cannabis use in the home, (2) improve parent communication about their own cannabis use and expectations about youth marijuana use, (3) improve monitoring, (4) increase positive reinforcement for youth abstinence, and (5) address parent negative emotions. Parents will meet in groups with an interventionist for two 75-minute sessions. Presentations, discussion, and roleplay will be used to help parents gain mastery of preventive parenting behaviors and related strategies to reduce adolescent marijuana use.
62182725|NCT05195892|EXPERIMENTAL|Sequence 2|Participants will receive a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 2 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 3.
62562181|NCT00972374|SHAM_COMPARATOR|Sham (no implant)|Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
62769734|NCT00509171|ACTIVE_COMPARATOR|1-Standard reamer|Standard reamer
62769735|NCT00509171|ACTIVE_COMPARATOR|2-Use of the Reamer-Irrigator Aspirator|Use of the Reamer-Irrigator Aspirator
62769736|NCT05630976|EXPERIMENTAL|Isavuconazole|This is a single arm study, all enrolled participants will receive the study medication.
62769737|NCT03601559|ACTIVE_COMPARATOR|Lactobacillus paracasei Lpc-37|Probiotic
62769738|NCT03601559|PLACEBO_COMPARATOR|Placebo|Inert placebo
62769739|NCT03031392||Peri-implantitis|Individuals with implants ≥2mm of radiographic bone loss
62769740|NCT03031392||non-peri-implantitis patients|Individuals with implants \<2mm of radiographic bone loss
62769741|NCT01699074|EXPERIMENTAL|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
62769742|NCT01699074|EXPERIMENTAL|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
62562182|NCT02419534|ACTIVE_COMPARATOR|Polyethylene glycol|In our study parents will be asked to start at 1g per day if they are less than 1 year of age and 2g per day in divided doses if they are older and will be asked to titrate the does according to the response up to the a maximum does of .5g/kg/day. In titrating the dose parent will be asked to increase the dose every 2 days until the child pass one normal BM per day without significant efforts. They should titrate down or hold treatment if the child developed lose BM or diarrhea. Caregiver will be asked to use placebo ointment by applying 5mm on fingertip to the anal verge area twice a day for the duration of the study.
62562183|NCT02419534|ACTIVE_COMPARATOR|Polyethylene glycol with Diltiazem|Parents will be instructed to apply 5 mm of ointment on a fingertip at the anal verge twice daily for the duration of the study
62562184|NCT06303141|OTHER|Closed Chain Exercises|Group A, serving as the control group, will undergo a structured rehabilitation regimen comprising closed chain exercises, icing, and bracing. The exercise component will focus on enhancing proprioception and strengthening the ankle joint. Participants will perform exercises including open eyes and closed eyes across arm movements for three sets lasting 60 seconds each, lateral step down exercises for three sets of 6-12 repetitions, semi-squat exercises for three sets of 6-12 repetitions, and Thera-band isometric exercises for three sets of 10-15 seconds each. These exercises are designed to promote ankle stability, improve range of motion, and enhance muscle strength. Additionally, icing and bracing will be utilized to reduce inflammation and provide external support to the injured ankle.
61994669|NCT05820971|EXPERIMENTAL|C-short plus usual practice|After accepting to review an article, peer reviewers will receive the automated, journal specific standard email with general information as per each journal's usual practice (e.g. where to access the manuscript, date when the peer review report is due). In addition, peer-reviewers who received a manuscript which was randomised to C-short will receive an additional email including a short version of the CONSORT checklist together with a short explanation of those items.
62562185|NCT06303141|EXPERIMENTAL|Neuromuscular training|Group B, designated as the experimental group, will undergo a comprehensive rehabilitation protocol combining neuromuscular training with closed chain exercises, icing, and bracing. The exercise regimen will target proprioception, neuromuscular control, and ankle stability. Participants will engage in a series of exercises including single leg raises for three sets lasting 30 seconds each, ankle eversion/inversion exercises for three sets of 25 repetitions, double hopping in place then out of place for three sets of 30 seconds, reaching exercises with feet and hands for three sets lasting 30-60 seconds each, and wobble board exercises for three sets lasting 30-60 seconds each. These exercises are aimed at improving balance, coordination, and muscle strength around the ankle joint. The addition of neuromuscular training enhances the proprioceptive feedback and control, which is crucial for injury prevention and functional recovery in athletes with ankle sprains.
62168941|NCT04923230|NO_INTERVENTION|Wait List|Parents randomly assigned to Wait List Delayed CAP (WL) will receive no intervention for the baseline to 3-month follow-up period. Thus, the WL condition will serve as a comparison group from baseline to the 3-month assessment point. After the 3-month follow-up assessment, WL parents will be offered the CAP intervention. The final assessment for the WL participants will function as a 3-month follow-up assessment, allowing us to aggregate data all 60 parent-adolescent dyads to conduct within group analyses of pre- to post-intervention change on key variables of interest.
62562186|NCT06303141|EXPERIMENTAL|Mobilization with movement|Group C, designated as an experimental group, will undergo a unique intervention combining mobilization with movement techniques, closed chain exercises, icing, and bracing. The focus of this intervention is to address joint dysfunctions and pain modulation while improving range of motion (ROM) in athletes with ankle sprains. Participants will receive joint mobilization with movement techniques, following the Mulligan approach, aimed at restoring normal joint mechanics and function. The protocol will involve three sets of six oscillations or glides each, targeting specific joint restrictions and impairments associated with ankle sprains. By integrating manual therapy with exercise and adjunct modalities like icing and bracing, this comprehensive approach aims to optimize joint function, reduce pain, and enhance overall rehabilitation outcomes in professional athletes with ankle injuries.
62168942|NCT04655521||COVID-19 patients|
62168943|NCT04655521||Healthy controls|
62168944|NCT04655521||Non-COVID-19 patients with respiratory tract infection|
62769743|NCT01699074|EXPERIMENTAL|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
62769744|NCT01699074|PLACEBO_COMPARATOR|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
62769745|NCT01699074|ACTIVE_COMPARATOR|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
62769746|NCT05153707|EXPERIMENTAL|Clinical Pharmacist-led discharge education program|Clinical pharmacist-led services
62769747|NCT05153707|NO_INTERVENTION|Control group|Usual care
62769748|NCT05077098|EXPERIMENTAL|ADXS-504 Monotherapy Dose Escalation|Subjects with Biochemically Recurrent Prostate Cancer will receive ADXS-504 with dose escalation schema.
62769749|NCT01927042|EXPERIMENTAL|Expert Cares Helping Others plus Treatment as Usual|The experimental treatment (ECHOs plus TAU) will consist of the standard treatment consisting of group psychotherapy and skills training, nutritional counselling, and meal support, PLUS self-help unguided DVD series for carers, providing education about eating disorders and coping strategies for supporting those living with eating disorders.
62168945|NCT05743114|EXPERIMENTAL|Sleep Onset Latency Crossover|Arm 1 is a crossover arm in which participants receive one block of active stimulation (experimental) and a second block in which the device is worn and actively recording, but not delivering phase-locked auditory stimulation (sham). The order of blocks is randomized for each participant.
62168946|NCT05743114|EXPERIMENTAL|Wake After Sleep Onset|This arm tests active stimulation during sleep onset, as well as additional stimulation if participants wake up during the night. One of 4 possible conditions are randomized for each stimulation even (within subject and within nights): Stimulation locked to alpha peak phase, stimulation locked to alpha trough phase, white noise (active sham), and no sound (control).
62168947|NCT01369706|OTHER|Hand-held metal detector|Exposure to two hand-held metal detectors
62168948|NCT06551116||HER2 Assay|Analysis of HER2 expression via QIF and mRNA assays
62390617|NCT03964311|OTHER|Emergency Room Evaluation Tool (ER2)|Patients who are 75 years and over, and who are brought to Emergency in stretchers will be evaluated based on the Emergency Room Evaluation Tool (ER2).
62562187|NCT04032405|ACTIVE_COMPARATOR|CAF+CTG|the combined connective tissue graft (CTG) with coronally advanced flap (CAF)
62562188|NCT04032405|EXPERIMENTAL|CAF+CTG+i-prf|the combined connective tissue graft (CTG) and injectable platelet rich fibrin (i-prf) with coronally advanced flap (CAF)
62390618|NCT05061329||60 Normal individuals|Normal sense of smell and absence of sino-nasal disease, upper airway allergies, and no intranasal medication
62390619|NCT05061329||60 Non-COVID-19 positive patients|with olfactory dysfunction
62390620|NCT05061329||15 COVID-19 positive patients|In the acute phase
62390621|NCT05061329||60 long COVID-19 patients|with olfactory dysfunction persisting for more than 12 weeks
62390622|NCT05061329||60 patients with chronic rhinosinuitis|initiating intranasal glucocorticoids
62390623|NCT05061329||15 patients with chronic rhinosinuitis|initiating biological treatment with either dupilumab or mepolizumab
62769750|NCT01927042|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as usual (TAU) consists of group psychotherapy and skills training, nutritional counselling, and meal support.
62769751|NCT03175146|EXPERIMENTAL|Experimental|Stereotactic Body Radiation Therapy
62769752|NCT01951313|EXPERIMENTAL|Egg consumption|No egg 75g of scrambled eggs 150g of scrambled eggs
62769753|NCT00262990|EXPERIMENTAL|Patupilone|
62562189|NCT03918629|EXPERIMENTAL|Clostridium difficile vaccine - 3 dose|All 3 doses are the Clostridium difficile vaccine
62562190|NCT03918629|EXPERIMENTAL|Clostridium difficile vaccine - 2 dose|2 of the 3 doses are the Clostridium difficile vaccine with the other being placebo
62562191|NCT03101956|EXPERIMENTAL|L/S Manipulation Study Group|
62769754|NCT00262990|ACTIVE_COMPARATOR|doxorubicin|
62769755|NCT05499624|EXPERIMENTAL|MicroTrend System|MicroTrend System is placed onto the subject's cheek and the subject will actively participate in the study for up to 6 hours, with up to 4 hours of sensor monitoring.
62769756|NCT03022981|EXPERIMENTAL|12 to < 18 Years Old|"PK Lead-in Phase: Sofosbuvir/Velpatasvir (SOF/VEL) 400/100 mg once daily for 7 days. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.~Treatment Phase: SOF/VEL 400/100 mg once daily for 12 weeks."
62769757|NCT03022981|EXPERIMENTAL|6 to < 12 Years Old|"PK Lead-in Phase: SOF/VEL 200/50 mg once daily for 7 days. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.~Treatment Phase: SOF/VEL 200/50 mg once daily for 12 weeks."
62769758|NCT03022981|EXPERIMENTAL|3 to < 6 Years Old|"PK Lead-in Phase: SOF/VEL 200/50 mg once daily for 7 days for participants who weigh ≥ 17 kg. SOF/VEL 150/37.5 mg once daily for 7 days for participants who weigh \< 17 kg. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.~Treatment Phase: SOF/VEL 200/50 mg once daily for 12 weeks for participants who weigh ≥ 17 kg. SOF/VEL 150/37.5 mg once daily for 12 weeks for participants who weigh \< 17 kg."
62769759|NCT01345565|EXPERIMENTAL|Hepatocyte Transplantation|See Below
62769760|NCT04151849||GLP-1 receptor agonist treatment|Patients starting treatment with any molecule belonging to the class of GLP-1 receptor agonist.
62769761|NCT04151849||SGLT-2 inhibitor treatment|Patients starting treatment with any molecule belonging to the class of SGLT-2 inhibitors.
62769762|NCT00351325|EXPERIMENTAL|dose escalation|
62390624|NCT00981266|OTHER|Augmentation|"The study population will consist of women aged 22 or over who are undergoing primary breast augmentation.~The Augmentation cohort will include candidates for general breast enlargement, post-lactational involution and/or asymmetry."
62390625|NCT00981266|OTHER|Augmentation Revision|"The study population will consist of women aged 22 or over who are undergoing augmentation revision.~The Augmentation Revision cohort will include candidates with previous augmentation with silicone-filled or saline-filled implants."
62390626|NCT05330728|EXPERIMENTAL|Massage group|Suggestions for lifestyle changes + abdominal massage will be performed.
62390627|NCT05330728|ACTIVE_COMPARATOR|Taping group|Suggestions for Lifestyle Changes + Kinesio taping will be performed.
62390628|NCT05330728|OTHER|Control group|Suggestions for lifestyle changes will be performed.
62390629|NCT00660816|ACTIVE_COMPARATOR|Arm I|Patients receive pemetrexed disodium IV over 10 minutes OR docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive standard chemotherapy with or without erlotinib hydrochloride in the absence of disease progression or unacceptable toxicity.
62769763|NCT03255876|EXPERIMENTAL|Enriched pomegranate juice|Participants will consume 200 ml of pure pomegranate juice enriched with grape seed and apple peel extracts concomitantly with 109 g of white bread
62390630|NCT00660816|EXPERIMENTAL|Arm II|Patients receive pemetrexed disodium IV over 10 minutes OR docetaxel IV over 60 minutes on day 1 and erlotinib hydrochloride PO once daily on days 2-19. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive standard chemotherapy with or without erlotinib hydrochloride in the absence of disease progression or unacceptable toxicity.
62769764|NCT03255876|PLACEBO_COMPARATOR|Placebo beverage|Participants will consume 200 ml of placebo drink concomitantly with 109 g of white bread
62769765|NCT00506194|EXPERIMENTAL|Insulin|Insulin therapy was initiated at a 75% total daily dose in the last day hospitalization with Insulatard. Two third of daily dose was administered before breakfast and the other was administered at bedtime. Insulin doses were titrated every 3 days to achieve target FPG and pre-supper blood glucose values between 90 and 130 mg/dl. Bedtime insulin doses were titrated based on FPG values and the pre-breakfast dose was titrated base on pre-supper blood glucose.
62769766|NCT00506194|ACTIVE_COMPARATOR|OAD|Subject in other OAD group was visited every two weeks in the two months and the every four weeks. The subjects will start with Gliclazide-MR 30mg before breakfast, The dosage was titrated based on the fasting blood glucose on the visiting day with the same target. Decreased by 30mg if blood glucose was \<70mg /dl, decreased by 15 mg if blood glucose was 70-90mg/dl, no change if blood glucose was 90-130mg/dl, increased by 15 mg if blood glucose was 131-160 mg/dl, increased by 30 mg if blood glucose \>160mg/dl. When the Gliclazide-MR dose each to the maximum dose of 60 mg twice daily, Metformin was added. The titration of Metformin was use 250mg for an adjust dosage with the same target.
62769767|NCT02717130|EXPERIMENTAL|Aripiprazole (Abilify Maintena)|Aripiprazole once monthly (300-400 mg for entire study duration) plus 14 days oral antipsychotic medication (first injection only) (dosage according to package inserts). After the 14 day oral lead-in, after the first injection of aripiprazole once monthly, only oral aripiprazole will be allowed as a rescue medication.
62769768|NCT03150277|EXPERIMENTAL|Plyometric-Resistance|This group will perform plyometric exercise first and then heavy resistance exercise
62769769|NCT03150277|EXPERIMENTAL|Resistance-Plyometric|This group will perform resistance exercise first and then plyometric exercise
62769770|NCT02839694|EXPERIMENTAL|Dose escalation cohort|dose escalation cohort
62769771|NCT02839694|EXPERIMENTAL|Expansion cohort|expansion cohort at MTD
62769772|NCT02839694|ACTIVE_COMPARATOR|expansion cohort with celecoxib|expansion cohort at MTD with celecoxib
62769773|NCT03006224|ACTIVE_COMPARATOR|Group S (non smoking and secondary smoking)|I want to see the effects of seconder smoking to intraoperative arterial oxygen tension during one lung ventilation for lobectomy surgery.
62769774|NCT03006224|ACTIVE_COMPARATOR|Group SS (secondary smoking)|I want to see the effects of seconder smoking to intraoperative arterial oxygen tension during one lung ventilation for lobectomy surgery.
62769775|NCT02435706|EXPERIMENTAL|Flapless immediate implant placement group|Flapless placement of immediate implant and temporary crown
62769776|NCT02435706|ACTIVE_COMPARATOR|Flap assisted immediate implant placement group|Flap elevation prior to placement of immediate implant and temporary crown
62769777|NCT03664583|EXPERIMENTAL|Intervention Group|Patients randomly assigned to the intervention group will be offered the ACHRU-Community Partnership Program (CPP) intervention in addition to usual primary care services offered by their local diabetes education centre or primary care setting. The CPP is a 6-month self-management intervention consisting of six core components: 1) home or virtual visits (up to 3) supported by phone calls by either a Registered Nurse (RN) or Registered Dietician (RD); 2) wellness sessions (up to 6, one per month) provided to patients and their caregivers at the location of the community partner or virtually; 3) monthly team case conferences with the provider team; 4) caregiver support; 5) collaboration with the primary care interprofessional team and other specialists; 6) nurse-led care coordination/system navigation.
62769778|NCT03664583|NO_INTERVENTION|Control Group|Those who are randomly assigned to the control group will continue to be offered usual primary care services through their local diabetes education centre or primary care setting. The services that comprise usual diabetes care vary across the provinces e.g., length and focus of educational sessions, whether classes are strongly recommended versus optional (e.g., foot care, cardiac health, eating and exercise interventions), home visits, access to on-site professionals (e.g., endocrinologist, dietitian, physiotherapist, exercise specialist, pharmacist), connections with support services and community resources, and type of follow-up services available. Details of usual care provided at each site will be recorded.
62769779|NCT01878994|PLACEBO_COMPARATOR|Counselling Group|Each family will receive a single monthly meeting, a total of 8 with 10 minutes duration each one. The sessions will take place in the consultation of the paediatrician and it will be delivered by the child's nurse or/and paediatrician. The sessions' contents are about promotion of healthy eating and physical activity habits.
62769780|NCT01878994|EXPERIMENTAL|Nereu Group|The Nereu treatment program is an intensive family-based behavioural multi-component lifestyle intervention. Consist in an intensive treatment of 8 months duration (from October to May, that is, an academic year). The intervention is a multidisciplinary intervention consisting in 4 structured components: (a) physical activity training for children, (b) family theoretical and practical sessions for parents, (c) behaviour strategies, that involves both parental and child participation (d) weekend extra activities.
62769781|NCT01243489|OTHER|patient diary|compliance supporting measure: patients uses patient diary from month 6 to 12
62769782|NCT01243489|OTHER|"Information service Leben mit CML"|"compliance supporting measure: patient uses the Information service Leben mit CML"
62769783|NCT05428813|EXPERIMENTAL|Experimental|The group to which art therapy techniques will be applied.
62769784|NCT05428813|NO_INTERVENTION|Control|The group that will continue their routine coping habits related to premenstrual syndrome.
61994670|NCT05820971|NO_INTERVENTION|Usual practice|After accepting to review an article, peer reviewers will receive the automated, journal specific standard email with general information as per each journal's usual practice.
62562192|NCT03101956|ACTIVE_COMPARATOR|Control Group|
62562193|NCT01941017||Minimal or mild endometriosis|Patients with minimal or mild endometriosis diagnosed via laparoscopy.
62562194|NCT01941017||Tubal obstruction without endometriosis|Patients with tubal obstruction due to infection or adhesion with absent evidence for endometriosis on laparoscopy
61994671|NCT00579111|EXPERIMENTAL|HLA-identical sibling transplant|Recipients of HLA identical sibling stem cell transplants
62562195|NCT02743325|ACTIVE_COMPARATOR|ALARA protocol|SVT ablation by ALARA protocol
62562196|NCT02743325|ACTIVE_COMPARATOR|current treatment|SVT ablation by conventional protocol
62562197|NCT02077140|EXPERIMENTAL|MDT-10013|Subjects will receive MDT-10013.
62562198|NCT02077140|ACTIVE_COMPARATOR|Standard of Care|Subjects will receive standard of care.
61994672|NCT00579111|EXPERIMENTAL|Unrelated Matched or Single Antigen Mismatched transplant|Recipients of unrelated matched or single antigen mismatched donor stem cell transplant or single antigen mismatched family donor stem cell transplants
62390631|NCT01745159|EXPERIMENTAL|continued tacrolimus treatment|children with moderate/severe atopic dermatitis treated with tacrolimus ointment and continuing to apply tacrolimus ointment during disease control period.
61994673|NCT01436812|PLACEBO_COMPARATOR|zero end-expiratory pressure|not applying PEEP during operation just applying TV=IBW\*6-8ml IBW = (male; 50+0.91\[(Ht-cm)-152.4\], female; 45.5 +0.91\[(Ht-cm)-152.4\], RR 8-12/min,
62390632|NCT01745159|NO_INTERVENTION|no additional treatment|children with moderate/severe atopic dermatitis treated with tacrolimus ointment and with no additional treatment during disease control period.
62390633|NCT01156636|ACTIVE_COMPARATOR|Sildenafil|
62390634|NCT01156636|PLACEBO_COMPARATOR|Placebo|
62390635|NCT04944966|EXPERIMENTAL|Group 1|"• Experimental: Group 1a: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 400mg once a day to test its safety and tolerability.~Interventions:~o Drugs: Maytenus senegalensis~• Experimental: Group 1b: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 600mg once a day to test its safety and tolerability.~Interventions:~o Drugs: Maytenus senegalensis~• Experimental: Group 1c: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days to test its safety and tolerability.~Interventions:~o Drugs: Maytenus senegalensis~• Experimental: Group 1d: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days to test its safety and tolerability.~Interventions:~o Drugs: Maytenus senegalensis"
62390636|NCT04944966|EXPERIMENTAL|Group 2a|"Group 2a: n=52, Adults aged 18 to 45 years diagnosed with natural acquired uncomplicated malaria will be treated with Maytenus senegalensis.~Patients will be treated with Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days.~Curative efficacy will be assessed by measure the portion of patients with Early Treatment Failure (ETF), Asexual parasite clearance time (PCT) and adequate Clinical and Parasitological Response (ACPR) for treatment at 28 days and 56 days after PCR correction of reinfection (ACPR 28 and 56 after PCR correction of reinfection~Interventions:~o Drugs: Maytenus senegalensis"
62390637|NCT04944966|ACTIVE_COMPARATOR|Group 2b|"Group 2a: n=52, Adults aged 18 to 45 years diagnosed with natural acquired uncomplicated malaria will be treated with Artemether-lumefantrine Patients will be treated with Artemether 20mg/lumefantrine 120mg administered orally by a six-dose regimen over 3 days.~Curative efficacy will be assessed by measure the portion of patients with Early Treatment Failure (ETF), Asexual parasite clearance time (PCT) and adequate Clinical and Parasitological Response (ACPR) for treatment at 28 days and 56 days after PCR correction of reinfection (ACPR 28 and 56 after PCR correction of reinfection~Interventions:~o Drugs: Artemether 20mg/lumefantrine 120mg"
62562199|NCT01723800|EXPERIMENTAL|Treatment (pemetrexed, carboplatin, PI3K inhibitor BKM120)|Patients receive pemetrexed disodium IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1, and PI3K inhibitor BKM120 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may receive courses of PI3K inhibitor BKM120 alone or PI3K inhibitor BKM120 and pemetrexed disodium after 4-6 courses with carboplatin in the absence of unacceptable toxicity or disease progression.
62562200|NCT04163003|EXPERIMENTAL|TAPAS|Participants will participate in the TAPAS intervention, which will consist of one in-person engagement session with a therapist and 8 weeks of web-based automated intervention prompts. The program will utilize empirically supported approaches for promoting sleep health, delivered in-person and via text-message, focusing on: tailored psychoeducation, motivation and efficacy to change sleep, extending sleep duration, and regularizing sleep timing across the week.
62562201|NCT04163003|EXPERIMENTAL|Sleep monitoring only, then TAPAS|Participants will participate in sleep monitoring only first, then participate in the TAPAS intervention. First, participants will monitor sleep with sleep diary, but they will not receive feedback or any other information on to sleep.TAPAS will consist of one engagement session with a therapist and 4 weeks of web-based automated intervention prompts. The program will utilize empirically supported approaches for promoting sleep health, delivered in-person and via text-message, focusing on: tailored psychoeducation, motivation and efficacy to change sleep, extending sleep duration, and regularizing sleep timing across the week. Sleep monitoring is proposed to last the same duration as the targeted intervention in this arm.
61994674|NCT01436812|ACTIVE_COMPARATOR|positive end expiratory pressure|applying PEEP 10cmH2O during operation just applying TV=IBW\*6-8ml IBW = (male; 50+0.91\[(Ht-cm)-152.4\], female; 45.5 +0.91\[(Ht-cm)-152.4\], RR 8-12/min,
61994675|NCT05748340|OTHER|Control group|21normal infant aged 3-6 months
61994676|NCT05748340|OTHER|Group a|21 patient of unilateral cleft lip had mishra technique repair
61994677|NCT05748340|OTHER|Group b|21 patient of unilateral cleft lip had modified Millard technique repair
62567757|NCT01292512|EXPERIMENTAL|Intervention group|"A) Professional level. B) Patient level.~Intervention~Professional level:~General Practitioners (GP) receive updated information on bereavement related symptoms, how to identify complicated grief, and the Dual Process Model (DPM) of coping.~GPs receive suggestions on how to provide psycho-educational support for the patient.~GPs are informed about the results of the initial assessment of their patient prognostic screening for complicated grief.~Patient level:~Patients receive updated information on bereavement related symptoms, the DPM of coping and suggestions on when to seek professional help.~Patients are informed of the results of their initial assessment of their prognostic grief screening.~Patients are encouraged to contact their GP if they worry about handling their bereavement reaction."
61994678|NCT03513484|EXPERIMENTAL|Treatment (nintedanib, azacitidine)|Participants receive nintedanib PO BID on days 1-28 and azacitidine IV or SC on days 1-7. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, participants may discontinue treatment, receive nintedanib every 4-8 weeks, or receive nintedanib and azacitidine every 4-8 weeks.
61994679|NCT05715203||Syndromic TAA|Subjets with clinical or genetic diagnosis of syndromic thoracic aortic aneurysms
62168949|NCT04466917|EXPERIMENTAL|ABP 215|"Subjects will be randomized to receive ABP 215 every 3 weeks (Q3W) for 6 cycles.~All subjects will receive carboplatin and paclitaxel after the ABP 215 IV infusion every Q3W for at least 4 and not more than for 6 cycles."
62168950|NCT04466917|ACTIVE_COMPARATOR|Bevacizumab|"Subjects will be randomized to receive Bevacizumab every 3 weeks (Q3W) for 6 cycles.~All subjects will receive carboplatin and paclitaxel after the Bevacizumab IV infusion every Q3W for at least 4 and not more than for 6 cycles."
62168951|NCT05070637|EXPERIMENTAL|No-touch laparoscopic radical nephrectomy|Group A patients will undergo a no-touch laparoscopic radical nephrectomy, with the dissection being done through the Gerota's fascia plane until exposure of the corresponding great vessel (vena cava on the right side, and aorta on the left side) is obtained. The renal pedicle will be directly isolated, and ligated using Weck® clips with no kidney manipulation.
62168952|NCT05070637|ACTIVE_COMPARATOR|Conventional laparoscopic radical nephrectomy|Group B patients will undergo a conventional laparoscopic radical nephrectomy approach, starting with opening of the Gerota's fascia, identification of the ureter, traction on the peri-renal fat below the ureter while dissecting cephalad until the renal pedicle is reached. The renal pedicle will then be isolated while maintaining traction on the kidney, and peri-renal fat, and ligated using Weck® clips.
62168953|NCT05070637|OTHER|Laparoscopic total nephrectomy control arm|Control arm in which a laparoscopic total nephrectomy will be performed in patients with hypo-functioning kidneys, and no renal cell carcinoma.
62168954|NCT03093597|ACTIVE_COMPARATOR|virgin coconut oil|All subjects will apply virgin coconut oil to a previously randomize section of the skin on the left or right forearm.
62168955|NCT03093597|ACTIVE_COMPARATOR|virgin jojoba oil|All subjects will apply virgin jojoba oil to a previously randomize section of the skin on the left or right forearm
62168956|NCT03093597|ACTIVE_COMPARATOR|virgin almond oil|All subjects will apply virgin almond oil to a previously randomize section of the skin on the left or right forearm
62168957|NCT03093597|ACTIVE_COMPARATOR|white petrolatum ointment|All subjects will apply white petrolatum ointment to a previously randomize section of the skin on the left or right forearm.
62168958|NCT05394727|EXPERIMENTAL|Needle-free injection first group|Use needle-free syringe for insulin injection in patients for 2 weeks, then replace it with conventional insulin pen injection for another 2 weeks.
62168959|NCT05394727|OTHER|Traditional insulin pen first group|Use conventional insulin pen for insulin injection in patients for 2 weeks, then replace it with needle-free syringe injection for another 2 weeks.
62168960|NCT04686370|ACTIVE_COMPARATOR|sandblasted acid-etched implants|implant will be installed intraforaminal
62168961|NCT04686370|EXPERIMENTAL|laser treated implants|implant will be installed intraforaminal
62168962|NCT01026103|EXPERIMENTAL|Tri Staple|This is a single arm study.
61994680|NCT05715203||Non-syndromic TAA|Subjets without clinical or genetic diagnosis of syndromic thoracic aortic aneurysms
62168963|NCT03145519|EXPERIMENTAL|OptiVein|Placement of IV-catheter and administration of treatment using OptiVein catheter.
62168964|NCT03145519|ACTIVE_COMPARATOR|Vasofix Certo|Placement of IV-catheter and administration of treatment using Vasofix Certo catheter.
62168965|NCT06182800|EXPERIMENTAL|Adebrelimab Combined with Bevacizumab and Docetaxel|"Adebrelimab: 1200 mg Adebrelimab is given on day 1 of each cycle, with 1 dosing cycle every 3 weeks. The dosing time window may be ±5 days, but within 72 hours before each dose, subjects must complete an examination including all clinically necessary tests to assess tolerability of continued dosing, in addition to imaging. Subjects are also advised to remain in the hospital for observation 72 hours after the first dose.~Bevacizumab: 7.5 mg/kg Bevacizumab administered intravenously on day 1 of each cycle, with 1 dosing cycle every 3 weeks.~Docetaxel: 60-75 mg/m2 Docetaxel is given on days 1 of each cycle by intravenous infusion for 1 dosing cycle every 3 weeks."
62168966|NCT06539520|EXPERIMENTAL|Aerobic Training Group A|Forty post-stroke patients will receive aerobic training program, plus selected physical therapy program.
62168967|NCT06539520|OTHER|Control Group B|Forty post-stroke patients will receive selected physical therapy program.
62168968|NCT05465278|EXPERIMENTAL|Alirocumab|Every patient enrolled witll receive treatment witl Alirocumab
62168969|NCT04881045|EXPERIMENTAL|Dose Escalation (Part 1)|Participants will receive PF-07257876 at escalating dose levels.
62168970|NCT04881045|EXPERIMENTAL|Dose Expansion (Part 2) - Cohort 1 (NSCLC)|Participants with non-small cell lung cancer (NSCLC) will receive PF-07257876 at the recommended dose from Part 1.
62168971|NCT04881045|EXPERIMENTAL|Dose Expansion (Part 2) - Cohort 2 (SCCHN)|Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive PF-07257876 at the recommended dose from Part 1.
62562202|NCT06294717|EXPERIMENTAL|Experimental Group|Progressive relaxation exercises will be explained and taught to the puerperant after cesarean section. Experimental Group (in the group where progressive relaxation exercises were applied); The first application will be made at the 8th postoperative hour. Before the application, the Puerperal Identification Form, Beck Anxiety Scale, Visual Analogue Scale (VAS) and Physiological Parameters forms will be filled out. Starting from the 8th post-op hour, the first, second and third applications will be made eight hours apart within a 48-hour period. On the second day, progressive relaxation exercises will be performed once, twice and three times at eight-hour intervals. At the end of the second day, the Postpartum Definition Form, Beck Anxiety Scale, Visual Analogue Scale (VAS) and Physiological Parameters forms will be filled in again.
62562203|NCT06294717|NO_INTERVENTION|Control Group|"No application will be made with participants in the control group. At the 8th postoperative hour, the Puerperal Identification Form, Beck Anxiety Scale, Visual Analogue Scale (VAS) and Physiological Parameters forms will be filled out. These participants will be asked not to engage in regular physical activity or sports for 2 days and not to make any changes in their living habits.~During the interview two days later, the Postpartum Identification Form, Beck Anxiety Scale, Visual Analogue Scale (VAS) and Physiological Parameters forms will be filled out again by the postpartum women."
62562204|NCT06072274|EXPERIMENTAL|Dementia VR education|The experimental group will participate in a dementia educational program combining VR lasting approximately 2-3 hours.The virtual reality educational modules predominantly offer first-person narratives that delineate various symptoms associated with dementia.
62562205|NCT06072274|NO_INTERVENTION|Traditional dementia education (lecture)|The control group will receive traditional education on dementia which is primarily taught by instructors.
62562206|NCT03686605||Cancer pain patients|
62562207|NCT00562848|EXPERIMENTAL|Subjects enrolled in single dose escalation cohort|Subjects will receive escalated doses of GSK962040 with a starting dose of 1 milligrams along with placebo in fasted state.
62562208|NCT00562848|EXPERIMENTAL|Subjects enrolled in gastric emptying cohort|Subjects will receive escalated doses of GSK962040 with a starting dose of 1 milligrams along with placebo in fasted state.
62168972|NCT02876003|EXPERIMENTAL|G-202 (Mipsagargin)|G-202 (Mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
62168973|NCT02609035|EXPERIMENTAL|Intervention|Patients who are either appointment-based medication synchronization calls, refill ready calls, or refill reminder calls at the pharmacy who have been identified as missing at least one vaccination. These patients will receive a telephonic prompt to get a vaccination.
62168974|NCT02609035|NO_INTERVENTION|Control|Patients who are either appointment-based medication synchronization calls, refill ready calls, or refill reminder calls at the pharmacy who have been identified as missing at least one vaccination. These patients will receive usual pharmacy care.
62562209|NCT00562848|EXPERIMENTAL|Subjects enrolled in gastro-enteral contractility cohort|Eligible subjects will receive GSK962040 and placebo in the fasted state in crossover manner.
62769785|NCT04863196|EXPERIMENTAL|Laser therapy Treatment Group|"Treatment evaluation and follow-up will be done for 15 days. The application of the laser at first will be done three times a week.~The application will be by points with continuous or selective technique, which will depend on each patient. The device is a pen type that will be by contact or without contact with the lesion, irradiation and the dose will be according to the calculation for each patient, using power in milliwatt and fluency, where the dose will vary according to area and patient, and may vary from 0.1 to 1J / cm² as calculated.~The laser tip will be disinfected before each use with 70% alcohol and later coated with plastic film. Patients, companion and operator will wear specific eye protection glasses and all biosafety rules will be followed during therapy."
62562210|NCT04221490|EXPERIMENTAL|Treatment|Treatment with the Edwards EVOQUE Tricuspid Transcatheter Valve Replacement System
62562211|NCT05460338|ACTIVE_COMPARATOR|Weekly Cholecalciferol Group|25 hemodialysis patients on oral cholecalciferol 50.000IU Cholecalciferol, once weekly, taken post-hemodialysis session for 3 months.
62168975|NCT02467231||Exposed|Females ages 11-35 to be exposed to alkylating agent chemotherapy
62168976|NCT02093117|EXPERIMENTAL|Recruitment maneuver|The recruitment maneuver will involve application of continuous positive airway pressure of 30 cm of water for 30 seconds.
62168977|NCT02093117|SHAM_COMPARATOR|Sham recruitment maneuver|The sham recruitment maneuver will involve application of continuous positive airway pressure of 5 cm of water for 30 seconds.
62168978|NCT05697393|ACTIVE_COMPARATOR|Shaker Pressure Band GERD patients with external laryngeal pressure|One week of Shaker pressure band
62168979|NCT05697393|PLACEBO_COMPARATOR|Shaker Pressure Band GERD patients without external laryngeal pressure|One week of sham Shaker pressure band (no external laryngeal pressure)
62562212|NCT05460338|ACTIVE_COMPARATOR|Monthly Cholecalciferol Group|25 hemodialysis patients on Oral 200.000IU Cholecalciferol, once monthly, for 3 months.
62168980|NCT02156479||Allo-HSCT recipients|Patients receiving an allogeneic hematopoietic stem cell transplantation for the first time, being either CMV seropositive or receiving a graft from a CMV seropositive donor or both, donor and recipient are CMV seropositive
62168981|NCT02113150|ACTIVE_COMPARATOR|remifentanil|remifentanil, short acting opioid
62168982|NCT02113150|ACTIVE_COMPARATOR|ketamine|ketamine, intravenous anesthetic
62168983|NCT02797795|EXPERIMENTAL|NEV801|"Part A - Dose escalation and de-escalation for the determination of the Maximum tolerated dose. All subjects will receive NEV801 intravenously on days 1, 8, 15 and 22 during each 28-day cycle.~Part B - Subjects will receive NEV801 at or below the highest tolerable dose from Part A."
62168984|NCT04053517||Observational (questionnaire administration)|Patients complete questionnaires about financial state and quality of life over 15 minutes. Patients' medical chart is also reviewed.
62168985|NCT02651961|ACTIVE_COMPARATOR|One stage exchange|One stage exchange of the chronically infected implant
62562213|NCT01323517|EXPERIMENTAL|Ipilimumab, Melphalan and Dactinomycin|This is a single-institution phase II trial with a primary outcome of progression free survival (PFS).
62562214|NCT02811510|ACTIVE_COMPARATOR|THC|10 mg Dronabinol will be administered orally.
62562215|NCT02811510|PLACEBO_COMPARATOR|Placebo|Placebo pill (no active cannabinoids).
62562216|NCT00666328|EXPERIMENTAL|clevidipine|This will be a single-arm study with no reference therapy.
62562217|NCT04089579|EXPERIMENTAL|MSC|One dose of 6x10e6 cells/kg administered intravenously.
62562218|NCT04089579|PLACEBO_COMPARATOR|Placebo Infusion|Placebo infusion
62168986|NCT02651961|ACTIVE_COMPARATOR|Two stage exchange|Two stage exchange of the chronically infected implant
62168987|NCT03110692|NO_INTERVENTION|Usual practice (control)|The usual practice group will rollover to the intervention arm after 3 months.
62390638|NCT04084275|EXPERIMENTAL|experimental group|Levine's conservation model was used as the theoretical framework for this study. A literature review was used to determine the contents of the intervention program. A nursing care program which consisted of 8 sessions, the first of which was at the hospital and the others at the homes of puerpera and which were held at different times and lasted 12 weeks in total, based on Levine's Conservation Model was provided to the women in the intervention group. Each session lasted approximately 60-120 minutes, according to the educational and practical contents.The puerpera were given trainings on different subjects based on the module during each session. For these trainings, the investigators prepared, in the light of the literature data, leaflets containing information about breastfeeding, personal hygiene, fatigue, nutrition and pilates exercises
62390639|NCT04084275|NO_INTERVENTION|control group|The puerpera in the control group received only the standard nursing care given after birth. Standard nursing care contain solely breastfeeding training. The puerpera in the control group were visited before they were discharged from the hospital to obtain their contact information and to administer them the pretest. A home visit at the end of postpartum month 3 was also planned and they were administered the posttest. After collecting the posttest data, the trainings given to the women in the intervention group on nutrition, sleep, fatigue and pilates exercises were also given to the women in the control group in consideration of the ethical dimension of the study; they were actively trained on pilates exercises by the investigator and the relevant leaflets were given to them by the end of their trainings.
62390640|NCT02961231|ACTIVE_COMPARATOR|PCV 2p+1|PCV 2p+1 schedule: WHO recommended 2 primary at 2, 4 months and a booster dose at 12 month
62390641|NCT02961231|ACTIVE_COMPARATOR|PCV 3p+0|PCV 3p+0 schedule: WHO recommended 3 primary doses at 2, 3 and 4 months
62562219|NCT04577560|EXPERIMENTAL|MII with PB biopsy|Five selected MII will undergo sequential polar biopsy; on day 0 \[PB1\] (36-42 hours post trigger injection) and if fertilization occurred on day 1 \[PB2\] (17-20 hours post ICSI). On day 5, 6 or 7, the resulting blastocyst will be biopsied.
62562220|NCT04577560|EXPERIMENTAL|MII with no PB biopsy|MII will not go under polar body biopsy. On day 5, 6 or 7, the resulting blastocyst will be biopsied.
62562221|NCT01109693|ACTIVE_COMPARATOR|Continue sertraline|Continue sertraline at the dosage at 3 weeks
62562222|NCT01109693|ACTIVE_COMPARATOR|Augment with mirtazapine|Add mirtazapine to sertraline
62562223|NCT01109693|ACTIVE_COMPARATOR|Switch to mirtazapine|Stop sertraline and switch to mirtazapine
62390642|NCT02961231|EXPERIMENTAL|PCV 1p+1|PCV 1p+1 schedule: one primary dose at 2 month and a booster at 12 month
62390643|NCT02961231|EXPERIMENTAL|PCV 0p+1|PCV 0p+1 schedule: no primary dose, only a booster at 12 month
62390644|NCT02943876|NO_INTERVENTION|Control|Serves as a control group, receiving generic information about depression and self-help.
62562224|NCT00632060|NO_INTERVENTION|1|Standard Care Control Group - Participants randomized to the standard care group will continue their use of non-prescription or prescription medication and reduced duty loads, as prescribed by the credentialed medical provider.
62562225|NCT00632060|EXPERIMENTAL|2|Manual / Manipulative Therapy Group: Participants randomized to the M/MT group will receive a course of M/MT along with standard care. The patient will see the chiropractor twice a week for the entire course of the study, regardless of manipulation or not.
62562226|NCT05361590|EXPERIMENTAL|Study group|Subjects in the study group will use the Lumoral device once a day according to the verbal and written instructions provided to them. In addition, they will brush their teeth twice daily in their customary manner while using the provided sonic toothbrush and regular toothpaste.
62168988|NCT03110692|EXPERIMENTAL|Intervention|Default initiation: Introduce a default prescription template in the palliative setting in order to reduce unnecessary daily image guided radiation.
62168989|NCT00588341|EXPERIMENTAL|Treatment|
62390645|NCT02943876|EXPERIMENTAL|Intervention|Serves as an intervention group, receiving personalized depression risk information determined by the sex-specific risk calculators, and generic information about depression and self-help.
62390646|NCT03846323|EXPERIMENTAL|Visiting policies: open 24h/24|Visiting policies: 24 hours a day, 7 days a week
62390647|NCT03846323|OTHER|Restriction of visiting policies|Restriction of visiting policies \< 6 hours
62390648|NCT00386035||1: DC Group|HIV infected participants who will stop or defer ART until the CD4 cell count drops below 250 cells/mm3 and who discontinue ART when CD4 cell count reaches above 350 cells/mm3. Participants are followed by episodic ART based on CD4 cell count.
62562227|NCT05361590|ACTIVE_COMPARATOR|Control group|Subjects in the control group will brush their teeth in their customary manner twice daily while using the provided sonic toothbrush and regular toothpaste. They will not receive any additional intervention.
62562228|NCT02858791||Healthy Controls|"Subjects are made up of healthy adults~Interventions:~Venous blood drawn before and after cardiopulmonary exercise test Will have a resting 12 lead EKG Undergo pulmonary function test"
62562229|NCT02858791||Affected|"Subjects have Pulmonary Hypertension Subjects have Pulmonary hypertension with Interstitial lung disease Subjects have Interstitial lung disease~Interventions:~Venous blood drawn before and after cardiopulmonary exercise test Will have a resting 12 lead EKG Undergo pulmonary function test"
62562230|NCT01400477|EXPERIMENTAL|DMXB-A-SR|Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR), 3-2, 4 dimethoxybenzylidene anabaseine sustained release (GTS-21)
62562231|NCT01400477|PLACEBO_COMPARATOR|Arm #2: Placebo Comparator|Inert capsule to resemble active drug.
62168990|NCT00126555|EXPERIMENTAL|Stratum I (Gefitinib, Radiotherapy, Surgery)|"Resectable Strata: Induction Gefitinib (60 days), Surgery followed 3-6 weeks later by daily Radiotherapy 5 days a week for approximately 6-7 weeks then after 4 weeks restart Maintenance Gefitinib for up to additional 12 months post radiation.~Gefitinib Induction Phase starting dose 250 mg/day, possible doubling to 500 mg/day for no response Day 15; Maintenance dose post radiation starts at same dose level as last dosing of Induction Phase."
62562232|NCT04959721|EXPERIMENTAL|Injection group|Patients in the injection group will be injected 10 mg (0.25 mL) of triamcinolone acetonide, mixed with 0.25 mL of 0.125% bupivacaine and 0.5 mL of normal saline.
62562233|NCT05993364|ACTIVE_COMPARATOR|Control group|The control group receive a standard rehabilitative treatment to improve the secretions management and the respiratory function. Besides, the control group receives a traditional rehabilitative treatment carried out by the speech and language pathologist.
62562234|NCT05993364|EXPERIMENTAL|Experimental group|The experimental group receives the same standard rehabilitative treatment performed with the control group. In addition, sessions with the EFA technology are provided.
62562235|NCT02000492|EXPERIMENTAL|Training|Football, circuit training or running 5x12 minutes or 3x 40 minutes
62562236|NCT02000492|NO_INTERVENTION|Control|
62562237|NCT04653038|EXPERIMENTAL|Unresectable, recurrent or metastatic melanoma|Cohort1: patients with unresectable, recurrent or metastatic melanoma who have failed prior immune checkpoint inhibitor therapy
62562238|NCT04653038|EXPERIMENTAL|Untreated mucosal or acral lentiginous melanoma|Cohort2: patients with untreated, unresectable recurrent or metastatic, mucosal or acral lentiginous melanoma
62562239|NCT03182231|EXPERIMENTAL|RYGB patients|Patients who will receive a RYGB surgery
62562240|NCT01240759|EXPERIMENTAL|S-707106 Dose A|One S-707106 A tablet + 3 Placebo A tablets
62562241|NCT01240759|EXPERIMENTAL|S-707106 Dose B|One S-707106 B tablet + 3 Placebo A tablets
62562242|NCT01240759|EXPERIMENTAL|S-707106 Dose C|S-707106 Dose C = Four S-707106 B tablets
62562243|NCT01240759|ACTIVE_COMPARATOR|Metformin|The standard of care dose of metformin for the individual patient + 3 Placebo A tablets
62769786|NCT04863196|ACTIVE_COMPARATOR|Barrier Dust Treatment Group|"The evaluation and follow-up of the treatment will be done for 15 days. The principle application will be made three times a week using the protective barrier powder over the entire affected area, forming a protective barrier when adhering to the skin.~For all patients, the injured area will be previously cleaned with 0.9% saline solution."
61994681|NCT02963649|EXPERIMENTAL|drug-eluting balloon IN.PACT 014|product is indicated for PTA in patients with obstructive disease of peripheral arteries with paclitaxel drug - elution.
62390649|NCT00386035||2: VS Group|HIV infected participants who continue ART to keep viral loads as low as possible, regardless of CD4 cell count.
62390650|NCT00469391|EXPERIMENTAL|GI Sleeve|medical device that mimics gastric bypass mechanism for weight-loss
62562244|NCT05630573|EXPERIMENTAL|TNM001 Injection dose 1|low dose administered
62562245|NCT05630573|EXPERIMENTAL|TNM001 Injection dose 2|medium dose administered
62562246|NCT05630573|EXPERIMENTAL|TNM001 Injection dose 3|high dose administered
62562247|NCT05630573|PLACEBO_COMPARATOR|placebo|placebo administered
62562248|NCT04785378|EXPERIMENTAL|Study Group|
62562249|NCT02716961|NO_INTERVENTION|Monotherapy|Barely epirubicin was instilled after TURBT. Epirubicin was immediately instilled in 24h after TURBT. Instillation was conducted regularly for a year: once in a week for 8 times, once in two weeks for 8 times, once in a month for 6 times.
62567758|NCT01292512|OTHER|Control group|Treatment as usual (in the Danish health care system).
62562250|NCT02716961|EXPERIMENTAL|Combination|Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. Intervention: GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
62562251|NCT03908125|OTHER|Continuous Glucose Monitoring Device|
62562252|NCT04933383|EXPERIMENTAL|AQ001S 0.125 mg/ml|AQ001S 0.125 mg/ml is a budesonide inhalation solution administered by nebulization once daily.
62562253|NCT04933383|ACTIVE_COMPARATOR|budesonide inhalation suspension 0.125 mg/ml|Budesonide 0.125 mg/ml is a budesonide inhalation suspension administered by nebulization once daily.
62562254|NCT06571110|ACTIVE_COMPARATOR|Traditional acupuncture|During TA, 9 acupuncture needles (Seirin 0.25 · 50 mm) are inserted at GV20,earShenmen,LI4,LI11,SP6,LR3,GB34,and bilateral ST 36. Needle insertion depth is approximately 2 cm for all TA points except for DU 20 and ear Shenmen, which have shallower insertion depths. All needles below the neck level are manually manipulated to elicit De Qi sensations.
62562255|NCT06571110|SHAM_COMPARATOR|Sham acupuncture|SA participants experience a non-skin penetrating pricking sensation at 9 non-acupuncture point locations, sham intervention did not penetrate the skin and was designed to not elicit De Qi. somatosensory component generated by this procedure would be likely to be less than the skin penetrating-TA protocol that elicited De Qi. The sham locations were within similar body locations as the TA points; however, the SA location is not on known acupuncture points or meridians.
62562256|NCT01404767|ACTIVE_COMPARATOR|Metoprolol oral dose or Placebo infusion|
62562257|NCT01404767|EXPERIMENTAL|Esmolol infusion or Placebo oral dose|
62562258|NCT02338648|EXPERIMENTAL|SUN-131 1.5% TDS|Subjects will be randomly assigned to receive SUN-131 1.5% TDS for the affected eye. All patches will be worn for 16±4 hours each day for 21 days.
62562259|NCT02338648|PLACEBO_COMPARATOR|Placebo TDS|Placebo Patch for Blinding Purposes
62769787|NCT01793259|OTHER|prefilled pen then prefilled syringe|weekly methotrexate injection with a prefilled pen during 3 weeks and subsequently with the prefilled syringe the last 3 weeks
62182726|NCT05195892|EXPERIMENTAL|Sequence 3|Participants will receive a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 1 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 3.
62390651|NCT00469391|SHAM_COMPARATOR|Sham Control|
62562260|NCT03359655|ACTIVE_COMPARATOR|Rectal misoprostol|200 mcg of misoprostol will be administered rectally- 2 hours previously. This intervention will be performed by a third party health professional who will be blinded to the procedure.
62562261|NCT03359655|ACTIVE_COMPARATOR|Rectal hyoscine butyl bromide|10 mg hyoscine butyl bromide administered rectally- 2 hours previously. This intervention will be performed by a third party health professional who will be blinded to the procedure.
62562262|NCT03359655|NO_INTERVENTION|Sham administration|A rectal examination will be performed by a third party health professional who will be blinded to the procedure. No drug will be administered
62562263|NCT06078124|EXPERIMENTAL|Sibling Support for Adolescent Girls in Emergencies (SSAGE)|Participants in this arm will participate in the Sibling Support for Adolescent Girls in Emergencies (SSAGE) intervention, along with three family members, for twelve weeks
62562264|NCT06078124|NO_INTERVENTION|Control arm|Care as usual
62562265|NCT02749188|OTHER|bladder stimulation|Bladder stimulation as a noninvasive technique of urine collection. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes.
62562266|NCT04413786|EXPERIMENTAL|oxytocin group|male subjects with oxytocin treatment
62562267|NCT04413786|PLACEBO_COMPARATOR|placebo group|male subjects with placebo treatment
62562268|NCT02957383|EXPERIMENTAL|wavelength|Wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)
62769788|NCT01793259|OTHER|prefilled syringe then prefilled pen|weekly methotrexate injection with a prefilled syringe during 3 weeks and subsequently with the prefilled pen the last 3 weeks
62769789|NCT03958708|EXPERIMENTAL|Treatment Arm|
62769790|NCT03198806|ACTIVE_COMPARATOR|Control group in supine position|"Intervention:~- Only treadmill aerobic exercise with 60 min recovery in supine position"
62390652|NCT03380806|ACTIVE_COMPARATOR|Arm 1|Conventional Radiotherapy (CRT) Prostate Boost Pelvic Radiation LHRH agonist
62390653|NCT03380806|EXPERIMENTAL|Arm 2|Stereotactic Body Radiotherapy (SBRT) Prostate Boost Pelvic Radiation LHRH agonist
62390654|NCT05943340|NO_INTERVENTION|Control group|Patients that are undergoing immobilization period after a distal radius fracture.
62390655|NCT05943340|EXPERIMENTAL|Experimental group|Patients that are undergoing immobilization period after a distal radius fracture.
62390656|NCT04697199|PLACEBO_COMPARATOR|Placebo group|patients received scaling and root planing using hand and ultrasonic instruments.
62390657|NCT04697199|ACTIVE_COMPARATOR|Probiotic group|"patients received SRP and by using blunt syringe, subgingival delivery of 1ml of probiotic suspension was applied to these sites at baseline (immediately after SRP), one, two and four weeks. Periodontal dressing was applied after placement of the drug.~After placement of the drug, patients were instructed to keep away from chewing hard or sticky food, brushing near the treated areas, or using any interdental aids for 24 hours."
62390658|NCT05038306|ACTIVE_COMPARATOR|Chinese Medicine|
62390659|NCT05038306|PLACEBO_COMPARATOR|Placebo|
62390660|NCT01289964|NO_INTERVENTION|Waiting list control group|No treatment within the study period, were allowed to continue physiotherapy and medication. Were offered the treatment after finishing the study
62390661|NCT01289964|ACTIVE_COMPARATOR|Treatment group|Received the 5 cupping treatments, application twice a week, non standardised application - individual determinations of trigger points
62562269|NCT02957383|EXPERIMENTAL|intensity|Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2).
62562270|NCT04780893|ACTIVE_COMPARATOR|Active VeNS|
62769791|NCT03198806|EXPERIMENTAL|Hydration group in supine position|"Interventions:~* Treadmill aerobic exercise with 60 min recovery in supine position~* Water intake"
62390662|NCT01738906|EXPERIMENTAL|Alcohol placebo and MSF|175 mL orange juice with 31 g Fantomalt maltodextrin and modified sham feeding of 40 g butter cake
62390663|NCT01738906|EXPERIMENTAL|Alcohol and MSF|65 mL vodka with 135 mL orange juice (ca 20 g alcohol)and modified sham feeding of 40 g butter cake
62390664|NCT01738906|EXPERIMENTAL|Alcohol placebo and consumption|175 mL orange juice with 31 g maltodextrin and consumption of 40 g butter cake
62390665|NCT01738906|EXPERIMENTAL|Alcohol and consumption|65 mL vodka with 135 mL orange juice and consumption of 40 g butter cake
62390666|NCT01738906|EXPERIMENTAL|Alcohol placebo and control|175 mL orange juice with 31 g maltodextrin and no oral exposure to butter cake
62390667|NCT01738906|EXPERIMENTAL|Alcohol and control|65 mL vodka with 135 mL orange juice and no oral exposure to butter cake
62562271|NCT04780893|SHAM_COMPARATOR|Sham VeNS|
62769792|NCT03198806|ACTIVE_COMPARATOR|Control group in orthostatic position|"Intervention:~- Only treadmill aerobic exercise with 10 min recovery in orthostatic position"
62769793|NCT03198806|EXPERIMENTAL|Hydration group in orthostatic position|"Interventions:~* Treadmill aerobic exercise with 10 min recovery in orthostatic position~* Water intake"
62769794|NCT05649592||Lumbar disc herniation patients|
62769795|NCT05649592||healthy volunteers|
62769796|NCT04566146|OTHER|45 patients with subacromial impingement syndrome|Forty-five patients between the age 18 and 45 years old, will be referred by orthopaedist as subacromial impingement syndrome (stage Ⅰ and ⅠⅠ Neer's classification)
62769797|NCT05583760|EXPERIMENTAL|Experimental: Osteopathic manipulation TUG for scaphoid bone|
62769798|NCT05583760|SHAM_COMPARATOR|Sham group: Sham osteopathic manipulation TUG for scaphoid bone|
62769799|NCT06523062|OTHER|no reproducibility of OWCET|
62769800|NCT06523062|NO_INTERVENTION|reproducibility of OWCET|
62769801|NCT01583816|EXPERIMENTAL|Resiquimod Gel 0.03% or placebo|Resiquimod gel 0.03% or placebo, once daily, 3x per week for 4 weeks, break of 8 weeks, repeated once
62769802|NCT01583816|EXPERIMENTAL|Resiquimod or placebo|Once daily, 7x within 2 weeks, break of 8 weeks, cycle repeated once
62769803|NCT01583816|EXPERIMENTAL|Resiquimod or vehicle|Once daily, 5x for 1 week, break of 8 weeks, cycle repeated once
62769804|NCT01583816|EXPERIMENTAL|Resiquimod gel 0.01%|Once daily, 3x/week until occurrence of biological endpoint or for a maximum of 8 weeks (no repetition of cycle), 8 weeks follow-up
62390668|NCT01657773||colorectal cancer, without nonalcoholic fatty liver disease|Patients were performed colonoscopy examination for colorectal cancer and who had been foud colorectal cancer proven by biopsy.Then the colorectal cancer patients who had not been diagnosed with nonalcoholic fatty liver disease was based on blood tests and abdomen ultrasound examination.
62390669|NCT01657773||colorectal cancer, with nonalcoholic fatty liver disease|Patients were performed colonoscopy examination for colorectal cancer and who had been foud colorectal cancer proven by biopsy.Then the colorectal cancer patients who had been diagnosed with nonalcoholic fatty liver disease was based on blood tests and abdomen ultrasound examination ultrasonography.
62390670|NCT00887601|EXPERIMENTAL|Part I|Subjects will receive placebo, MK3134, and donepezil in one of four treatment sequences.
62390671|NCT00887601|EXPERIMENTAL|Part II|Subjects will receive placebo and three different doses of MK3134 (1 mg, 5 mg, and 25 mg) in one of four treatment sequences.
62390672|NCT00611351|EXPERIMENTAL|Unrelated Donor Allogeneic|Matched unrelated donor allogeneic stem cell transplantation with a conditioning regimen of targeted busulfan, cyclophosphamide and thymoglobulin.
62390673|NCT03608189||ACL injury subjects|Subjects with anterior cruciate ligament injuries.
62562272|NCT04259671|EXPERIMENTAL|Intervention- My Autism Passport App|"Families will be given the application to upload to their mobile device and will be provided information on how to use the App by the research team. The contact information for a member of the research team who will be able to provide technical support will be available on the consent form. Families will use the mobile application for a total of 18 months.~Given that this is a pragmatic trial of a tool that tracks services, it also may be used to communicate service access to other providers."
62562273|NCT04259671|NO_INTERVENTION|Control-Standard of care|Families in the control group will continue with standard of clinical care, and receive any of the usual supports their clinic and region provides, including access to physicians, service navigators, social workers, nurses, etc.
62769805|NCT01583816|EXPERIMENTAL|Resiquimod gel 0.03%|Once daily, 3x/week until occurrence of biological endpoint or for a maximum of 8 weeks (no repetition of cycle), 8 weeks follow-up
62769806|NCT06256705|EXPERIMENTAL|PET-MRI|PET-MRI added in care pathway
62769807|NCT02060032|ACTIVE_COMPARATOR|Atorvastatin|1.2% atorvastatin local drug delivery
62769808|NCT02060032|SHAM_COMPARATOR|Simvastatin|1.2% simvastatin local drug delivery
62769809|NCT02060032|PLACEBO_COMPARATOR|Placebo|Placebo local drug delivery
62769810|NCT01472211|EXPERIMENTAL|intervention filter|children consuming purified and zinc enriched water delivered by a household-based water filter
62769811|NCT01472211|PLACEBO_COMPARATOR|placebo filter|children consuming purified water delivered by a household-based water filter
62769812|NCT01472211|ACTIVE_COMPARATOR|disinfection tablets|children will consume water treated with government promoted disinfection tablets (aquatabs)
62769813|NCT05787106|EXPERIMENTAL|PAtients withdrawn from alcohol|
62769814|NCT02913768|ACTIVE_COMPARATOR|Ondansetron|Intravenous Ondansetron 4 mg diluted in 10 mL of normal saline over 1 min, 5 min before spinal anaesthesia
62769815|NCT02913768|PLACEBO_COMPARATOR|control|Normal Saline 10 mL over 1 min, 5 min before spinal anaesthesia
62769816|NCT00584129|EXPERIMENTAL|1|Patients will receive pre-treatment swallowing exercises.
62769817|NCT00584129|ACTIVE_COMPARATOR|2|Post-treatment swallowing exercises.
62769818|NCT00918554|EXPERIMENTAL|Methotrexate|
62769819|NCT00918554|PLACEBO_COMPARATOR|Placebo|
62390674|NCT05959876|EXPERIMENTAL|Training group|Face-to-face perineal care training will be given to the relatives of the patients in the training group in the determined common time period. During the trainings, the presentation prepared in the power point program and the content of perineum care will be conveyed by the researcher in two 30-minute sessions using plain lecture, case study and question and answer techniques.
62562274|NCT05628597|ACTIVE_COMPARATOR|Fos Biomedical patch product|Participants will be randomized to 1 of 2 sequence permutations of the Fos Biomedical patch product and a placebo patch product, which will begin after randomization.
62562275|NCT05628597|PLACEBO_COMPARATOR|Fos Biomedical product: placebo|Participants will be randomized to 1 of 2 sequence permutations of the Fos Biomedical patch product and a placebo patch product, which will begin after randomization.
62562276|NCT02227563|EXPERIMENTAL|Active tDCS|active tDCS
62562277|NCT02227563|SHAM_COMPARATOR|control|sham (placebo) tDCS condition
62562278|NCT02276248|EXPERIMENTAL|radiotherapy+chemotherapy|Radiotherapy technique: Intensity-modulated radiation therapy total dose: 50 to 56 grays per fraction: 2 grays GDP chemotherapy: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
62562279|NCT04760080||Patients with a metastatic melanoma treated by dabrafenib/trametinib and hydroxychloroquine.|"Patients with a metastatic melanoma treated by dabrafenib/trametinib and hydroxychloroquine after acquired resistance to dabrafenib/trametinib.~Patients treated~* for a BRAF mutated metastatic melanoma in Pr Dalle's dermatology ward at Centre Hospitalier Lyon Sud,~* From January 2008 to June 2020~* who received a treatment by immunotherapy before receiving a treatment by dabrafenib/trametinib~* who became resistant to dabrafeib/trametinib~* and received after disease progression a treatment by dabrafenib/trametinib and hydroxychloroquine"
62769820|NCT05490108|EXPERIMENTAL|ZR202-CoV - Phase 1|Two doses of SARS-CoV-2 adjuvanted recombinant protein vaccine (prototype), 1 dose each on Day 0 and 28.
62390675|NCT05959876|ACTIVE_COMPARATOR|Control group|The participants in the control group will not be interfered with by the researcher during the research.
62390676|NCT02898662|EXPERIMENTAL|AZD1419|Dose adaption of AZD1419, 4 mg or 8 mg or 1 mg based on occurence of AE's
62390677|NCT02898662|PLACEBO_COMPARATOR|Placebo|Matching placebo
62390678|NCT00850356||Bariatric Surgery Patient (Sx)|Participants who are patients in an Adult Weight Management Clinic (AWMC) and undergo bariatric surgery.
62390679|NCT00850356||Medical Treamtent (Mx)|Participants who are patients in the same AWMC as above and are currently undergoing a medical treatment program that includes intensive lifestyle counseling (diets, exercise, behavioral modification).
62390680|NCT00850356||Wait-List (Wx)|Participants who are on the Wait-List for the AWMC, and waiting to undergo medical treatment program and/or bariatric surgery.
62390681|NCT04436042|EXPERIMENTAL|MyHand Treatment|Participants will use the MyHand device during repetitive grasp and release tasks.
62390682|NCT05356637|OTHER|Intervention Group Receiving Fastseal|
62390683|NCT02297672|EXPERIMENTAL|Breast seed implant|Stranded palladium seed interstitial radioactive seed implant to seroma with margin with 3 dimensional ultrasound and CT guidance
62769821|NCT05490108|EXPERIMENTAL|ZR202a-COV - Phase 1|Two doses of SARS-CoV-2 adjuvanted recombinant protein vaccine (variant), 1 dose each on Day 0 and 28.
62769822|NCT05490108|ACTIVE_COMPARATOR|Comirnaty® - Phase 1|Two doses of Comirnaty® (Pfizer-BioNTech), 1 dose each on Day 0 and 28.
62769823|NCT00566254|PLACEBO_COMPARATOR|Placebo|Participants had a starting dose of 1 mg/kg/day of placebo matching Zonisamide. Dose was titrated upwards with weekly dose increases until a dose of 8 mg/kg/day was reached at the end of the Titration Period (Week 8). Dose during the Maintenance Period remained unchanged from Week 8.
62769824|NCT00566254|EXPERIMENTAL|Zonisamide|Participants had a starting dose of 1 mg/kg/day of Zonisamide. Dose was titrated upwards with weekly dose increases until a dose of 8 mg/kg/day was reached at the end of the Titration Period (Week 8). Dose during the Maintenance Period remained unchanged from Week 8.
62390684|NCT02463812|EXPERIMENTAL|Intralipid|Patients will receive Intralipid infusion in the recovery room.
62390685|NCT02463812|PLACEBO_COMPARATOR|Control|Patients will receive infusion of normal saline in the recovery room.
62390686|NCT00507312|ACTIVE_COMPARATOR|1|Healthy subjects (with no evidence of cardiovascular disease).
62567759|NCT04750395|EXPERIMENTAL|Haloperidol|Every 24 hours, patients will receive two regular doses of OT Haloperidol 2.5mg. Patients may also receive up to two breakthrough doses within a minimum interval of one hour from the last dose. In total, up to four doses of medication will be prepared.
62769825|NCT01395407|EXPERIMENTAL|Cohort A|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Dose level Cohort A (Gy)~1. 21~2. 23~3. 25"
62390687|NCT00507312|EXPERIMENTAL|2|Patients with risk factors for heart failure
62390688|NCT00507312|EXPERIMENTAL|3|Patients with heart failure
62390689|NCT00950755|EXPERIMENTAL|Tositumomab and Iodine I 131 Tositumomab (anti-B1 antibody)|In the first phase (dosimetric dose) patients will receive an infusion of unlabeled Anti B1 Antibody (450 mg) followed by an infusion of Anti B1 Antibody (35 mg) which has been trace-labeled with 5 mCi of Iodine 131. Whole body gamma camera scans will be obtained following the dosimetric dose. Using the dosimetric data, a patient-specific dose of Iodine 131 Anti B1 Antibody to deliver the desired total body dose of radiotherapy will be calculated. In the second phase, (radioimmunotherapeutic dose), patients will receive an infusion of unlabeled Anti B1 Antibody (450 mg) followed by an infusion of 35 mg Anti B1 Antibody labeled with the patient-specific dose of Iodine 131 to deliver a whole body dose of 75 cGy. Patients will be treated with saturated solution potassium iodide, Lugol's solution, or potassium iodide tablets starting at least 24 hours prior to the first infusion and continuing for 14 days following the last infusion of Iodine 131 Anti B1 Antibody.
62769826|NCT01395407|EXPERIMENTAL|Cohort B|"Cohort B: resection cavity volume \> 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter).~Dose level Cohort B (Gy)~1. 18~2. 20~3. 22"
62769827|NCT01395407|EXPERIMENTAL|Cohort C|"Cohort C: resection cavity volume \> 14.1 cc and ≤ 35 cc (3 - 4 cm diameter).~Dose level Cohort C (Gy)~1. 15~2. 17~3. 19"
62769828|NCT03256786||Active warming|preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid
62168991|NCT00126555|EXPERIMENTAL|Stratum II (Gefitinib, Radiotherapy/Surgery)|"Unresectable Strata: Concomitant Radiation/Gefitinib and post-radiation (or post-surgery if surgery is indicated) Gefitinib. Daily Radiotherapy 5 days a week for approximately 6-7 weeks concurrent with Maintenance Gefitinib dose daily up to 12 months.~Gefitinib Induction Phase starting dose 250 mg/day, possible doubling to 500 mg/day for no response Day 15; Maintenance dose post radiation starts at same dose level as last dosing of Induction Phase."
62168992|NCT05517577|EXPERIMENTAL|Intervention group|An integrated Community-based package of interventions An integrated intervention consisting of behaviourchange communication, and male involvement will be delivered to pregnant women in their third trimester. They will receive 2 prenatal and five home visits. each visit will last 40-60 minutes. After delivery mother-newborn pairs will be followed up until six weeks.
62390690|NCT05078476|ACTIVE_COMPARATOR|Manchester Short Splint|Dorsal splint ending shortly behind the wrist. The splint will be worn for 6 weeks after surgery and the patient will perform active and passive exercises in the splint.
62390691|NCT05078476|EXPERIMENTAL|Relative Motion Flexion|In the relative motion splint the injured finger is positioned in relative flexion in the MCP joint to the adjacent fingers. Additionally to the relative motion flexion splint a wrist orthosis is adapted. Passive and active exercises will be performed out of the splint.
62390692|NCT00865176|EXPERIMENTAL|1|Eplerenone 50mg Tablets
62390693|NCT00865176|ACTIVE_COMPARATOR|2|INSPRA 50mg Tablets
62390694|NCT04000074|EXPERIMENTAL|Telephonic Services - Intervention|Persons in this group are linked with a telephonic case manager to help address their social needs.
62390695|NCT04000074|NO_INTERVENTION|Telephonic Services - Control|Persons in this group are similar in risk to those in the 'Telephonic Services - Intervention' arm, but are not linked with a case manager.
62390696|NCT04000074|EXPERIMENTAL|In-Person Services - Intervention|Persons in this group are linked with an in-person case manager who makes home visits to help address their social needs.
62390697|NCT04000074|NO_INTERVENTION|In-Person Services - Control|Persons in this group are similar in risk to those in the In-Person Services - Intervention' arm, but are not linked with a case manager.
62390698|NCT03646955|ACTIVE_COMPARATOR|Partial breast irradiation|External beam irradiation 40 Gy / 15 fractions, 5 fractions per week, 3 weeks
62390699|NCT03646955|NO_INTERVENTION|No partial breast irradiation|No radiation therapy
62390700|NCT00804596|OTHER|Subjects with diabetes|Subjects with diabetes use a new blood glucose monitoring system with subject capillary blood.
62390701|NCT02872129||166 women with FM/CWP|166 women with Fibromyalgia (FM) or Chronic Widespread Pain (CWP) that participated in an Randomised Controlled Trial called GAU in western Sweden 2004-2005.
62390702|NCT04274361|EXPERIMENTAL|Ketamine arm|Early ketamine infusion therapy at a rate of 3 mcg/kg/min. All ketamine infusions will be calculated based on ideal body weight (IBW), unless actual body weight is less than ideal. Ketamine infusion therapy will be continued for 48 hours. At 2-4 hours post-infusion the patient's pain will be reassessed. If the NPS is more than 5 the infusion will be increased to 5mcg/kg/min. Following each change in the infusion rate the patient's pain will be reassessed at 2-4 hours and adjustments made accordingly. Maximum infusion rate will be set at 9mcg/kg/min. Conversely, The RAAPS team should be notified if neurologic symptoms (hallucinations, delusions, disturbing dreams, vertigo) are developing and, at the discretion of the RAAPS service, a single dose of lorazepam or midazolam may be utilized. The infusion can be decreased from in 2 mcg/kg/min increments if there are symptoms believed to be related to the infusion that do not respond to benzodiazepines.
62390703|NCT04274361|PLACEBO_COMPARATOR|Placebo arm|The 65 patients randomized to the control arm will receive placebo saline solution at a rate equivalent.
62390704|NCT01234142|EXPERIMENTAL|Cohort 1|
62390705|NCT01234142|EXPERIMENTAL|Cohort 2|
62390706|NCT01234142|EXPERIMENTAL|Cohort 3|
62390707|NCT01234142|EXPERIMENTAL|Cohort 4|
62390708|NCT05785559|EXPERIMENTAL|Scarred uterus|Patients who have already undergone one or more cesarean section(s) during a previous pregnancy and for whom a cesarean section is indicated on a scheduled or emergency basis.
62390709|NCT05785559|EXPERIMENTAL|Scar dehiscence surgery|Patients who have already undergone one or more caesarean section(s) and for whom the surgical management of a dehiscence of a caesarean section scar is indicated outside of pregnancy.
62390710|NCT05785559|EXPERIMENTAL|Healthy uterus|"Patients with no history of caesarean section, pregnant with an indication for caesarean section: patients who have never had a caesarean section during a previous pregnancy or who are pregnant with their first pregnancy and for whom a caesarean section is indicated scheduled or urgently"
62390711|NCT02398643|OTHER|Early Pulmonary Education (EPE)|Patients randomized to EPE will receive focused education sessions by a Certified Respiratory Educator. Education sessions will start within two weeks of discharge from hospital.
62562280|NCT04760080||Patients with a metastatic melanoma treated by cytotoxic chemotherapy.|"Patients with a metastatic melanoma treated by cytotoxic chemotherapy after acquired resistance to dabrafenib/trametinib.~Patients treated~* for a BRAF mutated metastatic melanoma in Pr Dalle's dermatology ward at Centre Hospitalier Lyon Sud,~* From January 2008 to June 2020~* who received a treatment by immunotherapy before receiving a treatment by dabrafenib/trametinib~* who became resistant to dabrafeib/trametinib~* and received after disease progression under dabrafenib/trametinib a treatment by cytotoxic chemotherapy"
62182727|NCT05195892|EXPERIMENTAL|Sequence 4|Participants will receive a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 2 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A).
62390712|NCT02398643|OTHER|Usual Care|Patients randomized to usual care will receive general education sessions by a Certified Respiratory Educator within the month of being discharged.
62390713|NCT05997511|OTHER|COVID-19|Behavioral (SMS) Intervention
62562281|NCT03295071||Single-group study|This study is a multi-country retrospective and cross-sectional observational study of affected LHON subjects, based on retrospective subjects' medical chart abstractions and cross-sectional administration of patient-reported outcomes (PROs).
62562282|NCT03783767|EXPERIMENTAL|Leadership Intervention Group|Teachers in the intervention group will receive a half day workshop from a member of the research team. These teachers will then provide a four week training program to Grade 6/7 students, who will then deliver a 10-week fundamental movement skill (FMS) training program to Grade 3/4 students.
62562283|NCT03783767|NO_INTERVENTION|Waitlist Control|This group of students and teachers will act as a waitlist control group. Therefore, during the same time that the other group is receiving the intervention, this group will proceed with their normal practices.
62562284|NCT06160609|EXPERIMENTAL|Belantamab mafodotin + GSK3174998|
62562285|NCT04136314|EXPERIMENTAL|Gain-Frame Survey [A]|
62562286|NCT04136314|EXPERIMENTAL|Loss-Frame Survey [B]|
62562287|NCT06445998|EXPERIMENTAL|Group A (study group)|consisted of twenty hemiparetic patients received task oriented training in addition to traditional physical therapy program, 3 times per week for 3 month, every session for 1 hour (30 minutes task oriented training followed by 30 minutes traditional physical therapy program).
62562288|NCT06445998|ACTIVE_COMPARATOR|Group B (control group)|consisted of twenty hemiparetic patients received the traditional physical therapy program, 3 sessions/week for 3 month, each session for 1hour.
62562289|NCT01615458|ACTIVE_COMPARATOR|Usual Care|Patients will receive their usual care from providers at the clinic.
62562290|NCT01741987|ACTIVE_COMPARATOR|optive® eye drop|
62769829|NCT03256786||Control|no preoperative warming and room temperature intravenous fluid
62562291|NCT01741987|PLACEBO_COMPARATOR|fresh tears ® eye drop|
62562292|NCT04062669|EXPERIMENTAL|Low dose (Ld-) RG SAM (CNE) group|"In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) low dose formulation vaccine in one arm and one intramuscular injection of saline solution in the opposite arm at Days 1 and 61).~In Part 2 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) low dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)"
62182728|NCT05195892|EXPERIMENTAL|Sequence 5|Participants will receive a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B).
62562293|NCT04062669|EXPERIMENTAL|Medium dose (Md-) RG SAM (CNE) group|Healthy adults,18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) medium dose formulation vaccine in one arm and one intramuscular injection of saline solution in the opposite arm at Day 1.
62562294|NCT04062669|EXPERIMENTAL|Lower dose (Lrd-) RG SAM (CNE) group|Healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) lower dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)
62562295|NCT04062669|EXPERIMENTAL|Lowest dose (Ltd-) RG SAM (CNE) group|Healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) lowest dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)
62562296|NCT04062669|PLACEBO_COMPARATOR|Saline Placebo group|"In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive two intramuscular injections of saline placebo, one in each arm, according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61).~In Part 2 of the study, healthy adults, 18 to 40 years of age will receive one intramuscular injections of saline placebo in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)."
62562297|NCT04062669|ACTIVE_COMPARATOR|RabAvert group|"In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RabAvert in one arm and one intramuscular injection of saline solution in the other arm, according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61).~In Part 2 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RabAvert in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)."
62562298|NCT03390608||Women with T1ab breast cancer.|
62562299|NCT00818077||Metformin, Type 2 Diabetes|
62562300|NCT02256618|EXPERIMENTAL|Cell therapy|Infants who are born at the study sites, have moderate to severe encephalopathy, and have cord blood available for infusion
62562301|NCT03575052|EXPERIMENTAL|Drug - Pimavanserin|
62769830|NCT02365415|EXPERIMENTAL|Sirolimus|Patients randomized to this arm will receive 8 weeks of enteral Rapamycin (sirolimus), with dosage titrated to achieve target blood levels.
62769831|NCT02365415|NO_INTERVENTION|Control|No treatment.
62562302|NCT03575052|PLACEBO_COMPARATOR|Placebo|
62562303|NCT02892630||Pregnant ITP women|Pregnant women more than 18 years old, with primary ITP diagnosis before pregnancy
62562304|NCT02892630||Control ITP Women (Non pregnant)|Primary ITP women more than 18 years old, at more than one year from a precedent pregnancy
62562305|NCT02892630||De novo ITP pregnant women|Pregnant women more than 18 years old, with newly diagnosed thrombocytopenia during pregnancy
62769832|NCT00064402|EXPERIMENTAL|1|Arformoterol 50 mcg QD and placebo MDI
62769833|NCT00064402|EXPERIMENTAL|2|Arformoterol 25 mcg BID and Placebo MDI
62769834|NCT00064402|EXPERIMENTAL|3|Arformoterol 15 mcg BID and placebo MDI
62769835|NCT00064402|ACTIVE_COMPARATOR|4|Salmeterol MDI 42 mcg BID and placebo inhalation solution
62769836|NCT00064402|PLACEBO_COMPARATOR|5|Placebo MDI and placebo inhalation solution
62390714|NCT05997511|OTHER|Mental Health|Behavorial (SMS) Intervention
62390715|NCT00222066|EXPERIMENTAL|1|Fetal ovarian cyst aspiration performed as soon as possible
62390716|NCT00222066|NO_INTERVENTION|2|Expectative
62390717|NCT00656331|ACTIVE_COMPARATOR|1|Amlodipine
62390718|NCT00656331|ACTIVE_COMPARATOR|2|HCTZ
62562306|NCT04731805|EXPERIMENTAL|Moving On After Breast Cancer - Intervention Arm|Participants are randomized to the intervention arm after their breast cancer diagnosis (but before cancer surgery) and baseline measurements (T0) are taken. They are followed up again at 2 weeks after their breast cancer surgery (T1), and again at 3 months after surgery (T2). Participants are given the patient education materials (booklet, therapeutic exercise DVD, small ball, range of motion wand). The research assistant orients the participant to the education materials and summarizes each section of the booklet. The research assistant also teaches the participant how to do the therapeutic exercises in the booklet. All participants in the intervention also receive usual care.
62769837|NCT00587847|OTHER|Campath maintenance treatment|Single arm, open label trial of Campath on a maintenance schedule for patients who have had a response to prior conventional chemotherapy. Treatments consist of dose escalation (3, 10 and 30mg) during week 1 followed by weekly dosing of Campath at 30 mg once weekly for 7 weeks followed by Campath 30 mg every 2 weeks for 16 weeks followed by Campath 30 mg once every 3 weeks for 24 weeks. Total duration of treatment up to 48 weeks.
61994682|NCT02963649|ACTIVE_COMPARATOR|Standard angioplasty balloon|standard PTA balloon
62168993|NCT05517577|NO_INTERVENTION|Control group|First, we selected two districts that have similar characteristics and are adjacent to each other. Both districts have a total of 72 kebeles (the smallest administrative unit), 36 in each district. Then, we chose 20, 10 from each district, kebeles on the boundary of the two districts to act as a buffer zone, to prevent information contamination between the intervention and control clusters. Finally, 26 kebeles in the Dedo district will be assigned to the intervention group while 26 kebeles in the Seka Chekorsa district are assigned to control clusters. Allocation concealment will not be done for study participants, as they would certainly know if they are in the intervention group or not. However, data collectors will be blinded to the allocation assignment by not being informed about it, not being part of the trial implementers, and not being inhabitants of any of the kebeles. Moreover, data analysts will be blinded to group allocation.
62168994|NCT06003868|ACTIVE_COMPARATOR|control group|Physiotherapy will be applied for 8 weeks, 2 days a week, as one session per day (45 minutes).
62168995|NCT06003868|EXPERIMENTAL|hippotherapy group|"Physiotherapy will be applied for 8 weeks, 2 days a week, one session a day (45 minutes). In addition, the patients will be placed on the simulator and the starting position will be taught. your simulator They will be warned before and during the application to maintain the starting position throughout their movements.~pattern and will be run in the 1st stage of the 3-stage speed level."
62390719|NCT03484780|EXPERIMENTAL|VisONE ADS|Patients implanted with a VisONE stimulator and leads for receiving continual Synchronized Diaphragmatic Stimulation
62390720|NCT02549040|EXPERIMENTAL|Doravirine fixed sequence treatment|After a minimum 10 hour overnight fast, participants received a single oral dose during each of 5 periods. During Period 1, participants received Treatment B: Doravirine Type 1 dose (150 mg tablet \[40% drug loaded granule\]). During Period 2, participants received Treatment A: Doravirine 100 mg film coated tablet. During Period 3, participants received Treatment C: Doravirine Type 2 dose (150 mg tablet \[30% drug loaded granule\]). During Period 4, participants received Treatment D: Doravirine Type 3 dose (150 mg tablet \[50% drug loaded granule\]. During Period 5, participants received Treatment E: Doravirine Type 4 dose (100 mg tablet \[30% drug loaded granule\]). Each period was separated by a 14 day washout.
62390721|NCT02934919|EXPERIMENTAL|nalmefene|
62390722|NCT01506310|NO_INTERVENTION|Diet alone|
62390723|NCT01506310|EXPERIMENTAL|Behavioral therapy|
62390724|NCT01506310|EXPERIMENTAL|Exercise|
62769838|NCT02273713|EXPERIMENTAL|Nab-Paclitaxel|Nab-Paclitaxel added to first line treatment with Oxaliplatin and Capecitabine
62769839|NCT02737384|EXPERIMENTAL|Treatment|
62769840|NCT00513955|EXPERIMENTAL|Bortezomib plus CHOP|"Patients receive bortezomib IV over 3-5 seconds on days 1 and 8; doxorubicin hydrochloride IV, cyclophosphamide IV, and vincristine IV on day 1; and oral prednisolone on days 1-5.~Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Patients complete quality of life questionnaires at baseline, prior to each treatment course, and then at 30 days after completion of treatment.~After completion of study treatment, patients are followed at 30 days and then every 12 weeks thereafter."
62769841|NCT01896271|EXPERIMENTAL|treatment|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion; SABR dose varying from 8Gy-20Gy in 1-3 fractions.
62390725|NCT01506310|EXPERIMENTAL|Behavioral therapy and exercise|
62390726|NCT00575003|EXPERIMENTAL|1|
62769842|NCT00542061|EXPERIMENTAL|A|Device: monitoring services
62769843|NCT00542061|NO_INTERVENTION|B|Control group: no monitoring procedures
62390727|NCT00575003|PLACEBO_COMPARATOR|2|
62390728|NCT02906644|EXPERIMENTAL|Lorcaserin + Patch|Participants will receive lorcaserin (10mg twice a day) and nicotine patches (21mg/24hr) for 14 weeks, at which point the nicotine patch dosage will be reduced to 14mg/24hr for 1 week, followed by 7mg/24hr for 1 week.
62168996|NCT00516178|PLACEBO_COMPARATOR|Placebo|Saline (No lipid emulsion)
62168997|NCT00516178|EXPERIMENTAL|Fish oil emulsion|3 infusions of 0.2 g/kg omega-3 PUFA within 24 hours in cardiac surgery (continuous infusion post-PTCA)
62390729|NCT02906644|EXPERIMENTAL|Patch|Participants will receive nicotine patches (21mg/24hr) and placebo lorcaserin for 2 weeks; after 2 weeks participants will begin to receive active lorcaserin (10mg twice a day) along with the nicotine patches for 12 weeks, at which point the nicotine patch dosage will be reduced to 14mg/24hr for 1 week, followed by 7mg/24hr for 1 week.
62390730|NCT01880996|EXPERIMENTAL|Tai-chi/Qi-gong|30 gynecological cancer patients scheduled for the first or second line of chemotherapy treatment will be recruited for this study to receive Tai-chi/qigong treatment initiated at the beginning of chemotherapy therapy, once a week (45 min each), for 10 weeks.
62390731|NCT01880996|NO_INTERVENTION|Usual Care|30 gynecological cancer patients scheduled for primary or secondary chemotherapy treatment, will be evaluated by the same measures as the intervention group.
62390732|NCT02950428|EXPERIMENTAL|ACURATE neo™TA Delivery System|Patients implanted with ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™ TA Transapical Delivery System
62769844|NCT04683458||Paclitaxel-coated devices|Patients with symptomatic peripheral arterial occlusive disease or diabetic foot syndrome with chronic limb-threatening ischaemia who underwent endovascular revascularisation of the peripheral arteries in the lower limbs with any drug-coated medical device (e.g., drug-eluting stent, drug-coated balloon).
62769845|NCT04683458||Controlls|Patients with symptomatic peripheral arterial occlusive disease or diabetic foot syndrome with chronic limb-threatening ischaemia who underwent endovascular revascularisation of the peripheral arteries in the lower limbs with any medical device except drug-coated techniques (e.g., drug-eluting stent, drug-coated balloon).
62769846|NCT05172674||spontaneous pregnancies|
62769847|NCT05172674||pregnancies arising through IVF (homologus + hetereologus)|
62769848|NCT05606991|NO_INTERVENTION|CPAP on|Participants will continue with their usual continuous positive airway pressure (CPAP) therapy as advised by their treating physician.
62769849|NCT05606991|EXPERIMENTAL|CPAP off|Participants will be weaned off their usual continuous positive airway pressure (CPAP) therapy and enter a 2-week period of non-treatment.
62769850|NCT06506877|EXPERIMENTAL|Active|Active Phase: Implementation of Cognitive Risk Calculator (RC) and Brief Assessment of Cognitive Health (BACH)
62769851|NCT06506877|NO_INTERVENTION|Control|Control Phase: Prior to implementation of Cognitive Risk Calculator (RC) and Brief Assessment of Cognitive Health (BACH)
62168998|NCT06128434|EXPERIMENTAL|zinc carbonate nano-hydroxyapatite toothpaste|Biorepair toothpaste with 20 wt% zinc carbonate nano-hydroxyapatite
62390733|NCT00125736|EXPERIMENTAL|E0671 combination group|
62390734|NCT00125736|PLACEBO_COMPARATOR|placebo combination group|
62390735|NCT01569568||Subjects with OTCD|"males and females ages 7-60 years with OTCD who are able to undergo MRI and cognitive testing MRI scanning~1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing"
62390736|NCT01569568||Healthy controls|"males and females ages 7-60 years who are healthy controls who are able to undergo MRI and cognitive testing MRI scanning~1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing"
62390737|NCT03053466|EXPERIMENTAL|Single-Arm|APL-501
62390738|NCT02361372|EXPERIMENTAL|Kefir and CaCO3|Kefir were administered 1,600 mg kefir-fermented milk per day and an accompanying supplement of 1,500 mg CaCO3 for 6 months
62390739|NCT02361372|PLACEBO_COMPARATOR|Placebo and CaCO3|Placebo and 1,500 mg of CaCO3 daily for 6 months
62390740|NCT02127931|EXPERIMENTAL|ADHD group played Game|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD. The game was played on Sifteo cubes.
62390741|NCT02127931|ACTIVE_COMPARATOR|Control group played game|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD. The game was played on Sifteo cubes.
62390742|NCT02424227||Kidney Transplant Recipients|Adult living and deceased donor kidney transplant recipients will be eligible to participate in this study.
62390743|NCT00056472|ACTIVE_COMPARATOR|olanzapine/sertraline combination|sertraline plus olanzapine
62168999|NCT06128434|EXPERIMENTAL|8% arginine toothpaste|Colgate Sensitive Pro-Relief™ with pro-argin technology
62390744|NCT00056472|PLACEBO_COMPARATOR|olanzapine plus placebo|olanzapine (5 - 20mg/day) plus placebo
62390745|NCT04473989|PLACEBO_COMPARATOR|Placebo|Injection product without active teriparatide
62562307|NCT04731805|NO_INTERVENTION|Usual Care|Participants are randomized to the usual care arm after their breast cancer diagnosis (but before cancer surgery) and baseline measurements (T0) are taken. They are followed up again at 2 weeks after their breast cancer surgery (T1), and again at 3 months after surgery (T2). Usual care consists of pre-operative testing, pre-operative nursing education on care of the surgical incision and pain management followed by breast cancer surgery.
62769852|NCT05102968|ACTIVE_COMPARATOR|Rehabilitation with mobile application|Patients self-managed rehab exercise with a supportive mobile application
62769853|NCT05102968|ACTIVE_COMPARATOR|Rehabilitation under supervision|Patients received supervised physical therapy
62769854|NCT01264419|EXPERIMENTAL|Silk Road Embolic Protection System|Eligible subjects who are to receive a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
62390746|NCT04473989|EXPERIMENTAL|PTH 40ug/w|Injection product with active teriparatide
62390747|NCT00143039||NIH/SSIUGR fetuses|Group 1 includes pregnancies complicated by a fetus with either Non-Immune Hydrops or Severe Symmetrical IUGR.
62169000|NCT06128434|ACTIVE_COMPARATOR|Fluoride toothpaste|Signal cavity fighter toothpaste with Sodium Monofluorophosphate
62169001|NCT04374019|EXPERIMENTAL|Arm C: Ivermectin|Ivermectin
62169002|NCT04374019|EXPERIMENTAL|Arm D: Camostat Mesilate|Camostat Mesilate
62169003|NCT04374019|EXPERIMENTAL|Arm E: Artemesia annua|Artemesia annua tea or coffee
62169004|NCT04374019|EXPERIMENTAL|Arm F: Artesunate|Artesunate
62169005|NCT02366702||Individuals with Bilateral Transfemoral Amputation|
62390748|NCT00143039||Control-Normal fetus|Group 2 includes all normally appearing fetuses on U/S who will be having a diagnostic amniocentesis as part of their routine care.
62390749|NCT00302731|ACTIVE_COMPARATOR|1 equine estrogens m-progesteroneacetate|Menopausal women in first seven years of menopause randomized to arm 1 receive conjugated equine estrogens 0.45 mg combined with medroxyprogesteroneacetate 1.5 mg placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
62390750|NCT00302731|EXPERIMENTAL|2 estradiol estriol progesterone|Menopausal women in first seven years of menopause randomized to arm 2 estradiol .5mg, estriol 2.0mg, progesterone 100mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
62390751|NCT00302731|EXPERIMENTAL|4 estradiol progesterone|Menopausal women in first seven years of menopause randomized to arm 4 estradiol 0.5 mg, progesterone 100 mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
62390752|NCT00302731|EXPERIMENTAL|3 estriol progesterone|Menopausal women in first seven years of menopause randomized to arm 3 estriol 2.5mg, progesterone 100mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
62769855|NCT04619277||Ulsan Medical Center|Division of Cardiology, Department of Internal Medicine, Ulsan Medical Center, Ulsan, South Korea
62390753|NCT02049385|EXPERIMENTAL|Diazoxide|Subjects received 200-400 mg daily of diazoxide orally for three weeks; the dose was, adjusted depending on side effects and response.
62390754|NCT02049385|EXPERIMENTAL|Placebo|Subjects received a matched placebo for three weeks
62390755|NCT00689299|PLACEBO_COMPARATOR|Dose Group C|Standardized Allergenic Extract, Cat Hair (Felis domesticus) placebo
62390756|NCT00689299|ACTIVE_COMPARATOR|Dose Group A|Standardized Allergenic Extract, Cat Hair (Felis domesticus) 0.21 Units
62390757|NCT00689299|ACTIVE_COMPARATOR|Dose Group B|Standardized Allergenic Extract, Cat Hair (Felis domesticus)2.1 units
62390758|NCT03960476|EXPERIMENTAL|Access to Web-Based Intervention|All study participants will be given access to the web-based study intervention, PlanYourLifespan.org.
62390759|NCT02540811|EXPERIMENTAL|dCELL® ACL Scaffold|
62390760|NCT05357105||Regional Nerve Block Patients|Patients who receive regional nerve blocks as part of the anesthetic management prior to surgery.
62562308|NCT04777942|EXPERIMENTAL|neo-TACE-HAIC with surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h+5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
62769856|NCT04619277||Queen Elizabeth Hospital|Cardiology Department and Clinical Research Center, Queen Elizabeth Hospital II, Kota Kinabalu, Malaysia
62769857|NCT04619277||Pecking University Shougand Hospital|Department of Cardiology, Peking University Shougang Hospital, Peking, China
62769858|NCT04619277||Ulsan University Hospital|Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
62769859|NCT04619277||Kangwon National University School of Medicine|Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, South Korea
62769860|NCT04619277||Korea University Guro Hospital|Cardiovascular Center, Department of Cardiology, Korea University Guro Hospital, Seoul, South Korea
62769861|NCT04619277||Korea University Ansan Hospital|Department of Cardiology, Korea University Ansan Hospital, Ansan, South Korea
62769862|NCT02687516|EXPERIMENTAL|Family-based behavioral social facilitation therapy.|The FBSFT condition includes 17 weekly family-based treatment sessions at the hospital obesity clinic followed by monthly follow-up sessions with their local nurse and follow-up sessions at the hospital every third month for 2 years.The treatment targets both child and parent life-style; eating habits, physical activity, sedentary activity and sleep habits. Behavior modification techniques are systematically employed; such as self-monitoring, goal setting, reward systems, problem solving and stimulus control. In addition, FBSFT focuses on facilitating lifestyle change across different settings (family, friends, school and community) and harnessing social support for healthy habits, which is considered important for long-term weight control.
61994683|NCT06045039||Stent-balloon-stent (SBS) technique|Patients with coronary bifurcation lesions underwent stent-balloon-stent (SBS) technique. The procedure of this technique is to implant the stent into the side branch at the 1\~2mm, which is away from the opening of the branch, and then implant the stent into the main vessel. The guide wire enters the side branch from the mesh at the distal end of the main vascular stent, and the drug balloon is used to dilate the opening of the side branch, so that the opening area of the side branch is more than 5mm².
62562309|NCT04777942|ACTIVE_COMPARATOR|surgery alone|hepatic resection remove the liver tumors
62390761|NCT01527058|EXPERIMENTAL|68Ga-BNOTA-PRGD2 PET/CT scanning|Determine if 68Ga-BNOTA-PRGD2 PET/CT is safe and effective method for imaging of lung cancer
62390762|NCT05771415||Grannum placental maturity grade 0 and 1 (low maturity level|Women with low placental maturity grade (group 1, Grannum 0-1)
62390763|NCT05771415||Grannum placental maturity grade 2 and 3 (high maturity level)|Women with high placental maturity grade (group 2, Grannum 2-3)
62390764|NCT04915365|EXPERIMENTAL|Acetazolamide|Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
62390765|NCT04915365|PLACEBO_COMPARATOR|Placebo|"Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses~1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m."
62390766|NCT05617274||Mandibular flexure before sectioning of full arch fixed prosthesis|
62562310|NCT03642262|EXPERIMENTAL|Treatment A: Mucinex® ER 600 mg|Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.
62562311|NCT03642262|ACTIVE_COMPARATOR|Treatment B: Guaifenesin 200 mg|Guaifenesin 200 mg immediate release (IR) tablet thrice (at 0, 4, and 8 hours) by mouth under fasting condition.
62562312|NCT01950455|EXPERIMENTAL|NAV5001|
62562313|NCT06230744|OTHER|Lifestyle Intervention|Diet and exercise coaching
62562314|NCT06230744|EXPERIMENTAL|Lifestyle Intervention II|Diet and exercise coaching
62562315|NCT04178460|EXPERIMENTAL|Assigned Interventions|Niraparib combined with MGD013
62562316|NCT03660319|EXPERIMENTAL|Environmental Music Therapy|Music Therapy Intervention (EMT)
62562317|NCT03660319|NO_INTERVENTION|Control|Control - No Environmental Music Therapy. Does not experience Environmental Music Therapy during wait time in radiation oncology waiting room.
62769863|NCT02687516|ACTIVE_COMPARATOR|Treatment as usual|The TAU condition involves an assessment day with the multidisciplinary team (pediatrician, dietician, physical therapist and psychologist) at the hospital obesity clinic. Further a session with the nurse at the hospital clinic making a plan for behavioral lifestyle changes followed by monthly follow-up sessions with their local nurse and follow-up sessions at the hospital clinic every third month for 12 months. After 12 months they will be offered treatment by family-based behavioral social facilitation therapy (as in the other treatment arm).
62769864|NCT03841136|EXPERIMENTAL|anlotinib combined with EP|anlotinib combined with etoposide and platinum
62769865|NCT05302362|SHAM_COMPARATOR|Sham tDCS Group|Sham transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea); ramp-up 30sec to 1.5mA, 0mA stimulation for 19 min 30 sec.
62769866|NCT05302362|ACTIVE_COMPARATOR|Conventional tDCS Group|Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea); ramp-up 30sec to 1.5mA, continuous 1.5mA stimulation for 19 minutes, ramp-down 30sec to 0mA.
62769867|NCT05302362|EXPERIMENTAL|Tailored tDCS Group|Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea); ramp-up 30sec to 2.0mA, continuous 2.0mA stimulation for 19 minutes, ramp-down 30sec to 0mA.
62769868|NCT03410342|PLACEBO_COMPARATOR|Low Fruits and Vegetables (LFV)|"1 portion of fruits plus 1 portion of vegetables, of commonly consumed types per day.~Intakes are at 25th percentile of UK consumption (NDNS) and will exclude citrus fruits, cruciferous and allium vegetables."
62769869|NCT03410342|EXPERIMENTAL|High Fruits and Vegetables (HFV)|4 portions of fruits plus 4 portions of vegetables, of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
61994684|NCT05217550|EXPERIMENTAL|Intervention (Veggie Brek)|Nursery staff will present vegetables (raw carrot and cucumber batons) to children alongside their main breakfast food for five consecutive days every weekday morning for three weeks.
62562318|NCT04551456|PLACEBO_COMPARATOR|Placebo Infusion PBS|"The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to have standard of care plus placebo. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.~Assigned Interventions:~Biological/Vaccine: Biological/Vaccine: WJMSCs Vs.placebo"
62562319|NCT04551456|EXPERIMENTAL|Single dose Infusion WJMSCs|"The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to compare standard of care plus placebo to standard of care plus one time or three times in doses of 1x106 /kg of WJMSCs. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.~Biological/Vaccine:~WJMSCs Vs.placebo"
62562320|NCT04551456|EXPERIMENTAL|Infusion WJMSCs multiple doses|"The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to compare standard of care plus placebo to one time or three times at 30-day intervals for equal doses of 1x106 /kg of WJMSCs. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.~Biological/Vaccine:~WJMSCs Vs.placebo"
62769870|NCT03410342|EXPERIMENTAL|High Citrus fruits and Cruciferous vegetables (CC)|4 portions of citrus fruits plus 4 portions of cruciferous vegetables per day excluding any other types of fruits and vegetables including allium vegetables.
62769871|NCT03288363|EXPERIMENTAL|tDCS|20 sessions tDCS (DC-Stimulator Plus -Neuroconn) during 2 Weeks on temporal cortex - each session : 30 minutes - 2 mA - 2 sessions per day - evaluation at 12 weeks post-treatment
61994685|NCT05217550|NO_INTERVENTION|Control|Children will be served their normal breakfast (with no vegetables) across the three-week intervention period.
61994686|NCT01615471|ACTIVE_COMPARATOR|Large Group|In person group sessions in large group format (up to 125 others)
61994687|NCT01615471|ACTIVE_COMPARATOR|Small group|Small group in person sessions (up to 25 other participants)
61994688|NCT06377397|EXPERIMENTAL|Selective antibiotic group|Antibiotics will be administered selectively to a subset of at-risk neonates who develop clinical signs of sepsis.
61994689|NCT06377397|ACTIVE_COMPARATOR|Comparison group|Antibiotics will be pre-emptively administered to all neonates at risk of sepsis.
61994690|NCT01268111|EXPERIMENTAL|Vitamin D|ERgocalcifoerol 50,000 units q weekly for 8 weeks
62390767|NCT05617274||Mandibular flexure after sectioning of full arch fixed prosthesis|
62390768|NCT05136326|EXPERIMENTAL|Catartic: chemoradiotherapy plus temozolomide|"External-beam radiation: 50.4 GY (45 Gy in 25 fractions + Boost 5.4 Gy in 3 fractions over 5 weeks) in association with:~Capecitabine 825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks plus Temozolomide 75 mg/sqm p.o. 5 days/week for 5 weeks."
62562321|NCT01163201|EXPERIMENTAL|Treg Plus CD3+Teff Treatment|Includes dose adjustment of T regulatory (Treg) and CD3+ T effector (CD3+ Teff) cells in recipients of double UCB transplantation
62769872|NCT03288363|SHAM_COMPARATOR|sham stimulation|the same parameters of stimulation as with real current stimulation (time, parameters to be seen on the apparatus screen) 20 sessions during 2 Weeks on temporal cortex - each session : 30 minutes - 2 sessions per day.
62169006|NCT03121599|EXPERIMENTAL|18F-FLT PET/CT|"Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-Lthymidine) PET/CT (Positron Emission Tomography/ Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. \[18F\] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) \[18F\] FLT by intravenous infusion."
62169007|NCT06584578|EXPERIMENTAL|Whole-Body Electomyostimulation (WB-EMS)|Whole-Body Electromyostimulation
62169008|NCT06584578|EXPERIMENTAL|Pilates|Pilates
62390769|NCT04686396|EXPERIMENTAL|Interpositional Group|Demineralized bone matrix
62562322|NCT05801705||OFS+AI|patients undergoing ovarian function suppression (OFS) combined with aromatase inhibitor (AI)
61994691|NCT01268111|PLACEBO_COMPARATOR|Placebo|
62390770|NCT04686396|NO_INTERVENTION|Control|Without demineralized bone matrix
62390771|NCT02885506|EXPERIMENTAL|Cohort 1|Oral administration of P218 capsules 10 mg
62390772|NCT02885506|EXPERIMENTAL|Cohort 2|Oral administration of P218 capsules 30 mg
62390773|NCT02885506|EXPERIMENTAL|Cohort 3|Oral administration of P218 capsules 100 mg
62390774|NCT02885506|EXPERIMENTAL|Cohort 4|Oral administration of P218 capsules 250 mg
62390775|NCT02885506|EXPERIMENTAL|Cohort 5|Oral administration of P218 capsules 500 mg
62390776|NCT02885506|EXPERIMENTAL|Cohort 6|Oral administration of P218 capsules 750 mg
62390777|NCT02885506|EXPERIMENTAL|Cohort 7|Oral administration of P218 capsules 1000 mg
62390778|NCT02885506|PLACEBO_COMPARATOR|Cohort 8 - Pooled Placebo|Oral administration of P218 matching placebo
62390779|NCT02885506|EXPERIMENTAL|Fed - Fasted|Oral administration of P218 capsules 250 mg Under fed then fasted conditions.
62390780|NCT02885506|EXPERIMENTAL|Fasted - Fed|Oral administration of P218 capsules 250 mg Under fasted then fed conditions.
62562323|NCT05801705||OFS+TAM|patients undergoing ovarian function suppression (OFS) combined with tamoxifen (TAM)
62562324|NCT05801705||OFS+TOR|patients undergoing ovarian function suppression (OFS) combined with torimifene (TOR)
62562325|NCT02877901|ACTIVE_COMPARATOR|tolterodine-treated group|they will receive long acting tolterodine 4 mg at bedtime for 4 weeks. After that re-evaluation. then stop medication for two weeks (washout period).
62562326|NCT02877901|PLACEBO_COMPARATOR|placebo-control group|they will receive placebo at bedtime for 4 weeks. After that re-evaluation. then stop for two weeks (washout period). Then re-evaluate the nocturnal incontinence status and crosed over to receive long acting tolterodine 4 mg for 4 weeks. at the end the nocturnal incontinence status will be evaluated
62562327|NCT04119297|ACTIVE_COMPARATOR|Control|Routine care (Irregular cold application or gauze bandages wetted with isotonic solution or once daily heparinoid cream application) of the clinic was applied.
62769873|NCT03477058|EXPERIMENTAL|WO 3308 cosmetic product for topical use|WO 3308 is used to treat acute or chronic pruritus
61994692|NCT04448210|EXPERIMENTAL|Educational website intervention|The intervention is an educational website designed to teach youth (12-17 years) about pediatric clinical trials.
61994693|NCT04448210|NO_INTERVENTION|Wait-list control|The wait-list control group did not receive the intervention between the pre-test and post-test assessments. After completing the post-test questionnaire, youth in the wait-list control group had the option to receive access to the intervention (DigiKnowIt News).
62169009|NCT06584578|EXPERIMENTAL|Tai Chi|Tai-Chi exercise
62169010|NCT06584578|ACTIVE_COMPARATOR|Nutrition counseling|Nutrition counseling for 12 weeks
62169011|NCT04194541|EXPERIMENTAL|Treatment Group|Participants will be provided a kit containing 3 dressings: Cutimed Sorbact Hydroactive B, Cutimed Siltec, and Sorbion Sana multi-star. Participant can use their dressing of choice and can change their dressings as needed for 6 consecutive weeks.
62169012|NCT00867945||1. Pregnant Women|
62390781|NCT04225182|EXPERIMENTAL|with instrumented Orthosis|patient will follow 8 weeks of muscular strengthening with the orthosis connected to the phone app associated
62390782|NCT04225182|ACTIVE_COMPARATOR|without instrumented Orthosis|patient will follow 8 weeks of traditional muscular strengthening without orthosis
62390783|NCT02833142|EXPERIMENTAL|BIIB033-A|Staggered single dosing schema
62390784|NCT02833142|EXPERIMENTAL|BIIB033-B|Staggered single dosing schema
62390785|NCT06413030||Community-dwelling older adults|Persons over 60 years of age attending primary health care centers in the Bio Bio Region of Chile.
62390786|NCT04371068||Patients suspected of low-grade PJIs|Adult patients suspected of low-grade PJIs, who have a scheduled prosthesis removal or change and who meet the inclusion criteria
62390787|NCT04527458||Hospitalisations|All hospitalised COVID patients
62390788|NCT04527458||Critical care|All hospitalised COVID patients in critical care
62390789|NCT06448520|EXPERIMENTAL|Muscle Power Sprint Test (MPST)|All patients in this arm will be assessed through the MPST. We calculate the mean Power developed during the six short distance sprints, using time needed for each sprint and the weight of the study subject.
62390790|NCT02812602|EXPERIMENTAL|Lidocaine patch|The patients was randomly assigned to experimental group or placebo group. In this arm, lidocaine patches will be applied to the skin surrounding the surgical wound by one nurse practitioner. After more than 20 minutes the patch will be removed. Another nurse practitioner (double blinded) will remove the metal staples and record pain scale.
62390791|NCT02812602|PLACEBO_COMPARATOR|Placebo|The patients was randomly assigned to experimental group or placebo group. In this arm, a placebo patch will be applied to the skin surrounding the surgical wound by one nurse practitioner. After more than 20 minutes the patch will be removed. Another nurse practitioner (double blinded) will remove the metal staples and record pain scale.
62390792|NCT05304078|EXPERIMENTAL|TASK III Group|The Telehealth Assessment and Skill-Building Kit (TASK III) group
62390793|NCT05304078|ACTIVE_COMPARATOR|ISR Group|The Information, Support, and Referral (ISR) group
62390794|NCT04892095||Study participants|Adult subjects (men and women) aged 18 years or more, living in 12 European countries
62390795|NCT05907031|ACTIVE_COMPARATOR|active cTBS group|active cTBS combined with speech language therapy
62769874|NCT04330781|EXPERIMENTAL|Intervention group|N=123
62390796|NCT05907031|SHAM_COMPARATOR|sham cTBS group|sham cTBS combined with speech language therapy
62390797|NCT00808197|EXPERIMENTAL|1|Observatory, longitudinal, 3-years follow up study
62562328|NCT04119297|EXPERIMENTAL|Cold application|Cold application was applied for three days after craniotomy.
62562329|NCT04119297|EXPERIMENTAL|Heparinoid group|Heparinoid cream was applied for three days after craniotomy
62562330|NCT05430243|EXPERIMENTAL|Empagliflozin group|
62562331|NCT05430243|ACTIVE_COMPARATOR|standard treatment only group|
62562332|NCT03359408|NO_INTERVENTION|Care as usual|Care as usual, no intervention, just observation of natural change/ trajectories over time
62769875|NCT04330781|ACTIVE_COMPARATOR|Control group|N=31
62769876|NCT04336527|EXPERIMENTAL|Home Treatment with Peer Support|Patients receive a peer supported home treatment, i.e. treatment by a home treatment/crisis resolution team with a peer support worker.
62769877|NCT04336527|ACTIVE_COMPARATOR|Home Treatment without Peer Support|Patients receive conventional home treatment by a home treatment/crisis resolution team without contacts to a peer support worker.
62769878|NCT02054884|EXPERIMENTAL|Arm A: F16IL2 in combination with paclitaxel|
62769879|NCT02054884|EXPERIMENTAL|Arm B: Paclitaxel|
62390798|NCT02793024|EXPERIMENTAL|Arm 1 - Intervention|Counties will be randomized to receive the intervention or act as a delayed control. Students in the intervention arm will receive the 12-week intervention to improve shopping choices.
62390799|NCT02793024|NO_INTERVENTION|Arm 2 - Intervention|Control adolescents will not receive the intervention and will receive routine information normally distributed through schools.
62390800|NCT00987558|EXPERIMENTAL|Treatment Sequence A|Simvastatin 80mg treatment period followed by Simvastatin 80 mg + eslicarbazepine acetate 800 mg treatment period
62769880|NCT02698722|NO_INTERVENTION|Control|This group will receive verbal education about dialytic and non-dialytic therapies via a standardized script.
62769881|NCT02698722|EXPERIMENTAL|Intervention|This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
62769882|NCT00491608|EXPERIMENTAL|1|rThrombin
62769883|NCT02703688|EXPERIMENTAL|Healthy Homes|Behavioral Intervention
62769884|NCT02703688|ACTIVE_COMPARATOR|Usual Care|Counseling session delivered by pediatrician
62769885|NCT03695952||Hepatocellular carcinoma|Hepatocellular carcinoma patients treated with nivolumab
62769886|NCT03695952||Biliary Tract Cancer|Biliary tract cancer patients treated with pembrolizumab
62769887|NCT01781351|EXPERIMENTAL|taping the ankle|
62390801|NCT00987558|EXPERIMENTAL|Treatment Sequence B|Simvastatin 80mg + eslicarbazepine acetate 800 mg treatment period followed by Simvastatin 80 mg treatment period
62562333|NCT03359408|EXPERIMENTAL|Dementia Care Management (DCM)|"Subjects in this arm will be provided with Dementia Care Management adapted to the intersectoral setting."
62562334|NCT05191290|ACTIVE_COMPARATOR|heparin anticoagulation|standard heparin anticoagulation during plasmapheresis
62562335|NCT05191290|EXPERIMENTAL|citrate anticoagulation|sodium citrate anticoagulation during plasmapheresis
62562336|NCT01644851|EXPERIMENTAL|Executive function training|Executive function training
62562337|NCT01644851|PLACEBO_COMPARATOR|Word game training|Computer-based training in tasks related to verbal processing.
62562338|NCT01788826|EXPERIMENTAL|Prophylactic Mesh|Use of a prefascial polypropylene mesh when closing midline laparotomy
62769888|NCT02068560|EXPERIMENTAL|dDAVP infusion|During the 9 hour study period, the subjects will receive three doses of dDAVP infusion (0.0003micrg/kg, 0.0005micrg/kg, 0.004micrg/kg).
62769889|NCT06505759|ACTIVE_COMPARATOR|GROUP 1-SRP alone|control group is treated with SRP alone
62769890|NCT06505759|EXPERIMENTAL|GROUP 2-0.2% BROMELAIN gel|test group is treated with bromelain gel
62769891|NCT06505759|ACTIVE_COMPARATOR|GROUP 3-0.2% CHLORHEXIDINE gel|test group is treated with chlorhexidine gel
62769892|NCT00513396|EXPERIMENTAL|1|
62169013|NCT00867945||2. Non-Pregnant Controls|
62169014|NCT00867945||3. IVF controls|
62390802|NCT01851031|EXPERIMENTAL|the minor approach group|Thirty-six patients (the minor parotid anterior approach group) were treated with minor parotid anterior approach
62390803|NCT01851031|OTHER|control group|24 patients (control group) were treated with the retromandibular approach
62390804|NCT04506606|EXPERIMENTAL|Afferent effect on hemodynamics|Evaluate impact of group III/IV muscle afferents on femoral blood flow
62390805|NCT04506606|EXPERIMENTAL|Afferent effect on fatigue|Evaluate impact of group III/IV muscle afferents on exercise-induced changes in quadriceps twitch force
62562339|NCT01788826|EXPERIMENTAL|No prophylactic mesh closure|In this arm the laparotomy of the patients are closed with a running absorbable suture without a mesh
62562340|NCT00716599|NO_INTERVENTION|Control|Health centers continue with standard-of-care empiric case management
62562341|NCT00716599|EXPERIMENTAL|RDT training|Health centers randomly selected to receive training and RDTs, for use in routine patient case management
62562342|NCT01116271|EXPERIMENTAL|1|Selumetinib (AZD6244) in combination with irinotecan
62769893|NCT00513396|ACTIVE_COMPARATOR|2|
62769894|NCT00513396|PLACEBO_COMPARATOR|3|
62769895|NCT05477199|EXPERIMENTAL|Cognitive behavioral principles-based treatment program group|
62769896|NCT05477199|ACTIVE_COMPARATOR|Control group|
62769897|NCT00491374|EXPERIMENTAL|MFNS|
62769898|NCT00491374|PLACEBO_COMPARATOR|Placebo|
62169015|NCT04214548||Eczema|Patients diagnosed with eczema
62169016|NCT02481349|EXPERIMENTAL|Arm I (couple-based Hatha yoga program)|Patients and their partners attend up to 15, 45-60 minute sessions of Hatha yoga over the course of radiation therapy 5 times a week for 5-6 weeks. The program comprises four main components: joint loosening with breath synchronization; postures with deep relaxation techniques; breath energization with sound resonance; and meditation. At the fifth session, patients and their partners receive a DVD and are encouraged to practice on their own (individually and/or together) on the days when they do not meet with the instructor.
62169017|NCT02481349|ACTIVE_COMPARATOR|Arm II (waitlist control)|Patients receive standard of care provided by the health care team and complete questionnaires before and after radiation therapy.
62169018|NCT00833456||1|Seroquel SR: Patients whose symptoms are controlled with Seroquel SR and started with the therapy up to 1 month before the inclusion
62169019|NCT00833456||2|Atypical antipsychotics: Patients whose symptoms are controlled with atypical antipsychotic in once daily formulation (excluding Seroquel SR) and started with the therapy up to 1 month before the inclusion
62169020|NCT06121401|OTHER|Olaparib - Bevacizumab|Olaparib 300 mg 2\*daily + Bevacizumab 15mg/kg (q3w)
62169021|NCT00885859||1|responders: patients who have a pain reduction of 30% or more after two weeks TENS-treatment
62169022|NCT00885859||2|non-responders: patient who have a pain reduction smaller than 15% after two weeks TENS-treatment
62169023|NCT01003379|EXPERIMENTAL|TC-5619|TC-5619 capsules will be administered once a day in a forced titration scheme at 1 mg for 4 weeks, 5 mg for 4 weeks and 25 mg for 4 weeks (12 weeks total).
62169024|NCT01003379|PLACEBO_COMPARATOR|Placebo|
62390806|NCT04506606|EXPERIMENTAL|Effect of cardiac rehab|Evaluate effect of chronic exercise on influence of muscle afferents on limb blood flow
62390807|NCT01030731|EXPERIMENTAL|Ceftobiprole (end-stage renal disease subjects).|Ceftobiprole 250mg single dose over 2 hours.
62562343|NCT01385137|EXPERIMENTAL|Arm I|Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity.
62562344|NCT01385137|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity.
62562345|NCT02862236|EXPERIMENTAL|Hypericum perforatum (Remotiv, 250 mg)|
61994694|NCT05352295||infected|40 patients admitted to the IRCCS Galeazzi Orthopedic Institute for fracture with Covid 19 infection ascertained by nasal pharyngeal swab during the patients' clinical routine
61994695|NCT05352295||not infected ( control)|40 patients admitted to the IRCCS Galeazzi Orthopedic Institute for fracture without Covid 19 infection ascertained by nasal pharyngeal swab during the patients' clinical routine
62169025|NCT05406206|EXPERIMENTAL|HAIC combined with Fruquintinib|HAIC with fruquintinib until progression. Fruquintinib should be administrated within 1 week after HAIC.
62169026|NCT02910336||Cases|Orofacial Pain patients under went to quantitative sensory test
62169027|NCT02910336||Control|Volunteers and presented neither previous diagnostic of orofacial pain nor generalized pain, under went to quantitative sensory test
62169028|NCT00308009|ACTIVE_COMPARATOR|1|Group I, Prolapse repair and TVT concomitantly
62169029|NCT00308009|ACTIVE_COMPARATOR|2|Group II, Prolapse repair and TVT 3 months afterwards if necessary
62169030|NCT00675519|EXPERIMENTAL|BI|
62390808|NCT01030731|ACTIVE_COMPARATOR|Ceftobiprole (healthy subjects)|Ceftobiprole 250 mg single dose over 2 hours.
62390809|NCT04710628|EXPERIMENTAL|PEMBROLIZUMAB + LENVATINIB|"Pembrolizumab 200 mg will be administered to patients as 30-minute IV infusion every 3 weeks (a window of -5 minutes and +10 minutes is permitted).~Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab). Lenvatinib cannot be chewed"
62390810|NCT00387621|EXPERIMENTAL|Placebo First, then Nesiritide (Arm A)|In the first intervention period the subjects received subcutaneous placebo given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered. There was a 2 week washout period. In the second intervention period, the subjects received subcutaneous nesiritide given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered.
62562346|NCT02862236|EXPERIMENTAL|Hypericum perforatum (Remotiv, 500 mg)|
62562347|NCT03695783|EXPERIMENTAL|Online decision aid called IBD&me|IBD\&me is an online, freely available tool that allows patients to explore decision-making around biologic therapies for IBD at their own pace. It includes an educational component and an interactive exercise with a series of ratings tasks that generates a personalized preferences report for patients to share and discuss with their physician.
62169031|NCT06324188|OTHER|Early atrial fibrillation ablation|
62169032|NCT06324188|OTHER|Usual Care|
62169033|NCT02898350|ACTIVE_COMPARATOR|Pulsed Dye Laser treatment|Pulsed Dye Laser treatment after suture removal (3 sessions)
62169034|NCT02898350|ACTIVE_COMPARATOR|CO2 laser treatment|CO2 laser (3 treatment sessions) after suture removal
62169035|NCT02898350|ACTIVE_COMPARATOR|Combined PDL and CO2 Laser treatment|Combined PDL and CO2 Laser resurfacing (3 treatment sessions) after suture removal
62169036|NCT02898350|ACTIVE_COMPARATOR|Split PDL and CO2 Laser treatment|Half of the scar was not treated and served as a control, while the other half was treated with CO2 ablative fractional resurfacing immediately after surgery, in addition to the three combined PDL and CO2 treatment sessions after suture removal
62169037|NCT05680298|EXPERIMENTAL|AD patients|Pediatric patients (≥6 and \<12 years of age) with moderate-to-severe AD will receive a SC injection of dupilumab depending on the body weight
62562348|NCT03695783|ACTIVE_COMPARATOR|Standardized educational material|PDF file corresponding to the CCFA's online resource on biologic therapies, which is a well-researched and clearly presented overview of IBD biologic therapies, but without an active shared-decision making component.
61994696|NCT02180282|EXPERIMENTAL|Acne Treatment|Acne treatment using the M22-IPL acne filter
61994697|NCT04205760|NO_INTERVENTION|Control group|Standard Care as per local guidelines
61994698|NCT04205760|EXPERIMENTAL|Intervention|Oral nutrition support (ONS) and bed-cycling before surgery
61994699|NCT01940926|EXPERIMENTAL|68Ga-BNOTA-PRGD2|In patients with RA, single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 will be given at 30 minutes before PET/CT scanning to determine 68Ga-BNOTA-PRGD2 uptake in joints.
62169038|NCT05680298|NO_INTERVENTION|Healthy volunteers|Except for IMPs administration, skin barrier function assessments for healthy volunteers are conducted at the same time and in the same measurement conditions as for AD patients.
62169039|NCT05335811|EXPERIMENTAL|4-[18F]Fluoro-1-Naphthol|Participants will receive 1 injection of \[18F\]4FN
61994700|NCT01399242|ACTIVE_COMPARATOR|Certican, prednisona, EC-MPS|Twenty patients will be selected at 16 weeks of renal transplantation to convert a immunosuppression to certican,prednisone and myfortic. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation
61994701|NCT01399242|NO_INTERVENTION|Tacrolimus,Prednisona, EC-MPS|Twenty patients will be selected at 16 weeks of renal transplant to continue use EC-MPS,Tacrolimus and Prednisone. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation
62169040|NCT01427231|ACTIVE_COMPARATOR|Drink with 50 g glucose|The glucose drink contains 50 g of glucose soluted in 250 ml of water and lemon juice.
62169041|NCT01427231|ACTIVE_COMPARATOR|Drink with 100 gram of sacharose|The sacharose drink contains 100 g of sacharose soluted in 250 ml of water and lemon juice.
62169042|NCT01427231|PLACEBO_COMPARATOR|Placebo with sweeteners|The placebo contains a mixture of artificial sweeteners in order to have the same sweetness and appearance of the test drinks (the glucose drink and the sacharose drink).
62169043|NCT06127485|ACTIVE_COMPARATOR|Control group|The treatment received is a combination of physiotherapy and conventional occupational therapy sessions two days a week, with a duration of 60 minutes divided into 30 minutes of physiotherapy and 30 minutes of occupational therapy.
62169044|NCT06127485|EXPERIMENTAL|Experimental Group|The experimental group received 60 minutes of conventional rehabilitation combined with the Pilates Method, divided into 20 minutes of physiotherapy, 20 minutes of occupational therapy and 20 minutes of Pilates Method.
62390811|NCT00387621|EXPERIMENTAL|Nesiritide First, then Placebo (Arm B)|In the first intervention period the subjects received subcutaneous nesiritide given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered. There was a 2 week washout period. In the second intervention period, the subjects received subcutaneous placebo given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered.
62562349|NCT06162598|NO_INTERVENTION|Control Group|Children in the control group will undergo the routine preparation procedure applied in the emergency department. Before and after inhaler treatment, the child, parent, and nurse will be asked to fill out data collection forms to assess the child's anxiety and fear levels.
62567760|NCT04750395|EXPERIMENTAL|Olanzapine|Every 24 hours, patients will receive two regular doses of OT Olanzapine 5.0mg. Patients may also receive up to two breakthrough doses within a minimum interval of one hour from the last dose. In total, up to four doses of medication will be prepared.
61994702|NCT06254053|EXPERIMENTAL|Zirconomer Restorative material in primary molar|Arm one zirconomer restorative material (intervention)
62567761|NCT00359424|ACTIVE_COMPARATOR|intravenous (IV) rt-PA alone|Group one will receive the standard dose of intravenous (IV) rt-PA alone given over an hour.
62769899|NCT01560299|ACTIVE_COMPARATOR|group one|This group will be advised to discontinue methimazole 24-48 hour before iodine therapy
61994703|NCT06254053|ACTIVE_COMPARATOR|Glass Ionomer Cement in primary molar|Arm two Glass Ionomer cement (control)
62769900|NCT01560299|ACTIVE_COMPARATOR|group two|methimazole stopped 48-72 hour before radioiodine therapy
61994704|NCT03459664|EXPERIMENTAL|RECOVER|The intervention in the RECOVER stepped-care model includes specific evidence-based treatment options for severity grade 1 to 4.
61994705|NCT03459664|ACTIVE_COMPARATOR|Treatment As Usual|The active comparator is treatment as usual (TAU) and provides all common care options within the German health care system, depending on the severity grade 1 to 4.
62769901|NCT01560299|ACTIVE_COMPARATOR|group three|
62769902|NCT02274259|ACTIVE_COMPARATOR|Aflibercept|Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
61994706|NCT00490516|EXPERIMENTAL|1|
61994707|NCT00490516|EXPERIMENTAL|2|
61994708|NCT00490516|PLACEBO_COMPARATOR|3|
61994709|NCT04692961|EXPERIMENTAL|Patients after free flap harvested|Patients receiving peroneal artery-based free flap harvest
62169045|NCT03571347|EXPERIMENTAL|Self Help Plus|SH+ programme has been developed by WHO and collaborators working in the humanitarian field, with expertise in global mental health and psychosocial interventions. SH+ programme consists of a pre-recorded audio course, complemented with bibliotherapy, and thanks to this format not requiring much time from experts for implementation. SH+ consists of 5 sessions.
61994710|NCT02204748||DePuy Attune PS FB TKA|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system implanted by a single surgeon at least three months post-operative.
62169046|NCT03571347|OTHER|Enhanced Treatment As Usual|Control arm participants will receive routine social support and/or care according to ordinary practice and following local regulations. Additionally, they will receive baseline and follow-up assessments according to the study schedule, and information about freely available mental health services, social services and community networks providing support to asylum seekers and refugees, and NGOs' contact details.
62769903|NCT02274259|ACTIVE_COMPARATOR|Ranibizumab|Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
62769904|NCT01381536|EXPERIMENTAL|GSK1550188 1mg/kg or 10mg/kg|one shot IV
62769905|NCT01143194|EXPERIMENTAL|oréVida™ 60mg/day|
61994711|NCT02165319|ACTIVE_COMPARATOR|Barrel|Endotracheal tube with barrel-shaped cuff will be used during general anesthesia.
61994712|NCT02165319|ACTIVE_COMPARATOR|Tapered|Endotracheal tube with tapered-shaped cuff will be used during general anesthesia.
61994713|NCT04087122|EXPERIMENTAL|Esophageal warming|Patients receive the Attune Medical Esophageal Heat Transfer Device
61994714|NCT00819715||1|Small for gestational age preterm infants
62769906|NCT01143194|EXPERIMENTAL|oréVida™ 120mg/day (1)|
62562350|NCT06162598|EXPERIMENTAL|Ventriloquist Puppet group|The preparation for the procedure will be accompanied by a puppet before the treatment. The child will be told about the features of the puppet and will be introduced to it. The inhaler treatment application will be explained to the intervention group through the ventriloquist puppet method. By making the puppet talk using the ventriloquism technique, the child will be able to understand the procedure. The application of the inhaler will be shown to the child with the help of a nebulizer mask on the puppet. Before the application and after the inhaler treatment, the child, parent, and nurse will be asked to fill out the children's state anxiety scale and children's fear scale to evaluate the child's anxiety and fear levels.
62562351|NCT03345771|ACTIVE_COMPARATOR|Antimicrobial Barrier Dressing|postoperative wound dressing with either anti-microbial dressing placed in the operating room from surgery to postoperative day 7
62562352|NCT03345771|ACTIVE_COMPARATOR|Closed-incision Negative Pressure Therapy|portable NPWT device placed in the operating room from surgery to postoperative day 7
62562353|NCT05159947|EXPERIMENTAL|Test group (SPT-07A injection group)|
62562354|NCT05159947|PLACEBO_COMPARATOR|Control group (placebo group)|
61994715|NCT00819715||2|Appropriate for gestational preterm infants
61994716|NCT00868621||1|Control Group(CG)- Healthy age-matched volunteers with no urinary symptoms.
62169047|NCT04034602|EXPERIMENTAL|vibration group|plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
62390812|NCT00797043||Photon/Proton Radiation Therapy|Data consolidation and analysis
62390813|NCT03487562|EXPERIMENTAL|Sequence 1|Part I: A-B-D-C A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
62562355|NCT01664637|EXPERIMENTAL|TZP-102 three times a day|10 mg TZP-102 will be taken 30 minutes prior to each main meal for a total of three daily doses.
62562356|NCT01664637|PLACEBO_COMPARATOR|Placebo three times a day|Placebo will be taken 30 minutes prior to each main meal for a total of three daily doses.
62562357|NCT01628497||Positive filariasis test|Those testing positive for filariasis
62769907|NCT01143194|EXPERIMENTAL|oréVida™ 120mg/day (2)|
62769908|NCT01143194|PLACEBO_COMPARATOR|Placebo|
62562358|NCT01628497||Filariasis negative|
62769909|NCT03323190|EXPERIMENTAL|Inpatient COPD patient|All COPD patients meeting the inclusion criteria of this study will be exposed to inpatient COPD education and tested at a later date to determine if knowledge on COPD was gained.
62562359|NCT03075371|ACTIVE_COMPARATOR|intragastric glucose administration|
62562360|NCT03075371|PLACEBO_COMPARATOR|intragastric water administration|
62769910|NCT06061107|EXPERIMENTAL|Handbook for Geriatric Prearranged Medical Care Consultation|"The experimental group utilized a cartoon version of the Advance Care Consultation for the Elderly manual to facilitate the ACP process, which encompassed three components: an introduction to ACP, an overview of terminal medical care, and a discussion about the participants' preferences for their past, current, and future required medical care."
61994717|NCT00868621||2|Overactive Bladder Patients Group(OAB)- Patients with urgency of urination.
61994718|NCT00868621||3|Urinary Tract Infection Group(UTI)- Symptomatic patients with dysuria, urgency and frequency of urination with proven urine cultures of infection.
61994719|NCT04629287|EXPERIMENTAL|KPCXM18 for injection|KPCXM18 ，freeze-dried powder,single and multiple ascending doses, Intravenous route
62562361|NCT03686059|EXPERIMENTAL|punctal plug|SOFT PLUG® Preloaded Silicone Plugs by OASIS®
62562362|NCT03686059|EXPERIMENTAL|Combined|SOFT PLUG® Preloaded Silicone Plugs by OASIS® plus Daily intake of DHA (docosahexaenoic acid)
62562363|NCT03686059|NO_INTERVENTION|control|no medication was given
62562364|NCT02498197|EXPERIMENTAL|Participatory Intervention|Participatory intervention with workers and their leaders. Workshops with presentation of work tasks with excessive physical load and subsequently plans to reduce these loads
62562365|NCT02498197|ACTIVE_COMPARATOR|Control|Receive standard information about correct lifting technics, use of assistive technology, and ergonomics
62562366|NCT00995917|EXPERIMENTAL|Vitamin K acupoint injection|Participants will receive the vitamin K intervention within 2 days of the onset of painful menstrual cramps.
62562367|NCT00995917|SHAM_COMPARATOR|Saline Injection|Participants will receive the saline treatment within 2 days of the onset of painful menstrual cramps.
62562368|NCT06414941|EXPERIMENTAL|Dexmedetomidine on sleep quality with radical mastectomy|Dexmedetomidine infusion Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
62769911|NCT06061107|NO_INTERVENTION|Control group|No Intervention: standard clinical care
62769912|NCT00963768|EXPERIMENTAL|Cohort 1|JNJ-28431754 30 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
62169048|NCT04034602|ACTIVE_COMPARATOR|placebo group|the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
62169049|NCT06040138||Patients with prolonged weaning|Patients who have failed more than 3 spontaneous breathing trials, in pressure support ventilation, with hemodynamic and metabolic stability, and a regular and stable ventilatory pattern.
62169050|NCT00580047|ACTIVE_COMPARATOR|1 Zoledronic Acid|Zoledronic Acid 4mg intravenously once a year for 2 years
62390814|NCT03487562|EXPERIMENTAL|Sequence 2|Part I: B-C-A-D A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
62390815|NCT03487562|EXPERIMENTAL|Sequence 3|Part I: C-D-B-A A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
62562369|NCT06414941|EXPERIMENTAL|Dexmedetomidine plus low-dose esketamine on sleep quality with radical mastectomy|Dexmedetomidine and low-dose eskeamine combined infusion Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
62562370|NCT06414941|EXPERIMENTAL|Dexmedetomidine plus high- dose esketamine on sleep quality with radical mastectomy|Dexmedetomidine and high-dose eskeamine combined infusion Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
62562371|NCT01983566|ACTIVE_COMPARATOR|BI 207127 fasted|patient to receive BI 207127 as a single dose in fasted state
62562372|NCT01983566|EXPERIMENTAL|BI 207127 high fat|patient to receive BI 207127 as a single dose after a high fat breakfast
62390816|NCT03487562|EXPERIMENTAL|Sequence 4|Part I: D-A-C-B A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
62769913|NCT00963768|EXPERIMENTAL|Cohort 2|JNJ-28431754 100 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
62390817|NCT03487562|EXPERIMENTAL|A|Part II: (DWP14012 B mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
62169051|NCT00580047|ACTIVE_COMPARATOR|2 Alendronate|Alendronate 70mg orally once a week for 2 years
62390818|NCT03487562|EXPERIMENTAL|B|Part II: (DWP14012 A mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
62390819|NCT03487562|EXPERIMENTAL|C|Part II: (Lansoprazole 30 mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
62562373|NCT01983566|EXPERIMENTAL|BI 207127 low fat|patient to receive BI 207127 as a single dose after a low fat breakfast
62562374|NCT01983566|EXPERIMENTAL|BI 207127 with Omeprazole|patient to receive BI 207127 as a single dose after 4 days treatment with Omeprazole 40 mg once a day
62562375|NCT00816998|OTHER|Early|Participants randomized to this arm will begin physical therapy of their fractured wrist approximately one week following surgery
62769914|NCT00963768|EXPERIMENTAL|Cohort 3|JNJ-28431754 300 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
62169052|NCT00580047|PLACEBO_COMPARATOR|3 Placebo|Combination drug entity: calcium 1200 mg with vitamin D 800 International Units daily
62169053|NCT05071378|EXPERIMENTAL|Intervention Group|This arm will be enrolled in the intervention prior to any data collection
62169054|NCT05071378|NO_INTERVENTION|Wait listed control|This arm will receive the intervention after all study data is collected
62390820|NCT00736840|OTHER|CLD (chronic liver disease)|Chronic liver disease subjects with recent biopsy will be tested with a breath tests using a 13C enriched substrate metabolized by their liver
62390821|NCT01026727|EXPERIMENTAL|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|MPC-4326 300 mg or 400mg BID plus a 2-3 drug optimized background regimen (OBR)for 24 weeks.
62390822|NCT01026727|ACTIVE_COMPARATOR|3-4 drug antiretroviral drugs|3-4 commercially available antiretroviral (ARV)drugs for 24 weeks.
62169055|NCT01047306||No Treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIA to identify potential surrogate endpoints for future ERT trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral and imaging measures.
62390823|NCT00670098|EXPERIMENTAL|1|
62562376|NCT00816998|OTHER|Delayed|Participants randomized to this group will begin physical therapy of their fractured wrist approximately 6 weeks from their surgery. This is the approximate time frame in which therapy begins for patients not involved in the study. The term Delayed refers to therapy being delayed in starting from those in the study who begin therapy at one week post-operatively, not a delay in current care practice.
62390824|NCT00670098|EXPERIMENTAL|2|
62390825|NCT01832272|EXPERIMENTAL|Reinflation after early deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled (Reinflation after early tourniquet deflation).
62390826|NCT01832272|NO_INTERVENTION|No reinflation after early deflation|The tourniquet is released after cement implant fixation, and remained deflated without reinflation, even after hemostasis.
62390827|NCT00630942|EXPERIMENTAL|Single Arm, active treatment|
62390828|NCT04211506|EXPERIMENTAL|Sleep Arm 1|This will be the first of four arms of controlled sleep manipulation.
62390829|NCT04211506|EXPERIMENTAL|Sleep Arm 2|This will be the second of four arms of controlled sleep manipulation.
62390830|NCT04211506|EXPERIMENTAL|Sleep Arm 3|This will be the third of four arms of controlled sleep manipulation.
62390831|NCT04211506|EXPERIMENTAL|Sleep Arm 4|This will be the fourth of four arms of controlled sleep manipulation.
62169056|NCT05530083|EXPERIMENTAL|group education|The investigators will provide experimental groups with group education of smoking cessation, including lectures in groups of 50 to 100 people and panel discussion in groups of 5 to 10 people.
62390832|NCT02651311|EXPERIMENTAL|Block|"ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg.~Fentanyl in postanesthesia care unit(PACU), Ibuprofen in ward when pain scale (FLACC) is equal to or more than 4."
62390833|NCT02651311|PLACEBO_COMPARATOR|No block|Fentanyl in PACU, Ibuprofen in ward when pain scale (FLACC) is equal to or more than 4.
62390834|NCT02155725|EXPERIMENTAL|Human Fibrinogen concentrate|2 vials (200ml) / 3g intravenous
62390835|NCT02155725|PLACEBO_COMPARATOR|Placebo|2 vials (200ml)
62390836|NCT06263504|ACTIVE_COMPARATOR|receive standard treatment group|
62390837|NCT06263504|EXPERIMENTAL|comprehensive treatment group|
62562377|NCT03194542|EXPERIMENTAL|Luspatercept in subjects with MPN-associated myelofibrosis|Subjects across each of the cohorts (Cohort 1, Cohort 2, Cohort 3A, and Cohort 3B) will receive luspatercept.
62562378|NCT01615419||Cohort|
62562379|NCT03669510|ACTIVE_COMPARATOR|computer gaiuded IAN|Computer guided surgical technique
62562380|NCT03669510|EXPERIMENTAL|Classical technique|Non computer guided surgical technique
62390838|NCT04917666|EXPERIMENTAL|Treatment|Participants joined a 8-session horticultural therapy group program (60 minutes per session) over 8 weeks.
62390839|NCT04917666|OTHER|Comparison|Participants joined 4 sessions of individual, parallel, and table-top activities of their own interest, e.g. reading, drawing, coloring.
62390840|NCT06289543|NO_INTERVENTION|Starvation|Fasting for 6-8 hours before the operation
62562381|NCT01621334|EXPERIMENTAL|Motivational Enhancement Therapy|Motivational Enhancement Therapy
62562382|NCT01621334|OTHER|Educational brochure|Intimate Partner Violence, Substance Abuse, and HIV risky behaviors Education
62562383|NCT05867030|EXPERIMENTAL|Parsaclisib+rituximab|parsaclisib（2.5 mg QD，D1\~D14/ per28 days）+rituximab ( 375mg/m2, IV, C1D1\\D8\\D15\\D22, C2D1\\C3D1\\C4D1\\C5D1).
62390841|NCT06289543|ACTIVE_COMPARATOR|Water|drink 400ml of water 2 hours before the operation
62390842|NCT06289543|ACTIVE_COMPARATOR|oral carbohydrate|drink 400ml of solution 2 hours before the operation
62390843|NCT04064463|ACTIVE_COMPARATOR|Control Group|Standard care
62390844|NCT04064463|EXPERIMENTAL|Experimental Group|Standard care plus contingency management
62390845|NCT06139978||Pregnant women in male fetus|
62390846|NCT06139978||Pregnant women in female fetus|
62390847|NCT02990325|EXPERIMENTAL|ABX464 150mg|ABX464, 50mg per Capsule Three Capsules per day for 28 days
62390848|NCT02990325|EXPERIMENTAL|ABX464 50mg for 28 days|ABX464, 50mg per Capsule One Capsule per day for 28 days
62390849|NCT02990325|EXPERIMENTAL|ABX464 50mg for 84 days|ABX464, 50mg per Capsule One Capsule per day for 84 days
62390850|NCT02014753||CoCr-EES, 2-week OCT follow-up|Undergo primary PCI with cobalt-chromium everolimus-eluting stent (CoCr-EES) for AMI culprit lesion and perform OCT observation at 2-week after PCI.
62390851|NCT02014753||CoCr-EES, 3-month OCT follow-up|Undergo primary PCI with cobalt-chromium everolimus-eluting stent (CoCr-EES) for AMI culprit lesion and perform OCT observation at 3-month after PCI.
62390852|NCT05770882|EXPERIMENTAL|Part I safety; and Part II cohort expansion|"Part I: The safety of drug combination will be studied.~Part II: The drug combination will be further evaluated in the cohort expansion phase."
62562384|NCT05867030|EXPERIMENTAL|Parsaclisib+rituximab + lenalidomide|parsaclisib（2.5 mg QD，D1\~D14/ per28 days）+rituximab( 375mg/m2, IV, C1D1\\D8\\D15\\D22, C2D1\\C3D1\\C4D1\\C5D1)+lenalidomide( 20mg PO, D1-D21/Cycle, no more than 12cycles).
62390853|NCT02926833|EXPERIMENTAL|Phase 1 Cohort 1: KTE-C19 + ATZ (After 21 Days of KTE-C19)|Participants received conditioning chemotherapy consisting of 30 mg/m\^2 fludarabine and 500 mg/m\^2 cyclophosphamide intravenous (IV) infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10\^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg followed by 4 doses of atezolizumab (ATZ) (1200 mg/dose) IV infusion every 21 days, beginning 21 days following KTE-C19.
62390854|NCT02926833|EXPERIMENTAL|Phase 1 Cohort 2: KTE-C19 + ATZ (After 14 Days of KTE-C19)|Participants received conditioning chemotherapy consisting of 30 mg/m\^2 fludarabine and 500 mg/m\^2 cyclophosphamide IV infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg followed by 4 doses of ATZ (1200 mg/dose) IV infusion every 21 days, beginning 14 days following KTE-C19.
62562385|NCT00729664|EXPERIMENTAL|Anti-PDL-1 antibody (Arm 1)|BMS-936559 (MDX-1105)
62390855|NCT02926833|EXPERIMENTAL|Phase 1 Cohort 3: KTE-C19 + ATZ (After 1 Day of KTE-C19)|Participants received conditioning chemotherapy consisting of 30 mg/m\^2 fludarabine and 500 mg/m\^2 cyclophosphamide IV infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg followed by 4 doses of ATZ (1200 mg/dose) IV infusion every 21 days, beginning 1 day following KTE-C19.
62390856|NCT02926833|EXPERIMENTAL|Phase 2: KTE-C19 + ATZ (After 1 Day of KTE-C19)|Participants received conditioning chemotherapy consisting of 30 mg/m\^2 fludarabine and 500 mg/m\^2 cyclophosphamide IV infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg followed by 4 doses of ATZ (1200 mg/dose) IV infusion every 21 days, beginning 1 day following KTE-C19.
62390857|NCT05015959||mortality outcomes|mortality classification into preventable, potentially preventable and non-prevenatable
62390858|NCT06510192|EXPERIMENTAL|Yuva Sath Intervention|The Yuva Sath Intervention entails 6 one-on-one sessions delivered by peer counselors who will use an intervention manual consisting of modules and an intervention script. These sessions will occur over a period of 3 months. The intervention will also entail weekly check-in text messages from peer counselors. These weekly check-ins will occur over a period of 5 months.
62390859|NCT06510192|NO_INTERVENTION|Treatment as usual|The treatment as usual arm consists of a single motivational interviewing session that will be provided by existing counselors at the integrated care center where the trial will take place. Participants in this arm will not receive the Yuva Sath Intervention
62390860|NCT00768040|EXPERIMENTAL|Aliskiren 300 mg|Aliskiren 300 mg once daily for 12 weeks
62390861|NCT00768040|PLACEBO_COMPARATOR|Placebo|Matching placebo once daily for 12 weeks
62390862|NCT02573142|ACTIVE_COMPARATOR|Education-only|Subjects in the education-only control will receive standard of care clinical treatment in the Duke Healthy Lifestyles clinic and educational materials describing community-based resources for physical activity and how to access them.
62390863|NCT02573142|EXPERIMENTAL|Bull City Fit Intervention|Subjects in the Bull City Fit intervention will receive standard of care clinical treatment in the Duke Healthy Lifestyles clinic and unlimited access to a community-based wellness program that includes physical fitness activities and cooking classes.
62390864|NCT04929314|EXPERIMENTAL|Intervention|Participants in the intervention group receive specialised nursing care that focuses on the interactive communication model. The nurses who deliver care to participants in the intervention group receive specific education and training in order to be able to provide nursing based on the interactive communication model and more individualised nursing based on health literacy level.
62390865|NCT04929314|NO_INTERVENTION|Control|The participants in the control group receive usual care. The 98 municipalities in Denmark have a specialised role in community care and rehabilitation where nursing and practical help is carried out in the patients' own homes. Community care is usually provided at regular intervals based on a clinical evaluation of the patients' needs.
62390866|NCT03288987|EXPERIMENTAL|Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)|Bevacizumab+FOLFIRI-3 (irinotecan, leucovorin, and 5-FU). Bevacizumab (AryoGen) 5 mg/kg will be administered every 2 weeks.
62390867|NCT03288987|ACTIVE_COMPARATOR|Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)|Bevacizumab+FOLFIRI-3 (irinotecan, leucovorin, and 5-FU). Bevacizumab (Avastin®) 5 mg/kg will be administered every 2 weeks.
62390868|NCT05460468|EXPERIMENTAL|TMS-Randomized|Three different closed-loop conditions will be tested, each triggered by the presence of a sustained period of alpha-band power. In the first condition, arrhythmic TMS trains with a stochastic (randomized) inter-pulse interval, will be used to disrupt cortical alpha oscillations and thus be expected to enhance memory performance.
62562386|NCT00729664|EXPERIMENTAL|Anti-PDL-1 antibody (Arm 2)|BMS-936559 (MDX-1105)
62562387|NCT00729664|EXPERIMENTAL|Anti-PDL-1 antibody (Arm 3)|BMS-936559 (MDX-1105)
62562388|NCT00729664|EXPERIMENTAL|Anti-PDL-1 antibody (Arm 4)|BMS-936559 (MDX-1105)
62562389|NCT00729664|EXPERIMENTAL|Anti-PDL-1 antibody (Arm 5)|BMS-936559 (MDX-1105)
62562390|NCT05202314|EXPERIMENTAL|Immunotherapy group|After clinical success of colonic stenting, regardless of the MSI state all patients will receive Immunotherapy (Camrelizumab 200mg) for 2 cycles compined with neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 2-3 weeks after the last cycle of chemotherapy, type and extent of the surgery will be selected by the surgeon.
62562391|NCT02519686||Trendelenburg position maneuver|Trendelenburg (TD) positioning (supine with head tilt-down) is used in abdominal and gynecological surgery as well as during colonoscopy to allow better access to the pelvic organs, as gravity pulls the bowel out of the pelvic cavity and the rectosigmoid angle straightens.
62562392|NCT02519686||Left lateral position maneuver|Left Lateral (LL) position (patient laying on their side, traditionally used for colonoscopies)
62562393|NCT01757093|EXPERIMENTAL|Automatic tube compensation plus CPAP|The patients is going to undergo trials of spontaneous breathing with automatic tube compensation plus continuous positive airway pressure and later a trial with continuous positive airway pressure. During 30 minutes.
62562394|NCT01757093|ACTIVE_COMPARATOR|Continuous Positive Airway Pressure|The patients is going to undergo a trial of spontaneous breathing with continuous positive airway pressure and later with automatic tube compensation plus continuous positive airway pressure, during 30 minutes each.
62169057|NCT05530083|OTHER|conventional smoking cessation management|The investigators will provide control groups with conventional smoking cessation management, including regular follow-up of smoking status and giving advice of smoking cessation.
62169058|NCT01393314|ACTIVE_COMPARATOR|Honeywell HomMed Telemonitor|TeleCareOhio Monitor (Honeywell HomeMed) system provides in-home medical monitoring for patients with chronic disease such as heart failure.
62169059|NCT01393314|NO_INTERVENTION|Usual care|These participants receive usual care which consists of usual home-care with educational package.
62169060|NCT05301361|ACTIVE_COMPARATOR|Methylphenidate|
62169061|NCT05301361|PLACEBO_COMPARATOR|Placebo|
62562395|NCT01095276|PLACEBO_COMPARATOR|Nebulized saline|patients on mechanical ventilation who were randomized to receive a placebo comparator (vehicle solution for dornase alpha)
62562396|NCT01095276|ACTIVE_COMPARATOR|dornase alpha|patients on mechanical ventilation who were randomly assigned to receive dornase alpha by in-line nebulization
62169062|NCT01243658|EXPERIMENTAL|Oxytocin|Oxytocin
62169063|NCT01243658|PLACEBO_COMPARATOR|Placebo|Placebo
62169064|NCT02592928||Lleida Health Sector|"Lleida (168k inhabitants and 21 Primary Care centers). Primary Care centers from this health sector~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
62169065|NCT02592928||Vic Health Sector|"Vic (49k inhabitants and 11 Primary Care Centers). Primary Care centers from this health sector~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
62169066|NCT02592928||AISBE Health Sector|"Atenció Integral en Salut Barcelona Esquerra (AISBE) (540k inhabitants and 19 Primary Care centers). Primary Care centers from this health sector~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
62169067|NCT03373500|EXPERIMENTAL|Low Salt Diet|Dietary salt reduction: Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
62390869|NCT05460468|EXPERIMENTAL|TMS-Ordered|Three different closed-loop conditions will be tested, each triggered by the presence of a sustained period of alpha-band power. In the second condition, rhythmic (ordered) alpha-frequency TMS trains, with the expectation that this alpha stimulation will further entrain a synchronization during the task and thereby worsen memory performance.
62562397|NCT06087848|EXPERIMENTAL|MSC Intervention Group|"Participants will receive 100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cells in one intravenous infusion.~Additional systemic treatments can be repeated after a minimum of 3 months and data will be collected to investigate the potential preventive benefits it provides for the above indications. Additional doses are optional for all study participants enrolled in the study and will be managed in a separate consenting process. Study participants opting for an extra dose must at the time of the extra dose meet the same inclusion and exclusion criteria as participants being included for the first dose"
62562398|NCT04269369|EXPERIMENTAL|Group A|Dosage according to French guidelines
62169068|NCT03373500|NO_INTERVENTION|Standard Treatment|Patients will be instructed to continue with their usual diet, therefore no advice will be given about salt reduction.
62169069|NCT06089967||Immune checkpoint inhibitor treatment|Adult cancer patients starting standard of care immune checkpoint inhibitor therapy. Participants willing to provide biospecimens (blood, body fluids and/or tissue) for research purposes. Participants will be followed for samples, irAEs and clinical data for up to one year after the end of treatment.
62169070|NCT03389321|EXPERIMENTAL|Treatment A-B|All subjects will receive treatment A followed by treatment B. Treatment A consists of a single oral dose (1 mg) of riociguat (Adempas) on Day 1. Treatment B consists of a loading oral dose of 30 mg macitentan (Opsumit) (3 tablets of 10 mg) on Day 5, then 10 mg of macitentan once daily from Day 6 to Day 15, with a concomitant administration of riociguat (1 mg) on Day 10.
62169071|NCT06202547|EXPERIMENTAL|intraovarian injection of MSC-EVs|The patient is anesthetized and placed in a lithotomy position, after preparing and washing the vagina with normal saline, under transvaginal ultrasound guidance (Aloka-40000 vaginal probe, Japan) using needle puncture (Reproline medical Gmbh, Rheinbach/Germany). The injection of 2 ml of extracellular vesicles derived from MSCs (equivalent to 30 million cells) will be performed into one ovary of the patient (the accessible ovary).
62169072|NCT02134249|ACTIVE_COMPARATOR|Group A (Diosmin group)|In group A, (Diosmin group), 2 tab / 8 hs Diosmin ( 500mg) will be given from at day of HCG injection and for 14 days.
62169073|NCT02134249|ACTIVE_COMPARATOR|Group B(Cabergoline group)|while in group B (Cabergoline group), 1 tab/day Cabergoline(Dostinex)( 0.5 mg) will be given at day of HCG injection and for 8 days .
62390870|NCT05460468|SHAM_COMPARATOR|TMS-Sham|Three different closed-loop conditions will be tested, each triggered by the presence of a sustained period of alpha-band power. In a third condition, sham stimulation will be delivered at the same randomized inter-pulse interval, but with no TMS delivered to the brain.
62390871|NCT01088360||Patients with rheumatoid arthritis initiating abatacept|
62390872|NCT01088360||Pts with RA initiating other biologic disease-modifying drugs|
62390873|NCT01088360||Pts w/ RA non-biologic disease-modifying anti-rheumatic drugs|
62390874|NCT04415931|EXPERIMENTAL|Local infiltration analgesia group|This group of patients will receive local infiltration analgesia
62169074|NCT06103721|EXPERIMENTAL|Group Dexmedetomidine|This will be the intervention group. Patients entering this group through computer generated random numbers will receive nebulization Dexmedetomidine in the pre-operative area under the supervision of consultant anesthetist.
62390875|NCT04415931|ACTIVE_COMPARATOR|Interscalene block group|This group of patients will receive interscalene block
62390876|NCT02142075|EXPERIMENTAL|Daptomycin, IV|"* Patients with creatinine clearance ≥30 ml/min will receive 10 mg/kg of daptomycin (Cubicin®) once daily,~* Patients with creatinine clearance \<30 ml/min will receive the same daptomycin dose (10 mg/kg) but less frequently, every 48h instead of every day"
62562399|NCT04269369|EXPERIMENTAL|Group B|Dosage according to literature
62562400|NCT05278312|EXPERIMENTAL|Otago Exercise Program|Older adults will receive the Otago Exercise Program for 8 weeks plus health awareness videos.
62562401|NCT05278312|NO_INTERVENTION|Control group|Older adults will receive only health awareness videos every 2 weeks.
62562402|NCT05791435|EXPERIMENTAL|Biofeedback group|This group will receive biofeedback to assist with breathing
62562403|NCT05791435|EXPERIMENTAL|Non-Biofeedback group|This group will only have their breathing monitored after instruction
62562404|NCT02279875|EXPERIMENTAL|Linezolid 300 mg once per day|Half of a 600mg (scored) tablet
62562405|NCT02279875|EXPERIMENTAL|Linezolid 300 mg twice per day|Half of a 600mg (scored) tablet
62169075|NCT06103721|PLACEBO_COMPARATOR|Group Normal Saline|This will be the placebo or control group. Patients entering this group through computer generated random numbers will receive nebulization with Normal Saline (placebo) in the pre-operative area under the supervision of consultant anesthetist.
62169076|NCT06181968|ACTIVE_COMPARATOR|Treatment arm|Congestive therapy will be guided by findings on daily cardiac- and lung ultrasound
62562406|NCT02279875|EXPERIMENTAL|Linezolid 600 mg once per day (A)|600mg (scored) tablet
62169077|NCT06181968|SHAM_COMPARATOR|Control Arm|This arm will have the same ultrasound exams done daily as the treatment arm, but information will not be available for the treating physician for guiding therapy
62169078|NCT05430074|OTHER|HM Cast|
62390877|NCT03110497|EXPERIMENTAL|Single application brachytherapy|After external beam radiotherapy with or without chemotherapy as per standard, each study patient will undergo single application brachytherapy to deliver 3 High Dose Rate (HDR) fractions \[1st, 2nd and 3rd fractions of doses 9 Gy, 7 Gy and 7 Gy respectively\] keeping 6-12 hours of interval. All patients will undergo an inter-fraction Computed Tomography (CT) scan before delivery of second fraction. Plan will be re-optimized to reduce the dose to Organs at Risk (OAR's), only if the dose exceeds the dose constraints. Dose constraints being exceedingly hard in 1st fraction or before 2nd fraction even after re-planning will deem patient non-feasible but optimization will be done to give preference to OAR's while accepting some compromise in target doses.
62390878|NCT04406155||Patients with suspicion of rectosigmoid endometriosis|
62390879|NCT04576585|EXPERIMENTAL|Appetite lexicon training group|They will get appetite lexicon training in week three.
62562407|NCT02279875|EXPERIMENTAL|Linezolid 600 mg once per day (B)|600mg (scored) tablet
62390880|NCT04576585|ACTIVE_COMPARATOR|taste Lexicon training|They will get taste lexicon training In week three.
62562408|NCT02279875|EXPERIMENTAL|Linezolid 600 mg twice per day|600mg (scored) tablet
62562409|NCT02279875|EXPERIMENTAL|Linezolid 1200 mg once per day|Two 600mg (scored) tablets
62562410|NCT02279875|EXPERIMENTAL|Linezolid 1200 mg 3 times per week|Linezolid 1200 mg administered as a single oral dose three times per week (1200 mg: Day 1, 3, 5, 8, 10, and 12)
62562411|NCT02279875|ACTIVE_COMPARATOR|HRZE once per day|"Treatment will be administered orally once daily for 14 days per the~Subject's weight as follows:~30-37 kg: 2 tablets;~38-54 kg: 3 tablets;~55-70 kg: 4 tablets;~71 kg and over: 5 tablets."
61994720|NCT04629287|PLACEBO_COMPARATOR|Placebo|Placebo, freeze-dried powder,single and multiple ascending doses, Intravenous route
62169079|NCT05430074|OTHER|Fibreglass Cast|
62169080|NCT03319719|EXPERIMENTAL|Belotero® Balance with integral lidocaine|Belotero® Balance with integral lidocaine will be injected in one of the two NLF (split-face study design: treatment side will be randomized)
62169081|NCT03319719|ACTIVE_COMPARATOR|Belotero Balance without lidocaine|Belotero Balance without lidocaine will be injected in one of the two NLF (split-face study design: treatment side will be randomized)
62169082|NCT02081196|EXPERIMENTAL|CoolSculpting of the Flank With Alternate Treatment Parameters|Each subject served as their own control with 1 flank treated with CoolSculpting; the contralateral flank was untreated.
62390881|NCT05539664|EXPERIMENTAL|experimental Group|The test group will use the investigational medical device Hydrogen-Oxygen Generator with Nebulizer (Shanghai Asclepius Meditec Co., Ltd.) + basic treatment (the investigator provides corresponding symptomatic support treatment based on the condition of the patients)
62390882|NCT05539664|ACTIVE_COMPARATOR|Control Group|The control group will use the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen) + basic treatment
62390883|NCT05358158|EXPERIMENTAL|Drain-free group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with intraoperative chest tube removal.
62390884|NCT05358158|ACTIVE_COMPARATOR|Chest drain group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with a standard postoperative chest tube.
62562412|NCT01618175|EXPERIMENTAL|Home oxygen therapy|Infants with acute bronchiolitis of low to moderate severity will be discharged home with supplemental oxygen and monitored by phone calls and home visits.
62562413|NCT05634421||Dermatologists|Dermatologists who have no experience with OCT.
62562414|NCT05634421||Residents|Residents who have no experience with OCT
62562415|NCT05634421||Medical students|Medical students who have no experience with OCT
62562416|NCT05634421||Nurses|Nurses who have no experience with OCT
62562417|NCT05634421||Research physicians|
62562418|NCT02158156|EXPERIMENTAL|Excercise|10 weeks of home training on a cycle-ergometer. Exercise 30 minutes every other day or at least three times a week.
62562419|NCT04276181||Combined Nerve and Tendon Transfer (CNaTT) group|The surgical procedures are described in the section Detailed description
62562420|NCT04276181||Traditional transfer procedure group|The surgical procedures are described in the section Detailed description
62562421|NCT06266182|EXPERIMENTAL|ACT intervention|Participants in the ACT intervention arm will learn new adaptive ways to cope with difficulties (including difficult thoughts or feelings).
61994721|NCT01378338||Typical reflux symptom by EGD|Total 2000 subjects who has Typical reflux symptom by EGD
61994722|NCT06332716|EXPERIMENTAL|Treatment group based on organoid drug sensitivity testing|Develop relevant treatment plans through organoid drug sensitivity testing and guide the experimental group in medication use.
61994723|NCT06332716|OTHER|Historical control group|Select patients who have previously received full standardized treatment at our center as the control group to evaluate the effectiveness of organoid drug sensitivity screening.
61994724|NCT03322228|EXPERIMENTAL|Music Therapy|1 music therapy session, lasting approximately 45 min-1 hr
62562422|NCT06266182|OTHER|Education|Participants in the Education arm will become familiar with post-HCT recommendations. This will be a minimally enhanced usual care.
62562423|NCT04037787|NO_INTERVENTION|Usual care|Perioperative care for colorectal cancer cancer is managed according to current hospital clinical practice.
62562424|NCT04037787|EXPERIMENTAL|ERAS protocol|Perioperative care for colorectal cancer surgery is managed according to ERAS protocol.
62562425|NCT01125189|EXPERIMENTAL|Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg)|
62390885|NCT03005691||Whiplash-Pain|Subjects with chronic whiplash syndrome and pain. The inclusion criteria for pain include the presence of daily pain during the previous 8 weeks. Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale. The minimum will be 2 points. Subjects will be recruited between the 4 months until 2 years after the whiplash.
62562426|NCT01125189|EXPERIMENTAL|Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg)|
62169083|NCT02333071|EXPERIMENTAL|Bremelanotide (BMT/BMT)|"(Main Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 24 weeks~(OLE Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
62390886|NCT03005691||Whiplash-no Pain|Subjects with chronic whiplash syndrome and pain. The inclusion criteria for pain include the ausence of daily pain during the previous 8 weeks. Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale. The maximun will be 2 points. Subjects will be recruited between the 4 months until 2 years after the whiplash.
62169084|NCT02333071|PLACEBO_COMPARATOR|Placebo (PBO/BMT)|"(Main Study) PBO administered SC on an as-desired basis for 24 weeks~(OLE Study) subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
62169085|NCT00292305|EXPERIMENTAL|T-crush stenting|Percutaneous coronary intervention with implantation of a stent
62169086|NCT00292305|ACTIVE_COMPARATOR|Culotte stenting|Percutaneous coronary intervention with stent
62390887|NCT03005691||Non-injured|Subjects without whiplash syndrome. The inclusion criteria are defined as a absence of previous or actual symptoms or signs of neck pain.
62562427|NCT01125189|PLACEBO_COMPARATOR|Placebo plus peg-interferon alfa-2a and ribavirin|
62562428|NCT03093194|ACTIVE_COMPARATOR|Women going CS without vaginal preparation before surgery|Women going CS without vaginal preparation before surgery. No vaginal preparation before CS with Septal soap and septol.
62562429|NCT03093194|PLACEBO_COMPARATOR|Women going CS with vaginal preparation before surgery|Women going CS with vaginal preparation before surgery. vaginal preparation before CS with Septal soap and septol.
62562430|NCT04797104|EXPERIMENTAL|LIB003 (lerodalcibep)|300 mg (1.2 mL) SC Q4W
62562431|NCT04797104|PLACEBO_COMPARATOR|Placebo|1.2 mL SC Q4W
62562432|NCT02416063|ACTIVE_COMPARATOR|caudal Dexmedetomidine|"Drug:Caudal Bupivacaine 0.25% 1ml/kg .~Drug:caudal Dexmedetomidine 1μg /kg.~Intravenous :10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
62562433|NCT02416063|ACTIVE_COMPARATOR|Intravenous Dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Drug: Intravenous dexmedetomidine 1µg/kg in a 10 ml volume normal saline~Anesthesia was induced and maintained with sevoflurane"
62562434|NCT02416063|PLACEBO_COMPARATOR|Placebo|"Caudal: bupivacaine 0.25% 1ml/kg .~Intravenous: 10 ml Normal saline~Anesthesia was induced and maintained with sevoflurane"
62562435|NCT02615782|EXPERIMENTAL|A group|"1. Period 1: CKD-397 1T single oral administration under fasting condition~2. Period 2: CKD-397 1T single oral administration under fed condition (high fat meals)"
62562436|NCT02615782|EXPERIMENTAL|B group|"1. Period 1: CKD-397 1T single oral administration under fed condition (high fat meals)~2. Period 2: CKD-397 1T single oral administration under fasting condition"
62562437|NCT03458078|PLACEBO_COMPARATOR|Group C|Control group
62562438|NCT03458078|ACTIVE_COMPARATOR|Group Mg|Magnesium sulfate group
62562439|NCT03458078|ACTIVE_COMPARATOR|Group MDZ|Midazolam group
62562440|NCT01094704|EXPERIMENTAL|Hypertonic Saline - 1 hour|sodium chloride (7%); mucociliary clearance measured 1 hour post dose
62169087|NCT01863537|EXPERIMENTAL|Intervention|Multimedia Connect and the Multimedia facilitator training curriculum with a 4-day, face-to-face structured orientation and training for implementation, and planned, investigative team initiated telephone consultations with CBO staff to provide technical assistance at 2 and 4 months following the training workshop;
62390888|NCT01199874|ACTIVE_COMPARATOR|Primary 1: Rotavirus vaccine 6 and 10 weeks|EPI vaccines + rotavirus vaccine at 6 and 10 weeks
62562441|NCT01094704|EXPERIMENTAL|Hypertonic Saline - 4 hours|sodium chloride (7%); mucociliary clearance measured four hours post-dose.
62562442|NCT05169801|EXPERIMENTAL|Treatment group A|
62562443|NCT05169801|ACTIVE_COMPARATOR|Treatment group B|
62562444|NCT04898699|EXPERIMENTAL|PrEP+|PrEP+ is an experimental pre-exposure prophylaxis (PrEP)-focused prevention strategy providing daily oral tenofovir/emtricitabine (TDF/FTC) in combination with two adherence self-management interventions: (1) real-time feedback from point-of-care urine drug-level assay, (2) HIV self-testing and (3) 2-way text message reminders in addition to standard of care HIV risk-reduction counseling among male clients (MC) of female sex workers in Kisumu, Kenya.
62562445|NCT02236039|ACTIVE_COMPARATOR|Filtered air|Exposure for 2 hours to filtered air followed by a bronchoscopy 24 hours post exposure.
62562446|NCT02236039|EXPERIMENTAL|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by a bronchoscopy 24 hours post exposure.
62562447|NCT03324568|OTHER|Educational handout|
62562448|NCT03324568|EXPERIMENTAL|Video plus educational handout|
62562449|NCT06516068|EXPERIMENTAL|HRS-1893|
62562450|NCT06443528||Preterm infants with GA <32 weeks|
62562451|NCT04535492|OTHER|Colorectal Cancer Screening Recommended|The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years.
62390889|NCT01199874|EXPERIMENTAL|Primary 1: Rotavirus vaccine 6, 10 and 14 weeks|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks
62390890|NCT01199874|EXPERIMENTAL|Primary 1: Rotavirus vaccine 10 and 14 weeks|EPI vaccines + rotavirus vaccine at 10 and 14 weeks
62390891|NCT01199874|EXPERIMENTAL|Primary 2: Rotavirus vaccine withholding breast feeding|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks withholding breastfeeding
62390892|NCT01199874|EXPERIMENTAL|Primary 2: Rotavirus vaccine with immediate breast feeding|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks with immediate breastfeeding
62390893|NCT01199874|NO_INTERVENTION|Baseline seroconversion for rotavirus|EPI vaccines
62390894|NCT00247962|EXPERIMENTAL|A|
62390895|NCT00247962|ACTIVE_COMPARATOR|B|
62390896|NCT02711306|EXPERIMENTAL|GMN Diet|In the glucomannan noodle (GMN) diet, the participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks, with each serving of glucomannan noodles weighing up to 200 g with 2 g of glucomannan.
62390897|NCT02711306|PLACEBO_COMPARATOR|PN Diet|In the placebo noodle (PN) diet, the participants received the participants received the same amount of noodles without glucomannan.
62390898|NCT06030531||Inpatients|"Prospective participants who meet the study inclusion criteria will be identified by bi-weekly chart review of all new admissions to the acute inpatient spinal cord injury unit at the Shirley Ryan AbilityLab (SRAlab).~Eligible patients will be invited to participate by the clinical staff during their first week of admission."
62562452|NCT04535492|OTHER|Lung Cancer Screening Recommended|The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults ages 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.
62562453|NCT04535492|OTHER|Breast Cancer Screening Recommended|The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.
62562454|NCT02438423|EXPERIMENTAL|IIV delivered by MN patch by study staff|Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff
62562455|NCT02438423|ACTIVE_COMPARATOR|IIV delivered IM by study staff|Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff
62562456|NCT02438423|EXPERIMENTAL|IIV delivered by MN patch by subject|Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch self-administered by subject
62562457|NCT02438423|PLACEBO_COMPARATOR|Placebo MN patch by study staff|Placebo delivered by microneedle patch administered by study staff
62562458|NCT01742546|EXPERIMENTAL|Therapeutic ultrasound combine TENS|"Use therapeutic ultrasound with simultaneous TENS for 10 minutes/session for 10 sessions/course.~The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius), this device has treatment head described by the manufacturers as having surface area as 5.8 cm2, ERA (Effective Radiating Area) of 5.0 cm2 and BNR (Beam Non-uniform Ratio) as max. 5.0. For electrotherapy unit which composes of 2 channels, output characteristics are constant current (CC) or constant voltage (CV), resolution of output signal is in steps of 0.2 mA and timer is limited to 30 minutes during ultrasound and combination therapy are operated."
62562459|NCT01742546|SHAM_COMPARATOR|Therapeutic ultrasound with sham TENS|Use the same therapeutic ultrasound machine and place the electrode as experimental group but turn-off electrical current during treatment period
62562460|NCT04578873|EXPERIMENTAL|QPX7831 SAD Cohorts|oral, single ascending dose (or placebo)
62390899|NCT06030531||Control group|We will enroll non-injured healthy individuals to compare the level of biomarkers
62390900|NCT02390167|EXPERIMENTAL|Persons With Diabetes|Untrained Subjects WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System).
62390901|NCT04192552|ACTIVE_COMPARATOR|Apixaban|Patients currently taking apixaban that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
62390902|NCT04192552|ACTIVE_COMPARATOR|Dabigatran|Patients currently taking dabigatran that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
62562461|NCT04578873|EXPERIMENTAL|QPX7831 MAD Cohorts|oral, multiple ascending dose (or placebo)
62562462|NCT02949973|EXPERIMENTAL|Voclosporin|Voclosporin, oral, 23.7 mg twice daily (BID)
62562463|NCT06575634|EXPERIMENTAL|Supervised exercise training|
62562464|NCT06575634|NO_INTERVENTION|Control group|
61994725|NCT04471636|EXPERIMENTAL|Telemedicine Care|Patients receive assessment at baseline and at 30 day follow up. Patient receive a smart watch capeable of recording SpO2, ECG, and heart rate. Patients also receive access to 24/7 medical hotline for telemedical care. All public services of the health care system remain available.
61994726|NCT04471636|NO_INTERVENTION|Control|Patients receive assessment at baseline and at 30 day follow up. Patient have access to all services of the health care system, but do not receive a smart watch or medical hotline access.
61994727|NCT03320772|EXPERIMENTAL|TMVP1|The TMVP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of TMVP1-ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
62390903|NCT04192552|ACTIVE_COMPARATOR|Rivaroxaban|Patients currently taking rivaroxaban that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
62562465|NCT05611866|EXPERIMENTAL|Fecal Microbiota Transplantation|Recruited patients will receive Fecal Microbiota Transplantation
62562466|NCT01444339|EXPERIMENTAL|Pneumococcal Vaccine Formulation 1|Participants will receive an injection of pneumococcal vaccine (Formulation 1, 1 middle dose) on Day 0 and Day 30, respectively.
62562467|NCT01444339|EXPERIMENTAL|Pneumococcal Vaccine Formulation 2|Participants will receive an injection of Pneumococcal vaccine (Formulation 2, 2 low doses) on Day 0 and Day 30, respectively.
62562468|NCT01444339|EXPERIMENTAL|Pneumococcal Vaccine Formulation 3|Participants will receive an injection of pneumococcal vaccine (Formulation 3, 2 middle doses) on Day 0 and Day 30, respectively.
62390904|NCT02277418|EXPERIMENTAL|Child ETI withoutchest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
62562469|NCT01444339|EXPERIMENTAL|Pneumococcal Vaccine Formulation 4|Participants will receive an injection of pneumococcal vaccine (Formulation 4, 2 middle doses) on Day 0 and Day 30, respectively.
62562470|NCT01444339|EXPERIMENTAL|Pneumococcal Vaccine Formulation 5|Participants will receive an injection of pneumococcal vaccine (Formulation 5, 2 high doses) on Day 0 and Day 30, respectively.
62562471|NCT01444339|PLACEBO_COMPARATOR|Pooled placebo Group|Participants will receive an injection of a placebo on Day 0 and Day 30, respectively.
62390905|NCT02277418|EXPERIMENTAL|Child ETI with chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
62390906|NCT02277418|EXPERIMENTAL|Infant ETI with chest compressions|endotracheal intubation (ETI) during infant mannikin resuscitation with uninterrupted chest compressions.
62562472|NCT05748067|ACTIVE_COMPARATOR|Group 1: SDF, HVGIC & SSC|Silver diamine fluoride (SDF) will be clinically applied in the first visit. After 1 week of caries arrest, the tooth will be restored with a high viscosity glass ionomer (HVGIC) and stainless steel crown (SSC).
62562473|NCT05748067|ACTIVE_COMPARATOR|Group 2: SDF & SSC|Silver diamine fluoride (SDF) will be clinically applied in the first visit. After 1 week of caries arrest, the tooth will be restored with a SSC only.
62769915|NCT00963768|EXPERIMENTAL|Cohort 4|JNJ-28431754 600 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
62769916|NCT00963768|EXPERIMENTAL|Cohort 5|JNJ-28431754 at 30 mg/day, 100 mg/day, or 300 mg/day or placebo (the dose level to be determined from the prior cohort of patients tested and considered to be well tolerated).
62769917|NCT03702907||Normal Cognition|No diagnosis of a cognitive disorder
62562474|NCT05748067|ACTIVE_COMPARATOR|Group 3: HVGIC & SSC|The tooth will be restored in a similar fashion to atraumatic restorative treatment (ART technique) and restored with a high viscosity glass ionomer (HVGIC) and stainless steel crown (SSC).
62562475|NCT03743415|EXPERIMENTAL|Handbook|The Symptom Management and Survivorship Handbook is a self-care management handbook with each symptom chapter presented in an identical format: what the symptom is, how people describe the symptom, the causes of the symptom, strategies for managing the symptom and resources. The Handbook is available in English and Spanish. Each weekly call will begin with the symptom assessment. For each symptom rated at 4 or higher on a 0-10 scale of severity, the survivors will be referred for symptom self-management. During weeks 2-12, Handbook use since the last call (intervention enactment) and symptoms will be assessed. During weekly calls to caregivers, the caregivers will be notified of symptoms above threshold experienced by survivors and directed to the Handbook. During weeks 2-12, Handbook use and symptoms are assessed, a summary of survivors' symptoms provided. Calls will last about 10 minutes.
62769918|NCT03702907||Cognitive Disorder|Diagnosed with a cognitive disorder such as :Mild Cognitive Impairment, Alzheimer's disease, Frontotemporal Dementia, Lewy Body Dementia, Vascular Dementia, or other neurodegenerative condition.
62769919|NCT01998191|ACTIVE_COMPARATOR|Implicit Case note review (nurse)|"Notes to be reviewed using the implicit method by a nurse~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
62169088|NCT01863537|ACTIVE_COMPARATOR|Traditional Connect|The original, manualized version of Connect (CDC DEBI)and manualized facilitator training curriculum with a 4-day, face-to-face structured orientation and training for implementation, and planned, investigative team initiated telephone consultation with CBO staff to provide technical assistance at 2 and 4 months following the training workshop.
62769920|NCT01998191|ACTIVE_COMPARATOR|Implicit Case note review (MDT)|"Notes to be reviewed using the implicit method by an expert physician and nurse team.~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
62769921|NCT01998191|ACTIVE_COMPARATOR|Implicit Case note review (physician)|"Notes to be reviewed using the implicit method by an expert physician~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
62769922|NCT04499911|EXPERIMENTAL|Neural prolotherapy|Neural prolotherapy using isotonic dextrose 5% in water solution (about 5 ml). The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
62769923|NCT04515524||ROP patients from VGFTe-ROP-1920|Retinopathy of prematurity (ROP) who were treated with aflibercept and/or laser photocoagulation in study VGFTe-ROP-1920.
62769924|NCT02364440|EXPERIMENTAL|Ultherapy™ System|Ultherapy™ System
62769925|NCT06246071|EXPERIMENTAL|TYK-00540|"Escalation stage: Multiple doses of TYK-00540 tablets as monotherapy for oral administration to find the maximum tolerated dose. The administration frequency will be twice daily (BID), every 28 days as a cycle.~Expansion stage: an optimal dose of TYK-00540 tablets for cohort expansion. The administration frequency will be twice daily (BID), every 28 days as a cycle."
62769926|NCT06504069|EXPERIMENTAL|Prosocial VR Intervention|Participants in the VR intervention group will engage in a five-week gamified prosocial VR intervention program. The intervention will consist of five weekly sessions, each lasting between 10 to 15 minutes. Each session will depict a different daily life scenario, including a home, school, street, park, and shopping mall.
62769927|NCT06504069|NO_INTERVENTION|Waitlist control group|Participants in the waitlist condition will not receive VR intervention during the study.
62169089|NCT06537141|ACTIVE_COMPARATOR|graves disease patients|
62562476|NCT03743415|EXPERIMENTAL|TIP-C plus Handbook|Each survivor and caregiver will receive one 40-minute telephone call per week for 12 weeks. The Telephone Interpersonal Counseling (TIP-C) intervention 8-week protocol is the same for both survivor and caregiver. During weekly contacts, the counselors target social support behaviors using interpersonal communications techniques. Counselors can personalize the counseling intervention for the specific needs or interests as expressed during sessions while still adhering to a structured protocol. The final 4 weeks will be Handbook only.
62169090|NCT06537141|ACTIVE_COMPARATOR|multinodular goiter|
62562477|NCT02881684|EXPERIMENTAL|Treatment|"Intervention:~1. Device: Aspiration Therapy (AspireAssist)~   - Subjects randomized to the treatment group will undergo an endoscopic procedure to have the experimental device (i.e. the A-tube) inserted. This will be followed by regular follow up visits and lifestyle therapy matched to the control group. The device will be removed at the end of one year and this group will be observed for one year more to determine if there is any legacy effect.~2. Behavioral: Lifestyle Therapy Lifestyle therapy is a behavioral, diet and physical activity education program Other Name: Lifestyle Behavioral Therapy"
62390907|NCT02277418|EXPERIMENTAL|Infant ETI without chest compressions|Endotracheal intubation of infant mannikin during resuscitation without chest compressions.
62390908|NCT03537417||Tension pneumothorax group|Patients undergoing intentional pneumothorax for thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
62390909|NCT04046029|EXPERIMENTAL|Bivalirudin|
62390910|NCT04046029|ACTIVE_COMPARATOR|Heparin|
62390911|NCT02185638|EXPERIMENTAL|A20-50|"A20-50 (2 capsules). Each capsule contains:~Yerba Mate (Ilex paraguariensis), Guarana seed (Paullinia cupana), Magnesium Oxide , Caffeine , Damiana (Turnera microphylla), Green tea (Camellia sinensis), Ginger (Zingiber Officinale), Kola nut (Cola acuminate or nitida), Pyridoxine Hydrochloride, Tibetan Ginseng root (Rhodiola crenulata), Schisandra (Schisandra Chinensis), Jujube (Ziziphus Jujuba) , Cocoa nut (Theobroma cacao), Chinese Skullcap (Scutellaria Baicalensis), Black tea leaf (Thea sinensis), Rice flour (to fill)~Dose = 2 capsules have a total of 200 mg of caffeine"
62390912|NCT02185638|ACTIVE_COMPARATOR|YGD|"YGD blend (2 capsules). Each capsule contains:~Yerba Maté (leaf) , Guarana (seed) , Damiana (leaf) , Rice flour: to fill ,~The 2 capsules of the YGD blend contain about 40 mg xanthines (caffeine and caffeine-like stimulants)."
62390913|NCT02185638|PLACEBO_COMPARATOR|Placebo|"Placebo (2 capsules). Each capsule contains:~Rice Flour"
62390914|NCT04556942|EXPERIMENTAL|Group 1 (Immediate Group)|"Group 1:~Will receive at time T0 the baseline study specific measurements of the primary and secondary endpoints:~* Flow mediated dilation measurement~* Blood pressure, pulse, blood oxygenation saturation measurement~* Fit bit tracker counting steps and distance during 7 days~* SGRQ (St Georg Respiratory Questionnaire)~* Withdrawal of a blood sample for preservation for later examinations~This group will receive endobronchial valve placement (EVP) within 1-2 weeks after T0.~At T1 which will be 4-6 weeks after EVP the measurements done at T0 will be repeated."
62390915|NCT04556942|OTHER|Group 2 (Delayed Group)|"Group 2:~Will receive at time T0 the baseline study specific measurements of the primary and secondary endpoints:~* Flow mediated dilation measurement~* Blood pressure, pulse, blood oxygenation saturation~* Fit bit tracker counting steps and distance during 7 days~* SGRQ (St Georg Respiratory Questionnaire)~* Withdrawal of a blood sample for preservation for later examinations~This group will receive endobronchial valve placement (EVP) 6-8 weeks after T0. A few days before that the investigators repeat the measurement taken at T0."
62390916|NCT05277597|EXPERIMENTAL|The group (ET+S )|Participants exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.
62390917|NCT05277597|ACTIVE_COMPARATOR|The group (ET)|Participants exercised 60 minutes, 3 times per week
62562478|NCT02881684|ACTIVE_COMPARATOR|Control|"Intervention:~(1) Behavioral: Lifestyle Therapy Lifestyle therapy is a behavioral, diet and physical activity education program Other Name: Lifestyle Behavioral Therapy~- Subjects randomized to the control group will receive lifestyle management matched to the treatment group in the first year. At the end of one year, they will be crossed over to treatment and the A-tube will be inserted. They will then follow up the same follow up schedule of the treatment group during the first year."
62562479|NCT03802825|ACTIVE_COMPARATOR|Patient Navigation|Participants randomized to the patient navigation only arm will be referred to a KPNW patient navigator using a standard electronic health record-based referral process. Once the participant has completed the Your Current Life Situation (YCLS) assessment with study staff, the navigator will receive the referral and follow-up with the participant to address the social and economic needs identified. The patient navigator will follow-up with the participant 2-3 times over the 6 month period by phone or in-person about progress with the referral and help address additional needs that may develop during the 6-month intervention. Participant will also receive monthly mailing of American Diabetes Association educational materials.
62562480|NCT03802825|EXPERIMENTAL|Patient Navigation+Diabetes Self-Management Support|"In addition to receiving patient navigation as described, participants in this arm will also be referred to Project Access NOW by study staff using REDCap. Project Access NOW will connect participants to a community-based organization based on their preference, previous experience with an agency, geography, and capacity.~The CHW will follow-up with the participant to conduct a home visit and follow-up on community-based referrals already placed by the KPNW patient navigator and assess for additional needs. The timing of the diabetes self-management training will be based on the needs of the participant."
62562481|NCT05793164||Patients with postoperative folliculitis|Patients presented folliculitis in surgical-area lesions after hair transplantation within 9-month follow up.
62562482|NCT05793164||patients without postoperative folliculitis|Patients didn't present folliculitis in surgical-area lesions after hair transplantation within 9-month follow up.
62169091|NCT03427606|EXPERIMENTAL|Continuous Suture|
62169092|NCT03427606|ACTIVE_COMPARATOR|Single 5-points Suture|
62562483|NCT05135065|EXPERIMENTAL|Artificial Intelligence-Assisted Supervision Protocol|Measurement-based supervision protocol that incorporates fidelity measurement from a machine learning tool and feedback reports from this tool into a standardized supervision protocol for behavior therapy to task-shift burdensome supervision tasks to a machine, reducing costs and improving precision of fidelity measurement for agencies.
62562484|NCT05135065|NO_INTERVENTION|Enhanced Supervision as Usual (ESAU) Condition|ESAU therapists will be given standard, paper-based facilitation resources for STAND and will receive 4 hours of training on how to navigate these materials and self-assess fidelity. ESAU therapists will also be trained how to upload recordings into Care4 and complete self-assessments for each session. Supervisors will be given access to these data and recordings once uploaded (but not Lyssn scores or electronic facilitation resources).
62562485|NCT02734277||Group 1: Detectable C-peptide by MMTT|"Participants with detectable C-peptide at their:~* Last Immune Tolerance Network (ITN) T1DM week 104 study visit,~* Last AbATE (NCT00129259) follow-up visit, or~* Last ITN066AI T1DES visit~Detectable C-peptide is defined as a value above the lower limit of detection."
62769928|NCT06208566|EXPERIMENTAL|Conversational Agent Zenny|Participants received access to a self-help program delivered via an automated conversational agent on WhatsApp.
62769929|NCT06208566|ACTIVE_COMPARATOR|Web-based Wellness Resources|Participants received a list of three freely accessible wellness resources available on the web.
62769930|NCT02102399|EXPERIMENTAL|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
62769931|NCT02102399|EXPERIMENTAL|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
62769932|NCT04777266|EXPERIMENTAL|Experimental Music therapy Group|experimental group receiving the MT programme in addition to their usual treatment (pharmacological and psychosocial) (TAU + MT)
62169093|NCT05580783|EXPERIMENTAL|Experimental 54Fe|Participants will receive 54Fe at two time points throughout their menstrual cycle.
62169094|NCT05580783|EXPERIMENTAL|Experimental 57Fe|Participants will receive 57Fe at two time points throughout their menstrual cycle.
62769933|NCT04777266|ACTIVE_COMPARATOR|Control Non music therapy group|Group with usual treatment only (TAU).
62769934|NCT01631916|EXPERIMENTAL|Corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
62769935|NCT01631916|NO_INTERVENTION|Control|No intervention
62769936|NCT02718014|OTHER|pre menopause with periodontitis|non surgical periodontal therapy (SCALING \& ROOT PLANING) (SRP)
62390918|NCT04176809|EXPERIMENTAL|Interventional arm|The intervention will consist in an electronic measurement of HRQoL before each consultation with delivery scores to clinicians, who can discuss it with patients and coupled with therapeutic information. Patients will complete the EORTC-Quality of Life Questionnaire (QLQ)-C30 and the EORTC-QLQ-Breast (BR) 23 questionnaires using the CHES software before their consultation, via a touch pad or from their home via a secure web portal. Therapeutic information will consist on workshops on various themes. Only attendance Workshop 1 will be required, other workshops will be optional. The aim of workshop 1 is to inform patients about their ET and treatment benefits. Two additional optional workshops on nutrition (Workshop 2) and fatigue (Workshop 3) will be offered. This workshops will be collective. Every month, a letter encouraging patients to regularly take their medication will be sent. This letter will also include some tips on how to deal with some particular side effects of ET.
62390919|NCT04176809|NO_INTERVENTION|Control arm|Participants in the control arm will receive standard care. They will not undergo digital HRQoL collection, and therapeutic information workshops will not be proposed.
62390920|NCT03550989||Non-Smokers|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~* Abstinent for at least 12 months from the use of any nicotine and/or tobacco-containing product based on self-reporting.~* Must not be exposed to tobacco or nicotine-containing products use in any other substantial way (family, partner, workplace, etc.)."
62390921|NCT03550989||Cigarette Smokers|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~* Used at least 100 cigarettes~* Smokes cigarettes daily \> 1/day~* Uses IQOS less than daily~* Uses less than 30 HeatSticks/month~* Cigarette is \> 95% of tobacco/nicotine product (all product use)"
62390922|NCT03550989||IQOS Passive Users (not using IQOS)|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~* Used at least 100 HeatSticks~* Uses IQOS daily \> 1/day~* Smokes a cigarette less than daily~* Smokes less than 30 cigarettes/month~* IQOS is \> 95% of tobacco/nicotine product (all product use) - excluding other products (e-cig/Ploom/etc.)"
62390923|NCT03550989||IQOS Active Users (using IQOS)|"Each participant can participate in one Exposure Event only.~* Used at least 100 HeatSticks~* Uses IQOS daily \> 1/day~* Smokes a cigarette less than daily~* Smokes less than 30 cigarettes/month~* IQOS is \> 95% of tobacco/nicotine product (all product use) - excluding other products (e-cig/Ploom/etc.)"
62390924|NCT00511966||001|
62390925|NCT00511966||002|
62390926|NCT05421559|ACTIVE_COMPARATOR|conventional approach of thyroidectomy|conventional method of thyroidectomy with ST muscle retraction
62390927|NCT05421559|ACTIVE_COMPARATOR|transection approach of thyroidectomy|method of thyroidectomy with ST muscle transection
62169095|NCT05580783|EXPERIMENTAL|Experimental 58Fe|Participants will receive 58Fe at two time points throughout their menstrual cycle.
62169096|NCT00357747|EXPERIMENTAL|AEG35156 plus docetaxel|
62169097|NCT01233089|EXPERIMENTAL|CARE|Investigational single-vision contact lenses worn bilaterally on a daily wear basis and replaced monthly
62562486|NCT02734277||Group 2:Undetectable C-peptide by MMTT|"Participants without detectable C-peptide at their:~* Last ITN T1DM week 104 study visit,~* Last AbATE follow-up visit, or last~* ITN066AI T1DES visit~Undetectable C-peptide is defined as a value below the lower limit of detection."
62169098|NCT01233089|ACTIVE_COMPARATOR|AIR OPTIX AQUA|Commercially available single-vision contact lenses worn bilaterally on a daily wear basis and replaced monthly
62169099|NCT01233089|ACTIVE_COMPARATOR|AIR OPTIX AQUA MULTIFOCAL|Commercially available multifocal contact lenses worn bilaterally on a daily wear basis and replaced monthly
61994728|NCT03320772|ACTIVE_COMPARATOR|ICG|The ICG powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of this ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
61994729|NCT03221920|EXPERIMENTAL|Very Low Carbohydrate Diet|The patient will be evaluated for baseline clinical and laboratory values, and counselled on very low carbohydrate diet.
61994730|NCT03221920|NO_INTERVENTION|Control|The patient will be evaluated for baseline clinical and laboratory values, and counselled on normal healthy .
61994731|NCT03681457|OTHER|Group 1 - Normal Hepatic Function|Normal hepatic function - Control - control group
61994732|NCT03681457|EXPERIMENTAL|Group 2 - Mild Hepatic Impairment|Mild hepatic impairment - Child-Pugh A (Score 5-6)
62169100|NCT03967119||Laparoscopic surgery|"The following parameters are assessed and recorded at the following time points in all participants.~The parameters assessed: mean arterial pressure, heart rate, pulse oxygen saturation, SVV, PPV, PWV, peak inspiratory pressure, plateau pressure, positive end-expiratory pressure, respiratory rate (all dynamic variables are assessed at two levels of tidal volume- 6 ml/kg and 12 ml/kg).~The time points: T0, before anesthetic induction; T1, immediately after anesthetic induction; T2, immediately after pneumoperitoneum; T3, 10 min before desufflation; T4, immediately after desufflation.~The desufflation-induced hypotension is defined as more than 20 % decrease in MAP at T4 from MAP at T3."
62169101|NCT03049306|PLACEBO_COMPARATOR|Placebo Oral Tablet|Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, placebo of propranolol LA (Inderal ® LA) 80 mg will be administered orally at 6:30 PM, after dinner. Blood pressure will be measured before administration, at 10:30 PM, and 6:30 AM. They will sleep from 10:30 PM to 6:30 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will is crossed-over with active drug 1 week before or after this study night.
62169102|NCT03049306|ACTIVE_COMPARATOR|Propranolol Oral Tablet|Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, Propranolol LA (Inderal ® LA) 80 mg will be administered orally before sleep, at 6:30 PM, after dinner. Blood pressure will be measured before administration, at 10:30 PM, and 6:30 AM. They will sleep from 10:30 Pm to 6:30 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will be crossed-over to placebo 1 week later. This arm will is crossed-over with active drug 1 week before or after this study night.
62169103|NCT00228813|OTHER|Granulocyte Colony Stimulating Factor (G-CSF) stimulation|Participants will receive bone marrow from donors who undergo Granulocyte Colony Stimulating Factor (G-CSF) stimulation prior to bone marrow collection.
62390928|NCT03471143|EXPERIMENTAL|IV adrabetadex (VTS-270) for NPC1 infants|"Phase 1: Dosing frequency will be twice a week administered via a peripherally inserted central catheter (PICC) for six weeks for a total of 12 administrations. Doses 3-12 will occur as an outpatient.~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6 will receive 500 mg/kg Cohort 2: Subjects 7-12 will receive 1000 mg/kg Subjects who demonstrate significant reduction either in the glycine-conjugated trihydroxycholanic acid biomarker or serum bilirubin (direct bilirubin or direct bilirubin:total bilirubin ratio) will be allowed to crossover into the second phase of the study, an open-label phase of six months duration. In the this phase of the study, dosing frequency will be monthly with IV VTS-270 administered via peripheral IV access for six months for a total of six administrations."
62390929|NCT00847951|OTHER|Renal perfusion in Neonates|Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys.
62390930|NCT02621138||cerebral palsy|Age 6-12 years Gross Motor Function Classification System I-II
62390931|NCT02621138||control|Age 6-12 years
62390932|NCT00603369|EXPERIMENTAL|1|13 session group intervention including sexual health information, affect management skills, cognitive monitoring, and communication skills training.
62390933|NCT00603369|ACTIVE_COMPARATOR|2|2 session group intervention including sexual health information training.
62390934|NCT05453318|EXPERIMENTAL|Thermal ablation Arm|Treatment of cervical neoplasia by thermal ablation
62390935|NCT04472962|ACTIVE_COMPARATOR|Low-carbohydrate-high-protein pre-exercise meal|
62390936|NCT04472962|ACTIVE_COMPARATOR|High-carbohydrate-low-protein pre-exercise meal|
62390937|NCT04953182||Around the clock analgetic treatment|Patients that underwent hemorrhoidectomy and pain killers are prescribed every specific hour independent of pain degree, if necessary drugs can be administered on demand.
62390938|NCT04953182||On demand analgetic treatment|A pain killers list is prescribed by the physician and the nurse decides which drug to administer depending on a protocol of treatment based on the visual analog scale.
62390939|NCT04511533|EXPERIMENTAL|Treatment Arm|The recommended dosage of dacomitinib is 45 mg taken orally once a day at approximately the same time each day, until disease progression, participant refusal/lost to follow-up, or unacceptable toxicity occurs.
62390940|NCT05336877||Device: Aveir VR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention is required in this study.
62390941|NCT05336877||Device: Single-Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a single-chamber transvenous pacemaker as a comparator to the Aveir VR LP system study arm. No device intervention is required in this study.
62769937|NCT02718014|OTHER|post menopause with periodontitis|non surgical periodontal therapy (SCALING \& ROOT PLANING) (SRP)
62769938|NCT05277428|EXPERIMENTAL|Lactobacillus Plantarum APsulloc 331261(GTB1)|Take GTB1 capsule once daily for 4 weeks
62769939|NCT05277428|PLACEBO_COMPARATOR|Placebo|Take placebo capsule once daily for 4 weeks.
62562487|NCT02814604|EXPERIMENTAL|Traffic Light|"Participants in this group will download an app which features the nutrition information of the selected product in a multiple coloured traffic light format (i.e. the traffic light system shows a coloured round indicator for each of saturated fat, sugar, and sodium; shaded red (high), amber (medium) or green (low), according to thresholds set for each nutrient). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
62769940|NCT03041363|EXPERIMENTAL|Triheptanoin|Dose 1 C7 administered as 40% daily caloric intake. Dose 2. C7 administered as 45% daily caloric intake.
62562488|NCT02814604|EXPERIMENTAL|Health Star Rating System|"Participants in this group will download an app which features the nutrition information of the selected product in a form of 0-5 stars to provide an overall healthy rating. The Health Star Rating provides a rating for all products and products not meeting the criteria still carry the symbol (with no colored stars). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
62562489|NCT02814604|NO_INTERVENTION|Control|Participants in this group will only see the Nutrition Facts Table (as it appears on the product's package) when the product is scanned in the app.
62562490|NCT02814604|EXPERIMENTAL|High-in Warning Label|"Participants in this group will download an app which features the nutrition information of the selected product in a 'high-in' warning label format (i.e. stop signs for each of saturated fat, sugar, and sodium; according to thresholds set for each nutrient). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
62562491|NCT05821933|EXPERIMENTAL|cohort 1 RC108 plus Furmonertinib|phaes 1: RC108 plus Furmonertinib
62562492|NCT05821933|EXPERIMENTAL|cohort 2 RC108 plus Furmonertinib and Toripalimab|phaes 1: RC108 plus Furmonertinib and Toripalimab
62562493|NCT05821933|EXPERIMENTAL|cohort 3 RP2D RC108 plus Furmonertinib|phaes 2: RP2D RC108 plus Furmonertinib
62562494|NCT05821933|EXPERIMENTAL|cohort 4 RP2D RC108 plus Furmonertinib and Toripalimab|phaes 2: RP2D RC108 plus Furmonertinib and Toripalimab
62769941|NCT04279158|EXPERIMENTAL|patients with optic ataxia (OA)|
62769942|NCT04279158|EXPERIMENTAL|patients with hemispatial neglect|
62769943|NCT04279158|EXPERIMENTAL|patients with attention-deficit hyperactivity disorder|
62182729|NCT05195892|EXPERIMENTAL|Sequence 6|Participants will receive a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 1 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C).
62562495|NCT03271801|ACTIVE_COMPARATOR|Child Health Education|The child health education condition will participate in a family-based obesity treatment program for the first 40 minutes of each session, followed by 20 minutes designated to education about a child health topic. Parents and children will be asked to self-monitor sugar-sweetened beverages, fruits, vegetables, and minutes of physical activity and screen time.
62562496|NCT03271801|EXPERIMENTAL|Skills Training|The skills training condition will participate in a family-based obesity treatment program for the first 40 minutes of each session followed by 20 minutes of experiential learning about meal stimulus control strategies. Parents and children will be asked to self-monitor sugar-sweetened beverages, fruits, vegetables, and minutes of physical activity and screen time. In addition they will self-monitor the use the following stimulus control strategies: portion control, energy density and variety.
62562497|NCT06066268||1) Critical limb ischemia (CLI);|"1)Critical limb ischemia (CLI):~* Patients suffering from CLI undergoing lower limb revascularization via subgenual femoropopliteal bypass. muscle biopsies willbe taken.~* Patients suffering from terminal CLI and/or gangrene of the lower limb undergoing thigh amputation. Muscle biopsies will be taken.~* Patients suffering from terminal CLI and/or gangrene of the lower limb undergoing leg amputation. Muscle biopsies will be taken."
62769944|NCT04279158|ACTIVE_COMPARATOR|Healthy volunteers|
62769945|NCT04469348|EXPERIMENTAL|Healthy volunteers|"Healthy volunteers will be included. They will have nasal swab at the inclusion visit to detect contamination of S. Aureus.~* If contamination of S. Aureus: they will have 12 follow-up visits (1 per month)~* If no contamination of S. Aureus: their participation stops"
62769946|NCT02142413||Acute Ischemic Stroke|Patients older than 18 years with an acute ischemic stroke (according to WHO criteria), stroke onset within 2 days, language: German, MRI compatibility, admission to the stroke unit at the Charité, Campus Benjamin Franklin.
62769947|NCT00380419|EXPERIMENTAL|1|Participants will receive 16 sessions of interpersonal psychotherapy
62769948|NCT02713867|ACTIVE_COMPARATOR|Nivolumab 240 mg|Nivolumab 240 mg Every 2 Weeks
62169104|NCT03068676|EXPERIMENTAL|Space from depression|Space from Depression is an eight-module online CBT-based intervention for depression, composed of cognitive and behavioral components including self-monitoring and thought recording, behavioral activation, cognitive restructuring, and challenging core beliefs. Each module follows a structured format that incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.
62169105|NCT03068676|EXPERIMENTAL|Space from Anxiety|Space from Anxiety is an eight-module online CBT-based intervention for depression, composed of cognitive and behavioral components including self-monitoring and thought recording, behavioral activation, cognitive restructuring, and challenging core beliefs. Each module follows a structured format that incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.
62169106|NCT05526014||non-pregnant|negative b-hCG results 9 days after embryo transfer.
62169107|NCT05526014||pregnant with obstetric complications|Patients with a positive pregnancy result who develop obstetric complications such as preeclampsia, eclampsia, fetal growth restriction, oligohydramnios, polyhydramnios, preterm birth, gestational diabetes mellitus, antenatal bleeding and etc. after the 20th gestational weeks.
62169108|NCT05526014||pregnant without obstetric complications|Patients who have positive pregnancy results and do not have any obstetric complications such as preeclampsia, eclampsia, fetal growth restriction, oligohydramnios, polyhydramnios, preterm birth, gestational diabetes mellitus, antenatal bleeding and etc. during pregnancy.
62769949|NCT02713867|EXPERIMENTAL|Nivolumab 480 mg|Nivolumab 480 mg Every 4 Weeks
62769950|NCT03688555|EXPERIMENTAL|ACT-774312|Participants will receive ACT-774312 (400 mg twice daily) in the morning and evening with or without food for 12 weeks together with mometasone furoate nasal spray.
62769951|NCT03688555|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo twice daily in the morning and evening with or without food for 12 weeks together with mometasone furoate nasal spray.
62769952|NCT04145674|EXPERIMENTAL|25 mg d-methadone|The experimental drug is a tablet formulation of d-methadone HCl in dose strength of 25 mg.
61994733|NCT03681457|EXPERIMENTAL|Group 3 - Moderate Hepatic Impairment|Moderate hepatic impairment - Child-Pugh B (Score 7-9)
61994734|NCT03681457|EXPERIMENTAL|Group 4 - Severe Hepatic Impairment|Severe hepatic impairment - Child-Pugh C (score 10-15)
61994735|NCT05473312|EXPERIMENTAL|Intervention|"1. Community Sensitization~2. 28-day behaviour practice (Positive Deviance (PD) /Hearth sessions plus home practice)~3. Supplemental Print Information"
61994736|NCT05473312|NO_INTERVENTION|Control|Control households will continue with usual practices.
61994737|NCT04420156||i-ROP cohort|Premature infants who are at risk of retinopathy of prematurity(ROP) at participating study sites. As standard of care, babies who are born less than 31 weeks gestational age or less than 1500 grams are routinely screened for ROP. Families are approached to participate in this study where finding from babies' eye exams and associated retinal images along with demographic and other health data are collected and coded with unique identifier. No intervention is administered. The ROP exams and images obtained are done as a standard of care and would be performed even if there is no consent provided.
61994738|NCT01126996||MenC vaccinated healthy children|Children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.
62769953|NCT04145674|PLACEBO_COMPARATOR|Placebo|The placebo is an exact match to the active tablets in size, color and marking without the active ingredient d-methadone HCl.
62769954|NCT04518163|EXPERIMENTAL|study group|Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally plus 1gm tranexamic acid by intravenous infusion
62769955|NCT04518163|ACTIVE_COMPARATOR|control group|Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally plus saline by intravenous infusion
62769956|NCT03057470|ACTIVE_COMPARATOR|0% Bolus Insulin Correction|0% Bolus Insulin Correction
62769957|NCT03057470|ACTIVE_COMPARATOR|50% Bolus Insulin Correction|50% Bolus Insulin Correction
62769958|NCT03057470|ACTIVE_COMPARATOR|100% Bolus Insulin Correction|100% Bolus Insulin Correction
61994739|NCT06211725||neurovascular patients|
62769959|NCT03057470|ACTIVE_COMPARATOR|150% Bolus Insulin Correction|150% Bolus Insulin Correction
62769960|NCT00121641|EXPERIMENTAL|Saxagliptin 2.5 mg (A)|Metformin 500-2000 mg (as needed for rescue)
61994740|NCT00819416|EXPERIMENTAL|1|5% albumin
61994741|NCT00819416|OTHER|2|Normal saline
61994742|NCT06545370|NO_INTERVENTION|Control Group - No Intervention Group|the control group (Group A) will receive standard care based on the policies and protocols of primary health care
61994743|NCT06545370|EXPERIMENTAL|Intervention 1 group - Patients' education|the first intervention group (Group B) will receive nurse-led education through oral sessions, educational materials, and regular phone calls
61994744|NCT06545370|EXPERIMENTAL|Intervention 2 - Patients' and caregivers' education|the second intervention group (Group C) will receive the described nurse-led education while caregivers also undergo training through oral sessions, phone calls, and appropriately designed educational materials
62769961|NCT00121641|EXPERIMENTAL|Saxagliptin 5 mg (B)|Metformin 500-2000 mg (as needed for rescue)
62769962|NCT00121641|EXPERIMENTAL|Saxagliptin 10 mg (C)|Metformin 500-2000 mg (as needed for rescue)
62769963|NCT00121641|PLACEBO_COMPARATOR|Placebo (D)|Metformin 500-2000 mg (as needed for rescue)
62769964|NCT00121641|EXPERIMENTAL|Open-Label Treatment Cohort (Direct Enrollees) (E)|"Saxagliptin 10 mg~Metformin 500-2000 mg (as needed for rescue)"
62769965|NCT04014127||Controls|25 controls with preserved renal function
62769966|NCT04014127||Kidney Donors|25 living kidney donors who have donated a kidney at least 12 months prior to enrollment in the study.
62769967|NCT04014127||Pre-dialysis|25 patients with pre-dialysis chronic kidney disease stage 5
62769968|NCT04014127||Peritoneal dialysis|25 patients with chronic kidney disease stage 5 undergoing peritoneal dialysis
62769969|NCT06398925|EXPERIMENTAL|OCT461201 Dose Level 1|Single ascending dose of OCT461201 10 mg
62769970|NCT06398925|EXPERIMENTAL|OCT461201 Dose Level 2|Single ascending dose of OCT461201 50 mg
62769971|NCT06398925|EXPERIMENTAL|OCT461201 Dose Level 3|Single ascending dose of OCT461201 150 mg
62769972|NCT06398925|EXPERIMENTAL|OCT461201 Dose Level 4|Single ascending dose of OCT461201 450 mg
62769973|NCT06398925|PLACEBO_COMPARATOR|Placebo|Single dose of matching placebo
62769974|NCT04594863||cachexia|patients suffering from cachexia recently
62769975|NCT04594863||no cachexia|patients are not suffering from cachexia recently
62769976|NCT04762524|EXPERIMENTAL|Initiation on CVVH|Patients in this arm were initiated on CVVH, rather than CVVHD
62769977|NCT04762524|ACTIVE_COMPARATOR|Initiation on CVVHD|Patients in this arm were initiated on CVVHD, rather than CVVHDH
62769978|NCT01697943|EXPERIMENTAL|Roux-En-Y Pouch Reconstruction or Roux-En-Y Reconstruction|
62769979|NCT03470363|ACTIVE_COMPARATOR|Group Spinal anesthesia|"Knee surgery under spinal anesthesia~Intervention involves spinal administration of 12,5 mg bupivacaine and 2,5 microgram sufentanil."
62769980|NCT03470363|ACTIVE_COMPARATOR|Group Sevoflurane anesthesia|"Knee surgery under sevoflurane anesthesia~Intervention involves administration of inhaled sevoflurane for maintenance of general anesthesia"
61994745|NCT06133231|EXPERIMENTAL|Micronutrient|All participants will take the active micronutrient treatment; capsules of broad spectrum micronutrients.
61994746|NCT00805935|EXPERIMENTAL|Menotropin/Progesterone vaginal insert|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone vaginal insert (Endometrin®) 100 mg starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
62562498|NCT06066268||2)Controls|2)Controls: patients affected by infrarenal abdominal aortic aneurysm (AAA) free from CLI, affected and not affected by type 2 diabetes mellitus, undergoing endovascular exclusion surgery of the AAA (EVAR), similar by age and sex to CLI patients. Sartorius muscle biopsies will be taken.
62562499|NCT05628831|PLACEBO_COMPARATOR|Traditional surgery|This group of patients will be treated with standard technique (vaginal hysterectomy with anterior and/or posterior vaginal repair) for pelvic organ prolapse .
62562500|NCT05628831|ACTIVE_COMPARATOR|vNOTES PREFAP|This group of patients will be treated with vNOTES aproach using autologous graft isolated from posterior rectus fascia for pelvic organ prolapse.
62562501|NCT03743532|EXPERIMENTAL|E-Cigarette Switching (EC)|Participants were provided with an e-cigarette device and nicotine pods and advised to completely switch from combustible cigarettes to e-cigarettes. Although participants in the EC group did not earn incentives for combustible cigarette abstinence, they were yoked with a participant in the EC+FI group (described below), and they earned the same weekly incentive amount as their counterpart earned for combustible cigarette abstinence credited to a reloadable study credit card.
62562502|NCT03743532|EXPERIMENTAL|E-Cigarette Switching + Financial Incentives (EC+FI)|Participants assigned to the EC+FI group received ECs and pods and were instructed to switch from combustible cigarettes to e-cigarettes as described above for the EC group. Participants also earned escalating financial incentives for self-reported and carbon-monoxide-verified combustible cigarette abstinence via credits to a reloadable study credit card. Participants who reported combustible cigarette use and/or had a CO level \>6 ppm did not earn incentives that week, but could earn incentives at the next visit with the incentive value reset to the starting value.
62562503|NCT03084653||Survey|Close-ended survey questions were formed and will be sent to general surgeons by e-mail containing the web address of the survey.
62562504|NCT00780338|EXPERIMENTAL|1|Cohort 1: receives the Assets Getting To Outcomes intervention first. The AGTO intervention includes three types of assistance which are adapted to fit the needs and priorities of the individuals involved, as well as the inner and outer setting: (1) a manual of text and tools; (2) face-to-face training, and (3) onsite technical assistance (TA). These three types of assistance aim to improve the implementation process for each program. Two full-time, Maine-based staff, one with a master's and one with a bachelor's degree, provided AGTO tools, training, and TA to the intervention coalitions and programs during the two year intervention period. The tools are in the Search Institute-published manual, Getting To Outcomes with Developmental Assets: Ten steps to measuring success in youth programs and communities, which all intervention participants received.
62769981|NCT02035722|NO_INTERVENTION|Control group|AMD-related information is not given to patients randomized to the control group.
62769982|NCT02035722|ACTIVE_COMPARATOR|Video materials|Educational materials are presented in through a video (audio and visual)
62769983|NCT02035722|ACTIVE_COMPARATOR|Print materials|Educational materials are presented in the format of printed brochure (visual)
62769984|NCT04844086|EXPERIMENTAL|Infusion RPM CD19-mbIL15-CAR-T cell|"In this study, anti-CD19 autologous chimeric antigen receptor T-cells infusion produced by rapid personalized manufacture are used to treat patients with relapsed/refractory Advanced Lymphoid Malignancies.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to RPM CD19-mbIL15-CAR-T cell infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
62769985|NCT01563016|EXPERIMENTAL|Glucose & Depleting|participants will perform in a depleting task and receive a glucose drink
62769986|NCT01563016|PLACEBO_COMPARATOR|Glucose & non-depleting|participants will perform in a non-depleting task and receive a glucose drink
62769987|NCT01563016|NO_INTERVENTION|Placebo & depleting|participants will perform in a depleting task and receive a placebo drink
62769988|NCT01563016|NO_INTERVENTION|Placebo & non depleting|participants will perform in a non depleting task and receive a placebo drink
62769989|NCT01972685|OTHER|Cryo vs Transbronchial vs VATS biopsy|Each patient will be brought to the operating room and will undergo transbronchial, cryoprobe and VATS biopsy of the lung.
62769990|NCT05429073|EXPERIMENTAL|RGLS8429, first dose level|Eligible participants will receive subcutaneous injection of the first dose level RGLS8429 or placebo
62769991|NCT05429073|EXPERIMENTAL|RGLS8429, second dose level|Eligible participants will receive subcutaneous injection of the second dose level RGLS8429 or placebo
62769992|NCT05429073|EXPERIMENTAL|RGLS8429, third dose level|Eligible participants will receive subcutaneous injection of the third dose level RGLS8429 or placebo
62769993|NCT05429073|EXPERIMENTAL|RGLS8429, fourth dose level|Eligible participants will receive subcutaneous injection of the fourth dose level RGLS8429 or placebo
62769994|NCT01360177|EXPERIMENTAL|Radioactive Iodide and PET/CT|
62769995|NCT05035589||TCZ|The first 50 patients admitted to the ITU at Mater Dei Hospital with COVID-19 Pneumonia, to whom tocilizumab was administered
62769996|NCT05035589||Control|50 patients admitted to ITU at Mater Dei Hospital with COVID-19 Pneumonia, who did not receive Tocilizumab
62769997|NCT03779503|ACTIVE_COMPARATOR|midafilcon A|Subjects will be randomized to wear midafilcon A 1 day for one week of daily wear during the study.
62390942|NCT04450420|EXPERIMENTAL|Simulation based curriculum|"Three phases:~1. Self-study of an eBook - Participating trainees will be required to learn material pertaining to tunnel construction and general surgical principles during SICS from an eBook that has been developed by HelpMeSee.~2. Instructor led teaching - didactic training, lab activities to gain familiarity with instruments, simulator based training through deliberate practice, and debriefing with instructor.~3. Instructor supervised performance of surgery on patients in the operating room."
62390943|NCT04450420|ACTIVE_COMPARATOR|Standard training|Current standard curriculum for resident training.
62390944|NCT00915421||Prehospital hypothermia group|All patients included to the study
62390945|NCT01512758|EXPERIMENTAL|Alisertib 30 mg|Alisertib 30 mg enteric-coated tablets (ECT), orally, twice a day (BID) for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 16 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.
62390946|NCT01512758|EXPERIMENTAL|Alisertib 40 mg|Alisertib 40 mg ECT, orally, BID for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 7 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.
62390947|NCT02354027|EXPERIMENTAL|SHR3824 25mg/metformin 1000mg|Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.
62390948|NCT03396172|OTHER|Control|The intervention is an hospitalization with usual care. The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
62390949|NCT03396172|ACTIVE_COMPARATOR|FreeDom|"FreeDom strategy (early discharge, automated weaning at home, telemedicine, telereadaptation):~-initial conventional hospitalization before discharge home, O2 flow rate automatically titrated by FreeO2 (based on a SpO2 target). The hospital discharge will be possible if the definite criteria are met.~After hospital discharge, patient will have home hospitalisation. Automated oxygen flow titration, patient education will be conducted for using the telemedicine system, for questionnaires and for the tele-rehabilitation program will be initiated for home hospitalization,"
62390950|NCT02314299|EXPERIMENTAL|Low Dose Regimen|MTP-131 (Low Dose) sterile topical ophthalmic solution twice a day into the study eye
62390951|NCT02314299|EXPERIMENTAL|High Dose Regimen|MTP-131 (High Dose) sterile topical ophthalmic solution twice a day into the study eye
62390952|NCT02489994|EXPERIMENTAL|all subjects|Treatment with the ePrime radiofrequency microneedling device in the upper thighs and buttocks
62562505|NCT00780338|ACTIVE_COMPARATOR|2|Cohort 2: receives the Assets Getting To Outcomes intervention second, after Cohort 1 is done receiving the intervention.
62562506|NCT04816734|EXPERIMENTAL|Parents|Parents of children in need of home parenteral nutrition and participating in initial therapeutic education program of Necker-Enfants Malades hospital.
62769998|NCT03779503|ACTIVE_COMPARATOR|somofilcon A|Subjects will be randomized to wear somofilcon A 1 day for one week of daily wear during the study.
62769999|NCT06380894|EXPERIMENTAL|Virtual Reality Cognitive Training|The program consisted of two components: (1) psychoeducation on cognitive functioning and ways to maintain cognitive health, (2) VR multi-domain cognitive training tasks that target cognitive domains of attention, memory, and executive functioning.
62169109|NCT06094842|EXPERIMENTAL|Treatment (autologous L1CAM-specific CAR+EGFRt+ T cells)|Patients undergo leukapheresis to obtain PBMCs for T cell product manufacturing and may undergo bridging therapy at the discretion of the treating clinician on study. Patients then undergo lymphodepleting chemotherapy with cyclophosphamide IV and fludarabine IV on days -5, -4 and -33 or single agent bendamustine on days -4 and -3 at the discretion of the treating clinician and/or PI. Patients receive an autologous L1CAM-specific CAR+EGFRt+ T cells infusion on day 0. Based on disease response and persistence of CAR T cells, patients may receive additional lymphodepletion chemotherapy and an autologous L1CAM-specific CAR+EGFRt+ T cell infusion as soon as 6 weeks and no later than 24 weeks after the first infusion, or at the discretion of the PI. Patients also undergo ECHO or MUGA during screening. Patients undergo x-ray imaging, CT, bone scan, and blood sample collection throughout the trial. Additionally, patients may undergo tissue biopsy on the trial.
62169110|NCT06543407|ACTIVE_COMPARATOR|E-cigarette provision only|Participants randomized to this condition will receive a supply of NJOY Daily e-cigarettes for the first 8 weeks of the study.
62169111|NCT06543407|EXPERIMENTAL|SWITCH IT|Participants randomized to this condition will receive a supply of e-cigarettes and behavioral support and coaching, protocolized intervention, SWITCH IT, for the first 8 weeks of the study.
62169112|NCT06320509|OTHER|Shock population|Insertion of bladder urine probe (Oxylite Pro ® device) and assessment of continuous uPO2
62169113|NCT06320509|OTHER|Without Shock Population|Insertion of bladder urine probe (Oxylite Pro ® device) and assessment of continuous uPO2
62169114|NCT03743987|SHAM_COMPARATOR|control group|Apical resection group. Only root resection was applied without any other interventions (like prf or mta)
62169115|NCT03743987|EXPERIMENTAL|MTA group|Root resection was applied and MTA was inserted through the apical foramen
62169116|NCT03743987|EXPERIMENTAL|PRF group|Root resection was applied and PRF was placed to the surgically prepared area
62169117|NCT03743987|EXPERIMENTAL|MTA + PRF group|Root resection was applied. MTA was inserted through the apical foramen and PRF was placed to the surgically prepared area
62169118|NCT05364047|OTHER|Low-dose group, 18-59 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 25μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
62169119|NCT05364047|OTHER|Middle-dose group, 18-59 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 50μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
62169120|NCT05364047|OTHER|High-dose group, 18-59 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 100μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
62169121|NCT05364047|OTHER|Low-dose group, over 60 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 25μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
62169122|NCT05364047|OTHER|Middle-dose group, over 60 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 50μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
62390953|NCT00370994|ACTIVE_COMPARATOR|Caudal epidural injection|Caudal epidural with placement of catheter in sacral canal with injection of 5 mL of 2% preservative-free lidocaine, followed by 6 mL of 0.9% sodium chloride solution and 6 mg of non-particulate Betamethasone and 1 mL of sodium chloride solution
62562507|NCT03667222|EXPERIMENTAL|BPX-04 Active|BPX-04 1% minocycline topical gel
61994747|NCT00805935|EXPERIMENTAL|Menotropin/Progesterone in oil|"Menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in oil 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
62169123|NCT05364047|OTHER|High-dose group, over 60 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 100μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
62169124|NCT05141071|EXPERIMENTAL|Ivabradine|In the study group, Ivabradine(I) group; patients will receive an enteral Ivabradine (dissolved in distilled water) 5mg twice daily (every 12 hours) via a naso-gastric tube.
62169125|NCT05141071|PLACEBO_COMPARATOR|Placebo|the control group, Placebo (P) group; patients will receive 50 ml of saline twice daily also via a naso-gastric tube.
62390954|NCT00370994|ACTIVE_COMPARATOR|Percutaneous adhesiolysis|Pecutaneous adhesiolysis and targeted placement of Racz catheter with injection of 5 mL of 2% preservative-free lidocaine, followed by 6 mL of 10% sodium chloride solution and 6 mg of non-particulate Betamethasone and 1 mL of sodium chloride solution
62390955|NCT04808141|EXPERIMENTAL|Digital Rehabilitation|Home-based rehabilitation with a digital biofeedback system
62390956|NCT04808141|ACTIVE_COMPARATOR|Conventional rehabilitation at an outpatient clinic|
62562508|NCT03667222|PLACEBO_COMPARATOR|BPX-04 Vehicle|BPX-04 topical gel vehicle
62562509|NCT01608750|EXPERIMENTAL|pantoprazole|
62562510|NCT01608750|PLACEBO_COMPARATOR|folic acid|
62562511|NCT03596957|ACTIVE_COMPARATOR|Tolvaptan group|Treatment with tolvaptan for six weeks followed by six weeks observation without trial medication
62562512|NCT03596957|NO_INTERVENTION|Control group|No tolvaptan treatment but following the same visit and investigation plan as the subjects in the tolvaptan group
62562513|NCT02447211|ACTIVE_COMPARATOR|doxepin cream|Patients use doxepin cream 5% twice daily for two weeks
62562514|NCT02447211|PLACEBO_COMPARATOR|Placebo|Patients use cream without doxepin ingredient twice daily for two weeks
62562515|NCT01864993|EXPERIMENTAL|suspected NC gluten sensitive subjects|Patients referring gastrointestinal functional disorders will be selected and they will follow a gluten free diet
61994748|NCT00805935|ACTIVE_COMPARATOR|Follitropin beta/Progesterone vaginal insert|"Follitropin beta (Follistim Pen®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone vaginal insert (Endometrin®) 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
62169126|NCT04297839|ACTIVE_COMPARATOR|Control Group|"Patients in this group will receive heparin during hemodialysis sessions, at a dose of 1.000 units at the beginning and 500 units per hour in a syringe infusion pump.~If the patient has a contraindication for the heparin use, it will receive saline continuous administration.~This is the actual standard of care performed in extended hemodialysis sessions."
62169127|NCT04297839|EXPERIMENTAL|Citrate Group|Patients in this group will receive regional citrate anticoagulation, with acid-citrate-dextrose 2.2% (ACD). Dose of 3 mmol per liter of filtered blood. The systemic calcium levels are measured every two hours and a solution of calcium chloride is infused in a peripheral venous access, accordingly to citrate infusion rate and the systemic calcium values.
62169128|NCT04501354|EXPERIMENTAL|UC-Mesenchymal Stem Cell|Allogeneic Mesenchymal Stem Cell from umbilical cord
62770000|NCT06380894|ACTIVE_COMPARATOR|Active Control Group|Participants who were assigned to the active control group were provided treatment-as-usual, which included: (1) psychoeducation on MCI, cognitive functioning, and compensatory strategies, and (2) brain training cognitive stimulation booklet which consisted of weekly homework activities focusing on attention, memory, and executive functioning. Control participants were reviewed for 3 sessions monthly to follow up on their progress on the cognitive stimulation activity booklet.
62770001|NCT02262754|EXPERIMENTAL|PF-06372865|Daily BID dosing for 4 weeks
62770002|NCT02262754|PLACEBO_COMPARATOR|Placebo|Daily BID dosing for 4 weeks
62770003|NCT02262754|ACTIVE_COMPARATOR|Naproxen|Daily BID dosing for 4 weeks
62770004|NCT01009190|EXPERIMENTAL|ARM A|Carboplatin plus PF-01367338
62169129|NCT06647030|EXPERIMENTAL|Avatar.DTx|DTx sessions: participants will interact with the DTx twelve minutes per day for two weeks. We will obtain a personalized profile for each participant (relationship between training intensity and participant's performance). A digital artist will receive the profiles without personal or medical data and create fifteen unique artworks. The team, who will mint the artworks as NFTs on Ethereum and send them to the participants' digital wallets (or help them to set one up). The NFTs will be displayed on OpenSea. If the Ethereum blockchain stops its activity within two years of the NFT minting, the team will mint a new NFT for each participant in an alternative blockchain and compensate them with SGD150. After the last DTx session (regardless of study completion by the participant), a 60-minute interview will be conducted.
62169130|NCT02814279|ACTIVE_COMPARATOR|CAF plus connective tissue graft|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. The connective tissue graft was removed from the palate according to Bruno technique (1994) and sutured in position. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions.
62169131|NCT02814279|EXPERIMENTAL|Tunnel plus connective tissue graft|The tunnel flap was performed according to Zuhr et al., 2007. Following initial sulcular incisions, spit thickness flap was prepared using specific tunneling knives beyond the mucogingival junction and until flap gain mobility. The flap was laterally extended to adjacent papillae that were carefully detached by means of a full-thickness preparation. The connective tissue graft was insert into the tunnel. Sling sutures were performed involving the flap and graft to coronally cover 2 mm above the CEJ.
62169132|NCT06647355||I|The 'M' point is on the heels of both feet.
62169133|NCT06647355||II|The 'M' point is located on the heel of the left foot and the forefoot of the right foot.
62169134|NCT06647355||III|Point 'M' is located on the heel of the right foot and the forefoot of the left foot.
62169135|NCT06647355||IV|The point of maximum pressure is in the forefoot area of both feet.
62770005|NCT01009190|EXPERIMENTAL|ARM A EXPANSION|Carboplatin plus PF-01367338
62770006|NCT05105815|EXPERIMENTAL|IPM001|A neoantigen/tumor-specific antigen sensitized autoimmune cell injection
62770007|NCT01107782|EXPERIMENTAL|sildenafil|
62770008|NCT01107782|PLACEBO_COMPARATOR|Placebo control|
62770009|NCT04109833||no antibiotic therapy (ABT) in the first week of life|VLBWI with gestational age between 24+0 and 28+6 weeks of gestation without antibiotic treatment in the first week of life
62770010|NCT04109833||ABT in the first week of life|VLBWI with gestational age between 24+0 and 28+6 weeks of gestation with antibiotic treatment in the first week of life
62770011|NCT02322190|NO_INTERVENTION|Investigator chosen second line therapy|Investigator chosen second line therapy
62770012|NCT02322190|EXPERIMENTAL|Second line therapy + Extracorporeal Photopheresis|Second line therapy in addition to Extracorporeal Photopheresis (ECP)
61994749|NCT00805935|ACTIVE_COMPARATOR|Follitropin beta/Progesterone in oil|"Follitropin beta (Follistim Pen®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in oil 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
62169136|NCT06647355||V|The 'M' point is in the medial zone on both feet.
62169137|NCT06647355||VI|The 'M' point is located on the left midfoot and right rearfoot.
62770013|NCT00167661|EXPERIMENTAL|Campath 1-H|Campath 1-H
62770014|NCT03038893|EXPERIMENTAL|POCUS + EDUS|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
62770015|NCT03038893|ACTIVE_COMPARATOR|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
62770016|NCT02850900|EXPERIMENTAL|Internet Survey|Subject will receive an electronic survey weekly to complete
62770017|NCT02850900|NO_INTERVENTION|No Survey|No intervention
62169138|NCT06647355||VII|The 'M' point is located on the right midfoot and left rearfoot.
62169139|NCT00607737|EXPERIMENTAL|1|insulin detemir
62169140|NCT00607737|PLACEBO_COMPARATOR|2|saline
62562516|NCT01864993|EXPERIMENTAL|suspected NC gluten sensitive|Patients referring gastrointestinal functional disorders will be selected and they will follow a gluten free diet
61994750|NCT00606892|EXPERIMENTAL|Placebo First, varenicline, + IV Nic|Subjects received a Placebo tablet once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg).After a minimum of a 5 day washout subjects then received varenicline tablet (1mg). once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,0.7 mg per 70kg).
61994751|NCT00606892|EXPERIMENTAL|Varenicline first, placebo, + IV Nic|Subjects received Varenicline tablet (1 mg) per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg). After a washout of a minimum of 5 days subjects then received placebo tablet for per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,, and 0.7mg per 70 kg).
61994752|NCT04010721|OTHER|Experimental : experiment 1,2 and 3|"One user included participates all experiments:~* Visit 1 : experiment 1~* Visit 2 : experiment 2~* Visit 3 : experiment 3"
61994753|NCT03454074|EXPERIMENTAL|B-Fit intervention|Combines group education about brain health with individualized goal-setting and group problem-solving to help participants effectively integrate healthy behavioral changes into their everyday lives.
62169141|NCT01808144|EXPERIMENTAL|lesinurad 400 mg + febuxostat 80 mg|Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after implementation of protocol amendment 3, dated 07 October 2015.
62562517|NCT00886015|EXPERIMENTAL|TT Clamp|The TT clamp will be used in trichiasis surgery.
61994754|NCT03454074|ACTIVE_COMPARATOR|Education Only|Provide group education about healthy behavior changes without problem-solving component.
62562518|NCT00886015|ACTIVE_COMPARATOR|Standard BLTR Technique|Standard BLTR technique will be used in trichiasis surgery.
62562519|NCT03449732|EXPERIMENTAL|PDR measurement group A|Two measurements of PDR perioperatively before and after opioid administration in toddlers (28 days until 23 months)
61994755|NCT03454074|NO_INTERVENTION|Wait-list|No intervention administered. Will be offered intervention following a delay.
61994756|NCT06482008|EXPERIMENTAL|HAIC+adebrelimab+apatinib|
61994757|NCT03026257|EXPERIMENTAL|AOHG|Lotrafilcon B contact lenses with added wetting agent, worn bilaterally (in both eyes) for 30 days in a daily wear modality and cared for with either a hydrogen peroxide-based contact lens solution with added wetting agent or a POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent, as randomized
61994758|NCT03026257|ACTIVE_COMPARATOR|Habitual|Habitual silicone hydrogel contact lenses worn bilaterally for 30 days in a daily wear modality and cared for with participant's habitual multi-purpose solution (MPS)
62169142|NCT01808144|EXPERIMENTAL|lesinurad 200 mg + febuxostat 80 mg|
62169143|NCT03256760|EXPERIMENTAL|Endotoxin|Endotoxin 0.8 ng/kg body weight
62169144|NCT03256760|PLACEBO_COMPARATOR|Placebo|Placebo
62169145|NCT05306730|EXPERIMENTAL|FOCUS group|"Group of patients with chest pain undergoing FOCUS ( Focused Cardiac Ultrasound ).~Patients with odd registration number."
62169146|NCT05306730|ACTIVE_COMPARATOR|Non-FOCUS group|Patients with even registration number.
62169147|NCT02176512|EXPERIMENTAL|Sequence 1|"four treatment periods:~1. Treatment A~2. Treatment B~3. Treatment B~4. Treatment A"
62169148|NCT02176512|ACTIVE_COMPARATOR|Sequence 2|"four treatment periods:~1. Treatment B~2. Treatment A~3. Treatment A~4. Treatment B"
62562520|NCT03449732|EXPERIMENTAL|PDR measurement group B|Two measurements of PDR perioperatively before and after opioid administration in children (2 until 11 years)
62562521|NCT03449732|EXPERIMENTAL|PDR measurement group C|Two measurements of PDR perioperatively before and after opioid administration in adolescents (12 until 18 years)
62562522|NCT05738733|EXPERIMENTAL|MsChief Classic Natural Lubricant|MsChief Classic natural lubricant contains aqua, propylene glycol, hydroxyethyl cellulose, ethyl menthane carboxamide and methyl diisopropyl propionamide, aloe barbadensis leaf juice, benzoic acid, hippophae Rhamnoides extract, tocophersolan, sodium hydroxide. MsChief Classic natural lubricant is a special moisturizer with aloe vera, vitamin E and sea buckthorn. It not only conditions but also moisturises the skin. This lubricant is water-based is free of sugar or saccharine. This product does not contain paraben or glycerine. This product has a unique formulation pH ideal for intimate area.
62770018|NCT01554514|EXPERIMENTAL|low dose rituximab|this is a single-arm trial
62770019|NCT00065806|EXPERIMENTAL|1|Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes \[TLC\] diet, \[http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi\]), cardiovascular risk factor reduction counseling, hydroxychloroquine, low-dose aspirin, a multivitamin containing folate, plus atorvastatin at 10 mg or 20 mg depending on the patient's weight. Patients weighing more than 50 kg will receive 10 mg qd atorvastatin for the first month, which will be increased to 20 mg qd at the Day 30 visit and continue through month 36. Participants weighing less than 50kg will receive a maximum of 10 mg po qd for 36 months.
61994759|NCT03523546|EXPERIMENTAL|Cancer Episode Payment Model|Oncologists in this arm will be paid for each member's episode of care. The episode of care is 6 months in duration. Oncologists will have the opportunity to receive performance-based payments based upon a set of 6 quality metrics.
62169149|NCT03137654|ACTIVE_COMPARATOR|Affective Training|Subjects complete baseline assessment, 3 wks of training with versions of the tasks using emotionally-laden stimuli, and a post-training assessment. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
62169150|NCT03137654|ACTIVE_COMPARATOR|Neutral Training|Subjects complete baseline assessment, 3 wks of training with versions of the tasks using neutral stimuli, and a post-training assessment. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
62169151|NCT03137654|NO_INTERVENTION|Control (Non-active)|Subjects complete a baseline assessment and a secondary assessment approximately three weeks later. No active intervention is delivered. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
62562523|NCT05738733|EXPERIMENTAL|MsChief Ylang Ylang Natural Lubricant|MsChief Ylang Ylang natural lubricant contains aqua, propylene glycol, flavour, hydroxyethyl cellulose, ethyl menthane carboxamide and methyl diisopropyl propionamide, aloe barbadensis leaf juice, benzoic acid, hippophae Rhamnoides extract, tocophersolan, sodium hydroxide. MsChief Ylang Ylang natural lubricant is a special moisturizer with aloe vera, vitamin E and sea buckthorn It not only conditions but also moisturise the skin. This lubricant is water-based contain natural flavour and free of sugar or saccharine. This product does not contain paraben or glycerine. This product has a unique formulation pH ideal for intimate area.
62562524|NCT05738733|EXPERIMENTAL|MsChief Vanilla & Citrus Natural Lubricant|MsChief vanilla and citrus natural lubricant contain aqua, propylene glycol, flavour, hydroxyethyl cellulose, ethyl menthane carboxamide and methyl diisopropyl propionamide, aloe barbadensis leaf juice, benzoic acid, hippophae Rhamnoides extract, tocophersolan, sodium hydroxide. MsChief vanilla and citrus natural lubricant is a special moisturizer with Aloe vera, vitamin E and sea buckthorn. It not only conditions but also moisturise the skin. This lubricant is water based contain natural flavour and free of sugar or saccharine. This product does not contain paraben or glycerine. This product has a unique formulation pH ideal for intimate area.
62562525|NCT05738733|EXPERIMENTAL|MsChief Tea & Peach Natural Lubricant|MsChief tea \& peach natural lubricant contains aqua, propylene glycol, flavour, hydroxyethyl cellulose, ethyl menthane carboxamide and methyl diisopropyl propionamide, aloe barbadensis leaf juice, benzoic acid, hippophae Rhamnoides extract, tocophersolan, sodium hydroxide. MsChief tea \& peach natural lubricant is a special moisturizer with Aloe vera, vitamin E and sea buckthorn. It not only conditions but also moisturises the skin. This lubricant is water-based contains natural flavour and is free of sugar or saccharine. This product does not contain paraben or glycerine. This product has a unique formulation pH ideal for intimate area.
62562526|NCT05875402|EXPERIMENTAL|XKDCT080 treatment for patients with GCC target positivity|"Drug: XKDCT080 (chimeric antigen receptor T cell preparation targeting GCC)~Dosage form: Cell suspension~Dose: 30-50mL/bag~Medication method: intravenous drip~Frequency: Once"
62562527|NCT04255576|EXPERIMENTAL|Experimental: JMT103|Eligible subjects will receive JMT103 at a dose of 2 mg/kg SC Q4W with a loading dose of 2 mg/kg SC on study days 8 and 15.
62562528|NCT02280837||Patients with suspected or diagnosed coronary artery disease|
62770020|NCT00065806|PLACEBO_COMPARATOR|2|Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes \[TLC\] diet, \[http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi\]), cardiovascular risk factor reduction counseling, hydroxychloroquine, low-dose aspirin, a multivitamin containing folate, plus placebo at 10 mg or 20 mg depending on the patient's weight. Patients weighing more than 50 kg will receive 10 mg qd placebo for the first month, which will be increased to 20 mg qd at the Day 30 visit and continue through month 36. Participants weighing less than 50kg will receive a maximum of 10 mg po qd for 36 months.
62770021|NCT00464659|EXPERIMENTAL|Effective CPAP treatment|Effective Continuous Positive Airway Pressure treatment (CPAP) applied for 6 weeks
62169152|NCT01039558|ACTIVE_COMPARATOR|lansoprazole + ecabet sodium|
62169153|NCT01039558|PLACEBO_COMPARATOR|lansoprazole + placebo|
62169154|NCT01772121||HCV Cohort|A total of 1000 subjects were enrolled in the study and of that 500 subjects had a diagnosis of chronic HCV infection
62169155|NCT01772121||HBV Cohort|A total of 1000 subjects were enrolled in the study and of that 500 subjects had a diagnosis of chronic HBV infection
62169156|NCT01090076|EXPERIMENTAL|Abound|Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)
62169157|NCT01090076|PLACEBO_COMPARATOR|Placebo|Placebo comparator that contains none of the active ingredients
61994760|NCT03523546|NO_INTERVENTION|Fee for Service|Oncologists in this arm will not receive the intervention and will continue to be paid through fee-for-service.
61994761|NCT04439032||Spine Fusion using NanoBone|All patients in the study will be drawn from the individual surgeons' practice. Patients will be candidates for spinal fusion surgery after having failed conservative treatment or will have had spinal fusion surgery but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient.
62169158|NCT01304251|ACTIVE_COMPARATOR|Short-term fasting|short term fasting (i.e. 24 hours before and 24 hours after administration of chemotherapy) in 20 breast cancer patients
62169159|NCT01304251|PLACEBO_COMPARATOR|Healthy nutrition|20 breast cancer patients eat according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy.
62169160|NCT01313299|EXPERIMENTAL|Dysport 500 U|
62169161|NCT01313299|EXPERIMENTAL|Dysport 1000 U|
62169162|NCT01313299|PLACEBO_COMPARATOR|Placebo|
62169163|NCT03924193|ACTIVE_COMPARATOR|LDX|
62169164|NCT03924193|ACTIVE_COMPARATOR|Cognitive-Behavioral Therapy|
62169165|NCT03924193|ACTIVE_COMPARATOR|LDX and Cognitive Behavioral Therapy|
62562529|NCT03215212|EXPERIMENTAL|earplug|Ear plug made from polyurethane with (NRR= 29 db and SNR= 37 db) administered from 10 pm to 7 am.
62562530|NCT03215212|EXPERIMENTAL|eye mask|eye mask (18.5 cm, width 8.5cm, height -30mm )dark coloured cloth with 2 elasticised strap, covering both eyes administered from 10 pm to 7 am.
62770022|NCT00464659|SHAM_COMPARATOR|Sham CPAP treatment|Ineffective Continuous Positive Airway Pressure treatment (sham CPAP) applied for 6 weeks
62770023|NCT00562042||1|Patients diagnosed with acute pulmonary embolism were enrolled in this study.
62770024|NCT04190524|OTHER|Intervention/Control|Each subject will serve as their own control. The esophagus diameter will be measured on each subject, then cricoid pressure will be applied and the esophagus diameter will again be measured.
62169166|NCT06279637|EXPERIMENTAL|Joint Home-DM-BAT Intervention|A trained health educator will deliver the manualized Joint Home-DM-BAT intervention. Participants will receive 8-weekly sessions of diabetes education, problem solving around social needs, and behavioral activation via telephone; and 3 monthly booster sessions.
62169167|NCT06279637|ACTIVE_COMPARATOR|Usual Care|Patients randomized to the usual care arm will receive weekly mailings of diabetes education modules for 8 weeks and monthly mailings for 3 months to match the weekly and monthly booster sessions.
62770025|NCT00418587|EXPERIMENTAL|1|800 IU oral daily dose level
62169168|NCT01041599||Diabetic patients|Hypertensive and normotensive patients with type 2 diabetes mellitus
62169169|NCT01041599||Hypertensive patients|Patients with essential hypertension
62770026|NCT00418587|EXPERIMENTAL|2|2000 IU oral daily dose level
62770027|NCT00418587|EXPERIMENTAL|3|4000 IU oral daily dose level
62770028|NCT01908439|EXPERIMENTAL|Whole-body vibration|A new method for muscle reflex latency measurement
62390957|NCT06256679||Group 1: SHP pulsed radiofrequency and TTNS|Patients with interstitial cystitis who received superior hypogastric plexus pulsed radiofrequency and transcutaneous tibial nerve stimulation.
62390958|NCT06256679||Group 2: SHP pulsed radiofrequency|Group 2 included patients with interstitial cystitis who received only superior hypogastric plexus pulsed radiofrequency.
62390959|NCT00771420|ACTIVE_COMPARATOR|1|0.01mg/kg and 0.03mg/kg CAM-3001
62770029|NCT01237379||Health Controls|
62770030|NCT01237379||Bipolar Patients with High-Risk of Mania|
62770031|NCT01237379||Bipolar Patients with Ultra-High Risk|
62770032|NCT01237379||First Manic Episode Bipolar Youth|
62390960|NCT00771420|ACTIVE_COMPARATOR|2|0.1mg/kg CAM-3001
62770033|NCT02498990|EXPERIMENTAL|Weight reduction|
62770034|NCT04872998|EXPERIMENTAL|Reduced Activity|Reduction of daily step count by 70% for two weeks, followed by two week recovery to normal activity level
62770035|NCT03223623|ACTIVE_COMPARATOR|FHD|adults with Focal Hand Dystonia
62169170|NCT01041599||Healthy subjects|Healthy subjects
62169171|NCT02599376|ACTIVE_COMPARATOR|BMI less than 30|The drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid
62169172|NCT02599376|EXPERIMENTAL|BMI more than 40|The drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid
62169173|NCT05320861|EXPERIMENTAL|[14C]SJP-0008|
62390961|NCT00771420|ACTIVE_COMPARATOR|3|0.3mg/kg CAM-3001
62390962|NCT00771420|ACTIVE_COMPARATOR|4|1.0mg/kg CAM-3001
62390963|NCT00771420|ACTIVE_COMPARATOR|5|3.0mg/kgCAM-3001
62390964|NCT00771420|ACTIVE_COMPARATOR|6|10.0mg/kg CAM-3001
62390965|NCT00771420|PLACEBO_COMPARATOR|7|Placebo
62390966|NCT05217017|EXPERIMENTAL|Chronic pain|Fear-avoidance components scale
62182730|NCT02599493|EXPERIMENTAL|Low dose|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
62390967|NCT05294510|NO_INTERVENTION|Control|Children who present to a village health worker during a control period are evaluated and managed using the current standard of care per Uganda National Guidelines for Integrated Community Case Management (ICCM). Each village will experience both Control and Intervention conditions as the study employs a stepped wedge design.
62390968|NCT05294510|EXPERIMENTAL|Intervention|Children who present to a village health worker during an intervention period are evaluated and managed using a modified ICCM algorithm that includes point-of-care C-reactive protein testing. Each village will experience both Control and Intervention conditions as the study employs a stepped wedge design.
62390969|NCT04866147||Surgery patients|Patients who undergo various common surgical procedures
62390970|NCT06319365|EXPERIMENTAL|yoga group|the yoga practice of the group should be completed at the end of 12 weeks. Participants should be encouraged to practice at home 3 days a week for 3 months. An example of yoga practices in the research for women should be shared as a video.
62562531|NCT03215212|EXPERIMENTAL|ocean sound|Ocean sound a type of white noise administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
62770036|NCT03223623|PLACEBO_COMPARATOR|Healthy Volunteer|adult healthy volunteers
62770037|NCT04627935||COPD patients|Patients with a diagnosis of COPD aged over 60 years
62770038|NCT05869500|EXPERIMENTAL|Left Bundle Branch Area Pacing|
62770039|NCT05869500|ACTIVE_COMPARATOR|Right Ventricular Pacing|
62770040|NCT05671614||Critically ill patients|Critically ill patients with sudden onset of disease receiving mechanical ventilation, to be enrolled within 72 hours of admission, who are likely to need 7 days or more of ICU stay.
62770041|NCT05671614||Volunteers with a very good to excellent performance status|Elective hip surgery patients with a very good to excellent performance status, only limited to joint pain (ECOG 0)
62770042|NCT03328416|EXPERIMENTAL|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
62770043|NCT02718040|EXPERIMENTAL|Emervel Treatment Group|Eligible subjects received bilateral treatment of Nasolabial Folds (NLFs) and Marionette Lines (MLs) with Emervel Classic and/or Emervel Deep
62770044|NCT05458856|EXPERIMENTAL|Triptorelin embonate|All participants will receive triptorelin embonate 22.5 mg
62770045|NCT03758690|EXPERIMENTAL|Treatment Group|Treatment with the investigational device - High-Intensity Focused Electromagnetic (HIFEM) Field Device
62770046|NCT04326816|ACTIVE_COMPARATOR|Direct Composite Restorations (DCR)|"All teeth were reconstructed with directly applied composite restorations. No preparation of teeth was performed except in cases of sharp occlusal edges.~Rubberdam or cotton rolls and suction devices were used for moisture control. For bonding, a 3-step etch-and-rinse adhesive was applied according to manufacturer's instructions, using 37% phosphoric acid (DMG, Hamburg, Germany), Clearfil SA Primer, and Clearfil Photobond (Kuraray, Osaka, Japan). A micro-hybrid composite (Clearfil AP-X, Kuraray) was used for posterior restorations and palatal veneer restorations. Restorations were placed according to the DSO-technique (Direct Shaping by Occlusion). In front teeth, both a palatal and buccal veneer restoration was placed.~Experimental restorations were all restorations on first molars and all palatal veneer restorations on maxillary anterior teeth."
62770047|NCT04326816|EXPERIMENTAL|Indirect Composite Restorations (ICR)|"Indirect 'tabletop' restorations were placed on all first molars (n=4) and palatal veneers ('backings') (n=6) on maxillary anterior teeth. Remaining teeth received directly applied restorations. Preparation of teeth for indirect restorations was limited to removal of sharp edges.~All indirect restorations were laboratory manufactured using a micro-hybrid composite (Clearfil Estenia C\&B, Kuraray, Osaka, Japan). Adhesive surfaces of the restorations were air-abraded with aluminum-oxide powder (\<50 µm). Rubberdam or cotton rolls were used for moisture control during cementation. Seating of indirect restorations was checked intraorally, followed by cleaning of its adhesive surface with phosphoric acid 37% and application of silane (Clearfil Ceramic Primer, Kuraray, Osaka Japan).The adhesive surface of the abutment tooth was etched with phosphoric acid and ED-primer II (Kuraray) was applied. Finally, restorations were cemented, using Panavia F (Kuraray)."
62770048|NCT06177093|EXPERIMENTAL|Interventional|All radiotherapy will be delivered on the MR-linac
62770049|NCT03783494|EXPERIMENTAL|Target-controlled infusion (TCI)|Target-controlled infusion (TCI) with propofol up to 5.5µg/ml during an anticipated average maximal time of 15 minutes
62770050|NCT02198794|EXPERIMENTAL|Part A: SD-809|Participants will receive SD-809 orally twice daily (BID) starting at 12 mg/day, which will be titrated based on dyskinesia control and tolerability up to a maximum total dose of 48 mg/day. Participants who decline to participate in Part B, will continue at their stable dose of SD-809 BID up to Week 158.
62770051|NCT02198794|PLACEBO_COMPARATOR|Part B: Placebo|Participants will receive placebo matched to SD-809 for 1 week in randomized withdrawal period and thereafter will receive SD-809 (stable dose) for 12 weeks.
62770052|NCT02198794|ACTIVE_COMPARATOR|Part B: SD-809|Participants will receive SD-809 (stable dose) for 1 week in randomized withdrawal period and will continue to receive the same dose of SD-809 for an additional 12 weeks.
62770053|NCT02198794|EXPERIMENTAL|Part C: SD-809|EU participants who complete Part B and willing to continue in the study will continue treatment with SD-809 for 52 weeks at the dose administered during the 12-week open-label period of Part B.
62770054|NCT02401204||Neonates admitted to QSNICH NICU|All neonates admitted to the QSNICH NICU over a period of one year from March 2015 to March 2016 meeting the inclusion and exclusion criteria will be enrolled in the study. Readmitted neonates will be eligible to be enrolled again into the study.
62770055|NCT04608422|EXPERIMENTAL|Electrical stimulation|The patients will receive neuromuscular electrical stimulation on quadriceps muscle and sensory stimulation in the anatomical region of the kidneys.
62770056|NCT04608422|NO_INTERVENTION|Control|The patients only will be evaluated and reassessed.
62770057|NCT06137872|EXPERIMENTAL|Music Group|During the non-stress test shooting, the music group was allowed to listen to music via headphones once for at least 20 minutes.
62770058|NCT06137872|EXPERIMENTAL|Control Group|No application was made and non-stress test shooting was performed.
62770059|NCT03674879|NO_INTERVENTION|Phone Call|Follow up contact is attempted via phone call.
62770060|NCT03674879|EXPERIMENTAL|Text Message|Follow up contact is attempted via text message.
61994762|NCT01112527|EXPERIMENTAL|Arm A|Patients with Glioblastoma that has returned or grown after chemotherapy or radiation treatment and who will be having a standard operation to remove the tumor.
61994763|NCT01112527|EXPERIMENTAL|Arm B|Participants with glioblastoma at first recurrence who are not surgical candidates and who have not had prior anti-VEGF therapy.
62390971|NCT06319365|NO_INTERVENTION|control group|The control group should be continue standard hypertension treatment
62390972|NCT02702076|EXPERIMENTAL|Apomorphine|This arm will be treated with continuous subcutaneous infusion of apomorphine. The infusion will start with 1 mg/hr during the waking day (approximately 16 hours). The flow rate will be adjusted on a weekly basis, and may be increased with 0.5 to 1.0 mg/hr per discretion of the investigator, aiming at the disappearance of visual hallucinations. The duration of treatment is 4 weeks.
62562532|NCT00606112|PLACEBO_COMPARATOR|1|
62770061|NCT05623215||Cementless ATTUNE|Cementless ATTUNE Rotating Platform Cruciate Sacrificing Knee System
62770062|NCT05623215||Cementless LCS|Cementless LCS rotating platform Cruciate Sacrificing Knee System
62770063|NCT01420666|ACTIVE_COMPARATOR|Maxigesic 325|Maxigesic 325 (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day, orally, with food
62770064|NCT01420666|ACTIVE_COMPARATOR|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
62770065|NCT01420666|ACTIVE_COMPARATOR|Ibuprofen|ibuprofen 97.5mg, three tablets four times a day, orally, with food
62770066|NCT01420666|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62770067|NCT03106285|EXPERIMENTAL|Lactobacillus reuteri DSM17938|Oil drops
62770068|NCT03106285|PLACEBO_COMPARATOR|Placebo|Oils drops
62770069|NCT02520739|PLACEBO_COMPARATOR|Virgin Olive Oil|Virgin olive oil obtained by traditional procedures (VOO);
62770070|NCT02520739|EXPERIMENTAL|Optimized High Phenolic Content Oil|Optimized virgin olive oil with a high phenolic content (OHPCO);
62770071|NCT02520739|EXPERIMENTAL|Functional Olive Oil|Functional olive oil (FOO) with both high phenolic compounds and triterpene content.
62770072|NCT04182061|EXPERIMENTAL|The AMTE Protocol|"Will receive the AMTE (Aprende a Manejar tus Emociones) Protocol; this is a modified UP-A adapted as an internet-based program of T-CBT, consisting in 10 modules delivered over 12 weeks."
62770073|NCT04182061|NO_INTERVENTION|Waiting List Control Group|Participants in a 12-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
62770074|NCT01722292|EXPERIMENTAL|Phase 1b: LY2940680 + C + E|"Phase 1b Dose Escalation: Cycles 1-6 (21 day cycles) LY2940680 administered orally, once daily at escalating doses (100 milligrams \[mg\] up to 400 mg) in combination with etoposide (E) 100 milligram per square meter (mg/m\^2) administered by intravenous (IV) infusion on days 1, 2, 3 of each cycle and carboplatin (C) Area Under the Curve \[AUC\] 5 (mg•min/mL) administered by IV infusion on day 1 each cycle.~Phase 1b Maintenance: Cycles 7+ (21 day cycles) LY2940680 administered orally, once daily at the same dose as induction. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation."
62770075|NCT01722292|PLACEBO_COMPARATOR|Phase 2: Placebo + C + E|"Induction: Cycles 1-6 (21 day cycles) Placebo administered orally once daily in combination with etoposide 100 mg/m2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle.~Maintenance: Cycles 7+ (21 day cycles) Placebo administered orally once daily. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation."
62770076|NCT01722292|EXPERIMENTAL|Phase 2: LY2940680 + C+ E|"Induction: Cycles 1-6 (21 day cycles) LY2940680 (dose to be determined in Phase 1b portion) administered orally once daily in combination with etoposide 100 mg/m\^2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle.~Maintenance: Cycles 7+ (21 day cycles). LY2940680 (dose to be determined in Phase 1 portion) administered orally once daily."
62770077|NCT02174653|ACTIVE_COMPARATOR|EPs® 7630|"Active Comparator 20 mg EPs® 7630 film-coated tablet~* During the common cold free period: One film-coated tablet (20 mg) three times a day~* During a common cold episode: Two film-coated tablets (1 x 20 mg and 1x placebo) three times a day (in the morning, midday and evening; total daily dose 60 mg) over the individual treatment duration of 14 consecutive days."
62770078|NCT02174653|ACTIVE_COMPARATOR|EPs(R) 7630|"Active Comparator 20 mg EPs® 7630 film-coated tablet~* During the common cold free period: One film-coated tablet (20 mg) three times a day~* During a common cold episode: Two film-coated tablets (2 x 20 mg = 40 mg) three times a day (in the morning, midday and evening; total daily dose 120 mg) over the individual treatment duration of 14 consecutive days."
62169174|NCT04589689|EXPERIMENTAL|Intervention Group|The intervention group will participated in the The Insul-In This Together intervention, which consists of 6 weekly 30-minute online family sessions to discuss topics related to diabetes distress and parent-teen communication. Sessions include structured education, discussions, and skill-building activities related to parental involvement, parental monitoring, and parent-adolescent conflict. The intervention will be conducted by the PI or clinically trained research staff via Zoom. Online surveys, and glucose monitoring data will be captured at baseline and 3,6 and 12-month follow-ups. Brief surveys will also be conducted at 2-, 4-, and 6-week follow-ups (after every 2 sessions for the intervention group and later the control group). Participants will be asked to provide A1C test results that will be collected via chart review or from participants sharing their test results at baseline, 6-month, and 12-month follow-up.
62169175|NCT04589689|EXPERIMENTAL|Waitlisted Control Group|The waitlisted control group will receive the same intervention as the intervention group, but at the 6-month follow-up mark. The intervention will be conducted by the PI or clinically trained research staff via Zoom. Online surveys, and glucose monitoring data will be captured at baseline and 3,6 and 12-month follow-ups. Brief surveys will also be conducted at 2-, 4-, and 6-week from baseline. Participants will be asked to provide A1C test results that will be collected via chart review or from participants sharing their test results at baseline, 6-month, and 12-month follow-up.
62390973|NCT02702076|PLACEBO_COMPARATOR|Placebo|This arm will be treated with continuous subcutaneous infusion of placebo. The infusion will start with 1 mg/hr during the waking day (approximately 16 hours). The flow rate will be adjusted on a weekly basis, and may be increased with 0.5 to 1.0 mg/hr per discretion of the investigator aiming at the disappearance of visual hallucinations. The duration of treatment is 4 weeks.
61994764|NCT01112527|EXPERIMENTAL|Arm C|Participants with glioblastoma who are not surgical candidates and who are at first recurrence from a therapeutic regimen containing bevacizumab.
62390974|NCT06497816||COPD|Individuals with stable COPD
62562533|NCT00606112|PLACEBO_COMPARATOR|2|
62562534|NCT00606112|PLACEBO_COMPARATOR|3|
62770079|NCT02174653|PLACEBO_COMPARATOR|Placebo|"* During the common cold free period: One film-coated tablet (placebo) three times a day~* During a common cold episode: Two film-coated tablet (placebo) three times a day (in the morning, midday and evening) over the individual treatment duration of 14 consecutive days."
61994765|NCT05472558|EXPERIMENTAL|CB CAR-NK019|All subjects were intravenously administrated with CAR-NK019
61994766|NCT02901951|EXPERIMENTAL|HBV Group|Subjects aged 40 to 60 years old who received 3 or 4 doses of Engerix-B (HBV vaccine) 20 to 30 years ago and were administered with a single challenge dose of HBV vaccine in this study at Day 0 (Visit 1).
61994767|NCT03011359|EXPERIMENTAL|1) Conventional PCA mode|(Mode setting; total volume: 140 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 15 minutes)
61994768|NCT03011359|ACTIVE_COMPARATOR|2) Optimizing B.I PCA mode|Optimizing Basal Infusion (New) PCA mode(Mode setting; total volume: 140 ml, flow rate: changable by patients' requirement, bolus volume: 0.5 ml, and LOT: 15 minutes)
61994769|NCT00046735|EXPERIMENTAL|1|
62562535|NCT00606112|PLACEBO_COMPARATOR|4|
62770080|NCT03637712|EXPERIMENTAL|Screening Colonoscopy|Patients undergoing standard screening or surveillance colonoscopy will be included
62770081|NCT02831556||Emergency Department Subjects|Subjects that present to the Emergency Department with complaints necessitating abdominal or pelvic imaging.
62770082|NCT02831556||Non-patient volunteers|Duke employees that will voluntarily have an abdominal or pelvic ultrasound for with the sole purpose being for the study.
62770083|NCT04093804|ACTIVE_COMPARATOR|32mm Glenosphere|The control group will receive the standard 32mm glenosphere.
62770084|NCT04093804|EXPERIMENTAL|36mm Glenosphere|The experimental group will receive a 36mm glenosphere.
62770085|NCT04225819|EXPERIMENTAL|Vitamin D3 supplement|Two- 5,000 IU capsules, taken daily with a meal
62770086|NCT04225819|PLACEBO_COMPARATOR|Placebo|Two placebo capsules, taken daily with a meal
62770087|NCT05369481|EXPERIMENTAL|Sildenafil 2%|will receive topical sildenafil 2% twice daily for 6 months.
62770088|NCT05369481|EXPERIMENTAL|Minoxidil 5 %|will receive topical minoxidil 5 % twice daily for 6 months
62770089|NCT04797806|EXPERIMENTAL|combination therapy|Anlotinib Combined With Icotinib
62770090|NCT04797806|OTHER|monotherapy|Icotinib
62770091|NCT00487474||Sculptra|
62770092|NCT00471887|EXPERIMENTAL|Treatment-Single Arm|See intervention descriptions
62770093|NCT04356482|EXPERIMENTAL|single arm|"Determine the convalescent plasma dose to be administered to two groups: one severely ill (not intubated) and one very severely ill (intubated).~Second phase: safety and efficacy of the plasma dose found in the same two types of patients."
62770094|NCT05118490|EXPERIMENTAL|Group 1: People living with HIV infection without active TB|
62770095|NCT05118490|EXPERIMENTAL|Group 2: HIV-negative household contacts of adults with rifampicin-sensitive pulmonary TB|
62770096|NCT00708760||2|web based learning group
62770097|NCT00708760||1|paper based learning group
62770098|NCT05170789|EXPERIMENTAL|Intervention arm|This study employs a single, intervention arm or group, anticipated size of which is 18 patients, in which all enrolled subjects will receive the study drug, ESd.
62770099|NCT02624336|ACTIVE_COMPARATOR|DTC1 mouth wash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
62770100|NCT02624336|PLACEBO_COMPARATOR|Oradex mouth wash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
62770101|NCT02624336|PLACEBO_COMPARATOR|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
62770102|NCT00869401|EXPERIMENTAL|Group 1 (Phase II) dasatinib + radiation + temozolomide|Patients receive concomitant chemotherapy and radiation for cycle one for a total of 42 days, then patients receive adjuvant chemotherapy 28-42 days post cycle one treatment. Patients receive only dasatinib post cycle 8 until progressive disease, unacceptable adverse events or refusal.
62770103|NCT00869401|ACTIVE_COMPARATOR|Group 2 (Phase II) placebo + radiation + temozolomide|Patients receive concomitant chemotherapy and radiation for cycle one for a total of 42 days, then patients receive adjuvant chemotherapy 28-42 days post cycle one treatment. Patients receive only placebo post cycle 8 until progressive disease, unacceptable adverse events or refusal.
62770104|NCT01777945||Participants Receiving Capecitabine/Docetaxel|Participants received capecitabine and docetaxel according to individualized physician-prescribed regimens.
62390975|NCT06497816||Healthy Individuals|Healthy controls
62770105|NCT00527332|ACTIVE_COMPARATOR|A|Spinal anesthesia combined with intrathecal morphine. Spinal anesthesia applied in intervertebral space L3/L4 or L2/L3 with hyperbaric bupivacaine 20 mg and morphine 0.2 mg intrathecally. Sedation with propofol.
62770106|NCT00527332|ACTIVE_COMPARATOR|B|General anesthesia. General anesthesia induced with propofol, fentanyl and rocuronium, and maintained with propofol and oxygen in air. Rocuronium and fentanyl repeated when needed.
62770107|NCT06129929|EXPERIMENTAL|Hospital Jujutsu Group, HJJ Group|The intervention group participants who received the theoretical-based BJJ educational intervention.
62770108|NCT06129929|ACTIVE_COMPARATOR|Traditional lecture Group|The control group participants who received the traditional violence-prevention educational intervention.
62390976|NCT00943566|EXPERIMENTAL|Sufentanil Transdermal Delivery System|Experimental drug
62390977|NCT00943566|ACTIVE_COMPARATOR|Control|Sustained release morphine sulfate
62770109|NCT03890328|EXPERIMENTAL|RF group|radiofrequency-assisted spleen-preserving therapy group.
62770110|NCT03890328|NO_INTERVENTION|CT group|Conventional Treatment of Blunt Splenic Injury group.
62770111|NCT02703168||Immediate loading|Patients were allocated to treatment group in the core study. Immediate loading was defined as follows: Implant(s) will be restored with a temporary restoration on the day of surgery
62770112|NCT02703168||Early loading|Patients were allocated to treatment group in the core study. Early loading was defined as follows: Healing caps will be placed on the implant(s) immediately after surgery. A provisional restoration will be placed between day 28 to day 34 post surgery
62770113|NCT00875173|EXPERIMENTAL|Selenium|Sodium selenite 100 micrograms in capsugel by mouth diary for 365 consecutive days
62770114|NCT00875173|ACTIVE_COMPARATOR|Placebo|Capsugel for placebo (selenium 100 micrograms capsugel) by mouth diary for 365 consecutive days
62770115|NCT02198235|ACTIVE_COMPARATOR|Control NB + IV Dex + IV Bup|IV Dexamethasone (4 mg) + IV Buprenorphine (150 mcg)
62770116|NCT02198235|ACTIVE_COMPARATOR|Control NB + IV Dex|IV Dexamethasone (4 mg)
62770117|NCT02198235|EXPERIMENTAL|NB with Dex + Bup in block.|Dexamethasone (4 mg) Buprenorphine (150 mcg)
62770118|NCT03987386|ACTIVE_COMPARATOR|Arm I (conventional radiation therapy)|Patients undergo conventional radiation therapy daily over 7 weeks after standard of care surgery.
62770119|NCT03987386|EXPERIMENTAL|Arm II (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy over 4.5 weeks after standard of care surgery.
62770120|NCT04419441||treated patients|patients with relapsed/refractory Hodgkin lymphoma who received a treatment with the combination of radiotherapy and an immune checkpoint inhibitor
62770121|NCT04248335|EXPERIMENTAL|In Weight Management Program|Evaluate the effect of liver fat on pharmacology of PPI's, and if applicable midazolam
62390978|NCT04461899|OTHER|sclerotherapy|a sclerotherapy will be done in patients
61994770|NCT06520709||Postmenopausal osteoporosis|Postmenopausal osteoporosis
61994771|NCT06520709||Control group|Healthy group
62770122|NCT04248335|EXPERIMENTAL|Not in Weight Management Program|Evaluate the effect of liver fat on drug metabolism of PPI's, and if applicable midazolam
62770123|NCT02198690|EXPERIMENTAL|Mammography Decision Aid|Development and pilot testing of the decision aid (DA) has been described previously. In brief, the DA is written at a 6th grade reading level and includes information on 1) breast cancer risk factors for women \>75 years; 2) health/life expectancy; 3) likely outcomes if screened and not screened with mammography; 4) competing mortality risks; 5) breast cancer treatments; and 6) a values clarification exercise. The last page asks users their intentions of being screened on a 15-point validated scale and invites users to share this information with their clinician. PCPs whose patients are randomized to receive the DA will be sent a copy of the DA via email and a link to an optional training on using the DA (5 informational slides and a 3-minute video).
62562536|NCT02743624|OTHER|Pressure Support Titration|The analysis of the diagnostic accuracy of the breathing pattern variables, P 0.1 and the rate of tracheal muscle relaxation.
62562537|NCT04268771|EXPERIMENTAL|Arm A: DRL_RI|Subjects who have already received at least 1 full course comprising two 1000 mg infusions of either US-rituximab or EU-rituximab and are candidates for re-treatment with Rituximab, will be enrolled. DRL_RI will be administrated in combination with MTX as two 1000 mg infusions on Day 1 and Day 15
61994772|NCT00457938|OTHER|"Low fat diet is the drug"|Diet 10% fat versus 35% fat
61994773|NCT01810666|EXPERIMENTAL|Recombinant Factor VIII|
62562538|NCT04268771|ACTIVE_COMPARATOR|Arm B: US-Rituximab or EU-Rituximab|"Subjects who have already received at least 1 full course comprising two 1000 mg infusions of either US-rituximab or EU-rituximab and are candidates for re-treatment with rituximab, will be enrolled.~Patients enrolled in Arm -B will continue to receive US-rituximab or EU-rituximab. The rituximab reference product used (US-licensed rituximab \[Rituxan\] or EU-approved rituximab \[MabThera\]) should be the same in the prior and the randomized treatment course, respectively."
61994774|NCT04914910|EXPERIMENTAL|780G-780G|Participants will use MiniMed 780G system for 14 weeks + 14 weeks
61994775|NCT04914910|PLACEBO_COMPARATOR|Usual Care - 780G|Participants will continue with their usual insulin pump for 14 weeks. After completion of the first 14-week periode, they switch to 780G for another 14 weeks.
61994776|NCT00542919|EXPERIMENTAL|T-Cell|T-Cell (TCL): Peripheral and cutaneous T-cell lymphoma (PTCL, CTCL). Participants received enzastaurin 1125 milligram (mg) loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
61994777|NCT00542919|EXPERIMENTAL|Indolent B-Cell|Indolent B-Cell (IBCL): Small lymphocytic lymphoma, follicular lymphoma (Grade 1 or 2) and marginal zone lymphoma. Participants received enzastaurin 1125 mg loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
61994778|NCT00542919|EXPERIMENTAL|Aggressive B-Cell|Aggressive B-Cell (ABCL): Primary central nervous system (CNS) lymphoma, follicular lymphoma (Grade 3a and 3b) and aggressive lymphoma with prior clinical history of indolent lymphoma. Participants received enzastaurin 1125 mg loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
61994779|NCT05190120|ACTIVE_COMPARATOR|Femoral Block|Patients scheduled for knee arthroscopy will have a femoral nerve block done using 0.5% ropivacaine 20ml before surgery.
61994780|NCT05190120|EXPERIMENTAL|Adductor Canal Block|Patients scheduled for knee arthroscopy will have an adductor canal block done using 0.75% ropivacaine 13.3ml before surgery.
62390979|NCT03546101||Department of Kidney Medicine|Primarily transplant recipients undergoing monitoring for EBV and patients suspected for having PTLD.
62562539|NCT01585974||Group 1|
62562540|NCT01221870|EXPERIMENTAL|Tesetaxel once every 3 weeks|Tesetaxel 27 mg/m2 orally once every 21 days for up to 12 months
62562541|NCT01221870|EXPERIMENTAL|Tesetaxel once weekly|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks in a 28-day cycle for up to 12 months
62169176|NCT01309633|EXPERIMENTAL|Arm A|"1) Arm A~Day -6 to Day 0 (total 7 days):~Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
62169177|NCT01309633|EXPERIMENTAL|Arm B|"Arm B~Day -6 to Day 0 (total 7 days):~Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
62169178|NCT01309633|EXPERIMENTAL|Arm C|Arm C Day -7: IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered.
62169179|NCT01309633|EXPERIMENTAL|Arm D|Arm D Day -7: IV bevacizumab 2.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered
62562542|NCT03197480|OTHER|DME treatment group|"All patients will received 4 intravitreal injections of aflibercept.~Based on the OCT outcome they will be classified into 2 groups for assessment of biomarkers:~Less than 20% reduction in CRT on OCT or \<5 letter improvement of VA (if VA\<6/6 and CRT\>=340) Rapid (Mac Dry at M4) Delayed: Persistent fluid at M4, but more than 20% reduction in CRT on OCT"
62169180|NCT00537758|EXPERIMENTAL|1|Cognitive Behavior Therapy
62169181|NCT00537758|EXPERIMENTAL|2|Behavioral Weight Loss Treatment
62169182|NCT00537758|EXPERIMENTAL|3|CBT + BWL
62169183|NCT00972036|EXPERIMENTAL|Unresectable colon cancer patients with liver metastases|This study will be performed to evaluate the safety of Selective Internal Radiation Therapy (SIRT) in patients with liver only colorectal cancer metastases that have received hepatic arterial infusion pump and have progressed through at least one line of chemotherapy.
62182731|NCT02599493|ACTIVE_COMPARATOR|High dose|Patients will be randomly assigned to high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
62182732|NCT02554383|ACTIVE_COMPARATOR|Treatment A|Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
62390980|NCT03546101||Department of Hematology|Patients diagnosed with PTLD and other kinds of lymphoma. Patients undergoing hematopoietic stem cell transplantation and patients with hemophagocytosis.
62390981|NCT03546101||Department of pediatrics|Children undergoing transplantation. Children diagnosed with hemophagocytic lymphohistiocytosis.
62390982|NCT04972773|EXPERIMENTAL|MM + standard-therapy intervention group|In addition to receiving standard-therapy, participants will be asked to practice MM using a MM app for at least 10 minutes per day from weeks 0 to 8.
62390983|NCT04972773|NO_INTERVENTION|Standard-therapy control group|Participants randomized to the standard-therapy control group will receive their typical in- or out-patient therapy. This is expected to include small doses of MM.
62390984|NCT01376115||Subjects administered nelarabine|Subjects with T-cell acute lymphocytic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) prescribed nelarabine during study period
62390985|NCT03382639|EXPERIMENTAL|Luvadaxistat 50 milligrams (mg)|Participants received luvadaxistat 50 mg orally once daily (QD) for 12 weeks (Days 1 to 84).
62390986|NCT03382639|EXPERIMENTAL|Luvadaxistat 125 mg|Participants received luvadaxistat 125 mg orally QD for 12 weeks (Days 1 to 84).
62390987|NCT03382639|EXPERIMENTAL|Luvadaxistat 500 mg|Participants received luvadaxistat 500 mg orally QD for 12 weeks (Days 1 to 84).
62390988|NCT03382639|PLACEBO_COMPARATOR|Placebo|Participants received placebo (matching luvadaxistat) orally QD for 12 weeks (Days 1 to 84).
62390989|NCT01852565|EXPERIMENTAL|Darapladib+Diltizem Arm|Each subject will receive darapladib EC tablet 160 mg once daily for 10 days followed by darapladib EC tablet 160 mg once daily + diltiazem 240mg once daily for 14 days and then diltiazem 240mg once daily alone for three days
62178304|NCT05088538|NO_INTERVENTION|Control group|When the patients are in clinic,The Patient Information Form,Turkey Health Literacy Scale-32,Patient Learning Needs Scale,Functional Assessment Form,Knee Assessment Questionnaire and Quality of Life Scale Form will be filled.The second interview will be conducted on the second or third day after the surgery, just before the patients will be discharged.The Functional Assessment Form,Knee Assessment Questionnaire,Discharge Data Collection Form, and Quality of Life Questionnaire will be applied.The third interview will be performed 15 days after the surgery when the patients come for control or by phone.The 15th Day Recovery Process Data Collection Form and Knee Assessment Questionnaire will be applied.The last interview will be carried out six weeks after the surgery,either face-to-face or by phone,and the Functional Assessment Form,Knee Assessment Questionnaire, 6th Week Post-Discharge Recovery Process Data Collection Form,and Quality of Life Questionnaire will be applied again.
62178305|NCT05088538|EXPERIMENTAL|Intervention group|Unlike the control group, the intervention group will be given the education plan prepared by the researchers.
62178306|NCT00564564|EXPERIMENTAL|Quetiapine augmentation|Quetiapine up to 200mg/day plus SSRI at maximum tolerated or recommended dosage
62178307|NCT00564564|ACTIVE_COMPARATOR|Clomipramine augmentation|Clomipramine up to 150mg/day plus SSRI at maximum tolerated or recommended dosage
62178308|NCT06480331|EXPERIMENTAL|Ultrasound-guided fistuloplasty|After cleaning and draping the area of interest, local anaesthesia is given to the puncture site. A puncture needle is used to gain access to the arteriovenous fistula followed by a guide wire. Then, a sheath with an appropriate size is placed and a balloon catheter of adequate size is inserted over the guide wire and inflated for 2 minutes. Ultrasound is used in the subject group to monitor technical success. On table visualization of continuous segment of dilated vein to 5-6mm and continuous flow rate of more than 500ml/min signifies the end points of the procedure. After a satisfactory result, a figure of 8 suture is placed with manual inflow occlusion. Post procedure, patients will be observed for any signs of haematoma or bleeding. If there are no immediate complications, patients will be discharged on the same day.
62178309|NCT06480331|ACTIVE_COMPARATOR|Fluoroscopy-guided fistuloplasty|After cleaning and draping the area of interest, local anaesthesia is given to the puncture site. A puncture needle is used to gain access to the arteriovenous fistula followed by a guide wire. Then, a sheath with an appropriate size is placed and a balloon catheter of adequate size is inserted over the guide wire and inflated for 2 minutes. Ultrasound is used in the subject group to monitor technical success. On table fistulogram visualization of less than 30% recoil of the target lesion signifies technical success. After a satisfactory result, a figure of 8 suture is placed with manual inflow occlusion. Post procedure, patients will be observed for any signs of haematoma or bleeding. If there are no immediate complications, patients will be discharged on the same day.
62178310|NCT06140914||CRT|Heart failure patients that receive a CRT
62178311|NCT06140914||Control|Heart failure patients treated with medicines, without a CRT indication.
62178312|NCT03397316|NO_INTERVENTION|Marginal bone loss without grafting.|immediate implant placement in upper esthetic zone.
62178313|NCT03397316|ACTIVE_COMPARATOR|marginal bone loss with xenograft.|xenograft placement (Geistlich Bio-Oss) in immediate implant placement in upper esthetic zone between the residual labial bone and implant surface.
62178314|NCT03648684|EXPERIMENTAL|Caffeine-Based Expectancy Challenge|Participants will ingest caffeine under the guise of Adderall prior to completing tasks. They will engage in an expectancy challenge intervention designed to both challenge expectancies for prescription stimulants and promote safe caffeine use for cognitive/mood enhancement.
62178315|NCT03648684|PLACEBO_COMPARATOR|Placebo-Based Expectancy Challenge|Participants will ingest placebo under the guise of Adderall prior to completing tasks. They will engage in an expectancy challenge intervention designed to challenge expectancies for prescription stimulants.
62178316|NCT03648684|NO_INTERVENTION|Control|
62390990|NCT02554409||Pregnancy Cases|No Intervention as part of this protocol
61994781|NCT05982535|EXPERIMENTAL|Easy Dew MD Regen Cream|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
62562543|NCT03053752|EXPERIMENTAL|Transcutaneous Electric Stimulation|Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.
62562544|NCT01805089|ACTIVE_COMPARATOR|Melatonin 3 mg|Taken orally, once per day, at/around 9:00pm
62178317|NCT02246218|EXPERIMENTAL|RAVICTI|RAVICTI Oral Liquid should be administered just prior to breastfeeding or intake of formula or food. The recommended dosing regimen is 3-6 times per day depending on feeding schedule and at the discretion of the Investigator.
62178318|NCT02940210|EXPERIMENTAL|Mediclore®|adhesion barrier Mediclore 5cc, to apply medical device fully around thyroid gland following thyroidectomy
62178319|NCT02940210|NO_INTERVENTION|No treatment|No treatment, standard treatment for thyroidectomy
62178320|NCT00239681|EXPERIMENTAL|Rosuvastatin|Rosuvastatin 20 mg once daily
62178321|NCT00239681|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62178322|NCT04295018|EXPERIMENTAL|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
62178323|NCT01628341||Patients with diabetes (type 1 and 2)|
62178324|NCT05654298|EXPERIMENTAL|Ubrogepant|
62390991|NCT04956133|EXPERIMENTAL|Physical activity|Participants will be offered online, individualized physical activity sessions 2-3 times/week for 15-45 minutes/session for 8-12 weeks.
62562545|NCT01805089|PLACEBO_COMPARATOR|Placebo|Taken orally, once per day, at/around 9:00pm
62562546|NCT05303610||Experimental group|This group will consist of 28 patients with diagnosed Patellofemoral pain syndrome, aged between 25-50 years.
62562547|NCT05303610||Control group|Healthy individuals between the ages of 25-50 and without any orthopedic (Anterior cruciate ligament rupture, Meniscal tears etc.), neurological (Multipl sclerosis, Stroke etc) and rheumatological disorders (Rheumatoid arthritis, Ankylosing spondylitis etc.).
62562548|NCT00880412|EXPERIMENTAL|EHT 0202 40 mg bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
62562549|NCT00880412|EXPERIMENTAL|EHT 0202 80 mg bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
62562550|NCT00880412|PLACEBO_COMPARATOR|placebo bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
62562551|NCT06550999|EXPERIMENTAL|Adhesive strip repair|In this arm, patients will have their facial laceration properly cleaned and repaired with adhesive strips.
62562552|NCT06550999|EXPERIMENTAL|Suture strip repair|In this arm, patients will have their facial laceration properly cleaned and repaired with sutures of any material.
62562553|NCT02600936||Registry|A retrospective and prospectively maintained registry of patients who have undergone or will undergo vein stent placement for proximal venous outflow obstruction
62562554|NCT03834922||Total knee arthroplasty|Patients undergoing total knee arthroplasty
62562555|NCT03834922||Sternotomy|Patients undergoing sternotomy
62562556|NCT03834922||Breast|Patients undergoing breast surgery
62562557|NCT03834922||Endometriosis|Patients undergoing endometriosis-related surgery
62178325|NCT05654298|EXPERIMENTAL|Sumatriptan|
62178326|NCT04280679|OTHER|Arm of patient treated by HIFU|Compression bandages
62178327|NCT04402203|EXPERIMENTAL|Favipiravir + Standard Treatment|Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.
62390992|NCT01391026|NO_INTERVENTION|Usual care|Patients will receive usual care by their primary care physicians without automated referral to specialized providers.
62390993|NCT01391026|EXPERIMENTAL|Enhanced patient-centered care|Patients will be evaluated and treated in the advanced illness management clinic
62390994|NCT05754242|EXPERIMENTAL|Ascorbic acid|1.5 gr of ascorbic acid diluted in 100 ml of 0.9% saline solution will be administered intravenously during the anhepatic phase of liver transplantation
62562558|NCT02081027|EXPERIMENTAL|Riluzole|The maximum dose of riluzole to be used in this study is 200 mg per day divided BID
62562559|NCT02081027|PLACEBO_COMPARATOR|Placebo|Placebo will be administered in the same manner as the riluzole group, in order to maintain subject assignment throughout the study.
62562560|NCT06150937|EXPERIMENTAL|AEGIDA intervention arm|Four session behavioral intervention to promote consistent HIV testing, frequent HIV testing and intention to uptake PEP/PrEP.
62562561|NCT06150937|ACTIVE_COMPARATOR|AEGIDA control arm|Four session didactic intervention to promote self-screening for common health problems, including HIV self-testing.
62562562|NCT04231617|ACTIVE_COMPARATOR|CGRP and glibenclamide|Participants will recieve CGRP infusion after glibenclamide/placebo administration
62562563|NCT04231617|ACTIVE_COMPARATOR|CGRP and placebo|Participants will recieve CGRP infusion after glibenclamide/placebo administration
62562564|NCT02750618|EXPERIMENTAL|Burosumab Q2W|Burosumab subcutaneous (SC) injections every 2 weeks (Q2W) for a total of 160 weeks.
62562565|NCT01384474||CRM training of surgical teams|CRM : Crew resource Management
62770124|NCT02198690|PLACEBO_COMPARATOR|Home safety pamphlet|To reduce response bias and to compensate for the time and attention required by the intervention group to read the DA, patients in the control arm will be provided a two page pamphlet on home safety for older adults developed by the American Geriatrics Society (AGS) Foundation for Health in Aging. PCPs whose patients are randomized to the receive the home safety pamphlet, will be sent an email informing them that their patient will be coming in early to read health educational materials for older adults as part of a study. We otherwise do not plan any intervention for control group PCPs because we do not want to change their usual behavior. However, if PCPs in the control arm request a copy of the educational materials then we will email them a copy of the home safety pamphlet.
62770125|NCT02155530|EXPERIMENTAL|High efficacy statin group (homogeneous)|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
62562566|NCT01384474||No CRM training of surgical teams|CRM : Crew resource Management
62770126|NCT02155530|ACTIVE_COMPARATOR|Low efficacy statin group (homogeneous)|homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
62770127|NCT00819455|ACTIVE_COMPARATOR|2|In person lifestyle advice at baseline, 6, 12, 18 months.
62770128|NCT00819455|EXPERIMENTAL|1|In person lifestyle advice at baseline, 6, 12, 18 months. Receive reminders by internet based, mobile phone text messaging (Frequency, time and number(s) of messages according to participants requirement)
62770129|NCT05258539|EXPERIMENTAL|Women aged 18 to 85 years who come to the CRMP for a breast cancer risk assessment.|
62770130|NCT01943552|EXPERIMENTAL|ipratropium|500 mcg four times a day
62178328|NCT04402203|PLACEBO_COMPARATOR|Only Standard Treatment|Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
62178329|NCT03616236|ACTIVE_COMPARATOR|TAU|Participants will receive a referral to buprenorphine treatment in the community.
62770131|NCT01943552|PLACEBO_COMPARATOR|placebo|
62770132|NCT04546542||pSS patients under Hydroxychloroquine (HCQ) 2016-AAO dose|Patients under Hydroxychloroquine (HCQ) 2016-American Academy of ophtalmology (AAO) dose will have HCQ blood levels, disease activity and adherence evaltuated at study entry and before 3 and 6-months.
62770133|NCT02938273|EXPERIMENTAL|Bioimmunoradiotherapy|Concurrent Radiation therapy (i.e. 5 times a week, 7 weeks, total dose 70 Gy) with cetuximab (loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7) and Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months (wk 8,10, 12, 14, 16, 18, 20, 22, 24, 26.
62770134|NCT02759991|ACTIVE_COMPARATOR|HEV vaccine|Hecolin, 0.6 ml intramuscular injection day 0, 1 month and 6 months.
62770135|NCT02759991|PLACEBO_COMPARATOR|HBV vaccine|Hepa-B, 1 ml intramuscular injection day 0, 1 month and 6 months.
62770136|NCT01704703|EXPERIMENTAL|Experimental|FOLFIRI + panitumumab
62770137|NCT01779505|EXPERIMENTAL|GS-4774 at 10 yeast units (YU)|10 YU of GS-4774 given either weekly or monthly
62770138|NCT01779505|EXPERIMENTAL|GS-4774 at 40 YU|40 YU of GS-4774 given either weekly or monthly
62770139|NCT01779505|EXPERIMENTAL|GS-4774 at 80YU|80 YU of GS-4774 given either weekly or monthly
62390995|NCT05754242|PLACEBO_COMPARATOR|Saline solution|100 ml of 0.9% saline solution will be administered during the anhepatic phase of liver transplantation
62770140|NCT05484284|EXPERIMENTAL|All the patients|patients received two-stage primary total knee arthroplasty with low-dose antibiotics
62178330|NCT03616236|EXPERIMENTAL|BBT|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
62770141|NCT06181370|EXPERIMENTAL|AGMB-447|Participants will receive a single dose of AGMB-447 (part A), multiple doses of AGMB-447 over 7 days (part B) or multiple doses of AGMB-447 over 14 days (part C)
62178331|NCT04633213|EXPERIMENTAL|HBM9036 0.25% Ophthalmic Solution|HBM9036, Ophthalmic Solution, twice a day, in the morning and evening
62390996|NCT04698200|EXPERIMENTAL|Blood pressure|Measurement of brachial, central and beat-to-beat blood pressure.
62390997|NCT05358301|EXPERIMENTAL|Probiotic|Probiotic food supplement produced by SYNBIOTEC S.r.l.
62562567|NCT03662087|EXPERIMENTAL|HMA+DLI|For AL patients who achieved CR at pre-transplantation undergoing allo-HSCT, DLI was not given and immunosuppressant were withdrawn if patients were MRD persistently negative. MRD status were monitored every 30 days. If patients were MRD negative by Day+30 post-transplantation, MRD status would be continued to be monitored by Day+60. If patients were MRD positive by Day+30 post-transplantation, immunosuppressant were withdrawn. If MRD were persistently positive until Day+60 or MRD changed from negative by Day+30 to positive by Day +60 post-transplantation, HMA and DLI were given. DLI was given 48 hours after administration of HMA. DLI was given monthly until GVHD occurred or MRD became negative or a total of four times. If MRD changed from positive by Day+30 to negative by Day+60 post-transplantation, MRD status would be continued to be monitored by Day+90 post-transplantation. If patients were MRD positive by Day+90 post-transplantation, HMA and DLI were given as shown above.
61994782|NCT05982535|ACTIVE_COMPARATOR|Physiogel Stability Intensive Cream MD|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
62562568|NCT03662087|EXPERIMENTAL|DLI|For AL patients who achieved CR at pre-transplantation undergoing allo-HSCT, DLI was not given and immunosuppressant were withdrawn if patients were MRD persistently negative. MRD status were monitored every 30 days. If patients were MRD negative by Day+30 post-transplantation, MRD status would be continued to be monitored by Day+60 post-transplantation. If patients were MRD positive by Day+30 post-transplantation, immunosuppressant were withdrawn. If MRD were persistently positive until Day+60 or MRD changed from negative by Day+30 to positive by Day+60 post-transplantation, DLI was given. DLI was given monthly until GVHD occurred or MRD became negative or a total of four times. If MRD changed from positive by Day+30 to negative by Day+60 post-transplantation, MRD status would be continued to be monitored by Day+90 post-transplantation. If patients were MRD positive by Day+90 post-transplantation, DLI was given as shown above.
62562569|NCT00933907|EXPERIMENTAL|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Dermacyd PH_DESILSTY_FR (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
62562570|NCT04924400|ACTIVE_COMPARATOR|CHIP Program|GHP members randomized to the intervention arm will participate in the CHIP Program.
62562571|NCT04924400|ACTIVE_COMPARATOR|Usual Diabetes Care|GHP members assigned to the control arm will receive the routine standard of care for GHP members.
62770142|NCT06181370|PLACEBO_COMPARATOR|placebo|Participants will receive a single dose of placebo (part A), multiple doses of placebo over 7 days (part B) or multiple doses of placebo over 14 days (part C)
62178332|NCT04633213|PLACEBO_COMPARATOR|Placebo Ophthalmic Solution|placebo, Ophthalmic Solution, twice a day, in the morning and evening
62178333|NCT04741854|EXPERIMENTAL|Investigational Device|Participants will be asked to take home the investigational device to use at night while they sleep in place of their own device. The participant's therapy and comfort settings will be copied from their own device to the investigational device.
62178334|NCT03436550||Patients with Chronic Liver Disease|
62178335|NCT03436550||Control Group|
62562572|NCT04587687|EXPERIMENTAL|Treatment (brentuximab vedotin, bendamustine)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and bendamustine IV over 60 minutes on days 1 and 2. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who respond to combination treatment and do not experience excessive toxicity may continue to receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
62562573|NCT06280859|EXPERIMENTAL|Intervention|Participants in the intervention arm will receive the Hoosier Sport intervention 2-3 times a week (twice in PE class, and once in home room). This will involve learning new sport, exercise, and nutrition knowledge, as well as developing leadership skills.
62562574|NCT06280859|NO_INTERVENTION|Control|Participants in the control arm will not receive the Hoosier Sport intervention.
62770143|NCT01128088||PCA and Volulyte|
62770144|NCT01128088||PCA and Hartmann's|
62178336|NCT01661530|EXPERIMENTAL|Vitamin E enhanced diet|Range of three vitamin E enhanced soups (400g/tin) containing 18-20mg vitamin in natural food form. Three portions per week
62182733|NCT02554383|PLACEBO_COMPARATOR|Treatment B|Placebo made to match the study antibiotic will be taken bid orally for 10 days
62390998|NCT05358301|PLACEBO_COMPARATOR|Placebo|Placebo food supplement.
62390999|NCT05962073|NO_INTERVENTION|NIV|Non-invasive ventilation application for preoxygenation
62391000|NCT05962073|ACTIVE_COMPARATOR|HFNC|High flow oxygen therapy application for preoxygenation
62391001|NCT05129644|EXPERIMENTAL|P1101 24 mcg|A total of 6 subjects received single dose of 24 mcg P1101
62391002|NCT05129644|EXPERIMENTAL|P1101 48 mcg|A total of 6 subjects received single dose of 48 mcg P1101
62391003|NCT05129644|EXPERIMENTAL|P1101 90 mcg|A total of 6 subjects received single dose of 90 mcg P1101
62391004|NCT05129644|EXPERIMENTAL|P1101 180 mcg|A total of 6 subjects received single dose of 180 mcg P1101
62562575|NCT02500095|NO_INTERVENTION|Control|12 hours of fasting
62562576|NCT02500095|EXPERIMENTAL|Fasting and saline|72 hours of fasting and concomitant saline
62562577|NCT02500095|EXPERIMENTAL|Fasting and GHR blockade|72 hours of fasting and concomitant Growth hormone receptor (GHR) blockade with Pegvisomant (Somavert) for inhibition of the fasting-induced GH secretion
62562578|NCT00447174|EXPERIMENTAL|treatment|treatment manual
62562579|NCT00447174|NO_INTERVENTION|control group|
62562580|NCT03193684|EXPERIMENTAL|Treatment|empagliflozin 25 mg per day
62770145|NCT01128088||Spinal and Volulyte|
62770146|NCT01128088||Spinal and Hartmann's|
62391005|NCT05129644|EXPERIMENTAL|P1101 225 mcg|A total of 6 subjects received single dose of 225 mcg P1101
62770147|NCT04113460|EXPERIMENTAL|Yoga Group|The yoga group received the 8-week yoga sessions at work setting once a week by trained teacher followed by self practices.
62770148|NCT04113460|NO_INTERVENTION|Control Group|Participants had one introductory session on proper physical position and stretching exercises to be practiced daily during work.
62770149|NCT01569386|EXPERIMENTAL|low intensity physical activity|Daily low intensity physical activity by the half squat
62770150|NCT01569386|ACTIVE_COMPARATOR|stretch exercise and usual activity|They do whole body stretch exercise for 20 minute in a day
62770151|NCT02136056|EXPERIMENTAL|Self-management program (SMP)|Participants in the experimental group receive six weekly group-sessions of self-management and patient education; specifically targeting self-management of the return to work process and disease symptoms.
62770152|NCT02136056|NO_INTERVENTION|Treatment as usual|Participants in the control-group receive standard rehabilitation care and follow-up in the job-center.
62770153|NCT04462939|EXPERIMENTAL|Healthy lactating women - Supplement|At randomization (Visit 2), from four to six weeks after delivery, eligible actating women will be equally randomized to one of the study arms (supplementation arm or placebo arm) and will assume the supplement or placebo once daily for a duration of 12 weeks.
62770154|NCT04462939|PLACEBO_COMPARATOR|Healthy lactating women - Placebo|At randomization (Visit 2), from four to six weeks after delivery, eligible actating women will be equally randomized to one of the study arms (supplementation arm or placebo arm) and will assume the supplement or placebo once daily for a duration of 12 weeks.
62770155|NCT03755583|OTHER|EEN group|Received exclusive enteral nutrition after enrollment.
62770156|NCT01836081|EXPERIMENTAL|fluid responsiveness|
62770157|NCT03199391|EXPERIMENTAL|BioWick SureLock Implant|All subjects are part of a single arm. All subjects received the BioWick SureLock implant.
62770158|NCT00549770|EXPERIMENTAL|LCZ696 100 mg|Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
62770159|NCT00549770|EXPERIMENTAL|LCZ696 200 mg|Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
62770160|NCT00549770|EXPERIMENTAL|LCZ696 400 mg|Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
62770161|NCT00549770|ACTIVE_COMPARATOR|Valsartan 80 mg|Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
62770162|NCT00549770|ACTIVE_COMPARATOR|Valsartan 160 mg|Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsatan and AHU377 (5 tablets and 2 capsules) daily.
62770163|NCT00549770|ACTIVE_COMPARATOR|Valsartan 320 mg|Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
62770164|NCT00549770|EXPERIMENTAL|AHU377 200 mg|Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.
62770165|NCT00549770|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
62770166|NCT02576808|EXPERIMENTAL|Ginger extract|Drug
61994783|NCT02535741|OTHER|Triathlon CR Total Knee System|Primary total knee replacement
61994784|NCT01959620|NO_INTERVENTION|Assessment only|Participants will receive assessment only.
61994785|NCT01959620|EXPERIMENTAL|1-session exposure intervention|Participants will receive one session of exposure therapy.
61994786|NCT01959620|EXPERIMENTAL|3-session exposure intervention|Participants will receive three sessions of exposure therapy.
61994787|NCT02746562|EXPERIMENTAL|Freeze all|Transfer of a frozen, thawed blastocyst in a subsequent natural menstrual cycle
62391006|NCT05129644|EXPERIMENTAL|P1101 270 mcg|A total of 6 subjects received single dose of 270 mcg P1101
61994788|NCT02746562|NO_INTERVENTION|Fresh embryo transfer|Standard procedure
62562581|NCT03193684|PLACEBO_COMPARATOR|control|matching placebo 1 pill per day
62770167|NCT02576808|ACTIVE_COMPARATOR|Loratadine|Drug
62770168|NCT04208048||FLXfit 15|The FLXfit 15 device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.
62770169|NCT02901652|ACTIVE_COMPARATOR|NIPPV|"noninvasive respiratory support devices~This group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment."
62770170|NCT02901652|ACTIVE_COMPARATOR|BİPAP|"noninvasive respiratory support devices~This group receive Bi-Level Positive Airway Pressure (BIPAP) treatment."
62770171|NCT02440789|EXPERIMENTAL|Sirolimus|
62770172|NCT04109976|EXPERIMENTAL|Bimekizumab-SS|Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the prefilled safety syringe (SS).
62770173|NCT04109976|EXPERIMENTAL|Bimekizumab-AI|Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the auto-injector (AI).
62770174|NCT04622904|ACTIVE_COMPARATOR|lidocaine-magnesium group|combination of lidocaine and magnesium infusions
62770175|NCT04622904|ACTIVE_COMPARATOR|lidocaine-ketamine group|combination of lidocaine and ketamine infusions
62770176|NCT04622904|ACTIVE_COMPARATOR|lidocaine group|lidocaine infusion alone
62770177|NCT04066634|EXPERIMENTAL|Assist in Diagnosis|The Vivio Analysis Software is an analysis software that assists in identifying suspected systolic murmurs associated with aortic stenosis. The Vivio Analysis Software is used with the Vivio System, a non-invasive device used for the detection and amplification of sounds from the heart and arteries.
62770178|NCT02489812|EXPERIMENTAL|music|The Mozart Symphony No 40 in G minor K550 was played in headphones. While the child received restorative treatment in the teeth she heard music in a session and was subjected to other dental treatment session without listening to music. The cardiac and respiratory frequencies were measured with children's finger oximeter while the child listened to music and also in session in which she did not hear music. Changes in the measurements obtained by the oximeter showed levels of anxiety.
62770179|NCT04161781||Cohort 1|10 participants will receive one injection of 18F-BMS-986229 (370 MBq) and will then undergo whole-body PET/CT (80 mA) encompassing the vertex of the skull to the proximal thigh performed at 60 minutes (within the range of 55-70 minutes) postinjection. The scan itself is expected to last about 30 minutes and participants will be asked to remain in the waiting area or dedicated room for an additional 30 minutes post scan. The total time from injection will be 120 minutes. In both cohorts, participants whose treatment includes nivolumab and who have positive tumor localization observed at baseline will be asked to undergo an additional round of imaging.
62770180|NCT04161781||Cohort 2|25 participants may receive 370 MBq of 18F-BMS-986229 given intravenously and will undergo a single PET/CT scan 60 minutes (within the range of 55-70 minutes) postinjection. The scan itself is expected to last about 30 minutes and participants will be asked to remain in the waiting area or dedicated room for an additional 30 minutes post scan. The total time from injection will be 120 minutes. In both cohorts, participants whose treatment includes nivolumab and who have positive tumor localization observed at baseline will be asked to undergo an additional round of imaging. If the participant agrees, they will receive a second injection while undergoing nivolumab treatment (after at least 2 cycles or 6 weeksof therapy).
62770181|NCT01612455|NO_INTERVENTION|Standard of Care|Control participants will receive the narcology hospital's standard of care. With regard to linkage to HIV medical care, patients will be given printed information about where to obtain HIV medical care - the outpatient clinic that is involved in the intervention. Control patients will be referred to outpatient narcology care as part of standard of care. If control participants are newly diagnosed with HIV infection at the addiction hospital, they will receive HIV post test counseling consistent with CDC recommendations (this represents an enhancement of the current standard of care in Russia).
62178337|NCT01661530|PLACEBO_COMPARATOR|Non-enhanced dietary intervention|Range of three similar looking and tasting soups (400g/tin) with naturally low (\<3mg) vitamin E content. Three portions per week
62178338|NCT01558778|EXPERIMENTAL|Supportive care (whole body vibration)|Patients undergo mechanical stimulation over 20 minutes QD beginning on date of hospital admission and continuing through day 100 post-HCT, except for day 0 (date of transplant).
62178339|NCT05575661||Postprandial hypotension group|Patients who have a fall in systolic blood pressure of \>20 mm Hg, or a decrease to ≤90 mm Hg when preprandial systolic blood pressure is ≥100 mm Hg within 2 hours of the lunch
62178340|NCT05575661||No postprandial hypotension group|Patients who do not meet the postprandial hypotension criteria within 2 hours of the lunch
62178341|NCT04567797|EXPERIMENTAL|Exoskeleton|To compare the efficacy of four different exoskeleton devices, all participants will be asked to finish simulated construction tasks with each exoskeleton. Additionally, all participants will be asked to finish the same tasks without wearing an exoskeleton for reference.
62178342|NCT03371537||Hepatectomy|Patient undergoing laparotomy for liver resection. The aim is to measure the flow rates in the portal vein and the hepatic artery.
62178343|NCT01878383||Non-pregnant women/active HSV lesions|Women presenting to local health department
62391007|NCT05129644|ACTIVE_COMPARATOR|Pegasys 180 mcg|A total of 12 subjects received single dose of 180 mcg Pegasys
62770182|NCT01612455|EXPERIMENTAL|LINC Case Management (Intervention)|LINC Case Management (study Intervention) - see Intervention description
62770183|NCT02506686|EXPERIMENTAL|Meropenem|Meropenem i.v.
62770184|NCT06387641|ACTIVE_COMPARATOR|Control|Participants received routine community health services only.
62770185|NCT06387641|EXPERIMENTAL|Life Review|In addition to regular community health services，participants receive life review interventions life review intervention once a week for 6 weeks, with each session lasting45-60 minutes.
62770186|NCT05025722||Confirmed PXE participants|Participants who have index PXE/proband with established PXE and ABCC6 mutations identified.
62770187|NCT05025722||PXE carrier participants|Participants who are biological siblings of the PXE index case and confirmed as PXE carrier.
62178344|NCT01878383||Pregnant women/no active HSV lesions|Women presenting in active labor
62562582|NCT00659451|EXPERIMENTAL|2|Losartan
62562583|NCT00659451|ACTIVE_COMPARATOR|1|Amlodipine
62178345|NCT04635085|EXPERIMENTAL|Empowerment-based Cognitive behavioral therapy for insomnia for MCI (intervention)|Participants in the intervention group will participate in a 12-week empowerment-based CBT-I comprising face-to-face sessions supplemented with telephone follow-ups.
62178346|NCT04635085|NO_INTERVENTION|Social Activities provided by the community centers (active control)|The control group will not receive any structured cognitive training or sleep promoting interventions during the study period. The participants in the control group will continue to participate in the social activities offered by the elderly community centers. They have access to the newspapers, board games and computer facility in the centers. Upon completion of collecting all evaluation data for both groups at the three different time points, the empowerment-based CBT-I will be offered to participants in the control group.
62178347|NCT00207233|ACTIVE_COMPARATOR|1|Will receive MCT study oil to supplement into liquid meal replacements.
62178348|NCT00207233|PLACEBO_COMPARATOR|2|Will receive LCT oil to supplement into their liquid meal replacements.
62178349|NCT05897528||Diabetes Mellitus Positive Group|All patient that have a diagnosis of diabetes mellitus and COVID-19 Diagnosis
62178350|NCT05897528||Diabetes Mellitus Negative Group|All patient that do not have a diagnosis of diabetes mellitus but do have a diagnosis of COVID-19.
62178351|NCT04112641|PLACEBO_COMPARATOR|Placebo capsules|Subjects will take 2 capsules in the a.m. and 2 capsules in the p.m. daily for 84 days.
62770188|NCT05025722||Non-PXE normal participants|Participants who are biological siblings of PXE index case and confirmed as non-PXE normal.
62770189|NCT02893124|EXPERIMENTAL|PEG-IFN group|HBeAg-negative CHB patients with HBsAg \<1000 IU/ mL and HBV DNA\<100 IU/mL are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for at most 96 weeks.
62770190|NCT02893124|NO_INTERVENTION|NAs group|CHB patients do not need to change their NAs treatment.
62770191|NCT00646997||1|Patients with postoperative atrial fibrillation
62770192|NCT00646997||2|Patients without postoperative atrial fibrillation.
62770193|NCT01839656|EXPERIMENTAL|Nusinersen 6 mg|
62770194|NCT01839656|EXPERIMENTAL|Nusinersen 12 mg|
62770195|NCT03066167||Patients|Patients with oesophageal cancer and dysphagia
62770196|NCT03066167||Controls|Healthy Controls with no known dysphagia
62770197|NCT03619135|EXPERIMENTAL|Use of Buzzy Device|The Buzzy device was used for IV access for this arm.
62770198|NCT03619135|PLACEBO_COMPARATOR|Control|No Buzzy device was used - standard IV access for this arm.
62770199|NCT06364904|ACTIVE_COMPARATOR|Arm 1|"During each 21 days study cycle(up to 6 cycles), all participants will receive:~1. Tislelizumab: Taken 1x time at d1 each cycle or until it is determined participant must stop the drug.~2. Gemcitabine: d1, d8 each cycle or until it is determined participant must stop the drug.~3. Cisplatin: d2 each cycle or until it is determined participant must stop the drug.~Tislelizumab maintenance therapy:after chemoimmunotherapy, q3W until it is determined participant must stop the drug, or 2 years of treatment is completed."
62770200|NCT06364904|EXPERIMENTAL|Arm 2|"During each 21 days study cycle(up to 6 cycles), all participants will receive:~1. Tislelizumab: Taken 1x time at d1 each cycle or until it is determined participant must stop the drug.~2. Gemcitabine: d1, d8 each cycle or until it is determined participant must stop the drug.~3. Cisplatin: d2 each cycle or until it is determined participant must stop the drug.~4. Trilaciclib: d1, d2, d8 each cycle or until it is determined participant must stop the drug.~Tislelizumab maintenance therapy:after chemoimmunotherapy, q3W until it is determined participant must stop the drug, or 2 years of treatment is completed."
62770201|NCT01800656|EXPERIMENTAL|Ligate and let go|"Subjects are submitted to endoloop-assisted ligate and let go colorectal polypectomy."
62770202|NCT01800656|ACTIVE_COMPARATOR|Snare polypectomy|Subjects are submitted to endoloop-assisted snare colorectal polypectomy
62770203|NCT03055390|PLACEBO_COMPARATOR|Control|They received two ml of normal saline intravenously as a placebo
62178352|NCT04112641|EXPERIMENTAL|Nicotinamide Riboside (NIAGEN)|Subjects will take 2 250-mg capsules in the a.m. and 2 250- mg capsules in the p.m. daily (total daily dose is 1 g) for 84 days.
62178353|NCT05548413|ACTIVE_COMPARATOR|Patients - Attention Only|Patients with a confirmed diagnosis of heart failure.
62178354|NCT05548413|ACTIVE_COMPARATOR|Care Partners - Attention Only|Care partners of patients with a confirmed diagnosis of heart failure.
62178355|NCT05548413|EXPERIMENTAL|Patients - FamLit|Patients with a confirmed diagnosis of heart failure.
62178356|NCT05548413|EXPERIMENTAL|Care Partners - FamLit|Care partners of patients with a confirmed diagnosis of heart failure.
62178357|NCT00516828|EXPERIMENTAL|Sorafenib and Cytarabine|Cytarabine: subcutaneously twice daily from day 1 - 10. Sorafenib: Days 2-28; at the dose level assigned at registration. Sorafenib will be given orally twice daily.
62178358|NCT01938898|OTHER|Potential NICOLA Participants|All potential participants identified through the sampling strategy and contacted to take part in the NICOLA study
62770204|NCT03055390|ACTIVE_COMPARATOR|20 mg hyoscine butylbromide|They received (20mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
62770205|NCT03055390|ACTIVE_COMPARATOR|40 mg hyoscine butylbromide|They received (40mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
61994789|NCT03583424|EXPERIMENTAL|Treatment (venetoclax, BEAM)|Participants receive venetoclax PO QD on days -10 to -1, carmustine IV on day -6, etoposide IV BID on days -5 to -2, cytarabine IV BID on days -5 to -2, and melphalan IV on day -1. Participants then undergo hematopoietic cell transplantation on day 0.
62178359|NCT02325583|EXPERIMENTAL|Intraoral 30% Glucose in Newborns|0.5-1 mL 30% glucose solution was administered orally and the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added. After 2 consecutive oral glucose administration the newborns who did not keep motionless or sleep and had motion artefacts sedated with midazolam. The routine blood glucose level measurement was also performed in ICU.
62178360|NCT04505345|EXPERIMENTAL|Virtual reality cognitive training|Virtual reality cognitive training consists of a behavioral intervention of 10 sessions of training using virtual reality exercises depicting daily life activities from the Systemic Lisbon Battery aiming cognitive impairments.
62178361|NCT04505345|OTHER|Treatment-as-usual|Treatment-as-usual for alcohol use disorder (AUD) in our partner institution, a therapeutic community for rehabilitation of AUD, is conducted according to the Minnesota Model requiring alcohol abstinence.
62178362|NCT04441827|NO_INTERVENTION|Control|Usual care
62178363|NCT04441827|EXPERIMENTAL|Pranayama|Pranayama breathing exercise
62178364|NCT04441827|EXPERIMENTAL|Deep breathing exercise|Deep breathing exercise
62178365|NCT01911923|ACTIVE_COMPARATOR|No CPAP/PEEP and 100 % oxygen|This is the control group
62178366|NCT01911923|EXPERIMENTAL|CPAP/PEEP and 30 % oxygen|This is the intervention group
62178367|NCT04019249|EXPERIMENTAL|Experimental: Healthy Weight Coaching|Intervention: Healthy Weight Coaching.
62178368|NCT05908578|ACTIVE_COMPARATOR|High-Frequency Training|Exercise performed on a stationary bike four times per week. Total weekly exercise volume (the product of intensity, duration, and frequency) will be matched between groups. Intensity will be the same, so the high-frequency group will perform half the duration of exercise in each session compared to the low-frequency group.
62178369|NCT05908578|EXPERIMENTAL|Low-Frequency Training|Exercise performed on a stationary bike two times per week. Total weekly exercise volume (the product of intensity, duration, and frequency) will be matched between groups. Intensity will be the same, so the low-frequency group will perform double the duration of exercise in each session compared to the high-frequency group.
62770206|NCT02514005|ACTIVE_COMPARATOR|Manual therapy|Overall bilateral manipulation (L5-S1-SI), Hip joint gapping, Stretching the hip rotators with hip and knee flexion, Femorotibial Gapping, Decompression of connective tissue of the patellofemoral region, Internal and external joint line opening in laterality, Mobilization of the base of the fibula, Tibiofibular-talus gapping, and Muscle strengthening.
62770207|NCT02514005|EXPERIMENTAL|Manual therapy and Dry needling|Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps.
62770208|NCT05805644|EXPERIMENTAL|Robot mediated Impairment-oriented training(RMIT)|Participant receives 20 hours of robot mediated impairment-oriented training applied via the Optimo Regen
62178370|NCT04669002|EXPERIMENTAL|Phase 2A Cohort 1|Patients with advanced platinum resistant ovarian cancer who have received no more than 1 prior line of therapy which must be platinum-based chemotherapy
62178371|NCT04669002|EXPERIMENTAL|Phase 2A Cohort 2|Patients with advanced ovarian cancer who have received at least 1 prior line of therapy which must include at least 1 line of platinum-based chemotherapy followed by a PARP inhibitor as maintenance treatment as their last treatment regimen
62178372|NCT02412111|EXPERIMENTAL|Ivacaftor (Run-in Period)|Ivacaftor 150 milligram (mg) tablet orally every 12 hours for 4 weeks.
62178373|NCT02412111|EXPERIMENTAL|VX-661 + Ivacaftor (Active comparator period)|VX-661 100 mg and ivacaftor 150 mg fixed-dose combination tablet orally once daily in the morning and ivacaftor 150 mg tablet orally once daily in the evening for 8 weeks.
62178374|NCT02412111|ACTIVE_COMPARATOR|Ivacaftor monotherapy (Active comparator period)|Ivacaftor 150 mg tablet orally every 12 hours as monotherapy for 8 weeks.
62178375|NCT04202016|EXPERIMENTAL|Piezocision on high facial divergence|Piezocision Surgery prior to space closure with closing coil spring four months after extraction. Six weeks later, three other follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
62178376|NCT04202016|NO_INTERVENTION|High facial divergence|Space closure with coil spring four months after extraction. Six weeks later, three other follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
62178377|NCT04202016|EXPERIMENTAL|Piezocision on average facial divergence|Piezocision Surgery prior to space closure with closing coil spring four months after extraction. Six weeks later, three follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
62178378|NCT04202016|NO_INTERVENTION|Average facial divergence|Space closure with coil spring four months after extraction. Six weeks later, three other follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
62178379|NCT05725044|EXPERIMENTAL|Ginsengberry concentrate|This group takes Ginsengberry concentrate for 8 weeks.
62178380|NCT05725044|PLACEBO_COMPARATOR|Placebo|This group takes placebo for 8 weeks.
62178381|NCT03738306|EXPERIMENTAL|Mezieres Method|The Mézières treatment has 3 postures that could be adapted to each patient, depending on his/her needs to correct variations in the dorsal curve and promote diaphragmatic breathing. The first objective was to recover extensibility of the hypertonic muscle groups and, in particular, those in the low back muscular chain. The time of tratment will be of 1 hour, two times a week, during 5 weeks.
62178382|NCT03738306|ACTIVE_COMPARATOR|Conventional Physiotherapy|The treatment with conventional physiotherapy will include stretching of hamstrings, gluteus, (and others) hot pack, transcutaneous electrical nerve stimulation, ultrasound and some exercises of core performance.The time of treatment will be of 1 hour, two times a week, during 5 weeks.
62178383|NCT01501227|ACTIVE_COMPARATOR|Taper Guard Endotracheal Tube|Patients in the test group will be intubated with the Taper Guard Endotracheal Tube. The incidence of VAP, the length of ventilation, the length of intensive care stay, the length of hospital stay and the mortality rate will be monitored.
62178384|NCT01501227|SHAM_COMPARATOR|conventional endotracheal tube|Patients in the placebo comparator group will be intubated with the conventional Endotracheal Tube. The incidence of VAP, the length of ventilation, the length of intensive care stay, the length of hospital stay and the mortality rate will be monitored.
62178385|NCT05432999|EXPERIMENTAL|Intervention|This group will receive a focused extracorporeal shockwave therapy treatment (three applications over three weeks), applied to the spastic medial gastrocnemius.
62178386|NCT05432999|SHAM_COMPARATOR|Control|This group will go through the same procedures as the intervention group, but the shockwave device will not touch their skin and thus they will receive no therapeutic effect.
62178387|NCT06511375|EXPERIMENTAL|sprint training|"group 1 will perform sprint training for 4 weeks, 3 sessions per week~Participants will perform 6 maximal 25-m sprint with recovery period of 25 seconds after each sprint for four weeks and three sessions per week.~Participants will perform 10 m sprint 2 trials with 2 minutes recovery period between each trial for four weeks and three sessions per week.~Participants will perform Vertical jump, 2 trials with 1-minute recovery period between each trial for four weeks, three sessions per week."
62178388|NCT06511375|EXPERIMENTAL|power training|"GROUP 2 will perform POWER TRAINING for 4 weeks, 3 sessions per week Participants will perform Countermovement jump 2 trials, with 1-minute recovery between each trial for four weeks, three times per week.~Participants will perform squat jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week.~Participants will perform broad jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week."
62178389|NCT00005845|EXPERIMENTAL|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on weeks 1, 3, 5, and 7. Treatment repeats every 8 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62178390|NCT01354236||School dropouts|Students who quit school without graduation
62178391|NCT01354236||Controls|Normally enrolled students matched for age, gender, school and educational level
62178392|NCT02448498|EXPERIMENTAL|Strength Training Only|Participants in the strength-training only group will take part in a 9-month exercise intervention at a local exercise facility. They will engage in strength training 3 days per week for approximately 60 minutes each exercise session.
62178393|NCT02448498|EXPERIMENTAL|Aerobic Training Only|Participants in the aerobic training only group will take part in a 9-month exercise intervention at a local exercise facility. They will engage in aerobic training over 3 -5 days per week to achieve the targeted dose of 12 kcal/kg per week at a training intensity between 50-80% VO2 max.
62178394|NCT02448498|EXPERIMENTAL|Combination (Strength and Aerobic) Training|Participants in the combination (strength and aerobic training) group will take part in a 9-month exercise intervention at a local exercise facility. They will engage aerobic training that will expend 10 kcal/kg/week in combination with strength-training, 3 days per week.
62178395|NCT00582114|ACTIVE_COMPARATOR|1|Atenolol
62178396|NCT00582114|EXPERIMENTAL|2|Lisinopril
62178397|NCT02597036|EXPERIMENTAL|Part A LY3127804|Dose escalation of LY3127804 given intravenously (IV) every 2 weeks (Q2W) for 28 day cycle.
62178398|NCT02597036|EXPERIMENTAL|Part B LY3127804 + Ramucirumab Dose 1|Dose escalation of LY3127804 in combination with Ramucirumab given IV Q2W for 28 day cycle.
62178399|NCT02597036|EXPERIMENTAL|Part C LY3127804 + Ramucirumab Dose 2|LY3127804 in combination with Ramucirumab given IV Q2W for 28 day cycle.
62178400|NCT02597036|EXPERIMENTAL|Part D LY3127804 + Ramucirumab|LY3127804 and Ramucirumab given IV Q2W until participant qualifies for study discontinuation.
62562584|NCT03501823||Peripheral vascular disease|"All adult patients (aged 18 years and above) proven or highly suspected to have peripheral arterial or venous disease.~Ultrasound to be performed first in order to correct Photoacoustic tomography positioning.~Photoacoustic tomography to be performed after ultrasound"
62770209|NCT05805644|EXPERIMENTAL|Robot mediated impairment-oriented and task-specific training (RMIT+RMTT)|Participant receives a total of 20 hours of robotic therapy. 10 hours will be in the form of RMIT and 10 hours in the form of RMTT
62770210|NCT06241521||Myasthenia gravis patients|
62770211|NCT01393938|OTHER|Mullerian Duct Anomaly|
62770212|NCT02452203|EXPERIMENTAL|Floating|The participant will float supine in water with a high concentration of Epsom salt for 90 minutes.
62770213|NCT02452203|PLACEBO_COMPARATOR|Chair|The participant will lay in the supine position while reclined in a zero-gravity chair for 90 minutes.
62770214|NCT02744989|EXPERIMENTAL|Active tDCS|Stimulation will be performed using an tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl). The anode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex, assumed to correspond to a region including Brodmann's Areas (BA) 8, 9, 10, and 46, depending on the patient). The cathode will be located over a point midway between T3 and P3 (left temporo-parietal junction, assumed to correspond to a region including BA 22, 39, 40, 41, and 42, depending on the patient). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day for 5 consecutive weekdays. The twice daily sessions will be separated by at least 2 hours.
62770215|NCT02744989|SHAM_COMPARATOR|Sham tDCS|
62770216|NCT03480009|EXPERIMENTAL|Dextromethorphan, opted for narcotic prescription|Dextromethorphan hydrobromide and patient opts for narcotics (oxycodone or other standard narcotics)
62770217|NCT03480009|PLACEBO_COMPARATOR|Placebo, opted for narcotic prescription|Avicel PH101 (Microcrystalline Cellulose NF) and patient opts for narcotics (oxycodone or other standard narcotics)
62770218|NCT03480009|EXPERIMENTAL|Dextromethorphan, declined narcotic prescription|Dextromethorphan hydrobromide and patient declines narcotic
62178401|NCT02597036|EXPERIMENTAL|Part E LY3127804 + Ramucirumab + Paclitaxel|LY3127804 and Ramucirumab given IV Q2W and Paclitaxel given IV on day 1, 8, and 15 until participant qualifies for study discontinuation.
62178402|NCT02879799|EXPERIMENTAL|Implement Family Integrated Care|Dynamic education and support intervention for families of preterm infants.
62770219|NCT03480009|PLACEBO_COMPARATOR|Placebo, declined narcotic prescription|Avicel PH101 (Microcrystalline Cellulose NF) for Compounding and patient declines narcotic
62770220|NCT00647114|EXPERIMENTAL|1|V930
62770221|NCT00647114|EXPERIMENTAL|2|V932
62770222|NCT01284972||HINTEGRA|Patient Implanted with the HINTEGRA Total Ankle Prosthesis more than 2 years ago
62770223|NCT06507514|OTHER|Blinatumomab and Auto-HSCT Sandwich Strateg|
62770224|NCT04106102|ACTIVE_COMPARATOR|Transcramial Direct current stimulation|Implement of Transcramial Direct current stimulation
62770225|NCT04106102|PLACEBO_COMPARATOR|Placebo|
62770226|NCT05701449||Patients applying a prediction model for postoperative pulmonary complications|
62770227|NCT05701449||Patients non-applying a prediction model for postoperative pulmonary complications|
62770228|NCT02644382||Key Informant interviews|20 in-person or phone qualitative interviews with patients.
62770229|NCT02644382||Focus Groups|four qualitative focus groups of 6-10 women each.
62770230|NCT02644382||Physician Interviews|physician qualitative interviews over the telephone.
62770231|NCT02644382||Usual care cohort (pilot)|50 women who will be surveyed before and after their surgical consult
62770232|NCT02644382||Decision aid cohort (pilot)|50 women who will be surveyed before and after their surgical consult and will also be sent a web-based decision aid
62770233|NCT06282601|EXPERIMENTAL|Presbyacusis patients|
62178403|NCT02879799|NO_INTERVENTION|Monitor Standard Practices|Standard nursing care of preterm infants and their families.
62770234|NCT03510325|EXPERIMENTAL|Olanzapine|dosage form:po dosage:5-20mg frequency:qn duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
62770235|NCT03510325|EXPERIMENTAL|Risperidone|dosage form:po dosage:4-6mg frequency:2 doses duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
62770236|NCT03510325|EXPERIMENTAL|Amisulpride|dosage form:po dosage:0.4-1.2g frequency:2 doses duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
62770237|NCT03510325|EXPERIMENTAL|Aripiprazole|dosage form:po dosage:15-30mg frequency:qd duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
62770238|NCT03510325|EXPERIMENTAL|Paliperidone long-acting injection|dosage form:im dosage:75-150mg frequency:once a month duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
62770239|NCT02283307|EXPERIMENTAL|Reduced contrast DECT scan|Reduced Contrast Dual Energy CT
62770240|NCT01401699|EXPERIMENTAL|Optical Frequency Domain imaging System|Optical Frequency Domain Imaging (OFDI) balloon based imaging
62770241|NCT06203977|ACTIVE_COMPARATOR|REPAIR CKD cohort|Patients will receive open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.
62770242|NCT06203977|ACTIVE_COMPARATOR|REPAIR Dialysis cohort|Patients will receive open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.
62770243|NCT03235219|EXPERIMENTAL|Cohort 1 to 4: JNJ-64565111 or Placebo|Participants in cohort 1 to 4 in a ratio of 4:1 will receive a dose of JNJ-64565111 or placebo subcutaneously on Days 1, 8, 15 and 22. Cohort 1, 2 and 3 will be dosed in parallel. Dosing for subsequent cohort 4 will be escalated based on review by the Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29, but will not exceed from well-tolerated dose.
62770244|NCT03235219|EXPERIMENTAL|Cohort 5: JNJ-64565111 (Repeat or Lower Dose) or Placebo|Participants in ratio of 4:1 will receive a dose of JNJ-64565111 or placebo subcutaneously on Days 1, 8, 15 and 22, and may be modified. The dose can be repeated or lower than a dose previously assessed as well tolerated.
62770245|NCT01848847|EXPERIMENTAL|Full Bladder|Hysteroscopy conducted under full bladder.
62770246|NCT01848847|EXPERIMENTAL|Empty Bladder|Hysteroscopy conducted under empty bladder.
62770247|NCT06464861|EXPERIMENTAL|CD19-CAR-NK/T|All subjects were intravenously administrated with CAR-NK019 at day 0 with a dose of 2x10\^6/kg, and after 1 week will be infused with 7x19 CAR-T at the dose of 2x10\^6/kg
62770248|NCT01447121|EXPERIMENTAL|Intended Users of the System|Untrained subjects with diabetes use an investigational blood glucose monitoring system (Tatsu/Tradewind Investigational BG Monitoring System) to self-test capillary blood obtained from fingerstick.
62770249|NCT04804150|EXPERIMENTAL|Medical Device active or inactive|The medical device will be active, or inactive. Randomization will define when and how long time the medical device will plugged and active, and when and how long time the medical device will be unplugged and inactive. The patient won't know if the medical device is active or not
62178404|NCT02725008|ACTIVE_COMPARATOR|Control|Patients are given one dose of oral dexamethasone 0.6 milligrams per kilogram up to 16 milligrams in the ED and a second dose of 0.6 milligrams per kilogram up to 16 milligrams to take 24 hours after ED visit
62770250|NCT03908827|EXPERIMENTAL|Active BMAC treatment|60 mL of bone marrow will be aspirated from the iliac crest of each subject in the active treatment group. The bone marrow aspirate (BMA) will be centrifuged using a single spin protocol such that the red blood cells are minimized and the total nucleated and platelet cells are concentrated into a 12 mL volume of bone marrow aspirate concentrate (BMAC).
62770251|NCT03908827|NO_INTERVENTION|Wait List Control|Participants will continue with their usual treatment, inclusive of medications or conservative treatments and will continue with activity guidelines as previously provided by clinical staff whilst awaiting joint arthroplasty
62770252|NCT04946123|NO_INTERVENTION|methimazole (control)|Patients with hyperthyroidism under methimazole treatment
62178405|NCT02725008|EXPERIMENTAL|Investigational|Patients are given one dose of oral dexamethasone 0.6 milligrams per kilogram up to 16 milligrams in the ED and placebo to be taken 24 hours after ED visit
62178406|NCT01858064|EXPERIMENTAL|OROS-MPH|OROS-MPH is administered in capsule form daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90mg/day.
62178407|NCT04892602||Rheumatiod arthritis patients|
62178408|NCT04892602||Psoaritic arthritis|
62178409|NCT04892602||Control group|
62562585|NCT03501823||Oncology|"All adult patients (ages 18 years and above) proven or highly suspected to have solid organ malignancy Ultrasound to be performed first in order to correct Photoacoustic tomography positioning.~Photoacoustic tomography to be performed after ultrasound"
62562586|NCT03244306|EXPERIMENTAL|Autologous CD22-specific CAR T-cells expressing EGFRt|
62178410|NCT02073253|NO_INTERVENTION|Without performing any operation (Phase Control)|
62562587|NCT02932501||MRONJ|"Patients diagnosed of medication-related osteonecrosis of the jaw (MRONJ). Treatment strategies vary depending on the stage of MRONJ and can be of different nature as:~Conservative treatment Surgical treatment Adjuvant non-surgical treatment"
62562588|NCT00486785|EXPERIMENTAL|1|
62562589|NCT05214651|EXPERIMENTAL|novel double row group|This is the experimental group, and 26 participants will be enrolled, a novel double row technique will be using to repair the large - massive rotator cuff tears in in this group.
62770253|NCT04946123|EXPERIMENTAL|methimazole+L-carnitine+selenium (intervention)|Patients with hyperthyroidism under methimazole treatment + supplementation with L-carnitine and Selenium
62178411|NCT02073253|EXPERIMENTAL|With ventilatory support through NIV (NIV Phase)|
62178412|NCT05726552|EXPERIMENTAL|Laughter Therapy group|Hemodialysis patients(40) enrolled in the laughter therapy group will receive a total of 12 sessions of laughter therapy, 50 minutes, 3 days a week.
62178413|NCT05726552|NO_INTERVENTION|Control|No attempt will be made to hemodialysis patients in this group.
62178414|NCT03065439|EXPERIMENTAL|STarT Back Tool group 3|Patients scored as high risk patients by the STarT Back Tool
62178415|NCT03065439|EXPERIMENTAL|STarT Back Tool groups 1+2|Patients scored as low risk or medium risk patients by the STarT Back Tool
62178416|NCT00088543|EXPERIMENTAL|1 Low dose|total dose 4.5 mg/kg Thymoglobulin
62178417|NCT00088543|EXPERIMENTAL|2 High dose|total dose 8.5 mg/kg Thymoglobulin
62178418|NCT05050435||Early extubated (in operating room) patients after valvular cardiac surgery|
62178419|NCT05050435||Later extubated (in ICU) patients after valvular cardiac surgery|
62178420|NCT00772655|EXPERIMENTAL|Study Therapy|Induction therapy with a single course of 90Yttrium-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111Indium-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 up to a maximal dose of 12.000 MBq \[if platelets are below 150000/µl only 11 MBq/kg are administered). Observation for patients achieving complete clinical and molecular response or partial clinical response. Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2 (t14;18)-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
62562590|NCT05214651|ACTIVE_COMPARATOR|suture bridge double row group|This is the control group, and 26 participants will be enrolled, a suture bridge double row technique will be using to repair the large - massive rotator cuff tears in in this group in routine.
62562591|NCT00811733|EXPERIMENTAL|Ofatumumab|Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.
62562592|NCT02308969|OTHER|Placebo, LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.
62562593|NCT06344195|EXPERIMENTAL|Valacyclovir Group|participants will be given prescription of valacyclovir (2g immediate dose followed by 500mg 2 times daily for 3 days) along with the analgesic, Naproxen sodium, 550mg (SOS, if needed) Data will be recorded daily for 6 days
62770254|NCT05546073|NO_INTERVENTION|Control - Usual Care|Participants in the control-arm will undergo usual care. This covers clinical inspection, vital parameters (respiratory rate(breaths/min), saturation (%), blood pressure (mmHg), heart rate (beats/min), body temperature (celsius), and Glasgow Coma Scale) , and point-of-care blood-test for CRP and haemoglobin
62770255|NCT05546073|EXPERIMENTAL|Intervention - Advanced point-of-care technology|Participants in the intervention-arm will undergo usual care as well as advanced point-of-care technology.
62770256|NCT03334383|EXPERIMENTAL|Sponge group|Patients offered surgery with the retractor sponge
62770257|NCT03334383|NO_INTERVENTION|Control group|Patients receiving standard care: surgery in Trendelenburg position
62770258|NCT00094432|ACTIVE_COMPARATOR|A1|
62770259|NCT00094432|PLACEBO_COMPARATOR|A2|
62770260|NCT04391452|EXPERIMENTAL|Dietary supplement group|Group 1:50 stressed subjects who will have a 28-day intake of dietary supplement. Of the 50 stressed subjects, 20 subjects will participate in the fMRI exam. Dietary supplement is composed of Mg (150 mg), Vitamin B6 (0.7 mg), Vitamin B9 (100µg), Vitamin B12 (1.25 µg), rhodiola (222mg), and green tea/L-théanine (125 mg).
62178421|NCT06403098|NO_INTERVENTION|No External Nasal Dilator Strip|The control arm will last 7 consecutive nights and days. Participants will be asked to follow normal activity and sleep patterns. Immediately after waking the participants will measure their blood pressure and heart rate variability and complete a sleep diary to characterize subjective sleep quality. A wrist-based activity monitor will measure objective sleep quality during the control arm.
62391008|NCT04012866|EXPERIMENTAL|SEQ (sequential training group)|The sequential training group (SEQ) will first receive 30-minutes aerobic exercise training followed by 30-minutes computerized cognitive training. All participants will receive a training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
62562594|NCT06344195|ACTIVE_COMPARATOR|Control Group|this is control group and is prescribed with analgesic, Naproxen sodium, 550mg (SOS, if needed) only
62562595|NCT03432143|EXPERIMENTAL|Community Reviewers|24 community members will receive training and mentoring in reviewing manuscripts. Approximately 284 manuscripts will be randomized into the intervention group over the duration of the study. Manuscripts will be reviewed by both a community member and scientific reviewers.
62562596|NCT03432143|NO_INTERVENTION|Scientific Reviewers Only|Approximately 284 manuscripts will be randomized into the control group over the duration of the study. Manuscripts will be reviewed by multiple scientific reviewers. Community reviewers will not be involved in reviewing these manuscripts.
62178422|NCT06403098|EXPERIMENTAL|External Nasal Dilator Strip|The experimental arm will last 7 consecutive nights and days. Participants will be asked to follow normal activity and sleep patterns, but they will wear an external nasal dilator strip during sleep. Immediately after waking the participants will measure their blood pressure and heart rate variability and complete a sleep diary to characterize subjective sleep quality. A wrist-based activity monitor will measure objective sleep quality during the experimental arm.
62178423|NCT02205047|ACTIVE_COMPARATOR|Standard chemotherapy|Cisplatin/capecitabine or cisplatin/5-fluorouracil
62178424|NCT02205047|EXPERIMENTAL|Experimental arm 1|Cisplatin/capecitabine plus trastuzumab or cisplatin/5-fluorouracil plus trastuzumab
62770261|NCT04391452|PLACEBO_COMPARATOR|Placebo group|Group 2 (Placebo comparator (lactose)): 50 stressed subjects who will have a 28-day intake of placebo. Of the 50 stressed subjects, 20 subjects will participate in the fMRI exam.
62770262|NCT02291926|EXPERIMENTAL|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
62178425|NCT02205047|EXPERIMENTAL|Experimental arm 2|cisplatin/capecitabine plus trastuzumab and pertuzumab or cisplatin/5-fluorouracil plus trastuzumab and pertuzumab
62178426|NCT02427958|EXPERIMENTAL|Leuprorelin|Participants with body weight greater than or equal to (\>=) 20 kilogram (kg) will receive the recommended dose of leuprorelin 3.75 milligram (mg), injection, subcutaneously, once every 4 weeks for 96 weeks. Participants with body weight less than (\<) 20 kg will receive leuprorelin 1.88 mg, injection, subcutaneously, once every 4 weeks for 96 weeks.
62770263|NCT03445221|ACTIVE_COMPARATOR|Group I|Patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 3 days before surgery.
62178427|NCT05849571|NO_INTERVENTION|No Intervention: Control group|"* Consent is obtained with an informed consent form.~* Patient identification form is filled.~* The patient's mouth is evaluated using the World Health Organization Mucositis Classification and the International Pediatric Mucositis Rating Scale (ChIMES) before receiving chemotherapy. According to the World Health Organization Mucositis Classification, the frequency of oral care is decided.~* The patient's mouth is evaluated using the World Health Organization Mucositis Classification and the International Child Mucositis Evaluation Scale (ChIMES) on days 0, 7, and 14, and after each assessment, the frequency of oral care is determined and applied for 21 days. The final assessment is made on Day 21.~* The care given according to the frequency of oral care determined according to the score obtained by the patient in the World Health Organization Mucositis Classification is recorded on the Basic Oral Care Protocol Follow-up Chart."
62770264|NCT03445221|ACTIVE_COMPARATOR|Group II|Patients will continue preoperative oral conventional diet.
62770265|NCT03444454|EXPERIMENTAL|VRRS Khymeia|"The group will receive a kit home-based (a tablet home, an exercise equipment, access to a daily individualized training program).~The exercise program will be remotely charged by therapist on the patient's computer.~Each patient's performed session will be reviewed remotely by the therapist."
62770266|NCT03444454|ACTIVE_COMPARATOR|Usual care program|The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
62770267|NCT03444454|EXPERIMENTAL|VRRS Khymeia plus active tDCS|The group will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training
62178428|NCT05849571|EXPERIMENTAL|Experimental: Experimental Group|Unlike the control group, the experimental group is rinsed with 5 ml of coconut 4 times a day.
62770268|NCT03444454|ACTIVE_COMPARATOR|VRRS Khymeia plus placebo tDCS|The group will receive 5 sessions of an individualized home-based VRRS training combined with placebo tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training
62562597|NCT03875053|EXPERIMENTAL|Monitoring device, Quality of Life Assessment, Questionnaire|Patients wear the home sleep apnea machine overnight. Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.
62770269|NCT05441956|EXPERIMENTAL|TGRX-326|Subjects to be treated with the investigational drug TGRX-326
62770270|NCT05605171|EXPERIMENTAL|Posterior reconstruction urethrovesical anastomosis.|The intervention comprised of a 2-stitch approximation of the free edge of the Denonvilliers' fascia and posterior bladder wall cranially, to the posterior aspect of the rhabdosphincter and the posterior median raphe caudally, respectively, following prostate extraction. The aim of this approach is to ultimately restore the length of the urethrosphincteric complex, prevent its caudal retraction, and avoid undue tension on the subsequent vesicourethral anastomosis, and provide a posterior support to the urethral sphincter complex to facilitate its effective contraction.
62770271|NCT05605171|ACTIVE_COMPARATOR|Conventional urethrovesical anastomosis.|The conventional is fashioned with a continuous running technique that uses two sutures. The first suture is passed in a clockwise hemicircumferential manner, starting from outside in on the bladder neck at the 5 o'clock position and inside out on the urethra up toward the 12 o'clock position. The second suture is similarly run in a counter- clockwise hemicircumferential direction. The running sutures are snug down after each apposition to ensure there is no slack, and finally tied together with several knots at the 12 o'clock position.
62770272|NCT02451891|ACTIVE_COMPARATOR|Group 1a|MVA-EBO Z (1 x 10\^8 pfu)
62770273|NCT02451891|ACTIVE_COMPARATOR|Group 1b|MVA-EBO Z (1.5 x 10\^8 pfu)
62770274|NCT02451891|ACTIVE_COMPARATOR|Group 2|ChAd3-EBO Z (2.5 +/- 1.2 x 10\^10 vp) and MVA-EBO Z (1 x 10\^8 pfu) after 14 days
62770275|NCT02451891|ACTIVE_COMPARATOR|Group 3|ChAd3-EBO Z (2.5 +/- 1.2 x 10\^10 vp) and MVA-EBO Z (1 x 10\^8 pfu) after 28 days
62770276|NCT02451891|ACTIVE_COMPARATOR|Group 4|ChAd3-EBO Z (2.5 +/- 1.2 x 10\^10 vp) and MVA-EBO Z (1.5 x 10\^8 pfu) after 28 days
62178429|NCT05173233|EXPERIMENTAL|K-clipTM transcatheter annuloplasty system|
62178430|NCT06002633|ACTIVE_COMPARATOR|Alcohol|Participants will drink beverages containing alcohol.
62178431|NCT06002633|PLACEBO_COMPARATOR|Placebo|Participants will drink beverages containing a very low dose of alcohol (placebo condition).
62178432|NCT00690378|EXPERIMENTAL|1|NXL/104 ceftazidime
62178433|NCT00690378|ACTIVE_COMPARATOR|2|comparator 4 x daily
62178434|NCT02955706|EXPERIMENTAL|Active|Acetyl-L-carnitine (DongA ST)
62178435|NCT02955706|PLACEBO_COMPARATOR|placebo|Placebo of Acetyl-L-carnitine (DongA ST)
62178436|NCT05572385|ACTIVE_COMPARATOR|Patients with aphasia|Patients with a clinical aphasia (20 receptive, 20 expressive) with a specific logopedic treatment, with specific EEG measurement at start and end of treatment schedule.
62178437|NCT05572385|NO_INTERVENTION|Patients without aphasia|Patients with comparable stroke characteristics, but without clinical aphasia.
62178438|NCT01741311|EXPERIMENTAL|3H+ Group|3H+ (Holistic for HIV) group patients will receive the standard of drug treatment care (i.e., methadone maintenance treatment and case management) plus four weekly 60-minute HIV risk reduction groups, and a 60-minute booster session at 12 weeks, led by two facilitators trained and supervised by a licensed clinical psychologist. 3H+ is an HIV risk reduction and ART adherence intervention that provides coping skills training and is delivered in a group modality, addressing high risk drug- and sex-related HIV risk behaviors and ART adherence for opioid-dependent individuals living with HIV.
62178439|NCT01741311|ACTIVE_COMPARATOR|HHRP+ Group|HHRP+ (Holistic Health Recovery Program) is comprised of 12 two-hour weekly manual-guided group sessions with comprehensive HIV risk reduction content that addresses the medical, emotional, and spiritual needs of opioid-dependent individuals living with HIV. Each session is designed to last 2 hours and is co-facilitated by two trained facilitators, who address potential motivational conflicts of HIV+ individuals by providing them with self-protective as well as altruistic reasons for examining and changing their HIV risk behaviors and improving adherence behavior. Material is presented using cognitive remediation strategies.
62178440|NCT05380102||Single Arm Study (Cohort)|"All participants will be on standard telemetry monitoring for Heart Rate and Respiration Rate using the gold standard (Electrocardiography and Capnography respectively).~In addition, two contactless monitoring devices will be placed on the patient bed to measure data. These devices include EarlySense (USFDA approved ballistocardiography device) and Dozee VS (Investigational Device). Data from all devices will be measured simultaneously."
62770277|NCT05687006|NO_INTERVENTION|The CTA+CDU Group|Every patient included in the CTA+CDU group preoperatively underwent CT angiography of the abdominal wall. Based on the CTA examination XY coordinates of DIEA perforators localized within the area between 2 cm cranial and 10 cm caudal from the umbilicus and with a vessel calibre of more than 1 mm were determined. The day before the surgery, the main perforators were marked on the patient's abdomen according to the coordinates deducted from the CTA. These perforators were additionally examined using a LOGIQ S8/V1 CDU device with a linear transducer of frequency 4-11 MHz. Any additional perforators were marked nor have CTA deducted XY coordinates of marked perforators changed based on the CDU examination. The same sonography surgeon performed all CDU examinations. The time duration of the CDU examination was measured.
61994790|NCT06361628|EXPERIMENTAL|Educational sessions delivered by health promotors in Greece|In this approach, medical professionals and health promoters-trusted members of the community-will educate refugee and migrant parents. The focus is on enhancing awareness of HPV/MMR and fostering a greater willingness to vaccinate their children/adolescents. Multicultural schools and migrant associations are the locations where the educational sessions will be provided.
61994791|NCT06361628|EXPERIMENTAL|Educational sessions delivered by health promotors and healthcare professionals in the Netherlands|Trusted community health members will be trained and will act as health promotors in the intervention. Together with health care professionals they will offer educational sessions on HPV vaccination at locations close to where people live (in the neighborhoods) and locations communities are familiar with, such as community centers, schools, health centers, religious places or offices of foundations/non-governmental organizations. Together with local stakeholders it will be verified that locations are also acceptable for the target communities. A navigation component is also included and participants will be contacted 1 week and 3 months after the educational sessions and reminded to get vaccinated and will be asked if they still have questions or need help to find their way to get vaccinated.
61994792|NCT06361628|EXPERIMENTAL|Educational sessions delivered by health promotors in Poland|This intervention is based on the principle of face-to-face and online health education, where Ukrainian parents are educated by general practitioners to raise HPV/MMR awareness and increase willingness to child/adolescent vaccination.
61994793|NCT06361628|EXPERIMENTAL|Educational sessions delivered by health promotors in Slovakia|Roma health mediators will be trained on HPV vaccination and thereafter will offer educational sessions to the underserved communities. Educational sessions take place at either municipalities, schools, community centers, local health care providers and public health authorities.
62178441|NCT02786290|EXPERIMENTAL|Treatment Group|Receives intervention with the Zenflow Spring System.
62770278|NCT05687006|EXPERIMENTAL|The CDU Group|All patients included in the CDU group were examined a day before the surgery with the same CDU device by the same sonography surgeon as patients included in CTA + CDU group. During the examination, DIEA perforators were mapped and the following parameters were monitored: 1) XY coordinates of DIEA perforators localized within the area between 2 cm cranial and 10 cm caudal from the umbilicus and with a vessel calibre of more than 1 mm; 2) calibres of perforator arteries and veins; 3) PSV in the perforator artery \[cm/s\]; 4) velocity in the perforator vein \[cm/s\]; 5) the thickness of the subcutaneous tissue of the lower abdomen measured 4 cm caudal and lateral to the umbilicus. The time duration of the CDU examination was measured.
62178442|NCT05742659|EXPERIMENTAL|experimental group|
62178443|NCT05742659|NO_INTERVENTION|control group|
62562598|NCT04092868||cardiac surgery with extracorporeal circulation|"during the operation~Intervention Blood sample :~- Choay Heparin (pharmacokinetic) concentration: t = 5, 15, 30 minutes after the start of the heparin injection + t = 5, 30, 60 minutes after the start of extracorporeal circulation~* protamine dosage: t = 2, 5, 8, 10 and 15 min after protamine injection~* anti-X activity t = 0 before administration and at time 2, 5, 8, 10 and 15 min then at time 1, 3, 5, 6 and 7 hours after protamine injection~* thrombin generation test (TGT) activity (thrombinography) : t = 2, 5, 8, 10 and 15 min after protamine injection"
62178444|NCT00806598|EXPERIMENTAL|Thymoglobulin + Cyclosporin|Combination of Thymoglobulin 3.5 or 2.5 mg/kg/day intravenous (IV) for 5 days + Methylprednisone 1 mg/kg/day IV for 5 days, before each dose Thymoglobulin + Cyclosporin 5 mg/kg orally for 6 months following Thymoglobulin + Granulocyte - Colony Stimulating Factor (G-CSF) 5 microgram/kg subcutaneously daily up to 3 months
62770279|NCT03828474|EXPERIMENTAL|Acetazolamide 125mg twice daily|Acetazolamide pill 125mg twice daily by mouth, started the night prior to ascent and continued for 3 total doses
62178445|NCT00787813|ACTIVE_COMPARATOR|1|N-Acetyl Cysteine
62178446|NCT00787813|PLACEBO_COMPARATOR|2|placebo
62178447|NCT04339023|EXPERIMENTAL|OLP-Group|patients will receive in addition to TAU, 2 open-label Placebo (OLP) injections (containing each 5 ml of NaCl 9%) per day for two consecutive days following minimally invasive TLIF
62770280|NCT03828474|EXPERIMENTAL|Acetazolamide 62.5mg twice daily|Acetazolamide pill 62.5mg twice daily by mouth, started the night prior to ascent and continued for 3 total doses
62178448|NCT04339023|OTHER|TAU-group|The treatment as usual (TAU) group will serve as control group and will control for the natural course of postoperative pain under usual medication intake, following minimally invasive TLIF
62178449|NCT03159078|OTHER|Polymyxin B monotherapy|Intravenous piggyback with Polymyxin B and control(Normal saline)
62178450|NCT03159078|EXPERIMENTAL|Polymyxin B plus Carbapenem|Intravenous piggyback with Polymyxin B plus Carbapenem
62178451|NCT03769077|EXPERIMENTAL|Exergaming (Case) Group|"Participants assigned to the exergame condition will play the exergames for 30 minutes, 5 days a week for 3 weeks (15 exergame sessions). Outcomes will be acquired at baseline (before intervention), and at the end of every week during the 3 week intervention phase. Participants will also receive the current standard PT care at the Specialized Orthopedic and Developmental Rehab (SODR) inpatient unit at Holland Bloorview Kids Rehabilitation Hospital.~The research participants will be asked to complete the following self-report questionnaires: Patient Reported Outcome Measurement Information System Pediatric Pain Interference Scale (PROMIS-PI), the KIDSCREEN-27, Faces Pain Scale-Revised (FPS-R) and the Self-Reported Experiences of Activity Settings (SEAS)."
62391009|NCT04012866|EXPERIMENTAL|DUAL (dual training group)|The dual training group (DUAL) will receive aerobic exercise training and computerized cognitive training simultaneously. All participants will receive a training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
62770281|NCT02686320||Rheumatoid arthritis >65 years old|
62770282|NCT02686320||Rheumatoid arthritis <50 years old|
62770283|NCT01873248|EXPERIMENTAL|PET/CT with one-time administration of 68Ga-DOTATATE|Study participants will receive a one-time administration of 68Ga-DOTATATE and undergo a PET/CT imaging study. Scans will be performed with oral and IV contrast. The physicians of patient's receiving a 68Ga-DOTATATE PET/CT will be asked to fill out 2 questionnaires with questions pertaining to the patient's medical management. One questionnaire will be sent before the scan, and one shortly after the scan was performed and the results reported to the referring physician.
61994794|NCT04384757|ACTIVE_COMPARATOR|Open distal gastrectomy|An incision of 15\~20 cm length is made in the abdominal midline . Standard distal gastrectomy and omentectomy will be performed with D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, proper hepatic artery) . As a general rule, Billroth II method was used for gastric reconstruction for most cases
62178452|NCT03769077|NO_INTERVENTION|Comparison Group|"Participants will receive the current standard PT care at the Specialized Orthopedic and Developmental Rehab (SODR) inpatient unit at Holland Bloorview Kids Rehabilitation Hospital and will complete questionnaires and assessments at the same time points during study participation.~The research participants will be asked to complete the following self-report questionnaires: Patient Reported Outcome Measurement Information System Pediatric Pain Interference Scale (PROMIS-PI), the KIDSCREEN-27, Faces Pain Scale-Revised (FPS-R) and the Self-Reported Experiences of Activity Settings (SEAS)."
62562599|NCT01389050|NO_INTERVENTION|Follow-up|Data from these patients will be added to retrospectively gathered data from the PMH radiotherapy data bank (approximately 50 patients). The data collected will be analyzed using descriptive statistics.
62562600|NCT01389050|EXPERIMENTAL|Prospective|
62562601|NCT05469893|ACTIVE_COMPARATOR|Lenalidomide + Dexamethasone (LD)|"Each study treatment cycle lasts 28 days. Participants will be randomized into either Teclistamab arm or Lenalidomine + Dexamethoasone arm~* Lenalidomine~* Dexamethoasone"
62562602|NCT05469893|EXPERIMENTAL|Teclistamab|"Each study treatment cycle lasts 28 days. Participants will be randomized into either Teclistamab arm or Lenalidomine + Dexamethoasone arm~- Teclistamab-Per Protocol"
62562603|NCT00985504|EXPERIMENTAL|Duloxetine|
62178453|NCT03739697|ACTIVE_COMPARATOR|spontaneous breathing|spontaneous breathing after adminitration of anesthetics
62562604|NCT00985504|ACTIVE_COMPARATOR|Escitalopram|
62562605|NCT02174419|EXPERIMENTAL|nalbuphine HCl ER 90mg|nalbuphine HCl ER tablets 90 mg BID
62562606|NCT02174419|EXPERIMENTAL|nalbuphine HCl ER 180 mg|nalbuphine HCl ER tablets 180 mg BID
62562607|NCT02174419|PLACEBO_COMPARATOR|Sugar pill|Placebo tablets BID
62562608|NCT04341363|EXPERIMENTAL|Microneedling|Participants with androgenic alopecia will receive microneedling with a tattoo machine.
62562609|NCT01646372|ACTIVE_COMPARATOR|Control Group|This group gets a simulation based ACLS refresher as treatment, but no access to cognitive aids for any of the tests.
62770284|NCT05150210|EXPERIMENTAL|SP Surgical System|Pulmonary lobectomy and thymectomy procedures will be performed by da Vinci SP Surgical System.
62770285|NCT03805516|EXPERIMENTAL|Intervention|"1. . Daily use of a Fitbit Alta HRTM to identify behavior patterns.~2. 12 weekly SCOPP-CW educational modules delivered via WeChat.~3. 6 bi-weekly WeChat tailored messages based on based on the participant's tracker information, personal goals, and preferences"
62178454|NCT03739697|NO_INTERVENTION|mechanical ventilation|mechanical ventilation after adminitration of anesthetics and neuromuscula blockade
62178455|NCT04153422|EXPERIMENTAL|Treatment (IVIG)|Patients in the treatment arm will receive 2g/kg IVIG every 4 weeks (over 2 days, 1g/kg dose on Day 1 and 1g/kg dose on Day 2) for 24 weeks (6 doses total).
62178456|NCT04153422|PLACEBO_COMPARATOR|Placebo|Patients in the placebo arm will receive 0.9% NaCl infusions on the same schedule as the active treatment group (Day 1 and Day 2 every 4 weeks for 24 weeks total, (6 doses).
62178457|NCT03015597|EXPERIMENTAL|Contingency Management: smoking|"Contingency Management: smoking~Participants receive rewards contingent on biochemical verification of tobacco smoking abstinence"
62562610|NCT01646372|ACTIVE_COMPARATOR|2nd Control Group|This group receives a standard Simulation based ACLS refresher as the intervention, like the control group. No mention is made of Cognitive Aids in the teaching, but they are available during the post-test and retention post-test.
62562611|NCT01646372|EXPERIMENTAL|Cognitive Aid Group|This group receives Cognitive Aid based teaching as the intervention. They also have access to cognitive aids for post-test and retention post-test
62562612|NCT01808066|EXPERIMENTAL|Play Groundskeeper|This study will employ design-based research models (Laurel, 2003) to the executive-functioning training game GroundsKeeper by CogCubed; we will assess the quality of digital designs for learning (Barab \& Squire, 2004) using established qualitative data collection to analyze game play and player reaction over a three week period of time. We will assess the participants for their ability to stay engaged in play by observing their engagement in the game, time played, frequency of play, and the ability to complete a session over the course of three weeks while in school.
62562613|NCT03837054|OTHER|Breast cancer patients with external polychemotherapy|
62562614|NCT01294176|ACTIVE_COMPARATOR|Oral Lipoic Acid|Lipoic acid is a natural antioxidant available as an oral dietary supplement. A higher than average dose of 1200mg will be administered in this trial.
62562615|NCT01294176|PLACEBO_COMPARATOR|Avicel™|The placebo is Avicel™ (microcellulose crystal) and 4.3 mg quercetin (a bioflavanoid).
62562616|NCT03517540|EXPERIMENTAL|Arm A: Tropifexor (LJN452) - Dose 1|tropifexor 140 mcg, once daily; given orally
62562617|NCT03517540|EXPERIMENTAL|Arm B: Cenicriviroc (CVC)|CVC 150 mg, once daily; given orally
62562618|NCT03517540|EXPERIMENTAL|Arm C: Tropifexor (LJN452) Dose 1 + CVC|tropifexor 140 mcg + CVC 150 mg, once daily; given orally
62562619|NCT03517540|EXPERIMENTAL|Arm D: Tropifexor Dose 2 + CVC|tropifexor 90 mcg + CVC 150 mg, once daily; given orally
62562620|NCT01052480|EXPERIMENTAL|Plasma and Standard Care|Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies (Anti-Influenza Immune Plasma) in addition to standard care.
62562621|NCT01052480|ACTIVE_COMPARATOR|Standard Care|Participants will receive standard care.
62770286|NCT03805516|ACTIVE_COMPARATOR|Control|"1. . Daily use of a Fitbit Alta HRTM to identify behavior patterns.~2. 12 weekly non-tailored educational modules on general health topics delivered via WeChat."
62562622|NCT04517409|EXPERIMENTAL|GDHT|After hepatic resection (Dynamic phase), the patients received an initial hemodynamic assessment based on PPV, CI and MAP. First, preload was optimized by fluid loading until PPV was \<14% or VVS \<12%, subjects were given 4 ml kg-1 boluses colloid solution every 5 minutes. At this point, the patient's individual preload optimized CI was determined and used as the hemodynamic goal until the end of surgery. Only if this value was below 2.5 L/min/(m2), inotropes were applied to reach this minimum CI, serving as a safety parameter to prevent patients from low cardiac output. If PPV and CI were within the target range but MAP was below 65 mmHg or PPV/VVS\>1,2, vasopressors were started. After the initial assessment, patients were reassessed every 15 minutes intraoperatively to maintain values.
62770287|NCT01884415|EXPERIMENTAL|Second HBV vaccination cycle|Second cycle of HBV vaccination (0, 1 and 2 months)will be administered. Three intramuscular doses of 40 µg.
62562623|NCT04517409|OTHER|Control|"Before hepatic resection (Static phase) all patiens received continuous infusion of balanced crystalloid with the goal of CVP of 5 mmHg.~After hepatic resection (Dynamic phase), the patiens received colloid solution, vasopressors, and inotropes at the discretion of the anaesthetist, acording to CVP, MAP and orine output. In this group, CO monitoring was not performed. Intraoperative treatment goals in the control arm were flexible to avoid both extremes of clinical practice and practice misalignment"
62562624|NCT05928065||Children with low kinetic, non-deforming, non-open long bone trauma|"Children with low kinetic, non-deforming, non-open long bone trauma will be included.~Collection of datas of medical record."
62770288|NCT01884415|ACTIVE_COMPARATOR|Single dose of HBV vaccine|Single dose (40µg) of HBV vaccine will be administered at 6 months after 1 cycle of HBV vaccination
62770289|NCT06335355|EXPERIMENTAL|Treatment group A|
62770290|NCT06335355|ACTIVE_COMPARATOR|Treatment group B|
62770291|NCT06335355|ACTIVE_COMPARATOR|Treatment group C|
62562625|NCT03200990|EXPERIMENTAL|iVAC2L pVAD|Clinically indicated ventricular support for high-risk PCI with Pulsecath iVAC2L.
62770292|NCT05592132|EXPERIMENTAL|Intervention|Patients randomized in this arm will have the virtual reality headset associated to the standard care
62770293|NCT05592132|NO_INTERVENTION|Standard care|patients randomized in this arm will have standard care.
62178458|NCT03015597|PLACEBO_COMPARATOR|Contingency Management: attendance|"Contingency Management: attendance~Participants receive rewards contingent on attending the stop smoking clinic (independent of smoking status)"
62178459|NCT01585818|ACTIVE_COMPARATOR|standard dietary intervention (SDI) arm|The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre
62391010|NCT04012866|ACTIVE_COMPARATOR|CI (control intervention group)|The control intervention group (CI) will receive a control training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
62562626|NCT03949218||bipolar disorder(BD)|hospitalized patients BD patients in SMHC from 2009 to 2018; meet ICD-10 diagnosis of F31 bipolar disorder criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; hospitalized patients need to the first admission; age and gender is not limited
62770294|NCT02294331||Attain Performa™ LV Leads|Patients who meet all Inclusion criteria and no Exclusion criteria and are implanted with an Attain Performa™ LV lead.
62770295|NCT04754230|EXPERIMENTAL|1,000mg IV Tranexamic acid|Participants in this arm will be given a 1,000mg dose of intravenous tranexamic acid via saline infusion 15 minutes prior to the completion of surgery. They will keep a bleeding diary with daily entries each day until their first routine scheduled postoperative follow-up clinic visit one week after surgery.
62770296|NCT04754230|NO_INTERVENTION|Normal saline|Participants in this arm will not be given any extra intervention over their routine anesthetic care. They will continue to receive their normal saline infusion during surgery. They will keep a bleeding diary with daily entries each day until their first routine scheduled postoperative follow-up clinic visit one week after surgery.
62770297|NCT02419170|EXPERIMENTAL|Surgery/Apheresis/Cyclophosphamide/Vaccine|"* Standard of care surgery~* Apheresis (between Day -28 and Day -7) approximately 12 weeks after surgery~* Cyclophosphamide 300 mg/m\^2 intravenously (Day -4)~* Personalized vaccine (Day 1)~* Booster dose of personalized vaccine (Day 43)~* Booster dose of personalized vaccine (Day 85)"
62391011|NCT03301272|EXPERIMENTAL|Onabotulinumtoxin A Injection, then Placebo|Participants first receive Onabotulinumtoxin A Injection and following a 3-month washout, they receive Placebo
62391012|NCT03301272|EXPERIMENTAL|Placebo, then Onabotulinumtoxin A Injection|Participants first receive placebo injection and following a 3-month washout, they receive Onabotulinumtoxin A Injection.
62391013|NCT03822390||Patients|Patients older than 18 years undergoing colonoscopy in one the participating centres.
62391014|NCT04467216|EXPERIMENTAL|Intervention group|This arm will undertake VR simultaneous motor-cognitive training in 30 minutes session, twice a week for 8 weeks
62770298|NCT03877653|EXPERIMENTAL|Interventional|Single arm, active stimulation
62770299|NCT03877653|PLACEBO_COMPARATOR|Placebo|"When receiving sham stimulation, devices will be programmed to not actively deliver electrical stimulation but still deplete battery life to maintain blinding. Subjects will have to recharge batteries similar to receiving active stimulation.~Sites will not have access to WaveCrest programmer. Study devices can only be programmed by Stimwave representatives."
62770300|NCT00636051||1|staff Registered Nurses receiving EBP peer mentoring
62770301|NCT00636051||2|staff Registered Nurses not receiving EBP peer mentoring
62770302|NCT01447303||Outcomes following viscosupplemantation|Patients with documented knee osteoarthritis receiving viscosupplementation of the knee.
62770303|NCT04273022|EXPERIMENTAL|SCT Group|Fifteen SCT subjects will be recruited, consented, screened, and enrolled if they meet inclusion and exclusion criteria. Each subject will undergo a single bout of standardized exercise on a treadmill. Subjects will self-select treadmill speed at 0% grade and begin. After 3 minutes the grade will be increased by 1% every 2 minutes until the target heart rate (70% of heart rate reserve) is reached. Speed and grade will be held constant for 15 minutes, marking the end of the session.
62770304|NCT04273022|ACTIVE_COMPARATOR|Control Group|Five healthy subjects will be recruited, consented, screened, and enrolled if they meet inclusion and exclusion criteria. Each subject will undergo a single bout of standardized exercise on a treadmill. Subjects will self-select treadmill speed at 0% grade and begin. After 3 minutes the grade will be increased by 1% every 2 minutes until the target heart rate (70% of heart rate reserve) is reached. Speed and grade will be held constant for 15 minutes, marking the end of the session.
62770305|NCT05879575|EXPERIMENTAL|intervention group|receive weight training during 16-36 gestational weeks and observe pain condition
62770306|NCT05879575|NO_INTERVENTION|control group|observe pain condition
62562627|NCT03949218||major depressive disorder（MDD）|hospitalized patients MDD patients in SMHC from 2009 to 2018; meet ICD-10 diagnosis of F32 depressive disorder criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; hospitalized patients need to the first admission; age and gender is not limited
62562628|NCT03350282|EXPERIMENTAL|Mixture GAA-creatine|Mixture of guanidinoacetic acid and creatine monohydrate
62178460|NCT01585818|EXPERIMENTAL|LGI intervention arm|The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI. Participants will be provided with a list of low GI carbohydrates to consume during the intervention period and in addition, they will be provided with a supply of the staples for the same period
62178461|NCT01054365||Delayed Discharge Group (DDG)|D/C at least 24 hours after procedure or at usual discharge time (n =200)
62562629|NCT03350282|ACTIVE_COMPARATOR|Creatine|Creatine monohydrate
62562630|NCT00279435|PLACEBO_COMPARATOR|placebo|
62562631|NCT00279435|EXPERIMENTAL|visilizumab|
62562632|NCT02689154|EXPERIMENTAL|W8Loss2Go App|Subjects will complete all stages of W8Loss2Go mHealth intervention.
62567762|NCT00359424|EXPERIMENTAL|Endovascular therapy|Group two will receive a lower dose or a standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose (based on the location and extent of the blood clot) a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery.
62567763|NCT04961385||ChAd0x1 nCoV-19 vaccinees|Participants who received first dose of ChAdox-1 n COV-19 were recruited. Participants were eligible if they were more than 18 years old
62770307|NCT03412604|EXPERIMENTAL|tACS|Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 20 sessions on consecutive weekdays. The tACS intervention (20 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and MRI and cognitive function.
62770308|NCT04547361|EXPERIMENTAL|Cohort 1: Dose 1 E2511 or Placebo|Participants will receive Dose 1 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
62770309|NCT04547361|EXPERIMENTAL|Cohort 2: Dose 2 E2511 or Placebo|Participants will receive Dose 2 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
62770310|NCT04547361|EXPERIMENTAL|Cohort 3: Dose 3 E2511 or Placebo|Participants will receive Dose 3 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 (Treatment Period 1) under fasted condition followed by Dose 3 of E2511 or E2511 matched placebo, tablets, orally, once on Day 7 (Treatment Period 2) under fed condition. A washout period of 6 days will be maintained between the doses.
62770311|NCT04547361|EXPERIMENTAL|Cohort 4: Dose 4 E2511 or Placebo|Participants will receive Dose 4 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
62770312|NCT04547361|EXPERIMENTAL|Cohort 5: Dose 5 E2511 or Placebo|Participants will receive Dose 5 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
62770313|NCT04547361|EXPERIMENTAL|Cohort 6: Dose 6 E2511 or Placebo|Participants will receive Dose 6 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
62770314|NCT04547361|EXPERIMENTAL|Cohort 7: Dose 3 E2511 (Elderly Participants) or Placebo|Elderly participants will receive Dose 3 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
62770315|NCT05920408|EXPERIMENTAL|EXS21546|EXS21546 Granule in Capsule for oral administration
62770316|NCT02603445|EXPERIMENTAL|Follicular lymphoma (FL)|
62770317|NCT02603445|EXPERIMENTAL|Mantle cell lymphoma (MCL)|
62770318|NCT01423474|EXPERIMENTAL|Short treatment time (11 days)|
62770319|NCT01423474|EXPERIMENTAL|Long treatment time (29 days)|
62770320|NCT00434356|EXPERIMENTAL|1|
62770321|NCT00434356|PLACEBO_COMPARATOR|2|
62770322|NCT02925741|EXPERIMENTAL|Silk-Like Linens|Patients in the experimental arm will be cared for on silk-like bed linens.
62770323|NCT02925741|NO_INTERVENTION|Standard Cotton Linens|Patients in the standard of care arm will be cared for on standard cotton bed linens.
62770324|NCT00387647|EXPERIMENTAL|Azacitidine Treatment|Azacitidine 50 mg/m\^2 subcutaneously daily for 5 days (Monday through Friday) on days 1 through 5, every 28 days for 6-12 cycles.
62567764|NCT04501887||Matched therapy|Molecular profiling performed with actionable molecular alterations detected and target therapy was then conducted
62567765|NCT04501887||Unmatched therapy|Molecular profiling performed with actionable molecular alterations detected but therapy was conducted based on the guideline treatment
62770325|NCT03832608||Older adults and Sarcopenia|Older adults with and without Sarcopenia living in Valencia Province.
62770326|NCT03888118|EXPERIMENTAL|Study Group|A four-week rehabilitation program (Monday to Friday) involving the hour of individual ankle therapy and one hour therapy on the Luna EMG device.
62770327|NCT03888118|NO_INTERVENTION|Control group|A four-week rehabilitation program (Monday to Friday) involving two hours of individual ankle therapy.
62770328|NCT00864851|ACTIVE_COMPARATOR|Replagal 0.2 mg/kg, IV, every other week|Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every other week for 52 weeks.
62770329|NCT00864851|ACTIVE_COMPARATOR|Replagal 0.2 mg/kg, IV, weekly|Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every week for 52 weeks.
62770330|NCT00864851|ACTIVE_COMPARATOR|Replagal 0.4 mg/kg, IV, weekly|Patients randomized to receive Replagal 0.4 mg/kg via intravenous infusion every week for 52 weeks.
62770331|NCT04294771||Myocarditis and other cardiovascular toxicities ICI-related|Case reported in the World Health Organization (WHO)international pharmacovigilance database, or APHP Entrepot de Données de Santé (EDS) and French Système National Des Données de Santé (SNDS) Databases, with a chronology compatible with the drug toxicity
62567766|NCT04501887||No marker|Molecular profiling performed without any actionable molecular alterations detected, tranditional therapy based on the guideline was then conducted
62770332|NCT04294771||Non case|Non-case will be patients exposed to ICI without cardiovascular toxicities
62770333|NCT04302064|EXPERIMENTAL|Eplontersen|Single dose on Day 1 or multiple doses (every 4 weeks for 12 weeks) of Eplontersen administered SC.
62770334|NCT04302064|PLACEBO_COMPARATOR|Placebo|Single dose on Day 1 or multiple doses (every 4 weeks for 12 weeks) of Eplontersen-matching placebo administered SC.
62770335|NCT03580928|EXPERIMENTAL|Acalabrutinib/Venetoclax/Obinutuzumab|"* Acalabrutinib will be administered orally twice daily at 100 mg bid~* Venetoclax will be administered orally once daily, with dose ramp-up from 20 mg up to a final dose of 400 mg~* Obinutuzumab will be administered as per standard of care for 6 months with dosing at 100 mg on cycle 1 day 1, 900 mg on cycle 1 day 2, and then 1,000 mg on cycle 1 days 8, 15, and day 1 of cycles 2-6"
62770336|NCT02247180|EXPERIMENTAL|Cognitive Rehabilitation|cognitive rehabilitation for 12 weeks
62770337|NCT02247180|ACTIVE_COMPARATOR|Cognitive Training|standardized cognitive training in the domesticity
62770338|NCT04298424|EXPERIMENTAL|Peer-led|The experimental group will conduct a 4-week peer self-management program and receive the original outpatient routine care.
62770339|NCT04298424|NO_INTERVENTION|No Peer-led|The control group will only issue a self-management manual and receive the original outpatient routine care.
62178462|NCT01054365||Early Discharge Group (EDG)|D/C 6 hours after procedure if no indication for extended stay after randomization (n=200)
62567767|NCT01472692|ACTIVE_COMPARATOR|Febuxostat|
62391015|NCT04467216|NO_INTERVENTION|Control Group|This arm will be doing existing forms of motor-cognitive training in 30 minutes session, twice a week for 8 weeks
62391016|NCT00144417|ACTIVE_COMPARATOR|HRZE|isoniazid, rifampin, pyrazinamide, ethambutol, moxifloxacin-placebo
62391017|NCT00144417|EXPERIMENTAL|MRZE|moxifloxacin, rifampin, pyrazinamide, ethambutol, isoniazid-placebo
62567768|NCT01472692|PLACEBO_COMPARATOR|Placebo|
62567769|NCT01697748|PLACEBO_COMPARATOR|Telfa pad dressing|Telfa pad dressing placed over Cesarean wound after skin closure; the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
62770340|NCT06459882|EXPERIMENTAL|progressive relaxation exercises|Patients in the intervention group received 30-minute progressive relaxation exercises for 6 weeks.
62178463|NCT01269255|EXPERIMENTAL|Combination group|
62178464|NCT05277818||Patient with medical device DIVA®|Adult patient, operated for at least 12 months, having had surgery for a degenerative or traumatic mono-segmental lumbar disc herniation, without any other associated pathology, operated with DIVA® implant
62178465|NCT05277818||Patient without medical device DIVA®|Adult patient, operated for at least 12 months, having had surgery for a degenerative or traumatic mono-segmental lumbar disc herniation, without any other associated pathology, operated without DIVA® implant
62391018|NCT00987909|PLACEBO_COMPARATOR|Placebo|Solution resembling the active solutions, but without allergen extract
62391019|NCT00987909|EXPERIMENTAL|Cat hair allergen extract, dose group 1|
62391020|NCT00987909|EXPERIMENTAL|Cat hair allergen extract, dose group 2|
62391021|NCT00987909|EXPERIMENTAL|Cat hair allergen extract, dose group 3|
62391022|NCT01851434||healthy volunteers|age- and sex-matched to the participants with unilateral optic neuritis and a brain MRI suggestive of MS
62770341|NCT06459882|NO_INTERVENTION|control|Patients in the control group did not receive any intervention other than standard care practices.
62770342|NCT01137019|ACTIVE_COMPARATOR|Biolimus-eluting stent|
62770343|NCT01137019|ACTIVE_COMPARATOR|Everolimus-eluting stent|
62770344|NCT05660447|EXPERIMENTAL|Netarsudil 0.02%|For the study arm: one drop of rho-kinase (ROCK) inhibitor in the vitrectomized eye, once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
62770345|NCT05660447|PLACEBO_COMPARATOR|Artificial tears|Patients enrolled in the control group will receive a placebo (one drop of artificial tears) once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
62770346|NCT01716104|EXPERIMENTAL|Afalaza (2 tablets twice a day)|
62770347|NCT01716104|PLACEBO_COMPARATOR|Placebo (2 tablets twice a day)|
62770348|NCT04867694|NO_INTERVENTION|Control|The control group receiving the standards of care and the usual activities of the partners without additional support from the IRAM project for the implementation of the PASIM. This includes the usual Community Management of Acute Malnutrition (CMAM) program. This group will also continue to benefit from the BCC and screening services already existing in their areas.
62770349|NCT04867694|EXPERIMENTAL|Intervention|"The PASIM is delivered by the care groups. Each beneficiary is visited at home at least once a month (up to once a week if possible).~The package of activities includes :~Behavior change communication (all children in care groups)~Monthly delivery of a nutritional supplement: limited to \[6-11\] months old children diagnosed as non-wasted (green MUAC) or for \[6-59\] months old for 6 months after discharge from the national CMAM program.~Monthly delivery of a water purification input: limited to households with \[6-11\] months old children or with \[6-59\] months old children under CMAM treatment and for 6 months after discharge.~Delivery of micronutrient powders to \[12-23\] months old children.~Screening and referral for \[6-59\] months old children, formative supervision of MUAC measurement in families."
62770350|NCT03052140|OTHER|Treatment A, followed by Treatment B|Treatment group that will receive Treatment A for 14 days, followed by Treatment B for 14 days. There will be a minimum 7 day washout between Treatments. Lamelleye Dry Eye Drops and Optive Plus will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
62770351|NCT03052140|OTHER|Treatment B, followed by Treatment A|Treatment group that will receive Treatment B for 14 days, followed by Treatment A for 14 days. There will be a minimum 7 day washout between Treatments. Lamelleye Dry Eye Drops and Optive Plus will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
62770352|NCT04439994|ACTIVE_COMPARATOR|Hypertonic saline|Each participant will be given i.d. in 0.1 mL volumes of a hypertonic saline solution. The subject will be blinded to the hypertonic/isotonic administration.
62770353|NCT04439994|PLACEBO_COMPARATOR|Isotonic Saline|Each participant will be given i.d. in 0.1 mL volumes of a isotonic saline solution. The subject will be blinded to the hypertonic/isotonic administration.
62770354|NCT02495493|EXPERIMENTAL|Induction DCS chemotherapy|"1. Induction chemotherapy -- S-1 35mg/m2 bid day 1-14~   * Docetaxel 30 mg/m2 day1, 8~  * Cisplatin 30 mg/m2 day1, 8~2. Chemoradiotherapy : S-1 20 mg/m2 bid (Day 1-14, 21-28) cisplatin (30 mg/m2/day, Day 1,8, 21,28), Radiotherapy 45 Gy"
62770355|NCT03966131|EXPERIMENTAL|patients with complete denture for the first time|Arm that allows to follow the adaptation of this population to the new complete denture during the tasks of speech production and swallowing.
62770356|NCT03966131|EXPERIMENTAL|patients with complete denture used to their complete denture.|Arm that allows a descriptive cross-sectional study of tongue pressure measurements during the tasks of speech production and swallowing
62770357|NCT02484924||Clopidogrel Group|Those patients treated with clopidogrel for ACS (before new guideline implementation)
62770358|NCT02484924||Ticagrelor Group|Those patients treated with ticagrelor for ACS (after new guideline implementation)
62770359|NCT04729231|ACTIVE_COMPARATOR|Nasalis Sling Flap|
62770360|NCT04729231|ACTIVE_COMPARATOR|Lobed transposition flap|
62770361|NCT01415804|ACTIVE_COMPARATOR|stentgraft|Stentgraft
62770362|NCT01415804|NO_INTERVENTION|Medical management|Antihypertensive medication
62770363|NCT05135962|ACTIVE_COMPARATOR|RME (rapid expansion)|"Intervention orthodontic - maxillary expansion:~maxillary expansion with RME expander anchored on second deciduous molars. Activation: 1/turn day. RME was kept on teeth as a passive retainer and removed after one year from its application."
62770364|NCT05135962|EXPERIMENTAL|Leaf expander 450g (slow expansion)|Intervention orthodontic - maxillary expansion: maxillary expansion with Leaf Expander appliance anchored on second deciduous molars Activation: The leaves are preactivated in the laboratory to deliver 3mm of expansion. Reactivation is performed in the office by 10 quarter-turns of the screw per month until expansion has been completed. After active expansion, the Leaf Expander was kept on teeth as a passive retainer and removed after one year from its application.
62770365|NCT05135962|EXPERIMENTAL|Leaf self-expander 450g (slow expansion)|"Intervention orthodontic - maxillary expansion: maxillary expansion with Leaf self Expander appliance anchored on second deciduous molars.~Activation: self activation (preactivated). After active expansion the Leaf self expander was kept on teeth as a passive retainer and removed after one year from its application"
62178466|NCT06479486|OTHER|Functionality Assessment|Each participant will be provided with an informed consent form detailing the purpose of the study. After obtaining written consent, baseline data will be collected, including demographic information, medical history, and any pre-existing conditions.The participants will then undergo the post-laparotomy interventions as described. Throughout the intervention period, data will be collected using the tools mentioned: 6 minute Walk Test, 30 seconds sit to stand test, 2 Minute walk Test, and Timed Up and GO to determine any changes in their functionality test .For reliability, test retest will be conducted both on day 1 and on the next day.
62178467|NCT04815785|EXPERIMENTAL|A single set of test|The experimental apparatus consisted of artificial aortic valve, transporter and loading system
62178468|NCT01759238|EXPERIMENTAL|Chemoradiation|Chemoradiation with different radiotherapy regimes (depending on location and size of irradiated lesions; e.g. conventional radiotherapy with a total dose of 35 Gy, delivered in 2.5Gy fractions for 14 days or intensity-modulated and image-guided radiotherapy with a total dose of 40 Gy, delivered in 4.0 Gy fractions for 10 days or 3-8 fractions with 8-15 Gy) combined with bevacizumab (7.5mg/kg day 1) and capecitabine (825mg/m2 bid on day 1-5, 8-12 and 15-19)
62178469|NCT04815473|OTHER|Patients treated with AndraValvulotome|
62178470|NCT06544967||Male fetuses between 18 to 36 weeks|Ultrasound biometry
62178471|NCT06544967||Female fetuses between 18 to 36 weeks|Ultrasound biometry
62770366|NCT05135962|EXPERIMENTAL|Leaf expander 900g (slow expansion)|"Intervention orthodontic - maxillary expansion: maxillary expansion with Leaf Leaf Expander appliance anchored on second deciduous molars.~Activation: The leaves are preactivated in the laboratory to deliver 3mm of expansion. Reactivation is performed in the office by 15 quarter-turns of the screw per month until expansion has been completed. After active expansion the Leaf Expander was kept on teeth as a passive retainer and removed after one year from its application."
62770367|NCT05135962|EXPERIMENTAL|Leaf self-expander 900g (slow expansion)|"Intervention orthodontic - maxillary expansion: maxillary expansion with Leaf self Expander appliance anchored on second deciduous molars.~Activation: self activation (preactivated). After active expansion the Leaf self expander was kept on teeth as a passive retainer and removed after one year from its application"
62770368|NCT02212678|EXPERIMENTAL|N-acetylcysteine|Subjects will be provided 6000 mg/day of N-acetylcysteine (capsule) to be divided into 2 equal daily doses and taken orally for approximately 28 days
62770369|NCT06508242|ACTIVE_COMPARATOR|Vitamin D intervention group|50.000 IU of oral cholecalciferol/week
62178472|NCT06541340|ACTIVE_COMPARATOR|Traditional strategy|Traditional preoperative biliary drainage strategy with total bilirubin as the main indicator
62770370|NCT06508242|PLACEBO_COMPARATOR|Placebo group|Placebo treatment/week
62770371|NCT01875042|EXPERIMENTAL|TENS|Transcutaneous Electrical Nerve Stimulation
62770372|NCT01875042|SHAM_COMPARATOR|Sham TENS|Sham Transcutaneous Electrical Nerve Stimulation
62770373|NCT03829956|OTHER|Snoring and mild OSA|This cohort of participants has been diagnosed with primary snoring or mild obstruction sleep apnoea. A medical device (intra-oral tongue stimulation device) will be introduced for 6 weeks and the effects will be assessed by comparing the outcome measures before and after the intervention.
62770374|NCT00554658|ACTIVE_COMPARATOR|A|Patients will be taken quetiapine for the treatment of first episode schizophrenia.
62770375|NCT02408809|ACTIVE_COMPARATOR|Control|
62770376|NCT02408809|ACTIVE_COMPARATOR|Intervention|
62770377|NCT01462877|OTHER|Fenofibrate arm|
62770378|NCT00447473|OTHER|A|GM-CSF given in combination with ketoconazole and mitoxantrone in patients with progressive prostate cancer despite androgen deprivation and prior taxane containing chemotherapy
62770379|NCT02896270|EXPERIMENTAL|single arm|"Patients will start study treatment on Day1 and will be treated with a dose of 250mg twice daily of the valproic acid slow release formulation (Depakine Chrono© - Sanofi Pharma Belgium).~Control of valproic acid serum levels after 4 to 7 days. The dose will be progressively increased targeting valproic acid serum levels in the target range for use of the drug as an anti-epileptic (50-100µg/ml).~During the study, visits will be performed every month and at the end of treatment. The duration of the study is 12 months. Continuation of valproic acid after completion of the study will be at the investigators discretion."
62178473|NCT06541340|EXPERIMENTAL|Modified strategy|Modified preoperative biliary drainage strategy with prealbumin as the main indicator
62178474|NCT00826436||8 subjects for Cohort 1|
62770380|NCT02920515|EXPERIMENTAL|GnRHa(Triptorlin or Leuprorelin)|Triptorlin or Leuprelin 100ug/kg per 28 days
62770381|NCT02920515|ACTIVE_COMPARATOR|Traditional Chinese Medicines|Zhibo dihuang pills: 8 tablets twice a day by mouth for 6 months and Dabu ying pills: 6g twice a day by mouth for 6 months
62178475|NCT00826436||8 subjects for Cohort 2|
62178476|NCT00634426||1|De novo surgical cohort
62178477|NCT00634426||2|Nonoperative treatment cohort
62178478|NCT00634426||3|Secondary surgical treatment cohort
62178479|NCT01484314|EXPERIMENTAL|Migration Arm|Administration of eltrombopag to support platelets during chemotherapy
62178480|NCT01498783|EXPERIMENTAL|Treatment|"Participants meeting the eligibility requirements.~Intervention: 5-fluorouracil"
62770382|NCT02920515|NO_INTERVENTION|blank group|without therapy
62770383|NCT01435837|EXPERIMENTAL|Caffeine and hydration.|"200 mg of caffeine (over the counter caffeine tablet)~1 liter of water"
62770384|NCT01435837|PLACEBO_COMPARATOR|No caffeine, no hydration.|
62770385|NCT03281889|EXPERIMENTAL|Proton Radiotherapy|"* Patients will be treated with Proton Beam once daily 5 days per week.~* Doses will be prescribed such that maximum possible coverage is achieved"
62770386|NCT03472690|EXPERIMENTAL|Active|0.1 mL, self-administered subcutaneous injection, every second day
62770387|NCT03472690|PLACEBO_COMPARATOR|Placebo|0.1 mL, self-administered subcutaneous injection, every second day
62770388|NCT04980365|EXPERIMENTAL|Mindfulness|Participants will be asked to use the app Mindfulness Coach 10 minutes for 14 days.
62770389|NCT04980365|EXPERIMENTAL|Gratitude|Participants will be asked to use the app Grateful 10 minutes for 14 days.
62770390|NCT04980365|ACTIVE_COMPARATOR|Control|Participants will be asked to use the app Day One daily for 10 minutes. Participants will be writing a daily journal entry describing what they ate during the previous day for 14 days.
62770391|NCT05920772|EXPERIMENTAL|Intervention group|A smoking initiation prevention intervention (called KickAsh! intervention) will be implemented in 12 youth social work organisations offering sport and/or recreational activities, during a period of three months (October 2023 to December 2023).Youth workers will act as implementers of the intervention. Approximately 5 youth workers per organisation will participate in the study. Adolescents participating in the youth social work organisations will receive the intervention. Approximately 25 adolescents per organisation will participate in the study.
62770392|NCT05920772|NO_INTERVENTION|Control group|12 other youth social work organisations offering sport and/or recreational activities will be allocated to the control group. This group will not receive the KickAsh! intervention. Approximately 5 youth workers per organisation will participate in the study. Approximately 25 adolescents per organisation will participate in the study.
62770393|NCT03119389|EXPERIMENTAL|Donning Non-Sterile Gloves without HH|In this arm, entire units will be assigned education that hand hygiene before donning non-sterile gloves is NOT necessary. For Aim A, observations will be made on compliance at entry and exit with hand hygiene and glove use. For Aim B, samples will be obtained from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
62770394|NCT03119389|NO_INTERVENTION|HH before donning Non-Sterile Gloves|In this arm, entire units will be assigned education that hand hygiene before donning non-sterile gloves IS necessary. For Aim A, observations will be made on compliance at entry and exit with hand hygiene and glove use. For Aim B, samples will be obtained from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
62770395|NCT01120795|EXPERIMENTAL|pegylated interferon and ribavirin|Anti hepatitis C agents
62770396|NCT06237556|PLACEBO_COMPARATOR|Control group|Patients in the control group will receive placebo.
62770397|NCT06237556|EXPERIMENTAL|Melatonin group|Three days before the operation patients will receive 5 mg of melatonin (Melatonin, Nature Made, Canada, and USA) one hour before assigned sleep time until the time of discharge from hospital.
62770398|NCT00787215||no treatment|observational: no treatment involved
62770399|NCT02299076|OTHER|Usual care with minimal incentives|Participants in this arm receive usual care from the Pro-Change smoking cessation program, and receive compensation for enrolling and completing a survey at the end of the study.
62770400|NCT02299076|ACTIVE_COMPARATOR|Usual care with BE incentives|Participants in this arm receive usual care from the Pro-Change smoking cessation program, the chance to win money based on their behavior (behavioral economics incentives), and receive compensation for enrolling and completing a survey at the end of the study.
62770401|NCT04358159|EXPERIMENTAL|Ventralex|Repair with Ventralex patch in sublay position
62770402|NCT04358159|ACTIVE_COMPARATOR|Progrip|Repair with Progrip in Onlay position
62770403|NCT02633553|EXPERIMENTAL|radiotherapy group|complete resection and adjuvant radiotherapy
62770404|NCT02633553|NO_INTERVENTION|observation group|complete resection
62178481|NCT02661503|ACTIVE_COMPARATOR|BEACOPP|4 or 6 cycles of BEACOPP (21-day cycles) Bleomycin (B) Etoposide (E) Doxorubicin (A) Cyclophosphamide (C) Vincristine (O) Procarbazin (P) Prednisone (P). If FDG-PET is negative after two cycles patients will be given a total of four cycles. If FDG-PET is positive after two cycles patients will bev given a total of six cycles.
62178482|NCT02661503|EXPERIMENTAL|BRECADD|4 or 6 cycles of BRECADD (21.day cycles) Brentuximab Vedotin (BR) Etoposide (E) Cyclophosphamide (C) Doxorubicin (A) Dacarbazine (D) Dexamethasone (D). If FDG-PET is negative after two cycles patients will be given a total of four cycles. If FDG-PET is positive after two cycles patients will be given a total of six cycles.
62178483|NCT03378778||Less than 33% Tooth Structure remaining|Root canal treatment followed by CAD CAM restoration
62770405|NCT05529004|EXPERIMENTAL|Preoperative pregabalin to prevent postoperative nausea & vomiting in laparoscopic surgery.|participants receive pregapalin 75mg cap orally 30 min before surgery
62770406|NCT05529004|NO_INTERVENTION|placebo|participants hasn't receive pregapalin capsule
62178484|NCT03378778||33%-50% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
62178485|NCT03378778||50% -66% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
62770407|NCT01778920|EXPERIMENTAL|IV Injection of EC17|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
62770408|NCT03079726||Frail individuals (case)|Individuals classified as frail based on several clinical metrics
62770409|NCT03079726||Non-frail individuals|Individuals failing to meet criteria for frailty based on clinical metrics
62770410|NCT01969721|EXPERIMENTAL|T+O FDC dosage 1|Low dose
62770411|NCT01969721|EXPERIMENTAL|T+O FDC dosage 2|High dose
62770412|NCT01969721|ACTIVE_COMPARATOR|ICS/LABA FDC Dosage 1|Low dose
62770413|NCT01969721|ACTIVE_COMPARATOR|ICS/LABA FDC Dosage 2|High dose
62770414|NCT02349490|ACTIVE_COMPARATOR|Group A first line therapy|In group A, Seraseal is applied as initial method for hemostasis. If successful, the bleeding site isthen observed for 5 minutes. If bleeding remains active or recurs the institutional standard of care for hemostasis is applied.
62770415|NCT02349490|ACTIVE_COMPARATOR|Group B rescue therapy|In group B, Seraseal is applied as rescue therapy after an initial failure of the institutional standard method. If Seraseal was successful, the bleeding site was then observed for 5 minutes. If the bleeding remains active or recurs after Seraseal, alternative methods of hemostasis would be applied.
62178486|NCT03378778||More than 66% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
62178487|NCT06017336|EXPERIMENTAL|Inspiratory Muscle Training Group|Patients in the training group will be performed inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure.
62178488|NCT06017336|SHAM_COMPARATOR|Control Group|Control group will be given breathing exercises as a home program for 8 weeks.
62178489|NCT02975297|EXPERIMENTAL|Exenatide plus NRT plus counseling|Once weekly exenatide Injectable Product, Nicotine Replacement Therapy (NRT) Patch, smoking cessation counseling
62178490|NCT02975297|PLACEBO_COMPARATOR|Placebo plus NRT plus counseling|Once weekly placebo, Nicotine Replacement Therapy (NRT) Patch, smoking cessation counseling
62770416|NCT03016923|EXPERIMENTAL|FES Therapy|FES therapy will be administered over the course of 1 hour sessions that will be take place 3 times per week over 16 weeks, for a total of 48 sessions.
62770417|NCT05568550|EXPERIMENTAL|Arm 1 - Pembrolizumab and Olaparib|Patients with high-risk prostate cancer receiving combination therapy with Pembrolizumab and Olaparib.
62770418|NCT05568550|EXPERIMENTAL|Arm 2 - Pembrolizumab|Patients with high-risk prostate cancer receiving combination therapy with Pembrolizumab.
62770419|NCT03002311|NO_INTERVENTION|Control|Receiving current standard of care as designated by emergency department (ED) standard operating practice.
62770420|NCT03002311|EXPERIMENTAL|Epharmix/CareSignal eHealth Intervention|After randomization, participants receive text reminders to have a follow-up visit. The participant can respond to these messages via numerical or binary answers (Y/N).
62770421|NCT00140842||Obese girls|The inclusion criteria will be girls 12-18 years of age. According to the Centers for Disease Control and Prevention, the definition of obesity is a BMI higher than the 95th percentile for age and sex, and that of overweight is a BMI between the 85th and 95th percentiles. Cases will be defined as having a body mass index (BMI) greater than the 95th percentile for age according to the 2000 Centers for Disease Control and Prevention growth charts.
62770422|NCT00140842||Normal-weight girls|
62770423|NCT04123613|EXPERIMENTAL|2.0 µg/kg, multiple dose|n=45 with 15 Participants from cohort 1, 15 from cohort 2, and 15 from cohort 3
62770424|NCT04123613|EXPERIMENTAL|5.0 µg/kg, multiple dose|n=45 with 15 Participants from cohort 1, 15 from cohort 2 and 15 from cohort 3
62770425|NCT00885794|EXPERIMENTAL|0.5 mg Ranibizumab|3 intravitreal injections of 0.5 mg Ranibizumab every 5 weeks
62770426|NCT00885794|EXPERIMENTAL|1.0 mg of Ranibizumab|3 intravitreal injections of 1.0mg Ranibizumab every 5 weeks
62770427|NCT04140981||group 1|difficult intubation according to antropometric measurements
62770428|NCT04140981||group 2|not difficult intubation according to antropometric measurements
62770429|NCT04140981||group 3|difficult intubation according to ultrasound measurements
62770430|NCT04140981||group 4|not difficult intubation according to ultrasound measurements
62770431|NCT00805064|ACTIVE_COMPARATOR|ischemic CRVO|treatment was applied to this entity
62770432|NCT00805064|ACTIVE_COMPARATOR|non ischemic CRVO|treatment was applied to this entity
62770433|NCT00805064|ACTIVE_COMPARATOR|BRVO|treatment was applied to this entity
62770434|NCT04465812|NO_INTERVENTION|Standard health counseling at baseline|Standard health counseling at baseline
62770435|NCT04465812|EXPERIMENTAL|Self-monitoring and personalized feedback on smartphone app|"1. Patients will record their blood pressure (once 1-week for patients with hypertension, every 3-month for those without), blood glucose (once 1-month for patients with diabetes), serum lipid metabolism (every 3-month for patients with dyslipidemia) on app, and medical staff will suggest continuing monitoring and recording or recommend outpatient visit;~2. Patients will complete Pittsburgh sleep quality index test on app every 3-month, and medical staff will contact with patients with index \> 15 to assess detail clinical status and recommend outpatient visit if necessary;~3. Patients will complete Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) on app every 3-month, and medical staff will contact with patients with SAS\>49 or SDS\>52 to assess detail clinical status and recommend outpatient visit if necessary;~4. Patients will complete cognitive training games every week on app;~5. Medical staff will send health information on app"
62770436|NCT03530085|EXPERIMENTAL|Dec+Flu+Bu Conditioning Regimen|For AML patients older than 60 years in CR, Decitabine+ Fludarabine+Busulfan conditioning regimen was used (Decitabine 20mg/m2/day on days -9 to -7；Fludarabine(Flu) 30mg/m2/day on days -6 to -3；Busulfan (BU) 3.2 mg/kg/day on days -5 to -4).
62770437|NCT02882386|PLACEBO_COMPARATOR|Milk 1%|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
62770438|NCT02882386|EXPERIMENTAL|Whey protein concentrate 80 (WPC-80)|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
62178491|NCT03380364|EXPERIMENTAL|Group Undergoing Hysterosopy|This group will include 75 women with unexplained infertility. 5 mm rigid sheath Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.
62178492|NCT01977183|EXPERIMENTAL|Elderly adults with MSPrebiotic|30 g of MSPrebiotic (potato resistant starch) per day taken with 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi-solid food. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
62770439|NCT02882386|EXPERIMENTAL|Microparticulated whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
62770440|NCT02882386|EXPERIMENTAL|Hydrolyzed whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
62770441|NCT02882386|EXPERIMENTAL|Native whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
62178493|NCT01977183|PLACEBO_COMPARATOR|Elderly adults with Placebo|30 g of corn starch per day taken with 1 glass (approximately 250 mL) of non-heated fluid or or non-heated semi-solid food. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
62178494|NCT01977183|EXPERIMENTAL|General adult population with MSPrebiotic|30 g of MSPrebiotic (potato resistant starch) per day taken with 1 glass (approximately 250 mL) of non-heated fluid. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
62770442|NCT05266560|ACTIVE_COMPARATOR|Propofol injection group (1.5mg/kg)|The patients in the propofol group were given intravenous injection of propofol 1.5 mg/kg and succinylcholine 1 mg/kg in turn, and the interval between each drug administration was 1 minute, and electroconvulsive therapy was performed after the patients were anesthetized.
62770443|NCT05266560|EXPERIMENTAL|Ciprofol injection group(0.4mg/kg)|The patients in the ciprofol group were given intravenous injection of ciprofol 0.4 mg/kg and succinylcholine 1 mg/kg in turn. The interval between each drug administration was 1 minute, and the patients received electroconvulsive therapy after anesthesia.
62770444|NCT02947399|OTHER|I-124 in thyroid hormone withdrawal|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
62770445|NCT00012701||Group 1|
62770446|NCT03599323||Clotrimazole 1% (Empecid L Cream, BAYB5097)|Patients who self-selected Empecid L Cream, and who will have pharmacist intervention prior to purchase.
62770447|NCT01198509|ACTIVE_COMPARATOR|Rheumatoid Arthritis (RA) - doxycycline|Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive doxycycline, 100 mg twice a day, for 2 months.
62770448|NCT01198509|ACTIVE_COMPARATOR|Rheumatoid Arthritis (RA) - vancomycin|Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive vancomycin, 250 mg four times a day, for 2 weeks
62770449|NCT01198509|NO_INTERVENTION|RA, PsA, healthy|"Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive no antibiotic treatment for comparison with Doxycycline- and Vancomycin-treated patients.~Patients with psoriatic arthritis (PsA), to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.~Healthy individuals with no history of arthritis, to provide baseline samples of oral and intestinal microbiota for comparison with RA patients."
62770450|NCT03976284|EXPERIMENTAL|Garden-fresh produce and exercise (GFPE)|Participants are encouraged to double their consumption of minimally processed fiber-rich plant foods, especially garden-fresh produce from the church community garden. Participants are also encouraged to limit pro-inflammatory foods rich in saturated fat, sodium and added sugar. Participants are also encouraged to engage in 150 minutes of moderate to vigorous physical activity per week, most likely in the form of brisk walking.
62770451|NCT03545997|EXPERIMENTAL|Montelukast|Drug :Montelukast, capsule, 10mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months
62770452|NCT03545997|PLACEBO_COMPARATOR|Placebo|Drug: Mannitol, capsule, 350mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months
62770453|NCT04870541|ACTIVE_COMPARATOR|Patients receiving Ondansetron|
62770454|NCT04870541|ACTIVE_COMPARATOR|Patients receiving Nefopam|
62770455|NCT02030288|EXPERIMENTAL|Relational Agent plus Treatment as Usual|"Relational Agents are onscreen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change."
62770456|NCT02030288|NO_INTERVENTION|Treatment as Usual|Patients are routinely screened yearly for unhealthy alcohol use. Providers are prompted to provide elements of a brief intervention if the patient scores 5 or above on the AUDIT-C. Providers are also prompted to refer patients if they meet certain criteria for specialty alcohol treatment.
62770457|NCT03131739||Community Level Assessment|65 communities will undergo assessment of community / structural variables through review of public records and 3-5 key community interviewees per community.
62770458|NCT03131739||Individual Level Assessment|A subset of 6 communities will be elected through a stratification process. Youth will complete a set of protective factors measures and outcomes. Adults will complete a section of the Neighborhood Matters survey.
62770459|NCT01640665|EXPERIMENTAL|Sorafenib and Capecitabine|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses. Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days
62770460|NCT05294458|EXPERIMENTAL|Cotadutide solution for injection|"Period 1, subcutaneous injection of cotadutide solution~Period 2, subcutaneous injection of cotadutide solution~Period 3, subcutaneous injection of cotadutide solution"
62770461|NCT00318331|ACTIVE_COMPARATOR|A|Will receive enteral glutamine
62770462|NCT00318331|NO_INTERVENTION|B|No enteral glutamine given
62770463|NCT02739516|ACTIVE_COMPARATOR|Control|In letrozole stimulated cycle: On the day of ovulation trigger the patient received standard dose of Human chorionic gonadotropin (10,000 IU).
62770464|NCT02739516|EXPERIMENTAL|Study|In letrozole stimulated cycle: On the day of ovulation trigger the patient received hCG 10000 IU plus FSH co-trigger (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once .
62770465|NCT04397965|EXPERIMENTAL|Experimental: Continuous Monitoring|Intervention: Device: Cascade Continuous Glucose Monitoring System
62770466|NCT01572272||Open|Open group: Data derived from the Capnostream20p and displayed to the medical team. It will allow the treating physician and the nursing team to review the real time data and make clinical decisions based upon it if felt necessary.
62770467|NCT01572272||Masked|Data derived from the Capnostream20p will be recorded; however the medical staff will be masked from it and hence will not use it.
61994795|NCT04384757|EXPERIMENTAL|Laparoscopic distal gastrectomy|"5 trocar were used. The gastrocolic ligament was divided along the border of the transverse colon. ligating the left gastroepiploic vessels to remove group 4sb.~The right gastroepiploic vein was divided and the right gastroepiploic and the inferior pyloric artery were vascularized and cut at their origin from the gastroduodenal artery, just above the pancreatic head, to dissect group 6.~The dissection was continued along the hepatoduodenal ligament to removed group 5 and group 12a and along the common hepatic artery to remove group 8a and along the celiac axis to remove group 9.~The left gastric vein was prepared and separately divided and then the left gastric artery was vascularized to remove group 7.~The dissection was continued upward along the proximal branches of splenic vessels to remove group 11p and along the lesser curvature to remove group 1,3.~As a general rule, Billroth II method was used for gastric reconstruction for most cases"
62770468|NCT01820052|ACTIVE_COMPARATOR|Oral Iron|Patient will receive 230 mg of oral elemental iron daily for 3 months
62770469|NCT01820052|PLACEBO_COMPARATOR|Oral Placebo|Oral Placebo tablets will be administered daily for 3 months
62770470|NCT04631653|EXPERIMENTAL|Verisee|Screening diabetic retinopathy using Verisee software
62770471|NCT04150692|EXPERIMENTAL|Arm 1: Dara-SC Re-Escalation|-Re-escalation will include weekly dosing for two 4-week cycles (8 doses, Days 1, 8, 15, and 22 of each 28-day cycle) followed by dosing every-other-week thereafter (Days 1 and 15 of each 28-day cycle). Patients will remain on study treatment until meeting clinical progression.
62770472|NCT04150692|ACTIVE_COMPARATOR|Arm 2: Dara-SC|-Continued subcutaneous daratumumab and and hyaluronidase-fihj (1,800mg/30,000U, \[Dara-SC\])
62770473|NCT04906057|EXPERIMENTAL|Forced Aerobic Exercise (FE)|The FE group (N=10) will complete 45 minutes of FE on the custom-engineered cycle designed to augment pedaling rate to greater than 70 revolutions per minute (RPM's). The VE group (N=10) will exercise on an identical semi-recumbent cycle ergometer at their self-selected cadence without assistance.
62770474|NCT04906057|ACTIVE_COMPARATOR|Voluntary Aerobic Exercise (VE)|The VE group (N=10) will exercise on an identical semi-recumbent cycle ergometer for 45 minutes at their self-selected cadence without assistance.
62770475|NCT01800318|EXPERIMENTAL|Sham NESAP with 24% oral sucrose|"1. Sham NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. However, the Empi Select TENS unit will not be turned on. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~2. Infant will receive 1 ml of 24% oral sucrose solution given along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
62770476|NCT01800318|EXPERIMENTAL|NESAP with oral water|"1. NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. 10 minutes before the heel stick, the Empi Select TENS unit will be turned on with settings 3.5mA, 10 Hz. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~2. Infant will receive 1 ml of sterile water given via oral syringe along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given"
62770477|NCT01800318|EXPERIMENTAL|NESAP with 24% oral sucrose|"1. NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. The Empi Select TENS unit will be turned on ten minutes before the heel stick at settings 3.5 mA, 10 Hz. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~2. Infant will receive 1 ml of 24% oral sucrose solution given along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
62770478|NCT01800318|PLACEBO_COMPARATOR|Sham NESAP with oral water|"1. Sham NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. However, the Empi Select TENS unit will not be turned on. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~2. Infant will receive 1 ml of sterile water given via oral syringe along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
62770479|NCT05623111|ACTIVE_COMPARATOR|Incobotulinumtoxin-A|100 units of incobotulinumtoxin-A in 5ml of sterile saline around both distal ischial nerves.
62770480|NCT05623111|PLACEBO_COMPARATOR|Placebo|5ml sterile saline with small amounts of human albumin and sucrose (identical to binding agents in active vials)
61994796|NCT03383328|ACTIVE_COMPARATOR|NSAID + prednisolone, preoperative|"Combination of NSAID- and prednisolone eye drops. Treatment is initiated 3 days prior to surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day Prednisolone acetate 1% w/v, eye drops, 1 drop 3 times pr. day"
62391023|NCT01851434||Patients with unilateral optic neuritis|Recruitment will proceed until 10 participants with a brain MRI suggestive of MS (obtained at any time point during the study) have completed the study.
62391024|NCT01791166|EXPERIMENTAL|Pulmonary transplant|
62391025|NCT03815006|EXPERIMENTAL|Free Style Libre 2 device|At the start, a blood sample will be taken for the measurement of HbA1c. Training and education on the use of FSL2 will be provided by the research team. Participants will be advised to use flash glucose monitoring continuously for the next 24 weeks.
62567770|NCT01697748|ACTIVE_COMPARATOR|Silver-impregnated dressing|Silver-impregnated dressing placed over Cesarean wound after skin closure; the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
62567771|NCT03039504|EXPERIMENTAL|Potensa|succinate-based dietary supplement
62567772|NCT03039504|PLACEBO_COMPARATOR|Placebo|placebo
62770481|NCT00026377|EXPERIMENTAL|SU5416 in combination with hormone and radiation therapy|Subjects receive 5 months of hormone suppression therapy consisting of 1 month of Bicalutamide or Flutamide followed by 4 months of leuprolide or goserlin injections. After completion of at least 12 weeks of hormone therapy, subjects will receive 7 1/2 weeks of radiation therapy. SU5416 will be given by IV infusion starting 4 weeks before beginning radiation treatment and continuing until 4 weeks after completion of radiation. Multiple doses of SU5416 will be studied.
62770482|NCT05547789||Study group|
62770483|NCT05547789||Control group|
62770484|NCT06234215|ACTIVE_COMPARATOR|control group had functional task training|this group doing functional task training exercise for 50 min 3 times per week for two months
61994797|NCT03383328|ACTIVE_COMPARATOR|NSAID + prednisolone, postoperative|"Combination of NSAID- and prednisolone eye drops. Treatment is initiated on the day of surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day Prednisolone acetate 1% w/v, eye drops, 1 drop 3 times pr. day"
62770485|NCT06234215|EXPERIMENTAL|study group had functional task training combined with electrical stimulation|this group doing functional task training exercise combined with electrical stimulation for 50 min 3 times per week for two months
62770486|NCT04713332|ACTIVE_COMPARATOR|vitamin E|Oral intake of Vitamin E treatment will be given on a daily basis in a single-blind manner one day before the first day of RT and continued for 8 weeks. Patients in the group receiving 500 IU of d-alpha-tocopherol capsules orally (3 times daily).
62770487|NCT04713332|ACTIVE_COMPARATOR|Hydrogen rich water|Oral intake of HRW (2 ppm) treatment will be given on a daily basis in a single-blind manner one day before the first day of RT and continued for 8 weeks. The group of patients receiving Hydrogen water took an amount of 250 ml orally 3 times a day.
61994798|NCT03383328|EXPERIMENTAL|NSAID, preoperative|"NSAID eye drops as monotherapy. Treatment is initiated 3 days prior to surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day"
61994799|NCT03383328|EXPERIMENTAL|NSAID, postoperative|"NSAID eye drops as monotherapy. Treatment is initiated on the day of surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day"
62770488|NCT04713332|PLACEBO_COMPARATOR|placebo|Oral intake of placebo will be given on a daily basis in a single-blind manner one day before the first day of RT and continued for 8 weeks. The placebo group received 3 soft gel placebo capsules containing gelatin three times a day.
62770489|NCT04167072|EXPERIMENTAL|Scheduled removal|This group involves patients who will have the LAMS removed immediately after all the stones have been cleared from the gallbladder
62770490|NCT04167072|ACTIVE_COMPARATOR|Observation|This group involves patients who will be followed closely for 1 year after all the stones have been removed from the gallbladder. These patients will keep the stent in place for 1 year and at that time the patients will be offered removal of the stent.
61994800|NCT03383328|EXPERIMENTAL|Drop-less surgery|"A depot of dexamethasone is administered subtenonally during surgery.~Dexamethason Krka 4 mg/ml solution for injection/infusion. 0,5 ml equivalent to 2 mg of dexamethasone is administered once."
62770491|NCT01410812|EXPERIMENTAL|Suggested Tying|Receive same treatments as control group, but instead of receiving cash they receive 4 iTunes audio novels for their own iPods. Further, they are prompted to try to listen to those novels only when exercising at the gym in order to increase their attendance.
62770492|NCT01410812|EXPERIMENTAL|Forced Tying|Receives same treatment as the control group. However, in addition to receiving the cash, they also receive 4 iTunes audio novels for a loaned iPod that they will only have access to at the gym. They are told they may only listen to these novels only when at the gym in order to increase their attendance.
62770493|NCT01410812|EXPERIMENTAL|Control|Control group of participants who do not receive any intervention but are weighed at the beginning and end of a 10 week period and receive weekly emails asking them about their exercise. They also receive the equivalent cash value of 4 iTunes audio novels
62770494|NCT02337166|ACTIVE_COMPARATOR|Control|open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap
62770495|NCT02337166|EXPERIMENTAL|Test|open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap and application of a rhFGF-2/HA in the intrabony defect
62770496|NCT05391308|EXPERIMENTAL|Experimental arm|All patients will have pre-polysomnographie and post-polysomnographie mesurement.
61994801|NCT05798572|EXPERIMENTAL|Sildosin group|included 70 patients for whom flexible ureteroscopy (F-URS) was done with the daily preoperative intake of 8 mg silodosin for one week.
61994802|NCT05798572|EXPERIMENTAL|Placebo/control group|included 70 patients for whom flexible ureteroscopy (F-URS) was done with daily preoperative intake of placebo tablets.
62770497|NCT03668990|OTHER|persons with Multiple Sclerosis (MS)|"25 persons with MS Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.~Funcitonal-oriented upper limb movements are performed at two different test days."
61994803|NCT04076800|EXPERIMENTAL|Acupuncture|
62770498|NCT03668990|OTHER|stroke patients|"25 stroke patients Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.~Funcitonal-oriented upper limb movements are performed at two different test days."
62770499|NCT03668990|OTHER|Healthy controls|"50 healthy controls Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.~Funcitonal-oriented upper limb movements are performed at two different test days."
62178495|NCT01977183|PLACEBO_COMPARATOR|General adult population with Placebo|30 g of corn starch per day taken with 1 glass (approximately 250 mL) of non-heated fluid. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
61994804|NCT04076800|SHAM_COMPARATOR|Sham acupuncture|
62178496|NCT05413863|EXPERIMENTAL|Sequence: Biocon's Human Insulin R U-500-Biocon's Human Insulin R U-500- Humulin® R U-500|"Period 1:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 3:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
62770500|NCT05245877|EXPERIMENTAL|Preoperative thromboprophylaxis|Preoperatively initiated tromboprophylaxis
62770501|NCT05245877|NO_INTERVENTION|Postoperative thromboprophylaxis|Postoperatively initiated thromboprophylaxis
62770502|NCT05553275|ACTIVE_COMPARATOR|Group 1:Usual Care|
62770503|NCT05553275|EXPERIMENTAL|Group 2: Permissive Care|
62770504|NCT03386409|NO_INTERVENTION|Baseline|Participants receive the standard of care recommendations for safe firearm storage device usage.
61994805|NCT05209022|EXPERIMENTAL|Beetroot supplementation|One serving 140 mL of beetroot juice (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 3 h before initiating the testing session.
62770505|NCT03386409|EXPERIMENTAL|Free Device|Participants receive the standard of care recommendations for safe firearm storage device usage In addition, the study intervention is provision of a free safe firearm storage device (lock box, trigger lock and/or cable lock) for firearm storage at the time of enrollment.
62770506|NCT03386409|EXPERIMENTAL|Low Cost Device|Participants receive the standard of care recommendations for safe firearm storage device usage. In addition, the study intervention is the provision of a low cost ($5) firearm storage device (lock box, trigger lock and/or cable lock) for firearm storage at the time of enrollment.
62770507|NCT02207257|EXPERIMENTAL|Cohort 1|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 25 mg PER977 or placebo (n=10).
62770508|NCT02207257|EXPERIMENTAL|Cohort 2|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 50 mg PER977 or placebo (n=10).
62770509|NCT02207257|EXPERIMENTAL|Cohort 3|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 100 mg PER977 or placebo (n=10).
62770510|NCT02207257|EXPERIMENTAL|Cohort 4|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 300 mg PER977 or placebo (n=10). Study amendments expanded the cohort to include an additional 7 subjects (randomized 1:6 PER977:placebo) and up to an additional 4 placebo and 8 active subjects (ongoing).
62770511|NCT02207257|EXPERIMENTAL|Cohort 5|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 600 mg PER977 or placebo (n=10). A protocol amendment expanded the cohort to include an additional 2 placebo and up to an additional 4 active subject.
62770512|NCT01651091|EXPERIMENTAL|Meditation Awareness Training|
61994806|NCT05209022|PLACEBO_COMPARATOR|Placebo supplementation|One serving of beetroot juice depleted in NO3- (0.08 mmol of NO3-) as placebo (Beet It; James White Drinks Ltd, Ipswich, UK) after an overnight fast and 3 h before initiating the testing session.
61994807|NCT01217970|EXPERIMENTAL|placebo, Ibudilast 20 mg, then Ibudilast 50mg|Sequence: (1) Placebo, (2) Ibudilast 20 mg BID, then (3) Ibudilast 50 mg BID
62770513|NCT01651091|ACTIVE_COMPARATOR|Treatment as Usual|
62770514|NCT02725190|OTHER|Group 1|Normal sleep night.
62770515|NCT02725190|OTHER|Group 2|Sleepless night.
62770516|NCT02057809||Parent-child dyad|Children with Developmental Disabilities and their parents
62770517|NCT02057809||Therapits|Therapists experienced in serving children with developmental disabilities
62770518|NCT04343014|EXPERIMENTAL|Tongue Root Retractor|Patients in this arm will receive fibroscopic endotracheal intubation with tongue root retractors.
62770519|NCT04343014|ACTIVE_COMPARATOR|Conventional Fibroscope|Patients in this arm will receive fibroscopic endotracheal intubation without any other devices.
62770520|NCT00086099|EXPERIMENTAL|1|Idarubicin plus amifostine
62770521|NCT00086099|EXPERIMENTAL|2|Idarubincin
62770522|NCT02096263|EXPERIMENTAL|Infanrix hexa Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Infanrix hexa (lot A, lot B or lot C as per the group allocation) co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and Hiberix at 15-18 months of age by intramuscular injection in the anterolateral thigh.
61994808|NCT01217970|EXPERIMENTAL|Ibudilast 20 mg, Ibudilast 50mg, then placebo|Sequence: (1) Ibudilast 20 mg BID, (2) Ibudilast 50 mg BID, then (3) Placebo
61994809|NCT02130063|EXPERIMENTAL|iron isomaltoside 1000 (Monofer®)|iron isomaltoside 1000 (Monofer®)
61994810|NCT02130063|ACTIVE_COMPARATOR|iron sucrose (Venofer®)|iron sucrose (Venofer®)
62770523|NCT02096263|ACTIVE_COMPARATOR|Pediarix Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pediarix and ActHIB co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and ActHIB at 15-18 months of age by intramuscular injection in the anterolateral thigh.
62770524|NCT02096263|ACTIVE_COMPARATOR|Pentacel Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pentacel and Engerix co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Pentacel at 15-18 months of age by intramuscular injection in the anterolateral thigh.
62770525|NCT04083755|ACTIVE_COMPARATOR|Line A|One dose of Ferric carboxymaltose (1000mg) intravenous. Duration of administration 15 minutes.
62770526|NCT04083755|OTHER|Line B|No treatment or treatment oral with iron supplementation if iron-deficiency anemia
62770527|NCT01409369|EXPERIMENTAL|1|
62770528|NCT01409369|ACTIVE_COMPARATOR|2|
62770529|NCT05518526|EXPERIMENTAL|L-Annamycin|
62770530|NCT06411496||Scheduled or urgent surgery|This is a retrospective cohort study recruiting surgical patients at Galdakao-Usansolo Hospital between 2019 and 2022. We used anonymized patient level data from patients in waiting list to be intervened in four public hospitals in Basque Country.
62770531|NCT00238914|ACTIVE_COMPARATOR|CE plus oral naltrexone|Compliance enhancement plus oral naltrexone
61994811|NCT03303833||Persons with Lynch syndrome|
62391026|NCT03815006|NO_INTERVENTION|Self-monitoring of blood glucose|At the start, a blood sample will be taken for the measurement of HbA1c. Masked FSL will be applied for two weeks, during the last two weeks of control period. Education will focus on using fingerstick measurement for treatment optimisation.
62770532|NCT00238914|ACTIVE_COMPARATOR|BNT plus oral naltrexone|Behavioral naltrexone therapy plus oral naltrexone
62770533|NCT04476394|EXPERIMENTAL|1|Administered orally once
62770534|NCT06262256|NO_INTERVENTION|Control|Regular medical treatment for patients with metabolic syndrome.
62770535|NCT06262256|EXPERIMENTAL|High-intensity interval training|Regular medical treatment for patients with metabolic syndrome plus, 16 weeks of high-intensity interval training (3-times/week, 50 min/session conducted on stationary bike).
62770536|NCT03087526|EXPERIMENTAL|Couple at risk of transmitting a triplet-repeat disease|Expectant couple (pregnant woman between 9 and 34 weeks of gestation and her spouse) at risk of transmitting a triplet-repeat related genetic disease among Huntington disease, Myotonic Dystrophy type 1, Fragile X syndrome, Spinocerebellar Ataxia type 1, Spinocerebellar Ataxia type 2, Spinocerebellar Ataxia type 3
62770537|NCT05013970|OTHER|Knee osteoarthritis|Patients with mild to moderate osteoarthritis who suffer from persistent knee pain treated with catheter-directed geniculate artery embolization
62770538|NCT00359723|EXPERIMENTAL|Methylphenidate 0.4 mg/kg TID followed by placebo TID|As above
62770539|NCT00359723|EXPERIMENTAL|Placebo TID followed by methylphenidate 0.4 mg/kg TID|As above
61994812|NCT06149416|EXPERIMENTAL|Experimental Arms|Experimental: Healthy adult participants All participants are enrolled in the test group and receive the noninvasive adhesive reprocessed pulse oximeter sensors
61994813|NCT01136304||Adults with Type 1 Gaucher disease (GD1)|Adults with GD1 who are cared for at one of the participating research sites whether treatment naive or treated in past or currently with imiglucerase enzyme replacement treatment.
62391027|NCT04846543|OTHER|MRI scan 1st and 2nd year|Additionally to routinely follow up, there will be an MRI scan of enrolled patients after one and two years in some of the study sites
62770540|NCT02259985|EXPERIMENTAL|Itasetron tablet fed|
62770541|NCT02259985|ACTIVE_COMPARATOR|Itasetron tablet fasted|
62770542|NCT02259985|ACTIVE_COMPARATOR|Itasetron infusion fasted|
62770543|NCT02684188|NO_INTERVENTION|Standard hospital discharge services|Patients received standard discharge planning; the baseline and return to baseline groups were combined to form a single standard discharge group
62178497|NCT05413863|EXPERIMENTAL|Sequence: Biocon's Human Insulin R U-500-Humulin® R U-500- Humulin® R U-500|"Period 1:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 3:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
62770544|NCT02684188|EXPERIMENTAL|Enhanced rural discharge and transition|Enhanced rural discharge and transition involved conducting a functional needs assessment before discharge. Identified needs were shared with a Local Community Transition Coordinator (LCTC). Needs include such patient centered issues as housing, transportation, emotional support, support for completing daily chores, and assistance in securing local follow-up appointments. Once a patient returned home, the LCTC conduct a review of discharge orders to insure a patient can meet those recommendations. Then the LCTC worked with the patient to develop and implement a transition plan that linked the patient to local resources he or she can use to address needs. The LCTC also provided direct supports. This plan was implemented over the course of the first 30 days after discharge.
62770545|NCT06325319|EXPERIMENTAL|M-MAMA Champions group|Those study participants randomized to the intervention arm will receive the intervention being tested in this study. The intervention will be community engagement through the M-MAMA Champions on obstetric danger signs, birth preparedness, and complication readiness, whereby sensitization to pregnant women will be done. The sensitization package will be delivered by M-MAMA Champions and will encompass obstetric danger signs, birth preparedness, and complication readiness that will be adapted from the Ministry of Health, Tanzania. The package is being used to empower Community Health Workers (CHWs). The intervention is expected to be delivered in two (2) wards (4 Clusters) to be selected in Bahi Council, Dodoma for a period of one month from March to April 2024 and raise awareness by at least 20% in the intervention arm within a study period.
62178498|NCT05413863|EXPERIMENTAL|Sequence: Biocon's Human Insulin R U-500-Humulin® R U-500-Biocon's Human Insulin R U-500|"Period 1:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 3:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
62391028|NCT02569268||exposure population|No special intervention(s) .
62770546|NCT06325319|NO_INTERVENTION|Routine service group|The study participants who will be randomized to the control arm won't receive the intervention, instead, they will continue receiving the routine services. The routine services for pregnant women specifically on knowledge-related empowerment include the package delivered by the healthcare workers at the reproductive and child health clinics. The package is delivered during every Ante Natal Care (ANC) visit to the pregnant woman. The package contains basic information that is also tailored to the specific needs of pregnant women and is delivered with much emphasis to those who are prone to experience pregnancy-related complications for instance, those with Bad Obstetric History (BOH), cardiovascular diseases, or diabetics. The control groups are expected to be derived from two (2) wards (4 Clusters) to be selected in Bahi Council, Dodoma
61994814|NCT02660320|ACTIVE_COMPARATOR|Dermabrasion|Dermabrasion using dermaroller: The dermaroller is applied on the treated areas, this dermabrasion technique is based on micro holes performed using 540 micro needles (200µm depth) which should allow the penetration of the suspension cells or hyaluronic acid alone. Twelve passages will be performed on the treated area in order to achieve 60% of coverage.
62770547|NCT00877721|EXPERIMENTAL|balance treatment|
61994815|NCT02660320|PLACEBO_COMPARATOR|Laser|To prepare the graft recipient site, the upper layer of epidermis is removed by superficial dermabrasion using Erbium or CO2 ablative laser. The test area is ready to receive suspension cells when the dermis will appeared. The cells suspension will be applied on the wound.
61994816|NCT05336058||Gastric cancer group|We anticipate enrolling approximately 620 gastric cancer (GC) cases, comprising 20 sets of GC tumors and their corresponding peritumoral tissue samples, as well as a minimum of 600 plasma samples from patients across stages I to IV of GC. Pathological diagnosis is required.
61994817|NCT05336058||Negative group|A total of approximately 520 cases were included in the study, comprising 20 cases providing white blood cell samples from healthy individuals, and 500 patients diagnosed with gastric diseases other than gastric cancer (such as gastritis, atrophy, intestinal metaplasia, etc.), who provided plasma samples.
61994818|NCT02531412|EXPERIMENTAL|Spironolactone|Spironolactone 25 mg PO daily for three days. During five days investigators will collect values of plasma creatinine, sodium, potassium, blood ureic nitrogen, vital signs and urinary output.
61994819|NCT02531412|PLACEBO_COMPARATOR|Placebo|Placebo 25mg PO daily for three days During five days investigators will collect values of plasma creatinine, sodium, potassium, blood ureic nitrogen, vital signs and urinary output.
62770548|NCT01727791|EXPERIMENTAL|open label|
62770549|NCT01447160|EXPERIMENTAL|facet joint infiltration|The experimental group will be submitted to intra-articular infiltration of six facet joints (L3/L4;L4/L5;L5/S1 bilaterally) with triamcinolone hexacetonide
62770550|NCT01447160|ACTIVE_COMPARATOR|intramuscular injection|The control group which were submitted to triamcinolone acetonide intramuscular injection of six lumbar paravertebral points
62770551|NCT04356079||Migraine patients|
61994820|NCT03243812|ACTIVE_COMPARATOR|SS genotype group|"Sickle cell patients with SS genotype. Each subject will undergo the following :~1. Blood sample~2. Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test~3. Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.~4. Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
62770552|NCT04356079||Control|
62770553|NCT03031067|EXPERIMENTAL|Machine perfusion - Kidney|The marginal kidney will be perfused with oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion.
61994821|NCT03243812|ACTIVE_COMPARATOR|SC genotype group|"Sickle cell patients with SC genotype. Each subject will undergo the following :~1. Blood sample~2. Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test~3. Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.~4. Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
61994822|NCT03243812|ACTIVE_COMPARATOR|control group|"Healthy subjects. Each subject will undergo the following :~1. Blood sample~2. Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test~3. Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.~4. Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
61994823|NCT01495585|PLACEBO_COMPARATOR|Placebo|Placebo control
61994824|NCT01495585|EXPERIMENTAL|Group 1|lonafarnib 100mg
61994825|NCT01495585|EXPERIMENTAL|Group 2|lonafarnib 200mg
62770554|NCT03031067|NO_INTERVENTION|Static cold storage - Kidney|The marginal kidney that was stored to cold (SCS), previously.
62770555|NCT03031067|EXPERIMENTAL|Machine perfusion - Liver|The marginal liver will be perfused with oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion.
62770556|NCT03031067|NO_INTERVENTION|Static cold storage - Liver|The marginal liver that was stored to cold (SCS), previously.
62770557|NCT02447809|EXPERIMENTAL|Regular DAPT(IPA≤60%)|ASA and Clopidogrel
62770558|NCT02447809|ACTIVE_COMPARATOR|Regular DAPT(IPA>60%)|ASA and Clopidogrel
62770559|NCT05088668|EXPERIMENTAL|Agumented Reality combined with scapular exercises|Scapular exercises performed with glasses of augmented reality during sessions at clinic, and without glasses at home.
62770560|NCT05088668|ACTIVE_COMPARATOR|Scapular exercises|Scapular exercises performed all the time without glasses.
62770561|NCT06267638|EXPERIMENTAL|ketamine group|Participant will receive intraoperative ketamine during total knee arthroplasty by Ketamine 0.5mg /kg loading then 0.25 mg/kg/hours until end of surgery
61994826|NCT02020005|EXPERIMENTAL|non-flavored 2mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
62178499|NCT05413863|EXPERIMENTAL|Sequence: Humulin® R U-500-Biocon's Human Insulin R U-500-Biocon's Human Insulin R U-500|"Period 1:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 3:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
62562633|NCT04861077|EXPERIMENTAL|Breast [18F]FMISO-PET with contrast-enhanced magnetic resonance (MR)|"The patient will have a plastic peripheral intravenous catheter placed in the arm for administration of 10 millicuries (mCi)/10milliliters (mL) \[18F\]FMISO (≤ 15 µg/injected dose) followed by an uptake of 120 minutes.~The injection will be infused nominally over one minute followed by a saline flush. After uptake, the patient will be scanned on the PET/MR for 60 minutes and will receive a contrast injection of gadoteridol during the dynamic sequence of the exam. The patient can be scanned on the PET/CT if the PET/MR is unavailable. During this study patients will be scheduled for up to 3 imaging visits. The first imaging visit will be at baseline prior to starting immunotherapy and is required for study eligibility. If for some reason the patient cannot complete the remaining 2 imaging visits, only one additional imaging visit during the identified times is necessary to remain eligible."
62562634|NCT01585415|EXPERIMENTAL|Single Arm|Two weeks prior to the start of the preparative regimen, patients will begin taking vemurafenib. Patients will then receive lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine, followed by young TIL and high dose aldesleukin
62562635|NCT01344421||hip dysplasia|Patients with hip dysplasia
62562636|NCT01344421||Healthy people|Enrolled from the patients acquaintance circle
62562637|NCT01629251|ACTIVE_COMPARATOR|Closed-loop with standard meal insulin bolus|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard meal insulin dosing will be performed at each meal, following individual standard clinical practice.
62562638|NCT01629251|EXPERIMENTAL|Closed-loop with reduced meal insulin bolus|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. The standard meal insulin dose will be reduced by 20 to 50%.
62562639|NCT01837264|EXPERIMENTAL|Bone Marrow Cell Concentrate|
62562640|NCT01626482|PLACEBO_COMPARATOR|Sham tape|
62562641|NCT01626482|EXPERIMENTAL|Kinesio Tape|
62562642|NCT04982575|EXPERIMENTAL|Cagrilintide 2.4 mg and semaglutide 2.4 mg|Participants will receive cagrilintide and semaglutide once a week as injections for 32 weeks.
62562643|NCT04982575|ACTIVE_COMPARATOR|Cagrilintide 2.4 mg and placebo (semaglutide)|Participants will receive cagrilintide and placebo (semaglutide) once a week as injections for 32 weeks
62562644|NCT04982575|ACTIVE_COMPARATOR|Semaglutide 2.4 mg and Placebo (cagrilintide)|Participants will receive semaglutide and placebo (cagrilintide) once a week as injections for 32 weeks
62562645|NCT06068062|NO_INTERVENTION|Control group|Control group (Group A) undergo traditional teaching of skills as routinely carried out in gynecology department during clinical clerkship of three weeks.
62562646|NCT06068062|EXPERIMENTAL|Experimental group|Group B undergo intervention in the form of learning session where OSCE will be implemented on principles of Team-based learning.
62770562|NCT06267638|PLACEBO_COMPARATOR|Placebo group|Participant will receive intraoperative normal saline during total knee arthroplasty
62770563|NCT03847909|EXPERIMENTAL|DCR-PHXC|Intervention, drug, DCR-PHXC
62562647|NCT05595967|ACTIVE_COMPARATOR|Health education intervention|According the data collected in baseline survey, all participants will be divided into two groups: asymptomatic or mildly symptomatic and severe according the risk level of pelvic floor dysfunction. Intervention for high risk of pelvic floor women focus on emphasizing the need for medical care and access to medical resourced. The first intervention will be performed immediately after baseline survey. The second intervention will be repeated with the first one and performed three months after the first intervention. Both the two session contains modules focusing on heath related knowledge and pelvic floor muscle exercise.
62562648|NCT05595967|NO_INTERVENTION|Control without intervention|No health education is provided to the participants in the control group so as to investigate the effects of health education. However, materials provided to interventional group will also be sent to the control group after the completion of the study.
62562649|NCT03113864|PLACEBO_COMPARATOR|Placebo|Will be identical looking to treatment
62562650|NCT03113864|EXPERIMENTAL|Lutein|10 mg of FloraGLO Lutein
62562651|NCT01422200|EXPERIMENTAL|Subcutaneous|0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via subcutaneous route once
62770564|NCT03847909|PLACEBO_COMPARATOR|Placebo - Sterile Normal Saline (0.9% NaCl)|Placebo, sterile normal saline (0.9% NaCl) for subcutaneous (SC) injection
62770565|NCT05591716|ACTIVE_COMPARATOR|Unilateral flexible ureteroscopy|Transurethral removal of kidney stones
62770566|NCT05591716|ACTIVE_COMPARATOR|Bilateral flexible ureteroscopy|Transurethral removal of kidney stones
62770567|NCT03764267|ACTIVE_COMPARATOR|remifentanil|MAC group
62770568|NCT03764267|ACTIVE_COMPARATOR|general anesthetic|TIVA group
62770569|NCT05565768|EXPERIMENTAL|HZN-457|
61994827|NCT02020005|EXPERIMENTAL|non-flavored 4mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
62770570|NCT05565768|PLACEBO_COMPARATOR|Placebo|
62770571|NCT05792306|EXPERIMENTAL|The electrolyzed water spray group|Study staff will use the novel electrolyzed water spray device and spray for approximately 2-4 minutes on the participant's diseased area until half a bottle (20-40ml) of water is used.
62770572|NCT05792306|PLACEBO_COMPARATOR|Control group of water spray|Study staff will use the saline and spray for approximately 2-4 minutes on the participant's diseased area until half a bottle (20-40ml) of water is used.
62770573|NCT02189707|EXPERIMENTAL|Probiotic Bifidobacterium 1x1010 cfu|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
62770574|NCT02189707|EXPERIMENTAL|Probiotic Bifidobacterium 1x109 cfu|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
62770575|NCT02189707|PLACEBO_COMPARATOR|Placebo powder in capsules|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
62770576|NCT02145871|ACTIVE_COMPARATOR|Standard fluid management|The non-intervention group will receive maintenance crystalloid fluid at 10cc/kg/h. Blood loss will be replaced 1:1 with albumin. Transfusion will follow transfusion criteria. Fluid management will not be dependent on the EV1000
62770577|NCT02145871|EXPERIMENTAL|Goal directed fluid therapy (GDT)|In the GDT arm, patient's SV will be optimized before induction with crystalloid boluses prior to induction of general anesthesia. The GDT arm will have fluid therapy guided by the Edwards EV1000-clinical platform and maintenance crystalloid fluid will be 3cc/kg/h. During the surgical procedure when SVV rises above 12 an albumin bolus will be administered at 250 ml increments until the SVV falls below 8. Transfusion will follow transfusion criteria.
62562652|NCT01422200|ACTIVE_COMPARATOR|Intramuscular|0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via intramuscular route once
62770578|NCT01595191|ACTIVE_COMPARATOR|Music by Mozart|"The sequence by which Bach, Mozart, or no music were administered (over 3 consecutive days) was determined by randomization using random numbers. Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel). The music was played using a music player at a volume of 65-70 dB with attached speakers which were placed at a distance of 30 cm from the infant's ears. According to the American Academy of Pediatrics recommendations (5): the volume did not exceed 75dB and the background noise near the infant's ears was maintained below 45 dB. Music (Mozart or Bach) was initiated 10 minutes prior to the beginning of the metabolic measurements and continued for 30 minutes while energy expenditure (EE) was recorded. In the same manner EE was recorded for each infant with no music therapy."
62391029|NCT05607927|OTHER|Parks surgery group|The CRII patients received Parks surgery
62391030|NCT05607927|EXPERIMENTAL|PE-Bacon surgery group|The CRII patients received PE-Bacon surgery
62770579|NCT01595191|ACTIVE_COMPARATOR|Bach Music|"The sequence by which Bach, Mozart, or no music were administered (over 3 consecutive days) was determined by randomization using random numbers. Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel). The music was played using a music player at a volume of 65-70 dB with attached speakers which were placed at a distance of 30 cm from the infant's ears. According to the American Academy of Pediatrics recommendations (5): the volume did not exceed 75dB and the background noise near the infant's ears was maintained below 45 dB. Music (Mozart or Bach) was initiated 10 minutes prior to the beginning of the metabolic measurements and continued for 30 minutes while energy expenditure (EE) was recorded. In the same manner EE was recorded for each infant with no music therapy."
62770580|NCT03459053|EXPERIMENTAL|CBART|6 weeks participation in CBART protocol before beginning IVF treatment
62770581|NCT03459053|NO_INTERVENTION|Wait control|Participants will receive treatment as usual and will be able to receive the intervention after the study is complete.
62562653|NCT02383979|SHAM_COMPARATOR|Plasma Ball (Control)|"Subjects randomized to standard therapy will participate 14 days of daily mirror therapy sessions preoperatively which will consist of undergoing a sham therapy with a 22 plasma globe involving contralateral limb interaction with the sphere."
62562654|NCT02383979|EXPERIMENTAL|Experimental|Subjects randomized to the mirror therapy limb will undergo 14 days of daily mirror therapy sessions preoperatively which will consist of observing the unaffected limb reflected for 30 minutes in a mirror positioned in the midline to block the view of the affected limb.
62770582|NCT03442296|EXPERIMENTAL|Immediate Treatment Group|Immediate treatment with Baltimore HEARS intervention
62770583|NCT03442296|PLACEBO_COMPARATOR|Delayed Treatment Group|3-month delayed treatment with Baltimore HEARS intervention
62770584|NCT05632783|EXPERIMENTAL|chondroitin sulfate 800 mg tablets|oral chondroitin sulfate 800 mg tablet
61994828|NCT02020005|EXPERIMENTAL|mint-flavored 2mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
61994829|NCT02020005|EXPERIMENTAL|mint-flavored 4mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
62562655|NCT02383979|NO_INTERVENTION|Non-Surgical|Subjects will undergo 3 questionnaires and one functional fMRI exam. Imaging protocol will be identical to preoperative imaging protocol for amputation subjects. This data will aid in establishing baseline fMR activation values for all fMR paradigms tested. The control group will not be randomized to receive either perioperative plasma ball (sham) or mirror therapy.
62562656|NCT05086705|EXPERIMENTAL|Arm A (EMBr Wave)|Patients utilize the EMBr Wave device for 4 weeks, then crossover to arm B for 4 weeks.
62562657|NCT05086705|ACTIVE_COMPARATOR|Arm B (crossover)|Patients receive no treatment for 4 weeks, then crossover to arm A for 4 weeks.
62562658|NCT04390113|PLACEBO_COMPARATOR|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
62562659|NCT04390113|EXPERIMENTAL|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
62562660|NCT02996409|EXPERIMENTAL|High-Volume Image-Guided Injection|HVIGI: Injection of 50 cc ( 40 cc 0,9% sodium chloride solution + 10 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.
62562661|NCT02996409|PLACEBO_COMPARATOR|Low-Volume Image-Guided Injection|LVIGI: Injection of 2 cc (1.6 cc 0.9% Sodium chloride solution + 0.4 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.
62562662|NCT01499264|EXPERIMENTAL|MySkin patch|Hydrogel e polyurethane film
62562663|NCT01499264|ACTIVE_COMPARATOR|Traditional Dressing|
62562664|NCT00765102|EXPERIMENTAL|Romidepsin + Bortezomib|"Romidepsin was given as an infusion on Days 1, 8 and 15 of each 28-day cycle. Bortezomib was administered twice a week for two consecutive weeks (Days 1, 4, 8 and 11) followed by a 17-day rest period.~Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles."
62770585|NCT05632783|PLACEBO_COMPARATOR|placebo|oral placebo tablets matching the IP tablets
62562665|NCT05946993|OTHER|Intervention arm|Participants will attend 12-week programme that will include twice weekly exercise and assessment sessions.
62562666|NCT00940628|EXPERIMENTAL|1|
62562667|NCT00940628|OTHER|2|
62562668|NCT02125383|EXPERIMENTAL|Active tDCS|Receives 20 minutes of anodal tDCS three times while sleeping during the night.
62562669|NCT02125383|SHAM_COMPARATOR|Sham tDCS|Receives 20 minutes of sham tDCS three times while sleeping during the night.
62562670|NCT01580852|ACTIVE_COMPARATOR|Dead Sea Water|
62562671|NCT01580852|SHAM_COMPARATOR|Pool Water|
62562672|NCT03989102|EXPERIMENTAL|Arm 1|Arm 1: (n= 100) will receive 3 doses of PfSPZ Vaccine (9 x10(5)) via direct venous inoculation (DVI) at 1, 8, 29 days.
62562673|NCT03989102|EXPERIMENTAL|Arm 2|Arm 2: (n= 100) will receive 3 doses of PfSPZ Vaccine (1.8 x10(6)) via DVI at 1, 8, 29 days.
62770586|NCT05618418||Hospital admitted patients with alcoholic hepatitis|"Inclusion criteria:~Age ≥ 18 Bilirubin \> 50 micromol/L History of large alcoholic consumption in period prior to hospital admission (in the last six months) No bile-duct obstruction (investigated through US, CT og MRI)~Exclusion criteria:~Hepatocellulary carcinoma Viral hepatitis Autoimmune hepatitis Portal thrombosis Pregnancy Expected survival for less than one year caused by other diseases (based on decision from project responsible doctors)"
62770587|NCT01458028|EXPERIMENTAL|Arm 1|
62770588|NCT01458028|PLACEBO_COMPARATOR|Arm 2|
62770589|NCT02984449|EXPERIMENTAL|Pre+postoperative Cardiac rehabilitation|receive a cardiac rehabilitation program consisting of three phases. 1) A preoperative optimization phase (3x p/wk, 4-6 weeks, before surgery), 2) a postoperative in-patient phase (15 to 18 days in rehabilitation center, weekend at home) and, 3) an outpatient patient clinical rehabilitation phase (2x p/wk, 4 weeks). During each phase, patients will visit a physical therapist (group sessions of inspiratory muscle training (IMT), strength training, aerobic cycling and breath, cough and relaxation sessions), a dietician and a psychologist to optimize general health and receive advice on lifestyle, anxiety and stress management. Two additional components are coaching to stop smoking
62770590|NCT02984449|ACTIVE_COMPARATOR|Postoperative Cardiac rehabilitation|Patients who are randomized to the POST group receive an out-patient cardiac rehabilitation program after surgery. In general, this program starts three to six weeks after discharge (phase ǀǀ) and patients always start with an exercise program, which is supervised by a physical therapist for about six weeks (twice a week). On indication support of psychological and/or dietary consult is added.
62770591|NCT03959787|EXPERIMENTAL|Educational pamphlet and standard care|patients randomized to the educational pamphlet arm will receive the educational pamphlet
62770592|NCT03959787|NO_INTERVENTION|control group - standard care|Patients randomized to control arm, will receive the standard care.
62770593|NCT00038779|EXPERIMENTAL|Megadose T cell depleted|
62770594|NCT06547060||Cross-over self-control group|The current study utilizes the cross-over design. Therefore, only one group of participants will be studied using the self-control design. Each participant will undergo two conditions (control leggings vs. shortened resistance band leggings) at least one day apart.
62770595|NCT01662947|EXPERIMENTAL|DUT Arm|"DUT: Transtek Wrist Blood Pressure Monitor TMB-1117~Measurement: Blood Pressure~Groups/Cohorts: DUT"
61994830|NCT02020005|EXPERIMENTAL|non-flavored nicotine inhaler|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
62178500|NCT05413863|EXPERIMENTAL|Sequence: Humulin® R U-500 -Biocon's Human Insulin R U-500-Humulin® R U-500|"Period 1:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 3:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
62562674|NCT03989102|PLACEBO_COMPARATOR|Arm 3|Arm 3: (n=100): will receive 3 doses of normal saline (placebo) injection via DVI at 1, 8, 29 days.
62562675|NCT02894645|OTHER|Standard Risk (SR)|
62770596|NCT01662947|EXPERIMENTAL|Reference Arm|"Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.~Measurement: Blood Pressure~Groups/Cohorts: Reference"
62770597|NCT04705948|EXPERIMENTAL|ketamine group|ketamine gargle (0.5 mg/kg up to 30 ml dextrose water) 15 minutes before the operation
62770598|NCT04705948|EXPERIMENTAL|magnesium sulfate group|magnesium sulfate gargle (20 mg/kg up to 30 mL G5%) 15 minutes before the operation.
62770599|NCT04759365|EXPERIMENTAL|ASN51|ASN51 will be administered as an oral capsule
62770600|NCT04759365|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as an oral capsule
62770601|NCT02822976||Critically Ill Patient HbA1c<6.5|Patients admitted to an intensive care unit with a HbA1c \<6.5.
62770602|NCT02822976||Critically Ill Patient HbA1c≥6.5|Patients admitted to an intensive care unit with a HbA1c ≥6.5.
62770603|NCT00658307|EXPERIMENTAL|1|
62770604|NCT00658307|EXPERIMENTAL|2|
62770605|NCT00658307|SHAM_COMPARATOR|3|
62770606|NCT00673881|EXPERIMENTAL|Abt-335|ABT-335 (choline fenofibrate)
62770607|NCT00499902|OTHER|2 stages|This is a two-stage study. The first stage is in a three-tier dose escalation format, followed by a second stage during which subjects will be randomized in an equal proportion to up to 3 qualifying dose arms.
62770608|NCT03250572||control group|
62770609|NCT03250572||NAFLD patients without hepatic fibrosis|
61994831|NCT02020005|EXPERIMENTAL|mint-flavored inhaler|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
62562676|NCT02894645|OTHER|Intermediate Risk (IR)|
62562677|NCT02894645|OTHER|High risk (HR)|
62562678|NCT04696302|EXPERIMENTAL|Focus of attention in individuals post chronic stroke during seated lateral weight shifting|Feasibility study
62562679|NCT04696302|EXPERIMENTAL|Focus of attention in individuals post acute stroke during seated lateral weight shifting|Feasibility study
62770610|NCT03250572||NAFLD patients with hepatic fibrosis|
62770611|NCT03000036|OTHER|Cardiovascular Magnetic Resonance|Twenty-seven female patients were imaged in a 3T magnet after consecutively enrolled in the study if they had received a breast cancer diagnosis at the Center for Integral Attention to Women's Health (University of Campinas) and had prescribed endovenous doxorubicin as part of their chemotherapy regimen.
62770612|NCT02128945|EXPERIMENTAL|FLUDATEP|\[18F\] - Fludarabine PET/CT
62770613|NCT00792532||iMRI|
62770614|NCT03624452|EXPERIMENTAL|rIPC and exercise training|Those in the rIPC + exercise group will attend three 50 minute exercise sessions per week for 8 weeks at Liverpool John Moores University and 3 bouts of IPC per week at home at a time of their choice
62770615|NCT03624452|EXPERIMENTAL|rIPC only|Those randomly allocated into the rIPC group will self administer 3 bouts of IPC per week at home at a time of their choice.
62770616|NCT04196673|EXPERIMENTAL|Alcon SN60WF|Implantation of an intraocular lens Alcon SN60WF
62770617|NCT04196673|EXPERIMENTAL|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
62770618|NCT06266104|PLACEBO_COMPARATOR|Dye Spray Chromoendoscopy|Patients undergoing surveillance with dye spray chromoendoscopy
62770619|NCT06266104|ACTIVE_COMPARATOR|TXI|Patients undergoing surveillance with TXI (Texture and Colour Enhancement Imaging)
62770620|NCT06266104|ACTIVE_COMPARATOR|LCI|Patients undergoing surveillance with LCI (Linked Colour Imaging )
62770621|NCT03695965||study group|patients with history of ankle trauma or chronic lateral ankle pain
62770622|NCT05356338|NO_INTERVENTION|Control|The control group participants in this study will not receive any intervention as is the current standard of clinical care for excess sugary drink consumption. They will receive monthly check-in reminders from research staff to promote engagement and retention and will participate in data collection visits at baseline, 3 and 6 months.
62770623|NCT05356338|EXPERIMENTAL|Intervention|"Intervention participants will receive a 6-month behavioral intervention with the following components: A water promotion toolkit that includes water bottles, water flavor infusers, stickers to decorate bottles, children's book about water consumption, and instructions for other intervention components (how to view videos, download app, and prepare for calls) Two brief educational videos: a 5-minute video about healthy drink choices for the family and a 3-min video educating residents about local water. Ready, Set Gulp! app for families that will help all family members track their beverage intake, find out how much water and sugar they are consuming, set goals, compete for points, answer quiz questions and create new recipes for flavor infused water. A series of 14 interactive voice response phone calls to parents over 6 months that educate parents on topics relevant to improving family drink choices.~Two counseling sessions by a WIC nutritionist at months 2 and 4"
62770624|NCT03158350|EXPERIMENTAL|Stationary Bristle Technique (SBT)|Instructed brushing method. Participants are asked to brush twice daily, for 2 minutes at a time, following instructions for the Stationary Bristle Technique.
61994832|NCT05773430|EXPERIMENTAL|Targeted Neurocognitive Training|BrainHQ (POSIT Science Inc.) computerized cognitive training modules will be used as in our other studies; but these will focus on the two cognitive domains in which the participants exhibited the worst performance at baseline. Twenty hours or training will administer to each participant target these two cognitive domains (10 hours each). These programs have gaming components that encourage adherence. BrainHQ cognitive training products are tested and endorsed by the scientific community. A meta-analysis of computerized cognitive training in older adults found optimal therapeutic effects occurred when training sessions last at most 60 minutes and are administered 1-3 times per week - dosage parameters already incorporated in our study. This self-administered program uses touch-screen technology with tablets which allows computer novices to engage with the training exercises.
61994833|NCT05773430|NO_INTERVENTION|No-Contact Control Group|These participants will not receive any intervention.
62770625|NCT03158350|NO_INTERVENTION|Non-Stationary Bristle Technique (NSBT)|The control group will be asked to brush twice daily, for 2 minutes at a time, following their normal toothbrushing technique.
62770626|NCT01342614|ACTIVE_COMPARATOR|Fosinopril group|Fosinopril group received fosinopril, 10mg, once per day.
62770627|NCT01342614|EXPERIMENTAL|Metformin group|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
62770628|NCT00861016|EXPERIMENTAL|1|The patients with mild to moderate essential hypertension
62770629|NCT06438796|EXPERIMENTAL|Blinatumomab group|Blinatumomab group (Blinatumomab): 9 μg/d intravenously over 24 hours until the end of d14 days of dosing. Repeat every 3 months for a total of 4 courses. (Basis for Dose Selection: The recommended dose of blinatumomab for MRD-negative patients is 9ug/d)
61994834|NCT05504629|EXPERIMENTAL|Endurance Training (ET) plus Resistance Training (RT)|Concurrent training of Endurance Training plus Resistance Training order.
61994835|NCT05504629|ACTIVE_COMPARATOR|Resistance Training (RT) plus Endurance Training (ET)|Concurrent training of Resistance Training plus Endurance Training order.
61994836|NCT06286462|EXPERIMENTAL|CATSystem Intervention|Participants enrolled at intervention sites will receive CATSytem-supported cervical cancer screening and treatment services. Interventions received will include: text messages to patients and algorithm-driven alerts to providers when guideline-adherent cervical cancer screening and treatment services are required including: initial and follow up cervical cancer screening, on site treatment, and referral tracking.
62770630|NCT06438796|NO_INTERVENTION|Control group|Maintenance therapy in the control group was based on the routine maintenance therapy in each center (including but not limited to decitabine, sorafenib, prophylactic DLI, except for all types of CD19 mono- and dual-antibodies and CD22-ADC drugs).
62770631|NCT00851994||1|Patients having surgery
62770632|NCT06160830|ACTIVE_COMPARATOR|synbiotic|Patients in the synbiotic group will receive, for 10-12 weeks, Two capsules of synbiotic (Zist Takhmir Company) per day, each containing 500 mg of synbiotic. Patients in this group received a multispecies probiotic product (109 CFU/capsule) and fructo oligosaccharid as prebiotics.
62770633|NCT06160830|PLACEBO_COMPARATOR|placebo|Patients in the placebo group will receive Two capsules of placebo containing maltodextrin per day. The placebo powder will comparable in color, texture, and taste to the synbiotics. Supplement packaging will be done by Zist Takhmir Company.
62770634|NCT04570189||Phase I|Twenty subjects, 10 unventilated and 10 ventilated patients, will undergo clinical auscultation of the heart and lungs with the Auscul-X, a conventional stethoscope and an electronic stethoscope (Littmann 3200).
62770635|NCT04570189||Phase II|Twenty subjects, 10 unventilated and 10 ventilated patients, will undergo clinical auscultation of the heart and lungs with an Auscul-X with wireless capability, a conventional stethoscope and an electronic stethoscope (Littmann 3200). Phase II shall begin upon appropriate Health Canada approvals for the Auscul-X with wireless capability.
61994837|NCT06286462|NO_INTERVENTION|Standard of care|Participants enrolled at control sites will receive standard of care PMTCT services, with no CATSystem tracking or follow up
61994838|NCT01217060|EXPERIMENTAL|Docetaxel + 5-FU + Radiation + Surgery|Docetaxel 20 mg/m2 given by vein (IV) once a week up to 5 1/2 weeks. Dexamethasone 10 mg IV 30 minutes prior to weekly Docetaxel. 5-FU 300 mg/m2 IV, continuously for 96 hours 5 days a week for about 5 1/2 weeks. Radiation 50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks. Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
62770636|NCT03561935|EXPERIMENTAL|Propafenone group|Prescribtion of propafenone for the management of premature ventricular complex
62770637|NCT03561935|ACTIVE_COMPARATOR|Indenol group|Prescribtion of indenol for the management of premature ventricular complex
62770638|NCT04427852|EXPERIMENTAL|30 day Beef consumption|One serving of beef is consumed each day for 30 days.
62770639|NCT04427852|PLACEBO_COMPARATOR|30 day Veggie Patty consumption|One serving (1 patty) of a vegetable based protein source is consumed each day for 30 days. The weight of the food, total calories, grams of protein, and total fat are the same as the beef serving.
62770640|NCT06530888|EXPERIMENTAL|Process-based Cognitive Behavioral Therapy|"In PBT, treatment planning is based on a dynamic network analysis of EMA data collected during the baseline phase. Therapists identify the central node, significant edges, self-loops, and feedback loops between the nodes. Using this information, interventions are selected based on empirical evidence for mechanisms of change that correspond to the network characteristics.~These interventions are framed within an evolutionary framework as the variation, selection, and retention of an adaptive mode of the central node in relation to the specific context of the problem. The change in this key variable is monitored through daily judgments based on EMA. Treatment also focuses on additional targets to establish adaptive modes of the dimensions as defined in the positive network model. Concomitant medication is allowed and will be controlled in statistical analyses."
62770641|NCT06530888|ACTIVE_COMPARATOR|Routine practice (r-PT)|In r-PT, as opposed to PBT, a naturalistic setting is retained for treatment decisions. Treatment planning follows traditional theories about the factors maintaining the disorder and interventions changing them, e.g. avoidance and exposure in anxiety disorders or reduced reinforcement of activities and behavioral activation in depression. Interventions are based on common treatment manuals related to diagnoses, e.g. CBT for depression. Individual data from the behavioral analysis are used to tailor the techniques to the individual problems of the patients. Treatment process is largely structured by personal preferences of the therapist due to experience, knowledge or recommendations of the National guidelines for the mental health problem.Concomitant medication is allowed and will be controlled in statistical analyses.
62770642|NCT05823272|EXPERIMENTAL|oral nutritional supplement|In the oral nutritional supplement group, in addition to diet, and patients will also consume enteral nutrition powder (500 ml/d, 500kcal/d) lasted for 6 months after discharge.
62770643|NCT05823272|NO_INTERVENTION|control|In the control group, patients will receive nutrition counseling in addition to diet.
61994839|NCT04716023||Chronic Airflow obstruction / COVID-19|Patients with either chronic airflow obstruction of COVID-19
61994840|NCT04999046|EXPERIMENTAL|FUS treatment|FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2 (the focused ultrasound intensity in brain area considering transcranial attenuation), burst length: 3 ms, duration: three consecutive 5-minute FUS exposures with two 5-minute intermission intervals. The FUS exposure area will be the epileptogenic focus which is individually different and determined by standard clinical practice previously.
62562680|NCT05020860|ACTIVE_COMPARATOR|Triple Negative Breast Cancer (for tumors > 5 cm)|Paclitaxel IV plus carboplatin IV (+/- pembrolizumab IV) (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (+/- pembrolizumab IV) (4 cycles total)
62562681|NCT05020860|ACTIVE_COMPARATOR|Triple Negative Breast Cancer (for tumors < 5 cm)|Paclitaxel IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)
62562682|NCT05020860|ACTIVE_COMPARATOR|HER2-Positive Breast Cancer|Paclitaxel IV plus Trastuzumab IV plus Pertuzumab IV (or PHESGO) (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV administered (4 cycles total)
62562683|NCT05020860|ACTIVE_COMPARATOR|Hormone Receptor Positive Breast Cancer|Paclitaxel IV plus Carboplatin IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)
62562684|NCT01323400|EXPERIMENTAL|Pazopanib|"Pazopanib (800 mg/day) + Best supportive care according to the investigator's judgement.~Pazopanib treatment is started on the day after randomization until radiological progression according to RECIST or until documented toxicity. In case of radiological progression, pazopanib may be continued (if the investigator wishes so) if a clinical benefit (pain reduction, 1 point increase in performance status) is observed."
62562685|NCT01323400|OTHER|Best supportive care|Best supportive care according to the investigator's judgment. Upon progression, compassionate treatment by pazopanib is possible according to eligibility criteria.
62562686|NCT00780377|EXPERIMENTAL|Bradykinin|Patients have holter monitoring. Patients receive intracoronary bradykinin (0.2, 0.6, 2.0 ug/min) and have coronary sinus and coronary artery blood sampling for t-PA and O2 content.
62770644|NCT06276790||low-risk group|
62770645|NCT06276790||high-risk group|
62770646|NCT02182765|EXPERIMENTAL|Nevirapine|"Part I: Study days 15-43~Part II: Study day 44 to end of trial"
61994841|NCT04999046|SHAM_COMPARATOR|Sham treatment|Sham treatment is to mimic the FUS treatment procedure but without any energy. The ISPTA will be 0 W/cm2, duration: three repeating 5-minute sham exposures with two 5-minute intermission intervals.
62562687|NCT04907097|OTHER|MOF/placebo|During period 1 (4 weeks) participants will receive monomeric and oligomeric flavanols and during period 2 (4 weeks) placebo. Wash out period between two interventions will be 4 weeks. The daily dose of monomeric and oligomeric flavanols will be 200 mg (2 capsules once a day) and for placebo (2 capsules once a day).
62178501|NCT05413863|EXPERIMENTAL|Sequence: Humulin® R U-500-Humulin® R U-500-Biocon's Human Insulin R U-500|"Period 1:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD(Becton Dickinson) disposable syringe~Period 3:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
62562688|NCT04907097|OTHER|Placebo/MOF|During period 1 (4 weeks) participants will receive placebo and during period 2 (4 weeks) monomeric and oligomeric flavanols. The wash out period between two interventions will be 4 weeks. The daily dose of placebo will be 2 capsules once a day and for monomeric and oligomeric flavanols 200 mg (2 capsules once a day).
62562689|NCT00413582|ACTIVE_COMPARATOR|1|Epidural analgesia
62562690|NCT00413582|EXPERIMENTAL|2|IV narcotic analgesia
62562691|NCT03117153|EXPERIMENTAL|DA-5502 liquid toothpaste|"SMFP 760mg, CPC 50mg, tocopherol acetate 10mg, panthenol 100mg, Dipotassium glycyrrhizinate 20mg.~everyday 3 times for 6 weeks"
62562692|NCT03117153|PLACEBO_COMPARATOR|placebo|"no active ingredients~everyday 3 times for 6 weeks"
62562693|NCT05331001||Medical doctors|Medical doctors who are employed as permanent staff in a cardiac arrest center which provides extracorporeal membrane oxygenation.
62562694|NCT05331001||Nurses|Nurses who are employed as permanent staff in a cardiac arrest center which provides extracorporeal membrane oxygenation.
62562695|NCT04811872|EXPERIMENTAL|Intact umbilical cord milking (I-UCM)|
62562696|NCT04811872|EXPERIMENTAL|Cut-umbilical cord milking(C-UCM)|
62562697|NCT04811872|EXPERIMENTAL|Delayed Cord Clamping (DCC )|
62562698|NCT03630926||Prostate Cancer (PCa)|Comprised of men with biopsy-confirmed PCa who are scheduled for prostatectomy.
62562699|NCT03630926||Benign Prostatic Hypertrophy (BPH)|comprosed of men with benign prostatic hypertrophy (BPH) who are scheduled for transurethral resection of the prostate (TURP).
62562700|NCT03630926||Bladder/kidney stone|Comprised of men or women with bladder/kidney stones who are scheduled for a cystoscopy.
62562701|NCT02206854|EXPERIMENTAL|R-flurbiprofen|200 mg R-flurbiprofen in gelatine capsules once
62562702|NCT01071642|NO_INTERVENTION|continue ace-i and arb's versus dicontinue|
62562703|NCT01071642|ACTIVE_COMPARATOR|group b|
62562704|NCT01071642|ACTIVE_COMPARATOR|group c|
62562705|NCT01974518|ACTIVE_COMPARATOR|Rituximab|Inj Rituximab 1 gram IV given on day 0 and day 15
62562706|NCT01974518|ACTIVE_COMPARATOR|Combination of Rituximab and Cyclophosphamide IV|IV Rituximab 1gram on day 0 and 15 750 mg IV cyclophosphamide in 250 ml of NS over 2-3 hr on day 1 and day 16
62178502|NCT00720369|EXPERIMENTAL|CoEnzyme Q10|Open Label Study
62178503|NCT00720369|NO_INTERVENTION|Healthy Controls|Healthy controls completed all study procedures completed by the CoQ10 group but did not receive any study medication.
62562707|NCT02344667|EXPERIMENTAL|Cyberknife|Cyberknife based SBRT 36.25 Gy in 5 fractions
62562708|NCT02344667|EXPERIMENTAL|Volume Modulated Arc Therapy|Volume Modulated Arc Therapy based SBRT 36.25 Gy in 5 fractions
62562709|NCT00039559|OTHER|Early detection|
62562710|NCT04570332|EXPERIMENTAL|Single Arm|Patients will be treated with the combination of BO-112 and pembrolizumab. IT administration of BO-112 will be performed once weekly (QW) for the first 7 weeks and then once every three weeks (Q3W); pembrolizumab Q3W will be administered IV. The order of administration should be pembrolizumab then IT BO-112. BO-112 will be administered IT at a total dose of 1-2 mg at each administration to 1-8 tumor lesions using tuberculin (TB) syringes (or equivalent) with 20- to 25-gauge needles.
62562711|NCT06509932|EXPERIMENTAL|Jefcare Sterile Medical Sheets|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: Jefcare Sterile Medical Sheets and skin care regimen.
62562712|NCT06509932|OTHER|Molicare Premium Bed Mat|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: MoliCare Premium Bed Mats and skin care regimen.
62562713|NCT04427540|EXPERIMENTAL|Oxytocin|Single IM injection Oxytocin 17 micrograms
62562714|NCT02914912||GALS symptomatic patients group|"Patients with chronic mesenteric ischemia (CMI) symptoms shall be investigated with gastroscopy-assisted laser Doppler flowmetry and visible light spectroscopy.~The examination will be performed before and after the surgical or endovascular treatment for CMI.~Besides, the patients treated with either open or laparoscopic mesenteric bypass shall be examined during the operation with transserosal microcirculatory assessment of the stomach and duodenum using laser Doppler flowmetry and visible light spectroscopy."
62770647|NCT02182765|ACTIVE_COMPARATOR|Amprenavir|"Part I: Study days 0 to 43~Part II: Study day 44 to end of trial"
62770648|NCT02182765|ACTIVE_COMPARATOR|Abacavir|"Part I: Study days 0 to 43~Part II Study day 44 to end of trial"
62770649|NCT03639506|EXPERIMENTAL|autologous mitochondria transplantation|inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)
62770650|NCT03639506|ACTIVE_COMPARATOR|ICSI|only has intracytoplasmic sperm injection (ICSI)
62770651|NCT00086645|EXPERIMENTAL|citalopram hydrobromide|citalopram hydrobromide, up to 20 mg daily
62770652|NCT00086645|PLACEBO_COMPARATOR|placebo|placebo, up to equivalent of 20 mg of active comparator daily
62770653|NCT01608451|NO_INTERVENTION|No additional treatment|No Injection Vit D3 or Injection Progesterone prior to chemotherapy cycle
62770654|NCT01608451|ACTIVE_COMPARATOR|Inj. Proluton|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
62562715|NCT02914912||CMI caused by median arcuate ligament syndrome (MALS)|"Patients with chronic mesenteric ischemia (CMI) symptoms caused by MALS shall be investigated with gastroscopy-assisted laser Doppler flowmetry and visible light spectroscopy. The examination will be performed before and after the surgical or endovascular treatment for MALS.~Besides, the patients treated with an either open or laparoscopic technique for MALS shall be examined during the operation with transserosal microcirculatory assessment of the stomach and duodenum using laser Doppler flowmetry and visible light spectroscopy."
62770655|NCT01608451|ACTIVE_COMPARATOR|Inj. Arachitol|Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
62770656|NCT01608451|ACTIVE_COMPARATOR|Inj. Proluton and Inj. Arachitol|Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM and Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
62178504|NCT00630136||A|Adult parent or legally authorized representative (LAR) of child who has consented to undergo an out-patient endoscopy at Children's Mercy Hospital as a diagnostic procedure
62178505|NCT04583462|EXPERIMENTAL|Metformin|Metformin, started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
62770657|NCT06428812|EXPERIMENTAL|perineal package application group|This group includes those in the 2nd stage of labor upright position spontaneous pushing Hot application will be made
62770658|NCT06428812|NO_INTERVENTION|Routine hospital care|Routine hospital care
61994842|NCT03500328|ACTIVE_COMPARATOR|Early Aggressive Therapy|"Higher efficacy disease-modifying therapy (Early Aggressive Therapy) for treatment of multiple sclerosis~Early Aggressive Therapy choices and maximum allowable doses:~* Natalizumab (Tysabri), 300 mg IV every 4 wks~* Alemtuzumab (Lemtrada), 12 mg IV daily (QD) for 5 days; 1 year later: 12 mg IV QD for 3 days~* Ocrelizumab (Ocrevus), 300 mg IV every 2 wks (for 2 doses) at initiation; then 600 mg IV every 6 mths~* Rituximab (Rituxan), 1000 mg IV every 2 wks (for 2 doses); may repeat every 16-24 wks~* Cladribine (Mavenclad), 3.5 mg per kg body weight orally divided into 2 yrly treatment courses (1.75 mg per kg body weight each year); each yrly treatment course is divided into 2 treatment cycles; administer cycle dosage as 1 or 2 tablets QD over 4-5 consecutive days~* Ofatumumab (Kesimpta), 20 mg SC wkly for wks 0, 1 and 2; 20 mg subcutaneously (SC) monthly starting at wk 4~* Ublituximab-xiiy (Briumvi), 150 mg IV (first dose); 450 mg IV 2 wks after first dose; 450 mg IV q 24 wks"
62770659|NCT00167388|NO_INTERVENTION|group 1|All babies \<1250 gm at the time of the study are enrolled into this arm, and randomized to be NPO during the PRBC transfusion
62770660|NCT00167388|ACTIVE_COMPARATOR|group 2|Babies \<1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
62770661|NCT00167388|NO_INTERVENTION|group 3|All babies \>1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
62178506|NCT04583462|PLACEBO_COMPARATOR|Placebo|Placebo (coated tablet similar to metformin tablet titrated following the same schedule as in the experimental arm), started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
62178507|NCT01837797|PLACEBO_COMPARATOR|Placebo|Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
62562716|NCT02914912||Healthy individuals without CMI or MALS|A group of healthy individuals with no symptoms of CMI or MALS shall be investigated with gastroscopy-assisted laser Doppler flowmetry and visible light spectroscopy.
62562717|NCT01831661|ACTIVE_COMPARATOR|GLUCOPHAGE®XR|GLUCOPHAGE®XR (Metformin HCl extended-release tablets) 750 mg of Bristol-Myers Squibb Company, USA
62562718|NCT01831661|EXPERIMENTAL|Metformin Hydrochloride Extended-Release Tablets USP 750 mg|Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
62562719|NCT02839538|ACTIVE_COMPARATOR|local Infiltration|"Induction of General Anesthesia with Propofol(2mg/Kg) and Atracurium(0,5mg/Kg) . Pulmonary ventilation with laryngeal mask and Propofol infusion ( 100mcg/Kg/min.) After , Infiltration of 0.75% ropivacaine (10 ml) each side block injection of local anesthetic at perianal.~If necessary, fentanyl endovenous injection (50 mcg)."
62562720|NCT02839538|OTHER|Subarachnoidal block|"Sedation with midazolam 2 mg. After , Spinal block with 10 mg of hyperbaric 0.5% bupivacaine. Injection of anesthetic at subarachnoidal space with Quincke needle 27G.~If pain, local infiltration with lidocaine 1% (5 ml) in wound."
62770662|NCT00167388|EXPERIMENTAL|group 4|All babies \<1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
62770663|NCT05265507|EXPERIMENTAL|Glycopyrronium|Glycopyrronium (0.2mg) was intravenously given at the ending of the surgery.
62770664|NCT05265507|ACTIVE_COMPARATOR|Ondansetron|Ondansetron (4mg) was intravenously given at the ending of the surgery.
62770665|NCT04763187|ACTIVE_COMPARATOR|Control group|Lower molar extraction and filling of post-extraction alveolus with hemostatic sponge containing gentamicin.
62770666|NCT04763187|EXPERIMENTAL|PRGF group|Post-extraction alveolus is filled with PRGF.
62770667|NCT04763187|EXPERIMENTAL|PRF group|Post-extraction alveolus is filled with PRF.
62770668|NCT02616770|EXPERIMENTAL|S1226 (4%)|S1226 (4%) dosed as single dose for 2 minutes
62770669|NCT02616770|PLACEBO_COMPARATOR|Saline (for 4%)|3 mL saline and medical air as single dose for 2 minutes
62770670|NCT02616770|EXPERIMENTAL|S1226 (8%)|S1226 (8%) dosed as single dose for 2 minutes
62770671|NCT02616770|PLACEBO_COMPARATOR|Saline (for 8 %)|3 mL saline and medical air as single dose for 2 minutes
62770672|NCT02616770|EXPERIMENTAL|S1226 (12%)|S1226 (12%) dosed as single dose for 2 minutes
62770673|NCT02616770|PLACEBO_COMPARATOR|Saline (for 12%)|3 mL saline and medical air as single dose
61994843|NCT03500328|ACTIVE_COMPARATOR|Traditional Therapy|"First-line disease-modifying therapy (Traditional Therapy) for treatment of multiple sclerosis~Traditional Therapy choices and maximum allowable doses:~* Glatiramer acetate (Copaxone, Glatopa, and other generics), 20 mg SC daily, or 40 mg SC 3 times a wk~* Intramuscular (IM) interferon (Avonex), 30 mcg IM weekly~* SC interferon (Betaseron, Extavia, Rebif), 0.25 mg SC every other day (Betaseron, Extavia); 44 mcg SC 3 times a wk (Rebif)~* Pegylated interferon (Plegridy), 125 mcg SC every 14 days~* Teriflunomide (Aubagio), 14 mg PO QD~* Dimethyl fumarate (Tecfidera and generics), 240 mg PO twice a day (BID)~* Diroximel fumarate (Vumerity), 462 mg PO BID~* Monomethyl fumarate (Bafiertam), 190 mg PO BID~* Fingolimod (Gilenya and generics), 0.5 mg PO QD~* Siponimod (Mayzent), 1 mg PO QD or 2 mg PO QD~* Ozanimod (Zeposia), 0.92 mg PO QD~* Ponesimod (Ponvory), 20 mg PO QD~* Fingolimod ODT (Tascenso), 0.25 mg PO QD if \<=40 kg; 0.5 mg PO QD if \> 40 kg"
62178508|NCT01837797|EXPERIMENTAL|Brexpiprazole 1 mg|Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week followed by 1 mg/day.
62770674|NCT03409510|EXPERIMENTAL|Long-term UVB radiation|All participants received repeated UVB radiation for nine weeks. The treatment was identical for all participants.
62770675|NCT01117935|EXPERIMENTAL|Arm I|Patients undergo hypofractionated intensity modulated radiotherapy once daily, 5 days a week, for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with intermediate- and high-risk disease may also receive concurrent and adjuvant or long-term androgen deprivation therapy for up to 36 months.
62770676|NCT01232153|ACTIVE_COMPARATOR|NIV preoxygenation|
62770677|NCT01232153|NO_INTERVENTION|Classical preoxygenation|
62770678|NCT03095820|ACTIVE_COMPARATOR|Supportive therapy|The control group received supportive therapy for 12 weeks. In addition to a telephone call once a week and a home visit once a month, this program consisted of identification of physical problems, encouragement of general exercise, encouragement of pleasant activities, and so forth. The control program did not feature any specific goal setting by the participants, specific education about the benefits of achievement of such goals, or symbolic prizes.
62770679|NCT03095820|EXPERIMENTAL|Multidomain intervention|"As a multidomain intervention, four evidence-based therapeutic approaches (physical activity, healthy diet, social activity, and emotional regulation) were incorporated into the program.~In terms of the healthy diet intervention, we encouraged participants to perform at least 30 min of above-moderate physical activity, three times per week. In terms of the healthy diet intervention, the intervention consisted of encouraging participants to consume high quantities of fish, olive oil, legumes, vegetables, and fruit, at a frequency of at least twice a week. In terms of the social activity intervention, we encouraged participants to participate in social organizations, such as the senior center, the hall of the elderly, a fraternity, a reunion, and a clan gathering, at least once a week. In terms of the emotional regulation intervention, we a performed brief cognitive restructuring task for 20 min per visit."
62770680|NCT05059977|EXPERIMENTAL|TAK-881 0.4 g/kg (in-line warmed)|Participants will receive a single dose of TAK-881 comprising of 0.4 gram per kilogram (g/kg) (in-line warmed) Immune Globulin Subcutaneous (IGSC), 20 percent (%) at progressively increased infusion rates and Recombinant Human Hyaluronidase (rHuPH20) dose of 80 unit per gram (U/g) immunoglobulin G (IgG) on Day 1 of the study treatment period.
62770681|NCT05059977|EXPERIMENTAL|TAK-881 1.0 g/kg (in-line warmed)|Participants will receive a single dose of TAK-881 comprising of 1.0 g/kg (in-line warmed) IGSC, 20% at progressively increased infusion rates and rHuPH20 dose of 80 U/g IgG on Day 1 of the study treatment period.
62178509|NCT01837797|EXPERIMENTAL|Brexpiprazole 3 mg|Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week, 1 mg/day in the second week, followed by 3 mg/day.
62178510|NCT04546659|EXPERIMENTAL|Group A|Osteoarthritic patient receiving Conventional therapy and Retrowalking
62770682|NCT05059977|EXPERIMENTAL|TAK-881 1.0 g/kg (un-warmed)|Participants will receive a single dose of TAK-881 comprising of 1.0 g/kg (un-warmed) IGSC, 20% at progressively increased infusion rates and rHuPH20 dose of 80 U/g IgG on Day 1 of the study treatment period.
62770683|NCT03328858|OTHER|Ketogenic Diet|Participants will be provided a consultation with a ketogenic dietitian, and test the tolerance to the diet in an inpatient mode
62770684|NCT03710304|ACTIVE_COMPARATOR|oxytocin|20 IU oxytocin ampoules in 500 mL of intravenous solution infusion over 15 min after delivery of the baby.plus 2tab placebo buccal(ranitidine) plus 110 ml saline iv
62770685|NCT03710304|ACTIVE_COMPARATOR|Tranexamic acid plus misoprostol|400 μg misoprostol (2 tablets of 200 μg) or two placebo tablets were given buccally after spinal anesthesia and few minutes before skin incision; then 1 gm TA will be diluted in 100 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist before skin incision, plus 500 ml normal saline intravenous solution infusion over 15 min after delivery of the baby
62770686|NCT01454349|EXPERIMENTAL|PRX302|
62770687|NCT01454349|PLACEBO_COMPARATOR|Inactive substance|
62178511|NCT04546659|ACTIVE_COMPARATOR|Group B|Osteoarthritic patient receiving Conventional therapy
62770688|NCT02391961|EXPERIMENTAL|dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo. Within the trial, each patient serves as his own control.
62178512|NCT04292821||Patients consulting for breast lesion Bi Rads 4 or 5|Patients consulting for breast lesion Bi Rads 4 or 5
62178513|NCT00944996|ACTIVE_COMPARATOR|antidepressant|
62178514|NCT00944996|NO_INTERVENTION|Healthy volunteers|
62770689|NCT02391961|PLACEBO_COMPARATOR|placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo. Within the trial, each patient serves as his own control.
62770690|NCT05248503||Nurse|Pediatric nurses taking charge of the care of patients with epidermolysis bullosa at Necker Hospital
62770691|NCT02565810|EXPERIMENTAL|SB5 40mg|
62770692|NCT00951756|OTHER|High Fat Low Fiber Diet|
62770693|NCT00951756|OTHER|Low Fat High Fiber Diet|
62770694|NCT03070821|EXPERIMENTAL|Healthy elderly experimental group|Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
62770695|NCT03070821|EXPERIMENTAL|Patient group|Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
62770696|NCT03070821|SHAM_COMPARATOR|Healthy elderly sham-feedback group|Feedback of the postcentral gyrus using rtfMRI neurofeedback training (using 3T MRI).
62770697|NCT04395287||Preschool children|Attending public preschools in Svendborg, Denmark, at the time of recruitment
62182734|NCT04636957|EXPERIMENTAL|ciprofloxacin 0.3% plus fluocinolone acetonide 0.025%|Warm the otic solution by holding the vial in the hands for 1 to 2 minutes. Twist off the vial cap. Tilt the subjects' head to one side to keep the affected ear up. Instill the content of 1 vial in the ear (0.25mL). Gently pull the outer ear lobe upward and outward to allow the solution to flow into the ear canal. Keep the subjects' head tilted sideways for approximately 5 minutes to allow the drug time to penetrate the ear. Use twice daily (every 12±1h , morning and evening) for 7 consecutive days.
62770698|NCT04996082||Systemic sclerosis group|Patients with systemic sclerosis
62770699|NCT04996082||No Systemic sclerosis group|Patients without systemic sclerosis
62562721|NCT02249975|EXPERIMENTAL|C2 CryoBalloon Focal Ablation System|Cryoballoon ablation will be performed on patients with Barrett's Esophagus.
62562722|NCT02302469|OTHER|revlimid|a dose-escalation of revlimid
62770700|NCT06371534|EXPERIMENTAL|QL2109|QL2109, subcutaneous injection 3-5 min D1 (Day 1, single dose)
62770701|NCT06371534|ACTIVE_COMPARATOR|DARZALEX FASPRO®|DARZALEX FASPRO®, subcutaneous injection 3-5 min D1 (Day 1, single dose)
62770702|NCT04722757|EXPERIMENTAL|transanal IPAA|In the experimental arm, patients will undergo transanal dissection of the distal part of the rectum. After proctectomy, an ileal pouch-anal anastomosis (IPAA) will be created. A Gelpoint Path will be used to create access through the anus. Postoperative care will occur following the hospital specific protocols.
62770703|NCT04722757|ACTIVE_COMPARATOR|transabdominal IPAA|In the control group, proctectomy will occur through abdominal dissection (laparoscopy, single port laparoscopy, robotic or open). Postoperative care will occur following the hospital specific protocols.
62770704|NCT03495791|EXPERIMENTAL|EI development phase.|
62770705|NCT03495791|NO_INTERVENTION|Pilot-testing phase.|
62770706|NCT05314933|ACTIVE_COMPARATOR|Study drug|"Each subject receives either a single dose (SAD) or a multiple dose (MAD) of a 3.5% 2-Deoxyglucose as nasal spray solution.~The starting dose for the first cohort is 3.5 mg/day up to a maximum of 84 mg/day at cohort 6."
62770707|NCT05314933|PLACEBO_COMPARATOR|Placebo|Each subject receives either a single (SAD) or multiple (MAD) dose of placebo. The dose for each cohort is corresponding the amount of solution needed in the verum group.
62562723|NCT03690700|ACTIVE_COMPARATOR|active BFRE|14 consecutive SCI patients are block-randomized to active arm
62562724|NCT03690700|SHAM_COMPARATOR|sham BFRE|14 consecutive SCI patients are block-randomized to sham arm
62562725|NCT05682456|EXPERIMENTAL|High-fat shake|
62178515|NCT02738957|OTHER|Prenatal Counseling Group|"Patients in the PCG will receive specific counseling on breastfeeding consisting of three different counseling sessions during prenatal visits given by one two midwives involved in the study. The information will include: breastfeeding importance; how to prepare the nipples and breast for breastfeeding; the main complications and difficulties during the breastfeeding process and how to identify and overcome them; breastfeeding techniques and alternative positions for the simultaneous breastfeeding of twins, for example, double cradle, cradle-football or double-football, using illustrations and hands-on demonstration with doll models. During the counseling sessions patients will have the opportunity to discuss questions on breastfeeding."
62178516|NCT02738957|NO_INTERVENTION|Control Group|No breastfeeding counseling during the antenatal period will be provided. The Control Group will receive non-specific counseling with standard orientation regarding breastfeeding after delivery and during their postpartum hospitalization period. This standard orientation will be provided by one of the midwives of the hospital during a single counseling session with brief guidance covering the following topics: starting breastfeeding, hygiene, infants' conditions, colostrum/breast milk, infants' positions, duration of breastfeeding, frequency of feeds, mammary milking, and stopping breastfeeding.
62178517|NCT00537329|OTHER|Open|This is an open-label, multi-center, non-comparative 12 week study evaluating the efficacy and safety of anidulafungin in subjects with candidemia.
62178518|NCT04255173|EXPERIMENTAL|Geriatric osteoporotic patients|We measured different anthropometric and body composition measurements as body weight, BMI, percentage body fat, skeletal muscle index (SMI), ABSI, waist (WC) and hip circumference (HC) in geriatric population to investigate the relation to osteoporosis.
62178519|NCT03300609|EXPERIMENTAL|Arm I (panitumumab, leucovorin calcium, fluorouracil)|"INDUCTION Patients receive panitumumab IV over 30-60 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE:~Patients receive panitumumab IV over 30 minutes, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
62178520|NCT03300609|ACTIVE_COMPARATOR|Arm II (capecitabine)|"INDUCTION Patients receive panitumumab IV over 30-60 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE:~Patients receive capecitabine PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
62178521|NCT06455332|EXPERIMENTAL|All patients will part of the same follow-up study.|All patients will part of the same follow-up study. No treatment will be compared. Patients will be treated as recommended.
62178522|NCT04452409|ACTIVE_COMPARATOR|study (low level laser plus Mediterranean diet)|Active infra -red laser in addition to diet
62178523|NCT04452409|OTHER|control (Mediterranean diet only)|diet
62178524|NCT02348372|PLACEBO_COMPARATOR|GSK1278863A Placebo|5, 25 and 100 mg matched
62178525|NCT02348372|EXPERIMENTAL|GSK1278863A 10mg|A round, biconvex, white film coated tablet
62178526|NCT02348372|EXPERIMENTAL|GSK1278863A 25mg|A round, biconvex, white film coated tablet
62178527|NCT02348372|EXPERIMENTAL|GSK1278863A 50mg|A round, biconvex, white film coated tablet
62178528|NCT02348372|EXPERIMENTAL|GSK1278863A 100mg|A round, biconvex, white film coated tablet
62178529|NCT02853305|EXPERIMENTAL|Pembrolizumab + ST Chemotherapy (Pembro Combo)|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for a maximum of 35 doses PLUS standard therapy (ST) chemotherapy with EITHER cisplatin 70 mg/m\^2 IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine IV infusion 1,000 mg/m\^2 on Day 1 and Day 8 of each 3-week cycle, OR carboplatin at an area under the curve 5 (AUC 5) (or AUC 4.5 if required per local guidelines) IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine 1,000 mg/m\^2 IV on Day 1 and Day 8 of each 3-week cycle. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
62178530|NCT02853305|EXPERIMENTAL|Pembrolizumab (Pembro)|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for a maximum of 35 doses. Eligible participants who stop pembrolizumab with SD or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
62562726|NCT05682456|ACTIVE_COMPARATOR|Reference shake|
62562727|NCT00884117||Participants Infected with Influenza|Participants with a positive diagnostic test of influenza and/or displaying symptoms suggestive of influenza-like illness will be enrolled and followed for up to 10 days after informed consent for virological surveillance and assessment of clinical outcomes. Participants may receive treatment including oseltamivir, other treatment/medication, or no treatment.
62562728|NCT04231526|EXPERIMENTAL|ARM A - Pembrolizumab + Surgery|
62562729|NCT04231526|ACTIVE_COMPARATOR|ARM B - Surgery|
62562730|NCT03877835|OTHER|Ropivacaine|SSNB will be performed with 4 ml ropivacaine 5 mg/ml LSIB will be performed With 15 ml ropivacaine 7.5 mg/ml
62562731|NCT03154983|EXPERIMENTAL|First-line treatment|First-line treatment：treatment including Mesylate Apatinib Combined With Docetaxel and S-1(DS).DS Docetaxel 75mg/m2 d1 iv.drop 1h（one hour）， S-1(BSA\<1.25 40mg Po bid(twice a day), BSA \>=1.25-\<1.5 50mg Po bid, BSA \>=1.5 60mg Po bid), Q21d(21 days a cycle); Mesylate Apatinib 500mg Po QD(once a day) continuous use; until disease deterioration.
61994844|NCT00589953|PLACEBO_COMPARATOR|EPO###|"All subjects will be identified as a such by the study identifier EPO### where EPO designates enrollment in this study and ### is a numeric identifier (e.g. 103)."
62562732|NCT02954432|EXPERIMENTAL|Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
62178531|NCT02853305|ACTIVE_COMPARATOR|ST Chemotherapy (Chemo)|Participants receive ST chemotherapy with EITHER cisplatin 70 mg/m\^2 IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine IV infusion 1,000 mg/m\^2 on Day 1 and Day 8 of each 3-week cycle OR carboplatin at AUC 5 (or AUC 4.5 if required per local guidelines) IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine 1,000 mg/m\^2 IV on Day 1 and Day 8 of each 3-week cycle.
62178532|NCT00427778|EXPERIMENTAL|Incontinence ring then no intervention|Participants first were fitted with an incontinence ring, which they wore continuously for 4 weeks. The ring wa then removed and a washout period of 2 weeks followed. Then the second 4-week period with no ring was completed.
62562733|NCT02954432|SHAM_COMPARATOR|Sham tDCS + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
62562734|NCT00581672||questionnaires|Black men with prostate cancer
62562735|NCT05479864|OTHER|Anterior cervical corpectomy and fusion|removal of damaged vertebrae and intervertebral disc that are compressing the spinal cord and spinal nerves. Various graft materials or spacers are used to maintain height and stability followed by anterior plating
62562736|NCT05775965|EXPERIMENTAL|Rivaroxaban 10mg|Rivaroxaban 10mg daily for 35 days post hip fracture surgery
62562737|NCT05775965|EXPERIMENTAL|acetylsalicylic acid (ASA) 81mg daily|acetylsalicylic acid (ASA) 81mg daily for 35 days post hip fracture surgery
62562738|NCT02535026||Breast Cancer Participants|Breast tissue samples from female participants with a breast cancer diagnosis that undergo an anatomopathological examination of surgical specimens and/or core needle biopsies will be considered for analysis in this study.
62562739|NCT03395288|EXPERIMENTAL|RCT treatment arm|Participants in this arm will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days.
62562740|NCT03395288|NO_INTERVENTION|RCT control arm|Participants in this arm will not use any additional intervention.
62178533|NCT00427778|EXPERIMENTAL|No intervention then incontinence ring|Participants spend the first study 4-week period with no intervention. Then, a wasout period of 2 weeks followed. Participants were then fitted with an incontinence ring, which they wore continuously for 4 weeks.
62178534|NCT00582959|OTHER|1|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
62182735|NCT04636957|ACTIVE_COMPARATOR|ciprofloxacin 0.3%|Warm the otic solution by holding the vial in the hands for 1 to 2 minutes. Twist off the vial cap. Tilt the subjects' head to one side to keep the affected ear up. Instill the content of 1 vial in the ear (0.25mL). Gently pull the outer ear lobe upward and outward to allow the solution to flow into the ear canal. Keep the subjects' head tilted sideways for approximately 5 minutes to allow the drug time to penetrate the ear. Use twice daily (every 12±1h, morning and evening) for 7 consecutive days
62562741|NCT03395288|EXPERIMENTAL|Observational arm|Participants in this arm will either take a total of 1000 mg D-mannose in capsule form every 12 hours OR they will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days. Participants in this arm of the study have different home medications prior to study enrollment than participants in the RCT treatment arm.
62562742|NCT02431611|ACTIVE_COMPARATOR|Control condition|Control behavioral phone-based smoking cessation intervention
62562743|NCT02431611|EXPERIMENTAL|Biomarker Feedback Intervention|Biomarker feedback plus behavioral phone-based smoking cessation intervention
62562744|NCT02547012|EXPERIMENTAL|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
62562745|NCT02547012|ACTIVE_COMPARATOR|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.
62562746|NCT04886583||Gabi Baby Band|GSC 1
62770708|NCT05978635|PLACEBO_COMPARATOR|Group A|"Anesthesia provider asks the patient to take 4 deep breaths by intermittently stating take as deep a breath as you can. This is the standard of care technique for preoxygenation before induction of general anesthesia with the end point being 80% expired oxygen. The breath volumes in milliliters are recorded but not stated to the patient."
62770709|NCT05978635|EXPERIMENTAL|Group B|"Anesthesia provider asks the patient to take 4 deep breaths but provides coaching by informing the patient of the numeric volume (milliliters) to reach for every breath. Each tidal volume breath is measured using the anesthesia ventilator and the provider encourages the patient to achieve a higher tidal volume than previously achieved. For example, if the initial tidal volume achieved by the patient is 500 milliliter, the provider states, that was a 500 milliliter breath, now try to achieve a 1000mL breath. The numeric goal should continue to increase above the patient's actual tidal volume. The breath volumes are recorded."
62770710|NCT04033068|EXPERIMENTAL|Two MV-ZIKA-RSP vaccinations (high dose)|14 Participants will receive MV-ZIKA-RSP 1 x10E5/dose on day 0 and day 28
62770711|NCT04033068|EXPERIMENTAL|Two MV-ZIKA-RSP vaccination (low dose)|14 Participants will receive MV-ZIKA-RSP 2,5 x10E4 /dose on day 0 and day 28
62562747|NCT04535934||1 dose/week followed by 4 doses/week|Directly observed dosing regimen with 2 mg adenine 5+ (five stable-labeled nitrogens) as follows: 1 dose/week followed by 4 doses/week. The duration of each dosing regimen will be approximately 12 weeks. A washout period of approximately 12 weeks will separates the dosing regimens.
62562748|NCT04535934||3 doses/week followed by 7 doses/week.|Directly observed dosing regimen with 2 mg adenine 5+ (five stable-labeled nitrogens) as follows: 3 doses/week followed by 7 doses/week. The duration of each dosing regimen will be approximately 12 weeks. A washout period of approximately 12 weeks will separates the dosing regimens.
62770712|NCT04033068|EXPERIMENTAL|One MV-ZIKA-RSP vaccination (high dose) and one placebo|12 Participants will receive MV-ZIKA-RSP 1 x10E5/dose on day 0 and placebo on day 28
62770713|NCT04033068|PLACEBO_COMPARATOR|Two placebo injection|8 Participants will receive placebo on day 0 and placebo on day 28
62770714|NCT02107872|EXPERIMENTAL|dosing cohort 1|Patients will receive REGN1500 or placebo in dosing cohort 1
62770715|NCT02107872|EXPERIMENTAL|dosing cohort 2|Patients will receive REGN1500 or placebo in dosing cohort 2
62178535|NCT02582697|ACTIVE_COMPARATOR|Standard Arm - Standard BEP|"Participants 16 years or older will receive 4 cycles of Standard BEP as follows:~* Bleomycin 30,000 IU IV weekly for 3 doses~* Etoposide 100 mg/m2 IV on day 1 - 5~* Cisplatin 20 mg/m2 IV on day 1 - 5~* Pegylated G-CSF 6 mg SCI on day 6~Patients \< 16 years old and weighs ≥ 45 kg will receive:~* Bleomycin \*15,000 - 30,000 IU IV weekly for 3 doses~* Etoposide 100 mg/m2 IV on day 1 - 5~* Cisplatin 20 mg/m2 IV on day 1 - 5~* Pegylated G-CSF 6 mg SCI on day 6~Patients \<16 years old and weighs \< 45 kg will receive:~* Bleomycin \*15,000 - 30,000 IU IV weekly for 3 doses~* Etoposide 100 mg/m2 IV on day 1 - 5~* Cisplatin 20 mg/m2 IV on day 1 - 5~* Filgrastim 10mcg/kg/day on day 6, until post-nadir Absolute Neutrophil Count ≥1 x10\^9/ L~  * The dose of bleomycin is decided by the treating physician and based on the patient's Body Surface Area.~Each cycle is 3 weeks (21 days).~The planned total duration of treatment is 12 weeks."
62178536|NCT02582697|EXPERIMENTAL|Experimental Arm - Accelerated BEP|"Participants 16years or older will receive 4 cycles of Accelerated BEP as follows:~* Bleomycin 30,000 IU IV wkly for 2 doses~* Etoposide 100 mg/m2 IV on day 1 - 5~* Cisplatin 20 mg/m2 IV on day 1- 5~* Pegylated G-CSF 6 mg SCI on day 6~Patients \<16years and weighs ≥45 kg will receive:~* Bleomycin \*15,000 - 30,000 IU IV wkly for 2 doses~* Etoposide 100 mg/m2 IV on day 1 - 5~* Cisplatin 20 mg/m2 IV on day 1 - 5~* Pegylated G-CSF 6 mg SCI on day 6~Patients \<16years and weighs \<45 kg will receive:~* Bleomycin \*15,000 - 30,000 IU IV wkly for 2 doses~* Etoposide 100 mg/m2 IV on day 1 - 5~* Cisplatin 20 mg/m2 IV on day 1 - 5~* Filgrastim 10mcg/kg/day on day 6, until ANC ≥1 x10\^9/ L~Each cycle is 2 weeks (14days)~Following 4xBEP cycles, patients will receive additional bleomycin as follows:~- Bleomycin \*15,000 - 30,000 IU IV wkly for 4 doses~\* The dose of bleomycin is decided by the treating physician and based on the patient's BSA.~The planned total duration is 12 weeks."
62178537|NCT03228342|EXPERIMENTAL|Ultrasound shared|Patient will be assessed with ultrasound (GUS-7 score)
62178538|NCT03228342|EXPERIMENTAL|Ultrasound not shared|Patient will be assessed with ultrasound (GUS-7 score)
62178539|NCT01220856|EXPERIMENTAL|Reparixin|"Reparixin + Immunosuppression~Reparixin was administered at a dose of 2.772 mg/kg body weight/hour for 7 days (168 hours) at each transplant. It was administered as a continuous IV infusion into a (high-flow) central vein. Investigational Product infusion was to begin approximately 12 hours (range between 6 to 16 hours) before each pancreatic islet infusion was started. The Investigator identified the time to start study drug administration.~Reparixin was given to all patients of this arm using the same dosing solution (reparixin 11.00 mg/mL), but the pump rate was adjusted to provide an infusion rate of approximately 0.25 mL/kg/hour.~For immunosoppression regimen see the other arm description."
62178540|NCT01220856|NO_INTERVENTION|No experimental intervention|Immunosuppression only. Induction: First islet infusion: anti-thymocyte globulin (ATG), administered IV (central vein) at the dose of 1.5 mg/kg on Day -1, 0, 1, and 2 of islet infusion. The first ATG injection was preceded by a bolus IV injection of 500 mg methylprednisolone. Induction for the second islet infusion was to be administered per center practice. Maintenance: Mycophenolate mofetil (MMF), administered orally at the dose of 1 g twice a day, starting on Day -1 of the first islet infusion; Tacrolimus, administered orally starting on Day -1 of the first islet infusion at a dose of 0.087 mg/kg twice a day. Thereafter, dosing was to be targeted to blood trough levels of 8 to 10 ng/mL. Administration continued up to Month 3 after the first transplant. Rapamycin was to replace tacrolimus from Month 3 after the first transplant. It was to be administered orally at the starting dose of 0.1 mg/kg once a day, then targeted to a blood trough level of 10 to 12 ng/mL.
62178541|NCT05418686|EXPERIMENTAL|Colchicine-resistant Familial Mediterranean Fever patients|
62178542|NCT04082481|EXPERIMENTAL|TAK-988: Part A|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, once on Day 1 to healthy non-Japanese participants. Sentinel dosing will be done in the first 2 cohorts of Part A (Cohorts A1 and A2 \[fasted and fed dosing conditions\]). Dose escalation in Cohorts A2 to A6 will be based on emerging safety/tolerability, PK, and PD data from previous cohorts.
62178543|NCT04082481|EXPERIMENTAL|TAK-988: Part B|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, twice daily (6-hour interval) from Day 1 to Day 14 to healthy non-Japanese participants. Dose escalation will be based on review of the emerging safety/tolerability, PK, and PD data from previous cohorts and Part A.
62178544|NCT04082481|EXPERIMENTAL|TAK-988: Part C|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, twice daily (6-hour interval) from Day 1 to Day 7 to healthy non-Japanese participants. Dose will be determined based on previous multiple-rising dose (MRD) cohorts.
62178545|NCT04082481|EXPERIMENTAL|TAK-988: Part D|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, twice daily (6-hour interval) from Day 1 to Day 14 to HE non-Japanese participants. Dose will be determined based on previous MRD cohorts.
62178546|NCT04082481|EXPERIMENTAL|TAK-988: Part E|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, once on Day 1, followed by a washout period of 2 days and twice daily (6- hour interval) on Day 3 and continue to Day 17 to healthy Japanese participants. Dose will be determined based on previous MRD cohorts.
62178547|NCT04458181|EXPERIMENTAL|Treatment Group|Participants in this group will complete the intervention, Positive Peer Journaling (PPJ), while also continuing to attend intensive outpatient treatment for addiction.
62178548|NCT04458181|NO_INTERVENTION|Control Group|There will be no intervention for those randomized to the control group. However, they will complete assessment instruments throughout the study period while also continuing to attend intensive outpatient treatment for addiction.
62562749|NCT05596110|EXPERIMENTAL|TENS and KT|TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, KT will be applied to major postural muscles including the bilateral gluteus medius, quadriceps, and gastrocnemius of the participants.
62562750|NCT05596110|SHAM_COMPARATOR|TENS and sham taping|TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius, quadriceps, and gastrocnemius of the participants.
62770716|NCT02107872|EXPERIMENTAL|dosing cohort 3|Patients will receive REGN1500 or placebo in dosing cohort 3
62770717|NCT02107872|EXPERIMENTAL|dosing cohort 4|Patients will receive REGN1500 or placebo in dosing cohort 4
62770718|NCT02107872|EXPERIMENTAL|dosing cohort 5|Patients will receive REGN1500 or placebo in dosing cohort 5
62770719|NCT05818514|EXPERIMENTAL|[11C]AZ14132516|Pilot panel: up to 3 participants to complete 1 PET examination each during the course of the study Main panel: up to 6 participants to complete 2 PET examinations each during the course of the study
62178549|NCT01940289|ACTIVE_COMPARATOR|asymptomatic subjects attending podiatry clinic for nail care|Algometric meter readings for perception of pain These subjects will have an algometric pressure threshold meter reading taken during their routine treatment visit to establish Algometric meter readings for perception of pain
62178550|NCT01940289|ACTIVE_COMPARATOR|forefoot pain|Algometric meter readings for perception of pain forefoot pain severity measured by both VAS and algometric pressure meter
62770720|NCT06383104|EXPERIMENTAL|Experimental group|The intervention period will last 4 weeks, with a periodicity of 2 weekly sessions of 50 minutes each. The intervention of the experimental group will consist of a protocol using myofascial and proprioceptive neuromuscular facilitation techniques.
62178551|NCT02669134|ACTIVE_COMPARATOR|SonR optimization|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV"
62178552|NCT02669134|PLACEBO_COMPARATOR|Fixed settings|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming device programming: sensed AV delay of 125 ms, VV delay of 0 ms (simultaneous); SonR CRT Optimization programmed Off)."
62178553|NCT05089604|EXPERIMENTAL|LCPT|
62178554|NCT05089604|ACTIVE_COMPARATOR|IR-TAC|
62178555|NCT05231655||Bladder Cancer|
62178556|NCT05231655||Kidney Cancer|
62770721|NCT06383104|NO_INTERVENTION|Control group|Patients included in the control group will not receive any intervention, maintaining their activities of daily living in the same way as before the study.
62770722|NCT01291277|ACTIVE_COMPARATOR|Ligation: 1-week interval|Endoscopic variceal ligation performed at 1-week intervals
62770723|NCT01291277|ACTIVE_COMPARATOR|Ligation 2-week interval|Endoscopic variceal ligation performed at 2-week intervals
62770724|NCT05241925|EXPERIMENTAL|Combined Training + Resistance Training|"Combined training (continuous aerobic + resistance) The protocol will consist of supervised exercise lasting 1h10min each session (5 min of warm-up, 30 min of aerobic exercise, 30 min of resistance exercise and 5 min of cool-down/relaxation).~And Resistance Training~- Resistance exercise will be performed at 70-80% of one repetition maximum (1-RM); 2 to 3 sets of 8 to 12 repetitions. The main muscle groups will be trained using training equipment with free weights and body mass of the participants. Exercises included leg extension, seated bicep curl, squat, seated triceps extension, sit-up, seated shoulder press, and standing pulldown"
62178557|NCT05231655||Melanoma|
62562751|NCT05596110|SHAM_COMPARATOR|KT and sham TENS|KT will be applied to major postural muscles including the bilateral gluteus medius, quadriceps, and gastrocnemius of the participants. In addition, sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs.
62770725|NCT05241925|EXPERIMENTAL|Hitt Training + Resistance Training|"Combined training (high-intensity interval (IAI) + resistance) - Supervised exercise lasting 30 min each session (5 min warm-up, 20 min IAI and 5 min cool-down/relaxation).~And Resistance Training~- Resistance exercise will be performed at 70-80% of one repetition maximum (1-RM); 2 to 3 sets of 8 to 12 repetitions. The main muscle groups will be trained using training equipment with free weights and body mass of the participants. Exercises included leg extension, seated bicep curl, squat, seated triceps extension, sit-up, seated shoulder press, and standing pulldown"
62770726|NCT03163368|EXPERIMENTAL|Neoadjuvant stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to neurosurgical resection of the indexed brain metastasis. The dose of radiation to be administered to the indexed lesion will be established as a function of tumor size.
62178558|NCT05231655||Sarcoma|
62770727|NCT02184429|EXPERIMENTAL|Single Ascending Dose-1|Single ascending doses of PF-06669571 administered to healthy volunteers in a cross over study design
62178559|NCT05231655||Glioblastoma|
62178560|NCT05231655||Head and Neck Cancer|
62178561|NCT02742792|EXPERIMENTAL|Resistance training|Resistance training, twice a week during 12 weeks.
62178562|NCT02742792|OTHER|Advice on lifestyle|Patients receive advice on lifestyle. Patients will be asked to participate in the elderly group meetings the basic health unit linked to the hospital.
62178563|NCT04683328|EXPERIMENTAL|SCTA01 Group|SCTA01+Best Supportive Care
62178564|NCT04683328|PLACEBO_COMPARATOR|Placebo Group|Placebo+Best Supportive Care
62178565|NCT03713073|EXPERIMENTAL|Allogenic amnion chorion membrane|Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
62178566|NCT03713073|ACTIVE_COMPARATOR|Collagen dressing|Collagen dressing is used to cover wounds in dental surgery.
62178567|NCT06077877|EXPERIMENTAL|Part 1 - GSK4524101 Monotherapy|
62178568|NCT06077877|EXPERIMENTAL|Part 1 - GSK4524101 plus Niraparib|
62178569|NCT06077877|EXPERIMENTAL|Part 1 - GSK4524101 Food Effect Cohort|
62178570|NCT06077877|EXPERIMENTAL|Part 2 - GSK4524101 plus Niraparib|
62178571|NCT06077877|ACTIVE_COMPARATOR|Part 2 - Niraparib|
62178572|NCT01417702||Crohn´s disease - active|Patients in the active phase of the disease
62178573|NCT01417702||Crohn´s disease - quiescent|Patients in the quiescent phase of the disease
62562752|NCT05596110|SHAM_COMPARATOR|Sham TENS and sham taping|Sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius, quadriceps, and gastrocnemius of the participants.
62178574|NCT01417702||Ulcerative colitis - active|Patients in the active phase of the disease
62770728|NCT02184429|EXPERIMENTAL|Single Ascending Dose-2|Single ascending doses of PF-06669571 administered to healthy volunteers in a cross over study design
62770729|NCT02184429|EXPERIMENTAL|Multiple Ascending Dose-1|Daily dose of PF-06669571 in healthy volunteers
62178575|NCT01417702||Ucerative colitis - quiescent|Patients in the quiescent phase of the disease
62178576|NCT04510025||Non-COVID|We will enrol age, gender, BMI and co-morbidity matched non-COVID control subjects ( no serological evidence of previous infection or active symptoms).
62178577|NCT04510025||COVID-19|Hospitalised patients with moderate to severe infection (admitted for at least 2 days in hospital).
62178578|NCT03536078|NO_INTERVENTION|Phototherapy at hospital|Newborns with icterus that receive treatment while being admitted to hospital.
62178579|NCT03536078|EXPERIMENTAL|Home phototherapy|Newborns with icterus receiving phototherapy at home.
62178580|NCT02979171|ACTIVE_COMPARATOR|LMA-Classic|airway management with LMA-Classic
62178581|NCT02979171|ACTIVE_COMPARATOR|LMA-Flexible|airway management with LMA-Flexible
62178582|NCT02979171|ACTIVE_COMPARATOR|LMA-Proseal|airway management with LMA-Proseal
62178583|NCT02350855|EXPERIMENTAL|Intervention group|Patients in the intervention group were given dietary supplement (Improved Atta: 100 g) daily along with nutritional counseling and physical activity counseling for six months.
62178584|NCT02350855|OTHER|Control group|Patients in the control group were given nutritional and physical activity counseling for six months every fortnight.
62178585|NCT05321771|EXPERIMENTAL|Family caregiver application of HELP principles|The family caregiver will apply the principles of the HELP program in a structured manner following training by a nurse clinical specialist in geriatrics. The patient will be assessed daily by means of the Confusion Assessment Method (CAM) and the 4 'A's test (Arousal, Attention, Abbreviated Mental Test - 4, Acute change) (4AT) to determine delirium incidence.
62178586|NCT02368899|EXPERIMENTAL|Computerized Alcohol Misuse Intervention|Arm 1 is a cross-over randomized controlled trial (XRCT) comparing the short-term effects of the computerized alcohol misuse intervention (CAMI) vs. a generic health education attention-control (AC) condition in reducing past 30 day: (a) days of alcohol use, (b) days of heavy episodic drinking, (c) typical number of drinks consumed on a day of drinking, and (d) alcohol use in dangerous situations; (2) investigate changes in (a) patient motivation and (b) perceived norms as mediators of intervention effectiveness.
62562753|NCT02860156||HIV+/DD+|Subjects are HIV positive and have diastolic dysfunction
62562754|NCT02860156||HIV+/DD-|Subjects are HIV positive and do not have diastolic dysfunction
62562755|NCT02860156||HIV-/DD+|Subjects do not have HIV and have diastolic dysfunction
62770730|NCT02184429|EXPERIMENTAL|Multiple Ascending Dose-2|Daily dose of PF-06669571 in healthy volunteers
62562756|NCT02822937|EXPERIMENTAL|Placebo, Methylphenidate, Triazolam|The participants will receive placebo on the first day, 40mg Methylphenidate on the second day, and 0.375mg Triazolam on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
62770731|NCT02184429|EXPERIMENTAL|Multiple Ascending Dose-3|Daily dose of PF-06669571 in healthy volunteers
62770732|NCT02184429|EXPERIMENTAL|Multiple Ascending Dose-4|Daily dose of PF-06669571 in healthy volunteers
62178587|NCT02368899|PLACEBO_COMPARATOR|Attention Control (AC)|Arm 2 is not an active intervention but an attention control condition - it is not expected to exert any real intervention effect. Hence, any observed effects for the AC condition can be attributed to natural change via regression-to-the-mean, assessment reactivity, or a placebo effect. The effect size estimate of the intervention, both from an efficacy standpoint (i.e., above and beyond what change would have normally occurred) and an effectiveness standpoint (i.e., the magnitude of behavior change that can be expected in real-world implementation), can be readily calculated.
62178588|NCT00306956|EXPERIMENTAL|A|Recommendation to offer a pacifier to 15 days old newborn infants with successful breastfeeding
62770733|NCT02184429|EXPERIMENTAL|Multiple Ascending Dose-5|Daily dose of PF-06669571 in healthy volunteers
62770734|NCT02796508|EXPERIMENTAL|Non-action video game training|Experimental: Non-action video game training 16 1-hour training sessions with 10 non-action video game training selected games from Lumosity.
62178589|NCT00306956|ACTIVE_COMPARATOR|B|Recommendation not to offer a pacifier to normal newborn infant with successful breastfeeding at 15 days of age
62178590|NCT03243500|SHAM_COMPARATOR|Group C|"2.5 ml of lidocaine 2% 2.5 ml of bupivacaine 0.5% hyaluronidase powder 15 IU/ml~1 ml normal saline to make a total volume of 6 ml from which the patient received 5-6 ml through percaruncular peribulbar injection."
62178591|NCT03243500|ACTIVE_COMPARATOR|Group A|"5 mg atracurium 2.5 ml of lidocaine 2% 2.5 ml of bupivacaine 0.5% hyaluronidase 15 IU/ml~1 ml normal saline to make a total volume of 6 ml from which the patient received 5-6 ml through percaruncular peribulbar injection."
62178592|NCT02480751|EXPERIMENTAL|1: Exprimental (TRK-100STP)|high dose
62770735|NCT02796508|ACTIVE_COMPARATOR|Non-cognitive video game training|Active Control: Non-cognitive social video game training 16 1-hour training sessions with non-cognitive video game training with social games from The Sims.
62770736|NCT00987493|EXPERIMENTAL|Treatment with rituximab, bendamustine and lenalidomide|
62178593|NCT02480751|EXPERIMENTAL|2: Exprimental (TRK-100STP)|low dose
62178594|NCT02480751|PLACEBO_COMPARATOR|3: Placebo Comparator|Placebo
62178595|NCT02782572|EXPERIMENTAL|Exercise with Non-invasive ventilation|Patients with acute haert failure who performed aerobic exercise with non-invasive ventilation. This group also received conventional medical treatment.
62178596|NCT02782572|SHAM_COMPARATOR|Exercise|Patients with acute haert failure who performed aerobic exercise with placebo of non-invasive ventilation. This group also received conventional medical treatment.
62178597|NCT02782572|OTHER|Control|Patients who receiveid only conventional medical treatment and not performed exercise during protocol.
62178598|NCT03478410|OTHER|Atrial fibrillation|An epicardial fat biopsy will be taken from patients with chronic atrial fibrillation or paroxysmal atrial fibrillation who undergo any cardiac surgery
62178599|NCT03478410|OTHER|Control|An epicardial fat biopsy will be taken from patients without any history of atrial fibrillation who undergo any cardiac surgery
62178600|NCT00710814|EXPERIMENTAL|Leptin - Placebo|Leptin self-administered subcutaneously twice each day for 16 weeks, then Placebo for 16 weeks.
62178601|NCT00710814|PLACEBO_COMPARATOR|Placebo - Leptin|Placebo self-administered subcutaneously twice each day for 16 weeks, then Leptin for 16 weeks.
62178602|NCT06369857|EXPERIMENTAL|Pectopexy|"All operations will be performed with patient in loyd davies position, sterilization of the perineum then sterilization of the vagina.~Evacuation of the bladder and examination under anesthesia is done.~Skin incision through pfannenstiel one then incision of subcutaneous tissue, rectus sheath, separation of recti muscle and opening of parietal peritoneum.~A polypropylene mesh (30×30 cm, Ethicon, Inc., Somerville, NJ) is cut to obtain two long arms (15-20 cm long) and a rectangular piece (4-7 cm wide). The mesh is fashioned and fixed over the dissected uterine isthmus and anterior part of the cervix with separated number 1 Prolene and number 1 Vicryl sutures.~Peritoneal incision was made from the right round ligament toward the pelvic side wall .~The mesh arm is grasped and laterally pulled out So the rectangular part of the mesh will be on the anterior part of the cervix The mesh arms are suspended and sutured to Pectineal liga peritoneum is closed over the mesh"
62178603|NCT05469412|EXPERIMENTAL|Interventional group|Standard management combined with distraction by using technology (Tablets/iPads).
62178604|NCT05469412|ACTIVE_COMPARATOR|Control group|Standard management combined with pharmacological intervention (oral midazolam 0.5 mg/kg) administered at least 30 min before surgery (maximum 20mg).
62178605|NCT01293383|OTHER|LEO 90105|
62770737|NCT01131741|EXPERIMENTAL|Epinephrine|
62770738|NCT01131741|PLACEBO_COMPARATOR|Control|
62178606|NCT01293383|OTHER|Vehicle|
62178607|NCT03215342|EXPERIMENTAL|pGMT|Pediatric Goal Management Training
62770739|NCT05047575|EXPERIMENTAL|REASSURE Cohort 1|Survivors who are enrolled at time of a follow-up visit and who will be offered the REASSURE intervention at the next 6 month visit (including the opportunity to replace a visit with feedback communication).
62770740|NCT05047575|EXPERIMENTAL|REASSURE Cohort 2|Survivors who are enrolled prior to a follow-up visit and who will be offered the REASSURE PRO assessment and feedback communication (but not provided the opportunity to replace a visit with feedback communication).
61994845|NCT00589953|EXPERIMENTAL|EPO ###|"All subjects will be identified as a such by the study identifier EPO### where EPO designates enrollment in this study and ### is a numeric identifier (e.g. 103)."
62178608|NCT03215342|EXPERIMENTAL|pBHW|Pediatric Brain Health Workshop
62178609|NCT02943707|EXPERIMENTAL|treatment group: ABMSCi & drugs|ABMSCi: Autologous bone marrow stem cells infusion drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
62178610|NCT02943707|ACTIVE_COMPARATOR|control group: drugs|drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
62178611|NCT01436968|EXPERIMENTAL|ProstAtak®|Aglatimagene besadenovec (CAN-2409) + valacyclovir + radiation therapy +/- ADT
62562757|NCT02822937|EXPERIMENTAL|Placebo, Triazolam, Methylphenidate|The participants will receive placebo on the first day, 0.375mg Triazolam on the second day, and 40mg Methylphenidate on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
62770741|NCT01818440|ACTIVE_COMPARATOR|A|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method
62178612|NCT01436968|PLACEBO_COMPARATOR|Control|Placebo + valacyclovir + radiation therapy +/- ADT
62178613|NCT02967809||final diagnosis after portable echography|Experimental group: final diagnosis after portable cardiac echograph examination
62770742|NCT01818440|EXPERIMENTAL|B|Patients will have the procedure performed using the 3-D Roadmap software.With the 3DRoadmap, images from a Cone-Beam CT are analyzed. Software shows the vessels supplying the tumor and the plan is displayed on top of fluoroscopy
62770743|NCT01547091|EXPERIMENTAL|UC-MSCs Treatment|Patients in UC-MSCs treatment will be infused umbilical cord-derived mesenchymal stem cells intravenously only.
62770744|NCT01547091|ACTIVE_COMPARATOR|DMARDS|Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs).
61994846|NCT05410470||MF patients who received ruxolitinib treatment|
61994847|NCT01748253|ACTIVE_COMPARATOR|Telmisartan-amlodipine tablet administration group (morning)|
61994848|NCT01748253|ACTIVE_COMPARATOR|Telmisartan-amlodipine tablet administration group (bedtime)|
62178614|NCT02967809||final diagnosis without portable echography|Group control: Final diagnosis for patient ( same medical condition and history) hospitalized in units without portable cardiac echograph examination avaible
62178615|NCT05506215|EXPERIMENTAL|NovoSorb SynPath|Arm receives application on NovoSorb SynPath Dermal Matrix and appropriate Off-loading
62178616|NCT05506215|ACTIVE_COMPARATOR|Standard of Care|Arm receives application of wound dressing composed of 90% Collagen and 10% Alginate plus appropriate Off-loading
62178617|NCT02025478|EXPERIMENTAL|Enteral Donor Breastmilk|"* Donor breast milk will be pasteurized prior to use.~* Given orally or by nasogastric (NG) or nasojejunal (NJ) tube.~* Feeding will be supervised and will be advanced as quickly as tolerated with a goal of providing 40-50% of nutritional needs from the donor milk.~* It is recognized that the volume of enteral feeds will need to be adjusted per patient tolerance."
62178618|NCT04626271|EXPERIMENTAL|"ACR | U.S. Urine Analysis Test System"|Urine samples are collected and tested by a lay user, using the new home use device. The lay user test results are compared to the results obtained by testing the same urine sample on the comparison device.
62178619|NCT02869945|OTHER|COMT HH|COMT HH gene
62178620|NCT02869945|OTHER|COMT HL|COMT HL gene
62178621|NCT02869945|OTHER|COMT LL|COMT LL gene
62178622|NCT02960256||Patients admitted to an internal medicine department due to an|
62178623|NCT03212950|EXPERIMENTAL|Fast-CL|Glucose control using DreaMed Glucositter and Fiasp® (Fast-CL)
62178624|NCT03212950|ACTIVE_COMPARATOR|Regular-CL|Glucose control using DreaMed Glucositter and regular insulin Aspart
62178625|NCT04651556|ACTIVE_COMPARATOR|Parenteral Analgesia|receive ordinary analgesics via intravenous route as paracetamol (7.5- 10 mg/kg) and ketorolac (0.5 mg/kg).
62178626|NCT04651556|ACTIVE_COMPARATOR|Intraperitoneal instillation|receive (Magnesium sulphate 40 mg/kg and bupivacaine 4mg/kg) in 30 ml of isotonic 0.9%N.S intra peritoneal at the end of surgery.
62178627|NCT00487318|EXPERIMENTAL|Arm 1 Plus statin|The addition of fluvastatin or rosuvastatin or other statins to the standard of care of peginterferon and ribavirin.
62178628|NCT00487318|ACTIVE_COMPARATOR|2|Administration of the standard of care for hepatitis C of peginterferon and ribavirin.
62178629|NCT01650935|ACTIVE_COMPARATOR|Oxalate restricted|After a run-in period of 3 weeks patients are allocated into 2 groups. The Oxalate restricted group is prescribed an oxalate restricted diet. They are instructed to avoid oxalate-rich foods such as spinach, rhubarb, beets, chocolate, cereals, nuts, tea, wheat bran, and strawberries and to drink water in amounts of roughly 2 L during cold weather and 3 L during warm/hot weather.
62178630|NCT01650935|ACTIVE_COMPARATOR|DASH diet|The second group is asked to follow a calorie-controlled DASH diet plan. DASH is an eating pattern recommended by the 2005 Department of Health and Human Services Dietary Guidelines for Americans as a model of healthy eating for the majority of individuals in the population. This group eats a diet which includes higher fruit, vegetables, and low-fat dairy products and lower in saturated fat, total fat, and cholesterol, containing more whole grains and fewer refined grains, sweets, and red meat.
62178631|NCT04780971|OTHER|Post-PCI intra-coronary physiological and OCT measurements|After angiographically successful CTO PCI, intra-coronary physiologic assessment (RFR, FFR, CFR and IMR) of the CTO vessel will be performed directly. A staged procedure including several measurements is planned at 4 ± 2 weeks after the index procedure. These measurements consists of the same intra-coronary physiologic assessments at index procedure and OCT imaging of the stented segment in the CTO target vessel.
62178632|NCT00614588||observation group|Patients undergoing laparoscopic surgery requiring general anesthesia and a bladder catheter.
62178633|NCT03765515|EXPERIMENTAL|Q-Fix|"Q-Fix has the advantages of all-suture implant and has the same or better performance than the traditional anchor.~* Consistent activation effect~* Excellent performance~* Streamlined technique Q-fix is an experimental Arm."
62178634|NCT03765515|ACTIVE_COMPARATOR|Twinfix Ti|The Smith \& Nephew's marketed Twinfix Suture Anchor is selected as the control product. This product is composed of anchor, suture, suture needle and inserter. The anchor is made of Ti6Al4V titanium alloy conforming to ISO5832-3. The Durabraid suture is made of polyester (Polyethylene terephthalate) conforming to YY 0167. Ultrabraid suture is made of two materials of UHMWPE and polypropylene monofilaments conforming to GB/T 19701.1. The suture needle is made of Type 420B stainless steel conforming to YY/T 0726. The stem portion of inserter that comes into contact with the body is made of Type 630B stainless steel conforming to YY/T 0726.
62178635|NCT04366518|EXPERIMENTAL|Aim 2: Those with psychosis/hallucinations|Participants who have a psychosis spectrum diagnosis and frequent auditory hallucinations will be given Rivastigmine capsule versus placebo capsule.
62178636|NCT04366518|PLACEBO_COMPARATOR|Aim 1: Healthy Controls|Healthy controls will be given scopolamine patches versus placebo patch.
62178637|NCT02553577||Conventional cigarettes -only|Women who are pregnant and use conventional tobacco products -only
62178638|NCT02553577||Electronic Cigarette (ecig) (ENDS) -ONLY|Women who are pregnant and use electronic cigarettes (ecigs) -only
62178639|NCT02553577||Conventional + ecig use (DUAL)|Women who are pregnant and use conventional + ecigs (dual)
62178640|NCT03277677|ACTIVE_COMPARATOR|normal saline|
62178641|NCT03277677|ACTIVE_COMPARATOR|balanced solution|
62178642|NCT05082623|EXPERIMENTAL|Music group|"MusiCure® compositions specially composed for the music group will be performed twice a day, between 10.00-11.00 a.m. and 14.00-15.00 p.m., for five days with headphones and a music player. Before the application, the sound level of the ICU environment will be measured with a decibel meter. At the 0th minute of the music application, at the 30th minute after starting the music, and at the 60th minute after the end of the music, the characteristics of delirium, pain, sedation level, anxiety and vital parameters will be recorded with data collection tools."
62178643|NCT05082623|ACTIVE_COMPARATOR|Earplug group|In this group, patients will be given only earplugs. Before the application, the sound level of the ICU environment will be measured with a decibel meter. At the 0th minute of the intervention, at the 30th minute after starting intervention, and at the 60th minute after the end of the intervention, the characteristics of delirium, pain, sedation level, anxiety and vital parameters will be recorded with data collection tools.
62178644|NCT05082623|NO_INTERVENTION|Control group|The control group involves neither music intervention nor using earplug.
62178645|NCT03766373|ACTIVE_COMPARATOR|Drug: OP0201|
62178646|NCT03766373|PLACEBO_COMPARATOR|Drug: Placebo|
62178647|NCT06129045|EXPERIMENTAL|Group One, Video|One-time sleep hygiene education
62178648|NCT06129045|EXPERIMENTAL|Group Two, Video Plus Texts|One-time sleep hygiene education plus repeated education through automated text messaging
62178649|NCT06129045|NO_INTERVENTION|Group Three,|Control group with no intervention assigned
62562758|NCT02822937|EXPERIMENTAL|Methylphenidate, Placebo, Triazolam|The participants will receive 40mg Methylphenidate on the first day, placebo on the second day, and 0.375mg Triazolam on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
62178650|NCT01839786||PHTN patients|2. Patients who underwent RHC in the past and were diagnosed with PHTN (retrospective arm)
62178651|NCT03060213|EXPERIMENTAL|Fun For Wellness (FFW)|Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being.
62178652|NCT03060213|NO_INTERVENTION|Usual Care (UC)|The Usual Care (UC) group will conduct their lives as usual during the 30 day intervention period.
62178653|NCT04241887|EXPERIMENTAL|group PVB|standard analgosedation + paravertebral thoracic blockade with 20 ml 0.25% bupivacaine (Bupivacainum hydrochloricum WZF 0,5%, Polfa warszawa S.A.)
62178654|NCT04241887|ACTIVE_COMPARATOR|group BB|standard analgosedation + local anesthesia of the skin and subcutaneous tissue with 5ml 0,5% lignocaine (Lignocainum hydrochlorici, WZF 1%).
62178655|NCT05757778|EXPERIMENTAL|Neurotized Breast|"For patients undergoing bilateral implant-based breast reconstruction following nipple-sparing mastectomy, one breast will be neurotized by connecting the lateral intercostal nerve to the nipple with interposing standard nerve grafting techniques. The neurotized breast will serve as the experimental breast. The other breast will not receive any breast neurotizing procedure."
62391031|NCT04156464|ACTIVE_COMPARATOR|Phenobarbital based treatment|"* The phenobarbital group will undergo management with a phenobarbital based treatment protocol with additional symptom triggered therapies.~* On day 1, the phenobarbital group receive a loading dose of phenobarbital intravenous 10mg/kg (actual body weight) with a maximum dose of 1 g/100 mL~* On day 2 of study protocol, and no sooner than 12 hours after loading dose, phenobarbital 64.8 mg is administered every 12 hours for two doses.~* On day 3 of study protocol, patients will receive phenobarbital 32.4 mg every 12 hours for two doses.~* On day 4 of study protocol, patients will receive phenobarbital 32.4 mg once, to be given 24 hours after last scheduled dose.~* Throughout the 4 day protocol, the patient will have phenobarbital 65 mg every 6 hours as needed available either IM or IV, starting no sooner than 30 minutes after the loading dose."
62562759|NCT02822937|EXPERIMENTAL|Methylphenidate, Triazolam, Placebo|The participants will receive 40mg Methylphenidate on the first day, 0.375mg Triazolam on the second day, and placebo on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
62770745|NCT01547091|ACTIVE_COMPARATOR|UC-MSC+DMARDS|Patients will be treated in combination with UC-MSC and DMARDS.
62770746|NCT05130476|EXPERIMENTAL|NIRAF+ICGA|During thyroid surgery, near-infrared-induced autofluorescence is used for the identification of the parathyroid glands, combined with indocyanine green near-infrared angiography for identification of the parathyroid feeding vessels.
61994849|NCT00446147|PLACEBO_COMPARATOR|Placebo|one tablet twice per day, which is identical to pyridoxine
61994850|NCT00446147|EXPERIMENTAL|Pyridoxine|100 mg twice per day
61994851|NCT05946538|OTHER|Device accuracy observational arm|Two nasopharyngeal swabs will be collected from each enrolled participant and analysed on the AusDiagnostics in vitro diagnostic device panel and the comparator BioFire in vitro diagnostic device panel.
61994852|NCT03050879|EXPERIMENTAL|Indocyanine Green Tracer|Indocyanine Green Tracer will be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
61994853|NCT03050879|ACTIVE_COMPARATOR|No Indocyanine Green Tracer|Indocyanine Green Tracer will not be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
61994854|NCT05929092|EXPERIMENTAL|40 patients with malignant hematological diseases who underwent UCBT|
61994855|NCT00628602|EXPERIMENTAL|Rx Group|BION Therapy Group
61994856|NCT00628602|PLACEBO_COMPARATOR|Control Group|control group
61994857|NCT03326011|EXPERIMENTAL|Gait training group|Gait training with Samsung Hip Assist v1 All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions.
61994858|NCT02670655|EXPERIMENTAL|Group A (short-time iontophoresis group)|Group A was treated with iontophoresis-assisted AFL-PDT with a short incubation time (2 h)
61994859|NCT02670655|ACTIVE_COMPARATOR|Group B (short-time conventional group)|Group B was treated with conventional AFL-PDT with a short incubation time (2 h)
61994860|NCT02670655|ACTIVE_COMPARATOR|Group C (long-time conventional group)|Group C was treated with conventional AFL-PDT with a standard incubation time (3 h)
61994861|NCT03146234|EXPERIMENTAL|CAR-GPC3 T cells|"Autologous T Cells with a GPC3-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.~Lymphodepletion conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day -6 to Day -3 prior to CAR-GPC3 T cells infusion."
61994862|NCT03778151|ACTIVE_COMPARATOR|TRANSCRANIAL MAGNETIC STIMULATION|repetitive TRANSCRANIAL MAGNETIC STIMULATION (rTMS) will be applied over the precuneus to modulate DMN activity. The rTMS treatment will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 5 months (21 sessions, 100.800 pulses in total).
61994863|NCT03778151|SHAM_COMPARATOR|SHAM TRANSCRANIAL MAGNETIC STIMULATION|SHAM TMS will be applied over the precuneus. The SHAM protocol will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 5 months (21 sessions, 100.800 pulses in total).
61994864|NCT02956733|ACTIVE_COMPARATOR|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
61994865|NCT02956733|ACTIVE_COMPARATOR|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 \& 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
61994866|NCT00764621|EXPERIMENTAL|Arm 1|
61994867|NCT00764621|ACTIVE_COMPARATOR|Arm 2|
62562760|NCT02822937|EXPERIMENTAL|Triazolam, Placebo, Methylphenidate|The participants will receive 0.375mg Triazolam on the first day, placebo on the second day, and 40mg Methylphenidate on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
61994868|NCT00764621|ACTIVE_COMPARATOR|Arm 3|
61994869|NCT04327986|EXPERIMENTAL|Cohort 1 Phase 1A/Arm 1A|De-escalating doses of NHS-IL12 (M9241) in combination with bintrafusp alfa (M7824)
61994870|NCT04327986|EXPERIMENTAL|Cohort 2 Phase 1B/Arm 1B|De-escalating doses of NHS-IL12 (M9241) in combination with bintrafusp alfa (M7824) and stereotactic body radiotherapy (SBRT)
61994871|NCT04327986|EXPERIMENTAL|Phase II Cohort 3/Arm 2|Recommended phase 2 dose (RP2D) of bintrafusp alfa (M7824) and NHS-IL12 (M9241) in combination with stereotactic body radiotherapy (SBRT)
61994872|NCT01611181|ACTIVE_COMPARATOR|Hemoboost (iron supplementation)|A registered natural product containing specially haemolysed haemoglobin and iron dextran.
61994873|NCT01611181|ACTIVE_COMPARATOR|Kräuterblut (iron supplementation)|A registered natural product made from a number of herbs with ferrous gluconate as the active substance.
62562761|NCT02822937|EXPERIMENTAL|Triazolam, Methylphenidate, Placebo|The participants will receive 0.375mg Triazolam on the first day, 40mg Methylphenidate on the second day, and placebo on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
62562762|NCT06030297|EXPERIMENTAL|Biomarker Optimization (Stanford)|Screening for neuropathy, foot problems and diabetes Diode laser testing of C:Aδ ratio Non-invasive speckle imaging Quantitative sensory testing ZTlido 1.8% lidocaine patch testing in some subjects
62562763|NCT06030297|EXPERIMENTAL|Neuropathy assessment and biomarker testing (Utah)|History, physical, and neurological exam Nerve conduction study Medical record review of neuropathy history PROMIS pain severity and interference testing Brief pain inventory Norfolk quality of life questionnaire Quantitative sensory testing 3mm skin punch biopsy Diode laser testing of C:Aδ ratio Non-invasive speckle imaging
62562764|NCT06030297|ACTIVE_COMPARATOR|Crossover testing in participants with painful neuropathy (ZTlido 1.8% lidocaine patch)|History, physical, and neurological exam Nerve conduction study Medical record review of neuropathy history PROMIS pain severity and interference testing Brief pain inventory Norfolk quality of life questionnaire Quantitative sensory testing 3mm skin punch biopsy Diode laser testing of C:Aδ ratio Non-invasive speckle imaging ZTlido 1.8% lidocaine patch application to both feet for 7 days up to 12 hours per day.
61994874|NCT01611181|ACTIVE_COMPARATOR|Ferrofumerat (iron supplementation)|Ferrous sulphate
61994875|NCT00006489|ACTIVE_COMPARATOR|Naltrexone alone|Naltrexone alone
61994876|NCT00006489|ACTIVE_COMPARATOR|Naltrexone with CBT for PTSD|Naltrexone with CBT for PTSD
61994877|NCT00006489|ACTIVE_COMPARATOR|Placebo with CBT for PTSD|Placebo with CBT for PTSD
61994878|NCT00006489|PLACEBO_COMPARATOR|Placebo alone|Placebo alone
61994879|NCT05044806|EXPERIMENTAL|Ultrasound-guided-RIC group|Patients in the ultrasound-guided-RIC group will receive percutaneous coronary intervention (PCI), usual pharmacotherapy and pre-, per-, and post-operative ultrasound-guided remote ischemic conditioning (RIC). The pressure applied during cuff inflation is total occlusion pressure (TOP) determined with ultrasound measurement.
61994880|NCT05044806|EXPERIMENTAL|Traditional RIC group|Patients in the traditional RIC group will receive PCI, usual pharmacotherapy and pre-, per-, and post-operative traditional RIC. The pressure applied during cuff inflation is 20 mmHg above systolic blood pressure.
61994881|NCT05044806|OTHER|Control group|Patients in the control group will receive PCI and usual pharmacotherapy.
61994882|NCT01150929|ACTIVE_COMPARATOR|Fixed bearing|One of the 2 used implants.
61994883|NCT01150929|ACTIVE_COMPARATOR|Rotating platform|One of the 2 used implants.
61994884|NCT06047275||Test|Hep C positive
61994885|NCT06047275||Control|Hep C negative
61994886|NCT06208436||TMUCIH-PDAC|Between 2010 and 2021, the data of patients who underwent surgical resection and were pathologically diagnosed as PDAC from Tianjin Medical University Cancer Institute and Hospital (TMUCIH) were collected retrospectively.
61994887|NCT00872703||1|
61994888|NCT00872703||2|
61994889|NCT05832671|ACTIVE_COMPARATOR|US guided erector spinae muscle block|patients will receive US-guided erector spinae muscle block with a total volume of 0.4 mg/kg of 0.25% bupivacaine.
62770747|NCT02077543|EXPERIMENTAL|ProTool|Device: Brain Tissue Imprint - Medical Device (ProTool)
62770748|NCT03506919|EXPERIMENTAL|Arthitec 1|
62770749|NCT03506919|EXPERIMENTAL|Arthitec 2|
62770750|NCT02488460|NO_INTERVENTION|Normal math|This arm serves as the control group receiving regular math lessons
62770751|NCT02488460|EXPERIMENTAL|Active math|This arm serves as the intervention group receiving physically active math lessons
62770752|NCT00784485|EXPERIMENTAL|Xolair injections|All subjects receive active drug (Xolair-see 'interventions').
62770753|NCT02383771|EXPERIMENTAL|Single Anti-platelet Treatment|Ticagrelor
62770754|NCT02383771|EXPERIMENTAL|Dual Anti-platelet Treatment|Aspirin + Ticagrelor
62770755|NCT02383771|SHAM_COMPARATOR|Control|No Drug
62770756|NCT02383771|OTHER|CAD undergoing PCI|Patients with coronary artery disease undergoing percutaneous coronary intervention and receiving dual anti-platelet therapy (ticagrelor 90mg bid + aspirin 100mg daily)
62770757|NCT00237380|EXPERIMENTAL|Ataluren|"Cycle 1: Within the first 28-day period, ataluren treatment will be taken 3 times per day with meals for 14 days at doses of 4 milligrams/kilogram (mg/kg) (breakfast), 4 mg/kg (lunch), and 8 mg/kg (dinner); there will then be an interval of 14 days without treatment.~Cycle 2: Within the second 28-day period, ataluren treatment will be taken 3 times per day with meals for 14 days at doses of 10 mg/kg (breakfast), 10 mg/kg (lunch), and 20 mg/kg (dinner); there will then be an interval of 14 days without treatment."
62770758|NCT06421272|EXPERIMENTAL|APP-based emotion recognition trainning|Experimental group: ASD children were asked to do emotion recognition for eight weeks using iPAD. Two 15-minsute sessions each day was required.
62770759|NCT06421272|ACTIVE_COMPARATOR|APP-based memory training|Control group: ASD children were asked to do memory training (i.e. 1 back) for eight weeks using iPAD. Two 15-minsute sessions each day was required.
62770760|NCT05505526|EXPERIMENTAL|Electroacupuncture|Participants in EA group will receive treatment at bilateral Bladder Meridian (BL) 33 \[Zhongliao\], BL35 \[Huiyang\] and Spleen Meridian (SP) 6 \[Sanyinjiao\]. The EA treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 8 weeks.
62391032|NCT04156464|ACTIVE_COMPARATOR|Lorazepam based treatment|"* The lorazepam group will undergo management with a lorazepam based treatment protocol with additional symptom triggered therapies.~* On Day 1, the lorazepam group will be started on scheduled lorazepam 4 mg every 6 hours~* After day 1, the scheduled lorazepam dose will be modified based on the total lorazepam requirements from the previous day and divided into 4-6 doses.~* A lorazepam infusion, at physician discretion, will be available at any point if the dose of scheduled and PRN lorazepam being given is too high or frequent to effectively be administered.~* Once symptoms are well controlled on lorazepam based therapy, the total dose given over the past 24 hours will be calculated and weaned by approximately 10-20% per day when clinically appropriate.~* Throughout the entire protocol, 2-4 mg lorazepam IV q 30 minutes PRN will be available for a goal CIWA \<6 or RASS -1 to 0."
62391033|NCT04923009|EXPERIMENTAL|Simple-ICE group|Patients undergoing ablation using only ICE visualization and ablation catheter
62391034|NCT04923009|ACTIVE_COMPARATOR|Standard mapping catheter without ICE|Patients undergoing ablation using standard approach including diagnostic and mapping electrodes as well as ablation electrode
62770761|NCT05505526|SHAM_COMPARATOR|Sham electroacupuncture|Participants in SA group will receive treatment at bilateral sham BL33 \[Zhongliao\], sham BL35 \[Huiyang\] and sham SP6 \[Sanyinjiao\]. The SA treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 8 weeks.
62770762|NCT06265623||COPD patients with exertional desaturation|Patients with chronic obstructive pulmonary disease stages 2-3, groups B or E according to the GOLD Guideline (2023), who experience a drop in arterial oxygen saturation (by pulse oximetry) to \<90% or a drop by 4% or greater of the basal value during a six-minute walk test.
62770763|NCT06265623||COPD patients without exertional desaturation|Patients with chronic obstructive pulmonary disease stages 2-3, groups B or E according to the GOLD Guideline (2023), who do not experience a drop in arterial oxygen saturation (by pulse oximetry) to \<90% or a drop by 4% or greater of the basal value during a six-minute walk test.
62770764|NCT00007020|OTHER|Cholic Acid|
62770765|NCT00885781|EXPERIMENTAL|SMOFlipid|
62770766|NCT00885781|ACTIVE_COMPARATOR|Lipovenoes MCT|
62391035|NCT06427616|EXPERIMENTAL|Short Duration Moderate Intensity Soleus Push-ups (Group A)|Moderate intensity involving weighted soleus push-ups is performed till patient MHR is achieved.
62391036|NCT06427616|EXPERIMENTAL|Sustained Soleus Push-ups (Group B)|Sustained soleus push-ups will be performed for up to 270 min.
62391037|NCT02911285|EXPERIMENTAL|NAC/CBT|Participants will receive N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT) for 8 weeks.
62391038|NCT02911285|PLACEBO_COMPARATOR|Placebo/CBT|Participants will receive placebo pills and CBT for 8 weeks.
62770767|NCT03891914|EXPERIMENTAL|Symptomatic Multiple Myeloma on first-line treatment|
62770768|NCT05373693|PLACEBO_COMPARATOR|Control group|The subjects are randomized to wear SV lens
62770769|NCT05373693|EXPERIMENTAL|experimental group +2D|The subjects are randomized to wear special designed lens with +2D Peripheral Defocus.
62770770|NCT05373693|EXPERIMENTAL|experimental group +3D|The subjects are randomized to wear special designed lens with +3D Peripheral Defocus.
62770771|NCT05373693|EXPERIMENTAL|experimental group +4D|The subjects are randomized to wear special designed lens with +4D Peripheral Defocus.
62391039|NCT02362295||census|qualitative interview
62391040|NCT05020470|EXPERIMENTAL|Self-guided mAPA (S-mAPA)|S-mAPA group will be provided with instructions so that participants can learn to self-administer APA weekly for four weeks and then followed by weekly telecommunication for Q \& As.
62391041|NCT05020470|EXPERIMENTAL|In-Person Training + mAPA (IP-mAPA)|Participants will receive one in-person training after baseline data is collected and then will self-administer APA on the same schedule with weekly telecommunication as those in the mAPA group.
62770772|NCT00179036||Good blood flow|Group without any ischemia to the small intestine
62770773|NCT00179036||Poor blood flow|Group with partial ischemia to the small intestine
62770774|NCT05323071|ACTIVE_COMPARATOR|Control Group|Sucrose will be administered 2 minutes before the puncture following the current protocol of the unit. Venous or arterial puncture will be performed only in case it is required for therapeutic or care purposes.
61994890|NCT05832671|ACTIVE_COMPARATOR|ultrasound-guided caudal block|patients will receive an ultrasound-guided caudal block with 2.5 mg/kg of 0.25% bupivacaine to be injected over one minute period while observing an ultrasound longitudinal image.
61994891|NCT03323658|EXPERIMENTAL|Prevention (bexarotene)|Group 1 will apply 10mg bexarotene topically to one breast QOD for 4 weeks; Group 2 will apply 10mg bexarotene topically to one breast QOD for 1 week and then daily for 3 weeks after confirmation that toxicity is at an acceptable range; Group 3 will apply 10mg bexarotene topically to one breast QOD for 1 week, then daily for 1 week, and then 20mg daily for 2 weeks after confirmation that toxicity is at an acceptable range.
61994892|NCT00256152|NO_INTERVENTION|AF Suppression OFF|
61994893|NCT00256152|EXPERIMENTAL|AF Suppression ON|
61994894|NCT05457569||Parent Support Group - WP1|Group representatives (SOS Préma, The Neurogroup...)
61994895|NCT05457569||Parents of infants at a high risk of neurodevelopmental disorders - WP1|infants between 34 weeks' gestation and 4 months' corrected age at the time of the first focus group and with at least one risk factor for neurodevelopmental disorder
61994896|NCT05457569||Parents of children with developmental difficulties - WP1|"children between 18 and 48 months corrected age at the time of the first focus group:~* with at least one risk factor for neurodevelopmental disorder~* presenting an abnormal, non-transient clinical state"
61994897|NCT05457569||Health Professionals - WP1|Private physiotherapists, labor and delivery nurses of the Maternal and Child Protection, Centre d'action médico-sociale précoce (CAMSP) (psychomotricians, psychologists) and doctors involved in the care and follow up of children at risk of developmental disorders whose parents have agreed to participate in the study.
61994898|NCT05457569||Physiotherapist in a private practice - WP2|Physiotherapists working in a private practice
61994899|NCT05457569||Parents - WP2|parents of hospitalized children between 34 weeks of gestation and 4 months of corrected age with at least one risk factor for neurodevelopmental disorder
61994900|NCT05457569||PMI-CAMPS - WP2|Labor and delivery nurses from the Protection Maternelle et Infantile, CAMPS (psychomotricians, psychologists) and doctors involved in the care of children at risk of developmental disorders who are in charge of the follow-up of children whose parents have agreed to participate in the study.
61994901|NCT03829046|PLACEBO_COMPARATOR|Placebo|Placebo SC QM
61994902|NCT03829046|ACTIVE_COMPARATOR|Evolocumab|Evolocumab SC 420mg/dL QM
61994903|NCT03135041|EXPERIMENTAL|Fiber-containing dietary supplement|2 x 200 ml of fiber-enriched UHT milk during 12 weeks of energy restriction
61994904|NCT03135041|PLACEBO_COMPARATOR|Placebo|2 x 200 ml of UHT milk with maltodextrin during 12 weeks of energy restriction
61994905|NCT02985632|EXPERIMENTAL|Mild Hepatic Impairment Subjects|Subjects given an oral dose of BMS-986141.
61994906|NCT02985632|EXPERIMENTAL|Moderate Hepatic Impairment Subjects|Subjects given an oral dose of BMS-986141.
61994907|NCT02985632|EXPERIMENTAL|Healthy Subjects|Subjects given an oral dose of BMS-986141.
61994908|NCT04624321|EXPERIMENTAL|Access to tool|Access to the digital tool. They use the tool at their own and do the different themes that are available. They are recommended to use it at least every other week.
61994909|NCT04624321|PLACEBO_COMPARATOR|Usual care|They are followed by their ordinary healthcare provider.
61994910|NCT04056559|EXPERIMENTAL|SIngle arm|The research is based on a population of men and women practicing a sport at risk of oral trauma.
61994911|NCT06215963|EXPERIMENTAL|App for Independence-O (A4i-O)|Participants will be provided with A4i-O for one month.
61994912|NCT02579265|EXPERIMENTAL|Smoflipid 20%|"Smoflipid is a lipid emulsion containing soybean oil, MCTs (medium-chain triglycerides), olive oil, and fish oil. Smoflipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions."
62391042|NCT05020470|ACTIVE_COMPARATOR|Usual Care Control (UC)|"Participants will receive usual care only for their pain; after enrolled, patients will receive weekly telecommunication to control for attention and time. The content of the phone/video call will focus on the pain problem they have and the investigators will provide additional information published by the National Center for Complementary and Integrative Health Chronic Pain: In-Depth (https://www.nccih.nih.gov/health/chronic-pain-in-depth) which the investigators used in the R01 study for participants enrolled in the control group"
62391043|NCT01960036|NO_INTERVENTION|Treatment as usual (TAU)|Usual intensive outpatient treatment for substance use disorders
62391044|NCT01960036|EXPERIMENTAL|Mindful Awareness in Body-oriented Therapy (MABT)|A mind-body intervention to teach interoceptive skills for self-care.
62391045|NCT01960036|ACTIVE_COMPARATOR|Womens Health Education|A comparative arm to control for time and attention that involves education about the human body relevant to women's health.
62391046|NCT03936868||Tendon transfer for irreversible radial nerve palsy patient|Tendon transfer for irreversible radial nerve palsy patient who had irreversible damage to radial nerve due to trauma with different mechanism especially gun shot injury
62391047|NCT05331326|EXPERIMENTAL|HER2 Positive|Drug: RC48-ADC 2.0 mg/kg (HER2 Positive) 32 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
61994913|NCT02579265|ACTIVE_COMPARATOR|Intralipid® 20%|"Intralipid is a long-chain triglyceride emulsion derived from purified soybean oil and egg yolk phospholipids. Intralipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions."
61994914|NCT03632278|EXPERIMENTAL|Mindfulness psychoeducation programme|A MBPP will be conducted for 2 hours for each session, one a week for ten weeks, with 13-15 participants per group. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien \& Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).
62178656|NCT05757778|NO_INTERVENTION|Non-Neurotized Breast|"For patients undergoing bilateral implant-based breast reconstruction following nipple-sparing mastectomy, one breast will not receive any breast neurotizing procedure. The non-neurotized breast will serve as the control breast."
61994915|NCT03632278|NO_INTERVENTION|Treatment as usual|"The usual care group will receive routine psychiatric outpatient services, including monthly psychiatric consultation and treatment by a psychiatrist, psychiatric nursing advice and brief education according to the patient's psychosocial needs. There will be community mental health services, social welfare or financial assistance supported by medical social workers, whenever necessary.~Participants in this control may be aware that they are receiving no extra treatment which may result in negative expectancies and inflation of the treatment effect (Stoney \& Johnson, 2012). To eliminate the time effect and artificially inflated intervention effect, patients in the control group will receive telephone contact once a week to discuss their disease process and daily issues."
62562765|NCT06030297|PLACEBO_COMPARATOR|Crossover testing in participants with painful neuropathy (placebo patch)|History, physical, and neurological exam Nerve conduction study Medical record review of neuropathy history PROMIS pain severity and interference testing Brief pain inventory Norfolk quality of life questionnaire Quantitative sensory testing 3mm skin punch biopsy Diode laser testing of C:Aδ ratio Non-invasive speckle imaging Placebo patch application to both feet for 7 days up to 12 hours per day.
61994916|NCT02639104|EXPERIMENTAL|Cervical postural related neck pain|Patients recruit in this group who has a neck pain without radiculopathy. If the patient examination shows neurologic deficits, this patient will exclude in this study. All patients will undergo lateral cervical spine spot radiography and serratus anterior needle electromyography. Cervical segmental angle measurements will be done in all patients.
61994917|NCT02639104|SHAM_COMPARATOR|Control group|The healthy volunteers recruit in this group. All inviduals will undergo lateral cervical spot radiography and serratus anterior needle electromypography
61994918|NCT01449578|EXPERIMENTAL|Part A, Treatment 1|Dexpramipexole single dose (SAD Dose 1)
61994919|NCT01449578|PLACEBO_COMPARATOR|Part A, Treatment 1 placebo|Dexpramipexole single dose placebo (SAD Dose 1)
61994920|NCT01449578|EXPERIMENTAL|Part A, Treatment 2|Dexpramipexole single dose (SAD Dose 2)
61994921|NCT01449578|PLACEBO_COMPARATOR|Part A, Treatment 2 placebo|Dexpramipexole single dose placebo (SAD Dose 2)
61994922|NCT01449578|EXPERIMENTAL|Part A, Treatment 3|Dexpramipexole single dose (SAD Dose 3)
61994923|NCT01449578|PLACEBO_COMPARATOR|Part A, Treatment 3 placebo|Dexpramipexole single dose placebo (SAD Dose 3)
61994924|NCT01449578|EXPERIMENTAL|Part B, Treatment 1|Dexpramipexole multiple dose (MAD Dose 1)
62562766|NCT05166083||Trans man|"Trans man is assigned female at birth and identify as man"
62770775|NCT05323071|EXPERIMENTAL|Experimental Group|The administration of the sucrose dose is started by means of a syringe. Once 50% of the dose has been administered, puncture will be performed. The remaining 50% will be administered during the puncture. The pacifier will be left in the mouth until the end of the procedure, facilitating the non-nutritive sucking of the neonate.
62770776|NCT02774304|ACTIVE_COMPARATOR|arterial line|invasive haemodynamic monitoring
61994925|NCT01449578|PLACEBO_COMPARATOR|Part B, Treatment 1 placebo|Dexpramipexole multiple dose placebo (MAD Dose 1)
61994926|NCT01449578|EXPERIMENTAL|Part B, Treatment 2|Dexpramipexole multiple dose (MAD Dose 2)
61994927|NCT01449578|PLACEBO_COMPARATOR|Part B, Treatment 2 placebo|Dexpramipexole multiple dose placebo (MAD Dose 2)
61994928|NCT02307006|EXPERIMENTAL|Ceftaroline|Experimental comparator for surgical peri-operative prophylaxis for procedures at increased risk if MRSA infection
61994929|NCT02307006|ACTIVE_COMPARATOR|Cefazolin / Vancomycin|Standard of care comparator for surgical peri-operative prophylaxis for procedures at increased risk if MRSA infection
61994930|NCT01293240|EXPERIMENTAL|Lotrafilcon B|
61994931|NCT01451307||Gastrointestinal malformations|Children who underwent standardized neonatal pediatric surgery due to gastrointestinal malformations
61994932|NCT01451307||No gastrointestinal malformations|Control group of healthy children matched concerning gestational age, weight class and gender
62562767|NCT02847949|EXPERIMENTAL|Extension arm|IGN002 study drug will initially be administered at the same dose level and schedule that the subject was receiving at the conclusion of the other Spectrum sponsored IGN002 study, IGN002-101.
62562768|NCT04652115|EXPERIMENTAL|Defibrotide|Defibrotide IV
62178657|NCT05280743||MATERNAL cohort|Nursing mothers who underwent Cesarean Delivery and who are receiving oxycodone to treat post-operative pain
62562769|NCT00725868|OTHER|1|Data private hospitals, angioplasty, sampling of blood
62562770|NCT02741076|EXPERIMENTAL|Structured discontinuation opioid therapy Suboptimal Responder|
62562771|NCT02741076|EXPERIMENTAL|Structured discontinuation opioid therapy Optimal responders|
62770777|NCT02774304|EXPERIMENTAL|Cheetah®|non-invasive cardiac output
62770778|NCT01750359|ACTIVE_COMPARATOR|curcumin|
62770779|NCT01750359|PLACEBO_COMPARATOR|placebo|
62770780|NCT01055483|EXPERIMENTAL|LBH589|
62770781|NCT01908166|EXPERIMENTAL|Diagnostic (ultrasound elastography)|Patients undergo ultrasound elastography.
61994933|NCT04617691|EXPERIMENTAL|Group 1: Guselkumab PFS-U|Participants will receive single intravenous (IV) guselkumab formulation using UltraSafe Plus Passive Needle Guards (PFS-U) to create the IV solution.
61994934|NCT04617691|EXPERIMENTAL|Group 2: Guselkumab FVP|Participants will receive single IV guselkumab formulation using Final Vialed Product (FVP) to create the IV solution.
61994935|NCT03068975|EXPERIMENTAL|Alvimopan|Patients in the study group will be administered a post operative dose of Alvimopan
61994936|NCT03068975|PLACEBO_COMPARATOR|Placebo|Patients in the Placebo group will receive a placebo pill and will be compared with the study group
61994937|NCT05366439|EXPERIMENTAL|AT-752|AT-752 administered orally for 14 days
61994938|NCT05366439|PLACEBO_COMPARATOR|Placebo|Matching placebo administered orally for 14 days
61994939|NCT02165046|EXPERIMENTAL|SYN006 HFA MDI, 180/10 mcg/dose|SYN006 HFA MDI(Budesonide/Procaterol Hydrochloride, 180/10mcg), Single dose, 4 puffs
61994940|NCT02165046|ACTIVE_COMPARATOR|Pulmicort pMDI|Budesonide 200mcg, single dose, 4 puffs
61994941|NCT02165046|ACTIVE_COMPARATOR|Meptin Air 10mcg|Procaterol hydrochloride 10mcg, single dose, 4 puffs
61994942|NCT03305510||Vitamin D deficiency|The level of vitamin D is below 20ng/ml.
61994943|NCT03305510||Vitamin D insufficient|The level of vitamin D is between 20ng/ml and 30ng/ml.
61994944|NCT03305510||Vitamin D sufficient|The level of vitamin D is above 30ng/ml.
61994945|NCT02485028|EXPERIMENTAL|M→D→D+M|Mirodenafil(M) in period 1, Dapoxetine(D) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
61994946|NCT02485028|EXPERIMENTAL|M→D+M→D|Mirodenafil(M) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Dapoxetine(D) in period 3
61994947|NCT02485028|EXPERIMENTAL|D→M→D+M|Dapoxetine(D) in period 1, Mirodenafil(M) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
61994948|NCT02485028|EXPERIMENTAL|D+M→M→D|Dapoxetine+Mirodenafil(D+M) in period 1, Mirodenafil(M) in period 2, Dapoxetine(D) in period 3
61994949|NCT02485028|EXPERIMENTAL|D+M→D→M|Dapoxetine+Mirodenafil(D+M) in period 1, Dapoxetine(D) in period 2, Mirodenafil(M) in period 3
61994950|NCT02485028|EXPERIMENTAL|D→D+M→M|Dapoxetine(D) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Mirodenafil(M) in period 3
61994951|NCT05377528|EXPERIMENTAL|Dose Escalation: AGEN1571|Participants will receive AGEN1571 monotherapy.
61994952|NCT05377528|EXPERIMENTAL|Dose Escalation: AGEN1571 + Balstilimab|Participants will receive AGEN1571 with balstilimab.
61994953|NCT05377528|EXPERIMENTAL|Dose Escalation: AGEN1571 + Botensilimab|Participants will receive AGEN1571 with botensilimab.
61994954|NCT05377528|EXPERIMENTAL|Dose Escalation: AGEN1571 + Balstilimab + Botensilimab|Participants will receive AGEN1571 with balstilimab and botensilimab.
61994955|NCT05377528|EXPERIMENTAL|Dose Expansion|AGEN1571 administered at the RP2D for monotherapy or any combination therapy.
61994956|NCT04895384||Surgical Cohort|Placement of Edwards ClearSight and Masimo SET on patient intraoperatively.
61994957|NCT01660854|EXPERIMENTAL|Heterologous challenge|"Biological: Heterologous challenge with 5 infected mosquito bites (NF135) after previous CPS immunization and challenge.~Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone.~Other Name: atovaquone/proguanil"
62562772|NCT02741076|EXPERIMENTAL|Continuation of opioid therapy Suboptimal responders|
61994958|NCT01660854|ACTIVE_COMPARATOR|Challenge control|"Biological: Plasmodium falciparum mosquito challenge by the bites of 5 Plasmodium falciparum infected mosquitoes (NF135).~Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone.~Other Name: atovaquone/proguanil"
61994959|NCT03367377|EXPERIMENTAL|LY3209590|Escalating doses of LY3209590 administered by subcutaneous (SC) injection
61994960|NCT03367377|ACTIVE_COMPARATOR|Insulin glargine|Insulin glargine administered by SC injection
61994961|NCT03099551|ACTIVE_COMPARATOR|Manual Toothbrush users|Group using manual toothbrush Curaprox 5460 Ultra Soft
61994962|NCT03099551|ACTIVE_COMPARATOR|Sonic Toothbrush users|Group using sonic toothbrush Edel White
61994963|NCT04422145|ACTIVE_COMPARATOR|Interventional/intensive|Participants received a structured nurse led education programme surrounding hypoglycaemia. They were encouraged to use self monitoring of blood glucose (SMBG) and had their diabetes medications adjusted according to this. They also received information on how to avoid hypoglycaemia (including the effects of diet, exercise, alcohol and their medications) and how to treat hypoglycaemia should it occur.
61994964|NCT04422145|PLACEBO_COMPARATOR|Standard|Participants returned to their standard diabetes care provider with no intervention.
61994965|NCT04422145|NO_INTERVENTION|Observational|Participants were happy to have baseline characteristics collected and be followed up using electronic records in a longitudinal fashion but did not wish to be randomized. The observational and standard groups therefore received the same diabetes care.
61994966|NCT05112692|ACTIVE_COMPARATOR|PPOS group|Patients will be coadministered with Human Menopausal Gonadotrophin (HMG) 150-225 international unit/day (IU/d) via intramuscular injection and oral DYG 20mg/d from menstrual cycle day 3 (MC3) to the day of triggering. The starting dose of HMG is 150IU/day for patients with a high antral follicle count \>20 or slightly elevated basal FSH (7-10IU/L), and a daily dose of 225IU HMG is used for the other patients. The dose will be adjusted after day 5 of stimulation based on the ovarian response as assessed by serum hormone levels and transvaginal ultrasonography
61994967|NCT05112692|ACTIVE_COMPARATOR|GnRH antagonist|In the fixed GnRH antagonist protocol, daily s.c. administration of Cetrotide 0.25 mg will be initiated at 6th day of stimulation. HMG (150-225IU) will be administered daily from menstrual cycle day 3, and follicular monitoring will be performed every 2 to 3 days after 5 days of injections. The dose of hMG will be adjusted according to the ovarian response, as monitored by ultrasonography and the measurement of serum sex steroids. Treatment with hMG and GnRH antagonist will continue daily until the day when final oocyte maturation is triggered
61994968|NCT03272451|EXPERIMENTAL|culprit vessel intervention|culprit vessel PCI prior to contralateral angiography using a single transradial guiding catheter
61994969|NCT03272451|ACTIVE_COMPARATOR|traditional approach|complete coronary angiography followed by guiding catheter selection for culprit vessel PCI
61994970|NCT02038595|EXPERIMENTAL|Healthy subjects|Healthy subjects (male, female)
61994971|NCT01412866|EXPERIMENTAL|EDSS with CO monitor|Web-based electronic decision support system (EDSS) with carbon monoxide (CO) monitor and health-checklist
61994972|NCT01412866|ACTIVE_COMPARATOR|EDSS without CO monitor|Web-based electronic decision support system (EDSS) with health-checklist only
61994973|NCT05180903|EXPERIMENTAL|Bulk Fill resin composite restorations reinforced by ultra high molecular weight polyethylene.|Bulk Fill resin composite restorations (X-tra base \& GrandioSO, Voco, Cuxhaven, Germany) reinforced by ultra high molecular weight polyethylene. (Ribbond THM, Ribbond Inc, Seattle, WA, USA)
61994974|NCT05180903|ACTIVE_COMPARATOR|Bulk Fill resin composite restorations|Bulk Fill resin composite restorations (X-tra base \& GrandioSO, Voco, Cuxhaven, Germany)
61994975|NCT03002168|ACTIVE_COMPARATOR|Alpha-cyclodextrin|Two 1 gram Alpha-cyclodextrin tablets given per fat-containing meal. A total of 6 tablets (6 grams) per day for the first two consecutive days of active treatment period. Triolein radiolabeled with 100 microcuries of 3\^Hydrogen and Tripalmitin radiolabeled with 20 microcuries of 14\^Carbon given orally with liquid breakfast meal.
61994976|NCT03002168|PLACEBO_COMPARATOR|Placebo|Two Placebo Alpha-cyclodextrin tablets given per fat-containing meal. A total of 6 tablets per day for the first two consecutive days of placebo treatment period.Triolein radiolabeled with 100 microcuries of 3\^Hydrogen and Tripalmitin radiolabeled with 20 microcuries of 14\^Carbon given orally with liquid breakfast meal.
62391048|NCT05331326|EXPERIMENTAL|HER2 Low Expression|Drug: RC48-ADC 2.0 mg/kg (HER2 Low Expression) 32 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
62391049|NCT03164304|ACTIVE_COMPARATOR|One gram magnesium sulfate|Pregnant women with a diagnosis of severe pre-eclampsia will receive 1 g of mgso4 to prevent and control of convulsions
62391050|NCT03164304|EXPERIMENTAL|Two grams magnesium sulfate|Pregnant women with a diagnosis of severe pre-eclampsia will receive 2 g of mgso4 to prevent and control of convulsions
62562773|NCT02741076|EXPERIMENTAL|Structured Continuation of opioid therapy Optimal responders|
62562774|NCT02329015|EXPERIMENTAL|Health and Wellness program|Behavioral intervention
61994977|NCT00175890|PLACEBO_COMPARATOR|Placebo|Matching oral solution to Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
61994978|NCT00175890|EXPERIMENTAL|Levetiractem|10 % oral solution Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
61994979|NCT02114879|ACTIVE_COMPARATOR|Standard of Care Rehabilitation|
61994980|NCT02114879|EXPERIMENTAL|Enhanced Medical Rehabilitation|
61994981|NCT01846975|EXPERIMENTAL|Switch from SC to IV Abatacept and back|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
61994982|NCT01730183|EXPERIMENTAL|Bone marrow derived stem cells|Autologous Bone Marrow derived Stem Cells(BMSC) transplanted intrathecally into patients with spinal cord injury.
61994983|NCT02152410|EXPERIMENTAL|acupuncture group|The patient receives acupuncture session lasts between 20 to 30 minutes. Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA).
61994984|NCT02152410|ACTIVE_COMPARATOR|Morphine group|Each patient must receive a bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement (VAS\> 30).
61994985|NCT06276959||The population with a potential risk of proximal caries.|
61994986|NCT06256770||scleral contact lenses group|The selected patients were equipped with scleral contact lenses to evaluate their best corrected visual acuity, refraction, ocular surface condition, and fitting status of contact lenses.
61994987|NCT06256770||RGP group|The selected patients were equipped with RGP to evaluate their best corrected visual acuity, refraction, ocular surface condition, and fitting status of contact lenses.
61994988|NCT05058521||In-hospital VTE group|In-hospital VTE group includes patients who were with a hospital stay over 3 days and new-onset of VTE during their stay. Patients who presented for VTE were excluded.
61994989|NCT05058521||Negative group|Negative group includes patients who were with a hospital stay over 3 days and did not have a VTE during their hospital stay.
61994990|NCT03805022|EXPERIMENTAL|Arm A|"Control-Arm phase III high-risk CINSARC:~Patients will be treated by doxorubicin (60 or 75mg/m² day or 20- or 25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices of a 21-days cycle for up to 3 cycles in neoadjuvant setting Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting)."
61994991|NCT03805022|EXPERIMENTAL|Arm B|"Experimental-Arm phase III high-risk CINSARC:~Patients will be treated by doxorubicin (60 or 75mg/m² day or 20 or 25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices of a 21-days cycle for up to 6 cycles in neoadjuvant setting Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting)."
61994992|NCT03805022|EXPERIMENTAL|Prospective cohort|Patients will be treated at the discretion of the investigator
61994993|NCT00469482|ACTIVE_COMPARATOR|Sedation, RASS Targeted|Patient sedation utilizing standard of care methods (RASS Targeted)
61994994|NCT00469482|ACTIVE_COMPARATOR|Sedation,RASS Targeted plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring.
61994995|NCT01364090|ACTIVE_COMPARATOR|Standard Treatment Duration (24 weeks)|Subjects with detectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 24 and follow-up for an additional 24 weeks following treatment completion (48 weeks in total).
61994996|NCT01364090|EXPERIMENTAL|Shortened Treatment Duration (12 Weeks)|Subjects with undetectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 12 and follow-up for an additional 24 weeks following treatment completion (36 weeks in total).
61994997|NCT05300295|EXPERIMENTAL|Mentoring Program|The Autism Mentorship Program is a psychosocial intervention that pairs adults and adolescents with autism spectrum disorder (ASD) in one-to-one mentoring relationships. AMP involves weekly meetings in an afterschool setting and targets the socio-emotional health and social connectedness of adolescents and adults with ASD.
61994998|NCT03249779|EXPERIMENTAL|Scrambler|All participants will receive electrical stimulation applied to the lower extremities using the Scrambler.
61994999|NCT05603416|ACTIVE_COMPARATOR|Benegut|Dietary Supplement: Perilla frutescens extract
61995000|NCT05603416|PLACEBO_COMPARATOR|Placebo|Dietary Supplement: Placebo, no active ingredient
61995001|NCT03995212|ACTIVE_COMPARATOR|CR845 1.0 mg|Oral CR845 1.0 mg tablet administered twice daily
61995002|NCT03995212|PLACEBO_COMPARATOR|Placebo|Oral placebo tablet administered twice daily
62178658|NCT05280743||NEONATE-INFANT cohort|"Neonate encompasses a newborn from the age of birth until \<28 days of life. Infant refers to the period of 28 days of life until 1 year of life."
62178659|NCT02041312||Gastric cancer|No intervention
62562775|NCT02329015|ACTIVE_COMPARATOR|Physical Education Class|Behavioral intervention
61995003|NCT03700697|EXPERIMENTAL|Family Stress Module Intervention|Primary care clinicians will use the CHADIS Family Stress Module including the reviewing ACE, Positive Childhood Experiences, and FASS Plus questionnaires at designated child ages; address family stressors revealed using the motivational interviewing teleprompter and refer parents with stressors as indicated using the care coordination functionality.
61995004|NCT03700697|NO_INTERVENTION|Controls|Control primary care providers will provide care as usual.
61995005|NCT01001442|EXPERIMENTAL|BT062|BT062 was to be administered as single-dose IV infusions via a 0.22 μm in-line filter preferably in a forearm vein, according to medically accepted procedures on Days 1, 8, and 15 of each 28-day cycle. Alternatively BT062 may have been administered through a central venous line or a peripherally inserted central catheter (PICC). Other administration routes were only to be allowed after approval from Biotest. Each subject was to be monitored carefully for the effects of exposure to BT062. No subject was to have received more than 3 doses of BT062 per 28-day treatment cycle.
61995006|NCT04193475||Chest pain|Individuals presenting with chest pain requiring a stress echocardiogram.
61995007|NCT03411512||CHD|Newborns with structural congenital heart defects. The exclusion criteria were pulmonary or neurological disease, perinatal asphyxia, acute illness, prematurity and congenital abnormality other than CHD.
61995008|NCT03411512||Healthy controls|The control group comprised of healthy matched newborns without a diagnosed CHD.
61995009|NCT03098342|EXPERIMENTAL|MB-PDT for Onychomycosis|
61995010|NCT03098342|ACTIVE_COMPARATOR|Amorolfine for Onychomycosis|
61995011|NCT04618120|EXPERIMENTAL|Virtual Reality-based Exercise Group|"Virtual reality-based exercises, breathing exercises and patient education on general considerations.~Virtual reality-based exercises were done using the Microsoft Xbox 360 Kinect system. Among the 'Kinect Sports' games, especially tennis, table tennis, boxing and bowling games including upper extremity movements were selected. These games require all-directional and repetitive motion of the shoulder and elbow joint. Patients played the games using the operated / affected side arms. Between games, the patient was rested in a chair. In the meantime, deep breathing exercises were done.~The patients participated in virtual reality-based exercises 3 days a week (15-18 sessions in total) during the radiotherapy treatment continued (5-6 weeks). Each exercise session was set to last 30-40 minutes in total."
61995012|NCT04618120|EXPERIMENTAL|Exercise Group|"Stretching exercises, range of motion exercises, posture exercises, breathing exercises and patient education on general considerations.~11 different exercises consisting of shoulder range of motion in all directions, stretching exercises, posture exercises and breathing exercises were performed in the presence of a physiotherapist.The patients participated in this exercise program 3 days a week (15-18 sessions in total) during the radiotherapy treatment continued (5-6 weeks). One session of the exercises was completed in an average of 30-40 minutes. The same exercises were repeated in each session."
61995013|NCT04618120|NO_INTERVENTION|Control Group|Only patient education on general considerations.
62178660|NCT04419649|EXPERIMENTAL|KER-050 Cohort 1|Escalating doses of KER-050 administered subcutaneously every 4 weeks for up to 4 cycles. Participants have the option to continue to receive KER-050 once 4 cycles have been completed for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.
62562776|NCT02028897|ACTIVE_COMPARATOR|Conventional embryo culture|Conventional embryo culture in dishes, in droplets under oil.
62562777|NCT02028897|EXPERIMENTAL|Alternative embryo culture|Embryo culture in system using small enclosed containers
62562778|NCT01037218|EXPERIMENTAL|Udenafil 50 mg|50 mg Udenafil tablet plus 100 \& 150 mg placebo tablets
62562779|NCT01037218|EXPERIMENTAL|Udenafil 100 mg|100 mg Udenafil tablet plus 50 \& 150 mg placebo tablets
62562780|NCT01037218|EXPERIMENTAL|Udenafil 150mg|150 mg Udenafil tablet plus 50 \& 100 mg placebo tablets
61995014|NCT02423863|EXPERIMENTAL|Hiltonol Poly-ICLC|"Open labeled, non randomized adaptive 2-stage design protocol. 21 study subjects were enrolled in stage I of the protocol. Up to an additional 60 patients. . Enrolled study subjects will receive Poly-ICLC (Hiltonol®) treatment alone or in combination with anti-PD-1 (Nivolumab, Pembrolizumab or Cemiplimab) or anti-PD-L1 (Atezolizumab or Durvalumab) over 6 months as defined in study treatment described below. MRI or CT imaging will be done per SOC at screening, 3 and 6-month time points.~For purposes of analysis patients enrolled in Stage II of this study will be prospectively identified at initial screening as belonging to statistical Cohorts A, B, or C, which are based on patient status with regard to aPD1/aPDL1 therapy at study entry, (PD, SD, or treatment naïve). For purposes of this study, patient status is considered to be the primary eligibility variable, although sub analyses will also consider histology and particular checkpoint blocker used when possible."
61995015|NCT02155335|EXPERIMENTAL|Prefilled Syringe→Smartject™ Device|Golimumab 50 mg supplied in a prefilled syringe administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied in the Smartject 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab).
61995016|NCT02155335|EXPERIMENTAL|Smartject™ Device→ Prefilled Syringe|Golimumab 50 mg supplied in a Smartject administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied a prefilled syringe 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab.
62562781|NCT01037218|PLACEBO_COMPARATOR|Placebo|50, 100 \& 150 mg placebo tablets
62562782|NCT04828278|PLACEBO_COMPARATOR|Treatment 1|1,600 mg of Placebo (maltodextrin)
62562783|NCT04828278|ACTIVE_COMPARATOR|Treatment 2|1,500 mg of ASI (bonded arginine silicate) + 100 mg of inositol (nooLVL)
62562784|NCT01342380||Seroquel|Participants who received Seroquel
62770782|NCT02552862|ACTIVE_COMPARATOR|Vivomixx®|"Vivomixx® is a probiotic mixture of 8 proprietary strains. Thirty consecutive patients with cirrhosis and SBP will be randomized to receive Vivomixx® , sachets containing 450 x 109 bacteria, 2 every 12 hours during all the hospitalization until a maximum of 30 days (n=15), or placebo (n=15).~All patients will receive endovenous antibiotics and also intravenous albumin 1.5 g/kg weight the first day and 1 g/kg weight the third day of treatment. The management of patients will follow current guidelines."
62770783|NCT02552862|PLACEBO_COMPARATOR|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
62770784|NCT02560298|EXPERIMENTAL|Arm A (cisplatin, fluorouracil or capecitabine)|Patients receive cisplatin IV over 1-4 hours on day 1 and fluorouracil IV continuously over 24 hours on days 1-4. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients with complications associated with the central venous access which prevent further infusion of fluorouracil and only after discussion with the Chief Investigator receive capecitabine BID on days 1-4.
62770785|NCT02560298|EXPERIMENTAL|Arm B (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62770786|NCT01906112|NO_INTERVENTION|Controlled|No surgery for primary breast tumor.
62770787|NCT01906112|EXPERIMENTAL|Study|Surgery for primary breast tumor.
62562785|NCT01342380||Pioglitazone|Participants who received pioglitazone
62770788|NCT05300113||CNS Tumor|All patients age from 18-75 years with CNS tumors are included and count as one group
62770789|NCT03144869|EXPERIMENTAL|physical activity monitor only|"Children will wear a Runscribe accelerometer for two weeks. Runscribe is a small inertial sensor (weight 15g, size 35x25x7.5 mm). It can be attached to the body in several positions (wrist, waist, sacrum, chest, thigh, foot) and is used for monitoring movement. Runscribe does not beep, flash or have a visual display. It will not provide PA feedback to the individuals in real-time, only via a researcher after the data has been downloaded. In this study, we are not wishing to influence children's behaviour by providing PA feedback in real-time. We are trying to establish whether PA monitoring is feasible and acceptable - and further research could go on to explore the use of real-time PA feedback as an educational technique.~Phase 1 findings will help to determine: i) method of monitor distribution to participants (post, clinic or in-person), ii) preferred wear position."
62770790|NCT03144869|EXPERIMENTAL|physical activity monitor plus constant glucose monitor|Children using a personal constant glucose monitor (CGM) or CGM on loan from clinic as part of clinical care will be approached for Arm 2. These children will wear Runscribe at the same time as a CGM. Runscribe and CGM worn over the same 2 week period.
62770791|NCT03511469|EXPERIMENTAL|Control Group|Patients in this group will only received standardized rehabilitation protochol after Bankart surgery
62770792|NCT03511469|EXPERIMENTAL|Isokinetic Group|Patients in this group will receive concentric training for rotator cuff muscles with isokinetic device in addition the the standart rehabilitation protocol.
62770793|NCT03854539|EXPERIMENTAL|Active Stimulation 0.5|0.5 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles
62770794|NCT03854539|SHAM_COMPARATOR|Sham Stimulation|0.5mA intermittent transdermal stimulation of the aurical vagus stimulation5 Hz 30 seconds on/30 seconds off for five cycles
62770795|NCT03854539|NO_INTERVENTION|No Stimulation|0.0 mA (sham) intermittent transdermal stimulation of the aurical vagus stimulation, 0 Hz 30 seconds on/30 seconds off for five cycles
62770796|NCT03854539|EXPERIMENTAL|Active Stimulation 1.0|0.5 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles.
62770797|NCT03854539|EXPERIMENTAL|Active Stimulation 0.25|0.25 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles
62770798|NCT06473935||Women during pregnancy and postpartum|Women during the last trimester of gestation (28th-35th week of gestation) and during the 18 months following the child's birth
62770799|NCT05297526|EXPERIMENTAL|Intervention Group|The intervention group will receive a culturally adapted children's book that contains the same oral health educational information as the control brochure, but celebrates Tribe-specific culture and utilizes entertainment education. The children's book includes vibrant illustrations by a Tribal artist, and has eBook and audio narration options for multi-media use and/or those with limited literacy.
62770800|NCT05297526|ACTIVE_COMPARATOR|Control Group|The control group will receive a standard educational brochure about children's oral health designed by the the National Institutes for Health (NIH) for American Indian/Alaska Native parents.
61995017|NCT04216875||single primary care practices intervention|Independent primary care practices with one single medical doctor in the practice, usually ther owner of the practice working in his responsibility following the best practice procedure of the diabetes score.
62770801|NCT05577949|EXPERIMENTAL|Aerobics|This group will perform structured aerobics exercise program in addition to the standard treatment given for women with PCOS.
62770802|NCT05577949|NO_INTERVENTION|"Management used as Treatment As Usual"|This group will receive the standard management given for women with PCOS
62770803|NCT04476927|EXPERIMENTAL|DiaNose procedure|all subjects will be required to undergo the DiaNose exhalation test.
62770804|NCT03324919||Psoriasis, HRQL|Patients with a medical diagnosis of Psoriasis were enclosed.
62770805|NCT03324919||Urticaria, HRQL|Patients with a medical diagnosis of Urticaria were enclosed.
62770806|NCT03324919||Lupus erythematodes, HRQL|Patients with a medical diagnosis of Lupus were enclosed.
62770807|NCT01566578|EXPERIMENTAL|EGF Cream|
62770808|NCT01566578|PLACEBO_COMPARATOR|Placebo cream|
62770809|NCT04634942|EXPERIMENTAL|Cold Spray Group|Cold spray group injection process step; In addition to the IM injection procedure steps, Cryos cold spray was applied to patients in this group after skin cleansing. Cryos cold spray sprayed 3 puffs from a distance of 20 cm to the skin, and the injection process was performed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle while entering the tissue on the VAS.
61995018|NCT04216875||primary care group practice intervention|Independent primary care practices with more than one medical doctor working in their responsibility following the best practice procedure of the diabetes score.
62562786|NCT00794690|EXPERIMENTAL|black cohosh extract, liver|100 postmenopausal women
62562787|NCT03760432|EXPERIMENTAL|Surgery|OCT-guided custom laser CXL
62770810|NCT04634942|EXPERIMENTAL|ShotBlocker Group|ShotBlocker group injection process step; In addition to the IM injection procedure steps, after cleansing the skin of the patients in this group, the protruding part of the ShotBlocker was placed in contact with the skin. ShotBlocker was pressed firmly against the skin and the injection was made through the central opening of the ShotBlocker. ShotBlocker was removed from the skin after the injection was completed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle while entering the tissue on the VAS.
62770811|NCT04634942|NO_INTERVENTION|Control Group|Control group injection process step; The individuals in this group were injected by following the routine IM injection procedure steps. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle entering the tissue on the VAS.
62770812|NCT04634942|PLACEBO_COMPARATOR|Cold Spray Placebo Group|Cold spray placebo group injection procedure step; In addition to the IM injection procedure steps, the patients in this group were treated with tap water in a cold spray bottle after cleansing the skin. After spraying 3 puffs of tap water in a placebo bottle at a distance of 20 cm to the skin, the injection was performed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle entering the tissue on the VAS.
62770813|NCT04634942|PLACEBO_COMPARATOR|ShotBlocker Placebo Group|ShotBlocker placebo group injection procedure step; In addition to the IM injection procedure steps, in patients in this group, the non-protruding part of the ShotBlocker was placed in contact with the skin after skin cleaning. ShotBlocker was pressed firmly against the skin and the injection was applied through the central opening of the ShotBlocker. ShotBlocker was removed from the skin after the injection was completed.
62770814|NCT00618605|EXPERIMENTAL|1|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10\^9 virus particles (VP) given at Days 0, 28, and 168
62770815|NCT00618605|EXPERIMENTAL|2|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10\^10 VP given at Days 0, 28, and 168
62770816|NCT00618605|EXPERIMENTAL|3|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10\^11 VP given at Days 0, 28, and 168
62770817|NCT00618605|EXPERIMENTAL|4|2 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at a dose to be determined by the safety data from Arms 1, 2 and 3 given at Days 0 and 168
62770818|NCT03062241|EXPERIMENTAL|Cryoablation|The pulmonary vein (PV) isolation in patients randomized to intervention group.
62770819|NCT03062241|NO_INTERVENTION|Conventional treatment|Pharmacological treatment according to 2016 ESC (European Society of Cardiology) guidelines for the diagnosis and treatment of acute and chronic heart failure and to 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with European Association for Cardio-Thoracic Surgery (EACTS).
62770820|NCT00548717|EXPERIMENTAL|Siro/MMF|Sirolimus and Mycophenolate Mofetil as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF)
62770821|NCT00548717|EXPERIMENTAL|Siro/MMF/Bort|Sirolimus, Mycophenolate Mofetil, and Bortezomib as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF) Bortezomib (Velcade) \*added with study reopening in 2012
62770822|NCT04187976||Patients with moderate to severe uncontrolled asthma|Patients with moderate to severe uncontrolled asthma defined on clinical assessment and spirometric criteria. Non controlled asthma is considered when ACQ score ≥ 1.5 or in case of acute exacerbation
62770823|NCT04187976||Patients with recalcitrant CRSwNP requiring sinus surgery|The medical failure in CRSwNP is defined as persistent disease in spite of 3 courses of oral corticosteroid and double dose of local corticoid over 12 months
61995019|NCT04216875||single primary care practices no intervention|Independent primary care practices with one single medical doctor in the practice, usually ther owner of the practice working in his responsibility without the intervention (not using Diabetes score)
62391051|NCT05749159|EXPERIMENTAL|physiotherapy|New physical therapy: a disposable cup (soft cup) to take 1/3 cup of room temperature water and place it on a table. The patient takes a sitting or standing position. The middle finger of both hands press tightly against the nose to seal the nasal cavity. At the same time, press the ear screen with both hands to close the ear canal. After that, bite the cup with teeth (hands do not touch the cup), and drink up 1-2 mouthfuls of water.
62391052|NCT05749159|PLACEBO_COMPARATOR|alternative therapy|Alternative therapy: including routine physical therapy such as suffocation and drinking cold water, as well as drug therapy such as metoclopramide and Mianna.
62562788|NCT01674881|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy (MBCT)|This group will receive MBCT for 8 consecutive weeks.
62770824|NCT04187976||Patients with concomitant CRSwNP and uncontrolled asthma|Patients with concomitant CRSwNP and moderate to severe uncontrolled asthma
62770825|NCT04187976||Healthy subjects|Patients without any airway inflammatory disease or atopy
62770826|NCT05668663|EXPERIMENTAL|Elderly patients|"Only one group of patients will be constituted. It will be composed of 453 patients aged more than 75 years old and hospitalized in a geriatric acute care unit.~If the patient consent to participate in the study, a 4-mL blood sample will be collected concomitantly with a general laboratory evaluation that will be performed when the patient enters the unit.~No other sample will be taken., and tThe participation of the patient to the study will end after the result of the test or after the end of the vitamin C supplementation. A telephone call is organized to follow up on any adverse effectswith this blood sample collection.~No further visit is organised."
62770827|NCT05117203|EXPERIMENTAL|WB-EMS group|
62770828|NCT05117203|EXPERIMENTAL|EMS group|
62770829|NCT05117203|SHAM_COMPARATOR|Control group|
62770830|NCT01263015|EXPERIMENTAL|Dolutegravir (N=~394):|Dolutegravir 50mg once daily + abacavir/lamivudine as the fixed-dose combination once daily + Atripla placebo once daily
62770831|NCT01263015|ACTIVE_COMPARATOR|Atripla (N=~394):|Atripla once daily + Dolutegravir placebo once daily + abacavir/lamivudine as the fixed-dose combination placebo once daily
62770832|NCT00924404|EXPERIMENTAL|Xylitol|isotonic xylitol for sinus rinse
62770833|NCT00924404|ACTIVE_COMPARATOR|Saline|saline for sinus rinse
62770834|NCT00689793|ACTIVE_COMPARATOR|1|
62770835|NCT00689793|PLACEBO_COMPARATOR|2|
62770836|NCT03273660|EXPERIMENTAL|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|
62770837|NCT03921333|ACTIVE_COMPARATOR|Low dose plant extract|300 mg
62770838|NCT03921333|ACTIVE_COMPARATOR|Middle dose plant extract|500 mg
62770839|NCT03921333|ACTIVE_COMPARATOR|High Dose plant extract|700 mg
61995020|NCT04216875||primary care group practice no intervention|Independent primary care practices with more than one medical doctor working in their responsibility without the intervention (not using Diabetes score).
61995021|NCT00855036||Renal Injury|All patients who have a discernable injury to the renal parenchyma on CT scan from blunt trauma
61995022|NCT01781442||Patient Arm- temsirolimus|
61995023|NCT02927379|ACTIVE_COMPARATOR|ketamine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline +1 mg /kg ketamine (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision.
61995024|NCT02927379|ACTIVE_COMPARATOR|dexmedetomidine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline + 1µg/kg dexmedetomidine (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision.
62178661|NCT04419649|EXPERIMENTAL|KER-050 Cohort 2|Escalating doses of KER-050 administered subcutaneously every 4 weeks for up to 4 cycles. Participants have the option to continue to receive KER-050 once 4 cycles have been completed for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.
62391053|NCT00195117|NO_INTERVENTION|Control Group|This group received follow-up every 2-months for one year. Follow-up included questions about their asthma and how well they had been able to engage in their doctor approved physical activity goal.
62770840|NCT03921333|PLACEBO_COMPARATOR|Placebo control|Cellulose microcrystalline
62770841|NCT05521633|ACTIVE_COMPARATOR|Metformin Group|Group-A; every participant took 500 mg of metformin daily
62770842|NCT05521633|ACTIVE_COMPARATOR|Pioglitazone Group|Group-B; every participant took 30 mg of pioglitazone daily
62770843|NCT03693547|EXPERIMENTAL|utidelone|Utidelone Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle, administered to enrolled patients with advanced NSCLC
62562789|NCT01674881|OTHER|Waitlist control group|This group is a waitlist control group.
62562790|NCT05494944|OTHER|ThuLEP group|
62770844|NCT05226585|ACTIVE_COMPARATOR|In-person CBTi|CBTi of variable treatment length will be administered by trained study staff in-person.
62770845|NCT05226585|ACTIVE_COMPARATOR|Telehealth CBTi|CBTi of variable treatment length will be administered by trained study staff via HIPAA-compliant tele-video conference.
62770846|NCT05226585|ACTIVE_COMPARATOR|Internet CBTi|Self-paced CBTi of variable treatment length will be administered via Sleep Healthy Using The Internet (SHUTi).
62770847|NCT05226585|NO_INTERVENTION|Waitlist Control|Treatment will be postponed by 12 weeks.
62178662|NCT04419649|EXPERIMENTAL|KER-050 Cohort 3|Escalating doses of KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.
62770848|NCT03645109|EXPERIMENTAL|Vitamin D|Will receive capsules with 5,000 IU of vitamin D3, one capsule orally once a day for eight weeks
62770849|NCT03645109|PLACEBO_COMPARATOR|Placebo|Will receive capsules with placebo (talcum food grade) one capsule orally once a day for eight weeks
62770850|NCT04963907|ACTIVE_COMPARATOR|Active CES Therapy|Participants will be asked to use Alpha-Stim 60 minutes daily for 8 weeks. Active devices are programmed to emit a current intensity of 100 uA at 0.5 Hz and will be programmed to run for 60 minutes. Participants will not be able to adjust the settings on the devices.
62770851|NCT04963907|SHAM_COMPARATOR|Sham CES Therapy|Participants will be asked to use Alpha-Stim 60 minutes daily for 8 weeks. Sham devices are programmed to display a current intensity of 100 uA at 0.5 Hz and will be programmed to run for 60 minutes, but no current will be emitted from the device. Participants will not be able to adjust the settings on the devices.
62770852|NCT01317511|EXPERIMENTAL|Protein|Protein drink
62770853|NCT01317511|PLACEBO_COMPARATOR|Placebo|water
62178663|NCT04419649|EXPERIMENTAL|KER-050 Cohort 4|Escalating doses of KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.
62178664|NCT04419649|EXPERIMENTAL|KER-050 Cohort 5|Escalating doses of KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.
62770854|NCT02880527||patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis will be used:~1. medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;~2. general practitioners~3. the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )~5) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
62770855|NCT06137768|EXPERIMENTAL|Treatment group A: HRS-5965; high dose|
62770856|NCT06137768|EXPERIMENTAL|Treatment group B: HRS-5965; medium dose|
62770857|NCT06137768|EXPERIMENTAL|Treatment group C: HRS-5965; low dose|
62770858|NCT06137768|PLACEBO_COMPARATOR|Treatment group D: Placebo.|
62770859|NCT05257343|PLACEBO_COMPARATOR|Placebo|Daily dose (10 mL) of a visually identical liquid placebo supplement to be ingested on an empty stomach no sooner than 3 hours after consuming a meal.
62770860|NCT05257343|EXPERIMENTAL|Blood Builder Treatment|Daily dose (10 mL) of liquid iron supplement (Blood Builder®) formulation to be ingested on an empty stomach no sooner than 3 hours after consuming a meal.
62770861|NCT00565799|ACTIVE_COMPARATOR|1. Omentectomy|LAGB \& Omentectomy
62770862|NCT00565799|PLACEBO_COMPARATOR|2 No Omentectomy|LAGB Only
62770863|NCT01530607|ACTIVE_COMPARATOR|cyclophosphamide|Standard cyclophosphamide containing adjuvant or neoadjuvant chemotherapy
62770864|NCT01530607|EXPERIMENTAL|Goserelin (Zoladex)|Goserelin (Zoladex) plus Standard cyclophosphamide containing adjuvant or neoadjuvant chemotherapy
62770865|NCT01497613|ACTIVE_COMPARATOR|PRISM B: Notebook Condition|Telephone check-in calls and a notebook containing similar categories of information as the features on the PRISM C computer system such as a resource guide; games; classroom and information, calendar.
62178665|NCT04419649|EXPERIMENTAL|KER-050 Dose Confirmation Cohort|Participants to receive KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.
62178666|NCT02703753|EXPERIMENTAL|Intervention group|The intervention is an integral and multidisciplinary lifestyle intervention consisting of a healthy diet, appropriate physical activity and, if applicable, smoking cessation, customised to the needs of the women.
62770866|NCT01497613|EXPERIMENTAL|PRISM C: Computer Condition|A computer-based system designed to support socialization and access to resources; knowledge and prospective memory. The system is placed in the homes of those randomized to the condition for 12 months.
62770867|NCT06507917|EXPERIMENTAL|self-swabbing first|Group A self-swabbing then swabbing by a healthcare professional
62770868|NCT06507917|ACTIVE_COMPARATOR|swabbing by a healthcare professional first|swabbing by a healthcare professional and then self-swabbing
62770869|NCT01518504|EXPERIMENTAL|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
62770870|NCT01518504|SHAM_COMPARATOR|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
62770871|NCT02303106|ACTIVE_COMPARATOR|lamotrigine|lamotrigine alone
62770872|NCT02303106|EXPERIMENTAL|Lamotrigine + paracetamol|Lamotrigine + paracetamol
62770873|NCT04874090|EXPERIMENTAL|Interventional group|Investigator will apply the acupuncture treatment to the first group to the neck area. BL-15, BL-18, BL-23, BL-25, KB-4, Du-20, GB-20, CV-14, KB-10, Ex-26, Yin Tang, Ah-shi points will be used. 0.25x25 mm, sterile, steel, disposable, acupuncture needle will be used for acupuncture points and painful trigger points. The treatment will be applied twice a week, on average 10 sessions. Dry needling treatment will be applied to the patients by a certified physician. All patient will be performed the neck exercises program.
62770874|NCT04874090|OTHER|Exercises group|Patients will perform only neck exercises.
62770875|NCT06219395||Iron deficiency anaemia|Persons 18-85 years with Iron deficiency anaemia referred for gastroscopy and colonoscopy
62770876|NCT00889200|EXPERIMENTAL|Open-label Eszopiclone|Standard dosing of drug for 6 weeks for insomnia
62770877|NCT06530134|EXPERIMENTAL|With video feedback|Activation of on-board cameras during driving situation.
62178667|NCT02703753|NO_INTERVENTION|Control group|The control group will receive usual care, including standard lifestyle advices during consultation with the GP, midwife, obstetrician or at the child well being centre. Furthermore, the control group will receive 1 recipe for a healthy meal per week.
62770878|NCT06530134|OTHER|Without video feedback|Non-Activation of on-board cameras during driving situation.
62770879|NCT01072825||transgender people starting hormone treatment|
62770880|NCT02239146|EXPERIMENTAL|rFXIII|
62178668|NCT00853229|EXPERIMENTAL|pregabalin/placebo|pregabalin and placebo given using a cross-over design
62770881|NCT02239146|PLACEBO_COMPARATOR|Placebo|
62770882|NCT02530736||IPF_RESP|Pulmonary Rehabilitation: a 6 - 8 week exercise and education programme (this is part of usual care)
62178669|NCT00853229|EXPERIMENTAL|placebo/pregabalin|placebo and pregabalin given using a cross-over design
62178670|NCT03371121|OTHER|Chondro-gide - Geistlich|Arthroscopic use of chondro-gide to treat symptomatic osteochondral talar lesion
62178671|NCT03352882|OTHER|Open Label|All enrolled participants will undergo hepatic ultrasound with acoustic radiation force impulse (ARFI) before and 30 days after creation of TIPS.
62178672|NCT01230762|EXPERIMENTAL|001|dapoxetine 60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
62391054|NCT00195117|EXPERIMENTAL|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their asthma and how well they had been able to engage in their doctor approved physical activity goal, which was the same as the control arm. Additionally, subjects in this arm were encouraged to use positive affect and self-affirmation techniques to motivate an increased level of participation in their physical activity goal. These subjects also received small token gifts to remind them of their participation in this study.
62391055|NCT02924129|EXPERIMENTAL|Evoke SCS with Feedback|closed-loop/automatic stimulation
62391056|NCT02924129|ACTIVE_COMPARATOR|Evoke SCS with Conventional|open-loop/manual stimulation
62391057|NCT05398939||Acne cohort|Adults with acne vulgaris who are going to receive the third dose of COVID-19 vaccine.
62391058|NCT00519597|EXPERIMENTAL|I|Asymptomatic OSA (CPAP)
62391059|NCT00519597|NO_INTERVENTION|II|Asymptomatic OSA (no CPAP)
62391060|NCT00519597|ACTIVE_COMPARATOR|III|Symptomatic OSA (OSAS)
62391061|NCT00519597|NO_INTERVENTION|IV|Non-OSA
62391062|NCT05407168|EXPERIMENTAL|Group I (decision aid)|Patients review decision aid.
62391063|NCT05407168|ACTIVE_COMPARATOR|Group II (standard of care)|Patients receive standard of care.
62391064|NCT03355872|EXPERIMENTAL|HLX01|
62562791|NCT02853877|EXPERIMENTAL|Weekly Incentive|Participants in the Weekly Incentive arm will be asked to weigh in each week during a 12 week intervention period. They will receive tailored messages and have an opportunity to win a financial reward each week they meet their weight loss goal. Participants will be asked to complete a final weight measurement at week 24.
62562792|NCT02853877|NO_INTERVENTION|Weekly Weigh-In|Participants in the Weekly Weigh-In arm will be asked to weigh in each week during a 12 week intervention period. Participants will be asked to complete a final weight measurement at week 24.
62391065|NCT03355872|ACTIVE_COMPARATOR|Rituximab|
62391066|NCT04220294|ACTIVE_COMPARATOR|Interrupted sutures|Subcutaneous tissue closure by interrupted sutures.
62391067|NCT04220294|ACTIVE_COMPARATOR|Continuous sutures|Subcutaneous tissue closure by continuous sutures.
62391068|NCT04609436||Single arm|This is a single arm trial. The patient is his own control.
62391069|NCT02135848|EXPERIMENTAL|GSK1278863|Study Drug
62391070|NCT02135848|PLACEBO_COMPARATOR|Placebo|Placebo
62178673|NCT00989898|ACTIVE_COMPARATOR|Closed-loops at Dinner|Automated closed-loop control starts at 18:00
62178674|NCT00989898|ACTIVE_COMPARATOR|Closed-loop at Bedtime|Automated closed-loop control starts at 21:00
62178675|NCT05438446|EXPERIMENTAL|Renal Denervation Arm|Endovascular ultrasound renal denervation (Paradise renal denervation system, ReCor, CA, USA) (RDN)
62178676|NCT05438446|NO_INTERVENTION|Control|The patient will not receive any interventional therapy
62178677|NCT02148653|EXPERIMENTAL|Multifunctional diet (MFD)|Subjects eat a diet designed according to the Nordic Nutrition Recommendations with the addition of important amounts of various functional food concepts: Low GI and GI-modulating food items; Natural antioxidant-rich items, Long chain omega-3 fatty acid-rich fish; Betaglucan-rich barley and oat food/drinks; Cholesterol-modulating foods.
62178678|NCT02148653|EXPERIMENTAL|Control diet|Subjects eat a diet designed according to the Nordic Nutrition Recommendations but lacking the functional items included in the MFD.
62178679|NCT06105762|EXPERIMENTAL|Ketogenic Diet Arm|During an 8-week period, individuals enrolled in the experimental group will undergo a low-carbohydrate, high-fat ketogenic diet intervention. We will implement the Modified Atkins Diet (MAD), which is a nutritionally rich and diverse variant of the ketogenic diet. It restricts net carbohydrate intake to less than 20g per day.
62391071|NCT01403324|OTHER|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
62391072|NCT02073292|EXPERIMENTAL|c-RFA|cooled radiofrequency ablation
62391073|NCT02073292|ACTIVE_COMPARATOR|t-RFA|thermal radiofrequency ablation
62391074|NCT03515499|ACTIVE_COMPARATOR|Control|The control arm will have medication monitoring sensors placed on their asthma medications. They will have reminders to take their medicines and access to a mobile app that will show them trends in their medication use.
62391075|NCT03515499|EXPERIMENTAL|Treatment arm|The treatment arm will have medication monitoring sensors placed on their asthma medications. They will have reminders to take their medicines and access to a mobile app that will show them trends in their medication use. Additionally, they will be paid up to $1 per day for perfect medication adherence.
62391076|NCT03463980|EXPERIMENTAL|Compassion meditation (CM)|The CM participants will attend six weekly sessions (each 120 minute), and will be video and/or audiotaped. Each weekly CM session will entail a 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants will be encouraged to meditate at least 30 minutes a day and will be asked to track their daily meditation time and bring in their tracking sheet to each session.
62391077|NCT03463980|ACTIVE_COMPARATOR|Support group (SG)|SG participants will attend six weekly sessions, 90 minutes in length. It will be unstructured. Participants will use this time to talk about current concerns and to receive support and guidance from other group members and the leaders.
62391078|NCT03817814||Women with Breast Cancer|This is a cross-sectional survey of young women with breast cancer (YWBC) who received a consultation with an MSK Fertility Nurse Specialist before starting cancer treatment.
62391079|NCT00520273|EXPERIMENTAL|A|
62391080|NCT06035666|SHAM_COMPARATOR|Control|Control app
62391081|NCT06035666|EXPERIMENTAL|Intervention|Your World (vitality session + app)
62391082|NCT01042561|PLACEBO_COMPARATOR|placebo|This group will recieve the current standard of care for infants in the NICU, recieving infant formula that provides less than 400 IU of vitamin D a day.
62391083|NCT01042561|EXPERIMENTAL|Vitamin D|This group will recieve standard of care infant formulas that provide less than 400 IU of vitamin D a day, in addition they will be supplemented with 400 IU of vitamin D3 daily.
62391084|NCT06496347||healthy control (HC) group,|no intervention(s)
62391085|NCT06496347||MCI/dementia group|no intervention(s)
62391086|NCT00493909|ACTIVE_COMPARATOR|1|thoracic epidural analgesia
62391087|NCT00493909|ACTIVE_COMPARATOR|2|intrathecal opioids and thoracic paravertebral analgesia
62391088|NCT01390727|PLACEBO_COMPARATOR|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
62391089|NCT01390727|ACTIVE_COMPARATOR|Device-guided breathing|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
62391090|NCT03448458|EXPERIMENTAL|Gallium Ga 68-DOTATATE PET/CT|Patients receive gallium Ga 68-DOTATATE IV. Within 55-70 minutes, patients undergo PET (positron emission tomography)/CT (computed tomography).
62391091|NCT05608811|EXPERIMENTAL|Social Skills Training-intervention group|"Intervention group: Adolescents in the training group were given 8 sessions of Social Skills Training. At the end of the training, the final evaluation was made. Initial and final assessments were made face-to-face. The training was held via Zoom."
62391092|NCT05608811|ACTIVE_COMPARATOR|One Session General Social Skills-control group|The control group was informed about general social skills in one session. When the training given to the intervention group was completed, the final evaluation was made. Initial and final assessments were made face-to-face.
62562793|NCT03983525|EXPERIMENTAL|Goji berry|The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0 SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with either a 45-day supply of goji berries and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
62770883|NCT04738591|EXPERIMENTAL|DIABE-TEXT|Participants allocated to the intervention group will receive text messages in their mobile phones with content about diabetes management, general information about diabetes, medicines, diet and physical activity recommendations and motivational prompts to engage participants in a healthy lifestyle and a good adherence to medication plan. They will also receive reminders for healthcare visits, drug dispensation from the pharmacy and updated results from blood test records.
62770884|NCT04738591|NO_INTERVENTION|Usual care|Participants allocated to the control group will not receive any intervention apart from usual care.
62770885|NCT03871660|OTHER|Patients with diabetes on TPN|Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN.
62770886|NCT03871660|OTHER|Patients without diabetes on TPN|Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN.
62770887|NCT02024958||indirect calorimetry measurement|Measurement of energy expenditure in made by indirect calorimetry in patients laying down in a supine position on a bed during ongoing measure by connecting the calorimeter to the endotracheal tube (invasive mechanical ventilation) or to the facemask (non-invasive mechanical ventilation), or by using a transparent canopy in plexiglas to cover the head while room-air flows through and is mixed with the expirate (spontaneous breathing). This mixture of patient breath and room air is finally collected and analyzed by the IC device for O2 and CO2 concentrations, and used to calculate EE. EE is calculated using the modified Weir equation.
62770888|NCT02238015||surgery group|patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
62770889|NCT02238015||control group|patients' other eye that did not have surgery
62178680|NCT06105762|ACTIVE_COMPARATOR|Conventional Healthy Mixed Diet Arm|The control group will be provided with a standard balanced mixed diet following the recommendations for healthy nutrition by the Schweizerische Gesellschaft für Ernährung (Société Suisse de Nutrition). This diet will consist of an average daily caloric supply from carbohydrates of approximately 45 - 60%, as per the guidelines.
62178681|NCT02798913|EXPERIMENTAL|Short DAPT|Patients who will be treated after PTA with acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months
62178682|NCT02798913|EXPERIMENTAL|Long DAPT|Patients who will be treated after PTA with acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
62178683|NCT02241278|PLACEBO_COMPARATOR|Control|In the operating room, the anesthesiologist administered 50 mL of 0.9% saline intravenously to patients in the control group 30 minutes before surgical incision.
62178684|NCT02241278|EXPERIMENTAL|Ketamine|In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision. (a single dose).
62770890|NCT03226977|EXPERIMENTAL|NIPPV|NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
62770891|NCT03226977|ACTIVE_COMPARATOR|NCPAP|NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
62178685|NCT03793322|EXPERIMENTAL|Indocyanine-Green(ICG) injection group|
62178686|NCT01880437|EXPERIMENTAL|Vismodegib|
62178687|NCT05946122|PLACEBO_COMPARATOR|control group|
62178688|NCT05946122|ACTIVE_COMPARATOR|Active ( Ator) group|
62178689|NCT03618706|EXPERIMENTAL|involved-field RT + standard salvage treatment|Patients receiving involved-field RT on recurred lesions + standard salvage treatment for recurrent ovarian cancer
62770892|NCT02659319|EXPERIMENTAL|Family Lifestyle (FL; n = 117)|This arm includes the Family Food \& Lifestyle intervention (FL). Parents and children meet for 12 weekly, 90-minute psychoeducational groups in children's schools. They meet separately for 45 minutes and then conjointly for 45 minutes.
62770893|NCT02659319|EXPERIMENTAL|FL + Family Dynamics (FL+FD; n = 88)|This arm includes the Family Food \& Lifestyle + Family Dynamics interventions (FL+FD). Parents and children meet separately for the full 90-minute psychoeducation sessions. The first 45 minutes are devoted to the Family Food \& Lifestyle intervention and the second 45 minutes to the Family Dynamics intervention.
62770894|NCT02659319|EXPERIMENTAL|FL + Peer Group (FL+PG; n = 124)|This arm includes the Family Food \& Lifestyle intervention plus the 12-session, Peer Group intervention.
62770895|NCT02659319|EXPERIMENTAL|FL + FD + Peer Group (FL+FD+PG; n = 130)|This arm includes the Family Food \& Lifestyle intervention plus the Family Dynamics Intervention plus the Peer Group intervention.
62178690|NCT01104064|EXPERIMENTAL|Real rTMS combined with CIT|
62178691|NCT01104064|SHAM_COMPARATOR|Sham rTMS combined with CIT|
62770896|NCT02659319|NO_INTERVENTION|Control (n = 82)|Non-intervention control group
62562794|NCT03983525|ACTIVE_COMPARATOR|Lutein + zeaxanthin supplementation|The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0. SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with L/Z supplements which contains 6 mg of lutein and 4 mg of zeaxanthin and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
62562795|NCT05815212||Patients with DME|
62562796|NCT01769573|EXPERIMENTAL|100 TCID50|RG-HRV16 dose of 100 TCID50 administered intranasally (0.25ml per nostril) one time.
62178692|NCT02915562|ACTIVE_COMPARATOR|Depressive Group|GDS 15 (Geriatric Depression Score) ≥5 at baseline
62178693|NCT02915562|ACTIVE_COMPARATOR|Non-depressive Group|GDS 15 (Geriatric Depression Score) \<5 Points at baseline
62391093|NCT05936190|ACTIVE_COMPARATOR|Group L1|Group who gets 1 mg/kg/min IV lidocaine infusion during surgery
61995025|NCT02927379|PLACEBO_COMPARATOR|bupivacaine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision( control group).
61995026|NCT03302585|EXPERIMENTAL|High-Dose Vitamin D Treatment Group|"Patients in this arm will receive:~-5 days of high-dose oral vitamin D3 (50,000 IU daily x 5), followed by 85 days of moderate dose oral vitamin D3 (10,000 IU daily x 85 days)"
61995027|NCT03302585|PLACEBO_COMPARATOR|Placebo/Standard Vitamin D3 Group|"Patients in this arm will receive Placebo/Standard of Care Vitamin D3:~-5 days of placebo, followed by 85 days of standard of care dose of oral vitamin D3 (4,000 IU daily x 85 days)"
61995028|NCT05009810|EXPERIMENTAL|astaxanthin 4 mg|The astaxanthin 4 mg will be taken 1 capsule once daily for 2 months.
61995029|NCT05009810|EXPERIMENTAL|astaxanthin 6 mg|The astaxanthin 6 mg will be taken 1 capsule once daily for 2 months.
61995030|NCT05009810|PLACEBO_COMPARATOR|Placebo|The placebo will be taken 1 capsule once daily for 2 months.
61995031|NCT04033159|EXPERIMENTAL|cohort 1|DYN101 in a low dose (1.5 mg/kg), (unless the independent data monitoring committee \[IDMC\] advises otherwise). In each cohort, there will be 3-4 subjects with a mutation in DNM2 (subcohort a) and 2-3 subjects with a mutation in MTM1 (subcohort b).
62391094|NCT05936190|EXPERIMENTAL|Group L2|Group who gets 2 mg/kg/min IV lidocaine infusion during surgery
62391095|NCT04773691|EXPERIMENTAL|test group|
62391096|NCT04773691|PLACEBO_COMPARATOR|control group|
62391097|NCT06326138|EXPERIMENTAL|Group 1 - Roux en Y gastric bypass and Sleeve Gastrectomy|Edoxaban pharmacodynamic and pharmacokinetic will be evaluated before and 48 ± 5 hours after bariatric surgery (sleeve gastrectomy and Roux-en-Y gastric bypass).
61995032|NCT04033159|EXPERIMENTAL|cohort 2|DYN101 in a middle dose (4.5 mg/kg), (unless the IDMC advises otherwise). In each cohort, there will be 3-4 subjects with a mutation in DNM2 (subcohort a) and 2-3 subjects with a mutation in MTM1 (subcohort b).
62391098|NCT06326138|EXPERIMENTAL|Group 2 - Roux en Y gastric bypass|Edoxaban pharmacodynamic and pharmacokinetic will be evaluated at 12 ± 3 months following Roux-en-Y gastric bypass surgery.
62391099|NCT03520361|EXPERIMENTAL|Oral sulfate solution (OSS) taking group|On the evening before colonoscopy, drink 177ml of OSS (Suclear®) (473ml including water in container), additionally allow another 946 ml of water. On the day of colonoscopy, drink 177ml of OSS (473ml including water in container), additionally allow another 946 ml of water.
62391100|NCT03520361|ACTIVE_COMPARATOR|2L PEG/Asc taking group|On the evening before colonoscopy, drink 1L of 2L PEG/Asc (Haprep®) solution, additionally allow another 500 ml of water. On the day of colonoscopy, drink 1L of 2L PEG/Asc solution, additionally allow another 500 ml of water.
62391101|NCT04659356||Patients admitted in Intensive Care Units|All patients admitted in our ICU since august were enrolled in our study, after they have been informed and given their consent for their participation in this observational study.
62391102|NCT01004861|EXPERIMENTAL|PLX3397|
62391103|NCT01074086|EXPERIMENTAL|RAD 001|RAD 001 in day 1 and day 7 from 10 mg to 50 mg
62391104|NCT04862351|EXPERIMENTAL|TecHCR|12 weeks Hybrid between supervised exercise training and video call sessions Educational videos Dietary and exercise log
62391105|NCT04862351|OTHER|Centre-based|12 weeks usual care provided by the centre-based, outpatient cardiac rehabilitation clinic Dietary and exercise log
62391106|NCT03428490|EXPERIMENTAL|Fully Integrated Treatment|Evidence-based substance use treatment combined with Cognitive Behavioral Therapy (CBT) for Social Anxiety Disorder Intervention name: Fully integrated treatment
62562797|NCT01769573|EXPERIMENTAL|1,000 TCID50|RG-HRV16 dose of 1,000 TCID50 administered intranasally (0.25ml per nostril) one time.
62562798|NCT01769573|EXPERIMENTAL|10,000 TCID50|RG-HRV16 dose of 10,000 TCID50 administered intranasally (0.25ml per nostril) one time.
62562799|NCT01769573|PLACEBO_COMPARATOR|Placebo|Diluent administered intranasally (0.25ml per nostril) one time.
62562800|NCT01769573|EXPERIMENTAL|500 TCID50|RG-HRV16 dose of 500 TCID50 administered intranasally (0.25ml per nostril) one time.
62562801|NCT01828723|EXPERIMENTAL|SVF-Enriched Lipoinjection|
62562802|NCT05938023|EXPERIMENTAL|ATL1102 25mg|ATL1102 25mg administered subcutaneously once weekly
62562803|NCT05938023|EXPERIMENTAL|ATL1102 50mg|ATL1102 50mg administered subcutaneously once weekly
62562804|NCT05938023|PLACEBO_COMPARATOR|Placebo|Placebo is administered subcutaneously once weekly
62562805|NCT02536092|EXPERIMENTAL|755nm and 1064nm Nd:YAG laser|755nm and 1064nm Nd:YAG laser
62178694|NCT04233983|ACTIVE_COMPARATOR|Study Group|The study group consists of ERROR(endometrioma related reduction in ovarian reserve) patients who will undergo laparoscopic endometriosis surgery after ICSI procedure with freezing all embryos. The patients will wait about 6 months for spontaneous conception, if there is no pregnancy during this period, frozen embryo transfer will be performed.
62391107|NCT03428490|ACTIVE_COMPARATOR|Usual Intensive Outpatient Care|Evidence-based substance use disorder treatment Intervention name: Stand-alone Intensive Outpatient Program
61995033|NCT04033159|EXPERIMENTAL|cohort 3|DYN101 in a high dose (9 mg/kg), (unless the IDMC advises otherwise). In each cohort, there will be 3-4 subjects with a mutation in DNM2 (subcohort a) and 2-3 subjects with a mutation in MTM1 (subcohort b).
61995034|NCT03437785|EXPERIMENTAL|Experimental Group 1|Patients assigned to this group are treated with CKD-495 75mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 150mg, ,Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
61995035|NCT03437785|EXPERIMENTAL|Experimental Group 2|Patients assigned to this group are treated with CKD-495 150mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
61995036|NCT03437785|PLACEBO_COMPARATOR|Placebo Group|Patients assigned to this group are treated with 4 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
61995037|NCT03437785|ACTIVE_COMPARATOR|Active comparator Group 1|Patients assigned to this group are treated with Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of the Rebamipide 100mg Tab.)
61995038|NCT03437785|ACTIVE_COMPARATOR|Active comparator Group 2|Patients assigned to this group are treated with Rebamipide 100mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.)
62562806|NCT05913752|OTHER|Healthy Subjects - Part A|Part A: Single dose (\~ 24 ) Healthy Volunteers: At least four consecutive ascending dose cohorts (20 mg, 40, 80 and 160 mg) will be included in this part of the study in accordance with a pre-defined dose escalating scheme. In each cohort, 6 HVs will receive a single dose of investigation medicine product (CMND-100) starting with the lowest dose of 20 mg. Once dosed, the subjects will be sampled for PK for 24 hours following dosing and will be monitored for drug effects with a physical examination at the end of 24 hours after dosing and daily monitored for safety for a period of 1 week following dosing. Assuming no serious adverse reactions or limiting toxicity (grade 2 and higher) in up to 2, subjects are observed in this dose level, then the next 6 subjects are treated with the next escalated dose, in accordance with a pre-defined dose escalating scheme. The DSMB will review results and guide doses to be studied in Parts B, C and D.
62562807|NCT05913752|OTHER|AUD Subjects - Part B|Single dose (\~12): After DSMB review of part A, binge drinking/AUD subjects will be enrolled in at least 2 consecutive ascending single dose cohorts using the highest tolerable doses from Part A. The first cohort (n=6) will start with the lower ascending dose and sampled for PK for 24 hours following dosing and will be monitored for drug effects with a physical examination at the end of 24 hours after dosing and daily monitored for safety for a period of 1 week following dosing. Assuming no serious adverse reactions or limiting toxicity are observed in this dose level, then the next 6 subjects are treated with the next escalated dose. At the end of this part, real time PK data from the dose cohorts will be collected and analyzed. PK and safety information from this part of the study and from Part A will be reviewed by the DSMB and will guide the dose to be studied in Part D.
62770897|NCT00612508|ACTIVE_COMPARATOR|Desogen|"Drug: ethinyl estradiol and desogestrel~1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol; secen inactive pills every 28 days.~Subjects receive baseline vaginal biopsy, followed by treatment with the OC for six cycles and repeat biopsy at 3 and after 6 cycles"
61995039|NCT01660412|ACTIVE_COMPARATOR|pH altered first|The first injection administered will be the pH altered solution. The second injection will be the standard of care solution (opposite order). The remaining injections will be randomly assigned as either standard of care or pH altered.
62178695|NCT04233983|NO_INTERVENTION|Control Group|The control group consists of ERROR(endometrioma related reduction in ovarian reserve) patients who will be performed IVF\&ICSI procedure with fresh embryo transfer without surgery. If there is no pregnancy, patients will be operated then.
62178696|NCT05808855|EXPERIMENTAL|skin adhesive|two-component skin adhesive Glubran Tiss 2®
62178697|NCT05808855|ACTIVE_COMPARATOR|suture-based wound closure|suture-based wound closure
62391108|NCT01478490|EXPERIMENTAL|Treatment Arm 1A|mirabegron, poor metabolizers
62391109|NCT01478490|EXPERIMENTAL|Treatment Arm 1B|mirabegron, extensive metabolizers
62391110|NCT01478490|EXPERIMENTAL|Treatment Arm 2|mirabegron/metoprolol
62391111|NCT02569996|EXPERIMENTAL|Rituximab|Participants will receive rituximab 375 milligrams per meter square (mg/m\^2) every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
62567773|NCT05651321||stroke patients|Participants were tested for different taste perception thresholds using a three-point difference test, with samples materials for basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) were used to prepare different tastes and concentrations of liquids. The subjects will then evaluate the appearance (color, texture), taste, flavor, and texture of the six different flavored enteral nutrition preparations. The subjects will then perform manual sensory evaluation of the appearance (color, texture), odor, taste, texture, and other properties of the 6 different flavored enteral nutrition preparations.
62770898|NCT00612508|ACTIVE_COMPARATOR|NuvaRing|"Intravaginal Contraception~ethinyl estradiol (0.15 mg/d) and etonogestrel (0.12 mg/d) Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring~Subjects had baseline vaginal biopsy followed by 6 cycles of ring use and repeat biopsy at 3 and after 6 cycles"
62770899|NCT00667290|EXPERIMENTAL|1|
62770900|NCT00667290|NO_INTERVENTION|2|
62770901|NCT01401712|EXPERIMENTAL|Paravertebral catheter (ON-Q® Pain Relief System)|
62770902|NCT01401712|ACTIVE_COMPARATOR|Thoracic epidural catheter|
62770903|NCT06252441|ACTIVE_COMPARATOR|Rectal Diclofenac|This Group will include 23 patients who will receive 100 mg rectal diclofenac before ERCP.
62770904|NCT06252441|ACTIVE_COMPARATOR|Oral N-acetyl cysteine|This Group will include 23 patients who will receive 1200 mg N-acetyl cysteine in 150 cc water orally before ERCP.
62178698|NCT02271685|EXPERIMENTAL|Overestimate Parkinson's|People are told that overestimates on the sound estimation task are associated with being healthy and having a low risk of Parkinson's disease, whereas those who are accurate are more likely to develop the disease later in life.
62178699|NCT02271685|EXPERIMENTAL|Overestimate Alzheimers|People are told that overestimates on the sound estimation task are associated with being healthy and having a low risk of Alzheimers disease, whereas those who are accurate are more likely to develop the disease later in life.
62178700|NCT02271685|EXPERIMENTAL|Underestimate Parkinson's|People are told that underestimates on the sound estimation task are associated with being healthy and having a low risk of Parkinson's disease, whereas those who are accurate are more likely to develop the disease later in life.
62178701|NCT02271685|EXPERIMENTAL|Underestimate Alzheimers|People are told that underestimates on the sound estimation task are associated with being healthy and having a low risk of Alzheimers disease, whereas those who are accurate are more likely to develop the disease later in life.
62178702|NCT05264272||Prospective Study|HBV/HDV positive individuals
62178703|NCT05264272||Retrospective Study|patients positive for anti-HDV
62178704|NCT01209741|ACTIVE_COMPARATOR|1|MK-0974 12MoRT
62178705|NCT01209741|ACTIVE_COMPARATOR|2|MK-0974 5Mo5C
62770905|NCT04226040||DOW and illness perception|Exploration of the association between DOW and illness perception
62770906|NCT00265018|ACTIVE_COMPARATOR|Arm A|
62178706|NCT01209741|ACTIVE_COMPARATOR|3|MK-0974 12Mo5C
62178707|NCT03298633|ACTIVE_COMPARATOR|Intracytoplasmic Sperm Injection|On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in group A will undergone Intracytoplasmic Sperm Injection (ICSI) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
62178708|NCT03298633|ACTIVE_COMPARATOR|Conventional IVF|On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in this group will undergone Conventional In Vitro Fertilization (IVF) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
62178709|NCT00848068|OTHER|OD (Right Eye)|FID 114657 or OPTIVE
62178710|NCT00848068|OTHER|OS (Left eye)|FID 114657 or OPTIVE
62770907|NCT00265018|EXPERIMENTAL|Arm B|
62770908|NCT00265018|EXPERIMENTAL|Arm C|
62178711|NCT04676633|EXPERIMENTAL|Cohort 1: STP705 20 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
62178712|NCT04676633|EXPERIMENTAL|Cohort 2: STP705 40 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
62770909|NCT00265018|EXPERIMENTAL|Arm D|
62770910|NCT03166072|ACTIVE_COMPARATOR|Low-vision rehabilitation program|Participants and their care givers in Low-vision rehabilitation program will undergo a standardized interview to measure HRQoL using the time trade-off method (TTO), depression using the Patient Health Questionnaire (PHQ-9), anxiety using Generalized Anxiety Disorder (GAD-7) and Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48) at the first study visit and after Low-vision rehabilitation program.
62770911|NCT03166072|PLACEBO_COMPARATOR|No Intervention|Participants and their care givers will undergo a standardized interview to measure HRQoL using the time trade-off method (TTO), depression using the Patient Health Questionnaire (PHQ-9), anxiety using Generalized Anxiety Disorder (GAD-7) and Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48) at the first study visit and will continue to receive treatment as usual.
62770912|NCT02404649|ACTIVE_COMPARATOR|Bone Augmention|Two implant designs in a Sinus Bone Augmentation Procedure. Sinus bone augmentation with Puros Cortico-Cancellous Particulate Allograft (70% Cortico and 30% Cancelleous) (Zimmer Dental- Carlsbad, CA, USA)- one implant will be TMDI (Zimmer Dental- Carlsbad, CA, USA) and the second will be Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA). Implant stability will be determined by the initial insertion torque and RFV values at time of implant placement and after 1 month of healing on a monthly basis up until 12 months post implant placement.
62178713|NCT04676633|EXPERIMENTAL|Cohort 3: STP705 80 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
62178714|NCT04676633|EXPERIMENTAL|Cohort 4: STP705 160 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
62770913|NCT02404649|ACTIVE_COMPARATOR|Sinus elevation only|Two implant designs in a Sinus Floor Elevation Procedure. Placement of two dental implants as mentioned above in sinus bone augmentation by sinus elevation procedure, blood clot and CopiOs Pericardium Membrane (Zimmer Dental- Carlsbad, CA, USA) only. One implant will be TMDI (Zimmer Dental- Carlsbad, CA, USA) and the second will be Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA). Implant stability will be determined by the insertion torque and RFV values at time of implant placement and after 1 month of healing on a monthly basis up until 12 months post implant placement.
62178715|NCT04676633|EXPERIMENTAL|Cohort 5: STP705 320 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
62178716|NCT01493999|ACTIVE_COMPARATOR|Prasugrel arm|A loading dose of 60 mg prasugrel in patients with HPR after 600 mg clopidogrel.
62178717|NCT01493999|ACTIVE_COMPARATOR|Clopidogrel reloading|A maximum of three adjusted loading doses of 600 mg clopidogrel until normal platelet reactivity is achieved in patients with HPR after the first 600 mg clopidogrel.
62770914|NCT00999960|ACTIVE_COMPARATOR|1: without simulator|without simulator
62770915|NCT00999960|EXPERIMENTAL|2: with simulator|with simulator
62770916|NCT02210832|EXPERIMENTAL|Best practices for pregnant smokers|Five As plus referral to pregnancy-specific tobacco quit line
62770917|NCT02210832|EXPERIMENTAL|Best practices plus financial incentives|Best practices plus providing financial incentives contingent on biochemically verified abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks postpartum.
62770918|NCT02210832|NO_INTERVENTION|Never-smoker comparison condition|We will follow a group of never-smoker pregnant women matched to smokers on key sociodemographic and obstetrical characteristics for purposes of comparisons in birth/health outcomes at delivery and through 1 year postpartum
62770919|NCT00898859||1|Healthy, non-smoking
62770920|NCT00898859||2|healthy, ex-smoking
62770921|NCT00898859||3|healthy, current-smokers
62770922|NCT00898859||4|COPD, ex-smokers
62770923|NCT00898859||5|COPD, smokers
62770924|NCT02286323|EXPERIMENTAL|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
62770925|NCT02286323|EXPERIMENTAL|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
62770926|NCT01945684|EXPERIMENTAL|Botulinum toxin type A (DWP450)|DWP450: Botulinum toxin type A
62770927|NCT01945684|ACTIVE_COMPARATOR|Botulinum toxin type A (Botox®)|Botox®: Botulinum toxin type A
62770928|NCT01186640|EXPERIMENTAL|FCM-A followed by A-maintenance|First treatment phase: Chemoimmunotherapy A-FMC maximum 4 cycles. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c.
62770929|NCT00897390|OTHER|Arm A|Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fasted conditions
62770930|NCT00897390|OTHER|Arm B|Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fasted conditions
62770931|NCT00897390|OTHER|Arm C|Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fed conditions with a standard meal
62770932|NCT00897390|OTHER|Arm D|Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fed conditions with a standard meal
62178718|NCT05773027|EXPERIMENTAL|Sexual Assault and Alcohol Feedback and Education (SAFE)|SAFE includes a motivational interviewing session addressing alcohol use and risk for sexual aggression, a workshop addressing alcohol use and sexual aggression, and a booster session review.
62178719|NCT05773027|ACTIVE_COMPARATOR|Mindfulness-Based Control Condition|The program includes the same amount of contacts as SAFE, including an individual session focused on mindfulness and stress, a group session, and a booster session review.
62178720|NCT00519285|PLACEBO_COMPARATOR|Placebo|Placebo added to standard chemotherapy with docetaxel plus prednisone or prednisolone
62178721|NCT00519285|EXPERIMENTAL|Aflibercept|Aflibercept added to standard chemotherapy with docetaxel plus prednisone or prednisolone
62178722|NCT02258997||HbSS|Subjects are homozygous for the sickle hemoglobin mutation (HbS).
62178723|NCT02258997||HbS-beta thalassemia|Subjects are heterozygous for the HbS mutation and beta thalassemia
62770933|NCT04345718|EXPERIMENTAL|Interventional|Single subcutaneous injection of a 28-day formulation of extended-release buprenorphine within 72 hours of anticipated hospital discharge.
62770934|NCT04345718|ACTIVE_COMPARATOR|Treatment as Usual|Community standard of care that includes initiation of either methadone, sublingual (SL) buprenorphine, or naltrexone prior to hospital discharge.
62770935|NCT03897530|EXPERIMENTAL|Prevention|During the session, participants are presented with randomly ordered conditions: menthol cigarettes and five flavored e-cigarettes (menthol/mint, fruits, sweets, alcohol, snacks/meals), menthol cigarettes and both unflavored and tobacco-flavored e-cigarettes, non-menthol cigarettes and five flavored e-cigarettes, and non-menthol cigarettes and both unflavored and tobacco-flavored e-cigarettes. Participants' visual attention is evaluated by eye-tracking equipment.
62770936|NCT03594643||electronic cigarette|patient using electronic device, electronic cigarette
62770937|NCT03594643||control|patient not smoking nor using electronic cigarette
62770938|NCT04167865|NO_INTERVENTION|Control group|All patients will be instructed to wear the device for 1 hours for 12 weeks after being instructed on how to use the vacuum bell. The patient's relatives will be asked to keep a book in order to monitor their use. Patients who have not used the device for 5 consecutive days will be excluded from the study. The first group will be given awareness training on using one session orthosis and posture correction.
62770939|NCT04167865|ACTIVE_COMPARATOR|Exercise Group|In addition to the applications to the control group, mobilization, strengthening, posture and segmental breathing exercises will be given . All of these exercises will be combined with segmental breathing exercises depending on the location of the PE. Exercise therapy will be administered by a physiotherapist with 20 years of experience once a week and will be designed as a home program on the remaining days and will be asked to do 45 minutes twice a day (at least 4 times a week). The patient's relatives will be asked to keep a book to monitor the exercise. Patients who do not perform 5 consecutive exercise sessions will be excluded from the study. All treatments will be given for 12 weeks.
62178724|NCT02514577|EXPERIMENTAL|IDP-122 Lotion|Participants will apply IDP-122 Lotion (halobetasol propionate \[HP\] 0.01%) topically once daily for 8 weeks.
62770940|NCT00645463|EXPERIMENTAL|Group A|
62770941|NCT00645463|EXPERIMENTAL|Group B|
62770942|NCT04662372||Patients|Patients
62770943|NCT02537405|EXPERIMENTAL|BAY59-7939 granule|
62770944|NCT02537405|ACTIVE_COMPARATOR|BAY59-7939 tablet|
62770945|NCT05589883|EXPERIMENTAL|EMPOWER-Latinx intervention|Informal caregivers will meet with the interventionist one-on-one via telepsychiatry (e.g., WebEx, Zoom) for 6, 15-20 minute modules to be completed within about 2-3 days from initiation of the first module, not including the booster modules. Informal caregivers will complete study assessments as per the schedule of assessments.
62770946|NCT02064608|EXPERIMENTAL|AZD2014|This is a single arm study whereby a cohort of 20 patients with early high risk prostate cancer will be treated with a 15-day course of AZD2014 (mTOR inhibitor) treatment prior to radical prostatectomy.
62770947|NCT05173961|EXPERIMENTAL|Supportive Care (oncpatient application, survey)|Patients use the oncpatient mobile application over the course of radiation therapy. Patients also complete a survey on the final day of radiation treatment.
62770948|NCT01236235||ARV-naïve HIV patients initiated on ATV/RTV-based therapy|"Anti-retroviral (ARV)-naïve HIV patients initiated on ATV/RTV-based therapy between 2008-2010~One cohort being observed for 3 different countries"
62770949|NCT04102722|EXPERIMENTAL|Single Arm|All enrolled subjects will undergo breast cancer screening with mammography and the MUST device
62770950|NCT01918449|NO_INTERVENTION|Sleep Unit group|This group will have standard follow up in sleep unit at 1, 3 and 6 month. These patients will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counseling.
62770951|NCT01918449|EXPERIMENTAL|Primary Care group|This group will have standard follow up in primary care at 1, 3 and 6 month. These patients will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counseling.
62770952|NCT05910333||Quadrilateral distribution group|Patients with quadrilateral distribution of implants
62770953|NCT05910333||Linear distribution group|Patients with lineardistribution of implants
62770954|NCT01378429|EXPERIMENTAL|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
62770955|NCT01378429|PLACEBO_COMPARATOR|Placebo|
62770956|NCT05876247||Individuals treated for oral cancer|Dutch native speakers (18+) who will undergo surgical treatment for a T1 or T2 tumour on the tongue.
62770957|NCT05876247||Control speakers|Dutch native speakers (18+) without self-reported speech problems.
62770958|NCT03462186|EXPERIMENTAL|Intervention|Invitation to use healthfinder website
62178725|NCT02514577|ACTIVE_COMPARATOR|IDP-122 Vehicle Lotion|Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.
62178726|NCT01722045|EXPERIMENTAL|Open label IAI|
62178727|NCT05457322|EXPERIMENTAL|Behavioral intervention one|
62178728|NCT05457322|EXPERIMENTAL|Behavioral intervention two|
62178729|NCT03644524|EXPERIMENTAL|Heat Therapy|Subjects assigned to heat therapy underwent 30 1-hour hot tub sessions over 8-10 weeks (3-4 per week). The hot tub was set to 40.5 Celsius, and core temperature and heart rate were monitored throughout each session.Subjects were instructed to not make any other dietary or lifestyle changes.Cardiovascular and metabolic health assessments were made Pre (0 heat sessions), mid (after 14-16 heat sessions, \~4-5 weeks), and post (after all 30 heat sessions; \~8-10 weeks).
62178730|NCT03644524|NO_INTERVENTION|Time Control|Subjects were monitored at matched timepoints (start of study, 4-5 weeks, and 8-10 weeks) but not exposed to any intervention. Subjects were instructed to not make any dietary or lifestyle changes.
62770959|NCT03462186|NO_INTERVENTION|Control|No intervention
62770960|NCT02098889|ACTIVE_COMPARATOR|hyoscine-N-butyl bromide|A single dose intravenously(IV) 20ml hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose 20ml IV NaCl) on the active phase of labor
62770961|NCT02098889|PLACEBO_COMPARATOR|Saline(0,9NaCl)|Placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
62770962|NCT05474534|EXPERIMENTAL|Treatment Group|Mothers in the treatment group will complete pre- and post-treatment self-report surveys assessing trauma symptoms, mental health, parenting attitudes and behaviors, and infant crying patterns and socioemotional development. Mothers in the treatment group will be provided with a wearable neurofeedback device called the MUSE 2, to use at home for 4-6 10-minute sessions per week, over the course of 3 months. Mothers in the treatment group will complete weekly virtual surveys assessing emotional and behavioral self-regulation capacities (e.g., anger control, etc.) throughout the 3 month duration of this study phase. Mothers in the treatment group will also answer additional weekly questions about intervention uptake (i.e., no. of sessions completed in the past week) and feasibility (i.e.,barriers to treatment uptake, ease of use of the device, etc.).
62770963|NCT05474534|NO_INTERVENTION|Wait-list Control Group|Mothers in the wait-list control group will complete pre- and post-treatment self-report surveys assessing trauma symptoms, mental health, parenting attitudes and behaviors, and infant crying patterns and socioemotional development. Mothers in the wait-list control group will complete weekly virtual surveys assessing emotional and behavioral self-regulation capacities (e.g., anger control, etc.) throughout the 3 month duration of this study phase.
62770964|NCT00498888|ACTIVE_COMPARATOR|1|Women were prescribed a 3 month supply of Tolterodine SR 4 mg (Detrusitol SR 4 mg, Pfizer Pharmaceuticals Israel LTD) . After the randomization she needs to get the first prescription from her doctor, and followed this protocol every three weeks. Her doctor how already knows this research were explained how to take the drug. After finished this protocol she get the money she pay after sending the receipts and the empty boxes.
62770965|NCT00498888|ACTIVE_COMPARATOR|2|The Bladder training protocol aims o to increase the time interval between voids, either by a mandatory or self-adjustable schedule, so that incontinence is ultimately avoided and continence regained. It is generally comprised of three components: 1) patient education that includes information about bladder and how continence is usually maintained, 2) scheduled voiding- a 'timetable for voiding' which may fixed or flexible to suit the participant's rate of increase in interval between voids, commonly the aim is to achieve an interval of three to four hours between voids and 3) positive reinforcement- - psychological support and encouragement is generally considered important and usually provided by health care professional . Frequency volume chart (FVC) records the time and volumes of voided for 24 hours by the women between the appointments. Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
62770966|NCT00498888|ACTIVE_COMPARATOR|3|The Pelvic floor muscle training (PFMT) protocol based on National Institute for health and clinical excellence (NICE clinical guideline 40, 2006), that the PFMT programs should comprise at least eight contractions performed three times per day, and the trial of supervised PFMT of at least 3 months' duration . Each appointment the women maid three sets of eight to 12 slow maximal contractions sustained for 6-8 second, and asked to made this protocol every day, and taught to contract these muscle to suppress urge filling. Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
62770967|NCT00498888|ACTIVE_COMPARATOR|4|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for pelvic floor muscle training and bladder training and lifestyle advice and information about good bladder and bowel habits.
62770968|NCT05569694|EXPERIMENTAL|Women in the Community|Movement-Based pelvic health education
62770969|NCT05788133|EXPERIMENTAL|treatment|administration neuropsychological tests with pepper
62770970|NCT00552760|EXPERIMENTAL|Ramelteon|8 mg
62770971|NCT00552760|PLACEBO_COMPARATOR|Placebo|
62770972|NCT04958746|EXPERIMENTAL|Ciprofol|Ciprofol group：0.4/0.2mg/kg
62770973|NCT04958746|PLACEBO_COMPARATOR|Propofol|Propofol group：2.0/1.0mg/kg
62770974|NCT01458834|EXPERIMENTAL|Active attention training condition|
62770975|NCT01458834|PLACEBO_COMPARATOR|Control condition|
62770976|NCT03481426|EXPERIMENTAL|Workplace intervention group|Workers with back problems receive both information/advice and participatory workplace intervention organized by Occupational Health Physioterapist.
62770977|NCT03481426|NO_INTERVENTION|Information and advice group|Workers with back problems receive only information / advice by Occupational Health Physiotherapist, not the workplace intervention.
62770978|NCT06179316||preoperative patients|
62770979|NCT06179316||Patients in the 3rd postoperative month|
62770980|NCT06179316||Patients in the 6th month postoperatively|
62178731|NCT02468310|EXPERIMENTAL|Intervention districts|Access to protocols for management of obstetric and neonatal emergencies via text messaging on request in Intervention districts. Maternal and Neonatal emergency protocols
62178732|NCT02468310|NO_INTERVENTION|Control districts|No access to protocols for management of obstetric and neonatal emergencies via text messaging in control district
62770981|NCT02190890|EXPERIMENTAL|Dry needling: 4 local twitch responses|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until 4 local twitch responses were elicited.
62770982|NCT02190890|EXPERIMENTAL|Dry needling: 6 local twitch responses|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until 6 local twitch responses were elicited.
62770983|NCT02190890|EXPERIMENTAL|Dry needling: Until no more local twitch responses elicited|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until no more local twitch responses were elicited.
62770984|NCT02190890|ACTIVE_COMPARATOR|Control|The needle was inserted 1.5 cm away from the trigger point in the trapezius muscle and withdrawn without any consecutive insertion.
62770985|NCT05257369|EXPERIMENTAL|1.Blue-Green LED wide band phototherapy|"For experimental group was used Malysh phototherapeutic device (Luzar ltd, Belarus); it includes of eighteen blue- green super bright LEDs (12 blue (λmax 476 ) and 6 green (505 nm)."
62770986|NCT05257369|ACTIVE_COMPARATOR|2.Blue LED narrow band phototherapy|For control group was used blue LED BILI-THERAPY (Atom Medical Inc., Tokyo, Japan) in high-mode which have a 20 μW/cm2 with peak wavelength between (λmax 480 nm).
62178733|NCT06035185||Group 1- One Curve Mini 25/0.4|Root canal shaping will be completed with a heat-treated nickel titanium OneCurve Mini #25/0.4 rotary file (Micro-Mega, Besancon, France) after reaching the apical region with #10 K stainless steel files (Dentsply Maillefer, Ballaigues, Switzerland). The irrigation solution will be used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device (VDW Ultra; VDW, Munich, Germany). The tip will be activated a total of three times, each cycle lasting 20 s and involving the use of 1 ml of 3% NaOCl. Then 2 ml of 17% EDTA solution will be activated for 1 minute as described above. The ultrasonic tip will be placed 2 mm shorter than the working length without touching the canal walls.
62770987|NCT05191953|ACTIVE_COMPARATOR|Group ESPB|A bilateral ESPB (40 ml, %0.25 bupivacaine, totally) + IV morphine-PCA
62770988|NCT05191953|ACTIVE_COMPARATOR|Group ESPB+Superficial PIPB|A bilateral ESPB (40 ml, %0.25 bupivacaine, totally) and a bilateral superficial PIPB (20 ml, %0.25 bupivacaine, totally) + IV morphine-PCA
62770989|NCT00740623|EXPERIMENTAL|001|Carisbamate 800 mg/day for 14 weeks
62770990|NCT00740623|EXPERIMENTAL|002|Carisbamate 1,200 mg/day for 14 weeks
62770991|NCT00740623|PLACEBO_COMPARATOR|003|placebo for 14 weeks
62770992|NCT04326855|EXPERIMENTAL|20 patients with advanced COPD|This will be a cross sectional observational study. COPD patients will be recruited from those referred to the Pulmonary Rehabilitation programme at RVI Hospital in Newcastle upon Tyne. Potentially eligible patients will be identified by the physiotherapy team within the Trust, who will provide initial information about the study. Delegated investigators will confirm eligibility and discuss full details of the trial. Patients will be given time to consider participation in the trial before written informed consent is obtained.
62178734|NCT06035185||Group 2- One Curve Mini 35/0.4|Root canal shaping will be completed with a heat-treated nickel titanium OneCurve Mini #35/0.4 rotary file (Micro-Mega, Besancon, France) after reaching the apical region with #10 K stainless steel files (Dentsply Maillefer, Ballaigues, Switzerland). The irrigation solution will be used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device (VDW Ultra; VDW, Munich, Germany). The tip will be activated a total of three times, each cycle lasting 20 s and involving the use of 1 ml of 3% NaOCl. Then 2 ml of 17% EDTA solution will be activated for 1 minute as described above. The ultrasonic tip will be placed 2 mm shorter than the working length without touching the canal walls.
62770993|NCT02903394|EXPERIMENTAL|mLCI imaging|mLCI device images cervical epithelium
62770994|NCT00861718|EXPERIMENTAL|AZD7268|
62770995|NCT00861718|PLACEBO_COMPARATOR|Placebo|
62770996|NCT02995044|EXPERIMENTAL|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62770997|NCT00512291|EXPERIMENTAL|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses
62770998|NCT02517632|EXPERIMENTAL|Exercise group|This arm will be submitted to a exercise session and counseling from pharmaceutical and nutritional professionals.
62770999|NCT02517632|OTHER|Control group|This arm will have only the counseling from pharmaceutical and nutritional professionals.
62771000|NCT01472744|EXPERIMENTAL|Dance|Participants will be instructed in various forms of dances such as ballroom, swing, waltz, folk, and English country.
62771001|NCT01472744|ACTIVE_COMPARATOR|Strengthening, Stability, Stretching|Participants will be instructed in various forms of strength, stretching (flexibility) and stability (balance)exercises.
62771002|NCT01472744|EXPERIMENTAL|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate.
62771003|NCT01472744|EXPERIMENTAL|Walking + Nutritional Supplement|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. These participants will also be provided with a daily nutritionally balanced liquid, milk-based formula.
62771004|NCT03400813|NO_INTERVENTION|Control|Patients in this group continue their usual care without intervention.
62771005|NCT03400813|EXPERIMENTAL|R-TEP EMDR|Patients in R-TEP EMDR group will receive the intervention.
62771006|NCT06344260|EXPERIMENTAL|hNSC 20*10^6|Inoculation of 20\*10\^6 neural stem cells into the right lateral ventricle through a silicone catheter
62771007|NCT06344260|EXPERIMENTAL|hNSC 40*10^6|Inoculation of 40\*10\^6 neural stem cells into the right lateral ventricle through a silicone catheter
62771008|NCT06344260|PLACEBO_COMPARATOR|Saline Solution (placebo)|"Inoculation of saline (placebo) into the right lateral ventricle through a silicone catheter~The reservoir will be placed to all recruited patients in a first surgical session, after randomization half of the subjects will receive the drug product (further randomized for doses) and half the placebo. After three months (period of time considered the minimum for a correct clinical evaluation that does not risk having to exclude patients treated with placebo from subsequent treatment with cells due to excessive physical decline), patients that already received cells will also be infused with placebo while the others will be randomized and transplanted with one of the two cell doses previously mentioned"
62771009|NCT01278082|EXPERIMENTAL|A|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
62771010|NCT01278082|PLACEBO_COMPARATOR|B|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
62771011|NCT04494308||exacerbated|COPD patients admitted to the hospital for an exacerbation occurred within the past 10 days.
62771012|NCT04494308||stable|COPD stable patients with no exacerbations in the past 3 months
62771013|NCT00850941||Questionnaire|Prognostic factors and outcome for patients treated with radiation with curative intent for rising Prostate Specific Antigen (PSA) post-prostatectomy.
62771014|NCT05764174|ACTIVE_COMPARATOR|Factual messages|Participants in the arm with factual messages will listen to actual data on vaccination.
62771015|NCT05764174|ACTIVE_COMPARATOR|Narrative message|Participants the narrative messages will listen to messages appealing to emotions that were explored in a qualitative study conducted earlier.
62771016|NCT05764174|ACTIVE_COMPARATOR|Mixed messages|The mixed arm will combine both factual and narrative messages.
62178735|NCT01308047|EXPERIMENTAL|bupivacaine S75:R25|3 ml for subarachnoid block
62178736|NCT01308047|ACTIVE_COMPARATOR|bupivacaine (S50:R50)|3 ml subarachnoid block
62771017|NCT05764174|NO_INTERVENTION|Control arm|Participants in the control arm will not be provided with a message and will only be asked for whether they participant got vaccinated in the last two weeks.
62771018|NCT06184958|ACTIVE_COMPARATOR|Group A:Lidocaine group|5 mg/Kg lidocaine in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks
62178737|NCT00101998|EXPERIMENTAL|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally BID for 3 weeks.
62178738|NCT00101998|EXPERIMENTAL|Alvimopan 1 mg Once Daily (QD)|"0.5 mg of alvimopan was administered orally QD for 3 days, then 1 mg of alvimopan QD for the remaining 3 weeks. Placebo was administered orally QD to maintain the blind.~A protocol amendment dropped this arm because another study had demonstrated 1 mg QD treatment to have similar efficacy but a less favorable gastrointestinal-related safety profile compared with 0.5 mg BID treatment."
62178739|NCT00101998|EXPERIMENTAL|Alvimopan 1 mg Twice Daily (BID)|0.5 mg of alvimopan was administered orally BID for 3 days, then 1 mg of alvimopan BID for the remaining 3 weeks.
62178740|NCT00101998|PLACEBO_COMPARATOR|Placebo|Placebo was administered orally BID for 3 weeks.
62178741|NCT04533828|EXPERIMENTAL|68Ga-FAPI-04 PET/CT scanning|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
62178742|NCT00946634|EXPERIMENTAL|Ozone Gas|Endodontic protocol preconized by University of Sao Paulo associated to ozone gas 40 mg/L
62178743|NCT00946634|ACTIVE_COMPARATOR|Control|Regular endodontic protocol preconized by University of Sao Paulo
62178744|NCT00946634|EXPERIMENTAL|Aqueous Ozone|Endodontic protocol preconized by University of Sao Paulo associated to Aqueous ozone 40mg/L
62178745|NCT02591706|ACTIVE_COMPARATOR|Dental implant (C1)|"Internal Conical Connection: The C1 has a six-position cone index, except for the C1 narrow platform that has a four-position cone index. The conical connection is 2.00mm in depth, with a 12° cone. As a result of our meticulous manufacturing process a perfect fit between the implant and the abutment is achieved, eliminating micro-movements and minimizing bone resorption.~Patient will be randomly assigned to one of the two groups after flap opening."
62771019|NCT06184958|ACTIVE_COMPARATOR|Group B:Ketamine group|0.5 mg/Kg ketamine sulphate in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
62562808|NCT05913752|PLACEBO_COMPARATOR|AUD Subjects - Part C|Multiple dose (18) HVs: Once Part A has been completed, the data analysed and approved by the DSMB, Part C will be initiated. This part will consist of a repeated-dose cohort based on the higher tolerable dose found in Part A. HVs will be randomized into either the treatment or the placebo arm at a ratio of 2:1 (12 subjects treated with the investigation product and 6 subjects receiving placebo) and will receive the drug/placebo at a daily basis for a total of 10 consecutive days. Each subject will be sampled for PK for 24 hours after first and last dosing and will be daily monitored for drug effects and safety throughout the study period and until 1 week after the last dosing. Real time PK data will be collected and results analysed (as defined in Section 5.2). The PK and safety information gathered from in this part of the study will be evaluated by the DSMB and will guide the dose to be studied in Part D of this study.
62771020|NCT06184958|PLACEBO_COMPARATOR|Group C:Placebo group|Placebo 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
62771021|NCT01120925|EXPERIMENTAL|MNC|Bone marrow derived MNC
62771022|NCT01120925|EXPERIMENTAL|CD133|CD133 derived from Bone marrow
62771023|NCT01120925|PLACEBO_COMPARATOR|Control|Normal saline with 5% Human Serum Albumin
62771024|NCT04454593||Lateral patellar compression syndrome|Patients diagnosed with lateral patellar compression syndrome between February 2016 and April 2019
62771025|NCT04454593||patellar dislocation|Patients diagnosed with patellar dislocation between February 2016 and April 2019
62771026|NCT04454593||meniscus tear|Patients diagnosed with meniscus tear between February 2016 and April 2019
62771027|NCT04730427|EXPERIMENTAL|GX-I7|GX-I7
62771028|NCT04730427|PLACEBO_COMPARATOR|GX-I7 vehicle|GX-I7 vehicle
62771029|NCT03234491|ACTIVE_COMPARATOR|A-HCL low|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
62771030|NCT03234491|ACTIVE_COMPARATOR|A-HCL high|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
62771031|NCT03234491|ACTIVE_COMPARATOR|R-HCL|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
62178746|NCT02591706|EXPERIMENTAL|Dental implant (V3)|"The unique triangular shape of the coronal portion of the V3 implant results in less titanium and more bone and soft tissue visible in the esthetic zone, for a restorative-driven approach and easier soft tissue management. The V3 provides doctors with a more advantageous starting point; where greater volume of bone and soft tissue is achieved at the onset of implant placement.~Patient will be randomly assigned to one of the two groups after flap opening."
62178747|NCT02668198|EXPERIMENTAL|Endoscopic scar assessment|Using endoscope with high definition white light, high definition white light with near focus, narrow band imagining, and narrow band imaging with near focus.
62178748|NCT02893488|EXPERIMENTAL|SEQUENCE ABCDE|Participants will receive treatment A in period 1, treatment B in period 2, treatment C in period 3, treatment D in period 4 and treatment E in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with zero mineral content (ZMC) water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 milliliter (mL) stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 minutes(mins), re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
62178749|NCT02893488|EXPERIMENTAL|SEQUENCE BCDEA|Participants will receive treatment B in period 1, treatment C in period 2, treatment D in period 3, treatment E in period 4 and treatment A in period 5 (one treatment per period). Where A= EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
62178750|NCT02893488|EXPERIMENTAL|SEQUENCE CDEAB|Participants will receive treatment C in period 1, treatment D in period 2, treatment E in period 3, treatment A in period 4 and treatment B in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
62178751|NCT02893488|EXPERIMENTAL|SEQUENCE DEABC|Participants will receive treatment D in period 1, treatment E in period 2, treatment A in period 3, treatment B in period 4 and treatment C in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
62178752|NCT02893488|EXPERIMENTAL|SEQUENCE EABCD|Participants will receive treatment E in period 1, treatment A in period 2, treatment B in period 3, treatment C in period 4 and treatment D in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
62178753|NCT06386198|EXPERIMENTAL|Intervention|This is a single arm pilot intervention.
62178754|NCT01660919|PLACEBO_COMPARATOR|placebo|placebo
62178755|NCT01660919|ACTIVE_COMPARATOR|rosuvastatin 5|rosuvastatin 5 mg
62178756|NCT01660919|ACTIVE_COMPARATOR|rosuvastatin 10|rosuvastatin 10 mg
62178757|NCT01660919|ACTIVE_COMPARATOR|rosuvastatin 20|rosuvastatin 20 mg
62178758|NCT01300078|EXPERIMENTAL|MF101 10 grams/day|
62178759|NCT01300078|EXPERIMENTAL|MF101 15 grams/day|
62178760|NCT05241054|ACTIVE_COMPARATOR|Bupivacaine|Patients will receive local anesthesia by paranasal infiltration at the incision site with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine.
62178761|NCT05241054|ACTIVE_COMPARATOR|Nitroglycerine|Patients will receive an infusion of Nitroglycerine (TNG) (0.2-1μg/kg/min) will be started and adjusted to maintain mean arterial blood pressure between 55-65 mmHg.
62178762|NCT00269841|EXPERIMENTAL|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
62178763|NCT00269841|EXPERIMENTAL|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
62178764|NCT00269841|PLACEBO_COMPARATOR|Placebo|Matching placebo will be administered at Week 0, 2 and 6.
62178765|NCT02647645|ACTIVE_COMPARATOR|Cognitive Training|Cognitive training Sham tDCS
62178766|NCT02647645|EXPERIMENTAL|Cognitive Training with tDCS|Cognitive training Active tDCS
62178767|NCT01659047|EXPERIMENTAL|GS-1101|GS-1101 (oral; 150 mg BID)
62178768|NCT02678364|PLACEBO_COMPARATOR|Control egg group|Two or less control (non-biofortified) eggs per week
62178769|NCT02678364|ACTIVE_COMPARATOR|Vitamin D3-eggs group|Seven vitamin D3-biofortified eggs per week
62178770|NCT02678364|ACTIVE_COMPARATOR|25-Hydroxyvitamin D-eggs group|7 25-hydroxyvitamin D-biofortified eggs per week
62178771|NCT00157690|ACTIVE_COMPARATOR|1|Alendronate
62178772|NCT00157690|PLACEBO_COMPARATOR|2|Placebo
62178773|NCT06380647|EXPERIMENTAL|Group A(32 patients)|Group A patients were given intra venous acyclovir at dosage of 5-10 mg/kg/day into three doses for 7-14 days during their stay.Giant smear testing was done from suspected lesion on burn area to confirm viral infection
62178774|NCT06380647|PLACEBO_COMPARATOR|Group B (32 patients)|Group B patients were given intravenous normal saline 5-10 mg/kg into three doses as placebo for 7 to 14 days,Giant smear testing was done from suspected lesion on burn area to confirm viral infection
62178775|NCT05080842|EXPERIMENTAL|AC682|This arm will evaluate AC682 monotherapy administered in 28-day cycles. Up to 30 participants will participate in this dose escalation arm.
62178776|NCT01510002|ACTIVE_COMPARATOR|TT|Extracapsular total thyroidectomy
62178777|NCT01510002|EXPERIMENTAL|TT+CND|Extracapsular total thyroidectomy puls prophylactic central neck dissection
62178778|NCT01250847|EXPERIMENTAL|Seroquel-XR|The subjects At-Risk Mental States will be treated with Quetiapine(Seroquel-XR) from baseline to end of trial.
62771032|NCT02767739|EXPERIMENTAL|Physical, social and cultural activities|"Physical Activity: The training program will be supervised by a physical activity specialist and will consiste of two aerobic exercise sessions per week, including walking and stretching exercises after walking. Each session will be 60 minutes and the size of groups will be from 15 to 30 participants. Additionally, participants will receive advice about the health benefits of PA and PHC nurses using different strategies to encourage the adherence of participants to the program.~Social and cultural support activities. Activities will include: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons. These activities will be performed once a month."
62771033|NCT02767739|NO_INTERVENTION|Control Group|No intervention. We will measure the variables at the begining and after 9 months.
62771034|NCT02266875|EXPERIMENTAL|Hypertonic Saline|"Patients will receive nebulized hypertonic (3%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use).~Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale."
62178779|NCT01250847|EXPERIMENTAL|Schizophrenia Comparator|The subject with schizophrenia will be treated with standard treatment
62178780|NCT01250847|NO_INTERVENTION|Healthy Control Comparator|The subjects will not be required to treat
62178781|NCT04413877||Descriptive cohort study|"Prospective cohort study of community-dwelling adults ≥65-year-old living at home, with no other exclusion criteria than the inability to use the ICOPE Apps or communicate by telephone/video-call for any reason (cognitive or limited access to technologies like telephone/video-call).~Cohort study, designed to determine the incidence of frailty in community-dwelling older people during 1-year follow-up, starting the recruitment at a certain point of the COVID-19 pandemic and beyond."
62178782|NCT04364685|ACTIVE_COMPARATOR|Normal Walking|The participants performed 30 minutes on levelled surface on the track and field ground. Participants performed moderate intensity walking, self paced.
62178783|NCT04364685|EXPERIMENTAL|Sand Walking|The participants performed supervised walking on sand on the 20 meters pathway containing soft sand.The walking on sand for 30 minutes.
62178784|NCT05122741||Acute Myocardial Infarction|40 patients with clinical presentation of acute myocardial infarction undergoing primary percutaneous coronary intervention and eligible for dual antiplatelet therapy (DAPT) with either prasugrel or ticagrelor on top of aspirin.
62771035|NCT02266875|ACTIVE_COMPARATOR|Standard Saline|"Patients will receive standard saline (0.9%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use).~Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale."
62771036|NCT05571774||TTP|TTP patients
62771037|NCT05093803|ACTIVE_COMPARATOR|CONTROL GROUP|Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity.
62178785|NCT05122741||Chronic Coronary Syndrome|10 patients with stable coronary artery disease with an indication, according to current guidelines, to percutaneous coronary intervention and subsequent DAPT with aspirin and clopidogrel.
62178786|NCT05090475|EXPERIMENTAL|Experimental group in Koprivnica Križevci County|Hospital A-team provided academic detailing intervention to primary care physicians in Koprivnica Križevci county who agree to participate
62178787|NCT05090475|NO_INTERVENTION|Control group in Koprivnica Križevci county|Primary care physicians in Koprivnica Križevci county who did not agree to participate in academic detailing intervention
62178788|NCT05090475|NO_INTERVENTION|Control group in Bjelovar Bilogora county|Primary care physicians in Bjelovar Bilogora county without the academic detailing intervention
62178789|NCT03219307|EXPERIMENTAL|NOVOCART 3D|Matrix associated autologous chondrocyte implant
62178790|NCT04972539|EXPERIMENTAL|Sequence A|Period 1: AJU-A51R1 tablet(Dapagliflozin) and AJU-A51R2 tablet(Linagliptin), single dose Period 2: AJU-A51(FDC tablet, Linagliptin/Dapagliflozin), single dose
62178791|NCT04972539|EXPERIMENTAL|Sequence B|Period 1: AJU-A51(FDC tablet, Linagliptin/Dapagliflozin), single dose Period 2: AJU-A51R1 tablet(Dapagliflozin) and AJU-A51R2 tablet(Linagliptin), single dose
62178792|NCT04137861|ACTIVE_COMPARATOR|Mineral Trioxide Aggregate (MTA)|Root repair material
62178793|NCT04137861|EXPERIMENTAL|bioceramics|Root repair material
62178794|NCT03961997|OTHER|Lorlatinib 50 mg|Participants will receive a single dose of lorlatinib 50 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 50 mg on Day 15 of Period 2.
62562809|NCT05913752|OTHER|AUD Subjects - Part D|Multiple dose (18) subjects with binge drinking/AUD: Once Part B and Part C has been completed, the data analyzed and approved by the DSMB, Part D will be initiated. This part will consist of a repeated-dose cohort, based on the higher tolerable dose found in Part C and considering the dose effects found in Part B. Subjects will be randomized into either the treatment or the placebo arm at a ratio of 2:1 (12 subjects treated with the investigation product and 6 subjects receiving placebo) and will receive the drug/placebo at a daily basis for a total of 10 consecutive days. Each subject will be sampled for PK for 24 hours after first and last dosing and will be daily monitored for drug effects and safety throughout the study period and until 1 week after the last dosing. The PK and safety information gathered from in this part of the study will be evaluated by the DSMB.
62178795|NCT03961997|OTHER|Lorlatinib 75 mg|Participants will receive a single dose of lorlatinib 75mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 75 mg on Day 15 of Period 2.
62562810|NCT01953302|EXPERIMENTAL|"modified open mesh technique"|"We performed an open intraperitoneal mesh technique in all patients: we placed surgical mesh of appropriate size intraperitoneally with transfascial fixation and drainage."
62178796|NCT03961997|OTHER|Lorlatinib 100 mg|Participants will receive a single dose of lorlatinib 100 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 100 mg on Day 15 of Period 2.
62178797|NCT01544504|EXPERIMENTAL|Norepinephrine|Topical norepinephrine
62178798|NCT03134547|ACTIVE_COMPARATOR|low volume volatile anesthetics|1.0 % sevoflurane sedation via face mask , low dose sevoflurane group
62178799|NCT03134547|ACTIVE_COMPARATOR|high volume volatile anesthetics|2.5 % sevoflurane sedation via face mask, high dose sevoflurane group
62178800|NCT04326153|EXPERIMENTAL|experimental arm|Sintilimab+Albumin paclitaxel:+Carboplatin:
62771038|NCT05093803|EXPERIMENTAL|APP GROUP|Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity through the use of an app based on machine learning, so they have constant stimuli for the improvement of the parameters.
62771039|NCT00275756|EXPERIMENTAL|1|
62771040|NCT00275756|EXPERIMENTAL|2|
62771041|NCT00275756|EXPERIMENTAL|3|
62771042|NCT00885482|EXPERIMENTAL|Single arm|"Treatment simplification from a standard combined antiretroviral therapy including 2 NRTIs and Atazanavir with Ritonavir to Lamivudine plus Atazanavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy."
62771043|NCT02680470|EXPERIMENTAL|Virtual Observed Therapy|Intervention = Virtual observed therapy of participants taking TB therapy
62771044|NCT01725243|ACTIVE_COMPARATOR|Carbetocin 10mcg|Carbetocin 10mcg IV, once following delivery.
62771045|NCT01725243|ACTIVE_COMPARATOR|Carbetocin 20mcg|Carbetocin 20mcg IV, once following delivery.
62771046|NCT01725243|ACTIVE_COMPARATOR|Carbetocin 40mcg|Carbetocin 40mcg IV, once following delivery.
62771047|NCT01725243|ACTIVE_COMPARATOR|Carbetocin 60mcg|Carbetocin 60mcg IV, once following delivery.
62178801|NCT05466188||Outcome CPC Positive|Outcome CPC Positive
62178802|NCT05466188||Outcome CPC Negative|Outcome CPC Negative
62178803|NCT02106637|ACTIVE_COMPARATOR|study groups|study groups will receive Varenicline
62178804|NCT02106637|PLACEBO_COMPARATOR|control group|Participants allocated to the control group will receive placebo
62178805|NCT01252511|ACTIVE_COMPARATOR|long biliopancreatic limb, 75 cm|
62178806|NCT01252511|ACTIVE_COMPARATOR|long Roux limb, 150 cm|
62178807|NCT04295850||Low Dose Aspirin|"Pregnant singletons at high risk for preeclampsia based on:~* at least one high risk factor for preeclampsia: prior preeclampsia, chronic hypertension, pregestational diabetes, lupus, antiphospholipid antibody syndrome, or chronic kidney disease. OR~* at least two of the following: BMI\>30, black race, state insurance, IVF pregnancy, advanced maternal age, nulliparous or \>10yr from last delivery, prior adverse pregnancy outcome~who are planning to, but have not yet started, aspirin therapy \<16 weeks' gestation. Patients will take 81mg aspirin as prescribed."
62178808|NCT00995319||radiation patients|cancer patients with radiotherapy concerning the head and neck area/oral cavity
62178809|NCT01721083|EXPERIMENTAL|Z-Track immunization|Subject receives Intramuscular injection by z-track method during flu vaccination given by employee health Registered Nurse into deltoid muscle.
62178810|NCT01721083|ACTIVE_COMPARATOR|Bunch immunization|Subject receives Intramuscular injection by bunch method during flu vaccination given by employee health Registered Nurse into deltoid muscle.
62178811|NCT06214598|EXPERIMENTAL|AI Diet|Personalised diet rich in whole grains high in fibres, vegetables (particularly leafy greens and tomatoes), polyphenol-rich fruits (berries), and n-3 FAs foods (fatty fish, nuts, seeds and oils)
62178812|NCT06214598|ACTIVE_COMPARATOR|Supplements|2 gel capsules/d of fish oil (FO) + 3 gel capsules/d of evening primrose oil (EPO), containing 600 mg EPA, 400 mg DHA and 351 mg GLA + Standard diet: 55% carbohydrate, 15% protein and 30% fats
62178813|NCT06214598|PLACEBO_COMPARATOR|Placebo|Standard diet: 55% carbohydrate, 15% protein and 30% fats + placebo capsules
62178814|NCT02197143|EXPERIMENTAL|Esomeprazole|40 mg Esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
62562811|NCT03581864||Group of 14 patients with post-traumatic complete anirirdia|14 eyes with post-traumatic complete aniridia and aphakia treated withscleral fixation of BD IOL with measurements included ophthalmological comorbidities, best corrected visual acuity (BCVA), complications, and postoperative interventions.
62771048|NCT01725243|ACTIVE_COMPARATOR|Carbetocin 80mcg|Carbetocin 80mcg IV, once following delivery.
62771049|NCT01725243|ACTIVE_COMPARATOR|Carbetocin 100mcg|Carbetocin 100mcg IV, once following delivery.
62771050|NCT01725243|ACTIVE_COMPARATOR|Carbetocin 120mcg|Carbetocin 120mcg IV, once following delivery.
62562812|NCT05679375|ACTIVE_COMPARATOR|Intrathecal Ketamine|Patients will receive intrathecal Ketamine 0.1mg/kg added to bupivacaine and morphine.
62562813|NCT05679375|ACTIVE_COMPARATOR|Intravenous ketamine|Patients will receive IV Ketamine 0.25mg/kg after spinal anesthesia with bupivacaine and morphine.
62771051|NCT01725243|ACTIVE_COMPARATOR|Carbetocin 140mcg|Carbetocin 140mcg IV, once following delivery.
62178815|NCT02197143|EXPERIMENTAL|Ranitidine|50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
62178816|NCT02197143|EXPERIMENTAL|placebo|150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
62178817|NCT01006083||Low-risk patients, not on APAs|Patients not at risk of coronary and/or cerebrovascular disease, and not consuming APAs
62178818|NCT01006083||High-risk patients, not on APAs|Patients at high risk for cardio/cerebrovascular disease (diabetes mellitus, cigarette smoking, hypercholesterolemia, hypertension, morbid obesity), but not taking APAs.
62178819|NCT01006083||APA for primary prevention|High-risk patients with cardiovascular risk factors (as above), in whom APA is prescribed as primary prevention of coronary artery disease (CAD).
62178820|NCT01006083||APA for secondary prevention|Patients with a history of a coronary syndrome (stable/unstable angina); MI; transient ischemic attack (TIA)/stroke; severe carotid artery stenosis/stenting; or peripheral vascular disease, on APAs for secondary prevention.
62178821|NCT00107081|ACTIVE_COMPARATOR|Standard|Continued inpatient i.v. antibiotics
62178822|NCT00107081|EXPERIMENTAL|Experimental|Switch to outpatient p.o. antibiotics
62178823|NCT00840671|EXPERIMENTAL|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
62178824|NCT00840671|PLACEBO_COMPARATOR|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
62178825|NCT04376112|ACTIVE_COMPARATOR|Standard of Care|
62178826|NCT04376112|EXPERIMENTAL|Pharmacist Intervention|
62178827|NCT00948610|PLACEBO_COMPARATOR|Placebo|Placebo-participant will receive placebo saline solution via IV route.
62771052|NCT01054521|EXPERIMENTAL|Temperature-controlled RF (TCRF)|The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.
62771053|NCT01054521|ACTIVE_COMPARATOR|Bipolar RF (BRF)|The bipolar RF (BRF) probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
62771054|NCT04276974|EXPERIMENTAL|Organic first then non-organic|Organic diet then non-organic diet, each for 4 consecutive days
62771055|NCT04276974|EXPERIMENTAL|Non-organic first then organic|Non-organic diet then organic diet, each for 4 consecutive days
62771056|NCT01017445|EXPERIMENTAL|Quadricep strengthening exercise|Quadricep strengthening exercise
62771057|NCT04018742||Patients with an abscess|Patient diagnosed with a cerebral abscess at admission; and to benefit from an abscess puncture as part of routine care.
62771058|NCT03032445|EXPERIMENTAL|Alcoholic beer|At least 6% alcohol content
62771059|NCT03032445|PLACEBO_COMPARATOR|Non alcoholic beer|Less than 0.5% alcohol content
62178828|NCT00948610|ACTIVE_COMPARATOR|Remicade|Remicade-Participant will be given 10 mg/kg of drug via IV route.
62178829|NCT04719468|EXPERIMENTAL|Intervention|
62178830|NCT04719468|NO_INTERVENTION|Usual Treatment|usual treatment with the addition of joining 'Tea and Biscuit' sessions remotely
62178831|NCT02587013|EXPERIMENTAL|In situ uterine repair|The uterus is repaired in situ within the abdominal cavity, without exteriorization; intra-abdominal repair
62178832|NCT02587013|ACTIVE_COMPARATOR|Exteriorization of the uterus|The uterine incision is repaired with the exteriorization of the uterus; extra-abdominal repair
62178833|NCT03384771||MBSR Students|community-dwelling adults who register for relevant MBSR courses at University of Massachusetts Center for Mindfulness (UMass CFM), University of California San Francisco (UCSF), or participating community sites
62178834|NCT03384771||MBSR Teachers|those teaching MBSR courses at UMass CFM, UCSF, or participating community sites
62178835|NCT03384771||Raters|experience mindfulness teachers, recruited by invitation, who will participate in MBI-TAC training
62178836|NCT04938622|EXPERIMENTAL|Sedentary Control|Participants did not exercise but consumed a diet that has an appropriate number of calories to maintain body weight throughout the intervention (3 menstrual cycles).
62771060|NCT01742065|NO_INTERVENTION|Usual Care|Clinics in usual care will go about clinic practices to complete recommended screening for colorectal cancer.
62771061|NCT01742065|ACTIVE_COMPARATOR|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to a PDSA (Plan Do Study Act) cycle to refine or improve their process.
62178837|NCT04938622|EXPERIMENTAL|Exercising control|Participants exercised but were given extra calories to remain in energy balance throughout the intervention (3 menstrual cycles).
62178838|NCT04938622|EXPERIMENTAL|15 percent energy deficit (ED1)|Participants exercised for the equivalent of 15 percent of their daily caloric intake needs throughout the intervention cycles.
62178839|NCT04938622|EXPERIMENTAL|30 percent energy deficit (ED2)|Participants exercised for the equivalent of 30 percent of their daily caloric intake needs throughout the intervention cycles.
62178840|NCT04938622|EXPERIMENTAL|30 percent energy deficit 15/15 (ED2)|Participants exercised for the equivalent of 15 percent of their daily caloric intake needs throughout the intervention cycles, and their dietary intake was decreased by 15 percent to total a 30 percent energy deficit.
62178841|NCT04938622|EXPERIMENTAL|60 percent energy deficit (ED3)|Participants exercised for the equivalent of 30 percent of their daily caloric intake needs throughout the intervention cycles, and their dietary intake was decreased by 30 percent to total a 60 percent energy deficit.
62771062|NCT01270152|EXPERIMENTAL|group 50 mg ascorbic acid|this arm received a dose of 50 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
62771063|NCT01270152|EXPERIMENTAL|group 100mg ascorbic acid|this arm received a dose of 100 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
62771064|NCT01270152|EXPERIMENTAL|group 200mg ascorbic acid|this arm received a dose of 200 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
62771065|NCT02438345|ACTIVE_COMPARATOR|Treatment Arm 1|PRO 140: one SC dose, 350 mg, weekly for 24 weeks
62771066|NCT02438345|PLACEBO_COMPARATOR|Treatment Arm 2|PRO 140: one SC dose, placebo, weekly for 24 weeks
62771067|NCT03304067|EXPERIMENTAL|Intervention|
62771068|NCT03304067|NO_INTERVENTION|Control|
62771069|NCT02754960|ACTIVE_COMPARATOR|Thalidomide group|Patients were randomly assigned to the thalidomide group and received 100 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang Zhou, China) orally four times daily at 10 p.m. for four months.
62771070|NCT02754960|PLACEBO_COMPARATOR|Placebo group|Patients were randomly assigned to the placebo group and received 100 mg of thalidomide placebo (Pharmaceutical Co., Ltd. of Chang Zhou, China) orally four times daily at 10 p.m. for four months.
62771071|NCT02925728|EXPERIMENTAL|Nutrition with Finger-Food|Nutrition with Finger-Food
62771072|NCT02925728|ACTIVE_COMPARATOR|Nutrition without Finger-Food|Nutrition without Finger-Food
62771073|NCT04957758|ACTIVE_COMPARATOR|OC-01 (varenicline) nasal spray, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/mL
62771074|NCT04957758|PLACEBO_COMPARATOR|Placebo (vehicle control) nasal spray|Placebo (vehicle control) nasal spray
62771075|NCT05503888|EXPERIMENTAL|Almonertinib combined with SHR-1701|
62178842|NCT00766142|EXPERIMENTAL|Chemotherapy + Cetuximab|Surgery + Chemotherapy + Cetuximab
62178843|NCT02026505||Multiple Myeloma, Bortezomib|
62178844|NCT05354310|NO_INTERVENTION|Active reference group|Only baseline measurements will be done.
62178845|NCT05354310|EXPERIMENTAL|Metabolically compromised group|Group with metabolomic mortality scores above threshold will undergo intervention. Baseline and endline measurements.
62178846|NCT05354310|EXPERIMENTAL|Mobility compromised|Group with walking aids will undergo intervention. Baseline and endline measurements.
62178847|NCT05354310|EXPERIMENTAL|Knee replacement INT|Group with recent knee replacement surgery will undergo intervention. Baseline and endline measurements.
62178848|NCT05354310|NO_INTERVENTION|Knee replacement Control|Group with recent knee replacement surgery will undergo standard care. Baseline and endline measurements.
62771076|NCT05503888|PLACEBO_COMPARATOR|Almonertinib|
62771077|NCT05115747|EXPERIMENTAL|"Zero percentage weight off-loading group-A"|This group received the Mild to moderate aerobic exercise training on the Alter-G treadmill with the full weight-bearing for three months.
62771078|NCT05115747|EXPERIMENTAL|"Twenty-five percentage weight off-loading group-B"|"This group received the Mild to moderate aerobic exercise training on the Alter-G treadmill with the twenty-five percentage weight off-loading for three months."
62771079|NCT05115747|EXPERIMENTAL|"Fifty percentage weight off-loading group-C"|"This group received the Mild to moderate aerobic exercise training on the Alter-G treadmill with the fifty percentage weight off-loading for three months."
62771080|NCT05115747|EXPERIMENTAL|"Seventy-five percentage weight off-loading group-D"|"This group received the Mild to moderate aerobic exercise training on the Alter-G treadmill with the seventy-five percentage weight off-loading for three months."
62771081|NCT05115747|NO_INTERVENTION|Control group-E|Participated no aerobic exercise training.
62771082|NCT03880214||stem cells transplanted pediatric patients|screen pediatric patients at least 3 months after they undergo allogeneic hematopoietic stem cells transplantation to detect any risk factors for developing oral manifestations of chronic graft -versus-host disease during this period
62771083|NCT01439178|EXPERIMENTAL|Intravitreal Avastin Day 2|randomized to either treatment with preoperative IVB 2 days before PPV (Group A) or 7 days before PPV (Group B).
62771084|NCT01439178|ACTIVE_COMPARATOR|Intravitreal Avastin Day 7|randomized to either treatment with preoperative IVB 2 days before PPV (Group A) or 7 days before PPV (Group B).
62771085|NCT02986802||Genital herpes treated before third trimester|Women with genital herpes receiving treatment before the 3rd trimester
62771086|NCT02986802||Genital herpes treated only during third trimester|Women with genital herpes receiving treatment during the 3rd trimester
62771087|NCT02986802||Genital herpes untreated|Women with untreated genital herpes
62771088|NCT02986802||Control group|Women (controls) with neither genital herpes nor treatment
62771089|NCT01071629|ACTIVE_COMPARATOR|Combined interval and strength training|CHF Pts randomly designed at the combined interval and strength training group
62771090|NCT01071629|ACTIVE_COMPARATOR|Aerobic interval training|CHF Patients that randomly designed to participate at the interval training group
62178849|NCT02696863||filling a questionnaire and interview|"The questionnaire is tracking occupational carcinogens. It consists of 30 questions , fills an average of 3 minutes and includes three response categories: yes, no and do not know. A questionnaire will be added social and professional issues.~Interviews will be conducted with the patient to identify obstacles and facilitating elements"
62178850|NCT00478322|EXPERIMENTAL|INCB013739|
62178851|NCT00478322|PLACEBO_COMPARATOR|Matching Placebo|
62178852|NCT03892551||patients admitted to emergency ward|all patients admitted to the emergency ward and awaiting triage are observed
62178853|NCT02877264|EXPERIMENTAL|Vapendavir Capsule, 264 mg|Vapendavir phosphate salt administered orally as a single dose of two 132 mg hard gelatin capsules
62178854|NCT02877264|EXPERIMENTAL|Vapendavir Tablets, 264 mg|Vapendavir free base tablets containing 264 mg of vapendavir
62178855|NCT02877264|EXPERIMENTAL|Vapendavir Oral Suspension, 264 mg|Vapendavir free base as a 24 mg/mL oral suspension
62178856|NCT05659654|EXPERIMENTAL|Take ursodeoxycholic acid capsules daily for 4 weeks from the date of enrollment|Healthy volunteers took ursodeoxycholic acid capsules daily for 4 weeks from the date of enrollment
62178857|NCT03831646||dermatological patients|atopic dermatitis and psoriasis patients with mild and moderate severity of dermatoses in the stage of exacerbation
62178858|NCT06259513|EXPERIMENTAL|patients with omission of SLNB|early breast cancer patients with cT1-2N0 Luminal A subtype with omission of SLNB
62178859|NCT06259513|EXPERIMENTAL|patients with </=2 macrometastasis and omission of ALND|breast cancer patients with 1-2 macrometastasis on SLNB and had omission of ALND
62178860|NCT06259513|NO_INTERVENTION|patients with cT1-2N0 and SLNB|early breast cancer patients with cT1-2N0 Luminal A subtype and SLNB
62178861|NCT06259513|NO_INTERVENTION|patients with </=2 macrometastasis and ALND|breast cancer patients with 1-2 macrometastasis on SLNB and had ALND
62178862|NCT04011397|EXPERIMENTAL|Intervention group|Exercise intervention (reduced-exertion, high-intensity interval training) alongside normal treatment. \[low recruitment prohibited control arm\]
62178863|NCT06414005|EXPERIMENTAL|TPX-115|Subjects receive ultrasound-guided intratendinous injection of TPX-115
62178864|NCT06414005|PLACEBO_COMPARATOR|Placebo (Saline)|Subjects receive ultrasound-guided intratendinous placebo injection
62391112|NCT03164291|EXPERIMENTAL|Rifabutin|Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections or other NTM disease who fail therapy with other drugs ( i.e., rifampin)
62178865|NCT03187353|EXPERIMENTAL|Lisdexamfetamine, then Placebo|Participants will have a 50% chance of first receiving the active study medication. They will begin at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 6 weeks. After a washout period of 2 weeks they will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 6 weeks.
62391113|NCT04342858|OTHER|Standard of care|Control will receive standard oral hygiene instructions (OHI every three months)
62391114|NCT04342858|ACTIVE_COMPARATOR|Standard of care + Fluoride varnish|Intervention 1 will receive standard OHI and application of topical fluoride varnish containing 5% NaF (Duraphat varnish®, Colgate-Palmolive (UK) Ltd., Guildford, Surrey, UK) every three months
62391115|NCT04342858|EXPERIMENTAL|Standard of care + Fluoride varnish with Tricalcium phosphate|Intervention 2 will receive standard OHI and application of topical fluoride varnish containing 5% NaF + TCP (Clinpro white varnishTM, 3M ESPE, St Paul, MN, USA) every three months
62391116|NCT03646916|ACTIVE_COMPARATOR|Dexamethasone|
62391117|NCT03646916|NO_INTERVENTION|Non-treatment|
62771091|NCT00896649|EXPERIMENTAL|positron emission mammography|questionnaire administration digital mammography positron emission mammography
62771092|NCT03039894||Intervention|The middle school selected 2 advisory classrooms to participate in the Gradebook game during 6th grade. Students in these 2 classrooms were block randomized to teams by baseline grade book and student engagement scores. These small student teams stay together for an entire year and meet once or twice a week. Teams are led by 8th grade student team captains, picked by school staff for their positive leadership skills. Every 2 weeks throughout the year, teams are randomly matched in head-to-head competition. In each 2-week-long game (i.e. Gradebook Game), individual team members accrue points from teachers and administrators for academic performance, effort, and school behavior. Team wins are announced and public scoreboards are updated frequently. The investigators will collect student survey data at baseline and after the intervention, approximately 5-6 months apart.
62771093|NCT03039894||Control|The middle school has chosen three 6th grade classrooms that will not play the Gradebook game. The investigators will collect school gradebook and behavior information weekly for 8 to 10 time points before and after the intervention is implemented. Students will complete a survey at baseline and after the intervention, approximately 5-6 months apart.
62771094|NCT00203021|EXPERIMENTAL|Glatiramer Acetate: Delayed Start|Participants who were originally randomized to the placebo group in the 01-9001 and/or the 01-9001E studies received glatiramer acetate 20 milligrams (mg) subcutaneous (SC) injection daily at the start of this study. After 18 July 2014 (protocol amendment 12), participants were offered the opportunity to continue treatment with glatiramer acetate 20 mg daily or switch to glatiramer acetate 40 mg three times weekly (TIW). The treatment continued for up to 288 months.
62771095|NCT00203021|EXPERIMENTAL|Glatiramer Acetate: Early Start|Participants who were originally randomized to the glatiramer acetate 20 mg group in the 01-9001 and/or the 01-9001E studies continued to receive glatiramer acetate 20 mg SC injection daily at the start of this study. After 18 July 2014 (protocol amendment 12), participants were offered the opportunity to continue treatment with glatiramer acetate 20 mg daily or switch to glatiramer acetate 40 mg TIW. The treatment continued for up to 288 months.
62771096|NCT05377736|EXPERIMENTAL|Molecular testing|Descriptive and explorative study including identical molecular analyses applied to all included patients
62771097|NCT00860834|EXPERIMENTAL|1|Pediatricians and parents of children with asthma will participate in the asthma coaching program.
62771098|NCT00860834|ACTIVE_COMPARATOR|2|Children of parents enrolled in the study will receive usual asthma care from their pediatrician.
62771099|NCT06269419||Type 2 diabetes patients with no diabetic retinopathy|
62771100|NCT06269419||Type 2 diabetes patients with mild to moderate diabetic non-proliferative retinopathy|
62771101|NCT04232215|EXPERIMENTAL|HeraBEAT™ Intervention Group|Subjects will monitor their fetal heart beat once weekly using the HeraBEAT™ device. After approximately 8 weeks of monitoring subjects will crossover to using the doppler fetal heart rate monitor
61995040|NCT01660412|ACTIVE_COMPARATOR|Standard of Care first|The first injection administered will be the standard of care solution (SOC). The second injection will be the pH altered solution. The remaining injections will be randomly assigned as either standard of care or pH altered.
62178866|NCT03187353|EXPERIMENTAL|Placebo, then Lisdexamfetamine|Participants will have a 50% chance of first receiving the placebo, beginning with 1 sugar pill and increasing up to 3 pills after 4 weeks. Maximum time for taking the placebo is 6 weeks. After a washout period of 2 weeks, they will begin active study medication at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 6 weeks.
62178867|NCT03713697|EXPERIMENTAL|Pap testing|Women assigned to this arm were invited to get a Pap testing at the Basic Health Unit
62178868|NCT03713697|EXPERIMENTAL|Self-Collection for HPV testing|Women assigned to this arm were provided with a kit to engage in self-collection for HPV testing
62178869|NCT03713697|EXPERIMENTAL|Choice|Women assigned to this arm were given a choice between a Pap testing at the local Basic Health Unit or self-collection for HPV testing
62178870|NCT02161198|EXPERIMENTAL|Y-75|volunteers receive 3 packages twice a day up to 14 weeks
62178871|NCT02161198|PLACEBO_COMPARATOR|Placebo|volunteers receive 3 packages twice a day up to 14 weeks
62178872|NCT02453477|EXPERIMENTAL|Adults|"≥18 years (3 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.~The product will be injected intraosseously."
62391118|NCT01449604|ACTIVE_COMPARATOR|stereotactic radiosurgery|Radio surgery single fraction 12 Gy
62391119|NCT01449604|ACTIVE_COMPARATOR|stereotactic radiotherapy|Stereotactic radiotherapy hypo fraction 18 Gy in 3 fraction
62391120|NCT02062749|EXPERIMENTAL|Hyperthermic Intraperitoneal Chemotherapy|After cytoreductive surgery and lysis of adhesions, two large bore catheters are placed in the peritoneal cavity through the incision. Thirty minutes before HIPEC is begun, body temperature is cooled to 35°C. ). The catheters are connected to a perfusion circuit. Heated Oxaliplatin is added to the perfusate administered over 90 minutes. The starting dose of Oxaliplatin is 175 mg/m2.
62391121|NCT04717505||Healthy Control Group|Demographic information ( age, gender, occupation, weight, height) of all participants in the study will be recorded first. The cognitive functions of all participants within the scope of the study will be evaluated in the Standardized Mini Mental Test; The 10 Meter Walk Test for dual task assessments will be applied in 3 different ways, with a portable gait device with wearable sensors: 1-single task conditions, 2-dual task conditions (motor + cognitive), 3-dual task conditions (motor + motor).
62391122|NCT04717505||Rheumatological Condition Group|Demographic information (diagnosis, age, gender, occupation, weight, height) of all participants in the study will be recorded first. The cognitive functions of all participants within the scope of the study will be evaluated in the Standardized Mini Mental Test; The 10 Meter Walk Test for dual task assessments will be applied in 3 different ways, with a portable gait device with wearable sensors: 1-single task conditions, 2-dual task conditions (motor + cognitive), 3-dual task conditions (motor + motor). In addition, in order to evaluate their health status, only the case group will be applied Arthritis Impact Measurement Scales 2 (questionnaire) and Visual Analogue Scale for pain assessment.
62391123|NCT00808665|EXPERIMENTAL|Dexmedetomidine|At the beginning of spinal surgery, patients will receive 1 hour dexmedetomidine intravenous bolus of 0.7 mcg/kg, followed by infusion of dexmedetomidine at a rate of 0.5 mcg/kg/hour for 2 hours, followed by an infusion of dexmedetomidine at a rate of 0.2 mcg/kg/hour for the duration of the procedure and for 4 hours after the procedure.
62391124|NCT00808665|PLACEBO_COMPARATOR|Saline|Since this is a blinded study, at the beginning of spinal surgery, patients will receive a 1 hour 0.9% saline intravenous bolus at a rate and volume commensurate with a 0.7 mcg/kg/hour bolus of dexmedetomidine. Similarly, this will be followed with a saline infusion at a rate of 0.5 mcg/kg/hour for 2 hours, followed by an infusion of saline at a rate of 0.2 mcg/kg/hour for the duration of the procedure and for 4 hours after the procedure.
62391125|NCT05233956|EXPERIMENTAL|LNG IUS|Levonorgestrel intrauterine system
62391126|NCT05233956|ACTIVE_COMPARATOR|COC|Combined oral contraceptives with ferrous fumarate tablets in regimen
62391127|NCT05896605|ACTIVE_COMPARATOR|1 month after AZA treatment|Before medication, TPMT activity was normal, and azathioprine was started at small doses and added every two weeks after no adverse effects, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid. Low-dose hormone therapy was administered to all patients simultaneously.Blood (5ml) was collected from peripheral veins in 1 month after AZA treatment.
62771102|NCT04232215|ACTIVE_COMPARATOR|Standard Fetal Doppler Group|Subjects will monitor their fetal heart beat once weekly using the doppler fetal heart rate monitor. After approximately 8 weeks of monitoring subjects will crossover to using the HeraBEAT™ device
62771103|NCT06481085|EXPERIMENTAL|HDM1002 50 mg|Participants received 50 mg HDM1002 administered orally once daily (QD)
62771104|NCT06481085|EXPERIMENTAL|HDM1002 100 mg|Participants received maintenance dose of 100 mg with dose escalation starting from 50 mg HDM1002 administered orally once daily (QD)
62771105|NCT06481085|EXPERIMENTAL|HDM1002 200 mg|Participants received maintenance dose 200 mg with dose escalation starting from 50 mg, 100 mg and then 200 mg HDM1002 administered orally QD
62771106|NCT06481085|EXPERIMENTAL|HDM1002 400 mg|Participants received maintenance dose 200 mg with dose escalation starting from 50 mg, 100 mg, 200 mg and then 400 mg HDM1002 administered orally QD
62771107|NCT06481085|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo administered orally QD
62178873|NCT02453477|EXPERIMENTAL|Elderly children|"8-17 years (3 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.~The product will be injected intraosseously."
62562814|NCT03441412|EXPERIMENTAL|Ticagrelor/Epinephrine/Metoprolol|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
62562815|NCT03146806|EXPERIMENTAL|Intranasal ketamine treatment|Study participants who are receiving intranasal ketamine treatments.
62771108|NCT06481085|EXPERIMENTAL|HDM1002 200 mg bid|Participants received maintenance dose 400 mg with dose escalation starting from 25 mg, 50 mg, 100 mg and then 200 mg HDM1002 administered orally twice daily (BID)
62771109|NCT00753974||biological specimen|Biological specimen is taken from cardiovascular procedures that would have been discarded
62178874|NCT02453477|EXPERIMENTAL|Younger children|"3-7 years (4 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.~The product will be injected intraosseously."
62178875|NCT00093132|EXPERIMENTAL|Satraplatin|Satraplatin
62178876|NCT05598138|EXPERIMENTAL|Intervention|A blood sample (10 ml) will be taken for each patient included in the study
62562816|NCT02419989||CF patients|Male and female subjects with CF age 6 years and older who meet diagnostic criteria for NTM disease through participation in the PREDICT (Part A) study who are being offered NTM treatment.
62178877|NCT04921748||PD+FOG group|Patients affected by Parkinson's Disease with freezing of gait (PD+FOG group)
62178878|NCT04921748||PD-FOG group|Patients affected by Parkinson's Disease without freezing of gait (PD+FOG group)
62178879|NCT06292559|PLACEBO_COMPARATOR|Bilateral STN deep brain stimulation|Patients with Meige syndrome accepted STN DBS
62178880|NCT06292559|EXPERIMENTAL|Bilateral GPi deep brain stimulation|Patients with Meige syndrome accepted GPi DBS
62178881|NCT05661253|NO_INTERVENTION|Control group|will take general anesthesia without nerve block
62562817|NCT01836471|EXPERIMENTAL|QAW039 450 mg qd Non-atopic|QAW039 450 mg (3 capsules of QAW039 150 mg) qd combined with background ICS (100 μg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1.
62771110|NCT01187342||Non-striatal lesion group|acute ischemic Stroke in MCA territory of 10-100 cm³ with sparing of striatocapsular structures
62771111|NCT01187342||Striatal lesion group|acute ischemic stroke in MCA/AchA territory with involvement of at least 125 mm³ of striatocapsular structures
62771112|NCT01803867|PLACEBO_COMPARATOR|rHIgM22|"Cohorts 1-5: In each dosing cohort, the first 2 eligible patients will be enrolled and randomized 1:1 to receive rHIgM22 or placebo, and monitored for safety for a minimum of 7 days before the remaining 8 patients in the cohort are randomized (7 active: 1 placebo) and dosed.~Expanded Cohort: Upon establishment of a Maximally Tolerated Dose (MTD), a new group of 21 patients will be enrolled in an Expansion Cohort. Randomly assigned in a 1:1:1 ratio to 1 of 3 treatment groups: placebo, Investigational Product (IP) at MTD, or IP at one full dose level lower than MTD."
62562818|NCT01836471|PLACEBO_COMPARATOR|Placebo Non-atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with background ICS (100 μg fluticasone, bid). Non-atopic randomized in ratio of approximately 1:1.
62771113|NCT05893472|EXPERIMENTAL|The treatment group receiving the combination of venetoclax and HAA regimen.|Received induction therapy protocol： Docetaxel (HHT) 2.5mg/㎡/day, days 3-7 Aclarubicin (Acla) 20mg/day, days 3-7 Cytarabine (Ara-c) 100mg/㎡/day, days 3-7 (given as a 24-hour infusion) Venetoclax (VEN): 100mg on day 1, 200mg on day 2, and 400mg on days 3-8.
62771114|NCT00859742|EXPERIMENTAL|EBUS-TBNA|
62771115|NCT05632276|OTHER|ConvaFoam dressings|Participants wounds will be assessed and will be allocated ConvaFoam Border, Silicone or Non-Adhesive dressing based upon the investigator's clinical judgment. participants will receive a dressing as part of a protocol of care for up to a period of 4 weeks
62562819|NCT01836471|EXPERIMENTAL|QAW039 450 mg qd Atopic|QAW039 450 mg (3 capsules of QAW039 150 mg) qd combined with background ICS (100 μg fluticasone, bid). Atopic patients randomized in a ratio of approximate 1:1:1
62771116|NCT00801021|EXPERIMENTAL|Frio Oral Rinse|Prescription Mouth Rinse
62771117|NCT01754792|EXPERIMENTAL|Normal fasting glucose subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
62771118|NCT01754792|EXPERIMENTAL|Impaired fasting glucose subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
62771119|NCT01754792|EXPERIMENTAL|Diabetic subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
62771120|NCT00521664|ACTIVE_COMPARATOR|1|Therapeutic platelet transfusion (TP) strategy versus prophylactic platelet transfusion (PP) strategy. In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
62771121|NCT00521664|ACTIVE_COMPARATOR|2|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
62771122|NCT02797158|EXPERIMENTAL|Interventional Arm|
62771123|NCT04400929|EXPERIMENTAL|Group A: Treatment Group|Day 1 - 5: Receive study medication Leukine® 125mcg/m2 body surface area daily (via infusion into the vein) in addition to standard of care treatments
62771124|NCT04400929|PLACEBO_COMPARATOR|Group B: Placebo Group|Day 1 - 5: Receive normal saline 0.9% daily (via infusion into the vein) in addition to standard of care treatments
62771125|NCT04400929|EXPERIMENTAL|Group C|Day 6 - 10: Subjects in Group A who require mechanical ventilation to receive an additional 5 days of IV Leukine® 125mcg/m2 body surface area daily, in addition to standard of care treatments (based on the treating physician's assessment)
61995041|NCT02586493|EXPERIMENTAL|Placebo ELLIPTA inhaler|Subjects will be provided the ELLIPTA inhaler, which is a molded plastic two-sided inhaler that holds two individual blister strips containing either lactose or a blend of lactose and magnesium stearate. Subjects will continue to use regular COPD medications throughout the study as per protocol.
61995042|NCT04779684|EXPERIMENTAL|ACP by proxy pilot intervention group|All participants are included in the intervention group
61995043|NCT03249285|EXPERIMENTAL|Peri profile yes|patient with genetic Perindopril profile, receiving Perindopril treatment with 4-8 mg/day oral for 4-8 weeks
61995044|NCT03249285|EXPERIMENTAL|HCTZ profile yes|patient with genetic HCTZ profile, receiving HCTZ treatment with 12,5-25 mg/day oral for 4-8 weeks
62771126|NCT04400929|EXPERIMENTAL|Group D|Day 6 - 10: Subjects from Group B to receive study medication (based on the treating physician's assessment), Leukine® 125mcg/m2 body surface area daily (via infusion into the vein) in addition to standard of care treatments
62771127|NCT04400929|EXPERIMENTAL|Group E|Day 11 - 15: Subjects in Group D who require mechanical ventilation to receive an additional 5 days of IV Leukine® 125mcg/m2 body surface area daily, in addition to standard of care treatments (based on the treating physician's assessment)
62771128|NCT02851823|ACTIVE_COMPARATOR|Control Group|Mechanical periodontal treatment: Scaling and root planing were performed with periodontal curettes until the operator feels that root surface is clean, hard and smooth.
62771129|NCT02851823|EXPERIMENTAL|Test Group|Combined laser therapy: An Er:YAG laser (160 mj/pulse, 10 Hz) (AT Fidelis Fotona, Ljubljana, Slovenia) with water irrigation was first used to remove subgingival calculus and infected cementum.The Er:YAG laser beam was delivered into the periodontal pockets using a chisel-shaped quartz tip in contact mode under water irrigation, from a coronal to an apical direction with the tip inclined at 10o to 15o to the root surfaces. After Er:YAG laser application, Nd:YAG laser treatment (AT Fidelis Fotona, Ljubljana, Slovenia) was performed at an energy level of 100 mJ/pulse, and 20 Hz for removing pocket epithelium and detoxiﬁcation purpose. Irradiation was accomplished with a 320 μm fiber optic delivery system. The fiber was inserted into the periodontal pocket base in parallel alignment with the root surface, and the fiber was slowly moved from apical to coronal in a sweeping motion during the laser light emission.
62771130|NCT04621487|ACTIVE_COMPARATOR|concomitant|Concomitant therapy consists of 14 days pantoprazole 40 mg, amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg all twice daily.
62771131|NCT04621487|ACTIVE_COMPARATOR|tailored|Tailored therapy consists of 14 days antibiotic therapy according to H. Pylori strains antibiotic sensitivity test together with pantoprazole 40 mg twice daily.
62771132|NCT05385484|EXPERIMENTAL|Mobile banking account with incentives to save|Participants in the savings intervention group will be provided with basic information on the importance of saving for the future, as well as (a) lottery-based incentives to save, (b) opportunities to develop savings goals, and (c) periodic reminders about the savings incentives and goals. Participants will receive assistance in opening and using a mobile savings account and will receive an education session that emphasizes the importance of saving for the future. Participants will be told about lottery-based incentives for saving money in their account.
61995045|NCT03249285|ACTIVE_COMPARATOR|Peri no profile|patient with no genetic profile, receiving after randomisation Perindopril treatment with 4-8 mg/day oral for 4-8 weeks
61995046|NCT03249285|ACTIVE_COMPARATOR|HCTZ no profile|patient with no genetic profile, receiving after randomisation HCTZ treatment with 12,5-25 mg/day oral for 4-8 weeks
61995047|NCT03413553|ACTIVE_COMPARATOR|control group|patient will receive immediate implant alone.
61995048|NCT03413553|OTHER|intervention group|"immediate implant combined with connective tissue graft and platelet rich fibrin .~."
62771133|NCT05385484|NO_INTERVENTION|Basic health and financial education|Participants in the control group will be given basic information on the importance of saving for the future. In addition, health education curriculum developed by Impact Research \& Development Organization (IRDO) will be provided to participants with standard health education on places to seek services for HIV and STI prevention and treatment, including information on alcohol and transactional sex as risk factors for HIV transmission.
62771134|NCT02073851|EXPERIMENTAL|TriGuard™HDH|Patients undergoing TAVR will be treated wIth experimental device TriGuard™HDH
62771135|NCT03953872||ARB|Group of angiotensin receptor blockers(ARB) monotherapy users. A subject was considered as an ARB user when the total prescription days of ARB monotherapy was at least 30.
62771136|NCT03953872||combination of CCB and ARB|Group of calcium channel blockers(CCB) and angiotensin receptor blockers(ARB) combination users. A subject was considered as a CCB and ARB combination user when the total prescription days of CCB and ARB combination therapy was at least 30.
62771137|NCT03953872||CCB|Group of calcium channel blockers(CCB) monotherapy users. A subject was considered as a CCB user when the total prescription days of CCB monotherapy was at least 30.
62771138|NCT03953872||No treatment|Group of nonusers of antihypertensives. A subject was considered as a nonuser never received regular antihypertensive treatment or total prescription days of antihypertensives was less than 30.
62771139|NCT03199521||Atrial Fibrillation newly diagnosed, starting apixaban|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays before and after stabilisation(4 weeks) of their anticoagulation. This will allow to compare the effect of apixaban on endogenous fibrinolysis before and after treatment.
62771140|NCT03199521||Atrial fibrillation on stable warfarin treatment|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays on stable anticoagulation treatment. This will allow to compare the effect of apixaban against warfarin on endogenous fibrinolysis on stable treatment.
62562820|NCT01836471|ACTIVE_COMPARATOR|Fluticasone 150 mcg bid Atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with 150 μg ICS and with background ICS (100 μg fluticasone, bid). As a consequence total ICS was 250 μg fluticasone bid. Atopic patients randomized in ratio of approximately 1:1:1
62178882|NCT05661253|ACTIVE_COMPARATOR|SAP block group|After sterilization of the skin and draping, the high frequency linear probe of Sonosite M Turbo ultrasonography (FUJIFIM sonosite, Inc., Bothell, WA, USA) will be placed at the level of the midclavicular line in a sagittal plane. The second rib will be recognized at the axillary artery. The probe will be moved downward to count the ribs until the level of the ﬁfth rib in the mid-axillary line. At this time, the latissimus dorsi muscle (lying superficial) and the serratus anterior muscle (lying deep) will be clearly visualized under ultrasound . Next, A 22-gauge, 80 mm needle (Stimuplex D, B-Braun, Germany) will be inserted in plane relative to the ultrasound probe between the latissimus dorsi and the serratus anterior muscle. After confirming negative aspiration of blood, 1 ml normal saline will be injected for hydro-dissection sign to verify the needle tip, then a volume of 25 ml 0.25% bupivacaine will be injected superficially to serratus anterior muscle. .
62182736|NCT02351336||threatened preterm labour|"Women who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) :~* Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )~* Cervical dilataion \>1cm, \&/or~* Cervical effacement ≥ 80%"
62562821|NCT01836471|PLACEBO_COMPARATOR|Placebo Atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with background ICS (100 μg fluticasone, bid). Atopic patients andomized in ratio of approximately 1:1:1
62771141|NCT03199521||Atrial Fibrillation on stable aspirin treatment|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays on stable anticoagulation treatment. This will allow to compare the effect of apixaban against aspirin on endogenous fibrinolysis on stable treatment.
62771142|NCT03848767|EXPERIMENTAL|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
62771143|NCT01665352|EXPERIMENTAL|TTP054 400 mg|
62771144|NCT01665352|EXPERIMENTAL|TTP054 200 mg|
62771145|NCT01665352|EXPERIMENTAL|TTP054 800 mg|
62771146|NCT01665352|PLACEBO_COMPARATOR|Placebo|
62771147|NCT06362122|EXPERIMENTAL|patients with nasal polyps|
62771148|NCT05772078||Compliers|Attending to SPT every 4-6 months
62771149|NCT05772078||Erratic compliers|Attending to SPT once a year or sporadically
62771150|NCT05772078||Non compliers|Non-attenders to SPT
62771151|NCT03970616|EXPERIMENTAL|Tivozanib in Combination with Durvalumab|Tivozanib in Combination with Durvalumab
62771152|NCT00997620|PLACEBO_COMPARATOR|Placebo|Placebo treatment given as a once daily dose intranasally.in subjects with active seasonal allergic rhinitis.
62771153|NCT00997620|EXPERIMENTAL|Fluticasone Furoate|IFluticasone Furoate 110 mcg given intranasly once daily in am as an active treatment of seasonal allergic rhinitis
62771154|NCT04964323||PK Deficiency Diagnosed|Participants previously diagnosed with PK deficiency in Study AG348-C-008 (NCT03481738), will receive routine clinical care.
62771155|NCT00640367|EXPERIMENTAL|IA thrombolysis|IA recombinant tissue plasminogen activator and/or mechanical thrombolysis
62562822|NCT06506396||Patients with hematologic cancer scheduled to undergo HSCT or CAR T-cell therapy|"The participants will be selected at the Hematology Unit of Azienda USL-IRCCS di Reggio Emilia, Northern Italy, two months prior to undergoing transplantation or CAR-T cell treatment. Eligible participants must meet the following inclusion criteria: have hematologic cancer and be scheduled for HSCT or CAR T-cell therapy; be at least 18 years old; able to provide informed consent and actively participate in the study; proficient in understanding and communicating in Italian.~Patients who are unable to perform physical tests or have contraindications to movement will be excluded from the study"
62562823|NCT02544620||Total Hip arthroplasty|"* Unselected primary THA~* American Society of Anesthesiologists (ASA) score I/II~* Can be operated as #1 or #2~* No sleep apnea treated with Continuous positive airway pressure (CPAP)"
62562824|NCT02544620||Total Knee arthroplasty|"* Unselected primary TKA~* American Society of Anesthesiologists (ASA) score I/II~* Can be operated as #1 or #2~* No sleep apnea treated with Continuous positive airway pressure (CPAP)"
62562825|NCT02544620||unicompartmental knee arthroplasty|"* Unselected primary UKA~* American Society of Anesthesiologists (ASA) score I/II~* Can be operated as #1 or #2~* No sleep apnea treated with Continuous positive airway pressure (CPAP)"
62562826|NCT02100462|EXPERIMENTAL|Chlorthalidone 12.5 mg|Chlorthalidone 12.5 mg by mouth once daily for 2 weeks
62771156|NCT00640367|ACTIVE_COMPARATOR|IV rtPA|IV recombinant tissue plasminogen activator
62771157|NCT04250597|EXPERIMENTAL|Part 1 Dose Escalation|Drug: GNX102 Dose Escalation: 21 day dosing interval
62178883|NCT05661253|ACTIVE_COMPARATOR|modified SAP block group|The patient will be placed in the lateral decubitus position according to the selected site of surgical intervention. After sterilization of the skin and draping, the high frequency linear probe of Sonosite M Turbo ultrasonography ( FUJIFIM sonosite, Inc., Bothell, WA, USA) will be placed horizontally midway between tip of the scapula and posterior axillary line to identify the view of latissimus dorsi(lying superficial) and serratus anterior muscle(lying deep) over either the sixth or seventh rib. A 22-gauge, 80 mm needle (Stimuplex D, B-Braun, Germany) will be inserted in plane relative to the ultrasound probe from posteromedial to anterolateral direction toward posterior axillary line till reaching the interfacial plane between latissimus dorsi and serratus anterior muscle . After confirming negative aspiration of blood, 1 ml normal saline will be injected for hydro-dissection sign to verify the needle tip, then a volume of 25 ml 0.25% bupivacaine will be injected .
62562827|NCT02100462|EXPERIMENTAL|Hydrochlorothiazide 25 mg|Hydrochlorothiazide 25 mg by mouth once daily for 2 weeks
62562828|NCT02100462|ACTIVE_COMPARATOR|Aspirin 81 mg|Aspirin 81 mg by mouth once daily for 2 weeks
62771158|NCT04250597|EXPERIMENTAL|Part 2 Dose Escalation|Drug: GNX102 Dose Escalation: 7 day dosing interval
62771159|NCT04250597|EXPERIMENTAL|Part 3 Expansion|Drug: GNX102 Expansion: Selected dose level(s) and schedule(s) in expanded cohort(s)
62178884|NCT03404050|EXPERIMENTAL|Music and dance movement therapy group|Music and dance movement therapy group
62178885|NCT01121185|EXPERIMENTAL|MBL-HCV1|
62771160|NCT05340803|ACTIVE_COMPARATOR|Group A|Sedation by midazolam alone
62771161|NCT05340803|ACTIVE_COMPARATOR|Group B|Sedation by midazolam and dexmedetomidine during the first 24 hours
62178886|NCT01121185|PLACEBO_COMPARATOR|0.9% sodium chloride|
62178887|NCT02807961|PLACEBO_COMPARATOR|Placebo|Placebo comparator arm
62178888|NCT02807961|ACTIVE_COMPARATOR|Active treatment|ELX-02, active comparator
62178889|NCT04397146|EXPERIMENTAL|Single-blind sensory and satiety evaluation|In total 8 different ONS products are consumed and evaluated, each product on a separate test day. The order of products is randomized between study participants.
62182737|NCT04853134|PLACEBO_COMPARATOR|Standard Care|Standard of care as determined by the PI
62562829|NCT02151227||magnesium intake categories|comparators: categories of magnesium intake except lowest category of magnesium intake , controls: lowest category of magnesium intake
62771162|NCT05340803|ACTIVE_COMPARATOR|Group C|Sedation by midazolam and magnesium sulfate during the first 24 hours
62771163|NCT01058941|EXPERIMENTAL|Lipoic acid and Omega-3 fatty acids|Three 1-gram fish oil capsules per day (2 capsules in the morning and 1 capsule in the evening) plus two lipoic acid (LA) capsules per day in the morning. Total daily dose of study drug: 675 mg DHA, 975 mg EPA, 600 mg LA.
62771164|NCT01058941|PLACEBO_COMPARATOR|Placebo|Three placebo oil capsules per day (2 capsules in the morning and 1 capsule in the evening) plus two placebo LA capsules per day in the morning.
62771165|NCT03886155||Trigger Finger Biopsy|Biopsy of trigger finger tenosynovial tissue during trigger finger release surgery sent to pathology for amyloid-specific analysis
62771166|NCT00651625|EXPERIMENTAL|1|The intervention is the use of the reciprocating procedure device (RPD) (AVANCA Re No. 1091001) (intervention) (Arm 1) with and without ultrasound guidance (intervention) in a syringe and needle procedure in comparison to a conventional syringe (BD Ref 309604) (control, Arm 2).
62771167|NCT00651625|ACTIVE_COMPARATOR|2|The conventional syringe (BD Ref 309604) is used to performed the syringe and needle procedure and outcome (effect of procedure (pain scores at 2 weeks and 6 months compared to preprocedural pain scores), and procedural pain (pain scores during procedure) are determined) and compared to Arm 1.
62562830|NCT01239810||Control group|Receiving no treatment
62562831|NCT01239810||hyaluronic acid|treatment group receiving intraarticular hyaluronic acid
62562832|NCT06469905|EXPERIMENTAL|Erector Spina Plan Block group|ESPB will be applied to the patients in the study group. Stabilization exercises will be applied together with ESPB treatment. The needle will be inserted between the erector spinae muscle and the transverse process structures.The local anesthetic will be monitored to spread along the erector spinae muscle.
62562833|NCT06469905|EXPERIMENTAL|Stabilization exercises group|Stabilization exercises will be practiced to control group
62178890|NCT04875598|ACTIVE_COMPARATOR|Group 1|30 patients will be injected with local anesthetic into the fascia between the transversus abdominis and internal oblique muscles with the help of ultrasound from the designated area (Before the operation starts, TAPBwith 20 ml 0.25 % bupivacaine will be applied to the surgical side under ultrasonography)
62178891|NCT04875598|ACTIVE_COMPARATOR|Group 2|30 patients, local anesthetic injection will be made to the same area under laparoscopic direct vision. 50 mg Bupivacaine (0.25 % 20 ml bupivacaine solution) has been determined as the application dose and this amount will be applied in both groups.
62178892|NCT00405912|PLACEBO_COMPARATOR|Placeo|Placebo pill was identical in appearance to the active medication.
62771168|NCT04878692|EXPERIMENTAL|Onco-Rash arm|"In this arm label, patients will apply the Onco-Rash cream on selected zones (face, neck, thorax,...) twice a day, during 6 weeks.~This arm will be compared to the Onco-Neutral arm, in which the Onco-Neutral cream will be applied on selected zones (face, neck, thorax,...) twice a day, during 6 weeks."
62178893|NCT00405912|EXPERIMENTAL|St. John's Wort-900 mg/day|St. John's Wort - 300 mg tablets, 3 times a day.
62771169|NCT04878692|PLACEBO_COMPARATOR|Onco-Neutre arm|"In this arm label, patients will apply the Onco-Neutre cream on selected zones (face, neck, thorax,...) twice a day, during 6 weeks.~Onco-Neutral cream will be used as an experimental comparator to Onco-Rash cream.~This arm will be compared to the Onco-Neutral arm, in which the Onco-Neutral cream will be applied on selected zones (face, neck, thorax,...) twice a day, during 6 weeks."
62771170|NCT05517798|ACTIVE_COMPARATOR|Xenograft + resorbable collagen membrane|Bone grafting material (bovine origin) + resorbable collagen membrane (porcine origin)
62771171|NCT05517798|ACTIVE_COMPARATOR|Xenograft combined with EMD + resorbable collagen membrane|Bone grafting material (bovine origin) with enamel matrix derivative (porcine origin) + resorbable collagen membrane (porcine origin)
62771172|NCT01511809|EXPERIMENTAL|Atazanavir/ritonavir monotherapy|Patients will simplify therapy to ATV/RTV 300mg/100mg OD as monotherapy
62771173|NCT01511809|NO_INTERVENTION|Atazanavir/ritonavir triple therapy|Patients will continue the same regimen ATV/RTV 300mg/100mg OD plus 2 NRTIs as backbone
62771174|NCT01172574|EXPERIMENTAL|Motor control exercise|Subjects of the exercise group underwent a 3-month (13-week) treatment program directed on 3-weekly 1-hr one-to-one sessions by the researcher who had experience in the specific exercise treatment of the spinal region. During the next 3 months, the subjects were urged to perform the exercises alone at home at least once a day, and compliance was monitored by the activity quota chart given to them at the beginning of each study-month.
62771175|NCT01172574|NO_INTERVENTION|Control group|The control group underwent treatment throughout a 6-month period, directed by each patient's medical practitioner. This consisted of the patients carrying out regular weekly general exercises (walking and swimming). Three of them regularly attended other treatment providers involving group general exercise programs. Two patients received the application of local pain-relieving methods such as heat, massage, laser and ultrasound and one did nothing except for receiving osteoporotic medication.
62771176|NCT01306474||Prednisone|profess to convinced 1-1.5mg/Kg.d
62178894|NCT00405912|EXPERIMENTAL|St. John's Wort-1800 mg/day|St. John's Wort - 600 mg 3 times per day
62178895|NCT05070234||short stature children born small for gestational age|This group was defined as a group of children whose birth weight and/or birth length equal or less than -2 SD for sex and gestational age, and who had failed to catch up in growth, remaining short after 2 years old.
62178896|NCT03181906|EXPERIMENTAL|Pre-Consultation Medication Reconciliation|Participants underwent medication reconciliation service before their consultation with the attending doctor. A best possible medication history (BPMH) was created and saved as an electronic draft in the electronic medical record system.
62391128|NCT05896605|ACTIVE_COMPARATOR|6 months after AZA treatment|Before medication, TPMT activity was normal, and azathioprine was started at small doses and added every two weeks after no adverse effects, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid. Low-dose hormone therapy was administered to all patients simultaneously.Blood (5ml) was collected from peripheral veins in 6 months after AZA treatment.
62562834|NCT06498778||good outcome|"Modified Rankin Scale (mRS) scores were determined based on clinical examinations or telephone follow-ups at twelve months post sICH event. Consistent with prior literature, we defined good outcome as mRS = 0-2."
62771177|NCT01306474||methotrexate to band prednisone|profess to convinced 7.5-15mg/w, concoction prednisone profess to convinced 0.5-1mg/Kg.d
62771178|NCT01805388|EXPERIMENTAL|Regeneration Treatment Group|RTC with Triple Antibiotic Study Drug
62771179|NCT01805388|NO_INTERVENTION|Control Non-study Drug Group|RTC on contralateral tooth with no study drug
62771180|NCT02635997||patients on antiresorptive therapy|Ibandronate 150 mg per month + Vitamine D 400-800 IU and Calcium 500-1000 mg per day
62771181|NCT06464523|EXPERIMENTAL|Face to face education|In addition to the standard cervical cancer screening programme service, participants in this group received individual face-to-face health education on HPV and cervical cancer prevention through home visits and were given educational brochures. Participants in this group were interviewed a total of four times (four times face-to-face) during the research process.
62178897|NCT03181906|NO_INTERVENTION|Control|Participants in the control group proceeded with usual care, where the doctor reviewed the patient's condition and ordered an electronic prescription
62178898|NCT02037256|EXPERIMENTAL|A Treatment (bortezomib and filgrastim)|GROUP A: Bortezomib administered in the evening after comploetion of G-CSF collection or on day 6 of mobilization with G-CSF.
62562835|NCT06498778||poor outcome|"Modified Rankin Scale (mRS) scores were determined based on clinical examinations or telephone follow-ups at twelve months post sICH event. Consistent with prior literature, we defined poor outcome as mRS = 3-6."
62562836|NCT03495557|SHAM_COMPARATOR|Control|Simple closure
62562837|NCT03495557|EXPERIMENTAL|Experimental|Simple closure + mesh
62562838|NCT02976857|EXPERIMENTAL|C-CAR011|C-CAR011 infusion In the first cell therapy 0, 1 and 2 days, respectively 10%, 30% and 60% ratio three times reinfusion.
62178899|NCT02037256|EXPERIMENTAL|B Treatment (bortezomib and filgrastim)|GROUP B: Bortexomib administered on days 4 \& day 7, before administration of filgrastim.
62771182|NCT06464523|EXPERIMENTAL|Online education|In addition to the standard cervical cancer screening programme service, participants in this group received individual health education on HPV and cervical cancer prevention online via video call via WhatsApp application and were given a digital education brochure. Participants in this group were interviewed a total of four times (four times remotely) during the research process.
62771183|NCT06464523|NO_INTERVENTION|Control|During the research process, the participants in the control group did not receive any intervention other than the standard cervical cancer screening programme service. During the research process, the participants in the control group were interviewed face-to-face twice. After the termination of the study, health education on protection against HPV and cervical cancer was provided to the volunteer participants by a method they specified and an educational brochure was given.
62771184|NCT05307432|ACTIVE_COMPARATOR|Enhanced Usual Care|ED staff deliver SPI+ (Safety Planning Intervention plus 2 or more post-discharge telephone calls) to suicidal patients who are not admitted to an inpatient unit.
62771185|NCT05307432|EXPERIMENTAL|Suicide Prevention Consultation Center|ED staff refer suicidal patients not admitted to an inpatient unit to the off-site Suicide Prevention Consultation Center (SPCC). SPCC clinicians will deliver SPI+ (Safety Planning Intervention plus 2 or more post-discharge telephone calls) to patients via telehealth.
62771186|NCT01341717|EXPERIMENTAL|Sitagliptin along with metformin and insulin|
62771187|NCT01341717|ACTIVE_COMPARATOR|Glimepiride as an active comparator to Sitagliptin|
62771188|NCT01194622|EXPERIMENTAL|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
62771189|NCT01194622|ACTIVE_COMPARATOR|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
62771190|NCT01194622|ACTIVE_COMPARATOR|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
62771191|NCT01295970|ACTIVE_COMPARATOR|Radiosurgery (SRS)|
62771192|NCT01295970|ACTIVE_COMPARATOR|Surgery|
62771193|NCT02177838|EXPERIMENTAL|Treatment (cetuximab, cisplatin, EBRT)|Patients receive cetuximab IV over 60-120 minutes for 3 weeks. Patients then undergo EBRT over 6-7 weeks. Patients achieving response continue weekly doses of cetuximab until radiation therapy is completed. Patients unable to achieve response or progression receive cisplatin IV over 1-2 hours on days 1, 22, and 43 of radiation therapy.
62771194|NCT02796885||Possible hypophosphatasia|Patients attending metabolic bone services, not previously know to have HPP, with biochemistry suggestive of HPP Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
62771195|NCT02796885||Normal|Patients attending metabolic bone services, not previously know to have HPP, with normal HPP biochemistry Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
62771196|NCT02796885||Known hypophosphatasia|Patients attending metabolic bone services or registered with RUDY database, known to have HPP Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
62771197|NCT00007267|EXPERIMENTAL|1|Participants will receive individual cognitive behavioral therapy
62771198|NCT00007267|EXPERIMENTAL|2|Participants will receive self-help cognitive behavioral intervention facilitated by a psychologist
62771199|NCT00007267|ACTIVE_COMPARATOR|3|Participants will receive a disease/health education intervention
62178900|NCT01019499|ACTIVE_COMPARATOR|berry products|Berry products
62178901|NCT01019499|PLACEBO_COMPARATOR|control products|Control products
62178902|NCT01543906|EXPERIMENTAL|QLT091001|oral QLT091001 administered once daily for 7 days
62178903|NCT05022290|EXPERIMENTAL|Single-syringe technique|Patients in this arm will receive adenosine in a single syringe, diluted with normal saline up to 20 ml. The dosage of adenosine is according to the recommendation of ACLS guidelines, which recommended 6 mg as the first dose and 12 mg as the subsequent dose if SVT can not be terminated by the first dose.
62182738|NCT04853134|ACTIVE_COMPARATOR|Proxalutamide + Standard Care|Proxalutamide + standard of care as determined by the PI
62178904|NCT05022290|ACTIVE_COMPARATOR|Double-synring technique|Patients in this arm will receive adenosine using a double syringe, the first syringe contains only adenosine and the second syringe contains only normal saline 20 ml. Both syringes are connected to each other, and to the patient's IV portal with a stopcock. The administration must be done by two nurses one after another, adenosine syringe is injected first, then follow by normal saline. The dosage of adenosine is according to the recommendation of ACLS guidelines, which recommended 6 mg as the first dose and 12 mg as the subsequent dose if SVT can not be terminated by the first dose.
62178905|NCT05294406|EXPERIMENTAL|IPTp-DP|Pregnant women attending routine antenatal care visits in their second and third trimester are given a monthly, presumptive treatment dose of dihydroartemisinin-piperaquine of three tablets daily for three days (9 tablets). The first dose is given by directly observed therapy (DOT), and the remaining doses given to the women to take at home.
62178906|NCT03676478|NO_INTERVENTION|start enteral support @ POD1|The standard of care (SoC) in our department consists of enteral nutritional support of maximum 1000 kilocalories (kCal) through a peroperatively placed jejunostomy feeding tube started at POD 1. Oral caloric intake is resumed at POD 4.
62562839|NCT02123004|EXPERIMENTAL|Ticagrelor|"Investigational product/Dosage form and strength/Manufacturer:~ticagrelor/tablet /90mg/AstraZeneca 180mg loading dose for one day ,then 90mg per day for 4 weeks"
62178907|NCT03676478|ACTIVE_COMPARATOR|delayed start enteral support @ POD5|As study intervention (INT), a period of caloric restriction is set by starting the enteral nutritional support later, at POD 5. Oral caloric intake is resumed at POD 4, similarly as in the control group. This intervention results in a relative caloric defect of more than 4.000 kCal in the immediate postoperative course.
62178908|NCT04052997|EXPERIMENTAL|Camidanlumab Tesirine|Camidanlumab Tesirine is administered as a 30- minute intravenous (IV) infusion on Day 1 of each cycle (every 3 weeks). Camidanlumab Tesirine will be administered at a dose of 45 μg/kg every 3 weeks for 2 cycles, then 30 μg/kg for subsequent cycles.
62178909|NCT05851456|EXPERIMENTAL|R130 Treatment Group|Every 7-14 days,1-6 ml R130 （concentration of 1x10\^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral in patients with relapsed/refractory bone and soft tissue tumors.
62178910|NCT01993745||Study group|ECMO Patients survived
62178911|NCT01993745||Control|ECMO Patient died
62178912|NCT04599907|EXPERIMENTAL|Roll-In Cohort: N-SWEAT Patch|Subjects will be treated with N-SWEAT Patch
62178913|NCT04599907|EXPERIMENTAL|Randomized Cohort: N-SWEAT Patch|Subjects will be treated with N-SWEAT Patch
62178914|NCT04599907|SHAM_COMPARATOR|Randomized Cohort: Sham Patch|Subjects will undergo identical procedure with an inactive sham device
62178915|NCT04588519|EXPERIMENTAL|Active Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2 mA; channel 2: 100 Hz, mean intensity 0.6±0.2 mA
62562840|NCT02123004|ACTIVE_COMPARATOR|Clopidogrel|"Investigational product/Dosage form and strength/Manufacturer:~clopidogrel/tablet /75mg/Sanofi 300mg loading dose for one day ,then 75mg per day for 4 weeks"
62562841|NCT04327544|EXPERIMENTAL|Frailty Intervention group|A multi-domain intervention program that includes nutrition education and low to moderate multi-component exercise intervention.
62178916|NCT05527743|EXPERIMENTAL|Invasive Physiotherapy|
62562842|NCT04327544|NO_INTERVENTION|Control group|Respondents in the control group will not receive any nutritional education or exercise intervention activities.
62771200|NCT05389189|ACTIVE_COMPARATOR|CBT Care|"Intervention content~The MITIG.RA program incorporates the following key topics during the 8 weeks of intervention (1st phase):~(i) Psychoeducation on RA, sleep hygiene, exercise, and general nutritional recommendations (promote behavioural change and self-care, boost the sense of self-worth and self-efficacy) (ii) Activity engagement and pacing (iii) The functioning of the mind and its problematic patterns (iv) Focusing on the 'here and now' (mindfulness) (v) Learning new ways of self-relating - self-compassion (vi) Making room for suffering (acceptance); and (vii) Moving towards what matters (identification of valued life directions and promotion of consistent values and goals-directed behaviour).~Booster sessions, at 4 and 12 weeks after completion of the first phase"
62771201|NCT05389189|NO_INTERVENTION|TAU Care|Usual Care respecting international recommendations for the management of RA.
62771202|NCT01655147|EXPERIMENTAL|Abiraterone acetate + Rifampicin|Abiraterone acetate 1,000 mg (4 x 250 mg) on Day 1 of Period 1. Rifampicin 600 mg (2 x 300 mg) on Days 8 to 13, and Abiraterone acetate 1,000 mg (4 x 250 mg) on Day 14 of Period 2.
62771203|NCT06522971|EXPERIMENTAL|High-intensity interval training (HIIT)|High-intensity interval training during neoadjuvant chemotherapy
62771204|NCT06522971|NO_INTERVENTION|Low level of physical activity (CON)|Advised to maintain usual level of physical activity during neoadjuvant chemotherapy
62771205|NCT00685373|EXPERIMENTAL|Canakinumab (ACZ885)|Subcutaneous injection every 8 weeks based on participant's body weight. Body weight \>40 kilogram (kg): 150 milligrams (mg) per injection and body weight \<= 40 kg: 2 mg/kg per injection. For participants who did not experience sufficient symptomatic relief, an up-titration to the dose and/or more frequent doses were permitted as per protocol.
62771206|NCT05650671||"wheelchair user-seat group"|healthy subjects agreeing to participate in the study
62562843|NCT01441024|EXPERIMENTAL|1|DAS181
62771207|NCT03102567|EXPERIMENTAL|GLPG1205 50mg q.d.|oral hard gelatin capsules with 50 mg GLPG1205 for q.d. administration - compared to placebo
62771208|NCT03102567|PLACEBO_COMPARATOR|placebo|oral hard gelatin capsules containing placebo for q.d. administration
62178917|NCT05527743|PLACEBO_COMPARATOR|Sham Group|
62178918|NCT05004311|EXPERIMENTAL|Group A (severe renal function impairment)|Eight (8) participants with severe renal impairment.
62178919|NCT05004311|EXPERIMENTAL|Group B (healthy)|Eight (8) control participants, matched to the 8 severe renal impaired participants enrolled in Group A.
62182739|NCT04909671|ACTIVE_COMPARATOR|CAD arm|Patients allocated to CAD arm will receive during colonoscopy withdrawal high definition white light endoscopy aided with artificial intelligence device (Gi Genius, Medtronic)
62771209|NCT03102567|EXPERIMENTAL|GLPG1205 250 mg loading and 50mg q.d. maintenance|open label - oral hard gelatin capsules with 50 mg GLPG1205 for one time 250 mg loading dose and subsequent 50mg q.d. administration
62771210|NCT03570346|EXPERIMENTAL|Hemay005|6 subjects in each cohort(15mg, 30mg, 60mg) will receive Hemay005
62771211|NCT03570346|PLACEBO_COMPARATOR|Placebo|2 subjects in each cohort(15mg, 30mg, 60mg) will receive placebo
62771212|NCT03623061||Low Fibrinogen Level|Anonymised low fibrinogen adult samples from the laboratory (Low fibrinogen concentrations). Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
62182740|NCT04909671|PLACEBO_COMPARATOR|WLE arm|Patients allocated to WLE arm will receive during colonoscopy withdrawal high definition white light endoscopy as standart of care.
62182741|NCT02713971|EXPERIMENTAL|Gamepad|Biofeedback rehabilitation with Gamepad system.
62182742|NCT02713971|ACTIVE_COMPARATOR|Control|Conventional physiotherapy.
62562844|NCT01441024|PLACEBO_COMPARATOR|2|Placebo
62562845|NCT06205862|EXPERIMENTAL|FMT group|Participants are required to complete one colonoscopy and infuse 150ml of fecal suspension into the terminal ileum under endoscopy, performing the first fecal microbiota transplantation (FMT) on day 0. Subsequently, for 2 days continuously (day 1-2), the participants will undergo microbiota transplantation in the form of oral capsules, taking 40 FMT capsules within one day (20 capsules bid). Subsequently, participants will receive a maintenance treatment with oral FMT capsules (20 capsules bid) at 3, 6, and 9 months (approximately every 75 to 90 days). Participants will undergo their first follow-up colonoscopy between 6 to 12 months(the high-risk adenoma group will receive colonoscopy at 6 months, and the low-risk adenoma group will receive colonoscopy at 12 months).
62562846|NCT06205862|NO_INTERVENTION|No treatment group|Participants are required to complete one colonoscopy and during the procedure, 150ml of saline is infused into the terminal ileum on day 0. Subsequently, participants don't need any treatment. The participants will receive their first colonoscopy follow-up 6 to 12 months after enrollment.
62562847|NCT00454337|EXPERIMENTAL|Intensification arm|emtricitabine/TDF + efavirenz or lopinavir/ritonavir + enfuvirtide
62562848|NCT00454337|ACTIVE_COMPARATOR|Standard arm|emtricitabine/TDF + efavirenz or lopinavir/ritonavir
62562849|NCT05102682|EXPERIMENTAL|Balance rehabilitation exercise|Balance rehabilitation exercise program using exoskeleton device
62771213|NCT03623061||Normal Fibrinogen Level|Healthy non pregnant females presenting for elective gynaecology surgery (Normal non pregnant fibrinogen concentrations) Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
62771214|NCT03623061||High Fibrinogen Level|Healthy pregnant females presenting for elective caesarean section (Normal term pregnancy fibrinogen levels) Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
62771215|NCT05218226|EXPERIMENTAL|50 subjects with chemotherapy-induced thrombocytopenia|50 enrolled subjects will be picked up to take Avatrombopag at the indicated dose.
62771216|NCT01916850|EXPERIMENTAL|LX4211 Low Dose|400 mg of LX4211 administered once daily for 10 consecutive days
62771217|NCT01916850|EXPERIMENTAL|LX4211 High Dose|800 mg of LX4211 administered once daily for 10 consecutive days
62771218|NCT01916850|PLACEBO_COMPARATOR|Placebo|Identical placebo administered once daily for 10 consecutive days
62771219|NCT04133714|EXPERIMENTAL|multi-channel tDCS|"In the multi-channel tDCS stimulation group, a 1:4 (anode: cathode) approach was applied, with the central anode placed in the left dorsolateral prefrontal cortex (dlPFC) (reference 10-20 standard lead EEG), and the remaining cathode distributed around the central electrode.~The rising time and falling time of current are 30 seconds respectively. Stimulate 30 minutes daily for 10 days (Monday to Friday, once a day, weekend off)."
62771220|NCT04133714|EXPERIMENTAL|single-channel tDCS|"The anode electrode of the single-channel tDCS stimulation group was placed in the left dlPFC, and the cathode electrode was placed in the right orbital forehead.~The rising time and falling time of current are 30 seconds respectively. Stimulate 30 minutes daily for 10 days (Monday to Friday, once a day, weekend off)."
62771221|NCT04133714|SHAM_COMPARATOR|sham stimulation|The shame stimulation group had only 30 seconds of up and down stimulation, with no intermediate stimulation.
62771222|NCT04736134|EXPERIMENTAL|Active Treatment (BMS 986326) IV|Intravenous (IV)
62771223|NCT04736134|EXPERIMENTAL|Active Treatment (BMS 986326) SC|Subcutaneous (SC)
62771224|NCT04736134|PLACEBO_COMPARATOR|Placebo IV|
62771225|NCT04736134|PLACEBO_COMPARATOR|Placebo SC|
62771226|NCT04736134|PLACEBO_COMPARATOR|Multiple Ascending Dose Placebo SC|Placebo
62771227|NCT04736134|EXPERIMENTAL|Multiple Ascending Dose SC|BMS 986326 SC
62771228|NCT05275790|EXPERIMENTAL|Vestal active device|10 subjects to receive an active device plus a diet plan for 12 weeks.
62771229|NCT05661396|EXPERIMENTAL|Experimental group|
62771230|NCT05661396|NO_INTERVENTION|Control group|
62771231|NCT03612050|PLACEBO_COMPARATOR|Enhanced Usual Care|facilitate any clinical interventions
62771232|NCT03612050|EXPERIMENTAL|Meaning Centered Psychotherapy|raise patients' sense of meaning/purpose
62771233|NCT04384627|ACTIVE_COMPARATOR|Pre-IC GTV|The gross tumor volume (GTV) is delineated according to the pretreatment tumor extension
62771234|NCT04384627|EXPERIMENTAL|Post-IC GTV|The gross tumor volume (GTV) is delineated according to the post-IC tumor extension
62562850|NCT02288325|EXPERIMENTAL|Open-Label FETZIMA®|FETZIMA® (levomilnacipran extended release \[ER\]) taken orally during flexible dose titration up to 40, 80 or 120 mg once daily in 8-week run-in period followed by fixed dose of 40, 80 or 120 mg once daily in 12-week stabilization period.
62562851|NCT02288325|PLACEBO_COMPARATOR|Double-Blind Placebo|Dose-matched placebo taken orally once daily for 26 weeks during double-blind treatment period.
62562852|NCT02288325|EXPERIMENTAL|Double-Blind FETZIMA®|FETZIMA® (levomilnacipran ER) taken orally at fixed dose of 40, 80 or 120 mg once daily for 26 weeks during double-blind treatment period.
62771235|NCT01761773|EXPERIMENTAL|Group 1|Subjects with normal renal function: healthy normal adult subjects with an eGFR ≥ 90 mL/min/1.73m2.
62771236|NCT01761773|EXPERIMENTAL|Group 2|Subjects with mild renal impairment: adult subjects with a eCFR ≥ 90 mL/min/1.73m2.
62771237|NCT01761773|EXPERIMENTAL|Group 3|Moderate renal impairment: adult subjects with an eGFR between ≥30 - ≤ 59 mL/min/1.73m2.
62771238|NCT01761773|EXPERIMENTAL|Group 4|Severe renal impairment: adult subjects with an eGFR ≤ 29 mL/min/1.73m2, not on dialysis.
62771239|NCT05219669|EXPERIMENTAL|Intranasal Nalmefene 1 Spray in 1 Nostril|3 mg IN Nalmefene Hydrochloride dose (one 0.1 mL spray of a 30 mg/mL solution in one nostril)
62771240|NCT05219669|EXPERIMENTAL|Intranasal Nalmefene 2 Sprays in 1 Nostril|6 mg IN Nalmefene Hydrochloride dose (two 0.1 mL sprays of a 30 mg/mL solution in one nostril)
62771241|NCT05219669|EXPERIMENTAL|Intranasal Nalmefene 1 Spray in Each Nostril|6 mg IN Nalmefene Hydrochloride dose (one 0.1 mL spray of a 30 mg/mL solution in each nostril)
62771242|NCT05018741||Liver transplant|
62771243|NCT02618551|EXPERIMENTAL|Intervention|Patients will be treated by three bronchial thermoplasty sessions.
62771244|NCT03042260|EXPERIMENTAL|Trimethoprim-Sulfamethoxazole (TMP-SMX)|Trimethoprim-Sulfamethoxazole 180mg/800mg oral tablet, 3 times a week, for 6 months. Subjects may remain on the drug longer (maximum 1 year), if they continue to receive intermediate or high dose steroids at the end of 6 months.
62771245|NCT03042260|PLACEBO_COMPARATOR|Placebo|"Tablets that look exactly the same as the experimental drug, 3 times a week, for 6 months.~Subjects may remain on the placebo longer (maximum 1 year), if they continue to receive intermediate or high dose steroids at the end of 6 months."
62771246|NCT01345552|OTHER|SBRT|
62771247|NCT05363826|EXPERIMENTAL|Photochemotherapy as an adjuvant to surgical resection of glioblastoma|3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester (Photobac®) is injected 24 hours prior to surgical resection of a recurrent Glioblastoma or gliosarcoma. Immediately following the resection the cavity is treated with 50 joules/ square cm of 787 nm light .The drug dose is escalated using three patient cohorts until a dose limiting toxicity is reached or the upper limit of the 8 step escalation is reached.
62771248|NCT01510899|EXPERIMENTAL|Healthy Subjects Arm|
62771249|NCT01510899|EXPERIMENTAL|Renal Impaired Subjects Arm|
62771250|NCT03917550|EXPERIMENTAL|Recovery (Transdiagnostic & self)|A longitudinal study conducted before has shown that self-compassion, unconditional self-acceptance, self-esteem and self concept clarity could be considered risk factors for the severity of the clinical symptoms in anxiety and depression. This is the main reason why this arm consists of the Transdiagnostic intervention program for emotional disorders plus a number of intervention techniques targeting the self-concepts mentioned before. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms. Moreover, additional intervention techniques targeting self-concepts will be used to improve participants' self.
62178920|NCT05063123|OTHER|Single arm - Flotetuzumab|1 - 3 cycles of Flotetuzumab. Flotetuzumab will be administered intravenously via continuous (pump) administration. At least for the first 7 days of cycle 1, the drug will be administered in an inpatient hospital setting, but afterwards may be administered in an outpatient setting using an ambulatory pump configuration. Flotetuzumab will be dosed using multi-step increments in dosing over the first week as follows: 30, 60, 100, 200, 300, and 400 ng/kg/day each for 24 hours. On day 7, the dose will be increased to 500 ng/kg/day and administered as a continuous infusion for the remainder of cycle 1. After 1 cycle of flotetuzumab patients will proceed with alloHCT. However if there is a delay in access to transplantation, patients are allowed to receive up to 2 additional cycles flotetuzumab provided all non-hematologic toxicities have resolved to Grade \<2.
62178921|NCT04817930|EXPERIMENTAL|Patient specific chin implant|A patient specific chin peek implant was used for chin augmentation
62178922|NCT04817930|EXPERIMENTAL|computer guided advancement genioplasty|Computer guided advancement genioplasty using patient specific cutting and positioning guides
62178923|NCT05819047||Healthy|Healthy volunteers
62178924|NCT01272323||Placebo|Subjects previously randomised to receive placebo in study CP005
62178925|NCT01272323||Cat-PAD Group 1|Subjects previously randomised to receive Cat-PAD dose 1 in study CP005
62178926|NCT01272323||Cat-PAD Group 2|Subjects previously randomised to receive Cat-PAD dose 2 in study CP005
62178927|NCT00546078|EXPERIMENTAL|Cervarix™ 4-Dose Group|Subjects who had received 3 doses of Cervarix™ in study 580299/001 (NCT00689741), received a 4th dose of Cervarix™ on Day 0 in the current study.
62178928|NCT00546078|EXPERIMENTAL|Cervarix™ 3-Dose Group|Subjects who had received 3 doses of placebo in study 580299/001 (NCT00689741), received 3 doses of Cervarix™ (Day 0, Month 1 and Month 6) in the current study.
62178929|NCT04715503|EXPERIMENTAL|PET-IA|68Ga-DOTANOC 18F-FDG
62178930|NCT03190629|ACTIVE_COMPARATOR|High-flux hemodialysis|3 times per week
62178931|NCT03190629|EXPERIMENTAL|On line-hemodiafiltration|3 times per week
62771251|NCT03917550|ACTIVE_COMPARATOR|Transdiagnostic|This arm represents the Transdiagnostic intervention program for emotional disorders. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms.
62178932|NCT02638233|OTHER|Sofosbuvir 400mg/Ledipasvir 90 mg|Subjects will receive sofosbuvir 400mg q.d p.o and ledipasvir 90 mg q.d p.o (FDC) for 8 weeks
62178933|NCT02352077|EXPERIMENTAL|NeuroRegen Scaffold with BMMCs or MSCs transplantation|
62178934|NCT04771962|EXPERIMENTAL|DESFLURANE|desflurane group- this group of patients will be induced with sevoflurane and maintained with desflurane during spontaneous general anaesthesia
62567774|NCT05651321||cancer patients|Participants were tested for different taste perception thresholds using a three-point difference test, with samples materials for basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) were used to prepare different tastes and concentrations of liquids. The subjects will then evaluate the appearance (color, texture), taste, flavor, and texture of the six different flavored enteral nutrition preparations. The subjects will then perform manual sensory evaluation of the appearance (color, texture), odor, taste, texture, and other properties of the 6 different flavored enteral nutrition preparations.
62771252|NCT00324233|ACTIVE_COMPARATOR|SC|Speedicath (SC) catheter is a catheter for intermittent catherisation
62771253|NCT00324233|EXPERIMENTAL|SCCM|SpeediCath Compact Male (SCCM) is a compact catheter for intermittent catherisation to be used by males
62771254|NCT04386876|EXPERIMENTAL|Orvical-Kaletra-Orvical-Kaletra|In first and third periods of the study, participants received Orvical 200 mg/50 mg Film Tablet manufactured by World Medicine-Turkey. In second and fourth periods, they received Kaletra 200 mg/50 mg Film CoatedTablet manufactured by AbbVie Deutschland GmbH \& Co.-Germany. All periods were performed under fasting state.
62178935|NCT04771962|ACTIVE_COMPARATOR|SEVOFLURANE|the controlled group.patients will be induced and maintained with sevoflurane through out spontaneous general anaesthesia.
62178936|NCT05707715||Slight Forward Head Posture|This descriptive cross-sectional study which was approved by Çankırı Karatekin University Ethics Committee (Approval number:). There is FHP if the imaginary line between the tragus of the ear and the middle of the shoulder is not on the same line when viewed from the side. And the horizontal length between that two vertical lines indicates the severity of FHP. The level of FHP is classified as slight/severe/highly FHP according to that horizontal length. The slight FHP is accepted as between 0-2.5cm, and severe FHP above 2.5cm (27).
62182743|NCT02163798|EXPERIMENTAL|Tai Chi Group|Participants in this group received a 12-week instructor-led Tai Chi training program.
62391129|NCT05896605|ACTIVE_COMPARATOR|over 1 year after AZA treatment|Before medication, TPMT activity was normal, and azathioprine was started at small doses and added every two weeks after no adverse effects, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid. Low-dose hormone therapy was administered to all patients simultaneously.Blood (5ml) was collected from peripheral veins over 1 year after AZA treatment.
62391130|NCT05896605|NO_INTERVENTION|healthy control|Ten healthy volunteers with physical examination in our hospital were selected as the healthy control (HC) group. Serum samples from healthy controls were collected.
62391131|NCT04896476|EXPERIMENTAL|EchoMark|All subjects will undergo a physician exam prior an arteriovenous fistula creation per the institution's standard of care. After the fistula creation is completed, but prior to closure, the EchoMark will be implanted under the outflow vein.
62771255|NCT04386876|EXPERIMENTAL|Kaletra-Orvical-Kaletra-Orvical|In first and third periods of the study, participants received Kaletra 200 mg/50 mg Film Coated Tablet manufactured by AbbVie Deutschland GmbH \& Co.-Germany. In second and fourth periods, they received Orvical 200 mg/50 mg Film Tablet manufactured by World Medicine-Turkey. All periods were performed under fasting state.
62391132|NCT04334876|OTHER|High Risk Healthcare Workers|At home, finger prick, antibody test.
62391133|NCT06453421||chronic critical ill patients|Evaluation both of the clinical and pathophysiological characteristics of a group of chronically critical ill patients admitted to a pulmonary rehabilitation center and of their response to rehabilitation treatment
62562853|NCT02614326|EXPERIMENTAL|Memory Flexibility (MemFlex) Training|MemFlex training draws on cognitive bias modification and memory specificity training techniques (Raes et al., 2009; Dalgleish et al., 2014). MemFlex is primarily self-guided and aims to reduce autobiographical memory biases associated with depression. The training is presented over one face-to-face session and eight self-guided sessions. In the initial session, the researcher introduces cued-recall tasks used throughout the workbook, and guides the participant in completion of the tasks. When understanding of the basic principles is satisfactory, the researcher assists the participant to set a schedule for completion of the workbook over the following four weeks. The participant will receive a phone call at the beginning of week three to check progress, and clarify any difficulties.
62178937|NCT05707715||Severe Forward Head Posture|This descriptive cross-sectional study which was approved by Çankırı Karatekin University Ethics Committee (Approval number:). There is FHP if the imaginary line between the tragus of the ear and the middle of the shoulder is not on the same line when viewed from the side. And the horizontal length between that two vertical lines indicates the severity of FHP. The level of FHP is classified as slight/severe/highly FHP according to that horizontal length. The slight FHP is accepted as between 0-2.5cm, and severe FHP above 2.5cm (27).
62771256|NCT04430647|EXPERIMENTAL|phaco-UCP|Under peribulbar anesthesia, UCP was performed first, followed by phacoemulsification. UCP was performed using the same technique described before \[18\]. For all treatments, 2nd generation probe was used (EyeOP1, Eye Tech care; France) with the same parameters; Operating frequency was 21 MHz. Number of sectors activated was 6. Acoustic power was 2.45 W; duration of each shot was 8s; and the time between shots was 20s. The probe diameter (11, 12 or 13 mm) was determined according to the eye's biometric readings. The coupling cone was centered on the eye and kept in place with low vacuum suction, followed by introduction of the treatment probe inside the cone, then activation of the transducers by constantly pressing the foot switch. Once UCP treatment was finished, phacoemulsification was commenced
62771257|NCT04430647|ACTIVE_COMPARATOR|Phaco alone|A standard phacoemulsification was performed with 2.2 mm clear corneal incision, continuous curvilinear capsulorhexis, phacoemulsification and intrabagal implantation of foldable acrylic intraocular lens (AcrySof® IQ SN60WF monofocal; Alcon Laboratories Inc, Fort Worth, TX, USA) for all patients. Irrigation-aspiration was performed for at least 30 seconds to remove any viscoelastic from the anterior chamber. Reformation of the anterior chamber was done with balanced saline solution (BSS), followed by hydration of the corneal wound and side port.
62771258|NCT03562468|PLACEBO_COMPARATOR|Placebo|Each subject will be randomly assigned to receive placebo for an 8-week treatment period. Subjects will be instructed to take two capsules (placebo) in the morning with breakfast and two capsules (placebo) in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
62771259|NCT03562468|EXPERIMENTAL|TRU NIAGEN (nicotinamide riboside) 300 mg/day|Each subject will be randomly assigned to receive 300 mg/day of TRU NIAGEN (nicotinamide riboside) for an 8-week treatment period. Subjects will be instructed to take two capsules of TRU NIAGEN in the morning with breakfast and two capsules of TRU NIAGEN in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
62771260|NCT03562468|EXPERIMENTAL|TRU NIAGEN (nicotinamide riboside) 1000 mg/day|Each subject will be randomly assigned to receive 1000 mg/day of TRU NIAGEN (nicotinamide riboside) for an 8-week treatment period. Subjects will be instructed to take two capsules of TRU NIAGEN in the morning with breakfast and two capsules of TRU NIAGEN in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
62178938|NCT04254562|EXPERIMENTAL|Experimental Group: HYPE Services|The experimental arm will receive the HYPE intervention for 12 months.
62178939|NCT04254562|ACTIVE_COMPARATOR|Control Group: Enhanced Academic Services as Usual|"The control arm will receive a special personalized packet of resources available on campus and off-campus within a 10-mile radius, as enhanced academic services as usual."
62178940|NCT05846308|ACTIVE_COMPARATOR|Synchronous condition|This arm (n=30) will include a synchronous intervention only.
62178941|NCT05846308|ACTIVE_COMPARATOR|Non-synchronous condition|This arm (n=30) will include a non-synchronous intervention only.
62771261|NCT02434328|EXPERIMENTAL|Brolucizumab 6 mg|Single intravitreal (IVT) injection of brolucizumab at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit
62771262|NCT02434328|ACTIVE_COMPARATOR|Aflibercept 2 mg|Single IVT injection of aflibercept ophthalmic solution at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
62771263|NCT05989659||Patient - Home Dialysis|Patients transitioning to home dialysis
62771264|NCT05989659||Patient - Facility Hemodialysis|Patients transitioning to facility hemodialysis
62771265|NCT05989659||Caregivers - Home dialysis|Caregivers of patients transitioning to home dialysis
62771266|NCT05989659||Caregivers - Facility Hemodialysis|Caregivers of patients transitioning to facility hemodialysis
61995049|NCT03712410|ACTIVE_COMPARATOR|Group 1 (PISCES face to face)|"Family caregivers will receive three sessions of the PISCES intervention in person. The agenda for the first face to face visit for caregivers (suggested timeline 5-7 days after hospice admission) includes an explanation of the purpose of the visit/call. During the first session, the interventionist works on steps one and two of the ADAPT model, namely Attitude and Defining the Problem and Setting Realistic Goals. During the second visit (suggested timeline 11-13 days after hospice admission) the interventionist covers steps three and four of the ADAPT model. Step three encourages caregivers in being creative and generating alternative solutions. Step four focuses on predicting the consequences and developing a solution plan. The third visit (suggested timeline 16-18 days after hospice admission) focuses on step five, namely trying out the solution plan and determining if it works."
62182744|NCT02163798|EXPERIMENTAL|Walking Group|Participants in this group received a 12-week instructor-led brisk walking training program.
62771267|NCT06437912|EXPERIMENTAL|Injection 1 U / 0.1ml BTXA|Botulinum toxin type A (BTXA) was injected into both sides of the knife edge immediately after operation, the injection volume was 1U/0.1ml per point, the interval between the injection points on the same side of the knife edge was 1cm, and the distance of each injection point from the knife edge was 0.5cm. It was injected only once immediately after operation.
62771268|NCT06437912|EXPERIMENTAL|Injection 2.5U / 0.1ml BTXA|Botulinum toxin type A (BTXA) was injected into both sides of the knife edge immediately after operation, the injection volume was 2.5U/0.1ml per point, the interval between the injection points on the same side of the knife edge was 1cm, and the distance of each injection point from the knife edge was 0.5cm. It was injected only once immediately after operation.
62771269|NCT06437912|EXPERIMENTAL|Injection 5U / 0.1ml BTXA|Botulinum toxin type A (BTXA) was injected into both sides of the knife edge immediately after operation, the injection volume was 5U/0.1ml per point, the interval between the injection points on the same side of the knife edge was 1cm, and the distance of each injection point from the knife edge was 0.5cm. It was injected only once immediately after operation.
62771270|NCT06437912|ACTIVE_COMPARATOR|Injection 0.9%Nacl|Injection 0.9%Nacl Immediately after operation 0.9%Nacl was injected on both sides of the knife edge, the injection volume per point was 0.1ml, the interval between each injection point on the same side of the knife edge was 1cm, and each injection point was away from the knife edge 0.5cm. It was injected only once immediately after operation.
62771271|NCT04065633|EXPERIMENTAL|Part A sequence 1|
62771272|NCT04065633|EXPERIMENTAL|Part A sequence 2|
62771273|NCT04065633|EXPERIMENTAL|Part B sequence 1|
62771274|NCT04065633|EXPERIMENTAL|Part B sequence 2|
62771275|NCT05099159|EXPERIMENTAL|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily for 26 weeks.
62771276|NCT05099159|PLACEBO_COMPARATOR|Placebo + elinzanetant|Participants will receive matching placebo orally once daily for 12 weeks, followed by elinzanetant 120 mg for 14 weeks.
62771277|NCT01248871|ACTIVE_COMPARATOR|SEVO|sevoflurane-remifentanil/sufentanil combination
62771278|NCT01248871|ACTIVE_COMPARATOR|SERE|volatile agent only during reperfusion
62771279|NCT01248871|ACTIVE_COMPARATOR|propofol|propofol-remifentanil/sufentanil
62178942|NCT06158828|EXPERIMENTAL|Recipient, Myeloablative Conditioning (MAC)|Patients will undergo Myeloablative Conditioning (MAC) consisting of rabbit antithymocyte globulin (rATG), Busulfan, Fludarabine, and Thiotepa. All agents are administered intravenously. rATG is administered from days -9 to -7, followed by Busulfan and Fludarabine from days -6 to -3, and Thiotepa on day -2. On Day 0, patients will undergo infusion of the ex vivo TCRαβ/CD19+ depleted haploidentical HPC graft. On Day +7, patients will undergo infusion of the memory-like NK (ML NK) cells, followed by IL-2 subcutaneously 4 hours after the ML NK infusion. IL-2 will continue every other day through Day +19 for a maximum of 7 doses.
62178943|NCT06158828|EXPERIMENTAL|Recipient, Reduced Intensity Conditioning (RIC)|Patients will undergo Reduced Intensity Conditioning (RIC) consisting of rabbit antithymocyte globulin (rATG), Fludarabine, Melphalan, and Thiotepa. All agents are administered intravenously. rATG is administered from days -9 to -7. Fludarabine is administered from day -8 to day -5, followed by Thiotepa on day -4 and Melphalan on days -3 and -2. On Day 0, patients will undergo infusion of the ex vivo TCRαβ/CD19+ depleted haploidentical HPC graft. On Day +7, patients will undergo infusion of the memory-like NK (ML NK) cells, followed by IL-2 subcutaneously starting 4 hours after the ML NK infusion. IL-2 will continue every other day through Day +19 for a maximum of 7 doses.
62178944|NCT06158828|OTHER|Donor|Donors will undergo 2 leukapheresis collections. First, patients will be mobilized using G-CSF for 5 days followed by leukapheresis on the day prior to planned stem cell transplant. The second collection will occur on Day +6 after stem cell transplant and will be non-mobilized.
62178945|NCT06423677|ACTIVE_COMPARATOR|serratus posterior superior intercostal plane block + intravenous patient controlled analgesia|serratus posterior superior intercostal plane block will be administered to these group. after the extubation intravenous patient controlled analgesia (PCA) will also be administered to patients.
62178946|NCT06423677|ACTIVE_COMPARATOR|intravenous patient controlled analgesia|After the extubation, only intravenous patient controlled analgesia (PCA) will be administered to patients.
62178947|NCT02629419|EXPERIMENTAL|CAMB (Encochleated Amphotericin B)|Encochleated Amphotericin B (200 mg, 400 mg, 800 mg)
62178948|NCT04970381|EXPERIMENTAL|Rivaroxaban|Rivaroxaban: Patients with ventricular mural thrombus in the study receive rivaroxaban anticoagulant therapy for 12 weeks. The dosage of rivaroxaban was typically 20mg once daily, or 15mg once daily if patients were on dual antiplateletagents, or with creatinine clearance of 30-50mL/min.
62562854|NCT02614326|PLACEBO_COMPARATOR|Psychoeducation|The psychoeducation condition will also complete an initial face-to-face session. This session will cover the symptoms and causes of depression, and the workbook will be introduced. The workbook will consist of eight self-guided sessions that the individual will be required to complete over four weeks. The workbook content will cover the presentation of depression and basic information on factors associated with depression, such as worry, procrastination, and sleep difficulties. Each session consists of psychological theories of the topic, followed by a series of questions about the material to ensure participant engagement. The participant will receive a phone call from a team member at the beginning of week three to check progress, and clarify any difficulties.
62562855|NCT04868695|EXPERIMENTAL|Bilateral Spheno-Ethmoidectomy:|
62562856|NCT04868695|EXPERIMENTAL|Bilateral Fronto-Spheno-Ethmoidectomy + Draf 2b|
62562857|NCT04868695|EXPERIMENTAL|Draf Typ 3|
62562858|NCT02556320|EXPERIMENTAL|Epileptic patient|Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
62562859|NCT01985243|EXPERIMENTAL|Nutrition and agriculture|Intervention arm with integrated nutrition and agriculture education, skill building, and animal husbandry promotion
62562860|NCT01985243|EXPERIMENTAL|Iron-rich food & business literacy|Integrated business literacy and food supplementation program to promote school retention among female adolescents
62562861|NCT01985243|NO_INTERVENTION|IYC Comparison|Comparison group of infants and young children for the nutrition-agriculture intervention
62562862|NCT01985243|NO_INTERVENTION|Adolescent comparison|Comparison group for the adolescent business-food supplement intervention
62178949|NCT04176783|ACTIVE_COMPARATOR|Opioid|The opioid-based arm utilizes traditional, standard-of-care treatment for each applicable surgery. The medications (including dosage and frequency) used in this arm vary depending on the surgery being performed; however, tend to include medications in the opioid family such as Hydromorphone, Hydrocodone, Tramadol, or Oxycodone.
62562863|NCT01960257|EXPERIMENTAL|DHFS with IS-RM|Digital Health Feedback System (DHFS) Rifamate (combination of isoniazid 150 mg and rifampin 300 mg) over-encapsulated with ingestion sensor - 2 capsules orally daily (QD) administered orally preferably on an empty stomach first thing in the morning for 10-16 weeks, depending on time left to complete TB treatment.
62771280|NCT04715009||participants use smartphone less than 4 hours per day|participants use smartphone less than 4 hours per day
62178950|NCT04176783|ACTIVE_COMPARATOR|Opioid-Free|The opioid-free arm utilizes medications that do not belong to the opioid family of medications. All medications used are FDA-approved and no experimental medications are being used. The medications (including dosage and frequency) used in this arm vary depending on the surgery being performed; however, tend to include medications such as Gabapentin, Tylenol, Meloxicam, Bupivacaine, or Ketorolac.
61995050|NCT03712410|EXPERIMENTAL|Group 2 (PISCES delivered in a hybrid format)|In this group, participants will receive the PISCES intervention in three sessions; however, the first session will be delivered face to face and the other two via video. The three intervention sessions will be scheduled with a suggested timeline between days 5 and 18 of the hospice admission. The first session will take place in person (suggested timeline 5-7 days after hospice admission). After the first session where the in-person encounter will allow for the establishment of rapport between the interventionist and the caregiver, the second session (suggested timeline 11-13 days after hospice admission) and the third session (suggested timeline 16-18 days after hospice admissions) will be conducted via live videoconferencing. If the caregiver already has access to a computer and Internet, they will utilize the videoconferencing solution. If videoconferencing is not feasible, the sessions will be delivered over the regular phone.
62562864|NCT01960257|ACTIVE_COMPARATOR|SOC DOT|Isoniazid 300 mg -1 tablet orally QD plus rifampin 300 mg - 2 capsules orally QD, OR Rifamate (combination of isoniazid 150 mg and rifampin 300 mg) - 2 capsules orally QD preferably on an empty stomach first thing in the morning for 10-16 weeks, depending on time left to complete TB treatment.
62182745|NCT02163798|NO_INTERVENTION|Control Group|Participants in the control group did not receive intervention during the 12 weeks, and were told that they would be provided two sessions of free health and fitness evaluation with an interval of three months (12 weeks).
62562865|NCT03000192||Breast cancer|Women aged \<50 years
62562866|NCT03000192||Gynaecological cancers|Includes: cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer and vulval cancer
62562867|NCT03000192||Non-Hodgkin Lymphoma|Diffuse large B cell
62562868|NCT01636271||Group 1: subjects from LPL100601|randomized subjects in study LPL100601
62562869|NCT01636271||Group 2: subjects from SB480848/033|randomized subjects in study SB480848/033
62771281|NCT04715009||participants use smartphone more than 4 hours per day|participants use smartphone more than 4 hours per day
62771282|NCT05339282|EXPERIMENTAL|The experimental group in acute cholecystitis|"inclusion criteria~1. among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~2. cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~3. Gallbladder with surrounding organs due to gallbladder inflammation~4. Patients over 19 years of age~normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) was used before surgery."
62771283|NCT05339282|EXPERIMENTAL|The controled group in acute cholecystitis|"1. among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~2. cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~3. Gallbladder with surrounding organs due to gallbladder inflammation~4. Patients over 19 years of age~First-generation cephalosporin (Cefazolin inj., 1g, Cefazolin sodium, Chong-geun-dang pharm.co.) was used before surgery."
62771284|NCT04185506|EXPERIMENTAL|DBT and behavioral weight loss|The intervention is a 16-week group-based behavioral program consisting of a combination of Dialectical Behavioral Therapy (DBT) skills and behavioral weight loss techniques.
62562870|NCT04174274||positive|ventilator-associated pneumonia-developed group followed by mechanical ventilation
62562871|NCT04174274||negative|not ventilator-associated pneumonia-developed group followed by mechanical ventilation
62562872|NCT05651594|EXPERIMENTAL|Treatment (mFOLFOX6, pembrolizumab, propranolol)|Patients receive mFOLFOX6 (leucovorin IV, oxaliplatin IV, and fluorouracil IV), pembrolizumab IV, and propranolol PO on study. Patients also undergo tumor biopsy during screening and CT scans and collection of blood samples during screening and on study.
62562873|NCT06497907|EXPERIMENTAL|Patients with growth faltering|Patient with growth faltering whose weight still below -2 SD for age and sex on the WHO scores after 12 weeks of nutritional rehabilitation with polymeric formula, underwent upper gastrointestinal endoscopy and who were diagnosed as environmental enteropathy, received nutritional rehabilitation with peptide based formula for 8 weeks and were reassessed.
62771285|NCT04516551|EXPERIMENTAL|anti-CD19 allo-CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determining optimal dosage.~dosage: the number of anti CD19+CD22 CAR T cells~-1(if needed) 1×10\^6/KG~3×10\^6 /KG 6×10\^6 /KG 1×10\^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days or bendamustione (90mg/m2 per day) for two days prior to cell infusion."
62771286|NCT03708874||Group 1.Intraoperative bupivacaine|intraperitoneal bupivacaine wash-emergency laparoscopic cholecystectomy
62771287|NCT03708874||Group 2.Intravenous paracetamol|intravenous paracetamol-emergency laparoscopic cholecystectomy
62771288|NCT06201351||Adaptive radiotherapy group|MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.
62771289|NCT05285306|EXPERIMENTAL|PEACE Program|3 sessions of tailored coping skills related to pelvic examinations
62771290|NCT01065311|EXPERIMENTAL|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of certain aspects of cognitive behavioral therapy for depression (Beck et al., 1979) and components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
62771291|NCT01065311|ACTIVE_COMPARATOR|CBASP|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions.
62771292|NCT01065311|ACTIVE_COMPARATOR|Treatment-as-usual|"Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist"
62182746|NCT04308213|EXPERIMENTAL|Bone Marrow aspirate|All the patients enrolled in the study will be treated with the bone marrow aspirate obtained with the Bone Marrow Cellution Kit.
62562874|NCT05395117|EXPERIMENTAL|Treatment Arm A: High dose|"Participants will receive the Investigational Medicinal Product (IMP), AZD5462 Dose A starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin"
62771293|NCT02759536|EXPERIMENTAL|Boronophenylalanine and IHNI-based BNCT|
62562875|NCT05395117|EXPERIMENTAL|Treatment Arm B: Low dose|"Participants will receive the IMP, AZD5462 Dose B starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin"
62562876|NCT03164551|ACTIVE_COMPARATOR|GERI+ Incubator|
62771294|NCT05999110|EXPERIMENTAL|Exercise Group|The participants receive twelve weeks of a supervised personalised exercise program, based on aerobic and strength training. This group also receives a behavioral change session with a psychologist and nutritional advice session with a nutritionist.
62562877|NCT03164551|OTHER|Conventional incubator|
62562878|NCT01129297||BMI ≥ 35 kg/m2 and diabetes|BMI (Body Mass Index) ≥ 35 kg/m2 and diabetes defined by a fasting blood glucose ≥ 7 mmol/l and/or ≥ to 11.1 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
62178951|NCT02740205|NO_INTERVENTION|Control group|Hospital's standard EN support at the discretion of the Clinical Nutrition Service that is composed by physicians, dietitians, and students, provides nutritional assessments, recommendations and consultations for the in-patients that required nutrition support during their hospitalization stay. There is no protocols or algorithms for the nutritional support in our institution, the currently clinical practice of the EN is prescribed by the physician, dietitians and students during the morning rounds each 24h, the kind of EN formulas prescribed depends of the clinical status of the patient, when the patients required protein supplements modular protein supplements are added.
61995051|NCT03712410|EXPERIMENTAL|Group 3 (PISCESplus)|"PISCESplus is meant to be an enhanced version of the PISCES intervention including the original problem solving therapy modules with the addition of positive reappraisal elements. The suggested timeline for the first session which will be in person is 5-7 days after hospice admission. At the end of the first session, the interventionist will ask the caregiver to take the time to think about and identify some positive aspects of caregiving.~At the end of the second session (which is scheduled to take place via video approx. 11-13 days after admission) the interventionist will ask the caregiver to go over the benefits or positive aspects of caregiving that they had identified and ask them to comment as to why they perceive these as positive or beneficial.~The third session will also take place via video."
62178952|NCT02740205|EXPERIMENTAL|Algorithm for enteral nutrition support|Initial infusion of 20 to 40 ml/h, evaluated the tolerability in the next 8-12h, then the infusion can be increased 25 ml/ 8-12h for gastric infusion and 10-20 ml/h for the post-pyloric feeding, for bolus infusion an initial infusion of 125 ml each 4-5hrs and evaluated the tolerability in the next 8-12h. If the subject present intolerability to the EN, the action in the algorithm indicate hold the infusion 4h then restarted at 10 ml/h with prokinetics agents rather than the suspension. As a part of the intervention, several educational sessions for the medical, nutritionist and nurse staff were performed during the period of the study.
62178953|NCT04826419|ACTIVE_COMPARATOR|Non-invazive ozone therapy in a group|ozone therapy
62178954|NCT04826419|NO_INTERVENTION|Control group|control groups do not take ozone therapy
62178955|NCT05124002|EXPERIMENTAL|H101+HAIC|"Recombinant Human Adenovirus Type 5 (H101): intratumorally injected 3 days before HAIC. 1 vial (5.0 × 10\^11 vp) if the maximum diameters of lesion ≤ 5 cm, 2 vials (1.0 × 10\^12 vp) if the maximum diameters of lesion ≤ 10 cm, 3 vials (1.5 × 10\^12 vp) if the maximum diameters of lesion is \> 10 cm.~HAIC (FOLFOX): Oxaliplatin 50 mg + 5-FU 1.5 g + leucovorin calcium"
62178956|NCT05216393|EXPERIMENTAL|intervention|The intervention group will be mailed a Fitbit device and provided access to the RecTech Match website. Intervention participants will receive weekly calls for the first 6 weeks, and a call every other week for the following 6 weeks (9 in total) from a health coach to discuss progress, facilitate setting physical activity goals, and help mitigate obstacles to participate in physical activity in the community. Participants will be free to access the features and resources of the website. The Fitbit data will be collected on an ongoing basis and the participants will receive daily texts asking them to rate the amount of physical activity for the day.
62178957|NCT05216393|NO_INTERVENTION|Control|The control participants will not have access to the RecTech Match website; however, control participants will be directed to generic information available on the NCHPAD website, which includes the same information but is not delivered through RecTechMatch.com.
62178958|NCT06488885|ACTIVE_COMPARATOR|Experimental group|Nursin students
62178959|NCT06488885|NO_INTERVENTION|Control group|Nursin students
62178960|NCT01991925||quality of life, quality of care|hereditary haemochromatosis patients
62178961|NCT00536081|ACTIVE_COMPARATOR|A|Pegfilgrastim during all 6 cycles of chemotherapy
62178962|NCT00536081|EXPERIMENTAL|B|Pegfilgrastim during the first two cycles of chemotherapy
62178963|NCT00574483|EXPERIMENTAL|1|Unblinded treatment arm
62178964|NCT01748123|ACTIVE_COMPARATOR|Chlorthalidone|25mg daily orally for 8 weeks
62178965|NCT01748123|ACTIVE_COMPARATOR|Hydrochlorothiazide|50mg daily orally for 8 weeks
62178966|NCT04520074|NO_INTERVENTION|Follow-up|No interevention
62178967|NCT04520074|EXPERIMENTAL|three steps chemotherapy|Cyclophosphamide 400mg（250mg/m2）+Etoposide 100mg (70mg/m2)d1-d3 iv 4w/6cycles , followed by Carboplatin (AUC=5)+Cyclophosphamide 600mg(400mg/m2)d1-d2 iv 8w/6cycles.
62178968|NCT01476124|EXPERIMENTAL|Regimen A|Morphine placebo + GEn 600 mg
62178969|NCT01476124|EXPERIMENTAL|Regimen B|Morphine Extended release (60 mg) + GEn placebo
62178970|NCT01476124|EXPERIMENTAL|Regimen C|Morphine Extended release (60mg) + GEn 600 mg
62178971|NCT05557149|SHAM_COMPARATOR|Neutral VR|Ten minutes virtual reality exposure to neutral stimuli (e.g. neutral picture frames)
62178972|NCT05557149|EXPERIMENTAL|Cocaine VR|Ten minutes virtual reality exposure to cocaine use-related stimuli (i.e. peers using cocaine, cocaine paraphernalia, cocaine use preparing, cocaine use, etc.)
62178973|NCT05557149|OTHER|Relaxation|Ten minutes respiratory relaxation (eyes closed and sitted on a chair)
62178974|NCT03834155|EXPERIMENTAL|Hospital-based CR + Mobile Application|Traditional hospital-based cardiac rehabilitation with mobile application.
62562879|NCT01129297||BMI ≥ 35 kg/m2 with intolerance glucose|BMI (Body Mass Index) ≥ 35 kg/m2 with intolerance glucose defined by a fasting blood glucose\> 6 mmol/L and \<7 mmol/l and / or\> 7.8 mmol/l and \<11.1 mmol/l , 120 minutes after ingestion of glucose (oral glucose tolerance test)
62562880|NCT01129297||BMI ≥ 35 kg/m2 without diabetes|BMI (Body Mass Index)≥ 35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
62562881|NCT01129297||BMI <27 kg/m2 without diabetes|BMI (Body Mass Index) \<27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
62178975|NCT03834155|EXPERIMENTAL|Choice CR + Mobile Application|Choice of hospital or home-based cardiac rehabilitation with mobile application.
62562882|NCT01129297||27 < BMI < 35 kg/m2 without diabetes|BMI (Body Mass Index) \<27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
62178976|NCT03834155|EXPERIMENTAL|Hospital-based CR + Mobile Application + Nudge|Hospital-based cardiac rehabilitation with mobile application and nudges.
62178977|NCT03834155|EXPERIMENTAL|Choice CR + Mobile Application + Nudges|Choice of Hospital or home-based cardiac rehabilitation with mobile application and nudges.
62771295|NCT05999110|NO_INTERVENTION|Control Group|This group receive no exercise intervention. The group receives equally as the exercise group, a behavioral change session with a psychologist and nutritional advice session with a nutritionist.
62771296|NCT05938036|EXPERIMENTAL|Part A : ALT-100 mAB (Dose Escalation)|"90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.~Part A will assess 2 doses of ALT-100 mAb in sequentially enrolled cohorts of up to 9 participants in each cohort. (Randomised, Double-blind) Drug: ALT-100 mAb Dosage Form: Sterile liquid, pH 5.5, Dosage: 0.4 mg/kg (Cohort 1a) and 1.0 mg/kg (Cohort 2a) Dosage Form \& Route of Admin: Solution for IV Infusion"
62771297|NCT05938036|PLACEBO_COMPARATOR|Part A Placebo|Part A participants with acute respiratory distress syndrome (ARDS) (Randomised, Double-blind) Dosage Form \& Route of Admin: Normal Saline Solution for IV Infusion
62771298|NCT05938036|EXPERIMENTAL|Part B (Dose Expansion) ALT-100 mAb|Approximately 9 participants in each cohort in Part A, additional participants (up to 36 per dose cohort) may be enrolled into 2 dose expansion cohorts, the dose of which will be determined by the SRC. Drug: AT-02 Dosage: Will be decided by the SCR Route of Admin: Solution for IV Infusion
62771299|NCT02006069|EXPERIMENTAL|MPP ON|MPP ON: feature is enabled
62771300|NCT02006069|NO_INTERVENTION|MPP OFF|MPP OFF: feature not enabled
62771301|NCT04752345|ACTIVE_COMPARATOR|Control group|Pharmacoinvasive strategy, fibrinolysis combined with rescue PCI (in case of failed fibrinolysis) or routine early invasive strategy (in case of successful fibrinolysis)
62771302|NCT04752345|EXPERIMENTAL|Experimental group|Reduced-dose fibrinolysis combined with immediate invasive therapy
62771303|NCT00921453||Intervention 1|Participants using the prototype to receive expert system guided tailored internet information about the type of headache of a family member who provided anamnesis data for a common kind of headache.
62771304|NCT00921453||Control 1|Participants using search engines and portals to gather internet information about the type of headache of a family member who provided anamnesis data for a common kind of headache.
62771305|NCT00921453||Intervention 2|Participants using the prototype to receive expert system guided tailored internet information about the type of headache of a family member who provided anamnesis data for a less common kind of headache.
62562883|NCT02069015|EXPERIMENTAL|Enhanced discharge|Patient education about hypertension delivered through a touch-screen kiosk at 4 time points in addition to standard discharge.
62562884|NCT02069015|NO_INTERVENTION|Standard discharge|Standard discharge is patient instruction, instructions for follow-up to primary care and medication/prescription
62562885|NCT04368546||Patients|Metastatic cell carcinoma patients before sunitinib treatment, after 4 week on, after 2 week off and finally again 4 week on medication.
62562886|NCT04368546||Healthy controls|Age-matched subjects without known disease.
62562887|NCT06357897|EXPERIMENTAL|PEG-Chula|PEG-Chula is developed from local PEG 4000 used at King Chulalongkorn Memorial Hospital (KCMH) with the addition of sweetener and flavours and prepared into sachets labelled A, B, C and D.
62771306|NCT00921453||Control 2|Participants using search engines and portals to gather internet information about the type of headache of a family member who provided anamnesis data for a less common kind of headache.
62771307|NCT02504931|EXPERIMENTAL|Sertraline|"Subjects will receive a fixed dose of 150 mg sertraline per day. Sertraline dose will be gradually increased by giving sertraline subjects capsules filled with 50 mg for the first three days and then capsules filled with 100 mg for 4 days before beginning the 150 mg per day in the second week. After completing the study Visit 12, subjects will be given an additional two week supply of medicine to gradually taper down so as to minimize any withdrawal discomfort.~Subjects in the Sertraline arm also will receive COPE therapy (Concurrent Treatment with Prolonged Exposure)which involves 12 sessions of manualized cognitive and behavioral therapy including exposure therapy for PTSD."
62771308|NCT02504931|PLACEBO_COMPARATOR|Placebo|"Matching placebo capsules will be filled with corn starch only on the same schedule as the Sertraline.~Subjects in the Placebo arm also will receive COPE therapy (Concurrent Treatment with Prolonged Exposure)which involves 12 sessions of manualized cognitive and behavioral therapy including exposure therapy for PTSD."
62771309|NCT05039658|EXPERIMENTAL|Single agent treatment arm with IBI110|IBI110 administered at RP2D
62178978|NCT05192564|EXPERIMENTAL|EX Group|Conventional rehabilitation treatment plus exercise intervention under the supervision of exercise specialists two non-consecutive days per week for eight weeks.
62562888|NCT06357897|OTHER|Standard PEG|Standard PEG (Forlax) is prepared into the sachets labelled A, B, C and D with similar packaging and appearance.
62562889|NCT04086056||Children with craniosynostosis|Children with craniosynostosis who will be operated in prone position.
62562890|NCT02832687|ACTIVE_COMPARATOR|normal saline|Patients will receive 100 milliliters of normal saline with the first dose given preoperatively in the holding area followed by re-dosing every four hours from that point up to a maximum of 4 doses in 24 hours. Blinded medication will be prepared by research pharmacist.
62562891|NCT02832687|EXPERIMENTAL|acetaminophen|Patients 50kg or more will receive either 1000mg IV acetaminophen with the first dose given preoperatively in the holding area followed by re-dosing every four hours from that point up to a maximum of 4 doses or 4000mg in 24 hours. Patients \<50 kg will receive 12.5mg/kg to a maximum of 75 mg /per kg/per day as per the label dose with repeat dosing Q4 hours. Blinded medication will be prepared by research pharmacist in 100mL of normal saline
62771310|NCT05039658|EXPERIMENTAL|Combination treatment arm with IBI10 and sintilimab|IBI110 and sintilimab administered at RP2D
62771311|NCT05025696|EXPERIMENTAL|Intervention|Blacksoap(R) applied whole body twice daily
62771312|NCT05025696|PLACEBO_COMPARATOR|Control|Johnson and Johnsons Baby Soap applied whole body twice daily
62562892|NCT03224728||2 different Intraocular lenses|2 different intraocular lenses were compared
62562893|NCT05418933|EXPERIMENTAL|Intervention group|Family workshops with 5 courses, with 6-7 families in one course, 2 hours per session, one time per week, for a total of 6 weeks.
62562894|NCT04833751||Anesthesia for cardiovascular surgery or procedure|Patients undergoing anesthesia in an operating room or hybrid room for cardiovascular surgery or procedure.
62562895|NCT03473925|EXPERIMENTAL|Navarixin 30 mg + Pembrolizumab 200 mg|Participants received 30 mg navarixin via oral capsules once daily, plus 200 mg pembrolizumab via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years
62562896|NCT03473925|EXPERIMENTAL|Navarixin 100 mg + Pembrolizumab 200 mg|Participants received 100 mg navarixin via oral capsules once daily, plus 200 mg pembrolizumab via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
62562897|NCT00554385|EXPERIMENTAL|1|
62771313|NCT03631420|EXPERIMENTAL|UMC119-01|UMC119-01 is ex vivo cultured human umbilical cord tissue-derived mensenchymal stem cells product
62771314|NCT01013363|NO_INTERVENTION|No music|Participants will not use the digital music player during their procedure.
62771315|NCT01013363|EXPERIMENTAL|Music|Participants will use the digital music player during their procedure.
62771316|NCT05738720|EXPERIMENTAL|Homespirometer Group (HsGr)|"Patients will be taught to use the homespirometer device, download the phone application, use the application, use the video call feature, measure saturation and heart rate with the same device, and daily symptom scoring in the device's system.~Patients will be asked to perform pulmonary function tests with a spirometer device, measure saturation and heart rate, score symptoms, and write down any problems related to their illness twice a week on days without exercise. The evaluations made after 2 tests. They will be sent to the researchers via the device.andthe video containing the exercises after the first training will be sent to them via whatsapp for the exercise compliance of the patients. In the first exercise week, the first 2 exercise sessions will be done one-on-one via video call, and the exercises will be done correctly."
62178979|NCT05192564|ACTIVE_COMPARATOR|AC Group - ATTENTION CONTROL GROUP|Conventional rehabilitation treatment at home with unsupervised exercise intervention
62562898|NCT05178615|EXPERIMENTAL|Education group|Preoperative education
62562899|NCT05178615|NO_INTERVENTION|control|Traditionally care
62562900|NCT05972993|EXPERIMENTAL|Part A, Group 1: mRNA CR-04 10 µg +Placebo|mRNA 10 micrograms (µg) or placebo administered on day 1.
62562901|NCT05972993|EXPERIMENTAL|Part A, Group 2: mRNA CR-04 30 µg +Placebo|mRNA 30µg or placebo administered on day 1.
62771317|NCT05738720|ACTIVE_COMPARATOR|Control Group (CGr)|The same exercise training will be taught to the study group and the same exercise video will be sent to the patients via WhatsApp. The first 2 exercise sessions will be done one-on-one via video call (via whatsapp), and the exercises will be done correctly. Patients will be given an exercise diary and asked to take notes on their weekly exercises.
62771318|NCT04788862|EXPERIMENTAL|Group 1: High prior P. falciparum exposure|6 participants with high previous malaria exposure will be infected via IV administration of Plasmodium falciparum-infected human erythrocytes (planned dose of 1000 iRBCs) of the chloroquine-susceptible 3D7 strain.
62771319|NCT04788862|EXPERIMENTAL|Group 2: Low prior P. falciparum exposure|6 participants with no or low previous malaria exposure will be infected via IV administration of Plasmodium falciparum-infected human erythrocytes (planned dose of 1000 iRBCs) of the chloroquine-susceptible 3D7 strain.
62771320|NCT01030874|NO_INTERVENTION|Usual Rehabilitation Care|Usual rehab care
62771321|NCT01030874|EXPERIMENTAL|Experimental Treatment/Medication Review|Treatment for, and prevention of, orthostatic hypotension
62771322|NCT01927055|ACTIVE_COMPARATOR|Droxidopa|Droxidopa 100 mg, 200 mg, 300 mg
62771323|NCT01927055|PLACEBO_COMPARATOR|Placebo|Placebo
62771324|NCT06429189|EXPERIMENTAL|Home-based combined exercise|"Exercise intervention will be led by qualified exercise professionals online via Zoom. It will consist of two weekly 60-minute online exercise group sessions: a 5-minute warm-up, 30-minute resistance training, and a 20-minute aerobic exercise component, finishing with a 5-minute cooldown.~The warm-up will consist of mobility and activation movements. The resistance training component will consist of 9 exercises involving large muscle groups, performed with body weight or free weights. The exercises will be completed in 2-3 sets of 10-15 repetitions. The aerobic component will consist of low-impact dance exercises that move large muscle groups to increase heart rate. The cooldown will consist of breathing exercises and light stretches."
62771325|NCT06429189|PLACEBO_COMPARATOR|Active control group|The control group will receive weekly 30-minute supervised sessions with breathing, stretching, relaxation exercises, and meditation.
62771326|NCT02955459|EXPERIMENTAL|VNRX-5133|IV infusion
62771327|NCT02955459|PLACEBO_COMPARATOR|Placebo|IV infusion
62771328|NCT05454826|EXPERIMENTAL|Cold application group|applied relaxation exercise+ cold pack
62771329|NCT05454826|EXPERIMENTAL|control group|applied relaxation exercise
62771330|NCT00675896|EXPERIMENTAL|1|Quetiapine Fumarate Sustained Release(Seroquel SR)50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator, using patient tolerance and response as guidelines over the duration of the trial.
62771331|NCT00675896|PLACEBO_COMPARATOR|2|Placebo
62562902|NCT05972993|EXPERIMENTAL|Part A, Group 3: mRNA CR-04 100 µg +Placebo|mRNA 100µg or placebo administered on day 1.
62562903|NCT05972993|EXPERIMENTAL|Part B: mRNA CR-04 3 µg|mRNA 3 µg administered on day 1.
62562904|NCT05972993|EXPERIMENTAL|Part B: mRNA CR-04 10 µg|mRNA 10µg administered on day 1.
62771332|NCT03181295|NO_INTERVENTION|Usual care|Standard periodic health review (PHR) appointment. \[As patients will get a survey about PA levels prior to their PHR, this may affect their likelihood of addressing PA during their PHR.\]
62562905|NCT05972993|PLACEBO_COMPARATOR|Part B: Placebo|Placebo administered on day 1.
62562906|NCT01320995|EXPERIMENTAL|Experimental arm|In this arm, perineal ultrasound is used directly after delivery in order to hypothetically better detect anal lesions.
62562907|NCT01320995|NO_INTERVENTION|Standard arm|No perineal ultrasound immediately after delivery.
62771333|NCT03181295|EXPERIMENTAL|Usual care plus intervention|Standard PHR appointment plus personalized exercise Rx and resources
62771334|NCT06448819|EXPERIMENTAL|CDED group|Crohn's disease exclusion diet Partecipants received Crohn's disease exclusion diet or Mediterranean diet for 24 weeks
62178980|NCT04387903||Reoperation group|The group of patients who underwent pancreaticduodenectomy for management of periampullary tumors and required surgical reintervention afterwards for management of procedure-related complications as pancreatic fistula, bleeding, abdominal collection, biliary fistula, gastric fistula.
62178981|NCT04387903||No reoperation group|The group of patients who underwent pancreaticoduodenectomy for management of periampullary tumors and did not require surgical reintervention.
62178982|NCT03019198|EXPERIMENTAL|TXA|Performed an intravenous bolus administration of 15 mg/kg of TXA to the volunteers after the end of the anesthesia and 15 minutes prior to skin incision.
62562908|NCT04574713|EXPERIMENTAL|Candesartan 8 mg|
62562909|NCT04574713|EXPERIMENTAL|Candesartan 16 mg|
62562910|NCT04574713|PLACEBO_COMPARATOR|Control group|
62562911|NCT00861640|EXPERIMENTAL|Intravenous Omeprazole|100 cases of Intravenous Omeprazole
62562912|NCT00861640|EXPERIMENTAL|Oral Rabeprazole|100 cases of oral rabeprazole
62562913|NCT01991743|ACTIVE_COMPARATOR|Drug:Group 2.5|Administration of 2.5 mg bupivacaine
62562914|NCT01991743|ACTIVE_COMPARATOR|Group 5|Administration of 5 mg bupivacaine.
62562915|NCT01991743|ACTIVE_COMPARATOR|Group 7.5|Administration of 7.5mg bupivacaine.
62771335|NCT06448819|NO_INTERVENTION|Mediterranean group|
62562916|NCT01991743|ACTIVE_COMPARATOR|Group 10|Administration of 10 mg bupivacaine.
62562917|NCT01226082|EXPERIMENTAL|Transcranial Direct Current Stimulation|
62562918|NCT05173155|EXPERIMENTAL|Direct anterior approach for hemiarthroplasty|Patients in this arm will receive a hemiarthroplasty using the direct anterior approach (DAA)
62562919|NCT05173155|EXPERIMENTAL|Lateral approach for hemiarthroplasty|Patients in this arm will receive a hemiarthroplasty using the lateral approach
62771336|NCT02981966|ACTIVE_COMPARATOR|T2DM individuals on Dapagliflozin|Individuals with type 2 diabetes mellitus - dapagliflozin
62771337|NCT02981966|PLACEBO_COMPARATOR|T2DM individuals on Placebo|Individuals with type 2 diabetes mellitus on placebo
62771338|NCT02981966|ACTIVE_COMPARATOR|Normal Glucose Tolerance (NGT) on Dapagliflozin|Individuals with normal glucose tolerance - dapagliflozin
62771339|NCT02981966|PLACEBO_COMPARATOR|Normal Glucose Tolerance (NGT) Placebo|Individuals with normal glucose tolerance - on placebo
62771340|NCT05726890|EXPERIMENTAL|bedtime checking|"The intervention is based on the principles of graduated extinction, defined as an effective and recommended therapy in the treatment of bedtime problems and night-wakings by the AASM. The basic guidelines for this intervention are: (1) When the infant shows tired signs, he/she should be put to bed awake; (2) parents should minimize their involvement after putting the infant to bed; (3) if the child protests/cries, the parent should check the infant's crib every few minutes (e.g., 5 minutes), briefly comfort the infant without taking him/her out of the crib, and help the infant resume a sleeping position/find sleep aids (e.g., pacifier); (4) disengage and leave the crib until the next visit, (5) In order to increase consistency, the same parent should implement the intervention.~In the bedtime checking arm, parents will be instructed to implement the changes only at bedtime and will be asked to continue soothing their infant at night, as they normally do"
62771341|NCT05726890|ACTIVE_COMPARATOR|standard checking|"Same as for bedtime checking at bedtime, but in the standard checking arm, parents apply the intervention guidelines also when the infant wakes up during the night."
62771342|NCT06337591||patients with suspected primary bladder tumour (TV) at cystoscopy|
62771343|NCT06543927||group A|hemodialysis dependant
62771344|NCT06543927||group B|hemodialysis non dependant
62771345|NCT03168360|EXPERIMENTAL|Intensive group|cognitive rehabilitation therapy for 1 hour by cognitive therapist on every working day for 4 weeks
62771346|NCT03168360|ACTIVE_COMPARATOR|Conventional group|cognitive rehabilitation therapy for 30 minutes by cognitive therapist on every working day for 4 weeks
62771347|NCT05058846||Group I: No strong family history of pancreatic cancer|Participants in Group 1 consist of BRCA, ATM and PALB2 mutation carriers without a strong family history of pancreatic cancer and can choose to undergo annual magnetic resonance imaging (MRI)/Magnetic resonance cholangiopancreatography (MRCP) and EUS screening, or they may opt out of annual MRI screening. Participants also have the opportunity to co-enroll in the University of California, San Francisco (UCSF) BRCA Center Biorepository for biospecimen/biomarker collection and will complete surveys, including the optional eGene questionnaire, which involves co-enrollment in the eGene Study.
62771348|NCT05058846||Group II: Strong family history of pancreatic cancer|Participants in Group 2 consist of BRCA, ATM and PALB2 mutation carriers with a strong family history of pancreatic cancer. Participants may undergo annual MRI/MRCP screening and may also elect to get an endoscopic ultrasound (EUS) every other year. Participants also have the opportunity to co-enroll in the UCSF BRCA Center Biorepository for biospecimen/biomarker collection and will complete surveys, including the optional eGene questionnaire, which involves co-enrollment in the eGene Study.
62771349|NCT02365571|EXPERIMENTAL|LY3154207 (Part A)|LY3154207 administered in ascending doses once orally in two of three study periods
62771350|NCT02365571|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo matching LY3154207 administered once orally in one of three study periods.
62771351|NCT02365571|EXPERIMENTAL|LY3154207 (Part B)|LY3154207 administered once orally.
62771352|NCT02365571|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo matching LY3154207 administered once orally.
62771353|NCT02365571|EXPERIMENTAL|LY3154207 (Part C)|LY3154207 administered once orally on Day 1
62771354|NCT02365571|EXPERIMENTAL|LY3154207 + Itraconazole (Part C)|Itraconazole administered orally (twice daily on Day 3 and then once daily to Day 12). LY3154207 co-administered once orally, on Day 9. Timing and duration of itraconazole dosing may be adjusted based on data from Part A.
62771355|NCT02499042|EXPERIMENTAL|Oxygen reduction|post-ROSC oxygen reduced to 2L per minute then delivered to maintain oxygen saturation 90-94% to hospital
62771356|NCT02499042|ACTIVE_COMPARATOR|Standard Care|post-ROSC oxygen maintained ≥10L per minute to hospital
62771357|NCT00440310|EXPERIMENTAL|Litx + Chemotherapy|
62771358|NCT00440310|ACTIVE_COMPARATOR|Chemotherapy alone|
62391134|NCT03182673|EXPERIMENTAL|SHR7390, SHR-1210 and SHR3162|"Total 60-100 subjects with advanced solid tumors~In the two-drug combination therapy,subjects were received single oral doses of SHR7390，then accepted two drug combination therapy, SHR7390 is administered multiple daily oral doses of SHR7390 for 28 days for a treatment cycle. At the same time, SHR-1210 was given intravenously per 2 weeks at the 200mg fixed dose.~In the second study part, subjects accepted three drug combination therapy, SHR7390 is administered orally for 21 days and discontinued for 7 days in a 28-day treatment cycle,SHR3162 was administered orally twice a day for 28 days at a fixed dose of 100 mg. At the same time, SHR-1210 was given intravenously per 2 weeks at the 200mg fixed dose"
62391135|NCT01294319|EXPERIMENTAL|Sedentary young adults, SMCP|Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone
62391136|NCT01294319|EXPERIMENTAL|Endurance-trained young athletes, SMCP|Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone
62391137|NCT01294319|EXPERIMENTAL|Sedentary young adults, MSPC|Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone
62562920|NCT04122963|ACTIVE_COMPARATOR|High power group|The experimental group will receive AF ablation with 45 Watt and stricter stability criteria (3 mm for 3 seconds).
62178983|NCT03019198|PLACEBO_COMPARATOR|Control|This group underwent the same procedures of the TXA group, excepting the preoperative administration of the medication.
62771359|NCT04533230|EXPERIMENTAL|Educational intervention with prescription feedback|The manager and physicians at each intervention center will participate in a brief educational intervention about benzodiazepines and benzodiazepine-like hypnotics and receive 12 months of targeted feedback on prescription of these drugs. The education will cover national and regional treatment guidelines for anxiety, depression, and insomnia, which include guidelines on prescription of benzodiazepines and benzodiazepine-like hypnotics.
62771360|NCT04533230|ACTIVE_COMPARATOR|Information on guidelines|The manager and physicians at each center in the active control group will receive written information on national and regional treatment guidelines for anxiety, depression, and insomnia, which include guidelines on prescription of benzodiazepines and benzodiazepine-like hypnotics. These centers will not receive the onsite educational intervention or 12 months of targeted prescription feedback.
62771361|NCT04533230|NO_INTERVENTION|No active intervention: standard care|The manager and physicians at each primary health care center in the passive control group will receive no active intervention. The passive control group will consist of primary health care centers that are not actively participating in the study. Data will be gathered from regional registers and databases. Thus, there will be no need to contact or communicate directly with the centers. This arm will be used only if the General Data Protection Regulation continues to allow access to regional registers and databases in primary health care.
62771362|NCT03082352|EXPERIMENTAL|BF-Metoprolol Tablet 100mg|During the study session, healthy subjects will be administered a single dose of BF-Metoprolol Tablet 100mg after an overnight fast of approximately 10 hours
62771363|NCT03082352|ACTIVE_COMPARATOR|Betaloc Tablet 100mg|During the study session, healthy subjects will be administered a single dose of Betaloc Tablet 100mg after an overnight fast of approximately 10 hours
62771364|NCT03530670|ACTIVE_COMPARATOR|oral midazolam (demizolam)|"To prevent preoperative anxiety patient premedicated by 0.5 mg/kg oral midazolam.~In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale"
62771365|NCT03530670|ACTIVE_COMPARATOR|http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.|To prevent preoperative anxiety by watching a short movie ( at http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.) In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale
62771366|NCT03530670|ACTIVE_COMPARATOR|playing smartphone game|To prevent preoperative anxiety by playing smartphone game ( angry birds, subway surfers, snail Bob) In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale
62771367|NCT05119140|EXPERIMENTAL|Mesalamine and Hydroxychloroquine|All participants will be on Mesalamine and Hydroxychloroquine
62771368|NCT05192213|EXPERIMENTAL|Intervention|"1,5 g of vitamin C every 6 hours + 200 mg of thiamine every 12 hours + 50 mg of hydrocortisone every 6 hours~For 7 days or until patient's discharge/death"
62771369|NCT05192213|PLACEBO_COMPARATOR|Control|"Placebo 1 for vitamin C every 6 hours + Placebo 2 for thiamine every 12 hours + 50 mg of hydrocortisone every 6 hours~For 7 days or until patient's discharge/death"
62771370|NCT02744417|EXPERIMENTAL|Smoking cessation therapy|Non-surgical periodontal therapy and concurrent smoking cessation therapy, with Smoking cessation counseling, Nicotine replacement therapy, use of bupropion hydrochloride and varenicline
62771371|NCT00619489|EXPERIMENTAL|Vedolizumab 2 mg/kg|Participants received vedolizumab, 2 mg/kg, intravenously (IV), on Days 1, 15 and 43, and thereafter once every 8 weeks for up to 78 weeks.
62178984|NCT03836742||HF RCA|Cardiovascular surgery patients treated with hemofiltration with regional citrate anticoagulation
62178985|NCT03836170|EXPERIMENTAL|Laparoscopic cholecystectomy|A laparoscopic cholecystectomy was performed to remove the gallbladder
62771372|NCT00619489|EXPERIMENTAL|Vedolizumab 6 mg/kg|Participants received vedolizumab, 6 mg/kg, IV, on Days 1, 15 and 43, and thereafter once every 8 weeks for up to 78 weeks.
62771373|NCT02904590||IBD patients|Incidental patients with IBD controlled (including Crohn's disease, Ulcerative colitis and unclassified colitis)
62771374|NCT02782767|ACTIVE_COMPARATOR|Epidural catheter infusion|epidural catheter in the thoracic vertebra level to provide local anesthetic infusion
62771375|NCT02782767|EXPERIMENTAL|Wound catheter infusion|A multiorificed wound infusion catheter kept within the incision site to provide continuous local anesthetic infusion
62771376|NCT01300455|EXPERIMENTAL|Suvorexant (40 mg)|In Period 1, suvorexant (40 mg tablets) administered orally once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. Period 2 consists of placebo administered once daily for 4 consecutive days in the evening.
62178986|NCT05514197|EXPERIMENTAL|Vitamin C arm|Intravenous loading of 5g ascorbic acid before incision of wound
62771377|NCT01300455|PLACEBO_COMPARATOR|Placebo|In Period 1, placebo administered orally once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. In Period 2, suvorexant (40 mg tablets) administered once daily for 4 consecutive days in the evening.
62771378|NCT00843544|EXPERIMENTAL|Integrative Medicine|
62771379|NCT00843544|NO_INTERVENTION|Control|
62771380|NCT02062203|EXPERIMENTAL|AKB-6548 (therapeutic dose)|
62771381|NCT02062203|EXPERIMENTAL|AKB-6548 (supratherapeutic dose)|
62771382|NCT02062203|PLACEBO_COMPARATOR|Placebo|
62771383|NCT02062203|ACTIVE_COMPARATOR|Moxifloxacin|
62771384|NCT02878044|EXPERIMENTAL|Implementation Arm|
62771385|NCT04602923|EXPERIMENTAL|XEN Gel Stent implantation|Participants suffering from glaucoma who are candidates for XEN Gel Stent implantation
62771386|NCT04602923|EXPERIMENTAL|Trabeculectomy|Participants suffering from glaucoma who are candidates for trabeculectomy
62178987|NCT05514197|PLACEBO_COMPARATOR|Control arm|Intravenous loading of the same volume Normal saline as experimental arm
62771387|NCT04602923|EXPERIMENTAL|GDD implantation|Participants suffering from glaucoma who are candidates for GDD implantation (BGI or AGV)
62771388|NCT00042666|EXPERIMENTAL|LY317615|500 milligrams (mg), oral, daily (QD), up to six (6) 28-day cycles
62771389|NCT05164146|ACTIVE_COMPARATOR|propofol group|During the induction, propofol was controlled according to sedline (Psi target 40)
62771390|NCT05164146|EXPERIMENTAL|remimazolam group|During induction, remimazolam dose was controlled according to sedline (Psi target 40)
62771391|NCT04080323|EXPERIMENTAL|dinoprostone 3 mg|60 minutes before the surgery 3 mg of dinoprostone inserted vaginally
62178988|NCT02762292|EXPERIMENTAL|Patients|
62178989|NCT06480578|EXPERIMENTAL|ISS-SBDOH arm|Ingestion Sensor System (ISS) - Social and Behavioral Determinants of Health (SBDOH) arm
62178990|NCT06480578|NO_INTERVENTION|Usual Care (UC) arm|"Usual Care (UC) arm~UC is chosen as the control condition because it meets ethical and moral requirements to attempt treatment."
62178991|NCT05964751||patinets with lupus nephritis|patients diagnosed as lupus nehpritis
62178992|NCT05964751||pathents without lupus nephritis|sle pathients not diagnosed as lupus nephritis
62178993|NCT05964751||controls|controls will be matched for sex, age, and level of schooling withot history of connective tissue disorders, systemic active disease and renal history
62178994|NCT05338541|EXPERIMENTAL|Tucidinostat and etoposide|
62771392|NCT04080323|PLACEBO_COMPARATOR|placebo|60 minutes before the surgery 1 tablet of placebo inserted vaginally
62771393|NCT02566733|EXPERIMENTAL|Remiva|This experimental group will use a generic drug of remifentanil, Remiva™ from Hana Pharmaceutical company.
62771394|NCT02566733|ACTIVE_COMPARATOR|Ultiva|This arm group will use a brand-named drug of remifentanil, Ultiva™ from GlaxoSmithKline company.
62771395|NCT00165542||All patients|A PROTEIN levels in all patients and with all tumor types.
62178995|NCT03644615|EXPERIMENTAL|Mindfluness and usual care|
62178996|NCT03644615|OTHER|Usual Care|
62178997|NCT05377645|EXPERIMENTAL|Cervical mobilization|Mobilization Cyriax's cervical mobilization technique and traditional physiotherapy were applied to the intervention group. For Cyriax Mobilization technique, the patient was asked to lying supine position. Cervical ROM applied all directions. Also AP and ML glides applied to the cervical region. The treatment was done 3 times a week for 2 weeks. Also traditional physiotherapy techniques were applied to the experimental group. Traditional physiotherapy techniques were applied to the intervention group. Conventional TENS type was used. Continuous ultrasound type was applied with full contact technique.. And; isometric cervical strengthening exercises applied. The treatment was done 3 times a week for 2 weeks.
62178998|NCT05377645|ACTIVE_COMPARATOR|Traditional physiotherapy|Traditional physiotherapy techniques were applied to the intervention group. Conventional TENS type was used. Current transition time was set as 50-100 µs. TENS application is performed at a frequency of 100 Hertz for 20 minutes in amplitude that does not cause muscle contraction in the patient and creates a feeling of numbness and tingling. Continuous ultrasound type was applied with full contact technique. Ultrasound treatment was applied over the suboccipital area with circular movements towards the proximal and distal at a speed of 1-2.5 cm per second, at a dose of 1 W / cm2, for 6 minutes, with a frequency of 3 MHz. And; isometric cervical strengthening exercises applied. The treatment was done 3 times a week for 2 weeks.
62771396|NCT00915655|EXPERIMENTAL|DRV/rtv (darunavir/ritonavir)|Patients will receive darunavir tablets 2 x 400 mg in combination with ritonavir capsule 100 mg once daily for 48 weeks along with 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) ie, either zidovudine/lamivudine or abacavir/lamivudine
62771397|NCT01088854|EXPERIMENTAL|positive airway pressure|
62771398|NCT01755650|EXPERIMENTAL|D-18F FPM|
62771399|NCT01755650|EXPERIMENTAL|L-18F FPM|
62178999|NCT02483598|EXPERIMENTAL|Buspirone|Buspirone alone
62179000|NCT02483598|ACTIVE_COMPARATOR|Buspirone plus grapefruit juice|Buspirone plus grapefruit juice
62179001|NCT05998226|NO_INTERVENTION|Standard care (control group)|The clinicians from the control arm do not participate in VAT meetings. The antibiotic prescriptions prescribed by clinicians in the control group are extracted from the prescription system after the study period. Two researchers independently extract the data from patient files, including any culture results, and assess the antibiotic use based on the algorithm from the current guidelines that are used in NHs.
62391138|NCT01294319|EXPERIMENTAL|Endurance-trained young athletes, MSPC|Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone
62179002|NCT05998226|EXPERIMENTAL|Virtual Antimicrobial stewardship Team (VAT) (intervention group)|The VAT consists at least of a medical microbiologist and a clinician from the NH. Depending on the NH organization concerned and cooperation agreements, a pharmacist will or will not be involved. They conduct weekly consultations during 9 months to evaluate the antibiotic prescriptions of the clinician based on algorithms from current guidelines in use in the NH. This is an evaluation of standard care .
62391139|NCT01294319|EXPERIMENTAL|Sedentary young adults, CPSM|Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone
62562921|NCT04122963|ACTIVE_COMPARATOR|Standard group|The control group will receive AF ablation according to the standard CLOSE-protocol (35 Watt and stability criteria of 3 mm for 8 seconds)
62771400|NCT05781646|EXPERIMENTAL|Xpert|Centrifuged CSF sent for Xpert MTB/RIF
62771401|NCT03028987|OTHER|LAIV randomized|Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® .
62771402|NCT03028987|OTHER|IIV4 randomized|Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone®
62771403|NCT05792566|EXPERIMENTAL|Real life usability testing|"B) Real Life Usability Testing. We will conduct a real life usability test in a sample of 6 pediatric cancer survivors. EX@HOME: Patients will perform an individualized aerobic and resistance exercise intervention, choosing from a list of PA, progressing from light to moderate-to-vigorous intensity totaling 30-45 min/d, 4-5 weekly/wk. for 4 weeks. The social-cognitive-theory-based mobile app will support the exercise intervention. One-on-one messaging chats with a PA coach through the mobile app will facilitate exercise goal establishment and attainment."
62179003|NCT05676125||chronic ankle instabilty group|females with previous history of ankle sprain
62562922|NCT04918017|EXPERIMENTAL|Treatment based on subtypes: Epigastric Pain Syndrome (EPS)|EPS: treat with esomeprazole 40mg OD (proton pump inhibitor)
62562923|NCT04918017|EXPERIMENTAL|Treatment based on subtypes: Post Prandial Distress Syndrome (PDS)|PDS: treat with itopride 50mg TDS (prokinetic)
62562924|NCT04918017|EXPERIMENTAL|Treatment based on subtypes: Overlapped EPS/ PDS|Overlapped EPS/PDS: treat with itopride 50mg TDS first and add esomeprazole 40mg OD (if partially responded) or change to esomeprazole 40mg OD (if not responded)
62562925|NCT04918017|ACTIVE_COMPARATOR|Treatment with Proton Pump Inhibitor regardless of subtype|Treat with esomeprazole 40mg OD (proton pump inhibitor) regardless of subtype of functional dyspepsia
62562926|NCT05653557|EXPERIMENTAL|Shen Que Moxibustion group|
62562927|NCT05653557|NO_INTERVENTION|Control group|
62562928|NCT02279654||Lenalidomide Population|Patients with transfusion-dependent, low- or intermediate (int)-1risk MDS and isolated del (5q) who receive at least 1 dose of lenalidomide after 15th June 2007 and have been followed up for on the registry for 3 years or until death/consent withdrawal
62562929|NCT02279654||Background Population|All MDS patients who have been diagnosed on 15th June 2007 or later, have never been exposed to lenalidomide and have been followed up on the registry for 3 years or until death/consent withdrawal
62562930|NCT05832268||Sphincter damage|Women who suffered an injury to anal sphincter after a vaginal delivery and had a subsequent delivery after this injury
62562931|NCT05832268||Controls|Women who have had a at least two vaginal deliveries without suffering an injury to the anal sphincter
62562932|NCT04253418|EXPERIMENTAL|Nano-Pulse Stimulation (NPS) Treated Lesion|Nano-Pulse Stimulation of target lesion.
62562933|NCT06172270||Benign breast tumors|Performing contrast-enhanced ultrasound on benign breast tumors and analyzing the video images
62562934|NCT06172270||Malignant breast tumors|Performing contrast-enhanced ultrasound on malignant breast tumors and analyzing the video images.
62562935|NCT05220852|EXPERIMENTAL|Dry needling and exercise|Subjects in this group will undergo one session of dry needling in their upper trapezius muscles to address any overactive trigger points, and they will subsequently continue with neck exercises for a minimum of two weeks, three times per week.
62562936|NCT05220852|ACTIVE_COMPARATOR|Exercise|subjects in this group will have neck exercise only for 2 weeks minimum 3 times a week.
62179004|NCT05676125||control group|healthy feamles
62562937|NCT02291510|EXPERIMENTAL|500 mg Met DR BID|Two doses of 500 mg metformin delayed-release
62562938|NCT02291510|EXPERIMENTAL|1000 mg Met DR BID|Two doses of 1000 mg metformin delayed-release
62562939|NCT02291510|ACTIVE_COMPARATOR|1000 mg Met IR BID|Two doses of 1000 mg metformin immediate-release
62562940|NCT02291510|ACTIVE_COMPARATOR|2000 mg Met XR QD|Single dose of 2000 mg metformin extended-release
62562941|NCT04533737|EXPERIMENTAL|Arm 1 (brodalumab + dummy 1)|"Participants receive:~* Brodalumab 210 mg (1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks.~* Dummy 1 (placebo 1.0 ml) at Weeks 0, 4, and then every 8 weeks."
62562942|NCT04533737|ACTIVE_COMPARATOR|Arm 2 (guselkumab + dummy 2)|"Participants receive:~* Guselkumab 100 mg (1.0 ml) at Weeks 0, 4, and then every 8 weeks.~* Dummy 2 (placebo 1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks."
62562943|NCT01998919|EXPERIMENTAL|Tarceva + gemcitabine/platinum|
62562944|NCT01998919|PLACEBO_COMPARATOR|Placebo + gemcitabine/platinum|
62562945|NCT03162250|EXPERIMENTAL|DSTA4637S low dose level + SOC|DSTA4637S low dose level intravenous (IV) infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
62562946|NCT03162250|EXPERIMENTAL|DSTA4637S intermediate dose level+ SOC|DSTA4637S intermediate dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
62179005|NCT04693845|ACTIVE_COMPARATOR|Treatment as Usual|Community Mental Health Center Next Day Appointment clinic
62179006|NCT04693845|EXPERIMENTAL|Experimental|Collaborative Assessment and Management of Suicidality (CAMS)
62179007|NCT05426447|EXPERIMENTAL|Reduced protein diet|"A 6-week eucaloric dietary intervention of reduced protein intake (\~1g protein/kg body mass). The diet will, hence, contain \~7E% protein, \~63E% carbohydrate, and \~29E% fat.~Participants are free-living and receive all food pre-packed from the study kitchen. The energy provision will be set to match energy balance."
62179008|NCT05426447|ACTIVE_COMPARATOR|Normal protein diet|"A 6-week eucaloric dietary intervention of normal protein intake (\~2g protein/kg body mass). The diet will, hence, contain \~16E% protein, \~53E% carbohydrate, and \~30E% fat.~Participants are free-living and receive all food pre-packed from the study kitchen. The energy provision will be set to match energy balance."
62179009|NCT06277518||observation group,|the risk factors of patients with malignant tumors of digestive system meeting the inclusion criteria were observed without special intervention
62562947|NCT03162250|EXPERIMENTAL|DSTA4637S high dose level+ SOC|DSTA4637S high dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
62562948|NCT03162250|PLACEBO_COMPARATOR|Placebo + SOC|Placebo matched to DSTA4637S IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
62562949|NCT03707223|EXPERIMENTAL|experimental|"The interfaces Program"
62562950|NCT03707223|ACTIVE_COMPARATOR|control group|supported employment using the individual placement and support (IPS) model
62562951|NCT03992365|EXPERIMENTAL|Quiklean®|Quiklean® (32 tablets)
62562952|NCT03992365|ACTIVE_COMPARATOR|GroKlean-Prep with Dulcolax®|2 sachets of Klean-Prep with 1 tablet of Dulcolax®
62562953|NCT01069198|EXPERIMENTAL|Intervention group|
62562954|NCT01069198|PLACEBO_COMPARATOR|Non-intervention group|Non-intervention group will receive placebo following the same schedule as intervention group.
62562955|NCT04370132||Group of patient with liver venous deprivation|Group of patient with liver venous deprivation
62562956|NCT04370132||Group of patient with portal embolization|Group of patient with portal embolization
62562957|NCT02629315|ACTIVE_COMPARATOR|10% neutral buffered formaldehyde|Specimens will be fixed for 24-48hours in 10% neutral buffered formaldehyde and then dissected for lymph nodes.
62562958|NCT02629315|EXPERIMENTAL|Carnoy's solution|Specimens will be fixed for 24-48hours in Carno'ys solution and then dissected for lymph nodes.
62771404|NCT04825067|EXPERIMENTAL|Respiratory Sensor measurements|The participant will receive 2 Respiratory Sensors and 1 gateway with wireless compatibility and a welcome packet with instructions for use, a reminder description of the study purpose and procedures, and research staff contact information. Research staff will contact participants to ensure appropriate setup of the Respiratory Sensor and training on proper use. Research staff will ask the subject to place the Respiratory Sensor on the top left-side of the chest. The Respiratory Sensor continuously collects and monitors respiratory data. The participant will be instructed to change each Respiratory Sensor after 24-48 hours. Subjects will be asked to charge each Respiratory Sensor once it is removed. Subjects will exit the study upon completion of the 90-day follow-up.
62179010|NCT03583411||acute coronary syndrome (ACS) patients|ACS subjects hospitalized in the Cardiology 1 - UTIC department of ASST Grande Ospedale Metropolitano Niguarda between 2014 and 2017
62391140|NCT01294319|EXPERIMENTAL|Endurance-trained young athletes, CPSM|Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone
62391141|NCT01294319|EXPERIMENTAL|Sedentary young adults,PCMS|Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone
62562959|NCT03836690|EXPERIMENTAL|Donor T cells depleted of CD62L+ cells (CD62L- Tem)|Donors will undergo a steady state apheresis for the collection of T cells. Selection of CD62L- Tem at the required dose will be performed at UCL Centre for Cell, Gene and Tissue Therapeutics (CCGTT). Donor Tem will be infused into patients on day 24-32 following allo-Stem Cell Transplant.
62562960|NCT00479986|EXPERIMENTAL|Pioglitazone|
62562961|NCT00479986|ACTIVE_COMPARATOR|placebo|
62391142|NCT01294319|EXPERIMENTAL|Endurance-trained young athletes,PCMS|Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone
62771405|NCT00574548|EXPERIMENTAL|Group 1.1|Group 1.1 = 13vPnC then 13vPnC
62179011|NCT00878319|ACTIVE_COMPARATOR|Surgical|Surgical intervention: open reduction and internal fixation (ORIF)
62562962|NCT01270568|EXPERIMENTAL|Positive Psychology|8 weekly positive psychology exercises
62562963|NCT01270568|ACTIVE_COMPARATOR|Relaxation Response|Meditation-based treatment
62562964|NCT01270568|SHAM_COMPARATOR|Recollection|Recollection of daily events, recorded weekly
62771406|NCT00574548|EXPERIMENTAL|Group 1.2|Group 1.2 = 13vPnC then 23vPS
62771407|NCT00574548|EXPERIMENTAL|Group 2|Group 2 = 23vPS then 13vPnC
61995052|NCT03712410|EXPERIMENTAL|Group 4 (PISCESplus online)|Participants in this group receive the PISCES plus intervention (the PISCES intervention with the enhancement of the positive reappraisal elements) delivered fully online. All assessments and sessions take place online.
62179012|NCT00878319|ACTIVE_COMPARATOR|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
62179013|NCT00513058|EXPERIMENTAL|lapatinib + vinorelbine|"* starting with loading dose of lapatinib per os for 7 days~* then, combining lapatinib (oral daily continuous) + vinorelbine (intravenous, day 1 and 8 every 3 weeks)"
62179014|NCT00511797|EXPERIMENTAL|DRSP 1 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
62179015|NCT00511797|EXPERIMENTAL|DRSP 2 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
62562965|NCT02742662|EXPERIMENTAL|Smart Technology Group|The Smart Technology Group will receive a technology-based lifestyle intervention program which uses wearable technology, smartscales and smartphone applications to track and deliver feedback on caloric expenditure, physical activity, caloric intake and body weight. Participants will receive information through smartphone applications on strategies to make changes to their diet, physical activity, and weight-related behaviors along with standard 3 monthly in-person weight management visits.
62562966|NCT02742662|OTHER|Standard Weight Management Group|The Standard Weight Management Group will receive 3 monthly in-person weight management visits during which they will receive standard of care lifestyle recommendations in accordance with the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guideline.
62562967|NCT03000010|ACTIVE_COMPARATOR|Incisional Wound Vac|We will attach sponges and a suction tube to the incision after surgery. We will leave it on for 72 hours. From then on, patients will get the care that patients normally get after spinal fusion surgery.
62562968|NCT03000010|ACTIVE_COMPARATOR|Normal Gauze Bandage Group|We will cover patients incision with regular gauze bandages. These are the bandages that patients normally get after spinal fusion surgery. They will be left on for 72 hours.
62562969|NCT04038463|EXPERIMENTAL|Early Follicular Phase (EFP)|The group will engage in the Resistance Training intervention on the fourth day of their menstrual cycle, which will correlate with the middle of the early follicular phase (EFP).
62179016|NCT00511797|EXPERIMENTAL|DRSP 3 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
62179017|NCT00511797|PLACEBO_COMPARATOR|Placebo|1 tablet per day placebo for 28 days in each 28-day cycle
62179018|NCT01412632|EXPERIMENTAL|General vs deep sedation|General anesthesia: remifentanil and propofol Deep sedation: remifentanil, propofol and citanest
62391143|NCT02809651|EXPERIMENTAL|Ischemic stroke|patients suffering from ischemic stroke diagnosed by clinical examination and CT-scan
62391144|NCT02809651|EXPERIMENTAL|Brain tumor|patients diagnosed with a brain tumor diagnosed by clinical examination and CT-scan or MRI
62391145|NCT02809651|EXPERIMENTAL|Brain surgery|patients that have undergone brain surgery
62562970|NCT04038463|EXPERIMENTAL|Late Follicular Phase (LFP)|The group will engage in the Resistance Training intervention on the eleventh day of their menstrual cycle, which will correlate with the middle of the late follicular phase (LFP).
62562971|NCT04038463|EXPERIMENTAL|Early Luteal Phase (ELP)|The group will engage in the Resistance Training intervention on the eighteenth of their menstrual cycle, which will correlate with the middle of the early luteal phase (ELP).
62771408|NCT01751139|OTHER|Total Group|Subjects six months of age and older at the time of enrolment, recruited from randomly selected households originating from preselected mapped communities. Preferably the recruitment period occurred outside of the peak dengue transmission season, and continued until each site had reached its foreseen target. The expected period for recruiting the target sample size was approximately three months. Recruitment of replacement subjects was done during the low dengue transmission and the recruitment period depended on the number of subjects that need to be replaced. Enrolled subjects were subjects who either lived in households in study areas with support from the Family Health Physician Program (FHP) or the Larval Index Rapid Assay (LIRA) or with field research experience in the community (preferred) or where a similar system of mapped communities with potential for surveillance existed.
62771409|NCT05274360|EXPERIMENTAL|Experimental Group|Mobile evidence-based aphasia therapy
62771410|NCT05274360|ACTIVE_COMPARATOR|Control Group|Conventional aphasia therapy
62771411|NCT00909597|ACTIVE_COMPARATOR|pioglitazone|
62771412|NCT00909597|EXPERIMENTAL|taspoglutide 10mg|taspoglutide 10mg sc weekly
62771413|NCT00909597|EXPERIMENTAL|taspoglutide 10mg/20mg|taspoglutide 20mg sc weekly after 4 weeks of taspoglutide 10mg sc weekly
62771414|NCT02488993||Prospective Phase Rifaximin-α 550mg|Prospective data collection of patients treated with Rifaximin-α 550mg from point of study entry.
62771415|NCT02488993||Prospective Phase No Rifaximin-α 550mg|Prospective data collection of patients NOT treated with Rifaximin-α 550mg from point of study entry.
62771416|NCT02488993||Retrospective Phase|Review of medical records and electronic hospital admissions data for patients with HE who have not received Rifaximin-α 550mg within the previous 12 months.
62179019|NCT04461184|EXPERIMENTAL|Internet wellness intervention for aging|Feasibility components will be evaluated with a 5-point Likert scale may include open ended items for more detailed feedback. Participants will be asked to visit NDSU at the beginning and end of the intervention, and at 1-month follow-up. After written informed consent, each participant will complete a descriptive questionnaire at the beginning of the intervention period, and a health-related questionnaire at the beginning and end of the intervention, and at follow-up that includes self-rated health, current smoking status, smoking history, alcohol use, morbid conditions, functional disability, and depression status. Standing height and waist circumference will be collected with a tape measure. Body weight and composition will be measured with the InBody 570. Anthropometric and body composition assessments will be collected pre, post, and follow up.
62179020|NCT01065207|NO_INTERVENTION|patient|
62179021|NCT02160470|EXPERIMENTAL|Exposure with Retrieval|Exposure Therapy with Retrieval
62179022|NCT02160470|EXPERIMENTAL|Exposure with Compounding|Exposure Therapy with Compound Extinction
62179023|NCT02160470|EXPERIMENTAL|Exposure with Retrieval and Compounding|Exposure Therapy with Retrieval and Compound Extinction
62179024|NCT02160470|ACTIVE_COMPARATOR|Therapist-Guided Exposure Therapy|Therapist-guided Exposure Therapy
62179025|NCT03820570|EXPERIMENTAL|lichtenstein|hernia repair
62179026|NCT00740597|EXPERIMENTAL|Arm 1|pre-operative radiation + surgery PTV will receive a total dose of 50 Gy in 25 fractions, 2 Gy per fraction, 5 fractions per week, over approximately 5 weeks. Concurrently, the GTV2, if present, will receive 54 Gy in 25 fraction. Dose will be prescribed to the isodose volume that encompasses the PTV. All patients will be treated by 6 MV photon beam.
62179027|NCT05140707|EXPERIMENTAL|Intervention|For the patients in this group, a virtual reality device was provided to the patients and patients wear it during the port catheter implantation and after the port catheter implantation when they felt pain.
62562972|NCT04038463|EXPERIMENTAL|Late Luteal Phase (LLP)|The group will engage in the Resistance Training intervention on the twenty-fifth day of their menstrual cycle, which will correlate with the middle of the late luteal phase (LLP).
62562973|NCT04675099|ACTIVE_COMPARATOR|Control|Standard Early Intervention services
62771417|NCT00586976|EXPERIMENTAL|1|Ropivicaine infusion into the sternal wound
62771418|NCT00586976|PLACEBO_COMPARATOR|2|Normal saline infusion into the sternal wound
62771419|NCT03042130|EXPERIMENTAL|Iron Carboxymaltose|"standard of care + double dose of IV iron ferinject~the medicine will be given twice within one week."
62771420|NCT03042130|OTHER|control|standard of care
62771421|NCT01424228|PLACEBO_COMPARATOR|Placebo|Placebo 2 mg tablet once daily before breakfast
62179028|NCT05140707|NO_INTERVENTION|Control|For the patients in this group, there wasn't any specific intervention during or after the port catheter implantation.
62179029|NCT00601133||Patient Postural Instability|Participants having difficulty walking and with balance after cancer treatment that are leaving the M.D. Anderson rehabilitation hospital or after treatment through the rehabilitation mobile team.
62179030|NCT02145897|EXPERIMENTAL|Autologous Stromal Vascular Fraction|single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
62179031|NCT02145897|EXPERIMENTAL|Autologous Adipose Derived MSCs|One dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
62179032|NCT02145897|ACTIVE_COMPARATOR|Control|
62179033|NCT02125318|EXPERIMENTAL|Anagrelide CR (GALE-401)|
62179034|NCT02878421|ACTIVE_COMPARATOR|tobacco cigarette|Intervention: tobacco cigarettes min 15/day
62179035|NCT02878421|ACTIVE_COMPARATOR|e.cigarettes + 16mg nicotine & flavor|Intervention: One flavoured electronic cigarette 16mg nicotine/day
62179036|NCT02878421|ACTIVE_COMPARATOR|e.cigarettes + 0mg nicotine & flavour|Intervention: One electronic cigarette with flavour +0mg nicotine/day
62179037|NCT06176898|EXPERIMENTAL|Neurostimulating device.|
62179038|NCT06471907|PLACEBO_COMPARATOR|10 ml lumbar ESPB group|lumbar ESPB was performed with 10 ml of local anesthetics
62179039|NCT06471907|EXPERIMENTAL|20 ml lumbar ESPB group|lumbar ESPB was performed with 20 ml of local anesthetics
62182747|NCT00136682|ACTIVE_COMPARATOR|(PCEA)|patient-controlled epidural analgesia PCEA involves having an epidural catheter placed before surgery.The epidural catheter will be used during surgery to give drugs, such as morphine and a local anesthetic bupivacaine, which will help control pain. After surgery, a constant flow of pain-reducing medicine, such as morphine, will be given through the catheter. This is controlled by the patient.
62562974|NCT04675099|EXPERIMENTAL|Intervention|pCARE
62562975|NCT03691701|EXPERIMENTAL|Strict SBP Target|Home SBP target \< 120 mmHg or 90th percentile for age and height (whichever is lower)
62562976|NCT03691701|NO_INTERVENTION|Usual SBP Target|Usual care, no home SBP target
62562977|NCT04283240|ACTIVE_COMPARATOR|Sildenafil|50 mg sildenafil oral. One dose
62562978|NCT04283240|PLACEBO_COMPARATOR|Placebo|Placebo pill. One dose
62771422|NCT01424228|ACTIVE_COMPARATOR|prucalopride|Prucalopride 2 mg once daily before breakfast
62562979|NCT04756882|EXPERIMENTAL|study group|6 patients received 12.5 speywood unit/cm (SU/cm) Dysport intramuscular \& intradermal injections, within the first 5 postoperative days of the trauma
62562980|NCT04756882|NO_INTERVENTION|control group|of 6 patients that acted as the control group and received no treatment
62562981|NCT01486446|EXPERIMENTAL|XPF-002|XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
62562982|NCT01486446|PLACEBO_COMPARATOR|Placebo|XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
62179040|NCT06086119||Patients who will be subjected to total laryngectomy and placement of voice prosthesis|Prospective, multicenter observational study involving patients who will be subjected to total laryngectomy and placement of voice prosthesis.Evaluate the patient's quality of life and voice perception underwent surgery for the placement of a voice prosthesis, through the administration of validated quality of life questionnaires: EORTC QLQ - H\&N35; EORTC QLQ -C30, V-RQOL, VHI, SECEL3,4
62179041|NCT01525641||Patient with Parkinson's Disease|
62179042|NCT03142828|ACTIVE_COMPARATOR|Test (clorhexidine gel)|The healing abutments were covered by a chlorhexidine gel after the first week of the second surgery (2-stage implants).
62179043|NCT03142828|PLACEBO_COMPARATOR|Placebo|The healing abutments were covered without any antiseptic gel after the first week of the second surgery (2-stage implants).
62179044|NCT00865813|EXPERIMENTAL|Punch Biopsy|
62179045|NCT04882748|ACTIVE_COMPARATOR|Control|In the control arm, patients were laid down on the robot platform. Physiotherapists identified the trigger points and the robot was connected, providing the expected noise and vibration, but the air pressure was not applied. Thermotherapy and rehabilitation exercises were provided, as is the standard treatment for NSLBP at the Rehabilitation Service.
62179046|NCT04882748|EXPERIMENTAL|Robot massage|In the robot arm, a physiotherapist with more than 15 years of experience identified the trigger points in the patient, programmed the robot, and applied robot-controlled air pressure massage for 10 minutes. The ADAMO robot applies an air current to the trigger points on the back of the patient, guided by cameras and computer programs (https://adamorobot.com/). Thermotherapy and rehabilitation exercises were also applied.
62179047|NCT00721981||1|Regular treatment for non-small cell lung cancer (NSCLC)
62179048|NCT06257641|EXPERIMENTAL|High-intensity Mediterranean diet|Patients assigned to the intervention group will undergo dietary education for the adoption of the Mediterranean diet, with monthly monitoring - mostly online - by nutritionists with experience in the field. Patients will be given 500 ml of extra virgin olive oil per week and informative material about the Mediterranean diet, as well as recipes and weekly menus.
62179049|NCT06257641|NO_INTERVENTION|Standard of care|Patients assigned to the control group will be provided with standard recommendations for a low-fat diet with no monitoring by nutritionists.
62179050|NCT04367363||Community sample|We plan to recruit a representative sample of the Singapore population.
62179051|NCT03772041|EXPERIMENTAL|OPC-61815 injection 16 mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg
62179052|NCT03772041|ACTIVE_COMPARATOR|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo
62179053|NCT00945451|EXPERIMENTAL|CyberKnife irradiation|
62179054|NCT02428816|EXPERIMENTAL|Patients with Parkinson's Disease|Patients with PD will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)
62179055|NCT02428816|EXPERIMENTAL|Patients with MSA|Patients with MSA will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)
62179056|NCT02428816|EXPERIMENTAL|Controls|30 healthy controls will be submitted to an MRI acquisition and to behavioural evaluations in a sole visit
62179057|NCT00429442|ACTIVE_COMPARATOR|1|
62179058|NCT00429442|PLACEBO_COMPARATOR|2|
62179059|NCT02207036|EXPERIMENTAL|Facebook intervention|Assignment to private group on Facebook with 3 months of content delivered to the group.
62179060|NCT02207036|ACTIVE_COMPARATOR|Referral|Referral to smokefree.gov website
62179061|NCT05546736|EXPERIMENTAL|iCanWork Intervention|iCanWork includes 6 1-hour sessions with a VRC and 1 to 4 1-hour sessions with an OT. In the positive event that a participant has returned to work during the study, three of the six VRC sessions are reserved to support the participants in their transition to the workplace.
62562983|NCT00749450|EXPERIMENTAL|Arm I|Patients receive OxMdG or XELOX combination chemotherapy for a total of 12 courses for treatment lasting a total of 24 weeks.
62179062|NCT05546736|NO_INTERVENTION|Control|Participants randomized to the control group will receive their usual care and will be referred to the Cancer Work website for educational resources related to RTW. If they contact the team with RTW-related questions, they will be referred to their care teams.
62179063|NCT00392535|ACTIVE_COMPARATOR|Control arm|conventional radiotherapy (74 Gy delivered in 37 fractions over 7·4 weeks)
62562984|NCT00749450|EXPERIMENTAL|Arm II|Patients receive OxMdG or XELOX combination chemotherapy for a total of 6 courses for treatment lasting a total of 12 weeks.
62562985|NCT05264038|EXPERIMENTAL|Cohort 1|Participants will receive either low dose level of OC514 or placebo
62562986|NCT05264038|EXPERIMENTAL|Cohort 2|Participants will receive either mid dose level of OC514 or placebo
62562987|NCT05264038|EXPERIMENTAL|Cohort 3|Participants will receive either high dose level of OC514 or placebo
61995053|NCT02986620||AML patients|Adult AML patients with the IDH mutation test performed at diagnosis or relapse until January 31st, 2019.
61995054|NCT02196324|ACTIVE_COMPARATOR|serlopitant 5 mg tablets|serlopitant 5 mg tablets
62179064|NCT00392535|EXPERIMENTAL|Hypofractionated arm 1|Hypofractionated radiotherapy (60 Gy in 20 fractions over 4 weeks)
62179065|NCT00392535|EXPERIMENTAL|Hypofractionated arm 2|Hypofractionated radiotherapy (57 Gy in 19 fractions over 3·8 weeks)
62182589|NCT04695821|EXPERIMENTAL|Senti Arm|"In stage 1 of this study (6 patients), the patient will apply the device and complete the initial patient survey; questions are around usability, comfort (including feelings of pressure), and acceptability. The Investigator will record the time taken to apply the device. A brief 30 seconds of chest sounds will be recorded from each of the nine sensors on the device in three different settings: standing up, lying down, walking around.~In stage 2 of this study (10 patients; 6 of whom would be re-recruited from the first stage), the participant will use the device at home over five days. The Investigator will assess the participant daily for any signs of pressure sores or complications from using the device (including topical allergic reactions). The participant will complete a daily survey. The participant is encouraged to remove the device and apply it at their discretion. The participant can opt-out of wearing the device at any stage."
62391146|NCT02809651|ACTIVE_COMPARATOR|Intracranial hemorrhage|patients with intracranial hemorrhage diagnosed by clinical examination and CT-scan
62391147|NCT02809651|EXPERIMENTAL|Headache|patients with headache complaints and a normal CT-scan of the brain
62391148|NCT02809651|EXPERIMENTAL|Headtrauma|patients with head trauma and a normal CT-scan of the brain
62391149|NCT00563901||1|Adults with a high risk for high blood pressure from the ALLHAT study
62771423|NCT02728531|EXPERIMENTAL|Bendamustine, Rituximab, Cytarabine|"* Bendamustine on Days 1 and 2 of Cycles 1, 3, and 5.~* In Cycle 1, rituximab on Day 1 or 2 at the investigator's discretion. Given on Day 1 of Cycles 2 through 6.~* On Days 1 and 2 of Cycles 2, 4, and 6, cytarabine will be administered every 12 hours for a total of 4 doses.~* Growth factor will be administered subcutaneously within 72 hours of completion of each even-numbered cycles of chemotherapy.~* Leukapheresis will begin when the total WBC ≥ 5000/ μL and continue daily until collection of ≥ 2x106 CD34+ cells/kg (with a maximum of 5 courses of apheresis).~* Standard of care peripheral blood autologous stem cell harvest will proceed per institutional guidelines and begin during Cycle 6 following rituximab and cytarabine therapy, when the total WBC ≥ 5000/ μL. Collection will continue on a daily basis until collection of ≥ 2x106 CD34+ cells/kg."
62771424|NCT04958226|EXPERIMENTAL|Treatment (Midazolam + Capivasertib)|Midazolam will be administered on Cycle 1 Day 1 and Cycle 1 Day 8. Capivasertib will be administrated from Cycle 1 Day 2 as an intermittent schedule (4 days on/3 days off) until discontinuation. On Cycle 1 Day 12, Midazolam will be administrated with Capivasertib.
62771425|NCT02790814|EXPERIMENTAL|Moyo strap-on|Continous fetal heart rate monitoring
62771426|NCT02790814|ACTIVE_COMPARATOR|Hand-held fetoscope|Intermittent fetal heart rate monitoring
62391150|NCT01884142|NO_INTERVENTION|Heart Failure Untrained Group|Control Group
62391151|NCT01884142|EXPERIMENTAL|Heart Failure Exercise-trained Group|Aerobic Exercise Training
62771427|NCT01062061||VARIVAX|Attenuated live varicella vaccine was administered in usual practice. Recommended dosing is a single 0.5 mL subcutaneous injection in children 12 months to 12 years of age.
62771428|NCT01954316|EXPERIMENTAL|CFI-400945 fumarate Schedule A|CFI-400945 fumarate tablets daily dosing expansion at 64mg
62771429|NCT01954316|EXPERIMENTAL|CFI-400945 fumarate Schedule B|CFI-400945 fumarate tablets intermittent dosing schedule, 2 days on/5 days off. Escalation at following levels: 96mg, 128mg
62771430|NCT01954316|EXPERIMENTAL|CFI-400945 fumarate Schedule C|CFI-400945 fumarate tablets intermittent dosing schedule, 1 day on/6 days off. Escalation will start at MTD of Schedule B
62771431|NCT04665531|EXPERIMENTAL|Group A - Erector Spinae Catheter group|"Patients in the experimental group will receive the erector spinae catheter prior the surgery and will be administered local anesthetics for 48 hours post-operatively.~Anesthetic regimen: initial bolus of 20ml 0.5% levobupivacaine before the end of surgery. Then continually ropivacaine 0,2% 5ml/h with intermittent boluses 15ml ropivacaine 0,2% every 4h.~Both groups will receive multimodal analgetic treatment consisting of a patient-controlled (PCA) pump with opioid analgetics and a peripherally acting analgetic metamizol on a regular basis. The PCA pump will be set to intermittent boluses of 3mg piritramide with a lock-out time 15 min and a maximal number of 6 boluses /3 hours. Patients will receive metamizol 2,5g/12hours i.v. on the day of surgery and 500-1000mg / 6 hours orally on the first and second post-operative day."
62771432|NCT04665531|ACTIVE_COMPARATOR|Group B - Intercostal block|"Patients will receive standard treatment, i.e. the multi-level intercostal block administered at the end of the surgery by the surgeon. They will receive 20ml 0,5% levobupivacaine on 6 levels of the thoracic wall according to the operative wound level.~Both groups will receive multimodal analgetic treatment consisting of a patient-controlled (PCA) pump with opioid analgetics and a peripherally acting analgetic metamizol on a regular basis. The PCA pump will be set to intermittent boluses of 3mg piritramide with a lock-out time 15 min and a maximal number of 6 boluses /3 hours. Patients will receive metamizol 2,5g/12hours i.v. on the day of surgery and 500-1000mg / 6 hours orally on the first and second post-operative day."
62771433|NCT01528761|EXPERIMENTAL|Prosocial Behavior Physical Activity|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
62179066|NCT05624489|EXPERIMENTAL|Intervention|"Each participant-time point will be randomized between a prompt containing an engagement strategy vs. no prompt. A Bayesian algorithm will iteratively adjust the probability of receiving a prompt or no prompt at any time point, using brushing behavior data. Patterns suggesting positive effects of the prompts on brushing adherence will result in higher subsequent probabilities of receiving the prompts, whereas patterns suggesting null or negative effects will result in lower probabilities of receiving the prompts. A participant is assigned to an engagement prompt will be randomized equally between the three types of engagement strategies: (1) Standard reciprocity prompt: delivering non-contingent reward points as a gift to support goals; (2) Reciprocity by proxy prompt: delivering a message indicating a donation to the person's selected charity; (3) Curiosity prompt: delivering oral health information in a manner that motivates the participant to seek new knowledge and information."
62182590|NCT06086678|EXPERIMENTAL|Conventional physical therapy group|Strengthening exercises, stretching exercises for the weak and tightened muscles respectively, facilitation of equilibrium and protective reactions and breathing exercises in form of Deep breathing, Diaphragmatic breathing and Pursed lip breathing exercises
61995055|NCT02196324|PLACEBO_COMPARATOR|Placebo tablets|Placebo tablets
62179067|NCT01260207|EXPERIMENTAL|IVR group|Patients in this arm will receive IVR follow-up telephone calls at 1,3,6,9 and 12 months post-discharge consisting of predetermined questions related to medication management, smoking cessation, diet, exercise and education as recommended by the ACC/AHA BPG for ACS. Upon completion of the IVR follow-up, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
62179068|NCT01260207|NO_INTERVENTION|Usual care|Patients in this arm will not receive IVR follow-up. One year after discharge, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
62179069|NCT01540812||V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud|Vincristine in induction:5 mg/m2 i.v. days 1, 8, 15 and 22 in induction phase Daunorubicin in induction 45 mg/m2 i.v. days 1, 8, 15 and 22 Prednisone in induction: 60 mg/m2/ day, i.v. o p.o., days 1 to 14; 30 mg/m2/day, i.v. o p.o., days 15 to 21; 15 mg/m2/day i.v. o p.o., days 21 to 28 Metotrexato 12 mg days 1 and 22 (intrathecal) Cytarabine (ARA-C): 30 mg days 1 and 22 (intrathecal) Hydrocortisone: 20 mg days 1 and 22 (intrathecal) Idarubicin-induction 2 12 mg/m2, i.v., days 1, 3 and 5 Fludarabine in induction-2: Fludarabine 30 mg/m2, i.v., days, 1 to 5
62179070|NCT04723732|EXPERIMENTAL|Myrrh mouthwash|1% mouthwash of Commiphora myrrha made from resin extract. Participants will use 10 ml of the mouthwash twice daily for 14 days.
62179071|NCT04723732|ACTIVE_COMPARATOR|Chlorhexidine Mouthwash|Commercial 0.2% Chlorhexidine gluconate mouthwash (Avalon Pharma, Riyadh). Participants will use 10 ml of the mouthwash twice daily for 14 days.
62179072|NCT04723732|PLACEBO_COMPARATOR|Normal saline|Commercial 0.9% sodium chloride solution (Pharmaceutical solutions industry, Jeddah). Participants will use 10 ml of the mouthwash twice daily for 14 days.
62179073|NCT00488319|EXPERIMENTAL|001|Paliperidone ER1.5 to 12 mg tablet once daily for 6 months
62179074|NCT00953212|ACTIVE_COMPARATOR|Group A|Beta Blockers, Ascorbic Acid and Amiodarone
62179075|NCT00953212|ACTIVE_COMPARATOR|Group B|Beta Blockers and Ascorbic Acid
62179076|NCT00953212|ACTIVE_COMPARATOR|Group C|Beta Blockers and Amiodarone
62179077|NCT00953212|ACTIVE_COMPARATOR|Group D|Beta Blockers alone
62179078|NCT02628964|ACTIVE_COMPARATOR|4.5% e-cig|e-cigarettes with nicotine cartridges
62179079|NCT02628964|PLACEBO_COMPARATOR|0 mg e-cig|e-cigarettes with placebo cartridges (0mg).
62179080|NCT01647399||Phenotypic Clusters|500 urban youth
62179081|NCT02143310|EXPERIMENTAL|EVP|Subject who use the EVP for up to 2 years
62179082|NCT04700566|EXPERIMENTAL|Injection of Renuva Allograft adipose matrix in vocal fold|Injection of Renuva Allograft Adipose matrix in the vocal fold for vocal fold medialization and treatment of glottal insufficiency
62179083|NCT05465928|EXPERIMENTAL|Personalized rTMS|"The active arm will receive the personalized rTMS treatment with parameters as follows:~1. Neuroimaging biomarker-guided personalized selection for stimulation frequency: low frequency(1HZ) or high frequency (10HZ);~2. Neuroimaging biomarker-guided personalized selection for stimulation site: dorsalmedial prefrontal cortex or occipital cortex;~3. Schedule: 2 sessions per day, five days per week for a total of 20 sessions over 2 weeks."
62179084|NCT05465928|SHAM_COMPARATOR|sham stimulation rTMS|Sham stimulation arm will receive the same scheme of rTMS but with a sham coil.
62179085|NCT00941109|EXPERIMENTAL|1|
62179086|NCT00941109|EXPERIMENTAL|2|
62179087|NCT00941109|EXPERIMENTAL|3|
62179088|NCT00941109|EXPERIMENTAL|4|
62179089|NCT05904756||Metal framework group|Two sets of patients were made (10 patients/set) using random-generated numbers created by a computer program (Excel sheet). Conventional complete denture will be fabricated first and patient will wear the denture for 3 months. Then 4 implants will be placed according to all in 4 concept.after 3 months of asseointegration,the first 10 participants will recieve metal framework first. After 3 months, patient satisfaction and oral healthy related quality of lifewill be measured.
62182748|NCT00136682|ACTIVE_COMPARATOR|PCA|patient-controlled intravenous analgesia (PCA) PCA involves placing a tube into the patient's vein after surgery. The tube is connected to a pump that is controlled by the patient. The pump holds a medicine, such as morphine, that eases pain.
61995056|NCT01878201|EXPERIMENTAL|Fimasartan 30 mg|Take one capsule filled with a Fimasartan 30 mg in the every morning
62179090|NCT05904756||PEKK framework group|metal framework will be replaced by PEKK framework. After another 3 months, measurements will be repeated. The second 10 patients received polyetherketoneketone first, and after 3 months, measurements will be made. Then, polyetherketoneketone framework will be replaced by Metal framework and measurements( Patient satisfaction and oral healty related quality of life) will be repeated after another 3 months in across over design.
62562988|NCT01275846|EXPERIMENTAL|Health Guide using AHA protocols|Participants in the study will receive the use of the Intel Health Guide, a telehealth device, with AHA customized heart failure protocols, response algorithms and educational content. Participants interact with the Intel Health Guide device, receiving immediate feedback when transmitting vitals measures and health question responses to a site monitored by their nurse case managers. Nurse case managers review and address concerns raised in vitals and/or question responses through standard care protocols established by their institution. Nurse case managers strive to enhance the participants quality of life, support continuity of care, facilitate provision of services in the appropriate setting to promote positive health outcomes.
62562989|NCT01365819|PLACEBO_COMPARATOR|Sugar pill|Placebo
62562990|NCT01365819|EXPERIMENTAL|Varenicline|Varenicline (Chantix (R))
62562991|NCT06478498|EXPERIMENTAL|Non-donor group|Three healthy hookworm-naive volunteers will be infected with 50 Necator americanus L3 larvae in week 0, receive treatment in week 2, followed by another inoculation with 10 Necator americanus L3 larvae localised on one spot after which two biopsies will be taken (one from each arm). After this, they will be treated in week 5. The study ends in week 13.
62562992|NCT06478498|EXPERIMENTAL|Chronic donor group|"Two healthy hookworm-naive volunteers will be infected with 50 Necator americanus L3 larvae in week 0, receive treatment in week 2, followed by another inoculation with 10 Necator americanus L3 larvae localised on one spot after which two biopsies will be taken (one from each arm). After this, they receive additional inoculations (maximal dose 50 L3 larvae at one time) until egg outputs are \>1500 epg at the start of the donor phase.~In the donor phase, volunteers will be asked to donate faeces regularly (\~ 5 -10 times a year). Safety visits are scheduled at month 12 and 24. The study ends after approximately 2 years."
62562993|NCT02201693|EXPERIMENTAL|Cyclic exclusive MODULEN IBD|Cyclic exclusive MODULEN IBD for 2 weeks every 8 weeks
62562994|NCT02201693|EXPERIMENTAL|MODULEN IBD supplementation (25% of caloric requirements)|MODULEN IBD supplementation (25% of caloric requirements) alone A Physician not involved in the study design and blinded to the treatment arm will perform the evaluation of the patients during each study visit.
62562995|NCT04930289||LungGuard patients|Patients whose donor lung(s) was transported with the LungGuard device.
62179091|NCT01334762|EXPERIMENTAL|Letrozole/IUI|Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
62179092|NCT01334762|ACTIVE_COMPARATOR|CC/IUI|Patients received 100 mg CC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
62179093|NCT05566509||Breast Conservative Surgery|The patients who had minimally invasive surgery.
62179094|NCT05566509||Mastectomy|The patients who had invasive and destructive surgery.
62562996|NCT04930289||Standard Transport Patients|Patients whose donor lung(s) was transported with a method other than the LungGuard
62562997|NCT04930289||BAROGuard Patients|Patients whose donor lung(s) was transported with the BAROGuard device.
62562998|NCT01700972|EXPERIMENTAL|Imaging at 10-minute vs. 30-45-minutes|The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
62179095|NCT01657643|PLACEBO_COMPARATOR|Placebo|Every day for 12 weeks, subjects are asked to eat 5 grams of a placebo (strawberry-flavored candy powder)
62179096|NCT01657643|EXPERIMENTAL|Probiotics|Every day for 12 weeks, subjects are asked to eat 5 grams of a strawberry-flavored candy that contains probiotics \[daily dose minimum of 1 billion CFU of each Lactobacillus rhamnosus LGG® (LGG®), and Bifidobacterium animalis ssp lactis BB-12® (BB-12®)\]
62182591|NCT06086678|EXPERIMENTAL|Hydrotherapy and conventional physical therapy group|Strengthening exercises, stretching exercises for the weak and tightened muscles respectively, facilitation of equilibrium and protective reactions and breathing exercises in form of Deep breathing, Diaphragmatic breathing and Pursed lip breathing exercises in addition to hydrotherapy
62562999|NCT02001311|EXPERIMENTAL|chlorhexidine gel|anti microbial agent that prevents the formation of plaque and reduces caries risk
62563000|NCT00860795|ACTIVE_COMPARATOR|Echinacea|
62563001|NCT00860795|PLACEBO_COMPARATOR|placebo|
62563002|NCT02972619|EXPERIMENTAL|Intervention|Structured multicomponent intervention (MCI)
61995057|NCT01878201|ACTIVE_COMPARATOR|Valsartan 80 mg|Take one capsule filled with a Valsartan 80 mg in the every morning
62182749|NCT04060732||Flash Glucose Monitoring Device|"The Flash Glucose Monitoring-FGM is a real-time glycemic monitoring system called hybrid used by Diabetes Mellitus type 1 patients."
62771434|NCT01528761|ACTIVE_COMPARATOR|Healthy Aging (HA)|Behavioral: Healthy Aging (HA) The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
62771435|NCT00252616|EXPERIMENTAL|1|trophic feeds
62771436|NCT00252616|ACTIVE_COMPARATOR|2|Full-calorie feeds
62771437|NCT03597061|EXPERIMENTAL|Healthy Start to Feeding Intervention|Participants and their parents will participate in a 3 session intervention targeting healthy introduction of complementary foods. Intervention sessions will occur when the infant is 4, 6, and 9 months of age.
62771438|NCT03597061|NO_INTERVENTION|Control|Participants and their parents will complete pre- and post-treatment period study visits to assess study outcomes. They will receive no intervention.
62771439|NCT05969132|EXPERIMENTAL|Digital workflow-based Protocol|Fully digital guided gingivectomy procedure
62771440|NCT05969132|ACTIVE_COMPARATOR|Mock-up workflow-based Protocol|Convectional guided gingivectomy procedure
62771441|NCT01692665||stage 3 or stage 4 meibomiang gland dysfunction patients|stage 3 or stage 4 meibomiang gland dysfunction patients
62771442|NCT00235287|ACTIVE_COMPARATOR|A,AIIA|24 weeks of treatment with Candesartan, where Enalapril is added in the last 8 weeks.
62771443|NCT00235287|ACTIVE_COMPARATOR|A, ACE-I|24 weeks of treatment with Enalapril, where Candesartan is added in the last 8 weeks.
62771444|NCT00235287|ACTIVE_COMPARATOR|C, AIIA|8 weeks of treatment with Candesartan, followed by 8 weeks of treatment with Enalapril. The treatment in the last 8 out of the 24 weeks is a combination of Candesartan and Enalapril.
61995058|NCT06269081|EXPERIMENTAL|Supportive-Expressive Peer Social Support Group + Individual Strengths-Based Case Management|
61995059|NCT06269081|EXPERIMENTAL|Supportive-Expressive Peer Social Support Group|
61995060|NCT06269081|EXPERIMENTAL|Individual Strengths-Based Case Management|
61995061|NCT06269081|NO_INTERVENTION|HIV Information Only|This arm will not receive either of the interventions but will receive information on successfully aging with HIV.
61995062|NCT00592566|NO_INTERVENTION|1|Standard supportive care
61995063|NCT00592566|EXPERIMENTAL|2|Dexamethasone treatment
61995064|NCT00592566|EXPERIMENTAL|3|Desmopressin treatment
61995065|NCT05091008|ACTIVE_COMPARATOR|HCV without co-morbidities|Ledipasvir-Sofosbuvir fixed-dose combination one tablet (90 mg Ledipasvir, 400 mg Sofosbuvir), orally once daily at a fixed time with or without food for 12 weeks
61995066|NCT05091008|ACTIVE_COMPARATOR|HCV with co-morbidities|Ledipasvir-Sofosbuvir fixed-dose combination one tablet (90 mg Ledipasvir, 400 mg Sofosbuvir), orally once daily at a fixed time with or without food for 12 weeks
61995067|NCT01277354|ACTIVE_COMPARATOR|Cognitive Processing Therapy|Participants are seen weekly for six weeks for therapy. At visits 2, 4, and 6 they also complete ratings.
61995068|NCT01277354|PLACEBO_COMPARATOR|Waitlist|Participants come in at the end of weeks 2, 4, and 6 to complete ratings but do not receive therapy.
61995069|NCT00554437|EXPERIMENTAL|1|Intermediate-intensity, community-based, multifactorial falls intervention
61995070|NCT00554437|ACTIVE_COMPARATOR|2|Occupational therapist home safety evaluation
61995071|NCT04076774|EXPERIMENTAL|Wondaleaf female condom|Participants will be provided with 5 Wondaleaf condoms first at enrolment and switched to 5 FC2 condoms at the first follow up visit
61995072|NCT04076774|ACTIVE_COMPARATOR|FC2 Female condom|Participants will be provided with 5 FC2 condoms first at enrolment and switched to 5 Wondaleaf condoms at the first follow up visit
61995073|NCT02800330|OTHER|Arm A (e.g. sequence phase A-B-C)|In this arm patients will use regorafenib alone in the first cycle (treatment A), then regorafenib with esomeprazole concomitantly in the second cycle (treatment B) and at last they will use regorafenib with esomeprazole 3 hours before (treatment C)
61995074|NCT02800330|OTHER|Arm B (e.q. sequence phase C-B-A)|In this arm patients will use regorafenib with esomeprazole 3 hours before (treatment C), then regorafenib with esomeprazole concomitantly in the second cycle (treatment B) and at last they will use regorafenib alone (treatment A),
61995075|NCT00002524|EXPERIMENTAL|Regimen A|Regimen A: 5-Drug Combination Chemotherapy followed by Radiotherapy.
61995076|NCT00002524|EXPERIMENTAL|Regimen B|Regimen B: 4-Drug Combination Chemotherapy alternating with 3-Drug Combination Chemotherapy followed, as indicated, by Radiotherapy
61995077|NCT00002524|EXPERIMENTAL|Regimen C|Regimen C: 2-Drug Combination Chemotherapy with Drug Modulation followed, as indicated, by Radiotherapy.
61995078|NCT04145895|OTHER|Physician-directed Postoperative Activity Restriction|Postoperative activity restrictions prescribed by physician.
61995079|NCT04145895|OTHER|Self-directed Postoperative Activity Restriction|Postoperative activity restrictions self-determined (parent/guardian and/or patient).
61995080|NCT03072134|EXPERIMENTAL|Unresectable disease|Patients with unresectable tumors will undergo a biopsy followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.
61995081|NCT03072134|EXPERIMENTAL|Resectable disease|Patients with resectable tumors will undergo a resection followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.
61995082|NCT02283515|ACTIVE_COMPARATOR|group I - Rosuvastatin, 1.2 mg|Rosuvastatin- locally placed in intrabony defect sites.
61995083|NCT02283515|PLACEBO_COMPARATOR|group II - placebo|placebo-placed locally in intrabony defects.
62179097|NCT00953862|EXPERIMENTAL|Atomoxetine Treatment Arm|Patients who were identified as having adult ADHD on the ACDS were offered an open label treatment trial with atomoxetine, up to 120 mg/day over 10 weeks. Atomoxetine was titrated over a period of four weeks based upon clinical response and observed side-effects. All patients receiving atomoxetine gave written informed consent prior to participation and were assessed for ADHD symptoms via the Adult Investigator Adult ADHD Symptom Rating Scale (AISRS) every 1-2 weeks. All patients received a physical exam, review of systems and routine blood work prior to treatment. Data were analyzed for patients completing at least 2 weeks of atomoxetine therapy. Treatment response was pre-hoc defined as having a \>=30% reduction in total AISRS scores from baseline.
62771445|NCT00235287|ACTIVE_COMPARATOR|C, ACE|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg) , followed by 8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg) . The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
62179098|NCT04058236|EXPERIMENTAL|human albumin 5%|10 patients with pancreatic cancer will receive human albumin 5% in a restrictive goal directed fluid regime preoperatively for the first 24 hours.
62179099|NCT04058236|ACTIVE_COMPARATOR|gelofusine|10 patients with pancreatic cancer will receive gelofusine in a restrictive goal directed fluid regime preoperatively for the first 24 hours.
62179100|NCT01989949|EXPERIMENTAL|TP-434 (Eravacycline) via IV infusion|TP-434 (Eravacycline) reconstituted and administered via IV infusion at a dose of 1 mg/kg, every 12 hours, for 7 doses over 4 days.
62179101|NCT00632931|EXPERIMENTAL|A|Arm A: Drug/Placebo
62179102|NCT00632931|EXPERIMENTAL|B|Arm B: Placebo/Drug
62179103|NCT05350124|EXPERIMENTAL|Group 1|Vitamin C (200 mg) capsule, and vitamin E (400 IU) capsule every day for 12 weeks.
62179104|NCT05350124|EXPERIMENTAL|Group 2|Vitamin C (200 mg) capsule, and placebo every day for 12 weeks.
62179105|NCT05350124|EXPERIMENTAL|Group 3|Vitamin E (400 IU) capsule, and placebo every day for 12 weeks.
62179106|NCT05350124|EXPERIMENTAL|Group 4|Placebo capsule (2 pills) every day for 12 weeks.
62179107|NCT00204516|EXPERIMENTAL|mRNA Vacc|
62179108|NCT00761397||Study Program Group|
62179109|NCT00761397||Usual Care Group|
62179110|NCT00414583||Observation|all adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology
62179111|NCT02825277|OTHER|pathological group|pregnant women with preeclampsia and/or IUGR pregnancy with a planned or semi-urgent caesarean section or vaginal delivery will be recruited into this study.
62179112|NCT02825277|OTHER|physiological group|pregnant women with normal pregnancy with a planned caesarean section or vaginal delivery will be recruited into this study
62179113|NCT05155488||Participants With MPS II|Retrospective data of participants diagnosed with MPS II will be collected from the database (DATASUS) from January 1st, 2008 to September 30th, 2020 in this observational study.
62179114|NCT02151643|EXPERIMENTAL|Group 1 - PT20 400 mg tid|"PT20 400 mg tid (1.2 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
62179115|NCT02151643|EXPERIMENTAL|Group 2 - PT20 800 mg tid|"PT20 800 mg tid (2.4 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
62179116|NCT02151643|EXPERIMENTAL|Group 3 - PT20 1600 mg tid|"PT20 1600 mg tid (4.8 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
62179117|NCT02151643|EXPERIMENTAL|Group 4 - PT20 3200 mg tid|"PT20 3200 mg tid (9.6 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
62179118|NCT02151643|PLACEBO_COMPARATOR|Group 5 - Placebo tid|"Matched Placebo (for PT20) tid administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
62563003|NCT02972619|NO_INTERVENTION|Usual Care|Control group receive usual care in the polyclinics
62179119|NCT06127940|EXPERIMENTAL|Radiotherapy + sotorasib|Sotorasib is administered as an 8-week-introduction treatment and if response on a CT-scan is observed (stable disease or partial response), the patient is treated with stereotactic radiation therapy (SBRT) to 1-3 of the remaining lesions.
62179120|NCT05432700|NO_INTERVENTION|Control group: usual clinical practice.|"The women will receive an initial Health Literacy Survey (HLS-EU-Q16) via the email account registered on the platform. From this point until birth, no further notifications will be sent.~Subsequently, reminders will be planned via email to obtain information on BF follow-up, avoiding providing any extra information on BF and, where appropriate, referring to the BF support services available in their area, following a standard clinical practice. During pregnancy, the pregnancy programme of the local and national government provides parenting education and breastfeeding workshops, with various manuals published.~Surveys adapted to this group will be sent out at birth, at 15 days, 6 weeks, 3 and 6 months. The variables to be collected are socio-demographic, related to health literacy, obstetric-neonatal, and breastfeeding variables."
62179121|NCT05432700|EXPERIMENTAL|Intervention group: LactApp|"From the initial registration in LactApp during the third trimester, women will be able to consult all the information available in the application. The women will receive an initial Health Literacy Survey (HLS-EU-Q16), from this point until birth, no further notifications will be sent. A reminder schedule will be made via email to obtain information on the follow-up of the BF.~LactApp® works as a self-administered questionnaire based on decision trees constructed with questions and answers developed by professional breastfeeding experts, supported by scientific evidence and updated official health recommendations. In addition, the app will remind them of the topics according to the estimated date of birth provided. Surveys adapted to this group will be sent out at birth, at 15 days, 6 weeks, 3 and 6 months. The variables to be collected are socio-demographic, related to health literacy, obstetric-neonatal, and breastfeeding variables."
62179122|NCT03398421|EXPERIMENTAL|Subjects receiving nemiralisib and itraconazole|Eligible subjects will receive a single dose of 100 micrograms (mcg) nemiralisib on Day 1 in Period 1. Subjects will also receive a single dose of 200 milligrams (mg) itraconazole in the morning from Day 1 to Day 10 and single dose of 100 mcg nemiralisib on Day 5, one hour after the dose of itraconazole in Period 2. There will be a washout of at least 14 days between the administration of nemiralisib in Period 1 and Period 2.
62179123|NCT04239950|PLACEBO_COMPARATOR|Placebo|Placebo, orally, twice daily after breakfast and dinner for 12 weeks.
62179124|NCT04239950|EXPERIMENTAL|Ethyl Icosapentate 1.8g|Ethyl Icosapentate 0.9g, orally, twice daily after breakfast and dinner for 12 weeks.
62179125|NCT04239950|EXPERIMENTAL|Ethyl Icosapentate 3.6g|Ethyl Icosapentate 1.8g, orally, twice daily after breakfast and dinner for 12 weeks.
62179126|NCT04266613||All Subjects Enrolled|High immune risk transplant recipients who are undergoing routine management under current standard of care
62179127|NCT05853692|EXPERIMENTAL|Test|The investigational product be administered for 63 days. Patient will use a spray based on zinc gluconate (three times a day)
62179128|NCT05853692|ACTIVE_COMPARATOR|Control|The investigational product be administered for 63 days. Patient will use a solution based on sodium chloride and bicarbonate (5 times a day)
62179129|NCT03972397|EXPERIMENTAL|Intercostal Nerve Cryoablation plus SOC Pain Control|Standard of Care (SOC)
62179130|NCT03972397|ACTIVE_COMPARATOR|Standard of Care (SOC) Pain Control|
62179131|NCT04244422|ACTIVE_COMPARATOR|cyst enucleation using piezosurgery|SATLEC ACTEON peizotome 2 was used for bone cutting and separating the cystic lining from the surrounding bone.After complete removal of the cyst, the bony window was replaced back in place and the flap was sutured.
62179132|NCT04244422|ACTIVE_COMPARATOR|cyst enucleation using conventional surgery|A carbide bur was used to remove the bone to uncover the cyst. A periosteal elevator and a curette were used to aid in the removal of the cystic lesion.
62563004|NCT03354351||NB-Group|Stepped-care model comprising a hierarchy of interventions, from the least to the most intensive, matched to the cardiac man's needs. The model involves three steps: Step 1 (therapist-guided and self-guided 3-session psychoeducational program), Step 2 (Group sessions involving care partners), and Step 3 (individual or dyadic (patient and care Partner) sessions. As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
62563005|NCT03354351||ON-Group|Stepped-care model where men will need to follow a sequential treatment (Step 1 (self-guided), Step 2 (Group sessions), and Step 3 (individual or couple sessions). As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
62771446|NCT01021098||Natural History Study|The core Natural History Study of ILI is an observational, longitudinal cohort study using data from clinical findings, medical chart review, and diagnostic, virologic and immunologic laboratories to describe the epidemiology and immunology of ILI. This study aims to describe the clinical history of influenza and other viral respiratory pathogens in a population of US military active duty members and their dependents. The primary focus will be the etiology, natural history and immunology of ILI in otherwise healthy adults and children. We will recruit subjects with ILI in both the outpatient and inpatient setting, and will serially collect biological specimens (e.g. nasal/throat swabs, blood, rectal swabs) over a 28-day period. In addition, we will collect a single buccal (cheek) swab.
62771447|NCT01021098||HIV-Positive Cohort|In addition, given a number of human immunodeficiency virus (HIV)-infected subjects who serve in the active duty force, we will also examine a subset of HIV-positive military beneficiaries as part of this consortium. An additional objective of the study will be to descriptively examine the clinical and laboratory characteristics of ILI events among HIV-infected persons using the military's substantial experience in following a stable HIV-infected population. We will recruit subjects with ILI in both the outpatient and inpatient setting, and will serially collect biological specimens (e.g. nasal/throat swabs, blood, rectal swabs) over a 28-day period. In addition, we will collect a single buccal (cheek) swab.
62179133|NCT02353455||healthy|"donors/patients without liver disease, with and without ongoing drug therapy including buffy coat samples of healthy blood / thrombocyte donors.~After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed . Buffy coats are obtained anonymously."
62179134|NCT02353455||prior to therapy|History will be obtained and blood sampling will be performed in patients in whom a drug therapy with a drug with DILI potential is planned.
62179135|NCT02353455||iDILI|Patients with clinical suspicion of idiosyncratic drug-induced liver injury. After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed.
62179136|NCT02353455||non DILI|Patients with other forms of liver injury. After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed.
62179137|NCT01818427|EXPERIMENTAL|plasma|infusion of 2 units of plasma
62179138|NCT01818427|NO_INTERVENTION|standard air medical care|control group
62179139|NCT05678010|EXPERIMENTAL|Arm A, Dose Level 1|Participants have peripheral metastases only, without bowel and lung in SBRT treatment planning target. Once 2 dosing cohorts of safety data are available from concomitant dosing of AZD1390 with SBRT in Arm A, and provided that Arm A is advancing to Cohort 3, Arm B (with bowel and lung in SBRT treatment planning target \[PTV\]) may be triggered at the initial dose level).
62179140|NCT05678010|EXPERIMENTAL|Arm A, Dose Level 2|Participants have peripheral metastases only, without bowel and lung in SBRT treatment planning target. Once 2 dosing cohorts of safety data are available from concomitant dosing of AZD1390 with SBRT in Arm A, and provided that Arm A is advancing to Cohort 3, Arm B (with bowel and lung in SBRT treatment planning target \[PTV\]) may be triggered at the initial dose level).
62179141|NCT05678010|EXPERIMENTAL|Arm A, Dose Level 3|Participants have peripheral metastases only, without bowel and lung in SBRT treatment planning target. Once 2 dosing cohorts of safety data are available from concomitant dosing of AZD1390 with SBRT in Arm A, and provided that Arm A is advancing to Cohort 3, Arm B (with bowel and lung in SBRT treatment planning target \[PTV\]) may be triggered at the initial dose level).
62179142|NCT05678010|EXPERIMENTAL|Arm A, Dose Level 4|Participants have peripheral metastases only, without bowel and lung in SBRT treatment planning target. Once 2 dosing cohorts of safety data are available from concomitant dosing of AZD1390 with SBRT in Arm A, and provided that Arm A is advancing to Cohort 3, Arm B (with bowel and lung in SBRT treatment planning target \[PTV\]) may be triggered at the initial dose level).
62179143|NCT05678010|EXPERIMENTAL|Arm B, Dose Level 1|Participants have peripheral metastasis with bowel and lung in SBRT treatment planning target
62179144|NCT05678010|EXPERIMENTAL|Arm B, Dose Level 2|Participants have peripheral metastasis with bowel and lung in SBRT treatment planning target
62179145|NCT05678010|EXPERIMENTAL|Arm B, Dose Level 3|Participants have peripheral metastasis with bowel and lung in SBRT treatment planning target
62179146|NCT05678010|EXPERIMENTAL|Arm B, Dose Level 4|Participants have peripheral metastasis with bowel and lung in SBRT treatment planning target
62179147|NCT04904237|EXPERIMENTAL|aza-ven +MBF|treatment with aza-ven debulking therapy followed by allo-HSCT with MBF conditioning
62179148|NCT02996318|EXPERIMENTAL|Sirolimus coated Balloon|treatment of coronary DES-ISR with a sirolimus coated balloon
62771448|NCT01416428|EXPERIMENTAL|QDx2 Dosing Schedule|"QDx2 is defined as patients receiving Oprozomib Tablets once daily on Days 1, 2, 8, and 9 of the 14-day cycle.~The schedule will be evaluated in Phase 1 for MTD in patients with hematologic malignancies, and will also be evaluated in Phase 2 for ORR in patients with MM and WM."
62771449|NCT01416428|EXPERIMENTAL|QDx5 Dosing Schedule|"QDx5 is defined as patients receiving Oprozomib Tablets once daily on Days 1 to 5 of the 14-day cycle.~The schedule will be evaluated in Phase 1 for MTD in patients with hematologic malignancies, and will also be evaluated in Phase 2 for ORR in patients with MM and WM."
62771450|NCT03731260|EXPERIMENTAL|(Part 1) Avapritinib Dose 1 + BSC|Avapritinib will be administered orally in continuous 28-day cycles
62771451|NCT03731260|EXPERIMENTAL|(Part 1) Avapritinib Dose 2 + BSC|Avapritinib will be administered orally in continuous 28-day cycles
62179149|NCT02996318|ACTIVE_COMPARATOR|Paclitaxel coated balloon (SeQuent Please)|treatment of coronary DES-ISR with a paclitaxel coated balloon
62179150|NCT03361618|EXPERIMENTAL|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
62179151|NCT03361618|NO_INTERVENTION|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment.
62179152|NCT04335747||Group 1|Patients with inflammatory rheumatic diseases who are hospitalised due to a COVID-19 infection
62179153|NCT04335747||Group 2|Patients without inflammatory diseases who are hospitalised due to a COVID-19 infection
62179154|NCT04335747||Group 3|Patients with inflammatory rheumatic diseases who are having routine blood samples taken under the COVID-19 epidemic after inclusion and who have NOT been hospitalised due to a COVID-19 infection
61995084|NCT05909592||Healthy CrossFit participants and athletes|No intervention. The group will be monitored for incidence data of shoulder injuries (new or aggravated pre-existing)
61995085|NCT03214809|EXPERIMENTAL|Thoracic ultrasound protocol|ABCDE algorithm with Thoracic ultrasound protocol
62179155|NCT04335747||Group 4|Healthy subjects from the Danish Blood Donors have NOT been hospitalised due to a COVID-19 infection
62179156|NCT03796598|PLACEBO_COMPARATOR|Placebo|Oral and rectal placebo at visit 2 Oral placebo at day 30
61995086|NCT03214809|NO_INTERVENTION|No Thoracic ultrasound protocol|ABCDE algorithm without Thoracic ultrasound protocol
61995087|NCT03402438|EXPERIMENTAL|Normal (healthy subjects)|Healthy subjects matched for age, body weight and gender to the groups with renal impairment
61995088|NCT03402438|EXPERIMENTAL|Mildly renal impaired|Subjects with renal impairment and an estimated glomerular function rate between equal or above 60 and below 90 ml/min/1.75 m\*2
62179157|NCT03796598|ACTIVE_COMPARATOR|Group 3: Oral placebo and rectal FMT|Oral placebo and rectal FMT at visit 2 Oral placebo at day 30
62179158|NCT03796598|ACTIVE_COMPARATOR|Group 2: Oral FMT and rectal placebo|Oral FMT and rectal placebo at visit 2 Oral FMT at day 30
62563006|NCT03354351||QC-Group|Standard Stepped-care model where men will need to follow a sequential treatment (Step 1 (self-guided), Step 2 (Group sessions), and Step 3 (individual or couple sessions). As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
62771452|NCT03731260|EXPERIMENTAL|(Part 1) Avapritinib Dose 3 + BSC|Avapritinib will be administered orally in continuous 28-day cycles
62771453|NCT03731260|PLACEBO_COMPARATOR|(Part 1) Placebo + BSC|Placebo will be administered orally in continuous 28-day cycles
62771454|NCT03731260|EXPERIMENTAL|(Part 2) Avapritinib RP2D + BSC|Avapritinib will be administered orally in continuous 28-day cycles
61995089|NCT03402438|EXPERIMENTAL|Moderately renal impaired|Subjects with renal impairment and an estimated glomerular function rate between equal or above 30 and below 60 ml/min/1.75 m\*2
62563007|NCT06427746||Standard|stroke diagnosis in the pre-hospital settings, based on the CPSS scale assessed by lay rescuers
62563008|NCT06427746||Video call|stroke diagnosis in the pre-hospital settings, based on the CPSS scale assessed by lay rescuers during live video call with the healthcare personnel in EMS dispatch
62563009|NCT06427746||Video call + LARIO|stroke diagnosis in the pre-hospital settings, based on the CPSS + LARIO scales assessed by lay rescuers (with specific training on the 2 scales) during live video call with the healthcare personnel in EMS dispatch
62563010|NCT00677664|ACTIVE_COMPARATOR|A|Group which received Copaxone
62563011|NCT00677664|PLACEBO_COMPARATOR|B|Group which received Mannitol
62563012|NCT03781908|EXPERIMENTAL|Silver Nitrate Pleurodesis|Patients will receive 0.5% silver nitrate diluted in 50 ml distilled water with 10 ml of local anaesthetic lidocaine 1%
62563013|NCT03781908|ACTIVE_COMPARATOR|Indwelling Pleural Catheter|Catheters will be inserted in an outpatient setting under local anaesthesia.The typical drainage schedule is every other day using disposable plastic bottles (550 mL to 1 L)
62563014|NCT05685147|EXPERIMENTAL|Intervention group|the intervention group using morphology and niPGT-A
62563015|NCT05685147|NO_INTERVENTION|Control group|the control group based on morphology alone.
62563016|NCT02939677|OTHER|Targeted exercise|Targeted exercise intervention
62563017|NCT02939677|NO_INTERVENTION|care as usual|home based exercises
62563018|NCT02705365|EXPERIMENTAL|Patient Navigation|Patients assigned to the patient navigator (PN) arm will be sent a letter about the program with lung screening educational materials. The PN will educate eligible patients about lung screening, explore barriers to screening, coordinate scheduling an appointment with a provider, and possibly attend the visit with the patient. The PN will further coordinate scheduling the CT scan, help the patient obtain the test, and access any required follow-up. The PN will assess the patient's interest in quitting smoking and if so, offer and help to connect the smoker to existing cessation resources in the community and provide follow-up contacts to monitor adherence to treatments.
62563019|NCT02705365|ACTIVE_COMPARATOR|Usual Care|The control group will receive usual care during the 1-year study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results as well as smoking cessation guidance.
62563020|NCT05379413||Early BoNT treatment|Patients with PSS treated with BoNT within the first Quartile of injection timing distribution
62771455|NCT03731260|PLACEBO_COMPARATOR|(Part 2) Placebo + BSC|Placebo will be administered orally in continuous 28-day cycles
62563021|NCT05379413||Late BoNT treatment|Patients with PSS treated with BoNT within the third Quartile of injection timing distribution
62563022|NCT05379413||Not treated with BoNT|Natural controls with PSS not treated with BoNT
62563023|NCT00286104|ACTIVE_COMPARATOR|1|Bactiseal ventricular catheter (Rifampicin- and Clindamycin-impregnated)
62563024|NCT00286104|PLACEBO_COMPARATOR|2|Plain ventricular catheter
62563025|NCT04468568||Atosiban|Intravenous Atosiban as main tocolytic agent
62563026|NCT04468568||Terbutaline|Intravenous Terbutaline as main tocolytic agent
62771456|NCT03731260|EXPERIMENTAL|(Part 3) Avapritinib RP2D + BSC|Avapritinib will be administered orally in continuous 28-day cycles
62179159|NCT03796598|EXPERIMENTAL|Group 1: Dual Oral and rectal FMT|Dual Oral and rectal FMT at visit 2 Oral FMT at day 30
62771457|NCT03712111|EXPERIMENTAL|Norepinephrine 6 mcg|Mothers in this group will receive a bolus of Norepinephrine 6 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
62771458|NCT03712111|ACTIVE_COMPARATOR|Norepinephrine 10 mcg|Mothers in this group will receive a bolus of Norepinephrine 10 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
62771459|NCT02442258|EXPERIMENTAL|Group 1 - Mild Renal Impairment|Subjects with mild renal impairment. eGFR (by MDRD equation) range 60 - 89 mL/min/1.73 m2 as determined at Screening.
62771460|NCT02442258|EXPERIMENTAL|Group 2 - Moderate Renal Impairment|Subjects with moderate renal impairment. eGFR (by MDRD equation) range 30 - 59 mL/min/1.73 m2 as determined at Screening.
62179160|NCT04675398|ACTIVE_COMPARATOR|Open-loop deep brain stimulation|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving open-loop deep brain stimulation.
62179161|NCT04675398|ACTIVE_COMPARATOR|Randomized deep brain stimulation|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving closed-loop stimulation at random time points.
62179162|NCT04675398|ACTIVE_COMPARATOR|Deep brain stimulation during contralateral limb movement|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving closed-loop stimulation during time of contralateral limb movement.
62179163|NCT04675398|ACTIVE_COMPARATOR|Deep brain stimulation during contralateral limb rest|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving closed-loop stimulation during time of no movement for contralateral limb.
62771461|NCT02442258|EXPERIMENTAL|Group 3 - Severe Renal Impairment|Subjects with severe renal impairment. eGFR (by MDRD equation) range 15 - 29 mL/min/1.73 m2 as determined at Screening.
62179164|NCT00496626|EXPERIMENTAL|1|V501 (Gardasil®)
62179165|NCT00496626|PLACEBO_COMPARATOR|2|Placebo
62182750|NCT05064644|ACTIVE_COMPARATOR|Plant stanol ester comparator|Product that contains plant stanol ester
62771462|NCT02442258|EXPERIMENTAL|Group 4 - End Stage Renal Disease, Not Yet on Dialysis|Subjects with end stage renal disease, not yet on dialysis. eGFR (by MDRD equation) range \< 15 mL/min/1.73 m2 as determined at Screening.
62771463|NCT02442258|EXPERIMENTAL|Group 5 - Normal Renal Function|Subjects with normal renal function. eGFR (by MDRD equation) range ≥ 90 mL/min/1.73 m2 as determined at Screening.
62771464|NCT02442258|EXPERIMENTAL|Group 6 - End Stage Renal Disease, Requiring Dialysis.|Subjects with end stage renal disease, requiring dialysis. eGFR (by MDRD equation) \< 15 mL/min/1.73 m2 as determined at Screening.
62179166|NCT06236828||Endovascular Thrombectomy|For patients who onset within 4.5 hours and meet the criteria for intravenous thrombolysis treatment, they could receive intravenous thrombolysis treatment beforehand and bridging to endovascular therapy.
62179167|NCT06236828||Standard Medical Therapy|For patients who onset within 4.5 hours and met the criteria for intravenous thrombolysis treatment, recombinant tissue plasminogen activator (rt-PA) or urokinase, and other intravenous thrombolysis therapies should be pre-administrated.
62563027|NCT02816346|EXPERIMENTAL|Cohort 1: target dose of 500 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 500 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 510, 717, 588, and 567 CFU)."
62563028|NCT02816346|EXPERIMENTAL|Cohort 2: target dose of 1000 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1000 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 817 CFU), since the attack rate of shigellosis for Cohort 1 was below the protocol target of 60%."
62563029|NCT02816346|EXPERIMENTAL|Cohort 3: target dose of 1000 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1000 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 913 CFU. Although the target dose was the same as Cohort 2, the safety monitoring committee felt that the per-protocol a priori definition of shigellosis was too restrictive and that increasing the dose above 1000 CFU may lead to unnecessarily high toxicity."
62563030|NCT02816346|EXPERIMENTAL|Cohort 4: target dose of 1500 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1500 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 1760 CFU) since the attack rate of shigellosis for Cohort 2 and 3 was below the protocol target of 60%."
62563031|NCT02816346|EXPERIMENTAL|Cohort 5: target dose of CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1150 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 1760 CFU) as the final confirmatory cohort since it was felt that the disease rate and profile of Cohort 4 was appropriate."
62563032|NCT04231825|EXPERIMENTAL|Verum Stimulation|This group will receive 6-Hz tACS
62563033|NCT04231825|ACTIVE_COMPARATOR|Frequency Control|This group will receive 1-Hz tACS
62563034|NCT01598363|EXPERIMENTAL|Digoxin 0.5mg, Bardoxolone Methyl 20mg and 60mg|
62563035|NCT01598363|EXPERIMENTAL|Rosuvastatin 20mg, Bardoxolone Methyl 20mg and 60mg|
62563036|NCT03610204|EXPERIMENTAL|Deep massage (DM) group|"The therapist performs the deep massage with buffalo horn technique. A small rod with a cone-like end was used in the technique. By pressuring the rod end with a higher force against the body surface of the participant, it produces higher pressure that may release the deep-layer fascia of muscles. Thus this technique features a deep massage."
62179168|NCT02684955||Cerebral spectroscopy + pupillometry|During CPR, rSO2 will be monitored continuously as well as quantitative measurements of the pupillary light reaction every 5 minutes.
62179169|NCT04514692|EXPERIMENTAL|Phase I -Dose finding, Cohort 1|Dosing will occur in cohorts of 4 patients with the start at dose of GCSF will be 780 mcg x 3 days
62182751|NCT05064644|PLACEBO_COMPARATOR|Placebo comparator|Placebo product
62179170|NCT04514692|EXPERIMENTAL|Phase I -Dose finding, Cohort 2|Dosing will occur in cohorts of 4 patients, If 4 out of 4 patients achieve the target SUVmean, the GCSF dose will be 780 mcg x 2 days
62179171|NCT04514692|EXPERIMENTAL|Phase I -Dose finding, Cohort 3|Dosing will occur in cohorts of 4 patients, If 4 out of 4 patients achieve the target SUVmean, the GCSF dose will be 780 mcg x 1 day
62179172|NCT04514692|EXPERIMENTAL|Phase II-G-CSF|Phase 2 participants will be treated with the optimal dose of GCSF found in the phase 1 portion of the study.
62179173|NCT02957162|OTHER|Blood samples and Atorvastatin 80mg|All participants are given Atorvastatin 80mg as part of their standard care. The main study intervention is blood samples at days 1-2, 3-4 and 7-8.
62179174|NCT03463577||Exposed cohort women-on or after 1st day of 27th week of pregnancy|This group consisted of pregnant women who received the Tdap vaccine (Boostrix) on or after the 1st day of the 27th week of pregnancy during the period January 1, 2018 to January 31, 2019 who were not vaccinated with any other Tdap vaccine at any other time during the pregnancy.
62179175|NCT03463577||Unexposed historical cohort women|This group consisted of women matched to Exposed cohort women-on or after 1st day of 27th week of pregnancy group and pregnant at least one day during the historical period between January 1, 2012-December 31, 2014 and did not receive any Tdap vaccine during the pregnancy.
62179176|NCT03463577||Exposed cohort women-before 1st day of 27th week of pregnancy|This group consisted of pregnant women who received the Tdap vaccine (Boostrix) before the 1st day of the 27th week of pregnancy during the period January 1, 2018-January 31, 2019 who were not vaccinated with any other Tdap vaccine at any other time during the pregnancy.
62179177|NCT03463577||Exposed cohort infants-on or after 1st day of 27th week of pregnancy|This group consisted of infants whose mothers belong to Exposed cohort women-on or after 1st day of 27th week of pregnancy group.
62179178|NCT03463577||Unexposed historical cohort infants|This group consisted of infants whose mothers belong to the Unexposed historical cohort women group.
62563037|NCT03610204|ACTIVE_COMPARATOR|Superficial massage (SM) group|"The therapist performs the superficial massage with buffalo horn technique. By pressuring the rod end with a lower force against the body surface of the participant, it produces lower pressure. Thus this intervention features a superficial massage."
62563038|NCT02930499|EXPERIMENTAL|Hyaluronic Acid ECM (Hyalomatrix)|Hyalomatrix ECM will be applied to the target ulcer once weekly
62563039|NCT02930499|ACTIVE_COMPARATOR|Non-Adherent wound dressing (Mepilex)|Mepilex wound dressing will be applied to the target ulcer once weekly
62563040|NCT04369391|EXPERIMENTAL|SEP363856 150 mg|SEP363856 tablet 150 mg
62563041|NCT04369391|PLACEBO_COMPARATOR|Placebo|matched placebo
62563042|NCT04369391|ACTIVE_COMPARATOR|moxifloxacin 400 mg|moxifloxacin tablet 400 mg
62563043|NCT00691444|EXPERIMENTAL|1|Subjects will be given up to 0.5 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
62771465|NCT06301750|EXPERIMENTAL|Intermittent Oral-esophageal Tube Feeding group|This group is hospitalized, while conventional care and enteral nutrition support are provided to the two groups. The Intermittent Oral-esophageal Tube Feeding group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support
62563044|NCT00691444|EXPERIMENTAL|2|Subjects will be given up to 10 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
62771466|NCT06301750|ACTIVE_COMPARATOR|Nasogastric tube group|This group is hospitalized, while conventional care and enteral nutrition support are provided to the two groups. The Nasogastric tube group receives Nasogastric Tube Feeding for enteral nutrition support
62179179|NCT03463577||Exposed cohort infants-before 1st day of 27th week of pregnancy|This group consisted of infants whose mothers belong to the Exposed cohort women-before 1st day of 27th week of pregnancy group.
62179180|NCT02672397|EXPERIMENTAL|Hispanic Intervention|Hispanic subjects that receive additional epidural education \[44 patients\]
62563045|NCT00691444|EXPERIMENTAL|3|Subjects will be given up to 20 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
62563046|NCT01493518|PLACEBO_COMPARATOR|PLACEBO|
62771467|NCT00430937|EXPERIMENTAL|Daptomycin|4 mg/kg intravenous (i.v.) once daily
62179181|NCT02672397|NO_INTERVENTION|Hispanic Control|Hispanic subjects that receive standard of care \[44 patients\]
62179182|NCT02672397|EXPERIMENTAL|Non-Hispanic Intervention|Non-Hispanic subjects that receive additional epidural education \[44 patients\]
62179183|NCT02672397|NO_INTERVENTION|Non-Hispanic Control|Non-Hispanic subjects that receive standard of care \[44 patients\].
62179184|NCT02110511|EXPERIMENTAL|alpha-gal & blended lentils|3 capsules of alpha-gal taken with blended lentils
62179185|NCT02110511|EXPERIMENTAL|alpha-gal & whole lentils|3 calpsules of alpha-gal taken with whole lentils
62179186|NCT02110511|EXPERIMENTAL|alpha-gal & no lentils|3 capsules of alpha-gal taken with no lentils control
62563047|NCT01493518|EXPERIMENTAL|AMG 557|
62179187|NCT02110511|PLACEBO_COMPARATOR|Placebo & blended lentils|3 capsules of placebo taken with blended lentils
62179188|NCT02110511|PLACEBO_COMPARATOR|Placebo & whole lentils|3 capsules of placebo taken with whole lentils
62179189|NCT02110511|PLACEBO_COMPARATOR|Placebo & no lentils|3 capsules of placebo taken with no lentils control
62179190|NCT02999347||Cases|Women having undergone at least one pregnancy/delivery after their MUS surgery
62179191|NCT02999347||Controls|Every case will be matched with two controls. The controls will be matched with the study cases' age and year of surgery (+- 2 years of age if a perfect match is not obtainable). These controls have not undergone a subsequent pregnancy/delivery.
62179192|NCT04700878|EXPERIMENTAL|Internet-based compassion course|Therapist guided Internet-compassion course for workrelated stress.
62563048|NCT02912702|EXPERIMENTAL|L-DEP|Pegaspargase 2000U/m2 day5; doxorubicin hydrochloride liposome injection 25 mg/m2 day 1; etoposide 100 mg/m2 was administered once on the first day of every week; methylprednisolone 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
62563049|NCT02912702|ACTIVE_COMPARATOR|HLH-94 regimen|Etoposide 150 mg/m2 twice weekly for 2 weeks and then weekly; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
62771468|NCT00430937|ACTIVE_COMPARATOR|Pooled Comparator|
62563050|NCT00725283|EXPERIMENTAL|GSK2130579A Group|Patients with cytologically proven AML, as defined by the World Health Organization classification, who were administered a standard dose of GSK2130579A treatment. Patients received 24 doses of the study treatment over a period of approximately 4 years.
62563051|NCT03883997||Participants|Professional male soccer players from the second professional Mexican division.
62179193|NCT04700878|ACTIVE_COMPARATOR|General internet-based CBT stress management course|Therapist guided Internet-cognitive behavioral (CBT) course for workrelated stress.
62179194|NCT04700878|OTHER|Waitlist|Waitlist for 10 weeks, and thereafter the general internet-based CBT management course.
62179195|NCT03820869|ACTIVE_COMPARATOR|Control|Children with ASD
62563052|NCT00718874|EXPERIMENTAL|A, 1|low-carbohydrate (42%)
62563053|NCT00718874|EXPERIMENTAL|A,2|standard carbohydrate (55%) based on ADA recommendations
62563054|NCT01808846||Lean Adolescents|Kids aged 12-17 with body mass index less than 25% and normal glucose tolerance test results
62563055|NCT01808846||Obese Insulin Sensitive|Obese Insulin Sensitive Adolescents aged 12-17 with BMI\>95th% and whole body insulin sensitivity index \> 3.
62563056|NCT01808846||Obese Insulin Resistant Adolscent|Obese Insulin Resistant Adolescents 12-17 with BMI\> 95th% and WBISI\<1.2.
62771469|NCT06020443|OTHER|Patients with a high risk of lung cancer|
62771470|NCT00641082|EXPERIMENTAL|1|Clevudine
62771471|NCT00641082|ACTIVE_COMPARATOR|2|Adefovir
62179196|NCT03820869|EXPERIMENTAL|Intervention|Children with ASD
62179197|NCT02241447||Observation|the nurse identifies cases with severe AS and collects their data. Baseline data for each patient will be collected and a follow-up will be done after three months for each patient to determine his/her outcome and the treatment that was decided on
62179198|NCT02241447||Early information|in this arm, the physician referring a patient for echocardiography will be notified of a finding of severe aortic stenosis: the nurse brings cases with severe AS to the attention of the referring physician within a week (via phone, e-mail or letter) to make them aware of the diagnosis.
62179199|NCT02044614|OTHER|icodextrin-based peritoneal dialysis to hemodialysis|12-week course of adjuvant low-frequency icodextrin-based peritoneal dialysis to ongoing thrice-weekly maintenance hemodialysis
62179200|NCT01732341|EXPERIMENTAL|STENTYS self-apposing stent|Intervention to treat STEMI with the STENTYS self-apposing stent
62179201|NCT01732341|ACTIVE_COMPARATOR|VISION balloon-expandable stent|STEMI treatment with a VISION balloon-expandable stent
62179202|NCT03454659||high (0.8 )|The purpose of this study is to compare the effect of high 0.8 and low 0.4 FiO2 ventilation primarily on surgical field infection and secondarily on postoperative pulmonary complications in patients are undergoing supratentorial craniotomy surgeons.
62179203|NCT03454659||low (0,4) fiO2|The purpose of this study is to compare the effect of high 0.8 and low 0.4 FiO2 ventilation primarily on surgical field infection and secondarily on postoperative pulmonary complications in patients undergoing supratentorial craniotomy surgeons.
62179204|NCT01015378||Diverticulitis of the sigmoid colon - first episode|
62179205|NCT06454318||All patients|Patients undergoing polysomnography and having Wellue O2 ring wear when doing polysomnography
62563057|NCT00333320|PLACEBO_COMPARATOR|- Control|
62563058|NCT00333320|EXPERIMENTAL|-postconditioning group|
62771472|NCT05364762|EXPERIMENTAL|Prevention (PBSCs, cyclophosphamide, itacitinib, tacrolimus)|Patients undergo peripheral blood stem cell infusion on day 0. Patients receive cyclophosphamide IV QD on days 3 and 4, itacitinib PO QD on days 5-100, and tacrolimus IV or PO on days 6-65.
62179206|NCT04196829|EXPERIMENTAL|silver diamine fluoride ⁄ potassium Iodide|38% silver diamine fluoride and a saturated solution of potassium iodide
62179207|NCT04196829|ACTIVE_COMPARATOR|silver diamine fluoride|38% silver diamine fluoride
62771473|NCT03688568|EXPERIMENTAL|Imatinib Mesylate Arm|Imatinib Mesylate, given daily orally, 55 mg PO BID, if tolerated for 2 weeks increase to 110 mg/m2 BID, and further increase to 165 and final dosage to 220 mg/m2 bid if tolerated. Can continue for 12 months.
62771474|NCT06066073|EXPERIMENTAL|Lavender group|Patients who were included in this group were subjected to vapors of the lavender oil in waiting rooms, during dental therapy, and on day after dental procedures
62563059|NCT00194441|EXPERIMENTAL|1|Highly visible continually updating color coded bar computer display of cerebral perfusion pressure.
62563060|NCT00194441|PLACEBO_COMPARATOR|2|Bedside computer display with a blank screen except for a message indicating that the program is running.
62563061|NCT00707239|EXPERIMENTAL|A|
62771475|NCT06066073|PLACEBO_COMPARATOR|Control group|Patients who were included in this group were subjected to vapors of distal water in waiting rooms and during dental therapy
62179208|NCT01214681|PLACEBO_COMPARATOR|Placebo|
62179209|NCT01214681|EXPERIMENTAL|Hi-maize 260|
62179210|NCT01214681|EXPERIMENTAL|Polydextrose|
62563062|NCT00707239|EXPERIMENTAL|B|
62179211|NCT01214681|ACTIVE_COMPARATOR|Hi-maize 260 and polydextrose|
62179212|NCT00566345|EXPERIMENTAL|Influenza vaccine|Vero-cell derived influenza vaccine
62179213|NCT00566345|PLACEBO_COMPARATOR|Placebo|Phosphate buffered saline (packaged in syringes identical to those used for the investigational vaccine)
62179214|NCT00953511|OTHER|genetic|
62563063|NCT00707239|ACTIVE_COMPARATOR|C|
62563064|NCT02013817|EXPERIMENTAL|MabThera/Rituxan|
62563065|NCT04899180|OTHER|SPECT/CT|99mTc-PYP single-photon positive emission computed tomography with computed tomography
62563066|NCT00556946|OTHER|Combined Photodynamic & Pulsed Dye Laser Treatment|Treatment of Port Wine Stains
62563067|NCT01173484||Vomiting-predominant idiopathic gastroparesis|Vomiting with retching and nausea are the most bothersome symptoms
62771476|NCT04039152||The pre-antibiotics stewardship program phase|This phase included making NICU-specific antibiograms, choosing the antibiotic use evaluation measures, conducting antibiotic use evaluations, and designing the antibiotics stewardship program (ASP).
62771477|NCT04039152||The antibiotics stewardship program intervention phase|The ASP intervention phase included implementation of the ASP, which involved modifying the neonatal sepsis treatment protocol according to the local antibiotic susceptibility patterns and measuring its clinical outcomes.
62771478|NCT05587166|ACTIVE_COMPARATOR|The transverse short-axis group|
62771479|NCT05587166|EXPERIMENTAL|The oblique short-axis group:|
62771480|NCT01422668|ACTIVE_COMPARATOR|GI of Khalas dates|The Glycemic indices of the Khalas dates were measured for healthy and diabetic subjects.
62771481|NCT01422668|EXPERIMENTAL|GI of the Khalas dates with Coffee|measuring the effect of 100 ml of coffee consumption on the GI of the Khalas dates among healthy and diabetic subjects.
62771482|NCT01043588|OTHER|1 : TURP|Surgery: TransUrethral Resection of the Prostate
62771483|NCT01043588|OTHER|2 : PVP|Surgery: Photo selective Vaporization of the Prostate
62771484|NCT05671796|EXPERIMENTAL|Mesenchymal stem cell transplantation|Two intrathecal autologous bone marrow stem cell transplantation of 1 ml solution containing 5x10,000,000 MSCs each with a 90-day interval between applications.
62771485|NCT05671796|PLACEBO_COMPARATOR|Placebo|Two subcutaneous injections of 1 ml each, containing glycophysiological solution.with a 90-day interval between applications.
62771486|NCT04427449|EXPERIMENTAL|Experimental: Single arm 4SCAR-CD44v6 T cells to treat cancer|
62771487|NCT04784468||Covid-19|Covid-19 patients
62771488|NCT04784468||Influenza|Influenza patients
62771489|NCT04784468||Cotrol|Control group
62563068|NCT01173484||Dyspepsia-predominant idiopathic gastroparesis|Unpleasant or troublesome sensation (discomfort or pain) centered in the upper abdomen is the most bothersome symptom; this sensation may be characterized by or associated with upper abdominal fullness, fullness after small meals, bloating, or nausea
62563069|NCT01173484||Regurgitation-predominant idiopathic gastroparesis|Effortless regurgitation of acid or undigested food or heartburn is the most bothersome symptom
62771490|NCT00428207|ACTIVE_COMPARATOR|Insulin Aspart Versus Insulin Lispro|Insulin aspart will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Insulin aspart doses will be adjusted by the principal investigator as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Lispro).
62771491|NCT00428207|ACTIVE_COMPARATOR|Insulin Lispro Versus Insulin Aspart|Insulin lispro will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Dose will be adjusted as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Aspart).
62771492|NCT05696574|EXPERIMENTAL|Vaginal Misoprostol group|Women in this group will include 40 pregnant women who will be offered misoprostol (placed in the post-fornix of the vagina) in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
62771493|NCT05696574|EXPERIMENTAL|Oral Misoprostol group|Women in this group will include 40 pregnant women who will be offered oral misoprostol in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
62771494|NCT02886559|EXPERIMENTAL|DCCAG|Chidamide 30mg twice for one week decitabine 20mg/m\^2 for 5 days
62563070|NCT04587869|EXPERIMENTAL|Intervention|The intervention is an 8-session cognitive behavior therapy (CBT) group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM).
62563071|NCT04587869|NO_INTERVENTION|No-treatment control|Participants who are assigned to the control group will not receive the intervention.
62563072|NCT02968602|EXPERIMENTAL|Minocycline|Participants will take 50 mg minocycline capsules twice daily for 1 week, then take 100 mg capsules twice daily for 1 week.
62563073|NCT02968602|PLACEBO_COMPARATOR|Placebo|Participants will take capsules that match active drug, but contain no active ingredients, twice daily for week 1, and then will take capsules that match active drug, but contain no active ingredients, twice daily for week 2.
62563074|NCT02824120|EXPERIMENTAL|Comedy|patients in this group will watch a comedy film that will not exceed 30 minutes
62563075|NCT02824120|EXPERIMENTAL|Documentary|patients in this group will watch a documentary film that will not exceed 30 minutes.
62563076|NCT02166333|ACTIVE_COMPARATOR|200 IU/d|200 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
62563077|NCT02166333|ACTIVE_COMPARATOR|1000 IU/d|1000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
62563078|NCT02166333|ACTIVE_COMPARATOR|2000 IU/d|2000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
62563079|NCT02166333|ACTIVE_COMPARATOR|4000 IU/d|4000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
62563080|NCT04846569|EXPERIMENTAL|Transition Theory-based Intervention|Participants in the intervention arm will receive the Transition Theory-based intervention consisting of 4 sessions with a community health worker (2 during pregnancy, 2 postpartum) to support their transition from pregnancy to postpartum.
62563081|NCT04846569|ACTIVE_COMPARATOR|Enhanced Standard of Care Control|Participants in the control arm will receive the standard of care plus one session with a community health worker.
62179215|NCT00523549|EXPERIMENTAL|Standard treatment regimen|(Valsartan + Amlodipine to target SBP of \< 140 mmHg)
62771495|NCT04807387|EXPERIMENTAL|Healthy participants: acute|Healthy participants will wear one of two vaginal stents for 24 hours, followed by a 24 hour wash out period. They will then wear the second vaginal stent for 24 hours. After both stents have been worn, the participants will choose the most comfortable stent.
62771496|NCT04807387|EXPERIMENTAL|Healthy participants: chronic|Healthy participants will wear the stent chosen to be the more comfortable for 2 weeks without removal.
62771497|NCT04807387|EXPERIMENTAL|Pediatric participants: post vaginal surgery|Pediatric participants will wear the vaginal stent for 2 weeks after undergoing vaginal surgery.
62771498|NCT04807387|EXPERIMENTAL|Adult participants: post vaginal brachytherapy|Adult participants undergoing vaginal brachytherapy for cancer treatment will wear the stent for 2 weeks, be evaluated by a physician, and wear the stent for an additional 2 weeks.
62771499|NCT02967939|EXPERIMENTAL|DA-2802|DA-2802 319mg tablet qd
62771500|NCT02967939|ACTIVE_COMPARATOR|Viread®|Viread® 300mg tablet qd
62771501|NCT02929082|EXPERIMENTAL|Group 1 : volunteer patient|Group 1 will be constituted of 20 volunteer patients coming for abdominal MRI with no known hepatic disease, in order to determine the feasibility of FRM . A 5-minute- additional sequence to measure FRM will be done for the volunteers.
62771502|NCT02929082|EXPERIMENTAL|Group 2 : patient with resectable HCC|"Group 2 will be constituted of 60 patients with resectable HCC eligible for surgery. This group will enable to evaluate the gold standard.~A 5-minute- additional sequence to measure FRM will be done while MRI sequence."
62771503|NCT02929082|EXPERIMENTAL|Group 3 : patient with HCC eligible for TACE|"Group 3 will be constituted of 50 patients with HCC eligible for transplant with transcatheter arterial chemoembolization (TACE) treatment as pending treatment before transplant. This groups will enable to evaluate the efficiency of TACE through the necrosis percentage in treated HCC.~A 5-minute- additional sequence to measure FRM will be done while MRI sequence"
62771504|NCT00757692|EXPERIMENTAL|A|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
62771505|NCT00757692|ACTIVE_COMPARATOR|B|Bicalutamide at 50 mg will be administered orally, daily and continuously.
62771506|NCT06089941||Detection of circulating tumoral DNA|Blood assessment to detect circultating tumoral DNA
62771507|NCT03046979|EXPERIMENTAL|Apatinib|a molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
62771508|NCT03909828||Parkinson's disease patients|patients with Idiopathic Parkinsonism
62771509|NCT03385330|ACTIVE_COMPARATOR|LOWER oxygen saturation target group|Oxygen saturation (SpO2) target range 90--94%. The study intervention will begin in the hospital and will continue at home until 6 months corrected age (CA). Overnight continuous oximetry will be transmitted wirelessly to the study team. In hospital, inspired oxygen will be adjusted as needed to maintain target SpO2. Monitoring will continue after discharge, and oxygen flow will be titrated monthly according to a standardized algorithm.
62771510|NCT03385330|ACTIVE_COMPARATOR|HIGHER oxygen saturation target group|Oxygen saturation target range greater than or equal to 96%.The study intervention will begin in the hospital and will continue at home until 6 months CA. Overnight continuous oximetry will be transmitted wirelessly to the study team. In hospital, inspired oxygen will be adjusted as needed to maintain target SpO2. Monitoring will continue after discharge, and oxygen flow will be titrated monthly according to a standardized algorithm.
62771511|NCT00228865|EXPERIMENTAL|1|Testing performed on diabetic patients with decline in cognitive function at baseline and quarterly after the start of receiving pulsatile intravenous insulin therapy to assess continuing cognitive function ability.
62771512|NCT02759224|OTHER|Arm A (Lafutidine and Irsogladine maleate --> BRI-1501)|Subjects of Arm A take Lafutidine and Irsogladine maleate Individual tablets at 1st day as period I. And then, after wash out for 35 days, as period II, subjects of Arm A take a BRI-1501 tablet at 36th day
62771513|NCT02759224|OTHER|Arm B (BRI-1501 --> Lafutidine and Irsogladine maleate)|Subjects of Arm B take a BRI-1501 tablet at 1st day as period I. And then, after wash out for 35 days, as period II, subjects of Arm B take Lafutidine and Irsogladine maleate Individual tablets at 36th day
62771514|NCT01985763|EXPERIMENTAL|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin Genistein 60mg/day orally for 7 days every 2 weeks. Genistein will be administered beginning 4 days prior to FOLFOX or FOLFOX-Avastin and continuing the 3 days of chemotherapy.
62771515|NCT01435967||Cohort A|Children aged \<=5 years in Belgium, with opportunity to receive Rotarix, requiring hospitalisation during which rotavirus detection test was performed and with available results.
62771516|NCT02992535|EXPERIMENTAL|Single arm|Intense pulse light therapy (E-Schwin)
62771517|NCT00209898|ACTIVE_COMPARATOR|Rapid standard of care|Rapid standard of care treatment after screening
62771518|NCT00209898|ACTIVE_COMPARATOR|Ordinary standard of care|Subject put on ordinary waiting list for hcv treatment in Our outpatient clinic
62771519|NCT02066129|ACTIVE_COMPARATOR|Fluticasone 44 mcg|"Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of yellow zone symptoms."
62771520|NCT02066129|ACTIVE_COMPARATOR|Fluticasone 220 mcg|"Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of yellow zone symptoms."
62771521|NCT00812903|NO_INTERVENTION|Control|Control group
62771522|NCT00812903|EXPERIMENTAL|Exercise|Intervention group
62771523|NCT04455945||Open|Patients with open surgery for rectal cancer planned in our department.
62771524|NCT04455945||Laparoscopic|Patients with laparoscopic surgery for rectal cancer planned in our department.
62771525|NCT04337008|ACTIVE_COMPARATOR|Positive COVID 19 patient with no respiratory distress|
62179216|NCT00523549|EXPERIMENTAL|Intensive treatment regimen|(Valsartan + Amlodipine to target SBP \< 130 mm Hg)
62179217|NCT06478576|EXPERIMENTAL|multibranched stent graft system|Endovascular treatment of patients withThoracoabdominal Aortic Aneurysm using multibranched stent graft system
62771526|NCT04337008|EXPERIMENTAL|Positive COVID 19 patient with respiratory distress|
62179218|NCT03822377|EXPERIMENTAL|Ticagrelor orodispersible tablets|"STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as orodispersible tablets.~Intervention: administration of Ticagrelor 180 mg loading dose as orodispersible tablets."
62179219|NCT03822377|ACTIVE_COMPARATOR|Ticagrelor standard tablets|"STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as standard coated tablets.~Intervention: administration of Ticagrelor 180 mg loading dose as standard coated pills."
62563082|NCT05183139|EXPERIMENTAL|Cohort A: Ixazomib 4 mg + Pomalidomide 4 mg + Dexamethasone 40 mg|Ixazomib 4 mg (3 mg for participants with moderate or severe hepatic impairment, severe renal impairment, or end-stage renal disease requiring dialysis), capsules, orally, on Days 1, 8, and 15, along with pomalidomide 4 mg, capsules, orally from Days 1 to 21 and dexamethasone 40 mg (20 mg if the participant is over 75 years of age), tablets, orally on Days 1, 8, 15, and 22 of each 28-day cycle, for a maximum of 39 cycles or until disease progression or unacceptable toxicity leading to discontinuation of ixazomib or to a change in regimen. Participants who were taking modified doses of pomalidomide or dexamethasone can start at that dose level in the study.
62563083|NCT05183139|EXPERIMENTAL|Cohort B: Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 mg (3 mg for participants with moderate or severe hepatic impairment, severe renal impairment, or end-stage renal disease requiring dialysis), capsules, orally, on Days 1, 8, and 15, along with lenalidomide 25 mg capsules, orally, from Days 1 to 21 and dexamethasone 40 mg (20 mg if the participant is over 75 years of age), tablets, orally, on Days 1, 8, 15, and 22 of each 28-day cycle, for a maximum of 39 cycles or until disease progression or unacceptable toxicity leading to discontinuation of ixazomib or to a change in regimen. Participants who were taking modified doses of lenalidomide or dexamethasone can start at that dose level in the study.
62179220|NCT03719378|NO_INTERVENTION|Traditional Fluid|"* NPO Clears and Food after midnight.~* 2 Liters of lactated ringers administered by anesthesia intraoperatively.~* Postoperatively - 2 Liters of Crystalloid while in PACU and Inpatient Room for a Total of 4 Liters of Crystalloid within 24 hours. (Patient will receive 500 milliliters while in PACU and 1500 milliliters while in their Inpatient Room, for a total of 2 Liters).~* Normal diet postoperatively."
62179221|NCT03719378|EXPERIMENTAL|Oral Fluid|"* Pre Operative Oral Fluids (Patients encouraged to drink a minimum of 60 ounces of clear liquid per day for the 3 days prior to procedure.)~* NPO Food/Milk: none beginning 8 hours prior to procedure time.~* Pre Operative Oral Fluids (Patients are asked to drink 10 ounces of clear liquid 4 hours prior to their scheduled procedure time.)~* Preoperative holding area, IV is started in the patient with Lactated Ringers IV fluid at a rate of 75ml/hr. IV fluids will be stopped and hep-locked in the PACU when the patient is taking PO fluid; the total amount of IV fluids is not to exceed 500ml total.~* PO fluid protocol: a minimum of 60 ounces of liquid per day for 3 days."
62771527|NCT05980338|ACTIVE_COMPARATOR|control group|The patients are placed in supine position with knee preparation using an iodine-based product and drape in a sterile manner Then the ground pad of the radio frequency machine will be placed in the other leg (we used the Neurotherm NT1100 re generator) All the patients will be monitored by ECG, noninvasive blood pressure and pulse oximetry The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves ( superior medial genicular, superior lateral genicular and the inferior medial genicular nerves ). this group will receive radio frequency alone .
62771528|NCT05980338|EXPERIMENTAL|study group|this group will pass through the all steps but after the radiofrequency is done at each level a 1 ml of 70% alcohol will be injected making a total of 3 ml injection to each nerve.
62179222|NCT02861625||Group A|letter of condolence offering to the reliable person a post-death consultation with the reference physician (sent between J15 and J30 post death)
62179223|NCT02861625||Group B|no intervention, i.e without a letter of condolence proposing a consultation with the reference physician
62179224|NCT02741258|EXPERIMENTAL|Mepitel Film|Mepitel film will be placed on the patients' skin just before the start of the radiotherapy and will be replaced once a week until the end of the radiotherapy. In case of skin toxicities mepitel film will be placed until resolution of the toxicities. In case of new skin toxicities appearance the patient will be retreated with Mepitel.
62179225|NCT02741258|ACTIVE_COMPARATOR|Excipial U hydrolotion, Flammazin skin cream|Patients will be treated with aqueous (Excipial U hydrolotion) or antiseptic (Flammazine or Ialugen Plus) cream in case of skin erythema due to radiotherapy. In case of new skin toxicities appearance the patient will be retreated with standard of care treatment.
62563084|NCT03491293|ACTIVE_COMPARATOR|Behavioral Weight Loss + Text chat|Internet delivery of a behavioral weight control program via text in a group format facilitated by an experienced registered dietitian. Participants will have access to study materials including behavioral weight loss lessons on the study's website. Participants will weigh themselves daily and report their weight privately (data will only be accessible by research personnel) on the study website.
62563085|NCT03491293|EXPERIMENTAL|Behavioral Weight Loss + Video chat|Internet delivery of a behavioral weight control program via video in a group format facilitated by an experienced registered dietitian. Participants will have access to study materials including behavioral weight loss lessons on the study's website. Participants will be given smart scales to weigh daily, and weight will be transmitted to a secure website accessible only by research personnel.
62563086|NCT05566899|EXPERIMENTAL|EGD at time of routine screening colonoscopy|This happens on Day 0. Screening for EGD, biopsy samples from esophagus, stomach, gastrointestinal junction, and duodenum AE's.
62179226|NCT02356484||Major abdominal surgery cohort|In this surgical cohort, 4 inflammatory markers were measured: albumin, procalcitonin, CRP and lactate levels
62179227|NCT03524768||patients presenting with Chagas cardiomyopathy|Evaluation of systemic microvascular reactivity using laser speckle contrast imaging Evaluation of skin capillary density using video-capillaroscopy
62179228|NCT03524768||control group|Evaluation of systemic microvascular reactivity using laser speckle contrast imaging Evaluation of skin capillary density using video-capillaroscopy
62179229|NCT02604485|OTHER|Cohort|XOMA 358 dose level A, dose level B, dose level C, and dose level D.
62179230|NCT05951621|EXPERIMENTAL|Qigong group|On the basis of nutrition and exercise management and guidance, Qigong is exercised. Offline intensive learning once a week, 45-60 minutes each time, study for 12 weeks, and arrange online theory lecture once a week. In addition to concentrated learning, subjects in this group were required to practice themselves at home, at least once a day, each time for 30 minutes.
62563087|NCT01461694|ACTIVE_COMPARATOR|IPL|Half face treated with IPL
62771529|NCT03051594|ACTIVE_COMPARATOR|visual tactile assessment|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after visual tactile assessment.
62179231|NCT05951621|EXPERIMENTAL|Control group|guidance of nutrition and exercise
62179232|NCT01178177||SOT recipients|solid organ transplant recipients with invasive pulmonary aspergillosis
62391152|NCT02718131|ACTIVE_COMPARATOR|INFUSE Bone Graft (BMP-2)|Children with NF1 and tibial pseudarthrosis who require surgery will have the INFUSE bone graft added to their surgical protocol. After a standard surgical approach of resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest; in addition, the INFUSE bone graft in the form of a collagen sponge will be wrapped around the tibia during the surgical process.
62391153|NCT02718131|PLACEBO_COMPARATOR|Control Group|Children with NF1 and tibial pseudarthrosis who require surgery will receive the standard surgical protocol only. This includes resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest.
62771530|NCT03051594|ACTIVE_COMPARATOR|caries detector dye|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after after using caries detector dye to determine the excavation endpoint.
62563088|NCT01461694|ACTIVE_COMPARATOR|Alexandrite Laser|Half face treated with Alexandrite Laser
62563089|NCT01935141|EXPERIMENTAL|Low-Dose IV Contrast|A single intravenous dose of 30 ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.
61995090|NCT03402438|EXPERIMENTAL|Severely renal impaired|Subjects with renal impairment and an estimated glomerular function rate between below 30 ml/min/1.75 m\*2
62563090|NCT01935141|ACTIVE_COMPARATOR|Full-Dose IV Contrast|A single intravenous dose of 100ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.
62563091|NCT05650112|EXPERIMENTAL|FB-001 Healthy Volunteer|Healthy volunteer participants in Part 1 receive FB-001 (1 x 10\^12 viable cells) orally on Day 1 and Day 2 and FB-001 (1 x 10\^11 viable cells) orally on Days 3 to 10.
62563092|NCT05650112|PLACEBO_COMPARATOR|Placebo|Healthy volunteer participants receive placebo once a day, orally, for 10 days in Part 1.
62771531|NCT03051594|EXPERIMENTAL|fluorescent camera|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after after using fluorescent camera to determine the excavation endpoint.
62771532|NCT01329744|EXPERIMENTAL|Treatment|Recombinant IGF-I
62771533|NCT01329744|PLACEBO_COMPARATOR|Placebo|
62771534|NCT05011799|EXPERIMENTAL|Arm I (health education)|Participants attend 1-2 monthly peer educator-led education sessions about PCA genetic testing over 3 hours each for 18 months.
62771535|NCT05011799|ACTIVE_COMPARATOR|Arm II (cancer educational materials)|Participants receive mailed informational materials about PCA risk, family history, and genetic testing.
62771536|NCT00629798|EXPERIMENTAL|1|This is a single arm phase II trial to assess the efficacy (decrease the transplant related mortality) and safety of peri-transplant Palifermin in combination with a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with advanced MDS and AML evolved from MDS. The addition of Palifermin is to decrease the toxicity and the infection rate associated with this regimen and transplant type and to foster earlier immune reconstitution.
61995091|NCT05655611|EXPERIMENTAL|first rib mobilization|To perform the first rib mobilization, the patient remained lying supine with the head in the examiner's right hand. Examiner then palpated the left first rib and passively side-bended the patient's head to the left to relieve any muscular tension on the first rib. Patient was then asked to take a deep breath in and out. During exhalation, the examiner applied pressure to depress the first rib, holding it in place at the end of the exhalation. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation. This process was repeated three times in two sets, for a total of six first rib depression mobilizations
62179233|NCT01178177||Hematologic disease|Hematologic disease patients with invasive pulmonary aspergillosis
62391154|NCT00617942|EXPERIMENTAL|Neo-adjuvant cohort 1|
62391155|NCT00617942|EXPERIMENTAL|Neo-adjuvant cohort 2|
62771537|NCT04229836|EXPERIMENTAL|Tildrakizumab|Participants will receive subcutaneous (SC) injection of tildrakizumab 100 milligrams (mg).
62771538|NCT01494519|ACTIVE_COMPARATOR|Treament Arm 1|Definitive fixation with an external ring fixator.
62771539|NCT01494519|ACTIVE_COMPARATOR|Treatment arm 2|Definitive fixation with a locked IM nail or plate
61995092|NCT05655611|ACTIVE_COMPARATOR|muscle energy technique|All the patients will receive conventional physical therapy treatment and muscle energy techniques for shoulder flexion, abduction, internal and external rotation. Muscle energy technique was applied for five repetitions per set, five sets per session, one session per day, three days a week for three weeks with each repetition maintained for the duration of 7-10 seconds
62179234|NCT05101083|EXPERIMENTAL|Hearing Aid 1|New Receiver-in-Canal device, successor of previous device generation
62179235|NCT05101083|ACTIVE_COMPARATOR|Hearing Aid 2|Legacy Receiver-in-Canal device that is currently available on the market
62179236|NCT03094624|EXPERIMENTAL|Amusia|Since 2006, recruitment of amusia participants has been organized in the Lyon region, and some 20 participants (and their matched controls in terms of age, sex, laterality, musical practice, number of years of study) have already taken part various studies conducted at the CRNL. The recruitment of amusia participants and controls is continued in order to maintain a sufficient number of participants and compensate for the withdrawals within the cohort already constituted (lack of availability, geographical distance, etc.).
62179237|NCT03094624|SHAM_COMPARATOR|Matched controls|Matched controls of age, sex, laterality, musical practice, number of years of studies.
62563093|NCT05650112|EXPERIMENTAL|FB-001 Enteric Hyperoxaluria|Enteric hyperoxaluria participants in Part 2 receive FB-001 (1 x 10\^12 viable cells) orally on Day 1 and Day 2 and FB-001 (1 x 10\^11 viable cells) orally on Days 3 to 10.
62563094|NCT06476990|ACTIVE_COMPARATOR|Food-only group|
62563095|NCT06476990|EXPERIMENTAL|Food + CHW group|
62563096|NCT03842319|EXPERIMENTAL|Control|In patients allocated to the control group, the currently used Spanish Mediterranean diet will be recommended as part of a standard high-quality secondary prevention program, where the patient is invited to participate in a single 45 minute nutritional educational group session. Interventions: Microbiota analysis, Immunological analysis, Proteome analysis, Metabolome analysis, Clinical evaluation
62771540|NCT03346577||Patients with peripheral artery disease|located in the common and external iliac artery, the common and superficial femoral artery, the popliteal artery and/or the below-the-knee (BTK) arteries (anterior tibial artery, posterior tibial artery or peroneal artery).
62771541|NCT01086852|EXPERIMENTAL|FACTOR X|Human Coagulation Factor X
62771542|NCT01586455|EXPERIMENTAL|Group A|related cord blood with ≥3/6 HLA match to the patient and related HPDSC
62771543|NCT01586455|EXPERIMENTAL|Group B|unrelated cord blood with ≥ 4/6 HLA match to the patient and unrelated HPDSC
62771544|NCT01586455|EXPERIMENTAL|Group C|unrelated cord blood with ≥4/6 HLA match to the patient but related to HPDSC
61995093|NCT02045511|EXPERIMENTAL|Immediate Treatment Group|Immediate treatment with Baltimore HEARS intervention
62179238|NCT04853407|EXPERIMENTAL|LY03005 extended-release tablets 80 mg group|orally once a day
62771545|NCT01586455|EXPERIMENTAL|Group D|double unrelated cord blood units with ≥4/6 HLA match to patient and each other and unrelated HPDSC
62771546|NCT01633190||Rotavirus|- Children (0-16 years of age)admitted to hospital (through to December 31, 2020)
62771547|NCT01300988|ACTIVE_COMPARATOR|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
62771548|NCT01300988|PLACEBO_COMPARATOR|Placebo|Aprepitant (Emend®) placebo for 14 days
62771549|NCT04233944||Pregnant women and their infants|Mothers and their infants were followed throughout the first two years of the infant's life. Data were collected at enrollment, birth, 3, 6, 9,12, 18 and 24 months from the date of delivery.
62179239|NCT04853407|EXPERIMENTAL|LY03005 extended-release tablets 160 mg group|orally once a day
62179240|NCT04853407|PLACEBO_COMPARATOR|Placebo group|orally once a day
62179241|NCT01052389|EXPERIMENTAL|Aripiprazole|Aripiprazole (N05AX12)
62179242|NCT01052389|EXPERIMENTAL|Olanzapine|Olanzapine (N05AH03)
62179243|NCT01052389|EXPERIMENTAL|Haloperidol|Haloperidol (N05AD01)
62179244|NCT02085902|NO_INTERVENTION|standard anesthesia|
62179245|NCT02085902|EXPERIMENTAL|standard anesthesia with ropivacaine|ropivacaine
62179246|NCT02705625|EXPERIMENTAL|MIV-711:1|MIV-711 for a total of 26 w
62179247|NCT02705625|EXPERIMENTAL|MIV-711:2|MIV-711 for a total of 26 w
62179248|NCT02705625|PLACEBO_COMPARATOR|Placebo|Placebo for a total of 26 w
62179249|NCT02867098|EXPERIMENTAL|Cohort 1|Dose Level 1 XmAb5871 given SC Q14days X 3
62179250|NCT02867098|EXPERIMENTAL|Cohort 2|Dose Level 2 XmAb5871 given SC Q14days X 3
62179251|NCT02867098|EXPERIMENTAL|Cohort 3|Dose Level 3 XmAb5871 given SC Q14days X 3
62179252|NCT02867098|EXPERIMENTAL|Cohort 4|Dose Level 4 XmAb5871 given IV Q14days X 3
62179253|NCT02867098|EXPERIMENTAL|Cohort 5|Dose Level 5 XmAb5871 given SC Q7days X 3
62179254|NCT03030105|PLACEBO_COMPARATOR|A) P:P:P|Scopolamine placebo : BPN14770 placebo : Donepezil placebo
62179255|NCT03030105|PLACEBO_COMPARATOR|B) S:P:P|Scopolamine 0.5mg : BPN14770 placebo : Donepezil placebo
62179256|NCT03030105|EXPERIMENTAL|C) S:B:P|Scopolamine 0.5mg : BPN14770 10mg : Donepezil placebo
62771550|NCT04971941|ACTIVE_COMPARATOR|DV3 with first LB injection|Use of Dental Vibe with first long buccal block
62771551|NCT04971941|ACTIVE_COMPARATOR|DV3 with first LB and with IAN|Dental Vibe with first long buccal injection and inferior alveolar block
62771552|NCT04971941|EXPERIMENTAL|DV3 with 2nd LB|Use of DentalVibe with 2nd Long Buccal injection
62771553|NCT04971941|EXPERIMENTAL|DV3 with 2nd LB and IAN|Use of DentalVibe with 2nd long buccal and inferior alveolar nerve block
62771554|NCT01934309|EXPERIMENTAL|TB reminders|Receive existing reminders plus new patient-specific reminders about TB screening, prevention, and treatment
62771555|NCT01934309|NO_INTERVENTION|No TB reminders|Only receive existing reminders; no TB reminders
62771556|NCT03880344|EXPERIMENTAL|Vibration Therapy + Normal Out-Patient Physiotherapy|Patients' randomized to this group will receive vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months. Regular out-patient department physiotherapy will also be given. They will be assessed 6 weeks and 6 months post operatively.
62771557|NCT03880344|ACTIVE_COMPARATOR|Normal Out-Patient Department Physiotherapy|Patients randomized to this group will receive regular out-patient department physiotherapy postoperatively for 6 months. They will be assessed 6 weeks and 6 months post operatively.
62179257|NCT03030105|EXPERIMENTAL|D) S:B:P|Scopolamine 0.5mg : BPN14770 50mg : Donepezil placebo
62771558|NCT01624090|EXPERIMENTAL|1/mithramycin|Single agent intravenous (IV) mithramycin
62771559|NCT04989647|EXPERIMENTAL|A: Surgery only|"Radical hysterectomy, sentinel lymph node biopsy and systematic pelvic lymphadenectomy (PLND)\*. No further treatment will be administered.~\*PLND can be avoided in patients with tumours \< 4cm"
62771560|NCT04989647|EXPERIMENTAL|B: Surgery + radiothrerapy|"Radical hysterectomy, sentinel lymph node biopsy and systematic pelvic lymphadenectomy (PLND)\*, followed by adjuvant treatment.~\*PLND can be avoided in patients with tumours \< 4cm"
62771561|NCT04399915||Hyperoxalemia/Hyperuricemia Group|
62771562|NCT04399915||Hyperoxalemia/Hyperuricemia-free Group|
62771563|NCT04399915||Healthy Subjects|
62179258|NCT03030105|ACTIVE_COMPARATOR|E) S:P:D|Scopolamine 0.5mg : BPN14770 placebo : Donepezil 10mg
62179259|NCT03030105|EXPERIMENTAL|F) S:B:D|Scopolamine 0.5mg : BPN14770 50mg : Donepezil 10mg
62179260|NCT04389346|ACTIVE_COMPARATOR|Periapical surgery with PRF group|Autologous platelet aggregate (PRF) will be placed over the denuded root surface, following apicoectomy and before flap repositioning.
62179261|NCT04389346|PLACEBO_COMPARATOR|Control group without PRF|Flap will be repositioned following apicoectomy without placement of any autologous platelet aggregate.
62179262|NCT06126510|EXPERIMENTAL|Experimental: Single Arm|VG161:1.0 × 10 \^ 8 PFU daily for 3 consecutive days on Days 1-3 of each cycle (D1-D3)
62179263|NCT02956278|PLACEBO_COMPARATOR|BCRP Q141K CC|Participants that are homozygous reference for BCRP Q141K receive at least one 300 mg dose of allopurinol followed by blood/urine collection for up to 72 hours post-dose.
62179264|NCT02956278|EXPERIMENTAL|BCRP Q141K CA|Participants that are heterozygous for the BCRP Q141K allele receive at least one 300 mg dose of allopurinol, with blood/urine collections up to 72 hours post-dose.
62391156|NCT00617942|EXPERIMENTAL|Adjuvant cohort 1|
62391157|NCT00617942|EXPERIMENTAL|Adjuvant cohort 2|
61995094|NCT02045511|PLACEBO_COMPARATOR|Delayed Treatment Group|3-month delayed treatment with Baltimore HEARS intervention
62391158|NCT03339622|EXPERIMENTAL|smoked cannabis (PPP001)|280 mg dried cannabis pellet -(9% THC / 2% CBD per pellet)
62391159|NCT03339622|PLACEBO_COMPARATOR|THC free placebo|280 mg dried extracted cannabis pellet (0% THC / 0.6% CBD per pellet)
62391160|NCT03342209|EXPERIMENTAL|HFNC therapy|Fisher\&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy will be implemented to CO-poisoned patients. Oxygen flow rate will be started 60 L/min and be decreased as the patient has requested.
62391161|NCT04348825||Patients, depression|Patients who receive ECT as part of clinical care
62391162|NCT04348825||Healthy|Healthy controls who do not receive ECT but otherwise the same assessments.
62391163|NCT04348825||Patients, atrial fibrilation|Patients who receive Electro Cardio Version (ECV) due to Atrial Fibrilation
62391164|NCT04246996|ACTIVE_COMPARATOR|Gentamicin Arm|At the completion of the subjects surgery but prior to awakening from anesthesia, 80mg of gentamicin in 50 mL of normal saline will be infused into the subject's bladder through the standard-of-care transurethral catheter by the surgeon. The surgeon will then clamp the catheter and label the catheter with the clamping time. The catheter will be clamped to prevent the gentamicin from immediately flowing out of the bladder and thus allow the gentamicin time to have an effect. The subject will then proceed as usual to the postoperative anesthesia care unit. A member of the subject's care team will unclamp the catheter after 1 hour. The subject will otherwise have usual pre-operative and post-operative care.
62391165|NCT04246996|SHAM_COMPARATOR|Control Arm|If the patient is randomized to no instillation, at the end of the surgery but prior to awakening from anesthesia, the surgeon will clamp the catheter and label the catheter with the clamping time. The purpose of clamping the catheter for subjects receiving usual care will be to ensure patients are masked to study arm assignment if they wake up and notice their catheter. The subject will then proceed as usual to the postoperative anesthesia care unit. A member of the subject's care team will unclamp the catheter after 1 hour. The subject will otherwise have usual pre-operative and post-operative care.
62391166|NCT02502591|EXPERIMENTAL|intervention|Additional pain relief (a Pudendal Nerve Block (PNB)) will be administered during surgery in addition to routine care.
62391167|NCT02502591|NO_INTERVENTION|control|routine care only
62179265|NCT02956278|EXPERIMENTAL|BCRP Q141K AA|Participants homozygous for the BCRP Q141K allele receive at least one 300 mg dose of allopurinol with blood/urine collection for up to 72 hours post-dose.
62179266|NCT03927677|EXPERIMENTAL|Cohort|Period 1: LC350189 200mg Day 1\~ Day 4 qd, Period 2: Colchicine 0.6 mg Day 8 \~ Day 15 bid, Period 3 : LC350189 200mg (qd) + Colchicine 0.6 mg (bid) Day 16\~ 19
62179267|NCT05198206||The First Affiliated Hospital of Chongqing Medical University|
62179268|NCT05198206||West China Hospital|
62179269|NCT05198206||the First Affiliated Hospital of Xi'an Jiaotong University|
62179270|NCT05198206||Guangdong Provincial People's Hospital|
62179271|NCT05198206||Xiangya Hospital of Central South University|
62179272|NCT05198206||The Second Affiliated Hospital of Harbin Medical University|
62179273|NCT05198206||Yan'an Hospital of Kunming City|
62179274|NCT05198206||Zhongshan Hospital|
62179275|NCT05198206||Gansu Provincial People's Hospital|
62179276|NCT05198206||Qilu Hospital of Shandong University|
62179277|NCT05198206||Shanxi Provincial Cardiovascular Hospital|
62179278|NCT05198206||West China Second Hospital|
62179279|NCT05198206||The First Affiliated Hospital of Jilin University|
62179280|NCT05198206||Xinqiao Hospital, Army Medical University|
62179281|NCT05198206||The First Affiliated Hospital of Guangzhou Medical University|
62179282|NCT05198206||the Second Xiangya Hospital of Central South University|
62179283|NCT05198206||Shengjing Hospital of China Medical University|
62179284|NCT05198206||The Second Affiliated Hospital of Nanchang University|
62179285|NCT05198206||Henan Provincial People's Hospital|
62179286|NCT05198206||Southwest Medical University Hospital|
62179287|NCT05198206||The First Affiliated Hospital of Gannan Medical University|
62179288|NCT05198206||University-town Hospital of Chongqing Medical University|
62179289|NCT05198206||Chongqing Health Center for Women and Children|
62179290|NCT05198206||Kunhua Hospital|
62179291|NCT05198206||Changdu People's Hospital of Tibet|
62179292|NCT05198206||The Sixth People's Hospital of Chengdu|
62179293|NCT05198206||Chongqing Bishan District People's Hospital|
61995095|NCT04090554|OTHER|Cytosponge™|Single intervention arm of feasibility study
61995096|NCT02739269|ACTIVE_COMPARATOR|AMH group|Serum AMH measurement
62179294|NCT05198206||Sichuan Guangyuan People's Hospital|
62179295|NCT05198206||Xinjiang Military Region General Hospital|
62179296|NCT05198206||Xinjiang Uygur Autonomous Region People's Hospital|
62179297|NCT05198206||The First Affiliated Hospital of Anhui Medical University|
62179298|NCT05198206||Yantai Yuhuangding Hospital|
62179299|NCT04731142|EXPERIMENTAL|T2DEx remote care service|
62179300|NCT04731142|OTHER|Matched control group|This study will create a matched control group using propensity score matching (PSM), a quasi-experimental method used to mimic the characteristics of a randomised control trial that has been shown to reduce biases. PSM uses statistical techniques to construct an artificial control group by matching each study participant with a non-treated participant of similar characteristics. PSM computes the probability that a person would enrol in a program based on pre-defined characteristics, giving a 'propensity score'.
62179301|NCT00204828||1.|Children with asthma
62179302|NCT00204828||2.|Children without asthma
61995097|NCT02739269|SHAM_COMPARATOR|AFC group|AFC measurement
62179303|NCT01764698|EXPERIMENTAL|CALM-SUD|Participants receive the adaptation of the Coordinated Anxiety Learning and Management (CALM) protocol that demonstrated effectiveness in a large primary care sample. CALM will be adapted for those with anxiety and substance use disorder comorbidity, and will consist of an orientation session and 6 group treatment sessions. These participants will also receive substance abuse treatment as usual at a community Intensive Outpatient Program.
62179304|NCT01764698|ACTIVE_COMPARATOR|Treatment as usual|Participants in this arm receive the standard Intensive Outpatient treatment for their substance use disorder at a community addictions treatment facility.
62179305|NCT06545110|ACTIVE_COMPARATOR|group A|60 patient with sever alopecia areata
62179306|NCT06545110|PLACEBO_COMPARATOR|group B|60 healthy individuals
62179307|NCT06248112|EXPERIMENTAL|Sequence 1-Sacubitril and Valsartan test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Sacubitril 97 mg and Valsartan 103 mg test product, treatment 2= Sacubitril 97 mg and Valsartan 103 mg reference product.
62179308|NCT06248112|EXPERIMENTAL|Sequence 2-Sacubitril and Valsartan reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Sacubitril 97 mg and Valsartan 103 mg test product, treatment 2= Sacubitril 97 mg and Valsartan 103 mg reference product.
62179309|NCT01554293|EXPERIMENTAL|PBL 1427 capsules|
62179310|NCT01554293|PLACEBO_COMPARATOR|Matching placebo|
62179311|NCT04620369|EXPERIMENTAL|Arm A (rose geranium in sesame oil nasal spray)|Patients instill rose geranium in sesame oil nasal spray, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity.
62179312|NCT04620369|PLACEBO_COMPARATOR|Arm B (isotonic nasal saline)|Patients instill isotonic nasal saline, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity. After 2 weeks, patients may instill rose geranium in sesame oil nasal spray as in Arm A for an additional 2 weeks in the absence of unacceptable toxicity.
62179313|NCT01665599|EXPERIMENTAL|Testosterone gel (FE 999303)|"Subjects received a starting dose of 46 mg (two actuations) of testosterone gel (2%) daily in the morning. The dose was further titrated (increased or decreased - three actuations \[69 mg\] or single actuation \[23 mg\], respectively) based on serum testosterone concentrations.~Testosterone gel was applied using an applicator, to the shoulder/upper arm in a contralateral fashion."
62771564|NCT02980627|EXPERIMENTAL|Therapy with Mobile App Enhancement|Participants will complete initial assessments and then take part in a 3-month intervention consisting of 12 weekly individual therapy sessions with daily RR app use between sessions. At the end of the 3-month intervention period, an exit interview will be conducted and participants will complete a second assessment consisting of questionnaires and an ED diagnostic interview, a blood specimen for HbA1c, and 3-days of blinded CGM monitoring. Participants will then enter a 6-month follow-up period during which time they may continue to use the app, but will no longer attend individual sessions. Participants will be return to the clinic at 6 and 9 months for follow-up.
62771565|NCT03417986|EXPERIMENTAL|Group 1a: TEP 26 mg daily for 4d|
62771566|NCT03417986|EXPERIMENTAL|Group 1b: TEP 52 mg daily for 4d|
62771567|NCT03417986|EXPERIMENTAL|Group 2: TEP 26 mg daily for 54d|
62771568|NCT00896441|EXPERIMENTAL|Depressed patients|Depressed patients assigned in an open-label study of citalopram
62771569|NCT00896441|NO_INTERVENTION|Controls|Healthy controls used as a comparison (no intervention) group for change in resting-state fMRI over time
62771570|NCT05547165|ACTIVE_COMPARATOR|Primary Comparator|Interventional groups that subject will be randomly assigned to include Percutaneous Patent Ductus Arteriosus Closure (PPC) or Responsive Management. Those assigned to PPC will undergo active intervention to close a hemodynamically significant patent ductus arteriosus (HSPDA) whereas those assigned to Responsive Management will be treated to manage the symptoms of the HSPDA and permit natural closure over time.
62771571|NCT05547165|OTHER|Secondary Intervention|Sub-group of patients initially randomized to Responsive Management who may suffer a decline in health status that can be attributed to the presence of a hemodynamically significant patent ductus arteriosus (HSPDA). These patients, upon meeting pre-specified clinical criteria, will undergo active treatment via Percutaneous Patent Ductus Arteriosus Closure (PPC) as in the active comparator arm.
62771572|NCT03668834|ACTIVE_COMPARATOR|Dermabrasion with NCES|Intervention-Dermabrasion with autologous non cultured epidermal cell suspension Recipient site preparation using dermabrasion followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
62771573|NCT03668834|ACTIVE_COMPARATOR|Dermaroller with NCES|Intervention-Dermaroller with autologous non cultured epidermal cell suspension Recipient site preparation using dermaroller system followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
62771574|NCT03668834|ACTIVE_COMPARATOR|Liquid nitrogen induced blister with NCES|Liquid nitrogen induced blister with autologous non cultured epidermal cell suspension Recipient site preparation using liquid nitrogen induced blister followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
62771575|NCT04924478||Severe Asthma Patients Treated with Mepolizumab|Following treatment, patients will be stratified into responders or non-responders
62771576|NCT01123824|EXPERIMENTAL|Sequence clopidogrel 300/75 mg - 600/150 mg|"Period 1:~* Day 1: clopidogrel, 300 mg loading dose + placebo~* Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily~Period 2:~* Day 1: clopidogrel, 600 mg loading dose~* Day 2 to Day 5: clopidogrel, 150 mg, once daily~Each intake is at around 8:00 AM fasted for at least 10 hours"
62771577|NCT01123824|EXPERIMENTAL|Sequence clopidogrel 600/150 mg - 300/75 mg|"Period 1:~* Day 1: clopidogrel, 600 mg loading dose~* Day 2 to Day 5: clopidogrel, 150 mg, once daily~Period 2:~* Day 1: clopidogrel, 300 mg loading dose + placebo~* Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily~Each intake is at around 8:00 AM fasted for at least 10 hours"
62771578|NCT02710942|EXPERIMENTAL|SPHERE intervention|It is a comprehensive self-guided Internet-based cognitive-behavioral therapy (CBT) that includes three components: (1) the myWHI diary. (2) 30 multi-media learning topics that the user is encouraged to go through in a sequential way. The topics contain education information and teach strategies to cope better with their headaches.
62771579|NCT02710942|EXPERIMENTAL|PRISM intervention|It is a targeted self-guided Internet-based CBT intervention. PRISM was built upon the myWHI diary, an electronic headache diary. PRISM helps users discover their headache triggers by analyzing the inputted diary data using association rule mining. Once one or multiple headache triggers are identified the application uses an algorithm to provide the user with a few personalized recommendations to help them to cope with these triggers. The algorithm is based on the opinion of clinical experts (e.g., medical health professionals, psychologists). The user chooses recommendations to follow and sets goals in the application to follow them. To support the process, the application checks in with users about their goals and tracks goal completion.
62771580|NCT02710942|NO_INTERVENTION|Usual care|Participants can continue doing what they usually do to deal with their migraines.
62771581|NCT01862861||Peri or post-menopausal women.|Women with peri or post-menopausal vasomotor symptoms between 30 and 60 years of age.
62179314|NCT04793581|OTHER|Single Arm|Single-arm study
62179315|NCT02019238|PLACEBO_COMPARATOR|Group 1-Standard PVI ablation|Pulmonary Vein Isolation procedure combined with ablation of documented non-PV triggers of AF
62771582|NCT03753399|EXPERIMENTAL|High-dose acupuncture|Acupuncture for 7 times every 3 weeks (a cycle of chemotherapy) for 9 weeks
61995098|NCT00096512|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62179316|NCT02019238|ACTIVE_COMPARATOR|Group 2-PVI with empiric ablation|Pulmonary Vein Isolation procedure combined with empiric ablation of common sites of non-PV triggers of AF and locations that may sustain AF sources on long term arrhythmia control
62771583|NCT03753399|EXPERIMENTAL|Low-dose acupuncture|Acupuncture for 3 times every 3 weeks (a cycle of chemotherapy) for 9 weeks
62771584|NCT03753399|NO_INTERVENTION|Usual care|Chemotherapy without acupuncture
62771585|NCT00468403|EXPERIMENTAL|Allogeneic Pancreatic Islet Cells|Participants will receive up to three islet transplantations and continuous immunosuppressive therapy including belatacept
62563097|NCT03842319|EXPERIMENTAL|High-intensity MedDiet|Patients allocated to the interventional group will be individually evaluated by a dietitian and will participate in dedicated individual and group sessions at baseline, and at 3, 6, 9 and 12 months. In the interventional group, a personalized MedDiet will assess chemical and nutritional composition and total energy intake will be adapted to participant's weight, age, and requirements, and the dietitian's tailored advice to his/her individual needs. A 14-item dietary screen for adherence to the Mediterranean diet will be used to personalize the intervention and negotiate dietary changes. Furthermore, free virgin olive oil, recipes, shopping list and designed weekly menus will be provided to maximize the differences between groups. Interventions: MedDiet, Microbiota analysis, Immunological analysis, Proteome analysis, Metabolome analysis, Clinical evaluation, Diet evaluation
62563098|NCT01110590|EXPERIMENTAL|Arm 1|
62563099|NCT01110590|EXPERIMENTAL|Arm 2|
62563100|NCT01110590|EXPERIMENTAL|Arm 3|
62563101|NCT01110590|PLACEBO_COMPARATOR|Arm 4|
62563102|NCT06480838||msTBI|Subjects with moderate to severe TBI within the first week after initial injury
62563103|NCT06480838||Orthopedic control|Orthopedic trauma controls within the first week after initial injury
62563104|NCT05106491|OTHER|venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization|Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac Support (SCS).
62563105|NCT04166786|EXPERIMENTAL|Testosterone + Ethanol|Subjects receive a 3-day treatment with testosterone in combination with ethanol consumption. Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
62563106|NCT04166786|OTHER|Testosterone placebo + Ethanol|Subjects receive a 3-day treatment with testosterone placebo (vaseline) in combination with ethanol consumption. Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
62563107|NCT04166786|OTHER|Testosterone + Ethanol placebo|Subjects receive a 3-day treatment with testosterone in combination with ethanol placebo (lemon-flavoured water). Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
62563108|NCT04166786|PLACEBO_COMPARATOR|Testosterone placebo + Ethanol placebo|Subjects receive a 3-day treatment with testosterone placebo (vaseline) in combination with ethanol placebo (lemon-flavoured water). Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
62563109|NCT06288451|EXPERIMENTAL|Low dose oral calcitriol|
62563110|NCT06288451|ACTIVE_COMPARATOR|Usual care|
62563111|NCT04127227|EXPERIMENTAL|Sintilimab With P-GemOx|Sintilimab, 200mg, d1, intravenous drip; pegaspargase, 2000U/m2, d1, intravenous drip; gemcitabine, 1000mg/m2, d1,d8, intravenous drip; oxaliplatin, 130mg/m2, d1, intravenous drip; All patients received up to 6 treatment cycles of 21 days. Patients with CR or PR will receive Sintilimab maintenance therapy.
62563112|NCT01298804|EXPERIMENTAL|Problem Solving Education|
62563113|NCT01298804|NO_INTERVENTION|Control|
62563114|NCT06250296||Intervention group|All patients admitted to the ward implementing the foreseen intervention as to February 2024 (pilot phase)
62563115|NCT06250296||Control group|All patients admitted to the two wards implementing the foreseen intervention after the initial pilot phase
62563116|NCT05043480|EXPERIMENTAL|PEMF arm|In this single-arm study, all participants will be assigned to the intervention arm.
62563117|NCT06040710||Experimental: Intervention arm|All patients within the study are included in the intervention arm: polyp detected within these patients will be measured according to the study protocol using two different methods.
62563118|NCT06041451|EXPERIMENTAL|immunoglobulin group|This group of patients was treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days
62563119|NCT06041451|EXPERIMENTAL|methylprednisolone group|This group of patients was treated with methylprednisolone 500 MG Injection
62563120|NCT06041451|NO_INTERVENTION|control group|This group of patients was treated without immunoglobulin or hormone
62771586|NCT02471638|EXPERIMENTAL|Single arm study|PQ Bypass System for Femoropopliteal Bypass to complete percutaneous fem-pop bypass
62771587|NCT02393053|SHAM_COMPARATOR|subepithelial connective tissue graft|Surgery: Treatment with subepithelial connective tissue graft for gingival recession
62771588|NCT02393053|EXPERIMENTAL|non-pedicled buccal fat pad graft|Surgery: Treatment with non-pedicled buccal fat pad graft for gingival recession
62771589|NCT03031119|PLACEBO_COMPARATOR|Placebo|Tablets administered once or twice daily, with food, in Part A for 14 days.
62771590|NCT03031119|EXPERIMENTAL|PF-06835919|Tablets administered once or twice daily, with food, in Part A for 14 days. Tablets administered once or twice daily, for 4 days at a low dose and for 4 days at a higher dose, with food and atorvastatin in Part B.
62563121|NCT06041451|EXPERIMENTAL|mixed group|This group of patients was treated both with intravenous immunoglobulin and methylprednisolone.
62563122|NCT05221944||Patients on antithrombotic therapy|The study aimed to investigate if perioperative bleeding complications were more common in patients on antithrombotic therapy. We retrospectively reviewed patients with IC/BPS who underwent hydrodistension during January 2010 and May 2021. Patients with and without antithrombotic drugs were identified and grouped and their medical records were reviewed.
62563123|NCT05221944||Patients without antithrombotic therapy|Patients without antithrombotic drugs were identified as controls
62563124|NCT02925481|EXPERIMENTAL|Low dose Yoga|12 week online yoga for 60 minutes per week
62771591|NCT03031119|EXPERIMENTAL|atorvastatin|In Part B, tablets administered once or twice daily, with food, with and without a low dose of PF-06835919 for 4 days and a higher dose of PF-06835919 for 4 days.
62771592|NCT05770661||Myopes|To collect the ocular data among myopic children.
62771593|NCT05770661||Non-myopes|To collect the ocular data among non-myopic children.
62771594|NCT01030614|ACTIVE_COMPARATOR|Dexamethasone group|One hundred five patients were randomized to receive intravenous dexamethasone (8 mg) before laparoscopic cholecystectomy
62771595|NCT01030614|PLACEBO_COMPARATOR|Placebo group|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
62771596|NCT06383468|EXPERIMENTAL|AK120 600mg/300mg|AK120 600mg(first day) then 300mg Q2W subcutaneous injection thereafter until week 50.
62771597|NCT06383468|PLACEBO_COMPARATOR|Placebo/AK120 600mg to 300mg|placebo Q2W SC, then AK120 600mg at week 16, thereafter change to AK120 300mg Q2W subcutaneous injection until week 50.
62771598|NCT02231268||Depressive patients|
62771599|NCT06264284||epidural anesthesia|
62771600|NCT06264284||general anesthesia|
62771601|NCT03584555|ACTIVE_COMPARATOR|120 μm group|The subjects underwent SMILE using 120 μm cap.
62771602|NCT03584555|ACTIVE_COMPARATOR|140 μm group|The subjects underwent SMILE using 140 μm cap.
62771603|NCT00888641|NO_INTERVENTION|Normothermia|After arterial clamping, no ice slush will be used
62563125|NCT02925481|EXPERIMENTAL|Moderate dose Yoga|12 week online yoga for 150 minutes per week
62563126|NCT02925481|ACTIVE_COMPARATOR|Stretch and toning|12 week online stretching, toning exercises for 60 minutes per week
62771604|NCT00888641|EXPERIMENTAL|Hypothermia|After arterial clamping, the kidney will be surrounded in ice slush for 10 minutes
62771605|NCT05386316|EXPERIMENTAL|Intervention counties|Birthing persons who live in Kent County or Genesee County, Michigan, USA at the time of delivery.
62771606|NCT05386316|ACTIVE_COMPARATOR|Control counties|Birthing persons who live in the other Michigan, USA counties at the time of delivery.
62179317|NCT03264547|ACTIVE_COMPARATOR|Arm A|"Trastuzumab + pertuzumab + Taxane\*~\*Taxane is chosen from the following; Docetaxel or Paclitaxel"
62179318|NCT03264547|EXPERIMENTAL|Arm B|Trastuzumab+ Pertuzumab + Eribulin
62563127|NCT06012344|EXPERIMENTAL|Group A|20 participant randomly allocated they were administered in first phase with post facilitation stretch , 3rd phase with post isometric relaxation and then in 5th phase hamstring Nordic lower
62771607|NCT00847015|EXPERIMENTAL|Gemcitabine, Cisplatin, and Sunitinib|This is a phase II study of GCS (Gemcitabine, Cisplatin, and Sunitinib) as neoadjuvant chemotherapy in patients with muscle-invasive urothelial carcinoma of the bladder. Patients with muscle invasive urothelial carcinoma who are candidates for radical cystectomy will be enrolled.
62771608|NCT06360614|EXPERIMENTAL|Hand massage application|Hand massage will be applied to the intervention group for 4 weeks, 2 days a week (Monday and Friday), 2 sessions each day.
62771609|NCT06360614|PLACEBO_COMPARATOR|Control Group|The control group will receive routine monitoring and nursing care for 4 weeks.
62771610|NCT05583994|NO_INTERVENTION|Usual care ( control)|All participants in the trial will continue with their usual care as deemed appropriate by health care providers, this will usually comprise attendance at medical clinics, medication, and visits from PD nurse specialists. Participants may attend group activities or access resources as part of their usual care, though from experience such sessions are rarely intensive or prolonged. Participants will be asked to record their usual care and encouraged to avoid changing that practice unless specifically requested by a health care worker during the time they are participating in the trial.
62179319|NCT04362098|EXPERIMENTAL|Nurse home visits|Nurse home visits biweekly.
62771611|NCT05583994|EXPERIMENTAL|Optim Park Intervention|"A central component of the Optim-Park II intervention is to offer a single point of contact with a coordinator (appointed for the purpose of delivering the Optim-Park II intervention) to assess participants needs, have a discussion with participants to identify 3 main problems/targets PwPD and carers would most like to address based on their needs and then link up and refer participants to available community resources.~The coordinators will deliver the Optim-Park intervention for PwPD and their carers in three consultations: a consultation after the baseline assessment and randomization has been undertaken at the point of entrance to the study; a consultation in the middle of this period; and a follow-up consultation at exit at 3 months. Each consultation can last between 30 min and up to 2 hours. Each consultation can be with the pair of PwPD and carer or if appropriate, separately."
62179320|NCT04362098|NO_INTERVENTION|Usual care|Usual care.
62179321|NCT03738098|ACTIVE_COMPARATOR|Traditional Genetic Counseling|Standard of care genetic counseling session
62179322|NCT03738098|EXPERIMENTAL|GUÍA|Standard of care genetic counseling session with Genomic Understanding, Information and Awareness (GUÍA).
62179323|NCT05167513|EXPERIMENTAL|Uncontrolled Diabetes with Metformin or Metformin resistant|
62179324|NCT00951964|OTHER|1|patients receive the treatment in first and placebo in second part of study
62179325|NCT00951964|OTHER|2|patients receive placebo in first and treatment in second part of study
62179326|NCT01064505|EXPERIMENTAL|QPI-1007|
62179327|NCT02965053|EXPERIMENTAL|Period 1 Arm 1|EOS789 Dose 1 in treatment sequence 1, Placebo in treatment sequence 2
62179328|NCT02965053|EXPERIMENTAL|Period 1 Arm 2|Placebo in treatment sequence 1, EOS789 Dose 1 in treatment sequence 2
62563128|NCT06012344|EXPERIMENTAL|Group B|20 participant randomly allocated they were administered in first phase with post isometric relaxation 3rd phase with hamstring Nordic lower and then in 5th phase post facilitation stretch
62563129|NCT06012344|EXPERIMENTAL|Group C|20 participant randomly allocated they were administered in first phase hamstring Nordic lower 3rd phase with post facilitation stretch and then in 5th phase post isometric relaxation
62771612|NCT04468074|EXPERIMENTAL|Therapy Group|"Therapy Group participants start the treatment period with three 1 ½ hour introductory sessions:~1. An education session on the science behind chronic pain and a basic overview of the VR therapy.~2. A session to customize the VR experience to match the participant's own pain experience.~3. A training session on the use of the VR hardware and software.~Upon completion, participants begin using the VR therapy app at home once a day, 5 times a week (minimum), for a total of 8 weeks. The VR app contains different training exercises. A workbook provides a schedule and background on each of the training sessions.~Therapy Group participants may continue their other pain treatment regimes, and are asked to notify the research team of any changes."
62771613|NCT04468074|NO_INTERVENTION|Standard of Care (SOC) Group|The SOC Group (no-intervention) completes a daily pain survey. SOC Group participants are asked to maintain their pain treatment regimes, and are asked to notify the research team of any changes.
62771614|NCT03598751|EXPERIMENTAL|BCD-085|"Blinded period:~BCD-085 120 mg at weeks 0, 1, 2, 4, 6, 8, 10, 14, 18, 22~Open-label period:~BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54"
62179329|NCT02965053|EXPERIMENTAL|Period 2 Arm 1|EOS789 Dose 2 in treatment sequence 1, EOS789 Dose 2 + Sevelamer carbonate in treatment sequence 2
62563130|NCT06498856||Adult patients with hypoosmolar hyponatremia|Patients admitted to hospital with hypo-osmolar hyponatremia with uncertain primary cause. Eligible patients will receive a standardized intravenous infusion of isotonic saline.
62563131|NCT01125397|EXPERIMENTAL|Behavioral Intervention|
62563132|NCT01125397|NO_INTERVENTION|Control|These participants will be randomized to receive no behavioral intervention prior to bariatric surgery.
62563133|NCT01622257|EXPERIMENTAL|Cavitation US|Cavitation ultrasound was done using ultrasonic cavitation machine 2 times per week for 3 months
62563134|NCT01622257|EXPERIMENTAL|Metformin|Metformin oral tablets 500 mg were given three times daily
62563135|NCT01622257|EXPERIMENTAL|Cavitation US + metformin|Combination of both Cavitation US + Metformin
62179330|NCT02965053|EXPERIMENTAL|Period 2 Arm 2|EOS789 Dose 2 + Sevelamer carbonate in treatment sequence 1, EOS789 Dose 2 in treatment sequence 2
62179331|NCT00604513|EXPERIMENTAL|1|
62179332|NCT00604513|SHAM_COMPARATOR|2|
62179333|NCT00849745|EXPERIMENTAL|Systemic Lupus Erythematosus|"Nonmyeloablative allogeneic stem cell transplant~Patients must:~* Satisfy the American College of Rheumatology (ACR) criteria for the diagnosis of SLE~* Have Lupus nephritis, refractory and severe seizures or encephalopathy, severe pulmonary involvement, transfusion-dependent cytopenias, catastrophic antiphospholipid syndrome or vasculitis and/or immune complex deposition causing end-organ signs or symptoms.~* Have received a trial of corticosteroids equivalent to prednisone greater than or equal to 0.5 mg/kg/d for at least one month~* Have received a trial of IV cyclophosphamide pulse greater than 500 mg/square meter at least once within the previous 6 months, unless contraindicated because of severe cytopenias or intolerance."
62182592|NCT06086678|EXPERIMENTAL|Aerobic exercise and conventional physical therapy group|Strengthening exercises, stretching exercises for the weak and tightened muscles respectively, facilitation of equilibrium and protective reactions and breathing exercises in form of Deep breathing, Diaphragmatic breathing and Pursed lip breathing exercises in addition to aerobic exercise
62182593|NCT05560750|EXPERIMENTAL|Frenotomy|Patients who will have frenotomy soon after randomisation, on the same or next day
62182594|NCT05560750|ACTIVE_COMPARATOR|Oral physiotherapy|Patients whose parents are guided to give the child oral physiotherapy for 1 month
62563136|NCT00564850|EXPERIMENTAL|Triptorelin pamoate 11.25mg (Decapeptyl® SR)|
62771615|NCT03598751|PLACEBO_COMPARATOR|Placebo|"Blinded period:~Placebo at weeks 0, 1, 2, 4, 6, 8, 10, 14~* patients who don't achieve ACR 20 at week 16 will receive BCD-085 at weeks 18 and 22~* patients who achieve ACR 20 at week 16 will continue placebo at weeks 18 and 22~Open-label period:~BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54"
62179334|NCT00849745|EXPERIMENTAL|Systemic Sclerosis|"Nonmyeloablative allogeneic stem cell transplant~Patients must:~* Have diagnosis of SSc as defined by American College of Rheumatology and at high-risk for fatal outcome.~* Have (1) both a and b below and (2) at least one of c, d, or e.~* Diffuse cutaneous scleroderma with skin score of \>= 16~* Duration of systemic sclerosis \<= 3 years from the onset of first non-Raynaud's symptom.~* Presence of interstitial or pulmonary vascular lung involvement (FVC or DLCO \<70% of predicted) especially with evidence of alveolitis (abnormal bronchoalveolar lavage or high-resolution chest CT scan).~* Presence of myocardial disease~* History or presence of proteinuria \> 500 mg/24 hrs or serum creatinine \> the upper limit of normal."
62771616|NCT02193113|EXPERIMENTAL|KVD001 Injection Dose 1|Single 100 microliters (uL) intravitreal injection of KVD001 Injection Dose 1
62771617|NCT02193113|EXPERIMENTAL|KVD001 Injection Dose 2|Single 100uL intravitreal injection KVD001 injection Dose 2
62771618|NCT02193113|EXPERIMENTAL|KVD001 Injection Dose 3|Single 100uL intravitreal injection of KVD001 injection Dose 3
62771619|NCT02845076|ACTIVE_COMPARATOR|Decrease in duration|Weaning will be started with the liberation of patient from NIV during day-time and then nighttime support will be gradually reduced. From day 2 the daytime NIV will be gradually decreased in steps of at least 2 hours/day at the attending discretion. At day 2, nighttime discontinuation will be considered. When a patient reaches without the presence of any reinstitution criteria, the duration of NIV use as 4 hours per 16 hours during daytime, it will be liberated definitively from NIV.
62771620|NCT02845076|ACTIVE_COMPARATOR|Decrease in pressure and duration|Weaning will be started with the liberation of patient from NIV during day-time and then nighttime support will be gradually reduced. The level of pressure support will be decreased by 2-4 cmH2O per 4 hours during daytime in patients with good tolerance, with no change at night time. From day 2 the daytime NIV will be gradually decreased in steps of at least 2 hours/day at the attending discretion. At day 2, nighttime discontinuation will be considered, based on the vitals and ABGs recorded at 8 pm (see above), with gradual decrease of at least 2 hrs/night. When a patient reaches without the presence of any reinstitution criteria, the level of PS of 8 cmH20, it will be liberated definitively from NIV.
62771621|NCT02845076|ACTIVE_COMPARATOR|Abrupt discontinuation of NIV|Patients will be disconnected from NIV and oxygenated with a nasal cannula. Oxygen flow will be limited to a maximum of 5L/min.
62771622|NCT03591172|EXPERIMENTAL|propolis|natural antibacterial, anti-inflammatory irrigation solution
62179335|NCT06199206|EXPERIMENTAL|Intervention Group|Before the procedures, therapeutic games will be played with the children and people of the intervention groups with eLPi dolls and other play materials prepared in accordance with anatomy. The parent will be with the child during this game, which will be played in his/her own room.
62179336|NCT06199206|NO_INTERVENTION|Control Group|No therapeutic play will be made to children. Children will be verbally informed about the lumbar puncture.
62179337|NCT04713813|ACTIVE_COMPARATOR|Exercise group 1(Exercise via mechanical horse-riding simulator)|Exercise via mechanical horse-riding simulator; Subjects remained in sitting position for 30 minutes on the simulator during these sessions, with extension of the trunk and stabilization of the pelvis. Feet were placed on the footplates as the simulator produced a rhythmic and repetitive movement similar to a walking horse. The simulator can produce several modes of rhythmic and repetitive motions.
62179338|NCT04713813|ACTIVE_COMPARATOR|Exercise group 2 (Home exercises)|Home exercises will be consist of a warm-up, stretching, balance, back walking, fingertip walking exercises, the first of which is shown by the physiatrist or physiotherapist to the patients. These patients will be called twice a month to ask whether they have done the exercises, and the patients whose participation rate is below 80% will be excluded from the study by following the exercise schedule when they come to the physician's control monthly.
62182595|NCT05560750|NO_INTERVENTION|Follow-up|Patients whose frenotomy appointment will be set at 1 month age
62771623|NCT03591172|EXPERIMENTAL|Nano-propolis|natural antibacterial, anti-inflammatory irrigation solution
62771624|NCT03591172|ACTIVE_COMPARATOR|saline|sodium chloride irrigation solution
62771625|NCT05304312|EXPERIMENTAL|Women with Kegel Exercises book|"We gave the patient the Kegel Exercises guidebook for them to study, follow, and keep track of their exercise.~The Kegel Exercises regiment was 10 each slow and fast-twitch muscle contraction for a session. Three sessions a day needed to be done every day for 12 weeks."
62771626|NCT05304312|NO_INTERVENTION|Women without Kegel Exercises book|We did not give the Kegel Exercises guidebook for the patients We taught the same Kegel Exercises regiment that was 10 each slow and fast-twitch muscle contraction for a session. Three sessions a day and needed to be done every day for 12 weeks
62771627|NCT04394715|EXPERIMENTAL|Intervention|Providers will see an electronic alert for eligible patients who are at very high risk for future ASCVD events upon opening of the patient's order entry screen in the medical record.
62771628|NCT04394715|NO_INTERVENTION|Control|Providers will not see an electronic alert for any patients and will provide usual care. Silent alerts will be generated that will be sent to study team members.
62771629|NCT02963701|EXPERIMENTAL|Ibuprofen+Pseudoephedrine-HCl|Fixed dose combination
62771630|NCT02963701|ACTIVE_COMPARATOR|Ibuprofen+Pseudoephedrine-HCl (RhinAdvil®)|Fixed Dose Combination
62771631|NCT01294163|EXPERIMENTAL|Xenon|
62771632|NCT01294163|ACTIVE_COMPARATOR|Sevoflurane|
62771633|NCT01294163|ACTIVE_COMPARATOR|Total intravenous anaesthesia|
62771634|NCT03528005|NO_INTERVENTION|Control|A regular health education program was provided by case managers only.
62771635|NCT03528005|EXPERIMENTAL|Intervention|Multi-domain intervention included exercise,cognitive training, diet education, and disease consultation was conducted for two hours twice per week in the first month, once per week in the second month, and once per month since third month.
62771636|NCT02170909|EXPERIMENTAL|BIBR 1048 MS low dose|
62771637|NCT02170909|EXPERIMENTAL|BIBR 1048 MS medium dose|
62771638|NCT02170909|EXPERIMENTAL|BIBR 1048 MS high dose|
62771639|NCT02702687|EXPERIMENTAL|PEF Feedback|This group will have 9 visits across 15 months.
62771640|NCT02702687|ACTIVE_COMPARATOR|Control Feedback|This group will have 9 visits across 15 months.
62771641|NCT00677755|EXPERIMENTAL|Mf+Ms|The women in mifepristone combined misoprostol group (Mf+Ms) received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
62771642|NCT00677755|EXPERIMENTAL|Ms-alone|The control group (Ms-alone) patients were only administered 0.8 mg of misoprostol orally on day 3.
62771643|NCT02367404|NO_INTERVENTION|Control|Keigel's exercise
62771644|NCT02367404|ACTIVE_COMPARATOR|Duloxetine|Duloxetine 60mg for 3 months
62771645|NCT02367404|ACTIVE_COMPARATOR|Duloxetine + PMFT|Duloxetine 60mg for 3 months PMFT weekly for 3 months
62771646|NCT02367404|ACTIVE_COMPARATOR|Pelvic Floor Muscle Training|PMFT weekly for 3 months
62771647|NCT02133807|EXPERIMENTAL|Specific Lp(a) apheresis & Atorvastatin|"Specific Lp(a) apheresis was performed with Lp(a) Lipopak immunosorbent columns (POCARD Ltd., Moscow, Russia) with sheep polyclonal monospecific antibodies against human Lp(a)/apo(a) weekly during 18 months. On the background - standard medical therapy in accordance with the recommendations for secondary prevention of CHD."
62771648|NCT02133807|NO_INTERVENTION|Atorvastatin|Standard medical therapy in accordance with the recommendations for secondary prevention of CHD
62771649|NCT00438152|ACTIVE_COMPARATOR|Invirase® tablets|
62771650|NCT00438152|ACTIVE_COMPARATOR|Kaletra® tablets|
62771651|NCT05161689|EXPERIMENTAL|Mpowerment-based intervention|YMSM in this arm may be exposed to a multicomponent, multi-level, community mobilization, combination intervention to address the entire HIV Continuum of Prevention and Care.
62771652|NCT05161689|NO_INTERVENTION|Standard of care|YMSM in this arm will not be exposed to the intervention.
62771653|NCT01152177|ACTIVE_COMPARATOR|Electronic reminders|Electronic reminders
62771654|NCT01152177|NO_INTERVENTION|Usual care|usual care
62771655|NCT03569839||Patients undergoing surgery|Patients subject to TIVA
62771656|NCT01179061|EXPERIMENTAL|Apelin infusion|6 hour infusion of apelin peptide into circulation
62771657|NCT01179061|PLACEBO_COMPARATOR|Placebo|Infusion of saline into systemic circulation
62771658|NCT01422824||Cohort|
62771659|NCT03201159|EXPERIMENTAL|VLX103 150mg|In the first group, 150 mg dosing cohort, one VLX103 tablet will be administered daily for 14 days.
62771660|NCT03201159|EXPERIMENTAL|VLX103 300mg|In the second group, 300 mg dosing cohort, two VLX103 tablets will be administered daily for 14 days.
62771661|NCT03201159|EXPERIMENTAL|VLX103 450mg|In the third group, 450 mg dosing cohort, three VLX103 tablets will be administered daily for 14 days.
62771662|NCT00681993|ACTIVE_COMPARATOR|Standard ddAC chemotherapy with concurrent radiation therapy|Standard dose-dense Adriamycin and Cyclophosphamide (ddAC) chemotherapy and concurrent radiation therapy (RT)
62771663|NCT00681993|ACTIVE_COMPARATOR|Standard AC chemotherapy with concurrent RT|Standard Adriamycin and Cyclophosphamide (AC) chemotherapy and concurrent radiation therapy
62771664|NCT00681993|ACTIVE_COMPARATOR|Standard TCarbo H chemotherapy with concurrent RT|Standard Taxotere, Carboplatin and Herceptin (TCarbo H) chemotherapy and concurrent radiation therapy
62771665|NCT00681993|ACTIVE_COMPARATOR|Standard TAC chemotherapy with concurrent RT|Standard Taxotere, Adriamycin and Cyclophosphamide (TAC) chemotherapy with concurrent radiation therapy
62771666|NCT00681993|ACTIVE_COMPARATOR|Standard TC chemotherapy with concurrent RT|Standard Taxotere and Cyclophosphamide (TC) chemotherapy with concurrent radiation therapy
62771667|NCT03483298||elevated sperm DNA fragmentation|Couples with male partners who will be undergoing a TESA procedure secondary to elevated DNA fragmentation (\>25% DFI) as part of their routine IVF treatment will have half of the women's eggs inseminated with ejaculated sperm and the other half with surgically obtained sperm via the ICSI procedure
62179339|NCT02723513|EXPERIMENTAL|Preterm Adults|All enrolled preterm adults will undergo non-contrast enhanced MRI (using ultra-short echo time methods), hyperpolarized noble gas MRI (using hyperpolarized xenon-129), x-ray computed tomography (CT), pulmonary function tests, and questionnaires in a single visit.
62179340|NCT01834768|EXPERIMENTAL|A|Eplerenone
62179341|NCT03459612|PLACEBO_COMPARATOR|Placebo|Placebo administered orally in one of four study periods.
62771668|NCT03150732|ACTIVE_COMPARATOR|Systemic nalbuphine group|53 patients will receive nalbuphine systemically
62771669|NCT03150732|ACTIVE_COMPARATOR|Local nalbuphine group|53 patients will receive nalbuphine with local intravenous regional anesthesia (IVRA)
62771670|NCT02418104|EXPERIMENTAL|CHS-1701|CHS-1701 followed by CHS-1701
62771671|NCT02418104|ACTIVE_COMPARATOR|Neulasta|Neulasta followed by Neulasta
62771672|NCT01070108|ACTIVE_COMPARATOR|Set 1|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
62771673|NCT01070108|ACTIVE_COMPARATOR|set 2|2nd set received ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
62771674|NCT01070108|ACTIVE_COMPARATOR|set 3|3rd set one group had ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
62771675|NCT03191370|ACTIVE_COMPARATOR|Local Anaesthetic, no distraction|Will receive local (co-phenylcaine) anesthetic spray (Local Anesthetics,Topical) as an active comparator without distraction during the procedure.
62771676|NCT03191370|EXPERIMENTAL|Local Anaesthetic, with distraction|Will receive local (co-phenylcaine) anesthetic spray (Local Anesthetics,Topical) with distraction during the procedure. The simple distraction technique is the experimental intervention.
62771677|NCT03191370|NO_INTERVENTION|No Local Anaesthetic without distraction|Will receive no local (co-phenylcaine) anaesthetic spray without distraction during the procedure.
62771678|NCT03191370|EXPERIMENTAL|No Local Anaesthetic, with distraction|Will receive no local (co-phenylcaine) anesthetic spray with distraction during the procedure. The simple distraction technique is the experimental intervention.
62771679|NCT01629472|EXPERIMENTAL|VSLA + gender dialogue groups: treatment|
62771680|NCT01629472|ACTIVE_COMPARATOR|VSLA only: control|
62771681|NCT05340166|ACTIVE_COMPARATOR|Radiofrequency Neurolysis|Radiofrequency Neurolysis of genicular nerves
62771682|NCT05340166|EXPERIMENTAL|Chemical Neurolysis|Chemical Neurolysis of genicular nerves
62179342|NCT03459612|EXPERIMENTAL|100 milligrams (mg) Lasmiditan|100 mg lasmiditan administered orally in one of four study periods.
62179343|NCT03459612|EXPERIMENTAL|200 mg Lasmiditan|200 mg lasmiditan administered orally in one of four study periods.
62771683|NCT01375465|OTHER|Dior|One arm observational registry using the Dior paclitaxel eluting balloon for the treatment of de novo ostial bifurcated lesions.
62771684|NCT01392287|EXPERIMENTAL|Memantine hydrochloride|Older individuals with DSM IV TR Major Depression, with persistent symptoms of depression despite at least 8 weeks of treatment with standard pharmacotherapy, will be referred for a study of memantine hydrochloride augmentation. Healthy control subjects follow similar study schedule for baseline and endpoint but do not receive memantine hydrochloride.
62179344|NCT03459612|ACTIVE_COMPARATOR|Diphenhydramine|50 mg diphenhydramine administered orally in one of four study periods.
62179345|NCT05157737||BFNS group|(1) Epileptic seizure in neonatal period; (2) Epileptic seizure duration is short, which under spontaneous control in 4\~6 months; (3) The patient was in normal state of feeding, physical examination and psychomotor development; (4) There were no signs of hypsarrhythmia or burst suppression in EEG.
62179346|NCT05157737||DEE group|(1) Epileptic seizures occur within a week after birth and recur frequently; (2) Epilepsy is refractory; (3) Feeding difficulties, accompanied by moderate to severe mental retardation and psychomotor retardation; (4) The EEG showed hypsarrhythmia or burst suppression.
62179347|NCT05028946|EXPERIMENTAL|Cohort 1: Foralumab Dose Level 1|Participants will receive foralumab enteric coated capsules at dose level 1, administered orally once daily for 2 weeks (5 consecutive days in each week with a 2-day undosed safety assessment period after each 5 day treatment period).
62771685|NCT04519060|NO_INTERVENTION|No eye shields after dilated eye exam|Eye dilation for scheduled exam will be followed by routine clinical care.
62771686|NCT04519060|EXPERIMENTAL|Eye shields after dilated eye exam|Eye dilation for scheduled exam will be followed by routine clinical care and the application of eye shields. They will be worn until four (4) hours after the last dose of dilating eye drops.
62771687|NCT03759470||Evaluation of different methods for diagnosis of meningitis|"The CSF samples will be stored at -80°C until testing . CSF specimens will be prepared for GS and culture examinations by centrifugation at 3,000 rpm for 10 minutes at room temperaturetemperature.Culture will be performed by inoculating 1-2 drops of CSF sediment directly onto each of the following agar plates: horse-blood agar, Thayer-Martin agar, choc- olate agar and Sabouraud agar. Moreover, a broth tube (brain-heart infusion, BHI) will be inoculated with one drop of the sediment. Agar plates and broth will be incubated for 1 to 5 days at 35-37°C (with \~5% CO2, or in a candle-jar, for Thayer-Martin and chocolate agar) .~In addition to GS and culture method , India ink test and culture and latex agglutination test (LAT). LAT assay will be performed on CSF samples using Latex-antigen detection system kit.."
62179348|NCT05028946|EXPERIMENTAL|Cohort 2: Foralumab Dose Level 2|Participants will receive foralumab enteric coated capsules at dose level 2, administered orally once daily for 2 weeks (5 consecutive days in each week with a 2-day undosed safety assessment period after each 5 day treatment period).
62179349|NCT05028946|EXPERIMENTAL|Cohort 3: Foralumab Dose Level 3|Participants will receive foralumab enteric coated capsules at dose level 3, administered orally once daily for 2 weeks (5 consecutive days in each week with a 2-day undosed safety assessment period after each 5 day treatment period).
62179350|NCT05028946|EXPERIMENTAL|Cohort 4: Foralumab Dose Level 4|Participants will receive foralumab enteric coated capsules at dose level 4, administered orally once daily for 2 weeks (5 consecutive days in each week with a 2-day undosed safety assessment period after each 5 day treatment period).
62179351|NCT03230409|NO_INTERVENTION|Phase 1, Retrospective|Routine outpatient follow-up visits were scheduled as follows: (a) in patients receiving primary chemoprophylaxis or Latent Tuberculosis Infection (LTBI) treatment: baseline visit, and 2 weeks and 3 months later (end of treatment in most cases); (b) in patients treated for Tuberculosis disease: baseline visit, 2 weeks later and on a monthly basis thereafter.
62771688|NCT02359773||Group 1 - Non ischemic chest pain|No coronary artery disease (CAD) as confirmed by myoview, MRI or stress echo. Subjects will receive one MCG scan (intervention) using the QI Model 1.0 Magentocardiogram. This will be in addition to their current care and it will not be used to support clinical decision making.
62771689|NCT02359773||Group 2 - Myocardial infarction|Myocardial infarction confirmed by a troponin test (\>50ng/l) 12 hours after the onset of chest pain. Subjects will receive one MCG scan (intervention) using the QI Model 1.0 Magentocardiogram. This will be in addition to their current care and it will not be used to support clinical decision making.
62771690|NCT01280097||Prospective cohort study|Observational only
62771691|NCT02780973||Females|Female volunteers
62771692|NCT02780973||Males|Male volunteers
62179352|NCT03230409|EXPERIMENTAL|Phase 2, Prospective|"Four nurse-led interventions were implemented after Phase 1:~* Intervention 1: at baseline visit, the parents or carers of the children, were given a leaflet in the mother tongue. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.~* Intervention 2: a follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits.~* Intervention 3: the Eidus-Hamilton test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test.~* Intervention 4: a written questionnaire about adherence to anti-TB treatment on all the follow-up visits."
62179353|NCT04526314||Stage 3 with adjuvant chemotherapy|
62179354|NCT04526314||Stage 3 without adjuvant chemotherapy|
62179355|NCT03595423||Bioprosthesis|All patients operated on of isolated AVR with a bioprosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
62771693|NCT00547950|EXPERIMENTAL|1|drug
62179356|NCT03595423||Mechanical prosthesis|All patients operated on of isolated AVR with a Mechanical prosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
62771694|NCT04734587||Chronic Total Occlusion|Chronic total occlusion patients undergoing percutaneous coronary intervention.
62179357|NCT01612767|EXPERIMENTAL|Pro-Kinetic Energy Stent|
62179358|NCT02191527|EXPERIMENTAL|Point of Care Testing|The point-of-care devices will be located in the MCH services, where a trained lay counselor will do the tests.
62179359|NCT02191527|NO_INTERVENTION|Laboratory Testing - Standard of care|Samples sent to the laboratory for analysis, (standard of care)
62179360|NCT01084239|NO_INTERVENTION|Standard of care|Subjects in this arm (50% of the total cohort) continued to receive standard non-invasive evaluation of acute chest pain symptoms in the emergency department - mostly comprising of, but not limited to - exercise treadmill test, stress test with imaging and stress echocardiography.
61995099|NCT03569228|EXPERIMENTAL|Study 1 (In-the-Ear) Group|Experienced users of in-the-ear (ITE) hearing aids will receive replacement ITE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
62179361|NCT01084239|EXPERIMENTAL|Cardiac CT|Subjects in this arm (50% of the total cohort) were randomized to receive a cardiac computed tomography scan as part of the initial evaluation of acute chest pain symptoms, upon presentation to the emergency department.
62179362|NCT01222078|EXPERIMENTAL|otelixizumab|otelixizumab
62179363|NCT03098797|EXPERIMENTAL|Elamipretide, then Placebo|"Experimental Part 1: 12 weeks of single daily SC doses of 40 mg elamipretide in Treatment Period 1 followed by 12 weeks of treatment with placebo in Treatment Period 2 (separated by a 4 week washout period).~Experimental Open Label Extension Part 2: All subjects will receive Elamipretide 40mg SC daily injections for up to 168 weeks"
62771695|NCT04734587||Non-Chronic Total Occlusion|Non-Chronic total occlusion patients undergoing percutaneous coronary intervention.
62771696|NCT01498016|EXPERIMENTAL|Iv-Busulfan|iv busulfan 1.6mg/kg given q12h
62771697|NCT01761812|EXPERIMENTAL|Single arm study|
62771698|NCT00483002||Healthy smokers|
62771699|NCT05579769|ACTIVE_COMPARATOR|ArmA- Lymphoid|Total Body Irradiation and cyclophosphamide (TBI/Cy)
62771700|NCT05579769|ACTIVE_COMPARATOR|ArmB-Myeloid|TBF with comparable NRM in comparison to busulfan and cyclophosphamide (BuCy)
62771701|NCT05463991|EXPERIMENTAL|Bioengineered collagen implant|Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. Instead of an autologous oral bucal mucosa graft, the bioengineered collagen implant is sutured to the healty urethral area after incision of the urethra at the stricture location.
62771702|NCT04564872|EXPERIMENTAL|HSK7653 10 mg|
62771703|NCT04564872|EXPERIMENTAL|HSK7653 25 mg|
62771704|NCT04564872|ACTIVE_COMPARATOR|Linagliptin 5 mg|
62771705|NCT02708420|OTHER|Glidescope intubation|This standard GlideScope (GS) technique involves a midline laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
62771706|NCT02708420|OTHER|Macintosh Laryngoscope|This standard technique involves laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
62771707|NCT06312241|EXPERIMENTAL|Metacognitive Training-Silver BeWell|MCT-Silver BeWell is a cognitive-behavioral therapy based group intervention, which aims to improve insight for and change negative (meta)cognitive beliefs (e.g., negative mental filter), information-processing biases (e.g., mood-congruent memory), unhelpful behaviors (e.g., social withdrawal) and emotion-regulation (ER) strategies (e.g. rumination, avoidance of negative feelings) associated with the onset of depression. The training represents a variant of MCT-Silver for depression in later life developed for older adults without clinical depression.
62771708|NCT05919485|EXPERIMENTAL|Interventional-DLPFC|DLPC/F3-F4 group will consist of 20 PD-MCI patients and 20 aMCI patients; 2mA anodal tDCS over DLPFC The current density will be 0.06mA/cm2 from each electrode with total density of 0.054/cm2 and will be delivered for 20 minutes for the atDCS group for 5 days a week, for 10 days and a total of 10 sessions in 14 days.
62771709|NCT05919485|EXPERIMENTAL|Interventional-LPC|LPC/P3-P4 group will consist of 20 PD-MCI patients and 20 aMCI patients; 2mA anodal tDCS over LPC The current density will be 0.06mA/cm2 from each electrode with total density of 0.054/cm2 and will be delivered for 20 minutes for the atDCS group for 5 days a week, for 10 days and a total of 10 sessions in 14 days.
62771710|NCT05919485|SHAM_COMPARATOR|Sham|"Sham control group will consist of 40 patients (20 aMCI and 20 PD-MCI patients).~2mA anodal sham tDCS protocol. For the sham protocol, the stimulation will be delivered for one time with a very low current frequency, enough to cause slight tingling, and for 15 seconds long which will also be delivered for 20 minutes, 5 days a week, for 10 days and a total of 10 sessions in 14 days."
62771711|NCT05629910|EXPERIMENTAL|Interventional period: Automated adjustment of FiO2 by O2Matic|During the interventional period the O2Matic will operate in automatic mode using the Neonatal Study Profile. O2Matic will continuously adjust the O2 flow to adjust SpO2 within range based on readings from the pulse oximeter connected to O2Matic, while AIRVO-2 will adjust the flow of ambient air to keep the total gas flow constant.
62771712|NCT05629910|NO_INTERVENTION|Control period - manual adjustment of FiO2|During the control period, the bedside nurse will manually change FiO2 as per routine based on the reading from the Avant 9600 Nonin pulse oximeter connected to the central monitoring system), by changing oxygenflow from O2Matic as required to induce appropriate changes in SpO2:
62771713|NCT04969198|EXPERIMENTAL|Nicotine Patch + Nicotine Mini Lozenge|"No medication for 1 Week after Target Quit Day (TQD). Medication started 1 Week after TQD.~Patches (Nicotine): 14 mg Patches for 4 weeks postquit (Week 1-5), then 7 mg patches for 4 weeks (Week 6-9)~Mini Lozenge (Nicotine): 2 mg Mini Lozenges 5x per day (up to 20x day max) for 8 weeks post quit (Week 1-9)"
62771714|NCT04671992|ACTIVE_COMPARATOR|Ultrasound Guided Out of-Plane Technique|Ultrasound Guided Out of plane technique (probe applied by holding horizontal)
62771715|NCT04671992|ACTIVE_COMPARATOR|Ultrasound Guided In-Plane Technique|Ultrasound Guided Out of plane technique (probe applied by holding vbertical)
62771716|NCT02461888|EXPERIMENTAL|Ixazomib, CD|"Ixazomib, cyclophosphamide and dexamethasone (ICD) will be administered as part of a 28 days cycle until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~* Ixazomib 4mg orally on days 1, 8 and 15~* Cyclophosphamide 500mg orally on days 1, 8 and 15~* Dexamethasone 40mg orally on days 1-4 and 12-15"
62771717|NCT02461888|ACTIVE_COMPARATOR|CD|"Cyclophosphamide and dexamethasone (CD) will be administered as part of a 28 days cycle until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~* Cyclophosphamide 500mg orally on days 1, 8 and 15~* Dexamethasone 40mg orally on days 1-4 and 12-15"
62771718|NCT05010447|EXPERIMENTAL|Study Group|Participants receive the Virtual Coach App for one week at the beginning of their therapy and one week towards the end of their therapy.
62771719|NCT01536808|EXPERIMENTAL|Type 2 Diabetes Mellitus|
62771720|NCT00548899|OTHER|Sorafenib|Single Arm: All patients receive sorafenib in addition to the established chemotherapy
62771721|NCT01124981|PLACEBO_COMPARATOR|Albumin|
62771722|NCT01124981|EXPERIMENTAL|Haemocomplettan® P|
62771723|NCT01085032|EXPERIMENTAL|Arm A|Behavioral Counseling and Nicotine Patch
62771724|NCT01085032|PLACEBO_COMPARATOR|Arm B|Behavioral counseling and placebo patch
62771725|NCT01139827||normal|normal group has no diabetes.
62771726|NCT01139827||IGT|IGT group has impaired fasting glucose or impaired glucose tolerance.
62179364|NCT03098797|PLACEBO_COMPARATOR|Placebo , then Elamipretide|"Placebo Comparator Part 1: 12 weeks of single daily SC doses of placebo in Treatment Period 1 followed by 12 weeks of treatment with 40 mg elamipretide in Treatment Period 2 (separated by a 4 week washout period).~Placebo Comparator Open Label Extension Part 2: All subjects will receive Elamipretide 40mg SC daily injections for up to 168 weeks"
62179365|NCT05082662|EXPERIMENTAL|Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)|
62771727|NCT04218396|EXPERIMENTAL|Standard Treatment, Then Virtual Reality + Standard Treatment|Participants will have an initial painful bedside procedure (eg: bedside wound care or dressing change) under standard treatment only. After a washout period, they then will have a repeat procedure (eg: similar bedside wound care or dressing change) under standard treatment AND virtual reality
62771728|NCT04218396|EXPERIMENTAL|Virtual Reality + Standard Treatment, Then Standard Treatment|Participants will have an initial painful bedside procedure (eg: bedside wound care or dressing change) under standard treatment AND virtual reality. After a washout period, they then will have a repeat procedure (eg: similar bedside wound care or dressing change) under standard treatment only.
62771729|NCT03079856|EXPERIMENTAL|Brief Intervention|ED-based computer-guided intervention for substance use and HIV risk reduction utilizing Motivational Interviewing
62771730|NCT03079856|NO_INTERVENTION|Enhanced Usual Care|Substance use and sexual health services information within a brochure provided to participants
62771731|NCT03429257||Pregnant Women in Mukono Uganda|Single-group study
62771732|NCT00306644|EXPERIMENTAL|Arm 1|study drug
62771733|NCT02473276|ACTIVE_COMPARATOR|EPID PFM|"The group EPID PFM will receive 3 mg (6 ml) of preservative-free morphine, followed by 3 ml of sterile normal saline, to be administered through the epidural catheter.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses)."
62771734|NCT02473276|SHAM_COMPARATOR|EPID SAL|"The placebo group, EPID NS, will receive 6 ml of sterile normal saline via the epidural catheter followed by another 3 ml NS. Sixteen to 24 hours after receiving the first study drug,the patient will then receive the identical study drug (for a total of two doses)."
62771735|NCT02473276|ACTIVE_COMPARATOR|IT PFM|"The group, IT PFM will receive 200 micrograms (mcg) (0.4 ml) of preservative-free morphine via the intrathecal catheter, followed by a flush of the catheter with 2 ml of sterile saline.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses)."
61995100|NCT03569228|EXPERIMENTAL|Study 1 (Behind-the-Ear) Group|Experienced users of behind-the-ear (BTE) hearing aids will receive replacement BTE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
61995101|NCT03569228|NO_INTERVENTION|Study 2 (Open-Fit corrections)|Participants with hearing loss will be fitted monaurally with 12 stock non-custom, receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids using the standard in-situ approach and test box measures will be made of each fitting to develop correction factors for these styles.
62771736|NCT02473276|SHAM_COMPARATOR|IT SAL|The placebo group IT SAL will receive 0.4 ml and then 2 ml of sterile normal saline through the intrathecal catheter.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses).
62179366|NCT05082662|ACTIVE_COMPARATOR|Cataflam® 50 coated tablet (50 mg Diclofenac Potassium)|
62179367|NCT03847480|EXPERIMENTAL|Dose painting|Dose painting
62179368|NCT00821119|ACTIVE_COMPARATOR|NCPAP|preterm infants with nasal positive pressure ventilation as a primary mode of respiratory support in preterm infants with respiratory distress syndrome will be compared to preterm infants with nasal intermittent positive pressure ventilation
62179369|NCT00821119|EXPERIMENTAL|NIPPV|preterm with nasal intermittent positive pressure ventilation as a primary mode of respiratory support in preterm infants with respiratory distress syndrome
62179370|NCT04545476|EXPERIMENTAL|APIS Biomaterial on the Head|Participants in this group will receive the experimental APIS Biomaterial on the Head. One layer of APIS® will be applied to the post-operative wound covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape. The biomaterial will be reapplied if it is completely absorbed at follow up and the wound depth below the epithelial level.
62182752|NCT03479125||Historical emricasan or placebo subjects|Subjects with liver fibrosis or cirrhosis who have received at least one dose of emricasan or placebo in a prior IDN-6556 study including IDN-6556-07, IDN-6556-12, IDN-6556-14 or IDN-6556-17.
62771737|NCT01260545|EXPERIMENTAL|Infusion|A standard 3+3 design will be employed to determine maximum tolerated dose
62771738|NCT00751855|ACTIVE_COMPARATOR|1|Prolonged Exposure therapy with Hydrocortisone
62179371|NCT04545476|EXPERIMENTAL|APIS Biomaterial on the Lower Extremities|Participants in this group will receive the experimental APIS Biomaterial on the Lower Extremities. One layer of APIS® will be applied to the post-operative wound covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape. The biomaterial will be reapplied if it is completely absorbed at follow up and the wound depth below the epithelial level.
62563137|NCT01265862|ACTIVE_COMPARATOR|LMA-Fastrach® and GlideRite® tube|"* Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~* Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~* Insertion of LMA-Fastrach®, establishment of ventilation~* Evaluation of glottic view through LMA-Fastrach® using fibrescope~* Tracheal intubation with the GlideRite® tube through the LMA-Fastrach®~* With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
62563138|NCT01265862|EXPERIMENTAL|I-gel® and GlideRite® tube|"* Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~* Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~* Insertion of I-gel®, establishment of ventilation~* Evaluation of glottic view through I-gel® using fibrescope~* Tracheal intubation with the GlideRite® endotracheal tube through the I-gel®~* With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
62563139|NCT03410576||Carotid artery stenting|Patients undergo carotid artery stenting.
62563140|NCT03410576||Carotid endarterectomy|Patients receive elective carotid endarterectomy.
62563141|NCT01801943|EXPERIMENTAL|Cognitive Remediation Therapy Group|30 minute Cognitive Remediation Therapy and 60 minute Healthy Living Class three time per week
62563142|NCT01801943|EXPERIMENTAL|Walking Intervention Group|60 minutes of walking and 30 minutes of reading stimulation three times a week
62563143|NCT01801943|EXPERIMENTAL|Combination Group|30 minutes of Cognitive Remediation therapy and 60 minutes of walking three times a week
62563144|NCT01801943|EXPERIMENTAL|Healthy Living Group|60 minute Healthy Living Class and 30 minutes of reading stimulation three times a week.
62563145|NCT03587402|EXPERIMENTAL|Transcutaneous perineal stimulation|Patient is asked to lie down with legs slightly bend and two adhesive electrodes are attached transcutaneous on base of penis and on perineum. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
62563146|NCT03587402|ACTIVE_COMPARATOR|Anal stimulation|Patient is asked to lie down with legs slightly bend and an electrical probe is inserted into the anus. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
62563147|NCT02380586||Women in labor undergoing anesthesia care|Women in labor undergoing anesthesia care
62771739|NCT00751855|PLACEBO_COMPARATOR|2|Prolonged Exposure therapy with placebo
62563148|NCT00997841|ACTIVE_COMPARATOR|POC algorithm|cardiac surgery patients suffering from increased perioperative bleeding and being treated following Point of Care based algorithm
62563149|NCT00997841|ACTIVE_COMPARATOR|conventional algorithm|cardiac surgery patients suffering from increased perioperative bleeding and being treated following conventional coagulation management algorithm
62771740|NCT02540291|EXPERIMENTAL|E7046|Participants with tumor types that harbor high levels of myeloid infiltrate based on the Cancer Genome Atlas (TCGA).
62771741|NCT00857519|EXPERIMENTAL|Chemotherapy|Chemotherapy using Melphalan, Carboplatin.
62771742|NCT01443832||iron absorption|
62771743|NCT02983994||Patients with asthma with an inhaled steroid|Patients with a diagnosis of asthma with indication of Treatment with an inhaled steroid (CI)
62179372|NCT04545476|ACTIVE_COMPARATOR|Standard Secondary Intention Healing on the Head|Participants in this group will receive standard secondary intention wound healing post-operative care on the Head. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
62771744|NCT02983994||Patients with asthma with an inhaled Beta agonist|Patients with a diagnosis of asthma with indication of Treatment with an inhaled Beta agonist (LABA)
62771745|NCT02483390|EXPERIMENTAL|Intervention group: All dyads are in the intervention arm.|
62771746|NCT01979939|EXPERIMENTAL|A 1: DCV/ASV/BMS-791325 in treatment-naive subjects|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
62771747|NCT01979939|EXPERIMENTAL|A 2: DCV/ASV/BMS-791325 in treatment-experienced subjects|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
62771748|NCT01985360|ACTIVE_COMPARATOR|Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization (Percutaneous Coronary Intervention or Coronary Artery Bypass Graft Surgery) plus optimal medical therapy.
62771749|NCT01985360|ACTIVE_COMPARATOR|Conservative Strategy (CON)|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with OMT failure.
62771750|NCT06377891|EXPERIMENTAL|Emotional Resilience Group|Providing emotional resilience training to the experimental group.
62771751|NCT06377891|NO_INTERVENTION|Control group|There will be no intervention in the control group.
62771752|NCT03987906|EXPERIMENTAL|Symptom screening with Targeted Early Palliative Care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
62182753|NCT05887141|OTHER|Control Condition (no perspective change)|The intervention (two role-plays), however without using a perspective change afterwards.
62771753|NCT03987906|NO_INTERVENTION|Standard Oncology Care|The control arm receives standard oncology care, which includes routine symptom screening at every outpatient visit.
62182754|NCT05887141|EXPERIMENTAL|Perspective change condition|The intervention (two role-plays) with a perspective change after each role-play.
62771754|NCT05006144|OTHER|control group|control group
62771755|NCT05006144|EXPERIMENTAL|Experimental group|selective dorsal rhizotomy
62771756|NCT00903331|EXPERIMENTAL|ACT-064922|ACT-064922 tablet (macitentan), 10 mg, once daily
62179373|NCT04545476|ACTIVE_COMPARATOR|Standard Secondary Intention Healing on the Lower Extremities|Participants in this group will receive standard secondary intention wound healing post-operative care on the Lower Extremities. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
62179374|NCT05530382|EXPERIMENTAL|self-guided learning (video and hands-on simulation)|video-based self-directed learning
62179375|NCT05530382|NO_INTERVENTION|traditional instructor-led learning|traditional instructor-led learning in face-to-face workshop
62179376|NCT01658956|EXPERIMENTAL|Subcutaneous GCSF 5 µg/kg days 8 and 12|Prophylactic administration of GCSF on days 8 and 12 following chemotherapy
62179377|NCT01658956|NO_INTERVENTION|No intervention|
62179378|NCT00841607|EXPERIMENTAL|Pancreaticojejunostomy|Pancreaticojejunostomy reconstruction used following Whipple surgery.
62179379|NCT00841607|ACTIVE_COMPARATOR|Pancreaticogastomy|Pancreaticogastomy reconstruction used following Whipple surgery.
62179380|NCT01087814|ACTIVE_COMPARATOR|efavirenz|
62179381|NCT01087814|EXPERIMENTAL|over-encapsulated efavirenz|
62179382|NCT01980524|EXPERIMENTAL|acipimox+|250 mg at 0 and 180 minutes (one day)
62179383|NCT01980524|PLACEBO_COMPARATOR|Placebo|1 Tablet at 0 and 180 minutes (one day)
62179384|NCT05771597|EXPERIMENTAL|Home Biofeedback Therapy (HBT)|"1. HBT for patients with constipation and dyssynergic defecation:~2. HBT for patients with FI~3. HBT for patients with UI~All patients will be advised to practice HBT at least once or twice a day for six weeks."
62179385|NCT05771597|ACTIVE_COMPARATOR|Office Biofeedback Therapy (OBT)|"1. OBT for patients with constipation and dyssynergic defecation.~2. OBT for patients with FI.~3. OBT for patients with UI.~All patients will receive office biofeedback, once weekly, over six weeks."
62179386|NCT00458354|EXPERIMENTAL|Spinal Sealant|Dural repair with the Spinal Sealant System.
62179387|NCT00458354|ACTIVE_COMPARATOR|Standard Methods|Dural repair with standard methods such as the closing of the dura with stitches.
62179388|NCT05229341|EXPERIMENTAL|Diagnostic (needle biopsy, DDMS-2)|Patients undergo needle biopsy for collection of tissue samples. Tissue samples are analyzed using DDMS-2. Patients' medical records are also reviewed.
62179389|NCT01858051|ACTIVE_COMPARATOR|Cholecalciferol Bolus Dose|70 patients will receive a bolus pre-operative oral dose of 150,000 IU cholecalciferol 3-7 days before surgery
62179390|NCT01858051|ACTIVE_COMPARATOR|Cholecalciferol Divided Dose|70 patients will receive an oral 100,000 IU cholecalciferol dose 3-7 days before surgery and an additional oral 50,000 IU cholecalciferol dose on post-operative day 1
62179391|NCT01858051|PLACEBO_COMPARATOR|Sugar Pill|35 patients will receive a placebo pill orally 3-7 days before surgery
62179392|NCT04278495|ACTIVE_COMPARATOR|Losartan|"to receive the medication Cozaar (Losartan Potassium 25mg Merck Sharp \& Dohme-UK),"
62179393|NCT04278495|PLACEBO_COMPARATOR|Placebo|to receive either placebo
62771757|NCT00903331|PLACEBO_COMPARATOR|Placebo|Matching placebo, once daily
62179394|NCT00848393|ACTIVE_COMPARATOR|Fentanyl (High Dose)|This arm will receive a total of 25 mcg/kg of Fentanyl (High Dose) in two divided doses. First half-dose given at induction and second half-dose given before incision.
62179395|NCT00848393|ACTIVE_COMPARATOR|Fentanyl (Low Dose)|This arm will receive a total of 10 mcg/kg of Fentanyl (Low Dose). First half-dose will be given at induction and second half -dose given before incision.
62179396|NCT00848393|ACTIVE_COMPARATOR|Fentanyl (Low Dose) + Dexmedetomidine|This arm will receive10 mcg/kg of Fentanyl (Low Dose) -2 divided doses. Dexmedetomidine (Dex) loading dose-1 mcg/kg over 10 min, then Dex infusion at 0.5mcg/kg/hr.
62179397|NCT02721433|ACTIVE_COMPARATOR|4 weekly bone-targeted agent x 1 year|Bone targeting agents as standard of care
62179398|NCT02721433|ACTIVE_COMPARATOR|12 weekly bone-targeted agent x 1 year|Bone targeting agents as standard of care
62179399|NCT00993798|EXPERIMENTAL|SABER-Bupivacaine Treatment 1a|double-blind
62179400|NCT00993798|PLACEBO_COMPARATOR|Placebo SABER-Bupivacaine Treatment 1b|double-blind
62179401|NCT00993798|ACTIVE_COMPARATOR|Bupivacaine HCl Treatment 1c|double-blind
62179402|NCT00993798|EXPERIMENTAL|SABER-Bupivacaine Treatment 2a|double-blind
62179403|NCT00993798|PLACEBO_COMPARATOR|Placebo SABER-Bupivacaine Treatment 2b|double-blind
62179404|NCT00993798|ACTIVE_COMPARATOR|Bupivacaine HCl Treatment 2c|double-blind
62179405|NCT04650659||Part one of the project|83 patients with Systemic Sclerosis will perform three functional exercise tests on the same day. All 83 patients will be examined with NVC. Moreover, HRpQCT will be performed on all patients at baseline and after 1 year.
62179406|NCT04650659||Part two of the project|Half of the patients from part one of the project will be invited to repeat the three functional exercise tests approximately one week later in reverse order to determine test-retest reliability.
62179407|NCT02274623|EXPERIMENTAL|CTAP101 Capsules|CTAP101 Capsules daily
62179408|NCT06192719||Gallbladder Cancer/Dysplasia|Patients affected by gallbladder cancer or dysplasia, both before and after starting their treatment
62179409|NCT06192719||Gallstone disease|Patients affected by cholelithiasis before cholecystectomy (only patients scheduled for cholecystectomy will be recruited)
62179410|NCT05591170|EXPERIMENTAL|Study Group|"Participants received single, high, oral dose of vitamin D3 (120,000 IU), serum 25(OH)D3, 25(OH)D2, 24,25(OH)2D3, 3-epi-25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3/25(OH)D3 ratio, and 25(OH)D3/3-epi-25(OH)D3 ratio concentration (measured by LC-MS/MS) at baseline, 3 days and 7 days after bolus dose were measured.~The percentage of fat tissue was determined using Dual-Energy X-Ray Absorptiometry (DXA)."
62179411|NCT05591170|NO_INTERVENTION|Control Group|"Serum 25(OH)D3, 25(OH)D2, 24,25(OH)2D3, 3-epi-25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3/25(OH)D3 ratio, and 25(OH)D3/3-epi-25(OH)D3 ratio concentration (measured by LC-MS/MS) were measured at baseline, 3 days and 7 days after.~The percentage of fat tissue was determined using Dual-Energy X-Ray Absorptiometry (DXA)."
62179412|NCT01703845|EXPERIMENTAL|Tiotropium + Olodaterol (high dose)|Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT
62179413|NCT01703845|EXPERIMENTAL|Tiotropium + Olodaterol (low dose)|Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT
62179414|NCT01565252|NO_INTERVENTION|Stage 1|"Dietary regimens:~Stage1 - all participants (N=20) in first stage will receive two regular (high n-6 PUFA) hard-boiled eggs/day at breakfast for a three weeks period for each participant."
62771758|NCT02174744||numerical scale|
62179415|NCT01565252|EXPERIMENTAL|Stage 2|Stage 2 will be conduct after 3 weeks for wash-out with no eggs. All participants(N=20) in second stage will receive two high n-3 PUFA hard-boiled eggs/day at breakfast for a three weeks period for each participant.
62179416|NCT04570254|EXPERIMENTAL|Patients with septic shock|"Only one antioxidant will be administered, which the treating physician will decide following a previously established decision tree plus pentoxifylline via an oral or orogastric tube for five days.~With the following specifications:~1. Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours.~2. Vitamin E. 800 mg tablet. 800 mg dose every 24 hours.~3. Melatonin. Tablet 5 mg. A dose of 50 mg every 24 hours.~4. N-acetylcysteine. Tablet 600 mg. 600 mg dose every 12 hours.~The dose of pentoxifylline that all patients will receive is as follows:~a) Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours."
62179417|NCT04570254|EXPERIMENTAL|Patients without septic shock|"Only one antioxidant will be administered, which the treating physician will decide following a previously established decision tree plus pentoxifylline via an oral or orogastric tube for five days.~With the following specifications:~1. Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours.~2. Vitamin E. 800 mg tablet. 800 mg dose every 24 hours.~3. Melatonin. Tablet 5 mg. A dose of 50 mg every 24 hours.~4. N-acetylcysteine. Tablet 600 mg. 600 mg dose every 12 hours.~The dose of pentoxifylline that all patients will receive is as follows:~a) Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours."
62179418|NCT06345898|EXPERIMENTAL|JWK002 at Low Dose Group|Subretinal injection low dose of JWK002 in one eye
62179419|NCT06345898|EXPERIMENTAL|JWK002 at Medium Dose Group|Subretinal injection medium dose of JWK002 in one eye
62179420|NCT06345898|EXPERIMENTAL|JWK002 at High Dose Group|Subretinal injection high dose of JWK002 in one eye
62179421|NCT02763163||outdoor workers|Subjects with an excessive exposure to the sun on a daily basis
62179422|NCT02763163||office workers|Subjects who spend most of the day in a closed shaded room
62179423|NCT04251546||Observational group|Patients with suspected prostate cancer with a PSA test value of 4-10 ng / mL
62391168|NCT05355454|EXPERIMENTAL|STYLAGE® XXL Treatment Group|"Subjects randomized (5:1 ratio) to receive an initial treatment with STYLAGE® XXL Crosslinked Hyaluronic Acid Gel up to 8mL, based on the PI's assessment, in combination with the aesthetic goal of the subject, then an optional touch-up treatment session 4 weeks later, up to 4mL.~Subjects will also be offered an optional retreatment at week 72 after initial treatment, up to 8mL."
62179424|NCT02165397|EXPERIMENTAL|Randomized Study (Ibrutinib + Rituximab)|Ibrutinib: 420 mg (3 capsules x 140 mg) orally administered daily beginning from Day 1. Rituximab: 375 mg/m\^2 intravenous (IV) per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
62179425|NCT02165397|EXPERIMENTAL|Randomized Study (Placebo + Rituximab)|Placebo: 3 capsules of placebo orally administered daily beginning from Day 1. Rituximab: 375 mg/m\^2 IV per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
62179426|NCT02165397|EXPERIMENTAL|Open-Label Substudy (Ibrutinib)|Ibrutinib: 420 mg (3 capsules) orally administered daily beginning from Day 1.
62179427|NCT02921139|EXPERIMENTAL|Arm I|Stereotactic ablative radiotherapy (SABR)
62179428|NCT02921139|ACTIVE_COMPARATOR|Arm II|Re-transcatheter arterial chemoembolization (re-TACE)
62179429|NCT01016223|ACTIVE_COMPARATOR|Beclomethasone dipropionate inhaler|
62179430|NCT01016223|PLACEBO_COMPARATOR|Matched inhaler|
62179431|NCT04846855|EXPERIMENTAL|Ropivacaine 35%|Local Anesthesia with Ropivacaine
62179432|NCT01246219|EXPERIMENTAL|GH treatment|4 years of GH treatment
62179433|NCT01246219|PLACEBO_COMPARATOR|Placebo|1 year treatment with placebo followed by optional 3 years of GH treatment
62179434|NCT01246219|NO_INTERVENTION|Non treatment group|
62179435|NCT02562144|EXPERIMENTAL|Xylocaine spray|
62179436|NCT02562144|PLACEBO_COMPARATOR|Placebo|
62179437|NCT01246050|EXPERIMENTAL|Arm 1: Received HF Training|Providers will receive 3 days of HF training, receive access to clinical pharmacist medication titration serviced and receive performance feedback
62179438|NCT01246050|ACTIVE_COMPARATOR|Arm 2: No HF Training|CBOC Providers in the same CBOC who did not received HF Training, access to clinical pharmacist services or performance feedback
62179439|NCT02624375|EXPERIMENTAL|10 persons over 70 years of age that received Zostavax|10 persons over 70 years of age that received Zostavax (single 0.65-mL dose subcutaneously in the deltoid region of the upper arm)
62179440|NCT02767518|EXPERIMENTAL|Prehabilitation|Participants will be referred to the Michigan Surgical \& Health Optimization Program in the month leading up to their surgery. Individuals are encouraged to increase their physical activity, practice stress reduction, and other behaviors associated with good health.
62179441|NCT02767518|NO_INTERVENTION|Usual Care|Participants will follow the pre-operative instructions provided by their surgical team.
62179442|NCT02292485||Physicians - Texas Academy of Family Physicians|Physicians attending Texas Academy of Family Physicians event asked to fill out an anonymous survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
62182755|NCT01745276|EXPERIMENTAL|External pins coated by biphosfonate.|External pins coated by biphosfonate.
62182756|NCT01745276|ACTIVE_COMPARATOR|External pins coated by hydroxylapatite.|External pins coated by hydroxylapatite.
62771759|NCT02133313||Peritoneal Dialysis Patients|Patients on Peritoneal Dialysis
62771760|NCT02745535|EXPERIMENTAL|SOF/VEL/VOX|Fixed dose combination of SOF/VEL/VOX (Sofosbuvir 400mg/Velpatasvir 100mg/ Voxilaprevir 100mg) dosed once daily for 12 weeks.
62771761|NCT02982083|ACTIVE_COMPARATOR|Evista|20 postmenopausal women suffering from rheumatoid arthritis that take raloxifene hydrochloride 60 mg oral tablets every day for one year.
62179443|NCT02112513||salivary estriol measurement|Serum Estriol measurement via different assays is complex, expensive, labor intensive, time consuming, and generally performed at specific reference labs. Salivary Estriol level is an ideal potential surrogate for serum Estriol. It is convenient, non-invasive, and expedient. It may not, however, be as sensitive as serum estriol concentrations at detecting the association with glucocorticoid response. This study will collect both samples to determine which one is better suited for clinical use in this condition.
62771762|NCT02982083|PLACEBO_COMPARATOR|Placebo|20 postmenopausal women suffering from rheumatoid arthritis that take placebo pills every day for one year.
62771763|NCT04912752|OTHER|Case-Control|Copy number variation
62771764|NCT04912752|EXPERIMENTAL|Case-Control 1|Gene expression
62771765|NCT03654001|EXPERIMENTAL|Albumin + Balanced|"Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.~Balanced crystalloid solutions~According to the preference and the standard use of the participating center:~* Ringer Lactate~* Ringer Acetate~* Crystalsol"
62771766|NCT03654001|EXPERIMENTAL|Albumin + Saline|"Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.~Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl)."
62771767|NCT03654001|EXPERIMENTAL|Balanced|Balanced crystalloid solutions (Ringer Lactate, Ringer Acetate, Crystalsol)
62771768|NCT03654001|NO_INTERVENTION|Saline|Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl).
62771769|NCT06437067||non-infection group|patients without bacterial or fungal infection
62771770|NCT06437067||bacterial infection group|patients with bacterial infection
62771771|NCT06437067||fungal infection group|patients with fungal infection
62771772|NCT01399216|EXPERIMENTAL|Fucoidan supplement|
62771773|NCT01399216|PLACEBO_COMPARATOR|Placebo|
62771774|NCT04001595||Participants with FKRP gene mutation|
62771775|NCT01379300|EXPERIMENTAL|Dabigatran|Single 150-mg dose of dabigatran etexilate
62771776|NCT01379300|EXPERIMENTAL|Rivaroxaban|Single 20-mg dose of rivaroxaban
62179444|NCT02112513||serum estriol measure|we will determine if changes in maternal serum estriol represent a biomarker of response to antenatal corticosteroids as evidenced by neonatal development of RDS
62179445|NCT02112513||Betamethasone pharmacokinetic|we will determine if pharmacokinetic parameters and neonatal outcomes after antenatal corticosteroid use are associated with genetic polymorphisms in drug metabolizing enzymes, transporters, and steroid pathway genes
62179446|NCT02112513||betamethasone concentration and genetics|we will determine if maternal betamethasone concentrations and genetics are associated with maternal estriol changes or RDS development
62179447|NCT03911908|ACTIVE_COMPARATOR|ERC guided CPR (intervention/NIRS group)|CPR protocol according to current ERC guidelines (2015)
62179448|NCT03911908|NO_INTERVENTION|ERC-based CPR (control group)|modified CPR protocol based on current ERC guidelines (2015), extended by evaluation of NIRS readings and interventions to optimize CPR quality
62179449|NCT00634218|ACTIVE_COMPARATOR|1|Mail-based Self Help (MSH) treatment. Participants will receive the self-help manual developed specifically for LGBT smokers.
62771777|NCT01379300|NO_INTERVENTION|No intervention|No study drug will be administered
62771778|NCT01733433|EXPERIMENTAL|taped ankle|Subjects will be taped in at the ankle for a series of exercises.
62771779|NCT05002387|EXPERIMENTAL|Unicompartmental OA or equivocal findings in XR|After obtaining informed consent, patients will undergo needle arthroscopy, performed in the operating room prior to undergoing arthroplasty
62771780|NCT03615014|OTHER|Patients having trauma|Adults patients having trauma in the month before visiting emergency will fill questionnaires
62771781|NCT02505568|EXPERIMENTAL|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 and will be evaluated for the induction phase at Week 8. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion at Week 14, Week 22, and Week 30 in the maintenance phase and will be evaluated at Week 32.
62771782|NCT03441503|EXPERIMENTAL|Child HCAHPS: Automated Administration|"Child HCAHPS: Automated day-of-discharge survey~On the day of discharge at the hospital, parents will be contacted to solicit survey responses using patient televisions (GetWell) as follows:~Day 0 (Day of likely discharge): Respondent will be promoted to complete Child HCAHPS on their television as part of the routine discharge process. Respondent will also be asked for their email address to complete post-discharge items and their appropriate contact information will be collected.~Days 2-42: Standard hospital protocol (i.e., mail, email, or IVR) with the post-discharge questions."
62771783|NCT03441503|NO_INTERVENTION|Standard Administration of Child HCAHPS|Parents will be contacted to complete Child HCAHPS using the standard protocol for mail, email, or IVR survey administration. The surveys will be administered by the survey vendor contracted by the participating site to administer Child HCAHPS.
62771784|NCT01533922|EXPERIMENTAL|Tiotropium + olodaterol High dose QD|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in a fixed dose combination once daily
62771785|NCT01533922|EXPERIMENTAL|Tiotropium + olodaterol Low dose QD|patient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in a fixed dose combination once daily
62771786|NCT01533922|ACTIVE_COMPARATOR|Tiotropium 5 mcg QD|patient will receive tiotropium 5 mcg once daily
62771787|NCT01533922|ACTIVE_COMPARATOR|Olodaterol 5 mcg QD|patient will receive olodaterol 5 mcg once daily
62771788|NCT01533922|PLACEBO_COMPARATOR|Placebo QD|
62771789|NCT03258060|ACTIVE_COMPARATOR|Mechanical Dyssynchrony|Those with cardiac MRI evidence of mechanical dyssynchrony
62771790|NCT03258060|ACTIVE_COMPARATOR|No Mechanical Dyssynchrony|Those without mechanical dyssynchrony on cardiac MRI
62771791|NCT02058394||Cataract Phacoemulsification|Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
62771792|NCT01455194|ACTIVE_COMPARATOR|CIC 160|Two puffs of 40 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 160 mcg)
62771793|NCT01455194|ACTIVE_COMPARATOR|CIC 320|Two puffs of 80 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 320 mcg)
62179450|NCT00634218|ACTIVE_COMPARATOR|2|Mail-based Self Help plus an Internet-based Smoking Treatment (IST). In the IST condition, participants will receive the manual plus access to an Internet-based intervention that includes social support.
62179451|NCT00634218|ACTIVE_COMPARATOR|3|Mail-based Self-Help plus Telephone Counseling (TC). In the TC condition, participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions.
62771794|NCT01455194|ACTIVE_COMPARATOR|CIC 640|Two puffs of 160 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 640 mcg)
62771795|NCT02440126||Group A: Natalizumab Naïve|This group will consist of up to 10 people who are naïve to natalizumab (haven't received the drug before) and are just beginning therapy. These participants will meet with the study staff at Week 0 (Baseline) prior to their natalizumab infusion. They will then have a follow up appointment every 3 months for the first 12 months of their natalizumab infusions, for a total of 5 visits. Natalizumab concentration and other biomarkers will be measured at each visit.
62771796|NCT02440126||Group B: Intracycle Regular Dosing|This group will consist of at least 50 people who are on a regular infusing cycle of 28-31 days. These participants will be consented at Week 0 (Baseline) and asked to come back each week during their regular cycle at Week 1, Week 2, and Week 3, for a total of 4 study visits. Natalizumab concentration and other biomarkers will be measured during their participation in the study.
62771797|NCT02440126||Group C: Intracycle Extended Dosing|This group will consist of up to 60 people who are on an extended infusing cycle of greater than 30 days. These participants will be consented at Week 0 (Baseline) and asked to come back each week for a blood draw to measure Natalizumab concentration and other biomarkers during their extended cycle at Week 2, and Week 4, for a total of 3 study visits.
62771798|NCT02440126||Group D: Transition Dosing|This group will consist of up to 10 people who are on a regular infusing cycle of 28-30 days who will be transitioning to an extended dosing cycle. The decision to transition will be made by their treating neurologist. These participants will be consented at Week 0 (Baseline) and will be followed for 8 cycles. Natalizumab concentration will be measured at each cycle. During certain cycles, other biomarkers will be measured.
62771799|NCT01431885|ACTIVE_COMPARATOR|PLAT|Diagnosis of preterm labor will be made by the March of Dimes Preterm Labor Assessment Toolkit Algorithm B, incorporating transvaginal ultrasound measurement of cervical length, and vaginal fetal fibronectin
62771800|NCT01431885|PLACEBO_COMPARATOR|Cervical Change|Diagnosis of preterm labor will be made by cervical change by digital examination
62771801|NCT02846012|NO_INTERVENTION|CSCM Control|Control medium
62771802|NCT02846012|EXPERIMENTAL|CSCM2|New Formulation medium
62771803|NCT02631265|ACTIVE_COMPARATOR|Reduction of insulin basal rate at the time of exercise|
62179452|NCT00634218|ACTIVE_COMPARATOR|4|Mail-based Self-Help plus an Internet-based Intervention plus Telephone Counseling. Participants will receive a self-help manual, have access to an internet-based smoking treatment and participante in 6 telephone counseling sessions.
62179453|NCT03919318|EXPERIMENTAL|AH-Plus|
62179454|NCT03919318|EXPERIMENTAL|EndoSeal MTA|
62771804|NCT02631265|ACTIVE_COMPARATOR|Reduction of insulin basal rate 20 minutes prior to exercise|
62179455|NCT03919318|EXPERIMENTAL|Endosequence BC Sealer|
62771805|NCT02631265|ACTIVE_COMPARATOR|Reduction of insulin basal rate 40 minutes prior to exercise|
62771806|NCT00785174|ACTIVE_COMPARATOR|continuous positive airway pressure|respiratory assistance
62771807|NCT00785174|ACTIVE_COMPARATOR|NIPSV|respiratory assistance using face mak and ventilator to provide inspiratory pressure support and positive end expiratory pressure
62771808|NCT03150784|EXPERIMENTAL|Motor coordination difficulties|"Type: Experimental main~EPIC club: 60min session / 2 times weekly / 7 weeks"
62771809|NCT03150784|OTHER|Non motor coordination difficulties|"Type: Experimental comparator~EPIC club: 60min session / 2 times weekly / 7 weeks"
62771810|NCT03404622|ACTIVE_COMPARATOR|Postplacental IUCD Insertion during Cesarean section|IUCD inserted postplacental removal
62182757|NCT05609799|OTHER|Healthy females|One blood sample is collected on healthy females in reproductive age. The sample will be analyzed for volumen of leucocyte subsets.
62182758|NCT04360798|EXPERIMENTAL|Unilateral Exercise Group|The group to which exercise protocol consisting of strengthening, stretching, range of motion, static and dynamic postural control exercises will only be applied to the affected lower extremities of the participants.
62771811|NCT03404622|ACTIVE_COMPARATOR|6 Week Post-Cesarean Insertion of IUCD|IUCD inserted after six weeks post Cesarean section delivery
62771812|NCT01380704|EXPERIMENTAL|Active|
62771813|NCT01380704|PLACEBO_COMPARATOR|Placebo|
62771814|NCT04280874|ACTIVE_COMPARATOR|GROUP A|106 randomly selected pregnant women
62179456|NCT06213064||Study Product, THC Only Product, Placebo|"All study participants will receive and cross-over into each group: study product, thc-only product, and placebo groups.~Study Product Ingredient List:~Active Ingredients: 10mg THCV, 5mg THC Tapioca syrup, sugar, water, pectin, citric acid, natural flavors\*, coconut oil, sodium citrate, cannabis extract, soy lecithin,~Infused THC Gummy Ingredient List:~Active Ingredients: 5mg THC Tapioca syrup, sugar, water, pectin, citric acid, natural flavors\*, coconut oil, sodium citrate, cannabis extract, soy lecithin, THC.~Non-infused Placebo Gummy Ingredient List:~Tapioca syrup, sugar, water, pectin, citric acid, natural flavors\*, coconut oil, sodium citrate, soy lecithin."
62179457|NCT05296447||Roll Over|No intervention - all subjects that previously received RGX-314 in a parent study
62179458|NCT03598725|EXPERIMENTAL|ITI strategy|The low-dose ITI was Coagulation Factor VIII (50IU/kg, every other day) alone or combined with prednisone (2mg Kg-1/day, one month, then taper in three months) depending on the tendency of inhibitor, and Rituximab (375mg/square meter every week for 4 weeks) when the inhibitor titer ≥40BU/ml before or during ITI.Inhibitor and hemorrhage should be retested and recorded periodically.
62179459|NCT02971228|EXPERIMENTAL|Part 1, Lilly glucagon then ZP4207|In Part 1, 12 patients participated in 1-day treatment arms in random order (iPhone-based Bionic Pancreas using Lilly glucagon and iPhone-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
62179460|NCT02971228|EXPERIMENTAL|Part 1, ZP4207 then Lilly Glucagon|In Part 1, 12 patients participated in 1-day treatment arms in random order (iPhone-based Bionic Pancreas using Lilly glucagon and iPhone-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
62179461|NCT02971228|EXPERIMENTAL|Part 2, Lilly glucagon then ZP4207|In Part 2, it was planned to enrol up to 10 new patients to participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme. However, due to unavailability of the iLet, the sponsor decided to stop the trial upon completion of Part 1. Part 2 of the trial using the iLet was consequently not conducted.
62179462|NCT02971228|EXPERIMENTAL|Part 2, ZP4207 then Lilly Glucagon|In Part 2, it was planned to enrol up to 10 new patients to participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme. However, due to unavailability of the iLet, the sponsor decided to stop the trial upon completion of Part 1. Part 2 of the trial using the iLet was consequently not conducted.
62182759|NCT04360798|EXPERIMENTAL|Bilateral Exercise Group|The group to which exercise protocol consisting of strengthening, stretching, range of motion, static and dynamic postural control exercises will be applied to the both lower extremities of the participants.
62182760|NCT03219671|EXPERIMENTAL|nivolumab plus ipilimumab|nivolumab 240mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks
62391169|NCT05355454|OTHER|No-Treatment Control Group, then Delayed Treatment with STYLAGE® XXL|"No-Treatment for the first 6-month, then subjects will receive a delayed treatment with STYLAGE® XXL Crosslinked Hyaluronic Acid Gel up to 8mL, based on the PI's assessment, in combination with the aesthetic goal of the subject, then an optional touch-up treatment session 4 weeks later, up to 4mL.~Subjects will also be offered an optional retreatment at week 72 after initial treatment, up to 8mL."
62771815|NCT04280874|ACTIVE_COMPARATOR|GROUP B|106 randomly selected pregnant women
62771816|NCT06259682|OTHER|Intervention arm|Only one arm, all participants are given the treatment
62771817|NCT02406729|EXPERIMENTAL|Dengue 1,2,3,4 (attenuated) vaccine|Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC
62771818|NCT02406729|PLACEBO_COMPARATOR|Placebo|Placebo Single dose, SC
62771819|NCT05322330|EXPERIMENTAL|XPO-1 Inhibitor+CAR-T Cells|XPO-1 Inhibitor plus CAR-T Cells
62771820|NCT00745797|EXPERIMENTAL|Prophylactic WBRT|Take the whole brain radiotherapy radiotherapy
62771821|NCT00745797|NO_INTERVENTION|Observer Group|The first 14 days after randomization and patient follow-up after 1 month to complete the FACT-L questionnaire and the MMSE scale.
62771822|NCT03048760|EXPERIMENTAL|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scan \& 1 after approx. 2 weeks of radiotherapy treatment.
62771823|NCT02014584|EXPERIMENTAL|Dutasteride Arm|Subjects will receive dutasteride 0.5 milligrams (mg) administered orally once daily for 24 Weeks
62179463|NCT03989583||Children's feet temperature|The thermal images were taken from 162 children who were 9- 10 years old in two schools in Mérida (Badajoz), Spain. Their parents or legal guardians were informed and signed an informed consent. All children were taken infrared images, so that skin temperature was evaluated, by dividing the thermograms in regions of interest in dorsal and plantar images of each foot. Shoes were divided into two regions of interest. The measures were taken in two different days: the first day, children wore school footwear and the second sports shoes.
62179464|NCT01442077|ACTIVE_COMPARATOR|arm 1|Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments.
62179465|NCT01442077|ACTIVE_COMPARATOR|arm 2|Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.
62179466|NCT01442077|ACTIVE_COMPARATOR|arm 3|Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).
62179467|NCT01442077|ACTIVE_COMPARATOR|arm 4|Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
62179468|NCT02206945|EXPERIMENTAL|neurofeedback|Two imaging sessions of neurofeedback.
62179469|NCT02206945|PLACEBO_COMPARATOR|control feedback|Two imaging sessions of feedback
62179470|NCT01728688|ACTIVE_COMPARATOR|Conventional|conventional treatment \& antiviral treatment
62179471|NCT01728688|EXPERIMENTAL|conventional & PBSC transplantation|After three days G-CSF mobilization, Patients randomized to the intervention arm will receive autologous PBSCs transplantation at day1, and receive conventional treatment and antiviral treatment through the one year study visit and followed until one years study visit.
62179472|NCT04280562|EXPERIMENTAL|"Real SPR"|"Participants will receive the device which will run the real Sana Pain Reliever (SPR) protocol and a tablet with a mobile application to record pain levels and other questionnaires"
62179473|NCT04280562|SHAM_COMPARATOR|Sham SPR|Participants will receive the device which will run a sham SPR protocol and a tablet with a mobile application to record pain levels and other questionnaires
62179474|NCT05002530|EXPERIMENTAL|Aerosolized 13 cis retinoic acid and Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
62179475|NCT05002530|EXPERIMENTAL|Aerosolized All trans retinoic acid and Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized all trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
62391170|NCT01659437|ACTIVE_COMPARATOR|SR8|Streptomycin (S: 15 mg/kg per day, intramuscularly) in combination with rifampicin (R: 10 mg/kg per day, orally) for 8 weeks
62391171|NCT01659437|EXPERIMENTAL|CR8|Clarithromycin (C: 15 mg/kg per day, oral extended release formulation) in combination with rifampicin (10 mg/kg per day, orally) for 8 weeks
62179476|NCT05002530|PLACEBO_COMPARATOR|Standard therapy|Standard therapy
62179477|NCT04228354|EXPERIMENTAL|Semaglutide 0.68 mg/mL|Semaglutide administered with the PDS290 pen-injector
62179478|NCT04228354|EXPERIMENTAL|Semaglutide 1.0 mg/mL|Semaglutide administered with the PDS290 pen-injector
62179479|NCT03068221|ACTIVE_COMPARATOR|Poly Cystic Ovary Syndrome|anaerobic exercise in overweight patients with PCOS
62179480|NCT03068221|ACTIVE_COMPARATOR|non Poly Cystic Ovary Syndrome|anaerobic exercise in overweight patients without PCOS
62179481|NCT04317001|ACTIVE_COMPARATOR|Active treatment with modafinil|active intervention
62179482|NCT04317001|PLACEBO_COMPARATOR|Placebo|placebo intervention
62179483|NCT00008320|EXPERIMENTAL|ceramide cream|Topical ceramide cream is applied to all cutaneous lesions twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then at 1 and 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
62179484|NCT00691678|EXPERIMENTAL|chondroitin and glucosamine|Postmenopausal breast cancer patients that have joint symptoms induced by aromatase inhibitors and are receiving chondroitin and glucosamine.
62179485|NCT03449134|PLACEBO_COMPARATOR|Placebo|Participants receive dose-matched placebo tablets twice daily (BID) during the 12-week main study period and 40-week extension period.
62179486|NCT03449134|EXPERIMENTAL|Gefapixant 15 mg BID|Participants receive a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 12-week main study period and 40-week extension period.
62391172|NCT01317264|PLACEBO_COMPARATOR|Placebo milk drink|
62391173|NCT01317264|EXPERIMENTAL|Millk drink with oat β-glucan|
62771824|NCT02014584|PLACEBO_COMPARATOR|Placebo Arm|Subjects will receive placebo administered orally once daily for 24 Weeks
62179487|NCT03449134|EXPERIMENTAL|Gefapixant 45 mg BID|Participants receive a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 12-week main study period and 40-week extension period.
62179488|NCT05103098|EXPERIMENTAL|misoprostol 400 mcg|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 400 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (2 tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
62179489|NCT05103098|ACTIVE_COMPARATOR|misoprostol 800 mcg|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
62179490|NCT01046422|EXPERIMENTAL|BMS-770767 ± metformin (Treatment A)|
62179491|NCT01046422|EXPERIMENTAL|BMS-770767 ± metformin (Treatment B)|
62179492|NCT01046422|EXPERIMENTAL|BMS-770767 ± metformin (Treatment C)|
62179493|NCT01046422|EXPERIMENTAL|BMS-770767 ± metformin (Treatment D)|
62179494|NCT01046422|PLACEBO_COMPARATOR|Placebo ± metformin (Treatment E)|
62179495|NCT06250478|EXPERIMENTAL|Stroke patient|
62179496|NCT06250478|ACTIVE_COMPARATOR|Healthy controls|
62179497|NCT02068196|EXPERIMENTAL|Ipilimumab|Ipilimumab 3mg/kg
62391174|NCT01317264|EXPERIMENTAL|Milk drink with barley β-glucan|
62771825|NCT04033094||MorphaBond ER|
62771826|NCT04033094||Comparator Group|
61995102|NCT03569228|ACTIVE_COMPARATOR|Study 3 (open-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling using the standard of care approach, then undergoing a 4-week field trial.
61995103|NCT03569228|ACTIVE_COMPARATOR|Study 3 (closed-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling using the standard of care approach, then undergoing a 4-week field trial.
62179498|NCT05571306|EXPERIMENTAL|Intervention|Receives a three month intervention.
62179499|NCT05571306|NO_INTERVENTION|Care as usual|This arm is given care as usual provided at a General Practice in Denmark.
62179500|NCT03726983|EXPERIMENTAL|eHMP experimental group|"The experimental group received health management support and counseling,including:~1. GDM health care knowledge~2. self-awareness of health~3. self-monitoring of health status (i.e., recording weight and measurement data of metabolic syndrome risk factors and monitoring changes in data trends)~4. participation in discussions or browsing forums~5. healthy lifestyle guidance and counseling~6. reminder systems~7. a token system of earning points in exchange for prizes."
62391175|NCT01317264|EXPERIMENTAL|Milk drink with mutant-barley β-glucan|
62391176|NCT02515604|ACTIVE_COMPARATOR|Single dose group|
62771827|NCT04049929|EXPERIMENTAL|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
62771828|NCT03239938|EXPERIMENTAL|Modern pain neuroscience approach|Modern pain neuroscience approach
62771829|NCT03239938|ACTIVE_COMPARATOR|Usual care evidence-based physiotherapy|Usual care physiotherapy
62771830|NCT06288971|EXPERIMENTAL|Children with impairment in EF and in visuo-spatial abilities|Children aged 5 to 13 years old with a diagnosis of Cerebral Palsy, with EF impairment and visuo-spatial difficulties
62771831|NCT06288971|EXPERIMENTAL|Children with impairment in EF and in specific cognitive processes underlying academic skills|Children aged 5 to 13 years old with a diagnosis of Cerebral Palsy, with impairment in EF and in specific cognitive processes underlying academic skills
62391177|NCT02515604|ACTIVE_COMPARATOR|Repeated dose group|
62771832|NCT06288971|EXPERIMENTAL|Children with impairment in EF and in motor planning|Children aged 5 to 13 years old with a diagnosis of Cerebral Palsy, with impairment in EF and in motor planning
62771833|NCT06288971|NO_INTERVENTION|Typically developing children|Children aged 5 to 13 years old with no clinically documented disorders.
62771834|NCT02230813||Oral antibiotic therapy|Consecutive adult patients attending the study Emergency Departments with cellulitis will be considered eligible for recruitment to the study. Only those patients deemed suitable for oral antibiotic therapy and planned for discharge will be recruited to the study. Oral antibiotic therapy prescribed will be dependent on local institutional prescribing guidelines. For the purposes of the sites enrolling participants, the antibiotic of choice is oral flucloxacillin 500 milligrams four times daily for seven days. We will be assessing the treatment failure rate for this cohort of patients; namely, the number of patients requiring the primary outcome (change from oral to intravenous antibiotic therapy). We will also assess this group of patient for the secondary outcomes listed above.
62771835|NCT03713541||Patients with Anorexia nervosa (AN)|Female patients with Anorexia nervosa (AN, ICD-10: F50.0/1) of 14 years and older, receiving an initial treatment due to their AN (start of initial treatment no longer than 3 months ago, inpatient care: at least 7 days inpatient; outpatient care: at least 5 sessions with the same therapist) with sufficient language skills and no serious organic or psychiatric illnesses and no acute suicidality will be consecutively included in the study. No intervention.
62179501|NCT03726983|NO_INTERVENTION|Control group|only received usual care
62179502|NCT05546424||control|"Non-specific cognitive exercises included general advice from MS neuropsychologist specialists on how to manage cognitive difficulties and general cognitives exercises to improve cognitive performance elaborated at our MS Unit, using exercises like sudokus, crosswords and labyrinths.~This control group will require the completion of at least 30 minutes of cognitive exercises daily from Monday to Friday for 5 months. As a complement, patients will be instructed to read newspapers or magazines at least 15 minutes daily."
62179503|NCT05546424||Intervention EMRESERVA|"Specific cognitive rehabilitation program EM-Reserva will be provided by two specialized MS~Neuropsychologists in groups of 6 participants who will meet approximately an hour weekly, for 5 months.EM reserva cognitive program includes the following activities:~1. Cognitive leisure tasks~2. Physical exercises (workout exercises)~3. Activities that promote social relationships (social exercises)"
62179504|NCT04208347|EXPERIMENTAL|Apatinib and Camrelizumab and S-1 and Oxaliplatin|
62771836|NCT03713541||Carers of patients with AN|Significant caregivers in AN patients aged 14 to 15 years: parents; in AN patients aged 16 years and over: parents or other significant carer. No intervention.
62179505|NCT04208347|EXPERIMENTAL|Apatinib and S-1 and Oxaliplatin|
62179506|NCT04208347|ACTIVE_COMPARATOR|S-1 and Oxaliplatin|
62179507|NCT04237519|EXPERIMENTAL|SFL training|"Practice recommendation 3 times per week:~* Physical exercises: between 30 to 45 minutes that can be split during the day (e.g. 2x15 or 20 minutes, or 3x10 or 15 minutes during the same day).~* Cognitive exercises: minimum of 15 min."
62179508|NCT04237519|ACTIVE_COMPARATOR|Active control training|"Practice recommendation 3 times per week:~* Physical exercises: between 30 to 45 minutes that can be split during the day (e.g. 2x15 or 20 minutes, or 3x10 or 15 minutes during the same day).~* Cognitive exercises: minimum of 15 min."
62179509|NCT02490605|EXPERIMENTAL|occlusal plate group|"The sample group will receive an occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides). The occlusal plate will be made from Vacuum Form acetate with a thickness of 1.5 mm; the simultaneous, bilateral, occlusal contacts and the canine and anterior guides will be obtained by way of autopolymerizable, acrylic resin with the mandible in a centric relationship."
62563150|NCT05316207|ACTIVE_COMPARATOR|Intervention Group|IG was formed from 40 patients who received routine care, treatment and education services of the clinic after open heart surgery, and whose routine controls were determined by the randomization method. The patients in the IG would call by the researcher at least four times, at the end of the first, second, third and fourth weeks after discharge, to provide education and counseling via tele-nursing. In these phone calls, the current problems of the patient, if any, and the issues that should be paid attention to during the home care process after open heart surgery were explained.It was stated that, unlike the patients in CG, patients in IG would be called by the researcher at least four times at the end of the first, second, third and fourth weeks after discharge to provide education and counseling via tele-nursing.
62771837|NCT03713541||Physicians of patients with AN|Resident general practitioner, pediatrician, internist or gynecologist with at least one medical patient contact within the last 12 months. No intervention.
62771838|NCT03765827|EXPERIMENTAL|Vitamin E acetate|Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
62771839|NCT03765827|SHAM_COMPARATOR|Control group|No ointment will be applied
62179510|NCT02490605|ACTIVE_COMPARATOR|therapeutic exercises|The control group will only receive orientation to do physiotherapeutic exercises seeking to correctly position the mandible in the resting position (maxillar teeth should be approximately 2 mm away from the mandibular teeth) while the tip of the tongue is positioned and accommodated on the roof of the mouth over the incisive papilla on the hard palate (without touching the teeth). The exercise will consist of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth, 3 times per day, each period consisting of 3 sets with 15 repetitions.
62179511|NCT05051475|ACTIVE_COMPARATOR|radiofrequency ablation|Circumferential ablation with radiofrequency ablation will be performed for each segment of the BE starting from the proximal end with one ablation at 12J/cm2, followed by cleaning of mucosal slough with esophageal cap, patient extubation, cleaning of ablation device with wet gauze, and finally a second ablation at 12 J/cm2 (1 × 12J/cm2-clean-1 × 12 J/cm2). Focal ablations will be performed with three consecutive ablations at 12 J/cm2 without cleaning (simplified protocol).
62771840|NCT00724529||Serious Active Crohns Disease|Patients with severe active Crohns Disease who do not show any response to treatment with corticosteroids or immunosuppressive agents, and have no drug tolerance or contraindications to such treatments.
62771841|NCT00724529||Fistula-Type Active Crohns Disease|Patients with fistula-type Crohns Disease who do not show any response to general treatments such as antibiotics, drainage, or immunosuppressant.
62771842|NCT00724529||Ankylosing Spondylitis|Patients with Ankylosing Spondylitis who do not show adequate response to general treatments and with increased serological indices related to severe axial symptoms and inflammation.
62771843|NCT03500588||normotensive pregnant women more than 20 weeks gestation.|One hundred and forty-five pregnant women after 20 weeks with normal blood pressure were evaluated for VEGF gene mutation.
62771844|NCT03500588||Pregnant women after 20 weeks with preeclampsia.|One hundred and forty-five pregnant women after 20 weeks with preeclampsia were evaluated for VEGF gene mutation by using PCR and Pulsitality index of umbilical artery by doppler velocimetry.
62771845|NCT05334277|EXPERIMENTAL|Group A: Furmonertinib 80mg QD|Furmonertinib (AST2818) 80mg QD. All patients enrolled into this group will receive furmonertinib 80mg daily.
62771846|NCT05334277|EXPERIMENTAL|Group B1: Furmonertinib 80mg QD|Furmonertinib (AST2818) 80mg QD. All patients enrolled into this group will receive furmonertinib 80mg daily.
62771847|NCT05334277|EXPERIMENTAL|Group B2: Furmonertinib plus chemotherapy|Furmonertinib 80 mg QD and platinum-based chemotherapy All patients enrolled into this group will receive furmonertinib 80 mg daily, in combination with Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.
62771848|NCT05334277|EXPERIMENTAL|Group B3: Furmonertinib plus chemotherapy and bevacizumab|Furmonertinib 80 mg QD plus platinum-based chemotherapy and bevacizumab All patients enrolled into this group will receive furmonertinib 80 mg daily, in combination with Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.
62179512|NCT05051475|ACTIVE_COMPARATOR|hybrid argon plasma coagulation|Patients in the Hybrid argon plasma coagulation group will be treated with a single ablation per session with a power limitation of 60 W (pulsed mode (VIO® 300 D \& APC 2, PULSED APC®, Effect 2). No scraping with the endoscope cap and second ablation will be performed.
62563151|NCT05316207|NO_INTERVENTION|Control Group|The patients in the CG were formed from 40 patients who received routine care, treatment and education services of the clinic after open heart surgery, and who were determined by the randomization method, whose routine controls were made after discharge. No application was made to the patients in the CG by the researcher within the scope of the study. However, the researcher gave the phone number to the patients in the CG in terms of their right to receive ethical and professional care, and it was stated that they could call between 10:00 and 22:00 if needed. The reasons for calling the investigator from the CG were recorded .
62771849|NCT02004977|EXPERIMENTAL|Intervention arm|The role of the intervention arm (schools) is to improve access to the school breakfast program
62771850|NCT02004977|NO_INTERVENTION|Comparison arm|the role of the comparison arm (schools) is to maintain usual breakfast program at school
62771851|NCT02378207|EXPERIMENTAL|Group 1 H4:IC31|15 mcg H4/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
62771852|NCT02378207|EXPERIMENTAL|Group 2 H56:IC31|5 mcg H56/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
61995104|NCT03569228|EXPERIMENTAL|Study 3 (experimental open-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
62179513|NCT01037413|EXPERIMENTAL|EXC 001|
62563152|NCT05716308|EXPERIMENTAL|intervention group|Continuous nursing intervention was performed on the basis of the control group
62771853|NCT02378207|ACTIVE_COMPARATOR|Group 3 BCG (2-8 x 105 CFU)|Administered IM as 0.1 mL in either deltoid muscle at Day 0.
62771854|NCT02378207|PLACEBO_COMPARATOR|Group 4 Control Sodium Chloride 0.9%|Administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
62771855|NCT05549154|EXPERIMENTAL|High-dose vitamin D group|Vitamin D2 softgels 50,000 U/week
62771856|NCT05549154|EXPERIMENTAL|Low-dose vitamin D group|low-dose vitamin D group
62179514|NCT01037413|PLACEBO_COMPARATOR|Placebo|
62179515|NCT01984749|EXPERIMENTAL|Febuxostat treatment group|Once daily after breakfast (generally within 30 minutes after eating)
62771857|NCT05549154|PLACEBO_COMPARATOR|Control group|Placebo
62771858|NCT06347250|EXPERIMENTAL|Nerve block|The patients were given Nerve block and routine therapy for 10 days.
62771859|NCT06347250|PLACEBO_COMPARATOR|placebo|The patients were given placebo block and routine therapy for 10 days.
62771860|NCT03670784||Women_KPNC|Women of reproductive age who are enrolled in the US-health plan Kaiser Permanente Northern California (KPNC).
62771861|NCT03670784||Women_KPSC|Women of reproductive age who are enrolled in the US-health plan Kaiser Permanente Southern California (KPSC).
62771862|NCT06464419||Patients who will undergo RIRS surgery|Patients who will undergo RIRS surgery in the lithotomy position
62771863|NCT02312778|EXPERIMENTAL|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation is delivered to the subjects in the side lying position. The more restricted lumbar segment (mobility restriction) will be the target region for the manipulative procedure.
62771864|NCT02312778|NO_INTERVENTION|Sham Manipulation|Control Group who receives a simulated manipulation.
62179516|NCT01984749|NO_INTERVENTION|Non-febuxostat treatment group|No febuxostat treatment
62179517|NCT00275301|EXPERIMENTAL|Open-label Olanzapine.|Open-label Olanzapine.
62179518|NCT06452927|OTHER|Endoscopic Enucleation of the Prostate|Patients with urodynamically proven Detrusor Underactivity/Acontractility, who undergo endoscopic enucleation of the prostate (EEP).
62771865|NCT03556020|EXPERIMENTAL|High Dose Group|Maximally tolerated dose Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
62771866|NCT03556020|EXPERIMENTAL|Low Dose Group|Minimally effective dose Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
62771867|NCT02391493|EXPERIMENTAL|healthy early bilinguals|healthy early bilinguals functional magnetic resonance imaging
62771868|NCT02391493|EXPERIMENTAL|healthy late bilinguals|healthy late bilinguals functional magnetic resonance imaging
62771869|NCT02391493|EXPERIMENTAL|bilingual patients|bilingual patients suffering from low-grade glioma in the language areas functional magnetic resonance imaging
62771870|NCT05375864|EXPERIMENTAL|Paracetamol absorption test|
62771871|NCT01469403|NO_INTERVENTION|control group|Standard procedure for knee arthroplasty
62771872|NCT01469403|ACTIVE_COMPARATOR|Weight loss program|The intervention program consists of 8 weeks of low-diet, using formula foods, and dietary counseling before surgery. When using formula foods the patients can achieve a quicker weight reduction and a greater reduction in fat mass than using conventional dietetic hypo caloric diet.
62771873|NCT01994993|ACTIVE_COMPARATOR|Group 1 (ampicillin +gentamycin +metronidazole)|Ampicillin and gentamycin and metronidazole
62771874|NCT01994993|ACTIVE_COMPARATOR|Group 2 (ampicillin +gentamicin+clindamycin)|ampicillin and gentamicin and clindamycin
62771875|NCT01994993|ACTIVE_COMPARATOR|Group 3 (piperacillin-tazobactam and gentamicin)|piperacillin-tazobactam and gentamicin
62771876|NCT01994993|ACTIVE_COMPARATOR|Group 4 (metronidazole)|Per standard of care antibiotics, and Metronidazole
62771877|NCT01994993|ACTIVE_COMPARATOR|Group 5 (metronidazole/clindamycin/piperacillin-tazobactam)|metronidazole, clindamycin, or piperacillin-tazobactam
62771878|NCT05023278|PLACEBO_COMPARATOR|Placebo|Subjects in placebo arm will receive inactive placebo capsule daily for 7 consecutive days starting on day of primary arthroplasty surgery.
62771879|NCT05023278|EXPERIMENTAL|Venlafaxine|Subjects in venlafaxine arm will receive venlafaxine 37.5mg daily for 7 consecutive days starting on day of primary arthroplasty surgery.
61995105|NCT03569228|EXPERIMENTAL|Study 3 (experimental closed-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
62179519|NCT03712384||Young adult with severe anorexia|Young adult with severe Anorexia hospitalized during adolescence at Institut Mutualiste Montsouris
62179520|NCT00003162|ACTIVE_COMPARATOR|3.0 Gy x 10 fractions in two weeks|3.0 Gy x 10 fractions for a total dose of 30.0 Gy in two weeks
62179521|NCT00003162|EXPERIMENTAL|8.0 Gy x 1 fraction|8.0 Gy x 1 fraction for a total dose of 8.0 Gy in a single dose
62179522|NCT01601717|PLACEBO_COMPARATOR|Sugar pill|
62179523|NCT01601717|ACTIVE_COMPARATOR|RTI-336|
62771880|NCT00031460|EXPERIMENTAL|Acyclovir|
62179524|NCT04257747|SHAM_COMPARATOR|Healthy volunteers|
62179525|NCT04257747|ACTIVE_COMPARATOR|patients requiring radial forearm flap reconstruction|
62179526|NCT04257747|EXPERIMENTAL|patients having received hand allotransplantation|
62771881|NCT00031460|PLACEBO_COMPARATOR|Placebo|
62771882|NCT00290667|ACTIVE_COMPARATOR|Interventional: CHOP-14 + 8 x 2-weekly rituximab|Arm I (2-weekly rituximab): Patients receive rituximab IV 375 mg/m\^2 (females) and 500 mg/m\^2 (males) over 4 hours on days 0, 14, 28, 42, 56, 70, 84, and 98. Patients also receive pegfilgrastim subcutaneously on day 4 of each course.
62771883|NCT00290667|ACTIVE_COMPARATOR|Interventional: CHOP-14 + 8 x dose-dense rituximab|Arm II (pharmacokinetic-based dose-dense rituximab): Patients receive rituximab IV 375 mg/m\^2 (females) and 500 mg/m\^2 (males) over 4 hours on days -1, 0, 3, 7, 14, 21, 28, and 42. Patients also receive pegfilgrastim subcutaneously on day 4 of each course.
62771884|NCT05071430|ACTIVE_COMPARATOR|Active Treatment (HB-01)|Approximately 40 patients will receive HB-01 active study drug.
62771885|NCT05071430|PLACEBO_COMPARATOR|Placebo Treatment|Approximately 40 patients will receive a matched placebo.
62771886|NCT04969536|EXPERIMENTAL|Branched chain amino acid supplementation|Consumption of 8 ounces of water with addition of 2.5 g of leucine, 1.25 g of isoleucine, and 1.25 g of valine immediately prior to and again 30 minutes into a 60 minute treadmill run at 65% of VO2max.
62179527|NCT04593706|ACTIVE_COMPARATOR|keloids|each patient will be injection by all 4 steroids for comparison patients with 4 or more keloids will be injection with each steroid for different keloid
62179528|NCT04593706|ACTIVE_COMPARATOR|hypertrophic scars|each patient will be injection by all 4 steroids for comparison patients with a 11 cm hypertrophic scar will be injected by all 4 steroids along the scar with a 1 cm distance between each steroid
62179529|NCT03354234|EXPERIMENTAL|Stimuli of slowly increasing intensities|"1. 300-s check before the stimuli~2. LBNP is applied stepwise with 11.1 mmHg/15 s decrement to -100 mmHg, and then this value is sustained for 120 s~3. 180-second phase of rest between stimuli~4. 75°-HUT (5°/s) for 120 s after a 15-s reversing of the gravity vector (-30°)~5. 180-second phase of rest between stimuli~6. 75°-HUT (5°/s) accompanied by an exposure to an LBNP of -60 mmHg increased linearly by -4 mmHg/s, and then this value is sustained for 120 s during HUT~7. 120-s check after the stimuli"
61995106|NCT01234233|NO_INTERVENTION|Group 1|Control group - no intervention: no preoperative warming
62563153|NCT05716308|NO_INTERVENTION|control group|discharge guidance was performed according to routine nursing intervention at the time of discharge, and the patients were informed to return to the hospital for regular review (review was performed at 1 month, 3 months, half a year, 1 year, and 2 years after discharge, respectively).
62771887|NCT04969536|PLACEBO_COMPARATOR|Placebo|Consumption of 8 ounces of a flavor matched beverage sweetened with a sucralose-based drink mix immediately prior to and again 30 minutes into a 60 minute treadmill run at 65% of VO2max.
62182761|NCT06480877||IQOS users|Inclusion criteria were good general health, absence of any lesions below at or above the level of the oral mucosa, and minimum of 20 healthy teeth. Smokers had to meet the criteria for smoking experience that was at least 3 years (classic cigarette or THS) and daily consumption which should not be less than 5 cigarettes or heat sticks per day. Selected subjects were only cigarette smokers for Group I, and the same rule of selection was applied for IQOS users as Group II.
62771888|NCT03972410|EXPERIMENTAL|Eye Movement Desensitization and Reprocessing (EMDR)|The EMDR treatment will follow the EMDR Recent Birth Trauma Protocol. This protocol was recently developed by some of the colleagues collaborating in this research project (Catteneo et al., 2018). This EMDR protocol can be used to intervene immediately after birth, or at later times. The main purposes of early intervention is to prevent the onset and development of PTSD and Post-partum Depression in the mother during the months following childbirth and to facilitate mother-newborn bonding.
61995107|NCT01234233|ACTIVE_COMPARATOR|Group 2 - 10 min prewarming|10 min prewarming preoperatively
61995108|NCT01234233|ACTIVE_COMPARATOR|Group 3 - 20 min prewarming|20 min prewarming preoperatively
61995109|NCT01234233|ACTIVE_COMPARATOR|Group 4 - 30 min prewarming|30 min prewarming preoperatively
61995110|NCT00797082|EXPERIMENTAL|1|"MRI = Myocardial Perfusion Stress and MPS = Myocardial Perfusion Scintigraphy~* Diabetic patients~* Coronary insufficiency"
61995111|NCT03928951||Patients suffering from urinary infection|Patients consulting in one of Toulon - La Seyne sur Mer hospital emergency departments because of urinary infection
61995112|NCT00461695|OTHER|CMV-seropositive|Cytomegalovirus-seropositive individuals at screening (week 0). Intervention: Intervention: Vaccination against tick-borne encephalitis by intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
61995113|NCT00461695|OTHER|CMV-seronegative|Cytomegalovirus-seronegative individuals at screening (week 0). Intervention: Vaccination against tick-borne encephalitis by intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
61995114|NCT03741764|OTHER|Vivosorb|Only arm in study
61995115|NCT04905056|EXPERIMENTAL|ablation therapy in the treatment of lung cancer presenting as ground-glass nodules|
61995116|NCT01414335|PLACEBO_COMPARATOR|placebo|
61995117|NCT01414335|ACTIVE_COMPARATOR|amino acid composition|
61995118|NCT04656067|ACTIVE_COMPARATOR|Oxytocin(only)|oxytocin is given IV infusion 5-10 minutes before the start of skin incision in the Elective Cesarean Section
61995119|NCT04656067|ACTIVE_COMPARATOR|Tranexamic acid and Ethamsylate|Tranexamic acid and Ethamsylate are given IV slowly 5-10 minutes before the start of skin incision in the Elective Cesarean Section
61995120|NCT00903812||A|No intervention - observational study
61995121|NCT00963573|EXPERIMENTAL|loratadine/betamethasone oral solution|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
62179530|NCT03354234|EXPERIMENTAL|Stimuli of rapidly increasing intensities|"1. 120-s check before the stimuli~2. 75°-HUT (45°/s) for 60 s after a 3-s reversing of the gravity vector (-30°)~3. 180-second phase of rest between stimuli~4. LBNP decreases linearly by -20 mmHg/s to -100 mmHg, and then this value is sustained for 60 s.~5. 180 second phase of rest between stimuli~6. push-pull, i.e., 3 x 75°-HUT (45°/s) preceded by -30°-HDT (45°/s) and accompanied by an exposure to an LBNP of -60 mmHg decreased linearly by -20 mmHg/s, and then this value is sustained for 30 s during HUT~7. 120-s check after the stimuli"
62563154|NCT01255488|EXPERIMENTAL|EBN-Search (without full-text manuscripts)|In the intervention arm research subjects will be provided access to EBN-Search (a fictitious search engine) with nine abstracts relating to the clinical case but no full-text manuscripts.
62771889|NCT03972410|ACTIVE_COMPARATOR|Supportive Expressive Dynamic Psychotherapy (SEDP)|The SEDP treatment (Luborsky 1984; Book, 1998) is one of the most widespread treatments and can be considered the treatment as usual in Italian maternity wards. This intervention includes both supportive techniques (to create a positive, helpful and empathic relationship with the patient) and expressive techniques (aimed at helping the patient to express and to understand and change problems).
62179531|NCT02649361|EXPERIMENTAL|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62179532|NCT02649361|PLACEBO_COMPARATOR|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62179533|NCT00675038||1|Study participants will be patients who are cared for by the St. Jude Hematology Division and have developed iron overload and require liver biopsy.
62179534|NCT01753596|EXPERIMENTAL|30 healthy subjects|Subjects will receive 1 drop of Genteal HA eye drops in one randomly chosen eye, the other eye will receive placebo
62179535|NCT01753596|EXPERIMENTAL|30 patients with dry eye syndrome|Patients will receive 1 drop of Genteal HA eye drops in one randomly chosen eye, the other eye will receive placebo
62179536|NCT05507398|PLACEBO_COMPARATOR|control group|30 patients who will serve as a control group and will receive placebo tablets
62179537|NCT05507398|ACTIVE_COMPARATOR|metformin group|30 patients who will receive metformin 1000 mg/day.
62179538|NCT05507398|ACTIVE_COMPARATOR|atorvastatin group|30 patients who will receive atorvastatin 20 mg/day.
62179539|NCT01114308|EXPERIMENTAL|Probuphine|Patients are first inducted on SL BPN then switched to 4 buprenorphine implants
62179540|NCT01114308|PLACEBO_COMPARATOR|placebo implant|patients are first inducted on SL BPN then switched to 4 placebo implants
62179541|NCT01114308|ACTIVE_COMPARATOR|sublingual buprenorphine|patients are inducted on SL BPN, then continue on SL BPN
62179542|NCT01299298|EXPERIMENTAL|mipomersen|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose
62179543|NCT01299298|PLACEBO_COMPARATOR|placebo|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose
62771890|NCT01113346|EXPERIMENTAL|Filtrum-STI|
62771891|NCT01113346|PLACEBO_COMPARATOR|Placebo|
62771892|NCT05885737|EXPERIMENTAL|12-weeks double-blind period - Difelikefalin|
62179544|NCT06146413|EXPERIMENTAL|Double trigger|GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) and hCG ( 10000 IU) are administered 40 and 34 h before oocyte retrieval
62179545|NCT06146413|ACTIVE_COMPARATOR|HCG trigger|HCG ( 100000 IU/ I.M ) is administered 36 h before oocyte retrieval
62179546|NCT04882189||Capsulorhexis|Capsulotomies conducted by Capsulorhexis
62179547|NCT04882189||ZEPTO Precision Capsulotomy Device|Capsulotomies conducted by ZEPTO Precision Capsulotomy Device
62179548|NCT01984671|EXPERIMENTAL|Mobile Pain Coping Skills Training|Pain coping skills training
62179549|NCT01984671|NO_INTERVENTION|Standard Care Control|
62179550|NCT05715736|EXPERIMENTAL|SAD cohort|SAD cohorts 1-5. Randomised participants in each cohort will receive a single IV dose of APB-R3.
62179551|NCT05715736|PLACEBO_COMPARATOR|Placebo|SAD cohorts 1-5. 2 randomised participants of each cohort will receive a placebo.
62179552|NCT04001998|EXPERIMENTAL|Tablet vs Capsule Formulation|Single oral dose of BLD-2660 capsule or tablet formulation
62179553|NCT04001998|EXPERIMENTAL|Dose Proportionality|Single oral dose of BLD-2660 tablet formulation
62391178|NCT06439251|EXPERIMENTAL|Diclofenac Phonophoresis|The participants randomly allocated in Group A were receive the Phonophoresis (Ultrasound with Diclofenac gel for 5 minutes and intensities 1 MHz and 1.5 W/cm² pulsed waves was used in the therapy sessions on affected knee with diclofenac gel on ultrasound head) as experimental technique
62771893|NCT05885737|PLACEBO_COMPARATOR|12-weeks double-blind period - Placebo|
62771894|NCT05885737|EXPERIMENTAL|14-weeks optional open-label period following the double-blind period - Difelikefalin|
62179554|NCT05187000|SHAM_COMPARATOR|Sham Stimulation Group for Cross Study|Sham stimulation will be delivered on the patients head using a sham coil in the crossover study.
62179555|NCT05187000|EXPERIMENTAL|Individualized rTMS Group for Cross Study|Real stimulation will be delivered on individualized target using a real coil in the crossover study.
62179556|NCT04028947|NO_INTERVENTION|Standard TKA|Subjects will have the standard procedure.
62179557|NCT04028947|ACTIVE_COMPARATOR|TKA with Neurectomy|Subjects will the nerve excised and protected with soft tissue.
62563155|NCT01255488|ACTIVE_COMPARATOR|EBN-Search (with full text manuscripts)|Research subjects will be exposed to 9 abstracts and corresponding full-text manuscripts related to the simulated clinical encounter.
62563156|NCT06361680|EXPERIMENTAL|Group A|Will take Coenzyme Q10 soft gel capsules or tablets in a dose of 100-200mg of natural factors
62563157|NCT06361680|EXPERIMENTAL|Group B|Will not take Coenzyme Q10 soft gel capsules or tablets
62179558|NCT01328808|EXPERIMENTAL|group 2 Pain management|"In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.~In preterm and term neonates with a GA of less than 28 weeks 15 mg/kg dose of APAP will be given every 12 hrs by an intravenous infusion over 30-minute"
62179559|NCT04113928|EXPERIMENTAL|Broccoli & mustard seed soup|200ml acute feed
62179560|NCT04113928|ACTIVE_COMPARATOR|Broccoli soup|200ml acute feed
62179561|NCT00619983|ACTIVE_COMPARATOR|Donepezil|Donepezil 5 mg once per day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
62179562|NCT00619983|ACTIVE_COMPARATOR|Duloxetine|Group 2: Will receive duloxetine 30 mg twice a day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
62179563|NCT00619983|ACTIVE_COMPARATOR|Donepezil + Duloxetine|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
62179564|NCT00619983|PLACEBO_COMPARATOR|Placebo|Group 4:Will receive placebo pills. Gabapentin will be titrated in all groups beginning at week 8.
62179565|NCT01252056|NO_INTERVENTION|Control|
62179566|NCT01252056|ACTIVE_COMPARATOR|Probucol|Probucol treatment
62179567|NCT01252056|ACTIVE_COMPARATOR|Combination|Probucol and Cilostazol
62179568|NCT06475027||Group GB20|Group GB20 will received acupuncture at acupoint GB20 twice a week 8 weeks for efficacy evaluation. And we could use the exosome-miRNA, transcriptome, oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
62179569|NCT06475027||Group GB20 plus BL2|Group GB20 plus BL2 will received acupuncture at acupoint GB20 plus BL2 twice a week 8 weeks for efficacy evaluation. And we could use the exosome-miRNA, transcriptome, oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
62179570|NCT06475027||non AIDDES Healthy Controls (NHC)|"1. ACUDES: Healthy control group will not received any treatment. And we could use the exosome-miRNA, transcriptome, oral microbiota, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability to find the difference with the comparison between the dry eye syndrome and healthy control.~2. TBDESJS: Non DES SJS Healthy Controls (NHC) will received Chinese herbal tea TBDESJS 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation. And we could use the Schirmer's test, Tear breakup time, Ocular Surface Disease Index (OSDI), EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI), Pittsburgh Sleep Quality Index (PSQI), Ford Insomnia Response to Stress Test (FIRST), cytokine markers, Whole-genome genotyping, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose."
62179571|NCT06475027||Waiting list|Group Waiting list will not received any treatment. at acupoint GB20 plus BL2 twice a week 8 weeks for efficacy evaluation. And we could use the exosome-miRNA, transcriptome, oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
62179572|NCT06475027||Dry eye syndrome (DES)|Dry eye syndrome (DES) will received Chinese herbal tea TBDESJS 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation. And we could use the exosome-miRNA, transcriptome, Schirmer's test, Tear breakup time, Ocular Surface Disease Index (OSDI), EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI), Pittsburgh Sleep Quality Index (PSQI), Ford Insomnia Response to Stress Test (FIRST), cytokine markers, Whole-genome genotyping, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
62179573|NCT06475027||Sjögren's syndrome (SJS)|Sjögren's syndrome (SJS) will received Chinese herbal tea TBDESJS 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation. And we could use the exosome-miRNA, transcriptome, Schirmer's test, Tear breakup time, Ocular Surface Disease Index (OSDI), EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI), Pittsburgh Sleep Quality Index (PSQI), Ford Insomnia Response to Stress Test (FIRST), cytokine markers, Whole-genome genotyping, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
62179574|NCT06479525|EXPERIMENTAL|Group A|16 participants will be in experimental group giving them Big Toe flexor strengthening exercises protocol along with their normal sports training plan for eight weeks, measuring all values before giving them protocol and after protocol.
62771895|NCT03769311|EXPERIMENTAL|Pre-Operative Cetuximab Therapy|Two weekly doses of pre-operative cetuximab during the interval between diagnostic HNSCC biopsy and surgery (\~14 days), ensuring that no delay in standard of care (SOC) will occur. For dose #1, participants will receive cetuximab 400 mg/m2 via intravenous infusion over 2 hours (maximum infusion rate 10 mg/min) as per the standard of care loading regimen for cetuximab monotherapy. For dose #2, participants will receive cetuximab 250 mg/m2 via intravenous infusion over 1 hour (maximum infusion rate 10 mg/min) as per the standard of care dosing regimen for cetuximab monotherapy.
62771896|NCT05549375|EXPERIMENTAL|Neurorehabilitation of the Hand|
62771897|NCT00865839|EXPERIMENTAL|A|Metformin HCl 500 mg tablets, single dose
62179575|NCT06479525|EXPERIMENTAL|Group B|16 participants will be in experimental group giving them calf strengthening exercises protocol along with their normal sports training plan for eight weeks, measuring all values before giving them protocol and after protocol.
62179576|NCT02164136|EXPERIMENTAL|L-PANP-TME|Laparoscopy-assisted pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
62179577|NCT02164136|ACTIVE_COMPARATOR|O-PANP-TME|Open pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
62179578|NCT00352378|EXPERIMENTAL|Adriamycin plus Cyclophosphamide|Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1.
62771898|NCT00865839|ACTIVE_COMPARATOR|B|CLUCOPHAGE® XR 500 mg tablets, single dose
62771899|NCT00076232|EXPERIMENTAL|1|Participants will receive acyclovir for the duration of the study
62771900|NCT00076232|PLACEBO_COMPARATOR|2|Participants will receive acyclovir placebo for the duration of the trial
62771901|NCT04429399|OTHER|High positive end-expiratory pressure Ventilation|patient ventilated fixing high level of positive end expiratory pressure
62563158|NCT05603169|ACTIVE_COMPARATOR|High Intensity Resistance Training|This group will perform high intensity resistance training under supervised physiotherapist in a gym setting. The training load for the first 2 weeks will be 60%-75% of 1RM and increased to 75%-90% of 1RM the following weeks. Load would be increased if the participants will be able to perform 3 sets of 12 repetitions with that load.
62179579|NCT00352378|EXPERIMENTAL|Taxotere plus Xeloda|Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14
62179580|NCT04360083||Overweight and obese children|Overweight and obese children included in RéPPOP care programs between 2007 and 2010.
62771902|NCT04429399|OTHER|Low positive end-expiratory pressure Ventilation|patient ventilated fixing low level of positive end expiratory pressure
62771903|NCT06194500|EXPERIMENTAL|Carbon-14-Labeled [14C]-LY3549492 - Part A|Carbon-14-Labeled \[14C\]-LY3549492 administered as oral solution.
62771904|NCT06194500|EXPERIMENTAL|LY3549492 + [14C]-LY3549492 - Part B|LY3549492 administered as oral solution followed 3 hours later by \[14C\] LY3549492 will be administered as intravenous (IV) infusion.
62179581|NCT04343859|EXPERIMENTAL|IMMH-010|"After Dose escalation study, Dose expansion study will be conducted :~360mg and above,IMMH-010, QD or BID,Cycle1Day1-CycleN."
62179582|NCT02271659|EXPERIMENTAL|Brachytherapy boost|Brachytherapy boost with external beam radiotherapy. External beam radiotherapy of 46 Gy delivered to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds (110Gy) or high dose rate (14Gy) with iridium-192) only to the prostate. Each center will choose the appropriate brachytherapy technique
62179583|NCT02271659|ACTIVE_COMPARATOR|Exclusive external beam irradiation|Exclusive external beam radiotherapy. External beam radiotherapy of 46 Gy delivered to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
62179584|NCT02169921|EXPERIMENTAL|TurboHawk|This study is designed as a single arm study. For angioplasty, the Atherectomy Catheter, TurboHawk is used in this arm. Spider FX, the Distal Embolus Protection Device, can concomitantly be used with TurboHawk
62179585|NCT02220777|EXPERIMENTAL|1. ASP8477 and placebo|Part 1: SAD in postmenopausal females and Part 2: SAD in vasectomized male
62179586|NCT02220777|EXPERIMENTAL|2. ASP8477 alone|Part 3, fasted or fed
62179587|NCT02220777|EXPERIMENTAL|3. omeprazole alone|Part 4, Drug-Drug Interaction
62179588|NCT02220777|EXPERIMENTAL|4. ASP8477 + omeprazole|Part 4: Drug-Drug Interaction
62179589|NCT06271564|EXPERIMENTAL|Magnetite Zno Composite Nanoparticles|5% topical ZnO-Fe3O4 Magnetic Composite NPs gel applied 3 times per day for 6 weeks
62179590|NCT06271564|PLACEBO_COMPARATOR|Topical Placebo Gel|Topical Placebo Gel containing water, glycerin and Hydroxypropyl methylcellulose applied 3 times per day for 6 weeks
62179591|NCT05884983||Screening cohort|30-69 years old healthy participants in Zhongshan
62179592|NCT00787683|EXPERIMENTAL|Home-monitoring|Patients receive an additional home-monitoring (remote-monitoring) device (CardioMessengerII) following Biotronik Lumax ICD implantation. The device enables regular transmission and examination of ICD information via home-monitoring. Follow-up appointments in outpatient clinic are changed compared to standard care. While follow-up 1, 12, and 24 months after ICD implantation consist of outpatient clinic appointments, follow-up 3, 6, and 18 months after ICD implantation are conducted remotely.
62179593|NCT00787683|NO_INTERVENTION|Standard care|Patients randomised to the standard care group receive no home-monitoring device (CardioMessengerII) following Lumax ICD implantation. Patients have scheduled follow-up appointments at the ICD outpatient clinics at 1, 3, 6, 12, 18, and 24 months after ICD implantation.
62179594|NCT00985283|EXPERIMENTAL|Preventive home visit|receives preventive home visit intervention 4 times over 1 year
62563159|NCT05603169|ACTIVE_COMPARATOR|High Intensity Aerobic Training|This group will perform aerobic training under supervision of a physical therapist in gym setting. To calculate exercise intensity, the HR will be maintained at 75-90% of the maximum (HRmax). The training protocol will begin with a 5-minute warm-up and will end with a 5-minute cool down, during which the HR will be 60-75% of the HRmax. At least 90 min of exercise per week for obese PCOS patients, with treadmill walking that may include whole-body movement involving more than 2/3 of the muscles, the exercise intensity will be high intensity
62771905|NCT04378296|EXPERIMENTAL|Teledermatology|The 221 patients who are included in this group will be monitored from the Primary Care centers.
62771906|NCT04378296|NO_INTERVENTION|Conventional monitoring|The 221 patients included in this group will have to visit the dermatologist at the hospital.
62771907|NCT02412059|EXPERIMENTAL|Prednisolone|Pred Forte (prednisolone acetate ophthalmic suspension, USP) 1% sterile
62179595|NCT00985283|ACTIVE_COMPARATOR|comparison group|receives information packets on local services for older adults and health promotion material twice during 1 year
62179596|NCT03462498|ACTIVE_COMPARATOR|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists and clopidogrel monotherapy for 59 months
62179597|NCT03462498|ACTIVE_COMPARATOR|12-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists; 11-month DAPT composed of aspirin and clopidogrel and aspirin monotherapy for 48 months
62179598|NCT05029349|OTHER|VOC analysis|VOC analysis in exhaled air in patients hospitalised for stable severe COPD
62179599|NCT06271083|EXPERIMENTAL|Behavior therapy with exposure and response prevention|
62179600|NCT06271083|ACTIVE_COMPARATOR|Psychoeducation with general psychological support|
62179601|NCT03626311|EXPERIMENTAL|AKBM-3031|4g/day (2 capsules BID)
62179602|NCT03626311|PLACEBO_COMPARATOR|Placebo|4g/day (2 capsules BID)
62179603|NCT00082641|EXPERIMENTAL|Arm I|Patients receive vaccination comprising p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients with stage III disease), and at 6 and 12 weeks after completion of radiotherapy (for a total of 4 vaccinations).
62179604|NCT00082641|EXPERIMENTAL|Arm II|Patients receive vaccination comprising p53-infected autologous dendritic cells SC at 6, 8, 10, and 12 weeks after completion of radiotherapy.
62771908|NCT02412059|NO_INTERVENTION|Control|Patients in control group will not be given a corticosteroid as per usual standard of care.
62771909|NCT01038713|EXPERIMENTAL|Resectable; plastic stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive a plastic biliary stent to relieve their biliary obstruction.
62563160|NCT02220764|EXPERIMENTAL|Tooth-supported|Long-span tooth-supported zirconia based fixed dental prostheses
62179605|NCT06003023|ACTIVE_COMPARATOR|Living Well with Congenital Heart Disease (LIV-CHD) Intervention|In LIV-CHD, participants will receive a Fitbit and a tailored exercise prescription, as devised from their baseline exercise stress test results. They will also meet with a health coach for 9 virtual sessions over a period of 20 weeks. The content will focus on how to use the Fitbit along with health education pertinent to living a healthy lifestyle (e.g., sleep hygiene, stress management). Goal-setting and other cognitive behavioral strategies for health behavior change will not be discussed in this arm. Participants in the attention control arm will also receive text messages reminding them to wear their Fitbit.
62179606|NCT06003023|EXPERIMENTAL|Congenital Heart Disease Physical Activity Lifestyle (CHD-PAL) Intervention|In CHD-PAL, participants will receive a Fitbit and a tailored exercise prescription, as devised from their baseline exercise stress test results. They will also meet with a health coach for 9 virtual sessions over a period of 20 weeks. The content will focus on cognitive behavioral strategies, grounded in the Theory of Planned Behavior, to increase physical activity and healthy living. Participants in the intervention arm will also receive text motivational messages relevant to session content, as well as reminders to wear their Fitbit.
62563161|NCT02220764|ACTIVE_COMPARATOR|Implant-supported|Long-span implant-supported zirconia based fixed dental prostheses
62563162|NCT06146465||Pediatrics|attending and resident pediatrics physicians involved in pediatric patient management
62771910|NCT01038713|EXPERIMENTAL|Resectable; uncovered metal stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive an uncovered metal biliary stent to relieve their biliary obstruction.
62771911|NCT01038713|EXPERIMENTAL|Resectable; fully covered metal stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive a fully-covered metal biliary stent to relieve their biliary obstruction.
62771912|NCT01038713|EXPERIMENTAL|Unresectable; uncovered metal stent|Patients determined to have surgically non-resectable malignancy presenting with malignant biliary obstruction randomized to receive an uncovered metal biliary stent to relieve their biliary obstruction.
62771913|NCT01038713|EXPERIMENTAL|Unresectable; fully covered metal stent|Patients determined to have surgically non-resectable malignancy presenting with malignant biliary obstruction randomized to receive a fully-covered metal biliary stent to relieve their biliary obstruction.
62771914|NCT04159584|EXPERIMENTAL|Enrolled Subject|All subjects will undergo the medical music intervention.
62179607|NCT00658840|EXPERIMENTAL|1|"Primary objectives :~To evaluate the tumor response rate, local control rate and compliance (acute and late toxicity, esp. gastrointestinal tract toxicity) of concurrent chemo-radiotherapy with oral capecitabine in patients with unresectable locally advanced pancreatic carcinoma~Secondary objectives :~To evaluate the impact of concurrent chemo-radiotherapy with oral capecitabine in patients with unresectable locally advanced pancreatic carcinoma by analyzing the progression-free survival rate and overall survival rate."
62563163|NCT06146465||Non-Pediatrics physicians|attending and resident non-pediatrics physicians involved in pediatric patient management
62563164|NCT00998920|EXPERIMENTAL|10mg BID|S-equol capsule, oral, single dose
62771915|NCT03755661|EXPERIMENTAL|Intervention|This intervention arm is a combined in-person text messaging intervention
62771916|NCT03755661|NO_INTERVENTION|Assessment Only Control|The is the assessment only comparison condition
62771917|NCT03408210|ACTIVE_COMPARATOR|total body irradiation|Patient receives preparative therapy including cyclophosphamide and total body irradiation (TBI) of 10 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
62771918|NCT03408210|EXPERIMENTAL|total marrow and lymphoid irradiation|Patient receives preparative therapy including cyclophosphamide and total marrow and lymphoid irradiation of 12 Gy on Days -6 through -2, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
62771919|NCT00162266|EXPERIMENTAL|Abatacept (10 mg/Kg) - Open Label|
62771920|NCT00162266|EXPERIMENTAL|Abatacept (2 mg/kg) - Double blind|
62563165|NCT00998920|EXPERIMENTAL|20 mg BID|
62563166|NCT00998920|EXPERIMENTAL|40mg BID|
62563167|NCT00998920|EXPERIMENTAL|80 mg BID|
62563168|NCT00998920|EXPERIMENTAL|160 mg BID|
62563169|NCT00998920|PLACEBO_COMPARATOR|Placebo|
62771921|NCT00162266|EXPERIMENTAL|Abatacept (10 mg/kg) - Double blind|
62771922|NCT00162266|EXPERIMENTAL|Placebo - Double blind|
62771923|NCT03631277|EXPERIMENTAL|photo-activated oral disinfection|photo-activated oral disinfection is an advanced technology utilizing two non-toxic components, a photo-activating liquid and a LED light source that selectively target and abolish cariogenic bacteria and periodontal pathogens
62771924|NCT03631277|ACTIVE_COMPARATOR|calcium hydroxide|Calcium hydroxide is the gold standard for pulp capping, it permits reparative dentin bridge formation, maintains pulp vitality, protects the pulp against harmful stimuli and has antimicrobial effect
62771925|NCT02126007|EXPERIMENTAL|Sleep and Rhythm Intervention|This arm receives a 4-week behavioral intervention aimed at improving sleep and circadian rhythms, and thereby reducing fatigue.
62771926|NCT02126007|PLACEBO_COMPARATOR|Dietary Modifications|This arm receives a 4-week placebo intervention focused on dietary modifications for reducing fatigue.
62771927|NCT01357759|EXPERIMENTAL|Escalating doses of MORAb-022|Subjects with RA will be randomized into Cohorts 8 to 11, with each cohort consisting of five RA subjects per cohort (four active and one placebo).
62771928|NCT01357759|PLACEBO_COMPARATOR|Placebo|Subjects with RA will be also randomized into Cohorts 8 to 11, with each cohort consisting of five RA subjects per cohort (four active and one placebo).
62771929|NCT03826823|EXPERIMENTAL|infertile women|infertile women undergoing hysterosalpingography for evaluating fallopian tubes
62771930|NCT01420419|EXPERIMENTAL|Lanolin|Pea sized amount of lanolin to be applied to nipple and areola after every breast feed (approximately every 2-3 hours), until pain is completely resolved for a maximum of 7 days
62771931|NCT01420419|OTHER|Standard postpartum nursing care|Women in standard care control group may receive any other nursing intervention to manage their nipple pain, including (but not limited to): recommending application of expressed breast milk, analgesics (such as acetaminophen or ibuprofen), breast shells, air drying, changing position / latch, cold or warm compresses
62771932|NCT06373887|EXPERIMENTAL|Low carbohydrate diet|
62771933|NCT06373887|ACTIVE_COMPARATOR|Low fat diet arm|
62771934|NCT06508034|EXPERIMENTAL|Treatment (VSL#3® 450B)|Patients receive VSL#3® 450B (live freeze-dried lactic acid bacteria probiotic) PO QD at least 3 days prior or 1-2 weeks prior to starting standard care ICIs and then continue for 12 weeks. Patients also undergo stool and blood sample collections on study.
62771935|NCT01569230|EXPERIMENTAL|Individualized acupuncture|The patients in this group received individualized acupuncture prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on the pattern diagnosis, which is an unique diagnosis system of Oriental Medicine.
62771936|NCT01569230|EXPERIMENTAL|Standardized Acupuncture|The patients in this group received standardized acupuncture treatment using the same acupuncture points, applied by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on literature review of RCTs.
62771937|NCT01569230|SHAM_COMPARATOR|Sham acupuncture|Non-penetrating acupuncture device, Park-sham acupuncture, was applied to the patients. The appearance of the acupuncture is same but the needles do not penetrate the skin.
62771938|NCT01569230|NO_INTERVENTION|Waiting|No interventions were applied to the patients in this group. Only assessments were made at each visit.
62771939|NCT01975610|EXPERIMENTAL|CC-292 375mg|Treatment
62771940|NCT01975610|PLACEBO_COMPARATOR|Placebo|Control
62771941|NCT01762995|EXPERIMENTAL|Cohort 1|Subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive all four treatments (one per period) in a random order. Treatment A = single dose DTG 50 mg fasted. Treatment B = single dose DTG 50 mg + Calcium Carbonate 1200 mg fasted. Treatment C = single dose of DTG 50 mg + Calcium Carbonate 1200 mg fed. Treatment D = single dose DTG 50 mg 2 hours prior to single dose Calcium Carbonate 1200 mg fasted
62771942|NCT01762995|EXPERIMENTAL|Cohort 2|Subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive all four treatments (one per period) in a random order. Treatment A = single dose DTG 50 mg fasted. Treatment E = single dose DTG 50 mg + Ferrous Fumarate 324 mg fasted. Treatment F = single dose of DTG 50 mg + Ferrous Fumarate 324 mg fed. Treatment G = single dose DTG 50 mg 2 hours prior to single dose Ferrous Fumarate 324 mg fasted
62771943|NCT02343705|EXPERIMENTAL|Latella Knee Implant System|
62771944|NCT03442582||Afluria|Afluria exposure in pregnancy
62771945|NCT06231433|EXPERIMENTAL|Women affected by Systemic Sclerosis and vulvovaginal atrophy|CO2 vaginal laser
62771946|NCT03433105||1/patients with tracheostomy tubes and prolonged MV use|Patients who have tracheostomy tubes and with prolonged mechanical ventilation
62771947|NCT03984656|ACTIVE_COMPARATOR|AL group|patients will receive a local infiltration of 10 mL Lidocaine without epinephrine 20 mg/mL
62179608|NCT00495872|EXPERIMENTAL|VN|Valproic Acid + Sorafenib
62179609|NCT00495872|EXPERIMENTAL|VS|Valproic Acid + Sunitinib
62179610|NCT00495872|EXPERIMENTAL|VD|Valproic Acid + Dasatinib
62179611|NCT00495872|EXPERIMENTAL|VT|Valproic Acid + Erlotinib
62179612|NCT00495872|EXPERIMENTAL|VL|Valproic Acid + Lapatinib
62179613|NCT00495872|EXPERIMENTAL|VR|Valproic Acid + Lenalidomide
62771948|NCT03984656|EXPERIMENTAL|Serratus group|patients will receive ultrasound guided serratus plane block injection of 30 mL Ropivacaine 4.75 mg/mL
62771949|NCT04122170|ACTIVE_COMPARATOR|Bentracimab (PB2452)|PB2452 18 g Intravenous Infusion over a 16 hour duration.
62771950|NCT04122170|PLACEBO_COMPARATOR|Placebo|Placebo (0.9% Sodium chloride) intravenous Infusion over a 16 hour duration.
62771951|NCT01606033|OTHER|phase II non randomized study|"phase II non randomized study, Case : 40 patients description of patients feeling by questionnaires :~* Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~* understanding of the implications of participating in a clinical trial"
62771952|NCT01606033|OTHER|blind randomized phase II or III study|"blind randomized phase II or III study: control : 40 patients description of patients feeling by questionnaires :~* Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~* understanding of the implications of participating in a clinical trial"
62771953|NCT01606033|OTHER|open randomized phase II or III study|"open randomized phase II or III study : 40 patients description of patients feeling by questionnaires : Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~-understanding of the implications of participating in a clinical trial"
62771954|NCT01606033|OTHER|receiving standard treatment|"receiving standard treatment : 120 patients description of patients feeling by questionnaires :~-understanding of the implications of participating in a clinical trial"
62179614|NCT05832944|EXPERIMENTAL|Group HMD (30 patients)|"where the size of LMA will be according to measured hyomental distance by ultrasound as follows:~* If Less than 2 cm: LMA size 2 will be used.~* If 2-3 cm: LMA size 2.5 will be used.~* If more than 3 cm: LMA size 3 will be used."
62179615|NCT05832944|NO_INTERVENTION|Group CONTROL (30 patients)|where size selection will be based on the weight guide
62179616|NCT03697083|EXPERIMENTAL|Reminders Through Association Arm|participants will be prompted to think of a reminder cue that will help them remember to pick up the prescription.
62179617|NCT03697083|ACTIVE_COMPARATOR|Active Control Arm|Participants will be asked to think about where they will store their prescription.
62179618|NCT03697083|ACTIVE_COMPARATOR|Baseline Control Arm|Participants are thanked for enrolling in the reminder program.
62179619|NCT02610621|EXPERIMENTAL|Lumpectomy without sentinel node biopsy|Subjects will undergo standard of care lumpectomy. A biopsy of the sentinel node will not be performed. After surgery, subjects will receive standard of care radiation on the affected breast and chemotherapy.
62771955|NCT01836393|EXPERIMENTAL|placebo and plai|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of ...%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
62771956|NCT00538993|EXPERIMENTAL|1|Provider receives cue sheet to assist with counseling.
62771957|NCT00538993|NO_INTERVENTION|2|Provider does not receive cue sheet.
62771958|NCT04343118||Group Removal|All patient receiving surgical removal of plate osteosynthesis
62771959|NCT04437992||Pregnant women|"* Pregnant women resident in the Emilia Romagna region who access the combined test at regional counseling centers and hospital prenatal clinics.~* Women able to understand the information, participate in pre-test counseling and provide informed consent."
62771960|NCT00618878|ACTIVE_COMPARATOR|1|Electroacupuncture
62179620|NCT04841070|EXPERIMENTAL|Persistent pulmonary hypertension of the newborn.|Children aged 1 to 5 years who have been hospitalized in pediatric resuscitation service for the treatment of persistent pulmonary hypertension of the newborn.
62179621|NCT06478108|EXPERIMENTAL|IRSW-MIM|
62179622|NCT02633397|EXPERIMENTAL|Riociguat|Treatment Arm
62179623|NCT02633397|PLACEBO_COMPARATOR|Placebo|Placebo Arm
62179624|NCT05745181|EXPERIMENTAL|CAR-T Cell Infusion|Peripheral blood mononuclear cells were isolated, amplified and cultured in vitro, pretreated with FC regimen, and Anti-CD1a CAR-T cells were transfused.
62179625|NCT01673295|EXPERIMENTAL|RTX group|Subjects will receive a RTX infusion (1g) at w0, w2, w24, w48 and w72.
62179626|NCT01673295|ACTIVE_COMPARATOR|Control group|Subjects will not receive RTX infusions and will be followed in standard of care
62179627|NCT01891890|ACTIVE_COMPARATOR|Lamotrigine|Lamotrigine 7.0 mg/kg tablets or chewable tablets administered daily in 2 equally divided doses
62179628|NCT01891890|ACTIVE_COMPARATOR|Oxcarbazepine|Oxcarbazepine 25 mg/kg tablets or liquid administered daily in 2 equally divided doses
62179629|NCT01891890|ACTIVE_COMPARATOR|Levetiracetam|Levetiracetam 30 mg/kg tablet or liquid administered daily in 2 equally divided doses
62179630|NCT05734742|EXPERIMENTAL|Video|
62179631|NCT01631786||Preserved ovaries|Ovaries or ovarian segments that have been fixed in 10% Formalin
62179632|NCT01631786||Fresh/non-preserved ovaries|Ovaries that have been surgically removed and placed in sterile saline
62179633|NCT03758456|PLACEBO_COMPARATOR|HAL-MRE1 0 AUeq|15 subjects will receive placebo. Subjects will receive 7-9 incremental weekly injections. All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
62179634|NCT03758456|EXPERIMENTAL|HAL-MRE1 5,000 AUeq|10 subjects will receive HAL-MRE1 5,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 5,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 weeks). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
62179635|NCT03758456|EXPERIMENTAL|HAL-MRE1 10,000 AUeq|10 patients will receive HAL-MRE1 10,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 10,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 weeks). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
62771961|NCT00618878|ACTIVE_COMPARATOR|2|Laser Therapy
62771962|NCT03639142|EXPERIMENTAL|Plum group|Children will receive plums at dose 3,5g/kg/d as an oral treatment for constipation.
62771963|NCT03639142|ACTIVE_COMPARATOR|Polyethylene glycol group|Children will receive PEG at dose 0,5g/kg/d as an oral treatment for constipation.
62771964|NCT01364740|EXPERIMENTAL|PMP-300E, In-Lab PSG|PMP-300E, A 7-channel (nasal pressure, effort, snoring, SpO2, pulse rate, body position and movement) Level 3 portable monitor (11.2 x 3.3 x 5.5cm, 80g, Pacific Medico Co., LTD) to measure sleep-related breathing will be tested against conventional gold-standard In-Lab Polysomnography (sleep study)
62771965|NCT02032654|ACTIVE_COMPARATOR|Standard course|Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Flucloxacillin 500mg capsules, every 6 hours, for 6 days
62771966|NCT02032654|EXPERIMENTAL|Short course|Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Placebo (for flucloxacillin 500mg) 500mg capsules, every 6 hours, for 6 days
62771967|NCT05006508|EXPERIMENTAL|Usage of tool|Participants get access to the tool and use it regularly
62179636|NCT03758456|EXPERIMENTAL|HAL-MRE1 20,000 AUeq|10 patients will receive HAL-MRE1 20,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 20,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 year). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
62179637|NCT04213820|ACTIVE_COMPARATOR|Treatment as usual|Participants will receive treatment as usual at the eating disorder unit at the Child and adolescent psychiatric clinic and at the Psychiatric clinic during 4 weeks.
62179638|NCT04213820|EXPERIMENTAL|TMS and body image intervention|Participants will receive TMS and a body image intervention daily 5 times/week during 4 weeks
62179639|NCT04213820|SHAM_COMPARATOR|sham TMS and body image intervention|Participants will receive sham TMS and a body image intervention Daily 5 times/week during 4 weeks
62179640|NCT04124471|OTHER|Participants treated with PAP|This is a qualitative study for participants with Down Syndrome who use PAP to treat obstructive sleep apnea syndrome.
62179641|NCT02872519|EXPERIMENTAL|Experimental|Patients receive (S)-4-(3-\[18F\]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET scans. Patients undergo PET imaging scans during 0-45 minutes, 60-75 minutes, and 105-120 minutes after injection and within 4 weeks prior to surgery (Cohort A) or within 4 weeks of SOC imaging at diagnosis and prior to subsequent treatment (Cohort B).
62771968|NCT05006508|NO_INTERVENTION|Controls on usual care|Participants who get randomized to control cannot access the tool and get no further follow-up. Their development of type 2 diabetes or development of HbA1c is tracked via clinical registries.
62771969|NCT02772770||Non Operative: Rehabilitation, Bracing, Activity Restriction|
62771970|NCT02772770||Operative: Transphyseal|
62771971|NCT02772770||Operative: Partial Transphyseal|
62771972|NCT02772770||Operative: Physeal sparing by Anderson Technique|
62771973|NCT02772770||Operative: Physeal sparing by Micheli/Kocher Technique|
62771974|NCT01019837|EXPERIMENTAL|Monovalent MF59- Adjuvanted vaccine|Focetria (Monovalent MF59-Adjuvanted vaccine) 7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate Intra muscular
62771975|NCT04397458|SHAM_COMPARATOR|Sham Control|20 milliliters (mL) 0.9% saline on each side
62179642|NCT05027880|EXPERIMENTAL|Single-session Intervention of Growth Mindset for Anxiety (SIGMA)|The SIGMA intervention group adapts the SSI-GP protocol in two ways: (a) by introducing the growth mindset of negative emotions rather than personality and (b) providing experiential process of negative emotion change. SIGMA consists of five components: (a) an introduction to emotions and the brain for conveying a scientific understanding of emotion and growth mindset of negative emotions; (b) stories and testimonials from high-school-aged youths who described their beliefs that people's negative emotion states (e.g., anxiety, depression, and stress) are malleable, and how these mindsets influence their coping with anxiety; (c) emotion changing experience induced by short videos; (d) common questions and misconceptions about growth mindset; and (e) self-persuasion writing exercises in which the participants write notes to younger students about the growth mindset of negative emotion.
62179643|NCT05027880|EXPERIMENTAL|Single-session Intervention on growth mindset of personality (SSI-GP)|The SSI-GP intervention group uses the intervention protocol of Project Personality. Two bilingual native English and Chinese speakers translated it into Chinese and made adaptations to better fit the local context. The SSI-GP consist of five components: (a) an introduction to the brain about the potential of neuroplasticity and behavioural change; (b) written testimonials from older, high-school-aged youths of their belief in change of personality; (c) additional vignettes written by older youths about how growth mindset of personality helped them succeed following setbacks; (d) overview of common questions and misconceptions about growth mindset; and (e) an exercise of writing notes to younger students about the malleability of people's personal traits.
62179644|NCT05027880|ACTIVE_COMPARATOR|Active control group: Support therapy (ST)|The control condition is a structurally similar web-based session of supportive therapy. The goals of supportive therapy are to encourage the client to identify and express feelings and to share their emotions-both positive and negative-with close others. The ST group does not teach or emphasize specific skills or beliefs. The active control group includes the same number of activities as do the SIGMA and SSI-GP interventions. Also, to mirror the intervention groups as closely as possible, supportive therapy includes vignettes written by similar school-aged youths, who describe times when they benefited from sharing their feelings with friends or family members.
62771976|NCT04397458|EXPERIMENTAL|Quadratus Lumborum Block|20 mL solution with 0.25% bupivacaine (50 milligrams (mg)) and 3mg preservative-free dexamethasone on each side
62771977|NCT02920723|EXPERIMENTAL|Training|"For the patients who were allocated in the control group in the EXESAS study. In this group, patients will perform 3 sessions of one hour per week of the NeuroGyV training program. It is a physical activity program with one session of Nordic walking, one session of aquagym and one session of gymnastic. Program lasts 9 months."
62771978|NCT02920723|OTHER|Control|For the patients who were allocated in the training group in the EXESAS study. In this group, patients will receive only diets and physical activity counselling
62771979|NCT02138357|PLACEBO_COMPARATOR|Placebo Patch|"The Placebo is in the form of a patch. We will be using placebo patches labeled 5mcg/hour, 10mcg/hour, and 20mcg/hour that will be changed every 7 days.~Each subject will participate in this arm of the study for four weeks."
62771980|NCT02138357|EXPERIMENTAL|buprenorphine transdermal delivery system (BTDS)|"buprenorphine transdermal delivery system (BTDS), brand name Butrans. Butrans is in the form of a patch. We will be using 5mcg/hour, 10mcg/hour, and 20mcg/hour patches that will be changed every 7 days.~Each subject will participate in this arm of the study for four weeks."
62771981|NCT03770104|EXPERIMENTAL|Intervention Group (5.5 plus weight)|ETT insertion depth using Spanish recommendations Patients included in the intervention group arm who are included in the study will be intubated using Spanish recommendations (5.5 plus weight) to estimate insertion endotracheal tube depth. In addition, every arm will be divided into 2 subgroups depending on gestational age (under 32 weeks or equal/over 32 weeks' gestation).
62771982|NCT03770104|EXPERIMENTAL|Control Group (6 plus weight)|ETT insertion depth using international recommendations Patients included in the intervention group arm who are included in the study will be intubated using international recommendations (6 plus weight) to estimate insertion endotracheal tube depth. In addition, every arm will be divided into 2 subgroups depending on gestational age (under 32 weeks or equal/over 32 weeks' gestation).
62179645|NCT05027880|EXPERIMENTAL|SIGMA-BOOSTER|The SIGMA-BOOSTER group receives the same intervention as the SIGMA group, the only difference is that the SIGMA-BOOSTER group receives booster messages with core intervention content every 2 weeks between the 2-week post-test and the 2-month follow-up survey, that is, a total of 5 weekly booster messages are sent to the SIGMA-BOOSTER group, which will help us determine the most effective way of implementing the intervention.
62179646|NCT01522677|EXPERIMENTAL|PDT|Participants receive neoadjuvant 5-ALA and PDT.
62563170|NCT04412616|EXPERIMENTAL|ZZ06 0.03 mg/kg dose group|ZZ06 0.03 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
62563171|NCT04412616|EXPERIMENTAL|ZZ06 0.06 mg/kg dose group|ZZ06 0.06 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
62563172|NCT04412616|EXPERIMENTAL|ZZ06 0.12 mg/kg dose group|ZZ06 0.12 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
62563173|NCT04412616|EXPERIMENTAL|ZZ06 0.22 mg/kg dose group|ZZ06 0.22 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
62563174|NCT04412616|EXPERIMENTAL|ZZ06 0.39 mg/kg dose group|ZZ06 0.39 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
62179647|NCT06171503|EXPERIMENTAL|intervention group|participants on intervention group will receive letter of invitation to invite her partner to attend antenatal care clinic on subsequent visit 2 to 8 weeks
62179648|NCT06171503|NO_INTERVENTION|comparison group|participant on comparison group do not receive a letter but will receive routine care to attend antenatal care along with her partner on subsequent visit 2 to 8 weeks
62179649|NCT05065697||TAVR arm|Symptomatic severe aortic stenosis undergoing transfemoral TAVR of any devices
62179650|NCT05065697||SAVR arm|Symptomatic severe aortic stenosis undergoing isolated bioprosthetic surgical aortic valve replacement
62179651|NCT00703105|EXPERIMENTAL|Autologous Dendritic Cell Vaccination|DC vaccination with 1 x 10(6th) tumor lysate or WT1 and MUC1 peptide and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals(6 weeks)
62179652|NCT02275299|EXPERIMENTAL|Iguratimod and MTX combination|Drug:Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid) Drug:MTX 2.5 mg/tablet, taken orally once a week, 4 tablets/week
62179653|NCT02275299|ACTIVE_COMPARATOR|Leflunomide and MTX combination|Drug: Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid) Drug: Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week
62179654|NCT05692271|EXPERIMENTAL|Propranolol|Medication treatment regimen will consist of 12 weeks of 40 mg immediate-release propranolol BID
62179655|NCT05692271|PLACEBO_COMPARATOR|Placebo|Matching placebo will be administered BID for 12 weeks
62179656|NCT03762083|EXPERIMENTAL|pHyph, Gedea Pessary|Clinical performance, tolerability, safety and user experience of Gedea Pessary, a slow-release vaginal tablet for the treatment of BV.
62179657|NCT04204811||Participants with Ovarian Cancer|Participants are diagnosed with Stage III or Stage IV ovarian carcinoma (which includes primary peritoneal carcinoma or fallopian tube carcinoma)
62563175|NCT04412616|EXPERIMENTAL|ZZ06 0.70 mg/kg dose group|ZZ06 0.70 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
62771983|NCT06312033|EXPERIMENTAL|naturally cycling women starting with placebo|naturally cycling women during early follicular phase starting with placebo (order was randomly selected)
62771984|NCT06312033|EXPERIMENTAL|naturally cycling women starting with estradiol|naturally cycling women during early follicular phase starting with estradiol (order was randomly selected)
62771985|NCT04548362|EXPERIMENTAL|Meat meals|This arm contains a 4-way cross-over intervention study with meats
62179658|NCT02460536|EXPERIMENTAL|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
62179659|NCT02460536|ACTIVE_COMPARATOR|Exposure only +ABMT|Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
62391179|NCT06439251|ACTIVE_COMPARATOR|Mulligan Technique|The treatment involved routine physiotherapy with TENS at 80 Hz and a pulse duration of 50-100 μs, followed by a 15-minute hot pack. It also included stretching exercises for the hamstring and calf muscles, isometric strengthening of the quadriceps and VMO, straight leg raises with traction, and tibial gliding techniques. The MWM technique consisted of SLR with traction, repeated 10 times with 3 sets and a 1-minute interval in between.
62179660|NCT02460536|ACTIVE_COMPARATOR|Attention training only +ABMT|Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
62179661|NCT02460536|PLACEBO_COMPARATOR|Placebo group|Identical discrimination task including a single non-emotional stimulus in each trial.
62391180|NCT02038244|EXPERIMENTAL|Integrative Medicine|
62391181|NCT01327833||Cardiac Arrest|
62771986|NCT04548362|EXPERIMENTAL|Starchy meals|This arm contains a 4-way cross-over intervention study with
62179662|NCT04839614|EXPERIMENTAL|CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY|"Upon enrollment in the study at first appointment with gynecologic oncologist, referral to the BWH Center for Metabolic and Bariatric Surgery (CMBS).~* Schedule a series of appointments with a bariatric surgeon, nutritionist and psychologist, which is part of the approval process for weight loss surgery.~* Hysterectomy and weight loss surgery will then be scheduled on the same day within 8 weeks from first visit with the gynecologic oncologist for endometrial cancer or 12 weeks if you have endometrial pre-cancer.~* Series of post-operative visits with the bariatric surgeon and gynecologic oncologic surgeon as well as the nutritionist and psychologist."
62771987|NCT03141541|NO_INTERVENTION|Usual care|All patients receive a thorough physical examination by a rheumatologist or a chiropractor with a subsequent examination by a physiotherapist.The patients receive general information about the nature back pain, adjustment of analgesic treatment and clarification of any need of further diagnosing or assessment by a surgeon. The physiotherapist furthermore makes an assessment of the patients' physical capacity and function and provides guidelines for any exercise programme. Based on the physiotherapist's judgement, the patient may be referred to rehabilitation in the local community
62771988|NCT03141541|EXPERIMENTAL|Group based pain management intervention|In addition to usual care as described for the control group, the patients in the intervention group will participate in a cognitive group-based pain management intervention. The aim of the intervention is to improve the patients' understanding of their back pain problem, and that they learn different pain coping strategies. The intervention is based on cognitive behavioural therapy including elements of acceptance and commitment therapy, and furthermore uses different relaxation and breathing exercises.
62771989|NCT06219421||Patients|
62179663|NCT00374088|PLACEBO_COMPARATOR|Placebo|These patients receive a placebo infusion of D5W prior to and after surgery
62179664|NCT00374088|EXPERIMENTAL|N-Acetylcysteine|These patients receive a loading dose of N-Acetylcysteine 100 mg/kg in D5W IV 1 hour prior to surgery. They receive a maintenance infusion of N-Acetylcysteine 10 mg/kg/hr in D5W IV for 24 hours after surgery.
62391182|NCT01822782||Cases|"The study population consists of all consecutive women meeting inclusion/exclusion criteria and delivering at the Nîmes University Hospital, France during an inclusion period of 6 months. Cases are classified as those with a vaginal lesion due to delivery."
62563176|NCT04412616|EXPERIMENTAL|ZZ06 1.00 mg/kg dose group|ZZ06 1.00 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
62563177|NCT01057706|EXPERIMENTAL|9 months of chiropractic care and exercise|chiropractic, exercise
62563178|NCT01057706|ACTIVE_COMPARATOR|3 months of chiropractic care and exercise|chiropractic, exercise
62771990|NCT06219421||Controls|
62771991|NCT03782922|EXPERIMENTAL|Exercise Training Program|
62771992|NCT03782922|NO_INTERVENTION|Control|
62771993|NCT03025178|EXPERIMENTAL|Central venous catheterization|Central venous catheterization will be performed using 4Fr central venous catheter at left internal jugular vein in infant. The tip of central venous catheter will be confirmed by transthoracic echocardiography. The actual insertion depth of central venous catheter will be compared to the predicted insertion depth derived from two calculation methods using height and the distance between the anatomical landmarks.
62771994|NCT00628147|EXPERIMENTAL|Narrow band imaging colonoscope|narrow band imaging colonoscope
62179665|NCT00270647|EXPERIMENTAL|Vitamin E|Active or placebo vitamin E
62179666|NCT00270647|EXPERIMENTAL|Vitamin C|Active or placebo vitamin C
62179667|NCT00270647|EXPERIMENTAL|Multivitamin|Active or placebo multivitamin
62179668|NCT00270647|EXPERIMENTAL|Beta-carotene|Active or placebo beta-carotene
62563179|NCT06286683||Patients admitted to intensive care|Patients admitted to intensive care for aneurysmal subarachnoid hemorrhage (SAH) and eligible for their first out-of-bed mobilization
62771995|NCT00628147|NO_INTERVENTION|White Light|Conventional White Light Examination
62771996|NCT05141955|ACTIVE_COMPARATOR|Group Erector Spinae Plane Block (ESPB)|
62771997|NCT05141955|ACTIVE_COMPARATOR|Group Quadratus Lumborum Block (QLB)|
62771998|NCT05141955|OTHER|Group (C) (Control group)|
62179669|NCT03148483|EXPERIMENTAL|Early PT plus Fortified Milk|early periodontal therapy (during pregnancy) plus fortified milk
62179670|NCT03148483|EXPERIMENTAL|Early PT plus Plain Milk|early periodontal therapy (during pregnancy) plus plain milk
62179671|NCT03148483|EXPERIMENTAL|Delayed PT plus Fortified Milk|delayed periodontal therapy (after delivery) plus fortified milk
62179672|NCT03148483|PLACEBO_COMPARATOR|Delayed PT plus Plain Milk|delayed periodontal therapy (after delivery) plus plain milk
62179673|NCT00123019|ACTIVE_COMPARATOR|1|Minimal intervention; annual weight/waist assessment, questionnaire, and advice
62179674|NCT00123019|EXPERIMENTAL|2|Intensive intervention. All arm 1 activities plus ongoing environmental and group interventions in worksite for two years.
62771999|NCT05614648|ACTIVE_COMPARATOR|Clonidine Micropellets Injection|Clonidine Micropellets single dose injection into the lumbar epidural space
62772000|NCT05614648|SHAM_COMPARATOR|Sham Insertion|Sham Control non-epidural needle placement
62772001|NCT03358940|OTHER|patient with miscarriage complications or not|The day of inclusion, for patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
62772002|NCT02747017||CDI patients|Adults with a first episode of CDI within 2 years after solid-organ or stem-cell transplant.
62772003|NCT05097352|EXPERIMENTAL|High Intensity Interval Training (HIIT)|High-intensity interval training will be performed three times a week for a total of six weeks.
62772004|NCT05097352|SHAM_COMPARATOR|Waitlist Control|Waitlist participants were tested on the outcomes at the same time points as the treatment group (i.e., HIIT). Following completion of the waitlist treatment, participants will be eligible to receive a supervised exercise program (no data will be collected). The waitlist participants formed a no-treatment control group.
62772005|NCT05506839|OTHER|Intervention|Participants will be paired with an English language learner and engage in 8 weeks, 1 hour videoconferencing sessions.
62563180|NCT04429945|EXPERIMENTAL|Immersive Virtual Reality|A Virtual Reality headset will be used for 30 minutes twice per day outside of usual therapy times while in bed with bedrails raised. Virtual Reality games will be selected that will help with relaxation, pain, and arm and hand recovery after a stroke.
62772006|NCT06546072||Training cohort|We randomly assigned 569 patients from Sun Yat-sen Memorial Hospital of Sun Yat-sen University (SYSMH; Guangzhou, China) at a ratio of 3:1 to training (n = 456) and internal-validation (n = 113) cohorts.
62772007|NCT06546072||Internal validation cohort|We randomly assigned 569 patients from Sun Yat-sen Memorial Hospital of Sun Yat-sen University (SYSMH; Guangzhou, China) at a ratio of 3:1 to training (n = 456) and internal-validation (n = 113) cohorts.
62179675|NCT05124821||Certofix Paed|Paediatric patients in need for short-term (≤ 30 days) catheterisation of the superior vena cava using the Seldinger technique for infusion and volume therapy or parenteral nutrition, for administration of highly osmolar or very vein-irritating solutions/drugs, for continuous or intermittent monitoring of the central venous pressure, for blood sampling, or when peripheral venous puncture is not possible in state of shock, in patients with injured extremities or no detectable peripheral veins.
62772008|NCT06546072||External testing cohort 1|432 from Sun Yat-sen University Cancer Center (SYSUCC; Guangzhou, China) into external testing cohort 1.
62772009|NCT06546072||External testing cohort 2|198 from Dongguan Tungwah Hospital (DTH; Dongguan, China) and Shunde Hospital of Southern Medical University (SDHSMU; Guangzhou, China) into external testing cohort 2.
62772010|NCT05362474|EXPERIMENTAL|montelukast|montelukast 10mg orally once a day
62772011|NCT02758301||Diagnostic|The Reveal LINQ™ Insertable Cardiac Monitor (ICM) device will be inserted in all subjects for continuous monitoring. After the Reveal LINQ™ device is inserted, the LINQ™ HF investigational RAMware will be downloaded to the LINQ™ ICM.
62772012|NCT01031862|OTHER|Healthy Volunteers|12 healthy volunteers
62772013|NCT01566487|EXPERIMENTAL|Quetiapine fumarate tablets 300 mg|Quetiapine fumarate film-coated tablets 300 mg of Dr. Reddy's Laboratories Limited
62772014|NCT01566487|ACTIVE_COMPARATOR|Seroquel|Seroquel film-coated tablets 300 mg of Astrazeneca Pharmaceuticals, USA
62772015|NCT01992562|EXPERIMENTAL|Treatment|5 mcg ziconotide in 1ml of normal saline bolus intrathecal injection
62179676|NCT02716857|EXPERIMENTAL|Oxycodone extended-release|Egalet ADER oxycodone tablet
62772016|NCT01992562|PLACEBO_COMPARATOR|Placebo|1ml of normal saline bolus intrathecal injection
62179677|NCT02716857|PLACEBO_COMPARATOR|Placebo of Oxycodone extended-release|Egalet ADER oxycodone placebo tablet
62179678|NCT01586429||Epidural|
62772017|NCT02115360|ACTIVE_COMPARATOR|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 100 iu of calcitonin will be injected epidurally in Bupivacain-Calcitonin-fentanyl (BC) Group,
62772018|NCT02115360|ACTIVE_COMPARATOR|fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
62772019|NCT02950844|EXPERIMENTAL|STAR mapping guided ablation|Patients will undergo PVI guided ablation in addition to STAR mapping guided ablation. The impact on electrophysiological endpoints including cycle length prolongation and AF termination will be assessed.
62772020|NCT05104541|EXPERIMENTAL|Intervention Arm|"In addition to standard pharmacological treatment this group would receive diet comprising of 20-25 kcal and 1.2gm protein per kg ideal body weight per day.~The total distribution of the calories would be as 55-60% from carbohydrates, 25% from protein, and 20% from fat. The diet would be explained to the patient with the help of individual diet charts."
62772021|NCT01170078|EXPERIMENTAL|Arm A: Epoetin Hospira administered IV for three doses|
62772022|NCT01170078|ACTIVE_COMPARATOR|Arm B: Epogen administered IV for three doses|
62772023|NCT06423560||Residual disease > 20% of the total lung volume was considered pathological at follow-up CT|
62772024|NCT06423560||Residual disease < 20% of the total lung volume was considered pathological at follow-up CT|
62772025|NCT01132586|EXPERIMENTAL|Treatment (lenalidomide, cytarabine, idarubicin)|"INDUCTION:~COHORT I: Patients receive lenalidomide PO QD on days 1-21, cytarabine IV continuously over 96 hours on days 5-8, and idarubicin IV over 1 hour on days 5-7.~COHORT II: Patients receive lenalidomide PO QD on days 1-21, cytarabine IV continuously over 24 hours on days 5-11, and idarubicin as above.~Patients with residual disease on day 18 undergo a second course of induction therapy.~CONSOLIDATION:~COHORT I: Patients receive lenalidomide PO QD on days 1-14, idarubicin IV over 1 hour on days 5-6, cytarabine IV continuously on days 5-7. Treatment continues for 1 course in the absence of disease progression or unacceptable toxicity.~COHORT II: Patients 2 receive 4 courses of consolidation therapy comprising lenalidomide PO QD on days 1-14 and cytarabine IV every 12 hours on days 5, 7, and 9. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
62772026|NCT00249613|EXPERIMENTAL|Women-Only|Substance abuse treatment program for women only
62772027|NCT00249613|NO_INTERVENTION|Mixed-Gender|Substance abuse treatment program for both women and men
62772028|NCT00494910|EXPERIMENTAL|1|Meaning Centered Group Psychotherapy (MCGP)
62772029|NCT00494910|ACTIVE_COMPARATOR|2|standardized Supportive Group Psychotherapy
62772030|NCT04057885|EXPERIMENTAL|Device Arm|A prospective series of 10 patients will receive sensor-guided TKA using the this special Orthosensor™ VERASENSE™ Knee System assisted surgery for optimization of soft tissue balance
62772031|NCT04057885|ACTIVE_COMPARATOR|Standard of Care|10 patients will receive standard of care. Prior to cementing final implants, VERASENSE will be utilized with the standard of care group with the surgeon blinded to the data.
62772032|NCT06065436|EXPERIMENTAL|Collagenase Clostridium Histolyticum with Low Intensity Shockwave Therapy|Subjects will receive Collagenase Clostridium Histolyticum (CCH) intralesional injection with low-intensity shockwave therapy (LiSWT).
62772033|NCT06065436|ACTIVE_COMPARATOR|Collagenase Clostridium Histolyticum|Subjects will receive Collagenase Clostridium Histolyticum (CCH) intralesional injection per standard of care.
62772034|NCT03802903|EXPERIMENTAL|Remo-Wax|Test product will be applied into ear canal for 20-60 minutes.
62772035|NCT01597024|EXPERIMENTAL|Phase 1: Breakfast Study|
62772036|NCT01597024|EXPERIMENTAL|Phase 2: fMRI Study|
62772037|NCT02179814|EXPERIMENTAL|AMPT|"Experimental:~alpha-methyl-paratyrosine (AMPT, trade name: Demser), body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 time points over 24 hours"
62772038|NCT02179814|SHAM_COMPARATOR|Diphenhydramine & placebo|Diphenhydramine (25mg, trade name in Switzerland: Benocten) at the first medication intake time point, placebo at the second to fourth intake time point (medication intake over 24 hours)
62179679|NCT01586429||Femoral catheter|
62179680|NCT00143598|ACTIVE_COMPARATOR|Active ECS|Active Elastic Compression Stockings (ECS) 30-40 mm Hg compression at the ankle.
62179681|NCT00143598|PLACEBO_COMPARATOR|Placebo ECS|Placebo stockings with identical appearance to Active ECS and with \< 5 mm Hg compression at the ankle.
62182762|NCT06480877||Cigarette smokers|Inclusion criteria were good general health, absence of any lesions below at or above the level of the oral mucosa, and minimum of 20 healthy teeth. Smokers had to meet the criteria for smoking experience that was at least 3 years (classic cigarette or THS) and daily consumption which should not be less than 5 cigarettes or heat sticks per day. Selected subjects were only cigarette smokers for Group I, and the same rule of selection was applied for IQOS users as Group II.
62179682|NCT01707706|EXPERIMENTAL|Traditional Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, Neiguan PC6, Shenmen HT7, Sanyinjiao SP6, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (ITO ES160, Japan) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.4 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
62772039|NCT05548062||Hydroxyurea|Patients being treated with hydroxyurea at enrollment and for at least 18 months prior to enrollment. Patients may switch to ruxolitinib treatment during the study in case of inadequate response or intolerance.
62182763|NCT06480877||Control group-non smokers|Inclusion criteria were good general health, absence of any lesions below at or above the level of the oral mucosa, and minimum of 20 healthy teeth. Smokers had to meet the criteria for smoking experience that was at least 3 years (classic cigarette or THS) and daily consumption which should not be less than 5 cigarettes or heat sticks per day. Selected subjects were only cigarette smokers for Group I, and the same rule of selection was applied for IQOS users as Group II.
62772040|NCT05548062||Ruxolitinib|Patients on treatment with ruxolitinib who started treatment up to 18 months prior to enrollment.
62772041|NCT04190797|EXPERIMENTAL|Experimental|Photobiomodulation + patiente controled anaethesia (PCA) group (G1): patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device connected, 24h and 48h after the peripheral nerve block (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
62772042|NCT04190797|ACTIVE_COMPARATOR|Control|Placebo + PCA group (G2): patients undergoing knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve blockade (femoral nerve and obturator nerve). With conventional analgesia and with the PCA apparatus.
62772043|NCT06064123||Cardiac transplant recipients|The group consist of all recruited cardiac transplant recipients operated in Helsinki University Hospital
61995122|NCT03675490|EXPERIMENTAL|Exercise|Participants will engage in a physiotherapist-prescribed home exercise program with ABLE, the interactive technology. The exercises that will be prescribed are designed to improve functional mobility via challenging lower extremity strength and balance in a multicomponent exercise program. The difficulty of each exercise will be chosen at the discretion of the physiotherapist based on the participants' performance on the baseline assessments. The exercises will be prescribed at a moderate intensity (moderate balance challenge, 8-12 repetitions for strength exercises with the last few repetitions being challenging) and will be progressed over the study duration to ensure they remain a moderate challenge.
61995123|NCT06200675|EXPERIMENTAL|Compassion-based intervention|Participants assigned to this intervention will be asked to engage in one brief (10-15 minute) online compassion-focused exercise, where they will be asked to connect to their inner compassionate self. They will be asked to stay connected to that feeling while rereading what they wrote about their feelings of shame and imagining it was someone else who wrote it. Participants will then be asked to write a compassionate response to themselves. Participants will then be asked to reread this response while remaining connected to their compassionate self.
62772044|NCT03716661|NO_INTERVENTION|Control|Arm 1/control group: Participants who are treated with conservative plaster following National Clinical Guidelines.
62772045|NCT03716661|NO_INTERVENTION|Conservative|"Arm 2 and 3 consist of participants fulfilling the criteria for operative treatment following National Clinical Guidelines.~Arm 2: Patients randomized to conservative plaster treatment"
62772046|NCT03716661|OTHER|Operative|"Arm 2 and 3 consist of participants fulfilling the criteria for operative treatment following National Clinical Guidelines.~Arm 3: Patients randomized to operative treatment (ORIF)"
62772047|NCT00453973|EXPERIMENTAL|Maintenance Switch in Dialysis Participants|"Participants were from a prior Affymax peginesatide treatment study conducted in participants who were on dialysis and had been on Epoetin at study entry, and who were switched to peginesatide (NCT00434330). This group is categorized as Maintenance Switch in Dialysis Participants regardless of dialysis status at the start of or during this study."
62772048|NCT00453973|EXPERIMENTAL|Treatment Initiation in Non-Dialysis Participants|"Participants were from a prior Affymax peginesatide treatment study conducted in participants who were not on dialysis and not on erythropoiesis stimulating agents (ESAs), and who received peginesatide (NCT00228436). This group is categorized as Initiation of Treatment in Non-Dialysis Participants regardless of dialysis status at the start of or during this study."
62563181|NCT05643937|ACTIVE_COMPARATOR|The control group|The control group received routine health education after catheterization, including introducing the purpose, method, advantages and complications of PICC insertion to patients before catheterization and signing informed consent. During catheterization, PICC assistant explained relevant matters needing attention and cooperative actions to the patient. After catheterization, patients were instructed to carry out grip training and limb activities.
62563182|NCT05643937|EXPERIMENTAL|Experimental group|On the basis of routine health education in the control group, the experimental group screened the high-risk behaviors of patients through the questionnaire of daily life behavior habits, and formulated the precise and concrete health education program for their high-risk behaviors
62182596|NCT00680147|EXPERIMENTAL|Brief HPV vaccine informational intervention|Because we anticipated that knowledge and awareness of the HPV vaccine would be low in our study population, our CASI survey included a brief, informational overview of key facts concerning HPV vaccination prior to assessing vaccine acceptance, perceived barriers to vaccination, and intentions to vaccinate. The overview lasted approximately 3 minutes and consisted of a brief overview of key HPV vaccination facts that were presented visually (on the computer screen) and read aloud using a digital recording. HPV and vaccine knowledge, awareness, and attitudes items were administered prior to participants hearing the informational overview.
62563183|NCT04515147|EXPERIMENTAL|Part 1, Group 1: CVnCoV 6 μg|Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
62563184|NCT04515147|EXPERIMENTAL|Part 1, Group 2: CVnCoV 6 μg|Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
62563185|NCT04515147|EXPERIMENTAL|Part 1, Group 3: CVnCoV 12 μg|"Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be between the ages of 18 to 60 years old.~CVnCoV will be administered again as a booster vaccination on Day 180 in a sub-group of participants."
62563186|NCT04515147|EXPERIMENTAL|Part 1, Group 4: CVnCoV 12 μg|"Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged over 60 years old.~CVnCoV will be administered again as a booster vaccination on Day 57 or Day 180 in a sub-group of participants."
62772049|NCT05848765|EXPERIMENTAL|Round 1: Epcoritamab and lenalidomide|Epcoritamab (weekly for cycles 1 and 2 and on day 1 of cycles 3-12 for up to 12 cycles) and lenalidomide (daily for days 1-21 of each cycle for up for 12 cycles), cycles will be 28 day cycles.
62772050|NCT05848765|EXPERIMENTAL|Round 2|Investigation agent 2
62772051|NCT05848765|EXPERIMENTAL|Round 3|Investigation agent 3
62772052|NCT05848765|ACTIVE_COMPARATOR|All rounds: Investigator Choice Therapy|Choice of therapy to be selected by the Investigator for each patient prior to randomisation. The Investigator will choose between; RCHOP, RCVP, rituximab and bendamustine, rituximab and lenalidomide or bendamustine and obinutuzumab.
62772053|NCT02168985|EXPERIMENTAL|Attend TFH Program|Couples attend the three-day Faithful House Training program immediately
62772054|NCT02168985|NO_INTERVENTION|Wait-listed for TFH Program|Couples attend The Faithful House program three-months after the initial group
62179683|NCT01707706|ACTIVE_COMPARATOR|Minimal Acupuncture|"Patients will be treated superficially at points away from classic acupoints. The points include bilateral Forearm \[1 inch lateral to the middle point between HE3 and HE7\] , Upper arm \[1 inch lateral to LU 3 \], and Lower leg \[0.5 inch dorsal to GB39\]; for head, the non-acupoints include bilateral Head \[middle point between GB8 and ST8\], Forehead \[middle point between ST8 and GB14\], Neck \[middle point between TB16 and SI17\], and Ear \[the point on the helix, inferior to the apex\]. The points selected have been used in previous acupuncture studies as sham control. De qi is avoided during needling. The treatment procedure, electric-stimulation, frequency, duration and number of treatment sessions will be the same for the Traditional Acupuncture group."
62182597|NCT02892864|ACTIVE_COMPARATOR|Control arm|Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation.
62182598|NCT02892864|EXPERIMENTAL|Experimental Virtual Arm|Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.
62772055|NCT00002961|ACTIVE_COMPARATOR|Total body irradiation|Total body irradiation 1200 centigray
62772056|NCT00002961|ACTIVE_COMPARATOR|Busulfan|Busulfan 16 doses
62772057|NCT05776628|ACTIVE_COMPARATOR|Polydioxanone membrane|After flavectomy and manipulation of the spinal nerve and dura mater to resect the herniated intervertebral disk, the membrane will be placed on top of the dura mater.
62772058|NCT05776628|NO_INTERVENTION|Control|The microdiscectomy procedure will be performed routinely, without the addition of any device over the dura mater.
62772059|NCT00778895|EXPERIMENTAL|Fluviral F1 Group|Subjects 6 months to 3 years of age received if primed, 1 dose of formulation 1 of Fluviral vaccine at Day 0 and if unprimed, 2 doses of formulation 1 of Fluviral vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
62182764|NCT02215954|EXPERIMENTAL|Treatment arm [1]: FE 999169|One sachet on the day before colonoscopy, and another sachet on the day of colonoscopy
62563187|NCT04515147|ACTIVE_COMPARATOR|Part 1, Group 5: Hepatitis A vaccine|Participants will be vaccinated with a hepatitis A vaccine on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
62772060|NCT00778895|EXPERIMENTAL|Fluviral F2 Group|Subjects 6 months to 3 years of age received if primed, 1 dose of formulation 2 of Fluviral vaccine at Day 0 and if unprimed, 2 doses of formulation 1 of Fluviral vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
62563188|NCT04515147|ACTIVE_COMPARATOR|Part 1, Group 6: Pneumococcal vaccine|Participants will be vaccinated with a pneumococcal vaccine on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
62563189|NCT04515147|EXPERIMENTAL|Part 2, Group 1: CVnCoV 12 µg|Participants will be vaccinated with CVnCoV 12 µg on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
62772061|NCT00778895|ACTIVE_COMPARATOR|Vaxigrip Group|Subjects 6 months to 3 years of age received if primed, 1 dose of Vaxigrip vaccine at Day 0 and if unprimed, 2 doses of Vaxigrip vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
62772062|NCT01874938|EXPERIMENTAL|LY2875358|LY2875358 will be administered intravenously (IV) at 2000 milligram (mg) bi-weekly in 28 day Cycle.
62772063|NCT01723540|EXPERIMENTAL|Minilaparotomy cholecystectomy with ultrasonic scissors|Minilaparotomy vs laparoscopy
62772064|NCT01723540|ACTIVE_COMPARATOR|Laparoscopic cholecystectomy|Minilaparotomy vs laparoscopy
62772065|NCT05852821|EXPERIMENTAL|remote 5STS through videoconference|
62772066|NCT02648217|EXPERIMENTAL|IDegAsp U100 BID|
62772067|NCT02648217|ACTIVE_COMPARATOR|BIAsp U100 BID|
62772068|NCT02904655|ACTIVE_COMPARATOR|healthy diet|Participants were provided all meals and snacks for four weeks. Menus were created to target a healthy diet high in unsaturated fats.
62772069|NCT02904655|NO_INTERVENTION|control diet|Participants were instructed to consume their usual diet.
62772070|NCT02672592|ACTIVE_COMPARATOR|Anakinra|Anakinra//Kineret® 100mg s.c. bid
62772071|NCT02672592|PLACEBO_COMPARATOR|Placebo|Sodium Chloride 0.9% s.c. bid
62772072|NCT05167903|EXPERIMENTAL|Time-restricted eating|Participants in the TRE group will be instructed to consume all meals between 12pm to 8pm (8 h eating window with 16 h of fasting)
62772073|NCT05167903|EXPERIMENTAL|Normal Diet (ND)|The ND group will consume all meals between 6 am - 10 pm (16 h eating window with 8 h of fasting, ad-libitum)
62772074|NCT03046524||Parathyroid Carcinoma|Charts from participants with histopathological diagnosis of parathyroid carcinoma.
62182765|NCT02215954|EXPERIMENTAL|Treatment arm [2]: FE 999169|Two sachets on the day before colonoscopy
62772075|NCT03046524||Atypical Parathyroid Neoplasm|Charts from participants with parathyroid tumors with some atypical features found in parathyroid carcinoma, but not enough histologic criteria to make the diagnosis of parathyroid carcinoma.
62772076|NCT04054999|EXPERIMENTAL|Cyanokit|Single dose intraoperatively of Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes
62772077|NCT04054999|ACTIVE_COMPARATOR|Methylene Blue|Single dose intraoperatively of Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes
62772078|NCT02625870|EXPERIMENTAL|Omega-3-Acid Ethyl Esters 90 Soft Capsules|
62179684|NCT01707706|PLACEBO_COMPARATOR|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the site 1 inch beside the acupoints in order to avoid the acupressure effect. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
62772079|NCT02625870|PLACEBO_COMPARATOR|Corn Oil|
62772080|NCT02335060|EXPERIMENTAL|Active N-acetylcysteine and Active Delta-9-THC|
62772081|NCT02335060|PLACEBO_COMPARATOR|Placebo and Active Delta-9-THC|
62772082|NCT02335060|EXPERIMENTAL|Active N-acetylcysteine and Placebo|
62772083|NCT02335060|PLACEBO_COMPARATOR|Placebo and Placebo|
62772084|NCT02310997|EXPERIMENTAL|Fludarabine + Cyclophosphamide + TBI|"Patients aged 2-45 years (excluding AML, JMML and MDS patients aged \<16 years) will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:~Fludarabine 25mg/m\^2/day day -8 to -6 (total 75mg/m\^2) Cyclophosphamide 60mg/kg day -7 and -6 (total 120mg/kg) Total body irradiation 13 - 14.4Gy in 6-8 fractions"
62772085|NCT02310997|EXPERIMENTAL|Busulfan + Cyclophosphamide + Melphalan|"Patients aged \< 2 years and AML, JMML and MDS patients \<16 years will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:~Busulfan 3.2mg/kg/day in 2 or 4 doses per day, days -9 to -6 (total 12.8mg/kg). Cyclophosphamide 60mg/kg days -4 and -3 (total 120mg/kg) Melphalan 140mg/m\^2 day -2"
62772086|NCT04886700|EXPERIMENTAL|SG001|Recombinant Human Anti-PD-1 Monoclonal Antibody
62772087|NCT05946512|EXPERIMENTAL|yoga intervention|
62772088|NCT05946512|ACTIVE_COMPARATOR|social contact|
62772089|NCT03594214||Single arm|pre-treatment serum vitamin d level measured by ELISA kit in patients confirmed for diagnosis with invasive breast cancer and before receiving any treatment for breast cancer
62772090|NCT02074072|EXPERIMENTAL|Direct laryngoscope|Macintosh laryngoscope
62772091|NCT02074072|EXPERIMENTAL|Videolaryngoscope-1|Glidescope
62772092|NCT02074072|EXPERIMENTAL|Videolaryngoscope-2|Airwayscope
62772093|NCT03108508|EXPERIMENTAL|Prod1|G5 Siliplant
62772094|NCT03108508|EXPERIMENTAL|Prod2|Orgono Powder®
62772095|NCT03108508|EXPERIMENTAL|Prod3|G7 ALOE
62182766|NCT02215954|ACTIVE_COMPARATOR|Treatment arm [3]: Niflec|One to two pack(s) on the day of colonoscopy
62772096|NCT05505604|ACTIVE_COMPARATOR|PENG|Patients with hip fracture randomized to receive PENG block
62772097|NCT05505604|ACTIVE_COMPARATOR|FICB|Patients with hip fracture randomized to received FICB
62772098|NCT02270255|SHAM_COMPARATOR|Control group|Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.
62772099|NCT02270255|EXPERIMENTAL|Sup Hypogastric Nerve block group|Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.
62772100|NCT05577637|ACTIVE_COMPARATOR|group A topical tacrolimus 0.03% with uvb phototherapy|Group A :contain 30 patients who have been treated with topical 0.03% tacrolimus twice daily at night and then received uvb phototherapy thrice weekly for 12 weeks
62772101|NCT05577637|ACTIVE_COMPARATOR|Group B topical placebo twice daily with uvb phototherapy thrice weekly|Group B :contain 30 patients received uvb phototherapy only thrice weekly for 12 weeks
62772102|NCT04058548|EXPERIMENTAL|6MWT and STS|All participates will receive 6MWT and STS test
62772103|NCT04654260|EXPERIMENTAL|Behavioral Therapy for Irritability in Autism (BTIA)|BTIA consists of 15 ninety-minute weekly sessions that will be conducted with the teens and their parents by experienced therapists using a structured, detailed manual.
62772104|NCT04654260|ACTIVE_COMPARATOR|Psychoeducation and Supportive Therapy (PST)|PST consist of 15 weekly, ninety-minute sessions focused on learning about and discussing issues of diagnosis, treatment and educational services with an experienced therapist could be helpful to children on the autism spectrum and their families.
62772105|NCT03481621|ACTIVE_COMPARATOR|Group1a, Acupuncture on Vulvodynia|Focus on using the local points in pudendal nerve distribution area
62772106|NCT03481621|ACTIVE_COMPARATOR|Group1b, Acupuncture on Vulvodynia|Focus on traditional acupuncture using common meridian or distal points
62772107|NCT03481621|ACTIVE_COMPARATOR|Group2, Standard care or waiting lists|Standard care without acupuncture
62772108|NCT05921279||Anthracycline based chemotehrapy low and moderate risk|"Patients recieving anthracycline based chemotherapy who fall into the low and moderate risk category following HFA - ICOS cardiac risk assessment as per the European Society of Cardiology Guidelines.~These patients are monitored taking biobank bloods, bloods, ecg and cardiac echo as per the European Society of Cardiology guidelines whilst receiving chemotherapy."
62772109|NCT05921279||Anthracycline based chemotherapy - high and very high risk|"Patients who recieving anthracycline who fall into the high and very high risk category following HFA - ICOS cardiac risk assessment as per the European Society of Cardiology Guidelines.~These patients are monitored taking biobank bloods, bloods, ecg and cardiac echo as per the European Society of Cardiology guidelines whilst receiving chemotherapy."
62772110|NCT05921279||Herceptin targeted therapy - low and moderate risk|Patients who are recieving herceptin that fall into the low and moderate risk category following HFA-ICOS cardiac risk assessment as per the European Society of Cardiology Guidelines. These patients are monitored taking biobank bloods, bloods, ecg and cardiac echo as per the European Society of Cardiology Guidelines.
62563190|NCT04515147|ACTIVE_COMPARATOR|Part 2, Group 2: Hepatitis A vaccine|Participants will be vaccinated with a hepatitis A vaccine on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
62772111|NCT05921279||Herceptin targeted therapy - high and very high risk|Patients who are recieving herceptin that fall into the high and very high risk category following HFA-ICOS cardiac risk assessment as per the European Society of Cardiology Guidelines. These patients are monitored taking biobank bloods, bloods, ecg and cardiac echo as per the European Society of Cardiology Guidelines.
62772112|NCT03911024|ACTIVE_COMPARATOR|HIV|
62772113|NCT03911024|PLACEBO_COMPARATOR|General Health|
62772114|NCT03113604||Patients with untreated CHC not sorafenib|
62772115|NCT03113604||Patients with non-sorafenib CHC|
62772116|NCT03113604||Patients with CHCs responding to sorafenib|
62772117|NCT02495454|EXPERIMENTAL|Ga101-miniCHOP|"6 courses of GA101-miniCHOP regimen and 2 additional infusions of GA101, every 21 days (for a total of 6 courses of miniCHOP and 10 infusions of GA101).~GA101-miniCHOP regimen:~* Cycle 1 GA101: 1000 mg day 1, day 8 and day 15, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os~* Cycles 2-6 GA101: 1000 mg day 1, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os~* Two additional infusions of GA101: 1000 mg day 1, iv, every 21 days."
62772118|NCT02643589|EXPERIMENTAL|ATG 7.5mg/kg|ATG 7.5mg/kg group refers to treatment with ATG in the total dose of 7.5mg/kg.
62772119|NCT02643589|ACTIVE_COMPARATOR|ATG 10mg/kg|ATG 10mg/kg group refers to treatment with ATG in the total dose of 10mg/kg.
62772120|NCT04496453|EXPERIMENTAL|Childhood vaccination decision support tool|Participants receive childhood vaccination decision support tool
62772121|NCT03996317|NO_INTERVENTION|Standard care|Standard practice where 10L/min O2 is delivered to patient by mask when any fetal tracing abnormalities are identified.
62563191|NCT04515147|EXPERIMENTAL|Part 2, Group 3: CVnCoV 12 µg|Participants will be vaccinated with CVnCoV 12 µg on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
62563192|NCT04515147|ACTIVE_COMPARATOR|Part 2, Group 4: Pneumococcal vaccine|Participants will be vaccinated with a pneumococcal vaccine on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
62563193|NCT01515423|EXPERIMENTAL|Paliperidone palmitate 3-month (PP3M)|A formulation of paliperidone palmitate with a 3-month injection interval
62563194|NCT01515423|ACTIVE_COMPARATOR|Paliperidone palmitate 1-month (PP1M)|A formulation of paliperidone palmitate with a 1-month injection interval
62772122|NCT03996317|EXPERIMENTAL|Room air|O2 will be withheld at times when fetal tracing abnormalities are identified. Patient will continue to breath room air.
62772123|NCT00654459||A|
62772124|NCT00654459||B|
62772125|NCT05728073||Standard (non-ERCP) Group|Patients who underwent surgery for acute cholecystitis without a previous ERCP history.
62772126|NCT05728073||ERCP group|Patients who underwent surgery for acute cholecystitis with a previous ERCP history.
62772127|NCT02030990|EXPERIMENTAL|Mitomycin-C; 3 week FML steroid taper|Mitomycin-C 0.01% will be administered intraoperatively during PRK for 15 seconds. The patient will take a 3 week fluorometholone 1% topical steroid taper.
62772128|NCT02030990|EXPERIMENTAL|Mitomycin-C; 1 week FML steroid taper|Mitomycin-C 0.01% will be administered intraoperatively during PRK for 15 seconds. The patient will take a 1 week of fluorometholone 1% topical steroid.
62772129|NCT02030990|ACTIVE_COMPARATOR|No mitomycin-C; 8 week FML steroid taper|No mitomycin-C will be administered during the procedure. Instead a sham application of salt solution will be given for 15 seconds. The patient will take 8 weeks of topical fluorometholone 1% topical steroid drop taper.
62772130|NCT00911573|EXPERIMENTAL|A|Tigecycline
62772131|NCT00911573|ACTIVE_COMPARATOR|B|Clindamycin (or Vancomycin if needed)
62772132|NCT00845065|PLACEBO_COMPARATOR|Arm 1 (Control Arm)|Peginterferon alfa-2a (180 μg/week subcutaneously \[SC\]) plus ribavirin (1000 to 1200 mg/day orally \[PO\]) for 4 weeks followed by placebo (800 mg three times a day \[TID\] PO, using placebo matching SCH 503034 200-mg capsules) + peginterferon alfa-2a 180 μg/week SC plus ribavirin 1000 to 1200 mg/day PO divided twice daily (BID) for 48 weeks with 24 weeks post-treatment follow-up.
62772133|NCT00845065|EXPERIMENTAL|Arm 2 (Boceprevir Arm)|"Peginterferon alfa-2a (180 μg/week subcutaneously \[SC\]) plus ribavirin (1000 to 1200 mg/day orally \[PO\]) for 4 weeks followed by boceprevir (800 mg three times a day \[TID\] PO, using SCH 503034 200-mg capsules) + peginterferon alfa-2a 180 μg/week SC plus ribavirin 1000 to 1200 mg/day PO divided twice daily (BID) for 48 weeks~with 24 weeks post-treatment follow-up."
62772134|NCT01283542|EXPERIMENTAL|Pasireotide LAR|All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks
62772135|NCT04029818|EXPERIMENTAL|Probiotic|Volunteers will take a capsule with Bifidobacterium BSL_PS404 (3x109 cfu) daily.
62563195|NCT01778855|ACTIVE_COMPARATOR|Normothermia|IV t-PA and normothermia
62563196|NCT01778855|ACTIVE_COMPARATOR|Hypothermia|IV t-PA and hypothermia
62563197|NCT03551990|NO_INTERVENTION|Control group; patients without a tumor disease, surgery|Control group with patients without a tumor disease but with indication for surgery in close proximity to the M. rectus abdominis
62563198|NCT03551990|NO_INTERVENTION|Control group; tumor patients, surgery|Control group with patients with solid tumors; patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
62772136|NCT04029818|PLACEBO_COMPARATOR|Placebo|Volunteers will take a capsule with maltodextrin daily.
62772137|NCT03135210|ACTIVE_COMPARATOR|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
62772138|NCT03135210|EXPERIMENTAL|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
62772139|NCT04816604|EXPERIMENTAL|GB002 (seralutinib)|GB002 (seralutinib) inhaled orally twice per day (BID)
62772140|NCT02297555|NO_INTERVENTION|Conventional medical therapy|Conventional medical therapy is defined as the use of the latest lifestyle guidelines to optimize weight loss and glycaemic management, frequent home monitoring/titration strategies, use of latest approved drug therapy for treatment of hyperglycaemia and restoration of pancreatic B cell function, also for dyslipidemia and hypertension in addition to regular follow-up visits to a medical doctor from a multidisciplinary team
62772141|NCT02297555|EXPERIMENTAL|ENDOBARRIER®|The interventional therapy will be the device ENDOBARRIER® over conventional medical therapy
62772142|NCT02652468|EXPERIMENTAL|Peripheral Blood Stem Cell Transplant|"PREPARATIVE REGIMEN: Participants receive fludarabine phosphate IV over approximately 30 minutes on days -5 to -2, and mesna IV over 24 hours and cyclophosphamide IV over approximately 2 hours on days -5 and -4. Participants also undergo total nodal irradiation on day -1.~TRANSPLANT: Participants undergo T-Cell Receptor (TCR) alpha-beta/CD19 depleted hematopoietic stem cell transplant on day 0. If the graft contains less than 4 x 10\^6 CD34+ cells/kg participant body weight (BW), patients may receive a second graft on day 1.~GVHD PROPHYLAXIS: Participants receive mycophenolate mofetil orally twice a day (PO BID) on days -1 to 30, tacrolimus PO or IV on days 2-180 with a taper beginning on day 90 (given only if graft TCR alpha-beta+ cell content is over 1 x 10\^5 cells/kg ideal BW of the patient), and rituximab IV on day 2 (given only if graft B cell content exceeds 1 x 10\^5 cells/kg ideal BW of the participant)."
62179685|NCT00258362|EXPERIMENTAL|Patients with Endometrial Cancer|Patients with advanced or current endometrial cancer receiving treatment with induction docetaxel/carboplatin, radiation (Weekly, 5 days/week over 6-7 weeks, tailored 4500 cGy) and followed by 3 courses of consolidation docetaxel (75 mg/m\^2 on Day 1 of each course) /carboplatin (Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles).
62179686|NCT04520581|NO_INTERVENTION|Control|Use in the shape of an endotracheal tube.
62179687|NCT04520581|EXPERIMENTAL|"Group O"|"Just before the induction of medicine is injected, the assistant makes endotracheal tube into O shape."
62179688|NCT04100239|EXPERIMENTAL|Intervention Arm|Open continuous recruitment of participants to trial where all participants begin the study as 'control participants' and at regular 'steps' participants are allocated to next available intervention group and cross from the control to the intervention condition, until all groups have completed the intervention.
62179689|NCT03240497|EXPERIMENTAL|Cold Exposure|A group of subjects (n=12) that will receive an extensive course in cold exposure similar in length to our previous study (total of 10 days) before the endotoxemia experiment.
62179690|NCT03240497|EXPERIMENTAL|Strength Ventilation|A group of subjects (n=12) that will be trained in the strength ventilation breathing technique before the endotoxemia experiment.
62179691|NCT03240497|EXPERIMENTAL|Cold Exposure and Strength Ventilation|A group of subjects (n=12) that will receive both the cold exposure course (same as the STV group) as well as the training in the strength ventilation breathing technique (same as the CEX group) before the endotoxemia experiment.
62179692|NCT03240497|NO_INTERVENTION|Control group|A group of subjects (n=12) that will receive no training and will not be exposed to cold before the endotoxemia experiment.
62179693|NCT00487552|EXPERIMENTAL|1|palliative treatment of gastric outlet obstruction
62179694|NCT02760693||bipolar patients|unselected admissions of bipolar patients
62179695|NCT01077011|EXPERIMENTAL|Lubricant eye drop|Lubricant eye drop
62179696|NCT01077011|ACTIVE_COMPARATOR|GenTeal Gel|GenTeal Gel
62179697|NCT02306083|PLACEBO_COMPARATOR|Administration of the Placebo|Placebo three times a day.
62772143|NCT02843139||Children group|Children recruiters were categorized into three groups: obesity, overweight and normal control based on World Health Organization child growth standards.
62179698|NCT02306083|PLACEBO_COMPARATOR|Administration of the glucosamine sulfate|glucosamine sulfate 1500 mg three times a day
62179699|NCT00460564|ACTIVE_COMPARATOR|High-Dose BTX|
62179700|NCT00460564|PLACEBO_COMPARATOR|High-Dose Placebo|
62772144|NCT02843139||Adults group|Adults with type 2 diabetes were defined if the individual had a fasting plasma glucose (FPG) level ≥ 7.0 mmol/L.
62179701|NCT00460564|ACTIVE_COMPARATOR|Low-Dose BTX|
62179702|NCT00460564|ACTIVE_COMPARATOR|Low-Dose Placebo|
62563199|NCT03551990|EXPERIMENTAL|Intervention group; tumor patients, WB-EMS, surgery|Intervention group with patients with solid tumors who do perform an 8-week physical training in form of whole-body electromyostimulation (WB-EMS); patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
62563200|NCT05699941|EXPERIMENTAL|treatment arm|"Ectoin® Containing Inhalation Solution (EIL07) (Class-IIa MDD legacy medical device).~Taken twice daily over the period of 3 weeks (treatment) Inhalation of the content of EIL07 single dose (2.5 mL) by using a mesh nebulizer device."
62563201|NCT01281397||Patients undergoing elective cardiac surgery|Patients undergoing elective cardiac surgery will be enrolled in study. Data about antiplatelet therapy ingestion prior to surgery will be included.
62179703|NCT05031468||Group 1: Individuals vaccinated during pregnancy|Individuals who receive a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccine during pregnancy (up to 200 individuals per vaccine type)
62179704|NCT05031468||Group 2: Individuals vaccinated postpartum|Individuals who receive a SARS-CoV-2 vaccine postpartum (up to 65 individuals per vaccine type)
62563202|NCT05482698|EXPERIMENTAL|MC2-25 cream|MC2-25 cream Twice daily applications for 12 weeks
62563203|NCT05482698|PLACEBO_COMPARATOR|MC2-25 vehicle|MC2-25 vehicle Twice daily applications for 12 weeks
62563204|NCT03726697|EXPERIMENTAL|Tahneek|Infants receiving a single dose of soft date, prepacked by the pharmacy containing glucose equivalent to 200mg/kg at 1 hour after birth in the nursery.
62563205|NCT03726697|NO_INTERVENTION|CONTROL|Infants at risk for transient neonatal hypoglycemia following standard-of-care.
62563206|NCT00249301|EXPERIMENTAL|1|MLN8054
62563207|NCT03898791|EXPERIMENTAL|LY3295668 Erbumine Cohort A|LY3295668 erbumine administered orally.
62563208|NCT03898791|EXPERIMENTAL|LY3295668 Erbumine Cohort B|LY3295668 erbumine administered orally.
62563209|NCT03898791|EXPERIMENTAL|LY3295668 Part JP|LY3295668 erbumine administered orally.
62563210|NCT00311948|ACTIVE_COMPARATOR|Telephone counseling + interactive website|Teen has access to interactive website and receives tailored telephone counseling
62563211|NCT00311948|OTHER|Control with interactive website|Teen only has access to interactive website.
62179705|NCT05031468||Group 3: Infants of individuals vaccinated during pregnancy|Infants of individuals who receive a SARS-CoV-2 vaccine during pregnancy (approximately 200 infants per vaccine type)
62179706|NCT05031468||Group 4: Infants of individuals vaccinated postpartum|Infants of individuals who receive a SARS-CoV-2 vaccine postpartum (approximately 65 infants per vaccine type)
62179707|NCT05031468||Group 5: Individuals receiving additional vaccines during pregnancy|Individuals who receive additional SARS-CoV-2 vaccine(s), beyond the primary series, during pregnancy (up to 200 individuals).
62182767|NCT03043482|EXPERIMENTAL|Single VS-105/placebo to healthy|Single ascending dose VS-105 or placebo to healthy subjects
62563212|NCT01159808|EXPERIMENTAL|INX-08189|
62563213|NCT01159808|PLACEBO_COMPARATOR|Placebo|
62563214|NCT01341288|EXPERIMENTAL|Implant|Robotic implantation of brachytherapy seeds to treat prostate cancer
62563215|NCT00489632||Questionnaire|Children with leukemia and their families/caregivers.
62563216|NCT02066844|ACTIVE_COMPARATOR|Standard Manual Needle Injection|2cc of Celestone and 5cc of Lidocaine will be administered by the nurse or surgeon
62563217|NCT02066844|EXPERIMENTAL|Navigator Injection|2cc of Celestone and 5cc of Lidocaine will be administered using the Navigator by the nurse or surgeon
62772145|NCT03024866||Electronic Brachytherapy|Previously completed treatment for non-melanoma skin cancer using Xoft eBx Electronic Brachytherapy System
62772146|NCT03024866||Mohs Surgery|Previously completed treatment for non-melanoma skin cancer using Mohs Surgery
62772147|NCT01932255||prophylactic spinal tap|Microvascular decompression surgery approach at the Karolinska University Hospital, i.e. a small craniectomy (removal of bone without putting it back), and postoperatively serial prophylactic lumbar tap
62772148|NCT01932255||no prophylactic spinal tap|Microvascular decompression surgery approach at St Olavs Hospital Trondheim University Hospital and the University Hospital of North Norway, i.e. not comprising a policy of preventing CSF leak by performing prophylactic lumbar taps or its equivalents
62772149|NCT02995798||Group A|T-score ≥-1
62772150|NCT02995798||Group B|-2.5\<T-score\<-1.0
62772151|NCT02995798||Group C|T-score≤-2.5
62179708|NCT05031468||Group 6: Infants of individuals receiving additional vaccines during pregnancy|Infants of individuals who received additional SARS-CoV-2 vaccine(s), beyond the primary series, during pregnancy (approximately 200 infants).
62179709|NCT02257918|EXPERIMENTAL|Group 1|N = 70 subjects receive single oral dose , 2000 mg of AZD0914
62179710|NCT02257918|EXPERIMENTAL|Group 2|N =70 subjects receive single oral dose , 3000 mg of AZD0914
62179711|NCT02257918|ACTIVE_COMPARATOR|Group 3|N = 40 subjects receive single intramuscular dose, 500 mg of ceftriaxone
62179712|NCT01524419||women after vaginal birth|
62179713|NCT01845649|ACTIVE_COMPARATOR|Vehicle (3 Times/Week)|Vehicle applied to the vagina daily for 14 days followed by dosing 3 times per week for 10 weeks.
62179714|NCT01845649|EXPERIMENTAL|WC3011 Estradiol Vaginal Cream (3 Times/Week)|WC3011 Estradiol vaginal cream applied daily for 14 days followed by dosing 3 times per week for 10 weeks.
62563218|NCT04700670||Group 1|patients with cardiac surgery with CBP. Blood samples in the operating room, 5 to 10 minutes after neutralization of heparin by protamine
62772152|NCT03303612|OTHER|EP-based approach/pacemaker implant|"Subjects will undergo an EP study prior to hospital discharge and will receive a pacemaker implantation if the HV interval is ≥65 msec.~In the case where the electrical slowdown is not confirmed by the electrophysiological study, the participant will not have a pacemaker implantation."
62772153|NCT03303612|OTHER|Compared transcutaneous cardiac monitor|Subjects will undergo a minimum of 72 hour ECG monitoring in hospital and receive transcutaneous monitoring prior to hospital discharge for a duration of 30 days.
62179715|NCT06509945|EXPERIMENTAL|intervention arm|Participants will receive allogeneic peripheral blood stem cell transplantation.
62179716|NCT03233347|EXPERIMENTAL|Treatment (combination chemotherapy, nivolumab)|Patients receive doxorubicin IV over 3-5 minutes, vinblastine IV over 3-5 minutes, and dacarbazine IV over \>= 30 minutes, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients with PET-positive then receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. PET-positive patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. PET-negative patients receive nivolumab IV over 30 minutes on day 1 starting after AVD and BV treatment. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity.
62772154|NCT02048371|ACTIVE_COMPARATOR|Cohort A: Liposarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
62179717|NCT03115671|EXPERIMENTAL|Intervention|Each child participant in the Intervention group will be taking 4 capsules of Vayarin per day for 3 months. Each capsule contains 167mg Lipirinen, providing 75mg Phosphatidylserine (PS), 21.5mg EPA and 8.5mg DHA. This gives a daily dosage of 300mg PS and 120mg EPA/DHA. They may continue their treatment as usual provided there is no change in medication and intervention during the trial.
62772155|NCT02048371|PLACEBO_COMPARATOR|Cohort A: Liposarcoma, Placebo|"21 days on and 7 days off~Placebo"
62179718|NCT03115671|NO_INTERVENTION|Control|Participants in the Control group will not be given Vayarin. They may continue their treatment as usual provided there is no change in medication and intervention during the trial.
62179719|NCT06483386|EXPERIMENTAL|Treatment group|"Pyrotinib Maleate Tablets: Continuously administered from day 1 of the first course of treatment, 400 Mg/day, orally administered within 30 minutes after breakfast Trastuzumab: Subcutaneous injection, 600mg, d1, q3w Capecitabine: oral, 1000 mg/m2~, bid d1-14,q3w Premenopausal goserelin 3.6mg once every 28 days"
62182768|NCT03043482|EXPERIMENTAL|Multiple VS-105/placebo to healthy|Multiple ascending dose VS-105 or placebo to healthy subjects
62563219|NCT04700670||Group 2|patients who had cardiac surgery with CBP, between day 1 and day 5 after surgery.
62563220|NCT04700670||Group 3|hospitalized patients in intensive care unit, including patients on extracorporeal life support (ECLS).
62563221|NCT04700670||Group 4|patients hospitalized in a medical non-intensive care ward.
62772156|NCT02048371|ACTIVE_COMPARATOR|Cohort B: Osteosarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
62772157|NCT02048371|PLACEBO_COMPARATOR|Cohort B: Osteosarcoma, placebo|"21 days on and 7 days off~Placebo"
62772158|NCT02048371|ACTIVE_COMPARATOR|Cohort C: Ewing sarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
62772159|NCT02048371|ACTIVE_COMPARATOR|Cohort D: Rhabdomyosarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
62772160|NCT02048371|ACTIVE_COMPARATOR|Cohort E: Mesenchymal Chondrosarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
62772161|NCT00994994|ACTIVE_COMPARATOR|Tranexamic acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit.
62772162|NCT00994994|PLACEBO_COMPARATOR|Placebo|same volume of normal saline was given.
62179720|NCT03121612|EXPERIMENTAL|Dolphin CPAP|CPAP machine with oxygen intake and an on-board air compressor, and integrated blender and humidifier, delivering heated humidified blended gases through a Fisher-Paykel nasal mask. \[Also includes built-in Massimo pulse oximeter, though this is not used for this study, to prevent differential measurement error in SpO2 measurement\]
62179721|NCT03121612|ACTIVE_COMPARATOR|Fisher-Paykel CPAP|Fisher-Paykel (F\&P) CPAP machine with separate oxygen and medical air intakes, with third-party FP-compliant blender, and F\&P blender, delivering heated humidified blended gases through a Fisher-Paykel nasal mask.
62563222|NCT04003883||Emergency physicians|Emergency physicians doing shifts at the Medical University of Vienna's emergency response car will recieve a thorough cardiac pretesting. During shifts they will be attached to a Holter-ECG to detect changes in ST-T Segment and other ECG changes. Furthermore surrogate parameters of stress will be measured
62563223|NCT00789048|NO_INTERVENTION|Surgeon doesn't see|The surgeon doesn't see the radiograph prior to surgery
62563224|NCT00789048|EXPERIMENTAL|Surgeon does see|The surgeon can see the radiograph prior to surgery
62563225|NCT02471729|EXPERIMENTAL|Renal Denervation|patients with chronique heart failure will undergo EnligHTN™ Renal Denervation System as a complementary treatment of their therapy
62772163|NCT06089902||adult > 30 years|All adult patient \> 30 yrs undergoing diagnosis (incidental or not) of anomalous aortic origin of coronary arteries
62179722|NCT04967586||Preclinical medical students|
62179723|NCT04967586||Clinical medical students|
62179724|NCT00700453|ACTIVE_COMPARATOR|Control 1 Group|Subjects randomized to the Control 1 group will abstain from playing any video games for the entire study participation.
62179725|NCT00700453|ACTIVE_COMPARATOR|VG1- Control 2 Group|Subjects randomized to the Control 2 group will play a selected violent video game for 60-120 minutes/day during week 2 of the study and will abstain from any video game play during week 3 of the study.
62179726|NCT00700453|ACTIVE_COMPARATOR|VG1- VG2 group|Subjects randomized for VG1-VG2 group will play 60-120 minutes/day of a violent video game during weeks 2 \& 3 of study participation.
62179727|NCT00700453|ACTIVE_COMPARATOR|VG1-CT group|Subjects randomized to the VG1-CT group will play 60-120 minutes of a selected violent video game during week 2 of the study and play a selected computerized cognitive training program for 60-120 minutes/day during week 3 of the study.
62179728|NCT01410084|EXPERIMENTAL|Vitamin D3|100,000 IU vitamin D3 once monthly
62179729|NCT01410084|PLACEBO_COMPARATOR|Vitamin E|400 IU vitamin E once monthly
62179730|NCT06176053|EXPERIMENTAL|Regular statict stretching for six weeks|Twelve patients aged 18-65, diagnosed with fibromyalgia, will be recruited to participate in a six-week, supervised, home-based stretching program. Exercises are to be performed daily (6 minutes per day) for six weeks. Adherence will be supported, and weekly contact with each participant will be maintained via a mHealth application.
62179731|NCT05685953|EXPERIMENTAL|Active vaccine|Plasmid DNA vaccine, OC-007
62179732|NCT05685953|PLACEBO_COMPARATOR|Placebo|Sodium chloride solution (0.9 %)
62563226|NCT04069273|EXPERIMENTAL|Arm A|Pembrolizumab will be administered every 3 weeks in combination with ramucirumab + paclitaxel. The paclitaxel schedule differs between the 2 arms.
62563227|NCT04069273|EXPERIMENTAL|Arm B|Pembrolizumab will be administered every 3 weeks in combination with ramucirumab + paclitaxel. The paclitaxel schedule differs between the 2 arms.
62563228|NCT03885661|EXPERIMENTAL|Icosapent ethyl|Icosapent ethyl with a total daily dose of 4 grams, as 2 x 1 gram capsules by mouth twice daily, against a statin background
62563229|NCT03885661|NO_INTERVENTION|Usual Care|Statin background
62563230|NCT04383561|ACTIVE_COMPARATOR|stage 3 periodontitis|GCF and serum samples were collected before and after treatment from periodontitis patients.
62563231|NCT04383561|PLACEBO_COMPARATOR|Periodontally healthy controls|GCF and serum samples were collected from periodontally healthy controls at baseline for once.
62563232|NCT01857908||Abiraterone acetate|All patients will be receiving abiraterone acetate as per standard of care
62563233|NCT00571324|EXPERIMENTAL|Exendin-(9-39) first, the Vehicle|Exendin-(9-39) will be administered intravenously (IV) after an overnight fast. Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. The following day, after another overnight fast, normal saline (control) vehicle infusion will be administered intravenously (IV) over 6 hours. During both infusions, blood glucose levels will be measured every 20 minutes.
62772164|NCT06089902||Juvenile < 30 yrs|All young patient \<30 yrs undergoing diagnosis (incidental or not) of anomalous aortic origin of coronary arteries
62772165|NCT01524081|EXPERIMENTAL|APPE - antibiotic prophylaxis|Patients indicated for emergent appendectomy with antibiotic prophylaxis
62179733|NCT05183243|EXPERIMENTAL|Monotherapy Dose Escalation.|Treatment with GH21 alone, conducted until disease progression, intolerance or end of study.
62179734|NCT05725733|EXPERIMENTAL|children with ASD group.|ASD groups will be randomly divided into 4 subgroups according to their age (4-7 years old, 7-10 years old, 10-13 years old and, 14-18 years old). Also, ASD group will be categorized according to the symptoms severity using the childhood autism rating scale (CARS).
62179735|NCT05725733|ACTIVE_COMPARATOR|One hundred typically developed children or control group|They will be randomly divided into 4 subgroups according to their age (4-7 years old, 7-10 years old, 10-13 years old and, 14-18 years old)
62182769|NCT03043482|EXPERIMENTAL|Multiple VS-105/placebo to HD subjects|Multiple ascending dose VS-105 or placebo to hemodialysis (HD) subjects
62182770|NCT01675310|EXPERIMENTAL|medical nutrition therapy + metformin|medical nutrition therapy plus trans-gestational metformin (850mg 2 times day)
62772166|NCT01524081|EXPERIMENTAL|GERD - antibiotic prophylaxis|Patients indicated for emergent surgery due to gastroduodenal perforation with antibiotic prophylaxis.
62772167|NCT01524081|EXPERIMENTAL|ILEUS - antibiotic prophylaxis|Patients indicated for emergent due to small bowel obstruction with antibiotic prophylaxis
62563234|NCT00571324|PLACEBO_COMPARATOR|Vehicle first, then Exendin-(9-39)|Normal saline vehicle infusion will be administered intravenously (IV) after an overnight fast. The infusion will be given over 6 hours. The following day, after another overnight fast, Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. During both infusions, blood glucose levels will be measured every 20 minutes.
62179736|NCT00618917|EXPERIMENTAL|Radiation + MnSOD PL + Paclitaxel + Carboplatin|MnSOD PL (0.3, 3, or 30 mg) + (Paclitaxel + Carboplatin (45mg/m\^2)) + Radiation 1.9-2.1 Gy daily 5 times per week (4-6 hr after the first MnSOD PL dose). The total dose planned at 77.0 Gy with a range of 69-84Gy in 34-38 fractions over 7-8 weeks.
62563235|NCT05845424|EXPERIMENTAL|Aggressive treatment arm|In this group, high-intensity statin (rosuvastatin 20mg) combined with ezetimibe 10 mg will be prescribed regardless of patients' age, concomitant diabetes mellitus, or ASCVD risk.
62563236|NCT05845424|ACTIVE_COMPARATOR|Standard treatment arm|In this group, lipid lowering therapy will be followed according to the current guideline recommendation. A moderate-intensity statin (rosuvastatin 5 mg) will be prescribed for patients over 75 years of age or with diabetes mellitus. For non-diabetic patients aged 40-75 years, the use of statins will be determined by calculating the ASCVD risk score. (ASCVD risk \<7.5%: no statin use, ≥7.5 - \<20%: moderate-intensity statin \[rosuvastatin 5mg\], ≥ 20%: high-intensity statin \[rosuvastatin 20mg\])
62563237|NCT04207606||Epidural Steroid Injection Patients|Patients who are to receive an epidural steroid injection as an outpatient.
62563238|NCT01050829|EXPERIMENTAL|Arm 1|
62563239|NCT01050829|ACTIVE_COMPARATOR|Arm 2|
62563240|NCT03518008|OTHER|DD T2, then Clariti 1 Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable modality.
62563241|NCT03518008|OTHER|Clariti 1 Day, then DD T2|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second. Each product worn bilaterally for 1 week in a daily disposable modality.
62563242|NCT05630885|EXPERIMENTAL|CVC arm (Arm A)|Participants with pre-existing ART regimen of EFV will take CVC 300 mg. Participants with all other pre-existing ARTs will take CVC 150 mg.
62179737|NCT02185365||Developmental dysplasia of the hip (DDH)|Patients will complete 2 magnetic resonance imaging (MRI): T1-rho and dGEMRIC. The T1-rho MRI does not require the injection of a contrast agent, while the dGEMRIC MRI requires a gadolinium injection to visualize cartilage in the hip.
62563243|NCT05630885|PLACEBO_COMPARATOR|Placebo for CVC arm (Arm B)|Participants with pre-existing ART regimen of EFV will take placebo for CVC 300 mg. Participants with all other pre-existing ARTs will take placebo for CVC 150 mg.
62563244|NCT05343780|PLACEBO_COMPARATOR|Placebo|Placebo (Rice bran) in 2 capsules size 1, administered PO TID on empty stomach with plenty of water.
62179738|NCT02585141|EXPERIMENTAL|aspiration|Aspiration of perianal abscess(MEDIPLAST® 13 G, 2,5 x 110 mm) under general anesthesia followed by antibiotic treatment with Clindamycin tablet 300 mg 3 times daily for 7 days
62563245|NCT05343780|EXPERIMENTAL|Heptex-low dose|Low dose The contents of one capsule of Heptex is equally distributed and inserted into 2 capsules size 1, administered PO TID on empty stomach with plenty of water.
62179739|NCT02585141|ACTIVE_COMPARATOR|incision|Surgical incision of perianal abscess under general anesthesia.
62179740|NCT00264498|ACTIVE_COMPARATOR|1|Gemcitabine + Carboplatin
62179741|NCT00264498|EXPERIMENTAL|2|Gefitinib
62182771|NCT01675310|ACTIVE_COMPARATOR|medical nutrition therapy|medical nutrition therapy without trans-gestational metformin
62182772|NCT05845840|EXPERIMENTAL|BRII-297|Participants will receive a BRII-297 by Intramuscular injection
62563246|NCT05343780|EXPERIMENTAL|Heptex-high dose|High dose The contents of two capsule of Heptex is equally distributed and inserted into 2 capsules size 1, administered PO TID on empty stomach with plenty of water.
62772168|NCT01524081|PLACEBO_COMPARATOR|APPE - placebo|Patients indicated for emergent appendectomy without antibiotic prophylaxis. Placebo (saline) was administrated.
62182773|NCT05845840|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo by Intramuscular injection
62563247|NCT05045391||pulmonary tuberculosis (smear-positive) patients|Patients with pulmonary tuberculosis (smear-positive). Diagnosis of chronic pulmonary aspergillosis among patients with pulmonary tuberculosis (smear-positive)
62179742|NCT01797562|EXPERIMENTAL|Positive Response Rates: 7 new and 4 reformulated allergens|Subjects will be patched with TRUE Test Panels 1.3, 2,2 and 3.2. Panel 1 allergens nickel sulfate (0.60 mg/cm2), potassium dichromate (0.054 mg/cm2), fragrance mix (0.050 mg/cm2) and ethylenediamine dihydrochloride (0.050 mg/cm2), Panel 2 allergen Methyldibromoglutaronitrile (0.0053 mg/cm2) and Panel 3 allergens Gold sodium thiosulfate (0.075 mg/cm2), Hydrocortisone-17-butyrate (0.020 mg/cm2), Bacitracin (0.60 mg/cm2), Parthenolide (0.0030 mg/cm2), Disperse blue 106 (0.050 mg/cm2 in PVP), 2-Bromo-2-nitropropane-1,3-diol (Bronopol) (0.25 mg/cm2) will be evaluated
62179743|NCT04876768|EXPERIMENTAL|Use of 80% oxygen(high oxygen fraction) during ERCP|Anesthetist will open the envelope of randomly assigned groups which will assign patients to 80% FIO2(supplemental perioperative high oxygen fraction). 80% FIO2 will be maintained during the ERCP procedure. Maintaining oxygen saturation of \> 92% through administration of oxygen via nasal cannula, mask or ventilator will be per anesthetist discretion. Additional supplemental oxygen will be given to patients at any time, as necessary, to maintain oxygen saturation as measured by pulse oximeter \> 92%.
62179744|NCT04876768|ACTIVE_COMPARATOR|Use of 30% oxygen(normal oxygen fraction) during ERCP|Anesthetist will open the envelope of randomly assigned groups which will assign patients to 30% FIO2 (normal oxygen fraction). 30% FIO2 will be maintained during the ERCP procedure. Maintaining oxygen saturation of \> 92% through administration of oxygen via nasal cannula, mask or ventilator will be per anesthetist discretion. Additional supplemental oxygen will be given to patients at any time, as necessary, to maintain oxygen saturation as measured by pulse oximeter \> 92%.
62179745|NCT05132530|EXPERIMENTAL|Intervention Gruop|"Experimental: İntervention Group~Yoga practice will be practiced 2 days a week for 10 weeks."
62179746|NCT05132530|NO_INTERVENTION|Control Group|no intervention
62179747|NCT05841056|ACTIVE_COMPARATOR|Amiodarone maintenance therapy|Amiodarone 200 mg daily for four weeks
62179748|NCT05841056|NO_INTERVENTION|No Amiodarone maintenance therapy|No ongoing Amiodarone maintenance therapy for four weeks
62179749|NCT00420147|EXPERIMENTAL|Wedged Orthosis|Subjects were given a wedged inshoe orthosis
62179750|NCT00420147|PLACEBO_COMPARATOR|Neutral Orthosis|Subjects were given a neutral inshoe orthosis.
62179751|NCT02470299|EXPERIMENTAL|Ketorolac|Once deemed stable in the first 1-3 post-operative days, patients will be receive age-based ketorolac (30 mg \<65, 15mg \> 65) daily for three days
62391183|NCT01822782||Controls|"The study population consists of all consecutive women meeting inclusion/exclusion criteria and delivering at the Nîmes University Hospital, France during an inclusion period of 6 months. Controls are classified as those without a vaginal lesion due to delivery."
62563248|NCT05045391||pulmonary tuberculosis (smear-negative) patients|Patients with pulmonary tuberculosis (smear-positive). Diagnosis of chronic pulmonary aspergillosis among patients with pulmonary tuberculosis (smear-negative)
62563249|NCT05219760|ACTIVE_COMPARATOR|LIVIA 1|LIVIA 1 is a 12-week intervention composed of 10 sessions, whereby we recommend completing one session per week. It includes psychoeducational content and exercises that are based on empirically validated intervention tools, mainly issued from Cognitive-Behavioral Therapy.
62772169|NCT01524081|PLACEBO_COMPARATOR|GERD - placebo|Patients indicated for emergent surgery due to gastroduodenal perforation without antibiotic prophylaxis. Placebo (saline) was administrated.
62179752|NCT02470299|PLACEBO_COMPARATOR|Placebo|Once deemed stable in the first 1-3 post-operative days, patients will be receive placebo daily for three days
62179753|NCT04515628|EXPERIMENTAL|Period A: Rosuvastatin|
62179754|NCT04515628|EXPERIMENTAL|Period B: Branebrutinib|
62179755|NCT04515628|EXPERIMENTAL|Period C: Branebrutinib + Rosuvastatin and Branebrutinib|
62179756|NCT04515628|EXPERIMENTAL|Period D: Branebrutinib|
62179757|NCT04703257|PLACEBO_COMPARATOR|Control group|Patients in the control group will be instructed to take a placebo tablet three times a day for four days and patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
62179758|NCT04703257|ACTIVE_COMPARATOR|Intervention group|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
62179759|NCT01839383|ACTIVE_COMPARATOR|DCa1.25|using dialysate calcium concentration 1.25 mmol/L(DCa1.25)
62391184|NCT05964933|ACTIVE_COMPARATOR|Complete Pulpotomy|The tooth will be treated with Complete Pulpotomy.
62772170|NCT01524081|PLACEBO_COMPARATOR|ILEUS - placebo|Patients indicated for emergent due to small bowel obstruction without antibiotic prophylaxis. Placebo (saline) was administrated.
62772171|NCT03774342||CABG-patients|We will study one group of patients all scheduled for a Coronary Artery Bypass Grafting-procedure. This observational study consists of one group.
62772172|NCT00544284|EXPERIMENTAL|Treatment (temozolomide, bortezomib)|GROUP A: Patients receive oral temozolomide once a day on days 1-5 and bortezomib IV on days 2, 5, 9, and 12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. GROUP B: Patients receive temozolomide and bortezomib as in group A. Cohorts of patients in both groups receive escalating doses of both study drugs until the maximum tolerated doses are determined. All patients undergo blood sample collection periodically for pharmacokinetic studies. Samples are analyzed for bortezomib concentration (groups A and B) and trough levels of anticonvulsants (group A only).
62772173|NCT04320108|EXPERIMENTAL|Experimental group|3,000 pulses per time, low energy under 0.3 mJ/mm\^2, tolerable range
62772174|NCT04320108|SHAM_COMPARATOR|Control group|Sham therapy
62179760|NCT01839383|ACTIVE_COMPARATOR|DCa1.5|using dialysate calcium concentration 1.5mmol/L
62179761|NCT01839383|ACTIVE_COMPARATOR|DCa1.75|using dialysate calcium concentration 1.75mmol/L
62179762|NCT02381652|EXPERIMENTAL|Cingal/Cingal|Subjects who had received an injection of Cingal in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
62179763|NCT02381652|EXPERIMENTAL|Cingal/Monovisc|Subjects who had received an injection of Monovisc in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
62179764|NCT02381652|EXPERIMENTAL|Cingal/Saline|Subjects who had received an injection of Saline in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
62179765|NCT04938739|EXPERIMENTAL|Cognitive Behavioral therapy|to modify any erroneous beliefs about pain and disability and to promote coping strategies and self-efficacy through a graded activity.
62179766|NCT04938739|ACTIVE_COMPARATOR|Home program exercises|Patients in both groups carried out exercise therapy for six weeks. There will be an educational session for each patient to make sure the exercises will be done successfully and supervision once per week.
62179767|NCT02568878|EXPERIMENTAL|Creatine monohydrate|5 grams of daily creatine monohydrate by mouth for 8 weeks
62772175|NCT06507800||MATHEC cohort|French national registry of patients treated by Autologous haematopoietic stem cell transplantation (AHSCT) for their autoimmune disease
62772176|NCT06507800||Ottawa cohort|Patients treated by AHSCT for their autoimmune disease and followed in Ottawa Hospital
62772177|NCT06507800||Calgary cohort|Patients treated by AHSCT for their autoimmune disease and followed in Calgary Hospital
62179768|NCT04174222|ACTIVE_COMPARATOR|Moderate block|5-10mg rocuronium is administered to maintain train-of-four count 1-2. At the end of surgery, sugammadex 2mg/kg is administered IV for reversal of neuromuscular block.
62179769|NCT04174222|EXPERIMENTAL|Deep block|5-10mg rocuronium is administered to maintain train-of-four count 0, and post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
62179770|NCT00579748||1|
62179771|NCT05844865|OTHER|Subjects with Gastrointestinal Primary Tumor with or without Peritoneal Carcinomatosis|Subjects with gastrointestinal (GI) primary tumor with or without peritoneal carcinomatosis who are undergoing planned standard of care (SOC) surgical procedures. Biospecimens such as blood, peritoneal wash fluid and tumor samples will be obtained.
62179772|NCT00791297|ACTIVE_COMPARATOR|1|Contraceptive Vaginal Ring delivering a daily dose of 1500 μg of CDB-2914
62179773|NCT00791297|ACTIVE_COMPARATOR|2|Contraceptive Vaginal Ring delivering a daily dose of 2500 μg of CDB-2914
62182774|NCT02302703|ACTIVE_COMPARATOR|the low FODMAP diet|
62182775|NCT02302703|ACTIVE_COMPARATOR|Gluten free diet|
62772178|NCT05648682|EXPERIMENTAL|Saline|The patients in the group gargling with saline were given in a 500 ml bottle at each visit for one week of use. Patients were told that they should gargle using approximately two tablespoons of the solution given for each usage.
62772179|NCT05648682|EXPERIMENTAL|Sodium Bicarbonate|The sodium bicarbonate solution prepared by the researcher by mixing one teaspoon of baking soda (4.5 grams) into 500 ml of distilled water by the researcher was given to the patients in the group gargling with sodium bicarbonate for a one-week use at each interview. Patients were told that they should gargle using approximately two tablespoons of the solution given for each usage.
62563250|NCT05219760|EXPERIMENTAL|LIVIA 2.0|LIVIA 2.0 is a 12-week intervention composed of 10 sessions, whereby we recommend completing one session per week. It includes psychoeducational content and exercises that are based on empirically validated intervention tools, mainly issued from Cognitive-Behavioral Therapy but also from positive psychology and cognitive psychopathology frame.
62563251|NCT01904695|EXPERIMENTAL|Antihypertensive drugs & Herbs|Thiazide diuretics and ACE inhibitor and β-blocker \& Herbs for 8 weeks
62563252|NCT01904695|ACTIVE_COMPARATOR|Antihypertensive drugs|Thiazide diuretics and ACE inhibitor and β-blocker for 8 weeks
62563253|NCT02462798|PLACEBO_COMPARATOR|Whole grain rye bread|Whole grain rye bread, 200 g/d. Control intervention.
62563254|NCT02462798|EXPERIMENTAL|Whole grain sourdough rye bread|Whole grain rye bread, 200 g/d. Experimental intervention.
62563255|NCT05862623|EXPERIMENTAL|AER-01|Specified dose on specified days
62563256|NCT05862623|PLACEBO_COMPARATOR|Placebo|Specified dose on specified days
62563257|NCT04902027|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection|Subjects with Rrecurrent/metastatic Head and Neck Cancers will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles
62563258|NCT00751699|EXPERIMENTAL|1|Asacol 6x400 mg Q24h at 7 am for 7 days
62563259|NCT00751699|EXPERIMENTAL|2|Asacol 2x400 mg Q8h at 7 am, 3 pm, and 11 pm for 7 days
62563260|NCT00751699|EXPERIMENTAL|3|Lialda 2x1.2g Q24h at 7 am for 7 days
62563261|NCT04454255|EXPERIMENTAL|Primo-FunSpeech|Participants will begin the study by a period using FunSpeech (45 days) followed by a control period without the game (45 days). This sequence will be repeated once.
62563262|NCT04454255|EXPERIMENTAL|Primo-control|Participants will begin the study by a control period without the game (45 days) followed by a period using FunSpeech (45 days). This sequence will be repeated once.
62563263|NCT02675036|EXPERIMENTAL|Primary canine tooth|Extraction of primary canine tooth
62563264|NCT02675036|EXPERIMENTAL|Primary canine and primary molar teeth|Extraction of primary canine and primary first molar teeth
62772180|NCT05648682|EXPERIMENTAL|Thyme Honey|20 ml of honey was diluted in 100 ml distilled water bottles by the researcher to the patients in the group gargling with thyme honey. For a week's use, the patient was given five honey solutions in 100 ml bottles at one time at each visit. Patients were told that they should gargle using approximately two tablespoons of the solution given for each use.
62772181|NCT05648682|EXPERIMENTAL|Control|No solution was given to the patients in the control group by the researcher.
62772182|NCT05986617|EXPERIMENTAL|Wearable Device Group|Will be given InBody Band 2 to use while trying to achieve weight loss goal prior to total joint arthroplasty.
62772183|NCT05986617|NO_INTERVENTION|Control Group|Will not be given InBody Band 2 to use while trying to achieve weight loss goal prior to total joint arthroplasty.
62772184|NCT02153814|SHAM_COMPARATOR|Control|Will undergo sham procedure twice
61995124|NCT06200675|EXPERIMENTAL|Logic-based intervention|Participants assigned to this intervention will be asked to engage in one brief (10-15 minute) online logic-based exercise that was adapted from a thought record (Greenberger \& Padesky, 1995), which is often completed during cognitive behavioural therapy (CBT) treatment. Participants will be asked to reread what they wrote about their feelings of shame and chose a thought central to their shame to use for this exercise. Participants will be asked to generate evidence for and against their chosen thought, and then generate a more balanced thought. After the exercise, participants will be asked to reread their newly generated more balanced thought.
62182776|NCT05046093|EXPERIMENTAL|Single intervention arm - transbronchial cryobiopsy|Patients enrolled in this single arm will have lung nodules biopsied by transbronchial cryobiopsy.
62563265|NCT06405984|EXPERIMENTAL|Laboring Women|Women in labor who have consented to participation in the study.
62563266|NCT03454334|ACTIVE_COMPARATOR|AMO Tecnis Symfony|"Multifocal with extended range of vision, Diffractive, No Preloaded, Aspheric, +3.25 D near add and +2.17 D intermediate 6.0mm Hydrophilic~-0.20~Has nine diffractive steps, The proprietary achromatic technology corrects chromatic aberration. This creates improved contrast sensitivity."
62563267|NCT03454334|ACTIVE_COMPARATOR|AcrySof ReSTOR (Alcon Laboratories)|"Multifocal ,Diffractive, +3.00D and for Near, Aspheric, Has 9 steps (rings), Light: 41% for far; 41% for near: 18% reflected (lost).~6.0mm Silicone~-0.10 Bifocal ,One piece,Blue filter ,Central diffractive region of 3.6_mm for near and distance vision ,Apodised ,peripheral refractive region is dedicated to distance vision"
62563268|NCT03454334|ACTIVE_COMPARATOR|AT Lisa tri (CarlZeiss Meditec AG)|Trifocal, diffractive, +3.33 D near add and +1.66 D intermediate add at the IOL plane, aspheric (aberration correcting) Optic Diameter 6.0 mm Total Diameter 11.0 mm Haptic Angulation 0° Lens Design Single-piece, MICS Incision Size 1.8 mm Company Labeled A-Constant1 118.6 Diopter Range 0.0 to +32.0 D, 0.5 D increments ACD 5.32
62563269|NCT03454334|ACTIVE_COMPARATOR|PanOptix(Alcon Laboratories)|"Trifocal,Difractive,+3.25D Near,+2.17 D intermediate 6.0mm hydrophobic~-0.27 One piece ,aspheric , Focal 4.5 mm (15 diffractive zones)"
62563270|NCT04079218|EXPERIMENTAL|Estradiol Vaginal Insert|Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
62563271|NCT04079218|NO_INTERVENTION|No treatment|No intervention
62563272|NCT02088177|EXPERIMENTAL|Long-acting injectable naltrexone|Two doses of long-acting injectable naltrexone, 380 mg by intramuscular injection in the gluteal muscle at study day 1 and again between study days 28-30.
62563273|NCT05708248|EXPERIMENTAL|Group I|
62563274|NCT05708248|NO_INTERVENTION|Group II|
62563275|NCT02265393|ACTIVE_COMPARATOR|OTO-104|12 mg OTO-104 (dexamethasone)
62563276|NCT02265393|PLACEBO_COMPARATOR|Placebo|OTO-104 vehicle
62772185|NCT02153814|EXPERIMENTAL|One Endometrial Scratch Procedure|Will undergo one sham procedure and one endometrial scratch procedure
62772186|NCT02153814|EXPERIMENTAL|Two Endometrial Scratch Procedures|Will undergo endometrial scratch procedure twice
62772187|NCT03464916|EXPERIMENTAL|CAR2 Anti-CD38 A2 CAR-T Cells|Relapsed or Refractory Multiple Myeloma
62772188|NCT02090361|EXPERIMENTAL|skin graft with dermal matrix|Epidermization of the defect by applying a thin layer of autologous epidermis with addition of a dermal matrix
62772189|NCT02090361|PLACEBO_COMPARATOR|skin graft - classic procedure|Epidermization of the defect by applying a thin layer of autologous epidermis
62179774|NCT03020056|PLACEBO_COMPARATOR|waiting surgery|Cataract surgery will be performed at 1 year after enrollment.These participants will be provided with Phacolin eye drops(Zhongshan ophthalmic center, China).
62179775|NCT03020056|EXPERIMENTAL|expedited surgery|Cataract surgery will be performed within 4 weeks.
62563277|NCT04333160|EXPERIMENTAL|JTA-004|single knee intra-articular injection of JTA-004 solution (2ml)
62563278|NCT04333160|PLACEBO_COMPARATOR|placebo|single knee intra-articular injection of saline solution (2ml)
62563279|NCT04333160|ACTIVE_COMPARATOR|Hylan G-F 20|single knee intra-articular injection of Hylan G-F 20 (6ml)
62179776|NCT03401723|OTHER|Novices|"Any physician who has no experience of endoscopies or has done no more than 50 colonoscopies.~Each subject included are to perform on the Endoscopy Training System (ETS) during which data for 3D-Colonoscopy Progression Score and 3D-Colonoscopy Retraction Score is gathered."
62179777|NCT03401723|OTHER|Experienced|"Includes any physician who have succeeded more than 140 colonoscopies. Professional backgrounds include surgeons and gastroenterologists.~Each subject included are to perform on the ETS during which data for 3D-Colonoscopy Progression Score and 3D-Colonoscopy Retraction Score is gathered."
62563280|NCT01332344||Asthma patients treated with inhaled corticosteroids|Asthma subjects newly prescribed inhaled corticosteriods
62563281|NCT01480323|EXPERIMENTAL|Ipilimumab|Ipilimumab i.v. + Interleukin-2 intratumoral
62563282|NCT05382208|EXPERIMENTAL|Doxycycline|Doxycycline 100mg orally twice a day
62179778|NCT05764590|EXPERIMENTAL|AP-306|
62179779|NCT05764590|ACTIVE_COMPARATOR|Sevelamer Carbonate|
62179780|NCT04269434|NO_INTERVENTION|Screening|In the screening arm, Ng/Ct results will be sent by the STI Laboratory to the study physicians and these participants will be treated and partner contact tracing will be done.
62179781|NCT04269434|OTHER|No screening|In the no screening arm, the STI Laboratory will only process the samples/report the results from the non-screening arm at the end of the study.
62179782|NCT01667172|OTHER|point-of-care test for CRP|
62179783|NCT02622711|EXPERIMENTAL|DI Dietary Intervention|Individualized dietary counselling to reduce body weight
62563283|NCT05382208|PLACEBO_COMPARATOR|Placebo|Matching placebo orally twice a day
62563284|NCT01626001|EXPERIMENTAL|Cohort 1|Cohort of 18 subjects evaluated. Subject will receive 4DCT cine acquisition gated using a respiratory signal from real-time position management (RPM) gating system. Maximum number of allowable images that may be acquired increased from 3000 to 5999 images. Total imaging time for each subject \< 60 minutes.
62563285|NCT01626001|EXPERIMENTAL|Cohort 2|Reproducibility of optimal 4DCT acquisition method determined from cohort 1 tested with cohort of 18 study subjects. Three 4DCT images acquired, all with acquisition method determined from cohort 1. Cohort also receives two spiral-mode 4DCT acquisitions.
62563286|NCT02406690||Case Group|Patients who failed to achieve adequate endometrial lining during a synthetic embryo transfer. This group will undergo a Leuprolide prep cycle using estradiol valerate, progesterone in oil and subsequently undergo an endometrial biopsy and uterine aspiration.
62563287|NCT02406690||Control Group|Patients who have achieved an adequate endometrial lining. This group will undergo a Leuprolide prep cycle using estradiol valerate, progesterone in oil and subsequently undergo an endometrial biopsy and uterine aspiration.
62179784|NCT02622711|EXPERIMENTAL|PAI Physical Activity Intervention|Individualized physical activity counseling to reduce body weight
62179785|NCT02622711|EXPERIMENTAL|PADI Physical Activity+Diet Intervention|Individualized dietary and physical activity counseling to reduce body weight
62179786|NCT02622711|EXPERIMENTAL|LII Less Intensive Intervention|Materials and guidelines available to general public
62563288|NCT02685228|EXPERIMENTAL|decitabine & gemcitabine|"This group was treated by low dose decitabine combinated with gemcitabine regimen. decitabine: 5mg/m2 d1-d5; gemcitabine: 1.0g/m2,d8,d15,d22. 28days for one cycle.~every 28days for one cycle"
62563289|NCT02685228|ACTIVE_COMPARATOR|gemcitabine|This group was treated by gemcitabine only. Gemcitabine: 1.0g/m2, d8,d15,d22; 28 days for one cycle. every 28days for one cycle
62772190|NCT00290498|EXPERIMENTAL|Arm A|R-HCVAD + R-MTX/Ara-C ((Rituximab-HCVAD (rituximab, doxorubicin, cyclophosphamide, vincristine, and dexamethasone) alternating with Rituximab-Methotrexate-Cytarabine))
62772191|NCT00290498|ACTIVE_COMPARATOR|Arm B|"R-CHOP ((Rituximab-CHOP (Rituximab, cyclophosphamide, vincristine, and prednisone))~No longer recruiting for this study arm."
62772192|NCT00084656|EXPERIMENTAL|Arm 1|
62772193|NCT03395002|EXPERIMENTAL|Tiotropium/Salmeterol/Fluticasone|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Discair®
62772194|NCT03395002|ACTIVE_COMPARATOR|Tiotropium + Salmeterol/Fluticasone|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler® + Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus®
61995125|NCT06200675|ACTIVE_COMPARATOR|Placebo control condition|"Participants assigned to this condition will be asked to listen to a portion of an audio recording of The Hobbit (Tolkien, 2009) and then re-read what they wrote about their feelings of shame. They will then be asked to write a reflection about the thoughts and feelings arising from doing so. They will then be asked to re-read what they wrote in this reflection."
61995126|NCT04832464|ACTIVE_COMPARATOR|Balance Training Home plan|"The Control group is undergoing balance training only, 3 days a week, and will be for 8 weeks. Balance training includes 10minutes of warm-up and 30 minutes of balance exercises. A force plate will be used to measure the postural sways. Measurements will be taken at a base-line, after the first session, at mid-level (4th week) and at the end (8th week).~These exercises include Static Balance exercises(1-2weeks): Romberg with eyes open \& close, Tandem standing with eyes open \& close with alternate feet, Single leg stance.~Static/ Dynamic/ Anticipatory Postural Control (3-4weeks): Sit to Stand, FRT( forward reach test) that is forward, sideways, cross reach, and timed up and go test.~Static/ Dynamic/ Anticipatory? Reactive Postural Control (5-6weeks): Perturbations:~Controlled by the therapist in sitting \& standing, Throwing a ball, kicking a ball.~(7-8weeks): Combination of All"
61995127|NCT04832464|EXPERIMENTAL|BRACE Protocol: Balance training along with resistance, aerobic and cognitive excercises|"BRACE protocol for balance training 3 days a week for 8 consecutive weeks on alternate days.~These exercises include Static Balance exercises(1-2weeks) plus Chair rise 30 sec without using hands, 6-minute walk, count reverse from 50, push the wall, and reverse count from 20.~Static, dynamic, anticipatory postural control (3-4weeks) plus Stair climbing without using rails, marching in space, remember 5 words, name 5 animals, repeat 5 words, spell the word like APPLE, spell backward again.~Static, dynamic, anticipatory postural control (5-6weeks) plus Squatting, cycling, count even numbers from 1-50.~calculation: Addition, subtraction, multiplication, division. (7-8weeks): Combination of all."
61995128|NCT02592746|EXPERIMENTAL|Palbociclib + Exemestane + GnRH agonist|
61995129|NCT02592746|ACTIVE_COMPARATOR|Capecitabine|
62179787|NCT05864885|EXPERIMENTAL|Primary safety and pharmacokinetic data|To obtain primary safety and pharmacokinetic data on the ANR- 001.1 when applied topically, once daily, for 7 days to the scalp
62179788|NCT01249677|EXPERIMENTAL|insulin glargine|patients with type 2 diabetes on previous therapy with metformin were examined before and after eight weeks of treatment with insulin glargin, aimed to normalize fasting plasma glycaemia
62179789|NCT05139823|NO_INTERVENTION|Control|Controls receive usual care, which is a digital communication to the local home care team including a discharge care plan to the home care system, including information about the discharge diagnoses, and recommendations for particular attention to specific bodily functions and medical treatment regime. The patient's PCP receives a discharge summary from the treating hospital physician as usual.
62179790|NCT05139823|EXPERIMENTAL|Intervention|An appointment for a geriatric follow-up home visit is made with the patient and the municipal home care (community) nurse 2-5 days after discharge and only on weekdays. Relatives are informed about the visit and are welcome to join with the patient's acceptance. The local home care team as well as the patient's PCP receives the same digital discharge plan and discharge summary, respectively, as in the control group. While a follow-up visit is scheduled with the home care nurse, the PCP is invited to join too if available, either in person or by a video link. Administratively, the patients are treated as geriatric outpatients, with an in-home follow up instead of a visit in the Geriatric outpatient clinic.
62563290|NCT02926443|ACTIVE_COMPARATOR|One-on-one Usual Physiotherapy Care (Control)|The Ctl group (n =16) will receive physiotherapy usual care treatments during a 6-week period. The Ctl group will receive 2 physiotherapy treatments (30 minutes) in the clinic per week (total of 12 treatments) as well as an individualized home exercise program (HEP). Treatments will include range of motion exercises, manual therapy treatments, modalities, and strengthening exercises, as determined by the treating physiotherapist. Specific muscle group exercises and parameters will be documented by the treating physiotherapist on a provided summary sheet.
62772195|NCT02801890|EXPERIMENTAL|AD-MSC|The patients with ultra filtration failure (UFF) underwent AD-MSC injection.
62772196|NCT02801890|PLACEBO_COMPARATOR|Placebo|The patients with ultra filtration failure (UFF) underwent Placebo injection.
62772197|NCT05835583|EXPERIMENTAL|experimental|Members of the experimental group received routine home visits( by psychiatric mental nurses, and the nurse provided patients with answers to questions about medications or care and handling of life events), and plus a 1-hour theory based integrated program intervention for 12 times in the 1st, 3rd, 5th, 7th, 9th, 11th, 13th, 15th, 17th, 19th, 21st, and 23rd weeks, and each patient received a total of 12 hours of intervention.
61995130|NCT01879228|EXPERIMENTAL|Sitagliptin|The dose of sitagliptin (Januvia®) 100 mg tablet will be taken orally each morning for 6 months.
62179791|NCT03443063|EXPERIMENTAL|Group 1: Severe Renal Impairment|Participants with severe renal impairment (estimated glomerular filtration rate \[eGFR\] 15 to 29 milliliters per minute (mL/min/1.73 square meter \[m\^2\]) and not on dialysis) will receive a single dose of 10 milligrams (mg) lemborexant (oral tablet) in the morning after an overnight fast.
62179792|NCT03443063|EXPERIMENTAL|Group 2: Normal Renal Function|Participants with normal renal function (eGFR ≥90 mL/min/1.73 m\^2) demographically matched to participants in Group 1 will receive a single dose of 10 mg lemborexant (oral tablet) in the morning after an overnight fast.
62179793|NCT01223963||Macrolane|Women that have had breast enhancement with Macrolane Volume Restoration Factor.
62179794|NCT04865783|ACTIVE_COMPARATOR|Cryospray|Cryospray will be sprayed from a distance of 20-30 cm to the back of one hand.
62179795|NCT04865783|PLACEBO_COMPARATOR|Placebo|A saline solution will be sprayed from a distance of 20-30 cm to the back of the hand.
62179796|NCT00874497|EXPERIMENTAL|1 Tetomilast|
62179797|NCT00874497|PLACEBO_COMPARATOR|2 Placebo|
62179798|NCT04971629||Cohort 1|Patients with knee osteoarthritis who use medical cannabis to manage MSK symptoms.
62179799|NCT04971629||Cohort 2|Patients with knee osteoarthritis who do not use medical cannabis.
62179800|NCT03269513|EXPERIMENTAL|Intervention group|"Adolescent Obesity~The exercise program, nutritional counseling and oral health will last for five to three months and will be held in the gym and rooms of the University of Santa Cruz do Sul (UNISC).~The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week."
62179801|NCT03269513|NO_INTERVENTION|Control group|
62179802|NCT00957996|EXPERIMENTAL|Peramivir 300 mg|Peramivir 300 mg twice daily
62179803|NCT00957996|EXPERIMENTAL|Peramivir 600 mg|Peramivir 600 mg once daily
62179804|NCT05588544|ACTIVE_COMPARATOR|SRP only|Periodontal treatment by scaling and root planning
62179805|NCT05588544|EXPERIMENTAL|SRP + laser|Periodontal treatment by Laser-assisted scaling and root planning
62179806|NCT02896101|EXPERIMENTAL|Pimecrolimus Cream, 1%|Pimecrolimus Cream, 1 % (Glenmark Pharmaceuticals Ltd) topical application
62179807|NCT02896101|ACTIVE_COMPARATOR|Elidel®|Elidel® (Valeant Pharmaceuticals North America LLC) topical application
62179808|NCT02896101|PLACEBO_COMPARATOR|Placebo|Placebo of Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) topical application
62179809|NCT01606891|EXPERIMENTAL|parent-targeted intervention|experimental
62563291|NCT02926443|EXPERIMENTAL|Group Program (UpEx-NTP) (Exp)|The Exp group (n =16) will partake in a 6-week group Upper Extremity Neuromuscular Training Program that consists of postural education, strength exercises, motor control exercises, and upper extremity functional tasks common for active military personnel. The UpEx-NTP program consists of 35-45 minutes of exercise, three times a week for 6 weeks (18 treatments), supervised by a physiotherapist. The program consists of 11 stations with several variations of difficulty of the same exercise per station. The exercises of each station will be performed in order of difficulty. The participant chooses one exercise to perform per station based on their current ability while respecting their pain levels at 3/10 or less.
62563292|NCT03654612|EXPERIMENTAL|Apatinib+S-1|Patients with recurrent/metastatic head and neck malignancies received apatinib plus S-1 as second-line therapy.
62179810|NCT01606891|NO_INTERVENTION|Primary Care|Standard primary care
62179811|NCT06014502|EXPERIMENTAL|Phase 1a Solid Tumors|IMGS-001 will be administered in escalating doses, with a starting dose of 0.3 mg/kg every 2 weeks escalating up to a maximum dose of 15 mg/kg.
62179812|NCT06014502|EXPERIMENTAL|Phase 1b Ovarian Cancer|IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.
62179813|NCT06014502|EXPERIMENTAL|Phase 1b Colorectal Cancer|IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.
62179814|NCT06014502|EXPERIMENTAL|Phase 1b Triple-negative Breast Cancer|IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.
62179815|NCT06014502|EXPERIMENTAL|Phase 1b Bladder Cancer|IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.
62179816|NCT06014502|EXPERIMENTAL|Phase 1b Gastric or Esophageal Cancer|IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.
62179817|NCT05955547||APACHE-II|
62179818|NCT05955547||APACHE-Inf|
62179819|NCT04848376||Spine surgery|"Use these system:~(1) SmartLoc (2) SmartLoc Evo(3) Winloc (4) Vigor PEEK Cervical Disc Spacer (5) Combo C (6) Polymer Lumbar Disc Spacer (7) X'Plo (8) Rainboo (9) Combo L"
62179820|NCT01213992|ACTIVE_COMPARATOR|Monofer® 500 mg|500 mg iron isomaltoside 1000
62179821|NCT01213992|ACTIVE_COMPARATOR|Monofer® 1000 mg|1000 mg iron isomaltoside 1000
62179822|NCT04389827||Incident & Prevalent Patients|Incident and prevalent patients diagnosed with a kidney disease at participating centres
62179823|NCT01458964|ACTIVE_COMPARATOR|Quetiapine|Quetiapine will be administered orally, QHS at a dosage of 100 mg for 1 week increasing to a target dosage of 200 mg for 11 weeks.
62179824|NCT01458964|PLACEBO_COMPARATOR|Sugar pill|Sugar pill will be administered orally, QHS at a dosage of 100 mg for 1 week increasing to a target dosage of 200 mg for 11 weeks.
62179825|NCT02710097|EXPERIMENTAL|Active THC and Placebo Ethanol|
62179826|NCT02710097|EXPERIMENTAL|Active THC and Active Ethanol|
62179827|NCT02710097|EXPERIMENTAL|Placebo THC and Active Ethanol|
62772198|NCT05835583|NO_INTERVENTION|control|The control group received routine home visits by psychiatric mental nurses, and the nurse provided patients with answers to questions about medications or care and handling of life events. The visits and intervention time frequency were the same as those in the experimental group.
62772199|NCT00819494|SHAM_COMPARATOR|Healthy controls|
62179828|NCT02710097|PLACEBO_COMPARATOR|Placebo THC and Placebo Ethanol|
62179829|NCT00816647|ACTIVE_COMPARATOR|1|Medial patellofemoral ligament reconstruction
62179830|NCT00816647|ACTIVE_COMPARATOR|2|Medial reefing
62179831|NCT03813732|OTHER|orbital fracture|using the trans-conjunctival approach with lateral canthotomy
62179832|NCT06299553||Single group/cohort|Patients with DLBCL R/R disease non-transplant eligible
62179833|NCT05621928||cases with positive RT PCR result for Covid 19|Individuals aged 18 years or older, with a suspected clinical picture of COVID-19 virologically confirmed, that is, with positive RT-PCR for SARS-CoV-2 in a respiratory secretion sample collected in the first 7 days of the onset of symptoms , who did not have a positive RT-PCR result for SARS-CoV-2 in the 90 days preceding enrollment in the study.
62179834|NCT05621928||Control|Individuals residing in the vicinity of the case, aged 18 years or older, without a suspected clinical picture of COVID-19 and with RT-PCR negative for SARS-CoV-2 in a respiratory secretion sample collected at the time of inclusion, followed by confirmation of the absence of signs and symptoms suggestive of COVID-19 within the next 7 days.
62179835|NCT05621928||immunogenicity analyzes|a convenience sample composed of all cases exposed or not to vaccination and 200 controls, 100 vaccinated and 100 unvaccinated, for analysis of humoral response.
62179836|NCT05621928||assessment of cellular immunity|a sample of 100 vaccinated cases and 100 unvaccinated cases followed prospectively, and 100 vaccinated controls 100 unvaccinated controls assessed spot-on at enrollment.
62179837|NCT05621928||analysis of potential genetic risk factors for the occurrence of severe forms of COVID-19 (SRAG)|a total of 50 cases
62179838|NCT05285956|EXPERIMENTAL|Intervention|Participants (n=90) will be provided free access to and asked to register for the consumer-based mobile meditation app, Calm, on their phone. Participants will then receive an email containing one year of free access to Calm. Participants will be asked to use Calm at least 10 minutes per day for 8 weeks. Women will be asked to use 10 sessions of specific pregnancy content for the first four weeks and then will have autonomy to use the app how they prefer for the remainder of the study period (with continued encouragement to use the pregnancy meditations)
62179839|NCT05285956|NO_INTERVENTION|Control|Participants (n=90) will be asked to continue with usual care and complete survey measures at each time point.
61995131|NCT01879228|PLACEBO_COMPARATOR|Placebo|Placebo tablet will be taken orally each morning for 6 months.
62179840|NCT03696888|EXPERIMENTAL|Telecoach|A skills-training web-app teaching skills for reducing problematic alcohol use.
62179841|NCT03696888|ACTIVE_COMPARATOR|TeleCoach control|A web-app giving information on health-related consequences of alcohol consumption.
62179842|NCT01656486|EXPERIMENTAL|Stereotactic Radiation|Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery.
62179843|NCT02205541|EXPERIMENTAL|Eculizumab|"300mg concentrate for solution for infusion. According to the patient body weight, there will be 3 to 5 injections administered in IV infusion at D0, D7, D14, D21 and D28.~Eculizumab (ECZ) will be administrated intravenously as a 30-minute injection."
62772200|NCT00819494|ACTIVE_COMPARATOR|Patients with immediate reactions|
62772201|NCT00716742||1|bimatoprost 0.03% latanoprost 0.005% travoprost 0.004%
62772202|NCT00206934|PLACEBO_COMPARATOR|1|
62772203|NCT00206934|PLACEBO_COMPARATOR|2|
62772204|NCT01009177|EXPERIMENTAL|Bosentan|
62772205|NCT01009177|PLACEBO_COMPARATOR|Placebo|
62772206|NCT01364909|PLACEBO_COMPARATOR|Control (usual practice)|
62772207|NCT01364909|EXPERIMENTAL|Exercise|
62772208|NCT06269237|EXPERIMENTAL|IPL|Participants in the group with 3 sessions of IPL, 2 weeks apart.
62772209|NCT06269237|SHAM_COMPARATOR|control|Participants in the group with 2 sessions of IPL, 1 session of sham IPL, 2 weeks apart.
62772210|NCT03869476|EXPERIMENTAL|BioscoreSMP cohort|
62772211|NCT01694979||Single group: pelvic floor and breathing|This is a single group with repeated measures during variable breathing effort
62772212|NCT04628065|EXPERIMENTAL|Intervention Arm|Participants will receive a text message everyday to build behavioral skills and practice self-monitoring of three behavior goals: (1) reduce TV time to less than 2 hours per day; (2) take 10,000 steps or more every day; (3) do 20 minutes or more of structures exercise like prenatal yoga or dance videos every day. Participants will also receive two health coaching mobile phone session; an introduction session and one problem solving session.
62772213|NCT00638976|OTHER|1.Integrilin, GSK|Pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide (Integrilin, GSK) vs matched placebo.
62772214|NCT00638976|PLACEBO_COMPARATOR|2|Pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide (Integrilin, GSK) vs matched placebo.
62772215|NCT01264770|EXPERIMENTAL|Dosing Group A|Oral treatment and subcutaneous injection
62772216|NCT01264770|EXPERIMENTAL|Dosing Group B|Oral treatment and subcutaneous injection
62179844|NCT02205541|PLACEBO_COMPARATOR|Placebo|"Infusion of a solution with 5% glucose. The administration scheme will be the same as the Eculizumab arm : there will be 3 to 5 injections at D0, D7, D14, D21 and D28.~Placebo will be administrated intravenously as a 30-minute injection."
62179845|NCT03505255|ACTIVE_COMPARATOR|Group A|Group A: 40 patients will receive intraperitoneal neostigmine 0.25 mg in 30 ml normal saline and 1 ml normal saline intramuscular.
62563293|NCT05018182|EXPERIMENTAL|Neoadjuvant chemotherapy|4 cycles of neoadjuvant chemotherapy with FOLFOXIRI + operation + 5 cycles of adjuvant chemotherapy with XELOX
62179846|NCT03505255|ACTIVE_COMPARATOR|Group B|Group B: 40 patients will receive intraperitoneal neostigmine 0.5 mg in 30 ml normal saline and 1 ml normal saline intramuscular.
62179847|NCT03505255|ACTIVE_COMPARATOR|Group C|Group C: 40 patients will receive intramuscular neostigmine 0.5 mg in 1 ml volume plus 30 ml normal saline intraperitoneal.
62179848|NCT03505255|PLACEBO_COMPARATOR|Group D|Group D (control group): 40 patients will receive intraperitoneal 30 ml normal saline and 1 ml normal saline intramuscular.
62563294|NCT04691362|ACTIVE_COMPARATOR|Oral Tranexamic Acid|128 patients scheduled for primary total hip arthroplasty
62563295|NCT04691362|ACTIVE_COMPARATOR|Intravenous Tranexamic Acid|128 patients scheduled for primary total hip arthroplasty
62563296|NCT03692286|ACTIVE_COMPARATOR|AgNP/Ca(OH)|Patients receiving combined Silver nanoparticle/Calcium hydroxide administered as intracanal medication at the first visit after cleaning and shaping
62563297|NCT03692286|ACTIVE_COMPARATOR|AgNP|Patients receiving silver nanoparticles in gel form administered as intracanal medication at the first visit after cleaning and shaping
61995132|NCT01468506||Fistula patients|Consecutive patients with autogenous, brachio-cephalic, brachio-basilic or brachio-brachial arterio-venous fistula creation for hemodialysis
61995133|NCT01200797|EXPERIMENTAL|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62179849|NCT00960505|EXPERIMENTAL|Alternate day fasting (ADF)|Fast day diet: 25% energy intake, Feast day diet: Ad libitum energy intake (alternating days)
62179850|NCT00960505|EXPERIMENTAL|Calorie restriction (CR)|75% energy intake every day
62179851|NCT00960505|ACTIVE_COMPARATOR|Control|Usual diet
62563298|NCT03692286|ACTIVE_COMPARATOR|Ca(OH)|Patients receiving calcium hydroxide intracanal medication at the first visit after cleaning and shaping
62563299|NCT04029025|ACTIVE_COMPARATOR|Workflow A|Dentalwings DWOS Intraoral Scan (IOS A) + Dentalwings DWOS Implant Prosthetics Lab-Software (CAD A)
62563300|NCT04029025|ACTIVE_COMPARATOR|Workflow B|3Shape TRIOS Pod Intraoral Scan (IOS B) + Straumann CARES Lab-Software (CAD B)
62563301|NCT04029025|ACTIVE_COMPARATOR|Workflow C|Conventional Impression + conventional porcelain-fused-to metal iFDP (LabS C/CAD C).
62772217|NCT01264770|EXPERIMENTAL|Dosing Group C|Oral treatment and subcutaneous injection
62772218|NCT01264770|ACTIVE_COMPARATOR|Dosing Group D|Oral treatment and subcutaneous injection
62772219|NCT01264770|PLACEBO_COMPARATOR|Dosing Group E|Oral treatment and subcutaneous injection
62179852|NCT03834818|EXPERIMENTAL|COMPAS Participants|Patents between the ages of 18 and 90 who are undergoing orthopedic surgery at Duke Health will be eligible for enrollment.
62179853|NCT01828398|SHAM_COMPARATOR|sham-tDCS + UE robot-assisted therapy|This group will receive the same robot-assisted therapy of the intervention group, in association of sham-tDCS. This consists in a 30 seconds stimulation, with the same instrumentation and electrodes placement. This method of sham stimulation was previously validated.
62391185|NCT05964933|ACTIVE_COMPARATOR|Pulpectomy and Root Canal Treatment|The tooth will be treated with Pulpectomy and Root Canal Treatment.
62563302|NCT04181021|EXPERIMENTAL|Intervention|Providers and community-based promoters will participate in the VCAT workshop. Providers and community-based promoters will take part in two different workshops at different times.
62563303|NCT04181021|NO_INTERVENTION|Control|Providers and promoters in the control arm will not be invited to participate in the VCAT workshop.
62563304|NCT02707484|EXPERIMENTAL|Thalidomide Group（100mg）|Generic name:Thalidomide Dosage form:tablet, 25mg Dosage:100mg/day Frequency: 25mg, QID, Oral Duration:120 days
62772220|NCT02671565||Hyaluronic acid (HA) injection users|Patients with at least one procedure claim for intra-articular administration of hyaluronic acid (procedure codes: J7320, J7322, J7325, Q4084, J7317, Q4083, J7321, Q4085, J7323, Q4086, J7324, J7327, J7326) within 90 days after their first specialist (physical medicine, physical therapy, orthopedic surgeon, rheumatologist or orthopedic) visit will be considered as HA users.
62772221|NCT02671565||Corticosteroids (CS) injections users|Patients with at least one procedure claim for intra-articular administration of corticosteroids (procedure codes: J1020, J1030, J1040, J1094, J1100, J2920, J2930, J0702, J0704, J3300, J3301, J3302, J3303, J1700, J1710, J1720, J2650, J2920, J2930) within 90 days after their first specialist (physical medicine, physical therapy, orthopedic surgeon, rheumatologist or orthopedic) visit will be considered as CS users.
62772222|NCT02671565||HA non-users|Patients who do not have any claims for procedural or surgical intervention including HA and CS injections in first 90 days after their first specialist visit will be considered as HA non-users
62772223|NCT03238924|EXPERIMENTAL|Oxytocin|40 IU intranasal oxytocin spray
62772224|NCT03238924|PLACEBO_COMPARATOR|Placebo|Placebo is matching saline nasal spray
62772225|NCT05073198|EXPERIMENTAL|Experiment|Giving educational brochures about testicular cancer and Testicular Self-Examination to the students in the experimental group
62772226|NCT05073198|NO_INTERVENTION|Control|No intervention
62772227|NCT06094400|EXPERIMENTAL|Intervention|10-mintue headband-guided meditation session via Muse Medication App.
62772228|NCT06094400|OTHER|Control|10-minute resting session
62772229|NCT03718858|EXPERIMENTAL|Interscalene block|Under sterile precautions, a high frequency linear array transducer \[6-13 Megahertz (MHz), Sonosite M-Turbo\] probe will be placed in the transverse plane over the interscalene groove to visualize the carotid artery and the C5 and C6 nerve roots of the brachial plexus between the anterior and middle scalene muscles. A 5 cm 22 G insulated needle will then be inserted in line with the US probe in a lateral-to-medial approach until the needle tip is adjacent to the C5 and C6 roots. After negative aspiration for blood, 15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.
61995134|NCT03184181|EXPERIMENTAL|EPTE® group|The intervention for this group consisted of Therapeutic Percutaneous Electrolysis (EPTE®). Patient received EPTE® once week for four weeks associated with eccentric exercises device at home.
62179854|NCT01828398|EXPERIMENTAL|real-tDCS + UE robot-assisted therapy|"This group will receive continuous stimulation lasting 30 minutes during the session of robot-assisted therapy. The training session, which includes multiplanar, repetitive and target reaching movements, will be given 5 times a week for 2 weeks(REO Therapy System; Motorika, Medical LTD, Israel). Each session will last about 30 minutes.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the affected hemisphere and the cathode on the contralateral M1 area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries (Brainstim, EMS, Italy). This continuous stimulation lasted 30 minutes, with an intensity of 1mA."
62179855|NCT00384865|ACTIVE_COMPARATOR|Aspirin 81 mg + Simvastatin 40 mg|"Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months~Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months"
62179856|NCT00384865|ACTIVE_COMPARATOR|Aspirin 81 mg + Placebo|"Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months~Placebo taken orally, once a day for 6 months"
62179857|NCT00384865|ACTIVE_COMPARATOR|Placebo + Simvastatin 40 mg|"Placebo taken orally, once a day for 6 months~Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months"
62563305|NCT02707484|EXPERIMENTAL|Thalidomide Group（50mg）|Generic name:Thalidomide Dosage form:tablet, 25mg\&Placebo Dosage:50mg/day Frequency: 25mg BID \&Placebo, BID, Oral Duration:120 days
62563306|NCT02707484|PLACEBO_COMPARATOR|placebo -controlled Group|Generic name:Thalidomide Placebo Dosage form:tablet, Placebo Dosage:Placebo Frequency: Placebo, QID, Oral Duration:120 days
62179858|NCT00384865|PLACEBO_COMPARATOR|Placebo + Placebo|"Placebo taken orally, once a day for 6 months~Placebo taken orally, once a day for 6 months"
62179859|NCT00876499||Questionnaire|
62772230|NCT03718858|ACTIVE_COMPARATOR|Superior Trunk Nerve block|Under sterile precautions, a high frequency linear array transducer \[6-13 Megahertz (MHz), Sonosite M-Turbo\] probe will be placed in the transverse plane over the interscalene groove to visualize the carotid artery and the C5 and C6 nerve roots of the brachial plexus between the anterior and middle scalene muscles. The superior trunk will be identified by tracing the C5 and C6 nerve roots caudally towards the supraclavicular fossa on the anterior lateral portion of the neck. A 5 cm 22 G insulated needle will then be inserted in line with the US probe in a lateral-to-medial approach until the needle tip is properly positioned. After negative aspiration for blood, 15 mL ropivacaine 0.5% will be injected in 5 mL aliquots.
62772231|NCT02178267|EXPERIMENTAL|Lactobacillus reuteri|The study was performed by two groups. And these groups were constituted from the newborn preterm infants who are received probiotics (Lactobacillus reuteri) and no probiotics.
62772232|NCT01370759|EXPERIMENTAL|Colon-targeted cleaning capsule|
62772233|NCT05601661|EXPERIMENTAL|Treatment group|Participants in the treatment group will receive 18 goal-directed upper extremity rehabilitation therapy sessions with paired VNS over six weeks. Followed by 90 days home exercise program.
61995135|NCT03184181|ACTIVE_COMPARATOR|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises device at home. Patient received 3 sessions of dry needling a week for four weeks.
62179860|NCT05428592|EXPERIMENTAL|LVRNA009 study group|
62179861|NCT05428592|ACTIVE_COMPARATOR|CoronaVac® control group|
62179862|NCT00812838|EXPERIMENTAL|100 units of Botulinum Toxin Type A|Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline
62563307|NCT02881853|EXPERIMENTAL|Part A1|XmAb7195 for IV infusion; dose level 1; 4 once-weekly doses
62563308|NCT02881853|EXPERIMENTAL|Part A2|XmAb7195 for SC injection; dose level 1; 4 once weekly doses
62563309|NCT02881853|EXPERIMENTAL|Part A3|XmAb7195 for SC injection; dose level 2; 4 once weekly doses
62563310|NCT02881853|EXPERIMENTAL|Part A4|XmAb7195 for SC injection; dose level 3; 4 once weekly doses
62563311|NCT02881853|EXPERIMENTAL|Part A5|XmAb7195 for SC injection; dose level 4; 4 once weekly doses
62772234|NCT05601661|SHAM_COMPARATOR|Control Group|Participants in the control group will receive 18 goal-directed upper extremity rehabilitation therapy sessions with sham VNS over six weeks. Followed by 90 days home exercise program.
62772235|NCT03369613|ACTIVE_COMPARATOR|MRI - HC tDCS|Healthy controls in Phase 1 transcranial electrical stimulation set to direct current
62772236|NCT03369613|ACTIVE_COMPARATOR|MRI - HC tACS|Healthy controls in Phase 1- transcranial electrical stimulation set to alternating current
62772237|NCT03369613|ACTIVE_COMPARATOR|MRI - CD tCDS|Cervical dystonia in Phase 1 transcranial electrical stimulation set to direct current
62772238|NCT03369613|ACTIVE_COMPARATOR|MRI - CD tACS|Cervical dystonia in Phase 1 transcranial electrical stimulation set to alternating current
62563312|NCT02881853|EXPERIMENTAL|Part B6|XmAb7195 or placebo for SC injection; dose level 5; 4 once-weekly doses
62772239|NCT03369613|ACTIVE_COMPARATOR|Phase II - Stim|Cervical dystonia in Phase 2 transcranial electrical stimulation setting is active
62772240|NCT03369613|SHAM_COMPARATOR|Phase II - Sham|Cervical dystonia in Phase 2 transcranial electrical stimulation setting is sham
62772241|NCT01872013|EXPERIMENTAL|low dose ASP7991|
62772242|NCT01872013|EXPERIMENTAL|middle dose ASP7991|
62772243|NCT01872013|EXPERIMENTAL|high dose ASP7991|
62179863|NCT00812838|PLACEBO_COMPARATOR|Normal saline|"Injection solution will consist of 10 cc preservative free normal saline~Subjects had the choice of crossing over to ARM 1 at the end of 16 weeks.~Cross-over: For subjects in Arm 2, crossover to BOTOX treatment will begin after the Week 16 Visit by repeating the study schedule as for Week 0 to Week 16."
62563313|NCT02881853|EXPERIMENTAL|Part B7|XmAb7195 or placebo for SC injection; dose level 6; 4 once-weekly doses
62772244|NCT01872013|PLACEBO_COMPARATOR|Placebo|
62772245|NCT01281228|EXPERIMENTAL|exenatide|Infusion of exenatide; loading dose 50 ng/min during 30 min, followed by a maintenance dose 20ng/min for the rest of the tests.
62772246|NCT01281228|EXPERIMENTAL|exenatide + exendin (9-39)|exenatide infusion: loading dose 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the test. And infusion of exendin(9-39) 600pM/kg/min.
62772247|NCT01281228|PLACEBO_COMPARATOR|saline|saline infusion, with the same infusion speed
62772248|NCT01363934|EXPERIMENTAL|Group A|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
62772249|NCT01363934|EXPERIMENTAL|Group B|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
62772250|NCT01363934|EXPERIMENTAL|Group C|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
62772251|NCT01363934|EXPERIMENTAL|Group D|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
62772252|NCT01363934|ACTIVE_COMPARATOR|Darbepoetin alfa 30ug/kg by IV|Darbepoetin alfa 30ug/kg once intravenously
61995136|NCT03619109||Healthy Volunteers|No real intervention since samples from volunteers are not tested on Nanōmix eLab™ System near any volunteers. Leftover samples are stored at Sponsor for potential future analysis/ projects.
62563314|NCT02881853|EXPERIMENTAL|Part B8|XmAb7195 or placebo for SC injection; dose level 7; 4 once-weekly doses
62563315|NCT02881853|EXPERIMENTAL|Part B9|XmAb7195 or placebo for SC injection dose level 8; 4 once-weekly doses
62563316|NCT04815070||Diabetic|A group of diabetic patients who have fasted for at least 8 hours undergoing staged bilateral total knee arthroplasty.
62772253|NCT01363934|EXPERIMENTAL|Group H|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
62772254|NCT01363934|EXPERIMENTAL|Group I|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
62772255|NCT01363934|EXPERIMENTAL|Group J|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
62772256|NCT01363934|EXPERIMENTAL|Group K|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
62772257|NCT01363934|ACTIVE_COMPARATOR|Darbepoetin alfa 30ug/kg by SC|Darbepoetin alfa 30ug/kg once subcutaneously
62772258|NCT02116998|EXPERIMENTAL|GEN-004 with Aluminum Hydroxide|
62772259|NCT02116998|PLACEBO_COMPARATOR|Placebo|
62772260|NCT01856621|ACTIVE_COMPARATOR|Seretide Diskus and charcoal|Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal
62772261|NCT01856621|ACTIVE_COMPARATOR|Seretide Diskus|Single-dose of Seretide Diskus (50/500 mcg/inhalation)
62772262|NCT01856621|EXPERIMENTAL|SF Easyhaler and charcoal|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal
62772263|NCT01856621|EXPERIMENTAL|SF Easyhaler|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)
62772264|NCT00288314||PTSD|
62772265|NCT00288314||CONTROLS|
62772266|NCT02694952|ACTIVE_COMPARATOR|FAV-Africa|FAV-Africa infusion at enrollment, and then at two and six hours after enrollment, if necessary. To be given as unblinded rescue dose at twelve hours if fourth dose of antivenom necessary.
62772267|NCT02694952|EXPERIMENTAL|EchiTabPlus-ICP|EchiTabPlus-ICP infusion at enrollment, and then at two and six hours after enrollment, if necessary.
62179864|NCT03269695|EXPERIMENTAL|PF-06687234|PF-06687234 subcutaneous (SC) weekly (QW) x 12 doses
62772268|NCT04608734|EXPERIMENTAL|Buccal midazolam|
62772269|NCT04608734|ACTIVE_COMPARATOR|Intranasal midazolam|
62772270|NCT06071481|NO_INTERVENTION|Arm-1|Standard supportive care ( Plenty of oral fluid, Tab. Paracetamol 500mg)
62772271|NCT06071481|EXPERIMENTAL|Arm-2|Standard supportive treatment + 2,00,000 IU Vitamin D oral solution
62563317|NCT04815070||Non-Diabetic|A group of non-diabetic patients who have fasted for at least 8 hours undergoing staged bilateral total knee arthroplasty.
62772272|NCT06071481|EXPERIMENTAL|Arm-3|Standard supportive treatment + 4,00,000 IU Vitamin D oral solution
62772273|NCT00885300|EXPERIMENTAL|1|cloxacillin 100 mg/ml + heparin 1000iu/ml as catheter lock at the end of hemodialysis
62772274|NCT00885300|ACTIVE_COMPARATOR|2|heparin 1000iu/ml as catheter lock at the end of hemodialysis
62772275|NCT03469024|EXPERIMENTAL|Home rehabilitation program|It consists in a home rehabilitation program. Patients will recieve electroanalgesia with TENS and an exercise program following the McKenzie method. At first and second sessions, patients will be instructed on how to use electroanalgesia and how to perform the exercises. Then, patients will perform the therapy at home. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
62772276|NCT03469024|ACTIVE_COMPARATOR|e-Health program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
61995137|NCT04695132|EXPERIMENTAL|Illness Management and Recovery treatment programme (intervention group)|These patients receive the Illness Management and Recovery treatment. Treatment takes place during 2 Group sessions and 1 individual session per week.
62179865|NCT03269695|PLACEBO_COMPARATOR|Placebo|PF-06687234 matched Placebo SC QW x 12 doses
62772277|NCT03389737|EXPERIMENTAL|Experimental|Experimental group will have monthly contact with the physicians, during which the athletes will receive individualized care and guidance in support of their performance goals.
62772278|NCT03389737|ACTIVE_COMPARATOR|Control|Control group will not have monthly contact with the physicians.
62772279|NCT02970526||colorectal cancer survivors|
61995138|NCT04695132|NO_INTERVENTION|Treatment as usual (control group)|These patients receive treatment as usual consisting of the standard treatment given at the respective inpatient forensic mental health facility where they are admitted.
61995139|NCT00600756|EXPERIMENTAL|Quetiapine XR|
62179866|NCT04891471|EXPERIMENTAL|SRS/SBRT arm|Patients with five or more brain metastasis assigned by randomization to Stereotactic RadioSurgery (SRS) or Stereotactic Body RadioTherapy (SBRT) will be treated with a highly-conformal metastasis-directed single dose between 15 and 24 Gy or fractionated dose (e.g. 27 Gy in 3 fractions), respectively, depending on lesion size, while sparing clinically negative brain. The treatment will be delivered using five non-coplanar arcs and a mono-isocentric technique.
62179867|NCT04891471|ACTIVE_COMPARATOR|WBI arm|Patients with five or more brain metastasis assigned by randomization to Whole Brain Irradiation (WBI) will be treated using a 3D-Conformal RadioTherapy technique for a uniform dose delivery of 30 Gy in 10 daily/fractions to the target, that is entire brain.
62179868|NCT04745377||Control Group|Healthy volunteers from hospital personnel vaccinated for covid-19, who sign informed consent for recording of outcomes and monitor of antibody titers in 3 timepoints
62772280|NCT04067778|EXPERIMENTAL|Intervention Group|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
61995140|NCT00600756|ACTIVE_COMPARATOR|Risperidone|
61995141|NCT02235376||critical care|
62563318|NCT03858751|PLACEBO_COMPARATOR|Placebo|Placebo capsule before bedtime
62563319|NCT03858751|EXPERIMENTAL|LTM1201AZ|LTM1201AZ capsule before bedtime
62563320|NCT03858751|EXPERIMENTAL|LTM1201AT|LTM1201AT capsule before bedtime
62563321|NCT03858751|EXPERIMENTAL|LTM1201AG|LTM1201AG capsule before bedtime
61995142|NCT03183414||cardiac surgery patients|cardiac surgery patients with a significant peroperative aortic valve stenosis (gradient\>40mmHg and/or aortic valve area \<1cm2). During cardiac surgery measurements of right ventricular dysfunction were taken by echocardiography
61995143|NCT00788827|EXPERIMENTAL|Autologous CD34+ stem cells|Up to 5 x 10 log 8 of autologous stem cells on a single occasion
61995144|NCT05633706||Healthy|Not belonging to the other cohorts as described below.
61995145|NCT05633706||Irritable Bowel Syndrome|As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
61995146|NCT05633706||Crohns Disease|As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
62179869|NCT04745377||Cancer patients|Cancer patients with solid tumours, with active disease and/or undergoing active systemic treatment, who will be vaccinated for covid-19
62563322|NCT03858751|EXPERIMENTAL|LTM1201AD|LTM1201AD capsule before bedtime
62563323|NCT05221541|EXPERIMENTAL|Vibration|Vibration (WBV and Tendon vibration) will be applied to participants
62772281|NCT04067778|OTHER|Control Group|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy both random (approximately 32 to 40) and targeted biopsies (and/or removal of any polyps) will be undertaken.
62772282|NCT02868658|EXPERIMENTAL|Health-care workers|Health-care workers recruited in the study will have blood sampling and naso-pharyngeal bottle-brush sampling
62772283|NCT01987583|EXPERIMENTAL|Wet cupping and conventional treatment|"Wet cupping: Will be administered through 3 sessions every other day, on the 17th, 19th and 21st days of the lunar month.~Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department."
62772284|NCT01987583|ACTIVE_COMPARATOR|Conventional treatment|Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department
62563324|NCT03815500|EXPERIMENTAL|Patients with open surgical wounds|Patients with open surgical wounds will undergo enhanced packing education with curriculum designed for learners with low literacy, dyslexia or associated learning disorders.
61995147|NCT05633706||Ulcerative Colitis|As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
62563325|NCT03444662|PLACEBO_COMPARATOR|Placebo|Intervention: Dietary Supplement: Placebo supplement
62563326|NCT03444662|EXPERIMENTAL|Cognizin and Omega-3|Intervention: Dietary Supplement: Citicoline and Omega-3 supplement
62563327|NCT03444662|EXPERIMENTAL|Omega-3|Intervention: Dietary Supplement: Omega-3 supplement
62563328|NCT02745431|EXPERIMENTAL|Oxytocin nasal spray|Oxytocin nasal spray
62563329|NCT02745431|PLACEBO_COMPARATOR|Placebo nasal spray|Placebo nasal spray
62563330|NCT01325363|EXPERIMENTAL|Schizophrenia|Schizophrenic patients
62563331|NCT01325363|EXPERIMENTAL|Control|Neurotypical subjects
62563332|NCT05064397|EXPERIMENTAL|Eptinezumab|Participants will receive 4 intravenous (IV) infusions with eptinezumab at Baseline (Day 0) and at the end of Weeks 12, 24, and 36.
62563333|NCT05973188|ACTIVE_COMPARATOR|Group A, warfarin group|Patients started on warfarin, dose will be adjusted according to patient target INR (2-3)
62563334|NCT05973188|EXPERIMENTAL|Group B, Rivaroxaban (Xcept)|Patients started on rivaroxaban 20mg single dose in 24hours
62563335|NCT05973188|EXPERIMENTAL|Group C, Apixaban ( Apixaget)|Patients started on Apixaban 5mg or 2.5mg (12hours apart)
62563336|NCT05715229|ACTIVE_COMPARATOR|Arm A|"Arm A - Intervention arm (Immunotherapy and Chemotherapy)~Nivolumab 360 mg/kg every 3 weeks Ipilimumab 1 mg/kg every 6 weeks~Platinum- doublet Chemotherapy (Histology-based) 4 cycles depending on the investigator's discretion.~Carboplatin dosed at AUC 5, and either Paclitaxel 175 mg/m2 for squamous or Pemetrexed 500 mg/m2 for non-squamous"
62563337|NCT05715229|OTHER|Arm B|"Arm B - control arm (Immunotherapy only)~Nivolumab 360 mg/kg every 3 weeks Ipilimumab 1 mg/kg every 6 weeks"
62563338|NCT04595188|EXPERIMENTAL|Sulphur amino acids in Adults > 60|"Total sulphur amino acid, as methionine only: all subjects will receive up to 7 methionine test levels, without dietary cysteine, assigned in random order.~Minimum methionine, with excess dietary cysteine: all subjects will receive up to 7 methionine test levels, in the presence of excess and constant dietary cysteine, assigned in random order."
62563339|NCT00765505|EXPERIMENTAL|1|Exercise Group
61995148|NCT05633706||Celiac Disease|As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
61995149|NCT05633706||Functional Dyspepsia|As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
61995150|NCT01433107|EXPERIMENTAL|Terbinafine|Drug
61995151|NCT01433107|PLACEBO_COMPARATOR|Placebo|Drug
61995152|NCT03414346|EXPERIMENTAL|Exclusively ice pack:|Ice pack application: 500 grams of crushed ice.
61995153|NCT03414346|EXPERIMENTAL|Ice pack added 10% of water:|Wetted ice pack application: 500 grams of crushed ice added to 50 mL of water at room temperature.
61995154|NCT03414346|EXPERIMENTAL|Ice pack added 100% of water:|Wetted ice pack application: 500 grams of crushed ice added to 500 mL of water at room temperature.
61995155|NCT04702490|EXPERIMENTAL|MET409 A|MET409 Active (50mg)
61995156|NCT04702490|PLACEBO_COMPARATOR|MET409 P|MET409 Placebo (50mg)
62563340|NCT00765505|EXPERIMENTAL|Health Education Group|
62563341|NCT03275493|EXPERIMENTAL|Experimental: Cohort 1|This cohort will determine the safety and efficacy of CD19 CAR-T cells for CD19+ acute lymphoblastic leukemia
62563342|NCT03275493|EXPERIMENTAL|Experimental: Cohort 2|This cohort will determine the safety and efficacy of CD19 CAR-T cells with CRS suppression technology for CD19+ acute lymphoblastic leukemia.
62563343|NCT03088202|EXPERIMENTAL|Intervention arm|Educational program Standardized care pathways Early palliative care
62563344|NCT03088202|NO_INTERVENTION|Control arm|Usual care
62563345|NCT00824200|EXPERIMENTAL|Behavioral and Exercise Therapy (M-BET)|Multicomponent behavior and exercise therapy program (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene \& non-pharmacological management of peripheral edema. M-BET alone will be given with placebo capsules.
62563346|NCT00824200|ACTIVE_COMPARATOR|Drug Therapy w/ Behavioral Placebo|alpha-adrenergic antagonist medication with a placebo behavioral intervention
62563347|NCT00824200|ACTIVE_COMPARATOR|Combination Therapy|Combination therapy: MBET and alpha-adrenergic antagonist medication
62563348|NCT05882019|OTHER|Breast Exam with Bexa|Bexa exam to be performed on participants already scheduled for either screening or diagnostic mammography.
62563349|NCT05730933|EXPERIMENTAL|Intervention|
62563350|NCT05730933|NO_INTERVENTION|Control|
62563351|NCT03786588||Group A|Vaginal microbiota in gestation CPP women without HPV infection
62563352|NCT03786588||GroupB|Vaginal microbiota in gestation women without CPP and HPV infection
62563353|NCT04249102|EXPERIMENTAL|CGM Group|The study group will be provided with a Continuous Glucose Monitoring system (Guardian Connect from Medtronic).
62563354|NCT04249102|ACTIVE_COMPARATOR|FGM Group|The control group will be provided with a Flash Glucose Monitoring system (Abbott Diabetes Care).
62563355|NCT04242940|EXPERIMENTAL|Ponto 4 sound processor|All patients will be fitted with a bone-anchored sound processor (Ponto 4), unilaterally or bilaterally.
62563356|NCT05606640||Haemophilia|Adult males with severe or moderate haemophilia A or B
62563357|NCT00677937|EXPERIMENTAL|1|Intervention to include education and ongoing support
62563358|NCT00677937|NO_INTERVENTION|2|Control to receive standard care
62772285|NCT00109577|PLACEBO_COMPARATOR|2|Placebo comparator, 6 placebo capsules three times a day
62772286|NCT00109577|EXPERIMENTAL|1|nutritional supplement intervention, 6 nutritional supplement capsules three times a day; the nutritional supplement is a 36-ingredient micronutrient supplement (primarily vitamins and minerals) and is referred to as MCN36, because it contains 36 nutrients.
62772287|NCT02445573|ACTIVE_COMPARATOR|EA group|
62772288|NCT02445573|PLACEBO_COMPARATOR|Sham EA group|
62563359|NCT00795899|EXPERIMENTAL|1|Epirubicin/Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab in patients with HER-2 overexpression
62772289|NCT05403229|EXPERIMENTAL|Topiramate arm|"The experimental group receives a systemic steroid with/without intratympanic steroids as the standard treatment of SSNHL.~The experimental group receives additional oral topiramate for 6 weeks. The dosage of topiramate is 25 mg orally before bedtime with the weekly escalation of 25 mg up to 100 mg. The total duration of oral topiramate is 6 weeks."
62772290|NCT05403229|ACTIVE_COMPARATOR|Control arm|The control arm receives a systemic steroid with/without intratympanic steroids as the standard treatment of SSNHL.
62772291|NCT05023148|ACTIVE_COMPARATOR|Electroacupuncture with dietary intervention|"Acupoints stimulation with an electric stimulator on CV12 Zhongwan, CV9 Shuifen, CV6 Qihai, CV4 Guanyuan, ST25 Tianshu bilateral, SP15 Daheng bilateral, ST40 Fenglong bilateral using continuous 2 Hz for 30 minutes. Therapy sessions are three times a week for four weeks (total 12 times).~Dietary intervention means reducing 500 calories from usual calorie consumptions and will be done twice, at the beginning and 2 weeks after."
62772292|NCT05023148|ACTIVE_COMPARATOR|Thread embedded acupuncture with dietary intervention|"Acupoints stimulation by embedding PDO thread in CV12 Zhongwan penetrating to CV9 Shuifen using 27G x 60 mm, CV4 Guanyuan penetrating to CV6 Qihai using 27G x 40 mm, ST25 Tianshu penetrating to SP15 Daheng using 27G x 40 mm, and perpendicular in ST40 Fenglong bilateral using 31G x 25 mm. Therapy will be done only once.~Dietary intervention means reducing 500 calories from usual calorie consumptions and will be done twice, at the beginning and 2 weeks after."
62772293|NCT06448494||Prospective group|Patients who recieved geriatric perioperative car
62179870|NCT04805047|EXPERIMENTAL|Intervention:education and monitoring|regular education programs supported by a dietician in combination with urine sodium monitoring as a feedback
62179871|NCT04805047|NO_INTERVENTION|control|regular care
62179872|NCT05052723|EXPERIMENTAL|Cabozantinib and pembrolizumab|
62179873|NCT01589523|EXPERIMENTAL|GlycoCholic Acid, Study Drug|An open label, single arm, non-randomized, non-comparative, treatment study of Glycocholic Acid in the treatment of defects of bile acid metabolism.
62179874|NCT05135923|ACTIVE_COMPARATOR|Benchmark gluten-free products|Products containing less than 6g fibre per 100g product.
62772294|NCT06448494||Retrospective group|Patients who received standard surgical care
62772295|NCT05320159||Overall cohort: Secukinumab|Included all the patients treated with secukinumab
61995157|NCT04702490|EXPERIMENTAL|MET409A +Open-Label Empagliflozin|MET409 Active (50mg) + Empagliflozin (10mg)
62563360|NCT04039841|OTHER|Motor imagery evaluation|cohort study
62772296|NCT05320159||Bio-naive|Included PsO patients initiating treatment with secukinumab. Bio-naïve was defined as no observed treatment (i.e., injection, prescription or patient reported history) with any of the following biologic drugs of interest anytime pre-index: secukinumab, certolizumab, etanercept, adalimumab, infliximab, golimumab, ustekinumab, ixekizumab, brodalumab, abatacept, and guselkumab and risankizumab during all available history
62772297|NCT05320159||Bio-experienced|Included PsO patients initiating treatment with secukinumab. Patients had pre-index use of one or more of the biologic drugs of interest during all available history
61995158|NCT04702490|PLACEBO_COMPARATOR|MET409P +Open-Label Empagliflozin|MET409 Placebo (50mg) + Empagliflozin (10mg)
62179875|NCT05135923|EXPERIMENTAL|Optimised gluten-free products|Products containing less than 6g fibre per 100g product.
62179876|NCT05992636||low insufflation flow (10 lt/min)|Patiens who perform pneumoperitoneum with low insufflation flow (10 lt/min)
62179877|NCT05992636||high insufflation flow (40 lt/min)|Patiens who perform pneumoperitoneum with high insufflation flow (40 lt/min)
62179878|NCT04934241|EXPERIMENTAL|Self-Acupressure|Self-Acupressure Each application to the acupressure points (HT 7, CV17,PC 6, LI4,SP 6) will be done in 2 minutes and right and left)
62179879|NCT04934241|NO_INTERVENTION|Control group|Routine maintenance will be applied
62179880|NCT06344806|EXPERIMENTAL|Experimental Group|In the experimental group, the gamified training material was applied online to women. The gamified training material was made in an escape room design. Pregnant women need to solve problems with scenarios in order to leave the virtual room. Gamified elements are included in the game. The game lasted approximately 20 minutes and afterwards, the participant who passed all levels was given a virtual certificate.
62179881|NCT06344806|NO_INTERVENTION|Control|In the control group, pregnant women received the standard care provided in the hospital. No intervention was applied to this group.
62391186|NCT05772039|ACTIVE_COMPARATOR|Topical application of 38% Silver Diammine Fluoride Solution at Baseline|"* SDF is known for its corrosive nature therefore a plastic container or dappen dish will be used.~* 1 drop (0.05 ml) will be dispensed on a plastic container.~* 1 drop (2.24 F-ion mg/dose) SDF treats up to 5 tooth surfaces.~* Ultrafine microbrushes will be used to apply varnish."
62391187|NCT05772039|ACTIVE_COMPARATOR|Topical application of 38% Silver Diammine Fluoride Solution at 6 months|"* SDF is known for its corrosive nature therefore a plastic container or dappen dish will be used.~* 1 drop (0.05 ml) will be dispensed on a plastic container.~* 1 drop (2.24 F-ion mg/dose) SDF treats up to 5 tooth surfaces.~* Ultrafine microbrushes will be used to apply varnish."
62179882|NCT00494208|ACTIVE_COMPARATOR|1|
62179883|NCT00494208|ACTIVE_COMPARATOR|2|
62179884|NCT00494208|ACTIVE_COMPARATOR|3|
62179885|NCT00494208|ACTIVE_COMPARATOR|4|
62179886|NCT00494208|ACTIVE_COMPARATOR|5|
62179887|NCT00792259||1|Patients with Retinal Disease
62391188|NCT05772039|ACTIVE_COMPARATOR|Topical application of 38% Silver Diammine Fluoride Solution at 12 months|"* SDF is known for its corrosive nature therefore a plastic container or dappen dish will be used.~* 1 drop (0.05 ml) will be dispensed on a plastic container.~* 1 drop (2.24 F-ion mg/dose) SDF treats up to 5 tooth surfaces.~* Ultrafine microbrushes will be used to apply varnish."
62391189|NCT05772039|EXPERIMENTAL|Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish at baseline|"* 0.25 ml of the solution will be used which contains 12.5 mg of fluoride.~* Thin layer will be applied with sweeping horizontal brush strokes to all teeth present."
62563361|NCT02503540|OTHER|Aflibercept|Monthly aflibercept for 6 months and then every other month for 6 months.
62772298|NCT05320159||Systemic-naive|Included PsO patients initiating treatment with secukinumab. Systemic-naïve was defined as no observed treatment (i.e., injection, prescription or patient reported history) with any of the biologic treatments or with any of the following systemic (i.e., oral or injectable - no topical forms) drugs of interest pre-index: methotrexate, corticosteroids, acitretin or apremilast.
61995159|NCT02972632|EXPERIMENTAL|Vortioxetine 10-20 mg|Vortioxetine 10 mg, tablets, orally, once daily followed by a dose adjustment to a maximum of 20 mg, tablets, orally, once daily up to 12 weeks. The dose may be decreased by 5 mg based on participant's response and tolerability as judged by the investigator.
62179888|NCT00792259||2|Patients without Retinal Disease
62179889|NCT00792259||3|Normal Subjects
62391190|NCT05772039|EXPERIMENTAL|Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish at 6 months|"* 0.25 ml of the solution will be used which contains 12.5 mg of fluoride.~* Thin layer will be applied with sweeping horizontal brush strokes to all teeth present."
62563362|NCT04898283|EXPERIMENTAL|10,000 MG01 + 10,000 T521|10,000 TU/mL of MG01 + 10,000 TU/mL of T521 of subcutaneous immunotherapy
62563363|NCT04898283|EXPERIMENTAL|30,000 MG01 + 10,000 T521|30,000 TU/mL of MG01 + 10,000 TU/mL of T521 of subcutaneous immunotherapy
62563364|NCT04898283|PLACEBO_COMPARATOR|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients.
62772299|NCT05320159||Systemic-experienced|Included PsO patients initiating treatment with secukinumab. Systemic-experienced patients had pre-index use of one or more of the systemic drugs of interest.
62772300|NCT02905006|PLACEBO_COMPARATOR|Placebo|
62772301|NCT02905006|EXPERIMENTAL|Bimekizumab dosing regimen 1|
62772302|NCT02905006|EXPERIMENTAL|Bimekizumab dosing regimen 2|
62772303|NCT02905006|EXPERIMENTAL|Bimekizumab dosing regimen 3|
62772304|NCT02905006|EXPERIMENTAL|Bimekizumab dosing regimen 4|
62772305|NCT02905006|EXPERIMENTAL|Bimekizumab dosing regimen 5|
62772306|NCT02388542|EXPERIMENTAL|lifestyle counseling|we will have a trained peer mentor educating employees regarding lifestyle modification for control of cardiovascular disease risk factors and following them up for a duration of 3 months
62772307|NCT02705274|ACTIVE_COMPARATOR|Prompt Panretinal Photocoagulation|PRP= Panretinal Photocoagulation. PRP alone.
62179890|NCT06433440|EXPERIMENTAL|Group-1|"0.2 ml of PVRV Intradermally (ID) on the following days: Day0, Day3, and Day7~Biological: PVRV~PEP regimen"
62563365|NCT01514981|EXPERIMENTAL|AMG 761|
62563366|NCT01514981|PLACEBO_COMPARATOR|Placebo|
62772308|NCT02705274|EXPERIMENTAL|Bevacizumab with deferred PRP|Bevacizumab = Anti vascular endothelial growth factor. PRP= Panretinal photocoagulation. Intravitreal anti-VEGF with PRP only if indicated.
62772309|NCT03107988|EXPERIMENTAL|Cohort A1 (Dose-finding)|Lorlatinib will be given orally once daily continuously for 28 days. The dose level of lorlatinib will be assigned at the time of study registration. The starting dose for cohort A1 is 45 mg/m2/dose
62772310|NCT03107988|EXPERIMENTAL|Cohort A2 (Adult and large BSA)|Lorlatinib will be given at the adult recommended phase 2 dose (RP2D) of 100 mg orally once daily continuously for 28 days.
62772311|NCT03107988|EXPERIMENTAL|Cohort B1 (Expansion)|Lorlatinib will be given orally once daily continuously for 28 days at the RP2D defined by cohort A1. This cohort will not begin enrollment until the recommended phase 2 dose is established from the dose escalation cohort A1.
62772312|NCT03107988|EXPERIMENTAL|Cohort B2 (Combined w/ chemotherapy)|Lorlatinib will be given orally once daily continuously for 28 days, at the RP2D defined by cohort A1. Lorlatinib should be administered at least one hour prior to conventional chemotherapy (Cyclophosphamide and Topotecan) on days 1-5 of each cycle.
62772313|NCT05821725|EXPERIMENTAL|Group I|A gel containing Hyaluronic acid in combination with a hemostatic sponge
62772314|NCT05821725|ACTIVE_COMPARATOR|Group II|A hemostatic sponge alone
62772315|NCT06025812|EXPERIMENTAL|0-1-month immune program study group|According to the 0-1-month immunization schedule, two doses of 25 μg/0.5 ml Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells) were injected into the deltoid muscle of the upper arm.
62772316|NCT06025812|ACTIVE_COMPARATOR|0-1-month immune program control group|According to the 0-1-month immunization schedule, two doses of 25 μg/0.5 ml recombinant novel coronavirus protein vaccine (CHO cells) were injected into the deltoid muscle of the upper arm.
62772317|NCT06025812|EXPERIMENTAL|0-6-month immune program study group|"The subjects were from the LKM-2023-NCV-02 project and were vaccinated on a voluntary basis with 25 μg/0.5 ml Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells) at the visit 6 months after the exemption."
62563367|NCT00354913|EXPERIMENTAL|Imatinib mesylate+hydroxyurea|All patients receive imatinib mesylate and hydroxyurea orally on a daily, continuous basis. Dosing of imatinib mesylate is adjusted for patients who are also receiving p450-inducing anti-epileptic drugs.
62563368|NCT03019861|ACTIVE_COMPARATOR|Ayurvedic nutritional counseling|Patients will receive three Ayurvedic nutritional counselings (according to tradition) after 1, 3 and 8 weeks after Baseline.
62563369|NCT03019861|ACTIVE_COMPARATOR|Conventional nutritional counseling|Patients will receive three conventional nutritional counselings (according to German Nutrition Society - DGE) after 1, 3 and 8 weeks after Baseline.
62772318|NCT06025812|ACTIVE_COMPARATOR|0-6-month immune program control group|"The subjects were from the LKM-2023-NCV-02 project and were vaccinated on a voluntary basis with 25 μg/0.5 ml recombinant novel coronavirus protein vaccine (CHO cells) at the visit 6 months after the exemption."
62772319|NCT01826435|EXPERIMENTAL|Electronic Intervention|Over the three months, participants will receive a technology intervention. This will include text or email encounter notifications associated with appropriate mobile or online self-management information for medication adherence and behavior change.
62772320|NCT02532985|PLACEBO_COMPARATOR|Negative control|No added fiber
62772321|NCT02532985|ACTIVE_COMPARATOR|Positive fiber control|90g positive control fiber
62772322|NCT02532985|EXPERIMENTAL|Novel fiber 30g|30g novel fiber
62772323|NCT02532985|EXPERIMENTAL|Novel fiber 60g|60g novel fiber
62772324|NCT02532985|EXPERIMENTAL|Novel fiber 90g|90g novel fiber
62772325|NCT05674110|EXPERIMENTAL|Education and Support|online education and support meetings
62563370|NCT04604756|EXPERIMENTAL|Losartan group|Drug: Losartan
62772326|NCT01610986|EXPERIMENTAL|Glucose-fructose|Participants will take glucose-fructose drinks during training sessions
62772327|NCT01610986|EXPERIMENTAL|Water|Participants will take only water during training sessions
62563371|NCT04604756|PLACEBO_COMPARATOR|Placebo group|Drug: Placebo Oral Tablet
62772328|NCT00498121||VAP patient|
62772329|NCT00521222|ACTIVE_COMPARATOR|Arg/Arg genotype on Advair (Fluticasone with Salmeterol) HFA|Asthma patients with the Arg/Arg genotype who are randomized to continue the combination therapy of a specific long-acting beta 2 agonist (salmeterol) and inhaled corticosteroid (fluticasone) in the form of Advair HFA.
62772330|NCT00521222|ACTIVE_COMPARATOR|Gly/Gly genotype on Advair (Fluticasone with Salmeterol) HFA|Asthma patients with the Gly/Gly genotype who are randomized to continue the combination therapy of a specific long-acting beta 2 agonist (salmeterol) and inhaled corticosteroid (fluticasone) in the form of Advair HFA.
62772331|NCT00521222|EXPERIMENTAL|Arg/Arg genotype on Fluticasone HFA|Asthma patients with the Arg/Arg genotype who are randomized to fluticasone (Flovent HFA) alone.
62772332|NCT00521222|EXPERIMENTAL|Gly/Gly genotype on Fluticasone HFA|Asthma patients with the Gly/Gly genotype who are randomized to fluticasone (Flovent HFA) alone.
62772333|NCT03882645|EXPERIMENTAL|CHH-diet arm|"During the 4-week intervention period, free meals conformed to CHH-diet will be provided 3 times per daily (breakfast, lunch, dinner). Different center offers different meals of different cuisines but all conformed to CHH-diet. The main nutrientional healthy goal of different cuisines will be achieved through specific nutrient targets, including fat, carbohydrate, protein, dietary fiber, sodium, potassium, magnesium and calcium."
62772334|NCT03882645|OTHER|local usual diet arm|During the 4-week intervention period, three meals per day (breakfast, lunch, dinner) will be provided free of charge in line with local dietary characteristics. The energy,protein, carbohydrate, as week as dietary fiber, sodium, calcium, magnesium and potassium will be kept the same as that in the run-in phase.
62563372|NCT03014154|ACTIVE_COMPARATOR|Video training Game|"Patients were submitted prior to the treadmill warming the 2kmh during 1° minutes before each session. Then held 30 minutes of aerobic interval training with video game (10 rounds of 3 minutes with 30 seconds of rest between each), followed by 5 minutes of cool-down again on the mat. The game used for training was the reflex Ridge Kinect Adventure (Xbox-360). At a higher level, it is necessary for the child to perform a greater number of jumps, squats, lateral movements and arm movements. All the activity was monitored against FC and SpO2. To determine the intensity of physical activity energy expenditure assessments were made. In which four are for the pre and post intervention evaluation and sixteen training sessions."
62563373|NCT03014154|ACTIVE_COMPARATOR|Endurance muscle training|Patients were submitted prior to the treadmill warming the 2kmh during 1° minutes before each session. Then held 30 minutes of aerobic interval training with video game (10 rounds of 3 minutes with 30 seconds of rest between each) followed by 5 minutes of cool-down again on the mat.Then the children were subjected to low intensity to endurance muscle training with 3 sets of 15 repetitions to upper limbs diagonally primitive and flexion and extension to lower lumbs. All the activity was monitored against FC and SpO2.To determine the intensity of physical activity energy expenditure assessments were made. In which four are for the pre and post intervention evaluation and sixteen training sessions.
62563374|NCT04011722|EXPERIMENTAL|Portico™ NG (Navitor) valve, FlexNav™ Delivery System|Portico ™ NG (Navitor) valve implantation with the new generation Portico NG (Navitor) valve (23mm, 25mm, 27mm and 29mm sizes), and the second-generation FlexNav Delivery system (small and large), Portico™ NG (Navitor) Loading System(s) (small and large).
62772335|NCT02208349|EXPERIMENTAL|Video Laryngoscopy|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
62772336|NCT02208349|ACTIVE_COMPARATOR|Direct Laryngoscopy|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
62772337|NCT03726931|EXPERIMENTAL|[18F]FES|All patients will receive an additional PET/CT scan: \[18F\]FES PET/CT scan.
62772338|NCT02390180||Sorting all tastes|This group will receive 15 samples to taste and sort into groups. The samples included: a blank solution, hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, sodium chloride (2), citric acid, acetic acid, quinine, urea, monosodium glutamate, and inosine monophosphate.
62772339|NCT02390180||Sorting bitter tastes|This group will receive 12 samples to taste and sort into groups. The samples included: blank solutions (2), decenoic acid, oleic acid, linoleic acid, quinine (2), urea (2),caffeine, sucrose octaacetate, and propylthiouracil.
62772340|NCT02726945|EXPERIMENTAL|Low Dose SVF|This group of subjects will receive a low dose of SVF for treatment of knee OA.
62772341|NCT02726945|EXPERIMENTAL|High Dose|This group of subjects will receive a high dose of SVF for treatment of knee OA.
62179891|NCT06433440|EXPERIMENTAL|Group-2|"0.5 ml of PVRV Intramuscularly (IM) on the following days: Day0, Day3, and Day7, Day14 and Day28~Biological: PVRV~PEP regimen"
62391191|NCT05772039|EXPERIMENTAL|Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish at 12 months|"* 0.25 ml of the solution will be used which contains 12.5 mg of fluoride.~* Thin layer will be applied with sweeping horizontal brush strokes to all teeth present."
62563375|NCT04011722|EXPERIMENTAL|Navitor Titan Valve|Navitor Titan Valve (35mm) implantation with the large FlexNav Delivery system and Navitor Loading System - LG+.
62563376|NCT01293695|ACTIVE_COMPARATOR|Hypnosis|Receives 5 weeks of hypnotic relaxation therapy
62563377|NCT01293695|PLACEBO_COMPARATOR|Structured Attention|Meets with therapist for five weekly sessions, but receives no hypnotic relaxation therapy
62179892|NCT02767102|EXPERIMENTAL|Red wine with Melatonin|Rosso di Marco is a wine without MLT (previous screening). This wine will be enriched with 10 ng mL-1 MLT (MLT+) and used as experimental wine.
62179893|NCT02767102|PLACEBO_COMPARATOR|Red wine without Melatonin|Rosso di Marco is a wine without MLT (previous screening). This wine will be used as placebo treatment (PLC).
62179894|NCT03258502|EXPERIMENTAL|RV521|RV521 drug substance in capsule for oral administration
62179895|NCT03258502|PLACEBO_COMPARATOR|Placebo|Micro-crystalline cellulose in capsule for oral administration
62179896|NCT00874484|EXPERIMENTAL|1|
62179897|NCT00874484|PLACEBO_COMPARATOR|2|
62391192|NCT04076865|EXPERIMENTAL|EMLA|
62563378|NCT01205269|EXPERIMENTAL|First 50 mcg, then 200 mcg, then placebo|period 1: AZD8683 50 mcg, period 2: washout, period 3: AZD8683 200 mcg, period 4:washout, period5: placebo
62772342|NCT02726945|PLACEBO_COMPARATOR|Placebo|This group of subjects will receive a placebo with no SVF Cells for treatment of knee OA.
62772343|NCT05257707|EXPERIMENTAL|intervention|
62772344|NCT05614921|ACTIVE_COMPARATOR|External oblique intercostal plane block|Ultrasound-guided External oblique intercostal plane block before surgery
62772345|NCT05614921|ACTIVE_COMPARATOR|Wound infiltration|Wound infiltration to trocar sites before surgery
62391193|NCT00676468|OTHER|1|Active Montelukast + Fish Oil Placebo
62563379|NCT01205269|EXPERIMENTAL|First 50 mcg, then placebo, then 200 mcg|period 1: AZD8683 50 mcg, period 2: washout, period 3: placebo, period 4: washout, period5:AZD8683 200 mcg
62563380|NCT01205269|EXPERIMENTAL|First 200 mcg, then placebo, then 50 mcg|period 1: AZD8683 200 mcg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD8683 50 mcg
62179898|NCT05074277|NO_INTERVENTION|Control (8 hours nocturnal sleep)|Inpatient protocol involves 8-hour sleep opportunity during the biological night throughout.
62563381|NCT01205269|EXPERIMENTAL|First 200 mcg, then 50 mcg, then placebo|period 1: AZD8683 200 mcg, period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period 5: placebo
62563382|NCT01205269|EXPERIMENTAL|First placebo, then 200 mcg, then 50 mcg|period 1: placebo , period 2: washout, period 3: AZD8683 200 mcg, period 4: washout, period5: AZD8683 50 mcg
62563383|NCT01205269|EXPERIMENTAL|First placebo, then 50 mcg, then 200 mcg|period 1: placebo , period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period5: AZD8683 200 mcg
62563384|NCT00038402|EXPERIMENTAL|Herceptin + Taxol Followed by FEC|Herceptin starting 4 mg/kg intravenous (IV), then 2 mg/kg weekly for all other cycles neo-adjuvant chemotherapy and during FEC therapy for total 24 doses. Taxol 225 mg/m\^2 continuous IV over 24 hours each cycle; Fluorouracil 500 mg/m\^2 IV Days 1 at 3-4 week intervals; Cytoxan 500 mg/m\^2 IV on Day 1; Epirubicin 75 mg/m\^2 IV on Day 1. Four 21-day cycles.
62563385|NCT04259164|ACTIVE_COMPARATOR|QMF149|Mometasone furoaat / Indacaterol
62772346|NCT01266317|EXPERIMENTAL|Combined PEX, Rituximab and Steroids|"Standard Steroid Treatment: One gm of methylprednisolone I.V., on day 0, followed by 40 mg/day I.V. on days 1-4, and days 6-12 (or the P.O. prednisone equivalent). Methylprednisolone 100 mg I.V. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone I.V. (or P.O. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the principle investigator.~Plasma exchange (PEX) will consist of 1.5x estimated plasma volume exchanges for 3 successive days (0, 1,2) and then, after a one day interval to enable equilibration of autoantibodies sequestered in tissues, two more daily treatments on days 4 and 5.~Rituximab: One gm I.V. will be administered on day 5 (after completion of the last PEX) and day 13."
62772347|NCT03346967|EXPERIMENTAL|Stem cell Administration for female patients|Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for female patients
62772348|NCT03346967|EXPERIMENTAL|Stem cell Administration for male patients|Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for male patients
62772349|NCT04478578||Patients with febrile illness|Participants from approximately 650 villages, with a target number of 100,000 episodes of febrile illness, will be enrolled into this study.
62772350|NCT05203159|EXPERIMENTAL|ocean sound|The group that will listen to the ocean sound
62179899|NCT05074277|EXPERIMENTAL|Simulated Night Shift Work|Two inpatient stays, each involving a baseline night, followed by a 3-hour afternoon nap opportunity, and then three 12-hour night shifts, with 8-hour daytime sleep opportunity in between.
62179900|NCT01222702|EXPERIMENTAL|Cadazolid 250 mg|Subjects received 250 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
62179901|NCT01222702|EXPERIMENTAL|Cadazolid 500 mg|Subjects received 500 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
62179902|NCT01222702|EXPERIMENTAL|Cadazolid 1000 mg|Subjects received 1000 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
62179903|NCT01222702|ACTIVE_COMPARATOR|Vancomycin 125 mg|Subjects received one vancomycin capsule (125 mg) four times daily and reconstituted placebo-matching cadazolid suspension twice daily for 10 days
62179904|NCT01540578||Observational|Archived cell samples are analyzed for replication timing by flow cytometry, microarray, and single-cell fluorescence in situ hybridization (FISH) assays. Replication-timing results among cases and controls are also analyzed.
62179905|NCT03730662|EXPERIMENTAL|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
62179906|NCT03730662|EXPERIMENTAL|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
62179907|NCT03730662|EXPERIMENTAL|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
62391194|NCT00676468|OTHER|2|Active Fish Oil + Montelukast Placebo
62391195|NCT00676468|OTHER|3|Active Montelukast + Active Fish Oil
62563386|NCT04259164|EXPERIMENTAL|QVM149|Mometasone furoaat / Indacaterol / Glycopyrronium
62563387|NCT02116270|OTHER|Control group|Patients in this group control (normal renal function) are followed in the urology department. A blood sample is performed on the day of inclusion.
62563388|NCT02116270|EXPERIMENTAL|Severe renal failure|Patients in this group suffer from renal failure stage 4 and are not under dialysis. A blood sample is performed on the day of inclusion.
62563389|NCT02116270|EXPERIMENTAL|Peritoneal dialysis|Patients with renal failure, under peritoneal dialysis for at least 3 months. A blood sample is performed on the day of inclusion.
62563390|NCT02116270|EXPERIMENTAL|Hemodialysis|Patient with renal failure, under hemodialysis for at least 3 months. A blood sample is performed on the day of inclusion.
62563391|NCT02154607|NO_INTERVENTION|Symptomatic treatment|Symptomatic analgetic Treatment only was performed without any Manipulation of OLP lesions.
62563392|NCT02154607|ACTIVE_COMPARATOR|CO2-Laser Treatment|CO2-Laser Vaporisation was performed of OLP lesions under local anaesthesia.
62563393|NCT03939702|ACTIVE_COMPARATOR|Non-Bile Collection|On Day 1, all participants will receive a single oral solution dose of 200 mg \[14C\] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12
62563394|NCT03939702|ACTIVE_COMPARATOR|Bile Collection|On Day 1, all participants will receive a single oral solution dose of 200 mg \[14C\] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Approximately 1 hour after study drug administration, an ND tube may be positioned in approximately 3 selected participants for collection of bile.Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12
62772351|NCT05203159|ACTIVE_COMPARATOR|control group|The group that will not listen to sound
62772352|NCT01581619|EXPERIMENTAL|Partial Breast Irradiation|Partial Breast Irradiation using 40 Gy in 10 fractions over 2 weeks
62179908|NCT03730662|ACTIVE_COMPARATOR|Insulin Glargine|"Insulin glargine administered SC once a day. Doses were individualized and titrated according to protocol-defined targets.~The starting dose of insulin glargine was 10 IU/day at bedtime, titrated to a FBG \<100 mg/dL, following a treat-to-target (TTT) algorithm."
62179909|NCT00730847|EXPERIMENTAL|Cervarix Group|Healthy female subjects who received three doses of the Cervarix vaccine, administered intramuscularly in the deltoid region according to a 0, 1 and 6-month schedule.
62179910|NCT04134598|EXPERIMENTAL|Breast Irradiation (RT)|Breast Irradiation (RT)
62563395|NCT02179762|EXPERIMENTAL|Arm I (moderate intensity exercise)|Patients perform moderate intensity exercise on a stationary bike for 20-50 minutes, three days a week for 16 weeks.
62772353|NCT04907045|EXPERIMENTAL|Standard Implementation Plus Health Coaching|The clinic in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O.
62563396|NCT02179762|EXPERIMENTAL|Arm II (HIIT exercise on a standard stationary bike)|Patients perform HIIT exercise on a standard stationary bike, three days a week for 16 weeks.
62772354|NCT04907045|EXPERIMENTAL|Standard Implementation Plus Health Coaching and Practice Facilitation|The clinic in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O. Additionally, a practice facilitator will provide the clinic with support for implementation.
62772355|NCT05423392|EXPERIMENTAL|The first tasted group using 4% Articaine|"The group was divided into three subgroups depending on the age of the participials: 1st group from 5-9 years, 2nd from 10-13 years and 3th from 14-18 years.~Following placement of 5% lidocaine topical anaesthetic for 3 minutes prior to and at the site of needle penetration, patients were randomly given one of the following local anesthetic regimes administered by the principle investigator. For indicated dental treatment patients would receive 2.0 ml 4% articaine with 1:100,000 epinephrine as a local infiltration in the mucobuccal region,the lateral region of the lower jaw.Criteria for measuring efficacy would be to measure pain during anesthetic injection, 10 minutes after injection,during and after the intervention. The child's behavior would be monitored through all phases of clinical work by direct observation of the dentist( examiner) using the above methodology. After that, the examiner would fill in the questionnaire based on the answer of the child / parent (guardian)."
61995160|NCT01510119|EXPERIMENTAL|Intervention - Dose Level 1|RAD001 given 10mg/daily by mouth and 400mg hydroxychloroquine twice daily by mouth. Cycle 1 will include 1 week run-in of RAD001. Following this, both RAD001 and hydroxychloroquine given without interruption. Cycle 1 duration is 35 days; all subsequent cycles are 28 days. RAD001 and hydroxychloroquine continuously administered until progression of disease or unacceptable toxicity.
62179911|NCT04134598|ACTIVE_COMPARATOR|Endocrine Therapy (ET)|Endocrine Therapy (ET)
62179912|NCT02533349|ACTIVE_COMPARATOR|Proton pump inhibitor + prokinetics|Patient will be prescribed proton pump inhibitor (pantoprazole, 40mg, 1T QD) with prokinetics (Motilitone, 30mg, 1T, TID) for 3months.
62179913|NCT02533349|PLACEBO_COMPARATOR|Proton pump inhibitor + placebo|Patient will be prescribed proton pump inhibitor (pantoprazole, 40mg, 1T QD) with placebo (Motilitone, 30mg, 1T, TID) for 3months.
62179914|NCT01028755|EXPERIMENTAL|Arm 1|
62563397|NCT02179762|EXPERIMENTAL|Arm III (HIIT exercise on a cybercycle)|Patients perform HIIT exercise on a cybercycle using racing or other games, three days a week for 16 weeks.
62563398|NCT03971032|OTHER|Women undergoing hysteroscopy|Women presenting with abnormal bleeding, abnormal cervical or uterine findings who have consented to undergo hysteroscopy
62179915|NCT03626025|NO_INTERVENTION|Mass Learning Group|Participants underwent an eight-hour microsurgery training course in a single session under the mass-learning format.
62563399|NCT02350023|ACTIVE_COMPARATOR|Topical latanoprost|Topical latanoprost 0.005%
62563400|NCT02350023|ACTIVE_COMPARATOR|Topical betamethasone|Topical betamethasone 0.05%
62179916|NCT03626025|OTHER|Spaced Learning Group|Participants underwent two-hour microsurgery training sessions every week for a total of 4 sessions under the spaced learning format.
62179917|NCT02764177|EXPERIMENTAL|Protein|In this arm the subjects were provided with a PROTEIN drink to consume after exercise. This protein drink contained whey protein isolate that provided 0.3 g/ kg body mass of protein.
62179918|NCT02764177|EXPERIMENTAL|Carbohydrate|In this arm the subjects were provided with a CARBOHYDRATE drink to consume after exercise. This carbohydrate drink was energy matched to the protein drink in the other arm of the experiment.
62179919|NCT06434233|ACTIVE_COMPARATOR|Arm 1 - Opioid Post-Op Pain Regimen|"Patients randomized to Arm 1 will receive the current most commonly prescribed pain control regimen after a minimally invasive tubal sterilization procedure at discharge.~These medications include:~Tylenol 500 mg orally every 6 hours scheduled x 30 tablets Ibuprofen 600 mg orally every 6 hours scheduled x 30 tablets and Oxycodone 5 mg orally every 4 hours as needed x 12 tablets~All patients will be instructed to use Acetaminophen and Ibuprofen around the clock for the first 72 hours and as needed thereafter"
62563401|NCT02155127|EXPERIMENTAL|walking intervention|Subjects are randomized to walking/functional strength program with weekly coaching or usual care. The program is for 12 weeks. The intervention includes 3 lower extremity strengthening exercises, and progressive walking.
62563402|NCT02155127|NO_INTERVENTION|usual care|these subjects receive information on walking program, however do not receive any coaching over 12 weeks
62563403|NCT06491303||Distribution of studied patients by age in years.|Adult patients suffering of epilepsy aged 18 to 60 years old
62563404|NCT06491303||Distribution of studied patients by duration of levetiracetam administration in months|Adult patients suffering of epilepsy and receiving treatment of levetiracetam for at least 6 months
62563405|NCT04275011|ACTIVE_COMPARATOR|Static Posture and Balance Exercise|Participants in the control group will receive equal attention through a static posture and balance exercise class two times per week, in a small group setting.
62563406|NCT04275011|EXPERIMENTAL|Progressive Resistance and Impact Exercise|The exercise program will include two progressive resistance and impact exercise training sessions per week in a small group setting. Exercises will be individually tailored to the participants' abilities and designed to achieve a maximum 80-85% 1RM.
62563407|NCT06191289|EXPERIMENTAL|Transdermal Estradiol|.1mg per 24 hours transdermal estradiol applied to the skin weekly, for 14 days.
62563408|NCT06191289|PLACEBO_COMPARATOR|Placebo|Clear patch manufactured to mimic the E2 patch applied to the skin weekly, for 14 days.
62563409|NCT00357981|EXPERIMENTAL|ORTHO EVRA|"The approximate first two months of women's participation will be spent documenting baseline information about their health and well-being, work patterns and performance, and the economic impact of their menstruation. Subjects will then initiate two, two month intervals of continuous use of ORTHO EVRA.~Over this four month treatment period, subjects will document their health and well-being, work patterns and performance, and the economic impact of their menstruation while being treated with ORTHO EVRA. This will allow us to compare subjects' experiences pre- and post-treatment. The study's instruments will focus on eliciting information on the personal and economic costs of menstruation such as measuring time missed from work, changes in productivity and work satisfaction, and impact on quality of life."
62563410|NCT00848718|EXPERIMENTAL|MK-2206 + carboplatin + paclitaxel|MK-2206 combined with carboplatin and paclitaxel
62179920|NCT06434233|EXPERIMENTAL|Arm 2 - Non-Opioid Post-Op Pain Regimen|"Patients randomized to Arm 2 will not receive an opioid prescription after minimally invasive tubal sterilization procedures at discharge. They will receive only Tylenol and Ibuprofen as follows:~Tylenol 500 mg orally every 6 hours scheduled x 30 tablets Ibuprofen 600 mg orally every 6 hours scheduled x 30 tablets and~All patients will be instructed to use Acetaminophen and Ibuprofen around the clock for the first 72 hours and as needed thereafter.~Participants will be informed that if they need additional pain medications, these will not be withheld. Participants in the second arm who require additional pain medications will receive the same amount of oxycodone as in arm 1."
62563411|NCT00848718|EXPERIMENTAL|MK-2206 + docetaxel|MK-2206 combined with docetaxel plus pretreatment with a corticosteroid
62563412|NCT00848718|EXPERIMENTAL|MK-2206 + erlotinib|MK-2206 combined with erlotinib
62563413|NCT00864630|NO_INTERVENTION|Wait list|
62563414|NCT00864630|EXPERIMENTAL|Computer-based problem solving therapy|
62563415|NCT01681446|ACTIVE_COMPARATOR|interferon-alpha (IFN-alpha)|interferon-alpha is intramuscularly or subcutaneously injected at 30 μg three times a week or 50 μg twice a week for 18 months
62563416|NCT01681446|NO_INTERVENTION|control|no anti-cancer interventions were assigned
62179921|NCT01591655|EXPERIMENTAL|Mapracorat|Mapracorat ophthalmic suspension, 3%,
62179922|NCT01591655|PLACEBO_COMPARATOR|Vehicle|The vehicle of the mapracorat ophthalmic suspension
62179923|NCT04167228||CRE infected patients treated with ceftazidime-avibactam|Patients with infections caused by carbapenem resistant enterobacteria treated with ceftazidime-avibactam
62179924|NCT04167228||CRE infected patients treated with best available treatment|Patients with infections caused by carbapenem resistant enterobacteria treated with the best available treatment
62179925|NCT04016350|EXPERIMENTAL|Exercise Training with Inulin Propionate Ester|Study participants underwent 4 week supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation at doses of 10g / day.
62179926|NCT04016350|EXPERIMENTAL|Exercise Training with Placebo|Study participants underwent 4 week supervised moderate intensity exercise training combined with cellulose as placebo at doses of 10g / day.
62179927|NCT04528953|EXPERIMENTAL|interval group|
62179928|NCT04528953|EXPERIMENTAL|Qigong exercise|
62179929|NCT04528953|ACTIVE_COMPARATOR|continuous walking|
62179930|NCT04747821|EXPERIMENTAL|First group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the first week of study The vaccine is administrated in two doses with a four-weeks interval
62563417|NCT05359354|EXPERIMENTAL|Personalized neoantigen vaccine or neoantigen tumor vaccine + PD-1|In dose escalation phase, subject will only receive personalized neoantigen tumor vaccine. In dose expansion phase, subject will receive personalized neoantigen tumor vaccine combination with PD-1.
62563418|NCT05399472||Participant|"The participants must be teenage basketball players (12-17 years old).~The exclusion criteria are:~* have suffered in the last 3 months of lower limb musculoskeletal disorders such as pain for more than 7 days (ankle distortion outcomes, leg/foot fractures, plantar fasciopathy, metatarsalgias, etc);~* athletes who have undergone surgery on their lower limb."
62563419|NCT05581277|ACTIVE_COMPARATOR|Active Comparator: 6 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 6 days.
62563420|NCT05581277|ACTIVE_COMPARATOR|Active Comparator: 8 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 8 days.
62563421|NCT05581277|ACTIVE_COMPARATOR|Active Comparator: 10 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 10 days.
62563422|NCT04848155|ACTIVE_COMPARATOR|Older adults with MCI|
62563423|NCT04848155|ACTIVE_COMPARATOR|Caregivers|
62563424|NCT03898453|EXPERIMENTAL|Group EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient stabilisation Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care and questionnaires Follow-up 8 (three month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)
62563425|NCT03898453|OTHER|Group Control : support psychotherapy|"Visit 0 : patient inclusion (questionnaires and interview) Visits 1-7: several methods could be used: psychoeducation about cancer and psychotherapy, positive interaction and activity schedule, emotional support , relaxation, prevention techniques... Questionnaires will be completed by patients at visit 5 and 7.~Follow-up 8 (one month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)"
62179931|NCT04747821|EXPERIMENTAL|Second group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the second week of study The vaccine is administrated in two doses with a four-weeks interval
62179932|NCT04747821|EXPERIMENTAL|Third group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the third week of study The vaccine is administrated in two doses with a four-weeks interval
62179933|NCT04747821|EXPERIMENTAL|Fourth group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the fourth week of study The vaccine is administrated in two doses with a four-weeks interval
62179934|NCT02805985|EXPERIMENTAL|FLXfit™ TLIF Interbody Fusion Device|The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
62179935|NCT06050018|EXPERIMENTAL|YesMilkdiet|After one week baseline, the participants will be assigned to YesMilkdiet consuming milk and dairy products for 4 weeks
62563426|NCT02170220|EXPERIMENTAL|Vortioxetine 5 mg: Normal Hepatic Function Cohort|Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with normal hepatic function.
62563427|NCT02170220|EXPERIMENTAL|Vortioxetine 5 mg: Severe Hepatic Impairment Cohort|Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with severe hepatic impairment.
62563428|NCT01582776|EXPERIMENTAL|Lenalidomide and GA101|Ga101 and lenalidomide
62179936|NCT06050018|ACTIVE_COMPARATOR|NoMilkdiet|After one week baseline, the participants will be assigned to NoMilkdiet consuming another source of protein and without milk or dairy products for 4 weeks
62179937|NCT04641416||Noninvasive pump monitoring|All patients with the HeartMate 3 system implanted at the Medical University of Vienna, which are able and willing to understand and sign the informed consent form, and which do not meet any exclusion criteria will be included.
62179938|NCT00762645|EXPERIMENTAL|Travoprost 0.004% (Travatan)|One drop in each eye, once daily at 9 AM
62179939|NCT00762645|ACTIVE_COMPARATOR|Pilocarpine 1%|One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
62179940|NCT00709540|EXPERIMENTAL|single|10 subjects (8 active and 2 placebo)
62179941|NCT02822209|EXPERIMENTAL|Coordinating nurse added to the personalized care program|"The coordinating nurse (CN) is dedicated to the newly diagnosed patient to optimize their personalized care program.~* The CN is the connection between the medical team and the patient. They act according to the instructions from the multidisciplinary staff in charge of bronchopulmonary cancer patients.:~  e.g. Schedule an exam or an hospitalization, collect and share results of useful information to correct treatment's side effects etc~* Main contact of the patient, the general practitioner and the patient's relatives, they give practical information for the patient's case~* Quality of life questionnaires - EORTC QLQ-C30 and EORTC QLQ-LC13 - completed by the patient throughout the study.~* 2 Satisfaction questionnaires completed :~* satisfaction questionnaire - patient,~* satisfaction questionnaire - general practitioner or home nurse"
62563429|NCT04771572|EXPERIMENTAL|Dose Escalation Phase|Phase 1a dose-escalation will begin with group 1 and proceed until DLT is observed and MTD is established, or until an RP2D is established. Subjects enrolled in the dose cohorts will follow the 3+3 study design, starting with an accelerated step-up dosing schedule (with a starting dose of 20 mg, 50 mg, 100 mg once daily) until they reach the designated target dose (50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg). Once the MTD or RP2D is established for group 1, the phase 1a dose escalation can proceed for group 2. The starting dose level for group 2 will be one dose level below the MTD or RP2D established for group 1.
62563430|NCT04771572|EXPERIMENTAL|Dose Expansion Phase|Additional subjects will be recruited to further explore the safety, tolerability, PK, and efficacy in specific subject subgroups. One or more RP2D may be explored. Definition of these cohorts will be accomplished by protocol amendment, and in light of emerging data from Phase 1a.
62563431|NCT02129231|PLACEBO_COMPARATOR|placebo|calcined magnesia 100 mg tablets once a day for 16 weeks
62563432|NCT02129231|ACTIVE_COMPARATOR|ezetimibe/simvastatin|ezetimibe/simvastatin 10/20 mg tablets once a day for 16 weeks
62563433|NCT02129231|ACTIVE_COMPARATOR|rosuvastatin|rosuvastatin 20 mg tablets once a day for 16 weeks
62772356|NCT05423392|ACTIVE_COMPARATOR|The second tasted group using 2% Lidocaine-chloride|The group was divided into three subgroups depending on the age of the participials: 1st group from 5-9 years, 2nd from 10-13 years and 3th from 14-18 years. Following placement of 5% lidocaine topical anesthetic for 3 minutes prior to and at the site of needle penetration, patients were randomly given one of the following local anesthetic regimes administered by the principle investigator. For the indicated dental treatment will be used 2.0 ml 2% lidocaine with 1:80,000 epinephrine as an IANB anesthesia for n.alveolaris inferior. Criteria for measuring efficacy would be to measure pain during anesthetic injection, 10 minutes after injection,during and after the intervention. The child's behavior would be monitored through all phases of clinical work by direct observation of the dentist( examiner) using the above methodology. After that, the examiner would fill in the questionnaire based on the answer of the child / parent (guardian).
62772357|NCT03693911|EXPERIMENTAL|Prevention group|AcceptME- digital gamified Acceptance and Commitment Therapy prevention program
62772358|NCT03693911|NO_INTERVENTION|Waitlist control|Waitlist control group
61995161|NCT01510119|EXPERIMENTAL|Intervention - Dose Level 2 Phase 2|RAD001 given 10mg/daily by mouth and 600mg hydroxychloroquine twice daily by mouth. Cycle 1 will include 1 week run-in of RAD001. Following this, both RAD001 and hydroxychloroquine given without interruption. Cycle 1 duration is 35 days; all subsequent cycles are 28 days. RAD001 and hydroxychloroquine continuously administered until progression of disease or unacceptable toxicity.
62182777|NCT06385613|EXPERIMENTAL|Control Group|Patients who have undergone stoma surgery will be divided into two groups as control and intervention by simple randomization. Patients assigned to the control group will receive standard stoma care training applied by the clinic. Patients will be met before surgery and necessary information will be obtained. A total of 5 interviews will be conducted with patients in both groups.
62563434|NCT04798625||Rheumatoid arthritis|Patients with a clinical diagnosis of rheumatoid arthritis and treated with immunosuppressive medication
62563435|NCT04798625||Psoriatic arthritis|Patients with a clinical diagnosis of psoriatic arthritis and treated with immunosuppressive medication
62563436|NCT04798625||Spondyloarthritis|Patients with a clinical diagnosis of spondyloarthritis and treated with immunosuppressive medication
62563437|NCT04798625||Crohn disease|Patients with a clinical diagnosis of Crohn disease and treated with immunosuppressive medication
62563438|NCT04798625||Ulcerative colitis|Patients with a clinical diagnosis of ulcerative colitis and treated with immunosuppressive medication
62772359|NCT03329261|ACTIVE_COMPARATOR|Arm 1 (single dose)|Will receive a clopidogrel loading dose of 600 mg PO, then a daily dose of clopidogrel 75 mg PO until the angioplasty is performed. After coronary intervention, a daily dose of clopidogrel 150 mg PO for 7 days will be given, followed by a daily single dose of clopidogrel (75 mg PO) for 21 days. Maintenance therapy will be clopidogrel daily dose of 75 mg PO thereafter, until the end of the study.
62772360|NCT03329261|ACTIVE_COMPARATOR|Arm 2 (double dose)|Will receive a clopidogrel loading dose of 600 mg PO, then a daily dose of clopidogrel 75 mg PO until the angioplasty is performed. After coronary intervention, a daily dose of clopidogrel 150 mg PO for 7 days will be given, followed by a daily double dose of clopidogrel (150 mg PO) for 21 days. Maintenance therapy will be clopidogrel daily dose of 75 mg PO thereafter, until the end of the study.
62772361|NCT03001778|EXPERIMENTAL|Usability Testing|Prototype testing
62772362|NCT01274910|ACTIVE_COMPARATOR|Fish oil group|Treatment Group.
62772363|NCT01274910|PLACEBO_COMPARATOR|Control group|Placebo group
62772364|NCT03874390|EXPERIMENTAL|ozone therapy|control group only treated with Initial Periodontal Therapy (IPT), test group treated with IPT an adjunct to gasesos ozone therapy.
62772365|NCT03874390|ACTIVE_COMPARATOR|initially periodontal therapy|control group only treated with Initial Periodontal Therapy (IPT), test group treated with IPT an adjunct to gasesos ozone therapy.
62772366|NCT05200689|EXPERIMENTAL|Thoracotomy, KT|Patients in this group will undergo the same analgesia protocol as other groups. They will undergo the thoracotomy protocol, alongside the KT protocol.
62772367|NCT05200689|EXPERIMENTAL|Thoracoscopy, KT|Patients in this group will undergo the same analgesia protocol as other groups. They will undergo the thoracoscopy protocol, alongside the KT protocol.
62179942|NCT02822209|ACTIVE_COMPARATOR|Personalized care program as routine practice|"A personalized care program is decided for the newly diagnosed patient by the multidisciplinary team in charge of lung cancer.~The care provided will be organized by the medical team, and besides the oncologist, no principal coordinating contact will be in charge of the patient.~The quality of life questionnaire - EORTC QLQ-C30 and QLQ-LC13 - will be completed by the patient throughout the study.~* 2 Satisfaction questionnaires completed :~* satisfaction questionnaire - patient,~* satisfaction questionnaire - general practitioner or home nurse"
62179943|NCT00938990|ACTIVE_COMPARATOR|Midazolam|
62179944|NCT00938990|EXPERIMENTAL|Etomidate|
62179945|NCT01781013|EXPERIMENTAL|Technology-supported care|This arm consists of Clinic Resource Management (CRM) clinics and serves as our intervention arm where the tested technology is implemented. Our overarching aim in these comparisons is to assess the potential effects of technology-facilitated depression symptom monitoring, relapse prevention, and medication adjustments and to examine depression care receipt and symptom improvement, patient/provider acceptance, and cost.
62563439|NCT04798625||Autoimmune hepatitis|Patients with a diagnosis of autoimmune hepatitis and treated with immunosuppressive medication
62772368|NCT05200689|NO_INTERVENTION|Thoracotomy, Non-KT|Patients in this group will undergo the same analgesia protocol as other groups. They will undergo the thoracotomy protocol, without the KT protocol.
62772369|NCT05200689|NO_INTERVENTION|Thoracoscopy, Non-KT|Patients in this group will undergo the same analgesia protocol as other groups. They will undergo the thoracoscopy protocol, without the KT protocol.
62772370|NCT04619355||TVC K-Registry|
62772371|NCT02974894|EXPERIMENTAL|Probiotic|Capsules containing potato starch as a filler and Lactobacillus plantarum
62772372|NCT02974894|PLACEBO_COMPARATOR|Placebo|Capsules containing potato starch
62772373|NCT00880646|EXPERIMENTAL|1|
62772374|NCT00880646|PLACEBO_COMPARATOR|2|
62772375|NCT02648672|EXPERIMENTAL|BPN14770|A single oral dose of BPN14770.
62772376|NCT02648672|PLACEBO_COMPARATOR|Placebo|A single oral dose of placebo matching BPN14770
61995162|NCT01695785||Healthy weight|greater than or equal to the 5th to less than the 85th BMI percentile
62772377|NCT01665534|EXPERIMENTAL|Effect of salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks. During the low salt intake period, patients received a 10-20 mmol sodium diet + placebo tablets for two weeks.
62772378|NCT06287307|ACTIVE_COMPARATOR|Semaglutide 2.4mg|Patients in this group will receive the active comparator semaglutide 2.4mg. This is a medication which is distributed by an intramuscular injection once weekly.
62772379|NCT06287307|PLACEBO_COMPARATOR|Placebo|Patients in this group will receive the placebo. This is a placebo which is distributed by an intramuscular injection once weekly.
61995163|NCT01695785||Obese|greater than or equal to the 95th BMI percentile
62179946|NCT01781013|NO_INTERVENTION|Supported-Care|This arm consists of CRM (Clinic Resource Management) clinics and serves as one of the two control arms in the study.
62179947|NCT01781013|NO_INTERVENTION|Usual Care|This arm consists of non-CRM (Clinic Resource Management) clinics and serves as one of the two control arms in the study.
62179948|NCT03376698|ACTIVE_COMPARATOR|Colchicine 0.5 mg|
62179949|NCT03376698|ACTIVE_COMPARATOR|Colchicine 0.25 mg|
62179950|NCT03376698|PLACEBO_COMPARATOR|Placebo|
62772380|NCT02047097||dimethyl fumarate (DMF)|Patients with multiple sclerosis receiving dimethyl fumarate (DMF) under routine clinical care
62772381|NCT05319119||1.CT-FFR Related Group|Coronary diseased artery CTFFR\>80%, secondary prevention of coronary heart disease;Coronary diseased artery CTFFR≤80% revascularization at the lesion site and regular medication after PCI
61995164|NCT01314209|EXPERIMENTAL|dexmedetomidine|
62179951|NCT02600598|EXPERIMENTAL|LEO 43204 Group A|Group A - Experimental LEO 43204, applied once daily for 3 consecutive days in patients with actinic keratosis
62563440|NCT04798625||Liver transplant|Patients who have undergone liver transplantation and are treated with immunosuppressive drugs
62563441|NCT01185678||Group1|
62772382|NCT05319119||Coronary Angiography Related Group|Coronary diseased artery CTFFR≤80%, coronary angiography decision does not require revascularization but apply coronary heart disease secondary prevention medication;Coronary diseased artery CTFFR\>80%,However, revascularization was performed according to conventional angiographic decisions and postoperative regular service was performed.For multivessel disease, although coronary revascularization is performed, there are still diseased artery with CTFFR≤80% and no revascularization is performed.
62772383|NCT03327064|ACTIVE_COMPARATOR|Renal Transplant subjects receiving UAB30|Generally healthy renal transplant subjects receive UAB30 for 28 days with increased risk of non-melanoma skin cancer as evidenced by a history of prior squamous or basal cell skin cancer, ongoing or history of actinic keratoses and presence at baseline of at least 8 actinic keratosis on the face, neck, scalp and arms.
62563442|NCT00695461|EXPERIMENTAL|1|Receives Lactobacillus plantarum 299v in an oatmeal drink, at a concentration of 10(9) colony-forming-units/ml, 100 ml per day, starting one week before surgery, finishing 5 days after surgery.
62563443|NCT00695461|PLACEBO_COMPARATOR|2|Receives oatmeal drink, 100 ml per day, starting one week before surgery, finishing 5 days after surgery.
62563444|NCT05831878|EXPERIMENTAL|RC48-ADC|RC48-ADC as salvage treatment for HER2-low advanced breast cancer
62179952|NCT02600598|EXPERIMENTAL|LEO 43204 Group B|Group B - Experimental LEO 43204, applied once daily for 3 consecutive days in patients with actinic keratosis
62563445|NCT04117360||Dentofacial Disharmony Patients|Dentofacial disharmony patients who are seeking jaw surgery in UNC oral and maxillofacial surgery department and are seen in UNC orthodontic dentofacial disharmony clinic.
62563446|NCT01566188|EXPERIMENTAL|omega-3 from vegetal origin|
62563447|NCT01566188|PLACEBO_COMPARATOR|Placebo|
62179953|NCT06099288|EXPERIMENTAL|Home-Based Video and Motivational Interviewing Intervention|The intervention will be delivered in English or Spanish by a trained CHW and consists of three home-based visits with tailored print materials, text-messages delivered 2x/week, followed by monthly tailored print materials and phone calls during the last three months of the intervention. For in-home visits, the CHW will deliver a Motivational Interviewing session based on scripts developed in the R34. For phone calls, parents will receive a 30-minute Motivational Interviewing phone call to check in on goals and barriers and reinforce earlier concepts. For text messages, parents will be sent two times/week messages related to objectives targeted during that month's visit, such as parents setting good examples and giving children autonomy in eating. For print materials, parents will receive printed materials, highlighting nutrition and parental feeding guidance.
62563448|NCT03563430|EXPERIMENTAL|Active Recovery Group|Participants in this group will exercise for 15 minutes, for a range of 65 to 70% of the maximum heart rate.
62391196|NCT02735876|EXPERIMENTAL|acalabrutinib plus rituximab|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity. Rituximab IV infusions will be administered weekly for 4 weeks and on Day 1 of Cycle 3 through 8, and thereafter every other cycle for less than or equal to two years (approximately 200 subjects).
62391197|NCT02735876|ACTIVE_COMPARATOR|ibrutinib|Ibrutinib will be orally administered until disease progression or unacceptable toxicity (approximately 200 subjects).
62391198|NCT02735876|EXPERIMENTAL|acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity (approximately 50 subjects).
62391199|NCT05002049|EXPERIMENTAL|Citizen Science Behavioral Intervention|The intervention group (IG) participants will receive the whole citizen science intervention of the SEEDS project, and participants will be assessed at baseline and end-of-study.
62391200|NCT05002049|NO_INTERVENTION|Control Group (No intervention)|The controls group (CG) participants will not receive any kind of intervention, and participants will only be assessed at baseline and end-of-study.
62391201|NCT06036940|NO_INTERVENTION|First Control Group|The children in the first control group were given pre-operative patient education by the service nurse.
62391202|NCT06036940|EXPERIMENTAL|Second Experimental Group|The children in the second experimental group were given pre-operative patient education by the service nurse, also patient visits were provided by the operating room nurse and the operating room environment was explained through play.
62179954|NCT06099288|ACTIVE_COMPARATOR|Read Educate and Develop Youth (READY) Comparison|As done in the R34, the comparison group will receive an attention contact control intervention about school readiness promotion adapted from R.E.A.D.Y. (Read Educate and Develop Youth) designed by the Michigan Department of Education (Refs). Families in the comparison arm will receive the same intervention components as the intervention arm, but these will be focused on child reading rather than nutrition. Parents will send a video of themselves reading with a child, receive 3 home visits and 48 text-messages as well as newsletters for each visit. Instead of receiving cooking materials during the second home visit, they will receive books to read with their children.
62179955|NCT01965145|EXPERIMENTAL|Gevokizumab|Solution for subcutaneous injection, Dose 1
62179956|NCT01965145|PLACEBO_COMPARATOR|Placebo|Solution for subcutaneous injection, placebo
62772384|NCT03327064|PLACEBO_COMPARATOR|Renal Transplant subjects receiving placebo|Generally healthy renal transplant subjects receive placebo for 28 days with increased risk of non-melanoma skin cancer as evidenced by a history of prior squamous or basal cell skin cancer, ongoing or history of actinic keratoses and presence at baseline of at least 8 actinic keratosis on the face, neck, scalp and arms.
62772385|NCT03582696|OTHER|No Arms|Participants are not assigned to randomized study arms or groups.
62179957|NCT01695447|EXPERIMENTAL|duct-to-mucosa|duct-to-mucosa technique is used for pancreaticojejunostomy after pancreaticoduodenectomy
62179958|NCT01695447|ACTIVE_COMPARATOR|invagination|invagination technique is used for pancreaticojejunostomy after pancreaticoduodenectomy
62179959|NCT05470959|OTHER|ACTIVA bioactive|bioactive ionic resin composite
62179960|NCT05470959|OTHER|Riva LC|Resin-modifed glass ionomer
62179961|NCT01649505|EXPERIMENTAL|Arm I (fibrin sealant)|Patients undergo sharp dissection technique with fibrin sealant closure.
62772386|NCT02345096|ACTIVE_COMPARATOR|Saccharomyces cerevisiae CNCM I-3856|In this arm, subjects will be asked to consume one capsule of Saccharomyces cerevisiae CNCM I-3856 per day.
62772387|NCT02345096|PLACEBO_COMPARATOR|placebo|In this arm, subjects will be asked to consume one capsule of placebo per day.
62772388|NCT04229355|EXPERIMENTAL|DEB-TACE plus Sorafenib|Patients with unresectable hepatocellular carcinoma (HCC) in this group will receive drug-eluting bead transarterial chemoembolization (DEB-TACE).And then, they will receive sorafenib (400 mg/d, po, bid) one week after DEB-TACE therapy. The second DEB-TACE will be performed after one month later the first DEB-TACE. Lenvatinib will be taken orally for six months, untill tumor progression, or intolerable adverse reactions.
62772389|NCT04229355|EXPERIMENTAL|DEB-TACE plus Lenvatinib|Patients with unresectable hepatocellular carcinoma (HCC) in this group will receive drug-eluting bead transarterial chemoembolization (DEB-TACE).And then, they will receive lenvatinib (8 mg/d, po, qd) one week after DEB-TACE therapy. The second DEB-TACE will be performed after one month later the first DEB-TACE. Lenvatinib will be taken orally for six months, untill tumor progression, or intolerable adverse reactions.
62179962|NCT01649505|ACTIVE_COMPARATOR|Arm II (standard electrocoagulation)|Patients undergo standard electrocoagulation dissection technique.
62179963|NCT00185796|EXPERIMENTAL|TLI/ATG conditioning|Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).
62179964|NCT02702336|EXPERIMENTAL|EYTO-Kids Intervention Group|Adolescents will receive 16h of training (2h healthy lifestyle training, social marketing and communication, 6h to design activities, 2h session together with all intervention high-schools, 6h to practice and standardize activities) and 4h (1h/activity) to implement 4 activities in schools. The scholars will receive 4 activities designed by adolescents, focusing on: 1) increasing fruit consumption, 2) increasing vegetable consumption, 3) increasing physical activity practice and to reduce sedentary lifestyles and, 4) decreasing sugary drinks and fast-food consumption.
62179965|NCT02702336|NO_INTERVENTION|Control Group|The control group will not receive any kind of intervention (only the assessment).
62563449|NCT03563430|EXPERIMENTAL|Self-Massage with Foam Roller Group|This group will perform 15 minutes self-massage with foam roller following the exercise session.
62563450|NCT03563430|EXPERIMENTAL|Neuromuscular Electrical Stimulation|Participants of this group will be applied electrical stimulation on quadriceps femoris and hamstring muscles for 15 minutes while they are comfortable lying position.
62563451|NCT01567462|ACTIVE_COMPARATOR|Monopolar Electrocautery|The current treatment standard of care for patients who present de novo or with a recurrent bladder tumor is transurethral resection of the bladder tumor (TURBT) using monopolar electrocautery in the form a 90-degree loop electrode and has been used since its introduction in 1952. This intervention, accomplished endoscopically through the urethra, is both diagnostic and potentially therapeutic. An adequately performed TURBT will provide the pathologist with enough tissue to provide tumor grade and stage information.
62563452|NCT01567462|ACTIVE_COMPARATOR|PK Button Vaporization Electrode|Bipolar energy has been available for many years and has been readily adopted for the surgical treatment of benign prostatic enlargement and may provide advantages and solutions to the technical challenges of monopolar electrocautery. A further refinement on bipolar energy has been the recent introduction of the PlasmaKinetic (PK) Button Vaporization electrode which will be used in the intervention arm of this study. This electrode is already approved by the Food and Drug Administration (FDA) for this indication as well. The semi-spherical design of the electrode creates a plasma arc that glides over the tissue, transmitting energy to the cell layers adjacent to the arc which are then quickly vaporized.
62772390|NCT04229355|ACTIVE_COMPARATOR|DEB-TACE plus PD-1 inhibitor|Patients with unresectable hepatocellular carcinoma (HCC) in this group will receive drug-eluting bead transarterial chemoembolization (DEB-TACE).And then, they will receive PD-1 inhibitor (200 mg, iv, 3 weeks) one week after DEB-TACE therapy. The second DEB-TACE will be performed after one month later the first DEB-TACE. PD-1 inhibitor will be taken for six months, untill tumor progression, or intolerable adverse reactions.
62563453|NCT03458117|EXPERIMENTAL|Talimogene Laherparepvec (T-VEC)|Intralesional injections of T-VEC up to 4.0 mL of 10 to the 6 plaque-forming Units/mL (PFU/mL)
62772391|NCT01329913|EXPERIMENTAL|GT1-HCV 200 mg|
62772392|NCT01329913|EXPERIMENTAL|GT1-HCV 400 mg|
62772393|NCT01329913|EXPERIMENTAL|GTI-HCV 800 mg|
62772394|NCT01329913|EXPERIMENTAL|GT3-HCV 200 mg|
62772395|NCT01329913|EXPERIMENTAL|GT3-HCV 400 mg|
62772396|NCT01329913|EXPERIMENTAL|GT3-HCV 800 mg|
62772397|NCT05583032||ScanNav Anatomy PNB aided|Participants completing scans for regional anaesthesia with the aid of ScanNav Anatomy PNB.
62772398|NCT05583032||ScanNav Anatomy PNB unaided|Participants completing scans for regional anaesthesia without the aid of ScanNav Anatomy PNB.
62772399|NCT02552160||Patients on Duaklir® Genuair®|Patients on fixed-dose combination Duaklir® Genuair® (Aclidinium/Formoterol)
62772400|NCT02552160||Patients on Ultibro® Breezhaler®|Patients on fixed-dose combination Ultibro® Breezhaler® (Glycopyrronium/Indacaterol)
62772401|NCT02552160||Patients on Anoro®|Patients on fixed-dose combination Anoro® (Umeclidinium/Vilanterol)
62772402|NCT04350307|ACTIVE_COMPARATOR|22-Gauge Arm|Patient undergoing epidural injection in this arm will get 22-gauge Quincke needle
62772403|NCT04350307|ACTIVE_COMPARATOR|25-Gauge Arm|Patient undergoing epidural injection in this arm will get 25-gauge Quincke needle
62772404|NCT00001978||Study Cohort|Selected patients with proteinuria
62772405|NCT06047496|EXPERIMENTAL|Time restricted eating|Caloric intake restricted to a self-defined 8-10 hour window in each 24-hour period, for 12 weeks.
62772406|NCT06047496|NO_INTERVENTION|Standard eating|Normal eating schedule. Participants are expected to maintain their normal eating and dietary habits.
62772407|NCT03951090|EXPERIMENTAL|GARRT Arm|Participants in this arm complete an brief geriatric assessment, and the results of these assessments are given to providers with recommendations to address deficits identified by the geriatric assessment
62772408|NCT03951090|ACTIVE_COMPARATOR|Control Arm|Providers of participants of this group will not receive the results of the brief geriatric assessments. These participants will receive standard of care treatment
62772409|NCT04506203|EXPERIMENTAL|Air test|
62772410|NCT02456857|EXPERIMENTAL|Treatment (DAE)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over about 3 hours on day 1, bevacizumab IV over 90 minutes on day 1, and everolimus PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients will not receive bevacizumab during cycle 4 of therapy. Patients then undergo surgery.
62772411|NCT02557984|PLACEBO_COMPARATOR|Placebo|Placebo Pill
62772412|NCT02557984|EXPERIMENTAL|Amisulpride|400 mg Amisulpride (Solian®)
62772413|NCT02557984|EXPERIMENTAL|Naltrexone|50 mg Naltrexone (Naltrexin®)
62772414|NCT04928729|EXPERIMENTAL|Pursed Lip Breathing|
62772415|NCT04928729|EXPERIMENTAL|Pursed Lip Breathing +DB|
62772416|NCT04928729|EXPERIMENTAL|Conservative care|
62772417|NCT05011721|EXPERIMENTAL|Intervention with activity tracker|Women allocated to the intervention arm will used an activity tracker
62772418|NCT00370513|EXPERIMENTAL|Pazopanib Arm|Different doses of oral pazopanib once daily for the duration of the study starting on Day 1 of Treatment Period 1. Treatment continues until disease progression or withdrawl from study.
62772419|NCT05323097||Drowning-related OHCA|Drowning-related OHCA: YES
62179966|NCT06187597|EXPERIMENTAL|The study group|Patients will receive radiotherapy with prescribed dose of 54 Gy in 27 fractions, concurrently with S-1 chemotherapy. Then patients in the study group will receive toripalimab as consolidation therapy for up to 12 months (16 cycles) after the completion of chemoradiotherapy.
62179967|NCT06187597|ACTIVE_COMPARATOR|The control group|Patients will receive radiotherapy with prescribed dose of 54 Gy in 27 fractions, concurrently with S-1 chemotherapy. Then patients will be receive routine follow-up.
62772420|NCT05323097||All other OHCA|Drowning-related OHCA: NO
62772421|NCT00410306||Group 1|
62772422|NCT01071824|ACTIVE_COMPARATOR|Transverse coloplasty pouch (Short limb)|The short limb is the standard technique of transverse coloplasty pouch.
62772423|NCT01071824|EXPERIMENTAL|Transverse coloplasty pouch (Long limb)|The long limb relates to straight coloanal anastomosis.
62772424|NCT05224037|EXPERIMENTAL|Study group|This is a single-arm study. All the participants will undergo examinations with 2 devices
62772425|NCT00129961|EXPERIMENTAL|1|Conversion to a sirolimus-based regimen
62179968|NCT00979329||mRCC or GIST treated with sunitinib/sorafenib|
62179969|NCT03993496||EVAR Patients|Patients with infrarenal abdominal aortic aneurysm scheduled for elective endovascular aneurysm repair (EVAR) surgery will undergo intraoperative assessments of aneurysm wall pulsatility using ultrasound M-Mode.
62179970|NCT00654615|ACTIVE_COMPARATOR|1|"Intramedullary Radius Fixation (Micronail) - Group 1~A new device was developed to provide intramedullary distal radius fracture fixation. This new device allows the placement of the orthopaedic hardware inside the medullary canal of the radius."
62179971|NCT00654615|ACTIVE_COMPARATOR|2|"Volar Plate Fixation - Group 2~Volar locking plates provide rigid external fixation and are placed on the outside of the radius. Volar plates are placed directly on the distal radius using a metal plate contoured to the shape of the distal radius."
62179972|NCT01624597|NO_INTERVENTION|Usual Care|Participants will have a passive in-vehicle video device installed in their car to measure driving errors and safety behaviors.
62179973|NCT01624597|EXPERIMENTAL|In-vehicle video feedback|Participants will receive feedback from an in-vehicle video system. A light on the system will blink when a driving event has been recorded. Parents will receive a weekly report card of driving errors.
62772426|NCT00129961|ACTIVE_COMPARATOR|2|Continuation of a CNI-based regimen
62772427|NCT02968147|EXPERIMENTAL|Conventional ventilation|Catheter ablation for persistent atrial fibrillation with general anesthesia and conventional ventilation
62772428|NCT02968147|EXPERIMENTAL|Jet ventilation|Catheter ablation for persistent atrial fibrillation with general anesthesia and high frequency jet ventilation
62772429|NCT03878303|EXPERIMENTAL|AC0058TA|AC0058TA will be administered in 25 mg capsules orally at the following doses: 50 mg QD, 100 mg QD, 200 mg QD and 100 mg BID
62772430|NCT03878303|PLACEBO_COMPARATOR|Placebo AC0058TA|Placebo AC0058TA will be administered orally at the equivalent dose of investigational product
62772431|NCT03680872|EXPERIMENTAL|Spinal Cord Injury Participants|This group consists of individuals with tetraplegia receiving an investigational device called the Bidirectional Neural Bypass System.
62772432|NCT02663141|EXPERIMENTAL|Losartan|Oral losartan 50 mg daily for 6 months
62772433|NCT02663141|PLACEBO_COMPARATOR|Placebo|Oral placebo daily for 6 months
62772434|NCT05831254|EXPERIMENTAL|HEalth Literacy, e-Pulse (HELP)|
62772435|NCT05831254|ACTIVE_COMPARATOR|e-Pulse|
62179974|NCT01624597|EXPERIMENTAL|In-vehicle video feedback, parent communication|Participants will receive feedback from an in-vehicle video system. A light on the system will blink when a driving event has been recorded. Parents will receive a weekly report card of driving errors. Parents will participate in an intervention that provides input on teaching and communicating about driving skills and safety behaviors.
62179975|NCT03411798|EXPERIMENTAL|Experimental|Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR \& CRP reduce to normal and BASDAI\<4) maintenance.
62179976|NCT00197119|ACTIVE_COMPARATOR|Group Twinrix Adult|Subjects received Twinrix™ Adult (720/20) in a 0, 6 month schedule in the primary study.
62772436|NCT00428844|EXPERIMENTAL|Daptomycin 6 mg/kg|Daptomycin (6 mg/kg every 24 hours \[q24h\]) as a 30 minute intravenous (IV) infusion for 6 weeks (± one week).
62772437|NCT00428844|EXPERIMENTAL|Daptomycin 8 mg/kg|Daptomycin (8 mg/kg q24h) as a 30 minute IV infusion for 6 weeks (± one week).
62772438|NCT00428844|ACTIVE_COMPARATOR|Comparator|Vancomycin was administered at 1 gram every 12 hours (q12h) as a 60-minute infusion and teicoplanin was administered 6 mg/kg q24h as a 30-minute infusion also for 6 weeks (±1 week). Semi-synthetic penicillin (nafcillin, oxacillin, or flucloxacillin) was administered according to standard of care for 6 weeks (±1 week).
62772439|NCT00734721|ACTIVE_COMPARATOR|A|Presentation of factual information video
62772440|NCT00734721|ACTIVE_COMPARATOR|B|Presentation of injection syringe/needle
62772441|NCT00734721|ACTIVE_COMPARATOR|C|Presentation of emotional information video
62772442|NCT00734721|ACTIVE_COMPARATOR|D|Stress relaxation music
62772443|NCT04726059|SHAM_COMPARATOR|ABT+SHAM|The SHAM is low-intensity, ineffective stimulation delivered at the same anatomical location as TSCS.
62179977|NCT00197119|ACTIVE_COMPARATOR|Group Twinrix Junior|Subjects received Twinrix™ Junior (360/10) in a 0, 1, 6 month schedule in the primary study.
62179978|NCT01195740|EXPERIMENTAL|Attachment Based Family Therapy|
62179979|NCT01195740|ACTIVE_COMPARATOR|Enhanced Usual Care|
62179980|NCT02388113|EXPERIMENTAL|accumulated exercise|12 exercise sessions of 10 minutes each week, 2 per day, 1 day rest
62179981|NCT02388113|ACTIVE_COMPARATOR|traditional exercise|4 exercise sessions of 30 minutes each week, 3 in the training laboratory, 1 at home.
62179982|NCT00383630|EXPERIMENTAL|Group 1|Intramyocardial injection of bone marrow mononuclear cells + LVAD
62179983|NCT00383630|EXPERIMENTAL|Group 2|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells + LVAD
62179984|NCT00383630|OTHER|Group 3|LVAD alone
62179985|NCT03028259||lab results|monitoring of
62179986|NCT05899621||GR|Induction(six 21-day cycles): obinutuzumab (G), 1000mg, IV, D1/8/15 (C1), D1 (C2-6); lenalidomide (R), 25mg, PO, D2-11; Maintenance: obinutuzumab (G), 1000mg, every 3 months for 2 years; lenalidomide (R), 25mg, PO, D1-10, every 28 days for 6 cycles
62179987|NCT05899621||GB|Induction(six 21-day cycles): obinutuzumab (G) 1000mg, IV, D1/8/15 (C1), D1 (C2-6); bendamustine (B), 90 mg/m2, IV, D1-2; Maintenance: obinutuzumab (G), 1000mg, IV, every 3 months for 2 years
62563454|NCT02837731|EXPERIMENTAL|Treatment Starling SV monitor|A dynamic assessment of fluid responsiveness using the Starling SV monitor will be performed at every clinical decision point for the first 72 hours of study enrollment. Examples of a clinical decision point include a mean arterial pressure (MAP) of \< 65, the decision to give additional fluid volume, and the decision to either escalate or wean vasopressors. Fluid responsiveness will be assessed using a passive leg raise (PLR) to guide corresponding treatment.
62563455|NCT02837731|NO_INTERVENTION|Control|No required therapeutic protocol will be used for patient treatment, and is determined per the discretion of the physician and hospital standards.
62563456|NCT03973736||PDAC patients diagnosed in 2008-2011|
62563457|NCT03973736||PDAC patients diagnosed in 2013-2016|
62179988|NCT05899621||GCHOP|Induction(six 21-day cycles): obinutuzumab (G), 1000mg, IV, D1/8/15 (C1), D1 (C2-6); prednisone (P), 100 mg, PO, D1-5；cyclophosphamide (C), 750 mg/m2, IV, D1; vincristine (O), 1.4 mg/m2 (maximum 2 mg), IV, D1; doxorubicin (H), 50 mg/m2, IV, D1; Maintenance: obinutuzumab (G), 1000mg, IV, every 3 months for 2 years
62179989|NCT05850182|EXPERIMENTAL|Arm treated with lifestyle intervention|Patients with prostate cancer will receive a lifestyle intervention on diet and physical activity.
62179990|NCT05062837|EXPERIMENTAL|Hepatectomy Combined With Camrelizumab and Apatinib|Patients with CNLC IIIb hepatocellular carcinoma will receive hepatectomy. Two to four weeks later, they will receive camrelizumab and apatinib treatments.
62179991|NCT02624869|EXPERIMENTAL|Evolocumab|Participants receive 420 mg evolocumab administered by subcutaneous injection every 4 weeks (QM) for up to 80 weeks.
62182778|NCT06385613|EXPERIMENTAL|Mobile-based stoma care education group|Patients who have undergone stoma surgery will be divided into two groups as control and intervention by simple randomization. Patients assigned to mobile-based stoma care education groupwill receive mobile-based stoma care training prepared by the researcher. Patients will be met before surgery and necessary information will be obtained. A total of 5 interviews will be conducted with patients in both groups.
62179992|NCT03937232|ACTIVE_COMPARATOR|Cross-Education|Cross education has been defined as the unilateral training of a limb with resisted exercise for the benefit of transferring strength to the contralateral (often injured or immobilized) limb. Participants randomized to cross-education will be provided with a hand-grip strengthener, adjusted to provide resistance at 70-80% of their maximum grip strength. They will be given written, illustrated instructions for performing grip strengthening exercises for their uninjured hand in a seated position with both forearms comfortably supported; this will be demonstrated during the teaching session. The instructions will ask for the participant to complete 3 sets of 10 repetitions twice daily, with additional instructions for appropriate grading of resistance. A diary for tracking exercise completion and attendance for usual care will also be provided.
62182599|NCT04773730|ACTIVE_COMPARATOR|Posterior transversus abdominus block|"After the surgery end and while the patient in the supine position, with the side to be blocked is elevated~A 12-14 MHz linear array transducer will be placed transversely between the iliac crest and costal margin then slided from medial-lateral to visualize the posterior most part of the external oblique, internal oblique, and transversus abdominus muscles~Then 20 mL of bupivacaine0.25% will be injected between the transverses abdominus muscle and the fascia deep to the internal oblique muscle~The same steps will be repeated on the other side"
61995165|NCT02857777|EXPERIMENTAL|Cohort 1: Japanese elderly subjects (Esketamine)|Subjects will receive Treatment A (28 milligram \[mg\] of esketamine, administered as 1\*14 mg spray of esketamine in each nostril at Time 0) in Period 1, Treatment B (56 mg of esketamine, administered as 1\*14 mg spray of esketamine in each nostril at Time 0 and 5 minutes) in Period 2 and then Treatment C (84 mg of esketamine, administered as 1\*14 mg spray of esketamine in each nostril at Time 0, 5, and 10 minutes) in Period 3. A washout period of 5 to 14 days will separate each intranasal esketamine treatment regimen.
61995166|NCT02857777|ACTIVE_COMPARATOR|Cohort 2: Japanese healthy subjects (Esketamine)|Subjects will receive Treatment A in Period 1, Treatment B in Period 2 and then Treatment C in Period 3. A washout period of 5 to 14 days will separate each intranasal esketamine treatment regimen.
61995167|NCT00981006|EXPERIMENTAL|human cardiac stem cell therapy|single administration of 0.5 million cells/kg(patient body weight) of human cardiac stem cells and 200 microgram of bFGF at coronary artery bypass grafting (CABG)
61995168|NCT03507218||1|Children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
61995169|NCT02795728|EXPERIMENTAL|Experimental arm|Fuji type VII is a GIC based sealant with an additional property of high fluoride release
61995170|NCT02795728|ACTIVE_COMPARATOR|Resin based sealant|Helioseal F is a resin based sealant
61995171|NCT01907828|EXPERIMENTAL|Cardiac ablation + renal artery ablation|Renal artery ablation with the EnligHTN™ Renal Denervation System
61995172|NCT01907828|ACTIVE_COMPARATOR|Cardiac ablation|Cardiac ablation
61995173|NCT03190070|EXPERIMENTAL|Study group|All study participants are in the same group and will have their kidney function measured twice, before and after ingestion of protein, 1 g/(kg body weight). The protein will be given in the form of the protein drink Liquacel (Global Health Products, Rochester, NY).
61995174|NCT03307733|NO_INTERVENTION|Control Group|Control group received usual care plus a blinded Fitbit pedometer.
61995175|NCT03307733|ACTIVE_COMPARATOR|Intervention|Intervention group received a Fitbit pedometer with individualised physical activity targets and behaviour change techniques which were delivered via a closed Facebook group
61995176|NCT02849548|EXPERIMENTAL|suvorexant|10 to 20 mg to be administered after an evening written trauma narrative exposure session.
61995177|NCT02849548|PLACEBO_COMPARATOR|Placebo pill|A pill without active ingredients
61995178|NCT02506816||Olaparib|Drug exposure has a limited duration 28 (+/- 5) days.
61995179|NCT04802265||ILM peeling|ILM is peeled during epiretinal membrane surgery
61995180|NCT04802265||without ILM peeling|ILM is not peeled during epiretinal membrane surgery
61995181|NCT02680821|OTHER|Isolated ACL-revision|The standard operation with an isolated Anterior cruciate ligament.
61995182|NCT02680821|OTHER|Combined ACL and ALL surgery|An operation with an Anterior cruciate ligament combined with an anterolateral ligament.
61995183|NCT00613509|EXPERIMENTAL|Study Group 1: ALVAC melanoma vaccine|Participants will receive a multi-antigen of modified canarypox virus (ALVAC\[2\]) melanoma vaccine and granulocyte macrophage colony stimulating factor (GM-CSF) every 3 weeks, followed by 4 weeks of high-dose interferon alpha-2b 5 times per week.
61995184|NCT00613509|ACTIVE_COMPARATOR|Study Group 2: Interferon alpha-2b|Participants on 4 weeks of high-dose interferon alpha-2b 5 times per week. Participants who showed disease progression after Cycle 1 will be permitted to cross over to Group 1 treatment.
61995185|NCT01465646|ACTIVE_COMPARATOR|with idodine|
61995186|NCT01465646|EXPERIMENTAL|without iodine|
61995187|NCT04809909|EXPERIMENTAL|Peripheral stimulation of acupuncture points (PSAP)|Two electrode leads will be implanted and connected to an external neurostimulator for electrical stimulation of acupuncture points.
61995188|NCT04809909|ACTIVE_COMPARATOR|Peripheral nerve field stimulation (PNFS)|Two electrode leads will be implanted and connected to an external neurostimulator for electrical stimulation of the painful area.
61995189|NCT02766244|EXPERIMENTAL|ICG/SPY|Daily wound care with antibiotic ointments after cleansing plus evaluation using ICG/SPY fluorescence.
61995190|NCT05992506||Patients at risk of developing POD|"* Patients older than 60 years~* Scheduled for elective surgery of moderate or high risk (defined as that which requires a subsequent hospitalization of at least 3 days) under general anesthesia.~* Signed informed consent."
61995191|NCT00684853|ACTIVE_COMPARATOR|1|
62179993|NCT03937232|ACTIVE_COMPARATOR|Mirror Visual Feedback|Mirror visual feedback is the performance of movements with an uninjured hand in front of a mirror hiding the injured hand, thus creating the illusion of bilateral movement. Participants randomized to mirror visual feedback will be provided with a portable mirror and stand, and instructed with accompanying demonstration on how to set up on a table for comfortable visualization. They will be given written, illustrated instructions for performing mirror visualization of exercises completed by the uninjured hand only from a position of neutral rotation of the forearm. The instructions will ask for the participant to complete a three sets of 10 repetitions for finger flexion and extension (mimicking the fisting motion of the grip strengthening exercises) twice daily. A diary for tracking exercise completion and attendance for usual care will also be provided.
62179994|NCT03937232|EXPERIMENTAL|Cross-education + Mirror Visual Feedback|In this group, participants will perform the cross-education resistance exercise in front of the mirror, visualizing the performance of the resistance exercises. Participants randomized to cross education with mirror visual feedback will be provided with both a hand-grip strengthener and a portable mirror and stand, and instructed with accompanying demonstration on how to set up on a table for comfortable visualization. They will be given written, illustrated instructions for performing mirror visualization hand grip strengthening exercises completed by the uninjured hand only from a position of neutral rotation of the forearm. The instructions will ask for the participant to complete 3 sets of 10 repetitions twice daily, with additional instructions for appropriate grading of resistance. A diary for tracking exercise completion and attendance for usual care will also be provided.
62179995|NCT03937232|ACTIVE_COMPARATOR|Usual Care|Participants randomized to usual care will be encouraged to attend the recommended rehabilitation, and provided with a diary for frequency of rehab attendance, and tracking any exercises completed at home.
62179996|NCT01262118|EXPERIMENTAL|CP-690,550 (tasocitinib) 10 mg twice daily (BID)|
62179997|NCT01262118|NO_INTERVENTION|Healthy Volunteers|No intervention
62179998|NCT04768868|OTHER|IMP7068|"Part 1: Dose Escalation~The study will begin with open-label dose escalation in IMP7068 monotherapy treatment to determine the Maximum tolerated dose (MTD)~Part 2: Dose Expansion The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage. A total of 100 patients each with advanced solid tumor who has exhausted available treatment options will be evaluated."
62179999|NCT05730517|ACTIVE_COMPARATOR|Test group 1 (CP5HA Group)|Participants will receive investigational product 1 containing collagen (5 g/ 15 mL), hyaluronic acid (30 mg/ 15 mL) and vitamin C (80 mg/ 15 mL).
62180000|NCT05730517|PLACEBO_COMPARATOR|Placebo group|Placebo group participants will receive placebo syrup without active ingredients. (daily dose 15 mL: collagen: 0 mg, HA: 0 mg, vitamin C: 0 mg); continous administration of placebo product for 12 weeks.
62180001|NCT05730517|ACTIVE_COMPARATOR|Test group 2 (CP5 Group)|Participants will receive investigational product 2 containing collagen (5 g/ 15 mL) and vitamin C (80 mg/ 15 mL).
62180002|NCT03494855||Neonates|\<1 month of age SyMRI software used for brain imaging and radiological interpretation
62180003|NCT03494855||Infants|1mth - 2 years of age SyMRI software used for brain imaging and radiological interpretation
62180004|NCT03494855||Adolescents|2 - 12 years of age SyMRI software used for brain imaging and radiological interpretation
62180005|NCT03494855||Teenagers|13-18 years of age SyMRI software used for brain imaging and radiological interpretation
62180006|NCT03494855||Healthy Adults|Preliminary Evaluation SyMRI software used for brain imaging and radiological interpretation
62180007|NCT01657565||open appendectomy|
62180008|NCT01657565||laparscopic appendectomy|
62180009|NCT05172518|ACTIVE_COMPARATOR|Arm A|Taxane plus Intermittent Capecitabine
62563458|NCT02284581||Retrospective cohort|All consecutive metastatic breast cancers patients treated in the participating site with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from last contact with patient or death which ever event comes first retrospectively back until 1st of January 2000.
62180010|NCT05172518|EXPERIMENTAL|Arm B|Utidelone plus Intermittent Capecitabine
62180011|NCT05172518|ACTIVE_COMPARATOR|Arm C|Taxane plus Metronomic Capecitabine
62180012|NCT05172518|EXPERIMENTAL|Arm D|Utidelone plus Metronomic Capecitabine
62180013|NCT04604470||Standard treatment|Chemotherapy Chemoradiotherapy Radiotherapy Immunotherapy Or a combination of above
62180014|NCT04604470||ImmunoSABR treatment|"SABR combined immunotherapy~Radiotherapy combined immunotherapy"
62180015|NCT00383747|ACTIVE_COMPARATOR|Nicotine Patch|
62180016|NCT00383747|PLACEBO_COMPARATOR|Placebo Nicotine Patch|
62180017|NCT02406495|EXPERIMENTAL|filcon IV 1 and ocufilcon D|Habitual wearers of filcon IV 1 sphere lenses refitted with asphere ocufilcon D lenses.
62180018|NCT00935259|EXPERIMENTAL|Simvastatin 40 mg first, then placebo|Simvastatin 40 mg tablets once daily for 2 weeks followed by placebo for 2 weeks
62180019|NCT00935259|PLACEBO_COMPARATOR|Placebo first, then simvastatin 40 mg once daily|Placebo for 2 weeks followed by simvastatin 40 mg once daily for 2 weeks
62182779|NCT00705562|EXPERIMENTAL|1|Experimental milk protein based infant formula with varying carbohydrate and protein source
62180020|NCT04795583|EXPERIMENTAL|Prednisone|"Treatment adjusted by weight. Prednisone 25 mg capsules:~* ≤ 50kg = 2 capsules QD x 7 days (maximum dose = 50mg/day)~* 50 - 80kg = 3 capsules QD x 7 days (maximum dose = 75mg/day)~* \> 80kg = 4 capsules QD x 7 days (maximum dose = 100mg/day)"
62180021|NCT04795583|PLACEBO_COMPARATOR|Placebo|Capsules with the same appearance as Prednisone
62180022|NCT00820729||1|Patients with interstitial pulmonary disease
62180023|NCT01430078|EXPERIMENTAL|Regimen A|ASP015K oral tablet
62180024|NCT01430078|EXPERIMENTAL|Regimen B|ASP015K solution delivered to distal small bowel via oral capsule
62180025|NCT01430078|EXPERIMENTAL|Regimen C|ASP015K solution delivered to ascending colon via oral capsule
62180026|NCT01430078|EXPERIMENTAL|Regimen D|ASP015K solution delivered to distal transverse colon via oral capsule
62772444|NCT04726059|EXPERIMENTAL|ABT+TSCS|Therapeutic TSCS will be delivered during ABT using an isolated bipolar constant current stimulator. Continuous TSCS applied over the T11-T12 spinous processes at 5-40 Hz has been shown to induce stepping movements in participants with their legs in a gravity-independent position.
62180027|NCT05955963|EXPERIMENTAL|paediatric inflammatory bowel disease|
62180028|NCT00721214|EXPERIMENTAL|Arm A: 5-azacytidine|5-azacytidine as pre-transplant cytoreduction prior to allogeneic stem cell transplantation for High Risk Myelodysplatic Syndromes.
62180029|NCT00711997|EXPERIMENTAL|BC-819|Intratumoral administration of BC-819
62180030|NCT00980577|ACTIVE_COMPARATOR|NS|stimulating catheter will be inserted using stimulator
62180031|NCT06295042||Autologous Breast Reconstruction|Patients undergoing autologous breast reconstruction with free flaps
62180032|NCT06295042||Alloplastic Breast Reconstruction|Patients undergoing alloplastic breast reconstruction with implants or expander prosthesis
62563459|NCT02284581||Prospective cohort|All new consecutive metastatic breast cancers patients will be treated in the participating site with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from site activation to June 2023.
62772445|NCT04030247|EXPERIMENTAL|Plant Sterol|South Asian participants with moderate cardiovascular disease risk will receive standard of care in addition to the plant sterol supplement to take twice daily for 3 months.
62772446|NCT05378074|EXPERIMENTAL|MaxiPost|A time- and volume-controlled infusion pump is used to administer MaxiPost by intravenous infusion over 20 minutes.
61995192|NCT00684853|ACTIVE_COMPARATOR|2|
61995193|NCT01125111||robotic surgery group|
62772447|NCT05378074|PLACEBO_COMPARATOR|Placebo (isotonic saline)|A time- and volume-controlled infusion pump is used to administer placebo (isotonic saline) by intravenous infusion over 20 minutes.
62772448|NCT02645617|EXPERIMENTAL|Varnish|Dental varnish containing povidone iodine and sodium fluoride
61995194|NCT01125111||laparoscopic surgery group|
61995195|NCT01640366|EXPERIMENTAL|PICO negative pressure|Single-use Negative Pressure Wound Therapy
61995196|NCT01640366|NO_INTERVENTION|Standard of care dressing arm|Sterile gauze adhesive strips
61995197|NCT00925483|EXPERIMENTAL|daily long|daily long (4 hours, 6 times weekly) dialysis for 6 months
61995198|NCT00925483|EXPERIMENTAL|daily short|daily short (2 hours 6 times weekly) dialysis for 6 months
61995199|NCT00925483|EXPERIMENTAL|alternate day conventional|alternate day conventional (4 hours, 3 times weekly) dialysis for 6 months
61995200|NCT00925483|EXPERIMENTAL|alternate day long|alternate day long (8 hours, 3 times weekly) dialysis for 6 months
61995201|NCT02800356|EXPERIMENTAL|Pseudodrusen|Subthreshold 577 nm yellow wavelength laser photo-coagulator
61995202|NCT02800356|EXPERIMENTAL|Geographic atrophy|Subthreshold 577 nm yellow wavelength laser photo-coagulator
61995203|NCT01530321|EXPERIMENTAL|High dose spinal manipulation|18 visits for spinal manipulation
61995204|NCT01530321|EXPERIMENTAL|Moderate dose spinal manipulation|12 visits for spinal manipulation and 6 visits for light massage
61995205|NCT01530321|EXPERIMENTAL|Low dose spinal manipulation|6 visits for spinal manipulation and 12 visits for light massage
61995206|NCT01530321|OTHER|High dose massage|18 visits for light massage
61995207|NCT02233010||kidney function normal group|kidney function normal group : defined by the normal level of NGAL after post operation 4hrs
61995208|NCT02233010||kidney function decreased group|kidney function decreased group : defined by the increased level of NGAL after post operation 4hrs
61995209|NCT05698264|EXPERIMENTAL|NSCLC patients with EGFR mutation|"The cohort A will focus on the clonal evolution in EGFR mutated lung cancer patients by using circulating tumor DNA (ctDNA) analysis of paired baseline and end-of-treatment (EOT) plasma samples. This cohort will be compared to matched EGFR patients previously analyzed by our group.~Analysis of paired samples from this study will allow a dissection of events acquired through therapy, specifically which component of the combination therapy may be driving selection of the mutations in comparison with the control group without TTFields."
62772449|NCT03825237||With sleep bruxism by polysomnography|Adults (20 to 60 years) and elderly (\> 60 years), (WHO-World Health Organization, 2015) who had undergone polysomnography (PSG) from January 2015 to December 2017 were assessed. All self-reports and PSG exams were included and reviewed. The participants were excluded if they presented with a history of neurological or degenerative disorders, and any objection to take the polysomnography test.
62772450|NCT03825237||Without sleep bruxism by polysomnography|Adults (20 to 60 years) and elderly (\> 60 years), (WHO-World Health Organization, 2015) who had undergone polysomnography (PSG) from January 2015 to December 2017 were assessed. All self-reports and PSG exams were included and reviewed. The participants were excluded if they presented with a history of neurological or degenerative disorders, and any objection to take the polysomnography test.
62772451|NCT01642758|EXPERIMENTAL|Sodium 2,2 dimethylbutyrate|A single dose (20 mg/kg/day) of study drug will be taken once per day by mouth.
62563460|NCT02620293|EXPERIMENTAL|Eczema Emollient|Eczema Repair Emollient
62563461|NCT06283381|EXPERIMENTAL|Arm A: experimental group|no administration of Esomeprazole or any other proton pump inhibitor after the Endoscopic Sleeve Gastroplasty
62772452|NCT02265796|ACTIVE_COMPARATOR|Ranolazine|"Ranolazine 500 mg tablets~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
62772453|NCT02265796|PLACEBO_COMPARATOR|Sugar pill|"Sugar pill that looks like the drug ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
62772454|NCT04021823||DBS patients|Patients with treatment resistant major depression participating in the FORESEE III study.
62772455|NCT04021823||Healthy controls|Age- and sex-matched healthy controls undergoing analyses of neurodegenerative markers (neurofilament light protein) in blood and metabolomic analyses in blood and urine.
62772456|NCT02162966|EXPERIMENTAL|High Dose Colistin|High dose colistin protocol
62772457|NCT02162966|ACTIVE_COMPARATOR|Standard Dose Colistin|Standard dose of colistin
62772458|NCT00820872|EXPERIMENTAL|docetaxel + carboplatin + trastuzumab + lapatinib|"Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes on day 1, trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15, and oral lapatinib ditosylate on days 1-21 (TCHL). Treatment with TCHL repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30-90 minutes on day 1 and oral lapatinib ditosylate on days 1-21 (days 1-7 of course 12 only) (LT). Treatment with LT repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 6 months for 2 years and then annually for up to 8 years."
62772459|NCT02139904|PLACEBO_COMPARATOR|Active Symptom Control|Active symptom control includes palliative care and standard care methods used to manage symptoms
62772460|NCT02139904|ACTIVE_COMPARATOR|Vinorelbine|Active symptom control (ASC) as per local practice plus vinorelbine administered at a dose of 60mg/m2 orally on day 1, day 8 and day 15 on a 3- weekly cycle, incrementing to 80mg/m2 weekly on a 3-weekly cycle in the absence of any significant toxicity for subsequent cycles. Patients will continue chemotherapy until evidence of radiological progression (or unacceptable toxicity or patient withdrawal).
62772461|NCT02037490|EXPERIMENTAL|Grow2Gether Intervention|"Participants in the intervention group will:~* Participate in the Grow2Gether intervention~* Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network."
62180033|NCT01722864|EXPERIMENTAL|COV155|COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 10 to 35 days.
62180034|NCT04232878|ACTIVE_COMPARATOR|Active Comparator: Group 1 Period 1: 0.5mg CVL-936|Oral suspension/solution
62563462|NCT06283381|ACTIVE_COMPARATOR|Arm B: standard of care group|administration of Esomeprazole 40 mg twice a day for 4 weeks and 40 mg once a day for another 4 weeks after the Endoscopic Sleeve Gastroplasty
62563463|NCT01971528|NO_INTERVENTION|Stage 1: Health control|pilot study: Establishing the central and peripheral contributing factors to the voluntary muscle strength loss during a fatiguing exercise in young and PD groups.
62772462|NCT02037490|NO_INTERVENTION|Control|"Participants in the control group will:~* Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network."
62772463|NCT04571996|EXPERIMENTAL|ODM-104 and Panadol Zapp|
62772464|NCT00626405|EXPERIMENTAL|Arm I|Patients receive oral temozolomide on days 1-5 and bevacizumab IV over 30-90 minutes on days 1 and 15.
62772465|NCT00626405|EXPERIMENTAL|Arm II|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1.
62772466|NCT03743064|EXPERIMENTAL|100 mg anamorelin HCl|100 mg anamorelin HCl (administered as film-coated tablets in fasted condition) was to be taken orally once daily for a total of 24 weeks
62180035|NCT04232878|PLACEBO_COMPARATOR|Placebo Comparator: Group 1 Period 1: 0.5mg Matching Placebo|Matching Placebo; Oral suspension/solution
62772467|NCT03743064|PLACEBO_COMPARATOR|Placebo|Placebo (administered as matching placebo tablets in fasted condition) was to be taken orally once daily for a total of 24 weeks
62180036|NCT04232878|ACTIVE_COMPARATOR|Active Comparator: Group 1 Period 2:TBD mg CVL-936|Oral suspension/solution
62772468|NCT05772910|EXPERIMENTAL|EDUcation|The EDU group will assist to an individualized educative program based on intrinsic capacity optimization through lifestyle changes.
62772469|NCT05772910|EXPERIMENTAL|EXERcise|The EXER group will follow a program focused on the specific deficit of muscular power from a simple clinical test such as the STS and, in addition, they will be evaluated to be able to prescribe training individually (evaluation of training)
62772470|NCT05772910|EXPERIMENTAL|EDU-EXER|EDU-EXER group subject develops both interventions together.
62772471|NCT05772910|ACTIVE_COMPARATOR|CONtrol|CON group will continue the usual clinical treatment and their normal life.
62772472|NCT03848949|EXPERIMENTAL|Orthotic Group|Subjects enrolled in the orthotic group receive the orthotic (Evenup) meant to increase the effective leg length of the uninjured limb.
62772473|NCT03848949|NO_INTERVENTION|Control|Subjects enrolled in the control group receive the standard treatment associated with their injury (no orthotic)
62772474|NCT03465787|EXPERIMENTAL|Lurasidone HCL 160 mg|Lurasidone HCL 160 mg/day
62772475|NCT03465787|ACTIVE_COMPARATOR|Quetiapine XR 600 mg|Quetiapine XR 600 mg/day
62772476|NCT05962359|NO_INTERVENTION|Non-treatment Model Building|
62772477|NCT05962359|EXPERIMENTAL|Communication Treatment|
62180037|NCT04232878|PLACEBO_COMPARATOR|Placebo Comparator: Group 1 Period 2:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
62772478|NCT00444067|EXPERIMENTAL|Spinal Sealant System|Spinal Sealant System
62180038|NCT04232878|ACTIVE_COMPARATOR|Active Comparator: Group 1 Period 3:TBD mg CVL-936|Oral suspension/solution
62180039|NCT04232878|PLACEBO_COMPARATOR|Placebo Comparator: Group 1 Period 3:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
62180040|NCT04232878|ACTIVE_COMPARATOR|Active Comparator: Group 2 Period 1:TBD mg CVL-936|Oral suspension/solution
62772479|NCT00444067|ACTIVE_COMPARATOR|Standard of Care|Standard of care methods as an adjunct to sutured dural repair
62772480|NCT04702113|NO_INTERVENTION|Conventional Therapy (Controls)|Treatment with clopidogrel and no pre-emptive genotyping
62772481|NCT04702113|EXPERIMENTAL|Genotype-guided therapy (experimental)|"1. Treatment with clopidogrel 75 mg daily for non-carriers~2. Treatment with ticagrelor 90 mg twice daily for carriers"
62772482|NCT01864421||Deferred Clamping|Infants undergoing a deferring of umbilical cord clamping for 30 seconds or more
62772483|NCT01864421||Immeadiate Cord Clamping|Infants undergoing immediate umbilical cord clamping in the first 20 seconds of life.
62772484|NCT04195386|EXPERIMENTAL|Chemically activated Composite resin Alkasite|Single placement of composite resin on atypical cavities.
62772485|NCT04195386|ACTIVE_COMPARATOR|Resin-Modified Glass ionomer Cement|Single placement of Resin-Modified Glass ionomer Cement on atypical cavities.
62772486|NCT00462748|EXPERIMENTAL|1|Arm 1: Drug
62772487|NCT00462748|ACTIVE_COMPARATOR|2|Arm 2: Active comparator
62772488|NCT00462748|ACTIVE_COMPARATOR|3|Arm 3: Active comparator
62772489|NCT03046225|EXPERIMENTAL|Electrical stimulation|This group received application of transcutaneous electrical nerve stimulation (TENS) associated with conventional physical therapy (continuous passive movement device and exercises).
62772490|NCT03046225|ACTIVE_COMPARATOR|Physical therapy|This group received only conventional physical therapy (continuous passive movement device and exercises).
62772491|NCT02619643|EXPERIMENTAL|Primed PAS 1A|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
62772492|NCT02619643|EXPERIMENTAL|Unprimed PAS 1B|A single session of active paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied.
62180041|NCT04232878|PLACEBO_COMPARATOR|Placebo Comparator: Group 2 Period 1:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
62180042|NCT04232878|ACTIVE_COMPARATOR|Active Comparator: Group 2 Period 2:TBD mg CVL-936|Oral suspension/solution
62180043|NCT04232878|PLACEBO_COMPARATOR|Placebo Comparator: Group 2 Period 2:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
62180044|NCT04232878|ACTIVE_COMPARATOR|Active Comparator: Group 2 Period 3:TBD mg CVL-936|Oral suspension/solution
62180045|NCT04232878|PLACEBO_COMPARATOR|Placebo Comparator: Group 2 Period 3:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
62180046|NCT04232878|ACTIVE_COMPARATOR|Active Comparator: Group 3: TBD mg CVL-936|Oral suspension/solution
62180047|NCT04232878|PLACEBO_COMPARATOR|Placebo Comparator: Group 3: TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
62182780|NCT00705562|EXPERIMENTAL|2|Experimental milk protein based infant formula with varying carbohydrate and protein source
62772493|NCT02619643|SHAM_COMPARATOR|Sham PAS|A single session of sham paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied
62772494|NCT02619643|EXPERIMENTAL|Primed PAS 2A|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
62772495|NCT02619643|EXPERIMENTAL|Unprimed PAS 2B|A single session of active paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied.
62772496|NCT02619643|EXPERIMENTAL|Primed PAS 1C|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
62772497|NCT02619643|EXPERIMENTAL|Primed PAS 2C|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
62772498|NCT02078388||Breast cancer,Doxorubicin|Breast cancer patients who received at least one cycle of doxorubicin-containing adjuvant chemotherapy for treatment of early stage breast cancer at least 12 months ago and who had a pre-doxorubicin echocardiography done at NUHS will be enrolled. Study subjects will donate one sample of blood (20ml) for genetic and biomarker studies related to breast cancer and anthracyclines pharmacodynamics. An echocardiography will be performed to measure left ventricular ejection fraction, and compared with the subject's pre-doxorubicin echocardiography done at NUH. Correlative analysis will be performed between genetic variants and left ventricular ejection change.
62180048|NCT05082844|EXPERIMENTAL|Evaluation of clinical and radiographic findings after surgical treatment for cuff rotator lesion|Evaluation of the clinical-radiological results from the case series of patients surgically treated for cuff rotator lesions from 2009 to 2020 at the Shoulder-Elbow Department . At 12 months the result is considered stabilized, so we will proceed to collect all case histories that have passed this follow-up period.
62180049|NCT01136447|PLACEBO_COMPARATOR|Neurostimulation|Block catheter will be introduced using neurostimulation
62180050|NCT01136447|ACTIVE_COMPARATOR|Ultrasound|Block catheter will be introduced using ultrasound
62180051|NCT04699123|EXPERIMENTAL|Arm 1a - NC318 only|At the discretion of the treating physician, advanced NSCLC patients on arm 1a will receive NC318 alone.
62180052|NCT04699123|EXPERIMENTAL|Arm 1b - NC318 and Pembrolizumab|At the discretion of the treating physician, advanced NSCLC patients on arm 1b will receive combination therapy with NC318 and pembrolizumab.
62180053|NCT04699123|EXPERIMENTAL|Arm 1c - NC318 and Pembrolizumab|At the discretion of the treating physician, advanced NSCLC patients on arm 1b will receive combination therapy with NC318 and pembrolizumab.
62180054|NCT04699123|EXPERIMENTAL|Arm 2 (naïve to PD-1 axis inhibitor)- NC318 and Pembrolizumab|Arm 2 will enroll patients with advanced NSCLC who are naïve to PD-1 axis inhibitor therapy to receive therapy with NC318 in combination with pembrolizumab.
62180055|NCT04699123|EXPERIMENTAL|Arm 2a (naïve to PD-1 axis inhibitor)- NC318 and Pembrolizumab|Arm 2a will enroll patients with advanced NSCLC who are naïve to PD-1 axis inhibitor therapy to receive combination therapy with NC318 and pembrolizumab.
62180056|NCT03650673|OTHER|Diagnostic Test: Identification of subgroups of patients with|
62180057|NCT01438515|EXPERIMENTAL|Systemic decolonization|7-day course of 4% chlorhexidine gluconate daily washes and 2% mupirocin ointment to the anterior nares twice daily in addition to oral rifampin (600mg daily), and doxycycline (100mg twice daily)
62180058|NCT01438515|ACTIVE_COMPARATOR|Standard decolonization|7-day course of 2% mupirocin ointment to the anterior nares twice daily and 4% chlorhexidine gluconate washes once per day.
62180059|NCT04883021|EXPERIMENTAL|Dual Target Theta Burst Stimulation|The TMS intervention is open-label dual-target theta burst stimulation delivered in sequential fashion to the DLPFC and the MPFC.
62180060|NCT05596578||Group A|Patients who underwent an anatomical resection for NSCLC \<3 cm (lobectomy, bilobectomy, segmentectomy) with samples from the intrapulmonary stations 12, 13, and 14 lymph nodes and resection of lymph nodes station 10 and 11 during hilar separation.
62180061|NCT01700023||patients with leg-edema|patients with decompensated heart failure presenting with leg-edema
62772499|NCT01313962|EXPERIMENTAL|Flufirvitide-3|
62772500|NCT01313962|PLACEBO_COMPARATOR|Placebo|
62180062|NCT04205136|EXPERIMENTAL|Spironolactone|Dose of 25 mg daily that may be titrated up to 50 mg daily, if tolerated and will receive treatment as usual for obstructive sleep apnea.
62772501|NCT04133194|EXPERIMENTAL|1600 mg Asacol (mesalazine)|1600 mg mesalazine (Asacol) treatment regimen (1 tablet per day) for a year
62772502|NCT04133194|ACTIVE_COMPARATOR|800 mg Asacol (mesalazine)|800 mg mesalazine (Asacol) treatment regimen (3 tablets per day) for a year
62772503|NCT06030284|EXPERIMENTAL|BurstDR-SCS|Subjects implanted with BurstDR-SCS will be included in BurstDR-SCS arm.
62772504|NCT06030284|EXPERIMENTAL|Sham control arm|Subjects implanted with the BurstDR-SCS system will be included in the Sham control arm
62180063|NCT04205136|PLACEBO_COMPARATOR|Placebo|Placebo and will receive treatment as usual for obstructive sleep apnea.
62180064|NCT03714542|OTHER|Pre- and postoperative MRI|All patients will undergo a preoperative MRI and will have a postoperative follow-up with CT and MRI.
62180065|NCT04319614|EXPERIMENTAL|Tranexamic acid|
62180066|NCT04319614|PLACEBO_COMPARATOR|Saline|
62180067|NCT05479747|ACTIVE_COMPARATOR|Ibuprofen (Brufen)|Participants were handed Brufen (Ibuprofen) (Abbott chemical laboratories, Advil, USA) 600 mg 3 times daily for 3 days after meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.
62772505|NCT04397328|EXPERIMENTAL|Hydroxychloroquine 200mg|Regular Dose 400mg orally once, followed in 8 hours by 400mg, then 200mg twice a day for 4 consecutive days (5 days in total) Modified Dose 400mg orally once, followed in 8 hours by 400mg, then 200mg once a day for 4 consecutive days (5 days in total) Modified doses are for individuals with body weight below 40 kg, renal impairment with a creatinine clearance less than 10mls/min or QTc interval greater than 480 but less than 500.
62772506|NCT04397328|PLACEBO_COMPARATOR|Placebo Arm|The placebo arm will be matched to study drug to maintain the study blind. Regular Dose Placebo 2 tabs once, followed in 8 hours by 2 tabs, then 1 tab twice a day for 4 consecutive days (5 days in total) Modified Dose Placebo 2 tabs once, followed in 8 hours by 2 tabs, then 1 tab once a day for 4 consecutive days (5 days in total) Modified doses are for individuals with body weight below 40 kg, renal impairment with a creatinine clearance less than 10mls/min or QTc interval greater than 480 but less than 500.
62180068|NCT05479747|EXPERIMENTAL|Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)|Participants were handed Ambezim G (Trypsin 5 mg Chymotrypsin 5 mg) (Global Napi Pharmaceutical Company, Giza, Egypt) 3 times daily for 3 days one hour before meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.
62180069|NCT05479747|ACTIVE_COMPARATOR|Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)|Participants were handed Brufen (Ibuprofen) (Abbott chemical laboratories, Advil, USA) 600 mg 3 times daily for 3 days after meals and Ambezim G (Trypsin 5 mg Chymotrypsin 5 mg) (Global Napi Pharmaceutical Company, Giza, Egypt) 3 times daily for 3 days one hour before meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.
62182781|NCT00705562|EXPERIMENTAL|3|Experimental milk protein based infant formula with varying carbohydrate and protein source
62563464|NCT01971528|NO_INTERVENTION|Stage 1: PD subjects|pilot study: Establishing the central and peripheral contributing factors to the voluntary muscle strength loss during a fatiguing exercise in young and PD groups.
62180070|NCT05479747|PLACEBO_COMPARATOR|Placebo pills (Sugar pills)|Participants were handed postoperatively sugar pills (Placebo pills) (Department of pharmaceutics \& industrial pharmacy at Faculty of pharmacy Ain Shams University, Cairo, Egypt) 3 times daily for 3 days in tightly sealed envelope with an included written paper contained the instruction for dose administration.
62180071|NCT06065306||AD|Patient aged greater than 18, presented to the ED with first 24 hours of symptoms suggesting AD, including chest pain, upper back pain, syncope of unknown cause, symptoms of any acute perfusion deficit and confirmed AD.
62180072|NCT06065306||Healthy|Patients attending ED who do not have coronary disease, hypertension or aortic disease would be identified as healthy control.
62563465|NCT01971528|NO_INTERVENTION|Stage 2: Health subjects|pilot study: Finding optimal sensory stimulation parameters for PD individuals.
62180073|NCT03181282|EXPERIMENTAL|Physical Therapy|Participants assigned to Physical Therapy (PT) will attend a 1-hour visit with a physical therapist twice weekly for 8 weeks. The PT intervention, which will mirror traditional PT for those with PD, will include exercises designed to improve balance and gait.
62180074|NCT03181282|NO_INTERVENTION|Control|Participants in the control group will receive the current standard of care following STN-DBS. As such, STN-DBS settings and anti-PD medications will be optimized according to the determination of their neurologist in the same fashion as they will be in the experimental group. Those in the control group will not receive prescribed exercise from a physical therapist.
62772507|NCT03825159|EXPERIMENTAL|ES group|Using spinal orthosis with an integrated system of electric surface stimulation and heat sensing.
62180075|NCT05191836|EXPERIMENTAL|Pulpotomy in primary mandibular molars by using video game distraction.|
62563466|NCT01971528|NO_INTERVENTION|Stage 2: PD subjects|pilot study: Finding optimal sensory stimulation parameters for PD individuals.
62772508|NCT03825159|ACTIVE_COMPARATOR|brace group|Using spinal orthosis BRACE
62772509|NCT00756951|PLACEBO_COMPARATOR|1|Placebo
62772510|NCT00756951|ACTIVE_COMPARATOR|2|SCV-07 at a dose of 0.02 mg/kg
62772511|NCT00756951|ACTIVE_COMPARATOR|3|SCV-07 at a dose of 0.10 mg/kg
62772512|NCT00945230|EXPERIMENTAL|Actigraphic Neurosurgical Outcomes|Actigraphic measurements that will be obtained by attaching the actigraphic watch device to the individual's non-dominant wrist and operationally defined repeated observational measurements. All measurements will continue through a baseline period and continue through the identified post surgical period. Actigraphic measurements will occur every 30 seconds with brief periods of non-measurement during the actual neurosurgical procedure and periods when the actigraphic device has reached storage capacity (approximately every 22 days) when data is retrieved and the device prepared resume measurements.
62772513|NCT03153488|EXPERIMENTAL|Methylphenidate|Adult subjects (ages 18-45) receiving a Methylphenidate derivative medication
62772514|NCT03153488|EXPERIMENTAL|Amphetamine|Adult subjects (ages 18-45) receiving an Amphetamine derivative medication
62772515|NCT05670509|EXPERIMENTAL|Nasal administration of midazolam in home group|treatment with intranasal midazolam in children with known seizure disorder who were prescribed midazolam by pediatric neurologist at home with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5mg/spray). If the volume to be administered exceeded 1 mL, then the dose was divided between both nostrils to avoid runoff and swallowing. children with known seizure disorder who were prescribed midazolam by pediatric neurologist
62772516|NCT05670509|EXPERIMENTAL|buccal administration of midazolam in home group|treatment with buccal midazolam in children with known seizure disorder who were prescribed midazolam by pediatric neurologist at home with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
62772517|NCT05670509|EXPERIMENTAL|intramuscular administration of midazolam in home group|treatment with intramuscular midazolam in children with known seizure disorder who were prescribed midazolam by pediatric neurologist at home with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) administered via using 3 mm syringe in the front aspect of thigh
62772518|NCT05670509|EXPERIMENTAL|Nasal administration of midazolam in ER group|treatment with intranasal midazolam in children presenting to ER with acute seizures with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5mg/spray). If the volume to be administered exceeded 1 mL, then the dose was divided between both nostrils to avoid runoff and swallowing.
62563467|NCT01971528|EXPERIMENTAL|Stage 3: PD subjects|Investigating the long-term effects of combined sensory stimulating strengthening program on the activation level and central fatigue in PD individuals.
62563468|NCT01971528|NO_INTERVENTION|Stage 3: PD subjects (Control Subjects)|Investigating the long-term effects of combined sensory stimulating strengthening program on the activation level and central fatigue in PD individuals.
62563469|NCT03469700|EXPERIMENTAL|GA+PVB|Patients will receive general anesthesia with paravertebral block
62563470|NCT03469700|ACTIVE_COMPARATOR|GA+placebo PVB|Patients will receive general anesthesia with placebo block
62563471|NCT03327701|ACTIVE_COMPARATOR|Experimental|Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
62563472|NCT03327701|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
62563473|NCT03525405|EXPERIMENTAL|Single Dose|
62563474|NCT00395629|EXPERIMENTAL|ICL670 (Deferasirox)|Three dose cohorts: 5 mg/kg/day, 10 mg/kg/day, 15 mg/kg/day
62180076|NCT05191836|EXPERIMENTAL|Pulpotomy in primary mandibular molars by using audio visual distraction.|
62180077|NCT05191836|OTHER|Pulpotomy in primary mandibular molars without using any type of distraction aids|
62180078|NCT03015870|EXPERIMENTAL|Feedback|Behavioral: Vocal exercise with real-time feedback.
62180079|NCT03015870|ACTIVE_COMPARATOR|Recording|Behavioral: Vocal exercise with recording
62180080|NCT03849768|EXPERIMENTAL|HS-10296|110mg PO once daily
62180081|NCT03849768|ACTIVE_COMPARATOR|Gefitinib|250mg PO once daily
62180082|NCT01583738|EXPERIMENTAL|V0251|
62180083|NCT01583738|PLACEBO_COMPARATOR|Placebo|
62180084|NCT02216578|EXPERIMENTAL|cabozantinib|cabozantinib 60 mg oral daily
62180085|NCT02856490|ACTIVE_COMPARATOR|vSculpt with Vibration Only|vSculpt genital device used in vibration mode only.
62180086|NCT02856490|ACTIVE_COMPARATOR|vSculpt with Vibration and Light|vSculpt genital device used in vibration and light mode.
62180087|NCT02856490|ACTIVE_COMPARATOR|InTone Device|InTone genital device using electric muscle stimulation only.
62180088|NCT05857514|ACTIVE_COMPARATOR|Rectal indomethacin|
62563475|NCT02321657|EXPERIMENTAL|iPad app containing art, music and games|On entry to the anaesthetic room, children will be given an iPad (the intervention) with art, music and games to distract them. A nurse will help them engage with the iPad whilst the anaesthetists complete the anaesthetic. Once the child falls asleep, the iPad will be removed. This process is anticipated to last between 3 and 30 minutes depending on the time taken to anaesthetise the child.
62772519|NCT05670509|EXPERIMENTAL|buccal administration of midazolam in ER group|treatment with buccal midazolam in children presenting to ER with acute seizures with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
62180089|NCT05857514|ACTIVE_COMPARATOR|Pancreatic duct stent and rectal indomethacin|
62180090|NCT04778787|EXPERIMENTAL|the intervention group|The intervention group includes patients with decompensated chronic heart failure. The diagnosis will be made according to the criteria described above
62180091|NCT04778787|EXPERIMENTAL|the control group|The control group will be identical to the main group.
62180092|NCT01143883|EXPERIMENTAL|Silverlon Dressing|The Silverlon(Cura Surgical, Geneva, IL) dressing is applied to the surgical wound postoperatively. This dressing is coated with silver nylon.
62563476|NCT02321657|ACTIVE_COMPARATOR|Toys, books and games|On entry to the anaesthetic room, children will be given toys or games to distract them. A nurse will help them play whilst the anaesthetists complete the anaesthetic. Once the child falls asleep, the games will be removed. This process is anticipated to last between 3 and 30 minutes depending on the time taken to anaesthetise the child.
62563477|NCT00496717||1|There is only one arm and all patients will have their aortic calcium scoring by CT scan.
62563478|NCT06578039|EXPERIMENTAL|Study Group 1 (Low dose CordSTEM-ST)|Low dose CordSTEM-ST, 1 (single) administration
62563479|NCT06578039|EXPERIMENTAL|Study Group 2 (High dose CordSTEM-ST)|High dose CordSTM-ST, 1 (single) administration
62563480|NCT05827003|ACTIVE_COMPARATOR|Exercise|Individuals with a diagnosis of knee osteoarthritis who underwent supervised exercise under the guidance of a physiotherapist for 6 weeks, 2 days a week.
62772520|NCT05670509|EXPERIMENTAL|Intramuscular administration of midazolam in ER group|treatment with intramuscular midazolam in children presenting to ER with acute seizures with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) administered via using 3 mm syringe in the front aspect of thigh
62180093|NCT01143883|ACTIVE_COMPARATOR|Standard of Care Dressing|The standard plain gauze is used to dress the wound postoperatively
62180094|NCT05371145|EXPERIMENTAL|Carnosine intervention for patients with PAD|This is a single arm open labelled safety trial, where we will supplement carnosine for 3 months to subjects with non-claudication and claudication peripheral arterial disease (PAD), and determine if it improves walking ability.
62180095|NCT04786483|EXPERIMENTAL|Laughter Therapy group|All students enrolled in the laughter therapy group will receive a total of 10 sessions of laughter therapy, 60 minutes, 2 days a week.
62180096|NCT04786483|NO_INTERVENTION|Control|No attempt will be made to students in this group.
62180097|NCT02507687|EXPERIMENTAL|Stage 1: SLT (Primary Eye) / Bimatoprost SR 15 µg (Contralateral Eye)|"Participants enrolled prior to implementation of Protocol Amendment 3 receive the following treatment in each eye:~Assigned Primary Eye: Selective laser trabeculoplasty (SLT) administered on Day 1 followed by up to three sham bimatoprost SR administrations.~Contralateral Eye: Sham SLT administered on Day 1 followed by up to three bimatoprost SR 15 µg administrations.~Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2) and Week 32 (Cycle 3; participants who reach Week 32 prior to implementation of Protocol Amendment 3 only)."
62180098|NCT02507687|EXPERIMENTAL|Stage 1: Bimatoprost SR 15 µg (Primary Eye) / SLT (Contralateral Eye)|"Participants enrolled prior to implementation of Protocol Amendment 3 receive the following treatment in each eye:~Assigned Primary Eye: Sham SLT administered on Day 1 followed by up to three bimatoprost SR 15 µg administrations.~Contralateral Eye: SLT administered on Day 1 followed by up to three sham bimatoprost SR administrations.~Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2) and Week 32 (Cycle 3; participants who reach Week 32 prior to implementation of Protocol Amendment 3 only)."
62180099|NCT02507687|EXPERIMENTAL|Stage 2: SLT (Primary Eye) / Bimatoprost SR 10 µg (Contralateral Eye)|"Participants enrolled after implementation of Protocol Amendment 3 receive the following treatment in each eye:~Assigned Primary Eye: SLT administered on Day 1 followed by up to two sham bimatoprost SR administrations.~Contralateral Eye: Sham SLT administered on Day 1 followed by up to two bimatoprost SR 10 µg administrations.~Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2). After implementation of Protocol Amendment 6, Cycle 2 retreatment could occur after Week 16 and prior to Month 12 based on when retreatment criteria are met."
62182782|NCT00705562|EXPERIMENTAL|4|Experimental milk protein based infant formula with varying carbohydrate and protein source
62182783|NCT00705562|EXPERIMENTAL|5|Experimental milk protein based infant formula with varying carbohydrate and protein source
62182784|NCT05348668|EXPERIMENTAL|Hybrid dose-fraction Radiotherapy Arm|Patients in this arm would receive hybrid dose-fraction radiotherapy combined with immune checkpoint inhibitors.
62180100|NCT02507687|EXPERIMENTAL|Stage 2: Bimatoprost SR 10 µg (Primary Eye) / SLT (Contralateral Eye)|"Participants enrolled after implementation of Protocol Amendment 3 receive the following treatment in each eye:~Assigned Primary Eye: Sham SLT administered on Day 1 followed by up to two bimatoprost SR 10 µg administrations.~Contralateral Eye: SLT administered on Day 1 followed by up to two sham bimatoprost SR administrations.~Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2). After implementation of Protocol Amendment 6, Cycle 2 retreatment could occur after Week 16 and prior to Month 12 based on when retreatment criteria were met."
62180101|NCT03011905|EXPERIMENTAL|Dexamethasone|Single dose of dexamethasone (Dexagalen) 16 mg iv during operation.
62180102|NCT03011905|PLACEBO_COMPARATOR|Control|Single dose of NaCl, 4 ml, iv during operation.
62180103|NCT03239197||mother infant pair|mother infant pair, singleton infant, vaginal birth
62180104|NCT00195442||A|Patients with Hemophilia A
62772521|NCT02505360|OTHER|nasal and ear cartilage taken from the newborn|to compare biochemical and histological characteristics of both nasal and ear cartilage taken from the newborn at the time of surgical time cheilorhinoplasty
62772522|NCT05349383||Antibody-Drug Conjugate (ADC)|Sepsis-related toxicities induced by antibody-drug conjugate(ADC). Case reported in the FDA Adverse Event Reporting System (FAERS) of Sepsis-related toxicities of patient treated by ADC, with a chronology compatible with the drug toxicity Intervention: Drug: ADC
62772523|NCT05349383||Common cancer drug therapies other than ADC|"Sepsis-related toxicities induced by Common cancer drug therapies other than ADC.~Case reported in the FDA Adverse Event Reporting System (FAERS) of Sepsis-related toxicities of patient treated by Common cancer drug therapies other than ADC, with a chronology compatible with the drug toxicity~Intervention:~Drug: Chemotherapy, targeted therapy, immunotherapy and so on."
62772524|NCT02254395|EXPERIMENTAL|Deep Brain Stimulation|Stimulation is on.
62772525|NCT02254395|SHAM_COMPARATOR|Placebo|Sham Stimulation: Stimulation is off.
62772526|NCT02654665|EXPERIMENTAL|Liraglutide|Liraglutide will be administered once daily by subcutaneous injection at a starting dose of 0.6 mg, increasing at 0.6 mg/week increments to a maximum of 3.0 mg over the next 6 weeks, as tolerated.
62772527|NCT02654665|ACTIVE_COMPARATOR|Bariatric Surgery|Subjects will have outcomes measured within 28 days before surgery. Post-operative management and frequency of follow-up visits will be decided by the bariatric surgeon. Study visits for biochemical and endothelial function testing; MRI and liver biopsy and / or fibroscan will follow the same schedule as that of the lifestyle and liraglutide arms. Target weight loss for the first 26 weeks post-surgery is at least 30% of excess body weight.
62180105|NCT02712307|EXPERIMENTAL|5 days|Phenoxymethylpenicillin 800 mg x 4 for 5 days
62563481|NCT05827003|ACTIVE_COMPARATOR|Exercise&Topical Agent|Individuals with a diagnosis of knee osteoarthritis who had supervised exercise under the guidance of a physiotherapist for 6 weeks, 2 days a week, and in addition to this program, they used diclofenac gel 2 times a day, 4 days a week.
62563482|NCT05827003|ACTIVE_COMPARATOR|Topical Agent|Individuals with a diagnosis of knee osteoarthritis using diclofenac gel twice a day, 4 days a week, for 6 weeks
62563483|NCT01862978|EXPERIMENTAL|Heparin|Patient receiving Heparin
62563484|NCT01862978|EXPERIMENTAL|Nadroparin|Patient receiving nadroparin
62563485|NCT01862978|PLACEBO_COMPARATOR|Placebo|Patients receiving placebo
62563486|NCT05017792|OTHER|1- Before vaccination:|"To detect:~* COVID-19 IgG/IgM Rapid Test~* COVID-19 IgG/IgM by quantitative method(ELISA).~* D-dimer"
62563487|NCT05017792|OTHER|2-7 days after the first dose|Measuring D-dimer
62563488|NCT05017792|OTHER|3-Before the second dose:|To detect IgG and IgM To detect the level of Covid-19 Ig G antibodies titer in the blood, Quantitative Ig G titer should be measured. To detect the response of the immune system to the vaccine.
62563489|NCT05017792|OTHER|4-After 3 months from the second dose:|To detect the level ofCovid-19 Ig G antibodies titer in the blood, Quantitative Ig G titer should be measured. To detect the response of the immune system to the vaccine.
62772528|NCT02654665|ACTIVE_COMPARATOR|Diet modification and exercise|Exercise will be used to induce and maintain weight loss in a 26-week Weight Management Program. Each subject will follow an aerobic exercise prescription of moderate intensity (60-75% maximum heart rate) to expend 2000-3000 kcal/week, lasting 30-60 minutes each session (over 5-7 sessions). Subjects will be instructed by sports trainers, compliance reviewed and adjusted if necessary to maintain the targeted total energy expenditure to produce weight loss of at least 7% over 26 weeks.
62180106|NCT02712307|ACTIVE_COMPARATOR|10 days|Phenoxymethylpenicillin 1000 mg x 3 for 10 days
62180107|NCT01712295|EXPERIMENTAL|17% Salicylate with Ethyl Pyruvate|Subjects with plantar wart(s) will apply the product to warts twice a day for up to 16 weeks.
62180108|NCT01712295|ACTIVE_COMPARATOR|17% salicylate|subjects will apply 17% salicylate (standard of care treatment) to plantar skin wart(s) twice a day for up to 16 weeks
62180109|NCT05865925|EXPERIMENTAL|LY010616(30 mg/m2)|30 mg/m2 measured by Irinotecan hydrochloride, IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter)
62180110|NCT05865925|EXPERIMENTAL|LY010616(60 mg/m2)|60 mg/m2 measured by Irinotecan hydrochloride, IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter)
62391203|NCT06036940|EXPERIMENTAL|Third Experimental Group|The children in the third experimental group were given pre-operative patient education by the service nurse, and then the mother's voice recording was played until they went to the operating room.
62391204|NCT01809717|EXPERIMENTAL|Weight Lifting Exercises|
62391205|NCT05363046||Group A|Participants will complete the PD diary on 3 consecutive days in 1 week.
62563490|NCT05017792|OTHER|5-After 6 months from the second dose:|To detect the level ofCovid 19 Ig G antibodies titer in the blood, Quantitative Ig G titer should be measured. To detect the response of the immune system to the vaccine.
62563491|NCT02757053|EXPERIMENTAL|Guardian Cap|The set of high school football players wearing the Guardian Cap on their helmets
62563492|NCT02757053|NO_INTERVENTION|No Guardian Cap|The set of high school football players not wearing the Guardian Cap on their helmets
62563493|NCT03743051|EXPERIMENTAL|100 mg anamorelin HCl|100 mg anamorelin HCl (administered as film-coated tablets in fasted condition) was to be taken orally once daily for a total of 24 weeks
62563494|NCT03743051|PLACEBO_COMPARATOR|placebo|Placebo (administered as matching placebo tablets in fasted condition) was to be taken orally once daily for a total of 24 weeks
62563495|NCT04521062|OTHER|Dilapan S|Placement of dilators
62563496|NCT01628432|EXPERIMENTAL|conservative hysterectomy I|bilateral salpingectomy during hysterectomy with conservation of the ovaries
62180111|NCT05865925|EXPERIMENTAL|LY010616(90 mg/m2)|90 mg/m2 measured by Irinotecan hydrochloride, IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter)
62180112|NCT05865925|EXPERIMENTAL|LY010616(120 mg/m2)|120 mg/m2 measured by Irinotecan hydrochloride, IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter)
62180113|NCT05865925|EXPERIMENTAL|LY010616(150 mg/m2)|150 mg/m2 measured by Irinotecan hydrochloride, IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter)
62563497|NCT01628432|ACTIVE_COMPARATOR|conservative hysterectomy II|standard conservative hysterectomy with conservation of both ovaries and tubes
62563498|NCT02452944|EXPERIMENTAL|US-IFI group|"ultrasound-guided obturator nerve block with interfascial injection approach group (US-IFI; experimental group)~The stimulating needle without nerve stimulator advanced via an ultrasound to position the needle tip on the fascia between adductor longus and adductor brevis muscles. 10mL of local anesthetics were slowly injected. The needle was reinserted to position the needle tip on the fascia between adductor brevis and adductor magnus muscles, another 5mL of LA was injected.~After that, the needle was reinserted to the same spots attached with nerve stimulator at 1.0 mA. If adductor muscle twitching was shown, another 5mL of LA was injected, and it was documented as 'fail'."
62563499|NCT02452944|ACTIVE_COMPARATOR|US-NS group|ultrasound-guided obturator nerve block with nerve stimulating approach group (US-NS; control group) The stimulating needle attached to a nerve stimulator advanced via an ultrasound to position the needle tip on the fascia between adductor longus and adductor brevis muscles. The nerve stimulator was then turned on, and the stimulation current started at 0.5 mA. If adductor muscle twitching was observed on the sonogram even at the stimulation current 0.3mA, 10mL of local anesthetics were slowly injected. The needle was reinserted to position the needle tip on the fascia between adductor brevis and adductor magnus muscles. The stimulation current started at 0.5 mA. If adductor muscle twitching was visualized on the sonogram even at 0.3mA, another 5mL of LA was injected.
62563500|NCT05691127||Respiratory Diseased children|
62563501|NCT01890122|ACTIVE_COMPARATOR|Metformin HCl 500 mg|Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.
62182785|NCT02259062|ACTIVE_COMPARATOR|Music listening|
62563502|NCT01890122|ACTIVE_COMPARATOR|Alogliptin 12.5 mg|Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.
62563503|NCT01890122|EXPERIMENTAL|Alogliptin 12.5 mg + Metformin HCl 500 mg FDC|Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
62772529|NCT00459472|OTHER|Training|laparoscopic training curriculum: all general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
62772530|NCT03845595|EXPERIMENTAL|(LF-rTMS) group|Patients in the study group were treated with the contralesional (LF-rTMS) once per day for 20 minutes, Daily, 5 sessions per week (Sunday to Thursday), for 2 consecutive weeks in addition to the conventional upper limb physical therapy interventions.
62772531|NCT03845595|ACTIVE_COMPARATOR|Control group|Patients in the control group were treated with the conventional upper limb physical therapy interventions (40 minutes to 1 hour, daily, 5 times per week for two consecutive weeks )
62772532|NCT02163785|ACTIVE_COMPARATOR|Supine position|Abdominoperineal resection - perineal time- in supine position
62772533|NCT02163785|EXPERIMENTAL|Prone position|Abdominoperineal resection - perineal time- in prone position
62180114|NCT05865925|EXPERIMENTAL|LY010616(180 mg/m2)|180 mg/m2 measured by Irinotecan hydrochloride, IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter)
62180115|NCT03626805||Migraine patients|Migraine patients attending the Danish Headache Centre
62180116|NCT03626805||Healthy Controls|Age and sex matched
62180117|NCT05871190|ACTIVE_COMPARATOR|Test group|I-PRF is placed on the wound site after a gingivectomy with the conventional method and closed with a periodontal dressing
62180118|NCT05871190|PLACEBO_COMPARATOR|control group|closure of the wound site with only a periodontal dressing after a gingivectomy with the conventional method.
62563504|NCT01890122|PLACEBO_COMPARATOR|Placebo|Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
62180119|NCT00576823|EXPERIMENTAL|Alfuzosin solution - 2-7 years|Alfuzosin solution, daily dose divided in 3 doses given at breakfast, lunch and dinner to children 2-7 years of age.
62180120|NCT00576823|EXPERIMENTAL|Alfuzosin solution - 8-16 years|Alfuzosin solution, daily dose divided in 3 doses given at breakfast, lunch and dinner to children and adolescents 8-16 years of age who were not able to swallow tablets or preferred to take the solution or had a body weight \< 30 kg.
62180121|NCT00576823|EXPERIMENTAL|Alfuzosin tablet - 8-16 years|Alfuzosin tablet, daily dose divided in 2 doses given at breakfast and dinner to children and adolescents 8-16 years of age who were able to swallow tablets and had a body weight ≥ 30 kg.
62180122|NCT03964922|EXPERIMENTAL|immune escape mecanims|Cohort study with a representative sample of patients
62180123|NCT04787289|ACTIVE_COMPARATOR|Higher Standard dosing as per standard regimen|bevacizumab 15mg/kg + chemotherapy
62180124|NCT04787289|EXPERIMENTAL|Lower standard dosing bevacizumab plus chemotherapy|bevacizumab 7.5mg/kg + chemotherapy
62180125|NCT01101464|EXPERIMENTAL|Asenapine Sequence 1|
62180126|NCT01101464|EXPERIMENTAL|Asenapine Sequence 2|
62180127|NCT05500898|EXPERIMENTAL|Experimental 1|
62180128|NCT05500898|EXPERIMENTAL|Experimental 2|
62180129|NCT05500898|EXPERIMENTAL|Experimental 3|
62180130|NCT00918710||1|Patients with oropharyngeal squamous cell carcinomas
62563505|NCT02253511|EXPERIMENTAL|Cidan capsule|Patients who undergone operation and TACE were administered 1.35 g cidan capsules (Weida Pharmaceutical Co., Ltd., Beijing, China) three times a day for 3 months.
62563506|NCT02253511|NO_INTERVENTION|Control group|Patients were only accepted operation and TACE.
62563507|NCT04444011|EXPERIMENTAL|Anaprazole Sodium enteric-coated tablet|Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), one tablet each time.
62180131|NCT01540903|EXPERIMENTAL|Group 1 10,000 PfSPZ|12 volunteers, ID PfSPZ Challenge total dose 10,000 PfSPZ administered by 2 injections of 50µL each.
62180132|NCT01540903|EXPERIMENTAL|Group 2 25,000 PfSPZ|12 volunteers, ID PfSPZ Challenge total dose 25,000 PfSPZ administered in 4 injections of 10µL each.
62180133|NCT01540903|PLACEBO_COMPARATOR|Controls - saline|4 Volunteers, ID saline administered in 2 injections of 50µL each and 2 volunteers, ID saline administered in 4 injections of 10µL each.
62180134|NCT03544229|PLACEBO_COMPARATOR|Placebo|TAK-906 maleate placebo-matching capsules, orally, twice daily (BID) for up to 12 weeks.
62180135|NCT03544229|EXPERIMENTAL|TAK-906 Maleate 5 mg|TAK-906 maleate 5 mg, capsules, orally, BID for up to 12 weeks.
62180136|NCT03544229|EXPERIMENTAL|TAK-906 Maleate 25 mg|TAK-906 maleate 25 mg, capsules, orally, BID for up to 12 weeks.
62180137|NCT03544229|EXPERIMENTAL|TAK-906 Maleate 50 mg|TAK-906 maleate 50 mg, capsules, orally, BID for up to 12 weeks.
62180138|NCT02362347|ACTIVE_COMPARATOR|Usual care + exercise|Usual care + exercise
62180139|NCT02362347|NO_INTERVENTION|No care, no exercise|No care, no exercise
62180140|NCT02362347|EXPERIMENTAL|Usual care + exercise + compression vest|Usual care + exercise + London Health Sciences Centre - Compression Vest
62180141|NCT02565888|ACTIVE_COMPARATOR|Treatment A|Daclatasvir 30 mg QD film-coated tablet + atazanavir 300mg QD hard capsule + ritonavir 100mg QD from film-coated tablet for 10 days.
62180142|NCT02565888|EXPERIMENTAL|Treatment B|Daclatasvir 30 mg QD film-coated tablet + atazanavir 300mg QD hard capsule + cobicistat 150mg QD from film-coated tablet for 10 days.
62563508|NCT04444011|EXPERIMENTAL|Amoxicillin capsules|"Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), 2 capsules each time."
62180143|NCT03153098||Standard delivery|Participants will receive a behaviour change technique booklet, consultations (baseline, and optional at 3, 6, and 12 months), a booster phone call (week 2), motivational text messages (weeks 3, 6, and 12), and signposting to 12 weeks of exercise classes.
62180144|NCT03153098||Enhanced delivery|Participants will receive the same as intervention but the 12 weeks of exercise will be free and tailored to their needs, and there will be optional exercise 'buddies' available.
62180145|NCT04647318|EXPERIMENTAL|Compassion focused imagery, relaxation imagery and control task|Participants engage in three tasks (compassion focused imagery, relaxation imagery and control task), three or four times every three days.
62180146|NCT03962517|EXPERIMENTAL|Training with GEMS-H|"Participants will participate in 18 sessions of training + 5 sessions of testing for up to 3 month.~Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with the device."
62182786|NCT02259062|EXPERIMENTAL|Music listening with brief mindfulness|
62182787|NCT02259062|PLACEBO_COMPARATOR|Audio book intervention|
62772534|NCT05977166|ACTIVE_COMPARATOR|hyperbaric oxygen therapy ,breathing exercise,medical treatment|Hyperbaric oxygen treatment HBO treatment was given daily in the morning on 21 consecutive days. (HBOT) treatment is a procedure performed inside a pressured chamber (the Hyperbaric Chamber). The patient is place inside the chamber exposure to 100% oxygen at 2 ATA with 5 min air breaks every 20 min. Each session consisted of 60 min. Measurements will be taken in the morning before entering, the first and last session.
62772535|NCT05977166|ACTIVE_COMPARATOR|breathing exercise and medical treatment|"breathing exercise completely each session of three repetitions initially. Every repetition consisted of one round of intervention 10-15 times followed by a brief rest (normal breathing) of \<1 min (one repetition). Such 3 repetitions were given initially \& advanced till 10 repetitions (one session) by last day of the week. In this manner participants practised 3 sessions twice a day, for a total duration of about 10-20 min every day.Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day .~Vitamine C: The recommended dietary dose 200 mg/day vitamin C. Anticoagulation drugs (blood thinners), doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours"
62772536|NCT01339117|EXPERIMENTAL|High fermentable substrate diet|High fermentable substrate diet provided for two days
62772537|NCT01339117|EXPERIMENTAL|Low fermentable substrate diet|Low fermentable substrate diet provided for two days
62772538|NCT03678233|ACTIVE_COMPARATOR|Intervention|AndroGel® AndroGel 16.2 mg/L will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women
62772539|NCT03678233|NO_INTERVENTION|Control|In the control group, AndroGel will not be administered.
62772540|NCT02661672|EXPERIMENTAL|Patients with Brain Hemorrhage|Subjects will receive best medical management for ICH plus they will receive the MIES surgery and use of the Apollo or Artemis System for clot evacuation.
62772541|NCT01404455|OTHER|Normal pulse pressure|pulse pressure \<60mmHg
62772542|NCT01404455|OTHER|Wide pulse pressure|pulse pressure ≥60mmHg
62772543|NCT04023617|EXPERIMENTAL|Nivolumab + Docetaxel|"Nivolumab was administered at a dose of 300 mg on the first day of the 21-day cycle (every 3 weeks; q3w) when combined with docetaxel, and administered at a dose of 200 mg on the first day of each 14-day cycle (every 2 weeks; q2w) after stopping docetaxel treatment.~On the first day of each cycle (21 days), docetaxel 75 mg/m2 was infused by IV on Day 1 of each 21-day cycle for 4-6 cycles (judged by investigator)."
62772544|NCT04023617|ACTIVE_COMPARATOR|Nivolumab|Nivolumab was administered in the monotherapy group at a dose of 200 mg on the first day of each 14-day cycle (every 2 weeks; q2w).
62772545|NCT01175395|EXPERIMENTAL|IBI-20089/Lucentis|Alternate treatment of either 6.9 mg IBI-20089/Lucentis or 13.8 mg IBI-20089/Lucentis
62772546|NCT06307236|EXPERIMENTAL|Experimental|Group to be applied EFT
62772547|NCT06307236|NO_INTERVENTION|Control|No application will be made
62563509|NCT04444011|EXPERIMENTAL|Clarithromycin tablet|"Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), 2 tablets each time."
62563510|NCT04444011|EXPERIMENTAL|Anaprazole + Amoxicillin +Clarithromycin|"Cohort 1: Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods ( only once on the morning of D5 of treatment periods).~Cohort 2: Administered orally on an empty stomach once on the morning of D1 of treatment periods"
62563511|NCT04444011|EXPERIMENTAL|Anaprazole + Amoxicillin +Clarithromycin+Bismuth|Administered orally on an empty stomach once on the morning of D1 of treatment periods in cohort 2
62563512|NCT03525561|ACTIVE_COMPARATOR|acetazolamide arm|This is the arm of the study in which the volunteers will take the acetazolamide (Diamox) pill.
62182788|NCT03827850|ACTIVE_COMPARATOR|Cohort 1 FGFR trans|Cohort 1: Activating (high confidence) FGFR translocations (max. 15 patients) under daily Erdaifitinib treatment
62563513|NCT03525561|PLACEBO_COMPARATOR|placebo arm|This is the arm of the study in which volunteers will take the placebo.
62563514|NCT02394600|EXPERIMENTAL|Grastek®|48 participants will receive Grastek® once per day for 120 days. Grastek® is a standardized sublingual immunotherapy (SLIT) tablet containing 2800 BAU of standardized allergen extract from Timothy grass (Phleum pretense). This SLIT product is approved by Health Canada and the Food and Drug Administration (FDA) for the treatment of grass-pollen induced allergic rhinoconjunctivitis (AR) in Canada and the United States respectively.
62772548|NCT03343119||Hospitalised patients|No intervention
62772549|NCT03343119||Healthy volunteers|No intervention
62772550|NCT03343119||Dog owners (healthy volunteers)|No intervention
62772551|NCT03343119||Veterinarians (healthy volunteers)|No intervention
62772552|NCT03343119||Pig farmers (healthy volunteers)|No intervention
62772553|NCT03652467|EXPERIMENTAL|Deferoxamine|Patients are treated with deferoxamine and conventional TACE.
62772554|NCT03652467|ACTIVE_COMPARATOR|Conventional TACE|Patients are treated with conventional TACE.
62772555|NCT04316000||A - Removal of the Subepithelial Tumour|The subephitelial tumour is successfully removed by endoscopic band ligation without resection.
62563515|NCT02394600|PLACEBO_COMPARATOR|Placebo|48 participants will receive placebo once per day for 120 days.
62180147|NCT03962517|ACTIVE_COMPARATOR|Training without GEMS-H|"Participants will participate in 18 sessions of training + 5 sessions of testing for up to 3 month.~Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments without the device."
62180148|NCT01135030|ACTIVE_COMPARATOR|Posterior referencing|
62180149|NCT01135030|ACTIVE_COMPARATOR|Anterior referencing|
62563516|NCT03806114|OTHER|Anterior Approach Precautions|This group receives precautions and have a total hip arthroplasty with a posterior approach.
62180150|NCT00738985|PLACEBO_COMPARATOR|ezetimibe/simvastatin 10/20 mg + placebo|The intervention consisted of an isocaloric diet, an exercise program (30 min/day of aerobic activity) and ezetimibe (+) simvastatin 10/20 mg + placebo for 12 weeks. Safety and efficacy parameters are measured at baseline and 12 weeks later
62180151|NCT00738985|ACTIVE_COMPARATOR|ezetimibe/simvastatin 10/20 mg + MK0524A|The intervention consisted of an isocaloric diet, an exercise program (30 min/day of aerobic activity) and ezetimibe/simvastatin 10/20 mg + MK0524A 1 gr for 6 weeks, if efficacy achieved will continue with ezetimibe (+) simvastatin 10/20 mg + MK0524A 1 gr + placebo; if not achieved, will receive ezetimibe (+) simvastatin 10/20 mg + MK0524A 2 gr for 6 weeks.
62182789|NCT03827850|ACTIVE_COMPARATOR|Cohort 2 FGFR mut|Cohort 2: Activating (high confidence) hotspot FGFR mutations (max. 15 patients) under daily Erdafitinib treatment
62563517|NCT03806114|OTHER|Posterior Approach Precautions|This group receives precautions and have a total hip arthroplasty with a posterior approach.
62563518|NCT03806114|OTHER|Anterior Approach No Precautions|This group receives does not precautions and have a total hip arthroplasty with an anterior approach.
62180152|NCT03508934|ACTIVE_COMPARATOR|Intervention group (Continuous Glucose Monitroring and POC)|Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS) and Point of Care (POC) finger-stick blood glucose levels with application of hypoglycemia prevention protocol (activated based the GTS lower glucose alarms)
62180153|NCT03508934|PLACEBO_COMPARATOR|Control group (Point of Care-POC)|Hospitalized patients with DM2 will be monitored with POC blood glucose levels and application of hypoglycemia prevention protocol (activated based the POC values)
62180154|NCT05856578|EXPERIMENTAL|Mulberry Twig Alkaloid Tablet|Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet
62180155|NCT05856578|ACTIVE_COMPARATOR|Canagliflozin|Canagliflozin
62180156|NCT03429595|EXPERIMENTAL|Group 1: ATx201 GEL 2%|
62180157|NCT03429595|EXPERIMENTAL|Group 2: ATx201 GEL 4%|
62180158|NCT03429595|EXPERIMENTAL|Group 3: ATx201 GEL 4% plus vehicle|
62180159|NCT03429595|EXPERIMENTAL|Group 4: ATx201 GEL 4% plus vehicle|
62180160|NCT03429595|PLACEBO_COMPARATOR|Group 5: Vehicle|
62180161|NCT03311269|ACTIVE_COMPARATOR|ClariVein RES 1% Injection|Sodium Tetradecyl Sulfate 1% Injection single administration
62180162|NCT03311269|ACTIVE_COMPARATOR|ClariVein RES 3% Injection|Sodium Tetradecyl Sulfate 3% Injection single administration
62180163|NCT03586141|OTHER|noninvasive measurement of hemoglobin|All participating patients are measured by the Pronto® hemoglobin measurement tool
62180164|NCT01530087|EXPERIMENTAL|Treatment|CASTLE Barrier
62180165|NCT00264823|EXPERIMENTAL|1 - Experimental|
62180166|NCT00264823|NO_INTERVENTION|2 - Control|
62180167|NCT02118194||Paraplegia, spinal cord injury|An exoskeleton-assisted walking system for people with paralysis from spinal cord injury at thoracic level 1 and below (paraplegia) will be used.
62180168|NCT02652390|EXPERIMENTAL|Methylprednisolone 80 mg|Local injection of 80 mg Methylprednisolone into the carpal tunnel
62180169|NCT02652390|EXPERIMENTAL|Methylprednisolone 40 mg|Local injection of 40 mg Methylprednisolone into the carpal tunnel
62180170|NCT02652390|PLACEBO_COMPARATOR|Placebo|Local injection of saline into the carpal tunnel
62180171|NCT05510622||Recurrent pregnancy loss|Women with history of recurrent pregnancy loss
62180172|NCT05510622||Control|Normal fertile women
62180173|NCT03745378||Cases|Patients with diagnosis of Myeloproliferative Neoplasms (MPN) including Polycythemia Vera, Essential thrombocytopenia or Myelofibrosis, exposed or not exposed to JAK2V617F mutation, who experienced secondary cancer(s) diagnosed at presentation of MPN or during the course of the myeloproliferative disease.
62180174|NCT03745378||Controls|Patients with diagnosis of Myeloproliferative Neoplasms (MPN) including Polycythemia Vera, Essential thrombocytopenia or Myelofibrosis, exposed or not exposed to JAK2V617F mutation, without history of secondary cancer.
62180175|NCT02600585||Flublok|Recombinant influenza vaccine (RIV); Intramuscular injection of vaccine of recombinant uncleaved hemagglutinin (rHA0) derived from influenza A/H1N1, A/H3N2, and B viruses, as identified for the season by the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) in a total volume of 0.5 mL.
62180176|NCT02600585||Inactivated Influenza Vaccine|Injectable, inactivated, egg-based influenza vaccines (IIV); Intramuscular injection of vaccine (whether trivalent or quadrivalent) derived from influenza A/H1N1, A/H3N2, and B viruses, as identified for the season by the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) in a total volume of 0.5 mL.
62180177|NCT05469113|EXPERIMENTAL|Repaglinide - Period 1|Single dose of repaglinide administered orally.
62180178|NCT05469113|EXPERIMENTAL|Selpercatinib and repaglinide - Period 2|"Multiple doses of selpercatinib along with single dose of repaglinide administered orally.~There will be a 24-hour washout period between Period 1 and 2."
62180179|NCT04431219|EXPERIMENTAL|Ascending Dose Cohort|"The AD cohort will be first recruited and will include 5 patients: 1 patient per dose, sequentially recruited, the recruitment of the next dose level patient will be assessed by Data Safety Monitoring Board :~* Patient 1: 0.6 mg/Kg/day~* Patient 2: 1 mg/Kg/day~* Patient 3: 3 mg/Kg/day~* Patient 4: 6 mg/Kg/day~* Patient 5: 8 mg/Kg/day~Once the 5 AD patients complete LIS1 treatment, the sponsor and the DSMB will rule on the LIS1 dose to obtain an optimal CD3+ cells depletion, with a good safety profile and will determine the therapeutic dose."
62180180|NCT04431219|EXPERIMENTAL|Therapeutic Dose Cohort|"The TD cohort will be recruited once the therapeutic dose is defined. This cohort will be divided in 2 subgroups of respectively 2 and 3 patients sequentially recruited.~DSMB will review the safety and efficacy profile of the first 2 patients (Subgroup1) and decide:~* To continue at the same dose and recruit the next 3 patients of Subgroup 2~* To recruit the next 3 patients with a lower dose, estimated from AD as bringing efficient depletion~* To recruit the next patient with a higher dose (+2 mg/kg), if the depletion is not considered satisfactory and if the safety profile is considered acceptable~* To end the trial if LIS1 toxicity is too important vs its efficacy in CD3+ depletion.~If the decision to increase the dose after the first two TD patients is made, an additional DSMB review will be planned after patient 8. The DSMB will decide to maintain the dose for the last 2 patients or to get back to the previous dose"
62180181|NCT02496143|EXPERIMENTAL|Cohort 1|500 mg EC-18 dose or placebo
62180182|NCT02496143|EXPERIMENTAL|Cohort 2|1000 mg EC-18 dose orplacebo
62180183|NCT02496143|EXPERIMENTAL|Cohort 3|2000 mg EC-18 dose or placebo
62180184|NCT02496143|EXPERIMENTAL|Cohort 4|4000 mg EC-18 dose or placebo
62180185|NCT01627470||Cohort|Emergency Patients with applied arterial blood pressure measurement
62180186|NCT03906604|OTHER|Dominant hand-open Carpal Tunnel Release|Standard mini-open carpal tunnel release (standard of care) on the dominant hand.
62772556|NCT04316000||B - Non Removal of the Subepithelial Tumour|The subephitelial tumour is not successfully removed due to various reasons (size \>15-mm, not technical success,...).
62772557|NCT04316000||C - Not Observed or Benign Subepithelial Tumour|The subephitelial tumour is not observed or is a benign entity, which does not require further interventions for these patients.
62772558|NCT00295932|EXPERIMENTAL|Arm I|Patients receive cyclophosphamide IV and rituximab IV on day 1, oral prednisone on days 2-6, and bortezomib IV (at the MTD determined in phase I) on days 2, 5, 9, and 12. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
62772559|NCT00295932|EXPERIMENTAL|Arm II|Patients receive cyclophosphamide IV and rituximab IV on day 1, oral prednisone on days 2-6, and bortezomib IV (at the MTD determined in phase I) on days 2 and 8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
62772560|NCT00795288|EXPERIMENTAL|Simvastatin, 80 mg/day|Simvastatin, 80 mg/day for 21 days
62180187|NCT03906604|OTHER|Dominant hand-Incisionless thread carpal tunnel release|Incisionless thread carpal tunnel release on the dominant hand.
62180188|NCT06014047|EXPERIMENTAL|No-Touch vein|No-touch vein group has two No-touch saphenous vein grafts, anastomose to the right coronary or left coronary system. All patients also acquired LITA-LAD anastomosis to complete the revascularization.
62772561|NCT00795288|PLACEBO_COMPARATOR|Placebo|Placebo
62772562|NCT03893877|EXPERIMENTAL|nasal cannula|device:nasal cannula will be applied to patients for oxygenation under deep sedation
62772563|NCT03893877|ACTIVE_COMPARATOR|nasal mask|device:nasal mask will be applied to patients for oxygenation under deep sedation
62772564|NCT02153060|EXPERIMENTAL|20mg dexamethasone group|Dexamethasone 20 mg per day, 4 consecutive days
62180189|NCT06014047|ACTIVE_COMPARATOR|Radial artery|Radial artery group has one radial artery graft and one conventional saphenous vein graft, anastomose to the right coronary or left coronary system basing on surgeons' decision. All patients also acquired LITA-LAD anastomosis to complete the revascularization.
62180190|NCT02866071|ACTIVE_COMPARATOR|Ketamine|50mg IN Ketamine Hydrochloride
62180191|NCT02866071|PLACEBO_COMPARATOR|Placebo|50mg IN placebo
62180192|NCT06105112|EXPERIMENTAL|Hyaluronic acid|Minimally invasive surgical technique with a combined approach using hyaluronic acid gel and a bone xenograft.
62182790|NCT03827850|ACTIVE_COMPARATOR|Cohort 3 FGFR other|Cohort 3: Activating (low confidence) FGFR alteration (max. 20 patients)
62772565|NCT02153060|EXPERIMENTAL|40mg dexamethasone group|Dexamethasone 40 mg per day, 4 consecutive days
62772566|NCT03343600|EXPERIMENTAL|Imatinib|Imatinib (100 mg/tablet) 2# per day till D+100 after allo-HSCT or prophylaxis failure.
62180193|NCT06105112|ACTIVE_COMPARATOR|Enamel matrix derivatives|Minimally invasive surgical technique with a combined approach using enamel matrix derivatives gel and a bone xenograft.
62180194|NCT02185677||MSA-P|
62772567|NCT03343600|PLACEBO_COMPARATOR|Placebo|Placebo 2# per day till D+100 after allo-HSCT or prophylaxis failure.
62772568|NCT01024192|EXPERIMENTAL|1|Zolpidem 12.5mg tablet at bed time during 12 weeks
62772569|NCT05683015|EXPERIMENTAL|Standard of care - tildrakizumab|Patients will continue to receive tildrakizumab according to the standard dosing schedule: subcutaneous injections at weeks 0 and 4, then every 12 weeks (100mg)
62772570|NCT00537407|EXPERIMENTAL|Treatment Arm A|Debio 025 (alisporivir) 400 mg orally once daily + peg-IFNα2a 180 μg subcutaneously (sc) once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
62772571|NCT00537407|EXPERIMENTAL|Treatment Arm B|Debio 025 (alisporivir) 400 mg orally once daily for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
62772572|NCT00537407|EXPERIMENTAL|Treatment Arm C|Debio 025 (alisporivir) 400 mg orally once daily + peg-IFNα2a 180 μg sc once weekly for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
62180195|NCT02185677||MSA-C|
62180196|NCT00643435|EXPERIMENTAL|1|These residents receive training provided by standardized patient instructors, in use of self-efficacy enhancing interviewing techniques to support patient health behavior change,
62180197|NCT00643435|ACTIVE_COMPARATOR|2|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
62180198|NCT04680637|PLACEBO_COMPARATOR|Placebo + Standard of Care|
62772573|NCT00537407|EXPERIMENTAL|Treatment Arm D|Debio 025 (alisporivir) 800 mg orally once daily + peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
62772574|NCT00537407|EXPERIMENTAL|Treatment Arm E|Debio 025 (alisporivir) orally at a loading dose of 400 mg twice daily for 7 days followed by 400 mg/day for 22 days + peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
62772575|NCT01791101|EXPERIMENTAL|Eltrombopag|Eltrombopag 50 mg/daily.
62772576|NCT02647346|EXPERIMENTAL|Participant cohort|Participants with diabetes that each have a history of healed Diabetic Foot Ulcer (DFU) prior to enrollment.
61995210|NCT05698264|EXPERIMENTAL|NSCLC patients planned to receive PD-1 inhibitors|The cohort B will study the impact of TTField on the profile, activity, and proliferation of peripheral lymphocytes in NSCLC patients receiving PD-1 inhibitors concomitant to TTFields treatment. Lymphocytes will be purified from whole blood samples for the profile, proliferation, and activity analyzed by FACS.
61995211|NCT00966238|EXPERIMENTAL|VAX125|HA1 influenza vaccine
62180199|NCT04680637|EXPERIMENTAL|Efavaleukin Alfa Dose Level One + Standard of Care|
62180200|NCT04680637|EXPERIMENTAL|Efavaleukin Alfa Dose Level Two + Standard of Care|
62180201|NCT04680637|EXPERIMENTAL|Efavaleukin Alfa Dose Level Three + Standard of Care|
62180202|NCT00716066|EXPERIMENTAL|Treatment (immunosuppressive therapy followed by transplant)|Patients receive carmustine IV on day -6, etoposide IV and cytarabine IV BID on days -5 to -2, melphalan IV on day -1 and antithymocyte globulin IV on days -2 and -1. Patients then undergo autologous or syngeneic stem cell transplant on day 0. Patients also receive prednisone PO QD on days 7-21, followed by 2 week taper.
62391206|NCT05363046||Group B|Participants will complete the PD diary on 2 consecutive days in each of 2 consecutive weeks.
62563519|NCT03806114|OTHER|Posterior Approach No Precautions|This group receives does not receive precautions and have a total hip arthroplasty with a posterior approach.
62180203|NCT05917548|EXPERIMENTAL|Tele-education|The tele-education group will receive the same intervention as the comparison group with an educational reinforcement mediated by teledentistry. This intervention consists of 4 educational videos, designed for the elderly, promoting correct toothbrushing and flossing, detection, and prevention of dental caries, periodontal disease, and oral cancer. These four videos were sent via WhatsApp.
62772577|NCT04070066|EXPERIMENTAL|Digital didactic environment|Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
62772578|NCT04070066|ACTIVE_COMPARATOR|• Simulated scenario|The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
62772579|NCT02184832|EXPERIMENTAL|Low tryptophan diet|2 days of a low tryptophan diet
62772580|NCT02184832|EXPERIMENTAL|High tryptophan diet|2 days of a high tryptophan diet
62772581|NCT04446741||Acute Myeloid Leukemia (AML)|Newly diagnosed or relapsed/resistant AML
62772582|NCT01063088|EXPERIMENTAL|Vaccination|Single 0.5 mL intramuscular injection of PreFluCel 2009/2010
62772583|NCT03809910|EXPERIMENTAL|Prototype PTB (Gum line mode)|Participants will brush their teeth with prototype power toothbrush in Gum line mode with a fluoride toothpaste
62772584|NCT03809910|EXPERIMENTAL|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype power toothbrush in Gum line mode with a fluoride toothpaste. Following this, participants will brush their teeth with prototype power toothbrush in 'Interdental' mode with a fluoride toothpaste."
62772585|NCT03809910|SHAM_COMPARATOR|Reference MTB|Participants will brush their teeth with manual toothbrush and fluoride toothpaste.
62772586|NCT03809910|ACTIVE_COMPARATOR|Reference PTB|Participants will brush their teeth with reference power toothbrush and fluoride toothpaste.
62180204|NCT05917548|ACTIVE_COMPARATOR|Comparison|The comparison group receive a medical-dental-geriatric diagnosis and face-to-face standardized education via powerpoint presentation and use of dental models for the promotion of correct toothbrushing and flossing, detection, and prevention of dental caries, periodontal disease, and oral cancer.
62180205|NCT03937037|EXPERIMENTAL|Saline irrigation|CBD stone removal after routine ERCP procedure,100ml saline irrigation after a balloon occlusion cholangiogram confirming the absence of stones.
62180206|NCT03937037|NO_INTERVENTION|None saline irrigation|CBD stone removal after routine ERCP procedure, a balloon occlusion cholangiogram confirms the absence of stones.
62180207|NCT04865614||Etomidate group|Patients who received etomidate for induction of anaesthesia during interventional mitral valve repair (Mitraclip)
62180208|NCT04865614||Sevoflurane group|Patients who received sevoflurane for induction of anaesthesia during interventional mitral valve repair (Mitraclip)
62180209|NCT04758676|EXPERIMENTAL|Nutritional and physiotherapy protocol, BIA|Study subjects randomized into this study arm will be indicated for nutritional and physiotherapy protocol, based upon the obtained results of the measurements, using bioimpedance analysis.
62180210|NCT04758676|ACTIVE_COMPARATOR|Standard of care|Study subjects randomized into this study arm will be provided the current standard of care.
62180211|NCT03408223|ACTIVE_COMPARATOR|total body irradiation|Patient receives preparative therapy including cyclophosphamide and total body irradiation (TBI) of 10 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
62182791|NCT03209245|ACTIVE_COMPARATOR|Active AIT group|"Injection immunotherapy with Purethal Mites were administered as perennial therapy using the following regimen of injections: 1 dose- 0.1 ml, 2 doses - 0.2 ml, 3 doses - 0.5 ml every week, and 0.5 ml every four weeks during 24 months.~monitoring of allergen specific IgE monitoring of allergen specific IgG4"
62772587|NCT01026272||healthy subjects|subjects with no sign of inflammatory disease, or diagnosis of MS
62563520|NCT02045264|EXPERIMENTAL|Icatibant (30 mg)|30mg dose of icatibant is administered as a single subcutaneous injection in the abdominal area
62180212|NCT03408223|EXPERIMENTAL|total marrow and lymphoid irradiation|Patient receives preparative therapy including cyclophosphamide and total marrow and lymphoid irradiation of 12-20 Gy on Days -8 through -2, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
62180213|NCT00616577|EXPERIMENTAL|Group CB|Subjects in this arm will receive caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine after induction of general anesthesia prior to surgical incision.
62563521|NCT00093912|EXPERIMENTAL|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
62563522|NCT00093912|ACTIVE_COMPARATOR|sodium nitroprusside|Sodium nitroprusside (SNP) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
62563523|NCT04321629|EXPERIMENTAL|Autologous Fat Tissue Group|Group of patients treated with intra-articular injections of autologous adipose tissue.
62563524|NCT04321629|ACTIVE_COMPARATOR|PRP Group|Group of patients treated with intra-articular injections of platelet-rich-plasma.
62563525|NCT01616836|ACTIVE_COMPARATOR|continuous FNB|Bolus femoral nerve block (ropivacaine 0.5% 20 mL), continuous infusion 48 hours (ropivacaine 0.2%, 5 mL/h), placebo local infiltration
62772588|NCT01026272||Patients with MS|
62772589|NCT01410188|EXPERIMENTAL|OPA-6566 low dose|Treatment with OPA-6566 low dose
62772590|NCT01410188|EXPERIMENTAL|OPA-6566 medium dose|Treatment with OPA-6566 medium dose
62772591|NCT01410188|EXPERIMENTAL|OPA-6566 high dose|Treatment with OPA-6566 high dose
62772592|NCT01410188|ACTIVE_COMPARATOR|Latanoprost|Treatment with Latanoprost
62772593|NCT01410188|PLACEBO_COMPARATOR|Placebo|Placebo
62180214|NCT00616577|ACTIVE_COMPARATOR|Group CA|Group CA (Caudal After-control group) will receive caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine after completion of surgery but before emergence from anesthesia.
62182792|NCT03209245|PLACEBO_COMPARATOR|non-active, placebo treatment|symptomatic treatment with concomitant use of placebo injection monitoring of allergen specific IgE monitoring of allergen specific IgG4
62772594|NCT01410188|EXPERIMENTAL|OPA-6566 additional dose|Treatment with OPA-6566 additional dose
62772595|NCT01794442||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
62180215|NCT00616577|ACTIVE_COMPARATOR|Group LIA|Group LIA (Local Infiltration After-control group) will receive local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site at the conclusion of surgery but before emergence from anesthesia.
62180216|NCT02291809|EXPERIMENTAL|REMUNE|Remune vaccine consists of a suspension of killed HIV-1 virus particles that have been emulsified with Incomplete Freund's Adjuvant (IFA, a mixture of mannide mono-oleate and a highly purified mineral oil). Each dose is given by IM injection and contains 10 μg of p24 antigen in approximately 100 μg of total protein.
62180217|NCT02291809|PLACEBO_COMPARATOR|REMUNE Low Dose|Remune low dose vaccine consists of a suspension of killed HIV-1 virus particles that have been emulsified with Incomplete Freund's Adjuvant (IFA, a mixture of mannide mono-oleate and a highly purified mineral oil). Each dose is given by IM injection and contains 2.5 μg of p24 antigen in approximately 25 μg of total protein.
62180218|NCT03643497||Children with the usage of anti-infective drugs|Children received meropenem or linezolid monotherapy in the treatment of seven infectious diseases
62180219|NCT05840822|PLACEBO_COMPARATOR|Placebo|Nightly dose of two placebo capsules
62180220|NCT05840822|EXPERIMENTAL|75mg CBD|Nightly dose of one 75mg CBD capsule and one placebo capsule
62180221|NCT05840822|EXPERIMENTAL|150mg CBD|Nightly dose of two 75mg CBD capsules
62180222|NCT03272711|EXPERIMENTAL|Vortioxetine plus cognitive training|Vortioxetine (10 mg) plus cognitive training 5 times weekly for 30 minutes a day
62180223|NCT03272711|PLACEBO_COMPARATOR|Placebo plus cognitive training|Placebo plus cognitive training 5 times weekly for 30 minutes a day
62180224|NCT01481519|ACTIVE_COMPARATOR|dexamethasone 0.1%/povidone-iodine 0.4%|Patients were instructed to put one drop into each symptomatic eye four times daily for 7 days.
62180225|NCT01481519|PLACEBO_COMPARATOR|artificial tears|Patients were instructed to put one drop into each symptomatic eye four times daily for 7 days.
62180226|NCT00999141|EXPERIMENTAL|FS VH S/D 4 s-apr|One side of face will be treated with the investigational product (FS VH S/D 4 s-apr) as an adjuvant to the standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
62180227|NCT00999141|NO_INTERVENTION|Standard of Care (SoC)|Other side of face will receive standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
62180228|NCT01226485|EXPERIMENTAL|Taladegib|"Part A Cohort 1: 50 milligram (mg) taladegib administered orally QD on a 28-day cycle.~Part A Cohort 2: 100 mg taladegib administered orally QD on a 28-day cycle.~Part A Cohort 3: 200 mg taladegib administered orally QD on a 28-day cycle.~Part A Cohort 4: 400 mg taladegib administered orally QD on a 28-day cycle.~Part A Cohort 5: 600 mg taladegib administered orally QD on a 28-day cycle.~Part C: 400 mg taladegib administered orally QD. Participants with advanced solid tumors.~Part D: 400 mg taladegib administered orally QD. Participants with advanced basal cell carcinoma (BCC)."
62180229|NCT03161223|OTHER|A: Oral 5-azacitidine, durvalumab, romidepsin|Arm A: Patients will first undergo a 7-day lead-in phase of 5-azacitidine. 5-azacitidine will be administered orally from day 1 to day 14 (including the lead-in phase), durvalumab will be administered intravenously on day 8 and romidepsin intravenously on days 8 and 15 of a 28-day treatment cycle
62180230|NCT03161223|OTHER|B: durvalumab, pralatrexate, romidepsin|Arm B: Durvalumab will be administered intravenously on day 1, pralatrexate will be administered intravenously on days 1 and 15, and romidepsin will be administered intravenously on days 1 and 15. Each treatment cycle will last 28 days. All patients receiving pralatrexate will receive folic acid and vitamin B12 supplementation according to the drug package insert. Leucovorin rescue is also allowed at the dose of 15 mg orally twice daily on days 3 to 6 and 17 to 20.
62180231|NCT03161223|OTHER|C: durvalumab, romidepsin|Arm C: Durvalumab will be administered intravenously on day 1 and romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle
62180232|NCT03161223|OTHER|D: durvalumab, 5-azacitidine|Arm D: Patients will first undergo a 7-day lead-in phase of 5-azacitidine. 5-azacitidine will be administered orally from day 1 to day 14 (including the lead-in phase) and durvalumab will be administered intravenously on day 8 of a 28-day treatment cycle
62180233|NCT04830878|EXPERIMENTAL|Treatment|Methotrexate treatment
62180234|NCT01233271|EXPERIMENTAL|1|Space TGC system with incorporated eMPC advised insulin titration to establish glycaemic control
62180235|NCT04115956|EXPERIMENTAL|Melflufen and dexamethasone in combination|Intravenous infusion of melflufen Day 1 of 28 day cycles, in combination of dexamethasone on Days 1 and 2 of each 28-day cycle.
62180236|NCT00483080|EXPERIMENTAL|A: NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every 3 weeks or weekly
62180237|NCT02716688|EXPERIMENTAL|Radiotherapy and S-1 arm|Radiotherapy will be delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy. Preplanned concurrent S-1 (70mg/m²/day) will be administered on Day 1 for 14 days, every 3 weeks. After dCRT, maintenance S-1 will be given up to two cycles.
62180238|NCT05666817|EXPERIMENTAL|experiment group|Breastfeeding training will be given to each mother in the room she stays in the form of lectures and after the training, the question and answer method will be used. In addition, the practices explained by the researcher (the way of holding the baby, grasping the breast and positioning the baby appropriately for the baby, determining the position suitable for breastfeeding and the process of expressing and storing breast milk) will be demonstrated using the mother demonstration method in order to evaluate whether the mother understands the breastfeeding education after the breastfeeding training. Breastfeeding training will take approximately 40-45 minutes.
62563526|NCT01616836|ACTIVE_COMPARATOR|single FNB|femoral nerve block (ropivacaine 0.5% 20 mL), placebo femoral nerve block infusion, placebo local infiltration
62180239|NCT05666817|NO_INTERVENTION|Control group|No attempt will be made to the mothers in the control group following the pre-test application, within the scope of the post-test application before discharge; Breastfeeding Knowledge Level Diagnostic Form, LATCH Scale and Postnatal Self-Efficacy Scale will be applied. In addition to the breastfeeding education given to the intervention group following the post-test application to the mothers in the control group, a guide on the importance of breast milk and breastfeeding will also be given.
62180240|NCT01789619||Extended release tacrolimus (Advagraf®)|
62180241|NCT04240236|EXPERIMENTAL|Group S|Group S received scalp block with 20 ml of 0.5% bupivacaine
62180242|NCT04240236|PLACEBO_COMPARATOR|Group C|Group C will not have any intervention
62180243|NCT04687098|OTHER|Risk-adapted postremission treatment.|Induction (idarubicin, cytarabine), first consolidation (high dose cytarabine), risk- stratification: allogeneic matched related or unrelated donor transplant vs. consolidation courses.
62772596|NCT01794442||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of \>21 mmHg required
62180244|NCT04295330|EXPERIMENTAL|Lidocaine group|at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery.
62180245|NCT04295330|PLACEBO_COMPARATOR|placebo group|the same volume of normal saline will be administered during anesthesia.
62182793|NCT04703868|EXPERIMENTAL|YPI-011 10/500mg|Part A: 1 tablet administered before the breakfast during 7 days
62180246|NCT03892928|EXPERIMENTAL|Dexmedetomidine group|Dexmedetomidine was infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. If Ramsay sedation scale score reached 3, colonoscope was inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg was administrated as the rescue dose if body movement occurred during colonoscopy.
62180247|NCT03892928|OTHER|Propofol group|Propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reached 3. During the whole process, propofol was given intermittently to maintain Ramsay score 3 to 4. If body movement happened, propofol 10mg was administrated every time.
62180248|NCT01379703||Single patients group|Single HIV-1 infected patients group
62772597|NCT01794442||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of \< 21 mmHg
62180249|NCT01837589|OTHER|QCT and DXA|All the patients will have both QCT and DXA
62180250|NCT06201871|EXPERIMENTAL|Alcoholic patients|Patients will receive an inferior alveolar nerve block injection using 1.8 mL of 2% lidocaine with 1: 80 000 epinephrine using a direct Halsted approach.
62180251|NCT06201871|ACTIVE_COMPARATOR|Control patients|Patients will receive an inferior alveolar nerve block injection using 1.8 mL of 2% lidocaine with 1: 80 000 epinephrine using a direct Halsted approach.
62180252|NCT05364086||Observational (questionnaire, biospecimen, medical records)|Patients complete questionnaires and undergo collection of blood, saliva, and optional stool samples before 1st and 2nd infusion of immunotherapy. Blood samples will be collected 6 months after 1st infusion of immunotherapy, and then every year after 1st infusion of immunotherapy. A tumor sample will also be collected at the beginning of the study and patients medical records will be reviewed.
62180253|NCT05652790|EXPERIMENTAL|Enhanced Rehabilitation Programme (ERP)|"60-120 MINUTES OF ENHANCED REHABILITATION~Manual Therapy Hydrotherapy Exercise Strength and Conditioning Programmes Gait re-education Pilates/ Yoga Cognitive and Vocational Rehabilitation Occupation Therapy Interventions eg. Anxiety Management, Pacing, Cognitive Behavioural Therapy"
62180254|NCT05652790|OTHER|Standard Care|Standard care received at usual NHS facility
62180255|NCT06521294|EXPERIMENTAL|Group 1|SNAG
62772598|NCT00790478|PLACEBO_COMPARATOR|Placebo|Placebo -- lactose pill.
62180256|NCT06521294|ACTIVE_COMPARATOR|Group 2|Physiotherapy
62180257|NCT02654132|EXPERIMENTAL|Elotuzumab Arm|"Biological:Elotuzumab (BMS-901608; HuLuc63)~* Solution, Intravenous(IV),10 mg/kg(Cycles 1 and 2 weekly, on Days 1,8,15,22)~* Solution, Intravenous(IV),20 mg/kg(Cycle 3 and Beyond: Day 1)~Drug: Pomalidomide~•Capsules,Oral,4 mg,once daily, on Days 1-21~Other Name: Pomalyst~Drug: Dexamethasone~* Subjects ≤ 75 years old:~  •Tablets, Oral,28 mg, once daily on: Days 1,8,15,22(Cycles 1\&2) Day 1(Cycle 3 and Beyond)~  •Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1\&2) Day 1(Cycle 3 and Beyond)~  •Tablets, Oral,40 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)~* Subjects \> 75 years old:~  •Tablets, Oral,8 mg, once daily on: Days 1,8,15,22(Cycles 1\&2) Day 1(Cycle 3 and Beyond)~  •Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1\&2) Day 1(Cycle 3 and Beyond)~  •Tablets, Oral, 20 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)~Other Names:~Decadron,Dexamethasone ,Intensol,Dexpak,Taperpak"
62772599|NCT00790478|ACTIVE_COMPARATOR|Melatonin|Melatonin
62180258|NCT02654132|ACTIVE_COMPARATOR|Control Arm|"Drug: Pomalidomide~• Capsules, Oral, 4 mg, once daily, on Days 1-21 Other Name: Pomalyst~Drug: Dexamethasone~Subjects ≤ 75 years old:~• Tablets, Oral, 40 mg, weekly on Days 1, 8, 15 and 22~Subjects \> 75 years old:~• Tablets, Oral, 20 mg, weekly on Days 1, 8, 15 and 22,~Other Names:~* Decadron~* Dexamethasone Intensol~* Dexpak~* Taperpak"
62180259|NCT05219929|ACTIVE_COMPARATOR|Tetracycline First|Tetracycline for first 3 months, placebo for second 3 months.
62180260|NCT05219929|PLACEBO_COMPARATOR|Placebo First|Placebo for first 3 months, tetracycline for second 3 months.
62180261|NCT05863013|NO_INTERVENTION|Health education and home care|They will receive standard care: a therapeutic education session on admission, plus daily in-house early postoperative rehabilitation, delivered by a physiotherapist. The therapeutic educational session will involve counseling and self-care management, aiming to prepare patients for the postoperative period, emphasizing breathing exercises and sputum clearance techniques, pain control strategies and self-care. It will consist of smoking cessation education, respiratory retraining (pursed-lip breathing, diaphragmatic breathing, and segmental breathing), and secretion clearance training (coughing exercise, huffing, assisted coughing, and postural drainage).
62772600|NCT02264080|EXPERIMENTAL|WAL2014|
62772601|NCT02264080|PLACEBO_COMPARATOR|Placebo|
62772602|NCT06206811|EXPERIMENTAL|Part 1 - Single Ascending dose|To assess the safety and tolerability of single ascending doses of OD-07656 administered as an oral capsule
62772603|NCT06206811|EXPERIMENTAL|Part 2 - Multiple Ascending dose|To assess the safety and tolerability of multiple ascending doses of OD-07656 administered as an oral capsule
62772604|NCT06206811|EXPERIMENTAL|Part 3 - Food effect and relative bioavailability between dose forms|To assess the safety and tolerability of OD-07656 administered as an oral capsule or tablet
62772605|NCT06206811|EXPERIMENTAL|Part 4 - Pharmacokinetic drug interaction between midazolam and OD-07656|To assess the safety and tolerability of OD-07656 administered as an oral capsule or tablet following administration of midazolam
62772606|NCT05948046||Training group|Patients with symptomatic convergence insufficiency who had received visual training
62180262|NCT05863013|EXPERIMENTAL|Pulmonary rehabilitation|They will receive standard care described (AP) plus perioperative PR, with 20 preoperative and 60 postoperative sessions. The preoperative sessions will be held 2X/week, in addition to the home sessions 3X/week. Each outpatient session will last 2 hours and will consist of therapeutic education, aerobic exercises, resistance training of lower limbs, upper limbs and abdominal wall, and respiratory muscle training (RMT), which will include breathing pattern, positive expiratory pressure and inspiratory muscles training and home will last for 1h, unsupervised and personalized MRT plus 30 min of aerobic walking at an intensity of 60-80% of maximum HR. Participants will receive a portable pedometer and HR monitor. Postoperative rehabilitation will be offered only to the IG, from 1 month after surgery, with 60 sessions divided into 24 outpatient sessions performed 2X/week and 36 home sessions 3X/week. The postoperative program will last 12 weeks.
62772607|NCT05948046||Not training group|Patients with symptomatic convergence insufficiency who had not received visual training
62180263|NCT06462274||ICH group|Patients with CT-demonstrated Intracerebral Hemorrhage (ICH) within 72 hours after symptom onset admitted to Southwest hospital.
62180264|NCT06462274||Control group|Age- and sex-matched healthy individuals were recruited from volunteers.
62563527|NCT01616836|ACTIVE_COMPARATOR|LIA|placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia
62772608|NCT02623504|EXPERIMENTAL|Equetro|200-1200 mg of Equetro (carbamazepine) by mouth given in divided doses in the morning and in the evening. Dosage is titrated in 200 mg increments weekly as needed according to subject response.
62180265|NCT00003693|EXPERIMENTAL|MTD Group|
62563528|NCT05277883||Group|All patients scheduled for a total knee arthroplasty without any previous lower limb deformities or previous hip/knee surgery will be enrolled. A long leg standing x-ray and a CT scan of the lower limb will be obtained for every patient.
62563529|NCT03915301||ESPB|Erector spinae plane block group
62563530|NCT03915301||Opioids|Opioid group
62772609|NCT02623504|PLACEBO_COMPARATOR|Placebo|Placebo dosage to match the active Equetro treatment given in 2 daily doses in the morning and in the evening.
62182794|NCT04703868|EXPERIMENTAL|YPI-011 20/500mg|Part B: 1 tablet administered before the breakfast during 7 days
62772610|NCT03879421|ACTIVE_COMPARATOR|Group 1 (Epithelium-off accelerated CXL)|patients with corneal thickness \> 400 µm (thinnest location) were assigned into Epi-off accelerated CXL procedure
62772611|NCT03879421|ACTIVE_COMPARATOR|Group 2 (Epithelium-on accelerated CXL)|patients with corneal thickness \> 380 µm and \< 400 µm thinnest location) were assigned into Epi-on Trans-epithelial accelerated CXL procedure
62180266|NCT03260803|EXPERIMENTAL|postmenopausal osteopenic women receiveing Oligopin|postmenopausal osteopenic women receiving Oligopin ,150 mg ,once daily, 12 week
62772612|NCT05570409|EXPERIMENTAL|Immunosuppressive treatment|Mycophenolate mofetil (MMF) 1g bid and prednisolone at initially 1mg/kg in a step-down regime
62772613|NCT05570409|PLACEBO_COMPARATOR|Placebo|Mycophenolate mofetil (MMF) and prednisolone Placebo
62772614|NCT01096511||Group 1|
62772615|NCT06301295|EXPERIMENTAL|Ultrathin bronchoscopy with intratumoral washing|Each subject suspected of early-stage lung cancer will undergo bronchooscopic procedure for generic alteration with Next Generation Sequencing.
62180267|NCT03260803|PLACEBO_COMPARATOR|postmenopausal osteopenic women receiving placebo|postmenopausal osteopenic women receiving placebo, 150 mg,once daily,12 weeks
62180268|NCT01744756|EXPERIMENTAL|Subconjunctival Bevacizumab|One aplication of subconjunctival Bevacizumab 0,5 ml
62180269|NCT02153190|EXPERIMENTAL|HYBRID-OPEN|"Patients are randomized on the schedule; hybrid period and after open period. During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.~During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times. Overall, an increase of time spent in range when using artificial pancreas in the hybrid period should be observed with a reduction of both hypo and hyperglycemia episodes."
62772616|NCT00351962|EXPERIMENTAL|Schedule I (10 fractions)|Subjects will receive a total of 10 stereotactic radiation treatments, given over 3 weeks.
62772617|NCT00351962|EXPERIMENTAL|Schedule II (4 fractions)|Subjects will receive a total of 4 stereotactic radiation treatments, given over 2 weeks.
62772618|NCT05716204|EXPERIMENTAL|High force lateral distraction group|High force lateral distraction of the hip in maximun adjusted position.
62180270|NCT02153190|EXPERIMENTAL|OPEN-HYBRID|"Patients are randomized on the schedule: open period and after hybrid period. During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.~During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day. Overall, an increase of time spent in range when using artificial pancreas in the hybrid period should be observed with a reduction of both hypo and hyperglycemia episodes."
62180271|NCT01222533|EXPERIMENTAL|Tiotropium low|Tiotropium inhalation solution low dose
62772619|NCT05716204|SHAM_COMPARATOR|Placebo distraction group|Placebo lateral distraction of the affected hip in maximun adjusted position.
62772620|NCT04330027|EXPERIMENTAL|Growth factors|Patients in this group will receive one lyophilized Growth Factors injection supplied as a powder in a tightly sealed container.
62772621|NCT04330027|PLACEBO_COMPARATOR|Saline|Patients in this group will receive an injection with equal volume of saline; i.e 2ml of 0.9% sodium chloride.
62180272|NCT01222533|EXPERIMENTAL|Tiotropium medium|Tiotropium inhalation solution medium dose
62180273|NCT01222533|EXPERIMENTAL|Tiotropium high|Tiotropium inhalation solution high dose
62180274|NCT01222533|ACTIVE_COMPARATOR|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
62180275|NCT01222533|PLACEBO_COMPARATOR|Tiotropium placebo|Placebo inhalation solution
62180276|NCT01101997|EXPERIMENTAL|Experimental: Abdomen Treatment Group|All subjects were treated on the abdomen with the CoolSculpting system.
62180277|NCT05503693|EXPERIMENTAL|AP303|AP303
62180278|NCT05503693|PLACEBO_COMPARATOR|Placebo|Placebo
62772622|NCT02078648|EXPERIMENTAL|SL-701 + GM-CSF + Imiquimod|"Patients will receive SL-701 with the vaccine adjuvants granulocyte macrophage-colony stimulating factor (GM-CSF) injection and imiquimod topical cream.~A complete dose of study drug consists of the administration of a sequence of 3 agents, SL-701 emulsion SC injection, GM-CSF SC injection, and imiquimod topical cream, within a 5-minute time frame. Topical application of imiquimod cream at the injection site is repeated at 24 hours after each SL-701 emulsion injection. For each patient, SL-701 emulsion (SL-701 in Montanide®) will be administered by SC injection beginning on Day 1 with imiquimod topical cream 5% applied immediately (within 5 minutes after SL-701 emulsion injection) to the SL-701 emulsion injection site.~In addition to the SL-701 emulsion injection, the patient will receive a SC injection of GM-CSF 150 μg close to the injection site of SL-701 emulsion. An additional dose of imiquimod cream will be applied at the same site by the patient 24 hours later."
61995212|NCT01921179|EXPERIMENTAL|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
62180279|NCT02384278|EXPERIMENTAL|Internet-based CBT for alcohol problems|A 12-week internet-based cognitive behavior treatment (CBT) and relapse prevention program. The subjects will have access to a psychologist guiding them through the program.
62180280|NCT00878293|EXPERIMENTAL|A|Dose 1, 40 µg
62180281|NCT00878293|EXPERIMENTAL|B|Dose 2, 120 µg
62391207|NCT01473108|EXPERIMENTAL|Finerenone (20 mg solution)|3-fold crossover of single dose 20 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
62772623|NCT02078648|EXPERIMENTAL|SL-701; poly-ICLC 1.6mg; bevacizumab|SL-701 emulsion and the adjuvant poly-ICLC will be administered twice weekly for the initial 2 weeks, every 7 days during the subsequent 3 doses, and subsequently every 14 days for the subsequent 9 doses (16 doses total) through Week 22, and every 4 weeks thereafter. Bevacizumab will be administered every 2 weeks, subsequent to the administration of SL-701/poly-ICLC.
62772624|NCT01545973||Healthy Volunteers|Human subjects without chronic medical conditions, defined as conditions requiring chronic medication use.
62772625|NCT04115982|EXPERIMENTAL|Cholecalciferol|Cholecalciferol (Vitamin D3) 100 000 IU/2 mL
61995213|NCT01921179|ACTIVE_COMPARATOR|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
61995214|NCT03920631|EXPERIMENTAL|Cohort 1: Microtransplantation (MST)|MST:Infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
61995215|NCT03920631|EXPERIMENTAL|Cohort 2/2b: MST + Nivolumab|"2: Microtransplantation (Day 0) + nivolumab (3 mg/kg) every 2 weeks (beginning on Day+14)~2b: Microtransplantation (Day 0) + nivolumab (1 mg/kg) every 2 weeks (beginning on Day+14)."
61995216|NCT03920631|EXPERIMENTAL|Cohort 3/3b: MST + Nivolumab|"3: Microtransplantation (Day 0) + nivolumab (3 mg/kg) every 2 weeks (beginning on Day-1).~3b: Microtransplantation (Day 0) + nivolumab (1 mg/kg) every 2 weeks (beginning on Day-1)."
61995217|NCT03920631|EXPERIMENTAL|Cohort 4: Expansion|Microtransplantation (Day 0) + nivolumab (at RP2D)
61995218|NCT02606591|EXPERIMENTAL|Electroencephalograph (EEG) + Testing|Participants complete an electroencephalograph (EEG) cognitive tests, and provide a hair sample shortly after entering the study and again near the end of the school year. Hair sample tested to measure a stress hormone called cortisol.
61995219|NCT02356783|OTHER|Interlaminar|"Approach for lumbar epidural steroid injection for this arm will be interlaminar.~We will be implementing a wireless pedometer to each of the 15 patients in this group to measure our primary and secondary outcomes."
61995220|NCT02356783|OTHER|Transforaminal|"Approach for lumbar epidural steroid injection for this arm will be transforaminal.~We will be implementing a wireless pedometer to each of the 15 patients in this group to measure our primary and secondary outcomes."
61995221|NCT06450548|EXPERIMENTAL|Dynamic and static acquisition|Dynamic and static PET acquisitions with 18F-FDG and 68Ga-PSMA will be performed with a minimum of 24 hours and a maximum of 15 days between the two
61995222|NCT05001243|EXPERIMENTAL|Experimental PBOHB|Pilocarpine, brimonidine, Oxymetazoline combined with Hyaluronic Acid and Bromfenac combined in an ophthalmic solution to be randomly instilled in one eye.
61995223|NCT05001243|ACTIVE_COMPARATOR|Pilocarpine 5 mgs|Pilocarpine was instilled in the other oye.
61995224|NCT05001243|ACTIVE_COMPARATOR|Brimonidine 0.5 mgs|Brimonidine was instilled in the other eye.
61995225|NCT01321775|EXPERIMENTAL|Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet|
61995226|NCT05121883||Edaravone dexborneol group|Patients with edaravone dexborneol initiating within 48 hours of stoke onset at 37.5 mg/dose, once every 12 hours, and continuing for more than 7 days will be classified into this group.
61995227|NCT05121883||Standard medication group|Patients who do not recieve edaravone dexborneol will be classified into this group.
61995228|NCT06028945|EXPERIMENTAL|Group 1: VR-ET|Group 1 will receive the VR-ET for up to 10 days while in the EMU and complete a set of questionnaires at the first visit and after the last day of VR. A researcher will conduct a short exit interview with participants about their experience during their second visit. There will be a one-month follow-up phone interview with a researcher and participants will complete a final set of questionnaires.
61995229|NCT06028945|ACTIVE_COMPARATOR|Group 2: Neutral Game|"Group 2 will have access to a VR device with a neutral game for up to 10 days while in the EMU and complete a set of questionnaires at the first visit and after the last day of VR. A researcher will conduct a short exit interview with participants about their experience during their second visit. There will be a one-month follow-up phone interview with a researcher and participants will complete a final set of questionnaires."
62180282|NCT00878293|EXPERIMENTAL|C|Dose 3
62180283|NCT00878293|EXPERIMENTAL|D|Dose 4
62180284|NCT00878293|EXPERIMENTAL|E|Dose 5
62180285|NCT00878293|EXPERIMENTAL|F|Dose 6
62180286|NCT00878293|EXPERIMENTAL|G|Dose 7
62180287|NCT00878293|ACTIVE_COMPARATOR|H|Morphin
62391208|NCT01473108|EXPERIMENTAL|Finerenone (10 mg solution)|3-fold crossover of single dose 10 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
62391209|NCT01473108|EXPERIMENTAL|Finerenone (5 mg solution)|3-fold crossover of single dose 5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
62772626|NCT04115982|PLACEBO_COMPARATOR|Placebo|Placebo of Cholecalciferol (Vitamine D3) 100 000 IU/2 mL
62563531|NCT04755114|EXPERIMENTAL|Turkish Music Group|After the patient introduction form is filled, pain level, blood pressure, pulse and respiratory rate will be evaluated, saliva sample will be taken to determine the cortisol level and pre-test data will be collected (0 min). Immediately after the pre-test evaluations, the music group will be played to the music desired by the patient for 30 minutes. Immediately after the interventions, pain level, vital signs will be evaluated and saliva sample will be taken as a final test (30 minutes). The same procedures will be repeated in the 60th minute after the intervention to determine the duration of the interventions applied.
62563532|NCT04755114|EXPERIMENTAL|Comedy Film Group|fter the patient introduction form is filled, pain level, blood pressure, pulse and respiratory rate will be evaluated, saliva sample will be taken to determine the cortisol level and pre-test data will be collected (0 min). Immediately after the pre-test evaluations,the Comedy film group will watch a comedy movie video. Immediately after the interventions, pain level, vital signs will be evaluated and saliva sample will be taken as a final test (30 minutes). The same procedures will be repeated in the 60th minute after the intervention to determine the duration of the interventions applied.
61995230|NCT02975921|NO_INTERVENTION|Malignant Effusion - Usual Care|Patients who had a pleural effusion secondary to a malignant etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had usual care during and afterwards. Usual care is the TPC only with no intrapleural medications. They would have nursing care in the recovery area afterwards and home nursing three times weekly.
62180288|NCT00878293|PLACEBO_COMPARATOR|I|Placebo
62180289|NCT04103502||MicroPort Medial Pivot|Subjects will have been implanted with the MicroPort Medial Pivot TKA
62180290|NCT04103502||DePuy Attune|Subjects will have been implanted with the DePuy Attune PCR TKA
62563533|NCT04755114|NO_INTERVENTION|Control group|"After the patient introduction form is filled, pain level, blood pressure, pulse and respiratory rate will be evaluated, saliva sample will be taken to determine the cortisol level and pre-test data will be collected (0 min).~Pain level and vital signs will be evaluated and saliva sample will be taken for the final test (30th minute) and follow-up (60th minute) simultaneously with the administration group without any intervention."
62772627|NCT01331928|EXPERIMENTAL|Capecitabine, Oxaliplatin, Docetaxel , Gastric cancer|
62772628|NCT05492981|EXPERIMENTAL|Intervention|The intervention was a 16-minute educational video created by the study investigators which provided information about Down syndrome, diagnostic tests and screening tests. The screening tests covered in the video included the triple test, the combined first trimester screen and non-invasive prenatal screening. Information about how and when each of the tests were performed, their detection rates and possible results and their interpretations were covered in the video. The video was viewed by several healthcare providers and experts in the field of prenatal screening before the commencement of this study to ensure that the content was appropriate and adequate. The intervention was viewed by subjects on a portable tablet in a quiet room in the antenatal clinic. Subjects were then invited to ask their doctor any questions that they may have had about the video during the clinic consult which followed.
62772629|NCT05492981|NO_INTERVENTION|Control|Women in the control group were counselled by the referring doctor regarding the aneuploidy screening options of FTS or NIPS, and provided information about the procedures involved for each test, their detection rates, cost, and possible results of testing. The use of a written information leaflet was available to doctors as an adjunct to providing this information.
62772630|NCT03147638|EXPERIMENTAL|1 month|patient treated with Anti coagulation for one month
62772631|NCT03147638|ACTIVE_COMPARATOR|3 months|standard of care , treatment for 3 months
62772632|NCT05210426|EXPERIMENTAL|Pilates|The Pilates Group completed a 10-week. The intervention was performed in 20 sessions. The exercise program was created based on books and from the booklet acquired in the APPI Pilates Method training courses. Since the study was in preschool children, the basic level of Pilates was performed. Each exercise was performed 5 times for 30 minutes each twice a week .
62772633|NCT05210426|NO_INTERVENTION|Control|The Control Group did not perform any Pilates. The children in the CG continued their routine physical activities at school.
62772634|NCT04216355|EXPERIMENTAL|AZA with CAG derived regimen|Azacitidine 50mg/m²/day, D1-D5 (IV) Aclarubicin 5mg/m²/day, D1-D4 (IV) Cytarabine 10mg/m²/12h, D1-D6 (IV) G-CSF 5-10ug/kg/day, D1-D7 (SC)
62563534|NCT02763930|EXPERIMENTAL|CONTROL (dairy-free)|6 weeks experimental diet with all meals and foods provided to participants. The diet contain 32% of fat, 11% of saturated fat (SFA), 13% of mono-unsaturated fat (MUFA), 8% of polyunsaturated fat (PUFA) and 15% of proteins.
62563535|NCT02763930|EXPERIMENTAL|MILK (low fat dairy)|6 weeks experimental diet with all meals and foods provided to participants including 3 servings/day of milk (1% fat) per 2500 kcal. The diet contain 32% of fat, 11% of SFA, 13% of MUFA, 8% of PUFA and 15% of proteins.
62563536|NCT02763930|EXPERIMENTAL|GABA-rich cheese (high-fat dairy )|6 weeks experimental diet with all meals and foods provided to participants including 50g/day of GABA-rich cheddar cheese (approximately 32% fat). The diet contain 32% of fat, 13% of SFA, 13% of MUFA, 6% of PUFA and 15% of proteins.
62772635|NCT04764110|EXPERIMENTAL|Cyplexinol|900 mg daily (2 capsules) for 15 days
62772636|NCT04764110|PLACEBO_COMPARATOR|Placebo|2 capsules daily for 15 days
62563537|NCT03382236|EXPERIMENTAL|Real osteopathy|
62563538|NCT03382236|PLACEBO_COMPARATOR|Sham osteopathy|
62772637|NCT03772054|ACTIVE_COMPARATOR|Propofol|After spinal anesthesia, patients in this arm will receive an intravenous target controlled infusion to site effect (TCI/Ce) infusion of propofol to achieve hypnosis guided to a bispectral index (BIS) level of 40-60 during surgery.
62772638|NCT03772054|EXPERIMENTAL|Sevoflurane|After spinal anesthesia, patients in this arm will receive an inhalation induction with sevoflurane to achieve hypnosis guided to 0.7-0.9 minimum alveolar concentration (MAC) during surgery.
62563539|NCT02137252|EXPERIMENTAL|Naltrexone|The treatment schedule includes a daily dose of naltrexone for 5 weeks. Treatment will be initiated at 25 mg/day during the first week to improve tolerability. The dose will be escalated to 50 mg/day after one week barring significant early improvement in fatigue or adverse events precluding dose escalation, and participants will continue to take 50 mg/day (or 25 mg/day if dose is not escalated) for 4 weeks to complete a 5-week treatment period.
62180291|NCT03630692||observance of oral drug treatment|Study of observant or nonobservant patient behavior for their oral drug treatment
62772639|NCT01714258|EXPERIMENTAL|non invasive cardiac output measure|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients 20 times, throughout a period of about 45 min
62772640|NCT03576313|EXPERIMENTAL|intervention: IVM and DP|Mass Drug Administration with ivermectin (IVM) and dihydroartemisinin-piperaquine (DP) will be given to participants in the intervention villages plus the NMCP standard malaria control intervention
62772641|NCT03576313|ACTIVE_COMPARATOR|control: standard malaria control intervetions|Participants in the control clusters will receive only standard malaria control interventions such as Artemether Lumefantrine, LLINs, IRS, SMC and IPTp as implemented by the National Malaria Control Program (NMCP) of the Gambia
62180292|NCT05612646|ACTIVE_COMPARATOR|routine nursing and fake acupressure|control groups: receiving routine nursing and fake acupressure to improve constipation for 7 days during hospitalization.
62180293|NCT05612646|EXPERIMENTAL|acupressure|"The patients assigned to the experimental group received acupoint massage designed to improve constipation for 7 days during hospitalization. The selection of acupoints in this study includes Tianshu (double) (Tianshu, ST25: Stomach Meridian 25, the 25th point of the stomach meridian), Zhongwan (single) (Zhongwan CV12: Conception Vessel 12, the 12th point of the Ren meridian) ), Qihai Point (Single) (Qihai CV6: Meridian Vessel 6 Renmai 6th point) 3 points."
62180294|NCT04107181|EXPERIMENTAL|Patient surveillance|The introducer will be used during annual Pap smears for cervical cancer screening.
62180295|NCT04107181|EXPERIMENTAL|Healthy Volunteers|There will be 2 types of healthy volunteers recruited to participate in this arm. The home study is to determine ease of use/feasibility of the introducer. The other group of healthy volunteers will be interviewed only. The goal of this study is to better understand how to improve women's health through learning about women's perceptions of their reproductive anatomy, specifically the cervix, comfort in discussing reproductive health topics with providers, and thoughts on two tools used to see the cervix.
62563540|NCT02137252|PLACEBO_COMPARATOR|Sugar Pill|The treatment schedule includes a daily dose of equivalent placebo for 5 weeks. Treatment will be initiated at 25 mg/day during the first week to improve tolerability. The dose will be escalated to 50 mg/day after one week barring significant early improvement in fatigue or adverse events precluding dose escalation, and participants will continue to take 50 mg/day (or 25 mg/day if dose is not escalated) for 4 weeks to complete a 5-week treatment period.
62772642|NCT03204292||IVC/Ao|ultrasound, the inferior vena cava and abdominal aorta were measured. Inferior vena cava width was assessed at an interval of approximately 1 cm distal from connection of the hepatic vein to the inferior vena cava. No significant changes were observed in the width of the inferior vena cava during various respiratory phases, because of the positive pressure ventilation. The widest value was always chosen for the data. The assessment of the width of the abdominal aorta was performed above arise of the celiac trunk, at the height of the vein of the lower vena cava.
62563541|NCT01860365|EXPERIMENTAL|Complementary medicine counseling|Patients receiving chemotherapy who are referred by their oncology provider to complementary medicine consultation and treatment provided in addition to conventional supportive care
62563542|NCT01860365|ACTIVE_COMPARATOR|Conventional supportive care|Patients receiving conventional supportive care
62563543|NCT01922037|EXPERIMENTAL|Participants With Allergic Asthma|Participants with allergic asthma, who have decided to initiate treatment with omalizumab will be observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurs first.
62563544|NCT04801303|EXPERIMENTAL|Friedreich's Ataxia patients|"Friedreich's Ataxia patients that will receive treatment with Calcitrol 0.25mcg/24h for a year.~During the clinical trial:~* The effects of Calcitriol in the neurological symptoms of Friedreich's Ataxia patients will be evaluated before starting the treatment and after a year. The following scales will be used: SARA scale, 9-Hole Peg test, 8 meters walking test, PATA velocity test and Quality of life test with the SF36 questionnaire.~* The changes in the Frataxin's levels during the treatment with Calcitriol will be measured: before starting the treatment, and after fifteen days, 4 months, 8 months and 12 months of the treatment."
62563545|NCT06013007|EXPERIMENTAL|JINS approach|The JINS approach is described as inflating a stent balloon with nominal-pressure without decay for at least 30 seconds.
62563546|NCT05972902|EXPERIMENTAL|Dydrogesterone|For pituitary suppression, the patients receives Dydrogesterone (Duphaston 10 mg/twice daily, Abbott Healthcare, America) orally since day 2-3.
62563547|NCT05972902|ACTIVE_COMPARATOR|GnRH antagonist|For pituitary suppression, the patients receives GnRH antagonist (CETROTIDE 0.25MG , MERCK SERONO, Germany) 0.25 mg/day subcutaneously since the dominant follicles reached the diameter of 12-14 mm till trigger day.
62772643|NCT03431363||Observational group|Patient dosing options will be stratified into three groups defined as standard, frail/elderly (age \> 65 or ECOG 2), and cannabis-experienced (\> weekly use of cannabis in the past year outside of NYC Medical Marijuana program). NYC specified cannabis formulation options are defined by THC:CBD ratio as 1:1, low THC:high CBD, high THC:low CBD, and high THC:high CBD.
62772644|NCT02486250||Main Study Recruits|Participants are recruited to come into a clinic and take supervised cognitive tests both online and paper/pencil as well as take unsupervised online cognitive tests at home. Participants will also be given a spit kit in clinic to determine ApOE Status.
62772645|NCT02486250||MRI & PET Substudy|A subset of 34 participants from the Main Study Recruits will be invited to have an MRI and PET scan. The purpose of the sub-study is to obtain feasibility data for collecting longitudinal neuroimaging studies for participants in this sample.
62772646|NCT02486250||ReVeRe 1|A subset of 250 participants from the Main Study Recruits and all MRI \& PET Substudy participants will be invited to participate in ReVeRe 1. The purpose of ReVeRe is to validate an additional unsupervised online cognitive measure, administered via an iPad application.
62772647|NCT02486250||ReVeRe 2|A subset of approximately 80 participants from the Main Study Recruits and MRI \& PET Substudy participants will be invited to participate in ReVeRe 2. The purpose of ReVeRe 2 is to determine if performance on ReVeRe test battery is sensitive to amyloid positivity in cognitively intact older adults and also sensitive to longitudinal cognitive decline in this patient population.
62772648|NCT03013049|ACTIVE_COMPARATOR|Non cultured epidermal cell suspension|In 20 patients who have stable vitiligo with the duration of stability more than 3 months, non cultured epidermal cell suspension will be done. Patients will be divided into 2 subgroups of 10 patients each of stability duration of 3-6 months and more than 1 year respectively and non cultured epidermal cell suspension will be done.
62180296|NCT02900313|OTHER|Patients having cardiac surgery|Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
62182795|NCT05146206||Patients on RYALTRIS|Patients who are currently using RYALTRIS nasal spray.
62563548|NCT05972902|ACTIVE_COMPARATOR|GnRH agonist|For pituitary suppression, the patients receives (Decapeptyl, sc 0.1 mg/day) beginning in the afternoon of the 21st day of the cycle prior to stimulation
62563549|NCT00582101|EXPERIMENTAL|Family-based HIV|
62772649|NCT03013049|EXPERIMENTAL|Non cultured dermal cell suspension|In 20 patients who have stable vitiligo with the duration of stability more than 3 months, combination of non cultured epidermal cell suspension and non cultured dermal cell suspension will be done. Patients will be divided into 2 subgroups of 10 patients each of stability duration of 3-6 months and more than 1 year respectively and combination of non cultured epidermal cell suspension and non cultured dermal cell suspension will be done.
62772650|NCT02742311|ACTIVE_COMPARATOR|transforaminal endoscopic discectomy|
62772651|NCT02742311|ACTIVE_COMPARATOR|interlaminar endoscopic discectomy|
62772652|NCT02135978|EXPERIMENTAL|One-to-one training group for shoulder home exercise program|Patients will attend two sessions of one-to-one training with a physical therapist to learn the shoulder home exercise program. The sessions are 4 weeks apart. They will also review a handout on techniques to protect their shoulder during wheelchair propulsion and transfers.
62772653|NCT02135978|ACTIVE_COMPARATOR|Enhanced training group for shoulder home exercise program|Patients will attend four classes held each week for 4 consecutive weeks. The classes are led by a physical therapist and a peer mentor (with a spinal cord injury). Two to four research patients are in each class. Classes begin with an interactive education presentation on techniques and recommendations to protect the shoulder during transfers, wheelchair propulsion, raises and activities of daily living. This is followed by performance of the home exercise program. Patients will be called every 3 to 6 months by a peer mentor to receive encouragement, praise, and/or problem solve barriers to exercise.
62772654|NCT02135978|NO_INTERVENTION|Historical control group|Historical control group has received no intervention. Eligibility criteria, outcome measures and study duration for historical control group is matched for the experimental group and active comparator.
62772655|NCT01110382|EXPERIMENTAL|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose)will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium). Total duration of treatment 5 to 14 days.
62772656|NCT01110382|EXPERIMENTAL|Meropenem|Meropenem 20 mg/kg per dose (up to 1 g/dose) will be administered every 8 hours as 30-minutes IV (at least 3 days of IV meropenem only or IV meropenem followed by oral amoxicillin/clavulanate potassium). Total duration of treatment 5 to 14 days.
62772657|NCT02387294|EXPERIMENTAL|Age group 1: children (3-11 years)|"Intervention: Vaccination with Fluval AB Novo suspension for injection.~Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly."
62772658|NCT02387294|EXPERIMENTAL|Age group 2: adolescents (12-18 years)|"Intervention: Vaccination with Fluval AB Novo suspension for injection.~Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly."
62772659|NCT06520007||LCP - Low dose continuous protocol|Assumption of 50 mg of oral doxycycline per day for 3 months
62563550|NCT00582101|ACTIVE_COMPARATOR|Family-based HP|
62563551|NCT02729259|OTHER|Virtual Reality Snowworld|The subjects will receive Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
62563552|NCT02729259|OTHER|Virtual Reality slides of nature|The subjects will see several slides of the nature through virtual reality goggles during their wound care. The nurse will be doing the wound care.
62772660|NCT06520007||FPP - Full dose pulsed protocol|Assumption of 100 mg of oral doxycycline per day for 15 days per month (with a subsequent 15 days of washout) for 3 months
62772661|NCT06335953|EXPERIMENTAL|Intervention|"The intervention consists of the following:~1. Mailing a deprescribing educational brochure to PLWD and care partners;~2. PLWD and/or care partners will receive a single telehealth visit in which an embedded clinical pharmacist discusses the benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences;~3. Pharmacist-primary care provider (PCP) communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP."
61995231|NCT02975921|EXPERIMENTAL|Malignant Effusion with Pleurodesis|Patients who had a pleural effusion secondary to a malignant etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had intrapleural Povidone-Iodine administered at time of placement (100mL of 2% solution). They would have nursing care in the recovery area afterwards and home nursing three times weekly.
61995232|NCT02975921|NO_INTERVENTION|Benign Effusion - Usual Care|Patients who had a pleural effusion secondary to a benign etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had usual care during and afterwards. Usual care is the TPC only with no intrapleural medications. They would have nursing care in the recovery area afterwards and home nursing three times weekly.
61995233|NCT02975921|EXPERIMENTAL|Benign Effusion with Pleurodesis|Patients who had a pleural effusion secondary to a benign etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had intrapleural Povidone-Iodine administered at time of placement (100mL of 2% solution). They would have nursing care in the recovery area afterwards and home nursing three times weekly.
61995234|NCT06049056||General Practice 1|"General Practice 1 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a URL link to an online questionnaire"
62182796|NCT05146206||Patients on DYMISTA|Patients who are currently using DYMISTA nasal spray.
62772662|NCT06335953|ACTIVE_COMPARATOR|Delayed intervention (wait list control)|"The intervention consists of the following:~1. Mailing a deprescribing educational brochure to PLWD and care partners;~2. PLWD and/or care partners will receive a single telehealth visit in which an embedded clinical pharmacist discusses the benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences;~3. Pharmacist-primary care provider (PCP) communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP."
62772663|NCT04953624||CNAQ≤28|ALS patients with CNAQ ≤ 28
62772664|NCT04953624||CNAQ>28|ALS patients with CNAQ \> 28
62772665|NCT02441556|ACTIVE_COMPARATOR|standard medical therapy|Patients receive standard medical therapy alone.
62772666|NCT02441556|EXPERIMENTAL|endovascular + standard medical therapy|Patients receive endovascular treatment plus standard medical therapy.
61995235|NCT06049056||General Practice 2|"General Practice 2 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a URL link to an online questionnaire"
62180297|NCT04652011||Patients with chronic pelvic pain|Patients with chronic pelvic pain and a benign gynecologic disease associated, referring to our Unit, medically or surgically treated from 2010 to 2019
62180298|NCT01346462|EXPERIMENTAL|PaCT|The Patient-Centered Transition Arm
62180299|NCT01346462|NO_INTERVENTION|Control|Control group patients will receive routine care from the admitting hospital, including routine patient management, and discharge planning.
62180300|NCT06546761||Assigned to Best Medical Therapy (BMT) alone|Patients who have undergone successful carotid artery revascularization (endarterectomy of stenting) and are assigned to BMT alone within 14 days following revascularization.
62772667|NCT03222414|EXPERIMENTAL|Arm A: Conical then Cylindrical|BP recording with noninvasive conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring; then with traditional cylindrical BP cuff and direct invasive arterial pressure monitoring
62391210|NCT01473108|EXPERIMENTAL|Finerenone (20 mg as tablets)|3-fold crossover of single dose 20 mg BAY 94-8862 as 2 x 10 mg tablet, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
62772668|NCT03222414|ACTIVE_COMPARATOR|Arm B: Cylindrical then Conical|BP recording with noninvasive traditional cylindrical BP cuff and direct invasive arterial pressure monitoring; then with conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring
62772669|NCT04151277|EXPERIMENTAL|FOLFOX-A|"* nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first)~* Oxaliplatin: 85mg/m2, IV over 2 hours, day 1~* Folinic acid: 350 mg flat dose, IV over 2 hours, day 1~* 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours (or 48 hours as per standard practice))"
62180301|NCT06546761||Assigned to Best Medical Therapy (BMT) + coronary CT angiography + CT-FFRct analysis|Patients who have undergone successful carotid artery revascularization (endarterectomy of stenting) and are assigned to BMT plus coronary CT angiography (which must be completed within 14 days of randomization) and FFRct analysis to determine the functional significance of coronary lesions identified on the CT scan.
62772670|NCT04151277|ACTIVE_COMPARATOR|Abraxane and Gemcitabine|"* nab-paclitaxel: 125 mg/m2 IV over 30 minutes, day 1, 8, and 15 (administered first)~* Gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 (immediately following nab-paclitaxel)"
62772671|NCT03864913|EXPERIMENTAL|Randomized SQ vs IM|Subjects randomized to either SQ or IM testosterone injections follow study protocol.
62772672|NCT03864913|EXPERIMENTAL|Non-randomized SQ|Subjects choose to participate in study, but decline to randomize and select SQ injections. Follow same study protocol.
62772673|NCT03864913|EXPERIMENTAL|Non-randomized IM|Subjects choose to participate in study, but decline to randomize and select IM injections. Follow same study protocol.
62772674|NCT01792518|EXPERIMENTAL|linagliptin 5mg|linagliptin 5 mg once daily
62772675|NCT01792518|PLACEBO_COMPARATOR|placebo|matching placebo for linagliptin dose once daily
62772676|NCT01084681|ACTIVE_COMPARATOR|SILK Artery Reconstruction Device|One arm will receive only the commercially available SILK Artery Reconstruction Device \[flow diverter\] (no intracranial coils are to be used in association with the SILK device).
62772677|NCT01084681|ACTIVE_COMPARATOR|Coils|The other arm will be treated with commercially available intracranial coils: the coils can be used with eventual balloon remodeling and/or stents when necessary.
62772678|NCT01442805|EXPERIMENTAL|RV|Cognitive Behavioral Therapy with Virtual Reality Exposures
62772679|NCT01442805|EXPERIMENTAL|IMAGO|Cognitive Behavioral Therapy with Exposure Therapy through Imagination
62772680|NCT02887547|NO_INTERVENTION|Control|Control group, with traditional orthodontic mechanics for anterior retraction. Crevicular fluid will be collected during anterior retraction mechanics to identified biomarkers in the inflammatory process
62772681|NCT02887547|EXPERIMENTAL|Acceleration|Group with micro-osteoperforation for accelerated tooth movement during anterior retraction, Crevicular fluid will be collected during anterior retraction mechanics to identified biomarkers in the inflammatory process
61995236|NCT06049056||General Practice 3|"General Practice 3 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a URL link to an online questionnaire"
62180302|NCT01523951||Healthy volunteers|
62180303|NCT01504009|EXPERIMENTAL|Muscle strength|
62772682|NCT06297473|EXPERIMENTAL|Telephone-/video follow-up|Yearly routine review of patients status will take place by using telephone- or video consultation.
61995237|NCT06049056||General Practice 4|"General Practice 4 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a URL link to an online questionnaire"
62180304|NCT01603342|EXPERIMENTAL|clopidogrel|
62180305|NCT01603342|PLACEBO_COMPARATOR|Placebo|
62180306|NCT05110014|OTHER|Primary Care Office Visits|"The limited use dataset will contain the following data elements for each completed patient visit:~* Date of clinic visit (where each date is indicated by a number relative to the clinic's Launch Date)~* Clinic (designated by a unique study clinic identifier)~* Type of visit completed (for example, new patient visit, return patient visit, annual exam)~* Patient age~* Patient gender~* Patient race/ethnicity~* Patient primary insurance~* Nursing staff who roomed the patient (designated by a unique study identifier)~* Whether patient used mPATH-CheckIn program (Y/N)~* Whether nursing staff used mPATH Nursing Module to transmit mPATH data to electronic health record (Y/N)~* Whether patient has a diagnosis of depression in the problem list in the EHR (Y/N)~* Whether patient has an antidepressant medication listed in the active medication list ( (Y/N)~* Results of depression screening items~* Results of fall risk screening items~* Results of safety at home screening items"
62180307|NCT03179774|EXPERIMENTAL|Clinical registry-ER and OMT|In clinical registry setting, participants who selected Endovascular revascularization and optimal medical therapy as the treatment for carotid artery occlusion are enrolled.
62563553|NCT02729259|OTHER|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
62772683|NCT06297473|ACTIVE_COMPARATOR|Standard|Yearly routine review of patients status will take place as an in-person interview
62180308|NCT03179774|NO_INTERVENTION|Clinical registry-OMT|In clinical registry setting, participants who selected optimal medical therapy as the treatment for carotid artery occlusion are enrolled.
62563554|NCT01156779|EXPERIMENTAL|DA-3091|SR-exenatide
62563555|NCT01156779|PLACEBO_COMPARATOR|Placebo of DA-3091|Placebo
62563556|NCT01212237||fMRI Evaluation|"All patients will undergo the following standard imaging and radiotherapy procedures will be performed for each patient:~1. Standard MRI for radiotherapy treatment planning which takes about 60 minutes.~2. Radiotherapy treatment simulation with CT.~3. Radiotherapy treatment planning~4. Radiotherapy treatment~5. Routine follow-up every 3 months after the radiotherapy.~Special Procedures.~The following special imaging and radiotherapy procedures will be performed for each patient:~1. fMRI (30 minutes)~2. The 3MS examination, administered every 3 months during routine follow-up for one year after the completion of the radiotherapy."
62772684|NCT05837104|EXPERIMENTAL|Magnesium vitamin B6|Magnesium vitamin B6 (MagnéVie B6®) composed of Magnesium citrate (100mg) and Pyridoxine hydrochloride (10mg) in tablet form, taken three times daily for four weeks.
62772685|NCT05837104|PLACEBO_COMPARATOR|Placebo|Placebo tablet will be taken three times daily for four weeks.
62772686|NCT03463954|EXPERIMENTAL|Novilase Laser Ablation and excision|Eligible subject will receive image-guided laser ablation of a targeted malignant breast tumor. At 4-6 weeks following the ablation, she will receive a MRI and excision. Pathology and MRI will determine rate of complete ablation. Subject is expected to proceed with radiation and/or adjuvant therapy per standard of care.
62180309|NCT03179774|EXPERIMENTAL|RCT-ER and OMT|In randomized control trial setting, participants who are randomized to received endovascular revascularization and optimal medical therapy for carotid artery occlusion are enrolled.
62563557|NCT02418949|EXPERIMENTAL|Cyproheptadine + AMP|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of Active movement practice (AMP) treatment (1 hour sessions 3x/week). Dose will be titrated down to zero in the 2 weeks following treatment."
62563558|NCT02418949|PLACEBO_COMPARATOR|Placebo for Cyproheptadine + Stretching|"Placebo for Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of passive cyclical stretching treatment (1 hour sessions 3x/week). Each session will involve 20 min of stretching followed by 10 minutes of rest.~Dose will be titrated down to zero in the 2 weeks following treatment."
62180310|NCT03179774|NO_INTERVENTION|RCT-OMT|In randomized control trial setting, participants who are randomized to received optimal medical therapy for carotid artery occlusion are enrolled.
62563559|NCT02418949|ACTIVE_COMPARATOR|Cyproheptadine + Stretching|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of passive cyclical stretching treatment (1 hour sessions 3x/week). Each session will involve 20 min of stretching followed by 10 minutes of rest.~Dose will be titrated down to zero in the 2 weeks following treatment."
62563560|NCT02418949|ACTIVE_COMPARATOR|Placebo for Cyproheptadine + AMP|"Placebo for Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of Active movement practice (AMP) treatment (1 hour sessions 3x/week). Dose will be titrated down to zero in the 2 weeks following treatment."
62563561|NCT04197466|EXPERIMENTAL|Pelvic Floor Exercise Group|Pelvic floor muscle exercises will be recommended as a home program for 6 weeks every day of the week.
62563562|NCT04197466|EXPERIMENTAL|Kinesiotape Group|In addition to pelvic floor exercise,kinesio tape application will be performed by ligament technique to the sacral region.
62563563|NCT04197466|EXPERIMENTAL|Electrical Stimulation Group|In addition to pelvic floor exercise,electrical stimulation will be performed in the lying, sitting, stand up positions for 30 minutes
62563564|NCT01217112|ACTIVE_COMPARATOR|GWP42004 and placebo|Contains GWP42004 5 mg and placebo (excipients only)
62563565|NCT01217112|ACTIVE_COMPARATOR|1:1 GWP42003 : GWP42004|Contains 5 mg each of GWP42003 and GWP42004
62563566|NCT01217112|ACTIVE_COMPARATOR|20:1 GWP42003 : GWP42004|Contains 100 mg GWP42003 and 5 mg GWP42004
62563567|NCT01217112|PLACEBO_COMPARATOR|Placebo|Contains excipients only
62563568|NCT01217112|ACTIVE_COMPARATOR|GWP42003 and placebo|Contains 100 mg GWP42003 and placebo (excipients only)
62563569|NCT05922566|EXPERIMENTAL|fMRI scanning while Mukbang watching|"The fMRI scanning will be divided into 3 parts, includes structural image scans, resting state scans, and task state scans. For the task state function image scanning, participants will be asked to watch the specific video program which includes the food images and eating sound of Mukbang and General short videos without food cues.~Healthy kids and children with cancer hospitalized for radiotherapy and chemotherapy will both accept this intervention."
62563570|NCT01282684|ACTIVE_COMPARATOR|single oral dose of 200 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
62180311|NCT04662606|NO_INTERVENTION|Fasting-group|
62180312|NCT04662606|EXPERIMENTAL|Fed-group|
62180313|NCT03919409|EXPERIMENTAL|Part A: Cohort 1: TS-161 15 mg|Single dose of TS-161 15 mg or placebo in a fasted condition.
62563571|NCT01282684|ACTIVE_COMPARATOR|single oral dose of 400 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
62563572|NCT01282684|ACTIVE_COMPARATOR|single oral dose of 800 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
62563573|NCT01282684|ACTIVE_COMPARATOR|single oral dose of 1600 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
62563574|NCT01282684|ACTIVE_COMPARATOR|single oral dose of 1000 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
62563575|NCT01282684|ACTIVE_COMPARATOR|single oral dose of 1400 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
62563576|NCT01282684|PLACEBO_COMPARATOR|Placebo|2 patients per cohort will be randomly assigned to take placebo. 12 patients total will be randomized to take placebo in this study.
62563577|NCT02544438|EXPERIMENTAL|Astarabine|Astarabine
62563578|NCT04527133|EXPERIMENTAL|Stage 1/Group 1|Intravenous Aprotinin in addition to standard care: 1 000 000 KIU IV daily during 3 days
62563579|NCT04527133|EXPERIMENTAL|Stage 2/Group 2|Inhaled Aprotinin in addition to standard care: 625 KIU 4 times per day during 5 days
62563580|NCT04527133|EXPERIMENTAL|Stage 2/Group 3|Intravenous Aprotinin in addition to standard care that includes Favipiravir: 1 000 000 KIU IV daily during 5 days
62563581|NCT01875523|EXPERIMENTAL|Group 1 Treatment with serelaxin|Patients with severe renal impairment will receive a single 4 hour i.v. infusion of serelaxin
62563582|NCT01875523|EXPERIMENTAL|Group 2 Treatment with serelaxin|Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment
62563583|NCT01875523|EXPERIMENTAL|Group 3 Treatment with serelaxin|Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and treatment and PK will be done in dialysis-free interval
62563584|NCT01875523|EXPERIMENTAL|Group 4 Treatment with serelaxin|Healthy volunteers will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment
62563585|NCT00299325|EXPERIMENTAL|Rimonabant|Rimonabant 20 mg once daily with mild hypocaloric diet
62563586|NCT00299325|PLACEBO_COMPARATOR|Placebo|Placebo (for Rimonabant) once daily with mild hypocaloric diet
62563587|NCT05273528|EXPERIMENTAL|V-01-351/V-01D bivalence vaccine|
62180314|NCT03919409|EXPERIMENTAL|Part A: Cohort 2: TS-161 50 mg|Single dose of TS-161 50 mg or placebo which will be dosed first in a fasted condition, and then in a fed condition, with a washout period in between 2 dosing. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
62563588|NCT00615550|PLACEBO_COMPARATOR|Placebo|placebo vaginal gel
62563589|NCT00615550|ACTIVE_COMPARATOR|Prochieve|Progesterone 8% Vaginal Gel
62563590|NCT03655405|EXPERIMENTAL|Individual Deprescribing Intervention|Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).
62563591|NCT03655405|NO_INTERVENTION|Control|Participants allocated to the control group will receive usual care.
62563592|NCT00400374|EXPERIMENTAL|Erlotinib, Celecoxib|
62563593|NCT06031740|EXPERIMENTAL|Sclerotherapy with 1.5% polidocanol.|2mL (3%) polidocanol = 60mg; maximal dose: 1mL/column and 4mL/session.
62180315|NCT03919409|EXPERIMENTAL|Part A: Cohort 3: TS-161 100 mg|Single dose of TS-161 100 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
62563594|NCT06031740|ACTIVE_COMPARATOR|Foam sclerotherapy|Tessari's technique; 4mL 3% poilidocanol +16mL air; maximal dose: 2mL/column and 20mL/session.
62563595|NCT03620708|EXPERIMENTAL|Motivational Interviewing|35 minute individual motivational interviewing intervention concluding with a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line
62563596|NCT03620708|ACTIVE_COMPARATOR|Nicotine Replacement Therapy Sampling|Participants are provided with a 2-week supply of nicotine patches and a 2 week supply of nicotine lozenges with a recommendation to try them and are also given a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line.
62563597|NCT03620708|OTHER|Referral Only|Participants are provided with a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line.
62563598|NCT03253900|EXPERIMENTAL|Experimental group|A group of rowers to be administered to intervention on a Stable rowing simulator, a Slides based rowing simulator or a Tilt board based rowing simulator.
62563599|NCT03877068|EXPERIMENTAL|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|Patients will wear a real-time Dexcom G6 CGM, which provide BG readings every 5 minutes for up to 10 days. In addition, patients will undergo POC testing before meals and bedtime per hospital protocol. Insulin therapy will be titrated based on daily CGM printouts, which will include BG readings, glycemic excursions, hypoglycemia and severe hyperglycemia values throughout the day. Patients will wear a CGM in the current approved insertion site, the abdomen, and in the upper arm.
62563600|NCT03877068|ACTIVE_COMPARATOR|POC BG - Point-of-Care Blood Glucose monitoring|Glucose monitoring by POC testing will be performed before meals and at bedtime. Results will be uploaded in the electronic medical record (EMR) system. The research team together with the PCP team will adjust daily insulin orders based on POC readings (standard of care). In addition, patients will wear a 'blinded' CGM where no results will be visualized by patients, nursing staff, primary care physician (PCP) or research teams.
62563601|NCT02828579||Group 1|Patient with morbid obesity defined as a BMI above 40kg/m2 or 35kg/m2 with comorbidities who are qualified for bariatric surgery.
62563602|NCT00654095|EXPERIMENTAL|Ezetimibe + Atorvastatin|Ezetimibe 10 mg + Atorvastatin 20 mg
62563603|NCT02989220|EXPERIMENTAL|Intervention group|Will receive the PRCI in addition to the current recommended care pathway
62563604|NCT02989220|NO_INTERVENTION|Control Group|Will follow the current recommended care pathway
62563605|NCT05454319|EXPERIMENTAL|Biofeedback Treatment Group|Medical device
62563606|NCT02841761|EXPERIMENTAL|Treatment A (Midazolam)|Single dose of Midazolam 8 mg on Day 1
62563607|NCT02841761|EXPERIMENTAL|Treatment B1 (ACT-132577)|Single dose of ACT-132577 150 mg on Day 2; single dose of ACT-132577 50 mg on Day 3, Day 4, and Day 5.
62563608|NCT02841761|EXPERIMENTAL|Treatment B2 (Midazolam + ACT-132577)|Single dose of Midazolam 8 mg and single dose of ACT-132577 50 mg on Day 6
62563609|NCT03948516||Participants tested for Sickle cell disease|
62563610|NCT04900428|EXPERIMENTAL|COVI-DROPS|10 mg or 20 mg of COVI-DROPS administered intranasally
62180316|NCT03919409|EXPERIMENTAL|Part A: Cohort 4: TS-161 200 mg|Single dose of TS-161 200 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
62180317|NCT03919409|EXPERIMENTAL|Part A: Cohort 5: TS-161 400 mg|Single dose of TS-161 400 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
62563611|NCT04900428|PLACEBO_COMPARATOR|Placebo|1 mL administered intranasally
62772687|NCT02662179||Elderly patients with solid tumors|The group will include elderly patients with a malignant solid tumor: ovary cancer, breast cancer, digestive cancer (colo-rectal, pancreas), lung cancer or urinary tract cancer (including bladder cancer).
62772688|NCT01848366|EXPERIMENTAL|Biowave Treatment|Twelve weekly treatments
62772689|NCT03672786|ACTIVE_COMPARATOR|Control Group|Sedentary: Multicentrum® 2 months. Subjects maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 2 months
62772690|NCT03672786|EXPERIMENTAL|Experimental Group|Athletes: Multicentrum® 2 months. Subjects maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 2 months
62772691|NCT02098811|EXPERIMENTAL|1064nm laser Treatment Before Abdominoplasty|Patient will be treated with 1064nm Laser prior to abdominoplasty
62772692|NCT02098811|EXPERIMENTAL|940nm Laser Treatment Before Abdominoplasty|Patient will be treated with 940nm Laser prior to abdominoplasty
62772693|NCT03204422||Children's group|no intervention. participants, whose age was 5 to 18 years, were enrolled in Children's group.
62772694|NCT03204422||Adults group|no intervention. participants, whose age was over 18 years, were enrolled in Adults group.
62563612|NCT02549781|EXPERIMENTAL|Gambler performing Go-Nogo|"In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
62563613|NCT02549781|ACTIVE_COMPARATOR|Social layer performing Go-Nogo|"In this study, social player performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
62563614|NCT02549781|PLACEBO_COMPARATOR|non-gamer witnesses performing Go-Nogo|"In this study, non-gamer witnesses performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
62563615|NCT05031312|ACTIVE_COMPARATOR|inferior oblique anterior nasal transposition|Group A for inferior oblique anterior nasal transposition 2mmx2mm posterior and nasal to inferior rectus insertion to control vertical deviation especially large angle vertical deviation and V pattern with more potent postoperative effect in unilateral and bilateral cases
62563616|NCT05031312|ACTIVE_COMPARATOR|inferior oblique myectomy|Group B for inferior oblique myectomy to control vertical deviation but not of large angle which lead to residual inferior oblique overaction
62563617|NCT00317616||Unaffected individuals from families in which the genetic cause of ALS is known|This population would include pre-symptomatic individuals at genetic risk for ALS or a related neurodegenerative disorder (i.e., FTD).
62563618|NCT04227431||Tresiba®|A broad real world type 2 diabetes (T2D) patient population in China, treated with oral anti-diabetic drugs (OAD(s)) or basal insulin prior to treatment initiation with Tresiba®
62563619|NCT01965743|OTHER|Contraception Information Packet|Everyone in the study will receive the intervention, which is an information packet designed to facilitate conversations among peers about intrauterine contraception.
62180318|NCT03919409|EXPERIMENTAL|Part B: Cohort 6: TS-161 TBD|Single dose of TS-161 in a fasted condition. The dose level will be determined based on the results from the preceding cohorts.
62180319|NCT03919409|EXPERIMENTAL|Part C: Cohort 7: TS-161 TBD|Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.
62180320|NCT03919409|EXPERIMENTAL|Part C: Cohort 8: TS-161 TBD|Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.
62563620|NCT00333827|ACTIVE_COMPARATOR|Optimal Therapy|Optimal therapy for cardiac failure
62563621|NCT00333827|EXPERIMENTAL|cell therapy|stem cell
62563622|NCT01593670|EXPERIMENTAL|Patients With High Risk MDS|Patients who received treatment for high risk myelodysplastic syndromes (MDS). Treatment Received: Decitabine 10 mg/m\^2/day intravenous (IV) over 1 hour days 1-5; Vorinostat 200 mg by mouth (PO) twice a day days 6-15; Il-2 activated donor natural killer cells (NK) infusion IV over 15 to 60 minutes day 17; Interleukin-2 6 million units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17. Repeat treatment course 6 to 8 weeks after cycle 1 start date.
62563623|NCT03023215|EXPERIMENTAL|Guided Meditation Group (GM)|"Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB."
62563624|NCT03023215|ACTIVE_COMPARATOR|Focused Breathing Group (FB)|"Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.."
62563625|NCT03023215|ACTIVE_COMPARATOR|Standard of Care Group (SC)|"Participants listen to a 10 minute neutral-content audio clip from National Public Radio prior to stereotactic breast biopsy (SBB).~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB."
62563626|NCT01408290|EXPERIMENTAL|FAB-6011|- One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 2A/ and 32 subjects aged over 60 years /Group 2E/).
62563627|NCT01408290|EXPERIMENTAL|FAB-9011|- One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 3A/ and 32 subjects aged over 60 years/Group 3E/).
62563628|NCT01408290|EXPERIMENTAL|FLUVALAB|- One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 4A/ and 32 subjects aged over 60 years/Group 4E/).
62563629|NCT01408290|EXPERIMENTAL|FAB-3511|- One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 1A/ and 32 subjects aged over 60 years /Group 1E/).
62563630|NCT01194232|EXPERIMENTAL|Sildenafil|15 subjects will receive 8 week course of Sildenafil administered at a dose of 20 mg per dose three times per day.
62563631|NCT03268083|EXPERIMENTAL|Group A1|3 to 6 years
62563632|NCT03268083|EXPERIMENTAL|Group A2|3 to 6 years
62563633|NCT03268083|EXPERIMENTAL|Group A3|3 to 6 years
62563634|NCT03268083|EXPERIMENTAL|Group B1|2 to 35 months
62563635|NCT03268083|EXPERIMENTAL|Group B2|2 to 35 months
62563636|NCT03268083|EXPERIMENTAL|Group B3|2 to 35 months
62563637|NCT04993716||Cohort|Patient present in the SAU after an extra-hospital cardiac arrest
62563638|NCT05488743||7th and 8th grade students (children age 12-15 years) from the elementary school|
62563639|NCT02629939|NO_INTERVENTION|questionnaires|"Questionnaires will be distributed to families of heart patients to test the theoretical knowledge to perform CPR The questionnaires were distributed to internal, cardiology clinics and clinic T by a doctor, Paramedic or medical student. The family will be asked to fill out the questionnaire independently.~The questionnaires will be distributed in Hebrew, Arabic, Russian and English The research questionnaire will include questions about able to perform basic CPR"
62563640|NCT02629939|EXPERIMENTAL|to participate in a short course for learning CPR|": The investigators will offer patients and their relatives to participate in a short course for learning CPR.~Relatives will receive a prescription Containing a proposal for participation in the course~Prescription will be awarded in four places:~-.Family physicians as a suggestion during a routine visit / presentation of cardiac problem~* Heart Rehabilitation Institute - cardionegev~* Doctors internal medicine department as part of a patient's discharge letter with heart disease~* Doctors in cardiology clinic The prescription will be accompanied by several minutes of explanation about the program and its importance The investigators consider the level of responsiveness and participation, find out which arm yielded the highest number of participants (actual turnout of the total prescriptions distributed) And how to expand their activities"
62563641|NCT04302415||only liver metastasis|There is no other intervention, only clinical treatment.
62563642|NCT04302415||only lung metastasis|There is no other intervention, only clinical treatment.
62563643|NCT04302415||only brain|There is no other intervention, only clinical treatment.
62563644|NCT04302415||No distant metastasis|There is no other intervention, only clinical treatment.
62563645|NCT04302415||More than two organs metastasis|There is no other intervention, only clinical treatment.
62563646|NCT02591277||Harvoni|Adult patients with chronic genotype 1 HCV infection with or without compensated cirrhosis who take Harvoni as part of routine clinical care at a participating clinic/hospital.
62563647|NCT03696212|EXPERIMENTAL|grapiprant and pembrolizumab combination|Participants will be treated with grapiprant in combination with pembrolizumab.
62563648|NCT01051310|EXPERIMENTAL|CoreValve|
62563649|NCT05653830||Patients with chronic hepatitis B|Patients who meet the diagnostic criteria for chronic hepatitis B for long-term follow-up
62563650|NCT05653830||Patients with chronic hepatitis C|Patients who meet the diagnostic criteria for chronic hepatitis C for long-term follow-up
62563651|NCT05653830||Patients with chronic hepatitis D|Patients who meet the diagnostic criteria for chronic hepatitis D for long-term follow-up
62563652|NCT05653830||Patients with autoimmune liver disease（PBC\AIH\PSC）|Patients who meet the diagnostic criteria for autoimmune liver disease（PBC\\AIH\\PSC） for long-term follow-up
62563653|NCT05653830||Patients with NAFLD|Patients who meet the diagnostic criteria for NAFLD for long-term follow-up
62563654|NCT05653830||Patients with ALD|Patients who meet the diagnostic criteria for ALD for long-term follow-up
62563655|NCT05684874|EXPERIMENTAL|Pre- and post- radiotherapy multiparametric quantitative MRI|"Patients with STS of the limbs and trunk will be accrued during the initial radiotherapy consultation radiotherapy (prior to receiving radiotherapy).~Two quantitative multiparametric MRI will be performed. The first one will be acquired less than 14 days before the dosimetric scan, the second one 4 to 6 weeks after the end of the radiotherapy.~A tumor resection will be performed 6 to 8 weeks post-RT and an anatomopathological observation of the surgical specimen will be performed."
62563656|NCT05756595|EXPERIMENTAL|35kDa hyaluronan fragment HA35 injection|100 mg Hyaluronan is locally injected at the pain point or where the nerve trunk is innervated by the pain point.
62563657|NCT06209190|EXPERIMENTAL|Total marrow and lymphoid irradiation (TMLI)|TMLI will be added in doses of 12 Gy on days -3 to -1 divided into 6 fractions of 2 Gy every 12 hours for 3 days, which will be administered through a computed tomography tomotherapy system.
62563658|NCT02371538|EXPERIMENTAL|Donor Breastmilk|Donated human milk is subjected to pasteurization prior to use. Milk consumption is to be overseen by a Registered Dietician. Oral or enteral milk feeding will begin at 180 ml/day and will be advanced as quickly as tolerated to a goal of 360 ml/day for 6 weeks. If symptoms and stool tests for norovirus do not improve after 6 weeks, milk administration may continue for an additional 6 weeks.
62563659|NCT02680704|OTHER|PEEP Titration Arm|PEEP titrated mechanical ventilation
62180321|NCT03919409|EXPERIMENTAL|Part C: Cohort 9: TS-161 TBD|Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.
62180322|NCT04363853|EXPERIMENTAL|Tocilizumab tratment|"Tocilizumab (RoActembra). Vials of 20 ml with 400 mg (20mg/ml) and 4ml with 80 mg (20mg/ml). A singe 60-minute IV infusion of 8mg/kg (maximum dose of 800 mg). Dose was not adjusted for weight more than 100 kg. After first dose, if fiver persists within 12 hours, a second dose was administrated.~A maximum of two doses was allowed."
62180323|NCT01064882|EXPERIMENTAL|bimatoprost ophthalmic solution 0.005%|bimatoprost ophthalmic sterile solution 0.005%
62563660|NCT05669404|NO_INTERVENTION|Control Group (CG)|Patients continued to consume their usual diet for 3 months
62563661|NCT05669404|EXPERIMENTAL|Salt Restriction Group (SRG)|Patients continued to consume their usual diet, but they restricted sodium intake to 2,000 mg/ day for 3 months.
61995238|NCT06049056||General Practice 5|"General Practice 5 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a QR code providing access to an online questionnaire"
62180324|NCT01064882|EXPERIMENTAL|bimatoprost ophthalmic solution 0.015%|bimatoprost ophthalmic sterile solution 0.015%
62563662|NCT05669404|EXPERIMENTAL|DASH Diet combined with salt restriction Group (DDG)|Patients consumed the DASH diet for 3 months.
62563663|NCT05669404|EXPERIMENTAL|Mediterranean Diet combined with salt restriction Group (MDG)|Patients consumed the MedDiet diet for 3 months.
62563664|NCT01418378|ACTIVE_COMPARATOR|Sigma CR150|Sigma CR150 femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
62180325|NCT01064882|ACTIVE_COMPARATOR|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03%
62180326|NCT02243761|EXPERIMENTAL|DBT Based Skills Groups for Families|Family members of youth with concurrent disorder participate in a 12-week DBT based skills group led by therapists and/or peer facilitators.
62563665|NCT01418378|ACTIVE_COMPARATOR|Sigma CR|Sigma CR femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
62563666|NCT03798015||mitral valve surgery|outcome of mitral valve surgery (stroke yes or no)
62563667|NCT05118919|EXPERIMENTAL|Active|
62563668|NCT05118919|PLACEBO_COMPARATOR|Placebo|
61995239|NCT06049056||General Practice 6|"General Practice 6 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a QR code providing access to an online questionnaire"
62180327|NCT01138761|NO_INTERVENTION|Physician/resident instruction|This arm is standard of care instruction given to parents/caregivers of children with atopic dermatitis by the dermatologist and/or dermatology resident during a patient visit.
62180328|NCT01138761|ACTIVE_COMPARATOR|Nurse instruction|Following the usual standard of care instruction by physician/resident (which both the treatment group and the non-treatment group will receive); the dermatology nurse will give enhanced instruction about skin care and medications to the caregivers/parents who were randomized to the treatment group.
62391211|NCT01473108|EXPERIMENTAL|Finerenone (2.5 mg solution)|3-fold crossover of single dose 2.5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
62772695|NCT01515046|EXPERIMENTAL|Gemcitabine with escalating IV ascorbate|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off.~Ascorbate (vitamin C) given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbate / infusion for two infusions. Doses are then escalated in 25 gram increments until therapeutic window is achieved (350 mg/dL or above). Dose is then held at that level for the full cycle."
61995240|NCT06049056||General Practice 7|"General Practice 7 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a QR code providing access to an online questionnaire"
61995241|NCT06049056||General Practice 8|"General Practice 8 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a QR code providing access to an online questionnaire"
62180329|NCT03561597|EXPERIMENTAL|Mobile health application|Participants will undergo Kurbo program, a Mobile health application, for more detailed dietary and physical activity recommendations and implementation of behavioural changes. The patient's progress will be reviewed by the nurse clinician at one month post intervention to determine whether the BMI percentile has shown a reduction through the Kurbo Program. Patients that declined Kurbo intervention, has a BMI of more than 99th percentile or continue to have increase in their BMI percentile in Kurbo program, will be offered the high risk weight management clinic appointment for a more detailed multidisciplinary evaluation for targeted intervention. Patients that are able to engage with Kurbo intervention and showed a decrease in BMI percentile over 4 sessions of Kurbo will be offered the low risk weight management clinic (WMC). There will be a month 3 and month 6 visit for study measurements in this study.
62180330|NCT06157619||Formulation of Vitrification medium #1|Hydroxypropyl cellulose (HPC), Ethylene glycol, Dimethyl sulfoxide (DMSO) y trehalose
62180331|NCT06157619||Formulation of Vitrification medium #2|Human serum albumin (HSA), Ethylene glycol, Dimethyl sulfoxide (DMSO) \& sucrose
62563669|NCT01945814|EXPERIMENTAL|CTL for CMV seropositive donors|CTL for CMV seropositive donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors- three different dose levels are selected, starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
62563670|NCT01945814|EXPERIMENTAL|CTL for CMV naïve donors|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton)for CMV naïve donors-each group will undergo an identical dose escalation. Three different dose levels are selected, starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
62563671|NCT06415929||Patient with history|Patient with history of complete exeresis of the nail apparatus, with dermal matrix repair and total skin grafting
62563672|NCT01553552||Infected by Schistosoma haematobium|
62563673|NCT01553552||Not infected by Schistosoma haematobium|
62563674|NCT03277443|ACTIVE_COMPARATOR|Conventional Model Surgery|"Lateral Cephalogram with analysis and tracing of facial profile.~Modified model surgical tecnique:~1. Obtain wax bite registration.~2. Record face-bow transfer.~3. Duplication of articulating model for surgical simulation.~4. Measure all casts and bases in standard model surgery fashion.~5. Fabricate intermediate splint \& Final splint.~6. Condylar repositional splint."
62563675|NCT03277443|EXPERIMENTAL|Computer guided surgery|"Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.~Computer-aided planning for study group:~All planning will be done using specialized software (Anatomage Invivo 5.3) for preoperative surgical simulation and immediate postoperative evaluation.~Pre-operative Fabrication of computer aided surgical splint:~In the study group a stereo splint will be fabricated using rapid prototyping (RP) technique to guide the osteotomy and another one will be fabricated after virtual osteotomy to guide the surgical cuts. And stent for guided holes.~So that the osteotomy will be accomplished by the aid of computer guided templates that simulates the proper bite achieved preoperatively during surgical simulation and Planning."
62563676|NCT06188715|EXPERIMENTAL|Arm A: MOX 4/8 mg|Combination therapy of moxidectin (4 mg or 8 mg, i.e. 2 or 4 tablets of 2 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
62563677|NCT06188715|ACTIVE_COMPARATOR|Arm B: ALB|Placebo for moxidectin (2 or 4 tablets) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
62563678|NCT06188715|PLACEBO_COMPARATOR|Arm C: Placebo|Placebo for moxidectin (2 or 4 tablets) and placebo for albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
62563679|NCT00795093||1|552 GERD patients, partial responders to PPI treatment
62563680|NCT05477264|EXPERIMENTAL|Tislelizumab therapy|"Induction therapy: Tislelizumab combined with radiation~Maintenance therapy(after termination of combination therapy)"
62563681|NCT03711188|EXPERIMENTAL|IMM-101 (and nivolumab or ipilimumab)|Patients in cohort A were given IMM-101 in combination with nivolumab. Patients in cohort B who fail to respond to treatment with IMM-101 and nivolumab, and who meet certain criteria, have the option to change treatment on study to IMM-101 and ipilimumab.
62563682|NCT04056260|EXPERIMENTAL|ICG injection|ICG 0.5mg/ml x 0.5ml x 4 sites
62563683|NCT05709418|EXPERIMENTAL|Mathematics intervention|Low-performing children get targeted support with a scripted intervention
62180332|NCT06183905|EXPERIMENTAL|Imaging (multiparametric ultrasound and multiparametric MRI)|All patients will undergo multiparametric ultrasound and multiparametric MRI. In case of suspicious multiparametric ultrasound and/or multiparametric MRI,they will undergo combined targeted biopsy and systematic biopsy. In case of nonsuspicious imaging findings, only systematic biopsy will be performed.
62563684|NCT05709418|NO_INTERVENTION|Control group|Business as usual
62563685|NCT05786560|EXPERIMENTAL|Body image + nutrition education +self-compassion|For the treatment arm, girls will participate in the Body Project for about 30 minutes, then will be given about a 30 minute self-compassion-based nutrition education lesson. The nutrition topics will cover the basic biochemistry of nutrition, nutrition needs for teenage girls, and ways to find balance in eating, framed in the constructs of self-compassion. The three self-compassion constructs will be targeted in the following ways: (1) Mindfulness will involve bringing awareness to feelings and emotions about a time during the week where participants ate a food lower in nutritional value. (2) Common Humanity involves finding ways in which their experience connects to others and acknowledging that being human comes with imperfections. (3) Self-Kindness will involve having girls speak kind and understanding words to themselves as it relates to their eating-related downfall of the week.
62563686|NCT05786560|ACTIVE_COMPARATOR|Body image + nutrition education|For the control arm, participants will receive the same 30-minute Body Project class, then participants will be given a 30-minute nutrition education lesson. The nutrition lesson plans will have no components of self-compassion intertwined within the lesson, but the nutrition content will be the same as the treatment group.
62563687|NCT00869102|EXPERIMENTAL|GLP-1|
62563688|NCT04350892|ACTIVE_COMPARATOR|Roux-en-Y Gastric Bypass Surgery|
62563689|NCT04350892|ACTIVE_COMPARATOR|Sleeve Gastrectomy Surgery|
62563690|NCT04350892|ACTIVE_COMPARATOR|Very Low Calorie Diet|
62563691|NCT01976962|EXPERIMENTAL|Prostate stereotactic body RT with MR-guided boost|Patients will receive a dose of 36.25 Gy in 5 fractions to the entire prostate and proximal seminal vesicles with an additional boost to the dominant lesion for a total of 40 Gy in 5 fractions.
62563692|NCT02094352|EXPERIMENTAL|Ketamine Infusion + Epidural Infusion + Booster Infusion|"Inpatient: Patients will receive a subanesthetic continuous intravenous infusion of KETAMINE 500mg/500ml in 0.9% Sodium Chloride with an epidural infusion.~Outpatient: Patients will receive three ketamine booster infusions over the course of three months."
62563693|NCT02094352|PLACEBO_COMPARATOR|Control Group + Epidural Infusion + Booster Infusion|"Inpatient: Patients will receive a subanesthetic continuous intravenous infusion of SALINE 500mg/500ml in 0.9% Sodium Chloride with an epidural infusion.~Outpatient: Patients will receive three saline booster infusions over the course of three months."
62563694|NCT03981835||Post -PCI Patients scheduled for Cardiac Surgery|Post -PCI Patients (PCI within the last 2 years) who are currently on Dual- Antiplatelet (DAPT) Medication or have a current indication for DAPT, who will be undergoing Cardiac Surgery. No intervention will be administered.
62563695|NCT03981835||Post -PCI Patients scheduled for Non- Cardiac Surgery|Post -PCI Patients (PCI within the last 2 years) who are currently on Dual- Antiplatelet (DAPT) Medication or have a current indication for DAPT, who will be undergoing Non-Cardiac Surgery. No intervention will be administered.
62563696|NCT06031090|ACTIVE_COMPARATOR|Group Cl (clonidine group)|will be given intravenous Clonidine 0.5 µg/kg diluted in 10ml normal saline 20 minutes before spinal anesthesia
62563697|NCT06031090|ACTIVE_COMPARATOR|Group G (granisetron group)|will be given intravenous 1mg of granisetron 20 minutes before spinal anesthesia.
62563698|NCT06031090|PLACEBO_COMPARATOR|Group C (control group)|will be given intravenous10ml normal saline 20 minutes before spinal anesthesia
62563699|NCT06129448||Diabetes Mellitus|We will include in this group patients with a diagnosis of T1DM, determined according to the World Health Organization criteria, who need insulin treatment and whose diabetes duration is more than 1 year. Patients will not have additional chronic diseases and will not have any other medical treatments other than insulin.
62563700|NCT06129448||Healthy Children|Patients will not have additional chronic diseases or other medical treatments. They will often be selected on a voluntary basis from patients who apply to pediatric cardiology with symptoms such as murmur or chest pain.
62563701|NCT01017536|PLACEBO_COMPARATOR|Placebo|Thirteen subjects received placebo vaccine that did not contain any AERAS-402.
62563702|NCT01017536|EXPERIMENTAL|Investigational Vaccine|Thirteen subjects received active vaccine 3 x 10\^10 vp AERAS-402.
62563703|NCT02920762||Buprenorphine|
62563704|NCT02920762||Fentanyl|
62563705|NCT02920762||Hydromorphone HCl|
62563706|NCT02920762||Morphine Sulfate|
62563707|NCT02920762||Morphine Sulfate Beads|
62563708|NCT02920762||Oxycodone HCl|
62180333|NCT05426161|EXPERIMENTAL|Botulinum Toxin A|Open-label study
62180334|NCT04119206||Control|Normonatremic control, no intervention.
62180335|NCT04119206||Fluid restriction|Hyponatremic patients (serum sodium \<135mmol/L): restriction of fluid intake \< 1L
62391212|NCT02450656|EXPERIMENTAL|Afatinib plus selumetinib|Combination of afatinib and selumetinib at the optimal dose and regimen as determined in the phase I part of this study
62391213|NCT02450656|ACTIVE_COMPARATOR|Control|Standard-of-care second line treatment for non small cell lung cancer (docetaxel)
62391214|NCT05657301|EXPERIMENTAL|KH631 Dose 1|KH631 One-Time Intraocular Injection Dose Level 1
62563709|NCT02920762||Oxymorphone HCl|
62563710|NCT02920762||Tapentadol|
62563711|NCT01350362|EXPERIMENTAL|Tideglusib 1000 mg Q.D.|Group dosed with 1000 mg once daily for 26 weeks/extension
62563712|NCT01350362|EXPERIMENTAL|Tideglusib 1000 mg Q.O.D.|Group dosed with 1000 mg once every other day for 26 weeks/extension
62563713|NCT01350362|EXPERIMENTAL|Tideglusib 500 mg Q.D.|Group dosed with 500 mg once daily for 26 weeks/extension
62563714|NCT01350362|PLACEBO_COMPARATOR|Placebo|Once daily administration for 26 weeks/extension
62563715|NCT06578299|EXPERIMENTAL|Inetetamab and Paclitaxel ± Pertuzumab|"Inetetamab and Paclitaxel ± Pertuzumab Inetetamab：was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~Paclitaxel：Docetaxel 75mg/m2, albumin paclitaxel 260mg/m2, or paclitaxel liposomes 175mg/m2) is administered intravenously on the first day of every three weeks, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~Pertuzumab：was administered as an intravenous (IV) loading dose of 840mg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420mg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination."
62563716|NCT03993847||Prospective Cohort of Undiagnosed Back Pain|"All consecutive patients referred to a rheumatologist with current undiagnosed back pain of ≥3 months duration with onset ≤45 years of age will comprise the prospective cohort.~This is a classification study; no intervention will be administered"
62563717|NCT01861223|EXPERIMENTAL|afatinib + nimotuzumab|
61995242|NCT06049056||General Practice 9|"General Practice 9 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a URL link and a QR code providing access to an online questionnaire"
61995243|NCT06049056||General Practice 10|"General Practice 10 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a URL link and a QR code providing access to an online questionnaire"
62180336|NCT04119206||Tolvaptan 3.75mg|Hyponatremic patients (serum sodium \<135mmol/L): tolvaptan 3.75 mg tablet; The serum sodium concentration was controlled at 6:00 pm. Those patients, whose serum sodium concentration further dropped below 132 mmol/L, were treated with a second tablet of tolvaptan and the serum sodium was measured the next day at 8:00 am. Those patients, whose serum sodium was increased by not more than 5 mmol/L underwent the next blood check on the next day at 8:00 am. Those patients, whose serum sodium increased by more than 5 mmol/L were treated by 1L tea/water or a 500 mL 5% glucose infusion.
62180337|NCT04119206||Tolvaptan 7.5mg|Hyponatremic patients (serum sodium \<135mmol/L): tolvaptan 7.5 mg tablet; The serum sodium concentration was controlled at 6:00 pm. Those patients, whose serum sodium concentration further dropped below 132 mmol/L, were treated with a second tablet of tolvaptan and the serum sodium was measured the next day at 8:00 am. Those patients, whose serum sodium was increased by not more than 5 mmol/L underwent the next blood check on the next day at 8:00 am. Those patients, whose serum sodium increased by more than 5 mmol/L were treated by 1L tea/water or a 500 mL 5% glucose infusion.
62180338|NCT00586118||1-Sevo|Sevoflurane/ACD group (n=60)
62180339|NCT00586118||2-Propofol|Propofol group (n=60)
62180340|NCT03974698|ACTIVE_COMPARATOR|Anterolateral approach|Standard x-ray on all operated patients was taken pre- and postoperative and at 3 and 12 moths. Including an AP pelvis and lateral view of the hip.
62563718|NCT04556682||Patients who underwent Rotational atherectomy (RA)|The device contains rapidly rotating burr that is coated with microscopic diamond chips, which debulks the calcified plaque by grinding the calcified atheroma into small particles facilitating stent passage and expansion. Both transfemoral or transradial approach can be used. Regular PCI guidewire can be used to cross the often complex anatomy then switching to a rotablation dedicated guidewire over a microcatheter. Burr sizes vary from 1.25mm up to 1.75mm (in certain cases bigger calibers may also be used) aiming to achieve plaque modification .
61995244|NCT06092515|EXPERIMENTAL|Fermented High Zinc Wheat Flour Flatbread|Participants in this arm will receive fermented whole wheat flatbreads made from wheat variants with a high zinc content, ranging. These flatbreads are prepared through traditional fermentation methods.
62180341|NCT03974698|ACTIVE_COMPARATOR|Lateral approach|Standard x-ray on all operated patients was taken pre- and postoperative and at 3 and 12 moths. Including an AP pelvis and lateral view of the hip.
62180342|NCT05089981|ACTIVE_COMPARATOR|NAC group|IV N acetyl cysteine 300mg will be administered in doses as described in protocol
62180343|NCT05089981|PLACEBO_COMPARATOR|NAC Placebo group|IV Placebo of N acetyl cysteine will be administered in doses as described in protocol (Placebo will be normal saline in a look alike preparation with same volume as active NAC arm)
62180344|NCT05563636|OTHER|control (group S)|patients will be given standard PRF treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, voltage 37-41 V, time 120 s.
62180345|NCT05563636|EXPERIMENTAL|group H|patients will be given high-voltage long-term PRF treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, the voltage range of 50-90 V, At the beginning, the patient will feel a severe burning sensation in the original pain area, and slowly after the patient tolerates it. Increase the voltage and gradually increase to the maximum voltage that the patient can tolerate (up to 70-90 V) until the end of 900 s.
62391215|NCT05657301|EXPERIMENTAL|KH631 Dose 2|KH631 One-Time Intraocular Injection Dose Level 2
61995245|NCT06092515|EXPERIMENTAL|Unfermented High Zinc Wheat Flour Flatbread|Participants in this arm will receive unfermented whole wheat flatbreads made from wheat variants with a high zinc content. These flatbreads provide a source of bioavailable zinc without the fermentation process.
62391216|NCT05657301|EXPERIMENTAL|KH631 Dose 3|KH631 One-Time Intraocular Injection Dose Level 3
62391217|NCT05657301|EXPERIMENTAL|KH631 Dose 4|KH631 One-Time Intraocular Injection Dose Level 4
62391218|NCT05657301|EXPERIMENTAL|KH631 Dose 5|KH631 One-Time Intraocular Injection Dose Level 5
62563719|NCT04556682||Patients who underwent Intravascular lithotripsy (IVL)|The Coronary IVL System consists of an IVL Balloon Catheter with 2 integrated emitters, a Lithotripsy Generator, and a Connector Cable. These emitters create sonic pressure waves that selectively fracture calcium and alter vessel compliance facilitating stent passage and expansion. It is available in 2.5- to 4.0-mm diameters and 12 mm in length, with an inflation pressure of 4 atm used for delivering the treatment. Every catheter can emit a maximum of 80 pulses at a rate of one pulse per second. The IVL balloon catheter is chosen based on the reference lumen of the vessel and after pre-dilatation of the lesion (preferably with a non-compliant balloon) 10-30 pulses are given, usually with interval deflation to allow distal perfusion. If the lesion exceeds the 12 mm balloon length, the balloon can be repositioned and the IVL repeated .
62563720|NCT04798833|EXPERIMENTAL|Integrated Newborn Care Kit|"The integrated newborn care kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, three misoprostol tablets (200ug each), 4% chlorhexidine solution, sunflower oil emollient, temperature monitoring strip or sticker, a fleece blanket, a reusable, non-electric, heating device, and a pictorial instruction guide. Lady Health Workers will be equipped with a hand-held electronic scale to identify low birth weight newborns.~Participants in this arm will receive the same local standard of care as the no intervention arm."
62563721|NCT04798833|NO_INTERVENTION|Control (Local Standard of Care)|"In the control arm, LHWs will deliver the local standard of care, which entails both anti-natal and post-natal LHW home visits. As part of standard practice, LHWs visit pregnant women in their homes during the 3rd trimester, at which time these health workers:~* Provide instructions regarding proper nutrition during pregnancy~* Encourage that delivery take place in a facility~* Discuss the fundamentals of safe water, sanitation, and hygiene behavior~* Encourage exclusive breastfeeding~These community health workers will identify early danger signs in newborns such as infections and teach caregivers to identify the same symptoms, so that early interventions can be made. If danger signs are identified, the LHW will refer newborns to the appropriate level of health care."
62563722|NCT06521996|EXPERIMENTAL|M-CHOP (Mosunetuzumab combined with CHOP)|"M-CHOP (Mosunetuzumab IV combined with CHOP)~Investigational medicinal product (IMP) for this study is mosunetuzumab which will be provided by the Sponsor~CHOP regimen, dexamethasone, rasburicase, acetaminophen/paracetamol, diphenhydramine methylprednisolone, allopurinol and tocilizumab are considered non-investigational medicinal products (NIMPs)."
62563723|NCT02481089||training group|
62563724|NCT04722432|EXPERIMENTAL|Système de cathéter détachable dehors du scope (DDS)|
62563725|NCT03490110|EXPERIMENTAL|State regulation skill training|This arm utilizes a training system designed to strengthen goal-directed cognitive-emotional state regulation skills. The emphasis is on practice and active application of skills across a range of challenge contexts. Digital scenarios provide experiential learning opportunities, allowing Veterans to apply skills to tackle challenges that are calibrated to maximize learning. Coaches guide learning for successful application of skills to challenges in personal life.
62563726|NCT03490110|ACTIVE_COMPARATOR|Treatment-as-usual|In this arm, participants receive clinical care as usual in VA and other clinics.
62563727|NCT01402570|EXPERIMENTAL|Glutathione supplement|All subjects will be taking a glutathione supplement.Glutathione is a naturally occuring antioxidant and a nonessential amino acid.
62563728|NCT01465412|EXPERIMENTAL|Mild Hepatic Impaired (HI) Part 1|Participants with mild chronic liver disease enrolled in Part 1 received one 5-mg preladenant tablet, orally, on Day 1.
62563729|NCT01465412|ACTIVE_COMPARATOR|Healthy to Match Mild HI Part 1|Healthy volunteers with normal hepatic function matched to participants with mild chronic liver disease by race, age, BMI, and gender, enrolled in Part 1 received one 5-mg preladenant tablet, orally, on Day 1.
62563730|NCT01465412|EXPERIMENTAL|Moderate HI Part 2|Participants with moderate chronic liver disease enrolled in Part 2 received one 5-mg preladenant tablet, orally, on Day 1.
62563731|NCT01465412|ACTIVE_COMPARATOR|Healthy to Match Moderate HI Part 2|Healthy volunteers with normal hepatic function matched to participants with moderate chronic liver disease by race, age, BMI, and gender, enrolled in Part 2 received one 5-mg preladenant tablet, orally, on Day 1.
62563732|NCT02223546||healthy subject|healthy subject, every 3 hour measurement
61995246|NCT06092515|EXPERIMENTAL|Fortified Wheat Flour flatbread|Participants in this arm will receive flatbreads made from whole wheat flour fortified post-harvest to contain a zinc content
61995247|NCT06092515|ACTIVE_COMPARATOR|Low Zinc Wheat flatbread|Participants in this arm will receive whole wheat flatbreads made from wheat variants with a low zinc content
62180346|NCT06289023|EXPERIMENTAL|HA-WBRT-SIB|Patients with lung cancer and brain metastases undergo HA-WBRT-SIB using image-guided radiotherapy, receiving a total dose of 30-36 Gy delivered in 18-20 fractions to the whole brain (CTV), while the dose to the GTV is boosted to 44 Gy-52 Gy in 18-20 fractions, ﬁve times a week. The optimal mean dose (Dmean) to the bilateral hippocampus should optimally be ≤ 8 Gy, with a mandatory maximum dose (Dmax) to the hippocampus not exceeding 10 Gy; the preferred Dmean to the hippocampus PRV should optimally be ≤ 9 Gy, while the mandatory Dmax to the hippocampus PRV should be ≤ 12 Gy. The HVLT-R immediate recall scores are obtained at baseline and 1, 3, and 6 months after treatment.
61995248|NCT00710320||Cover and Uncover|Procedure/Surgery
61995249|NCT03559075||Group 1|Participants will be randomized into group 1 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
61995250|NCT03559075||Group 2|Participants will be randomized into group 2 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
62391219|NCT02120573|ACTIVE_COMPARATOR|medical students|medical students took part in workshop
62563733|NCT00025025||Arm I|"Participants eat no red meat and take no nonsteroidal anti-inflammatory drugs (NSAIDs) and no vitamin C or multivitamins for 3 days prior to and during stool sample collection. Participants collect stool samples 3 different times and perform fecal occult blood (FOB) test smears from each stool. After each collection, participants ship the whole stool and FOB test smear to their participating center for blinded multitarget DNA-based assay panel (MTAP) testing.~Within 2 months after stool sample collection, participants have their blood drawn for additional MTAP testing and undergo colonoscopy."
62563734|NCT00025025||Arm II|"Participants take no vitamin C or multivitamins for 3 days before and during stool sample collection. Participants collect stool samples and FOB test smears and samples are tested as in arm I.~Within 2 months after stool sample collection, participants have their blood drawn for additional MTAP testing and undergo colonoscopy."
62563735|NCT02332629|ACTIVE_COMPARATOR|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
62563736|NCT02332629|PLACEBO_COMPARATOR|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
62563737|NCT03011827|EXPERIMENTAL|Prospective cohort|Fibrinogen and/or platelet administration
62563738|NCT01962103|EXPERIMENTAL|nab-paclitaxel|nab-paclitaxel 100-240 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle.
62563739|NCT01962103|EXPERIMENTAL|Phase 1: Nab-Paclitaxel 120 mg/m^2|nab-paclitaxel 120 mg/m\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
62563740|NCT01962103|EXPERIMENTAL|Phase 1: Nab-Paclitaxel 150 mg/m^2|nab-paclitaxel 150 mg/m\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
62563741|NCT01962103|EXPERIMENTAL|Phase 1: Nab-Paclitaxel 180 mg/m^2|nab-paclitaxel 180 mg/m\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
62563742|NCT01962103|EXPERIMENTAL|Phase 1: Nab-Paclitaxel 210 mg/m^2|nab-paclitaxel 210 mg/m\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
62563743|NCT01962103|EXPERIMENTAL|Phase 1: Nab-Paclitaxel 240 mg/m^2|nab-paclitaxel 240 mg/m\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
62563744|NCT01962103|EXPERIMENTAL|Phase 1: Nab-Paclitaxel 270 mg/m^2|nab-paclitaxel 270 mg/m\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
62563745|NCT01962103|EXPERIMENTAL|Phase 2: Ewing's Sarcoma|Participants with Ewing's sarcoma: nab-paclitaxel at the RP2D (240 mg/m\^2 in participants weighing \> 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
62563746|NCT01962103|EXPERIMENTAL|Phase 2: Neuroblastoma|Participants with neuroblastoma: nab-paclitaxel at the RP2D (240 mg/m\^2 in participants weighing \> 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
62563747|NCT01962103|EXPERIMENTAL|Phase 2: Rhabdomyosarcoma|Participants with rhabdomyosarcoma: nab-paclitaxel at the RP2D (240 mg/m\^2 in participants weighing \> 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
62563748|NCT00471679|EXPERIMENTAL|Ethanol-Lock Treatment|Ethanol instillation and removal will be carried out by one of the investigating physicians, a pediatric surgical nurse practitioner, or a dedicated research nurse. Syringes containing a 70% ethanol solution will be pre-filled in the PDH pharmacy and dispensed to the nurse caring for a particular patient. The volume of ethanol to be administered into each lumen of the central line will be specific to each patient's catheter and will be determined at enrollment.
62563749|NCT01780519|OTHER|L/VL APOE e3/e4 carrier|long and very long poly - T variants of TOMM40 and APOE e3/e4 carrier
62563750|NCT01780519|OTHER|L/S APOE e3/e4 carrier|long and short poly - T variants of TOMM40 and APOE e3/e4 carrier
62563751|NCT01780519|OTHER|S/VL APOE e3/e3 carrier|short and Very long poly - T variants of TOMM40 and APOE e3/e3 carrier
62563752|NCT01780519|OTHER|VL/VL APOE e3/e3 carrier|Very long poly - T variants of TOMM40 and APOE e3/e3 carrier
62563753|NCT01780519|OTHER|S/S APOE e3/e3 carrier|short poly - T variants of TOMM40 and APOE e3/e3 carrier
62563754|NCT03517163||Prospective Group|Individuals enrolled or just finished kindergarten who were diagnosed with Autism Spectrum Disorder through the DSM-5 diagnostic criteria
62563755|NCT02647710|EXPERIMENTAL|PHAT Life Intervention|PHAT Life: Preventing HIV/AIDS Among Teens, is a uniquely-tailored intervention designed for recently-arrested juvenile offenders on probation. The program will teach teens about HIV/AIDS, sexually transmitted infections, and safer decision-making. PHAT Life draws on social learning theory and a Social-Personal Framework to address individual and social mechanisms related to HIV-risk, including emotion regulation, peer norms, partner communication, relationship characteristics, and HIV/AIDS/STI and substance use knowledge, attitudes, and beliefs.
62563756|NCT02647710|ACTIVE_COMPARATOR|Health Promotion Control|A health promotion program focusing on nutrition, physical activity, substance use, and sexual health.
62563757|NCT01221519|EXPERIMENTAL|1|AZD1656
62563758|NCT01221519|EXPERIMENTAL|2|AZD1656
62563759|NCT01221519|EXPERIMENTAL|3|AZD1656
62563760|NCT05322772||children with epilepsy|epilepsy diagnosed clinically EEG
62563761|NCT05322772||children with febrile convulsions|the child has high grade fever from 6 month to 6 years not recurrent duration less than 15 minute or atypical febrile convulsions
62563762|NCT05322772||children with cns infection|"the child has fever, neck, rigidity DCL~+or- CSF analysis"
62563763|NCT05322772||children with electrolyte imbalance, hypoglycemia|abnormal values of electrolyte hypoglycemia
62563764|NCT05322772||children with poisoning|history of ingestion or inhalation of toxic substance
62563765|NCT05322772||children with encephalopathy|the child complains of brain disease or mal function with altered mental status as a complication of primary illness as kidney failure ,cirrhosis, etc.
62563766|NCT05322772||children with trauma|history of trauma imaging study done
62563767|NCT05322772||children with genetic cause|the child has congenital anomaly as chromosomal abnormality, metabolic disease, mitochondrial disease
62563768|NCT05322772||others|children not fulfilling the previous groups
62563769|NCT02198170|EXPERIMENTAL|ketoconazole-placebo|Treatment Period 1: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: Placebo orally once daily + single oral dose of 5 mg lenvatinib of fifth day on 19-day treatment period
62563770|NCT02198170|EXPERIMENTAL|placebo-ketoconazole|Treatment Period 1: Placebo orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period
62563771|NCT04323163|EXPERIMENTAL|Yoga Group|Participants will be led through a beginner yoga course taught by a certified yoga instructor. Classes will meet three times a week for 60 minutes over the 6 month study duration. Sessions will focus on yoga postures, breathing, and meditative practices and may utilize mats, blocks, belts, and blankets.
62563772|NCT04323163|EXPERIMENTAL|Aerobic Group|Trained exercise instructors will lead participants through an aerobic group exercise class. Sessions will begin with a 15-20 minute aerobics class and increase in duration over the 6 months capping off at 40-minutes per session. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program.
62563773|NCT04323163|ACTIVE_COMPARATOR|Stretching Toning Group|Participants randomized to this group will meet three times a week for an hour-long structured group exercise session. This group will perform stretching and toning exercises using resistance bands, balance disks, and exercise mats.
62563774|NCT03822091|ACTIVE_COMPARATOR|TERLIPRESSIN GROUP|
62563775|NCT03822091|EXPERIMENTAL|TERLIPRESSIN WITH NORADRENALINE GROUP|
62563776|NCT02731430|ACTIVE_COMPARATOR|group I: morphine group|received 0.3mg morphine (0.3ml) added to 1.2ml of bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
62563777|NCT02731430|PLACEBO_COMPARATOR|group II: control group|received 0.3ml saline added to 1.2mlof bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
62563778|NCT03427294||Care providers involved in lumbar arthrodesis|surgeons, physiotherapists, behavioral therapists, researchers, occupational therapists
62563779|NCT04534530||Experimental|"The experimental group systematic screening for ischemic heart disease will be identified during the screening period by performing at least one systematic screening examination, regardless of the frequency, for ischemic heart disease in patients. diabetics at very high cardiovascular risk, without known coronary heart disease, by at least one non-invasive functional cardiovascular exploration outside the resting ECG."
62391220|NCT02120573|ACTIVE_COMPARATOR|general population|general population took part in workshop
62391221|NCT02120573|ACTIVE_COMPARATOR|nonmedical students|all students from different subjects, non medical and paramedical
62391222|NCT05751850|EXPERIMENTAL|HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate|
62391223|NCT05751850|ACTIVE_COMPARATOR|nab-paclitaxel; gemcitabine|
62391224|NCT02050945|EXPERIMENTAL|Patients with COPD|Patients with COPD are to be trained 3 times a week for 8 weeks
62391225|NCT02050945|ACTIVE_COMPARATOR|Control patients with COPD|Control patients with COPD are to be trained 3 times a week for 8 weeks
62391226|NCT05615948|OTHER|Intervention Group|All individuals 18 years old or older who have Major Depressive Disorder and have failed to achieve response or remission to at least one proven antidepressant trial with minimum affective dose for a duration of at least 6 weeks.
62391227|NCT01617356|ACTIVE_COMPARATOR|Dextrose Injection|
62563780|NCT04534530||Control|"The control group Absence of systematic screening for ischemic heart disease will be identified during the pre-selection period by the absence of a non-invasive functional cardiovascular exploration (examinations mentioned above) in T2D with very high cardiovascular risk, with no known coronary heart disease, apart from performing a resting ECG"
62563781|NCT04398004|EXPERIMENTAL|Clarithromycin arm|Treatment will last for seven days. Every patient will receive one tablet of 500 mg of clarithromycin every 12 hours. It is explicitly stated that all other treatment is allowed with the only exclusion the parallel intake of a) any other drug of the macrolide class of antibiotics; and/or b) hydroxychloroquine or chloroquine phosphate. Drugs contraindicated with the intake of clarithromycin are also not allowed, as they are described in the local label information.
62563782|NCT06080269|EXPERIMENTAL|Intervention arm|The participants in the intervention arm will be receiving technology based training along with the conventional therapy
61995251|NCT03559075||Group 3|Participants will be randomized into group 3 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
62563783|NCT06080269|ACTIVE_COMPARATOR|Control arm|The participants in the control arm will be receiving the regular conventional therapy program
62563784|NCT02571478|EXPERIMENTAL|7-Month Wait List Group|Couples will be randomly assigned to a wait list group. This group will wait seven months before starting The Marriage Checkup.
62563785|NCT02571478|EXPERIMENTAL|MC Right Away|Couples will be randomly assigned to receive The Marriage Checkup right away.
62563786|NCT03760692|ACTIVE_COMPARATOR|Group i-gel|Insertion of the airway device. The size of the airway device used is based on the manufacturers' recommendations and evaluation of its clinical performance
62563787|NCT03760692|EXPERIMENTAL|Group Ambu Auragain|Insertion of the airway device. The size of the airway device used is based on the manufacturers' recommendations and evaluation of its clinical performance
62563788|NCT03943043|EXPERIMENTAL|gemcitabine oxaliplatin nab-paclitaxel|combination at different dose of gemcitabine, oxaliplatin and nab-paclitaxel
61995252|NCT03559075||Group 4|Participants will be randomized into group 4 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
61995253|NCT03559075||Group 5|Participants will be randomized into group 5 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
62391228|NCT01617356|ACTIVE_COMPARATOR|Sterile Water Injection|
62563789|NCT01134939||HIV-infected women and men|
62563790|NCT04980807||CMT Patients|Individuals with Charcot-Marie-Tooth Disease Types 1 and 2.
62563791|NCT04980807||Healthy Controls|Healthy age-matched volunteers
62563792|NCT05236335|EXPERIMENTAL|Ketone ester|
62563793|NCT05236335|PLACEBO_COMPARATOR|Placebo|
62563794|NCT03974867|EXPERIMENTAL|Oral Prednisone Group|36 participants in Group 1 will receive oral prednisone 1mg/kg/d (maximum daily dosage is no more than 60mg) for 7 days, followed by a 7-day taper.
62391229|NCT03606018|EXPERIMENTAL|Insulin Lispro Mix 25|Single subcutaneous administration of Insulin Lispro Mix 25 in dose 0.4 IU / kg
62391230|NCT03606018|ACTIVE_COMPARATOR|Humalog® Mix 25|Single subcutaneous administration of Humalog® Mix 25 in dose 0.4 IU / kg
62391231|NCT04065711|EXPERIMENTAL|RAP Treatment|Each treatment area will receive 30-40 minutes (30-40 individual doses) of RAP treatment.
62391232|NCT02702115|EXPERIMENTAL|Cohort 1: SB-318: Starting Dose 1.00E+13 vg/kg|A single dose of each of the three components of SB-318 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
62563795|NCT03974867|EXPERIMENTAL|Intratympanic Methylprednisolone Group|36 participants in Group 2 will receive 7 intratympanic 40mg/ml methylprednisolone injections in 14 days, one injection every other day.
61995254|NCT03559075||Group 6|Participants will be randomized into group 6 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
61995255|NCT03559075||Group 7|Participants will be randomized into group 7 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
61995256|NCT03559075||Group 8|Participants will be randomized into group 8 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
61995257|NCT00302133|EXPERIMENTAL|Naltrexone add on to valproate|Naltrexone hydrochloride 50 mg capsule daily for 12 weeks add on to valproate
62391233|NCT02702115|EXPERIMENTAL|Cohort 2: SB-318 at Next Ascending Dose 5.00E+13 vg/kg|A single dose of each of the three components of SB-318 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
62391234|NCT02702115|EXPERIMENTAL|Cohort 3: SB-318 at Next Ascending Dose 1.20E+14 vg/kg|A single dose of each of the three components of SB-318 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
62563796|NCT04537078|ACTIVE_COMPARATOR|the progestin primed double stimulation group|luteal phase priming using combined contraceptive pills from day 21 of the previous cycle for one week by Gynera tab. Controlled ovarian hyper-stimulation with 225-375 IU of gonadotropins will be started day 2-3 of menses after vaginal ultrasound confirming the absence of ovarian cysts. Duphaston at 20 mg/day will be started from the first day of the ovulation induction.Decapeptyl in a dose of 2 ampules of 0.2 mg will be administered when leading follicle \>18 mm in diameter for triggering.Then, Controlled ovarian hyper-stimulation the next day after the previous oocyte pickup simultaneously with Duphaston. Starting from the next menstrual cycle Day 3, patients will receive oral estradiol valerate (Cyclo-Progynova (white tablets) daily.When endometrial thickness ≥ 7 mm.Embryo transfer will be scheduled on Day 3, 4 or 5 with maximum number of 3 class A embryos whether of cleavage or blastocyst stage.
62563797|NCT04537078|ACTIVE_COMPARATOR|the flexible GnRh antagonist|This step will be done twice in two different cycles In each cycle: luteal phase priming using combined contraceptive pills from day 21 of the previous cycle for one week by Gynera tab. Controlled ovarian hyper-stimulation using antagonist protocol will be used. Stimulation with 225-375 IU of gonadotropins will be started day 2-3 of menses after vaginal ultrasound confirming the absence of ovarian cysts. Cetrotide ampule will be given daily as the biggest oocyte reaches size 14 mm. Decapeptyl ampules 0.2 mg will be administered when leading follicle \>18 mm in diameter. While in the second cycle HCG triggering (Choriomon)in a dose of 10,000 IU will be administered when the leading follicle \>18 mm in diameter. Embryo transfer will be scheduled on Day 3, 4 or 5 with maximum number of 3 class A embryos whether of cleavage or blastocyst stage that will be a mixture of the thawed embryos of the first cycle and fresh embryos of the second cycle.
62563798|NCT00515970|EXPERIMENTAL|1|Clinical or histologic diagnosis of nodular BCC
62563799|NCT00515970|ACTIVE_COMPARATOR|2|Clinical or histologic diagnosis of nodular BCC
62563800|NCT00515970|EXPERIMENTAL|3|Clinical or histologic diagnosis of superficial BCC
62563801|NCT00515970|ACTIVE_COMPARATOR|4|Clinical or histologic diagnosis of superficial BCC
62563802|NCT06475547||POAF|Patients who develop postoperative atrial fibrillation.
62563803|NCT06475547||Non-POAF|Patients who do not develop postoperative atrial fibrillation.
62563804|NCT00101270|EXPERIMENTAL|Treatment (irinotecan hydrochloride, oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
62563805|NCT04223336|NO_INTERVENTION|Control Group|When a participant in the control group is identified via a mandatory baseline questionnaire as having low levels of physical activity and/or low levels of fruits/vegetable consumption, the practitioner seeing this participant during their visit will not receive any computer alerts for physical activity and fruits/vegetable consumption. However, practitioners will still have access to the physical activity and diet data as part of the baseline assessment (Screening). Practitioners will also continue to have access to all the same resources as they currently do (treatment as usual).
61995258|NCT00302133|PLACEBO_COMPARATOR|Placebo add on to valproate|Placebo comparator one capsule daily for 12 weeks add on to valproate
61995259|NCT00594464|EXPERIMENTAL|1|Rotigotine
61995260|NCT04745897|EXPERIMENTAL|eTB Catalogue of Recommendation (eTB)|New eTB catalogue of recommendations website (eTB).
62391235|NCT03984851||Group A: Surgicel Group|a retrospective cohort study. Two groups were assigned, the first under the care of the author \[AA\], in which patients of his group underwent cold dissection tonsillectomy and achieved hemostasis via surgicel (without bipolar cautery). While group B patients (consisted of 2 surgeons) underwent cold dissection tonsillectomy and attained hemostasis with bipolar cautery. The main outcome that was pursued was postoperative tonsillectomy bleeding
62391236|NCT03984851||Group B: Bipolar Cautery group|a retrospective cohort study. Two groups were assigned, the first under the care of the author \[AA\], in which patients of his group underwent cold dissection tonsillectomy and achieved hemostasis via surgicel (without bipolar cautery). While group B patients (consisted of 2 surgeons) underwent cold dissection tonsillectomy and attained hemostasis with bipolar cautery. The main outcome that was pursued was postoperative tonsillectomy bleeding
62391237|NCT04455958|EXPERIMENTAL|Group I (lopinavir/ritonavir)|Patients receive lopinavir/ritonavir PO BID for 14 days in the absence of disease progression or unacceptable toxicity.
62391238|NCT04455958|PLACEBO_COMPARATOR|Group II (placebo)|Patients receive placebo PO BID for 14 days in the absence of disease progression or unacceptable toxicity.
62391239|NCT05475119|EXPERIMENTAL|Participants diagnosed with Obstructive Sleep Apnea|The participants will sleep three nights at the sleep lab and undergo in their first night, Polysomnography (PSG). Then at random, some of them will do CPAP titration in the second night followed by HFNC titration in the third night. While others will do HFNC titration in the second night followed by CPAP titration in the third night
62391240|NCT05147194|NO_INTERVENTION|Control group|Blank group
62391241|NCT05147194|EXPERIMENTAL|Trimetazidine group|The participates received treatments of trimetazidine
62391242|NCT00241371|EXPERIMENTAL|Clofarabine|4 mg/m2 IV over 1 hour on days 1-5 of each 28 day cycle.
62391243|NCT05270564|ACTIVE_COMPARATOR|Drain|Surgical drains used as routine
62391244|NCT05270564|EXPERIMENTAL|No drain|No surgical drain used
62391245|NCT01926964||Early breast cancer patients|Patients with ER-positive, HER2 negative, pN0 or pN1a and resected primary breast cancer R0 resection.
62391246|NCT05236829||Healthy group|Healthy women aged 18-55 who have not been diagnosed with any chronic disease and pituitary adenoma
62391247|NCT05236829||Patient with Prolactinoma group|Women between the ages of 18-55 diagnosed with Prolactinoma
62391248|NCT02207413|EXPERIMENTAL|Influsplit Tetra_IP Adult Group|Subjects in the Influsplit Tetra_IP group aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by investigational process (IP) at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm.
62563806|NCT04223336|EXPERIMENTAL|Intervention Group|When a participant in the intervention group is identified via mandatory baseline questionnaire as having low levels of physical activity and/or low levels of fruits/vegetable consumption, the practitioner seeing this participant during their visit will receive computer alerts (screening), prompting to provide participant with a brief intervention (risk communication) and a self-monitoring resource for physical activity and/or fruits/vegetable consumption.
62563807|NCT04409145|EXPERIMENTAL|VT30|VT30 is a PI3K-inhibitor prodrug, formulated as a topical gel and dispensed from a metered dose pump; administration is once or twice daily, applied to target-treatment area(s) on the skin. One pump action dispenses 250 µL of gel, intended to treat an area of 140 cm2.
62563808|NCT04760977||Trauma patients in shock|The study focuses on hypotensive trauma patients assisted by HEMS teams
62563809|NCT01115244|EXPERIMENTAL|Dapsone gel, 5%|ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
62563810|NCT01115244|NO_INTERVENTION|Not treated|One arm of the patient will be left untreated.
62563811|NCT04886843|ACTIVE_COMPARATOR|Cold Therapy|The patients have seated the knee joints in full extension and both ankle joints in a neutral position. Neuromuscular electrical stimulation (NMES) was applied to the non-affected side ankle dorsiflexors for five days, five sessions for a week. In addition to this application, a cold pack was applied on the affected side dorsiflexor muscle skin. The cold pack was applied on a moist towel for five minutes. A five-minute break was given and a further 5-minute cold application was repeated. The cold application was done simultaneously with NMES.
61995261|NCT04745897|ACTIVE_COMPARATOR|World Health Organization Tuberculosis Website (WHO TB)|Current method of accessing tuberculosis (TB) recommendations using World Health Organization (WHO) website (WHO TB).
62563812|NCT04886843|PLACEBO_COMPARATOR|Control|The patients have seated the knee joints in full extension and both ankle joints in a neutral position. Neuromuscular electrical stimulation (NMES) was applied to the non-affected side ankle dorsiflexors for five days, five sessions for a week.
62563813|NCT04988269||Patients (Cases)|"Adult consecutive patients that visited the Emergency Department of LAIKO General Hospital of Athens, Greece from May to July 2021 due to confirmed COVID-19 and related symptomatology.~Blood sampling on the day of admission (one time point) and saliva sampling at 4 different time points (0.800, 12.00, 18.00,22.00) the next day (all sampling in one day)."
62180347|NCT05423548||Children with congenital deafness|Children with congenital deafness followed in the ENT department of the Necker hospital and having benefited before their 10 months, from a pilot consultation, filmed, jointly carried out by a child psychiatrist from the Therapeutic Childhood and Deafness Unit of St Maurice Hospitals (UTES) and a psychologist from the ENT department of Necker for the neurodevelopmental risk assessment, between May 2018 to April 2020.
62180348|NCT04522778|EXPERIMENTAL|Device|Those in the device arm will be given two wearable central line securement devices and the investigators will encourage continuous wear throughout the duration of the study.
62563814|NCT04988269||Healthy Controls|Age and gender matched healthy individuals without COVID-19. Blood sampling (at day 1) and saliva sampling at different time points (0.800, 12.00, 18.00,22.00) the next day (all sampling in one day-day 2).
62563815|NCT02165163|EXPERIMENTAL|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
61995262|NCT00500422|EXPERIMENTAL|Doxil + Gemcitabine + Velcade|Doxil Starting dose of 20 mg/m\^2 intravenous (IV) over 2 hours on Day 1 and Gemcitabine 500 mg/m\^2 IV over 30 minutes on Days 1 and 8; Velcade Starting dose of 0.7 mg/m\^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles.
62180349|NCT04522778|ACTIVE_COMPARATOR|Traditional Securement Dressing|Those is the non-device arm will continue to wear a traditional central line securement dressing as is the standard of care.
62180350|NCT05097898|EXPERIMENTAL|Patients with chronic HFpEF coming for scheduled day hospitalization or consultation|"* Clinical examination focusing on congestion~* Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds~* Blood sample retrieved for biological assessment and biobanking~* Telephone follow-up"
62180351|NCT02315053|OTHER|Low dose FDG PET/CT 5x|Stage II/III NSCLC will undergo a Low dose FDG PET/CT 5x during treatment (CCRT).
62180352|NCT00251264|ACTIVE_COMPARATOR|Open|
62563816|NCT02165163|NO_INTERVENTION|Control|The control group will keep their normal activity without receiving any intervention.
62563817|NCT01900769|EXPERIMENTAL|Blood Volume Dilution|
62180353|NCT00251264|ACTIVE_COMPARATOR|Arthroscopic|
62180354|NCT03895697|EXPERIMENTAL|Dasiglucagon batch A crossover to dasiglucagon batch B|V2: Single fixed dose (subcutaneous injection) of dasiglucagon batch A then at V3: Single fixed dose (subcutaneous injection) of dasiglucagon batch B
62180355|NCT03895697|EXPERIMENTAL|Dasiglucagon batch B crossover to dasiglucagon batch A|V2: Single fixed dose (subcutaneous injection) of dasiglucagon batch B then at V3: Single fixed dose (subcutaneous injection) of dasiglucagon batch A
62180356|NCT00027976|EXPERIMENTAL|Group 1 active arm|receipt of active drug
62180357|NCT00027976|EXPERIMENTAL|Group 2 active arm|receipt of active drug
62180358|NCT00027976|EXPERIMENTAL|group 2 placebo arm|receipt of placebo
61995263|NCT05478070|OTHER|Dexcom CGM|Proof of concept randomized study to evaluate the utility of Dexcom-G6 continuous glucose monitors for assessment of glycemic control in pregnant and postpartum women with insulin-requiring diabetes mellitus during hospitalizations
61995264|NCT02990169|ACTIVE_COMPARATOR|Goldmann Tonometer|determine if the CATS tonometer prism effectively reduces sensitivity to IOP errors produced by corneal thickness and therefore provides a more accurate IOP reading compared to the reference tonometer (Goldmann prism), based upon the correction value table for Goldmann tonometer prism
61995265|NCT02990169|ACTIVE_COMPARATOR|CATS tonometer|determine if the CATS tonometer prism effectively reduces sensitivity to IOP errors produced by corneal thickness and therefore provides a more accurate IOP reading compared to the reference tonometer (Goldmann prism), based upon the correction value table for Goldmann tonometer prism
62563818|NCT04503148|EXPERIMENTAL|TIVA group|Patients receiving the total intravenous anesthesia using propofol
62563819|NCT04503148|ACTIVE_COMPARATOR|inhalation group|Patients receiving inhalation anesthesia using sevoflurane or desflurane
62563820|NCT03857646|OTHER|Intralipid|
62563821|NCT03857646|OTHER|SMOF lipid|
62563822|NCT00489957||Normals|
62563823|NCT00489957||Cardiomyopathy|
62563824|NCT05435027|EXPERIMENTAL|GRT-R914, HIV-negative (Part A)|Participants in this ≥18 to 65-year-old Part A are naïve to SARS-CoV-2 (Cohorts A1, A2, and A3) or SARS-CoV-2 convalescent (Cohorts A4, A5, A6). Cohorts will receive doses of GRT-R914 administered as prime and boost on Days 1 and Day 29, or as boost 6 months after primary SARS-CoV-2 infection.
62563825|NCT05435027|EXPERIMENTAL|GRT-R912, HIV-negative (Part B)|Participants in this ≥18 to 65-year-old Part B are naïve to SARS-CoV-2 (Cohorts B1, B2) or SARS-CoV-2 convalescent (Cohorts B3, B4). Cohorts will receive doses of GRT-R912 administered as prime and boost on Days 1 and 29, or as boost 6 months after primary SARS-CoV-2 infection. Parts B, C, and D will be run in parallel.
62563826|NCT05435027|EXPERIMENTAL|GRT-R912 or GRT-R914, People Living with HIV (PLWH) (Part C)|Participants in this ≥18 to 65-year-old Part C are people living with HIV but naïve to SARS-CoV-2 (Cohorts C1, C4) or living with HIV but SARS-CoV-2 convalescent (Cohorts C2, C3, C5, C6). Cohorts will receive doses of GRT-R912 or GRT-R914 administered as prime and boost on Days 1 and 29, or as boost 6 months after primary SARS-CoV-2 infection. Parts B, C, and D will be run in parallel.
62563827|NCT05435027|EXPERIMENTAL|GRT-R918, HIV-negative and PLWH, With and Without Prior Vaccination (Part D)|Participants will be ≥18 and \<60 years or ≥60 years, HIV-Negative and PLWH with no prior vaccination to SARS-CoV-2 (Cohorts D1, D2, D5, D6) or with prior vaccination to SARS-CoV-2 (Cohorts D3, D4, D7, D8). Cohorts will receive doses of GRT-R918 administered as prime and boost on Days 1 and 29, or as boost ≥2 months after prior SARS-CoV-2 vaccination. Parts B, C, and D will be run in parallel.
62563828|NCT01699009|EXPERIMENTAL|Vegan diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks.
62563829|NCT01699009|PLACEBO_COMPARATOR|Supplement group|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
62180359|NCT03000647|ACTIVE_COMPARATOR|Guided Pelvic floor exercises|Pelvic floor exercises guided by a physiotherapist
62180360|NCT03000647|ACTIVE_COMPARATOR|Non-guided pelvic floor exercises|Pelvic floor exercises not guided
62180361|NCT00853736|EXPERIMENTAL|A|Oxycodone hydrochloride tablet 30 mg
62180362|NCT00853736|ACTIVE_COMPARATOR|B|Roxicodone™ tablet 30 mg
62563830|NCT04781803|EXPERIMENTAL|Arm 1|Cyclosporine 6 mg/kg orally divided into two doses per day starting in the morning on day 0 after transplantation, mycophenolic acid 1 gram orally (2 tablets 500 mg) from day 0 post-transplant and PT-CY at 50 mg/kg per day on day +3 and +4.
62563831|NCT04781803|NO_INTERVENTION|Arm 2|Cyclosporine 6 mg/kg orally divided into two doses per day starting in the morning on day +5 of the transplant, mycophenolic acid 1 gram orally (2 tablets of 500 mg) from day +5 post-transplant and post-transplant cyclophosphamide (PT-CY) at 50 mg/kg per day on days +3 and +4
62563832|NCT05143060|EXPERIMENTAL|Cereal fiber powder|Cereal fiber powder
61995266|NCT04489706|EXPERIMENTAL|P53 mutation arm|patients of recurrent and metastatic ovarian cancer and endometrial cancer associated with P53 mutation
62563833|NCT05143060|PLACEBO_COMPARATOR|Pure glucose powder|Pure glucose powder
62563834|NCT05522192|EXPERIMENTAL|Venetoclax-Mitoxantrone liposome|"Phase I~Mitoxantrone liposome~* Level 1: 24mg/m\^2, ivgtt, d1;~* Level 2: 30mg/m\^2, ivgtt, d1;~* Level 3: 36mg/m\^2, ivgtt, d1;~Venetoclax: 100mg po d1, 200mg po d2, 400mg po d3-28.~Every 4 weeks is a cycle, a total of 2 cycles, the first cycle to observe DLT.~Phase II~Mitoxantrone liposome: RP2D~Venetoclax: 100mg po d1, 200mg po d2, 400mg po d3-28.~28 days is a cycle, and a maximum of 6 cycles can be carried out. If the patient achieves CR, CRi or PR, if the patient can tolerate it, it will be used for 6 cycles; if the patient is suitable for transplantation, it can also enter the transplantation path; If the patient was evaluated as NR (no response) after 2 cycles, he could withdraw from the study."
62563835|NCT05794100|ACTIVE_COMPARATOR|Test 1|No-sugar chewable candy containing Soluble Corn Fiber + Inulin + Allulose provided at a dose of 1 serving equivalent
62180363|NCT01975636|EXPERIMENTAL|E2609|Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
62180364|NCT03025997|ACTIVE_COMPARATOR|Active yoghurt|Yoghurt snack containing encapsulated lipid
62180365|NCT03025997|PLACEBO_COMPARATOR|Placebo yoghurt|"Yoghurt snack containing non-encapsulated lipid~+ empty encapsulation matrix"
62563836|NCT05794100|ACTIVE_COMPARATOR|Test 2|No-sugar chewable candy containing Soluble Corn Fiber + Inulin + Allulose provided at a dose of 1.75 serving equivalent
62563837|NCT05794100|ACTIVE_COMPARATOR|Test 3|No-sugar chewable candy containing Soluble Corn Fiber + Inulin + Allulose provided at a dose of 2.5 serving equivalent
62563838|NCT05794100|ACTIVE_COMPARATOR|Test 4|No-sugar chewable candy containing Soluble Corn Fiber + Inulin + FOS provided at a dose of 1 serving equivalent
61995267|NCT01589081|ACTIVE_COMPARATOR|Female Smokers (Luteal Phase)|
62391249|NCT02207413|ACTIVE_COMPARATOR|Influsplit Tetra_LP Adult Group|Subjects in the Influsplit Tetra_LP aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by currently licensed process (LP) at Day 0. Influsplit Tetra™ vaccine produced by currently LP was administered intramuscularly in the deltoid region of left or non-dominant arm.
62563839|NCT05794100|ACTIVE_COMPARATOR|Test 5|No-sugar chewable candy containing Soluble Corn Fiber + Inulin + FOS provided at a dose of 1.75 serving equivalent
61995268|NCT01589081|ACTIVE_COMPARATOR|Female Smokers (Follicular Phase)|
61995269|NCT01901003|PLACEBO_COMPARATOR|placebo group|placebo
61995270|NCT01901003|ACTIVE_COMPARATOR|no premedication group|no premedication
61995271|NCT01901003|EXPERIMENTAL|Lorazepam group|lorazepam
62563840|NCT05794100|ACTIVE_COMPARATOR|Test 6|No-sugar chewable candy containing Soluble Corn Fiber + Inulin + FOS provided at a dose of 2.5 serving equivalent
62563841|NCT05794100|ACTIVE_COMPARATOR|Test 7|No-sugar chewable candy containing Maltitol + Polydextrose provided at a dose of 1 serving equivalent
62563842|NCT05794100|ACTIVE_COMPARATOR|Test 8|No-sugar chewable candy containing Maltitol + Polydextrose provided at a dose of 1.75 serving equivalent
62563843|NCT05794100|ACTIVE_COMPARATOR|Test 9|No-sugar chewable candy containing Maltitol + Polydextrose provided at a dose of 2.5 serving equivalent
62563844|NCT05794100|PLACEBO_COMPARATOR|Test 10|Control chewable candy made with sugar and provided at a dose of 1 serving equivalent
62563845|NCT05990374|ACTIVE_COMPARATOR|Dulaglutide|Once a week, subcutaneous injection
62563846|NCT05990374|ACTIVE_COMPARATOR|semaglutide|Once a week, subcutaneous injection
62180366|NCT05810441||Typical celiac disease|"* symptomatic subjects (gastro-intestinal or extra-intestinal symptoms) tested positive for serum anti-ttg concentrations and with pathological intestinal biopsy;~* symptomatic and asymptomatic subjects at risk of CD (first-degree relatives of CD patients or subjects with autoimmune disorders) tested positive serum CD antibodies and with atrophic intestinal mucosa"
62180367|NCT05810441||Potential celiac disease|Symptomatic subjects tested positive for both serum CD antibodies and anti-ttg-m but with normal intestinal mucosa
62563847|NCT05990374|ACTIVE_COMPARATOR|Loseenatide|Once a week, subcutaneous injection
62563848|NCT05990374|ACTIVE_COMPARATOR|tirzepatide|Once a week, subcutaneous injection
62563849|NCT05990374|ACTIVE_COMPARATOR|elbenatide|Once a week, subcutaneous injection
62180368|NCT05810441||Control group|Adult and pediatric subjects with inflammatory gastro-intestinal disorders (Crohn disease and ulcerative colitis in acute phase or in remission), oncologic diseases (tumors of the gastro intestinal tract) and infectious diseases (eg Helicobacter pylori gastritis) tested negative for serum anti-ttg
62180369|NCT05938478||Tralokinumab-Exposed Cohort|Pregnant women with AD exposed to tralokinumab anytime during pregnancy, or within 16 weeks before conception
62180370|NCT05938478||AD Cohort- Phototherapy or Systemic Treatment Exposed|Pregnant women with AD who have not been exposed to tralokinumab, but who have been exposed to phototherapy or systemic therapy for the treatment of AD during pregnancy
62180371|NCT05938478||AD Cohort - With or Without Treatment|Pregnant women with AD who may or may not have received treatment for AD, but who have not been exposed to any dose of tralokinumab, phototherapy or systemic therapy during pregnancy
62563850|NCT05990374|ACTIVE_COMPARATOR|original treatment|Once a week, subcutaneous injection
62563851|NCT05990374|PLACEBO_COMPARATOR|placebo|The patients will be treated according to the original protocol
62563852|NCT06478121||Case with confirmed disease-causing genetic change|"Cases with confirmed disease-causing genetic change that results in beta cells not working properly.~Consent, collection of clinical data and blood samples, MRI (optional)"
62563853|NCT06478121||Control (without the variant of interest)|Sex-matched controls with similar age and BMI (age +/-15%, BMI +/- 3 kg/m2). Consent, collection of clinical data and blood samples, MRI (optional)
62563854|NCT03778346|EXPERIMENTAL|CAR-T therapy in multiple myeloma|In order to assess the safety and validity of using the Fourth Genenation of CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD38-CART , Integrin β7-CART or 10 different combinations ,subjects will receive 10\^6-10\^7/Kg transduced CAR-T cells at one time.
62563855|NCT01164020|PLACEBO_COMPARATOR|placebo control|this only receives placebo (dextrose)
62563856|NCT01164020|EXPERIMENTAL|placebo and exercise|this is trained and receives placebo
62180372|NCT05938478||Tralokinumab-Exposed Case Series|Pregnant women with AD exposed to tralokinumab anytime during pregnancy, or within 16 weeks before conception, who don't meet the eligibility criteria for the tralokinumab-exposed cohort group
62180373|NCT06172998|NO_INTERVENTION|healthy subject|
62180374|NCT06172998|NO_INTERVENTION|low BPV group|
62180375|NCT06172998|EXPERIMENTAL|high BPV group|
62180376|NCT03432650|EXPERIMENTAL|QLB Block + Standard of Care|"Patients will receive either a spinal (4cc Mepivacaine) or combined spinal epidural anesthetic (dose up 50 5 cc 2% lidocaine) with IV sedation. Intraoperative anti-emetics will consist of IV ondansetron and IV dexamethasone. Intra-operative analgesics will be IV fentanyl, IV acetaminophen, IV ketorolac, and IV ketamine. No Block will be given.~Patients will receive a single shot anterior QLB (30cc 0.5% Bupivacaine with 2mg preservative free dexamethasone)."
62563857|NCT01164020|EXPERIMENTAL|creatine supplementation|this is non-exercise trained and receives creatine supplementation
62563858|NCT01164020|EXPERIMENTAL|Creatine and Exercise|this is exercised trained and receives creatine supplementation
62563859|NCT03447587|EXPERIMENTAL|Electroacupuncture|Subjects will receive 4 weeks of acupuncture following with a semi-standardized protocol.
62563860|NCT03447587|PLACEBO_COMPARATOR|Sham acupuncture group|Subjects will receive sham acupuncture with the same sterilization procedure as traditional acupuncture group.
62563861|NCT01329380||Adalimumab|Participants with ankylosing spondylitis (AS) receiving treatment with adalimumab (Humira) as prescribed by their physician.
62563862|NCT02905240|EXPERIMENTAL|nSTRIDE APS|Autologous Protein Solution prepared using the nSTRIDE APS Kit
62563863|NCT02905240|OTHER|Saline|Saline control
62563864|NCT06301542||In-laboratory|Patients will be brought to the laboratory for functional electrical stimulation mobility assessment.
62563865|NCT06301542||In-home|Patients will undergo functional electrical stimulation mobility assessment in their home.
62563866|NCT06436976|EXPERIMENTAL|LT-002 (Lactobacillus reuteri ATG-F4) arm|The group that will be consuming probiotics (LT-002 (Lactobacillus reuteri ATG-F4)) for 12 weeks. The subjects will take a daily intake of 4 x 10\^10 colony forming unit (CFU) of LT-002.
62563867|NCT02593695|EXPERIMENTAL|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
62563868|NCT02593695|ACTIVE_COMPARATOR|Standard Control|Fluoxetine
62563869|NCT02166515||experiment group|patients with cervical cancer, endometrial cancers or ovary cancer
62563870|NCT02166515||control group|postmenopausal women with benign tumor
62563871|NCT03816020|ACTIVE_COMPARATOR|NR Group|Participants receiving Nicotinamide Riboside capsules, 500mg BI'D for 30 days
62563872|NCT03816020|PLACEBO_COMPARATOR|Placebo Group|Participant receiving Placebo BIDfor 30 days
62563873|NCT04608318|EXPERIMENTAL|I (Ibrutinib)|Ibrutinib p.o. will be administered until occurrence of unacceptable toxicity, progression of CLL or end of trial, whichever occurs first.
62563874|NCT04608318|EXPERIMENTAL|VG (Obinutuzumab + Venetoclax)|12 cycles (q 28d): Obinutuzumab i.v. + Venetoclax p.o. will be administered for 6 cycles, followed by 6 additional cycles of Venetoclax alone
62563875|NCT04608318|EXPERIMENTAL|VI (Venetoclax + Ibrutinib)|15 cycles (q 28d): Ibrutinib p.o. + Venetoclax p.o. will be administered for a total of 12 cycles with a prior Ibrutinib monotherapy lead-in of 3 cycles
62563876|NCT02017210||Lean/normal weight|Individuals with body mass index (BMI)\<25 kg/m\^2 in the baseline study
62563877|NCT02017210||Overweight/Obese Insulin-Sensitive|Individuals with BMI\>25kg/m\^2 who were deemed insulin-sensitive by the hyperinsulinemic -euglycemic clamp (with M/I value above median for men and women separately)
61995272|NCT02269462||Pregnant women - efavirenz|Pregnant women taking 600 mg efavirenz daily as part of combination antiretroviral therapy for PMTCT and for their own health
61995273|NCT02269462||Nursing mothers - efavirenz|Nursing mothers taking 600 mg efavirenz daily as part of combination antiretroviral therapy for PMTCT and for their own health and their breastfed babies
62180377|NCT03432650|NO_INTERVENTION|Standard of Care|Patients will receive either a spinal (4cc Mepivacaine) or combined spinal epidural anesthetic (dose up 50 5 cc 2% lidocaine) with IV sedation. Intraoperative anti-emetics will consist of IV ondansetron and IV dexamethasone. Intra-operative analgesics will be IV fentanyl, IV acetaminophen, IV ketorolac, and IV ketamine. No Block will be given.
61995274|NCT02269462||Pregnant women - nevirapine|Pregnant women taking 200 mg nevirapine twice daily as part of combination antiretroviral therapy for PMTCT and for their own health
61995275|NCT02269462||Nursing mothers - nevirapine|Nursing mothers taking 200 mg nevirapine twice daily as part of combination antiretroviral therapy for PMTCT and for their own health and their breastfed babies
62180378|NCT05226039|OTHER|Young adult group|One group will consist of 20 to 30 year olds. Participants will complete all three visits that include both the treatment (exercise visit) and the control (rest) visits. The treatment visit will consist of 20 minutes of moderate intensity aerobic exercise on a stationary bike.
62180379|NCT05226039|OTHER|Older adult group|The other group will consist of 60 to 70 year olds. Participants will complete all three visits that include both the treatment (exercise visit) and the control (rest) visits. The treatment visit will consist of 20 minutes of moderate intensity aerobic exercise on a stationary bike.
62563878|NCT02017210||Overweight/Obese Insulin-Resistant|Individuals with BMI\>25kg/m\^2 who were deemed insulin-resistant by the hyperinsulinemic -euglycemic clamp (with M/I value under median for men and women separately)
61995276|NCT04401891|NO_INTERVENTION|Routine Pre-Operative Education in MD office prior to surgery|
61995277|NCT04401891|EXPERIMENTAL|Formal Pre-operative education/therapy prior to surgery|
61995278|NCT04760158|EXPERIMENTAL|Taping group|A new star taping technique and exercises were applied to participants.
61995279|NCT04760158|SHAM_COMPARATOR|Sham Taping Group|Sham patellar taping and exercises were applied to participants.
61995280|NCT04760158|OTHER|control group|Only exercises were applied to participants.
61995281|NCT05834296|EXPERIMENTAL|Active|ALZN002 (autologous DCs pulsed with E22W mutant peptide).
61995282|NCT05834296|PLACEBO_COMPARATOR|Placebo|Saline ID and IV administrations.
61995283|NCT01772641|EXPERIMENTAL|Scheduled Gradual Reduction + Varenicline|Participants will be given the behavioral intervention of Scheduled Gradual Reduction along with the smoking cessation drug, Varenicline.
62180380|NCT05167032|EXPERIMENTAL|Cognitive Multisensory Rehabilitation (CMR) Group|"After the baseline testing, participants in the CMR group will receive 8 weeks of one-on-one, in-person therapy, 3 times a week, for 45 min. The CMR sessions will be recorded on video.~The participants will undergo clinical assessments and MRI scans at 3 time points: at baseline; a post-intervention after the first 8 weeks of CMR and a clinical assessment (no MRI) at 3 months."
62180381|NCT05167032|ACTIVE_COMPARATOR|Adaptive Fitness Group|"After the baseline testing, participants in the adapted fitness group will start with a fitness assessment and then complete a fitness program under supervision for 8 weeks, 3x/week, for 45 min. Staff at the Courage Kenny Rehabilitation Institute will monitor training adherence through a log sheet.~The participants will undergo clinical assessments and MRI scans at 3 times points: at baseline; a post-intervention after the first 8 weeks of adaptive fitness and a clinical assessment (no MRI) at 3 months."
62391250|NCT02207413|EXPERIMENTAL|Influsplit Tetra_IP 3-17y Group|Subjects in the Influsplit Tetra_IP group aged between 3 years to \<9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by investigational process (IP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by IP at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
62180382|NCT02487251|EXPERIMENTAL|Experimental: Phase 1 Usual Exposure|Participants receive no additional information about healthy eating, family mealtimes, nutrition education or meal planning beyond any usual coverage of these areas.
62180383|NCT02487251|EXPERIMENTAL|Experimental: Phase 1 Mealtime support activities|Participants will engage in mealtime support activities such as healthy eating classes, cooking demonstrations, provision of cookware, receipt of mealtime ingredients, receipt of prepared meals, make and eat meals).
62180384|NCT02487251|EXPERIMENTAL|Experimental: Phase 2- Usual Exposure|Participants receive no additional information about healthy eating, family mealtimes, nutrition education or meal planning beyond any usual coverage of these areas.
62180385|NCT02487251|EXPERIMENTAL|Experimental: Phase 2- Meal Delivery and Receipt of Cookware|Participants will receive two prepared meals weekly for 12 weeks and will receive a comprehensive set of cookware
62180386|NCT02107547|ACTIVE_COMPARATOR|Biceps tenodesis|32 subjects in the study will receive biceps tenodesis as a surgical intervention
62563879|NCT01962610|EXPERIMENTAL|ePCA and Pain keycept intervention|Study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit
62563880|NCT01962610|NO_INTERVENTION|Usual Care|No study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit
62563881|NCT02915718|EXPERIMENTAL|experimental group|protein A immunoadsorption for 5 days
62563882|NCT02915718|NO_INTERVENTION|control group|non intervention
62563883|NCT03453775|ACTIVE_COMPARATOR|Ultrasound guided infiltration|"Ultrasound guided periradicular lumbar infiltration. Prone position. Lumbar spine level located in a median sagittal plane (spinous processes). High resolution curved 5MHz ultrasound probe. Probe is then rotated 90° for a median transverse image. Transverse plane translation towards desired side to have in the same plane: spinous process, vertebral blade, zygapophysial articulation, lateral facet, transverse process. Needle passes skin at 45° angle, directed in plane to the foramen. Fluoroscopy then performed to check needle's correct position. Poorly positioned needles will be replaced to obtain an intra-foraminal/epidural periradicular diffusion of the contrast medium. Once position is confirmed, Depomedrol 40mg + lidocaine 2% (1ml) is injected."
62563884|NCT03453775|ACTIVE_COMPARATOR|Fluoroscopy guided infiltration|"Fluoroscopy guided periradicular lumbar infiltration. Prone position. Anatomical identification by radioscopy: antero-posterior and sagittal planes. Needle placement in an anteroposterior view, needle is then advanced in an inclined plane of 20° with respect to the initial axis, tunnel vision type image. Foramen is then reached in a sagittal view (not to progress too far in the intra-foraminal level). Needle progression is secured by neurostimulation (territory concerned by the root, intensity 0.2 milliampere to be at a distance of 1mm from the nerve root). Once needle is in place, fluoroscopy is performed to verify correct positioning (Omnipaque 300mg/ml of Iohexol, 0.2 to 0.5ml). Once position confirmed, mixture Depomedrol 40mg + lidocaine 2% (1ml) is injected."
62563885|NCT03990467|EXPERIMENTAL|Patients treated by amikacin and piperacillin|ICU patient with a sepsis treated by amikacin and piperacillin/tazobactam
62563886|NCT04127279|EXPERIMENTAL|Enriched Cream|The enriched cream is self-administered and contains a blend of 4 essential oils, namely Juniperus phoenicea gum extract, Copaifera officinalis resin, Aniba rosaeodora wood oil and Juniperus virginiana oil.
62563887|NCT04127279|ACTIVE_COMPARATOR|Placebo Cream|Cream devoid of essential oils, self-administered
62563888|NCT01123811|EXPERIMENTAL|Cetuximab IF|Treatment with combination of Cetuximab and Irinotecan 5-FU
62563889|NCT00793871|EXPERIMENTAL|sunitinib|single agent sunitinib, single arm
62563890|NCT00949637|EXPERIMENTAL|Scouting curricular implementation|Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
62563891|NCT00949637|ACTIVE_COMPARATOR|Standard-care attentional control|Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
62563892|NCT00571142|ACTIVE_COMPARATOR|1|Renal disease
62563893|NCT00571142|ACTIVE_COMPARATOR|2|Without renal disease
62180387|NCT02107547|ACTIVE_COMPARATOR|Labral repair|32 subjects in the study will receive labral repair as a surgical intervention
62180388|NCT00796614|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo to tamsulosin hydrochloride via opened capsules every day for 14 weeks
62180389|NCT00796614|EXPERIMENTAL|Low dose|Participants received 0.001 - 0.002 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
62180390|NCT00796614|EXPERIMENTAL|Medium dose|Participants received 0.002 - 0.004 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
62180391|NCT00796614|EXPERIMENTAL|High dose|Participants received 0.004 - 0.008 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
62180392|NCT01198847|ACTIVE_COMPARATOR|Low intensity arm|Written information about a healthy lifestyle
62180393|NCT01198847|EXPERIMENTAL|High intensity arm|Lifestyle support (PA, sleep, food intake) using MI
62180394|NCT05494281|EXPERIMENTAL|Placebo|
62180395|NCT05494281|EXPERIMENTAL|Serratus anterior plane block|
62180396|NCT02109107|EXPERIMENTAL|Erchonia EZ6 Laser|The Erchonia EZ6 Laser is a 6 headed scanner composed of 6 independent 17 milliWatts (mW), 635 nanometer (nm) red laser diodes mounted in scanner devices. It is a variable frequency, pulsed wave laser device.
62180397|NCT01586533|EXPERIMENTAL|Zoenasa-1:4|
62180398|NCT01586533|ACTIVE_COMPARATOR|Mesalamine Enema|
62180399|NCT01231464|PLACEBO_COMPARATOR|placebo|vehicle placebo nasal spray
62563894|NCT03313180|EXPERIMENTAL|Nintedanib|"Patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) who took part in the parent trials 1199.214 (Nintedanib or Placebo) or 1199-0340 (Nintedanib). Patients continued in this trial and received Nintedanib 150 mg (milligram) twice daily (bid) unless they had reduced their dose to 100 mg bid trial medication (Nintedanib or Placebo) in the parent trial.~Patients receiving 100 mg bid trial medication at the end of the parent trial could receive either Nintedanib 100 mg bid or 150 mg bid at the discretion of the investigator."
62563895|NCT06084325||FND Patients|Group of patients with functional neurological disorders
62563896|NCT06084325||Healthy control|Age matched group control of healthy participant
62563897|NCT03751033|EXPERIMENTAL|BSS and DisCoVisc|Following lens removal and removal of all OVD from the anterior chamber during cataract surgery, the chamber will be filled with BSS and the main incision hydrated with BSS. Intraoperative aberrometry, using the Optiwave® Refractive Analysis with VerifEye+ (ORA), will be performed, and the results of aphakic refraction and suggested IOL power will be recorded in triplicate. Immediately following, the BSS will be replaced with DisCoVisc; and, triplicate readings will be measured under the same conditions.
62563898|NCT03767153|EXPERIMENTAL|80 pin applicator|
62563899|NCT03767153|ACTIVE_COMPARATOR|160 pin applicator|
62180400|NCT01231464|EXPERIMENTAL|FFNS|fluticasone furoate nasal spray
62180401|NCT05082285|EXPERIMENTAL|ABCWY-2Gen low dose Group|Participants receive 3 doses of the MenABCWY-2Gen low dose vaccine.
62180402|NCT05082285|ACTIVE_COMPARATOR|MenB+MenACWY-TT Group|Participants receive 3 doses of both the meningococcal group B (MenB) vaccine and the meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine.
62180403|NCT05082285|EXPERIMENTAL|ABCWY-2Gen high dose Group|Participants receive 3 doses of the MenABCWY-2Gen high dose vaccine in.
62563900|NCT04944043|EXPERIMENTAL|TQ05105 Tablet|TQ05105 tablet 10mg given orally, twice daily in 28-cycle.
62563901|NCT00722137|ACTIVE_COMPARATOR|R-CHOP|Rituximab 375 mg/m\^2, Cyclophosphamide 750 mg/m\^2, Doxorubicin 50 mg/m\^2, Vincristine 1.4 mg/m\^2, and Prednisone 100 mg/m\^2
62563902|NCT00722137|EXPERIMENTAL|VcR-CAP|Rituximab 375 mg/m\^2, Cyclophosphamide 750 mg/m\^2, Doxorubicin 50 mg/m\^2, VELCADE 1.3 mg/m\^2, and Prednisone 100 mg/m\^2
62563903|NCT06219811|EXPERIMENTAL|Mandibular implant-retained overdenture reinforced with a Co-Cr framework|The patient received a mandibular implant-retained acrylic overdenture reinforced with a Co-Cr framework. The framework is manufactured by milling polymethylmethacrylate (PMMA) and then the PMMA undergo conventional casting to produce cobalt chromium (Co-Cr) framework. The framework included in the overdenture by conventional processing technique.
62563904|NCT06219811|ACTIVE_COMPARATOR|Mandibular implant-retained overdenture reinforced with a PEKK framework|The patient received a mandibular implant-retained acrylic overdenture reinforced with a Polyetherketoneketone (PEKK) framework. The framework is manufactured by milling PEKK the framework included in the overdenture by conventional processing technique.
62563905|NCT03351608|EXPERIMENTAL|Sugammadex 2 mg/kg (Part A)|Single intravenous (i.v.) bolus of sugammadex at 2 mg/kg.
62563906|NCT03351608|EXPERIMENTAL|Sugammadex 4 mg/kg (Part A)|Single i.v. bolus of sugammadex at 4 mg/kg.
62563907|NCT03351608|EXPERIMENTAL|Sugammadex 2 mg/kg (Part B)|Single i.v. bolus of sugammadex at 2 mg/kg.
62180404|NCT05082285|EXPERIMENTAL|ABCWY-1Gen Group|Participants receive 3 doses of the MenABCWY-1Gen vaccine.
62563908|NCT03351608|EXPERIMENTAL|Sugammadex 4 mg/kg (Part B)|Single i.v. bolus of sugammadex at 4 mg/kg.
62180405|NCT02959177|EXPERIMENTAL|120 milligrams (mg) Galcanezumab|120 mg galcanezumab (LY2951742) administered subcutaneously (SC) once a month for 6 months.
62180406|NCT02959177|EXPERIMENTAL|240 mg Galcanezumab|120 mg galcanezumab (LY2951742) administered SC once a month for 6 months.
62180407|NCT02959177|PLACEBO_COMPARATOR|Placebo|Placebo administered SC once a month for 6 months.
62180408|NCT04339140|EXPERIMENTAL|Zafirlukast|Zafirlukast will be taken orally at a pre-determined dose 2x daily for 28 day cycle up to 1 year.
62180409|NCT04342598||Adult outpatient pulmonary MDR-TB patients|
62180410|NCT04342598||Household contact controls|
62180411|NCT04342598||Non-household contact controls|
62180412|NCT04137302|ACTIVE_COMPARATOR|Topical hydrocortisone administration|dermal cream (twice a day, 2.5 g of cream, 1% hydrocortisone during 5 days)
62180413|NCT04137302|ACTIVE_COMPARATOR|Systemic hydrocortisone administration|tablets (once a day, 50 mg, morning, during 50 days)
62180414|NCT04713176|EXPERIMENTAL|DWJ1248 with Remdesivir|Camostat mesylate 200 mg, Remdesivir
62180415|NCT04713176|PLACEBO_COMPARATOR|Placebo with Remdesivir|Placebo, Remdesivir
62180416|NCT03550183|EXPERIMENTAL|mesenchymal stem cells|Selected patients with Parkinson's disease were randomly divided into a therapy group and a control group. Umbilical Cord Derived Mesenchymal Stem Cells(UC-MSCs) at a dose of 10-20 million by intravenous infusion.Patients in the therapy group treated once a week with UC-MSCs. Each course of treatment Lasted 3 weeks.
62180417|NCT00903071|ACTIVE_COMPARATOR|REAL PPL|REAL+PPL profiles PCP performance using real electronic medical record derived data to identify each PCP's specific failures of decision making in HT care antecedent to the personalized learning intervention.
62180418|NCT00903071|ACTIVE_COMPARATOR|SIM PPL|SIM+PPL, profiles PCP performance using simulated cases to identify each PCP's specific failures of decision making in HT care antecedent to the personalized learning intervention.
62563909|NCT03351608|ACTIVE_COMPARATOR|Neostigmine (Part B)|Single i.v. bolus containing neostigmine (50 μg/kg; up to 5 mg maximum dose) in combination with either glycopyrrolate (10 μg/kg) or atropine sulfate (20 μg/kg).
62563910|NCT04579952|EXPERIMENTAL|Intervention Group|The IG will receive a 20 minute program of active tDCS (2mA intensity, anode placed on primary motor cortex controlateral to the TKA, cathode placed on controlateral supraorbital region) followed by a 30 minute exercise program, 5 days a week, for 2 consecutive weeks.
62563911|NCT04579952|PLACEBO_COMPARATOR|Control Group|The CG will receive a 20 minute program of sham tDCS (15 seconds of activation and then no stimulation, same position of IG) followed by the same 30 minute exercise program, 5 days a week, for 2 consecutive weeks.
62563912|NCT01268631|ACTIVE_COMPARATOR|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks. The assessing person will contact patients by phone every week during the treatment period to receive the pain score for the last 24 hours, so we will have an indication of the effect among patients will discontinue medication. Patients will be asked to visit the clinic during the last week of treatment, for assessment of clinical pain (questionnaires) and pain modulation.
62563913|NCT01268631|ACTIVE_COMPARATOR|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 4 weeks. Drug should not be taken with meals. Same protocol will be applied as for Duloxetine.
62563914|NCT05457686|EXPERIMENTAL|kinesiology group|In the group receiving kinesiology treatment, kinesiotaping is applied to the sub-knee region in accordance with the lymphatic correction technique from the first postoperative day to reduce edema and pain. Accordingly, the proximal part of the tape is placed close to the lymph node. In our study, as stated in the literature, the proximal part of the tape will be adhered to the fibular head area next to the lymph nodes without applying any stretching. Then 5-10% stretching is applied and the distal part is adhered. 2 separate bands are applied so that the strips cross each other (from the medial and lateral of the knee). On the first postoperative day, on the third day, the patients will be taped with kinesio tape and discharged on the fourth day. After discharge, they will be asked to remove the tapes after 3 days as they were taught.
62563915|NCT05457686|SHAM_COMPARATOR|sham taping group|Sham application will be taped with a plaster from the same area on the same days as the kinesio application. No tension will be applied while taping. The difference of the plaster from the kinesiotape is that it does not contain tension and does not allow stretching.
62563916|NCT05457686|OTHER|only physical therapy group(control group)|"Conservative will be explained on the second day after the operation. Go for a visit with a local cold application 20 times once a day. Ankle pumping exercises, deep breathing exercises, isometric and hip exercises will be planned with a load that can be applied to students who are being applied for bed training.~Increased the number and allowance of exercises; isotonic knee and exercises that make you feel It will be added. You will be discharged on the 4th day after the surgery on the 2nd or 3rd day. You will do home exercises after discharge. On the 10th day, you will be called for control."
62563917|NCT03977064|EXPERIMENTAL|Intensive treatment group|The intensive treatment group will pass a life-style intervention program including consequent escalation of measures to reach sustained reduction of 10% of initial body weight at minimum.
62563918|NCT03977064|NO_INTERVENTION|Standard treatment group|Patients will be taken care of by general physician without lifestyle program.
62563919|NCT04752852|EXPERIMENTAL|Dexamethasone|Patients with odd numbers were assigned to group A. 8 mg/2 ml dexamethasone was injected intravenously sixty minutes before the induction of anaesthesia
62563920|NCT04752852|PLACEBO_COMPARATOR|Placebo|Patients with even numbers were assigned to group B. Two millilitres (ml) normal saline (0.9%) was given intravenously 60 minutes before the induction of anaesthesia.
62563921|NCT03953976|EXPERIMENTAL|PET-CT at 3 months and ENT evaluation|Treatment to the gross primary and nodal disease (70 Gy), with suspicious nodes treated to 66.5 Gy, all in 35 fractions. CT and PET-CT are required for nodal assessment. Restaging PET-CT must be performed between 11-14 weeks from the completion of treatment. The patient must see an otolaryngologist after the PET-CT to decide on post-treatment neck dissection per the surgeon's judgement. Patients will then be seen every 3 months (+/- 2 weeks) for the first year, and then at least every 6 months (+/-2 weeks) until the 36 month. Subsequent and intervening follow-up visits will be made per physician preference
62563922|NCT03870880|EXPERIMENTAL|Risperidone ISM 75 mg|"Patients assigned to this arm will receive 75 mg of Risperidone ISM during the open label extensión (OLE).~Patients enter the study as rollover patients from the study NCT03160521, along with newly enrolled de novo patients."
62563923|NCT03870880|EXPERIMENTAL|Risperidone ISM 100 mg|"Patients assigned to this arm will receive 100 mg of Risperidone ISM during the open label extensión (OLE).~Patients enter the study as rollover patients from the study NCT03160521, along with newly enrolled de novo patients."
62563924|NCT04291313|PLACEBO_COMPARATOR|Current recommended dose of vitamin D|Women in this study arm receive 10 µg of vitamin D3 per day, which is the dose in a standard prenatal multivitamin and the dose currently recommended by the Danish Health Authorities to all pregnant women. They will receive a prenatal vitamin containing 10µg of vitamin D + a placebo supplement.
62563925|NCT04291313|EXPERIMENTAL|Higher dose of vitamin D|Women in this arm receive 90µg of vitamin D3 per day: 10 µg from a standard prenatal multivitamin + an additional supplement containing 80µg of vitamin D3.
62563926|NCT05845632||Short time to treatment (<30 days)|Patients with high-risk HNcSCC with a time to treatment (date of pathological diagnosis to date of start treatment) of less than 30 days.
62563927|NCT05845632||Long time to treatment (30 days or more)|Patients with high-risk HNcSCC with a time to treatment (date of pathological diagnosis to date of start treatment) of 30 days or more.
62563928|NCT02250898|EXPERIMENTAL|Experimental/Myofascial|The intervention group will receive Myofascial Massage Therapy specific to breast/chest/shoulder of the affected side(s). These massages will include a variety of techniques specifically aimed at reducing pain, inflammation, and tissue sensitivity while also increasing mobility by breaking up scar tissue and thick fibrosis. The intervention massages will include the following specific techniques: skin glide, j stroking, vertical stroking, strumming, fascial stretch, circular friction, deep fascial restriction release, arm pull, side latissimus dorsi stretch, twisting, moist heat application, cold therapy, and lymphatic drainage. These massages will be twice a week at 30 minutes per massage for a period of 2 months after study enrollment.
62563929|NCT02250898|ACTIVE_COMPARATOR|Control/Global Relaxation|The control group will receive a general full body massage referred to as a Global Relaxation massage. The massage technique used here will be relaxation massage, avoiding the breast/chest/arm area. This includes light kneading and stroking in order to restore a sense of well- being. The relaxation massage will also be twice a week at 30 minutes per massage for a period of 2 months, avoiding the area of the affected shoulder/shoulders. In this way they are still being seen and touched by a massage therapist, without receiving the intervention treatment.
62563930|NCT06576973|EXPERIMENTAL|Adbelimumab, chemotherapy and apatinib|Preoperative neoadjuvant therapy for 4 cycles. Radical surgery is performed 4-6 weeks after the last dose. Postoperative radiotherapy is determined according to the clinical situation and pathological stage of the patient. Adbelimumab can be aintained for a maximum of 1 year. During the study, patients were be followed until disease progression, withdrawal of informed consent, loss of follow-up, or death.
62563931|NCT04538781||Same Day Discharge|Patients undergoing a-fib ablation procedures who were closed with VASCADE MVP and were discharged the same day.
62563932|NCT06545539|EXPERIMENTAL|Fall Preparedness Class Participants|Participants who meet inclusion and exclusion requirements of the study and sign an informed consent.
62563933|NCT02842710|EXPERIMENTAL|GeneXpert®|Detection is carried out after a sample within the patient's nasal cavity. The swab containing the sample is placed in the PLC GeneXpert® Cepheid . The analysis takes one hour . The results leave automatically.
62563934|NCT04369274|EXPERIMENTAL|Interventional|All subjects will briefly be placed on the automated BVM compressor device. Measurements obtained while on this device will be compared to those obtained in the same subject prior to mechanical ventilation and while on a conventional ventilator.
62563935|NCT06456775|EXPERIMENTAL|Single arm|All participants in the study received a supported self-management intervention for depression delivered from distance.
62563936|NCT03979482||PAH patients|Male and female subjects, aged between 20 and 60 years old. Absence of obesity/diabètes. PAH patients presenting with metabolic syndrome (MS).
62563937|NCT03979482||Sedentary healthy patients|Male and female subjects, aged between 20 and 60 years old. Absence of obesity/diabètes. Healthy but sedentary subjects.
62563938|NCT01882959||Placebo|
62563939|NCT01882959||Intervention|Radiofrequncy Denervation
62563940|NCT04698044||Healthy|Have not chronic disease
62563941|NCT04698044||Cancer|Have cancer
62563942|NCT04698044||Non-Cancer Crhronic Disease|Have non-cancer chronic disease
62563943|NCT02355639|EXPERIMENTAL|Clobetasol propionate 0.05 % ointment|Active drug
62563944|NCT02355639|EXPERIMENTAL|Betamethasone dipropionate 0.064 % ointment|Active drug
62563945|NCT02355639|PLACEBO_COMPARATOR|Petrolatum ointment|Placebo drug
62563946|NCT01807754||Imaging scans for breast cancer screening|"To simulate the performance of the combination of three new breast imaging systems to digital mammography and hand-held ultrasound that are currently used to find and evaluate breast masses.~These three different systems make images of the breast in several ways to find breast masses and to distinguish normal and abnormal masses. This may result in less unnecessary call-backs from mammography."
61995284|NCT01772641|EXPERIMENTAL|Scheduled Gradual Reduction + Placebo Drug|Participants will be given the behavioral intervention, SGR, along with a placebo drug matching the schedule of the VN group.
62563947|NCT00563693|EXPERIMENTAL|A|The patients use ASV
62563948|NCT00563693|ACTIVE_COMPARATOR|B|Patients without ASV
62563949|NCT00879307|EXPERIMENTAL|1|Use of quetiapine
62563950|NCT02996227|EXPERIMENTAL|TAP block with Exparel|Bilateral Transversus Abdominis Plane (TAP) block procedure following injection of liposomal bupivacaine (Exparel)
62563951|NCT02996227|ACTIVE_COMPARATOR|Epidural analgesia with Bupivacaine|Epidural catheters with an infusion of Bupivacaine standard solution without additives
62563952|NCT04158167|OTHER|oxytocin|All subjects will receive both oxytocin and placebo in a counterbalanced design
62563953|NCT02857816|OTHER|NURO System PTNM Therapy|Subjects will undergo 12 PTNM therapy sessions, administered weekly, utilizing the NURO system.
62563954|NCT02247778|ACTIVE_COMPARATOR|conventional plate osteosynthesis|Standard procedure
62563955|NCT02247778|ACTIVE_COMPARATOR|mini-incision-type osteosynthesis|mini-incision
62563956|NCT00391768|EXPERIMENTAL|oseltamivir (Tamiflu®)|
62563957|NCT02042157|EXPERIMENTAL|Bidet use|This arm will have a bidet installed in their home bathroom and be instructed how to use it. This arm will use the bidet for usual toileting for a period of two years.
62563958|NCT02042157|PLACEBO_COMPARATOR|Usual Toileting|This group will toilet as usual.
62563959|NCT02042157|EXPERIMENTAL|Caregivers of PT in Arm 1 (bidet use)|"Participants with functional impairment will be randomized into one of two arms (bidet use or usual toileting). Their caregivers will be enrolled and their randomization is bundled with the study participant who they care for. This arm will care for participants who have been randomized to bidet."
61995285|NCT01772641|EXPERIMENTAL|Basic Advice + Varenicline|Participants will be given basic advice about quitting smoking along with the smoking cessation drug Varenicline
61995286|NCT01772641|PLACEBO_COMPARATOR|Basic Advice + Placebo Drug|Participants will be given basic advice along with a placebo drug matching the schedule of the VN group.
62563960|NCT02042157|PLACEBO_COMPARATOR|Caregivers of PT in Arm 2 (usual toileting)|"Participants with functional impairment will be randomized into one of two arms (bidet use or usual toileting). Their caregivers will be enrolled and their randomization is bundled with the study participant who they care for. This arm will care for participants who have been randomized to usual toileting."
62563961|NCT03751098|OTHER|1-TR/PE, 2-Placebo, 3-Placebo|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the designated treatment in each eye.
62563962|NCT03751098|OTHER|1-Placebo, 2-Placebo, 3-TR/PE|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the designated treatment in each eye.
61995287|NCT03551210|EXPERIMENTAL|Nemonoxacin|"Nemonoxacin solution for infusion, 500 mg (250 ml), daily, as single intravenous infusion over 90-110 minutes followed by infusion of Placebo (100 ml), solution for infusion, over a minimum duration of 60 minutes.~Then will be switched to oral therapy with Nemonoxacin capsules, 500 mg once daily (two 250 mg capsules)."
62563963|NCT01011816|EXPERIMENTAL|BIOSTAT BIOLOGX|One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc
62563964|NCT01011816|PLACEBO_COMPARATOR|Saline|One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc
62563965|NCT01294774|EXPERIMENTAL|KRP203 - 1.2 mg|
62563966|NCT01294774|PLACEBO_COMPARATOR|Placebo to KRP203 - 1.2 mg|
62563967|NCT01699373|EXPERIMENTAL|Ultrasound-assisted|Pre-procedural ultrasound scan performed
62563968|NCT01699373|NO_INTERVENTION|Manual Palpation|
62563969|NCT02359955|EXPERIMENTAL|Zero-Degree Teeth, then Anatomic Teeth|edentulous patients who were first treated with zero-degree teeth complete denture, then with anatomic teeth complete denture
61995288|NCT03551210|ACTIVE_COMPARATOR|Tavanic®|"Tavanic® solution for infusion, 500 mg (100 ml), daily, as single intravenous infusion over a minimum duration of 60 minutes with previous infusion of Placebo (250 ml), solution for infusion, over 90-110 minutes.~Then will be switched to oral therapy with Tavanic®, over-encapsulated film coated tablets, 500 mg once daily (two capsules each containing 250 mg film coated tablet)."
62180419|NCT00903071|NO_INTERVENTION|Control|No intervention -control group
62563970|NCT02359955|EXPERIMENTAL|Anatomic Teeth, then Zero-Degree Teeth|edentulous patients who were first treated with anatomic teeth complete denture, the with zero degree teeth complete denture
62563971|NCT04104503|EXPERIMENTAL|Part A|
62563972|NCT04104503|EXPERIMENTAL|Part B group 1|"Treatment period 1: Fasted + iv;~Treatment period 2: Fasted;~Treatment period 3: High-fat meal"
62563973|NCT04104503|EXPERIMENTAL|Part B group 2|"Treatment period 1: High-fat meal;~Treatment period 2: Fasted + iv;~Treatment period 3: Fasted"
62563974|NCT04104503|EXPERIMENTAL|Part B group 3|"Treatment period 1: Fasted;~Treatment period 2: High-fat meal;~Treatment period 3: Fasted + iv"
62563975|NCT03700983|EXPERIMENTAL|Nutri-PEITC jelly|a single serving of 200 g Nutri-PEITC jelly
62563976|NCT04456777|EXPERIMENTAL|1group|patients with vortioxetine
62563977|NCT04456777|PLACEBO_COMPARATOR|2 group|patients without vortioxetine
62563978|NCT05457023||Collegiate Women Soccer Players|National Collegiate Athletic Association (NCAA) players.
62563979|NCT06307886||patients diagnosed with endometrium cancer|
62563980|NCT03842917||Patient starting bevacizumab treatment for cancer|Taken biological samples (urine and blood) and blood pressure measurement on patients starting bevacizumab treatment for cancer
62563981|NCT04487613|ACTIVE_COMPARATOR|Moringa oleifera leaf|Participants received Moringa oleifera leaf 450 mg capsule orally twice daily for 3 days.
62563982|NCT04487613|PLACEBO_COMPARATOR|Placebo|Participants received placebo capsule orally twice daily for 3 days.
62563983|NCT01946620|EXPERIMENTAL|Flutiform 250/10 micrograms|Flutiform 250/10 µg (2 puffs twice daily)
62563984|NCT01946620|EXPERIMENTAL|Flutiform 125/5 micrograms|Flutiform 125/5 µg (2 puffs twice daily)
62563985|NCT01946620|ACTIVE_COMPARATOR|Formoterol 12 micrograms|Formoterol 12 µg 1 puff twice daily
62563986|NCT05206513|PLACEBO_COMPARATOR|Placebo|"Placebo dosed for 14 weeks (double-blind treatment period) followed by open-label valbenazine treatment.~Participants may opt to enter an open-label valbenazine treatment extension phase."
62563987|NCT05206513|EXPERIMENTAL|Valbenazine|"Valbenazine dosed for 14 weeks (double-blind treatment period) followed by open-label valbenazine treatment.~Participants may opt to enter an open-label valbenazine treatment extension phase."
62563988|NCT02670226|OTHER|Case group|The intervention, specific to the study, is to take samples at baseline on patients with Amyotrophic Lateral Sclerosis
62563989|NCT02670226|OTHER|Control group|The intervention, specific to the study, is to take samples at baseline on patients without neurological disease
62563990|NCT01047566|EXPERIMENTAL|Addition of dronedarone|Addition of Dronedarone to existing rate control medication (beta blocker and/or calcium antagonist)
61995289|NCT03289507|ACTIVE_COMPARATOR|Treatment1|Longvida Capsule formulation A
61995290|NCT03289507|ACTIVE_COMPARATOR|Treatment 2|Longvida Capsule formulation B
61995291|NCT03289507|EXPERIMENTAL|Treatment3|Curcuma longa extract of Rhizomes
61995292|NCT04664504|ACTIVE_COMPARATOR|Group CRT|concurrent chemoradiotherapy → TME → adjuvant chemotherapy (control group)
61995293|NCT04664504|EXPERIMENTAL|Group SCRT|Short-course radiotherapy→ consolidation chemotherapy → TME (experimental group)
62180420|NCT05583708|EXPERIMENTAL|Experimental: Pembrolizumab + Lutetium Lu177|"All patients will receive pembrolizumab once every 6 weeks + Lutetium Lu177 dotatate once every 2 months~Pembrolizumab Cycle=6 weeks (for up to 2 years) Lutetium Lu177 dotatate Cycle=2 months (4 doses total)"
62180421|NCT02108626|ACTIVE_COMPARATOR|E-Cigarette with nicotine|Electronic cigarette with cartridge fluid containing nicotine
62180422|NCT02108626|PLACEBO_COMPARATOR|E-Cigarette without nicotine|Electronic cigarette with cartridge fluid containing no nicotine (placebo)
62563991|NCT01047566|ACTIVE_COMPARATOR|Dose Increase|Dose increase of existing rate control medication (beta blocker or calcium antagonist or digoxin)
62563992|NCT02913677|ACTIVE_COMPARATOR|group 1|prolonged minimal enteral nutrition
62563993|NCT02913677|PLACEBO_COMPARATOR|group 2|slowly advancing enteral nutrition
62563994|NCT00349219|EXPERIMENTAL|1|erlotinib followed at progression by gemcitabine and cisplatin
62563995|NCT00349219|ACTIVE_COMPARATOR|2|cisplatin and gemcitabine chemotherapy for 6 cycles, followed at progression by erlotinib
62563996|NCT04667637|PLACEBO_COMPARATOR|0.9% NaCl|Intravenous injections of 0.9% NaCl BID for 12 ±2days.
62563997|NCT04667637|EXPERIMENTAL|Edaravone Dexborneol|Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 12 ±2days.
62563998|NCT05066503|ACTIVE_COMPARATOR|Delirious subjects receiving active study product|Subjects will ingest an oral amino-acid containing nutritional supplement twice daily for up to 4 days.
62563999|NCT05066503|PLACEBO_COMPARATOR|Delirious subjects receiving placebo|Subjects will ingest a flavored, sweetened, inactive drink twice daily for up to 4 days.
62564000|NCT05066503|NO_INTERVENTION|Non-delirious control subjects who receive no intervention|Subjects receive no intervention and are observed for 2-3 days.
62564001|NCT04687969||COHORT A: PROSTATE CANCER PATIENTS|"Primary prostate cancer patients scheduled to undergo radical prostatectomy.~* Twenty five (25) prostate cancer patients will undergo two \[18F\]DCFPyL PET/MRI scans and~* Sixty (60) additional prostate cancer patients will undergo one \[18F\]DCFPyL PET/MRI scan."
62564002|NCT04687969||COHORT B: SOLID TUMOR PATIENTS|"Patients with known or suspected solid tumors (hepatocellular carcinoma, glioma, clear cell renal carcinoma).~Up to fifty (50) patients will undergo up to three \[18F\]DCFPyL PET/MRI scans"
62564003|NCT05889754||Hemophilia Group|The PedHAL questionnaire will be administered to children aged 4-17 years with a diagnosis of hemophilia twice, one week apart. For construct validity assessment, the questionnaire will be compared with the Hemophilia Functional Independence Score (HJHS).
62564004|NCT00852059|EXPERIMENTAL|Immediate release|Treatment with immediate release (IR) methylphenidate (Medikinet®) in the morning and 3-4 h later (twice a day)
62564005|NCT00852059|ACTIVE_COMPARATOR|Extended release|Treatment with extended release (ER) methylphenidate (Medikinet reatard®) applied with breakfast(once daily)
62564006|NCT02056223|EXPERIMENTAL|paracetamol|Boluses of intravenous paracetamol at 15 mg/Kg four time a day for three consecutive days.
61995294|NCT04664504|EXPERIMENTAL|Group es-SCRT|Local dose increase of Short-course radiotherapy→ consolidation chemotherapy → TME (experimental group)
62180423|NCT03158935|EXPERIMENTAL|Advanced metastatic melanoma (Cohort 1)|Cyclophosphamide and fludarabine followed by Tumor-Infiltrating Lymphocytes (TILs), Interleukin-2 (IL-2), and pembrolizumab
62180424|NCT03158935|EXPERIMENTAL|Advanced ovarian cancer (Cohort 2):|Cyclophosphamide followed by Tumor-Infiltrating Lymphocytes (TILs), Interleukin-2 (IL-2), and pembrolizumab
62180425|NCT02998619||Radiotherapy|Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes
62564007|NCT02056223|ACTIVE_COMPARATOR|Intravenous ibuprofen|Standard boluses of ibuprofen at 10-5-5-mg/Kg/dose once a day for three consecutive days.
62564008|NCT05058482|EXPERIMENTAL|Non-adhesive Liquid Embolic System(NALES)|
62564009|NCT05058482|ACTIVE_COMPARATOR|Onyx Liquid Embolic System& Marathon Flow Directed Micro Catheter|
62564010|NCT02188147|EXPERIMENTAL|SWD 1000|Short Term Wearable Defibrillator
62564011|NCT01045187|OTHER|endometrial cancer|Patients are treated with electronic brachytherapy for an FDA cleared indication.
62564012|NCT03563599|EXPERIMENTAL|Telacebec (Q203) tablet|
62564013|NCT03563599|ACTIVE_COMPARATOR|Rifafour e-275|
61995295|NCT03007511|EXPERIMENTAL|Fidmi|Placement of Fidmi enhanced enteral feeding device; internal tubes replacement during follow up and device removal after 3 month from placement Fidmi enhanced enteral feeding device
62564014|NCT01787292|EXPERIMENTAL|Stretching Exercise Intervention|A. Light stretching and balance exercises under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted to be under 50% of age-related maximum.
62564015|NCT01787292|EXPERIMENTAL|Aerobic Exercise Intervention|B. Interval aerobic cycling under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted between 50-85% of age-related maximum.
62564016|NCT01787292|EXPERIMENTAL|Self Monitoring Intervention|C. 6 month self-monitored training phase during which time participants will exercise using a take home bike ergometer.
62564017|NCT01146119|EXPERIMENTAL|Multimeric-001, Adjuvanted|64 subjects received 2 injections of Adjuvanted Multimeric-001, 500 mcg with an interval of 21 days and then 60 days later were further immunized with a 15% dose of commercial seasonal trivalent vaccine (season 2011).
61995296|NCT04585516||Patient with suspected colorectal cancer|All patients that were admitted to the department of surgery with suspected colorectal cancer between January 2016 and December 2018 (n=459).
61995297|NCT04585516||Patients admitted according to the standardized course of care for colorectal cancer|All patients that were admitted to the endoscopy department according to the standardized course of care for colorectal cancer between September 2016 and December 2018 (n=1271).
62564018|NCT01146119|ACTIVE_COMPARATOR|PBS and TIV 15%|32 subjects received 2 injections of PBS (Phosphate Buffered Saline) with an interval of 21 days and then were further immunized 60 days later with a 15% dose of commercial seasonal trivalent vaccine (season 2011).
62564019|NCT01146119|PLACEBO_COMPARATOR|Placebo, Adjuvanted|32 subjects received Adjuvanted PBS (Placebo) with an interval of 21 days.
62564020|NCT01146119|EXPERIMENTAL|Co-administration M-001 and TIV 15%|24 subjects received 2 injections on the same day, one injection containing Adjuvanted Multimeric-001 500 mcg and the other containing TIV 15%.
62564021|NCT01146119|EXPERIMENTAL|Co administration of M-001 and TIV 50%|24 subjects received 2 injections on the same day, one injection containing Adjuvanted Multimeric-001 500 mcg and the other containing TIV 50%.
62564022|NCT01146119|ACTIVE_COMPARATOR|Co administration of PBS and TIV 50%|24 subjects received 2 injections on the same day, one injection containing PBS and the other containing TIV 50%.
62564023|NCT06039501|EXPERIMENTAL|Family Perspective Program|"Families of critically ill patients will receive a program designed to enhance equitable communication and emotional support.~Questionnaires will be completed by primary surrogate decision makers, ICU support counselors, and ICU care team members (physicians, nurses, social workers). Meetings between families and ICU support counselors will be audio recorded (optional). Meetings between families and ICU care teams will be audio recorded (optional). Interviews with participants will be completed (optional)."
61995298|NCT04585516||Patients < 50 years that were admitted for gastroscopy|All patients younger than 50 years that were admitted to the endoscopy department for a gastroscopy between jan 2018 and April 2019 (n= 1915)
62180426|NCT02956083|ACTIVE_COMPARATOR|Lipid based artificial tears|Patients use lipid based artificial tears
62180427|NCT02956083|ACTIVE_COMPARATOR|Non-lipid based artificial tears|patients use non-lipid based artificial tears
62180428|NCT02956083|PLACEBO_COMPARATOR|Saline|patients use saline
62180429|NCT04728932|EXPERIMENTAL|Levosimendan|A continuous infusion of Levosimendan will be administered over 24 h, with no initial bolus. The starting infusion rate will be 0.15 µg/kg/min and will be increased to 0.20 µg/kg/min after 2 hours in the absence of rate-limiting side effects
62180430|NCT04728932|PLACEBO_COMPARATOR|Placebo|A continuous infusion of Placebo will be administered over 24 h, with no initial bolus. The starting infusion rate will be 0.15 µg/kg/min and will be increased to 0.20 µg/kg/min after 2 hours in the absence of rate-limiting side effects
62564024|NCT06039501|NO_INTERVENTION|Usual Care|"Families of critically ill patients will receive usual care, which involves regular and routine meetings between families and the ICU care team.~Questionnaires will be completed by primary surrogate decision makers and ICU care team members (physicians, nurses, social workers). Meetings between families and ICU care teams will be audio recorded (optional). Interviews with participants will be completed (optional)."
62564025|NCT03507634|ACTIVE_COMPARATOR|Opioid Based Anesthesia|General anesthesia will be induced using Propofol , fentanyl , and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with Remi-fentanyl and Sevoflurane.
62564026|NCT03507634|ACTIVE_COMPARATOR|Opioid Free Anesthesia|General anesthesia will be induced using dexmedetomidine and lidocaine started 10 minutes before induction, Propofol and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with IV infusion of dexmedetomidine , lidocaine and Sevoflurane.
62564027|NCT03306745|EXPERIMENTAL|Study group|"* 1 soft capsule/day containing 500mg omega-3 fatty acids~* one tablet/day containing 800mg folic acid, 70mg selenium, 30 mg Vitamin E, 4 mg catechin, 12 mg glycyrrhizin, and 30 mg coenzyme Q10"
62180431|NCT03955354|EXPERIMENTAL|experimental arm|SHR1210 plus apatinib
62180432|NCT02592707|EXPERIMENTAL|177Lu-IPN01072|177Lu-IPN01072 administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
62180433|NCT05229770|EXPERIMENTAL|Fruit smoothie|Participants randomised to the intervention arm will receive a 250 ml fruit smoothie as diet supplement for 20 weeks in addition to the regular OAT clinic follow-up. The fruit smoothies will be marketed products including combinations of the following fruits: apple, pineapple, mango, bananas, orange, blueberries, passion fruit, coconut, lime, and blackcurrant. The participants will receive a mixture of different smoothie types with the option of removing alternatives based on preferences. Fruit smoothie products will come in plastic bottles and will be delivered directly to the participants on a weekly basis. Each participant will receive a total of seven smoothie bottles per week with an oral agreement with each participant to consume one of these per day. Delivery of fruit smoothie will generally be given in parallel with delivery of OAT medication.
62180434|NCT05229770|NO_INTERVENTION|Standard|Participants randomised to standard treatment will receive regular OAT clinic follow-up without added supplementation.
62564028|NCT03306745|PLACEBO_COMPARATOR|Control group|200µg folic acid - two capsules per day
62564029|NCT04871776|EXPERIMENTAL|"Why messaging"|In this arm, patients will be sent an electronic patient portal message a few days in advance of their office visit. Messages will focus on reasons to get the COVID booster vaccine, including protecting self and loved ones or the idea of herd immunity.
62564030|NCT04871776|EXPERIMENTAL|"How messaging"|"In this arm, patients will be sent an electronic patient portal message a few days in advance of their office visit. How messages will focus on the details of obtaining a vaccination at MGB, what to expect, and how to prepare for the visit."
62564031|NCT04871776|ACTIVE_COMPARATOR|Usual Care|In this arm, patients will not receive any additional message about their upcoming visit, beyond what they already receive by the health system.
62564032|NCT04273113|EXPERIMENTAL|Heart Rate Variance (HRV) biofeedback training|Patients to participate in 15 biofeedback sessions, 3 times a week (5 weeks in total).
62564033|NCT01925729|EXPERIMENTAL|ragweed|ragweed -- 1000PNU intranasal spray
62564034|NCT01925729|EXPERIMENTAL|histamine|5 mg intranasal spray
62564035|NCT01925729|EXPERIMENTAL|pseudoephedrine|pseudoephedrine -- 60 mg orally
62564036|NCT01925729|EXPERIMENTAL|oxymetazoline|oxymetazoline 0.05% solution intranasal spray
62564037|NCT03295838|EXPERIMENTAL|Mentalization-based Treatment|MBT was conducted according to the treatment manual developed by Bateman \& Fonagy. Patients were offered individual sessions with a psychotherapist and group sessions with 6-8 participants and 1-2 group therapists for 18 months. An introductory psycho-educational component (9-12 sessions) was also offered focusing on explicit mentalising skills (i.e. understanding one's own or others' intentions). Group and individual MBT focused on implicit mentalising towards self and others.
62564038|NCT04182178||Gastroesophageal reflux|Laparoscopic total (Nissen) or posterior 270 degree (Toupét) partial fundoplication for the treatment of gastroesophageal reflux disease.
62564039|NCT02691052||Pts receiving nab-paclitaxel/gemcitabine|Patients with metastatic pancreatic cancer undergoing a firstline therapy with nab-paclitaxel and gemcitabine will be asked to fill in an EORTC QLQ-C30 questionnaire and an additional questionnaire on worries about quality of life impairments every 4 weeks. No further intervention.
62564040|NCT03228979|ACTIVE_COMPARATOR|Structured Semi-Interactive Prevention|The intervention arm will receive a Structured Semi-Interactive Stroke Prevention Package including patient workbook, short messaging services and health education videos for a period of one-year in addition to standard of care as per current guidelines
62564041|NCT03228979|NO_INTERVENTION|Control group|Patients will receive standard post stroke care for 1 year
62564042|NCT04464174|EXPERIMENTAL|Ipatasertib plus capecitabine|Arm A: Ipatasertib (GDC-0068) 400 milligrams (mg) tablets administered orally once a day (noon) on Days 1-14 of each 21-day cycle plus capecitabine 1000 mg/m2 tablets orally twice a day (morning and evening; equivalent to 2000 mg/m2 total daily dose), for 14 days (followed by a 7-day rest period) every 21-day cycle.
62564043|NCT04464174|EXPERIMENTAL|Ipatasertib plus Eribulin|Arm B: Ipatasertib (GDC-0068) 400 mg tablets administered orally once a day on Days 1-14 of each 21-day cycle plus eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle.
62564044|NCT04464174|EXPERIMENTAL|Ipatasertib plus carboplatin plus gemcitabine|Arm C: Ipatasertib (GDC-0068) 400 mg tablets administered orally once a day on Days 1-14 of each 21-day cycle plus carboplatin AUC5 on Day 1 administered intravenously plus gemcitabine 1000 mg/m2 administered intravenously over 30 minutes on Days 1 and 8, every 21-day cycle.
62564045|NCT05265286|EXPERIMENTAL|Arm 1 prophylaxis treatment|"Subjects of high dose group are being received four doses of FRSW117. dosing on day1(ED1), day8(ED2), day15(ED3), day22(ED4) respectively.~Subjects of low dose group are being received four doses of FRSW117. dosing on day1(ED1), day8(ED2), day15(ED3), day22(ED4) respectively.~All subjects are being received PK assessment in ED1 and ED4."
62564046|NCT05238298|EXPERIMENTAL|rTMS Group|Participants will receive continuous theta burst stimulation (cTBS) for a 10-day period (10 sessions). If feasible for the participant, all stimulation sessions will be held at the same time of the day.
62564047|NCT02242812|EXPERIMENTAL|Telmisartan|MICARDIS®
62564048|NCT02242812|ACTIVE_COMPARATOR|Metoprolol succinate|BELOC ZOK®
62564049|NCT01198470|EXPERIMENTAL|TRIUMPH® Artificial Disc|Treatment of degenerative disc disease with the TRIUMPH Lumbar Artificial Disc. This is a non-randomized pilot study with only one arm (no control).
62564050|NCT05002634|EXPERIMENTAL|undenatured collagen type II (UCII) supplement|The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months.
62564051|NCT03035617|PLACEBO_COMPARATOR|Controlled Arm|Mesh will be soaked in normal saline solution as is routinely done.
62564052|NCT03035617|EXPERIMENTAL|Intervention Arm|Mesh will be soaked in .5% bupivacaine solution before application.
62564053|NCT01109212|EXPERIMENTAL|Bindarit|Patients treated with bindarit 2x300 mg bid plus irbesartan 2x150 mg once a day for 12 weeks
62564054|NCT01109212|PLACEBO_COMPARATOR|Placebo|patients treated with placebo 2 tablets bid plus irbesartan 2x150 mg once a day for 12 weeks
62564055|NCT03195829|EXPERIMENTAL|Computerized cognitive stimulation|Computerized Cognitive Stimulation was administered to intervention group (IG).
62564056|NCT03195829|ACTIVE_COMPARATOR|Multimedia-based internet activities|Multimedia-based internet activities was administered to active control group (ACG).
62564057|NCT05439096|EXPERIMENTAL|Functional Exercise|"* 2 stretching exercises~* 1 yoga exercises~* 2 core strengthening exercises~* 2 pelvic area exercises~* Kegel exercises~* Warm up for 5 minutes the apply perform exercise 3 times a week for 8 weeks and 45 minutes duration at a time"
62564058|NCT05439096|EXPERIMENTAL|High Frequency Transcutaneous Electrical Nerve Stimulation|"High frequency TENS by below mentioned parameters will be applied.~* Pulse waveform = Biphasic waveform~* Pulse recurrence = 50 to 120 Hz~* Phase duration = 100 µsec~* Current amplitudes = highest tolerable intensity with continuous adjustment~* Skin arrangement = flawless skin region.~* Type of electrodes = Self-adhesive~* Size and location of electrodes = It will be adjusted specifically to each woman according to the typical area of her pain."
62564059|NCT04135677|ACTIVE_COMPARATOR|DAPT group|asprin 100mg qd together clopidogrel 75mg for 24 weeks
62564060|NCT04135677|EXPERIMENTAL|Anticoagulation group|rivaroxaban 20mg qd for for 12 weeks and continued DAPT(asprin 100mg qd together clopidogrel 75mg) for 24 weeks
62564061|NCT01791894|EXPERIMENTAL|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62564062|NCT04149821|EXPERIMENTAL|Cohort A Post BTKi Therapy|Patients who progress after a BTKi containing regimen
62564063|NCT04149821|EXPERIMENTAL|Cohort B Post BCL-2 Therapy|"* Patients who progress after BCL-2 containing regimens~* Patients who progress on a regimen containing both a BTKi and a BCL-2 inhibitor"
62564064|NCT03903289|EXPERIMENTAL|Automated red cell exchange|Automated red cell exchange
62564065|NCT03903289|ACTIVE_COMPARATOR|Manual red cell exchange|Manual red cell exchange
62180435|NCT00103272|EXPERIMENTAL|Treatment (17-AAG and bortezomib)|"Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1-6 hours on days 1, 4, 8, and 11 and bortezomib IV over 3-5 seconds on days 4, 8, and 11 of course 1 and on days 1, 4, 8, and 11 of all subsequent courses.~Treatment repeats every 21 days for 3-12 courses provided patient is receiving clinical benefit. Patients achieving objective response may discontinue therapy to undergo stem cell transplantation."
62180436|NCT01860807|EXPERIMENTAL|Ibudilast|Ibudilast 50 mg twice daily
62180437|NCT01860807|PLACEBO_COMPARATOR|Placebo|matching placebo twice daily
62180438|NCT05251857|EXPERIMENTAL|Animation Education Program Applied to Laparoscopic Sleeve Gastrectomy Patients|The intervention group is the group in which the investigors applied animation education program Intervention: Behavioral: Animation Education Program
62180439|NCT05251857|NO_INTERVENTION|Standard Clinical Care Applied to Laparoscopic Sleeve Gastrectomy Patients|The control group is the group that receives standard clinical care
62564066|NCT03903289|SHAM_COMPARATOR|Simple red cell transfusion|Simple red cell transfusion
62564067|NCT04018131|ACTIVE_COMPARATOR|Cimetidine|
62564068|NCT04018131|PLACEBO_COMPARATOR|Placebo|
62564069|NCT06070519|EXPERIMENTAL|Sigle arm study|HF patients who meets all the inclusion and none of the exclusion criteria
62564070|NCT01710865|EXPERIMENTAL|Ultraseal Sealant|Both Ultraseal XT Hydro and Ultraseal XT Plus will be applied on patients.
62564071|NCT04743544||Voriconazole|All eligible patients will be followed up for voriconazole related adverse drug events and efficacy
62564072|NCT05140200|EXPERIMENTAL|Cohort 1: Participants receiving GSK3511294 at Dose level 1|
62564073|NCT05140200|EXPERIMENTAL|Cohort 2: Participants receiving GSK3511294 at Dose level 2|
62564074|NCT04114929|EXPERIMENTAL|Threshold-Based|Patients will be prescribed exercise based on ventilatory thresholds from a maximal cardiopulmonary exercise test
62564075|NCT04114929|ACTIVE_COMPARATOR|Standard Care|Patients will be prescribed exercise based on standard guidelines
62180440|NCT04899401|EXPERIMENTAL|Standard of care +PediaFlù®|
62180441|NCT04899401|ACTIVE_COMPARATOR|Standard of care|
62180442|NCT01069328|EXPERIMENTAL|Arm 1|
62564076|NCT04646265|EXPERIMENTAL|periodontal treatment|non-surgical root debridement
62564077|NCT02701465|EXPERIMENTAL|Intervention group|The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.
62564078|NCT02701465|ACTIVE_COMPARATOR|Control group|The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
62564079|NCT01999816|EXPERIMENTAL|Lifestyle Redesign|Occupational therapist led lifestyle redesign program to prevent pressure ulcers
62564080|NCT01999816|NO_INTERVENTION|Control|Usual care
62564081|NCT03725488||Active|Evaluate stress among dental students by Questionnaire
62564082|NCT03725488||the present level of stress, comfort zone & coping with stress|Evaluate how stress was coped, the coping mechanisms used through Questionnaire
62564083|NCT00620945|EXPERIMENTAL|1|Treatment Group
62180443|NCT01069328|EXPERIMENTAL|Arm 2|
62564084|NCT04024046||Control - Placebo|"1. Placebo Drink-Mix Daily for 180 days~2. Placebo Capsules Daily for 180 days"
62564085|NCT04024046||Group 1|"1. Uqora Drink-Mix Daily for 180 days~2. Placebo Capsules Daily for 180 days"
62564086|NCT04024046||Group 2|"1. Uqora Drink-Mix Daily for 180 days~2. Uqora Capsules Daily for 180 days"
62564087|NCT05335837||General Anesthesia|patients received general anesthesia for inguinal hernia repair
62564088|NCT05335837||Regional Anesthesia and Sedation|patients received ilioinguinal/iliohypogastric nerve blocks and sedation for inguinal hernia repair
62564089|NCT00840957||A|Rhumatoid arthritis patient currently receiving infliximab
62564090|NCT00117273|EXPERIMENTAL|1|
62180444|NCT01069328|EXPERIMENTAL|Arm 3|
62180445|NCT01069328|EXPERIMENTAL|Arm 4|
62564091|NCT00117273|ACTIVE_COMPARATOR|2|
62564092|NCT00117273|ACTIVE_COMPARATOR|3|
62564093|NCT06261307|EXPERIMENTAL|Music intervention|"Groups: Children with (risk group, appr. 50%) or without (control group, appr. 50%) familial risk for dyslexia.~In each arm, the children will follow the same training protocol consisting of weekly 0.5-1-hour training sessions for six months. Training sessions are organized at fixed times and locations in fixed groups of 5-10 parent-child dyads and an experienced instructor.~The music intervention consists of social, structured and playful group sessions that involve joint singing, playing with musical instruments, moving to and listening to music. Based on the results of a previous intervention study by the investigators on the benefits of vocal music exposure on speech processing (Virtala et al., 2023), joint singing will be emphasized in the music intervention. The aims of the music intervention are to support caregiver-child interaction and the development of musical abilities."
62180446|NCT01069328|EXPERIMENTAL|Arm 5|
62180447|NCT01069328|EXPERIMENTAL|Arm 6|
62180448|NCT02970357|OTHER|Enrolled patient|Every patient of the Mulhouse Hospital with a type 1 diabetes who joins the study will be followed for 10 months. They will fill in the DIAPASON questionnaire and the quality of life WHO-5 questionnaire on the day of enrollment and 10 months after enrollment, at the end of the study. Young patients followed for a type 1 diabetes at the Mulhouse Hospital usually come every two months to see the pediatric endocrinologist, so the data collected for a regular visit will also be collected for the study every two months between the enrollment and the end of study participation.
61995299|NCT04585516||Patients >80 years that were admitted for colonoscopy|All patients older than 80 years that were admitted to the endoscopy department for a colonoscopy between Sept 2016 and Jan 2019 (n= 981)
61995300|NCT06241027|EXPERIMENTAL|Nerve flossing technique|Nerve flossing technique will be repeated 3 times a week for 15 minutes per session include 2 sets of 10 repetitions for 4 weeks
61995301|NCT06241027|EXPERIMENTAL|Myofascial release|Myofascial release technique will be given to the patients 3 times a week for 10 minutes with a total 4 weeks of treatment plan.
62564094|NCT06261307|ACTIVE_COMPARATOR|Circus intervention|"Groups: Children with (risk group, appr. 50%) or without (control group, appr. 50%) familial risk for dyslexia.~In each arm, the children will follow the same training protocol consisting of weekly 0.5-1-hour training sessions for six months. Training sessions are organized at fixed times and locations in fixed groups of 5-10 parent-child dyads and an experienced instructor.~The circus intervention consists of social, structured and playful group sessions that involve acrobatics and other age-appropriate motor exercises with the caregiver, and familiarizing with the art and equipment of circus and acrobatics. The aims of the circus intervention are to support caregiver-child interaction and the development of motor skills."
62180449|NCT01161628|EXPERIMENTAL|Rituxan|All patients receive Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
62564095|NCT01786161|EXPERIMENTAL|Vancomycin with continuous infusion|24 hours continuous infusion
62564096|NCT01786161|ACTIVE_COMPARATOR|Vancomycin with intermittent dose interval|infusion rate 1000mg/hr
62564097|NCT04093310|EXPERIMENTAL|Word catheter|The abscess is incised and the Word catheter is inserted into the residual cavity to create a neo-channel to prevent recurrence. The catheter is removed after 4 weeks during a consultation
62564098|NCT04093310|ACTIVE_COMPARATOR|Incision-drainage|This procedure performed under general or loco-regional anaesthesia consists in incising the abscess, draining the pus build-up and placing a wick in the residual cavity to promote progressive healing from the inside out.
62564099|NCT04417452||Mothers / children after diabetes in pregnancy|The study collective is composed of mother-child pairs after gestational diabetes, which were supervised in the Competence Center for Diabetes and Pregnancy at the University Hospital of Jena. The patients can decide to fill in an online questionnaire. For all other parts of the study, only patients who have been informed individually or on behalf of their legal guardian about the nature of the study after a detailed and understandable explanatory discussion with an investigator and who have given written consent will be included in the study.
62564100|NCT04417452||Controls|The control collective is composed of mother-child pairs who were cared for at the same time as the study collective at the University Hospital Jena. This collective is status post singleton pregnancy and term birth. The patients can decide to fill in an online questionnaire. For all other parts of the study, only patients who have been informed individually or on behalf of their legal guardian about the nature of the study after a detailed and understandable explanatory discussion with an investigator and who have given written consent will be included in the study.
62564101|NCT05231811|EXPERIMENTAL|experimental group|During the massage; A pillow will be placed under the patient's leg and a disposable cover will be placed on the pillow. During the massage, pregnant women will be massaged with baby oil or vaseline cream. The soles of the pregnant women will be rubbed by the practitioner's fingers. The practitioner will make circular movements by applying pressure to the sole of the pregnant woman's feet with her thumb, and will apply pressure to the foot with up and down movements, using the joint protrusions on the upper surface of the hand that she has made into a fist. The heel and ankle will be squeezed between the thumb and forefinger of the researcher and kneaded and the massage will be terminated.
62564102|NCT05231811|NO_INTERVENTION|control group|no intervention will be made in the control group
62564103|NCT03631680||'Bilateral Oophorectomy Surgery' Group|Premenopausal women planning to undergo a laparoscopic, elective bilateral oophorectomy surgery.
62564104|NCT03631680||'Comparative (Control)' Group|Premenopausal women with normal menstrual cycles from a previously completed study at Pennington Biomedical Research Center \[NCT01748994\] will serve as a comparator (control) group.
62180450|NCT06130397||Readers/participants|"Reader Selection: 18 readers will be selected from the following five clinical specialty groups (3 readers each):~* Emergency Medicine~* Trauma and Orthopaedic Surgery~* Emergency Nurse Practitioners~* Physiotherapy~* General Radiology~* Radiographers~And from the following level of seniority/experience:~* Consultant/Senior/Equivalent - \>10yrs experience~* Middle Grade/Registrar/Equivalent - 5-10yrs experience~* Junior Grade/Senior House Officer/Equivalent - \<5yrs experience~Each specialty reader group will include 1 reader at each level of experience.~Readers will be recruited from across 5 NHS organisations which comprise the Thames Valley Emergency Medicine Research Network (www.TaVERNresearch.org):~* Oxford University Hospitals NHS Foundation Trust~* Royal Berkshire NHS Foundation Trust~* Buckinghamshire Healthcare NHS Trust~* Frimley Health NHS Foundation Trust~* Milton Keynes University Hospital NHS Foundation Trust"
62564105|NCT01931436|EXPERIMENTAL|Qing'E pill|Administered twice a day, and each 9 g
62564106|NCT02391688|EXPERIMENTAL|Treatment A|"Oral intake of:~caffeine 50 mg dextromethorphan 10 mg omeprazole 10 mg flurbiprofen 10 mg midazolam 1 mg"
62564107|NCT02391688|EXPERIMENTAL|Treatment B|"Oral intake of:~fexofenadine 25 mg"
62564108|NCT02391688|EXPERIMENTAL|Treatment C|"Oral intake of:~bupropion 20 mg"
61995302|NCT05339139|EXPERIMENTAL|Ci-Ca Arm|The study population will include critically ill subjects who are a minimum of 18 years old, in an acute setting, requiring CRRT. the Subjects will receive Regional Citrate Anticoagulation (RCA) which will be delivered by MultiFiltiratePRO system
62180451|NCT06130397||Ground truthers|Two consultant musculoskeletal radiologists. A third senior musculoskeletal radiologist's opinion (\>20 years experience) will undertake arbitration.
62564109|NCT02391688|EXPERIMENTAL|Treatment D|"Oral Intake of Geneva cocktail (A+B+C):~caffeine 50 mg dextromethorphan 10 mg omeprazole 10 mg flurbiprofen 10 mg midazolam 1 mg fexofenadine 25 mg bupropion 20 mg"
62564110|NCT03327259|ACTIVE_COMPARATOR|Activity Planning Only|
62564111|NCT03327259|EXPERIMENTAL|Enhanced Activity Planning|Activity planning with therapist guided activity practice.
62564112|NCT01805063||Fire suppression|Firefighters will attend for vascular assessments following a night shift where they have performed fire suppression
62564113|NCT01805063||Non-fire emergency duty|Firefighters will attend for vascular assessments following a night shift where they have had an emergency response without fire suppression eg. road traffic collision.
62564114|NCT01805063||Sedentary shift|Firefighters will attend for vascular assessments following a night shift where they have remained sedentary throughout the shift.
62564115|NCT04948346||patient with ALS|
62564116|NCT04948346||patient'spouse(without ALS)|
62180452|NCT04240600|EXPERIMENTAL|Hyperproteic, hypercaloric formula|Each patient will receive 2 bottles per day of Supportan DKN during the hospital stay (nutritional contribution: 600 kcal and 40 g of protein).
62180453|NCT04240600|ACTIVE_COMPARATOR|Standard formula|Each patient will receive 2 cans or bottles per day of Fresubin® Original DRINK (nutritional contribution: 474.2 kcal and 17.6 g of protein).
62564117|NCT02946463|EXPERIMENTAL|Ravulizumab|
62564118|NCT02946463|ACTIVE_COMPARATOR|Eculizumab|
62564119|NCT06323681|EXPERIMENTAL|Peginterferon α-2b based treatment group|
62180454|NCT00816556|ACTIVE_COMPARATOR|Estriol|Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
62564120|NCT06323681|ACTIVE_COMPARATOR|NAs monotherapy group|
62564121|NCT00656656|OTHER|Immunoadsorption/Dexamethasone/Rituximab|
62564122|NCT04178902|EXPERIMENTAL|Part A: ABBV-467 Dose Escalation|ABBV-467 administered by intravenous (IV) infusion at various doses until a recommended phase 2 dose is determined.
62564123|NCT04178902|EXPERIMENTAL|Part B: ABBV-467 Dose Expansion|ABBV-467 administered by intravenous (IV) infusion at recommended phase 2 dose as identified in Part A.
62564124|NCT04122300|EXPERIMENTAL|Euphrasia arm|Euphrasia eye drops® (Weleda AG, Arlesheim) is administrated at a dose of one drop in each eye four times a day over a period of 96 hours.
62564125|NCT04122300|PLACEBO_COMPARATOR|Placebo arm|Placebo (0.9% NaCl) is administrated at a dose of one drop in each eye four times a day over a period of 96 hours.
62564126|NCT03120780|ACTIVE_COMPARATOR|Low Dose Fentanyl|Low dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 20 mcg fentanyl (Fentanyl 20 mcg)
62564127|NCT03120780|EXPERIMENTAL|High Dose Fentanyl|High dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 100 mcg fentanyl (Fentanyl 100 mcg)
62564128|NCT03525080|EXPERIMENTAL|PET Arm|
62564129|NCT01033903|EXPERIMENTAL|Misoprostol 800 micrograms intravaginally|
62564130|NCT01033903|NO_INTERVENTION|expectant managment|
62564131|NCT02666937||ICU-patients (prospective)|Critically ill patients (18 years and older) on mechanically ventilation who have an arterial line and require bloodgasanalysis for medical reasons
62180455|NCT00816556|ACTIVE_COMPARATOR|Estradiol|Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
62564132|NCT02666937||Emergency Department (prospective)|Patients (18 years and older), who are presented to the Emergency Department, and require bloodgasanalysis for medical reasons
61995303|NCT01666756|EXPERIMENTAL|Treatment (Chinese herbal formulation PHY906 and sorafenib)|Patients receive Chinese herbal formulation PHY906 PO BID on days 1-4, 8-11, 15-18, 21-24 and sorafenib tosylate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62180456|NCT00816556|PLACEBO_COMPARATOR|Vanicream Lite|Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
62180457|NCT01411449||Group 1|
62180458|NCT00130910|EXPERIMENTAL|1|Albendazole
62180459|NCT00130910|PLACEBO_COMPARATOR|2|
62564133|NCT02666937||Pulmonary department (prospective)|Patients (18 years and older) who visit the outpatient clinic of the pulmonary department for different pulmonary functional test and require bloodgasanalysis for medical reasons
62564134|NCT02666937||Pulmonary department (retrospective)|Patients (18 years and older) who visited the outpatient clinic of the pulmonary department in the past of the VU medical centre in Amsterdam or the Medical Centre Alkmaar for different pulmonary functional test and required bloodgasanalysis for medical reasons
62564135|NCT03669211|EXPERIMENTAL|Cardiac stress test|
62564136|NCT04423991|EXPERIMENTAL|Exposed group|All patients were exposed to the algorithm and were characterized as being likely responders to hydroxychloroquine treatment. Treatment decisions regarding the administration of hydroxychloroquine were made independently by care providers.
61995304|NCT01649258|EXPERIMENTAL|Supportive care (antiemetics)|Patients receive granisetron transdermal system patch 24-48 hrs before the initiation of chemotherapy. Patients wear the granisetron transdermal system patch for 7 days. Patients receive fosaprepitant dimeglumine IV over 15 minutes on day 1 of chemotherapy. Treatment repeats every 2 or 3 weeks for up to 4 courses in the absence of unacceptable toxicity.
62180460|NCT06183411|OTHER|Children with DCD|
61995305|NCT00348556|EXPERIMENTAL|Nesiritide|Subjects received an intrarenal infusion of nesiritide at 0.005 microgram/kg/min for 6 hours, 0.01 microgram/kg/min for 6 hours, 0.02 microgram/kg/min for 6 hours, and 0.03 microgram/kg/min for 6 hours.
61995306|NCT04947332|OTHER|Auto-inoculation recipients|Auto-inoculation of wart to be performed
61995307|NCT04242888|EXPERIMENTAL|Rotator Cuff Facilitation|The function of Rotator cuff muscles is passively augmented in one of the 5 trials
61995308|NCT04242888|EXPERIMENTAL|Serratus Anterior Stretch|Seratus anterior muscles is stretched through a novel technique
61995309|NCT04242888|EXPERIMENTAL|Posterior Capsular Stertch|Posterior capsule is stretched through a novel maneuver
62180461|NCT02946307|EXPERIMENTAL|small vessel cohort:Restore DEB|receiving the treatment with Restore DEB（dimeter\>2.00 mm） in small vessel cohort
62180462|NCT02946307|ACTIVE_COMPARATOR|small vessel cohort:Resolute DES|receiving the treatment with Resolute DES in small vessel cohort
62180463|NCT02946307|OTHER|very small vessel cohort:Restore DEB|receiving the treatment with Restore DEB（dimeter:2.00 mm）in very small vessel cohort
62180464|NCT04514172|EXPERIMENTAL|With exoskeleton|The experimental trial will be performed with exoskeleton.
62180465|NCT04514172|EXPERIMENTAL|Without exoskeleton|The experimental protocol will be performed without exoskeleton.
62180466|NCT00560313|EXPERIMENTAL|4CMenB|
62180467|NCT00560313|EXPERIMENTAL|MenACWY CRM|
62180468|NCT04114812|EXPERIMENTAL|Blended learning|Participants in the blended learning group will be taught abdominal ultrasound by an e-learning platform and practical near-peer tutoring classes over 16 weeks, summing up to 5 hours of e-learning and 16 hours of near-peer tutoring classes.
62180469|NCT04114812|ACTIVE_COMPARATOR|Standard course|Participants in the standard course or control group will participate in a 2.5-day course in abdominal ultrasound, comprising 5 hours of lectures and 16 hours of ultrasound training.
62180470|NCT05828563|ACTIVE_COMPARATOR|pesticide applicators|This group contain cases
62180471|NCT05828563|ACTIVE_COMPARATOR|control|control group
62180472|NCT04811339|EXPERIMENTAL|Open label BSS|All patients will be assigned to the treatment group for the first 10 patients treated with open label BSS.
62180473|NCT04811339|PLACEBO_COMPARATOR|Randomized BSS or Placebo|The Subsequent 50 patients will be randomized to either placebo or BSS. The patients will be assigned by envelope containing a symbol for either active drug or placebo (or other suitable randomization event) by a member of the research team not directly involved in the clinical trial.
62564137|NCT06299891|EXPERIMENTAL|Drug Intervention|Active drug dose escalation and adjustment: The drug had been used in adolescents with obesity before. For this trial, the FDA approved dose titration will be followed until the highest tolerable dose is reached.
62564138|NCT06299891|PLACEBO_COMPARATOR|Placebo|Matching placebo using capsules matching the appearance of the active drug.
62564139|NCT06304987|EXPERIMENTAL|CRT+PD-1 inhibitor+PCSK9 inhibitor|Receive long-course radiotherapy in weeks 1-5: 50 Gy/25 f, 2 Gy/day, days 1-5/week; for 5 consecutive weeks; Simultaneously receive 30 days of capetabine treatment at weeks 1-2, weeks 3-5, and weeks 6-8, 825-1000mg/m2, bid, po, days 1-5/week; PD-1 inhibitor: 200mg, iv.gtt, single dose Infusion, a cycle of 21 days, a total of 3 cycles. Carry out at 2 weeks (days 8-14), 5 weeks (days 29-35), and 8 weeks (days 50-56) after the start of radiotherapy; PCSK9 inhibitor: 600 mg, subcutaneous injection, 1, 7 weeks.
62564140|NCT06304987|ACTIVE_COMPARATOR|CRT+PD-1 inhibitor|Receive long-course radiotherapy in weeks 1-5: 50 Gy/25 f, 2 Gy/day, days 1-5/week; for 5 consecutive weeks; Simultaneously receive 30 days of capetabine treatment at weeks 1-2, weeks 3-5, and weeks 6-8, 825-1000mg/m2, bid, po, days 1-5/week; PD-1 inhibitor: 200mg, iv.gtt, single dose Infusion, a cycle of 21 days, a total of 3 cycles. Carry out at 2 weeks (days 8-14), 5 weeks (days 29-35), and 8 weeks (days 50-56) after the start of radiotherapy.
62564141|NCT02597439|ACTIVE_COMPARATOR|Omega-3 fatty acids|Subjects will be treated daily with 1.2 gram omega-3 polyunsaturated fatty acids (720 mg eicosapentaenoic acid (EPA) and 480 mg Docosahexaenoic acid(DHA)) for six months.
62564142|NCT02597439|PLACEBO_COMPARATOR|Placebo|Subjects will be treated daily with placebo for six months. Placebo capsules will contain a 1:1 combination of coconut oil and medium chain triglycerides because these do not contain polyunsaturated fatty acids and have no impact on omega-3 fatty acid metabolism. Placebo capsules also contain the same amount of vitamin E as the omega-3 capsules and 1% fish oil to mimic flavour and taste.
62564143|NCT02655822|EXPERIMENTAL|Cohort 1 - Closed|Ciforadenant
62564144|NCT02655822|EXPERIMENTAL|Cohort 2 - Closed|Ciforadenant
62564145|NCT02655822|EXPERIMENTAL|Cohort 3 - Closed|Ciforadenant
62564146|NCT02655822|EXPERIMENTAL|Cohort 4|Ciforadenant + atezolizumab
62564147|NCT02655822|EXPERIMENTAL|Cohort 5 - Closed|Ciforadenant
62564148|NCT04148326||Patients|Patients who have been diagnosed with Parkinson's Disease
62564149|NCT01628900|ACTIVE_COMPARATOR|ambulatory|Patient will be treated for 7 days at home, then 3 follow-up visit at hospital.
62564150|NCT01628900|ACTIVE_COMPARATOR|hospitalisation|7 days for mono-antibiotherapy at hospital.
62564151|NCT01445730|EXPERIMENTAL|After fructose feeding|After 3 month fructose diet 75 g/day
62564152|NCT06095921|EXPERIMENTAL|Self Management Intervention Program|That program was created by sending 40-minute videos 1 day a week for 8 weeks. The programme was developed both according to the achievements of previous self-management studies and according to the occupations that individuals with SSc have difficulty with.
62564153|NCT06095921|NO_INTERVENTION|Statistical Analysis|One week after the program, the biostatistician evaluated the results.
62564154|NCT03676608|EXPERIMENTAL|Bee wax mammary areolae|"Usual educational care plus the product.~The product to be valued are mammary areolae made by hand with organic beeswax. Despite its honey aroma, it does not contain honey. The wax used for the manufacture of the areolae is operculum. This wax is used and not another because it avoids possible residues and allergies that may contain other types of waxes. The operculum wax is used as a thickener in pharmacy and cosmetic products as a fat base in ointments and creams."
62564155|NCT03676608|ACTIVE_COMPARATOR|Control|Usual educational care.
62564156|NCT04850417|EXPERIMENTAL|Beta-blockers and Short Antiplatelet Therapy|"Beta-blockers (experimental) and Short Antiplatelet Therapy (experimental). Aspirin alone recommended for Short Antiplatelet Therapy~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
62564157|NCT04850417|EXPERIMENTAL|Beta-blockers and Long Antiplatelet Therapy|"Beta-blockers (experimental) and Long Antiplatelet Therapy. Aspirin and Clopidogrel recommended in Long Antiplatelet Therapy~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
62564158|NCT04850417|EXPERIMENTAL|No Beta-blockers and Short Antiplatelet Therapy|"No Beta-blockers and Short Antiplatelet Therapy (experimental). Aspirin alone recommended in Short Antiplatelet Therapy~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
62564159|NCT04850417|ACTIVE_COMPARATOR|No Beta-blockers and Long Antiplatelet Therapy|"No Beta-blockers and Long Antiplatelet Therapy. Aspirin and Clopidogrel recommended in Long Antiplatelet Therapy~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
62564160|NCT04614519|ACTIVE_COMPARATOR|Conventional group|Insufflation pressure at 12mmHg and conventional instrumentation
62564161|NCT04614519|EXPERIMENTAL|Low impact laparoscopy group|Insufflation pressure at 7mmHg and micro-laparoscopy instrumentation
62564162|NCT06231225|NO_INTERVENTION|control group|not assign respiratory training
61995310|NCT04242888|EXPERIMENTAL|Acromioclavicular Joint Mobilization|Acromio clavicular joint is mobilized posterio-anterior
62180474|NCT01398644|ACTIVE_COMPARATOR|Phlebotomy -intervention phlebotomy|Patients are treated with phlebotomy if ferritin level \>50 ug/l
62564163|NCT06231225|EXPERIMENTAL|treatment group|assign respiratory training
62564164|NCT05481632|EXPERIMENTAL|Physician AI-assisted diagnosis group|
62564165|NCT05481632|SHAM_COMPARATOR|Physician Independent Diagnostic Group|
62564166|NCT03741868||Stage IV non-small cell lung cancer|60 - stage IV non-small cell lung cancer patients will be recruited through the Wake Forest Baptist Comprehensive Cancer Center to complete the quantitative portion of the study. We will use purposive sampling to assure representation of patients at different stages in immunotherapy (i.e., initiating treatment, anticipating scan results, after onset of immune-related side effects).12-15 of the 60 patients who complete the survey and who express interest in providing feedback on programs and participating in future research will be recruited to complete the qualitative portion of the study
62564167|NCT04146441|EXPERIMENTAL|SonoVue|SonoVue + chemotherapy
62564168|NCT04146441|ACTIVE_COMPARATOR|control|chemotherapy
62564169|NCT03649568|EXPERIMENTAL|Pork|1 ounce lean pork
62564170|NCT03649568|ACTIVE_COMPARATOR|Egg|1 large whole egg
62564171|NCT03649568|EXPERIMENTAL|Black beans|0.5 cups cooked black beans
62564172|NCT03649568|EXPERIMENTAL|Almonds|1 ounce almonds
62564173|NCT02261272|EXPERIMENTAL|CBT for insomnia|Cognitive-behavioral therapy for insomnia
62564174|NCT02261272|ACTIVE_COMPARATOR|Sleep Hygiene|Psychoeducational intervention based on standard sleep hygiene advices
62564175|NCT05661474|EXPERIMENTAL|Fitostimoline® hydrogel group|Participant randomized to the Fitostimoline® hydrogel group underwent sharp surgical debridement at each visit (every 2 weeks) to remove necrotic tissue and slough. After debridement operation, was performed disinfection with povidone-iodine, and cleansing with sterile saline solution. Then was applaied Fitostimoline ® hydrogel, finally the wound was covered with gauze.
62564176|NCT05661474|ACTIVE_COMPARATOR|Saline gauze group|Participant randomized to the Saline gauze group underwent sharp surgical debridement at each visit (every 2 weeks) to remove necrotic tissue and slough. After debridement operation, was performed disinfection with povidone-iodine, and cleansing with sterile saline solution. Then was applaied saline gauze, finally the wound was covered with gauze.
62564177|NCT04044989|EXPERIMENTAL|Root resorption (total)|The resorption cavities on the root surface were determined and the volumes of the cavities were measured in CTAn software (micro-CT).
62564178|NCT04044989|EXPERIMENTAL|Root resorption (local)|The resorption cavities on the root surface (palatal, buccal, distal and mesial root surfaces) were determined and the volumes of the cavities were measured in CTAn software (micro-CT).
62564179|NCT02035371|EXPERIMENTAL|FIAsp|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
62564180|NCT02035371|ACTIVE_COMPARATOR|NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
62564181|NCT01036282|EXPERIMENTAL|Computerized Cognitive Remediation|Two arms: 1. Computerized Cognitive Remediation treatment using COGPACK. and 2. PositScience. Each arm is further randomized to either MindReader or no Mindreader.(Social Cognition Training).
62564182|NCT01036282|EXPERIMENTAL|CRT + Social Cognition Training|Two 45-minute sessions of Computerized Cognitive Remediation using COGPACK, one 45-minute discussion session, plus one 45 minute Mind Reader Interactive Guide to Emotions per week for 12 weeks. compared to two 45-minute sessions of PositScience, plus one 45-min Discussion session plus one minute of Mind Reader, Interactive Guide to Emotions
62564183|NCT05818228|EXPERIMENTAL|Video with Childhood Maltreatment-Related Content|Participants will view a video of an actor describing the story of an individual who experienced childhood maltreatment and how they overcame its effects on their life.
62564184|NCT05818228|NO_INTERVENTION|Video without Childhood Maltreatment Content|Participants will view a lifestyle video of an actor describing their day-to-day experiences, without any childhood maltreatment-related themes.
62564185|NCT00360282|OTHER|With Vertigo; Placebo - Rizatriptan|This group received placebo on visit 1 and Rizatriptan on visit 2.
62564186|NCT00360282|OTHER|With Vertigo; Rizatriptan - Placebo|These subjects received Rizatriptan on visit 1 and placebo on visit 2.
62564187|NCT00360282|OTHER|Without Vertigo; Placebo - Rizatriptan|This group received placebo on visit 1 and Rizatriptan on visit 2.
62564188|NCT00360282|OTHER|Without Vertigo; Rizatriptan-Placebo|This group received Rizatriptan on visit 1 and placebo on visit 2.
61995311|NCT04242888|EXPERIMENTAL|Pragmatic Interventions|"The pragmatic interventions is a set of interventions which include~1. Rotator cuff facilitation~2. Posterior capsular stretch~3. Serratus anterior muscle stretch~4. Acromioclaicualr joint mobilization~5. Thoracic spine manipulation and~6. Stretch to the subclavious muscles"
61995312|NCT04471753||Patients with disorders of consciousness|Patients with medical diagnosis of prolonged disorders of consciousness (≥28 days) were included in neurosurgery, neurology, and neurorehabilitation units.
61995313|NCT04105621||Drug addicts|This group included drug addicts lived in drug rehablitation center.
61995314|NCT04105621||Healthy population|We recruited the healthy participants from the Westlake N-of-1 Trials for Macronutrient Intake (NCT04125602) as healthy control
61995315|NCT01341886|ACTIVE_COMPARATOR|metformin|patients who receive metformin in addition to levothyroxine
61995316|NCT01341886|PLACEBO_COMPARATOR|levothyroxine|patients who receive only levothyroxine
61995317|NCT00426283|EXPERIMENTAL|Flovent 1760 mcg|Fluticasone propionate 880 mcg twice daily for 3 months
62564189|NCT05029037|EXPERIMENTAL|Group A|80 patients randomized to group A will receive two doses (High) of vitamin C intravenously, twice a day for seven days.
62564190|NCT05029037|PLACEBO_COMPARATOR|Group B|80 patients assigned to group B will receive two doses of Dextrose 500 mL, twice a day for seven days.
62564191|NCT01570790|EXPERIMENTAL|Cohort 1|
62564192|NCT01570790|EXPERIMENTAL|Cohort 2|
62564193|NCT01570790|EXPERIMENTAL|Cohort 3|
62564194|NCT06370169|OTHER|Endoscopic ultrasound Placement of coil and glue|"Single arm study The standard treatment of bleeding gastric varices is obliteration with placement of coil and glue~Duration 1,3,06 months for observation of gastric varices bleeding..."
62564195|NCT01437436||obesity|otitis media patient with obesity
62564196|NCT01437436||non obesity|otitis media patient with non obesity
62564197|NCT02523755|ACTIVE_COMPARATOR|Epidural analgesia Ropivacaine|Placement of an epidural catheter to achieve pain relief
61995318|NCT00426283|PLACEBO_COMPARATOR|Placebo|Placebo twice daily for 3 months
61995319|NCT02445027|EXPERIMENTAL|MGH OCT Imaging Capsule|Subject will swallow the OCT capsule and images will be acquired using the OCT Imaging system.
61995320|NCT02153411||8645 asthmatic patients|Men and women, 18 years of age and older. Asthmatic since at least one year before inclusion. Patient's informed consent obtained.
61995321|NCT06221033|EXPERIMENTAL|manual hyperinflation group|this group will receive manual hyper inflation technique as a treatment modality
62564198|NCT02523755|SHAM_COMPARATOR|Absence of epidural analgesia|No placement of an epidural catheter either because of patient refusal or contraindication
62564199|NCT04969406|EXPERIMENTAL|Imaging by BOSS System|Imaging by the BOSS System
62564200|NCT04776629|ACTIVE_COMPARATOR|Active Treatment|"Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes.~Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months."
62564201|NCT04776629|PLACEBO_COMPARATOR|Placebo|"Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes.~Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months."
61995322|NCT06221033|EXPERIMENTAL|diaphragmatic proprioceptive neuromuscular facilitation group|this group will receive diaphragmatic proprioceptive neuromuscular facilitation technique
62564202|NCT04345237|EXPERIMENTAL|Experimental group 1 (TS + placebo)|"Training twice a week, with wave periodization. Traditional training (TS) in two circuits. Each exercise is separated by a rest period of 3 minutes and 5 minutes between circuits.~Daily consumption for 3 months of placebo milk."
62564203|NCT04345237|EXPERIMENTAL|Experimental group 2 (TS + leucine)|"Training twice a week, with wave periodization. Traditional training (TS) in two circuits. Each exercise is separated by a rest period of 3 minutes and 5 minutes between circuits.~Daily consumption for 3 months of milk enriched with leucine."
62564204|NCT04345237|EXPERIMENTAL|Experimental group 3 (HRC + placebo)|"Training twice a week, with wave periodization. High intensity training (HRC) on two circuits. Each exercise is separated by a rest period of 35 seconds and 5 minutes between circuits.~Daily consumption for 3 months of placebo milk."
62564205|NCT04345237|EXPERIMENTAL|Experimental group 4 (HRC + leucine)|"Training twice a week, with wave periodization. High intensity training (HRC) on two circuits. Each exercise is separated by a rest period of 35 seconds and 5 minutes between circuits.~Daily consumption for 3 months of milk enriched with leucine."
62180475|NCT01398644|EXPERIMENTAL|Erythrocytapheresis|Patients are treated with erythrocytapheresis if serum ferritin level \>50ug/l
62180476|NCT05061069|EXPERIMENTAL|Infants with permanent hearing loss|Each infant with permanent hearing loss in Flanders will be offered a vestibular screening by means of the cVEMP (cervical vestibular evoked myogenic potentials) test to screen for vestibular deficits.
62564206|NCT04345237|EXPERIMENTAL|Experimental group 5 (no physical exercise + leucine)|"The subjects will not carry out any type of physical activity.~Daily consumption for 3 months of milk enriched with leucine."
62564207|NCT04345237|NO_INTERVENTION|Control (no physical exercise + placebo)|"The subjects will not carry out any type of physical activity.~Daily consumption for 3 months of placebo milk."
61995323|NCT06221033|OTHER|control group|this group will receive the traditional physiotherapy techniques ( percussion , shaking , breathing ex )
61995324|NCT04098458|EXPERIMENTAL|NDURE|NDURE is a navigation-based, multilevel intervention targeting barriers to timely, guideline-adherent PORT at the patient-, healthcare team-, and organization-levels.
62180477|NCT02506881|EXPERIMENTAL|BCD-066 → Aranesp - subcutaneous|Volunteers in this group initially will receive a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
62180478|NCT02506881|EXPERIMENTAL|Aranesp → BCD-066 - subcutaneous|Volunteers in this group initially will receive a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
62180479|NCT02506881|EXPERIMENTAL|BCD-066 → Aranesp - intravenous|Volunteers in this group initially will receive a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
62180480|NCT02506881|EXPERIMENTAL|Aranesp → BCD-066 - intravenous|Volunteers in this group initially will receive a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
62180481|NCT03353142|EXPERIMENTAL|Equal Breathing|
62180482|NCT02101268|EXPERIMENTAL|Arm 1: Momelotinib|Participants will receive open-label momelotinib for 24 weeks during the randomized treatment phase, after which they will be eligible to receive momelotinib in an extended treatment phase for up to an additional 204 weeks.
62391251|NCT02207413|ACTIVE_COMPARATOR|Influsplit Tetra_LP 3-17y Group|Subjects in the Influsplit Tetra_LP group aged between 3 years to \<9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by LP at Day 0. Influsplit Tetra™ vaccine produced by LP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
62391252|NCT02207413|EXPERIMENTAL|Influsplit Tetra_IP 6-35m Group|Subjects in the Influsplit Tetra_IP group aged between 6 months to 35 months received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by investigational process (IP). Influsplit Tetra™ vaccine produced by IP was administered intramuscularly the anterolateral region of left thigh for subjects below 12 months of age and in the deltoid region of left or non-dominant arm in subjects ≥ 12 months of age (Day 0) and in the anterolateral region of right thigh for subjects below 12 months of age and in the deltoid region of right or dominant arm in subjects ≥ 12 months of age (Day 28).
62564208|NCT02021929|EXPERIMENTAL|Sorafenib|400 mg (2 capsules) taken by mouth once a day
62564209|NCT02021929|PLACEBO_COMPARATOR|Placebo|2 capsules taken by mouth once a day
62564210|NCT02350283|EXPERIMENTAL|Solitaire Device|Interventional treatment with Solitaire. After the procedure, the patients will be admitted to intensive care unit. Standard medical management will be provided to these patients.
62564211|NCT02350283|NO_INTERVENTION|Medical treatment|Standard medical treatment alone.
62564212|NCT02570308|EXPERIMENTAL|Dose escalation|Dose escalation cohorts of the intra-patient escalation regimen.
61995325|NCT00632554|EXPERIMENTAL|1|prednisolone therapy for three months
61995326|NCT00632554|ACTIVE_COMPARATOR|2|prednisolone therapy for six months
61995327|NCT05664724|EXPERIMENTAL|Receives interdisciplinary sessions|Interdisciplinary care by a team that includes: orthopedic surgeon, physiotherapist, a patient navigator, and the patient
61995328|NCT01955070|EXPERIMENTAL|Implementation|Multimedia Presentation for Ketamine sedation
61995329|NCT01955070|EXPERIMENTAL|Intervention|Multimedia Presentation for Ketamine sedation
61995330|NCT01955070|NO_INTERVENTION|Control|Patients that received the standard consent with signed consent form
61995331|NCT03569371|EXPERIMENTAL|INCB054707|
61995332|NCT02450227|ACTIVE_COMPARATOR|Spinach - Whole leaf (10 mg lutein)|"1-2: Group given whole leaf as first intervention Whole leaf spinach (10 mg lutein) given every second day for a 15 days period.~Followed by:~Minced spinach (10 mg lutein) given every second day for a 15 days period."
62564213|NCT02570308|EXPERIMENTAL|Dose expansion|Dose expansion cohort with the recommended phase 2 dose of the intra-patient dose escalation regimen.
62564214|NCT04012021|EXPERIMENTAL|EX-VIVO SPECIMENS|"Three groups of ex-vivo surgical specimen:~Group A: native livers in transplant recipients Group B: liver grafts excluded for donation Group C: primary pancreatic cancer"
62564215|NCT05982470|EXPERIMENTAL|treatment group|"Estradiol gel 2.5 g (containing 17β estradiol 1.5mg) once daily (percutaneous application)\* in combination with progesterone soft capsules 100mg once daily (oral) for 12 months~Note :~\* Usage and dosage of estradiol gel: A dose of ruler is applied to the skin of the arm, shoulder, head and neck, abdomen, thigh or face every morning or evening. It is dry about two minutes after application. It is non-irritating, colorless, or milky white and tasteless, and is best used after bathing."
62564216|NCT05982470|PLACEBO_COMPARATOR|control group|"Estradiol placebo gel 2.5g (containing 17β estradiol 0mg) once daily (percutaneous application) \*in combination with progesterone placebo soft capsules(containing progesterone 0mg) 100mg once daily (oral) for 12 months~Note :~\* Usage and dosage of estradiol placebo gel : A dose of ruler is applied to the skin of the arm, shoulder, head and neck, abdomen, thigh or face every morning or evening. It is dry about two minutes after application. It is non-irritating, colorless, or milky white and tasteless, and is best used after bathing."
62564217|NCT05689320|EXPERIMENTAL|Intervention|The intervention group will first receive 3 times EMA per day for 21 consecutive days. This assessment length was designed to capture participants' exposure to alcohol marketing for a long period of time. The EMA will include questions about self-reported exposure to and /or responses to alcohol marketing. The intervention group participants should complete at least two EMA surveys in a day and need to comply with the intervention at least 85% of the time.
62564218|NCT05689320|NO_INTERVENTION|Control|The control group will first receive 3 times EMA per day for 21 consecutive days. This assessment length was designed to capture participants' exposure to alcohol marketing for a long period of time. The EMA will include questions about self-reported exposure to and /or responses to alcohol marketing. The conrol group participants should complete at least two EMA surveys in a day and No intervention will be provided after completing the 21 consecutive days EMA documentation.
62564219|NCT04089631|EXPERIMENTAL|Chemotherapy|"Capecitabine mono or Capecitabine/Oxaliplatin as investigator choice:~Patients who are positive for postoperative ctDNA (ctDNApos) and not microsatellite instable are randomized (2:1) to adjuvant chemotherapy with capecitabine or to follow up.~Capecitabine 2 x 1250 mg/m\^2, oral (d1-14), repeated at day 22 (- 2 ... + 6 days). Patients with a GFR between 30 and 50 ml/min start with capecitabine dose of 2 x 1000 mg/m\^2. Treatment duration: 8 cycles (approx. 6 months)~Capecitabine, if combined with Oxaliplatin (investigator choice):~If the investigation decides to add oxaliplatin, the following schedule should be used:~\[Oxaliplatin 130 mg/m\^2 i.v. (2 hours on d1)\] Capecitabine 2 x 1000 mg/m\^2, oral (d1-14), repeated at day 22 (- 2 ... + 6 days) Treatment duration: 4 or 8 cycles (approx. 3 or 6 months)"
62564220|NCT04089631|NO_INTERVENTION|Follow-up|Patients negative for postoperative ctDNA (ctDNAneg) are randomized (1:4) to follow-up within CIRCULATE or to routine follow up outside the Trial protocol.
62564221|NCT02009553||Information sheet, Applied|In this group, all patients will receive the information sheet one month before the procedure
62564222|NCT02009553||Information sheet, not applied|In this group, patients will not receive a pre-procedural information sheet
62564223|NCT02545569|ACTIVE_COMPARATOR|Hearing Device Type A|In the ear (ITE) hearing aid, 1-3 weeks wearing
62564224|NCT02545569|EXPERIMENTAL|Hearing Device Type B|In the ear (ITE) hearing aid, 1-3 weeks wearing
62564225|NCT01059838|EXPERIMENTAL|single subject|
62564226|NCT00799890|EXPERIMENTAL|Sunphenon|
61995333|NCT02450227|EXPERIMENTAL|Spinach - Minced (10 mg lutein)|"2-1: Group given minced spinach as first intervention Minced spinach (10 mg lutein) given every second day for a 15 days period.~Followed by:~Whole leaf spinach (10 mg lutein) given every second day for a 15 days period."
62564227|NCT00799890|PLACEBO_COMPARATOR|Placebo|
62564228|NCT02899182|PLACEBO_COMPARATOR|conventional group|the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
62564229|NCT02899182|EXPERIMENTAL|Nitrous Oxide NO|The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
62564230|NCT04004442|EXPERIMENTAL|Avelumab + AVB-S6-500|
62564231|NCT03618693|EXPERIMENTAL|spinal analgesia SSS|"Patients will receive a spinal analgesia (group SSS) with a single shot of bupivacaine 0.5% combined with fentanyl intrathecally during induction of anaesthesia. The technique used is referred to daily practice.~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3\* per day for 48 hours intravenously and 1 gr 4\* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets (per oral administration).~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
62564232|NCT03618693|EXPERIMENTAL|TAP block|"Patients will receive a TAP block with a single shot of ropivacaine 0.375% combined with clonidine bilaterally. The technique used is referred to daily practice. The blocks will be performed under ultrasound guidance.~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3\* per day for 48 hours intravenously and 1 gr 4\* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets (per oral administration).~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
62564233|NCT03618693|ACTIVE_COMPARATOR|Standard|"Standard care for prostatectomy in the investigators institution consists in the concomitant systemic administration of lidocaine to standard general anaesthesia. Lidocaine will administered initially during induction with a bolus of 1.5 mg per kgBW, followed by an infusion of 1.5 mg per kgBW per hour for 24 hours.~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3\* per day for 48 hours and 1 gr 4\* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets.~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
62564234|NCT00365794|EXPERIMENTAL|Single arm|Open label treatment without masking with each participant serving as his own control. Measurements are compared before and after treatment.
62564235|NCT02271334|EXPERIMENTAL|Treatment T1|One inhalation of 110 mcg A006 DPI. Total 110 mcg
62564236|NCT02271334|EXPERIMENTAL|Treatment T2|One inhalation of 220 mcg A006 DPI. Total 220 mcg.
62564237|NCT02271334|ACTIVE_COMPARATOR|Treatment R1|One inhalation of 90 mcg Proventil® MDI. Total 90 mcg.
62564238|NCT02271334|ACTIVE_COMPARATOR|Treatment R2|Two inhalations of 90 mcg Proventil® MDI. Total 180 mcg
62564239|NCT01803672|EXPERIMENTAL|health talk and adventure-based training|Participate will join a four-day integrated health education and adventure-based training programme, which contains education talks, workshop and adventure-based training activities. The programme will be implemented on four different days within six months in a day camp training centre. The integrated programme will be implemented in small group with maximum 15 participants in one group. Health education talks and workshop will be implemented in between adventure-based training activities in day camp centre, which will be conducted by healthcare professionals working in a local university.
62180483|NCT02101268|ACTIVE_COMPARATOR|Arm 2: Best Available Therapy (BAT)|Participants in the BAT treatment arm will receive open-label treatment at doses and schedules determined by the investigator in accordance with standard of care. Therapy may be changed at any time during the study except during the screening period. After completion of the randomized treatment phase, participants will be eligible to receive momelotinib for the duration of the study during the extended treatment phase for up to 204 weeks.
61995334|NCT04499586|EXPERIMENTAL|Radiotherapy Combined With Raltitrexed and Irinotecan|Each cycle lasts 3 weeks. Administration of Raltitrexed and Irinotecan weekly followed by a 2 week 'rest' period with no drug given. Raltitrexed is given by IV infusion at a dose of 3mg/m2. Irinotecan is given by IV infusion at a dose of 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7).Radiation: 45-55Gy/25-30Fx
61995335|NCT04891848||migraine with aura|51 patients with MA
61995336|NCT04891848||migraine without aura|51 patients with migraine without aura
62564240|NCT01803672|PLACEBO_COMPARATOR|Placebo Control|Participants will receive an amount of time and attention that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
62564241|NCT01724710||chronic ulcer|1x1cm2 tissue from chronic ulcer wound
62564242|NCT01724710||normal skin|1x1x0.1 cm3 normal skin from graft
62564243|NCT02263560||Post-stroke patients|Patients who experienced stroke and who already recover gait abilities.
62564244|NCT02263560||Control population|Participants matching the criterion (age and gender) of the patients' group.
62564245|NCT00485719|EXPERIMENTAL|1|Twice daily (bid) dosing
62564246|NCT00485719|EXPERIMENTAL|2|Once daily (qd) dosing
62564247|NCT00520065|EXPERIMENTAL|#1|Diabetes specific enteral product
62564248|NCT00520065|ACTIVE_COMPARATOR|#2|Standard enteral feeding
62564249|NCT00372684||1|with severe malaria hospitalized in ICU
62564250|NCT00372684||2|with uncomplicated malaria
62564251|NCT02335437||Acute EBV infection|
62564252|NCT02335437||Healthy controls|
62564253|NCT02725554|ACTIVE_COMPARATOR|Delayed Continuation Group|All Subjects will be implanted with the StimRelieve HALO System. Subjects randomized to the delayed continuation group will have their systems deactivated until their 3 months follow-up visit. After this visit the stimulation will be reactivated.
62564254|NCT02725554|EXPERIMENTAL|Continued Stim Group|All Subjects will be implanted with the StimRelieve HALO System. Subjects randomized to the continued stim group will continue with active stimulation and monitored at defined intervals for data collection and device reprogramming, if needed.
62564255|NCT01580124|ACTIVE_COMPARATOR|PVI alone|Pulmonary vein isolation alone in persistent atrial fibrillation
62564256|NCT01580124|ACTIVE_COMPARATOR|PVI + Defragmentation + linear lesions|AF ablation continuation aiming for AF termination
62564257|NCT02640261||Group 1|Single embryo transfer on day 5, according to standard embryo morphological criteria
62564258|NCT02640261||Group 2|Single embryo transfer on day 5, chosen on the basis of both embryo morphological criteria and levels of cytokines measured in the individual FF.
62564259|NCT04396262|EXPERIMENTAL|HTD-blueberry beverage with white bread|The beverage prepared using hydro-thermodynamic processing of whole wild blueberries.
62564260|NCT04396262|EXPERIMENTAL|Sweetened water (control) with white bread|The water control of the same volume and with the same amount of available carbohydrate as HTD-blueberry beverage.
62564261|NCT06479538|EXPERIMENTAL|Group A|17 participants will be in experimental group A giving them Post isometric relaxation of Quadratus lumborum for four weeks, measuring all values before giving them protocol and after protocol.
62564262|NCT06479538|EXPERIMENTAL|Group B|17 participants will be in experimental group B giving them Post facilitation stretching of Quadratus lumborum for four weeks, measuring all values before giving them protocol and after protocol.
62564263|NCT01200693|ACTIVE_COMPARATOR|ZES|Patients with coronary bifurcation lesions treated by Zotarolimus eluting stent
62564264|NCT01200693|ACTIVE_COMPARATOR|SES|Patients with coronary bifurcation lesions treated by Sirolimus eluting stent
62564265|NCT01200693|ACTIVE_COMPARATOR|EES|Patients with coronary bifurcation lesions treated by Everolimus eluting stent
62564266|NCT00304850|EXPERIMENTAL|R+ / K+|
62564267|NCT00304850|EXPERIMENTAL|R+ / K-|
62564268|NCT00304850|EXPERIMENTAL|R- / K+|
62564269|NCT00304850|PLACEBO_COMPARATOR|R- /K-|
62564270|NCT04362592|EXPERIMENTAL|Percutaneous Technique|"The percutaneous technique uses endoscopic scopes through the maternal skin and uterus to perform the surgery. A variation of the percutaneous technique is the mini-laparotomy technique, which uses an endoscopic scope through an incision on the abdomen, smaller than a laparotomy (mini-laparotomy), and smaller endoscopic scopes through the maternal skin and uterus to perform the surgery."
62564271|NCT04362592|EXPERIMENTAL|Laparotomy/Uterine Exteriorization Technique|The laparotomy/uterine exteriorization technique consists of performing a laparotomy (incision into the abdominal cavity), exteriorizing the uterus, and using endoscopic scopes through the uterus to perform the correction.
62564272|NCT04760431|ACTIVE_COMPARATOR|Group A|Trastuzumab, Taxanes and Pertuzumab
62564273|NCT04760431|EXPERIMENTAL|Group B|Trastuzumab, Taxanes and TKIs
62564274|NCT01411150|EXPERIMENTAL|Creatine|
62564275|NCT06033911|NO_INTERVENTION|No App|No intervention. Participants will be given access to a web-based submission portal.
61995337|NCT04891848||tension type headache|48 patients with tension type headache
61995338|NCT04891848||healthy controls|80 healthy participants
61995339|NCT02244580|EXPERIMENTAL|MammaTyper™|MammaTyper™ kit will be used tio assess tumor material of patients enrolled into the FinHer trial.
62564276|NCT06033911|PLACEBO_COMPARATOR|FoodFlip© App with no nutrition symbol|Intervention control: participants will have access to food information in the shape of a Nutrition Facts table through FoodFlip©. Participants will have access to a submission portal linked to their study ID through the app.
62564277|NCT06033911|ACTIVE_COMPARATOR|FoodFlip© App with 'high-in' nutrition symbol|Intervention: Participants will have access to food information through FoodFlip© with Health Canada's 'high-in' nutrition symbol. ©. Participants will have access to a submission portal linked to their study ID through the app.
62180484|NCT03924934||Possible CA-HRE|Patients with suspected CA-HRE, discharged home after a previous hospitalization or outpatient visit during which CA-HRE was isolated from a clinical culture (approximately 210 patients)
62180485|NCT03924934||HA-HRE|Hospitalized patients with healthcare-associated HRE, who are not discharged home (HA-HRE) (210 selected control patients)
62564278|NCT02573051|ACTIVE_COMPARATOR|Misoprostol plus isosorbide mononitrate|this group will receive 800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries) plus 40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company) will be inserted into the posterior vaginal fornix
62564279|NCT02573051|ACTIVE_COMPARATOR|Misoprostol plus placebo|This group will receive misoprostol 800 µg plus placebo in the same site.
62564280|NCT03910400|EXPERIMENTAL|MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
62564281|NCT03910400|EXPERIMENTAL|Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
62564282|NCT06127342|EXPERIMENTAL|Moderate Intensity Exercise|"Visit 1: Participants will complete study screening, PTSD assessments, and provide written narrative for a traumatic event and a neutral control event.~Visit 2: Participants will complete baseline structural MRI scans before completing 8 trials of imaginal exposure - 4 neutral then 4 trauma narratives - with psychophysiological and fMRI measurement. Following completion of the imaginal exposure task, the participant will perform Moderate-Intensity Exercise (30-min at 70-75% max HR with 5-min warm-up and 5-min cool-down at 40-50% max HR), on a stationary bike.~Visit 3: Participants will complete the same imaginal exposure with measurement of psychophysiology, fMRI, and subjective emotional responding."
62564283|NCT06127342|ACTIVE_COMPARATOR|Low Intensity Exercise|"Visit 1: Participants will complete study screening, PTSD assessments, and provide written narrative for a traumatic event and a neutral control event.~Visit 2: Participants will complete baseline structural MRI scans before completing 8 trials of imaginal exposure - 4 neutral then 4 trauma narratives - with psychophysiological and fMRI measurement. Following completion of the imaginal exposure task, the participant will perform Low-Intensity Exercise (control; 40-mins at 40-50% max HR),on a stationary bike.~Visit 3: Participants will complete the same imaginal exposure with measurement of psychophysiology, fMRI, and subjective emotional responding."
62564284|NCT04749485|EXPERIMENTAL|HX008|
62564285|NCT03507361|EXPERIMENTAL|MUSIC|Music will be administered through a normal computer equipped with a technology (Sound-of-Soul) that translates the patient's heart rate variability (HRV) into sounds according to a digital computer music-library. Music will start 10 minutes before and will end at the completion of the interventional procedure
61995340|NCT01530971|NO_INTERVENTION|room air|no supplemental oxygen in intraoperative period
61995341|NCT01530971|EXPERIMENTAL|Oxygen|Supplemental 3LPM oxygen via canula
62564286|NCT03507361|NO_INTERVENTION|DUMB EARPHONES|Dumb earphones will be placed over patient's ears starting 10 minutes before and ending at the completion of the interventional procedure.
61995342|NCT02304224|NO_INTERVENTION|Control|the patients with sepsis admitted in the intensive care unit aren't applied with eye masks at night
61995343|NCT02304224|EXPERIMENTAL|Eye masks|the patients with sepsis in the intensive care unit are applied with eye masks at night in the duration of admission
61995344|NCT03802448|ACTIVE_COMPARATOR|Control group|"composed of fifteen pregnant women who only wore a natural wrist splint during sleeping for 4 weeks.~A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping"
61995345|NCT03802448|EXPERIMENTAL|Study group|"a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.~Myofascial wrist retinaculum (Transverse carpal ligament) release.~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique)."
62180486|NCT03924934||HA-HRE discharged home|Patients eventually discharged home, either directly or through another facility, after a hospitalization during which HA-HRE was isolated from a clinical culture (100)
62180487|NCT03924934||Community contacts|Contacts of patients with HRE (approximately 1,500)
62180488|NCT05267678||Pregnant women with history of recurrent miscarriage|
62180489|NCT03463434|EXPERIMENTAL|Air Fluidized Therapy|Patients will be placed on the Envella AFT bed
62180490|NCT03463434|ACTIVE_COMPARATOR|Continuous Low Pressure-LAL|Patients will receive a Continuous low pressure mattress with low air loss
62180491|NCT02125136|EXPERIMENTAL|Gem/nab-Pac|2 further cycles Gem/nab-Pac (duration of each cycle 28 days)
62180492|NCT02125136|EXPERIMENTAL|FOLFIFINOX|4 cycles combination therapy with 5-fluorouracil/folinic acid, irinotecan, oxaliplatin (FOLFIFINOX) - duration of each cycle 14 days
62564287|NCT03529513||Depressed|Subjects currently experiencing a moderate-to-severe major depressive episode are clinically evaluated over approximately 2-week period. 24-hour ECG data recordings are collected during each of the two weeks. Subjects may continue on current treatment regimen.
61995346|NCT00677807|EXPERIMENTAL|Indacaterol 150 µg|"Indacaterol 150 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
62180493|NCT02394964||Systemic Lupus Erythematosus|Blood, stool, and swab samples will be collected at baseline, week 4, and week 8 and compared with control samples
62564288|NCT03529513||Control|Subjects not currently experiencing a major depressive episode are clinically evaluated over approximately 2-week period. 24-hour ECG data recordings are collected during each of the two weeks. Subjects may continue on current treatment regimen.
62564289|NCT04073537|EXPERIMENTAL|Experimental group|Anlotinib hydrochloride capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and paclitaxel 175mg/m2 D1 q3w, carboplatin AUC 5mg/mL/min D1 q3w.
62564290|NCT04073537|PLACEBO_COMPARATOR|Placebo group|Anlotinib hydrochloride placebo given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and paclitaxel 175mg/m\^2 D1 q3w, carboplatin AUC 5mg/mL/min D1 q3w.
62564291|NCT03191383|EXPERIMENTAL|GSK3003891A vaccine formulation 1 mother Group|Subjects in this group will receive a single 30µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
62564292|NCT03191383|EXPERIMENTAL|GSK3003891A vaccine formulation 2 mother Group|Subjects in this group will receive a single 60µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
62564293|NCT03191383|EXPERIMENTAL|GSK3003891A vaccine formulation 3 mother Group|Subjects in this group will receive a single 120µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
62564294|NCT03191383|PLACEBO_COMPARATOR|Control group|Subjects in this group will receive a single placebo injection, intramuscularly into the deltoid region of the non-dominant arm.
62564295|NCT03191383|NO_INTERVENTION|GSK3003891A vaccine formulation 1 infant Group|Infants born to mothers vaccinated with a single 30µg dose of the investigational GSK3003891A vaccine
62564296|NCT03191383|NO_INTERVENTION|GSK3003891A vaccine formulation 2 infant Group|Infants born to mothers vaccinated with a single 60µg dose of the investigational GSK3003891A vaccine
62564297|NCT03191383|NO_INTERVENTION|GSK3003891A vaccine formulation 3 infant Group|Infants born to mothers vaccinated with a single 120µg dose of the investigational GSK3003891A vaccine
62564298|NCT03191383|NO_INTERVENTION|Control infant Group|Infants born to mothers who received a single placebo injection
62564299|NCT02712320|EXPERIMENTAL|LMIS 50 mg|50 mg leuprolide mesylate administered subcutaneously, when given as two separate injections 6 months apart (Month 12 and Month 18 from the initiation of Protocol FP01C-13-001)
62564300|NCT02074241||Positive Expression|Expression analysis:Positive expression of DNA repair-related genes(XPC, XPF, Brca1, Rad51,SNF5, etc) in bladder cancer specimens.
62180494|NCT02394964||Subacute Cutaneous Lupus Erythematosus|Blood, stool, and swab samples will be collected at baseline, week 4, and week 8 and compared with control samples
62180495|NCT02394964||Control|Blood, stool, and swab samples will be collected for comparison to each disease group
62564301|NCT02074241||Negative Expression|Expression analysis:Negative expression of DNA repair-related genes(XPC, XPF, Brca1, Rad51, SNF5,etc) in bladder cancer specimens.
62564302|NCT04230551|ACTIVE_COMPARATOR|Reference Group|Five symptomatic HOCM patients with severe LVOT obstruction will undergo PTSMA
61995347|NCT00677807|EXPERIMENTAL|Indacaterol 300 µg|"Indacaterol 300 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
61995348|NCT00677807|PLACEBO_COMPARATOR|Placebo|"Placebo once-daily (o.d.) via SDDPI.~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
61995349|NCT02904057|EXPERIMENTAL|Treatment Group|The treatment group will receive Radiesse (+) injectable implant up to 3.0 cc per jawline.
62564303|NCT04230551|EXPERIMENTAL|Study Group|Five asymptomatic HOCM patients with severe LVOT obstruction will undergo PTSMA
62564304|NCT04230551|NO_INTERVENTION|Observation Group|Five asymptomatic HOCM patients with severe LVOT obstruction will not undergo PTSMA
62180496|NCT02394964||Cutaneous T-Cell Lymphoma|Blood and swab samples will be collected for comparison to each disease group
62180497|NCT02394964||Autoimmune Disorders|Blood, stool, and swab samples will be collected for comparison to each disease group
62180498|NCT02713737|EXPERIMENTAL|HFNC group|HFNC: Heated humidified high-flow nasal cannula.
62564305|NCT03550677|EXPERIMENTAL|Group General Anesthesia|These group patients will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10 mg-20 mg rocuronium and a proper size laryngeal mask airway will be placed to secure the airway. The lungs will be ventilated with a mixture of 50% and 50% oxygen.
62564306|NCT03550677|EXPERIMENTAL|Group Ankle Block|These group patients will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10 mg-20 mg rocuronium and a proper size laryngeal mask airway will be placed to secure the airway. The lungs will be ventilated with a mixture of 50% and 50% oxygen. After than an ankle block will be performed in patient group block patients using a mixture of 5 ml of 2% lidocaine and 10 ml of 0.5 bupivacaine the same amount placebo (saline) in group placebo under the guidance of peripheral nerve stimulator then the anesthesia will be disconnected and LMA will be removed. The patients will be transferred from postoperative care unit toward after they are eligible for discharge according to the modified scoring system.
62564307|NCT03059017|EXPERIMENTAL|Niosomal salbutamol sulphate inhalers|Niosomes
62564308|NCT03059017|PLACEBO_COMPARATOR|salbutamol sulphate inhalers|control testing
62564309|NCT02309320|EXPERIMENTAL|ALX-0171|Inhalation of ALX-0171 during 3 consecutive days
62564310|NCT02309320|PLACEBO_COMPARATOR|Placebo|Inhalation of Placebo during 3 consecutive days
61995350|NCT02904057|NO_INTERVENTION|Control Group|The control group is not treated. They will undergo assessments such as photographs, jaw grading and jaw function tests.
61995351|NCT03417388|EXPERIMENTAL|Intensive Medical Treatment (IMT)|"The IMT-assigned women will receive high dose potent statin, and moderate dose of an ACE-I (lisinopril) or ARB (losartan). Aspirin will also be recommended to IMT women without contraindications or bleeding risk. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and face-time with site staff to reduce bias."
61995352|NCT03417388|ACTIVE_COMPARATOR|Usual Care (UC)|"The UC-assigned women will maintain standard of care. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and face-time with site staff to reduce bias."
62180499|NCT02713737|ACTIVE_COMPARATOR|NIV group|NIV: Noninvasive ventilation.
62180500|NCT00788164|EXPERIMENTAL|Groups 1-3|Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine intramuscularly (IM) on days 1 and 29 and TA-HPV vaccine IM on day 57.
62180501|NCT00788164|EXPERIMENTAL|Group 4|Patients receive topical imiquimod on days 1, 29, and 57.
62180502|NCT00788164|EXPERIMENTAL|Group 5|Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and TA-HPV vaccine as in groups 1-3, and imiquimod as in group 4.
62180503|NCT02330562|EXPERIMENTAL|Phase 1: MRZ + BEV; Phase 2: MRZ alone|"Part1-Phase1: MRZ 10 minute IV infusion on Days 1, 8, and 15 plus BEV IV infusion on Days 1 and 15 of each 28-day cycle.~Part2-Phase2: MRZ 10 minute IV infusion administered on Days 1, 8, and 15 of each 28-day cycle.~Part3-Phase2: All subjects will receive IV MRZ infusion and IV BEV infusion. MRZ will be administered as a 10-minute, IV infusion on Days 1, 8, and 15 of every 28-day cycle using intra-patient dose escalation. Starting dose will be 0.8 mg/m2.~Part4- Phase1: All subjects will receive MRZ enterally by NG tube as a bolus on Days 1, 8 and 15 of the first 28-day cycle and BEV IV infusion on Day 15 of the first 28-day cycle. For subsequent 28-day treatment cycles, MRZ will be administered as an IV at the recommended dose and schedule determined in Part 1, with BEV IV on Days 1 and 15.~Part5-Phase1: All subjects will receive IV MRZ infusion and IV BEV infusion. MRZ will be administered as a 10-minute, IV infusion at 0.8 mg/m2 on Days 1, 8, and 15 of every 28-day cycle 0.8 mg/m2"
62182797|NCT02785445|OTHER|All participants (single arm)|All study participants once enrolled into the study were asked to collect their midstream urine in the designated device urine cups. The urine sample was then tested sequentially; first by the Dip.io Home Based Dipstick Analyzer (first intervention) and by the ACON U500 Mission® U500 Urine Analyzer (comparative device - second intervention). Part of the participants (100 out of 302) were asked to perform the Dip.io urine test by themselves for the user performance evaluation.
62564311|NCT02120118|EXPERIMENTAL|Radiation; Hyperthermia; Chemotherapy|Patients will be treated with radiotherapy with 50Gy/22fx/6 weeks, plus hyperthermia 42℃ ± 0.5℃ for 40 minutes within 2hr after irradiation, once a week since the 1st week of radiation for a total of 6 times. The regimen of concurrent chemotherapy will cisplatin 30mg/m2 and taxotere 20mg/m2 per week for 6 weekly cycles.
62564312|NCT00523848|EXPERIMENTAL|Arm 1|Patients receive low-dose oral thalidomide once a day on days 1-28, bortezomib IV on days 1, 4, 15, and 18, and doxorubicin hydrochloride liposome IV over 60-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity
62564313|NCT02283424|ACTIVE_COMPARATOR|chemotherapy|Carboplatin,350mg/m2,1/3weeks Docetaxel,75mg/m2,1/3weeks
62564314|NCT02283424|EXPERIMENTAL|Icotinib|Icotinib, 125mg,3/D,2years
62564315|NCT01038986||CureXcell treated|Patients with chronic and/or refractory wounds for at least 4 weeks with no improvement that have been referred by their physician for CureXcell treatment
62180504|NCT05930132|OTHER|classic lateral lamellectomy|"Regarding the lateral lamellectomy technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000; the sickle knife was used to open the concha then the scissor was used to remove the lateral lamella with its covering mucosa in one block.~No middle meatus packing was applied. Systemic antibiotics and steroids (0.5 mg / kg prednisolone) were given for two weeks after the surgery. The patients were instructed to use local nasal irrigations (2 ml of budesonide 0.5 mg / ml mixed with 250 ml of normal saline) two times daily for a month postoperatively. Patients were followed up at the end of each month throughout the six months follow-up period."
62182798|NCT01049386|ACTIVE_COMPARATOR|Sugar absorption test|In 150 mL of water four different sugars will be dissolved. Absorption will be calculated based on concentrations of sugars in 0-5 hours urine and 0-24 h collected urine.
62564316|NCT05610397||1 level STALIF® C Ti|25 patients who have a 1 level implant with STALIF® C Ti
62564317|NCT05610397||1 level STALIF® C FLX|25 patients who have a 1 level implant with STALIF® C FLX
62391253|NCT02207413|ACTIVE_COMPARATOR|Influsplit Tetra_LP 6-35m Group|Subjects in the Influsplit Tetra_LP group aged between 6 months to 35 months received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Influsplit Tetra™ vaccine produced by LP was administered intramuscularly the anterolateral region of left thigh for subjects below 12 months of age and in the deltoid region of left or non-dominant arm in subjects ≥ 12 months of age (Day 0) and in the anterolateral region of right thigh for subjects below 12 months of age and in the deltoid region of right or dominant arm in subjects ≥ 12 months of age (Day 28).
61995353|NCT00294164|EXPERIMENTAL|Serostim® 4 mg daily|
61995354|NCT00294164|EXPERIMENTAL|Serostim® 4 mg alternate days|
62391254|NCT00422942|EXPERIMENTAL|1|
61995355|NCT00294164|PLACEBO_COMPARATOR|Placebo|
61995356|NCT03786757|EXPERIMENTAL|Rivaroxaban|rivaroxaban will be added in addition to dual antiplatelet therapy.
61995357|NCT03786757|NO_INTERVENTION|dual antiplatelet therapy (DAPT)|Conventional dual antiplatelet therapy will be adopted.
61995358|NCT02189421|OTHER|Direct peroral cholangioscopy|Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
62391255|NCT04917536|ACTIVE_COMPARATOR|rotator cuff approach|the nail is inserted through the supra-spinatus tendon, which is closed at the end of the surgery
62564318|NCT05610397||1 level STALIF® M Ti|25 patients who have a 1 level implant with STALIF® M Ti
62564319|NCT05610397||1 level STALIF® M FLX|25 patients who have a 1 level implant with STALIF® M FLX
62564320|NCT05610397||2 level STALIF® C Ti|25 patients who have a 2 level implant with STALIF® C Ti
62564321|NCT05610397||2 level STALIF® C FLX|25 patients who have a 2 level implant with STALIF® C FLX
62564322|NCT05610397||2 level STALIF® M Ti|25 patients who have a 2 level implant with STALIF® M Ti
62564323|NCT05610397||2 level STALIF® M FLX|25 patients who have a 2 level implant with STALIF® M FLX
62564324|NCT03482518|EXPERIMENTAL|Intervention Group|The intervention group volunteers will receive a pair of custom slippers with perforated synthetic leather cover with elements in insoles. They will be advised to wear the slipper for 4 hours in the first week and up to 8 hours after that period. Should any part of you feel uncomfortable, the participant should return immediately so that the appropriate adjustments are made in the slipper
62564325|NCT03482518|SHAM_COMPARATOR|Control group|"The control (sham) group volunteers will receive a pair of custom slippers with perforated synthetic leather cover as those used by GI.~The difference will be that these slippers will not have the elements in the insoles."
62564326|NCT05774561|ACTIVE_COMPARATOR|Arm A - Oropharyngeal cancer patients|In total, approx. 200 OPC cancer patients will be enrolled in the study Arm A, with both prospective and retrospective parts enrolling 100 OPC patients. The Arm A will enroll patients from the Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Olomouc. Pre-treatment primary samples of fresh or FFPE tissue samples will be collected. Liquid biopsies (gargle lavage, oropharyngeal smear, breath condensate, and blood sample) will be collected. Obtained samples will be tested by CE-IVD (device complies with European in vitro diagnostic Directive) marked HPV diagnostic test. A laboratory developed digital droplet PCR assay will be used for ct HPV DNA detection. Sampling will be performed at pre \& post treatment check-ups, and every 3 months for 3 years and every 6 months for 2 years.
62564327|NCT05774561|ACTIVE_COMPARATOR|Arm B - Cervical cancer patients|Into the study Arm B will be enrolled 80 patients with CC and 120 patients with HSIL, and 80 patients will be enrolled into the retrospective part. The Arm B will enroll patients from the Department of Gynecology and Obstetrics, University Hospital Olomouc. Pre-treatment primary samples of fresh or FFPE tissue samples will be collected. Liquid biopsies (cervicovaginal swab and blood sample) will be collected. Obtained samples will be tested by CE-IVD marked HPV diagnostic test. A laboratory developed digital droplet PCR assay will be used for ct HPV DNA detection. Sampling will be performed at pre \& post treatment check-ups, and every 3 months for 2 years and every 6 months for 3 years.
61995359|NCT03037788|EXPERIMENTAL|WO3979|Formulation containing WO3979 for topical application
61995360|NCT03037788|EXPERIMENTAL|WO3970|Formulation containing WO3970 for topical application
61995361|NCT03037788|EXPERIMENTAL|WO3992|Formulation containing WO3992 for topical application
62564328|NCT02702128|ACTIVE_COMPARATOR|Tranexamic acid|1g of Tranexamic acid on 1hour and 1g of tranexamic acid on 8 hours
62564329|NCT02702128|PLACEBO_COMPARATOR|saline solution|30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
62564330|NCT01038336|EXPERIMENTAL|Multimedia HLPP|Multimedia Hearing Loss Prevention Program (HLPP)
62564331|NCT01038336|ACTIVE_COMPARATOR|Hearing Conservation Brochure|Hearing Conservation Brochure (HCB)
62564332|NCT01038336|NO_INTERVENTION|Standard-of-Care|Standard-of-Care (SoC)
62564333|NCT03972904|EXPERIMENTAL|Intervention group|The Light-Fat Rice® group
62564334|NCT03972904|PLACEBO_COMPARATOR|Control group|The comparable energy staple food group
62564335|NCT03638804|EXPERIMENTAL|89Zr-KN035 injection|
62564336|NCT03817853|EXPERIMENTAL|Obinutuzumab+Chemotherapy|Participants received 6-8 cycles of obinutuzumab, combined with 6 or 8 cycles of standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone/methylprednisolone \[CHOP - 21-day cycle) or bendamustine (28-day cycle), or cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone \[CVP - 21-day cycle\]). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. The investigator is free to choose the chemotherapy for each patient. Obinutuzumab and chemotherapy is administered during induction phase and obinutuzumab monotherapy is administered during maintenance phase.
61995362|NCT03037788|PLACEBO_COMPARATOR|Placebo of WO3988|Formulation containing Placebo of WO3988 for topical application
61995363|NCT05398978|EXPERIMENTAL|Intervention|The intervention arm will be registered in th e-Register database and recieve voice calls and text messages
62180505|NCT05930132|OTHER|submucosal conchoplasty|Regarding the submucosal conchoplasty technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000. The mucosa was incised by blade 15 starting from the axilla posteriorly up to the attachment with the basal lamella. The mucosa covering the lateral lamella was dissected using the freer dissector. The lateral lamella was removed using a through cut forceps then the mucosa was repositioned. The bony skeleton of the medial lamella was preserved
61995364|NCT05398978|NO_INTERVENTION|Control|The control group will be enrolled and followed until their delivery. They will not get the intervention.
61995365|NCT05513378|EXPERIMENTAL|With Needle Guide|A needle guide adapted to a micro-convex ultrasound probe will be used in ultrasound-guided catheterisation of the subclavian vein using the long-axis approach with an in-plane needling technique
61995366|NCT05513378|NO_INTERVENTION|Without Needle Guide|A micro-convex ultrasound probe without needle guide will be used in ultrasound-guided catheterisation of the subclavian vein using the long-axis approach with an in-plane needling technique
61995367|NCT01388634||Study cohort|Patients with prolonged length of hospital stay (\>5 days) or readmission after ventral hernia repair
61995368|NCT01388634||control group|Patients without prolonged length of hospital stay (\>5 days) or readmission after ventral hernia repair
61995369|NCT05423067|OTHER|BUAO|"The study done in two phases:~1. Phase one from October 2011to May 2012 pilot study including twenty nine (29) premenopausal patients followed up for six months~2. Phase two from October 2012 till May 2014. Including Eighty nine (89) premenopausal patients"
62180506|NCT04756206|ACTIVE_COMPARATOR|Dutasteride|Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo.
62180507|NCT04756206|PLACEBO_COMPARATOR|Placebo|same form and color of Dutasteride tablet was given at the same regimen to act as a placebo
62564337|NCT02389829|ACTIVE_COMPARATOR|Hydromorphone|Hydromorphone 1mg, administered as intravenous drip over 5 minutes. Patients can receive second 1mg dose at 1 hour.
62564338|NCT02389829|ACTIVE_COMPARATOR|Prochlorperazine|"Prochlorperazine 10mg, administered as intravenous drip over 5 minutes. Diphenhydramine 25mg co-administered.~Patients can receive second 10mg dose at 1 hour."
62564339|NCT03170362|EXPERIMENTAL|Intervention group|Pharmacogenetic test results will be provided to the provider within 72 hours of randomization in order to facilitate choice in selecting antidepressants.
62564340|NCT03170362|NO_INTERVENTION|Delay results group|The comparator arm will not receive results at the time of randomization but will get results after the 24 week assessment (thus the results are delayed).
62564341|NCT04378725|NO_INTERVENTION|Control School|"When a student is screened as a smoker. The student will only be receiving Brief Intervention Advice from the dentist.~Brief Intervention advice: delivered to all schoolchildren regardless of smoking status by the dentist. Brief information of dangers of smoking was embedded in the generic lecture of Dental Health Education given to the whole school in large group."
62564342|NCT04378725|EXPERIMENTAL|Intervention School|The Intervention schools: Screened smokers were given Advanced Intervention sessions. After discussion with the State's oral health deputy director and district's programme coordinator, for the purpose of this study, the interval of the Advance Intervention session was decided at 1-month interval.
62564343|NCT05017337||BASILICA-A|"Breast implant associated anaplastic large cell lymphoma (BIA-ALCL) patients recruited both retrospectively and prospectively.~Pre- and post-operative (3m and 12m) blood samples taken from prospectively recruited patients. Patients undergoing surgery + neo-adjuvant chemotherapy will be invited to donate an additional blood sample following the end of their neo-adjuvant chemotherapy.~Diagnostic pathology: Where possible fresh seroma aspirate / capsular tissue will be obtained, if not possible the FFPE embedded seroma or tissue block will be requested.~Post-operative pathological FFPE tissue samples obtained from all recruited patients."
62564344|NCT05017337||BASILICA-C|"Patients undergoing capsule related surgery (any-grade of capsular contracture, irradiated and unirradiated capsules) recruited prospectively.~Pre- and post-operative (3m) blood samples taken from all patients. Intra-operative tissue sampling (capsular washings, 2 samples of ADM and 2 samples of non-ADM capsule) from all patients."
62564345|NCT05017337||BASILICA-N|"Implant naive patients undergoing implant insertion surgery recruited prospectively.~Pre- and post-operative (3m and 12 m) blood samples taken from all patients."
62180508|NCT04782518||Participants with PD|Adults with Parkinson Disease. This is an observational study without an intervention.
62180509|NCT02206932|OTHER|Sofosbuvir + Simeprevir|Subjects will be enrolled and treated with simeprevir 150 mg and sofosbuvir 400 mg once daily for 12 weeks
62180510|NCT01187407|EXPERIMENTAL|12 or 18 mg flexible dose LY2216684 + SSRI|"LY2216684: flexible dose of 12 or 18 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to a 12 or 18 mg flexible dose of LY2216684.~During the AT Phase, participants first received 6 mg LY2216684 QD for 3 days, followed by 12 mg QD for the next 11 days. Then, based on efficacy and tolerability, dosage could be increased to 18 mg QD over the next 6 weeks. Participants on 18 mg QD could have had their dose decreased back to 12 mg QD. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
62182799|NCT01049386|EXPERIMENTAL|Sugar absorption test and high-fat breakfast|In 150 mL of water four different sugars will be dissolved. Absorption will be calculated based on concentrations of sugars in 0-5 hours urine and 0-24 h collected urine. Subjects will eat a high-fat breakfast together with the sugar drink, to investigate the disturbance caused by fat in intestinal absorption.
62564346|NCT03389932|NO_INTERVENTION|Standard of Care (Control)|For patients who are randomized to the control condition and who are or become potentially eligible for transplant during their enrollment in the study, they will not receive any additional interventions during the study period. Patients in this condition will only receive the education that is administered by the KPSC Kidney Transplant Program and will not receive any educational materials designed for the intervention group of this study.
62391256|NCT04917536|EXPERIMENTAL|rotator cuff split approach|the nail is inserted through the rotator cuff split, between the supra-spinatus tendon and the long part of the biceps
62564347|NCT03389932|EXPERIMENTAL|Patient-Guided|Patients in the ET@Home study condition will receive four modules of video and print transplant education over a 6-month period. After each module is mailed, 3 postcards are mailed weekly that recap important transplant educational content covered within the videos. Patients will have the opportunity to participate in a texting component of ET@Home that also sends small pieces of educational content and learning reminders by phone each week.
62564348|NCT00802048|EXPERIMENTAL|1|48h postoperative infusion of ropivacaine
62564349|NCT00802048|PLACEBO_COMPARATOR|2|48h postoperative infusion of NaCl.
62564350|NCT04620746|ACTIVE_COMPARATOR|Skin Testing Arm|These subjects with reported PCN allergy and reported low risk responses will receive skin testing followed by oral challenge
62564351|NCT04620746|ACTIVE_COMPARATOR|Direct Oral Challenge|These subjects with reported PCN allergy and low risk responses will bypass skin testing and have direct oral challenge with amoxicillin
62564352|NCT00663390|EXPERIMENTAL|I|
62564353|NCT01943214||Type II DM body constitution|Type II diabetes mellitus, body constitution
62564354|NCT03984500|OTHER|Education|"During phase 1 of this study parents who attend in person education sessions will be recruited to have their standard sessions video-taped, timed, and reviewed by the SCTaware Team. Subjects will complete before and after education questionnaires that will then be reviewed to see how much participants learned about SCT, how education was not clear and/or appropriate (too much medical jargon). The SCTaware education will then be created based on review of these videos and participants' survey responses.~For phase 2 of the study, the same recruitment strategy will be utilized. Participants will receive SCTaware and complete before and after questionnaires for evaluation. Participants in this phase will also complete follow-up questionnaires at 1 and 6 months."
62564355|NCT04154254|EXPERIMENTAL|Dementia Patients|
62564356|NCT06578611||Non-smokers|Patients who did not smoke at recruitment and during follow-up.
62564357|NCT06578611||Continuous smokers|Patients who smoked at recruitment and during follow-up.
62564358|NCT06578611||Smoking quitters|Patients who smoked at recruitment but quitted during follow-up.
62564359|NCT00636519|EXPERIMENTAL|Stage A|Botulism Antitoxin Bivalent (Equine) Types A and B Vs. Placebo
62564360|NCT00636519|EXPERIMENTAL|Stage B|Botulism Antitoxin Heptavalent (Equine) Types A-G Vs. Placebo
62772696|NCT00989781|EXPERIMENTAL|PCOS women|"Each subject will undergo pelvic 3D ultrasound followed by an iv recombinant human chorionic gonadotropin (r-hCG) stimulation test. One month later the r-hCG test will be repeated 24 hr after an injection of recombinant human follicle stimulating hormone (FSH).~After 1 month, subjects will receive a 7 hr dose-response infusion of adrenocorticotropin (ACTH) with blood sampling. Dexamethasone will be given prior to ACTH.~After 1 month, subject will receive r-hCG as described above followed the next day by an oral glucose tolerance test (OGTT). Subsequently, subjects will take Diazoxide 3 times a day for 2 weeks. At weekly intervals (2 weeks), the r-hCG stimulation test will be repeated followed the next day by an OGTT as described above."
62182800|NCT03000348|ACTIVE_COMPARATOR|High Dose, Once per day|Patient takes one oral dose of Cysteamine (high dose) per day, in the morning. The patient takes two oral placebo doses, one at mid-day and one in the evening.
62391257|NCT02948998|NO_INTERVENTION|control|The participants in control group do not take spironolactone.
62391258|NCT02948998|EXPERIMENTAL|spironolactone|The participants in spironolactone group take 10-20mg spironolactone orally and daily.
62564361|NCT00063934|EXPERIMENTAL|Treatment (oblimersen, doxorubicin, docetaxel)|"PHASE I (COMPLETED AS OF 8/16/04): Patients receive oblimersen IV continuously on days 1-6 interrupted only to administer doxorubicin IV over 15 minutes and docetaxel IV over 60 minutes on day 6. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 7-13 or pegfilgrastim SC on day 7. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~PHASE II: Patients receive doxorubicin, docetaxel, G-CSF or pegfilgrastim, and oblimersen at the MTD as in phase I.~Patients with resectable tumors after 6 courses undergo surgical resection."
62564362|NCT02571673||Survivors of head and neck cancer|Data collection will take place in two parts. Aim 1: Part 1 will enroll 10 patients at MSK to participate in component pilot testing and usability testing of HN-STAR and the associated surveys. We will also elicit feedback from the NP. After incorporating any changes to HN-STAR or the surveys based on findings from Aim 1: Part 1, Aim 1: Part 2 will enroll 30 additional patients from MSK and 15 from HH to provide feedback on usability. We will also survey each patient's PCP in Aim 1: Part 2.
62564363|NCT04945395|EXPERIMENTAL|FES and conventional training|The experimental group will wear the Functional electrical stimulation system L3100 Go for dorsiflexion of the ankle during conventional rehabilitation interventions involving the lower extremity led or instructed by a physiotherapist.
62564364|NCT04945395|ACTIVE_COMPARATOR|AFO and Conventional training only|The control group will wear an ankle-foot-orthosis (AFO) to enhance dorsiflexion of the foot while taking part in conventional rehabilitation interventions involving the lower extremity led or instructed by a physiotherapist.
62564365|NCT06151873|ACTIVE_COMPARATOR|Healthy subjects|control group sample, healthy subjects without musculoskeletal, neurological or vestibular disorders may participate.
62564366|NCT06151873|EXPERIMENTAL|Subjects with neurological damage|Subjects with cerebral palsy/acquired brain damage belonging to the Spanish National Soccer Team with cerebral palsy and acquired brain damage may participate as an experimental group.
62564367|NCT05330117|EXPERIMENTAL|Active TENS|In the active treatment group, the TENS unit will remain on up to 30 minutes (10 minutes pre-procedure, during the procedure and during the questionnaires).
62564368|NCT05330117|SHAM_COMPARATOR|Control TENS|The sham stimulation group will undergo the same procedure; however, the TENS stimulation current will be reduced to a minimal detectable level and turned off after 20 seconds.
62180511|NCT01187407|EXPERIMENTAL|6 mg fixed dose LY2216684 + SSRI|"LY2216684: fixed dose of 6 mg, administered orally, QD for 8 weeks, adjunctive to an SSRI~Prior to entering the AT Phase, participants completed a 3-week CF Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to 6 mg fixed dose of LY2216684.~During the AT Phase, participants received a 6 mg fixed dose of LY2216684 adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the DC Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
62180512|NCT01187407|PLACEBO_COMPARATOR|Placebo + SSRI|"Placebo: administered orally, QD for 8 weeks, adjunctive to an SSRI~Prior to entering the AT Phase, participants completed a 3-week CF Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to placebo.~During the AT Phase, participants received placebo (administered orally, QD) adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the DC Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
62180513|NCT04106713|EXPERIMENTAL|Individual Therapy|The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.
62180514|NCT04106713|EXPERIMENTAL|Internet-delivered Cognitive Behavioural Therapy (iCBT)|"The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: 1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven \[behaviours\] (EDBs), are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing \[behavioural\] and emotional awareness, and situational and interoceptive exposure to emotion cues."
62180515|NCT04106713|EXPERIMENTAL|Group CBT|The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.
62180516|NCT04106713|NO_INTERVENTION|Delayed Waitlist|Participants in the Waitlist group will be recruited from those referred for psychotherapy and who are not assigned to either group or iCBT and not planned for psychotherapy at IMH for 8 weeks or more from the point of consent.
62180517|NCT04106713|NO_INTERVENTION|Treatment as Usual (TAU)|Participants in the Treatment as Usual (TAU) group are individuals who are not assigned to psychotherapy at IMH. They will be recruited from outpatient services and emergency services at IMH.
62180518|NCT04260399|EXPERIMENTAL|Lavender Aromatherapy|Passive exposure via an ambient essential oil diffuser to lavender aromatherapy
62180519|NCT04260399|PLACEBO_COMPARATOR|Placebo Aromatherapy|Passive exposure via an ambient essential oil diffuser to saline water aromatherapy
62180520|NCT01125566|ACTIVE_COMPARATOR|Arm B: trastuzumab with vinorelbine|patients receive weekly intravenous infusion of trastuzumab and vinorelbine
62180521|NCT01125566|EXPERIMENTAL|Arm A: BIBW 2992 with vinorelbine|patients receive BIBW 2992 tablets once daily combined with weekly intravenous infusion of vinorelbine
62180522|NCT01163955|OTHER|Sitting in a chair|Sitting in a chair with back support and feet flat on the ground
62180523|NCT01163955|OTHER|Sitting on the Floor|Sitting on the floor without back support, crossed leg style
62180524|NCT01963572|EXPERIMENTAL|surveillance group (SG)|SG will have health education brochure and free class from the first visit post-operatively but CG will only have the brochure. Moreover, SG will be screened every time when they visit the clinics. If there is any early sign of impairment, professional advice and counseling will be given additionally.
62180525|NCT01963572|NO_INTERVENTION|general care group (CG)|CG raises any health-related question, they can be answered.
62180526|NCT02179853|EXPERIMENTAL|Anakinra|This is a dose escalation study (4 mg/kg, 6 mg/kg and 8 mg/kg).
62180527|NCT02494752|EXPERIMENTAL|Stem cell enriched|Fat graft will be enriched with ex vivo expanded stem cells
62180528|NCT02494752|ACTIVE_COMPARATOR|Non stem cell enriched|Fat graft will not be enriched with ex vivo expanded stem cells
62180529|NCT04254419|EXPERIMENTAL|NK cell infusion|"For source PBMCs from the patient, up to 3ml/kg (maximum 150ml) of heparinized peripheral blood will be drawn. NK cell product will be manufactured by a GMP facility. Once the NK cell goes through the appropriate procedures, it will undergo a lot release testing and cryopreservation by day 14 for infusion.~If NK cells fail to meet release criteria or are insufficient in number for the dose level assigned, collection of PBMCs may be repeated up to 2 additional times.~Duration of study therapy is up to 12 weeks and nine doses of NK cells."
62180530|NCT02925936|ACTIVE_COMPARATOR|Cathode|Thyroid facing the cathode end of xray machine
62180531|NCT02925936|ACTIVE_COMPARATOR|Anode|Thyroid facing the anode end of xray machine
62180532|NCT06310798|EXPERIMENTAL|Inter-professional team test|Dental hygienists, nursing assistants and older adults participating in new model for oral health planning in ordinary home settings.
62180533|NCT06310798|NO_INTERVENTION|Oral health planning control|Dental hygienists, nursing assistants and older adults participating in oral health planning in ordinary home settings (business as usual).
62391259|NCT02271763|ACTIVE_COMPARATOR|Palpating neck|Subjects will have their neck palpated by an anesthesiologist to locate their cricothyroid membrane
62391260|NCT02271763|EXPERIMENTAL|Ultrasound neck|Subjects will have their neck scanned with ultrasound by an anesthesiologist to locate their cricothyroid membrane
62391261|NCT01332422||Pediatric patients prescribed ADOAIR|Pediatric patients with asthma prescribed ADOAIR during study period
62180534|NCT01628289|OTHER|free screening group|Subjects in this group receive free diabetic retinopathy screening.
61995370|NCT01874262|EXPERIMENTAL|Active group|The software application used on the patients' smart phones in the active group, will contain both the e-diary and the mobile-phone based patient support. Patients will receive feedback by the mobile-phone based support not only on the data they enter into the mobile-phone based patient support but also on their reported daily ticagrelor use.
62180535|NCT01628289|OTHER|Pay screening group|Subjects in this group receive diabetic retinopathy screening with charging a co-payment.
62391262|NCT02276274|EXPERIMENTAL|Fasted dosing followed by fed dosing|Oral administration
62564369|NCT02945241|EXPERIMENTAL|Cystatin C-guided vancomycin dosing algorithm|Cystatin C is an endogenous cysteine proteinase inhibitor produced by all nucleated cells and a biomarker used routinely to estimate glomerular filtration rate either alone or in combination with creatinine. This new dosing algorithm includes patient weight, individualized goal trough concentration, and glomerular filtration rate (expressed with the CKD-EPI creatinine-cystatin C equation in mL/min) to determine dose and frequency.
62564370|NCT02945241|OTHER|Creatinine clearance guided vancomycin dosing|Historical controls for the quality improvement project had doses based on weight and interval established with the creatinine clearance using the Cockcroft-Gault equation.
62564371|NCT02859766|EXPERIMENTAL|Abicipar Pegol_Repeat Dose|Treatment Group 1: Abicipar pegol 2 mg administered to the study eye by intravitreal injection, 3 injections 4 weeks apart. \[Day 1, Weeks 4 and 8\]
62564372|NCT02859766|EXPERIMENTAL|Abicipar Pegol_Single Dose|Treatment Group 2: Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1.
62564373|NCT01984320|ACTIVE_COMPARATOR|Coasting|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 to 3 days until drop of estradiol to a safe level to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
62564374|NCT01984320|ACTIVE_COMPARATOR|Cabergoline|In their ICSI cycle patients will take 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
62564375|NCT01984320|ACTIVE_COMPARATOR|Coasting and Cabergoline|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 day plus receiving 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
62564376|NCT02653963|NO_INTERVENTION|Conventional AGV|A limbus-based conjunctival peritomy was created 4mm posterior to the limbus and Tenon's capsule was dissected. The AGV Plate was secured to the sclera 8 mm posterior to the limbus. The tube was trimmed to an appropriate length and inserted into the anterior chamber through a corneoscleral track. The tube was fixed to the episclera with a 10-0 nylon mattress suture. A donor sclera was fashioned to cover the exposed part of the tube and was secured to the sclera using 10-0 nylon sutures. The conjunctiva and Tenon were closed using 10-0 nylon suture.
62564377|NCT02653963|EXPERIMENTAL|Triamcinolone adjuctival AGV|Subtenon Periplate 10 mg triamcinolone acetonide around the AGV plate after fixation of AGV Plate to the sclera
62564378|NCT02375971|EXPERIMENTAL|Ranibizumab 0.2 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
61995371|NCT01874262|PLACEBO_COMPARATOR|The control group|In this group the patients will have access to the e-diary only, in which they will report their daily use of ticagrelor. The patients in the control group will not receive any feed-back.
61995372|NCT05771181|EXPERIMENTAL|Vitamin E in combination with Fuquinitinib and Tislelizumab|Patients will be treated with Vitamin E, Fuquinitinib and Tislelizumab.
62180536|NCT03185702||Patients with Turner Syndrome|Chromosomal diagnosis and typical features
62180537|NCT03185702||Unaffected controls|Normal females and unaffected family members
62180538|NCT01280747||1|Eligible fibromyalgia patients receive usual care with pregabalin prior authorization requirements in place
62180539|NCT01280747||2|Eligible fibromyalgia patients receive usual care without pregabalin prior authorization requirements in place
62180540|NCT01280747||3|Eligible painful diabetic peripheral neuropathy patients receive usual care with pregabalin prior authorization requirements in place
62180541|NCT01280747||4|Eligible painful diabetic peripheral neuropathy patients receive usual care without pregabalin prior authorization requirements in place
62391263|NCT02276274|EXPERIMENTAL|Fed dosing followed by fasted dosing|Oral administration
61995373|NCT02739191|EXPERIMENTAL|Intervention|Prophylactic negative pressure wound therapy
61995374|NCT01968642|EXPERIMENTAL|Educational Intervention|"Attending physicians in the intervention arm will receive the following multi-faceted educational intervention on transthoracic echocardiogram appropriateness: 1) a lecture at the beginning of the study period, which describes Appropriate USe Criteria (AUC) and highlights common clinical scenarios for which outpatient echocardiograms are ordered, 2) an electronic pocket cared via email that provides tips on appropriate ordering of echocardiograms, and 3) an individualized monthly feedback report that categorizes echocardiograms ordered over the preceding month. The feedback report will contain the number of echocardiograms ordered during the month and how many are classified as appropriate, inappropriate, or uncertain based on the 2011 AUC."
61995375|NCT01968642|NO_INTERVENTION|Control Group|Attending physicians in the control arm will have their echocardiogram orders tracked and classified, but will not receive any feedback on their ordering behavior.
61995376|NCT06310512|EXPERIMENTAL|Intervention group|Intervention group patients will undergo structured drug treatment management at their first visit. During on-site follow-up at 1, 3, and 6 months, as well as telephone follow-up at the second week, 2 and 4 months, the patient's condition will be evaluated, corresponding information will be collected, and possible intervention measures will be taken for the patient.
62564379|NCT02375971|EXPERIMENTAL|Ranibizumab 0.1 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
62564380|NCT02375971|ACTIVE_COMPARATOR|Laser therapy|Laser treatment to each eye on Day 1 (Baseline), with supplementary treatments allowed
61995377|NCT06310512|NO_INTERVENTION|Non-Intervention group|For non intervention group patients, pharmacists evaluate the patient's condition and collect corresponding information at the first visit and on-site follow-up at 1, 3, and 6 months, explain the dosage and dosage of drugs to the patient, and remind them of medication contraindications. Necessary intervention measures are taken at the 6th month.
61995378|NCT05539807|EXPERIMENTAL|Intervention|All participants receive the intervention
61995379|NCT03222843|EXPERIMENTAL|Arm 1|oral hetrombopag at an initial dose of 2.5 mg once daily
62564381|NCT03079986|EXPERIMENTAL|Ignoring CL (group A)|Standard care irrespective of CL.
62564382|NCT03079986|ACTIVE_COMPARATOR|Dietary treatment (group B)|Dietary treatment with medium-chain triglyceride diet (MCT-diet) until resolution of CL.
62564383|NCT04084067|EXPERIMENTAL|Indocyanine green (ICG)|Participants will receive a single dose of 1.5 mg/kg of ICG intravenously over 15 minutes prior to surgery.
62564384|NCT05928078|NO_INTERVENTION|Control|Participants will develop their usual activity
62564385|NCT05928078|EXPERIMENTAL|Intervention|Participants will use the e-Health platform
62564386|NCT00157846|EXPERIMENTAL|BiV Pacing|Biventricular pacing for 3 months, subsequently right ventricular pacing for 3 months
62564387|NCT00157846|ACTIVE_COMPARATOR|RV Stimulation|Right ventricular pacing for 3 months, subsequently biventricular pacing for 3 months
62564388|NCT05446701||60 case|Sixty patients diagnosed as NMOSD based on the recently revised 2015 international consensus diagnostic criteria for NMOSD (9) ,attending Neurology clinic, Asyut University hospitals, Asyut university and Kasr Al-Ainy multiple sclerosis/neuroimmunology clinic, Cairo University hospitals, Cairo University, Egypt, through one and half year from study onset
62564389|NCT05446701||60 control|Sixty healthy volunteers, without any neurological or systemic medical diseases, age and sex matched , will be enrolled as healthy controls(HCs).
62564390|NCT01537601|OTHER|Antibiotic prophylaxis alone|Children will be on antibioprophylaxis and will not have a circumcision.
61995380|NCT03222843|EXPERIMENTAL|Arm 2|oral hetrombopag at an initial dose of 5 mg once daily
62564391|NCT01537601|EXPERIMENTAL|Circumcision and antibiotic prophylaxis|Children will have a circumcision at the time of valve resection and will be on antibioprophylaxis
62564392|NCT01114035|EXPERIMENTAL|Patients|intestinal epithelial dysplasia
62564393|NCT01114035|OTHER|Control|Children without intestinal epithelial dysplasia
62564394|NCT03661359|EXPERIMENTAL|Social Determinants of Health|Intervention will be the Social Determinants of Health Referrals.
61995381|NCT03222843|PLACEBO_COMPARATOR|Arm 3|oral placebo at an initial dose of 2.5 mg once daily
62564395|NCT03242408|EXPERIMENTAL|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate, LPCN 1021 150 mg TU three times a day
62564396|NCT03577080|ACTIVE_COMPARATOR|ET+RT+ NMES|neuromuscular electrical training NMES
62564397|NCT03577080|PLACEBO_COMPARATOR|ET+RT|placebo neuromuscular electrical training NMES
62564398|NCT00901550|ACTIVE_COMPARATOR|Methotrexate|A drug for RA patient
62564399|NCT00901550|ACTIVE_COMPARATOR|Infliximab|for RA treatment
62564400|NCT01170429|EXPERIMENTAL|I. Procaterol Hydrochloride|Meptin (Procaterol hydrochloride) Tablets, 25µg twice daily orally plus inhaled budesonide 200µg twice daily for eight weeks;
62564401|NCT01170429|PLACEBO_COMPARATOR|II. Procaterol hydrochloride placebo|Meptin placebo (Procaterol hydrochloride) Tablets, 25µg twice daily orally plus inhaled budesonide 200µg twice daily for eight weeks;
62564402|NCT05566522||Experimental Group|Those between the ages of 20-75, Those with musculuskeletal disorders, choronic and neurological disease
62564403|NCT05566522||Control Group|Healty group
62564404|NCT05584956|ACTIVE_COMPARATOR|Group 1|n=22): Patients will receive traditional treatment and L- carnitine 50mg/kg/day orally (maximum dose 3g per day)
61995382|NCT03222843|PLACEBO_COMPARATOR|Arm 4|oral placebo at an initial dose of 5 mg once daily
61995383|NCT00951093||Patients assessed for GERD|Patients who had an open gastric bypass were assessed for GERD before and after surgery following the Montreal Consensus through a validated questionnaire in Portuguese language
61995384|NCT01902446||Chlorhexidine gluconate|Intubated subjects transported by one air service will be treated with 5 mL chlorhexidine gluconate 0.12% applied for at least 30 seconds during helicopter transport.
61995385|NCT01902446||Normal saline (placebo)|Intubated subjects assigned transported by another air service will not have any additional treatment (in addition to usual care) during helicopter transport.
61995386|NCT04300569||Patients and Caregivers: Overall Population|"Overall population of this study will include both patients with ISWRD associated with AD-D, AD-D with CVD, and/or VaD, and care givers of patients. Patients and caregivers will undergo all study procedures. Caregivers may care either for a patients who undergo all study procedure (including interview) as well for patients who do not undergo any study procedures but give consent or assent for the use of their medical records in the study (non-interviewed patient)."
61995387|NCT02243878|EXPERIMENTAL|Arm A (treatment)|"Participants will receive Stereotactic radiotherapy, a 16 Gy dose of radiation, delivered to the macula.~Participants will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met."
61995388|NCT02243878|SHAM_COMPARATOR|Arm B (control)|"Participants will receive a sham treatment.~Participants will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met."
61995389|NCT02166190|EXPERIMENTAL|Radiofrequency Ablation (EndoHbp probe)|Radiofrequency Ablation using EndoHPB Probe
61995390|NCT02166190|ACTIVE_COMPARATOR|Stenting only|Stenting only
61995391|NCT05669079|EXPERIMENTAL|Arm A|decitabine (Chia Tai Tianqing Pharma) 15 mg/m2 daily intravenously for consecutive 3 days (day 1 to day 3), combined with umbilical cord blood infusion (day 8)
61995392|NCT05669079|ACTIVE_COMPARATOR|Arm B|Supportive therapy: G-CSF for patients with absolute neutrophil count ≤ 1.5 × 109/L, rhTPO/TPO-R with platelet count ≤ 30 × 109/L, EPO with hemoglobin ≤ 85g/L.
61995393|NCT06175143|EXPERIMENTAL|GR2002 injection 1|GR2002 injection dose 1/Placebo，multiple-dose，Subcutaneous，high frequency
61995394|NCT06175143|EXPERIMENTAL|GR2002 injection 2|GR2002 injection dose 2/Placebo，multiple-dose，Subcutaneous，high frequency
61995395|NCT06175143|EXPERIMENTAL|GR2002 injection 3|GR2002 injection dose 3/Placebo，multiple-dose，Subcutaneous，high frequency
61995396|NCT06175143|EXPERIMENTAL|GR2002 injection 4|GR2002 injection dose 3/Placebo，multiple-dose，Subcutaneous，low frequency
61995397|NCT03221595|EXPERIMENTAL|Operative|Patients in the operative arm will undergo best medical management, in addition to surgical stabilization of their displaced rib fractures within 72 hours of admission to the hospital.
62180542|NCT03142321|EXPERIMENTAL|Vedolizumab 300 MG Injection [Entyvio]|Vedolizumab will be initiated at 300 mg intravenous (IV) dosing at 0, 2 and 6 weeks followed by the 1st maintenance with 300 mg IV at week 14. Patients who have not achieved clinical response at week 14 will be eligible to undergo dose escalation to 4 weekly dosing of vedolizumab depending on the judgement of the treating gastroenterologist.
62180543|NCT04623359|EXPERIMENTAL|Patients|Patient with constipation will have a high resolution manometry
62180544|NCT04623359|OTHER|Healthy volunteers|Healthy volunteers will have a high resolution manometry
62180545|NCT01821729|EXPERIMENTAL|Experimental Arm|FOLFIRINOX, Losartan, Proton Beam Radiation Therapy
62180546|NCT02264964|EXPERIMENTAL|internal jugular vein catheterization|900 patients will be received temporary central vena catheterization in right internal jugular vein with non-cuff GamCath® catheter.They will undergo AVF creation.
62180547|NCT02264964|EXPERIMENTAL|femoral vein catheterization|500 patients will be received temporary central vena catheterization in femoral vein with non-cuff GamCath® catheter, which are unsuitable for right internal jugular vein catheterization.They will undergo AVF creation.
62180548|NCT01990313|EXPERIMENTAL|Activa PC+S|
62180549|NCT02813213|ACTIVE_COMPARATOR|Standard skin graft|"This group is comprised of patients' wound halves that will receive meshed (1:3) split thickness skin graft (0.3-0.5mm thickness). This half will be covered with a standard tie over dressing. The dressing will be removed at day 5, and then it will be removed every 3 days up to the 14th day."
62182600|NCT04773730|ACTIVE_COMPARATOR|Quadratus lumborum block type 2|"After the surgery end and while the patient in the supine position, with the side to be blocked is elevated~A2-5 MHz curved array transducer will be placed at the level of the antero-superior iliac spine then the external oblique muscle will be followed posterolaterally until its posterior border will be visualized The probe will be tilted down to identify a bright hyperechoic line After that 20 mL of bupivacaine 0.25% will be injected under direct visualization on the posterior surface of quadrates lumborum muscle~The same steps will be repeated on the other side"
62564405|NCT05584956|ACTIVE_COMPARATOR|Group 2|n=22): Patients will receive traditional treatment and Sildenafil 0.25mg/kg/dose every 6 h orally (maximum dose 60 mg per day)
62564406|NCT01882985|EXPERIMENTAL|Treatment (docetaxel and lycopene)|Patients receive docetaxel IV over 1 hour on day 2 and lycopene PO once daily on days 1-21. Treatment repeats every 21days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
62564407|NCT06012188|EXPERIMENTAL|Experimental group|Children in the experimental group will be given a sleeping companion toy.
62564408|NCT06012188|NO_INTERVENTION|Control group|No intervention will be made on the control group.
62564409|NCT02661880|EXPERIMENTAL|listening to preferred music choices|All patients will be invited to complete the McGill Quality of Life Questionnaire - Revised (McGill QOL-R) upon admission to the unit. The Questionnaire will not be part of the permanent medical record and the participants will remain anonymous. Afterwards participants will be asked if they would like to listen to music during their stay in the hospital. Music will be selected according to their choices from an i-Tunes playlist. Participants will be invited to listen to music at their own discretion. Prior to discharge from the hospital or after 3 days all willing participants will be again invited to complete the McGill QOL-R questionnaire.
62564410|NCT04060667|EXPERIMENTAL|Intervention|
62564411|NCT04060667|NO_INTERVENTION|control|
62564412|NCT01473823|PLACEBO_COMPARATOR|Placebo oil|Canola oil with high oleic acid content flavored with lemon supplied as 5 ml daily.
62564413|NCT01473823|ACTIVE_COMPARATOR|Omega-3 LCPUFA|"The omega-3 LCPUFA supplementation comprises of 5 ml daily of Möller's Tran flavored with lemon. This dose provides the child with 1200 mg of omega-3 fatty acid of which 600 mg is DHA and 400 mg is EPA."
62564414|NCT06136533||Obesity Hypoventilation Syndrome Group|Individuals diagnosed with OHS over the age of 18 years who met the inclusion criteria and who were followed up by Istanbul University Faculty of Medicine, Department of Chest Diseases
62564415|NCT06136533||Obesity Hypoventilation Syndrome with Sarcopenic Obesity group|Individuals over the age of 18 years with a diagnosis of OHS and sarcopenic obesity who met the inclusion criteria and who were followed up by Istanbul University Faculty of Medicine, Department of Chest Diseases.
62564416|NCT01555749|EXPERIMENTAL|NNC172-2021 low dose / Placebo|
61995398|NCT03221595|NO_INTERVENTION|Non-operative|Patients in the non operative arm will undergo best medical management of their displaced rib fractures.
61995399|NCT01876069|ACTIVE_COMPARATOR|22 gauge ProCore needle aspiration|EUS-guided pancreatic mass aspiration with 22 gauge ProCore needle
61995400|NCT01876069|ACTIVE_COMPARATOR|22 gauge Fine needle aspiration|EUS-guided pancreatic mass aspiration with 22 gauge Fine needle
62182601|NCT01618578||Patients with CRPS|24 patients with CRPS of the upper limb type 1 were included into the study.
62564417|NCT01555749|EXPERIMENTAL|NNC172-2021 high dose / Placebo|
62564418|NCT05159531|EXPERIMENTAL|Standard model of care|Delivery of PrEP care through the local standard of care.
62564419|NCT05159531|ACTIVE_COMPARATOR|mHealth model of care|Delivery of PrEP care through the Freddie® mobile Health (mHealth) platform.
62564420|NCT01167140|EXPERIMENTAL|Cryo-Touch II|
62564421|NCT06021405|EXPERIMENTAL|Tape stripping|
62564422|NCT05526638|EXPERIMENTAL|New/ recurrent mycosis fungoides patients|New' Recurrent mycosis fungoides treatment will receive be assessed for both serum and tissue levels of IL-15 and IL-15 Rα prior to and after treatment with phototherapy
62564423|NCT05928507||Adult Category 1 -fresh prospective|NP swabs from the Adult population \>17 years, collected prospectively from adults presenting with symptoms of respiratory illness. Tested within 72 hours of collection.
62180550|NCT02813213|EXPERIMENTAL|Skin micro graft|"This group is comprised of the patients' wound halves that will receive skin micro grafts. To obtain this grafts the investigators will use Xpansion micro-autografting system. They will use 0.8 x 0.8 mm skin grafts with a graft to graft distance of 4mm (1:50 expansion).This half will be covered with a special hydrogel dressing with keratinocyte growth factor (Epilife medium with calcium) 1.5ml for each 14 square centimeters of the wound. This half will be covered with a wet adhesive foam dressing and then it will be covered up with a non-adherent interface dressing (tegaderm). The dressing will be removed at day 5, and then it will be removed every 3 days up to the 14th day. Each time of dressing change only the non-adherent interface dressing will be removed, and the area will be bathed with keratinocyte growth factor solution."
62180551|NCT04106453|EXPERIMENTAL|navigated microwave ablation|microwave ablation is performed laparoscopically with navigation
62180552|NCT04106453|ACTIVE_COMPARATOR|ultrasound guided microwave ablation|microwave ablation is performed laparoscopically with ultrasound guidance
62180553|NCT00721929|EXPERIMENTAL|adrenal mass group|
62180554|NCT00934414|EXPERIMENTAL|Smokers|
62180555|NCT00934414|EXPERIMENTAL|Non-Smokers|
62180556|NCT01268098|EXPERIMENTAL|25 µg dose|25 µg
62180557|NCT01268098|EXPERIMENTAL|50 µg dose|50 µg
62564424|NCT05928507||Pediatric Category 1 -fresh prospective|P swabs from the pediatric population \<=17 years, collected prospectively from pediatrics presenting with symptoms of respiratory illness. Tested within 72 hours of collection.
62564425|NCT05928507||Adult Category 2 -frozen prospective|NP swabs from the Adult population \>17 years, were collected prospectively from adults presenting with symptoms of respiratory illness. Frozen following CLSI guidelines to be Tested at a later time point approximately 3 months.
62564426|NCT05928507||Pediatric Category 2 -frozen prospective|NP swabs from the pediatric population \>17 years, were collected prospectively from pediatrics presenting with symptoms of respiratory illness. Frozen following CLSI guidelines to be tested at a later time point approximately 3 months.
62180558|NCT04383847|EXPERIMENTAL|Main study|There is only 1 arm because this is a feasibility and acceptability pilot.
62180559|NCT02238106|EXPERIMENTAL|Salmeterol inhalation powder, medium dose|administered via HandiHaler®
62180560|NCT02238106|ACTIVE_COMPARATOR|Salmeterol inhalation powder, low dose|administered via HandiHaler®
62180561|NCT02238106|ACTIVE_COMPARATOR|Salmeterol inhalation powder, high dose|administered via HandiHaler®
62180562|NCT02238106|ACTIVE_COMPARATOR|Serevent® Diskus®|administered via Diskus®
62180563|NCT02238106|PLACEBO_COMPARATOR|Placebo|administered via Diskus® or HandiHaler®
62772697|NCT00989781|EXPERIMENTAL|Normal women|"Each subject will undergo pelvic 3D ultrasound followed by an iv recombinant human chorionic gonadotropin (r-hCG) stimulation test. One month later the r-hCG test will be repeated 24 hr after an injection of recombinant human follicle stimulating hormone (FSH).~After 1 month, subjects will receive a 7 hr dose-response infusion of adrenocorticotropin (ACTH) with blood sampling. Dexamethasone will be given prior to ACTH.~After 1 month, subject will receive r-hCG as described above followed the next day by an oral glucose tolerance test (OGTT). Subsequently, subjects will take Diazoxide 3 times a day for 2 weeks. At weekly intervals (2 weeks), the r-hCG stimulation test will be repeated followed the next day by an OGTT as described above."
62772698|NCT01946126||Chronic Migraine Diagnosis|This is a retrospective chart review for patients diagnosed with Chronic Migraine. There is no intervention in this study.
62772699|NCT01946126||Other Headache Diagnoses|This is a retrospective chart review of patients with headache diagnoses other than Chronic Migraine. There is no intervention in this study.
62180564|NCT04842526|EXPERIMENTAL|Anlotinib and irinotecan combined with temozolomide|
62180565|NCT00409591|ACTIVE_COMPARATOR|1|"NVP-NVP:~* In women, one NVP 200 mg tablet at onset of labor;~* In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours"
62180566|NCT00409591|EXPERIMENTAL|2|"PL-NVP:~* In women, one placebo tablet at onset of labor;~* In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours"
62180567|NCT00409591|EXPERIMENTAL|3|"LPV/r:~* In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery"
62180568|NCT00466089|EXPERIMENTAL|1|RT + Tarceva
62180569|NCT00466089|NO_INTERVENTION|2|RT
62180570|NCT05653973|EXPERIMENTAL|assessment of microvascular function|The investigators use intradermal microdialysis to deliver acetylcholine, acetylcholine + L-NAME, endothelin-1, endothelin-1 + BQ-788, and endothelin-1 + BQ-123 to the cutaneous microvasculature.
62180571|NCT04858321|EXPERIMENTAL|Passive heating|8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature \~38.5 °C and \<39 °C) sessions over a period of 14 days.
62180572|NCT03650335||group I|with a total of 20 mL 0.25% bupivacaine injection to be administered
62180573|NCT03650335||group II|with a total of 30 mL 0.25% bupivacaine injection to be administered
62180574|NCT05184621|ACTIVE_COMPARATOR|efficacy|Including Primary outcome: changes in axial length of the eye. Secondary outcome: Equivalent spherical lens variation Other indicators: ① Changes in visual acuity with lenses, corrected visual acuity, and intraocular pressure.② Observation of changes in corneal thickness, anterior chamber depth, ciliary body thickness, and crystal thickness.Observation of fundus tissue structure of macula and peri-optic disc area. Observation of fundus choroidal/retinal thickness.Adherence index: frequency of device use.
62182602|NCT01618578||Patients with unilateral upper limb pain|21 patients with unilateral upper limb pain served as controls.
62182603|NCT01618578||healthy subjects|24 healthy subjects were age- and sex matched to patients with CRPS.
62180575|NCT05184621|ACTIVE_COMPARATOR|safety|"Description of safety parameters: Adverse events, device defects during the test.~Method and time selection for evaluation, recording, and analysis of safety parameters. Adverse events and device defects were recorded from the beginning of each subject's enrollment to the end of the group for evaluation. Safety indicators:① Incidence of allergic reactions.② Posterior image time more than 5 minutes.③ The decrease of near vision.④ The grade of side effects such as self-induced photophobia and blurred vision.⑤ Elevated intraocular pressure, headache, nausea, and vomiting, etc."
62182604|NCT05672771|EXPERIMENTAL|Different Mixed Condition (DM)|Training in both Lexical Decision Span and Category Span in Phase 1 (which are both different from the target task Reading Span in Phase 2).
62772700|NCT01452503|ACTIVE_COMPARATOR|PATH Women's Condom|PATH Women's Condom
62772701|NCT01452503|ACTIVE_COMPARATOR|FC2 female condom|Female Health Company's FC2 female condom
62772702|NCT01452503|ACTIVE_COMPARATOR|Reddy 6 female condom (V-Amour)|Reddy 6 female condom (Commercially known as the V-Amour female condom)
62772703|NCT01641822|ACTIVE_COMPARATOR|AZLI|Participants will be randomized to receive 3 cycles of treatment, each cycle consisting alternating regimens: AZLI for 28 days followed by TIS for 28 days.
62772704|NCT01641822|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive 3 cycles of treatment, each cycle consisting alternating regimens: placebo to match AZLI for 28 days followed by TIS for 28 days.
62772705|NCT06166329|EXPERIMENTAL|chair lift test|
62772706|NCT04383938|EXPERIMENTAL|Safety Lead In|Patients with advanced solid tumors. Up to 3 dose levels evaluated.
62772707|NCT04383938|EXPERIMENTAL|Expansion 1|Patients with advanced gastric cancer.
62772708|NCT04383938|EXPERIMENTAL|Expansion 2|Patients with advanced urothelial/bladder cancer.
62772709|NCT04383938|EXPERIMENTAL|Expansion 3|Patients with advanced NSCLC.
62772710|NCT02160444|EXPERIMENTAL|CBT plus Parent as CBT Coach Training|CBT plus Parent as CBT Coach Training
62772711|NCT06071156|ACTIVE_COMPARATOR|CMR-guided therapy management,|The scheme of Anakinra treatment was three months at full dosage, the next three months of therapy at full dosage every other day, and the last three months at halved dosage every other day until the end of treatment. Cardiac magnetic resonance \[no pericardial edema and/or late gadolinium enchantment (LGE)\] guided each anakinra dose reduction. If the tests were positive for ongoing pericardial inflammation \[pericardial edema present or LGE present\], the reduction was postponed, and one more month of therapy was administered before the reduction.
62772712|NCT06071156|ACTIVE_COMPARATOR|CRP-guided therapy management,|The scheme of Anakinra treatment was three months at full dosage, the next three months of therapy at full dosage every other day, and the last three months at halved dosage every other day until the end of treatment. Laboratory tests \[C-reactive protein (CRP) \<0.6 mg/dL\] guided each anakinra dose reduction. If the tests were positive for ongoing systemic inflammation (CRP \> 0.6 mg/dL), the reduction was postponed, and one more month of therapy was administered before the reduction.
62772713|NCT03989323||Patients treated with immunotherapy|Patients receiving for the first time an immunotherapy treatment for their cancer (Checkpoints inhibitors, such as PD-1 or PD-L1 or CTLA4...). Patients will be enrolled before starting the immunotherapy treatment and will be followed up for 5 years or until the permanent discontinuation of the immunotherapy treatment to describe the arm.
62772714|NCT06464965|EXPERIMENTAL|CB CAR-NK182|Set 3 dose groups: dose group 1(2 × 10\^6/kg/time, cell infusion on days 0,7 and 14, respectively, 3 times in total), dose group 2(4 × 10\^6/kg/time, cell infusion on days 0,7 and 14, respectively, 3 times in total), dose group 3(8 × 10\^6/kg/time, cell infusions were performed on days 0,7 and 14, respectively, for a total of 3 times). Each dose will enroll 3-6 subjects, each subject will be observed for at least 28 days after receiving the first dose, and the long-term follow-up period will be 2 years after each patient's first dose infusion.
62772715|NCT01441700|ACTIVE_COMPARATOR|Prone position|
62772716|NCT01441700|ACTIVE_COMPARATOR|Supine position|
62772717|NCT06502834|PLACEBO_COMPARATOR|Placebo|Placebo vial (10ml of glycerol 10% and 10% maltrodextrin)
62772718|NCT06502834|EXPERIMENTAL|D piger|D. piger vial with 109 colony forming units (CFU) (=108 CFU D. piger per ml in 10ml of glycerol 10% and 10% maltrodextrin).
62772719|NCT03925688||without heterotopic ossification|There had not existed radiographic evidences of heterotopic ossification.
62772720|NCT03925688||with heterotopic ossification|There had existed radiographic evidences of heterotopic ossification or formatted ectopic lamellar bone.
62772721|NCT01818492|EXPERIMENTAL|NI-0501|NI-0501 administered by IV infusion at a starting dose of 1 mg/kg.
62772722|NCT04452773|EXPERIMENTAL|Manremyc|Participants will receive daily oral administration of a capsule of Manremyc for 14 days in the morning with breakfast
62772723|NCT04452773|PLACEBO_COMPARATOR|Placebo|Participants will receive daily oral administration of a capsule of Placebo for 14 days in the morning with breakfast
62772724|NCT02491424|EXPERIMENTAL|Fixation of ITAP to lower limb amputees.|"Direct skeletal fixation of ITAP to lower limb amputees. 20 patients in the study will be fitted with Intraosseous Transcutaneous Amputation Prosthesis.~The device has been designed to be surgically implanted in a one stage procedure."
62772725|NCT03233126|EXPERIMENTAL|KRN23|Subjects will receive subcutaneous injections of KRN23 every 2 weeks from Week 0 through Week 128
62772726|NCT02785614|EXPERIMENTAL|II-1|"This is 2-period, 2 cross (2x2) crossover design was used. each 3 males and 3 females, give the following two different crossover treatments in the following sequence:~R: trazodone hydrochloride tablets 50mg for 3 times per day for 7 days T: trazodone hydrochloride prolonged-release tablets 150 mg per day for 7 days. Wash-out period is 14 days."
62772727|NCT02785614|EXPERIMENTAL|II-2|"This is 2-period, 2 cross (2x2) crossover design was used. each 3 males and 3 females, give the following two different crossover treatments in the following sequence:~T: trazodone hydrochloride prolonged-release tablets 150 mg per day for 7 days R: trazodone hydrochloride tablets 50mg for 3 times per day for 7 days. Wash-out period is 14 days."
61995401|NCT05449730||Yoga instructor|(a) overall good health and can cooperate with orders reasonably; (b) between the ages of 25 to 60 years old; (c) no limb or leg discrepancy; (d) no history of surgery on the lower limbs or spine; (e) no history of musculoskeletal injury over the lower back in the past six months; (f)practice yoga three to six days per week and at least ten years of experience in yoga
62564427|NCT05885425||100 patients with stabile chronic heart failure with remote control|Group 1 is the intervention group, their health status will be monitored telemetrically for a half year by several electronic devices (for measurement of hearth frequency, blood pressure, blood saturation and periodically ECG recordings). Data will be periodically transmitted to the doctor in the ambulance. If measured data will indicated any worsening of heath (decompensation of circulation), physician will adjust the treatment remotely.
62564428|NCT05885425||Non-intervention group: 100 patients with stabile chronic heart failure without remote control|Group 2 with patients with chronic heart failure in the non-intervention group, they will not be contacted by own physician for half a year - the planned periodic control will be scheduled after half a year.
62564429|NCT00444002||Hepatitis C - Steatosis|Patients with chronic Hep C infection undergoing liver biopsy with \>=5% steatosis on liver biopsy
62564430|NCT00444002||Hepatitis C - no steatosis|Patients with chronic Hep C infection without steatosis on liver biopsy (\<5% of hepatocytes involved)
62564431|NCT02179892|ACTIVE_COMPARATOR|Group 1-Exparel|Bupivacaine Extended-Release Liposome Injection (Exparel)will be administered via TAP block procedure
62564432|NCT02179892|ACTIVE_COMPARATOR|Group 2-Bupivacaine and Dexamethasone IV|Bupivacaine and Dexamethasone Injection will be administered via TAP block procedure.
62564433|NCT01080482|ACTIVE_COMPARATOR|Prograf® Capsule 5 mg|
62564434|NCT01080482|EXPERIMENTAL|Tacrolimus Capsule 5 mg|
62564435|NCT05565248|EXPERIMENTAL|VCTX211 unit|
62564436|NCT02686931||Control|Control: Normal developmental children with orthopedic disease
62564437|NCT02686931||Experimental|Experimental: Developmental delayed children
62564438|NCT03303313|EXPERIMENTAL|Cemdisiran|
62564439|NCT04169269|ACTIVE_COMPARATOR|Enoxaparin|enoxaparin injectable, 40 milligram subcutaneous injection daily for 20 days
62564440|NCT04169269|ACTIVE_COMPARATOR|Rivaroxaban|rivaroxaban oral 10 milligram tablet daily for 20 days
62564441|NCT01449656||LMA proseal|
62564442|NCT01449656||LMA Supreme|
62564443|NCT05943756|EXPERIMENTAL|Signature Strengths|In this arm, participants would participate in in an intervention program meant to improve well-being in individuals who have sustained a brain injury.
61995402|NCT05449730||Healthy adult control|(a) overall good health and can cooperate with orders reasonably; (b) between the ages of 25 to 60 years old; (c) no limb or leg discrepancy; (d) no history of surgery on the lower limbs or spine; (e) no history of musculoskeletal injury over the lower back in the past six months; (f) no experience with yoga training; (g)participated in regular exercise 2 or 3 times a week
62182605|NCT05672771|EXPERIMENTAL|Different Single Condition (DS)|Training in the Lexical Decision Span in Phase 1 (which is different from the target task Reading Span in Phase 2).
62564444|NCT05943756|ACTIVE_COMPARATOR|TBI Education Course|In this arm, participants would participate in in an intervention program meant to improve well-being in individuals who have sustained a brain injury.
62564445|NCT01821235|EXPERIMENTAL|Neurontin® (gabapentin) batch A|
62564446|NCT01821235|EXPERIMENTAL|Neurontin® (gabapentin) batch B|
62564447|NCT01821235|EXPERIMENTAL|Gabasandoz® (gabapentin) batch A|
61995403|NCT01166685|ACTIVE_COMPARATOR|Everolimus-eluting stent|A Xience Prime stent (Everolimus-eluting stent) is implanted in significant coronary lesions.
62564448|NCT01821235|EXPERIMENTAL|Gabasandoz® (gabapentin) batch B|
62564449|NCT03608033|EXPERIMENTAL|OMS721|Administration of OMS721
61995404|NCT01166685|ACTIVE_COMPARATOR|Bare-metal stent|Implantation of a bare-metal stent
62564450|NCT03608033|PLACEBO_COMPARATOR|Placebo|Administration of Vehicle (D5W or Saline Solution)
62564451|NCT04570839|EXPERIMENTAL|Dose Escalation Cohorts.|Up to 5 sequential dose escalation cohorts of COM701 in combination with fixed doses of BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks until a maximum tolerated dose or recommended dose for expansion is identified.
62564452|NCT04570839|EXPERIMENTAL|Cohort 1 Expansion Cohort A (ovarian cancer)|Single arm: subjects with platinum resistant/refractory epithelial ovarian cancer, primary peritoneal or fallopian tube cancer will be randomized to receive study treatment with COM701 in combination with BMS-986207 and nivolumab. The study drugs will be administered IV every 4 weeks.
62564453|NCT04570839|EXPERIMENTAL|Cohort 2 Expansion Cohort (endometrial cancer).|Single arm: subjects with MSS-endometrial cancer will receive study treatment with COM701 in combination with BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks.
62564454|NCT04570839|EXPERIMENTAL|Cohort 3 Expansion Cohort (basket cohort - high PVRL2 tumors).|Single arm: subjects with tumor types with high expression of PVRL2 will receive study treatment with COM701 in combination with BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks.
62182606|NCT05672771|ACTIVE_COMPARATOR|Same Task (ST) Practice Control|Training in Reading Span task in Phase 1 (which is the same as target task in Phase 2).
62182607|NCT05672771|PLACEBO_COMPARATOR|Non-WM Placebo Control (PC)|Training in a speeded Lexical Decision task only (which has no memory component) in Phase 1 prior to Phase 2 training in WM.
62564455|NCT04570839|EXPERIMENTAL|Cohort 4 Expansion Cohort (Head and Neck cancer).|"Two arms: subjects with head and neck cancer. Equal number of subjects in each of the 2 arms. One arm will enroll subjects who have not previously received treatment with an immune checkpoint inhibitor, the other arm will enroll subjects who have received prior treatment with an immune checkpoint inhibitor.~All subjects will receive study treatment with COM701 in combination with BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks."
61995405|NCT01166685|EXPERIMENTAL|Biodegradable Polymer-DES|Implantation of a Biodegradable Polymer-DES
62564456|NCT01014546|EXPERIMENTAL|Treatment (arsenic trioxide with or without ascorbic acid)|Patients receive arsenic trioxide PO QD in orange juice on days 1-21. Patients may also receive ascorbic acid PO QD on days 1-21. Treatment repeats every 28 days for up to 168 days in the absence of disease progression or unacceptable toxicity.
62564457|NCT00502242|ACTIVE_COMPARATOR|A|Capsule - initial treatment is 5 mg (active)- oral - once per day
62564458|NCT00502242|PLACEBO_COMPARATOR|B|Capsule - initial treatment is 5 mg (placebo) - oral - once per day
62564459|NCT03373877|EXPERIMENTAL|Dose 1: PU-H71 225 mg/m2 + ruxolitinib|Cohort 1
62564460|NCT03373877|EXPERIMENTAL|Dose 2: PU-H71 300 mg/m2 + ruxolitinib|Cohort 2
62564461|NCT03373877|EXPERIMENTAL|Dose 3: PU-H71 400 mg/m2 + ruxolitinib|Cohort 3
62564462|NCT03373877|EXPERIMENTAL|Dose 4: PU-H71 600 mg/m2 + ruxolitinib|Cohort 4
61995406|NCT02882555|EXPERIMENTAL|Children|"12 concentrations of caspaicin are administered: - 0.6, 1.2, 2.4, 4.8, 9.8, 19.5, 39, 78.1, 156.2, 312.5, 625, 1250 μmol/l. Capsaicin concentration eliciting at least 2 coughs (C2) or 5 coughs (C5) is determined.~At least 1-hour-interval from capsaicin dose titration (in order to minimize tachyphylaxy)~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls (normal saline) in random order at baseline~At least 1-hour-interval (in order to minimize tachyphylaxy)~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls in random order during exercise, when heart rate is maximum"
61995407|NCT02882555|ACTIVE_COMPARATOR|Adults|"As reference for more precise assessment of effects of development.~12 concentrations of caspaicin are administered: 0.49, 0.98, 1.95, 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250, 500, 1000 μmol/l. Capsaicin concentration eliciting at least 2 coughs (C2) or 5 coughs (C5) is determined.~At least 1-hour-interval from capsaicin dose titration (in order to minimize tachyphylaxy)~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls (normal saline) in random order at baseline~At least 1-hour-interval (in order to minimize tachyphylaxy)~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls in random order during exercise, when heart rate is maximum"
61995408|NCT01751607||genetic variants|AFib patients with or without the genetic variants
62564463|NCT02866305|EXPERIMENTAL|HRCT with bullae, treatment conservative|Patients undergo High-resolution CT scan, and significant bullae are identified (i.e. \> 1 cm). Afterwards randomised to conservative treatment with conventional chest-tube drainage.
62564464|NCT02866305|EXPERIMENTAL|HRCT no bullae, treatment conservative|Patients undergo High-resolution CT scan, and no significant bullae are identified (i.e. \> 1 cm). Afterwards randomised to conservative treatment with conventional chest-tube drainage.
62564465|NCT02866305|EXPERIMENTAL|HRCT with bullae, treatment VATS.|Patients undergo High-resolution CT scan, and significant bullae are identified (i.e. \> 1 cm). Afterwards randomised to active treatment with VATS bullectomy and mechanical pleurodesis.
62564466|NCT02866305|EXPERIMENTAL|HRCT no bullae, treatment VATS.|Patients undergo High-resolution CT scan, and no significant bullae are identified (i.e. \> 1 cm). Afterwards randomised to active treatment with VATS bullectomy and mechanical pleurodesis.
62564467|NCT02613793||Preterm pre-eclampsia (cases)|Pregnant patients diagnosed with pre-eclampsia prior to 35 weeks gestation
62564468|NCT02613793||Pregnant patients (controls)|Age- and gestation-matched pregnant patients who are not suffering with pre-eclampsia, hypertensive disease or any other neuropsychiatric condition
62564469|NCT01754155|OTHER|Vitamin E Polyethylene and RSA|All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.
62564470|NCT04483830|PLACEBO_COMPARATOR|group A|patient with the early stages of COVID-19 to received an oral dose of placebo twice a day for 21 days
62564471|NCT04483830|ACTIVE_COMPARATOR|group B|patient in the early stages of COVID-19 to received an oral dose of 500LRU of sulodexide twice a day for 21 days.
62564472|NCT04885881|ACTIVE_COMPARATOR|Ozone therapy group|Patients with myofascial pain syndrome receiving ozone injection
62564473|NCT04885881|ACTIVE_COMPARATOR|Lidocaine injection group|Patients with myofascial pain syndrome receiving lidocaine injection
62564474|NCT01955928|EXPERIMENTAL|Online Cognitive behavioral treatment for insomnia|Online Cognitive behavioral treatment for insomnia
62564475|NCT01955928|NO_INTERVENTION|Waiting-list|Waiting-list
62564476|NCT05494710|EXPERIMENTAL|Bleomycin electrosclerotherapy treatment|Bleomycin electrosclerotherapy treatment administered. The combination of Bleomycin and electroporation of the treated area is called electrochemotherapy (ECT).
62564477|NCT04936763|EXPERIMENTAL|Janesse 20|
62180576|NCT02754869||Control Subject-Drug Study|The first part of this investigation is an interventional blinded cross over study with two dosing dates spread at least one week apart. Each volunteer will receive baseline scans before drug/placebo which will be used to assess intra---patient variation over the two study dates after which the drug or saline placebo will be administered with each volunteer acting as their own control to assess software ability to quantify changes in bowel motility.
62180577|NCT02754869||Dysmotility Subjects-Drug Study|The second component of this study will be exactly the same for the participants with dysmotility except the time to repeat scan will be reduced with a follow up time aimed at around 1---3 days reducing patient time off medication
62180578|NCT02754869||Reference Range Study|The third component of this study will assess basal small bowel motility in larger numbers of healthy controls, dysmotility subjects and irritable bowel syndrome to establish reference ranges to inform future clinical investigations and guide clinical decision making using global motility scoring. Each scan will last around 20 minutes and will not involve follow up or use of pharmaceutical agents.
62180579|NCT02754869||Desmotility Reversibility Study|The fourth component of the study will assess small bowel motility in a cohort of Crohns disease patients will small bowel disease before and 11---16 weeks after starting anti TNF alpha therapy, or undergoing endoscopic dilatation of a small bowel stricture. Each scan will last around 45 minutes
61995409|NCT05768854|ACTIVE_COMPARATOR|Intravenous Bisphosphonates (IV-BP) -> Setrusumab|"Participants on IV-BP will continue their existing dose/regimen per investigator discretion; for participants not on IV-BP, the dose/regimen will be determined by the investigator.~After the active-controlled period, participants will receive Setrusumab during the extension period"
62180580|NCT05330351||Pediatric Trauma Patients|Pediatric patients (\<18 years old) who have suffered a traumatic event requiring surgical fixation within 48 hours prior to time to arrival in the operating room.
62180581|NCT02588989||transposition of the great arteries|Patients with a TGA
62564478|NCT04672577||Arboviral infection or malaria positive cohort|
62564479|NCT03063437|EXPERIMENTAL|Active: Encapsulated Fecal Microbiota Preparation|Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.
62564480|NCT03063437|PLACEBO_COMPARATOR|Placebo: Encapsulated Placebo|Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, and 28 days, and 6 months.
62564481|NCT04826081||Case|women who contracted symptomatic dengue fever during pregnancy
62564482|NCT04826081||Control|women who did not contract symptomatic dengue fever during pregnancy
62564483|NCT00712712|EXPERIMENTAL|Patient who has undergone radiofrequency ablation of bone metastases|Patient who has undergone radiofrequency ablation of bone metastases, localized, causing pain refractory to radiotherapy or not accessible to new irradiation, biphosphonates and well-conducted morphine analgesic treatment.
62564484|NCT02571491|EXPERIMENTAL|Ketamine Hydrochloride|"Received a combination of ketamine, remifentanil and morphine hydrochloride established by the following dosage regimen:~* KETAMINE HYDROCHLORIDE 0,5mg/Kg Intravenous bolus administered during the anesthetic induction, followed by 2 mcg / Kg / min of intravenous infusion during and after surgery until 72 hours postoperation~* during surgery remifentanil 0,3 mcg / kg / min.~* at the end of the operation morphine hydrochloride150 mcg / kg, PCA infusion postoperatively."
62182608|NCT01944449|EXPERIMENTAL|Whey Protein (WPC) at breakfast|The subjects in Whey Protein (WPC) group will consume WPC (35gr) powder in bottles mixed with 250 ml milk, making a total of 42 g protein, at breakfast, for 12 weeks.
62182609|NCT01944449|EXPERIMENTAL|Other Protein Sources at breakfast|The subjects will consume also 42 g protein at breakfast but from different source, for 12 weeks.
61995410|NCT05768854|EXPERIMENTAL|Setrusumab|Participants will receive Setrusumab during the active-controlled and extension period
61995411|NCT03034993|EXPERIMENTAL|Text Messaging|This group will receive text messages with appointment reminders, medication taking education and motivation, and for reporting of mood.
61995412|NCT03034993|PLACEBO_COMPARATOR|Control|This group will receive simple text messages about general health promotion, such as about the importance of drinking water on hot days, using sunscreen, etc.
62182610|NCT01944449|ACTIVE_COMPARATOR|Low Protein at breakfast|The subjects will consume 17 g protein breakfast namely from soy for 12 weeks.
62182611|NCT05365087||TS Cohort|Patients who chose the Transoral Fundoplication (TF) prior to the Laparoscopic Sleeve Gastrectomy (LSG) procedure.
62564485|NCT02571491|PLACEBO_COMPARATOR|Placebo|"Received a combination of physiological serum, remifentanil and morphine hydrochloride established by the following dosage regimen:~* 0,9 % physiological serum 0,5mg/Kg administered by an intravenous (IV) line during the anesthetic induction, followed by 2 mcg / Kg / min of intravenous infusion during and after surgery until 72 hours postoperation~* during surgery remifentanil 0.3 mcg / kg / min.~* at the end of the operation morphine hydrochloride150 mcg / kg, PCA infusion postoperatively."
62564486|NCT01070368|EXPERIMENTAL|Food challenge, skin test|Skin test by two extract commercial, and in-house extract. and open challenge with wheat (except in patient with history of wheat anaphylaxis: assume as challenge positive)
62564487|NCT05202197||Experimental|Alzheimer´s patients
61995413|NCT00353743|ACTIVE_COMPARATOR|1|Patients that receive up to 10 days of doxycycline 200mg/day and metronidazole 500mg/day
61995414|NCT00353743|PLACEBO_COMPARATOR|2|Patients that do not receive antibiotics, only placebo
62564488|NCT02793869||Total cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
62564489|NCT02793869||Anterior cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
62564490|NCT02793869||Interior cataracts group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
61995415|NCT00402675|ACTIVE_COMPARATOR|Immediate Intervention|Patients with NSTEMI undergo immediate invasive angiography (\< 2 hours)
61995416|NCT00402675|ACTIVE_COMPARATOR|Early Intervention|Patients with NSTEMI undergo early invasive angiography (12-48 hours)
62180582|NCT01395511|EXPERIMENTAL|Acupuncture|"About ten acupuncture points are selected from the following points to be used. Local Acupoints : SI14, SI15, BL10, BL12, BL13, BL14, TE15, GB20, SI9~Distal Acupoints :~* Upper extremities: LU6, LU7, LU9, LI11, HT3, SI2, SI3, SI5, SI7, PC4, PC6, TE5~* Lower extremities: SP3, SP4, BL59, BL60, BL61, BL62, BL66, KI3, KI4,KI6, KI7, GB40, GB41, LR4~All Acupuncture points were prepared with 70% alcohol pads, and disposable stainless steel needles were used. Most of acupuncture were inserted vertically 1\~1.5cm in depth until patient can feel De-Qi. (No more additional stimulation)"
62564491|NCT02793869||Posterior cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
62564492|NCT01479075|EXPERIMENTAL|intranasal insulin in patients|intranasal insulin is applied to diabetic patients under fasting conditions
62564493|NCT01479075|EXPERIMENTAL|intransal insulin in study participants|intranasal insulin is applied to healthy patients under fasting conditions
62772728|NCT06368908|EXPERIMENTAL|Transcutaneous functional magnetic muscle stimulation|Transcutaneous Functional Magnetic Stimulation (FMS) Peripheral neuromuscular system stimulation will be conducted for the quadriceps femoris muscle using a magnetic stimulator (Tesla stym, Iskra Medical, Otoče, Slovenia). For magnetic stimulation, we will use pulse trains (20-50 Hz) with intensities ranging from 0.5 to 2.5 Tesla. The stimulation trains will be up to 3-6 seconds long, and the duty cycle will be varied from 1:1 to 1:10. Muscles will be stimulated with a magnetic field intensity that triggers visible contraction. The stimulation will last for 55 minutes per selected limb and will be performed 5 days a week.
61995417|NCT00402675|ACTIVE_COMPARATOR|Selective invasive angiography|Patients with NSTEMI undergo selective invasive angiography
61995418|NCT05987865|EXPERIMENTAL|People with Parkinson's disease or Healthy Control|The experimental arm involves either patients with PD or healthy control, who will receive both experimental or non-experimental (control) intervention conditions.
61995419|NCT04583930||Patients with Haemophilia A|"* Patients suffering from moderate to severe haemophilia A~* Age ≥ 18-years~* Treatment with FVIII prophylaxis~* Submitted written informed consent"
61995420|NCT05328830|EXPERIMENTAL|Instrument assisted soft tissue mobilization group|Instrument assisted soft tissue mobilization will be applied after 30 minutes of DOMS creation
61995421|NCT05328830|EXPERIMENTAL|Foam roller|Foam roller will be applied after 30 minutes of DOMS creation
61995422|NCT05328830|NO_INTERVENTION|control group|no intervention
62182612|NCT05365087||RNY Cohort|Patients who chose the Laparoscopic Roux-enY Gastric Bypass procedure.
62182613|NCT05365087||LSG Cohort|Patients with no evidence of GERD who undergo LSG and complete standard surveillance endoscopy
62180583|NCT01395511|NO_INTERVENTION|Waiting list group|"No Intervention Comparator~The waiting-list group did not receive acupuncture treatment and participants were permitted to receive usual care including physical therapy and exercise and were not permitted to take analgesics and antiphlogistics during the periods."
61995423|NCT01627938|EXPERIMENTAL|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1
61995424|NCT01627938|PLACEBO_COMPARATOR|Placebo plus Mitoxantrone (MX)|Placebo + MX (12 mg/m2)
62180584|NCT02349256||Diagnosed with Somatic Syndrome Disorder|Group of participants that are screened and meet criteria for diagnosis of Somatic Syndrome disorder will be asked if they wish to take part in a 1-1 qualitative interview with the researcher.
62180585|NCT02222883||patients with primary diagnosis|patients with primary diagnosis of ovarian cancer for testing of BRCA status regarding germline and somatic mutation
62180586|NCT02222883||patients with platinum-sensitive recurrence|patients with platinum-sensitive recurrence of ovarian cancer for testing of BRCA status regarding germline and somatic mutation
62180587|NCT03776162|ACTIVE_COMPARATOR|ACL Reconstruction(BPTB Graft)|Procedure/Surgery ACL Reconstruction (Bone Patellar Tendon Bone Graft): Standard of care surgical procedure Patellar Tendon Autograft ACL reconstruction, in which a bone-patellar tendon-bone graft from the front of the knee is taken to replace the torn ACL.
62180588|NCT03776162|EXPERIMENTAL|Bridge Enhanced ACL Restoration|Procedure/Surgery Bridge Enhanced ACL Restoration (BEAR): The surgical repair of the ACL using the BEAR technique involves surgically placing a sponge (the BEAR implant) between the torn ends of the ACL, providing a sponge for the ligament ends to group into.
62180589|NCT03602248|EXPERIMENTAL|Speed endurance training protocol A|"Performance of two different speed endurance training protocols:~Speed endurance training protocol A will consist of 1 set of 8 repetitions interspersed by 2,5 minutes of recovery with a work to rest ratio of 1:5 (25-30 seconds all out work)."
62180590|NCT03602248|EXPERIMENTAL|Speed endurance training protocol B|Speed endurance training protocol B will consist of 1 set of 8 repetitions interspersed by 4 minutes of recovery with a work to rest ratio of 1:8 (25-30 seconds all out work)
62180591|NCT03602248|NO_INTERVENTION|Control condition|No training protocol will be performed, the participants will perform only the measurements for performance and muscle damage and neuromuscular fatigue
62180592|NCT01095913|EXPERIMENTAL|IC-Green Injections|ICG Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
62180593|NCT03530488|ACTIVE_COMPARATOR|Lidocaine group|intrauterine and intracervical instillation of 4 ml of lidocaine 2% diluted in 15 ml normal saline 5 minutes before hystroscopy
62180594|NCT03530488|PLACEBO_COMPARATOR|control group|intrauterine and intracervical instillation of 19 ml normal saline 5 minutes before hystroscopy
62180595|NCT04675905||PACORUS-D Main cohort|Eligibility, Endpoints as described above
62180596|NCT04675905||PACORUS-D Delirium-Subcohort|Eligibility: patients aged \>= 65 years undergoing noncardiac nonneurosurgical procedures (definition see above); Endpoints as described above; additional explanatory variable: postoperative Delirium detected by CAM on postoperative day 1 and 2
62180597|NCT04747210|ACTIVE_COMPARATOR|Trainig workshop and Coaching one-on-one|Ten-hour training workshop that was divided into three sessions outside working hours. Coaching one-on-one in the daily routines and natural environment.
62180598|NCT04747210|ACTIVE_COMPARATOR|Trainig workshop|Assistants receive ten-hour training workshop that was divided into three sessions outside working hours.
62564494|NCT01479075|PLACEBO_COMPARATOR|placebo in patients|placebo spray is applied intranasally in type 2 diabetes patients under fasting conditions
61995425|NCT06432530||37 patients with type 1 Modic Changes (MCs)|Diagnoses of brucella spondylodiscitis and type 1 MCs were supported by microbiological, serological, and radiological diagnostic tools. Based on the diagnostic tools and criteria, cases diagnosed with lumbar brucella spondylodiscitis or lumbar type 1 MCs in the past 5 years and who had simultaneously lumbar Magnetic Resonance Imaging (MRI), Complete Blood Count (CBC) test, C-reactive protein (CRP), and Erythrocyte Sedimentation Rate (ESR) results, and aged 18-65 years were selected to yield a study population
61995426|NCT06432530||35 patients with brucella spondylodiscitis|Diagnoses of brucella spondylodiscitis and type 1 MCs were supported by microbiological, serological, and radiological diagnostic tools. Based on the diagnostic tools and criteria, cases diagnosed with lumbar brucella spondylodiscitis or lumbar type 1 MCs in the past 5 years and who had simultaneously lumbar Magnetic Resonance Imaging (MRI), Complete Blood Count (CBC) test, C-reactive protein (CRP), and Erythrocyte Sedimentation Rate (ESR) results, and aged 18-65 years were selected to yield a study population
61995427|NCT01188694|EXPERIMENTAL|Psychotherapy plus Methylene Blue, USP|
61995428|NCT01188694|PLACEBO_COMPARATOR|Psychotherapy Plus Placebo|
62180599|NCT01340040|EXPERIMENTAL|MEDI-573|MEDI-573
62180600|NCT03722693||Experimental group|Experimental group included subacute stroke patients with initial wrist extension. Each participant will receive 28 therapy sessions in total, that are divided into four blocks of 7 sessions. During the first 7 sessions the participant will receive standard care treatment (S), this block will be followed by first Functional electrical stimulation based treatment (FES intervention) block with 7 sessions of protocol A (AUTO or FUNCTION). Third block will consider additional 7 sessions of standard care (S). Fourth block will include 7 sessions of Functional electrical stimulation based treatment (FES intervention) with other type of treatment B (FUNCTION or AUTO).
62564495|NCT01479075|EXPERIMENTAL|placebo in study participants|placebo spray is applied intranasally in healthy participants under fasting conditions
62564496|NCT01479075|EXPERIMENTAL|taNVS|Transcutanoues auricular vagus nerve stimulation is applied for 14 min in the external ear in healthy participants
62564497|NCT01479075|PLACEBO_COMPARATOR|Sham stimulation|Sham stimulation in the ear lobe is applied for 14 min in healthy participants
62564498|NCT05733169|EXPERIMENTAL|Hearing impaired group|The hearing impaired group will compare the reference condition with the intervention condition.
62564499|NCT01082328|EXPERIMENTAL|Kuvan®|
62564500|NCT01532934|EXPERIMENTAL|brief therapy|motivational enhancement therapy for substance use
61995429|NCT01188694|OTHER|Delayed Psychotherapy|
61995430|NCT03595878|ACTIVE_COMPARATOR|Randomized Arm - Control Group|Patients randomized to this group will receive standard WBRT.
61995431|NCT03595878|EXPERIMENTAL|Randomized Arm - Intervention Group|Patients randomized to this group will receive parotid sparing WBRT.
61995432|NCT03595878|NO_INTERVENTION|Observational Arm|Patients enrolled in this arm will be treated per their treating physician's choice.
61995433|NCT00956124||uveitic patients|
61995434|NCT00956124||patients with diabetes|
61995435|NCT04056195|EXPERIMENTAL|SKI-O-703 200 mg|2 capsules of 100 mg SKI-O-703 BID (twice a day) 12 hours apart + 2 capsules of placebo during 12 weeks
61995436|NCT04056195|EXPERIMENTAL|SKI-O-703 400 mg|4 capsules of 100 mg SKI-O-703 + 0 capsules of placebo during 12 weeks
62180601|NCT05648513|EXPERIMENTAL|Motivational Interview|"Parent Attitudes About Childhood Vaccines Survey (PACV) will be implemented to the pregnant women consulting to Atatürk City Hospital. Subjects with vaccine hesitancy will be randomly distributed to groups, and in this way, experimental (n=26) and control (n=26) groups will be formed. Routine antenatal monitoring will be kept with the control group. With the experimental group, on the other hand, motivational interviewing method will be implemented for 4 sessions of about 45 minutes each. Interviews will be held at 4 separate weekends, 1 session for each. Interviews will be performed via online means or face to face.~Personal Details Form It is the survey form that includes such socio-demographic aspects of the participants as their ages and educational backgrounds, and their opinions about vaccines."
62180602|NCT05648513|NO_INTERVENTION|Control Group|Control Group Experimental Group ( n=26 ) Routine antenatal monitoring will be kept with the control group. Routine antenatal monitoring Completion of motivational interviewing session Inspection of the vaccine card 1st and 2nd postnatal months and implementation of Parent Attitudes About Childhood Vaccines Survey (PACV) Personal Details Form It is the survey form that includes such socio-demographic aspects of the participants as their ages and educational backgrounds, and their opinions about vaccines.
62180603|NCT02798692|ACTIVE_COMPARATOR|Low dose HB-101 group|Intervention:Three administrations of a low dose of HB-101
62564501|NCT01532934|PLACEBO_COMPARATOR|Standard Care|standard care
62564502|NCT02257073|EXPERIMENTAL|CBT|Cognitive-behavioral treatment
62564503|NCT02257073|SHAM_COMPARATOR|WLT|Waiting in list
62564504|NCT00253435|EXPERIMENTAL|All the patients enrolled in the study|"This is a single arm study. The following description applies to all the patients who are enrolled in the study:~On Day -21, patients receive 131I-MIBG infusion.~On Day -7, Day -6, Day -5, patients receive Carboplatin, Etoposide, Melphalan.~On Day -4, patients receive Carboplatin, Etoposide.~On Day -3, Day -2, Day -1, patients rest.~On Day 0, patients receive peripheral blood stem cell infusion.~Dosing of Carboplatin, Etoposide and Melphalan is based upon whole body dosimetry (cGy) estimates.~Filgrastim 5 micrograms/kg/day S.C. or IV will be given daily beginning on Day 0.~Local radiation therapy is to be given to previously non-irradiated primary and metastatic sites of disease."
62564505|NCT06485102||Patients undergoing surgery|A retrospective data collection will be conducted for all the patients, that between jan. 2012 and dec. 2023, were operated because of a carotid stenosis in the University Clinic for Vascular and Endovascular Surgery in Augsburg. This stenosis may have been symptomatic or asymptomatic. The surgery must respect the latest quality assurance for that period.
62564506|NCT01667718|ACTIVE_COMPARATOR|Levofloxacin-triple therapy|Lansoprazole (Proton Pump Inhibitor), Levofloxacin, Amoxicillin
62564507|NCT01667718|EXPERIMENTAL|Levofloxacin-quadruple therapy|Lansoprazole (Proton Pump Inhibitor),Bismuth, Levofloxacin, Amoxicillin
62564508|NCT05707273|EXPERIMENTAL|Treatment (CD19-CAR T cells)|Patients undergo T cell leukapheresis, receive fludarabine and cyclophosphamide IV, and then receive CD19-CAR T cell infusion IV on study.
62564509|NCT01647386||MBT Revision Component|
62564510|NCT01042353|EXPERIMENTAL|E test|
61995437|NCT04056195|PLACEBO_COMPARATOR|Placebo|4 capsules of placebo during 12 weeks
61995438|NCT01933048|OTHER|Healthcare Worker Administration|FluMist administered by a Healthcare Worker
61995439|NCT01933048|EXPERIMENTAL|Self-Administration|FluMist self-administered by subject
61995440|NCT03200678|EXPERIMENTAL|ACLR Group|experimental: ACL surgery Intervention: isokinetic assessment
62391264|NCT04204967|EXPERIMENTAL|transdermal fentanyl|transdermal fentanyl will be administered with a starting dose of 50 mcg/hr simultaneously with the preexistent remifentanil continue infusion. Remifentanil infusion rate will be increased or decreased based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit. After randomization, the transdermal fentanyl dose can be modified every 24 hours according to the study protocol to achieve the desired effect in terms of PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected
61995441|NCT03200678|OTHER|Control group|other Intervention: isokinetic assessment
61995442|NCT00695838||1|
61995443|NCT00891358|EXPERIMENTAL|Focus Group|Participants in focus groups will meet and discuss their intervention needs.
61995444|NCT00136149|EXPERIMENTAL|Immediate implants|
61995445|NCT03678155|ACTIVE_COMPARATOR|Treatment as usual + app (without alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Because alarms will not be generated, physicians will not know if an undesired event is occuring despite the app is actually collecting data.
61995446|NCT03678155|EXPERIMENTAL|Treatment as usual + app (with alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
61995447|NCT06019156|EXPERIMENTAL|metaverse group|
61995448|NCT06019156|ACTIVE_COMPARATOR|YouTube group|
61995449|NCT06019156|NO_INTERVENTION|Control group|
61995450|NCT02767427|ACTIVE_COMPARATOR|At-Home Chlorhexidine|Those randomized into the chlorhexidine group will be asked to shower the night before surgery, and to use a standardized pre-packaged Chlorhexidine Wipes (chlorhexidine gluconate wipes) on their surgical site after thoroughly drying those areas. They will be asked to use a second wipe in each area the morning of surgery. Those who forget to use the wipe in the morning were allowed to use the wipe in the pre-operative area and included if this occurs more than one hour before skin prep.
61995451|NCT02767427|EXPERIMENTAL|No At-Home Chlorhexidine|Participants in this group will not use chlorhexidine wipes (no intervention), as is standard of care, prior to their surgical site being cleansed by the surgical team pre-operatively.
62180604|NCT02798692|ACTIVE_COMPARATOR|Medium dose HB-101 group|Intervention:Three administrations of a middle dose of HB-101.
62564511|NCT01042353|ACTIVE_COMPARATOR|standard culture method|
62564512|NCT02954484|ACTIVE_COMPARATOR|PREGABALIN|All subjects receive intravenous PCA morphine, paracetamol 1g po six hourly and etoricoxib 120mg po once daily. Subjects receive pregabalin 75mg orally preoperatively followed by 75mg at night for two days. During surgery, patients received general anaesthesia with femoral nerve block on the side of surgery.
62564513|NCT02954484|PLACEBO_COMPARATOR|PLACEBO|All subjects receive intravenous PCA morphine, paracetamol 1g po six hourly and etoricoxib 120mg po once daily. Subjects receive either placebo tablet (of identical appearance to pregabalin) orally preoperatively followed by 75mg at night for two days. During surgery, patients received general anaesthesia with femoral nerve block on the side of surgery.
61995452|NCT02802280|OTHER|Cardiovascular risk in HCV patients|"Intervention:~The only intervention to be carried out along the study will consist of a complete evaluation of cardiovascular risk of HCV patients both at baseline (pre-treatment) and after HCV treatment, through performing different tests (see below)~Chronic HCV patients who are going to be treated with new DAAs according to current guidelines will be studied at different times before and after the end of the treatment.~The participation in the study will not influence neither the indication to treat nor the treatment used.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines"
62564514|NCT01966757||Neuronal ceroid lipofuscinosis patients|Caregiver of patient with NCL to provide information regarding patient's sleep habits
62564515|NCT02566213|OTHER|Motor skills measurements|
62564516|NCT04733066||Non-treatment Group|"1. Quality of life assessment (SBS-QoL, SF- 36)~2. Nutrition status assessment (BIA, BMI)~3. Assessment of functional absorptive small bowel length (citrulline)~4. Clinical data (nutritional program, stool characteristics)"
61995453|NCT03846258|ACTIVE_COMPARATOR|Low bicarbonate arm (22 mmol/L)|PHOXILLUM solutions are used as a replacement solution in Continuous Renal Replacement Therapy. The one to be used in this study has bicarbonate concentration of 22 mmol/L.
61995454|NCT03846258|ACTIVE_COMPARATOR|High Bicarbonate (32 mmol/L)|PrismaSATE is another replacement solution used in Continuous Renal Replacement Therapy. The one to be used in this study has bicarbonate concentration of 32 mmol/L.
62180605|NCT02798692|ACTIVE_COMPARATOR|High dose HB101 group|Intervention:Three administrations of a high dose of HB-101.
62180606|NCT02798692|PLACEBO_COMPARATOR|Placebo group|Intervention:Three administrations of placebo (diluent)
62564517|NCT04733066||Teduglutide-treated Group|"1. Quality of life assessment (SBS-QoL, SF- 36)~2. Nutrition status assessment (BIA, BMI)~3. Assessment of functional absorptive small bowel length (citrulline)~4. Clinical data (nutritional program, stool characteristics)"
62180607|NCT04661514|EXPERIMENTAL|Safety, Tolerability, and Treatment|On dosing day, each participant will receive 1 x 25 mg treatment bottle containing 5 x 5 mg oral capsules of psilocybin. The administration session will last approximately 4-6 hours and will be supported by a lead therapist and an assisting therapist.
62180608|NCT02716077|EXPERIMENTAL|Single arm|FDG PET/CT scan pre-therapy
62180609|NCT04012658||Patients with the genetic diagnosis of Wilson's Disease|
62180610|NCT04012658||Asymptomatic Wilson's Disease carriers|
62180611|NCT04012658||Relatives of Wilson's Disease patients or carriers|
62180612|NCT04012658||Unrelated healthy controls|
62180613|NCT05253079|ACTIVE_COMPARATOR|subcostal transversus abdominis plane block group|subcostal transversus abdominis plane block
62180614|NCT05253079|ACTIVE_COMPARATOR|erector spinae plane block group|erector spinae plane block
62180615|NCT03272698|EXPERIMENTAL|Ketamine (HIKER)|Patients in the HIKER arm will receive a single dose of ketamine 0.50 mg/kg, which is enough to achieve a full anaesthetic effect (i.e., unconsciousness mimicking the GA regimen above), on 8 successive weekdays.
62180616|NCT03272698|ACTIVE_COMPARATOR|Ketamine-ECT (EAST)|Patients in the EAST arm will initially receive intravenous ketamine 0.75 mg/kg, remifentanil 1 mcg/kg (to reduce discomfort), and succinylcholine 0.75 mg/kg (for safety). Based on patients' anaesthetic response, the attending anaesthesiologist is given the freedom to vary the dose of remifentanil and succinylcholine as well as administer propofol to achieve safe and acceptable anaesthetic conditions. As per the Saskatoon Health Region's care standard, patients in the EAST arm will receive eight ECT sessions (on a bi/triweekly schedule) delivered by the attending psychiatrist with either unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method.
62180617|NCT00892944|EXPERIMENTAL|1|AZD2516
62180618|NCT05829135|EXPERIMENTAL|Treatment group|All participants will be fit with Acuvue Oasys with Transitions.
62180619|NCT00329550|EXPERIMENTAL|CZP 400 mg / Placebo|Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)
62180620|NCT00329550|EXPERIMENTAL|CZP 400 mg / CZP 200 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)
62180621|NCT00329550|EXPERIMENTAL|CZP 400 mg / CZP 400 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)
62180622|NCT01677949|EXPERIMENTAL|ALL patients receiving transplant|Patients intent on receiving an allogeneic hematopoietic cell transplantation (allo-HCT) with the diagnosis of acute lymphoblastic leukemia (ALL) along with Clofarabine, Etoposide and Cyclophosphamide.
62180623|NCT01677949|EXPERIMENTAL|AML patients receiving transplant|Patients intent on receiving an allogeneic hematopoietic cell transplantation (allo-HCT) with the diagnosis of acute myeloid leukemia (AML) along with Clofarabine, Etoposide and Cyclophosphamide.
62180624|NCT06480253|EXPERIMENTAL|Helmet|Partecipants will be started on Continuous Positive Airway Pressure using the Helmet interface
62180625|NCT06480253|ACTIVE_COMPARATOR|Oronasal Mask|Partecipants will be started on Continuous Positive Airway Pressure using the oronasal mask interface
62182801|NCT03000348|ACTIVE_COMPARATOR|High Dose, Twice per day|Patient takes two oral doses of Cysteamine (high dose) per day, one in the morning and one in the evening. The patient takes one oral placebo dose, at mid-day.
62180626|NCT05710198|EXPERIMENTAL|citicoline eye drops 2%|Citicoline eye drops 2%. One drop in the study eye three times daily throughout the 3-year trial. Patients will be treated with any IOP-lowering agent to control IOP and study treatments should be administered at least 20 minutes after IOP lowering medication.
62564518|NCT05496205|EXPERIMENTAL|iN1011-N17, Oral capsule, Single Ascending Dose|The IP or placebo will be orally administered in the morning on Day 1, following a 10-hour overnight fast.
62564519|NCT05496205|EXPERIMENTAL|iN1011-N17, Oral Suspension, Single Ascending Dose|The IP or placebo will be orally administered in the morning on Day 1, following a 10-hour overnight fast.
62564520|NCT05496205|EXPERIMENTAL|iN1011-N17, Nanoparticle Capsule, Single Ascending Dose|The IP or placebo will be orally administered in the morning on Day 1, following a 10-hour overnight fast.
62564521|NCT05496205|PLACEBO_COMPARATOR|Placebo|The IP or placebo will be orally administered in the morning on Day 1, following a 10-hour overnight fast.
62564522|NCT01231451|EXPERIMENTAL|All Subjects|All Subjects will receive the same intervention
62564523|NCT03205878|ACTIVE_COMPARATOR|Control group|Patients will receive standard care, being CPAP treatment
62564524|NCT03205878|EXPERIMENTAL|Intervention group|Patients will receive CPAP and telecoaching
62564525|NCT02448485||Aortic Valve Intervention|Consecutive symptomatic patients who underwent aortic valve intervention (SAVR or TAVI) for the treatment of severe AS since 2010
62564526|NCT02448485||Conservative Treatment|Asymptomatic patients with aortic stenosis followed conservatively at our department
62564527|NCT06127316|NO_INTERVENTION|NoCDO|Participants will complete study activities without a CDO
62564528|NCT06127316|EXPERIMENTAL|0cm Distraction|Participants will complete study activities while wearing a CDO with 0cm of heel distraction height
62564529|NCT06127316|EXPERIMENTAL|1cm Distraction|Participants will complete study activities while wearing a CDO with 1cm of heel distraction height
62564530|NCT06127316|EXPERIMENTAL|2cm Distraction|Participants will complete study activities while wearing a CDO with 2cm of heel distraction height
62564531|NCT00778817|EXPERIMENTAL|Arm II (Mitotane + IMC-A12)|Patients receive mitotane as in arm I and anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once every 2 weeks in the absence of disease progression or unacceptable toxicity.
62564532|NCT02386267|EXPERIMENTAL|L-leucine pills|L-leucine , dose- 700mg/m2 , per os, three time a day, course duration 6 months
62564533|NCT02097329|EXPERIMENTAL|Cohort 1: Palbociclib under fed conditions|
62564534|NCT02097329|EXPERIMENTAL|Cohort 2: Palbociclib under fed conditions|
62564535|NCT01108172|ACTIVE_COMPARATOR|Usual Care|
62564536|NCT01108172|EXPERIMENTAL|Virtual Ward|
62564537|NCT05888220|EXPERIMENTAL|warm salt water group|The patients were told how to prepare and apply the temperature and salt ratio of the water to be used in the hand and foot bath (280 grams of rock salt to 8 liters of water) with a demonstration method with video training. video tutorial tablet It was done in a quiet environment in the hospital, in a room with the patient and the researcher. The temperature of the water and the duration of application were determined based on research that previously examined the effectiveness of warm water and warm salt water baths in various patient groups. Bath hours were determined to be between 21:00 and 22:00 in order to prevent the patients from doing any activity after this application and to provide relaxation and rest after the bath. Starting 1 day after the training, each patient is at home for six weeks from 21:00 to He applied a warm salt water bath at 41°C for 20 minutes to his hands and feet three times a week between 21:00-22:00.
62564538|NCT05888220|EXPERIMENTAL|warm water group|The patients were told how to prepare and apply the temperature of the water to be used in the hand and foot bath with video training and demonstration method. The video training was carried out using a tablet in a quiet environment in the hospital in a room with the patient and the researcher. The temperature of the water and the duration of application were determined based on research that previously examined the effectiveness of warm water and warm salt water baths in various patient groups. Bath hours were determined to be between 21:00 and 22:00 in order to prevent the patients from doing any activity after this application and to provide relaxation and rest after the bath. Starting 1 day after the training, each patient applied a 20-minute warm water bath at 41°C every other day, three times a week between 21:00 and 22:00 at home for six weeks, on their hands and feet.
62564539|NCT05888220|NO_INTERVENTION|control group|No intervention was made for the patients. Visual Analog Scale, Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire, Pittsburgh Sleep Quality Index, Health Assessment Questionnaires were re-administered at the end of the sixth week in this group.
62564540|NCT01169064|ACTIVE_COMPARATOR|Silver-containing surgical dressing|Self adhesive 4 x 10 dressing impregnated with nanocrystalline silver
62564541|NCT01169064|ACTIVE_COMPARATOR|Cloth adhesive dressing|Soft cloth adhesive wound dressing
62180627|NCT05710198|PLACEBO_COMPARATOR|Placebo eye drops|Placebo eye drops. One drop in the study eye three times daily throughout the 3-year trial. Patients will be treated with any IOP-lowering agent to control IOP and study treatments should be administered at least 20 minutes after IOP lowering medication
62180628|NCT00292981|EXPERIMENTAL|C1 Esterase Inhibitor|
62180629|NCT00996814|EXPERIMENTAL|Proactive Ethics Intervention|These patients have an ethics consultant involved in their care beginning on the fifth day of treatment in the ICU
62180630|NCT00996814|NO_INTERVENTION|Usual Care|These patients receive usual care in the ICU.
62180631|NCT02418845|EXPERIMENTAL|SYM-1219|Administered orally
62180632|NCT02418845|PLACEBO_COMPARATOR|Placebo|Administered orally
62391265|NCT04204967|ACTIVE_COMPARATOR|IV Remifentanil alone|remifentanil infusion is administered alone, the infusion rate will be increased or decreased according to the study protocol based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit
62564542|NCT00987818|EXPERIMENTAL|PCT guided antibiotic therapy|
62564543|NCT00987818|PLACEBO_COMPARATOR|Standard antibiotic therapy|
62564544|NCT05663112|ACTIVE_COMPARATOR|Arm with massage|"5 ml of isosulfan blue will be injected into the subareolar region. 5-minutes massage will be applied.~Drug: Isosulfan Blue 5 ml"
62564545|NCT05663112|EXPERIMENTAL|Arm without massage|"5 ml of isosulfan blue will be injected into the subareolar region. No massage will be applied.~Drug: Isosulfan Blue 5 ml"
61995455|NCT02928510||Basic Science (biospecimen collection, idelalisib)|Patients receive a physical examination during visit 1. A stool sample, blood sample, and 6 biopsies are collected at visit 2, and patients undergo a flexible fiberoptic sigmoidoscopy. Patients receive idelalisib PO twice daily BID after visit 2. Treatment continues in the absence of disease progression or unacceptable toxicity. A third research visit occurs upon development of idelalisib-associated diarrhea/colitis symptoms. Patients with diarrhea/colitis symptoms undergo a full colonoscopy and collection of stool and blood samples. Control patients with no diarrhea/colitis symptoms undergo all needed tests and assessments including a flexible fiberoptic sigmoidoscopy and collection of stool and blood samples. All patients undergo optional biospecimen collection at the time of disease progression.
62180633|NCT03477825|PLACEBO_COMPARATOR|Placebo|"Group A: Placebo group (n = 10)~* Supplement appearing similar to Herbal formulations~* Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~* Dose: subjects in this group will take 4 placebo tablets per day"
62180634|NCT03477825|EXPERIMENTAL|Rubia Cordifolia|"Group B: R. cordifolia group (n = 10)~* 2,000 mg R. cordifolia per day - supplied by Banyan Botanicals and following standard supplementation doses on commercially available supplement (https://www.banyanbotanicals.com/manjistha-tablets/)~* Each tablet contains 500 mg of R. cordifolia per tablet."
62180635|NCT03477825|EXPERIMENTAL|Triphala|"Group C: Triphala group (n= 10)~* Tablets of Triphala will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/triphala-tablets-11/)~* Each tablet contains mix Emblica officinalis, Terminalia bellerica, and Terminalia chebula~* Dose: subjects will take 4 tablets per day, with a total dose of 2,000 mg of total herb."
62180636|NCT03245463|ACTIVE_COMPARATOR|Teaching Method A|Patient will receive an educational handout on self-management strategies. Patient will be asked to take the handout home to read and to call the office if he/she has any questions.
62180637|NCT03245463|ACTIVE_COMPARATOR|Teaching Method B|Patient will receive an educational handout on self-management strategies. A provider will review the handout with the patient (approximately 5 minutes including a question-and-answer session).
62180638|NCT05592236|EXPERIMENTAL|Study group|Dynamic compression garments for 2 hours a day in addition to standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
62180639|NCT05592236|ACTIVE_COMPARATOR|Control Group|Standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
62180640|NCT01395849||Patients prescribed fluticasone and salmeterol|Patients with asthma prescribed fluticasone and salmeterol during study period
62564546|NCT03901677|EXPERIMENTAL|Tai-chi training|Tai-chi training performe as a group exercise. Duration for tai chi exercise will be 60 minutes for 2 days per week for 12 weeks. Each session includes 10 min warm-up and cool-down and 40 min Tai Chi exercises. During exercises, attention paid to correct positioning of the upper and lower extremity joints, and mentally concentration achieve. Slow and controlled movements will carry out by a specialized physiotherapist.
62564547|NCT05240898|EXPERIMENTAL|RO7623066 Monotherapy (Dose Escalation)|RO7623066 will be administered orally once daily (QD) continuously as monotherapy. Once the maximum tolerated dose (MTD) for RO7623066 monotherapy has been reached this concludes the Dose Escalation phase.
62564548|NCT05240898|EXPERIMENTAL|RO7623066 + Olaparib (Dose Escalation and Expansion)|RO7623066 will be tested in combination with olaparib. Escalating dose levels will be tested until the maximum tolerated dose (MTD), or lower, of RO7623066 is reached or MTD, or lower, of the combination is reached (whichever occurs first). Combination arms can enroll concurrently. Olaparib will be dosed per standard of care (SoC).
62180641|NCT05542121|PLACEBO_COMPARATOR|Standard of Care|60 min OT sessions; 3 sessions per week; for 4 weeks;-- augmented Standard therapy - consisting of PT, OT and SLP. Clinical Assessment (B1-pre, B2-post, B3-follow-up#1, B4-follow-up#2).
62564549|NCT05240898|EXPERIMENTAL|RO7623066 + Carboplatin (Dose Escalation and Expansion)|RO7623066 will be tested in combination with carboplatin. Escalating dose levels will be tested until the maximum tolerated dose (MTD), or lower, of RO7623066 is reached or MTD, or lower, of the combination is reached (whichever occurs first). Combination arms can enroll concurrently. Carboplatin will be dosed per standard of care (SoC).
62564550|NCT05240898|OTHER|RO7623066 + Olaparib Backfill Cohort|Once safety data has been obtained in the RO7623066 + Olaparib arm during the dose escalation phase, Backfill cohorts will be used to determine the Recommended Dose for Expansion of RO7623066 + Olaparib.
62564551|NCT05240898|OTHER|RO7623066 Food Effect Cohort|The effect of food intake on the PK of RO7623066 will be explored at a dose close to the Maximum Tolerated Dose (MTD) and/or at Recommended Phase II Dose (RP2D) or at a relevant dose level for a minimum of 12 participants that have at least one tumor mutation of interest.
62564552|NCT06391307|ACTIVE_COMPARATOR|Crystallized phenol|In this group, the classic non-operative technique is employed. The pilonidal sinus is debrided under local anesthesia, followed by the injection of crystallized phenol into the wound.
61995456|NCT03767218|EXPERIMENTAL|Late follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from the late follicular phase of the menstrual cycle onwards. Start of GnRH antagonist (ganirelix 0.25mg/day) when serum LH \> 10 IU/L, till day of trigger.
62180642|NCT05542121|EXPERIMENTAL|Robot-Assisted Therapy with Rehab CARES system|"60 min sessions; 3 sessions per week; for 4 weeks;----of Upper Limb therapy using 1 or more affordable robots. Robot sessions can be group play and/or single play.~Robot Assessment (B1-pre, B2-post, B3-follow-up#1, B4-follow-up#2)"
62180643|NCT03561025|ACTIVE_COMPARATOR|18F-FDG-PET/MRI|
62180644|NCT03561025|EXPERIMENTAL|18F-GE180-PET/MRI|
62180645|NCT03440983|EXPERIMENTAL|MRI data acquiring in healthy volunteers|MRI data acquiring in healthy volonteers
62180646|NCT02712190|EXPERIMENTAL|Low - High frequence sequence|High-Frequency non-invasive ventilation (HF-NIV) with 2 different settings, sequence of respiratory rate 250/min and respiratory rate 500/min
62180647|NCT02712190|EXPERIMENTAL|High - Low frequence sequence|High-Frequency non-invasive ventilation (HF-NIV) with 2 different settings, sequence of respiratory rate 500/min and respiratory rate 250/min
62180648|NCT01255761|OTHER|RAPID3 to assess response to Cimzia|"RAPID3 is a subject-based assessment tool used to assess subject's response to Cimzia.~Subjects will be randomized to a patient measure tool, a tool based on patient-report outcomes (RAPID3); using a total score of 30 points"
62180649|NCT01255761|OTHER|CDAI to assess response to Cimzia|"CDAI is an investigator-based assessment tool used to assess subject's response to Cimzia.~Subjects will be randomized to a clinical measures tool, a tool based on Investigator measures without the need for a lab value (CDAI)"
62564553|NCT06391307|EXPERIMENTAL|Crystallized phenol + Exosome|In this group, the classic non-operative technique is employed. The pilonidal sinus is debrided under local anesthesia, followed by the injection of crystallized phenol + Exosome into the wound.
62564554|NCT06391307|EXPERIMENTAL|Crystallized phenol + Stem Cell|In this group, the classic non-operative technique is employed. The pilonidal sinus is debrided under local anesthesia, followed by the injection of crystallized phenol + Stem cell into the wound.
62564555|NCT06391307|EXPERIMENTAL|Crystallized phenol + Exosome + Stem Cell|In this group, the classic non-operative technique is employed. The pilonidal sinus is debrided under local anesthesia, followed by the injection of crystallized phenol + Stem cell + Exosome into the wound.
62564556|NCT02714218|EXPERIMENTAL|Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg IV|Specified dose on specified days
62180650|NCT03436043|EXPERIMENTAL|Transmural stenting|In patients of walled off necrosis with disconnected pancreatic duct syndrome, metal stent will be removed at 3-4 weeks followed by transmural plastic stenting in the residual cavity.
62180651|NCT03436043|NO_INTERVENTION|No stenting|In patients of walled off necrosis with disconnected pancreatic duct syndrome, metal stent will be removed at 3-4 weeks without any further intervention.
62180652|NCT02176564||Chronic obstructive pulmonary disease|Patients with COPD treated with inhaled bronchodilators
62180653|NCT02854397||patients with hereditary angioedema|A blood sample will be performed in crisis and 7 days after the crisis.
62180654|NCT02854397||patients with angioedema resulting of mast cell activation|A blood sample will be performed in crisis and 7 days after the crisis.
62180655|NCT02854397||healthy patients, without angioedema|A quantity of additional blood was taken from eligible patients who had a scheduled blood sample.
62180656|NCT02230306|EXPERIMENTAL|Cobimetinib in Combination with Vemurafenib|"Vemurafenib (960 mg twice a day) will be taken on Days 1 - 28 of each 28-day treatment cycle. The first dose of vemurafenib should be taken in the morning, and the second dose should be taken in the evening. Vemurafenib can be taken with or without a meal and should be taken with a glass of water.~Cobimetinib (60 mg once a day) will be taken on Days 1 - 21 of each 28-day treatment cycle. The cobimetinib tablet should be taken at approximately the same time each day in the morning with the vemurafenib dose, but no later than 4 hours after the scheduled time. Cobimetinib can be taken with or without a meal and should never be chewed, cut, or crushed and should be taken with a glass of water."
62180657|NCT04896684||Patient screened or followed-up for IBS or IBD or colorectal cancer|Blood and colon biopsy sampling
62180658|NCT01674803|ACTIVE_COMPARATOR|Orsiro|
61995457|NCT03767218|ACTIVE_COMPARATOR|Early follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards. Initiation of GnRH antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger.
61995458|NCT06258148|EXPERIMENTAL|TG103, 7.5 mg|TG103 (7.5 mg) will be administered via subcutaneous injection once a week in subjects with type 2 diabetes.
62180659|NCT01674803|ACTIVE_COMPARATOR|Synergy|
62180660|NCT01674803|ACTIVE_COMPARATOR|Resolute Integrity|
62180661|NCT02236663|EXPERIMENTAL|App Based Safety Decision Aid|Personalized App-Based Safety Decision Aid
62180662|NCT02236663|ACTIVE_COMPARATOR|Control App|Usual Care Safety Plan
62180663|NCT04637516|ACTIVE_COMPARATOR|Programme Version 60 sec frequency|"This version of the program BlinkBlink has a presentation frequency of 60 sec"
62180664|NCT04637516|PLACEBO_COMPARATOR|Programme Version 300 sec frequency|"This version of the program BlinkBlink has a presentation frequency of 300 sec"
62180665|NCT01046591||Cleft|Those with a repaired cleft palate
62180666|NCT01046591||Comparison|Those without a cleft palate repair
62180667|NCT03812367||Group 1|The denosumab naïve group
61995459|NCT06258148|PLACEBO_COMPARATOR|TG103, 7.5 mg placebo|Placebo will be administered via subcutaneous injection once a week in subjects with type 2 diabetes.
61995460|NCT06258148|EXPERIMENTAL|TG103, 15 mg|TG103 (15 mg) will be administered via subcutaneous injection once a week in subjects with type 2 diabetes.
61995461|NCT06258148|PLACEBO_COMPARATOR|TG103, 15 mg placebo|Placebo will be administered via subcutaneous injection once a week in subjects with type 2 diabetes.
61995462|NCT03197532||Group 1|Otherwise healthy, mid-reproductive aged women between the ages of 20 and 35 years previously exposed to high dose alkylating agent therapy (or have an alkylator score of 1 or more), and at least 1 year from cancer treatment.
61995463|NCT03197532||Group 2|Healthy, mid-reproductive aged women between the ages of 20 to 35 who have not been exposed to cancer therapy.
61995464|NCT03197532||Group 3|Reproductive aged women between the ages of 43-50 who have not been exposed to cancer therapy, nor have a history of infertility
61995465|NCT03509675|PLACEBO_COMPARATOR|Placebo|Placebo suspension was compounded with the same taste as the active medication but without the active ingredient.
62180668|NCT03812367||Group 2|The zoledronic acid naïve group
62564557|NCT02714218|EXPERIMENTAL|Ipilimumab 3 mg/kg IV + Nivolumab 1 mg/kg IV|Specified dose on specified days
61995466|NCT03509675|ACTIVE_COMPARATOR|Active ingredient|The topical suspension of the topical NSAID was 100 mg per 5 ml concentration of ibuprofen, with similar ingredients as OTC children's ibuprofen and was compounded by an external drug service.
62180669|NCT03812367||Group 3|The chronic denosumab (\> 1 year with at least 3 biannual injections)
61995467|NCT01172652|EXPERIMENTAL|ziprasidone|
61995468|NCT01172652|PLACEBO_COMPARATOR|Placebo|
61995469|NCT04446065|EXPERIMENTAL|Previfenon®|Participants will receive coded non-transparent bottles of Previfenon®, each containing 90 EGCG capsules (250 mg per capsule plus excipients) The total EGCG dose per patient will be 750 mg/day (3 capsules) for 40 consecutive days as minimum or a maximum variable time between 60 to 70 days. It will be divided into three daily intakes of one capsule of Previfenon® every 8 hours.
61995470|NCT04446065|PLACEBO_COMPARATOR|Placebo|Participants will receive coded non-transparent bottles of placebo, each containing 90 starch capsules (250 mg plus excipients) under the same dosage, frequency and duration that Previfenon@ arm.
62180670|NCT03812367||Group 4|The chronic zoledronic acid (≥2 years with at least 2 annual injections)
62180671|NCT01721746|EXPERIMENTAL|BMS-936558 3 mg/kg (IV)|BMS-936558 3 mg/kg solution for injection by intravenous (IV), every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
62182614|NCT00244907|ACTIVE_COMPARATOR|Genistein vs. Risedronate|Healthy post menopausal women who have been dosed with Ca41. Intervention, 100 mg Gensitein from soy protein isolate for 50 days. After a 50 day washout risedronate (Actonel- 5mg per day) for 50 days
62564558|NCT02714218|EXPERIMENTAL|Nivolumab 6 mg/kg IV + Ipilimumab 1 mg/kg|Specified dose on specified days
62564559|NCT03827499|EXPERIMENTAL|Ex-HMB|HMB dietary supplementation and Multicomponent physical exercise program
62564560|NCT03827499|EXPERIMENTAL|NoEx-HMB|HMB Dietary supplementation
62564561|NCT03827499|PLACEBO_COMPARATOR|Ex-Plac|Multicomponent physical exercise program
62564562|NCT03827499|NO_INTERVENTION|Controls|No intervention
62182802|NCT03000348|ACTIVE_COMPARATOR|High Dose, Three times per day|Patient takes three oral doses of Cysteamine (high dose) per day, one in the morning, one at mid-day and one in the evening.
61995471|NCT06195397|EXPERIMENTAL|Experimental: Intervention Group|A total of 12 hours of Evidence-Based Education intervention was applied to students in the intervention group, spread over 7 sessions.
62564563|NCT05733429|EXPERIMENTAL|eye cervical re-education|patients will receive eye cervical re-education three times a week for four weeks
62564564|NCT05733429|EXPERIMENTAL|motor imagery therapy|patients will receive motor imagery therapy three times a week for four weeks
62564565|NCT05733429|ACTIVE_COMPARATOR|conventional physical therapy|patients will receive conventional physical therapy three times a week for four weeks
62564566|NCT00922064|EXPERIMENTAL|ECT|
62564567|NCT04872686|EXPERIMENTAL|Oral and nasal spray to moderately ill COVID-19 positive patient|Drug Name: Povidone-Iodine Dosage form: 0.6% Povidone-Iodine Dosage: 2 puff 0.6% PVP-I in each nostril and 2 puff inside mouth Frequency and duration: Single
62564568|NCT04872686|EXPERIMENTAL|Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity|Drug Name: Povidone-Iodine Dosage form: 0.6% Povidone-Iodine Dosage: 2 puff 0.6% PVP-I in each nostril and 2 puff inside mouth Frequency and duration: hourly for 4 hours in a single day
62564569|NCT04872686|EXPERIMENTAL|Oral and nasal spray to healthy volunteer|Drug Name: Povidone-Iodine Dosage form: 0.6% Povidone-Iodine Dosage: 2 puff 0.6% PVP-I in each nostril and 2 puff inside mouth Frequency and duration: 3-4 times interval but not more than 4 times a day for 30 days
62564570|NCT04872686|PLACEBO_COMPARATOR|Oral and nasal spray by distilled water to control group|Placebo comparator: Distilled water Dosage form: Oral and Nasal spray will be provided by Distilled water
62564571|NCT04083885|EXPERIMENTAL|Virtual Reality|Participants receive 8 weeks of home-based or facility-based virtual reality training, supervised remotely and asynchronously, in addition to their usual activity.
62564572|NCT04083885|NO_INTERVENTION|Usual Care|Participants perform their usual activities.
62564573|NCT02157376|EXPERIMENTAL|Esomeprazole active treatment|iv esomeprazole 30 min intermittent infusions given for maximum 14 days
62564574|NCT02157376|ACTIVE_COMPARATOR|Cimetidine active treatment|iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
62564575|NCT01343043|EXPERIMENTAL|Cohort 1 treated with NY-ESO-1 T Cells|High NY-ESO-1 expression and the use of cyclophosphamide plus fludarabine as the lymphodepleting chemotherapy.
62564576|NCT01343043|EXPERIMENTAL|Cohort 2 treated with NY-ESO-1 T Cells|Low NY-ESO-1 expression and the use of cyclophosphamide plus fludarabine as the lymphodepleting chemotherapy.
62564577|NCT01343043|EXPERIMENTAL|Cohort 3 treated with NY-ESO-1 T Cells|High NYESO-1 expression and the use of cyclophosphamide only for lymphodepletion rather than fludarabine as the lymphodepleting chemotherapy.
62564578|NCT01343043|EXPERIMENTAL|Cohort 4 treated with NY-ESO-1 T Cells|High NY-ESO-1 expression and the use of reduced dose cyclophosphamide plus fludarabine regimen as the lymphodepleting chemotherapy.
62564579|NCT05771077|EXPERIMENTAL|patients have White spot lesions|White spot lesions (WSLs) are defined as enamel surface and subsurface demineralization, without cavitation. These manifestations represent the first clinical observation of the progression of dental caries, with the possibility of being reversed
62772729|NCT06368908|NO_INTERVENTION|Control|the quadriceps femoris muscle of the control leg will not be stimulated by Transcutaneous Functional Magnetic Stimulation
61995472|NCT06195397|NO_INTERVENTION|No Intervention: Control Group|No training was given.
61995473|NCT01955057||Smokers with lung cancer|
61995474|NCT01895673||PET-MRI|Twenty patients with RFA/MWA for CRLM or RFA/MWA of recurrent liver lesions after prior local treatment of CRLM and are eligible to undergo MRI-scanning are included when they have adequate renal function. Patients that do not meet inclusion criteria for undergoing an MRI scan are excluded.
61995475|NCT02983071|EXPERIMENTAL|Once-Daily G1T38 Dosing|G1T38 (lerociclib) orally (once daily) in combination with fulvestrant.
62182803|NCT03000348|PLACEBO_COMPARATOR|Placebo|Patient takes three oral doses of placebo, one in the morning, one at mid-day and one in the evening.
62564580|NCT01611883|EXPERIMENTAL|Ezetimibe|10 mg oral dose once daily for 24 weeks
62564581|NCT01611883|PLACEBO_COMPARATOR|Placebo|Placebo to match ezetimibe orally once daily for 24 weeks
62564582|NCT03771911|OTHER|AED guided|"Laypeople will be guided by an Automatic External Defibrillator's (AED) voice instructions during the cardiopulmonary resuscitation.~No other help is available."
62772730|NCT02613169|EXPERIMENTAL|Isoniazid|Isoniazid (INH) \~10 mg/kg (7-15 mg/kg), will be administered once daily to infants in INH arm for 12 months.
62772731|NCT02613169|NO_INTERVENTION|No Isoniazid|No INH will be administered to this arm.
62772732|NCT02790021|NO_INTERVENTION|Complex decongestive therapy|Group A will continue complex decongestive therapy consisting of skin care, manual lymphatic drainage, and compression therapy using compression stockings.
62180672|NCT01721746|ACTIVE_COMPARATOR|Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)|"Dacarbazine: 1000mg/m2, Powder for IV solution, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~Carboplatin: Area under the concentration-time curve (AUC) 6, solution for injection, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~Paclitaxel: 175 mg/ m2, solution for injection, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends"
62180673|NCT05980819|EXPERIMENTAL|All Volunteers|All volunteers will partake in this educational study at the same timepoints, there will be no blinding, but there will be an unbiased recruitment effort
61995476|NCT02983071|EXPERIMENTAL|Twice-Daily G1T38 Dosing|G1T38 (lerociclib) orally (twice daily) in combination with fulvestrant.
62564583|NCT03771911|OTHER|Telephone guided|"Laypeople will be guided by telephone assistance (from an Emergency Call Center) during the cardiopulmonary resuscitation.~AED voice instructions are also available."
62564584|NCT01624571|EXPERIMENTAL|Group 1|300mg/day
62564585|NCT01624571|EXPERIMENTAL|Group 2|600mg/day
62564586|NCT01624571|EXPERIMENTAL|Group 3|900mg/day
61995477|NCT01168024|EXPERIMENTAL|CINCOR™ System Treatment|Use of the CINCOR™ System and CCS-1 device during the pericutanous coronary intervention (PCI) procedure plus Standard of Care peri-procedural hydration for the prevention of contrast induced nephropathy (CIN).
61995478|NCT01168024|OTHER|Standard of Care|The control group will receive a peri and post-procedural hydration rate.
61995479|NCT02990611||Cohort 1: Nivolumab/Ipilimumab combination therapy|Participants who start a new systemic therapy with nivolumab/ipilimumab combination therapy for the first time
62180674|NCT01432522|EXPERIMENTAL|epinephrine IN, epinephrine IM, saline IN|"1. Intranasal saline~2. Intramuscular epinephrine~3. Intranasal epinephrine"
62564587|NCT01624571|PLACEBO_COMPARATOR|Placebo|Control Group
62564588|NCT05643703|EXPERIMENTAL|One-layered Suture|One-layered Suture in transvaginal diverticulum resection
62564589|NCT05643703|EXPERIMENTAL|Two-layered Suture|Two-layered Suture in transvaginal diverticulum resection
62564590|NCT02182843|EXPERIMENTAL|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
62564591|NCT04064138|ACTIVE_COMPARATOR|Peritoneal block|patients will receive peritoneal block as an adjuvant analgesic technique.
62564592|NCT04064138|ACTIVE_COMPARATOR|Ultrasound guided erector spinae plane block|Patients will receive ultrasound guided erector spinae plane block
62564593|NCT06409845||Episodic migraine|Patients affected by migraine with an episodic pattern (\< 15 monthly migraine days) with or without aura according to ICHD-III criteria.
61995480|NCT02990611||Cohort 2: Nivolumab monotherapy|Participants who start a new systemic therapy with nivolumab monotherapy for the first time
61995481|NCT02990611||Cohort 3: Nivolumab adjuvant therapy|Participants who start adjuvant treatment with nivolumab after complete surgical tumor resection and no evidence of disease
61995482|NCT04925011|OTHER|Roxadustat|Starting doses of 20, 50, 70 or 100 mg/30,70,90,or 120mg based on weight and dialysis or not.
61995483|NCT01735656|EXPERIMENTAL|DK-culotte & Resolute stents|Double kissing culotte technique for true bifurcation lesion with Resolute stents
61995484|NCT01735656|ACTIVE_COMPARATOR|DK-crush & Resolute stents|Double kissing crush technique for true bifurcation lesion with Resolute stents
61995485|NCT04060407|EXPERIMENTAL|Advanced Melanoma|Patients with advanced melanoma.
61995486|NCT04657133|EXPERIMENTAL|Intervention group|Subjects in the intervention group will receive remote ischemic conditioning and standard background medical treatment.
61995487|NCT04657133|PLACEBO_COMPARATOR|Sham group|Subjects in the placebo group will receive sham remote ischemic conditioning and standard background medical treatment alone.
61995488|NCT00454168|EXPERIMENTAL|Arm I|Patients receive PR1 leukemia peptide vaccine and sargramostim (GM-CSF) subcutaneously.
61995489|NCT00454168|ACTIVE_COMPARATOR|Arm II|Patients receive placebo vaccine and GM-CSF subcutaneously.
61995490|NCT04278534|EXPERIMENTAL|Arm I (VERT)|Patients complete a radiation therapist-led education module using virtual reality over 30 minutes at the first treatment appointment, prior to radiation therapy treatment.
62564594|NCT06409845||Chronic migraine|atients affected by chronic migraine (\> 15 monthly headache days with at least 8 days with migraine features) according to ICHD-III criteria.
62564595|NCT02992041|EXPERIMENTAL|Lower dose VVZ-149 Injections|
62564596|NCT02992041|EXPERIMENTAL|Higher dose VVZ-149 Injections|
62564597|NCT02992041|PLACEBO_COMPARATOR|Placebo|
62564598|NCT01952392||Control group|Patients aged 18 years or more with an acute coronary syndrome, agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
62564599|NCT01952392||Case group|Patients aged 18 years or more with a history of acute coronary syndrome (i.e. a recurrent MI after myocardial history or unstable angina), agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
62564600|NCT02944539||Gastric cancer group|300 consecutive patients were recruited, who have diagnosed with gastric cancer by biopsy
62564601|NCT02944539||Control group|The 300 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
62564602|NCT04205643|EXPERIMENTAL|CT-P13 SC|
62564603|NCT04205643|PLACEBO_COMPARATOR|Placebo SC|
62180675|NCT02049515|EXPERIMENTAL|IPI-145|IPI-145 was administered orally and supplied as 5 mg and 25 mg formulated capsules.
62180676|NCT02049515|ACTIVE_COMPARATOR|Ofatumumab|Ofatumumab was administered as an intravenous (IV) infusion and was supplied in single-use vials at two strengths, 100 mg/5 milliliters (mL) and 1000 mg/50 mL.
62180677|NCT04116281|EXPERIMENTAL|Supervised group|Supervised group
62180678|NCT04116281|OTHER|No supervised group|Control group
62180679|NCT00605566|EXPERIMENTAL|I|Patients will receive sorafenib and cyclophosphamide.
62180680|NCT04755023|EXPERIMENTAL|Treatment Arm|Administration of 6 cycles of chemotherapy
62564604|NCT00014495|EXPERIMENTAL|bismuth Bi 213 monoclonal antibody M195 & cytarabine|"Patients receive cytarabine IV continuously on days 1-5. Beginning between days 7 and 14, patients receive Bi213 MOAB M195 IV over 5 minutes up to 4 times daily over 1-4 days. Patient also receive filgrastim (G-CSF) subcutaneously daily beginning 24 hours after the final Bi213 MOAB M195 infusion and continuing until blood counts recover. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 to 6 patients receive escalating doses of Bi213 MOAB M195 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, subsequent patients are treated at the MTD.~Patients are followed twice weekly for 4 weeks and then monthly for 3 months"
62564605|NCT04020666||HUK group|On the basis of routine treatment for cerebral infarction, patients in the HUK group were also given Urinary Kallidinogenase at 0.15 PNA unit/day, for a 10-day course.
62772733|NCT02790021|EXPERIMENTAL|Lymphaticovenous anastomosis (LVA)|Group B will undergo an LVA procedure under local anesthesia in surgical daycare setting. Patients are not allowed to wear compression stockings or have decongestive therapy for four weeks after the surgery.
62772734|NCT03668405|EXPERIMENTAL|Lu AF20513 high dose|
61995491|NCT04278534|ACTIVE_COMPARATOR|Arm II Control Group I (usual education materials)|Patients receive the usual verbal and written education materials at the first treatment appointment, prior to radiation therapy treatment.
61995492|NCT04278534|ACTIVE_COMPARATOR|Arm II Control Group II (face-to-face education module)|Patients complete a radiation therapist-led face-to-face education module at the first treatment appointment, prior to radiation therapy treatment.
61995493|NCT04278534|ACTIVE_COMPARATOR|Observational Cohort (usual education materials)|Observational patients receive the usual verbal and written education materials at the first treatment appointment, prior to radiation therapy treatment.
61995494|NCT00179985||Training|Behavioral: Newborn Individualized Care and Assessment Program (NIDCAP)
61995495|NCT04682821|EXPERIMENTAL|with Artificial intelligence assistant system|The experiment group would receive the training with the help of artificial intelligence assistant system in addition to the common training. The system is an non-invasive AI system which could help the endoscopists to diagnosis and monitor the blind spot during the gastroscope.
61995496|NCT04682821|NO_INTERVENTION|without Artificial intelligence assistant system|The control group would receive the training without the help of artificial intelligence assistant system. That is, they would receive the common training process.
61995497|NCT05273268|ACTIVE_COMPARATOR|Control Arm|The control arm (target enrollment; n=180) will receive the US government-standard guidelines for dietary advice in the form of the USDA dietary recommendations digital leaflet.
61995498|NCT05273268|EXPERIMENTAL|Intervention Arm|The intervention arm (target enrollment; n=180) will receive personalized dietary guidelines created by machine learning algorithms using their personal anthropometric, gut, dietary and medical information as inputs. The guidelines will be delivered in the form of a smartphone/ smart device app.
61995499|NCT01747083|EXPERIMENTAL|A|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mgx2tablets))under fasting condition
61995500|NCT01747083|EXPERIMENTAL|B|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mgx2tablets))under fed condition
61995501|NCT05544838|NO_INTERVENTION|LMA with standard insertion technique|Standard LMA insertion technique; LMA held like a pen and index finger placed at the junction of LMA tube and cuff. Index finger used to press LMA against hard palate and posterior pharyngeal wall until definite resistance felt at the base of hypopharynx. LMA then held with non- dominant hand and index finger removed.
61995502|NCT05544838|EXPERIMENTAL|Rotational LMA insertion technique|Rotational LMA insertion; LMA inserted like guedel airway insertion: LMA proximally grasped close to anaesthesia circuit attachment. Insertion was conducted with LMA cuff facing towards nose, hard palate and then advanced into the base of hypopharynx until resistance was felt. At this point, LMA rotated at 180 degree anti-clockwise and LMA tube black line positioned and confirmed on the nasal side.
61995503|NCT02049242|ACTIVE_COMPARATOR|Triple tourniquet|
61995504|NCT02049242|ACTIVE_COMPARATOR|Single tourniquet|
61995505|NCT06437210|EXPERIMENTAL|Viusid Group|Oral administration of viusid oral solution 30 mL 3 times a day with the main meals (breakfast, lunch and dinner) for 30 days.
61995506|NCT06437210|PLACEBO_COMPARATOR|Placebo Group|Oral administration of placebo 30 mL 3 times a day with the main meals (breakfast, lunch and dinner) for 30 days.
61995507|NCT06276257|EXPERIMENTAL|Paravertebral block|Preoperative paravertebral block on the side of mastectomy in addition to usual analgesia.
61995508|NCT06276257|ACTIVE_COMPARATOR|Usual analgesia|Usual analgesia, as per anesthesiologist's preferences.
61995509|NCT05504655||Observational NAC group|Based on a FDA approved 3-bag regime, NAC (Molecular weight:163) was administrated intravenously, initially 150 mg/kg in 200 mL of 0.9%NaCL for 60 minutes (first bag), followed by 50 mg/kg in 500 mL of 0.9%NaCL for 4 hours (second bag), and then 100 mg/kg in 1000 mL of 0.9%NaCL for 16 hours (third bag)
61995510|NCT05504655||Observational Non NAC group|N-acetylcysteine given IV at 600 mg every 12 hours till discharge from ICU.
61995511|NCT05516576|EXPERIMENTAL|endoscopic gastroplasty with endomina®|
61995512|NCT05516576|NO_INTERVENTION|control|
61995513|NCT05824806|ACTIVE_COMPARATOR|PRP protocol A|Composed of 30 patients who will receive an intra-articular injection of platelet-rich plasma (PRP A), once a week, for three consecutive weeks
61995514|NCT05824806|ACTIVE_COMPARATOR|PRP protocol B|Composed of 30 patients who will receive an intra-articular injection of platelet-rich plasma (PRP B), once a week, for three consecutive weeks
62180681|NCT01869998||Low risk group (A)|(A)Vortex depth≥0.45
62180682|NCT01869998||High risk group 1 (B)|(B)Vortex depth\<0.45 with anticoagulation
62180683|NCT01869998||High risk group 2 (C)|(C)Vortex depth \<0.45 without anticoagulation
62180684|NCT04353817|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to ELX/TEZ/IVA and placebo matched to IVA in the treatment period for 24 weeks.
62180685|NCT04353817|EXPERIMENTAL|ELX/TEZ/IVA|Participants weighing less than (\<) 30 kilograms (kg) at screening received ELX 100 mg qd/TEZ 50 mg qd/IVA 75 mg every 12 hours (q12h) and participants weighing greater than equals to (\>=) 30 kg at screening received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.
62180686|NCT02674009||laBCC Participants|Participants with laBCC who received at least one dose of Vismodegib in routine clinical practice for 32 months (between 02 Aug 2013 and 31 Mar 2016).
62180687|NCT05612451|EXPERIMENTAL|non-setting calcium hydroxide|Regenerative Endodontic Procedure utilizing non-setting calcium hydroxide as intracanal medicament
62180688|NCT05612451|EXPERIMENTAL|modified triple antibiotic paste|Regenerative Endodontic Procedure utilizing modified triple antibiotic paste as intracanal medicament
62180689|NCT06014970|EXPERIMENTAL|Health and Wellness Curriculum|Trained instructors will provide the Health and Wellness Curriculum at the Ravenswood City schools. Each school receiving the curriculum will have a dedicated space and receive a 30 minute class twice a week. Through group discussion, nutrition and character education, and breathing exercises, students will receive instruction to focus their attention, calm their minds, reduce stress, and think before reacting.
62564606|NCT04020666||control group|The control group were given routine treatment for cerebral infarction, including anti-platelet aggregation, anticoagulation, lipid-lowering and plaque stabilizing, free radical scavenging, nerve nutrition and brain protection.
62564607|NCT02964481||Malignant Hyperthermia Phenotype cases|Samples from persons who identify as having the malignant hyperthermia phenotype by the North American MH Registry (NAMHR)
62180690|NCT06014970|NO_INTERVENTION|Control|All control participants go through the same assessment procedures as the experimental group without any intervention.
62180691|NCT03184818||No antibacterial from other provider (Arm 1)|Patients with symptomatic, uncomplicated urinary tract infection presenting without a prescription for an antibacterial from another health care practitioner.
62180692|NCT03184818||Antibacterial from other provider (Arm 2)|Patients with symptomatic, uncomplicated urinary tract infection or asymptomatic bacteriuria presenting with a prescription for an antibacterial from another health care practitioner.
62180693|NCT04346485|EXPERIMENTAL|SP TFL RIRS with 145 mcm fiber|Superpulse thulium fiber laser RIRS with 145 mcm laser fiber
62564608|NCT02964481||Caffeine Halothane Contracture Test negative controls|Controls who had negative Caffeine Halothane Contracture Test (CHCT) from North American MH Registry (NAMHR)
62564609|NCT02819024|EXPERIMENTAL|Treatment (dexamethasone, 18F-FLT PET)|Patients receive dexamethasone PO BID on days 1-5. Patients undergo 3 18F-FLT PET scans. One scan within 7 days prior to the start of dexamethasone, one scan on day 3 after the 5th dose of dexamethasone, and one scan 6-9 days after the last dose of dexamethasone.
62564610|NCT05306028|EXPERIMENTAL|Metformin or insulin treatment|
62564611|NCT01351649|OTHER|attention control|Sessions with school nurse to discuss health-promoting topics and after-school health-promoting workshop. Physical activity and healthy eating were not addressed.
62564612|NCT01351649|EXPERIMENTAL|physical activity|
62564613|NCT00455403|EXPERIMENTAL|Chloroquine Subjects|Participants will receive 80 mg of chloroquine on a daily basis.
62564614|NCT00455403|PLACEBO_COMPARATOR|Placebo Subjects|Participants will receive a placebo comparator tablet on a daily basis.
62772735|NCT01176565|ACTIVE_COMPARATOR|Standard SBP Reduction Arm|"Intravenous nicardipine hydrochloride will be used as necessary (pro re nata or PRN) as the primary agent in lowering SBP.~The goal for the standard BP reduction group will be to reduce and maintain SBP \< 180 mmHg for 24 hours from randomization. 160 mmHg is the target SBP for this arm.~For the standard group, SBP below the assigned treatment range is not artificially elevated to stay within the range if lower SBP occurs with nicardipine turned off (no fluid bolus given unless SBP falls below 110 mmHg with nicardipine off and there is risk for hypotension). Euvolemic fluid maintenance is encouraged for all patients according to their medical needs, which may differ."
62564615|NCT00856193|PLACEBO_COMPARATOR|Placebo then NVA237 50μg|Placebo 50 μg capsules followed by NVA237 50 μg capsules for inhalation once daily with Concept 1 device.
62564616|NCT00856193|EXPERIMENTAL|NVA237 50μg then placebo|NVA237 50 μg capsules followed by matching placebo 50 μg capsules for inhalation once daily with Concept 1 device.
62180694|NCT04346485|EXPERIMENTAL|SP TFL RIRS with 200 mcm fiber|Superpulse thulium fiber laser RIRS with 200 mcm laser fiber
62180695|NCT04346485|ACTIVE_COMPARATOR|Ho:YAG RIRS with 200 mcm fiber|Ho:YAG laser RIRS with 200 mcm laser fiber
62180696|NCT03742817|EXPERIMENTAL|Sweet-Flavor 4.5% Nicotine (Salt)|Participants will self-administer a sweet-flavored e-cigarette containing 4.5% nicotine by volume.
62564617|NCT00722228|EXPERIMENTAL|Autologous or Allogeneic tumor cells|Intervention: 5 vaccine doses, 3 weeks apart, injected subcutaneously.
62564618|NCT00707629||Insulin Pump Therapy|Children on insulin pumps for at least three years. Subjects must have type 1 diabetes for at least five years and diagnosed under the age of 5.
62564619|NCT01901458|EXPERIMENTAL|IDL-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® IDL-Set in combination with the Spectra Optia® cell separator and the WBC-D program
62564620|NCT01901458|ACTIVE_COMPARATOR|MNC-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® Collection Set in combination with the Spectra Optia® cell separator and the MNC program
62564621|NCT03357068|ACTIVE_COMPARATOR|Control|Autogenous bone block surgery without treatment of bone surfaces.
62564622|NCT03357068|EXPERIMENTAL|Acid|Autogenous bone block surgery with citric acid treatment of bone block and recipient site
62564623|NCT02835547||Systemic lupus erythematosus|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
62564624|NCT02835547||Rheumatoid arthritis|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
62564625|NCT02835547||Psoriasis|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
62564626|NCT02835547||Scleroderma|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
62564627|NCT02835547||Hematopoietic stem cells transplants|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
62564628|NCT02835547||Kidney transplants|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
62772736|NCT01176565|ACTIVE_COMPARATOR|Intensive SBP Reduction Arm|"Intravenous nicardipine hydrochloride will be used as necessary (pro re nata or PRN) as the primary agent in lowering SBP.~The goal for the intensive BP reduction group will be to reduce and maintain SBP \< 140 mmHg for 24 hours from randomization. 125 mmHg is the target SBP for this arm.~For the intensive group, SBP falling below 110 mmHg (lower limit of the assigned treatment range) with nicardipine off is treated with normal saline fluid bolus to prevent or remedy hypotension. Euvolemic fluid maintenance is encouraged for all patients according to their medical needs, which may differ."
62772737|NCT00437255|ACTIVE_COMPARATOR|1|Clobex® Spray
61995515|NCT05824806|PLACEBO_COMPARATOR|Hyaluronic acid|Composed of 30 patients who will receive an intra-articular injection of 2 mL of intra-articular hyaluronic acid (AHI), once a week, for three consecutive weeks.
61995516|NCT01289769|ACTIVE_COMPARATOR|dexmedetomidine|
61995517|NCT01289769|PLACEBO_COMPARATOR|control|
61995518|NCT02603432|EXPERIMENTAL|Arm A|Avelumab plus Best Supportive Care (BSC)
62180697|NCT03742817|PLACEBO_COMPARATOR|Sweet-Flavor 0 mg/mL Nicotine (Free-Base)|Participants will self-administer a sweet-flavored e-cigarette containing 0 mg/mL nicotine.
62564629|NCT03173898|EXPERIMENTAL|primary periodontal ligament anesthesia|PDL anesthesia versus local infiltration
62564630|NCT03173898|ACTIVE_COMPARATOR|local infiltration|PDL anesthesia versus local infiltration
62564631|NCT05888363||Rectal foreign body removed in emergency department|All patients where the removal of the rectal foreign body was successful in the emergency department
62772738|NCT00437255|ACTIVE_COMPARATOR|2|Taclonex® Ointment
62772739|NCT06298201|EXPERIMENTAL|E-Based Physical Exercise Intervention|A randomized controlled trial (RCT) aimed at evaluating the effects of an e-based PE intervention at home in addition to conventional PE on the disability progression of pwMS comorbid conditions.
62772740|NCT06298201|NO_INTERVENTION|Conventional Physical Exercise|Conventional Physical Exercise will receive no e-based PE intervention
62772741|NCT01427634|ACTIVE_COMPARATOR|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
62772742|NCT01427634|OTHER|Control|Usual Care
62772743|NCT01650740|EXPERIMENTAL|Open-label duloxetine|12 week treatment with duloxetine
62772744|NCT01650740|EXPERIMENTAL|Open-label Placebo|4 weeks of open label placebo with option to continue or switch to duloxetine for remaining 8 weeks.
62772745|NCT01650740|EXPERIMENTAL|Supportive clinical management|4 weeks of supportive clinical management visits with option to continue or switch to duloxetine for remaining 8 weeks.
62564632|NCT05888363||Rectal foreign body removed in operating room|All patients where the removal of the rectal foreign body was not successful in the emergency department and required removal in the operating room
62180698|NCT03742817|EXPERIMENTAL|Sweet-Flavor 6 mg/mL Nicotine (Free-Base)|Participants will self-administer a sweet-flavored e-cigarette containing 6 mg/mL nicotine.
62180699|NCT03742817|ACTIVE_COMPARATOR|Usual e-Cigarette|Participants will self-administer either their preferred brand combustible cigarette or e-cigarette with usual nicotine nicotine concentration.
62180700|NCT02675803|EXPERIMENTAL|VAY736|VAY736 active
62180701|NCT02675803|PLACEBO_COMPARATOR|Placebo|VAY736 placebo
62564633|NCT05495282|NO_INTERVENTION|Group A: Traditonal Lecture|Group A (n=30) will receive a baclofen pump refill and programming instruction via the traditional lecture method performed by a single faculty member. The traditional lecture will consist of a PowerPoint lecture for 30 minutes, a demonstration of the refilling and programming technique for 10 minutes, and participant hands-on practice refilling and programming a baclofen pump for 20 minutes. Group A will have time to practice refilling and programming baclofen pumps with the guidance of a single faculty member during the traditional 60-minute lecture.
62180702|NCT02032264|EXPERIMENTAL|Comprehensive Chromosome Screening|Trophectoderm biopsy will be performed on all blastocysts and CCS via next generation sequencing screening performed on biopsy samples. Patients will proceed with a single or double embryo transfer of the one or two morphologically best euploid embryos
62567775|NCT05651321||healthy people|Participants were tested for different taste perception thresholds using a three-point difference test, with samples materials for basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) were used to prepare different tastes and concentrations of liquids. The subjects will then evaluate the appearance (color, texture), taste, flavor, and texture of the six different flavored enteral nutrition preparations. The subjects will then perform manual sensory evaluation of the appearance (color, texture), odor, taste, texture, and other properties of the 6 different flavored enteral nutrition preparations.
61995519|NCT02603432|OTHER|Arm B|"Best Supportive Care (BSC) alone~Following the planned interim analysis for this study, eligible patients in Arm B whose cancer has not worsened and are still in the watch and wait part of the study will be given the option to receive Avelumab plus BSC. Prior to this, Arm B patients received BSC alone. All patients who choose not to receive Avelumab will be discontinued."
61995520|NCT02656108|EXPERIMENTAL|omiited controlled cord traction|neither controlled cord traction nor fundal pressure will be applied. The placenta will be delivered physiologically and signs of placental separation will be awaited
62180703|NCT02032264|PLACEBO_COMPARATOR|No Comprehensive Chromosome Screening|The patients in this group will proceed with a single or double embryo transfer of the one or two morphologically best embryos.
62180704|NCT01744743|ACTIVE_COMPARATOR|preconception|Participants will be included according to their first outpatient visiting time. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
62180705|NCT01744743|ACTIVE_COMPARATOR|early conception|Participants will be included according to their first outpatient visiting time before 15+6 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
62180706|NCT01744743|PLACEBO_COMPARATOR|late conception|Participants will be included according to their first outpatient visiting time after 16 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
61995521|NCT02656108|ACTIVE_COMPARATOR|controlled cord traction|the cord will be held in one hand and the other hand will be placed just above the woman's pubic boneto stabilize the uterus during cord traction
62180707|NCT05159986|EXPERIMENTAL|Group Diadynamic and Exercises|Group Diadynamic and Exercises received Diadynamic currents associated to Exercise three times a week for 8 weeks following initial assessment (n=30, 60 knees) Diadynamic currents was performed with the following parameters: application of the two-phase current and then the long-term one. Each current was applied for 4 minutes on the medial and lateral sides of the knee.
62180708|NCT05159986|EXPERIMENTAL|Group Exercises|Group Exercises received only exercises three times a week for 8 weeks following initial assessment (n=30, 60 knees).
62180709|NCT03972865|EXPERIMENTAL|Participants of the race|Participants of the race are healthy triathlete volunteers who will participate in August 2019 in the Embrun (EmbrunMan) long-distance triathlon (Ironman)
62182804|NCT03000348|ACTIVE_COMPARATOR|Low Dose, Three times per day|Patient takes three oral doses of Cysteamine (low dose) per day, one in the morning, one at mid-day and one in the evening.
61995522|NCT02478138|OTHER|Surgical - therapeutic|patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system
61995523|NCT02382081|EXPERIMENTAL|Patient-initiated shared care|"Patient-initiated shared care hospital reviews in which there were one planed hospital review every year and if needed additional reviews initiated by the patient.~Access to nurse-run telephone helpline with direct access to a contact nurse."
61995524|NCT02382081|NO_INTERVENTION|Control|Traditional, routine hospital reviews every three-fourth month.
62180710|NCT04103086|EXPERIMENTAL|The aromatherapy arm|"Free aromatherapy (70% menthol and 30% propanediol). All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
62180711|NCT04103086|PLACEBO_COMPARATOR|The placebo arm|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
62564634|NCT05495282|EXPERIMENTAL|Group B: Microvideo|Group B (n=30) will receive an asynchronous 10-minute micro-video on the topic for which no face-to-face interaction with faculty will be conducted. The micro-video will be provided on a 12.9-inch iPad pro for each participant to view individually. The micro-video group will also have the opportunity to practice pump refilling before the post-evaluation. Participants in Group B will have the micro-video instruction available while practicing hands-on baclofen pump refilling and programming. The maximum time allowed to view the micro-video and practice hands-on baclofen pump refilling and programming will be 30-minutes. The time that each participant in group B spends reviewing the micro-video and practicing hands-on pump refilling and programming will be recorded. The participant may view and rewind the video as many times as needed in the 30-minute period. The live demonstration and the procedural video describe identical steps involved in refilling and programming the baclofen pump.
62564635|NCT05961046||1|Patients with a history of successful myopic LASIK/PRK and underwent bilateral uncomplicated cataract surgery with non-toric Alcon Vivity IOL
62564636|NCT06301438||dalpiciclib|dalpiciclib oral day 1-21, every 28 days
62564637|NCT01013272|ACTIVE_COMPARATOR|Entecavir|Ongoing entecavir 0.5mg daily
62564638|NCT01013272|ACTIVE_COMPARATOR|Lamivudine|Switch to lamivudine 100mg daily
62564639|NCT05790681|EXPERIMENTAL|Participants with Type 2 Diabetes|Participants will receive single subcutaneous (s.c.) fixed dose of insulin icodec (700 units per milliliter \[U/mL\]) that is 5.6 units per kilogram (U/kg) bodyweight. Subjects will be followed up for 5 weeks after dosing.
62564640|NCT02285101|EXPERIMENTAL|Cohort 1|PEG-BCT-100 at 0.5 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 0.5 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 0.5 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 0.5 mg/kg until disease progression at the discretion of the investigator.
62564641|NCT02285101|EXPERIMENTAL|Cohort 2|PEG-BCT-100 at 1.0 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 1.0 mg/kg on days 22 (week4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 1.0 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 1.0 mg/kg until disease progression at the discretion of the investigator.
62564642|NCT02285101|EXPERIMENTAL|Cohort 3|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 1.7 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 1.7 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 1.7 mg/kg until disease progression at the discretion of the investigator.
62564643|NCT02285101|EXPERIMENTAL|Cohort 4|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 2.7 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 2.7 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 2.7 mg/kg until disease progression at the discretion of the investigator.
62564644|NCT02285101|EXPERIMENTAL|Cohort 5|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 4.0 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 4.0 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 4.0 mg/kg until disease progression at the discretion of the investigator.
62564645|NCT02285101|EXPERIMENTAL|Cohort 6|PEG-BCT-100 at a dose to be determined administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT-100 will be administered at at a dose to be determined on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at at a dose to be determined. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at at a dose to be determined until disease progression at the discretion of the investigator.
62564646|NCT03832569|EXPERIMENTAL|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
62564647|NCT04012736||Celiac disease|Celiac disease subjects enrolled after diagnosis and before gluten free diet initiation
62564648|NCT04012736||Control|Healthy controls with no chronic condition
61995525|NCT04782908|EXPERIMENTAL|Transcatheter tricuspid valve edge-to-edge repair|Patients will undergo transcatheter tricuspid valve edge-to-edge repair (TTVR) and hemodynamic characteristics will be analysed on a multimodal approach using cardiac magnetic resonance imaging and pressure volume loop analysis before and after TTVR.
62391266|NCT02438787|PLACEBO_COMPARATOR|Group 1 (placebo)|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 24 all participants (with the exception of participants who qualified for early escape \[EE\]) will be re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52. Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52.
61995526|NCT02526407|NO_INTERVENTION|Control|Participants continue with usual care. No planned intervention.
62564649|NCT01352572|EXPERIMENTAL|antidepressant response|antidepressant response are refered the patients having a 50 ≤ Decrease rate(%) of HAM-D score
61995527|NCT02526407|ACTIVE_COMPARATOR|Group play|Participants take part in 10 weeks of group play activities for one hour per week with their baby in a community setting alongside any usual care they may be receiving.
61995528|NCT02526407|EXPERIMENTAL|Singing|Participants take part in 10 weeks of group singing activities for one hour per week with their baby in a community setting alongside any usual care they may be receiving.
61995529|NCT02166489|EXPERIMENTAL|mesenchymal stem cell transplantation|Intravenous injection of mesenchymal stem cell in patients with PKD
61995530|NCT03202862|EXPERIMENTAL|ESR1 mutated|ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer after previous aromatase inhibitor therapy
61995531|NCT01695811||FLAK|FLAK
61995532|NCT01695811||PKP|Retrospective
61995533|NCT00749983|EXPERIMENTAL|1|creatine intake
61995534|NCT00749983|PLACEBO_COMPARATOR|2|placebo (dextrose) intake
61995535|NCT03114137||sickle cell patients|"* age: five-year-old or more~* major sickle cell syndrome confirmed by hemoglobin phenotype: SS, SC, SBeta+ or Sbeta0~* steady state defined as the absence of vaso-occlusive crisis for the previous 15 days, absence of fever or infectious disease for the previous 8 days and absence of transfusion for the previous 2 months"
61995536|NCT03114137||control patients|"* volunteer parents or siblings of sickle cell patients~* hospital staff or their children matched on country and age +/- 3 ans with the patients"
61995537|NCT00524446|NO_INTERVENTION|ST-DI|Standard treatment - delayed intervention. Counselling on complementary feeding + Vitamin A (200,000 IU) every 6 months until 36 months + 1 kg maize / soy flour 2-weekly (71 g / day) between 18 and 30 months of age.
61995538|NCT00524446|EXPERIMENTAL|FSm|Fortified Spread (milk). Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
61995539|NCT00524446|EXPERIMENTAL|FSs|Counselling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
61995540|NCT00524446|EXPERIMENTAL|LP|Likuni Phala. Counseling + Vitamin A as for ST-DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
61995541|NCT04925063|EXPERIMENTAL|Metformin+ADT+abiraterone|Drug: Metformin The starting daily dose of metformin is 500mg once daily, to be increased to 2000mg once daily if tolerated until disease progression Drug: Abiraterone Abiraterone 1000mg once daily until disease progression
61995542|NCT04925063|NO_INTERVENTION|ADT+abiraterone|Drug: Abiraterone Abiraterone 1000mg once daily until disease progression
61995543|NCT00816699|PLACEBO_COMPARATOR|1|Routine anesthetic risk information
62564650|NCT01352572|ACTIVE_COMPARATOR|antidepressant non-response|antidepressant non-response are refered the patients having a 50 \> Decrease rate(%) of HAM-D score
61995544|NCT00816699|ACTIVE_COMPARATOR|2|Preprint preoperative risk information
61995545|NCT05142761||Posterior component separation|Patients undergoing posterior component separation
61995546|NCT01822132|EXPERIMENTAL|Extended release naltrexone|One dose of intramuscular injection of 380mg extended-release naltrexone.
61995547|NCT01822132|PLACEBO_COMPARATOR|Placebo|One dose of intramuscular injection of placebo.
61995548|NCT03493828|ACTIVE_COMPARATOR|TAP using Bupivacaine 0.5%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
61995549|NCT03493828|ACTIVE_COMPARATOR|TAP using Bupivacaine 0.25%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
61995550|NCT03493828|PLACEBO_COMPARATOR|Placebo|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
61995551|NCT04974658|ACTIVE_COMPARATOR|The block group (ISP)|After aseptic preparation of the injection area, the needle will be introduced in-plane through the skin and advanced into the fascial plane between the semispinalis cervicis and semispinalis capitis muscles. After negative aspiration for blood, 20 ml of 0.25% bupivacaine on each side will be injected for each block.
61995552|NCT04974658|PLACEBO_COMPARATOR|control group (C)|No block will be performed
62564651|NCT02716714|ACTIVE_COMPARATOR|ingenol mebutate gel 0.015%|Applied on face and scalp for three days.
62564652|NCT02716714|ACTIVE_COMPARATOR|ingenol mebutate gel 0.05%|Applied on trunk and extremities for two days.
61995553|NCT05225558|EXPERIMENTAL|Combination therapy - Vancomycin IV plus Delpazolid 800 mg, PO, BID|"Intravenous vancomycin dosed as per 2020 IDSA guideline~Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an intermittent infusion are recommended for most patients with normal renal function when assuming a MICBMD of 1 mg/L.~Depending on the investigator's judgment, it is allowed to change to daptomycin after at least one week of administration of vancomycin, and also it is allowed to change to oral antibiotics other than oxazolidinones after two weeks of administration of vancomycin (including daptomycin)."
62564653|NCT04703972|EXPERIMENTAL|Bipolar Patients with connected devices|Patients with bipolar disorder provided with connected devices (wristwatch and wristband)
62564654|NCT02365441|ACTIVE_COMPARATOR|Arm A|imatinib 400mg orally daily continuously
62180712|NCT00764270|ACTIVE_COMPARATOR|Lipoic acid treatment|Participants take lipoic acid with a washout period before or after placebo.
62180713|NCT00764270|PLACEBO_COMPARATOR|Placebo treatment|Participants take placebo with a washout period before or after lipoic acid treatment
62180714|NCT00535093|NO_INTERVENTION|1|All patients fulfilling inclusion criteria will be evaluated for GAS infection using both a rapid streptococcus test and also a standard throat culture
62180715|NCT04868253|EXPERIMENTAL|EMB-001|EMB-001 will be administered utilizing capsules which contain 240 mg of metyrapone and 8 mg of oxazepam (240/8 mg). Subjects will be prescribed 3 capsules (total of 720 mg metyrapone and 24 mg oxazepam) taken twice daily for a total of 12 weeks. After week 12, or if indicated and possibly for a subject who is being discontinued early, subjects will take one capsule of EMB-001, 240/8 mg, twice a day for one additional week (taper dose).
62180716|NCT05606198||COVID|641,407 patients with a SARS-CoV-2 infection in the year 2020.
62180717|NCT05606198||Non-COVID|Matched patients with no SARS-CoV-2 infection during the study period.
62564655|NCT02365441|EXPERIMENTAL|Arm B|alternating 28-day periods of imatinib 400mg orally daily for 21 to 25 days followed by a washout (drug free) period of 3 to 7 days, then regorafenib 160mg orally daily for 3 weeks followed by a 7 day washout (drug free) period.
62564656|NCT05768711|EXPERIMENTAL|Azacidine+Venetoclax|"Azacitidine will be administered subcutaneously at the standard dose of 75 mg/m²/d either on days 1-7 or using a 5-2-2 schedule of the 28 day-cycles.~Patiens will be exposed to Venetoclax during the first 7 or 14 days of the 28 day-cycles (number of days of Venetoclax determined during the safety run-in phase).~At cycle 1, Venetoclax will be given orally with 3-day ramp-up, at 100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 7 or 14 of the cycle.~At all subsequent cycles, Venetoclax will be given orally at 400 mg on days 1 to 7 or 14 of the cycle.~Treatment duration will be 24 months."
62564657|NCT01186068|EXPERIMENTAL|V-101 Cream 0.01% Concentration|Low dose
61995554|NCT05225558|PLACEBO_COMPARATOR|Monotherapy - Vancomycin IV plus Placebo of Delpazolid|"Intravenous vancomycin dosed as per 2020 IDSA guideline~Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an intermittent infusion are recommended for most patients with normal renal function when assuming a MICBMD of 1 mg/L.~Depending on the investigator's judgment, it is allowed to change to daptomycin after at least one week of administration of vancomycin, and also it is allowed to change to oral antibiotics other than oxazolidinones after two weeks of administration of vancomycin (including daptomycin)."
61995555|NCT03950518|EXPERIMENTAL|One-drug Regimes|Drug: Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
61995556|NCT03950518|EXPERIMENTAL|Two-drug Regimes|Anlotinib Hydrochloride Capsules Arginine hydrochloride
62180718|NCT05851664|ACTIVE_COMPARATOR|Group Direct laryngoscopy (DL)|Group DL: intubated with direct laryngoscopy type Macintosh.
62180719|NCT05851664|EXPERIMENTAL|Group vidéo Laryngoscopy (VL)|Group VL: intubated with a video laryngoscope type McGrath
62180720|NCT03123419|OTHER|Vaccine|All patients who consent to be in the study will receive Appointment reminders.
62180721|NCT01013506|EXPERIMENTAL|Letrozole +/-goserelin, OSI-906 (Arm I )|Patients receive oral letrozole once daily on days 1-28 plus subcutaneous goserelin (the latter for pre-menopausal women only) on day 1 and oral IGF-1R inhibitor OSI-906 twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62180722|NCT01013506|EXPERIMENTAL|Letrozole +/- goserelin, OSI-906, erlotinib (Arm II)|Patients receive oral letrozole and subcutaneous goserelin (the latter for pre-menopausal women only) and oral IGF-1R inhibitor OSI-906 as in arm I. Patients also receive oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62180723|NCT02990923|NO_INTERVENTION|Control|In this group, patients will use traditional standard hemodialysis connector and receive typical disinfection management
62180724|NCT02990923|EXPERIMENTAL|Only High-Flow Valve|In this group, patients will use High-Flow Needleless Valve instead of traditional standard hemodialysia connector, but still receiving typical disinfection management
62180725|NCT02990923|EXPERIMENTAL|Both Divices|In this group, patients will receive both High-Flow Needleless Valve and DualCap Disinfection Devices in hemodialysis
62180726|NCT02082418|EXPERIMENTAL|Healthy|healthy control subjects
62180727|NCT02082418|EXPERIMENTAL|MCI|mild cognitive impariments
62180728|NCT02082418|EXPERIMENTAL|Dementia|established diagnosis of dementia
62180729|NCT01396200|EXPERIMENTAL|Hydroxychloroquine (Cohort B)|Infusional cyclophosphamide 300mg/m2/day for 4 days IV and dexamethasone 40mg/day orally or IV for 4 days on days 1 through 4. Hydroxychloroquine oral will be given on days 5 through 28 of cycle 1 and every day of all subsequent cycles (to be given with milk or food at approximately the same time each day)
62564658|NCT01186068|EXPERIMENTAL|V-101 Cream 0.06% Concentration|Mid-dose
62564659|NCT01186068|EXPERIMENTAL|V-101 Cream 0.1% Concentration|Mid-dose
62564660|NCT01186068|EXPERIMENTAL|V-101 Cream 0.15% Concentration|High dose
62564661|NCT01186068|PLACEBO_COMPARATOR|Vehicle|Cream without an active ingredient
62567776|NCT05601739||Lumbar degenerative disc disease|The case group was made of 50 patients, 24 women (48%) and 26 men (52%) with several clinical symptoms suggestive of LDD and the condition confirmed by MRI.
62567777|NCT05601739||Healthy|The control group was made of 44 healthy volunteers.
62180730|NCT01396200|EXPERIMENTAL|Rapamycin (Cohort A)|Infusional cyclophosphamide 300 mg/m2/day for 4 days IV and dexamethasone 40 mg/day orally or IV for 4 days on days 3 through 6. Rapamycin oral loading dose will be given on day 1 followed by an oral daily dose for an additional 5 days (days 2 through 6) to be given on an empty stomach at approximately the same time each day suggested 11 am)This dosing schedule is the same for all cycles.
62180731|NCT04382768|EXPERIMENTAL|Luarprofen|Inhaled Hypertonic ibuprofen 50 mg tid
62180732|NCT03002922|EXPERIMENTAL|Healthy subjects|Subject will self-apply the test sunscreen formula to his/her face with the goal of applying 0.65 to 0.85 grams. Subject should sweat profusely.
62180733|NCT03987490|EXPERIMENTAL|Parents of Girls|Parents of 11-to-12-year-old girls who did not have records of the HPV vaccine in the EHR or Medicaid claims.
62180734|NCT03987490|EXPERIMENTAL|Parents of Boys|Parents of 11-to-12-year-old girls who did not have records of the HPV vaccine in the EHR or Medicaid claims.
61995557|NCT03950518|EXPERIMENTAL|Three-drug Regimes|Anlotinib Hydrochloride Capsules Arginine hydrochloride Levamisole Hydrochloride
61995558|NCT04488120|EXPERIMENTAL|Occlutech septal occluder ( Figulla Flex II)|Occlutech septal occluder (Figulla Flex II)
61995559|NCT04488120|ACTIVE_COMPARATOR|Amplatzer Septal Occluder (ASO)|St. Jude AGA septal occluder (Amplatzer ASO)
61995560|NCT01945489|EXPERIMENTAL|OnabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) 100U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).
61995561|NCT01945489|OTHER|Placebo/OnabotulinumtoxinA|Placebo (Normal saline) injected into the detrusor on Day 1, followed by an injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).
61995562|NCT04248816|EXPERIMENTAL|Usual Care|Standard of care
61995563|NCT04248816|EXPERIMENTAL|Opt-out|Facilitated outreach and opt-out framing
61995564|NCT04248816|EXPERIMENTAL|Opt-out + Incentive|Facilitated outreach and opt-out framing plus a financial incentive
62180735|NCT02531399|EXPERIMENTAL|Healthy Subjects|20 healthy female and male volunteers, age 18-45 years, non-smokers. Measurements with FDOCT, DVA, LDV and LSFG will be done in all healthy subjects.
62180736|NCT05024409|EXPERIMENTAL|Orthotic + Occupational Therapy|
62180737|NCT05024409|ACTIVE_COMPARATOR|Occupational Therapy alone|
61995565|NCT02731729|EXPERIMENTAL|ipilimumab and nivolumab|For patients in the combination arm, nivolumab will first be administered intravenously at a dose of 1 mg/kg of body weight over a period of 60 minutes, once every 3 weeks for four doses. Thirty minutes after the completion of each nivolumab infusion, patients will receive 3 mg/kg of ipilimumab over a period of 30 minutes.
61995566|NCT02731729|EXPERIMENTAL|ipilimumab|In the ipilimumab monotherapy group, patients will receive 3 mg/kg of ipilimumab over a period of 30 minutes once every 3 weeks for four doses.
61995567|NCT04019743|EXPERIMENTAL|Group 1|"1. Period 1: Treatment A~2. Period 2: Treatment B~3. Period 3: Treatment C"
61995568|NCT04019743|EXPERIMENTAL|Group 2|"1. Period 1: Treatment C~2. Period 2: Treatment A~3. Period 3: Treatment B"
61995569|NCT04019743|EXPERIMENTAL|Group 3|"1. Period 1: Treatment B~2. Period 2: Treatment C~3. Period 3: Treatment A"
61995570|NCT04019743|EXPERIMENTAL|Group 4|"1. Period 1: Treatment C~2. Period 2: Treatment B~3. Period 3: Treatment A"
61995571|NCT04019743|EXPERIMENTAL|Group 5|"1. Period 1: Treatment B~2. Period 2: Treatment A~3. Period 3: Treatment C"
61995572|NCT04019743|EXPERIMENTAL|Group 6|"1. Period 1: Treatment A~2. Period 2: Treatment C~3. Period 3: Treatment B"
61995573|NCT01224249|ACTIVE_COMPARATOR|Fish and shellfish|
61995574|NCT01224249|NO_INTERVENTION|Control|Assessment only
61995575|NCT04693585|EXPERIMENTAL|Arm 1: live support|Real-time live voice call plus standard of postnatal care.
61995576|NCT04693585|EXPERIMENTAL|Arm 2: asynchronous support|Text-based, asynchronous, on-demand social support plus standard of postnatal care
61995577|NCT04693585|EXPERIMENTAL|Arm 3: both live and asynchronous support|Real-time live voice call plus standard of postnatal care; text-based, asynchronous, on-demand social support plus standard of postnatal care
61995578|NCT04693585|NO_INTERVENTION|Arm 4: control|Standard of postnatal care.
62180738|NCT04969224|EXPERIMENTAL|ELX/TEZ/IVA|Participants received ELX 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period approximately 13 weeks.
62180739|NCT02005068|EXPERIMENTAL|Acute Osteomyelitis - Non MRSA|For treatment of Acute osteomyelitis (\< 6 months duration) Non MRSA isolate- Ceftaroline 600 MG (milligram) IV (intra-venous) every 8 hours for 6 weeks.
62180740|NCT02005068|EXPERIMENTAL|Acute osteomyelitis MRSA isolate|For treatment of Acute osteomyelitis (\< 6 months duration) MRSA isolate- Ceftaroline 600 MG IV every 8 hours for 8 weeks.
62180741|NCT02005068|EXPERIMENTAL|Prosthetic joint infection|For treatment of prosthetic joint infection Ceftaroline 600 mg IV every 8 hours for 6 weeks.
62567778|NCT05164770|EXPERIMENTAL|Zanubrutinib+R+chemotherapy|Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
61995579|NCT02908113|OTHER|preterm infants|physiological data collection, behavioral, cerebral hemodynamics, physical environmental newborns studied in response to visual stimuli / auditory or visual-auditory calibrated
61995580|NCT02908113|OTHER|term infants|physiological data collection, behavioral, cerebral hemodynamics, physical environmental newborns studied in response to visual stimuli / auditory or visual-auditory calibrated
61995581|NCT04157946||Focal|ARDS was classified according to the pattern that adopted the loss of aeration in the chest CT in the two groups: focal (predominant commitment in the dependant region) and non- focal (patched or diffused involvement of the entire lung)
61995582|NCT04157946||Non-Focal|ARDS was classified according to the pattern that adopted the loss of aeration in the chest CT in the two groups: focal (predominant commitment in the dependant region) and non- focal (patched or diffused involvement of the entire lung)
62180742|NCT02244268||Patient with symptomatic of benign prostatic hyperplasia|
62180743|NCT02537145||Obese pregnant women|20 obese pregnant women (BMI ≥ 30)
62180744|NCT02537145||Lean pregnant women|20 lean pregnant women (BMI 18,5 - 25)
62180745|NCT05259436|EXPERIMENTAL|Caregiver-Child Intervention|Investigators will examine the immediate psychosocial, behavioral, and child biologic response to three caregiver-child interventions depending on site of enrollment. Each interventions contain overlapping core elements, but also contribute unique facets, allowing us to examine overall intervention effects, as well as unique settings (e.g. home vs. clinic) and delivery effects (1:1 vs. group), providing insight for future direction.
62180746|NCT05259436|ACTIVE_COMPARATOR|Enhanced Primary Care|Navigational services for social need resources.
62180747|NCT05238363|EXPERIMENTAL|HLX07|HLX07 1500mg ivgtt Q3W
62180748|NCT06028217||survival group|patients still survive at 28 days
62180749|NCT06028217||mortality group|patients die within 28 days
61995583|NCT01325779|ACTIVE_COMPARATOR|subcutaneous heparin|
61995584|NCT01325779|ACTIVE_COMPARATOR|subcutaneous enoxaparin|
62180750|NCT04410549|EXPERIMENTAL|COVID-19 patient with pulmonary thrombosis|"* patients with COVID-19, high D-dimer levels and contrast CT scan negative for pulmonary thrombosis~* patients with contrast CT scan positive for pulmonary embolism in areas where contrast CT scan was negative."
62180751|NCT01143545|EXPERIMENTAL|1|Allogeneic tumor cell vaccine + chemotherapy
61995585|NCT00692770|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (BID)
62564662|NCT02530723|EXPERIMENTAL|Once a week|Group 1 will be invited to perform resistance training exercise 1 day/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
62564663|NCT02530723|EXPERIMENTAL|Twice a week|Group 2 will be invited to perform resistance training exercise 2 days/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
62564664|NCT02530723|EXPERIMENTAL|Thrice a week|Group 3 will be invited to perform resistance training exercise 3 days/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
61995586|NCT00692770|PLACEBO_COMPARATOR|Placebo|Participants received 2 tablets of placebo orally twice daily (BID)
61995587|NCT03453450||Health TAPESTRY volunteers|Volunteers in a primary care setting connecting with Health TAPESTRY clients
61995588|NCT03453450||Health TAPESTRY Volunteer Coordinators|The coordinators of volunteers
61995589|NCT02311465|EXPERIMENTAL|Palliative Care + Standard of Care|Consenting patients will be approached by a research nurse to complete quality of life questionnaires (baseline measures) either in the oncology clinics or infusion clinics. Patients assigned to early palliative care will meet with a member of the palliative care team after enrollment and completion of the initial questionnaires to receive and review patient-oriented materials detailing palliative care services. Patients will then receive a comprehensive initial consult with a palliative care provider (a trained physician, nurse or nurse practitioner). Additional consults with the palliative care service will be scheduled approximately every 6 weeks for the duration of the study period (one year) at the discretion of the patient and palliative care provider.
61995590|NCT02311465|NO_INTERVENTION|Standard of Care|Patients will receive standard care from their oncologist. An assessment of health related quality of life will be conducted at regular oncology clinic visits at baseline and 3,6,9,and 12 months.
61995591|NCT04081948|ACTIVE_COMPARATOR|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
62180752|NCT04124198|EXPERIMENTAL|Transoral robotic surgery (TORS)|
62182805|NCT03000348|ACTIVE_COMPARATOR|Mid-Range Dose, Three times per day|Patient takes three oral doses of Cysteamine (mid-range dose) per day, one in the morning, one at mid-day and one in the evening.
62182806|NCT06216795||kidney transplant group|
62182807|NCT01155076|EXPERIMENTAL|Vitality product|Proprietary blend of ginseng, cordyceps, and pomegranate
61995592|NCT04081948|SHAM_COMPARATOR|Group S = Sham block group|In group S, sham block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml normal saline will be administered for block.
61995593|NCT04889742|EXPERIMENTAL|Hyperthermia|Patients will receive 6-8 treatments additional loco-regional hyperthermia concurrent to re-irradiation. Hyperthermia will start on the third day of fractionated radiotherapy and will be given twice per week. According to site of recurrent disease either deep-regional, capacitive or superficial hyperthermia devices may be used.
62564665|NCT02530723|NO_INTERVENTION|wait-control|Participants in this group will serve as controls prior to participating in power training in 1 of the above treatment groups. The control period will last as long as the exercise period, or 3 months. Controls will participate in the same testing time points as the exercisers (baseline, midpoint, and post-intervention).
62564666|NCT03484962|EXPERIMENTAL|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
61995594|NCT03507556|EXPERIMENTAL|Triple paste and induced bleeding|The triple paste is a mixture of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol will be used and next visit intracanal bleeding will be induced
61995595|NCT02199405|EXPERIMENTAL|massage and Sishi Daoyin|Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
62564667|NCT03484962|ACTIVE_COMPARATOR|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length\<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
62564668|NCT03484962|NO_INTERVENTION|No intervention|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
61995596|NCT02199405|ACTIVE_COMPARATOR|conventional massage and cervical traction|Conventional massage , 15 minutes, three times one week for 4 weeks Cervical traction , 15 minutes, three times one week for 4 weeks
62564669|NCT02458144|OTHER|"MIS anterior group"|"Total Hip Arthroplasty anterior surgical approach"
61995597|NCT06255535|EXPERIMENTAL|active iTBS group|active iTBS over DLPFC
61995598|NCT06255535|SHAM_COMPARATOR|Sham group|sham iTBS over DLPFC
61995599|NCT00681499||malignant|eg. hepatocellular carcinoma, colorectal liver metastases
61995600|NCT00681499||benign|eg. liver cysts, traumatic liver injuries, adenoma etc
61995601|NCT03837548|EXPERIMENTAL|Training with Neurofeedback|
61995602|NCT03837548|EXPERIMENTAL|The other Training with Neurofeedback|
61995603|NCT01256112|EXPERIMENTAL|NAE + Behavioral Intervention|Parents of participants receive training in behavioral support at home, in addition to a standard nutrition and physical activity education (NAE) program.
61995604|NCT01256112|ACTIVE_COMPARATOR|Nutrition/Activity Education|Parents and participants receive a standard nutrition and physical activity education (NAE) program.
61995605|NCT01301222|EXPERIMENTAL|octreotide|octreotide arm 100mcg for 5 days. control has no octreotide
62564670|NCT02458144|OTHER|"MIS anterolateral group"|"Total Hip Arthroplasty anterolateral surgical approach"
62564671|NCT00958828|OTHER|Nelfilcon A / Narafilcon A|Nelfilcon A contact lenses, then Narafilcon A contact lenses
61995606|NCT05013983|EXPERIMENTAL|Low-dose vaccine (6-11 years)|three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
62564672|NCT00958828|OTHER|Narafilcon A / Nelfilcon A|Narafilcon A contact lenses, then Nelfilcon A contact lenses
61995607|NCT05013983|EXPERIMENTAL|Medium-dose vaccine (6-11 years)|three doses of medium-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
61995608|NCT05013983|EXPERIMENTAL|Medium-dose vaccine (12-17 years)|three doses of medium-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
62567779|NCT05164770|ACTIVE_COMPARATOR|R+chemotherapy|R-CHOP; R-DA-EPOCH; R-HD MTX
62567780|NCT03244761||The standard HFT|The high-flow oxygen was delivered via tracheostomy using a standard HFT.
61995609|NCT05013983|EXPERIMENTAL|High-dose vaccine (12-17 years)|three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
61995610|NCT05013983|PLACEBO_COMPARATOR|Low-dose placebo (6-11 years)|three doses of low-dose placebo at the schedule of day 0, 21，42.
61995611|NCT05013983|PLACEBO_COMPARATOR|Medium-dose placebo (6-11 years)|three doses of medium-dose placebo at the schedule of day 0, 21，42.
61995612|NCT05013983|PLACEBO_COMPARATOR|Medium-dose placebo (12-17 years)|three doses of medium-dose placebo at the schedule of day 0, 21，42.
62772746|NCT05843318|EXPERIMENTAL|Pre-meal water + Hypocaloric diet|premeal water ( 500 ml) before each main meal, three times per day + hypocaloric diet
62772747|NCT05843318|EXPERIMENTAL|Daily water + Hypocaloric diet|total daily water prescription (1500 ml/d) + hypocaloric diet
62772748|NCT05843318|ACTIVE_COMPARATOR|Hypocaloric Diet alone|hypocaloric diet with not instructions regarding water intake
62772749|NCT02228096|EXPERIMENTAL|tisagenlecleucel (CTL019)|Pediatric patients with relapsed/refractory B-cell ALL
62772750|NCT02478580|EXPERIMENTAL|Nuvigil|A single oral dose of Nuvigil at 150mg dose in preoperative area
62772751|NCT02478580|PLACEBO_COMPARATOR|Placebo|A single oral placebo will be given in preoperative area
61995613|NCT05013983|PLACEBO_COMPARATOR|High-dose placebo (12-17 years)|three doses of high-dose placebo at the schedule of day 0, 21，42.
61995614|NCT02852031||Hypoplastic Left Heart Syndrome|Infants diagnosed with Hypoplastic Left Heart Syndrome (HLHS)
61995615|NCT03408015|EXPERIMENTAL|Normal, asymptomatic non-lens wearers|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
61995616|NCT03408015|EXPERIMENTAL|Dry eye subjects, non-lens wearers|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
61995617|NCT03408015|EXPERIMENTAL|Contact lens wearers with discomfort|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
61995618|NCT00005833|EXPERIMENTAL|R115777|R115777, 300mg PO BID on Days 1-21. 1 cycle=28 days.
61995619|NCT02155738|PLACEBO_COMPARATOR|Placebo|100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
61995620|NCT02155738|EXPERIMENTAL|IV Acetaminophen|100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
62182615|NCT00244907|ACTIVE_COMPARATOR|Genistein dose and source|Healthy post menopausal women will consume 5 products containing varying quantities of genistein from different sources for 50 days each in a randomized order. Each intervention period is separated by a 50 day washout period. Intervention: A) 50 mg genistein from soy protein isolate, B) 100 mg genistein from soy protein isolate, C)50 mg genistein from Novasoy, D) 100 mg genistein from Novasoy, E) 100 ng genistein from 50% Novasoy and 50% soy protein isolate
62182808|NCT01155076|PLACEBO_COMPARATOR|Placebo|Placebo
62564673|NCT06348069|EXPERIMENTAL|Pharmacy-based PrEP refills + gift cards|Participants who have, in addition to the standard practice of refill pickups at CESHHAR clinics, the opportunity to retrieve PrEP refills at private pharmacies, and who receive gift card incentives at the designated refill time-points of 1, 3, and 6 months.
62564674|NCT06348069|EXPERIMENTAL|Control (Standard of Care)|Participants who do not have the opportunity to retrieve PrEP refills at private pharmacies. PrEP refill pick-ups are available through CESHHAR Zimbabwe's existing network of clinical sites.
62564675|NCT06101966||cervical cancer patients with radiotherapy|The overall dose should be more than 75 Gy. patients received surgery should be excluded.
62564676|NCT05663125|EXPERIMENTAL|LITT with Early Application of Temozolomide|Patients will receive the early use of temozolomide sooner after Laser interstitial thermal therapy (LITT).
62564677|NCT05958043|EXPERIMENTAL|3D-printed group|The patients randomized to the 3D-printed group will receive a 3D-printed full arch implant-supported provisional restoration.
62564678|NCT05958043|OTHER|CAD/CAM- milled group|The patients randomized to the CAD/CAM-milled group will receive a PMMA-milled full-arch implant-supported provisional restoration.
62564679|NCT01977105|EXPERIMENTAL|Pilot Intervention Group|Mothers who are screened and determined to be eligible for this single-group pilot study will be enrolled along with their infants in the Grow Together peer group intervention.
62564680|NCT03573973|EXPERIMENTAL|Fresh fruit and vegetable placement intervention|The intervention is a store refurbishment programme that includes the creation of a new fresh fruit and vegetable section at the store entrance with expanded range thus improving the availability and position of fresh fruit and vegetables.
62564681|NCT03573973|SHAM_COMPARATOR|Control|The control condition is the existing store layout with a limited range of fresh fruit and vegetables that are placed at the back of the store.
62567781|NCT03244761||The modified HFT|The high-flow oxygen was delivered via tracheostomy using a modified HFT.
62772752|NCT03818425||Clinical Population|In- and Out-Patients diagnosed with depression (F32, F33), anxiety disorder (F40, F41; ICD-10) or posttraumatic stress disorder (F43.1; ICD-10)
62772753|NCT03818425||Healthy Controls|Subjects with no previous or actual mental disorder
62772754|NCT04420260|EXPERIMENTAL|Treatment oropharyngeal spray + immunostimulant emulsion|Active principle oropharyngeal spray + Active principle immunostimulant taken PO.
62772755|NCT04420260|PLACEBO_COMPARATOR|Placebo|Placebo oropharyngeal spray + Placebo emulsion was taken PO.
62772756|NCT04190004|EXPERIMENTAL|vasopressin|All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design
62772757|NCT04190004|PLACEBO_COMPARATOR|Placebo|All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design
62180753|NCT04124198|ACTIVE_COMPARATOR|Intensity-Modulated Radiation Therapy (IMRT)|"Patients with clinical T1N0 stage are offered accelerated radiotherapy to 66 Gy/33fractions with concurrent nimorazole.~Patients with clinical T2N0 stage are offered either accelerated radiotherapy to 66 Gy/33fractions with the option of weekly cisplatin to fit patients or hyper-fractionated accelerated radiotherapy to 76 Gy/56fractions both with concurrent nimorazole.~Patients with clinical T1-T2, N1 stage are offered accelerated radiotherapy to 66 Gy/33 fractions and nimorazole with the addition of concurrent weekly cisplatin 40 mg/sqm to fit patients."
62182616|NCT00381888|EXPERIMENTAL|Patients Treated with Fondaparinux|Patients treated with at least one dose of Fondaparinux (2.5 mg subcutaneous, Days 1-28 by mouth).
62564682|NCT01164293|EXPERIMENTAL|Atopy patch test|Atopy patches were applied on food allergy patient's back for 48 hrs then the patches were removed. Reaction was evaluated at 48 and 72 hrs after applying atopy patch test
62564683|NCT01127997||study A|post-breakfast meal tolerance test + post-lunch meal tolerance test
62564684|NCT01127997||study B|fasting + post-lunch meal tolerance test
62564685|NCT03726827||population|self selected members of the general population who perceive a value in having a Fibroscan screening test of their liver
62564686|NCT00574704|EXPERIMENTAL|1|
62564687|NCT00574704|PLACEBO_COMPARATOR|2|
62564688|NCT00574704|EXPERIMENTAL|3|
61995621|NCT03356496|EXPERIMENTAL|Intervention|Patient provided with instructions and video for the use of an incentive spirometry device. Patient instructed to use incentive spirometry device as frequently as every hour while awake but at least 4 times daily for at least 10 breathing cycles for 1-3 weeks before surgery. Patient instructed to record usage and any physical complaints in a diary.
62564689|NCT00574704|PLACEBO_COMPARATOR|4|
62564690|NCT01421979|EXPERIMENTAL|exposure under sleep deprivation|Examination of the effects of EDs in combination with alcohol consumption and sleep deprivation.
62564691|NCT01421979|EXPERIMENTAL|Exercise after consumption|Examination of the effects of EDs in combination with alcohol consumption and exercise.
62564692|NCT04861753||Reiki|"The modern-day Reiki (pronounced ray-kee) practiced in the United States originated in Japan with Mikao Usui in the early 1900s. Reiki is a complementary and adjuvant therapeutic technique. Reiki, which is classified as an energy healing therapy, is a technique of channeling universal energy in order to reduce stress, promote relaxation, and enhance well-being."
62564693|NCT04861753||Back massage|Massage therapy involves the manipulation of the soft tissues of the body by touch. It consists of gentle movements such as effleurage, petrissage and percussion.
62564694|NCT04861753||Control|Routine postoperative care was given to the control group without any intervention
62564695|NCT01401764|OTHER|Platform II, PASS, ARG 100|
62564696|NCT00669669|EXPERIMENTAL|Treatment (chemotherapy, autologous stem cell transplant)|See Detailed Description
62564697|NCT01342523|EXPERIMENTAL|No CIS/No loz/No Email/Lite Website/Brief Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, No nicotine lozenge, No motivational emails, lite website, brief mailed booklet"
62564698|NCT01342523|EXPERIMENTAL|CIS/No loz/No email/Lite Website/Brief booklet|"This arm of the project will address the following question:~Does the following treatment provide efficacy relative to others:~CIS calls, no NRT lozenge, no motivational email, Lite website, Brief mailed booklet"
62564699|NCT01342523|EXPERIMENTAL|no CIS/Loz/No email/lite website/brief booklet|"This arm of the project will address the following question:~Does this combination of services achieve effectiveness compared to others:~No CIS phone counseling, NRT lozenge, no motivational email, lite website, brief mailed booklet"
62564700|NCT01342523|EXPERIMENTAL|No CIS/no loz/email/lite website/brief booklet|"This arm of the project will address the following question:~Does this combination of services lead to greater abstinence:~No CIS counseling calls, no NRT lozenge, motivational emails, lite website, brief mailed booklet."
62564701|NCT01342523|EXPERIMENTAL|No CIS/No loz/No email/Full website/Brief booklet|"This arm of the project will address the following question:~Does this combination of services lead to greater abstinence?~No CIS counseling, no NRT lozenge, no motivational email, full website, brief mailed booklet"
61995622|NCT03356496|NO_INTERVENTION|Control|Patient receives only usual care as provided by perioperative healthcare providers.
61995623|NCT05438069||Patients with elevated LDL-cholesterol (hypercholesterolemia)|Application of si RNA Inclisiran to reduce serum LDL-cholesterol levels.
61995624|NCT02179996|ACTIVE_COMPARATOR|Three vaccine injections|Infants in this study arm will receive three vaccine injections at two, three and four months after birth (vaccine: DTP-pertussis-Hib).
62564702|NCT01342523|EXPERIMENTAL|No CIS/No loz/No email/lite website/full booklet|"This arm seeks to answer the question:~Does this combination of services achieve efficacy compared to others:~No CIS counseling, no NRT lozenge, no motivational email, lite website, full mailed booklet"
62564703|NCT01342523|EXPERIMENTAL|CIS/Loz/No email/Lite website/Brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, lite website, brief mailed booklet"
62564704|NCT01342523|EXPERIMENTAL|CIS/No loz/Emails/Lite Website/Brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, motivational emails, lite website, brief mailed booklet"
62564705|NCT01342523|EXPERIMENTAL|CIS/No loz/no email/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, No motivational emails, full website, brief mailed booklet"
62564706|NCT01342523|EXPERIMENTAL|CIS/No loz/no email/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, No motivational emails, lite website, full mailed booklet"
62564707|NCT01342523|EXPERIMENTAL|No CIS/Loz/emails/Lite Website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, lite website, brief mailed booklet"
62564708|NCT01342523|EXPERIMENTAL|No CIS/Loz/No emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, lite website, full mailed booklet"
62772758|NCT01896583|EXPERIMENTAL|ASP7147|ASP7147, 300 mg, tablet, twice per day for 4 weeks oral
62564709|NCT01342523|EXPERIMENTAL|No CIS/Loz/No emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, full website, brief mailed booklet"
62564710|NCT01342523|EXPERIMENTAL|no CIS/no loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, full website, brief mailed booklet"
62564711|NCT01342523|EXPERIMENTAL|no CIS/no loz/emails/lite web/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, lite website, full mailed booklet"
62564712|NCT01342523|EXPERIMENTAL|no CIS/no loz/no email/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, No motivational emails, full website, full mailed booklet"
62564713|NCT01342523|EXPERIMENTAL|CIS/loz/emails/lite website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, lite website, brief mailed booklet"
62564714|NCT01342523|EXPERIMENTAL|CIS/loz/no email/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, full website, brief mailed booklet"
62564715|NCT01342523|EXPERIMENTAL|CIS/loz/no email/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, lite website, full mailed booklet"
62564716|NCT01342523|EXPERIMENTAL|CIS/no loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, full website, brief mailed booklet"
62564717|NCT01342523|EXPERIMENTAL|CIS/no loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, lite website, full mailed booklet"
62564718|NCT01342523|EXPERIMENTAL|CIS/no loz/no email/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, No motivational emails, full website, full mailed booklet"
62564719|NCT01342523|EXPERIMENTAL|No CIS/loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, full website, brief mailed booklet"
62564720|NCT01342523|EXPERIMENTAL|No CIS/loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, lite website, full mailed booklet"
62564721|NCT01342523|EXPERIMENTAL|No CIS/loz/no emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, full website, full mailed booklet"
62564722|NCT01342523|EXPERIMENTAL|no CIS/no loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, full website, full mailed booklet"
62564723|NCT01342523|EXPERIMENTAL|CIS/loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, full website, brief mailed booklet"
62564724|NCT01342523|EXPERIMENTAL|CIS/loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, lite website, full mailed booklet"
62564725|NCT01342523|EXPERIMENTAL|No CIS/loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, full website, full mailed booklet"
62564726|NCT01342523|EXPERIMENTAL|CIS/no loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, full website, full mailed booklet"
62564727|NCT01342523|EXPERIMENTAL|CIS/Loz/no Emails/Full Website/Full Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, full website, full mailed booklet"
62564728|NCT01342523|EXPERIMENTAL|CIS/Loz/Emails/Full Website/Full Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, full website, full mailed booklet"
62564729|NCT00594165|EXPERIMENTAL|Rotigotine|Rotigotine
62564730|NCT05523102|EXPERIMENTAL|Paracetamol|Paracetamol 15mg/kg 6 hourly for 48 hours post-operatively
62772759|NCT01896583|PLACEBO_COMPARATOR|Placebo|oral
61995625|NCT02179996|EXPERIMENTAL|Two vaccine injections|Infants in this study arm will receive two vaccine injections at two and four months after birth (vaccine: DTP-pertussis-Hib).
61995626|NCT01519856||tablet|
61995627|NCT06184425|ACTIVE_COMPARATOR|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|
61995628|NCT06184425|EXPERIMENTAL|Dural Puncture Epidural technique using 27 G Whitacre needle|
61995629|NCT05188859|EXPERIMENTAL|Treatment|"Regimen:~1. Sintilimab, 200mg, ivgtt d1, q3w, 21 days per cycle~2. Anlotinib, 12mg, po, qd, d1-14, q3w, 21 days per cycle~3. Pemetrexed, 500mg/m², ivgtt , d1, q3w, 21 days per cycle, 4-6 cycles.~4. Cisplatin, 75mg/m2 , ivgtt, d1, q3w/Carboplatin, AUC 5.0, ivgtt, d1, q3w, 21 days per cycle, 4-6 cycles."
61995630|NCT00784511|EXPERIMENTAL|1 vitamin D3|vitamin D3, 4000 IU/d
61995631|NCT00784511|PLACEBO_COMPARATOR|2|placebo
62180754|NCT01746277|OTHER|combined group|combined group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
62182809|NCT03318783|ACTIVE_COMPARATOR|GSK2256294|10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.
62564731|NCT05523102|ACTIVE_COMPARATOR|Ketorolac|Ketorolac 0.5mg/kg 8 hourly for 48 hours post-operatively
62564732|NCT04200651|EXPERIMENTAL|DEXTENZA® arm|This arm will receive the DEXTENZA® insert after cataract surgery and MIGS.
62564733|NCT04200651|ACTIVE_COMPARATOR|Prednisolone acetate 1% arm|This arm will receive the prescription for daily prednisolone acetate 1% eye drops after cataract surgery and MIGS.
62180755|NCT01746277|OTHER|sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
62564734|NCT03077737|EXPERIMENTAL|Population health management|Population health management for smoking cessation in low-income smokers: the Choose to Change intervention
62180756|NCT01588210|EXPERIMENTAL|Glass Ionomer Cement group|a high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany)
62564735|NCT03077737|ACTIVE_COMPARATOR|Enhanced usual care|Usual clinic-based care enhanced by an EHR system that can deliver an electronic referral for quitline treatment
62564736|NCT03045263|ACTIVE_COMPARATOR|Pivotal Response Treatment|Pivotal Response Training with children ages 3-6 years of age with an Autism Spectrum Disorder diagnosis
62564737|NCT03045263|NO_INTERVENTION|Waitlist Control|Children in WL will be offered treatment following WL condition.
62564738|NCT04909853|EXPERIMENTAL|PF-07321332|PF 07321332/ritonavir
62564739|NCT02152904||Peptic ulcer bleeding patients|Endoscopy
62180757|NCT01588210|EXPERIMENTAL|Resin Based Fluoride Group|white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein)
62180758|NCT01588210|PLACEBO_COMPARATOR|Resin Based sealant|white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany)
62564740|NCT05006287|EXPERIMENTAL|Non-Vitamin K Oral Anticoagulant (NOAC) Group|Anticoagulation with a NOAC (Apixaban, Dabigatran, Edoxaban, Rivaroxaban)
62564741|NCT05006287|ACTIVE_COMPARATOR|Warfarin Group|Anticoagulation with warfarin to target INR 2.5
62564742|NCT02628808||Autism Spectrum Disorder|For all patients included in the study, core assessment carried out by either collaborating partners consists of diagnosis using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Patients with profound intellectual disability or with a known medical cause of autism, such as neurocutaneous syndromes, Fragile X, metabolic disorders, extreme prematurity, congenital rubella and other prenatal or postnatal neurological infections or gross dysmorphology, will be excluded.
62180759|NCT05887739||GLUT1DS|Patients affected by GLUT1 deficiency syndrome
62180760|NCT05887739||Healthy controls|Age and sex matched healthy controls
62180761|NCT03204500|EXPERIMENTAL|Active treatment with dual therapy|This group is composed by 20 ALS subjects under 600mg valproate and 600 mg of litium carbonate per day, during 21 months. The tablets are given orally with meals.
62564743|NCT02628808||controls|Age 6 to 40 Healthy individuals with or without idiopathic surgical or urological conditions (e.g. orthopaedic conditions, hernia repairs, renal malformations, pre- or post-circumcision, phimosis, balanitis, scoliosis, congenital hip dislocation, adenoid or tonsil removal, dental procedures such as wisdom tooth extraction, cosmetic procedures such as removal of skin tags or cleft lip repairs, non-head injuries such as fractures, drainage of subungual or perichondrial haematomata).
62564744|NCT04823468|EXPERIMENTAL|Experimental group|In addition to conventional dietary instruction and individualized nutritional counselling, patients were given additional ONS (Abbott®Ensure of 55.8 g tid) from the beginning to the end of radiotherapy.
62564745|NCT04823468|OTHER|Control group|Conventional dietary instruction and individualized nutritional counselling from the beginning to the end of radiotherapy.
62564746|NCT04421131|EXPERIMENTAL|mIVAA|Screened for cervical cancer with mIVAA in mobile units
62564747|NCT03809975|ACTIVE_COMPARATOR|Control Arm|"Current model of care~Patients will undergo the current standard of care in the Orthopaedic Outpatient Clinic in Tan Tock Seng Hospital. Patients will undergo routine consultation with an orthopaedic surgeon and will be provided with standard treatment as necessitated based on the assessment of the orthopaedic surgeon. Subsequent follow up appointments will be scheduled at the discretion of the orthopaedic surgeon. Patients will be referred to the physiotherapists, dietitian and psychologists as necessary for regular or adhoc sessions at the discretion of the allied health professional."
62564748|NCT03809975|EXPERIMENTAL|Intervention Arm|"Multidisciplinary Community Program~Community based, personalized, structured, 12-week multidisciplinary program that includes Orthopaedics, Physiotherapy, Dietitics, Psychology interventions. This intervention involves the use of formal assessment such as BMI and psychological questionnaires to determine the need for dietetics or psychological intervention. In addition, there are educational sessions to improve patient's understanding of osteoarthritis and improve their activation level. An optional support group session will be arranged at approx. 3-4 months after completion of the 12-week intervention program to improve sustainability of treatment effect."
62564749|NCT02913118|EXPERIMENTAL|standard antibiotic treatment +AS injection|Andrographolid Sulfonate Injection (AS Injection) plus one of 3 antibiotics in China CAP Guideline
62180762|NCT03204500|PLACEBO_COMPARATOR|placebos|This group is composed by 20 ALS subjects under placebo. Blue tablets ( placebo of VPA) and white tablets (placebo of Li) are administered under the same conditions.
62180763|NCT01351337|OTHER|intraoperative functional monitoring|intraoperative functional monitoring
62180764|NCT03100864|EXPERIMENTAL|Spesolimab|
62180765|NCT04513275||schizophrenia patient group|Schizophrenia patients with first episode and disease duration of 5, 10, 20, and 30 years
62180766|NCT02287740|EXPERIMENTAL|Tai Ji Quan: Moving for Better Balance|This protocol involves training 2 times a week for 6 months.
62180767|NCT02287740|ACTIVE_COMPARATOR|Multimodal Exercise|This protocol involves training 2 times a week for 6 months.
62564750|NCT02913118|PLACEBO_COMPARATOR|standard antibiotic treatment + AS placebo|AS placebo (NS injection) plus one of 3 antibiotics in China CAP Guideline
62564751|NCT05370040|EXPERIMENTAL|Phase 1 Cohort 1A|AAHI-SC2 on Day 1 at dosage 25 μg IM
62564752|NCT05370040|EXPERIMENTAL|Phase 1 Cohort 1B|AAHI-SC2 on Day 1 at dosage 50 μg IM
62564753|NCT05370040|EXPERIMENTAL|Phase 1 Cohort 1C|AAHI-SC2 on Day 1 at dosage 70 μg IM
62564754|NCT05370040|EXPERIMENTAL|Phase 1 Cohort 2A|AAHI-SC3 on Day 1 at dosage 25 μg IM
62180768|NCT02287740|SHAM_COMPARATOR|Stretching|This protocol involves participation of 2 times a week for 6 months.
62180769|NCT03517111|EXPERIMENTAL|Nutrition/substance use prevention|Parenting and nutrition curriculum targeting substance use prevention and diet improvement.
62180770|NCT03517111|ACTIVE_COMPARATOR|Substance use prevention only|Parenting curriculum targeting substance use prevention only.
62180771|NCT03517111|SHAM_COMPARATOR|Academic success program|Control program focused only on academic success.
62180772|NCT02923609|EXPERIMENTAL|SC Group|In Phase 1 of the study, all patients will be treated with optimization of medical therapy for 6 months. Thereafter, all patients will cros over to Phase 2 of the study, where they will receive transendocardial CD34+ cell therapy. Follow-up of Phase 2 will last for 6 months. At the time of enrollment (6 months before cell therapy), at time of cell therapy, and 6 months thereafter we will perform detailed clinical evaluation, laboratory assays, echocardiography, 6-minute walk test, and measure plasma levels of N-terminal pro B-type natriuretic peptide (NT-proBNP).
62180773|NCT02605096|EXPERIMENTAL|MRI group|"This arm assess the use of MRI as the first line examination of suspected scaphoid fracture (replacing conventional plain x-ray).~Patients with negative findings will receive a splint and contact card to a specialist wrist clinic if the pain persists for ten to fourteen days after initial presentation.~Patients with positive findings will receive a plaster cast and undergo a CT scan (to evaluate displacement) and will be referred to the fracture clinic. Furthermore, if the CT scan confirms a displaced fracture, that might require surgery, the patient should be seen by a Hand Specialist at fracture clinic.~All patients enrolled in the pilot should undergo a 4-view plain x-ray 3 months after the initial ED/UCC presentation."
62564755|NCT05370040|EXPERIMENTAL|Phase 1 Cohort 2B|AAHI-SC3 on Day 1 at dosage 50 μg IM
62564756|NCT05370040|EXPERIMENTAL|Phase 1 Cohort 2C|AAHI-SC3 on Day 1 at dosage 85 μg IM
62564757|NCT05370040|PLACEBO_COMPARATOR|Phase 2 Control arm|EUA or approved vaccine on Day 1
62564758|NCT05370040|EXPERIMENTAL|Phase 2 Experimental arm 1|AAHI-SC2 on Day 1 Dose TBD as determined in phase 1 study
62564759|NCT05370040|EXPERIMENTAL|Phase 2 Experimental arm 2|AAHI-SC3 on Day 1 Dose TBD as determined in phase 1 study
62564760|NCT05370040|EXPERIMENTAL|Phase 2 Experimental arm 3|AAHI-SC3 on Day 1 and 29 Dose TBD as determined in phase 1 study
62772760|NCT04054466|EXPERIMENTAL|Experimental group|Intervention with counselling designed
62772761|NCT04054466|OTHER|Control group|Intervention with habitual counselling
62564761|NCT01380912||breast cancer|"1. Patients operated with mastectomy and axillary dissection, who are randomised to injection of methylprednisoloneacetate in the cavity~2. Patients operated with mastectomy and axillary dissection, who are randomised to injection of saline solution in the cavity~3. Patients operated with mastectomy and Sentinel Node Operation, who are randomised to injection of methylprednisoloneacetate in the cavity~4. Patients operated with mastectomy and Sentinel Node Operation, who are randomised to injection of saline solution in the cavity"
62180774|NCT02605096|ACTIVE_COMPARATOR|X-ray group|"This arm is the current standard of care pathway for the diagnosis of patients with suspected scaphoid fracture. This includes an initial clinical assessment on arrival to the Emergency Department of Urgent Care Centre followed by a plain x-ray (using a 4-view scaphoid protocol).~Patients with negative/positive findings for scaphoid fracture in the initial X-ray will be immobilised with a splint/plaster cast.~All patients will be referred to an initial fracture clinic and a proportion of patients are likely to require additional imaging scans (usually CT but also MRI) and follow-up appointments in the fracture clinic. All patients enrolled in the pilot should undergo a 4-view plain x-ray 3 months after the initial ED/UCC presentation."
62180775|NCT03068793||Patients with Recent Onset Schizophrenia|Individuals who have been diagnosed with Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder within the past five years and meet our research criteria for symptoms indicative of these diseases within the past five years.
62564762|NCT06162364|EXPERIMENTAL|VR group|In this group, students were taught surgical hand washing and sterile dressing skills through theoretical training, demonstration, and VR glasses. Later, a theoretical knowledge assessment test was administered, and they were subjected to a skill evaluation exam in the laboratory.
62564763|NCT06162364|NO_INTERVENTION|theoretical training group|In this group, students were taught surgical hand washing and sterile dressing skills through theoretical training and demonstration. Later, a theoretical knowledge assessment test was administered, and they were subjected to a skill evaluation exam in the laboratory.
62180776|NCT03068793||Patients with Major Depressive Disorder|Individuals who have been diagnosed with Major Depressive Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
62180777|NCT03068793||Patients with Gambling Disorder|Individuals who have been diagnosed with Gambling Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
62180778|NCT03068793||Patients with Post Traumatic Stress Disorder|Individuals who have been diagnosed with Post Traumatic Stress Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
62180779|NCT03068793||Healthy Controls|Individuals who have not met criteria for a psychiatric, mood, or gambling disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric, mood, or gambling disorder.
62180780|NCT04658654|PLACEBO_COMPARATOR|Placebo|Placebo oral capsule, once daily for 24 weeks
62180781|NCT04658654|EXPERIMENTAL|Roflumilast 50ug|Roflumilast (50 microgram) oral capsule, once daily for 24 weeks
62564764|NCT06162364|EXPERIMENTAL|video training group|In this group, students were taught surgical hand washing and sterile dressing skills through theoretical training, demonstration, and two-dimensional video. Later, a theoretical knowledge assessment test was administered, and they were subjected to a skill evaluation exam in the laboratory.
62180782|NCT04658654|EXPERIMENTAL|Roflumilast 100ug|Roflumilast (100 microgram) oral capsule, once daily for 24 weeks
62180783|NCT01685086||Patients with severe chronic kidney disease|
62180784|NCT01685086||Patient with peritoneal dialysis|
62564765|NCT03798028|EXPERIMENTAL|UC-MSCs treatment|the participants will receive the single-dose UC-MSCs (1×10\^6 cells/kg ) in combined with the present treatment.
62564766|NCT03798028|NO_INTERVENTION|no UC-MSCs treatment|the participants will receive the placebo in combined with the present treatment.
62564767|NCT05669625|EXPERIMENTAL|Experimental Group|Single subcutaneous injection of the investigational vaccine (0.5 ml)
62564768|NCT05669625|PLACEBO_COMPARATOR|Placebo Group|Single subcutaneous injection of the investigational placebo (0.5 ml)
62564769|NCT03490552|SHAM_COMPARATOR|group A|include clots which have been extracted by mechanical thrombectomy and with definite stroke etiology and submitted to the RNA analysis in blinded coded label .
62180785|NCT01685086||Patients with hemodialysis|
62564770|NCT03490552|EXPERIMENTAL|group B|include all clots which have been extracted by mechanical thrombectomy and with unknown stroke etiology and submitted to RNA analysis in cryptogenic label.
62564771|NCT01960413|EXPERIMENTAL|Montelukast added to Hydroxyurea|Oral montelukast therapy taken daily for eight weeks with current hydroxyurea regiment
62564772|NCT01960413|PLACEBO_COMPARATOR|Placebo added to Hydroxyurea|Oral placebo taken daily for eight weeks with current hydroxyurea regiment
62564773|NCT02389309|EXPERIMENTAL|Treatment (dasatinib, cyclophosphamide, temsirolimus)|Patients receive dasatinib PO BID on days 1-21, cyclophosphamide PO QD on days 1-21, and temsirolimus IV over 30-60 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing stable disease or better may continue treatment with the approval of the Study Chair.
62564774|NCT02239731|EXPERIMENTAL|FDX104 (4% Doxycycline)|Active ingredient: Doxycycline Concentration: 4% Route: Topical Dosage schedule: Twice daily, morning and evening. Prophylactic treatment to prevent the rash associated with EGFRI treatment. patients will apply a thin layer of the drug twice daily for five weeks to one half of face
62180786|NCT06497712|EXPERIMENTAL|Hypnosis|Patients will be hypnotized by a trained person before suturing.
62564775|NCT02239731|PLACEBO_COMPARATOR|Placebo foam|Active ingredient: None Route: Topical Dosage schedule: Twice daily, morning and evening. Patients will apply a thin layer of the placebo twice daily for five weeks to the opposite half of the face of which they received active treatment.
62564776|NCT05112081|EXPERIMENTAL|Botox injections|Patients randomised to the intervention arm will be treated with injection of 100 units of botox in 10 ml sterile saline close to superficial inguinal ring.
62564777|NCT05112081|PLACEBO_COMPARATOR|Sterile saline injections|Patients randomised to the control arm will be treated with injection of 10 ml sterile saline close to superficial inguinal ring.
62564778|NCT03397589|EXPERIMENTAL|CHW Arm|The intervention is community health worker (CHW) services. CHWs trained in oral health will be assigned to half of the sites. Participants in these sites will be offered four in-person visits and follow-up phone calls over 12-months. These visits can occur at the location of the family's preference (recruitment site, home, or mutually-agreed upon other location). A core curriculum of oral health topics will be covered during visits, with an emphasis on developing and sustaining healthy oral health management routines for the entire family.
62564779|NCT03397589|NO_INTERVENTION|Wait-list Control Arm|This arm will receive usual care. After completion of the final data collection at one year, participants and sites allotted to this arm will be offered CHW services.
62564780|NCT01272050|ACTIVE_COMPARATOR|Arm A: 64 Gy - Radiation Therapy|Arm A: 64 Gy (32 x 2 Gy) without hormonal treatment
62564781|NCT01272050|ACTIVE_COMPARATOR|Arm B: 70 Gy - Radiation Therapy|Arm B: 70 Gy (35 x 2 Gy) without hormonal treatment
62564782|NCT02418884|OTHER|CAD+DM|Using self controlled study to validate the hypothesis that the treatment of rosuvastatin could increase the score of CAC density in CAD patients with diabetes mellitus.
62180787|NCT06497712|NO_INTERVENTION|Standard of Care|Stitches will be performed without hypnosis as usual
62182617|NCT01795521|EXPERIMENTAL|Stereotactic Body Radiotherapy (SBRT)|All eligible patients will be offered Stereotactic Body Radiotherapy using Four-dimensional computed tomography (4D-CT) planning (as a minimum), delivering a dose of 60 Gy in 8 fractions of 7.5 Gy on alternate days over a planned treatment time of 2.5 weeks
62180788|NCT06065709|EXPERIMENTAL|Mindfulness breath awareness meditation group|"Mindfulness breath awareness meditation will be performed nine times in total, once every eight hours within 72 hours, to the pregnant woman who is hospitalised in the perinatology service of the hospital with the diagnosis of preeclampsia. Each session will last 30 minutes.~A 4-stage mindfulness breath awareness meditation includes the following stages:~Stage 1 - Body Harmony. Stage 2 - Counting as you Exhale Stage 3 - Counting while Breathing Stage 4 - Sit Still and Witness."
62180789|NCT06065709|NO_INTERVENTION|control group|only mindfulness breath awareness meditation will not be applied to the control group.
62564783|NCT05989061|EXPERIMENTAL|PEEK customized healing abutment.|"Group I (Customized PEEK Healing Abutment):~13 patients will receive guided delayed implant and a customized PEEK healing abutment placed simultaneously with implant surgery"
62564784|NCT05989061|ACTIVE_COMPARATOR|Titanium customized healing abutment.|"Group II (Customized Titanium Healing Abutment):~13 patients will receive guided delayed implant and a customized titanium healing abutment placed simultaneously with implant surgery."
62564785|NCT01842438|EXPERIMENTAL|Behavioral: psychosexual intervention|6-sessions of couple support focused on relationships and psychosexual functioning
62564786|NCT01842438|NO_INTERVENTION|Control|This group will not receive the intervention during the life-span of the project
62564787|NCT06201923|EXPERIMENTAL|Group I (Thyme H)|0.2% thyme honey mouth rinse (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day.
62564788|NCT06201923|PLACEBO_COMPARATOR|Group II (Saline G)|normal saline oral rinse
62564789|NCT03376724|EXPERIMENTAL|Functional exercise|
62564790|NCT03376724|ACTIVE_COMPARATOR|Control Group|
62564791|NCT05338164|EXPERIMENTAL|Cerclage group|cervical cerclage between 14 and 20 weeks will be done by one of the three authors.
62564792|NCT05338164|NO_INTERVENTION|No Cerclage group|Routine follow up without cerclage
62564793|NCT00660517|EXPERIMENTAL|MP29-02|azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray
62564794|NCT00660517|ACTIVE_COMPARATOR|azelastine Hcl 548 mcg|azelastine Hcl 548 mcg nasal spray
62564795|NCT00660517|ACTIVE_COMPARATOR|fluticasone propionate 200 mcg|fluticasone propionate 200 mcg nasal spray
62564796|NCT00660517|PLACEBO_COMPARATOR|placebo|placebo nasal spray
62564797|NCT03850483|PLACEBO_COMPARATOR|Vehicle cream QD|Vehicle cream applied once daily (QD)
62564798|NCT03850483|EXPERIMENTAL|PF-06700841 0.1% cream QD|PF-06700841 0.1% cream applied once daily (QD)
62564799|NCT03850483|EXPERIMENTAL|PF-06700841 0.3% cream QD|PF-06700841 0.3% cream applied once daily (QD)
62564800|NCT03850483|EXPERIMENTAL|PF-06700841 1% cream QD|PF-06700841 1% cream applied once daily (QD)
62564801|NCT03850483|EXPERIMENTAL|PF-06700841 3% cream QD|PF-06700841 3% cream applied once daily (QD)
62564802|NCT03850483|EXPERIMENTAL|PF-06700841 0.3% cream BID|PF-06700841 0.3% cream applied twice daily (BID)
62564803|NCT03850483|EXPERIMENTAL|PF-06700841 1% cream BID|PF-06700841 1% cream applied twice daily (BID)
62564804|NCT03850483|PLACEBO_COMPARATOR|Vehicle cream BID|Vehicle cream applied twice daily (BID)
62564805|NCT03850483|EXPERIMENTAL|PF-06700841 3% cream BID|PF-06700841 3% cream applied twice daily (BID)
62564806|NCT04727905|EXPERIMENTAL|energy drink|Intake after exercise
62564807|NCT04727905|PLACEBO_COMPARATOR|Seasoned water|Intake after exercise
62564808|NCT05029518|EXPERIMENTAL|Treatment A: SMP-100 dissolved in water administered under fasting conditions|12 subjects，For Treatment A, SMP-100 will be dissolved in a total of 240 mL of water and administered orally to each subjects, and a hand and mouth check will be performed to ensure consumption of the medication. Subjects will be required not to wear dentures or mouth piercing at the time of dosing. No food will be allowed from at least 10 hours before dosing until at least 4 hours post-dose.
62564809|NCT05029518|EXPERIMENTAL|Treatment B: SMP-100 tablets administered under fasting conditions|12 subjects，For Treatment B, SMP-100 tablets will be administered to each subject with 240 mL of water and a hand and mouth check will be performed to ensure consumption of the medication. The dosing procedure must be completed within 2 minutes. In the event that subjects cannot swallow all tablets with 240 mL of water, additional water may be allowed up to a maximum total volume of 400 mL. No food will be allowed from at least 10 hours before dosing until at least 4 hours post-dose.
62564810|NCT05029518|EXPERIMENTAL|Treatment C: SMP-100 tablets administered under fed conditions|"12 subjects，For Treatment C, SMP-100 tablets will be administered to each subject with 240 mL of water and a hand and mouth check will be performed to ensure consumption of the medication. The dosing procedure must be completed within 2 minutes. In the event that subjects cannot swallow all tablets with 240 mL of water, additional water may be allowed up to a maximum total volume of 400 mL.~After a supervised fast of at least 10 hours, subjects will be served a high-fat, high-calorie meal of approximately 800 to 1000 calories (approximately 50% of total caloric content of the meal derived from fat). This test meal should derive approximately 150, 250, and 500-600 calories from protein, carbohydrate, and fat, respectively. Subjects should start the meal approximately 30 minutes prior to drug administration. Subjects will be required to completely eat the meal in 30 minutes or less. No food will be allowed until at least 4 hours post-dose."
62564811|NCT01310842||Pilot Smoking Cessation|4 weeks nicotine patch therapy, self-help materials, and 5 in-person counseling sessions.
62564812|NCT01310842||Smoking Cessation|4 weeks nicotine patch therapy, self-help materials, and 7 in-person counseling sessions.
62564813|NCT06128330|ACTIVE_COMPARATOR|Standard dose group|The standard dose group will receive a bolus of 20 mg/kg tranexamic acid after anaesthesia induction.
62180790|NCT02005393|OTHER|FICE Imaging System followed by NBI|Images Captured with FICE Image Acquisition System (experimental) followed by NBI Image Acquisition System (standard of care); always in that order. Imaging took place in esophagus, gastric, duodenum and/or colon.
62567782|NCT01818271|ACTIVE_COMPARATOR|conventional physical Therapy|will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises
61995632|NCT05124665|EXPERIMENTAL|Social Support|"CHWs will offer HIV testing to the individual nominated by the index patient as most likely to test. If this person is not present, CHWs will decide which contact should be offered testing first. CHWs will use a prosocial script for HIV testing: Knowing your status sets a good example for your household. CHWs will follow an opt-out strategy: This test kit is approved by the Ministry of Health and used in KCCA health facilities. I am going to offer you a free HIV test now, is that okay?. If the initial household contact who is offered HIV testing agrees to test, the CHW will ask if he/she is willing to share his/her decision to test with other members of the household: Would you like to share your decision to test with the others? Sharing is completely optional. However, learning that someone else in their household decided to test sometimes gives people the strength to test themselves. Sharing your decision might help another person find the strength to test."
61995633|NCT05124665|NO_INTERVENTION|Standard of Care|As a control for the socio-behavioral intervention, the control arm will lack the socio-behavioral intervention components. The order of testing invitation will be decided by the CHW; and CHWs will be trained at baseline to provide standard, opt-in framing of test offers, without any mention of asking contacts to share their testing decision with other household contacts. Oral HIV kits will also be used in control households.
61995634|NCT04721990|EXPERIMENTAL|Automatic Sound Management 3.0|Current SONNETEAS listeners, who meet the eligibility criteria, will be tested with their current listening configuration and also fit with a SONNET2EAS, programmed with Automatic Sound Management 3.0 (under the Investigational Device Exemption).
61995635|NCT04296981|EXPERIMENTAL|video-based patient information|Viewing an explanatory video (8 minutes) to improve communication and understanding of stroke issues and stages of the continuum of care
61995636|NCT03504358||Analysis before liver resection|Multivariate analysis of predictive factors associated with survival
61995637|NCT03504358||Different risk group|Low-risk group, moderate-risk group, high-risk group
62564814|NCT06128330|EXPERIMENTAL|Low dose group|The low dose group will receive a bolus of 10 mg/kg tranexamic acid. In addition 1 mg/kg tranexamic acid will be added to the priming of the extracorporeal circuit (ECC) and a continuous infusion of 1mg/kg/h tranexamic acid will be started after the bolus infusion until the end of surgery.
62564815|NCT02843048|EXPERIMENTAL|Exercise training|Exercise training plus standard medical follow-up care
62564816|NCT02843048|ACTIVE_COMPARATOR|Standard medical care|Standard medical follow-up care only
62564817|NCT01731119|EXPERIMENTAL|Flexible Dose Latuda©|Lurasidone (Latuda©)dose will be determined solely by the clinician in accordance with the best interests of each participant.
62564818|NCT04006639|ACTIVE_COMPARATOR|Bilateral superficial cervical plexus block with Bupiv|Patients, who will have tracheostomy procedure, might receive bilateral superficial cervical plexus block with 10 mL of Bupivacaine 0.5% (20 mL spuit with 25 G 1.5 inch needle) on each side before tracheostomy procedure.
62564819|NCT04006639|ACTIVE_COMPARATOR|Local infiltration of Lidocaine 2%|Patients, who will have tracheostomy procedure, might receive local infiltration of Lidocaine 2% (5 mL spuit with 25 G 1.5 inch needle) before tracheostomy procedure.
62564820|NCT06359223|EXPERIMENTAL|caffeine group|Participants who meet the inclusion criteria after cesarean section and are assigned to the caffeinated coffee group by randomization method will be informed about the research and their verbal and written consent will be obtained. Immediately before coffee application (6-12-18 hours after surgery), women's pain intensity and bowel motility will be evaluated. Women will then be asked to consume 100 ml of unsweetened caffeinated coffee at 6, 12 and 18 hours after surgery. 6,12,18. Half an hour after coffee consumption, women will be evaluated for pain using VAS. At the same time, the women's bowel sounds, gas passing and defecation will be recorded during these hours.
61995638|NCT03504358||Model comparison|Comparison of models in predicting survival
61995639|NCT01749722|EXPERIMENTAL|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
61995640|NCT05503719|EXPERIMENTAL|Absorbable Suture|Surgical wounds of this arm will be closed with an absorbable suture.
62180791|NCT03201536|ACTIVE_COMPARATOR|sutures|zipLine3 device verses conventional sutures
62564821|NCT06359223|ACTIVE_COMPARATOR|control group|No application will be made to the participants in this group. After the cesarean section, women will be evaluated for pain with VAS at 6-12-18 hours and half an hour after 6-12-18 hours, and their bowel sounds, flatulence and defecation will be recorded.
62564822|NCT05227859|EXPERIMENTAL|Piezocision therapy|In this group of patients, the canine will be retracted in association with piezocision.
62564823|NCT05227859|EXPERIMENTAL|Low-level laser therapy|In this group of patients, the canine will be retracted in association with LLLT.
62564824|NCT05227859|ACTIVE_COMPARATOR|Conventional treatment|In this group of patients, the canine will be retracted conventionally without any acceleration intervention.
62564825|NCT02092376|ACTIVE_COMPARATOR|Intervention|The loading dose of 300 000 IU is divided into three doses (100 000 IU) and will be given over the first months. All patients in the intervention group will receive the first loading dose of 100 000 IU at day of discharge. The second (2 weeks) and third (4 weeks postoperative) administration will be given based on the 25-hydroxy vitamin D concentration. After the last respectively third loading dose a maintenance dose of 3420 IU per day should maintain the high 25-hydroxy vitamin D concentration. It should be administered for up to 46 weeks (until follow-up visit)
62564826|NCT02092376|PLACEBO_COMPARATOR|Placebo|The placebo loading dose (oil) is divided into three administrations and will be given over the first months. All patients in the placebo group will receive the first placebo loading dose at day of discharge. After the last placebo loading dose a maintenance dose of 3420 IU per day should maintain the 25-hydroxy vitamin D concentration. It should be administered for up to 46 weeks (until follow-up).
61995641|NCT05503719|ACTIVE_COMPARATOR|Non-absorbable suture|Surgical wounds of this arm will be closed with a non-absorbable suture.
62564827|NCT01368601|ACTIVE_COMPARATOR|CPAP (positive airway pressure)|To evaluate if continuous positive airway pressure(CPAP) on the lung undergoing lobectomy can decrease the inflammatory response PPC (postoperative pulmonary complications).
61995642|NCT05437978|EXPERIMENTAL|"Adapted Physical Activity (APA) program called Cap Sport Santé 83"|
61995643|NCT05772533|ACTIVE_COMPARATOR|Group A (SAPB)|Ultrasound-guided SAPB will be applied while the patient is in the supine position.
61995644|NCT05772533|ACTIVE_COMPARATOR|Group B (PENG block)|Ultrasound-guided PENG block will be performed under strict aseptic precautions and patient's arm will be placed in external rotation and abducted at 45 degrees
61995645|NCT04049656|EXPERIMENTAL|HFVI intervention group|Subjects in the HFVI intervention group will be monitored in the same manner as the control group, but the HFVI monitor display will also be available to the anesthesia provider in real time. Bolus doses of 25ug or 50 ug of fentanyl will be recommended to be administered when the HFVI values begin to decrease below 50, and as needed based on the judgment of the clinician responsible for the case. All anesthetic medications that are given, patient events, and vital sign recordings will be included in the anesthetic record and data collection forms.
62180792|NCT03201536|ACTIVE_COMPARATOR|Zip3 Device|
62180793|NCT05999565|EXPERIMENTAL|Motor Imagery Training|"Motor Imagery Training Motor Imagery Training will be applied only to the 2nd group, under the supervision of a physiotherapist, twice a week for 8 weeks, for 20 minutes each session. The treatment duration for the 2nd group will be planned to be a total of 50 minutes, including both motor imagery and motor control exercises. Motor imagery sessions will take place in a quiet environment, with individuals comfortably seated.~Lateralization Training Kinesthetic Imagery Visual Imagery Mirror-Image Active Exercise: Between weeks 6 and 8 of motor imagery training, the active exercises (Stretching Exercises, Active Exercises, and Endurance Exercises) will be actively performed in front of a mirror"
61995646|NCT04049656|NO_INTERVENTION|Standard of Care Group|Subjects receiving a balanced maintenance anesthetic consisting primarily of a sevoflurane hypnotic (titrated to a BIS range of 40-60) and fentanyl analgesia. Subjects randomized to the control group (Standard Practice) will have analgesia administered as needed according to standard clinical monitoring and practice requirements based on the judgment of the clinician responsible for the case. The HFVI monitor will be applied, but the display will be masked in this control group population.
61995647|NCT03523117|ACTIVE_COMPARATOR|Ferric Caroboxymaltose|Ferric Carboxymaltose - 2 doses (day 0 and day 7) at 15 mg/kg to a maximum single dose of 750 mg (whichever is smaller) up to a maximum of total dose of 1500 mg administered as either an undiluted IV push at a rate of 100 mg (2mL)/minute OR in no more than 250 mL of normal saline and infused over 15 minutes.
61995648|NCT03523117|ACTIVE_COMPARATOR|Oral Ferrous Sulfate|Oral Ferrous Sulfate - will receive an age-dependent formulation of oral ferrous sulfate daily for 28 days as follows: participants \<12 years of age will receive 6 mg (elemental iron)/kg/day divided into 2 daily doses of an oral liquid formulation, either drops or elixir, and participants ≥12 will receive 2 daily doses of oral tablets. Infants and children (ages 1 to \<4 years) will receive oral ferrous sulfate drops, while children (ages ≥4 to \<12 years) will receive oral ferrous sulfate elixir. Adolescents (ages ≥12 to 17 years) will receive an oral ferrous sulfate tablet (65 mg of elemental iron/tablet/dose) twice a day (BID). The maximum daily dose for all participants is 130 mg of elemental iron.
62182810|NCT03318783|PLACEBO_COMPARATOR|Placebo|10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.
62391267|NCT02438787|EXPERIMENTAL|Group 2 (ustekinumab 45 mg)|Ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (\<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
62564828|NCT01368601|NO_INTERVENTION|Control without CPAP|
62564829|NCT01524159|PLACEBO_COMPARATOR|placebo group|This group will receive placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
62180794|NCT05999565|EXPERIMENTAL|Motor Control Exercise|"Stretching Exercises: Stretching exercises will be applied to the cervical muscles, pectoral muscles, back, and shoulder muscles. Individuals will be asked to perform flexion, extension, lateral flexion, and rotational normal joint movements in the cervical region, and hold the end position for a few seconds. All stretching exercises will be performed for 15 repetitions.~Active Exercises: To strengthen the cervical muscle groups, individuals will be taught how to use a mild to moderate resistance theraband for cervical flexion, extension, and lateral flexion, without compromising the chin tuck movement. Each movement will be performed for 10 repetitions, with 5-second rest intervals between exercises.~Endurance Exercises: Before starting the endurance exercises, individuals will be taught the contraction of deep cervical flexors to gain automatic postural stabilization, and they will be instructed to maintain this movement in every exercise and activity."
62182618|NCT00345800|EXPERIMENTAL|Sodium Oxybate|"* Active Substance: Sodium Oxybate~* Pharmaceutical form: Oral Solution~* Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks~* Route of administration: Oral"
62182619|NCT04244149|EXPERIMENTAL|Intervention group|Participants will exert an exercise prolonged session
61995649|NCT05781438|EXPERIMENTAL|In-home standing and walking intervention|Infants will participate in the in-home standing and walking intervention for 16 weeks. In addition, infants will continue with any intervention in the community recommended by their health care team.
61995650|NCT01165866|ACTIVE_COMPARATOR|Treatment 1.|Metoclopramide 0.3 mg/kg max 10 mg in burette and mixed with normal saline to make up 50 cc of medication and normal saline as a single intravenous dose. Complete blood count,serum electrolytes,renal function,HCO3 level will be requested.Oral fluid will be started thereafter and increased gradually until patient discharge.
62180795|NCT06412796||Subcostal Transversus Abdominis Plane (SCTAP) block.|SCTAP Block is performing by USG probe positioned on the anterior abdominal wall immediately inferior to the costal margin and then needle advanced to 2 to 3 cm lateral to the aponeurosis of the external oblique muscles, internal oblique muscles, and transversus abdominis in the TAP. Saline 0.5mL was injected to determine the position of the transverse fascia and 15-20 ml local anesthetics injected both in right and left sides of abdomen.
62180796|NCT06412796||External Oblique Intercostal (EOI) block|EOI block is performed by placing the US probe in paramedian sagittal orientation at the T6-7 level and visualizing the external oblique and intercostal muscles. Local anesthetics inject the under the external oblique muscle.
62180797|NCT02970305|EXPERIMENTAL|Pimavanserin|Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth
61995651|NCT01165866|OTHER|Treatment2.|Ondansetron 0.15 mg/kg max 4 mg in burette and mixed with normal saline to make up 50 cc of medication and normal saline to be given over 10 minutes,then patient will be kept NPO for one hour after completion of the anti emetic infusion and last episode of vomiting . Oral fluid will be started thereafter and increased gradually until fully tolerated and the patient is ready for discharge
62180798|NCT02970305|PLACEBO_COMPARATOR|Placebo|Placebo, taken as two tablets + background antipsychotic, once daily by mouth
62180799|NCT01487902|EXPERIMENTAL|ADT arm|Concomitant androgen deprivation treatment
62180800|NCT01487902|ACTIVE_COMPARATOR|No ADT arm|No concomitant androgen deprivation treatment arm
62180801|NCT05744583|ACTIVE_COMPARATOR|Packed red blood cell|control
62180802|NCT05744583|EXPERIMENTAL|Low titer whole blood|case
62180803|NCT01946555||Worst pain, Average pain|"It is necessary that patients are treated for their baseline pain with opioid medications 3rd step (WHO guidelines), having seven different provisions molecules (morphine, methadone, fentanyl, buprenorphine, oxycodone, hydromorphone and tapentadol), and that they receive opioid rescue medication, based on free choice among the options available on the market (in the form of transmucosal fentanyl: OTFC - lollipop, buccal buccal tablets, sublingual tablets, nasal spray in aqueous solution, with pectin nasal spray, morphine or other opioid oral immediate release or intravenously)."
62180804|NCT04731675|EXPERIMENTAL|AMB-05X|Subjects will receive an intra-articular injection of AMB-05X once every 2 weeks for 12 weeks (for 6 treatments total).
62180805|NCT05010902||Multiple sclerosis|Patients with clinically isolated syndrome, relapsing-remitting or progressive multiple sclerosis
62180806|NCT00904722|EXPERIMENTAL|CT-011 in combination with Rituximab|Combination of the immunotherapy drugs, CT-011 and rituximab.
62180807|NCT05528822|EXPERIMENTAL|Group F: H-FICB under ultrasound guidance before general anesthesia|Group F was subjected to a high fascia iliaca compartment block under ultrasound guidance before general anesthesia.
61995652|NCT06262841|EXPERIMENTAL|Piezosurgery group|"In the experimental group, a piezosurgery device was used to remove the bone surrounding the impacted third molar.~Intervention: Device: Piezosurgery"
61995653|NCT06262841|ACTIVE_COMPARATOR|Conventional group|"In the control group, conventional burs were used to remove the bone surrounding the impacted third molar.~Intervention: Device: Conventional burs"
61995654|NCT01262885|EXPERIMENTAL|Part A Cohort 1|GSK2251052 500 mg (6 subjects), Placebo (1 subject)
62180808|NCT05528822|EXPERIMENTAL|Group P: PENG block under ultrasound guidance before general anesthesia|Group P was subjected to a pericapsular nerve group (PENG) Block under ultrasound guidance before general anesthesia.
62180809|NCT03758703|EXPERIMENTAL|Pre-recorded music intervention group|The experimental group will be receiving the pre-recorded music care intervention. The intervention is to be delivered once a day for 30 minutes, over one week, on a portable Bluetooth speaker system. Participants will select their own music from the list of pre-recorded songs playlist and are free to switch to another playlist within their treatment arm should they desire. This music was specifically designed for use in palliative care. Specifically, all songs are played at 60 beats per minute to mimic resting heart rate. Instrumentation was specifically chosen to be soothing and calming
62180810|NCT03758703|ACTIVE_COMPARATOR|Pre-recorded soothing poetry group|The control group will be provided pre-recorded soothing poetry which they will self-select. Participants are allowed to switch playlists within their treatment arm each day should they desire. This control group is designed to control time, attention, and placebo effect. Thus, the soothing poetry will be offered the identical time duration of listening to recorded soothing poetry readings and played at the same time the intervention group receives the pre-recorded music.
62182620|NCT00467298|EXPERIMENTAL|Self-management|Novel intensive self-management education and exercise program of four weeks
62564830|NCT01524159|ACTIVE_COMPARATOR|bromelain group|Bromelain Group This group will receive bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
61995655|NCT01262885|EXPERIMENTAL|Part A Cohort 2|GSK2251052 1000 mg (6 subjects), Placebo (1 subject)
62564831|NCT02720718|EXPERIMENTAL|Stratafix|"Patients undergoing laparoscopic RYGB (antecolic, antegastric, linear anastomosis-technique) using unidirectional barbed (knotless) sutures: Stratafix Unidirectional 2/0."
62564832|NCT02720718|ACTIVE_COMPARATOR|Vicryl|"Patients undergoing laparoscopic RYGB (antecolic, antegastric, linear anastomosis-technique) using classic sutures: Vicryl 2/0."
61995656|NCT01262885|EXPERIMENTAL|Part A Cohort 3|GSK2251052 2000 mg (6 subjects), Placebo (1 subject)
62564833|NCT06091813|NO_INTERVENTION|No Directed Dietary Intervention|Control group without any directed dietary modifications
61995657|NCT01262885|EXPERIMENTAL|Part A Cohort 2 - fed|GSK2251052 1000 mg (6 subjects), Placebo (1 subject)
61995658|NCT01262885|EXPERIMENTAL|Part B Cohort 1|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
61995659|NCT01262885|EXPERIMENTAL|Part B Cohort 2|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
61995660|NCT01262885|EXPERIMENTAL|Part B Cohort 3|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
61995661|NCT01262885|EXPERIMENTAL|Part A Cohort 4|Placebo (1 subject), GSK2251052 (6 subjects) dose to be determined
61995662|NCT02282956|EXPERIMENTAL|study group|single shot, posterior tibial nerve block with 5 ml of Ropivacaine 0,75% before surgery postoperative PCA pump with morphine and droperidol (DHBP®) for the next 24 hours.
61995663|NCT02282956|OTHER|controll Group|After surgery: standard analgesic treatment by PCA (patient controlled analgesia) pumps with morphine and Droperidol (DHBP®) for the next 24 hours.
61995664|NCT03999411|PLACEBO_COMPARATOR|Usual Care|Participants will receive brief advice to adhere to ART brief advice to quit smoking, 6-week supplies of nicotine-replacement therapy (NRT), and self-help materials to quit smoking and adhere to ART.
62564834|NCT06091813|EXPERIMENTAL|Medical Nutrition Therapy|
61995665|NCT03999411|ACTIVE_COMPARATOR|Smoking cessation only intervention|"Participants in this group will receive the usual care (UC) for adherence to ART, one in-person orientation sessions, 6-week supplies of NRT the Crave-to-Quit app, and two brief follow-up phone calls."
62182621|NCT00467298|NO_INTERVENTION|Usual care|Usual care- cardiac or pulmonary rehabilitation exercise program of 8 weeks duration
62564835|NCT05933733||Salvage treatment after locoregional recurrence|Participants who previously completed standard treatment for breast cancer and experienced locoregional recurrence alone will be undergo salvage treatment including surgery and/or radiation therapy.
62564836|NCT02627313|EXPERIMENTAL|GammaPod|GammaPod tumour bed boost
62564837|NCT01874808||Healthy|Healthy
62564838|NCT01874808||ALS with postural instability|ALS with postural instability
62564839|NCT01874808||ALS without postural instability|ALS without postural instability
62564840|NCT03332355|EXPERIMENTAL|PAC-1 in combination with temozolomide|Temozolomide (PO) will be dosed at 150 mg (adjusted for body size area \[m2\]) daily for 5 days starting on day 8 at cycle 1, and then for each successive cycle. In Component 2, the first PAC-1 dose will be 1 dose level lower than the PAC-1 MTD established in Component 1, and the maximum dose will not exceed 450 mg. PAC-1 will be taken in the morning on days 1-21 in each 28-day cycle.
62564841|NCT02394210||Group 1|Patients in relapse/biological progression (under the criteria of the IMW (International Myeloma Workshop) Consensus Panel 1 not receiving treatment until clinical relapse.
62564842|NCT02394210||Group 2|"Patients in relapse/biological progression receiving anti-MM treatment at the time of relapse/biological progression): Patients in this group may receive conventional anti-myeloma treatment as per routine clinical practice at the participating site:~1. Upon relapse/biological progression, defined as per the criteria of the IMW (International Myeloma Workshop) Consensus Panel Panel1 Or~2. Upon a significant relapse of paraprotein, defined as:~   * Duplication of M-component in two consecutive readings taken ≤2 months apart; or~  * An increase in absolute levels of serum M-protein ≥1 g/dL or M-protein in urine at ≥500 mg/24h, or~  * Increase in light chain levels ≥20 mg/dL with an abnormal ratio in two consecutive readings taken ≤2 months apart), which suggests the presence of biological progression/relapse criteria, but without including any clinical details of those involved in clinical relapse."
62564843|NCT06250582|EXPERIMENTAL|virtual reality therapy, then standard of care|During the intervention phase (A) participants will receive virtual reality therapy during their dialysis sessions over a period of one month. After a washout phase of one week, participants will run through a control phase (B, standard of care) also for a period of one month. Subjects will be randomized to an AB or BA sequence.
61995666|NCT03999411|EXPERIMENTAL|Combined smoking cessation and HIV intervention|Participants in this group will receive everything given in the Smoking Cessation Only arm and will also use the emocha app and will receive a tutorial explaining the app content and features. The study team will explain to participants that the app will help them in tracking dose-by-dose medication adherence by recording a video for themselves taking their medication.
61995667|NCT02440386|NO_INTERVENTION|Control|The control arm receives standard of care. Standard of care involves referral for ART services and follow-up calls (maximum of 6) to assess whether linkage to care has occurred.
62564844|NCT06250582|EXPERIMENTAL|standard of care, then virtual reality therapy|During the control phase (B) participants will be treated according to standard of care over a period of one mont. After a washout phase of one week, participants will run through an intervention phase (A) and will receive virtual reality therapy during their dialysis sessions. Also for a period of one month. Subjects will be randomized to an AB or BA sequence.
61995668|NCT02440386|EXPERIMENTAL|Incentive|The incentive arm receives standard of care plus a R300 voucher. The R300 voucher can be exchanged for cash if the participant starts ART at any clinic of their choice within three months from study enrollment.
61995669|NCT06213402||Sickle cell anaemia and other related sickle diseases|Patients with sickle cell disease and related diseases in current regular follow-ups in European-Union health centers
61995670|NCT06213402||Thalassemia and related diseases|Patients with Thalassemia disease and related diseases in current regular follow-ups in European-Union health centers, stratified by age, gender, and/or variants/type if applicable.
62564845|NCT04311866|ACTIVE_COMPARATOR|Spica cast|Standard practice for the management of the femoral shaft fractures.
62564846|NCT04311866|EXPERIMENTAL|Synthetic fabric|Offer resistance, durability and low weight to treatment of femoral shaft fractures
62564847|NCT02094482|OTHER|OSAS Palatal Implant|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate .
62564848|NCT05000151||Patients|Hypermobile Ehlers-Danlos patients (n=21)
62564849|NCT05000151||Healthy subjects|Healthy subjects recruited from the clinic's staff (n=21) Age, Gender and BMI matched with hEDS patients
62564850|NCT05338840|EXPERIMENTAL|MULLIGAN|ROTATIONAL MOVEMENT
62564851|NCT05338840|EXPERIMENTAL|Medial gapping technique|Medial gapping technique
62564852|NCT01160692|EXPERIMENTAL|Arm 1|
62564853|NCT01160692|PLACEBO_COMPARATOR|Arm 2|
62564854|NCT06444919|EXPERIMENTAL|Capsaicin 8%|patch 179 mg, 30 min
61995671|NCT06213402||Pyruvate Kinase Deficiency and related diseases|Patients with Pyruvate Kinase Deficiency and related diseases in current regular follow-ups in European-Union health centers, stratified by age, gender, and/or variants/type if applicable.
62182622|NCT03628196||Quality Improvement Program Basic and Enhanced Phase|Patients that meet the eligibility criteria and participate in the QIP.
62182623|NCT03628196||Retrospective Group|Patients seen a year prior to the QIP period at the clinic but that did not participate in the QIP.
62564855|NCT06444919|SHAM_COMPARATOR|Capsaicin 0.04%|patch low dose, 30 min
62564856|NCT03493191|EXPERIMENTAL|0.5 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 0.5μg/kg SHR0410 (n=6) or placebo (n=2)
62180811|NCT06254300|EXPERIMENTAL|Intervention Group|The intervention group will participate in a supervised online exercise prehabilitation program that will extend throughout the chemotherapy until one week before the scheduled surgery. The exercise program will consist of three sessions per week, each lasting 60 minutes. The design of the prehabilitation program is based on exercise prescription recommendations for cancer survivors and will be tailored to each patient's initial functional capacity. The exercise sessions will be conducted at home through an online platform, enabling real-time interaction among groups of patients.
62564857|NCT03493191|EXPERIMENTAL|1 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 1μg/kg SHR0410 (n=6) or placebo (n=2)
62564858|NCT03493191|EXPERIMENTAL|2 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 2μg/kg SHR0410 (n=6) or placebo (n=2)
62564859|NCT03493191|EXPERIMENTAL|5 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 5μg/kg SHR0410 (n=6) or placebo (n=2)
62564860|NCT03493191|EXPERIMENTAL|10 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 10μg/kg SHR0410 (n=6) or placebo (n=2)
62564861|NCT03493191|EXPERIMENTAL|20 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 10μg/kg SHR0410 (n=6) or placebo (n=2)
62564862|NCT03926117|PLACEBO_COMPARATOR|Placebo|Matching placebo
62564863|NCT03926117|EXPERIMENTAL|Ziltivekimab 7.5 mg|
62564864|NCT03926117|EXPERIMENTAL|Ziltivekimab 15 mg|
62564865|NCT03926117|EXPERIMENTAL|Ziltivekimab 30 mg|
62564866|NCT01277601|EXPERIMENTAL|TDF+Peg-IFN 48 Weeks|TDF plus Peg-IFN for 48 weeks
62564867|NCT01277601|EXPERIMENTAL|TDF 48 Weeks + Peg-IFN 16 Weeks|TDF plus Peg-IFN for 16 weeks, followed by TDF alone for an additional 32 weeks
62564868|NCT01277601|ACTIVE_COMPARATOR|TDF 120 Weeks|TDF monotherapy for 120 weeks
62564869|NCT01277601|ACTIVE_COMPARATOR|Peg-IFN 48 Weeks|Peg-IFN monotherapy for 48 weeks
62564870|NCT01804946|EXPERIMENTAL|Ergoferon (1 tablet 3 times a day)|1 tablet per 1 intake: on day 1 of the treatment 8 tablets (1 tablet every 30 minutes for the first 2 hours, then 1 tablet 3 times a day with equal intervals starting on the same day. From day 2 to day 5 1 tablet TID.
62564871|NCT01804946|ACTIVE_COMPARATOR|Oseltamivir(Tamiflu): 75 mg two times a day.|Oseltamivir for 5 days (75 mg b.i.d.).
62564872|NCT03665220|EXPERIMENTAL|Ergonomic adjustment group|Ergonomic intervention program at home for post-stroke patients. The ergonomic adjustments made were based on a prior assessment of the patient's needs in this respect, using a purpose-made home inspection form.
62564873|NCT03665220|EXPERIMENTAL|Kinesiotherapy + ergonomics group|A Kinesiotherapy plus ergonomic adjustments program for post-stroke patients. This group received, in addition to the ergonomic adjustments described above, sessions of postural orientation and kinesiotherapy (therapeutic exercises).
62564874|NCT03665220|ACTIVE_COMPARATOR|Healthcare education|A conservative intervention program for post-stroke patients
62564875|NCT04166474|EXPERIMENTAL|Dolutegravir|
62564876|NCT01976182|ACTIVE_COMPARATOR|METHOTREXATE|"In step 1, 55 patients will receive methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take~In step 2, responders at Month 4 (CR or PR) will be treated during 8 additional months with methotrexate at the same dosage.~Non responders at Month 4 will be randomized and treated either by:~* Cyclophosphamide delivered at 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take between Month 5 and Month 8, decreased to 50 mg orally once daily beyond Month 8 for responders at Month 8;~* Ciclosporine A delivered at 3 mg/kg per day (at split doses of 1.5 mg/kg in the morning and 1.5 mg/kg at night) orally administered."
62564877|NCT01976182|ACTIVE_COMPARATOR|CYCLOPHOSPHAMIDE|"In step 1, 55 patients will receive cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take.~In step 2, responders at Month 4 (CR or PR) will be treated during 8 additional months with cyclophosphamide (at 50 mg orally once daily);~Non responders at Month 4 will be randomized and treated either by:~* Methotrexate administered at 10 mg/m2 orally once a week (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take;~* Ciclosporine A delivered at 3 mg/kg per day (at split doses of 1.5 mg/kg in the morning and 1.5 mg/kg at night) orally administered."
62564878|NCT03648320|EXPERIMENTAL|Peanut oral immunotherapy|Desensitisation using peanut flour
62772762|NCT04166760|ACTIVE_COMPARATOR|WHE (regular whey protein)|Regular whey protein. The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast and dinner for 2 days in the patient's own environment.
62564879|NCT04868708|EXPERIMENTAL|AK104+Paclitaxel+Cisplatin/Carboplatin|"AK104 intravenously(IV) every 3 weeks (Q3W)~Paclitaxel 175mg/m2 IV every 3 weeks (Q3W)~Cisplatin 50mg/m2 or Carboplatin AUC5 IV every 3 weeks (Q3W)"
62564880|NCT04868708|EXPERIMENTAL|AK104+Bevacizumab+Paclitaxel+Cisplatin/Carboplatin|"AK104 every 3 weeks (Q3W)~Bevacizumab 15mg/kg IV every 3 weeks (Q3W)~Paclitaxel 175mg/m2 IV every 3 weeks (Q3W)~Cisplatin 50mg/m2 or Carboplatin AUC5 IV every 3 weeks (Q3W)"
62564881|NCT04868708|EXPERIMENTAL|AK104|AK104 IV every 2 weeks (Q2W)
62564882|NCT01759472||montelukast，vitamin C pill|leukotriene receptor antagonist:(montelukast)，montelukast (10 mg, once per night)，56 days vitamin C pill:100mg，once per night，56 days
62564883|NCT01759472||montelukast, vitamin C pill|montelukast:10 mg, once per night，56 days vitamin C pill:100mg，once per night，56 days
62564884|NCT02694822|EXPERIMENTAL|AGEN1884|anti-CTLA-4 antibody
62772763|NCT04166760|EXPERIMENTAL|speWHE (specific whey protein compound)|Specific whey protein compound. The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast and dinner for 2 days in the patient's own environment.
61995672|NCT06213402||Red Blood Cell membrane disorders and related diseases|Patients with Reb Blood Cell membrane disorders and related diseases in current regular follow-ups in European-Union health centers, stratified by age, gender, and/or variants/type if applicable.
61995673|NCT05394675|EXPERIMENTAL|Dose Escalation: DS-9606a|Participants who will receive an intravenous (IV) dose of DS9606a starting at 0.016 mg/kg every 3 weeks.
61995674|NCT05394675|EXPERIMENTAL|Dose Expansion: DS-9606a|Participants with ovarian cancer who will receive an intravenous (IV) dose of DS9606a at the recommended dose for expansion (RDE) every 3 weeks.
61995675|NCT01856751||haemophilia|Patients with acquired haemophilia. Patients with haemophilia A with inhibitor.
61995676|NCT04046185|EXPERIMENTAL|pd-1 inhibitor and progesterone|Toripalimab. 240mg intravenous injection, every 3 weeks, 4 times. Megestrol Acetate Tablets, 160mg, po, once a day.
61995677|NCT04046185|ACTIVE_COMPARATOR|progesterone|Megestrol Acetate Tablets, 160mg, po, once a day.
61995678|NCT03575884|EXPERIMENTAL|Screen Time Reduction Curriculum|Fit5Kids curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices.
61995679|NCT03575884|NO_INTERVENTION|Control|Students will be taught the standard preschool curriculum.
61995680|NCT02218333|PLACEBO_COMPARATOR|Control drink|An isocaloric drink to milk
61995681|NCT02218333|EXPERIMENTAL|Milk|Protein enriched milk (Styrk)
61995682|NCT01847391|EXPERIMENTAL|Cohort 1|Randomized to 6 mg once daily (Days 1-7) followed by 3 mg once daily (Days 8-21) of GS-6615 or matching placebo
61995683|NCT01847391|EXPERIMENTAL|Cohort 2|Randomized to 12 mg once daily (Days 1-7) followed by 6 mg once daily (Days 8-21) of GS-6615 or matching placebo
61995684|NCT01847391|EXPERIMENTAL|Cohort 3|Randomized to 20 mg once daily (Days 1-7) followed by 9 mg once daily (Days 8-21) of GS-6615 or matching placebo
61995685|NCT05967962|EXPERIMENTAL|traumatic (scenes of injury and death during combat)|"In the experimental group participants will be exposed to a traumatic scene, to simulate combat exposure by watching 16 min traumatic combat scenes from the TV series When Heroes Fly."
61995686|NCT05967962|ACTIVE_COMPARATOR|non-traumatic (neutral) film|"In this active control group, participants will be watching 16 min. non-traumatic, neutral scene showing combatants as well (scenes from the YouTube series Warriors)."
61995687|NCT05464004|ACTIVE_COMPARATOR|conventional physical therapy|stretching, strengthening and balance exercises
61995688|NCT05464004|EXPERIMENTAL|Nintendo Wii balance board therapy|Nintendo Wii balance board therapy in combination with conventional physical therapy
62772764|NCT06106919||dienogest|
62772765|NCT06106919||GnRH agonist|
62772766|NCT06106919||GnRH antagonist|
62772767|NCT02283203|ACTIVE_COMPARATOR|APOTEL max|Active drug; water for injection at a volume of 100ml with added 1g of paracetamol and inactive ingredients (ΑPOTEL max®), infused within 15 minutes. Available in 100ml bags.
62772768|NCT02283203|PLACEBO_COMPARATOR|Placebo|Placebo; water for injection at a volume of 100ml with added inactive ingredients, infused within 15 minutes. Available in 100ml bags.
62772769|NCT04129385|NO_INTERVENTION|Group S|Control group (Group S: 54 patients); this group will undergo the standard laparoscopic procedure (the procedure is done in Trendelenburg position). While in Trendelenburg position and prior to wound closure and with laparoscopic port valves open, the patient's abdomen will be passively deflated. The patients will be placed in supine head up position in the post anesthesia care unit (PACU).
62772770|NCT04129385|EXPERIMENTAL|Group T|Intervention group (Group T: 54 patients); the patients will be subject to the same maneuver as in arm 1 prior to wound closure but will be positioned in a 20 degree Trendelenburg position once fully awake and cooperative in the PACU and will remain in this position for the first 24 hours post operatively, even after they are transferred to their rooms on the American University of Beirut Medical Center (AUBMC) floors. The maximum time allowed in a straight-up position will be three 15-minute intervals over a 24-hour period (the first interval being a clear fluids intake at 12 hours postoperatively).
62772771|NCT03629912|EXPERIMENTAL|Exercise + Health Education + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating exercises AND health information on fall risks + diet/nutrition.
62772772|NCT03629912|ACTIVE_COMPARATOR|Exercise + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating exercises ONLY.
62772773|NCT03629912|ACTIVE_COMPARATOR|Health Education + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating health information on fall risks + diet/nutrition ONLY.
62772774|NCT03629912|NO_INTERVENTION|Bingo Only|Participants use the Bingocize app to play bingo only.
62772775|NCT05735756|ACTIVE_COMPARATOR|Citalopram 20mg|
62772776|NCT05735756|PLACEBO_COMPARATOR|Placebo|
62772777|NCT05308927||Incident patients|Children initiated Norditropin® upon their inclusion in the study but independently from the decision to participate in this study
62772778|NCT05308927||Prevalent patients - finished growth upon inclusion|Children were already treated with Norditropin® before their inclusion in the study and finished their growth upon their inclusion. Data collected retrospectively from medical records
62772779|NCT05308927||Prevalent patients - not finished growth upon inclusion|Children were already treated with Norditropin® before their inclusion in the study and did not finish their growth upon inclusion. Data collected both retrospectively and prospectively
62772780|NCT04379999|ACTIVE_COMPARATOR|Atorvastatin|Atorvastatin (LIPITOR) 20 milligram tablet daily for 6 weeks
62772781|NCT04379999|ACTIVE_COMPARATOR|Atorvastatin and Aspirin|Atorvastatin (LIPITOR) 20 milligram tablet and Aspirin 325 mg tablet daily for 6 weeks
62772782|NCT05121324|EXPERIMENTAL|Intervention|This arm will be exposed to the study intervention: a standardized seizure protocol.
62772783|NCT05121324|ACTIVE_COMPARATOR|Control|This arm will be exposed to the emergency medical services (EMS) agency's existing seizure protocol; this is the control arm
62772784|NCT01554995|EXPERIMENTAL|LCB01-0371|active
62772785|NCT01554995|EXPERIMENTAL|Linezolid|comparator
62564885|NCT05244057|EXPERIMENTAL|Hepalatide + TAF + PEG-IFN|Patients will receive 6.3mg Hepalatide +25mg Tenofovir alafenamide+ 90ug Pegylated Interferon for 48 weeks with a further follow-up period of 24 weeks.
61995689|NCT03467633|EXPERIMENTAL|High-intensity interval training (HIIT)|Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the University of Ottawa Heart Institute prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
61995690|NCT03467633|NO_INTERVENTION|Usual Care Control|Participants assigned to the control group will have usual care, which involves no behavioural interventions leading up to their electro-cardioversion.
61995691|NCT00886431|EXPERIMENTAL|Vitrification|The embryos of patients allocated to this arm will be cryopreserved by vitrification.
61995692|NCT00886431|NO_INTERVENTION|Slow cooling|The embryos of patients allocated to this arm will be cryopreserved by the slow cooling method, which is the standard method (=no intervention)
61995693|NCT00895791|ACTIVE_COMPARATOR|1|AXXESS Biolimus A9-eluting bifurcation stent
61995694|NCT00895791|ACTIVE_COMPARATOR|2|culotte stenting with use of 2 drug eluting stents
62564886|NCT05244057|PLACEBO_COMPARATOR|Placebo+ TAF + PEG-IFN|Patients will receive Placebo +25mg Tenofovir alafenamide + 90ug Pegylated Interferon for 48 weeks with a further follow-up period of 24 weeks.
62564887|NCT03858972|EXPERIMENTAL|Tesetaxel (oral) and capecitabine (oral)|"Cohort 1: Tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle.~Cohort 2: On Cycle 1, Day -1, either a single morning dose of capecitabine at 825 mg/m2 (Cohort 2A) or 1,250 mg/m2 (Cohort 2B). On Cycle 1, Day 1, a single dose of tesetaxel (27 mg/m2), followed 2 hours later by capecitabine (825 mg/m2), followed by an evening dose of capecitabine (825 mg/m2). Capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the morning dose on Day 2 through evening dose on Day 14 of Cycle 1. Starting with Cycle 2, tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle."
62564888|NCT00857675|EXPERIMENTAL|Adefovir Dipivoxil|ADV 10mg tablets once daily
62182624|NCT03628196||Concurrent Group|Patients seen during the QIP period at the clinic but that did not participate in the QIP.
61995695|NCT00006916|EXPERIMENTAL|Radiation therapy followed by bleomycin via Ommaya reservoir|60.0 Gy/30 fractions x 2.0 Gy. Then within 2-6 weeks after completion of radiation therapy or at the time a patient experiences disease progression during or immediately after completion of radiation therapy, if clinically feasible, a modified Ommaya reservoir is implanted with the delivery catheter in the tumor or tumor cyst/cavity. Bleomycin, 15 units per week, is then given via the Ommaya reservoir without interruption for a maximum of two years as long as there is no toxicity above grade 3 or evidence of disease progression.
62180812|NCT06254300|NO_INTERVENTION|Control Group|Participants from the control group will be offered optimal medical care, which includes general advice about healthy lifestyle including regular physical activity participation according to the current guidelines.
62391268|NCT02438787|EXPERIMENTAL|Group 3 (ustekinumab 90 mg)|Ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (\<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
62564889|NCT00857675|PLACEBO_COMPARATOR|Adefovir Dipivoxil matched placebo|Adefovir Dipivoxil matched placebo one tablet once daily
62564890|NCT01837901|SHAM_COMPARATOR|Sham|OkuStim is used to determine the phosphene threshold, device is turned on but no stimulation is performed.
62564891|NCT01837901|EXPERIMENTAL|150%|OkuStim is used to determine the phosphene threshold, and then to administer transcorneal electrostimulation with a stimulation strength corresponding to 150% of the patient's phosphene threshold.
62564892|NCT01837901|EXPERIMENTAL|200%|OkuStim is used to determine the phosphene threshold, and then to administer transcorneal electrostimulation with a stimulation strength corresponding to 200% of the patient's phosphene threshold.
62564893|NCT03096860|EXPERIMENTAL|Alcohol consumption and hookah|
62564894|NCT03096860|PLACEBO_COMPARATOR|Placebo consumption and hookah|
61995696|NCT05940974||Shoulder arthroplasty|All adult patients undergoing primary total shoulder replacement surgery at the Traumatology, Orthopedics and Joint Pathology Clinic of the I.M. Sechenov First Moscow State Medical University (Sechenov University) who meet the inclusion criteria (described below) will be included.
62564895|NCT00520377|EXPERIMENTAL|1|MD05
62564896|NCT00520377|ACTIVE_COMPARATOR|2|Beta-TCP and autologous bone
62564897|NCT05035290|EXPERIMENTAL|Negative pressure ventilation|Negative pressure application after extubation
62564898|NCT05035290|NO_INTERVENTION|Standard approach|Standard approach - oxygentherapy based on patients need
61995697|NCT06391866||Experimental group 1|Patients scheduled for elective cardiac surgery, such as coronary artery bypass grafting (CABG) or valve replacement, involving extracorporeal circulation (ECC) with a duration less than 60 minutes.
61995698|NCT06391866||Experimental group 2|Patients undergoing scheduled cardiac procedures, including coronary artery bypass grafting (CABG) or valve replacement, requiring extracorporeal circulation (ECC) for more than 60 minutes.
62180813|NCT00305097|EXPERIMENTAL|Caffeinated coffee|Caffeinated coffee
62391269|NCT05963581|EXPERIMENTAL|Salsa Dancing|Participants will complete eight weeks of a salsa course in Oxford (of which they need to attend six classes to remain in the study), followed by a one-month follow-up time point.
62391270|NCT05963581|NO_INTERVENTION|Waitlist Control|Participants will wait twelve weeks, completing the questionnaires and tasks at the same study time points as participants in the experimental condition.They will then be offered the opportunity to complete the eight-week salsa course. Should they choose to participate in the salsa course, they will additionally be offered the opportunity to complete questionnaires at two additional time points.
62564899|NCT00843765|ACTIVE_COMPARATOR|TCM integrated group|800 patients with acupuncture, massage and basic Chinese medicine treatment
62564900|NCT00843765|ACTIVE_COMPARATOR|Western Medicine group|400 patients with modern rehabilitation techniques and Western Medicine basic treatment
62564901|NCT05783063|ACTIVE_COMPARATOR|active stimulation|Intermittent theta burst stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 5 days.
62564902|NCT05783063|SHAM_COMPARATOR|Sham stimulation|Sham stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 5 days.
62564903|NCT05680519|EXPERIMENTAL|Intervention group|The participants will also be given a Practical Resource Hub for Healthy Life leaflet containing information on various applications. The participants will receive a brief telephone intervention using the Ask, Warn, Advise, Refer and Do-it-again (AWARD) model. For the advice step, the research assistant will ask about the priority the participants place on engagement in desirable health-related lifestyle practices identified in the completed behavioural risk factor survey. The participants will also be asked to choose the goal that they consider easiest to achieve, such as quitting or reducing smoking, consuming more vegetables or less fatty foods or sugary drinks, performing more exercise or reducing alcohol consumption. The participants will be encouraged to quit health-risk behaviours (or adopt a healthy lifestyle) sequentially, but they will also be able to choose to quit them simultaneously if they are confident in doing so.
61995699|NCT06391866||Control group:|Patients scheduled for cardiac surgical procedures such as coronary artery bypass grafting (CABG) without extracorporeal circulation, and for carotid endarterectomy in neurologically asymptomatic patients prior to the procedure.
62180814|NCT00305097|EXPERIMENTAL|Decaffeinated coffee|Decaffeinated coffee
62180815|NCT00305097|ACTIVE_COMPARATOR|No coffee|
62180816|NCT00104637|ACTIVE_COMPARATOR|Sildenafil / Placebo|Sildenafil first, followed by washout, followed by placebo
62180817|NCT00104637|PLACEBO_COMPARATOR|Placebo / Sildenafil|Placebo first, followed by washout, followed by Sildenafil
62180818|NCT05797883|EXPERIMENTAL|FOLFOX/FOLFIRI|q2w, after 8 cycles of medication or patient intolerance or disease progression;
62180819|NCT01317706|ACTIVE_COMPARATOR|Bishop score|
62564904|NCT05680519|PLACEBO_COMPARATOR|Control group|The participants will also be given a Practical Resource Hub for Healthy Life leaflet containing information on various applications. The control group participants will receive a brief telephone intervention based on the AWARD model and delivered by the trained research assistant, similar to that delivered to the intervention group. However, the research assistant will simply advise the participants to modify their health-risk behaviours and/or adopt a healthy lifestyle practice. In addition, the research assistant will send regular SMS messages to the participants at a similar frequency to the intervention group, but these messages will contain only general health advice. The participants will also receive follow-up for outcome assessments with the same schedule as those in the intervention group.
62564905|NCT05682209|ACTIVE_COMPARATOR|Octreotide group|Received 100µg of octreotide intravenously 8-hourly for 5 days from the first post-operative day
62564906|NCT05682209|PLACEBO_COMPARATOR|Control group|Received 1ml of sterile water intravenously 8-hourly for 5 days from the first post-operative day
62564907|NCT05629858|EXPERIMENTAL|6-hour Time restricted eating (TRE)|Ad libitum food intake from 1-7 pm every day Fasting from 7-1 pm every day (18-h fast)
62564908|NCT05629858|EXPERIMENTAL|Calorie restriction (CR)|25% energy restriction every day
62564909|NCT05629858|EXPERIMENTAL|Control|Usual diet
62564910|NCT06283329||Group A|a group of patients receiving systematic decurarization using neostigmine , a unique dose of 40 µg/kg associated with atropine 20 µg/kg
61995700|NCT02353247|OTHER|Norethindrone acetate (aygestin)|Norethindrone acetate (aygestin) will be used to manage bothersome bleeding. Patients will be prescribed aygestin 5 mg by mouth twice daily for one month, followed by aygestin 5 mg by mouth once daily for two months. Medication will then be discontinued. Patients will be evaluated in the office three months after medication initiation, and then again six months after medication initiation. If the patient is unable to take norethindrone acetate (aygestin) due to medical contraindications or cost, they will receive medroxyprogesterone acetate (provera) 10 mg once daily as alternate oral progesterone. Figure 1 below highlights the study
62180820|NCT01317706|ACTIVE_COMPARATOR|transvaginal ultrasound|
62180821|NCT01885923|ACTIVE_COMPARATOR|20% antisychotic dose increase in prodromes|Antipsychotic dose increase upon prodromes occurence detected by Device- ITAREPS system. All antipsychotics currently registered in Czech Republic will be allowed in this study. All patients will remain on antipsychotic treatment adjusted prior enrollment, so that dose adjustment will be based on their ordinary medication. Participants will be instructed to complete the 10-item EWS Questionnaire upon SMS request sent automatically weekly to their mobile phones. EWSQ detects proportional worsening of the symptoms compared to the last week's score of the questionnaire. Individual EWSQ scores will be sent by participants back to the ITAREPS system as a SMS. If the total score exceeds the given score threshold, an immediate ALERT would be declared and announced to the investigator as an e-mail message and a therapeutic intervention is requested. After detecting the early warning signs by ITAREPS, an immediate 20% increase in the dose of antipsychotic will be required.
62180822|NCT01885923|NO_INTERVENTION|Treatment as usual|In the control group (treatment-as-usual) participants will not be enrolled in the ITAREPS system.
62180823|NCT05098756|EXPERIMENTAL|Art therapy group|Experimental group received 8-week art therapy. Art therapy uses different themes and materials to art-making.
62180824|NCT05098756|NO_INTERVENTION|No intervention group|No intervention group maintain the institution's original daily routine and participation in activities.
62180825|NCT01653249|EXPERIMENTAL|vaccination|an escalating dose study of a vaccine consisting of four HPV-16 E6 peptides in combination with Candin® to determine the clinically optimum dose (COD), immunologically optimal dose (IOD), and maximum tolerated dose (MTD). An additional 30 subjects will be vaccinated at the final dose (apparent COD) for further assessment of clinical response.
62180826|NCT03344406||Subjects with asthma|Subjects with moderate to severe asthma will be interviewed via telephone. Subjects will complete a daily diary including the E-RS: COPD and supplemental asthma items for 7 days.
62182625|NCT03557242|OTHER|Warfarin plus Aspirin|100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to warfarin plus low dose aspirin for 30-45 days
62182626|NCT03557242|OTHER|Aspirin Monotherapy|100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to low dose aspirin monotherapy for 30-45 days
62564911|NCT06283329||Group B|a group of patients extubated through clinical criteria without use of neostigmine
62564912|NCT02446067|NO_INTERVENTION|Healthy control|No Repetitive Transcranial Magnetic Stimulation (rTMS)
62564913|NCT02446067|ACTIVE_COMPARATOR|Active rTMS group|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
62564914|NCT02446067|SHAM_COMPARATOR|Sham rTMS group|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
62564915|NCT04682808|EXPERIMENTAL|Dose Escalation and Expansion|FCN-338 will be given orally in ascending doses in patients with relapsed or refractory CLL/SLL , until the maximum tolerated dose or recommended dose is reached. Followed by up to 43 patients enrolled in the expansion cohort at the recommended dose.
62564916|NCT01244438|EXPERIMENTAL|FP-1039|FP-1039
62564917|NCT04527692||Child|Children/adolescents from 1 to 18 years of age with a serious illness requiring follow-up by a regional pediatric palliative care resource team and/or temporarily hospitalized.
62564918|NCT04527692||Parents|Adult person with parental authority over a child between the ages of 1 and 18 who is a carrier of a serious illness and requires follow-up by a regional pediatric palliative care resource team and/or is temporarily hospitalized.
62564919|NCT01378728||Patients with chronic or acute wounds.|Patients with chronic or acute wounds.
62180827|NCT04472988|EXPERIMENTAL|Eye Movement Desensitization and Reprocessing|"30 participants will be randomly allocated to the EMDR group. They will receive a 90 minutes session of EMDR each week for twelve weeks. The sessions will be conducted by clinicians or psychotherapists specialized in EMDR, and the participants will be randomly allocated to them.~EMDR is a structured, goal-oriented, short-term intervention organized around traumatic or stressful memories. This method was discovered in 1981 by F. Shapiro and represented an evidence-based treatment, one of the two first-line trauma treatment recommended for use with adults (NICE, 2005; World Health Organization, 2013). EMDR proved effective by hundreds of researches and has also been shown to be useful in alleviating physical symptoms such as pain or increased autonomic activity. But to our knowledge, research on EMDR efficacy in the treatment of autoimmune thyroiditis has not been previously reported."
62564920|NCT04457908|OTHER|intelligent|receive the neurological function assessment by artificial intelligence
62564921|NCT04457908|NO_INTERVENTION|manual|receive the neurological function assessment by doctor
62180828|NCT04472988|PLACEBO_COMPARATOR|Placebo|30 participants will be randomized to the placebo group. The placebo goup will receive an intervention that does not include working on past traumatic memories, it will be more focused on present and future.
62180829|NCT04472988|ACTIVE_COMPARATOR|Treatment as Usual|30 participants will be randomized to this group. They will continue only the medical treatment for Hashimoto their doctor prescribed to them.
62180830|NCT00581841||1|Healthy adult participants with no history of knee injury or osteoarthritis.
62564922|NCT04097054|EXPERIMENTAL|Intervention|Patients in the interventional arm are operated after augmented planning of the procedure. The plan is prepared by the surgeon and made available to the study team a day prior to the procedure and on a screen in the OR during the procedure. The plan includes the current and next operative step, the used equipment and the approximate time used as well as the estimated time of when the procedure will end.
62180831|NCT02941848|EXPERIMENTAL|Group1|"C → A + B~A : HGP0816 B : HGP1404 C : HCP1306"
62564923|NCT04097054|NO_INTERVENTION|Control|In the control cases no particular planning and distribution of operative plan is performed. The standard preparation only includes the distribution of information on the desired positioning of the patient, necessary special equipment and the overall estimated OR time.
62564924|NCT05922722||Participants with lupus|
62564925|NCT04593485|EXPERIMENTAL|Cohort 1|patients with postoperative recurrence of malignant melanoma of the female genital tract requiring adjuvant therapy, Camrelizumab for injection
62564926|NCT04593485|EXPERIMENTAL|Cohort 2|patients with metastatic or unresectable malignant melanoma of the female genital tract, Camrelizumab for injection
62564927|NCT04686799|EXPERIMENTAL|SD-doxycycline group|12 weeks SD-doxycycline: doxycycline hyclate 20 mg tablet by mouth twice daily
62564928|NCT01205776|ACTIVE_COMPARATOR|Percutaneous Coronary Intervention|Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
62564929|NCT01205776|ACTIVE_COMPARATOR|Coronary Artery Bypass Graft|Those patients receiving CABG
62772786|NCT03563365|EXPERIMENTAL|Replenix|Replenix power of 3 cream with Resveratrol applied twice daily
62772787|NCT03563365|EXPERIMENTAL|Replenix and Adapalene and Benzoyl Peroxide gel|Replenix power of 3 cream with Resveratrol applied twice daily and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily
62772788|NCT03563365|ACTIVE_COMPARATOR|Adapalene and Benzoyl Peroxide gel|Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily
62772789|NCT05839704|EXPERIMENTAL|Bilateral Erector Spinae Plane Block|Patients in this arm will receive standard anaesthesia as per our bariatric anaesthesia protocol. They will also receive preoperative ultrasound guided bilateral single shot erector spinae plane blocks at the level of the 8th transverse process.
62772790|NCT05839704|ACTIVE_COMPARATOR|Abdominal Wall Blocks|Patients in this arm will receive standard anaesthesia as per our bariatric anaesthesia protocol. They will also receive bilateral subcostal transversus abdominus plane blocks and a left sided serrratus plane block, postoperatively, while under general anaesthetic.
62772791|NCT03443427|EXPERIMENTAL|Schedule 0-2-6 Group|Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 181 (Month 6) and one dose of placebo at Day 361 (Month 12).
62772792|NCT03443427|EXPERIMENTAL|Schedule 0-2-12 Group|Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 361 (Month 12) and one dose of placebo at Day 181 (Month 6).
62772793|NCT03433534||Pharmacokinetic of Nivolumab|Patients under nivolumab (Opdivo 10 MG/ML) for the treatment of non small cell lung carcinoma or renal cell carcinoma. Measure of nivolumab residual concentration 14 days after administration of nivolumab and just before the new perfusion.
62772794|NCT01272869|ACTIVE_COMPARATOR|Sensura|SenSura is the reference product and the product is already commercially available
62772795|NCT01272869|EXPERIMENTAL|Morfeus|The test product is the product with the proposed new filter (Morfeus)
62772796|NCT02134288|ACTIVE_COMPARATOR|Belatacept|Belatacept 10mg/kg administered intravenously on days 1, 4, 15, and 28, weeks 8 and 12. Then continue at 5mg/kg every 4 weeks throughout the completion of the study.
62772797|NCT02134288|ACTIVE_COMPARATOR|Everolimus|Everolimus 1.5 mg/kg twice a day by mouth, the dose will be adjusted after Day 3.
62772798|NCT02263261|OTHER|Flex HD Pliable Perforated HADM|Single Arm
62772799|NCT02087722|EXPERIMENTAL|KI1001|
62772800|NCT02087722|PLACEBO_COMPARATOR|Placebo|
62772801|NCT01707927||Trifecta|Degenerated aortic valve with indication for aortic valve replacement
62772802|NCT01707927||mosaic Ultra|Need a aortic valve replacement
62772803|NCT01762813||open and laparoscopic surgery|Patients with primary and or metastatic colorectal cancer (CRC) eligible for curative surgery will be included. Subcohorts may be based on either colon cancer, rectal cancer, metastatic cancer, surgery (laparoscopy or open), node negative and node positive disease, and molecular profiling.
62180832|NCT02941848|EXPERIMENTAL|Group2|"A + B → C~A : HGP0816 B : HGP1404 C : HCP1306"
62564930|NCT01984333|EXPERIMENTAL|Online cognitive training|Online cognitive training will provides eight sessions of a computerized training game. Each session will last about 30-40 minutes, and participants will undergo 2 sessions each week over a 4-week period.
62564931|NCT01984333|NO_INTERVENTION|Waitlist control|This is a 1-month waitlist control to be compared with the active online cognitive training intervention. This is a no intervention control group.
62564932|NCT05000164|EXPERIMENTAL|Market Product|Eligible subjects will be dispensed the study lenses in a bilateral fashion and will be in the treatment for approximately 5 weeks.
62564933|NCT03145844||Direct Acting Agents|No Intervention
62564934|NCT04488341|OTHER|aerobic exercises in addition to diet|The study group will receive aerobic exercises in addition to diet recommendations
62564935|NCT04488341|OTHER|diet recommendations|control group will receive diet recommendations
62564936|NCT05902884|OTHER|Patients|Patients with FSHD
62564937|NCT05902884|OTHER|Controls|Healthy volunteers
62564938|NCT05933018|OTHER|type 1 diabetes|patients with type 1 diabetes underwent liver elastography
62180833|NCT05264142|EXPERIMENTAL|CYP2C19 Rapid Metabolizers (RM)|CYP2C19 rapid metabolizers (RM) are characterized by one normal function allele and one increased function allele
62180834|NCT05264142|EXPERIMENTAL|CYP2C19 Normal metabolizers (NM)|CYP2C19 normal metabolizers (NMs) harboring two normal function alleles defined by the lack of any characterized polymorphisms.
62180835|NCT05264142|EXPERIMENTAL|CYP2C19 Intermediate metabolizers (IM)|CYP2C19 intermediate metabolizers (IMs) are characterized by the presence of one normal function allele and one no function allele or one no function allele and one increased function allele.
62180836|NCT01181219|EXPERIMENTAL|CXL without epithelial removal|Application of Riboflavin and the consequent UV-irradiation with intact corneal epithelium
62180837|NCT01181219|ACTIVE_COMPARATOR|CXL with epithelial removal|Corneal epithelial removal prior to Riboflavin and the consequent UV-irradiation
62180838|NCT01742845|ACTIVE_COMPARATOR|control group|landmark-based superficial cervical block is used. After insertion of the needle superficially below the skin, 20 to 30 ml of 4.75 mg/ml ropivacaine are injected fan-like in the subcutaneus plane.
62180839|NCT01742845|EXPERIMENTAL|echo group|ultrasound-guided intermediate cervical block was performed. The probe is placed perpendicular to the skin, in the horizontal plane at the C3-C4 level. Needle is inserted in-plane. 10 ml ropivacaine 4.75mg/ml are injected under ultrasound control, 5 ml injected when needle is withdrawn under ultrasound control, 5 ml in the subcutaneous plane.
62564939|NCT01268553|EXPERIMENTAL|Active treatment|This is the only arm in the trial. All enrolled subjects will be attempted to transition to inhaled treprostinil. There is no placebo and control arm.
62564940|NCT03029286|EXPERIMENTAL|Personalized Web Intervention Arm|Women will be assigned to view a tailored website featuring their personalized risk information for breast cancer related to breast density and other factors.
62564941|NCT03029286|ACTIVE_COMPARATOR|Usual Care Arm|Women will be assigned to view a website that will take them to the American Cancer Society website to view general risk information for breast cancer related to breast density.
62180840|NCT03900026|PLACEBO_COMPARATOR|Placebo Treatment|Participants will receive subcutaneous injections of the placebo Q2W (every 2 weeks)
62180841|NCT03900026|EXPERIMENTAL|Evolocumab Treatment|Participants will receive subcutaneous injections of 140mg of evolocumab Q2W (every two weeks)
62180842|NCT06343649|EXPERIMENTAL|Visual Explicit Motor Imagery|6 exercises of Explicit Motor Imagery, administered on alternate days, using visual inputs in the form of images.
62180843|NCT06343649|EXPERIMENTAL|Auditory Explicit Motor Imagery|6 exercises of Explicit Motor Imagery, administered on alternate days, using auditory inputs in the form of audio recordings.
62180844|NCT02821078|EXPERIMENTAL|Participants|"In addition to the standard clinical MR protocol, 2 added sequences:~* 4D flow imaging sequence~* standard 2D-PhaseContrast at portal trunk level as reference"
62564942|NCT01978132|ACTIVE_COMPARATOR|Primary hyperaldosteronism|"patients with primary hyperaldosteronism will be subjected to the intervention forearm ischemia and reperfusion (20 minutes of forearm ischemia and 20 minutes of reperfusion).~Primary endpoint is the reduction in brachial FMD by forearm ischemia-reperfusion, as a measure of endothelial ischemia-reperfusion injury"
62564943|NCT01978132|PLACEBO_COMPARATOR|Primary hypertension|"Patients with primary hypertension (PHA excluded)will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.~Primary endpoint is the reduction in brachial FMD by forearm ischemia-reperfusion, as a measure of endothelial ischemia-reperfusion injury"
62772804|NCT00389675|EXPERIMENTAL|Darusentan|Darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily
62564944|NCT05079672|ACTIVE_COMPARATOR|Group Dexmedetomidine|The patient will receive Dexmedetomidine, at the rate of 0,3μg/ kg/h, in continuous intravenous infusion from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.
62564945|NCT05079672|PLACEBO_COMPARATOR|Group 0,9% Saline|The patient will receive a 0,9% saline, in continuous intravenous infusion, from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.
62564946|NCT02445261|ACTIVE_COMPARATOR|normal growth|120 woman with normal fetal growth will be subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound will be done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone. UA resistance indices, number of fetal kicks, the loss of acceleration and variability, and the appearance of decelerations were assessed
62564947|NCT02445261|ACTIVE_COMPARATOR|growth restricted group|70 woman with l growth restricted fetus will be subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound will be done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone. UA resistance indices, number of fetal kicks, the loss of acceleration and variability, and the appearance of decelerations
62564948|NCT06431724||Women >65 years who are considered at risk of developing cervical cancer|200 women \>65 years who are considered at risk of developing cervical cancer.
62564949|NCT06431724||Primary care providers and gynecologic providers|100 Licensed Primary Care and Gynecologic Providers which includes APRNs, PAs, and Physicians.
62564950|NCT04445025|EXPERIMENTAL|Test group|Subjects will receive the medication elagolix
62564951|NCT04445025|ACTIVE_COMPARATOR|Control group|Subjects will receive leuprolide acetate
62564952|NCT03984864|EXPERIMENTAL|Exercise therapy Chosen|
62564953|NCT03984864|ACTIVE_COMPARATOR|Exercise therapy no Chosen|
62564954|NCT05531630|EXPERIMENTAL|AB: Xylitol-Saline|Patients in the AB arm will first receive Xylitol, followed by saline
62564955|NCT05531630|EXPERIMENTAL|BA: Saline-Xylitol|Patients in the BA arm will first receive saline, followed by Xylitol
62564956|NCT01686373|EXPERIMENTAL|Activa Dose II Real tDCS|Actual delivery of electrical stimulation
61995701|NCT05381584|ACTIVE_COMPARATOR|fractionated intraumbilical microports group|two 4-5-mm micro ports will be done intra umbilically; a 4-mm scope is inserted through one of them, followed by a 4-mm catheter inserter through the second intra umbilical port.
61995702|NCT05381584|EXPERIMENTAL|fully monitored entry group|only one 4mm intra umbilical port will be done and a second port at a point of lies 8 cm from midline and 5 cm above anterior superior iliac spine. After performing laparoscopic evaluation of the pelvis the telescope will be moved from the umbilical port to the ancillary port and the catheter loaded inserter will be introduced through the umbilical port its insertion will be fully monitored from the point of entry at the umbilicus until the pelvic floor.
62564957|NCT01686373|PLACEBO_COMPARATOR|Activa Dose II Sham tDCS|Sham delivery of electrical stimulation
62564958|NCT00126750|OTHER|Arm 1|
62564959|NCT03764774|EXPERIMENTAL|LY3463251 Single dose|Single dose of LY3463251 administered subcutaneously (SC)
62564960|NCT03764774|PLACEBO_COMPARATOR|Placebo Single dose|Single dose of placebo administered SC
62564961|NCT03764774|EXPERIMENTAL|LY3463251 Multiple Dose|Multiple doses of LY3463251 administered SC
62564962|NCT03764774|PLACEBO_COMPARATOR|Placebo Multiple Dose|Multiple doses of placebo administered SC
62564963|NCT05023915|ACTIVE_COMPARATOR|diammonium glycyrrhizinate enteric-coated capsule + high-dose dexamethasone|Diammonium glycyrrhizinate enteric-coated capsule orally at a dose of 150mg tid for 3 months, combining with dexamethasone (given orally at a dose of 40 mg qd for 4 days). Patients who do not respond to the treatment may receive another cycle of high-dose dexamethasone therapy with an interval of 10 days.
62564964|NCT05023915|ACTIVE_COMPARATOR|High-dose dexamethasone|Dexamethasone orally at a dose of 40 mg qd for 4 days. Patients who do not respond to the treatment may receive another cycle of high-dose dexamethasone therapy with an interval of 10 days.
62564965|NCT02240056||TTC|postmenopausal women with acute Takotsubo cardiomyopathy (TTC), diagnosis by coronary angiography within 24 hours of symptom onset
62564966|NCT02240056||NSTEMI / STEMI|postmenopausal women with acute ST elevation myocardial infarction (NSTEMI / STEMI), diagnosis by coronary angiography within 24 hours of symptom onset
62564967|NCT02240056||healthy subjects|healthy postmenopausal women without coronary artery disease
61995703|NCT06100666||Adults|Academic and administrative staff working at Tarsus University
61995704|NCT01547416|EXPERIMENTAL|combined general/epidural anesthesia|epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. Epidural analgesia was maintained using the patient-controlled analgesia technique.
62564968|NCT01973439|OTHER|Abacavir Once versus Twice Daily|This is a single arm study. Intervention 1: PK assessment while on Twice Daily Abacavir (Week 0) Intervention 2: PK assessment while on Once Daily Abacavir (Week 4)
62564969|NCT00571740|ACTIVE_COMPARATOR|Arm I (second-line therapy)|Patients receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 46 hours beginning on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
62564970|NCT00571740|EXPERIMENTAL|Arm II (second-line therapy)|Patients receive bevacizumab and modified FOLFOX7 as in arm I. Patients also receive cetuximab IV over 2 hours on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
62564971|NCT02834520||oral lichen planus|30 patients suffering from reticular, erosive and atrophic oral lichen planus
62564972|NCT02834520||control subjects|30 individuals age, gender and periodontal status matched with oral lichen planus patients and not suffering from any oral mucosal lesions or periodontal disease.
62564973|NCT05154045|EXPERIMENTAL|Experimental Formula|One 330 ml serving of study product
62564974|NCT05154045|ACTIVE_COMPARATOR|Test Meal|40 g Instant oatmeal
62772805|NCT00389675|ACTIVE_COMPARATOR|Guanfacine|Guanfacine 1 mg capsules administered orally once daily
61995705|NCT01547416|ACTIVE_COMPARATOR|General anesthesia|Patients allocated to general anesthesia group did not receive epidural anesthesia.
61995706|NCT00184262|ACTIVE_COMPARATOR|ERP cognitive therapy|
62180845|NCT00858507|EXPERIMENTAL|Personal Health Assessment/RN Brief Intervention|RN-based medical outreach, administration of a personal health assessment and brief intervention
62564975|NCT00808210|EXPERIMENTAL|Ocrelizumab 200mg|Participants received two intravenous (IV) infusions of 200 mg ocrelizumab administered on Day 1 and Day 15 and placebo IV infliximab infusions administered on Day 1, Day 15, Week 6, and Week 14. In addition to the study medication, all patients were to receive methotrexate at a stable dose of 7.5-25 mg/week and folic acid or equivalent at a dose of 5 mg/week to minimize methotrexate toxicity.
62564976|NCT00808210|ACTIVE_COMPARATOR|Infliximab 5mg/kg|Participants received four IV infusions of 5 mg/kg infliximab administered on Day 1, Day 15, Week 6, and Week 14 and placebo ocrelizumab infusions administered on Day 1 and Day 15. In addition to the study medication, all patients were to receive methotrexate at a stable dose of 7.5-25 mg/week and folic acid or equivalent at a dose of 5 mg/week to minimize methotrexate toxicity.
62564977|NCT00961103||SMA II and SMA III|patients with SMA II and SMA III
62564978|NCT06189196|EXPERIMENTAL|Group A|BLOW BOTTLE
62564979|NCT06189196|EXPERIMENTAL|Group B|ACBT
62564980|NCT04050761||Monotherapy|Participants diagnosed with recurrent or metastatic squamous cell carcinoma of the Head and Neck and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of SCCHN.
62564981|NCT05306002|OTHER|Antioxidant therapy|The patient will get a nutritional personalized treatment with the following characteristics: hypocaloric diet, rich in micronutrients related with DNA reparation and polyphenols, with the next distribution: 45% carbohydrates, 30% lipids, 25% protein, \<10% saturated fats, \>10% unsaturated fats, based on the recommendations of the American Institute for Cancer Research (AICR).
62564982|NCT03841864|OTHER|Grade 1 Vein Visualization|Visual vein classification grade described as excellent Visualization. Objective vein criteria to be included in this group are vein raised above skin and wider than 1mm. Initial IV placement will be traditional attempt but subsequent attempts will be provider discretion for traditional vs ultrasound guided placement
62564983|NCT03841864|OTHER|Grade 2A Vein Visualization|Veins that don't fit grade 1 or 2b classification (see respective group descriptions). This groups visual vein classification is described as fair visualization. Initial IV placement will be traditional attempt but subsequent attempts will be provider discretion for traditional vs ultrasound guided placement
62564984|NCT03841864|OTHER|Grade 2b Vein Visualization|Only faint vein shadow appearance described as poor visualization. Initial IV placement attempt will be ultrasound guided
62564985|NCT03841864|OTHER|Grade 3 Vein Visualization|No vein visualization. Initial IV placement attempt will be ultrasound guided
62564986|NCT05800717|OTHER|Treatment|Receives SCISM-D.
62564987|NCT01967862|EXPERIMENTAL|Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)|Patients first undergo CT scan and bone scan. Patients with negative results from the CT and bone scans then undergo WB MRI scan using diffusion-weighted MRI, axial MRI scan using 3-Tesla MRI, and fluorine F 18 sodium fluoride PET/CT scan.
62564988|NCT04852744|OTHER|Borderline girls with PTSD|"* female~* Age between 13 and 17 years inclusive~* Diagnosis of borderline personality disorder according to the criteria of the Diagnostic and Statistical Manual for mental disorders, fifth edition (DSM-5; American Psychiatric Association, 2013; SIDP-IV)~* Post-traumatic stress disorder according to DSM-5 criteria (American Psychiatric Association, 2013; K-SADS-PL)~* Level of general psychopathology compatible with participation in the study (score\> 20 on the CGA-S)~* Oral and written comprehension of the French language~* Affiliation to the social security scheme~* Informed consent signed by the legal representatives holding the exercise of parental authority and the adolescent herself"
62564989|NCT04852744|OTHER|Borderline girls without PTSD|"* female~* Age between 13 and 17 years inclusive~* Diagnosis of borderline personality disorder according to the criteria of the Diagnostic and Statistical Manual for mental disorders, fifth edition (DSM-5; American Psychiatric Association, 2013; SIDP-IV)~* Level of general psychopathology compatible with participation in the study (score\> 20 on the CGA-S)~* Oral and written comprehension of the French language~* Affiliation to the social security scheme~* Informed consent signed by the legal representatives holding the exercise of parental authority and the adolescent herself"
62564990|NCT04852744|OTHER|Healthy controls|"* female~* Age between 13 and 17 years inclusive~* Absence of mental disorder according to DSM-5 (American Psychiatric Association, 2013 ; K-SADS-PL et SIDP-IV)~* Oral and written comprehension of the French language~* Affiliation to the social security scheme~* Informed consent signed by the legal representatives holding the exercise of parental authority and the adolescent herself"
62564991|NCT00660244||1|
62772806|NCT05400421||Device Calibration & Algorithm Training|The data obtained from this group will be used to a) quantify the relationship between PWV measured at the groin versus the thigh for less intrusive future piezo sensor placement and b) train the proposed device for the next cohort.
61995707|NCT00184262|EXPERIMENTAL|ERP behavioral therapy|
61995708|NCT01977586|EXPERIMENTAL|Metastatic renal cell carcinoma|Patients with clear cell renal cell carcinoma treated with anti-angiogenic therapies
61995709|NCT05696834||sclerotherapy and bone marrow|Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst
61995710|NCT04695938|OTHER|MRI|MRI examination
61995711|NCT02065648||Syngo NATIVE MRA|All consenting participants will receive an additional non-contrast Syngo NATIVE MRA sequence prior to contrast injection their standard of care MRA.
61995712|NCT01257373||patiens with Firebird 2 stent|The group of 1300 patients, in which only Fireibrd2 stent is implanted, will be collected. All inclusive patients should be definitely diagnosed type 2 diabetic mellitus （DM）, either before or during the present hospitalization and with complex coronary lesion.
61995713|NCT00581074|ACTIVE_COMPARATOR|G|grapefruit
61995714|NCT00581074|ACTIVE_COMPARATOR|J|Juice
61995715|NCT00581074|PLACEBO_COMPARATOR|W|placebo
62180846|NCT00858507|PLACEBO_COMPARATOR|Social Work-Administered Outreach|Social work based outreach (usual care)
62182811|NCT04919733|EXPERIMENTAL|Non fluoroscopy CIED implant|Try to reduce as much as possible the fluoroscopy needed to implant a CIED pacemaker or defibrillator using a 3-D mapping system
62564992|NCT05569681|ACTIVE_COMPARATOR|Bemiparin 3500 IU|"Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
62564993|NCT05569681|ACTIVE_COMPARATOR|Bemiparin 5000 IU|"Bemiparin sodium 5000 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group patients and 30 days in very high-risk group surgical patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
62564994|NCT04924387|EXPERIMENTAL|Experimental Group (EXP group)|The experimental group (EXP Group) is going to follow a programme of stabilisation through specific therapeutic exercises of the lumbopelvic centre. Two weekly sessions will be programmed for 12 weeks, making a total of 24 sessions. Each sesión will have a duration of 60 minutes, the first 5 minutes for a warm-up and the last 10 for a cool-down phase of active stretching. All patients will start learning how to activate the abdominal muscles in the first training session. The exercise progression will be adapted according to the capacity of each patient, considering their pain levels. The exercices will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rests between series will be of 30 seconds, and between exercies of 2-3 minutes.
62564995|NCT04924387|ACTIVE_COMPARATOR|Experimental Group and Manual Therapy (MT Group)|Additionally to the core exercises previously exposed in Group EXP, Group MT will lay on the stretcher first, where the physiotherapist will work on a manual therapy thrust. The patient will receive an impulse technique in lateral decubitus position, with high velocity and low range on both sides.
62564996|NCT04924387|ACTIVE_COMPARATOR|Experimental Group and Kinesio Tape (KT Group)|"The experimental group plus kinesio tape (KT Group) will go previously through physiotherapy, where a kinesio tape band will be applied (kinesio tape Nondolens 5cm x 5cm black color), in Y technique, by applying the KT base in neutral position of the lumbar spine without any tension on the tape."
62564997|NCT03688308|EXPERIMENTAL|Shoulder arthroscopy with BMAC|This arm will have patients who receive surgical intervention with arthroscopic rotator cuff repair along with 3-4cc of BMAC produced from the Harvest/Terumo BCT system
62564998|NCT03688308|ACTIVE_COMPARATOR|Shoulder arthroscopy alone|This arm will have patients who receive surgical intervention with arthroscopic rotator cuff repair without administration of BMAC.
62180847|NCT04930003|EXPERIMENTAL|Experimental: Phase 1 Adult-vaccine (A Sample, blind study)|Group 1 (phase 1): 22 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
62180848|NCT04930003|PLACEBO_COMPARATOR|Phase 1 Adult-Placebo (A Sample, blind study)|Group 2 (phase 1): 22 volunteers aged 18-50 years who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
62180849|NCT04930003|EXPERIMENTAL|Phase 2 Adult-Vaccine, twice vaccination (An Open study)|Group 3 (phase 2): 50 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
62180850|NCT04930003|EXPERIMENTAL|Phase 2 Elderly-Vaccine, twice vaccination (An Open study)|Group 4 (phase 2): 50 volunteers from 50 years old and elder who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
62564999|NCT04084951|EXPERIMENTAL|Part 1 Monotherapy Dose Escalation Phase|"In Part 1, SQZ-PBMC-HPV as a monotherapy is administered on Day 1 of every 3 week cycles for up to a year. In Cohort 3 (double-priming), SQZ-PBMC-HPV is also administered on Day 2 of Cycle 1. There are at least 3 groups (Cohorts) in this Phase as follows:~* Cohort 1: specified dose SQZ-PBMC-HPV~* Cohort 2: specified dose SQZ-PBMC-HPV~* Cohort 3: specified dose SQZ-PBMC-HPV double-priming"
62565000|NCT04084951|EXPERIMENTAL|Part 2 Combination Safety Phase|"In Part 2, SQZ-PBMC-HPV in combination with immune checkpoint inhibitors (1) atezolizumab, (2) ipilimumab, (3) nivolumab, or (4) nivolumab and ipilimumab, is administered every 3 weeks for up to a year except atezolizumab may be given up to 2 years; and ipilimumab will be administered four times (in a timeframe less than a year) if safety allows. There are 4 groups (Cohorts) in this Phase as follows:~* Cohort 4: SQZ-PBMC-HPV RP2D (Recommended Phase 2 Dose) plus atezolizumab~* Cohort 5: SQZ-PBMC-HPV RP2D plus ipilimumab~* Cohort 6: SQZ-PBMC-HPV RP2D plus nivolumab~* Cohort 7: SQZ-PBMC-HPV RP2D plus nivolumab and ipilimumab"
62565001|NCT04084951|EXPERIMENTAL|Part 3 Monotherapy Dose Expansion Phase|"In Part 3, SQZ-PBMC-HPV is administered at the RP2D to patients enrolled in HPV16+ cancer-type specific cohorts. There are 4 groups (Cohorts) in this Phase as follows:~* Cohort 8: SQZ-PBMC-HPV RP2D in HPV16+ head and neck cancer patients~* Cohort 9: SQZ-PBMC-HPV RP2D in HPV16+ cervical cancer patients~* Cohort 10: SQZ-PBMC-HPV RP2D in HPV16+ anal cancer patients~* Cohort 11: SQZ-PBMC-HPV RP2D in other HPV16+ cancer patients"
62565002|NCT06399380|EXPERIMENTAL|Manual mobilization group|Manual mobilization of the carpal bones
62565003|NCT06399380|PLACEBO_COMPARATOR|Placebo group|Placebo
62565004|NCT04080427|PLACEBO_COMPARATOR|Placebo capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will administer a single oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to each weekly exposure session (up to 9 sessions) in a standard prolonged exposure treatment protocol comprising 12 session overall.~Half of the participants will receive 7.5mg dronabinol (n=50) and the other half of the participants will receive placebo (n=50)."
62565005|NCT04080427|EXPERIMENTAL|Dronabinol 7.5 milligram oral capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will administer a single oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to each weekly exposure session (up to 9 sessions) in a standard prolonged exposure treatment protocol comprising 12 session overall.~Half of the participants will receive 7.5mg dronabinol (n=50) and the other half of the participants will receive placebo (n=50)."
61995716|NCT03492190||adults|"Select the individual:~Healthy, non-pregnant adults 18-65 years of age, not taking any medication, including NSAIDs, not taking antibiotics within 4 weeks of study, BMI within 18-35 range and stable weight.~Exclusion criteria: children and elderly (over 65), pregnancy, diagnosed with non-communicable or communicable disease, being under restrictive diet, antibiotics within 4 weeks of study, medications within 4 weeks of study. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, adults will be eat the bean enrichment of deuterium for availability protein, collected urine, saliva and blood."
62180851|NCT04930003|EXPERIMENTAL|Phase 2 Adult-Vaccine, single vaccination (An Open study)|Group 5 (phase 2): 50 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml
62180852|NCT04930003|EXPERIMENTAL|Phase 2 Elderly-Vaccine, single vaccination (An Open study)|Group 6 (phase 2): 50 volunteers from 50 years old and elder who will be the QazCoVac-P - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml
62180853|NCT00591591|EXPERIMENTAL|OSA|Persons with suspected obstructive sleep apnea (OSA) undergoning overnight sleep evaluation
62180854|NCT00591591|NO_INTERVENTION|Controls|Healthy controls
62180855|NCT00318097||MAS patients|patient with clinical diagnosis of MAS
62180856|NCT00318097||controls|age matched, tanner stage matched controls
62180857|NCT01238393|EXPERIMENTAL|Ranibizumab|('intravitreal ranibizumab' )
62180858|NCT00831012|EXPERIMENTAL|Group 1|Group 1 will consist of healthy participants receiving an immunization of 10\^3 PFU rDEN3delta30/31-7164
62565006|NCT03442751|EXPERIMENTAL|Epithelium-on CXL Treatment Group|Study eye receives Test Article A, Test Article B, and exposed to cross-linking dose of UVA light generated by the KXL medical device system
62772807|NCT05400421||Device & Algorithm Testing|The gold-standard and new device values will be collected from this group to validate the previously trained system.
62772808|NCT02541786|ACTIVE_COMPARATOR|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
62772809|NCT02541786|EXPERIMENTAL|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
62772810|NCT03233035|PLACEBO_COMPARATOR|placebo group|Intranasal placebo pulverisation
62772811|NCT03233035|ACTIVE_COMPARATOR|Ketamine group|Intranasal ketamine pulverisation
62772812|NCT03703323|EXPERIMENTAL|Rotative thromboelastometry analysis|Evaluation of diagnostic properties of coagulation by rotative thromboelastometry in patient with digestive hemorrhage in predictive value of mortality.
62180859|NCT00831012|EXPERIMENTAL|Group 2|"Group 2A will consist of healthy participants who will receive an immunization of 10\^5 PFU of rDEN3delta30/31-7164 vaccine or placebo. Group 2A participants will be enrolled if less that 90% of Group 1 participants seroconvert to DEN3 by Study Day 42.~Group 2B will consist of healthy participants who will receive an immunization of 10\^1 PFU of rDEN3delta30/31-7164 vaccine or placebo. Group 2B participants will be enrolled if more that 90% of Group 1 participants seroconvert to DEN3 by Study Day 42."
62180860|NCT04080063|EXPERIMENTAL|adapted physical activity|a personalized care will be offered in terms of adapted physical activity
62180861|NCT01319175|EXPERIMENTAL|Training group|
62180862|NCT01113164|EXPERIMENTAL|Ondansetron, Placebo, Sertraline|LL-carriers receiving ondansetron compared to either placebo or sertraline, will result in a significant reduction in alcohol consumption.
62180863|NCT01113164|EXPERIMENTAL|Sertraline, Placebo, Ondansetron|SL and SS-carriers receiving sertraline compared to either placebo or ondansetron, will result in a significant reduction in alcohol consumption.
62180864|NCT02331810|EXPERIMENTAL|SAR113244|Single subcutaneous dose of SAR113244
62180865|NCT02331810|PLACEBO_COMPARATOR|Placebo|Single subcutaneous dose of placebo
62180866|NCT01921114|ACTIVE_COMPARATOR|BioFlo™ PICC|BioFlo™ Peripherally Inserted Central Catheter (PICC)
62180867|NCT01921114|ACTIVE_COMPARATOR|Bard® PowerPICC SOLO2®|Bard® Dual-Lumen PowerPICC SOLO2®
62180868|NCT03146754|EXPERIMENTAL|Stable ADHF patients|Lung ultrasound to access b lines
62180869|NCT03146754|ACTIVE_COMPARATOR|Control Patients|Patients without any cardiopulmonary disease will be control patients for the active subjects, age-matched accordingly.
62180870|NCT04037943|EXPERIMENTAL|Low-dose group|Low-dose group will received 30 grams of walnuts everyday during the study period of 6 months.
62180871|NCT04037943|EXPERIMENTAL|High-dose group|High-dose group will received 60 grams of walnuts everyday during the study period of 6 months.
62180872|NCT04037943|NO_INTERVENTION|Control group|Control group will received non-edible gifts during the study period of 6 months.
62180873|NCT02725528|ACTIVE_COMPARATOR|collagenase injection|This procedure will be performed either in a minor procedure room or the hand clinic as per surgeon's routine practice. Collagenase will be administered with or without local anesthesia. As this is a pragmatic study there may be more than one digit injected at a time just as surgery occurs on more than one digit at a time. A recently published study by Gaston et al confirmed that two concurrent injections of collagenase to 2 affected joints in the same hand are generally well tolerated and the frequency of most adverse events (AEs) is similar to those reported in studies that use single sequential injections.
62565007|NCT03442751|SHAM_COMPARATOR|Sham Treatment/Control Group|Sham eye receives Placebo and and exposed to mock dose of UVA light generated by the KXL medical device system
62565008|NCT05986604|EXPERIMENTAL|TranS-C+MSI|Transdiagnostic Intervention for Sleep and Circadian Dysfunction will be combined with the Memory Support Intervention
62565009|NCT05986604|ACTIVE_COMPARATOR|TranS-C alone|The Transdiagnostic Sleep and Circadian Intervention will be delivered alone
62565010|NCT05533593||AKI Group|
62565011|NCT05533593||Non-AKI Group|
62565012|NCT01283464|ACTIVE_COMPARATOR|Retinol|Retinol 1.0% cream
62565013|NCT01283464|ACTIVE_COMPARATOR|Tretinoin|Tretinoin 0.02% cream
62180874|NCT02725528|ACTIVE_COMPARATOR|limited palmar fasciectomy|The Dupuytren's cord will be excised under local anesthesia in a minor procedure room setting or main operating room under local or general anesthetic depending on the complexity of the disease and the surgeon's routine. As this is a pragmatic study comparison of collagenase injections (novel intervention) to limited palmar fasciectomy as it is actually presently performed in all settings academic or community (local in minor room or general/local anesthetic in the main operating room) will be examined. Surgery will be performed according to the operating surgeon's preferred technique i.e. zig-zag Brunner incision or straight incision with z-plasty closure of the skin.
62180875|NCT05172557|EXPERIMENTAL|Healthy Living Program|In addition to usual clinical Inflammatory Bowel Disease medical care, subjects will participate in a Wellness Program.
62180876|NCT00799136|OTHER|One|Rituxan with EPOCH and Antiretrovirals
62180877|NCT02895243|EXPERIMENTAL|Prehabilitation|
62180878|NCT02895334|EXPERIMENTAL|MyHeartBaby|Caregivers will complete Telehealth Psychosocial Sessions and 4 follow up assessments.
62180879|NCT02895334|NO_INTERVENTION|Standard of Care|Caregivers will complete 4 follow up assessments.
62565014|NCT04320225||Lower vitamin D level group|The vitamin D level is lower than 20 nmol/L.
62565015|NCT04320225||Higher vitamin D level group|The vitamin D level is higher than 20 nmol/L.
62565016|NCT02079623||Pancreatic cancer|Patients with locally advanced pancreatic cancer.
62565017|NCT04074733||Patients with fractures|
62565018|NCT06356714|EXPERIMENTAL|Nocardia Rubra Cell Wall Skeleton +prior Second- or Third-line Regimens|The patient has previously received second- or third-line treatment for advanced or metastatic colorectal cancer and has developed a potentially hazardous SD (Stable Disease) status. They will add to the original treatment regimen of Nocardia Rubra Cell Wall Skeleton.
62565019|NCT06581341|EXPERIMENTAL|Group 1|Combination of transcranial magnetic stimulation and percutaneous tibial nerve stimulation.
62565020|NCT06581341|EXPERIMENTAL|Group 2|Repetitive Transcranial Magnetic Stimulation (rTMS):
62565021|NCT06581341|EXPERIMENTAL|Group 3|Percutaneous tibial nerve stimulation.
62565022|NCT02182492|EXPERIMENTAL|Glucocorticoid|Fluticasone propionate nasal spray
62565023|NCT02182492|EXPERIMENTAL|Clarithromycin|Clarithromycin tablet
62565024|NCT01410097|EXPERIMENTAL|Lifestyle intervention|Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.
62565025|NCT01410097|PLACEBO_COMPARATOR|Diabetes Support and Education (DSE)|It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
62565026|NCT04931732||Diagnosis|
62565027|NCT04931732||Relapse|
62565028|NCT02598232|EXPERIMENTAL|1,414nm Nd:YAG laser|It has high absorption coefficient in water and a short pulse width.
62565029|NCT00707148|ACTIVE_COMPARATOR|Group 2: Control|16 pregnant women to receive: antepartum: saline; postpartum; Tdap vaccine.
62565030|NCT00707148|EXPERIMENTAL|Group 1: Intervention|32 pregnant women to receive: antepartum: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) vaccine; postpartum: saline.
62565031|NCT00707148|ACTIVE_COMPARATOR|Group 3: Control|32 non-pregnant women to receive a single dose of Tdap vaccine.
62565032|NCT02075567|EXPERIMENTAL|Therapy adaption T1DM|
62565033|NCT00482768|EXPERIMENTAL|1|Intervention clinics will receive practice facilitation visits at regular intervals over a 12-month period.
62565034|NCT00482768|NO_INTERVENTION|2|Control clinics will deliver usual care for patients with diabetes.
62565035|NCT00937976|OTHER|Control-delayed periodontal therapy|
62565036|NCT00937976|OTHER|Intensive Periodontal Therapy|
62565037|NCT02291042|EXPERIMENTAL|Suppository|Patients will receive a single antispasmodic muscarinic suppository after induction of anesthesia but before insertion of urological scope for surgery. The suppository is composed of Belladonna (16.2 mg) and Opium (30 mg) in a water soluble base manufactured as Belladonna and Opium Supprettes.
62565038|NCT02291042|NO_INTERVENTION|Control|Patients will be provided with routine care.
62565039|NCT02063477|PLACEBO_COMPARATOR|Product one|150 mg (maltodextrin)/day (75 mg maltodextrin included in 280 mg/gelule; 2 times/day: morning and evening) of Placebo plus Dietary Approaches to Stop Hypertension (DASH)
62565040|NCT02063477|ACTIVE_COMPARATOR|Product two|150 mg Oligopin/day (75mg Oligopin included in 280mg/gelule; 2 times/day: morning and evening) of Oligopin® plus Dietary Approaches to Stop Hypertension (DASH)
62565041|NCT00736697|EXPERIMENTAL|1|
62565042|NCT04610190|EXPERIMENTAL|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 20-30 minutes functional gait training on varied environments with device.
62565043|NCT05638126|EXPERIMENTAL|Part 1|HRS-1780 table or placebo single dose
62565044|NCT05638126|EXPERIMENTAL|Part 2|HRS-1780 table or placebo single dose with food effect
62565045|NCT05638126|EXPERIMENTAL|Part 3|HRS-1780 table or placebo multiple dose
62565046|NCT05232383|ACTIVE_COMPARATOR|Wp|
62565047|NCT05232383|ACTIVE_COMPARATOR|Wn|
62565048|NCT05232383|ACTIVE_COMPARATOR|Gn|
62565049|NCT05232383|ACTIVE_COMPARATOR|Gp|
62565050|NCT05232383|ACTIVE_COMPARATOR|Rp|
62565051|NCT05232383|ACTIVE_COMPARATOR|Rn|
62565052|NCT00933023|EXPERIMENTAL|Mild steroid|1%hydrocortisone for 8 weeks
62565053|NCT00933023|EXPERIMENTAL|Potent Steroid|
62565054|NCT04857658|ACTIVE_COMPARATOR|extraction treatment|patients will be referred for extraction of the upper and lower first premolars to relieve the crowding.
62565055|NCT04857658|NO_INTERVENTION|non-extraction treatment|Leveling and alignment of the moderate crowding will be performed through a recall visits of 4 weeks for wire activation. inter-proximal reduction step might be done if needed.
62565056|NCT01707394|EXPERIMENTAL|Group 1: Apixaban (low dose)|
62565057|NCT01707394|EXPERIMENTAL|Group 2A: Apixaban (low dose)|
62565058|NCT01707394|EXPERIMENTAL|Group 2B: Apixaban (low dose)|
62565059|NCT01707394|EXPERIMENTAL|Group 3: Apixaban (low dose)|
62565060|NCT01707394|EXPERIMENTAL|Group 4: Apixaban (low dose)|
62565061|NCT01707394|EXPERIMENTAL|Group 5: Apixaban (low dose)|
62565062|NCT01707394|EXPERIMENTAL|Group 2A (higher dose): Apixaban (low dose)|
62565063|NCT03848260|EXPERIMENTAL|Determine device feasibility|"by evaluating efficacy and safety of the device prototype. Test the device one time (duration: 60-120 mins/each time) and second time within 12 months.~Intervention: using the magnetic device prototype"
62565064|NCT02162537|OTHER|Arm A (standard arm)|Arm A: Initial Cerebral Radiotherapy and Chemotherapy (Cisplatin and pemetrexed with or without Bevacizumab)
62565065|NCT02162537|OTHER|Arm B (experimental arm)|Arm B: Chemotherapy (Cisplatin and pemetrexed with or without Bevacizumab) and Cerebral Radiotherapy if clinical or radiological progression brain
62565066|NCT00576589|EXPERIMENTAL|CE-326,597|
62565067|NCT00576589|PLACEBO_COMPARATOR|Placebo|
62565068|NCT02972879|ACTIVE_COMPARATOR|Therapeutic Modalities|"* Group 1: Metal orthotic, keeping 0º of the extension of the proximal interphalangeal joint, during all day, for 5 weeks, stopping the use only for bathing~* Group 2: 10 LLLT sessions applications on the A1 pulley and lump formed on the flexor tendon of the the affected finger; Two sessions per week, five weeks of treatment.~* Group 3: Paraffin bath 2 times a week for 20 minutes (total of 10 sessions)."
62565069|NCT02972879|ACTIVE_COMPARATOR|Corticosteroid injection|Group 4: Corticosteroid injection in the A1 pulley, 1 application.
62565070|NCT02473172|EXPERIMENTAL|Pressure Support Ventilation|Assisted mechanical ventilation
62565071|NCT02473172|EXPERIMENTAL|Neurally Adjusted Ventilatory Assist|Assisted mechanical ventilation
62565072|NCT01598844||High risk patients with aortic stenosis|Transapical aortic valve implantation using a transcatheter heart valve for aortic stenosis.
62565073|NCT01598844||High risk patients with AI|Transapical aortic valve implantation using a transcatheter heart valve for aortic regurgitation.
62565074|NCT02585947|EXPERIMENTAL|tenofovir for 24 weeks|"* prophylactic (preemptive) treatment~* 300mg for 24 weeks~* once daily"
62565075|NCT02585947|EXPERIMENTAL|tenofovir for 48 weeks|"* prophylactic (preemptive) treatment~* 300mg for 48 weeks~* once daily"
62565076|NCT02464007|EXPERIMENTAL|sSIFN-co|Dose escalation of rSIFN-co
62565077|NCT03920124|EXPERIMENTAL|High intensity interval exercise|Completion of four separate step and walk-based high intensity interval exercise sessions, followed by completion of six week unsupervised (at home) high intensity interval exercise intervention
62565078|NCT01928472|EXPERIMENTAL|Group A|H7N9c low dose with adjuvant
62565079|NCT01928472|EXPERIMENTAL|Group B|H7N9c medium dose with adjuvant
62565080|NCT01928472|EXPERIMENTAL|Group C|H7N9c high dose with adjuvant
62565081|NCT01928472|EXPERIMENTAL|Group D|H7N9c high dose without adjuvant
62565082|NCT02174692|EXPERIMENTAL|Elderly|"Exercise One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum~2 minutes rest between sets"
62565083|NCT02174692|EXPERIMENTAL|Young|"Exercise~One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum~2 minutes rest between sets"
62565084|NCT04965038|ACTIVE_COMPARATOR|Thrombolysis (interventional study)|Alteplase (0.9 mg per kg body weight; 10% as bolus; remaining over one hour) will be administered intravenously within 4.5 hours of symptom onset
62565085|NCT04965038|PLACEBO_COMPARATOR|Placebo (interventional study)|Placebo (0.9 mg per kg body weight; 10% as bolus; remaining over one hour) will be administered intravenously within 4.5 hours of symptom onset
62565086|NCT04965038|NO_INTERVENTION|Observational study|The prospective REVISION observational study will enroll patients within 12 hours of symptom onset
62565087|NCT00444535|EXPERIMENTAL|Oral lapatinib tablets in combination with IV bevacizumab|1500 mg oral lapatinib (once daily) plus 10 mg/kg intravenous bevacizumab (every two weeks)
62565088|NCT01593774|EXPERIMENTAL|Melatonin|Tablet melatonin 3 mg/day at 9 pm as intervention group for eight week
62565089|NCT01593774|PLACEBO_COMPARATOR|Placebo|Placebo (with the same shape and taste as melatonin) at 9 pm as control group
62565090|NCT03102996|EXPERIMENTAL|Verum|Patients will receive Nephrotrans.
62565091|NCT03102996|PLACEBO_COMPARATOR|Placebo|Patients will receive Placebo.
62565092|NCT05953051|EXPERIMENTAL|ACLr with bone/PrP-composite|"During surgery, the drilled bone debris is collected in a sterile filtered chamber.~Then the bone debris is mixed with PrP. After fixation of the graft the composite is inserted into the drilled tunnel at the interface between tendon to bone. The intraarticular aperture sites are sealed by use of fibrin that is previously gathered out of the PrP as well."
62565093|NCT05953051|ACTIVE_COMPARATOR|ACLr standard|No insertion of additional material after ACL graft fixation.
62565094|NCT05932537||subcutaneous contraceptive implants|patients who have benefited from explantation of a subcutaneous contraceptive implant in the gynecology operating room
62565095|NCT01545167||African Americans with pancreatitis|pancreatitis
62565096|NCT01545167||African Americans without Pancreatitis controls|people without pancreatitis
62565097|NCT04361773|ACTIVE_COMPARATOR|Photobiomodulation group|In this group, PBM will be applied daily using LED devices until the lesion presents healthy granulation tissue, absence of necrosis and purulent secretion and, therefore, is suitable for primary closure, closure by flap or graft or for healing by second intention. At this point, the protocol will be finalized.
62180880|NCT04493645|ACTIVE_COMPARATOR|Standard of Care (SOC)|Participants will be randomized to receive standard of care rehabilitation (SOC) for a period of 6 weeks.The investigators will prospectively follow participants assigned to the SOC group for 24 months following completion of their assigned SOC intervention.
62180881|NCT04493645|EXPERIMENTAL|Foot Intensive Rehabilitation (FIRE)|Participants will be randomized to receive foot intensive rehabilitation (FIRE) for a period of 6 weeks.The investigators will prospectively follow participants assigned to the FIRE group for 24 months following completion of their assigned SOC intervention.
61995717|NCT03492190||Children|"Fifty children will be recruited from ages varying from 1 to 3 years and of both sexes. Children who use medications, who do not habitually consume beans, will be excluded and when there is no explicit written authorization from the parents or guardians.~All the children with different status of nutrition will be eaten the beans. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, children will be eat the bean enrichment of deuterium for availability protein, collected urine or saliva depend on the best biological samples of pilot study (adult)."
62180882|NCT01175564|EXPERIMENTAL|Active|Each cohort will have 9 volunteers that will receive TC-5214
62565098|NCT04361773|SHAM_COMPARATOR|Sham group|Sham group participants will receive the application of the disconnected device, for the same period. The characteristic sound of the device will be activated by means of recording.
62565099|NCT00722969|EXPERIMENTAL|A|
62180883|NCT01175564|PLACEBO_COMPARATOR|Placebo|Each cohort will have 3 volunteers that will receive placebo
62180884|NCT02371720|EXPERIMENTAL|Adults - Mobile DOT|Subjects with SCD that are older than 21 years old will receive comprehensive medication adherence management (Mobile DOT) after 1 month assessment period. The subjects will receive the Mobile DOT intervention for 24 months.
62180885|NCT02371720|ACTIVE_COMPARATOR|Adults - standard of care then Mobile DOT|Subjects with SCD that are older than 21 years old will receive standard of care for the first 12 months. They will then crossover to the comprehensive medication adherence management plan (Mobile DOT) after 1 month assessment period for the remaining 12 months.
62180886|NCT02371720|EXPERIMENTAL|Children - Mobile DOT|Subjects with SCD that are younger than 21 years old will receive comprehensive medication adherence management (Mobile DOT) after 1 month assessment period. The subjects will receive the Mobile DOT intervention for 24 months.
62565100|NCT05712083|EXPERIMENTAL|Treatment Group|This is a single arm clinical trial.
62565101|NCT03266861||Patients undergoing exercise oximetry|Patients with PAD referred for treadmill testing and exercise oximetry
62565102|NCT02618291|EXPERIMENTAL|Active Geriatric Evaluation (AGE tool)|The Active Geriatric Evaluation is a comprehensive assessment and management tool consisting of a 20-minute clinical screening instrument (Brief Assessment Tool, BAT) to identify 8 geriatric syndromes, and complementary diagnostic evaluations and propositions of management \& treatment for each syndrome.
62565103|NCT02618291|ACTIVE_COMPARATOR|Usual care|"No specific intervention will be provided to the patients, except what family practitioners (FPs) usually do. In this regard, it is possible that some FPs might use structured interventions similar to the AGE tool. This will be neither encouraged nor discouraged. FPs in the usual care arm will be asked to perform one BAT after 2 years of follow-up, at the final patient visit."
62565104|NCT02259010|EXPERIMENTAL|Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg|All participants were to complete Part A prior to Part B. Part A: Alisertib 30 mg, tablets, orally, on Days 1 and 10 plus itraconazole, 200 mg, oral solution, once daily on Days 5 to 13. Part A and B were separated by a washout period of at least 10 days (and up to 4 weeks). Part B: Alisertib 50 mg, tablets, orally, twice daily, for 7 days in 21-day cycles until disease progression or unacceptable toxicity (up to 16 cycles).
62565105|NCT01842230|EXPERIMENTAL|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|
62565106|NCT01842230|ACTIVE_COMPARATOR|Telmisartan 80mg and S-amlodipine 5mg|
61995718|NCT03492190||Elderly|Fifty individuals of both sexes will be recruited, previously evaluated by complete clinical / laboratory examination and medical history. The elderly will be excluded from antiinflammatory, chemotherapeutic, corticoid, allergy and bean aversion or antibiotic therapy. These drugs could interfere with protein bioavailability. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, elderly will be eat the bean enrichment of deuterium for availability protein, collected urine or saliva depend on the best biological samples of pilot study (adult).
61995719|NCT06338345|EXPERIMENTAL|Piperacillin Tazobactam|75 patients under VA-ECMO receiving a novel administration of Piperacillin Tazobactam.
61995720|NCT06338345|EXPERIMENTAL|Cefepime|75 patients under VA-ECMO receiving a novel administration of Cefepime.
61995721|NCT06338345|EXPERIMENTAL|Meropenem|75 patients under VA-ECMO receiving a novel administration of Meropenem.
61995722|NCT04686864|EXPERIMENTAL|Parent Support Group|Support and psychoeducation in a group setting for parents who have a child or adolescent with an eating disorder.
61995723|NCT01941446|EXPERIMENTAL|pre-generated treatment scheme|Treatment A: Eravacycline (TP-434) 1.5 mg/kg administered intravenously over 60 minutes and one placebo oral tablet
61995724|NCT01941446|PLACEBO_COMPARATOR|Pre-generated tratment scheme|Treatment B: Placebo (0.9% sodium chloride) administered intravenously over 60 minutes and one moxifloxacin 400 mg oral tablet
61995725|NCT01941446|PLACEBO_COMPARATOR|Moxifloxacin|Treatment C: Placebo (0.9% sodium chloride) administered intravenously over 60 minutes and one placebo oral tablet
61995726|NCT03978364|EXPERIMENTAL|azacitidine|"azacitidine~azacitidine 75mg/m2，iH，qd， d1-7"
62565107|NCT06250621|EXPERIMENTAL|Test Group (GD)|in this group were considered implant sites treated with a digitally guided surgery procedure
62565108|NCT06250621|ACTIVE_COMPARATOR|Control Group (FH)|in this group were considered implant sites treated without a digitally guided surgery procedure
62565109|NCT02253589|NO_INTERVENTION|Waiting list|Participants will assessment only during study, same intervention after posttest
61995727|NCT03978364|ACTIVE_COMPARATOR|azacitidine combined HHT|azacitidine+HHT azacitidine 75mg/m2，iH，qd， d1-7 HHT 3mg/m2,ivdrip qd,d1-3
61995728|NCT04601545|EXPERIMENTAL|VR therapy group|Pulmonary rehabilitation supplemented by VR therapy
62565110|NCT02253589|EXPERIMENTAL|Intervention|Participants assigned to this arm will receive the modified ASSIST-linked Brief Intervention
62565111|NCT04092556|ACTIVE_COMPARATOR|tDCS (M1)|The participants will be submit to tDCS applied over the motor cortex (M1)
62565112|NCT04092556|ACTIVE_COMPARATOR|tDCS (Cerebellar cortex)|The participants will be submit to tDCS applied over the cerebellar cortex
62565113|NCT04092556|SHAM_COMPARATOR|Sham stimulation|The participants will be submit to sham stimulation
61995729|NCT04601545|ACTIVE_COMPARATOR|Active Control Group|Pulmonary rehabilitation supplemented by Schultz Autogenic Training
62180887|NCT02371720|ACTIVE_COMPARATOR|Children - standard of care then Mobile DOT|Subjects with SCD that are younger than 21 years old will receive standard of care for the first 12 months. They will then crossover to the comprehensive medication adherence management plan (Mobile DOT) after 1 month assessment period for the remaining 12 months.
62565114|NCT04425057|EXPERIMENTAL|Interval training|Physiotherapy program during two months: Interval training at a high intensity, inlcuding a warm-up and a cool-down. Aerobic exercises, resistance exercises, stretching
62565115|NCT04425057|NO_INTERVENTION|Control group|No physiotherapy
62180888|NCT01888809|EXPERIMENTAL|Comprehensive preventive services|Combined comprehensive services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
62565116|NCT04615273|EXPERIMENTAL|Lonapegsomatropin|Lonapegsomatropin administered once-weekly by subcutaneous injection
62565117|NCT04615273|PLACEBO_COMPARATOR|Placebo|Placebo for Lonapegsomatropin administered once-weekly by subcutaneous injection
62565118|NCT04615273|ACTIVE_COMPARATOR|Somatropin|Somatropin administered once-daily by subcutaneous injection
62565119|NCT06214195|EXPERIMENTAL|treatment group|Provide preventive treatment with Shengmai San
62565120|NCT06214195|NO_INTERVENTION|control group|No preventive intervention
62565121|NCT00600730|EXPERIMENTAL|1|Hyperinsulinemic euglycemic clamp with fMRi
62565122|NCT00600730|EXPERIMENTAL|2|Hyperinsulinemic hypoglycemic clamp with fMRI
61995730|NCT04297930||Paul Glaucoma Implant Surgery|Patients who had surgery with the Paul Glaucoma Implant
61995731|NCT02636465||obese healthy adults|persons with BMI\> 30 kg/m2
61995732|NCT02636465||obese COPD patients|COPD-patients (GOLD I-IV Group A-D) with BMI\> 30 kg/m2
61995733|NCT02636465||OHS-patients|patients with defined OHS: BMI\>30 kg/m2 and sleep related breathing disease, no COPD
62180889|NCT01888809|ACTIVE_COMPARATOR|Screening and referral|Annual screening and referral for services as needed
62180890|NCT01584323|ACTIVE_COMPARATOR|Pomegranate pills|treatment with pomgranate pills to women suffering preterm premature rupture of membranes
62565123|NCT04596774||Group 1|Group 1 patients were applied traditional approach. Patients received intraoperative 10 mL/kg/h IV izolen infusion. Opioids and PONV prophylaxis were applied when required.
62565124|NCT04596774||Group 2|Group 2 received Enhanced Recovery After Surgery (ERAS) approach. Patients did not preoperatively smoke for 48 hours, drank clear liquids until the last 2 hours and received 6 mL/kg/h IV izolen infusion intraoperatively. In these; gastric aspiration was applied before extubation, PONV prophylaxis was supported routinely, and patient controlled analgesia was added to the routine analgesia plan for the first postoperative 48 hours.
62565125|NCT01730053|ACTIVE_COMPARATOR|Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received rosuvastatin 20 mg over-encapsulated tablet orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablet orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
62565126|NCT01730053|ACTIVE_COMPARATOR|Ezetimibe 10 mg + Rosuvastatin 10 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
62565127|NCT01730053|EXPERIMENTAL|Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg SC injection Q2W, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
62565128|NCT01730053|ACTIVE_COMPARATOR|Rosuvastatin 40 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received rosuvastatin 40 mg over-encapsulated tablet orally QD, placebo for alirocumab Q2W SC injection, and placebo for ezetimibe QD over-encapsulated tablet orally added to stable LMT for 24 weeks.
62565129|NCT01730053|ACTIVE_COMPARATOR|Ezetimibe 10 mg + Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for alirocumab Q2W SC injection added to stable LMT for 24 weeks.
62565130|NCT01730053|EXPERIMENTAL|Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg Q2W SC injection, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
62565131|NCT02754804||PAD patients|Patients with grade 1 claudication Measurement of biomechanic parameters while walking on treadmill
62565132|NCT01706341|ACTIVE_COMPARATOR|acetate Ringer's solution|Administering acetate Ringer's solution that contains no glucose as an initial infusion A total infusion volume of acetate Ringer's solution is 1500ml
62565133|NCT01706341|ACTIVE_COMPARATOR|acetate Ringer's solution with 1% glucose|Administering the acetate Ringer's solution that contains 1% glucose as an initial infusion A total infusion volume of the acetate Ringer's solution containing 1% glucose is 1500ml (containing 15g of glucose)
62565134|NCT01004497|EXPERIMENTAL|Modified Hyper-CVAD + Dasatinib|Dasatinib: 100 mg once daily, PO, for 4 weeks Cyclophosphamide: 300 mg/m2, IV, every 12 hours, days 1\~3 Vincristine: 1.4 mg/m2/day (maximum 2 mg/day), IV, days 4 \& 11 Daunorubicin: 45 mg/m2/day, IV, days 4 \& 11 Dexamethasone: 40 mg/day, IV, days 1\~4 \& days 11\~14 Cytarabine: 2 g/m2, IV, every 12 hours, days 1\~5 Mitoxantrone: 12 mg/m2/day, IV, days 1\~2
62565135|NCT04280692|EXPERIMENTAL|Group 1: PfSPZ 6,400|"Group 1 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 6,400 sporozoites.~Group 1 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg).~Group 1 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)"
62565136|NCT04280692|EXPERIMENTAL|Group 1: PfSPZ 12,800|"Group 2 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 12,800 sporozoites~Group 2 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg).~Group 2 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)"
62565137|NCT04280692|EXPERIMENTAL|Group 3: PfSPZ 25,600|"Group 3 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 25,600 sporozoites~Group 3 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg).~Group 3 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)"
62565138|NCT05520073|EXPERIMENTAL|Lactobacillus and Vitamin C|Lactobacillus and Vitamin C supplements daily self-administration for 14 days
62565139|NCT05520073|PLACEBO_COMPARATOR|Vitamin C|Vitamin C supplements daily self-administration for 14 days
62565140|NCT02083744|ACTIVE_COMPARATOR|Control Group|Usual care group - patients will receive scales to take home and heart failure literature for self-monitoring of heart failure. Patients will complete final questionnaires
62565141|NCT02083744|EXPERIMENTAL|Psychoeducational Counseling|"1-on-1 psychoeducation session conducted by a bilingual research nurse at the clinic site or in the patient's home. Patients will receive a scale to measure weight, a diary to record weight and symptoms of heart failure, and telephone follow-up from the research nurse to reinforce the content of the education program every other week.~Focus-groups - Perception of the intervention will be assessed with two focus groups."
61995734|NCT03532997|EXPERIMENTAL|Intervention|"The investigators aim to introduce patients with advanced cancer to supportive care resources, including specialty palliative care, through a novel app called ELOS (stands for extra layer of support) in a prospective cohort study. The investigators will compare participant acceptance of this new electronic tool to industry standards and follow ultimate referrals to outpatient palliative care compared to historical, matched controls."
61995735|NCT00824863|EXPERIMENTAL|one arm|All 10 patients receive ketoconazole 2% foam in the uncontrolled study.
61995736|NCT01858012||HCV infection|patients with hepatitis C infection
61995737|NCT01858012||non-HCV infection|healthy controls
61995738|NCT04952194|EXPERIMENTAL|Stalevo group|Stalevo is taken five times a day, three hours apart. Compare the incidence of dyskinesia.
62565142|NCT01068860|EXPERIMENTAL|Canakinumab 150 mg + Metformin|Eligible participants received a single subcutaneous injection Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening
62565143|NCT01068860|PLACEBO_COMPARATOR|Placebo + Metformin|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening
62565144|NCT01068860|EXPERIMENTAL|Canakinumab 150 mg + Metforimin + Sulfonylurea|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
62565145|NCT01068860|PLACEBO_COMPARATOR|Placebo + Metforimin + Sulfonylurea|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
62565146|NCT01068860|EXPERIMENTAL|Canakinumab 150 mg + Met + Sulfonyl + Thiazolidinedione|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose, and a Thiazolidinedione (Thiaz)at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
62565147|NCT01068860|PLACEBO_COMPARATOR|Placebo + Met + Sulfonyl + Thiazolidinedione|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose, and a Thiazolidinedione (Thiaz)at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
62565148|NCT01068860|EXPERIMENTAL|Canakinumab 150 mg + Insulin|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus for 3 months prior to screening and be on a stable dose of Insulin, 2 insulin injections per day for a total daily dose of less than 100 U with or without Metformin (Met)for 3 months prior to screening
61995739|NCT04952194|ACTIVE_COMPARATOR|Control group|Carbidopa and Levodopa Sustained-release Tablets is taken five times a day, three hours apart. Compare the incidence of dyskinesia.
61995740|NCT02250196|ACTIVE_COMPARATOR|PEG-Asc|group 1 (PEG-Asc, N=100) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
61995741|NCT02250196|ACTIVE_COMPARATOR|SPMC 2|group 2 (SPMC 2, N=100) received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
61995742|NCT06031974||DISCO Intervention|"Patients included to the DISCO-CT study and randomized to the experimental arm, ie. subjected to optimal medical treatment in accordance with European Society of Cardiology recommendations + DASH diet (Dietary Approaches to StopHypertension) and strict monitoring of eating and lifestyle behaviors~n=46"
62180891|NCT01584323|PLACEBO_COMPARATOR|placebo pills|treatment with placebo to women with preterm premature rupture of membranes
62180892|NCT01993628|EXPERIMENTAL|Alzheimer's disease (AD)|Rey figure test and MRI
62180893|NCT01993628|EXPERIMENTAL|Lewy body's dementia (LBD)|Rey figure test and MRI
62565149|NCT01068860|PLACEBO_COMPARATOR|Placebo + Insulin|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus for 3 months prior to screening and be on a stable dose of Insulin, 2 insulin injections per day for a total daily dose of less than 100 U with or without Metformin (Met)for 3 months prior to screening
62565150|NCT01068860|EXPERIMENTAL|Canakinumab 150 mg in patients with IGT|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg. Patients must have had Impaired Glucose Tolerance (IGT) as defined by the World Health Organization (WHO) criteria confirmed at screening visit.
61995743|NCT06031974||Control|"Patients included to the DISCO-CT study and randomized to the control arm, ie. subjected to optimal medical treatment in accordance with European Society of Cardiology recommendations alone~n=46"
61995744|NCT03145441|EXPERIMENTAL|CytoSorb®|The CytoSorb® filter will be installed into the cardiopulmonary bypass circle during cardiac transplantation in this study group (30 patients)
61995745|NCT03145441|NO_INTERVENTION|Control|No filter will be installed into the cardiopulmonary bypass circle in this group (30 patients).
61995746|NCT01709695|EXPERIMENTAL|guanfacine hydrochloride XR|Flexible dose titration of guanfacine extended release (Intuniv; active medication). The medication is titrated in doses from 1 - 4 mg once daily
61995747|NCT01709695|PLACEBO_COMPARATOR|Placebo Group|Flexible dose titration of placebo
61995748|NCT03168672|OTHER|Global ICON|The study device is the GLOBAL ICON stemless humeral component, consisting of the Anchor Plate and Humeral Head.
61995749|NCT04895592|EXPERIMENTAL|Arm A (SRS, low dose dexamethasone, surgery)|Patients undergo SRS to the brain metastasis for 1-3 fractions over 1-5 days. Patients also receive low dose dexamethasone PO or IV for 2-21 days until the day of surgical resection. Patients then undergo surgical resection.
62565151|NCT01068860|PLACEBO_COMPARATOR|Placebo in patients with IGT|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had Impaired Glucose Tolerance (IGT) as defined by the World Health Organization (WHO) criteria confirmed at screening visit.
62565152|NCT02663869||HIV Aging-Young|200 patients
62565153|NCT02663869||HIV Aging-Old|200 patients
62565154|NCT02663869||controls|1200 patients
62565155|NCT05969184|EXPERIMENTAL|four-drug treatment group|"CDK4/6 inhibitor (Qilu): 125mg, oral Qd from the 1st to the 21st day of the 28 day cycle Trastuzumab (Hanquyou): on the first day of the 21 day cycle, the initial dose was 8mg/kg, and the intravenous infusion was 90 minutes; Every 3 weeks thereafter, the dose is 6mg/kg, and the intravenous infusion is 30\~90 minutes Pertuzumab: on the first day of the 21 day cycle, the initial dose was 840mg, intravenous infusion was 60 minutes, and then once every 3 weeks, the dose was 420mg, and the infusion time was 30-60 minutes.~Letrozole selected by the doctor: 2.5mg, oral Q24H or exemestane from the 1st to the 21st day of the 21 day cycle: 25mg, oral Q24H from the 1st to the 21st day of the 21 day cycle. The efficacy is evaluated every 2 months (CR, PR, SD, PD)."
62565156|NCT04083638||Group 1|Control group
62565157|NCT04083638||Group 2|Feeding will not stop during the transfusion
62565158|NCT04145154|EXPERIMENTAL|Plasma|Subjects to whom platelet rich plasma is applied
61995750|NCT04895592|EXPERIMENTAL|Arm B (SRS, high dose dexamethasone, surgery)|Patients undergo SRS to the brain metastasis for 1-3 fractions over 1-5 days. Patients also receive high dose dexamethasone PO or IV for 2-21 days until the day of surgical resection. Patients then undergo surgical resection.
62565159|NCT04145154|NO_INTERVENTION|Advanced cure|Subjects to whom advanced healing is performed
62565160|NCT01890681|ACTIVE_COMPARATOR|Back to Sleep|"The Back to Sleep arm will encourage safe sleep practices to reduce the risk of Sudden Infant Death Syndrome (SIDS) in child care and at home. This include:~1. center and family self-assessment,~2. center intervention materials delivered several times over the 6-month period, and;~3. parent handouts~After the intervention period, comparator centers will receive an abbreviated version of the Baby NAP SACC intervention."
62565161|NCT01890681|EXPERIMENTAL|Baby NAP SACC|"The intervention will include four complementary and mutually reinforcing components:~1. center and family self-assessment;~2. targeted technical assistance by Baby NAP SACC consultant for providers and parents;~3. training workshops for child care providers; and~4. parent outreach and support."
62565162|NCT03588403||Arm A:Tomotherapy|Patients with non-disseminated nasopharyngeal carcinoma receiving Tomotherapy.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.
61995751|NCT01869192|ACTIVE_COMPARATOR|Arm A|Arm A: Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then surgery, then Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment
62180894|NCT05654805|ACTIVE_COMPARATOR|Supplementation with insoluble cereal fiber|Drinking powder supplement providing 7,5 grams of insoluble fiber per sachet, taken twice daily over a period of 12 weeks without any changes in dietary behavior, caloric intake or physical activity
62180895|NCT05654805|PLACEBO_COMPARATOR|Supplementation with placebo|Drinking powder supplement providing no insoluble fiber, but maltodextrin, taken twice daily over a period of 12 weeks without any changes in dietary behavior, caloric intake or physical activity
62565163|NCT03588403||Arm B: IMRT|Patients with non-disseminated nasopharyngeal carcinoma receiving IMRT.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.
62565164|NCT05002231|EXPERIMENTAL|Losmapimod 15 mg oral tablet in healthy subjects (Treatment Regimen A)|Subjects will be randomized to 1 of 6 treatment sequences to receive one 15 mg tablet of losmapimod administered orally under fasted conditions. Subjects will fast overnight (nothing to eat or drink except water) for at least 10 hours before each study drug administration. Subjects will remain fasted for 4 hours after dosing with study drug. Washout period of 48 hours between dosing.
62565165|NCT05002231|EXPERIMENTAL|Losmapimod two 7.5 mg oral tablets in healthy subjects (Treatment Regimen B)|Subjects will be randomized to 1 of 6 treatment sequences to receive two 7.5 mg tablets of losmapimod administered orally under fasted conditions. Subjects will fast overnight (nothing to eat or drink except water) for at least 10 hours before each study drug administration. Subjects will remain fasted for 4 hours after dosing with study drug. Washout period of 48 hours between dosing.
62565166|NCT05002231|EXPERIMENTAL|Losmapimod one 15 mg oral tablet in healthy subjects (Treatment Regimen C)|Subjects will be randomized to 1 of 6 treatment sequences to receive one 15 mg tablet of losmapimod administered orally under fed conditions. Subjects will fast overnight (nothing to eat or drink except water) for at least 10 hours before breakfast and will receive a high-fat breakfast approximately 30 minutes before dose administration. Subjects must consume the meal within 25 minutes or less. Washout period of 48 hours between dosing.
62565167|NCT00256074|OTHER|Standard Therapy Group|Standard therapy group. Will receive high carbohydrate, low fat enteral feeding, (16.7% protein, 30% fat and 53.3% carbohydrate). The target rate is determined by the treating physician and dietician, for a minimum of 5 days following randomisation.
61995752|NCT01869192|ACTIVE_COMPARATOR|Arm B|Arm B: Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then surgery, then Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment
61995753|NCT03250468|EXPERIMENTAL|CBT-I|Participants randomized to receive the intervention will attend 6 weekly group-based CBT-I sessions. Each 90-minute group will include 6-12 participants.
61995754|NCT03250468|NO_INTERVENTION|Wait-list control|The wait-list control group will receive treatment as per our standard cardiac rehabilitation program. After completion of the 3-month follow-up questionnaire, wait-list control participants may take part in the intervention.
61995755|NCT04368884||Healthcare workers|The healthcare workers who are being tested for COVID-19 would be included in this group
61995756|NCT04368884||OPD patients|Individuals outside from the hospital who are coming for the COVID-19 testing will be included in this group
61995757|NCT04368884||IPD COVID-19 cases|Admitted positive cases of COVID-19 in the hospital will be included in this group
61995758|NCT02733536|EXPERIMENTAL|Scenario A|manikin with normal standard airway
61995759|NCT02733536|EXPERIMENTAL|Scenario B|Cervical immobilization using a standard Patriot cervical extraction collar (Oessur Americas, Foothill Ranch, CA, USA), applied to the manikin's neck by an instructor.
62180896|NCT02999737|OTHER|Platelet Rich Plasma for 4 sessions|Autologous Platelet Rich Plasma injected in the scalp monthly x 3 then every 3 months x 1
61995760|NCT02733536|EXPERIMENTAL|Scenario C|Cervical immobilization using a vacuum mattress (Ferno-Washington, Inc. Wilmington, OH, USA), applied to the manikin's neck by an instructor
62180897|NCT02999737|OTHER|Platelet rich plasma for 2 sessions|Autologous Platelet Rich Plasma injected in the scalp every 3 months
62180898|NCT05352971||Patients with multiple sclerosis|
61995761|NCT02469116|EXPERIMENTAL|Arm 1: (docetaxel, carboplatin, pegylated G-CSF)|"* Docetaxel intravenously over 1 hour followed by carboplatin intravenously over 30 minutes-1 hour on day 1 every 21 days for maximum of 6 cycles~* Pegylated G-CSF on day 2 every 21 days for maximum of 6 cycles"
61995762|NCT03848845|EXPERIMENTAL|Part 1: Dose escalation|Subjects will receive belantamab mafodotin at escalating doses of 2.5 milligrams per kilograms (mg/kg) and 3.4 mg/kg along with 200 mg pembrolizumab via intravenous (IV) infusion on Day 1 of each 21-day cycle to establish RP2D. There will be maximum of 35 cycles of combination treatment.
61995763|NCT03848845|EXPERIMENTAL|Part 2: Expansion cohort|Subjects will receive belantamab mafodotin at RP2D along with 200 mg pembrolizumab via IV infusion on Day 1 of each 21-day cycle. There will be maximum of 35 cycles of combination treatment.
61995764|NCT02534831|EXPERIMENTAL|Soft Tissue Manual Therapy Protocol|Soft tissue manual therapy protocol. Seven techniques of manual therapy in 30 minutes.
61995765|NCT01831232|EXPERIMENTAL|Treatment (pravastatin sodium, idarubicin, and cytarabine)|Patients receive pravastatin sodium PO QD on days 1-8, idarubicin IV over 10-15 minutes on days 4-6, and cytarabine IV continuously on days 4-7. Treatment repeats every 28-56 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
61995766|NCT05520008|EXPERIMENTAL|Active group (AG)|Active group (AG). The AG (n=15) will play game-based foot and ankle exercises via a mobile application on a tablet. They will be asked to wear a foot sensor that is connected to the tablet during the exercise. They will be asked to play the game for 5-minutes, daily. They will do this in conjunction with wearing a compression garment for a period of 4 weeks.
61995767|NCT05520008|NO_INTERVENTION|Control group (CG)|Control Group (CG). The CG (n=15) will wear a compression garment for four weeks.
61995768|NCT03179176|EXPERIMENTAL|HFUD utilisation|
61995769|NCT05402995|ACTIVE_COMPARATOR|Standard operative debridement and spanning external fixator (reference/control group)|This is the standard of care management. Patient will go to the operating room (OR) first for irrigation and debridement with normal saline and external fixation. Will return to OR at a later date for definitive fixation.
61995770|NCT05402995|EXPERIMENTAL|Spanning external fixator with Irrisept irrigation (treatment group 1)|Patient will go to the operating room (OR) first for irrigation and debridement with Irrisept (the experimental irrigation solution) and external fixation. Will return to OR at a later date for definitive fixation.
61995771|NCT05402995|EXPERIMENTAL|Antibiotic-coated medullary nail with saline irrigation (treatment group 2)|Patient will go to the operating room (OR) for treatment with an antibiotic-coated nail and have irrigation and debridement with normal saline.
61995772|NCT05402995|EXPERIMENTAL|Antibiotic-coated medullary nail with Irrisept irrigation (treatment group 3)|Patient will go to the operating room (OR) for treatment with an antibiotic-coated nail and have irrigation and debridement with Irrisept (the experimental irrigation solution).
61995773|NCT05393557|ACTIVE_COMPARATOR|Upfront|"Immediately after restoration of distal flow, they will receive:~i. Small dose Tirofiban (intra-coronary bolus of 25µg/Kg),\[22\] ii. Nitroglycerin 100-200 µg,\[12\] iii. Verapamil 100-200 µg (excluding patients with 2nd or 3rd degree AV block, bradycardia HR \< 60, or systolic BP \<100 mmHg)\[5\] iv. Two cycles of balloon up-balloon down (15 seconds occlusion, 15 seconds open artery; repeated two times).~v. The rest of the procedure will be completed as standard practice."
61995774|NCT05393557|NO_INTERVENTION|Control|pPCI procedure will be performed as per standard practice.\[2\] Bail-out use of any pharmaceutical products will be allowed as per guidelines recommendations (such as: GPi in case of no-reflow or thrombotic complications).
61995775|NCT02635191|EXPERIMENTAL|Tailored Group|In tailored therapy, medications will be adjusted according to the antimicrobial susceptibility testing (including Clarithromycin sensitivity) and cytochrome P450 isoenzyme 2C19 genotype. 10 days regimen will be prescribed.
61995776|NCT02635191|ACTIVE_COMPARATOR|Standard group|In standard triple therapy, children will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) for 10 days.
61995777|NCT02062307||control patients|BMI and age matched healthy male subjects
61995778|NCT02062307||hypogonadism patients|unconfounded group of patients with hypogonadism
62180899|NCT05656963||Idiopathic membranous nephropathy|Patients with idiopathic membranous nephropathy proved by renal biopsy
62180900|NCT05656963||Non-Idiopathic membranous nephropathy|Other primary glomerular diseases except membranous nephropathy
62565168|NCT00256074|OTHER|Alternative Therapy Group|2.Alternative therapy group will receive high-fat, low carbohydrate enteral feeding, (16.7% protein, 55.2% fat and 28.1% carbohydrates. At a target rate determined by the treating physician and dietician, for a maximum of 5 days following randomisation.
62565169|NCT00739882|ACTIVE_COMPARATOR|Efalizumab|
62565170|NCT00739882|PLACEBO_COMPARATOR|Placebo|
62565171|NCT02990741||Usual screening group|ECG recordings at baseline plus at 1 and 2 year of follow-up; three ECG recordings in total.
62565172|NCT02990741||Intensive screening subgroup|ECG recordings at baseline plus quarterly during follow-up, at months 3, 6, 9 ,12, 15, 18, 21 and 24; 9 ECG recordings in total.
62565173|NCT02990741||More intensive screening subgroup|ECG recordings at baseline plus weekly during the first month of follow-up and quarterly afterwards, at weeks 1, 2, 3 and 4 and months 3, 6, 9, 12, 15, 18, 21 and 24; 13 ECG recordings in total.
62565174|NCT00110396|EXPERIMENTAL|Rebif New Formulation Cohort|
62565175|NCT06077578||Healthcare professionals|Healthcare professionals, including nurses, physicians, physiotherapists, occupational therapists, and radiotherapists, have at least one year experience in caring for hospitalized children will be recruited.
62180901|NCT05656963||Diabetic kidney disease|Patients with clinical diagnosis of diabetes and kidney disease
62180902|NCT01845311|EXPERIMENTAL|ReZolve2 Treatment Group|
62180903|NCT01193218|EXPERIMENTAL|BI 10773 low dose QD|BI 10773 tablets low dose once a day
62180904|NCT01193218|EXPERIMENTAL|BI 10773 mid-low dose QD|BI 10773 tablets mid-low dose once a day
62565176|NCT06077578||Previously hospitalized children|Previously hospitalized children who had received a hospital play service provided by hospital play specialists.
62565177|NCT06077578||parents|Parents of previously hospitalized children who had received a hospital play service provided by hospital play specialists.
62180905|NCT01193218|EXPERIMENTAL|BI 10773 mid-high dose QD|BI 10773 tablets mid-high dose once a day
62180906|NCT01193218|EXPERIMENTAL|BI 10773 high dose QD|BI 10773 tablets high dose once a day
62565178|NCT01040572||Obesity recidivism after gastric bypass|
62565179|NCT05602168|EXPERIMENTAL|experimental:Acute leukemia/myelodysplastic or myeloproliferative disease|blood sampling, bone marrow aspirate, and buccal swab
62180907|NCT01193218|PLACEBO_COMPARATOR|Placebo|Placebo tablets once a day
62180908|NCT05442073||Type I: ΔPes≥30%ΔPEEP|
62180909|NCT05442073||Type II: ΔPes<30%ΔPEEP|
62180910|NCT03782610||Primary Study Cohort|450 Infants
62565180|NCT03114605|EXPERIMENTAL|Mindfulness|Mindfulness-based Intervention (8 sessions - 2 hours each- 1 session/week)
62565181|NCT03114605|NO_INTERVENTION|Control|Waiting List
62565182|NCT06123637|EXPERIMENTAL|Analgesia nociception index group|
62565183|NCT06123637|PLACEBO_COMPARATOR|Standard group|
62565184|NCT01696123|EXPERIMENTAL|MLC601|MLC601 (NeuroAid, Moleac Pte. Ltd, Singapore) (0.4 g per capsule) was prescribed as one capsule three times daily without an escalation dose.
62565185|NCT03207815|EXPERIMENTAL|Filgotinib|Participants will receive filgotinib 200 milligrams (mg) once daily for up to 52 weeks along with a standardized prednisone burst of 60 milligrams per day (mg/day) at Day 1/Baseline followed by a protocol-defined mandatory taper schedule up to Week 15.
62565186|NCT03207815|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo to match filgotinib once daily for up to 52 weeks along with a standardized prednisone burst of 60 mg/day at Day 1/Baseline followed by a protocol-defined mandatory taper schedule up to Week 15.
62565187|NCT03801135|NO_INTERVENTION|Electrolyte&Albumin Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin.
62565188|NCT03801135|EXPERIMENTAL|Fibrinogen Treatment Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin. Fibrinogen concentrate will be infused afterwards.
62180911|NCT03782610||Validation Cohort|225 Infants. Will allow subsequent validation of models derived from the Primary Study Cohort.
62180912|NCT05411874|EXPERIMENTAL|Chidamide plus HD-DXM|"Chidamide (orally at 5 mg biw for 24 weeks)~HD-DXM (orally at 40 mg daily for 4 days)"
62180913|NCT05411874|ACTIVE_COMPARATOR|HD-DXM|HD-DXM (orally at 40 mg daily for 4 days )
62565189|NCT03801135|ACTIVE_COMPARATOR|FFP Treatment Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution, albumin and fresh frozen plasma.
62565190|NCT03215680||Tanzanian Women of Reproductive Age|Healthy women of reproductive age living in Tanzania in an area with hot and temperate climate
62565191|NCT03215680||South African Women of Reproductive Age|Healthy women of reproductive age living in South Africa in an area with hot and temperate climate
62180914|NCT05343208|EXPERIMENTAL|Cognitive Behavioral Therapy Group|The group received online Cognitive Behavioral Therapy via the My-E-Health. Patients were issued a preTest psychometric assessment and a post therapy assessment using the Burnout Psychometrics provided within the My-E-Health's online ecosystem. All patients were required to validate the accuracy of the assessments during a follow-up of their results.
62180915|NCT05343208|NO_INTERVENTION|Control Group|The Control Group received no online therapy. Patients were issued a preTest psychometric assessment and a post therapy assessment using the Burnout Psychometrics provided within the My-E-Health's online ecosystem. All patients were required to validate the accuracy of the assessments during a follow-up of their results.
62180916|NCT03082612|EXPERIMENTAL|African American cancer patients|Patients will be required to participate in intervention activities and 5 data collection interviews. Interviews to complete both open-ended interviews and quantitative measures will take approximately 45 minutes. The actual administration of the intervention (viewing of video recordings) will take approximately 30 minutes with all sessions to occur over a 3 week period.
62180917|NCT03082612|EXPERIMENTAL|Family caregivers|Family caregivers will be required to participate in intervention activities and 5 data collection interviews. Interviews to complete both open-ended interviews and quantitative measures will take approximately 45 minutes. The actual administration of the intervention (viewing of video recordings) will take approximately 30 minutes with all sessions to occur over a 3 week period.
61995779|NCT00006012|EXPERIMENTAL|topotecan + paclitaxel + filgrastim + TRT + radiation|"Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 5. Patients receive filgrastim (G-CSF) subcutaneously (SC) daily beginning 24 hours after the last dose of chemotherapy and continuing until blood counts recover. Treatment repeats every 3 weeks for 2 courses.~After 2 courses of treatment, patients undergo TRT twice daily for 5 consecutive days for 5 weeks. During TRT, patients receive cisplatin IV, oral etoposide, and amifostine SC daily prior to TRT.~At 4 weeks after completion of TRT, patients receive 2 additional courses of topotecan, paclitaxel, and G-CSF every 3 weeks followed by prophylactic cranial irradiation.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
62180918|NCT00801086|EXPERIMENTAL|1|MTS-01 (7% Tempol gel)
62180919|NCT00801086|PLACEBO_COMPARATOR|2|Vehicle
62180920|NCT02974725|EXPERIMENTAL|LXH254+LTT462|
61995780|NCT01564303|NO_INTERVENTION|2. Acetylcysteine group (NAC+S) , aside with the saline, will|2. Acetylcysteine group (NAC+S) , aside with the saline, patients will be given orally Acetylcysteine at a dose of 600 mg twice daily, on the day before and on the day of administration of the contrast agent.
61995781|NCT01564303|EXPERIMENTAL|CAR+S , aside with the saline, carnitne will be adminstrated|Carnitine group (Car+S), aside with the saline, patients will be administrated with 20 mg/kg carnitine over 10 minutes 2 hours prior to the administration of the contrast agent and 8 hours after CT.
61995782|NCT01564303|EXPERIMENTAL|Phosphodiesterase type 5 inhibitor group (PDE5+S), aside with|4. Phosphodiesterase type 5 inhibitor group (PDE5+S), aside with the saline patients will be given orally 20 mg tablets of PDE5 Tadalafil once daily 2 hours prior to the administration of the contrast agent and in the subsequent day.
62180921|NCT02974725|EXPERIMENTAL|LXH254+Trametinib|
62180922|NCT02974725|EXPERIMENTAL|LXH254+Ribociclib|
62180923|NCT02406274|EXPERIMENTAL|Contrast Enhanced Spectral Mammography|
62180924|NCT02918292|EXPERIMENTAL|Haplo Bone Marrow HSCT|Patients will be treated with a preparative regimen of Antithymocyte Globulin (ATG) (4.5 mg/kg), fludarabine (150 mg/m\^2), cyclophosphamide (29 mg/kg), and low dose total body irradiation (TBI) (200 cGy) before undergoing the haplo HSCT. GVHD prophylaxis will be with post-HSCT cyclophosphamide (100 mg/kg), tacrolimus, and mycophenolate mofetil (MMF). G-CSF will be administered post-transplant.
62180925|NCT02800421||no organ damage|no evidence of HLI and CI-AKI
62180926|NCT02800421||CI-AKI only|CI-AKI, but no HLI
62180927|NCT02800421||HLI only|HLI, but no CI-AKI
62180928|NCT02800421||combined CI-AKI and HLI|Both CI-AKI and HLI
62180929|NCT04648852||Participants in the third wave of the HUNT study|General population participating in the third wave of the HUNT study
62180930|NCT04648852||Participants in the second wave of the HUNT study|General population participating in the second wave of the HUNT study
62180931|NCT04017897|EXPERIMENTAL|Experimental|
62180932|NCT03199300||Anthracylines-treated with toxicity|Patients with toxicity during/after treatment with anthracylines.
62180933|NCT03199300||Anthracyclines-treated without toxicity|Patients without toxicity during/after treatment with anthracylines.
61995783|NCT01564303|NO_INTERVENTION|Control group (S) will be treated without any extra agents|Control group ( S ) , which will be treated without any extra agents, just Saline (0.9 %) will be given I.V. at a rate of 1 ml per kilogram of body weight per hour for 12 hours before and 12 hours after administration of the contrast agent.
62180934|NCT03199300||Trastuzumab-treated with toxicity|Patients with toxicity during/after treatment with trastuzumab.
62565192|NCT01662635||ALK-BREAK APART|"We reviewed 230 consecutive cases of NSCLC that were retrieved from oncologic molecular laboratory and diagnostic pathology unit at the Instituto Nacional de Cancerologia, Mexico city, between 2011 and 2014. Samples were sent to the unit of pathological anatomy, a Pathologist confirmed the histologic diagnosis. The only inclusion criterion was the availability of tissue for biomarker studies. Clinical and pathologic details of these patients were included in a database, obtained from medical records.~For ALK fusion testing, we applied dual-color, break-apart FISH, RT-qPCR, and immunohistochemistry. Interpretation of the results was done in double-blind manner without knowing the results by other methods."
62565193|NCT00180843|PLACEBO_COMPARATOR|saline control|nebulized saline
62565194|NCT00180843|ACTIVE_COMPARATOR|salbutamol and ipratropium bromide nebules|salbutamol 2.5 mg and ipratropium bromide 0.5 mg
62565195|NCT04588168|EXPERIMENTAL|Experimental: Chemotherapy + mpMRI + surgery|"Baseline mpMRI /Neoadjuvant chemotherapy /Immediate mpMRI /Cystectomy and Lymphadenectomy / Postoperative pathology~Drug: Chemotherapy Procedure: Immediate Multiparametric MRI Procedure: Cystectomy and Lymphadenectomy"
62565196|NCT04588168|EXPERIMENTAL|Experimental: Chemotherapy + surgery|"Baseline mpMRI /Neoadjuvant chemotherapy /Cystectomy and Lymphadenectomy / Postoperative pathology~Drug: Chemotherapy Procedure: Cystectomy and Lymphadenectomy"
62565197|NCT01278186|EXPERIMENTAL|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon catheter (SeQuent Please, B. Braun)
62565198|NCT01278186|EXPERIMENTAL|Paclitaxel-eluting stent|Paclitaxel-eluting stent
62565199|NCT04087759|EXPERIMENTAL|Treatment Sequence BAE|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral test tablet 1 under fasted condition (Treatment B) in period 1, followed by bedaquiline oral reference tablet under fasted condition (Treatment A) in period 2, thereafter will receive bedaquiline oral test tablet 1 under fed condition (Treatment E) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
62565200|NCT04087759|EXPERIMENTAL|Treatment Sequence CAF|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral test tablet 2 under fasted condition (Treatment C) in period 1, followed by bedaquiline oral reference tablet under fasted condition (Treatment A) in period 2, thereafter will receive bedaquiline oral test tablet II under fed condition (Treatment F) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
62565201|NCT04087759|EXPERIMENTAL|Treatment Sequence DAG|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral test tablet 3 under fasted condition (Treatment D) in period 1, followed by bedaquiline oral reference tablet under fasted condition (Treatment A) in period 2, thereafter will receive bedaquiline oral test tablet 3 under fed condition (Treatment G) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
62565202|NCT04087759|EXPERIMENTAL|Treatment Sequence ABE|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral reference tablet under fasted condition (Treatment A) in period 1, followed by bedaquiline oral test tablet 1 under fasted condition (Treatment B) in period 2, thereafter will receive bedaquiline oral test tablet 1 under fed condition (Treatment E) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
62565203|NCT04087759|EXPERIMENTAL|Treatment Sequence ACF|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral reference tablet under fasted condition (Treatment A) in period 1, followed by bedaquiline oral test tablet 2 under fasted condition (Treatment C) in period 2, thereafter will receive bedaquiline oral test tablet 2 under fed condition (Treatment F) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
62565204|NCT04087759|EXPERIMENTAL|Treatment Sequence ADG|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral reference tablet under fasted condition (Treatment A) in period 1, followed by bedaquiline oral test tablet 3 under fasted condition (Treatment D) in period 2, thereafter will receive bedaquiline oral test tablet 3 under fed condition (Treatment G) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
62565205|NCT02221336|PLACEBO_COMPARATOR|Non-MONARCA II system|Use of smartphone for normal communicative purposes only. No self-monitoring and no feedback loop.
62565206|NCT02221336|EXPERIMENTAL|The MONARCA II system|Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop
62180935|NCT03199300||Trastuzumab-treated without toxicity|Patients without toxicity during/after treatment with trastuzumab.
62180936|NCT03199300||Cisplatin-treated with toxicity|Patients with toxicity during/after treatment with cisplatin.
62180937|NCT03199300||Cisplatin-treated without toxicity|Patients without toxicity during/after treatment with cisplatin.
62180938|NCT03199300||Bleomycin-treated with toxicity|Patients with toxicity during/after treatment with bleomycin.
61995784|NCT06308991|EXPERIMENTAL|Yakson touch|"The Yakson method continued for 15 minutes with steady touch (5 minutes), compassionate caressing (5 minutes), and repetition of steady touch (5 minutes). In the Yakson touch method, the palms of the practitioner and all fingers were kept in close contact so that the infants did not feel pressure.~1. Steady touch (5 minutes): One hand rested on the chest and abdomen of the preterm infant, while the other hand supported the back and hip of the preterm infant.~2. Compassionate Caress (5 minutes): In the same hand position, the practitioner repeated caressing and resting for 5 minutes: Caress (1 minute), rest (30 seconds), caress (1 minute), rest (30 seconds), and caress (2 minutes). The practitioner caressed the infants' chest and belly with a 1 cm diameter clockwise circular movement every 10 seconds.~3. Steady touch (5 minutes): The practitioner followed the steady touch procedure as previously described."
61995785|NCT06308991|EXPERIMENTAL|Gentle Human Touch|While the practitioner placed one hand on the crown of the preterm infant on the eyebrow line with the fingertip touch for 15 minutes, the other hand was placed on the lower abdomen covering the waist and hip of the infant.
62180939|NCT03199300||Bleomycin-treated without toxicity|Patients without toxicity during/after treatment with bleomycin.
62565207|NCT06220851||COPD|COPD patients aged 40 years or older with a postbronchodilator ratio of forced expiratory volume at one second (FEV1) to forced vital capacity (FVC) \<0.7.
62565208|NCT01577212|EXPERIMENTAL|Individualized dose escalation|Individualized dose escalation on the basis of the dose to the organs at risk.
62565209|NCT02850146|EXPERIMENTAL|18F-AV-1451|50 individuals who are cognitively normal, older, Aβ not elevated and enrolled in the LEARN study will undergo 18F-AV-1451 imaging procedures at 4 time points over a 4.5 year period.
62565210|NCT02104674|PLACEBO_COMPARATOR|Placebo|
62565211|NCT02104674|ACTIVE_COMPARATOR|Singulair (montelukast)|
62565212|NCT02104674|EXPERIMENTAL|lebrikizumab|
62565213|NCT01223118|EXPERIMENTAL|Oocyte Vitrification|Each patient will have oocytes randomized into two groups immediately after retrieval. Half of oocytes will be vitrified, thawed and inseminated. The other half will be inseminated only. All embryos will be biopsied for PGD prior to transfer and one embryo from each group will be transferred (vitrification and control groups). Following delivery, buccal swabs will be collected on all infants.
62565214|NCT04047667||CBCT guided TBCB|Patients with ILD who met the following including criteria from September 2018 to July 2019 were suggested to receive TBCB under CBCT guidance: more than 18 years old, diffuse parenchymal lung diseases without a diagnosis after integration of clinical profile, laboratory tests and HRCT features, FVC more than 50%, DLCO more than 35%, patients without acute exacerbation within one month, patients without bleeding diathesis, anticoagulant therapy, using antiplatelet drugs, patients without pulmonary hypertension, respiratory failure, liver or kidney disfunction, or cardiac insufficiency, PLT more than 50 x 109/L. All included patients signed the informed consent.
62565215|NCT05368844|EXPERIMENTAL|Active iTBS|rTMS treatments will employ the Brainsway stimulator (Brainsway Ltd, Israel). Prior to the first treatment (no more than 5 days prior), each subject's motor threshold (MT) will first be determined according to published methods (Schutter, van Honk, 2006; Julkunen et al, 2009). This location, as well as the stimulation target spot, will be marked at the first session on the scalp and standard methods will be used to target this spot during treatment sessions. The modified BeamF3 scalp heuristic will be used to localize the treatment site over the left DLPFC (Mir-Moghtadaei et al., 2015). Subjects will complete 5 treatments days. A treatment day will consist of 10 treatment sessions with the start of each session timed to be at least 50 minutes from the previous session.
62565216|NCT05368844|SHAM_COMPARATOR|Sham iTBS|The BrainsWay Model 104 with H4 coil has an integrated sham coil. The sham condition will start with the same clicking noise as the active TMS condition. Every helmet has a corresponding sham H-coil encased in the same helmet. The sham coil induces only a negligible sub-threshold field in the brain while making an identical noise and inducing some scalp sensation. Subjects will complete 5 treatments days. A treatment day will consist of 10 treatment sessions with the start of each session timed to be at least 50 minutes from the previous session. Subjects in this arm will have the option of receiving the Active iTBS protocol after they complete the 5 days of 10 daily treatment sessions.
62565217|NCT01097889|ACTIVE_COMPARATOR|Treatment Group 1|
61995786|NCT06308991|OTHER|Routine Care|All infants in the control, Yakson, and GHT groups were applied swaddling as the routine practice of the clinic before and during painful procedures.
61995787|NCT01468766|ACTIVE_COMPARATOR|Resistance training|
61995788|NCT01468766|ACTIVE_COMPARATOR|Relaxation training|
62180940|NCT04655742|EXPERIMENTAL|single arm, treatment group|Subjects in the treatment group will be implanted with the VitaFlow™ Transcatheter Aortic Valve System
62565218|NCT01097889|EXPERIMENTAL|Treatment Group 2|
62565219|NCT06455566||Leadless pacemaker implantation through right internal jugular vein|
62565220|NCT04400383|EXPERIMENTAL|AB011 Injection|AB011 Injection treatment. This phase 1 trial will include two stages, a single treatment stage and a Combo treatment stage.
62565221|NCT01801865|EXPERIMENTAL|MRI for Neonates|All participants will receive an MRI in the NICU scanner in the GE OPTIMA 1.5T MRI at CCHMC.
62565222|NCT00632268|EXPERIMENTAL|A|Drug:RAD001 Drug:Cisplatin Drug:5-FU
61995789|NCT00978328||001|oxycodone immediate release (OXYRX) Characteristics of pts. receiving prescription medications containing OXYRX
62180941|NCT00087555|EXPERIMENTAL|2|Sodium oxybate 6.0 g per day.
62180942|NCT00087555|PLACEBO_COMPARATOR|3|Placebo (one of two doses matching active treatment by volume).
62180943|NCT00087555|EXPERIMENTAL|1|Sodium oxybate 4.5 g per day.
62180944|NCT05871918|EXPERIMENTAL|TCbHP|"Experimental group (TCbHP) :~Taxotere (75mg/m2) + Carboplatin (AUC=5)~Trastuzumab 6mg/kg(initial dose 8mg/kg)~Pertuzumab 420mg(initial dose 840mg)~1/21d times 6 cycle"
62180945|NCT05871918|PLACEBO_COMPARATOR|ddEC-THP|"Epirubicin (90mg/m2)+ cyclophosphamide (600mg/m2) 1/14d×4 cycle~Taxol (80mg/m2) 1/7d x 12w~Trastuzumab 6mg/kg(initial dose 8mg/kg) 1/21d ×4 cycles~Pertuzumab 420mg(initial dose 840mg) 1/21d x 4 cycles"
62180946|NCT04622371|EXPERIMENTAL|moderate exercises group|Patients received 30 minutes of aerobic exercise at 40-60% of maximum heart rate
62180947|NCT04622371|EXPERIMENTAL|Light exercises group|Patients treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.
62180948|NCT03475056|EXPERIMENTAL|Group 1: cAd3-Marburg vaccine (1x10^10 PU)|cAd3-Marburg vaccine (1x10\^10 PU) administered intramuscularly (IM) with needle and syringe in a volume of 1 mL
62180949|NCT03475056|EXPERIMENTAL|Group 2: cAd3-Marburg vaccine (1x10^11 PU)|cAd3-Marburg vaccine (1x10\^11 PU) administered IM with needle and syringe in a volume of 1 mL
62180950|NCT02886169|EXPERIMENTAL|High fat meal with Sacha Inchi|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar
62180951|NCT02886169|PLACEBO_COMPARATOR|unsupplemented group|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
62180952|NCT03500666|EXPERIMENTAL|Robot lateral neck lymph node dissection|Robot neck lateral lymph node dissection was performed in patients with thyroid cancer and lateral cervical lymph node metastasis.
62180953|NCT03500666|EXPERIMENTAL|Total endoscopic lateral cervical lymph node dissection|Patients with thyroid cancer and lateral cervical lymph node metastases underwent total endoscopic neck dissection.
62565223|NCT01003873||Bypass gastric|First arm is represented by obese patients that will be studied before and after a gastric bypass. They will be studied before surgery as well as 1 month and 6 months after surgery.
62565224|NCT01003873||Lifestyle intervention|The second group is represented by obese patients that will be studied before lifestyle intervention, 6 months after the beginning of the intervention and after a time that will allow patients to lose the same amount of weight that patients that had been through surgery had lost one month after surgery.
62565225|NCT01003873||Control subjects|The third group is a control group of normal weight people that will be studied at one time and after 6 months with stable weight.
62565226|NCT05052957|EXPERIMENTAL|stem cell mobilization after radiation therapy|Participants at University Hospitals-Seidman Cancer Center (UH-SCC) will receive stem cell mobilization after 6 weeks of standard of care (SOC) radiotherapy. Followed by SOC chemotherapy.
61995790|NCT01876485|EXPERIMENTAL|Arm 1: Empowering Patients in Chronic Care (EPIC)|Patients in the intervention arm will receive the Empowering Patients in Chronic Care group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
61995791|NCT01876485|ACTIVE_COMPARATOR|Arm 2: Enhanced Usual Care (EUC)|The Enhanced Usual Care (EUC) arm will serve as a concurrent control group to compare to the intervention arm of the study. Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
61995792|NCT02245243|EXPERIMENTAL|Delafloxacin|Single Dose 300 mg IV
61995793|NCT04468932|EXPERIMENTAL|Active TMS first|After completing their baseline assessment, participants randomized to this arm will initially take part in a 2-week TMS intervention. After the midpoint assessment and subsequent a 1-month washout, these participants will then complete a 2-week sham TMS period prior to their final assessment.
62180954|NCT02175745|EXPERIMENTAL|Diagnostic (FDOPA-PET/CT or PET/MRI)|Patients receive 18F-fluoro-dihydroxyphenylalanine (18F-FDOPA) intravenously (IV) and then undergo positron emission tomography / computed tomography (PET/CT) or PET/magnetic resonance imaging (PET/MRI) scans 10 to 30 minutes later.
62180955|NCT02361879|EXPERIMENTAL|Ulipristal acetate|Womens will be treated with 5 mg/day of oral ulipristal acetate for 3 months
62180956|NCT02361879|ACTIVE_COMPARATOR|Leuprolile acetate|women will be treated with 1 IM injection of leuprolide acetate 11,25 mg in in the luteal phase
62180957|NCT04440059|EXPERIMENTAL|ICP-022|Subjects will take ICP-022 150mg once daily (QD).
62180958|NCT02785731||Women with a pelvic mass|Women diagnosed with a pelvic mass (defined as a simple, complex or a solid ovarian cyst / pelvic mass) who are scheduled for a laparotomy or laparoscopy for removal of the pelvic mass. Must have a pelvic imaging study performed within 60 days prior to surgery and a research blood draw within 60 days prior to surgery.
62180959|NCT03418181|OTHER|Standard Haemodialysis|Thrice weekly dialysis (control arm) - dialysis dose will not be adjusted according to Residual Kidney Function and subjects will be dialysed initially for 3.5-4 hours thrice weekly to ensure a target minimum eKt/V of 1.2.
62180960|NCT03418181|EXPERIMENTAL|Incremental dialysis|"Twice weekly dialysis - dialysis dose will be adjusted according to Residual Kidney Function.~Patients will commence dialysis for 3.5-4 hours twice weekly and have residual renal urea clearance formally measured by interdialytic urine collection at the end of the week following dialysis initiation. Subsequent to this, dialysis dose will be adjusted."
62180961|NCT01801839||SIRS,sepsis,normal|"SIRS~(1) temperature \> 38 centigrade or \< 36 centigrade; (2) pulse rate \> 90 beats/min; (3) ventilation rate \> 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) \< 32 mmHg; (4) white blood cell (WBC) count \>1 2,000/μL or \< 4000/μL , or \> 10% immature cells.~sepsis~SIRS + infection.~normal~not SIRS and have no infection."
62180962|NCT04252300|EXPERIMENTAL|Healthy subjects_Period 1|Healthy adults from USA receive a single dose of rosuvastatin (interaction drug) in Period 1.
62180963|NCT04252300|EXPERIMENTAL|Healthy subjects_Period 2|The healthy adults from Period 1 receive both rosuvastatin + BAY1817080 in Period 2.
62180964|NCT01619462|OTHER|Synflorix or PCV10|130 children will receive Synflorix at 1-2-3 months
62180965|NCT01619462|OTHER|Prevenar 13|130 children will receive Prevenar 13 at 1-2-3 months
62180966|NCT06018688|EXPERIMENTAL|osimertinib and aspirin|Osimertinib and Aspirin starting at a dose of 80 mg and 100mg once a day, orally with meals.The participants will undergo a two-month combination therapy, unless there is tumor progression (worsening) or intolerable toxic reactions that necessitate early termination of the drug treatment. Aspirin will be discontinued one week prior to the surgery.
62180967|NCT03440047|EXPERIMENTAL|Fuji Flim Processor VP-7000|Screening or surveillance colonoscopy using Fuji Flim Processor VP-7000, Light Source BL-7000
62180968|NCT02503982|EXPERIMENTAL|Solid Organ Transplanted children|Intervention: treatment with prophylactic oral valganciclovir with a fixed dose of 17 mg/kg once daily for prophylaxis, and stratified dose reductions for impaired renal function. Max dose was 900 mg.
62565227|NCT04849403|OTHER|The group USG was applied|USG was applied to the patients who underwent Laparoscopic sleeve gastrectomy for research trocar site hernia after 2-4 years from the surgery. Carter Thomasson suture passer was used to close fascial defect in all patients.
61995794|NCT04468932|EXPERIMENTAL|Sham treatment first|After completing their baseline assessment, participants randomized to this arm will initially take part in a 2-week sham TMS period. After the midpoint assessment and subsequent a 1-month washout, these participants will then complete a 2-week TMS intervention prior to their final assessment.
62180969|NCT03109509|ACTIVE_COMPARATOR|Fitbit-only Group|Participants randomized to the FB group were provided a Fitbit Zip activity monitor and were instructed on how to wear the monitor, how to pair the activity monitor to their smartphone, and asked to provide our team consent to access their Fitbit data through Fitbit's Application Programming Interface (API)
62180970|NCT03109509|EXPERIMENTAL|Fitbit + Pokémon Go Group|Participants randomized to the FB+P group received the same Fitbit Zip activity monitor and text message reminders as the FB group. This group was also shown how to download the Pokémon Go application to their smartphone and were provided brief instructions on how to play the game. Participants were instructed to simply explore the game and play it at their leisure. Participants were not provided any specific goals related to game play or physical activity in general.
62180971|NCT02956356|PLACEBO_COMPARATOR|Control treatment + oral glucose|Control treatment as preload and then an oral glucose load of 75g enriched with C13 sodium acetate (for determination of gastric emptying rates)
62180972|NCT02956356|ACTIVE_COMPARATOR|SATIOSTAT treatment + oral glucose|SATIOSTAT treatment as preload and then an oral glucose load of 75g enriched with C13 sodium acetate (for determination of gastric emptying rates)
62180973|NCT02956356|PLACEBO_COMPARATOR|Control treatment + meal intake|Control treatment as preload followed by a test meal
62180974|NCT02956356|ACTIVE_COMPARATOR|SATIOSTAT treatment + meal intake|SATIOSTAT treatment as preload followed by a test meal
62565228|NCT04766892|EXPERIMENTAL|mavacamten (MYK-461)|
62565229|NCT02151747||Sanger|BRCA 1/2 test results by Sanger sequencing
62565230|NCT02151747||NGS|BRCA 1/2 test results by NGS
61995795|NCT02581696|OTHER|Single arm|This is a follow-up study of BR-LAF-CT-101, a phase 1 study to evaluate the drug-drug interaction and safety of Lafutidine and Irsogladine maleate in healthy adult volunteers. Subjects judged to be appropriate to this study by screening.
62565231|NCT04831021|EXPERIMENTAL|Patients issued from dialysis units (clinic)|
62565232|NCT00460811|ACTIVE_COMPARATOR|72 ug linaclotide acetate|
62565233|NCT00460811|ACTIVE_COMPARATOR|145 ug linaclotide acetate|
62565234|NCT00460811|ACTIVE_COMPARATOR|290 ug linaclotide acetate|
62565235|NCT00460811|ACTIVE_COMPARATOR|579 ug linaclotide acetate|
62565236|NCT00460811|PLACEBO_COMPARATOR|Matching Placebo|
62565237|NCT01955278|EXPERIMENTAL|Creation of defitinive end colostomy|Patients undergoing elective laparoscopy assisted colorectal surgery, with the creation of a permanent end colostomy
62565238|NCT05698901||Group A|"1. 18 years or older~2. Male or female with Fabry disease diagnosed~3. Presence of any one of following abnormal criteria of either: 1) Cardio-specific Biomarker; 2) Abnormal elevated value of plasma Gb3 or Lyso-Gb3; 3) Electrocardiography (ECG); 4) Cardio-specific Image.~4. ERT Treatment naïve Fabry patients"
61995796|NCT03919461|ACTIVE_COMPARATOR|Propranolol and etodolac|Both study medications will be given orally for an intervention phase of 20 days as follows. Etodolac:400mg PO bid for the entire intervention period, Propranolol (slow release): 20 mg PO b.i.d. for 5 preoperative days; 80 mg PO b.i.d. on the day of surgery; 40 mg PO b.i.d. for the first post-operative week and 20 mg PO b.i.d. for the second post-operative week.
61995797|NCT03919461|PLACEBO_COMPARATOR|Placebo|Same schedule as in the active comparator arm
61995798|NCT04675216||Posterior fossa lesion|This group will be integrated by patients with posterior fossa lesion that likely to rise the posterior fossa intracranial pressure
61995799|NCT04675216||Post-operative posterior fosa surgical patients|This group will be integrated by patients operated for posterior fossa lesions in which we will try to find out what range of posterior fossa pressure is to be expected in this situation
61995800|NCT00649675|EXPERIMENTAL|1|Meloxicam Tablets 15 mg
61995801|NCT00649675|ACTIVE_COMPARATOR|2|Mobic® Tablets 15 mg
61995802|NCT03688412||Cook lead extraction devices|The Cook lead extraction devices are indicated for use in patients requiring percutaneous removal of CIED leads, indwelling catheters and foreign objects.
61995803|NCT01596764|PLACEBO_COMPARATOR|Treatment A|Administration of LOP Placebo (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), Placebo (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To assess WGT, OCT and CTT under placebo condition.
61995804|NCT01596764|PLACEBO_COMPARATOR|Treatment B|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), Placebo (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To assess WGT, OCT and CTT under loperamide-induced obstipation condition.
61995805|NCT01596764|ACTIVE_COMPARATOR|Treatment C|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), NLX-ER (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To describe the effects of repeated-dose naloxone in preventing loperamide-induced delay of WGT, OCT and CTT and measure pharmacokinetics of naloxone.
61995806|NCT01596764|ACTIVE_COMPARATOR|Treatment D|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), MNTX-ER (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To describe the effects of repeated-dose methylnaltrexone in preventing loperamide-induced delay of WGT, OCT and CTT and measure pharmacokinetics of methylnaltrexone.
61995807|NCT05349149|EXPERIMENTAL|Tocilizumab|Participants will receive one 30 min intravenous infusion of tocilizumab/Actemra® (Roche). The dose will be 8 mg/kg bodyweight or a maximum of 800mg. Tocilizumab is dissolved in 100 mL 0.9% saline.
61995808|NCT05349149|PLACEBO_COMPARATOR|Saline|As placebo, participants will receive one 30 min intravenous infusion of 100 mL 0.9% saline.
61995809|NCT02310139||Failed/Difficult Colonoscopy|Patients referred for colonoscopy because of previously failed attempt at complete caecal intubation.
61995810|NCT00560690|PLACEBO_COMPARATOR|Placebo|standard treatment with pegylated interferon and ribavirin + placebo
61995811|NCT00560690|EXPERIMENTAL|Metformin|standard treatment with pegylated interferon and ribavirin + metformin
61995812|NCT01515683|EXPERIMENTAL|An anaesthetic nurse|
61995813|NCT01515683|ACTIVE_COMPARATOR|Theatre nurse + An anaesthetic nurse|Support from theatre nurse and an anaesthetic nurse
61995814|NCT01515683|EXPERIMENTAL|A nurse from ward + an anaesthesic nurse|Support from a nurse from the ward and an anaesthetic nurse
61995815|NCT01515683|EXPERIMENTAL|Optional relative + an anaesthetic nurse|Support from an optional relative and an anaesthetic nurse
61995816|NCT05678062|OTHER|Lung- and cardiac ultrasound, as well as optic nerve sheath diameter.|Maternal ultrasound examinations will be performed after normal obstetric treatment protocols have been completed, i.e., the conduction of the study will contribute no delay in routine or emergency patient management. Ultrasound examination will be repeated after 72-96 hours, subject to the same conditions. An ultrasound examination (approximately 35-40 minutes in duration) will be performed. The ultrasound examination will consist of evaluation of lung- and cardiac ultrasound, as well as optic nerve sheath diameter.
61995817|NCT00323973|EXPERIMENTAL|1|
61995818|NCT00323973|PLACEBO_COMPARATOR|2|Placebo
61995819|NCT01503827|EXPERIMENTAL|WBRT|Patients will receive WBRT after local treatment. A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
61995820|NCT01503827|NO_INTERVENTION|Observation|No Intervention
61995821|NCT01552239|EXPERIMENTAL|1 Arm|"Stratum A:~R0, primary wound closure~Stratum B:~R0, secondary wound closure~Stratum C:~R1, tertiary wound closure"
61995822|NCT03203902|ACTIVE_COMPARATOR|Psychoeducation and Therapeutic Touch|"6-week psychoeducation group. The following 1-hour modules will be delivered:~Week 1: Anger Management and Conflict Negotiation Week 2: Meditation and Breathing Techniques Week 3: Nutrition Week 4: Exercise, Leisure, and Recreation Week 5: Sleep Week 6: Wellness Recovery Action Plan (WRAP)~Directly after the psychoeducation group is completed, 30-minute therapeutic touch will be administered."
61995823|NCT03203902|PLACEBO_COMPARATOR|Psychoeducation and Sham Therapeutic Touch|"6-week psychoeducation group. The following 1-hour modules will be delivered:~Week 1: Anger Management and Conflict Negotiation Week 2: Meditation and Breathing Techniques Week 3: Nutrition Week 4: Exercise, Leisure, and Recreation Week 5: Sleep Week 6: Wellness Recovery Action Plan (WRAP)~Directly after the psychoeducation group is completed, 30-minute sham therapeutic touch will be administered."
62180975|NCT05787145|EXPERIMENTAL|Let's Discuss Health Group|Patients in this group will be encouraged to prepare each of the four medical encounters targeted in the trajectory in radiation oncology using Let's Discuss Health website, which are the initial visit, the mid-treatment visit, the end-of-treatment visit and the 3-month post-treatment visit.
62180976|NCT05787145|NO_INTERVENTION|Usual Care Group|Patients in this group will received the usual care in the radiation oncology care pathway.
61995824|NCT03203902|NO_INTERVENTION|Control|No intervention
62180977|NCT06040047|EXPERIMENTAL|PNF plus mobilization|This single group will receive passive mobilization and proprioceptive neuromuscular facilitation for cervical region.
62180978|NCT05635955|EXPERIMENTAL|Remimazolam|Intravenous Remimazolam will be co-administrated with esketamine.
62180979|NCT05635955|ACTIVE_COMPARATOR|Propofol|Intravenous Propofol will be co-administrated with esketamine.
62180980|NCT00344253|EXPERIMENTAL|1|Interferon beta 3x weekly
62180981|NCT00344253|ACTIVE_COMPARATOR|2|Methotrexate sc 20 mg weekly
62565239|NCT05698901||Group B|"1. 18 years or older~2. Male or female with Fabry disease diagnosed~3. Presence of any one of following abnormal criteria of either: 1) Cardio-specific Biomarker; 2) Abnormal elevated value of plasma Gb3 or Lyso-Gb3; 3) Electrocardiography (ECG); 4) Cardio-specific Image.~4. Agalsidase beta (ERT) exposed or treated Fabry patients"
62565240|NCT02630251|EXPERIMENTAL|GSK2820151 arm|An accelerated dose escalation phase will be utilized in order to minimize sub-optimal drug exposures, followed by a conventional 3+3 dose escalation phase to achieve MTD. Initially, one subject per dose cohort will be recruited (accelerated dose escalation phase) until the first instance of a \>=Grade 2 drug related toxicity or dose-limiting toxicity (DLT). Further cohorts will be recruited in blocks of three subjects (3+3 dose escalation phase). Projected dose levels are 3 mg, 6 mg, 12 mg, 20 mg, 40 mg, 60 mg, 100 mg, 150 mg, 200 mg, and 300 mg. Additional subjects may be enrolled at previously cleared dose levels in order to obtain further data for PK and/or PD analysis. Once MTD is determined, additional subjects (18 subjects total at MTD) may be enrolled to collect additional safety data.
61995825|NCT04049539|EXPERIMENTAL|Treatment (liposome-encapsulated daunorubicin-cytarabine)|Within 14-33 days after the start of previous cycle of chemotherapy, patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.
61995826|NCT04409288|EXPERIMENTAL|Group A|Apalutamide followed by Enzalutamide Study participants will receive 12 weeks of oral apalutamide (240mg) daily, followed by five weeks of washout period, and then 12 weeks of oral enzalutamide (160mg) daily.
61995827|NCT04409288|EXPERIMENTAL|Group B|Enzalutamide followed by Apalutamide Study participants will receive 12 weeks of oral enzalutamide (160mg) daily, followed by five weeks of washout period, and then 12 weeks of oral apalutamide (240mg) daily.
61995828|NCT01220271|EXPERIMENTAL|Phase 1: 160 mg LY2157299|"During Radiation therapy:~* Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~* LY2157299: 80 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.~* Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~* LY2157299: 80 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.~* Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
61995829|NCT01220271|EXPERIMENTAL|Phase 1: 300 mg LY2157299|"During Radiation therapy:~* Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~* LY2157299: 150 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.~* Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~* LY2157299: 150 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.~* Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
62180982|NCT02883179|ACTIVE_COMPARATOR|lidocaine injection|5 mL of 2% lidocaine anhydrous solution (Depocaine) will be injected slowly along the lines of the edges of the perineal tears after delivery, with frequent aspirations to avoid intravascular injection.
62180983|NCT02883179|EXPERIMENTAL|lidocaine-prilocaine cream|5-g dose of Lidocaine-prilocaine cream will be applied to the intact tissue around each tear for 5 minutes before suturing
62180984|NCT02138253|EXPERIMENTAL|IDN-6556|IDN-6556 25 mg BID
62180985|NCT02138253|PLACEBO_COMPARATOR|Placebo|Placebo BID
62180986|NCT06064370||laparoscopic right adrenalectomy|laparoscopic right adrenalectomy for pheochromocytoma
62565241|NCT00648791|EXPERIMENTAL|1|Finasteride Tablets 5 mg
62180987|NCT06064370||laparoscopic left adrenalectomy|laparoscopic left adrenalectomy for pheochromocytoma
62180988|NCT05698862|ACTIVE_COMPARATOR|Probiotic|Probiotic supplement (Lactobacillus brevis)
62180989|NCT05698862|PLACEBO_COMPARATOR|Placebo|Placebo (maltodextrin)
62180990|NCT06339567|OTHER|Thrombotic profil|
62180991|NCT01734473|EXPERIMENTAL|Study day 1|Hydrolyzed casein protein. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
62180992|NCT01734473|EXPERIMENTAL|Study day 2|Hydrolyzed casein protein + carbohydrates. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
62180993|NCT01734473|EXPERIMENTAL|Study day 3|Hydrolyzed casein protein + leucine. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
62565242|NCT00648791|ACTIVE_COMPARATOR|2|Proscar Tablets 5 mg
62565243|NCT01702623|ACTIVE_COMPARATOR|Oxcarbazepine first, then Trileptal|Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period)
62180994|NCT01734473|EXPERIMENTAL|Study day 4|Hydrolyzed casein protein + carbohydrates + leucine. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
62180995|NCT01734473|EXPERIMENTAL|Study Day 5|4 levels of hydrolyzed casein protein + carbohydrates
62180996|NCT06074653|EXPERIMENTAL|Experimental group A|Subjects will receive 8 sessions of Mulligan Bent Leg Raise technique on dominant side
62180997|NCT06074653|EXPERIMENTAL|Experimental group B|Subjects will receive 8 sessions of PNF Contract Relax technique on dominant side
62180998|NCT01561456|EXPERIMENTAL|AXL1717|AXL1717
62180999|NCT01561456|ACTIVE_COMPARATOR|Docetaxel|Docetaxel
62565244|NCT01702623|ACTIVE_COMPARATOR|Trileptal first, then Oxcarbazepine|Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period
62565245|NCT02257346|ACTIVE_COMPARATOR|Lidocaine|Intravenous lidocaine 1.5 mg/Kg bolus dose and 2mg/Kg/hr infusion
62565246|NCT02257346|PLACEBO_COMPARATOR|Normal Saline|Intravenous normal saline infusion
62565247|NCT05582889|EXPERIMENTAL|Experimental: Immediate Fitbit Intervention|Participants randomized to this arm receive the 12-week Fitbit intervention; participants then crossover and are observed (no health coaching) for an additional 12-weeks. The Fitbit intervention includes a Fitbit activity tracker, the free Fitbit smartphone app, and 6 Health Coaching calls.
62565248|NCT05582889|ACTIVE_COMPARATOR|Comparator: Delayed Fitbit Intervention|Wait-listed; participants maintain their usual physical activity for 12-weeks; participants then crossover and receive the full 12-week Fitbit intervention.
62565249|NCT02343653|ACTIVE_COMPARATOR|Nutrition|Participants receive a controlled diet consisting of 1.2-1.5 g of protein/kg/day for 12 weeks according to guidelines for enteral nutrition and patients with cirrhosis. The group receives dietary guidance and protein supplements.
62565250|NCT02343653|EXPERIMENTAL|Nutrition and strength training|"Participants in this group receive same controlled diet consisting of 1.2-1.5 g of protein/kg/day for 12 weeks as the No intervention-group. Participants will also receive supervised strength training 3 x 60 min./week for 12 weeks. The group receives dietary guidance and protein supplements, which on training days should be consumed within 30 minutes after exercise."
62565251|NCT05643014||Firefighters over 18 years old|This is a within subject, observational study of firefighters. This study will involve three sample collections including buccal cells and urine samples; one collection pre and two collections post-structural fire exposure.
62565252|NCT00489918|PLACEBO_COMPARATOR|Macroflux® placebo|Macroflux® placebo patch
62565253|NCT00489918|EXPERIMENTAL|Macroflux® 20 mcg|Macroflux® 20 mcg patch
62565254|NCT00489918|EXPERIMENTAL|Macroflux® 30 mcg|Macroflux® 30 mcg patch
62565255|NCT00489918|EXPERIMENTAL|Macroflux® 40 mcg|Macroflux® 40 mcg patch
62565256|NCT00489918|ACTIVE_COMPARATOR|FORTEO®|FORTEO® 20 mcg injection
62565257|NCT02635594|EXPERIMENTAL|Carnipure® tartrate|1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate
62565258|NCT02635594|PLACEBO_COMPARATOR|Placebo|1000mg cellulose + 475mg L-tartaric acid
62565259|NCT03976271|ACTIVE_COMPARATOR|T1DM poor glycaemic control|patients with type 1 diabetes and poor glycaemic control (HbA1c \>8% / \>64 mmol/mol will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
62181000|NCT03415399|EXPERIMENTAL|i.v. arm|ET190L1 ARTEMIS™ T cells administered by intravenous (IV) infusion
62181001|NCT03384147|EXPERIMENTAL|Drinking|"Occasional drinkers assigned to start with a 3week drinking period (women 1 u/day - men 2 u/day)~Followed by crossover without washout to 3 week abstaining period"
62181002|NCT03384147|EXPERIMENTAL|Abstaining|"Habitual drinkers assigned to start 2 weeks of abstaining from alcohol~Followed by crossover without washout to 3 weeks drinking (women 1 u/day - men 2 u/day)"
62181003|NCT00571077||A|"This is a a single arm study evaluating the efficacy and accuracy of EIS in detecting malignant thyroid nodules.~PAtients with thyroid nodules scheduled for surgery will undergo EIS examination."
62391271|NCT03841500|ACTIVE_COMPARATOR|Aperture (biocomposite screw) fixation|"16 patients in this arm underwent ACL reconstruction with the allograft fixed in the femoral tunnel with a biocomposite interference screw (BioComposite Screw, Arthrex, North Naples, FL; or MILAGRO screw, DePuy Mitek, Raynham, MA, USA).~Intervention: ACL reconstruction with the allograft fixed in the femoral tunnel with a biocomposite interference screw."
62391272|NCT03841500|ACTIVE_COMPARATOR|Suspensory (endobutton) fixation|"17 patients in this arm underwent ACL reconstruction with the allograft secured in the femoral tunnel with a cortical button (TightRope, Arthrex, North Naples, FL, USA).~Intervention: ACL reconstruction with the allograft secured in the femoral tunnel with a cortical button."
62181004|NCT04634955|ACTIVE_COMPARATOR|S1 transforaminal injection with oboique view|S1 transforaminal injection with oblique fluoroscopic view
62565260|NCT03976271|ACTIVE_COMPARATOR|T1DM impaired awareness|patients with type 1 diabetes and impaired awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
62565261|NCT03976271|ACTIVE_COMPARATOR|T1DM Normal awareness|patients with type 1 diabetes and normal awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
62565262|NCT03976271|ACTIVE_COMPARATOR|T2DM + Insulin|patients with type 2 diabetes with insulin treatment for at least 1 year will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
62565263|NCT03976271|ACTIVE_COMPARATOR|Healthy control T2DM|healthy controls without diabetes and age, gender and BMI matched with diabetes type 2 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
62565264|NCT03976271|ACTIVE_COMPARATOR|Healthy control T1DM|Healthy controls without diabetes and age, gender and BMI matched with diabetes type 1 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
62565265|NCT04598061||Newborns or Infants less than 7 kg undergoing an infra-umbilical surgery|Newborns or Infants less than 7 kg undergoing an infra-umbilical surgery
62181005|NCT04634955|ACTIVE_COMPARATOR|S1 transforaminal injection with AP view|S1 transforaminal injection with anteroposterior fluoroscopic view
62565266|NCT03232359||SPE/HELLP group|This group included 24 pregnant women (gestational age of \>20 weeks) who were diagnosed as having TMA with provisional diagnosis of pre-eclampsia, HELLP syndrome. immature platelets fraction assessment within 12 hours of diagnosis
62565267|NCT03232359||TTP/HUS group|This group included 13 pregnant women (gestational age of \>20 weeks) who were diagnosed as having TMA with provisional diagnosis of TTP/HUS. HELLP syndrome. immature platelets fraction assessment within 12 hours of diagnosis
62565268|NCT03232359||Control group|This group included 20 pregnant women (gestational age of \>20 weeks) having normal pregnancy with normal blood pressure and platelet count.
62565269|NCT01210560|EXPERIMENTAL|20 mg MR|
62391273|NCT03737305|ACTIVE_COMPARATOR|Control Group|Control group of conventional therapy with manual distraction performed by the physiotherapist in the office (active comparator)
62565270|NCT01210560|EXPERIMENTAL|40 mg MR|
62565271|NCT01210560|EXPERIMENTAL|60 mg MR|
62565272|NCT01210560|EXPERIMENTAL|120 mg MR|
62565273|NCT01210560|EXPERIMENTAL|120 mg IR|
62181006|NCT06276517||patients with subarachnoid hemorrhage|Patients hospitalized in Lariboisière intensive care unit for subarachnoid hemorrhage
62181007|NCT03044587|EXPERIMENTAL|Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|Nal-IRI \[Irinotecan liposome\], 5-FU \[5-Fluorouracil\], Leucovorin Cycle q2w
62565274|NCT01803451|EXPERIMENTAL|hyperglycemic clamp-Meal tolerance test|these studies are to evaluate the effect of exendin-9 on insulin secretion before and after meal ingestion in patients after bariatric surgeries compared to non-surgical controls
62565275|NCT01803451|EXPERIMENTAL|Labeled meal tolerance test|The effect of GLP-1 receptor blockade on glucose tolerance and glucose kinetics are evaluated in the group patients with bariatric surgery vs. nonsurgical using exendin-9-39 infusion during one of the the 2-day dual tracer studies of meal tolerance test
62565276|NCT05867251|EXPERIMENTAL|Phase 1, monotherapy (Part 1A)|Escalating doses of once daily, oral AVZO-021 in 28-day cycles.
62181008|NCT03044587|OTHER|Arm Cisplatin + Gemcitabine (Arm B, standard of care)|Cisplatin, Gemcitabine Cycle q3w
62181009|NCT06382571||Sub - target dose group|Patients who received sub - target dose of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs).
62181010|NCT06382571||Target dose group|Patients who received target dose or maximal tolerated dose of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs)
62181011|NCT01044901||Subjects with Sickle Cell Disease (SCD)|38 clinically stable black patients with Sickle Cell Disease (SCD) (including individuals with hemoglobin SS, SC, and β-thalassemia demonstrated by high-performance liquid chromatographic separation or gel electrophoresis).
62181012|NCT01044901||Healthy Volunteers|13 healthy control subjects were frequency matched to patients with SCD on age, sex, and race.
62181013|NCT05066919|EXPERIMENTAL|Operative treatment|Patients treated with open plantar fasciotomy
62181014|NCT05066919|ACTIVE_COMPARATOR|Conservative treatment|Patients treated non-operatively with exercise
62181015|NCT04887701|EXPERIMENTAL|Non-hormonal device therapy|Daily non-hormonal device therapy
62565277|NCT05867251|EXPERIMENTAL|Phase 1, combination (Parts 1B and 1C)|"Escalating doses of once daily, oral AVZO-021 in 28-day cycles starting at least 1 DL below the monotherapy MTD/RP2D dose in combination with:~1B1) fulvestrant~1B2) palbociclib plus either fulvestrant or letrozole~1B3) ribociclib plus either fulvestrant or letrozole~1B4) abemaciclib plus either fulvestrant or letrozole~1B5) sacituzumab govitecan-hziy~1C) carboplatin"
62565278|NCT05867251|EXPERIMENTAL|Phase 2, monotherapy (Part 2A)|Oral doses of AVZO-021 in 28-day cycles at the RP2D determined in Part 1A.
62565279|NCT05867251|EXPERIMENTAL|Phase 2, combination (Parts 2B and 2C)|"Oral doses of AVZO-021 in 28-day cycles at the RP2D determined in Parts 1B/1C, in combination with:~2B1) fulvestrant~2B2) palbociclib plus either fulvestrant or letrozole~2B3) ribociclib plus either fulvestrant or letrozole~2B4) abemaciclib plus either fulvestrant or letrozole~2B5) sacituzumab govitecan-hziy~2C) carboplatin"
62565280|NCT01899482|EXPERIMENTAL|Manual Lymphatic Drainage|One educational session in group, and 10 individual sessions of manual lymphatic drainage in lower extremity, during approximately one month.
62565281|NCT01899482|ACTIVE_COMPARATOR|Control|One educational session in group.
62565282|NCT00519857|ACTIVE_COMPARATOR|1|Tibolone
62565283|NCT00519857|PLACEBO_COMPARATOR|2|Placebo
62565284|NCT05992337||Women with breast cancer treated with chemotherapeutics without signs of cardiotoxicity|
62565285|NCT05992337||Women with breast cancer treated with chemotherapeutics with signs of cardiotoxicity|
62565286|NCT06205771|NO_INTERVENTION|NP|normal pregnancy and preeclampsia pregnancy
62565287|NCT06205771|EXPERIMENTAL|PE|preeclampsia
62565288|NCT01358435|EXPERIMENTAL|Wosulin 70/30|Wosulin 70N /30R is a recombinant Human Insulin with 30 % Regular Insulin Human Neutral and 70% Isophane Insulin, 600 nmol/ml, 100 IU/ml.
62565289|NCT01358435|ACTIVE_COMPARATOR|Novolin 70/30|Novolin 70/30 is a Recombinant Human Insulin with 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection
62565290|NCT05535777|ACTIVE_COMPARATOR|Enhanced Text Reminders with Callback by Person|"Participants in this arm will receive up to 3 R/R messages by text. R/R message will receive a phone call back by a call center agent if they press 1 in response to a question on the original text message. The call center agent's job is to schedule patients for clinical visits. These call center agents will be trained by our faculty and staff and will have the usual HIPAA and other patient confidentiality training."
62565291|NCT05535777|ACTIVE_COMPARATOR|Enhanced Bidirectional Text Reminders|"Participants in this arm will receive a text message from a call center agent if they press 1 in response to a question on the original text message. The bidirectional texts will have an agent who can answer questions and schedule an appointment through text message back-and-forth conversations with the patient. Bidirectional texts will be exchanged on a HIPAA compliant bidirectional text messaging platform. The patient will use the regular SMS function on their cellphone and the agent will receive and respond to the bidirectional text on the HIPAA compliant platform."
61995830|NCT01220271|EXPERIMENTAL|Phase 2: Established dose LY2157299|"During Radiation therapy:~* Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~* LY2157299: Phase 1 established dose taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.~* Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~* LY2157299: Phase 1 established dose taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.~* Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
61995831|NCT01220271|EXPERIMENTAL|Phase 2: no LY2157299 (control)|"During Radiation therapy:~* Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~* Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
61995832|NCT01127750|EXPERIMENTAL|FTY720|
61995833|NCT03389464|EXPERIMENTAL|confrontation group|computer-based confrontation with dysfunctional beliefs
61995834|NCT03389464|NO_INTERVENTION|control group|no computer-based confrontation with dysfunctional beliefs
61995835|NCT03323489|EXPERIMENTAL|celiac radiosurgery, single fraction|Celiac Plexus Radiosurgery
61995836|NCT02835274|EXPERIMENTAL|Ring mode followed by Unrestricted mode|omni-directional stimulation followed by unrestricted Mode stimulation
61995837|NCT02835274|ACTIVE_COMPARATOR|Unrestricted mode followed by ring mode|Unrestricted Mode stimulation followed by omni-directional stimulation
61995838|NCT00914030||A1|Patients with schizophrenia
61995839|NCT00914030||A2|Control subjects matched individually with patients with schizophrenia
61995840|NCT00914030||B1|Adult subjects with autism
61995841|NCT00914030||B2|Control subjects matched individually with adult subjects with autism
61995842|NCT00914030||C1|Children with autism
61995843|NCT00914030||C2|Control subjects matched individually with children with autism
61995844|NCT02903667|EXPERIMENTAL|bone grafting|The possibility of counteracting unfavourable ridge modelling after multiple tooth extractions by placing bone grafting material in the fresh extraction sites.
61995845|NCT02903667|SHAM_COMPARATOR|natural healing|ridge modelling after multiple tooth extractions.
61995846|NCT01398111|ACTIVE_COMPARATOR|Treatment R2|
61995847|NCT01398111|ACTIVE_COMPARATOR|Treatment R1|
61995848|NCT01398111|PLACEBO_COMPARATOR|Placebo|
61995849|NCT01398111|EXPERIMENTAL|Treatment T|
61995850|NCT01892930|EXPERIMENTAL|Treatment (SBRT, nephrectomy)|Patients undergo SBRT on day 1 and undergo partial or radical nephrectomy on day 29.
61995851|NCT06111365||IVF|Women undergoing fresh IVF treatment using their own eggs or donor eggs
61995852|NCT05461131|EXPERIMENTAL|BPZE1|Participants will receive an intranasal dose of BPZE1 via the mucosal atomization device followed by a dose of the challenge strain (B. Pertussis strain 1917) approximately 60-120 days later. Participants will receive azythromycin for 3 days beginning 14 days after after administration of the challenge strain.
61995853|NCT05461131|PLACEBO_COMPARATOR|Placebo|Participants will receive an intranasal dose of placebo via the mucosal atomization device followed by a dose of the challenge strain (B. Pertussis strain 1917) approximately 60-120 days later. Participants will receive azythromycin for 3 days beginning14 days after after administration of the challenge strain.
61995854|NCT04497233||Prospectively validation group|Two diagnosis methods will be used in the prospective validation section, one is traditional qualitative and quantitative method, the other is artificial intelligence prediction model based on videos to compare the diagnostic efficacy.
61995855|NCT05082077||LIVERguard patient|Patients whose donor liver was transported with the LiverGuard device.
61995856|NCT05082077||Standard Transport Patients|Patients whose donor liver was transported with a method other than the LiverGuard
61995857|NCT00984854|EXPERIMENTAL|Intradermal Juvidex|
61995858|NCT00984854|PLACEBO_COMPARATOR|Placebo (vehicle)|
61995859|NCT01991171|EXPERIMENTAL|Kinesio Taping|Participant will receive application of Kinesiotaping in their thigh on quadriceps muscle
61995860|NCT01991171|PLACEBO_COMPARATOR|Kinesio Taping Placebo|Participant will receive application of placebo Kinesiotaping in their thigh on quadriceps muscle
61995861|NCT01991171|NO_INTERVENTION|Control Group|This participants will not receive intervention
61995862|NCT01997268|PLACEBO_COMPARATOR|Placebo|Placebo 6 capsules (1.24 g each) daily for 12 weeks
61995863|NCT01997268|EXPERIMENTAL|SC401B 2 capsules|SC401B 2 capsules (1.24 g each) + 4 placebo capsules daily for 12 weeks
61995864|NCT01997268|EXPERIMENTAL|SC401B 4 capsules|SC401B 4 capsules (1.24 g each) + 2 placebo capsules daily for 12 weeks
61995865|NCT01997268|EXPERIMENTAL|SC401B 6 capsules|SC401B 6 capsules (1.24 g each) daily for 12 weeks
62181016|NCT04887701|SHAM_COMPARATOR|Sham Therapy|Daily non-hormonal sham device therapy
62181017|NCT05277090|EXPERIMENTAL|polyethyleneglycol only|participants take 2L of polyethyleneglycol only
62181018|NCT05277090|EXPERIMENTAL|polyethyleneglycol puls Inulin|participants take 2L of polyethyleneglycol, subsequently take 15g inulin per day.
62181019|NCT05277090|EXPERIMENTAL|polyethyleneglycol puls probiotic combination product|"Participants take 2L of polyethyleneglycol, subsequently take 15g probiotics combination product (including Bifidobacterium lactis, Lactobacillus plantarum, inlulin, Vitamin C) per day. The probiotic combination product, named Mei Ri Yi Jun was produced by Wedge Pharmaceuticals."
62181020|NCT05185297|NO_INTERVENTION|Standard care|Participants will continue with standard care provided by the family physician.
62181021|NCT05185297|EXPERIMENTAL|Recreational Futsal, plus standard care|Participants will participate in 2-3 weekly one hour sessions of Recreational Futsal, during 3 months, while maintaining standard care provided by the family physician.
62181022|NCT02675218||Patients with rheumatoid arthritis.|Rheumatoid arthritis diagnosis according to ACR (American College of Radiology)/EULAR 2010 classification criteria.
62181023|NCT04124783|EXPERIMENTAL|Cooling Bolero|
61995866|NCT06392243|EXPERIMENTAL|Experimental group|In the experimental group, intracardiac and large blood vessel imaging, intracardiac Doppler flow assessment and guidance of intracardiac intervention were performed by intracardiac ultrasound imaging system of Sonosemi Medical Co., Ltd.
62181024|NCT01489917|NO_INTERVENTION|Compression without adjustment|TR band (Terumo medical) applied. The TR band is then deflated gradually till pulsatile bleeding is observed under the transparent plastic inflatable chamber and then 1-2 cc of air is placed back in the TR band chamber to stop bleeding. The band is left in place for 2 hours and not adjusted further unless patient complained of symptoms or bleeding occurred.
62181025|NCT01489917|EXPERIMENTAL|Patent hemostasis & heparin|TR-band is placed and positioned similarly to the other study arm. However, in theses cases, patency is evaluated at the time of application of the TR-band, and monitored every 15 minutes afterwards till the band is removed and hemostasis completed. After TR-band placement, if maintenance of radial artery patency is obtained, no heparin is administered and TR band is left in place for 1-hour. If radial artery patency is not maintained, a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the band is left in place for 2 hours.
62181026|NCT04833426|ACTIVE_COMPARATOR|Testosterone therapy|Daily application of two pump auctions of 16.2mg/ml testosterone gel. Dosage may be altered depending on clinical response
62181027|NCT04833426|PLACEBO_COMPARATOR|Placebo therapy|Daily application of two pump auctions of placebo gel.
62181028|NCT03231332|EXPERIMENTAL|H.pylori Eradication index|Microbiome diversity detection in Participants Positive for H.pylori and undergoing Eradication therapy with Clarythromycin-containing eradication therapy
62181029|NCT03231332|NO_INTERVENTION|Control|Microbiome diversity detection in Participants Without H.pylori Eradication therapy
62181030|NCT03231332|ACTIVE_COMPARATOR|H.pylori Eradication comparative|Microbiome diversity detection in Participants Positive for H.pylori and undergoing Eradication therapy with high dose Amoxicillin and bismuth containing eradication therapy
62565292|NCT05535777|NO_INTERVENTION|Standard Text Reminders|Participants in this arm will receive up to 3 text messages, reminding them about the importance of influenza vaccination. The standard texts will include a clinic call back number and patient portal self-scheduling for patients to schedule their influenza vaccines. The direct scheduling texts includes a direct number to an agent that can help schedule and answer questions on the phone in real time. The texts with a direct number to schedule will link a specified phone number to call and schedule. This number would be answered by a central agent quickly and a patient could schedule their flu shot at any clinic site. This specific phone number would not go through the multiple option menus a patient would normally experience when calling their clinic.
62565293|NCT01244568|NO_INTERVENTION|Usual care|
61995867|NCT06392243|ACTIVE_COMPARATOR|Control Group|The control group was treated with SOUNDSTAR 3D Diagnostic Ultrasound catheter (SNDSTR10G) and Vivid IQ, intracardiac and macrovascular imaging of the heart, assessment of intracardiac Doppler flow, and guidance for intracardiac intervention
62181031|NCT03591627||AF or AFl patients|Patients with AF or AFl in whom TEE will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period.
62181032|NCT05807269||People with stroke|Participants with stroke or risk factors for stroke
62181033|NCT00733226|ACTIVE_COMPARATOR|1 Broncho-Vaxom|The children received one capsule per oral, OM-85 BV (3.5 mg) per day for the first 10 consecutive days of each month for 3 consecutive months.
62565294|NCT01244568|EXPERIMENTAL|Prostate cancer treatment DESI|
62181034|NCT00733226|PLACEBO_COMPARATOR|2 (Placebo OM-85 BV)|The children received one capsule per oral, placebo per day for the first 10 consecutive days of each month for 3 consecutive months.
62181035|NCT06409559|OTHER|Rim plate group|This group will consist of 30 patients where the posterior wall fracture will be operatively stabilized with a pelvic reconstruction plate and interfragmentary screws placed through the plate.
61995868|NCT02857452||Lupus|
62181036|NCT06409559|OTHER|Buttress plate group|This group will consist of 30 patients where the posterior wall fracture will be operatively fixed with a buttress plate applied under compression without interfragmentary lag or position screws.
62181037|NCT03880825|OTHER|Metformin Only|
62181038|NCT03880825|OTHER|Levoketoconazole Only|
62565295|NCT02146937|EXPERIMENTAL|Combination therapy- bicalutamide and finasteride|3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily
62565296|NCT05394818|EXPERIMENTAL|SHR-A2009|
62565297|NCT01884246|EXPERIMENTAL|Self-care CVD risk reduction|A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
62181039|NCT03880825|OTHER|Levoketoconazole + Metformin|
62181040|NCT02547597|EXPERIMENTAL|Carvedilol|Carvedilol 25 mg twice a day
62181041|NCT02547597|ACTIVE_COMPARATOR|Atenolol|Atenolol 50 mg twice a day
62181042|NCT00644878|EXPERIMENTAL|Nilotinib|
62565298|NCT01884246|ACTIVE_COMPARATOR|Referral to primary care provider|The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
62181043|NCT03347266|EXPERIMENTAL|VVZ-149 injections|VVZ-149 injections will be mixed with saline, then intravenous infusion for 10hr. The drug product will be administrated with a 1000mg for 10 hours.
62181044|NCT03347266|PLACEBO_COMPARATOR|Placebo|Placebo group will receive an water for injection the same volume and period of experimental group.
62181045|NCT00175045|EXPERIMENTAL|Lansoprazole IV 30 mg QD|
62181046|NCT00175045|ACTIVE_COMPARATOR|Lansoprazole Capsule 30 mg QD|
62181047|NCT00951678||ER patients|"Subjects must be 18 yrs or older, male or female, and must have the anatomy that we will be examining. Patients will be given the option of enrolling in the study whilst being cared for in Tampa General Hospital Emergency Room.~We anticipate enrolling normal, healthy volunteers, elderly persons (\>65) not cognitively impaired, persons with social, economic or educational disadvantages , and persons who do not understand English fluently."
62181048|NCT06477276|EXPERIMENTAL|Amygdala TI|5 sessions will be delivered in 3 weeks
62181049|NCT06477276|SHAM_COMPARATOR|Controlled TI|5 sessions will be delivered in 3 weeks
62181050|NCT05390996|ACTIVE_COMPARATOR|condensation drilling technique|condensation of bone (osseodensefecation technique)
62565299|NCT02478944|EXPERIMENTAL|Inflammatory bowel disease|Patients with Crohn's disease and ulcerative colitis undergoing manometry
62565300|NCT02300831||NSCLC|The eligible patient population of this study will comprise of advanced 2nd line NSCLC patients who are screened for two randomised clinical trials (RCTs) sponsored by AstraZeneca (AZ): SELECT-1 and SELECT-2 trials, but who do not meet eligibility criteria for those trials
62565301|NCT02724319||Left heart catheterization patients|Patients presenting to the UF Health Jacksonville cardiac catheterization laboratory for left heart catheterization for suspected coronary artery disease and intent to undergo percutaneous coronary intervention will be targeted for enrollment and will be genotyped by SpartanRX
62181051|NCT05390996|SHAM_COMPARATOR|conventional drilling technique|control group
62181052|NCT05268497|EXPERIMENTAL|Esketamine|Participants will receive esketamine nasal spray (Dose 1 or Dose 2) twice weekly for 4 weeks (Induction Phase), followed by once a week dose (Dose 1 or Dose 2) for 8 weeks (Maintenance Phase), in conjunction with an oral antidepressant. Clinician-directed cognitive behavioral therapy (CBT) supplemented with the Mindset app will be administered by a clinician following esketamine dosing once the participants is considered ready to engage in therapy, based on the clinician judgement of CBT readiness.
62181053|NCT00823446|EXPERIMENTAL|Revera Wound Care|
62565302|NCT01129063|EXPERIMENTAL|Sequence clopidogrel 75 / 75 / 300 mg|"Period 1: clopidogrel 75 mg single dose~Period 2: clopidogrel 75 mg single dose~Period 3: clopidogrel 300 mg single dose~Each intake is at around 8:00 AM under fasted conditions."
62565303|NCT01812109|EXPERIMENTAL|Hutchison Technologies Inspectra StO2 NIRS|Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy (NIRS) evaluation of acute scrotum per protocol
62567783|NCT01818271|EXPERIMENTAL|community-based group rehabilitation|"Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:~* Advanced dynamic tasks, including stepping and other transitional tasks to treadmill \& over ground walking) with use of various inexpensive exercise assistive equipment such as mini-exercise stepper or elliptical machines.~* Treadmill walking exercise program."
62567784|NCT04577404|EXPERIMENTAL|MT-1186|Oral Edaravone administered once daily for 10 days out of 14, followed by a 14-day drug- free period
62181054|NCT00823446|PLACEBO_COMPARATOR|Normal Saline|
62567785|NCT00765687|NO_INTERVENTION|Observation|
62565304|NCT04268225|EXPERIMENTAL|Ultrasound Guided Dynamic Needle Tip Positioning Technique|In this arm the US transducer, protected with a sterile cover and sterile gel will be placed in the short axis above the distal end of the selected vein, moving the probe to place the vein in the center of the ultrasound screen under the middle mark of the image. The catheter needle will be inserted close to the transducer. The needle tip will be visualized as a white dot on the ultrasound screen. Then, the transducer will be shifted slightly proximally until the white dot disappears from the screen. The needle and the transducer will be moved alternately toward the patient several times to visualize the needle tip in real time. After penetrating the anterior wall of the vein, these steps will be repeated a few more times with a smaller insertion angle to visualize the white dot in the vein. Finally, the outer catheter will be fully advanced and the needle core will be extracted.
62565305|NCT04268225|ACTIVE_COMPARATOR|Traditional insertion group|For traditional insertion technique insertion attempt will be blind or tactile. Otherwise, the same protocol and measurements as elaborated for the US guided group will be applied.
62565306|NCT03652051|EXPERIMENTAL|AZR-MD-001 Low Dose|AZR-MD-001 Low Dose will be dosed up to once daily.
62565307|NCT03652051|EXPERIMENTAL|AZR-MD-001 Mid Dose|AZR-MD-001 Mid Dose will be dosed up to once daily.
62565308|NCT03652051|EXPERIMENTAL|AZR-MD-001 High Dose|AZR-MD-001 High Dose will be dosed up to once daily.
62565309|NCT03652051|SHAM_COMPARATOR|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to once daily.
62565310|NCT06404398|EXPERIMENTAL|OMNICHROMA|one single shade
62565311|NCT06404398|EXPERIMENTAL|Ceram. x spectra|multi- shade
62565312|NCT05514561||Patients with chronic lower gastrointestinal symptoms|We enroll adults older than 18 years with chronic lower GI symptoms for more than 1 month and are scheduled for a colonoscopy. The lower GI symptoms consist of any of the followings; lower abdominal pain, constipation, diarrhea, rectal bleeding, change in stool caliber, and abdominal bloating.
62565313|NCT01412567|ACTIVE_COMPARATOR|Vaccine+HBIG|
62565314|NCT01412567|PLACEBO_COMPARATOR|Vaccine+Placebo|
62181055|NCT03503383||Controlled group|pregnant women without any medical disorders during pregnancy
62565315|NCT01981460|NO_INTERVENTION|Chloroprep and biopatch|Both arms are cleaned with chloroprep and a biopatch is placed on each arm.
62565316|NCT01981460|EXPERIMENTAL|Methylene blue and light treatment|Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
62565317|NCT00419991|NO_INTERVENTION|1 Tigecycline|
62565318|NCT04524793|OTHER|Endovenous Microwave Ablations|Patients that have undergone Endovenous Microwave Ablation from ECO (Nanjing ECO Microwave System Co., Ltd) to treat primary great and short saphenous vein reflux
62565319|NCT01129427|EXPERIMENTAL|Group clopidogrel - clopidogrel + pantoprazole|"Period 1:~* Day 1: clopidogrel 300 mg loading dose~* Day 2 to Day 5: clopidogrel 75 mg, once daily~Period 2:~* Day -7 to Day -1: pantoprazole 80 mg, once daily~* Day 1: clopidogrel 300 mg loading dose + pantoprazole 80 mg concomitantly~* Day 2 to Day 5: clopidogrel 75 mg + pantoprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions."
62565320|NCT01129427|PLACEBO_COMPARATOR|Group placebo - placebo + pantoprazole|"Period 1:~* Day 1: placebo loading dose~* Day 2 to Day 5: placebo, once daily~Period 2:~* Day -7 to Day -1: pantoprazole 80 mg, once daily~* Day 1: placebo loading dose + pantoprazole 80 mg concomitantly~* Day 2 to Day 5: placebo + pantoprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions."
62565321|NCT01129427|EXPERIMENTAL|Group clopidogrel + pantoprazole - clopidogrel|"Period 1:~* Day -7 to Day -1: pantoprazole 80 mg, once daily~* Day 1: clopidogrel 300 mg loading dose + pantoprazole 80 mg concomitantly~* Day 2 to Day 5: clopidogrel 75 mg + pantoprazole 80 mg concomitantly, once daily~Period 2:~* Day 1: clopidogrel 300 mg loading dose~* Day 2 to Day 5: clopidogrel 75 mg, once daily~Each intake is under fasted conditions."
62565322|NCT01129427|PLACEBO_COMPARATOR|Group placebo + pantoprazole placebo|"Period 1:~* Day -7 to Day -1: pantoprazole 80 mg, once daily~* Day 1: placebo loading dose + pantoprazole 80 mg concomitantly~* Day 2 to Day 5: placebo + pantoprazole 80 mg concomitantly, once daily~Period 2:~* Day 1: placebo loading dose~* Day 2 to Day 5: placebo, once daily~Each intake is under fasted conditions."
62565323|NCT01131455|ACTIVE_COMPARATOR|Fusion+ACP+Autograft|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus, external rotation and neutral foot dorsiflexion). The arthrodesis undertaken for all groups will be the standard arthroscopic ankle arthrodesis with portals to the ankle (anterior medial / anterior lateral), skin incision only technique with dissection through the capsule and penetration to the joint. Standard debridement of the gutters, tibia osteophyte, tibia-talor joint resection and autograft preparation will be performed in the joint. Depending on randomization of the subject, (Autologous concentrated Plasma)ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and reduced.
62565324|NCT01131455|ACTIVE_COMPARATOR|Fusion + ACP +DBM|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus and external rotation and neutral foot dorsiflexion). Depending on the randomization of the subject, (Autologous Concentrated Plasma)ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and then reduced.
62565325|NCT01131455|NO_INTERVENTION|Standard-Fusion +Autograft only|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus and external rotation and neutral foot dorsiflexion). The arthrodesis undertaken for all groups will be the standard arthroscopic ankle arthrodesis with portals to the ankle (anterior medial / anterior lateral), skin incision only technique with blunt dissection through the capsule and penetration to the joint. Depending on the randomization of the subject, ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and then reduced.
62565326|NCT02482688|EXPERIMENTAL|Multisensory Acute|Multisensory intervention delivered within 2 months post-stroke.
62565327|NCT02482688|EXPERIMENTAL|Multisensory Chronic|Multisensory intervention delivered 6 months post-stroke.
62565328|NCT02482688|ACTIVE_COMPARATOR|Unisensory Acute|Unisensory intervention delivered within 2 months post-stroke.
62565329|NCT02482688|ACTIVE_COMPARATOR|Unisensory Chronic|Unisensory intervention delivered 6 months post-stroke.
62565330|NCT06271148||Female surgeons|Female surgeons
62565331|NCT01508611|ACTIVE_COMPARATOR|30% silver diammine fluoride|The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied in erupting molars with a disposable microbrush for 3m. Then the surface will be washed for 30s.
62565332|NCT01508611|ACTIVE_COMPARATOR|cross-toothbrushing|Children will be oriented to proceed cross-toothbrushing in erupting molars
62565333|NCT01456754|EXPERIMENTAL|High feeding frequency (14x)|
62565334|NCT01456754|EXPERIMENTAL|low feeding frequency (3x)|
62565335|NCT01253902|ACTIVE_COMPARATOR|bimatoprost ophthalmic solution 0.01%|One drop of bimatoprost ophthalmic solution 0.01% (Lumigan®) administered to affected eye(s), once daily in the evening for 12 weeks.
62565336|NCT01253902|ACTIVE_COMPARATOR|travoprost ophthalmic solution 0.004%|One drop of travoprost ophthalmic solution 0.004% (Travatan Z®) administered to affected eye(s), once daily in the evening for 12 weeks.
62565337|NCT01253902|ACTIVE_COMPARATOR|latanoprost ophthalmic solution 0.005%|One drop of latanoprost ophthalmic solution 0.005% (Xalatan®) administered to affected eye(s), once daily in the evening for 12 weeks.
62565338|NCT01571323|ACTIVE_COMPARATOR|Misoprostol|
62565339|NCT01571323|ACTIVE_COMPARATOR|Oxytocin|
62565340|NCT01571323|ACTIVE_COMPARATOR|Oxytocin and Misoprostol|
62565341|NCT05005507|EXPERIMENTAL|Arm 1: JNJ-73763989 + nucleos(t)ide analog (NA) + pegylated interferon alpha-2a (PegIFN-alpha-2a)|Participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks for 24 weeks plus NA treatment (either entecavir \[ETV\], tenofovir disoproxil or tenofovir alafenamide \[TAF\] tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly for 24 weeks.
62565342|NCT05005507|EXPERIMENTAL|Arm 2: JNJ-73763989 + NA + PegIFN-alpha-2a|Participants will receive JNJ-73763989 SC injection once every 4 weeks for 24 weeks plus NA treatment (either ETV, tenofovir disoproxil, or TAF tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly from Week 12 till Week 24.
62181056|NCT03503383||Diseased group|Patients complaining of hypertension with pregnancy
62181057|NCT02237625||Medical History of HPP Patients|Patient clinical data will be collected related to the diagnosis, onset, progression, treatment course and outcome for patients with HPP.
62181058|NCT02732002|EXPERIMENTAL|OCBRA group.|This group of patients will follow the proposed methodological approach for work related injuries rehabilitation.
62565343|NCT05005507|EXPERIMENTAL|Arm 3: JNJ-73763989 + NA + PegIFN-alpha-2a|Participants will receive JNJ-73763989 SC injection once every 4 weeks for 24 weeks plus NA treatment (either ETV, tenofovir disoproxil or TAF tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly from baseline till Week 12.
62565344|NCT03114930|OTHER|Standard output|
62181059|NCT02725398|EXPERIMENTAL|Buscopan group|First to use standard white light to observe, to record spasm score, to observe the lesion.Buscopan (BSP, 20mg) is administered by endoscopic nurse, recorded blindly.
62391274|NCT03737305|EXPERIMENTAL|Distractor Test Group|Test group with manual distraction performed by the physiotherapist in the office and the condylar distraction performed by the patient with the condylar distraction device in an ambulatory basis.
62391275|NCT01793012||critically ill intensive care patients|Treatment with one or more of the following antibiotics: piperacillin/tazobactam, cefepime, meropenem, ciprofloxacin, linezolid, colistin
62391276|NCT05794347|EXPERIMENTAL|Group-A (Vertical sitting traction)|This session will be followed by the application of the continuous mechanical traction in the vertical sitting position with a belt around the chest. A total of 30 minutes session per day with 5 sessions per week for 12 weeks will be provided to the participants in this group
62181060|NCT02725398|ACTIVE_COMPARATOR|Scopolamine group|First to use standard white light to observe, to record spasm score, to observe the lesion.Scopolamine is administered by endoscopic nurse, recorded blindly.
62181061|NCT02725398|PLACEBO_COMPARATOR|physiological saline group|First to use standard white light to observe, to record spasm score, to observe the lesion. Physiological saline is administered by endoscopic nurse, recorded blindly.
62181062|NCT03271918|EXPERIMENTAL|Study Group|This group received cabergoline, in a total week dose of 3.5 mg, starting 6 months after transphenoidal surgical approach with evidence of tumoral rest in MRI and pituitary adenoma hystopathological confirmation.
62181063|NCT03271918|NO_INTERVENTION|Control Group|This group was followed, with clinical visits in same frequency of study group, but without intervention.
62391277|NCT05794347|ACTIVE_COMPARATOR|Group-B (supine lying traction)|Following the conventional treatment, continuous mechanical traction will be applied in the supine lying position with a traction force equal to 50% of the total body weight. A total of 20 minutes session per day with 5 sessions per week will be provided to the participants in group B.
62565345|NCT03114930|OTHER|Non standard output|
62565346|NCT03048708|EXPERIMENTAL|Obese patients treated with bariatric surgery|Patients with morbid obesity who were eligible for and willing to have bariatric surgery performed
61995869|NCT05410626|EXPERIMENTAL|original|This study use 18 and 36 mg of original prolong-release methylphenidate. Dosing of Medication is equivalent to immediate-release. Medication administration is once daily in the morning.
61995870|NCT05410626|ACTIVE_COMPARATOR|generic|This study use 18 and 36 mg of generic prolong-release methylphenidate. Dosing of Medication is equivalent to immediate-release. Medication administration is once daily in the morning.
61995871|NCT00112242|EXPERIMENTAL|1. Melan-A ELA|500 mcg Melan-A ELA analog peptide + 1 ml Montanide ISA-51
62565347|NCT03048708|NO_INTERVENTION|Obese patients not treated with bariatric surgery|Age and BMI matched patients with morbid obesity who either were not eligible for or were not willing to have bariatric surgery performed - no sufficient number of matched patients has completed the study; the arm of obese patients not treated with bariatric surgery has been discarded for the purpose of the analyses
62565348|NCT04742400|EXPERIMENTAL|Tolebrutinib (Cohort A)|Tolebrutinib 60 mg/day for 48 weeks, Tolebrutinib 120 mg/day for 96 weeks
62565349|NCT04742400|EXPERIMENTAL|Tolebrutinib (cohort B)|Tolebrutinib 120 mg daily
62565350|NCT04742400|EXPERIMENTAL|tolebrutinib (initial cohort)|Tolebrutinib 60 mg daily
62565351|NCT01954576|EXPERIMENTAL|NovoTTF therapy|Patients undergo NovoTFF therapy at least 18 hours daily for 6 months (bevacizumab-naive) or 4 months (bevacizumab-refractory). Treatment may continue for up to 2 years in patients experiencing CR, PR, or SD.
62565352|NCT02064816|EXPERIMENTAL|Rebif® Morning Administration|
62565353|NCT02064816|EXPERIMENTAL|Rebif® Evening Administration|
62565354|NCT04463407|NO_INTERVENTION|Control group|Participants keep their normal routine without intervention.
62565355|NCT04463407|EXPERIMENTAL|Experimental group|Participants receive a single nutritional intervention previous to a critical period.
62565356|NCT02647008|EXPERIMENTAL|ACTIVE TENS|ACTIVE TENS
61995872|NCT00112242|EXPERIMENTAL|2. Melan-A ELA + NY-ESO-1b + MAGE-A10|500 mcg Melan-A ELA analog peptide + 500 mcg NY-ESO-1b(A) analog peptide + 500 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51
61995873|NCT00112242|EXPERIMENTAL|3. Melan-A ELA + NY-ESO-1b + MAGE-A10 + CpG|500 mcg Melan-A ELA analog peptide + 500 mcg NY-ESO-1b(A) analog peptide + 500 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51 + 2.5 mg CpG-7909/PF-3512676
61995874|NCT00112242|EXPERIMENTAL|4. Melan-A EAA/ELA + NY-ESO-1lp + MAGE-A10+ CpG|"* If patient is HLA-A2 positive: 100 mcg Melan-A EAA native peptide (during first cycle) or 100 mcg ELA analog peptide (during other cycles) + 500 mcg NY-ESO-1lp long peptide + 100 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676~* If patient is HLA-A2 negative: 500 mcg NY-ESO-1lp long peptide+ 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676"
61995875|NCT00112242|EXPERIMENTAL|5. Melan-A EAA/ELA + NY-ESO-1lp + MAGE-A10+ CpG+ IL-2|"* If patient is HLA-A2 positive: 100 mcg Melan-A EAA native peptide (during first cycle) or 100 mcg ELA analog peptide (during other cycles) + 500 mcg NY-ESO-1lp long peptide + 100 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676 + low dose IL-2~* If patient is HLA-A2 negative: 500 mcg NY-ESO-1lp long peptide+ 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676 + low dose IL-2"
62181064|NCT02587897||Dental Hygiene Students|Students enrolled in the 2-year dental hygiene academic coursework programs at the University of Southern California and Loma Linda University who are exposed to high-intensity work-related hand activities as part of their training program.
62181065|NCT02587897||Occupational Therapy Students|Students enrolled in the 2-year occupational therapy academic coursework program at the University of Southern California.
62565357|NCT02647008|PLACEBO_COMPARATOR|PLACEBO|INACTIVE TENS
62565358|NCT02647008|NO_INTERVENTION|CONTROL|NO TENS
62565359|NCT05357521||Borderline personality disorder|female patients between 18 and 25 years old meeting DSM V criteria for borderline personality disorder
62565360|NCT05357521||Control|female participants between 18 and 25 years old, with no psychiatric history, not meeting criteria for borderline personality disorder
62565361|NCT03494712|EXPERIMENTAL|S 95010|Increasing single doses of S 95010 to 5 subjects.
62565362|NCT03494712|PLACEBO_COMPARATOR|Placebo|Increasing single doses of Placebo to 2 subjects.
62565363|NCT04751552|ACTIVE_COMPARATOR|Levobupivacaine group|Patients receive an ESPB with the local anaesthetic levobupivacaine
62565364|NCT04751552|PLACEBO_COMPARATOR|Placebo group|Patients receive an ESPB with 0,9% saline
62565365|NCT03048214|SHAM_COMPARATOR|General Anaesthesia|Patients would receive routine general anaesthesia for their distal radial fracture surgery
62565366|NCT03048214|EXPERIMENTAL|Regional Anaesthesia|Patients would receive routine infraclavicular nerve block for their distal radial fracture surgery
62565367|NCT03592238|EXPERIMENTAL|Aerobic Exercise Intervention|Participants will exercise on a motor-driven treadmill at a constant speed during the 23-min period.
62565368|NCT03592238|ACTIVE_COMPARATOR|Trier Social Stress Test for Children|The Trier Social Stress Test for Children consists of a speech task in which children must finish a story and a mental arithmetic task, completed in front of a camera and two neutral observers.
62565369|NCT03592238|PLACEBO_COMPARATOR|Seated Rest|Participants will sit in a comfortable chair, placed in the same room as the motor-driven treadmill, for a period of 25-min.
62565370|NCT02314026|EXPERIMENTAL|Suspected NASH|13C-Octanoate, 13C-Methacetin
62565371|NCT04656756|EXPERIMENTAL|Experimental Group|The mothers in the experimental group (60) were administered.
62565372|NCT04656756|NO_INTERVENTION|Control Group|The mothers in the control group (60) were given the routine care.
62565373|NCT05809869|EXPERIMENTAL|Durvalumab in combination with tremelimumab and radioembolisation|"1. Tremelimumab 300 mg intravenous infusion on week 1 only~2. Durvalumab 1500mg intravenous infusion on week 1, 5, 9, 13, 17, 21 and 25, for a total of 7 cycles~3. Radioembolisation with yttrium-90 microspheres on week 2 only"
62565374|NCT06007001|EXPERIMENTAL|Telemedicine|Patients in the intervention group will receive weekly teleconsultation of 30 minutes during 8 weeks through the secure Edumeet platform. In pilot 1, tele-rehabilitation training will be performed by a remote physiotherapist and will consist of a series of rehabilitation exercises. In pilot 2, tele-psychological support will be performed by a remote psychologist and will consist of techniques for managing emotions and stress. In the intervention group, patients will also have the possibility to wear a smartwatch to automatically collect physical parameters.
62565375|NCT06007001|NO_INTERVENTION|Usual care|Patients in the control group will receive usual care.
62565376|NCT01268670|ACTIVE_COMPARATOR|Ibuprofen|Subjects will receive topical LET and oral ibuprofen.
62565377|NCT01268670|ACTIVE_COMPARATOR|Oxycodone|Subjects will receive topical LET and oral oxycodone.
62181066|NCT02517528|EXPERIMENTAL|ABT-450/r/ABT-267 + ABT-333 + Ribavirin|ABT-450/r/ABT-267 once daily + ABT-333 twice daily + weight-based RBV divided twice daily for 12 weeks
62565378|NCT01268670|PLACEBO_COMPARATOR|Placebo|Subjects will receive topical LET and oral placebo.
62565379|NCT03292666||Extended anticoagulation|Patients with acute VTE treated with oral anticoagulants for \> 3 months
62565380|NCT03292666||No extended anticoagulation|Patients with acute VTE treated with oral anticoagulants for no longer than 3 months
62565381|NCT02028663|EXPERIMENTAL|CJ-12420 Amg|50 volunteers will be administered CJ-12420 Amg
62181067|NCT05678647|EXPERIMENTAL|Oral sucrosomial Iron (SiderAl Forte®)|Oral sucrosomial Iron (SiderAl Forte®) is given to blood donors after blood donation
62565382|NCT02028663|EXPERIMENTAL|CJ-12420 Bmg|50 volunteers will be administered CJ-12420 Bmg
62181068|NCT05678647|ACTIVE_COMPARATOR|Oral iron sulphate (Duroferon®)|Oral iron sulphate (Duroferon®) is given to blood donors after blood donation
62181069|NCT06276205|EXPERIMENTAL|Vitamin D + Levothyroxine|
62565383|NCT02028663|EXPERIMENTAL|CJ-12420 Cmg|50 volunteers will be administered CJ-12420 Cmg
62565384|NCT02028663|ACTIVE_COMPARATOR|Esomeprazole 40mg|50 volunteers will be administered Esomeprazole 40mg
62565385|NCT00261209|EXPERIMENTAL|Collagenase Injection|Injection of collagenase into adhesion restricting tendon gliding
62565386|NCT05603871||ligamentoplasty of ligamentum teres|"The patients will be examined for:~1. Length of both lower limbs in relation to each other.~2. Length of both lower limbs according to patient age.~3. Presence of hump related to the outer surface of the hip~4. Presence of pain, abnormal gait, Trendlenburg test.~An addition to the steps of the open reduction, the following were done:~1. Identification of ligamentum teres~2. Ligamentoplasty of ligamentum teres"
62565387|NCT00867529|EXPERIMENTAL|Treatment (rituximab pre- and post-transplant)|Patients receive rituximab IV, pre- and post-transplant, on days -3, 10, 24, and 38. Patients undergo donor peripheral blood stem cell transplant on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity.
62565388|NCT01935609|EXPERIMENTAL|Couples counseling|Intervention to promote couples' adjustment (TCI) - The TCI was developed based upon considerable clinical experience and research review. The TCI is a structured approach to helping couples after brain injury address issues related to relationship quality and emotional well-being. The TCI is implemented in five or six (optional parenting session) session. Each session is in-person and lasts for 120 minutes.
62181070|NCT06276205|ACTIVE_COMPARATOR|Levothyroxine Alone|
62181071|NCT01172639|OTHER|CoBRA classic high risk group|"* Methotrexate 15mg tablet by mouth, weekly for entire trial~* Sulfasalazine 2g tablet by mouth, daily for 40 weeks~* Prednisone tablet by mouth, weekly step down scheme 60 - 40 - 25 - 20 - 15 - 10 mg daily for 6 weeks, followed by 7.5mg daily till week 28, then further tapered down to stop at week 32"
62181072|NCT01172639|OTHER|CoBRA slim high risk group|"* Methotrexate 15mg tablet by mouth, weekly for entire trial~* Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32"
62565389|NCT01935609|NO_INTERVENTION|Waitlist Control|Couples are randomly assigned to the treatment group or waitlist control (WLC) group. Couples will complete the study measures on 2 occasions, 5 weeks apart. In fairness, WLC couples will then be offered the opportunity to participate in the intervention.
62565390|NCT05823233|EXPERIMENTAL|Study group|Cold application+Deep friction+Home exercise+Eccentric stretching
62565391|NCT05823233|EXPERIMENTAL|Control Group|Cold application +Deep friction +Home exercise
62565392|NCT05308953|EXPERIMENTAL|NVG-291 SAD|Doses will begin at the lowest dose level in Cohort 1, increasing in dose with each subsequent cohort to the highest dose level in Cohort 6 or until a maximum tolerated dose (MTD) is reached.
62565393|NCT05308953|EXPERIMENTAL|NVG-291 MAD|Participants will receive 1 dose daily for for 14 consecutive days. The maximum starting dose for MAD will be 2 dose levels lower than the maximum dose achieved during SAD. There will be a maximum of 3 dosing cohorts in Part 2. The maximum daily dose in Part 2 will not exceed the maximum daily dose tolerated in Part 1.
62565394|NCT05308953|EXPERIMENTAL|NVG-291 MAD - Males and Premenopausal Females|Participants will receive 1 dose daily for for 14 consecutive days. The dose maximum daily dose in Part 3 will not exceed the maximum daily dose tolerated in either Part 1 or 2.
62565395|NCT04344483|ACTIVE_COMPARATOR|Group A ( Lidocaine + Adrenaline)|Group A patients will receive 2% Lidocaine and 1:100,000 adrenaline soaked gauze over skin graft donor site of thigh per operatively for 10 minutes. After 10 minutes this dressing will be removed and sufratul dressing will be applied over donor site.
62181073|NCT01172639|OTHER|CoBRA avant-garde high risk group|"* Methotrexate 15mg tablet by mouth, weekly for 40 weeks (continued for entire trial if randomized to Methotrexate monotherapy at week 40)~* Leflunomide 10mg tablet by mouth, daily for 40 weeks (continued for entire trial if randomized to Leflunomide monotherapy at week 40)~* Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32"
62181074|NCT01172639|OTHER|CoBRA slim low risk group|"* Methotrexate 15mg tablet by mouth, weekly for entire trial~* Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32"
62181075|NCT01172639|OTHER|Tight Step Up low risk group|"* Methotrexate 15mg tablet by mouth, weekly for entire trial~* No oral steroids allowed during the first year of the trial"
62181076|NCT03462368|ACTIVE_COMPARATOR|Control|Root surface treatment by scaling and root planing
62181077|NCT03462368|EXPERIMENTAL|antimicrobial photodynamic therapy|Root surface treatment by antimicrobial photodynamic therapy
62181078|NCT03462368|ACTIVE_COMPARATOR|Photobiomodulation|Treatment of the whole surgical site with laser
62181079|NCT06045663|ACTIVE_COMPARATOR|laminectomy group|"patient will divided into two group the first group will undergo cervical laminectomy while the second group will undergo cervical laminectomy with lateral mass fixation .all surgical related events and comorbidities will be recorded.~the patient will examine after 3 months of operation and patient's myelopathy grade and functional status was evaluated after 6 months using modified Japanese orthopedic association (mJAO) score. Radiological Follow-up by using plain X-rays, 6 months follow up assessment of cervical spine sagittal alignment using (C2-C7) Cobb's angle and MRI scan if needed follow up will be at our department follow up clinic ."
62181080|NCT06045663|ACTIVE_COMPARATOR|laminectomy with lateral mass fixation|"patient will divided into two group the first group will undergo cervical laminectomy while the second group will undergo cervical laminectomy with lateral mass fixation .all surgical related events and comorbidities will be recorded.~the patient will examine after 3 months of operation and patient's myelopathy grade and functional status was evaluated after 6 months using modified Japanese orthopedic association (mJAO) score. Radiological Follow-up by using plain X-rays, 6 months follow up assessment of cervical spine sagittal alignment using (C2-C7) Cobb's angle and MRI scan if needed follow up will be at our department follow up clinic ."
62181081|NCT04271566|EXPERIMENTAL|Experimental|Patients receiving an education program along with usual medical care
62181082|NCT04271566|NO_INTERVENTION|Non Experimental|Patients receiving usual medical care
62181083|NCT02869906||FFR and iFR|The investigators compare FFR and iFR values in the acute phase of STEMI and in the subacute phase, 5-7 days after STEMI.
62181084|NCT01624298|NO_INTERVENTION|Wait List Control Group|The wait list control group will be asked to wait for approximately 4 1/2 months before being reassessed and then, unless found to be ineffective or harmful, receive the intervention being provided by the counselor.
62181085|NCT01624298|EXPERIMENTAL|Intervention Group|Children randomized into the intervention group will immediately receive the Trauma Focused Cognitive Behavioral Therapy with a trained counselor for 12 weeks.
62565396|NCT04344483|PLACEBO_COMPARATOR|Group B ( Normal Saline)|Group B patients will receive normal saline soaked gauze over skin graft donor site of thigh intraoperatively for 10 minutes. After 10 minutes this dressing will be removed and sufratul dressing will be applied over donor site
62181086|NCT01681199|EXPERIMENTAL|Fluvastatin extended release tablet|Fluvastatin extended release tablet 80mg/day
62181087|NCT02205099|EXPERIMENTAL|SKL15508 High Dose|SKL15508 High Dose
62565397|NCT04802486|EXPERIMENTAL|Arm 1: Exercise Intervention and Standard Care|A home-based exercise intervention as well as standard care for your cancer as prescribed by your oncologist
62565398|NCT04802486|NO_INTERVENTION|Arm 2: Standard Care|Standard care for your cancer as prescribed by your oncologist
62772813|NCT02334397|ACTIVE_COMPARATOR|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program. Specifically, Total Control is a comprehensive pelvic fitness and wellness program designed by board-certified female pelvic medicine and reconstructive surgery (FPMRS) practitioners as well as physical therapists that combines pelvic floor and core muscle strengthening. Subjects will participate in 1 standardized class per week during their second trimester for a total of 6 weeks. Women will also participate in a weekly educational session which will include keynote speakers who are experts in various aspects of the labor and delivery process. Women in this group will complete questionnaires and consent to use of their delivery outcomes. Women will also wear pedometers to track daily general activity.
62772814|NCT02334397|NO_INTERVENTION|Control Group|This group will consist of eligible women who were not randomized to the fitness and education program. Participants will complete questionnaires and consent to use of their delivery outcomes. Women will also wear pedometers to track daily general activity.
62181088|NCT02205099|EXPERIMENTAL|SKL15508 Medium Dose|SKL15508 Medium Dose
62565399|NCT01422889||ION Registry|The ION Registry population was designed to collect real world safety and clinical outcomes data. There were 1120 subjects were enrolled, however 9 subjects did not receive a study stent therefore 1111 subjects were eligible for follow up.
62565400|NCT05280444|EXPERIMENTAL|Lipiodol-TACE with Idarubicin|The initial dose of idarubicin is 10 mg and the maximum tolerated dose is 20 mg. Idarubicin is first dissolved in water for injection to make a solvent of 2mg/ml, which is then mixed with lipiodol to make an emulsion with a ratio of 1:2. Lipiodol-idarubicin emulsion is slowly injected, followed by embolization with embolic agents.
62565401|NCT02588898||Patients with type 2 diabetes|Patients (both men and women) with diagnosed type 2 Diabetes for at least 5 years. Blood collection and electrophysiological tests were performed.
62565402|NCT02588898||Controls free of diabetes|Controls (both men and women) are people of the same age who are free of Diabetes. Blood collection and electrophysiological tests were performed.
62565403|NCT03312036|EXPERIMENTAL|CPFA Patients|Patients affected by acute or acute on chronic liver failure who undergo Coupled plasma filtration and adsorption (CPFA) to recover their basal liver function or as a bridge to liver transplantation. The intervention is CPFA treatment which lasts 6 hour length. The intervention can be repeated for a maximum of 5 times.
62565404|NCT03098719|EXPERIMENTAL|Intervention|
62565405|NCT03098719|NO_INTERVENTION|Control|
62565406|NCT05433818|EXPERIMENTAL|Skin-to-skin care|"Pregnant women will assigned to SSC were inform about SSC. SSC will ensured postpartum in a supported diagonal-flexion position continuously by the researchers for 45-120 minutes. Mothers in group A also benefit from the hospital's routine breastfeeding education service.~As a result, after the SSC application, the mother will be evaluated with the breastfeeding efficiency scale and the maternal attachment scale."
62565407|NCT05433818|ACTIVE_COMPARATOR|Breastfeeding Education|Group B will received face-to-face breastfeeding education in the first phase of labor. A copy of the brochure will given to the pregnant women. In the early postpartum period, breastfeeding will encouraged practically and observed by the researchers. Participants' questions will answered. As a result, after the breastfeeding education, the mother will be evaluated with the breastfeeding efficiency scale and the maternal attachment scale.
62181089|NCT02205099|EXPERIMENTAL|SKL15508 Low Dose|SKL15508 Low Dose
62181090|NCT02205099|PLACEBO_COMPARATOR|Placebo|Placebo
62181091|NCT03964181||Students Grades 3-12|
62181092|NCT03964181||Parents of Students Grades K-12|
62181093|NCT03964181||School Based Teachers and Staff Grades K-12|
62181094|NCT03577756||Infants with cystic fibrosis|Twelve months infants with cystic fibrosis will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Rough Motor Function Measure.
62181095|NCT03577756||Healthy infants|Twelve months healthy infants will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Rough Motor Function Measure.
62565408|NCT05433818|NO_INTERVENTION|Kontrol|No intervention will made to Group C by the researchers. Participants will benefit from the hospital's routine care and breastfeeding education services. As a result, postpartum mother will be evaluated with breastfeeding efficiency scale and maternal attachment scale.
62565409|NCT05027659|EXPERIMENTAL|intervention|This study was carried out with two groups. Virtual reality glasses were used for the intervention group.
62565410|NCT05027659|NO_INTERVENTION|control|No application was made to the control group, standard procedure was followed.
62565411|NCT04969328|ACTIVE_COMPARATOR|ParTNer-STEPs|Parents and adolescents will receive the ParTNER-STEPs program and standard care.
62565412|NCT04969328|NO_INTERVENTION|Standard care|The adolescent and their parents will receive standard care
62565413|NCT01819233|EXPERIMENTAL|Behavioral dietary intervention|Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet. Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy). Patients undergo radiation therapy QD 5 days a week for 6 weeks.
62565414|NCT00396071|EXPERIMENTAL|1|Vildagliptin 100 mg qd
62565415|NCT00396071|PLACEBO_COMPARATOR|2|Matching placebo
62565416|NCT04295408|PLACEBO_COMPARATOR|PLACEBO|Pericapsular Nerve Group block with 40 ml saline
62565417|NCT04295408|EXPERIMENTAL|Pericapsular nerve group block|Pericapsular Nerve Group block with 2 mg.kg-1Ropivacaine in 40 ml of saline
62565418|NCT03016884|EXPERIMENTAL|RA patients|RA patients will be administered Zostavax vaccine once 2 weeks before initiation of bDMARD, and be monitored accordingly
62565419|NCT03016884|EXPERIMENTAL|Healthy Controls|healthy control patients will be administered Zostavax vaccine and be monitored accordingly
62181096|NCT03051997|EXPERIMENTAL|Caregiver Contingency Management + Usual Drug Court Treatment|This group will receive a caregiver contingency management intervention plus the standard outpatient substance abuse treatment services provided at JDC.
62181097|NCT03051997|ACTIVE_COMPARATOR|Usual Drug Court Treatment|This group will receive the standard outpatient substance abuse treatment services provided at JDC.
61995876|NCT03585452|ACTIVE_COMPARATOR|Group C|Patients with typical anesthetic regimen: premedication: 2 mg estazolam p.o. and 10 mg morphine s.c. - 1 hour before procedure. Preoxygenation and induction of anaesthesia: remifentanyl 1 µg/kg, etomidate 0.3 mg/kg, pancuronium 0.1 mg/kg and intubation. Maintenance of the anesthesia: remifentanyl 0.2-0.5 µg/kg/min and propofol 2-4 mg/kg/min infusions. Ventilation with Air/O2. Additionally: nitroglycerine infusion or phenylephrine 0.05-0.1 mg boluses will be used for normotension maintenance at demanding doses. Subsequently typical CABG procedure with normothermic CPB will be performed. Weaning from CPB will be performed with inotropic support (dobutamine) and vasodilator (nitroglycerine) administration - with patients dependent doses. Routine recovery after surgery.
61995877|NCT03585452|EXPERIMENTAL|Group D|Regimen will be the same with additional dexmedetomidine infusion: with loading dose: 0.5 µg/kg/h through 1 hour and then dose will be reduced to 0.25 µg/kg/h and infusion will be continued during surgery and postoperative period to the total dose of 200 µg. Anesthetics and opioids doses will be adjusted under hemodynamic and eeg sensor - SedLine Masimo.
61995878|NCT01719185|EXPERIMENTAL|Phentermine and B12|Those in the experimental group will take 37.5 mg of phentermine daily as well as receive 1000 mg intramuscular injections of B12 weekly.
61995879|NCT01719185|ACTIVE_COMPARATOR|Phentermine|Those in the control group will take phentermine 37.5 mg daily as well as receive 1000 mg intramuscular injections of saline weekly.
61995880|NCT00578942|EXPERIMENTAL|Campath Purged Non-myeloablative ASCT|Campath Purged Non-myeloablative Allo Stem Cell Transplant (ASCT) in lymphoma, myeloma, or marrow failure: leukemia or myelodysplasia; and solid tumors
61995881|NCT01139528|ACTIVE_COMPARATOR|Operative treatment|Closed reduction of the fracture and osteosynthesis with 2-3 intramedullary K-wires (Bouquet method), cast treatment for 7-10 days followed by 5 weeks of buddy-strapping before removal of the K-pins
62181098|NCT05495919|EXPERIMENTAL|Control Group|No intervention was performed to reduce anxiety in the control group
62181099|NCT05495919|EXPERIMENTAL|video interaction group|Before the training, the students took videos and during the lesson, the videos were evaluated and feedback was given.
62565420|NCT05104437|EXPERIMENTAL|0-1-4 schedule group|Subjects receive the booster vaccine 3 months after the second dose.
62565421|NCT05104437|EXPERIMENTAL|0-1-6 schedule group|Subjects receive the booster vaccine 5 months after the second dose.
62565422|NCT01429948||Case group|Healthy subjects with silent cerebral infarction
62565423|NCT01429948||Control group 1|Patients with acute cryptogenic embolic stroke
62181100|NCT05495919|EXPERIMENTAL|Flipped Training|Before the training, educational materials were given to the students, and they were discussed with the students in the lesson.
62181101|NCT01046825|OTHER|Group A|"Completely resected stage I or completely resected abdominal stage II lesions.~Group A will include: COPAD x 2 cycles."
62181102|NCT01046825|OTHER|Group B|"All cases not eligible for Group A or Group C. (Murphy Stage III and non-CNS Stage IV)~Group B will include the intervention COP, COPD M3, CYM as follows:~Pre-Phase: COP~Induction: COPAD M3 x 2 cycles~Consolidation: CYM x 2 cycles."
62182627|NCT03557242|OTHER|Registry Arm|Upto an additional 100 subjects with preexisting indication for anti coagulation (e.g. atrial fibrillation, deep venous thrombosis, pulmonary embolism) or who are not eligible for randomization after TAVR due to development of a new indication for anti coagulation will be enrolled in the registry arm of the study.
62565424|NCT01429948||Control group 2|Patients with acute stroke with conventional stroke mechanisms
62565425|NCT04947007|ACTIVE_COMPARATOR|Group 1|In this group, US guided suprascapulary and axillary nerve block will be performed with 15cc+15c local anesthetic.
61995882|NCT01139528|NO_INTERVENTION|Conservative treatment|No attempt of reduction of the fracture, 7-10 days of cast treatment followed by 5 weeks of buddy-strapping
61995883|NCT02957175||Patients that develop SIRS|Immunophenotyping of patients that develop SIRS after heart surgery
61995884|NCT02957175||Patients that develop no SIRS|Immunophenotyping of patients that develop no SIRS after heart surgery
61995885|NCT05230212|EXPERIMENTAL|Pecan Breakfast Shake|Participants will be given a breakfast shake consisting primarily of pecans, and 1% milk.
62182628|NCT01151514||nrHA-AKI patients|Patients with hospital-acquired acute kidney injury not referred to the nephrologists
62565426|NCT04947007|ACTIVE_COMPARATOR|Group 2|In this group, US guided suprascapulary and axillary nerve block will be performed with 10cc+10c local anesthetic.
62565427|NCT04947007|ACTIVE_COMPARATOR|Group 3|In this group, US guided suprascapulary and axillary nerve block will be performed with 5cc+5c local anesthetic.
62565428|NCT04947007|ACTIVE_COMPARATOR|Group 4|In this group, US guided suprascapulary and axillary nerve block will be performed with serum physiologic.
62565429|NCT02009852||Oral cancer|"Subjects who suffer from oral cancer.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
62565430|NCT01997476|EXPERIMENTAL|Combined EUS, e-PFT and sEUS Testing|"Establish the advantage of combined EUS, ePFT \& sEUS testing to provide a more definitive diagnostic assessment, rather than each test alone.~Establish the advantage of reduced time and cost of combining EUS and ePFT, rather than when done separately."
62565431|NCT00113763|EXPERIMENTAL|Panitumumab plus best supportive care|Panitumumab will be administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants develop progressive disease or are unable to tolerate study drug. Participants will also receive best supportive care (BSC) as judged appropriate by the investigator and according to institutional guidelines.
61995886|NCT05230212|ACTIVE_COMPARATOR|Cream Breakfast Shake|Participants will be given a breakfast shake consisting primarily of heavy whipping cream.
61995887|NCT02502266|ACTIVE_COMPARATOR|Phase II Arm I (reference regimen)|Patients undergo physician's choice of standard of care chemotherapy, comprising either paclitaxel IV over 60 minutes on days 1, 8, 15, and 22 every 28 days (Regimen I); pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 every 28 days (Regimen II); or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 every 28 days or days 1-5 every 21 days (Regimen III). Treatment continues in the absence of disease progression or unacceptable toxicity. No modification of the assigned regimens, such as additional drugs (gemcitabine, or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016)
61995888|NCT02502266|EXPERIMENTAL|Phase II Arm II (cediranib maleate, olaparib)|Patients receive cediranib maleate PO QD and olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
61995889|NCT02502266|EXPERIMENTAL|Phase II Arm III (cediranib maleate)|Patients receive cediranib maleate PO daily continuously. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
61995890|NCT02502266|EXPERIMENTAL|Phase II Arm IV (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study. (In July 2018, the Data Monitoring Committee voted to exclude the olaparib alone regimen).
61995891|NCT02502266|ACTIVE_COMPARATOR|Phase III Arm I (reference regimen)|Patients undergo physician's choice standard of care chemotherapy as in Phase II Arm I. No modification of the assigned regimens, such as additional drugs (gemcitabine or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016)
61995892|NCT02502266|EXPERIMENTAL|Phase III Arm II (cediranib maleate, olaparib)|Patients receive cediranib maleate PO and olaparib PO as in Phase II Arm II. Patients also undergo CT and MRI throughout the study.
61995893|NCT02502266|EXPERIMENTAL|Phase III Arm III (single-agent cediranib maleate)|Patients receive cediranib maleate PO as determined by the Phase II study. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
62565432|NCT00113763|OTHER|Best Supportive Care|Best supportive care will be defined in this study as the best care available as judged appropriate by the investigator and according to institutional guidelines and will include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any symptomatic therapy as clinically indicated. For the purpose of this study, best supportive care will not include anti-neoplastic chemotherapy.
62565433|NCT01564693||ANOREXIC CANCER PATIENTS|Nine lung cancer patients were diagnosed as anorexic based on the results obtained by the appetite assessment tools we used. These patients were studied by fMRI regarding the hypothalamic activity.
62565434|NCT01564693||NON-ANOREXIC CANCER PATIENTS|Four lung cancer patients were diagnosed as non-anorexic based on the results obtained by the appetite assessment tools we used. These patients were studied by fMRI regarding the hypothalamic activity.
62182629|NCT01151514||lrHA-AKI patients|Patients with hospital-acquired acute kidney injury whao are late referred to the nephrologists
62565435|NCT01564693||CONTROL GROUP|Two healthy volunteers with normal appetite were studied by fMRI regarding the hypothalamic activity.
62565436|NCT01270438|EXPERIMENTAL|Arm I (RO4929097, combination chemotherapy, bevacizumab)|Patients receive FOLFOX6 regimen comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46 hours, and bevacizumab IV over 30-90 minutes on days 1-2. Patients also receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62565437|NCT01270438|EXPERIMENTAL|Arm II (combination chemotherapy, bevacizumab)|Patients receive FOLFOX6 regimen and bevacizumab as in arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62565438|NCT02648139|EXPERIMENTAL|Experimental dentifrice|Dentifrice containing the extract of Eugenia uniflora rip fruit. Each 10 ml of E. uniflora L. dentifrice comprises the following components: Hydroalcoholic extract of the ripe fruit of E. uniflora L. (3.0%), preservatives (parabens; 0.02 g), and dentifrice base (silicon dioxide, sodium lauryl sulfate, white dye, aromatic compounds, sodium saccharin, and Gangrez sodium salt; q.s.p.). Intervention protocol: three times per day (pea-like amount), for seven consecutive days.
62565439|NCT02648139|ACTIVE_COMPARATOR|Control Dentifrice|"Control dentifrice - Colgate total 12 (fluoride, 1500 ppm and triclosan, 0.3%)~Intervention protocol: three times per day (pea-like amount), for seven consecutive days."
62565440|NCT04261803||Familial Hypercholesterolemia children|
62565441|NCT04261803||Control children|
62565442|NCT04530188|EXPERIMENTAL|inhaled sedation with sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
61995894|NCT03532464|EXPERIMENTAL|Patient treated by doxycycline|"The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.~Antibiotics will be dispensed in their usual packaging with a clinical trial label."
61995895|NCT03532464|ACTIVE_COMPARATOR|Patients treated by azithromycin|"The patients in the azithromycin group take 4 tablets of 250 mg in the morning as a single dose.~Antibiotics will be dispensed in their usual packaging with a clinical trial label."
62565443|NCT04530188|ACTIVE_COMPARATOR|intravenous sedation with propofol|intravenous sedation with propofol, as already used in our ICU
62182630|NCT01059188|EXPERIMENTAL|Cetuximab, Cisplatin, Docetaxel, Radiotherapy and Surgery|
62182631|NCT02308098|EXPERIMENTAL|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh
61995896|NCT04484324|EXPERIMENTAL|60 seconds|60 seconds stretching group Stretching exercises for upper Trapezius and Levator the examiner will passively place the participant's head into flexion, side-bending away and rotation towards the side to be stretched (for upper trapezius muscle) and flexion, side-bending away and rotation away from the side to be stretched (for levator scapula ). The patient introduces a light resisted effort to take the stabilized shoulder towards the ear and the ear towards the shoulder. The contraction is sustained for 10 seconds and, upon complete relaxation of effort, the therapist gently eases the head/ neck into an increased degree of side-bending and rotation, where it is stabilized, as the shoulder is stretched caudally. The examiner will depress the participant's shoulder with 100 Newton's of force measured with pressure dynamometer. Once the examiner achieved this level of force, he maintains the stretch for 60 seconds . The procedure is repeated three times.
61995897|NCT04484324|EXPERIMENTAL|30 seconds|The same procedures while the therapist will maintain the stretch for 30 seconds.
61995898|NCT04484324|EXPERIMENTAL|15 seconds|The same procedures while the therapist will maintain the stretch for 15 seconds.
61995899|NCT04484324|PLACEBO_COMPARATOR|control|The therapist maintains the same manual contact without stretching force
61995900|NCT03740425||Transfusion|Patients requiring blood transfusion after transcatheter aortic valve implantation (TAVI)
61995901|NCT03740425||No Transfusion|Patients not requiring blood transfusion after transcatheter aortic valve implantation (TAVI)
61995902|NCT03756610|ACTIVE_COMPARATOR|Active tACS & active boosting group|The active tACS \& active boosting group will be stimulated with 10 sessions of active alternating current stimulation (tACS) and 5 booster sessions of active tACS.
61995903|NCT03756610|OTHER|Active tACS & sham boosting group|The active tACS \& sham boosting group will be stimulated with 10 sessions of active alternating current stimulation (tACS) and 5 booster sessions of sham tACS.
61995904|NCT03756610|SHAM_COMPARATOR|Sham tACS & sham boosting group|The sham tACS \& sham boosting group will be stimulated with 10 sessions of sham alternating current stimulation (tACS) and 5 booster sessions of sham tACS.
62181103|NCT01046825|OTHER|Group C|"Any CNS involvement and/or bone marrow involvement ≥ 25% blasts. For CNS involvement one or more of the following applies:~1. Any L3 blasts in CSF~2. Cranial nerve palsy (if not explained by extracranial tumor)~3. Clinical spinal cord compression~4. Isolated intracerebral mass~5. Parameningeal extension: cranial and/or spinal~Group C will include the intervention COP, COPADM8, CYVE as follows:~Pre-Phase: COP~Induction: COPADM8 cycle 1~Induction: COPADM8 Cycle 2~Consolidation: CYVE x 2 cycles~and Maintenance"
61995905|NCT02945527|ACTIVE_COMPARATOR|Acetazolamide|750 mg acetazolamide p.o. divided in three dily doses, for 10 days
61995906|NCT02945527|ACTIVE_COMPARATOR|Dexamethasone|8 mg p.o. divided in three daily daily doses, for 2 days followed by gradual tapering
62181104|NCT01062971|ACTIVE_COMPARATOR|A|IOP Dorzolamide-Timolol-Brimonidine group
62181105|NCT01062971|ACTIVE_COMPARATOR|B|IOP dorzolamide-timolol group
62565444|NCT04026490|EXPERIMENTAL|Immediate intervention|The student will have a conversation with an Interventionist.
62565445|NCT04026490|ACTIVE_COMPARATOR|Waitlist intervention|These students will be approached for intervention for the months following the implementation of the immediate intervention group using the same procedures.
62565446|NCT03869619||All enrolled patients|All patient who signed the consent form for participation to the study
61995907|NCT02945527|NO_INTERVENTION|No additional anti-edema treatment|No additional treatment
61995908|NCT06424054|EXPERIMENTAL|eChemoCoach Group|Patients assigned to the intervention arm fill in the eChemoCoach questionnaires. They will be asked to report their side effects at baseline (2 - 4 days before their first chemotherapy cycle) and weekly thereafter. Moreover, they can report their symptoms at any time in case of potential toxicity, with a maximum of once a day. Non-responders receive reminders. Both intervention and control groups receive standard monitoring and coaching, including pre-scheduled checks for side effects before chemotherapy. Patients in both groups are asked to complete questionnaires measuring the impact on HRQoL, anxiety, distress, and patient empowerment at baseline, 10 weeks, and 20 weeks post-chemotherapy initiation. Usability of the eChemoCoach will be assessed through an online survey for patients and healthcare professionals using the System Usability Scale
62181106|NCT03776877||Arterial Ischemic Stroke (AIS)|"All patients (prospective and retrospective) included will have to present an Arterial Ischemic Stroke (AIS) from a large cerebral vessel occlusion.~The participation in the study will consist in:~* Plasmatic collection at the time of AIS, for study of plasma biomarkers~* Additional standardized blinded clinical evaluation at three months after the thrombectomy realized during a phone call, particularly via an assessment of the modified Rankin score."
62181107|NCT05523479|ACTIVE_COMPARATOR|Online education about risk-stratified post-extubation NIV/HFNC|During this period, ICU providers receive traditional online education that demonstrates the evidence supporting use of preventive post-extubation respiratory support (NIV or HFNC) over conventional post-extubation oxygen and supports the implementation of risk-stratified, preventive post-extubation NIV/HFNC.
62182632|NCT02308098|EXPERIMENTAL|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh
62565447|NCT02760108||Index case|Patients with a family history of Parkinson's/parkinsonism, and/or early onset Parkinson's/parkinsonism. The first individual member from a family who is recruited to the study.
62565448|NCT02760108||Affected relatives|Patients with Parkinson's/parkinsonism who are first or second degree relatives of an Index Case.
62565449|NCT02760108||Unaffected relatives|Participants who do not have Parkinson's/parkinsonism and are first or second degree relatives of an Index Case.
61995909|NCT06424054|NO_INTERVENTION|Control group|Patients in the control group receive standard of care. Both intervention and control groups receive standard monitoring and coaching, including pre-scheduled checks for side effects before chemotherapy. Patients in both groups are asked to complete questionnaires measuring the impact on HRQoL, anxiety, distress, and patient empowerment at baseline, 10 weeks, and 20 weeks post-chemotherapy initiation.
61995910|NCT04862156|EXPERIMENTAL|Normothermic Machine Perfusion (NMP)|Following the routine retrieval procedure of the liver, it will be placed on the OrganOx metra for Normothermic Machine Perfusion (NMP) for transport per the Investigational Plan and the Instructions for Use.
62181108|NCT05523479|ACTIVE_COMPARATOR|Interprofessional education about risk-stratified post-extubation NIV/HFNC|During this period, ICU providers receive interprofessional education that demonstrates the evidence supporting use of preventive post-extubation respiratory support (NIV or HFNC) over conventional post-extubation oxygen and supports the implementation of risk-stratified, preventive post-extubation NIV/HFNC.
62181109|NCT05523479|ACTIVE_COMPARATOR|Clinical protocol about risk-stratified post-extubation NIV/HFNC|During this period, ICU providers deploy a clinical protocol that supports the implementation of risk-stratified, preventive post-extubation NIV/HFNC.
62181110|NCT05523479|ACTIVE_COMPARATOR|Interprofessional education plus clinical protocol about risk-stratified post-extubation NIV/HFNC|During this period, ICU providers receive interprofessional education and use a clinical protocol that supports the implementation of risk-stratified, preventive post-extubation NIV/HFNC.
62181111|NCT05523479|ACTIVE_COMPARATOR|Online education about post-extubation HFNC|During this period, ICU providers receive traditional online education that demonstrates the evidence supporting use of preventive post-extubation respiratory support (NIV or HFNC) over conventional post-extubation oxygen and supports the implementation of preventive post-extubation HFNC for all eligible patients.
62181112|NCT05523479|ACTIVE_COMPARATOR|Interprofessional education about post-extubation HFNC|During this period, ICU providers receive interprofessional education that demonstrates the evidence supporting use of preventive post-extubation respiratory support (NIV or HFNC) over conventional post-extubation oxygen and supports the implementation of preventive post-extubation HFNC for all eligible patients.
62181113|NCT05523479|ACTIVE_COMPARATOR|Clinical protocol about post-extubation HFNC|During this period, ICU providers deploy a clinical protocol that supports the implementation of preventive post-extubation HFNC for all eligible patients.
62181114|NCT05523479|ACTIVE_COMPARATOR|Interprofessional education plus clinical protocol about post-extubation HFNC|During this period, ICU providers receive interprofessional education and use a clinical protocol that supports the implementation of preventive post-extubation HFNC for all eligible patients.
62181115|NCT05523479|NO_INTERVENTION|Usual care|During this period, ICU providers receive no structured education about preventive, post-extubation respiratory support therapies
62181116|NCT04733599||Adults with pain due to brachial plexus avulsion injury|Adult patients with history of brachial plexus avulsion injury referred for consideration of neuromodulation using high frequency neurostimulation will be considered.
62181117|NCT03380598|ACTIVE_COMPARATOR|Usual care|Usual care according to regular treatment routines at the clinic during 6 months.
62181118|NCT03380598|ACTIVE_COMPARATOR|CLOSS|Usual care plus using a web based support system for self-monitoring weight at physical activity.
62181119|NCT00808899|EXPERIMENTAL|1|Fixed doses of IV temsirolimus concomitantly with two courses of fixed dosages of irinotecan, 2 days off, repeated daily 5 times.If initial dosages are not tolerable, subsequent patients will be given a reduced dosage of temsirolimus with irinotecan.If this dosage combination is not tolerable,irinotecan dosage will be decreased.If this dosage combination is not tolerable.Further enrollment to initial six week treatment will be terminated.Second course of irinotecan will begin on day 22, response will be determined after six weeks. Resection of primary tumor will be attempted after initial therapy.Following initial treatment children will undergo alternating courses of induction chemotherapy with cyclophosphamide,doxorubicin,etoposide,topotecan, and cisplatin.First cohort of 17 patients will receive Block 2 with temsirolimus for all three courses, weekly 2 times.If this is not tolerated subsequent patients will receive Block 2 chemotherapy with reduced dosages of temsirolimus.
62181120|NCT03591432|EXPERIMENTAL|THRIVE|Using transnasal humidified rapid insufflation ventilatory exchange (THRIVE) oxygenation technique in elderly patients undergoing induction of anesthesia.
62181121|NCT03591432|ACTIVE_COMPARATOR|Facemask|Using facemask technique in elderly patients undergoing induction of anesthesia.
61995911|NCT05506202|EXPERIMENTAL|Intervention group|In intervention group, one extra physiotherapeutic intervention, Basic Body Awareness Therapy (BBAT), will be provided before ending each visit (on top of basic and advanced respiratory physiotherapy interventions as control group). Each BBAT last for 30-45 minutes. Therapist will verbally guide patients to perform twelve simple and soft movements, including lying, sitting, standing, walking and relational movements in a quiet and secured environment. Therapist will allow patients to explore the movement and the experience. Therapist will also guide patients in shifting focus between balance, free breathing and mental awareness Following principles in BBAT, BBAT movements will be selected for patients as home exercises.
62181122|NCT06198413|EXPERIMENTAL|LX102 Dose 1|Low dose of LX102
62181123|NCT06198413|EXPERIMENTAL|LX102 Dose 2|Mid dose of LX102
62181124|NCT06198413|EXPERIMENTAL|LX102 Dose 3|High dose of LX102
62181125|NCT03957408|EXPERIMENTAL|Visual Stimuli|Participants will be presented various visual stimuli in which accommodative response is measured.
61995912|NCT05506202|ACTIVE_COMPARATOR|Control group|Both basic and advanced respiratory physiotherapy interventions, including respiratory muscles training, breathing techniques, bronchial hygiene maintenance, assisting in non-invasive ventilation therapy and oxygen therapy titration, are provided according to assessment findings. There is an eight-week training program for both groups, therapist will provide one home visit per week and continuously for eight weeks for each patient.
61995913|NCT00420524|EXPERIMENTAL|Arm A (Normal liver function)|
61995914|NCT00420524|EXPERIMENTAL|Arm B (Mild liver dysfunction)|
61995915|NCT00420524|EXPERIMENTAL|Arm C (Moderate liver dysfunction)|
62181126|NCT01042717|EXPERIMENTAL|Plerixafor|Plerixafor 16 hours
62181127|NCT05143138||fEVAR|Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent in conjunction with a fenestrated stent graft to allow endovascular aneurysm repair
62181128|NCT05143138||bEVAR|Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent in conjunction with a branched stent graft to allow endovascular aneurysm repair
62181129|NCT05143138||fEVAR and bEVAR|Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent in conjunction with a branched and fenestrated stent graft to allow endovascular aneurysm repair
62181130|NCT01940406|EXPERIMENTAL|Stimulation procedure|Stimulation procedure
62181131|NCT05706636|ACTIVE_COMPARATOR|Early localized vitiligo on topical treatment|Cases will only receive topical steroids/ calcineurin inhibitors and targeted phototherapy
62181132|NCT05706636|ACTIVE_COMPARATOR|Early localized vitiligo on topical and systemic treatment|Cases will receive oral mini-pulse steroids, topical steroids/ calcineurin inhibitors and targeted phototherapy
62181133|NCT06301971|EXPERIMENTAL|Emraclidine 30 mg|Participants will receive a single oral dose of 30 milligrams (mg) (approximately 75 microcurie \[μCi\]) \[14C\]-emraclidine on Day 1.
62565450|NCT04904497|EXPERIMENTAL|Early Occupational Therapy|These sessions will be implemented by occupational therapists trained in ICU, who will conduct 20 sessions of 30 min, distributed depending on the level of sedation, i) SAS (Sedation-Agitation Scale) 1 patients have one session each 48 h, evaluating the change of sedation level each 24 h; ii) SAS 2 patients have one session each 24 h, iii) SAS 3-5 have two sessions every day. The sessions will begin once the patient needs mechanical ventilation for at least 12 h
62565451|NCT04904497|NO_INTERVENTION|Standard|"The ASDM protocol will be implemented to mechanically ventilated patients in the ICU, following the aspects recommended by experts and the current evidence. For this, the team of medical, nurses, and physiotherapist will be trained to understand and facilitate the ASDM actions that each one must implement.~Occupational Therapy interventions for control group will be allowed for this group only before 1 week after the first day on light sedation"
61995916|NCT05676957|EXPERIMENTAL|Study group|The subjects will be considered to be enrolled in the study group of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the study group of the trial to allow endovascular therapy with the Thermogard XP3 Intravascular Temperature Management (IVTM) System after recanalization.
61995917|NCT05676957|NO_INTERVENTION|Control group|The subjects will be considered to be enrolled in the control group of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the control group of the trial.
61995918|NCT03729531|ACTIVE_COMPARATOR|Conventional|The perivascular tissue is stripped off when harvesting the vein, and saline will be used to distend the vein to check for leakage.
61995919|NCT03729531|EXPERIMENTAL|No-touch|The vein will be harvested by frequency electrotome and the perivascular tissue will be preserved, the vein will not be distended.
61995920|NCT06209736|EXPERIMENTAL|Study Drug OMS906|Repeat-dose OMS906 5 mg/kg IV administration at 4-week intervals
61995921|NCT04152512||Whole Cohort|Whole cohort administration of questionnaire at 7 times
61995922|NCT02658890|EXPERIMENTAL|Combination Therapy (Dose Escalation)|BMS 986205 + Nivolumab specified dose at specified intervals.
61995923|NCT02658890|EXPERIMENTAL|Combination Therapy (Dose Expansion)|BMS 986205 + Nivolumab specified dose at specified intervals.
61995924|NCT02658890|EXPERIMENTAL|Combination Therapy 2 (Dose Expansion)|BMS 986205 + both Nivolumab and ipilimumab specified dose at specified intervals
62181134|NCT01218425|EXPERIMENTAL|Medication|In this study, a crossover design is applied. All participants receive all three treatments in randomized order on separate days.
62181135|NCT05382910|EXPERIMENTAL|MG-K10 Q2W|Received MG-K10 300 mg subcutaneous injection every 2 weeks
62181136|NCT05382910|EXPERIMENTAL|MG-K10 Q4W|Received MG-K10 300 mg subcutaneous injection every 4 weeks
62181137|NCT05382910|PLACEBO_COMPARATOR|Placebo|The placebo group will receive 2 ml of placebo subcutaneously administered every 2 weeks.
62181138|NCT01648478|EXPERIMENTAL|Single Arm|
62181139|NCT01165359|EXPERIMENTAL|Part A: ITX 5061|Participants will receive ITX 5061 once a day for 3 days.
62181140|NCT01165359|PLACEBO_COMPARATOR|Part A: Placebo|Participants will receive placebo once a day for 3 days.
62181141|NCT01165359|EXPERIMENTAL|Part B: ITX 5061|Participants will receive ITX 5061 once a day for 14 days.
62181142|NCT01165359|PLACEBO_COMPARATOR|Part B: Placebo|Participants will receive placebo once a day for 14 days.
62181143|NCT01165359|EXPERIMENTAL|Part C: ITX 5061|Participants will receive ITX 5061 once a day for 28 days.
62181144|NCT01165359|PLACEBO_COMPARATOR|Part C: Placebo|Participants will receive placebo once a day for 28 days.
62181145|NCT05665413|EXPERIMENTAL|strocking technique|
62181146|NCT05665413|EXPERIMENTAL|ergon technique|
62181147|NCT03876002|EXPERIMENTAL|[18F]PBR06|To perform kinetic modeling using plasma-based (metabolite corrected plasma concentration) or reference region based methods or simplified quantification methods to assess the ability of \[18F\]PBR06 PET to measure microglial activation in brain.
62181148|NCT01580995|EXPERIMENTAL|Valacyclovir|Valacyclovir 500 mg po bid
62181149|NCT01580995|PLACEBO_COMPARATOR|Placebo|Matching placebo twice daily
61995925|NCT02148172|ACTIVE_COMPARATOR|Standard Plyometric Training|Participants will undergo treatment 2 times a week for 8 weeks with plyometric exercises deemed to be consistent with best practice delivered at a standard dosage of sets and repetitions.
62181150|NCT01384383|EXPERIMENTAL|Arm 1|Response-Guided Therapy with GS-5885 30 mg plus GS-9451 200 mg, plus PEG and RBV for 6 or 12 weeks.
62181151|NCT01384383|EXPERIMENTAL|Arm 2|Response-Guided Therapy with PEG and RBV for 24 weeks.
62181152|NCT06252090|EXPERIMENTAL|MBT-A|Short term Mentalization-based treatment for adolescents (psychotherapy).
62181153|NCT01035047|NO_INTERVENTION|Inpatient Care|This is the comparison arm. Patients are admitted to the hospital and undergo usual care.
62181154|NCT01035047|EXPERIMENTAL|CDU-CMR Protocol|Patients will be transferred to the clinical decision unit and undergo a stress cardiac MRI evaluation.
62181155|NCT01902498|EXPERIMENTAL|Aspirin 162mg twice daily|Patients will receive 162mg twice daily during the postoperative period, until day 7 postop or the end of hospitalization.
62181156|NCT01902498|ACTIVE_COMPARATOR|Aspirin 325mg daily|Patients will receive 325mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
61995926|NCT02148172|EXPERIMENTAL|Plyometric Training with BWS|Participants will undergo treatment 2 times a week for 8 weeks with plyometric exercises deemed to be consistent with best practice with a treatment volume of sets and repetitions that exceeds standard practice. Higher number of practice trials will be completed with body weight support (BWS) to reduce load. Participants will start at 30 percent of body weight and will be slowly weaned away over time.
61995927|NCT05250024|EXPERIMENTAL|UHMWP Cranioplasty|synthetic reconstruction of cranial defects using computer guided milled UHMWP implants
62565452|NCT01956773|EXPERIMENTAL|MeTree - Patient|MeTree collects family health history data and generates risk scores and specific risk-based recommendation for preventive care to patients as clinical decision support.
62565453|NCT01956773|EXPERIMENTAL|MeTree - Provider|MeTree collects family health history data and generates risk scores and specific risk-based recommendation for preventive care to providers as clinical decision support.
61995928|NCT05250024|ACTIVE_COMPARATOR|PEEK Cranioplasty|synthetic reconstruction of cranial defects using computer guided milled PEEK
61995929|NCT02237170||Castration Resistant Metastatic Prostate Cancer|Castration Resistant Metastatic Prostate Cancer with no history of prior systemic chemotherapy
62181157|NCT01902498|ACTIVE_COMPARATOR|Aspirin 81mg daily|Patients will receive 81mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
62181158|NCT01792596|OTHER|pasta|1. Plain pasta
62181159|NCT01792596|OTHER|pasta with protein|Pasta with protein
62181160|NCT01792596|OTHER|pasta with fiber|Pasta with Fiber
62181161|NCT05041725|EXPERIMENTAL|remimazolam infusion|Intraoperative remimazolam infusion for postoperative sedation
62181162|NCT00195884|EXPERIMENTAL|Aerobic Group|Aerobic training is divided into three stages: the Starter phase (during the run-in period), the Progression phase, and the Maintenance phase. All aerobic activities are performed on a cycle ergometer, treadmill, elliptical exercise machine or stairclimber. Subjects are free to vary the machine(s) used from one visit to the next. Exercise intensity is standardized using Polar Heartminder heart rate monitors that display the subject's heart rate and emits a warming signal when heart rate is outside the prescribed training zone, thus guiding the subject in adjustment of the work load up or down to achieve the desired intensity.
62181163|NCT00195884|EXPERIMENTAL|Resistance Group|"Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~* Group A: abdominal crunches, seated row (back), seated biceps curls, supine bench press (chest), leg press, shoulder press (shoulders and neck); leg extension (quadriceps)~* Group B: abdominal crunches, lat pulldown (back), sitting chest press (chest), leg press, upright row (shoulders and neck), triceps pushdown, leg curls (hamstrings).~Subjects are instructed to exhale while lifting a weight and inhale while lowering it, in order to minimize blood pressure excursions. Warm-up and cooldown are the same as for aerobic training."
62181164|NCT00195884|EXPERIMENTAL|Combined Aerobic and Resistance Training|Combined aerobic and resistance training. This group will perform both aerobic and resistance training programs, as described above. The aerobic and resistance components are performed on the same days, in varying orders.
62181165|NCT00195884|NO_INTERVENTION|Control Group|Members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program.
62181166|NCT03450148|EXPERIMENTAL|Pavlok wristband with electric stimulus|Participants in intervention group will wear wristband and will get a slight electric stimulus when they press the device
62181167|NCT03450148|PLACEBO_COMPARATOR|Pavlok wristband without electric stimulus|Participants in control group will wear wristband and will not get a slight electric stimulus when they press the device
61995930|NCT03489395|EXPERIMENTAL|Edoxaban|Used for Treatment. All patients will receive edoxaban 60 mg once a day, with open-label design, for 4 weeks. Edoxaban daily dose will be reduced to 30 mg/day in case of: body weight ≤60 kg, or concomitant therapy with verapamil/quinidine/dronedarone.
61995931|NCT06156592||Severe aortic stenosis group|Patients with severe aortic stenosis who are undergoing open aortic valve replacement under high spinal in combination with light general anesthesia.
61995932|NCT06156592||Severe mitral regurgitation group|Patients with severe mitral regurgitation who are undergoing open mitral valve replacement under high spinal in combination with light general anesthesia.
61995933|NCT02843945|EXPERIMENTAL|Directional Brachytherapy Source Implant|Patients undergoing a pancreatic cancer resection will receive a CivaSheet LDR directional brachytherapy implant at the time of surgery. The directional nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.
61995934|NCT03784573|ACTIVE_COMPARATOR|Dog + handler|
61995935|NCT03784573|PLACEBO_COMPARATOR|No dog|
61995936|NCT04448899|ACTIVE_COMPARATOR|Ivabradine|"Patients administered Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability.~Patients were followed up after 1 week of initiation of ivabradine therapy then monthly till the end of the study."
61995937|NCT04448899|PLACEBO_COMPARATOR|Control|Patients administered a placebo twice daily. Patients were followed up after 1 week of initiation of the study then monthly till the end of the study.
61995938|NCT03898661|EXPERIMENTAL|local collagenase|Patients receiving local injection of collagenase (0.9 mg XiapexR) into the esophageals stricture
61995939|NCT06042036||acute hypoxemic respiratory failure|Patients with acute hypoxemic respiratory failure transitioning to a spontaneous mode of mechanical ventilation ( PSV, APRV, NAVA, PAV+, CPAP)
61995940|NCT06307275|ACTIVE_COMPARATOR|Non Fasting|For four week: Participants will keep their normal food intake with no restrictions on when to eat. Participants will keep their normal weekly exercise routine.
61995941|NCT06307275|EXPERIMENTAL|Fasting|For four weeks: Fasting for 16 hours from participant last meal of the previous evening's meal to the first meal of the next day. Then for 8 hours, participant is able to eat. During the fasting, participants are allowed to consume water and black coffee/tea. Participants will also keep their normal weekly exercise routine.
61995942|NCT06343844|OTHER|case control registry|left ventricular remodeling measurement with cardiac echography
61995943|NCT03447665|NO_INTERVENTION|Control|Infant sleep monitoring and parental surveys only
61995944|NCT03447665|EXPERIMENTAL|Intervention (Bedtime only)|Infant behavioral sleep intervention implemented at bedtime only. Parents are instructed to soothe/help their infant back to sleep after night wakings. Includes a tailored sleep schedule and bedtime routine, as well as support from a sleep interventionist.
61995945|NCT03447665|EXPERIMENTAL|Intervention (All night)|Infant behavioral sleep intervention implemented at bedtime and after each subsequent infant night waking. Includes a tailored sleep schedule and bedtime routine, as well as support from a sleep interventionist.
61995946|NCT02076412|EXPERIMENTAL|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
62181168|NCT06543550|EXPERIMENTAL|Implantable Gestrinone|Implantation of Gestrinone pellets - Eligible patients will undergo implantation of Gestrinone pellets (bio meds Brasil, Florianópolis, Brazil) subcutaneously, in the gluteal region, using aseptic technique under local anesthesia. Patients will use 1.6mg/kg of weight to treat endometriosis. A second implantation procedure will be performed 6 months after the first, allowing evaluation of the effects of the therapy over a period of 12 months.
61995947|NCT02076412|OTHER|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
61995948|NCT02732834||Part 1: Lung patients|Following informed consent, the patient will complete the patient questionnaire, either electronically, by phone, or on paper. Patients who prefer to complete the survey electronically will be emailed a link to access to a secure electronic (web-based) version of the study assessment which they will have access to from any computer. We will include an introductory email with the survey link. Will audio-record actual patient-physician clinical consultations with lung cancer patients at Memorial Sloan Kettering (MSK). Completing the survey will take about 15 minutes. Answer a few open-ended questions about the consultation with the doctor. We will audio record your answers to these questions. This will take about 15 minutes.
61995949|NCT02732834||Part 1: Thoracic physicians and clinicians|Will have 5 visits/consultations with their patients audio recorded.
62181169|NCT06543550|ACTIVE_COMPARATOR|Oral Dienogest|Patients will receive the medication to be administered orally at 2mg daily for 12 months.
62181170|NCT00486928||AVR|All consecutive patients in the study period
62181171|NCT02511340|EXPERIMENTAL|Flumatinib mesylate tablet 600 mg qd|Flumatinib, 600mg, qd
62181172|NCT00177372|EXPERIMENTAL|1|Mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
62181173|NCT02279992|EXPERIMENTAL|Vardenafil + Carboplatin|Vardenafil (Levitra®) 20 mg oral administered 1 hour prior to start of craniotomy + Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy
62181174|NCT02279992|ACTIVE_COMPARATOR|Carboplatin Alone|Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy
62181175|NCT00005064|EXPERIMENTAL|Treatment (bortezomib)|Patients receive PS-341 IV bolus twice weekly for 4 weeks followed by 2 weeks of rest. Treatment continues for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression.
62181176|NCT01359722|EXPERIMENTAL|N-Acetylcysteine|N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.
62181177|NCT01359722|PLACEBO_COMPARATOR|Control|This group will receive only the infusion of saline in the same doses and infusion rate.
61995950|NCT02732834||Part 2: Lung patients|Following informed consent, the patient will complete the patient questionnaire, either electronically, by phone, or on paper. Patients who prefer to complete the survey electronically will be emailed a link to access to a secure electronic (web-based) version of the study assessment which they will have access to from any computer. Completing the survey will take about 15 minutes.
61995951|NCT02732834||Part 2: Thoracic and pulmonary clinicians|Following informed consent, clinicians will be scheduled to participate in a 2 hour training on empathic communication with lung cancer patients. Surveys will be collected from 6 patients (3 pre-training, 3 post-training). Clinicians will complete one standardized patient assessment before training (pre-SPA) and one assessment after training (post-SPA). These are 12-minute video-recorded clinic consultations with standardized patients (trained actors).
61995952|NCT05605665|ACTIVE_COMPARATOR|Low-dose interleukin-2|One million IU of IL-2 was injected subcutaneously once twice a week for 12 weeks.
62565454|NCT04674215|EXPERIMENTAL|intervention group|"Data about sociodemographic and clinical characteristics of the patients in all groups were collected. Their mobility status and general anxiety levels were evaluated.~The patients in the intervention group were given a planned in-bed turning and mobilization training in the patient's room by the researcher one day before the surgery. This training included explaining the importance of postoperative mobility, demonstrating the correct in-bed turning and mobilization steps through pictures with the Illustrated In-Bed Turning and Mobilization Training Material, answering questions (if any), and finally, simulating postoperative in-bed turning and the first mobilization using the role-playing technique in collaboration with the patient."
62565455|NCT04674215|OTHER|control group|"Data about sociodemographic and clinical characteristics of the patients in all groups were collected. Their mobility status and general anxiety levels were evaluated.~Patients in the control group received routine clinical care. This care included the provision of verbal information to the patient at different times by the primary physician and/or nurse about postoperative in-bed turning and mobilization and answering questions if any."
62565456|NCT02124655|EXPERIMENTAL|Essential oils/0.2% chlorhexidine/Sterile water|A) 20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1). -----14 days----- B) 10 mL rinses for 30 seconds with 0.2% chlorhexidine/2 times daily (1/0/1). -----14 days----- C) 20 mL rinses for 30 seconds with sterile water (1/0/1).
62565457|NCT06181188|EXPERIMENTAL|Ketamine and Midazolam|Patients will receive 1mg of midazolam and a bolus of 0.25 - 0.5mg/kg of ketamine to initiate sedation. Additional 10-20mg of ketamine will be given every 3-5 minutes to achieve adequate sedation. If additional anxiolysis is needed, additional doses of midazolam will be given every 3-5 minutes in 1mg increments. .
61995953|NCT05605665|ACTIVE_COMPARATOR|Rapamycin|Rapamycin 0.5ml once per day for 12 weeks.
62565458|NCT06181188|ACTIVE_COMPARATOR|Midazolam and Fentanyl|Patient will receive midazolam and fentanyl in 1mg and 25mcg increments respectively until adequate procedural sedation is achieved. Additional increments will be given every 3-5 minutes as needed to achieve adequate sedation.
61995954|NCT05605665|EXPERIMENTAL|Low-dose interleukin-2 and rapamycin|One million IU of IL-2 was injected subcutaneously twice a week and rapamycin 0.5ml once per day for 12 weeks.
61995955|NCT00816725|EXPERIMENTAL|Self-help course and information|
62181178|NCT01404533|EXPERIMENTAL|Iron supplement without food|
62565459|NCT04846712||patients with a first ankle sprain|50 patients with a first ankle sprain will be included. Data will be collected of medical record.
62565460|NCT01925430||Comparative product|A device which monitors sleep/wake states
62565461|NCT01925430||Screening device|This device will screen for sleep-breathing disorders
62565462|NCT02822014|OTHER|FDG-PET/CT arm|We performed baseline FDG-PET/CT, another FDG-PET/CT after 2 months of TB treatment and a PET/CT at the end of treatment in 18 HIV/TB patients. We correlated evolution of FDG uptake with clinical evolution of patients.
62565463|NCT05021393|EXPERIMENTAL|Intervention Group|The intervention group will receive the services from a clinical pharmacist and the existing standard care available in the medical oncology ward.
62565464|NCT05021393|NO_INTERVENTION|Control Group|The standard care includes the current existing care provided to patients in the hospital. In addition, it includes all the available medical and non-medical services except the service provided by the clinical pharmacist.
62565465|NCT05492604|EXPERIMENTAL|Connected soles|FEETME® connected tool
61995956|NCT02531321|EXPERIMENTAL|Ritonavir|Participants taking antiretroviral regimens including ritonavir-boosted protease inhibitors will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
61995957|NCT02531321|ACTIVE_COMPARATOR|Control|Participants taking antiretroviral regimens known not to interact with oral contraceptives will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
61995958|NCT01571661|EXPERIMENTAL|Part A Treatment 1|GSK189075A 20mg
62181179|NCT01404533|EXPERIMENTAL|Iron supplement with food|
62181180|NCT01404533|EXPERIMENTAL|Iron fortificant with food|
62565466|NCT05492604|OTHER|Treadmill|Reference system the GAITRite® walkway
62565467|NCT05396027|NO_INTERVENTION|Control Group|Participants (healthy or physically disabled) in the control group do not require to perform audio-guided deep breathing for 14 days continuously
62565468|NCT05396027|EXPERIMENTAL|Experimental Group with Audio-guided deep breathing|Participants (healthy or physically disabled) in the interventional group need to perform 5 mins audio-guided deep breathing with 6 deep breaths per minute for 14 days continuously
62565469|NCT01506115|EXPERIMENTAL|HCC with bile duct invasion|Photodynamic therapy with biliary drainage in patients with bile duct invasion of unresectable HCC
62565470|NCT02809729|PLACEBO_COMPARATOR|placebo|The patients will receive 0.9% saline for intravenous bottle with 100ml looks identical to the antibiotic at the start of anesthetic induction
61995959|NCT01571661|EXPERIMENTAL|Part A Treatment 2|GSK189075A 50mg
61995960|NCT01571661|EXPERIMENTAL|Part A Treatment 3|GSK189075A 150mg
61995961|NCT01571661|EXPERIMENTAL|Part A Treatment 4|GSK189075A 500mg
62181181|NCT01767662|EXPERIMENTAL|manipulation|home program for parents manipulation
62181182|NCT01767662|PLACEBO_COMPARATOR|observe|observation
62181183|NCT04649125|ACTIVE_COMPARATOR|standard|standard radiotherapy 5 fractions
62181184|NCT04649125|EXPERIMENTAL|single fraction dose escalation|8Gy to Planned Target Volume, 12Gy to Clinical Target Volume +/- 14Gy to Gross Target Volume
62565471|NCT02809729|ACTIVE_COMPARATOR|cefazolin|The patients will receive 2 g of cefazolin diluted in 0.9% saline by endovenous at the start of anesthetic induction
61995962|NCT01571661|EXPERIMENTAL|Part A Treatment 5|GSK189075A 1000mg
61995963|NCT01571661|PLACEBO_COMPARATOR|Placebo|Placebo
61995964|NCT01571661|EXPERIMENTAL|Part B Low dose|low dose chosen from Part A
61995965|NCT01571661|EXPERIMENTAL|Part B High Dose|high dose chosen from Part A
61995966|NCT05206474|EXPERIMENTAL|IRADYN|"One group, all patients will receive IRADYN® (intra-articular administration).~One course of IRADYN® at baseline, consisting of a mono-dose intra-articular administration (2ml).~From week 1 to week 6, injection will be performed, if necessary, during the visit, following the dosage reported in the instruction for use / summary of product characteristic."
61995967|NCT04907032|EXPERIMENTAL|Posterior Tibial Nerve Stimulation with Mirabegron|One arm of the study will receive PTNS combined with mirabegron. In the PTNS with mirabegron arm, the patient will take a 50 mg dose daily for 12 weeks of the trial. This arm of the study will have 27 patients randomized to this arm of the study. The percutaneous approach entails insertion of a 36-gauge needle electrode at a 60 degree angle approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. A portable electrical stimulator delivers an adjustable current in the range of 0.5-9 mA. The generators commonly are set for a pulse frequency of 20 Hz with a goal of creating a motor and/or sensory response in the foot. The stimulation sessions last for 30 min once per week for 12 continuous weeks.
61995968|NCT04907032|PLACEBO_COMPARATOR|Posterior Tibial Nerve Stimulation Plus Placebo|The other arm of the study will receive PTNS with placebo. In the PTNS with placebo arm, the patient will receive a placebo daily during the 12-week trial. PTNS will be performed as described: The percutaneous approach entails insertion of a 36-gauge needle electrode at a 60 degree angle approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. A portable electrical stimulator delivers an adjustable current in the range of 0.5-9 mA. The generators commonly are set for a pulse frequency of 20 Hz with a goal of creating a motor and/or sensory response in the foot. The stimulation sessions last for 30 min once per week for 12 continuous weeks.
61995969|NCT03528746|EXPERIMENTAL|Isometric exercise|Participants will complete isometric quadriceps exercise
61995970|NCT03528746|ACTIVE_COMPARATOR|Isotonic exercise|Participants will complete dynamic leg extension
61995971|NCT00894335||1|Pheochromocytoma
61995972|NCT00894335||2|Conn-Syndrome
61995973|NCT00894335||3|Cushing disease
61995974|NCT00894335||4|Metastasis
62565472|NCT03886610||Healthy controls|Individuals without spinal cord injury
62565473|NCT03886610||Subacute SCI patients|Subacute patients with spinal cord injury (duration \>2 weeks)
62565474|NCT03886610||Chronic SCI patients|Patients with chronic spinal cord injury (duration ≥24 months)
62565475|NCT01094574|ACTIVE_COMPARATOR|Alfentanil|Experimental inflammation, and tissue injury sites were created, an infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
62565476|NCT01094574|ACTIVE_COMPARATOR|Propranolol|Experimental inflammation and tissue injury sites were created, an infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
61995975|NCT00894335||5|Non-functional tumor
61995976|NCT01339351|NO_INTERVENTION|Usual Psychosocial Care|Participants are free to use any psychosocial care available to cancer patients. No restrictions to participation in other groups or services.
61995977|NCT01339351|EXPERIMENTAL|Therapeutic Group by teleconference|ten 90 minute group sessions by teleconference. Lead by social workers. Sessions focus on information, story sharing and coping.
61995978|NCT04400396||target HM fortification|Contemporary cohort fed HM with target fortification
61995979|NCT04400396||standard HM fortification|Historical cohort fed HM with standard fortification
61995980|NCT02027844|EXPERIMENTAL|Cartoon|cartoon watching by children during inhalational induction of anesthesia in the operating room
61995981|NCT02027844|ACTIVE_COMPARATOR|Paretnal presence|parental presence with their children during inhalational induction of anesthesia in the operating room
61995982|NCT02027844|EXPERIMENTAL|Combined|parental presence and cartoon watching by children during inhalational induction of anesthesia in the operating room
61995983|NCT01723163|EXPERIMENTAL|Intervention|Abstinence Reinforcement Therapy (ART)
61995984|NCT01723163|OTHER|Control|Telephone Counseling
62565477|NCT01094574|PLACEBO_COMPARATOR|Placebo|Experimental inflammation and tissue injury sites were created, an infusion of normal saline was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
62565478|NCT02000960|EXPERIMENTAL|Triheptanoin|All subjects will receive the study treatment which includes adding triheptanoin to the ketogenic diet with a goal intake of 35% total calories provided by triheptanoin (max 100 ml oil/day.
61995985|NCT02691286||Cardiogenic Shock STEMI|Patients admitted to the hospital with the diagnosis with STEMI complicated with cardiogenic shock
61995986|NCT02691286||No Cardiogenic Shock STEMI|Patients admitted to the hospital with the diagnosis with STEMI without cardiogenic shock
61995987|NCT04606979|EXPERIMENTAL|Parkinson Disease - Group 1a - Active tDCS first|Half of the subjects with PD will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects with PD will receive sham (placebo) tDCS.
61995988|NCT04606979|SHAM_COMPARATOR|Parkinson Disease - Group 1b - Sham tDCS first|Half of the subjects with PD will receive sham tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects with PD will receive active (anodal, real) tDCS.
61995989|NCT04606979|EXPERIMENTAL|Healthy Controls - Group 2a - Active tDCS first|Half of the healthy controls will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the healthy controls will receive sham (placebo) tDCS.
61995990|NCT04606979|SHAM_COMPARATOR|Healthy Controls - Group 2b - Sham tDCS first|Half of the healthy controls will receive sham tDCS in the first session. Following cross-over and a three-week washout-period, this half of the healthy controls will receive active (anodal, real) tDCS.
61995991|NCT04332289||PHH patients|Patients following Roux-en-Y gastric bypass surgery (≥1 year ago) with confirmed post-prandial hyperinsulinemic hypoglycemia
61995992|NCT04332289||Healthy controls|Non-PHH, non-surgical healthy individuals
61995993|NCT04827043|EXPERIMENTAL|Quadratus lumborum block|QLB group: will receive 0.3ml/Kg bupivacaine 0.25% ( keeping in mind not to exceed the maximum recommended toxic dose of plain bupivacaine which is 2.5 mg/Kg \& 3mg/Kg with epinephrine), single injection sonar guided.
62181185|NCT06406868|EXPERIMENTAL|Telerehablitation|"The treatment plan of both groups will be the same according to the exercise plan given by American Cancer Society guidelines for breast cancer patients.~Frequency :10 repetitions Intensity: Moderate Time: Once a day"
62181186|NCT06406868|ACTIVE_COMPARATOR|Outpatient Rehablitation|"The treatment plan of both groups will be the same according to the exercise plan given by American Cancer Society guidelines for breast cancer patients.~Frequency :10 repetitions Intensity: Moderate Time: Once a day"
62181187|NCT05772195||Before major system reorganisation|Theme 1 - elective recovery plan 2017/18-2019/20
62181188|NCT05772195||Before major system reorganisation - intra-pandemic|Theme 1 - elective recovery plan 2020/21-2021/22
62181189|NCT05772195||Post system reorganisation|Theme 1 - elective recovery plan 2023/24 and 2024/25
62181190|NCT05927636||Study population|Patients with cancer referred for systemic treatment of the outpatient clinic at the departments of Medical Oncology at participating centres.
62181191|NCT02934542|NO_INTERVENTION|Control Group|Patients in this group will undergo an elective standard laparoscopic procedure with a designated OR staff to maneuver the laparoscopic camera. The procedures will be performed according to the hospital and OR routine procedure.
61995994|NCT04827043|EXPERIMENTAL|Thoracic paravertebral block|PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.
62181192|NCT02934542|EXPERIMENTAL|AutoLap Group|Patients in this group will undergo a laparoscopic procedure using the AutoLap system. In this group the surgeon will use the AutoLap system to hold and control the movements of the laparoscopic camera.
62181193|NCT03328910||Analgesia monitoring|After anesthesia induction, all participants received standard anesthesia monitoring, SPI monitor (GE Healthcare, Helsinki, Finland) and bispectral index (BIS). BIS was kept between 40-60, whereas no specific target was determined for SPI. At the end of surgery, anesthesia was terminated and the patients were stimulated to wake up. After the participants were able to breathe spontaneously and obey verbal commands, extubation was carefully performed, and the monitoring of SPI was stopped.
62565479|NCT06371924|ACTIVE_COMPARATOR|Static Cold Storage|The donor liver will be flushed in situ with 4C UW preservation solution (or HTK) through the aorta and portal vein, retrieved, and transported to the transplant centre in an icebox.
62181194|NCT04493697|ACTIVE_COMPARATOR|Experimental 1|A ThermoNeuroModulation device will be worn by the participant that delivers warm waveforms in one ear (42 °C) and cool waveforms (17 °C) in the other ear.
62181195|NCT04493697|PLACEBO_COMPARATOR|Experimental 2|A ThermoNeuroModulation device will be worn by the participant that will neither warm nor cool.
62181196|NCT04678765|ACTIVE_COMPARATOR|Ultrasound-guided distal peripheral nerve block|Patients will receive the ultrasound-guided distal peripheral nerve block (locoregional anesthesia)
61995995|NCT04357210||primary sphincteroplasty|end-to-end primary sphincteroplasty with interrupted sutures
61995996|NCT04357210||muco-muscular advancement flap|A U-shaped muco-muscular flap was mobilized and fixed to the anoderm with one-row interrupted absorbable sutures
61995997|NCT04357210||full-thickness low rectum posterior semicircular mobilization|Proximal parts of the internal sphincter and the longitudinal muscle were carefully separated from the underlying external sphincter and puborectalis muscle, moving further in the cranial direction, the Waldeyer's fascia was exposed and incised. Full-thickness posterior semicircular flap was fixed to anoderm
61995998|NCT05686265||Patients|Patients with SAH (see eligibility criteria below).
62181197|NCT04678765|EXPERIMENTAL|Ultrasound-guided quadruple-injection axillary nerve block|Patients will receive the ultrasound-guided quadruple-injection axillary nerve block (locoregional anesthesia)
61995999|NCT05686265||Controls|Healthy controls (see eligibility criteria below).
61996000|NCT02935465|EXPERIMENTAL|Mindfulness-Oriented Recovery Enhancement|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
62181198|NCT02230293|ACTIVE_COMPARATOR|Conventional Group|Conventional treatment and follow up
62181199|NCT02230293|EXPERIMENTAL|Multidisciplinary Group|Multidisciplinary assistance
62181200|NCT04717947||Short interval group|≤ 8weeks between the end of neoadjuvant therapy and surgery
62181201|NCT04717947||Intermediate interval group|\> 8 and ≤ 12 weeks between the end of neoadjuvant therapy and surgery
62181202|NCT04717947||Long interval group|\> 12 weeks between the end of neoadjuvant therapy and surgery
62181203|NCT06039592||Modified Drug Therapy Group|Patient in this group will undergo a one-year course of medication, including Captopril(tablet, 0.3mg/kg, tid), Metoprolol(tablet, 0.2mg/kg, bid), Spironolactone(tablet, 2-4mg/kg, bid), Torsemide(tablet, 0.2-0.5mg/ mg, bid), and Potassium Citrate(powder, 0.06g/kg, tid).
61996001|NCT02935465|ACTIVE_COMPARATOR|Support Group|Participants will attend a support group weekly for eight weeks.
61996002|NCT05886959|EXPERIMENTAL|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"* A breath break with kindness is practiced.~* Encourage them to think about how threat, impulse and sedative systems have developed in their own lives.~* A safe place application is made.~* Courtesy meditation is done."
61996003|NCT05886959|EXPERIMENTAL|Session 2: Threat and Self-Compassion|"* A breath break with kindness is practiced.~* Building a compassionate relationship with resilience and kindness meditation: a benevolent practices are made.~* A hand on your heart and a compassionate comrade practices are made."
61996004|NCT05886959|EXPERIMENTAL|Session 3: Unraveling the Knots of Desire and Patterns Agenda|"* Talk about homework.~* A breath break with kindness is practiced.~* Establishing a compassionate relationship with desire, guided meditation to discover the inner pattern, courtesy meditation: a good friend practices are made."
61996005|NCT05886959|EXPERIMENTAL|Session 4: Internalizing compassion|"* Pretend-to-pretend practice is made for participants to observe themselves.~* In addition to the previous practices, the practice of internalizing compassion is made in order to increase their expanded mindfulness.~* Courtesy meditation: a neutral person, kindness towards your body, which is based on mindfulness practices and increases body awareness and mindful movement, is carried out. During the day, they will be informed that they should do the walking with kindness practice on their own"
61996006|NCT05886959|EXPERIMENTAL|Session 5: Me and others - Expanding the circle|"* A compassionate letter application is made by asking participants to think about a situation they encountered recently or some time ago and is still causing distress. It is explained that they can gain insight with this application.~* Courtesy meditation: the 'difficult' person, compassion and breathing: yourself and compassionate breathing: others practices are made"
61996007|NCT05886959|EXPERIMENTAL|Session 6: Growing happiness|"* Revisiting the good practice is carried out to define the five sense organs for the participants.~* Forgiveness, Asking for forgiveness, forgiving others, gratitude practices are carried out.~* The practice is expanded as kindness meditation: groups and all beings."
62181204|NCT06039592||Traditional Drug Therapy Group|Patient in this group will undergo a one-year course of medication, including Torsemide(tablet, 0.2-0.5mg/mg, bid) and Potassium Citrate(powder, 0.06g/kg, tid).
62181205|NCT00461123|EXPERIMENTAL|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
62181206|NCT00461123|PLACEBO_COMPARATOR|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
62181207|NCT04117815||study group|"Patients with breast or gynecological cancer planning to undergo chemotherapy Chemotherapy can be neoadjuvant, adjuvant or palliative Up to two lines of chemotherapy are allowed. Adjuvant therapy counts as one line.~Chemotherapy regime is associated with alopecia. Chemotherapy must be planned for at least 4 cycles of taxane or antracycline- based chemotherapy regimen No alopecia of any reason (up-front) No overt cognitive impairment and fluent in German Written informed consent Age 18 and older"
62181208|NCT04117815||reference group|"For the purpose of comparison, a reference sample will be included in the study applying to the following inclusion criteria:~Patients with breast or gynecological cancer planning to undergo chemotherapy Chemotherapy can be neoadjuvant, adjuvant or palliative Up to two lines of chemotherapy are allowed. Adjuvant therapy counts as one line.~Chemotherapy regime is associated with alopecia. Chemotherapy must be planned for at least 4 cycles of taxane or antracycline- based chemotherapy regimen Refuse to undergo scalp cooling Patients who have been excluded for the study group for the reason of migraine Written informed consent Age 18 and older~Patients from the reference group complete the same survey as the study group. Group comparisons will be adjusted for baseline body image and reasons for refusal."
61996008|NCT05886959|EXPERIMENTAL|Session 7: Weaving Wisdom and Compassion into Daily Life|"* Participants are made to choose a day in their life and allow a few minutes to pause in a mindful way.~* A breather for wise and compassionate action, calmness meditation and joy sharing meditation practices are carried out."
61996009|NCT05886959|EXPERIMENTAL|Session 8: Living with the Heart|"* The participants are told about the applications that they can apply for, where they need help to develop compassion towards self-healing skills, and the whole training is evaluated.~* The river of life application, which evaluates mindfulness in depth, is carried out.~* An overall summary of the 8-session study is made and feedback is received."
62181209|NCT02264236|EXPERIMENTAL|P10s-PADRE vaccine|Subjects will be immunized by administration of either three or four doses of P10s-PADRE vaccine over a six-week period at a dose level of 500 micrograms (µg) per injection depending on the slandered of care therapy they receive for their lung cancer.
62565480|NCT06371924|ACTIVE_COMPARATOR|Normothermic Regional Perfusion|The donor aorta and inferior cava vein will be cannulated, followed by descending thoracic aorta cross-clamp and initiation of perfusion (Cardiohelp device) with the donor's own blood at 37C for 2h (while monitoring pump flow, venous O2 saturation, lactate and ALT), followed by in-situ flush with 4C preservation solution as in SCS arm.
62565481|NCT06371924|ACTIVE_COMPARATOR|Hypothermic oxygenated perfusion|The liver will be retrieved and preserved as in SCS arm. Then, on arrival to the transplant unit, the portal vein and hepatic artery will be cannulated, and the liver perfused with hypothermic oxygenated solution (VitaSmart device) for 2h.
61996010|NCT00153400|EXPERIMENTAL|Enhanced Lifestyle Intervention|Three health coaching sessions or Lifestyle Programs on physical activity and nutrition are delivered to each woman. Support is offered by community health workers.
61996011|NCT01116232|EXPERIMENTAL|anti-thymocyte globulin, rituximab, sirolimus, tacrolimus,|"anti-thymocyte globulin: Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter~Rituximab: The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour;~For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).~Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose."
61996012|NCT01520363|ACTIVE_COMPARATOR|Study drug-dextromethorphan (DM)|MECP2 mutation positive subjects randomized to receive DM
61996013|NCT01520363|PLACEBO_COMPARATOR|Placebo group|MECP2 positive subjects randomized to the placebo compound
61996014|NCT02492139|OTHER|Pumping|Each particpant will pump with the current pumpset one week and then two weeks with the pumpset
61996015|NCT01889316|OTHER|AN24 in addition to new device (Novii)|"FDA-cleared device (The AN24 device) used in conjunction with the new device (Novii).~Both devices will be placed on the patient's abdomen. Hence the patient acts as their own control."
62565482|NCT05511870|EXPERIMENTAL|Etripamil Nasal Spray 70mg|Etripamil Nasal Spray 70mg single dose
62565483|NCT05511870|PLACEBO_COMPARATOR|Etripamil Placebo Nasal Spray 70mg|Etripamil Placebo Nasal Spray 70mg single dose
61996016|NCT01556204|EXPERIMENTAL|Robotic Surgery|Robotic surgery using the da Vinci Surgical System
62181210|NCT01068405|EXPERIMENTAL|Methotrexate|Patients with digital arthritis receiving methotrexate treatment at 10mg/week during 12 months
62181211|NCT01068405|PLACEBO_COMPARATOR|Placebo|Patients with digital arthritis receiving placebo at 10mg/week during 12 months
62565484|NCT06449482|EXPERIMENTAL|selinexor venetoclax Azacitidine|"In the dose-increasing stage, the subject induction therapy was designed using a 3+3 design. selinexor 60mg QW, 40mg BIW, or 60mg BIW, in combination with venetoclax 100mg d1 200mg d2 400mg d3-28, orally once a day, and azacitidine 75mg/m2, d1-7, subcutaneously. The medication regimen was repeated every 28 days. In this case, RP2D is determined based on MTD, safety, and all other data.~During this study period, there were a total of 4 courses. The treatment cycle of the subjects will include 2 cycles of induction therapy and up to 2 cycles of consolidation therapy."
61996017|NCT01556204|ACTIVE_COMPARATOR|Laparoscopy|Laparoscopic assisted resection of endometriosis will be performed using up to five 5mm ports.
61996018|NCT01301872|OTHER|1|All patients meet ALI/less severe ARDS criteria
61996019|NCT03601754|EXPERIMENTAL|Closed Loop Stimulation (CLS)|Prior to enrollment, the patient would have received Biotronik pacemaker with His bundle lead placement for at least 30 days and CLS will be programmed ON for at least 7 days as part of routine care.
61996020|NCT02838212||Drug-related deaths|fatal adverse drug reactions
61996021|NCT02838212||non drug-related deaths|deaths for other causes different as drugs
61996022|NCT01581463|ACTIVE_COMPARATOR|Liothyronine, Sodium|Healthy adults.
61996023|NCT02281552|EXPERIMENTAL|tofacitinib modified release tablet|
61996024|NCT02281552|ACTIVE_COMPARATOR|tofacitinib immediate release tablet|
61996025|NCT03530475|ACTIVE_COMPARATOR|placenta previa|cases diagnosed as placenta previa diagnosed by ultrasound and doppler
61996026|NCT03530475|ACTIVE_COMPARATOR|placenta accreta|placenta previa diagnosed as placenta accreta by ultrasound and doppler
61996027|NCT00136084|EXPERIMENTAL|HDAC (High-Dose Cytarabine)|Since limited characters are allowed in this passage, please see detailed Description for HDAC.
62565485|NCT00124501|ACTIVE_COMPARATOR|SMT|Standard Medication Treatment
61996028|NCT00136084|EXPERIMENTAL|LDAC (Low-Dose Cytarabine)|Since limited characters are allowed in this passage, please see detailed Description for LDAC.
61996029|NCT04296552|EXPERIMENTAL|12 week lowFODMAP dietary intervention|Patients with IBS-D are enrolled in a 12 week strict lowFODMAP dietary intervention study.
61996030|NCT00422032|EXPERIMENTAL|15 mg/m^2 Clofarabine|Lower Dose Clofarabine Group A: 15 mg/m\^2 intravenous (IV) over 1 hour daily for 5 days
61996031|NCT00422032|EXPERIMENTAL|30 mg/m^2 Clofarabine|Higher Dose Clofarabine Group B: 30 mg/m\^2 IV over 1 hour daily for 5 days
61996032|NCT03062475|EXPERIMENTAL|lifestyle intervention group|Pregnant women allocated to this group receive lifestyle intervention. With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake. With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed or encourage them to do moderate cycling.
61996033|NCT03062475|NO_INTERVENTION|control group|Pregnant women allocated to this group receive standard prenatal care.
61996034|NCT04395937|ACTIVE_COMPARATOR|respiratory physiotherapy|exercises to improve the way of breathing
61996035|NCT04395937|EXPERIMENTAL|respiratory physiotherapy and physical exercises|intensity determined by the VO2max measured during ergospirometric measure
61996036|NCT04395937|NO_INTERVENTION|control group|
61996037|NCT05729334|EXPERIMENTAL|Subjects with skin lesions who meet all inclusion criteria and none of the exclusion criteria|Subjects with skin lesions who meet all inclusion criteria and none of the exclusion criteria.
61996038|NCT04830527|EXPERIMENTAL|Intervention group|Patients in experimental group will receive EMA prompts. Therapists in this group will receive a summarized PDF report before the beginning of the first psychotherapy session. The report will include graphic summarized data from the EMA prompts.
61996039|NCT04830527|ACTIVE_COMPARATOR|Control group|"Patients in control group will receive the EMA prompts in the same manner as patients in the experimental group.~Therapists in this group will not receive the PDF reports, and instead will get raw scores from a screening evaluation conducted with patients in the recruitment phase of the study."
61996040|NCT05094934|ACTIVE_COMPARATOR|Normal renal function|All participants will receive 100 mg of NNC0385-0434 in an oral tablet per day for 10 days
61996041|NCT05094934|EXPERIMENTAL|Mildly decreased renal function|All participants will receive 100 mg of NNC0385-0434 in an oral tablet per day for 10 days
61996042|NCT05094934|EXPERIMENTAL|Moderately decreased renal function|All participants will receive 100 mg of NNC0385-0434 in an oral tablet per day for 10 days
61996043|NCT05094934|EXPERIMENTAL|Severely decreased renal function|All participants will receive 100 mg of NNC0385-0434 in an oral tablet per day for 10 days
61996044|NCT05143970|EXPERIMENTAL|IPH5301 administration|"Part I- Dose escalation:~Escalating dose levels of IPH5301 will be evaluated.~Part II-Cohort Expansion:~IPH5301 will be administrated in combination with trastuzumab and paclitaxel"
61996045|NCT02795390|EXPERIMENTAL|Chinese herbal medicine|MaZiRenWan 10g plus HuangQi 20g are chosen as the core prescription. Furthermore, six herbal granules can be added according to the syndrome differentiated for individual participant. They are ShuDiHuang 15g and Danggui 10g for deficiency of blood, Maidong 15g and ShengDiHuang 10g for deficiency of Yin, and RouCongRong 15g and Niuxi 10g for deficiency of Yang.
62565486|NCT00124501|EXPERIMENTAL|BART|Biofeedback-assisted Relaxation Training plus SMT
61996046|NCT02795390|PLACEBO_COMPARATOR|Placebo|Placebo is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%), and caramel (0.34%) to achieve color, smell, taste, and texture comparable to the herbal granules.
61996047|NCT01199211||Exercise training, women, marathon.|Other: prospective study with no intervention
61996048|NCT04715399||Cross-sectional|
61996049|NCT04715399||Longitudinal|
61996050|NCT06273345||Single arm|
61996051|NCT05705063|EXPERIMENTAL|Bipolar Patients|Patients follow ketogenic diet for 16 weeks, with monitoring of physical and psychological health and coaching support
61996052|NCT01933867|EXPERIMENTAL|Water immersion colonoscopy|Water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
61996053|NCT01933867|ACTIVE_COMPARATOR|Air insufflation colonoscopy|Standard room air insufflation during both colonoscope insertion and withdrawal.
61996054|NCT02347748|EXPERIMENTAL|Group A - Reading pre-procedure script|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
61996055|NCT02347748|EXPERIMENTAL|Group B - Reading pre-extubation script|Patients will be read a pre-extubation script;
61996056|NCT02347748|EXPERIMENTAL|Group C - Reading 2 scripts|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area Patients will be read a pre-extubation script
61996057|NCT02347748|NO_INTERVENTION|Group D|Patients will not be read any script
61996058|NCT00854581|EXPERIMENTAL|Induction (Up to Day 21)|"For one cycle, up to Day 21. All participants are enrolled to induction therapy phase, then move to the maintenance therapy phase if they achieve complete response (PR) or partial response (PR). Participants who achieve a clinical CR at Day 14 response assessment will go on to Part 1 maintenance therapy. Patients who achieve a PR will receive 7 more days of induction therapy and then go on to Part 1 Maintenance Therapy.:~* Zidovudine:~  * Days 1-2: 1.5 grams intravenously (IV) twice daily~ * Days 3-21: 1.5 grams IV twice daily~* Interferon alfa-2b (IFN):~  * 5 10 million units (mu) intravenously twice daily"
62181212|NCT05549336||PD-1-treated tumor patients|Tumor patients who are initiating receive chemotherapy that includes PD-1 inhibitors.
62181213|NCT05549336||non-PD-1-treated tumor patients|Tumor patients who are initiating receive chemotherapy that not includes PD-1 inhibitors.
62565487|NCT01724697|ACTIVE_COMPARATOR|conventional treatment|conventional treatment \& antivrial treatment.
62565488|NCT01724697|EXPERIMENTAL|BMSC transplantation|conventional treatment \& antiviral treatment \& autologous bone marrow stem cell transplantation via hepatic artery
62565489|NCT01607515|OTHER|suspected PH|Patients who undergo right heart catheterization for PH diagnosis undergo impedance cardiography
62565490|NCT02760537|EXPERIMENTAL|Lay Health Worker Intervention|LHWs conducted phone interventions by reminding participants of a series of vaccinations at months 1, 2, and 5 among those assigned to the intervention group. Those who had health insurance were encouraged to complete vaccinations through their providers. If participants did not have health insurance, LHWs provided resources to help those in the intervention access vaccinations by referring them to free vaccine events in the community.
62181214|NCT05230030|NO_INTERVENTION|Observational|
62182633|NCT02308098|EXPERIMENTAL|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh
62182634|NCT02308098|EXPERIMENTAL|Symbicort Turbuhaler 320/9 ug/inhalation 1 inh|Symbicort Turbuhaler 320/9 ug/inhalation 1 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh
62565491|NCT02760537|PLACEBO_COMPARATOR|Placebo (a list of resources)|Those in the control group received a list of resources along with their results by mail that offered free vaccinations, such as local health departments.
62565492|NCT06490224|PLACEBO_COMPARATOR|Control|Usual patient reported outcome measures
62565493|NCT06490224|EXPERIMENTAL|Experimental|Usual patient reported outcome measures + new visual display of responses to subjective health questions
62565494|NCT01124994|ACTIVE_COMPARATOR|Mucosectomy|Patients in this arm are undergoing mucosctomy after previous confocal laser endomicroscopy.
62565495|NCT05755919|OTHER|Patients with epilepsy|Epilepsy surgery will be performed as a part of the clinical management of patients with drug-resistant epilepsy.
62565496|NCT02088762||1 cm safety margin|1 cm safety margin
62565497|NCT02088762||2 cm safety margin|2 cm safety margin
62565498|NCT04016675|EXPERIMENTAL|Study Group|Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery
62565499|NCT04016675|ACTIVE_COMPARATOR|Control Group|Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy
62565500|NCT05401617|NO_INTERVENTION|control group|patient benefiting from a traditional anesthesia consultation as performed daily in the department (control group). The information will be delivered according to local customs and the MAR: oral, which can be supplemented by the delivery of the SPARADRAP booklet and the written documents usually delivered
62565501|NCT05401617|EXPERIMENTAL|experimental group|patient benefiting, in addition to this traditional anesthesia consultation, from additional information via the computerized tool. The operation of this tool will be explained by paramedical staff and its access will be free as soon as you leave the consultation.
62565502|NCT05711108||Long Term Care Residents Using Glucose Lowering Medication|
62565503|NCT04578301||Surgery|Patients with and without liver cirrhosis undergoing surgery.
62565504|NCT05576142||Case Group|Patients from this group were diagnosed from allergic rhinitis and/or asthma.
61996059|NCT00854581|EXPERIMENTAL|Part 1 Maintenance (Up to Day 60)|"From Treatment Day 14 or 21 to start of Month 3 (Day 60). Study participants move on to Part 1 Maintenance Therapy only if they achieve complete response (CR) or partial response (PR) after induction therapy. Restaging and molecular evaluation of disease at start of Month 3:~* Zidovudine: 600 mg orally twice daily in all phases of Maintenance Therapy~* PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly~* Participants then proceed to Part 2 maintenance."
62565505|NCT05576142||Control Group|Healthy children.
62565506|NCT02978118||Group A: Renal Cell Carcinoma|Subjects in Group A (patients with locally advanced, high grade or metastatic renal cell carcinoma starting immunotherapy) will have blood collected at baseline, at the time of a standard of care cytoreductive surgery (if applicable), 12 weeks, 24 weeks, 52 weeks and upon disease progression on treatment for analysis of peripheral blood mononuclear cells (PBMCs), circulating tumor cells (CTCs), metabolites, cytokines and angiokines. Urinary and fecal specimens will be collected at baseline, at the time of a standard of care cytoreductive surgery (if applicable), 12 weeks, 24 weeks, 52 weeks and upon disease progression. Tissue will be collected at the time of a standard of care cytoreductive surgery (if applicable).
62565507|NCT02978118||Group B: Urothelial Carcinoma|Subjects in Group B (patients with locally advanced, high grade or metastatic urothelial carcinoma starting immunotherapy) will have blood collected at baseline, at the time of a standard of care cytoreductive surgery (if applicable), 12 weeks, 24 weeks, 52 weeks and upon disease progression on treatment for analysis of peripheral blood mononuclear cells (PBMCs), circulating tumor cells (CTCs), metabolites, cytokines and angiokines. Urinary and fecal specimens will be collected at baseline, at the time of a standard of care cytoreductive surgery (if applicable), 12 weeks, 24 weeks, 52 weeks and upon disease progression. Tissue will be collected at the time of a standard of care cytoreductive surgery (if applicable).
62565508|NCT03214601|EXPERIMENTAL|Relay Branch System|Subjects who receive the Relay Branch System for repair which includes those with aneurysmal disease, penetrating atherosclerotic ulcer (PAU), and chronic uncomplicated Type B aortic dissection.
62181215|NCT05230030|EXPERIMENTAL|Improvisation Workshops|Participants will take part in an improvisation curriculum containing a uniquely designed series of flexibly-timed improvisation workshops administered during the study period. Using published guidelines, workshops will have groups of approximately 10 study participants and last on average 2 hours under the instruction of an expert medical improvisation facilitator.
62181216|NCT00548847|EXPERIMENTAL|GM-CSF, Interferon-α-2b|
62181217|NCT02154347|EXPERIMENTAL|KAD-1229/KAD-1229|Patients are administered KAD-1229 for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with insulin throughout the study.
62181218|NCT02154347|OTHER|Placebo/KAD-1229|Patients are administered Placebo for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with Insulin throughout the study.
62181219|NCT04310527|EXPERIMENTAL|Treatment A: Administration of enasidenib fasted|A single oral 100 mg dose of enasidenib reference formulation will be given under fasted condition.
62565509|NCT05434988||Laparoscopic appendectomy|The laparoscopic appendectomy group is the group that includes patients who underwent appendectomy using the laparoscopic approach
62565510|NCT05434988||Open appendectomy|The open appendectomy group is the group that includes patients who underwent appendectomy using laparoscopic approach
62565511|NCT04323410|EXPERIMENTAL|Cast immobilization|"In the casting group, padded synthetic dorsal above elbow and volar below elbow splints are applied in ED without local or general anesthesia. Dorsal displacement and shortening of the radius are not corrected, but the forearm is attempted to be manipulated straight during application of the splints. The casted forearm is then supported by a collar and cuff sling. Splints are removed in an outpatient clinic at 4 weeks.~Cast immobilization is discontinued after 4 weeks and when the fracture site is nontender. If palpated tenderness is still present, the patient is given a dorsal forearm splint which can be removed (maximum of 2 weeks usage)."
62565512|NCT04323410|ACTIVE_COMPARATOR|Percutaneus pinning|In the surgery group, a padded dorsal above elbow splint is applied in ED. Reduction and percutaneous pinning are performed under anesthesia in operating room by an experienced attending pediatric orthopedic surgeon within 7 days from the injury. Pin fixation is performed with two 1.6 mm pins. Padded dorsal above elbow and volar below elbow splints are applied. Splints and pins are removed at the outpatient clinic at 4 weeks after surgery.
62565513|NCT02539940||Patients with critical limb ischemia|Patients undergoing endovascular intervention of below-the-knee arteries with ELUTAX SV DEB (drug-eluting balloon).
62565514|NCT06575478|EXPERIMENTAL|prescription ABA|Fuling Yunhua Granules and Dihuang Baoyuan Granules
62565515|NCT06575478|PLACEBO_COMPARATOR|prescription ABA-matched placebo|Fuling Yunhua Granules placebo and Dihuang Baoyuan Granules placebo
62565516|NCT06575478|EXPERIMENTAL|prescription BAB|Fuling Yunhua Granules and Dihuang Baoyuan Granules
62565517|NCT06575478|PLACEBO_COMPARATOR|prescription BAB-matched placebo|Fuling Yunhua Granules placebo and Dihuang Baoyuan Granules placebo
62565518|NCT01089400||Influenza A/H1N1 patients|
62181220|NCT04310527|EXPERIMENTAL|Treatment B: Administration of enasidenib fasted|A single oral 100 mg dose of enasidenib test formulation will be given under fasted condition.
62181221|NCT04310527|EXPERIMENTAL|Treatment C: Administration of ensidenib fed|A single oral 100 mg dose of enasidenib test formulation will be given under fed condition.
62181222|NCT04301115|ACTIVE_COMPARATOR|conventional group|conventional partial denture
62181223|NCT04301115|EXPERIMENTAL|attachment group|unlateral attachment retained partial denture
62181224|NCT04301115|EXPERIMENTAL|tooth implant supporeted prosthesis|tooth implant supported bridge
62181225|NCT06480279||Non-fallers|Elderly without history of fall
62565519|NCT01089400||Non influenza A/H1N1 patients|
62181226|NCT06480279||Fallers-low risk|Elderly with a history of falling 1 time within the last year.
62181227|NCT06480279||Fallers-moderate risk|Elderly with a history of falling twice within the last year.
62181228|NCT06480279||Fallers-high risk|Elderly with a history of falling \>2 times within the last year.
62181229|NCT00508859|EXPERIMENTAL|Active, 1|sertraline
62565520|NCT02094274|EXPERIMENTAL|LAS40468|Single dose, administered via Genuair® dry powder inhaler (DPI)
62565521|NCT02094274|ACTIVE_COMPARATOR|Salmeterol/fluticasone propionate|Single dose, Seretide® (salmeterol fluticasone propionate) administered via Accuhaler™
62565522|NCT02094274|PLACEBO_COMPARATOR|Placebo|Single dose administered via Genuair® or Accuhaler™ dry powder inhaler (DPI)
62565523|NCT01431716|EXPERIMENTAL|EFI/ACT-385781A|EFI/ACT-385781 administered by continuous intravenous infusion via a central venous catheter using an ambulatory infusion pump
62565524|NCT05225272||Patients undergoing on-pump cardiac surgery|The investigators aim to conduct a bidirectional (prospective and retrospective) observational, cohort study including on-pump cardiac surgery patients.
62565525|NCT04404543|EXPERIMENTAL|Escalation Cohort|"Five dose levels will be tested according to the 3 + 3 dose-escalation design.~The dose-limiting toxicity (DLT) will be assessed from the first administration of SYHA1807 to the end of the first cycle (28 days)."
62565526|NCT04404543|EXPERIMENTAL|Dose Expansion Cohort|Once the RP2D has been determined, an expansion cohort of up to 12\~40 subjects will be enrolled in order to better characterize the clinical activity and safety profile of the RP2D.
62565527|NCT04526288|ACTIVE_COMPARATOR|Arm A (alloHCT)|Patients undergo alloHCT.
62565528|NCT04526288|EXPERIMENTAL|Arm B (CPX-351, alloHCT)|Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment may repeat for an additional cycle for a total of 2 cycles (on days 1 and 3 only of cycle 2) in the absence of disease progression or unacceptable toxicity. Within 60 days after completion of CPX-351, patients undergo alloHCT.
62565529|NCT03533517|EXPERIMENTAL|AccuCinch® Ventricular Restoration System|
62181230|NCT00508859|PLACEBO_COMPARATOR|Placebo|placebo
62181231|NCT02877732|EXPERIMENTAL|Concussed Subject|EYE-SYNC eye-tracking device, Level of Alertness, SCAT-3 subtests (Symptom, Immediate memory, Balance and Orientation), Simple Reaction Time subtest of ANAM-SRT and DEM. Investigators will be collecting medical history and demographics from each subject.
62565530|NCT05344560|EXPERIMENTAL|test/control/control|Eligible subjects that are habitual contact lens wearers will be randomized into the (test/control/control) sequence and will wear two different study lenses one at a time bilaterally over three wear periods.
62565531|NCT05344560|EXPERIMENTAL|control/test/test|Eligible subjects that are habitual contact lens wearers will be randomized into the (control/test/test) sequence and will wear two different study lenses one at a time bilaterally over three wear periods.
62565532|NCT01332669|ACTIVE_COMPARATOR|chemoembolization|HCC patients received chemoembolization
62181232|NCT02877732|ACTIVE_COMPARATOR|Control Subject|EYE-SYNC eye-tracking device, Level of Alertness, SCAT-3 subtests (Symptom, Immediate memory, Balance and Orientation), Simple Reaction Time subtest of ANAM-SRT and DEM. Investigators will be collecting medical history and demographics from each subject.
62181233|NCT06149143||Cardiac Function Monitoring|Subjects scheduled for cardiac catheterization will undergo measurement with the Cardiac Performance System non-invasive device for a brief period before the catheterization procedure.
62181234|NCT03510806|PLACEBO_COMPARATOR|Placebo|taste, color, and calorie-matched to supplement
62565533|NCT01332669|OTHER|Historical use of c-TACE using Lipiodiol and doxorubicin|The control arm will be of the patients that have been treated historically in the centers with conventional TACE (that is Lipiodiol plus doxorubicin).
62565534|NCT00964067|ACTIVE_COMPARATOR|Treadmill group|Interval exercise performed on treadmills, supervised
62565535|NCT00964067|ACTIVE_COMPARATOR|Exercise groups|Supervised and organised in groups of ten
62181235|NCT03510806|EXPERIMENTAL|Supplement|Proprietary protein and fruit extract blend
62181236|NCT06076824|EXPERIMENTAL|Intervention group (Glucocorticoid treatment)|
62181237|NCT06076824|PLACEBO_COMPARATOR|Control group|Saline solution (0.9%)
62565536|NCT00964067|ACTIVE_COMPARATOR|home-based exercise|Interval training at home, free choice of modality
62565537|NCT00644215|EXPERIMENTAL|1|5-FU injection has been done
62565538|NCT00644215|EXPERIMENTAL|2|Mitomycin drop has been administrated
62181238|NCT02356796|EXPERIMENTAL|Multidisciplinary group treatment|"Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.~The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months."
62181239|NCT02356796|ACTIVE_COMPARATOR|Standard physiotherapy treatment|Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
62181240|NCT02190552||EmboTrap® Revascularization Device|The EmboTrap® Revascularization Device is the investigational device
62181241|NCT02051985|EXPERIMENTAL|Aerobic exercise training|
62181242|NCT02051985|ACTIVE_COMPARATOR|Standard physical therapy|
62181243|NCT01232569|EXPERIMENTAL|Tocilizumab 162 mg sc|Patients will receive tocilizumab 162 mg subcutaneously (sc) every 2 weeks for 24 weeks.
62181244|NCT01232569|PLACEBO_COMPARATOR|Placebo sc|Patients will receive placebo subcutaneously (sc) every 2 weeks for 24 weeks.
62181245|NCT02230709|EXPERIMENTAL|Dry needling|Dry needling treatment on the trigger point number 2 of the trapezius muscle.
62565539|NCT03749330|OTHER|CHOP CICU|CICU Team And Loved Ones Communicating (CICU TALC)
62565540|NCT03719469||Green tea group|A total of 100 subjects (aged 18-65 years) who were diagnosed as RA with moderate to severe activity at the division of rheumatology and clinical immunology at Mansoura University,After starting green tea supplement (4 to 6 cups/day; 60 to 125 mg catechins), patients were evaluated for therapeutic response at baseline and 12, and 24 weeks.
61996060|NCT00854581|EXPERIMENTAL|Part 2A Maintenance (Up to 12 Months)|"Participants achieving a CR with undetectable clonal disease. Participants will receive therapy for as long as response is maintained:~* Zidovudine: 600 mg orally twice daily~* PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly"
62565541|NCT03719469||control group|fifty healthy normal subjects were included in this study as controls.
62565542|NCT03711786|ACTIVE_COMPARATOR|Basic implementation package|Ten Malawi non-communicable diseases clinics will be randomized 1:1 to one of two implementation strategies to be used for two years followed by a 12-month follow-up period.
61996061|NCT00854581|EXPERIMENTAL|Part 2B Maintenance (Up to 12 Months)|"Participants achieving a CR with minimal residual disease (by multiplex PCR) or PR in Part 1:~* Zidovudine: 600 mg or 300 mg orally twice daily, per protocol~* PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly, per protocol~* Valproic acid, 250 mg orally twice daily, per protocol"
61996062|NCT03921710|ACTIVE_COMPARATOR|CAPA-IVM|Immature oocytes are culture in the new capacitation-IVM system.
61996063|NCT03921710|ACTIVE_COMPARATOR|Standard-IVM|Immature oocytes are cultured in the standard IVM system.
61996064|NCT02246803|ACTIVE_COMPARATOR|CABG+pulmonary vein isolation|CABG+pulmonary vein isolation procedure
61996065|NCT02246803|ACTIVE_COMPARATOR|Isolated CABG|Isolated CABG procedure
62181246|NCT02230709|ACTIVE_COMPARATOR|"TENS and dry needling"|Application of TENS current after dry needling treatment.
62181247|NCT02108652|EXPERIMENTAL|Cohort 2: Participants With Second-line or Beyond Treatments|Participants with advanced disease who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting will receive atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.
62181248|NCT02554422|EXPERIMENTAL|PalpEar|Intraoperative palpation of the ossicles using the PalpEar device, to measure mobility of the ossicle chain.
62565543|NCT03711786|EXPERIMENTAL|Enhanced implementation package|Ten Malawi non-communicable diseases clinics will be randomized 1:1 to one of two implementation strategies to be used for two years followed by a 12-month follow-up period.
62565544|NCT03869320|EXPERIMENTAL|ACT-1004-1239|ACT-1004-1239 will be given as a single oral dose under fasting conditions. Eight doses are planned with a starting dose of 1 mg. The ADME characteristics and absolute bioavailability using a 14C-radiolabeled microtracer will be evaluated as part of the SAD, after the first 3 cohorts have been performed.
62565545|NCT03869320|PLACEBO_COMPARATOR|Placebo|Matching placebo will be given as a single oral dose under fasted conditions. Matching placebo for the oral and intravenous administration of the 14C-radiolabeled ACT-1004-1239 will also be available.
62565546|NCT03869320|EXPERIMENTAL|Food-effect subpart: ACT-1004-1239|ACT-1004-1239 will be given under both fasted (first period) and fed (second period) conditions. The food effect will be evaluated after the first 3 cohorts have been performed.
62565547|NCT03869320|PLACEBO_COMPARATOR|Food-effect subpart: Placebo|Matching placebo will be given under both fasted (first period) and fed (second period) conditions.
62565548|NCT03298386|EXPERIMENTAL|"Intervention Group STOPP/START"|Training of General Practitioners with the tool STOPP/START Systematic medication review by GP with STOPP/START
62181249|NCT00184197|EXPERIMENTAL|Botox|
62181250|NCT00184197|PLACEBO_COMPARATOR|placebo|
62181251|NCT02048683|EXPERIMENTAL|burn ICU patients|Determination of plasmatic concentrations of sevoflurane at different times of a short term sedation of sevoflurane in burn versus non burn ICU patients
62565549|NCT03298386|NO_INTERVENTION|Control group|Patient's usual care by the general practitioner (who will not be trained in the STOPP/START tool)
62772815|NCT01581008|EXPERIMENTAL|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
62772816|NCT01581008|ACTIVE_COMPARATOR|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
62772817|NCT05004129|EXPERIMENTAL|Tideglusib|Weight adjusted tideglusib, orally, once daily
62772818|NCT00607399|EXPERIMENTAL|Single arm|
62772819|NCT04578561||Prophylactic mesh|Patients who received a prophylactic mesh after emergency surgery due to high risk of incisional hernia.
62772820|NCT04578561||Suture|Patients who's laparotomies closure was using only suture without any abdominal wall reinforcement
62772821|NCT03908970|EXPERIMENTAL|1% OPA-15406|Twice daily
62772822|NCT03908970|PLACEBO_COMPARATOR|Placebo|Twice daily
62772823|NCT02831790|EXPERIMENTAL|Educational Intervention|Participants in the intervention group will have access to the 3 teaching videos, \~3:30-5:00 minutes in duration each, beginning several weeks prior to the preadmission clinic (as soon as written consent is obtained).
62772824|NCT02831790|NO_INTERVENTION|Usual Care|Participants in the usual care will not be offered an intervention and will not be made aware of the existence of the teaching videos.
62772825|NCT05528133|EXPERIMENTAL|Radiosensitivity Index optimized|Participants will be assigned to optimized arm based on their RSI score. Participants will receive whole breast radiation therapy with or without regional lymph node irradiation as appropriate with or without a boost to the lumpectomy cavity.
62772826|NCT05528133|ACTIVE_COMPARATOR|Radiosensitivity Index not optimized|Participants will receive standard of care whole breast radiation therapy with or without regional lymph node irradiation as appropriate with a boost to the lumpectomy cavity.
62772827|NCT00718341|ACTIVE_COMPARATOR|1|
62772828|NCT00718341|PLACEBO_COMPARATOR|2|
61996066|NCT06255652||Obstetrician and gynaecological procedures|Patients for obstetricians
61996067|NCT00094965|EXPERIMENTAL|1|
61996068|NCT00999024||Healthy subjects|20 healthy subjects will be included
62565550|NCT06055205|EXPERIMENTAL|PAC-plan|"The patients receive a Pain- and Coordination plan (PAC-plan) at discharge from the hospital. The PAC-plan includes:~* Upon discharge, patients have a patient-centered conversation and receive written information covering patient education on opioids, a tapering plan, and a plan for contact and follow-up with the general practitioner. The information is based on the Norwegian National Guide for Addictive Medications.~* Before discharge, patients are scheduled an appointment with the GP, preferably within the first 2 weeks (2-4 weeks), for a follow-up regarding the injury and pain management.~* The GP is invited to maintain contact with the study nurse at the hospital for one year. The general practitioner can call for consultation with the study nurse, and if necessary, be connected with relevant medical specialists for advice and eventually further follow-up."
62565551|NCT06055205|NO_INTERVENTION|Control|Treatment and follow-up as usual.
62565552|NCT06574607|EXPERIMENTAL|experimental group|
62565553|NCT06574607|ACTIVE_COMPARATOR|control group|
62565554|NCT03428152||Hypo|The participants with a superior hypogastric block
62565555|NCT03428152||NoHypo|The participants without a superior hypogastric block; the patients with an epidural catheter, who receive a different block technique (ie: TAP block), or who are unsuitable for SHP block (ie: if retro-peritoneum is opened intraoperatively by the surgeon)
62565556|NCT05863663||endometriosis|Women diagnosed with endometriosis between 18-50 years old
62565557|NCT06015724|EXPERIMENTAL|Pancreatic Ductal Adenocarcinoma|
62772829|NCT03957876|EXPERIMENTAL|intravenous CPX-351 with potential maintenance therapy|Single agent CPX-351 administered at the standard FDA approved dose of 44 mg/m2 intravenously on days 1, 3, 5 of the induction cycle. If participants achieve complete remission (CR), complete remission with incomplete count recovery (CRi) or partial remission (PR), they will be eligible to continue on to maintenance therapy, which will consist of CPX351 at a dose of 15.4 mg/m2 every 28 days. Participants can receive up to 4 cycles of maintenance therapy.
61996069|NCT00999024||COPD Patients|20 Patients with Grade IV COPD will be included
61996070|NCT03748199|EXPERIMENTAL|POL6014|multiple ascending doses: 80, 160 and 40 mg once or twice daily
61996071|NCT03748199|PLACEBO_COMPARATOR|Placebo|Placebo will be administered orally at a dose and frequency matched to POL6014
61996072|NCT05272982||Successful weaning group|Criteria of weaning included resolution of the primary cause of intubation, adequate cough without excessive tracheobronchial secretions, PaO2 \> 60 mmHg with positive end-expiratory pressure ≤ 8 cmH2O, fraction of inspired oxygen ≤ 0.4, respiratory rate \< 30 per minute, appropriate pH for patients' baseline respiratory status, and stable cardiovascular status.
61996073|NCT05272982||Failed weaning group|Weaning failure will be defined as a patient need for reintubation or noninvasive ventilation within 48 h after extubation due to the presence of one or more of the following criteria: altered mental status tachypnea (respiratory rate more than 35 breaths per minute), oxygen saturation less than 90% or PaO2 less than 60 mmHg on a fraction of inspired oxygen of 40%, an apparent increase in accessory respiratory muscle activity, evident facial signs of respiratory distress and hemodynamic instability (Heart rate \>140 b/min, systolic blood pressure \>180 or \< 90mmHg )
61996074|NCT01185795|EXPERIMENTAL|Cardioviva™ yogurt|
61996075|NCT01185795|PLACEBO_COMPARATOR|Placebo yogurt|
62181252|NCT02048683|OTHER|non burn ICU patients|Determination of plasmatic concentrations of sevoflurane at different times of a short term sedation of sevoflurane in burn versus non burn ICU patients
62565558|NCT06015724|EXPERIMENTAL|Refractory Non-Small Cell Lung Cancer|
62565559|NCT02950415|OTHER|virtual + coaching|Parent is present virtually via an internet pad (iPad) and has received coaching about how best to verbally soothe child
61996076|NCT02062762|EXPERIMENTAL|Online-MBSR|8 week mindfulness based stress reduction online
61996077|NCT02062762|ACTIVE_COMPARATOR|Expressive Writing Online|Online distributed expressive writing intervention as active control
61996078|NCT01752855|EXPERIMENTAL|New formulation of adalimumab 40 mg every other week|New formulation adalimumab 40 mg every other week
62181253|NCT05639478|EXPERIMENTAL|Intervention group|Patients in the intervention group will perform face to face foot-related exercises for 12 weeks.
62181254|NCT05639478|NO_INTERVENTION|Control group|Participants in the control group will not receive any specific intervention in addition to the treatment recommended by the health professionals team (doctors, nurses, podiatrists), which includes pharmacological treatment, and self-care recommendations and foot care by international consensus.
62565560|NCT02950415|OTHER|virtual + no coaching|Parent is present virtually via an internet pad (iPad) and has not received coaching about how best to verbally soothe child
62772830|NCT04773236|ACTIVE_COMPARATOR|Buffered Local anesthesia|Sodium bicarbonate with 2% lidocaine and 1:80.000 epinphrine
62772831|NCT04773236|PLACEBO_COMPARATOR|Non Buffered Local anesthesia|2%lidocaine with 1:80.000 epinphrine.
62772832|NCT00448331||positive screen, negative screen|Positive screens are those who received positive feedback regarding their answers to a mental illness screening assessment. Negative screens received feedback stating that they did not screen positive for any mental illness.
62772833|NCT04356040|EXPERIMENTAL|Main Study|
62772834|NCT04356040|EXPERIMENTAL|High Standard Power Sub-Study|
62565561|NCT02950415|OTHER|physical + coaching|Parent is physically present and has received coaching about how best to verbally soothe child
62565562|NCT02950415|OTHER|physical + no coaching|Parent is physically present and has not received coaching about how best to verbally soothe child
62565563|NCT05364866||Medical treatment group|Using class I or class III AAD to maintain sinus rhythm
62565564|NCT05364866||Cryoballoon ablation group|Pulmonary vein isolation by cryoballoon ablation using Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters (23mm and 28mm)
62565565|NCT01537042|EXPERIMENTAL|Rotigotine|"Rotigotine Transdermal Patch~1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h."
62565566|NCT01537042|PLACEBO_COMPARATOR|Placebo|Transdermal patch matched according to patch size and appearance.
62565567|NCT04606212|EXPERIMENTAL|Losartan group|
62565568|NCT04606212|PLACEBO_COMPARATOR|Placebo group|
61996079|NCT00249470|EXPERIMENTAL|Abstinence & Work|Participants in the Abstinence \& Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
61996080|NCT00249470|OTHER|Work Only|Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
61996081|NCT02382016|EXPERIMENTAL|Investigational treatment|Macitentan film-coated tablet 10 mg once daily.
61996082|NCT02382016|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet once daily.
62181255|NCT00698555|EXPERIMENTAL|Group A|
62181256|NCT00698555|EXPERIMENTAL|Group B|
62181257|NCT00698555|EXPERIMENTAL|Group C|
62181258|NCT00698555|EXPERIMENTAL|Group D|
62181259|NCT00698555|EXPERIMENTAL|Group E|
62181260|NCT00698555|ACTIVE_COMPARATOR|Group F|
62181261|NCT05021822|ACTIVE_COMPARATOR|Block Group|
62181262|NCT05021822|NO_INTERVENTION|Control Group|
62181263|NCT02316288|EXPERIMENTAL|Therapy|Mindfulness and Acceptance Therapy
62181264|NCT02316288|ACTIVE_COMPARATOR|Education|Health Education
62181265|NCT00217022|ACTIVE_COMPARATOR|Budesonide|9 mg daily
62565569|NCT03560401|EXPERIMENTAL|Brace group|After spinal surgery, patients in the brace group were instructed to wear a rigid brace (Knight-Taylor \[chairback\] brace) full-time for 12 weeks, except when bathing or lying in bed.
62565570|NCT03560401|NO_INTERVENTION|No brace group|After spinal surgery, patients in the no brace group were instructed to wear a soft corset for 2 weeks, after which it was weaned off.
62565571|NCT04517305||Pyrotinib plus vinorelbine|Patients used pyrotinib plus vinorelbine as treatment for metastatic breast cancer.
61996083|NCT06145009|EXPERIMENTAL|Time Restricted Eating|Participants will limit their eating (all food and caloric beverages) to an eating window of 10 hours per day for 4 weeks. The eating window must end by 8pm. Water and non-caloric beverages are allowed outside of the eating window. No other changes are required to the types or total amount of food eaten.
61996084|NCT02888847|ACTIVE_COMPARATOR|Philips Zoom! White Speed whitening lamp|Philips Zoom! White Speed whitening lamp
61996085|NCT02888847|SHAM_COMPARATOR|Philips Zoom! Advanced power lamp|Philips Zoom! Advanced power whitening lamp
61996086|NCT02933242|EXPERIMENTAL|Stereotactic arm|Stereotactic ablative radiotherapy
61996087|NCT00401765|EXPERIMENTAL|Cohort 1A (Docetaxel and CNTO 328)|In cohort 1A, 75 mg/m2 docetaxel will be administered in run-in phase and 75 mg/m2 docetaxel every 3 weeks and 6 mg/kg CNTO 328 every 2 weeks will be administered in the treatment phase.
62181266|NCT00217022|PLACEBO_COMPARATOR|Placebo|three tablets daily
62181267|NCT02171247|ACTIVE_COMPARATOR|Isovue 370|Isovue 370 is a contrast agent with increased iodine concentration.
62181268|NCT02171247|ACTIVE_COMPARATOR|Visipaque 320|Standard protocol is Visipaque 320.
62181269|NCT03978078|EXPERIMENTAL|Biological collection|"For all the patients include in the study :~- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment~In parallel to this biological collection, standardized clinical data will be entered into a database"
62181270|NCT03100136|EXPERIMENTAL|[11C]PF-06809247|A dose intravenous injection of \[11C\]PF-06809247 followed by PET scanning.
62181271|NCT00884013||1|Quality Payment and all clinical reminders turned on
62181272|NCT00884013||2|Quality Payment and ABCS measures reminders turned on
62181273|NCT00884013||3|Quality Payment and non-ABCS measures reminders turned on
62181274|NCT00884013||4|Quality Reporting and Recognition with all clinical reminders turned on
62181275|NCT00884013||5|Quality Reporting and Recognition with ABCS measures reminders turned on
62181276|NCT00884013||6|Quality Reporting and Recognition with non-ABCS measures reminders turned on
62181277|NCT02736955|EXPERIMENTAL|Valbenazine|Fixed dose of valbenazine administered once daily for up to 72 weeks
62181278|NCT02004106|EXPERIMENTAL|Part 1: RO6895882 Single Ascending Dose|Participants will receive RO6895882 at ascending doses (\</= 6 mg) as a single intravenous (IV) infusion.
62565572|NCT01606358||Ovarian Cancer|
62181279|NCT02004106|EXPERIMENTAL|Part 2: RO6895882 Dose Escalation Monotherapy|Participants in different cohorts will receive RO6895882 at ascending doses as IV infusion qw, q2w or q3w. After completion of Part 2 all participants have the option to receive the recommended RO6895882 dose once defined in Part 2 at the discretion of investigator.
62565573|NCT02361099|EXPERIMENTAL|Monitoring by SENTINEL application|Patients randomized to this arm will connect once a week to SENTINEL application to do a self-evaluation of several symptoms. A CT- scan will be scheduled only when there is an alert of the application.
62565574|NCT02361099|NO_INTERVENTION|Conventional Monitoring|Patients randomized to this arm will have a CT-scan every 3 months.
62565575|NCT03725306|EXPERIMENTAL|Librata|Librata Endometrial Ablation Device
62565576|NCT02844413|EXPERIMENTAL|study group|implementation of aerobic interval training
61996088|NCT00401765|EXPERIMENTAL|Cohort 1B (Docetaxel and CNTO 328)|In cohort 1B, 6 mg/kg CNTO 328 will be administered in run-in phase and 75 mg/m2 docetaxel will be administered every 3 weeks plus 6 mg/kg CNTO 328 will be administered every 2 weeks in the treatment phase.
62181280|NCT02004106|EXPERIMENTAL|Part 3: RO6895882 MTD Expansion|Participants will receive RO6895882 at MTD determined in Part 2 as IV infusion qw, q2w or q3w.
62181281|NCT05584813|NO_INTERVENTION|ground control binocular|Intervention: pressure chamber environment Procedures: Colour vision tests were performed under normoxia with both eyes three times in a row for appropriate comparability to the simulated flight stages pre-peri-post hypoxia in the intervention groups
62565577|NCT02844413|NO_INTERVENTION|control group|control group
62181282|NCT05584813|NO_INTERVENTION|ground control monocular|Intervention: pressure chamber environment Procedures: Colour vision tests were performed under normoxia with one eye at a time three times in a row for appropriate comparability to the simulated flight stages pre-peri-post hypoxia in the intervention groups
62181283|NCT05584813|EXPERIMENTAL|10,000 ft, 60 min, monocular pre-peri-post|"Intervention: Hypoxia equivalent to an altitude of 10.000 ft. for 60 minutes~Procedures: Colour vision tests were performed with one eye at a time, thereby:~* pre intervention with no hypoxia administered~* during intervention with hypoxia equivalent to an altitude of 10.000 ft. for 60 minutes~* post intervention with no hypoxia administered"
62565578|NCT03972189|EXPERIMENTAL|TQ-B3101|TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
62565579|NCT03161470|ACTIVE_COMPARATOR|Standard Repositioning|Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) without the mechanical chair.
62565580|NCT03161470|EXPERIMENTAL|Mechanical Chair Repositioning|Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) with the mechanical chair.
62565581|NCT03161470|SHAM_COMPARATOR|Sham Treatment|Participants randomly selected for the sham arm will undergo be strapped into the mechanical chair as for the treatment arm but will only undergo the test positions for BPPV-the Dix-Hallpike maneuver. No BPPV repositioning treatment will be completed at the first encounter. At the follow-up visit, standard BPPV treatments (canalith repositioning procedure) will be completed.
62565582|NCT00656422|EXPERIMENTAL|insulin Levemir|
62565583|NCT00656422|EXPERIMENTAL|insulin Lantus|
62565584|NCT06133608|EXPERIMENTAL|Experimental|"Patients in the intervention group will be educated by watching videos on the first day after surgery, in addition to routine clinical education. On the 10th post-operative day, the patients will be called by the researcher and the Tampa Kinesiophobia Scale and Fall Activity Scale will be administered."
62565585|NCT06133608|NO_INTERVENTION|Control|"The control group will receive routine clinical training. On the 10th post-operative day, the patients will be called by the researcher, and the Tampa Kinesiophobia Scale and Fall Activity Scale will be administered."
62565586|NCT00762710|EXPERIMENTAL|1 - Prazosin Medication|Following randomization, participants in this arm will receive a 2-week titration of Prazosin followed by 10 weeks of stable dosing of Prazosin. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.
62565587|NCT00762710|PLACEBO_COMPARATOR|2 - Placebo Medication|Following randomization, participants in this arm will receive a 2-week titration of placebo followed by 10 weeks of stable dosing of placebo. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.
62565588|NCT03550495|NO_INTERVENTION|Control|Patients will undergo standard of care including the use of the ABCDEF bundle; psychiatry team will not be involved on daily ICU rounds.
62565589|NCT03550495|EXPERIMENTAL|Intervention|Patients will receive standard ICU care, including the use of the ABCDEF bundle, but will also receive the intervention of psychiatry involvement; the psychiatry team will participate in daily ICU rounds with the ICU team to help identify, prevent, and treat ICU delirium and identify other psychiatric disorders which may be otherwise undetected by the ICU team.
62565590|NCT03131752|EXPERIMENTAL|Intervention Group|"The patients will be evaluated on 4 phases: at the first contact (at least 24 hours after drug therapy and at most 48 hours), 7 days, 30 days and 3 months after the first contact. They will be submitted to an anamnesis, assessment of muscular strength, physical activity level, functional capacity, dyspnea on activity daily living and quality of life.~The intervention will last 7 days for all the patients. Three phases will be performed: warm up, knee muscle strengthening with elastic bands and stretch/relax."
62772835|NCT05037513|ACTIVE_COMPARATOR|CDC-PrEP|1 session PrEP education following CDC guidelines delivered one on one by an Advanced Practice Registered Nurse to individual clients in the syringe service program setting
62181284|NCT05584813|EXPERIMENTAL|15,000 ft, 15 min, binocular|"Intervention: Hypoxia equivalent to an altitude of 15.000 ft. for 15 minutes~Procedures: Colour vision tests were performed with both eyes, thereby:~* pre intervention with no hypoxia administered~* during intervention with hypoxia equivalent to an altitude of 15000 ft. for 15 minutes~* post intervention with no hypoxia administered"
62182635|NCT03558282||Maxillary Anterior Implant|Subjects who have a single implant restoration in the maxillary anterior position with sufficient baseline data. Recession observation and crown contour observation of the implant will be completed.
62391278|NCT04196010|EXPERIMENTAL|Treatment (CI-CLAM, G-CSF)|Patients receive CI-CLAM consisting of cladribine and cytarabine via CIV on days 1-2, 1-3, 1-4, 1-5, or 1-6 depending on dose level assignment, and mitoxantrone via CIV on days 1-2 or 1-3 depending on dose level assignment. G-CSF may be added at the discretion of the treating physician, as per standard of care. Patients that do not achieve a response of MRD-negative CR after the first cycle are eligible to receive a second cycle of CI-CLAM. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity.
62391279|NCT01452685|PLACEBO_COMPARATOR|Placebo|
61996089|NCT00401765|EXPERIMENTAL|Cohort 2 (Docetaxel and CNTO 328)|In cohort 2, 75 mg/m2 docetaxel will be administered in run-in phase and 75 mg/m2 docetaxel plus 9 mg/kg CNTO 328 will be administered every 3 weeks in treatment phase.
62182636|NCT04834063||NAFLD Cases|Non- alcoholic fatty liver disease
62391280|NCT01452685|EXPERIMENTAL|TAK-385 10 mg QD|
62565591|NCT03131752|NO_INTERVENTION|Control Group|"The patients will be evaluated on 4 phases: at the first contact (at least 24 hours after drug therapy and at most 48 hours), 7 days, 30 days and 3 months after the first contact. They will be submitted to an anamnesis, assessment of muscular strength, physical activity level, functional capacity, dyspnea on activity daily living and quality of life.~Patients will be not receive intervention."
62565592|NCT00706459||1|Patients with lumbar back pain scheduled for back surgery.
62565593|NCT00706459||2|Patients with degenerative disease without classic discogenic back pain
62565594|NCT00706459||3|Normal control without back pain.
62181285|NCT05584813|EXPERIMENTAL|15,000 ft, 60 min, monocular|"Intervention: Hypoxia equivalent to an altitude of 15.000 ft. for 60 minutes~Procedures: Colour vision tests were performed with one eye at a time, thereby:~* pre intervention with no hypoxia administered~* during intervention with hypoxia equivalent to an altitude of 15.000 ft. for 60 minutes~* post intervention with no hypoxia administered"
62565595|NCT00706459||4|Post Surgical discectomy patients
62565596|NCT00706459||5|disc specimens
62565597|NCT03328507|EXPERIMENTAL|BLI4900|BLI4900 Bowel Preparation
62565598|NCT03328507|ACTIVE_COMPARATOR|PEG Control|Polyethylene glycol-based bowel preparation
62565599|NCT02502149|EXPERIMENTAL|rFVIIIFc (15K scale) 1000 IU vial|Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc (15K scale) 1000 IU vial at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 1000 IU vial.
62565600|NCT02502149|EXPERIMENTAL|rFVIIIFc (15K scale) 6000 IU vial|Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc high strength vial (15K scale) at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 6000 IU vial.
62565601|NCT00661557|EXPERIMENTAL|Mencevax Primed Group|Subjects who were previously vaccinated with meningococcal vaccine Mencevax ACWY in study NCT00227422 received in the current study a single dose of meningococcal conjugate vaccine Nimenrix, administered intramuscularly in the deltoid muscle of the non-dominant arm.
62565602|NCT00661557|ACTIVE_COMPARATOR|Mencevax Naive Group|Subjects who did not receive (or had not received in the preceding 10 years) any meningococcal vaccination received in the current study a single dose of meningococcal conjugate vaccine Nimenrix, administered intramuscularly in the deltoid muscle of the non-dominant arm.
62565603|NCT01886677|EXPERIMENTAL|Immediate diet and exercise intervention|A healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week
62565604|NCT01886677|OTHER|Delayed diet and exercise intervention|This arm will receive the same diet and exercise intervention as the experimental arm once recovery from prostatectomy is achieved.
62565605|NCT04958213|OTHER|Conventional physical therapy|Conventional physical therapy (Hotpack, TENS and Ultrasound) and home exercise program (isometric and isotonic exercises) will be applied to this group for 4 weeks (20 sessions).
62181286|NCT00887198|PLACEBO_COMPARATOR|Placebo + prednisone|Placebo plus prednisone
62181287|NCT00887198|EXPERIMENTAL|Abiraterone + prednisone|Abiraterone acetate plus prednisone
62181288|NCT03977571|EXPERIMENTAL|Deferred nephrectomy|Surgery after induction therapy with IO/IO or a TKI/IO-combination, followed by maintenance therapy with nivolumab or a TKI/IO-combination.
62181289|NCT03977571|ACTIVE_COMPARATOR|No surgery|Induction therapy wih IO/IO or a TKI/IO-combination, followed by maintenance therapy with nivolumab or a TKI/IO-combination.
62181290|NCT04651309|OTHER|Ultrasound group|Labor progress assessed by US, avoiding digital exams as much as possible;
62565606|NCT04958213|ACTIVE_COMPARATOR|Dextrose prolotherapy treatment|This group will be treated with 15% dextrose prolotherapy around and inside the knee, 2 times with a two-week interval, and home exercise program (isometric and isotonic exercises).
62565607|NCT02150226|EXPERIMENTAL|Experimental: Zirconia monolithic crowns and bridges|Evaluation of Lava Plus zirconia dental crowns and bridges
62565608|NCT05304130|EXPERIMENTAL|Healthy Japanese participants receiving otilimab|
62772836|NCT05037513|EXPERIMENTAL|SBCM-PrEP|Multi-session Strengths-Based Case Management intervention adapted for PrEP related educational content delivered one on one by an Advanced Practice Registered Nurse to individual clients in the syringe service program setting
61996090|NCT00401765|EXPERIMENTAL|Cohort 3 (Doctaxel and CNTO 328)|In cohort 3, 75 mg/m2 docetaxel will be administered in the run-in phase and 75 mg/m2 docetaxel plus 12 mg/kg CNTO 328 will be administered every 3 weeks in treatment phase.
61996091|NCT00058825|EXPERIMENTAL|Stem Cell Transplant|Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.
62391281|NCT01452685|EXPERIMENTAL|TAK-385 20 mg QD|
61996092|NCT05761379|EXPERIMENTAL|PBM therapy 1|PBM therapy was performed with a low-intensity laser (Airdoc, MPC Co.,Ltd., Beijing, China) with an irradiance of 0.6±0.2 mW, a wavelength of 650 nm±10 nm, and illumination of approximately 400 lux on average. The lighting spot for therapy is a dot. Only one eye will be treated with PBM therapy.
61996093|NCT05761379|EXPERIMENTAL|PBM therapy 2|PBM therapy was performed with a low-intensity laser (Airdoc, MPC Co.,Ltd., Beijing, China) with an irradiance of 0.3±0.2 mW, a wavelength of 650 nm±10 nm, and illumination of approximately 400 lux on average. Only one eye will be treated with PBM therapy.
61996094|NCT05761379|PLACEBO_COMPARATOR|Control|Single vision spectacles correction only.
61996095|NCT00573027|OTHER|Single Arm|"1. fill out baseline demographic and health/medical history questionnaires, CV risk factors, reasons of diagnosis of ischemia, information of coronary artery, and medication use~2. undergo clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory (Appendix);~3. undergo noninvasive Peripheral Artery Tonometry (PAT) testing (Appendix);~4. undergo clinically indicated Cardiac Magnetic Resonance (CMR) imaging (Appendix) to detect subendocardial ischemia (if indicated and referred by the treating physician). The three tests (heart catheterization with adenosine coronary flow reserve testing, acetylcholine provocative vasomotor testing during heart catheterization, cardiac MRI) are performed for standard care.~5. have blood and urine testing.~6. fill out health questionnaires~7. be followed prospectively 6-week, 6-month, and annually for clinical status"
61996096|NCT04804462|EXPERIMENTAL|Virtual Reality Meditation for Fatigue|Participants will experience Virtual Reality Meditation in the comfort of their own home.
61996097|NCT04537728|EXPERIMENTAL|My Healthy Brain Version 2|an 8-week group program that directly targets multiple lifestyle factors associated with brain health and prevention of CD
61996098|NCT00752583|EXPERIMENTAL|1|Peritoneal dialysis
61996099|NCT00752583|ACTIVE_COMPARATOR|2|Haemodialysis
61996100|NCT05427396|OTHER|JS004 200 mg in combination with Toripalimab Injection 240 mg was administered every 3 weeks|
62391282|NCT01452685|EXPERIMENTAL|TAK-385 40 mg QD|
62391283|NCT01452685|OTHER|Leuplin|
62565609|NCT02528877|EXPERIMENTAL|Supportive care (ruxolitinib phosphate, tacrolimus, sirolimus)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV on days -9 to -5 and melphalan IV over 20 minutes on day -4. Beginning greater than 48 hours after completion of melphalan, patients undergo peripheral blood stem cell or bone marrow transplant according to standard guidelines on day 0.~GVHD PROPHYLAXIS: Patients receive ruxolitinib phosphate PO BID on days -3 to 30 tapered to day 60, tacrolimus IV continuously or PO BID on days -3 to 100 , and sirolimus PO QD on day -3 to 100. Treatment continues in the absence of disease progression or unacceptable toxicity."
62565610|NCT00405561|EXPERIMENTAL|AMT2003|
62565611|NCT00513695|EXPERIMENTAL|Treatment (neoadjuvant chemotherapy before surgery)|Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
62565612|NCT04910100|EXPERIMENTAL|Nebivolol Ophthalmic Suspension 1 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
62181291|NCT04651309|NO_INTERVENTION|Control group|Labor progress assessed according to the regular protocol
62181292|NCT01051102|EXPERIMENTAL|IDegAsp|
62181293|NCT01051102|ACTIVE_COMPARATOR|BIAsp 30|
62181294|NCT01081119|EXPERIMENTAL|Project CHOICE|Middle school receives Project CHOICE
62181295|NCT01081119|NO_INTERVENTION|No Project CHOICE|Middle school does not receive Project CHOICE
61996101|NCT03592433|EXPERIMENTAL|I Can PIC|The I Can PIC website will be provided to participants randomized to the experimental/intervention group.
61996102|NCT03592433|NO_INTERVENTION|Attention Control|Participants randomized to the attention control group will be provided a link to a website developed by the American Cancer Society Cancer Action Network.
61996103|NCT00588445|EXPERIMENTAL|Treatment|
61996104|NCT02122588||OVATAR study patients|Females with serous and endometrioid ovarian, peritoneal and fallopian tube cancer 18 years and older, diagnosed 3 months before enrolment into the study or later, consented to participate in this non-interventional study, who are being treated for OC, FTC (Fallopian Tube Cancer) and PC (Peritoneal Cancer) in the oncology hospitals/departments in the Russian Federation.
61996105|NCT00709371|PLACEBO_COMPARATOR|Placebo|Combination tablet containing Zonisamide SR placebo plus bupropion SR placebo SR = Sustained Release
61996106|NCT00709371|ACTIVE_COMPARATOR|Bupropion 360|Combination tablet containing Zonisamide SR placebo plus bupropion SR 360 mg/day; SR = Sustained Release
61996107|NCT00709371|ACTIVE_COMPARATOR|Zonisamide 120|Combination tablet containing Zonisamide SR 120 mg/day plus bupropion SR placebo; SR = Sustained Release
61996108|NCT00709371|ACTIVE_COMPARATOR|Zonisamide 360|Combination tablet containing Zonisamide SR 360 mg/day plus bupropion SR placebo; SR = Sustained Release
61996109|NCT00709371|EXPERIMENTAL|Zonisamide 120/Bupropion 360|Combination tablet containing Zonisamide SR 120 mg/day plus bupropion SR 360 mg/day; SR = Sustained Release
61996110|NCT00709371|EXPERIMENTAL|Zonisamide 360/Bupropion 360|Combination tablet containing Zonisamide SR 360 mg/day plus bupropion SR 360 mg/day; SR = Sustained Release
62181296|NCT02752217|EXPERIMENTAL|Inspiratory Muscle Training (IMT)|"Subjects in the inspiratory muscle training (IMT) group will perform loaded deep breathing exercise at 6 breaths/min using BreatheMaxยฎ device. The IMT protocol at 6 breathing rate (inspiratory time = 4 seconds and expiratory time = 6 seconds) with load at 25 percent of MIP for eighth weeks.~The pressure will be control by pressure manometer and duty cycle are control by subjects count duration for inspiration and expiration during training. The program will perform at home for 10 breaths/min/set, 6 sets/day with at least 1 minutes rest between sessions, 7 days/week for 8 weeks"
61996111|NCT03549247||quality of life in periodontal healthy|250 individuals who have teeth pocket depth is at most 3 mm and there is no loss of attachment, no radiological bone loss and no gingival inflammation determeined for their quality of life
62565613|NCT04910100|EXPERIMENTAL|Nebivolol Ophthalmic Suspension 0.5 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
62565614|NCT04910100|EXPERIMENTAL|Timolol Ophthalmic Suspension 0.5 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
62565615|NCT04910100|ACTIVE_COMPARATOR|Timolol Ophthalmic Solution 0.5 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
61996112|NCT03549247||quality of life in gingivitis|250 individuals who have teeth pocket depth in the mouth is at most 3 mm and there is no loss of attachment, no radiological bone loss and have chronic gingival inflammation with the sign of bleeding determeined for their quality of life
62181297|NCT02752217|PLACEBO_COMPARATOR|Control|Subjects in the control (CON) group will perform breathing exercise with inspiratory load at 2 cmH2O at 6 breathing rate using one BreatheMAXยฎ device. The pressure will be control by pressure manometer and duty cycle are control by subjects count duration for inspiration and expiration during training. The program will perform at home for 10 breaths/min/set, 6 sets/day with at least 1 minutes rest between sessions, 7 days/week for 8 weeks
62181298|NCT02627898|EXPERIMENTAL|Green tea extract|Individuals with T2DM controlled with metformin or glibenclamide, or both; with no hypertension neither treated with insulim
62181299|NCT02627898|PLACEBO_COMPARATOR|Placebo|Individuals with T2DM controlled with metformin or glibenclamide, or both; with no hypertension neither treated with insulim
62181300|NCT00992121|OTHER|Part I and 2 week dosing Part II|Part I - bevacizumab 3 infusions at 2 week intervals Part II - pazopanib dosing 2 weeks in 3-week cycles
62181301|NCT00992121|OTHER|Part I and 3 week dosing Part II|Part I - bevacizumab 3 infusions at 2 week interval, Part II - pazopanib dosing 3 weeks in 3-week cycles
62182637|NCT04834063||control|healthy individual with normal liver on abdominal ultrasound
62182638|NCT02546505|NO_INTERVENTION|Control|The current situation with current way brands show or not nutritional information on Front of Pack (FoP) - without consumer information
62182639|NCT02546505|EXPERIMENTAL|Intervention n°1|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods. No additional consumer information
62565616|NCT00550355|EXPERIMENTAL|1|
62565617|NCT00550355|EXPERIMENTAL|2|
62565618|NCT00550355|EXPERIMENTAL|3|
62565619|NCT00550355|PLACEBO_COMPARATOR|4|
62565620|NCT04217096|EXPERIMENTAL|paclitaxel liposome + S-1|paclitaxel liposome at 175 mg/m\^2 on day 1; S-1 at a dose according to the body surface area（\<1.25m\^2，40mg Bid；1.25\~1.5m\^2,50mg Bid；\>1.50m\^2,60mg Bid，d1-14，q3w）
62565621|NCT00127231|EXPERIMENTAL|1 Brief Intervention|The brief intervention will include two sessions that review drinking patterns and behavior change strategies as well as two telephone calls to reinforce session content.
62565622|NCT00127231|ACTIVE_COMPARATOR|2 Standard Care Arm|
61996113|NCT03549247||quality of life in periodontitis|250 individuals who have more than 30% of teeth in the mouth which have pocket depths equal or more than 4mm and clinical attachment levels equal or more than 5mm and have radiologically detected bone loss determeined for their quality of life
62565623|NCT02534805||Patient Buddy|Subjects and caregivers will be given iphones loaded with the App that will be used to enter medications, issues and orientation questions. They will be seen at day 15 and day 30 and will receive a phone call day 7 and day 21 inquiring about issues that would need medical attention
62565624|NCT02595918|EXPERIMENTAL|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on days -56, -42, -28, and -14 in the absence of disease progression or unacceptable toxicity. Patients then undergo nephrectomy or metastasectomy on day 0.
62565625|NCT00080912|EXPERIMENTAL|Arm I|Patients receive single-fraction radiotherapy (8 Gy) on day 1.
62565626|NCT00080912|ACTIVE_COMPARATOR|Arm II|Patients receive multiple-fraction radiotherapy (to a total of 20 Gy) over 5 days or over 8 days if re-irradiation of the spine and/or whole pelvis is involved AND prior initial radiotherapy was given in multiple fractions.
61996114|NCT00928928|ACTIVE_COMPARATOR|Open group|Group of patients operated with open approach for colorectal cancer
62182640|NCT02546505|EXPERIMENTAL|Intervention n°2|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods. Additional consumer information specifically targeting nutritional information and explaining the 5-CNL will be performed (this information will consist in a concept shown to respondents before the shopping session).
62182641|NCT03705364|NO_INTERVENTION|Wait List Control Group|Wait list control group
62182642|NCT03705364|EXPERIMENTAL|Fall Management program|Intervention arm
62565627|NCT04432766|EXPERIMENTAL|Low dose|
61996115|NCT00928928|ACTIVE_COMPARATOR|laparoscopic group|Group of patients operated with laparoscopic approach for colorectal cancer
61996116|NCT01978314|EXPERIMENTAL|Cohort 1|eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
62565628|NCT04432766|EXPERIMENTAL|Medium dose|
62565629|NCT04432766|EXPERIMENTAL|High dose|
62565630|NCT05984199|EXPERIMENTAL|Morphologic Disease: Cohort 1|VCAR33 Dose Level 1
62565631|NCT05984199|EXPERIMENTAL|Morphologic Disease: Cohort 2|VCAR33 Dose Level 2
62565632|NCT05984199|EXPERIMENTAL|Morphologic Disease: Cohort 3|VCAR33 Dose Level 3
62565633|NCT05984199|EXPERIMENTAL|MRD Positive: Cohort 1|VCAR33 Dose Level 1
62565634|NCT05984199|EXPERIMENTAL|MRD Positive: Cohort 2|VCAR33 Dose Level 2
62565635|NCT05984199|EXPERIMENTAL|MRD Positive: Cohort 3|VCAR33 Dose Level 3
62565636|NCT02768818|EXPERIMENTAL|Intervention|Probiotic VIVOMIXX™
62565637|NCT02768818|PLACEBO_COMPARATOR|Control|Placebo
62565638|NCT02586974|EXPERIMENTAL|Group H+WB|32 patients will receive warmed, humidified CO2 insufflation with the Humigard® device, along with the hot air warming blanket used as a routine in our institution (forced air warming blanket at 38°C : Bear Hugger®)
62565639|NCT02586974|NO_INTERVENTION|Group WB|32 patients will receive standard CO2 insufflation, along with the hot air warming blanket used as a routine in our institution (forced air warming blanket at 38°C : Bear Hugger® and a standard insufflation with non-humidified, non-heated CO2)
62565640|NCT03432104|EXPERIMENTAL|Verum|This arm receives 1 x 450 mg-capsule of Oxxynea®, a blend of polyphenol-rich fruit and vegetable extracts
62565641|NCT03432104|PLACEBO_COMPARATOR|Placebo|This arms receives 1 x 450 mg-capsule of Placebo, containing maltodextrin only
62565642|NCT00400023|EXPERIMENTAL|1|"During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence A: Single dose of 50 mg S-1 (2 capsules of 25 mg) on Day 1 followed by a single dose of 800 mg FT (8 capsules of 100 mg) on Day 8~* Sequence B: Single dose of 800 mg FT on Day 1 followed by a single dose of 50 mg S-1 on Day 8"
61996117|NCT01978314|EXPERIMENTAL|Cohort 2|eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
62565643|NCT00400023|ACTIVE_COMPARATOR|2|"During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence A: Single dose of 50 mg S-1 (2 capsules of 25 mg) on Day 1 followed by a single dose of 800 mg FT (8 capsules of 100 mg) on Day 8~* Sequence B: Single dose of 800 mg FT on Day 1 followed by a single dose of 50 mg S-1 on Day 8"
62565644|NCT02727946|OTHER|optimal resuscitation|This group of multiple trauma patients will be resuscitated with crystalloids, analgesics, blood products as needed. Then follow up of the difference between arterial and venous CO2 to difference between arterial and venous oxygen tension, serum lactate, renal function, other organ affection along over the short hospital stay period
62565645|NCT03729167|EXPERIMENTAL|Scaling and root planing|Teeth that have been given a prognosis of hopeless and treatment planned for extraction will be scaled and root planed with various non-surgical instruments prior to extraction. The teeth will then be photographed and assessed for remaining hard accretion deposits to determine the effectiveness of the instruments.
61996118|NCT01978314|EXPERIMENTAL|Cohort 3|eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
61996119|NCT01978314|EXPERIMENTAL|Cohort 4|a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol
61996120|NCT01978314|EXPERIMENTAL|Cohort 5|eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
61996121|NCT02280980|EXPERIMENTAL|Combined rehabilitation protocol|The usual rehabilitation protocol in the physiotherapy department is supplemented with a three weeks home protocol of oculomotor and gaze stability exercises.
61996122|NCT02280980|NO_INTERVENTION|Usual rehabilitation protocol|The usual rehabilitation protocol in the physiotherapy department for patients after stroke.
61996123|NCT02258204|PLACEBO_COMPARATOR|tPA-placebo|"tPA infusion : 0.9 mg/kg (90 mg maximum), 10% of the total dose is administered as an initial IV bolus dose over 1 minute and the remainder of the dose is infused over 60 minutes.~Saline infusion : 0.15 mL/kg IV bolus (maximum 15 mL) followed by an IV infusion of 0.15 mL/kg over 60 minutes (maximum 15 mL)."
61996124|NCT02258204|EXPERIMENTAL|tPA-ketamine|"tPA infusion : 0.9 mg/kg (90 mg maximum), 10% of the total dose is administered as an initial IV bolus dose over 1 minute and the remainder of the dose is infused over 60 minutes.~Ketamine infusion : 0.15 mg/kg IV bolus (maximum 15 mg) followed by an IV infusion of 0.15 mg/kg over 60 minutes (maximum 15 mg)."
61996125|NCT00458653|EXPERIMENTAL|Group A|Post-transplant vaccination
61996126|NCT00458653|EXPERIMENTAL|Group B|Pre- and post-transplant vaccination
61996127|NCT00265824|ACTIVE_COMPARATOR|bevacizumab alone|
61996128|NCT00265824|EXPERIMENTAL|Bevacizumab + erlotinib|
61996129|NCT02481895|EXPERIMENTAL|Experimental|E-neurocognitive module training.
61996130|NCT02481895|NO_INTERVENTION|Control|The group will note receive any sort of add-on training, just the recommendations from the therapists.
61996131|NCT01811095|EXPERIMENTAL|Training arm|"The training arm participates in the robotic suturing simulation curriculum, a proficiency curriculum that it is focused on the goal of achieving proficiency targets for five simulator tasks. Those six tasks are : Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2, and Suture sponge 3. The curriculum also includes a sixth task, Suturing Skills (Symbionix): Horizontal suturing defect. Participants are encouraged to complete this task ten times rather than to attain a certain score. Participants set their own hours about when and how much to train during the 5 week intervention period. They are instructed that approximately one hour per week over 5 weeks will be required to achieve the targets, on average."
61996132|NCT01811095|PLACEBO_COMPARATOR|Control|Participants in this group carry on with regular training (residents) or regular clinical work (attending surgeons) without robotic simulator training during the five week period when they are in the control group.
61996133|NCT00308711|EXPERIMENTAL|MVI 100|Misoprostol vaginal insert 100 mcg over 24h
61996134|NCT00308711|EXPERIMENTAL|MVI 50|Misoprostol vaginal insert 50 mcg over 24h
61996135|NCT00308711|ACTIVE_COMPARATOR|Cervidil 10 mg vaginal insert|Cervidil 10 mg over 24h
61996136|NCT01539187|EXPERIMENTAL|VizAblate intervention|VizAblate System with subject serving as her own control
61996137|NCT01162382|EXPERIMENTAL|Transcranial Magnetic Stimulation|Open-label transcranial magnetic stimulation
61996138|NCT00660348|ACTIVE_COMPARATOR|morphine|morphine given traditionally (IV, pill, patch). This is standard of care dosing.
61996139|NCT00660348|ACTIVE_COMPARATOR|Intrathecal pump|Pump internal used to deliver morphine. This is a newer method for delivery of morphine. Morphine is FDA approved for intrathecal use. The intrathecal pump will be titrated gradually to effect by the interventional pain medicine team. These are the maximum doses and concentrations in keeping with the Polyanalgesic Consensus Conference guidelines: Dose (mg/day):15 ; Conc (mg/cc): 20
61996140|NCT02313753|ACTIVE_COMPARATOR|SAFE|Safety Assessment and Follow-up Evaluation Protocol
61996141|NCT02313753|EXPERIMENTAL|CLASP|Coping Long Term with Active Suicide Program Protocol
62565646|NCT01650688||Epiblepharon|subjects demonstrating prominent corneal touch by cilia and/or related subjective symptoms
62181302|NCT02200978|ACTIVE_COMPARATOR|ATO and chemotherapy|"Induction:~ATRA 25mg/m2 d1-CR ≯42 days; ATO 0.16mg/kg d5-CR ≯42 days; mitoxantrone (MA) 10mg/m2 d3, or 7mg/m2 d2-4 (high risk).~Consolidation 1:~ATRA 25mg/m2 d1-15; MA 10mg/m2 d1-2; Intrathecal injection (IT)：Ara-C 15mg (age \< 1 year), or 20 mg (1-3 years), or 30 mg ( \> 3 years), dexamethasone 2mg.~Consolidation 2:~ATRA 25mg/m2 d1-15; ATO 0.16mg/kg d1-15; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Consolidation 3:~ATRA 25mg/m2 d1-15; ATO 0.16mg/kg d1-15; MA 10mg/m2 d1; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Maintenance:~① ATO 0.16mg/kg.d w1-2; ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. ② ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. Rotation between ① and ② until the end of maintenance."
62181303|NCT02200978|EXPERIMENTAL|RIF and chemotherapy|"Induction:~ATRA 25mg/m2 d1-CR ≯42 days; RIF 0.135/kg d5-CR ≯42 days; mitoxantrone (MA) 10mg/m2 d3, or 7mg/m2 d2-4 (high risk).~Consolidation 1:~ATRA 25mg/m2 d1-15; MA 10mg/m2 d1-2; Intrathecal injection (IT)：Ara-C 15mg (age \< 1 year), or 20mg (age 1-3 years), or 30mg (age \> 3 years), dexamethasone 2mg.~Consolidation 2:~ATRA 25mg/m2 d1-15; RIF 0.135/kg d1-15; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Consolidation 3:~ATRA 25mg/m2 d1-15; RIF 0.135/kg d1-15; MA 10mg/m2 d1; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Maintenance:~① RIF 0.135/kg.d w1-2; ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. ② ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. Rotation between ① and ② until the end of maintenance treatment."
62181304|NCT06191861|EXPERIMENTAL|Most hoped for future self, 3 dose|Participants complete a writing task in which they think and write about their most hoped for future self, weekly for 3 weeks (i.e., at each session).
61996142|NCT02534766||Patients who attended the MISSION COPD clinics|COPD patients who attended the MISSION COPD clinics, identified as having uncontrolled or potentially severe COPD or unrecognised COPD from GP records by the MISSION clinical team
62391284|NCT04686591|EXPERIMENTAL|AZD9977|"In Period 1, one 100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capsules) and one 100 µg dose of \[14C\]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL).~In Period 2, one 100 mg dose of \[14C\]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)."
62565647|NCT04529629||primary aldosteronism|
62565648|NCT04529629||pheochromocytoma|
61996143|NCT02534766||Health Care Professionals|Health Care Professionals who attended the MISSION COPD clinics in a professional/ clinical capacity.
62565649|NCT04529629||adrenocortical carcinoma|
62565650|NCT01772173||subjects with diabetes developing hypertension|subjects with diabetes not developing hypertension
61996144|NCT01063595|EXPERIMENTAL|Octaplas LG|Participants received 1200 mL of Octaplas LG intravenously once.
61996145|NCT01063595|ACTIVE_COMPARATOR|Octaplas SD|Participants received 1200 mL of Octaplas SD intravenously once.
62565651|NCT05237167|EXPERIMENTAL|Ultrasound|After randomization, these subjects will undergo diagnostic point-of-care ultrasound
62565652|NCT05237167|ACTIVE_COMPARATOR|Radiograph|After randomization, these subjects will undergo diagnostic plain radiograph
62565653|NCT06025357|EXPERIMENTAL|L-citrulline|L-citrulline: 10 grams/day
62565654|NCT06025357|EXPERIMENTAL|Placebo|Microcrystalline Cellulose
62565655|NCT02590497|EXPERIMENTAL|Diagnostic (MRI, tumor tissue analysis)|Patients undergo MRI before and after gadolinium contrast administration, including 3D volumetric T1-weighted sequence, FLAIR sequence, diffusion weighted imaging, and perfusion MRI. Tissue samples are also analyzed for the tumor genetic profile.
62565656|NCT05693259|EXPERIMENTAL|EARW group|Patients in EARW group drink EARW (pH 9.5) 10 mL/kg body weight per a day using experimental device installed in the house for 6 weeks. We recommend to drink water in empty stomach three or four times a day. The water generated from device will be administered immediately, not to be stored.
62565657|NCT05693259|SHAM_COMPARATOR|PW group|Patients in PW group drink PW (pH 9.5) 10 mL/kg body weight per a day using Sham device installed in the house for 6 weeks. We recommend to drink water in empty stomach three or four times a day. The water generated from device will be administered immediately, not to be stored. Sham device was built in the same shape and operation as the experimental device.
62565658|NCT00977093|EXPERIMENTAL|Perfusion CMR examination|All patients will undergo perfusion CMR examination, single-photon emission computed tomography, and conventional invasive coronary angiography.
61996146|NCT02178384|EXPERIMENTAL|Altered-cast technique|Removable partial dentures will be made using altered-cast technique for free saddles.
62565659|NCT02858804|EXPERIMENTAL|Etoposide|50 mg/m2, IV, d1-4
62565660|NCT02858804|EXPERIMENTAL|Doxorubicin|10 mg/m2, IV, d1-4
61996147|NCT02178384|ACTIVE_COMPARATOR|Precision attachments|Removable partial dentures will be made using precision attachments which will be located on the distal abutment teeth.
61996148|NCT02178384|ACTIVE_COMPARATOR|Resilient layer|Removable partial dentures will be made using a resilient-layer on the distal extension of each appliance.
61996149|NCT04628312|EXPERIMENTAL|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
61996150|NCT02753062|EXPERIMENTAL|bendamustine, rituximab|Bendamustine plus subcutaneous Rituximab treatment of 6 cycles. Rituximab 1400mg subcutaneous over 5mins on day 1 and bendamustine 120mg/m2 + NS 500mL iv over 1hour on day 1 and 2.
61996151|NCT02245542||BPH patients|
61996152|NCT01132495|OTHER|Cohort A: PCI plus OMT|PCI plus optimal medical treatment
62565661|NCT02858804|EXPERIMENTAL|Dexamethasone|30 mg/d, d1-5
62565662|NCT02858804|EXPERIMENTAL|Vincristine|0.4 mg/m2, IV, d1-4
62565663|NCT02858804|EXPERIMENTAL|Cyclophosphamide|750 mg/m2 ,d5
61996153|NCT01132495|OTHER|Cohort A: OMT alone|Optimal medical treatment alone
61996154|NCT01132495|OTHER|Cohort B|FFR \> 0.80; treatment according to local practice
62565664|NCT02858804|EXPERIMENTAL|Cytarabine|2g/m2, q12h, d1
62565665|NCT02858804|EXPERIMENTAL|Cisplatin|100mg/ m2,IV, d1
62565666|NCT02858804|EXPERIMENTAL|Rituximab|375 mg/m2 IV, d1
62565667|NCT02858804|EXPERIMENTAL|Thalidomide|50-150mg/d, po, d1-28
61996155|NCT05638373|EXPERIMENTAL|One shade universal composite|shade matching composite
61996156|NCT05638373|ACTIVE_COMPARATOR|Nanohybrid resin composite|Conventional Nanohybrid resin composite
61996157|NCT03942978|ACTIVE_COMPARATOR|Longitudinal Equity Action Plan (LEAP)|Heart failure patients admitted with a principal diagnosis of heart failure to general medicine service and admitted to a general medicine pod that is randomized to the intervention arm.
61996158|NCT03942978|NO_INTERVENTION|Standard Care|Heart Failure patients admitted to a general medicine pod at our institution, which is not randomized to intervention arm. Patients will be treated for their heart failure as per standard of care while admitted to the hospital.
61996159|NCT05551143|EXPERIMENTAL|LiftKit Intervention|All participants will have access to the LiftKit that provides them with a set of tools that should reduce the physical demands experienced by EMS providers when lifting and moving patients in their homes, thereby reducing the risk of musculoskeletal disorders (MSDs).
61996160|NCT02984410|OTHER|Intensity-Modulated Radiation Therapy (IMRT)|PTV prescription to tumor and high risk areas will be delivered daily for 5 days per week to a total dose of 66-70Gy in 2 Gy/fraction over 6 weeks, elective/prophylactic mucosal and nodal areas will receive a total dose of 54.25- 54.45 Gy in 33-35 fractions of 1.55-1.65 Gy over 6 weeks.
61996161|NCT02984410|OTHER|Trans Oral Surgery (TOS)|"The following surgical techniques are allowed:~Transoral Robotic Surgery (TORS) Transoral Microsurgery (TLM) Conventional trans-oral Surgery (CTOS)"
61996162|NCT01556529|EXPERIMENTAL|risk profile information|patient gets information on quantitative individual complication risk profile and patient gets standard T2DM DMP care
61996163|NCT01556529|ACTIVE_COMPARATOR|Control|Control group: patient gets standard T2DM DMP care
62565668|NCT02858804|EXPERIMENTAL|Prednisone|0.5mg/Kg, po, qod
62565669|NCT02435693|EXPERIMENTAL|PHARMACEUTICAL CARE programe|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
62565670|NCT02435693|OTHER|control|without pharmaceutical care programe (control)
62565671|NCT01597323||Treatment Group|Healthy Male of Female between ages 35 and 60 with presence of mild to moderate facial photodamage (sun damage) and presence of mild to moderate facial wrinkling
62565672|NCT05313503|EXPERIMENTAL|Ketogenic Diet|Ketogenic diet
61996164|NCT00955266|ACTIVE_COMPARATOR|Calcium Chloride|Calcium chloride, 10mg/kg
62565673|NCT06360172|EXPERIMENTAL|MI|Participants in the study group ill obtain six MI sessions. According to Miller and Rollnick's principles, the motivational interviewing group's framework was inspired by the six motivational interviewing sessions in the intervention's booklet Based on the assumption that six to twelve persons in a group are usually necessary for group therapy to be effective, a group of seven students was formed .
61996165|NCT00955266|PLACEBO_COMPARATOR|Placebo|Normal saline
61996166|NCT02064907|EXPERIMENTAL|Dexlansoprazole OD Tablets + Dexlansoprazole Capsules|Two Dexlansoprazole 30 mg, delayed-release orally disintegrating tablets, orally, once daily for 5 days in Period 1, followed by a 7 day washout period, followed by one dexlansoprazole 60 mg, capsule, orally, once daily for 5 days in Period 2.
61996167|NCT02064907|EXPERIMENTAL|Dexlansoprazole Capsules + Dexlansoprazole OD|Dexlansoprazole 60 mg, capsules, orally, once daily for 5 days in Period 1, followed by a 7 day washout period, followed by two dexlansoprazole 30 mg, delayed-release orally disintegrating tablets, orally, once daily for 5 days in Period 2.
61996168|NCT02795559|OTHER|Lean|Subjects within the range of desirable body weight (BMI\<25)
61996169|NCT02795559|OTHER|OWO|Subjects who are overweight or obese (BMI between 25 and 40)
61996170|NCT01508780|EXPERIMENTAL|Pulmonary Arterial Hypertension, bosentan|Subjects include patients being diagnosed with pulmonary arterial hypertension and starting treatment with bosentan.
62565674|NCT06360172|NO_INTERVENTION|Control|The control group will receive only the routine teaching with no extra interventions
62565675|NCT05115851|EXPERIMENTAL|Anodal tDCS cerebellar stimulation group:|Anodal tDCS cerebellar stimulation
61996171|NCT00941083|EXPERIMENTAL|RAL QD 800 mg/24 hs|
62565676|NCT05115851|EXPERIMENTAL|Anodal tDCS cerebral (M1) stimulation group:|Anodal tDCS cerebral (M1) stimulation
62565677|NCT05115851|SHAM_COMPARATOR|Sham Group|Sham
62565678|NCT03392727|EXPERIMENTAL|Study Box & Education Session|Parents are provided a baby box and infant health and safety products and participate in a face to face educational session
62565679|NCT03392727|ACTIVE_COMPARATOR|Community Box & Online Education|Parents are informed how to receive a free box from a community site and are provided a guide to online resources for prenatal and infant health promotion
61996172|NCT00941083|ACTIVE_COMPARATOR|RAL BID 400 mg/12 hs|
61996173|NCT00941083|EXPERIMENTAL|RAL BID to QD|
61996174|NCT06151236|EXPERIMENTAL|Neoadjuvant Treatment|"Nivolumab and relatlimab will be administered in a fixed dose combination (FDC). The FDC product contains nivolumab and relatlimab in a protein-mass ratio of 3:1 (nivolumab 240 mg and relatlimab 80 mg): in a 20 mL concentrate solution per single vial. The dose and dosing regimen for this study is nivolumab 480 mg and relatlimab 160 mg - 2 vials per infusion. This was primarily based on the observed benefit/risk profile observed in metastatic melanoma patients from Study CA224-020 pharmacokinetics (PK), pharmacodynamics, and extensive nivolumab monotherapy clinical experience. In addition, the Phase 2/3 Study CA224-047 established this dose as active in unresectable and metastatic melanoma.~This study is open label and single arm, with all patients scheduled to receive two doses of nivolumab and relatlimab FDC prior to surgery on days 1 and 29."
62565680|NCT02418182|PLACEBO_COMPARATOR|Control|Control group participants will receive unlabelled 2 non-active placebo tablets approximately 1 hour prior to transvaginal oocyte retrieval procedure.
62565681|NCT02418182|EXPERIMENTAL|Experimental|Experimental group participants will receive 2 acetaminophen 500mg tablets approximately 1 hour prior to transvaginal oocyte retrieval procedure.
62565682|NCT02726009|EXPERIMENTAL|Degarelix|
61996175|NCT03861260|OTHER|Rigid Cystoscopy and Urethral dilatation|Rigid cystoscopy, performed under General Anaesthetic, followed by intervention of urethral dilatation with Hagar dilators.
61996176|NCT03861260|OTHER|Flexible cystoscopy and Glycosaminoglycan Layer replacement|Flexible cystoscopy, under Local Anaesthetic, followed by the intervention, which is 6 installations of Ialuril (a Glycosaminoglycan Layer replacement)
61996177|NCT03372213||2003-2004|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
61996178|NCT03372213||2005-2006|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
61996179|NCT03372213||2011-2012|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
61996180|NCT03372213||2013-2014|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
61996181|NCT02427321||Cystoscopy cohort|"Video recording of flexible cystoscopic examination. All participants enrolled on the study will have video from their flexible cystoscopic examination recorded.~Diagnosis and pathology information will be collected from the participants medical notes for a period of eight weeks following the recorded cystoscopy."
61996182|NCT04663555|EXPERIMENTAL|DEX 20 mg|Patients in the intervention group after randomization will receive dexamethasone 20 mg intravenously once daily on day 1-5, followed by dexamethasone 10 mg intravenously once daily on day 6-10.
61996183|NCT04663555|ACTIVE_COMPARATOR|DEX 6 mg|Patients in the control group after randomization will receive dexamethasone 6 mg day 1-10.
61996184|NCT00620594|EXPERIMENTAL|BEZ235 Alone, Dose Escalation|
61996185|NCT00620594|EXPERIMENTAL|BEZ235 + trastuzumab, Dose Escalation|
61996186|NCT00620594|EXPERIMENTAL|BEZ235 Alone, MTD Expansion|
62565683|NCT02930772|EXPERIMENTAL|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62565684|NCT00315458|EXPERIMENTAL|BTDS|Buprenorphine transdermal patches 10 or 20 mcg/h
62565685|NCT00315458|PLACEBO_COMPARATOR|Placebo|Placebo to match buprenorphine transdermal patch 10 or 20
62565686|NCT05208190|EXPERIMENTAL|Clozapine|treatment with clozapine naturalistically administered (as per clinical guideline).
61996187|NCT00620594|EXPERIMENTAL|BEZ235 + Trastuzumab, MTD Expansion|
62181305|NCT06191861|EXPERIMENTAL|Most hoped future self, 1 dose|Participants complete a writing task in which they think and write about their most hoped for future self one time (on the third session).
62565687|NCT05208190|ACTIVE_COMPARATOR|Treatment as usual|open label naturalistic treatment as usual with any antipsychotic other than clozapine
61996188|NCT03521986|EXPERIMENTAL|Subxiphoid uniportal VATS|Standard Subxiphoid single-port video assisted mediastinal thymectomy, no use of rib-spreader.
62565688|NCT03922321|EXPERIMENTAL|RVT-1401|RVT-1401 680 milligrams (mg) weekly for two weeks followed by 340 mg weekly for four weeks, administered subcutaneously
62565689|NCT03192449|EXPERIMENTAL|Albendazole 400mg p.o. single dose|Volunteers receive 1 tablet albendazole 400mg (GSK) fasting.
62565690|NCT03458442|EXPERIMENTAL|Intervention Arm|Standard surgical training + simulation-based surgical training
62565691|NCT03458442|ACTIVE_COMPARATOR|Control Arm|Standard surgical training
62565692|NCT05399784|EXPERIMENTAL|Early & Often Postpartum Care|Visit at 2-3 and 6 weeks postpartum.
62565693|NCT05399784|PLACEBO_COMPARATOR|Standard Postpartum Care|Visit at 6 weeks postpartum.
62565694|NCT02807129|EXPERIMENTAL|patients|
62565695|NCT05531812|EXPERIMENTAL|G2R with individual coaching|
62565696|NCT05531812|EXPERIMENTAL|G2R with group coaching|
62565697|NCT05531812|NO_INTERVENTION|Control|
62565698|NCT03055676|EXPERIMENTAL|Early drain removal|Removing drain(s) on postoperative day 3 (n = 166)
62565699|NCT03055676|ACTIVE_COMPARATOR|Late drain removal|Removing drain(s) on postoperative day 5 or later (n = 166)
61996189|NCT03521986|ACTIVE_COMPARATOR|Intercostal uniportal VATS|Standard Intercostal single-port video assisted mediastinal thymectomy, no use of rib-spreader.
61996190|NCT01312584|PLACEBO_COMPARATOR|Non alkalised High Flavanol|Non-alkalised high flavanol cocoa drink containing 1745 mg of total flavanols
61996191|NCT01312584|ACTIVE_COMPARATOR|Alkalised high Flavanol|Alkalised high flavanol cocoa drink (medium alkalisation) containing 410 mg of total flavanols
61996192|NCT01312584|ACTIVE_COMPARATOR|Alkalised Low Flavanol|Alkalised low flavanol cocoa drink (heavily alkalised) containing 1.26 mg of total flavanols
61996193|NCT05203263|EXPERIMENTAL|Condition 1 : Prototype (810A-v1) and Frequency of application 1|Application of the prototype (810A-v1) at Day 0, Day 1, Day 2, Day 3, Day 4 and Day 5.
62181306|NCT06191861|EXPERIMENTAL|Most feared future self, 3 dose|Participants complete a writing task in which they think and write about their most feared future self, weekly for 3 weeks (i.e., at each session).
62565700|NCT04015271|EXPERIMENTAL|Action Observation + Repetitive Task Practice|Action Observation (AO) therapy regimen will include watching a 6 minute video of another person completing a specified functional task (Putting on a shirt, pick up a sandwich and bring to mouth, eat food with a spoon, or cut meat with knife and fork). Subjects will be instructed to carefully watch the AO video and prepare to physically perform the task immediately after observing the video. The Repetitive Task Practice (RTP) therapy regimen emphasizes repeated physical performance with the hemiplegic upper limb for 24 minutes of a specified functional task that is matched to the AO recording. The AO + RTP regimens will be repeated for a total of 60 minutes. Each Subject will complete a Home Exercise Program (HEP) will include practicing components and movement patterns of the functional task that was difficult for the patient to perform during RTP intervention for 30 minutes each day outside of scheduled intervention sessions.
62565701|NCT04015271|PLACEBO_COMPARATOR|Placebo Video + Repetitive Task Practice|The control placebo videos (PV) will be 6 minutes, and will include a series of changing static images without animals, human beings, or sound (i.e. pictures of buildings, trees, cruise ships, mountains, beach umbrellas, beds, and tables). A Repetitive Task Practice (RTP) therapy regimen will be completed immediately after observing the PV, which emphasizes repeated physical performance with the hemiplegic upper limb for 24 minutes of a specified functional task. These tasks include putting on a shirt, picking up a sandwich and bringing it to mouth, eating food with a spoon, or cutting meat with knife and fork. The PV + RTP regimens will be repeated for a total of 60 minutes. Each Subject will complete a Home Exercise Program (HEP) will include practicing components and movement patterns of the functional task that was difficult for the patient to perform during RTP intervention for 30 minutes each day outside of scheduled intervention sessions.
62565702|NCT04983472||Observational Group|Individuals diagnosed with Chronic Obstructive Pulmonary Disease by the Department of Pulmonology of the Faculty of Medicine of Bolu Abant Izzet Baysal University will be referred to the Department of Physiotherapy and rehabilitation of the Faculty of Health Sciences of Bolu Abant Izzet Baysal University
62565703|NCT03583580|EXPERIMENTAL|Accelerated Partial Breast Irradiation|Accelerated partial breast irradiation (APBI) to the region of tumour bed
61996194|NCT05203263|EXPERIMENTAL|Condition 2 :Prototype (810B-v1) and Frequency of application 1|Application of the prototype (810B-v1) at Day 0, Day 1, Day 2, Day 3, Day 4 and Day 5.
61996195|NCT05203263|EXPERIMENTAL|Condition 3 : Prototype (810A-v1) and Frequency of application 2|Application of the prototype (810A-v1) at Day 0, Day 7, Day 14, Day 21, Day 28 and Day 35.
61996196|NCT05203263|EXPERIMENTAL|Condition 4 : Prototype (810C-v1) and Frequency of application 2|Application of the prototype (810C-v1) at Day 0, Day 7, Day 14, Day 21, Day 28 and Day 35.
61996197|NCT05203263|ACTIVE_COMPARATOR|Condition 5 : Prototype (810C-v1) and Frequency of application 3|Application of the prototype (810C-v1) at Day 0, Day 14, Day 28, Day 42, Day 56 and Day 70.
61996198|NCT01127334||Systolic Heart Failure, Dyssynchrony, CRT-D|Patients with systolic heart failure and dyssynchrony that have a CRT-D that have not been optimized in the past 3 months.
61996199|NCT02434835|EXPERIMENTAL|[14C]KWA-0711|
62181307|NCT06191861|EXPERIMENTAL|Most feared future self, 1 dose|Participants complete a writing task in which they think and write about their most feared future self one time (on the third session).
62181308|NCT06191861|EXPERIMENTAL|Balanced self (hoped and feared self), 3 dose|Participants complete a writing task in which they think and write about their most hoped for and feared future self, weekly for 3 weeks (i.e., at each session).
62181309|NCT06191861|EXPERIMENTAL|Balanced self (hoped and feared self), 1 dose|Participants complete a writing task in which they think and write about their most hoped for and feared future self one time (on the third session).
62181310|NCT06191861|PLACEBO_COMPARATOR|Control, 3 dose|Participants in this condition complete a task in which they think and write about a trip to the zoo weekly for 3 weeks (i.e., at each session).
62181311|NCT06191861|PLACEBO_COMPARATOR|Control, 1 dose|Participants in this condition complete a task in which they think and write about a trip to the zoo one time (on the third session).
62181312|NCT01309243|EXPERIMENTAL|FTC/RPV/TDF|
62181313|NCT01309243|EXPERIMENTAL|EFV/FTC/TDF|
62181314|NCT00349622|ACTIVE_COMPARATOR|Ceftriaxone|"Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day."
62181315|NCT00349622|PLACEBO_COMPARATOR|Placebo|"One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day."
62181316|NCT00279877|ACTIVE_COMPARATOR|vertebroplasty|vertebroplasty
62181317|NCT00279877|ACTIVE_COMPARATOR|kyphoplasty|kyphoplasty
61996200|NCT03876327|EXPERIMENTAL|PD patients that will receive FMT|fecal microbial transplantation once at the beginning of the study-15 patients.
61996201|NCT03876327|NO_INTERVENTION|PD patients that will not receive FMT|do not receive treatment-35 patients.
61996202|NCT03876327|NO_INTERVENTION|healthy people live with PD patients|do not receive treatment-50 participants.
61996203|NCT05009394|ACTIVE_COMPARATOR|Targeted Muscle Reinnervation (TMR)|The surgical procedure comprises three steps: preparation of the donor nerve, identification of a motor branch to the targeted muscle, and nerve coaptation. To prepare the donor nerve, the surgeon will identify the nerve with a painful neuroma and resect the neuroma up to healthy fascicles. Next, the surgeon will identify a motor branch to a nearby target muscle and will confirm muscle contraction using a hand-held nerve stimulator. The motor branch to the target muscle will be transected as close as possible to its entry point without tension. In the final step, the previous nerve stump from which the neuroma was resected will be transferred and coapted to the newly severed motor branch that innervates the target muscle and secured by 2-3 non-resorbable monofilament sutures. The surgery time is approximately 2-3 hours and it takes place in the hospital.
62181318|NCT05278013|EXPERIMENTAL|Glue Group (GG)|Randomization will take place utilizing serial randomization to Glue Group (GG) and No Glue Group (NG) where skin closure will be assigned serially to a week of GG alternating with a week NG.
62181319|NCT05278013|NO_INTERVENTION|No Glue Group (NG)|Randomization will take place utilizing serial randomization to Glue Group (GG) and No Glue Group (NG) where skin closure will be assigned serially to a week of GG alternating with a week NG.
62181320|NCT02196168|EXPERIMENTAL|Arm I (WEE1 inhibitor MK-1775, cisplatin)|Patients receive WEE1 inhibitor MK-1775 PO BID for 5 doses beginning on day 1 and cisplatin IV over 1 hour on day 1.
62181321|NCT02196168|ACTIVE_COMPARATOR|Arm II (placebo, cisplatin)|Patients receive placebo PO BID for 5 doses beginning on day 1 and cisplatin IV over 2 hour on day 1.
61996204|NCT05009394|ACTIVE_COMPARATOR|Regenerative Peripheral Nerve Interface (RPNI)|The RPNI procedure involves construction of a residual peripheral nerve split into several nerve fascicles and implanted into free skeletal muscle grafts. First, the surgeon identifies the nerve with a painful neuroma and resect the neuroma up to healthy fascicles. Then, a longitudinal intraneural dissection will be performed exposing its fascicles. Next, autologous muscle grafts will be harvested from a healthy donor site, and the dissected nerve stumps will be placed parallel to the muscle fibers. The nerve stump will be secured to the muscle graft, thereafter the graft will be wrapped around the nerve stump and anchored in the folded graft, thus creating an RPNI. This will be repeated for each fascicle obtained from splitting the transected nerve. Lastly, the RPNIs will be placed in a protected area. The surgery time is approximately 2-3 hours and it takes place in the hospital.
62181322|NCT02740361|EXPERIMENTAL|Deprexis|This group will receive access to the web-based Deprexis program, an online tool based on principles of cognitive behavioral therapy. Contents include (1) psychoeducation, (2) behavioral activation, (3) cognitive modification, (4) mindfulness and acceptance, (5) interpersonal skills, (6) relaxation, physical exercise and lifestyle modification, (7) problem solving, (8) expressive writing and forgiveness, (9) positive psychology, and (10) emotion-focused interventions.
62565704|NCT05545722|EXPERIMENTAL|life coaching group with diabetes|Individuals with diabetes in the intervention 1 group will be interviewed for 'life coaching with diabetes'. Coaching is a set of systems that make people think deeply and reveal their own awareness and potential. A coach is a person who deliberately applies all these systems with awareness. Life coaching sessions with diabetes are based on the philosophy of coaching. Sessions are continued with questions that will enable the individual to realize the deficiencies in diabetes self-management. It helps the person with diabetes to discover solutions.This training will last for 3 months, once in 10 days. A total of 9 interviews will be provided.
62565705|NCT05545722|EXPERIMENTAL|Standard diabetes education|Standard diabetes education will be given to individuals with diabetes in this group. This training will last for 3 months, once in 10 days. A total of 9 interviews will be provided.
62181323|NCT02740361|EXPERIMENTAL|DeprexisPlus|This group will receive the web-based Deprexis program (see above) plus scheduled e-mail contact (1x/week)
62565706|NCT05545722|NO_INTERVENTION|control group|only pre-test and post-test were applied to this group. The patients in this group are the patient group who received training from the diabetes nurse of the hospital.
62565707|NCT01415518|OTHER|1|budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
62565708|NCT01415518|OTHER|2|ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
62565709|NCT01779843|EXPERIMENTAL|Treatment|"Induction: 100 mg/m2/day Cytarabine intravenous, days 1-7 of induction cycle. 12 mg/m2/day Idarubicin intravenous, days 1-3. Alisertib orally, twice a day for one week starting on day 8, dose escalation-starting dose 10 mg PO BID.~Consolidation: Cytarabine 3 g/m2 by IV infusion over 3 hours given every 12 hours on Days 1, 3 and 5 (subjects younger than age 60) or Cytarabine 2 g/m2 per day by IV infusion over 3 hours on days 1-5 (subjects at or older than age 60)"
62565710|NCT05183841|ACTIVE_COMPARATOR|Bronchodilator|The intervention will be a combination of 2 drugs, ipratropium (20 mcg) and fenoterol (50mcg). Ipratropium is an anticholinergic bronchodilator, and fenoterol is a beta-agonist bronchodilator. The medication will be delivered to the patient via an inhaler device with spacer, at leat 20 minutes before the constant load exercise test (CLET). Patient will be asked for a total exhalation, followed by an appropriate spacer mouthpiece placement and the first of eight puffs (30 seconds interval between puffs) will be delivered through the opposite extremity of the spacer. Patient will be instructed to perform five tidal volume breaths for each puff.
62565711|NCT05183841|PLACEBO_COMPARATOR|Placebo|The placebo will be delivered via an inhaler device with spacer (identical to the bronchodilator device), at least 20 minutes before the constant load exercise test (CLET). Patient will be asked for a total exhalation, followed by an appropriate spacer mouthpiece placement and the first of eight puffs (30 seconds interval between puffs) will be delivered through the opposite extremity of the spacer. Patient will be instructed to perform five tidal volume breaths for each puff.
62565712|NCT05183841|NO_INTERVENTION|Control|A paired healthy control group will be assessed by a constant load exercise test (75% from maximal load achieved on the cardiopulmonary exercise test) concomitant to the optoelectronic plethysmography to compare mechanical respiratory parameters to the bronchiectasis patients during the placebo assessment. In addition they will also use an accelerometer for 7 consecutive days.
62565713|NCT02768480|ACTIVE_COMPARATOR|Primary Care|Patients will be followed by primary care team exclusively.
62565714|NCT02768480|EXPERIMENTAL|Phone Calls Support and Primary Care|Patients will be followed by primary care team and supported by periodic nurse phone calls.
62565715|NCT05849727|EXPERIMENTAL|TQH3821 tablets 200 mg|Oral administration of TQH3821 tablets 200 mg, twice a day for 24 weeks.
62565716|NCT05849727|PLACEBO_COMPARATOR|TQH3821 tablets matching placebo|The placebo group was taken orally until the end of week 12. At the end of week 12, the placebo group was switched to the oral administration of TQH3821 tablets 200 mg until the end of week 24.
62565717|NCT02820974||Healthy control|Healthy women of child bearing age (25-39) with regular cycles.
62565718|NCT02820974||Perimenopause|Women at the age of 40-54 with irregular cycles filling in th criteria of perimenopause.
62565719|NCT02820974||Menopause|Women at the age of over 55 without normal cycles filling in th criteria of menopause.
61996205|NCT05009394|ACTIVE_COMPARATOR|Standard neuroma treatment, neuroma excision, and muscle burying|The standard neuroma treatment, also called neuroma transposition, includes excision of the terminal neuroma and burying the nerve into an adjacent deep muscle.The standard neuroma treatment entails the excision of the terminal neuroma and then implanting the nerve into an adjacent muscle. Firstly, the surgeon will identify the nerve with a painful neuroma and thereafter resect the neuroma up to healthy fascicles. Next, the surgeon will identify a nearby muscle which is not involved in joint motion and has limited output opportunities for the nerve. The nerve will then be channeled at least 1 cm inside the muscle without applying any tension to it and secured by 1-2 non-resorbable monofilament sutures. The identified nerve with the painful neuroma will not be treated with any additional therapy than the resection (e.g., diathermy, pharmacotherapy, crushing, etc.). The surgery time is approximately 1-2 hours and it takes place in the hospital.
61996206|NCT00743652|EXPERIMENTAL|Group1|Subjects 6 weeks to \<10 months of age with 0 prior dose of Prevnar.
61996207|NCT00743652|EXPERIMENTAL|Group 2|Subjects \<12 months of age with 1 prior dose of Prevnar.
61996208|NCT00743652|EXPERIMENTAL|Group 3|Subjects \<12 months of age with 2 prior doses of Prevnar.
61996209|NCT00743652|EXPERIMENTAL|Group 4|Subjects ≥12 months to \<2 years of age.
61996210|NCT00743652|EXPERIMENTAL|Group 5|Subjects ≥2 years to \<5 years of age
61996211|NCT04625608|OTHER|Standard care|Participants in this arm shall receive 3.6 ml/kg of water a minimum of 1 hour prior to the induction of general anaesthesia. This is standard practice in the 2 participating institutions.
61996212|NCT04625608|EXPERIMENTAL|Paracetamol arm|Participants in this arm shall receive 3 ml/kg of water plus 15 mg/kg of oral paracetamol suspension a minimum of 1 hour prior to the induction of general anaesthesia.
61996213|NCT00915512|EXPERIMENTAL|Paliperidone extended-release (ER)|
61996214|NCT06167395|EXPERIMENTAL|Beta Alanine high dose|Consumption for 30 days.
61996215|NCT06167395|EXPERIMENTAL|Beta Alanine low dose|Consumption for 30 days.
61996216|NCT06167395|PLACEBO_COMPARATOR|Control group|Consumption for 30 days.
61996217|NCT01193491|EXPERIMENTAL|IPI-493|
61996218|NCT06148922|EXPERIMENTAL|Intervention|Intervention group parents will receive a 2-hour workshop delivered by a registered nurse with a MHFA training certificate, in groups of up to 10 parents. Parents will receive a leaflet summarizing the training contents after the workshop. At 1 week and 1-, 3-, and 6-month follow-ups, the trained registered nurse will send a 5-minute reminder video via WhatsApp/WeChat to parents describing the key MHFA techniques. A set of online questionnaires will also be delivered to the parent-child dyads at these follow-ups.
61996219|NCT06148922|NO_INTERVENTION|Control|The control group will receive no intervention. Only completing the sets of questionnaire.
61996220|NCT06148922|OTHER|Intervention (Interview)|Parents in the intervention group with the highest and lowest mental health literacy scores will be purposively invited to participate in one-to-one semi-structured interviews to explore their experience of the intervention.
61996221|NCT05297539|NO_INTERVENTION|Control Group|Control group who will do usual rehabilitation + visualization of videos representing monuments + a 3-meter round-trip walk
61996222|NCT05297539|EXPERIMENTAL|Experimental group 1|Experimental group 1 who will do usual rehabilitation + visualization of non focused point-light human actions + a 3-meter round-trip walk
61996223|NCT05297539|EXPERIMENTAL|Experimental group 2|Experimental group 2 who will do usual rehabilitation + visualization of focused point-light human actions + a 3-meter round-trip walk
61996224|NCT02221310|EXPERIMENTAL|Gemtuzumab Ozogamicin|Conditioning therapy with Gemtuzumab Ozogamicin in combination with busulfan and cyclophosphamide chemotherapy followed by allogeneic stem cell transplantation.
61996225|NCT05685290|EXPERIMENTAL|Intervention group|Pushing with saline technique
61996226|NCT05685290|ACTIVE_COMPARATOR|Control group|Traditional method
61996227|NCT04732637||COVID Positive|Individuals who have recently tested positive for COVID19 by RTPCR, with active infection.
61996228|NCT04732637||COVID Negative|Individuals who have recently tested negative for COVID19 by RTPCR.
62181324|NCT02740361|NO_INTERVENTION|Waitlist Control|Participants randomized to the control group will wait for access to the Deprexis program (waitlist control) for 6 months. After the 6-month waiting period, participants in this group will have full access to Deprexis.
62181325|NCT03237247||Benign|cases with benign biliary stricture
62181326|NCT03237247||Calcular OJ|cases with calcular extrahepatic cholestasis
62565720|NCT06549842|ACTIVE_COMPARATOR|Group 1-Regular dose heparin|Patients in this arm will be labeled as Group 1. Patients will receive a standard heparin dose (50U/Kg) with a total compression time of 2 hours using the TR band ®.
62565721|NCT06549842|EXPERIMENTAL|Group 2-Low dose heparin|Patients in this arm will be labeled as Group 2. Patients will receive a reduced heparin dose (25 U/Kg) and a compression time of 60 minutes using the VASOBand™, with simultaneous ipsilateral ulnar artery compression.
62565722|NCT03218995|EXPERIMENTAL|Eteplirsen|Eteplirsen will be administered once every 7 days by intravenous (IV) infusion starting on Day 1 for up to 96 weeks. The starting dose will be 2 milligrams/kilogram (mg/kg) eteplirsen, with escalation to 4, 10, 20, and 30 mg/kg for 10 weeks, and then participants will continue to receive eteplirsen at 30 mg/kg for the duration of the study.
62565723|NCT04553731|EXPERIMENTAL|The mHealth-based program|The experimental group used the mHealth app and Mi Smart Band 5 on managing and preventing excessive GWG among overweight and obese women during pregnancy
62565724|NCT04553731|NO_INTERVENTION|The standard antenatal treatments with no mHealth-based elements|controls received standard antenatal treatments with no mHealth-based elements
62565725|NCT03853174|ACTIVE_COMPARATOR|ET|Active Comparator: ET Endurance training were prformed. Intensity was gradually increased.
62565726|NCT03853174|OTHER|RT|Resistance training were prformed. Intensity was gradually increased.
62565727|NCT04316429|ACTIVE_COMPARATOR|Egg phase:|Participants will meet with a registered dietitian and receive instructions to include 2 eggs per day for 6 weeks as part of their otherwise vegan diets.
62181327|NCT03237247||Malignant Distal|cases with malignant distal extrahepatic cholestasis
62181328|NCT03237247||Malignant Proximal|cases with malignant proximal extrahepatic cholestasis
62181329|NCT03237247||Intrahepatic|cases with intrahepatic cholestasis
62181330|NCT02383407|EXPERIMENTAL|Stimulation group 2 Hz|Patient will be randomized to a stimulation group of 2 Hz using Medtronic deep brain stimulation device
62181331|NCT02383407|EXPERIMENTAL|Stimulation group 5 Hz|Patient will be randomized to a stimulation group of 5 Hz using Medtronic deep brain stimulation device
62181332|NCT04684966|EXPERIMENTAL|Experimental group (EG)|"Randomized intervention in the NMES (GE) group:~Patients in the NMES group will receive, in addition to conventional rehabilitation, combined quadriceps femoris and triceps surae NMES.~Detail of the NMES :~* Stimulation is performed in a semi-seated position, biphasic current, 8 channels in total (possibility of 16 electrodes).~* One device per lower limb of each patient is necessary: 4 electrodes are placed on the quadriceps and 4 electrodes on the triceps, on each lower limb.~* Stimulation frequency: 50hz.~* Pulse duration: 400 μs.~* Contraction time: 6 seconds.~* Rest time: 6 seconds.~* The intensity must generate a visible muscular contraction and must be well supported. by the patient.~* The voluntary contraction accompanies the electrical stimulation.~* Surface electrode 50 × 50 mm."
62182643|NCT06332300|EXPERIMENTAL|Adebelimumab+famitinib+chemotherapy|Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with non-squamous NSCLC with soft meningeal metastases who have failed EGFR-TKI therapy
62565728|NCT04316429|PLACEBO_COMPARATOR|Control phase:|The participants will consume a vegan diet for 6 weeks.
62565729|NCT00980863|ACTIVE_COMPARATOR|Lifestyle intervention to increase physical activity|
62565730|NCT00980863|NO_INTERVENTION|waiting control group|
62565731|NCT00114140|EXPERIMENTAL|Temozolomide + Radiation Therapy (RT)|Daily temozolomide plus concurrent radiotherapy followed by temozolomide
62565732|NCT00964574|EXPERIMENTAL|APIDRA + LANTUS basal|The 2 first weeks, patients will receive subcutaneous injection of Insulin Glulisine and Insulin Glargine once daily in hospital. The rest of the treatement is to be take at home until week 12
62772837|NCT01972789|EXPERIMENTAL|Intensive retinal fluid regimen|Ranibizumab 0.5mg is given monthly for the first 3 months followed by an individualised treatment regimen as determined by disease activity defined by a loss of ≥5 letters, new retinal haemorrhage, presence of any IRF or SRF on OCT.
62182644|NCT00843115||Observational|This study was non-interventional and simply followed for 3 months patients initiating a treatment with donepezil
62565733|NCT02810626|NO_INTERVENTION|Control|Control Group (surgical standard of care): Subjects 18 years and younger diagnosed with a pediatric brain tumor, and who are eligible for surgical treatment will be recruited. All subjects will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol. Surgery will be carried out according to usual standard of care, without the use of processing for DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative quality of life assessments, functional testing and clinical outcome tests will be conducted at this post-operative period (6-months).
62181333|NCT04684966|SHAM_COMPARATOR|Control group (CG)|"Patients in the control group (GC) will receive, in addition to the classical rehabilitation, the combined sham NMES of the quadriceps femoris and triceps surae.~Detail of the NMES :~* It is carried out 5 times a week for 4 weeks, supervised by a physiotherapist.~* The device used will be the same as in the EG group.~* Stimulation is performed in a semi-seated position, biphasic current, 8 channels in total (16 electrodes can be used).~* One device per lower limb of each patient is required: 4 electrodes are placed on the quadriceps and 4 electrodes on the triceps, on each lower limb.~* Stimulation frequency: 5hz.~* Pulse duration: 100 μs.~* Contraction time: 6 seconds.~* Rest time: 6 seconds.~* The intensity must generate a visible muscle contraction and must be well supported by the patient.~* The voluntary contraction accompanies the electrical stimulation.~* Surface electrode 50 × 50 mm."
62181334|NCT05073549|EXPERIMENTAL|Collaborative antimicrobial stewardship group|Collaborative antimicrobial stewardship intervention will be implemented in NICUs of this group.
62181335|NCT00907946|EXPERIMENTAL|NT prior to PCNL|"A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one week prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~1. Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~2. If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol."
62565734|NCT02810626|OTHER|Interventional|Interventional Group (involvement of all BrightMatter™ products): Subjects 18 years and younger diagnosed with a pediatric brain tumor and who are eligible for surgical treatment will be recruited. All subjects will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol and will be sent to the interventional technology (BrightMatter Bridge) for quality control. The QC'ed images will then be sent to a pre-operating planning software (BrightMatter Plan) for planning the surgical approach. Surgery will be carried out with guidance from the exported plan and the intra-operative neuro-navigation software, BrightMatter Guide, with the use of post-processing DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative quality of life assessments, functional testing and clinical outcome tests will be conducted at this post-operative period (6-months).
62181336|NCT00907946|NO_INTERVENTION|NT at the surgery|A bladder urine culture will be obtained prior to surgery and appropriate antibiotic treatment will be initiated if necessary. The nephrostomy tract will be placed at the time of surgery under fluoroscopic guidance. All patients will receive empiric intravenous peri-operative antibiotics at induction. Renal pelvis urine and stone will be collected for culture and post-operative treatment will be initiated if necessary.
62565735|NCT06534762|EXPERIMENTAL|Miraberon|Subjects were given mirabeeron 100mg/day orally once a day in the morning until disease progression. When there are related or possible related side effects of the study drug mirabeeron, and according to NCI-CTCAE V 5.0, when subjects have more than or equal to grade 3 related toxicity, the administration should be delayed until grade 2 or lower to baseline, and the dose will be reduced by 50%, and subsequent dose increase is not allowed. If the pre-dose criteria are not met within 28 days, the drug will be permanently discontinued.
62565736|NCT03808649|ACTIVE_COMPARATOR|Individualized group|Participants are given different volume of a preparation of mannitol based on BMI as oral contrast agent over an hour prior to the examination.
62565737|NCT03808649|EXPERIMENTAL|conventional group|Participants are given 1500ml of a preparation of mannitol as oral contrast agent over an hour prior to the examination.
62565738|NCT04848064|EXPERIMENTAL|Treatment (mogamulizumab, chemotherapy, NK cells)|Patients receive mogamulizumab IV over 60 minutes on day -7 and fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients receive NK cell infusion on day 0. Patients then receive mogamulizumab IV over 60 minutes on days 0, 7, 14, and 28, then every 2 weeks thereafter in the absence of disease progression or unacceptable toxicity.
62565739|NCT06019546||PEQUOD|Patients undergoing cardiac surgery with cardiopulmonary bypass whose parameters of interest will be registered during cardiopulmonary bypass by the Livanova BE-CAPTA monitor.
62565740|NCT03911232|EXPERIMENTAL|Enhanced recovery|rocuronium 2 effective dose at anesthesia induction sugammadex after skin incision and before extubation (total 2 mg/kg iv)
62565741|NCT03911232|NO_INTERVENTION|Conventional anesthesia|standard general anesthesia protocol (1 effective dose of rocuronium at anesthesia induction)
61996229|NCT01802957|OTHER|St. Paul and Networked Health Centers|An uncontrolled before and after design with baseline and follow-up cross sectional measurements will be used at the overall site level (St. Paul Hospital and the 8 associated HCs). There will be no control unit.
61996230|NCT04283643|EXPERIMENTAL|Healthy Human Subjects|Healthy human subjects will complete study procedures in the research lab at UVA. They will complete pain-related behavioral questionnaires and undergo experimental pain testing for temperature and laser stimuli for real and control conditions of brain stimulation.
61996231|NCT04283643|EXPERIMENTAL|Acute Pain Patients|Acute Pain Patients will complete study procedures in the hospital or clinic at UVA. They will complete pain-related behavioral questionnaires and undergo experimental pain testing for temperature and laser stimuli for real and control conditions of brain stimulation, as well as rate their ongoing pain.
62565742|NCT06287385|EXPERIMENTAL|Formula fed|Goat-milk Based Formula (Stage 3)
62565743|NCT02154568|EXPERIMENTAL|Hyperpolarized helium MRI of the chest|
62565744|NCT01969149|EXPERIMENTAL|Exenatide group|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
61996232|NCT04283643|EXPERIMENTAL|Chronic Pain Patients|Chronic Pain Patients will complete study procedures in the hospital or clinic at UVA. They will complete pain-related behavioral questionnaires and undergo experimental pain testing for temperature and laser stimuli for real and control conditions of brain stimulation, as well as rate their ongoing pain.
61996233|NCT05651464|ACTIVE_COMPARATOR|Intervention: Prophylactic antibiotic treatment|Application of 15-20 mg per kgKG Vancomycine I.V. prior to ECMO liberation
61996234|NCT05651464|NO_INTERVENTION|Control Arm: No prophylactic antibiotic treatment|Control group - no intervention.
61996235|NCT02347527|EXPERIMENTAL|Active Implicit Priming (MRI sample)|Participants will complete active implicit priming, in which food images are implicitly primed (i.e., below conscious awareness) with images of positive or negative affect. In addition to measures of food image ratings, this group completed a visual food cues scan during fMRI to assess change in neuronal response to food cues. They also completed a measure of food intake post-intervention.
61996236|NCT02347527|PLACEBO_COMPARATOR|Control Implicit Priming (MRI sample)|Participants will complete a control implicit priming intervention, which matches the active intervention, but with neutral stimuli as primes. In addition to measures of food image ratings, this group completed a visual food cues scan during fMRI to assess change in neuronal response to food cues. They also completed a measure of food intake post-intervention.
62181337|NCT04438330|EXPERIMENTAL|Nickel allergic individuals|Nickel sulfate hexahydrate in petrolatum. Exposed in a patch test dose-range with a max concentration of 5% nickel sulfate hexahydrate
62565745|NCT01969149|ACTIVE_COMPARATOR|Insulin group|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
62565746|NCT05375357|EXPERIMENTAL|APF + L-PRF|Application of a layer of L-PRF to protect the donor area after uncovering implant procedure using Apically Positioned Flap (APF).
62565747|NCT05375357|ACTIVE_COMPARATOR|APF without L-PRF|The donor area is left to heal by secondary intention after APF in the implant uncovering procedure.
62565748|NCT00865228|EXPERIMENTAL|Lapaquistat Acetate 100 mg QD (morning)|
61996237|NCT02347527|EXPERIMENTAL|Active Implicit Priming (Behavioral-only sample)|Participants will complete active implicit priming, in which food images are implicitly primed (i.e., below conscious awareness) with images of positive or negative affect.
61996238|NCT02347527|PLACEBO_COMPARATOR|Control Implicit Priming (Behavioral-only sample)|Participants will complete a control implicit priming intervention, which matches the active intervention, but with neutral stimuli as primes.
62181338|NCT04438330|ACTIVE_COMPARATOR|non-nickel allergic individuals|Nickel sulfate hexahydrate in petrolatum. Exposed in a patch test dose-range with a max concentration of 5% nickel sulfate hexahydrate
62565749|NCT00865228|EXPERIMENTAL|Lapaquistat Acetate 100 mg QD (evening)|
62565750|NCT00865228|EXPERIMENTAL|Lapaquistat Acetate 50 mg BID|
62565751|NCT00865228|PLACEBO_COMPARATOR|Placebo BID|
62565752|NCT03014583|EXPERIMENTAL|HF/TCS/BURST|HF/TCS/BURST
62565753|NCT03014583|EXPERIMENTAL|HF/BURST/TCS|HF/BURST/TCS
62565754|NCT03014583|EXPERIMENTAL|BURST/HF/TCS|BURST/HF/TCS
62565755|NCT03014583|EXPERIMENTAL|BURST/TCS/HF|BURST/TCS/HF
62565756|NCT03014583|EXPERIMENTAL|TCS/BURST/HF|TCS/BURST/HF
62565757|NCT03014583|EXPERIMENTAL|TCS/HF/BURST|TCS/HF/BURST
62565758|NCT01441648||experimental group|(1) age 20-35 years old (2) myopia less than -6.00D and astigmatism less than -1.50D (3) previous soft contact lens wear discontinued for at least 2 weeks. Exclusion criteria includes: (1) subjects with previous Rigid Gas Permeable (RGP) wear (2) any ocular inflammation or infection, dry eye syndrome, glaucoma, ocular trauma or surgery, and topical medication instillation (3) diabetic mellitus (4) pregnancy (5) any corneal disorders or dystrophies.
62565759|NCT01478412||Males with prostate adenocarcinoma|English speaking males with histologically confirmed prostate adenocarcinoma and diagnosis of low risk or intermediate risk prostate cancer.
62565760|NCT03486808|EXPERIMENTAL|Dual stimulation|i) anodal stimulation of left inferior frontal cortex ii) anodal stimulation on left dorsolateral prefrontal cortex
62565761|NCT03486808|ACTIVE_COMPARATOR|IFG stimulation|anodal stimulation of left inferior frontal cortex
62565762|NCT03486808|ACTIVE_COMPARATOR|DLPFC stimulation|anodal stimulation on left dorsolateral prefrontal cortex
62565763|NCT03486808|SHAM_COMPARATOR|Sham stimulation|sham stimulation
62565764|NCT02935712|EXPERIMENTAL|Part A|Three cohorts with 9 subjects and each cohort received 2 treatments (AZD8601+Placebo/ Placebo+Placebo)
62565765|NCT02935712|EXPERIMENTAL|Part B|Subjects received 2 treatments (AZD8601+Placebo)
62565766|NCT02715193|EXPERIMENTAL|REMD-477 Treatment A|Administered as a single SC dose in subjects with Type 1 Diabetes
62565767|NCT02715193|PLACEBO_COMPARATOR|Matching placebo|Administered as a single SC dose in subjects with Type 1 Diabetes
62565768|NCT02385773|EXPERIMENTAL|PTM202|PTM202
62565769|NCT02385773|PLACEBO_COMPARATOR|Enfamil Puramino|Formal Placebo
62565770|NCT04867226|ACTIVE_COMPARATOR|colchicine drug|participant in this group will be given a colchicine tablet alone or add to their Current treatment, Colchicine 0.5 mg twice daily (reduced to 0.5 mg/day, in patients with low body weight or develop side effect like gastrointestinal symptoms ),For 14 days or until symptoms subsides.
62565771|NCT04867226|ACTIVE_COMPARATOR|usual care|control group will receive usual care COVID-19 treatment according to Iraqi protocol guideline and will not receive colchicine.
62565772|NCT00226499|EXPERIMENTAL|MMRV Group|Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).
62565773|NCT00226499|EXPERIMENTAL|OKAH Group|Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.
62565774|NCT00226499|ACTIVE_COMPARATOR|MMR Group|Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).
62565775|NCT05642871||Magnetic Resonance Multifunctional Imaging|
62565776|NCT01994148|EXPERIMENTAL|Laparoscopy|Laparoscopy has been increasingly applied in patients with abdominal trauma , as an diagnostic and therapeutic modality. In this arm, we will include 100 Hemodynamically stable patients with gastrointestinal trauma, all of them will receive laparoscopic exploration,laparoscopic repair of the gastrointestinal injury will be attempted.
62565777|NCT04955353|EXPERIMENTAL|AVC-H2|Participants received Avicenna Hydrolyzed Chicken Collagen Type II (AVC-H2), 2.5g daily, for 8 weeks.
62565778|NCT04955353|PLACEBO_COMPARATOR|Placebo|Participants received placebo of matching amount to that of AVC-H2 daily for 8 weeks.
62565779|NCT01554527|EXPERIMENTAL|CPAP treatment|Children randomized to this arm will receive 6 months of CPAP (or BPAP) treatment, beginning at approximately 4 months after AT, in addition to standard of care. For analysis purposes those children who were non-adherent (CPAP use \<4 hours per night) vs. adherent (CPAP use at least 4 hours per night) will be analyzed separately.
62565780|NCT01554527|OTHER|No CPAP treatment|Children randomized to this comparison arm will not be treated with CPAP or BPAP, but will be followed for approximately 10 months after AT while receiving standard of care.
62565781|NCT06485921|ACTIVE_COMPARATOR|Ischemic compression GROUP|This group will receive 90 seconds of ischemic compression on myofascial trigger points in the trapezius, levator scapulae, supraspinatus, infraspinatus, and splenius cervicis, along with exercises and suggestions for workplace modifications.
62565782|NCT06485921|ACTIVE_COMPARATOR|Instrument assisted soft tissue mobilization Group|This group will receive 40 seconds of sweeping and 60 seconds of swiveling by instrument-assisted soft tissue mobilization on myofascial trigger points in the trapezius, levator scapulae, supraspinatus, infraspinatus, and splenius cervicis muscles, along with exercises and suggestions for workplace modifications.
62565783|NCT06485921|EXPERIMENTAL|Control Group|This group will only receive exercises and suggestions for workplace modifications.
62565784|NCT03302169|EXPERIMENTAL|Posterior Rhabdosphincter Reconstruction|Patients in who posterior rhabdosphincter reconstruction is performed
62565785|NCT03302169|ACTIVE_COMPARATOR|Standard Technique|Patients in who posterior rhabdosphincter reconstruction is NOT performed, Standard technique.
62565786|NCT06490055||Gastric cancer chemotherapy responders received second-line chemotherapy|"Responders according to the response evaluation criteria in solid tumors (RECIST).~A panel of microRNA, whose expression level is tested exosomal microRNA from blood sample before second-line chemotherapy with reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)"
62565787|NCT06490055||Gastric cancer chemotherapy non-responders received second-line chemotherapy|"Non-responders according to the response evaluation criteria in solid tumors (RECIST).~A panel of microRNA, whose expression level is tested exosomal microRNA from blood sample before second-line chemotherapy with reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)"
61996239|NCT01991002|OTHER|14/21 diet|"Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.~The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group."
61996240|NCT04445558|EXPERIMENTAL|Membrane PEPA®|Patient will use the membrane PEPA® for the dialysis
61996241|NCT04445558|ACTIVE_COMPARATOR|Standard membrane of dialysis|Patient will use a standard membrane for the dialysis
62565788|NCT04036695|EXPERIMENTAL|Reveal LINQ insertable cardiac monitoring system|In this all study, participants will have the option to undergo an insertion procedure of the Reveal LINQ insertable cardiac monitoring system on a dialysis or non-dialysis treatment day at University Hospital. The implantable loop recorder will be monitored at least once a week for up to 12 months.
62565789|NCT05469737|EXPERIMENTAL|Part I - Oral-Aza (Dose 1)|
62565790|NCT05469737|EXPERIMENTAL|Part I - Oral-Aza (Dose 2)|
62565791|NCT05469737|EXPERIMENTAL|Part II - Oral-Aza (RP3D)|RP3D: Recommended Phase 3 Dose
62565792|NCT05469737|EXPERIMENTAL|Part II - Placebo|
62565793|NCT01820143|EXPERIMENTAL|Treatment sequence ADBC|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
62565794|NCT01820143|EXPERIMENTAL|Treatment sequence BACD|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
62565795|NCT01820143|EXPERIMENTAL|Treatment sequence CBDA|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
62565796|NCT01820143|EXPERIMENTAL|Treatment sequence DCAB|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
62565797|NCT05331378|EXPERIMENTAL|Test myopia control lenses|A myopia control spectacle lenses (test lenses) will be given to 1 arm to wear for 12 months.
62565798|NCT05331378|OTHER|Single vision lenses|A single vision spectacle lenses (control lenses) will be given to 1 arm to wear for 12 months.
62565799|NCT05587595||children with complicated sickle cell disease hospitalised in pediatric intensive care unit (PICU)|
62565800|NCT05587595||children with complicated sickle cell disease hospitalised but not in intensive care unit|
62565801|NCT04905901|EXPERIMENTAL|Tranexamic acid 500 mg|Nebulized tranexamic acid 500 mg 15 minutes before operation
62565802|NCT04905901|EXPERIMENTAL|Tranexamic acid 1gm|Nebulized tranexamic acid 1 gm 15 minutes before operation
62565803|NCT04905901|PLACEBO_COMPARATOR|Saline placebo|Normal saline nebulization 15 minutes before operation
62565804|NCT03956979|EXPERIMENTAL|JM-010 group A|Group A (JM-010 dose fixed combination drug(tablet)) +Placebo 2
62565805|NCT03956979|EXPERIMENTAL|JM-010 group B|Group B (JM-010 8/0.8mg dose fixed combination drug(tablet)) + Placebo 1
62565806|NCT03956979|PLACEBO_COMPARATOR|Placebo|Double-dummy - 2 tablets = Placebo 1 +Placebo 2
62181339|NCT01176318|EXPERIMENTAL|erdosteine|standard care plus erdosteine for 10 days
62181340|NCT01176318|PLACEBO_COMPARATOR|placebo|Standard care for exacerbation of COPD plus placebo
62565807|NCT05583461|EXPERIMENTAL|PEEP level according to the low PEEP-FiO2 table|Positive end-expiratory pressure (PEEP) level selected based on patient's fraction of inspired oxygen (FiO2) according to the low PEEP-FiO2 table proposed by the Acute Respiratory Distress Syndrome Network Guidelines
62565808|NCT05583461|EXPERIMENTAL|PEEP minimizing the risk of overdistension and atelectasis|Positive end-expiratory pressure (PEEP) level selected based on the intersection between the curves of the cumulative percentages of compliance loss due to alveolar overdistension and atelectasis, respectively, as assessed with an electrical impedance tomography-based decremental PEEP trial
62565809|NCT05583461|EXPERIMENTAL|PEEP minimizing the risk of overdistension|Highest positive end-expiratory pressure (PEEP) level associated with no alveolar overdistention selected based on the curve of the cumulative percentage of compliance loss due to alveolar overdistension, as assessed with an electrical impedance tomography-based decremental PEEP trial
62565810|NCT05583461|EXPERIMENTAL|PEEP minimizing the risk of atelectasis|Lowest positive end-expiratory pressure (PEEP) level associated with no alveolar collapse selected based on the curve of the cumulative percentage of compliance loss due to alveolar collapse, as assessed with an electrical impedance tomography-based decremental PEEP trial
61996242|NCT02086110|ACTIVE_COMPARATOR|Prebiotic only first, then synbiotic|This group will receive prebiotic only (bovine milk oligosaccharides, administered orally twice per day for a daily total of 0.3 g per pound of body weight) for the first five weeks, followed by a two week break with no treatment, and then will receive the synbiotic (Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally) for the next five weeks.
62181341|NCT02138656|ACTIVE_COMPARATOR|Best standard care only - not blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice.~Parents aware that infant is not receiving chiropractic treatment"
61996243|NCT02086110|ACTIVE_COMPARATOR|Synbiotic first, then prebiotic only|This group will receive the synbiotic (Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally) for the first five weeks, followed by a two week break with no treatment, and then will receive the prebiotic only (bovine milk oligosacharrides, administered orally twice per day for a daily total of 0.3 g per pound of body weight) for the next five weeks.
61996244|NCT02508636|EXPERIMENTAL|Combination Therapy: Enzalutamide, Leuprolide, Radiotherapy|"Participants will receive Enzalutamide: 160 mg per day, to begin within 0-7 days of the date of the first Luteinizing Hormone-Releasing Hormone (LHRH) agonist administration for total duration of 24 months as well as a single Leuprolide 7.5mg injection every month; single 22.5 mg injection every 3 months; single 30mg injection every 4 months; single 45 mg injection every 6-months based on the manufacturer for a total of 24 months.~Radiation therapy should begin approximately 8 weeks (+/- 1 week) after the date of the first LHRH agonist/antagonist injection of hormone therapy is given and continue for a total of 5 weeks."
62181342|NCT02138656|SHAM_COMPARATOR|Best Standard Care and Sham - Blind|Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus sham chiropractic treatment. Parents unaware of whether infant is receiving real treatment or sham.
62181343|NCT02138656|EXPERIMENTAL|BSC & Chiropractic - Not blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus real chiropractic treatment.~Parents aware that infant is receiving chiropractic treatment."
62181344|NCT02138656|EXPERIMENTAL|BSC & Chiropractic - Blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus real chiropractic treatment.~Parents not aware that infant is receiving chiropractic treatment."
62181345|NCT01917006|EXPERIMENTAL|OnabotulinumtoxinA Dose 1|OnabotulinumtoxinA Dose 1 injected into specified muscle per protocol on Day 1.
62181346|NCT01917006|EXPERIMENTAL|OnabotulinumtoxinA Dose 2|OnabotulinumtoxinA Dose 2 injected into specified muscle per protocol on Day 1. Participants were eligible for another treatment after 12 weeks.
62181347|NCT01917006|EXPERIMENTAL|OnabotulinumtoxinA Dose 3|OnabotulinumtoxinA Dose 3 injected into specified muscle per protocol on Day 1.
62565811|NCT04405037|EXPERIMENTAL|Alvimopan Group|"Patients randomized to the study group will be given a maximum of 3 doses of Alvimopan 12mg orally, 12 hours apart. Alvimopan will be given from the time of diagnosis of postoperative ileus to the time of return of bowel function or the maximum 3 doses. Subsequent Alvimopan doses will be given if there is no return of bowel function or if symptoms of distension and/or nausea persist despite some return of bowel function.~All patients will follow a standard ERAS pathway after surgery, with early feeding and ambulation, along with opioid minimizing measures as is our standard postoperative protocol."
62565812|NCT04405037|NO_INTERVENTION|Control Group|Control patients will follow a standard ERAS pathway after surgery, including NPO status, IV fluid rehydration, and nasogastric decompression, early feeding and ambulation, along with opioid minimizing measures as is our standard postoperative protocol.
62565813|NCT01842360|EXPERIMENTAL|MV130|The subjects will receive daily dose of MV130 during 12 months
62181348|NCT01917006|EXPERIMENTAL|OnabotulinumtoxinA Dose 4|OnabotulinumtoxinA Dose 4 injected into specified muscle per protocol on Day 1.
62565814|NCT01842360|PLACEBO_COMPARATOR|Placebo|The subjects will receive daily dose of placebo during 12 months
62181349|NCT01917006|EXPERIMENTAL|OnabotulinumtoxinA Dose 5|OnabotulinumtoxinA Dose 5 injected into specified muscle per protocol on Day 1.
62181350|NCT01917006|EXPERIMENTAL|OnabotulinumtoxinA Dose 6|OnabotulinumtoxinA Dose 6 injected into specified muscle per protocol on Day 1.
62565815|NCT04469595|ACTIVE_COMPARATOR|ILUVIEN Arm|Intravitreal ILUVIEN
62565816|NCT04469595|ACTIVE_COMPARATOR|Aflibercept Arm|Intravitreal aflibercept
62565817|NCT05529550||Patients|67 children in the age group of 2-18 years with confirmed diagnosis of Beta thalassemia major.
62565818|NCT05529550||Healthy control|35 healthy children
62565819|NCT04090229|EXPERIMENTAL|ASLAN004|
62565820|NCT04090229|PLACEBO_COMPARATOR|ASLAN004 Placebo|
62565821|NCT05570240||OA group|Knee osteoarthritis patients who were scheduled to receive elective total knee replacement surgery which need spinal anesthesia.
62565822|NCT05570240||Control group|Control group patients were scheduled to receive elective general surgery or urological surgery with spinal anesthesia.
62565823|NCT02568189|EXPERIMENTAL|Sepsis 1|Sepsis patients receiving SonoSite Maxx Series Ultrasound System ultrasound prior to clinical orders including medication and fluid orders being placed by the treating physician
62565824|NCT02568189|ACTIVE_COMPARATOR|Sepsis 2|Sepsis patients having SonoSite Maxx Series Ultrasound System ultrasound performed after clinical orders have been placed by the treating physician
62565825|NCT02568189|EXPERIMENTAL|Gastroenteritis 1|Patients with gastroenteritis receiving SonoSite Maxx Series Ultrasound System ultrasound prior to having orders placed by treating physician
62181351|NCT01917006|PLACEBO_COMPARATOR|Placebo|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
62181352|NCT04804059|EXPERIMENTAL|Cohort A|\[14C\]-APX001 Oral Solution
62181353|NCT04804059|EXPERIMENTAL|Cohort B|\[14C\]-APX001 Solution for Infusion
62181354|NCT03897361|EXPERIMENTAL|"Gene Therapy with CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST)"|"This is a single arm study without randomization. Eligible subjects will receive the final product: CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST)."
62181355|NCT04418180|ACTIVE_COMPARATOR|GROUP1|group receiving single dose fenofibrate
62181356|NCT04418180|ACTIVE_COMPARATOR|GROUP2|group receiving double dose fenofibrate
62181357|NCT04418180|PLACEBO_COMPARATOR|GROUP3|photo therapy only
62181358|NCT01338805|EXPERIMENTAL|BGG492|hard gelatin capsule for oral administration at 50 mg TID, 100 mg TID or 150 mg TID
62181359|NCT02273700||the Study Population|"The study population consists of patients in the cardiology department at the Nîmes University Hospital with non-valvular atrial fibrillation and who are candidates for treatment with a direct oral anticoagulant: Rivaroxaban (Xarelto®). Patients will be selected according to criteria designed to result in a homogeneous population (associated anticoagulants, etc., see below). For this study, patients must not have had a direct oral anti-Xa (activated Factor 10) in the 6 months preceding enrollment.~Intervention: Rivaroxaban"
62181360|NCT00280020|EXPERIMENTAL|CBT|
62181361|NCT00280020|EXPERIMENTAL|TCC|
62181362|NCT00280020|ACTIVE_COMPARATOR|SS|
62181363|NCT01311414|EXPERIMENTAL|cafedrine/theodrenalin|
62181364|NCT05832619|OTHER|Waiting list group|This group will include 40 patients with MDD who will be treated with oral SSRIs only, the dosage of which will be determined by the psychiatrist. After 6 weeks, patients could choose 6 weeks' intradermal acupuncture treatments free of charge.
62181365|NCT05832619|SHAM_COMPARATOR|SIA+SSRIs group|This group will include 40 patients with MDD who will be treated with sham intradermal acupuncture combined with SSRIs. Acupoints related to MDD will be stimulated by acupuncturists and the dosage of oral SSRIs will be determined by the psychiatrist.
62181366|NCT05832619|EXPERIMENTAL|AIA+SSRIs group|This group will include 40 patients with MDD who will be treated with active intradermal acupuncture combined with SSRIs. Acupoints related to MDD will be stimulated by acupuncturists and the dosage of oral SSRIs will be determined by the psychiatrist.
62181367|NCT02277067|ACTIVE_COMPARATOR|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
62181368|NCT02277067|ACTIVE_COMPARATOR|Misoprostol|Misoprostol ( Misotac, Sigma, Egypt) is a stable, synthetic form of prostaglandin E1 analogue. Patients wil be given 600 microgram of misotac immediately postoperative.
62181369|NCT04473053|EXPERIMENTAL|Nafamostat|It is intended that the licensed dose (0.2mg/kg/hr) in Japan will be used. Patients randomised to Nafamostat will receive a continuous intravenous infusion at 0.2 mg/kg/hr for 7 days. If a participant is discharged from hospital or can no longer receive this treatment, the treatment will be stopped.
62181370|NCT04473053|EXPERIMENTAL|TD139|"Patients will inhale 5mg x 2 (10 mg) twice daily for the first 48 hrs and then subsequently 5mg x 2 (10 mg) once daily for the remaining 12 days. Unless a participant is discharged from hospital or can no longer use an inhaler - in which case treatment will be stopped at such time.~CE marked inhalers will be provided by the Manufacturer. All patients will receive guidance on how to use the inhaler by an appropriately trained member of the research team. Two individual inhalers will be used by each patient over the course of the 14 day study period (each inhaler will be used by one patient for 7 days) and will be thoroughly cleaned with an antiseptic wipe before and after each use."
61996245|NCT04541875||Cystic fibrosis|"Patients aged 18+ and diagnosed with cystic fibrosis.~Patients will answer the MAR-Scale once every three months for a year."
61996246|NCT04541875||Hemophilia A or B|"Patients aged 18+ and diagnosed with hemophilia A or B.~Patients will answer the MAR-Scale once every three months for a year."
62181371|NCT04473053|ACTIVE_COMPARATOR|Standard of Care|Nafamostat and TD139 will be compared to the Standard of Care arm.
62181372|NCT04473053|EXPERIMENTAL|Allogeneic SARS-CoV-2 VSTs|This is an early dose escalation safety trial phase Ib/IIa interventional clinical trial with SARS-CoV-2 VSTs. This is a standalone arm of the Define study and will not be compared to any other trial appendices. A dose escalation strategy from 2x104 cells/kg to 2x106 cells/kg (based on standard 75kg weight) will be administered to patients with COVID-19 infection, and patients will be followed up to ensure their safety.
62181373|NCT04705402|EXPERIMENTAL|Patients randomized to receive the treatment arm of mannitol.|The mannitol solution used in the hospital contain 18% mannitol in 500ml solution. An equivocal volume of 2.8 cc / kg body weight, which will be given intravenously with the use of an Ivac pump, infused for a duration of 15 minutes through an existing peripheral intravenous access catheter within 15-30 minutes prior to renal artery reperfusion
62181374|NCT04705402|PLACEBO_COMPARATOR|(Control arm) Study participants will receive a 0.9% saline solution|(Control arm) Study participants randomized to this arm will receive a 0.9% saline solution at a dose of 2.8 cc / kg, infused within 15-30 minutes prior to renal artery reperfusion through an existing intravenous access catheter (either through an central or peripheral intravenous infusion).
62181375|NCT06438692|SHAM_COMPARATOR|2C3L group|Ablation Procedure：2C3L
62181376|NCT06438692|EXPERIMENTAL|2C3L-plus group|Ablation Procedure：2C3L combined with Marshall ethanol ablation
62181377|NCT00250640||Group 1|
62391285|NCT02114723|ACTIVE_COMPARATOR|Medical Taping Concept|"3 band of a special and hypoallergenic tape, called Cure Tape ® (2 strips of 12 x 5 cm and 1 strip of 20 cm x 5 cm) are attached to the abdominal and lower back. One piece of 12 cm in length is applied right from below the navel and reached to where the pubic hair below, and another piece of 12 cm in length is applied to make a cross shape with the first piece (inside 11-12 dermatomes area). The piece of 20cm in length is placed horizontally to the lower back.~The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears"
61996247|NCT04541875||Idiopathic pulmonary fibrosis|"Patients aged 18+ and diagnosed with idiopathic pulmonary fibrosis.~Patients will answer the MAR-Scale once every three months for a year."
61996248|NCT04541875||Myasthenia gravis|"Patients aged 18+ and diagnosed with myasthenia gravis.~Patients will answer the MAR-Scale once every three months for a year."
61996249|NCT04541875||Sickle cell disease|"Patients aged 18+ and diagnosed with sickle cell disease.~Patients will answer the MAR-Scale once every three months for a year."
62565826|NCT02568189|ACTIVE_COMPARATOR|Gastroenteritis 2|Patients with gastroenteritis having SonoSite Maxx Series Ultrasound System ultrasound after initial clinical orders are placed by treating physician
62565827|NCT03305965|EXPERIMENTAL|Patient navigation|
62565828|NCT03305965|NO_INTERVENTION|Care as usual|
61996250|NCT02433236|EXPERIMENTAL|Fostamatinib Disodium tablet 100 mg|Fostamatinib Disodium tablet 100 milligram (mg) by mouth twice a day for 15 months
61996251|NCT02433236|EXPERIMENTAL|Fostamatinib Disodium tablet 150 mg|Fostamatinib Disodium tablet 150 milligram (mg) by mouth twice a day for 15 months
61996252|NCT00856908|EXPERIMENTAL|1|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
61996253|NCT00856908|PLACEBO_COMPARATOR|2|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
61996254|NCT00873548||PFNA_Asia treated|
61996255|NCT00265473|EXPERIMENTAL|Allogeneic Islets of Langerhans|Islet infusion
61996256|NCT02822469|EXPERIMENTAL|Manual Therapy Treatment Group|Severe and Moderate TMD patients who filled the inclusion criteria who will receive the Manual Therapy Treatment
62181378|NCT01804998|EXPERIMENTAL|Laparoscopic Sentinel Node Biopsy|Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in this arm
62565829|NCT01543438|NO_INTERVENTION|Control|current standard of care
62565830|NCT01543438|EXPERIMENTAL|Intervention Group|receives video prescription
62391286|NCT02114723|PLACEBO_COMPARATOR|Cross tape|Two pieces of special and squared tape of 2.5 x 2 cm called Cross Tape ® are attached to the external side of the thigh at the hip joint area (outside 11-12 dermatomes area)
62565831|NCT01853813|OTHER|Bevacizumab and FOLFIRI|Bevacizumab 5 mg/kg d1 q14 in combination with FOLFIRI (Irinotecan, leucovorin, 5FU I.V.bolus and 5FU I.V. c.i.)
62565832|NCT06116188||Patients with Mild cognitive impairment|20 study volunteers with a diagnosis of MCI due to AD or early AD or episodic memory decline during the last 6 months from the local memory clinics and by contacting doctors who treat and diagnose memory disorders. Patients with Alzheimer´s dementia - i.e. cognitive impairment severe enough to cause problems in activities of daily living - will not be included in the study due to the study protocol which requires co-operation and the ability to lie still in the PET scanner for approximately 60 minutes.
62565833|NCT06116188||Healthy controls|"We will also recruit 20 cognitively unimpaired controls, matched for age and gender for the patients group.~Inclusion criteria for the cognitively unimpaired group for the present study are:~i) no subjective cognitive complaints ii) CERAD (consortium to establish a registry for Alzheimer´s Disease) test battery at screening visit: CERAD total score within the normal range iii) clinical dementia rating (CDR) = 0, based on an interview with the study volunteer´s spouse or close relative iv) age 55 to 80 years"
62565834|NCT05201287|EXPERIMENTAL|VIA Disc Nucleus Pulposus Allograft|A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 or 2 levels, L1-S1.
62565835|NCT01707160|EXPERIMENTAL|Treatment period 1|
62391287|NCT01382758||Acute kidney injury|The group of patients who develop acute kidney injury as defined by the pediatric RIFLE criteria.
61996257|NCT02822469|PLACEBO_COMPARATOR|Placebo Ultrasound Treatment Group|Severe and Moderate TMD patients who filled the inclusion criteria who will receive the Placebo Treatment.
61996258|NCT00665184|EXPERIMENTAL|High force LE resistance training|High force lower extremity resistance training + Standard exercise care. The high force lower extremity resistance training group will participate in a 3 day per week progressive eccentric ergometry program that will be gradually increased over 3 weeks from 5-20 minutes per day and remain at that duration for the next 9 weeks. In addition, they will engage in exercises including moderate intensity aerobic training, concentric upper extremity resistance training and stretching (axial mobility exercises).
61996259|NCT00665184|ACTIVE_COMPARATOR|Standard Care Control Group|"Standard care exercise group: The standard care control group is an active control group, i.e., individuals who will engage in our standard of care (an evidence based exercise program). These exercises include moderate intensity aerobic training (15 minutes), concentric upper extremity resistance training (5-10 minutes), balance training (5 minutes), and stretching (axial mobility exercises-5-10 minutes)."
62391288|NCT01382758||No acute kidney injury|The patients who do not develop acute kidney injury
62391289|NCT02837874|ACTIVE_COMPARATOR|Isoperistaltic|Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
61996260|NCT02310919|EXPERIMENTAL|Low dose hCG plus FSH co-trigger|On the day of ovulation trigger the patient will receive hCG 1,500 IU SQ plus FSH 450 IU SQ
61996261|NCT02310919|ACTIVE_COMPARATOR|Standard dose of hCG alone|On the day of ovulation trigger the patient will receive standard dose of hCG (10,000 or 5,000 IU SQ)
62391290|NCT02837874|EXPERIMENTAL|Antiperistaltic|Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
62565836|NCT01707160|ACTIVE_COMPARATOR|Treatment period 2|
62565837|NCT02597504|ACTIVE_COMPARATOR|Standardization|individuals assigned to this group will be healthy volunteers and will take the Quick Test.
62565838|NCT02597504|EXPERIMENTAL|Validity and Reliability|"Reliability:~Test-Retest~Validity:~Concurrent:Quick Test administered with ImPACT online Discriminant: Concussed patient administered Quick Test Construct: Determine agreement between Quick Test and and paper and pencil test."
62565839|NCT02157935|ACTIVE_COMPARATOR|Symbicort pMDI|Symbicort pMDI, budesonide/formoterol, 160/4.5 μg x 2 actuations BID, for oral inhalation
62565840|NCT02157935|ACTIVE_COMPARATOR|Formoterol Turbuhaler|Formoterol Turbuhaler, 4.5 μg x 2 actuations BID, for oral inhalation
62565841|NCT03603912|NO_INTERVENTION|Control|Written educational literature on healthy eating and exercise guideline
62565842|NCT03603912|EXPERIMENTAL|Metformin|Metformin ER up to 750 mg twice daily
61996262|NCT00437684|EXPERIMENTAL|A|LPV/r: LPV/r monotherapy and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
61996263|NCT00437684|ACTIVE_COMPARATOR|B|LPV/r+ selected NUCS and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
61996264|NCT02581384|EXPERIMENTAL|Cohort 1 Dose Level 1 [Phase I]|Participants with Wilms tumors or other primary renal tumors. Stereotactic Body Radiotherapy (SBRT) Dose Levels for each target lesion are three 8 Gy fractions for 24 Gy total.
61996265|NCT02581384|EXPERIMENTAL|Cohort 1 Dose Level 2 [Phase I]|Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
61996266|NCT02581384|EXPERIMENTAL|Cohort 1 Dose Level 3 [Phase I]|Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.
61996267|NCT02581384|EXPERIMENTAL|Cohort 2 Dose Level 2 [Phase I]|Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
61996268|NCT02581384|EXPERIMENTAL|Cohort 2 Dose Level 3 [Phase I]|Participants with Ewing sarcoma or rhabdomyosarcoma.SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.
62181379|NCT01804998|ACTIVE_COMPARATOR|Laparoscopy Assisted Gastrectomy|Conventional procedure is laparoscopy assisted gastrectomy in early gastric cancer patient.
62391291|NCT01199913||desflurane and sevoflurane|Subjects will be randomized to either desflurane or sevoflurane. They will be given the Mini Mental State exam at 1, 6 and 24 hours after the end of anesthesia.
62565843|NCT03603912|EXPERIMENTAL|Lifestyle/Risk Factor Modification|Lifestyle/Risk Factor Modification (LRFM): Diet/nutrition, exercise, and risk factor modification
62565844|NCT03603912|EXPERIMENTAL|Metformin + LRFM|Metformin ER up to 750 mg twice daily + Lifestyle/Risk Factor Modification (LRFM) diet/nutrition, exercise, and risk factor modification
62565845|NCT03603912|NO_INTERVENTION|No Atrial Fibrillation|Written educational literature on healthy eating and exercise guideline
61996269|NCT02581384|EXPERIMENTAL|Cohort 2 Dose Level 2 [Phase II]|Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
61996270|NCT00187746|EXPERIMENTAL|Age 18-25 years|African American subjects between the ages 18 to 25 years given Adefovir dipivoxil.
61996271|NCT00187746|EXPERIMENTAL|Age 48-55 years|African American subject between the ages 48 to 55 years given Adefovir dipivoxil.
61996272|NCT03134066||Treatment-resistant depression patients|Subjects with TRD who have been deemed appropriate for (and have decided to receive) clinical, non-research ketamine treatment at the ketamine clinic at Massachusetts General Hospital. As this is an assessment-only observational study, no treatment assignment or randomization procedures will be used.
61996273|NCT03736850|EXPERIMENTAL|CS3006|
62565846|NCT04814381|EXPERIMENTAL|Ketamine + Magnesium|patients in the experimental group will receive 0.5mg/kg of ketamine over 2 hours, diluted in 50cc of NaCl 0.9% and 3g of magnesium sulfate over 30 minutes diluted in 250cc of NaCl 0.9%.
62181380|NCT03980132|EXPERIMENTAL|Preoperative Lugol Solution preparation|Patients will receive Lugol Solution preparation for 10 days before thyroidectomy
62181381|NCT03980132|NO_INTERVENTION|No preparation|Patients will not receive preparation before thyroidectomy
62181382|NCT01691547|EXPERIMENTAL|UMEC/VI+FF|UMEC (500 µg)/VI(100 µg) (blended together) and FF (400 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
62181383|NCT01691547|EXPERIMENTAL|UMEC+VI|UMEC (500 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
62565847|NCT04814381|ACTIVE_COMPARATOR|Control|patients in the control group will receive 25mg of hydroxyzine over 2 hours, diluted in 50cc of NaCl 0.9% and 250cc of NaCl 0.9% over 30 minutes
62565848|NCT04636775||Immunotherapy naïve NSCLC patients|Microbiome in immunotherapy naïve NSCLC patients receiving PD-1/L1 blockade
62565849|NCT06147193|ACTIVE_COMPARATOR|Power training Group|with baseline intervention and power training interventions
62565850|NCT06147193|OTHER|Baseline Group|baseline interventions and without power training interventions
62565851|NCT04931277|OTHER|stepped cataract surgery|
62565852|NCT02204072|EXPERIMENTAL|BI 836845 & Enzalutamide|
62565853|NCT02204072|ACTIVE_COMPARATOR|Enzalutamide|
62565854|NCT03478215|EXPERIMENTAL|Mesenchymal Stromal Stem Cells Infusion|"Intervention: Mesenchymal stromal stem cells infusion. This is the active investigational intervention, administered intravenously at surgery and day 4 post-transplant in a dose-escalation fashion beginning as 1x10\^6 cells for the first dose group, 2x10\^6 cells for the second dose group, or 3x10\^6 cells for the last dose group. The infusion set-up will be covered to mask the group assignment.~Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care."
62565855|NCT03478215|PLACEBO_COMPARATOR|Placebo Infusion|Placebo: A normal saline infusion. This is the placebo intervention to occur at surgery and day 4 post-transplant. The infusion set-up will be covered to mask the group assignment. Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care.
62565856|NCT05786950|EXPERIMENTAL|bronchodilators|compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)
61996274|NCT02978287|NO_INTERVENTION|BAVU Solution 0. hour (control)|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 0. hour
61996275|NCT02978287|EXPERIMENTAL|BAVU Solution 6. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 6. hour
61996276|NCT02978287|EXPERIMENTAL|BAVU Solution 12. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 12. hour
61996277|NCT02978287|EXPERIMENTAL|BAVU Solution 18. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 18. hour
61996278|NCT02978287|EXPERIMENTAL|BAVU Solution 24. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 24. hour
61996279|NCT02995785|OTHER|Experimental:simulation-based training|Experimental
61996280|NCT02995785|OTHER|Active comparatorr: traditional training|Traditional
61996281|NCT04759625|EXPERIMENTAL|Biscuit enriched with mushroom powder|Daily consumption of a novel biscuit enriched with mushroom powder containing 3g of β-glucans
61996282|NCT04759625|PLACEBO_COMPARATOR|Placebo biscuit|Daily consumption of a placebo biscuit
61996283|NCT03010878|EXPERIMENTAL|Yoga Arm|Yoga administered twice a week for 8 weeks. Self-management education sessions administered once a month through the University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic (Pain Clinic). Yoga interventions were administered twice a week at the Pain Clinic.
61996284|NCT03010878|EXPERIMENTAL|Wait-list Control Arm|Participants received only self-management intervention, which is provided once a month through the University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic.
61996285|NCT06167018||Nurse-delivered, gut-directed hypnotherapy|Adult patients suffering from irritable bowel syndrome (IBS), with symptoms refractory to standard treatment. Patients referred to a tertiary care center were included.
62565857|NCT00937573||Xience V|Percutaneous coronary intervention with Xience V stent placement
62565858|NCT00937573||Historical BMS|Percutaneous coronary intervention with bare metal stent placement prior to availability of Cypher, Taxus, or Xience V drug eluting stents at WFUBMC
62565859|NCT00937573||Historical DES|Percutaneous coronary intervention with drug eluting stent placement prior to availability of Xience V drug eluting stents at WFUBMC
62565860|NCT00937573||Contemporary BMS|Percutaneous coronary intervention with bare metal stent placement after Xience V drug eluting stents were available for use at WFUBMC
61996286|NCT02734888|OTHER|Healthy control|"Will undergo PET scan as a negative control"
61996287|NCT02734888|OTHER|Tobacco cigarette smoker|"Will undergo PET scan as a positive control"
61996288|NCT02734888|OTHER|E-cigarette user|Will undergo PET scan
61996289|NCT04977323|EXPERIMENTAL|TICK-B group as intervention group|TICK-B group: The children will receive the pictures they want. They will be asked to trace and color the pictures that need coloring. The nurse will color with children during the procedure. And after the procedure, the child will take his or her picture which he colored during the procedure.
61996290|NCT04977323|EXPERIMENTAL|Watching cartoons|Watching cartoons: In this group, children will watch cartoons as they like. Watching will continue until the procedure is complete.
61996291|NCT04977323|EXPERIMENTAL|Group listening to music|Listening to music: In this group, children will listen to cartoon music as they like. Listen will continue until the procedure is complete.
61996292|NCT04977323|NO_INTERVENTION|Standard care provided group as control group|Control group. The kids in this group will be allowed to keep their family near. The routine blood taking
61996293|NCT04079985|EXPERIMENTAL|Experimental Group|"The experimental Group underwent a therapeutic intervention based on sessions of kinesitherapy , which is defined as a set of therapeutic procedures that use movement for the treatment and prevention of diseases of the locomotive apparatus. The experimental group also underwent AAT. We conducted a total of 12 weekly sessions of 60 minutes each with 10 participants."
61996294|NCT04079985|ACTIVE_COMPARATOR|Control Group|"The Control Group underwent a therapeutic intervention based on sessions of kinesitherapy , which is defined as a set of therapeutic procedures that use movement for the treatment and prevention of diseases of the locomotive apparatus without the presence of the therapy dog."
62181384|NCT01691547|EXPERIMENTAL|FF+VI|FF (400 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
62181385|NCT01691547|EXPERIMENTAL|FF+UMEC|FF (400 µg) and UMEC (500 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
62181386|NCT03628183|ACTIVE_COMPARATOR|Hydrolysate Infant Formula 1|Ready to feed infant formula in can
61996295|NCT00358202|ACTIVE_COMPARATOR|1 cefepime|
61996296|NCT00358202|ACTIVE_COMPARATOR|2 ceftriaxone|
62181387|NCT03628183|EXPERIMENTAL|Hydrolysate Infant Formula 2|Ready to feed infant formula in bottle
62391292|NCT01922336|EXPERIMENTAL|SB2|SB2 (Study drug)
61996297|NCT04633096|EXPERIMENTAL|tailored feedback|Using a randomized-controlled study design one third of the participants will receive individually tailored feedback after depression screening. The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The information is tailored to the participant's individual symptom profile, illness perceptions and preferences.
61996298|NCT04633096|EXPERIMENTAL|standardized feedback|Using a randomized-controlled study design one third of the participants will receive a standard feedback after depression screening. The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
61996299|NCT04633096|NO_INTERVENTION|no feedback|Using a randomized-controlled study design one third of the participants will not receive any feedback.
61996300|NCT00712465|EXPERIMENTAL|1|AZD1305 tablet
61996301|NCT00712465|EXPERIMENTAL|2|AZD1305 tablet + digoxin
61996302|NCT00712465|ACTIVE_COMPARATOR|3|Digoxin
61996303|NCT01607983|EXPERIMENTAL|inhaled nitric oxide|
61996304|NCT05862064|EXPERIMENTAL|Arm-A|"SHR1210 (carrelizumab): 200 mg in combination with chemotherapy (described below) intravenously (IV), Q2W, and famitinib (10 mg) orally once daily (QD). This was followed by maintenance therapy with SHR1210 (carrelizumab) (200 mg, IV every 2 weeks \[Q2W\]) and famitinib (10 mg) orally once daily (QD) to complete treatment with a total duration of 1 year from the first dose.~Chemotherapy: Intensive intravenous dose of epirubicin (80-90 mg/m2) + IV cyclophosphamide (600 mg/m2) repeated administration of Q2W for a total of 4 doses, followed by (IV) paclitaxel (80 mg/m2) once weekly (QW) for 12 weeks."
62181388|NCT01841112|PLACEBO_COMPARATOR|Placebo|Subjects received matching placebo to the BI-409306 (film-coated tablet/s), administered orally on day 1 for single dose (SD) segment and on day 3 to day 9 for multiple dose (MD) segment
62565861|NCT00937573||Contemporary DES|Percutaneous coronary intervention with Cypher or Taxus drug eluting stent placement after Xience V drug eluting stents were available for use at WFUBMC
62565862|NCT02140151|NO_INTERVENTION|Sham|Sham Injection
61996305|NCT05862064|SHAM_COMPARATOR|Arm-B|Chemotherapy: Intensive intravenous dose of epirubicin (80-90 mg/m2) + IV cyclophosphamide (600 mg/m2) repeated administration of Q2W for a total of 4 doses, followed by (IV) paclitaxel (80 mg/m2) once weekly (QW) for 12 weeks.
61996306|NCT00758628|ACTIVE_COMPARATOR|1|Bromfenac
62565863|NCT02140151|ACTIVE_COMPARATOR|Quarterly Ranibizumab 0.5mg|Quarterly intravitreal injection of 0.5mg ranibizumab
62565864|NCT02461433|EXPERIMENTAL|Prevena|After surgery this group will receive the Prevena device (negative pressure wound therapy).
62565865|NCT02461433|ACTIVE_COMPARATOR|Standard dressing|After surgery this group will receive standard of care dressings on their surgical wound.
61996307|NCT00758628|PLACEBO_COMPARATOR|2|Blink
61996308|NCT01250470|EXPERIMENTAL|Treatment (vaccine therapy)|"Patients receive Montanide ISA-51/survivin peptide vaccine SC followed by sargramostim SC on day 0. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~TREATMENT EXTENSION: After completion of study treatment, select patients may receive additional doses of Montanide ISA-51/survivin peptide vaccine SC and sargramostim SC. Treatment repeats every 3 months in the absence of disease progression or unacceptable toxicity."
61996309|NCT06367465||Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c|Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c virus infection and a history of past or current drug use.
62181389|NCT01841112|EXPERIMENTAL|BI-409306 25 milligram (mg) SD|Subjects received 25 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
62181390|NCT01841112|EXPERIMENTAL|BI-409306 50 mg SD|Subjects received 50 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
62181391|NCT01841112|EXPERIMENTAL|BI-409306 100 mg SD|Subjects received 100 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
62391293|NCT01922336|ACTIVE_COMPARATOR|EU Remicade|EU sourced Remicade (Reference drug)
62565866|NCT06008652|EXPERIMENTAL|DR-0201|Subjects in this arm will receive a single dose of DR-0201
62565867|NCT06008652|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive a single dose of placebo
62565868|NCT03832764||ANSPEC-PRO|These patients are selected (after randomized selection) to be monitored non-invasively for pain level via prototype ANSPEC-PRO - correlated to a NRS number given by the awake patient in PACU/ICU.
61996310|NCT00768729|EXPERIMENTAL|1|"Participants who have been maintained on MMF at study entry will start the study on 600 mg/m2 MMF orally daily. Participants who have been maintained on Azathioprine due to MMF intolerance will receive 1 mg/kg Azathioprine orally daily.~Participants will continue receiving sirolimus throughout the study. However, MMF or Azathioprine will be withdrawn gradually over a period of at least 6 months. Dosage will be reduced by 25% initially and by 25% every subsequent 2 months resulting in complete withdrawal by 6 months."
61996311|NCT01855295|EXPERIMENTAL|Protein Supplementation|Hemodialysis patients with inflammation and low body mas index to receive protein dietary advice and protein supplements while on dialysis
61996312|NCT01071928|EXPERIMENTAL|Docetaxel and ASA404 in Combination|
61996313|NCT03324763||stool sampling|
62181392|NCT01841112|EXPERIMENTAL|BI-409306 100 mg MDBI-409306 100 mg SD & MD|Subjects received 100 mg multiple dose of BI-409306 (film-coated tablet/s), administered orally once on day 3 to day 9. A wash-out period of 48 hours was included before the second dose (first does of multipled dose segment) was administered. Subjects were considered for both single dose (following first dose) and multiple dose purposes.
61996314|NCT02721316|EXPERIMENTAL|Supported with intensive nursing follow|Supported with intensive nursing follow post hospitalization the team of hospital output of the unit to 12 weeks after discharge. These interviews will be conducted at the hospital, at home or by phone and their pace will be adjusted according to the patient's condition. The expected duration of close outpatient follow-up is of maximum 3 months.
61996315|NCT02721316|NO_INTERVENTION|usual care|For control patients, monitoring will be identical to their usual care as part of their pathology.
62181393|NCT06338436|EXPERIMENTAL|single-arm objective performance criteria (OPC)|According to the National Medical Products Administration (NMPA) Guidance on Proton and Carbon Ion treatment system clinical evaluation and clinical trial, the objective performance criteria for the validity of medical device treatment for trial use should be at least 80%, with an expected target of 95% in which the validity is defined as: Complete Response (CR) + Partial Response (PR)+ Stable Disease (SD), and the definition of tumor disease control rate in this clinical trial is basically identical. Therefore, the clinical trial did not have a control group, but using single-arm objective performance criteria, when evaluating ProBeam radiotherapy for tumor patients, the main validity evaluation index of tumor disease control rate; the main safety evaluation by incident of acute radiation injury and adverse event.
61996316|NCT03594097|EXPERIMENTAL|Treatment cookies|
61996317|NCT03594097|ACTIVE_COMPARATOR|Control cookies|
61996318|NCT00714064|ACTIVE_COMPARATOR|23vPPV in Pregnancy|
61996319|NCT00714064|ACTIVE_COMPARATOR|23vPPV at Birth|
61996320|NCT00714064|OTHER|Control|Control
62181394|NCT02765308||Healthy volunteers|healthy age matched with cases volunteers as controls
62181395|NCT02765308||Uveitis with raised IOP|Recurrent (\> 5 attacks) idiopathic acute anterior uveitic with raised intraocular pressure
61996321|NCT02459977|EXPERIMENTAL|No basiliximab group|The investigators omit basiliximab induction therapy in one to three-HLA mismatched living donor renal transplants.
61996322|NCT02459977|ACTIVE_COMPARATOR|Basilixiab group|Age and sex matched patients who underwent one to three-HLA mismatched living donor renal transplants with basiliximab induction therapy (Control group)
61996323|NCT02457403|EXPERIMENTAL|ROTEM|Transfusion guided by ROTEM during OLT
61996324|NCT02457403|ACTIVE_COMPARATOR|Conventional|Transfusion guided by conventional labs
61996325|NCT04090593|EXPERIMENTAL|Educational Module Intervention|Intervention arm patients receive educational mobile module related to chronic condition that contributed to reason for admission.
61996326|NCT04090593|NO_INTERVENTION|Hospital Practice Control|Control arm patients receive current, standard practice as related to patient education in the hospital (this does not include an educational mobile module).
61996327|NCT02268409|EXPERIMENTAL|Luspatercept Extension Population|Participants receive luspatercept 0.6, 0.8, 1.0, or 1.25 mg/kg administered by subcutaneous injection on Day 1 of each 21-day cycle for up to 87 cycles (up to approximately 5 years). Participants will receive the highest tolerated dose level of luspatercept that they were assigned in the base study unless a dose modification was required.
61996328|NCT00889083||Control|Non septic patients needing hepatic surgery
61996329|NCT00889083||Sepsis|Septic patients needing surgery for peritonitis
61996330|NCT00684606|EXPERIMENTAL|1|Transcervical Foley catheter with IV Oxytocin
62565869|NCT03832764||MEDSTORM|These patients are selected (after randomized selection) to be monitored non-invasively for pain level via MEDSTORM - correlated to a NRS number given by the awake patient in PACU/ICU.
62565870|NCT00527774||A|HCV(+) maintenance hemodialysis patients
61996331|NCT00684606|NO_INTERVENTION|2|Transcervical Foley catheter only
62181396|NCT02765308||Uveitis with with normal IOP|Recurrent (\> 5 attacks) idiopathic acute anterior uveitic with normal intraocular pressure
62181397|NCT02735356|EXPERIMENTAL|Treatment (itraconazole and placebo)|Patients apply itraconazole topically BID and placebo topically BID for 12 weeks.
62181398|NCT01061853|EXPERIMENTAL|T|TOPICAL SIROLIMUS AND PETROLATUM IN ORABASE
62181399|NCT01061853|ACTIVE_COMPARATOR|C|TOPICAL BETAMETHASONE 0.05% in ORABASE AND PHOSAL
62565871|NCT00527774||B|HCV(-) maintenance hemodialysis patients
62565872|NCT05079542|EXPERIMENTAL|Immediate implant placement|Implant is placed immediately after tooth extraction.
62565873|NCT05079542|ACTIVE_COMPARATOR|Delayed implant placement|Implant is placed 8 weeks after tooth extraction.
61996332|NCT01331616|EXPERIMENTAL|Bevacizumab (Avastin)|
61996333|NCT00504686|ACTIVE_COMPARATOR|1|manual therapy - thoracic spine thrust manipulation
61996334|NCT00504686|ACTIVE_COMPARATOR|2|therapeutic exercise
61996335|NCT05764213|NO_INTERVENTION|Screening Brief Intervention & Referral to Treatment (SBIRT)|This group will receive in-person screening and referral to treatment assessment.
61996336|NCT05764213|EXPERIMENTAL|Listening to Women & Pregnant & Postpartum People (LTWP)|This group will receive text-message-based SBIRT with phone-based assessment and referral to treatment. The SBIRT is a survey with 9 questions related to depression, anxiety, substance abuse (alcohol, cigarettes, and other drugs including prescription medication), and domestic violence.
61996337|NCT05155384|EXPERIMENTAL|biopsychosocial model-based treatment|Biopsychosocial model-based management will be applied including pain neuroscience education, functional exercises, and relaxation training.
61996338|NCT05155384|ACTIVE_COMPARATOR|Conventional physiotherapy|Conventional physiotherapy will be applied including standard exercises and electrical stimulation.
61996339|NCT03164967|OTHER|Active Drug|All subjects will receive Bivigam based on their prior dosing to be adjusted as clinically necessary.
61996340|NCT02016625|EXPERIMENTAL|1 Cyclosporine + Faldaprevir|
61996341|NCT02016625|EXPERIMENTAL|2 Tacrolimus + Faldaprevir|
61996342|NCT03547713|EXPERIMENTAL|Study group|social feedback and neuropsychological assessment
62181400|NCT02146521||patients undergoing CT|Emergency department's patients undergoing CT scanning for evaluation of acute abdominal pain and tenderness
62181401|NCT01087749|EXPERIMENTAL|Chronic Kidney Disease|Propranolol, Losartan, and Eprosartan will be administered to patients who have been diagnosed with Chronic Kidney disease and have a glomerular filtration rate (GFR) below 40ml/min.
62181402|NCT01087749|EXPERIMENTAL|Healthy Volunteers|Propranolol, Losartan, and Eprosartan will be administered to healthy volunteers without chronic kidney disease.
62565874|NCT05079542|EXPERIMENTAL|Lithium disilicate crown|Crown out of Lithiumdisilicate is inserted onto the implant.
62565875|NCT05079542|ACTIVE_COMPARATOR|Zirconia Crown|Crown out of Zirconia is inserted onto the implant.
62565876|NCT02540382|EXPERIMENTAL|covered stent|"Procedure/Surgery: Jugular vein puncture and catheterization. Device: RUPS-100 (COOK Company) sheath, 8 mm balloon, Pigtail catheter, 8 mm covered stents (Bard, Fluency).~Drug (including placebo): No Biological/Vaccine: No Radiation: No Behavioral (e.g., Psychotherapy, Lifestyle Counseling): No Genetic (including gene transfer, stem cell and recombinant DNA): No Dietary Supplement (e.g., vitamins, minerals): No."
61996343|NCT02086942|EXPERIMENTAL|modified VCD regimen1|"Induction therapy：modified VCD regimen1 for 4 cycles,28 Days per Cycle.Intensive therapy：modified VCD regimen1 for 5 cycles.~Maintenance treatment:CP for 12 cycles. Interval between every two cycles for one month.~Interventions:~Drug: Bortezomib 1.6mg/m2 SC,Days 1, 6, 11, 16; Drug:Cyclophosphamide 300mg/m2 VD,Days 1-3; Drug: Dexamethasone 40 mg/d VD,Days 1, 6, 11,16; We undertook a pharmacodynamic substudy at selected sites. Blood samples were collected in cycle 1 on day 1, 6,11,16 before the dose was given and at several time points after dosing. We analysed whole blood samples to measure 20S proteasome chymotryptic activity, with a standard method. Pharmacodynamic parameters were calculated by analysis of percentage inhibition of 20S proteasome activity-time data."
61996344|NCT02086942|EXPERIMENTAL|modified VCD regimen2|"Induction therapy：modified VCD regimen1 for 4 cycles,28 Days per Cycle.Intensive therapy：modified VCD regimen 2 for 5 cycles.~Maintenance treatment:CP for 12 cycles. Interval between every two cycles for one month.~Interventions:~Drug: Bortezomib 1.3mg/m2 SC,Days 1, 6, 11, 16; Drug:Cyclophosphamide 300mg/m2 VD,Days 1-3; Drug: Dexamethasone 40 mg/d VD,Days 1, 6, 11,16; We undertook a pharmacodynamic substudy at selected sites. Blood samples were collected in cycle 1 on day 1, 6,11,16 before the dose was given and at several time points after dosing. We analysed whole blood samples to measure 20S proteasome chymotryptic activity, with a standard method. Pharmacodynamic parameters were calculated by analysis of percentage inhibition of 20S proteasome activity-time data."
61996345|NCT05522465|EXPERIMENTAL|prednisone group|prednisone 4mg/kg.d
61996346|NCT05522465|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone 0.6mg/kg.d
61996347|NCT04736797||Patient|Transgender people who seek hormone treatment
61996348|NCT04736797||Control participants|volunteers without gender dysphoria
61996349|NCT06440031|EXPERIMENTAL|CaMaPi|
61996350|NCT06440031|ACTIVE_COMPARATOR|TAU|
61996351|NCT00819988|PLACEBO_COMPARATOR|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
61996352|NCT00819988|EXPERIMENTAL|Pregabalin|Single dose of 75 mg given 30-60 minutes preoperatively, then 50 mg every 8 hours for 3 days postoperatively if creatinine clearance \> 60 ml/min OR 25 mg every 8 hours for 3 days postoperatively if creatinine clearance 30-60 ml/min
61996353|NCT01939587|EXPERIMENTAL|PBF-680 5 mg|5 mg of PBF-680
61996354|NCT01939587|EXPERIMENTAL|PBF-680 20 mg|20 mg of PBF-680
61996355|NCT01939587|PLACEBO_COMPARATOR|Placebo|Placebo
62565877|NCT02540382|OTHER|bare stent|"Surgery: Jugular vein puncture and catheterization. Device: RUPS-100 (COOK Company) sheath, 8 mm balloon, Pigtail catheter, 8 mm bare stents (EV3, protégé; Cordis, Smart).~Drug (including placebo): No Biological/Vaccine: No Radiation: No Behavioral (e.g., Psychotherapy, Lifestyle Counseling): No Genetic (including gene transfer, stem cell and recombinant DNA): No Dietary Supplement (e.g., vitamins, minerals): No."
62565878|NCT02546375||Chronic Myeloid Leukaemia|Patients diagnosed with chronic myeloid leukaemia treated with Bosutinib
62565879|NCT01958437|EXPERIMENTAL|Cognitively intact older adults - ACTIVE tDCS|Group receives active brain stimulation
61996356|NCT02180516||Meloxicam|
61996357|NCT02180516||Other NSAIDs|
61996358|NCT01871363|EXPERIMENTAL|preoperative chemoradiation|"* radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.~* capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),~* bevacizumab: at dose 5 mg/kg on days -1, 15,31.~* Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
61996359|NCT01538862|EXPERIMENTAL|Granulocyte Colony Stimulating Factor (GCSF)|GCSF 10mcg/kg/d subcutaneously (SQ) for 7 days
61996360|NCT04781634|EXPERIMENTAL|prime CAR- T cells|Patients will be be treated with CD19 and CD22 prime CAR- T cells
61996361|NCT05905484|EXPERIMENTAL|Bemnifosbuvir (BEM) therapeutic dose|oral tablets
61996362|NCT05905484|EXPERIMENTAL|Bemnifosbuvir (BEM) supratherapeutic dose|oral tablets
61996363|NCT05905484|PLACEBO_COMPARATOR|Placebo|oral tablets
61996364|NCT05905484|ACTIVE_COMPARATOR|Moxifloxacin|oral tablet
61996365|NCT06391788|EXPERIMENTAL|Thoracoscopic trans-mitral myectomy|patients who undergo thoracoscopic Morrow procedure
62565880|NCT01958437|ACTIVE_COMPARATOR|MCI ACTIVE tDCS|Group receives active brain stimulation
62565881|NCT01958437|SHAM_COMPARATOR|Cognitively intact older adults - SHAM tDCS|Group receives sham brain stimulation
61996366|NCT06391788|ACTIVE_COMPARATOR|Modified extended Morrow myectomy|patients who undergo modified extended Morrow myectomy
61996367|NCT04116645||Group 1|singleton pregnancies
62181403|NCT00822666|ACTIVE_COMPARATOR|1|patients homozygous for the 2C19\*1 genetic variant
62565882|NCT01958437|SHAM_COMPARATOR|MCI SHAM tDCS|Group receives sham brain stimulation
61996368|NCT04116645||Group 2|Twin pregnancies
61996369|NCT00984581|EXPERIMENTAL|Intradermal avotermin|
61996370|NCT00984581|PLACEBO_COMPARATOR|Placebo|
61996371|NCT02561975|EXPERIMENTAL|Patient suffering from complex congenital heart disease|
62565883|NCT04146792|EXPERIMENTAL|body acceptance program|
62565884|NCT04146792|ACTIVE_COMPARATOR|writing creativity program|
62565885|NCT02583451|EXPERIMENTAL|Treatment A|Treatment A is a placebo tablet matching lemborexant and placebo tablet matching zopiclone on nights in the clinic; placebo tablet matching lemborexant on nights at home.
62565886|NCT02583451|EXPERIMENTAL|Treatment B|Treatment B is zopiclone 7.5 mg tablet and placebo tablet matching lemborexant on nights in the clinic; placebo tablet matching lemborexant on nights at home.
62181404|NCT00822666|EXPERIMENTAL|2|carriers of the 2C19\*2 genetic variant (homozygous or heterozygous)
62181405|NCT02224183|ACTIVE_COMPARATOR|Education|Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.
62565887|NCT02583451|EXPERIMENTAL|Treatment C|Treatment C is lemborexant 2.5 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 2.5 mg tablet on nights at home.
62565888|NCT02583451|EXPERIMENTAL|Treatment D|Treatment D is lemborexant 5 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 5 mg tablet on nights at home.
61996372|NCT02630784|EXPERIMENTAL|Homecare ventilator|NIV with a dedicated ventilator for homecare, functioning with a turbine and with vented mask (exhalation by a calibrated leak)
61996373|NCT02630784|ACTIVE_COMPARATOR|ICU ventilator|NIV with a dedicated ICU ventilator, functioning with non-vented masks and an exhalation valve.
61996374|NCT00805766|EXPERIMENTAL|TA-650|
61996375|NCT01520116|EXPERIMENTAL|Stage 1 - Arm 1 - Dose 1|
61996376|NCT01520116|EXPERIMENTAL|Stage 1 - Arm 2 - Dose 2|
61996377|NCT01520116|EXPERIMENTAL|Stage 1 - Arm 3 - Dose 3|
61996378|NCT01520116|EXPERIMENTAL|Stage 1 - Arm 4 - Dose 4|
61996379|NCT01520116|PLACEBO_COMPARATOR|Stage 1 - Arm 5 - Vehicle|
61996380|NCT01520116|EXPERIMENTAL|Stage 2 - Arm 1 - Dose A - to be selected based on Stage 1|
61996381|NCT01520116|EXPERIMENTAL|Stage 2 - Arm 2 - Dose B - to be selected based on Stage 1|
61996382|NCT01520116|ACTIVE_COMPARATOR|Stage 2 - Arm 3 -Timoptic 0.5% BID|
61996383|NCT02501980||Screening|All participants will be tested for HBsAg by using serum samples. Among those who are positive for HBsAg, further clinical work-ups including AFP test and ultrasonography for liver exam will be performed. Repeated check-ups will be performed in 6-months among HBsAg positive group and 3-years among HBsAg negative group.
61996384|NCT02501980||Non-screening|All subjects in this arm will be followed by linkage to Cancer Register and Population Register.
62565889|NCT02583451|EXPERIMENTAL|Treatment E|Treatment E is lemborexant 10 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 10 mg tablet on nights at home.
62772838|NCT01972789|EXPERIMENTAL|Relaxed retinal fluid regimen|Ranibizumab 0.5mg is given monthly for the first 3 months followed by an individualised treatment regimen as determined by disease activity defined by a loss of ≥5 letters, new retinal haemorrhage, presence of IRF or SRF \>200 um on OCT.
62181406|NCT02224183|ACTIVE_COMPARATOR|Yoga|Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
62181407|NCT02361177|EXPERIMENTAL|oxytocin|Intranasal 24 IU oxytocin self-administration.
62565890|NCT03408938||Continuous Hb monitoring with Masimo Radical|"Plethysmography Variability Index (PVI) is a measure of the dynamic changes in the perfusion index (PI) that occur during the respiratory cycle . PVI = ﴾PI Max - PI Min﴿ ÷ PI Maxx 100 %.~PVI has the potential to provide useful information concerning changes in the balance between intrathoracic airway pressure and intravascular fluid volume. Trending of PVI may be useful in monitoring surgical patients, both intraoperatively and postoperatively, for appropriate hydration states. For example, a rising PVI may indicate developing hypovolemia and gives an alarm for the need of appropriate fluid and or blood products transfusion supported by the patient hemoglobin level"
62565891|NCT03856125|EXPERIMENTAL|PENS plus exercise group|4-week intervention program with 2 weekly treatment sessions, one of percutaneous electrical stimulation and supervised exercise and the other one, domiciliary exercise.
61996385|NCT00806884|OTHER|Control Arm1|Normal optimal medical and physiotherapy treatment
61996386|NCT00806884|EXPERIMENTAL|Treatment Arm 2|Physiotherapy musculoskeletal interventions in addition to normal optimal medical and physiotherapy care
61996387|NCT02787473|EXPERIMENTAL|pemetrexed+carboplatin/cisplatin+radiation therapy->docetaxel|Patients received pemetrexed 500mg/m2 days 1,29+cisplatin 25 mg/m2 days 1-3,29-31 + Radiation 6000 cGy (200 cGy/day). Patients with complete response(CR), partial response(PR) or stable disease(SD) with manageable toxicity received docetaxel 60 mg/m2 days 57,78.
61996388|NCT05894642||Long Covid Pain Patients|
61996389|NCT05894642||Control Group, healthy people|Patients that had had Covid-19 but did not developed chronic pain or other chronic symptoms.
61996390|NCT02858245||Commercial MitraClip® patients|Patients with Degenerative Mitral Regurgitation receiving MitraClip® Device
61996391|NCT02972216||Nolbaxol|For Nonsmall Cell Lung Cancer (NSCLC) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour every 3 weeks (a study medication cycle) and up to 4 study medication cycles throughout this study. For Squamous Cell Carcinoma of the Head and Neck (SCCHN) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour followed by cisplatin 60 \~ 75 mg/m2 for 1-3 hours or based on the general practice of the site every 3 weeks and up to 4 study medication cycles throughout this study.
62181408|NCT02361177|PLACEBO_COMPARATOR|placebo|Intranasal placebo. 125 mg of 0.5% cholorobutanol to 50 ml saline, with approximately 5 pH. The solution will then be sterilized using a 0.22 micron filter.
62181409|NCT01964339||BMI greater than or equal to 30kg/m2 -venous|BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.
62181410|NCT01964339||BMI greater than or equal to 30kg/m2 - arterial|BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.
62181411|NCT00143741|OTHER|Lipitor|
62391294|NCT01922336|ACTIVE_COMPARATOR|US Remicade|US sourced Remicade (Reference drug)
62181412|NCT02204319|EXPERIMENTAL|Cold Laser Treatment|Cold laser used off of the body over the vulvar involved area. The device to be used in this study is the Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device. Weekly visits x 6 with 5 minute treatments over vulva and sacral nerve roots each.
61996392|NCT02972216||Taxotere|For Nonsmall Cell Lung Cancer (NSCLC) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour every 3 weeks (a study medication cycle) and up to 4 study medication cycles throughout this study. For Squamous Cell Carcinoma of the Head and Neck (SCCHN) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour followed by cisplatin 60 \~ 75 mg/m2 for 1-3 hours or based on the general practice of the site every 3 weeks and up to 4 study medication cycles throughout this study.
61996393|NCT05180461|EXPERIMENTAL|Part 0 Pilot group emodepside 15mg Once a day (OD) 1 day|emodepside tablets 15 milligrams once a day for 1 day
61996394|NCT05180461|EXPERIMENTAL|Part 1 emodepside 30mg OD 1 day|emodepside tablets 30 milligrams once a day for 1 day
62181413|NCT06209047|EXPERIMENTAL|drug group|this arm will include half number of cases(which will be 35 cases) selected in a randomized manner and will undergo bronchoscopic airway clearance followed by local instillation of gentamicin(80 mg once) and dexamethasone(5 mg) once.
62181414|NCT06209047|NO_INTERVENTION|control group|his arm will include the other half number of cases(35 cases) selected in a randomized manner and will receive only conventional treatment without intervention.
62181415|NCT05382598|ACTIVE_COMPARATOR|Early renal replacement therapy (RRT) group|"In this group of patients, RRT will be initiated if the patient either presents with or develops AKI, while mechanically ventilated, provided that he is in stage 2 according to KDIGO classification.~RRT will not be delayed till the presence of an urgent indication for the procedure.~A trial of furosemide stress test will be applied before proceeding towards early RRT after volume optimization."
62181416|NCT05382598|ACTIVE_COMPARATOR|Late renal replacement therapy (RRT) group|"This group of patients will receive RRT if they develop any of the following indications:~* Severe hyperkalemia (\> 6.5 mEq/L).~* Oliguria with failed response to diuretics in the presence of life-threatening pulmonary edema requiring high ventilatory settings i.e. PEEP \>10 in addition to FiO2 \> 50%.~* Severe metabolic acidosis (PH \<7.15).~* Uremic pericarditis, encephalopathy or coagulopathy."
62181417|NCT02282059||sunitinib group|patients with progressive, unresectable, advanced or metastatic well-differentiated pNET
62181418|NCT01137877|ACTIVE_COMPARATOR|Infant Formula #1|Milk-based Infant Formula Powder
62181419|NCT01137877|EXPERIMENTAL|Investigational Infant Formula #1|Investigational Milk-based Infant Formula Powder
61996395|NCT05180461|EXPERIMENTAL|Part 1 emodepside 15mg OD 7 days|emodepside tablets 15 milligrams once a day for 7 days
61996396|NCT05180461|EXPERIMENTAL|Part 1 emodepside 15mg OD 14 days|emodepside tablets 15 milligrams once a day for 14 days
61996397|NCT05180461|EXPERIMENTAL|Part 1 emodepside 15mg twice a day (BID) 10 days|emodepside tablets 15 milligrams twice a day for 10 days
61996398|NCT05180461|PLACEBO_COMPARATOR|Part 1 placebo|matching placebo of emodepside tablets
62181420|NCT01137877|EXPERIMENTAL|Investigational Infant Formula #2|Investigational Milk based infant formula powder
62181421|NCT01137877|ACTIVE_COMPARATOR|Human Milk|Reference group
62181422|NCT04970693|EXPERIMENTAL|Furmonertinib 80mg combined with radiotherapy|This group will enroll NSCLC patients who are oligoprogressive after first/second generation EGFR-TKI therapy. These patients will receive furmonertinib 80mg combined with radiotherapy as following therapy.
62181423|NCT04970693|EXPERIMENTAL|Furmonertinib 160mg combined with radiotherapy|This group will enroll NSCLC patients who are oligoprogressive after third generation EGFR-TKI therapy. These patients will receive furmonertinib 160mg combined with radiotherapy as following therapy.
61996399|NCT05180461|EXPERIMENTAL|Part 2 emodepside dose regimen A|emodepside tablets, dose regimen A selected from regimens tested in Part 1
61996400|NCT05180461|EXPERIMENTAL|Part 2 emodepside dose regimen B|emodepside tablets, dose regimen B selected from regimens tested in Part 1
61996401|NCT05180461|ACTIVE_COMPARATOR|Part 2 ivermectin|ivermectin, single oral dose of 150 micrograms per kilogram by weight
61996402|NCT01515800|EXPERIMENTAL|Text message reminder|Patients undergo a text message education checklist involving confirmation of cellular telephone capability to receive text messages, how to retrieve and read messages, including a confirmation evaluation, at baseline and at any time a patient obtains a new cellular telephone. Patients then receive a text message twice a week at 8 o'clock in the morning (for each time zone) for up to 3 years. Additionally, patients receive standard follow-up care.
61996403|NCT01515800|NO_INTERVENTION|No text message reminder|Patients receive standard follow-up care.
62181424|NCT04219878|ACTIVE_COMPARATOR|Know@Home App or Website and Test Kit|Participants in this study arm will have access to Know@Home, a mobile HIV prevention app or website and will receive mail-out HIV self-testing kits.
62181425|NCT04219878|ACTIVE_COMPARATOR|Mail-Out Testing Kit Only|Participants in this study arm will receive mail-out HIV self-testing kits.
62565892|NCT03856125|SHAM_COMPARATOR|Sham PENS plus exercise group|4-week intervention program with 2 weekly treatment sessions, one of sham percutaneous electrical stimulation and supervised exercise and the other one, domiciliary exercise.
62181426|NCT00521443||Normal|Embryos derived from morphologically normal MII oocytes
61996404|NCT06032312||1|metabolic healthy obese
62181427|NCT00521443||Irregular Shapes|Embryos derived from irregularly shaped oocytes.
62181428|NCT00521443||Large PVS|Embryos derived from oocytes with large perivitelline space.
62181429|NCT00521443||Dark Zona|Embryos derived from oocytes with dark zona pellucida
62181430|NCT00521443||Dark cytoplasm|Embryos derived from oocytes with dark cytoplasm
62565893|NCT02965573|ACTIVE_COMPARATOR|ARGX-113|During the Treatment period, eligible patients will be randomized at a 1:1 ratio to receive ARGX-113
62565894|NCT02965573|PLACEBO_COMPARATOR|Placebo|During the Treatment period, eligible patients will be randomized at a 1:1 ratio to receive placebo
61996405|NCT06032312||2|metabolic unhealthy obese
61996406|NCT03023085|EXPERIMENTAL|BLI4700|BLI4700 Bowel Preparation
62181431|NCT00521443||Vacuolar cytoplasm|Embryos derived from oocytes with vacuolated cytoplasm
62181432|NCT00521443||Central granulation|Embryos derived from oocytes with centrally granulated cytoplasm
62181433|NCT00521443||Double extra|Embryos derived from oocytes with double extracytoplasmic abnormalities
62181434|NCT00521443||Double combined|Embryos derived from oocytes with any combination of one extracytoplasmic and one cytoplasmic anomaly
62181435|NCT00521443||Double cytoplasmic|Embryos derived from oocytes with any two cytoplasmic anomalies
62181436|NCT00521443||Triple extra|Embryos derived from oocytes with triple extracytoplasmic anomaly
62181437|NCT00521443||Triple combined|Embryos derived from oocytes with triple combined anomalies
62181438|NCT02360865|EXPERIMENTAL|COPD|Acute exercise bouts
62181439|NCT02360865|ACTIVE_COMPARATOR|Healthy|Acute exercise bouts
62181440|NCT05673499||Infants|Infant subjects ≤ 60 weeks post-menstrual age who are undergoing surgery for congenital malformations
62181441|NCT04059887|EXPERIMENTAL|Atezolizumab|Atezolizumab 1200 mg will be administrated every 3 week cycle
62181442|NCT04673877|EXPERIMENTAL|Bier Block Group|Subjects will receive antibiotic Vancomycin from a Bier Block (injected into an arm vein with a tourniquet up to keep antibiotics in the arm). Samples will be collected from bone and tissue that is normally removed during surgery.
62391295|NCT00498069|ACTIVE_COMPARATOR|1|Injection of autologous bone marrow concentrate into ischemic tissues of the lower extremity
61996407|NCT04779866|EXPERIMENTAL|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
61996408|NCT04779866|ACTIVE_COMPARATOR|White Noise Hypnosis Control|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
61996409|NCT06146036|EXPERIMENTAL|HIIT snacks|3 x 6×1 minute cycling intervals at 90% at HRmax
61996410|NCT06146036|EXPERIMENTAL|Sprint snaks|3×20-second 'all-out' cycling with 1-4 hours recovery between sprints
61996411|NCT06146036|EXPERIMENTAL|Control|No exercise. Rest.
61996412|NCT02101502|ACTIVE_COMPARATOR|Institutional Capacity|Questioner for institutional employee about Institutional Capacity
62181443|NCT04673877|ACTIVE_COMPARATOR|Systemic Intravenous IV Group|Subjects will receive antibiotic Vancomycin through intravenous administration. Samples will be collected from bone and tissue that is normally removed during during surgery.
62181444|NCT02026245|EXPERIMENTAL|5DT electronic data glove|"Using the electronic data gloves to perform a set routine of movements.~Intervention: Data gloves to perform movements"
62181445|NCT02026245|EXPERIMENTAL|Tyndall/UU electronic data glove|"Using the electronic data gloves to perform a set routine of movements~Intervention: Data gloves to perform movements"
62181446|NCT00176475|EXPERIMENTAL|Therapeutic allogeneic lymphocytes with rituximab|
61996413|NCT02101502|ACTIVE_COMPARATOR|Educational Effectiveness|Questioner for medical and assistant staffs about Educational Effectiveness
62565895|NCT01930162|EXPERIMENTAL|HSC835|Patients with hematologic malignancies requiring UCB transplant with a NMA conditioning regimen.
61996414|NCT02101502|ACTIVE_COMPARATOR|Health-care|Questioner for medical, assistant staffs and patients about Quality Assurance System in Health-care
61996415|NCT06137443|EXPERIMENTAL|Balance Training|The study included five participants who were over 18 years of age and had experienced a spinal injury within the past year. These participants were classified as AIS D (American Spinal Injury Association Impairment Scale). Patients underwent treatment for eight weeks, with walking and balance exercises on Andago performed three days a week. In addition, conventional in-bed exercises, including stretching, strengthening, and mobility exercises, were administered for 40 minutes, two days a week.
61996416|NCT03759756||AI visible group|the endoscopic novices analyzing the images can see the automatic diagnosis of AI during the process
61996417|NCT03759756||AI invisible group|the endoscopic novice analyzing the images can not see the automatic diagnosis of AI during the process
61996418|NCT04766242|EXPERIMENTAL|Intervention group|The intervention group will receive 10 healing session of 45-60 minutes as an adjunct to usual care, approximately once a week.The usual care will consist of the treatment plan made by their GP when they were diagnosed with moderate depression.
61996419|NCT04766242|OTHER|Control group|The control group will receive usual care as prescribed by their GP when they were diagnosed with moderate depression.
61996420|NCT02084628|EXPERIMENTAL|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole \[mmol\]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent \[%\] solution) manually.
61996421|NCT04134247|EXPERIMENTAL|PD-1 combined with chemotherapy|21 days every cycle, assessment after 3-cycle
61996422|NCT04134247|ACTIVE_COMPARATOR|chemotherapy|21 days every cycle, assessment after 3-cycle
61996423|NCT02211469|EXPERIMENTAL|Panel 1: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
61996424|NCT02211469|EXPERIMENTAL|Panel 2: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
62181447|NCT01501292||Immature oocytes (GV, M-I)|
62181448|NCT01501292||Mature oocytes (M-II)|
62181449|NCT01009138|EXPERIMENTAL|Diabetes-Specific CBT (DS-CBT)|Cognitive Behavioral Intervention (Group) focusing on Diabetes-Specific Problems
62181450|NCT01009138|ACTIVE_COMPARATOR|Standard Diabetes Education|Standard Diabetes Education Lessons will be given to quantify the unspecific antidepressive Effects of Participation in Group Sessions with social Contact and Acquisition of Knowledge.
62181451|NCT03336697||Parkinson's disease subjects|Patients with untreated or treated Parkinson's disease ages 45-75.
61996425|NCT02211469|EXPERIMENTAL|Panel 3: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
61996426|NCT02211469|EXPERIMENTAL|Panel 4: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
62181452|NCT03336697||Healthy control subjects|Healthy control subjects ages 45-75.
61996427|NCT06034509||TBI Group|Participants in this group will have been identified as sustaining a traumatic brain injury (mild, moderate, severe, or penetrating).
61996428|NCT06034509||High-blast exposed control group|Participants in this group will have no history of traumatic brain injury AND will have a lifetime history of greater than 10 blast exposures.
61996429|NCT06034509||Low-blast exposed control group|Participants in this group will have no history of traumatic brain injury AND will have a lifetime history of less than 10 blast exposures.
61996430|NCT01236755|EXPERIMENTAL|ortho-k lenses|Children were switched to wear ortho-k lenses for 7 months after wearing single-vision glasses for 7 months
61996431|NCT04911738|EXPERIMENTAL|Plane A for the cross-over (Immersion in a virtual tilted room)|"Half of participants will perform the experiment according the plane A, which corresponds to the following order: verticality perception (Baseline, effect during the intervention, post-effect), then active vertical body orientation (Baseline, effect during the intervention). The intervention is an immersion in a virtual static and tilted environnement (18°).~During the intervention, participants will be immersed in a virtual tilted room for 15 minutes (after 5 minutes of pre -installation adjustments), then verticality perception or active body orientation assessments are performed while the participant is still virtually immersed (approximately 25 minutes). Participants will be immersed in a tilted virtual room for 45 minutes each day."
61996432|NCT04911738|EXPERIMENTAL|Plane B for the cross-over (Immersion in a virtual tilted room)|"Half of participants will perform the experiment according the plane B, which corresponds to the following order: active vertical body orientation (Baseline, effect during the intervention), then verticality perception (Baseline, effect during the intervention, post-effect). The intervention is an immersion in a virtual static and tilted environnement (18°).~During the intervention, participants will be immersed in a virtual tilted room for 15 minutes (after 5 minutes of pre -installation adjustments), then verticality perception or active body orientation assessments are performed while the participant is still virtually immersed (approximately 25 minutes). Participants will be immersed in a tilted virtual room for 45 minutes each day."
62181453|NCT04517877|EXPERIMENTAL|Caring Light Training|Caring Light mobile app with coping skills training.
61996433|NCT04632251|OTHER|Familiarisation|The first 2 patients per site (N = 10 in total) are considered to be sufficient to enable further familiarisation with the procedure and use of the probe in addition to the usability work and training that the sites did prior to the start of this study.
61996434|NCT05825898||Conservative management|Patients with TR who did not undergo a tricuspid valve intervention
61996435|NCT05825898||Isolated tricuspid valve surgery|Patients with TR who underwent a Isolated tricuspid valve surgery.
61996436|NCT05825898||Transcatheter tricuspid valve intervention|Patients with TR who underwent a transcatheter tricuspid valve intervention.
61996437|NCT01763775|EXPERIMENTAL|Transtek 125X|Which measured by DUT (Transtek 125X): GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B.
61996438|NCT01763775|EXPERIMENTAL|Transtek 950D|Measured by Reference (Transtek 950D): GBF-950-D.
61996439|NCT06058195||Group QLB (quadratus lumborum plane block)|"Group QLB (quadratus lumborum plane block): 20 ml of 0.25% bupivacaine will be used each time for plane block on both sides. Patients will be sedated with 1 mg midazolam and 50 mcg fentanyl intravenously in the preoperative preparation room in the operating room and 20 ml of 0.25% bupivacaine was administered bilaterally on each side under ultrasound guidance. After the block application, the patient was taken to the operating room and standard general anaesthesia was applied.~- Plane block applications will be applied only once in the preoperative period"
61996440|NCT06058195||Group TAPB (transverse abdominis plane block)|Group TAPB (transverse abdominis plane block): 20 ml of 0.25% bupivacaine will be used each time for plane block on both sides. Patients will be sedated with 1 mg midazolam and 50 mcg fentanyl intravenously in the preoperative preparation room in the operating room and 20 ml of 0.25% bupivacaine was administered bilaterally on each side under ultrasound guidance. After the block application, the patient was taken to the operating room and standard general anaesthesia was applied.
61996441|NCT06058195||Group IVA (Intravenous analgesia)|Group IVA (Intravenous analgesia): These patients will be administered 1000 mg paracetamol intravenously in the preoperative waiting room in the operating room approximately 20-30 minutes before induction of anaesthesia. No block procedure will be performed. Patients will not be given any analgesic medication before awakening from anaesthesia.
62181454|NCT04517877|ACTIVE_COMPARATOR|Educational Training|Traditional educational program.
62181455|NCT05019313||COVID 19 positive patients|"COVID19 positive patients with hypoxemic acute respiratory failure hospitalized in intensive care unit.~This study evaluates diaphragmatic contractility with ultrasound, blood gas analytical parameters during weaning from invasive mechanical ventilation"
62181456|NCT03694626|ACTIVE_COMPARATOR|Healthy Control subjects|
62181457|NCT03694626|ACTIVE_COMPARATOR|TBI Patients without photosensitivity|
62181458|NCT03694626|ACTIVE_COMPARATOR|Migraine patients without photosensitivity|
62181459|NCT03694626|ACTIVE_COMPARATOR|Migraine patients with photosensitivity|
61996442|NCT05771259||Group A|Participants who didn't undergo body contouring surgery after bariatric surgery.
61996443|NCT05771259||Group B|Participants who underwent body contouring surgery after bariatric surgery.
62181460|NCT03694626|ACTIVE_COMPARATOR|TBI patients with photosensitivity|
62181461|NCT03357978|OTHER|A-T patients|"A-T patients aged 2 to 45 years with and without immunoglobulin G Substitution~* bioelectrical impedance Analysis~* blood draw~* transient elastography (FibroScan)~* ataxia score~* Five-Times-Sit-to-Stand Test"
62181462|NCT00677092|EXPERIMENTAL|Imatinib Mesylate (IM) Treatment|Imatinib mesylate 400 milligrams (mg) orally once daily for 4 months. Dosage was reduced to 200 mg if the participant developed gastrointestinal intolerance or alopecia.
62181463|NCT00962689||Chronic Rhinosinusitis|Patients with chronic rhinosinusitis as defined by American Academy of Otolaryngology-Head and Neck Surgery and American Rhinologic Society guidelines
62181464|NCT00962689||Control Group|Patients undergoing endoscopic sinus surgery for diseases other than chronic rhinosinusitis (i.e., access to pituitary gland, etc)
61996444|NCT04865432|EXPERIMENTAL|UVB treatment|Participants will first undergo an evaluation of each individual's sensitivity to the Solius Photobiological System UVB using the device titration system for the first 5 weeks. Once determined, participants will participate in a 4-week intervention where they will be exposed to their individualized titration evaluation.
61996445|NCT02071524|ACTIVE_COMPARATOR|Cristalloid|group cristalloid (ringer lactate)
61996446|NCT02071524|ACTIVE_COMPARATOR|colloids|colloid: cristalloid in according to cardiac output
61996447|NCT01230931|EXPERIMENTAL|Vitagel and Standard of Care|This group of patients will receive the vitagel topical surgical hemostat spray intra-operatively, along with all the other standards of care.
61996448|NCT01230931|ACTIVE_COMPARATOR|Standard of Care|This group of patients will receive the standard of care for hemostasis in acetabular surgery (electrocautery/ligation of bleeding vessels, fracture reduction and stabilization, cell-saver, lap packing). They will not receive the vitagel product.
61996449|NCT06190808|EXPERIMENTAL|Single Arm|All members of the arm will have a CGM place and glucose concentration downloaded.
61996450|NCT05179733|EXPERIMENTAL|ZR2|six courses of zanubrutinib, rituximab and lenalidomide
62181465|NCT02104505|ACTIVE_COMPARATOR|700 mg Gamma Tocopherol daily x 14days|Gamma Tocopherol supplement
62565896|NCT02040129|EXPERIMENTAL|Acrysof toric IOL|Acrysof Toric intraocular lens in congenital cataract
62565897|NCT03187301|EXPERIMENTAL|APL-130277|APL-130277 at the dose determined in the dose titration phase
61996451|NCT05179733|ACTIVE_COMPARATOR|R-miniCHOP|six courses of rituximab combined with low-dose CHOP
61996452|NCT03850873|EXPERIMENTAL|TQB3616|TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m to 120mg once daily
61996453|NCT02127632|ACTIVE_COMPARATOR|Group ETT (endo tracheal tube)|Group ETT (Endotracheal tube Group). In the ETT group for women no. 7-7.5 tube will use. ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
62181466|NCT02104505|PLACEBO_COMPARATOR|Placebo|Safflower oil capsules
62565898|NCT03187301|PLACEBO_COMPARATOR|Placebo|Placebo
62565899|NCT03187301|ACTIVE_COMPARATOR|moxifloxacin|moxifloxacin at a single 400mg dose
62772839|NCT06140459|EXPERIMENTAL|Disabled children|Special education school students
62772840|NCT06140459|ACTIVE_COMPARATOR|Healthy children|Systemically healthy school children
62181467|NCT03536702|EXPERIMENTAL|Creative Writing Workshop|The intervention arm will receive a dedicated workshop for one and a half hours every 2 weeks for 3 months.
62181468|NCT03536702|ACTIVE_COMPARATOR|Independent Writing - Control Group|The control arm will receive a book (i.e., Writing Down Bones by Natalie Goldberg) on creative writing and asked to read and do writing activities for one and a half hours once every two weeks for 3 months.
62181469|NCT02735434|EXPERIMENTAL|Internet-based ACT|Brief clinical psychiatric assessment to determine eligibility (video-based).
62181470|NCT02735434|ACTIVE_COMPARATOR|Internet-based discussion forum|Brief clinical psychiatric assessment to determine eligibility (video-based).
62181471|NCT03703349|EXPERIMENTAL|Preoperative oral Magnesium|Magnesium sulfate 8 tablets (8 x 0.4 g) per day, PO, for the 3 days preceding the surgical intervention
62181472|NCT03703349|PLACEBO_COMPARATOR|Control|Placebo oral tablet, for Magnesium Sulfate tablets, PO, for the 3 days preceding the surgical intervention
62565900|NCT02829320|EXPERIMENTAL|GSK1278863|Subjects will receive GSK1278863 once daily orally at a starting dose of 4 milligrams (mg) on Day 1, and continued until the day of Week 4. From Weeks 4 to 24, interruption of treatment or dose adjustments will be made within the maintenance dose range of 1 mg to 24 mg according to the dose adjustment algorithm to achieve and/or maintain Hgb within the target range (10.0 to 12.0 g/dL) based on the Hgb value measured every 4 weeks. Dose changes will be made every 4 weeks. Iron replacement therapy will be given according to the standard starting criteria.
61996454|NCT02127632|EXPERIMENTAL|Group LM-S(Laryngeal mask supreme Group)|Experimental: Group LM-S Group LM-S (Laryngeal mask supreme Group) For \<50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) will insert.
61996455|NCT00500370|EXPERIMENTAL|Group A|
61996456|NCT00500370|PLACEBO_COMPARATOR|Group B|
61996457|NCT02696369|EXPERIMENTAL|2% Lidocaine HCL:Epinephrine inj.|2% Lidocaine HCL with epinephrine 1:200,000
62181473|NCT03075098|EXPERIMENTAL|colposcopy of intraepithelial carcinoma|Digital colposcope will be used to detect the swede score of the lesion
62181474|NCT03046797|EXPERIMENTAL|B group|Mask ventilation will be continued and fiberoptic intubation will be performed from Boussignac valve opening by an experienced anesthetist.
62181475|NCT03046797|ACTIVE_COMPARATOR|C group|mask ventilation will be terminated then fiberoptic intubation will be done by an experienced anesthetist.
62565901|NCT05463796||HEREDITARY RISK|"Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data.~Tissue samples will be collected during a routine visit.~Participants will be asked to donate any of the following tissue types:~* Blood~* Buccal swab (saliva) or mouthwash~* Urine~* Stool~* Biopsy or surgical tissue (i.e., bone marrow)~* Bodily fluids~* Other tissues"
62565902|NCT05463796||EXPOSED HIGH RISK|"Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data.~Tissue samples will be collected during a routine visit.~Participants will be asked to donate any of the following tissue types:~* Blood~* Buccal swab (saliva) or mouthwash~* Urine~* Stool~* Biopsy or surgical tissue (i.e., bone marrow)~* Bodily fluids~* Other tissues"
62772841|NCT04778800|EXPERIMENTAL|almonertinib 110mg PO once daily|
62772842|NCT04778800|EXPERIMENTAL|almonertinib 160mg PO once daily|
62772843|NCT04778800|EXPERIMENTAL|almonertinib 220mg PO once daily|
61996458|NCT02696369|ACTIVE_COMPARATOR|2% Lidocaine HCL:Epinephrine inj. (3M)|2% Lidocaine HCl with epinephrine 1:80,000
62181476|NCT04158973|EXPERIMENTAL|VTE prophylaxis based on bleeding risk assessment|Patients will undergo a bleeding risk assessment to determine their entering VTE prophylaxis. Low bleeding risk patients will have once daily sc LMWH prophylaxis. Intermediate bleeding risk patients will have q 12 h sc low dose unfractionated heparin prophylaxis. High bleeding risk patients will have mechanical prophylaxis. Assigned prophylaxis can be interrupted as clinical judgement requires, e.g., for peri-procedural reasons. When patients are discharged, if they have low risk of bleeding at the time of discharge, whatever their bleeding risk assessment at the time of randomization, will begin 5 mg rivaroxaban prophylaxis (two 2.5 mg tablets) once daily with food, starting on the day of discharge, for 15 days.
62181477|NCT04158973|ACTIVE_COMPARATOR|Routine VTE prophylaxis in local clinical practice|VTE risk assessment and prophylaxis if indicated during hospitalization according to current policies for hospitals in China but no further treatment prophylaxis after discharge.
62181478|NCT03109652|ACTIVE_COMPARATOR|IV TXA alone|One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.
62181479|NCT03109652|EXPERIMENTAL|IV TXA and Oral TXA 5 days|"One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.~Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 5."
62181480|NCT03109652|EXPERIMENTAL|IV TXA and Oral TXA 2 days|"One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.~Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 2."
62181481|NCT02836262|EXPERIMENTAL|HIT Hip Replacement System (HRS)|Single group assignment with historical controls.
62181482|NCT03433183|EXPERIMENTAL|Selumetinib and Sirolimus|A Simon's two-stage phase 2 trial of MEK inhibitor selumetinib in combination with the mTOR inhibitor sirolimus to determine the safety and clinical benefit in patients with unresectable or metastatic MPNSTs. Both agents will be given orally on an empty stomach. Selumetinib will be given orally at a dose of 50mg twice daily continuously. Sirolimus will be given orally at a dose of 4mg once daily with a cycle 1 day 1 loading dose of 12mg. Each cycle will be considered 28 days.
62181483|NCT01709123|PLACEBO_COMPARATOR|placebo|Placebo supplementation in pill form for 3 months following randomization after a placebo run-in period.
62565903|NCT05463796||PRECURSOR LESIONS|"Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data.~Tissue samples will be collected during a routine visit.~Participants will be asked to donate any of the following tissue types:~* Blood~* Buccal swab (saliva) or mouthwash~* Urine~* Stool~* Biopsy or surgical tissue (i.e., bone marrow)~* Bodily fluids~* Other tissues"
61996459|NCT04362917||FDR-|"Adults with a first degree relative with T1D, who have tested negative for islet autoantibodies.~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
61996460|NCT04362917||FDR+|"Adolescents and adults with a first or second degree relative with T1D, who has tested positive for at least one islet autoantibody.~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
62181484|NCT01709123|EXPERIMENTAL|chromium niacinate|Chromium niacinate supplementation (200ug or 500ug/day) in pill form for 3 months following randomization after a placebo run-in period
62181485|NCT03396211|EXPERIMENTAL|Apatinib with Nivolumab|Participants will receive an oral dose of apatinib once per day with a fixed dose of nivolumab given intravenously every 2 weeks.
62391296|NCT00498069|PLACEBO_COMPARATOR|2|Injection of placebo into ischemic tissues of the lower extremity
62565904|NCT05463796||FAMILY MEMBERS|These family members will be identified by the patients participating in the study. Blood, buccal cells, or saliva or oral rinses will be collected in one of three ways from family members of patients (i) at the time of consent; (ii) via a mailed blood kit or saliva kit; or (iii) at a separate appointment scheduled by the consented participant
62565905|NCT03005587||Cirrhotics with no previous decompensation|
62565906|NCT03005587||Cirrhotics with previous one or more than one decompensation|
62565907|NCT03038542|EXPERIMENTAL|Treatment Text Arm|
62565908|NCT03038542|ACTIVE_COMPARATOR|Standard Text Arm|
62181486|NCT02413606|EXPERIMENTAL|Intervention|reduced follow-up schedule: 4 follow-up visits, after 3, 12, 24 and 36 months
62181487|NCT02413606|NO_INTERVENTION|control|regular follow-up schedule according to the guideline, 10-13 visits during 5 years
62181488|NCT00637247|EXPERIMENTAL|imexon + gemcitabine|imexon + gemcitabine
62181489|NCT00637247|ACTIVE_COMPARATOR|Placebo + gemcitabine|Placebo in combination with gemcitabine
62181490|NCT01853059||IMRT|Prospective longitudinal assessment of patients receiving intensity-modulated radiation therapy for anal cancer
62181491|NCT01853059||Conventional|Cross-sectional analysis of patients receiving conventional radiotherapy
62181492|NCT03299413|EXPERIMENTAL|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be given as a cell suspension in aseptic buffered solution in disposable vials with no preservative agents. The cells will be injected every two weeks at a total of three doses, 120 million cells in 10mls divided on two IV boli for each dose
62181493|NCT02238964|ACTIVE_COMPARATOR|Strattice™ Reconstructive Tissue Matrix|Strattice(TM) Reconstructive Tissue Matrix will be placed intra-peritoneally fashion. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl).
62181494|NCT02238964|ACTIVE_COMPARATOR|Standard closure|"Fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The technique recommended is the fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. This technique can include either interrupted or continuous sutures.~Closure of the muscle, soft tissues and skin is up to the discretion of the operating surgeon."
62181495|NCT04300322|ACTIVE_COMPARATOR|Cervical pessary|Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
62181496|NCT04300322|ACTIVE_COMPARATOR|Vaginal Progesterone|Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
62181497|NCT00092521|EXPERIMENTAL|1|V501
62181498|NCT00092521|PLACEBO_COMPARATOR|2|Placebo
62181499|NCT00092521|EXPERIMENTAL|3|HPV 16 Monovalent Vaccine
62181500|NCT02782208|ACTIVE_COMPARATOR|Acipimox/GH substitution|Drug: Acipimox Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day Other Name: Tablet Olbetam 250 mg Continue GH substitution as usually.
62565909|NCT05481892|EXPERIMENTAL|Cellular Home blood pressure (BP) monitoring with minimal support|Patients will be instructed to write down their blood pressures (BP) in a BP log that will be provided to them at the time of enrollment. Study staff will access the patient's home BP measurements on the BP device dashboard and send a summary of the home BP measurements (mean, median, % of BP measurements at goal) to the primary care provider in a telephone encounter (TE) 3 to 5 days prior to the next scheduled visit.
62565910|NCT05481892|ACTIVE_COMPARATOR|Cellular Home blood pressure (BP) monitoring with pharmacist support for treatment intensification|For patients randomized to this intervention arm, a pharmacist will review the home blood pressure (BP) measurements and use an evidence-based algorithm to make recommendations for medication intensification. If the patient has a primary care provider (PCP) appointment within 2 weeks, the pharmacist will send a telephone encounter (TE) with BP measurements and medication recommendations to the PCP 3 -5 days prior to the scheduled appointment. If the patients has no appointment scheduled within two weeks, the pharmacist will call the patient and prescribe medication intensification if the patient is amenable.
62181501|NCT02782208|ACTIVE_COMPARATOR|Acipimox/GH pause|Drug: Acipimox Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day Other Name: Tablet Olbetam 250 mg Pause GH substitution to days prior to the study day.
62181502|NCT02782208|PLACEBO_COMPARATOR|Placebo/GH substitution|Drug: Placebo tablets Continue GH substitution as usually.
62181503|NCT02782208|PLACEBO_COMPARATOR|Placebo/GH pause|Drug: Placebo tablets Pause GH substitution to days prior to the study day.
62181504|NCT02941419|EXPERIMENTAL|Platelet lysate injection|Injection of platelet lysate intramuscularly in the gastrocnemius muscle
62181505|NCT01603771||Combined|Participants assigned to this group have been randomized to the Combined group of the parent study, Combining Exercise and Cognitive Training to Improve Everyday Function(EXACT)(Unique Protocol ID 201102416). Participants perform a 6-month standardized aerobic training program at a local recreational center, 3 times per week for 1 hour. Participants in this group also perform an 8-week cognitive training program 3 days per week for 1 hour, during months 5 and 6. The cognitive training program is computer-based, and focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. The cognitive training is conducted on concurrent days with aerobic exercise training sessions, also on site at the recreational center.
62182645|NCT01728207|EXPERIMENTAL|IMMU-114|IMMU-114 will be administered subcutaneously (under the skin) once or twice weekly for 3 weeks followed by one week of rest. Treatment cycles will continue until disease worsening or toxicity. Various dose levels will be studied.
62182646|NCT02072798|ACTIVE_COMPARATOR|preoperative antibiotic|iv Cefuroxime 1,5g administered 15-60 minutes before incision
62182647|NCT02072798|ACTIVE_COMPARATOR|postoperative antibiotic|iv Cefuroxime 1,5g administered after umbilical cord clamping
62565911|NCT05481892|NO_INTERVENTION|Non-randomized usual care|To compare the two intervention arms with usual care, investigators will extract electronic health record (EHR) data on active San Francisco Health Network (SFHN) adult patients (age 18+) with diagnosis of hypertension who made at least one primary care visit during the study period.
62565912|NCT01703260|EXPERIMENTAL|Roflumilast + pioglitazone|Roflumilast dose and pioglitazone dose, orally for up to 4 months
62565913|NCT01703260|EXPERIMENTAL|Roflumilast|Roflumilast dose and pioglitazone matching-placebo dose orally for up to 4 months.
62565914|NCT01703260|EXPERIMENTAL|Pioglitazone|Pioglitazone dose, orally and roflumilast matching-placebo dose, orally for up to 4 months
62565915|NCT04714424||Participants undergoing vision exams|
62565916|NCT06427668|ACTIVE_COMPARATOR|Part A: Active SPG302 to be administered to adult participants with AD|Cohort 1: 12 participants with Alzheimer's Disease will be randomized in a 2:1 ratio to receive SPG302 or placebo. Study intervention will be 300 mg orally once daily for 28 days (cycle 1). All participants will receive open-label SPG302 for cycles 2-7. This arm may be expanded to cohort 2: 12 additional participants pending review of data, for additional dose exploration.
62565917|NCT06427668|PLACEBO_COMPARATOR|Part A: Placebo comparator to be administered to adult participants with AD|Cohort 1: 12 participants with Alzheimer's Disease will be randomized in a 2:1 ratio to receive SPG302 or placebo. Study intervention will be placebo capsule orally daily for 28 days (cycle 1). All participants will receive open-label SPG302 for cycles 2-7. This arm may be expanded to 12 additional participants as cohort 2 pending review of data, for additional dose exploration.
62565918|NCT06427668|EXPERIMENTAL|Part B: Expansion Cohort|Dose to be used and size of dosing cohort to be determined by Data Safety and Monitoring Committee following completion of Part A.
62565919|NCT05748925|ACTIVE_COMPARATOR|study group|study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food for one ye
62565920|NCT05748925|ACTIVE_COMPARATOR|control group|Control group: will receive placebo as add on drug once daily with or without food for one year.
62565921|NCT05393037|EXPERIMENTAL|V116 + Placebo|Part A: Participants will receive a single intramuscular (IM) dose of V116 on Day 1, and a single IM dose of placebo on Week 8. Part B: Participants will receive a single IM dose of PCV15 between 10 to 18 months after V116.
62565922|NCT05393037|ACTIVE_COMPARATOR|PCV15 + PPSV23|Participants will receive a single IM dose of PCV15 on Day 1, and a single IM dose of PPSV23 on Week 8.
62565923|NCT06517602|EXPERIMENTAL|Moringa|The experimental group received for 3 months a daily supplementation of 10g of Moringa oleifera leaf powder to consume within the two main meals.
62565924|NCT06517602|NO_INTERVENTION|Control|The control group were asked to refrain from consuming Moringa oleifera leaves throughout the study period (3 months).
62565925|NCT05310682|EXPERIMENTAL|DIPH-intervention districts|Twelve districts were randomly selected from the North Shewa Zone of the Amhara region, Ethiopia. These districts were matched with the comparison arm based on health system performance and distance. The DIPH intervention is implemented at the district health administration office level.
62565926|NCT05310682|NO_INTERVENTION|Non-intervention districts|Twelve districts were randomly selected from the North Shewa Zone of the Amhara region, Ethiopia. These districts were matched with the DIPH intervention arm based on health system performance and distance.
62565927|NCT06122792|ACTIVE_COMPARATOR|Standard Therapy|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic hemostasis according to the center protocol.~Standard combined endoscopic and pharmacological therapy as secondary prophylaxis (carvedilol + repeated endoscopic injection of tissue adhesives until the eradication of the gastric varices)."
62565928|NCT06122792|EXPERIMENTAL|Preemptive TIPS|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic hemostasis according to the center protocol.~Performance of TIPS in the first 72 hours following initial endoscopic hemostasis."
62565929|NCT03005704|EXPERIMENTAL|Antiplatelet Treatment|Subjects will be treated with five days of ticagrelor in combination with acetylsalicylic acid.
62565930|NCT03005704|NO_INTERVENTION|Control|Subjects will not receive antiplatelet treatment and their PRP will be used as the source of untreated platelets in laboratory mixing studies.
62565931|NCT00662584|EXPERIMENTAL|1|This was an open-label study - all subjects received the intervention (rTMS treatment)
62565932|NCT01858844|ACTIVE_COMPARATOR|CHEST COMPRESSION TECHNIQUE 2|The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR(respiratory rate)(timer for 1 minute); HR (heart rate) and SpO2(oxygen saturation) through pulse oximetry in infants without atelectasis.
62772844|NCT04370379|EXPERIMENTAL|low dose of IBI302|
62772845|NCT04370379|EXPERIMENTAL|high dose of IBI302|
62772846|NCT04370379|ACTIVE_COMPARATOR|2mg aflibercept|
62772847|NCT05017662|OTHER|Data collection|
62181506|NCT01603771||Control|Participants assigned to this group have been randomized to the Control group of the parent study, Combining Exercise and Cognitive Training to Improve Everyday Function(EXACT)(Unique Protocol ID 201102416). Participants perform a 6-month home exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes and record their activity on a calendar. Participants also attend weekly 1-hour Health Education sessions for 8 weeks, during months 5 and 6. These sessions cover topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and home energy conservation.
62181507|NCT03104777|NO_INTERVENTION|Control Group|No intervention materials will be distributed in the control schools during the intervention period.
62181508|NCT03104777|EXPERIMENTAL|Intervention Group|Intervention materials will be distributed to parents of children in years 3 - 6.
62181509|NCT02906475|OTHER|Intervention: standardized skin care regimen|Intervention: The milk lotion will be applied once daily on the total body including the face by the parents or care givers at home. If bathing is needed, the bathing addendum is used in addition to water.
62181510|NCT02906475|NO_INTERVENTION|Control|In the control group no predetermined or standardized skin care regimen is prescribed.
62181511|NCT04735913|OTHER|Fasting group|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
62181512|NCT04735913|EXPERIMENTAL|Postprandial group|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®)orally after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
62565933|NCT01858844|EXPERIMENTAL|CHEST COMPRESSION TECHNIQUE|The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR (timer for 1 minute); HR and SpO2 through pulse oximetry in infants with atelectasis.
62565934|NCT04858646|EXPERIMENTAL|Aerobic exercises|Subjects in A group was treated with different types of aerobic exercises such as 10 minute walking, 10 minute trampoline exercise and 10 minutes ball throwing activities
62565935|NCT04858646|ACTIVE_COMPARATOR|Conventional physical therapy|Traditional physical therapy The group B was treated with conventional therapy. Conventional treatment protocol passive ROM and stretching passive ROM for 15 minutes and stretching for 15 minutes. Treatment duration for both groups will be 30 minutes. Each subject received total 30 sessions of the treatment, with 5 treatment sessions per week for 6 weeks. Post treatment reading were collected after end of 6th weeks.
62565936|NCT02965001|EXPERIMENTAL|68Ga-NOTA-AE105|All participants have an uPAR-PET/CT scan performed before initiation of the routine radiotherapy
62565937|NCT04025099|EXPERIMENTAL|Internal Cues|"Over 10 weeks, participants will be asked to participate in the following:~1. Classes (held in STAR Tower 419/420 IPE Space and Conference Room 413)~   * One \~60-minute Intuitive Eating class per week (total = 10 classes);~  * Two \~60-minute yoga classes per week (total = 20 classes);~  * Repeat one of the \~60-minute yoga classes each week on the participants' own, in a space participants feel comfortable, using a video recording (total = 10 classes).~2. Assessments (held in STAR tower)~   * Three \~60-minute assessments\* which will include:~     1. Height \& weight measurements (taken privately)~    2. A questionnaire that asks about participants' relationship with their body and eating and activity behaviors~    3. Collection of participants' heart rate overnight (on their own)~    4. Collection of participants' saliva three times in one day (on their own)"
62567786|NCT04051671|EXPERIMENTAL|Active tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) during the first 20 mins of conventional physical therapy (about 1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow continuously during 20. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
62772848|NCT00785343|ACTIVE_COMPARATOR|Conventional Treatment|
62772849|NCT00785343|EXPERIMENTAL|Robotic and Conventional Therapy|
62181513|NCT05023200||Population|Adults (age ≥18 years) identified by their treating clinician as having lower limb cellulitis that requires intravenous or oral antibiotic treatment either from the hospital or another service based outside of the hospital, which will conduct ongoing follow-up regardless of location.
61996461|NCT04362917||Control|"Adults with no family history of Type 1 Diabetes, who have tested negative for islet autoantibodies~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
61996462|NCT00217542|EXPERIMENTAL|Treatment (chemotherapy, biological therapy)|Patients receive azacitidine SC once daily on days 1-4 and 15-17 and recombinant interferon alfa-2b SC on days 8, 10, 12, 15, 17, 19, 22, 24, and 26 during course 1. Beginning in course 2 and for all subsequent courses, patients receive azacitidine SC once daily on days 1-3 and 15-17 and interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 12 total courses in the absence of disease progression or unacceptable toxicity.
61996463|NCT00091299|EXPERIMENTAL|warfarin|
62565938|NCT04025099|ACTIVE_COMPARATOR|External Cues|"Over the next 10 weeks, participants will be asked to participate in the following:~1. Classes (held in STAR Tower 419/420 IPE Space)~   * One \~60-minute Healthy Eating class per week (total = 10 classes);~  * Participants will be provided with a UD group fitness membership. Using this membership, participants will be asked to attend at least 2 cardio fitness classes per week and do an additional 30 minutes of heart-raising activity on participants' own (total = 3 exercise sessions/week).~2. Assessments (held in STAR tower)~   * Three \~60-minute assessments\* which will include:~     1. Height \& weight measurements (taken privately)~    2. A questionnaire that asks about participants' relationship with their body and eating and activity behaviors~    3. Collection of participants' heart rate overnight (on their own)~    4. Collection of participants' saliva three times in one day (on their own)"
61996464|NCT02612532|EXPERIMENTAL|LuCID|"Standardised exhaled volatile organic compound collection by ReCIVA breath sampler (http://www.owlstonenanotech.com/medical/products/reciva) for analysis of volatile organic compounds by Lonestar (http://www.owlstonenanotech.com/medical/products/lonestar)"
61996465|NCT04237428|EXPERIMENTAL|hCD19 CAR-T cells Infusion|
61996466|NCT05155228|EXPERIMENTAL|Attachment Regulation and Competency|Weekly individual psychotherapy for 24 weeks using the Attachment Regulation and Competency intervention.
61996467|NCT05155228|ACTIVE_COMPARATOR|Treatment as usual|Weekly individual psychotherapy for 24 weeks.
61996468|NCT05756686|EXPERIMENTAL|Breathing Group 1|Arm 1 will receive an 8-week remotely delivered intervention that consists of a set of breathing practices through 60-minute weekly virtual group sessions (1day/week) with a 20-minute daily home sessions (in between weekly sessions; 6 days/week).
61996469|NCT05756686|ACTIVE_COMPARATOR|Breathing Group 2|Arm 2 will receive an 8-week remotely delivered intervention that consists of slow breathing practices through 60-minute weekly virtual group sessions (1day/week) with a 20-minute daily home sessions (in between weekly sessions; 6 days/week).
61996470|NCT00005669|ACTIVE_COMPARATOR|1 - Metformin HCL|Subjects receive metformin plus a weight loss program
61996471|NCT00005669|PLACEBO_COMPARATOR|2 - Placebo|Subjects receive placebo plus a weight loss program
61996472|NCT03602937|EXPERIMENTAL|Renastep|All participants to incorporate Renastep into their usual dietary regime.
62565939|NCT04025099|NO_INTERVENTION|Assessment Only|"Over the next 10 weeks, participants will be asked to participate in the following:~a. Assessments (held in STAR tower)~•Three \~60-minute assessments\* which will include:~1. Height \& weight measurements (taken privately)~2. A questionnaire that asks about participants' relationship with their body and eating and activity behaviors~3. Collection of participants' heart rate overnight (on their own)~4. Collection of participants' saliva three times in one day (on their own)"
62565940|NCT06071364||chronic nonspecific low back pain patients|Twenty-nine participants experienced chronic non-specific low back pain for over three months without any referred pain in their legs.
61996473|NCT05085977|EXPERIMENTAL|TARA-002|TARA-002 is a lyophilized biological preparation for instillation containing cells of Streptococcus pyogenes (Group A, type 3) Su strain treated with benzylpenicillin.
61996474|NCT02078583|EXPERIMENTAL|Remifentanil，midazolam|Remifentanil 1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02\~0.1mg/kg/h continuous intravenous pump for 7days or extubation
61996475|NCT02078583|EXPERIMENTAL|Fentanyl，midazolam|Fentanyl 1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02\~0.1mg/kg/h continuous intravenous pump for 7days or extubation
62181514|NCT04047771|EXPERIMENTAL|SCB-313|
61996476|NCT02078583|PLACEBO_COMPARATOR|Normal saline|Normal saline1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02\~0.1mg/kg/h continuous intravenous pump for 7days or extubation
62181515|NCT02726035|EXPERIMENTAL|Group 1 A-ABAB|After 4 week open label oral naltrexone run-in, participants are randomized to 2 groups (50% each). Group 1 will receive oral naltrexone 50 mg daily during weeks 5-7 (3 weeks). They will switch to placebo for weeks 8-10, then return to naltrexone for weeks 11-13, then placebo for weeks 14-16 (i.e., A-ABAB double crossover design, participants act as own controls). Study drug and placebo will be encapsulated so as to appear identical.
62181516|NCT02726035|EXPERIMENTAL|Group 2 A-BABA|After 4 week open label oral naltrexone run-in, participants are randomized to 2 groups (50% each). Group 2 will receive oral placebo once daily during weeks 5-7. They will then be switched to oral naltrexone 50 mg daily for weeks 8-10, then return to placebo for weeks 11-13, then naltrexone for weeks 14-16 (i.e., A-BABA double crossover design, participants act as own controls). Study drug and placebo will be encapsulated so as to appear identical.
62181517|NCT01586975|ACTIVE_COMPARATOR|Clopidogrel 75 mg|Clopidogrel 75 mg daily
62181518|NCT01586975|ACTIVE_COMPARATOR|Aspirin 81 mg|open-label Aspirin 81 mg daily
62181519|NCT01586975|ACTIVE_COMPARATOR|Aspirin > 300mg|open-label Aspirin over 300 mg daily
62181520|NCT06511518|OTHER|Benchmark study|The results will be compared with those of a benchmark study, i.e. historical cohort of the same target group who received face-to-face CBT provided by psychologists in the TIRED study.
62181521|NCT04071509|EXPERIMENTAL|Percutaneous Lung Biopsy|
62565941|NCT06071364||Asymptomatic subjects|Twenty-nine subjects without symptoms of low back pain
62565942|NCT02182115|ACTIVE_COMPARATOR|standard of care|Surgeon's routine for preoperative showering.
62565943|NCT02182115|EXPERIMENTAL|antiseptic bundle|"Patients to use study bundle for 5 days prior to scheduled surgery with the following medications to use at home.~1. Chlorhexidine gluconate soap applied for bathing daily.~2. Chlorhexidine gluconate mouthrinse used to rinse mouth twice daily.~3. Nasal mupirocin to applied inside nostrils twice daily."
62565944|NCT03260556|ACTIVE_COMPARATOR|Pirfenidone|Pirfenidone titrated to three 267 mg tablets three times a day
62565945|NCT03260556|PLACEBO_COMPARATOR|Placebos|Placebo titrated to three tablets three times a day
62565946|NCT03053037|ACTIVE_COMPARATOR|Group S|mesial canals in Group S will be instrumented to size 25
62565947|NCT03053037|ACTIVE_COMPARATOR|Group L|mesial canals in Group L will be instrumented to size 35
62565948|NCT03558425|EXPERIMENTAL|TR group|Period 1: Test drug(CKD-381) Period 2: Reference drug(D026)
62565949|NCT03558425|EXPERIMENTAL|RT group|Period 1: Reference drug(D026) Period 2: Test drug(CKD-381)
62565950|NCT05047692|EXPERIMENTAL|Group 1: Low dose|The subject will receive a single dose of AdCLD-CoV19-1(5.0x10\^10VP) as an intramuscular injection.
62565951|NCT05047692|EXPERIMENTAL|Group 2: High dose|The subject will receive a single dose of AdCLD-CoV19-1(1.0x10\^11VP) as an intramuscular injection.
62565952|NCT06205160|EXPERIMENTAL|All subjects|
62565953|NCT06121817|EXPERIMENTAL|Durian|250 g of durian aril (isocaloric)
62565954|NCT06121817|OTHER|Banana|417.6 g of banana (isocaloric)
62565955|NCT05651048|EXPERIMENTAL|BEMER Group|BEMER application with routine treatment protocol
62565956|NCT05651048|EXPERIMENTAL|Kinesiotape Group|Kinesiotape application with routine treatment protocol
62565957|NCT05651048|EXPERIMENTAL|Control Group|routine treatment protocol
62565958|NCT05889117|EXPERIMENTAL|Waitlist-control-treatment-group|After a 2-week control waitlist period, patient receive 30 treatments.
61996477|NCT00277212|EXPERIMENTAL|A1|Phase 1: Single-Blind Treatment, Lamotrigine + Aripiprazole ; Phase 2 Double-Blind Treatment: Lamotrigine + Aripiprazole
61996478|NCT00277212|PLACEBO_COMPARATOR|A2|Phase 2 Double-Blind Treatment: Lamotrigine + Placebo
62181522|NCT04232800|EXPERIMENTAL|Riboflavin|Participants in this group will receive 100mg riboflavin TID during study participation.
62181523|NCT04232800|PLACEBO_COMPARATOR|Placebo|Participants in this group will receive inert placebo capsules TID during study participation.
62181524|NCT02332083|EXPERIMENTAL|Intervention group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (start with 3 up to 6 Hz, noise 4) T1 - intervention 4 weeks (SR-WBV (start with 3 up to 6Hz, noise 4 \& Exergame) - T2
62181525|NCT02332083|SHAM_COMPARATOR|Sham Comparator|T0 - intervention 4 weeks (SR-WBV 1 Hz, noise 1) - T1 - intervention 4 weeks (SR-WBV 1 Hz, noise 1 \& Aktiv Tramp) - T2
62181526|NCT01134380||[*1] Genotype - Good responders to Clopidogrel|This group of patients is defined thanks to the DNA extracted from their saliva: \[\*1\] genotype patients are good responders to clopidogrel
62181527|NCT01134380||[*2] genotype with adapted thienopyridine treatment|This group of patients is defined thanks to the DNA extracted from their saliva: \[\*2\] genotype patients are bad responders to clopidogrel and their thienopyridine treatment has been adapted
62181528|NCT03809286|EXPERIMENTAL|Active Stimulation|Participants will be receiving active rTMS.
62565959|NCT01966120|ACTIVE_COMPARATOR|BF-200 ALA gel|Photodynamic therapy with BF-RhodoLED in combination with BF-200 ALA.
62565960|NCT01966120|PLACEBO_COMPARATOR|Placebo to BF-200 ALA gel|Photodynamic therapy with BF-RhodoLED in combination with a nanoemulsion gel formulation similar to BF-200 ALA, but without the active ingredient 5-aminolevulinic acid.
62565961|NCT00497068|EXPERIMENTAL|tobacco abstinent contingent voucher|Tobacco abstinent contingent voucher condition
62565962|NCT00497068|EXPERIMENTAL|non-contingent|Participants receive vouchers non-contingent upon tobacco use status
62565963|NCT00497068|OTHER|no voucher|This is the standard care intervention
62565964|NCT02592577|EXPERIMENTAL|Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T|
62565965|NCT06415708|EXPERIMENTAL|Obinutuzumab Combined With Bendamustine|
62565966|NCT00636246|EXPERIMENTAL|Sertraline/[S,S]-Reboxetine-satellite150/4|
62565967|NCT00636246|EXPERIMENTAL|Sertraline/[S,S]-Reboxetine-satellite150/6|
62565968|NCT00636246|ACTIVE_COMPARATOR|sertraline-satellite|
62565969|NCT00636246|ACTIVE_COMPARATOR|sertraline-main|
62565970|NCT00636246|EXPERIMENTAL|Sertraline/[S,S]-Reboxetine-satellite150/2|
62565971|NCT00636246|PLACEBO_COMPARATOR|Placebo|
62565972|NCT00636246|EXPERIMENTAL|Sertraline/[S,S]-Reboxetine-main|
62565973|NCT00636246|ACTIVE_COMPARATOR|[S,S]-reboxetine-main|
62565974|NCT00641992||1|Response to medical treatment
62565975|NCT00641992||2|Failure to medical treatment (surgery or percutaneous resolution)
61996479|NCT04743661|EXPERIMENTAL|Recurrent Medulloblastoma|This arm aims to estimate event-free survival (EFS) and overall survival (OS) following therapy with irinotecan, temozolomide, bevacizumab, and compartmental (intraOmmaya) radioimmunotherapy (cRIT) 131I-omburtamab in patients with recurrent medulloblastoma. Patients with recurrent medulloblastoma will undergo surgery if feasible prior to study entry, followed by Induction Chemotherapy with irinotecan, temozolomide, and bevacizumab on study as per the Children's Oncology Group (COG) trial ACNS0821. Following 2 or 4 courses of chemotherapy and if radiographic disease status is stable or improved, patients will receive 2 therapeutic doses of 50 mCi cRIT 131I-omburtamab during Radioimmunotherapy. Following Radioimmunotherapy, patients may resume to Maintenance Chemotherapy with irinotecan, temozolomide, and bevacizumab for up to 12 total courses of chemotherapy or until disease progression, whichever occurs sooner.
62181529|NCT03809286|SHAM_COMPARATOR|Sham Stimulation|Participants will be receiving sham stimulation with a smaller coil housed within the rTMS device.
62181530|NCT01688453|ACTIVE_COMPARATOR|Group 1:|Socially advantaged overweight or obese adolescents are allocated to the standard care management.
62181531|NCT01688453|EXPERIMENTAL|Group 2|Socially less advantaged overweight or obese adolescents are allocated to the standard care management.
62181532|NCT01688453|EXPERIMENTAL|Group 3|Socially less advantaged overweight or obese adolescents are allocated to the strengthened care management.
62181533|NCT02483845|EXPERIMENTAL|Natalizumab|Natalizumab therapy will be given at 300mg intravenously every 4 weeks for 24 weeks
62181534|NCT01589549|EXPERIMENTAL|Mesenchymal stromal cell therapy|Mesenchymal stromal cell therapy in addition to corticosteroid therapy
62181535|NCT01589549|ACTIVE_COMPARATOR|Corticosteroid therapy|
62181536|NCT03565692||Patients treated by LUMACAFTOR-IVACAFTOR|Patients treated by LUMACAFTOR-IVACAFTOR (or other ivacaftor combinations) Patients over 6 years who are currently able to benefit from LUMACAFTOR-IVACAFTOR (or other ivacaftor combinations) according the mutation eligibility criteria and for whom conventional microbiological analysis of sputum samples and stool will be collected during their follow-up after the treatment onset.
62565976|NCT01730989|EXPERIMENTAL|Estromineral Serena Plus|"Estromineral Serena Plus is an association of soy isoflavones, Lactobacillus sporogenes, magnolia, chaste tree, Vitamin D3, calcium and magnesium.~1 tablet oad for 12 weeks"
62565977|NCT01730989|ACTIVE_COMPARATOR|Estromineral|"Estromineral is an association of soy isoflavones, Lactobacillus sporogenes, Vitamin D3, and calcium.~1 tablet oad for 12 weeks"
62565978|NCT00717912|EXPERIMENTAL|Arm 1|Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup
62565979|NCT00717912|EXPERIMENTAL|Arm 2|Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Experimental sweetener syrup
62565980|NCT00717912|EXPERIMENTAL|Arm 3|Experimental sweetener syrup / Classical sugar syrup / Experimental sweetener syrup / Classical sweetener syrup / Classical sugar syrup / Classical sugar syrup / Experimental sweetener syrup
62565981|NCT00717912|EXPERIMENTAL|Arm 4|Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup / Classical sugar syrup / Classical sweetener syrup
62565982|NCT00717912|EXPERIMENTAL|Arm 5|Classical sugar syrup / Experimental sweetener syrup / Classical sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup
62565983|NCT00717912|EXPERIMENTAL|Arm 6|Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Classical sugar syrup
62565984|NCT04853472||Early Stage Peri-Menopause|Mild cycle irregularity over the last 3-6months (minimum), variation of \>6 days in length between consecutive cycles including shortened and longer cycles (but not \>60 days in length)
62565985|NCT04853472||Late Stage Peri-Menopause|Late stage peri-menopause: Irregular cycles with prolonged periods of amenorrhea \>60 days in length (but less than 12 months)
62565986|NCT04853472||Post-Menopause|Greater than 12 months since last menstrual period
62565987|NCT01664663|ACTIVE_COMPARATOR|Arm A:Standard radiochemotherapy|Radiotherapy with 2 Gy per fractions 5 fractions a week to 68 Gy to the planning target volume. Three courses of cisplatin 75 mg/m2 day 1and vinorelbine 25 mg/m2 day 1+8. Two courses concomitant with radiation.
62565988|NCT01664663|EXPERIMENTAL|Arm B Escalated radiochemotherapy|Radiotherapy with 2 Gy per fraction 5 or 6 times a week to 68-84 Gy to the planning target volume due to normal tissue tolerance constraints. Dose to lung tissue, esophagus and spinal cord will be considered. Three courses of cisplatin 75 mg/m2 day 1 and vinorelbine 25 mg/m2 day 1+8 will be given, two courses concomitant with radiation.
62565989|NCT06448923|EXPERIMENTAL|Low CBD dose|Participants will receive 25 mg orally twice daily during a meal for a month
62565990|NCT06448923|EXPERIMENTAL|Moderate CBD dose|Participants will receive 50 mg orally twice daily during a meal for a month
62565991|NCT06448923|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo orally twice daily during a meal for a month
62565992|NCT03828721|ACTIVE_COMPARATOR|Control - screen time reduction|Families assigned to the control arm in each age category will receive customary ROR, including the provision of an age-appropriate children's book, and reading-related developmental surveillance and anticipatory guidance. In addition, control families will receive a new children's book reinforcing AAP screen-based media recommendations.
61996480|NCT04743661|EXPERIMENTAL|Recurrent Ependymoma|This is a feasibility cohort. The primary objective is to assess feasibility of incorporating cRIT 131I-omburtamab for patients with recurrent ependymoma and to assess dosimetry. Patients must have progressed after initial surgery, radiation therapy, or other therapies. Patients will undergo surgery (if feasible) prior to study entry with the goal of achieving stable or better disease. Tumor tissue (archived or new) will be tested for B7H3 prior to enrollment. If positive, patients will enroll on Stratum 2 and receive one dosimetry dose (2 mCi) of cRIT 131I-omburtamab with nuclear medicine scintigraphy using SPECT during the Dosimetry Course (14 days in length). Following the Dosimetry Course and within 2 weeks of the dosimetry dose, patients may continue to Radioimmunotherapy to receive 2 therapeutic doses (50 mCi) of cRIT 131I-omburtamab.
61996481|NCT05873465|ACTIVE_COMPARATOR|Non-users|Patients that don't use cannabis and will be submitted to sedation.
62565993|NCT03828721|EXPERIMENTAL|Rx for Success Smartphone Application|"Families in the intervention arm in both age categories will receive enhanced ROR involving the provision of the Rx for Success (RS) application at the baseline visit (6 months old and 18 months old, respectively). No additional intervention will take place, other than push notifications and other content such as demonstration videos built into the RS application."
62565994|NCT01416454||Elective Cesarean delivery, age <35 yrs|Women undergoing elective cesarean delivery with a spinal anesthetic who are less than 35 y of age (at the time of delivery).
62565995|NCT01416454||Elective Cesarean delivery, age =>35 yrs|Women undergoing elective Cesarean delivery with a spinal anesthetic who are =\> 35 yrs of age (at the time of delivery).
62565996|NCT02659423||Green Dot BIC 1|"Bystander Intervention Components Clusters will include at least a component of Green Dot.~E.g. Comparisons will be made across schools that have Green Dot versus those that don't have Green Dot. (BIC 1)"
62565997|NCT02659423||Online BIC 2|"Bystander Intervention Components Clusters will include at least a component of online bystander training.~E.g. Comparisons will be made across schools that have online bystander training versus those that do not. (BIC 2)"
62565998|NCT02659423||Alternative programs BIC 3|"Bystander Intervention Components Clusters will include at least a component of Green Dot.~E.g. Comparisons will be made across schools that have alternative program versus those that do not. (BIC 3)"
62565999|NCT02767011|EXPERIMENTAL|THEM|Patients receive telehealth electronic health care monitoring.
62566000|NCT02767011|NO_INTERVENTION|Standard of Care (SOC)|Patients receive normal standard of follow-up care
62566001|NCT06487832|EXPERIMENTAL|GLP-1|Acute administration of 0.25 mg semaglutide (0.19 ml)
62181537|NCT04866433|EXPERIMENTAL|Binaural group|Play realtime binaural sound applied music through headphones
62181538|NCT04866433|ACTIVE_COMPARATOR|Audio group|Play music through headphones.
62181539|NCT04866433|SHAM_COMPARATOR|Control group|Wear headphones that do not produce sound.
62566002|NCT06487832|PLACEBO_COMPARATOR|Placebo|Acute administration of 0.19 ml NaCl
62181540|NCT03918447|EXPERIMENTAL|Maximum bardoxolone methyl dose of 20 mg|"Patients randomized to receive bardoxolone methyl with a baseline ACR less than or equal to 300 mg/g will be titrated to a maximum dose of 20 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2 and 20 mg at Week 4.~Patients will continue to receive study drug through Week 100, and will not receive study drug during a 12-week off-treatment period between Weeks 100 and 112."
62566003|NCT06273319|PLACEBO_COMPARATOR|Group 1: Patients who will receive 15 litres oxygen therapy|: Patients who will receive 15 litres oxygen therapy, will be applied throughout the transaction.Patient saturation and complications such as bronchospasm and laryngospasm respiratory arrest will be recorded throughout the procedure.
62566004|NCT06273319|ACTIVE_COMPARATOR|Group 2: Patients who will receive 30 litres oxygen therapy|Patients who will receive 30 litres oxygen therapy,will be applied throughout the transaction.Patient saturation and complications such as bronchospasm and laryngospasm respiratory arrest will be recorded throughout the procedure.
62566005|NCT03658785|EXPERIMENTAL|TIL,IL-2,Cyclophosphamide,Fludarabine|"Biological: TIL On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine).~Drug: Aldesleukin 125,000 IU/kg IV/day (based on total body weight) beginning within 24 hours of cell infusion and continuing for up to 2 weeks) Drug: Cyclophosphamide On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.~Drug: Fludarabine Days -5 to -1: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days."
62566006|NCT06577961|EXPERIMENTAL|Experimental group|Vorolanib combined with cadonilimab
62566007|NCT05340764|ACTIVE_COMPARATOR|2-hour infusion of infliximab|"2 hour infusion of infliximab~Infliximab: Infliximab is an effective and commonly used medication to treat patients with IBD. Patients in this group received the standard 2 hour infusion of infliximab and serves as the control group."
62566008|NCT05340764|EXPERIMENTAL|1-hour infusion of infliximab|"1 hour infusion of infliximab~Infliximab: Infliximab is an effective and commonly used medication to treat patients with IBD. Patients in this group received the reduced 1 hour infusion of infliximab and serves as the study group."
62566009|NCT04131660|EXPERIMENTAL|AVAPS-AE mode|A volume targeted pressure support ventilation mode
62566010|NCT04131660|ACTIVE_COMPARATOR|S/T mode|A pressure support ventilation mode
62566011|NCT01811342||Hemoglobin Measurement|Patients requiring intra-operative hemoglobin measurement.
62566012|NCT03241849|OTHER|Modified surgical technique for placenta accreta|
62566013|NCT04693208|EXPERIMENTAL|Laser|Laser light will be applied to the surgery site after tonsils excision.
62566014|NCT04693208|NO_INTERVENTION|Standard care|
62566015|NCT05491551|EXPERIMENTAL|Mindfulness-Based Treatment|Using mindfulness and meditative strategies to control craving
62566016|NCT05491551|EXPERIMENTAL|Cognitive Behavioral Therapy|Thinking of negative consequences to control craving
62566017|NCT05491551|NO_INTERVENTION|Control|No regulatory strategy
62566018|NCT04680000|ACTIVE_COMPARATOR|Standard BCBT-CP|Brief Cognitive Behavior Therapy for Chronic Pain (BCBT-CP) is a seven-module intervention for chronic pain based on the efficacious specialty-care, ten-session version of this treatment called Cognitive Behavioral Therapy for Chronic Pain (CBT-CP).
61996482|NCT05873465|EXPERIMENTAL|Users that will stop use 72h before the procedure|Patients that use cannabis and will stop using 72 hours before sedation.
61996483|NCT05873465|EXPERIMENTAL|Users that will stop use 12h before the procedure|Patients that use cannabis and will stop using 12 hours before sedation.
61996484|NCT02776228|EXPERIMENTAL|benzodiazepine|The patient which will be in the Experimental arm (after randomization) will receive 0.25 mg of Brotizolam (short acting benzodiazepine) for six weeks from the day of discharge.
61996485|NCT02776228|PLACEBO_COMPARATOR|placebo|The patient which will be in the placebo arm (after randomization) will receive placebo for six weeks from the day of discharge.
61996486|NCT04249258|EXPERIMENTAL|Dobutamine|Measurements of various conduction parameters will be taken at baseline as is standard protocol for an EPS. Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min. At each of these dosages the same conduction parameters will be measured. A comparison will then be made between the conduction parameters at baseline and when the Dobutamine is administered.
61996487|NCT00862784|EXPERIMENTAL|IMC-1121B (ramucirumab) + mFOLFOX-6|This regimen will be repeated every 2 weeks until disease progression, unacceptable toxicity, or withdrawal.
61996488|NCT01505127|EXPERIMENTAL|TAK-438 20 mg BID|"TAK-438 20 mg, tablets, orally, twice daily for 1 week~Lansoprazole placebo-matching capsules, orally, twice daily for 1 week~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week"
61996489|NCT01505127|EXPERIMENTAL|Lansoprazole 30 mg BID|"TAK-438 placebo-matching tablets, orally, twice daily for 1 week~Lansoprazole 30 mg, capsules, orally, twice daily for 1 week~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week"
61996490|NCT01485523||Patients|A = Patients with allergic rhinitis sensitized to dust mites
61996491|NCT01485523||Control Subjects|B = control subjects with allergic rhinitis not sensitized to dust mites C = control subjects without allergic rhinitis
61996492|NCT04760210|ACTIVE_COMPARATOR|Control Group|"Pre-physiotherapy session:~1. Tens~2. Infrared/Moist Heat heat for 10 minutes at the low back region.~3. Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~4. Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~5. Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~6. Postural Education~7. Home Plan with lumbar Sacral Support~Bed rest after the controlled treatment is recommended for this group."
61996493|NCT04760210|ACTIVE_COMPARATOR|Decompression|"Pre-physiotherapy session:~1. Tens~2. Infrared/Moist Heat heat for 10 minutes at the low back region.~3. Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~4. Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~5. Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~6. Postural Education~7. Home Plan~Decompression therapy session after the controlled treatment is recommended for this group."
61996494|NCT04760210|ACTIVE_COMPARATOR|ELDOA|"Pre-physiotherapy session:~1. Tens~2. Infrared/Moist Heat heat for 10 minutes at low back region.~3. Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~4. Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~5. Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~6. Postural Education~7. Home Plan~Segmental Spinal ELDOA Exercise after the controlled treatment is recommended for this group."
61996495|NCT03051048||Group 1|The patient received reperfusion therapy between 1999 January 1 and 2009 December 31
61996496|NCT03051048||Group 2|The patient received reperfusion therapy between 2010 January 1 and 2016 December 31
61996497|NCT04244786|ACTIVE_COMPARATOR|active anodal tDCS to ventrolateral prefrontal cortex (VLPFC)|"active anodal tDCS to ventrolateral prefrontal cortex (VLPFC).~1.5 milliamp (mA) anodal tDCS over right ventrolateral prefrontal cortex; 12 20-minute administrations over 6-sessions"
61996498|NCT04244786|SHAM_COMPARATOR|sham anodal tDCS to VLPFC|"sham anodal tDCS to VLPFC~Identical electrode montage, 12 administrations of sham tDCS over 6 sessions."
61996499|NCT04244786|OTHER|Discontinued prior to randomization|Participants who enrolled in the study but discontinued before being randomized to either active or sham arms of the study
61996500|NCT02182375|EXPERIMENTAL|BI 201335 NA|"400 mg raltegravir (bid) from day 1-14 and once on day 15;~240 mg BI 201335 NA (bid) from day 7-14 with a loading dose of 480 mg in the morning of day 6 and once on day 15"
61996501|NCT01418937|EXPERIMENTAL|HPV Group|
61996502|NCT06484608|EXPERIMENTAL|Isotonic Fluid Group|Neonates in this group will receive isotonic/normal saline with 5% dextrose in 0.9% saline as their maintenance fluid therapy post-surgery. This intervention aims to maintain serum sodium levels and reduce the risk of hyponatremia and other complications.
61996503|NCT06484608|ACTIVE_COMPARATOR|Hypotonic Fluid Group|Neonates in this group will receive hypotonic saline with 5% dextrose in 0.45% saline as their maintenance fluid therapy post-surgery. This intervention is being compared to isotonic fluid therapy to evaluate its effectiveness and safety in maintaining electrolyte balance and preventing hypernatremia and edema.
61996504|NCT04147312|EXPERIMENTAL|Treatment group|Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21days each cycle, and use 2 cycles
61996505|NCT04147312|PLACEBO_COMPARATOR|control group|Placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
62566019|NCT04680000|EXPERIMENTAL|Standard BCBT-CP with Telephone Booster|"Participants will receive standard BCBT-CP as described in the Standard BCBT-CP arm. They will also receive telephone or video teleconference booster contacts as follows:~BCBT-CP Booster Contacts are intended to refresh BCBT-CP content without introducing new skills. To accomplish this, Booster Contacts are manualized (see appended Booster Protocol form) to cover assessment of pain since last contact, review of most recent BCBT-CP module(s) and reminder about the next BCBT-CP appointment (if one is scheduled)."
61996506|NCT00586469|EXPERIMENTAL|Old Bulk|This group receives a full dose of Fluviral made from aged bulk material
62566020|NCT01650480|EXPERIMENTAL|Intervention group|
62566021|NCT01650480|NO_INTERVENTION|Control group|
62566022|NCT01106560|ACTIVE_COMPARATOR|Anterior Approach Group|(AMIS)
62566023|NCT01106560|ACTIVE_COMPARATOR|Posterior Approach Group|(Posterior)
62566024|NCT03686943||Elderly|Patient over 75 years seen with the mobile extra hospital geriatric team
62566025|NCT01557504|EXPERIMENTAL|Sitagliptin/metformin XR followed by placebo|Day 1 (Period 1): participants will receive a single dose of two sitagliptin/metformin XR tablets with a low- to moderate-fat meal (breakfast). Days 2-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
62566026|NCT01557504|PLACEBO_COMPARATOR|Placebo only|Days 1-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
62566027|NCT01027520|EXPERIMENTAL|Intervention|Application of Coban dressing
62566028|NCT00571727|EXPERIMENTAL|mecasermin, injections BID of rhIGF-1|
62566029|NCT00573690|EXPERIMENTAL|Group 1|Patients receive cisplatin IV over 1 hour on day 2 of courses 1 and 2 and on day 1 of all subsequent courses; etoposide IV over 30 minutes on days 1-3; and oral sorafenib tosylate once or twice daily on days 1-21. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.
62566030|NCT00573690|EXPERIMENTAL|Group 2|Patients receive carboplatin IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Patients also receive sorafenib tosylate as in group 1. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.
62566031|NCT02872714|EXPERIMENTAL|Cohort A-ID (Intermittent Dose) Pemigatinib|Pemigatinib in subjects with FGFR3 mutations or fusions.
62566032|NCT02872714|EXPERIMENTAL|Cohort A-CD (Continuous Dose) Pemigatinib|Pemigatinib in subjects with FGFR3 mutations or fusions.
62566033|NCT02872714|EXPERIMENTAL|Cohort B Pemigatinib|Pemigatinib in subjects with other FGF/FGFR alterations.
62566034|NCT00425932|NO_INTERVENTION|Rituximab/Placebo|Patients will be randomized at Baseline to either Placebo or Rituximab. At Week 24 and up to Week 48 if patient DAS28 score is \>2.6, patient will be retreated with open label Rituximab.
62566035|NCT00425932|ACTIVE_COMPARATOR|Open Label|At Week 24 or any time up to Week 48 if the Patient DAS 28 \> 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
61996507|NCT00586469|ACTIVE_COMPARATOR|New Bulk|This group receives a full dose of Fluviral made from new material
61996508|NCT01157533|EXPERIMENTAL|Vancomycin Loading|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
62772850|NCT05276895|ACTIVE_COMPARATOR|(Quercetin +Fisetin)|"20 participants with symptomatic knee osteoarthritis and ultrasonography defined effusion-synovitis will take natural Senolytic agents.~The senolytic agents act by Hit-and-run strategy therefore, intermittent dosing regimens will be applied. 1250 mg/day quercetin + 1000mg/day Fisetin for 3 consecutive days every 3 weeks.over 12 weeks"
61996509|NCT00483964|EXPERIMENTAL|A|The group getting the study drugs, Bacopa monnieri and Nardostachys jatamansi
61996510|NCT00483964|ACTIVE_COMPARATOR|B|The group getting Olanzapine
62772851|NCT05276895|ACTIVE_COMPARATOR|Quercetin +Fisetin +Glycyrrhizin)|20 participants with symptomatic knee osteoarthritis and ultrasonography-defined effusion-synovitis will take Quercetin 1250 mg + Fisetin 1000 mg for 3 consecutive days followed by 100mg/day Glycyrrhizin for one week every 3 weeks over 12 weeks .
62772852|NCT05276895|PLACEBO_COMPARATOR|Placebo|Placebo controlled group
62772853|NCT03681613|EXPERIMENTAL|Exercise Therapy With CNS Treatment|NEMEX program combined with a CNS-focused protocol
62772854|NCT03681613|EXPERIMENTAL|Exercise Therapy alone|NEMEX program alone
62772855|NCT02483949|NO_INTERVENTION|Control|
61996511|NCT02205593|PLACEBO_COMPARATOR|Control|patient group receiving regular follow-up visits (baseline, 3 months, 6 months, 9 months)
61996512|NCT02205593|ACTIVE_COMPARATOR|Haut Tief patient education|patient group receives the educational program with regular follow-up visits (baseline, 3 months, 6 months, 9 months).
61996513|NCT01725191|EXPERIMENTAL|Treatment (tivantinib)|Patients receive tivantinib PO BID on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
61996514|NCT01482260||Primary Cutaneous Malignant Melanoma|
61996515|NCT01482260||Cutaneous Malignant Melanoma Metastases|
61996516|NCT01482260||Benign Melanocytic Nevi|
62772856|NCT02483949|EXPERIMENTAL|Intervention|Lifestyle intervention with peer-counseling follow-up
62772857|NCT02093910|EXPERIMENTAL|Monosialotetrahexosylganglioside|each patient in this arm received velcade+dexamethasone (VD) regimen（bortezomib,1.3mg/㎡，subcutaneously injection，d1,8,15,22；dexamethasone,20mg d1-2, 8-9,15-16,22-23）every 4 weeks; and monosialotetrahexosylganglioside was used at the dosage of 100mg/d intravenously at d1-2,8-9,15-16,22-23 every cycle.
62772858|NCT03083223||lung disease|Patients with lung disease
62772859|NCT00813891|ACTIVE_COMPARATOR|Pre-PDT|Participants in this group will receive an intraocular Ranibizumab injection one week prior to the first PDT with verteporfin.
62772860|NCT00813891|ACTIVE_COMPARATOR|Post-PDT|Participants in this group will receive an intraocular Ranibizumab injection one week post the first PDT with verteporfin.
62772861|NCT00813891|ACTIVE_COMPARATOR|No PDT|Participants in this group will receive an intraocular Ranibizumab injection with no accompanying PDT with verteporfin.
62772862|NCT01057485|EXPERIMENTAL|AF ablation and AV node ablation|Patients will receive the combined procedure of AF ablation as well as AV node ablation
61996517|NCT01837628|ACTIVE_COMPARATOR|Lidocaine gel|Intraurethral Lidocaine gel 2%
61996518|NCT01837628|EXPERIMENTAL|Paraffin Oil|Intraurethral injection
62181541|NCT03918447|EXPERIMENTAL|Maximum bardoxolone methyl dose 30 mg|"Patients randomized to receive bardoxolone methyl with a baseline ACR greater than 300 mg/g will be titrated to a maximum dose of 30 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2, 20 mg at Week 4 and 30 mg at Week 6.~Patients will continue to receive study drug through Week 100, and will not receive study drug during a 12-week off-treatment period between Weeks 100 and 112."
62181542|NCT03918447|PLACEBO_COMPARATOR|Placebo|"Patients randomized to placebo will remain on placebo capsules throughout the study, undergoing sham titration.~Patients will continue to receive placebo capsules through Week 100, and will not receive capsules during a 12-week off-treatment period between Weeks 100 and 112."
62772863|NCT01057485|ACTIVE_COMPARATOR|AV node ablation|Patient will receive AV node ablation alone
62772864|NCT03778463|EXPERIMENTAL|Synovectomy|
61996519|NCT05719363|EXPERIMENTAL|POC ON|6MWT with Inogen Rove 6 POC turned ON
61996520|NCT05719363|SHAM_COMPARATOR|POC OFF|6MWT with Inogen Rove 6 POC turned OFF
61996521|NCT04845607|EXPERIMENTAL|Prophylactic amiodarone|
61996522|NCT04845607|NO_INTERVENTION|Conventional management|
61996523|NCT02340299|EXPERIMENTAL|nHFOV|"Immediately after extubation, nHFOV is provided via binasal prongs. Ventilator settings: Frequency set at 10 Hz, I:E ratio 33:66, amplitude 20 cm H2O, Pmean 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.~The weaning process is left to the discretion of the attending physician. Maximum amplitude 30 cm H2O, minimum frequency 9 Hz, maximum Pmean 8 cm H2O.~For infants in the nHFOV-group who fail nHFOV (see definition below), but do not need immediate reintubation, a non-invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
62181543|NCT01257412|EXPERIMENTAL|1|
62566036|NCT01739205|EXPERIMENTAL|Lifestyle counseling|"CALM-D Intervention Session Topic Weekly~1. I Welcome to the CALM-D Program. Getting Started Being Active, Losing Weight and Managing Stress~2. I Negative Thoughts and Emotions~3. G Where's the Fat?/Three Ways to Eat Less Fat~4. G Taking Your Medications/Stress and You Bi weekly~5. G Move Those Muscles/Being Active: A Way of Life~6. G Challenging and Changing Negative Thoughts~7. G Healthy Eating~8. G Problem Solving Monthly~9. G Four Keys to Healthy Eating Out~10. G Social Support/Communication~11. G Take Charge of What's Around You/Tip the Calorie Balance~12. G The Slippery Slope of Lifestyle Change~13. G Jump Start Your Activity Plan~14. G Assertiveness/Make Social Cues Work for You.~15. G You Can Manage Stress~16. G Life Goals~17. G Ways to Stay Motivated Abbreviations: I = Individual session; G = Group session"
61996524|NCT02340299|ACTIVE_COMPARATOR|nCPAP|"Immediately after extubation, nCPAP is provided via binasal prongs. Ventilator settings: CPAP level set at 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.~The weaning process is left to the discretion of the attending physician. Maximum CPAP level 8 cm H2O, maximum flow 8 l/min.~For infants in the nCPAP-group who fail nCPAP (see definition below), but do not need immediate reintubation, Rescue-nHFOV via binasal prongs may be provided. The decision to attempt Rescue-nHFOV and the ventilator settings used are at the discretion of the attending clinician."
61996525|NCT05167162|ACTIVE_COMPARATOR|Group 1: Compression technique|20 participants make up the compression technique group.
61996526|NCT05167162|ACTIVE_COMPARATOR|Group 2: Massage techniques|20 participants make up the massage technique group.
62181544|NCT01257412|EXPERIMENTAL|2|
62181545|NCT01257412|PLACEBO_COMPARATOR|3|
62566037|NCT00373230|EXPERIMENTAL|1|Internet based telemedicine weight maintenance program
62566038|NCT00373230|ACTIVE_COMPARATOR|2|In person weight maintenance monthly consultations
62566039|NCT05953935|EXPERIMENTAL|A-E group|Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments, in patients with ulcers of venous etiology.
62566040|NCT05953935|EXPERIMENTAL|B-E group|Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments in patients with diabetic foot ulcers.
62566041|NCT05953935|EXPERIMENTAL|A-C grouop|Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments in CDH.
62181546|NCT04633785||wrist BP|
62181547|NCT03772509|EXPERIMENTAL|CATI|Introduction and consent via computer assisted telephone interview
62181548|NCT03772509|NO_INTERVENTION|IVR|Introduction and consent via interactive voice response
62772865|NCT03778463|NO_INTERVENTION|No synovectomy|
62181549|NCT03481556|EXPERIMENTAL|A (melflufen+bortezomib+dex)|Melflufen 30 mg and 40 mg or 20 mg i.v. Day 1 of each 28-day cycle in combination with bortezomib at 1.3mg/m² S.Q. on Days 1, 4, 8, 11 and dexamethasone 20 mg (12 mg ≥ 75 years) Days 1, 4, 8, 11 and 40 mg (20 mg ≥ 75 years) on Day 15 and 22 of each 28-day cycle.
61996527|NCT05167162|ACTIVE_COMPARATOR|Group 3: Hydromassage|20 participants make up the hydromassage technique group.
61996528|NCT05167162|ACTIVE_COMPARATOR|Group 4: Active recovery technique.|20 participants make up the active recovery technique group.
61996529|NCT03033472|EXPERIMENTAL|Clindamycin|600 mg of Clindamycin orally 30 minutes before root canal treatment
61996530|NCT03033472|PLACEBO_COMPARATOR|Placebo|placebo 30 minutes Orally before treatment
61996531|NCT00850031|EXPERIMENTAL|AcuFocus Corneal Inlay|Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.
62181550|NCT03481556|EXPERIMENTAL|B (melflufen+daratumumab+dex)|Melflufen 30 mg and 40 mg or 20 mg i.v. Day 1 of each 28-day cycle in combination with daratumumab 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks. Dexamethasone p.o. 40 mg weekly (20 mg weekly for patients age ≥ 75 years).
62181551|NCT01607931|NO_INTERVENTION|Resting Trial|a 1 hour period of rest immediately prior to OGTT or isoglycemic clamp
62181552|NCT01607931|EXPERIMENTAL|Exercise Trial|a 1 hour cycling exercise bout immediately prior to the OGTT or isoglycemic clamp
62181553|NCT02643511|EXPERIMENTAL|Prostate biopsy,Hemiablative focal Brachytherapy|This is a non-randomized, Phase II study examining the efficacy in terms of postimplant dosimetry (primary endpoint) as well as the secondary endpoints of QOL changes, toxicity, local control with post-treatment biopsy outcomes and comparison with historical whole-gland cohorts in men with early stage low volume prostate cancer treated with hemiablative focal brachytherapy
62566042|NCT05953935|EXPERIMENTAL|B-C grouop|Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under subthermal conditions plus standard clinical treatments in CDH.
62566043|NCT05953935|EXPERIMENTAL|C-C group|Standard clinical treatments established on the basis of the treatment standards of the International Working Group on the Diabetic Foot (IWGDF), in the case of diabetic foot ulcers (2, 3). For ulcers of venous etiology, the treatment standards according to the guidelines of the Spanish Association of Vascular Nursing and Wounds (Asociación Española de Enfermería Vascular y Heridas) will also be applied.
62566044|NCT05754892|OTHER|Patients with ACC|These patients will be followed up and proposed a search for targetable molecular alterations
62566045|NCT05754892|OTHER|Patients with MPP|These patients will be followed up and proposed a search for targetable molecular alterations
62566046|NCT01592786|EXPERIMENTAL|Memantine Hydrochloride (HCl)|Once daily oral administration of open-label memantine for up to 48 weeks: 6-week dose-titration period followed by up to 42-week maintenance period.
62566047|NCT00328497|EXPERIMENTAL|1|Panzem NCD will be dosed orally at a level of 1,000 mg, four times daily for 28 consecutive days and bevacizumab will be administered at a dose of 5 mg/kg as an intravenous bolus on Day 1 and Day 15 of the Treatment Period
62566048|NCT02268916|EXPERIMENTAL|Intervention|OT-led counseling based on home activity pattern
62566049|NCT02268916|PLACEBO_COMPARATOR|Wait-listed|Usual activity during the study. At the end of the study, will receive OT-led counseling
62566050|NCT04181294|EXPERIMENTAL|Pre-intervention|Baseline data on patient characteristics and outcomes will be collected for 4 months prior to intervention.
62566051|NCT04181294|EXPERIMENTAL|Post-intervention|The quality improvement intervention will be conducted sequentially at all 3 medical centers (LAC-USC, Olive View, and Harbor-UCLA Medical Centers). Data on patient characteristics and outcomes will be collected for 4 months after the intervention
62566052|NCT05206006|OTHER|Control Group|As routine care, the choice of the initial antibiotic regimen will be let to the discretion of the emergency physician.
62566053|NCT05206006|EXPERIMENTAL|computerized decision support app (CDSA) Group|
62566054|NCT05418881|OTHER|postoperative Spot Measurements|Measurement of vital signs via 4 different tracking devices in the setting of post-anaesthesia care unit. Simultaneous collection of vital signs measured by the gold standard of clinical monitoring (ecg, blood-gas-analysis, invasive blood pressure, transmissive photoplethysmography).
62566055|NCT05418881|OTHER|Longitudinal postoperative Measurements|Continuous measurement of vital signs and activity level with tracking devices for the postoperative period in the patient ward up until 21 days postoperative.
62566056|NCT05798975|EXPERIMENTAL|Aerobic Physical Exercise|Cycle ergometer exercise
61996532|NCT04584710|EXPERIMENTAL|10 mg daily RTB101|"RTB101~TORC1 inhibitor"
61996533|NCT04584710|PLACEBO_COMPARATOR|Placebo|Placebo
61996534|NCT04700748|OTHER|Diffusion-weighted MRI to predict treatment response in stereotactic radiotherapy of CNS metastases.|Patients with brain metastases who will receive radiotherapy to the brain will undergo diffusion-weighted magnetic resonance imaging (MRI) at the same time as dose planning MRI is performed, after end of radiotherapy, and after 3 and 6 months after end of radiotherapy.
61996535|NCT06485271||cohort 1|First-line
62566057|NCT05798975|EXPERIMENTAL|Resistance Physical Exercise|Exercise with weights
62772866|NCT03656081|PLACEBO_COMPARATOR|Itraconazole & inhaled placebo|Itraconazole 200 mg x 2/day associated with inactive nebulised treatment (isotonic saline) twice a week during 24 weeks.
61996536|NCT06485271||cohort 2|Second-line
62566058|NCT05798975|NO_INTERVENTION|Control|No exercise. Rest
61996537|NCT06485271||cohort 3|Third-line and above
61996538|NCT03856437|EXPERIMENTAL|Gain-framed messages|Participants in this arm receive gain-framed HPV vaccination messages.
61996539|NCT03856437|EXPERIMENTAL|Loss-framed messages|Participants in this arm receive loss-framed HPV vaccination messages.
61996540|NCT03856437|ACTIVE_COMPARATOR|Control messages|Participants in this arm receive non-framed HPV vaccination messages.
62566059|NCT04209452|NO_INTERVENTION|Control|No intervention will be provided for participants enrolled in the control group.
62566060|NCT04209452|EXPERIMENTAL|Rehearsal|Participants will receive instruction on rehearsal strategy.
61996541|NCT02039609||Omnivores|No intervention, habitual diet
61996542|NCT02039609||Vegetarians|No intervention, habitual diet
61996543|NCT02039609||Vegans|No intervention, habitual diet
61996544|NCT02039609||Vegetarians consuming fish|No intervention, habitual diet
62181554|NCT02741713|SHAM_COMPARATOR|Interscalene Block plus Sham Block|"Twenty subjects will receive an ultrasound guided interscalene nerve block using the Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. A Sham Block of in area of PECS Pectoralis block will be done to allow for assessment of the intervention. Using the Solution for Injection in Sham Block."
61996545|NCT02881996|EXPERIMENTAL|IV tylenol|Post-operatively, all patients will be placed on a standard patient/nurse controlled analgesia (PCA) according to our pain service protocol which included ketorolac. A 3 hours after first dose of ketorolac, patients in the acetaminophen arm will then receive scheduled 10mg/kg of IV acetaminophen every 6hrs for a total of 3 days in between doses of ketorolac. PCA Pumps will be discontinued with the return of bowel function and transition to oral intake in all patients as per the current protocol. If a patient in the acetaminophen arm is transitioned off of PCA prior to 3 days, IV acetaminophen will be stopped at that time as well. Patients in the control group only may receive oral/rectal acetaminophen as needed for treatment of fevers.
61996546|NCT02881996|ACTIVE_COMPARATOR|No IV tylenol|Same as above without IV tylenol.
62181555|NCT02741713|ACTIVE_COMPARATOR|Interscalene plus PECS Blocks|"Twenty patients will receive an ultrasound guided interscalene nerve block Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. For the Intervention, these subjects will also a PECS Pectoralis 1 and 2 Blocks using the Solution for Injection PECS Blocks, dosed at the PECS1 location and PECS2 location as described by Blanco, et al."
61996547|NCT00082433|EXPERIMENTAL|A|
61996548|NCT00082433|ACTIVE_COMPARATOR|B|
61996549|NCT04076969|EXPERIMENTAL|Integrated Educational Session|The anemic pregnant women in the study group received an integrated health education in one session. The educational session was steered as 40-minutes session in a personalized manner. The educational session content included; disease specific information, effect of anemia on maternal and neonatal outcome, management possibilities, the effectiveness, benefits and disadvantages of treatment options, identify diet rich with iron, false dietary habits prevent iron absorption and the balanced diet and meals.
61996550|NCT04076969|OTHER|Routine follow up|Routine follow up
61996551|NCT01010048|EXPERIMENTAL|progesterone,tamsulosin,propantheline Bromide and nifedipine|different effect of these drugs use to treat urinary calculus after ESWL
62181556|NCT04759950|EXPERIMENTAL|Physical exercise & cognitive training group|The Physical exercise \& cognitive training group receives a multicomponent physical exercise program combined with computer-based cognitive training.
62181557|NCT04759950|EXPERIMENTAL|Mindfulness & cognitive training group|The Mindfulness \& cognitive training group receives mindfulness-based stress reduction therapy combined with computer-based cognitive training.
62181558|NCT04759950|ACTIVE_COMPARATOR|Cognitive training group|The Cognitive training group, as an active control group, receives only computer-based cognitive training.
62181559|NCT00779064|EXPERIMENTAL|Arm 1|
62181560|NCT00779064|EXPERIMENTAL|Arm 2|
62181561|NCT04162236||High Risk of Preeclampsia|"Women with a singleton pregnancies attending for prenatal care in the maternal and fetal Medicine Unit will be asked to participate if they meet the following criteria:~1)High risk for preeclampsia according to first trimester screening (maternal risk factors, blood preassure, PPAP-A, mean pulsatility index (PIm) of the uterine arteries (UtA) at 11.0 to 13.6 weeks of gestation (n=280).~Women in this group will be subdivided in cases and controls according to the later development of preeclampsia:~* cases: women developing PE (estimated n=40)~* controls: women not developing PE (estimated n=240)"
62566061|NCT04209452|EXPERIMENTAL|Reinforcement|Participants will receive reinforcement for correct recall.
62566062|NCT04209452|EXPERIMENTAL|Rehearsal + Reinforcement|The participants in this group will receive instruction on rehearsal strategy and reinforcement for correct recall.
62566063|NCT02162134|OTHER|no chewing gum.|the no chewing gum group was control and receive no chewing gum postoperatively. While they received all other medications like anesthesia, antibiotics etc
62566064|NCT02162134|EXPERIMENTAL|sugar free chewing gum|sugar free chewing was given to patients 4 hours after surgery then continue it 8 hourly (20 to 25 minutes each time) until oral feeding is started.
62772867|NCT03656081|EXPERIMENTAL|Itraconazole & inhaled Ambisome®|Itraconazole 200 mg x 2/day associated with inhaled liposomal amphotericin B (Ambisome®) at 25 mg twice a week during 24 weeks
61996552|NCT06291558|EXPERIMENTAL|Face to face Exercise Group|In the face-to-face exercise group called Group 1, students will implement an exercise program of respiratory exercises and resistance exercises with the physiotherapist. Exercises will be held for 8 weeks
61996553|NCT06291558|EXPERIMENTAL|Telehealth Exercise Group|In the online (telehealth) exercise group, group 2 will be applied by the students with the help of the physiotherapist. Exercises will be held for 8 weeks
62566065|NCT02162134|EXPERIMENTAL|sugared chewing gum|sugared chewing gum will be given 4 hours after surgery then continue it 8 hourly (20 to 25 minutes each time) until oral feeding is started
61996554|NCT06291558|NO_INTERVENTION|Control Group|In the control group called Group 3, students will not be given any exercise program.
61996555|NCT01365273|NO_INTERVENTION|Bridal Veil together with staples|Standard of care. Bridal Veil is fixed over the graft with staples.
61996556|NCT01365273|ACTIVE_COMPARATOR|Mepitel One|Device, dressing
62566066|NCT00982787|EXPERIMENTAL|1|
62566067|NCT00982787|PLACEBO_COMPARATOR|2|
62566068|NCT05695612|EXPERIMENTAL|Novaloc Attachment|
62566069|NCT05695612|ACTIVE_COMPARATOR|Locator attachment|
62566070|NCT00505713|EXPERIMENTAL|1|Dose Level 1 of escalating doses of Rexin-G i.v.
62566071|NCT00505713|EXPERIMENTAL|3|Dose Level 3 of escalating doses of Rexin-G i.v.
62566072|NCT00505713|EXPERIMENTAL|4|Dose Level 4 of escalating doses of Rexin-G i.v.
62566073|NCT00505713|EXPERIMENTAL|5|Dose Level 5 of escalating doses of Rexin-G i.v.
62566074|NCT00505713|EXPERIMENTAL|2|Dose Level 2 of escalating doses of Rexin-G i.v.
62566075|NCT01521832|EXPERIMENTAL|Dose Group A|
62566076|NCT01521832|EXPERIMENTAL|Dose Group B|
62566077|NCT01521832|EXPERIMENTAL|Dose Group C|
62566078|NCT01521832|EXPERIMENTAL|Dose Group D|
62566079|NCT01521832|EXPERIMENTAL|Dose Group E|
62566080|NCT01521832|EXPERIMENTAL|Dose Group F|
62566081|NCT01521832|EXPERIMENTAL|Dose Group H|
61996557|NCT06188442|ACTIVE_COMPARATOR|DoxyODPrEP|Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. If they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex.
61996558|NCT06188442|ACTIVE_COMPARATOR|DoxyPEP|Participants in the DoxyPEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex.
61996559|NCT01622855|EXPERIMENTAL|PPRS video|Prevention of post sexual assault stress
61996560|NCT01622855|NO_INTERVENTION|Standard care|Receipt of standard services
61996561|NCT00193882|ACTIVE_COMPARATOR|A: Radiotherapy|Radiotherapy alone
61996562|NCT00193882|EXPERIMENTAL|B: Chemo-radiotherapy|Chemotherapy (Cisplatin + 5-Fluorouracil ) and Radiotherapy
61996563|NCT02808286|EXPERIMENTAL|Hybrid|"The hybrid emotion-focused treatment consists of 10-15 individual 1/1,5 hour sessions. It includes the following stages (examples of methods in parathesis)~Stage I. Analysis of emotions and pain (Validation, Compassion, Chain analysis, Values \& goals).~Stage II. Developing skills (Dialectics, Self-validation, Self-compassion, emotion regulation skills).~Stage III. Exposure training (Exposure for emotionally sensitive stimuli, exposure in vivo for avoided movements).~Stage IV. Maintenance (Identifying key elements, Planning for flare-ups)."
61996564|NCT02808286|ACTIVE_COMPARATOR|internet Cognitive Behavior Therapy (iCBT)|CBT pain treatment, delivered via the internet consists of 8, weekly, modules and includes topics such as pain education, pain coping strategies (e.g. pacing), relaxation, cognitive restructuring, problem solving, stress and sleep management, conflict resolution. Patients read materials included in each module and do homework tasks on which they report back to the therapist via the internet. The therapist gives written feedback and guidance after each module. See reference for details.
61996565|NCT06287346||One-piece|One-piece CeraRoot dental implants
61996566|NCT06287346||Two-piece (TL)|Two-piece CeraRoot TL dental implants
61996567|NCT00590954|EXPERIMENTAL|Treatment|Following a diagnosis of tumor recurrence or progression, all patients will receive perifosine monotherapy until toxicity, progression, or death.
61996568|NCT02674620|NO_INTERVENTION|Conservative|Standard conservative care of concussion
61996569|NCT02674620|EXPERIMENTAL|Treadmill|Aerobic exercise treatment for concussion
61996570|NCT04292730|EXPERIMENTAL|Part A: Remdesivir (RDV), 5 Days|Participants will receive continued standard of care (SOC) therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
61996571|NCT04292730|EXPERIMENTAL|Part A: Remdesivir, 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
61996572|NCT04292730|ACTIVE_COMPARATOR|Part A: SOC Therapy|Participants will receive continued standard of care therapy.
61996573|NCT04292730|EXPERIMENTAL|Part B: Extension Treatment, Remdesivir 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
61996574|NCT02825836|EXPERIMENTAL|TL-895 80/160 mg QD in R/R Participants|Participants received TL-895 80 mg powder in capsule (PiC) orally once daily (OD) for 3 days followed by TL-895 160 mg OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
61996575|NCT02825836|EXPERIMENTAL|TL-895 300 mg QD in R/R Participants|Participants received TL-895 300 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
62566082|NCT01521832|EXPERIMENTAL|Dose Group I|
62566083|NCT01521832|EXPERIMENTAL|Dose Group J|
62566084|NCT01521832|EXPERIMENTAL|Dose Group K|
62566085|NCT01521832|EXPERIMENTAL|Dose Group L|
62566086|NCT03131817|EXPERIMENTAL|PD with mood disorder or impulsivity|This is a single-center study of the neurophysiology of non-motor symptoms such as anxiety, depression, and impulsivity that are comorbid in Parkinson's Disease.
62772868|NCT01600092|EXPERIMENTAL|RotaTeq™ Experimental Formulation|Three 2.0 mL oral doses of RotaTeq™ experimental formulation. Vaccination 1 will be administered between 6 and 12 weeks of age and the third vaccination will be administered before 32 weeks of age. Each vaccination will be separated from the next by ≥ 4 weeks (28 days)
62772869|NCT01600092|ACTIVE_COMPARATOR|RotaTeq™ Existing Formulation|Three 2.0 mL oral doses of RotaTeq™ existing formulation. Vaccination 1 will be administered between 6 and 12 weeks of age and the third vaccination will be administered before 32 weeks of age. Each vaccination will be separated from the next by ≥ 4 weeks (28 days).
61996576|NCT02825836|EXPERIMENTAL|TL-895 600 mg QD in R/R Participants|Participants received TL-895 600 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
61996577|NCT02825836|EXPERIMENTAL|TL-895 300 mg BID in R/R Participants|Participants received TL-895 300 mg PiC orally twice daily (BID) in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
62772870|NCT03855852|ACTIVE_COMPARATOR|Xenograft and Collagen membrane|Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge when 2-4 mm of implant threads exposure .
62772871|NCT03855852|EXPERIMENTAL|Xenograft and A-PRF|Placing the implant with xenograft and A-PRF at esthetic zone of maxillary ridge when 2-4 mm of implant threads exposure .
62772872|NCT03134339|EXPERIMENTAL|saline 0.00mcg/kg/s|0.00 mcg/kg/s The day order will be randomized per day
62772873|NCT03134339|EXPERIMENTAL|0.24mcg/kg/s|0.24 mcg/kg/s The day order will be randomized per day
62772874|NCT03134339|EXPERIMENTAL|0.048mcg/kg/s|0.048 mcg/kg/s The day order will be randomized per day
62772875|NCT03134339|EXPERIMENTAL|0.024 mcg/kg/s|0.024 mcg/kg/s The day order will be randomized per day
61996578|NCT02825836|EXPERIMENTAL|TL-895 900 mg QD in R/R Participants|Participants received TL-895 900 mg PiC orally QD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
61996579|NCT02825836|EXPERIMENTAL|TL-895 100 mg BID in R/R Participants|Participants received TL-895 100 mg BID orally with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
61996580|NCT02825836|EXPERIMENTAL|TL-895 150 mg BID in R/R Participants|Participants received TL-895 150 mg BID orally with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
61996581|NCT02825836|EXPERIMENTAL|TL-895 150 mg BID in Treatment Naïve Participants|Participants received TL-895 150 mg BID orally with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
62772876|NCT04023682|OTHER|Anesthesia Provider hands|"Each provider will serve as their own control.~Control phase is at baseline using standard hygiene practices.~Intervention phase will include the addition of Provodine hand sanitizer"
61996582|NCT02825836|EXPERIMENTAL|TL-895 100 mg BID in Treatment Naïve Participants|Participants received TL-895 100 mg BID orally with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
61996583|NCT02825836|EXPERIMENTAL|TL-895 150 mg BID & navtemadlin 240mg QD in R/R Participants without 17p(del)|Participants received navtemadlin 240 mg administered QD on Days 1-7 in combination with TL-895 150 mg BID orally with food for 28 days with in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
61996584|NCT02825836|EXPERIMENTAL|TL-895 150 mg BID & navtemadlin 240mg QD in Treatment Naïve Participants without 17p(del)|Participants received navtemadlin 240 mg administered QD on Days 1-7 in combination with TL-895 150 mg BID orally with food for 28 days with in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
61996585|NCT02825836|EXPERIMENTAL|TL-895 150 mg BID & navtemadlin 240mg QD in R/R Participants with 17p(del)|Participants received navtemadlin 240 mg administered QD on Days 1-7 in combination with TL-895 150 mg BID orally with food for 28 days with in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
61996586|NCT04473651|EXPERIMENTAL|Part A: Single dose of Lu AG06479 or Placebo|
61996587|NCT04473651|EXPERIMENTAL|Part B: Repeated dose of Lu AG06479 and Food interaction|"Sequence B1: Fed - Fasting - Fasting~Sequence B2: Fasting- Fed - Fasting~Sequence B3: Fasting- Fasting - Fed"
61996588|NCT01944995|EXPERIMENTAL|group B|
61996589|NCT01944995|EXPERIMENTAL|group A|
61996590|NCT04067362|PLACEBO_COMPARATOR|no fiber|Breakfast with hot chocolate with no fiber
61996591|NCT04067362|EXPERIMENTAL|chicory root flour|Breakfast with hot chocolate with chicory root flour
61996592|NCT04067362|EXPERIMENTAL|chicory root fiber supplement|Breakfast with hot chocolate with chicory root fiber supplement
61996593|NCT01520129|OTHER|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
61996594|NCT03871127||Left main coronary disease|
62181562|NCT04162236||Patients with Preeclampsia|Women with a singleton pregnancies attending for prenatal care in the maternal and fetal Medicine Unit will be asked to participate if they develop PE. Inclusion criteria: Patients presented with clinical signs and symptoms of preeclampsia (N=60).
62772877|NCT04997525|ACTIVE_COMPARATOR|Natural cycle|These women will follow their natural cycle and receive one injection of hCG for stimulation of ovulation before embryo transfer
62772878|NCT04997525|ACTIVE_COMPARATOR|Estradiol and progesterone|These women will receive daily estradiol and progesterone tablets/capsules before and after embryo transfer. Treatment will continue until gestational age 9+6
62772879|NCT04997525|ACTIVE_COMPARATOR|Gonadotropin|These women will receive daily gonadotropin injection before embryo transfer. Ovulation will be stimulated using hCG injection.
62566087|NCT06506916|EXPERIMENTAL|Cohort A|Study participants with moderate to severe plaque PSO without concomitant active PsA (Cohort A) receive bimekizumab dosage regimen 1 from Baseline up to Week 16 and bimekizumab regimen 2 from Week 16 up to Week 48. Study participants, fulfilling randomization criteria receive bimekizumab dosage regimen 2 or 3 from Week 48 to Week 96. Study participants who do not meet the criteria for randomization receive bimekizumab dosage regimen 2 to Week 96.
62181563|NCT04162236||Control group|Healthy pregnant women with at low risk PE screening at 11.0 to 13.6 weeks of gestation (n=100).
62181564|NCT04249518|NO_INTERVENTION|nurse instruction of CPAP|Normal extradition. 45 minutes face to face with a nurse.
62181565|NCT04249518|EXPERIMENTAL|Video extradition|Access to 7 min video - explaining how to start CPAP and how to adjust the mask.
62566088|NCT06506916|EXPERIMENTAL|Cohort B|Study participants with moderate to severe plaque PSO with concomitant active PsA (Cohort B) receive bimekizumab dosage regimen 1 from Baseline up to Week 16 and bimekizumab regimen 2 from Week 16 up to Week 48. Study participants, fulfilling randomization criteria receive bimekizumab dosage regimen 2 or 3 from Week 48 to Week 96. Study participants who do not meet the criteria for randomization receive bimekizumab dosage regimen 2 to Week 96.
62566089|NCT06506916|NO_INTERVENTION|Control Cohort|Healthy participants, who will not receive IMP during the study.
62566090|NCT01808417|EXPERIMENTAL|Near Infrared Imaging|The intervention to be administered is the indocyanine green for NIR Lymphatic Mapping. All study subjects will receive this same intervention; there is only one arm.
62566091|NCT01333592|EXPERIMENTAL|KAD-1229|
62566092|NCT03216122|ACTIVE_COMPARATOR|Control group (CG)|The implant will be loaded after 3-4 months of placement (Conventional/Delayed Loading)
62566093|NCT03216122|ACTIVE_COMPARATOR|Test group (TG)|The implant will be loaded non-occlusally within 3-4 days of placement (Immediate Loading)
62566094|NCT01474174||Supportive care (vaccine therapy)|Patients receive trivalent influenza vaccine IM on day 0.
62181566|NCT04266002|OTHER|HIV-1 infected adult associated neurocognitiv|HIV-1 infected adult subjects with HIV-associated neurocognitive disorders despite effective antiretroviral therapy in plasma for more than one year, analyzing the evolution of cognitive disorders with Global Deficit Score and HAND classification, and markers of macrophagic inflammation in blood and cerebrospinal fluid, after a change in HIV treatment with an increased of the new scale CHARTER score ≥ 3 (total treatment score to be ≥ 9)
62181567|NCT04296422|ACTIVE_COMPARATOR|Conventional Gynecologic Treatment group|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
62181568|NCT04296422|EXPERIMENTAL|Low dose acupuncture group|Acupuncture has fewer acupuncture points.
62181569|NCT04296422|EXPERIMENTAL|High dose acupuncture group|Acupuncture has more acupuncture points.
62566095|NCT00302380||un-medicated subjects with ADHD|
62566096|NCT00302380||subjects without ADHD|
62566097|NCT02056210|EXPERIMENTAL|Stem cell mobilization in diabetic patients|Injection of Mozobil (Plerixafor / AMD3100) in diabetic patients
62566098|NCT02056210|EXPERIMENTAL|Stem cell mobilization in non diabetic subjects|Injection of Mozobil (Plerixafor / AMD3100) in non diabetic subjects
62566099|NCT03669380||conservative treatment|Conservative treatment consisted of bowel rest, intravenous fluid therapy, nutritional support, strict blood pressure control, anticoagulation (with or without antiplatelet) and close observation
62566100|NCT03669380||Interventional and surgical treatment|Interventional and surgical treatment
62566101|NCT06577428|EXPERIMENTAL|RAY1225 - Upper Arm|Participants received 3mg RAY1225 by subcutaneous injection on upper arm.
62566102|NCT06577428|EXPERIMENTAL|RAY1225 - Thigh|Participants received 3mg RAY1225 by subcutaneous injection on thigh.
62772880|NCT02476474|ACTIVE_COMPARATOR|3 cm start of resection|The line of resection for the Laparoscopic Sleeve gastrectomy will start at 3 cm from pylorus (antrum).
62772881|NCT02476474|ACTIVE_COMPARATOR|6 cm start of resection|The line of resection for the Laparoscopic Sleeve gastrectomy will start at 6 cm from pylorus (antrum).
62772882|NCT06530719|EXPERIMENTAL|Osimertinib group|"Experimental: Osimertinib 80mg QD~All patients will only receive Osimertinib 80mg QD.~Dose may be reduced to allow for the management of related toxicity."
62772883|NCT02237482|EXPERIMENTAL|Small periacetabular bone defects|Patients with cup loosening and small periacetabular bone defects
62772884|NCT02237482|EXPERIMENTAL|Large periacetabular bone defects|Patients with cup loosening and large periacetabular bone defects
62772885|NCT05833724|EXPERIMENTAL|Chidamide|Chidamide tablets orally, twice a week.
62772886|NCT00909740|EXPERIMENTAL|1|
62772887|NCT06256991|EXPERIMENTAL|Patiromer|All participants will receive patiromer 8.4g/d (powder for oral suspension) during one of the two 12-week study periods. Following a 6-week washout, participants will switch from the patiromer arm to the placebo arm or vice versa (cross-over design).
62772888|NCT06256991|PLACEBO_COMPARATOR|Placebo|All participants will receive placebo 8.4g/d (powder for oral suspension) during one of the two 12-week study periods. Following a 6-week washout, participants will switch from the patiromer arm to the placebo arm or vice versa (cross-over design).
62772889|NCT04183088|EXPERIMENTAL|Part 1: Tislelizumab intravenously + regorafenib orally|Part 1 is a single-arm study. All eligible patients will receive tislelizumab 200 mg intravenously on day 1 every 3 weeks plus regorafenib orally 80 mg per day.
62772890|NCT04183088|EXPERIMENTAL|Groups (1) of part 2: Tislelizumab intravenously + regorafenib|Tislelizumab 200 mg intravenously on Day 1+Regorafenib its dosage in the randomized cohort will be determined according to results in the safety cohort.
62566103|NCT06577428|EXPERIMENTAL|RAY1225 - Abdomen|Participants received 3mg RAY1225 by subcutaneous injection on abdomen.
62566104|NCT00323453|EXPERIMENTAL|Experimental Arm|The experimental arm will undergo open appendectomy utilizing the Alexis® retractor (wound protection device utilized intraoperatively), followed by standardized wound closure.
62566105|NCT00323453|PLACEBO_COMPARATOR|Control Arm|Open appendectomy and standardized wound closure
62566106|NCT04025060|EXPERIMENTAL|Caffeine-free Soda|Consumption of caffeine-free soda daily for two weeks
62566107|NCT04025060|EXPERIMENTAL|Carbonated Water|Consumption of unsweetened, carbonated water daily for two weeks
62566108|NCT04025060|ACTIVE_COMPARATOR|Regular Soda|Consumption of regular soda daily for two weeks
61996595|NCT03251573||Normal cognitive function|The cognitive impairment classification algorithm We classified subjects as having no, mild, or major cognitive impairment using criteria from the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) as a guideline.20 The age and/or education-adjusted raw score of each individual cognitive test was calculated and compared with the age and/or education-adjusted published norms for Chinese populations.14 Specifically, age- and education-adjusted scores less than 1.5 standard deviations (SDs) below the adjusted mean of the published population norms on all tests in all domains indicated no cognitive impairment; scores of 1.50 to 1.99 SDs and 2.0 or more SDs below the adjusted mean of the published norms on at least one test in at least one domain indicated mild cognitive impairment and major cognitive impairment, respectively
62181570|NCT06002321||HFpEF|The HFpEF group includes patients with signs and/or symptoms of heart failure and LVEF \> 50% and objective evidence of structural and/or functional cardiac abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures, including raised natriuretic peptides.
62566109|NCT03540888|EXPERIMENTAL|Deep Transverse Friction Massage group|Deep transverse friction massage group. Participants were taught by one of the examiners how to sit and perform pre-exercise self-massages on their tested leg musculotendinous junction (MTJ). The procedure consisted of applying friction massage by fingertips transversely to the hamstrings tendon, in a sitting position. The tendon was located over four finger widths proximal to the medial and lateral epicondyles of the femur. One examiner carefully monitored how the technique was performed to assure the precision of the application. This massage technique was applied over a duration of 30 seconds.
62566110|NCT03540888|ACTIVE_COMPARATOR|Dynamic stretching intervention|The dynamic stretching intervention was included for its positive effects on agility and muscle strength. Participants in this group, swung their tested leg actively into hip flexion while keeping their knee fully extended and their ankle fully plantar flexed until a stretch was felt in the posterior thigh. This was repeated over 30 seconds and included in the participant's warm-up phase.
62181571|NCT06002321||HFmrEF|The HFmrEF group includes patients with signs and/or symptoms of heart failure and LVEF 41-49%.
62181572|NCT06002321||HFrEF|The HFrEF group includes patients with signs and/or symptoms of heart failure and LVEF \< 40%.
62181573|NCT01927822||Pregnancy|Women who underwent termination of pregnancy at second trimester due to a variety of causes
62181574|NCT04964245|EXPERIMENTAL|Respiration monitoring group|The respiration is simultaneously measured by accelerometer, thermographic camera, Impedance Tomography, and mattress sensor.
62566111|NCT03540888|ACTIVE_COMPARATOR|Static stretching intervention|In the static stretching intervention, all participants laid on the floor in a supine position with both feet pointing upwards, with the tested limb in full knee extension and the foot in a relaxed position. The tested limb was moved up passively to a point of slight pain or discomfort at the posterior aspect of the thigh. This technique puts the hamstrings muscle at its greatest possible length. This position should be held for 30 seconds and was performed three times for a total of one minute and 30 seconds, 15 minutes after a match or training. The contralateral leg was stabilized by means of another collaborator in order to prevent compensation by rotation or elevation of the pelvis.
62566112|NCT03252535|EXPERIMENTAL|Cellavita HD Lower Dose|The participants randomized to this group will receive a total of 9 intravenous administrations of 1x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
62566113|NCT03252535|EXPERIMENTAL|Cellavita HD Higher Dose|The participants randomized to this group will receive a total of 9 intravenous administrations of 2x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
62566114|NCT03252535|PLACEBO_COMPARATOR|Placebo Group|The participants randomized to this group will receive a total of 9 intravenous administrations divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
62566115|NCT01481948|EXPERIMENTAL|story plus behaviorial procedures|The girls randomized to this arm of the study will view an interactive story about 6 8-10 year old African American girls who seek to find clues to solve a mystery about the town in which they live. The episodes will contain information about healthy nutrition and physical activity, as well as basic information about physical activity and kitchen safety tips, developmentally appropriate recipes, and portion sizes. Girls randomized to this arm of the study will also engage in key behavior change procedures, such as goal setting, problem solving, and self monitoring.
62566116|NCT01481948|ACTIVE_COMPARATOR|story only|The girls randomized to this arm of the study will view an interactive story about 6 8-10 year old African American girls who seek to find clues to solve a mystery about the town in which they live. The episodes will contain information about healthy nutrition and physical activity, as well as basic information about physical activity and kitchen safety tips, developmentally appropriate recipes, and portion sizes. Girls randomized to this arm of the study will not engage in key behavior change procedures, such as goal setting, problem solving, and self monitoring.
61996596|NCT03251573||cognitive impairment|The cognitive impairment classification algorithm We classified subjects as having no, mild, or major cognitive impairment using criteria from the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) as a guideline.20 The age and/or education-adjusted raw score of each individual cognitive test was calculated and compared with the age and/or education-adjusted published norms for Chinese populations.14 Specifically, age- and education-adjusted scores less than 1.5 standard deviations (SDs) below the adjusted mean of the published population norms on all tests in all domains indicated no cognitive impairment; scores of 1.50 to 1.99 SDs and 2.0 or more SDs below the adjusted mean of the published norms on at least one test in at least one domain indicated mild cognitive impairment and major cognitive impairment, respectively
62181575|NCT01800539|EXPERIMENTAL|Provider Education Model (PEM)|condition wherein providers will receive specially structured training during their typical home visits based by Kennedy Krieger Institute (KKI) staff
62566117|NCT01481948|NO_INTERVENTION|Wait list control|This group will participate in data collection only; after the 3rd data collection point, they will be given access to the intervention
62566118|NCT01238159|EXPERIMENTAL|CCRT+MIDLE|Patients who are planned to be treated with CCRT plus MIDLE chemotherapy. CCRT means concurrent chemoradiation, and MIDLE represent systemic chemotherapy.
62772891|NCT04183088|ACTIVE_COMPARATOR|Groups (2) of part 2: regorafenib|"Daily dose of regorafenib 80mg/day is for week 1; Daily dose of regorafenib 120mg/day is for week 2; Daily dose of regorafenib 160mg/day is for week 3; Dosing-free interval is for week 4.~* The dose of regorafenib will not be escalated if treatment-related AE \> grade 1 occurs at the previous dose level.~* For subjects in the group 2, when imaging evaluation of tumor response indicates stable disease or progressive disease, according to RECIST v1.1, study treatment will be shifted to regorafenib + tislelizumab combination regimen."
62772892|NCT01688908|NO_INTERVENTION|Control Arm|Participants in this arm will not accept the endoscopic screening and only baseline and follow-up interview will be conducted in this arm.
62772893|NCT01688908|EXPERIMENTAL|Screening Arm|Participants in this arm will accept a baseline endoscopic screening, questionnaire investigation and follow-up interview. Subsequent re-examination and further medical services would be arranged among individuals who already have high-grade lesions found at baseline screening.
62772894|NCT06149377||Training cohort|Patients (n=386) who accepted neoadjuvant systemic therapy followed surgery were from fujian medical university union hospital from April 1, 2012, to May 30, 2022.
62772895|NCT06149377||External validation cohort|Patients (n=211) who accepted neoadjuvant systemic therapy followed surgery were from Fujian Cancer Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University and No. 900 Hospital of The Joint Logistic Support Force from April 1, 2012, to May 30, 2022.
62772896|NCT06149377||Test cohort|Patients (n=119) who accepted sentinel lymph node biopsy followed axillary lymph node dissection after neoadjuvant systemic therapy was retrospectively collected from June 1,2022 to May 31, 2023.
62772897|NCT05512013|EXPERIMENTAL|Ibuprofen|Participants will consume a single dose of ibuprofen prior to a plyometric exercise bout
62772898|NCT05512013|EXPERIMENTAL|Celecoxib|Participants will consume a single dose of celecoxib prior to a plyometric exercise bout
62772899|NCT05512013|EXPERIMENTAL|Flurbiprofen|Participants will consume a single dose of flurbiprofen prior to a plyometric exercise bout
62772900|NCT05512013|PLACEBO_COMPARATOR|Placebo|Participants will consume a single dose of an inert placebo prior to a plyometric exercise bout
62566119|NCT06575322||Neoadjuvant therapy+ Surgery group( Group A)|The patient was diagnosed with head and neck squamous cell carcinoma (stage I-IVA), untreated, and planned to undergo surgical treatment + combined chemotherapy and immunotherapy.
62566120|NCT06575322||Direct surgery group (Group B)|The patient was diagnosed with head and neck squamous cell carcinoma (stage I-IVA), untreated, and planned to undergo surgery.
62566121|NCT02128854|EXPERIMENTAL|Tablets Intervention|Individuals randomized to this arm will receive: 1) peripheral devices for monitoring blood glucose, blood pressure, and weight; 2) 8 weekly tablet-delivered education and skills training sessions; 3) two booster sessions delivered via tablet-based videoconferencing at 3 and 6 months.
62566122|NCT02128854|NO_INTERVENTION|Usual Care|Apart from study visits, individuals randomized to the Usual Care group will receive usual care for diabetes management as provided by their primary care physician. The provider will be responsible for determining changes in the treatment regimen and determining the timing of follow-up visits for diabetes care. Between scheduled office encounters, contact will be initiated by the individual.
62181576|NCT01800539|NO_INTERVENTION|Treatment-as-Usual (TAU)|condition wherein providers continue with their existing practices
62566123|NCT01092234|ACTIVE_COMPARATOR|Traditional ward|
62181577|NCT03199768||Single-bed rooms|Patients are admitted to single-bed rooms at the newly built hospital in the period 20th of March to the 1th of September 2017
62566124|NCT01092234|EXPERIMENTAL|Observational unit|Organizational change. Innovative organization of in-hospital care
62566125|NCT06385652|EXPERIMENTAL|Head to head PET imaging comparison between 18F-FDG and 68Ga-NB381 for MM diagnosis|"1. 68Ga-NB381 PET/CT Examination: The patient will be intravenously injected with prepared and quality-controlled 68Ga-NB381 (0.05-0.1 mCi/kg). Two hours post-injection, a full-body scan will be conducted using the Shanghai United Imaging uMI 780 PET/CT, covering from the top of the head to the mid-thigh. If indeterminate lesions are identified in routine imaging, delayed imaging will be performed for further evaluation. The patient should lie in a supine position and breathe calmly. Data will be reconstructed using the OSEM method to obtain coronal, sagittal, and transverse PET and PET/CT fused images.~2. 18F-FDG PET/CT Examination: Patients must fast for more than 6 hours before the examination. 18F-FDG (0.05-0.1 mCi/kg) will be administered intravenously, and one hour later. Same requirement as mentioned above."
62181578|NCT03199768||Multi-bed rooms|Patients are admitted at multi-bed rooms with one to two fellow patients at the old hospital in the period 15th of September 2016 to the 19th of March 2017
61996597|NCT03366064|EXPERIMENTAL|Pemetrexed and donor NK cell infusion|Eligible patients with stage 4 non-small cell lung cancer receive NK cells derived from HLA-haploidentical family donors. One week prior to NK cell infusion, patients receive pemetrexed (500 mg/m2) intravenous infusion
61996598|NCT00829881|PLACEBO_COMPARATOR|1|Participants will receive a placebo capsule, administered orally, once per study visit.
61996599|NCT00829881|EXPERIMENTAL|2|Participants will receive a betahistine capsule, administered orally, once per study visit.
62181579|NCT02180347||Multifocal contact lenses|Coopervision Proclear Multifocal
62181580|NCT02180347||Single vision contact lenses|Coopervision Proclear Sphere
62566126|NCT06341751|EXPERIMENTAL|Psychological treatment|Blended treatment, i.e., both physical face-to-face sessions and internet-based asynchronous support. Treatment period is 4-6 months (6 months primary endpoint).
62566127|NCT00848913|ACTIVE_COMPARATOR|Rehabilitation without strength training|Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
62566128|NCT00848913|EXPERIMENTAL|Rehabilitation with strength training|Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of fractured limb every day during admission.
62566129|NCT03549078|EXPERIMENTAL|Intervention|Participants will complete an initial assessment within 2 weeks prior to starting the course or during the first class. The course will include 10 sessions conducted on a weekly basis. Following completion of the course, participants will again complete another assessment during the last class or within 2 weeks of course completion. Participants may be invited to complete assessments at 3- and 6-months following course completion.
61996600|NCT06159972|EXPERIMENTAL|EndoFLIP|Intraop EndoFLIP measurements
61996601|NCT00806546|EXPERIMENTAL|NP101|sumatriptan iontophoretic transdermal patch
61996602|NCT06072547|EXPERIMENTAL|Complete flavor profile of on! nicotine pouches|This study arm will provided with access to all varieties of 4mg on! nicotine pouch products throughout the trial.
61996603|NCT06072547|ACTIVE_COMPARATOR|Non-Flavored on! nicotine pouches only|This study arm will provided with access to non-flavored (i.e., Original) 4mg on! nicotine pouch products throughout the trial.
62181581|NCT03382288|EXPERIMENTAL|Examination of participants|Examination of participants by means of the investigational device, Eyestar 900 as well as the comparative devices.
61996604|NCT06072547|ACTIVE_COMPARATOR|Non-Flavored then complete flavor on! nicotine pouches|This study arm will provided with access to non-flavored (i.e., Original) 4mg on! nicotine pouch products during the first 3 weeks of the trial and then access to all varieties of 4mg on! nicotine pouch products during the last 3 weeks of the trial.
62181582|NCT06442163|EXPERIMENTAL|All Clinically stable OHS patients with a body mass index of 30 kg/m2 and daytime hypercapnia (PaCO2|Each participant underwent initial baseline diagnostic polysomnograms (PSG) documenting the presence of OSA based on standard diagnostic criteria. After baseline (PSG) and patient's consent, patients performed full night CPAP titration in the sleep laboratory within 7 days of the baseline PSG, and AVAPS-AE titration.
62566130|NCT03666130|ACTIVE_COMPARATOR|endoscopic septoplasty|in this arm the participants will undergo endoscopic septoplasty for correction of the deviated nasal septum
62566131|NCT03666130|ACTIVE_COMPARATOR|conventional septoplasty|in this arm the participants will undergo conventional septoplasty operation for correction of the deviated nasal septum that will done by surgical traditional septoplasty technique using head lamb and anterior rhinoscopy
62181583|NCT01913626|EXPERIMENTAL|cognitive group therapy|patient with subjective memory complains will participate in cognitive group therapy including eight meetings of practicing cognitive strategy to improve the memory .
62566132|NCT06142604|EXPERIMENTAL|Flecainide|Participants randomized to the flecainide arm will be prescribed a single 300mg dose of oral flecainide, to be given as soon as possible after study randomization. Rate controlling drugs will be prescribed and titrated to achieve a heart rate of less than 100 beats per minute and symptom minimization.
62566133|NCT06142604|NO_INTERVENTION|No flecainide|Participants randomized to the no flecainide arm will not be prescribed flecainide. Rate controlling drugs will be prescribed and titrated to achieve a heart rate of less than 100 beats per minute and symptom minimization.
62566134|NCT04204109|EXPERIMENTAL|Interprofessional case-based learning|The experimental intervention will be the interprofessional group receiving case-based learning about gastro-intestinal toxicities and side effects of children and adolescents with cancer.
62566135|NCT04204109|ACTIVE_COMPARATOR|Monoprofessional case-based learning|The control group is the monoprofessional group that will receive the same case-based learning as the intervention group.
62566136|NCT06080243|ACTIVE_COMPARATOR|Experimental-Standard Regime Malaria Vaccine Group1|Participants receiving three doses of R21/Matrix-M1 malaria vaccine at months 0, 1 and 2.
62566137|NCT06080243|ACTIVE_COMPARATOR|Experimental-Standard Regime Malaria Vaccine Group2|Participants receiving normal saline (placebo) at month 0 and two doses of R21/Matrix-M1 malaria vaccine at month 1 and 2
62566138|NCT06080243|ACTIVE_COMPARATOR|Experimental-Standard Regime Group3|Participants receiving three doses of normal saline (placebo) at months 0, 1 and 2
62181584|NCT04678713|EXPERIMENTAL|Fat rich diet|Participants consuming 3 days of fat rich diet
62181585|NCT04678713|EXPERIMENTAL|Carbohydrate rich diet|Participants consuming 3 days of carbohydrate rich diet
61996605|NCT04209179|EXPERIMENTAL|PCO371 Low Dose and Low administration frequency|PCO371 low dose and low administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).
61996606|NCT04209179|EXPERIMENTAL|PCO371 High Dose and Low administration frequency|PCO371 high dose and low administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).
62566139|NCT01790984|EXPERIMENTAL|High sugar low starch diet|A high sugar, low starch diet was provided by the exchange of two thirds of the participants daily intake of carbohydrate. This was achieved by exchanging foods with low sugar to starch content, with foods containing a high sugar to starch content to reach a target ratio of starch to sugar of 1:1.2
62566140|NCT01790984|EXPERIMENTAL|Low sugar high starch diet|A high sugar, low starch diet was provided by the exchange of two thirds of the participants daily intake of carbohydrate. This was achieved by exchanging foods with a high sugar to starch content, with foods containing a low sugar to starch content to reach a target ratio of starch to sugar of 5:1
62566141|NCT00869622|ACTIVE_COMPARATOR|Risedronate|Active drug
62566142|NCT00869622|PLACEBO_COMPARATOR|Placebo + Calcium and Vitamin D|All patients both on placebo and active bisphosphonate to receive calcium and vitamin D
62566143|NCT03391219|ACTIVE_COMPARATOR|intravitreal Bevacizumab|
62566144|NCT03391219|ACTIVE_COMPARATOR|intravitreal Bavacizumab and Fasudil|
62566145|NCT03513237|EXPERIMENTAL|Cervical dilation group|the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal after extraction of placenta and membranes and will remove the outer gloves after digital dilatation of the cervix.
62566146|NCT03513237|NO_INTERVENTION|no cervical dilation group|No cervical dilation will be done.
62566147|NCT03451890|EXPERIMENTAL|Cohort 1: E2730 40 mg|Participants will receive a single oral dose of E2730 40 milligrams (mg) under fasted conditions.
61996607|NCT04209179|EXPERIMENTAL|PCO371 High Dose and High administration frequency|PCO371 high dose and high administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).
61996608|NCT04209179|PLACEBO_COMPARATOR|Placebo|Placebo by oral administration.
61996609|NCT06517147|EXPERIMENTAL|Rate of change in core temperature during CRYOGENX cooling|Participants will visit the laboratory on three occasions during this randomized, counter-balanced crossover study. The first visit will enable preliminary data collection and familiarisation to take place. The second and third visits will be experimental sessions (CRYOGENX cooling vs regular cooling), with the order of these randomised. The rate of change in core temperature during cooling observed in the two trials will be compared by paired sample t-tests.
61996610|NCT06517147|EXPERIMENTAL|Rate of change in core temperature during regular cooling|Participants will visit the laboratory on three occasions during this randomized, counter-balanced crossover study. The first visit will enable preliminary data collection and familiarisation to take place. The second and third visits will be experimental sessions (CRYOGENX cooling vs regular cooling), with the order of these randomised. The rate of change in core temperature during cooling observed in the two trials will be compared by paired sample t-tests.
61996611|NCT03880903|EXPERIMENTAL|normal saline with bronchdilator|will recieve treatment with nebulized brochodilator(salbutamol) and normal saline every 4 to 6 hours
61996612|NCT03880903|EXPERIMENTAL|hypertonic saline with bronchodilator|will recieve treatment with nebulized bronchodilator(salbutamol) and hypertonic saline every 4 to 6 hours
61996613|NCT03880903|EXPERIMENTAL|hypertonic saline only|will recieve treatment with nebulized hypertonic saline 3% in adose of 4 ml every 4 to 6 hours
61996614|NCT04963582|EXPERIMENTAL|Acupuncture Group|Bilateral LI4 acupuncture is administered before IUD insertion. Pain perception is evaluated by 10 points rated VAS after completion of the procedure.
61996615|NCT04963582|NO_INTERVENTION|Control Group|IUD insertion is proceeded without any intervention. Pain perception is evaluated by 10 points rated VAS after completion of the procedure.
61996616|NCT02394938|EXPERIMENTAL|MUSIC|In addition to the standard care, heart failure patients assigned to the music group will listen recorded classical music.
61996617|NCT02394938|NO_INTERVENTION|CONTROL|Heart Failure patients assigned to the control group will receive standard care only. The standard care will consist in nursing and medical counselling, self-care education and medication.
61996618|NCT03870152|EXPERIMENTAL|EC treatment (Intervention Arm)|Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline. Follow-up is the same as for Control Arm patients: a bronchoscopy surveillance visit at 6, 12, 24, and at 36 months post-randomisation; with further bronchoscopy surveillance visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
61996619|NCT03870152|NO_INTERVENTION|AFB Surveillance (Control Arm)|Patients randomised to the surveillance (Control Arm) will have: bronchoscopy surveillance at 6, 12, 24, and at 36 months post-randomisation; with further bronchoscopy surveillance visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
62181586|NCT02765386|EXPERIMENTAL|Cochlear Implant Recipients|Newly implanted cochlear implant recipients with post-implantation acoustic hearing.
62566148|NCT03451890|PLACEBO_COMPARATOR|Cohort 1: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
62566149|NCT03451890|EXPERIMENTAL|Cohort 2: E2730 80 mg|Participants will receive a single oral dose of E2730 80 mg under fasted conditions.
62566150|NCT03451890|PLACEBO_COMPARATOR|Cohort 2: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
62566151|NCT03451890|EXPERIMENTAL|Cohort 3: E2730 120 mg|Participants will receive a single oral dose of E2730 120 mg under fasted conditions.
62566152|NCT03451890|PLACEBO_COMPARATOR|Cohort 3: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
62566153|NCT03451890|EXPERIMENTAL|Cohort 4: E2730 160 mg|Participants will receive a single oral dose of E2730 160 mg under fasted conditions.
61996620|NCT02781103|EXPERIMENTAL|Guided imagery plus active tDCS|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
62566154|NCT03451890|PLACEBO_COMPARATOR|Cohort 4: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
62566155|NCT01016951|EXPERIMENTAL|A|AZD9164
61996621|NCT02781103|SHAM_COMPARATOR|Guided imagery plus Sham tDCS|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will be turned off. The device will remain in place, however, for 20 minutes while the subject listens to a guided imagery CD specifically designed for women with chronic pelvic pain.
61996622|NCT05994716|NO_INTERVENTION|Observation group|
61996623|NCT05994716|EXPERIMENTAL|Telemonitoring|
61996624|NCT05788458|ACTIVE_COMPARATOR|Group A|will receive 20 ml of 0.25 % bupivacaine
61996625|NCT05788458|ACTIVE_COMPARATOR|Group B|will receive 20 ml of 0.375 % bupivacaine.
61996626|NCT05788458|ACTIVE_COMPARATOR|Group C|will receive 20 ml of 0.5 % bupivacaine.
61996627|NCT03808168|ACTIVE_COMPARATOR|Arm 1|Nivolumab, 3 mg/kg Iv, day 1
61996628|NCT03808168|ACTIVE_COMPARATOR|Arm 2|Nivolumab, 3 mg/kg IV, days 1, 15, 29
61996629|NCT05881473|OTHER|Group cervical: (control group):|This group includes (40) patients. The patient will be placed in a supine position with the head turned to the contralateral side for adequate exposure of the neck and the upper chest. A linear high-frequency ultrasound probe (6-13 MHz, Sonosite) will be placed at the lateral side of the neck over the midpoint of the sterno-cleido-mastoid muscle at the level of the cricoid cartilage, which corresponds with the C6 transverse process. Once the muscle is identified, the probe will then be moved posteriorly until the posterior tapering edge of the muscle is identified where the interscalene groove between the anterior and middle scalene muscles is identified. Then, the superficial cervical plexus (SCP) will be visualized. A five-cm block needle will then be introduced from lateral to medial using the posterior-in-plane technique until its tip is placed near the SCP above the prevertebral fascia.10 mL of 0.5% Bupivacaine will be deposited.
62181587|NCT02198261||Predicted as non-responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as non-responders. 5% minoxidil topical foam will be administered to subjects in this group.
62181588|NCT02198261||Predicted as responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as responders. 5% minoxidil topical foam will be administered to subjects in this group.
62181589|NCT00433797|EXPERIMENTAL|1|Tomato
62181590|NCT00433797|EXPERIMENTAL|2|Multi-diet
62181591|NCT00433797|ACTIVE_COMPARATOR|3|Control
62181592|NCT01347268|EXPERIMENTAL|withdrawing GnRH agonists|
62566156|NCT01016951|PLACEBO_COMPARATOR|B|Placebo
62566157|NCT00516841|EXPERIMENTAL|volociximab|15 mg/kg volociximab once weekly
62566158|NCT03525223|ACTIVE_COMPARATOR|dialysate [Na+] 138 mmol/l|Intervention: Change of dialysate \[Na+\] from 138 mmol/l to 142 mmol/l The dialysate \[Na+\] will be increased by 2 mmol/l per week and kept constant for 5 weeks (altogether 6 weeks). Before and after intervention tissue \[Na+\] will be determined by sodium MRI. Additionally body fluid distribution (by bioimpedance spectroscopy) and central arterial pressure wave form, pulse wave velocity as well as flow-mediated vasodilatation will be assessed.
62566159|NCT03525223|ACTIVE_COMPARATOR|dialysate [Na+] 142 mmol/l|Intervention: Change of dialysate \[Na+\] from 142 mmol/l to 135 mmol/l The dialysate \[Na+\] will be decreased by 2 mmol/l per week for 3 weeks and by 1mmol/l for 1 further week. Afterwards the dialysate \[Na+\] will be kept constant for 5 weeks (altogether 8 weeks). Before and after intervention tissue \[Na+\] will be determined by sodium MRI. Additionally body fluid distribution (by bioimpedance spectroscopy) and central arterial pressure wave form, pulse wave velocity as well as flow-mediated vasodilatation will be assessed.
62566160|NCT02450201|EXPERIMENTAL|Part 1: Reproducibility|Pyruvate injection followed by an MRI scan. 2-3 weeks after imaging #1: a second pyruvate injection followed by an MRI scan.
62566161|NCT02450201|EXPERIMENTAL|Part 2: Treatment Response|Pyruvate injection followed by an MRI scan. 2 months after imaging #1: a second pyruvate injection followed by an MRI scan.
62566162|NCT05706272|EXPERIMENTAL|Intervention primary care practices|"The participants in the intervention primary care practices arm will receive a holistic CGA using the PASTEL assessment tool. An elderly team including a doctor and nurse will work around the patient. The intervention includes increased care coordination."
62566163|NCT05706272|ACTIVE_COMPARATOR|Matched control primary care practices|The participants in the matched control primary care practices arm will receive care as usual at the matched control primary care centers.
62566164|NCT05441488|EXPERIMENTAL|Masitinib (4.5)|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control.
62181593|NCT01347268|EXPERIMENTAL|GnRH antagonist administration|
62181594|NCT02296203|EXPERIMENTAL|cetuximab and irinotecan|
62181595|NCT01625676|EXPERIMENTAL|CIAT-Group|Patients received a modified constraint-induced therapy schedule
61996630|NCT05881473|OTHER|Group clavipectoral: (study group)|"This group includes (40) patients will have medial and lateral clavipectoral (CPB) block ultrasound guided using 20 ml Bupivacaine 0.5% for medial and lateral block equally after induction of general anesthesia.~The patient will be placed in a supine position with the head turned to the contralateral side, and the shoulder will be padded with a small pillow. a 6- to 13-MHz linear array probe will be used for regional anesthesia. During CPB, an ultrasound probe will be placed on both the inner and outer one-third of the anterior surface of the clavicle. Using the in-plane technique, a 22-gauge needle will be inserted and advanced into the space between the periosteum of the clavicle and clavipectoral fascia in a caudal to cephalad direction, and a total of 20 mL of 0.5% Bupivacaine will be equally injected medially and laterally"
62566165|NCT05441488|PLACEBO_COMPARATOR|Placebo|Participants receive a matched dose placebo, given orally twice daily.
62566166|NCT00688350|EXPERIMENTAL|Behavioral feedback|Behavioral feedback intervention to improve adherence to antihypertensive medication
62566167|NCT00688350|NO_INTERVENTION|Control|Control group
61996631|NCT04406064|EXPERIMENTAL|Viral Specific T-cells (VSTs)|
61996632|NCT02608112||Participants with Moderate to Severe RA|Participants with moderate or severe RA, naïve to TCZ treatment (IV or SC), and who have no contra-indication to TCZ SC therapy as per the local label are included.
62181596|NCT01625676|ACTIVE_COMPARATOR|standard treatment group|patients received a standard aphasia therapy
62181597|NCT03245762|ACTIVE_COMPARATOR|Intranasal oxytocin|Intervention: 4 IU/day of intranasal oxytocin via a nasal spray device each morning.
62181598|NCT03245762|PLACEBO_COMPARATOR|IN-placebo|Intervention: 4 IU/day of placebo via nasal spray device each morning.
62181599|NCT05896111|EXPERIMENTAL|designed physiotherapy program|"These exercises included:~Passive stretching exercises for elbow and wrist flexors. Weight-bearing exercises for the upper limbs. Stimulation of the protective reactions of the upper limbs in all directions. Strengthening exercises for antagonists of the spastic muscles, including elbow and wrist extensors, using different toys and motivation to encourage the children to perform the desired exercises (El-shamy, 2018).~The treatment session for 1hour 5 days / week for 4 weeks."
62181600|NCT05896111|EXPERIMENTAL|Whole body vibration.|Each child will be seated on an armless chair in front of the platform and instructed to flex both shoulders at 90°, slightly bend both elbows, and then bend the trunk forward to allow both hands to be placed on the platform. Each subject will be allowed to hold the palms slightly off the platform to minimize discomfort and prevent strong stimulation of the organs, eyes, and head.
62181601|NCT04959461|EXPERIMENTAL|webCHAT|Single session 20-40minute self-guided web program that discusses promotes healthy decision making around driving and discusses the risks of alcohol and cannabis-influenced driving.
62181602|NCT04959461|ACTIVE_COMPARATOR|Usual Care|Existing driving school education
62566168|NCT06439550|EXPERIMENTAL|Serplulimab，Trastuzumab and SOX|Within 4 weeks after surgery, patients will be enrolled in the study and started on Serplulimab (300mg, q3w) + Trastuzumab (First dose 8mg/kg, maintenance 6mg/kg, q3w) + oxaliplatin (130mg/m2, q3w) + Tegafur (40mg/m2, bid d1-d14, q3w). Among them, oxaliplatin + Teggio can be used for 4-6 cycles according to the patient's tolerance, and Serplulimab + trastuzumab can be continued until 12 months or tumor recurrence or metastasis
62566169|NCT03017404|EXPERIMENTAL|treatment group:35 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
62566170|NCT03017404|EXPERIMENTAL|treatment group:40 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
62566171|NCT03017404|EXPERIMENTAL|treatment group:45 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
62566172|NCT03017404|EXPERIMENTAL|treatment group:50 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
62566173|NCT03977896|EXPERIMENTAL|11C-MET PET/MRI|
62566174|NCT04181892|EXPERIMENTAL|CAF+ CTG positioned apical to the CEJ|Connective tissue graft covered by a coronally advanced flap which CTG apical of the CEJ level
62566175|NCT04181892|OTHER|CAF+CTG positioned on the CEJ|Connective tissue graft covered by a coronally advanced flap which CTG on the CEJ level
62566176|NCT00708383|EXPERIMENTAL|1|Embryo culture medium supplemented with 0.5% HSA and 10% SSS
62566177|NCT00708383|ACTIVE_COMPARATOR|2|Embryo culture medium supplemented with 0.5% HSA only
62566178|NCT05613205|EXPERIMENTAL|Step 1a low dose without adjuvant Group|Participants 18 to 50 years of age randomized to receive 2 doses of TYP04A Low Dose without adjuvant investigational vaccine, administered at Day 1 and Day 169.
62566179|NCT05613205|ACTIVE_COMPARATOR|Step 1a control Group|Participants 18 to 50 years of age randomized to receive 1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine at Day 1 and 1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine at Day 169.
62566180|NCT05613205|EXPERIMENTAL|Step 1b low dose with adjuvant Group|Participants 18 to 50 years of age randomized to receive 2 doses of TYP03A Low Dose adjuvanted investigational vaccine, administered at Day 1 and Day 169.
62566181|NCT05613205|ACTIVE_COMPARATOR|Step 1b control Group|Participants 18 to 50 years of age randomized to receive 1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine at Day 1 and 1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine at Day 169.
62566182|NCT05613205|EXPERIMENTAL|Step 2 full dose without adjuvant Group|Participants 18 to 50 years of age randomized to receive 2 doses of TYP04B Full Dose without adjuvant investigational vaccine, administered at Day 1 and Day 169.
62566183|NCT05613205|EXPERIMENTAL|Step 2 full dose with adjuvant Group|Participants 18 to 50 years of age randomized to receive 2 doses of TYP03B Full Dose adjuvanted investigational vaccine, administered at Day 1 and Day 169.
62566184|NCT05613205|ACTIVE_COMPARATOR|Step 2 control Group|Participants 18 to 50 years of age randomized to receive 1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine at Day 1 and 1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine at Day 169.
62566185|NCT01322243|OTHER|Dietary Intervention: Fasted State|Participants will be randomized to a dietary intervention of a fasted or fed group upon admission.
62566186|NCT01322243|OTHER|Dietary Intervention: Fed State|Participants will be randomized to a dietary intervention of a fasted or fed group upon admission
62566187|NCT01617993||Women undergoing IVF treatment|Women undergoing IVF treatment
62566188|NCT06143917|EXPERIMENTAL|parent-child sleep intervention|Participants in the intervention will receive both the standardized usual care and parent-child sleep education, heart rate variability biofeedback training, and counseling and support.
62566189|NCT06143917|NO_INTERVENTION|Control|Participants in the control group will receive attention from the research nurse and the standardized usual care.
62566190|NCT04249960|NO_INTERVENTION|Transition as usual|Young people in this group will receive usual care and transition as usual, they will be our control group.
62181603|NCT02062112|NO_INTERVENTION|Unflavored group|The patient will mix 1 gallon of polyethylene glycol with water and drink as directed by his/her endoscopist. No flavoring will be added.
62181604|NCT02062112|ACTIVE_COMPARATOR|Flavored group|The patient will mix 1 gallon of polyethylene glycol with water, add flavoring to the entire solution and drink at the time specified by his/her endoscopist.
62181605|NCT02062112|ACTIVE_COMPARATOR|Liberal group|The patient will mix 1 gallon of polyethylene glycol with water. Fill 2 cups with the solution. The patient will add flavoring to one cup and drink both the flavored and unflavored solutions in the cups. The patient will then determine how he/she wants to drink the rest of the bowel preparation laxatives based on their taste preference and drink at the time specified by his/her endoscopist.
62181606|NCT03247361|EXPERIMENTAL|High-intensity IMT|"High-intensity IMT + Aerobic/resistance exercise~IMT: Training loads will be adjusted weekly to the maximal inspiratory pressure (MIP). In the first 2 weeks as adaptation, the protocol will be of 2 minutes warm-up with intensity 20% of MIP. The training will have 7 peaks of intensity with 70% of MIP for 30 sec, with 30-sec of passive rest between the peaks, finishing the training with 20% of MIP for 2 min, totaling 10 min and 30 sec. From the third week the protocol will be of 2 min warm-up with intensity 30% of MIP. The training will have 7 peaks of intensity with 70% of MIP for 60 sec, with 60-second of passive rest between the peaks, finishing the training with 20% of MIP for 2 min, totaling 17 min.~Exercise: see group Combined aerobic/resistance exercise"
62181607|NCT03247361|ACTIVE_COMPARATOR|Low-intensity IMT|"Low-intensity IMT + Aerobic/resistance exercise~IMT:Training loads will be also adjusted weekly to the maximal inspiratory pressure (MIP). In the first two weeks as adaptation, the protocol will be of 2 minutes warm-up with intensity 20% of MIP. The training will be held with 3 sets of 15 repetitions, with 40% of MIP, finishing the training with 20% of MIP for 2 minutes. From the third week the protocol will be of 2 minutes warm-up with intensity 30% of MIP. The training will be held with 3 sets of 15 repetitions, with 60% of MIP, finishing the training with 30% of MIP for 2 minutes.~Exercise: see group Combined aerobic/resistance exercise"
62566191|NCT04249960|EXPERIMENTAL|Managed transition|Young people in this group will do the managed transition, they will be our experimental group.
62566192|NCT05124808|EXPERIMENTAL|Intensive glycemic targets|Participants in this arm will target a fasting blood glucose of \<90 mg/dL and 1 hour post-prandial blood glucose values \<120 mg/dL.
62566193|NCT05124808|ACTIVE_COMPARATOR|Standard glycemic targets|Participants in this arm will target a fasting blood glucose of \<95 mg/dL and 1 hour post-prandial blood glucose values \<140 mg/dL.
62566194|NCT01444664|EXPERIMENTAL|Aneurysm|
62566195|NCT04817124|EXPERIMENTAL|stimulation group|Anodal tDCS+ intensive cognitive Training
62566196|NCT04817124|SHAM_COMPARATOR|sham group|Sham tDCS + intensive cognitive Training
62566197|NCT02845024|ACTIVE_COMPARATOR|oral doxycycline|Oral capsules of doxycycline 100 mg were used
62566198|NCT02845024|PLACEBO_COMPARATOR|oral placebo capsule|oral placebo capsule were used
62566199|NCT02859337|ACTIVE_COMPARATOR|UPA-ECx1 followed by ECx2|Ulipristal acetate 30mg orally x 1 dose, washout cycle and then in the next menstrual cycle, 60mg x 1 dose. Timing of dosage depends on follicle measurements.
62566200|NCT02859337|EXPERIMENTAL|UPA-ECx2 followed by ECx1|Ulipristal acetate 60mg orally x 1 dose, washout cycle, and then in next menstrual cycle 30mg orally x 1 dose. Timing of dosage depends on follicle measurements.
62566201|NCT02859337|OTHER|UPA-ECx1 Normal BMI/weight|Ulipristal acetate 30mg orally x 1 dose. timing of dosage depends on follicle measurements. This is to obtain a normal BMI control group.
62566202|NCT02940262|EXPERIMENTAL|Treatment (68Ga-PSMA-11)|Patients receive gallium Ga 68-labeled PSMA-11 IV. Beginning 50-100 minutes after receiving gallium Ga 68-labeled PSMA-11, patients undergo PET imaging.
62566203|NCT03861390|ACTIVE_COMPARATOR|Prednisone, then Placebo|Participants will receive prednisone following WSP exposure. After a 4-week washout period, participants will receive placebo following WSP exposure.
62566204|NCT03861390|PLACEBO_COMPARATOR|Placebo, then Prednisone|Participants will receive placebo following WSP exposure. After a 4-week washout period, participants will receive prednisone following WSP exposure.
62566205|NCT01074268|EXPERIMENTAL|IDeg OD|
62566206|NCT01074268|ACTIVE_COMPARATOR|IDet|
62566207|NCT04287075||Surgery|Participants who elect to undergo surgery for the treatment of their chronic, neuropathic pain
62566208|NCT04287075||Non-surgery|Participants who elect to not have surgery for the treatment of their chronic, neuropathic pain
62566209|NCT05434156|EXPERIMENTAL|Cohort 1 (Part 1)|A single 10-minute intravenous infusion of 0.25 mg ELE-101 or placebo (randomized as 6 active and 2 placebo)
62566210|NCT05434156|EXPERIMENTAL|Cohort 2 (Part 1)|A single 10-minute intravenous infusion of 0.75 mg ELE-101 or placebo (randomized as 6 active and 2 placebo)
62566211|NCT05434156|EXPERIMENTAL|Cohort 3 (Part 1)|A single 10-minute intravenous infusion of 2.0 mg ELE-101 or placebo (randomized as 6 active and 2 placebo)
62566212|NCT05434156|EXPERIMENTAL|Cohort 4 (Part 1)|A single TBD minute intravenous infusion of TBD mg ELE-101 or placebo (randomized as 6 active and 2 placebo)
62566213|NCT05434156|EXPERIMENTAL|Cohort 5 (Part 1)|A single TBD minute intravenous infusion of TBD mg ELE-101 or placebo (randomized as 6 active and 2 placebo)
62566214|NCT05434156|EXPERIMENTAL|Cohort 6 (Part 2)|A single TBD minute intravenous infusion of TBD mg ELE-101
62566215|NCT02748304|PLACEBO_COMPARATOR|control|just follow up after liver resection in HCC patients
62566216|NCT02748304|ACTIVE_COMPARATOR|sorafenib|use sorafenib after liver resection in HCC patients
62566217|NCT02748304|ACTIVE_COMPARATOR|sorafenib and aspirin|use sorafenib and aspirin after liver resection in HCC patients
62566218|NCT05356000|OTHER|Subjects who will follow low-oxalate diet followed by visit to research clinic|30 stone-forming participants will be recruited to this study.
62566219|NCT02455206|ACTIVE_COMPARATOR|Usual Care|outpatient pulmonary Rehabilitation program
62566220|NCT02455206|EXPERIMENTAL|Counseling|outpatient pulmonary Rehabilitation program plus physical activity counseling
62566221|NCT05442502||The conventional overlap group|In conventional overlap group, after firing the stapler, two openings were converted into a single entry hole to create an end-to-side esophagojejunostomy, and the entry hole was closed with full-thickness running suture using barbed sutures intracorporeally.
62566222|NCT05442502||The OGT-assisted group|In OGT group, the anvil fork was inserted into the esophageal mucosa canal by movement of the connection of fork-OGT-gastric tube.
62566223|NCT04969679|ACTIVE_COMPARATOR|E. coli Nissle 1917 (Mutaflor®)|Active group will receive E. coli Nissle 1917 (Mutaflor®).
62566224|NCT04969679|PLACEBO_COMPARATOR|Placebo|Placebo group will receive placebo drug.
62566225|NCT01171144||Gastroenteritis Group|All children suffering with gastroenteritis
62566226|NCT04073927|ACTIVE_COMPARATOR|Sodium butyrate|3.6 g sodium butyrate. 6 capsules twice daily for 12 weeks.
62566227|NCT04073927|PLACEBO_COMPARATOR|Placebo|Placebo. 6 capsules twice daily for 12 weeks.
62566228|NCT00387335|EXPERIMENTAL|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62566229|NCT01692860|EXPERIMENTAL|High protein consumption|Intervention, energy restriction. This arm has a dietary protein intake of 1.5g/kg/d
62566230|NCT01692860|PLACEBO_COMPARATOR|Normal protein consumption|Intervention, energy restriction. This arm has a dietary protein intake of .8g/kg/d
62181608|NCT03247361|SHAM_COMPARATOR|Aerobic/resistance exercise|"Sham IMT + Aerobic/resistance exercise~Aerobic session will consist of a 4-min of warm-up, 20 minutes of exercise, and 4 min of cool-down. Intensity will set by the formula: Training HR = (maximum HR - resting HR) × intensity % + resting HR. Patients will exercise using 30 seconds, high-intensity work phases 0.7% followed by 1-minute recovery bouts 0.5%. Resistance exercise will consist of dynamic lower and upper limb exercise. Upper limb exercises will include 3 sets of exercises for each muscle group performed with 10 repetitions each. Lower limb exercises will include 3 sets of exercises for each muscle group performed with 12 repetitions each. Resistance exercises will be performed at 12-MR."
62566231|NCT03838536|EXPERIMENTAL|Whole egg powder|Participants are given whole egg powder which contains high levels of the nutrients choline, lutein, and docosahexaenoic acid.
62566232|NCT03838536|PLACEBO_COMPARATOR|Egg white powder|The participants are given an egg white powder that does not contain the target nutrients (choline, lutein, and docosahexaenoic acid).
62566233|NCT00915018|EXPERIMENTAL|neratinib plus paclitaxel|
62566234|NCT00915018|ACTIVE_COMPARATOR|trastuzumab plus paclitaxel|
62566235|NCT04247113|EXPERIMENTAL|PBP-B|Parent-based Prevention following a Bariatric Surgery (PBP-B) is a 6-session parent-based program designed to guide parents who have undergone a weight loss surgery and their partners in developing healthy eating habits in their children
62566236|NCT02119013|EXPERIMENTAL|OCTEOTRIDE|Octeotride, 20 mg monthly intramuscular injection for 3 years
62566237|NCT02119013|PLACEBO_COMPARATOR|PLACEBO|Placebo (salin soluction), intramuscular injection monthly for 3 years
62566238|NCT01671228|EXPERIMENTAL|decision aid|The Yorkshire Dialysis Decision Aid (YoDDA). Delivered as a leaflet in clinic and a web resource outside the NHS.
62566239|NCT01671228|EXPERIMENTAL|Decision Aid + values task|The Yorkshire Dialysis Decision Aid (YoDDA) + values clarification questions. delivered as a leaflet in clinic and a web-based resource outside the NHS.
62566240|NCT01671228|EXPERIMENTAL|Decision Aid + patient stories|The Yorkshire Dialysis Decision Aid (YoDDA) + patient stories. Delivered as an web-based resource outside the NHS.
62566241|NCT01671228|NO_INTERVENTION|usual predialysis education|The consultations and information usually provided by the predialysis health professionals
62566242|NCT02327871|EXPERIMENTAL|Esophageal cooling|Specific treatment: The placement of the ECD will follow standard recommendations as per Instructions for Use. The ECD will be connected to the Gaymar console (Meditherm III, Gamida, France). In our institution, TH is performed in all patients resuscitated from an OHCA except those presenting exclusion criteria. TH can be initiated as soon as possible by administration of cold saline at 4°C if necessary followed by application of the available cooling device (blankets, endovascular methods, etc) aiming a target temperature of 32-34°C for 24 hours as recommended. 8-11,13 For all enrolled patient, the ECD will hereby replace the other cooling device usually used in our ICU.
62566243|NCT03754335|EXPERIMENTAL|Lumbar puncture|Lumbar puncture in addition to a predefined analgesic protocol Patients will be randomized between the 3rd and 5th days following aneurismal rupture.
62181609|NCT00210678||Group: 1|Men with premature ejaculation (PE)
62181610|NCT00210678||Group: 2|Men without PE
62181611|NCT02235623|OTHER|Stage 1- Single-stage Fowler-Stephens orchidopexy (FSO)|Stage 1 single surgery to clip the vessels to the testis, divide the spermatic vessels and bring the testis into the scrotum.
62566244|NCT03754335|ACTIVE_COMPARATOR|Sham lumbar puncture|Sham lumbar puncture in addition to a predefined analgesic protocol Patients will be randomized between the 3rd and 5th days following aneurismal rupture.
62181612|NCT02235623|OTHER|Stage 2- Two-stage Fowler-Stephens orchidopexy (FSO)|Stage 2 2 surgeries: 1st surgery-Clip vessels to testis. 2nd surgery done 6-12 months later, divide the spermatic vessels and bring the testis into the scrotum.
62566245|NCT03945227|PLACEBO_COMPARATOR|Arm A (consolidation only arm)|Arm A (consolidation only arm) will be treated with standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 regimen. --For concurrent chemoradiation therapy, chemotherapeutic agents will follow the one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 D1, D8, D29, and D36; IV infusion - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 2 weeks after completion of radiation therapy (± 7 days), PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
62567787|NCT04051671|ACTIVE_COMPARATOR|Sham tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) during the first 20 mins (sham mode) of conventional physical therapy (about 1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
62181613|NCT05750277|EXPERIMENTAL|Early Time-Restricted Eating|This group will self-select their eating window as long as it is between 8am-6pm, and will aim to fast within this window as many occasions as possible between Monday-Friday for 4 weeks.
62181614|NCT05750277|NO_INTERVENTION|Control|This group will maintain their habitual lifestyle for 4 weeks.
62181615|NCT03016949|EXPERIMENTAL|Group A|3 doses IPV IM at 10, 14 \& 36 weeks of age incl. blood sampling at 10, 18, 36 \& 40 weeks.
62181616|NCT03016949|EXPERIMENTAL|Group B|3 doses f-IPV ID at 10, 14 \& 36 weeks of age incl. blood sampling at 10, 18, 36 \& 40 weeks.
62181617|NCT03016949|EXPERIMENTAL|Group C|2 doses IPV IM at 14 \& 36 weeks of age incl. blood sampling at 14, 18, 36 \& 40 weeks.
62181618|NCT03016949|EXPERIMENTAL|Group D|2 doses f-IPV ID at 14 \& 36 weeks of age incl. blood sampling at 14, 18, 36 \& 40 weeks.
62181619|NCT03016949|EXPERIMENTAL|Group E|3 doses IPV IM at 6, 14 \& 36 weeks of age incl. blood sampling at 6, 18, 36 \& 40 weeks.
62181620|NCT03016949|EXPERIMENTAL|Group F|3 doses f-IPV ID at 6, 14 \& 36 weeks of age incl. blood sampling at 6, 18, 36 \& 40 weeks.
62181621|NCT05885269|ACTIVE_COMPARATOR|Group A applied Clobetasol Propionate 0.05%|Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months.
62181622|NCT05885269|ACTIVE_COMPARATOR|Group B applied topical Tacrolimus 0.1%|Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months.
62566246|NCT03945227|EXPERIMENTAL|Arm B (concurrent arm)|Arm B (concurrent arm) will be treated with PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 regimen. --For concurrent chemoradiation therapy, chemotherapeutic agents will follow one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 days 1,8,29, and 36; IV infusion - Concurrent PDR001 400mg at D1, D29 - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 4 weeks after last dose of PDR001, PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
62566247|NCT01983540|EXPERIMENTAL|Study Group 1|Participants who received 3 doses of DTaP-IPV-Hep B-PRP\~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of the same investigational vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
62566248|NCT01983540|EXPERIMENTAL|Study Group 2|Participants who received 3 doses of DTaP-IPV-Hep B-PRP\~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of Infanrix hexa vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
62566249|NCT01983540|ACTIVE_COMPARATOR|Study Group 3|Participants who received 3 doses of Infanrix hexa vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of DTaP-IPV-Hep B-PRP\~T vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
62566250|NCT05720741|EXPERIMENTAL|Project THINK|Project THINK is a 30-minute self-guided digital intervention designed to teach children and adolescents how to change the way that they think. Specifically, Project THINK is based on the principles of cognitive restructuring, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project THINK uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for assessing the presence of unhelpful thoughts and replacing them with more helpful ones. Although not yet formally tested in a randomized trial, Project Think has been used by hundreds of students, and feedback has been very positive.
62181623|NCT02622256|EXPERIMENTAL|Health System: HTN Intervention|Investigators will identify patients with known hypertension (ICD-9 code 401.9), from the Penn Data Store (PDS). Participants will be asked to complete 3 short surveys.
61996633|NCT06452940|NO_INTERVENTION|Control Group|Diabetes education will be given at the beginning and ways to prevent type 2 diabetes will be explained.Evaluation will be made at the beginning and at the end of 16 weeks.
61996634|NCT06452940|EXPERIMENTAL|Exercise Group|Diabetes education will be given at the beginning and ways to prevent type 2 diabetes will be explained.Clinical pilates exercises will be performed.It will consist of a warm-up, main exercise and a cool-down period.Exercises will start with 10 repetitions and will be gradually increased in 3-week periods.Before the exercise training begins, all participants will be informed about clinical pilates and its basic principles will be explained. In the first session; The 5 key elements of pilates that should not be disrupted during exercises are; breathing, centering, rib cage placement, shoulder placement, head and neck placement will be taught. Exercise program will be done 3 days a week for 16 weeks.
61996635|NCT04430439|EXPERIMENTAL|Psychosocial stress|Participants will complete the Trier Social Stress Test (TSST) immediately following consumption of their assigned meal type (low or high GI).
62566251|NCT05720741|PLACEBO_COMPARATOR|Project SHARE|Intervention delivered in a web browser that focuses on encouraging feelings disclosure to trusted others using facts about the brain, testimonials from peers, and writing exercises (also referred to as Sharing Feelings Intervention; Schleider et al., 2021).
61996636|NCT04430439|ACTIVE_COMPARATOR|Control non-stress|Participants will complete a non-stress relaxed task immediately following consumption of their assigned meal type (low or high GI).
61996637|NCT05534763|EXPERIMENTAL|IERGD|I-ER GD is a 10-week intervention directed to the person with GD, provided via the internet with therapist-support. During treatment, participants have an assigned psychologist to interact with and be offered support by, either through feedback on assignments, asynchronous chats or, if needed, by telephone. I-ER GD will focus on increasing adaptive emotion regulation skills, healthy identity development, interpersonal effectiveness skills, coping and building a resilient lifestyle through psychoeducation on gender minority stress, practicing adaptive emotion regulation skills, and reducing emotional and behavioral avoidance.
61996638|NCT05534763|OTHER|IER SUPPORT|I-ER Support is a 5-week intervention directed to a support person, provided as an optional addition to I-ER GD. I-ER Support is administered in the same manner and in parallel to the I-ER GD intervention. Treatment content is based on the same principles as I-ER GD, but from the perspective of increasing emotional support and understanding of GD. The support person could benefit from increased coping and emotion regulation skills, as they may also be exposed to discrimination or stigma due to having a transgender child, sibling or loved one. In better understanding the processes of being stigmatized and with improved emotion regulation skills, the support person may offer better support and help alleviate burdening effects for the individual with GD. For this reason, I-ER support is primarily aimed at people without trans-experience.
62566252|NCT01776437|EXPERIMENTAL|Treatment A|Period 1: fasted control → Period 2: fed control
62566253|NCT01776437|EXPERIMENTAL|Treatment B|Period 1: fed control → Period 2: fasted control
62566254|NCT03242473|EXPERIMENTAL|Lactated Ringers (LR)|The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.
62566255|NCT03242473|EXPERIMENTAL|Normal Saline (NS)|The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.
62566256|NCT06438029|EXPERIMENTAL|Education group|The forms used in the study were collected by the researcher through face-to-face interviews in seminar halls in schools. Firstly, the students in the experimental group will be trained on disaster and disaster response. The trainings were organised as a total of four sessions with a two-week interval of twenty minutes in each session. Personal Information Form and Disaster Intervention Self-Efficacy Scale were filled as pre-test in the seminar halls of the schools under the supervision of the researcher.
62566257|NCT06438029|NO_INTERVENTION|Control group|Personal Information Form and Disaster Response Self-Efficacy Scale will be applied to the students in the control group as a pre-test. No training will be given to the control group. In the last stage of the research, the Disaster Response Self-Efficacy Scale will be applied to the control group as a post-test and the data collection process will be terminated. After the last test was applied to the groups, training materials will be given to the people who demanded from the control group.
62566258|NCT06577779|ACTIVE_COMPARATOR|Seven weeks of Jornay PM treatment|Enrolled participants will begin with a two-week observation stabilization before starting treatment with Jornay PM. Participants found to have ≥30% change in their total Adult ADHD Investigator Symptom Rating Scale (AISRS) scores during the two-week observation stabilization period treatment will be discontinued from the study. Remaining participants will initiate a 7 week open-label treatment with Jornay PM.
62566259|NCT06577779|EXPERIMENTAL|Five weeks of Jornay PM treatment|Enrolled participants will begin with a two-week observation stabilization before starting treatment with Jornay PM. Participants found to have ≥30% change in their total Adult ADHD Investigator Symptom Rating Scale (AISRS) scores during the two-week observation stabilization period treatment will be discontinued from the study. Remaining participants will initiate a 5 week open-label treatment with Jornay PM followed by a two week observation period; not receiving Jornay PM.
62566260|NCT04617743||High residual volume|Bladder tumor patients with high residual volume
62566261|NCT04617743||Low residual volume|Bladder tumor patients with low residual volume
62181624|NCT02622256|NO_INTERVENTION|Health System: HTN Control, survey only|Investigators will identify patients with known hypertension (ICD-9 code 401.9), from the Penn Data Store (PDS). Participants will be asked to complete 3 short surveys. Participants in this arm will be exposed to daily messages about heart health and asked to tweet about health.
61996639|NCT03812965|EXPERIMENTAL|Group 1 - Botulinum Toxin type A (4 points of application)|4 points of Botulinum Toxin application in the muscles: Levators labii superioris alaeque nasi muscle and Levators labii superioris muscle (n=10 Patients)
61996640|NCT03812965|EXPERIMENTAL|Group 2 - - Botulinum Toxin type A (2 points of application)|2 points of Botulinum Toxin application in the muscles: Levators labii superioris alaeque nasi muscle (n=10 Patients)
62181625|NCT00210964|EXPERIMENTAL|001|ceftobiprole plus placebo ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
62181626|NCT00210964|ACTIVE_COMPARATOR|002|linezolid plus ceftazidime linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
62566262|NCT04212325|ACTIVE_COMPARATOR|Group C (Continuous sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
62566263|NCT04212325|ACTIVE_COMPARATOR|Group S (sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block with the single injection at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
62566264|NCT01230086|ACTIVE_COMPARATOR|ICD implantation only|ICD Implantation without testing of defibrillation threshold testing
62566265|NCT01230086|ACTIVE_COMPARATOR|Modified upper limit of vulnerability testing|"Modified testing of upper limit of vulnerability"
62566266|NCT01230086|ACTIVE_COMPARATOR|VF-Induction|traditional VF-induction with T-Wave shock
62566267|NCT05010538||Sarecycline|Eligible patients will be prescribed with commercially available sarecycline at a dosage of 1.5 mg/kg/day and followed for 12 weeks post initiation of treatment.
62566268|NCT04748562|ACTIVE_COMPARATOR|400 mg progesterone group|Taking 400 mg vaginal progesterone
62566269|NCT04748562|ACTIVE_COMPARATOR|200 mg progesterone group|Taking 200 mg vaginal progesterone
62566270|NCT05233553||post-COVID-patients|
62566271|NCT04430556|OTHER|Volumetric changes in response to sertraline or escitalopram|
62566272|NCT00216580|EXPERIMENTAL|Risperidone, long-acting injectable|
62181627|NCT00837395||premenstual asthma|women with asthma have an increase in asthma symptoms during the premenstrual or menstrual period
62181628|NCT05554926|EXPERIMENTAL|[4-14C] AEF0117|Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the dose administration. Up to 8 subjects will be enrolled to ensure that 6 subjects complete the study. Subjects will be admitted into the study site on Day -1. On the morning of Day 1, all subjects will receive a single oral dose of 2 mg containing approximately 100 μCi of \[4-14C\]AEF0117 approximately 1 hour after completion of a low-fat breakfast
62181629|NCT00833898|NO_INTERVENTION|Caregiver Control|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care.
62181630|NCT00833898|EXPERIMENTAL|Caregiver Intervention|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation Paced Respiration and Relaxation (PEPRR), which included one-on-one psychoeducation, stress management intervention, with paced respiration.
62566273|NCT02237469||Prone and supine simulation|Women with breast cancer receiving simulation in prone and in supine position for adjuvant radiation treatment.
62566274|NCT01532856|ACTIVE_COMPARATOR|Group A induction therapy|Thalidomide + Cyclophosphamide + Dexamethasone
62566275|NCT01532856|ACTIVE_COMPARATOR|Group B induction therapy|thalidomide + dexamethasone
62566276|NCT01532856|ACTIVE_COMPARATOR|Group C induction therapy|thalidomide + melphalan + prednisone
62566277|NCT01446536|NO_INTERVENTION|Control group|This arm which was control group, was randomly selected among patients with acute decompensated heart failure in whom the checklist was not used. This group was managed as per the standard guidelines.
62566278|NCT01446536|ACTIVE_COMPARATOR|Checklist (intervention) cohort|checklist was used in this group arbitrarily by their treating physician
62566279|NCT03176303||Pulsed Electromagnetic Field|one group all of whom will be treated with the PEMF device
62566280|NCT05209867|EXPERIMENTAL|CBD Intervention|Participants will self-administer CBD daily for 2 months.
62566281|NCT05408130|EXPERIMENTAL|Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device|All patients randomized to the intervention arm will receive 5 cycles of ischemia/reperfusion in the non-paralyzed upper limb or if no upper limb paralysis non-dominant arm. They will receive it once daily for a period of 7 days or during hospital stay whichever is shorter.
62566282|NCT05408130|SHAM_COMPARATOR|Sham Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device|In the sham group subjects will receive pressure sensation by keeping the pressure at 30 mmHg for 3 min in both arms All patients in sham and intervention group will receive standard of care management for ischemic stroke.
62181631|NCT01904136|EXPERIMENTAL|Treatment (NK cells, allogeneic stem cell transplant)|"MYELOABLATIVE CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 30 minutes on day -7, fludarabine IV over 1 hour on days -7 to -4, undergo TBI on day -3, and NK cells IV over 30 minutes on day -2 or -1.~NON-MYELOABLATIVE CONDITIONING REGIMEN: Patients receive melphalan IV over 30 minutes on day -7, fludarabine IV over 1 hour on days -7 to -4, undergo TBI on day -3, and receive NK cells IV over 30 minutes on day -2 or -1.~TRANSPLANT: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.~POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, tacrolimus IV beginning on day 5 for 2 weeks and then PO for approximately 4 months, and mycophenolate mofetil PO TID beginning on day 5 for approximately 6-7 months.~NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28-90."
62181632|NCT02720588||ASD group|Subjects have a clinical diagnosis of autistic disorder or Asperger disorder defined by the DSM-IV criteria
62181633|NCT02720588||Sibling group|Sex-matched unaffected siblings of ASD probands
62181634|NCT02720588||TD group|Typically developing controls without lifetime ASD or a family history of ASD
62181635|NCT06279299|EXPERIMENTAL|Lateral Pelvic lymph node dissection|After performing TME surgery, further conduct lateral pelvic lymph nodes dissection.
62181636|NCT05329233||minimal flow|For minimal-flow anesthesia, oxygen 0.3 L/min and medical air 0.2 L/min (FGF 0.5 L/min, FiO2 68%) were administered to patients in group M.
62181637|NCT05329233||low flow|For low-flow anesthesia, oxygen 0.37 L/min and medical air 0.63 L/min (FGF 1 L/min, FiO2 50%) were administered to patients in group L.
62567788|NCT04116840|EXPERIMENTAL|MT1002 for Injection|Single Ascending Dose following Intravenous Bolus/Infusion Administration in Healthy Subjects
62567789|NCT02729025|PLACEBO_COMPARATOR|Placebo|Participants received placebo to evolocumab by subcutaneous injection once a month (QM) for 12 weeks.
62567790|NCT02729025|EXPERIMENTAL|Evolocumab 420 mg QM|Participants received 420 mg evolocumab by subcutaneous injection once a month (QM) for 12 weeks.
62181638|NCT05329233||high flow|For high-flow anesthesia, oxygen 1 L/min and medical air 3 L/min (FGF 4 L/min, FiO2 40%) were administered to patients in group H.
62181639|NCT02478385|ACTIVE_COMPARATOR|Birth environment labour room|Supportive care of labour room designed with special attention on sound and light effects, covering medical devices and insulation from outside noise
62181640|NCT02478385|PLACEBO_COMPARATOR|Labour in a standard labour room|The woman gives labour in a standard labour room
62181641|NCT00767247||1|Male or female with arterial hypertension
62181642|NCT06339710|EXPERIMENTAL|Short treatment 1|benznidazole 300 mg daily for the first 2 weeks plus placebo for the last 6 weeks or
62181643|NCT06339710|EXPERIMENTAL|Short Treatment 2|benznidazole 300 mg daily for the first 4 weeks plus placebo for the last 4 weeks
62181644|NCT06339710|ACTIVE_COMPARATOR|Standard treatment|benznidazole 300 mg daily for 8 weeks
62181645|NCT01921777|EXPERIMENTAL|Traumeel|Traumeel tablets by mouth the total amount for 72 hours will be 26 tablets
62181646|NCT01921777|PLACEBO_COMPARATOR|Placebo|The Placebo tablets (300 mg lactose monohydrate and 1,5 mg magnesium stearate) by mouth the total amount for 72 hours will be 26 tablets
61996641|NCT03335982|OTHER|transendoscopic enteral tubing in mid-gut|A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia. The feasibility, safety, success rate, and satisfaction with TET placement were evaluated for enteral nutrition or fecal microbiota transplantation.
61996642|NCT04154228|EXPERIMENTAL|Lymphoma Patients|
62566283|NCT01468337|EXPERIMENTAL|Interferon gamma-1b|"Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. A single dropperette contains 1 mL of topical interferon gamma-1b (Actimmune®) at a concentration of 200 µg/mL, which is equivalent to 28 drops. Each drop provides a dose of 7 µg of investigational product.~All participants will receive interferon gamma-1b for two weeks. Doses of interferon gamma-1b eye drops will be escalated among participants during this initial 2-week period; however, additional doses will be dispensed to participants if needed at Week 4 or after the initial 8-week study period. Participants eligible for additional doses after 8 weeks will be administered the maximum dose of 4 drops 4 times daily for a total daily dose of 112 μg."
61996643|NCT03342976|ACTIVE_COMPARATOR|Cases|"Pre-frail subjects will use an ICT platform (my-AHA platform) embedded in a mobile phone and a fit-band that will continuously monitor physical and cognitive activities.~Interventions regarding physical, cognitive, psychological and social domains will be prescribed and monitored through the my-AHA platform. In addition, sleep and dietary habits will be investigated and tailored interventions will be suggested."
61996644|NCT03342976|PLACEBO_COMPARATOR|Controls|"Pre-frail subjects will be followed according to best standard of care protocols. Interventions regarding physical, cognitive, psychological and social domains will be prescribed. In addition, sleep and dietary habits will be investigated and tailored interventions will be suggested."
62181647|NCT04531813|EXPERIMENTAL|Cumulative Irritation Test|Participants received butenafine HCl 1% cream on the skin test site, 0.3% solution of sodium lauryl sulfate on the skin Positive Control test site, and a blank patch on the skin Negative Control test site daily (excluding weekends) for 21 days, or 15 applications.
62181648|NCT04830761|EXPERIMENTAL|Habit - Motivation group|First: 2 weeks habit intervention; Second: 2 weeks motivation intervention
62181649|NCT04830761|EXPERIMENTAL|Habit - Social group|First: 2 weeks habit intervention; Second: 2 weeks social intervention
62181650|NCT04830761|EXPERIMENTAL|Habit - Habit group|4 weeks habit intervention
62566284|NCT05788172||Participants|Female 18-30 year olds, who have already been labelled with stable iron isotopes at least 12 months prior to study start.
62566285|NCT01283451||Exercise|NIRS values of all participants will be measured at baseline and following each 30-60 second exercise.
62566286|NCT03858153|EXPERIMENTAL|Exercise|Exercise for Cancer Patients (EXCAP©®) involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
62566287|NCT03858153|ACTIVE_COMPARATOR|Nutrition Education|Nutrition education involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
62566288|NCT05871281|ACTIVE_COMPARATOR|Pelvic floor muscle training group|All subjects attended individual physiotherapy procedures, the duration of one of which was 60 minutes. One woman was assigned a total of 8 contact procedures over four weeks. During the individual procedures, exercises were selected and modified according to the women's ability to perform them. All women were taught correct abdominal breathing while lying down, to activate the abdominal muscles. Also, all were trained to perform Kegel exercises, explaining their benefits. In order to diversify and modify the exercises, they were performed with auxiliary means, i.e. using balls, gymnastic sticks, a bench, elastic bands, a physiotherapy wall, yoga blocks, rollers, weights and an aerial yoga band.
62567791|NCT05208931||adhesion|the group in which the adhesion of neuroepithelial detachment was observed after Anti-vascular endothelial growth factor therapy
61996645|NCT00097721|EXPERIMENTAL|E7389|
61996646|NCT03946397|EXPERIMENTAL|Multisensory massage|
61996647|NCT03946397|NO_INTERVENTION|Control|
61996648|NCT04262037|EXPERIMENTAL|HPPV|will receive high frequency positive pressure ventilation during cardiopulmonary bypass at tidal volume 2 ml/kg and respiratory rate 80. Lung ultrasound will be done at the beginning and end of surgery
61996649|NCT04262037|EXPERIMENTAL|CPPV|will receive continuous positive airway pressure of 10 cmH2o during the bypass. Lung ultrasound will be done at the beginning and end of surgery
61996650|NCT04262037|NO_INTERVENTION|Control|will be disconnected from the ventilation (passive deflation). Lung ultrasound will be done at the beginning and end of surgery.Lung ultrasound will be done at the beginning and end of surgery
61996651|NCT04160793|OTHER|Genital Nerve Stimulation|Stimulation of the DNP
61996652|NCT04538066|ACTIVE_COMPARATOR|Bryostatin 1|20ug Bryostatin will be administered over 45 minutes IV. The course of treatment will include 7 doses over the first 12 weeks, followed by a second identical treatment period beginning 30 days after completion of the first treatment period.
62181651|NCT04830761|EXPERIMENTAL|Motivation - Habit group|First: 2 weeks motivation intervention; Second: 2 weeks habit intervention
62181652|NCT04830761|EXPERIMENTAL|Motivation - Social group|First: 2 weeks motivation intervention; Second: 2 weeks social intervention
62181653|NCT04830761|EXPERIMENTAL|Motivation - Motivation group|4 weeks motivation intervention
62181654|NCT04830761|EXPERIMENTAL|Social - Habit group|First: 2 weeks social intervention; Second: 2 weeks habit intervention
62181655|NCT04830761|EXPERIMENTAL|Social - Motivation group|First: 2 weeks social intervention; Second: 2 weeks motivation intervention
62181656|NCT04830761|EXPERIMENTAL|Social - Social group|4 weeks social intervention
62181657|NCT03216941|ACTIVE_COMPARATOR|ketamine|assessment of agitation status with Ramsay Sedation Scale administration of ketamine 10 mg / ml IM one dose supervision of vital signs registration of time of ketamine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of ketamine administration) withdrawal of patient from the study if other medication was needed (aside of ketamine)
62391297|NCT06370494|EXPERIMENTAL|Virtual Making Moves with Diabetes [MMWD] Group|Virtual asynchronous training and periodic one-on-one counseling with a clinical diabetes educator, either a Registered Nurse (RN) or Registered Dietitian Nutritionist (RDN). The program was recognized by the American Diabetes Association during this study. The intervention included 8 hours of online diabetes education, 30 minute 1:1 virtual education and counseling with a diabetes educator, and 3 and 6-month follow-ups.
62566289|NCT05871281|EXPERIMENTAL|Pelvic floor muscle electrostimulation group|Electrostimulation was performed with a Kegel 8 home elektrostymulator. The subjects were prescribed two electrostimulation programs: PO3 in the morning and PO10 in the evening. The duration of the PO3 program was 45 minutes, and was intended for general strengthening of the pelvic floor muscles. The duration of the PO10 program is 40 minutes. and it is prescribed for stress incontinence. Duration of interventions 4 week.
62566290|NCT02531308|EXPERIMENTAL|R-CHOP with Metformin|"Rituximab 375 mg/m2 IV infusion Day 1 Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 (2 mg cap) IV Day 1 Prednisone 100 mg PO Days 1-5 Pegfilgrastim 6 mg subcutaneous within 72 hours of cyclophosphomide Metformin 500 mg PO daily D 1-7, 500 mg twice daily D8-21, 850 mg twice daily D22 - 30days post study.~Cycles are 21 days. Above treatment given for 4 cycles, then restaging done. If complete response (CR) or partial response (PR), 2 more cycle given; stable disease (SD) or progressive disease (PD)- salvage therapy off study."
62566291|NCT05261542||normal colorectal epithelium|Tissue samples from normal colorectal epithelium are collected during colectomy in every colorectal cancer patient
62566292|NCT05261542||cancer colorectal epithelium|Tissue samples from colorectal cancer are collected during colectomy in every colorectal cancer patient
62566293|NCT06032208|EXPERIMENTAL|Patients receiving Hemodialysis|A group of hemodialysis patients will be receiving the Theranova dialyzer during their regular scheduled dialysis sessions to remove larger middle molecules.
62566294|NCT03412136|EXPERIMENTAL|Control|
62391298|NCT06370494|EXPERIMENTAL|App Group|Smartphone application for more continuous but less structured chat support. This app was recognized by the American Diabetes Association. The intervention included access to online diabetes support tools and ability to message a diabetes specialist for support, and 3 and 6-month follow-ups.
62391299|NCT06370494|EXPERIMENTAL|Combo Group|A combined approach for maximal support and reinforcement. The intervention included 8 hours of online diabetes education, 30 minute 1:1 virtual education and counseling with a diabetes educator, access to the app with online diabetes support tools and ability to message a diabetes specialist for support, and 3 and 6-month follow-ups.
62566295|NCT03412136|EXPERIMENTAL|Glucose|
62566296|NCT03412136|EXPERIMENTAL|Protein|
62566297|NCT05885503|EXPERIMENTAL|RC-28E|RC-28E 2.0 mg will be initially intravitreal injected (IVT) 5 times at 4 week intervals from week 0 to week 16, then every 8 weeks until week 48.
62566298|NCT05885503|ACTIVE_COMPARATOR|Aflibercept|Aflibercept 2.0mg will be received IVT once every 4 weeks for 5 consecutive times from week 0 to week 16, then once every 8 weeks till week 48.
62566299|NCT01353430||VCP families|Patients with a personal or family history of VCP associated disease.
62566300|NCT02835625|ACTIVE_COMPARATOR|Digital Breast Tomosynthesis|"Synthetic Mammography (SM) + Digital Breast Tomosynthesis (DBT)~The SM+DBT will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.~Women selected for further assessment (positive screening exam) will be recalled."
62566301|NCT02835625|ACTIVE_COMPARATOR|Digital mammography|The digital mammograms will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.
62566302|NCT05756660|EXPERIMENTAL|Stratum 1- Regimen CS|Cisplatin sensitive/no progression on cisplatin (when given at first diagnosis)
62566303|NCT05756660|EXPERIMENTAL|Stratum 2A- Regimen CSS|Cisplatin resistant or progressed on cisplatin after initial response (when given at first diagnosis)
62566304|NCT05756660|EXPERIMENTAL|Stratum 2B- Regimen CSS|Wilms tumor, GCT, Neuroblastoma
61996653|NCT04538066|PLACEBO_COMPARATOR|Placebo|Placebo will be administered over 45 minutes IV. The course of treatment will include 7 doses over the first 12 weeks, followed by a second identical treatment period beginning 30 days after completion of the first treatment period.
62566305|NCT01699672|EXPERIMENTAL|Group and Individual information|The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
62566306|NCT01699672|NO_INTERVENTION|Individual information|Standard information about disease and treatment from doctor and nurse given at 2 occasions.
62566307|NCT00942578|EXPERIMENTAL|Single Arm - 4 Drug Combination|A two dose level escalation of Lenalidomide from 15mg to 20mg to 25mg- standard 3+3 dose escalation approach in combination with docetaxel, Bevacizumab and prednisone.
62566308|NCT00733421|EXPERIMENTAL|1|"Active study drug:~Etoricoxib 90 mg once daily"
62566309|NCT00733421|ACTIVE_COMPARATOR|2|Tramadol 100 mg slow release twice daily
62566310|NCT04494386|EXPERIMENTAL|ULSC in Phase 1 Open Label|"Intravenous (IV) infusion of ULSC in 20 patients with COVID-19 ARDS:~In Phase 1, two separate cohorts per group will receive either a single dose (one infusion) or repeat dose regimen (two infusions separated by 48-hour interval). The first cohort enrolled will receive the single dose; the next cohort enrolled will be administered the repeat dose regimen."
62566311|NCT04494386|EXPERIMENTAL|ULSC in Phase 2a Randomized|"Intravenous (IV) infusion of ULSC in 30 patients with COVID-19 ARDS:~In Phase 2a, 30 patients assigned ULSC will receive either a single dose (one infusion) or repeat dose regimen (two infusions separated by 48-hour interval). The ULSC dosing regimen will be chosen based on Phase 1 data of safety and tolerability."
62566312|NCT04494386|PLACEBO_COMPARATOR|Placebo in Phase 2a Randomized|"Intravenous (IV) infusion of carrier control in 10 patients with COVID-19 ARDS:~In Phase 2a, 10 patients assigned Placebo will receive either single dose (one infusion) or repeat dose (two infusions separated by 48-hour interval) of carrier control; the dosing regimen will correspond to that of the experimental arm."
62566313|NCT05030883|EXPERIMENTAL|unreliable source|In this condition participants receive a news message from an unreliable source
62566314|NCT05030883|EXPERIMENTAL|reliable source|In this condition participants receive a news message from an reliable source
62566315|NCT05030883|EXPERIMENTAL|no source|In this condition participants receive a news message without a source
62566316|NCT02621359|EXPERIMENTAL|Quadruple therapy|Nitazoxanide (500mg bid), Levofloxacin (500 mg once daily), Omeprazole (40 mg bid) and doxycyclin (100 mg twice daily) were prescribed for 14 days.
62566317|NCT02567123|EXPERIMENTAL|Experimental|Runners are switched from a rearfoot strike running pattern to a forefoot strike running pattern.
62566318|NCT02567123|NO_INTERVENTION|Control|Runners continue to use their normal rearfoot strike running pattern with no intervention in place.
62566319|NCT06301763|EXPERIMENTAL|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on health condition. The observation group receives IOE for enteral nutrition support.54 cm.
61996654|NCT04400721|NO_INTERVENTION|PCIA arm|Standard post-operative treatment with patient-controlled intravenous analgesia (Piritramide bolus = 2mg, bolus interval = 7 minutes, max 4 hour dose = 30mg)
61996655|NCT04400721|ACTIVE_COMPARATOR|ESP block arm|ultrasound guided Erector spinae block (Single shot of 30ml of 0.5% solution of Naropin \[Ropivacaine\])
61996656|NCT04400721|ACTIVE_COMPARATOR|IC block arm|3 ml of 0.5% solution of Naropin \[Ropivacaine\] per intercostal space, up to a maximum of 30ml
61996657|NCT06441734||study group|
61996658|NCT06441734||control group|
62566320|NCT06301763|ACTIVE_COMPARATOR|nasogastric tube feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on health condition.The control group receives NGT for enteral nutrition support
62566321|NCT02095548|EXPERIMENTAL|SM04690, 0.03mg/2mL|Single, intra-articular injection of SM04690, 0.03mg/2mL
62566322|NCT02095548|EXPERIMENTAL|SM04690, 0.07mg/2mL|Single, intra-articular injection of SM04690, 0.07mg/2mL
62566323|NCT02095548|EXPERIMENTAL|SM04690, 0.23mg/2mL|Single, intra-articular injection of SM04690, 0.23mg/2mL
62566324|NCT02095548|PLACEBO_COMPARATOR|Placebo|Single, intra-articular injection of placebo
61996659|NCT01365390||Cohort A|Subjects aged \< 6 years who are registered in primary care clinics of any of the participating countries (Estonia, Lithuania, Poland, Romania and Slovenia).
61996660|NCT03961100|EXPERIMENTAL|Part 1|Participants will be randomly assigned to one of the three treatment sequences (T1T2R, T2RT1, RT1T2). In each treatment sequences, participants will cross-over to three periods taking different formulations of entrectinib. Entrectinib will be administered as a single 600 milligram (mg) oral dose under fed condition in three different formulations. Test formulation 1 (T1): film-coated mini-tablet; Test formulation 2 (T2): film-coated mini-tablet; Reference formulation (R): hard capsule.
62391300|NCT01331876|EXPERIMENTAL|reference therapy|20 OCD patients following 15 sessions of the reference CBT (Bouvard,2006)
62566325|NCT02764671|EXPERIMENTAL|10μg/0.5ml recombinant HBV vaccine|5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.
62566326|NCT00697905|EXPERIMENTAL|A|
62566327|NCT00697905|ACTIVE_COMPARATOR|B|
62567792|NCT05208931||no adhesion|group in which there was no adherence of neuroepithelial detachment after Anti-vascular endothelial growth factor therapy
62566328|NCT05797181|EXPERIMENTAL|Dietary and Behavioral Change Group|"The experimental group will be required to adhere to a diet consisting of a 10-15% reduction in carbohydrate and a 1.2-1.4 g/kg body weight/day intake of protein.~The participants will receive 4 times face-to-face meetings (on the first day and on week 1,5 and 9).~Each face-to-face interview will last approximately 30 minutes. During the interview researcher will help the participants to determine their nutritional behaviors, plan and implement the diet."
62566329|NCT04762017|EXPERIMENTAL|OCS-05|Once daily IV infusions of OCS-05 (n=18) for 5 consecutive days
62566330|NCT04762017|PLACEBO_COMPARATOR|Placebo|Once daily IV infusions of Placebo (n=18) for 5 consecutive days
62566331|NCT00739661|EXPERIMENTAL|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
62566332|NCT00739661|PLACEBO_COMPARATOR|Placebo to vismodegib|Patients received placebo to vismodegib orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
62566333|NCT00762255|EXPERIMENTAL|A - Phase I Dose Escalation|Dose Escalation - Irinotecan and bevacizumab are given IV on days 1 and 15 of each cycle. Vorinostat is given orally on days 1-7 and 15-21 of each cycle.
62566334|NCT00762255|EXPERIMENTAL|B - Treatment at Maximum Tolerated Dose (MTD)|MTD - Treatment at maximum tolerated dose
62566335|NCT04576286|EXPERIMENTAL|Holmium en bloc resection|Holmium en bloc resection procedure will be done under either general or spinal anesthesia, using a Holmium laser device (Cyber Ho, Quanta device, Milano, Italy). We will use a 30-40-watt power, 1-2 joules and 20-30 MHz frequency
62566336|NCT04576286|ACTIVE_COMPARATOR|bipolar en bloc resection|bipolar en bloc tumor resection of urinary bladder tumors
62566337|NCT03790501||People living with HIV (PLHIV).|We will recruit and enroll 850 people living with HIV (PLHIV) to participate in this longitudinal observational study.
62566338|NCT00938769|OTHER|Self-Efficacy Training for Caregivers|The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.
62566339|NCT00938769|OTHER|Comparison Conditions for Caregivers|Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for support.
62566340|NCT02992353|ACTIVE_COMPARATOR|Three-port pulmonary resection surgery|Treated by traditional video assisted thoracoscopic three-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
62566341|NCT02992353|ACTIVE_COMPARATOR|Single-port or two-port surgery|Treated by minimally invasive video assisted thoracoscopic single-port or two-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
62566342|NCT06258538|EXPERIMENTAL|distal robot-assisted and task-oriented therapy|Participants in the Circuit group received interventions for 20-min exoskeleton(EXO) and 20-min end-effector(EE) robot-assisted therapy, followed by 20-min uni- and 20-min bi- task-oriented therapy/session, 3 sessions/week for 6 consecutive weeks.
62566343|NCT06258538|EXPERIMENTAL|distal robot-assisted therapy alone|Participants in the Robot group received interventions for 40-min exoskeleton(EXO) and 40-min end-effector(EE) robot-assisted therapy/session, 3 sessions/week for 6 consecutive weeks.
62566344|NCT06258538|ACTIVE_COMPARATOR|task-oriented therapy alone|Participants in the task-oriented therapy(TOT) group received interventions for 40-min uni- and 40-min bi- task-oriented therapy/session, 3 sessions/week for 6 consecutive weeks.
62566345|NCT01683435|EXPERIMENTAL|hylauronin binding assay|HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
62566346|NCT04356547|ACTIVE_COMPARATOR|Fiberoptic intubation using laryngeal mask AuraGain|Participants should perform an fiberoptic tracheal intubation through the AuraGain laryngeal mask, in a pediatric simulator. Will be evaluated the success rate at the first attempt and other secondary outcomes
62566347|NCT04356547|ACTIVE_COMPARATOR|Fiberoptic intubation without laryngeal mask|Participants should perform an fiberoptic tracheal intubation without laryngeal mask, in a pediatric simulator. Will be evaluated the success rate at the first attempt and other secondary outcomes
62566348|NCT06068543|EXPERIMENTAL|Epigallocatechin-3-Gallate (EGCG)|800mg Epigallocatechin-3-Gallate (EGCG) pills AND 250mg Ascorbic Acid (Vitamin C) once daily
62566349|NCT06068543|PLACEBO_COMPARATOR|Microcrystalline cellulose (MCC)|800mg microcrystalline cellulose (MCC) pills AND 250mg Ascorbic Acid (Vitamin C) once daily
62566350|NCT01358929|EXPERIMENTAL|1|
62566351|NCT01358929|PLACEBO_COMPARATOR|2|
62566352|NCT05455541||Hospitalized patients with an indication for POCUS examination|Patient with an accepted indication for point of care echo study that are clinical stable.
62566353|NCT02044120|EXPERIMENTAL|niraparib and temozolomide|Niraparib (capsule) and temozolomide (capsule) will be taken together.
62566354|NCT02044120|EXPERIMENTAL|niraparib and irinotecan|Niraparib will be taken orally and irinotecan will be administered intravenously.
62566355|NCT02044120|EXPERIMENTAL|niraparib, irinotecan and temozolomide|Niraparib and temozolomide will be taken orally. Irinotecan will be administered intravenously.
62566356|NCT02913183|EXPERIMENTAL|young Fresh Frozen Plasma|"1. Drug: young plasma will be administered as 2 unit /day over a course of 3 consecutive days after stroke onset.~2. Drug: young plasma exchange over a course of 3 consecutive days after stroke onset."
62566357|NCT02913183|PLACEBO_COMPARATOR|old Fresh Frozen Plasma|"1. Old plasma will be administered as 2 unit /day over a course of 3 consecutive days after stroke onset.~2. Old plasma exchange over a course of 3 consecutive days after stroke onset.~3. Patients will receive usual care and drug use in hospital."
62566358|NCT01750775|EXPERIMENTAL|Shensong Yangxin capsule|Shensong Yangxin capsule 4 granules t.i.d. by mouth for 8weeks
62566359|NCT01750775|PLACEBO_COMPARATOR|placebo Capsule|placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
62566360|NCT02240212|EXPERIMENTAL|Part 1: Dose-escalation (weekly paclitaxel)|The dose escalation will be started from Cohort A (afuresertib combined with weekly paclitaxel regimen at 80 mg/m\^2 d1, 8,15, q4w). The starting dose in Cohort A will be 125 mg afuresertib QD to indentify MTD
62566361|NCT02240212|EXPERIMENTAL|Part 1: Dose-escalation (3 weeks Paclitaxel)|Once its MTD is identified, and then the study will move to dosing Cohort B (afuresertib combined with 3 weekly paclitaxel regimen at 175 mg/m\^2 d1, q3w. Cohort B (afuresertib combined with 3 weekly paclitaxel regimen at 175 mg/m\^2 d1, q3w). The starting daily dose of Cohort B will be 25 mg less than the MTD dose from Cohort A for afuresertib. If it is tolerated, then the dose escalation schedule will be followed in Cohort B until the MTD in this Cohort is reached. If the starting dose is not tolerated, then dose de-escalation will be explored until the MTD in this Cohort is reached. Once two dimensions of the MTD are achieved, then the optimal regimen for paclitaxel and MTD for afuresertib combined with paclitaxel based on the toxicity profile will be identified
62566362|NCT02240212|EXPERIMENTAL|Part 2: Experimental Cohort|The optimal regimen for paclitaxel and MTD for afuresertib combined with paclitaxel based on the toxicity profile will be administered
62566363|NCT03175263||Patients with chronic migraine|Patients with chronic migraine refractory to conventional treatments
62566364|NCT06573463|ACTIVE_COMPARATOR|Conventional band and loop|Conventional band and loop is the most widely used space maintainer, and the most effective. It shows high success rate and good patient compliance, but it needs more than one visit to be applied.
62566365|NCT06573463|ACTIVE_COMPARATOR|Prefabricated band and loop|Prefabricated space maintainer requires only one visit as it fits into the patient's mouth at the clinic without needing the dental lab. It comes in a kit with different band sizes.
62566366|NCT06244329|EXPERIMENTAL|High frequency repetitive transcranial magnetic stimulation|10 Hz rTMS is applied to the left dorsolateral prefrontal cortex (DLPFC). The individual DLPFC is located using the Beam F3 method. The stimulation intensity is 100% of the resting motor threshold of the left primary motor cortex. Each session of stimulation lasts for around 9 mins. We apply 6-session rTMS, with 2-3 times per week.
62567793|NCT05208931||разрыв|group in which neuroepithelial detachment rupture was observed after anti-vascular endothelial growth factor therapy
62391301|NCT01331876|EXPERIMENTAL|experimental therapy|20 OCD patients following 15 sessions of reference CBT associated with a new psychopedagogic task developed by our team.
62391302|NCT00298506|ACTIVE_COMPARATOR|FK506+MMF|
62391303|NCT02033369|EXPERIMENTAL|Pramipexole|Six weeks of treatment with oral pramipexole, initiated at 0.25 mg/day and titrated to a maximum daily dose of 2.5 mg.
62391304|NCT02033369|NO_INTERVENTION|Healthy Control|Healthy volunteers were matched to MDD group subjects by age, gender, and ethnicity, and will have no lifetime psychiatric disorders.
62181658|NCT03216941|ACTIVE_COMPARATOR|olanzapine|assessment of agitation status with Ramsay Sedation Scale administration of olanzapine 10 mg / ml IM one dose supervision of vital signs registration of time of olanzapine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of olanzapine administration) withdrawal of patient from the study if other medication was needed (aside of olanzapine)
62566367|NCT06244329|EXPERIMENTAL|Sham repetitive transcranial magnetic stimulation|Sham rTMS is applied to the left dorsolateral prefrontal cortex (DLPFC). The individual DLPFC is located using the Beam F3 method. The stimulation intensity is 20% of the resting motor threshold of the left primary motor cortex, which is deemed completely ineffective in modulating brain excitability. We apply 6-session sham rTMS, with 2-3 times per week.
62566368|NCT02580110|EXPERIMENTAL|sucrose|14 days intervention with daily intake of a beverage (1000 ml) including 66g sucrose.
62181659|NCT01430208|ACTIVE_COMPARATOR|mini-resectoscope|
62181660|NCT01430208|ACTIVE_COMPARATOR|tradiorional resectoscope|
62566369|NCT02580110|EXPERIMENTAL|stevia glycosides|14 days intervention with daily intake of a beverage (1000ml) including 0.220 g stevia glycosides.
62566370|NCT02580110|EXPERIMENTAL|saccharin|14 days intervention with daily intake of a beverage (1000ml) including 0.216g saccharin.
62566371|NCT05505435|ACTIVE_COMPARATOR|DMPA-SC|self-administered subcutaneous depot medroxyprogesterone acetate 104 mg
62566372|NCT05505435|ACTIVE_COMPARATOR|DMPA-IM|provider-administered intramuscular depot medroxyprogesterone acetate 150 mg
62566373|NCT03640533|EXPERIMENTAL|Nanit-Insights intervention group|Nanit-Insights is an app-based intervention that provides parents with personalized sleep recommendations, based on their infant's developmental stage and weekly sleep data.
62566374|NCT03640533|NO_INTERVENTION|Nanit-monitor control group|Participants in the control group will be given the same monitoring device, that will serve in this group as a baby-monitor only, without providing sleep recommendations to parents.
62566375|NCT00736164|EXPERIMENTAL|Arm I|Patients receive oral selenomethionine once daily for 8-9 weeks.
62566376|NCT00736164|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo once daily for 8-9 weeks.
62566377|NCT05949346|EXPERIMENTAL|MFNT Intervention (Treatment Group)|Parents of children with dyslexia who are randomized in Treatment Group will first take part in a pre-tested 4-session MFNT intervention programme. The parents will participate in lectures, group discussions, video demonstrations, and in-group exercises offered in these four mentored sessions, while their children will attend the second and fourth sessions.
62567794|NCT02229760|EXPERIMENTAL|TPV/r (Tipranavir co-administered with low dose ritonavir)|
62181661|NCT01430208|ACTIVE_COMPARATOR|bettocchi resectoscope|
62181662|NCT04338230|EXPERIMENTAL|Experimental: Experimental group|Women aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score of 23 and above points). Progressive muscle relaxation exercises are applied to the intervention group as 30-minute sessions three times a week for eight weeks.
62566378|NCT05949346|EXPERIMENTAL|MFNT Intervention (Wait Listing Control Group)|Families of children with dyslexia who are randomized in Wait Listing Control Group receive services as usual by the school personnel during the intervention period. The 4-session MFNT intervention program will be delivered to them after the intervention period.
62181663|NCT04338230|NO_INTERVENTION|No Intervention: Control group|Women aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score of 23 and above points).
62181664|NCT03842631||Superficial Group|Hemangioma depth evaluated by B-ultrasonoscope is lower than or equal to 6mm. After enrollment, patients would be subject to external use of Timolol Maleate 0.5% Oph Soln for the treatment of hemangioma.
62181665|NCT03842631||Deep Group|Hemangioma depth evaluated by B-ultrasonoscope is more than 6mm. After enrollment, patients would be subject to external use of Timolol Maleate 0.5% Oph Soln for the treatment of hemangioma.
62181666|NCT01863797|ACTIVE_COMPARATOR|Early induction|"Induction was performed if membranes were still intact and cervical dilation was less than four centimetres five hours after medication for therapeutic rest. For participants with an unripe cervix intravaginal prostaglandin E2 (PgE2, dinoproston) was used. A transcervical catheter (BARD) was inserted if this procedure was possible 19 and if cervical dilatation permitted, amniotomy was performed. The physician in charge performed all assessments and procedures except amniotomy.~When the participants reached the active phase they were monitored according to the clinical guidelines."
62181667|NCT01863797|EXPERIMENTAL|expectant management|The participants in the control group awaited spontaneous onset of labour as long as possible (expectant management). If contractions had ceased or subsided after the therapeutic rest women could be discharged from hospital, but were still included in the study. When reaching the active phase of labour women were monitored according to the clinical guidelines.
62566379|NCT02645240|EXPERIMENTAL|Heparin injection|Injection of low molecular weight heparin in patients with acute mesenteric ischemia to assess outcome
62566380|NCT00294866|ACTIVE_COMPARATOR|A|Receive Paricalcitol
62566381|NCT00294866|NO_INTERVENTION|B|Paricalcitol on hold
62181668|NCT06471608|ACTIVE_COMPARATOR|Standard care|"Chest tube drainage with hospital management~* chest tube drainage (with a straight or pigtail drain, less than ≤ 14 Fr in diameter, inserted using the Seldinger versus Seldinger technique, or using the standard drainage technique with an internal mandrel drain), followed by post-procedure imaging prior to transfer to the department, in accordance with standard practice (chest X-ray or low-dose CT scan, depending on management practices at the center).~* Hospitalisation in a hospital department (pulmonology, thoracic surgery, short-stay emergency unit, critical care, according to the usual pathway of the center in which the patient is included).~* In-hospital monitoring until complete resolution of pneumothorax and drain removal (average 4-6 days)."
62566382|NCT04322994|NO_INTERVENTION|Control|Control subjects will undergo their scheduled procedure and recovery with the usual care. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
62181669|NCT06471608|EXPERIMENTAL|Ambulatory management|- Chest tube drainage in emergency department (Furhmann drain connected to Heimlich valve), connected to suction system at -5 to -10 cm H2O until bubbling stops and ambulatory management after monitoring in the emergency department
62181670|NCT06009445||AKI group|"Acute kidney injury (AKI) was defined according to the Kidney Disease Improving Global Outcome (KDIGO) classification using both creatinine and urine output criteria.~The KDIGO guidelines define AKI as follows:~* Increase in serum creatinine by ≥0.3 mg/dL (≥26.5 micromol/L) within 48 hours, or~* Increase in serum creatinine to ≥1.5 times baseline, which is known or presumed to have occurred within the prior seven days, or~* Urine volume \<0.5 mL/kg/hour for six hours"
62181671|NCT06009445||Non AKI group|Patients who will no develop Acute kidney injury (AKI).
62181672|NCT06320327|EXPERIMENTAL|CBD Group|This group will apply the CBD cream in accordance with the manufacturer's recommendations at designated time points throughout the study.
62181673|NCT06320327|PLACEBO_COMPARATOR|Placebo Group|This group will apply a placebo moisturizer cream that will match the scent, volume, and viscosity of the CBD cream.
62566383|NCT04322994|EXPERIMENTAL|Intervention|"Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-4L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.~Intervention: Device: High-flow nasal cannula"
62566384|NCT04191174||Adults undergoing lung resection for lung cancer|
62181674|NCT06320327|NO_INTERVENTION|Control Group|This group will not apply any cream and will skip all cream-related procedures during the study.
62181675|NCT05665322|ACTIVE_COMPARATOR|Control|
62566385|NCT04261829||Autologous Fat Transfer|
61996661|NCT03961100|EXPERIMENTAL|Part 2|Participants will be randomly assigned to one of the two treatment sequences (TR, RT). In each treatment sequences, participants will cross-over to two periods taking different formulations of entrectinib. Entrectinib will be administered as a single 200 mg oral dose under fasted condition in two different formulations. Test formulation (T): hydroxypropyl methylcellulose (HPMC) capsule; Reference formulation (R): hard capsule.
62181676|NCT05665322|EXPERIMENTAL|Porto-scanner guidance with Angio-CT|
62391305|NCT03578341|EXPERIMENTAL|Colostrum|Group 1:(Colostrum): Preterm infants under 32 SDG will receive orally colostrum 0.3 mL every 4 h during three days.
62391306|NCT03578341|PLACEBO_COMPARATOR|Placebo|Group 2: (Placebo): Preterm newborns under 32 SDG who will receive orally sterile water 0.3 mL every 4 h during three days.
62391307|NCT05648305||General Dental Practitioners|Cohort 1 consisted UK Armed Forces Personnel that received root canal treatment within the study period by General Dental Practitioners.
62391308|NCT05648305||Dentists with Specialist Interest (DWSI)|Cohort 2 consisted UK Armed Forces Personnel that received root canal treatment within the study period by DWSI, clinicians that had undertaken a 1-year post-graduate programme in Endodontics.
61996662|NCT01192971|EXPERIMENTAL|A: 850mg|A: Experimental apatinib 850 mg qd p.o, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62181677|NCT05564546|EXPERIMENTAL|People exposed to sargassum seaweed stranding|"Participant living on the Atlantic coast of Martinique island (hit by the strandings), close (less than 300 meters) to sargassum seaweed stranding areas: exposed group (85 subjects).~Participants will be examined directly at their place of residence.~Participants will be examinated two times:~* at Visit 1 - Day 0 during the strandings period,~* at Visit 2 - M+6 months (+/-1 month) after the end of the strandings."
61996663|NCT01192971|EXPERIMENTAL|B: 750mg|B: Apatinib 750 qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
61996664|NCT02308735||Control|Pregnant women without either gestational or pre-gestational diabetes mellitus (and their offspring).
61996665|NCT02308735||A1 IDM|Pregnant women with abnormal glucose tolerance test but normal fasting serum glucose levels (and their offspring).
61996666|NCT02308735||A2 IDM|Pregnant women with abnormal glucose tolerance test and fasting hyperglycemia (and their offspring).
61996667|NCT02308735||PGDM - IDM|Pregnant women with diabetes mellitus diagnosed prior to current pregnancy (and their offspring).
62566386|NCT01915602|EXPERIMENTAL|Refametinib and Sorafenib (Nexavar)|In Cycle 1 reduced sorafenib dose (600 mg daily; 200 mg in the morning + 400 mg in the evening) is administered, which is escalated to the standard dose in Cycle 2, if no Hand-foot skin reaction (HFSR), fatigue, or gastrointestinal (GI) toxicities of grade 2 or higher occur. For the purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Progressive Disease (PD) {PD as defined by mRECIST criteria or clinical progression \[e.g. Eastern Cooperative Oncology Group performance status (ECOG PS) of ≥3\], treatment may be continued past radiological progression, provided the patient derives clinical benefit as judged by the treating physician.}, Death, Unacceptable toxicity, Subject withdraws consent, Treating physician determines discontinuation of treatment is in the subject's best interest, Substantial non-compliance with the protocol
62566387|NCT02445248|EXPERIMENTAL|Tisagenlecleucel|Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel.
62566388|NCT04933019|OTHER|Clindamycin Resistance Genes among Staphylococcus Isolates by Using Real Time PCR|
62566389|NCT04933019|OTHER|Clindamycin sensetive Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR|
61996668|NCT00691496|EXPERIMENTAL|1|Receives HIV testing and counseling and 5 week intervention
61996669|NCT00691496|NO_INTERVENTION|2|Receives only HIV Testing and Counseling
61996670|NCT05129072|EXPERIMENTAL|kalifilcon A Daily Disposable Toric LD213001 lens|kalifilcon A Daily Disposable Toric LD213001 lens in SKUs +6D, +3D, 0D, -3D, -6D, and -9D
62181678|NCT05564546|ACTIVE_COMPARATOR|People not exposed to sargassum seaweed stranding|"Participant living on the Caribbean coast of Martinique island (not hit by the strandings): unexposed group (85 subjects).~Participants will be examined directly at their place of residence.~Participants will be examinated two times:~* at Visit 1 - Day 0 during the strandings period,~* at Visit 2 - M+6 months (+/-1 month) after the end of the strandings."
62566390|NCT04030442|PLACEBO_COMPARATOR|Smoked cannabidiol 0%|
62566391|NCT04030442|ACTIVE_COMPARATOR|Smoked cannabidiol 9.7%|
62566392|NCT02042508|EXPERIMENTAL|Paraplegic patients|
62566393|NCT04771208|OTHER|Pre-Post Trial|Native Hawaiian participants from Homestead and Group Assisted Living (N=110) will partake in a pre-post study design. Participants will receive a baseline survey (as described below), view the ACP video intervention, and receive a post-intervention survey, which includes the same items as the baseline survey. In-person or phone interviews will be done at three and six months.
62566394|NCT04771208|NO_INTERVENTION|Randomized Clinical Trial: Control Group|In the ambulatory clinics we will conduct a randomized controlled trial (N=110), and randomize (1:1) to either the video (intervention) or usual care (control) arm. The control group will receive usual care. All participants will have a baseline survey, be randomized to intervention or control, and receive a post-intervention survey, which includes the same items as the baseline survey. Follow-up in person or by phone interviews will be done at three and six months.
62566395|NCT04771208|EXPERIMENTAL|Randomized Clinical Trial: Intervention Group|In the ambulatory clinics we will conduct a randomized controlled trial (N=110), and randomize (1:1) to either the video (intervention) or usual care (control) arm. The intervention group will use the ACP video decision aid. All participants will have a baseline survey, be randomized to intervention or control, and receive a post-intervention survey, which includes the same items as the baseline survey. Follow-up in person or by phone interviews will be done at three and six months.
62566396|NCT01096719|EXPERIMENTAL|Energy Density|
62566397|NCT01096719|ACTIVE_COMPARATOR|Lifestyle Treatment|
62566398|NCT01096719|EXPERIMENTAL|Energy Density + Lifestyle Treatment|
61996671|NCT00476021|EXPERIMENTAL|Postplacental IUD insertion|immediate postplacental levonorgestrel-releasing IUD (Mirena) insertion
61996672|NCT00476021|ACTIVE_COMPARATOR|Delayed IUD insertion|delayed levonorgestrel-releasing IUD (Mirena) insertion (6-8 weeks after delivery)
62181679|NCT06379698|ACTIVE_COMPARATOR|personalized 3D kidney model|exchange time with the personalized 3D model of the kidney to be operated on as information support
62181680|NCT06379698|ACTIVE_COMPARATOR|generic 3D kidney model|exchange time with the generic 3D model of the kidney to be operated on as information support
62181681|NCT04525456|EXPERIMENTAL|Reduxium|1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days
62181682|NCT05076136|EXPERIMENTAL|Regional treatment|Group A was given regional treatment with baseline treatment protocol
62181683|NCT05076136|ACTIVE_COMPARATOR|Standard physiotherapy treatment|Group B was given standard physiotherapy treatment with baseline protocol
62181684|NCT02580968|EXPERIMENTAL|electro-acupuncture|100hz, 2min. electro-acupoint: LI4(Large Intestine4) with LV3(Liver3).5times a week. lasting for 4 weeks.
62181685|NCT02580968|ACTIVE_COMPARATOR|routin medicine|one tablet of flunarizine hydrochloride tablet per day. lasting for 20days
62181686|NCT03167177|EXPERIMENTAL|NANT Melanoma Vaccine|"A combination of agents will be administered to subjects in this study:~avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, nivolumab, omega-3-acid ethyl esters, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-6207, GI-6301, and haNK."
62566399|NCT04434339|EXPERIMENTAL|group 1|"ESP block group ,Patients received preoperative US guided ESP block on BOTH sides to be operated upon 30 minutes before being transferred to the OR"
62181687|NCT03867552|EXPERIMENTAL|Altered gas (86% CO2, 10% N2O, 4% O2)|Surgery with the use of the altered insufflation gas (86% CO2, 10% N2O, 4% O2)
62181688|NCT03867552|ACTIVE_COMPARATOR|Standard gas (100% CO2)|Surgery with the use of the standardized gas (100% CO2)
62181689|NCT05373225|EXPERIMENTAL|Shock wave Therapy|This group will be composed of subjects who represented the experimental group 1. They will receive shock wave therapy
62181690|NCT05373225|EXPERIMENTAL|Acetic acid shockwave phonophoresis therapy|This group will be composed of subjects who represented the experimental group 2. They will take 6 sessions with Time between sessions 5-7 days plus exercise and dietary advice
62181691|NCT05373225|ACTIVE_COMPARATOR|conventional physical therapy program|"This group will be composed of subjects who represented the control group~Exercise program:~* Standing calf-stretching exercise~* Towel stretch: stretching exercise~* Ice bottle~* Towel pickup exercise~* Marble pickups exercise~* Calf raises exercises -Static and dynamic balance exercise"
62181692|NCT03783858|OTHER|Single|
62181693|NCT06133868|ACTIVE_COMPARATOR|Group I (Experimental group) Chamomile|"- · Describing the method for the child to become familiar with~· The patient will inhale natural chamomile oil in a separate room prior to the intervention. Three drops (0.1 cc per drop) will be poured on a cotton roll, and patients will inhale the oil without skin contact for 3 min."
62566400|NCT04434339|EXPERIMENTAL|group 2|"TAB group ,Patients received bilateral lower TAB 30 min before being transferred to the OR"
62566401|NCT04434339|NO_INTERVENTION|group 3|"the control group, Patients will not receive any block."
62566402|NCT01839890|EXPERIMENTAL|Bare metal Stent plus Paclitaxel Balloon|Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux)®
62566403|NCT01839890|ACTIVE_COMPARATOR|Bare metal Stent|Conventional Bare Stent
62566404|NCT00804310|EXPERIMENTAL|Lapatinib and Ixabepilone|
62566405|NCT05311059|EXPERIMENTAL|Ovarian drilling|Drilling needle was introduced and connected by monopolar current, held against ovarian surface for 4 seconds using a power of 40 watt, 4 puncture was done in each ovary with putting into consideration that the puncture must be not superficial and it must go deep through the main substance of the ovary
62566406|NCT04651933||Epithelial ovarian cancer patients sensitive to platinum based chemotherapy|
61996673|NCT03033407|EXPERIMENTAL|Intervention-Maintenance group|Intervention was adding 'Tailored mobile coaching messages' onto conventional diabetes management. This study was divided into two phases. In six-month phase 1 study, the participants in I-M group received tailored mobile coaching. And during the second half six-month phase 2 study, they could receive only regular information messages without individualized coaching.
61996674|NCT03033407|ACTIVE_COMPARATOR|Control-Intervention group|Intervention was adding 'Tailored mobile coaching messages' onto conventional diabetes management. In six-month phase 1 study, the participants in Control-Intervention group maintained usual care for diabetes. During the second half six-month phase 2 study, they received tailored mobile coaching.
61996675|NCT00838227|EXPERIMENTAL|One arm|Study withdrawn due to lack of funds.
61996676|NCT04062916||women with endometriosis|65 women whose main symptom was pain and who did not respond to medical treatment and underwent endometriosis surgery
61996677|NCT02094716|EXPERIMENTAL|Permethrin Foam 4%/ Permethrin Foam 4%|First treatment with Permethrin Foam 4% with potential to re-treat with Permethrin Foam 4%, if necessary.
61996678|NCT02094716|EXPERIMENTAL|Permethrin Foam 5%/ Permethrin Foam 5%|First treatment with Permethrin Foam 5% with potential to re-treat with Permethrin Foam 5%, if necessary.
61996679|NCT02094716|PLACEBO_COMPARATOR|Vehicle Foam / Permethrin Foam 4%|First treatment with Vehicle with potential to re-treat with Permethrin Foam 4%, if necessary.
61996680|NCT02094716|PLACEBO_COMPARATOR|Vehicle / Permethrin Foam 5%|First treatment with Vehicle with potential to re-treat with Permethrin Foam 5%, if necessary.
61996681|NCT03321669|ACTIVE_COMPARATOR|Increased Fat Diet|
61996682|NCT03321669|SHAM_COMPARATOR|Low Fat Diet|
61996683|NCT02850003|EXPERIMENTAL|IDP-120 Gel|Gel
61996684|NCT01959542|EXPERIMENTAL|MRIs and PSA Blood Test|"* Visit 1 (8 weeks after starting ADT): PSA blood test and prostate MRI~* Visit 2 (6 weeks after starting EBRT): PSA blood test and prostate MRI~* Visit 3 (on last day of EBRT): PSA blood test~* Visit 4 (6 months after starting ADT): PSA blood test and prostate MRI"
61996685|NCT05591326|EXPERIMENTAL|Cases in RT1 class according to gingival recession depth|Depth of gingival recession in mandibular anterior teeth, according to the 2017 Periodontal Classification, cases in RT1 class will be included.
61996686|NCT05113186|EXPERIMENTAL|Neoadjuvant and adjuvant therapy with lenvatinib|"* Neoadjuvant therapy with lenvatinib to complete a 3-week course, stopping 1 week before the planned date of PA procedure~* Adjuvant therapy with lenvatinib for 3 months starting after the PA evaluation (± 14 days) The daily dose of lenvatinib will be 12 mg (≥60 kg) or 8 mg (\<60 kg). Lenvatinib will be taken within 2 hours after a light meal, preferably in the morning."
61996687|NCT04200248|EXPERIMENTAL|Sham + RBM-007|Sham + RBM-007 intravitreal injection
61996688|NCT04200248|EXPERIMENTAL|RBM-007 + Aflibercept|RBM-007 + Aflibercept intravitreal injection
61996689|NCT04200248|ACTIVE_COMPARATOR|Sham + Aflibercept|Sham + Aflibercept intravitreal injection
62566407|NCT04651933||Epithelial ovarian cancer patients resistant to platinum based chemotherapy|
62566408|NCT05834725|EXPERIMENTAL|Resilience Coaching plus Usual Care|Promoting Resilience in Stress Management (PRISM) is a 1:1, remotely delivered, resilience coaching program for adolescents with chronic illness, consisting of skill-building sessions in stress management, goal setting, cognitive re-framing, and benefit-finding. Sessions are held every 1-2 weeks for a total of 4 required and one optional session and each session lasts about 30-45 minutes.
62566409|NCT05834725|ACTIVE_COMPARATOR|Usual Care|Usual care consists of an individualized treatment combining physical therapy, occupational therapy and psychological counseling. This is determined by the treating provider.
61996690|NCT03476096||Control|healthy pregnant women
61996691|NCT03476096||Pre-eclampsia|high-risk pregnant women
61996692|NCT00579826|EXPERIMENTAL|Letrozole|Letrozole, 2.5 mg daily for 6 months
62566410|NCT06388083|EXPERIMENTAL|LBS-008, Tinlarebant|5 mg tablet taken orally once a day
61996693|NCT00579826|PLACEBO_COMPARATOR|Placebo|Placebo, daily for 6 months
61996694|NCT06146530|EXPERIMENTAL|Treatment|"Participants in the treatment arm will have access to Cerina for 6 weeks.~The intervention (Cerina) consists of 7 sessions of Cognitive Behavioural Threapy (CBT) for the treatment of GAD. Each session contains a range of information and tasks/exercises to help the user understand the condition of GAD, the treatment approach, and how it will apply to them."
61996695|NCT06146530|ACTIVE_COMPARATOR|Wait-list|Participants in the waiting-list control condition will have access to the campus-based well-being services offered by the Student Wellbeing team.
61996696|NCT01256593||Pregabalin (Lyrica) capsule|"Patients administered Pregabalin capsule."
62566411|NCT06388083|PLACEBO_COMPARATOR|Placebo|Placebo tablets for tinlarebant 5 mg prepared similarly
62566412|NCT03321318|EXPERIMENTAL|A group|AK-R215, test drug
62566413|NCT03321318|ACTIVE_COMPARATOR|B group|reference drug, Bazedoxifene 20mg, Cholecalciferol 800IU
62566414|NCT00776035||Men with heart failure|Men with obesity-related heart failure
62566415|NCT00776035||Women with heart failure|Women with obesity-related heart failure
62566416|NCT04947865|EXPERIMENTAL|Post-stroke Stiff-Knee Gait Participants|Individuals with post-stroke Stiff-Knee gait
62566417|NCT04947865|EXPERIMENTAL|Healthy Individuals|Healthy Individuals
62566418|NCT01809080||2020|
62566419|NCT01809080||2019|
62566420|NCT01809080||2018|
62566421|NCT01809080||2017|
62566422|NCT01809080||2016|
62566423|NCT01809080||2015|
62566424|NCT01809080||2014|
62566425|NCT01809080||2013|
62566426|NCT01809080||2012|
62566427|NCT01809080||2011|
61996697|NCT01760148||Interferon and ribavirin|All the patients followed the standard treatment protocol.
61996698|NCT01438970|OTHER|ALFApump system implantation|Implantation of ALFApump system
61996699|NCT03169946|ACTIVE_COMPARATOR|Test Group|Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement (RCT with CHX-MTZ,OFD).
62566428|NCT01809080||2010|
62566429|NCT01809080||2009|
62566430|NCT01809080||2008|
62566431|NCT01809080||2007|
62566432|NCT01809080||2021|
62566433|NCT01809080||2022|
62566434|NCT01809080||2023|
62566435|NCT01809080||2024|
62566436|NCT01809080||2025|
62566437|NCT01809080||2026|
62566438|NCT04855760|EXPERIMENTAL|REL-1017|"Roll-over participants received 25 mg REL-1017 (one 25 mg REL-1017 tablet), orally, per day, either as a monotherapy or in addition to their ongoing antidepressant (ADT), rolling over from the monotherapy study REL-1017-303 or the adjunctive therapy studies REL-1017-301 and REL-1017-302, respectively.~De Novo participants received a 75 mg REL-1017 loading dose (three 25 mg REL-1017 tablets) on Day-1 of the 365-day treatment period. From Day-2 to Day-365, participants received 25 mg REL-1017 either as monotherapy or as adjunctive therapy."
62566439|NCT01879384|EXPERIMENTAL|Microdialysis with CMA 70 catheter|CMA 70 catheter directly positioned in bone tissue
62566440|NCT00337701|EXPERIMENTAL|1|
62566441|NCT00337701|EXPERIMENTAL|2|
62566442|NCT01972191||Group 1|Group 1 : Bare eye marking group
62566443|NCT01972191||Group 2|Group 2 : Pendulum attached marker group
62566444|NCT01972191||Group 3|Group 3 : Horizontal slit beam assisted marker group
62566445|NCT00105547|EXPERIMENTAL|1|800 mg BID
62566446|NCT00105547|PLACEBO_COMPARATOR|2|BID dosing
62566447|NCT04931030|EXPERIMENTAL|Low carbohydrate diet (LCBD)|Subjects are given a dietary prescription of 20g of carbohydrate daily in addition to standard low protein diet of 0.6-0.7g/kg/day and low salt diet.
62566448|NCT04931030|NO_INTERVENTION|Low protein diet only (LPD)|Subjects are given the standard dietary advice of chronic kidney disease of low protein diet of 0.6-0.7g/kg/day and low salt diet.
62566449|NCT05532111|EXPERIMENTAL|RT-R Group|Rituximab combined with tacrolimus induction + rituximab maintenance
62566450|NCT05532111|EXPERIMENTAL|RT-T Group|Rituximab combined with tacrolimus induction + tacrolimus maintenance
62566451|NCT05532111|EXPERIMENTAL|PC-C Group|Glucocorticoid combined with cyclophosphamide induction + maintenance
61996700|NCT03169946|ACTIVE_COMPARATOR|Positive Control Group :|Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement(RCT with CHX,OFD).
61996701|NCT05244629|ACTIVE_COMPARATOR|Bare Metal Stent|
61996702|NCT05244629|ACTIVE_COMPARATOR|Covered Stent|
61996703|NCT03674060|EXPERIMENTAL|SYO-1644 100mg|SYO-1644 tablet, PO, 1 100mg tablet
61996704|NCT03674060|EXPERIMENTAL|SYO-1644 150mg|SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet
61996705|NCT03674060|EXPERIMENTAL|SYO-1644 200mg|SYO-1644 tablet, PO, 2 100mg tablet
61996706|NCT03674060|ACTIVE_COMPARATOR|Nexavar|Nexavar 200mg/tablet, PO, 1 tablet
61996707|NCT00911703||Acute heart failure|Subjects with an ED diagnosis of acute decompensated heart failure .
61996708|NCT03012100|EXPERIMENTAL|Arm I (FRalpha peptide vaccine, sargramostim)|Patients receive cyclophosphamide PO BID on days 1-7 and 15-21 of cycle 1 only. Starting cycle 2, patients receive multi-epitope folate receptor alpha peptide vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for cycles 2-7 and every 6 months for cycles 8-14 in the absence of disease progression or unacceptable toxicity.
61996709|NCT03012100|PLACEBO_COMPARATOR|Arm II (placebo, sargramostim)|Patients receive cyclophosphamide as in Arm I. Starting cycle 2, patients receive placebo vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for cycles 2-7 and every 6 months for cycles 8-14 in the absence of disease progression or unacceptable toxicity.
61996710|NCT01076907|EXPERIMENTAL|Warm water loading of sigmoid colon|Warm water loading of sigmoid colon and irrigation when spasms occur.
61996711|NCT01076907|PLACEBO_COMPARATOR|Control|No water loading, only air and waiting for spasms to subside.
62181694|NCT06133868|ACTIVE_COMPARATOR|- Group II (Experimental group) Lavender|"* Describing the method for the child to become familiar with.~* The patient will inhale natural lavender oil (100% pure Lavandula) in a separate room prior to the intervention. Three drops (0.1 cc per drop) of lavender oil will be poured on a cotton roll, and patients will inhale the oil without skin contact for 3 min"
62181695|NCT06133868|PLACEBO_COMPARATOR|- Group III (Control group) Cotton with saline|"* Describing the method for the child to become familiar with~* The patient will inhale a clear cotton roll with saline."
62181696|NCT03587519|EXPERIMENTAL|Early ileostomy closure|Early ileostomy closure will be performed 7 to 12 days after with ileal j-pouch anal anastomosis (IPAA) and loop ileostomy (IPAA).
62181697|NCT03587519|ACTIVE_COMPARATOR|Late ileostomy closure|Late ileostomy closure will be performed 8 - 12 weeks after IPAA.
62566452|NCT04815889|NO_INTERVENTION|Control group|Recruitment of the control group is done through the county parts that have not yet been included in the clinical trial of new methods. This means that children / families are not withheld from treatment they would otherwise receive.
62566453|NCT04815889|ACTIVE_COMPARATOR|PRIMUS parent training group and preschool teacher training group|The parents have undergone PRIMUS Group-based parent support program for 5 half days This parenting education for preschool children with developmental problems but without the requirement of diagnosis Hellström (2019) has been designed and tested in other parts of the country but not scientifically validated, which can be done in this study. The preschool teachers may participate for half a day in education together with the parents as a practical implementation in the child's everyday life.
62181698|NCT01167192|EXPERIMENTAL|Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation|"Cisplatin 75 mg/m\^2 IV every 21 days for 4 cycles or Carboplatin AUC 6 IV every 21 days for 4 cycles.~Radiation beginning cycle 2 day 1 daily for 5-6 weeks 45-50 Gy.~Recommended mastectomy~Recommended adjuvant chemotherapy~-doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 for 14 days for 4 cycles followed by paclitaxel 175 mg/m2 for 14 days for 4 cycles)"
62181699|NCT01292577|EXPERIMENTAL|CET/PT|Behavioral Intervention: Participants will receive adapted Cognitive Enhancement Therapy/Personal Therapy.
62566454|NCT04815889|OTHER|Demand-driven intervention|"The PLUSS toddler team makes a management plan as referral to Habilitation Center, Child and Adolescent Psychiatry, Speech Therapist, or interventions eg:~* Support in the child's everyday environment home / preschool~* Targeted parent training group: toilet, sleep, food, everyday structure, handle behavioural problems~* Web Courses Each individual intervention is evaluated afterwards with the study questionnaire."
62566455|NCT01058642|EXPERIMENTAL|ADL5747|ADL5747 150 milligrams (mg) administered orally as 1 ADL5747 150-mg capsule and 1 placebo capsule twice daily (BID) for 14 days during 1 of 2 Treatment Periods.
62566456|NCT01058642|PLACEBO_COMPARATOR|Placebo|"Placebo: two placebo capsules administered orally BID for 14 days during 1 of 2 Treatment Periods.~Participants were also administered placebo orally BID during a 14-day washout period that took place between Treatment Period 1 and Treatment Period 2."
62566457|NCT01058642|ACTIVE_COMPARATOR|Pregabalin|Pregabalin administered orally as a dose of 1 pregabalin 75-mg capsule and 1 placebo capsule BID for the first 3 days, increased to a dose of 1 pregabalin 150-mg capsule and 1 placebo capsule BID for the last 11 days of 1 of 2 fourteen-day Treatment Periods, followed by a dose of 1 pregabalin 75-mg capsule and 1 placebo capsule BID for 3 days as a taper period.
62181700|NCT01292577|ACTIVE_COMPARATOR|Treatment as Usual|Behavioral Intervention: Participants will receive treatment as usual.
62566458|NCT01864902|EXPERIMENTAL|anti-CD33 CAR T cells|Patients receive anti-CD33-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
62566459|NCT01544985|EXPERIMENTAL|sucrose po|88% sucrose solution (Syrup B.P.)
62566460|NCT01544985|PLACEBO_COMPARATOR|placebo po|sterile water
62181701|NCT04223128|ACTIVE_COMPARATOR|Magnesium sulfate group(M)|Participants in group (M) will receive 50 mg/kg MgSO4 in 100 ml isotonic saline intravenous (I.V) over 20 minutes prior to induction of general anesthesia by 30 minutes then ultrasound guided TAPblock after closure of the abdomen
62181702|NCT04223128|ACTIVE_COMPARATOR|Dexamethasone group(D)|participants in group (D) will receive 2 mg Dexamethasone in 100 ml isotonic saline IV then ultrasound guided TAPblock after closure of the abdomen
62566461|NCT02838732|EXPERIMENTAL|L-carnitine supplementation|All participants received L-carnitine supplementation (500 mg per tablet per day, provided by GNC) for one month. Oral carnitine challenge tests and fecal sampling were conducted both before and after the intervention.
62566462|NCT06363344|OTHER|multi professional and comprehensive management of patients|An advanced practice nurse who is a member of the PICU team monitors patients. Contact with children and their family is established shortly before leaving intensive care, and the child and his family are seen again few days after by the nurse where the child was discharged, then closely in the 3 months following discharge (at 1 and 3 months).
61996712|NCT02302196||Autologous Fat Grafting of the breast|Approximately 100 women who have had a lumpectomy and qualify, will be offered Autologous Fat Grafting (AFG) procedure. Patients will be assessed 3 months post grafting for safety and efficacy by Breast-Q survey, mammography BIRADS scoring and physical assessment. The AFG may be repeated x 2 at a 3-6 month interval if deemed necessary by the treating surgeon, then reassessed again 3 months later in the same way. Repeat mammogram will be done 1 year post AFG.
62566463|NCT03270657|OTHER|Intraoperative Recording During DBS Implant Surgery|Participants will be recruited and enrolled from individuals who have Parkinson's disease (PD) and who already are scheduled to undergo the planned deep brain electrode placement for treatment of their movement disorder. Intraoperative recordings of participants' neural signals will be made through the implanted deep brain electrode(s).
62566464|NCT03447925|EXPERIMENTAL|Medicinal Plant X Salicylate|Treatment Group (TG) will receive topical treatment with medicinal plant and Salicylate Group (SG) will receive topical treatment with salicylate 10%, both once a day, for 30 consecutive days.
62566465|NCT03447925|EXPERIMENTAL|Medicinal Plant X Vaseline|Treatment Group (TG) will receive topical treatment with medicinal plant and Control Group (CG) will receive topical treatment with vaseline cream, both once a day, for 30 consecutive days.
62566466|NCT00083382|EXPERIMENTAL|Thalidomide + Bisphosphonate|200 mg/day Thalidomide + 90 mg Pamidronate OR 4 mg Zometa every 2 weeks for 2 months and then every 4 weeks as maintenance therapy
62566467|NCT04169893|PLACEBO_COMPARATOR|Arm Title: Placebo (fasting)|fasting
62566468|NCT04169893|PLACEBO_COMPARATOR|Placebo (feeding)|after meal
62566469|NCT04169893|EXPERIMENTAL|TS-142, 1 mg|fasting
62566470|NCT04169893|EXPERIMENTAL|TS-142, 3 mg|fasting
62566471|NCT04169893|EXPERIMENTAL|TS-142, 10 mg (fasting)|fasting
62566472|NCT04169893|EXPERIMENTAL|TS-142, 10 mg (feeding)|after meal
62566473|NCT04169893|EXPERIMENTAL|TS-142, 30 mg|fasting
62566474|NCT02962583|EXPERIMENTAL|Probiotic|Daily probiotic consumption
62566475|NCT02962583|PLACEBO_COMPARATOR|Placebo|Daily placebo consumption
62566476|NCT05729360|EXPERIMENTAL|Patients with a verified diagnosis of COVID-19|
62566477|NCT05272111|EXPERIMENTAL|Fascia Therapy|Group A will receive Fascia therapy
61996713|NCT02302196||Control arm standard treatment|Retrospective chart review will be done in 100 women who have undergone standard treatment for breast contour defect after lumpectomy.The control group will be measured by compiling BIRADS scores as well as frequency of subsequent surgical intervention (as necessitated by increased BIRADS scores or by new physical findings on exam) over a 5 year period post lumpectomy.
62566478|NCT05272111|EXPERIMENTAL|Facial Manipulation|Group B will receive Facial manipulation
62566479|NCT02050386||Cold pressor stimulation|Immersion of the foot in 0-2 degrees C water for 50 seconds.
62566480|NCT02050386||Sham Stimulation|Immersion of the foot in room temperature water for 50 seconds.
62566481|NCT05598112|EXPERIMENTAL|FMT capsules|FMT capsules containing extensively screened donor stool. FMT capsules will be orally taken on week 0, week 4, week 8, week 12, week 24, week 36, week 48, week 60, week 72, week 84.
62566482|NCT05598112|PLACEBO_COMPARATOR|Placebo capsules|Placebo capsules that do not contain donor stool or any active drug. Placebo capsules will be orally taken on week 0, week 4, week 8, week 12, week 24, week 36, week 48, week 60, week 72, week 84.
62566483|NCT05570682|ACTIVE_COMPARATOR|Manual induction|General Anesthesia induction: Fentanyl 2 mcg/kg, Propofol 2 mg/kg, Rocuronium 0.6 mg/kg General Anesthesia mainteneance: Propofol 4-6 mg/kg/h to keep an adequate sedation level (BIS between 40-60; entropy between 40-60)
62566484|NCT05570682|EXPERIMENTAL|Target Controlled Induction|"General Anesthesia induction: Fentanyl 2 mcg/kg, Propofol TCI with Schneider site effect model starting from 2 mcg/ml and increasing the dose untile loss of consciousness, Rocuronium 0.6 mg/kg.~General Anesthesia mainteneance: Propofol TCI with Schneider site effect model in order to keep an adequate sedation level (BIS between 40-60; entropy between 40-60)"
62566485|NCT02174640|ACTIVE_COMPARATOR|Coffee|Coffee Beverage
62566486|NCT02174640|PLACEBO_COMPARATOR|Water|Water
62566487|NCT00677547||1|Kidney transplant recipients
62566488|NCT00677547||2|Healthy volunteers
62566489|NCT02613832|EXPERIMENTAL|EPAP Group|The EPAP devices increase the alveolar pressure. This effect is obtained through valves that generate a resistance to airflow during expiration.
62181703|NCT04223128|PLACEBO_COMPARATOR|Placebo group(C)|participants in group (C) will receive 100 ml isotonic saline IV (placebo) by the same route and over the same duration as control then ultrasound guided TAPblock after closure of the abdomen
61996714|NCT03172936|EXPERIMENTAL|Dosing Schedule A|Patients were treated with MIW815 (ADU-S100) via intratumoral injection for 3 weeks followed by one week off in combination with a fixed intravenous dose of PDR001 given once per month
62181704|NCT01304771|ACTIVE_COMPARATOR|Synbiotic AKSB|Participants (healthy \> 65 year old persons) will be randomized to take the synbiotic AKSB. All participants will also receive inactivated trivalent Influenza vaccine while being on the AKSB. We will assess safety of the AKSB in this setting. We will also assess the stool microbiology in relation to vancomycin-resistant enterococcus and probiotic strain enterococcus. We will also assess influenza vaccine response in patients on AKSB
62181705|NCT01304771|PLACEBO_COMPARATOR|Talc Placebo|Participants (healthy \> 65 year old persons) will be randomized to take the placebo. All participants will also receive inactivated trivalent Influenza vaccine while being on the placebo. We will also assess the stool microbiology in relation to vancomycin-resistant enterococcus. We will also assess influenza vaccine response in patients on placebo.
62566490|NCT02613832|EXPERIMENTAL|Breath Stacking Group|The Breath Stacking consists on the implementation of subsequent inspiratory efforts through a one way valve, which allows stacked volume of gas during each inspiration, until it reaches a maximum lung volume.
62566491|NCT00929968|PLACEBO_COMPARATOR|Placebo to VAK694|
62566492|NCT00929968|EXPERIMENTAL|VAK694|
62566493|NCT00929968|ACTIVE_COMPARATOR|Fluticasone propionate|
62566494|NCT05315037|OTHER|Resistance Training|Bench press, Deadlift, Seated overhead press machine
62566495|NCT03283566|ACTIVE_COMPARATOR|Hydroxychloroquine|Administered pre-transplant through 3 months after surgery.
62566496|NCT03283566|PLACEBO_COMPARATOR|Placebo|Placebo treatment following the same schedule as Arm 1 (i.e. Hydroxychloroquine).
62566497|NCT03762265|PLACEBO_COMPARATOR|Placebo Then Rilzabrutinib|In BT period, participants received placebo orally twice daily (BID) up to 37 weeks along with sponsor-provided corticosteroids (CS). After at least two weeks of control of disease activity (CDA; no new lesions and established lesions begin to heal), based on protocol-specified clinical criteria, investigators could decrease the CS dose to a minimum of 5 milligrams (mg) prednisone/prednisolone per day from Week 29 to Week 37. Post completion of BT period, eligible participants received rilzabrutinib 400 mg BID up to Week 61 in OLE period and those who were eligible after OLE period completion, continued the same treatment until Week 109 in LTE period according to protocol-specified criteria.
62566498|NCT03762265|EXPERIMENTAL|Rilzabrutinib Then Rilzabrutinib|In BT period, participants received rilzabrutinib 400 mg orally BID up to 37 weeks along with sponsor-provided CS. After at least two weeks of CDA (no new lesions and established lesions begin to heal), based on protocol-specified clinical criteria, investigators could decrease the CS dose to a minimum of 5 mg prednisone/prednisolone per day from Week 29 to Week 37. Post completion of BT period, eligible participants received rilzabrutinib 400 mg BID up to Week 61 in OLE period and those who were eligible after OLE period completion, continued the same treatment until Week 109 in LTE period according to protocol-specified criteria.
62566499|NCT03175705|EXPERIMENTAL|Autologous T cell therapy+Tegafur+Interleukin-2 (IL-2)|Autologous in vitro expanded HCC antigens-specific CD8+ T lymphocytes in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with relapsed/advanced HCC.
61996715|NCT03172936|EXPERIMENTAL|Dosing Schedule B|Patients were treated with MIW815 (ADU-S100) via intratumoral injection given once a month in combination with a fixed intravenous dose of PDR001 given once per month
61996716|NCT04037553||Group 1|Patients underwent right ear surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, lateral neck rotation (approximately 60-70 degrees to the left) was applied to the patients and ICP values were documented following 3 respiration cycles.
62181706|NCT05068271|EXPERIMENTAL|Multi-Domain Exercise Program|"Time: 6 months, total of 150 min of exercise per week.~Intervention: aerobic training, muscular fitness training, balance, flexibility, meditation, and social interaction."
62181707|NCT05068271|OTHER|Control Group|"Time: 6 months, total of 60 min of online educational course per week.~Intervention: educational materials relating to the effects of exercise on cognitive function and aging-related cognitive decline."
61996717|NCT04037553||Group 2|Patients underwent left ear surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, lateral neck rotation (approximately 60-70 degrees to the right) was applied to the patients and ICP values were documented following 3 respiration cycles.
61996718|NCT04037553||Group 3|Patients underwent left head and neck surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, gel pillow with the height of 4,5 cm was placed under the shoulders of patients to extend the neck. Following 3 respiration cycles, the ICPs were noted. Then, right or left lateral neck rotation was applied depending on the operation side (approximately 60-70 degree to the opposite site). After 3 respiration cycles, ICPs were documented again.
61996719|NCT01581632|OTHER|LipiScan/LipiScan IVUS|valuation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
62181708|NCT03478046|EXPERIMENTAL|Obese individuals|Apparently healthy, weight-stable, obese and physically inactive male volunteers will be recruited. Intervention is an 8 to 10% weight loss induced by chronic exercise training and dietary modification
62566500|NCT04741750|NO_INTERVENTION|Usual Care within Community Clinics|Complete blood count, comprehensive metabolic panel, international normalized ratio, HCV RNA, hepatitis B virus (HBV) serologies, point of care HIV test, and point of care liver fibrosis measurement. HCV genotype if required by patient's insurance for prior authorization. Care for opioid use disorder and skin infection is offered. Completion of the initial visit workup is sufficient to initiate a prior authorization request for DAAs from payers and an appointment for MAT follow-up in a community clinic if indicated. Patient coordination; authorization with insurance companies; scheduling appointments, follow-up, and ancillary support services will be conducted by a Patient Navigator. Patients are seen every 2-4 weeks for monitoring and adherence support. HCV treatment regimens are at the discretion of the treating provider in accordance with AASLD/IDSA guidelines and insurance requirements. Twelve weeks after HCV therapy completion, SVR12 HCV RNA and SVR12 CMP tests will be obtained.
62566501|NCT04741750|EXPERIMENTAL|Simplified Care within a Mobile Medical Unit|Simplified Care treatment is the same as for Usual Care with the exception that it is taking place within a mobile medical clinic that is scheduled to deliver treatment in alignment with regular syringe exchange services.
62566502|NCT02712554|EXPERIMENTAL|Treatment A:CL-108 22.5mg/975mg/37.5mg|CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth
62566503|NCT02712554|EXPERIMENTAL|Treatment B:CL-108 37.5mg/1625mg/62.5mg|CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth
62566504|NCT02712554|ACTIVE_COMPARATOR|Treatment C:M366 22.5mg/975mg|M366 22.5 mg/975 mg tablet by mouth
62566505|NCT02712554|ACTIVE_COMPARATOR|Treatment D: M366 37.5mg/1625mg|M366 37.5 mg/1625 mg tablet by mouth
62566506|NCT02712554|PLACEBO_COMPARATOR|Treatment E: Placebo|Placebo 0 mg tablet by mouth
62566507|NCT06476301|NO_INTERVENTION|warfarin group|A 3-6-month anticoagulation therapy with warfarin is recommended after the BPV surgery. Patients allocated to the warfarin group will adhere to a target INR range of 2 to 3. Patients 65 \> years old and low weight should take warfarin 2.5mg/day and all other patients should take 5mg/day. During hospitalization, the INR will be reassessed daily, and regular measurements (at least every four weeks) should be conducted post-discharge to ensure ongoing patient stability.
62566508|NCT06476301|EXPERIMENTAL|rivaroxaban group|Patients allocated to the rivaroxaban group will be administered a dose of 20 mg orally once daily (to be taken with food), or 15 mg once daily in patients with moderate renal impairment at screening (defined as creatinine clearance rate, CrCl between 30 and 49 mL/min).
62566509|NCT06061120||Questionnaire - Supraventricular arrhythmia|Questionnaire about triggers and stops of supra ventricular arrhythmia
62566510|NCT06061120||Extended ECG - Effect of electrophysiological ablation|Extended signal-averaged ECGs in patients with ablation of supra ventricular ablation
62566511|NCT06061120||Extended ECG - Virtual atrial Electrocardiogram|Improve visualisation of atrial arrhythmia by means of extended signal-averaged ECGs
62566512|NCT05468294|EXPERIMENTAL|Ph I: F16IL2 + Nivolumab|"Patients will receive a fixed dose of Nivolumab and the following increasing dose levels of F16IL2: 15, 30, 50 and 70 Mio IU.~Once the RD is established, 17 patients will receive a fixed dose of Nivolumab and F16IL2 at the RD, established during the Phase I part of the study."
62566513|NCT01702220|EXPERIMENTAL|CBT|
62566514|NCT01702220|ACTIVE_COMPARATOR|Enhanced Community Care (ECC)|
62566515|NCT03004638|EXPERIMENTAL|MEDI6012 40 mg|Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
62566516|NCT03004638|PLACEBO_COMPARATOR|Placebo|Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
62566517|NCT03004638|EXPERIMENTAL|MEDI6012 120 mg|Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
62566518|NCT03004638|EXPERIMENTAL|MEDI6012 300 mg|Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
62566519|NCT03004638|EXPERIMENTAL|MEDI6012 IV Push|Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
62566520|NCT03004638|PLACEBO_COMPARATOR|Placebo IV Push|Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
62566521|NCT06020911|ACTIVE_COMPARATOR|Biodentine|17 primary second molars of 17 children will be capped with Biodentine.
62566522|NCT06020911|ACTIVE_COMPARATOR|Theracal light cured|17 primary second molars of 17 children will be capped with Theracal light cured
61996720|NCT01755416|PLACEBO_COMPARATOR|Closed loop with sensor and Insulin|subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
61996721|NCT01755416|ACTIVE_COMPARATOR|Closed loop with sensor, Insulin and Liraglutide|Subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner, on Day 1.
61996722|NCT06115538|ACTIVE_COMPARATOR|levodopa benserazide group|levodopa benserazide (100+25 mg)
61996723|NCT06115538|ACTIVE_COMPARATOR|levodopa carbidopa entakapon grubu|levodopa carbidopa entacapone (100+25+200 mg)
62181709|NCT01108042|EXPERIMENTAL|Taxotere, Cisplatin, 5-Fluorouracil (5-FU)|Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out.
62181710|NCT05499143||Parents of children with DCD or related movement difficulties|
62566523|NCT06507410|ACTIVE_COMPARATOR|Propofol group|"Patients will receive induction of sedation as follow:~Continuous propofol infusion will be given with syringe pump for maintenance, with the initial rate set at 25-75 mic/kg/min IV during the first 10-15 min. To avoid administering sedatives at rates greater than clinically necessary, infusion rates will be gradually titrated to 25-50 mic/kg/min and regulated with the clinical response, with an onset of peak drug action expected to occur within 2 min."
62566524|NCT06507410|EXPERIMENTAL|Propofol combined with clonidine group|Patients will receive 2 μg/kg of clonidine for injection intravenously 30 min before induction of sedation, administered over 10 min.
62566525|NCT01846364|EXPERIMENTAL|A|Subjects with proliferative thyroid disease
62566526|NCT05919797|EXPERIMENTAL|All participants|Calorie restricted diet and treatment with Naltrexone/Bupropion
62566527|NCT02124915||Transtibial amputees|
62566528|NCT06016205|ACTIVE_COMPARATOR|Morphine group (n= 25):|
62181711|NCT00637832|EXPERIMENTAL|single group|
62181712|NCT05748678|EXPERIMENTAL|Use of the compression apparel|All participants
62181713|NCT00855322|EXPERIMENTAL|1|Gym group exercise intervention
62566529|NCT06016205|ACTIVE_COMPARATOR|PECS group (n= 25):|
62566530|NCT05823935|ACTIVE_COMPARATOR|Bakay purse string group|Bakay purse string will be used to close the vaginal cuff after total laparoscopic hysterectomy for benign lesions.
62566531|NCT05823935|ACTIVE_COMPARATOR|Cuff closure via vaginal route group|Vaginal cuff closure via vaginal route with continuous locked suturing will be used to close the vaginal cuff after total laparoscopic hysterectomy for benign lesions.
62566532|NCT06576921|EXPERIMENTAL|S-P-SOX group|"Neoadjuvant treatment phase: 1.Serplulimab, 4.5 mg intravenously on day 1; 2.Nap-paclitaxel, 260 mg/m2 intravenously on days 1; 3.Oxaliplatin (OXA), 130mg/ /m2, intravenously on days 1; 4.Tigio (S-1), 40-60 mg orally twice daily on days 1 to 14.~The above treatments will be administered every 3 weeks for three preoperative cycles. Dose adjustment is not allowed and delayed dosing is allowed.~Surgery phase: Surgery was scheduled 3 to 4 weeks after completion of the last cycle of neoadjuvant treatment. All surgical procedures are performed according to the guidelines of the Japanese Research Society for the Study of Gastric Cancer.~Adjuvant treatment phase: Adjuvant treatment started 3 to 8 weeks after surgery. Patients will receive three 3-week cycles of adjuvant treatment with S-P-SOX."
62181714|NCT00855322|EXPERIMENTAL|2|Hydrotherapy group exercise intervention
62181715|NCT00855322|NO_INTERVENTION|3|Control group
62181716|NCT04660578|EXPERIMENTAL|Single Group|A.Chohan continuous squeezing suture (ACCSS); An Obstetrical procedure using half circle 40mm round body polyglactin 910 suture #1 (Vicryl plus by Ethicon®), for controlling hemorrhage from the lower uterine segment, in patients with placenta previa / accreta for the prevention of hysterectomy at cesarean section.
62181717|NCT02073721|EXPERIMENTAL|electrostimulation with exercises MAPs|this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.
62181718|NCT02073721|ACTIVE_COMPARATOR|exercises MAPs|This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor
62566533|NCT06576921|PLACEBO_COMPARATOR|P-SOX group|"Neoadjuvant treatment phase: 1.Nap-paclitaxel, 260 mg/m2 intravenously on days 1; 2.Oxaliplatin (OXA), 130mg/ /m2, intravenously on days 1; 3.Tigio (S-1), 40-60 mg orally twice daily on days 1 to 14.~The above treatments will be administered every 3 weeks for three preoperative cycles. Dose adjustment is not allowed and delayed dosing is allowed.~Surgery phase: Surgery was scheduled 3 to 4 weeks after completion of the last cycle of neoadjuvant treatment. All surgical procedures are performed according to the guidelines of the Japanese Research Society for the Study of Gastric Cancer.~Adjuvant treatment phase: Adjuvant treatment started 3 to 8 weeks after surgery. Patients will receive three 3-week cycles of adjuvant treatment with P-SOX."
62566534|NCT04309396|EXPERIMENTAL|Breath analyzer|Candidates who, after the screening period are eligible to receive the AIRE device.
62566535|NCT02999750|OTHER|individual therapy|individual therapy
62566536|NCT00972790|SHAM_COMPARATOR|Control Group|The patients in the control arm will receive sham nerve blocks with 20 ml of saline + epinephrine 1:200,000, in a manner identical to that described for the treatment group.
62566537|NCT00972790|ACTIVE_COMPARATOR|Intervention Group|The patients in the intervention group will receive bilateral scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000.
62566538|NCT05626296||Phlegm-heat syndrome in ischemic stroke|"Phlegm-heat syndrome: the score of Phlegm-dampness syndrome ≥10 with the score of Internal fire syndrome ≥10 in Diagnostic Scale for Syndrome Elements of Ischemic Stroke"
62566539|NCT05626296||Non-phlegm-heat syndrome in ischemic stroke|"Non-phlegm-heat syndrome: the score of Phlegm-dampness syndrome \<10 with the score of Internal fire syndrome \<10 in Diagnostic Scale for Syndrome Elements of Ischemic Stroke"
62566540|NCT05626296||Healthy subjects|
62566541|NCT00961675|ACTIVE_COMPARATOR|FST201|
62566542|NCT00961675|ACTIVE_COMPARATOR|Ciprodex|
62566543|NCT05632861|EXPERIMENTAL|Experimental group|HuHuangLianzonggan capsule, 4 pills, take orally after meals, 2 times a day
62566544|NCT05632861|PLACEBO_COMPARATOR|Placebo group|HuHuangLianzonggan capsule placebo, 4 pills, take orally after meals, 2 times a day
62566545|NCT06534970||Facial reconstruction patients|Reconstruction of the lower or middle third of the face using a pedicled flap or microanastomosed free flap following excision of a benign or malignant tumor of the oral cavity or face, osteonecrosis of the jaws, or traumatic loss of facial substance
62566546|NCT04103125|OTHER|Janesse|Janesse® 20 (Cross-linked Hyaluronic Acid) Injection: follow the instruction for use
62566547|NCT03364725|EXPERIMENTAL|Open Label Treatment Arm|Treatment arm using Glecaprevir-pibrentasvir for treatment of all patients
62566548|NCT05013710||Plan A Health|Founded in 2018, Plan A Health, Inc seeks to address health care disparities in rural communities by improving access to reproductive and sexual care. Beginning April 2021, the first Plan A mobile health clinic opened, serving five counties in the Mississippi Delta. The care team in the clinic includes a community health worker, nurse practitioner, volunteer providers, residents, and a collaborating physician.
62566549|NCT05013710||Just the Pill|Just The Pill offers telemedicine appointments by phone or online for sexual and reproductive health needs that is delivered to the patient's home. The organization is also opening a mobile health clinic that will deliver care directly to communities.
62566550|NCT05013710||University of Florida Mobile Outreach Clinic|The mission of the Mobile Outreach Clinic is to reduce health disparities by providing best practice, flexible, low-barrier primary care at no cost to patients unable to access the healthcare system. They focus on addressing the social barriers that drive health inequities and educating health professions students in an environment that equips them to become the socially conscious medical providers of the future.
62566551|NCT06534320|EXPERIMENTAL|DA-302168S|This study includes single-dose ascending and multiple-dose ascending studies. SAD study may contain 7 dose groups of 2.5 mg, 7.5 mg, 15 mg, 30mg, 50mg, 75mg and 100 mg. MAD study contains 1-4 dose groups which were evaluated in SAD study to be tolerated.
62566552|NCT06534320|PLACEBO_COMPARATOR|Placebo of DA-302168S|This study includes single-dose ascending and multiple-dose ascending studies. SAD study may contain 7 dose groups of 2.5 mg, 7.5 mg, 15 mg, 30mg, 50mg, 75mg and 100 mg. MAD study contains 1-4 dose groups which were evaluated in SAD study to be tolerated.
62566553|NCT01799629|EXPERIMENTAL|Intervention|Intervention group will receive the glycerin suppository
62181719|NCT05310747|EXPERIMENTAL|Artwork present + social connection high|Individuals participate in an exercise to prime a feeling of high social connection and then explore a virtual museum exhibit with artwork for 10 minutes
62181720|NCT05310747|EXPERIMENTAL|Artwork present + social connection low|Individuals participate in an exercise to prime a feeling of low social connection and then explore a virtual museum exhibit with artwork for 10 minutes
62566554|NCT01799629|NO_INTERVENTION|Control|Normal care
62566555|NCT02874625|ACTIVE_COMPARATOR|Treatment 1|Dental restoration performed with glass-ionomer materials.
62566556|NCT02874625|EXPERIMENTAL|Treatment 2|Dental restoration performed with resin-based composites.
62566557|NCT00385047|EXPERIMENTAL|Group A|FMP 2.1 50 μg FMP2.1/AS01B
62566558|NCT00385047|EXPERIMENTAL|Group B|FMP 2.1 50 μg FMP2.1/AS02A
62566559|NCT00568451|EXPERIMENTAL|PC (previously treated)|Previously chemotherapy treated cohorts: Paclitaxel and Carboplatin (PC)
62566560|NCT00568451|EXPERIMENTAL|PC (chemo naive)|Chemotherapy-naive cohorts: Paclitaxel and Carboplatin (PC)
62566561|NCT00568451|EXPERIMENTAL|TMZ (previously treated)|Previously chemotherapy treated cohorts: Temozolomide (TMZ)
62566562|NCT00568451|EXPERIMENTAL|TMZ (chemo naive)|Chemotherapy-naive cohorts: Temozolomide (TMZ)
62566563|NCT01207024||knee MRI|knee MRI for all patients undergoing bariatric surgery as usual care
62566564|NCT04232865|EXPERIMENTAL|Bןםפ Sטדאקצ|Biop Colposcopy procedure
61996724|NCT05489315|OTHER|Traditional Positioning|Participants who are randomly assigned to NOT receive a peanut ball will undergo placement on a wedge pillow and/or traditional positioning during their labor progression at 6cm cervical dilation.
61996725|NCT05489315|EXPERIMENTAL|Peanut Ball Positioning|Participants who are randomly assigned to receive a peanut ball will be positioned with a peanut ball at 6cm cervical dilation.
61996726|NCT01554891||Cohort 1|100 OEF/OIF/OND veterans returning to Joint Base Lewis-McChord and Fort Bragg who screen positive for TBI on the Post Deployment Health Assessment (PDHA) TBI screen
61996727|NCT01554891||Cohort 2|100 OEF/OIF/OND veterans seeking care at Northern New England VA Research Consortium (NNEVARC) VA Medical Centers (VAMCs) who screen positive for TBI on VA Level 1 TBI screen
61996728|NCT01554891||Cohort 3|200 participants in WRNMMC and Fort Belvoir Community Hospital Brain Indices Study (100 with mild TBI; 100 without mild TBI).
62181721|NCT05310747|EXPERIMENTAL|Artwork absent + social connection high|Individuals participate in an exercise to prime a feeling of high social connection and then explore a virtual museum exhibit with no artwork for 10 minutes
62181722|NCT05310747|ACTIVE_COMPARATOR|Artwork absent + social connection low|Individuals participate in an exercise to prime a feeling of low social connection and then explore a virtual museum exhibit with no artwork for 10 minutes
62181723|NCT05310747|NO_INTERVENTION|Hanging control group|Individuals will receive no exposure to any independent variables (i.e. artwork: present or absent; social connection prime: high or low) for 10 minutes before completing their final survey.
62391309|NCT01200758|ACTIVE_COMPARATOR|Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)|Eight cycles of rituximab IV infusion (375 mg/m\^2; rituximab induction) in combination with up to 8 cycles of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) or cyclophosphamide, vincristine, prednisolone (CVP) chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\^2) once every 8 weeks for 24 months.
62566565|NCT04390919||high group|high group: monocyte count≥0.445×10\*9 cells/L
62566566|NCT04390919||low group|low group: monocyte count\<0.445×10\*9 cells/L;
62566567|NCT06578221|EXPERIMENTAL|Kegel Pelvic Floor Muscle Exercise Group|Kegel exercises will be performed by the researcher within the first 8 hours after being taken to the clinic room to perform the Kegel pelvic floor muscle exercises while in the supine position. Urinary retention and comfort level of patients will be evaluated after surgery.
62566568|NCT06578221|NO_INTERVENTION|Control Group|Urinary retention and comfort level of patients will be evaluated after surgery.
62566569|NCT04955405|EXPERIMENTAL|Seven telemedicine visits|Will receive the seven visit telemedicine protocol
62566570|NCT04955405|NO_INTERVENTION|Control - Usual Care|Will not receive the protocol
62566571|NCT04571905|OTHER|Syntellix Treatment Arm|General anaesthesia, open fracture reduction, insertion of the appropriate screw with x-ray control and documentation intraoperatively, cast immobilisation Use of bioresorbable Magnezix CS or CBS Screws, if intraoperatively suitable bioresorbable screws not available, use of conventional ostesynthesis screws
62566572|NCT06114381|EXPERIMENTAL|Home Based Physical Exercise|This group composed of 30 participants who will receive full body physical exercise 6 days per week in addition to sun exposure as well as their vitamin D supplement for 6 weeks.
62566573|NCT06114381|EXPERIMENTAL|Diet management group|This group composed of 30 participants who will receive dietary management and sun exposure as well as their vitamin D supplement for 6 weeks.
62566574|NCT06114381|EXPERIMENTAL|Sun Exposure and supplements|This group composed of 30 participants who will receive only sun exposure as well as their vitamin D supplement for 6 weeks.
61996729|NCT06231303||Patient with lupus nepheritis|
61996730|NCT06231303||Healthy persons of the same age|
61996731|NCT00661700|PLACEBO_COMPARATOR|Arm 2|
61996732|NCT00661700|EXPERIMENTAL|Arm 1|
61996733|NCT02150564|OTHER|Navigation only group|Sonowand system will be used for navigation control arm as well as sononavigation experimental arm.Navigation will be used to plan the craniotomy and throughout the procedure as desired by the operating surgeon. At no point of time however will the Ultrasound be used.
62566575|NCT06114381|NO_INTERVENTION|Control group|This group composed of 30 participants who didn't receive any intervention
62566576|NCT04807764|EXPERIMENTAL|Real transspinal stimulation delivered during standing followed by locomotor training|Transspinal tonic stimulation of the thoracolumbar region will be delivered at a frequency of 30 Hz during standing with as needed body weight support (BWS) in a standing frame or in the Lokomat to ensure safety.
62566577|NCT04807764|EXPERIMENTAL|Real transspinal stimulation delivered while lying supine followed by locomotor training|Transspinal tonic stimulation will be delivered at a frequency of 30 Hz while lying supine.
62566578|NCT04807764|SHAM_COMPARATOR|Sham transspinal stimulation delivered during standing followed by locomotor training|One sham group will be receiving transspinal stimulation during standing at an intensity where sensation is absent.
62566579|NCT02508350|EXPERIMENTAL|daptomycin|Daptomycin for injection 10-12mg/kg/day,determination of plasma concentration
62566580|NCT00086619|EXPERIMENTAL|constant dose|Participants will receive synthetic human parathyroid hormone fragment 1-34 (hPTH 1-34) once-daily in a constant dose of 30 mcg/day.
62566581|NCT00086619|EXPERIMENTAL|ascending dose|Participants will receive synthetic human parathyroid hormone fragment 1-34 (hPTH 1-34) once-daily in a dose that ascends at 6 month intervals (20-30-40 mcg/day).
62566582|NCT01616797|EXPERIMENTAL|Computerized intervention|Participants will be asked to visit a customized website and engage in computerized exercises. Cognitive and emotion training games.
62566583|NCT01616797|SHAM_COMPARATOR|Control|Participants will be asked to visit a customized website and engage in computerized games.
62566584|NCT02871011|PLACEBO_COMPARATOR|Control|Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
62566585|NCT02871011|EXPERIMENTAL|Nitric oxide|Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
62566586|NCT01494883|NO_INTERVENTION|Treatment as usual|
62566587|NCT01494883|EXPERIMENTAL|Mindfulnes Based Stress Reduction|A weekly training of eight session lasting two and a half hours.
61996734|NCT02150564|EXPERIMENTAL|SonoRCT Test group|Surgery to resect the tumor with the aid of sononavigation. In addition to the navigation function, the Ultrasound will be available at all times. This study will help in assessing the usefulness sononavigation in improving radicality of resection in malignant gliomas and also to access the accuracy of SonoWand in predicting residue.
61996735|NCT04964453|PLACEBO_COMPARATOR|Placebo|Healthy subjects were given a single dose of placebo tablet(s) matched to the active treatment, subjects receiving placebo were equally distributed across dose groups. Tablet(s) were taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
61996736|NCT04964453|EXPERIMENTAL|2.5 mg BI 474121|Healthy subjects were given a single dose of 2.5 milligram (mg) of BI 474121 as a single (2.5 mg) uncoated tablet taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
61996737|NCT04964453|EXPERIMENTAL|5 mg BI 474121|Healthy subjects were given a single dose of 5 milligram (mg) of BI 474121 as two (2.5 mg) uncoated tablets taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
61996738|NCT04964453|EXPERIMENTAL|10 mg BI 474121|Healthy subjects were given a single dose of 10 milligram (mg) of BI 474121 as a single (10 mg) uncoated tablet taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
61996739|NCT04964453|EXPERIMENTAL|20 mg BI 474121|Healthy subjects were given a single dose of 20 milligram (mg) of BI 474121 as two (10 mg) uncoated tablets taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
61996740|NCT05369351|EXPERIMENTAL|Standard treatment+mirabegron|In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.
61996741|NCT05369351|OTHER|Standard treatment|Patients will receive usual care
61996742|NCT05263492|EXPERIMENTAL|Pembrolizumab & Lenvatinib|Lenvatinib, 20 mg administered orally (PO) once daily (QD) during each 21-day cycle, and Pembrolizumab, 200 mg administered by intravenous (IV) infusion on day 1 of each 21-day cycle.
61996743|NCT03266328||group 1|ST elevated myocardial infarction patient presented to assiut university hospital for Primary Percutaneous Coronary Intervention (PPCI) and their age is up to 40 years old
61996744|NCT03266328||group 2|ST elevated myocardial infarction patient presented to assiut university hospital for Primary Percutaneous Coronary Intervention (PPCI) and their age is more than 40 years old
61996745|NCT03013543|EXPERIMENTAL|16p11.2 Cohort|Participants with chromosomal rearrangement of the p11.2 region of chromosome 16 (16p11.2) locus causing obesity received setmelanotide once daily (QD) via subcutaneous (SC) injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
61996746|NCT03013543|EXPERIMENTAL|AS Cohort|Participants with Alström syndrome (AS) received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
61996747|NCT03013543|EXPERIMENTAL|BBS Cohort|Participants with Bardet-Biedl syndrome (BBS) received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
61996748|NCT03013543|EXPERIMENTAL|MC4R Cohort|Participants with melanocortin-4 receptor (MC4R) deficiency obesity received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
62181724|NCT06213519|EXPERIMENTAL|SOX+sintilimab+HIPEC|Patient will receive SOX regimen (oxaliplatin 100mg/m2, d1, S-1 BSA\<1.25m2 40mg, twice a day; 1.25m2 ≤ BSA \< 1.5m2 50mg, twice a day; BSA ≥ 1.5m2 60mg, twice a day; d1-14) chemotherapy combined with sintilimab (200mg, d1), once every three weeks. In the first cycle, HIPEC (paclitaxel 80 mg/m2, d1-d3) will be administrated, and HIPEC or intraperitoneal chemotherapy (paclitaxel 80 mg/m2, d1) will be administrated in the second and third cycles according to the patient's condition. Then, another 3-cycle SOX regimen of systemic chemotherapy. After the end of 6 cycles, maintain treatment with a combination of S-1 and sintilimab until disease progression or intolerable toxicity.
62181725|NCT04012723|EXPERIMENTAL|MY01 Device|"Device: MY01 Device~Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure"
62181726|NCT04785430||Patients who underwent elective inguinal hernia surgery|Patients who have applied to the general surgery outpatient clinic of Bakırköy Dr Sadi Konuk Training and Research Hospital, diagnosed with inguinal hernia and underwent hernia repair surgery.
62566588|NCT02290756|ACTIVE_COMPARATOR|Parenting program and toolkit|The intervention arm of the study will have the low cost evidence based toolkit delivered to the the pregnant women for the duration of their pregnancy and the parenting program delivered to the newborn for 12 months.
62566589|NCT02290756|OTHER|Control- toolkit|The control arm of the study will only have the low cost evidence based toolkit delivered to the the pregnant women for the duration of their pregnancy.
62566590|NCT00522730|EXPERIMENTAL|1|Parenteral nutrition
61996749|NCT03013543|EXPERIMENTAL|POMC/PCSK1/LEPR Heterozygous Cohort|Participants with pro-opiomelanocortin (POMC)/proprotein convertase subtilisin/kexin type 1 (PCSK1)/leptin receptor (LEPR) heterozygous mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
61996750|NCT03013543|EXPERIMENTAL|POMC/PCSK1/LEPR Composite Heterozygous Cohort|Participants with POMC/PCSK1/LEPR composite heterozygous mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
62566591|NCT00522730|ACTIVE_COMPARATOR|2|Enteral nutrition
62566592|NCT00603473|EXPERIMENTAL|gabapentin|
62566593|NCT02422446|EXPERIMENTAL|EPA arm|EPA arm will receive 4 grams per day of EPA (icosapent ethyl) taken twice a day
62566594|NCT02422446|NO_INTERVENTION|Control|Control group will not receive EPA
62566595|NCT00020787|EXPERIMENTAL|Treatment|See intervention description.
61996751|NCT03013543|EXPERIMENTAL|POMC/PCSK1/LEPR Compound Heterozygous Cohort|Participants with POMC/PCSK1/LEPR compound heterozygous mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
61996752|NCT03013543|EXPERIMENTAL|SH2B1 Cohort|Participants with steroid receptor coactivator (SRC) homology 2B adapter protein 1 (SH2B1) haploinsufficiency received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
61996753|NCT03013543|EXPERIMENTAL|SMS Cohort|Participants with Smith-Magenis Syndrome (SMS) received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
62181727|NCT04785430||Patients who underwent emergency inguinal hernia surgery|Patients who have applied to the emergency clinic of Bakırköy Dr Sadi Konuk Training and Research Hospital, diagnosed with incarcerated inguinal hernia and underwent hernia repair surgery.
62181728|NCT01313624|EXPERIMENTAL|AZLI-AZLI|Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
62181729|NCT01313624|PLACEBO_COMPARATOR|Placebo-AZLI|Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
62181730|NCT01154270|EXPERIMENTAL|IMRT + C12-boost|(8 x 3 GyE) carbon ion therapy followed by 50 Gy IMRT (2 Gy/ Fx)corresponding to a total dose of approximately 74 GyE.
62566596|NCT03697343|OTHER|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm) and|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm) and no margin as defined by the RTOG 9005
62566597|NCT03697343|OTHER|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm margin
62566598|NCT00004208|ACTIVE_COMPARATOR|Arm A: ATG + CSA|"Treatment consists of 15 mg/kg ATG (Mérieux; horse antithymocyte globulin; i.e. 1.5 vial/10 kg of body weight/day) given over 8-12 hours for 5 consecutive days.~Cyclosporine A (CSA) will be administered orally in a dose of 2.5 mg/kg bid starting day 1 and continued through day 180."
62566599|NCT00004208|OTHER|Arm B: Supportive care|Patients randomized to this arm will be treated as outpatients.
62566600|NCT03489642|EXPERIMENTAL|COPD Telehealth Program|Participants will take part in a structured telehealth program for 12 weeks. Web-based educational tools will be made available to participants. Study participants will meet with a registered respiratory therapist two times per week.
62566601|NCT03139851|OTHER|Cyclophosphamide and Pembrolizumab|"The treatments received are:~* cyclophosphamide (50 mg/day, daily, per os)~* pembrolizumab (200 mg every 3 weeks, intravenously \[IV\]). On days 1, cyclophosphamide should be taken first and pembrolizumab infusion initiated within 1 hour after cyclophosphamide intake."
61996754|NCT03013543|EXPERIMENTAL|SRC1 Cohort|Participants with steroid receptor coactivator 1 (SRC1) mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
61996755|NCT04566237|EXPERIMENTAL|24 months follow up after vitrectomy|Objective Scatter Index (OSI) and Average Lens Density (ALD) at inclusion, then 3 months, 12 months and 24 months after vitrectomy
61996756|NCT00748475|EXPERIMENTAL|Neurofeedback|
61996757|NCT02270866|EXPERIMENTAL|TNM(trademark) - thermoneuromodulation|TNM (thermoneuromodulation device). A standardized active thermal neuromodulation waveform will be used for all patients. The device is noninvasive and does not use electrical stimulation.
61996758|NCT04561401|EXPERIMENTAL|rTMS + IPRP|25 youth aged 10-18 years with severe chronic pain will be invited to partake in the Intensive Pain Rehabilitation Program, where they will receive Repeated Transcranial Magnetic Stimulation as one of their treatment interventions.
61996759|NCT04561401|ACTIVE_COMPARATOR|IPRP|Youth within this arm will not be receiving the rTMS intervention. Rather, they will only be enrolled within the IPRP.
61996760|NCT05742880|SHAM_COMPARATOR|Without Facemask|Wearing no mask.
61996761|NCT05742880|ACTIVE_COMPARATOR|Wearing a Facemask|Wearing a surgical facemask
61996762|NCT05742880|ACTIVE_COMPARATOR|Wearing a FFP2-Mask|Wearing a FFP2- Mask
62566602|NCT04309383||ShuntCheck|Participants will be administered the ShuntCheck diagnostic test.
62566603|NCT05714865|EXPERIMENTAL|LISA Arm|Eligible subjects who have respiratory distress syndrome (Anderson Silverman Score \>4) managed on continuous positive airway pressure (CPAP) will receive surfactant via a thin catheter while on CPAP.
61996763|NCT01529424|EXPERIMENTAL|Group 1|Non-extensive PK/non post-prandial
62181731|NCT02529371|EXPERIMENTAL|UriCap-RM|The device is comprised of a reusable part and a single use adhesive tape. The device is removed once daily and the reusable part is rinsed, dried and reapplied with a new adhesive tape.
62181732|NCT02447432|EXPERIMENTAL|10Pn_4d Group|Subjects received 10Pn-PD-DIT, in its investigational 4-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
62181733|NCT02447432|ACTIVE_COMPARATOR|10Pn Group|Subjects received 10Pn-PD-DIT, in its licensed 1-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
62181734|NCT01686074||Chronic fatigue syndrome|
62181735|NCT01686074||fibromyalgia|
62181736|NCT01686074||chronic fatigue syndrome + fibromyalgia|
62181737|NCT01686074||healthy sedentary control|
62181738|NCT03920735||Opportunistic infection|Immunocompromised or frail patients with an opportunistic infection
62181739|NCT03920735||Control group|Immunocompromised or frail patients with no opportunistic infection
62566604|NCT01823328|ACTIVE_COMPARATOR|Ketamine|Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
62566605|NCT01823328|ACTIVE_COMPARATOR|Etomidate|Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
62566606|NCT01193777|PLACEBO_COMPARATOR|Saline|
62566607|NCT01193777|EXPERIMENTAL|L-Carnitine|
61996764|NCT01529424|EXPERIMENTAL|Group 2a|Extensive PK
61996765|NCT01529424|EXPERIMENTAL|Group 2b|Post-prandial assessment
61996766|NCT01529424|EXPERIMENTAL|Group 3|Stable dose of fibrate
61996767|NCT01529424|EXPERIMENTAL|Group 4|Fredrickson Type 1 dyslipidemia
61996768|NCT02656641|NO_INTERVENTION|Control|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will not complete any scales during other sessions.
61996769|NCT02656641|EXPERIMENTAL|Continuous Client Feedback|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will then complete symptoms scales, specifically the Patient Health Questionnaire-9 and Generalized Anxiety Disorder 7-Item Scale before each other session. The treating clinician will review and discuss their results and at the beginning of each session.
61996770|NCT02656641|EXPERIMENTAL|Continuous Self Feedback|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will then complete symptoms scales, specifically the Patient Health Questionnaire-9 and Generalized Anxiety Disorder 7-Item Scale before each other session. The treating clinician will not have access to these results.
61996771|NCT02885155||Patients with pulmonary arterial hypertension|
62181740|NCT03618810||PEGCSF first level prophylactic use|The first level prophylactic use of PEG-rhG-CSF. The Prophylactic use of PEG-rhG-CSF in all cycles of chemotherapy.
62566608|NCT02996968|EXPERIMENTAL|Self-removal group|The patients randomized to the self-removal group will be provided with a diagrammatic handout and will be instructed to remove their indwelling urinary catheter at home on the morning of Postoperative day 7.
62566609|NCT02996968|NO_INTERVENTION|Office-removal group|The patients randomized to the office-removal group will visit the office for a repeat voiding trial on postoperative day 6-8 (postoperative day 7 will be encouraged). At this visit, the patients will undergo a backfill voiding trial.
62566610|NCT06368297|EXPERIMENTAL|Acute effect of ketone monoester supplementation|To investigate the acute effect of ketone monoester ingestion on brain cortical plasticity using high-frequency rTMS.
62566611|NCT06368297|EXPERIMENTAL|Effects of a 2-week ketogenic diet or ketone monoester supplementation|"To evaluate the impact of short-term ketogenic dieting and ketone monoester supplementation on brain plasticity.~To investigate structural and functional brain adaptations to short-term ketogenic dieting and ketone supplementation.~To assess the relationship between changes in brain plasticity and the brain's structural and functional adaptations and changes in circulating levels of brain-derived neurotrophic factors and key central acting hormones (i.e., insulin and leptin) due to ketogenic dieting and ketone monoester supplementation."
62566612|NCT01408511|EXPERIMENTAL|Arm 1|
61996772|NCT02340533|EXPERIMENTAL|adenomyosis|females attending the gynecology outpatient clinic complaining of chronic pelvic congestion will get enrolled in the study. Two dimensional ultrasonography will be performed to asses the presence or absence of adenomyosis or any associated lesions. All the patients were then be subjected to office hysteroscopy and endo-myometrial biopsies will be taken. Histopathological examination of the samples will then be done. From these recruited patients, some will be indicated to perform hysterectomy. The final diagnosis will then be based on the histopathological examination of the specimen retrieved from hysterectomy. The accuracy of the ultrasound and the hysteroscopic endo-myometrial biopsy will then be compared and assessed.
61996773|NCT02882321|EXPERIMENTAL|Treatment (oxidative phosphorylation inhibitor IACS-010759) Cohort 1|"IACS-010759 Starting dose: 0.5 mg~INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7."
61996774|NCT02882321|EXPERIMENTAL|Treatment (oxidative phosphorylation inhibitor IACS-010759) Cohort 2|"IACS-010759 Starting dose: 1 mg~INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7."
61996775|NCT02882321|EXPERIMENTAL|Treatment (oxidative phosphorylation inhibitor IACS-010759) Cohort 3|"IACS-010759 Starting dose: 2 mg~INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7.~MAINTENANCE PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 8 and 15 of course 1 and on days 1, 8, and 15 of subsequent courses. Treatment repeats every 21 days for subsequent courses for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients may receive additional courses of oxidative phosphorylation inhibitor IACS-010759 at the discretion of study doctor."
61996776|NCT02882321|EXPERIMENTAL|Treatment (oxidative phosphorylation inhibitor IACS-010759) Cohort 4|"IACS-010759 Starting dose: 2.5 mg~INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7.~MAINTENANCE PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 8 and 15 of course 1 and on days 1, 8, and 15 of subsequent courses. Treatment repeats every 21 days for subsequent courses for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients may receive additional courses of oxidative phosphorylation inhibitor IACS-010759 at the discretion of study doctor."
62181741|NCT03618810||PEGCSF second level prophylactic use|The second level prophylactic use of PEG-rhG-CSF. The Prophylactic use of PEG-rhG-CSF in the next cycle until FN or 4 grade neutropenia happened.
62181742|NCT05351489|EXPERIMENTAL|Dexmedetomidine 5 μg group (D5 group )|Dexmedetomidine 5 μg group (D5 group ): Patients will receive 2 mL heavy bupivacaine 0.5% and Dexmedetomidine 5 μg intrathecal.
62181743|NCT05351489|ACTIVE_COMPARATOR|Dexmedetomidine 10 μg group (D10 group )|dexmedetomidine 10 μg group (D10 group ): Patients will receive 2 mL heavy bupivacaine 0.5% and Dexmedetomidine 10 μg intrathecal .
62181744|NCT05046249||Chiropractic clinicians|Swiss chiropractic clinicians
62181745|NCT03991598|EXPERIMENTAL|intervention|EDs 1 to 7 will then be randomly phased-in INT every 3 months.
62181746|NCT03991598|NO_INTERVENTION|control|During the first 6 months and throughout CTRL time
62181747|NCT06478134|EXPERIMENTAL|TriMix|A new-generation tear substitute containing cross-linked hyaluronic acid 0.15%, trehalose 3%, liposomes 1% and sterylamine 0.25%.
62181748|NCT06478134|ACTIVE_COMPARATOR|Hyaluronic acid|0.15% Hyaluronic acid tear substitute.
62181749|NCT00263484|EXPERIMENTAL|"dtZ regimen, Initial therapy"|"To test the efficacy of the dtZ regimen in previously untreated patients with multiple myeloma."
62181750|NCT03467698|EXPERIMENTAL|Active tDCS|active HD-tDCS will be administered
62181751|NCT03467698|SHAM_COMPARATOR|Sham tDCS|sham HD-tDCS will be administered
62181752|NCT05097209|EXPERIMENTAL|Camrelizumab arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 \& 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Camrelizumab 200mg will be given every 3 weeks for 3 cycles started on day 1 of induction chemotherapy and every 2 weeks for 9 cycles thereafter.
62181753|NCT05097209|ACTIVE_COMPARATOR|Chemoradiation arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 \& 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT.
62181754|NCT04156347|EXPERIMENTAL|Phase I Open Label Study|Phase I Single Arm
62181755|NCT03049098||Success at the simulation|Participant could correctly set the pacing unit to obtain electrical and mechanical pacing of the mannequin in nine minutes.
62181756|NCT03049098||Failed the simulation|Participant could not correctly set the pacing unit to obtain electrical and mechanical pacing of the mannequin in nine minutes.
62566613|NCT04468022|ACTIVE_COMPARATOR|Toric Trifocal IOL|Twenty patients (20) underwent Toric Trifocal IOL surgery (first group)
62181757|NCT05158283|EXPERIMENTAL|Intervention: Chocolate balloon|Chocolate balloon group
62181758|NCT05158283|EXPERIMENTAL|Intervention: plain balloon|plain balloon group
62181759|NCT04303546||< 30 years|
62181760|NCT04303546||30-60 years|
62181761|NCT04303546||> 60 years|
62181762|NCT01200927|NO_INTERVENTION|Typically Developing Infants|Typically developing infants (5 months old, SD .5 months at entry) were followed longitudinally as a comparison for postural variables. The primary outcome measure is Center of Pressure (COP) data, from which linear and nonlinear variables were extracted. The Gross Motor Function Measure (GMFM) sitting subsection was our clinical outcome measure.
62181763|NCT01200927|ACTIVE_COMPARATOR|Home Program|Home program (1x/week for 8 weeks). The primary outcome measure is Center of Pressure (COP) data, from which linear and nonlinear variables were extracted. The Gross Motor Function Measure (GMFM) sitting subsection was our clinical outcome measure.
62181764|NCT01200927|ACTIVE_COMPARATOR|Perceptual-motor intervention|Perceptual-motor intervention (2x/week for 8 weeks. The primary outcome measure is Center of Pressure (COP) data, from which linear and nonlinear variables were extracted. The Gross Motor Function Measure (GMFM) sitting subsection was our clinical outcome measure.
62181765|NCT01004185|EXPERIMENTAL|High Dose|2.0 - 4.8 g/day Asacol dependent on body weight
62566614|NCT04468022|ACTIVE_COMPARATOR|Toric Trifocal IOL RELEX SMILE|Twenty patients (20) underwent Toric Trifocal IOL and RELEX SMILE surgery (second group)
62566615|NCT06306898|ACTIVE_COMPARATOR|IPPV|Intermittend-Positive-Pressure-Ventilation
61996777|NCT02584504|EXPERIMENTAL|Alirocumab 150 mg Q4W|Double-blind treatment period(DBTP):participants received Alirocumab 150 mg subcutaneous injection every 4 week(Q4W) alternating with placebo(for alirocumab)Q4W added to lowest-strength statin therapy(atorvastatin 5 mg daily),stable non-statin LMT/diet therapy alone for 12weeks. Participants completed DBTP,entered open-label treatment period(OLTP),received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg every 2 weeks(Q2W) at Week 24(OLTP:Week 12),when targeted LDL-C level at Week 20 not achieved as Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012:1) ≥100 mg/dL(2.59 mmol/L) in heterozygous familial hypercholesterolemia (heFH) participants/non-familial hypercholesterolemia (non-FH)participants with history of documented coronary heart disease;2) ≥120 mg/dL(3.10 mmol/L)in non-FH participants with history of documented diseases/other risk factors as categorized in primary prevention category III)
62181766|NCT01004185|EXPERIMENTAL|Low Dose|1.2 - 2.4 g/day Asacol dependent upon body weight
62181767|NCT05219578|EXPERIMENTAL|RTX-224 Dose Escalation|Phase 1: RTX-224 monotherapy dose escalation in Solid Tumors, administered intravenously on Day 1 of each cycle.
62181768|NCT05219578|EXPERIMENTAL|RTX-224 Dose Expansion|Phase 2: RTX-224 monotherapy dose expansion in Solid Tumors, administered intravenously on Day 1 of each cycle.
62181769|NCT03756168|EXPERIMENTAL|All subjects|
62181770|NCT04469062|EXPERIMENTAL|Mirikizumab|Mirikizumab administered intravenously (IV) and subcutaneously (SC).
62181771|NCT04469062|ACTIVE_COMPARATOR|Vedolizumab|Vedolizumab administered IV.
62181772|NCT04469062|PLACEBO_COMPARATOR|Placebo|Placebo administered SC and IV.
62566616|NCT06306898|ACTIVE_COMPARATOR|CCSV|Chest Compression Synchronized Ventilation
62566617|NCT06306898|ACTIVE_COMPARATOR|Bag-Device-Ventilation|Ventilation with a Ventilation Bag
62566618|NCT01461486|ACTIVE_COMPARATOR|Continuous Positive Airway Pressure|Intervention group
61996778|NCT02584504|EXPERIMENTAL|Alirocumab 150 mg Q2W|In DBTP, participants received Alirocumab 150 mg subcutaneous (SC) injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg daily), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to Japan Atherosclerosis Society(JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
62391310|NCT01200758|EXPERIMENTAL|Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)|First cycle of rituximab IV infusion (375 mg/m\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
62566619|NCT01461486|ACTIVE_COMPARATOR|Oral Appliance (BRD)|Intervention group
62391311|NCT03585829|ACTIVE_COMPARATOR|hydrocortisone|hydrocortisone 20 mg per day: 15 mg at pre-dawn meal and 5 mg at dinner
62391312|NCT03585829|ACTIVE_COMPARATOR|prednisolone|Prednisolone 5 mg at pre-dawn meal and a placebo (starch) at dinner
62566620|NCT01461486|NO_INTERVENTION|Hygiene sleep care|Control group
62391313|NCT02443727|EXPERIMENTAL|Intranasal oxytocin group|Participants will self-administer a single dose of 24 IU oxytocin (Syntocinon, Novartis; three puffs per nostril, each with 4 IU oxytocin, 6 puffs total).
62391314|NCT02443727|PLACEBO_COMPARATOR|Placebo group|"The placebo is identical to the oxytocin formulation with the exception of the active compound.~Participants will self-administer three puffs per nostril of placebo (6 puffs total)."
62566621|NCT01982513||Term pregnant patients|"ASA I-II term (36-40 weeks) non-laboring women with singleton pregnancies who are admitted at MSH for induction of labor, elective cesarean section or for observation for any medical reason.~These patients will be examined in 4 positions with the ultrasound."
62181773|NCT06547671|EXPERIMENTAL|Comfort room|"Use of the sensory comfort room located in the unit itself, decorated in soft and relaxing tones with motifs inspired by nature. It has relaxation sofas, rocking chair, aromatherapy, chromotherapy, projector, music of the user's choice, weighted blanket mats, balls of various sizes......... to teach people admitted to the area alternatives to cope and control anxiety and prevent the escalation of agitation, as well as to guide them in strategies to help them relax.~In addition, as usual clinical practice, both before and after the intervention, verbal de-escalation techniques will be used, for which the professionals in the area have been trained with a verbal de-escalation course specifically for working in the area.~The intervention is not unique but in several uses of the sensory comfort room in each patient. The intervention will last approximately 30 minutes and can be used several times during the day. Furthermore, patients received the same follow up than the control group."
62566622|NCT05307874|EXPERIMENTAL|Part 2 ICT01 + Low dose SC IL-2 + Pembrolizumab|The best regimen of ICT01+IL-2 will be combined with pembrolizumab at the approved dose since the combination of ICT01+IL-2 induces upregulation of PD-1 on g9d2 T cells and in the TME.
62566623|NCT05307874|EXPERIMENTAL|Dose level 2 ICT01 + Low dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
61996779|NCT02584504|PLACEBO_COMPARATOR|Placebo Q2W|In DBTP, participants received Placebo (for alirocumab) SC injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
61996780|NCT01733914|EXPERIMENTAL|Acupuncture|Experimental group
61996781|NCT01733914|SHAM_COMPARATOR|Waiting list|Control group
62181774|NCT06547671|NO_INTERVENTION|Usual clinical practice|Follow up of patients, in the same way as in routine clinical practice.
62566624|NCT05307874|EXPERIMENTAL|Dose Level 1 ICT01 + High dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
62566625|NCT05307874|EXPERIMENTAL|Dose level 1 ICT01 + Low dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
62566626|NCT05307874|EXPERIMENTAL|Dose level 3 ICT01 + Low dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
62566627|NCT05307874|EXPERIMENTAL|Dose level 4 ICT01 + Low dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
62566628|NCT05307874|EXPERIMENTAL|Dose level 5 ICT01 + Low dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
62566629|NCT00714857|EXPERIMENTAL|1|Patients receiving dexmedetomidine sedation
62566630|NCT04111289|ACTIVE_COMPARATOR|Patient received upstream high bolus dose of tirofiban|"* After consenting for primary PCI ,the patient will be assigned to one arm ( either upstream high bolus dose IV before going to cath lab or selective downstream administration according to operator discretion )~* Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)~* Randomization will be performed by Microsoft Excel where random order will be generated for the study population"
62566631|NCT04111289|ACTIVE_COMPARATOR|Patients did not receive upstream high bolus dose of tirofiban|Patient receive tirofiban downstream selectively according to operator discretion
62566632|NCT02730910|EXPERIMENTAL|Purple Wheat Crackers|Bran-enriched purple wheat wholegrain crackers served in 120 g portion.
62181775|NCT05158023|PLACEBO_COMPARATOR|Placebo every two weeks q2w|Placebo q2w - placebo loading dose equivalents at Baseline and Week 1, then placebo dose equivalents every 2 weeks (q2w) from Week 2 to Week 14.
62181776|NCT05158023|EXPERIMENTAL|ASLAN004 300 mg q2w|ASLAN004 300 mg q2w - loading doses at Baseline and Week 1, followed by regular doses of 300mg q2w from Week 2 to Week 14.
62391315|NCT02297867|EXPERIMENTAL|ADSCs|One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
62391316|NCT06163144||Patients CKD 4, CKD 5 non- HD|chronic kidney disease patients non hemodialysis
62391317|NCT06163144||Patients with ESRD on Regular -HD|end stage renal disease patients on hemodialysis
62566633|NCT02730910|EXPERIMENTAL|Purple Wheat Granola Bars|Bran-enriched purple wheat wholegrain granola bars served in 160 g portion.
62566634|NCT00639756|OTHER|1|Placebo
62566635|NCT00639756|ACTIVE_COMPARATOR|2|Allopurinol given for 2 weeks with diet
62566636|NCT03239535|EXPERIMENTAL|Mesenchymal stem cells|Mesenchymal stem cells, Intramuscular injection
62566637|NCT03239535|PLACEBO_COMPARATOR|Normal saline|Normal saline, Intramuscular injection
62566638|NCT04124731|EXPERIMENTAL|Sintilimab plus anlotinib|Sintilimab and anlotinib combination therapy
61996782|NCT04146727||ICU Duration|The total study duration is determined by their length of stay in the ICU.
62181777|NCT05158023|EXPERIMENTAL|ASLAN004 400 mg q2w|ASLAN004 400 mg q2w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 400 mg ASLAN004, alternating with placebo dose equivalents, q2W from Week 4 to Week 14.
62391318|NCT02359942|EXPERIMENTAL|Citric acid group|Giving the citric acid (4g) as test meal before UBT
62391319|NCT02359942|NO_INTERVENTION|Controlled group|No use of test meal
62391320|NCT06212973|EXPERIMENTAL|Epinastine hydrochloride eye drops group|Administered Epinastine hydrochloride eye drops+Simulating Azelastine hydrochloride eye drops bilaterally, twice daily
62566639|NCT04124731|ACTIVE_COMPARATOR|Control|Standard platinum-based chemotherapy
62181778|NCT05158023|EXPERIMENTAL|ASLAN004 400 mg every four weeks q4w|ASLAN004 400 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 400 mg or alternating placebo (q2W) to Week 14.
62181779|NCT05158023|EXPERIMENTAL|ASLAN004 600 mg q4w|ASLAN004 600 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 600 mg ASLAN004, alternating with placebo dose equivalents, q2W from Week 4 to Week 14.
62181780|NCT03921242||Metformin Cohort|Group of study participants having both Type 2 Diabetes and Chronic Kidney disease and meeting the study's inclusion criteria for whom metformin was prescribed at baseline for this first time in each patient's medical history.
62391321|NCT06212973|ACTIVE_COMPARATOR|Azelastine hydrochloride eye drops group|Administered Azelastine hydrochloride eye drops+Simulating Epinastine hydrochloride eye drops bilaterally, twice daily
62391322|NCT00967811|EXPERIMENTAL|1. Formulation E1|Formulation E1 of Latanoprost-PPDS
62391323|NCT00967811|EXPERIMENTAL|2. Formulation E2|Formulation E2 of Latanoprost-PPDS
62391324|NCT04160884|ACTIVE_COMPARATOR|A|0.6mg/kg of ICG, iv
62181781|NCT03921242||Sulfonylurea Cohort|Group of study participants having both Type 2 Diabetes and Chronic Kidney disease and meeting the study's inclusion criteria for whom sulfonylurea was prescribed at baseline for this first time in each patient's medical history.
62181782|NCT03921242||DPP4 Inhibitor Cohort|Group of study participants having both Type 2 Diabetes and Chronic Kidney disease and meeting the study's inclusion criteria for whom a DPP4 Inhibitor was prescribed at baseline for this first time in each patient's medical history.
62391325|NCT04160884|EXPERIMENTAL|B|0.2mg/kg of ICG, iv
62391326|NCT03220620||GDT Group|receives goal-directed therapy
62391327|NCT03220620||Not GDT Group|receives no individualized goal-directed therapy
62391328|NCT00723060|ACTIVE_COMPARATOR|1|escitalopram high dose group
62391329|NCT00723060|ACTIVE_COMPARATOR|2|escitalopram conventional group
62391330|NCT03721406|OTHER|Ropivacaine|"* 25 ml single dose of 0.5% ropivacaine~* continuous infusion of ropivacaine 0.2% with a constant infusion rate of 14 ml/h"
62181783|NCT03921242||SGLT2 Inhibitor Cohort|Group of study participants having both Type 2 Diabetes and Chronic Kidney disease and meeting the study's inclusion criteria for whom an SGLT2 Inhibitor was prescribed at baseline for this first time in each patient's medical history.
62181784|NCT03921242||GLP1 Receptor Agonist Cohort|Group of study participants having both Type 2 Diabetes and Chronic Kidney disease and meeting the study's inclusion criteria for whom a GLP1 receptor agonist was prescribed at baseline for this first time in each patient's medical history.
62181785|NCT00541671|PLACEBO_COMPARATOR|1|Patients will then be randomized to receive placebo, consisting of 10ml of normal saline solution to be administered intravenously with the narcotic
62181786|NCT00541671|ACTIVE_COMPARATOR|2|Patients will be randomized to 6.25mg of promethazine, consisting of 0.25ml of promethazine diluted in 9.75ml of normal saline.
62181787|NCT04205955|EXPERIMENTAL|Arm I (diet modification coaching, motivational messages)|Patients receive diet modification coaching via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6.
62181788|NCT04205955|ACTIVE_COMPARATOR|Arm II (standard of care, motivational messages)|Patients receive general healthy living education via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6.
62181789|NCT00369603|EXPERIMENTAL|Razadyne ER|galantamine treatment group
62181790|NCT00369603|EXPERIMENTAL|Aricept|Aricept Treatment Group
62181791|NCT05235841|EXPERIMENTAL|AG|The group that met the criteria of the study and applied acupressure protocol before Coronary Angiography
62181792|NCT05235841|NO_INTERVENTION|CG|BEFORE CORONARY ANGIOGRAPHY, THE GROUP WITHOUT ANY INTERVENTION, CONTROL GROUP
62181793|NCT04234503|EXPERIMENTAL|Ethics Quarter|Nurse managers perform 12 educational packages in web-page www.etiikanvartti.fi.
62181794|NCT04234503|NO_INTERVENTION|Standard organisational ethics structures|Nurse managers continue in their standard organisational ethics structures
62181795|NCT00223210|ACTIVE_COMPARATOR|Quetiapine|
62566640|NCT06118801|EXPERIMENTAL|Probiotic group|Mothers of premature babies in this group will be given breast milk and breastfeeding training immediately after birth in order to ensure that they can give only breast milk to their babies, and at the same time, 80 ml of probiotic supplements will be given once a day for 20 days.
61996783|NCT04146727||Transplant through 1 month at Home|Time from surgery through 1 month at home. Maximum duration is length of stay in the ICU plus 1 month at home.
62181796|NCT00223210|PLACEBO_COMPARATOR|Placebo|Inactive ingredient matching the active medication in appearance
62181797|NCT04786756|ACTIVE_COMPARATOR|Lateral Approach of Costoclavicular Block|US-guided lateral approach costoclavicular block with 1 mg/kg Bupivacaine (%0,25)
62181798|NCT04786756|ACTIVE_COMPARATOR|Medial Approach of Costoclavicular Block|US-guided medial approach costoclavicular block with 1 mg/kg Bupivacaine (%0,25)
62181799|NCT01919398|EXPERIMENTAL|LY2940680|"Cohort 1: 100 mg LY2940680 administered orally daily in 28-day cycles. Cohort 2: 200 mg LY2940680 administered orally daily in 28-day cycles. Cohort 3: 400 mg LY2940680 administered orally daily in 28-day cycles.~Treatment with LY2940680 continued until disease progression, unacceptable toxicity, or other discontinuation criteria were met."
62181800|NCT02137499|ACTIVE_COMPARATOR|Healthy subjects|Healthy subjects, free from vascular disease
62181801|NCT02137499|EXPERIMENTAL|Superficial venous insufficiency|Clinically symptomatic and ultrasound evidence of superficial venous insufficiency
62181802|NCT02137499|EXPERIMENTAL|Deep venous insufficiency|Clinically symptomatic and ultrasound evidence of deep venous insufficiency
62181803|NCT02137499|EXPERIMENTAL|Deep venous obstruction|Clinically symptomatic and ultrasound evidence of deep venous obstruction
62181804|NCT03112408|EXPERIMENTAL|FORWARD (Axe 1)|
62181805|NCT03112408|EXPERIMENTAL|BACKWARD (Axe 1)|
62181806|NCT03112408|EXPERIMENTAL|CONTROL (Axe 1)|
61996784|NCT05601310||Control group|in the group, the participants exhibited negative results or \<50% obstruction upon coronary artery CT or coronary angiography. The group did not have coronary heart disease and diabetes
61996785|NCT05601310||T2DM group|in the group, the participants exhibited negative results or \<50% obstruction upon coronary artery CT or coronary angiography. The group did not have coronary heart disease but have type 2 diabetes mellitus.
62181807|NCT03112408|EXPERIMENTAL|ADAPTATION (Axe 2)|
62181808|NCT03112408|EXPERIMENTAL|CONTROL (Axe 2)|
62181809|NCT05851040||With Wheatgrass, tulsi formulation|People using Wheatgrass and Tulsi formulation or individual
62181810|NCT05851040||With Wheatgrass, tulsi formulation and allopathic drugs|People using Wheatgrass and Tulsi formulations or individuals with chronic disease medicine.
62181811|NCT05851040||Same age group not using any medication|
62181812|NCT05738447|EXPERIMENTAL|Treatment Cohort|With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and the intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1-month interval.
62181813|NCT05001997|ACTIVE_COMPARATOR|Diet A - Lactose free probiotic yogurt|Plain flavoured lactose free probiotic yogurt (contains Lactobacillus acidophilus and Bifidobacterium lactis)
62181814|NCT05001997|PLACEBO_COMPARATOR|Diet B - Lactose free yogurt (non-probiotic)|Plain flavoured lactose free yogurt (contains only starter cultures)
62181815|NCT04307641|EXPERIMENTAL|Intervention|Pharmacists who received in the intervention.
62181816|NCT04307641|NO_INTERVENTION|Control|Pharmacists who did not received in the intervention.
62181817|NCT02878759|EXPERIMENTAL|Wristbot|WristBot will be used as diagnostic tool to evaluate the novel technology and the associated protocol for proprioception quantification during rehabilitation. The main objective is to provide clinicians with a reliable instrument able to overcome the limitations in proprioceptive measurement by current clinical methodologies.
62391331|NCT03169842|EXPERIMENTAL|Cyst fluid glucose|Single arm- cyst fluid glucose will be measured from pancreatic cyst fluid aspirate
62391332|NCT05474482|EXPERIMENTAL|kinesio taping with 75 to 100 % stretch and exercises|Kinesio taping with stretching exercises and yoga will be given to patients for 8 weeks.
62391333|NCT05474482|EXPERIMENTAL|kinesio taping without exercises|Kinesio taping alone will be given to patients for 8 weeks.
61996786|NCT05601310||T2DM+AMI group|In the group, we eventually recruited 30 adult patients who were firstly diagnosed ST-elevation myocardial infarction (STEMI) within 12 hours of appearance chest pains or other AMI symptoms and had no previous history of coronary artery disease (CAD). Peripheral venous blood samples were drawn from subjects on admission or prior to coronary revascularization.
61996787|NCT02803918|EXPERIMENTAL|Lixisenatide|Administration of 3 ascending repeated doses of lixisenatide once daily and subcutaneously. Background therapy (metformin and basal insulin) will be administered daily about the same time as usually done.
61996788|NCT02803918|PLACEBO_COMPARATOR|Placebo|Administration of 3 ascending repeated doses of matching placebo once daily and subcutaneously. Background therapy (metformin and basal insulin) will be administered daily about the same time as usually done.
61996789|NCT00233727|ACTIVE_COMPARATOR|HPV DNA Testing + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women."
61996790|NCT00233727|ACTIVE_COMPARATOR|VIA + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women."
61996791|NCT00233727|NO_INTERVENTION|Delayed Evaluation and Treatment|Patients will undergo a similar screening process at entry, but will be randomized to have evaluation and treatment delayed until 6 months after screening.
61996792|NCT02012595||Parkinson's patients|Participants with Parkinson's Disease
61996793|NCT02012595||Healthy Controls|Healthy participants
61996794|NCT05198570||Intravenous Aciclovir|Patients receiving intravenous aciclovir for prophylaxis or treatment of herpes virus infections
62181818|NCT05380128||MG group|Unrelated patients with MG were included in the study. They were enrolled in the Neurology Department of Beijing Tongren Hospital, Capital Medical University and fulfilled the clinical and electromyography diagnostic criteria for acquired MG. Simply, all MG patients met the following diagnostic criteria: typical symptoms of fluctuating muscle weakness, positive result of neostigmine test, and decremental response to low-frequency repetitive nerve stimulation. Information on age at onset, AChR / MuSK Abs status (partly), thymus status, involved muscles at onset and Osserman type at the maximum worsening during 2 years follow-up were obtained and used as the grouping basis of sub-classifications. They were genotyped for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms
62181819|NCT05380128||Healthy control|The geography and ethnically matched control group consisted of 146 unrelated healthy subjects. They were genotyped for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms.
61996795|NCT05198570||Oral Aciclovir|Patients receiving oral aciclovir/valaciclovir for prophylaxis or treatment of herpes virus infections
61996796|NCT06287892||HCM group|Patients diagnosed with HCM
61996797|NCT06287892||Control group|Subjects without HCM
61996798|NCT02204891|EXPERIMENTAL|Probiotics in SIBO|Administration of probiotics in patients with IBS and SIBO
61996799|NCT02204891|ACTIVE_COMPARATOR|Probiotics|Administration of probiotics in patients with IBS without SIBO
61996800|NCT05248516|OTHER|Control|no nutritional treatment administered
61996801|NCT05248516|EXPERIMENTAL|Simplified treatment|children are provided with 1 sachet of RUTF until discharge
61996802|NCT05248516|ACTIVE_COMPARATOR|Standard treatment|"children are provided nutritional treatment according to their weight-for-height z-score (WHZ) and their weight:~1. children with a WHZ\<-3 will receive 200kcal/kg/d of nutritional product until discharge~2. children with a WHZ between -3 and -2 are provided with 1 sachet of RUTF until discharge~3. children with a WHZ \>= -2 will not be provided any nutritional treatment"
62181820|NCT00320814|EXPERIMENTAL|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
61996803|NCT03015051|EXPERIMENTAL|High flow|High flow (2 L/kg/min) nasal cannula oxygen therapy
61996804|NCT03015051|ACTIVE_COMPARATOR|Low flow|Low flow (max 3 L/min) oxygen therapy
61996805|NCT02582099|ACTIVE_COMPARATOR|Gentamicin|Gentamicin nasal irrigation in chronic rhinosinusitis amount 20 ml each pernostril
61996806|NCT02582099|PLACEBO_COMPARATOR|Normal saline|Normal saline nasal irrigation in chronic rhinosinusitis amount 20 ml each pernostril
61996807|NCT03388138|ACTIVE_COMPARATOR|K-Lens|etafilcon A with ketotifen. Subjects between the ages of 18-40 will be randomized into the K-Lens arm and will be scheduled for a total of two study visits with approximately 6-9 days in between.
61996808|NCT03388138|PLACEBO_COMPARATOR|Placebo Contact Lens|1-Day Acuvue. Subjects between the ages of 18-40 will be randomized into the Placebo arm and will be scheduled for a total of two study visits with approximately 6-9 days in between.
61996809|NCT03387449|EXPERIMENTAL|Bimanual Arm Training|Children in the study will all receive the same treatment, which includes 9 weeks of training on the bimanual arm trainer robotic device.
62181821|NCT00718393||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
62391334|NCT05474482|ACTIVE_COMPARATOR|kinesio taping without stretch to tape|kinesio taping without any stretch, applied as control for 8 weeks.
61996810|NCT05893420|EXPERIMENTAL|Intervention Arm|Intervention Arm (experimental): eCARTv5 will monitor all adult medical-surgical (ward) patients at hospitals that implement the tool in their EHR. A pre vs. post analysis will be done to compare the impact of the tool at the intervention hospitals.
61996811|NCT05893420|ACTIVE_COMPARATOR|Control Arm|Control Arm (active comparator): hospital sites that do not implement eCARTv5 will be active comparator.
61996812|NCT04360564||Recurrent pregnancy loss|All women with \>/=2 pregnancy loss before 20 weeks gestational age
61996813|NCT04360564||Primary recurrent pregnancy loss|Primary RPL is defined by those with \>/=2 pregnancy loss before 20 weeks gestational age before the first birth
61996814|NCT04360564||Secondary recurrent pregnancy loss|Secondary RPL is defined by those with \>/=2 pregnancy loss before 20 weeks gestational age occurring after the first birth
61996815|NCT04360564||No history of recurrent pregnancy loss|Those with 0 or 1 previous spontaneous pregnancy loss.
61996816|NCT01323075||Renal insufficiency group|Patients in this group have renal insufficiency as defined by a creatinine clearance of \< 30 ml/min without dialysis. These patients do not have diabetes.
61996817|NCT01323075||Diabetic group|These patients have diabetes, but not renal insufficiency.
61996818|NCT01323075||Non-exposed group|These patients have neither a neurological nor a metabolic disease and a creatine clearance of \> 90 ml/min
61996819|NCT02643654|PLACEBO_COMPARATOR|Placebo|The placebo product is manufactured following the same procedures and batch records used to manufacture the MABp1 drug product. The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
61996820|NCT02643654|ACTIVE_COMPARATOR|MABp1|MABp1 is a recombinant human IgG1 monoclonal antibody specific for human interleukin-1α (IL-1α). The entire MABp1 heavy and light chain sequences are identical to those found in naturally-occurring human IgG1κ, with the light and heavy chain variable regions being identical to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy individual. It is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
61996821|NCT04685304|EXPERIMENTAL|PGx-guided care|Pharmacogenetic results (e.g., CYP2D6, CYP2C9) and a pharmacist consultation will be provided to their primary care provider. This consultation note (PharmD consult) will aid primary care providers in the interpretation and application of PGx results in prescribing decisions. The ultimate prescribing decision is at the discretion of the primary care provider and patient.
62181822|NCT01765452|EXPERIMENTAL|Closone|75mg/100mg per day, 8weeks, PO
62181823|NCT01765452|ACTIVE_COMPARATOR|Plavix with Astrix|75mg per day, 8weeks, PO 100mg per day, 8weeks, PO
62181824|NCT00428025|PLACEBO_COMPARATOR|placebo suppository|
62181825|NCT00428025|ACTIVE_COMPARATOR|diclofenac suppository|
62181826|NCT02719262|EXPERIMENTAL|Intervention|installing ventilation in the workplace
62391335|NCT03280446|EXPERIMENTAL|30 pre-menopause and post-menopause women|Thirty healthy women with mild to moderate pelvic prolapse above the ages of 18 seeking treatment for vaginal laxity
62391336|NCT05419791|EXPERIMENTAL|Lokomat Group I (Endurance)|"* Faster application used with Lokomat gait training~* Conventional Physiotherapy"
62391337|NCT05419791|EXPERIMENTAL|Lokomat Group II (Attention and Motivation)|"* Smile and Gabarello applications used with Lokomat gait training~* Conventional Physiotherapy"
62181827|NCT05225636|ACTIVE_COMPARATOR|Radial access|The ischemic stroke treatment will be performed through the radial artery (as first option)
62391338|NCT05419791|EXPERIMENTAL|Lokomat Group III (Activity Timing)|"* High Flyer, Curve Pursuit and Treasures applications used with Lokomat gait training~* Conventional Physiotherapy"
62566641|NCT06118801|NO_INTERVENTION|control group|There will be no intervention for mothers of preterm babies in this group, and they will be trained on breast milk and breastfeeding so that they can give only breast milk to the baby.
62181828|NCT05225636|ACTIVE_COMPARATOR|Femoral access|The ischemic stroke treatment will be performed through the femoral artery (as first option)
62181829|NCT02849405|OTHER|Arteriosclerosis|Hyperspectral camera for arteriosclerosis Diagnostic
62181830|NCT02849405|OTHER|Healthy controls|Hyperspectral camera for healthy control Diagnostic
62181831|NCT00338949|ACTIVE_COMPARATOR|Control|Participants on risperidone or olanzapine who will remain on risperidone or olanzapine and do not switch to ziprasidone
62391339|NCT05419791|OTHER|Control|-Only Conventional Physiotherapy
62391340|NCT02477631|EXPERIMENTAL|Deferiprone|patient treated with study drug
62181832|NCT00338949|EXPERIMENTAL|Switch|Participants who enter on risperidone or olanzapine and switch to ziprasidone
62181833|NCT01817712|EXPERIMENTAL|Individual Placement and Support (IPS)|The IPS intervention must achieve a rating of \>66 of a possible 75 points on the Supported Employment Fidelity Scale. The fidelity ratings are conducted by the National IPS Fidelity Monitor at biannual on-site monitoring visits.
62181834|NCT01817712|ACTIVE_COMPARATOR|VA Transitional Work Program (TWP)|TWP will adhere to a lower rating (less than or equal to 55 of a possible 75 points) on the Supported Employment Fidelity Scale rated by the National Fidelity Monitor. The TWP specialist participates in face-to-face supervision with the local Compensated Work Therapy (CWT) team according to the CWT manager's schedule.
62181835|NCT04609839||Patient admitted to intensive care unit for COVID-19|
62181836|NCT05869032||Cohort 1 (n=10)|Gender: Male Age: 20-29
62181837|NCT05869032||Cohort 2 (n=10)|Gender: Female Age: 20-29
62181838|NCT05869032||Cohort 3 (n=10)|Gender: Male Age: 30-39
62181839|NCT05869032||Cohort 4 (n=10)|Gender: Female Age: 30-39
62181840|NCT05869032||Cohort 5 (n=10)|Gender: Male Age: 40-49
62181841|NCT05869032||Cohort 6 (n=10)|Gender: Female Age: 40-49
62181842|NCT05869032||Cohort 7 (n=10)|Gender: Male Age: 50-59
62181843|NCT05869032||Cohort 8 (n=10)|Gender: Female Age: 50-59
62566642|NCT04710654|OTHER|Control|"1. Behavioural therapy~2. Exercise program"
62566643|NCT04710654|ACTIVE_COMPARATOR|connective tissue manipulation|
62566644|NCT04710654|ACTIVE_COMPARATOR|Interferential current stimulation (100 Hz frequency)|
62566645|NCT04710654|ACTIVE_COMPARATOR|Interferential current stimulation (0-100 Hz frequency)|
62566646|NCT04585256|ACTIVE_COMPARATOR|Trendelenburg|Women positioned in the trendelenburg position during external cephalic version.
62181844|NCT05370547|EXPERIMENTAL|high NOXA expression|NOXA IHC score \> 4; Bridging therapy was allowed but not containing chidamide; n=60.
62181845|NCT05370547|EXPERIMENTAL|low NOXA expression and no chidamide intervention|NOXA IHC score \< 4; Bridging therapy was allowed but not containing chidamide; n=30.
62181846|NCT05370547|EXPERIMENTAL|low NOXA expression and chidamide intervention|NOXA IHC score \< 4; Bridging therapy containing chidamide alone or combination; n=30.
62181847|NCT03924947|EXPERIMENTAL|Part 1 Double-Blind Creon MP / Creon|After receiving open-label currently marketed Creon delayed release (Creon DR) capsules during a pre-randomization period, participants receive double-blind Creon DR capsules manufactured by modernized process pellets (Creon MP) in treatment period 1, followed by double-blind Creon DR capsules in treatment period 2. Participants also receive open-label currently marketed Creon DR for an interval of up to 28 days between periods 1 and 2, and during a 30-day follow-up period after period 2.
62181848|NCT03924947|EXPERIMENTAL|Part 1 Double-Blind Creon / Creon MP|After receiving open-label currently marketed Creon DR capsules during a pre-randomization period, participants receive double-blind Creon DR capsules in treatment period 1, followed by double-blind Creon MP in treatment period 2. Participants also receive open-label currently marketed Creon DR for an interval of up to 28 days between periods 1 and 2, and during a 30-day follow-up period after period 2.
62181849|NCT03924947|EXPERIMENTAL|Part 2 Double-Blind Creon AAPIS / Creon|After receiving open-label currently marketed Creon DR capsules during a pre-randomization period, participants receive double-blind Creon DR capsules manufactured at an alternate active pharmaceutical ingredient site (Creon AAPIS) in treatment period 1, followed by double-blind Creon DR capsules in treatment period 2. Participants also receive open-label currently marketed Creon DR for an interval of up to 28 days between periods 1 and 2, and during a 30-day follow-up period after period 2.
62181850|NCT03924947|EXPERIMENTAL|Part 2 Double-Blind Creon / Creon AAPIS|After receiving open-label currently marketed Creon DR capsules during a pre-randomization period, participants receive double-blind Creon DR capsules in treatment period 1, followed by double-blind Creon AAPIS in treatment period 2. Participants also receive open-label currently marketed Creon DR for an interval of up to 28 days between periods 1 and 2, and during a 30-day follow-up period after period 2.
62181851|NCT04932226|OTHER|All participants|Each participant is his/her own control. Each will have all four interventions in random order.
62181852|NCT03739255|EXPERIMENTAL|Cacicol20|One drop of Cacicol20 will be applied 4-6 hours after the surgery, in one of the randomly chosen eye, and thereafter one drop daily until the reepithelialization is completed.
62181853|NCT03739255|PLACEBO_COMPARATOR|Placebo|One drop of conservative free artificial tear (Oculac, Thea Laboratories) will be applied to one eye at the same time when Cacicol20 is instilled to the other eye.
62181854|NCT01717170|EXPERIMENTAL|Tocilizumab (4 mg/kg)|Tocilizumab (4 mg/kg) as an intravenous infusion over 1 hour at day 0, 30, 60, 90, 120, and 150.
62181855|NCT01717170|EXPERIMENTAL|Tocilizumab (8 mg/kg)|Tocilizumab (8 mg/kg) as an intravenous infusion over 1 hour at day 0, 30, 60, 90, 120, and 150.
62181856|NCT02571998|EXPERIMENTAL|Treatment|Omiganan (CLS001) Topical Gel applied once daily
62181857|NCT02571998|PLACEBO_COMPARATOR|Vehicle Gel|Vehicle Topical Gel applied once daily
62181858|NCT01585441|EXPERIMENTAL|Finasteride 5 mg|Participants randomly assigned to the finasteride 5 mg arm were instructed to take one capsule daily for three months.
62181859|NCT01585441|PLACEBO_COMPARATOR|Placebo|Participants randomly assigned to the placebo arm will instructed to take one capsule daily for three months.
62181860|NCT04560478|ACTIVE_COMPARATOR|Pro Seal Sealant|ProSeal Sealant was applied to the facial surfaces of the maxillary anterior teeth (canine to canine)
62181861|NCT04560478|ACTIVE_COMPARATOR|MI Varnish|MI Fluoride Varnish was applied to the maxillary anterior teeth (canine to canine)
62181862|NCT00174798|PLACEBO_COMPARATOR|Placebo|
62181863|NCT00174798|EXPERIMENTAL|SSR240600C|
62181864|NCT00174798|ACTIVE_COMPARATOR|Tolterodine|
62181865|NCT02749136|EXPERIMENTAL|Perioperative chemotherapy|"* Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles~* Postoperative gemcitabine, every 4 weeks, 3-6 cycles"
62566647|NCT04585256|NO_INTERVENTION|Control|Women positioned on their back during external cephalic version.
62566648|NCT01796392|EXPERIMENTAL|EBV and Optimal Medical Management|This study arm will undergo EBV treatment along with optimal medical management, including smoking cessation program, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
62391341|NCT01986179|ACTIVE_COMPARATOR|Telephone Interpretation|These families will be assigned to use telephone interpretation throughout the ED visit.
62566649|NCT01796392|OTHER|Optimal Medical Management|This study arm will receive maximal medical management, including smoking cessation program support if necessary, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
61996822|NCT04685304|ACTIVE_COMPARATOR|Standard care|"Care for study subjects will occur without PGx results at the discretion of the study subject, their primary care provider.~After the active participation ends (i.e. after the three month follow up is complete), PGx results and a PharmD consult will be provided similar to the PGx-guided arm."
61996823|NCT02132585||Sjogren|Sjogren Patients evaluated with Speckle tracking echocardiography
61996824|NCT02132585||Control|Controls Speckle tracking echocardiography
61996825|NCT01147185|OTHER|Intensive training|Locomotor training using a robotic device of at least 50 minutes
61996826|NCT01147185|ACTIVE_COMPARATOR|Standard training|Locomotor training using a robotic device of maximally 25 minutes
61996827|NCT01845792|EXPERIMENTAL|Cabazitaxel with Abiraterone Acetate|Cabazitaxel administered as a single intravenous dose every 3 weeks, in combination with abiraterone acetate and prednisone taken daily.
61996828|NCT01845792|ACTIVE_COMPARATOR|Cabazitaxel Alone|Cabazitaxel administered as a single intravenous dose every 3 weeks
61996829|NCT00741884|EXPERIMENTAL|Arm 1|
61996830|NCT00741884|EXPERIMENTAL|Arm 2|
61996831|NCT00741884|EXPERIMENTAL|Arm 3|
61996832|NCT00741884|ACTIVE_COMPARATOR|Arm 4|
61996833|NCT00741884|PLACEBO_COMPARATOR|Arm 5|
61996834|NCT04180696|EXPERIMENTAL|AdaptivCRT ON (aCRT ON, treatment group)|"AdaptivCRT programmed to Adaptive Bi-V and LV The aCRT algorithm has been developed to provide RV-synchronized LV pacing when intrinsic AV conduction is normal or BiV pacing otherwise."
61996835|NCT04180696|ACTIVE_COMPARATOR|AdaptivCRT OFF (aCRT OFF, control group)|"AdaptivCRT programmed to Nonadaptive CRT (standard CRT). Control group subjects will be optimized per physician's discretion. The method of AV and VV optimization in the control group will be collected."
61996836|NCT05508412|EXPERIMENTAL|Intervention with HRV monitor|
61996837|NCT05508412|EXPERIMENTAL|Intervention without HRV monitor|
61996838|NCT02097355|EXPERIMENTAL|TriVox Active|Provider using TriVox for clinical care
61996839|NCT02097355|NO_INTERVENTION|TriVox Delayed-start|Providers not using TriVox for clinical care
61996840|NCT00445328|ACTIVE_COMPARATOR|B|
61996841|NCT00445328|EXPERIMENTAL|A|
61996842|NCT00902642|NO_INTERVENTION|control group|
62391342|NCT01986179|EXPERIMENTAL|Video Interpretation|These families will be assigned to use video interpretation throughout the ED visit.
61996843|NCT00902642|ACTIVE_COMPARATOR|Course on psychosocial factors|an eight day university training course for physical therapists designed to integrating psychosocial factors in clinical practice on a patient level
61996844|NCT02263066||Group 1|Chinese hemophilia A pediatric patients with medical records who had accepted regular prophylaxis, totally/partially with rFⅧ between Nov. 1st 2007 and May 31st 2013
61996845|NCT01554566|EXPERIMENTAL|honey, no honey|
61996846|NCT02597010|EXPERIMENTAL|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
61996847|NCT02597010|PLACEBO_COMPARATOR|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
61996848|NCT05564663|EXPERIMENTAL|PTSD Coach App + Brief Support|PTSD Coach App + Brief Support will include brief instruction and support for the use of the PTSD Coach App developed by the study team. The PTSD Coach App incorporates evidence-based assessment, psychoeducation, and self-management strategies for PTSD symptoms that are customizable to the user.
61996849|NCT05564663|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|EUC will include brief psychoeducation regarding PTSD and alcohol use disorder (AUD) and resources for PTSD-related mental health treatment.
61996850|NCT04741165|EXPERIMENTAL|Experimental: HX008+Bevacizumab|Participants receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus bevacizumab 15 mg/kg, IV, Q3W.
61996851|NCT04741165|EXPERIMENTAL|Experimental: HX008+Lenvatinib|Participants receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) orally once a day (QD).
62391343|NCT06338527|ACTIVE_COMPARATOR|Experimental group|The researchers placed 2 drops of lavender oil on gauze in a box each night 30 minutes before the patient went to bed and placed it 15 to 20 centimeters from the pillow.
62391344|NCT06338527|ACTIVE_COMPARATOR|Control group|The control group had no aromatherapy intervention during the study period.
62566650|NCT01780012|EXPERIMENTAL|Intervention|Osteoporosis prevention program: Women will receive oral and written information and advices on osteoporosis, a letter and a leaflet on osteoporosis management to give to their family physician, and phone call reminders.
62566651|NCT01780012|NO_INTERVENTION|Control|Control women will receive usual post-fracture care without information
62566652|NCT06017258|EXPERIMENTAL|Dose Level 1|Participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
62566653|NCT06017258|EXPERIMENTAL|Dose Level 2|Participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
62566654|NCT06017258|EXPERIMENTAL|Step-Down Dose|Participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
62566655|NCT01044615||Mild traumatic brain injury patients|Subjects who have a verifiable diagnosis of mild traumatic brain injury sustained within 24 months prior to enrollment
62566656|NCT01044615||Normal Control|Normal, healthy adults with no history of brain injury.
62566657|NCT06270576|ACTIVE_COMPARATOR|Asthma Group|Subjects diagnosed with one of the three asthma endotypes being studied (T2, T1, or T17).
62566658|NCT06270576|ACTIVE_COMPARATOR|Control Group|Subjects with no diagnosis of asthma or other respiratory disease and are deemed healthy.
62566659|NCT02880670|EXPERIMENTAL|Single dose of radiolabeled BMS-986142|
62566660|NCT03566199|EXPERIMENTAL|Treatment (MTX110)|Participants receive panobinostat nanoparticle formulation MTX110 IT by CED infusion on day 1 or days 1 and 2 as determined by dose level. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
62566661|NCT04208451|EXPERIMENTAL|Experimental group|Patients on hemodialysis who consumed one month Standardized Aronia Melanocrpa extract
62566662|NCT02640664|EXPERIMENTAL|Ranibizumab 0.2 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
62566663|NCT02640664|EXPERIMENTAL|Ranibizumab 0.1 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
62566664|NCT02640664|NO_INTERVENTION|Laser therapy|Laser therapy
62566665|NCT05023447|EXPERIMENTAL|BRIDGE Intervention (+Service as Usual)|"Brief, intensive assessment and integrated formulation (BRIDGE) intervention is guided by the evidence base of Cognitive Analytic Therapy (CAT) with young people (aged 14-25) with features of BPD using an early intervention model and in collaboration with an established Glasgow programme, Intensive Support and Monitoring Service (ISMS). ISMS focuses on reaching a shared formulation with the young person and the multi-agency system that supports them.~BRIDGE is delivered over 3-6 months and includes :- an intensive assessment, including BPD symptoms, copresenting difficulties, neurodevelopmental profile, life events history and psychosocial functioning; up to 16 sessions of Cognitive Analytic Therapy (CAT) and the development of a shared formulation with a multi-agency group. Further development of this formulation with the young person, using CAT principles (Reformulation, Recognition and Revision) and, where clinically applicable, their family and service-providers."
62566666|NCT05023447|ACTIVE_COMPARATOR|Service as Usual|Services as Usual (SAU) For participants randomised to SAU, a routine letter of their participation will be shared with their service provider(s), including their GP. SAU, is likely to range from social services, mental-health services, forensic services to no services in some cases. Pathways to care and service involvement will be mapped and described for each participant. Treatment fidelity to SAU will therefore not be assessed, but the nature and intensity of SAU in different contexts will be described in detail through the qualitative process evaluation.
62566667|NCT01120808|EXPERIMENTAL|All Participants|Participants were registered competitors in RacingThePlanet 6 stage 7 day 155mile (250km) ultramarathon.
62566668|NCT02092298|EXPERIMENTAL|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Laparoscopic HIPEC consists of Mitomycin C 30 mg and Cisplatin 200 mg for 60 minutes, performed 2-8 weeks after completion of systemic chemotherapy. Loading dose Sodium Thiosulfate 7.5 gm/M2 infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by infusion pump over 12 hours.
62566669|NCT03102606|ACTIVE_COMPARATOR|Docetaxel (75 mg/m2) + pegfilgrastim (6 mg) + placebo matching plinabulin|Arm 1
62566670|NCT03102606|EXPERIMENTAL|Docetaxel (75 mg/m2) + plinabulin (40 mg) + placebo matching pegfilgrastim|Arm 2
62566671|NCT01069601|EXPERIMENTAL|transplanted adults|male and female adults who have previously undergone solid organ transplantation or allogeneic or autologous BMT
62566672|NCT05541003|EXPERIMENTAL|Experimental Arm|All participants will receive NBT-NM108 prepared as muffin (each contains 30 g of the product) for 4 weeks. The dosage will be 2 muffins a day. This dosage of NBT-NM108 will provide 24 g/day of dietary fibers.
62566673|NCT06532578|EXPERIMENTAL|Cohort 1|
62566674|NCT06532578|EXPERIMENTAL|Cohort 2|
62566675|NCT06532578|EXPERIMENTAL|Cohort 3|
62566676|NCT06532578|EXPERIMENTAL|Cohort 4|
62566677|NCT06532578|EXPERIMENTAL|Cohort 5|
61996852|NCT04649775|ACTIVE_COMPARATOR|Device intervention|Intervention participants will receive the AirFLO2 device and training via video with reinforcement from the coordinator how to use and to self-apply it. Clinical data will be recorded before and after intervention. Questionnaires will be completed at baseline and at serial time points after intervention starts.
62181866|NCT00634920|EXPERIMENTAL|Everolimus (CNI-free)|Patients in this group were converted to everolimus immunosuppressive therapy. The patients in the everolimus group were treated with everolimus, off-label (CNI-free) use, and EC-MPS and corticosteroids in accordance with local practice and approved label. Conversion to everolimus was as follows: Day 1: begin everolimus 3 mg in the evening. Usual morning dose of CsA and 50% reduced evening dose of CsA Day 2: everolimus 2 mg in the morning and 2 mg in the evening, complete discontinuation of CsA Day 3 or 4, and onwards: everolimus according to trough level 6-10 ng/mL.The given total daily dose of the immunosuppressive drugs (everolimus) was divided into two (equal) doses, applied 12 hours apart.
62181867|NCT00634920|ACTIVE_COMPARATOR|Control (CsA)|Patients in the control group continued on an immunosuppressive regimen. The patients in this Control group were treated with CsA, EC-MPS and corticosteroids in accordance with local practice and approved label. The given total daily dose of the immunosuppressive drugs (CsA and EC-MPS) was divided into two (equal) doses, applied 12 hours apart.
62181868|NCT04011423|EXPERIMENTAL|Unstable shoes|Wearing unstable shoes during the whole-body vibration training
62566678|NCT06055361|EXPERIMENTAL|BxC-I17e (Single Dose)|"* Subcutaneous (SC) injection of 25, 50, or 100 ug BxC-I17e~* Single dose on Day 1"
62566679|NCT06055361|PLACEBO_COMPARATOR|Placebo (Single Dose)|"* Subcutaneous (SC) injection of the matching placebo~* Single dose on Day 1"
62566680|NCT06055361|EXPERIMENTAL|BxC-I17e (Multiple Dose)|"* Subcutaneous (SC) injection of 50, or 100 ug BxC-I17e~* 4 doses on Day 1, 15, 29, and 43"
62566681|NCT06055361|PLACEBO_COMPARATOR|Placebo (Multiple Dose)|"* Subcutaneous (SC) injection of the matching placebo~* 4 doses on Day 1, 15, 29, and 43"
62566682|NCT01833481||THA using direct-anterior surgical approach|Patients will have undergone THA using a direct-anterior surgical approach and will undergo fluoroscopy surveillance while walking.
62566683|NCT01833481||THA using anterior-lateral approach|Patients will have undergone THA using an anterior-lateral surgical approach and will undergo fluoroscopy surveillance while walking.
62566684|NCT01833481||THA using posterior-lateral approach|Patients will have undergone THA using a posterior-lateral surgical approach and will undergo fluoroscopy surveillance while walking.
62566685|NCT01602211|EXPERIMENTAL|Arm I (INSPIRE internet full program access)|Participants receive full access to the INSPIRE internet site comprising an individually tailored program with a greeting home page with links to each target area, a 'My Health Action Plan' health care guideline for transplant survivors, self-care tips and tool pages for each complication and major issues for HCT survivors, a section for each complication (mood, energy, heart health, strengthening bones, second cancers), resource pages, opportunities to send secure messages with questions or comments on any topic, opportunities to request additional assistance or information, mobile texting options, and social media links (Twitter/Facebook/Pinterest) maintained and monitored by the Social Media Specialist.
62566686|NCT01602211|EXPERIMENTAL|Arm II (delayed program access control)|Participants receive annotated website links to existing transplant and cancer survivor sites, followed by delayed access to the INSPIRE internet program after 1 year.
62566687|NCT01099618|ACTIVE_COMPARATOR|Metformin|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg (n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
61996853|NCT04649775|NO_INTERVENTION|Standard of Care- Control|Participants will receive standard of care, clinical data will be recorded. Baseline and end of study questionnaires will be performed.
61996854|NCT05923203|EXPERIMENTAL|Adult use of EAS|Clinical intervention; Adults with CI and the fitting of electric and acoustic stimulation (EAS) technology in the implanted ear(s).
62181869|NCT04011423|ACTIVE_COMPARATOR|Stable shoes|Wearing stable shoes during the whole-body vibration training
62391345|NCT01988844||Children with cerebral palsy|Children diagnosed with cerebral palsy are included in this group. An assessment and an intervention will be carried out.
61996855|NCT05923203|EXPERIMENTAL|Pediatric use of EAS|Clinical intervention; Children with CI and the fitting of electric and acoustic stimulation (EAS) technology in the implanted ear(s).
62566688|NCT01099618|ACTIVE_COMPARATOR|Sitagliptin|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000 mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg (n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
61996856|NCT05923203|NO_INTERVENTION|Children with Normal Hearing|Children with normal hearing; acoustic only
62181870|NCT04882033|EXPERIMENTAL|Concurrent chemoradiotherapy plus anlotinib|Concurrent chemoradiotherapy plus anlotinib for 4-6 cycles This study will include a sequential evaluation of 3 subjects per dose group. Low-dose groups: anlotinib 8mg per day with concurrent chemoradiotherapy. Middle-dose groups: anlotinib 10mg per day with concurrent chemoradiotherapy. High-dose groups: anlotinib 12mg per day with concurrent chemoradiotherapy.
62181871|NCT00591409|PLACEBO_COMPARATOR|Rocuronium + Placebo|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
62181872|NCT00591409|EXPERIMENTAL|Rocuronium + 0.5 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
62391346|NCT00829595|EXPERIMENTAL|1|IBD, on both an anti-TNF agent and an immunomodulator
62566689|NCT01099618|PLACEBO_COMPARATOR|Placebo|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000 mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg(n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
62566690|NCT01057316|EXPERIMENTAL|Study Group A|
62566691|NCT01057316|EXPERIMENTAL|Study Group B|
62566692|NCT01057316|EXPERIMENTAL|Study Group C|
62566693|NCT00672724|EXPERIMENTAL|Ramelteon 8 mg QD|
62566694|NCT00672724|PLACEBO_COMPARATOR|Placebo|
62566695|NCT04501237|NO_INTERVENTION|Bruxers without sleep hygiene instructions|
62566696|NCT04501237|EXPERIMENTAL|Bruxers with sleep hygiene instructions|
62566697|NCT02437773|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy - Adolescents|12 Cognitive-Behavioral Therapy sessions scheduled weekly over a 12-week period.
62566698|NCT02437773|OTHER|Stress Management Therapy - Adolescents|"12 SMT sessions scheduled weekly over a 12-week period.~After study completion, the OCD subjects who received SMT may derive benefit for non-OCD anxiety symptoms. They will be offered a 12-week course of CBT with a study therapist to directly target OCD symptoms (i.e., a partial cross-over)."
62566699|NCT02437773|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy - Adults|12 CBT sessions scheduled weekly over a 12-week period.
62566700|NCT02437773|OTHER|Stress Management Therapy - Adults|"12 SMT sessions scheduled weekly over a 12-week period.~After study completion, the OCD subjects who received SMT may derive benefit for non-OCD anxiety symptoms. They will be offered a 12-week course of CBT with a study therapist to directly target OCD symptoms (i.e., a partial cross-over)."
62566701|NCT02437773|OTHER|Healthy Control - Adolescents|Healthy control adolescents matched to gender, race and socioeconomic status (SES) with adolescent patients with OCD will be enrolled. These healthy adolescents will be scanned with fMRI before and after 12 weeks, but without any intervention (i.e., no therapy).
61996857|NCT05923203|NO_INTERVENTION|Adults with Normal Hearing|Adult with normal hearing; acoustic only
61996858|NCT02136667||Exposed|Women with a history of preeclampsia 10 years ago
61996859|NCT02136667||Unexposed|Women with a history of uncomplicated pregnancy 10 years ago
61996860|NCT04734496||Chronic Liver Disease|Patients with end-stage liver disease. Standard of care treatment will be nutrition and exercise as per European Association Study of Liver nutrition guidelines.
61996861|NCT04734496||Rheumatoid Arthritis/Psoriatic arthropathy|Patients requiring biological therapy due to ongoing inflammation (requiring anti-Tumour Necrosis Factor therapy) - i.e. standard of care - escalation in therapy
61996862|NCT04734496||Inflammatory Bowel Disease|Patients with Crohns or Ulcerative Colitis with ongoing inflammation (requiring anti-Tumour Necrosis Factor therapy) - i.e. standard of care - escalation in therapy
61996863|NCT04734496||Healthy volunteers (n=20)|Healthy volunteers
61996864|NCT00031174||1|Blood components collected using apheresis from normal volunteers.
61996865|NCT00031174||2|Blood components collected using apheresis from patients with rheumatic or kidney diseases.
61996866|NCT06420154|EXPERIMENTAL|Treatment group|
62566702|NCT02437773|OTHER|Healthy Control - Adults|Healthy control adults matched to gender, race and socioeconomic status (SES) with adult patients with OCD will be enrolled. These healthy adults will be scanned with fMRI before and after 12 weeks, but without any intervention (i.e., no therapy).
62181873|NCT00591409|EXPERIMENTAL|Rocuronium + 1.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
62566703|NCT02437773|OTHER|Optional CBT - Adolescents|OCD adolescent participants who were randomized to the SMT and have completed all study procedures will be offered an additional 12 weeks of Optional Cognitive-Behavioral Therapy.
62566704|NCT02437773|OTHER|Optional CBT - Adults|OCD adult participants who were randomized to the SMT and have completed all study procedures will be offered an additional 12 weeks of Optional Cognitive-Behavioral Therapy.
62566705|NCT03321500|EXPERIMENTAL|Versacyl soft liner|Versacryl soft liner are flexible biocompatible materials with a reported predictable long term performance, durable bonding to acrylic denture bases, high fatigue endurance, excellent wear characteristics and solvent resistance with almost no free monomer in the processed material
62181874|NCT00591409|EXPERIMENTAL|Rocuronium + 2.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
62181875|NCT00591409|EXPERIMENTAL|Rocuronium + 4.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
62181876|NCT00591409|PLACEBO_COMPARATOR|Vecuronium + Placebo|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
62181877|NCT00591409|EXPERIMENTAL|Vecuronium + 0.5 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
62181878|NCT00591409|EXPERIMENTAL|Vecuronium + 1.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
62181879|NCT00591409|EXPERIMENTAL|Vecuronium + 2.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
62181880|NCT00591409|EXPERIMENTAL|Vecuronium + 4.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
62181881|NCT06370117|NO_INTERVENTION|control group (n= 34)|"Control group (n=34) Routine vascular access was performed on the children in the control group. Apart from this, no other application was made.~Before the procedure; Introductory Information Form, Wong-Baker Facial Expression Rating Scale and Child Fear and Anxiety Scale were filled out by the researcher.~Process order; Routine vascular access was performed. A stopwatch was used for the procedure time and the procedure time was recorded. The Child Fear and Anxiety Scale and the Wong-Baker Facial Expression Rating Scale were completed again."
62181882|NCT06370117|EXPERIMENTAL|Buzzy Group (n= 34)|Before the procedure; 60 seconds before starting the vascular access process, the Buzzy® tool was placed in the procedure area and cold and vibration application was started. The tourniquet was tied 10-12 cm above the vein to be treated. The Buzzy® tool was fixed to the middle part of the procedure area and the tourniquet, approximately 2 cm above the IV catheter entry site. As soon as the vascular access was established, the Introductory Information Form, Wong-Baker Facial Expression Rating Scale, and Child Fear and Anxiety Scale were filled out by the researcher. Process order; Application with the Buzzy® tool continued throughout the process. A stopwatch was used to time the procedure and the Buzzy® tool was removed when the procedure was completed. The Child Fear and Anxiety Scale and the Wong-Baker Facial Expression Rating Scale were completed again.
62181883|NCT06370117|EXPERIMENTAL|Music video listening group (n= 34)|"The children in study group II were listened to music starting from 60 seconds before the vascular access procedure until the procedure ended.~Before the procedure; A music video was played 60 seconds before starting the intravenous access procedure. The Introductory Information Form, Wong-Baker Facial Expression Rating Scale, and Child Fear and Anxiety Scale were filled in by the researcher.~Process order; Music video playback continued. A stopwatch was used for the procedure time. As soon as the vascular access was established, the Child Fear and Anxiety Scale and the Wong-Baker Facial Expression Rating Scale were filled out again."
62391347|NCT00829595|EXPERIMENTAL|2|IBD, not on any immunosuppressive medications
62391348|NCT00829595|ACTIVE_COMPARATOR|3|Healthy, non-IBD, not on immunosuppressive medications (control arm)
62566706|NCT03321500|ACTIVE_COMPARATOR|Silicone-based soft liner|Resilient liners were introduced in the1950s and have been used since then as a gold standard material to increase the tolerance, retention and comfort of complete dentures. Resilient liners also known as 'soft liners' can be classified as temporary or permanent, cold-cured or heat-cured.Resilient liners can be divided into two main types: plasticized acrylic resins and silicone elastomers.
61996867|NCT02188485|EXPERIMENTAL|ENGAGE: a social engagement intervention|ENGAGE is a brief psychotherapy that specifically targets increased social engagement and activity. The study will use the ENGAGE manual developed by Drs. Alexopoulos, Arean and their colleagues, focusing on increased engagement in activities that allow subjects to be social (targeting thwarted belongingness) or contribute to the well-being of others (targeting perceived burdensomeness).
61996868|NCT02188485|NO_INTERVENTION|Care-as-Usual|Care as usual in primary care with study assessments.
61996869|NCT02342704|EXPERIMENTAL|natalizumab|Open-label natalizumab 300 mg IV every 4 weeks (Q4W)
61996870|NCT02342704|ACTIVE_COMPARATOR|fingolimod|Open-label fingolimod 0.5 mg once daily orally
61996871|NCT03369938|EXPERIMENTAL|exercise training intervention|
62182648|NCT00002716|EXPERIMENTAL|Arm I - laparotomy + conventional surgery + chemotherapy|"Patients undergo laparotomy for placement of a hepatic artery catheter and then subcutaneous placement of a hepatic artery infusion pump. Patients with unresected primary disease also undergo resection at the time of catheter and pump placement. Beginning within 1-2 weeks after surgery, patients receive floxuridine, dexamethasone, and leucovorin calcium (CF) via continuous hepatic artery infusion on days 1-14. Treatment for patients continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life and medical resource utilization are assessed at baseline, every 3 months for 1 year, and then at 18 months.~Patients are followed every 3 months."
62566707|NCT04209790|OTHER|Neoadjuvant chemoradiation and surgical resection|The experimental part of the study would be this selection of resectable patients and sequencing neoadjuvant chemoradiation prior to surgery.
61996872|NCT03369938|NO_INTERVENTION|usual care|
61996873|NCT03592615|EXPERIMENTAL|Cataract group|All participants in this arm undergo cataract surgery for the purpose of vision correction.
61996874|NCT03592615|EXPERIMENTAL|Refractive error group|All participants in this arm undergo corneal refractive surgery for the purpose of vision correction.
62566708|NCT01460238||No treatment|No intervention. Each patient will have blood drawn at a standard of care venipuncture.
61996875|NCT00911261|EXPERIMENTAL|Single Arm|
61996876|NCT00714259|OTHER|Non Myeloablative Treatment|"Non-myeloablative Transplant Conditioning Chemotherapy :~Fludarabine - 30 mg/m2/day x 3 days Total Body Irradiation - 200cGy x1 dose Infusion of Stem Cells - On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10\*6 CD34+ cells per kilogram of recipient weight."
61996877|NCT03425812|EXPERIMENTAL|Non- NSAIDS group|To withdraw NSAIDS therapy
61996878|NCT03425812|ACTIVE_COMPARATOR|NSAIDS group|To continue NSAIDS therapy
61996879|NCT02759120|EXPERIMENTAL|Antimicrobial therapy|Co-trimoxazole OR doxycycline
61996880|NCT02759120|OTHER|Standard of care|Standard of care for patients with IPF for comparison
61996881|NCT04939727|EXPERIMENTAL|OUD-CDS + Suicide Risk Model associated CDS (Intervention arm)|Providers that practice in the clinics in this intervention arm will receive access to the OUD-CDS + Suicide Risk Model associated CDS, for all eligible encounters.
61996882|NCT04939727|NO_INTERVENTION|Control|"Providers that practice in the clinics in this control arm will not receive any access to the OUD-CDS + Suicide Risk Model associated CDS, however these clinical decision-support tools will run silently in the background, collecting data on eligible encounters."
61996883|NCT00423891|EXPERIMENTAL|Arm 1: Entecavir|
61996884|NCT01466192|EXPERIMENTAL|MP-424|
61996885|NCT04116164|EXPERIMENTAL|Dosimetry and targeting|"Three sub-cohorts in cohort 1 will receive one slow bolus IV injection of 2 mg 111In-DOTA-h11B6 with 0, 8 and 18 mg unlabeled h11B6 respectively.~In cohort 2, up to 6 patients will receive a slow bolus IV injection of 2 mg 111In-DOTA_h11B6 with any unlabeled h11B6 as determined from cohort 1, and will be imaged at one time-point"
61996886|NCT04638465||A - Surgery Only|"Participants with the following diagnosis will receive transoral robotic surgery with neck dissection:~* Base of Tongue/Non-Tonsil Oropharynx - Stage: cT1-2, cN0 or N1 (single node)~* Tonsil - Stage: cT1-3, cN0 or N1 (single node)~* Unknown primary - Stage: cT0 N1 (single node)~Radiation also given if indicated by intermediate or high risk features following surgery."
61996887|NCT04638465||B - Surgery with Adjuvant Therapy|"Participants with the following diagnosis will receive surgery followed by 6 Cycles of Cisplatin 40 mg/m2:~* Base of Tongue/Non-Tonsil Oropharynx - Stage: cT1-2, cN1 (2-4 nodes) or N2~* Tonsil - Stage: cT1-3, N1 (2-4 nodes)~Radiation also given if indicated by intermediate or high risk features following surgery."
61996888|NCT04638465||C - Concurrent Chemo/Radiation Therapy - Dose Level 1|"Participants with the following diagnosis will receive 6 Cycles of Cisplatin 40 mg/m2 + 60 Gy Radiation:~* Tonsil - Stage: cT1-3, N2~* Unknown Primary - Stage: cT0, N2"
61996889|NCT04638465||D - Concurrent Chemo/Radiation Therapy - Dose Level 2|"Participants with the following diagnosis will receive 7 Cycles of Cisplatin 40 mg/m2 + 70 Gy Radiation:~* Base of Tongue/Non-Tonsil Oropharynx - Stage: cT3-4, any N~* Base of Tongue/Non-Tonsil Oropharynx - Stage: cAny T, N3~* Tonsil - Stage: cT1-3, N3~* Tonsil - Stage: cT4, any N~* Unknown Primary - Stage: cT0, N3"
61996890|NCT02385175||Adults with suspected Eustachian tube dysfunction|Age 18+ with possible Eustachian tube dysfunction on the basis of symptoms and examination findings.
61996891|NCT02850536|EXPERIMENTAL|anti-CEA CAR-T cells|Three infusions of gene-modified anti-CEA T cells over the course of 3 weeks into the hepatic artery via a percutaneous approach along with low dose IL-2.
62391349|NCT03100929|EXPERIMENTAL|Elective cesarean section|Any patient undergoing elective cesarean section. Ultrasound
62566709|NCT05098522|EXPERIMENTAL|Arm 1: IRL201104|IRL201104 IV on Day 1, Day 14, Day 28, Day 42, Day 56, Day 70
62566710|NCT05098522|PLACEBO_COMPARATOR|Arm 2: Placebo|Placebo IV on Day 1, Day 14, Day 28, Day 42, Day 56, Day 70
62566711|NCT06180096|EXPERIMENTAL|Riociguat film coated tablets|Riociguat 2.5 mg film coated tablets
62566712|NCT06180096|ACTIVE_COMPARATOR|Adempas Filmtabletten|Adempas (Riociguat) 2.5 mg Filmtabletten
62566713|NCT01290068|EXPERIMENTAL|ReSTOR +3|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL, bilateral implantation
61996892|NCT02958839||Recurrence Group|In the case control trial, patients who have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
61996893|NCT02958839||Non-recurrence Group|In the case control trial, patients who do not have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
61996894|NCT05691231||Simplify Disc|Extended follow-up of subjects treated with the Simplify Disc during IDE study NCT03123549 and followed in the post-approval study NCT04980378.
62391350|NCT06098976|EXPERIMENTAL|Water Jet|The patients were taught how to clean their teeth with the Water Jet device (Water Jet, JollyDent, Damascus, Syria) before starting the dental cleaning procedures. Special heads for patients undergoing orthodontic treatment provided by the company were used with each device. The patient applied the Water Jet device on each tooth separately for 10 seconds starting from the upper jaw to the lower jaw.
62181884|NCT06370117|EXPERIMENTAL|Buzzy+ Music video listening Group (n= 34)|Before the procedure; 60 seconds before starting the vascular access process, a music video was played and cold and vibration application was started with the Buzzy® tool.60 seconds before the procedure began, the Buzzy® tool was placed on the procedure area and cold and vibration application was initiated.Moreover,a music video was played. The tourniquet was tied 10-12 cm above the vein to be treated.The Buzzy® tool was fixed to the middle part of the procedure area and the tourniquet, approximately 2 cm above the IV catheter entry site. Introductory Information Form, Wong-Baker Facial Expression Rating Scale and Child Fear and Anxiety Scale were filled in by the researcher.Process order; application continued. A stopwatch was used for the procedure time.When vascular access was established, the Child Fear and Anxiety and Wong-Baker Facial Expression Rating Scale were filled out again.Once the process was finished, the buzzy was removed and the music video was closed.
62566714|NCT01290068|EXPERIMENTAL|ReSTOR +3 Toric|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative corneal astigmatism, bilateral implantation, or implanted in 1 eye with AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL in the other eye
62566715|NCT01290068|ACTIVE_COMPARATOR|Monofocal|Monofocal IOL, bilateral implantation
61996895|NCT02306512|ACTIVE_COMPARATOR|Standard vs. IF MART-1|"Samples removed with MMS within the first 3 mm margin from the tumor will be the first section. They will be processed as a conventional H\&E frozen section and section stained with IHC MART-1. Samples removed with MMS within 3-6 mm from tumor margin will be the second section. They will be processed with fluorescent MART-1 antibodies. Based on the pre-defined characteristics MMS surgeon will evaluate each MART-1 immunofluorescent section as no evident melanoma or possible melanoma or present melanoma. Dermatopathologist will secondarily review each section scoring them in the same manner. If standard H\&E, IHC, or immunofluorescence is recorded as present melanoma or possible melanoma a third section from 6-9mm will have the same procedure described before."
61996896|NCT02306512|ACTIVE_COMPARATOR|IF MART-1 versus IF cocktail|In the second arm of the study, assuming that immunofluorescence with MART-1 proves to be superior or at least equivocal to regular MART-1 IHC, the same method will be applied, but the control sections will be stained with fluorescent MART-1 antibodies and compared to a section stained with a cocktail of fluorescent melanocytic antibodies.
61996897|NCT04338711|EXPERIMENTAL|Treatment A|Single oral 10 mg dose of tofacitinib MR E1 administered in the fasted state.
61996898|NCT04338711|EXPERIMENTAL|Treatment B|Single oral 10 mg dose of tofacitinib MR E2 administered in the fasted state.
61996899|NCT04338711|EXPERIMENTAL|Treatment C|Single oral 10 mg dose of tofacitinib MR E3 administered in the fasted state.
61996900|NCT04338711|EXPERIMENTAL|Treatment D|Single oral 10 mg dose of tofacitinib MR E1 administered in the fed state.
61996901|NCT04338711|EXPERIMENTAL|Treatment E|Single oral 10 mg dose of tofacitinib MR E3 administered in the fed state.
61996902|NCT04338711|ACTIVE_COMPARATOR|Treatment F|Single oral 10 mg dose of tofacitinib IR Solution (10 mL of the 1 mg/mL solution) administered in the fasted state.
61996903|NCT02627612|EXPERIMENTAL|TM RWB PLUS Pro Vetus|Research participants will receive an introductory email from the research team informing them that they were randomly assigned to this group and request that they voluntarily join TM RWB and receive mentorship from their matched and assigned mentor. In addition to TM RWB membership, research participants will also receive approximately four months of mentorship from a ProVetus mentor to assist them in further transitioning within the five domains.
61996904|NCT02627612|ACTIVE_COMPARATOR|TM RWB ONLY|Research participants will receive an introductory email from the research team informing them that they were randomly assigned to this arm and request that they voluntarily join TM RWB. Weekly emails will provide lists of voluntary physical/social activities available to all Chapter members. No participation is required in these activities.
61996905|NCT02627612|NO_INTERVENTION|Control Group (Waitlist)|Research participants (recent Veterans) will be placed on a waitlist for approximately sixteen months. Based on their desires, the research participants in this group will have opportunity to belong to TM RWB plus receive approximately four months of mentorship from trained, peer-mentors (who are TM RWB volunteers).
61996906|NCT01020058|ACTIVE_COMPARATOR|Lichtenstein in local anesthesia (LLA)|Patient operated in local anesthesia, with an anterior mesh repair according to Lichtenstein
61996907|NCT01020058|ACTIVE_COMPARATOR|TEP|Patient receives a totally extraperitoneal laparoscopic repair
61996908|NCT05145829|EXPERIMENTAL|Melanoma patients|All patients will undergo lymphatic mapping with SPIO, 99mTc and PB.
61996909|NCT02549508|EXPERIMENTAL|AutoCPAP with SensAwake On, then SenAwake Off|Participants will start AutoCPAP treatment with SensAwake on for 4 weeks. After 4 weeks, the will cross over to SensAwake off for another 4 weeks.
61996910|NCT02549508|EXPERIMENTAL|AutoCPAP with SensAwake Off, then SensAwake On|Participants will start AutoCPAP treatment with SensAwake Off for 4 weeks. After 4 weeks, the will cross over to SensAwake On for another 4 weeks.
61996911|NCT04111094||HF|Diagnosed heart failure as described by recent guidelines. Inclusion criteria will be applied: i) minimum one symptom typical of HF: positive physical examination (e.g., bilateral oedema, increased jugular pressure) or positive clinical history (e.g., orthopnoea, history of coronary vascular disease, history of arterial hypertension, exposition to cardiotoxic drug/radiation, diuretic use); b-type natriuretic peptide (BNP) or N-terminal pro-BNP levels ≥35 or ≥125 pg/ml, respectively; and iii) classification as New York Heart Association (NYHA) functional class 2 or 3. There is no prespecified inclusion criterion with respect to left ventricular ejection fraction as congestive symptoms and prevalence of kidney dysfunction are comparable in patients with HF across the left ventricular ejection fraction spectrum.
61996912|NCT04111094||Diabetes mellitus/hypertension|Diagnosed diabetes mellitus, with/without treatment
61996913|NCT04111094||Hypertension|Diagnosed hypertension, with/without treatment
61996914|NCT04111094||Cystic kidney diseases|Diagnosed cystic kidney diseases, with/without treatment
61996915|NCT04111094||Tubulointerstitial diseases|Diagnosed tubulointerstitial diseases, with/without treatment
61996916|NCT04111094||Glomerular diseases|Diagnosed glomerular diseases, with/without treatment
62181885|NCT04068051|EXPERIMENTAL|AXS-07|
62566716|NCT05654376|EXPERIMENTAL|Group art therapy|Cycle of 6 2-hours bimonthly group art therapy sessions.
61996917|NCT04607993|EXPERIMENTAL|Prone position ventilation technique|Prone position ventilation for children with congenital heart disease after surgery
62181886|NCT06468267|EXPERIMENTAL|intervention arm|Participants will receive allogenetic hematopoietic stem cell transplantation (allo-HSCT) with the reduced intensity conditioning regimen including thiotepa(5mg / kg / d-7d ( 1d )), fludarabine (30mg / m2 / d, -6d--2d ( 5d )), Ara-C (1g / m2 / d, -6d--2d ( 5d )), and busulfan(3.2mg / kg / d, -4d-3d ( 2d )).
62181887|NCT04991350|ACTIVE_COMPARATOR|Ranibizumab Group|Patients will receive monthly ranibizumab injections for 3 months.
62181888|NCT04991350|ACTIVE_COMPARATOR|Bevacizumab Group|Patients will receive monthly bevacizumab injections for 3 months.
62566717|NCT05374122|EXPERIMENTAL|DSOC + AI-biopsy guidance|"This group is comprised by patients with suggestive malignant biliary lesions assessed by DSOC for biopsy. In this group, the investigators aim to use as a complement tool an AI model for the detection of features suggestive of malignancy to perform the biopsy on the detecting bounding box signal.~A further follow-up of 6 months is necessary for a confirming diagnosis of neoplastic lesions."
61996918|NCT04607993|NO_INTERVENTION|Control group|conventional postoperative position, no prone position ventilation
61996919|NCT00855088|EXPERIMENTAL|Darunavir, ritonavir, etravirine|Single arm trial looking at the pharmacokinetics of darunavir, ritonavir, etravirine in healthy volunteers.
61996920|NCT05892848||cases group|childern and adolescents with type 1 diabetes
61996921|NCT05892848||control group|age and sex matched control childern and adolsecents
61996922|NCT02112825|EXPERIMENTAL|Exercise|12 weeks of blended supervised-home based exercise 3-4 times per week for 30-45 minutes
61996923|NCT02112825|NO_INTERVENTION|control|Control group asked to continue usual activities
61996924|NCT01354496|EXPERIMENTAL|Cohort 1 - LY2409021 reference form|A 20 milligram (mg) LY2409021 dose, reference form administered orally in the fasted state
61996925|NCT01354496|EXPERIMENTAL|Cohort 1 - LY2409021 medium test form fed|Single 20 mg LY2409021 test form with medium particle size administered orally immediately after ingestion of a standardized high-fat meal
61996926|NCT01354496|EXPERIMENTAL|Cohort 1 - LY2409021 medium test form fasted|Single 20 mg LY2409021 test form with medium particle size administered orally in the fasted state
61996927|NCT01354496|EXPERIMENTAL|Cohort 2 - LY2409021 low test form fasted|Single 20 mg LY2409021 test form with low particle size administered orally in the fasted state
61996928|NCT01354496|EXPERIMENTAL|Cohort 2 - LY2409021 medium test form fasted|Single 20 mg LY2409021 test form with medium particle size administered orally in the fasted state
61996929|NCT01354496|EXPERIMENTAL|Cohort 2 - LY2409021 high test form fasted|Single 20 mg LY2409021 test form with high particle size administered orally in the fasted state
61996930|NCT00253578|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62181889|NCT04192539|ACTIVE_COMPARATOR|Control|
62181890|NCT04192539|ACTIVE_COMPARATOR|Inflammation|
62181891|NCT04192539|ACTIVE_COMPARATOR|Benign group|
62181892|NCT04192539|ACTIVE_COMPARATOR|Malignant group|
62181893|NCT04302051||Study Group|The hepatic fat estimation will be performed on the same subjects with the use of the thermo-acoustic device and by MRI-PDFF. The data obtained from the two estimations will be compared.
62566718|NCT05374122|ACTIVE_COMPARATOR|DSOC biopsy without AI guidance|This group is comprised by patients with suggestive malignant biliary lesions assessed by DSOC for biopsy without AI guidance. A further follow-up of 6 months is necessary for a confirming diagnosis of neoplastic lesions.
62566719|NCT03197142||Out-of-hospital cardiac arrest|All the patients who suffered an out-of-hospital cardiac arrest in the Lombardia Region
61996931|NCT03751085|EXPERIMENTAL|AW frame|AW frame biopsy
61996932|NCT00747968|ACTIVE_COMPARATOR|glp-1-analogue|During hyperglycemic clamp and GLP-1-analogue versus placebo infusion 15 patients will be heart OR CNS-PET scanned
61996933|NCT00747968|PLACEBO_COMPARATOR|placebo|During hyperglycemic clamp and GLP-1-analogue versus placebo infusion 15 patients will be CNS OR heart-PET scanned.
61996934|NCT04035304|EXPERIMENTAL|Mindfulness Coach Mobile App|Participants in this condition will complete 3 assessments: initial, end of month two and end of month four. Each participant, following initial assessment will be provided with a link to download the Mindfulness Coach mobile app as well as with brief recommendations for how to use the app over the subsequent 16 weeks of the study. Mindfulness Coach is a mobile app for iPhone and Android, developed by the VA National Center for PTSD in collaboration with National Center for Telehealth and Technology (T2).
62181894|NCT04457544||Retrospective patients|The investigators will review the hospital records at the investigational site for SCAD events having occurred over the last 5 years. All SCAD patients aged ≥18 years, not presenting atherosclerotic or iatrogenic coronary dissection will be informed about the SwissSCAD study by phone and will be given at least one week to decide if they wish to participate. We plan to include 500 patients in the retrospective arm.
62181895|NCT04457544||Prospective patients|Patients presenting at the hospital with newly diagnosed SCAD will be informed of the SwissSCAD study and will be given at least one week to decide if they wish to participate. We plan to include 500 patients in the prospective arm.
62181896|NCT04225000|ACTIVE_COMPARATOR|Exercise Group|Hip \& Knee Exercises
62181897|NCT04225000|EXPERIMENTAL|Mobilization Group|Tibiofemoral joint anterior-posterior mobilization combined Hip \& Knee Exercises
62181898|NCT04141800||Heart failure (HF) outpatients with reduced ejection fraction|"Heart Failure (HF) with reduced ejection fraction (REF): Patients with confirmed diagnosis of HF and with ejection fraction\<40%.~Hyperkalaemia: K+values\> 5,4 mEq/L.~Optimal doses: the maximum doses of renin-angiotensin-aldosterone related drugs that, according to the physician's judgement, the patient can receive. If any of these drugs (ACIEs, ARB-II, MRAs or sacubitril-valsartan) is de novointroducedat the initial visit, optimal doses will be not considered established.~A previous personal history of diseases and/or outcomes will be registered according to the usual practice of every centre."
62181899|NCT03665753|EXPERIMENTAL|Ketorolac 10mg|Subjects will be administered 10 mg of Ketorolac.
62181900|NCT03665753|EXPERIMENTAL|Ketorolac 20mg|Subjects will be administered 20 mg of Ketorolac
62181901|NCT03665753|EXPERIMENTAL|Ketorolac 30mg|As a part of standard care, subjects will be administered 30 mg of Ketorolac.
62181902|NCT03299127|EXPERIMENTAL|imagery rescripting|bibliotherapy, intervention is provided by pdf-manual (either short or long version, i.e. 2 active arms, each 1/3 of sample receives either short or long version)
62181903|NCT03299127|NO_INTERVENTION|wait-list control|wait-list control, participants receive intervention manual upon completion of post-assessment (1/3 of sample)
62181904|NCT04605198|EXPERIMENTAL|Modified Mindfulness-based Stress Reduction|
62181905|NCT04605198|ACTIVE_COMPARATOR|Health Promotion Attention Control|
62181906|NCT01101334|EXPERIMENTAL|CS-7017 plus erlotinib|
62181907|NCT01101334|ACTIVE_COMPARATOR|erlotinib|
62181908|NCT00543101|ACTIVE_COMPARATOR|Switch to DRV/r|Switch to DRV/r at a dose of 600/100 BID for 48 weeks
62181909|NCT00543101|ACTIVE_COMPARATOR|Continue on Current Dual Boosted PI|Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (\< 400 copies/ml) for the first 24-weeks of the study and are followed for an additional 24 weeks
62181910|NCT00694733|PLACEBO_COMPARATOR|1|Men on placebo injections for 4 months
62181911|NCT00694733|ACTIVE_COMPARATOR|2|Men who receive Depo Lupron for 4 months, then are replaced with testosterone and aromatase inhibitor for 4 months.
62181912|NCT00694733|ACTIVE_COMPARATOR|3|Men who receive Depo Lupron for 4 months, then are replaced with testosterone and placebo for 4 months.
62181913|NCT00694733|PLACEBO_COMPARATOR|4|Women on placebo cream
62181914|NCT00694733|ACTIVE_COMPARATOR|5|Women on estrogen cream
62181915|NCT03239418|EXPERIMENTAL|EyeStim Group|Receive an active NMES treatment to the targeted muscles controlling eyelid function.
62181916|NCT03239418|SHAM_COMPARATOR|Control Group|Undergo all the same procedures as the EyeStim group except receive a sham NMES treatment.
62181917|NCT05579665|EXPERIMENTAL|Platelet-rich Plasma (PRP)|Platelet-rich plasma administered 5 times as an intra-articular injection under ultrasound guidance as a series of one weekly injections to the affected knee. 1 weekly injections are of leukocyte poor, buffer/additive free, singe spin, platelet-rich plasma averaging 3mL in volume.
62181918|NCT05579665|EXPERIMENTAL|Conditioned Medium From Umbilical Cord Mesenchymal Stem Cell Culture (MSCs) Secretome|Conditioned Medium From Umbilical Cord Mesenchymal Stem Cell Culture (MSCs) Secretome administered 5 times as an intra-articular injection under ultrasound guidance as a series of one weekly injections to the affected knee. 1 weekly injections are Conditioned Medium From Umbilical Cord Mesenchymal Stem Cell Culture (MSCs) Secretome averaging 2 mL in volume.
62181919|NCT05579665|EXPERIMENTAL|Hyaluronic Acid (HA)|Hyaluronic Acid administered 5 times as an intra-articular injection under ultrasound guidance as a series of one weekly injections to the affected knee. 1 weekly injections are of low molecular weight hyaluronan in a 2mL injection.
62181920|NCT06215417|EXPERIMENTAL|HDA|Human dermal allograft (LifeNet Health Arthroflex graft)
61996935|NCT04035304|NO_INTERVENTION|No Treatment Control Group|Participants in this condition will initially be provided with links to resources for Veterans with PTSD (http://ptsd.va.gov) and will be told that they will be contacted again in 8 weeks (60 days) to complete a second assessment. Each participant will then be provided with a link to download the Mindfulness Coach mobile app and with brief recommendations for how to use the app over the subsequent 8 weeks of the study (see description above). Participants will participate in a final follow up survey 8 weeks after receiving the app.
62181921|NCT06215417|ACTIVE_COMPARATOR|Regeneten|Bovine collagen patch xenograft (Smith \& Nephew Regeneten)
62566720|NCT05695001||No Intervention: Baseline therapy|Basic therapy is the routine practice of an institution for the treatment of patients with acute pancreatitis without signs of infection
61996936|NCT04475289||Patients with an coronary artery anomaly (focus on ACAOS)|Patients eligible for study participation have a CAA and a prior, clinically indicated testing (noninvasive and/or invasive measurement) at our institution to evaluate the hemodynamic significance of this coronary anomaly. They will be approach either after start of this study (retrospective inclusion) or before their testing (prospective inclusion).
61996937|NCT05254262||Elderly patients|Patients age 70 or older, who are admitted in hospital for surgical operation (elective or emergency surgery)
61996938|NCT05210790|EXPERIMENTAL|Rusfertide|Rusfertide (32 Weeks) - Rusfertide (124 Weeks Open-label)
61996939|NCT05210790|EXPERIMENTAL|Placebo|Placebo (32 Weeks) - Rusfertide (124 Weeks Open-label)
61996940|NCT01269697|ACTIVE_COMPARATOR|Nutrof|patient receive the treatment of Nutrof Total
61996941|NCT01269697|PLACEBO_COMPARATOR|Placebo of Nutrof|Patient receive the treatment of the placebo of Nutrof Total
61996942|NCT04209309|EXPERIMENTAL|leDLPFC|single session rTMS of the left dorsolateral prefrontal cortex for 15 min (60 trains with 50 stimuli; 10 sec intertrain interval; 10 Hz; 110% RMT; 3000 pulses; coil positioning over the 10-20 EEG coordinate position F3)
61996943|NCT04209309|EXPERIMENTAL|riDLPFC|single session rTMS of the right dorsolateral prefrontal cortex for 15 min (60 trains with 50 stimuli; 10 sec intertrain interval; 10 Hz; 110% RMT; 3000 pulses; coil positioning over the 10-20 EEG coordinate position F4)
61996944|NCT04209309|SHAM_COMPARATOR|shamDLPFC|single session sham rTMS over the medial prefrontal cortex for 15 min (60 trains with 50 stimuli; 10 sec intertrain interval; 10 Hz; 110% RMT; 3000 pulses; coil positioning over the midline with tilted coil)
61996945|NCT01767922|EXPERIMENTAL|Extramel 10 mg - 140 UI SOD|This arm receives daily one capsule Extramel 10 mg containing 140 UI of SOD.
61996946|NCT01767922|PLACEBO_COMPARATOR|Placebo - exipients only|This arm receives daily one capsule Placebo containing excipients only.
61996947|NCT05316662||Semaglutide|Participants with T2D will be assessed for clinical parameters associated with the once-daily use of oral semaglutide who have not previously been treated with injectable glucose-lowering medication in routine clinical practice.
61996948|NCT05371600|ACTIVE_COMPARATOR|Group M|Patients receive midazolam IV at 0.04 mg/kg (group M).
61996949|NCT05371600|PLACEBO_COMPARATOR|Group C|Patients receive an equal volume of saline IV (group C, control group).
61996950|NCT03144492||self-reported healthy individuals|"Self-reported healthy individuals avoiding blood draw on the days participants are feeling under the weatheror sick. In that case, study team can delay the blood draw until the subject feels better, but this would not preclude anyone from participating."
61996951|NCT02051465|EXPERIMENTAL|LumenR Retractor|Endoscopic removal of polyp using modified overtube LumenR Retractor
62181922|NCT00115336|ACTIVE_COMPARATOR|1-Intravenous ketorolac and oral placebo|Intravenous ketorolac and oral placebo
62566721|NCT05695001||Experimental: Basic therapy + Efferon CT|Basic therapy is a routine practice of the institution for the treatment of patients with acute uninfected pancreatitis in combination with extracorporeal hemoperfusion (Efferon CT)
62566722|NCT01590225|EXPERIMENTAL|Part A: boceprevir + peginterferon alpha-2b + ribavirin|
62566723|NCT01590225|EXPERIMENTAL|Part B: boceprevir + peginterferon alpha-2b + ribavirin|
62566724|NCT00529503|EXPERIMENTAL|1|SGN-40, rituximab, etoposide, carboplatin, ifosfamide
62181923|NCT00115336|ACTIVE_COMPARATOR|2-Intravenous placebo and oral ibuprofen|Intravenous placebo and oral ibuprofen
62181924|NCT05895968|NO_INTERVENTION|Preoperative|
62181925|NCT05895968|EXPERIMENTAL|postoperative (2 weeks)|
62181926|NCT05895968|EXPERIMENTAL|postoperative (4 weeks)|
62181927|NCT05895968|EXPERIMENTAL|postoperative (3 months)|
61996952|NCT02051465|ACTIVE_COMPARATOR|Removal without overtube|Endoscopic removal of polyp without overtube
61996953|NCT04723212||Younger healthy adults|Healthy subjects in the age group of 18-30 years old, and without history of any neurological condition
62181928|NCT04662983|EXPERIMENTAL|Experimental group|The participants were subjected to a 15-minute training session, once a day for 5 consecutive days. HTC VIVE Pro (HTC Corporation, New Taipei, Taiwan) goggles and accessories were used. It is specialized equipment consisting of a high-resolution screen goggles and headphones, using an Intel WiGig Wireless connection, and the technology allows for free 360 degrees of movement. The interaction in virtual reality is performed using two controllers held by the player. The movement of the controllers and goggles is tracked by two sensors. The game area covered about 5m2, in the form of a rectangle, determined by the location of motion sensors, as recommended by the manufacturer. The participant received visual information when approaching the boundaries of the game field. A Beat Saber music game was used to conduct training sessions.
62181929|NCT03108638||R3 Supervisor Strategy Region 1|First cohort to be trained and monitored with remote coaching in the R3 model
61996954|NCT04723212||Older healthy adults|Healthy subjects aged 55 years and older, and without history of any neurological condition
62181930|NCT03108638||R3 Supervisor Strategy Region 2|Second cohort to be trained and monitored with remote coaching in the R3 model
62181931|NCT03108638||R3 Supervisor Strategy Region 3|Third cohort to be trained and monitored with remote coaching in the R3 model
62181932|NCT03108638||R3 Supervisor Strategy Region 4|Fourth cohort to be trained and monitored with remote coaching in the R3 model
62181933|NCT06342245|EXPERIMENTAL|radiofrequency coblation micro-tenotomy + endoscopic Achilles debridement|The patient will lie prone on the surgical table, and the area of tendinopathy will be visualized with endoscopy. Endoscopic-assisted creation of a percutaneous mesh (quincunx) pattern of 1mm skin incisions will be made over the area of tendinopathy with a 5mm distance between each incision. Radiofrequency micro-tenotomy with low-temperature controlled ablation will be performed with the TOPAZ (Smith and Nephew) wand, which has a 1mm tip, and full thickness 1mm RF tendon debridement at 5mm intervals will be performed. Incisions will be fixed with sterile strips
62181934|NCT06342245|NO_INTERVENTION|endoscopic Achilles debridement only|"Minimally invasive and endoscopic procedures yield lower complication rates with similar patient satisfaction compared to open procedures. Minimally invasive and endoscopic procedures were recommended as the future surgical treatment of Achilles midportion tendinopathy.~Both the control and the intervention group will undergo endoscopic Achilles tendon debridement. The procedure will be performed in the operating theatre under general or regional anesthesia. The patient will lie prone on the operating table, and the leg will be prepared and draped under sterile technique. Two co-axial 0.5cm endoscopic portals will be created as per standard protocol, and a 4mm scope will be introduced for visualization."
62181935|NCT04180306|OTHER|Inpatient pediatric oncology patients|All patients admitted to the pediatric oncology ward will be in the cohort
62181936|NCT00066378|EXPERIMENTAL|Arimidex + Iressa® 250 mg|Arimidex + Iressa® 250 mg Treatment should be administered until documented disease progression, unacceptable toxicity as judged by the responsible physician or patient refusal
62181937|NCT00066378|ACTIVE_COMPARATOR|Arimidex + Placebo|Treatment should be administered until documented disease progression, unacceptable toxicity as judged by the responsible physician or patient refusal
62181938|NCT02751801||Adults and children with hypophosphatasia|Healthcare use interview
62181939|NCT00610025|ACTIVE_COMPARATOR|1|10 patients with no previous abdominal surgeries, pre-insufflation of the abdomen using a veress needle (standard procedure for insufflating the abdomen for laparoscopic surgery)
62181940|NCT00610025|ACTIVE_COMPARATOR|2|10 patients with history of previous abdominal surgeries, pre-insufflation of the abdomen using veress needle (standard procedure for insufflating the abdomen for laparoscopic surgery)
62181941|NCT00610025|ACTIVE_COMPARATOR|3|10 patients with no previous history of abdominal surgeries, no veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
62566725|NCT00529503|PLACEBO_COMPARATOR|2|placebo, rituximab, etoposide, carboplatin, ifosfamide
62566726|NCT02017158|EXPERIMENTAL|Virtual Sprouts|The Virtual Sprouts intervention arm will play Virtual Sprouts in a school-based implementation of the game.
61996955|NCT05932446|EXPERIMENTAL|LY3819469 (Reference)|LY3819469 administered subcutaneously (SC).
61996956|NCT05932446|EXPERIMENTAL|LY3819469 (Test)|LY3819469 administered SC.
61996957|NCT01344447|EXPERIMENTAL|Arm 1|
61996958|NCT05618106|EXPERIMENTAL|low FODMAP diet|Cross-over design with 3 variations
61996959|NCT05225896||DNER ataxia|Patients with well-characterized DNER antibodies.
61996960|NCT02984384|ACTIVE_COMPARATOR|Low Molecular Weight Heparin (LMWH)-Enoxaparin|Injection of 30 mg enoxaparin, twice a day via injection
61996961|NCT02984384|ACTIVE_COMPARATOR|Acetylsalicylic acid (ASA)-Aspirin|Enteral ingestion or administration of 81 mg ASA, twice a day
61996962|NCT04990934||Video Telemedicine|20 participants will have used video telemedicine for appointments with their treating oncologist.
61996963|NCT04990934||Telephone Telemedicine|10 participants will have used telephone telemedicine for appointments with their treating oncologist.
61996964|NCT05072353|EXPERIMENTAL|Treatment|DFU Patients are subjected to digital or transmetatarsal amputation. The treatment is provided during the amputation surgical session according to the SEFFI technique. The SEFFICARE® system (SEFFILINE S.r.l., Via delle Lame, 98, 40122 Bologna, Italy) is a disposable commercially available device. The device is provided in a sterile bag without any drugs. The SEFFI is a 5-step technique meaning preparation, anesthesia, harvesting, washing, and fluidification. The resulting tissue (2.5 mL per syringe) is ready for grafting. The stumps are closed by primary intention following adipose tissue injection.
61996965|NCT03606681|ACTIVE_COMPARATOR|Calcium Hydroxide (Dycal)|Indirect pulp capping treatment with Calcium Hydroxide
61996966|NCT03606681|EXPERIMENTAL|Mineral Trioxide Aggregate (ProRoot MTA)|Indirect pulp capping treatment with Mineral Trioxide Aggregate
61996967|NCT03606681|EXPERIMENTAL|Theracal LC|Indirect pulp capping treatment with Theracal LC
61996968|NCT01726699||Cancer Diagnosis|
61996969|NCT01904708|NO_INTERVENTION|Sedentary Visit|Subjects will do quiet, sedentary activities for 8 hours. Hourly blood draws and breath sampling will be collected. Bolus C13-Lysine will be given at hour 4.
61996970|NCT01904708|ACTIVE_COMPARATOR|Exercise Visit|Subjects will do quiet, sedentary activities until hour 5. Blood and breath samples will be collected. At hour 4, subject will consume a bolus of C13-Lysine and immediately walk on a treadmill at a moderate intensity (exercise at 75% of max heart rate) for 45 minutes.
61996971|NCT02479152|ACTIVE_COMPARATOR|LUCAS 2 AD|LUCAS 2 AD will be used for CPR
61996972|NCT02479152|OTHER|LUCAS2|LUCAS2 will be used for CPR
61996973|NCT00721695|EXPERIMENTAL|1|OMS302 Irrigation Solution
61996974|NCT00721695|ACTIVE_COMPARATOR|2|OMS302-PE HCl Irrigation Solution
61996975|NCT00721695|PLACEBO_COMPARATOR|3|Standard topical mydriatics and BSS Irrigation Solution
61996976|NCT04300972|OTHER|fixed dose|
61996977|NCT04300972|EXPERIMENTAL|weight and body type adapted dose|
62181942|NCT00610025|ACTIVE_COMPARATOR|4|10 patients with history of previous abdominal surgeries, no veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
62181943|NCT00610025|ACTIVE_COMPARATOR|5|10 patients, all with no previous mid to upper abdominal surgeries, no Veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
62181944|NCT00610025|ACTIVE_COMPARATOR|6|10 patients, all with previous mid-to-upper abdominal surgeries, no Veress needle pre-insufflation, endoscopic take-down of intra-abdominal adhesions (if identified)
62181945|NCT05514171||Neoadyuvant therapy|Patients with borderline or resectable ADK subjected to neoadyuvant therapy
62181946|NCT05514171||Upfront surgery|Patients with borderline or resectable ADK who undergo upfront surgery
62181947|NCT06208878||Non Interventional|All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study.
61996978|NCT03591575|EXPERIMENTAL|Deferiprone|Subjects in this group will receive deferiprone oral solution at a dosage up to 75 milligrams per kilogram of body weight (mg/kg) per day, divided into 3 equal doses
61996979|NCT03591575|PLACEBO_COMPARATOR|Placebo|Subjects in this group will receive placebo solution at a volume equal to what they would receive if they were in the active arm, divided into 3 equal doses
61996980|NCT00534235|ACTIVE_COMPARATOR|Posterolateral Fusion w/Pedicle Screws|Control: Posterolateral fusion and implantation of pedicle screws after decompression
61996981|NCT00534235|ACTIVE_COMPARATOR|coflex Interlaminar Technolgy|Investigative: Implantation of coflex Interlaminar Technology after decompression
62181948|NCT02841345|OTHER|Bipolar|bipolar patients type I or II (DSM-IV TR), euthymic phase
62181949|NCT02841345|OTHER|Schizophrenic|schizophrenic loss or paranoid or undifferentiated patients
62181950|NCT02841345|OTHER|Control|control group (paired in age and sex for patients)
61996982|NCT01474642|ACTIVE_COMPARATOR|Capecitabine/Cisplatin(XP)|Capecitabine AND Cisplatin
61996983|NCT01474642|ACTIVE_COMPARATOR|Capecitabine/Paditaxel(XG)|Capecitabine + Paditaxel(genexol)
61996984|NCT01147653|ACTIVE_COMPARATOR|Autologous UCB Reinfusion First,Then Placebo|Subjects receive their autologous umbilical cord blood cells at Baseline, than placebo at Year 1.
61996985|NCT01147653|PLACEBO_COMPARATOR|Placebo First, Then Autologous UCB Reinfusion|Subjects receive placebo at Baseline, then autologous umbilical cord blood cell reinfusion at Year 1.
61996986|NCT00703547|EXPERIMENTAL|Subjects receiving treatment in cohort 1|Subjects will receive one of the following sequences; ABDF,BADF, BDAF or BDFA (A=Placebo, B= GSK586529 dose 1 (3 milligrams), D = GSK586529 dose 3, F = GSK586529 dose 5).
61996987|NCT00703547|EXPERIMENTAL|Subjects receiving treatment in cohort 2|Subjects will receive one of the following sequences; ACEG,CAEG, CEAG or CEGA (A = Placebo, C= GSK586529 dose 2, E = GSK586529 dose 4, G = GSK586529 dose 6)
61996988|NCT02202928|SHAM_COMPARATOR|Chemo-radiotherapy|After accepting concurrent radiotherapy and chemotherapy according to NCCN guidelines, patients will just regularly follow up.
61996989|NCT02202928|EXPERIMENTAL|DC-CIK|After accepting concurrent radiotherapy and chemotherapy according to NCCN guidelines, patients will receive 3 cycles of autologous tumor lysate pulsed DC-CIK treatment.
61996990|NCT05209685|EXPERIMENTAL|Experimental|Resistance exercise with blood flow restriction
61996991|NCT05209685|ACTIVE_COMPARATOR|Control|Traditional resistance exercise
61996992|NCT02290288|ACTIVE_COMPARATOR|SSF|1. vaginal surgery arm (SSF)
61996993|NCT02290288|ACTIVE_COMPARATOR|LSC|laparoscopic surgery arm (LSC)
62181951|NCT03023423|EXPERIMENTAL|Treatment Arm A: Atezolizumab|Participants in Treatment Arm A will receive Atezolizumab 1,200 milligram (mg) intravenously (IV) on Day 1 of every 21-day cycle. Participants with confirmed disease progression based on RECIST 1.1 may cross over to Arm B and receive daratumumab and atezolizumab, provided crossover eligibility criteria are met.
62181952|NCT03023423|EXPERIMENTAL|Treatment Arm B: Atezolizumab and Daratumumab|Participants will receive daratumumab 16 milligram per kilogram \[mg/kg\] (Safety Run-in and Treatment Arm B) Intravenously (IV) weekly for 3 cycles (Day 1, 8 and 15), and Day 1 of every 21-day cycle thereafter. Atezolizumab will be administered at 1200 mg IV on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter. Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met.
61996994|NCT00972803|EXPERIMENTAL|pistacia Mutica|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
61996995|NCT00972803|PLACEBO_COMPARATOR|placebo|The subjects were asked to use a mouthwash containing Placebo twice a day for 4 days.
61996996|NCT00972803|ACTIVE_COMPARATOR|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
61996997|NCT00832403||polytetrafluoroethylene|
61996998|NCT04552366|EXPERIMENTAL|Group A: Intramuscular administration|24 subjects. 5E10 VP of Ad5-nCoV on Day 0 and on Day 56.
61996999|NCT04552366|EXPERIMENTAL|Group B: Mixed administration|24 subjects. An intramuscular administration of 5E10 VP of Ad5-nCoV on day 0 and a mucosal administration of 2E10 VP on Day 28.
61997000|NCT04552366|EXPERIMENTAL|Group C: Mucosal administration, high dose|24 subjects. A mucosal administration of 2E10 VP of Ad5-nCoV on Day 0 and Day 28.
62181953|NCT02592499|EXPERIMENTAL|HM III|Patients randomized to mechanical circulatory support will be treated with the HeartMate III (HM III) left ventricular assist device system.
62181954|NCT02592499|ACTIVE_COMPARATOR|OMM, Optimal Medical Management|"Patients randomized to OMM will be treated according to international guidelines.~ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J. 2012 Jul;33(14):1787-84"
62181955|NCT03167047|ACTIVE_COMPARATOR|Caudal block|"Caudal epidural given for post-operative pain relief. Dose used is 1.5ml/kg of weak Levo-Bupivacaine solution (0.125%).~Patients will also receive standardised pain relief of paracetamol and fentanyl"
62181956|NCT03167047|ACTIVE_COMPARATOR|Nerve block|"Peripheral nerve block given for post operative pain relief. Levo-Bupivacaine 0.25% 2mg/Kg given under ultrasound guidance.~Patients will also receive standardised pain relief of paracetamol and fentanyl"
62181957|NCT02592681|EXPERIMENTAL|verum acupuncture|Participants will receive real needle insertion. The needles will be left in the acupoint for 20 min, with a manual rotation at a ten-min interval. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian).
62181958|NCT02592681|ACTIVE_COMPARATOR|acupressure|Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Duration of each session will be 15 min.
62181959|NCT02592681|SHAM_COMPARATOR|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan).
62181960|NCT01359683|OTHER|A|This is a prospective observational study. 100 patients in one arm scheduled for cardiac surgery will be enrolled. ECG tracings will be obtained when subject is at rest, in supine position, before induction of anesthesia (within 24 hours prior to induction), after induction of general anesthesia, right before emergence from anesthesia (or before transportation to the ICU if the subject remains intubated), and within 24 hours post-operatively; additional ECG readings may be obtained during the surgery if deemed necessary.
62181961|NCT03530462||patient with first-line and second-line|patients who received intravenous second-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis),in addition to first-line immunotherapy (rituximab, cyclophosphamide)
62181962|NCT03530462||patients with first-line only|patients who received first-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis)only
62181963|NCT03530462||healthy control|healthy individuals without a history of psychiatric or neurologic disease
62181964|NCT01171183|PLACEBO_COMPARATOR|Placebo|
62181965|NCT01171183|ACTIVE_COMPARATOR|Carvedilol controlled release|controlled release carvedilol (Coreg CR) at 80 mg/day in once daily dosing
62181966|NCT03607617||Wedge 1|Five randomized clinics will implement SDH tool.
62181967|NCT03607617||Wedge 2|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
62181968|NCT03607617||Wedge 3|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
62566727|NCT02017158|NO_INTERVENTION|Control group|The control group will consist of students who will not play the Virtual Sprouts game at school.
61997001|NCT04552366|EXPERIMENTAL|Group D: Mucosal administration, low dose|24 subjects. A mucosal administration of 1E10 VP of Ad5-nCoV on day 0 and Day 28.
62181969|NCT03607617||Wedge 4|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
62181970|NCT03607617||Wedge 5|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
62181971|NCT03607617||Wedge 6|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
62181972|NCT01966978|ACTIVE_COMPARATOR|Control: Metformin, Insulin Detemir, Insulin Aspart|Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
62181973|NCT01966978|ACTIVE_COMPARATOR|Metformin, insulin determir, Liraglutide|"Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)"
62181974|NCT05441098||Neoadjuvant therapy|Patients with breast cancer treated with neoadjuvant therapy attending each center from 2010-2020.
62181975|NCT05238155||Orthotopic Liver Transplantation recipients prior to protocol implementation date|Orthotopic Liver Transplantation recipients are discharged following transplantation, they are typically prescribed a triple immunosuppression maintenance regimen, consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid.
62181976|NCT05238155||Orthotopic Liver Transplantation recipients after protocol implementation date|Over the last several years, there have been changes made to this protocol, and the current protocol now suggests consideration for the omission of the antimetabolite at discharge if there is a donor-recipient age discrepancy that is greater than 30 years. This change was made with the intention to reduce the risk of GVHD, given that a greater disparity in donor-recipient age may put these patients at a higher risk for GVHD.
62181977|NCT05870228|OTHER|Single-arm intervention group|Single-arm intervention
62566728|NCT02931344|EXPERIMENTAL|Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
62566729|NCT00890383|NO_INTERVENTION|Crystalloid only|patients will receive crystalloid fluids only for volume therapy of severe trauma
61997002|NCT04552366|ACTIVE_COMPARATOR|Group E: Intramuscular administration, one dose|24 subjects. An intramuscular administration of 5E10 VP of Ad5-nCoV on day 0.
61997003|NCT04552366|EXPERIMENTAL|Group F: Intramuscular administration, two doses|24 subjects. Two intramuscular administrations of 5E10 VP of Ad5-nCoV at left and right arms on day 0.
62566730|NCT00890383|ACTIVE_COMPARATOR|Colloid + Crystalloid arm|Goal directed volume therapy for severe trauma resuscitation
62566731|NCT00593723|EXPERIMENTAL|IMRT + Concurrent chemotherapy|"180 cGy daily fractions to a total dose of 5400 cGy to PTV1 and 200 cGy daily fractions to a total dose of 6000 cGy to PTV2. Once a day, five days a week, for approximately 6 weeks.~Planned chemotherapy: cisplatin (75 mg/m2) day 1 and 5-FU (1000 mg/m2) days 1-4 on weeks 1, 5, 10, and 14 of therapy. Please note that drug regimens and doses may vary and will be at the discretion of the medical oncologist."
62566732|NCT03285516|EXPERIMENTAL|START|The Safety Aid Reduction Treatment (START) protocol will consist of eight group sessions, delivered once weekly, lasting approximately one hour in duration. START will be delivered in-person by the PI and group co-leader.
61997004|NCT02413827|EXPERIMENTAL|Phase l: varlilumab and ipilimumab|
61997005|NCT02413827|EXPERIMENTAL|Phase ll: varlilumab & ipilimumab, +/- CDX-1401 & poly-ICLC.|
61997006|NCT04935476|ACTIVE_COMPARATOR|Treatment|"Participants will receive standard of care and Dapsone per os (PO) twice daily for 21 days. If a dose is missed, it should not be replaced.~Dosage form: Dapsone oral tablet"
61997007|NCT04935476|PLACEBO_COMPARATOR|Control|"Participants will receive standard of care and placebo per os (PO) twice daily for 21 days. If a dose is missed, it should not be replaced.~Dosage form: Placebo oral tablet"
61997008|NCT04514575||High-FFP|Patients transfused with an FFP:RBC ratio of 2:3 to 3:3 (0.7 - 1.0)
61997009|NCT04514575||Low-FFP|Patients transfused with an FFP:RBC ratio at or below 1:3 (0.0 - 0.3).
61997010|NCT01071512|EXPERIMENTAL|Tysabri|Natalizumab 300 mg IV every 4 weeks
61997011|NCT04637958||pain|THA
61997012|NCT04637958||no pain|THA
61997013|NCT05799092|EXPERIMENTAL|Invasive approach group|Invasive coronary angiography will be performed as next diagnostic step in symptomatic patients with non-high risk obstructive CAD on CCTA..
61997014|NCT05799092|ACTIVE_COMPARATOR|Non-invasive approach group|Usual care of non-invasive ischemia testing (exercise electrocardiography \[ECG\], stress echocardiography by exercise or pharmacologic agent, nuclear test including SPECT or PET, stress cardiac magnetic resonance \[MR\]) will be performed as next diagnostic step in symptomatic patients with non-high risk obstructive CAD on CCTA.
61997015|NCT02239809|ACTIVE_COMPARATOR|Active Stimulation|Patients assigned to active stimulation arm will receive electrical stimulation during the study.
61997016|NCT02239809|PLACEBO_COMPARATOR|Placebo Stimulation|Patients assigned to the placebo arm did not receive stimulation electrical stimulation for 24 weeks. After this period the participants randomized to sham stimulation will be moved to the active stimulation and will be followed until study completion.
61997017|NCT05920434|EXPERIMENTAL|Foot reflexology group|Individuals in the foot reflexology group were treated by the researcher once a week for a total of 60 minutes, 30 minutes on each foot, for 6 weeks (28,29) (Figure 2C).
61997018|NCT05920434|EXPERIMENTAL|Foot bath group|In the first meeting, each participant in the foot bath group was informed about the way of doing a footbath in practice. Each participant in the foot bath group was asked to apply a foot bath for 10 minutes, 3 times a week, and twice a day for 6 weeks. A plastic foot bath tub (42 x 37 x 12 cm) without a massage function is provided for each of the participant s (Figure 2D). In order not to miss the applications, the participant was followed up by phone on the specified days (3 times a week, Monday-Wednesday-Friday). Th participant was told that the foot bath water should be at 40 degrees celsius and that his feet should be kept in water for 10 minutes, approximately 10 cm above the ankle (24). The participant came to the clinic for the forms and protective sensory examination in the 2nd, 4th, and last week.
61997019|NCT05920434|NO_INTERVENTION|Control group|Forms and protective sensory examination tests were applied to the participant s in the control group, as in the intervention groups, and no application was made other than standard nursing care.
61997020|NCT01606046|ACTIVE_COMPARATOR|vapocoolant spray|
61997021|NCT01606046|ACTIVE_COMPARATOR|topical anesthetic agent|
61997022|NCT01606046|NO_INTERVENTION|Control|no interventions
61997023|NCT04289116|EXPERIMENTAL|We Test|Each participant or couple will receive MI-CST + observation of ACT videos + CHTC. Youth have the choice of attending the baseline visit alone or with their partner and have the option to bring their partner in later after completing the baseline alone.
61997024|NCT04289116|ACTIVE_COMPARATOR|Individual HIV Testing and Counseling|Individual HIV Testing and Counseling (IHTC). Youth have the choice of attending the baseline visit alone or with their partner and have the option to bring their partner in later after completing the baseline alone.
61997025|NCT03041012|PLACEBO_COMPARATOR|antiretrovirals|Standard of care
61997026|NCT03041012|ACTIVE_COMPARATOR|antiretrovirals + romidepsin|Standard of care + LRA
61997027|NCT03041012|ACTIVE_COMPARATOR|antiretrovirals + 3BNC117|Standard of care + bNAb
61997028|NCT03041012|ACTIVE_COMPARATOR|antiretrovirals + romidepsin + 3BNC117|Standard of care + LRA + bNAb
62391351|NCT06098976|ACTIVE_COMPARATOR|Manual toothbrush|Manual toothbrush: The patients were taught to use the modified vertical method, and the patient brushed the teeth of the upper and lower jaws using traditional toothbrushes (Diamond, JolleyDent, Damascus, Syria), and anti-plaque toothpaste (Elgydium, UniPharma Co., Ltd, Ashrafiyat Sahnaya, Syria).
62566733|NCT02821026|EXPERIMENTAL|Omental islet transplant|At the time a suitable islet preparation becomes available, the patient will receive allogeneic islet cells placed in an omental pouch. Islet transplant will be performed under Anti-Thymocyte Globulin induction immunosuppression (5 doses, day -2 prior to transplant to day 2 post-transplant). Maintenance mycophenolate mofetil therapy (1-2 g/day as BID dosing) will be started on Day -1 pre-transplant. Tacrolimus will be administered orally twice daily on Day 1 post-transplant to maintain a trough level of 10-12 ng/mL for 3 months, then 6-10 ng/mL thereafter. Etanercept will be given IV before the islet transplant (50 mg), and then at 25 mg (subcutaneously) on POD +3, +7 and +10. Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
62566734|NCT05122182|EXPERIMENTAL|Interventional Arm|Titratable candesartan with commencing dose 4mg tablets twice daily (daily dose 8 mg) + fixed dose repagermanium one x 120mg immediate release capsule twice daily (total daily dose 240mg). Treatment will continue for 28 days.
61997029|NCT05961774|EXPERIMENTAL|High frequency repetitive transcranial magnetic stimulation|This group will receive high frequency repetitive transcranial magnetic stimulation.
61997030|NCT05961774|ACTIVE_COMPARATOR|Neuromuscular electrical stimulation|This group will receive neuromuscular electrical stimulation.
61997031|NCT01970683|EXPERIMENTAL|VSL #3|probiotics given orally BID
61997032|NCT01970683|OTHER|placebo|Near-identically appearing placebo
61997033|NCT00380393|EXPERIMENTAL|GSK257049 Group|Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of GSK257049 vaccine administered intramuscularly in the left deltoid muscle at Days 0, 30 and 60.
61997034|NCT00380393|ACTIVE_COMPARATOR|Rabipur Group|Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine administered intramuscularly in the left deltoid muscle at Days 0, 30 and 60.
61997035|NCT05111132|EXPERIMENTAL|7.5 ml/kg|Group 1, receiving a fluid challenge of 7,5 ml/kg in 5 minutes
61997036|NCT05111132|EXPERIMENTAL|12.5 ml/kg|Group 2, 12.5 ml/kg of fluid challenge in 5 minutes
61997037|NCT03999307|EXPERIMENTAL|Low-Level Laser Therapy (LLLT)|In the LLLT group, a low-level laser with wavelength of 808 nm, output of 250 mW, energy of 4 Joules per point and application time of 16 seconds per point will be applied on each tooth of the six maxillary anterior teeth according to this protocol: the root will be divided theoretically into 2 halves; gingival and cervical, and laser will be applied in the center of each half from both buccal and palatal sides which means 4 application points and a total energy of 16 Joules per tooth.
61997038|NCT03999307|EXPERIMENTAL|Flapless Corticopuncture|In the flapless corticopuncture group, 3 interdental punctures located between the roots of the six maxillary anterior teeth from both the buccal and palatal sides, will be done using a 1-mm diameter round surgical Tungsten bur with 1 mm depth and 1.5 mm space between each puncture. These punctures start 2 mm from the free gingiva. Besides, an additional 2 parallel set of punctures with the same dimensions of the interdental ones will be done in the extraction sockets from both the buccal and palatal sides.
61997039|NCT03999307|EXPERIMENTAL|Control|Patients in control group will undergo typical orthodontic treatment only with no LLLT or flapless corticopuncture application.
61997040|NCT02135224|ACTIVE_COMPARATOR|Fentanyl|20 microgram per hour
61997041|NCT02135224|PLACEBO_COMPARATOR|Normal saline|0.4 ml per hour
61997042|NCT00755066|EXPERIMENTAL|F|Fluticasone propionate 200 µg intranasal
62566735|NCT05122182|PLACEBO_COMPARATOR|Control Arm #1|Titratable candesartan with commencing dose 4mg tablets twice daily (daily dose 8 mg) + matched placebo repagermanium one capsule twice daily. Treatment will continue for 28 days.
61997043|NCT00755066|PLACEBO_COMPARATOR|P|Placebo intranasal spray
62391352|NCT06115343|EXPERIMENTAL|Experimental Group|Conscious Awareness application consists of 6 recordings of 30 minutes for 6 weeks.
62566736|NCT05122182|PLACEBO_COMPARATOR|Control Arm #2|Titratable matched placebo candesartan one tablet twice daily + matched placebo repagermanium one capsule twice daily. Treatment will continue for 28 days.
62566737|NCT05829083|EXPERIMENTAL|Hypercapnic COPD patient - Asymmetric or conventional nasal high flow cannula|Patients with acute exacerbation of COPD and mild to moderate hypercapnic respiratory failure will be randomized to NHF oxygen therapy with asymmetric cannula OR conventional cannula
62566738|NCT05829083|ACTIVE_COMPARATOR|Hypercapnic COPD patient - Conventional or asymmetric nasal high flow cannula|Patients with acute exacerbation of COPD and mild to moderate hypercapnic respiratory failure will be randomized to NHF oxygen therapy with conventional cannula or Asymmetric cannula
62566739|NCT00181857||1|Children of Adults with ADHD NOS
62566740|NCT02779920|EXPERIMENTAL|Per oral pylorotomy|Patients with gastroparesis (significant prolongation of gastric emptying) not improved prokinetic and antiemetic treatments undergoing per oral pylorotomy
61997044|NCT00983580|EXPERIMENTAL|Arm I (acetylsalicylic acid and eflornithine)|Patients receive acetylsalicylic acid PO once daily and eflornithine PO twice daily on days 1-28.
61997045|NCT00983580|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO three times daily on days 1-28.
61997046|NCT00062569|EXPERIMENTAL|1|
61997047|NCT00062569|EXPERIMENTAL|2|
61997048|NCT01171716|OTHER|Dietary Protein Intake|LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
61997049|NCT01427088|EXPERIMENTAL|repetitive TMS|repetitive TMS is a quantified stimulation method of specifie area of brain, for which CR Technology, TAMAS for repetitive TMS was used.
61997050|NCT04288622|EXPERIMENTAL|ESM-derived personalised feedback (ESM-F) group|Participants will be required to participate in an ESM data collection procedure. Participants will be required to complete a beep-questionnaire 3 days a week, over a 6-week period. The mobile app will be programmed to emit a beep 10 times per day at random intervals between 7.30 and 22.30. At each beep, participants will use the app to digitally complete a brief beep-questionnaire, which covers current affect, current context and activities. Moreover, participants will receive weekly standardized feedback on personalized patterns of positive affect.
61997051|NCT04288622|NO_INTERVENTION|ESM group|Participant will be required to participate in the same ESM data collection procedure as the ESM-F group. The personalised feedback report will be given to the participant after the whole study period (32 weeks) instead of weekly during data collection process.
61997052|NCT04288622|NO_INTERVENTION|Control (CON) group|Participants will not be required to participate in the 6-week ESM data collection procedure. They will also receive the personalised feedback report based on the ESM data collected at baseline and week 7.
61997053|NCT03442075||Group 1|Group 1 an analgesic suppository was applied
61997054|NCT03442075||Group 2|Group 2 was administered analgesic orally
61997055|NCT03442075||Group 3|Group 3 was given trans rectal gel
62391353|NCT06115343|NO_INTERVENTION|Control Group|Participants in the control group engage in 6 sessions of 30-minute social activity for 6 weeks.
62391354|NCT02637869||Control Group - non-intervention|Clinics that did not participate in the APM project
62181978|NCT05277077|EXPERIMENTAL|Experimental Group|In addition to the conservative treatment, the experimental group will follow PNE sessions (one session per week over six consecutive weeks). Each session will take between 45 min and 1 h. The physiotherapist with 6 years of clinical and PNE experience will conduct all sessions. PNE will be conducted in line with international guidelines and covered the neurophysiology of pain, transition from acute to chronic pain, and the nervous system ability to modulate the pain experience. The theoretical information will be complemented with pictures and diagrams based on previous procedures. A booklet with the contents of each session and containing a mixture of text, figures, and activities to perform between sessions will be developed for the purpose of this study and given to participants. Time devoted to PNE will decrease from session 1 (60 min) to session 6 (15 min).
62181979|NCT05277077|ACTIVE_COMPARATOR|Control Group|"The control group will follow a conservative treatment. The 90-minute-long training sessions will be held 5 days per week. The training program will include the following exercises: cold-pack for 20 minutes; 20 minutes of Conventional TENS; 3 minutes of soft tissue massage for deltoid and biceps muscles; scapula and glenohumeral joint mobilizations; towel sliding and duster slide exercises on the wall; wand-assisted bilateral shoulder elevation; external rotation in increasing abduction angles, internal rotation in abduction, horizontal adduction and functional internal rotation exercises; strengthening exercises; finger ladder exercises; activation of deltoid, rotator cuff, and scapular muscles at chest level as the degree of active elevation increases; anterior elevation using an elastic band; strength training in Full Can position; closed kinetic chain trainings; isometric exercises of the periscapular muscles, deltoid and trapezius; and posterior capsule stretching."
62181980|NCT01168245|EXPERIMENTAL|NICE-System NeuroAD|Treatment Group
62181981|NCT01168245|SHAM_COMPARATOR|Sham-TMS|Control Group
62181982|NCT03520062|EXPERIMENTAL|GLP-1 Receptor Agonist (Liraglutide)|3.0mg daily dose
62181983|NCT03788122|OTHER|Parents eligible for fetal surgery|Parents eligible for fetal surgery will undergo two or three in-depth face-tot-face interviews, to determine their perception of acceptability of fetal surgery.
62181984|NCT03632005|OTHER|Sterile Dressing|Standard of care treatment - Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
62181985|NCT03632005|ACTIVE_COMPARATOR|Vacuum Assisted Closure|The Prevena™ System, a type of vacuum assisted closure, is indicated for use over clean, closed incisions that continue to drain following sutured or stapled closure. It acts by removing exudate, helping hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment.
62181986|NCT03140566|EXPERIMENTAL|Clinical assessment plus IVC diameter|Decongesting treatment guided by clinical assessment and ultrasound evaluation of the inferior vena cava diameter
62181987|NCT03140566|SHAM_COMPARATOR|Clinical assessment only|Decongesting treatment guided by clinical assessment alone
62181988|NCT01560871|SHAM_COMPARATOR|Low-intensity IMT Plus Walking|"Inspiratory Muscle Training (IMT) intensity was set at 15% PImax. The walking program consisted of walking every day at an intensity of somewhat hard to hard on the Borg's Rating of Perceived Exertion (RPE) scale. Participants were encouraged to walk at 10 to 15 minutes, once to twice a day initially, then progressed to 45-50 minutes a day by the end of the six weeks, if they could tolerate."
62181989|NCT01560871|EXPERIMENTAL|High-intensity IMT Plus Walking|"Inspiratory Muscle Training (IMT) intensity was set at 60% PImax.~The walking program was the same as the one for the control group."
62181990|NCT03582345|EXPERIMENTAL|EEG/fMRI|The presented project will include only one arm constituted by patients affected by pharmacoresistant epilepsies elegible for respective surgery. Patients will be identified by RU1 and RU2. The definition of drug-resistant epilepsy requires: (a) the failure of at least two first-line AEDs; (b) the occurrence of an average of one seizure per month for \> 18 months; (c) no more than 3-month seizure free hiatus during those 18 months (Berg et al., 2006).
62181991|NCT02895321|EXPERIMENTAL|Patients with dentin hypersensitivity|"Patients with evident clinical signs of dentin hypersensitivity. The following dental materials will be used following the manufacturers' instructions: Cavex Bite\&White ExSense and Colgate Protection Caries and Placebo gel.~In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.~The effectiveness will be evaluated: immediately after application and after 2, 4, 8 weeks."
62181992|NCT05154240|ACTIVE_COMPARATOR|INS018_055|oral doses of INS018_055_single dose; oral doses of INS018_055_multiple ascending dose over 10days.
62181993|NCT05154240|PLACEBO_COMPARATOR|Placebo|No active ingredient. Frequency similar to the 2 arms above.
62181994|NCT02419209|EXPERIMENTAL|Individualised Homeopathic Remedy|A single individualised homeopathic remedy will be administered to each participant in the form of medicated sucrose pillules. The potency, dosage and frequency of administration will be individualised for each participant in accordance with the laws that govern homeopathic prescribing.
62181995|NCT05817474|EXPERIMENTAL|Group T|Group T: received lidocaine (2 %) 2 ml and tranexamic acid 2 ml in each tonsillar bed;
62181996|NCT05817474|PLACEBO_COMPARATOR|Group N|Group N (Control group): received 4 ml of normal saline in each tonsillar bed.
62182649|NCT00002716|EXPERIMENTAL|Arm II - conventional surgery + chemotherapy|"Patients receive CF IV and fluorouracil IV on days 1-5. Patients with unresected primary disease undergo resection within 3-4 weeks before initiation of chemotherapy.~Treatment for patients continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life and medical resource utilization are assessed at baseline, every 3 months for 1 year, and then at 18 months.~Patients are followed every 3 months."
61997056|NCT03442075||Group 4|Group was performed peri prostatic infiltration.
61997057|NCT03442075||Group 5|Group was performed by placebo oral
61997058|NCT04226482|ACTIVE_COMPARATOR|New Device|Laparoscopic appendectomy will be done using new ultrasonic shears.
61997059|NCT04226482|EXPERIMENTAL|Used Device|Laparoscopic appendectomy will be done using reprocessed ultrasonic shears.
62181997|NCT02972242|ACTIVE_COMPARATOR|Modified Field of View|In patients randomized to undergo the modified non-contrast CT scan to assess coronary calcification burden, this study will be performed by a radiologist and cardiologist as follows: axial acquisition obtained at 70% of the R-R interval using the following parameters: rotation time 0.35 sec; collimation of 64 x 0.625mm; detector coverage of 20.0 mm; axial thickness 2.5; tube voltage 80kV and tube current 250mA. The scan length will be from 1 cm below the carina to the level beneath the proximal coronary vessels defined as the greatest diameter of the apex of the right atrium.
62181998|NCT02972242|PLACEBO_COMPARATOR|Standard Field of View|In patients randomized to standard coronary artery calcium scoring, this scan will be performed in usual axial fashion obtained at 70% of the R-R interval using the following parameters: rotation time 0.35 sec; collimation of 64 x 0.625mm; detector coverage of 20.0 mm; axial thickness 2.5; tube voltage, 120 kV and tube current 250mA. The scan length, in accordance with current protocol, will be from 1 cm below the carina through the diaphragms.
62182650|NCT05313347||Healty Participants with varying BMI|30 healthy participants with a body mass index ranging from 17.5 to 35kg/m2.
62182651|NCT01149876|EXPERIMENTAL|Nu Skin Product|
62566741|NCT03045211|EXPERIMENTAL|In-Home Standing Table|"Participants in this arm will receive a dynamic standing table to be used in their home for at least two hours per day for at least five days per week for a 16-week period. Specific activities will be tracked with a logbook. PD subjects will be coached by a physical therapist on proper body positioning at the table, use of anti-fatigue mat, and optimal monitor height. The physical therapist will adhere to the neutral body positioning guidelines as provided by the OSHA. The physical therapist will also perform an in-home safety assessment of the office or room in which the table will be placed to ensure safety not only for the users but also for family members or children. The physical therapist will monitor each participant throughout the study by making biweekly compliance phone calls.~In addition, this group will received standard of care, which is weekly group exercise sessions during the 16-week period of table use."
61997060|NCT03298750|EXPERIMENTAL|Mechanical stimulation|Mechanical stimulation of ovarian tissue
61997061|NCT02588924||Second University of Naples|the present research project is aimed at measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
61997062|NCT02588924||Neuromed IRCCS|the present research project is aimed at measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
61997063|NCT02188615|EXPERIMENTAL|experimental group|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE
61997064|NCT02188615|ACTIVE_COMPARATOR|Radical Chemoradiotherapy|only Radical Chemoradiotherapy
61997065|NCT02188615|ACTIVE_COMPARATOR|Mckeown MIE|only Mckeown MIE
61997066|NCT00876304|EXPERIMENTAL|PF-04802540|
61997067|NCT00876304|PLACEBO_COMPARATOR|Placebo|
61997068|NCT03331692|OTHER|TIVA group|"The participants scheduled for elective ENT procedures or for elective discectomy. The surgery was performed under totally intravenous anesthesia.~During procedure, monitoring of the proper level of general anesthesia both clinical and instrumental was performed."
61997069|NCT03331692|OTHER|VA group|The participants scheduled for elective ENT procedures or for elective discectomy. The surgery was performed under volatile anesthesia. During procedure, monitoring of the proper level of general anesthesia both clinical and instrumental was performed.
61997070|NCT02452151|EXPERIMENTAL|Infliximab-biosimilar|Infliximab-Biosimilar (Inflectra) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment. In total 4 to 6 doses of the study drug will be administered while continuing patient's dosing intervals, ranging between 6 to 10 weeks.
61997071|NCT02452151|ACTIVE_COMPARATOR|Infliximab-Innovator|Infliximab-Innovator (Remicade) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment. In total 4 to 6 doses of the study drug will be administered while continuing patient's dosing intervals, ranging between 6 to 10 weeks.
62181999|NCT00579449|ACTIVE_COMPARATOR|HF 36|For those randomly assigned to the 3-year HFD group, services begin during the third trimester of pregnancy. These families are assigned a Family Support Worker, who begins to initiate contact with the family at approximately 6 months gestation, when possible, so that the family can be engaged and services begun at seven months gestation. The Family Support Worker will provide home visiting services according the existing HFD model, which combines the empirically supported Parents as Teachers Curriculum (see attached description of the Parents as Teachers curriculum) provided in accordance with Healthy Families America standards of service delivery. The 3-year HFD group will receive services to the child's third birthday.
61997072|NCT06000865|ACTIVE_COMPARATOR|Interactive action video-game training (AVG)|AVG using a Nintendo Switch gaming station will be administered in 20 sessions over 10 weeks (45 minutes per session, 2 sessions per week). Participants will be in standing position with game controllers or sensors attached to the body while playing games involving muscle stretching and strengthening exercises.
61997073|NCT06000865|EXPERIMENTAL|Conventional physical training (PT)|Participants in the PT will receive 45-minutes conventional physical training.
61997074|NCT02462967|ACTIVE_COMPARATOR|2 mg/kg GR MD 02|GR MD 02 in a dose of 2 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions
61997075|NCT02462967|ACTIVE_COMPARATOR|8 mg/kg GR MD 02|GR MD 02 in a dose of 8 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions
61997076|NCT02462967|PLACEBO_COMPARATOR|Placebo|Phosphate buffered saline solution administered every other week over a 52 week period for a total of 26 infusions
61997077|NCT01734551|ACTIVE_COMPARATOR|Morphine|Initial dose is 0.4mg/kg/day, divided every 3-4 hours, given PO with feeds. Drug is required until symptoms of withdrawal no longer cause the infant feeding, behavior, or elimination problems, up to 3 months.
61997078|NCT01734551|ACTIVE_COMPARATOR|Clonidine|Dose is started at 5 mcg/kg/day, given PO with feeds, divided every 3-4 hours. Drug is required until symptoms of withdrawal no longer cause the infant feeding, behavior, or elimination problems, up to 3 months.
61997079|NCT03221933|EXPERIMENTAL|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses.
62182000|NCT00579449|ACTIVE_COMPARATOR|HF 18|For those randomly assigned to the 18-month HFD group, services begin during the third trimester of pregnancy. These families are assigned a Family Support Worker, who begins to initiate contact with the family at approximately 6 months gestation, so that the family can be engaged and services begun at seven months gestation. The Family Support Worker will provide home visiting services according the existing HFD model, which combines the empirically supported Parents as Teachers Curriculum (see attached description of the Parents as Teachers curriculum) provided in accordance with Healthy Families America standards of service delivery. Services for this group are terminated when the child is 18 months old, with clinically necessary referrals made for ongoing psychosocial and health needs.
62182001|NCT00579449|ACTIVE_COMPARATOR|YC|For those assigned to the Yearly Checkup group, a clinically-trained member of the HFD team will make yearly home visits to conduct the evaluation assessment. Information about community services and assistance with referrals are provided based on needs identified.
62182002|NCT00579449|NO_INTERVENTION|MCC|Women placed in the community services as usual (Maternity Care Coordination only) group will receive no additional services or assessments as a part of this study.
62182003|NCT06055842|ACTIVE_COMPARATOR|lateral incisor group|Patients having two mandibular implants in lateral incisor positions.
62182004|NCT06055842|ACTIVE_COMPARATOR|canine group|Patients having two mandibular implants in canine positions
62182005|NCT03171532|ACTIVE_COMPARATOR|4 strand hamstring ACL reconstruction|The hamstring tendons will be harvested by standard technique and the lengths of the Semitendinosus and Gracilis tendons will be measured after clearing all adherent muscle tissue. The ends will be prepared and folded in middle to prepare4-strand graft.
62182006|NCT03171532|ACTIVE_COMPARATOR|5 strand hamstring ACL reconstruction|The hamstring tendons will be harvested by standard technique and the lengths of the Semitendinosus (ST) and Gracilis (GR) tendons will be measured after clearing all adherent muscle tissue. For 5-strand graft, minimum length of ST and GR in consideration would be 24 cm and 16 cm respectively. For 5-strand group the ST tendon will be be folded twice and sutured on itself to make a three strand graft and then GR tendon will be folded once along with it to make a final 5-strand graft.
62182007|NCT04888117||Laparoscopic cholecystectomy|Subject has a diagnosis of acute cholecystitis and is admitted through the ER for a laparoscopic cholecystectomy.
62566742|NCT03045211|NO_INTERVENTION|Standard of Care|this group will received standard of care only, which is weekly group exercise sessions during a 16-week period. Instructions, coaching, and compliance phone calls will also be provided to the participants of this arm such that both arms have the same amount of contact time with the physical therapist.
61997080|NCT03221933|EXPERIMENTAL|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided doses.
61997081|NCT03258827|EXPERIMENTAL|Exercise with a towel|There are 30 old adults in this group who receives exercise program with a towel.
61997082|NCT03258827|PLACEBO_COMPARATOR|Home-based exercise|There are 30 old adults in this group who is suggested a home-based program focuses on walking activity at fast speed.
61997083|NCT05326503|EXPERIMENTAL|Meal with polyphenol supplement (PPS)|Iron-rich test meal labelled with stable iron isotope as ferrous sulfate, consumed with the polyphenol supplement.
62182008|NCT04888117||Robotic-assisted cholecystectomy|Subject has a diagnosis of acute cholecystitis and is admitted through the ER for a robotic-assisted cholecystectomy.
61997084|NCT05326503|PLACEBO_COMPARATOR|Meal with placebo|Iron-rich test meal labelled with stable iron isotope as ferrous sulfate, consumed with placebo supplement (maltodextrin).
61997085|NCT05326503|EXPERIMENTAL|Drink with PPS|Iron-fortified drink labelled with stable iron isotope as ferrous sulfate, consumed with the polyphenol supplement.
61997086|NCT05326503|PLACEBO_COMPARATOR|Drink with placebo|Iron-fortified drink labelled with stable iron isotope as ferrous sulfate, consumed with placebo supplement (maltodextrin).
61997087|NCT01327404||Depressed|Patients with Major Depressive Disorder
61997088|NCT01327404||Diabetic|Patients with Type 2 Diabetes
61997089|NCT01327404||Diabetic/Depressed|Patients with both diabetes and major depressive disorder
61997090|NCT01327404||Healthy Controls|
61997091|NCT02389504|ACTIVE_COMPARATOR|Standard Physical Therapy Protocol|Regular Physical Therapy Protocol. Standard treadmill running, monitoring heart rate
61997092|NCT02389504|EXPERIMENTAL|Exertion Physical Therapy Protocol|Exertional Physical Therapy Protocol. Dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
61997093|NCT02513524||Direct Observed Therapy test|Patients with resistant hypertension (as defined in the eligibility criteria) will be enrolled. They will all have undergone 24 hour ambulatory blood pressure monitoring (ABPM) before enrollment. As part of the study, the subjects will undergo direct observed therapy testing, followed by another 24 hour ABPM, which will be repeated at 1 month.
61997094|NCT01963390||Testosterone therapy|The study population is a cohort of testosterone deficient men who are planning on undergoing testosterone therapy at an outpatient men's health clinic.
61997095|NCT03080558|EXPERIMENTAL|endometriosis recto vaginal node|
61997096|NCT04659785|EXPERIMENTAL|Fluzoparib + Apatinib|Fluzoparib and apatinib will be administered continuously and orally in combination, 28 days per cycle, until disease progression or unacceptable toxicity.
62182009|NCT02459405|EXPERIMENTAL|NIR anastomotic perfusion assessment|"Patient will have their anastomosis assessed after they receive 7.5 to 9 mg of Indocyanine green intravenously (at a concentration of 2.5mg/ml).~The microvascularisation assessment will be performed using a near infrared device(Pinpoint device), allowing to increase reality.~This procedure will be repeated twice during the surgery, the first time before and the second time after the anastomosis has been done."
62566743|NCT04998565|EXPERIMENTAL|Routine care|Routine care for early postpartum breast engorgement, including reverse pressure technique over areola, along with hand expression of breastmilk.
62566744|NCT04998565|EXPERIMENTAL|Routine care plus EA|"Routine care for early postpartum breast engorgement, including reverse pressure technique over areola, along with hand expression of breastmilk.~plus: Electrical acupuncture on body acupoints"
62566745|NCT04998565|EXPERIMENTAL|Routine care plus TENS|"Routine care for early postpartum breast engorgement, including reverse pressure technique over areola, along with hand expression of breastmilk.~plus: Transcutaneous electrical nerve stimulation on breasts"
62566746|NCT02498704|SHAM_COMPARATOR|Sham Needling intervention, Control|Sham dry needling, group does not receive true dry needling intervention.
61997097|NCT00253383|EXPERIMENTAL|ENABLE (concurrent palliative care)|telephone based ENABLE educational intervention
62566747|NCT02498704|EXPERIMENTAL|Dry Needling Intervention, experimental|Group receives true dry needling intervention.
62566748|NCT02178657|EXPERIMENTAL|Bone marrow transplantation low dose|Intra-arterial autologous bone marrow mononuclear cells injection (dose 2x10\^6 per kilogram)
61997098|NCT00253383|ACTIVE_COMPARATOR|Usual Care|Supportive and palliative usual care services at DHMC, Behavioral
61997099|NCT03645668|EXPERIMENTAL|Experimental group|meropenem injection, 1.0g, q8h,intravenous infusion ,0.5g/0.5h+0.5g/4h
61997100|NCT03645668|OTHER|Control group|meropenem injection, 1.0g, q8h,continuous intravenous infusion duration ,1h
61997101|NCT02355327|EXPERIMENTAL|Laselle Kegel Exerciser|
61997102|NCT02355327|ACTIVE_COMPARATOR|Pelvic floor muscle exercises|
61997103|NCT03909542||Ileostomy Closure|Patients who have undergone an ileostomy closure procedure.
62182010|NCT01449747|ACTIVE_COMPARATOR|study group|sitagliptin hypo-response patients
62182011|NCT01449747|SHAM_COMPARATOR|control group|sitagliptin response patients
62566749|NCT02178657|EXPERIMENTAL|Bone marrow transplantation high dose|Intra-arterial autologous bone marrow mononuclear cells injection (dose 5x10\^6 per kilogram)
62566750|NCT02178657|NO_INTERVENTION|Control|
62182012|NCT02101983|EXPERIMENTAL|Outpatient HiDAC Consolidation|Patients will receive 2 cycles of 1.5 grams/m2/day of intravenous cytarabine once daily for six consecutive days. Toxicity will be monitored through the duration of treatment. Observation will be complete upon count recovery and resolution of toxicity after the second cycle.
62182013|NCT02101983|ACTIVE_COMPARATOR|Quality of Life Comparison Group|Patients receiving outpatient intravenous cytarabine will complete the EORTC QLQ-C30 quality of life form on the last day of each cycle of chemotherapy.
62182014|NCT04263805|EXPERIMENTAL|Vignette with research climate|Participants in this arm will receive vignettes describing a dilemma situation in research (e.g adding honorary author) with additional sentence describing research climate (i.e. an environment where their peer had detrimental practice in a similar situation)
62182015|NCT04263805|ACTIVE_COMPARATOR|Vignette without research climate|Participants in this arm will receive vignettes describing a dilemma situation in research without the additional sentence describing research climate
62182016|NCT04672798|EXPERIMENTAL|BRITEPath|"Participants will receive the components in BRITEPath from a mental health (MH) clinical trained by the study staff/PI's on how to implement BRITE safety planning with fidelity.~First, the MH clinician will review possible barriers to implementation of the safety plan and problem-solve appropriately with patient and parent(s); (2) BRITE is the emotion regulation/safety planning app loaded on the patient's smartphone that populated with support from Guide2BRITE; and (3) BRITEBoard, a clinician dashboard that shows app use, change in distress and symptoms ratings, and can be used for shared decision making with parents, patients, and PCPs. Clinicians will review adolescent's skill development and app content with parents. Prior to discharge or following acute increases in suicide risk."
62182017|NCT04672798|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Participants in the TAU group will receive treatment from their mental health clinician which may include safety planning.
62182018|NCT04632212|EXPERIMENTAL|1|Tax (ON) Food Labels (ON) Ordering (ON) Substitution (ON)
62182019|NCT04632212|EXPERIMENTAL|2|Tax (ON) Food Labels (ON) Ordering (ON) Substitution (OFF)
62182020|NCT04632212|EXPERIMENTAL|3|Tax (ON) Food Labels (ON) Ordering (OFF) Substitution (ON)
62182021|NCT04632212|EXPERIMENTAL|4|Tax (ON) Food Labels (ON) Ordering (OFF) Substitution (OFF)
62182022|NCT04632212|EXPERIMENTAL|5|Tax (ON) Food Labels (OFF) Ordering (ON) Substitution (ON)
62182023|NCT04632212|EXPERIMENTAL|6|Tax (ON) Food Labels (OFF) Ordering (ON) Substitution (OFF)
62182024|NCT04632212|EXPERIMENTAL|7|Tax (ON) Food Labels (OFF) Ordering (OFF) Substitution (ON)
62182025|NCT04632212|EXPERIMENTAL|8|Tax (ON) Food Labels (OFF) Ordering (OFF) Substitution (OFF)
62182026|NCT04632212|EXPERIMENTAL|9|Tax (OFF) Food Labels (ON) Ordering (ON) Substitution (ON)
62182027|NCT04632212|EXPERIMENTAL|10|Tax (OFF) Food Labels (ON) Ordering (ON) Substitution (OFF)
62182028|NCT04632212|EXPERIMENTAL|11|Tax (OFF) Food Labels (ON) Ordering (OFF) Substitution (ON)
62182029|NCT04632212|EXPERIMENTAL|12|Tax (OFF) Food Labels (ON) Ordering (OFF) Substitution (OFF)
62182030|NCT04632212|EXPERIMENTAL|13|Tax (OFF) Food Labels (OFF) Ordering (ON) Substitution (ON)
62182031|NCT04632212|EXPERIMENTAL|14|Tax (OFF) Food Labels (OFF) Ordering (ON) Substitution (OFF)
62182032|NCT04632212|EXPERIMENTAL|15|Tax (OFF) Food Labels (OFF) Ordering (OFF) Substitution (ON)
62182033|NCT04632212|NO_INTERVENTION|16|Tax (OFF) Food Labels (OFF) Ordering (OFF) Substitution (OFF)
62182034|NCT00489645|PLACEBO_COMPARATOR|1|Placebo, euglycemia
62182035|NCT00489645|EXPERIMENTAL|2|Pramlintide, euglycemia
62182036|NCT00489645|PLACEBO_COMPARATOR|3|placebo, hyperglycemia
62182037|NCT00489645|EXPERIMENTAL|4|pramlintide, hyperglycemia
62182038|NCT04085705||Patients with diabetic foot ulcers|All patients with diabetic foot ulcers will undergo a PATCH test to determine the prevalence of contact allergies against wound dressings.
62182039|NCT01610830||Group A|have skin involvement +/- an extra renal disease (arthritis, digestive and/or HSP without renal disease. The absence of renal disease is defined by the absence of hypertension (BP \<95th percentile for height in children, BP \<140/90 mmHg in adults with no known history of hypertension), the absence of hematuria (\<5 RBCs per mm3), the absence of proteinuria (proteinuria \<0.1 g/24h) and the absence of renal dysfunction (MDRD\> 80 ml / min).
62182040|NCT01610830||group B|"HSP with renal impairment, defined by the presence of renal dysfunction (calculated clearance \<60 ml/min) and/or proteinuria (daily proteinuria greater than 0.3 g) and/or hematuria (more than 5000 RBC per ml or 5 RBC per mm3). We distinguish:~* Group B1 patients with moderate renal disease if renal biopsy was not indicated or no evidence of histologic severity in renal biopsy (histological classification class 1 or 25)~* Group B2 patients with severe renal impairment, with signs of histological severity in renal biopsy (class 3, 4 or 5)."
62182652|NCT01149876|EXPERIMENTAL|Nu Skin product with galvanic spa system|
62182653|NCT01149876|ACTIVE_COMPARATOR|Tretinoin cream 0.05|
62182654|NCT01149876|PLACEBO_COMPARATOR|over the counter moisturizer|
61997104|NCT05252533|EXPERIMENTAL|Cohort 1: Juvenile Psoriatic Arthritis (jPsA)|Participants (aged greater than or equal to \[\>=\] 5 to less than \[\<\] 18 years) will receive ustekinumab at the dose and frequency as prescribed by their treating health care professional (HCP).
62182041|NCT03889873|EXPERIMENTAL|Drinking; No network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using first-person pronouns.
62182042|NCT03889873|EXPERIMENTAL|Drinking; Network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using first-person pronouns.
62182043|NCT03889873|EXPERIMENTAL|Drinking; No network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using third-person pronouns.
62182044|NCT03889873|EXPERIMENTAL|Drinking; Network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using third-person pronouns.
62182045|NCT03889873|EXPERIMENTAL|Smartphone; No network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using first-person pronouns.
62182046|NCT03889873|EXPERIMENTAL|Smartphone; Network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using first-person pronouns.
62182047|NCT03889873|EXPERIMENTAL|Smartphone; No network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using third-person pronouns.
62566751|NCT01198223|OTHER|drug: garlic extract, nystatin|Drug: garlic extract 40mg/dl or nystatin suspension 100000 iu/ml tid for one month Patients had been clinically with denture stomatitis and confirmed by oral medicine specialist were selected for the study. Gender, age, medical history, erythema types, size, and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received garlic extract and second group used nystatin suspension for 1 month. Each patients was examined at the beginning of the therapy ,and then every 1 weeks up to 1 months .
62566752|NCT00116818|EXPERIMENTAL|Arm 1|
62566753|NCT00216125|OTHER|Pre-Randomization|Prior to randomization patients received Cisplatin 50 mg/m\^2 days 1,8,29,36 + Etoposide 50 mg/m\^2 days 1-5, 29-33 + Radiation 5940 cGy (180 cGy/day). Patients with CR, PR or SD with manageable toxicity were randomized to either Docetaxel arm or Observation only arm.
62566754|NCT00216125|ACTIVE_COMPARATOR|Consolidation Docetaxel|Docetaxel 75 mg/m\^2 q3wk X 3 cycles.
62566755|NCT00216125|NO_INTERVENTION|Observation Only|Patients were followed for Observation.
62566756|NCT03035825|EXPERIMENTAL|Oral Moisturizing Jelly|Daily intake of oral moisturizing jelly 5 times/day for two months
62566757|NCT03035825|ACTIVE_COMPARATOR|Artificial saliva|Daily use of non-edible oral lubricating gel 5 times/day for two months
61997105|NCT05252533|EXPERIMENTAL|Cohort 2: Pediatric Psoriasis (PsO)|Participants (aged \>=6 to \<18 years) will receive ustekinumab at the dose and frequency as prescribed by their treating HCP.
61997106|NCT05853133|ACTIVE_COMPARATOR|Group E|ESP block will be applied bilaterally, 20 ml of %0.25 bupivacaine between the erector spinae muscle and transverse process at the 11th thoracic level.
61997107|NCT05853133|ACTIVE_COMPARATOR|Group W|Subfascial and subcutaneous wound infiltration is performed (20 ml of 0.25% bupivacaine each).
62182048|NCT03889873|EXPERIMENTAL|Smartphone; Network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using third-person pronouns.
62182049|NCT03779477|EXPERIMENTAL|Coping with Stress Course|The Coping with Stress Program that consists of 8 sessions will be implemented to the experimental group. 8-10 adolescents will be included in this program. The session frequency will be one session per week. After the completion of 8 sessions, two 90-minute sessions will be carried out each month in the following two months.
62182050|NCT03779477|NO_INTERVENTION|Control|There will be no intervention in the control group. If the program will be effective, this group will also undergo the Coping with Stress Program after the termination of the study.
62182655|NCT03127878|ACTIVE_COMPARATOR|Active-control|High-intensity endurance exercise of lower-limb with strengthening exercise of upper- and lower-limb
62566758|NCT02897778|ACTIVE_COMPARATOR|Entinostat|Participants received a single oral supratherapeutic dose of 15 mg entinostat under fasted conditions.
62566759|NCT02897778|PLACEBO_COMPARATOR|Placebo|Participants received a single dose of placebo-matching entinostat under fasted conditions.
61997108|NCT00962130|EXPERIMENTAL|Blood Glucose Measurement|Subjects have sensors placed on skin before surgery and these sensors will measure the subject's glucose until the third day after surgery when they are removed.
61997109|NCT03689556||FLT PET/CT|Patients with locoregionally recurrent nasopharyngeal carcinoma (LR-NPC) will receive FLT PET/CT scans before CIRT and after completion of CIRT.
61997110|NCT03863028||Novice|Residents with no individual experience in TUR-B defined as no prior hands-on surgical experience in TURB
61997111|NCT03863028||Intermediates|Residents who have performed 10 to 30 TURBs.
61997112|NCT03863028||Experienced|Consultants with experience in the procedure defined as more than 100 TURBs.
62182051|NCT01005368||Group 1|Blood and bone marrow is collected at baseline, 3 months after completion of induction therapy, 2 months after completion of consolidation therapy, 1 year after completion of study treatment, and at disease relapse. Samples are analyzed by FISH for interphase cytogenetics, PCR for IgV_H mutational status, flow cytometry for surface expression of CD38 cells, western blot to assess Mcl-1, Bcl-2, BAK-1, ATM, ZAP-70, and Bar expression, and sequencing for p53 and ATM function.
61997113|NCT06106971|EXPERIMENTAL|Balloon-occluded retrograde transvenous obliteration|"Information of drug:~3% sodium tetradecyl sulfate injection Name: Fibro-vein injection Manufacturer: STD Pharmaceutical Products Ltd."
61997114|NCT06106971|ACTIVE_COMPARATOR|Endoscopic cyanoacrylate injection|"Information of drug:~N-butyl-2-cyanoacrylate Name: Histoacryl blue Manufacturer: Braun, Melsungen, Germany"
61997115|NCT05233436|EXPERIMENTAL|Part 1A Dose Escalation Monotherapy|Participants will receive PF-07265028 at escalating dose levels.
61997116|NCT05233436|EXPERIMENTAL|Part 1B Dose Escalation Combination|Participants will receive PF-07265028 at escalating dose levels in combination with sasanlimab fixed dose
61997117|NCT05233436|EXPERIMENTAL|Part 2A Dose Expansion Combination (SCCHN)|Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive PF-07265028 in combination with sasanlimab at the recommended dose from Part 1B
61997118|NCT05233436|EXPERIMENTAL|Part 2A Dose Expansion Combination (UC)|Participants with urothelial cancer (UC) will receive PF-07265028 in combination with sasanlimab at the recommended dose from Part 1B
61997119|NCT05233436|EXPERIMENTAL|Part 2A Dose Expansion Combination (Gastric/GEJ)|Participants with gastric/gastroesophageal junction cancer (Gastric/GEJ) will receive PF-07265028 in combination with sasanlimab at the recommended dose from Part 1B
61997120|NCT05233436|EXPERIMENTAL|Part 2A Dose Expansion Combination (NSCLC)|Participants with non small cell lung cancer (NSCLC) will receive PF-07265028 in combination with sasanlimab at the recommended dose from Part 1B
61997121|NCT05233436|EXPERIMENTAL|Part 2A Dose Expansion Combination (selected tumor types)|Participants with selected tumor types will receive PF-07265028 in combination with sasanlimab at the recommended dose from Part 1B
61997122|NCT05233436|EXPERIMENTAL|Part 2B Dose Expansion Monotherapy (selected tumor types)|Participants with selected tumor types will receive PF-07265028 single agent at the recommended dose from Part 1A.
61997123|NCT01192152|EXPERIMENTAL|5 mg saxagliptin + 2 Glucophage XR 500 mg tablet|
61997124|NCT01192152|EXPERIMENTAL|FDC tablet (5 mg saxa + 1000 mg metformin XR) (single dose)|under fed state, single dose
62182052|NCT04035330|EXPERIMENTAL|etidronate in sodium hypochlorite|It comes in a capsule containing 0.9 g of etidronate powder, which should be mixed immediately with 10 mL of a NaOCl solution of choice directly before treatment, resulting in a combined irrigant containing both active chlorine and approximately 9% etidronate. Irrigation with a total volume of 25 ml for each case
62182053|NCT04035330|ACTIVE_COMPARATOR|sodium hypochlorite|irrigation with 2.5% NaOCl with a total volume of 25 ml for each case
62182054|NCT04438382|EXPERIMENTAL|Arm A (infliximab)|Patients receive infliximab IV on day 1 followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive an additional dose of infliximab IV on day 14 at the discretion of the treating physician.
61997125|NCT01192152|EXPERIMENTAL|FDC tablet (5 mg saxa + 1000 mg metformin XR) (4 days)|under fed state, 4 days
61997126|NCT02927028|OTHER|Chewing group|50 individuals, both male and female, between the ages of 18 and 60 years old, with a BMI between 18-35 kg/m2 from any ethnic/racial background will be recruited. Participants must have natural dentition and rate the hedonic value of all study foods between 3 and 7 on a 9-point category scale.
61997127|NCT01665274|ACTIVE_COMPARATOR|XELOX adjuvant group|"D2 resection~XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 6 cycles"
61997128|NCT01665274|EXPERIMENTAL|XELOX neoadjuvant|"XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 3 cycles chemotherapy before operation.~D2 resection~After operation:~CR/PR: XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 3 cycles chemotherapy after operation. SD/PD:,ST(Drug: S-1，40-75mg twice daily. d1-14 q3w Drug: Paclitaxel IV infusion 135mg/m2 d1; q3w) 3 cycles chemotherapy after operation."
61997129|NCT02872636|EXPERIMENTAL|Treatment Group|
61997130|NCT01347437|NO_INTERVENTION|Condition|In the comparison condition, participants will receive MEMS only.
61997131|NCT01347437|EXPERIMENTAL|Positive STEPS|"* Participants will receive one on one Positive STEPS counseling sessions (\~1 hour sessions per week for 5 weeks).~* Participants will receive motivational reminders to take medications sent via text message to their cell phones.~* Participants will receive the Medication Event Monitoring Systems (MEMS) pill cap monitoring device to measure antiretroviral medication adherence."
61997132|NCT06076694|EXPERIMENTAL|Group A|TNP-2198 capsules 400 mg + rabeprazole sodium enteric-coated tablets 20 mg + amoxicillin capsules 1 g; Twice daily (BID) for 14 days
61997133|NCT06076694|EXPERIMENTAL|Group B|TNP-2198 capsules 600 mg + rabeprazole sodium enteric-coated tablets 20 mg + amoxicillin capsules 1 g; BID for 14 days
61997134|NCT06076694|EXPERIMENTAL|Group C|TNP-2198 capsule 600 mg + rabeprazole sodium enteric-coated tablets 20 mg; Three times daily (TID) for 14 days
61997135|NCT06076694|EXPERIMENTAL|Group D|TNP-2198 capsules 600 mg + rabeprazole sodium enteric-coated tablets 20 mg + amoxicillin capsules 1g; TID for 7 days
61997136|NCT06076694|ACTIVE_COMPARATOR|Control group|Rabeprazole sodium enteric-coated tablets 20 mg + amoxicillin capsules 1 g
62182055|NCT04438382|EXPERIMENTAL|Arm B (intravenous immunoglobulin therapy)|Patients receive intravenous immunoglobulin therapy IV over 2-5 days per institutional guidelines followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity.
62182056|NCT02014883|EXPERIMENTAL|GLUT1 DS|
62566760|NCT02538575|EXPERIMENTAL|6-minute walk test|
62182057|NCT03700372|EXPERIMENTAL|IOWA Approach Cardiac Ablation|Subjects who are treated with the IOWA Approach Cardiac Ablation System for paroxysmal atrial fibrillation.
62182058|NCT04363710|EXPERIMENTAL|Intervention group|Participants in this arm were advised intervention of Low Calorie Diet (800-1000 Kcal/day) for 8 weeks without any anti diabetic medication
62182059|NCT04363710|NO_INTERVENTION|Control Group|Participants in this arm were kept on their standard medical treatment
62182060|NCT03845023|PLACEBO_COMPARATOR|2-Night at Home|An initial 2-night, at-home blinded baseline period in which all subjects received placebo
62182061|NCT03845023|EXPERIMENTAL|3-Night Run In|AD036 Dose 1 (Low Dose: 25/5) or Placebo
61997137|NCT01650363|ACTIVE_COMPARATOR|Acupuncture, homeopathy, osteopathy and reflexology|patients will receive combinations of acupuncture, homeopathy, osteopathy and reflexology
62182062|NCT03845023|EXPERIMENTAL|7-Night|A 7-night treatment period in which subjects received the treatment to which they were randomized, i.e., 1 of the 3 different fixed-dose combinations of drugs, or placebo
62182063|NCT03845023|NO_INTERVENTION|End of Study|End of Study Visit
62182064|NCT04226898|EXPERIMENTAL|Synbiotic Supplement|The active synbiotic supplement consists of a stick/packet containing 4 strains of probiotic microorganisms: Lactobacillus acidophilus, LA-5® (material number 501082 FD LAK KGPharma); Lactobacillis paracasei subsp. paracasei, L. CASEI 431® (material number 684301 FD L. casei 431 HA Granulate); Lactobacillus rhamnosus, LGG® (material number 699817 FD LGG HA-W-IF); and Bifidobacterium animalis subsp. lactis, BB-12® (material number 699813 FD BB-12 HA-W-IF). In addition, the stick/sachet contains 5 g inulin. The product is a powder which participants will be asked to take with liquid or food. In this arm, the participant will take 1 powder stick of the synbiotic supplement once a day for 12 weeks after a 2-week placebo run-in.
62182065|NCT04226898|PLACEBO_COMPARATOR|Inert Compound|The inert compound placebo looks identical to the synbiotic supplement. In this arm, the participant will take 1 powder stick of the placebo daily for 12 weeks after a 2 week placebo run-in.
62182066|NCT04573556||Lemborexant|Participants with insomnia will initiate treatment with lemborexant 5 milligram (mg), tablet, orally as per the clinical judgment of the treating physician as part of routine clinical care. Dosage and administration of lemborexant tablet will be according to package insert and actual dosing and frequency will be decided by physician including dose escalation from initial dose of 5 mg up to 10 mg once daily. All participants will be observed prospectively for up to 24 weeks.
62182067|NCT02648711|EXPERIMENTAL|CRLX101 alone|Subjects will receive weekly infusion of CRLX101 alone. Starting dose is 12 mg/m\^2 and the next dose level is 15 mg/m\^2 (or 10 mg/m\^2 if 12 mg/m\^2 is not well tolerated. No other dose levels will be explored.
62182068|NCT02648711|EXPERIMENTAL|CRLX101 in combination with bevacizumab|Subjects receive weekly infusion of CRLX101 in combination with bi-weekly bevacizumab (10 mg/kg. The starting dose is 12 mg/m\^2 and the next dose level is 15 mg/m\^2. No other dose levels will be explored.
62182069|NCT02648711|EXPERIMENTAL|CRLX101 in combination with mFOLFOX6|Subjects receive weekly infusion of CRLX101 for 3 of every 4 weeks in combination with bi-weekly mFOLFOX6 (oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 and 5FU 400 mg/m\^2 bolus followed by 2400 mg/m\^2 continuous infusion). The starting dose is 12 mg/m\^2 and the next dose level is 15 mg/m\^2.
62182070|NCT01316887|EXPERIMENTAL|GSK573719/GW642444|125/25 mcg once-daily
62182071|NCT01316887|EXPERIMENTAL|GSK573719|125 mcg once-daily
62182072|NCT01316887|PLACEBO_COMPARATOR|Placebo|inactive
62182073|NCT05010668|EXPERIMENTAL|Cryoablation in combination with Sintilimab plus lenvatinib|
62182074|NCT02215213|ACTIVE_COMPARATOR|Intervention Group|Arm 1 is receiving vitamin D supplementation in 2000 IU/day ,
62182075|NCT02215213|ACTIVE_COMPARATOR|Arm 2 intervention group|Arm 2 is receiving vitamin D supplementation in 4000/IU per day
62182076|NCT02215213|ACTIVE_COMPARATOR|Arm 3 control group|Arm 3 is receiving vitamin D supplementation in 400 IU/day
62182077|NCT04018885|EXPERIMENTAL|ALA 2.5% 0.5h|Topical application of 2.5% ALA for 0.5 hour
62182078|NCT04018885|EXPERIMENTAL|ALA 2.5% 1.5h|Topical application of 2.5% ALA for 1.5 hours
62182079|NCT04018885|EXPERIMENTAL|ALA 2.5% 3h|Topical application of 2.5% ALA for 3 hours
61997138|NCT01650363|PLACEBO_COMPARATOR|homeopathic placebo medication|
61997139|NCT04753164|EXPERIMENTAL|100 mg twice daily (b.i.d.) ACT-539313|
61997140|NCT04753164|PLACEBO_COMPARATOR|Placebo|
61997141|NCT03666078||normal vaginal delivery|
61997142|NCT03666078||assisted vaginal delivery|
61997143|NCT03666078||elective cesarean delivery|
61997144|NCT03666078||emergency cesarean delivery|
61997145|NCT03650907|EXPERIMENTAL|Group exercise program by coach|
61997146|NCT03650907|SHAM_COMPARATOR|Self exercise|
62182080|NCT04018885|EXPERIMENTAL|ALA 5% 0.5h|Topical application of 5% ALA for 0.5 hour
62182081|NCT04018885|EXPERIMENTAL|ALA 5% 1.5h|Topical application of 5% ALA for 1.5 hours
62182082|NCT04018885|EXPERIMENTAL|ALA 5% 3h|Topical application of 5% ALA for 3 hours
62182083|NCT04018885|EXPERIMENTAL|ALA 10% 0.5h|Topical application of 10% ALA for 0.5 hour
62182084|NCT04018885|EXPERIMENTAL|ALA 10% 1.5h|Topical application of 10% ALA for 1.5 hours
62182085|NCT04018885|EXPERIMENTAL|ALA 10% 3h|Topical application of 10% ALA for 3 hours
62182086|NCT00957398||IBS-D|12 IBS-D patients who will all undergo MTS.
62182087|NCT00957398||IBS-C|12 IBS-C patients who will all undergo MTS.
62182088|NCT00713206|ACTIVE_COMPARATOR|Dental implant (Osseotite)|Dental implants placed simultaneously with graft augmentation material.
62182089|NCT00713206|NO_INTERVENTION|Control group|Dental implants placed into graft augmentation material that has four months to heal.
62182090|NCT00510198|ACTIVE_COMPARATOR|Control Arm 1: SOC and CC with OptiVol|Standard of Care and Cardiac Compass with OptiVol as the Control. Intervention is standard of care, such as symptom assessment with the addition of viewing Cardiac Compass trends and the OptiVol diagnostic.
62182091|NCT00510198|ACTIVE_COMPARATOR|Control Arm 2: SOC|Intervention is Standard of Care alone, such as assessment of symptoms, only. Device trending information, but OptiVol is not allowed.
61997147|NCT04371380|EXPERIMENTAL|OLI phase followed by Injection phase|Participants will be administered cabotegravir at a dose of 30 mg plus rilpivirine dose of 25 mg once daily with meal on Day 1 to Day 28 in OLI phase. There will be 10 to 14 days wash out period after OLI. This will be followed by an injection phase, wherein participants will receive 600 mg cabotegravir long acting given as one 3 milliliter (mL) IM injection plus 900 mg rilpivirine long acting given as one 3 mL IM injection on Day 1.
61997148|NCT05358496||NAFLD cohort|
61997149|NCT05358496||Validation cohort|
61997150|NCT05894681|EXPERIMENTAL|intervention group|To the intervention group; Training and Care Guide psychoeducation program based on Watson Human Care Theory, prepared for the prevention of postpartum depression, will be implemented as six interviews and each interview will be 90 minutes. Before the psychoeducation, the pregnant women were asked to fill out the Personal Information Form, Edinburgh Postpartum Depression Scale, and the Multidimensional Scale of Perceived Social Support. After the diagnosis with a detailed anamnesis, the Training and Care Guide for the Prevention of Postpartum Depression was applied to the pregnant women with the psychoeducation program and a guide booklet was given to them. The interview was done face to face. Pregnant women were given counseling over the phone when they had questions about education. In the last interview, pregnant women were asked to fill out the Patient Satisfaction Evaluation Form according to Watson Improvement Processes.
61997151|NCT05894681|EXPERIMENTAL|control group|Personal Information Form, Edinburgh Postpartum Depression Scale, and Multidimensional Scale of Perceived Social Support were filled in to the control group during the interview. Pregnant women were given routine care applied to pregnant women who applied for antenatal controls in FHCs. The interview was done face to face.
62182092|NCT02932085|ACTIVE_COMPARATOR|rTMS + Wash-out period + Sham|"* Five consecutive daily repetitive transcranial magnetic stimulation sessions (Neurostar TMS Therapy System, NeuroStar XPLOR System)~* Two weeks wash-out period~* Five consecutive daily sham stimulation sessions"
62182093|NCT02932085|SHAM_COMPARATOR|Sham + Wash-out period + rTMS|"* Five consecutive daily sham stimulation sessions (Neurostar TMS Therapy System, NeuroStar XPLOR System)~* Two weeks wash-out period~* Five consecutive daily repetitive transcranial magnetic stimulation sessions"
62182094|NCT06546423|ACTIVE_COMPARATOR|B/HPIV3/HMPV-PreF-A vaccine|A single dose of intranasal B/HPIV3/HMPV-PreF-A will be administered by a Vax300 VaxINator atomization device.
62182095|NCT06546423|ACTIVE_COMPARATOR|B/HPIV3/HMPV-F-B365 vaccine|A single dose of intranasal B/HPIV3/HMPV-F-B365 will be administered by a Vax300 VaxINator atomization device.
62566761|NCT03389204|ACTIVE_COMPARATOR|Breast surgery and exercise|Patient that underwent breast surgery only without other intervention with exercise of the upper limb and instruction to continue after discharge.
62566762|NCT03389204|ACTIVE_COMPARATOR|Breast surgery and no exercise|Patient after breast surgery alone are discharged without exercise and instructions.
62566763|NCT03389204|ACTIVE_COMPARATOR|Breast, axilar surgery with exercise|Patients that underwent surgery of the breast and axilar lymph node surgery with exercise of the upper limb and instruction to continue after discharge.
62566764|NCT03389204|ACTIVE_COMPARATOR|Breast, axillar surgery without exercise|The patients that underwent surgery of the breast and axilar nodes samples or dissection are discharged without exercise and instructions.
62566765|NCT06136091||Asthma group|Participants ages 6 to 17 year old in the asthma group will be seen in clinic quarterly for one year, during periods of disease control when they are not on systemic corticosteroids (SCS)
62182096|NCT06546423|PLACEBO_COMPARATOR|Placebo|A single dose of intranasal Lactated Ringer's Solution for Injection will be administered by a Vax300 VaxINator atomization device.
62182097|NCT03807817|EXPERIMENTAL|Moderate Alcohol|
62182098|NCT03807817|EXPERIMENTAL|Low Alcohol|
62566766|NCT06136091||Non-asthma group|Participants in the non-asthma group will be seen at two scheduled visits in clinic at 3 and 12 months and will have telephone visits at 6 and 9 months
62566767|NCT00874575|PLACEBO_COMPARATOR|1|Control
62566768|NCT00874575|EXPERIMENTAL|2|Beta-hydroxy-Beta-methylbutyrate, 3 g/d
62566769|NCT00874575|EXPERIMENTAL|3|Vitamin D, 2000 IU/d
62566770|NCT00874575|EXPERIMENTAL|4|Beta-hydroxy-Beta-methylbutyrate (3 g/d) + Vitamin D (2000 IU/d)
62566771|NCT01422564|ACTIVE_COMPARATOR|Metal on Metal|Metal on Metal articulation system
61997152|NCT02665416|EXPERIMENTAL|Part I: Selicrelumab, Vanucizumab/Bevacizumab|Participants will receive a fixed dose of vanucizumab, 2 grams via IV infusion on Days 1 and 15 of every 28-day cycle. Selicrelumab will be given SC in ascending dose levels on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment will continue as long as the participant experiences clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (expected 24 months). Due to the discontinuation of Vanucizumab development, Participants ongoing in Part I will switch from Vanucizumab to Bevacizumab. All the dose escalation has been performed using Vanucizumab.
61997153|NCT02665416|EXPERIMENTAL|Part II: Selicrelumab, Bevacizumab|Bevacizumab will be administered via IV infusion on days 1 and 15 of every 28-day cycle. Selicrelumab will be given SC after the Bevacizumab infusion at the dose determined in the Part I of the study on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment will continue as long as the participant experiences clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part II of the study (expected 18 months).
61997154|NCT01015352|ACTIVE_COMPARATOR|Arm A|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days for 6 courses and 12 additional maintenance courses in responders.
61997155|NCT01015352|ACTIVE_COMPARATOR|Arm B|"Azacitidine: 75mg/sqm SQ per day for 5 days every 28 days for 6 courses AND~Epoetin beta : 60000U weekly SQ injections (to be adapted according to Hb as described above)~12 additional maintenance courses are planned in responders"
61997156|NCT03437122|EXPERIMENTAL|All|
61997157|NCT02679911|EXPERIMENTAL|Loceryl NL|Amorolfine hydrochloride NL 5% to be applied once weekly for 12 weeks on all affected toenails of one foot
61997158|NCT02679911|ACTIVE_COMPARATOR|Ciclopirox NL|Ciclopirox NL 8% to be applied once daily for 12 weeks on all affected toenails of the opposite foot
62182099|NCT03807817|ACTIVE_COMPARATOR|Placebo Alcohol|
62182100|NCT03807817|ACTIVE_COMPARATOR|No Alcohol|
62182101|NCT06122454|ACTIVE_COMPARATOR|Tenofovir alafenamide Fumarate tablets|TAF is taken orally under postprandial conditions, and subjects begin eating breakfast within 30 minutes of taking the drug. The 25mgQD group is given a single daily dose for 24 consecutive weeks, and continues to take the drug for 48 weeks after completing the 24-week treatment.
62182102|NCT06122454|EXPERIMENTAL|Hepenofovir Fumarate Tablets|After taking HTS tablets orally under postprandial conditions, subjects began to eat breakfast within 30 minutes before taking the drug. The 10mgQD and 20mgQD dose groups were administered once daily for 24 consecutive weeks, and continued to be administered for 48 weeks after completing the 24-week treatment. The 40mgQOD group was administered once every other day for 24 weeks, and continued to be administered for 48 weeks after completing the 24-week treatment.
62182103|NCT04865510|ACTIVE_COMPARATOR|Citrate|The RCA group CRRT were performed with Prisma flex or (Baxter Healthcare/Gambro Spain) or Informed machine with citrate pump. The function mode was continuous venovenous hemodiafiltration (CVVHDF) in postdilution mode with ST 150 filter sets. The substitution fluid was Accusol or Prismocal B22 .The dose of dialysis was 20-25 ml/kg/hr with blood flow 150-200 ml/min. Trisodium citrate solution (4%,136mmol/L) was infused into the arterial line prior to the blood pump at a dose of 4 mmol/L of plasma flow. Calcium chloride (5% 340 mmol/L elemental calcium) was infused into the venous return to maintain systemic ionized calcium in the normal range (0.99-1.30 mmol/L) and the targets values for ionized calcium (iCa2+) after the dialysis membrane were 0.25-0.35 mmol/L. The rale of calcium infusion was adjusted in a timely manner based on repeated measurements of calcium concentration
62182104|NCT04865510|PLACEBO_COMPARATOR|Heparin-free|The heparin- free group The circuit was periodically flushed with 50 ml saline via access limb every 30 minutes .When pre-filter pressure started to rise, additional saline flushes would be given.
62182105|NCT02089438|EXPERIMENTAL|Saxagliptin|Ssaxagliptin is given before breakfast
62182106|NCT02089438|EXPERIMENTAL|´Sitagliptin|Sitagliptin is given before breakfast
62182107|NCT02089438|EXPERIMENTAL|Vildagliptin|Vildagliptin is given before breakfast
62566772|NCT01422564|ACTIVE_COMPARATOR|HCLPC|THA using Highly Cross Linked Polyethylene cup System
62566773|NCT03628664|ACTIVE_COMPARATOR|CT planned total knee arthroplasty|Surgeon will follow the CT plan
62566774|NCT03628664|NO_INTERVENTION|Non CT planned total knee arthroplasty|Surgeon will not follow the CT plan
62566775|NCT02147834|ACTIVE_COMPARATOR|Ranolazine|"Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
62566776|NCT02147834|PLACEBO_COMPARATOR|Sugar pill|"Sugar pill that looks like the drug ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
61997159|NCT02455310||Outpatients with dementia|Medication use will be evaluated among outpatients with dementia in intervention and control counties, as well as statewide to evaluate the long-term effectiveness of the statewide intervention.
61997160|NCT02455310||Nursing home residents|Medication use and behavioral outcomes will be evaluated among nursing home residents in intervention and control counties, as well as statewide to evaluate the long-term effectiveness of the statewide intervention.
61997161|NCT01591473|EXPERIMENTAL|FluMist + Ampligen, Group 1|Nasal administration; dose group 1; FluMist + Poly I:Poly C12U 50 ug; 3 doses separated by 28 days
61997162|NCT01591473|EXPERIMENTAL|FluMist + Ampligen, Group 2|Nasal administration; dose group 2; FluMist + Poly I:Poly C12U 200 ug; 3 doses separated by 28 days
62182108|NCT03271749|NO_INTERVENTION|Conventional|The participants of this arm will receive the convencional pre operative, anesthesia and postoperative care for lung resections for treatment of lung neoplasms
62566777|NCT05844293|OTHER|Cohort 1|6 subjects injected with 25 mg dose of FXI-GalNAc-siRNA 2 subjects with Saline
62566778|NCT05844293|OTHER|Cohort 2|6 subjects injected with 50 mg dose of FXI-GalNAc-siRNA 2 subjects with Saline
62566779|NCT05844293|OTHER|Cohort 3|6 subjects injected with 100 mg dose of FXI-GalNAc-siRNA 2 subjects with Saline
62566780|NCT05844293|OTHER|Cohort 4|6 subjects injected with 200 mg dose of FXI-GalNAc-siRNA 2 subjects with Saline
62566781|NCT05844293|OTHER|Cohort 5|6 subjects injected with 400 mg dose of FXI-GalNAc-siRNA 2 subjects with Saline
62566782|NCT06179914||Adolescence and Youth with cancer|Participants were diagnosed with cancer before 18 years old and aged between 10 and 24 years
62566783|NCT02114424|ACTIVE_COMPARATOR|Positional vibrator belt|Positional belt to avoid supine sleep.
62566784|NCT02114424|NO_INTERVENTION|No Night balance|the first 2 months without Night Balance
62566785|NCT02356588|EXPERIMENTAL|Sufentanil Tablet 30 mcg|A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.
62566786|NCT02356588|PLACEBO_COMPARATOR|Placebo Tablet|A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.
62566787|NCT01006122|PLACEBO_COMPARATOR|Placebo|
62566788|NCT01006122|ACTIVE_COMPARATOR|PF-03654746|At the end of the second arm of the study, the patient will have completed the study and have a 7-10 day follow-up visit.
62566789|NCT05231473|NO_INTERVENTION|Standard|The participants are assigned according to the implanted and functioning program of each center. In this case, without Nurse Enhanced Recovery After Surgery Coordinator. It will be the control group. ERAS program will be working without this role.
61997163|NCT01591473|EXPERIMENTAL|FluMist + Ampligen, Group 3|Nasal administration; dose group 3; FluMist + Poly I:Poly C12U 500 ug; 3 doses separated by 28 days
61997164|NCT01591473|EXPERIMENTAL|FluMist + Ampligen, Group 4|Nasal administration; dose group 4; FluMist + Poly I:Poly C12U 50 ug; 3 doses separated by 28 days
61997165|NCT01591473|EXPERIMENTAL|FluMist + Ampligen, Group 5|Nasal administration; dose group 5; FluMist + Poly I:Poly C12U 1250 ug; 3 doses separated by 28 days
61997166|NCT01591473|EXPERIMENTAL|FluMist + Placebo, Group 6|Nasal administration; dose group 6; FluMist + placebo; 3 doses separated by 28 days
61997167|NCT00259090|ACTIVE_COMPARATOR|1|Anastrozole Monotherapy
61997168|NCT00259090|EXPERIMENTAL|2|Fulvestrant Monotherapy
61997169|NCT00259090|EXPERIMENTAL|3|Anastrozole + Fulvestrant
61997170|NCT05548023|OTHER|unprotected left main coronary artery disease treated with PCI|
62182109|NCT03271749|EXPERIMENTAL|PROSM interventional|The participants of this arm will receive the PROSM protocol pre operative, anesthesia and postoperative care for lung resections for treatment of lung neoplasms
62182110|NCT04458818|EXPERIMENTAL|Prolene Mesh Implant|The Group of Patients who were offered Prolene mesh Laryngeal implants for Vocal Cord Medialization.
62566790|NCT05231473|EXPERIMENTAL|Nurse Coordinator|The participants are assigned according to the implanted and functioning program of each center. In this case, with Nurse Enhanced Recovery After Surgery Coordinator. It will be the intervention group. ERAS program will be working with this role.
62566791|NCT03207269|EXPERIMENTAL|High protein no carbohydrate|Dietary. Two eggs will be consumed 30 minutes prior to bedtime. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
62566792|NCT03207269|ACTIVE_COMPARATOR|High protein carbohydrate containing|Dietary. A low-fat yogurt will be consumed 30 minutes prior to bedtime. Protein will be matched to the high protein bedtime snack condition. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
62566793|NCT03207269|NO_INTERVENTION|Control no snack|No snack will be consumed prior to bed.
62566794|NCT06410482|EXPERIMENTAL|US guided caudal block Anesthesia|Children will receive caudal block analgesia
62566795|NCT06410482|ACTIVE_COMPARATOR|Dorsal penile nerve block Anesthesia|Children will receive Penile block analgesia
61997171|NCT00555984|ACTIVE_COMPARATOR|Total Intravenous anesthetic|Intravenous anesthetics (propofol + remifentanil) for maintenance of General Anesthesia
61997172|NCT00555984|ACTIVE_COMPARATOR|Volatile Anesthetic|Inhalational anesthetics (sevoflurane+remifentanil) for maintenance of General Anesthesia. Patients receive Sevoflurane as a volatile anesthetic and remifentanil as an IV agent for maintenance of general anesthesia.
62182111|NCT04228406|EXPERIMENTAL|GST-HG161|There are 7 dose cohorts, including60mg, 150mg, 300mg, 450mg, 600mg, 750mg, 900mg QD in the dose escalation stage and GST-HG161 will be administered orally to patients once daily for each dose cohort. Recommended dose in the dose expansion stage will be determined by the results in the dose escalation stage .
62566796|NCT04747119|EXPERIMENTAL|study group|received the conventional selected exercise program in addition to muscle energy technique
62566797|NCT04747119|EXPERIMENTAL|control group|received the conventional selected exercise program
62566798|NCT01707810|SHAM_COMPARATOR|Conventional method|In the conventional method IVC was clamped during the anhepatic phase and venous return was maintained by a portal femoral axillary venovenous bypass with a centrifugal pump. In these cases, IVC reconstruction was performed by end-to-end anastomosis above and below the liver.
62566799|NCT01707810|EXPERIMENTAL|Piggyback method|In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.
62566800|NCT00380133|EXPERIMENTAL|Randomised, double-blind, five-way crossover|A randomised, double-blind, double-dummy, placebo-controlled, five-way crossover study to assess the effects of single oral doses of SB-681323 (7.5 mg and 25 mg) and prednisolone (10 mg and 30 mg) on biomarkers in induced sputum and blood in COPD patients.
62566801|NCT06459219||Ongoing (symptoms min 3 years)|"Ongoing intermittent allergic rhinoconjunctivitis to birch pollen with moderate to severe symptoms according to ARIA guidelines for at least 10 years Positive Skin prick test (SPT) to birch pollen and/or Bet v 1-specific IgE ≥0.35kUA/L as measured by ImmunoCAP~≥60 y"
61997173|NCT02863835|EXPERIMENTAL|Intervention 1|"A 1:1 randomisation will be performed to decide the order of the administration of salbutamol and CPAP. All participants will receive both interventions in a cross-over fashion. Salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure.~Each participant will then have continuous assessment of the following whilst self venting:~* Spirometry - FEV1, FVC, MVV~* Muscle strength measurements: MIP, MEP, SNIP~* Borg scale, mMRC, Visual Analogue Scale for breathlessness~* Electrical impedance tomography~* EMGpara~* Transcutaneous measurement of CO2 and 02 level~* End-tidal CO2 monitoring~* Pneumotachography"
61997174|NCT00816868|EXPERIMENTAL|non-small cell lung cancer (NSCLC)|erlotinib in combination with capecitabine as first-line treatment in elderly patients with stage IIIB/IV adenocarcinoma non-small cell lung cancer (NSCLC)
61997175|NCT05595993|EXPERIMENTAL|Cilostazol|Oral administration of 200 mg cilostazol.
61997176|NCT05595993|PLACEBO_COMPARATOR|Placebo|
61997177|NCT05324163|EXPERIMENTAL|X0002 spray group|X0002 spray 17.5mg, twice a day; Celecoxib placebo 200mg, once a day
61997178|NCT05324163|ACTIVE_COMPARATOR|Celecoxib capsule Group:|X0002 spray placebo 17.5 mg, twice a day; Celecoxib capsule 200mg, once a day
61997179|NCT05324163|PLACEBO_COMPARATOR|The placebo group|X0002 spray placebo 17.5 mg, twice a day; Celecoxib placebo 200mg, once a day
61997180|NCT04043312|SHAM_COMPARATOR|Control|Patients will receive one hour of sham stimulation.
61997181|NCT04043312|EXPERIMENTAL|Active|Patients will receive one hour of active magnetic stimulation to the left stellate ganglion.
62182112|NCT03409562|EXPERIMENTAL|Pain Neurophysiology Education and motor control training|This group will undergo two pain neurophysiology education sessions prior to motor control training.
62182113|NCT03409562|ACTIVE_COMPARATOR|motor control training alone|This group will only perform motor control training.
62182114|NCT01832662|EXPERIMENTAL|Coffee|4 cups/day of 2.5g of coffee each
61997182|NCT01275066|PLACEBO_COMPARATOR|Placebo|
62182115|NCT01832662|ACTIVE_COMPARATOR|coffee polyphenols mixed with placebo|4 cups/day of 2.5g of product each
62182116|NCT01832662|PLACEBO_COMPARATOR|maltodextrin enriched with caffeine|4 cups/day of 2.5g of product each
62182117|NCT02882841|OTHER|Single-arm study|
62182118|NCT01200485|EXPERIMENTAL|Rasburicase Alone|Rasburicase by vein on Day 1 (0.15 mg/kg or a flat dose of 3 mg) as a single dose, plus as needed dosing (until day 5), during cycle 1 (21 day cycle).
62566802|NCT06459219||Previous (no symptoms past 3 years)|"History of intermittent allergic rhinoconjunctivitis to birch pollen ongoing with moderate to severe symptoms according ARIA guidelines26 for at least ten years (verified by at least one medical record including SPT results), but no symptoms for at least the three past consecutive seasons Positive or negative SPT to birch pollen and Bet v 1-specific IgE ≤ or ≥0.35kUA/L as measured by ImmunoCAP~≥60 y"
62566803|NCT06459219||No (never symptoms)|"No history of and no ongoing allergic rhinoconjunctivitis to birch pollen Negative SPT to birch pollen and Bet v 1-specific IgE ≤ 0.35kUA/L~≥60 y"
62566804|NCT03825796|EXPERIMENTAL|Treatment (CPX-351, enasidenib mesylate)|See detailed description
62566805|NCT00745862||1|female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment
62566806|NCT00718614|OTHER|1|Patients with long standing IDDM (\>10 years) and no diabetic retinopathy
62566807|NCT00718614|OTHER|2|Patients with long standing IDDM (\>10 years) and mild non-proliferative diabetic retinopathy
62566808|NCT00718614|OTHER|3|Patients with long standing IDDM (\>10 years) and moderate to severe non-proliferative diabetic retinopathy
62566809|NCT00718614|OTHER|4|healthy volunteers, matched for age and sex
62566810|NCT04502654||Pilot group|As a pilot Group for observating variable rehabilitation under individual baselines.
62182119|NCT01200485|EXPERIMENTAL|Arm A (Rasburicase)|Participants randomized to Rasburicase (0.15 mg/kg) by vein on day 1 plus as needed dosing (until day 5) during Cycle 2.
62566811|NCT00950014|EXPERIMENTAL|Percentage format only|Numbers are presented in percentage format (e.g., 35%, 0.2%) only.
62566812|NCT00950014|EXPERIMENTAL|Fixed frequency format only|Numbers are presented in fixed frequency format only (5 out of 1000, 0.6 out of 1000). Denominators remains the same for each number.
62566813|NCT00950014|EXPERIMENTAL|Variable frequency format|Frequency denominators are adjusted to keep the numerator greater than 1, so they may change throughout the survey (e.g., 6 out of 1000, 42 out of 100)
62566814|NCT00950014|ACTIVE_COMPARATOR|Fixed combination format|Numbers are presented with both percentages and frequencies, and frequency denominators remain fixed (e.g., _ out of 1000).
62566815|NCT00950014|EXPERIMENTAL|Variable combination format|Numbers are presented with both percentages and frequencies, but frequency denominators may vary (e.g., _ out of 1000, _ out of 100).
62566816|NCT06323824|EXPERIMENTAL|Office-based methadone|Under special Drug Enforcement Administration (DEA) exception, Clinician prescribes methadone and oral methadone is administered and/or dispensed at a pharmacy which also has an exception to do so. All randomized controlled trial (RCT) participants are offered additional behavioral treatments (e.g., individual, group, telehealth, phone-based).
62566817|NCT06323824|ACTIVE_COMPARATOR|Office-based buprenorphine (BUP)|Clinician prescribes BUP formulations that are dispensed at a pharmacy or administered in the office (e.g., extended-release formulations). All RCT participants are offered additional behavioral treatments (e.g., individual, group, telehealth, phone-based).
62566818|NCT03277287|EXPERIMENTAL|Group A|Fractional CO2 laser will be applied on cleft lip scar 3 weeks post-surgical
62566819|NCT03277287|EXPERIMENTAL|Group B|Fractional CO2 laser will be applied on cleft lip scar 3 months post-surgical
61997183|NCT01275066|EXPERIMENTAL|BMN 110 Weekly|
61997184|NCT01275066|EXPERIMENTAL|BMN 110 Every Other Week|
61997185|NCT00937690||infrared imaging of cutaneous lesions|patients and volunteers with cutaneous lesions, with and without clinically detectable melanoma, and with one or more palpable cutaneous lesions
62182120|NCT01200485|EXPERIMENTAL|Arm B (Allopurinol)|Participants randomized to Allopurinol (300 mg/day) by vein each day on Days 1-5 of Cycle 2.
62182121|NCT01825317|ACTIVE_COMPARATOR|NeuroAD|Treatment by the NeuroAD device, real treatment by synchronized TMS+cognitive training
62182122|NCT01825317|SHAM_COMPARATOR|Sham NeuroAD|Sham TMS+cog, has the same sound and appearance, patients come for the same number of treatments and are exposed to the same procedure.
62182123|NCT00595647|ACTIVE_COMPARATOR|1|Percutaneous coronary intervention
62182124|NCT00595647|PLACEBO_COMPARATOR|2|Percutaneous coronary intervention
62566820|NCT03277287|NO_INTERVENTION|Group C|No intervention
62182125|NCT03694262|EXPERIMENTAL|Treatment|Cycle length = 21 days Atezolizumab 1,200mg IV on day 1 Bevacizumab 15mg/kg IV on day 1 Rucaparib 600mg orally twice daily by continuous dosing
62182656|NCT03127878|EXPERIMENTAL|Upper-limb additional training|High-intensity endurance exercise of upper- and lower-limb with strengthening exercise of upper- and lower-limb
62182657|NCT00188825|EXPERIMENTAL|basiliximab|
62566821|NCT01554462|ACTIVE_COMPARATOR|ADHD active|4 month intervention with EPA/DHA in ADHD group
62182126|NCT03330171|OTHER|HIV-unexposed children|HIV-unexposed children enrolled in a randomized open label study on the pneumococcal conjugate vaccine (PCV1+1) will be invited to participate in this study. Children enrolled in the PCV1+1 study will receive all vaccines included in the South African public immunization program. Measles vaccine (0.5 mL, subcutaneous injection) will be adminstered at 6 months of age and 12 months of age. Varicella vaccine (0.5 mL, subcutaneous injection) or Hepatitis-A vaccine (0.5 mL, intra-muscular injection) will be administered to the participants at 18 months of age as an additional benefit for participating in the study.
62182127|NCT03330171|OTHER|HIV-exposed children|A cohort of HIV-exposed children will be recruited. Measles vaccine (0.5 mL, subcutaneous injection) will be adminstered at 6 months of age and 12 months of age. Varicella vaccine (0.5 mL, subcutaneous injection) or Hepatitis-A vaccine (0.5 mL, intra-muscular injection) will be administered to the participants at 18 months of age as an additional benefit for participating in the study.
62182128|NCT04759846|EXPERIMENTAL|Group with normal hepatic function|Normal hepatic function
62182129|NCT04759846|EXPERIMENTAL|Group with moderate hepatic impairment|Moderate hepatic impairment (Child-Pugh Class B)
62182130|NCT04759846|EXPERIMENTAL|Group with severe impairment|Severe impairment (Child-Pugh Class C)
62182131|NCT01361958|EXPERIMENTAL|T1 received 0.625 mg NOMAC + 1.5 mg E2|
62182132|NCT01361958|EXPERIMENTAL|T2 received 1.25 mg NOMAC + 1.5 mg E2|
62182133|NCT01361958|EXPERIMENTAL|T3 received 2.5 mg NOMAC + 1.5 mg E2|
62182134|NCT01361958|EXPERIMENTAL|T4 received 2.5 mg NOMAC + Lactose|
62182135|NCT04548297||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
62182136|NCT04548297||Healthy group|Healthy individuals without chronic disease
62182658|NCT00188825|PLACEBO_COMPARATOR|placebo|
62182659|NCT00241969|EXPERIMENTAL|Behavioral and Nutrition Treatment|The behavioral and nutrition treatment combines individualized nutritional counseling that targeted increasing energy and fat intake and parent training in behavioral child-management skills based on social learning theory to improve meal-time behaviors.
62391355|NCT02637869||Alternative Payment Model -intervention|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
62391356|NCT03852901|EXPERIMENTAL|Single Arm|Single group
62391357|NCT05411705|EXPERIMENTAL|rhTPO|The study in a 2:1 randomization ratio (110 subjects to rhTPO).
62566822|NCT01554462|PLACEBO_COMPARATOR|ADHD Placebo|4 month dietary intervention with placebo in ADHD group
62566823|NCT01554462|ACTIVE_COMPARATOR|Active Healthy control|4 month dietary intervention with DHA/EPA in healthy control group
61997186|NCT05098353|EXPERIMENTAL|Quetiapine 25-75 mg|"There is one arm in this study. Patients will take quetiapine in dose 25-75 1-3 times a day.~Dose and its frequency can be adjusted by researcher during first 2 weeks (till visit 2), after that patients will take stable dose of quetiapine till week 6 (visit 3)."
62182137|NCT04561167|EXPERIMENTAL|Cuspal reduction in MOD Cavity in endodontically treated teeth|Cavity design is of prime importance for the restoration of endodontically treated teeth. The cavity design plays an important role in the protection of the remaining tooth structure as well as the restoration. Cuspal reducuction and further coverage by the CAD/CAM generated indirect resin composite restoration has been proved in literature by the retrospective study done by (Chrepa V et al 2014) which studied 189 posterior endodontically treated teeth receiving indirect composite onlays with a median follow up time of 37 months and suggested this type of restoration as a viable option with 100% tooth survival and 96.8% restoration survival.
62182138|NCT04561167|ACTIVE_COMPARATOR|No cuspal reduction in endodontically treated teeth|In the present study, choosing the comparator to be the cavity design without cuspal reduction and further coverage (inlay) is done as an attempt to reduce the application of inlays in endodontically treated teeth. In accordance to the in-vitro study done by (M. D. Al Amri et al 2016) which tested the fracture resistance of endodontically treated mandibular first molars with conservative access cavity and different restorative techniques, catastrophic failures were highest in the composite group (100%), followed by the inlay and the amalgam groups (91.67%) and this was referred to the adhesive bonding mechanism of the composite restoration and the wedging effect of the inlay and the amalgam restorations (Rivera EM andWalton RE 2015)
62182139|NCT01628406||Patients treated at the neurosurgery department|Patients treated at the neurosurgery department
62182140|NCT05544318|EXPERIMENTAL|Intervention|Extra nutritional support
62182141|NCT05544318|NO_INTERVENTION|Control|Usual care
62182142|NCT03305809|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered orally once a day (QD).
62182143|NCT03305809|EXPERIMENTAL|10 milligram (mg) LY3154207|Participants received 10 mg LY3154207 administered orally QD.
62182144|NCT03305809|EXPERIMENTAL|30 mg LY3154207|Participants received 30 mg LY3154207 administered orally QD.
62182145|NCT03305809|EXPERIMENTAL|75 mg LY3154207|Participants received 75 mg LY3154207 administered orally QD.
62182146|NCT05393622|EXPERIMENTAL|Intervention, Placement of Device & Stimulation|Placement of neurostimulation device \& stimulation of prefrontal cortex target
62182147|NCT00159198||1|Patients with frontotemporal dementia and amyotrophic lateral sclerosis
62182148|NCT00159198||2|Relatives (first and second degree) of patients presenting an association of frontotemporal dementia with amyotrophic lateral sclerosis
62182149|NCT04589403|PLACEBO_COMPARATOR|0.9% Sodium Chloride Injection USP|Placebo will be 50 mL normal saline (Sodium Chloride), USP sterile solution administered by IV infusion over 30 minutes.
62182150|NCT04589403|EXPERIMENTAL|OPT101|The starting dose for the Phase 1a study is 0.16 mg/kg, which is 35-fold lower than the dog NOAEL (10mg/kg), on a mg/m2 basis. The dosing frequency for the MAD study was selected based on dosing performed in the supporting animal model studies. For an additional safety factor, the dose and volume infusion rates for the 0.16 mg/kg dose in humans will be 67-fold and 14-fold lower than the dogs dosed at 10mg/kg/min and mL/kg/min basis, respectively. For both Phase 1a and 1b, OPT101 will be administered by a slow IV infusion over 30 minutes.
62182151|NCT00610571|EXPERIMENTAL|Oral Topotecan and Temodar|Two separate strata to accrue independently. Stratum 1: Patients taking receiving Dilantin, Tegretol, Trileptal or Phenobarbital. Stratum 2: Patients on anti-convulsants other than Dilantin, Tegretol, Trileptal or Phenobarbital or patients not on any anti-convulsants
62566824|NCT01554462|PLACEBO_COMPARATOR|Healthy placebo|4 month dietary intervention with placebo in healthy control group
62182152|NCT06151847|EXPERIMENTAL|Treatment (Lifileucel)|Lifileucel (LN-144) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy. A tumor sample is resected from each patient for lifileucel manufacturing. Patients then receive the lifileucel regimen which consists of a reduced dose non-myeloablative lymphodepletion, lifileucel infusion followed by interleukin-2.
61997187|NCT01572038|EXPERIMENTAL|Pertuzumab + Trastuzumab + Taxane|Participants will receive pertuzumab and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first. Taxane chemotherapy can be either docetaxel, paclitaxel or nab-paclitaxel as per investigator's choice.
61997188|NCT05962411|NO_INTERVENTION|Dress in School Uniforms|Simulated clients dress in school uniforms, enter e-cigarette stores, and act as minor buyers.
62391358|NCT05411705|OTHER|Control|The study in a 2:1 randomization ratio (55 subjects to control group).
62566825|NCT04994210|EXPERIMENTAL|Sintilimab+Chidamide|Sintilimab：200mg(fixed dosage), ivd, qd, q21d Chidamide: 30mg,biw,continued oral
62566826|NCT01568892|EXPERIMENTAL|DTG 50 mg BID|Subjects will receive dolutegravir (DTG) 50 milligrams (mg) twice daily (BID) and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the Double-blind (DB) Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.
62566827|NCT01568892|EXPERIMENTAL|Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase|Subjects will receive matching placebo BID and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the DB Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.
61997189|NCT05962411|EXPERIMENTAL|Dress in Professional Attire|"Simulated clients dress in business casuals, enter e-cigarette stores, and act as potential adult e-cigarette buyers."
61997190|NCT00262067|EXPERIMENTAL|Bevacizumab + chemotherapy|Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle plus one of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
61997191|NCT00262067|PLACEBO_COMPARATOR|Placebo + chemotherapy|Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + 1 of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
62182153|NCT03696641|ACTIVE_COMPARATOR|glazed IPS e.max|lithium disilicate glazed crowns that proved to have a good color stability
61997192|NCT01161329|NO_INTERVENTION|Control group|Participants in the control group are instructed to live their ordinary life.
61997193|NCT01161329|EXPERIMENTAL|Intervention group|Exercising two times/week according to the High-Intensity Functional Exercise Program (HIFE) in groups of 5-7 patients in combination with motivational discussions.
61997194|NCT05062265|ACTIVE_COMPARATOR|Tight Rope Fixation|
61997195|NCT05062265|ACTIVE_COMPARATOR|tight rope fixation w/ AITFL repair augmentation with an internal brace|
61997196|NCT02610699|ACTIVE_COMPARATOR|Smartphone otoscope/Conventional otoscope|Participating clinicians will use a smartphone otoscope for one month followed by a conventional otoscope for one month, alternating monthly, for a total of 6 months to examine children between 6 months and 18 years of age who have clinical signs of acute otitis media (AOM).
61997197|NCT02610699|ACTIVE_COMPARATOR|Conventional otoscope/Smartphone otoscope|Participating clinicians will use a conventional otoscope for one month followed by a smartphone otoscope for one month, alternating monthly, for a total of 6 months to examine children between 6 months and 18 years of age who have clinical signs of acute otitis media (AOM).
61997198|NCT04804709|EXPERIMENTAL|FUS using Oral Panobinostat|All patients enrolled in the study will be treated with oral Panobinostat after receiving Focused Ultrasound treatment (FUS) with microbubbles and neuro-navigator-controlled sonication.
61997199|NCT03925727|EXPERIMENTAL|1% Tavilermide ophthalmic solution|
61997200|NCT03925727|EXPERIMENTAL|5% Tavilermide ophthalmic solution|
61997201|NCT03925727|PLACEBO_COMPARATOR|Vehicle ophthalmic solution|
61997202|NCT04654533|EXPERIMENTAL|COSC|"Eight weekly manualized sessions of Circle of Security Classroom (COSC), delivered in groups, two hours per session, 5-10 childcare providers per group.~COSC is facilitated by a psychologist who is a registered COSP facilitator and who has completed the an additional COSC online training."
62182154|NCT03696641|EXPERIMENTAL|polished IPS e.max|polished lithium disilicate crowns with the polishing kit
62182155|NCT06183671|EXPERIMENTAL|Ascending Single Doses|48 participants, 6 single ascending dose (SAD) cohorts (Cohorts 1 to 6). Within each cohort, 8 participants will be randomized in a 6:2 ratio, 6 participants receiving JX09 and 2 receiving placebo
62182156|NCT06183671|EXPERIMENTAL|Ascending Multiple Doses|32 participants, 4 multiple ascending dose (MAD) cohorts (Cohorts 7 to 10). Within each cohort, 8 participants will be randomized in a 6:2 ratio, 6 participants receiving JX09 and 2 receiving placebo
62182157|NCT06183671|EXPERIMENTAL|Food Effect|12 participants,1 single-dose food effect (FE) cohort (Cohort 11), open-label, two-sequence, two-period, crossover design, participants will be randomly assigned to 1 of the 2 crossover sequences
62567795|NCT05302401|EXPERIMENTAL|Women receiving uninterrupted midwife support during the intrapartum period|28. - Visual Analog Scale will be applied to determine the Wijma Birth Expectation/Experience (W-DEQ A) Scale and birth fear in order to determine the birth fears of pregnant women in the 36th week. During outpatient checks, the first saliva cortisol samples will be taken by researcher Meserret Aslan between 8:30 and 09:00 in the morning. Researcher Meserret Aslan will provide six hours of online pregnancy training to pregnant women in the experimental group and provide uninterrupted midwife support during the intrapartum period.Within the first half hour of postpartum after birth, saliva cortisol samples of women will be repeated by researcher Meserret Aslan. Between the 24th and 72nd hours before postpartum discharge procedures take place, saliva cortisol samples of women will be taken for the last time by researcher Meserret Aslan from the experimental group.
61997203|NCT04654533|NO_INTERVENTION|Control|"Usual care control condition, i.e., standard practice in the participating childcare centers.~Teams of childcare providers are allocated to either COSC or waitlist in clusters, and baseline and follow-up measures are collected parallel in both groups. Childcare providers allocated to the waitlist will receive COSC after the follow-up data have been collected."
61997204|NCT05775978|EXPERIMENTAL|UGRComp group|This arm will instruct the students on the Más Presente program. This is a socio-emotional competence-based program which has been designed following the European LifeComp framework. This program is a combination of theory and practice aimed at developing the core elements of personal, social and learning to learn key competences for lifelong learning.
61997205|NCT05775978|EXPERIMENTAL|MBSR group|This arm will instruct the students on the Mindfulness-Based Stress Reduction (MBSR) program. The MBSR is a secular, evidence-based practice originally developed for chronic pain, but which has reported positive results among an array of clinical and nonclinical populations. This program aims to cultivate non-judgmental attention to and awareness of present moment experience while promoting stress reduction.
61997206|NCT05775978|ACTIVE_COMPARATOR|Neuro-muscular stimulation group|"The students in this arm will receive training on physical wellbeing and neuro-muscular stimulation.~Non-specific factors such as number and duration of sessions, or instructor training and qualifications will match the other 2 experimental groups. Active ingredients such as mindfulness or socio-emotional training are not contained in the program."
61997207|NCT04501614|EXPERIMENTAL|Ponatinib|Ponatinib tablet or age appropriate formulation (AAF) \[i.e., capsules with ponatinib minitablets\], based on age and weight, in combination with chemotherapy backbone, orally, once daily in both reinduction block and consolidation block (35 days each including 29 days of treatment followed by rest period from chemotherapy for a minimum of 6 days consisting of daily ponatinib only) in Phase 1 to determine RP2D. In Phase 2 participants will receive ponatinib at RP2D in combination with chemotherapy backbone.
61997208|NCT02194868||donors of hematopoietic stem|Adult and minor donors of hematopoietic stem
61997209|NCT02194868||patients requiring allogeneic hema|Adult and minor patients (recipients) requiring allogeneic hema
61997210|NCT03382106|EXPERIMENTAL|Smoking Cessation Group 1|80 normal smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews), between the ages of 21 and 65 will be studied to assess inflammation and heterogeneity of Perfused Blood Volume prior to and following a 3 month smoking cessation program. In 40 of the 80 subjects during the smoking cessation program, we will provide three times per day Sildenafil 20 milligrams (MG) (Viagra) for the full 3 months of the smoking cessation period. We select a three-month cessation program to maximize the likelihood of compliance with cessation yet providing enough time for a resolution of lung injury to take place. Pulse wave velocity, carotid artery compliance and stiffness and pressure wave reflection will be measured.
62182158|NCT02542423|OTHER|patients undergoing cardiac surgery|
62182159|NCT04012086|EXPERIMENTAL|physical therapy (PT)|The physical therapy program consisted of 6 individual sessions/week, each lasting 60 minutes for 4 weeks in addition to their usual pharmacological therapy
62182160|NCT04012086|NO_INTERVENTION|No physical therapy (CT)|Subjects in CT group received only standard medication.
62182161|NCT04658550||Remote Weight Loss Behaviour Modification Program with Meal Replacements|This is the prospective study group who will receive 26-weeks of weight loss and maintenance counselling in a remote setting and a low-calorie meal replacement as part of their usual care.
62182162|NCT04658550||In Person Weight Bahaviour Modification Program with Meal Replacements|This is the retrospective study group who received 26-weeks of weight loss and maintenance counselling in person and a low-calorie meal replacement as part of their usual care.
62182163|NCT01949883|EXPERIMENTAL|CPI-0610|
61997211|NCT03382106|PLACEBO_COMPARATOR|Smoking Cessation Group 2|80 normal smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews), between the ages of 21 and 65 will be studied to assess inflammation and heterogeneity of Perfused Blood Volume prior to and following a 3 month smoking cessation program. In 40 of the 80 subjects during the smoking cessation program, we will provide three times per day placebo oral tablet for the full 3 months of the smoking cessation period. We select a three-month cessation program to maximize the likelihood of compliance with cessation yet providing enough time for a resolution of lung injury to take place. Pulse wave velocity, carotid artery compliance and stiffness and pressure wave reflection will be measured.
61997212|NCT03382106|EXPERIMENTAL|Non-Smokers Group 1|20 non-smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews) between the ages of 21 and 65 will be studied to compare the heterogeneity of Perfused Blood Volume with that of smokers for a 3 month period of time. We will provide 10 females and 10 males three times per day Sildenafil 20 milligrams (MG) (Viagra) for the full 3 months.
61997213|NCT03382106|NO_INTERVENTION|Non-Smokers Group 2|20 non-smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews) between the ages of 21 and 65 will be studied to compare the heterogeneity of Perfused Blood Volume with that of smokers for a 3 month period of time. 10 females and 10 males will not receive any medication for the full 3 months.
62182164|NCT06454201|ACTIVE_COMPARATOR|robotic natural orifice specimen extraction surgery for middle rectal cancer|After the body is free, the tumor segment of the bowel is pulled out through the anus. Excise the tumor segment of the colon outside the anus.
61997214|NCT03214627|EXPERIMENTAL|Anemia Control Model IV iron and ESA|"Anemia Control Model (ACM) algorithm to recommend monthly IV and ESA dose over a 6 month period~IV iron: given monthly as required - dosing recommendation by ACM over 6 a month period~Erythropoiesis-Stimulating Agent (ESA): given monthly as required - dosing recommendation by ACM over 6 a month period"
62182165|NCT06454201|SHAM_COMPARATOR|robotic transabdominal specimen extraction surgery for middle rectal cancer|After internal mobilization, the tumor segment of the bowel was removed through an abdominal incision. Excise the tumor segment of the bowel outside the incision.
62182166|NCT02401971|EXPERIMENTAL|Arm A (thalidomide+CPT-11)|Patients will receive CPT-11 180 mg/m\^2 ivgtt ,over 90 minutes on day 1, every 21 days for one cycle, four cycles ,and oral thalidomide 100 mg/d qn. Maintenance therapy with thalidomide in the same dose is performed until disease progression.
61997215|NCT00881946|EXPERIMENTAL|GSK2119183|
61997216|NCT00834912|EXPERIMENTAL|1: Tramadol HCl (Confab Laboratories) fasting|
61997217|NCT00834912|EXPERIMENTAL|2: Tramadol HCl (Confab Laboratories) fed|
62182167|NCT02401971|EXPERIMENTAL|Arm B (CPT-11)|Patients will receive CPT-11 180 mg/m\^2 ivgtt ,over 90 minutes on day 1, every 21 days for one cycle, four cycles.
61997218|NCT00834912|EXPERIMENTAL|3: Tramadol HCl (Trillium Healthcare) fasting|
62182168|NCT00025662|EXPERIMENTAL|RFT5-SMPT-dgA Isolex system|RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin used in allogeneic stem cell transplantation (SCT) in older patients with hematologic malignancies using a graft manipulation process
62182169|NCT01965106|ACTIVE_COMPARATOR|QPI-1007 Injection|single intravitreal (IVT) injection of QPI-1007
62182170|NCT01965106|SHAM_COMPARATOR|Control|Placebo (Sham injection procedure)
62182171|NCT01263925|EXPERIMENTAL|Alprostadil|Alprostadil (Prostaglandin E1) intravenous and matching Placebo to Pentoxifylline oral
62182172|NCT01263925|ACTIVE_COMPARATOR|Pentoxifylline|Pentoxifylline oral and matching Placebo to Alprostadil (Prostaglandin E1) intravenous
62182173|NCT01185171|EXPERIMENTAL|ZD1839 500mg by mouth (po) daily|Single arm, two-stage, phase II trial of induction therapy with carboplatin and paclitaxel, followed by ZD1839, 5-FU, hydroxyurea, and hyperfractionated radiotherapy, followed by adjuvant ZD1839 alone.
61997219|NCT02861950|ACTIVE_COMPARATOR|Caudal block|Patients will receive a caudal block with 0.75-1ml/kg of 0.2% ropivacaine.
61997220|NCT02861950|ACTIVE_COMPARATOR|Penile Nerve Block|Patients will receive a dorsal penile nerve block with up to 0.75ml/kg of 0.25% bupivacaine.
61997221|NCT03341988|OTHER|Ombitasvir (25 mg ), Paritaprevir (150 mg ) once daily|Ombitasvir (25 mg once daily), Paritaprevir (150 mg once daily), Ritonavir (100 mg once daily)Ribavirin (RBV): weight-based and divided bid (1000 mg/day if \< 75kg or 1200 mg/day if ≥ 75kg) given to 50 chronic HCV infected patients with renal impairment for 12 week
62182174|NCT04255745|NO_INTERVENTION|Assessment-only control|30 Assessment-only control group will be mailed (standard or electronic) NIH/National Institutes on Aging (NIA) Go4Life® educational materials once a month for 3 months. Exercise logs documenting weekly exercise activities, duration, time and effort will be requested to be sent back.
62182175|NCT04255745|EXPERIMENTAL|Intervention|60 Intervention group will receive 12 weeks of supervised resistance training following the American Heart Association and American College of Sports Medicine guidelines for older adults. Exercises will include a mixture of upper-body and lower body strength exercises. Training load will be determined based on initial 1-repetition maximum tests (1-RM). Initial exercise load will start off at low resistance (40-50% 1RM) with more frequent repetitions per exercise, and will gradually increase weight load and intensity over the exercise training period.
61997222|NCT03616912|PLACEBO_COMPARATOR|Placebo|Participants received two placebo tablets: one matching baricitinib 4 milligram (mg) and one matching baricitinib 2 mg administered orally every day (QD) for 52 weeks.
62182176|NCT04257422|EXPERIMENTAL|Intentional Rounding|In the centers randomized to Intentional Rounding the ward nurses will have to adopt a new proactive care method towards hospitalized patients
61997223|NCT03616912|EXPERIMENTAL|2 mg Baricitinib|Participants received one Baricitinib 2 mg tablet and one placebo tablet matching Baricitinib 4 mg administered QD for 52 weeks.
61997224|NCT03616912|EXPERIMENTAL|4 mg Baricitinib|Participants received one Baricitinib 4 mg tablet and one placebo tablet matching baricitinib 2 mg administered orally every day (QD) for 52 weeks.
61997225|NCT03616912|PLACEBO_COMPARATOR|Placebo Maximum Extended Enrollment (MEE)|Participants received two placebo tablets: one matching baricitinib 4 mg and one matching baricitinib 2 mg administered orally QD for 52 weeks.
61997226|NCT03616912|EXPERIMENTAL|2 mg Baricitinib (MEE)|Participants received one Baricitinib 2 mg tablet and 1 placebo tablet matching Baricitinib 4 mg administered QD for 52 weeks.
61997227|NCT03616912|EXPERIMENTAL|4 mg Baricitinib (MEE)|Participants received one Baricitinib 4 mg tablet and one placebo tablet matching baricitinib 2 mg administered orally every day (QD) for 52 weeks.
62566828|NCT00762814|EXPERIMENTAL|Parkinson subjects with freezing|"Each subject will have been diagnosed with Parkinson disease and will serve as his/her own control. Inclusion criteria: history of consistent freezing with ambulation in a straight line and/or when turning, normal central and peripheral neurological function, at least grade 4 strength and normal joint ranges of motion in both legs, normal somatosensory function in the feet (joint position sense), except for their neurological diagnosis and use of levodopa, each must have had clear benefit from levodopa for at least some of his/her PD symptoms, and all subjects with PD must be able to walk independently for 10 feet.~Exclusion criteria include: serious medical problem that would impair the ability to undergo testing, use of neuroleptic or other dopamine-blocking drug, use of drugs that might affect balance, history or evidence of other neurological deficit that could interfere, such as previous stroke or muscle disease, or participants who are unable to provide informed consent."
62566829|NCT02756143|NO_INTERVENTION|Control Group|Non- supervised physical exercise program during pregnancy
62566830|NCT02756143|EXPERIMENTAL|Exercise Group|Supervised physical exercise program during pregnancy
62566831|NCT02805153|EXPERIMENTAL|Experimental/PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy.
62566832|NCT02805153|ACTIVE_COMPARATOR|Active Comparator/rhG-CSF|patients received daily subcutaneous injections of rhG-CSF(filgrastim) 5 ug/ kg/day. Injections on day 3 after chemotherapy and continued daily until an ANC of at least 10.0 X 10\^9/L was documented after the expected nadir, or for a maximum of 14 days
62566833|NCT03173118|OTHER|suspected chronic pancreatitis patients|Patients with suspected chronic pancreatitis will undergo Endoscopic ultrasound elastography to assess whether this detects chronic pancreatitis.
62566834|NCT03173118|OTHER|Assessment of abdominal pain patients|Patients who are referred for assessment of abdominal pain without risk factors or any other tests suggesting chronic pancreatitis will undergo Endoscopic ultrasound elastography
62566835|NCT03299660|EXPERIMENTAL|Avelumab|Long course chemoradiotherapy (LCCRT) comprised of 50.4 Gy radiotherapy in conjunction with 5FU (225mg/m2/day continuous infusion)/Capecitabine (825 mg/m2 BID on RT days) over 5. 5 weeks, followed by 4 cycles of Avelumab. This is then followed up with surgical resection
62566836|NCT02285361||GIOTRIF|
62566837|NCT00420420|EXPERIMENTAL|MK0249|
62566838|NCT00420420|PLACEBO_COMPARATOR|placebo|
61997228|NCT05071703|EXPERIMENTAL|Trilaciclib, carboplatin, etoposide, Topotecan|Trilaciclib plus Carboplatin combined with Etoposide OR Topotecan (ES-SCLC patients)
61997229|NCT01839448||GD diagnosis before 24 weeks|"Patients in this group are diagnosed with gestational diabetes (GD) before 24 weeks of amenorrhea by means of a fasting blood glucose test \>= 0.92 g/l.~Intervention: Post-partum oral glucose tolerance test"
62182177|NCT04257422|NO_INTERVENTION|Control|In randomized controlled centers, nurses guarantee the standard care provided by the ward
62182178|NCT05937815|EXPERIMENTAL|patients with cystic fibrosis|patients with cystic fibrosis before and one year after the start of treatment with elexacaftor/tezacaftor/ivacaftor
62182179|NCT05286437|EXPERIMENTAL|Intervention|Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole
62182180|NCT01597583|EXPERIMENTAL|Use of MobileMedMinder|
62182181|NCT01597583|NO_INTERVENTION|Usual care|
62566839|NCT05473832|EXPERIMENTAL|Group 1|
62566840|NCT05473832|EXPERIMENTAL|Group 2|
62566841|NCT05473832|EXPERIMENTAL|Group 3|
62566842|NCT05473832|EXPERIMENTAL|Group 4|
62566843|NCT00488644|EXPERIMENTAL|Levothyroxine + Liothyronine|Levothyroxine 75 mcg by mouth (PO) Daily for 8 Weeks + Liothyronine 15 mcg PO Daily for 8 Weeks
62566844|NCT02491866|OTHER|psychiatric patients|patients with schizophrenia, bipolar disorder or depression according DSM V criteria
62566845|NCT01063738|ACTIVE_COMPARATOR|ICU Recovery Manual & placebo supplement|Patients will receive the standard self-directed rehabilitation package and a placebo nutritional supplement
62566846|NCT01063738|EXPERIMENTAL|ICU recovery manual & amino acid (AA) supplement|Patients will receive the standard self-directed rehabilitation package with the essential amino acid supplement
62566847|NCT01063738|EXPERIMENTAL|PEPSE & placebo supplement|Patients will receive the standard self-directed rehabilitation package plus PEPSE and the placebo nutritional supplement
62566848|NCT01063738|EXPERIMENTAL|PEPSE & AA supplement|Patients will receive the standard self-directed rehabilitation package plus PEPSE and the essential amino acid nutritional supplement
62566849|NCT01555632|PLACEBO_COMPARATOR|Arm I (placebo)|Patients receive placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
62566850|NCT01555632|EXPERIMENTAL|Arm II (atorvastatin calcium)|Patients receive atorvastatin calcium PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
62566851|NCT06516237|OTHER|to develop novel imaging and molecular biomarkers of fibrosis|50 Consecutive adult (18 years of age and older) patients, undergoing routine investigations by colonoscopy or sigmoidoscopy, will be enrolled and undergone routine biopsies in the distal colon and intestinal ultrasound with Shear wave elastography measurements.
62566852|NCT06327139|ACTIVE_COMPARATOR|Arm One: Conventional 5 point closed face immobilisation mask.|Participants will be immobilized using the standard of care immobilization for patients receiving radical radiation therapy to the head and neck which is a five point closed face mask. The thermoplastic mask immobilizes the patients head, neck and shoulders fully. Participants randomized to this group will not be monitored using intra fraction surface guided monitoring.
62566853|NCT06327139|EXPERIMENTAL|Arm Two: 5 point open face immobilization mask|Participants will be immobilized using the 5 point open face immobilization mask. The thermoplastic mask immobilizes the participants head, neck and shoulders however the mask does not cover the patients anterior portion of the participants face or chest Participants randomized to this group will be monitored using intra fraction surface guided monitoring.
62566854|NCT06327139|EXPERIMENTAL|Arm Three: 3 point open face immobilization mask|Participants will be immobilized using the 3 point open face immobilization mask. The thermoplastic mask immobilizes the patients head only and does not cover the participants face. Participants randomized to this group will be monitored using intra fraction surface guided monitoring.
62566855|NCT03611647|ACTIVE_COMPARATOR|Probiotic|
62566856|NCT03611647|PLACEBO_COMPARATOR|Placebo|
62566857|NCT02334878|EXPERIMENTAL|Stem cells,Mesenchymal|Periurethral injection of autologous bone-marrow derived stem cells.
62566858|NCT02334878|ACTIVE_COMPARATOR|surgery (TVT)|Tension-free vaginal tape operation: a midurethral sling operation
62566859|NCT00784329|EXPERIMENTAL|Optical Frequency Domain Imaging|Optical Frequency Domain Imaging System used during Lung and Bronchial biopsies to detect cancerous tissue. Tissue imaging results will be compared to tissue biopsy results.
62566860|NCT03307772|PLACEBO_COMPARATOR|placebo drink|The placebo drink consists of fermented low-fat milk with no added Lactobacillus GG.(placebo)
62566861|NCT03307772|ACTIVE_COMPARATOR|LGG Drink (|The probiotic drink consists of fermented low-fat milk with added Lactobacillus GG. (probiotics)
62566862|NCT03307772|ACTIVE_COMPARATOR|FOS Drink|The prebiotics drink consists of fermented low-fat milk with fructooligosaccharides. (prebiotics)
62566863|NCT03307772|ACTIVE_COMPARATOR|LGG e FOS Drink|The probiotics and prebiotics drink consists of acidified low-fat milk with added Lactobacillus GG and fructooligosaccharides (prebiotics and probiotics)
62566864|NCT02869347|ACTIVE_COMPARATOR|Conestat alfa|Intravenous injection of Conestat alfa, for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U (2 vials, each diluted in 14ml sterile water).
62566865|NCT02869347|PLACEBO_COMPARATOR|Sodium chloride 0.9%|Intravenous injection of sodium chloride 0.9%.
62566866|NCT06343415|ACTIVE_COMPARATOR|GAIT-assisted training|"Gait-assisted training in the Lokomat Pro, (Hocoma, Switzerland) for five consecutive days. The Lokomat Pro is a fully automated robotic training device consisting of a treadmill, a body weight support system, two motor-driven leg orthoses, a screen for augmented feedback and a therapist-controlled computer.~The orthoses drive the swing phase of the gait, and their guidance force is adjusted between 10-100%. The body weight support can be adjusted between 10-100% of the body weight. The maximum walking speed is 3 km/h, and the cadence of the orthoses is calibrated to the treadmill.~The Lokomat has five different emergency and safety stops. Every 5 minutes, an automatic signal reminds the therapist to check in; if not, the Lokomat will automatically stop. Only therapist that has gone through specific education can operate the Lokomat."
62566867|NCT06343415|ACTIVE_COMPARATOR|STEP-assisted training|"Step-assisted training in the Erigo Pro, (Hocoma, Switzerland) for five consecutive days.~The computer-controlled tilt table consists of a verticalization table up to 90° and a choice of cyclic leg movements in three distinct patterns, between 8-80 steps/minute adjustable between 0-100% guidance force. The tilt table can be used with functional electric stimulation (FES). Weight-bearing of the legs is possible between 0-50 kg.~The Erigo has one safety stop and an emergency release handle in case of a power failure during operation. Only therapist that has gone through specific introduction can operate the Erigo."
62566868|NCT02696668|ACTIVE_COMPARATOR|modified FaME|Participants in the modified FaME group will receive a 16 weeks falls rehabilitation programme which will be tailored and progressed according to their abilities and their needs by the physiotherapist / instructor providing the rehabilitation at the hospital.
61997230|NCT01839448||GD diagnosed at 24 to 28 weeks|"Patients in this group are diagnosed with gestational diabetes between 24 and 28 weeks of amenorrhea based on a normal fasting blood glucose level before 24 weeks of amenorrhea AND an abnormal oral glucose tolerance test between 24 and 28 weeks of amenorrhea.~Intervention: Post-partum oral glucose tolerance test"
61997231|NCT00951431|EXPERIMENTAL|PPI|
61997232|NCT00951431|PLACEBO_COMPARATOR|Control|
61997233|NCT01865825||Esophageal barium xray|"We will recruit 20 patients with GERD without dysphagia for an esophageal barium xray for esophageal diameter measurements.~The 20 Gastroesophageal Reflux Disease (GERD) patients will complete the Mayo Dysphagia Questionnaire 30-day and the Eosinophilic Esophagitis Actitivy Index (EEsAI) questionnaires"
62182660|NCT00241969|ACTIVE_COMPARATOR|Education and Attention Control|The education and attention control treatment provides education and served as a behavioral placebo in terms of controlling for attention and contact frequency provided. Families are provided with information including general nutrition, enzyme therapy, respiratory infection control, and typical child development anticipatory guidance and safety for preschool- aged children.
62566869|NCT02696668|EXPERIMENTAL|Multisensory|Participants in the multisensory group will receive balance exercises training which will be tailored and progressed to their abilities and needs.
61997234|NCT05667233|ACTIVE_COMPARATOR|Train to failure|Training regime will be highly uncomfortable since it will be both physically and psychologically challenging to push to momentary muscular fatigue (MMF; i.e., failure).
62566870|NCT03827681|EXPERIMENTAL|TIPS + Vasoactive Drug|
62566871|NCT03827681|ACTIVE_COMPARATOR|SEMS + Vasoactive Drug|
62566872|NCT01591096|EXPERIMENTAL|Tissue plasminogen activator|All patients will receive study drug.
62182182|NCT02930252|EXPERIMENTAL|Niti-S Biliary ComVi Stent|"Device:~Niti-S Biliary ComVi Stent is a hollow cylindrical stent fabricated by knitting first and second super-elastic shape memory alloy wires to make a net-like structure. A plurality of interlocked points allow each of the inside and outside stent bodies to contract and expand in the longitudinal direction and to apply a force against the longitudinal contraction. A hollow polytetrafluoroethylene (PTFE) membrane tube is closely fitted between the inside and outside stent bodies, with each of overlapped ends of the PTFE membrane tube and the inside and outside stent bodies integrated into a single structure."
62391359|NCT01258738|ACTIVE_COMPARATOR|etanercept|In Period 1 : Subjects will receive via a prefilled syringe an active dose equivalent to 1.0ml of Etanercept solution once weekly SC once weekly. Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
62566873|NCT01554670|NO_INTERVENTION|arthroscopic subacromial decompression|A thorough subacromial decompression was performed as described by Neer (which include coracoacromial ligament resection, excision of the anterio-lateral tip of the acromion and thorough debridement of the bursa).
62566874|NCT01554670|ACTIVE_COMPARATOR|decompression+RF micro-tenotomy|A thorough subacromial decompression was performed as described by Neer (which include coracoacromial ligament resection, excision of the anterio-lateral tip of the acromion and thorough debridement of the bursa).an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
62566875|NCT00194402|ACTIVE_COMPARATOR|1|Atorvastatin 10 mg for 12 weeks followed by Slo-Niacin (titrated from 500 to 1500 mg over 8 weeks) taken with atorvastatin 10 mg for an additional 12 weeks
62566876|NCT00194402|ACTIVE_COMPARATOR|2|Slo-Niacin (titrated from 500 to 1500 mg over 8 weeks) for 12 weeks followed by atorvastatin 10 mg taken with Slo-Niacin 1500 mg for an additional 12 weeks
62566877|NCT00553839|OTHER|Ketamine|Then a 2 mg/kg IV bolus of Ketamine hydrochloride will be given as part of general anesthesia for procedure
62566878|NCT01795391||Tegaderm HP|Patients whose intravasculare devices dressings are made exclusevely with Tegaderm HP dressings.
62566879|NCT01795391||Advanced|Patients whose intravasculare devices dressings are made exclusevely with Advanced dressings
62566880|NCT00834509||Obstructive Sleep Apnea (OSA)|OSA participants will be treated with a CPAP/APAP treatment, per standard clinical care.
62566881|NCT00834509||Control|Control participants will not receive APAP/CPAP treatment, if not diagnosed with OSA.
62566882|NCT03077815|OTHER|arm movement more than a total of at least 30 minutes a day|Using the provided rubber ball grip the ball movement on a daily basis, and grip the ball at a time 3-5 seconds, every 5 minutes, daily at least 6 rounds (for example, according to the daily morning, noon and night-time sports training in the two groups), to reach an arm movement more than a total of at least 30 minutes a day
62566883|NCT03077815|OTHER|arm movement and local press strength 50 mmHg at the upper arm|Using the provided rubber ball grip the ball movement on a daily basis, and grip the ball at a time 3-5 seconds, every 5 minutes, daily at least 6 rounds (for example, according to the daily morning, noon and night-time sports training in the two groups), to reach an arm movement more than a total of at least 30 minutes a day with Elbow proximal 4 (2\~6) local press strength 50 mmHg at the upper arm
62566884|NCT04873947||healthy adult volunteer|Subject is 18 to 50 years of age. Subject is a non-smoker or who has not smoked within 2 days prior to the study.
62566885|NCT01822730|EXPERIMENTAL|paliperidone|paliperidone arm,6mg/pill,6-12mg/day,non-forced titration method.last2-4weeks.
62566886|NCT01822730|ACTIVE_COMPARATOR|.Risperidone|Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks
62566887|NCT06210243|EXPERIMENTAL|C752|
61997235|NCT05667233|ACTIVE_COMPARATOR|Train to non-failure|Training regime will be moderately uncomfortable as participants will be training at a close proximity to failure (4-0 repetitions in reserve; i.e., non-failure).
62182183|NCT02930252|ACTIVE_COMPARATOR|Niti-S Stent (D-type)|"Device:~The Niti-S Stent (D-type) maintains a desired bent shape corresponding to the specific target lesion. It is comprised of a hollow cylindrical stent body fabricated by knitting first and second super-elastic shape memory alloy wires to make a net-like structure with a plurality of interlocked points capable of allowing the stent body to contract and expand in the longitudinal direction and to apply a force against the longitudinal contraction of the stent body.~The wires are made of a shape memory alloy through a process of shaping the alloy then heat-treating the wires to allow restoration of the original shape at a predetermined temperature."
62566888|NCT01315392|ACTIVE_COMPARATOR|delayed closure|wounds packed open with normal saline wet to dry gauze dressings and were returned to the operating room 36 to 72 hours after initial procedure for debridement and definitive closure.
61997236|NCT02838277||Lipedema|Women with all stages of lipedema
62182184|NCT04038749|EXPERIMENTAL|Pharmaceutical method- Bromocriptine|
62182185|NCT04038749|EXPERIMENTAL|Pharmaceutical method- Cabergoline|
62182186|NCT04038749|OTHER|Without medications that inhibit lactation|
62566889|NCT01315392|ACTIVE_COMPARATOR|immediate wound closure|traumatic and surgical wounds closed at initial surgical intervention
62566890|NCT05966077|EXPERIMENTAL|SMS|Sending an SMS 48 hours before the 3-month evaluation call planned as part of the VigilanS Lorraine system
61997237|NCT02838277||Dercum's disease|Men and women with nodular, mixed and diffuse Dercum's disease
62566891|NCT05966077|NO_INTERVENTION|Without SMS|without Sending an SMS 48 hours before the 3-month evaluation call planned as part of the VigilanS Lorraine system
61997238|NCT02838277||Control|Sex, age and BMI matched controls.
61997239|NCT02838277||Familial Multiple Lipomatosis|Women and men with multiple lipomas and/or angiolipomas
61997240|NCT02838277||Madelung's disease|Men and women with different types of Madelung's disease.
61997241|NCT02825303|EXPERIMENTAL|Novel workplace - first half|Intervention: A novel two-desk sit-to-stand workstation for 23 weeks; provided within the first half of the study. Traditional workstation within the second half of the study.
61997242|NCT02825303|EXPERIMENTAL|Novel workplace - second half|Intervention: A novel two-desk sit-to-stand workstation for 23 weeks; provided within the second half of the study. Traditional workstation within the frist half of the study.
61997243|NCT02825303|NO_INTERVENTION|Control group|Control group subjects did not encounter any changes in their regular office environments. Traditional workstation for both halves of the study.
62182812|NCT01502306|EXPERIMENTAL|Telephone counseling|One-on-one, proactive telephone counseling to quit smoking; The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling begins immediately after intake, if the client is available for a 30-minute session or by appointment at the clients' convenience. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls. The follow-up calls (about 10 minutes) will be scheduled as follows: a reminder call if the quit date is more than one week out for the initial counseling, on the quit date, 4-7 days after the quit date, and 10-14 days after the quit date.
62566892|NCT04499144|EXPERIMENTAL|modified buccal flap and subepithelial connective palatal flap|
62566893|NCT05194826|EXPERIMENTAL|Fascia lata membrane|
62566894|NCT05194826|ACTIVE_COMPARATOR|Connective tissue graft both with xenogenic lamina membrane|
62566895|NCT00191477|EXPERIMENTAL|A|
62566896|NCT00191477|PLACEBO_COMPARATOR|B|
62566897|NCT04395456|EXPERIMENTAL|AMY-101|
62566898|NCT04395456|PLACEBO_COMPARATOR|Placebo|
62566899|NCT06149975|EXPERIMENTAL|Intervention|"In addition to the usual care, the study participants receive the motor-cognitive training StepIt. The StepIt will be conducted as an approximately 15-minute one on one training for at least 3 to max. 10 sessions during the stay at the hospital."
61997244|NCT04985630|EXPERIMENTAL|Mitopure Challenge to assess blood levels of Urolithin A after dietary and Mitopure intake|Mitopure challenge with diet (Pomegranate juice- Before) followed by Mitopure supplementation (After) to compare levels in blood spots of UA-Glucuronide (in ng/mL)
61997245|NCT03715608|NO_INTERVENTION|Control group|Patients in the control group received routine TKA surgery and perioperative management without any other interventions.
62566900|NCT04455308|EXPERIMENTAL|Subjects with chilblains|
62566901|NCT04455308|ACTIVE_COMPARATOR|Subjects without chilblains|
62566902|NCT01067105|EXPERIMENTAL|ciclesonide|ciclesonide HFA 160 μg once daily
62566903|NCT04340037||proximal ureteral stone patient|Patients underwent percutaneous nephrolithotomy treating unilateral, solitary and proximal ureteral stones.
62566904|NCT00298272|EXPERIMENTAL|Double-blind/Open Label Rituximab|"The double-blind rituximab treatment group received rituximab 500 mg by intravenous (IV) infusion on Day 1 and Day 15. After 24 weeks (primary endpoint completion), participants continued post-treatment follow-up (PTFU) visits through Week 56, and entered a 48-week Safety Follow-Up (SFU). At any time between Week 24 and Week 40 of PTFU, eligible participants could enter the rituximab open label (OL) arm, and restart the 56-week treatment/follow-up schedule (rituximab 500 mg by IV infusion on Day 1 and Day 15) prior to the 48-week SFU.~Prior to rituximab infusion, participants were premedicated with methylprednisolone 100 mg IV. Participants received folate ≥5 mg weekly. Background therapy (stable dose for the duration of the study) included: a tumor necrosis factor (TNF) inhibitor; either etanercept 50 mg subcutaneous injection (SC) weekly or adalimumab 40 mg SC once every 2 weeks; methotrexate (MTX) 15 to 25 mg by mouth or by intramuscular injection (IM) weekly."
62566905|NCT00298272|OTHER|Double-blind Placebo/Open Label Rituximab|"The double-blind placebo treatment group received saline solution IV on Day 1 and Day 15. After 24 weeks (primary endpoint completion), participants continued post-treatment follow-up (PTFU) visits through Week 56, and entered a 48-week Safety Follow-Up (SFU). At any time between Week 24 and Week 40 of PTFU, eligible participants could enter the rituximab open label (OL) arm, and restart the 56-week treatment/follow-up schedule (rituximab 500 mg by IV infusion on Day 1 and Day 15) prior to the 48-week SFU.~Prior to each infusion of placebo, participants were premedicated with methylprednisolone 100 mg IV. Participants received folate ≥5 mg weekly. Background therapy (stable dose for the duration of the study) included: a tumor necrosis factor (TNF) inhibitor; either etanercept 50 mg subcutaneous injection (SC) weekly or adalimumab 40 mg SC once every 2 weeks; methotrexate (MTX) 15 to 25 mg by mouth or by intramuscular injection (IM) weekly."
62566906|NCT04335123|EXPERIMENTAL|Open Label Losartan|50 patients with COVID-19 and respiratory failure who meet criteria and agree to participation in the study will be placed on losartan 25 mg once daily on study day 0. If parameters are met the dose of losartan will be increased to 50 mg once daily on study day 3. Participants will continue losartan until they experience resolution of respiratory failure (normal oxygen levels on room air), are discharged from the hospital, meet stoppage criteria or complete 14 days of therapy.
62566907|NCT04335123|NO_INTERVENTION|External Control|Matched - contemporaneous control who met enrollment criteria and were treated at UKHS during the COVID-19 pandemic period.
62566908|NCT02929771|EXPERIMENTAL|Intervention Group|In addition to usual care, the intervention group will receive the Samsung GearVR with head mounted display (HMD), controller, and headphones. They will situated in front of the nurse and beside/on the lap of the parent, or they may be lying supine. The VR intervention will use auditory and visual stimuli (simulating the peaceful underwater environment) to distract the child before, during, and after the SCP needle insertion. Children will be allowed to 'try-out' the VR system before the SCP access to familiarize themselves with the equipment. The entire study will be videotaped.
62566909|NCT02929771|ACTIVE_COMPARATOR|Control Group|In addition to usual care, participants in the control group will be seated with their parent and in front of the nurse, according to preference. Children will watch an age appropriate video selected by an oncology-affiliated child life specialist on an iPad, while wearing the same headphones used in the experimental condition. The RA will hold the iPad and positioned within a meter of the child so that the child can still see the iPad without the RA interfering in the clinical procedure. The entire study will be videotaped.
62566910|NCT04059835|ACTIVE_COMPARATOR|standard|Standard bra, soft
62566911|NCT04059835|EXPERIMENTAL|compression bra|experimental bra, compression and stabile
62566912|NCT06131814|EXPERIMENTAL|Group 1|:- The INT program will involve a standard warm-up and cool down. The INT program involve exercises aimed at improving core stability, power, and strength. These exercises will progressed to more demanding exercises over the 8-week training program. The intensity increased by adding more repetitions, resistance, and through exercise modifications. Integrated resisted exercises include opposite arm and leg lift, bridging, side lying lift, ball back extension, push up 5 times repetition twice a week in first 4 week and then progress to 10 times repetition twice a week from 5-8th week of session
62566913|NCT06131814|EXPERIMENTAL|Group 2|The ISO program involved participants first performing a series of standardized warm up and cool down exercises before and after the training program, respectively. Specifically, the participants rode a stationary bike for 10 minutes followed by static stretching of the calves, hip flexor, and low back. The ISO program began with 5 time repetition and lower body resistance exercises for the first 4 weeks and progressed to 10 exercises for the last 4 weeks. The exercise resistance used in the ISO program also progressed over the 8 weeks. The static stretches were repeated as part of the cool down after completing the ISO program. Isolated exercises include leg press, bench press, Ab crunch, barbell curl and back squat
62391360|NCT01258738|PLACEBO_COMPARATOR|PLACEBO|In Period 1: Subjects will receive in a prefilled syringe with a PLACEBO dose equivalent to 1.0 ml of placebo solution once weekly SC Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
62566914|NCT01156181|EXPERIMENTAL|Cervical discharge removal|Cervical discharge will be removed using a cotton swab before embryo transfer during ICSI cycles
62566915|NCT01156181|ACTIVE_COMPARATOR|Control|Embryo transfer without any intervention
62566916|NCT04454203|EXPERIMENTAL|Mepivacaine Block Group|Infiltration of local anesthetic (mepivacaine) above and beside the femoral artery through a perineural catheter.
62566917|NCT04454203|PLACEBO_COMPARATOR|Saline Sham Group|Infiltration of salt water (saline) above and beside the femoral artery through a perineural catheter.
62391361|NCT01247376|NO_INTERVENTION|No Cooling and compression|
62182187|NCT06180863|EXPERIMENTAL|Oral azacitidine (CC-486)|"Patients on study will receive 300 mg CC-486 for 14 out of 28 days per cycle with dose modification according to the Onureg United States Prescribing Information (USPI). Up to 3 cycles of CC-486 will be allowed, and a minimum of 1 cycle is to be given prior to transplant. Multiple cycles will be allowed only if donor-specific or logistical issues prevent transplantation after the first cycle. CC-486 will be dispensed on day 1 of each treatment cycle and only 1 cycle equivalent is to be dispensed at the beginning of each cycle.~Post-transplant maintenance with CC-486 can be started 60 days (range 60-120 days) after hematopoietic progenitor cell infusion which should allow time for count and graft recovery after post-transplant cyclophosphamide (PTCY). The CC-486 maximum preferred pre-emptive dose post-ASCT is 200 mg daily, which will be administered for 14 of 28 days per cycle (max 12 cycles)."
62182188|NCT02724293|PLACEBO_COMPARATOR|Group I (placebo)|patients received placebo.
62182189|NCT02724293|ACTIVE_COMPARATOR|Group II (pregabaline 300 once)|patients received pregabalin 300 mg 2 hours preoperatively.
62182190|NCT02724293|ACTIVE_COMPARATOR|Group III (pregabaline 300 twice)|patients received pregabalin 300 mg 2 hours preoperatively and 12 hours after the preoperative dose.
62182191|NCT02724293|ACTIVE_COMPARATOR|Group IV (pregabaline 600)|patients received pregabalin 600 mg 2 hours preoperatively
62182192|NCT05684666|EXPERIMENTAL|SBE Group|Slow Breathing Exercise (SBE) was performed by the participants of SBE group. Sixteen participants included in this group.
62182193|NCT05684666|EXPERIMENTAL|PMR Group|Progressive Muscle Relaxation (PMR) Technique was performed by the participants of the PMR group. It included 16-participants for the study.
62182194|NCT05684666|EXPERIMENTAL|Combined Group|Sixty participants from the combined group performed both Slow Breathing Exercise and Progressive Muscle Relaxation technique in this study.
62566918|NCT03153904|EXPERIMENTAL|MATCH Training plus MATCH Consultation|Therapists at local, community clinics attend a 6-day training on the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems (MATCH; Chorpita \& Weisz, 2009). After the training, therapists participate in weekly consultation meetings that are led by a MATCH Consultant from the study team. MATCH Consultants review sessions and the clinical monitoring and feedback system, provide recommendations for upcoming sessions, and review MATCH modules via role-plays and models.
62566919|NCT03153904|ACTIVE_COMPARATOR|MATCH Training only|Therapists at local, community clinics attend a 6-day training on the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems (MATCH; Chorpita \& Weisz, 2009). After the training, therapists use MATCH as they think best and receive supervision from supervisors at the clinic.
62566920|NCT02450149|EXPERIMENTAL|Sorafenib|Sorafenib 400 mg will be administered orally twice a day for 28 days.
62566921|NCT06521060||Tru cut biopsy|A single arm, prospective, multicentric cohort study. A total of 250 patients is planned to be enrolled, accounting for an estimated 15% dropout rate.
62566922|NCT02922751||All Subjects|All subjects will be recruited from the Children parent studies: LOGIC (NCT00571272), BASIC (NCT00345553) and PROBE (NCT00061828) and will undergo Liver Stiffness Measurement (LSM). Subjects in these studies have one or more of the following conditions: biliary atresia (BA), Alpha1 Anti-trypsin Deficiency (A1AT) or Alagille Syndrome (ALGS).
62566923|NCT04341493|EXPERIMENTAL|Nitazoxanide + hydroxychloroquine|Hydroxychloroquine 400 mg PO every 12 hours for two days and then 200 mg PO every 12 hours for four days + Nitazoxanide 500 mg PO every 6 hours for six days
62566924|NCT04341493|ACTIVE_COMPARATOR|Hydroxychloroquine|Hydroxychloroquine 200 mg PO every 12 hours for 7 days
62566925|NCT05084027|EXPERIMENTAL|treatment group|older patients accepting venetoclax combining with fludarabine and melphalan as conditioning regimen prior to allogeneic hematopoietic stem cell transplantation treatment
62566926|NCT02233387|EXPERIMENTAL|[18F] HX4 PET imaging|injection with \[18F\] HX4 and PET imaging at baseline and after 20 Gy radiotherapy
62182195|NCT05684666|NO_INTERVENTION|Control Group|No intervention was received/performed by the sixteen participants of the control group in this study.
62566927|NCT00815932|EXPERIMENTAL|1-CRPS|10 tDCS naïve patients with CRPS-related neuropathic pain in upper limb
62566928|NCT00815932|EXPERIMENTAL|2-DN|20 tDCS naïve patients with diabetic neuropathy
62566929|NCT00815932|EXPERIMENTAL|3-RPNP|20 tDCS naïve patients with resistant peripheral neuropathic pain
62566930|NCT00815932|EXPERIMENTAL|4-CIPN|10 tDCS naïve patients with CIPN-Chemotherapy Induced Pain Neuropathy patients
62566931|NCT00827008|EXPERIMENTAL|1, verum|
62182196|NCT03146325|EXPERIMENTAL|PYLERA AND OMEPRAZOLE|14-DAY COURSE OF 3-1 PYLERA (3 CAPSULES QID) PLUS OMEPRAZOLE (BID)
62182197|NCT03146325|PLACEBO_COMPARATOR|PLACEBO|MATCHING PLACEBOS
62182198|NCT00998829||Study population|The group comprises the entire study population
62182199|NCT01001962|ACTIVE_COMPARATOR|Metformin|527 Patients treated with Metformin 850x2mg titrated to 1000x2mg Daily oral
62182200|NCT01001962|ACTIVE_COMPARATOR|Empagliflozin|527 Patients treated with empagliflozin 10mg titrated to 25 mg Daily oral
62182201|NCT02217488|EXPERIMENTAL|DG3173|
62182202|NCT02217488|PLACEBO_COMPARATOR|Vehicle|
62391362|NCT01247376|EXPERIMENTAL|Intervention with cooling and compression|
62182203|NCT00142688|EXPERIMENTAL|1|Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
62182204|NCT00142688|ACTIVE_COMPARATOR|2|Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
62182205|NCT00129649|NO_INTERVENTION|control group|This group received usual care and did not receive a telephone reminder
62182206|NCT00129649|ACTIVE_COMPARATOR|telephone reminder group|This group received a telephone reminder for their clinic appointment
61997246|NCT03715608|EXPERIMENTAL|Intervention group|The patients in the intervention group received professional psychological interventions include psychological counseling and corresponding medication after the operation. Other perioperative treatments were the same as the patients in the control group. Psychotherapy was based on the clinical expertise of the psychosocial specialist, who selected the most appropriate plan for each patient.
62182207|NCT04414631|ACTIVE_COMPARATOR|active treatment arm|treatment with conestat alfa in addition to standarf of care
62182208|NCT04414631|NO_INTERVENTION|Standard of care treatment arm|Standard of care treatment established at the centers
62182209|NCT05612841||non metastatic castration resistant prostate cancer|
62182210|NCT05612841||metastatic castrare naïve prostate cancer|
62182211|NCT01525498||1 day catheter removal|Participants randomized to group 1 will have their catheter removed 1 day after surgery.
62182212|NCT01525498||2 day catheter removal|Participants randomized to group 2 will have their catheter removed 2 days after surgery.
62182213|NCT05678686|ACTIVE_COMPARATOR|Routine Exercise Group|Conventional swallowing therapy exercises will be given to the routine exercise group.
62182214|NCT05678686|EXPERIMENTAL|PNF Exercise|Head-neck PNF (Proprioceptive Neuromuscular Facilitation) movement patterns will be applied to the participants with the combined isometric contraction technique.
62182215|NCT05678686|EXPERIMENTAL|CTAR Exercise|CTAR (Chin Tuck Against Resistance) exercises will be applied to the participants.
62566932|NCT05161260|EXPERIMENTAL|Yoga Breathing (YB)|A first production version of a mobile application that guides users through proscribed yoga breathing exercises.
62566933|NCT05161260|EXPERIMENTAL|Attention Control|A first production version of a mobile application that guides users through an attention control activity, presented as methods for mindfulness.
62566934|NCT05561673|ACTIVE_COMPARATOR|HBs-alum Group|Participants receive three doses of GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide, one each at Day 1, Day 31 and Day 181.
62566935|NCT05561673|EXPERIMENTAL|HBs-AS03 Group|Participants receive two doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03, adjuvant system, one each at Day 1 and Day 31.
62566936|NCT05561673|EXPERIMENTAL|HBs-AS04 Group|Participants receive two doses of GSK's Hepatitis B vaccine adjuvanted with GSK's AS04, adjuvant system, one each at Day 1 and Day 31.
62566937|NCT05561673|EXPERIMENTAL|HBs-AS37_formulation 1 Group|Participants receive two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1, one each at Day 1 and Day 31.
62566938|NCT05561673|EXPERIMENTAL|HBs-AS37_formulation 2 Group|Participants receive two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2, one each at Day 1 and Day 31.
62566939|NCT02301013|EXPERIMENTAL|Urinary incontience surgery|Patients who is between 25 to 70 years old and positive stress test and have TVT or TOT operations with diagnoses of stress urinary incontinence and mixed urinary incontinence .
62566940|NCT06461325||Bianchi|Gastroschisis treated by the Bianchi procedure
62566941|NCT06461325||Schuster|Gastroschisis treated by the Schuster procedure
62182216|NCT05260554||using fosfomycin|The patients in this group; have been prescribed fosfomycin for 7 days (3 doses, two days apart).
62182217|NCT05260554||using cranberry extract|The patients in this group; took 7 days (1 tablet each day) of cranberry tablets.
62566942|NCT06461325||Sutureless|Gastroschisis treated by the Sutureless procedure
62566943|NCT06461325||Vacuum Assisted Closure|Gastroschisis treated by Vacuum Assisted Closure
61997247|NCT06242210|EXPERIMENTAL|Pursed Lip Breathing Technique|Patient will be asked to attain fowler's position by placing a pillow in front of his trunk to support a comfortable breathing pattern. Then, patient will be instructed to inhale through nose deeply until no more air can be inhaled and which will be followed by a slow expiration through pursed or rounded lip, like at the time of whistling.Patient will also be demonstrated visually for the proper breathing pattern even for once to multiple times till complete understanding before performing itself. The technique will be administered to the patient under supervision for 10 minutes, and the patient will be instructed to use this trained exercise in his daily routine as per needed.
61997248|NCT06242210|EXPERIMENTAL|Stacked Breathing|Patient will be asked to attain recumbent position by lying supine at a reclining angle to support a comfortable breathing pattern. Then, patient will be instructed to inhale slowly and deeply once through nose and hold it, then inhale again slowly and deeply through nose and trap the air in again over the first one, then inhale again until no more air can be inhaled and which will be held for a bit then followed by a slow and quiet expiration. Patient will also be demonstrated visually for the proper breathing pattern even for once to multiple times till complete understanding before performing itself
62566944|NCT04714879|EXPERIMENTAL|Slow oscillating transcranial direct current stimulation (so-tDCS)|7 experimental daytime naps with so-tDCS of different frequencies (fixed frequency of 0.75 Hz versus individually adapted frequency) and durations (5 min, 2 min, 30 sec) (Crossover assignment, applicable for each participant)
62182218|NCT04035577|EXPERIMENTAL|Extended usability of a mobile self-help intervention|Participants will have open access to the Intellicare Hub app for 8-weeks and be surveyed at Baseline, 4-weeks, and 8-weeks
62566945|NCT04714879|SHAM_COMPARATOR|Sham stimulation|sham so-tDCS during a daytime nap (Crossover assignment, applicable for each participant)
62182219|NCT01652859|EXPERIMENTAL|Liposomal Amphotericin B|Generic drug
62566946|NCT00806403|ACTIVE_COMPARATOR|thrombolysis|
62566947|NCT00806403|ACTIVE_COMPARATOR|invasive|
62566948|NCT03747523|EXPERIMENTAL|Healthy Group|40 Healthy individuals will receive a single dose of ergocalciferol (200,000 units)
62566949|NCT03747523|EXPERIMENTAL|ADTKD-MUC1 Group|40 individuals with ADTKD-MUC1 (Autosomal Dominant Tubulo-Interstitial Kidney Disease- a rare disease caused by mutation in MUC1) will receive a single dose of ergocalciferol (200,000 units)
62182220|NCT01652859|ACTIVE_COMPARATOR|AmBisome|RLD
62182221|NCT03052712|ACTIVE_COMPARATOR|Patients|battery of tests of social cognition
62182222|NCT03052712|ACTIVE_COMPARATOR|Control|battery of tests of social cognition
62182223|NCT01754532||Schizophrenia patients|
62182224|NCT05629247|OTHER|Screening|
62182225|NCT05914415|PLACEBO_COMPARATOR|Control|standard preoperative training
62182226|NCT05914415|EXPERIMENTAL|Experimental|structured training app
62182227|NCT03487263|EXPERIMENTAL|IC14 dose level 1|For the initial 3 patients: intravenous IC14 at a dosage of 2 mg/kg on Study Day 1, then 1 mg/kg once daily on Study Days 3-5 for 4 total doses
62182228|NCT03487263|EXPERIMENTAL|IC14 dose level 2|For the subsequent 7 patients: intravenous IC14 at a dosage of 4 mg/kg/day on Day 1, followed by IC14 2 mg/kg/day on Days 2-4
62182229|NCT05282641|EXPERIMENTAL|Collagen hydrolysate|30 subjects will consume the protein hydrolysate daily for 4 weeks
62182230|NCT05282641|PLACEBO_COMPARATOR|Placebo|30 subjects will consume the placebo daily for 4 weeks
62182231|NCT01117129|EXPERIMENTAL|A|
62182232|NCT01117129|PLACEBO_COMPARATOR|B|
62566950|NCT06396117||patients who have KS|Group one is patients with Klinefelter syndrome confirmed as 47, XXY on karyotyping undergoing mTESE for non-obstructive azoospermia
62566951|NCT06396117||Patient who does not have KS|Group two consists of patients with a normal karyotyping undergoing mTESE for non-obstructive azoospermia
62566952|NCT04939831|EXPERIMENTAL|1|the group of LRH
62566953|NCT04939831|ACTIVE_COMPARATOR|2|the group of ARH
62566954|NCT00717392||Hippotherapy_ADHD|10 children with ADHD who receive hippotherapy
62566955|NCT00717392||Hippotherapy_ASD|10 children with ASD who receive hippotherapy
62566956|NCT00717392||Control_ADHD|10 children with ADHD who DO NOT receive hippotherapy
62566957|NCT00717392||Control_ASD|10 children with ASD who DO NOT receive hippotherapy
62566958|NCT02454608|EXPERIMENTAL|Treatment|Verapamil HCl, capsules for oral administration, 80mg, TID, for 8 weeks
62566959|NCT02454608|PLACEBO_COMPARATOR|Control|Placebo, capsules for oral administration, TID, for 8 weeks
62566960|NCT02454608|EXPERIMENTAL|Open Label|Verapamil HCl, capsules for oral administration, 80mg, TID, for 1 year
62566961|NCT02367651|EXPERIMENTAL|Pazopanib|Subjects will receive pazopanib 800 mg once daily during each 28-day treatment period until disease progression, unacceptable adverse event (AE)/serious adverse event (SAE), death or withdrawal of consent
62566962|NCT02367651|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo once daily during each 28-day treatment period until disease progression, unacceptable AE/SAE, death or withdrawal of consent
62566963|NCT01079468||Total Hip Arthroplasty|
62566964|NCT01079468||Total Hip Resurfacing Arthroplasty|
62566965|NCT01963104|EXPERIMENTAL|Automated hearing test|Subjects will take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.
62566966|NCT01963104|EXPERIMENTAL|Pure-tone Screener test|Subjects will take a pure-tone hearing screening test and then receive recommendations for hearing healthcare follow-up.
62566967|NCT01963104|EXPERIMENTAL|Digits-in-noise test|Subjects will take a digits-in-noise test and then receive recommendations for hearing healthcare follow-up.
62566968|NCT01963104|EXPERIMENTAL|No screening test|This group of subjects will not receive a screening test.
62566969|NCT01963104|EXPERIMENTAL|Automated hearing test/Motivation video|Subjects will take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up. They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
62566970|NCT01963104|EXPERIMENTAL|Pure-tone Screener/Motivation video|Subjects will take a pure-tone hearing screening test and then receive recommendations for hearing healthcare follow- up. They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
62182233|NCT00611715|EXPERIMENTAL|First line/hormone-therapy naive|
62182234|NCT00611715|EXPERIMENTAL|Second-line/prev hormone-therapy tx|
62182235|NCT04249050|EXPERIMENTAL|Intervention group|The intervention group is receiving a nutritional drink containing potential immune stimulating ingredients (fish oil, arginine, nucleotides)
62182236|NCT04249050|NO_INTERVENTION|Control group|The Control group is receiving the hospital´s Standard Of Care.
62566971|NCT01963104|EXPERIMENTAL|Digits-in-noise test/Motivational video|Subjects will take a digits-in-noise test and then receive recommendations for hearing healthcare follow-up.They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
62182237|NCT02455999|EXPERIMENTAL|SYL1001 eye drops dose C|SYL1001 eye drops dose C administration via the ophthalmic route
62566972|NCT01963104|EXPERIMENTAL|No screening test/Motivational video|This group of subjects will not receive a screening test. They will watch a brief video that shows how hearing works and learn about the different types of hearing loss
62182238|NCT02455999|EXPERIMENTAL|SYL1001 eye drops dose D|SYL1001 eye drops dose D administration via the ophthalmic route
62182239|NCT02455999|PLACEBO_COMPARATOR|Placebo|Placebo eye drops administration via the ophthalmic route
62182240|NCT04390412|EXPERIMENTAL|Low Dose Radiotherapy|0.5 Gy radiation to both lungs in an AP/PA fashion
62566973|NCT01963104|EXPERIMENTAL|Home Hearing Screening Test|Subjects will be taught the set-up for a home hearing screening test, take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.
62391363|NCT04174430||mild to moderate bronchiolitis|Bronchiolistis patients without Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks, Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency and Neurologic disease
62566974|NCT01963104|EXPERIMENTAL|Home Hearing Screening Test/Brief video|"Subjects will be taught the set-up for a home hearing screening test, take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.~They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss."
62566975|NCT01279317|EXPERIMENTAL|vinegar co-ingestion|25 ml vinegar is added to glucose containing beverage
62566976|NCT01279317|PLACEBO_COMPARATOR|Placebo co-ingestion|25 ml vinegar is substituted by 25 ml water
62566977|NCT01408303|PLACEBO_COMPARATOR|Olive Oil|olive oil: 4 g/day + prescription statin
62566978|NCT01408303|EXPERIMENTAL|Epanova, 2 g|omega-3-carboxylic acids, 2g/day + prescription statin
62566979|NCT01408303|EXPERIMENTAL|Epanova, 4 g|omega-3-carboxylic acids, 4g/day + prescription statin
62566980|NCT03673969|ACTIVE_COMPARATOR|MGB|Mini gastric bypass
62566981|NCT03673969|ACTIVE_COMPARATOR|Roux enY gastric bypass|Roux enY gastric bypass
62391364|NCT01230073|ACTIVE_COMPARATOR|ICD traditional follow-up|ICD with traditional follow-up in the outpatient clinic
62391365|NCT01230073|ACTIVE_COMPARATOR|Home-Monitoring|Home-Monitoring
62566982|NCT03634969|EXPERIMENTAL|Normal Renal Function|
62566983|NCT03634969|EXPERIMENTAL|Mild Renal Impairment|
62566984|NCT03634969|EXPERIMENTAL|Moderate Renal Impairment|
62566985|NCT03634969|EXPERIMENTAL|Severe Renal Impairment|
62566986|NCT03634969|EXPERIMENTAL|End-Stage Renal Disease (ESRD)|ESRD participants and are on chronic hemodialysis
62566987|NCT04851301|ACTIVE_COMPARATOR|Naloxone|NARCAN® Naloxone Nasal Spray will be used to determine how the opioid tone shapes VR-induced hypoalgesia. Participants will be stratified for sex and then randomized to naloxone (The dose of naloxone will be 4 mg, so 0.1 mL of 40 mg/ml naloxone solution given intranasally) or saline (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.
62566988|NCT04851301|SHAM_COMPARATOR|Saline|Saline group, where participants will be given saline solution (4mg) via an identical spray device. Participants will be stratified for sex and then randomized to saline arm (The dose of saline will be (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.
62566989|NCT04851301|OTHER|Natural History|Natural history group, where participants will not be given any drugs. Participants will be stratified for sex and then randomized to the Natural History group.
62566990|NCT05914597|OTHER|Participant|Patients with lower gastrointestinal symptoms who have been selected by overseeing clinician meeting NHS England criteria to undergo colon capsule endoscopy as part of their standard of care and are 18 or over .
62566991|NCT05370599|ACTIVE_COMPARATOR|Amlodipine 2.5 mg + Home BP monitoring with cuffed device|Use of at least the minimum dose of amlodipine and use of a home BP monitoring device for BP monitoring
62566992|NCT05370599|EXPERIMENTAL|Chlorthalidone 12.5 mg + Home BP monitoring with cuffed device|Use of at least the minimum dose of chlorthalidone and use of a home BP monitoring device for BP monitoring
62566993|NCT05370599|EXPERIMENTAL|Losartan 12.5 mg daily + home BP monitoring with cuffed device|Use of at least the minimum dose of losartan and use of a home BP monitoring cuffed device only for BP monitoring
62566994|NCT05370599|EXPERIMENTAL|amlodipine 2.5 mg daily + home BP monitoring with patch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a patch for BP monitoring
62566995|NCT05370599|EXPERIMENTAL|Chlorthalidone 12.5 mg daily + home BP monitoring with patch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a patch for BP monitoring
62566996|NCT05370599|EXPERIMENTAL|Losartan 12.5 mg daily + home BP monitoring with patch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a patch for BP monitoring
62182241|NCT06325345|OTHER|Standard Medical Therapy|Standard Medical Treatment will be administered by board certified gastroenterologists through the EDS Clinic gastroenterology clinical care pathway. Therapies will be individualized to the participants' current symptoms and severity of symptoms as per current clinical guidelines for management of IBS. Potential therapies that may be administered include dietary changes, supplemental fibre, and pharmacotherapy (including neuromodulators) as appropriate.
61997249|NCT05016232|EXPERIMENTAL|Strength Based Case Management (SBCM) & PrEP adherence training and counseling|"Stage 1: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.~Stage 2: Stepped Intervention:~1. Initially TGW in this arm will receive daily 2-way gender-affirming text message reminders, and~2. Then those continuing to have poor adherence will receive the 4 (once per week for 3 to 4 weeks) more intensive counseling session with a clinical interventionist."
61997250|NCT05016232|NO_INTERVENTION|Standard of Care:Stage 1 and Stage 2|Stage 1: Referral to local PrEP clinic Stage 2: Standard clinical PrEP care: Doctor visit every three months to assess for side effects, do blood work, and receive a HIV test.
62182242|NCT06325345|EXPERIMENTAL|Standard Medical Therapy plus Gut-Directed Hypnotherapy|In addition to Standard Medical Therapy, participants randomized to this arm will attend 8 sessions of gut-directed hypnotherapy by a trained behavioral therapist. The treatment protocol developed for the proposed study was adapted from the empirically-supported Manchester Protocol for gut-directed hypnotherapy. At each visit, a voluntary, pleasant, and dream-like state of deep relaxation will be induced and suggestions made for greater relaxation, abdominal comfort, and normalization of gut function. The first session will be 90 minutes in duration and the remaining sessions will be 60 minutes. At the first session, participants will be provided with 30 minutes of education on the nature of the gut-brain axis and hypnotherapy before they undergo hypnotherapy.
62182243|NCT04719715||Cases with ANCA vasculitis|Indirect immunofluorescence (IIF) will be performed as well as myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays and evaluated
62182244|NCT04719715||Controls with autoimmune diseases other than ANCA vasculitis|Indirect immunofluorescence (IIF) will be performed as well as myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays and evaluated
62182245|NCT02046798|EXPERIMENTAL|14C labeled ASP3652|
62182246|NCT03087331|EXPERIMENTAL|Pharmacist intervention|Within the pharmacist intervention arm, pharmacists will do medication reviews, assessment, recommendations, education.
62182247|NCT00765154|ACTIVE_COMPARATOR|Group 1|Immediate switch from NNRTI/PI to DRV/r
62182248|NCT00765154|ACTIVE_COMPARATOR|Group 2|Switch after 10 weeks from NNRTI/PI to DRV/r
62182249|NCT06437119|EXPERIMENTAL|Nutrition supplement group|The compound plant nutrients include extracts of licorice, sophora, wild cherry berry, dendrobium officinale, and pomegranate. They should be taken three times a day, one pack at a time, brewed and dissolved in warm water, and taken with meals or after meals.
62182250|NCT06437119|PLACEBO_COMPARATOR|placebo group|A placebo with an indistinguishable appearance and color. 3 times a day, 1 pack at a time, dissolve in warm water and take with meals or after meals.
62182251|NCT00296010|EXPERIMENTAL|CASA-nil PLD|Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
62566997|NCT05370599|EXPERIMENTAL|amlodipine 2.5 mg daily + home BP monitoring with watch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a watch for BP monitoring
62566998|NCT05370599|EXPERIMENTAL|chlorthalidone 12.5 mg daily + home BP monitoring with watch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a watch for BP monitoring
62566999|NCT05370599|EXPERIMENTAL|losartan 12.5 mg daily + home BP monitoring with watch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a watch for BP monitoring
62567000|NCT03481673|EXPERIMENTAL|Intervention|This pre-experimental pilot project is a single group, pretest-posttest design with a 6-week post-intervention follow-up. A single group design was chosen for this feasibility pilot study because the COPE for Asthma intervention is newly adapted for 8 to 12-year-old children with asthma in an urban setting. The intervention will consist of 7 weekly sessions (30 minutes each). COPE for Asthma is a manualized, cognitive behavior skills-building intervention to improve the physical and mental health outcomes of children with asthma and elevated symptoms of anxiety or depression. Surveys with children and their parents/caregivers (CGs) will occur at baseline, immediately post-intervention and 6 weeks' post-intervention.
62567001|NCT02066701||Endoscopy Barrett's|Patients undergoing clinically indicated upper endoscopy will be invited to participate. Patients who are known to have Barrett's Esophagus as well as patient who do not will be approached for enrollment
62182252|NCT00296010|ACTIVE_COMPARATOR|CASA-Nil|No adjuvant therapy
62182253|NCT00296010|EXPERIMENTAL|CASA-CM PLD|Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
62182254|NCT00296010|ACTIVE_COMPARATOR|CASA-CM CM|Low-dose, metronomic cyclophosphamide and methotrexate (CM) for 16 weeks
62182255|NCT01458080||Patients w/secondary thrombocytopenia related to hepatitis C|Patients w/secondary thrombocytopenia related to hepatitis C
62567002|NCT02066701||Endoscopy control|Patients undergoing clinically indicated upper endoscopy will be invited to participate. Patients who are known to have Barrett's Esophagus as well as patient who do not will be approached for enrollment
62567003|NCT04473222|EXPERIMENTAL|Sleep Well! Intervention|Participants in this condition will begin the Sleep Well! intervention after initiating baseline, daily diary, and actigraph procedures. Sleep Well! will be provided over approximately 6-8 weeks and will include 3 sessions. Intervention sessions will typically last about an hour, but session length may vary.
62567004|NCT04473222|OTHER|Enhanced Usual Care|The enhanced usual care condition will occur between 6 and 8 weeks. At randomization to this condition, participants will be provided with an evidence-based sleep guidelines for young children from the CHOP Parent Family Education manual. Participants in this condition will also be able to consult with their primary care physician for management of child sleep. Consistent with usual care in the CHOP system, the primary care physician may manage the sleep concern or choose to make a referral to the CHOP sleep center or to other behavioral health services internal or external to the CHOP system. Of note, the CHOP Parent Family Education handouts provide contact information for the CHOP Sleep Center and direct readers to follow-up with their primary care provider for further guidance.
62567005|NCT05507073|ACTIVE_COMPARATOR|Manual Total Hip Replacement|Manual Total Hip Replacement
62182256|NCT04710186||Male patients with PAD|The cohort was built to collect information about the role of androgen receptor, insulin receptor and Insulin-like Growth Factor 1 Receptor (IGF-IR) expression in patients with peripheral artery disease referred to Vascular Surgeon Specialist.
62182257|NCT00168493|ACTIVE_COMPARATOR|intervention|there is no sham or placebo control arm It is a single arm study
62182258|NCT05247476|ACTIVE_COMPARATOR|L-T4 therapy group|Patients with refractory hypothyroidism still receive L-T4 therapy as usual.
62182259|NCT05247476|EXPERIMENTAL|L-T4+T3 therapy group|Patients with refractory hypothyroidism receive L-T4+T3 therapy
62182260|NCT04862676|EXPERIMENTAL|Experimental Arm:single|Repeated treatments with hyperbaric oxygen on Days 0, +1 and +2 of high-dose therapy melphalan and autologous transplants.
62567006|NCT05507073|EXPERIMENTAL|Robot-Assisted Total Hip Replacement|Robot-Assisted Total Hip Replacement
62567007|NCT05760196|EXPERIMENTAL|Recurrent or metastatic advanced head and neck malignancy|Patients with a clear pathological diagnosis, imaging diagnosis, and history, no clear recommended standard treatment or inability to tolerate standard treatment, and a clear measurable lesion
62567008|NCT05679739|EXPERIMENTAL|Individualized blood pressure strategy|Hemodynamic optimization performed to an individualized target mean arterial pressure in the first 72 hours post ROSC based on cerebral perfusion assessed serially.
62567009|NCT05679739|NO_INTERVENTION|Standard-of-care group|Hemodynamic optimization to a target mean arterial pressure of ≥65mmHg throughout the first 72 hours post-ROSC.
62567010|NCT00047073|EXPERIMENTAL|Phase 1|See intervention description.
62567011|NCT00047073|EXPERIMENTAL|Phase 2|See intervention description.
62567012|NCT04632186|EXPERIMENTAL|Intervention|"3 sessions with 3 different interventions 1) Transcutaneous electric nerve stimulation (TENS)- at the shoulder according to current best evidence and practice 2) EXOPULSE Mollii suits- local stimulation at the shoulder, 3) EXOPULSE Mollii suit- according to current best experienced practice~The order in which the participants´ receive the different treatments will be randomized.~Each session lasts for approximately 2.5 hours (approximately 60 min for assessment, 30 min for settings and adjustments and 60 min for treatment)"
62567013|NCT06140537|EXPERIMENTAL|Dapagliflozin|Participants will receive dapagliflozin 10mg daily
62182261|NCT00630552|EXPERIMENTAL|Phase 1b AMG 655 3mg/kg|Subjects were treated with one of 2 dose levels of AMG 655 (3 mg/kg) with gemcitabine.
62391366|NCT04495166|EXPERIMENTAL|Motherly app with brief psychotherapy|Participants in this arm will receive intervention via Motherly 1.0, an app that delivers behavioral activation strategies and psychoeducational content to promote changes in sleep, nutrition, and physical activity habits. It has also functionalities that help participants to engage in prenatal care, breastfeeding, and social support, and to stimulate child development. In addition will undergo brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation.
62567014|NCT06140537|PLACEBO_COMPARATOR|Placebo|Participants will receive one placebo tablet daily
62567015|NCT05944471|NO_INTERVENTION|Control group|The Inadequate Milk Perception Scale was administered to the mothers to determine the mothers who thought that their milk was inadequate by face-to-face interview method before discharge from the hospital after delivery. Mothers with low scale scores were randomly assigned to the control group as described in the intervention group. Then, Personal Information Form-1, Tendency to Discontinue Breastfeeding Scale and Breastfeeding Self-Efficacy Scale were applied to the mothers. The mothers determined as the control group were called by the investigators via telehealth application between the 2nd-5th days, 13th-17th days, 38th-40th days, 2nd-3rd months, 4th-5th months and at the end of the 6th month and the relevant forms were applied again. No intervention was made to the mothers in the control group.
62182262|NCT00630552|EXPERIMENTAL|Phase 1b AMG 655 10mg/kg|Subjects were treated with one of 2 dose levels of AMG 655 (10 mg/kg) with gemcitabine.
62182263|NCT00630552|EXPERIMENTAL|Phase 2 AMG 655|Subjects were treated with the dose of AMG 655 (10mg/kg) in combination with gemcitabine. Gemcitabine (1000 mg/m2) was administered by intravenous infusion on days 1, 8 and 15 of each 28 day cycle followed by the AMG 655 infusion on days 1 and 15 after completion of the gemcitabine infusion.
62182264|NCT00630552|EXPERIMENTAL|Phase 2 AMG 479|Subjects were treated with the dose of AMG 479 (12 mg/kg) in combination with gemcitabine. Gemcitabine (1000 mg/m2) was administered by intravenous infusion on days 1, 8 and 15 of each 28 day cycle followed by the AMG 479 infusion on days 1 and 15 after completion of the gemcitabine infusion.
62182265|NCT00630552|PLACEBO_COMPARATOR|Phase 2 AMG 655-placebo|Subjects were treated with the dose of AMG 655-placebo in combination with gemcitabine. Gemcitabine (1000 mg/m2) was administered by intravenous infusion on days 1, 8 and 15 of each 28 day cycle followed by the AMG 655-placebo infusion on days 1 and 15 after completion of the gemcitabine infusion.
62182266|NCT05277506|EXPERIMENTAL|smile arc protection bonding strategy group|female patients with mild crowding will recieve orthodontic brackets bonding using smile arc protection bonding strategy
62567016|NCT05944471|EXPERIMENTAL|Intervention Group|"Insufficient Milk Perception Scale, Personal Information Form, Tendency to Discontinue Breastfeeding Scale and Breastfeeding Self-Efficacy Scale were also administered to the mothers. After discharge, training videos and written documents were sent to the mothers individually via telehealth application once a week. Visualised messages explaining breastfeeding and that breastmilk is sufficient for the baby were also sent via telehealth application five days a week. Mothers were video-called between 10.00-17.00 on weekdays and live support was provided by the investigators. Mothers in the intervention group were called via telehealth application between the 2nd-5th days, 13th-17th days, 38th-40th days, 2nd-3rd months, 4th-5th months and at the end of the 6th month postpartum and the relevant forms were applied again. In addition, the qualitative questions in the Semi-structured Interview Form were asked at the end of the 6th month."
62567017|NCT04180020|ACTIVE_COMPARATOR|TAU|Treatment as Usual (TAU).
62567018|NCT04180020|EXPERIMENTAL|ID/LAB|Infectious Disease management of OUD with Long-Acting injectable buprenorphine (ID/LAB).
62567019|NCT02644954|ACTIVE_COMPARATOR|Metformin|Topical coal tar and topical calcipotriol + oral metformin 850mg twice daily
62567020|NCT02644954|PLACEBO_COMPARATOR|Placebo|Topical coal tar and topical calcipotriol
62567021|NCT01436513|EXPERIMENTAL|A|Premarin reference tablet as a single oral dose under fasted conditions
62567022|NCT01436513|EXPERIMENTAL|B|Premarin new tablet as a single oral dose under fasted conditions
62567023|NCT01436513|EXPERIMENTAL|C|Premarin reference tablet as a single oral dose under fed conditions
62567024|NCT01436513|EXPERIMENTAL|D|Premarin new tablet as a single oral dose under fed conditions
62567025|NCT06488430|EXPERIMENTAL|Multidomain intervention package for preventing cognitive decline|A multidomain intervention including nutritional advice, physical activity, cognitive stimulation training, social support and engagement and management of vascular risk factors.
62567026|NCT05325177|ACTIVE_COMPARATOR|Group 1 infants|(n=15) will receive three doses of standard-dose Ibuprofen. (10-5-5 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
62567027|NCT05325177|ACTIVE_COMPARATOR|Group 2 infants|(n = 15) will receive three doses of high-dose Ibuprofen Motrin. (20-10-10 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
62567028|NCT00198718|EXPERIMENTAL|Infant vitamin A Mother vitamin A|Infant received 50,000 IU vitamin A, mother received 400,000 IU vitamin A
62567029|NCT00198718|EXPERIMENTAL|Infant vitamin A Mother placebo|Infant received 50,000 IU vitamin A, mother received placebo
62567030|NCT00198718|EXPERIMENTAL|Infant placebo, mother vitamin A|Infant received placebo, mother received 400,000 IU vitamin A
62567031|NCT00198718|EXPERIMENTAL|Infant received placebo, mother received placebo|Infant and mother received placebo
62567032|NCT01677468|EXPERIMENTAL|Intermediate embolization|TACE with substatsis using gelfoam
62182267|NCT05277506|ACTIVE_COMPARATOR|MBT placement guide group|female patients with mild crowding will recieve orthodontic brackets bonding using MBT placement guide
62182268|NCT05038709|EXPERIMENTAL|Pink Pad|Hip arthroscopy using The Pink Pad Hip Kit Patient Positioning System (Xodus Medical, New Kensington, PA). The pad is placed between the patient and the traction table, using a perineal post.
62182269|NCT05038709|NO_INTERVENTION|Control (No pad)|Hip arthroscopy in the usual fashion, no pad, using traction table with perineal post.
62567033|NCT01677468|ACTIVE_COMPARATOR|Complete embolization|TACE with complete embolization using gelfoam
62567034|NCT00928291|EXPERIMENTAL|Group 1 - PCT group|interventions on antibiotic therapy will be based on circulating PCT levels
62567035|NCT00928291|ACTIVE_COMPARATOR|Group 2 - Control group|antibiotic therapy will be guided by appropriate guidelines, and will be left at the discretion of caregivers.
62567036|NCT01775111|SHAM_COMPARATOR|Cognitive Training|Cognitive Training (riddles, skill games, ...) is performed twice a week in small groups
62567037|NCT01775111|EXPERIMENTAL|Strength Training|Progressive strength training is applied, meaning that the intensity is adjusted continuously in order to obtain a sufficient training stimulus. Exercises are chosen to involve the major muscle groups and are performed by using the own body weight or elastic bands.
62567038|NCT01775111|EXPERIMENTAL|Strength Training and Supplement|In addition to strength training as described above, participants receive a water-soluble dietary supplement 9x/week (FortiFit, Nutricia) consisting of 20.7 g of protein (56 En%, 19.7 g whey protein, 3 g leucine,\> 10 g essential amino acids), 9.3 g carbohydrates (25 En%, 0.8 BE), 3.0 g fat (18 En%), 1.2 g fiber (2 En%), 800 IU (20μg) of vitamin D, 250mg calcium, vitamins B6 and B12, folic acid and magnesium.
62567039|NCT04630002|EXPERIMENTAL|Cohort 1: GSK3640254 then DRV/RTV then GSK3640254 + DRV/RTV|Cohort 1 will include 3 periods. In Period 1 GSK3640254 will be administered (Treatment A). In Period 2 DRV/RTV will be administered (Treatment B). In Period 3 GSK3640254 (Treatment A) and DRV/RTV (Treatment B) will be administered.
62567040|NCT04630002|EXPERIMENTAL|Cohort 2: GSK3640254 then ETR then GSK3640254 + ETR|Cohort 2 will include 3 periods. In Period 1 GSK3640254 will be given (Treatment A). In Period 2 ETR will be given (Treatment C). In Period 3 GSK3640254 (Treatment A) and ETR (Treatment C) will be administered.
62182270|NCT05190471|EXPERIMENTAL|Relapsed/Refractory AML - BP1002 monotherapy|BP1002 monotherapy dose escalation
61997251|NCT03179085|ACTIVE_COMPARATOR|Usual Care / Delayed Intervention|Participants randomized to the control group will receive usual care by their provider for 12 months. They will also attend one group class taught by CHRs in which they will learn basic information about diabetes prevention. DI participants will receive publicly-available literature that reinforces the information given in class, and they will have no other contact with study staff aside from during study data collection visits at baseline and 12 months. After 12 months of usual care, patients will enter into the delayed intervention where they will complete 12 months of Home-Based Kidney Care (HBKC).
62182271|NCT05190471|EXPERIMENTAL|Relapsed/Refractory AML - BP1002 in combination with decitabine|BP1002 single dose in combination with decitabine
62567041|NCT04630002|EXPERIMENTAL|Cohort 3: GSK3640254 then GSK3640254 + DRV/RTV + ETR|Cohort 3 will include 2 periods. In Period 1 GSK3640254 will be administered (Treatment A). In Period 2 GSK3640254 (Treatment A), DRV/RTV (Treatment B), and ETR (Treatment C) will be administered.
62567042|NCT05261087||Factory worker|Workers working in the TPI blade factory will be included in the study. Those working in the wind vane production at the factory are divided into departments. The 65.5 main mold workers, which will require the most attention, will be included in our work.
62182272|NCT05961982|EXPERIMENTAL|Treatment (EUS-RFA)|Patients undergo standard of care EUS-FNA followed by EUS-RFA on study and may undergo repeat EUS-RFA or EUS-guided chemoablation during surveillance. Patients undergo MRI/MRCP, CT, or EUS-FNA at baseline and at follow-up timepoints.
62182273|NCT04629937|EXPERIMENTAL|SPECT acquisitions|All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.
62567043|NCT03941808|EXPERIMENTAL|Drug|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
62567044|NCT03941808|PLACEBO_COMPARATOR|Placebo|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
62567045|NCT03735277|EXPERIMENTAL|HPC, Cord Blood|HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10\^8 total nucleated cells with a minimum of 1.25 × 10\^6 viable CD34+ cells in a volume of 25 milliliters.
62567046|NCT03970629|ACTIVE_COMPARATOR|Robotic Assisted TKA|Robotic Assisted TKA via ROSA Robot
62567047|NCT03970629|ACTIVE_COMPARATOR|Conventional TKA|Conventional TKA
62020837|NCT03000894|NO_INTERVENTION|Standard care|Only standard care will be provided to this group. Medications will be prescribed and referral to community nurse, social worker and psychologist will be made by the doctors according to their need.
62391552|NCT06234995|EXPERIMENTAL|Patients with Parkinson's Disease|Patients with PD complete motor response inhibitions tasks under multiple conditions, depending on the study aim they are participating in. Those who are participants in Aim 1 of the study are able to also participate in Aims 2 and 3 if they are having a clinically indicated DBS leads implanted. Patients with PD will participate in the study for approximately 18 months which includes one preoperative visit, intraoperative data collection and two post-operative visits. As part of the motor inhibition tasks, EEG signals will be recorded. A cap similar to a swim cap will be placed on the head of the subject, and gel will be applied to the hair to get a good signal. Electrodes will be attached to the cap for recording of brain signals. A few additional flat electrodes will be placed on the skin to record hand muscle activity (for GNG task) and near the eyes to record eye movements. Accelerometer sensors will be utilized to record arm movements (for MSS task).
62020838|NCT04273958|EXPERIMENTAL|Virtual reality|The intervention will consist of the use of a virtual reality helmet during the painful medical procedure. The content has been developed by a private company with the goal of providing a relaxing and soothing exploration of a virtual world.
62391553|NCT06234995|NO_INTERVENTION|Healthy Controls|Healthy participants complete motor response inhibition tasks during two study visits. Healthy controls will participate for approximately one month, which includes two study visits. As part of the motor inhibition tasks, EEG signals will be recorded. A cap similar to a swim cap will be placed on the head of the subject, and gel will be applied to the hair to get a good signal. Electrodes will be attached to the cap for recording of brain signals. A few additional flat electrodes will be placed on the skin to record hand muscle activity (for GNG task) and near the eyes to record eye movements. Accelerometer sensors will be utilized to record arm movements (for MSS task).
62391554|NCT02146274||Ischemic Stroke Patients|Patients who have had an ischemic stroke that are hospitalized in an acute-care setting.
62391555|NCT00532233|EXPERIMENTAL|1|QAX576
62391556|NCT03331939|EXPERIMENTAL|No stimulation|All patients will receive three different stimulations
62391557|NCT03331939|OTHER|Beta (25-30 Hz)|Vagal nerve stimulator will be set to Beta (25-30 Hz)
62567796|NCT05302401|NO_INTERVENTION|Women who do not receive uninterrupted midwife support during the intrapartum period|Between the 28th and 36th weeks, the pregnancy diagnosis form will be applied by the researcher to the pregnant women in the control group. 28. - Visual Analog Scale will be applied to determine the Wijma Birth Expectation/Experience (W-DEQ A) Scale and birth fear in order to determine the birth fears of pregnant women in the 36th week. During outpatient checks, the first saliva cortisol samples will be taken by researcher Meserret Aslan between 8:30 and 09:00 in the morning. After birth, postpartum from control groups will be repeated by researcher Meserret Aslan in the first half hour. Between the 24th and 72nd hours before postpartum discharge procedures take place, saliva cortisol samples of women will be taken for the last time by researcher Meserret Aslan from the control groups.
62567797|NCT02779010|EXPERIMENTAL|Hand washing with soap|Hand washing with soap and health education every 2 weeks for 6 months
62567798|NCT02779010|NO_INTERVENTION|Books and pens|Books and pens for every 2 months for 6 months
62567799|NCT05710835||irritant medications group|Patients who used midline catheter to infuse irritant medications.
62391558|NCT03331939|OTHER|Theta (5 Hz)|Vagal nerve stimulator will be set to Theta (5 Hz)
62391559|NCT02482727|NO_INTERVENTION|non-occlusion training group|The control (non-occlusion training) group will follow the standard post-operative distal radius fracture rehabilitation protocol. Treatment will include passive, active assistive,active range of motion (P/AA/AROM) to wrist, forearm and hand; desensitization as needed; edema control as needed; heat/cold modalities as needed; and strengthening exercises.
62391560|NCT02482727|EXPERIMENTAL|occlusion training with DELFI PTS ii tourniquet|The occlusion training group will follow the same protocol as described above but will utilize occlusion training with the strengthening exercises. Investigators will use an established occlusion training protocol already being. Intervention: occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
62391561|NCT01224171|PLACEBO_COMPARATOR|Placebo|Participants received placebo intravenous infusion at Weeks 0, 2 and 6.
62391562|NCT01224171|EXPERIMENTAL|Vedolizumab|Participants received 300 mg intravenous vedolizumab at Weeks 0, 2, and 6.
62391563|NCT06519903|ACTIVE_COMPARATOR|BREATH Intervention Group|During initial meeting before randomization, all patients was administered the SUDS, STAI-I, and STAI-II scales by another clinical nurse. Following this, patients were taken to a quiet, well-ventilated, and well-lit room for the BREATH breathing technique session. Following a brief training session, the BREATH technique was applied in individual sessions lasting approximately 24 min. The post-test SUDS, STAI-I, and STAI-II scales were administered by the clinical nurse.
62391564|NCT06519903|NO_INTERVENTION|Control Group|Patients in the control group were administered the Demographic Information Form, SUD, STAI-I, and STAI-II as a pre-test. No intervention was administered in the control group. After the pre-test, the patient was placed in a quiet, well-ventilated, and well-lit room for 24 minutes. Subsequently, the SUD, STAI-I, and STAI-II scales were administered as post-tests.
62567800|NCT05710835||nonirritant medications group|Patients who used midline catheter to infuse nonirritant medications.
62567801|NCT05002218|EXPERIMENTAL|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
62735096|NCT04586452|EXPERIMENTAL|AAA Group (Aim 3B-Reproducibility)|20 (10 men; 10 women) will receive a second PET/CT imaging study performed 10-14 days after the first PET/CT in order to determine the ability to reproduce the uptake results. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
62772901|NCT06380010|ACTIVE_COMPARATOR|Intervention Group|Each participant was assigned to a highly skilled dietician. The dietician implemented an individualized daily dietary regimen according to the Mediterranean diet produced by the clinical decision support system (CDSS) software. The CDSS was utilized to calculate all necessary components for the synthesis of the dietary plan, which was renewed every 15 days. Participants of the Intervention group obtained unique login credentials for the CDSS and received instruction on its operation from the designated dietitians. They were directed to access their CDSS account remotely on a weekly basis in order to monitor their nutritional status (body weight and healthy eating) and to complete a three-day dietary journal; this information was automatically accessible to the dietitians. Telephone interviews were conducted every other week in order to supplement the nutritional and lifestyle consultations. In addition, unanticipated phone calls requesting 24-hour dietary recalls were received.
62772902|NCT06380010|NO_INTERVENTION|Control Group|"The Control group participants were not provided with CDSS. They simply got basic lifestyle instructions based on the National Dietary Guidelines for Children and Adolescents during phone call sessions with the dieticians every 15 days. The ladies in the Control group were directed to maintain a food diary for three consecutive days each week, which they then transmitted to the designated dietician via email. Once again, unsolicited phone calls were conducted in order to acquire 24-hour dietary recalls."
62772903|NCT02475616|EXPERIMENTAL|PCO371|Single oral dose of PCO371
62772904|NCT02475616|PLACEBO_COMPARATOR|Placebo Comparator|Single oral dose of placebo
62391565|NCT02441387||Antidepressant treatment|"According to their previous treatment history and clinical presentation, patients may take:~Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year."
62772905|NCT00697281|EXPERIMENTAL|1|Dose level 1
62772906|NCT00697281|EXPERIMENTAL|2|Dose level 2
62772907|NCT00697281|EXPERIMENTAL|3|Dose level 3
62772908|NCT00697281|EXPERIMENTAL|4|Dose level 4
62772909|NCT00697281|EXPERIMENTAL|5|Dose level 5
62772910|NCT01443663|EXPERIMENTAL|Group 1 (Previously Received H5N1 VN 04 ca Vaccine)|Participants will have previously received two doses of 10\^7.5 tissue culture infectious dose (TCID)50 of H5N1 A/VN/1203/04 x A/AA/6/60 ca LAIV (H5N1 VN 04 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
62772911|NCT01443663|EXPERIMENTAL|Group 2 (Previously Received H5N1 HK 03 ca Vaccine)|Participants will have previously received two doses of 10\^7.5 TCID50 of H5N1 A/HK/213/03 x A/AA/6/60 ca LAIV (H5N1 HK 03 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
62772912|NCT01443663|EXPERIMENTAL|Group 3 (Previously Received H7N3 ca Vaccine)|Participants will have previously received two doses of 10\^7.5 TCID50 of H7N3 A/ck/BC/CN-6/04 x A/AA/6/60 ca LAIV (H7N3 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
62772913|NCT01443663|EXPERIMENTAL|Group 4 (Have Not Previously Received LAIV)|Participants will have not previously received an LAIV of any kind. In this study, they will receive one dose of the H5N1 vaccine at baseline.
62772914|NCT01443663|EXPERIMENTAL|Group 5 (Have Not Previously Received LAIV)|Participants will have not previously received an LAIV of any kind. In this study, they will receive two doses of the H5N1 vaccine at baseline and Day 28.
62772915|NCT01297205|EXPERIMENTAL|PNEUMOSTEM®|
62567802|NCT05002218|ACTIVE_COMPARATOR|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre- training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge.
62567803|NCT05808374|EXPERIMENTAL|Part 1|Single Dose Incremental (SAD) Trial - Healthy Persons：HRS-5635 vs. Placebo
62567804|NCT05808374|EXPERIMENTAL|Part 2a|Multiple Dose Increase (MAD) Study - Patients Receiving Consolidation Therapy：HRS-5635 vs. Placebo
62772916|NCT04576689|EXPERIMENTAL|Low dose|One (1) IBE-814 IVT Implant (70 μg Dexamethasone) Route of administration: intravitreal injections
62567805|NCT05808374|EXPERIMENTAL|Part 2b|Patients not receiving consolidation treatment：HRS-5635 vs. Placebo
62567806|NCT05445713||Cohort 1|Asymptomatic subjects found to be PCR/antigen/antibody-positive during routine screening for SARS-CoV-2 infection
62567807|NCT05445713||Cohort 2|Symptomatic outpatients who were confirmed to have COVID-19 through a positive PCR/antigen test
62567808|NCT05445713||Cohort 3|Inpatients surviving hospitalisation for severe COVID-19 and who were PCR/antigen-positive
62772917|NCT04576689|EXPERIMENTAL|High dose|Two (2) IBE-814 IVT Implant (140 μg Dexamethasone) Route of administration: intravitreal injections
62772918|NCT02344901||atrial fibrillation patients|\>18 year old. Atrial fibrillation patients without mitral stenosis or any prosthesis.
62772919|NCT01873690|PLACEBO_COMPARATOR|Placebo|Placebo
62772920|NCT01873690|ACTIVE_COMPARATOR|Ciprofloxacin|Ciprofloxacin
62772921|NCT02186717|EXPERIMENTAL|Chewing gum|Chewing gum
62772922|NCT02186717|NO_INTERVENTION|No Chewing Gum|No Chewing Gum
62772923|NCT04157283||Group 1|60 male patients
62772924|NCT04157283||Group 2|60 female patients
62772925|NCT01980719||Healthy, Age-Matched|
62772926|NCT01980719||Fatigued|
62772927|NCT01980719||Not Fatigued|
62772928|NCT05548985|PLACEBO_COMPARATOR|control group|oral metoclopramide 10 mg, Metoclopramide tablet was chosen as a placebo because it has the same appearance of midodrine tablet with no cardiovascular effects
62772929|NCT05548985|ACTIVE_COMPARATOR|Midodrine group|oral midodrine tablet (5 mg)
62020839|NCT04273958|ACTIVE_COMPARATOR|Computer screen|The comparator will consist in the screening of the same virtual world on the computer screen.
62772930|NCT01831817|EXPERIMENTAL|5% calcium sodium phosphosilicate/ sodium monofluorophosphate|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
62772931|NCT01831817|ACTIVE_COMPARATOR|0% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
62772932|NCT01831817|ACTIVE_COMPARATOR|Sodium monofluorophosphate|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
62772933|NCT01831817|ACTIVE_COMPARATOR|Sodium fluoride|Dentifrice containing 1100 ppmF as sodium fluoride
62772934|NCT06506890|OTHER|comparing the difference in reduction of bioaerosols between HVAC filters|comparing the difference in reduction of bioaerosols between HVAC filters.
62772935|NCT05004948|ACTIVE_COMPARATOR|Resistance exercise group|This group has conducted a resistance exercise program (50-60% of 1RM, for 40-50 min) thrice weekly for consecutive twelve weeks plus metformin medication.
62772936|NCT05004948|ACTIVE_COMPARATOR|Aerobic exercise program|This group has conducted an aerobic exercise program ( 50-70% maxHR, for 40-50 min) thrice weekly for consecutive twelve weeks plus metformin medication.
62772937|NCT05004948|NO_INTERVENTION|Metformin group|This group received only metformin without any exercise intervention.
62772938|NCT03514901|EXPERIMENTAL|Experimental combination beyond Focal Progression|Local treatment (i.e. surgery, radiotherapy) + Vemurafenib 240mg tablets (4 tabs/twice daily for 28 consecutive days) + Cobimetinib 20mg tablets (3 tabs/day for 21 consecutive days) beyond focal progression.
62391566|NCT02441387||Antidepressant treatment & Psychoeducation intervention|Antidepressant treatment and psych education program (10 weekly sessions).
62391567|NCT00616005|OTHER|1|Pts taking EIAEDs
62391568|NCT00616005|OTHER|2|Pts not taking EIAEDs
62391569|NCT04191928|EXPERIMENTAL|Apixaban dosing|Subjects to receive single dose of apixaban
62391570|NCT04676581||Aeromonas infection|
62391571|NCT04676581||No infected|
62391572|NCT04676581||bacterial infection|
62391573|NCT05614362|EXPERIMENTAL|Channa striatus extract|Channa striatus group was given 3x1 500mg dose of Channa striatus for 21 days
62391574|NCT05614362|PLACEBO_COMPARATOR|Placebo|Placebo group was given 3x1 dose of maltodextrin for 21 days
62391575|NCT02108561||Breast Cancer|Post Surgical Her2 testing
62391576|NCT05323370||Patientes with lymphangioleiomyomatosis|no intervention administered. Recruitment in pneumology department
62391577|NCT05323370||Patientes with tuberous sclerosis complex without Lymphangioleiomyomatosis|no intervention administered. Recruitment in neurology department
62391578|NCT05323370||Healthy women volunteers|no intervention administered. Recruitment in clinical investigation centre
62391579|NCT02903121|EXPERIMENTAL|Tamoxifen|Tamoxifen 10 mg (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
62391580|NCT02903121|PLACEBO_COMPARATOR|Placebo|Placebo (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
62391581|NCT04035369|ACTIVE_COMPARATOR|Endophthalmitis Post Intravitreal Injections - TAI|Patients 18 years and older with presumed infectious endophthalmitis after non-steroid intravitreal injections randomized to TAI
62391582|NCT04035369|ACTIVE_COMPARATOR|Endophthalmitis Post Intravitreal Injections - PPV|Patients 18 years and older with presumed infectious endophthalmitis after non-steroid intravitreal injections randomized to PPV
62391583|NCT03473821|NO_INTERVENTION|Neuromuscular Training|Participants in this group will undergo rehabilitation for ACL injury consisting of neuromuscular training according to care-as-usual treatment common to physical therapy professionals.
62391584|NCT03473821|EXPERIMENTAL|MOTIFS|Participants in this group will receive an intervention that has been developed according to our new training model, known as MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS). In this intervention, patients will receive a neuromuscular training rehabilitation program with integrated dynamic motor imagery.
62391585|NCT04390711||Healthy subjects|We included 40 age- and gender-matched healthy subjects to serve as the control group, who had normal blood pressure, serum fasting glucose, lipid profile, and renal function.
62391586|NCT04390711||T2DM with CAD|Diagnosis of T2DM was made according to the criteria of the American Diabetes Association. All patients were tested by angiography, with CAD diagnosed if luminal diameter narrowing was estimated visually at ≥50% in a major epicardial coronary artery.
62391587|NCT04390711||T2DM without CAD|Diagnosis of T2DM was made according to the criteria of the American Diabetes Association.T2DM without CAD was diagnosed if no luminal diameter narrowing was estimated visually at ≥50% in a major epicardial coronary artery.
62391588|NCT01475981|EXPERIMENTAL|Dose 1 JTK-853 (fasted condition)|
62391589|NCT01475981|EXPERIMENTAL|Dose 2 JTK-853 (fasted condition)|
62391590|NCT01475981|EXPERIMENTAL|Dose 3 JTK-853 (fasted condition)|
62391591|NCT01475981|EXPERIMENTAL|Dose 2 JTK-853 (fed condition)|
62391592|NCT01475981|EXPERIMENTAL|Dose 3 JTK-853 (fed condition)|
62391593|NCT01475981|EXPERIMENTAL|Dose 4 JTK-853 (fed condition)|
62391594|NCT01475981|EXPERIMENTAL|Dose 5 JTK-853 (fed condition)|
62391595|NCT01475981|EXPERIMENTAL|Dose 6 JTK-853 (fed condition)|
62391596|NCT01475981|EXPERIMENTAL|Dose 7 JTK-853 (fed condition)|
62391597|NCT01475981|EXPERIMENTAL|Dose 5 JTK-853 (high-fat fed condition)|
62391598|NCT01475981|PLACEBO_COMPARATOR|Placebo|
62391599|NCT04480905|SHAM_COMPARATOR|Sham tape group|in supine, full knee extension position, apply the sham tape from the anterior inferior iliac crest to the middle of the lower leg
62391600|NCT04480905|EXPERIMENTAL|Dynamic tape group|in supine, full knee extension position, apply the dynamic tape from the anterior inferior iliac crest to the middle of the lower leg
62391601|NCT04557189|EXPERIMENTAL|Ondansetron 4 mg IV|Participants received prophylaxis with ondansetron 4 mg, intravenously (IV) immediately before induction and TAK-951 placebo subcutaneously (SC) approximately 30 to 45 minutes before the end of surgery (wound closure).
62391602|NCT04557189|EXPERIMENTAL|TAK-951 4 mg SC|Participants received prophylaxis with ondansetron placebo IV immediately before induction and TAK 951 4 mg, SC, approximately 30 to 45 minutes before the end of surgery (wound closure).
62772939|NCT03514901|ACTIVE_COMPARATOR|Pembrolizumab or Nivolumab|Pembrolizumab daily dose 2 mg/kg milligram(s)/kilogram or Nivolumab daily dose 3 mg/kg milligram(s)/kilogram.
62772940|NCT00450034|EXPERIMENTAL|1|
62020840|NCT05184413|EXPERIMENTAL|Multimodal treatment|Therapeutic Exercise plus Pain Neuroscience Education
62182814|NCT01502306|EXPERIMENTAL|Phone counseling, NRT and incentives|"One-on-one, proactive telephone counseling to quit smoking; The counseling addresses behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls.~Nicotine patches (four weeks' worth) are sent directly to clients. Dosage is 21 mg if smoking 11 or more per day, 14 mg if smoking 6-10 per day and 7mg if smoking \<6 per day.~Gift cards (to one of 4 major chains) are $20 for the first counseling session and $10 for each additional one (up to five sessions total)."
62391603|NCT00902122|EXPERIMENTAL|1|Five times of p53 gene intratumoral injection are given before surgery,then radical surgery will be conducted.
62567809|NCT05445713||Cohort 4|Participants vaccinated in clinical trials in 2020 prior to widespread community exposure, and hence protected from severe COVID-19 (and possibly Long-COVID) if subsequently infected.
62567810|NCT01817868||Group 1|
62567811|NCT02036073|EXPERIMENTAL|EPO|In EPO group, the EPO was given by 500IU/kg every other day intravenously for 2 weeks. Recombinant human erythropoietin was configured by the hospital pharmacy intravenous Center Configuration, melted configured with saline to 1ml/kg solution. For severe patients, they were started to treat with EPO when their vital signs, blood pressure were stable.
62567812|NCT02593838|OTHER|CTP and SPECT-MPI|Every patient enrolled will undergo CT-MPI and SPECT-MPI. The latter is clinically indicated,.
62567813|NCT00105079|EXPERIMENTAL|saquinavir/ritonavir|saquinavir mesylate 1000 mg twice daily (BID) + ritonavir 100 mg BID + emtricitabine/tenofovir disoproxil fumarate 200/300 mg orally every day for 48 weeks.
62567814|NCT00105079|ACTIVE_COMPARATOR|lopinavir/ritonavir|lopinavir/ritonavir 400/100 mg BID + emtricitabine/tenofovir disoproxil fumarate 200/300 mg orally every day for 48 weeks.
62567815|NCT01534338|EXPERIMENTAL|Mindfulness Meditation|The MAPs program is based on experiential training in mindfulness meditation offered at the UCLA Mindful Awareness Research Center (MARC). A certified UCLA instructor will provide didactic training in mindfulness meditation in a group-based setting. Participants will be guided through in-class meditation practices and will be assigned daily meditation homework. Active program components include sitting and walking somatosensory-focused meditation, audio-guided body scan meditation, and loving kindness meditation. Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary. In addition to the MAPs training, sleep hygiene material will also be presented to match the sleep hygiene material in the sleep education condition.
62567816|NCT01534338|ACTIVE_COMPARATOR|Sleep Education|The sleep education condition is founded on knowledge acquisition. In the sleep seminar condition, a trained health educator will provide didactic presentations on sleep, sleep hygiene, sleep problems, and potential solutions to sleep problems in a group-based setting. Active components of sleep education include increasing knowledge of sleep biology, identifying characteristics of healthy and unhealthy sleep, sleep problems, and self-monitoring of sleep behavior. Participants attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary. The health education condition is comparable to MAPs in terms of time, attention, group support, and participant expectancy of a benefit in sleep parameters.
62567817|NCT04672837|EXPERIMENTAL|Manual Therapy Group|"10 sessions of Pediatric Manual Therapy, once a week. Soft cervical mobilisation, myofascial induction and cranial techniques will be administered. Educational physiotherapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be also administered."
62567818|NCT04672837|ACTIVE_COMPARATOR|Stretching Group|"A protocol of Stretching at home. 3-5 sessions twice a day. Each stretch will be maintain10 to 30 seconds. Each session 15 will take no less than 15 minutes. 7 days a week.~Educational Physical Therapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be administered."
62772941|NCT05205655|ACTIVE_COMPARATOR|positive group|asymptomatic or mildly symptomatic participants positive for SARS-CoV-2 RNA
62772942|NCT05205655|EXPERIMENTAL|negative group|no evidence of SARS-CoV-2 by real-time RT-PCR
62182815|NCT01165398||Residents, PAs, mid level providers|Lehigh Valley Health Network residents, physician assistants, and mid level providers who place central lines and attend the central lines simulation course
62182816|NCT00409409|EXPERIMENTAL|300 IR|300 IR grass pollen allergen extract tablet
62182817|NCT00409409|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62772943|NCT00629473|EXPERIMENTAL|Arm AM: advanced malignancies|Dose Escalation - 9 dose cohorts NPI-0052 on Days 1, 8, 15 every 28 days NPI-0052 doses ranging from 0.1 to 0.9 mg/m2
62020841|NCT05184413|ACTIVE_COMPARATOR|Unimodal treatment|Therapeutic Exercise
62020842|NCT05507411|OTHER|CCR-Watch and Wait|
62182818|NCT02023905|EXPERIMENTAL|Arm 1: Everolimus|If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If activation is present, patients will be treated with single-agent everolimus at 10 mg daily continuously for up to 24 cycles, after which patients will be followed with interval MRIs until progression.
62214556|NCT06610656|ACTIVE_COMPARATOR|pacifier applications group|In this group, infants will receive only pacifier therapy. The aim is to provide comfort and support for sleep through the use of pacifiers. White noise will not be utilized in this group. This intervention focuses solely on assessing the effects of pacifier use without any additional auditory stimuli
62214557|NCT03975777|EXPERIMENTAL|low-intensity exercise - high-intensity exercise|low-intensity exercise session followed by a high-intensity exercise session separated by a minimum of 14 days
62214558|NCT03975777|EXPERIMENTAL|high-intensity exercise - low-intensity exercise|high-intensity exercise session followed by a low-intensity exercise session separated by a minimum of 14 days
62391604|NCT00902122|ACTIVE_COMPARATOR|2|surgery
62391605|NCT00902122|EXPERIMENTAL|3|p53 gene therapy
62567819|NCT00105859|OTHER|1|
62182819|NCT02023905|EXPERIMENTAL|Arm 2: Everolimus and Temozolomide|If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If activation is not present, patients will be treated with combined everolimus and Temozolomide (TMZ). Everolimus will be given at 10 mg daily continuously for up to 24 cycles, and Temozolomide will be dosed initially at 150 mg/m\^2 per day for 5 days out of a 28-day cycle for up to 12 cycles, after which patients will be followed with interval MRIs until progression.
62567820|NCT01285362|ACTIVE_COMPARATOR|Fish Oil Supplementation (Group A)|Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of docosahexaenoic acid (DHA).
62567821|NCT01285362|PLACEBO_COMPARATOR|Placebo Supplementation (Group B)|Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
62567822|NCT05506046|EXPERIMENTAL|Reduced Nicotine Messages|Participants will receive messages with information about reduced nicotine cigarettes.
62567823|NCT05506046|EXPERIMENTAL|Modified Risk Messages|Participants will receive messages with information about e-cigarettes.
62567824|NCT05506046|EXPERIMENTAL|Combined Message -- Reduced Nicotine + Modified Risk Exposure|Participants will receive messages about reduced nicotine cigarettes and about e-cigarettes.
62567825|NCT05506046|OTHER|Control|Participants will receive messages about bottled water which should have no impact on the outcomes of interest.
62567826|NCT03626402|EXPERIMENTAL|Intervention|"These patients will be exposed to the educational intervention, including viewing the video, Planning for the Care You Want, and meeting with a lay health advisor to discuss advance care planning and initiate plans, as patients wish."
62567827|NCT03626402|NO_INTERVENTION|Control - Usual Care|These patients will not be exposed to the educational intervention and will receive usual care. All patients will be mailed an informational brochure about advance care planning with a reminder letter two weeks after completing their baseline survey.
62567828|NCT01591538||lifestyle condition|
62567829|NCT05453227|ACTIVE_COMPARATOR|Zinc Group|25 cases will be undergo treatment with active ingredient
62567830|NCT05453227|PLACEBO_COMPARATOR|Plcebo Group|25 cases will be undergo treatment with placebo
62567831|NCT03308890|ACTIVE_COMPARATOR|Arm 1|0.5mg Entecavir QD for 6 months after cessation of TDF and clinical observation for up to 6 months after the end of study follow-up.
62567832|NCT03308890|ACTIVE_COMPARATOR|Arm 2|0.5mg Entecavir QD for 12 months after cessation of TDF and clinical observation for up to 6 months after the end of study follow-up.
62567833|NCT03308890|NO_INTERVENTION|Arm 3|No consolidation arm and observation only and clinical observation for up to 6 months after the end of study follow-up.
62567834|NCT05526677||dynamic navigation group or static guide group|"Every patient has 2 missing in one jaw The missing tooth will be restored with one-visit single implant immediate loading.~One implant placed is assisted with dynamic navigation system, and the other one is assisted with static surgical guide."
62567835|NCT02927951|EXPERIMENTAL|pregabalin at 150 mg bid|Each subject was randomized to the treatment for 6 weeks, followed by a 2 week washout period, and then completed the other arm of the study.
62772944|NCT00629473|EXPERIMENTAL|Arm MM: multiple myeloma|Dose Escalation - 8 dose cohorts NPI-0052 on Days 1, 4, 8, 11 every 21 days NPI-0052 doses ranging from 0.075 to 0.6 mg/m2 Dexamethasone 20 mg oral or IV day before and day after NPI-0052 dosing.
62182820|NCT02023905|EXPERIMENTAL|Arm 3: Everolimus (1p/19q co-deletion present)|If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If 1p/19q co-deletion is present, patients will be treated with single-agent everolimus at 10 mg daily continuously for up to 24 cycles, after which patients will be followed with interval MRIs until progression.
62182821|NCT01397500|ACTIVE_COMPARATOR|Genotropin|"6 months Genotropin (open treatment)~Daily dose:~Male \< 45 years: 0,4 mg; ≥ 45 years: 0,2 mg Female \< 45 years: 0,5 mg; ≥ 45 years: 0,3 mg Starting with half of the dose for the first 4 weeks."
62391606|NCT00902122|ACTIVE_COMPARATOR|4|p53 gene therapy plus radioactive iodine
62391607|NCT04967729|OTHER|LUS ultrasound and standard of care|Subjects will perform a lung ultrasound in order to determine the ability of patients to take an ultrasound from their homes. The lung ultrasound will be coupled with telehealth clinical support to monitor the severity of COVID-19 patients and provide standard of care. All subjects will receive the lung ultrasound technology and daily calls for teleguidance through the ultrasound and standard of care to monitor symptoms.
62567836|NCT02927951|PLACEBO_COMPARATOR|Placebo|Each subject was randomized to the treatment for 6 weeks, followed by a 2 week washout period, and then completed the other arm of the study.
62567837|NCT02055924|EXPERIMENTAL|Ibrutinib and immunochemotherapies|Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
62567838|NCT03454061|EXPERIMENTAL|Intervention|Physical activity intervention
62567839|NCT03454061|NO_INTERVENTION|Control|Keep usual activities in kindergarten
62567840|NCT00031590|EXPERIMENTAL|Study Treatment|"All subjects will undergo routine surgical staging of their tumor. Treatment must begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with vincristine. 4 weeks after radiation and vincristine treatment is completed, all subjects will begin 9 cycles (each cycle lasts 6 weeks) of maintenance chemotherapy which will be given as 2 different drug combinations, Regimen A (Lomustine, Vincristine, and Cisplatin) and Regimen B (Cyclophosphamide, given with Mesna, and Etoposide \[IV and oral\]) which will be given in the following order: AABAABAAB (total of 54 weeks)."
62567841|NCT04769193|EXPERIMENTAL|Adipeau face cream|Cosmetic cream
62567842|NCT00813072|EXPERIMENTAL|1. PEP02|liposome irinotecan
62567843|NCT00813072|ACTIVE_COMPARATOR|2. irinotecan|
62567844|NCT00813072|ACTIVE_COMPARATOR|3. docetaxel|
62567845|NCT03033992|EXPERIMENTAL|Treatment (Optune System)|Patients must have a histologically confirmed diagnosis of supratentorial high-grade glioma or supratentorial ependymoma that is recurrent, progressive or refractory. All patients will use the study device Optune System (Tumor Treating Fields, TTFields).
62391608|NCT06343259|ACTIVE_COMPARATOR|General Anesthesia|After preoxygenation, intravenous fentanyl (1 μg/kg), propofol (2 mg/kg), and rocuronium (0.6 mg/kg) will be used for anesthesia induction. Intubation will be performed with a 7.0-8.0 sized tube, followed by the initiation of mechanical ventilation (tidal volume: 6-8 ml/kg, respiratory rate: 12 breaths/min). Sevoflurane will be used to maintain anesthesia (0.7-1 MAC), and remifentanil infusion will be administered for analgesia. Postoperatively, tramadol (1 mg/kg) and paracetamol (10 mg/kg) will be administered intravenously. Neuromuscular blockade will be reversed using sugammadex. Patients with an Aldrete Recovery Score ≥9 will be transferred to the post-anesthesia care unit after extubation.
62391609|NCT06343259|ACTIVE_COMPARATOR|Spinal Anesthesia|Patients will be positioned laterally with the hip to be operated on the lower side, and skin asepsis will be ensured, followed by sterile draping. A dural puncture will be performed at the L3-4 spinal level using a 22-25 gauge Quincke-tip spinal needle. After the detection of cerebrospinal fluid, 7.5 mg of 0.5% hyperbaric bupivacaine will be slowly injected. Following a 10-minute interval, the sensory block level will be assessed using the pinprick test and modified Bromage scale, aiming for a T10 sensory block. Surgery will commence upon achieving adequate sensory block. Postoperatively, patients will be transferred to the recovery room. Patients failing to attain sufficient sensory block and experiencing pain will undergo transition to general anesthesia, terminating their cases.
62391610|NCT03577028|EXPERIMENTAL|Fixed IV|HPN424 administered once weekly via IV infusion in doses ranging from 1.3 to 150 ng/kg
62391611|NCT03577028|EXPERIMENTAL|1 Prime Step IV 36 ng/kg Target|Step-dosing IV cohort who received a single Prime Dose followed by the Target Dose (12/36 ng/kg)
62391612|NCT03577028|EXPERIMENTAL|1 Prime Step IV 225-300 ng/kg Target|Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (100/300 ng/kg and 75/225 ng/kg\]
62391613|NCT03577028|EXPERIMENTAL|2 Prime Step IV 300 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (50/150/300 ng/kg with prior chemotherapy and 50/150/300 ng/kg no prior chemotherapy)
62391614|NCT03577028|EXPERIMENTAL|2 Prime Step IV 450 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (100/300/450 ng/kg and 50/150/450 ng/kg)
62391615|NCT03577028|EXPERIMENTAL|Fixed SC|Fixed subcutaneous dose (120 ng/kg)
62391616|NCT03961984||Complex anal fistula|Patients with complex transsphincteric anal fistulas were treated with Biodesign® plug.
62391617|NCT05728528|EXPERIMENTAL|PK-guided EHL FVIII concentrates prophylaxis with moderate intensity physical activities|PK-guided EHL FVIII concentrates prophylaxis with moderate intensity physical activities
62567846|NCT03033992|EXPERIMENTAL|Treatment (Concurrent Optune/focal radiation therapy followed by Optune-only therapy)|Patients must have newly diagnosed DIPG (a typical DIPG on MR imaging, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, without histologic confirmation; atypical DIPG undergoing a biopsy and the tumor is a diffuse glioma WHO Grade II-IV with OR without H3 K27M mutation; or pontine lesions that do not meet these MR imaging criteria with histologically confirmed diffuse glioma WHO Grade II-IV with H3 K27M- mutation). This arm will consist of two parts: a phase I component to evaluate the safety and tolerability of concurrent Optune and RT, and a phase II component to evaluate the feasibility of concurrent Optune and RT and the efficacy associated with this approach compared to historical controls.
62567847|NCT02851121|OTHER|Healthy volunteers|
62772945|NCT00665236|EXPERIMENTAL|1|Craniosacral therapy administered once a week for an hour by a trained craniosacral therapist.
62772946|NCT00665236|ACTIVE_COMPARATOR|2|Low-strength static magnets placed around the body for periods of up to an hour once a week.
62772947|NCT05074420|EXPERIMENTAL|Baricitinib|Baricitinib given orally to participants daily
62391618|NCT05728528|ACTIVE_COMPARATOR|PK-guided EHL FVIII concentrates prophylaxis alone|PK-guided EHL FVIII concentrates prophylaxis alone
62391619|NCT05262946|ACTIVE_COMPARATOR|control|control arm: usual care and foot care education.
62391620|NCT05262946|EXPERIMENTAL|experimental|experimental arm: sensorimotor training, foot care education and usual care
62391621|NCT05611281|EXPERIMENTAL|GS3-007 oral liquid|"78 subjects: Part 1 SAD 36 subjects: A total of 6 dose groups of 0.4 mg/kg, 0.8 mg/kg, 1.6 mg/kg, 3.2 mg/kg, 4.8 mg/kg and 6.4 mg/kg are planned. Once a day, a total of one dose.~Part 2 MAD 30 subjects: Three dose groups of 0.8 mg/kg, 1.6 mg/kg and 3.2 mg/kg were planned，The drug was administered once a day for 7 days Part 3 Food effects 12 subjects: Planned in 1.6mg/kg dose group。Once a day, a total of one dose."
62772948|NCT05498116|PLACEBO_COMPARATOR|Placebo|One capsule daily
62772949|NCT05498116|EXPERIMENTAL|Montelukast|One 10mg capsule daily
62020843|NCT05507411|OTHER|CCR-Surgery|
62391622|NCT05611281|PLACEBO_COMPARATOR|Placebo GS3-007 oral liquid|"Part 1 SAD: A total of 6 dose groups of 0.4 mg/kg, 0.8 mg/kg, 1.6 mg/kg, 3.2 mg/kg, 4.8 mg/kg and 6.4 mg/kg are planned. Once a day, a total of one dose.~Part 2 MAD: Three dose groups of 0.8 mg/kg, 1.6 mg/kg and 3.2 mg/kg were planned，The drug was administered once a day for 7 days"
62391623|NCT03216499|EXPERIMENTAL|Treatment (HIF-2 alpha inhibitor PT2385)|"Patients receive HIF-2 alpha inhibitor PT2385 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pharmacological Study~Laboratory Biomarker Analysis~Pharmacogenomic Study"
62391624|NCT01531049|EXPERIMENTAL|Varenicline|A varenicline treatment group (with motivational interview technique combined with varenicline and placebo transdermal patch). Intervention with Nicorette 15mg /16 h patch
62391625|NCT01531049|EXPERIMENTAL|Nicotine cutaneous patch 15mg|Intervention with Varenicline for 12 weeks. Nicotine cutaneous patch 15mg/16h
62391626|NCT01531049|EXPERIMENTAL|Nicotine cutaneous patch 10mg|Intervention with Placebo transdermal patch for 8 weeks. Nicotine cutaneous patch 10mg/16h
62391627|NCT01531049|PLACEBO_COMPARATOR|Placebo cutaneous patch|No active medication.One transdermal patch/16 h.Total duration was 8 weeks.
62772950|NCT04394936|EXPERIMENTAL|Guselkumab|Guselkumab 100 mg/ml in prefilled syringe, subcutaneous injection, administered on day 0, 28 and 84.
62772951|NCT04394936|PLACEBO_COMPARATOR|Placebo|Sodiumchloride 0,9% solution for injection, subcutaneous injection, administered on day 0, 28 and 84.
62772952|NCT04394936|NO_INTERVENTION|Healthy volunteers|Healthy volunteer cohort (observational)
62020844|NCT05507411|OTHER|Non-CCR|
62182822|NCT01397500|ACTIVE_COMPARATOR|Testosterone undecannoate|18 weeks testosterone undecanoate/placebo (double-blind treatment) 1000 mg/4 ml at baseline and after 6 weeks
62391628|NCT04646668|ACTIVE_COMPARATOR|E-Cigarette then Heat not burn.|We will use a 1:1 fashion randomization to product order (combustible cigarette, e-cigarette, heat-not-burn device.
62567848|NCT03538288|EXPERIMENTAL|Twenty sessions of rTMS|Twenty sessions of rTMS will be applied to treatment seeking participants.
62567849|NCT04831853|EXPERIMENTAL|Supervised self-swabbing followed by conventional swabbing|the subjects will first benefit from a 5 minutes explanation on how to perform self-swabbing and will then performed the swabbing under the supervision of a trained healthcare professional
62567850|NCT04831853|EXPERIMENTAL|Conventional swabbing followed by supervised self-swabbing|the subject will undergo conventional nasopharyngeal swabbing performed by a trained healthcare professional first.
62182823|NCT01397500|NO_INTERVENTION|control group|No Intervention.
62391629|NCT04646668|ACTIVE_COMPARATOR|Heat not burn then E-Cigarette|We will use a 1:1 fashion randomization to product order combustible cigarette, heat-not-burn device, e-cigarette.
62391630|NCT04369599|EXPERIMENTAL|V/Q System|Participants with acute respiratory failure will undergo therapy with the V/Q System.
62391631|NCT00806000||Athletes|
62567851|NCT02220738|EXPERIMENTAL|ABT-957|ABT-957 administered twice-daily for 7 days
62567852|NCT02220738|PLACEBO_COMPARATOR|Placebo|Placebo administered twice-daily for 7 days
62567853|NCT00506415|EXPERIMENTAL|Open label: Rivastigmine (5 cm^2 / 10 cm^2)|Rivastigmine 5 cm\^2 transdermal patch once a day during the first 4 weeks of open label treatment followed by rivastigmine 10 cm\^2 transdermal patch once a day from week 4 to week 24, 36 or 48.
62567854|NCT00506415|EXPERIMENTAL|Double blind: Rivastigmine (10 cm^2)|Rivastigmine transdermal patch 10 cm\^2 and placebo to rivastigmine 15 cm\^2 once daily for 48 weeks during the double blind period.
62567855|NCT00506415|EXPERIMENTAL|Double blind: Rivastigmine (15 cm^2)|Rivastigmine transdermal patch 15 cm\^2 and placebo to rivastigmine 10 cm\^2 once daily for 48 weeks during double blind period.
62567856|NCT00506415|EXPERIMENTAL|Extended open label Rivastigmine (10 cm^2)|Rivastigmine 10 cm\^2 transdermal patch once a day during 48 weeks open label treatment running in parallel to the double blind period.
62567857|NCT04267809|EXPERIMENTAL|Metformin group|22 subjects will receive Metformin 1000mg twice daily for 7 consecutive days (Days 1-7). On Day 4, subjects will be administered one dose of YF17D before metformin dosing.
62567858|NCT04267809|PLACEBO_COMPARATOR|Placebo group|22 subjects will receive placebo twice daily for 7 consecutive days (Days 1-7). On Day 4, subjects will be administered one dose of YF17D before placebo dosing.
62772953|NCT00734071|PLACEBO_COMPARATOR|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
62772954|NCT00734071|EXPERIMENTAL|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
62182824|NCT04532762|EXPERIMENTAL|Coldamaris akut|One puff (140µl) into each nostril
62182825|NCT04532762|PLACEBO_COMPARATOR|Placebo|One puff (140µl) into each nostril
62182826|NCT01584518|ACTIVE_COMPARATOR|CHF peptide|Diuresis based on CHF-P
62182827|NCT01584518|ACTIVE_COMPARATOR|Non CHF peptide|Diuresis based on clinical judgement without data for CHF-P
62182828|NCT00371462|ACTIVE_COMPARATOR|Arm 1|MOVE! level 2 group weight loss counseling, the VA standard of care alone (Standard Care);
62391632|NCT04426227|EXPERIMENTAL|Group Gaze|The gaze-trained group will be shown a video, derived from the eye tracker, of an expert's visual control whilst performing the ultrasound task. Participants will be made aware of the target-focused gaze strategy (lengthy and stable fixations on the needling target), and the manner in which the gaze shifted from target to tools (hands, needle and transducer) in a fast, smooth fashion. They will then be advised to try to mimic the gaze strategy of the expert while undertaking the needling task as their first training task. After completion of this training task, participants will be shown their own video data, as captured by the eye tracker. Participants will be asked to comment on differences between their own video and the expert video they had previously seen. This feedback process will be replicated a further four training task attempts. Participants in this group will therefore undergo a total of five training attempts of the needling task.
62391633|NCT04426227|ACTIVE_COMPARATOR|Group Discovery|The discovery learning group will be given no video feedback and will be instructed to perform five training attempts at the needling task without further training or feedback.
62391634|NCT04977622||Primary Progressive MS (PPMS)|Clinically definite MS patients with identified primary-progressive disease onset, within 10 years of diagnosis
62391635|NCT04977622||Non-neurological controls (HC)|Age and sex matched to the PPMS patients
62567859|NCT05527535||AI screening group|Diabetes mellitus patients undergo diabetic retinopathy screening by AI
62567860|NCT05527535||Manual screening group|Diabetes mellitus patients undergo diabetic retinopathy screening by health care personnel
62567861|NCT01852448||Patients with Cystic Fibrosis|Blood or saliva sample collection and medical record review.
62567862|NCT04940273|EXPERIMENTAL|remifentanil|Continuous infusion of remifentanil at a dose of 0.02、0.04、0.06、0.08 ug/kg/min for 30 minutes in sequence.
62567863|NCT01683318|EXPERIMENTAL|Treatment|Patients will undergo Thermal Pulsation treatment of Meibomian Gland Dysfunction using the TearScience System (Lipiflow).
62567864|NCT04663529||CLADE|contact lens wearers with DED
62567865|NCT04663529||non-CLADE|DED without contact lens wear
62567866|NCT04663529||NC|normal control
62567867|NCT05798182||ICU patients|Adult patients admitted to the ICU.
62567868|NCT05774938||Standard EVAR|Infrarenal abdominal aortic aneurysms treated with standard EVAR off-the-shelf devices.
62567869|NCT05774938||Complex EVAR|Paravisceral aortic aneurysms treated with fenestrated or branched EVAR devices.
62567870|NCT04040140|EXPERIMENTAL|APA Treatment|Oncology patients with a pain rating of four or greater will receive APA treatment for patients' cancer-related pain. The ear points will be determined by the corresponding body points related to the patient's specific pain. Pain data will be tracked by electronic surveys and Electronic Health Records.
62735097|NCT01706731|ACTIVE_COMPARATOR|TAU plus Cognitive-behavioral Therapy|Participants randomized to this group will receive treatment as usual plus cognitive behavioral therapy (CBT) provided by trained Buddhist monks.
62182829|NCT00371462|EXPERIMENTAL|Arm 2|MOVE! level 2 + Personal Digital Assistant decision support tool (PDA) (Treatment)
62391636|NCT03769792|EXPERIMENTAL|Impedance spectroscopy|"24 women will be included in the study and divided into two subgroups.~12 of them (first subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 1 or 2 in OASIS classification.~Remaining 12 (second subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 3 or 4 in OASIS classification.~The planned interventions are:~* Blood and faeces tests~* Impedance spectroscopy test~* Full gynecological and proctological examination~* Transanal ultrasonography~* Anorectal manometry"
62182830|NCT04038671|EXPERIMENTAL|Activated Carbon Dressing|A low-adherent, comprised of 100% pure activated carbon and also conforms to body contours to maintain contact with the incision surface. The dressing may be used either dry or moistened with sterilized water over dry or discharging, partial and full thickness wounds.
62182831|NCT04038671|ACTIVE_COMPARATOR|Knitted Cellulose Acetate Mesh|a non-adhering dressing, comprised of a knitted cellulose acetate mesh impregnated with a specially-formulated petrolatum emulsion.
62182832|NCT04038671|ACTIVE_COMPARATOR|Antimicrobial Alginate Dressing with Silver|a non-adherent antimicrobial alginate dressing with silver
62182833|NCT05376878|EXPERIMENTAL|Treatment ( 64Cu-DOTA-trastuzumab PET/MRI)|Patients receive trastuzumab IV over 15 minutes on day 0. Patients then receive 64Cu-DOTA-trastuzumab IV and then undergo PET/MRI scan on day 1. Patients undergo repeat brain MRI every 6 weeks for 24 weeks and then every 9 weeks until disease progression. Patients then receive trastuzumab deruxtecan IV every 21 days in the absence of disease progression or unacceptable toxicity.
62182834|NCT06386445||XJTU Cohort of allo-HSCT|all the patients underwent allogeneic stem cell transplantation
62182835|NCT00038155|OTHER|1|
62567871|NCT06348355|EXPERIMENTAL|Healthy Volunteers|Healthy volunteers will undergo two PET examinations and will receive 2 single IV doses of \[11C\]savolitinib (total ≤ 20 µg) and radioactivity of 400 ± 10% mBq/70 kg/per PET-CT examination, with total radiation exposure during the study of 3.86 mSv. Healthy volunteers will receive a single 300 mg dose of oral savolitinib approximately 2 hours after the end of the first PET examination and approximately 2 hours before the second IV dose of \[11C\]savolitinib. The second PET examination can be performed on a separate day, within 14 days after the first PET examination. Oral savolitinib will be given on the same day as the second PET examination.
62567872|NCT01001273|EXPERIMENTAL|Study Group|Hyperinsulinemic Normoglycemic Clamp will be started at the time of surgery (before incision) and will be continue for 3 days.
62567873|NCT01001273|NO_INTERVENTION|Control Group|Patients in the control group will receive standard care.
62567874|NCT01478776|ACTIVE_COMPARATOR|diabetes, omega-3|patient with type 2 diabetes who receive 4gr/day omega-3
62567875|NCT01478776|PLACEBO_COMPARATOR|placebo, diabetes|patient with type 2 diabetes who receive 4 cap of placebo/day
62772955|NCT05303688|EXPERIMENTAL|Drug: Dexketoprofen Tremetamol|50 mg iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, Istanbul, Turkey) were administrated 30 minutes before incision in the treatment group (deksketoprofen trometamol n= 15)
62772956|NCT05303688|PLACEBO_COMPARATOR|Drug: Steril Salin (control)|iv sterile saline were administrated 30 minutes before incision in the placebo group (saline n= 15)
62772957|NCT06499883|EXPERIMENTAL|Pocket Ark|
62772958|NCT03256435|EXPERIMENTAL|Treatment Arm|RAMP PrEP initiation, adherence, and retention intervention package as well as standard of care (access to a financial advocate and clinical staff to support, facilitate, and assist in linkage to the established PrEP clinic at Open Arms and to facilitate initiation of, and obtaining, PrEP medications)
62772959|NCT03256435|NO_INTERVENTION|Control Arm|Standard of care (access to a financial advocate and clinical staff to support, facilitate, and assist in linkage to the established PrEP clinic at Open Arms and to facilitate initiation of, and obtaining, PrEP medications)
62772960|NCT05941260||Male patients above the age of 50|"All male patients aged 50 or more with benign prostatic hyperplasia who are scheduled for any planned endourological procedure will be included in our study.~* Routine cystourethroscopy is a standard procedure in any endourological procedure, whatever the type of procedure.~* With advanced imaging technology, it is possible through 3D scanning processes of analyzing photos and videos and digitally defining depth, to create 3D models of the tissues and channels, from endoscopy videos.~* We are going to record this diagnostic cysto-urethroscopy of all patients, and we will send these videos for pre-processing and analysis by virtual computational reconstruction, so that an accurate model could be constructed with a digital model of the urethra geometry and a numerical model of the flow inside the urethra."
62772961|NCT02337985|EXPERIMENTAL|Treatment (R-EPOCH, rHIV7-shI-TAR-CCR5RZ-transduced HSPC)|"Patients receive prednisone PO BID on days 1-5; rituximab IV on day 1; etoposide IV over 96 hours, doxorubicin hydrochloride IV over 96 hours and vincristine sulfate IV over 96 hours on days 1-4; and cyclophosphamide IV over 30-60 minutes on day 5. Patients then receive filgrastim SC QD beginning on day 6 and continuing until absolute neutrophil count recovers. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic stem/progenitor cells IV on day 0 (48 hours after the final combination chemotherapy course.)"
62772962|NCT05747417|EXPERIMENTAL|prism glasses|prisms glasses are advised with ranging of 4prism diopters to 10 prism diopters
62182836|NCT03616860|EXPERIMENTAL|Focused Ultrasound (FUS) BBB Disruption|The Exablate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing standard of care chemotherapy.
62182837|NCT04582513||Pre-checklist implementation group|Patients undergoing major elective surgery where intraoperative handover occurs. This handover is performed according to current hospital standard without a standardized checklist.
62182838|NCT04582513||Post-checklist implementation group|Patients undergoing major elective surgery where intraoperative handover occurs. This handover is performed after implementation of the AnCHor-CHecklist, a standardized checklist based on the SBAR concept.
62182839|NCT05372471|OTHER|mHealth|Intervention group (mHealth platform users).
62182840|NCT05372471|OTHER|Control|Usual Care
62182841|NCT06436495|EXPERIMENTAL|Study Cohort|The complete study group will be given hair-wash intervention post baseline evaluations.
62182842|NCT06497790||Acute stroke patients|All patients of the participating clinics who have a suspected diagnosis of stroke
62182843|NCT06497790||Non-neurologic ICU patients|All patients of the participating clinics who are being treated in intensive care due to a non-neurological disease
62391637|NCT00650975|ACTIVE_COMPARATOR|ELCA|Laser Thromboablation
62391638|NCT00650975|ACTIVE_COMPARATOR|PTCA|PTCA (Direct Stenting)
62391639|NCT03284931|EXPERIMENTAL|SAGE-217 high dose|SAGE-217
62391640|NCT03284931|EXPERIMENTAL|SAGE-217 low dose|SAGE-217
62391641|NCT03284931|PLACEBO_COMPARATOR|Placebo|Placebo
62391642|NCT03438773|OTHER|Envarsus|Study group - Envarsus once daily in addition to standard of care.
62391643|NCT03438773|OTHER|Tacrolimus|Control group - Tacrolimus twice daily in addition to standard of care.
62567876|NCT00597610|EXPERIMENTAL|1|
62567877|NCT02678793|OTHER|Subjects who have completed Study 4975-MN-202 will be eligible|Subjects who have completed Study 4975-MN-202 will be eligible to receive open-label treatment with CNTX-4975 200 μg in Study 4975-MN-203 if they meet the inclusion/exclusion criteria.
62567878|NCT03437863|EXPERIMENTAL|Mobile application|Participants recruited from a self-management course are asked to use (single time) a mobile application to support reflection of personal strengths. The participant borrows an Ipad and uses the application to 1) reflect and identify their strengths by reviewing a list of examples, 2) define personal goals, and 3) link strengths to goals.
62567879|NCT00838903|EXPERIMENTAL|albiglutide + metformin|Albiglutide + metformin + placebo sitagliptin + placebo glimepiride
62567880|NCT00838903|ACTIVE_COMPARATOR|sitagliptin + metformin|Sitagliptin + metformin + placebo albiglutide + placebo glimepiride
62567881|NCT00838903|ACTIVE_COMPARATOR|glimepiride + metformin|Glimepiride + metformin + placebo albiglutide + placebo sitagliptin
62567882|NCT00838903|ACTIVE_COMPARATOR|metformin + placebo|Metformin + placebo albiglutide + placebo sitagliptin + placebo glimepiride
62567883|NCT00288626|EXPERIMENTAL|MS Treatment|Autologous peripheral blood stem cell grafts were CD34+ selected; the participants then received high-dose treatment with carmustine, etoposide, cytarabine, and melphalan as well as rabbit antithymocyte globulin before autologous HCT.
62567884|NCT06224556|EXPERIMENTAL|Intervention Group|"All the 608 patients will be evaluated by their General Practitioners through the Brief-MPI scale, which is based on the Comprehensive Geriatric Assessment (CGA).~Based on the score obtained at the Brief-MPI, the patient will receive a Personalised Prevention Program (PPP) concerning the following domains: 1) motor, 2) cognitive, 3) nutritional, 4) polypharmacotherapy, 5) vaccination prevention, 6) basal and instrumental activities, 7) co-habitation. Patients will receive brochures containing practical advice and recommendations to be implemented over a 12-month period; in the case of high Brief-MPI risk scores, patients will be referred for specialist examinations and/or in-depth diagnostics.~In addition, saliva samples will be collected to assess biomarkers of oxidative stress and, in a subsample of 210 subjects, the composition of the oral microbiota will also be analysed."
62567885|NCT06224556|NO_INTERVENTION|Control group|Patients will receive the standard clinical practice by their General Practitioners, without being evaluated by the CGA or receiving the personalized prevention program (PPP). No saliva sample will be collected.
62772963|NCT05747417|NO_INTERVENTION|presbyopic glasses|simple presbyopia glasses according to age are advised
62772964|NCT04451473|EXPERIMENTAL|ERAS- Group|Patients underwent surgery for lung cancer accepted the enhanced recovery after surgery (ERAS).
62772965|NCT04451473|OTHER|Control- Group|Patients underwent surgery for lung cancer without enhanced recovery after surgery (ERAS).
62772966|NCT04466527|EXPERIMENTAL|Treatment|Subjects in this arm will undergo laser treatment on their active acne vulgaris lesions. Subjects will serve as their own control.
62772967|NCT06260969||Endovascular therapy|Direct balloon dilation vs stenting vs embolectomy + tirofiban vs embolectomy + balloon dilation vs embolectomy + balloon dilation + intracranial stenting
62772968|NCT05633329|EXPERIMENTAL|single ESPB|single injection at level T8
62772969|NCT05633329|EXPERIMENTAL|dual ESB|dual injection at level T7 and T9
62772970|NCT03468582|EXPERIMENTAL|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
62391644|NCT03650387|EXPERIMENTAL|RADIESSE® (+) Lidocaine|
62391645|NCT02176031|EXPERIMENTAL|Natalizumab|"Natalizumab-~* (Day 0 and 28) Fixed dose Intravenous infusion over one hour. 2 hours observation completion of the infusion~* At 4 weeks, if there has been less than a complete response participants can be treated with a second dose of natalizumab.~* If participants have no response after one dose, they will be not be given a second dose.~* Participants who receive a second dose of natalizumab will be evaluated for response at day 56 after first treatment dose administered.~* Participants will be assessed for response to therapy with natalizumab at day +28, day +56, day +100, day + 180, and day +365.~* Commercial supplies of Methylprednisolone (or equivalent steroid) will be utilized. The formulation, preparation and route of administration will be as per package insert"
62391646|NCT04763460|ACTIVE_COMPARATOR|Baseline CRT programming|The comparator arm patients will remain at baseline CRT programming for the first 6 months, and then will crossover to the experimental arm and CRT device will be programmed to optimal settings derived from the electrocardiographic assessment for the following 6 months.
62567886|NCT04653012|EXPERIMENTAL|Macro-microelectrode implantation|Implantation of macro-micro electrodes of the Adtech Benkhe-Fried type in epileptic patients who are undergoing evaluation with intracranial EEG electrodes
62567887|NCT00991237|EXPERIMENTAL|Pain reduction|
62567888|NCT02694172|NO_INTERVENTION|Lean non diabetic|Lean and healthy subjects receiving no intervention
62567889|NCT02694172|EXPERIMENTAL|Overweight non diabetic|fiber rich cereal bars, two bars a day for 4 weeks
62567890|NCT02694172|EXPERIMENTAL|Overweight diabetic|fiber rich cereal bars, two bars a day for 4 weeks
62772971|NCT04253457|EXPERIMENTAL|Corticosteroid injection|Single injection of 1ml of triamcinolone (40mg/1ml)
62772972|NCT04253457|ACTIVE_COMPARATOR|Corticosteroid and local anaesthetic injection|Single injection of 1ml of triamcinolone (40mg/1ml) + 1ml 1% Lidocaine
62772973|NCT01008124|EXPERIMENTAL|Liberatory Maneuver|Liberatory Maneuver
62772974|NCT01008124|PLACEBO_COMPARATOR|Placebo Maneuver|Placebo Maneuver
62182844|NCT06497790||Non-neurologic patientes|All patients of the participating clinics who are being treated due to a non-neurological disease
62772975|NCT01833234||People with epilepsy|People with epilepsy who have have had at least one seizure in the prior year.
62772976|NCT03203733|EXPERIMENTAL|'Cooral™'|oral cooling with use of cooling device
62772977|NCT03203733|ACTIVE_COMPARATOR|cryotherapy|Cryoterapy consists of ice cubes or crossed ice and used as standard treatment for oral cooling.
62182845|NCT02039544|EXPERIMENTAL|Xuebi formula|Xuebi formula , one dosage ,every day, treat 6 months.
62391647|NCT04763460|EXPERIMENTAL|Electrocardiography-guided optimal CRT programming|The experimental arm patients will have CRT device programmed based on the electrocardiographic assessment for 12 months.
62391648|NCT02574429|EXPERIMENTAL|Cognitive Processing Therapy|Individuals who have either completed Standard Dialectical Behavior Therapy (DBT) for Borderline Personality Disorder (BPD) and/or are currently enrolled in DBT who have co-occuring PTSD.
62391649|NCT04034225|EXPERIMENTAL|SNS-301 added to pembrolizumab|"* SNS-301~* Pembrolizumab"
62391650|NCT01733394|EXPERIMENTAL|Generic A - Generic B - Brand - Generic A - Brand - Generic B|Sequence 1
62391651|NCT01733394|EXPERIMENTAL|Generic B - Brand - Generic A - Generic B - Generic A - Brand|Sequence 2
62391652|NCT01733394|EXPERIMENTAL|Brand - Generic A - Generic B - Brand - Generic B- Generic A|Sequence 3
62772978|NCT04971252||Co existance of diabetes mellitus and chronic kidney disease|Study basic coagulation profile and platelet indices among those patients with combined diabetes mellitus and chronic kidney disease
62772979|NCT04971252||Diabetes mellitus without chronic kidney disease|Study basic coagulation profile and platelet indices among those patients with diabetes mellitus only
62772980|NCT04971252||Chronic kidney disease without diabetes mellitus|Study basic coagulation profile and platelet indices among those patients with chronic kidney disease without diabetes mellitus
62772981|NCT03446417|EXPERIMENTAL|Phase 1|Up to 9 sequential dose escalation cohorts to determine maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is identified.
62772982|NCT03446417|EXPERIMENTAL|Phase 2|"MTD/RP2D in subjects:~Cohort 1: with T790M mutation in epidermal growth factor receptor (EGFR) gene, and are osimertinib naïve.~Cohort 2: EGFRm amenable to EGFR inhibitor therapy (eg, exon 19 del, L858R) and who have never been treated with EGFRis."
62772983|NCT03959202|EXPERIMENTAL|Intervention|Based on the self-efficacy theory, participants in the intervention arm will receive personalized, circadian-based activity guidelines, a 2-hour in person education session, real time physical activity self-monitoring, interactive prompts, biweekly phone consultation with the research team, and financial incentives for achieving weekly physical activity goal.
62772984|NCT03959202|PLACEBO_COMPARATOR|Control|The control group will receive general education on physical activity for older adults and continue daily activity and healthcare routine. Participants in this group will also receive a Go4Life program book from the National Institute on Aging.
62391653|NCT00995202|OTHER|Standard Monitoring CEA/ Standard Imagery|No specific follow-up of CEA and Standard imagery
62391654|NCT00995202|OTHER|Intensive monitoring CEA/ Standard Imagery|Intensive follow-up CEA and Standard imagery .
62182846|NCT02039544|PLACEBO_COMPARATOR|Placebo|placebo,has the same taste and color as Xuebi formula one dosage ,every day, treat 6 months.
62391655|NCT00995202|OTHER|Intensive Monitoring CEA / Intensive Monitoring Imagery|Intensive follow-up CEA and Intensive imagery
62391656|NCT00995202|OTHER|Standard Monitoring CEA/ Intensive Monitoring Imagery|No specific follow-up of CEA and Intensive Imagery
62391657|NCT05494047|EXPERIMENTAL|Tetravalent influenza vaccine developed by Sinovac Biotech Co.|The group will be formed by 800 individuals. 200 from 3 to 8 years old, 200 from 9 to 17 years old, 200 from 18 to 64 years old and 200 subjects 65 years and older. They will receive an unique dose of the tetravalent influenza vaccine developed by Sinovac Biotech Co.(H1N1, H3N2 and 2 strains of influenza B). Subjects 3 to 8 years will receive 2 doses of influenza vaccine unless they have receipt of 2 previous doses of any influenza vaccine or they have an history of previous influenza.
62391658|NCT05494047|ACTIVE_COMPARATOR|Vaxigrip Tetra TM|The group will be formed by 800 individuals. 200 from 3 to 8 years old, 200 from 9 to 17 years old, 200 from 18 to 64 years old and 200 subjects 65 years and older. They will receive an unique dose of the tetravalent influenza vaccine Vaxigrip Tetra TM(H1N1, H3N2 and 2 strains of influenza B). Subjects 3 to 8 years will receive 2 doses of influenza vaccine unless they have receipt of 2 previous doses of any influenza vaccine or they have an history of previous influenza.
62772985|NCT01207089|PLACEBO_COMPARATOR|1|
62772986|NCT01207089|EXPERIMENTAL|2|AZD8329
62772987|NCT06107660|EXPERIMENTAL|Study Group|"Patients in the study Group will receive 20ml 1.3% Liposomal bupivacaine (Exparel®) dose of 266mg with 40 ml of 0.25% bupivacaine.~The local anesthetic solution will be administered bilaterally in the plane between the lumber transverse process and the erector spinae muscles to block the dorsal and ventral rami of the spinal nerves under ultrasound guidance using a standard block needled. A total of 60 ml solution will be injected -30 ml on each side of the spinal column."
62791479|NCT00787865||Motor Disability|Children at risk of developing motor disability
62791480|NCT06334848|OTHER|treatment of stress urinary incontinence by transobturator tape|patients with stress urinary incontinence are treated by transobturator tape
62791481|NCT06334848|OTHER|treatment of stress urinary incontinence by mini sling|patients with stress urinary incontinence are treated by mini sling
62567891|NCT03641014|EXPERIMENTAL|Sequential pH culture (7.23 then 7.35)|A split embryo at day 3 to continue culture at a pHe of 7.23±0.02 or to be cultured at a pH of 7.35±0.02 and monitor the effect on blastocyst development.
62182847|NCT04081389|EXPERIMENTAL|CKM weeks 1-3, doxorubicin, cyclophosphamide)|Patients receive celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV on days 1-3 of weeks 1-3, as well as paclitaxel IV over 1 hour once weekly on day 1. Treatment continues for a total of 12 weeks in the absence of disease progression or unacceptable toxicity. 1-3 weeks after last dose of paclitaxel, patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.
62182848|NCT02650986|EXPERIMENTAL|Cohort I (cyclophosphamide, TCR/dnTGFbetaRII)|Patients undergo leukapheresis on day -6 and receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.
62182849|NCT02650986|EXPERIMENTAL|Cohort II (decitabine, cyclophosphamide, TCR/dnTGFbetaRII)|Patients undergo leukapheresis on day -6 and receive decitabine IV over 1 hour on days -6 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.
62182850|NCT04427878|EXPERIMENTAL|patients with Covid-19|
62567892|NCT03641014|NO_INTERVENTION|Continuously pH culture at 7.23|Embryo culture from day 0 to 5 or 6 at 7.23
62772988|NCT06107660|ACTIVE_COMPARATOR|Control Group|"Patients in the control group will receive 60ml of 0.25% bupivacaine with 5 mg preservative free dexamethasone and 150 mcg Epinephrine (in a 1:400,000 dilution).~The local anesthetic solution will be administered bilaterally in the plane between the lumber transverse process and the erector spinae muscles to block the dorsal and ventral rami of the spinal nerves under ultrasound guidance using a standard block needled. A total of 60 ml solution will be injected -30 ml on each side of the spinal column."
62772989|NCT01375608|OTHER|decitabine|active treatment
62772990|NCT00895661|OTHER|rituximab|single-arm, open-label, interventional
62772991|NCT05418491||Partially hydrolyzed protein Infant formula|Originating from A.R.T. cohort.
62772992|NCT05418491||Standard infant formula|Originating from A.R.T. cohort.
62772993|NCT05418491||Exclusively breastfed infants|Originating from A.R.T. cohort.
62772994|NCT00958217|EXPERIMENTAL|Cognitive Processing Therapy-Modified|12 individually delivered sessions of Cognitive Processing Therapy-Modified (CPT-M) provided once weekly following initial group delivery of 12 sessions of Integrated Cognitive Behavioral Therapy
62772995|NCT00958217|ACTIVE_COMPARATOR|Integrated Cognitive Behavioral Therapy|12 individually delivered sessions of Integrated Cognitive Behavioral Therapy (ICBT) once weekly following initial group delivery of 12 sessions of ICBT
62772996|NCT00958217|NO_INTERVENTION|Integrated Cognitive Behavioral Group Therapy|All participants were enrolled in an initial group-delivered Integrated Cognitive Therapy Group, consisting of 12 sessions over approximately 12 weeks prior to randomization to one of the study individually delivered interventions (CPT-M or ICBT). Individuals who were no longer participating in the study at the end of group sessions were not randomized.
62182851|NCT03990298|OTHER|All subjects|Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages.
62182852|NCT06336512|OTHER|serum zonulin|
62182853|NCT02565550|EXPERIMENTAL|IBS patients|eat the low FODMAPs diet for one week
62182854|NCT02565550|ACTIVE_COMPARATOR|healthy controls|eat the low FODMAPs diet for one week
62182855|NCT00936962|EXPERIMENTAL|Group 1 NeisVac C vaccine - 0 doses|NeisVac C (Meningococcal C) vaccine - 0 doses
62182856|NCT00936962|EXPERIMENTAL|Group 2 NeiscVac C - 2 doses|2 priming doses of NeisVac C vaccine at 2 and 4 mths of age
62182857|NCT00936962|EXPERIMENTAL|Group 3 NeiscVac C - 1 dose|1 priming dose of NeisVac C vaccine at 2 mths of age
62182858|NCT03297762|EXPERIMENTAL|Gamification|Use of continuous glucose monitor (Dexcom G5) with proactive intervention and incentives for time in use.
62182859|NCT03297762|ACTIVE_COMPARATOR|Standard care|Use of continuous glucose monitor (Dexcom G5) per usual care.
62182860|NCT05000099||phone calls|patients choosing phone calls as preferred communication technique
62391659|NCT04409262|EXPERIMENTAL|Remdesivir + Tocilizumab (RDV+TCZ)|Participants assigned to the RDV+TCZ arm will receive a 10-day treatment course of RDV, plus one infusion of TCZ on Day 1.
62772997|NCT06316440|EXPERIMENTAL|Noise-canceling Group|Intraoperative intervention with noise-canceling earphones was performed to isolate the noise
62182861|NCT05000099||video call|patients choosing video calls as preferred communication technique
62182862|NCT03717883||Healthy subjects|
62182863|NCT03717883||Subjects with ADPKD|
62182864|NCT01084993|ACTIVE_COMPARATOR|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
62182865|NCT01084993|ACTIVE_COMPARATOR|Heparin|70 U/kg or standard practice
62182866|NCT03889054|NO_INTERVENTION|Control|Current clinical management
62182867|NCT03889054|ACTIVE_COMPARATOR|Structured health education program|Patient will be referred to a specific consultation to carry out this intervention.
62182868|NCT02874573|ACTIVE_COMPARATOR|Treatment Group|Subjects in the tocilizumab group will receive a 4 mg/kg infusion at baseline, and weeks 4 and 8, as per the recommended starting dosing for rheumatoid arthritis
62182869|NCT02874573|PLACEBO_COMPARATOR|Control Group|Subjects in the placebo group will receive an infusion of normal saline (with the same packaging and volume as the tocilizumab group) at baseline, and weeks 4 and 8.
62182870|NCT01957592||Subjects with diabetes mellitus (type 2)|
62772998|NCT06316440|NO_INTERVENTION|Control Group|After general anesthesia, the intervention of wearing noise-canceling earphones was not given
62772999|NCT04435990|EXPERIMENTAL|Experimental:10,000 MM09|10,000 TU/mL of subcutaneous immunotherapy
62773000|NCT04435990|EXPERIMENTAL|Experimental: 30,000 MM09|30,000 TU/mL of subcutaneous immunotherapy
62391660|NCT04409262|ACTIVE_COMPARATOR|Remdesivir + Placebo (RDV+Placebo)|Participants assigned to the RDV+ placebo arm will receive a 10-day treatment course of RDV, plus one infusion of TCZ-placebo on Day 1.
62391661|NCT04060589||Cohort Observation|This is a cohort study where participating men will be asked to donate blood, urine, tissue in addition to access to standard of care tissue and medical data (including imaging files). Men will also consent to longer term healthcare data linkage.
62391662|NCT00396864|EXPERIMENTAL|NPI-0052|Advanced Solid Tumor Malignancies and Refractory Lymphoma
62773001|NCT04435990|PLACEBO_COMPARATOR|Placebo subcutaneous|The same solution and presentation as the active treatment, but without any active ingredients.
62182871|NCT06009744|SHAM_COMPARATOR|Vit C y zinc bajo|Parenteral nutrition + Vitamin C 100-300 mg/d y zinc 3-5 mg/d
62182872|NCT06009744|ACTIVE_COMPARATOR|Vit C and zinc alto|Parenteral nutrition + Vitamin C 1000-2000 mg/d y zinc 10-15 mg/d
62773002|NCT02325297|EXPERIMENTAL|Letter of condolence|Letter of condolence 15 days after the death of the relative.
62773003|NCT02325297|NO_INTERVENTION|No letter of condolence|No letter of condolence
62391663|NCT01663246|ACTIVE_COMPARATOR|Healthy Adults|Healthy adults over the age of 18, with no history of surgery to the salivary glands, or cancer therapy.
62773004|NCT03212456|EXPERIMENTAL|Opioid-free|The patients of this group will receive opioid-free anesthesia
62773005|NCT03212456|ACTIVE_COMPARATOR|Non opioid-free|The patients in this group will receive the same induction and maintenance drugs of the experimental group but with fentanyl 3 - 5 mcg/kg on induction and during the procedure as needed.
62391664|NCT01663246|ACTIVE_COMPARATOR|Radiation for Head and Neck Cancer|History of radiation therapy for head and neck cancer.
62391665|NCT05946564|EXPERIMENTAL|Pioglitazone (ACTOS®)|Pioglitazone given once a day, orally, at 30 mg dose, for 26 weeks
62391666|NCT05946564|PLACEBO_COMPARATOR|Placebo of pioglitazone|Placebo of pioglitazone, given once a day, orally, for 26 weeks
62391667|NCT01345162|OTHER|ketorolac|Patients will be given intraoperative analgesia with Ketorolac and tramadol before the the end of surgery, then Ketorolac postoperative 10mg 1cp x 3/die, from the day of surgery for 4 days after surgery.
62391668|NCT01345162|OTHER|acetaminophene+tramadol|Patients will be given intraoperative analgesia with Ketorolac and tramadol before the the end of surgery, then postoperative Patrol (acetaminophene 325mg+tramadol 37,5mg) 1cp x 3/die for 4 days after surgery.
62773006|NCT00576472|EXPERIMENTAL|Treatment|
62773007|NCT06334614|EXPERIMENTAL|iReach Device group|The iReach Device group will undergo the clinical trial with the device in addition to the normal clinical activity
62391669|NCT01310426||anal sphincter damage|After assessing women after vaginal delivery, a comparison will be made between those with anal sphincter damage and those women without.
62773008|NCT06334614|NO_INTERVENTION|Normal clinical activity group|The Normal clinical activity group will continue their normal clinical activity
62391670|NCT02118493|EXPERIMENTAL|Benign Biliary Stenosis, Laser|Subjects that undergo the experimental intervention, that being single use of a laser excision catheter.
62391671|NCT03285581|OTHER|truSculpt RF|Subjects will receive RF treatments
62391672|NCT05630326||ESBL UTI|all infants with UTIs caused by ESBL producing organisms
62391673|NCT05630326||Non-ESBL UTI|all infants with UTIs caused by non-ESBL producing organisms
62391674|NCT05630326||ESBL UTI with COVID-19|all infants with UTIs caused by ESBL producing organisms with COVID-19 infection
62391675|NCT05630326||ESBL UTI without COVID-19|all infants with UTIs caused by ESBL producing organisms without COVID-19 infection
62391676|NCT02486263|EXPERIMENTAL|Study|Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions
62391677|NCT02486263|OTHER|Conventional|Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.
62391678|NCT04717700|EXPERIMENTAL|B -selinexor-lenalidomide/bortezomib-dexamethasone|"Alternating cycles of:~Selinexor oral 40mg once weekly Lenalidomide oral 25mg d 1-21 Dexamethasone 20mg d 1+2, 8+9 and 15+16 i 28 days cycles and Selinexor oral 80mg once weekly Bortezomib sc 1.3mg/sqm once weekly Dexamethasone 20mg d 1+2, 8+9 and 15+16 in 28 days cycles for up to 16 cycles (8 of each, alternating) followed by continuos selinexor 40mg(once weekly)-lenalidomide-dexamethasone~for up to 16 cycles followed by continuos lenalidomide-dexamethasone"
62391679|NCT05561192|EXPERIMENTAL|diaphragmatic breathing exercises group|Intervention with diaphragmatic breathing exercises will take place in the last 15 minutes of Physical Education classes, focusing on diaphragmatic breathing. This breathing is also characterized by reducing the respiratory cycle or rate, and it can use the count of seconds in a progressive way, either in the inhalation through the nose while the abdomen expands, in the support or blockage or also called pause, and finally in the expiration, also performed by the nostrils. The creation of an inhalation and exhalation pattern becomes important as it has a direct relationship with the reduction of the activities of the sympathetic nervous system and the increase of the activity of the parasympathetic nervous system, also influencing the motor activities, the brain mass, the quality of the sleep and the attenuation of stressors.
62773009|NCT01192828|EXPERIMENTAL|Taurine|Treatment with Taurine
62773010|NCT03553082|ACTIVE_COMPARATOR|Total intravenous anesthsia|Patients in this group will receive Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance.
61997516|NCT02151448|EXPERIMENTAL|vaccine + chemokine modulatory regimen|Week 1 (at recovery from surgery; ≥ 6 weeks post-surgery)-Priming Vaccine dose; no chemokine modulation; 1 day: αDC1 vaccine; Oral celecoxib, 200 mg, before \& after treatment on day of vaccination; Weeks 2-3 -Rest; Week 4 (target) - Booster C1; Mon: αDC1 vaccine;Tues - Fri: Systemic Chemokine Modulation Regimen. Oral celecoxib, 200 mg, BID on vaccination days \& CKM. Celecoxib will be dced after CKM on Fri. Rintatolimod only administered on Wed \& Fri.; Week 5-7 -Rest; Week 8 (target) -Booster C2; Monday: αDC1 vaccine. Oral celecoxib, 200 mg, BID on days of vaccination and CKM. Tues - Fri:Systemic Chemokine Modulation Regimen. Rintatolimod only administered on Wed \& Fri. Celecoxib will be dced after CKM on Fri.; Week 9-11 -Rest; Week 12 (target) -Booster C3; Monday: αDC1 vaccine. Tues-Fri: Systemic Chemokine Modulation Regimen. Rintatolimod only administered on Wed \& Fri. Oral celecoxib, 200 mg, BID, given on days of vaccination and CKM. Celecoxib will be discontinued after CKM on Fri.
62020845|NCT04093934|EXPERIMENTAL|Intervention|Children in the intervention arm will receive sessions of psychosocial stimulation every two weeks at the community clinics for one year. The intervention includes songs, games, book and toy activities for undernourished children and nutritional and developmental messages for their mothers.
62020846|NCT04093934|NO_INTERVENTION|Wait-listed control|The wait-listed controls will be only tested at baseline and after a year. Following completion of the 2nd test, they will be included in the study and receive the same intervention provided to children in the experimental arm.
62182873|NCT03550053|ACTIVE_COMPARATOR|Intraoperative plate bending|Plate will be bent intraoperatively, which is the standard of care, for this surgery
62182874|NCT03550053|ACTIVE_COMPARATOR|Preoperative plate bending|A 3D printed model of the patient's mandible will be used to bend the plate preoperatively by the surgeon. The pre-bent plate will be brought into the operating room on the day of surgery.
62391680|NCT05561192|EXPERIMENTAL|Cardiorespiratory and strength exercise group|"Intervention with cardiorespiratory and strength physical exercises will always occur in the first 15 minutes of each class. Cardiorespiratory exercises and localized muscular resistance will be developed involving all muscle groups, adapted to the materials and school equipment available. The exercises developed will be primarily calisthenics, to facilitate a possible replication within the school environment. A circuit with 4 stations will be elaborated, where one station will offer a cardiorespiratory stimulus, containing the following exercises: jumping jacks, jumping rope, stationary running, going up and down steps and burpees. The other three stations will be composed of localized muscular resistance exercises, involving lower limbs (squat, lunge and isometric chair), upper limbs (flexion) and trunk (abdominal).~The time of execution of the exercises in each station will be of 1 minute."
62391681|NCT05561192|EXPERIMENTAL|Cooperative sports activities group|The intervention of cooperative sports activities that will integrate the physical education class will be based on the cooperative learning model and elaborated through the aforementioned points. Intervention sessions will last 20 minutes, being held during the main part of the class. Activities will be planned that prioritize reflection, thinking and sharing of ideas among students, by proposing challenges within the sport. For example, how to get out of a certain type of marking within a game, or in the case of cooperative games, with the principle that students cooperate with each other to solve a proposed challenge (for example, how long a team can remain dominating the volleyball without it falling to the ground?).
62567893|NCT00287534|EXPERIMENTAL|1|Anastrozole
62567894|NCT00287534|ACTIVE_COMPARATOR|2|Tamoxifen
62567895|NCT06125652|EXPERIMENTAL|anti Tim-3/CD123 CAR-T cell therapy|Enrolled patients will receive prespecified dose of autologous CAR-T cells.
62773011|NCT03553082|ACTIVE_COMPARATOR|Sevoflurane|Patients in this group will receive sevoflurane 8% and fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance.
62182875|NCT04250688|EXPERIMENTAL|Esko Bionics Suit + Functional Electrical Stimulation|
62391682|NCT05561192|ACTIVE_COMPARATOR|Comparator Group|The classes that will form the comparator group will carry out the Physical Education classes according to the planning previously prepared by the professors of the discipline and that are already part of the syllabus of the semester and/or the school year of the classes. These contents, within the proposal of the two schools, are already consolidated and are centered on the teaching of sport through methodologies aimed at a pedagogical proposal mostly analytical, partial or characterized by the traditional model (technicist model). In these classes, the activities are practiced through the model of direct instruction of teaching, where the teacher acts as the main figure of the teaching-learning process.
62567896|NCT06267924|EXPERIMENTAL|1. Moderate or Worse (MoW) Arm|Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the experimental device.
62567897|NCT06267924|SHAM_COMPARATOR|2. Moderate or Worse (MoW) Arm|Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the sham device.
61997517|NCT02627599||Chronic Obstructive Pulmonary Disease|"* More than 12 million adults are diagnosed with COPD~* COPD is the 3rd leading cause of death in the U.S.~* Breathing difficulty is the major reason patients seek medical attention~* COPD patients requiring hospitalization are associated with higher costs~* Oximetry is an important tool for assessing need for Long-Term Oxygen Therapy~* LTOT has been proven to improve survival and quality of life~* Patients provided with a breath responsive variable bolus oxygen conserving device:~  1. support increased activity~ 2. improve quality of life~ 3. increase functional capability~ 4. reduce portable oxygen source utilization~ 5. maintain and/or improve oxygen saturation"
61997518|NCT05164900|EXPERIMENTAL|patients with nasal pterygium.|
61997519|NCT05087654|EXPERIMENTAL|Experimental group|Received the Combination of 3D VR and Hands-on Horticultural Activities.
61997520|NCT05087654|NO_INTERVENTION|Comparison group|Received scheduled activities, such as physical fitness, paper cutting, etc., without any gardening activities.
61997521|NCT03424031|EXPERIMENTAL|Verticalization|the patient will be placed in the most vertical position possible.
61997522|NCT03424031|NO_INTERVENTION|Passive mobilization|Passive mobilization of the lower limb deficit
61997523|NCT00532285|EXPERIMENTAL|Paclitaxel/Gemcitabine|paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8) every 3 weeks, 4 cycles
61997524|NCT04431037|EXPERIMENTAL|Early oral feeding group(A)|Patients admitted in the HDU postoperatively.NG tube and foley's catheter removed within 12 hours and patients allowed oral sips on day 1 with gradual shift to liquid diet after 12 hrs and semisolid food started after 24 hours later.Patients were given i/v antibiotics,painkillers and i/v PPIs and shifted to oral pain killers on 2nd POD.
61997525|NCT04431037|NO_INTERVENTION|Traditional postoperative care group(B)|Patients in this group were managed traditionally
61997526|NCT02526069|OTHER|SweetSpot users|Participants will interact with the smartphone application for as long or as little as they wish. They will be asked to complete questionnaires at baseline (pre), 4 weeks (post), and to attend an interview.
61997527|NCT05851729|EXPERIMENTAL|Kegal exercises with postural correction|
61997528|NCT05851729|EXPERIMENTAL|Kegal exercises without postural correction|
61997529|NCT02611492|ACTIVE_COMPARATOR|Intensive Arm (A)|"4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)~+ Post-SCT Maintenance"
61997530|NCT02611492|EXPERIMENTAL|Light Arm (B)|"4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)~+ Post-SCT Maintenance"
61997531|NCT02376946|ACTIVE_COMPARATOR|Actipatch|The study group will be comprised of subjects that will receive PEMF ActiPatchTM treatment for postoperative management of pain and edema.
62182876|NCT04250688|NO_INTERVENTION|Control|
62391683|NCT00921973|ACTIVE_COMPARATOR|VAX102|Simultaneous administration of VAX102 1 ug i.m. plus TIV
62391684|NCT00921973|PLACEBO_COMPARATOR|Placebo|
62391685|NCT04865380|NO_INTERVENTION|No Tranexamic Acid|The anesthesiologist will not administer Tranexamic Acid at any point.
62735098|NCT01706731|SHAM_COMPARATOR|TAU plus routine counselling|Participants randomized into this group will receive treatment as usual (TAU) plus plus routine psychological support from non-CBT monks.
61997532|NCT02376946|PLACEBO_COMPARATOR|Placebo|The control group will be comprised of the subjects that will receive a placebo patch as treatment for postoperative management of pain and edema.
61997533|NCT00751816||Supportive Care|head and neck cancer survivors who are undergoing chemotherapy and radiation therapy
61997534|NCT03040635|EXPERIMENTAL|Risdiplam '2' Milligrams (mg)|A single dose of 2 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
61997535|NCT03040635|EXPERIMENTAL|Risdiplam '6' mg|A single dose of 6 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
61997536|NCT03040635|EXPERIMENTAL|Risdiplam '12' mg|A single dose of 12 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
61997537|NCT03040635|PLACEBO_COMPARATOR|Placebo|A single dose of placebo will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
61997538|NCT02242838||Hypertensive patients|
61997539|NCT04780386|EXPERIMENTAL|NVP-1805|NVP-1805
61997540|NCT04780386|ACTIVE_COMPARATOR|NVP-1805-R1 and NVP-1805-R2|coadministration of NVP-1805-R1 and NVP-1805-R2
62020847|NCT02747940|EXPERIMENTAL|patients with chronic migraine|flunarizine for patients with chronic migraine
62182877|NCT01044836|EXPERIMENTAL|Etanercept|
62182878|NCT04160910|ACTIVE_COMPARATOR|5-hydroxytryptophan|"Dosage of 5-hydroxytryptophan will be determined by weight:~If subject weighs less than 100lbs: 50mg twice a day If subject weights more than 100lbs: 100mg twice a day"
62182879|NCT04160910|PLACEBO_COMPARATOR|Placebo|"Dosage of placebo will be determined by weight:~If subject weighs less than 100lbs: 50mg twice a day If subject weights more than 100lbs: 100mg twice a day"
62182880|NCT02442245|PLACEBO_COMPARATOR|Placebo|Placebo group will receive microcrystalline cellulose
62391686|NCT04865380|EXPERIMENTAL|Intravenous Tranexamic Acid|1g of Tranexamic Acid will be administered intravenously prior to the start of the operation.
62391687|NCT04401982||Glaucoma Suspect|Individuals with a diagnosis of glaucoma suspect
62020848|NCT02747940|EXPERIMENTAL|patients with fibromyalgia|pregabalin for patients with fibromyalgia
62391688|NCT05070182||Patients with brain damage|"ICU patients with brain damage (due to cardiac arrest, intracranial hemorrhage or traumatic brain injury). and GCS upon entry \<=8.~All patients will be examined with a transcranial doppler (TCD) and a metabolic computer (for the measurements of REE) After the final diagnosis the patients' characteristics will be compared according to if they were brain dead or not"
62391689|NCT00026559|EXPERIMENTAL|Healthy volunteers|"Sub-study A: Working memory task / Participant performed a working memory task in two conditions, under threat of shock and in safety and asked to remember verbal and nonverbal stimuli from the current stimulus on the screen (N-back task) Sub-study C: Sustained attention to response task (SART) / participant was presented with stimuli and either initiated a response (i.e. go) or inhibited their response (i.e. stop) based on what stimuli were presented Sub-study D: Stroop task/ In the classic Stroop test, the name of a color is printed in a color that conflicts or does not conflict with the word. In the emotional Stroop, the words emotional words. The participant's task was to name the color of the word Pilot studies / (1) Shocks were delivered via electrodes located on the forearm or fingers while participant performed a working memory or vigilance task or (2) Subject performed cognitive tasks during alternating safe and threat periods"
62391690|NCT04382209|ACTIVE_COMPARATOR|Erector Spinae plane block group|Erector spinae plane block will be administrated to this group. An intravenous patient controlled analgesia device will be given to the patients postoperatively.
62391691|NCT04382209|SHAM_COMPARATOR|Control group|An intravenous patient controlled analgesia device will be given to the patients postoperatively
62391692|NCT04722731|EXPERIMENTAL|Confident Parents - Brave Children|"The Confident Parents - Brave Children (CPBT) is a group parent training targeted to anxious parents, delivered by a psychologist via video conference (the Zoom software solution).~The CPBT will comprise six 120-minutes digital sessions. One month after the last group session, all parents will be offered to have an individual booster session with a psychologist over Zoom."
62391693|NCT04722731|ACTIVE_COMPARATOR|Self-help book|"In the control group, participants will receive a parenting book, titled What all parents ought to know. This is a self-help book for parents, partly based on the scientifically evaluated parent program All Children in Focus."
62391694|NCT04099940|EXPERIMENTAL|Virtual Reality Avatar Therapy (VRAT)|In the VRAT, patients with schizophrenia and acoustic hallucinations design a visual and auditory recreation (avatar) of the entity to which they attribute their hallucinations. Working with a therapist over the course of several sessions, participants change the avatar from controlling to benevolent.
62391695|NCT04099940|ACTIVE_COMPARATOR|Assertiveness Training Program (ATP)|The ATP is a transdiagnostic cognitive behavioural treatment programme, which aims to increase self-confidence and social competence in patients with a psychiatric disorder.
62391696|NCT00783822|OTHER|intervention|rapid genetic counseling and testing
62773012|NCT04934085||Study group|subjects who had tested positive and recovered from COVID-19
62391697|NCT00783822|NO_INTERVENTION|control|usual care
62391698|NCT04115020|EXPERIMENTAL|Naltrexone first then placebo|Naltrexone for 8 weeks, then placebo for 8 weeks, blinded cross-over design
62391699|NCT04115020|EXPERIMENTAL|Placebo first then naltrexone|Placebo for 8 weeks, then naltrexone for 8 weeks, blinded cross-over design
62391700|NCT01476982||Emergency Department Patients|Patients presenting to the Emergency Department complaining of chest pain.
62567898|NCT04744649|ACTIVE_COMPARATOR|Control group|"The patients with combined positive score (CPS) of PD-L1 protein expression≥5 were randomised to control group(N=40), will receive the neoadjuvant regime of XELOX or SOX.~XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1. Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40\~60mg Bid, d1\~14, q3w; Capecitabine: 1000mg/m2 Bid, d1-14, q3w; Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles."
62567899|NCT04744649|EXPERIMENTAL|Experimental group|"The patients with combined positive score (CPS) of PD-L1 protein expression≥5 were randomised to experimental group(N=40), will receive the neoadjuvant regime of JS001+XELOX or SOX.~XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1. JS001: 240mg, ivdrip, d1, q3w; S-1:40\~60mg Bid, d1\~14, q3w; Capecitabine: 1000mg/m2 Bid, d1-14, q3w; Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles."
62567900|NCT04744649|OTHER|Exploratory group|"All the patients of Epstein-Barr virus-positive (EBV(+)) \[N=15\]or mismatch repair-deficient (dMMR)/ microsatellite instability-high (MSI-H)\[N=15\] , will be assigned to exploratory group, and will receive the neoadjuvant regime of JS001+XELOX or SOX.~XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1. JS001: 240mg, ivdrip, d1, q3w; S-1:40\~60mg Bid, d1\~14, q3w; Capecitabine: 1000mg/m2 Bid, d1-14, q3w; Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles."
62020849|NCT02747940|EXPERIMENTAL|patients with chronic migraine and fibromyalgia|flunarizine and pregabalin for patients with chronic migraine and myalgia
62584728|NCT05121714|OTHER|Evaluation of CYP1A2 inhibition and induction potential by ABX464|Using a fixed-sequence crossover study design, the Pharmacokinetics (PK) of caffeine (50 milligrams (mg) single oral dose) will be evaluated in the absence and presence of ABX464 (50 mg once daily for 14 days) in 24 healthy subjects. Caffeine will be administered on Day 1 in the absence of ABX464, on Day 4 simultaneously with ABX464 to evaluate potential CYP1A2 inhibition by ABX464, and on Day 17 simultaneously with ABX464 following 14 days of once daily dosing of ABX464 to evaluate potential CYP1A2 induction by ABX464.
62584729|NCT05121714|OTHER|Evaluation of ABX464 as a substrate for CYP1A2|Using a fixed-sequence crossover study design, the PK of ABX464 (50 mg single oral dose) will be evaluated in the absence and presence of fluvoxamine (100 mg once daily for 10 days) in 36 healthy subjects. ABX464 will be administered on Day 1 in the absence of fluvoxamine and on Day 11 simultaneously with fluvoxamine following 10 days of once daily dosing of fluvoxamine to evaluate whether ABX464 is a substrate for CYP1A2
62584730|NCT06149585||Intra-Lock Fusion Implants|These patients will receive Intra-Lock Fusion Implants during implant placement
62584731|NCT06149585||Tapered Pro Implants|These patients will receive Tapered Pro Implants during implant placement
62584732|NCT00671359|EXPERIMENTAL|after fast|Administration of a single oral dose of 600mg TR-701 to subjects in the fasted state.
62020850|NCT01658683|EXPERIMENTAL|Exercise Facilitator Intervention|The intervention employs small group counseling teleconferences (5),personal telephone contacts (3) and community Heart Wise Exercise program demonstrations.
62391701|NCT05671302|EXPERIMENTAL|Walk Together|Walk Together involves four sessions delivered in patients' primary care clinic over approximately two months. Sessions are dyadic (i.e., all sessions include the patient and a family support person), last 30-90 minutes, and are delivered by a trained family therapist. The intervention is a culturally-response, family-based intervention that is strengths-based and includes components of integrative behavioral couples therapy and motivational interviewing. The goals of the intervention are to (a) optimize family support and communication, (b) improve hypertension knowledge, (c) enhance self-management goal-setting, and (d) increase shared problem-solving to address self-management adherence barriers. Environmental barriers to adherence are also addressed consistent with standard care.
62182881|NCT02442245|ACTIVE_COMPARATOR|Treatment|Treatment group will get 2 g daily of XSurge in microcrystalline cellulose
62391702|NCT05125458||Subjects with dermatological diseases|500 Subjects attending the Dermatology outpatient clinic of the Vanvitelli University hospital with a diagnosis of psoriasis or hidradenitis suppurativa or atopic dermatitis of any grade of severity.
61997541|NCT05312671|EXPERIMENTAL|Atezolizumab with Platinum and Etoposide, followed by cystectomy.|"The study population will include male and female patients over the age of 18 with invasive (cT1-cT4) small cell / neuroendocrine carcinoma of the bladder (MIBC), with or without urothelial cancer component, who are eligible for platinum based chemotherapy and immunotherapy. All patients will be fit to undergo surgical resection of their cancer by cystectomy. Patients with resectable N1 disease within the true pelvis are eligible.~Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg Day 1 of every 21 day cycle with chemotherapy x 4 cycles. Following cystectomy, Atezolizumab maintenance Q 21 days will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status (e.g., symptomatic deterioration such as pain secondary to disease), or up to 1 year (e.g., 16 cycles)."
61997542|NCT05309603|ACTIVE_COMPARATOR|Unloaded Walking|Walking on a treadmill without wearing a pack
61997543|NCT05309603|EXPERIMENTAL|Loaded Walking High|Walking on a treadmill while wearing a 30% body mass load with the weight placed at the high-back
61997544|NCT05309603|EXPERIMENTAL|Loaded Walking Mid|Walking on a treadmill while wearing a 30% body mass load with the weight placed at the mid-back
61997545|NCT03553732||Active Surveillance Patients|Patients who elect to be monitored by an Active Surveillance protocol for prostate cancer
61997546|NCT05409027|EXPERIMENTAL|Single Arm|"Each subject will receive between 1 to 15 mg SPI-62 QD PO for up to 14 days.~Each subject will receive up to 12 mcg cortisone-d8 SC during each of one or more study visits."
61997547|NCT04176003||Patients with CPPD|
61997548|NCT04176003||Healthcare professionals working with CPPD patients|
61997549|NCT04176003||Stakeholders working on behalf of CPPD patients|
61997550|NCT00738972|ACTIVE_COMPARATOR|Valsartan 80 mg + Paravastin 40 mg|Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)
61997551|NCT00738972|ACTIVE_COMPARATOR|Valsartan 80 mg + Simvastatin 40 mg|Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)
61997552|NCT00738972|EXPERIMENTAL|Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg|Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)
61997553|NCT00738972|ACTIVE_COMPARATOR|Valsartan 80 mg|Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)
61997554|NCT03299192|EXPERIMENTAL|Tai Chi|twice weekly classes for 12 weeks and then weekly for 6 weeks, every other week for 6 weeks and monthly for 3 months
61997555|NCT03299192|ACTIVE_COMPARATOR|Health Education|twice weekly classes for 12 weeks
61997556|NCT03299192|ACTIVE_COMPARATOR|Usual Medical Care|the usual care to which participants are entitled by their health insurance
61997557|NCT05211128||Radical prostatectomies|
61997558|NCT05211128||Total hysterectomies|
61997559|NCT05211128||Thoracic lobectomies|
61997560|NCT05211128||Partial nephrectomies|
62182882|NCT02442245|SHAM_COMPARATOR|Control Group|The control group will be included to quantify or describe the effects of the acute exercise training but will not receive any supplement
62182883|NCT00542932|NO_INTERVENTION|I|
62182884|NCT00542932|ACTIVE_COMPARATOR|II|Exercise
62182885|NCT04913623||Correlation of intramedullary pressure and systemic inflammatory parameters in cemented THA|
62182886|NCT04913623||Correlation of intramedullary pressure and systemic inflammatory parameters in non cemented THA|
61997561|NCT05207020|EXPERIMENTAL|Blood sugar levels estimated by analysis of exhaled air|
61997562|NCT05928910|EXPERIMENTAL|SmileyScope VR Group|Participants in this group will wear the SmileyScope VR set during the PNE procedure for approximately 40 minutes.
61997563|NCT05928910|EXPERIMENTAL|No VR Group|Participants in this group will receive standard of care treatment.
62020851|NCT01658683|NO_INTERVENTION|Usual Care|Usual care for cardiac rehab graduates provided by the University of Ottawa Heart Institute Minto Prevention \& Rehabilitation Centre and the Cardiovascular Rehabilitation and Prevention Centre at the University Health Network.
62182887|NCT00345709||National Research Registry Enrollment|Patient, living or deceased, with a pathologically-confirmed diagnosis of Ovarian Cancer.
62182888|NCT04302649|EXPERIMENTAL|Intervention group|Patients received Peritoneal Equilibration Test (PET). In the intervention group, dialysate was warmed in a specific microwave oven calibrated to 37°C and infusion temperature was confirmed to be 37°C before infusion
62182889|NCT04302649|NO_INTERVENTION|Control group|Patients received Peritoneal Equilibration Test (PET). In the control group, current practice was used (batch warming with a pad calibrated to 37°C) and dialysate temperature was measured just before infusion.
62182890|NCT00643318|EXPERIMENTAL|CyberKnife Stereotactic Radiosurgery|
62182891|NCT02602353|EXPERIMENTAL|Loxoprofen Pain Patch|One Active Pain Patch containing loxoprofen applied once daily for 3 days
62182892|NCT02602353|PLACEBO_COMPARATOR|Placebo Patch|One Placebo Patch applied once daily for 3 days
62182893|NCT02602353|OTHER|No Treatment|No Treatment for 3 days
62182894|NCT05242822|EXPERIMENTAL|Part A - dose escalation|Dose escalation of KIN-3248 in patients with solid tumors
62182895|NCT05242822|EXPERIMENTAL|Part B - dose expansion|Dose expansion evaluating the recommended dose and schedule of KIN-3248 identified from Part A
62182896|NCT00716547|EXPERIMENTAL|1|
62182897|NCT00716547|EXPERIMENTAL|2|
62391703|NCT05125458||Subjects with HIV or HBV|500 Subjects attending the Infectious diseases outpatient clinic of the Vanvitelli University hospital and with HIV or HBV infection.
62391704|NCT00669253|EXPERIMENTAL|1|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
62391705|NCT00669253|ACTIVE_COMPARATOR|2|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods (ultrasonic and manual means)
61997564|NCT04270838|EXPERIMENTAL|Group AC1 (Adult low dose)|Volunteers aged 18-45 years. Volunteers will receive a standalone dose of 2.5×10\^10 vp ChAdOx2 RabG on D0. Volunteers will receive two doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
61997565|NCT04270838|EXPERIMENTAL|Group AC2 (Adult high dose)|Volunteers aged 18-45 years. Volunteers will receive a standalone dose of 5×10\^10 vp ChAdOx2 RabG. Volunteers will receive two doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
61997566|NCT04270838|EXPERIMENTAL|Group AC3 (Adult preferred dose)|Volunteers aged 18-45 years. Volunteers will receive a preferred dose of ChAdOx2 RabG on D0. The adult preferred dose will be 2.5×10\^10 vp OR 5×10\^10 vp. Volunteers will receive two doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
62182898|NCT00716547|ACTIVE_COMPARATOR|3|
62182899|NCT00716547|PLACEBO_COMPARATOR|4|
62182900|NCT02392663|ACTIVE_COMPARATOR|Hypertonic saline solution|"Hypertonic saline (7%) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).~Both patients and physiotherapist will be blind to the intervention."
62182901|NCT02392663|ACTIVE_COMPARATOR|Hyaneb solution|"Hyaneb (acid hyaluronic + hypertonic saline \[7%\]) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).~Both patients and physiotherapist will be blind to the intervention."
62182902|NCT02392663|PLACEBO_COMPARATOR|Isotonic saline solution|"Isotonic saline (0,9%) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).~Both patients and physiotherapist will be blind to the intervention."
62182903|NCT05168137|PLACEBO_COMPARATOR|Placebo|prescribed placebo of colchicine
62182904|NCT05168137|ACTIVE_COMPARATOR|Colchicine|Prescribed colchicine 0.6 mg PO daily
62182905|NCT03046381|OTHER|Tocilizumab|Tocilizumab 162mg 1x weekly as subcutaneous syringe
62391706|NCT00669253|ACTIVE_COMPARATOR|3|Surgery at baseline for all deep pockets using conventional methods (ultrasonic and manual means)
62391707|NCT04201444|EXPERIMENTAL|Patient group|
62391708|NCT04201444|ACTIVE_COMPARATOR|Remission control group|
62391709|NCT04201444|ACTIVE_COMPARATOR|Bilateral surrenalectomy control group|
62391710|NCT03919682|EXPERIMENTAL|Training, Phase 1|Community health workers and nurses affiliated with 7 health centers received the breast cancer early detection trainings in April-May 2015
62391711|NCT03919682|EXPERIMENTAL|Training, Phase 2|Community health workers and nurses affiliated with 7 health centers received the breast cancer early detection trainings in November-December 2015
62391712|NCT03919682|NO_INTERVENTION|Control|6 health centers served as controls and did not receive training during the study period
62391713|NCT03117192|EXPERIMENTAL|Zinc sulfate|Zinc sulfate is provided in the form of syrup at a dose of 1.5 mg/kg/day, maximum 50 mg/day.
62567901|NCT06043674|ACTIVE_COMPARATOR|Monotherapy Cohort: Obinutuzumab and Glofitamab|"Study procedures will be conducted as follows:~* Baseline visit with screening procedures, including bone marrow biopsy and Positron Emission Tomography (PET) or Computed Topography (CT) scans.~* PET/CT scans after 4, 8, and 12 cycles of therapy and at 6 and 15 months after end-of-treatment.~* Cycle 1:~  * Day 1, 2, and 7 of 21- day Cycle: Predetermined dose of Obinutuzumab 1x daily.~ * Day 8 and 15 of 21- day Cycle: Predetermined dose of Glofitamab 1x daily. Hospitalization will be required for initial dose and post-dose observation.~* Cycle 2 - 12~  --Day 1 of 21-day Cycle: Predetermined dose of Glofitamab 1x daily. Hospitalization will be required for second dose and post-dose observation~* End of treatment visit.~* Follow up visits: for months 10 - 24, visits will be every 3 months. For months 25 - 60 visits will be every 6 months.~* After completion of a 10-patient safety lead-in cohort, enrollment will open to the other two cohorts."
62773013|NCT04934085||Control group|healthy subjects who did not have COVID-19, the controls will be matched to the study group for gender and age
61997567|NCT04270838|EXPERIMENTAL|Group AV1 (Adult single-visit Verobab)|Volunteers aged 18-45 years. Volunteers will receive Rabies IRV on D0. Volunteers will receive two further doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
62182906|NCT00607997|EXPERIMENTAL|All Study Patients|"* Schedule A: 72 mg/m2 vosaroxin Days 1, 8 and 15~* Schedule B: 72 mg/m2 vosaroxin on Days 1 and 8~* Schedule C: 72 mg/m2 on Days 1 and 4, or~* Schedule C: 90 mg/m2 on Days 1 and 4"
62391714|NCT03117192|PLACEBO_COMPARATOR|Sucrose syrup|Sucrose syrup is used as placebo, its provided in the form of syrup with similar appearance and taste.
62391715|NCT04087551|EXPERIMENTAL|Developing the list of items for BRFES|Two groups of six community-dwelling older adults will participate in a focus group session. Each focus group session will begin with a trained facilitator using a session guide welcoming the participants and introducing the participants in the group. The session will adopt a nominal group method which includes silent generation of ideas, sharing of an idea in a 'round robin' fashion, group discussion to clarify ideas and then completing the session with anonymous voting to include items into a list of items to be included in the Balance Recovery Falls-Efficacy Scale (BRFES).
62391716|NCT02028052|OTHER|ROSE|In the case of ROSE, sampling frequency will occur similarly, but no additional samples will be taken in the case of provision of a preliminary diagnosis.
62773014|NCT05141461|SHAM_COMPARATOR|Group C|The patients will be received an ultrasound-guided interscalene brachial plexus block with 15 mL bupivacaine 0.5%.
62773015|NCT05141461|EXPERIMENTAL|Group Dex|The patients will be received an ultrasound-guided interscalene brachial plexus block with 15 mL bupivacaine 0.5% and 5 mg intravenous dexamethasone.
62773016|NCT05275530|NO_INTERVENTION|Standard of Care|"No Intervention-Standard Care~UCLA Health has a mailed FIT outreach program. This group will receive standard FIT mailer protocol. They will receive a tailored MyChart message indicating the importance of CRC screening and not be presented with a choice for screening modalities."
62773017|NCT05275530|EXPERIMENTAL|FIT Choice|This group will receive a tailored message via MyChart with information about CRC screening and using the FIT kit for noninvasive screening. They will then have to actively choose if they want CRC screening with a FIT kit vs no screening. If they opt for screening, the investigators will mail them a FIT kit.
62773018|NCT05275530|EXPERIMENTAL|Colonoscopy Choice|This group will receive a tailored message via MyChart with information about CRC screening and colonoscopy for CRC screening. They will then have to actively choose if they want CRC screening with a colonoscopy vs no screening. If they opt for screening, the investigators will direct them to our patient navigators to get scheduled for a colonoscopy.
62391717|NCT02028052|OTHER|NO ROSE|In the case of no ROSE, sampling frequency will be predetermined at 4 needle aspirations per site
62391718|NCT00209079|ACTIVE_COMPARATOR|1|
62773019|NCT05275530|EXPERIMENTAL|Dual Choice|This group will receive a tailored message via MyChart with information about CRC screening and using either the FIT kit or colonoscopy for CRC screening. They will then have to actively choose if they want CRC screening with a FIT kit, a colonoscopy, or no screening. If they opt for screening, the investigators will either mail them a FIT kit or direct them to our patient navigators to schedule a colonoscopy, depending on their choice.
62773020|NCT02544997|EXPERIMENTAL|Poziotinib|12mg P.O. for 2wks q21days
62773021|NCT03403023|EXPERIMENTAL|DES treated patients|This single group of patients is imaged by the Tear Film Imager (TFI) device before and after treatment with Restasis, the treatment indicated for their condition.
62773022|NCT05622214|EXPERIMENTAL|Plant based nutrition|Plant based nutritional formula based on almond and buckwheat
62773023|NCT00904072||accepted|The suggestions provided by the CDSS which were accepted by the physicians.
62773024|NCT00904072||denied|The suggestions provided by the CDSS which were denied by the physicians.
62773025|NCT03737877|EXPERIMENTAL|Diet modification|
62791482|NCT06727292|PLACEBO_COMPARATOR|Placebo|The placebo has similar characteristics as the verum instant drink.
62773026|NCT06264297|ACTIVE_COMPARATOR|GROUP I|RFP on the affected level or levels will be carried out during three cycles of 120 s, limited to a temperature of 42° and a voltage of 45V
62773027|NCT06264297|EXPERIMENTAL|GROUP II|RFP on the affected level or levels will be carried out during three cycles of 120 s, limited to a temperature of 42° and a voltage of 65V
62773028|NCT00251251|ACTIVE_COMPARATOR|1. Optimal Medical therapy plus ICD|
62584733|NCT00671359|EXPERIMENTAL|After high fat food|Administration of a single oral dose of 600mg TR-701 to subjects in the fed state.
62773029|NCT00251251|ACTIVE_COMPARATOR|2. Optimal Medical Therapy plus CRT/ICD|
62773030|NCT05764915|EXPERIMENTAL|RGT-264 monotherapy|The study is composed of dose escalation stage and dose expansion stage. RGT-264 will be administered orally daily alone as monotherapy in both stages. In the dose escalation stage, the subjects will receive once daily of RGT-264 monotherapy across approximately 6 ascending dose levels. The starting dose is 10 mg/day. In the dose expansion stage, the subjects will receive RGT-264 treatment at the recommended dose from dose escalation part.
62773031|NCT01075984|ACTIVE_COMPARATOR|POS IV 200 mg single dose (Cohort 0)|POS 200 mg IV single dose infused over 1.5 hours on Day 1 followed 12 hours later by POS oral 400 mg, then by POS oral 400 mg BID on Days 2 through 6 and a single morning dose on Day 7 (Cohort 0)
62791483|NCT06727292|EXPERIMENTAL|Food supplement|Powder for an instant drink preparation with orange flavor /taste
62182907|NCT06308185||Neonates with seizures|Newborns born at term or prematurely who have had epileptic seizures documented by electroencephalogram in the neonatal period
62182908|NCT03022578|EXPERIMENTAL|Treatment (LITT, lomustine)|Patients undergo LITT at baseline and receive lomustine PO on day 1. Treatment with lomustine repeats every 42 days for up to 6 cycles in the absence of disease progression or unaccepted toxicity.
62182909|NCT00566839|EXPERIMENTAL|1|
62182910|NCT00566839|ACTIVE_COMPARATOR|2|
62182911|NCT01961674|EXPERIMENTAL|Capsinoid arm|On capsinoids
62584734|NCT04641325|EXPERIMENTAL|Exercise Intervention Group|Group of up to 20 patients will receive all of the preliminary outcome measure testing (cardiovascular, musculoskeletal, and psychological screening) in addition to exercise intervention education, demonstration, and follow up to ensure compliance and safety.
62584735|NCT06683313||adductor canal block add ipack|Patients who received ipack add femoral canal block for postoperative analgesia
62584736|NCT06683313||femoral block add popliteal sciatic|Patients who underwent popliteal sciatic block add femoral block for postoperative analgesia
62584737|NCT04875728|ACTIVE_COMPARATOR|Arm A (cefazolin, surgical resection)|Patients receive cefazolin IV and then undergo standard of care surgical resection within 1 hour.
62584738|NCT04875728|EXPERIMENTAL|Arm B (surgical resection)|Patients undergo standard of care surgical resection.
62584739|NCT06441838|EXPERIMENTAL|Listening to Surah Inshirah|Experimental group patients; A patient descriptive characteristics form will be administered, and the pre-test Depression, Stress, Anxiety Scale and Warwick-Edinburgh Mental Well-Being Scale will be administered. Then, Surah Inshirah will be listened to and the final test, Depression, Stress, Anxiety Scale and Warwick-Edinburgh Mental Well-Being Scale will be administered.
62584740|NCT06441838|NO_INTERVENTION|control group|intervention group patients; Patient descriptive characteristics form, Depression, Stress, Anxiety Scale and Warwick-Edinburgh Mental Well-Being Scale will be administered. Then, the Depression, Stress, Anxiety Scale and Warwick-Edinburgh Mental Well-Being Scale will be administered 1 month later without any intervention.
62584741|NCT06685614|ACTIVE_COMPARATOR|direct|traditional direct bonding
62584742|NCT06685614|ACTIVE_COMPARATOR|indirect|traditional indirect bonding, bracket transfer tray made using cast model
62584743|NCT06685614|EXPERIMENTAL|3D-printed tray|virtual bracket bonding and 3D print out indirect bracket bonding transfer tray using CAD/CAM technique
62182912|NCT01961674|PLACEBO_COMPARATOR|Placebo arm|Placebo
62391719|NCT00724243||Rheumatoid Arthritis Patients in Slovakia|Rheumatoid arthritis patients in Slovakia who are starting treatment with infliximab for the first time, in accordance with normal clinical practice.
62391720|NCT05707104|EXPERIMENTAL|Pilates exercises|performing Pilates exercises three times per week for 6 weeks while maintaining their regular physical activity and nutritional plans.
62391721|NCT05707104|EXPERIMENTAL|plyometric exercises|performing plyometric exercises three times per week for 6 weeks while maintaining their regular physical activity and nutritional plans.
62391722|NCT02503111|EXPERIMENTAL|Ablative therapy|Ablative therapy involving electrocautery (EC) will occur for participants with AIN-2 and AIN-3. The Hyfrecator ® 2000 Electrosurgical System will be used for EC therapy.
62773032|NCT01075984|PLACEBO_COMPARATOR|Dextrose 5% in water (Cohort 0)|Placebo IV single dose infused over 1.5 hours on Day 1 followed 12 hours later by POS oral 400 mg, then by POS oral 400 mg BID on Days 2 through 6 and a single morning dose on Day 7 (Cohort 0)
62773033|NCT01075984|EXPERIMENTAL|POS IV 200 mg BID (Cohort 1)|POS 200 mg IV infused over 1.5 hours BID on Day 1, followed by POS 200 mg IV once daily on Days 2 through 14, then by POS 400 mg oral BID through Day 28 (Cohort 1)
62773034|NCT01075984|EXPERIMENTAL|POS IV 300 mg BID (Cohort 2)|POS 300 mg IV infused over 1.5 hours BID on Day 1, followed by POS 300 mg IV once daily on Days 2 through 14, then by POS 400 mg oral BID through Day 28 (Cohort 2). After Day 5, POS IV was administered continuously or intermittently, depending on oral tolerability.
62773035|NCT01075984|EXPERIMENTAL|POS IV 300 mg BID (Cohort 3)|POS 300 mg IV infused over 1.5 hours BID on Day 1, followed by POS 300 mg IV once daily on Days 2 through 5, then by POS 200 mg oral TID or POS 400 mg oral BID through Day 28, or POS 200-300 mg IV once daily as required (Cohort 3). After Day 5, POS IV was administered continuously or intermittently, depending on oral tolerability.
62773036|NCT06430515|EXPERIMENTAL|Intratumoral Injection of Chemotherapy|Fine-needle puncture guided by CT or ultrasound and infusion of chemotherapeutic agents (e.g. cisplatin, oxaliplatin, etc.) via the tumour increases the local drug concentration in the tumour, improves therapeutic efficacy and reduces drug resistance and systemic adverse effects.
62391723|NCT02503111|ACTIVE_COMPARATOR|Active Surveillance|The control arm includes active surveillance with observation alone; no treatment in AIN-2 and -3.
62391724|NCT03947073|NO_INTERVENTION|Standard of Care|Subjects with newly diagnosed gestational diabetes are randomized to standard of care diabetes education.
62773037|NCT05105867|EXPERIMENTAL|Anti-CD19 Universal CAR-T Cells injection|Anti-CD19 Universal CAR-T Cells injection will be administered by vein after lymphodepletion .
62773038|NCT02747511|ACTIVE_COMPARATOR|Haloperidol|
62773039|NCT02747511|PLACEBO_COMPARATOR|Placebo|
62773040|NCT02272218|OTHER|LAGB|There is only one arm for this study, since this study involves a single cohort receiving the same intervention, laparoscopic gastric banding (LAGB) surgery.
62182913|NCT04267471|EXPERIMENTAL|Tai Chi|3 sessions of Tai Chi per week for 12 weeks
62182914|NCT04267471|ACTIVE_COMPARATOR|Walking|3 sessions of walking per week for 12 weeks
62182915|NCT04267471|NO_INTERVENTION|Waiting-list|
62391725|NCT03947073|EXPERIMENTAL|Interactive Educational Application|Subjects with newly diagnosed gestational diabetes are randomized to standard of care plus an interactive educational application.
62391726|NCT00875043||1. flat Jackson table|All measurements previously described will be done with the patient in the prone postion and Jackson table flat.
62391727|NCT00875043||2. Elevated Jackson tablet|All measurements previously described will be performed with subjects placed prone on the elevated Jackson table.
62584744|NCT06685614|EXPERIMENTAL|3D-printed model|virtual bracket bonding and 3D print out digital model with brackets; indirect bracket bonding transfer tray made using 3D-printed model
62391728|NCT01354964|EXPERIMENTAL|Vitamin D|Participants received weekly oral vitamin D drops using a weight-based calculated dosage for up to six months.
62391729|NCT01354964|PLACEBO_COMPARATOR|Placebo|Participants received weekly oral placebo drops (similar in taste and appearance to vitamin D) for up to six months.
62391730|NCT00660829|PLACEBO_COMPARATOR|1|Placebo
62391731|NCT00660829|ACTIVE_COMPARATOR|2|0.15% Azelastine Hydrochloride
62391732|NCT03771859||Participants who initiate adjuvant treatment with nivolumab|
62391733|NCT05951881||Urgent care unit patients with medication|All patients admitted to the emergency department who agree to describe their medication
62584745|NCT04067726|EXPERIMENTAL|Denosumab|"* Subcutaneous injection of denosumab at a dose of 60 mg at two time points: baseline and 6 months~* Participants will also be instructed to take calcium and vitamin D supplements daily for 12 months between baseline examination and 12-month mammographic breast density examination.~* Mammographic breast density will be assessed at three time points in all participants: baseline, 12 months, and 24 months. A 36-month optional assessment may also occur.~* Biopsies and blood draws will occur for research purposes at baseline and 12 months."
62584746|NCT04067726|PLACEBO_COMPARATOR|Placebo|"* Subcutaneous injection of the placebo at a dose of 60 mg at two time points: baseline and 6 months~* Participants will also be instructed to take calcium and vitamin D supplements daily for 12 months between baseline examination and 12 month mammographic breast density examination~* Mammographic breast density will be assessed at three time points in all participants: baseline, 12 months, and 24 months. A 36 month optional assessment may also occur.~* Biopsies and blood draws will occur for research purposes at baseline and 12 months."
62791484|NCT05258149|EXPERIMENTAL|TEST/CONTROL/CONTROL|Eligible subjects will be randomized into the sequence TEST/CONTROL/CONTROL.
62791485|NCT05258149|EXPERIMENTAL|CONTROL/TEST/TEST|Eligible subjects will be randomized into the sequence CONTROL/TEST/TEST
62791486|NCT01295645|EXPERIMENTAL|Standard of Care + Cidofovir|Cidofovir 0.5 mg/kg IV 3 x week for 4 weeks
62791487|NCT01295645|ACTIVE_COMPARATOR|No Cidofovir|Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
62391734|NCT00683852|ACTIVE_COMPARATOR|Drug 2mg/Drug 5mg|patients randomly assigned to the drug/drug sequence, the dose of aripiprazole will be 2 mg/day during the first phase of the study, and 5 mg/day in the second phase.
62773041|NCT06546176|OTHER|Group A(end to end with Omega suture)|After the rectum was divided with a linear stapler, the circular stapler was placed allowing the anvil rod to penetrate the rectal stump near the linear stapler line. An omega suture including both ends of the linear stapler line was placed. The linear stapler line was approximated around the anvil rod of the circular stapler in an omega shape fashion as the omega suture was tied. This technique resulted in a complete resection of linear stapler line by the circular stapler.
62391735|NCT00683852|ACTIVE_COMPARATOR|Placebo/Drug 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study.
62391736|NCT00683852|PLACEBO_COMPARATOR|Placebo/Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study.
62391737|NCT02205580|EXPERIMENTAL|Sufentanil infusion rate 0.02μg•kg-1•h-1|Sufentanil infusion rate 0.02μg•kg-1•h-1 lasted for 48 hours
62391738|NCT02205580|EXPERIMENTAL|Sufentanil infusion rate 0.03μg•kg-1•h-1|Sufentanil infusion rate 0.03μg•kg-1•h-1 lasted for 48 hours
62391739|NCT02205580|EXPERIMENTAL|Sufentanil infusion rate 0.04μg•kg-1•h-1|Sufentanil infusion rate 0.04μg•kg-1•h-1 lasted for 48 hours
62584747|NCT02940418|ACTIVE_COMPARATOR|Dose 1 mil/kg|"Adipose mesenchymal cells with bone marrow mononuclear cells.~Two doses with a 6 month interval of allogenic Adipose mesenchymal cells +1 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
62584748|NCT02940418|ACTIVE_COMPARATOR|Dose 10 mil/kg|"Adipose mesenchymal cells with bone marrow mononuclear cells.~Two doses with a 6 month interval of allogenic Adipose mesenchymal cells +10 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
62773042|NCT06546176|OTHER|Group B (end to anterior rectal wall)|"A burse string suture was applied over the anvil of the circular stapler at the transection point of the descending colon using prolene 2/0.~The circular stapler introduced though the anus and its rod directed toward the anterior rectal wall and colorectal anastomosis was performed."
62773043|NCT06221748|EXPERIMENTAL|Disitamab Vedotin + Cadonilimab|Disitamab Vedotin With Cadonilimab
62773044|NCT06221748|EXPERIMENTAL|Disitamab Vedotin|Disitamab Vedotin arm
62773045|NCT06221748|EXPERIMENTAL|Paclitaxel|Paclitaxel Arm
62773046|NCT01364701|ACTIVE_COMPARATOR|Maximal dose sildenafil|4 tablets of sildenafil 100mg are given for on demand use
62773047|NCT01364701|ACTIVE_COMPARATOR|Tadalafil 20mg maximal dose|4 tablets of tadalafil 20mg are given for on demand use
62773048|NCT01364701|ACTIVE_COMPARATOR|Combination half dose|4 tablets of sildenafil 50mg and tadalafil 10mg are given for on demand use
62773049|NCT00548236|EXPERIMENTAL|1|Immediate participation in a 16-week exercise program
62773050|NCT00548236|NO_INTERVENTION|2|Control population; will receive exercise plan after 16-week control period
62773051|NCT06303856|EXPERIMENTAL|Active Breathing Exercises|The observation group is the only group of the participants.The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Active Breathing Exercises, with weekends off and training conducted only on weekdays. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors.
62391740|NCT03710395|ACTIVE_COMPARATOR|Wild homozygous for ABCG2 c.421C>A|Chronic hypertensive breastfeeding women (18-45 years old) genotyped as wild homozygous for ABCG2 c.421C\>A.
62391741|NCT03710395|EXPERIMENTAL|Variant genotypes for ABCG2 c.421C>A|Chronic hypertensive breastfeeding women (18-45 years old) genotyped as heterozygous or mutant homozygous for ABCG2 c.421C\>A.
62391742|NCT01673204|EXPERIMENTAL|Calcitriol|Calcitriol
62391743|NCT01673204|PLACEBO_COMPARATOR|Placebo|Placebo
62391744|NCT05423600|EXPERIMENTAL|BES+TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
62773052|NCT06522399||patients with obstructed defecation who undergo TAMIS mucosectomy|patients with obstructed defecation and rectocele or intussuception
62773053|NCT00760838|EXPERIMENTAL|Azithromycin|"Azithromycin 250 mg~1x/day during 5 days 3x/week afterwards"
62773054|NCT00760838|PLACEBO_COMPARATOR|placebo|"Placebo~1x/day during 5 days 3x/week afterwards"
62773055|NCT04607122|EXPERIMENTAL|Landiolol group|Landiolol infusion (2µg/kg/min) administrated after the surgery, on arrival at the ICU, until restoration of an effective oral beta-blocker treatment.
62773056|NCT04607122|PLACEBO_COMPARATOR|Placebo group|Saline solution infusion administrated after the surgery, on arrival at the ICU, until restoration of an effective oral beta-blocker treatment.
62391745|NCT05423600|EXPERIMENTAL|BES+sham TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) sham treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
62391746|NCT04868760|ACTIVE_COMPARATOR|Group B: ipilimumab|Ipilimumab, 0.1 and 0.3mg/kg, will be administrated intravenously in 30-60 minutes.
62391747|NCT04868760|EXPERIMENTAL|Group A: IBI310|IBI 310, 0.1 and 0.3mg/kg, will be administrated intravenously in 30-60 minutes.
62391748|NCT04297111|PLACEBO_COMPARATOR|Placebo|Maltodextrin containing capsule
62391749|NCT04297111|EXPERIMENTAL|Probiotic|Probiotic containing capsule
62773057|NCT03843801|ACTIVE_COMPARATOR|Volume reduction|Intragastric sutures are done to reduce the volume of the stomach
62773058|NCT03843801|ACTIVE_COMPARATOR|Gastric emptying reduction|Intragastric sutures are done to slower the gastric emptying
62773059|NCT03843801|ACTIVE_COMPARATOR|Increasing distension|Intragastric sutures are done to maximalize the gastric distension
62391750|NCT05124145||surveillance network|The surveillance network is made of 200 health professionals from 85 practices
62391751|NCT02917369||Normal lung tissue|Normal lung tissue from LCLC patients
62391752|NCT02917369||LCLC tissues|LCLC tissues from LCLC patients
62391753|NCT02917369||Metastasis tissues|Metastasis tissues from LCLC patients
62391754|NCT03971773|EXPERIMENTAL|Patient ongoing hypnosis sessions|
62773060|NCT05922241|EXPERIMENTAL|Costophrenic assisted cough|While doing Costophrenic assist: at the end of expiration, the therapist gives a quick stretch to the diaphragm and intercostals to facilitate more complete inhalation by compressing the chest at the costophrenic angle toward the central tendon of the diaphragm. This is done several times to fill the lungs. The patient is then instructed to hold the air in the lungs. As the patient gets ready to cough, the therapist performs a diaphragmatic assist by applying a strong pressure up and in toward the central tendon
62773061|NCT05922241|EXPERIMENTAL|Anterior chest compression|Anterior chest compression: the therapist places one arm across the patient's pectorals and the other parallel to it on the lower abdomen. After the patient takes a maximal breath, the therapist pushes down to help the patient cough. The greatest force is applied through the lower chest during expulsion
62773062|NCT00086411|EXPERIMENTAL|1: Bup+MM|bupropion and MM counseling with placebo patch
62773063|NCT00086411|EXPERIMENTAL|2 Bup+Mayo|bupropion and Mayo counseling with placebo patch.
62773064|NCT00086411|PLACEBO_COMPARATOR|3 Patch+MM|patch and MM counseling with placebo pills
62773065|NCT00086411|EXPERIMENTAL|4 Patch+Mayo|patch and Mayo counseling with placebo pills
62391755|NCT02759939|EXPERIMENTAL|Arm 1|
62391756|NCT02759939|EXPERIMENTAL|Arm 2|
62391757|NCT02759939|EXPERIMENTAL|Arm 3|
62391758|NCT02759939|NO_INTERVENTION|Arm 4|
62391759|NCT01383317|ACTIVE_COMPARATOR|RIPC|A tourniquet on the thigh will be inflated to 300 mmHg for 5 minutes then deflated for 5 minutes. This will be repeated three times
62773066|NCT06507384||Patients undergoing elective plastic surgery, evaluated with the AI-based risk assessment model.|"This cohort includes patients undergoing elective plastic surgery who are evaluated using an AI-based risk assessment model. The AI model analyzes clinical data and patient history to generate personalized risk scores and recommendations to minimize surgical complications.~Based on the AI-generated risk scores, patients are divided into three risk groups: low, moderate, and high-risk. The model provides tailored recommendations for each patient's altered risk factor, such as weight management, smoking cessation, blood pressure monitoring, and specialist consultations, to address specific risk factors and improve surgical outcomes."
62773067|NCT00454584|EXPERIMENTAL|CNTO 1275 45 mg|Patients will receive CNTO 1275 45 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on Physician's Global Assessment (PGA) response at Week 12 and initial treatment assignment.
62773068|NCT00454584|EXPERIMENTAL|CNTO 1275 90 mg|Patients will receive CNTO 1275 90 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.
62391760|NCT01383317|SHAM_COMPARATOR|Sham RIPC|A tourniquet on the thigh will be inflated to 15 mmHg for 5 minutes then deflated for 5 minutes. This will be repeated three times
62391761|NCT02087085|EXPERIMENTAL|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye, administered by intravitreal injections using the Brimonidine Drug Delivery System (Brimo DDS®) applicator every 3 months from Baseline (Day 1) through Month 21.
62391762|NCT02087085|SHAM_COMPARATOR|Sham|Sham treatment (control) in the study eye, administered by intravitreal injections using a needleless drug delivery system (DDS) applicator every 3 months from Baseline (Day 1) through Month 21.
62391763|NCT03908658|ACTIVE_COMPARATOR|Inspiratory Muscle Training and Nasal High Flow|Inspiratory Muscle Training will start as soon as the patient wakes up and is cooperative, ventilated with support settings. Nasal High Flow will be applied immediately after extubation. IMT intervention will continue until patient's discharge from the ICU
62391764|NCT03908658|ACTIVE_COMPARATOR|Inspiratory Muscle Training and Venturi mask|IMT will start as soon as the patient wakes up and is cooperative, ventilated with support settings. Venturi mask will be applied immediately after extubation. IMT intervention will continue until patient's discharge from the ICU
62584749|NCT05454761|EXPERIMENTAL|Lifestyle medicine intervention with self-tracking tools|Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness. Self-tracking tools including a smartphone application and an Actigraphy will be given.
62773069|NCT00454584|ACTIVE_COMPARATOR|Etanercept 50 mg|Patients will receive Etanercept 50 mg twice weekly through Week 12. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.
62773070|NCT00946673|EXPERIMENTAL|vorinostat & stereotactic radiosurgery|
62773071|NCT02949388|PLACEBO_COMPARATOR|Placebo|Placebo Comparator: Placebo daily Two (2) placebo capsules given twice daily (AM and PM) for 84 (± 2 days
62773072|NCT02949388|ACTIVE_COMPARATOR|300 mg (150 mg BID)|Active Comparator: 300 mg of Prurisol daily One (1) capsule containing 100 mg Prurisol and one (1) capsule containing 50 mg of Prurisol given twice (AM and PM) for 84 (± 2) days
62773073|NCT02949388|ACTIVE_COMPARATOR|400 mg (200 mg BID)|Active Comparator: 400 mg of Prurisol daily Two (2) capsule each containing 100 mg Prurisol given twice daily (AM and PM) for 84 (± 2) days
62773074|NCT00326248|EXPERIMENTAL|Arm 1|
62773075|NCT00351273|ACTIVE_COMPARATOR|Azithromycin and Rifampin|Participants received Azithromycin and Rifampin
61997568|NCT04270838|EXPERIMENTAL|PC1a (Paediatric low dose)|Volunteers aged 2-6 years. Volunteers will receive a standalone dose of 1×10\^10 vp ChAdOx2 RabG on D0. Volunteers will receive two doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
61997569|NCT04270838|EXPERIMENTAL|PC1b (Paediatric low dose)|Volunteers aged 2-6 years. Volunteers will receive a half adult preferred dose of ChAdOx2 RabG on D0. The adult preferred dose will be 2.5×10\^10 vp OR 5×10\^10 vp. Volunteers will receive two doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
61997570|NCT04270838|EXPERIMENTAL|PC2 (Paediatric high dose)|Volunteers aged 2-6 years. Volunteers will receive a full adult preferred dose of ChAdOx2 RabG on D0. The adult preferred dose will be 2.5×10\^10 vp OR 5×10\^10 vp. Volunteers will receive two doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
61997571|NCT04270838|EXPERIMENTAL|PC3 (Paediatric preferred dose)|Volunteers aged 2-6 years. Volunteers will receive a paediatric preferred dose of ChAdOx2 RabG on D0. The paediatric preferred dose will be 50-100% of the adult preferred dose. Volunteers will receive two doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
62020852|NCT01870843|EXPERIMENTAL|Escitalopram|Participants will receive escitalopram 10 mg per day for 1 week and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
62584750|NCT05454761|EXPERIMENTAL|Pure lifestyle medicine intervention|Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness.
62584751|NCT05454761|NO_INTERVENTION|Care-As-Usual|continue receiving the routine care as usual and be given a smartphone-based LM intervention after the completion of follow-up assessments
62735099|NCT03391557|EXPERIMENTAL|Patients with the UE examination|Patients with enlarged intrathoracic lymph nodes(≥1cm) and/or 18-FDG high uptake (SUV Max \> 2.5) without bleeding tendency, abnormal coagulation function and serious cardiac dysfunction were finally selected.
62735100|NCT03529617||Critically ill patients|Patients admitted on ICU.
62773076|NCT00351273|ACTIVE_COMPARATOR|Doxycycline and Rifampin|Participants received Doxycycline and Rifampin
62773077|NCT00351273|PLACEBO_COMPARATOR|received placebo|Participants received placebo
62773078|NCT03396510|EXPERIMENTAL|IMPROVED intervention|Patients randomized to the IMPROVED intervention will self-report their symptoms each day using a tablet computer. If any patient refuses or is unable to complete the symptom assessment on the computer, the study team will permit them to use paper versions. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden. Patients randomized to IMPROVED will have their symptoms presented to their inpatient oncology team, but the study team will not provide guidance about what actions to take in response to patients' symptoms.
62773079|NCT03396510|NO_INTERVENTION|Usual Care|Usual Care per hospital standard will be administered. Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports.
62773080|NCT03959982|EXPERIMENTAL|HHHFA Randomized Group|Subjects will be randomized to use the HHHFA device during bedtime for at least 4 hours. Subjects will complete MRC, SGRQ, CAT, CASA-Q and PSQI questionnaires. They will do spirometry, 6-minute walk, and CT scan. These interventions will be done at baseline and at the completion of their study (6 weeks). Spirehealth Device will be worn by subject daily for 12 weeks.
62773081|NCT03959982|ACTIVE_COMPARATOR|Control Group|Subjects will complete MRC, SGRQ, CAT, and PSQI questionnaires. They will do spirometry, 6-minute walk, and CT scan. These interventions will be done at baseline and at the completion of their study (6 weeks). Spirehealth Device will be worn by subject daily for 12 weeks.
62773082|NCT03837288|NO_INTERVENTION|Vaginal progesterone only|continue on vaginal progesterone only
62773083|NCT03837288|EXPERIMENTAL|Cervical cerclage plus vaginal progesterone|cerclage with vaginal progesterone.
62773084|NCT01274429|EXPERIMENTAL|Open label peanut flour|Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.
62773085|NCT01267175|EXPERIMENTAL|X54 pump|All subjects transferred from current pump to X54
62773086|NCT02025439|EXPERIMENTAL|rTMS Alone followed by rTMS+AMA|Subjects assigned to rTMS Alone will receive 30 sessions of rTMS. Two rTMS sessions will be provided per day, four days per week.After first completing rTMS Alone, subjects will receive rTMS plus Amantadine. A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.
62773087|NCT02025439|EXPERIMENTAL|AMA Alone followed by rTMS+AMA|Subjects who are assigned to the Amantadine Alone group will receive 28 doses of Amantadine (100mg BID) every day for 28 days. After first completing Amantadine Alone subjects will receive rTMS plus Amantadine. A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.
62391765|NCT03747731||Resistive Index and Peep Titration|"Enrolled patients will receive a sequential, step-wise increase in PEEP from 0 cmH2O to 12 cmH2O. The inter-lobar arterioles will be sampled at each PEEP increment and the IR will be measured as the average of three values recorded at the upper and lower pole and at the mesorenes in each kidney.~Gas exchanges, HR, systolic, diastolic and mean PA, Pmax, P1 and P2 airway, total resistance and ohmic resistance and static respiratory compliance indexed for body weight (RRSmaxI, RRSminI, CrsI) will be measured at each Peep Level.~The physiologic measurements will be obtained at regular intervals (within 15 minutes at each PEEP level) throughout the PEEP titration period."
62773088|NCT03532217|EXPERIMENTAL|PROSTVAC/Ipilimumab/Nivolumab/Neoantigen DNA vaccine|"* Within 60 days after the last chemo, patients will start a priming dose of PROSTVAC-V, and subsequent doses of PROSTVAC- F (weeks 0, 2, 5, 8, 11, 14, and 17). During Treatment A phase, subjects should receive nivolumab intravenously on Day 1 of each cycle every 3 weeks for 6 doses. Ipilimumab on Day 1 of each cycle every 3 weeks for 2 doses.~* Patients will then receive a neoantigen DNA vaccine with continuous nivolumab treatment. The vaccine will be administered starting approximately week 21 by intramuscular injection for a total of 6 treatments every 28 days +/-7 days. Each DNA vaccination will be 4 mg vaccine administered intramuscularly using a TriGrid electroporation device. Patients will receive nivolumab at 480 mg every 28 days concurrently with neoantigen DNA vaccine. This is Treatment B. In the event the DNA vaccine production is delayed, patients will receive single agent nivolumab every 4 weeks beginning week 21 until the vaccine is ready"
62773089|NCT00443781|OTHER|PD and F.A.D. diagnostic testing|
62773090|NCT02700165|EXPERIMENTAL|CoolSculpting with CoolMini|The treatments are designed to see if fat in the submandibular/submental area (chin), can be reduced using cryolipolysis.
62773091|NCT06340490|EXPERIMENTAL|RJMty19 (CD19-CAR-DNT Cells)|The trial is divided into two parts: Part A is a dose escalation trial with three dose groups (5×10\^6 CAR+ cells/kg, 1×10\^7 CAR+ cells/kg, 2×10\^7 CAR+ cells/kg at day 0), with 9-18 patients planned to be enrolled. Part B is a dose-expansion trial in which 3\~6 patients will receive RJMty19 infusions at RP2D dose levels
62773092|NCT03133312|EXPERIMENTAL|Chlorhexidine Gluconate|Pre-operative vagina preparation with Chlorhexidine Gluconate Intervention: Drug: Chlorhexidine Gluconate Other Name: Chlora-Prep
62773093|NCT03133312|EXPERIMENTAL|Povidone-Iodine Scrub and Paint|Pre-operative vagina preparation with Povidone-Iodine Scrub and Paint Intervention: Drug: Povidone-Iodine Scrub and Paint Other Name: Betadine
62773094|NCT03307031|EXPERIMENTAL|High Volume Group|Performed four weekly sessions, during 10 weeks with 45 to 55 minutes per session.
62773095|NCT03307031|EXPERIMENTAL|Low Volume Group|Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
62020853|NCT05972447|OTHER|non-restorable mandibular molar teeth|patients with non restorable mandibular molar teeth without any periapical pathosis to be extracted and implanted immediately using ultrawide diameter dental implants
62773096|NCT03307031|PLACEBO_COMPARATOR|Control Group|Did not exercise, during 10 weeks.
62773097|NCT05883722|EXPERIMENTAL|RA group|The RA group received adjunctive right atrial ablation in addition to left side ablation.
62773098|NCT05883722|ACTIVE_COMPARATOR|Control group|The control group received left side ablation only.
62735101|NCT03529617||Hematology patients|Patients admitted on the hematology ward.
62773099|NCT01241071|EXPERIMENTAL|Myofascial treatment|Myofascial release techniques of different muscles implicated in low back pain
62773100|NCT01241071|PLACEBO_COMPARATOR|Placebo|
62773101|NCT02567045|EXPERIMENTAL|Fecal occult blood testing|"Annual FIT and colonoscopy in case of a positive test. Fecal occult blood testing: annual FIT (two rounds) without diet restriction, one stool sample. Positive cut-off = 10 μg Hemoglobin/g feces.~Colonoscopy will be performed in case of a positive FIT."
62391766|NCT00800085|NO_INTERVENTION|FDR of type 1 diabetes patients receiving glucose 20%|First Degree Relatives of diabetes type 1 patient with a high, intermedian or low risk (accoring to the criteria of the protocol), for developing diabetes type 1.
62567902|NCT06043674|EXPERIMENTAL|Combination A Group: Obinutuzumab, Glofitamab, and Polatuzumab Vedotin|"Study procedures will be conducted as follows:~* Baseline visit with screening procedures, including bone marrow biopsy and PET/CT scans.~* PET/CT scans after 4, 8, and 12 cycles of therapy and at 6 and 15 months after end-of-treatment.~* Cycle 1:~  * Day 1, 2, and 7 of 21- day Cycle: Predetermined dose of Obinutuzumab 1x daily.~ * Day 8 and 15 of 21- day Cycle: Predetermined dose of Glofitamab 1x daily. Hospitalization will be required for initial dose and post-dose observation.~* Cycle 2 - 7:~  - Day 1 of 21-day Cycle: Predetermined dose of Glofitamab 1x daily. Predetermined dose of Polatuzumab Vedotin 1x daily.~* Cycle 8 - 12~  - Day 1 of 21-day Cycle: Predetermined dose of Glofitamab 1x daily.~* End of treatment visit.~* Follow up visits: for months 10 - 24, visits will be every 3 months. For months 25 - 60 visits will be every 6 months."
62773102|NCT02567045|ACTIVE_COMPARATOR|one-time Colonoscopy|One-time Colonoscopy with sedation
62773103|NCT02083887|ACTIVE_COMPARATOR|Group 1: ChAd63 ME-TRAP / MVA ME-TRAP at 16/24 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 infants aged 16 weeks at time of first vaccination vaccinated with ChAd63 ME-TRAP 5 x 10\^10 vp (virus particles) intramuscular (IM) at 16 weeks and MVA ME-TRAP 1 x 10\^8 pfu (plaque forming units) IM at 24 weeks.
62773104|NCT02083887|ACTIVE_COMPARATOR|Group 2: ChAd63 ME-TRAP / MVA ME-TRAP at 8/16 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 healthy infants aged 8 weeks at the time of first vaccination vaccinated with ChAd63 ME-TRAP 5 x 10\^10 vp IM at 8 weeks and MVA ME-TRAP 1 x 10\^8 pfu IM at 16 weeks
62773105|NCT02083887|ACTIVE_COMPARATOR|Group 3: ChAd63 ME-TRAP / MVA ME-TRAP at 1/8 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 healthy infants aged 1 week will be vaccinated with ChAd63 ME-TRAP 5 x 10\^10 vp IM at 1 week and MVA ME-TRAP 1 x 10\^8 pfu IM at 8 weeks.
62020854|NCT01219738|EXPERIMENTAL|budesonide 360ug|asthmatic subject received different doses of inhaled budesonide in random other
62182916|NCT04735198|ACTIVE_COMPARATOR|Experimental group|Patients with midgut neuroendocrine tumor who will undergo only primary tumor surgery.
62182917|NCT04735198|EXPERIMENTAL|Control group|Patients with midgut neuroendocrine tumor that will undergo through primary tumor surgery combined with prophylactic cholecystectomy.
62391767|NCT05102773||Ancillary-correlative (questionnaire, sample collection, CT)|Patients complete a FFQ at baseline, undergo collection of stool samples at baseline, within 2 days of starting corticosteroid treatment (if applicable), when asked for a control sample, and at 12 weeks, and undergo collection of blood samples and CT at baseline and 12 weeks.
62391768|NCT06428331|EXPERIMENTAL|Dose Escalation|Several dose levels are tentatively planned for Phase 1
62391769|NCT04806191|EXPERIMENTAL|Intervention|Patients will be assessed by GPs who have attended an outreach workshop and trained at using an evidence based strategy for shoulder examination and treatment. GPs will have access to a decision support tool and patients is offered a tailored information package for self management.
62391770|NCT04806191|ACTIVE_COMPARATOR|Treatment as usual (TAU)|The participants enrolled in the control period will receive treatment as offered in general practice.
62773106|NCT02083887|NO_INTERVENTION|Group 4: Control|20 healthy infants aged 16, 8 and 1 weeks will be enrolled into this group. (Five infants will be randomised to each of Groups 1 and 2 respectively while 10 infants aged 1 week will be randomised to Group 3). All twenty infants will receive EPI vaccinations only.
62773107|NCT04465968|EXPERIMENTAL|CRT + Durvalumab ± Surgery + Durvalumab|Concurrent chemoradiotherapy (cisplatin+S-1+radiotherapy 66Gy)+2 courses of durvalumab followed by Surgery and adjuvant durvalumab for resectable SST or chemoradiotherapy (cisplatin+S-1+radiotherapy 66Gy) followed by maintenance durvalumab for unresectable SST.
62773108|NCT02152527||Trimetazidine|Patients for coronary artery bypass grafting surgery who had preoperative trimetazidine usage in standard ischemic coronary disease therapy.
62773109|NCT02152527||Control|Patients for coronary artery bypass grafting surgery who had standard therapy for ischemic coronary disease without trimetazidine.
62020855|NCT01219738|EXPERIMENTAL|budesonide 720ug|asthmatic subject received different doses of inhaled budesonide in random other
62773110|NCT05094830|EXPERIMENTAL|Stomach Intestinal Pylorus Sparing (SIPS)|Patients undergoing SIPS procedure as their bariatric surgery of choice.
62020856|NCT01219738|EXPERIMENTAL|budesonide 1440ug|asthmatic subject received different doses of inhaled budesonide in random other
62020857|NCT01219738|PLACEBO_COMPARATOR|placebo|asthmatic subject received inhaled placebo
62182918|NCT05221177|EXPERIMENTAL|Training|Participants in this arm will perform six suspension training exercises (acute bout per exercise) at two different conditions (30 and 45 seconds).
62182919|NCT05221177|NO_INTERVENTION|Control|Participants in this arm will receive no intervention.
62182920|NCT01016418|EXPERIMENTAL|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
62182921|NCT02283021||NSCLC Patients|Sample biopsies from normal and cancerous lung tissue.
62182922|NCT02283021||Patients without NSCLC|Sample biopsies from normal lung tissue.Control group.
62182923|NCT03032640|ACTIVE_COMPARATOR|Group 1- Healthy Lean subjects|Group 1 will receive Sodium Saccharin 200mg capsule, 2x/day, Day 1-14
61997572|NCT04270838|EXPERIMENTAL|PV1 (Paediatric single-visit Verobab)|Volunteers aged 2-6 years. Volunteers will receive Rabies IRV (Verorab) as a 2 site ID on D0. Volunteers will receive two further doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
62020858|NCT01219738|EXPERIMENTAL|Budesonide720ug 4 times|asthmatic subject received 720ug of inhaled budesonide 4 times separated by 30 minutes.
62182924|NCT03032640|ACTIVE_COMPARATOR|Group 2- Healthy Lean subjects|Group 2 will receive Placebo 500mg capsule, 2x/day, Day 1-14
62182925|NCT03032640|ACTIVE_COMPARATOR|Group 3- Healthy Lean subjects|Group 3 will receive Sodium Saccharin 200mg + lactisole 335mg capsule, 2x/day, Day 1-14
62391771|NCT01722552|EXPERIMENTAL|adherence feedback|Intervention subjects will receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time (as indicated by lack of a Wisepill opening). They will then participate in monthly interactive counseling sessions using summaries of their previous month's behavior. Patients whose mean adherence in the previous month was \<95% will be required to have a counseling session, while those with higher adherence will be given the option to have a counseling session.
62391772|NCT01722552|ACTIVE_COMPARATOR|standard of care|Control subjects will use the electronic monitoring devices just like the intervention arm, but will receive standard of care. They will not receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time, and they will not have access to the summaries of their previous month's behavior for use in interactive counseling sessions, though they will be encouraged to engage in counseling.
62391773|NCT04550234|EXPERIMENTAL|Treatment 1|Subjects will receive verinurad prolonged release HPMC capsule and allopurinol tablet in fasted state on Day 1.
62391774|NCT04550234|EXPERIMENTAL|Treatment 2|Subjects will receive verinurad/allopurinol FDC capsule in fasted state on Day 1.
62773111|NCT04881747|ACTIVE_COMPARATOR|100 milligram (mg) Lasmiditan immediate release (IR) (Reference)|Participants received 100 mg lasmiditan as IR tablet formulation administered orally.
62182926|NCT03032640|ACTIVE_COMPARATOR|Group 4- Healthy Lean subjects|Group 4 will receive Lactisole 335mg capsule, 2x/day, Day 1-14
62182927|NCT00730821|EXPERIMENTAL|1|
62182928|NCT01227928|EXPERIMENTAL|pazopanib|experimental medication
62020859|NCT04278326|EXPERIMENTAL|Experimental|"1. Patients infected by oncogenic HPV and presented a high grade cervical dysplasia or a cervical cancer~2. Patients with cervical or vaginal cancer~3. All patients"
62182929|NCT01227928|PLACEBO_COMPARATOR|placebo|placebo comparator
62182930|NCT05897983|EXPERIMENTAL|Rocabado exercises plus TENS|Rocabado exercises plus TENS and traditional exercises For 8 weeks,Rocabado exercises form of 2 parts , 6×6×6 exercises part are repeated 6 times a day for 20 minutes for each repetition and mobilization exercises are done by the therapist 3 times a week for 20 min ,each mobilization is performed for 10-15 times and repeated for 5-6 times. TENS is used, with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 mA and the pulse width is between 50-200 microseconds, The TENS will be applied for 20 min 2 sessions/week for 8 weeks, Traditional exercises are passive , active Rom exercises and massage, these exercises are performed for 30 minutes and repeated 2 times daily
62391775|NCT04550234|EXPERIMENTAL|Treatment 3|Subjects will receive verinurad/allopurinol FDC capsule in fed state on Day 1.
62567903|NCT06043674|EXPERIMENTAL|Combination B Group: Obinutuzumab, Glofitamab,and Atezolizumab|"Study procedures will be conducted as follows:~* Baseline visit with screening procedures, including bone marrow biopsy and PET/CT scans.~* PET/CT scans after 4, 8, and 12 cycles of therapy and at 6 and 15 months after end-of-treatment.~* Cycle 1:~  * Day 1, 2, and 7 of 21- day Cycle: Predetermined dose of Obinutuzumab 1x daily.~ * Day 8 and 15 of 21- day Cycle: Predetermined dose of Glofitamab 1x daily. Hospitalization will be required for initial dose and post-dose observation.~* Cycle 2 - 12~  - Day 1 of 21-day Cycle: Predetermined dose of Glofitamab 1x daily. Predetermined dose of Atezolizumab 1x daily.~* End of treatment visit.~* Follow up visits: for months 10 - 24, visits will be every 3 months. For months 25 - 60 visits will be every 6 months."
62773112|NCT04881747|EXPERIMENTAL|100 mg Lasmiditan oral disintegrating (OD) Without Water (Test)|Participants received 100 mg lasmiditan as OD tablet formulation administered orally without water.
62773113|NCT04881747|EXPERIMENTAL|100 mg Lasmiditan OD With Water (Test)|Participants received 100 mg lasmiditan as OD tablet formulation administered orally with water.
62791488|NCT03770221|EXPERIMENTAL|Financial Incentive|"Participants will receive usual brief, intensive case management to connect them to health and social services and supports in the community.~Additionally, participants in this arm will receive $20 for every week they maintain contact with CATCH service providers, as required by their care plan. Contact can be by phone, text, email, or in person with CATCH service providers over 6 months of follow up, or until they are successfully transitioned to longer-term supports (for up to $80/month per participant)."
62020860|NCT06534307||Placebo|children of mothers that have been taken placebos during participation of PETN study
62182931|NCT05897983|EXPERIMENTAL|Rocabado exercises|Rocabado exercises part (1): 6×6×6 exercises are (1).The rest position of the tongue , (2). Shoulder retraction exercises, (3). Stabilized head flexion ,( 4). The axial extension of the neck , (5).Control of TMJ rotation , (6).Rhythmic stabilization technique . part (2): Joint mobilization) includes Distraction given with anterior glide, with anterior and lateral glide right/left \& Lateral glide without distraction. Plus Traditional exercises.
62182932|NCT05897983|EXPERIMENTAL|Transcutaneous electrical nerve stimulation device|TENS is used, frequency of 120 Hz and an intensity range of 0 to 99.5 mA and the pulse width is between 50-200 microseconds. TENS electrodes are placed bilaterally on mandibular elevator muscles, on the superficial masseter muscle above the gonial angle, and bilaterally on the upper back ,The TENS will be applied for 20 min 2 sessions/week for 8 weeks. Plus Traditional exercises.
62182933|NCT01700322|ACTIVE_COMPARATOR|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
62182934|NCT01700322|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
62773114|NCT05940818|EXPERIMENTAL|experimental group|In the study group, the intensive care oral care frequency assessment scale was applied to 55 patients at the end of the 16th hour, in addition to the assessment of pain and thirst at the 1st, 4th, 8th, and 16th hours postoperatively. In patients with a thirst of 3 and above, the bedside was lifted 30-450 times (to prevent bronchoaspiration), and cold water spray (kept in the refrigerator at +4°C and stored) was sprayed 3 times (approximately 2 ml) into the mouth of the patient every hour. Evidence suggests that the risk of bronchoaspiration is minimal up to the 50 mL and 1.5 mL/kg limit of gastric volume (Doi et al., 2021). For this, it is thought that the application of an average of 32 ml of cold water applied to the patients is reliable. The standard oral care of the clinic was applied to the patients who needed oral care. It was also recorded how many times oral care was given to the patients included in the study within 16 hours.
62182935|NCT01700322|ACTIVE_COMPARATOR|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
62182936|NCT01402063|EXPERIMENTAL|radiation plus PPX(CT2103|"Radiation therapy, Monday through Friday, for 6 weeks for a total of 30 treatments~+ intravenous PPX every week x 6 weeks for a total of 6 treatments"
62182937|NCT01402063|ACTIVE_COMPARATOR|radiation + Temozolomide|"Radiation therapy, Monday through Friday, for 6 weeks for a total of 30 treatments~+ Daily oral temozolomide(TMZ) (7 days) x 6 wks for a total of 42 days"
62391776|NCT04550234|EXPERIMENTAL|Treatment 4|Subjects will receive verinurad prolonged release HPMC capsule and allopurinol tablet in fed state on Day 1.
62391777|NCT04550234|EXPERIMENTAL|Treatment 5|Subjects will receive verinurad prolonged release gelatin capsule in fasted state on Day 1.
62567904|NCT03515005|EXPERIMENTAL|Lay Health Advisors|Intervention patients will meet monthly in small groups with a trained Lay Health Advisor.
62773115|NCT05940818|NO_INTERVENTION|control group|In the control group, standard nursing care was applied to 55 patients with the pain, thirst and intensive care oral care frequency assessment scale at the 1st, 4th, 8th, and 16th hours postoperatively.
62773116|NCT02526108|EXPERIMENTAL|HIFT|High Intensity Functional Training group exercise session. Each session is 45 minutes. Participants will be asked to complete 3 sessions.
62773117|NCT05643586|EXPERIMENTAL|Prasugrel Group|Patient treated with 60 mg prasugrel 12 hours before the procedure
62773118|NCT05643586|EXPERIMENTAL|Ticagrelor|Patient treated with 180 mg ticagrelor 12 hours before the procedure
62773119|NCT06104956|EXPERIMENTAL|Experimental group : Imposed weaning protocol|The flow of the HFNO will remain high (50-60 L/min) guaranteeing the effectiveness of the HFNO on the wash-out of the anatomical space. At the same time, weaning will begin with a gradual reduction in FiO2 of 0.1 every 4 hours. To achieve this reduction, the patient will have to meet the safety targets of a stable respiratory rate at rest (no increase) and pulsed oxygen saturation (SpO2). The SpO2 target will be 92-95%. Once the FiO2 has stabilised at 0.4 for 4 hours, the nurse will initiate a 10 L/min reduction in the flow of HFNO every 4 hours. The oxygen therapy support may be changed for standard oxygen when the HFNO flow rate is 40L/min with an FIO2 of 0.4 for 4 consecutive hours.
62773120|NCT06104956|ACTIVE_COMPARATOR|Control group|Weaning methods will be left to the free choice of the practitioner. Any change in the HFNO setting must be made on medical prescription. A minimum SpO2 objective is required (SpO2 ≥92%).
61997573|NCT04270838|EXPERIMENTAL|PV2 (Paediatric two-visit Verobab)|Volunteers aged 2-6 years. Volunteers will receive Rabies IRV (Verorab) as a 2 site ID on D0. Volunteers will receive two further doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
61997574|NCT04765358|OTHER|All Participants|All participants were provided with a commercially available CGM system. Training and data collection for the study was completed remotely. After initial CGM training (initiation of unblinded CGM use or initial training with virtual clinic) was completed, participants were followed by the virtual clinic team for approximately six months. Psychosocial screening questionnaires were administered at enrollment and during follow up. The virtual clinical team member followed up with the study participant if there was an elevated score on the psychosocial screening questionnaires. After the initial six months of follow up, participants who decided to continue to use CGM were asked to extend follow up and complete questionnaires, submit HbA1c samples, and share data. During the extended follow up phase, participants were able to contact the virtual clinic with questions or to request assistance as needed.
61997575|NCT00375843|ACTIVE_COMPARATOR|Level 1 Treatment: Escitalopram|Level 1 participants who are assigned to escitalopram
61997576|NCT00375843|ACTIVE_COMPARATOR|Level 2: Sertraline|Participants from Level 1 who do not achieve remission with escitalopram enter Level 2 and switch to sertraline
61997577|NCT03909009|ACTIVE_COMPARATOR|Active rTMS|Group 1 will receive high frequency repetitive transcranial magnetic stimulation (10hz-HF-rTMS) A total 14 sessions of HF-rTMS, 10 sessions daily (5 days/week, 2 weeks) and 4 sessions weekly (1 day/week, 4 weeks).
61997578|NCT03909009|SHAM_COMPARATOR|Sham rTMS|Group 2 will receive sham stimulation. A total 14 sessions of sham-rTMS, 10 sessions daily (5 days/week, 2 weeks) and 4 sessions weekly (1 day/week, 4 weeks).
61997579|NCT06259331|EXPERIMENTAL|Cohort 1|Up to 15 healthy, lactating women will be enrolled in the study.
61997580|NCT04930887|ACTIVE_COMPARATOR|Exparel|Patients receive an endoscopically guided injection of Exparel (Bupivacaine).
62391778|NCT05984914|EXPERIMENTAL|PSAI group|Participants are enrolled in the Pythagorean Self-Awareness Intervention (PSAI) where they receive weekly group sessions of 120 min for 8 weeks and they receive information about stress and lifestyle modifications and they are also instructed to practice the PSAI at bedtime and in the morning, every day, at home.
62391779|NCT05984914|ACTIVE_COMPARATOR|Control group|One day seminar where they receive information about stress and lifestyle modifications
62391780|NCT02960802|ACTIVE_COMPARATOR|kidney transplant patient|kidney transplantation is intervention
62391781|NCT02960802|NO_INTERVENTION|healthy control|no intervention
62391782|NCT01829529|EXPERIMENTAL|Amoxicillin|All subjects receive one dose of 2 g Amoxicillin
62567905|NCT03515005|NO_INTERVENTION|Usual Care|Control patients will receive usual care from their doctors.
62567906|NCT05867602|EXPERIMENTAL|Intervention arm|the intervention group will receive intravenous human albumin at a dose of (1g/kg), with a minimum dose of 50g and a maximum dose of 100g, plus SOC
62567907|NCT05867602|NO_INTERVENTION|Control arm|the control arm will receive the standard of care (SOC), including moderate sodium restriction, maximal daily tolerated doses of diuretics, and post-paracentesis albumin
62567908|NCT01775813|EXPERIMENTAL|Obese metformin arm|Double-blinded placebo-controlled trial of metformin during puberty, treatment arm Dosage form: Metformin 1000 mg tablets Dosage: 1000 mg by mouth twice daily Duration: From early puberty (Tanner 2-3) until puberty completion (Tanner 5), approximately 3 years
62773121|NCT01112111||75 PCOS Patients - step up regime|Group A will be comprised of 75 patients and these will receive a low dose step stimulation regime
62773122|NCT01112111||75 PCOS patients -step down regime|Group B will be comprised of 75 patients who will receive a step down regime of stimulation
62773123|NCT01112111||75 PCOS patients - sequential regime|Group C will be comprised of 75 patients who will be treated using a sequential stimulation regime
62773124|NCT04659694|OTHER|Single arm study|This study only contains one arm
61997581|NCT04930887|PLACEBO_COMPARATOR|Saline|Patients receive an endoscopically guided injection of saline
62567909|NCT01775813|PLACEBO_COMPARATOR|Obese placebo arm|Double-blinded placebo-controlled trial of metformin during puberty, placebo arm Dosage form: Placebo stamped to match 1000 mg metformin tablets Placebo comparator: Stamped placebo pill matching metformin dose Dosage: 1000 mg by mouth twice daily Duration: From early puberty (Tanner 2-3) until puberty completion (Tanner 5), approximately 3 years
62567910|NCT01775813|NO_INTERVENTION|Obese - NT|"Comparator group for the observational comparison of metabolic changes in youth with normal weight and obesity as they progress through puberty.~Duration: From early puberty (Tanner 2-3) until puberty completion (Tanner 5), approximately 3 years"
62773125|NCT00828152|EXPERIMENTAL|1|Internet-delivered CBT. Contact with therapist thru an e-mail system. 12 weeks.
61997582|NCT03348358|PLACEBO_COMPARATOR|control|No music during labor
62567911|NCT01775813|NO_INTERVENTION|Normal weight|"Comparator group for the observational comparison of metabolic changes in youth with normal weight and obesity as they progress through puberty.~Duration: From early puberty (Tanner 2-3) until puberty completion (Tanner 5), approximately 3 years"
62567912|NCT05618704|EXPERIMENTAL|Hydrolyzed protein infant formula|All subjects will take the hydrolyzed protein infant formula
62567913|NCT06187012||Hypertensive pregnancy|
62567914|NCT03027635|EXPERIMENTAL|PleurX|The PleurX catheter is a tunnelated peritoneal catheter, designed for permanent placement in the peritoneal cavity. The catheter is placed by a physician under sterile conditions. Drainage of ascites is done using vacuum bottles connected to the catheter. This can be managed by a home nurse or the patient.
62773126|NCT00828152|PLACEBO_COMPARATOR|2|On line discussion group.
62773127|NCT05597618|NO_INTERVENTION|No Intervantion Group|"Application Steps of Control Group New Graduated Nurses The control group nurses will be required to fill in the Introductory Information Questionnaire, Empowerment Information Evaluation Questionnaire, Nursing Structural Empowerment Scale, and Psychological Empowerment Scale in the randomization process."
61997583|NCT03348358|EXPERIMENTAL|Quiet music|Women hearing quiet music during labor
62567915|NCT03027635|ACTIVE_COMPARATOR|Large Volume Paracentesis|Large volume paracentesis is performed in sterile technique, a small incision is made through the skin, and a catheter is inserted through muscle and peritoneum. After the procedure, the patient remains in hospital for observation until the fluid is drained.
62791489|NCT03770221|ACTIVE_COMPARATOR|Usual Care|Participants will receive usual brief, intensive case management to connect them to health and social services and supports in the community.
61997584|NCT03348358|EXPERIMENTAL|Rhythmic music|Women hearing rhythmic music during labor
62391783|NCT04678557|EXPERIMENTAL|Sentinel units (aka Cohort 1)|VC-01 Combination Product; Up to ten (10) VC-01 sentinels
62773128|NCT05597618|EXPERIMENTAL|Experimental Group|"Application Steps of Experimental Group New Graduated Nurses In the first stage, the experimental group nurses will be required to fill in the Introductory Information Questionnaire, Information Evaluation Questionnaire for Empowerment, Nursing Structural Empowerment Scale, and Psychological Empowerment Scale in the randomization process.~In the second stage, the theoretical part of the training program will be given to nurses as group training in a physical environment. After the training, the first part of the Training Evaluation Form and the Empowerment Information Evaluation Questionnaire will be applied.~In the third stage, nurses will be required to use the developed mobile-compatible online training program for 6 months.~In the fourth stage, Education Evaluation Form, the Nursing Structural Empowerment Scale, the Psychological Empowerment Scale, and the Empowerment Information Evaluation Questionnaire will be applied to the nurses after 6 months."
62773129|NCT03499327|ACTIVE_COMPARATOR|Wheat germ oil (UV treated)|Wheat germ oil (UV treated)
62773130|NCT03499327|PLACEBO_COMPARATOR|Wheat germ oil (untreated)|Wheat germ oil (untreated)
62773131|NCT03499327|NO_INTERVENTION|Control|no study products
62773132|NCT02259855|EXPERIMENTAL|Mild hepatic insufficiency|
62773133|NCT02259855|EXPERIMENTAL|Moderate hepatic insufficiency|
62773134|NCT02259855|EXPERIMENTAL|Healthy subjects|
62773135|NCT01536483|EXPERIMENTAL|Butyrate|"New born with a birth weight \<1000g: Seven enemas of butyrate will be performed every 2 days from PND5~New born with a birth weight \>1000g: Seven enemas of butyrate will be performed every day from PND5"
61997585|NCT03862391|ACTIVE_COMPARATOR|Postsurgical Pain|pain is defined as unpleasant sensation that can range from mild, localized discomfort to agony.
62391784|NCT04678557|EXPERIMENTAL|Dose-finding units (aka Cohort 2)|VC-01 Combination Product; Up to twelve units implanted of which up to nine (9) are VC-01-DF (dose-finding) implants and the rest are VC-01 sentinels
61997586|NCT03862391|ACTIVE_COMPARATOR|Postanesthesia nausea and vomiting|nausea defined as feeling of sickness or discomfort in the stomach that may come with an urge to vomit.
61997587|NCT03433664|EXPERIMENTAL|Treatment|Each treatment half of the scar received three standardised CO2 laser treatments using the DeepFX setting hand piece (Ultrapulse, Lumenis), performed under general anaesthetic at 4-6 week intervals. All treatments consisted of a single pass of 300Hz, 5% density and 50mJ energy with minimal overlapping. Post-operatively all laser treatment and control zones had emollient applied and silicone dressings which were removed at 48 hours. Further emollient was applied twice daily for 2 weeks to all areas of the scar. Standard care scar management (including silicone, massage and pressure garments) was directed by burn occupational therapists and was continued for all areas of scar.
62391785|NCT02780869|EXPERIMENTAL|Investigational|HEMOBLAST Bellows
62391786|NCT02780869|ACTIVE_COMPARATOR|Control|Absorbable gelatin sponge, USP with thrombin
62391787|NCT01156857|EXPERIMENTAL|A|Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
62391788|NCT01156857|EXPERIMENTAL|B|Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of progestin (oral tablets).
62773136|NCT01536483|NO_INTERVENTION|Therapeutic Abstention|The protocol will pretend enema: instillation in the diaper the product under consideration, to make the two indistinguishable processes (time, odor, wicking diaper ...)
62773137|NCT04387266||Modified reduce-volume target IMRT|Patients with newly diagnosed, non-metastatic NPC was given modified reduce-volume target IMRT
62773138|NCT03628729|EXPERIMENTAL|Embrace™ WetBond™ Pit & Fissure Sealant.|pits and fissures will be sealed with bioactive pits-and-fissure sealant
62773139|NCT03628729|ACTIVE_COMPARATOR|Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA|Pits and fissures will be sealed by fluoride releasing resin based pits and fissures sealant
62773140|NCT05549557|EXPERIMENTAL|IMM40H|IMM40H is a monoclonal antibody with target CD70.
61997588|NCT03433664|NO_INTERVENTION|Control|Each control half of the scar received emollient applied twice daily for 2 weeks to all areas of the scar after each treatment. Standard care scar management (including silicone, massage and pressure garments) was directed by burn occupational therapists and was continued for all areas of scar.
61997589|NCT01011517|EXPERIMENTAL|grape seed supplement|Nature's Pearl 650 mg, two capsules daily
61997590|NCT01011517|PLACEBO_COMPARATOR|placebo|placebo
62391789|NCT02661789|ACTIVE_COMPARATOR|GnRHa|Goserelin 3.6 mg implant
62391790|NCT02661789|PLACEBO_COMPARATOR|Placebo|Injection of saline
62567916|NCT02984865|ACTIVE_COMPARATOR|group S|Patients were attach with PCA containing 100ml combination of sulfentanyl 2.5ug/kg and flubiprofen axetil 100mg after receiving the loading dose of sulfentanyl 5 ug and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
62773141|NCT06087978|EXPERIMENTAL|14C RPT193 400 mg|Radiolabelled RPT193
62773142|NCT01840098|ACTIVE_COMPARATOR|control|Isocaloric carbohydrate drink
62773143|NCT01840098|ACTIVE_COMPARATOR|low leucine content drink|A soy protein drink
62773144|NCT01840098|ACTIVE_COMPARATOR|high content of leucine drink|A whey protein drink
62773145|NCT01840098|ACTIVE_COMPARATOR|low leucine content + HMB drink|Soy protein drink added HMB
62791490|NCT00536471|EXPERIMENTAL|A|duloxetine 60 milligrams (mg) every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months
62020861|NCT06534307||PETN|children of mothers that have been taken in PETN during participation of PETN study
62020862|NCT02010385|ACTIVE_COMPARATOR|Octreotide|One subcutaneous injection - 1 mL
62020863|NCT02010385|PLACEBO_COMPARATOR|Saline|One subcutaneous injection - 1 mL
62020864|NCT01242488|EXPERIMENTAL|CDP6038 60 mg sc every 2 weeks plus methotrexate|
62020865|NCT01242488|EXPERIMENTAL|CDP6038 60 mg sc every 4 weeks plus methotrexate|
62020866|NCT01242488|EXPERIMENTAL|CDP6038 120 mg sc every 2 weeks plus methotrexate|
62020867|NCT01242488|EXPERIMENTAL|CDP6038 120 mg sc every 4 weeks plus methotrexate|
62020868|NCT01242488|EXPERIMENTAL|CDP6038 240 mg sc every 2 weeks plus methotrexate|
62020869|NCT01242488|EXPERIMENTAL|CDP6038 240 mg sc every 4 weeks plus methotrexate|
62020870|NCT01242488|ACTIVE_COMPARATOR|Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate|
62391791|NCT02054624|ACTIVE_COMPARATOR|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by one-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
62391792|NCT02054624|ACTIVE_COMPARATOR|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by conference telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
62391793|NCT02054624|ACTIVE_COMPARATOR|Health Education Control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight."
62391794|NCT05617417|OTHER|The women with stress urinary incontinence administered injectable platelet-rich fibrin|Injectable platelet-rich fibrin was prepared by centrifuging venous blood samples from women with stress urinary incontinence. The obtained autologous material was injected into the anterior vaginal wall, approximately 1.5 cm below the urethral meatus, without applying a local anesthetic. The procedure was repeated for the same patient three times with an interval of one month. The severity of urinary incontinence was evaluated by filling out questionnaires before and after the procedure.
62391795|NCT05363787|EXPERIMENTAL|The effect of therapeutic touch on sleep patterns of elderly patients|The important effects of the therapeutic approach made by the researcher to the elderly patients hospitalized in the intensive care unit will be evaluated.
62391796|NCT05363787|NO_INTERVENTION|Determining the sleep pattern of the Control Group|It will be evaluated whether there is a change in sleep patterns without intervention in the control group.
62773146|NCT01746173|EXPERIMENTAL|CHOEP + High Dose Therapy + Auto SCT|Patients received 6 cycles of induction chemotherapy: Cyclophosphamide, Doxorubicin, Vincristine, Etoposide and Prednisone (CHOEP) (5 if previously received 1 cycle of CHOP). CHOP was given at standard doses, with a dose of etoposide of 100 mg/m2 intravenously (IV) or 200 mg/m2 orally added on days 1-3 of each cycle. Patients who did not achieve a partial (PR) or complete (CR) remission at restaging after either 3 or 6 cycles were taken off study. Responders after 6 cycles had stem cell (SC) mobilization using filgrastim and plerixafor (if necessary) within 4 weeks of the end of induction. SC mobilization, harvesting, and reinfusion were performed per standard institutional protocol. A minimum collection of 2x106 CD34+ cells/kg was required to proceed to autologous stem cell transplant. Conditioning was comprised of gemcitabine 2700 mg/m2 on days -8 and -3, IV busulfan 105 mg/m2 days -8 to -5, and melphalan 60 mg/m2 given daily on days -3 and -2 (per MD Andersen protocol).
62773147|NCT02103413|EXPERIMENTAL|EUS-BD|EUS-BD using a fully or partially covered self-expanding metallic stent will be performed by EUS guided 19 G needle puncture.
62773148|NCT02103413|EXPERIMENTAL|PTBD|PTBD with 8.5F catheter will be inserted under fluoroscopic and/or ultrasonography guidance by experienced interventional radiologists.
62773149|NCT00849108|EXPERIMENTAL|Cohort 1: dose range and dose interval|Patients to receive either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during pharmacological or exercise stress, over a 1-day or 2-day period.
62182938|NCT02726477|EXPERIMENTAL|Wuling San|"This is a double-blinded, randomized placebo-controlled, multi-center clinic trial, using before and after treatment measurements.~A total of 200 clinical diagnosed BCRL participants with affected arm circumference 10-40% larger than unaffected arm, are randomly allocated to two groups: the Wuling San group or the placebo group, where the intervention group administers Wuling San, at a dosage of 1g/kg, twice a day for six weeks. The primary outcome measurement will be the percentage of limb volume changes measured by perometry."
62773150|NCT00849108|EXPERIMENTAL|Cohort 2: Pharm&exercise stress Efficacy|"Patients to receive 2 IV bolus injections of BMS747158:1 at rest and 1 at stress~For the Pharmacologic (Adenosine) Stress:~* Doses at rest to range between 2.9 and 3.4 mCi.~* Doses under stress to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~* Doses at rest were to range between 1.7 and 2.0 mCi.~* Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi."
62773151|NCT01105585|EXPERIMENTAL|ZCB00 IOL|Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens (IOL) randomly assigned to one eye, with AcrySof Natural IQ (SN60WF) IOL in the fellow eye for contralateral implantation
62773152|NCT01105585|ACTIVE_COMPARATOR|SN60WF IOL|AcrySof Natural IQ (SN60WF) intraocular lens (IOL) randomly assigned to one eye, with Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens in the fellow eye for contralateral implantation
62773153|NCT01391988|ACTIVE_COMPARATOR|Electric Scalpel Mastectomy|Radical mastectomy with electric scalpel
62391797|NCT03080675|EXPERIMENTAL|Experimental|Nutritional blend of ingrédients including vitamins and fish oil
62391798|NCT03080675|PLACEBO_COMPARATOR|Control comparator:|control product does not contain any of the active ingredients and is matched for carbohydrate content to the active intervention.
62773154|NCT01391988|EXPERIMENTAL|Harmonic scalpel mastectomy|Radical Mastectomy with harmonic scalpel
62773155|NCT05678452|ACTIVE_COMPARATOR|LP-HoLEP|2J/25Hz setting
62567917|NCT02984865|EXPERIMENTAL|group N1|Patients were attach with PCA containing 100ml combination of nalbuphine 1.5mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
62773156|NCT05678452|ACTIVE_COMPARATOR|HP-HoLEP.|2J/50Hz setting
62020871|NCT01242488|PLACEBO_COMPARATOR|Placebo sc every 2 weeks plus methotrexate|
62020872|NCT01242488|PLACEBO_COMPARATOR|Placebo sc every 4 weeks plus methotrexate|
62391799|NCT04561960|ACTIVE_COMPARATOR|Control|"Participants will be trained to perform oral hygiene using the modified bass technique.~The participants will be asked to brush their teeth twice daily using a manual tooth brush and fluoridated toothpaste containing 1450ppm of fluoride"
62182939|NCT02726477|PLACEBO_COMPARATOR|placebo|A total of 200 clinical diagnosed BCRL participants with affected arm circumference 10-40% larger than unaffected arm, are randomly allocated to two groups: the Wuling San group or the placebo group, where the placebo group administers a placebo powder, at a dosage of 1g/kg, twice a day for six weeks. The primary outcome measurement will be the percentage of limb volume changes measured by perometry.
62182940|NCT04485754|EXPERIMENTAL|Telemedicine FU|Telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
62182941|NCT04485754|ACTIVE_COMPARATOR|Office FU|Office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
62182942|NCT01161446|EXPERIMENTAL|Home Testing|
62182943|NCT01161446|NO_INTERVENTION|Standard Testing|
62182944|NCT00139581|EXPERIMENTAL|1|Pimecrolimus b.i.d.
62182945|NCT00139581|EXPERIMENTAL|2|Pimecrolimus o.d. and placebo o.d.
62182946|NCT00970320|NO_INTERVENTION|Control group, RCT2|Participants reporting anal incontinence 6 months postpartum receiving written information only for 6 months. After 6 months they are offered the same intervention as the intervention group, i.e. PFMT for 6 months.
62182947|NCT00970320|ACTIVE_COMPARATOR|Intervention group, RCT 2|Participants reporting anal incontinence 6 months postpartum receiving pelvic floor muscle training (PFMT) for 6 months (+6 months).
62182948|NCT00970320|NO_INTERVENTION|Control group, RCT3|Women with obsteric anal sphincter injury receiving written information only for 6 months. After 6 months they are offered the same intervention as the intervention group, i.e. PFMT for 6 months.
62182949|NCT00970320|ACTIVE_COMPARATOR|Intervention group, RCT 3|Women with obsteric anal sphincter injury receiving pelvic floor muscle training (PFMT) for 6 months (+6 months).
62182950|NCT00970320|NO_INTERVENTION|Prevalence Study|1571 primiparae delivering at Ostfold Hospital Trust or St. Olav's Hospital during the period May 2009 to December 2010.
62182951|NCT05689281|EXPERIMENTAL|PrEP peer navigation|Culturally informed health care empowerment and PrEP peer navigation and support through social determinant of health stressors
62182952|NCT04224259|EXPERIMENTAL|ultrasound pre-scan group|Perform ultrasound pre-scan before central venous cannulation
62182953|NCT04224259|SHAM_COMPARATOR|landmark guidance group|Use the traditional landmark method to perform central venous cannulation
62182954|NCT02634814|EXPERIMENTAL|TENS and Therapeutic Exercise|Patients assigned to the TENS+Therapeutic Exercise (TE) group will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN), and 8 hours of TENS per day (150 pulses per second, 150 msec phase duration at a patient-perceived strong sensory intensity). Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program.
62182955|NCT02634814|SHAM_COMPARATOR|Sham TENS and Therapeutic Exercise|"Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (\~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day. Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program."
62391800|NCT04561960|EXPERIMENTAL|Miswak|Participants will be trained to chew and condition a miswak stick Participants will be asked to use the miswak stick twice daily
62391801|NCT04561960|EXPERIMENTAL|Miswak Paste|"Participants will be trained to perform oral hygiene using the modified bass technique.~The participants will be asked to brush their teeth twice daily using a manual tooth brush a non-fluoridated toothpaste containing miswak extract"
62567918|NCT02984865|EXPERIMENTAL|group N2|Patients were attach with PCA containing 100ml combination of nalbuphine 2mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
62773157|NCT01457846|EXPERIMENTAL|AZD4547|AZD4547 taken orally in tablet formation, 80mg b.d., in a 2 week on, 1 week off schedule
62391802|NCT02005458|EXPERIMENTAL|YPEG-rhG-CSF 20μg/kg|20μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
62391803|NCT02005458|EXPERIMENTAL|YPEG-rhG-CSF 30μg/kg|30μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
62391804|NCT02005458|EXPERIMENTAL|YPEG-rhG-CSF 45μg/kg|45μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
62391805|NCT02005458|ACTIVE_COMPARATOR|PEG-rhG-CSF 100μg/kg|100μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
62391806|NCT02619942|ACTIVE_COMPARATOR|D2 radical operation group|In D2 radical operation group(D2), the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes, which along the feeding vessels.
62391807|NCT02619942|EXPERIMENTAL|CME group|In complete mesocolic excision group (CME), in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodesmshould be entirely removed.
62391808|NCT02828098|EXPERIMENTAL|Part 1: BO-112 IT|BO-112 dose 1 (starting dose) intratumoral injection. BO-112 dose 2, 3 and 4 are expected to be tested, upon confirmation of the safety profile of the starting dose.
62391809|NCT02828098|EXPERIMENTAL|Part 2: BO-112 IT|"Combination treatment of BO-112 intratumoral injections with standard of care nivolumab intravenous treatment~Or Combination treatment of BO-112 intratumoral injections with standard of care pembrolizumab intravenous treatment"
62391810|NCT02015858||Epidural analgesia|Postoperative patients with epidural analgesia
62391811|NCT02015858||Oral analgesics|Postoperative patients with oral analgesics
62391812|NCT04629235|ACTIVE_COMPARATOR|24 hours of bedrest|- 24 hours of bedrest
62791491|NCT00536471|PLACEBO_COMPARATOR|B|placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months
62773158|NCT01457846|ACTIVE_COMPARATOR|Paclitaxel|Paclitaxel - 80mg/m² as a 1 hour infusion given weekly on days 1, 8 and 15 of a 28 day cycle (up to the maximum number of cycles per local practice)
62773159|NCT03566121|OTHER|Continent women|Women with ICI-Q=0 Pelvic ultrasound / Urodynamic ultrasound
62773160|NCT03566121|EXPERIMENTAL|Incontinent women|Women with ICI-Q≥1 Pelvic ultrasound / Urodynamic ultrasound
62773161|NCT00208351|ACTIVE_COMPARATOR|1) Ultima LX Collared Stem - Non-Polished/Blasted Finished|A collared non-polished blasted finished cementless femoral component for use in total hip replacement.
62773162|NCT00208351|ACTIVE_COMPARATOR|2) Ultima LX Collared Stem - Polished Finished|A collared polished finished cementless femoral component for use in total hip replacement.
62773163|NCT00208351|ACTIVE_COMPARATOR|3) Ultima LX Collarless Stem - Non-Polished/Blasted Finished|A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
62773164|NCT00208351|ACTIVE_COMPARATOR|4) Ultima LX Collarless Stem - Polished Finished|A collarless polished finished cementless femoral component for use in total hip replacement.
62773165|NCT05971836||Subjects with Reproductive Disorders|Individuals with reproductive disorders and their affected and unaffected family members
62773166|NCT05876845|EXPERIMENTAL|Intervention Group|
62773167|NCT03943849|EXPERIMENTAL|Particulate bone graft plus autogenous dental pulp tissue|Dental pulp will be isolated from teeth extracted for non-periodontal reasons chairside. The isolated dental pulp will be mixed with hydrated particulate bone graft, and the mixture will be placed in the debrided extraction socket. The socket will be covered by a resorbable collagen membrane and sutured.
62773168|NCT03943849|ACTIVE_COMPARATOR|Particulate bone graft|Hydrated particulate bone graft will be placed in the debrided extraction socket. The socket will be covered by a resorbable collagen membrane and sutured.
62773169|NCT05104671|ACTIVE_COMPARATOR|Scapular stabilization exercises|Group I (control group) will receive scapular stabilization exercises.
62773170|NCT05104671|EXPERIMENTAL|Thoracic manipulation.|Group II will receive scapular stabilization exercises and thoracic manipulation.
62773171|NCT05104671|EXPERIMENTAL|Myofascial release|Group III will receive scapular stabilization exercises and myofascial release by instrument assisted soft tissue mobilization techniques.
62773172|NCT00976586||Patients wiht Incontinentia Pigmenti|Patients wiht Incontinentia Pigmenti
62391813|NCT04629235|EXPERIMENTAL|Intervention group|- Wonder around after 8 hours of bedrest
62391814|NCT03405324|ACTIVE_COMPARATOR|active tDCS|a single session over the primary motor cortex with constant current of 2mA intensity was applied for 20 minutes with a 5-second ramp phase at the beginning applied to the participant patient before chemotherapy .
62391815|NCT03405324|SHAM_COMPARATOR|sham tDCS|a single session over the primary motor cortex with constant current of 2mA intensity was applied for 20 minutes with a 5-second ramp phase at the beginning applied to the participant patient before chemotherapy switched off after 30 second without the patient knowledge .
62391816|NCT04981080||Symptom of voiding dysfunction|Women with lower urinary tract symptoms including voiding symptoms but without cystocele who visited the urogynecological department of a medical center for urodynamic evaluation were reviewed
62773173|NCT05450627||Case|Adult patients diagnosed with pancreatic exocrine insufficiency of any etiology
62773174|NCT00578630||1|All Pediatric Oncology and Bone Marrow Transplantation Service patients with a histologically proven tumor for whom there is an intent to treat with chemotherapy
62773175|NCT04942990|EXPERIMENTAL|exercise training group|The duration of the study was targeted as 8 weeks. Our trainings consist of 3 sessions per week, with an average of 45 minutes of calisthenic exercises per session. Exercises initially started with an average of 30 minutes, 10 repetitions, gradually increased difficulty once every two weeks, time increased to 45 minutes movements were modified for those who were forced to perform the exercise program. The program was completed with 5 minutes of warm-up and 5 minutes of cooling exercises before exercise training. All exercises were conducted on a video chat platform supervised by an experienced physiotherapist.
62773176|NCT04942990|NO_INTERVENTION|control group|no exercise was given
62773177|NCT02100306|EXPERIMENTAL|Patients|"Patients will receive:~Auditory Feedback 100% Auditory Feedback 50% alternate"
62773178|NCT03930992|EXPERIMENTAL|1 Arm: Experimental|Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man with HIV infection plus osteoporosis
62773179|NCT03930992|ACTIVE_COMPARATOR|2 Arm: Active comparator|Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man with HIV infection plus osteoporosis
62773180|NCT03930992|EXPERIMENTAL|3 Arm: Experimental|Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man without HIV infection plus osteoporosis
62773181|NCT03930992|ACTIVE_COMPARATOR|4 Arm: Active comparator|Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man without HIV infection plus osteoporosis
62020873|NCT04402645||Chronic pulmonary hypertension|Diagnosis on echocardiography at 36 weeks CGA using standard criteria (flat interventricular septal motion or right ventricular dilatation)
62391817|NCT04981080||No symptom of voiding dysfunction|Women with lower urinary tract symptoms but without cystocele or voiding symptoms who visited the urogynecological department of a medical center for urodynamic evaluation were reviewed
62391818|NCT02067065|EXPERIMENTAL|Non-anesthesiologist propofol sedation|Bolus propofol sedation by non-anesthesiologist
62391819|NCT02067065|ACTIVE_COMPARATOR|Anesthesiologist administered propofol|Propofol sedation administered by an anesthesiologist
62391820|NCT02908815|EXPERIMENTAL|4 weeks active treatment|4 weeks of rTMS active treatment applied using an active rTMS coil.
62773182|NCT02519569|EXPERIMENTAL|Intervention group|Internet-based cognitive-behavioral therapy for complicated grief
62773183|NCT01424280|EXPERIMENTAL|Active drug|
62773184|NCT01424280|PLACEBO_COMPARATOR|Placebo|
62773185|NCT01912534|ACTIVE_COMPARATOR|Valsartan|Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.
62773186|NCT01912534|PLACEBO_COMPARATOR|Placebo|Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.
62773187|NCT01331967|EXPERIMENTAL|Pioglitazone, Placebo|
62773188|NCT05052593|EXPERIMENTAL|Compressive myofascial release|". patients in this group will receive treatment through CMR that includes shaking the muscle belly of vastus lateralis for 30 seconds. Then the hip is fully extended on treatment table and CMR is applied on Vastus lateralis muscle for 1 minute. Treatment consists of broad strokes applied with clinicians knuckles to release superficial restrictions, followed by more specific strokes applied with clinicians' thumb on tight muscle. Strokes are applied at a contact point of 45 degree. with pressure directed from distal to proximal.~Conventional treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)"
61997591|NCT03738943|EXPERIMENTAL|ATP, Ach, SNP|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.~Acetylcholine: 1, 4, 8, and 16 μg/dl forearm volume/min for 3 minutes each.~Sodium Nitroprusside: 0.25, 0.5, 1, and 2 μg/dl forearm volume/min for 3 minutes each.~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
62773189|NCT05052593|ACTIVE_COMPARATOR|Conventional treatment|Patients in this group will receive treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)
62773190|NCT04104880|EXPERIMENTAL|Continuous Positive Airway Pressure (CPAP) group|Three-month CPAP use
62773191|NCT01551524|EXPERIMENTAL|Intravenous Erwinia|
61997592|NCT03738943|EXPERIMENTAL|ATP, ADP, AMP|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.~Adenosine Diphosphate: 20, 40, 80, and 160 μg/dl forearm volume/min for 3 minutes each.~Adenosine Monophosphate: 25, 50, 100, and 200 μg/dl forearm volume/min for 3 minutes each.~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
62020874|NCT04402645||No chronic pulmonary hypertension|Confirmed on echocardiography at 36 weeks CGA
62020875|NCT05273892|EXPERIMENTAL|Diet + Activity + Sleep|
62773192|NCT05284916||patients admitted at Sohag University Hospital diagnosed with liver diseases|The study will be conducted in two stages. The first one is a retrospective collection of the data from patients records during the period from Feburary 2017 to January 2018 and the second stage will include agroup of patients that will be admitted to Tropical Medicine and Gastroenterology Department within 6months after protocol acceptance
62773193|NCT06194344|EXPERIMENTAL|Individualized imagery|
62773194|NCT06194344|ACTIVE_COMPARATOR|Control|
62773195|NCT05855343|EXPERIMENTAL|BIDI Stick e-cigarette|
62773196|NCT06352255|EXPERIMENTAL|Digital block with carpule.|The study group will be made up of subjects who will undergo anesthetic block with carpule.
62020876|NCT05273892|ACTIVE_COMPARATOR|Diet + Activity|
62391821|NCT02908815|EXPERIMENTAL|2 weeks active treatment|2 weeks of rTMS active treatment applied using an active rTMS coil.
62773197|NCT06352255|ACTIVE_COMPARATOR|Digital block with syringe.|The control group will be made up of the subjects who will undergo anesthetic block with syringe.
62773198|NCT05399004||Observational (survey)|Patients complete surveys over 15-20 minutes at baseline and at 3, 6, and 12 months.
62773199|NCT05091515||Health workers|Medical personnel: doctors, nurses.
62773200|NCT00683969|EXPERIMENTAL|1|
62773201|NCT00683969|PLACEBO_COMPARATOR|2|
62773202|NCT03143751|EXPERIMENTAL|Continuous hyperosmolar therapy|Standard cares plus continuous hyperosmolar therapy (NaCl20%)
62773203|NCT03143751|NO_INTERVENTION|Control|Standard cares alone.
62391822|NCT02908815|SHAM_COMPARATOR|4 weeks sham treatment|4 weeks of rTMS sham treatment applied using a modified rTMS coil which does not stimulate the brain.
62391823|NCT02908815|SHAM_COMPARATOR|2 weeks sham treatment|2 weeks of rTMS sham treatment applied using a modified rTMS coil which does not stimulate the brain.
62773204|NCT01040364||Interna hernia after primary gastric bypass|
62773205|NCT01224444||All adenomatous polyps|Standard polypectomy snare of adenomatous polyps (included serrated adenomas) from ≤5mm to ≤20mm.
62391824|NCT02715089||Precise treatment|All patients should accept next-generation sequencing (NGS) test before treatment.
62773206|NCT02591368|ACTIVE_COMPARATOR|Ligament reconstr. tendon interposition|Ligament reconstruction, tendon interposition.
62391825|NCT01696175||PICU admittance|Children equipped with an arterial and a central venous catheter within 12 hours after admittance to a Dutch PICU
62391826|NCT02856295|ACTIVE_COMPARATOR|clexane according to weight group|clexane dose adjusted for woman's weight according to: weight \< 90 kg - 40mg, 91-130kg - 60 mg, 131-170kg - 80mg, \>170kg-100mg.
62391827|NCT02856295|ACTIVE_COMPARATOR|clexane mg per kg|clexane dose of 1mg/kg up to 120 mg
62391828|NCT01068015|EXPERIMENTAL|Intervention|This arm receives free circumcision service, POL intervention, intensive HIV counseling and intensive condom promotion.
62391829|NCT01068015|NO_INTERVENTION|usual|This arm receives no extra HIV prevention services.
62391830|NCT01674868|EXPERIMENTAL|Fluoxetine|Subjects will take 20 mg fluoxetine daily for 90 days after stroke
62391831|NCT01674868|PLACEBO_COMPARATOR|placebo|Subjects will take one pill daily for 90 days after stroke.
62391832|NCT01143662|EXPERIMENTAL|Group 1|Ypeginterferon alfa-2b 90mcg per week
62773207|NCT02591368|ACTIVE_COMPARATOR|Mini Tight rope with one-suture|Mini Tight rope with one suture
62773208|NCT02591368|ACTIVE_COMPARATOR|Mini Tight rope with two-suture|Mini Tight rope with two sutures
62773209|NCT02273960|EXPERIMENTAL|Arm A: BMS-986004|BMS-986004 solution intravenously (IV) as specified
62773210|NCT02273960|EXPERIMENTAL|Arm B: BMS-986004|BMS-986004 solution intravenously as specified
61997593|NCT03738943|EXPERIMENTAL|ATP, UTP, Adenosine|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.~Uridine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.~Adenosine: 3.125, 6.25, 12.5, and 25 μg/dl forearm volume/min for 3 minutes each.~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
62567919|NCT02984865|EXPERIMENTAL|group N3|Patients were attach with PCA containing 100ml combination of nalbuphine 2.5mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
62735102|NCT05529082||Opioid Attitudes and Beliefs survey|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
61997594|NCT01225445|EXPERIMENTAL|Treatment|ramipril 2.5 mg daily
61997595|NCT01225445|NO_INTERVENTION|Control|
61997596|NCT05181111|EXPERIMENTAL|Monitoring Group|wearable sensor, besides usual care monitoring
62391833|NCT01143662|EXPERIMENTAL|Group 2|Ypeginterferon alfa-2b 135mcg per week
62391834|NCT01143662|EXPERIMENTAL|Group 3|Ypeginterferon alfa-2b 180mcg per week
62773211|NCT02273960|EXPERIMENTAL|Arm C: BMS-986004|BMS-986004 solution intravenously as specified
62773212|NCT02273960|EXPERIMENTAL|Arm D: BMS-986004|BMS-986004 solution intravenously as specified
62773213|NCT00149175||Neurodegenerative disorders with cognitive impairment|
62773214|NCT00149175||Control|
62773215|NCT00149175||At risk reactive|
62773216|NCT06504186|OTHER|NGS-MRD relapsed B-ALL after autologous/allogeneic transplantation|"* Ph-negative B-ALL: bephedolumab (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles.~* Ph-positive B-ALL: treatment with bephytoin + TKIs, bephytoin (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles.~* Premedication with dexamethasone:~  3)For adults, premedication with dexamethasone 20 mg was administered 1 hour prior to the first dose of each cycle ofblinatumomab, prior to dose escalation (eg, Cycle 1 Day 8), and when the infusion was restarted 4 hours or more after treatment interruption.~Pediatric patients were pre-treated with dexamethasone 5 mg/m2 up to a maximum of 20 mg prior to the first dose ofblinatumomabduring Cycle 1, prior to dose escalation (eg, Cycle 1 Day 8), and when the infusion was resumed 4 hours or more after interruption of therapy during Cycle 1"
62391835|NCT01143662|ACTIVE_COMPARATOR|Group 4|Pegasys 180mcg per week
62391836|NCT04737226|EXPERIMENTAL|Basketballers|
62391837|NCT04737226|EXPERIMENTAL|Volleyballers|
62391838|NCT04737226|EXPERIMENTAL|Runners|
62391839|NCT03811782|EXPERIMENTAL|Single-task Training Group|Single-task walking group
62391840|NCT03811782|EXPERIMENTAL|Dual-task Training Group|Dual-task walking group
62391841|NCT03811782|EXPERIMENTAL|Analogy Training Group|Analogy walking group
62391842|NCT00290329|EXPERIMENTAL|Group A|
62391843|NCT03984643|EXPERIMENTAL|Deep Brain Stimulation|Subjects in this study will have been implanted with a DBS lead in the VIM as part of their routine clinical care and have an existing set of brain MRI's.
62391844|NCT00914472|EXPERIMENTAL|Test|Heparin - Hipolabor
62391845|NCT00914472|ACTIVE_COMPARATOR|Ative comparator|Heparin - APP
62391846|NCT02264132|EXPERIMENTAL|Pramipexole ER tablet versus Pramipexole IR tablet|
62391847|NCT02264132|EXPERIMENTAL|Pramipexole IR tablet versus Pramipexole ER tablet|
61997597|NCT05181111|OTHER|Usual Care group|usual care monitoring
61997598|NCT04853225||Main cohort|COPD, chronic bronchitis and healthy participants (never smoker) from Type A and Type B hospitals will be included.
61997599|NCT04853225||Sub-cohort|COPD, chronic bronchitis and healthy participants (never smoker) from selected Type A hospitals will be included.
61997600|NCT01742793|EXPERIMENTAL|Arm L: subjects with lymphoma|"The following dosing steps will be applied to the dose-escalation, phase-I component of the study for patients with lymphoma who are eligible to enter Arm L:~Dose Level Arm L Lenalidomide dose Oral Romidepsin Dose Intravenous~* 2 10mg D1-7, D15-21 6mg D1, 8, 15~* 1 10mg D1-7, D15-21 8mg D1, 8, 15~  1. 10mg D1-21 8mg D1, 8, 15 2 15mg D1-21 8mg D1, 8, 15 3 15mg D1-21 10mg D1, 8, 15 4 15mg D1-21 12mg D1, 8, 15 5 15mg D1-21 14mg D1, 8, 15 6 25mg D1-21 14mg D1, 8, 15~     * The first patient in arm L will be entered into the study at dosing level one."
61997601|NCT01742793|EXPERIMENTAL|Arm M: subjects with myeloma|"The following dosing steps will be applied to the dose-escalation, phase-I component of the study for patients with myeloma who are eligible to enter Arm M:~Dose Level Arm M Lenalidomide dose Oral Romidepsin Dose Intravenous Dexamethasone~* 2 15mg D1-7, D15-21 6mg D1, 8, 15 20mg D1,8,15,22~* 1 15mg D1-7, D15-21 8mg D1, D8, 15 20mg D1,8,15,22~  1. 15mg D1-21 8mg D1, 8, 15 20mg D1,8,15,22 2 25mg D1-21 8mg D1, 8, 15 20mg D1,8,15,22 3 25mg D1-21 10mg D1, 8, 15 20mg D1,8,15,22 4 25mg D1-21 12mg D1, 8, 15 20mg D1,8,15,22 5 25mg D1-21 14mg D1, 8, 15 20mg D1,8,15,22~     * The first patient in arm M will be entered into the study at dosing level one."
61997602|NCT00215046|EXPERIMENTAL|Drug|no randomization, all patients receive experimental drugs
61997603|NCT02188238||Saliva Sample Collection|Collection of stimulated whole mouth saliva . Whole mouth saliva is collected through stimulation by inert gum, and collecting saliva in a sterile tube.
61997604|NCT01331694||COPD|copd patients 65 years and older
61997605|NCT04813796|EXPERIMENTAL|mRNA-1283 Dose Level 1|Participants will receive 2 intramuscular (IM) injections of mRNA-1283 at Dose Level 1 on Day 1 and Day 29.
61997606|NCT04813796|EXPERIMENTAL|mRNA-1283 Dose Level 2|Participants will receive 2 IM injections of mRNA-1283 at Dose Level 2 on Day 1 and Day 29.
61997607|NCT04813796|EXPERIMENTAL|mRNA-1283 Dose Level 3|Participants will receive 2 IM injections of mRNA-1283 at Dose Level 3 on Day 1 and Day 29.
61997608|NCT04813796|EXPERIMENTAL|mRNA-1273|Participants will receive 2 IM injections of mRNA-1273 at a pre-specified dose for this study on Day 1 and Day 29.
61997609|NCT04813796|EXPERIMENTAL|Placebo / mRNA-1283|Participants will receive 1 IM injection of study drug-matching placebo on Day 1 and 1 IM injection of mRNA-1283 at a pre-specified dose on Day 29. Participants may be offered an opportunity to receive an additional injection of mRNA-1273 at the pre-specified dose on Open-Label Day 1.
61997610|NCT03411473|EXPERIMENTAL|AGEN1884 with pembrolizumab|AGEN1884 in combination with pembrolizumab
61997611|NCT04625751||T2DM +CAN|
61997612|NCT04625751||T2DM -CAN|
61997613|NCT04625751||Healthy control|
62567920|NCT02984865|OTHER|Group ESRD|30 patients with ESRD who underwent PD catheter placement using left lateral transversus abdominis plane (TAP) block combined with rectus sheath (RS) block from our center. The TAP and RS blocks were respectively conducted with 15 ml of 0.5% ropivacaine and 10 ml of 0.5% ropivacaine. Pain intensity was evaluated by verbal rating scale (VRS), and the degree of patient and surgeon satisfaction was qualified by a categorical scale.
62567921|NCT05912881|PLACEBO_COMPARATOR|Placebo|Participants receive placebo olfactory training kits that only contain medium chain triglycerides that lack any discernible odor
62567922|NCT05912881|EXPERIMENTAL|Treatment|Participants receive treatment olfactory training kits that contain essential oils that have scents (lavender, lemon, clove, eucalyptus)
62567923|NCT05962333|EXPERIMENTAL|Intra-arterial delivery of autologous MABs|Autologous MABs will be injected three times in left arm to treat biceps brachii muscle
62567924|NCT03171805|EXPERIMENTAL|Propranolol group|Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
61997614|NCT05846620||Women|
61997615|NCT05846620||Men|
61997616|NCT02953990|EXPERIMENTAL|MOMS Program|The MOMS Program involves: (1) mindfulness of symptoms and goal-setting through a nurse-participant partnership, and (2) 12 weeks of weekly community-based group prenatal yoga classes (75 minutes each) and self-directed home activity. Participants will engage in 12 weeks of weekly community-based group prenatal yoga classes (75 minutes each) and self-directed home practice.
62567925|NCT03171805|NO_INTERVENTION|control group|Propranolol was not given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
62567926|NCT04407182|EXPERIMENTAL|Viusid Plus Asbrip|"Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours or standard care. Viusid and Asbrip will be administered orally.~A total of 60 subjects will be randomized 2: 1 in this study. 40 patients will be assigned to Viusid plus Asbrip plus standard of care.~Treatment duration: 21 days."
62567927|NCT04407182|NO_INTERVENTION|Control|"A total of 60 subjects will be randomized 2: 1 in this study. 20 Control patients will be assigned to standard of care.~Treatment duration: 21 days."
62567928|NCT02762942|ACTIVE_COMPARATOR|Vaginal misoprostol alone|Women in this group will receive 25mcg of vaginal misoprostol every 4 hours up to a maximum of 5 doses. Misoprostol will be stopped in case of a favorable cervix or if the patient is in active labor. In case of no progression after 5 doses of misoprostol, intravenous oxytocin will be perfused 4 hours after the last dose of misoprostol according to local protocols
61997617|NCT04155008|ACTIVE_COMPARATOR|Patients with fair to good appetite|"The patients with fair-good appetite (score on CNAQ more than 24) will not receive any pharmacological agents and will receive nutrition intervention alone.~CNAQ = Council on Nutrition Appetite Questionnaire"
62391848|NCT05299905|EXPERIMENTAL|Semi-CAVE|
61997618|NCT04155008|EXPERIMENTAL|Patients with poor to fair appetite|"The patients with poor-fair appetite (score on CNAQ less than 24) will be provided nutrition intervention by the Registered Dietitian and then put into one of three pharmacological groups.~CNAQ = Council on Nutrition Appetite Questionnaire"
61997619|NCT03098511|OTHER|Neurological Diagnostic Evaluation|Exams performed according to a determined schedule following admission in the intensive care unit in order to validate CT-perfusion as an accurate ancillary test for neurological diagnostic.
62391849|NCT05299905|EXPERIMENTAL|Head-mounted display system|
62391850|NCT04662957|EXPERIMENTAL|Probiotic preparation|Multi-strain probiotic mixture. The daily dose was five billion (2 capsules/day).
62391851|NCT04662957|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin comparable in color, texture and taste to the probiotic mixture (2 capsules/day).
62182956|NCT02634814|ACTIVE_COMPARATOR|Therapeutic Exercise Only|The role of the comparison group is to provide data on how traditional TE affects the outcome measures. The TE only group will allow us to assess how the addition of TENS to traditional TE will augment the effects of traditional TE. Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program.
62391852|NCT01070511|EXPERIMENTAL|Tadalafil|
62584752|NCT05021874|ACTIVE_COMPARATOR|Physiotherapeutic procedures: magnetotherapy|Magnetotherapy is a pulsating, non-homogeneous magnetic field generated by the Viofor JPS apparatus (Med \& Life, Poland) will be applied using an elliptical applicator with a beam width of approx. 5 cm. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
62773217|NCT05228561|NO_INTERVENTION|Control Group|After the physician involved in the study asks the participants for their biochemical tests (FBC, HbA1C, LDL-C, HDL-C, Total K, Triglyceride), the outpatient dietitian will give routine nutrition education to the participants. In addition, a data collection form including socio-demographic information, health history, nutrition history and height, weight, waist circumference measurements will be made and filled by the thesis student.
62391853|NCT01070511|PLACEBO_COMPARATOR|Placebo|
62391854|NCT04796649|EXPERIMENTAL|Standard and B-Cure Pro|Subjects from the Standard and B-Cure Pro group will receive standard care and in addition will self-treat at home daily with the B-Cure device.
62391855|NCT04796649|ACTIVE_COMPARATOR|Standard treatment + Sham laser|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
62391856|NCT03204331|EXPERIMENTAL|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
62773218|NCT05228561|EXPERIMENTAL|Study Group|The software developed for this research will be downloaded to the phones of the participants in the intervention group. With this software prepared, written and visual information (pictures, mini-videos) will be given to participants every day for 3 months on diabetes, self-management of diabetes and nutrition. Whether the participants read the messages or not will also be monitored through this software. At the end of 3 months, the participants in the intervention and control groups will be invited again, and their biochemical parameters and self-management status will be measured according to the diabetes self-management scale. Data will be collected through face-to-face interviews in the outpatient clinic, and weight will be measured with the bioelectrical impedance analyzer in the outpatient clinic, height will be measured with a height meter fixed to the wall, and waist circumference will be measured with a non-stretchable measuring tape.
62773219|NCT03420105|OTHER|Group A|Patients perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
62391857|NCT03204331|EXPERIMENTAL|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
62391858|NCT03204331|PLACEBO_COMPARATOR|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
62391859|NCT04946331|EXPERIMENTAL|Control|participants receive no surgical treatment
62391860|NCT04946331|EXPERIMENTAL|Rib Fixation Surgery|participants receive surgical treatment
62391861|NCT06421727|OTHER|Rehabilitation by optokinetic stimulation and virtual reality exercises .|combined vestibular rehabilitation incorporating optokinetic stimulation and virtual reality exercises (by device Virtual reality system(Meta Quest 2_Advanced All-In-One Virtual Reality Headset_ 128 GB)) on persistent postural perceptual dizziness patients.
62391862|NCT02844751|EXPERIMENTAL|Cohort 1|Interventions assigned by Principal Investigator
62391863|NCT02844751|EXPERIMENTAL|Cohort 2|Interventions assigned by Principal Investigator
62182957|NCT05605561|EXPERIMENTAL|Intervention Group (Digital Story)|The web-based digital story preparation process will be completed as a 3-5 minute short film by using pictures, videos, voiceovers and various video editing techniques by the researcher trained in storytelling. The digital story will be prepared in an appropriate format, taking into account the cognitive development and period characteristics of school children (7-12 years old).
62391864|NCT03844620|EXPERIMENTAL|Arm I (ctDNA testing, regorafenib, TAS-102)|Patients will receive either regorafenib by mouth on days 1-21 every 28 day cycle or TAS-102 by mouth twice daily on days 1-5 and 8-12 every 28 day cycle. Patients in this arm will get ctDNA testing and will continue treatment beyond 1st cycle depending on ctDNA results. Beyond that patients will continue treatment in the absence of disease progression or unacceptable toxicity.
62773220|NCT03420105|OTHER|Group B|Patients perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
62182958|NCT05605561|NO_INTERVENTION|Standard Maintenance Group|It is the standard of care given according to the hospital's policies and procedures.
62182959|NCT06003699|EXPERIMENTAL|Mindfulness training group|Participants will receive 4 weeks of mindfulness-based training and then continue to have access to the mindfulness training exercise throughout the second training interval.
62182960|NCT06003699|ACTIVE_COMPARATOR|Wait-list Control Group|Participants will not receive 4 weeks of mindfulness-based training during the first training interval; they will receive 4 weeks of mindfulness training during the second training interval.
62182961|NCT06410339||rock climbers|rock climbers of varying experience levels 18-40 years old
62182962|NCT06410339||control|non rock climbers 18-40 years old
62182963|NCT01058083|EXPERIMENTAL|BMS-770767 (Treatment A)|
62182964|NCT01058083|EXPERIMENTAL|BMS-770767 (Treatment B)|
62391865|NCT03844620|ACTIVE_COMPARATOR|Arm II (SOC)|Patients will receive either regorafenib by mouth on days 1-21 every 28 day cycle or TAS-102 by mouth twice daily on days 1-5 and 8-12 every 28 day cycle as per standard of care. Patients in this arm will continue treatment in the absence of disease progression or unacceptable toxicity.
62584753|NCT05021874|ACTIVE_COMPARATOR|Physiotherapeutic procedures:magneto-led therapy|Magneto-led therapy is a synergistic action of a slowly changing magnetic field generated by the Viofor JPS apparatus (Med \& Life, Poland) and LED diodes with the wavelength of 860 nm were applied using an elliptic magnetic-light (IR) applicator with a diameter of 5 \[cm\] containing 47 infrared diodes. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
62182965|NCT01058083|EXPERIMENTAL|BMS-770767 (Treatment C)|
62735103|NCT05774249|ACTIVE_COMPARATOR|Ultrasound guided pectointercostal fascial plane block group|using 20 mL of 0.25% bupivacaine with adrenaline 1:400,000
62182966|NCT01058083|EXPERIMENTAL|BMS-770767 (Treatment D)|
62182967|NCT01058083|PLACEBO_COMPARATOR|Placebo (Treatment E)|
62182968|NCT03912974|ACTIVE_COMPARATOR|Pretreatment with escitalopram|Pretreatment with escitalopram (10 mg for 7 days orally, 20 mg for another 7 days orally), followed by administration of psilocybin (25 mg orally) on the study day
62182969|NCT03912974|PLACEBO_COMPARATOR|Pretreatment with placebo oral capsule|Pretreatment with placebo, followed by administration of psilocybin (25 mg orally) on the study day
62391866|NCT01176422||advanced Myelodysplastic Syndrome or acute myeloid leukemia|advanced MDS and AML with/without associated cytogenetic abnormality
62182970|NCT04333147|EXPERIMENTAL|Otilimab 90 mg|Participants who received Otilimab 90mg in a qualifying study and continued on Otilimab 90mg in study 209564 or participants who received either tofacitinib 5mg (study 201790 or 201791) or sarilumab 200mg (study 202018) in a qualifying study and were exposed for the first time to Otilimab 90mg in study 209564. Otilimab 90mg was administered through subcutaneous (SC) injection once weekly.
62391867|NCT03125421|OTHER|control period|standard preventive methods of pressure sores in each center
62391868|NCT03125421|EXPERIMENTAL|experimental period|experimental multifaceted preventive methods of pressure sores
62391869|NCT01215045||ReSTOR +4|AcrySof ReSTOR Aspheric +4
62391870|NCT03350009||High and low grade embryos|The distribution for the high and low grade embryos is based on common morphological grading criteria.
62391871|NCT03350009||High and low quality follicles|The distribution for the high and low grade oocytes is based on common morphological grading criteria and on different features of the participants such as age.
62773221|NCT03420105|OTHER|Healthy volunteers|Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
62773222|NCT02414620|EXPERIMENTAL|Dental Vibe|New oscillating device for reduction in pain during dental anesthesia
62773223|NCT06507150|EXPERIMENTAL|AIME - AI-assisted migraine education|Intervention group: it receives AI-assisted migraine education in addition to standard migraine education
61997620|NCT01522066|EXPERIMENTAL|Perineural catheter|Local anesthetic will be delivered through an indwelling perineural catheter
62182971|NCT04333147|EXPERIMENTAL|Otilimab 150 mg|Participants who received Otilimab 150mg in a qualifying study and continued on Otilimab 150mg in study 209564 or participants who received either tofacitinib 5mg (study 201790 or 201791) or sarilumab 200mg (study 202018) in a qualifying study and were exposed for the first time to Otilimab 150mg in study 209564. Otilimab 150mg was administered through subcutaneous (SC) injection once weekly.
62182972|NCT01134471|NO_INTERVENTION|Control|
62182973|NCT01134471|ACTIVE_COMPARATOR|Bonewax|Patients treated with the hemostatic bonewax
62182974|NCT01134471|ACTIVE_COMPARATOR|Ostene|Patients treated with the hemostatic Ostene
62182975|NCT05671978|PLACEBO_COMPARATOR|neutral position|intubation was performed in the neutral position
62567929|NCT02762942|EXPERIMENTAL|Vaginal misoprostol + Foley catheter|Women in this group will receive 25mcg of vaginal misoprostol every 4 hours up to a maximum of 5 doses. At the same time a 16French Foley catheter will be inserted through the internal os with visualization of the cervix by sterile speculum examination. The catheter balloon will be inflated with 30 ml of sterile normal saline solution and then the catheter will be taped with gentle traction to the inner thigh of the patient until spontaneous expulsion. If this does not occur, the catheter will be deflated and removed after 12 hours. Misoprostol will be stopped in case of a favorable cervix or if the patient is in active labor. In case of no progression after 5 doses of misoprostol, intravenous oxytocin will be perfused 4 hours after the last dose of misoprostol.
62182976|NCT05671978|EXPERIMENTAL|back-up head elevated position|he trachea was intubated in the back-up head elevated position
62182977|NCT04111900|EXPERIMENTAL|Sleep/Circadian Friendly|initiation of sleep/circadian rhythm friendly intervention the first night spent in MICU after enrollment until patient transfers/discharges, ceases participation, or meets exclusion criteria.
62182978|NCT04111900|NO_INTERVENTION|Usual Care|Usual care within intensive care unit
62182979|NCT03171116||CKD-CT|subjects with CKD stages II-V under conservative treatment
62182980|NCT03171116||CKD-HD|subjects with CKD stage V on hemodialysis
62182981|NCT03171116||RTx renal transplant|renal transplant recipients
62182982|NCT03171116||Controls|control subjects
62567930|NCT01024504|EXPERIMENTAL|XELOX/Avastin|Capecitabine Oxaliplatin Bevacizumab
62182983|NCT00569192|EXPERIMENTAL|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
62182984|NCT00569192|PLACEBO_COMPARATOR|Placebo|Placebo delivered by nebulization twice daily for 12 weeks
62182985|NCT00569192|EXPERIMENTAL|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
62182986|NCT00585975|EXPERIMENTAL|Bromfenac Ophthalmic Solution 0.18%|
62182987|NCT00585975|EXPERIMENTAL|Xibrom 0.09%|
62182988|NCT02049112|EXPERIMENTAL|Salivary equivalent|Single dose stick without any active substance
62182989|NCT02049112|SHAM_COMPARATOR|Aequasyal|Multidose moisturizing oral spray without any active substance
62182990|NCT02049112|SHAM_COMPARATOR|Biotene|Multidose moisturizing oral spray without any active substance
62182991|NCT00085111|EXPERIMENTAL|Arm I|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62567931|NCT03181633|EXPERIMENTAL|ACH-0144471|All participants will receive ACH-0144471 during the treatment period.
62567932|NCT04152837|EXPERIMENTAL|Lixivaptan|Lixivaptan oral capsules, 100-200 mg twice daily
62567933|NCT01534442|ACTIVE_COMPARATOR|Atropin|Atropin
62773224|NCT06507150|NO_INTERVENTION|SME -Standard Migraine Education|Control group: it receives standard migraine education only
62773225|NCT02998034|EXPERIMENTAL|Cemented monoblock hemiarthroplasty|The cemented monoblock hemiarthroplasty is a double tapered polished stem with a hemiarthroplasty head cemented in place (Zimmer incorporated, UK)
62773226|NCT02998034|EXPERIMENTAL|Hyroxyapatite coated prosthesis|the Furlong Hyroxyapatite coated prosthesis (JRI orthopaedics limited UK) is a hydroxyapatite coating uncemented a hip prosthesis with a hemiarthroplasty head. The implant is uncemented.
62773227|NCT05432479|EXPERIMENTAL|Active|Arm receiving investigation product (probiotic)
62773228|NCT05432479|PLACEBO_COMPARATOR|Placebo|Arm receiving placebo
62773229|NCT04595162|EXPERIMENTAL|CAR-T treatment group|The patients will receive one dose of GC019F.
62773230|NCT02858921|EXPERIMENTAL|Sequential D + T, THEN Pembrolizumab|Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day for 1 week, then followed by treatment with Pembrolizumab 2mg/kg delivered intravenously at weeks 1, 3, and 6, then once every 3 weeks from week 6 for 46 weeks.
62773231|NCT02858921|EXPERIMENTAL|Concurrent D + T AND Pembrolizumab|Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day + Pembrolizumab 200mg intravenously once every 3 weeks for 6 weeks, the Pembrolizumab alone for 46 weeks
62182992|NCT02719925|EXPERIMENTAL|Mineral water rich in magnesium|- 1,5 L per day of mineral water containing 160 mg/L of magnesium
62182993|NCT02719925|ACTIVE_COMPARATOR|Water low in magnesium|- 1,5 L per day of mineral water containing 50 mg/L of magnesium
62182994|NCT01401114||Group 1|Drug (incl. Placebo)
62182995|NCT05220956|OTHER|Intermittent fasting|This arm will undergo a TRF diet (Time-Restricted Feeding) for 12 weeks.
62182996|NCT05220956|OTHER|DGE diet|This control arm is not a subject to any time restrictions concerning eating, solely patients will be trained according to the 10 rules of healthy nutrition of the DGE.
62182997|NCT02584036||Receiving Influenza Vaccine|Patients who receive an influenza vaccine at a participating pharmacy site will be eligible to: a) receive a vaccination forecast review, b) be evaluated for unmet vaccination needs, c) receive patient education, and d) have vaccination needs met.
62182998|NCT02144168|ACTIVE_COMPARATOR|prebiotics-free enteral formula|Patients in this arm will be receiving standard, prebiotics-free enteral formula : Osmolite 1 cal
62182999|NCT02144168|EXPERIMENTAL|prebiotics containing enteral formula|Patients in this arm will be receiving prebiotics containing enteral formula:Ensure Fos for 14 days
62183000|NCT05082207|EXPERIMENTAL|Remote Ischaemic preconditioning (RIPC)|The group underwent Remote Ischemic Preconditioning.
62183001|NCT05082207|SHAM_COMPARATOR|Sham Group|Sham control group without remote ischemic preconditioning
62773232|NCT02858921|EXPERIMENTAL|Pembrolizumab ONLY|Pembrolizumab 200mg intravenously once every 3 weeks alone for 52 weeks.
62391872|NCT03017066|EXPERIMENTAL|Infant formula|Patients were given infant formula 6 hours prior to surgery. Gastric volume was assessed before ingestion, 1 hour prior to the surgery, and before the induction of general anesthesia using ultrasound.
62391873|NCT03017066|EXPERIMENTAL|Carbohydrate drink|Patients were given carbohydrate drink 2 hours prior to surgery. Gastric volume was assessed before ingestion, 1 hour prior to the surgery, and before the induction of general anesthesia using ultrasound.
62391874|NCT05186220|EXPERIMENTAL|Cardioneuroablation|After 3D mapping of the surface of the left and right atrium and the superior vena cava (Ensite Navx or Carto system), localization of ganglion plexus (GP) will be performed either anatomically and/or by means of high frequency stimulation (HFS). The anterior and superior right sided GP will always be ablated per protocol. Other GP will be ablated according to interventional electrophysiologist judgement. The endpoint of the ablation procedure will be 1) absence of a vagal response after HFS from the right jugular vein and 2) an increase in at least 10 bpm as compared to baseline.
62391875|NCT05186220|ACTIVE_COMPARATOR|Permanent pacemaker implantation|A dual chamber pacemaker implantation will be performed. The device will be programmed in a AAI-DDDR mode to avoid unnecessary ventricular pacing.
62391876|NCT01488227|EXPERIMENTAL|Vitamin D|Vitamin D
62391877|NCT01488227|PLACEBO_COMPARATOR|Oil pill|Contains vegetable and soybean oil supplied by Nature Made by Pharmavite LLC located in Northridge, CA and is United States Pharmacopeia (USP) certified.
62391878|NCT00033514|EXPERIMENTAL|treatment|please see intervention description
62391879|NCT02332460||Infliximab|Patients treated with Infliximab
62391880|NCT04220502|EXPERIMENTAL|Magic Shave Powder Gold|This group will receive magic shaving powder gold and instructions on how to apply it. They will keep a log for their facial hair removal
62391881|NCT04220502|OTHER|Traditional Methods|This group will continue using traditional razors with the standard of care directions to shave. They will keep a log of their facial hair removal
62391882|NCT02714621|NO_INTERVENTION|Feasibility of MR-HIFU for painful gynaecological metastases|Investigating whether it would be possible to use the MRgHIFU system to treat recurrent gynaecological cancers.
62391883|NCT02714621|EXPERIMENTAL|Treatment using MR-HIFU of painful gynaecological metastases|Testing whether MRgHIFU could be an effective treatment for the symptoms of recurrent gynaecological cancers (pain and bleeding)
62391884|NCT02993133|EXPERIMENTAL|60 patients will be used to build and validate the system|The first 30 patients will be used to build and validate the pharmacokinetic modeling of MPA in pemphigus.The 30 patients included later will provide additional data.
62391885|NCT01519648||Acute leukemia patients|Patients with de novo or relapsed acute myeloid and lymphoid leukemia
62391886|NCT01519648||Allo- or auto- transplant recipients|
62391887|NCT00134563|EXPERIMENTAL|Teriflunomide 7 mg|Teriflunomide 7 mg once daily for 108 weeks
62391888|NCT00134563|EXPERIMENTAL|Teriflunomide 14 mg|Teriflunomide 14 mg once daily for 108 weeks
62391889|NCT00134563|PLACEBO_COMPARATOR|Placebo|Placebo (for teriflunomide) once daily for 108 weeks
62391890|NCT00367380|EXPERIMENTAL|Group 1|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 413ABM
62391891|NCT00367380|EXPERIMENTAL|Group 2|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 414WRR
62391892|NCT00367380|EXPERIMENTAL|Group 3|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 418JAL
62391893|NCT06403605|EXPERIMENTAL|SOC primary dressing with MIRRAGEN™|Mirragen Wound Matrix MIRRAGEN™ Advanced Wound Matrix is intended for the use in the management of wounds including diabetic ulcers. Wound matrix to be used per manufacturer instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing
62391894|NCT06403605|ACTIVE_COMPARATOR|SOC primary dressing with FIBRACOL™|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
62183002|NCT02643745|EXPERIMENTAL|Nephrology Intervention|Nephrology intervention before surgery:
62391895|NCT02984228|ACTIVE_COMPARATOR|Platelet-rich plasma (PRP)|Patients will receive an injection of PRP.
62391896|NCT02984228|ACTIVE_COMPARATOR|Hyaluronic Acid|Patients will receive an injection of hyaluronic acid.
62391897|NCT03217565|EXPERIMENTAL|Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 days to <6 months|Pediatric participants 28 days to \<6 months of age will receive a single dose (SD) intravenous (IV) infusion of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.
62773233|NCT02072395|EXPERIMENTAL|Band/Plication|Treatment -- band/plication
62773234|NCT05777239|EXPERIMENTAL|Dental Implant Approach for Crestal Sinus Elevation|
62391898|NCT03217565|EXPERIMENTAL|Part A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 months to <24 months|Pediatric participants 6 months to \<24 months of age will receive an SD IV infusion of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.
62391899|NCT03217565|EXPERIMENTAL|Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (full term) birth to <28 days|Full term (FT) neonates from birth to \<28 days of age will receive an SD IV infusion of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.
62391900|NCT03217565|EXPERIMENTAL|Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (full term) birth to <28 days|FT neonates from birth to \<28 days of age will receive multiple dose (MD) IV infusions of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg, administered twice daily for 3 days.
62567934|NCT01534442|PLACEBO_COMPARATOR|Placebo|Saline
62773235|NCT02012049|EXPERIMENTAL|Risperdal OD / Risperdal Quicklet|Risperdal OD (investigational drug) + Risperdal Quicklet (control drug)
62183003|NCT02643745|NO_INTERVENTION|Standard of Care|No nephrology intervention before surgery (standard of care)
62183004|NCT01340014|OTHER|AZARGA/COSOPT|1 drop AZARGA instilled in each eye twice a day for 7 days, followed by 1 drop COSOPT instilled in each eye twice a day for 7 days. A 48-hour washout period separated the two treatment periods.
62183005|NCT01340014|OTHER|COSOPT/AZARGA|1 drop COSOPT instilled in each eye twice a day for 7 days, followed by 1 drop AZARGA instilled in each eye twice a day for 7 days. A 48-hour washout period separated the two treatment periods.
62183006|NCT01324700|ACTIVE_COMPARATOR|High severity group: Escitalopram|Participants with Baseline score of 20 or above on the 17-item Hamilton Rating Scale for Depression (HRSD) AND 3 or more courses of oral corticosteroids in the past 12 months were stratified into high severity group. Then these participants were further stratified into escitalopram group.
62183007|NCT01324700|ACTIVE_COMPARATOR|Low severity group: Escitalopram|Participants with Baseline HRSD score of less than 20 AND fewer than 3 courses of oral corticosteroids in the past 12 months were stratified into low severity group. Then these participants were further stratified into escitalopram group.
62183008|NCT01324700|PLACEBO_COMPARATOR|High severity group: Placebo|Participants with Baseline score of 20 or above on the 17-item Hamilton Rating Scale for Depression (HRSD) AND 3 or more courses of oral corticosteroids in the past 12 months were stratified into high severity group. Then these participants were further stratified into placebo group.
62183009|NCT01324700|PLACEBO_COMPARATOR|Low severity group: Placebo|Participants with Baseline HRSD score of less than 20 AND fewer than 3 courses of oral corticosteroids in the past 12 months were stratified into low severity group. Then these participants were further stratified into placebo group.
62183010|NCT02584881|EXPERIMENTAL|Intervention|A safe opioid prescription protocol will be implemented with these trauma patients
62183011|NCT02584881|NO_INTERVENTION|Control|Standard care at discharge will be implemented with these trauma patients
62183012|NCT03470792|EXPERIMENTAL|Microcirculation-assisted|ECMO blood flow will be adjusted by conventional clinical conditions, hemodynamic parameters and microcirculation parameters
62183013|NCT03470792|ACTIVE_COMPARATOR|Control|ECMO blood flow will be adjusted by clinical conditions and conventional hemodynamic parameters
62183014|NCT00605995|EXPERIMENTAL|Simvastatin|Simvastatin, 20 mg Tablet, given once daily. Dosage increased to 40 mg/day at the end of week 4 until endpoint.
62183015|NCT00605995|PLACEBO_COMPARATOR|Placebo|Placebo pill, similar in its appearance to Simvastatin, taken once daily for the duration of the trial.
62391901|NCT03217565|EXPERIMENTAL|Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (preterm) birth to <28 days|Preterm (PT) neonates from birth to \<28 days of age will receive an SD IV infusion of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.
62391902|NCT03217565|EXPERIMENTAL|Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (preterm) birth to <28 days|PT neonates from birth to \<28 days of age will receive MD IV infusions of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg, administered twice daily for 3 days.
62391903|NCT03217565|EXPERIMENTAL|Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 days to <24 months|Pediatric participants 28 days to \<24 months of age will receive an SD oral suspension of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.
62391904|NCT03217565|EXPERIMENTAL|Part B Group 5: Single Dose Oral Tedizolid Phosphate (full term) birth to <28 days|FT neonates from birth to \<28 days of age will receive an SD oral suspension of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.
62391905|NCT03217565|EXPERIMENTAL|Part B Group 6: Single Dose Oral Tedizolid Phosphate (preterm) birth to <28 days|PT neonates from birth to \<28 days of age will receive an SD oral suspension of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.
62183016|NCT02894905|EXPERIMENTAL|AL-335 (Cohort 1)|Participants with mild impaired renal function will receive a single oral dose of AL-335 800 milligram (mg) (given as 2\*400-mg tablets).
62183017|NCT02894905|EXPERIMENTAL|AL-335 (Cohort 2)|Participants with moderate impaired renal function will receive a single oral dose of AL-335 800 mg (given as 2\*400-mg tablets).
62183018|NCT02894905|EXPERIMENTAL|AL-335 (Cohort 3)|Participants with severe impaired renal function will receive a single oral dose of AL-335 800 mg (given as 2\*400-mg tablets).
62183019|NCT02894905|EXPERIMENTAL|AL-335 (Cohort 4)|Participants with normal renal function will receive a single oral dose of AL-335 800 mg (given as 2\*400-mg tablets).
62183020|NCT05417802||Stroke with acute stroke|"Inclusion criteria~* Episode of single stroke within the past twelve weeks~* Individuals' age over 18 years old.~Exclusion criteria~* Pregnant women , neurological disorders other than stroke (i.e. Parkinson's), non-ischemic stroke~* Individuals with severe cognitive impairments (demonstrating difficulty to understand, read, and answer the questions in writing)~* Individuals with difficulties to listen the instruction and video of the robotic device"
62183021|NCT03584256||gymnasts|Female gymnasts, older than 13 years, with status of ineternational or national level,
62183022|NCT03584256||swimmers|Female swimmers, older than 12 years, with status of ineternational or national level,
62391906|NCT05314621|ACTIVE_COMPARATOR|Pataday® Once Daily Relief Extra Strength and Saline Nasal Spray|Pataday® Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%) will be administered bilaterally and saline nasal spray will be administered nasally (within 5 minutes of eyedrop) at Visits 3 and 4a.
62183023|NCT04230668|EXPERIMENTAL|CPT + SRM|Participants will be randomized to teletherapy sessions of Cognitive Processing Therapy + Suicide Risk Management for PTSD-BPD which will be administered twice weekly over 6 weeks, for a total of 12 sessions.
62183024|NCT04230668|EXPERIMENTAL|TAU + SRM|Participants will be randomized to teletherapy sessions with only Suicide Risk Management for PTSD-BPD which will be administered once a week for 6 weeks, for a total of 6 sessions.
62183025|NCT03428464|EXPERIMENTAL|Sodium bicarbonate|During the treatment period, participants will receive 0.5 mEq/kg-lean body weight (LBW)/day of oral sodium bicarbonate for 8 weeks.
62183026|NCT03428464|PLACEBO_COMPARATOR|Placebo|During the control period, participants will take the same number of placebo capsules as if they were assigned 0.5 mEq/kg-LBW/day of sodium bicarbonate.
62183027|NCT00644956|ACTIVE_COMPARATOR|Arm 1|
62183028|NCT00644956|ACTIVE_COMPARATOR|Arm 2|
62183029|NCT04150185||live liver donors|Live liver donors undergoing donor hepatectomy
62183030|NCT04008147|ACTIVE_COMPARATOR|High Iron Group|15 women taking 100 mg iron twice daily for 4 days (800 mg).
62183031|NCT04008147|ACTIVE_COMPARATOR|Low Iron Group|15 women taking 30 mg iron once daily for 14 days (420 mg).
62183032|NCT03343210|EXPERIMENTAL|cancer patient|cancer patient
62183033|NCT03343210|ACTIVE_COMPARATOR|no cancer patient|no cancer patient
62183034|NCT04668703|EXPERIMENTAL|combined cataract surgery and intravitreal Conbercept injection|Subjects will receive conbercept injections at a dose of 0.5 mg/eye at the conclusion of cataract surgery.
62183035|NCT04668703|NO_INTERVENTION|cataract surgery alone|Subjects will undergo cataract surgery by phacoemulsification and intraocular lens implantation.
62183036|NCT00865137|EXPERIMENTAL|1 FK506E|
62567935|NCT03827993|NO_INTERVENTION|Routine surveillance|"Routine surveillance consists of attending gynecologic oncology office visits and being provided with an educational pamphlet discussing common sexual health concerns in gynecologic cancer patients, describing vaginal dilators, moisturizers, and lubrication. Resources for psychosocial counseling, physical therapy, and the sexual health clinic will be provided as well.~Participants will have follow up at baseline, 3, 6, 9, and 12 months. Baseline visit consists of the initial visit where the Female Sexual Function Index (FSFI) screen was performed. Subsequent follow up visits will consist of FSFI, Female Sexual Distress Scale (FSDS), Kessler 10 surveys, and clinical assessment with Vaginal Assessment Scale and Vulvar Assessment Scale (VAS and VuAS)."
62735104|NCT05774249|PLACEBO_COMPARATOR|control group|using 20 mL of normal saline 0.9%
62183037|NCT06546150|EXPERIMENTAL|RE002 T cell adoptive immunotherapy|3+3 dose increasing design was adopted, and the dose increasing scheme was as follows (deviation 30%): low dose group: 4×109, middle dose group: 8×109, and high dose group: 1.6×1010. If the subjects in the lower dose group continue to benefit clinically after the first T cell infusion treatment, the second T cell infusion treatment can be carried out after the researcher's suggestion and the sponsor's consent. The second infusion can be carried out within 6 months of the disease progression, and the interval between the last infusion and the last infusion is at least 8 weeks.
62183038|NCT04136600|EXPERIMENTAL|EGFR antibody arm|Participants received a dose of 500 mg/m2 Cetuximab iv on Day 1 of cycle every 3 weeks, or 400mg Nimotuzumab on Day 1 of cycle, every week, until disease progression. 12 cycles of mFOLFOX (5-fluorouracil (5-FU) 1,200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, and oxaliplatin 85 mg/m2 biweekly). 6-8 cycles of CapOX (Xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks). 6-8 cycles of SOX (S-1, 60mg for BSA\>1.5, 50 mg for 1.5\>BSA\>1.25 , 40mg for BSA\<1.25 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks)
62183039|NCT04136600|PLACEBO_COMPARATOR|Placebo arm|12 cycles of mFOLFOX (5-fluorouracil (5-FU) 1,200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, and oxaliplatin 85 mg/m2 biweekly). 6-8 cycles of CapOX (Xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks). 6-8 cycles of SOX (S-1, 60mg for BSA\>1.5, 50 mg for 1.5\>BSA\>1.25 , 40mg for BSA\<1.25 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks)
62183040|NCT05879562|EXPERIMENTAL|MoCA-Xpresso first|Participants in the study will complete the MoCA-Xpresso test before the digital-MoCA classic test.
62183041|NCT05879562|EXPERIMENTAL|MoCA-Xpresso second|Participants in the study will complete the digital-MoCA classic test before the MoCA-Xpresso test.
62183042|NCT00695825|EXPERIMENTAL|A1|Consumption of low GI food product on day 1 Consumption of high GI food product on day 2
62183043|NCT00695825|EXPERIMENTAL|A2|Consumption of high GI food product on day 1 Consumption of low GI food product on day 2
62183044|NCT00774423|PLACEBO_COMPARATOR|Placebo|MAIN EXCIPIENT OF THE RILUTEK
62183045|NCT00774423|ACTIVE_COMPARATOR|Riluzole|RILUTEK
62183046|NCT03884062||DAAs-SVR.|annual incidence of HCC in chronic hepatitis C patients with advanced liver fibrosis (F3 and F4) after achieving DAAs-SVR.
62183047|NCT03146897|ACTIVE_COMPARATOR|Super Cereal Plus with amylase|
62183048|NCT03146897|ACTIVE_COMPARATOR|Corn-soy Blend Plus and Vegetable Oil|
62183049|NCT03146897|ACTIVE_COMPARATOR|Corn-soy Whey Blend and Vegetable Oil|
62183050|NCT03146897|ACTIVE_COMPARATOR|Ready-to-Use-Supplementary Food|
61997621|NCT01522066|ACTIVE_COMPARATOR|Single-shot block|Local anesthetic will be delivered by the conventional, single-shot method.
61997622|NCT03759067|ACTIVE_COMPARATOR|LD group|clopidogrel 600 mg once loading, usually 2-24 h before the procedure
62183051|NCT04094181||VPRIV Participants|Participants who has been transitioned from ERTs/SRTs to VPRIV, the data will be collected retrospectively from time of transition until the point at which participant begins in this study and then will be followed up prospectively for 12 months.
62183052|NCT03094455|EXPERIMENTAL|Experimental group|AOT is based on the observation of meaningful actions followed by their execution
62183053|NCT03094455|OTHER|Control group|Children will continue standard care for 3 weeks and then will receive the AOT as the Experimental group
62183054|NCT05604508|ACTIVE_COMPARATOR|Status Quo|This condition will allow for many posters with pricing information to be displayed.
62183055|NCT05604508|EXPERIMENTAL|Reduced Poster|This condition will allow for a reduced number of posters with pricing information to be displayed.
62183056|NCT05604508|EXPERIMENTAL|No price|This condition will allow for many posters with no pricing information to be displayed.
61997623|NCT03759067|EXPERIMENTAL|MD group|After randomization, the routine therapy using daily clopidogrel 75mg
61997624|NCT03759067|ACTIVE_COMPARATOR|RL group|After randomization, additional clopidogrel 300 mg reloading for patients who were taking a maintenance dose.
61997625|NCT03718442||Breast cancer patients - lumpectomy|Women who are 18 years or older, have Ductal carcinoma in situ (DCIS) or invasive breast-conserving surgery, have not had previous chest radiotherapy. 20 patients who meet above study population criteria will be enrolled in this study.Shaved margins for each lumpectomy site will be excised with either Bovie (3 sides) or PhotonBlade (3 sides) for each patient. The effect of PhotonBlade vs Bovie on pathology assessment of lumpectomy shaved surgical margins will be compared.
61997626|NCT02206516|EXPERIMENTAL|patients|Stimulation using tDCS will be administered daily, 5 days a week for 4 weeks. each session will last 22 minutes during which the anode electrode will be positioned over the right Inferior Frontal Gyrus (IFG) and the Katode electrode over the right Orbito Frontal Gyrus (OFG).
61997627|NCT02280174|EXPERIMENTAL|Drug: linagliptin|linagliptin 5 mg/d for 12 weeks
61997628|NCT02280174|NO_INTERVENTION|Drug: standard treatment|sulfonylurea treatment for 12 weeks
62183057|NCT01253447|EXPERIMENTAL|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 200 mg orally once a week for each 28 day treatment cycle
62183058|NCT01816685|EXPERIMENTAL|CPAP|Patients in the CPAP group will be instructed to wear an autotitrating positive airway pressure (APAP) device any time they sleep prior to surgery and on postoperative days 0, 1, and 2.
62183059|NCT01816685|NO_INTERVENTION|Routine Care|
62183060|NCT05399615|EXPERIMENTAL|Hospitalized Patients|"Patients hospitalized in internal ward at Poriya Medical Center"
62183061|NCT05399615|EXPERIMENTAL|Controls|Healthy volunteers
62183062|NCT01196585|EXPERIMENTAL|Patients under CT- guided pleural biopsy|Arm A: Patients who go under CT-guided pleural needle biopsy for pleural diseases
62183063|NCT01196585|EXPERIMENTAL|Patients under ultrasonography guided needle biopsy|Arm B: Patients who go under ultrasonography guided cutting needle pleural biopsy for pleural diseases
62183064|NCT00890799|EXPERIMENTAL|occluders|Shanghai pmVSD occluder (LEPU Medical Tech-nology Co, Ltd, Beijing, China) was used in this study.
62183065|NCT02739776||A|Pt receiving standard Epidural block care for vaginal delivery
62183066|NCT03819751|OTHER|MRI-targeted prostate biopsy|Participants receive both type of MRI-targeted biopsy. Patients are randomized with one half having visual registration first and the other half having software registration first.
62183067|NCT01145820|EXPERIMENTAL|Juice Plus|
62183068|NCT01145820|PLACEBO_COMPARATOR|Placebo|
62391907|NCT05314621|ACTIVE_COMPARATOR|Tears Naturale® II and Flonase® Allergy Relief|Tears Naturale® II will be administered bilaterally and Flonase® Allergy Relief (fluticasone propionate) will be administered nasally (within 5 minutes of eyedrop) at Visits 3 and 4a.
62183069|NCT04212780|ACTIVE_COMPARATOR|Treatment Naive|Participants receiving Long-term stimulation of the thalamus via dual leads for Essential Tremor
62183070|NCT04212780|ACTIVE_COMPARATOR|Refractory Participants|Patients with recurrent, debilitating intention tremor despite ongoing, optimized VIM DBS therapy
62183071|NCT02767609|EXPERIMENTAL|Magentic Resonance Imaging|magnetic Resonance Imaging.
62183072|NCT01114139|EXPERIMENTAL|Ferumoxytol|Participants received a total of 2 doses of IV ferumoxytol 510 milligrams (mg) (17 milliliters \[mL\]). The first IV 510 mg dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose, for a total cumulative dose of 1.02 grams (g).
62183073|NCT01114139|PLACEBO_COMPARATOR|Placebo|Participants received a total of 2 doses of IV saline (17 mL). The first IV dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose.
62735105|NCT00588237|EXPERIMENTAL|1|Paclitaxel, Cisplatin, Bevacizumab
62391908|NCT01207427|PLACEBO_COMPARATOR|Placebo|Each participant received 1 placebo capsule orally twice daily (BID) during the Run-in Placebo Period (1 week), the Double-blind Treatment Period (4 weeks), and the Run-out Placebo Period (1 week).
62391909|NCT01207427|EXPERIMENTAL|ADL5945 0.1 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally BID for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.1-milligrams (mg) ADL5945 capsule orally BID for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally BID for 1 week.
61997629|NCT03492333|EXPERIMENTAL|Gluten free diet|Single arm
61997630|NCT01499888|EXPERIMENTAL|Allogeneic Non-Myeloablative Stem Cell Transplantation|The transplant regimen will consist of alemtuzumab 1mg/kg divided over five days, 300 cGy TBI, followed by sirolimus dosed for a target serum trough level of 10- 15 ng/mL.
61997631|NCT01933906|EXPERIMENTAL|P1101|"P1101 50µg s.c. will be administered every 2 weeks in addition to preexisting imatinib treatment. In the absence of dose limiting toxicities after 12 weeks, the dose will be escalated to 100µg every 2 weeks.~Maximum treatment duration will not expand 18 months."
61997632|NCT04724850||COVID-19 patients|All patients diagnosed with COVID-19 in the community of Extremadura from the beginning of the epidemic to its ending in Spain.
61997633|NCT01045564|EXPERIMENTAL|A|One dose of study vaccine (GSK 1557484A) on Day 0, Day 182, and Day 364
61997634|NCT01045564|EXPERIMENTAL|B|One dose of study vaccine (GSK 1557484A) on Day 0, Day 91, and Day 364
61997635|NCT01045564|EXPERIMENTAL|C|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
61997636|NCT01045564|EXPERIMENTAL|D|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
61997637|NCT01045564|EXPERIMENTAL|E|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
61997638|NCT04601051|EXPERIMENTAL|Polyneuropathy Part 1: NTLA-2001|Participants, assigned to one of 4 dose-escalation cohorts, will receive a single dose of NTLA-2001.
61997639|NCT04601051|EXPERIMENTAL|Polyneuropathy Part 2: NTLA-2001|Participants, assigned to the dose-expansion cohort, will receive a single dose of NTLA-2001.
61997640|NCT04601051|EXPERIMENTAL|Cardiomyopathy Part 1 (UK only): NTLA-2001|Participants, assigned to one of 2 dose-escalation cohorts, will receive a single dose of NTLA-2001.
61997641|NCT04601051|EXPERIMENTAL|Cardiomyopathy Part 2 (UK only): NTLA-2001|Participants, assigned to the dose-expansion cohort, will receive a single dose of NTLA-2001.
61997642|NCT04601051|EXPERIMENTAL|Polyneuropathy Follow-on Dosing (PN Part 1 Dose Level 1 Subjects only): NTLA-2001|Participants assigned to the follow-on dosing cohort will receive a subsequent dose of NTLA-2001.
61997643|NCT01185873|EXPERIMENTAL|1|
61997644|NCT06237166|EXPERIMENTAL|mylovia + TAU|"Participants allocated to the intervention group will receive access to mylovia in addition to treatment as usual (TAU).~mylovia is a digital health application designed for women with sexual dysfunction, accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT). Topics addressed by mylovia are psychoeducation, relaxation and mindfulness exercises, strategies to improve self-esteem, development of passionate attitudes and situations, dealing with differences in desire in a relationship, and sensate focus exercises.~The program operates through interactive dialogues, which are accompanied by illustrations, audio recordings, motivational text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days."
61997645|NCT06237166|NO_INTERVENTION|information material + TAU|Participants allocated to the control group will receive access to information material about treatment and counseling options in addition to treatment as usual (TAU).
61997646|NCT00326664|EXPERIMENTAL|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
61997647|NCT00847444|ACTIVE_COMPARATOR|AA|Drug intervention
62773236|NCT02012049|EXPERIMENTAL|Risperdal Quicklet / Risperdal OD|Risperdal Quicklet (control drug) + Risperdal OD (investigational drug)
62773237|NCT04771325|OTHER|Arm 1|Women are normally escorted to the health facilities by one or more family members and or friends. Women usually labor in an open first stage room where more than one woman is admitted sometimes with curtains to separate the beds with one person allowed besides her to provide support. The support persons do not have designated roles to play during this process. Routine analgesia is not given neither is continuous fetal monitoring. Midwives,
62773238|NCT04771325|EXPERIMENTAL|Arm 2|One session of training on admission in labor. The training will focus on emotional and physical support; emotional support including being Present, demonstrating a caring and positive attitude, saying calming verbal expressions, using humor, praise, encouraging and acknowledging efforts during the process of pushing the baby. Physical support including supporting her to change position favoring upright positions, walking with her, giving her drinks and food, massage, reminding her to go and pass urine, helping her find a comfortable position for pushing, wipe her face with cool cloth and help her breast feed
62773239|NCT01238965|EXPERIMENTAL|Arm I|Patients receive oral panobinostat 3 times a week. Patients also receive leucovorin calcium IV over 2 hours on days 1 and 15 followed by fluorouracil IV continuously over 46 hours on days 1-2 and 15-16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62735106|NCT02289196|EXPERIMENTAL|Vx-006: 0,5mg|Six injections of Vx-006 at 0,5 mg + Montanide ISA51™ will be administrated every 3 weeks
62773240|NCT01369186|ACTIVE_COMPARATOR|Morphine|Vendal 5 mg i.v. bolus injection
61997648|NCT00847444|ACTIVE_COMPARATOR|BA|Lifestyle intervention
61997649|NCT00847444|NO_INTERVENTION|BB|No individualized lifestyle intervention program.
61997650|NCT02501096|EXPERIMENTAL|Lenvatinib + Pembrolizumab|Participants with one of the tumors: non-small cell lung cancer, renal cell carcinoma, endometrial cancer, urothelial cancer, squamous cell carcinoma of the head and neck, melanoma or leiomyosarcoma.
61997651|NCT03671291|EXPERIMENTAL|Recently infected with HIV|Men and women recently infected with HIV and have been eligible for PrEP based on the recommendation of french national regulatory agency regarding the prescription of Truvada® in prophylaxis to HIV exposure. The potential reasons behind these missed opportunity of Pre-exposure prophylaxis will be studied through a self-administrated questionnaire.
61997652|NCT00539838|EXPERIMENTAL|Ocrelizumab 1000 mg|Ocrelizumab was administered i.v. at a dose on Days 1 and 15, followed by 1000 mg i.v. at Week 16 and then every 16 weeks
61997653|NCT00539838|EXPERIMENTAL|Ocrelizumab 400 mg|Ocrelizumab was administered at a dose 400 mg i.v. on Days 1 and 15, followed by 400 mg i.v. at Week 16 and then every 16 weeks
61997654|NCT00539838|PLACEBO_COMPARATOR|Placebo|Placebo infusions were administered on Days 1 and 15, followed by placebo infusion at Week 16 and then every 16 weeks
62773241|NCT01369186|PLACEBO_COMPARATOR|Placebo|Sodium chloride 0.9% i.v. bolus injection
62773242|NCT06124456|PLACEBO_COMPARATOR|Usual Care Control Group|
62773243|NCT06124456|EXPERIMENTAL|Moderate-intensity Exercise Intervention|
62773244|NCT06124456|EXPERIMENTAL|Vigorous-intensity Exercise Intervention|
62773245|NCT00516035|EXPERIMENTAL|1|0.50 ml (0.25 ml in each nostril) of Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca) administered by nasal spray at two timepoints (at study entry and between Weeks 4 and 8)
62773246|NCT00474461|EXPERIMENTAL|Treatment group|Patients in this arm received intracoronary expanded autologous c-kit positive cardiac stem cells.
62773247|NCT00474461|NO_INTERVENTION|Control group|Patients in this arm did not receive any intervention.
62773248|NCT02708355|EXPERIMENTAL|Esomeprazole 20 mg once daily|Esomeprazole 20 mg administered orally in the morning and placebo administered orally in the evening
62773249|NCT02708355|EXPERIMENTAL|Esomeprazole 20 mg twice daily|Esomeprazole 20 mg administered orally in the morning and esomeprazole 20 mg administered orally in the evening
61997655|NCT02752932|OTHER|HNSCC -PDX development|Participants with HNSCC who will undergo curative surgery will be included in this group. This involves PDX development only, no drug testing will be done on the PDX.
61997656|NCT02752932|OTHER|RMHNSCC -PDX drug testing|Participants with RMHNSCC who are under palliative treatment will be included in this group. Drug testing on PDX per Investigator's choice (upto 4): PDX will be developed and upto four Chemotherapeutics (that are funded in Ontario) will be tested on the PDX. Chemotherapeutics will be selected at the discretion of the treating Medical Oncologists. Result of the drug testing will be provided to the responsible physician and can be utilized in patient care.
61997657|NCT03189628|EXPERIMENTAL|stromal vascular fraction|Transplantation of resuspended SVF
61997658|NCT03189628|PLACEBO_COMPARATOR|saline|1 ml saline without cells will be used as placebo.
61997659|NCT04183556|ACTIVE_COMPARATOR|1/NSAI(nonsteroidal anti-inflammatory agent) group|Patients with naproxen drug therapy for early onset dysmenorrhea.
61997660|NCT04183556|PLACEBO_COMPARATOR|2/NSAI+ Turmeric (1 gram oral powder formula per day )|NSAI(nonsteroidal anti-inflammatory agent) + Turmeric for early onset dysmenorrhea (1 gram oral powder formula in mens time)
62214559|NCT05191940|OTHER|Particle radiotherapy|According to the radiation plan using protons or carbon ions (between 25 and a maximum of 40 Gy). Planning Target Volume 1 : 25 Gy (Relative Biological Effectiveness) in 5 fractions of 5 Gy (Relative Biological Effectiveness) Planning Target Volume 2 : A simultaneous integrated boost (SIB) will be delivered to the Planning Target Volume 2: 40 Gy (Relative Biological Effectiveness) in 5 fractions of 8 Gy (Relative Biological Effectiveness).
62214560|NCT01089881||Group 1|patients with BPH
62735107|NCT02289196|EXPERIMENTAL|Vx-006: 1mg|Six injections of Vx-006 at 1 mg + Montanide ISA51™ will be administrated every 3 weeks
62773250|NCT02708355|PLACEBO_COMPARATOR|Placebo|Placebo administered orally in the morning and placebo administered orally in the evening
62773251|NCT01973556|EXPERIMENTAL|Pharmacist-Physician Collaborative Medication Management|Pharmacist-Physician Collaborative Medication Management
62773252|NCT01973556|NO_INTERVENTION|Usual Care|
62773253|NCT02474251|ACTIVE_COMPARATOR|Group A|25 cognitively normal elderly subjects (age 55-75), newly enrolled or currently participating in R01HL118624-01 (IRB S12-03068), a 2-year longitudinal on-going study that is aimed at examining the longitudinal associations between SDB and cognitive decline in the elderly.
62773254|NCT02474251|ACTIVE_COMPARATOR|Group B|20 cognitively normal adults (age 30-75) with severe SDB (Apnea Hypopnea index \[AHI\]-all \>30/hour) and good CPAP compliance from Mt. Sinai School of Medicnie (MSSM)
62214561|NCT01089881||Group 2|patients with newly diagnosed prostate cancer
62391910|NCT01207427|EXPERIMENTAL|ADL5945 0.25 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally BID for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.25-mg ADL5945 capsule orally BID for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally BID for 1 week.
62391911|NCT06320821||RAKT|robot-assisted kidney transplant patients
62391912|NCT06320821||OKT|open kidney transplant patients
62391913|NCT00625027||Group 1|Children presenting to the Emergency Department under the care of a parent or guardian, between 0600 and 2400 during the study period.
62391914|NCT03464162|EXPERIMENTAL|Social Network Meetings Group|"This arm will receive Social Network Meetings for a 6 month period. Meetings may occur as often as 3 times a week when there is a crisis or more commonly would occur once every other week. These meetings will last between 60 and 90 minutes and will take place for however long the clients and their social networks would like within the project period. Ideally, each client and his/her Social Network would participate in 4 meetings during the 6 month period. This group would continue to receive care as usual with the addition of these meetings.~\*Final sample in this arm was N=3."
62391915|NCT03464162|NO_INTERVENTION|No Social Network Meetings Group|"This arm will not receive the Social Network Meetings intervention. Clients in this arm will participate in the study for 6 months and receive care as usual during this time.~\*Final sample in this arm was N=1."
62391916|NCT03464162|OTHER|Social Network Members|"This arm is comprised of individuals who are social network members of clients who are receiving the Social Network Meetings intervention.~\*Final sample in this arm was N=3 (social network members of arm 1)."
62391917|NCT05069623|EXPERIMENTAL|VB10.2129 Part 1 Dose escalaton|0.3 mg, 1 mg or 3 mg will be administered by two IM injections 21 days apart.
62391918|NCT05069623|EXPERIMENTAL|VB10.2210 Part 1 Dose escalation|0.3 mg, 1 mg or 3 mg will be administered by two IM injections 21 days apart.
62391919|NCT05069623|EXPERIMENTAL|VB10.2129 Part 2 Dose expansion|The seleceted dose from Part 1 will be administered IM in a two-dose schedule.
62391920|NCT05069623|EXPERIMENTAL|VB10.2210 Part 2 Dose expansion|The seleceted dose from Part 1 will be administed IM in a two-dose schedule.
62735108|NCT02289196|EXPERIMENTAL|Vx-006: 5mg|Six injections of Vx-006 at 5 mg + Montanide ISA51™ will be administrated every 3 weeks
62391921|NCT05756062|EXPERIMENTAL|DHA group|Supplementation with a highly-concentrated docosahexaenoic acid (DHA) triglyceride (1000 g/day) for 3 months
62391922|NCT05756062|NO_INTERVENTION|Control group|Routine care
62391923|NCT06337773|EXPERIMENTAL|Treatment group|The survivors receiving 8 weeks (90 mins per weeks) on-line percious nursing education intervention
62391924|NCT06337773|NO_INTERVENTION|Control group|As usual
62391925|NCT03502265|EXPERIMENTAL|Otteroo adjunct|A single-subject research design will be used: measures of infant development will be collected across a 4-week baseline period (standard care), 4 weeks of intervention (standard care and Otteroo use), and a 4 weeks of reversal/retention period (standard care). There is only one arm due to the study design. It is a within-subjects comparison, not a between-subjects comparison of different study arms.
62773255|NCT01154543||HIV positive, gential HSV,Famvir™ 500mg bd, suppressive|
62773256|NCT01759823|EXPERIMENTAL|mesenchymal stem cell transplantation|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of \>0.4unit/Kg for blood glucose control.
62214562|NCT01089881||Group 3|patients who have received curative treatment for prostate cancer and are suspicious of recurrence/metastases because of a persistent increase in their serum PSA.
62735109|NCT02289196|EXPERIMENTAL|Vx-006: 10mg|Six injections of Vx-006 at 10 mg + Montanide ISA51™ will be administrated every 3 weeks
62773257|NCT01759823|SHAM_COMPARATOR|Control|vildagliptin+metformin+pioglitazone and on Insulin \>0.4unit/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1
62773258|NCT01759823|EXPERIMENTAL|MNC's TRANSPLANTATION|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of \>0.4unit/Kg for blood glucose control.
62773259|NCT01742689|EXPERIMENTAL|Desmopressin intranasal spray|Patients in this arm will receive 40 microgram desmopressin intranasal spray \& 100 milligram indomethacin suppository
62391926|NCT02668510|EXPERIMENTAL|Platelet Rich Plasma Injection Group|shockwave therapy within standard of care using Ossatron system with intervention injection of platelet rich plasma (PRP) using Arthex system, into the plantar fascia at the calcaneal origin
62391927|NCT02668510|PLACEBO_COMPARATOR|Placebo injection group|shockwave therapy with placebo normal saline injection
62391928|NCT00987857|ACTIVE_COMPARATOR|2 yearly endoscopies|Two years endoscopies
62391929|NCT00987857|EXPERIMENTAL|endoscopy at need|Endoscopy only when patient reports symptoms
62391930|NCT05463315|EXPERIMENTAL|Moziak Device|Applying Moziak Device Compared to Standard Manual Compression
62391931|NCT00203294|ACTIVE_COMPARATOR|Lidocaine 2%, Bupivicaine 0.5% and saline|Adult patients with CDH, and headache of at least moderate intensity at time of treatment, were randomized to receive bilateral GONB and trigger point injections in the cervical paraspinal and the trapezius muscles bilaterally.
62391932|NCT00203294|ACTIVE_COMPARATOR|Lidocaine 2%, Bupivicaine 0.5% and triamcinolone 40 mg|Adult patients with CDH, and headache of at least moderate intensity at time of treatment, were randomized to receive bilateral GONB and trigger point injections in the cervical paraspinal and the trapezius muscles bilaterally.
62773260|NCT01742689|PLACEBO_COMPARATOR|Placebo intranasal spray|Patients in this group will receive placebo nasal spray \& 100 milligram indomethacin suppository
62773261|NCT01914653|EXPERIMENTAL|Pre-radiated|
62773262|NCT01914653|EXPERIMENTAL|Not radiated|
62773263|NCT01914653|EXPERIMENTAL|Post-radiated|
62773264|NCT05152810|EXPERIMENTAL|Active Transcranial Magnetic Stimulation|
62773265|NCT05152810|PLACEBO_COMPARATOR|Transcranial magnetic resonance imaging placebo|
62773266|NCT00779207|EXPERIMENTAL|1|weight loss
62183074|NCT06545812|ACTIVE_COMPARATOR|Physical therapy for disc herniation|Conservative treatment in the form of physical therapy consists of several physical factors, namely laser therapy, ultrasound and transcutaneous electroneurostimulation (TENS). Blood samples for analysis for multicomplex quantitative analysis of anti-inflammatory cytokines (interleukin 1β (IL-1β), interleukin 6 (IL-6), interleukin 8 (IL-8), interferon gamma (INF-γ), tumor necrosis factor alpha or gamma (TNF-α), chemokine ligand 3 (CCL3) and matrix metalloproteinases MMP-3 and MMP-9
62183075|NCT06545812|ACTIVE_COMPARATOR|Epidural steroid injection (ESI)|Minimally invasive methods such as epidural steroid injection (ESI). Blood samples for analysis for multicomplex quantitative analysis of anti-inflammatory cytokines (interleukin 1β (IL-1β), interleukin 6 (IL-6), interleukin 8 (IL-8), interferon gamma (INF-γ), tumor necrosis factor alpha or gamma (TNF-α), chemokine ligand 3 (CCL3) and matrix metalloproteinases MMP-3 and MMP-9
62183076|NCT04823364|ACTIVE_COMPARATOR|Medically healthy adults diagnosed with ADHD|Medically healthy adults diagnosed with ADHD (men and women) ages 18-40 years (N= 35), treated with Amphetamines (Mixed Amphetamine salts (Attent) or short-acting methylphenidate (Ritalin)
62567936|NCT03827993|EXPERIMENTAL|Dedicated sexual health clinic appointment|"Dedicated sexual health clinic appointment with a physician provider focused on sexual health in this population. This will consist of the provider performing a focused history and physical, who will then determine need for appropriate treatment and management, which may consist of recommendations for medications, psychosocial counseling, physical therapy, and/or dilator use, but are not required.~The participants will follow up at 3, 6, 9, and 12 months after initial visit, either with the sexual health focused provider or their primary gynecologic oncologist, as determined by the needs of the participant per the provider."
62567937|NCT01146639|EXPERIMENTAL|MDCT and additional DynaCT|
62773267|NCT00779207|EXPERIMENTAL|2|Weight loss and exercise
62773268|NCT01609413|EXPERIMENTAL|AlgaeCal|Calcium supplements derived from ocean algae. One dose equals 3 capsules containing 180 mg calcium each.
62773269|NCT01609413|ACTIVE_COMPARATOR|Caltrate 600|Proprietary calcium supplement. One dose contains 600 mg of calcium.
62183077|NCT04823364|NO_INTERVENTION|Control|HCS (N= 25) volunteers ages 18-40 years, who did not report ADHD or any other illness or medical conditions, and who do not take chronically medications, will be enrolled from the general population.
62183078|NCT01650883|EXPERIMENTAL|Cholecaliferol 50,000 IU PO Q10 days x 40 days|Patients in this arm receive Cholecalciferol (vitamin D3) via PO route every 10 days for 40 days for a total of 200,000 IU of Vitamin D3. They also receive daily 1200 mg of Calcium Carbonate via PO route daily for 40 days.
62773270|NCT04014387|ACTIVE_COMPARATOR|Zolpidem Arm|Participants will be given one week of Zolpidem.
62183079|NCT01650883|EXPERIMENTAL|Cholecalciferol 5,000 IU PO daily x 40 days|Patients in this arm receive 5,000 IU of Cholecalciferol (Vitamin D3) via PO route daily for 40 days for a total of 200,000 IU. These patients also receive 1200 mg of daily Calcium Carbonate via PO route for 40 days.
62391933|NCT01111331|EXPERIMENTAL|BI 10773 25 mg|1 tablet 25 mg BI 10773 qd for 5 days
62567938|NCT01330823|ACTIVE_COMPARATOR|L-Carnitine|L-Carnitine 4 g daily for Intervention
62567939|NCT01330823|PLACEBO_COMPARATOR|Placebo|Placebo (tartaric acid)
62773271|NCT04014387|ACTIVE_COMPARATOR|Suvorexant Arm|Participants will be given one week of Suvorexant.
62773272|NCT04014387|PLACEBO_COMPARATOR|Placebo Arm|Participants will be given one week of a placebo pill.
62773273|NCT04819295||Latinx Adolescents|
62773274|NCT04819295||Parents of Latinx Adolescents|
62773275|NCT04819295||Healthproviders|
62773276|NCT00763945||1|Patients representing to the hospital with acute coronary syndrome
62773277|NCT03470753|ACTIVE_COMPARATOR|Exercise Amount|Phase 1: 2 or 4 exercises.
62773278|NCT03470753|ACTIVE_COMPARATOR|Type of instruction|Phase 1: Handout on paper versus handout and visual demonstration/performance.
62773279|NCT03470753|ACTIVE_COMPARATOR|Delivery Type|Phase 2: Handout vs electronic delivery
62773280|NCT03470753|EXPERIMENTAL|Reminder Type|Phase 2: Mobile reminders vs no mobile reminders
62773281|NCT01587092|PLACEBO_COMPARATOR|Usual Working Condition Group|Participants assigned to the usual working condition control group will continue to work in their usual environment and accustomed manner. The control group participants will have access to the Workstations at the completion of study.
62773282|NCT01587092|ACTIVE_COMPARATOR|WorkStation Intervention Group|Participants will be asked to walk for up to 1.5 hours per day on the treadmill. This will be split into two 45 minute sessions per day. Behavioral support will focus on adherence to frequency (attending scheduled sessions). Participants self-select speed of walking and time (they have up to 45 minutes allotted, but may choose less as they like).
62773283|NCT01033318|EXPERIMENTAL|Part 1 A-1|"Part 1; Panel A; Sequence 1:~2 mg MK1809 / placebo / 50 mg MK1809 / 150 mg MK1809 / 100 mg Losartan"
62773284|NCT01033318|EXPERIMENTAL|Part 1 A-2|"Part 1; Panel A; Sequence 2:~Losartan / 10 mg MK1809 / placebo / 150 mg MK1809 / 280 mg MK1809"
62773285|NCT01033318|EXPERIMENTAL|Part 1 A-3|Part 1; Panel A; Sequence 3 2 mg MK1809 / 10 mg MK1809 / Losartan / Placebo / 280 mg MK1809
61997661|NCT01023165|EXPERIMENTAL|IV bolus insulin, metabolic integrity|Diabetic patients will complete diagnostic testing and complete quality of life questionnaires at baseline and every six months thereafter while enrolled in the study to monitor and assess progress with metabolic integrity and complications resulting from their diabetes. Comparisons will be performed on lab values performed at baseline and every six months thereafter. Supervising physician may request testing be performed more frequently as deemed medically necessary, testing may include retinal photography, nerve conduction and labs. Meds and medical intervention information is collected weekly at the Intravenous Bolus Insulin treatment sessions. An annual evaluation is performed to review clinical data collected and evaluate progress for analysis and comparison.
61997662|NCT00892164|ACTIVE_COMPARATOR|FOCUS (Group A)|Patients submitted to total thyroidectomy with the use of the FOCUS harmonic scalpel device
61997663|NCT00892164|ACTIVE_COMPARATOR|LIGASURE (Group Β)|Patients submitted to total thyroidectomy with the use of the electrothermal bipolar vessel sealing device
61997664|NCT02299531|EXPERIMENTAL|Low Energy Density, Small Portions|Low meal energy density and small portion sizes
61997665|NCT02299531|EXPERIMENTAL|Low Energy Density, Medium Portions|Low meal energy density and medium portion sizes
61997666|NCT02299531|EXPERIMENTAL|Low Energy Density, Large Portions|Low meal energy density and large portion sizes
61997667|NCT02299531|EXPERIMENTAL|High Energy Density, Small Portions|High meal energy density and small portion sizes
62567940|NCT03035383|EXPERIMENTAL|Purse String Technique|Thyroidectomy closure is performed using purse string technique.
62567941|NCT03035383|ACTIVE_COMPARATOR|Conventional technique|Thyroidectomy closure is performed using conventional technique.
62567942|NCT01653821|EXPERIMENTAL|Carotid body excision|Patients undergoing unilateral or bilateral removal of carotid body.
62773286|NCT01033318|EXPERIMENTAL|Part 1 A-4|Part 1; Panel A; Sequence 4 2 mg MK1809 / Losartan / 50 mg MK1809 / 150 mg MK1809 / Placebo
62567943|NCT02101944|EXPERIMENTAL|Treatment (dexamethasone, carfilzomib, Reolysin)|Patients receive dexamethasone intravenously (IV), carfilzomib IV over 30 minutes, and Reolysin IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62773287|NCT01033318|EXPERIMENTAL|Part 1 A-5|"Part 1; Panel A; Sequence 5:~Placebo / 10 mg MK1809 / 50 mg MK1809 / Losartan / 280 mg MK1809"
62773288|NCT01033318|EXPERIMENTAL|Part 1 B-1|"Part 1; Panel B; Sequence 1:~5 mg MK1809 / Placebo / 100 mg MK1809 / 210 mg MK1809 / Placebo with food"
62773289|NCT01033318|EXPERIMENTAL|Part 1 B-2|"Part 1; Panel B; Sequence 2:~5 mg MK1809 / 25 mg MK1809/ Placebo / Losartan / 25 mg MK1809 with food"
62773290|NCT01033318|EXPERIMENTAL|Part 1 B-3|"Part 1; Panel B; Sequence 3:~5 mg MK1809 / Losartan / 100 mg MK1809 / 210 mg MK1809 / Losartan with food"
62773291|NCT01033318|EXPERIMENTAL|Part 1 B-4|"Part 1; Panel B; Sequence 4:~Losartan / 25 mg MK1809/ 100 mg MK1809 / Placebo / 25 mg MK1809 with food"
61997668|NCT02299531|EXPERIMENTAL|High Energy Density, Medium Portions|High meal energy density and medium portion sizes
61997669|NCT02299531|EXPERIMENTAL|High Energy Density, Large Portions|High meal energy density and large portion sizes
61997670|NCT03127969|OTHER|Fluidotherapy treatment|Patients who received fluidotherapy and joint protection and exercise
61997671|NCT03127969|OTHER|Joint protection and exercise|Patients who received joint protection and exercise
61997672|NCT01471548|EXPERIMENTAL|TKI258|dose escalation
61997673|NCT01138228||Normal vision|This within-subjects design is counter balanced for order. Each operator sees the subject's arm either initially with the normal eye or with the device, then repeats with the second condition (i.e., device or normal vision).
62773292|NCT01033318|EXPERIMENTAL|Part 1 B-5|"Part 1; Panel B; Sequence 5:~Placebo / 25 mg MK1809/ Losartan / 210 mg MK1809 / 25 mg MK1809 with food"
62773293|NCT01033318|EXPERIMENTAL|Part 2 C-1|"Part 2; Panel C; Sequence 1:~50 mg MK1809 / Placebo / 150 mg MK1809 / 210 mg MK1809 / Losartan"
62773294|NCT01033318|EXPERIMENTAL|Part 2 C-2|"Part 2; Panel C; Sequence 2:~50 mg MK1809 / 100 mg MK1809/ Placebo / Losartan / 280 mg MK1809"
62773295|NCT01033318|EXPERIMENTAL|Part 2 C-3|"Part 2; Panel C; Sequence 3:~Losartan / 100 mg MK1809/ 150 mg MK1809 / 210 mg MK1809 / Placebo"
62773296|NCT01033318|EXPERIMENTAL|Part 2 C-4|"Part 2; Panel C; Sequence 4:~50 mg MK1809 / Losartan / 150 mg MK1809 / Placebo / 280 mg MK1809"
62773297|NCT01033318|EXPERIMENTAL|Part 2 C-5|"Part 2; Panel C; Sequence 5:~Placebo / 100 mg MK1809/ Losartan / 210 mg MK1809 / 280 mg MK1809"
62773298|NCT03407885|EXPERIMENTAL|Experimental|Bundled payments for knee and hip replacement
62773299|NCT03407885|NO_INTERVENTION|Control|No intervention
62773300|NCT04445376|EXPERIMENTAL|Intervention Group (Ventilatory)|Breathing Exercise and Aerobic Training will be provided to all the patients.The training session will be given 3 days a week.
62773301|NCT04445376|EXPERIMENTAL|Intervention (Non ventilatory)|Breathing Exercise and Aerobic Training will be provided to all the patients.The training session will be given 3 days a week.
62773302|NCT03993834||Normal modified Allen Test|Patients undergoing transradial coronary angiography with a modified Allen-Test ≤ 15 seconds
62567944|NCT01487395|ACTIVE_COMPARATOR|Donepezil|Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
62773303|NCT03993834||Abnormal modified Allen Test|Patients undergoing transradial coronary angiography with a modified Allen-Test \> 15 seconds
62183080|NCT04055415|EXPERIMENTAL|Intervention group|The MSCs of 1×10\*6/kg will be given in Central venous catheterization for injection at a total 100 ml . Once every week#a total of two times. The Conventional drug therapy（expectorant，bronchodilator） is used.
62183081|NCT04055415|OTHER|Control group|The Conventional drug therapy（expectorant，bronchodilator） is used with the control group
61978521|NCT04826770||AZD/MOD/BNT|Subject receiving one dose of AZD 1222 (Vaxzevria®, Covishield®, ChadOx1 nCoV-19, Oxford University/Astra-Zeneca) followed by one dose of mRNA-1273 (Spikevax®, elasomeran (INN), Moderna) as heterologous basic immunization and one dose of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as booster vaccination
61997674|NCT01138228||Vein Imaging Device|This within-subjects design is counter balanced for order. Each operator sees the subject's arm either initially with the normal eye or with the device, then repeats with the second condition (i.e., device or normal vision).
61997675|NCT02165930|EXPERIMENTAL|Treatment A|
61997676|NCT02165930|EXPERIMENTAL|Treatment B|
61997677|NCT00184015|EXPERIMENTAL|Schedule A|
61997678|NCT00184015|EXPERIMENTAL|Schedule B|
61997679|NCT04705285|EXPERIMENTAL|Erbium:Yag Laser|Patients allocated to the erbium:yag laser are going to undergo 2 sessions of vaginal laser, separated by one month each other.
61997680|NCT04705285|ACTIVE_COMPARATOR|Pelvic floor training|Patients allocated to pelvic floor training, are goin to undergo 10 sessions of pelvic floor exercises coached by an expert physiotherapist.
62183082|NCT05425225|EXPERIMENTAL|Low level LASER therapy|low level laser therapy in continues wave at a wavelength in the near infrared of 830nm. Power density will be 670 mW/cm2. The treatment time per point will be 30 seconds. Probe head will be placed with light pressure on the calf muscles. Three consecutive treatments will be given in a session, with 5 seconds break in between, giving a total irradiation time of 90 seconds
62183083|NCT05425225|ACTIVE_COMPARATOR|Conventional physical therapy|sustained stretching (10 seconds hold), strengthening exercise, balance training and gait training
62183084|NCT00519064|ACTIVE_COMPARATOR|Arm 1|
62183085|NCT00519064|ACTIVE_COMPARATOR|Arm 2|
62183086|NCT04185922|EXPERIMENTAL|Hemopatch|The RARP and BPLND are performed in the usual manner. Towards the end of the operation, Hemopatch is laid over the ends of raw truncated lymphatic tissue.
62183087|NCT04185922|NO_INTERVENTION|Control|The RARP and BPLND are performed in the usual manner. Hemopatch will not be applied to control group.
62183088|NCT02964546||Blood sample|
62567945|NCT01487395|PLACEBO_COMPARATOR|Placebo|The placebo will be presented as tablet comparable to ARICEPT
62567946|NCT04539184|EXPERIMENTAL|Motion Style Acupuncture treatment|Motion Style Acupuncture treatment (2-3 times/week, 2 weeks)
61997681|NCT03149250||Pregnant Preeclampsia|"Pregnant between 35th and 40th week of pregnancy Preeclampisa~Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling"
61997682|NCT03149250||Pregnant No-Preeclampsia|Control Group 1 Pregnant between 35th and 40th week of pregnancy No Preeclampsia Healthy Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling
61997683|NCT03149250||Not Pregnant|"Control group 2 Healthy and not pregnant control group~Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling."
61997684|NCT04055688||Participants with known or suspected high grade gliomas|
61997685|NCT01024296|EXPERIMENTAL|Gastric Bypass Surgery Patients|Surgical site closure using Port Close device
62183089|NCT01413022|ACTIVE_COMPARATOR|Group A (FOLFIRINOX chemotherapy)|"Patients receive FOLFIRINOX chemotherapy comprising of:~* oxaliplatin 85 mg/m2 IV on Day 1~* irinotecan 180 mg/m2 IV on Day 1~* leucovorin 400 mg/m2 IV on Day 1~* 5FU 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1~Treatment is repeated every 14 days for 6 cycles."
62391934|NCT01111331|EXPERIMENTAL|BI 10773 25 mg + Warfarin 25 mg|1 tablet 25 mg BI 10773 qd for 7 days plus 5 tablets 5 mg warfarin single dose
62567947|NCT04539184|ACTIVE_COMPARATOR|Acupuncture treatment|Acupuncture treatment (2-3 times/week, 2 weeks)
62567948|NCT01397877|EXPERIMENTAL|stratum 1|Patients with low grade disease (grade 1 or 2) with positive or negative mutational status
62567949|NCT01851122|PLACEBO_COMPARATOR|Placebo capsule|
62567950|NCT01851122|EXPERIMENTAL|L-theanine capsule|
62567951|NCT00710450||1|Allergic Asthma
62567952|NCT00710450||2|Allergic Rhinitis
62773304|NCT05807984|EXPERIMENTAL|carbon ion therapy for unresectable local recurrent rectal cancer|
62773305|NCT05553418|EXPERIMENTAL|"In-Clinic wear first"|Participant will wear the devices first during 27 hr in-clinic wear first followed by injection, then a short-term wear period in-clinic followed by injection, and finally at home for 27 hrs followed by injection.
62773306|NCT05553418|EXPERIMENTAL|"Home wear first"|Participant will wear the devices at home first with return to clinic for injection, followed by a short-term wear period in-clinic for injection, and finally during a 27hr in-clinic stay for injection
62773307|NCT02497690|ACTIVE_COMPARATOR|In-person ART|In-person approach to provide ART.
62183090|NCT01413022|EXPERIMENTAL|Group B (FOLFIRINOX and PF-04136309)|"Patients receive FOLFIRINOX chemotherapy comprising of:~* oxaliplatin 85 mg/m2 IV on Day 1~* irinotecan 180 mg/m2 IV on Day 1~* leucovorin 400 mg/m2 IV on Day 1~* 5FU 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1~* PF-04136309 500 mg PO BID on days 1-14~Treatment is repeated every 14 days for 6 cycles."
62183091|NCT03420261|ACTIVE_COMPARATOR|Crystalloid group|individualized goal-directed fluid optimization (cardiac preload) by 250 ml boluses of 0.9% saline (up to a maximum of 30 ml/kg)
62183092|NCT03420261|EXPERIMENTAL|Colloid group|individualized goal-directed fluid optimization (cardiac preload) by 250 ml boluses of HES 130/0.4 (up to a maximum of 30 ml/kg, VOLUVEN ®, Fresenius Kabi)
62183093|NCT00818870|ACTIVE_COMPARATOR|Omeprazole 20 mg|
62183094|NCT00818870|EXPERIMENTAL|Vecam 20/300|
62391935|NCT01111331|ACTIVE_COMPARATOR|Warfarin 25 mg|5 tablets 5 mg warfarin single dose
62391936|NCT01073384|EXPERIMENTAL|BDP 3 mg|1 mg TID
62391937|NCT01073384|EXPERIMENTAL|BDP 6 mg|2 mg TID
62391938|NCT01073384|EXPERIMENTAL|BDP 9 mg|3 mg TID
62773308|NCT02497690|EXPERIMENTAL|Telehealth ART|Telemedicine technology approach (e.g. interactive video) to provide ART.
62391939|NCT01073384|EXPERIMENTAL|BDP 12 mg|4 mg TID
62391940|NCT05205681||Pandemic Group|All patients who underwent emergency appendicectomy for suspected acute appendicitis between March 2020 and February 2021
62391941|NCT05205681||Control Group|All patients who underwent emergency appendicectomy for suspected acute appendicitis between March 2019 and February 2020
62391942|NCT00757380|ACTIVE_COMPARATOR|Group 1|Trypan Blue
62391943|NCT00757380|ACTIVE_COMPARATOR|Group 2|Brillant Blue
62391944|NCT05994690|ACTIVE_COMPARATOR|Standard arm Rc|3 consolidation courses (HAM + HA3E + FLA)
62391945|NCT05994690|EXPERIMENTAL|Investigational arm Rc|2 consolidation courses (HAM + FLA)
62391946|NCT05994690|ACTIVE_COMPARATOR|Standard arm Ri|No addition om gemtuzumab ozogamicin (GO) to the first induction course of CD33-positive AML
62773309|NCT02872532|EXPERIMENTAL|Testicular tissue|Children faced with a fertility threatening diagnosis or treatment plan will be offered testicular tissue cryopreservation, particularly if pre-pubescent and without other options to preserve fertility.
61997686|NCT03688672|OTHER|Apioc Lens|All subjects will wear the same, Apioc Contact Lens design.
62183095|NCT00818870|EXPERIMENTAL|Vecam 40/300|
62183096|NCT01822145||ICD recipients|ICD recipients with documented cardiac arrest or ventricular arrhythmias
62183097|NCT01531907||Obese|Premenopausal women, 25 - 40 years with BMI of ≥30kg/m2
62391947|NCT05994690|EXPERIMENTAL|Investigational arm Ri|Addition om gemtuzumab ozogamicin (GO) to the first induction course of CD33-positive AML
62183098|NCT01531907||Lean|Premenopausal women, 25 - 40 years with BMI of 18.5-24.9 kg/m2
62391948|NCT04454281|EXPERIMENTAL|Naloxone HCl Low dose: 0.02 mg|This arm will receive 0.02 mg naloxone hcl on the experimental visit and balance salt solution on the control visit.
62391949|NCT04454281|EXPERIMENTAL|Naloxone HCl High dose: 0.08 mg|This arm will receive 0.08 mg naloxone hcl on the experimental visit and balance salt solution on the control visit.
62183099|NCT06360952||leukopenia|Participants that have abnormal laboratory results for leukopenia. Participants will be assigned to all cohorts they have abnormal laboratory results for.
62183100|NCT06360952||leukocytosis|Participants that have abnormal laboratory results for leukocytosis. Participants will be assigned to all cohorts they have abnormal laboratory results for.
62183101|NCT06360952||neutropenia|Participants that have abnormal laboratory results for neutropenia. Participants will be assigned to all cohorts they have abnormal laboratory results for.
62183102|NCT03602222|ACTIVE_COMPARATOR|In-person training LGBT mental health|In-person training LGBT mental health: Participants randomized to the in-person condition will receive training in LGBT-affirmative mental health counseling face-to-face.
62183103|NCT03602222|EXPERIMENTAL|Mobile training LGBT mental health|Mobile training LGBT mental health: Participants randomized to the mobile training condition will receive training in LGBT-affirmative mental health counseling while on the web.
62183104|NCT01799109|EXPERIMENTAL|nebulization ms and albuterol|magnesium sulfate 150mg \& albuterol 2.5mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
62183105|NCT01799109|ACTIVE_COMPARATOR|nebulized albuterol|albuterol 2.5mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
62391950|NCT04115969||Patients with non-invasive ventilation|
62391951|NCT03641599||heart failure with preserved ejection fraction|
62391952|NCT03641599||heart failure with mid range ejection fraction|
62391953|NCT03641599||heart failure with reduced ejection fraction|
62391954|NCT02178982||standard treatments of ARDS|
62391955|NCT02178982||protocol treatment of ARDS|
62391956|NCT01114191|EXPERIMENTAL|Arm 1|
62391957|NCT00224757|ACTIVE_COMPARATOR|Aspirin|Ascal 100mg once daily
62391958|NCT00224757|ACTIVE_COMPARATOR|Coumarin derivates|Acenocoumarol or fenprocoumon
62773310|NCT01756443|ACTIVE_COMPARATOR|Premixed group|Patients will receive sciatic nerve block with premixed 7.5 mls of 2% lidocaine/adrenaline and 7.5 mls of 0.5% bupivacaine followed by an interval of 90 seconds with an injection of same amount of both drugs.
62773311|NCT01756443|EXPERIMENTAL|Sequential Group|Patients will receive a sciatic nerve block with 15 mls of 2% lidocaine/adrenaline followed by an interval of 90 seconds with 15 mls of 0.5% bupivacaine.
62773312|NCT01878331||Roxolid|Patient do not receive an intervention in the extension study. Rather they are followed on the implant treatment from the core study which included a split-mouth design where all patients received both a Roxolid and SLActive implant.
61997687|NCT03217227||Healthy Volunteer|"Healthy Volunteers will undergo the following study procedures:~1. Cardiovascular Magnetic Resonance Imaging with Exercise Bike~2. Blood Sampling~3. Activity and Lifestyle Questionnaires~4. Fat Mass Measurement"
62183106|NCT01799109|EXPERIMENTAL|nebulized ms|magnesium sulfate 150mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
62391959|NCT01785342||Indeterminate Pulmonary Nodule|The goal will be accomplished by recruiting 500 smokers with indeterminate pulmonary nodules (0.7cm - 3.0cm) on chest CT who will undergo fiberoptic bronchoscopy and will be followed for 2 years until a final diagnosis is made. Biosample and imaging collection will be done.
62567953|NCT04335851|EXPERIMENTAL|Physical Activity Group|"Individuals in this group will be given walk at home exercise video made by American Hearth Association. Videos for each week will be chosen by therapist. They will be asked to do exercise 3 days a week for 4 weeks by following the videos. The intensity and duration of the exercises will be gradually increased by therapists each week. Exercise follow-ups will be done over the phone and by asking individuals to keep an exercise diary."
61997688|NCT03217227||Patients with Stable Angina|"Patients will undergo the following study procedures:~1. Cardiovascular Magnetic Resonance Imaging with Exercise Bike~2. Blood Sampling~3. Cardiac Catheterization~4. Activity, Lifestyle and Medication Compliance Questionnaires~5. Fat Mass Measurement~6. Retinal Photography (Optional)~7. I123 MIBG scan (Optional)"
61997689|NCT06273228|EXPERIMENTAL|Parent participants|Parents receive access to the FCU Online website and telehealth coaching/ support provided by a trained mental health provider. The FCU Online website includes a brief 5-minute assessment, feedback on parents' responses, and online tools to support parenting in areas that were identified as challenges by the assessment. These tools include animated videos, parenting tips, and interactives to help practice parenting skills. Telehealth coaching will focus on Wellness and Self-Care, Parenting and Substance Use, Positive Parenting, Proactive Parenting, and Supervision and Limit Setting.
61997690|NCT02237846|ACTIVE_COMPARATOR|Intra-articular knee injection of UC-MSC|Human umbilical cord tissue-derived mesenchymal stem cells administered into the knee joint once
61997691|NCT02237846|ACTIVE_COMPARATOR|IV injection of UC-MSC|Human umbilical cord tissue-derived mesenchymal stem cells administered once per day for 3 consecutive days
61997692|NCT00075335|EXPERIMENTAL|AMD 3100 (Mozobil plerixafor)|AMD 3100 (Mozobil plerixafor)mobilized peripheral blood hematopoietic progenitor cells from healthy volunteers will be characterized by cellular content and immunological properties.
61997693|NCT05859295|OTHER|Low-Level Light Therapy|All subjects will receive 3 15-minute treatments of low level light therapy
61997694|NCT00006890|EXPERIMENTAL|Prednisone plus Thalidomide|After Autologous Stem Cell Infusion
61997695|NCT05112666||Cancer patients with VTE|Adults diagnosed with active (primary or metastatic) cancer experiencing a hospitalization or emergency department admission or a primary care visit with an incident venous thromboembolism (VTE), being administered rivaroxaban or other direct-acting oral anticoagulants (DOACs) or a low molecular weight heparin (LMWH) will be included.
61997696|NCT00607282|PLACEBO_COMPARATOR|Placebo|normal control group
62183107|NCT00392704|EXPERIMENTAL|Intervention|"All patients initially received treatment with paclitaxel 200 mg/m2, 3 hour IV infusion days 1 and 22; carboplatin area under the curve (AUC) 6.0 IV, days 1 and 22; 5-fluorouracil (5-FU) 200 mg/m2 daily by 24-hour continuous IV infusion, days 1 to 43; bevacizumab 15 mg/kg IV infusion days 1 and 22.~One to three weeks after completing neoadjuvant therapy, patients began treatment with concurrent chemoradiation, bevacizumab, and erlotinib. Radiation therapy began on day 1, with 1.8-Gy single daily doses, Monday through Friday, to a total dose of 68.4 Gy. Paclitaxel 50 mg/m2 was administered by 1-hour IV infusion on days 1 and 22. Erlotinib 150 mg by mouth daily began concurrently with radiation therapy and continued daily during the 7-week course of radiation."
62183108|NCT01726049|ACTIVE_COMPARATOR|Sildenafil|Sildenafil orally 3 times 20mg for 2 weeks , followed by 3 times 60 mg for 10 weeks
62567954|NCT04335851|NO_INTERVENTION|Control Group|Physically inactive individuals will be included to study as control. Individuals will be asked to continue their daily routines.
62567955|NCT05810012|EXPERIMENTAL|PENG Block Group|
61997697|NCT00607282|EXPERIMENTAL|Udenafil|oral administration of placebo for Udenafil (Dong-A Pharmaceutical co., Ltd, Seoul, Korea)
61997698|NCT01100411|ACTIVE_COMPARATOR|Air Optix Aqua|Contact lens material: Lotrafilcon A
61997699|NCT01100411|ACTIVE_COMPARATOR|Biofinity|Contact lens material: Comfilcon A
61997700|NCT01100411|ACTIVE_COMPARATOR|Proclear|Contact lens material: Omafilcon A
61997701|NCT01100411|ACTIVE_COMPARATOR|Acuvue Oasys|Contact lens material: Senofilcon A
61997702|NCT01100411|ACTIVE_COMPARATOR|Acuvue 2|Contact lens material: Etafilcon A
61997703|NCT01100411|ACTIVE_COMPARATOR|Purevision|Contact lens material: Balafilcon A
61997704|NCT00404352|ACTIVE_COMPARATOR|RNF 44 mcg three times weekly|
61997705|NCT00404352|ACTIVE_COMPARATOR|RNF 44 mcg once weekly and placebo twice weekly for blinding|
61997706|NCT00404352|PLACEBO_COMPARATOR|Placebo three times weekly|
61997707|NCT04413578|EXPERIMENTAL|Dexcom G6 (Intervention Group)|• Intervention group: CGM using a Dexcom G6 to measure glycosylated hemoglobin levels every five minutes. Patients will be asked to download the Dexcom G6 and Clarity applications (to have access to their real-time data) and be given a link to complete an exit survey in REDCap near the end of their study participation. Data will be sent via Bluetooth and then exported by the Intermountain research team into a Tableau (or similar) dashboard for data analysis/comparison
62391960|NCT01700452||patients suspected of having lung cancer|Subjects presenting with 0.8 - 3 cm solitary pulmonary nodules with high probability for malignance. The subject must be scheduled for a lung biopsy procedure to determine clinical diagnosis.
62391961|NCT00937703|PLACEBO_COMPARATOR|Group1: Control group|face to face visit à T4mounths
62183109|NCT01726049|PLACEBO_COMPARATOR|Placebo|placebo orally 3 times 20mg tablets, followed by 3 times 60 mg for 10 weeks
62391962|NCT00937703|ACTIVE_COMPARATOR|Group2: IVS Group|face to face visit at T4mounths plus telephone visits each 2 weeks
62391963|NCT00937703|ACTIVE_COMPARATOR|Group3: PDAphone group|PDA system face to face visit at T4mounths plus telephone visits each 2 weeks
62391964|NCT03773146|NO_INTERVENTION|Control|No airtime incentive was given for completing the survey
62391965|NCT03773146|EXPERIMENTAL|1X Incentive|1X Airtime Incentive
62391966|NCT03773146|EXPERIMENTAL|Lottery|Lottery Airtime Incentive
62391967|NCT01102439|ACTIVE_COMPARATOR|Standard dose clopidogrel|300 mg Loading x 1 day, 75 mg/d x 13 days
62391968|NCT01102439|EXPERIMENTAL|Double dose clopidogrel|600 mg Loading x 1 day, 150 mg/d x 6 days, 75 mg/d x 7 days
62183110|NCT00230945|EXPERIMENTAL|1|Patient-oriented education and support intervention
62391969|NCT01102439|ACTIVE_COMPARATOR|Standard dose aspirin|Aspirin 81mg/d x 14 days
62391970|NCT01102439|EXPERIMENTAL|High dose aspirin|Aspirin 325 mg/d x 14 days
62391971|NCT03355001||Skin Closure|Monosyn® Quick will be used for skin closure for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
62391972|NCT03355001||Urology|Monosyn® Quick will be used in urology for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
62391973|NCT03355001||Gynecology|Monosyn® Quick will be used in gynecology for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
62391974|NCT01356615|EXPERIMENTAL|enoxaparin|enoxaparin sodium (Clexane) (40 mg) followed prospectively for 3 months (36 dialyses)
62391975|NCT01356615|ACTIVE_COMPARATOR|standard unfractionated heparin|standard unfractionated heparin followed prospectively for 3 months (36 dialyses)
62391976|NCT04926129||Subgroup 1|Participant's eye with Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) ≥74 letters (Equivalent to: Snellen 6/9 or 20/32; decimal 0.63; Logarithm of the minimum angle of resolution \[LogMAR\] 0.2) will be enrolled.
62391977|NCT04926129||Subgroup 2|Participant's eye with ETDRS BCVA 34-73 letters, inclusive (Equivalent to: Snellen 6/12 - 6/60 or 20/40 - 20/200; decimal 0.5 - 0.1; LogMAR 0.3-1.0) will be enrolled.
62391978|NCT02972658|EXPERIMENTAL|AZES Lanabecestat 20 milligrams (mg)/AZFD Lanabecestat 20 mg|Participants who received Lanabecestat 20 mg in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
62567956|NCT05810012|EXPERIMENTAL|FICB Group|
62567957|NCT05872269|EXPERIMENTAL|Saroglitazar 4 mg tablets|Oral (once daily ) during 364 days/52 weeks of treatment period.
62567958|NCT04328038||USA|Cohort from the USA
62183111|NCT00230945|EXPERIMENTAL|2|Couple-oriented education and support intervention
62391979|NCT02972658|EXPERIMENTAL|AZES Lanabecestat 50 mg/AZFD Lanabecestat 50 mg|Participants who received Lanabecestat 50 mg in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.
62567959|NCT04328038||Germany|Cohort from Germany
62773313|NCT01878331||SLActive|Patient do not receive an intervention in the extension study. Rather they are followed on the implant treatment from the core study which included a split-mouth design where all patients received both a Roxolid and SLActive implant.
62773314|NCT04094584|EXPERIMENTAL|Multimodal Intervention|"The intervention is multimodal and consists of:~1. Intramuscular injections of 380mg extended-release Naltrexone, given once monthly for 3 months.~2. Case Management services"
62773315|NCT04607876|ACTIVE_COMPARATOR|Standard of Care|The FAR Control Arm will involve risk factor assessment in first degree relative subjects and implementation of an education program for the randomized participants and their primary care provider.
62791492|NCT05192460|EXPERIMENTAL|neoantigen tumor vaccine with or without PD-1/L1|In dose escalation phase, subject will only receive neoantigen tumor vaccine. In dose expansion phase, subject will receive neoantigen tumor vaccine combination with PD-1/L1.
62773316|NCT04607876|OTHER|Enhanced Intervention|"This intervention will involve risk factor assessment and web based risk factor management.~* Technological facilitators including a population health care management portal which will be used to facilitate risk factor management to monitor risk factor control, and to facilitate new symptom and complications management;~* Telemedicine to allow FAR Coordinator and providers capability for evaluation and management in home/facility, which facilitates real time communication and collaboration and virtual evaluation of the subject when higher level of intervention is required~* Educational portal provides a common educational platform for professional and subject education around stroke symptoms, complications, recovery and risk factor management, and lifestyle changes.~* FAR EI teams will be coordinated at FAR Central where a centralized group of specialists initiate and monitor risk factor mitigation strategies tailored to the individual participant."
62773317|NCT04841369|EXPERIMENTAL|1A|Subjects received four doses of PCV13i at 2 months of age (At least 6 weeks old)
62773318|NCT04841369|ACTIVE_COMPARATOR|1B|Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old)
62773319|NCT04841369|EXPERIMENTAL|2A|Subjects received four doses of PCV13i at 3 months of age
62773320|NCT04841369|EXPERIMENTAL|3A|Subject received three doses of PCV13i at 7 to 11 months of age
62773321|NCT04841369|ACTIVE_COMPARATOR|3B|Subject received three doses of PCV13 at 7 to 11 months of age
62773322|NCT04841369|EXPERIMENTAL|4A|Subjects received two doses of PCV13i at 12 to 23 months of age
62773323|NCT04841369|ACTIVE_COMPARATOR|4B|Subjects received two doses of PCV13 at 12 to 23 months of age
62773324|NCT04841369|ACTIVE_COMPARATOR|5A|Subjects received one dose of PCV13i at 2 to 5 years old.
62773325|NCT04841369|ACTIVE_COMPARATOR|5B|Subjects received one dose of PCV13 at 2 to 5 years old.
62773326|NCT04598269|EXPERIMENTAL|ATI-1777|ATI-1777 topical solution 2.0% w/w, twice daily
62773327|NCT04598269|PLACEBO_COMPARATOR|Vehicle|Vehicle topical solution, twice daily
62773328|NCT01365624|EXPERIMENTAL|Ketorolac tromethamine|
62773329|NCT04527939|ACTIVE_COMPARATOR|three-dimensional endorectal ultrasonography|three-dimensional endorectal ultrasonography
62773330|NCT04527939|SHAM_COMPARATOR|magnification chromoendoscopy.|magnification chromoendoscopy.
62773331|NCT02789891|EXPERIMENTAL|D2 Lymphadenectomy including No. 14v|Laparoscopic distal gastrectomy with D2 lymphadenectomy including No. 14v lymph node dissection will be performed for the treatment of patients assigned to this group
62773332|NCT02789891|ACTIVE_COMPARATOR|D2 lymphadenectomy excluding No. 14v|Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v lymph node dissection will be performed for the treatment of patients assigned to this group
62773333|NCT02618668|EXPERIMENTAL|Ketamine / Propofol Admixture|Ketamine / Propofol Admixture: I.V propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+ 4 ml saline in a 20-ml syringe which resulted in 0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol.
62773334|NCT02618668|ACTIVE_COMPARATOR|Propofol|I.V propofol 2 mg/kg
62773335|NCT03755908||asthmatic children|Children with the diagnosis of asthma and normal spirometry results. Each subject will undergo evaluation including: asthma control questionnaire, spirometry, FOT and Fractional exhaled nitric oxide (FeNO).
62773336|NCT01628003|ACTIVE_COMPARATOR|healthy persons|
62773337|NCT01628003|EXPERIMENTAL|patients after moderate-severe TBI|
62773338|NCT04828005|EXPERIMENTAL|Intranasal Nalmefene|Nalmefene hydrochloride nasal spray, 3mg, 1 spray
62773339|NCT04828005|ACTIVE_COMPARATOR|Intranasal Naloxone|Naloxone hydrochloride nasal spray, 4mg, 1 spray
62773340|NCT03964792|EXPERIMENTAL|DREPAGLOBE drug product|The DREPAGLOBE is a genetically modified cell therapy product that consists of autologous human CD34+ hematopoietic stem and progenitor cells (HSPCs) that are enriched in CD34+ cells which have been transduced ex vivo with the lentiviral vector, GLOBE1, expressing an anti-sickling β-globin protein (AS3) containing three amino acid substitutions in the wild-type β-globin gene.
62773341|NCT03392623|OTHER|Control group|Macules of melasma without any treatment
62773342|NCT03392623|EXPERIMENTAL|Niacinamide group|Macules of melasma treated with topical Niacinamide cream 4% for 8 weeks
62773343|NCT03392623|EXPERIMENTAL|Retinoic acid group|Macules of melasma treated with topical retinoic acid 0.05% for 8 weeks
62391980|NCT02972658|EXPERIMENTAL|AZES Placebo/AZFD Lanabecestat 20 mg|Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
62773344|NCT03392623|PLACEBO_COMPARATOR|Sunscreen group|Macules of melasma treated with sunscreen cream with a 50 sun protection factor for 8 weeks
62773345|NCT03465553|EXPERIMENTAL|Short course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation.
62773346|NCT03281304|EXPERIMENTAL|CP-690,550 5 mg|CP-690,550 5 mg tablet by mouth twice a day (BID)
62773347|NCT03281304|EXPERIMENTAL|CP-690,550 10 mg|CP-690,550 10 mg BID
62773348|NCT02472613|EXPERIMENTAL|traditional acupuncture & placebo|Apply traditional acupuncture to treat the ischemic post-stroke depression according to TCM theory.
62773349|NCT02472613|ACTIVE_COMPARATOR|sham-acupoint acupuncture & fluoxetine|Fluoxetine was given at a dose of 20 mg/day. sham-acupoint will be penetrated for treat the ischemic post-stroke depression.
62773350|NCT06079151|EXPERIMENTAL|Nasal high-flow 30 L/min and then 50 L/min|The patient will be placed successively under nasal high-flow 30 L/min during 20 min and then 50 L/min during 20 min.
62773351|NCT06079151|EXPERIMENTAL|Nasal high-flow 50 L/min and then 30 L/min|The patient will be placed successively under nasal high-flow 50 L/min during 20 min and then 30 L/min during 20 min.
62773352|NCT06019806|EXPERIMENTAL|postural correction group A|"1. Chin tuck (deep cervical flexor)~2. Strengthening shoulder retractors~3. Sternocleidomastoid muscle stretch~4. Pectoralis stretch"
62773353|NCT06019806|ACTIVE_COMPARATOR|Control group B|postural Correction education
62773354|NCT06135610||Pre-COVID|Patients identified in Kern County who presented to the emergency department with a gunshot wound (GSW), stab wound, or assault between March 2019 and February 2020 The group was further sub-classified based on the incident zip code. Kern County zip codes were combined into urban regions as NW (zip codes:93312, 93314), NE (93301, 93305, 93306, 93308), SW (93311, 93313), and SE (93304, 93307, 93309, 93241), with a separate category defined as rural (outside Bakersfield city limits).
62183112|NCT04924049|EXPERIMENTAL|Experimental|The video-assisted education group also received routine treatment and care per protocol. Additionally, this patient group watched patient education through video in the patient room before TKR. The contents of the VE were developed by the researchers and included early postoperative care for TKR (knee positioning, early mobilization, pain control, and cold application), ADLs at home (bathing and toileting, eating, sleeping, vehicle driving, housekeeping, sexual life, praying, and maintaining home safety), and gradual exercise at home (for the first 90 days after discharge).
62567960|NCT04614909|EXPERIMENTAL|Arm A Newly diagnosed glioblastoma treated with pamiparib- ARM CLOSED|Participants undergoing resection for a presumed newly diagnosed glioblastoma (nGBM) will be treated with pamiparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive pamiparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
62567961|NCT04614909|EXPERIMENTAL|Arm B Recurrent glioblastoma treated with pamiparib|Recurrent glioblastoma (rGBM) patients who are scheduled for surgery and expected to receive postoperative fractionated radiotherapy (RT) will be treated with pamiparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive pamiparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
62183113|NCT04924049|NO_INTERVENTION|Control|The control group received routine treatment and care per protocol.
62183114|NCT01271023|EXPERIMENTAL|Closed-Loop Control|The Control to Range algorithm will be used in conjunction with continuous glucose monitoring and insulin pump delivery to manage the subject's blood glucose.
62183115|NCT05816577|ACTIVE_COMPARATOR|EcN|E Coli Nissle wildtype 10\^11 once daily for 7 days
62183116|NCT05816577|EXPERIMENTAL|EcN colibactin-knockout|EcN colibactin-knockout 10\^11 once daily for 7 days
62183117|NCT00937521|OTHER|1|Vaccine candidate formulation I
62567962|NCT04614909|EXPERIMENTAL|Arm C Recurrent glioblastoma treated with olaparib - ARM CLOSED|Arm C will be an exploratory arm in recurrent glioblastoma patients (rGBM) treated with Olaparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive olaparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
62183118|NCT00937521|OTHER|2|Vaccine candidate formulation II
62183119|NCT00937521|OTHER|3|Vaccine candidate formulation III
62183120|NCT00937521|OTHER|4|Vaccine candidate formulation IV
62183121|NCT00937521|OTHER|5|Vaccine candidate formulation V
62183122|NCT00937521|OTHER|6|Vaccine candidate formulation VI
62183123|NCT00937521|OTHER|7|Control
62183124|NCT00937521|OTHER|8|Vaccine candidate formulation I with antipyretic
62183125|NCT05694962|EXPERIMENTAL|Treatment group|supportive care and standard of care drug therapies (i.e., glucocorticosteroids, Paxlovid, etc.) plus 1.5Gy single treatment of whole-lung radiation therapy
62391981|NCT02972658|EXPERIMENTAL|AZES Placebo/AZFD Lanabecestat 50 mg|Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.
62391982|NCT04309175|EXPERIMENTAL|Slow-Fast|
62391983|NCT04309175|EXPERIMENTAL|Fast-Slow|
62567963|NCT06576336|ACTIVE_COMPARATOR|2D group|patients underwent to 2D laparoscopic adrenalectomy for adrenal mass.
62567964|NCT06576336|EXPERIMENTAL|3D group|patients underwent to 3D laparoscopic adrenalectomy for adrenal mass.
62567965|NCT04943146||control group|
62183126|NCT05694962|NO_INTERVENTION|Control group|supportive care and standard of care drug therapies (i.e., glucocorticosteroids, Paxlovid, etc.)
62183127|NCT05588947|EXPERIMENTAL|Tele-TaCAS|Two Take Charge sessions delivered by telehealth six weeks apart, the first being at 2 to 16 weeks after stroke, the earliest possible time after discharge to the community.
62183128|NCT05588947|ACTIVE_COMPARATOR|Control|Life After Stroke: Survivor Stories video played by telehealth at 2 to 16 weeks after stroke, the earliest possible time after discharge to the community.
62183129|NCT04959578|ACTIVE_COMPARATOR|Erythropoietin|Recombinant Human Erythropoietin
62567966|NCT04943146||P+A group|aspirin: tablet 100mg qd 2-5weeks prednisone: tablet 10mg qd 2-5weeks
62391984|NCT02324426|EXPERIMENTAL|Reduced Glutathione|The study medication is packaged in sterile 1 ml pre-filled syringes, each containing 200 mg/ ml of reduced glutathione (GSH), which will be delivered intranasally.
62391985|NCT00394173|EXPERIMENTAL|1|
62773355|NCT06135610||COVID|Patients identified in Kern County who presented to the emergency department with a gunshot wound (GSW), stab wound, or assault between March 2020 - February 2021. The group was then further sub-classified based on the incident zip code. Kern County zip codes were combined into urban regions as NW (zip codes:93312, 93314), NE (93301, 93305, 93306, 93308), SW (93311, 93313), and SE (93304, 93307, 93309, 93241), with a separate category defined as rural (outside Bakersfield city limits).
62183130|NCT04959578|EXPERIMENTAL|Darbepoetin alfa|Darbepoetin Alpha
62391986|NCT00394173|PLACEBO_COMPARATOR|2|
62391987|NCT03342807|EXPERIMENTAL|Group Insulin|
62773356|NCT04231916|EXPERIMENTAL|Patients aged 5-18 years|"Patients with Osteogenesis Imperfecta (with known vertebral fractures)for phase one of the study.~Patients with Osteogenesis Imperfecta for phase 2 of the study In both groups patients will be aged 5 years and over"
62773357|NCT01954563|EXPERIMENTAL|Group 1|Receive 5x10\^7 MVA85A by aerosol at day 0, followed by boost intradermal vaccination of 5x10\^7 MVA85A at day 28.
62773358|NCT01954563|EXPERIMENTAL|Group 2|Receive 5x10\^7 MVA85A by intradermal injection at day 0, followed by boost aerosol vaccination of 5x10\^7 MVA85A at day 28.
62773359|NCT01954563|EXPERIMENTAL|Group 3|Receive 5x10\^7 MVA85A by intradermal injection at day 0, followed by boost intradermal vaccination of 5x10\^7 MVA85A at day 28.
62773360|NCT00558272|EXPERIMENTAL|AZD0530 175 mg|AZD0530 (saracatinib) 175 mg once daily
62773361|NCT00558272|EXPERIMENTAL|Zoledronic Acid 4 mg|Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period
62773362|NCT05771961|ACTIVE_COMPARATOR|Rotational Atherectomy|Patients who are scheduled to have rotational atherectomy will be labeled in this group; patients in this group will have invasive and non-invasive microvascular testing before and after the rotational atherectomy procedure.
62773363|NCT05771961|ACTIVE_COMPARATOR|Conventional Stenting|Patients who are scheduled to have conventional stenting will be labeled in this group; patients in this group will have invasive and non-invasive microvascular testing before and after the conventional stenting procedure.
62773364|NCT03101085|OTHER|S-equol First, Then Placebo|In this arm, participants receive S-equol 50mg twice daily for one month, followed by placebo twice daily for one month. There was no washout period.
62773365|NCT03101085|OTHER|Placebo First, Then S-equol|In this arm, participants receive placebo twice daily for one month, followed by S-equol 50mg twice daily for one month. There was no washout period.
62773366|NCT03704610|EXPERIMENTAL|INFLIXIMAB|Infliximab 5 mg/kg D1-D15, then infliximab every 4 weeks W6-W10-W14
62773367|NCT03704610|OTHER|Placebo|placebo injection D1-D15 then infliximab 5 mg/kg W6-W8-W12-W16-W20
62391988|NCT03342807|EXPERIMENTAL|Group Aphesis|
62391989|NCT06349109||WPW group|
62391990|NCT06349109||Control Group|
62391991|NCT05585099|EXPERIMENTAL|Experimental|Participants will walk in retro walking exercise on lower body positive pressure treadmill.
62183131|NCT05587452||Healthy group|People without colorectal adenoma or cancer
62183132|NCT05587452||Advanced adenoma group|People with colorectal adenoma
62183133|NCT05587452||Colorectal cancer group|People with colorectal cancer
62391992|NCT05585099|OTHER|Control|Participants will walk in forward walking exercise on lower body positive pressure treadmill.
62391993|NCT01028599|EXPERIMENTAL|Exercise|
62391994|NCT05375058||pandemic group (2020)|includes patients who presented to the hospital during the period of acute restrictions and shutdowns extending from the 17th of March to the 6th of June 2020
62391995|NCT05375058||pre-pandemic group (2019)|which represents the same period in the previous year
62391996|NCT02361606|EXPERIMENTAL|Internet CBT intervention|Eligible candidates were offered to participate in an internet cognitive behavioral intervention.
62391997|NCT03016520|EXPERIMENTAL|Test drug|DWJ1392
62773368|NCT03492931|EXPERIMENTAL|Treatment arm|Single dose of ticagrelor based on age
62773369|NCT05903859|EXPERIMENTAL|Full dose group|Participants in this group will receive the full dose of probenecid for a total of 90 days.
62773370|NCT05903859|EXPERIMENTAL|Half dose group|Participants in this group will receive half the dose of probenecid for a total of 90 days.
62791493|NCT04748614||Before SARS-Cov2|Before SARS-Cov2
62183134|NCT04005456|OTHER|N of 1 Tent|Personalized dietary supplements, food plans, and behavioral change support program for a broad group (both an employee population and those recruited from practitioner practices) inclusive of all study Participants and specifically generally healthy individuals, those with established disease/conditions requiring a personalized approach, those with diseases/conditions currently with low prevalence in our study population and those women currently pregnant or breastfeeding.
62183135|NCT04005456|OTHER|Wellness Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals characterized by minimal physical complaints and laboratory biomarkers of modest clinical significance.
62773371|NCT05903859|PLACEBO_COMPARATOR|Control-placebo group|Participants in this group will receive a placebo dose (No active ingredient) for a total of 90 days.
62773372|NCT00229502||1|Subjects receiving Avonex
62183136|NCT04005456|OTHER|Elevated Homocysteine Bucket|Personalized dietary supplements, food plans, and behavioral change support program for individuals from the Wellness Umbrella with elevated homocysteine level ≥ 10.4 µmol/L.
62183137|NCT04005456|OTHER|Dental Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals with established dental disease.
62183138|NCT04005456|OTHER|Immune Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals with autoimmune/inflammatory conditions (excluding metabolic disorders/atherosclerosis)
62183139|NCT04005456|OTHER|Elevated Anti-Nuclear Antibodies (ANA) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with elevated levels of antinuclear antibodies (preclinical symptomatology only).
62391998|NCT03016520|EXPERIMENTAL|Reference drug|DWC20164
62773373|NCT00229502||2|Subjects receiving Rebif
62773374|NCT00229502||3|Subjects receiving Copaxone
62773375|NCT00229502||4|Healthy controls
62773376|NCT04035746||Single-group study|Assessment of microcirculation, brain plasticity and clinical function
62773377|NCT05656781|EXPERIMENTAL|Intervention Arm - Brief Intervention & Contact|Brief education about suicidal behaviour and follow up contacts for 6 months in addition to treatment as usual. follow up will occur at the following time points post discharge: weeks 1, 2, 4, 6, 8, 12, 16 and 20. this will occur in addition to treatment as usual.
62773378|NCT05656781|NO_INTERVENTION|Control|Control will continue treatment as usual which is whatever the clinical team decides upon post discharge. Data will be collected on repeated suicidal behaviour through medical records with consent.
62773379|NCT00257660|EXPERIMENTAL|1|Drug: abobotulinumtoxinA (Dysport®)
62773380|NCT00257660|PLACEBO_COMPARATOR|2|Placebo
62773381|NCT05933590||Chronic Migraine Group|This group consists of 25 individuals diagnosed with chronic migraine. They will undergo cervical joint repositioning error assessment in different head positions.
62773382|NCT05933590||Control Group|This group consists of 25 age-matched healthy controls without a history of migraine. They will undergo the same cervical joint repositioning error assessment in different head positions.
62391999|NCT02247726|PLACEBO_COMPARATOR|Treatment Group A|Saline Placebo (0.5mL injection)
62392000|NCT02247726|EXPERIMENTAL|Treatment Group B|RSV F vaccine with adjuvant (0.5mL injection)
62773383|NCT06297005||Vapers|Women who vape during pregnancy
62773384|NCT06297005||Smokers|Women who smoke tobacco during pregnancy
62773385|NCT06297005||Controls|Women who neither smoke tobacco or vape during pregnany
62773386|NCT01623388||Phase I|
62773387|NCT01412385|EXPERIMENTAL|Epoch 1 (intravenous pre-study treatment) + Epoch 2|Study Epoch 1 (13 weeks): treatment with KIOVIG (once every 3 or 4 weeks, dose as during pre-study period) + Study Epoch 2 (same for all subjects, 51 weeks): treatment with IGSC, 20% (every week, dose to be calculated on the basis of weekly equivalents)
62773388|NCT01412385|EXPERIMENTAL|Epoch 1 (subcutaneous pre-study treatment) + Epoch 2|Study Epoch 1 (12 weeks): treatment with SUBCUVIA (once every week or once every two weeks, dose as during pre-study period) + Study Epoch 2 (same for all subjects, 51 weeks): treatment with IGSC, 20% (every week, dose to be calculated on the basis of weekly equivalents)
62791494|NCT04748614||After SARS-Cov2|After SARS-Cov2
62567967|NCT03866681|EXPERIMENTAL|Patients cohort|A total of 40 patients with refractory classic PNH will be included and will be intervened by a combined therapy including sirolimus and low-dose warfarin
62567968|NCT02375360||Children 8-12- control|Children aged 8-12 years with food allergy who are not undergoing oral immunoterapy
62183140|NCT04005456|OTHER|Autoimmune Conditions Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with an established diagnosis of an autoimmune conditions (Systemic Lupus Erythematosus, Rheumatoid Arthritis, Inflammatory Bowel Disease and Hashimoto's Thyroiditis) with ANA level \>1:80 titer, rheumatoid factor (RF) ≥ 14 IU/ml, fecal calprotectin ≥ 50 mcg/g and thyroid autoantibody levels specifically thyroglobulin antibodies ≥ 115 IU/ml and/or thyroid peroxidase antibodies ≥ 35 IU/ml.
62183141|NCT04005456|OTHER|Symptomatic Fatigue/Myalgias Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a broad employee health group with symptoms of persistent fatigue and myalgias.
62183142|NCT04005456|OTHER|Gastrointestinal Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of gastrointestinal health and of environmental toxicity or dysfunction related to detoxification of external toxins and internal metabolites.
62183143|NCT04005456|OTHER|Irritable Bowel Syndrome (IBS) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of gastrointestinal health.
62567969|NCT02375360||Parents 0-12 - control|Parents to children aged 0-12 years with food allergy who are not undergoing oral immunoterapy
62567970|NCT02375360||Children 8-12 - OIT|Children aged 8-12 years with food allergy who are undergoing oral immunoterapy
62567971|NCT02375360||Teenagers 13-17 - OIT|Teenagers aged 13-17 years with food allergy who are undergoing oral immunoterapy
62567972|NCT02375360||Adults >18 - OIT|Adults\> 18 years with food allergy who are undergoing oral immunoterapy
62567973|NCT02375360||Parents 0-12 - OIT|Parents to children aged 0-12 years with food allergy who are undergoing oral immunoterapy
62567974|NCT02375360||Parents 13-17 - OIT|Parents to teenagers aged 13-17 years with food allergy who are undergoing oral immunoterapy
62567975|NCT04665219|ACTIVE_COMPARATOR|Control group|Only receive a standard message.
62567976|NCT04665219|EXPERIMENTAL|Test group|Receive HBM-based messages.
62567977|NCT02309476|EXPERIMENTAL|PASCAL Laser, Green Laser 0.75|"Barely Visible Pascal laser grid using 532nm green wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
62773389|NCT03127423|EXPERIMENTAL|Hybrid ablation group|Patients in this group will receive one-stop intervention with totally thoracoscopic surgical ablation and percutaneous catheter ablation.
62791495|NCT06244667|ACTIVE_COMPARATOR|cervical faset median block with lidocaine|cervical faset median block with lidocaine
61997708|NCT04413578|PLACEBO_COMPARATOR|Contour NextOne (Standard of Care) Glucometer|• Control group: A standard finger-prick protocol that will require patients to continue with their daily fingerprick regimen established by their physician. This group will be given a Contour Next One meter to ensure that each patient is receiving the same level of accuracy by the same device. A review by Ekhlaspour et al of 17 glucose meters demonstrated wide variability, with only two devices achieving the 2013 ISO standard (with the most accurate being the Contour Next). Patients in the control group will be asked to download the Contour Next application which will send data via Bluetooth similar to above. Data will be aggregated, and protected health information removed prior to analysis (by Intermountain Healthcare and Savvysherpa). At the end of the study, patients will be asked to complete a short survey in REDCap about their willingness to participate in future studies.
61997709|NCT05372120|EXPERIMENTAL|ICP-192|20 mg once daily
61997710|NCT05274256|OTHER|patients with missing teeth in maxillary aesthetic zone|
62567978|NCT02309476|EXPERIMENTAL|PASCAL Laser, Green Laser 1 burn|"Barely Visible Pascal laser grid using 532nm green wavelength, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
62567979|NCT02309476|EXPERIMENTAL|PASCAL Laser, 70% Yellow Laser 0.75|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
62567980|NCT02309476|EXPERIMENTAL|PASCAL Laser, 70% Yellow Laser 1|"Pascal EM at 70% 577nm yellow, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
62567981|NCT02309476|EXPERIMENTAL|PASCAL Laser, 40% Yellow Laser 0.75|"Pascal EM at 40% 577nm yellow, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 40% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
62773390|NCT03127423|ACTIVE_COMPARATOR|Thoracoscopic surgical ablation group|Patients in this group will receive only totally thoracoscopic surgical ablation with Fuwai lesion set.
61997711|NCT03941522|EXPERIMENTAL|Intervention group (23-hour stay)|Patients randomized to the group 23-hour stay will be discharged on the day after their surgery if they meet the discharge criteria.
62567982|NCT02309476|EXPERIMENTAL|PASCAL Laser, 40% Yellow Laser 1|"Pascal EM at 40% 577nm yellow laser grid, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 40% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
62567983|NCT05893823||Cases|Patients that have symptomatic psoas impingement in a protruding acetabular cup documented by a Pelvis CT scan
62567984|NCT05893823||Controls|Asymptomatic patients with a protruding acetabular cup documented by a Pelvis CT scan
62567985|NCT00059930|EXPERIMENTAL|Adjuvant Hepatic Arterial Infusion & Combination Chemotherapy|This is a Phase I study with the primary objective of defining the maximum tolerated dose of hepatic arterial floxuridine (FUDR) and dexamethasone (Dex) given via an implanted pump in combination with intravenous oxaliplatin plus systemic fluorouracil (5FU)/leucovorin (LV) in the adjuvant setting after resection of hepatic metastases from colorectal cancer. A total of eleven dose levels will be considered.
62567986|NCT04303689|EXPERIMENTAL|Colchicine|3 weeks of treatment with colchicine
62567987|NCT04303689|PLACEBO_COMPARATOR|Placebo|3 weeks of placebo-treatment
62773391|NCT00590577|EXPERIMENTAL|001|Paliperidone palmitate 25 mg eq. Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8 36 64
62773392|NCT00590577|EXPERIMENTAL|002|Paliperidone palmitate 100 mg eq. Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8 36 64
62183144|NCT04005456|OTHER|Detoxification Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of environmental toxicity or dysfunction related to detoxification of external toxins and internal metabolites.
62183145|NCT04005456|OTHER|Wellness Detoxification Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals characterized by minimal physical complaints and normal biomarkers.
62567988|NCT01700062|EXPERIMENTAL|Medium calorie|
62567989|NCT01700062|EXPERIMENTAL|standard calorie|
62567990|NCT02348918|ACTIVE_COMPARATOR|Luminate 1.0mg group|Stage 1- Luminate 1.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
62773393|NCT00590577|EXPERIMENTAL|003|Paliperidone palmitate 150 mg eq. Paliperidone palmitate 150 mg eq. i.m. Days 1 8 36 64
62773394|NCT00590577|PLACEBO_COMPARATOR|004|Placebo Placebo i.m. Days 1 8 36 64
62773395|NCT06386705|EXPERIMENTAL|Experimental: Phase 1a|Dose Escalation/Evaluation
62773396|NCT06386705|EXPERIMENTAL|Experimental: Phase 1b|TSN084 recommended Phase 2 dose administered to separate cohorts of patients with selected malignancies harboring mutations including but not limited to MET exon14 skipping mutation and MET amplification.
62791496|NCT06244667|ACTIVE_COMPARATOR|cervical faset median block with prilocaine|cervical faset median block with prilocaine
62773397|NCT01281085||No treatment|Shoulder conditions including rotator cuff condition treated conservatively, shoulder instability treated conservatively, diaphyseal humerus fracture or subcapital humerus fracture treated surgically and frozen shoulder
62567991|NCT02348918|ACTIVE_COMPARATOR|Luminate 2.0mg group|Stage 1 -Luminate 2.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
62567992|NCT02348918|ACTIVE_COMPARATOR|Luminate 3.0mg group|Stage 1- Luminate 3.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
62567993|NCT02348918|ACTIVE_COMPARATOR|Avastin® group|Stage 1- Avastin 1.25 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Avastin injection at weeks 12, 16, or 20 for a total of at least 3 and up to 6 Avastin injections. Sham injections may be performed at weeks 12, 16, and 20 if prn Avastin is not required.
62567994|NCT02348918|ACTIVE_COMPARATOR|Avastin then Luminate 1.0 mg IVT + sham injection|Stage 2 - Week 0 (Baseline): Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 1.0 mg IVT + sham injection Weeks 12 and 16: Sham IVT
62567995|NCT02348918|ACTIVE_COMPARATOR|Avastin then Luminate 0.5 mg IVT + sham injection|Stage 2- Week 0 (Baseline); Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + sham injection Weeks 12 and 16: Sham IVT
62567996|NCT02348918|ACTIVE_COMPARATOR|Sham then Luminate 1.0 mg + Avastin 1.25 mg IVT|Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Luminate 1.0 mg + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
62567997|NCT02348918|ACTIVE_COMPARATOR|Sham then Luminate 0.5 mg IVT + Avastin 1.25 mg IVT|Stage 2 : Week 0: Sham IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
62567998|NCT02348918|ACTIVE_COMPARATOR|Avastin 1.25 mg + Sham IVT|Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Avastin 1.25 mg + Sham IVT Weeks 12 and 16: Avastin PRN
62567999|NCT02549326|PLACEBO_COMPARATOR|Obese, placebo|Placebo daily for 12 weeks
62568000|NCT02549326|ACTIVE_COMPARATOR|Obese, vitamin D|Vitamin D3 50 µg / daily for 12 weeks
62568001|NCT02549326|PLACEBO_COMPARATOR|Control, placebo|Placebo daily for 12 weeks
62568002|NCT02549326|ACTIVE_COMPARATOR|Control, vitamin D|Vitamin D3 50 µg / daily for 12 weeks
62568003|NCT04852419|EXPERIMENTAL|ZN-c5 50mg QD dose cohort|Phase 1b trial of monotherapy cohort with ZN-c5 as single agent will be evaluated with ZN-c5 50 mg administered orally, once daily. Safety lead in phase will be applied.
62568004|NCT04852419|EXPERIMENTAL|Zn-c5 150mg QD dose cohort|Once safety and tolerability are established in ZN-c5 150 mg Dose QD in Chinese population, then it is possible to initiate the second monotherapy cohort with 150 mg QD or alternative dose well established in oversea population for preliminary efficacy and safety.
62568005|NCT02166931|PLACEBO_COMPARATOR|placebo|placebo with the same color, order, taste as BRAND'S® Essence of Chicken , 70cc daily for 2weeks
62568006|NCT02166931|EXPERIMENTAL|Chicken Essence|BRAND'S® Chicken Essence 70cc, daily for 2 weeks
62568007|NCT03137641||Nurses in contact with chemotherapies|"It is a nurses cohort, who administer chemotherapies or are in charge of patients treated by chemotherapie. Three urine samples are collected:~first : between 0 to 3h before the beginning of the workday second : between 0 to 2h after the end of the workday third : between 7 to 10h after the end of the workday"
62568008|NCT00403481|EXPERIMENTAL|Active treatment|Blood pressure (BP) measurements were taken every three weeks for 12 weeks. In accordance with their BP results, participants either stayed on their current medication or were started on the next higher regimen at the 3, 6, or 9 week visits. All participants began at 20 mg olmesartan, once daily for 3 weeks. The next higher regimen was olmesartan 40 mg, followed by olmesartan 40 mg + 12.5 mg hydrochlorothiazide, followed by olmesartan 40 mg + 25 mg of hydrochlorothiazide.
62568009|NCT03144661|EXPERIMENTAL|Part 1|Subjects with HCC, cholangiocarcinoma, or esophageal, nasopharyngeal, or serous ovarian cancers, regardless of FGF/FGFR alteration status.
62568010|NCT03144661|EXPERIMENTAL|Part 2 Cohort A|Subjects with HCC with FGF19 amplification.
62568011|NCT03144661|EXPERIMENTAL|Part 2 Cohort B|Subjects with HCC without FGF19 amplification.
62568012|NCT03144661|EXPERIMENTAL|Part 2 Cohort C|Subjects with cholangiocarcinoma or esophageal, nasopharyngeal, or serous ovarian cancers (regardless of FGF/FGFR status), or other solid tumor malignancies with documented FGF19/FGFR4 alteration.
62568013|NCT00566241|EXPERIMENTAL|IGF-1|Recombinant human IGF-1
62568014|NCT00566241|PLACEBO_COMPARATOR|Placebo|Placebo
62568015|NCT00313196|NO_INTERVENTION|1|
62568016|NCT00313196|EXPERIMENTAL|2|
62568017|NCT00304798|EXPERIMENTAL|Admission|Admission
62568018|NCT00304798|NO_INTERVENTION|Discharge|Discharge
62568019|NCT01585051|ACTIVE_COMPARATOR|vitamin D|Intervention: Intramuscular injection of 300 000 U of 25(OH)vitamin D
62568020|NCT01585051|PLACEBO_COMPARATOR|placebo|administration of 0.9 % NaCl as a placebo
62568021|NCT00916851||Control group|Normally developing children and adolescents
62568022|NCT00916851||ADHD group|Children and adolescents with ADHD
62568023|NCT00916851||ASD group|Children and adolescents with ASD
62568024|NCT01051960|EXPERIMENTAL|ambrisentan|ambrisentan dosed at either 5mg or 10mg orally once per day
62568025|NCT00230659||HHT patients|Patients with hereditary haemorrhagic telangiectasia. Blood sample to be taken.
62568026|NCT00230659||Controls|People without hereditary haemorrhagic telangiectasia. Blood sample to be taken.
62773398|NCT02880150|OTHER|Elite climbers|Elite climbers selected in a national group for their previous performances at high altitude
62183146|NCT04005456|OTHER|Metabolic Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia).
62183147|NCT04005456|OTHER|Consequences of Metabolic (Dys)function Bucket C/S Design|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia). C/S = crossover
62183148|NCT04005456|OTHER|Consequences of Metabolic (Dys)function Bucket R/I Design|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia). R/I = randomization/inclusion
62568027|NCT01414582|EXPERIMENTAL|Anodal tDCS and Motor Training|Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
62568028|NCT01414582|SHAM_COMPARATOR|Sham tDCS and Motor Training|Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
62568029|NCT06280911|EXPERIMENTAL|Date fruit group|"* Pregnant women were asked to consume 6 (about 65 gr) per day of dry date (Medjoul species) provided by the researcher until the birth of the 37th gestational age.~* Dry date fruit provided by the researcher was given to the women to consume (42 pieces per week).~* It has been stated that pregnancies should end the consumption of dates when actual uterine contractions begin.~* Within the first 24 hours of labor, information on labor was recorded in the delivery file and structured information form."
62568030|NCT06280911|EXPERIMENTAL|Nipple group|"* The pregnancies are requested to stimulate a nipple (three minutes a day, one minute in the morning, one noon, one minute in the evening) and three minutes in the other nipple (one minute morning, one noon, one minute evening) with naked fingures and moderate pressure by pulling and rounding.~* The pregnancies were stated to terminate the nipple stimulation when the actual uterine contractions onset.~* Within the first 24 hours of labor, information on labor was recorded in the labor file and structured information form."
62568031|NCT06280911|NO_INTERVENTION|Control group|"• Within the first 24 hours of labor, information on labor was recorded in the delivery file and structured information form."
62568032|NCT00971438|EXPERIMENTAL|Diagnostic imaging|Patients with a scoring suggesting an equivocal diagnosis of acute appendicitis are randomised to either diagnostic imaging (US or CT) or a repeat examination after 4-8 hours in-hospital observation.
62568033|NCT00971438|ACTIVE_COMPARATOR|Repeat examination after observation|Patients with a clinical scoring suggesting an equivocal diagnosis of appendicitis are randomised to either 4-8 hours of in-hospital observation or diagnostic imaging (US or CT)
62568034|NCT00243126|EXPERIMENTAL|Family-Based Risk Reduction Intervention|The intervention will be delivered in five, two-hour, small group sessions, across five weeks (group will meet once per week). Each of the 5 modules consists of 3 sessions: a one-hour session for the daughters meeting together with each other, a one-hour session for the mothers meeting together with each other; and a one-hour session in which the daughters and mothers meet together. Therefore, each week, the daughters will meet as a group for one hour of each module, while the mothers meet as a group for one hour, and for one hour the mothers and daughters will all meet together.
62568035|NCT00243126|NO_INTERVENTION|No Treatment Control Group Condition|A no treatment control group condition will be utilized for this preliminary feasibility study. Participants in this condition, both mothers and adolescents will be assessed at baseline, immediate post-intervention, at 3-month follow-up and at 6-month follow-up.
62183149|NCT04005456|OTHER|Ketogenic Product Development Exploratory Group|Subgroup investigation in participants (classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia) during their 8- or 12-week ketogenic program intervention phase
62568036|NCT00551239|ACTIVE_COMPARATOR|Arm I (control)|Patients receive rituximab IV on day 1 and fludarabine phosphate IV on days 2-4. Treatment repeats every 28 days for up to 6 courses.
62183150|NCT04005456|OTHER|Reproductive Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a group of participants with conditions associated with reproductive and hormonal health (including polycystic ovary syndrome, premenstrual syndrome, endometriosis, peri-menopause and menopausal conditions, women currently pregnant or breastfeeding, testosterone deficiency and andropause/late onset hypogonadism, and prostate health).
62568037|NCT00551239|EXPERIMENTAL|Arm II|Patients receive rituximab and fludarabine phosphate as in arm I. Patients also receive pixantrone IV on day 2. Treatment repeats every 28 days for up to 6 courses.
62568038|NCT00287040|NO_INTERVENTION|1 - Usual Care|This arm looks at mammogram adherence in those individuals who at this time are not receiving booster mammogram interventions.
62568039|NCT00287040|EXPERIMENTAL|2. DVD Intervention|This arm will receive the initial information provided in usual care and will also receive booster mammography interventions via DVD.
62568040|NCT00287040|EXPERIMENTAL|3. Telephone Counseling|This arm will receive the initial information provided in usual care and receive boosters through tailored telephone counseling.
62568041|NCT05896865|EXPERIMENTAL|Postoperative radiation therapy to breast / chest wall and regional lymph node area|"Patient achieved complete response after neoadjuvant chemotherapy will receive postoperative radiation therapy with dose of 42.4 Gy in 16 fractions to whole breast / chest wall and regional lymph node area. Internal mammary or supraclavicular lymph node area boost will be simultaneously delivered with total dose of 53.6 Gy in 16 fractions.~Patient with partial response, stable disease, or progressive disease after neoadjuvant chemotherapy will receive postoperative radiation therapy with dose of 42.4 Gy in 16 fractions to whole breast / chest wall and regional lymph node area. Internal mammary or supraclavicular lymph node area boost will be simultaneously delivered with total dose of 56.0 Gy in 16 fractions."
62773399|NCT02880150|OTHER|Sea level sportsmen|Control group with similar anthropometric, age, gender and maximal normoxic oxygen consumption that the elite climber group
62773400|NCT03298399|EXPERIMENTAL|MSC dose level 1|The first three subjects (minimum) will receive four weekly infusions of MSCs.
62568042|NCT01268982|EXPERIMENTAL|preserved socket|sockets will be filled with DFDBA and covered with absorbable membrane. Primary coverage will be achieved by full thickness mucosal flap advancement over each socket.
62568043|NCT03493854|ACTIVE_COMPARATOR|Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy|Participants will receive 8 cycles of investigator's choice of neoadjuvant chemotherapy. This will include either: 1) 4 cycles of dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks (Q2W) (given with granulocyte colony-stimulating factor \[G-CSF\] support as needed according to local guidelines) followed by paclitaxel Q1W for 12 weeks; or 2) 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab will be given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.
62568044|NCT03493854|EXPERIMENTAL|Arm B: FDC of Pertuzumab and Trastuzumab SC + Chemotherapy|Participants will receive 8 cycles of investigator's choice of neoadjuvant chemotherapy. This will include either: 1) 4 cycles of ddAC Q2W (given with G-CSF support as needed according to local guidelines) followed by paclitaxel once every week (QW) for 12 weeks; or 2) 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The fixed-dose combination (FDC) of pertuzumab and trastuzumab will be given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of the FDC of pertuzumab and trastuzumab SC for a total of 18 cycles.
62183151|NCT04005456|OTHER|Perimenopausal and Menopausal Transitions Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with conditions associated with reproductive and hormonal health specifically peri-menopause and menopausal conditions.
61997712|NCT03941522|NO_INTERVENTION|Control group (conventional hospitalization)|Patients randomized to the group conventional hospitalization will be hospitalized as per the current conventional care after ileostomy closure.
62183152|NCT04005456|OTHER|Premenstrual Syndrome Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with conditions associated with reproductive and hormonal health specifically premenstrual syndrome.
62392001|NCT03699774|EXPERIMENTAL|All Participants|"In treatment Period 1 (Day 1 through Day 4), on Day 1, participants receive a single dose of rosuvastatin 10 mg orally with food, and in Period 2 (Day 1 through Day 16), starting on Day 1, participants receive DS-8500a 75 mg orally qd with food for 16 days with concomitant administration of a single dose of rosuvastatin 10 mg qd on Day 14.~In both the periods, rosuvastatin and DS-8500a are administered after an overnight fast of 8 hours and within 10 minutes after consuming a standardized breakfast of 500 calories."
62392002|NCT01343121|OTHER|sample collection|"This is a single arm study. Patients will be seen on day 1, 8, 15 and 22 and will have the following samples collected:~* Pre gemcitabine urine sample~* Blood sample 30 minutes post Gemcitabine infusion~* Urine and blood sample 2 hours post Gemcitabine infusion"
62392003|NCT01809028|ACTIVE_COMPARATOR|EUS FNA with 2 passes|biopsy with 2 passes of the needle
62568045|NCT02825017|EXPERIMENTAL|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62568046|NCT04367181|EXPERIMENTAL|ELGA group|"\*Less than 29 weeks Gestational Age (GA) preemies (100)~DCS monitoring will be performed for up to 72 hours starting within 2 days after birth. In a subgroup of infants, we will also perform additional measurements with aEEG and FDNIRS. At a second stage we will add Transcranial Doppler Ultrasound (TCD)"
61997713|NCT02757079|EXPERIMENTAL|NPC-15 Granule|NPC-15 granule 1 mg, 2 mg or 4 mg once a day, administered orally before going to bed.
61997714|NCT04889625|EXPERIMENTAL|Test/Control/Control|Eligible subjects will be randomized to one of two possible lens wear sequences, Test/Control/Control.
62183153|NCT04005456|OTHER|Polycystic Ovary Syndrome (PCOS) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with PCOS with signs/symptoms/biomarkers of both metabolic dysfunction and hormonal derangements.
62183154|NCT04005456|OTHER|Andropause/Late Onset Hypogonadism Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of men with conditions associated with reproductive and hormonal health specifically testosterone deficiency and andropause/late onset hypogonadism.
62183155|NCT06551168|EXPERIMENTAL|Heat Acclimation|Participants in this arm will undergo heat acclimation sessions
62183156|NCT06551168|ACTIVE_COMPARATOR|Control|Participants in this arm will undergo heart rate matched training volume
62392004|NCT01809028|ACTIVE_COMPARATOR|EUS FNA with 4 passes|biopsy with 4 passes of the needle
62568047|NCT02124200|OTHER|EGO/CE4, 9mg nicotine|
61997715|NCT04889625|EXPERIMENTAL|Control/Test/Test|Eligible subjects will be randomized to one of two possible lens wear sequences, Control/Test/Test.
61997716|NCT04915391||Group of controls|Control group of 40 patients with ≥1 bare metal stent which in a posterior catheterization performed by clinical follow-up had no restenosis
61997717|NCT04915391||Group of cases|Group of cases with 20 patients with ≥1 bare metal stent and 20 patients with ≥1 drug eluting stent which had restenosis in a posterior catheterization performed by clinical follow-up.
62773401|NCT03298399|EXPERIMENTAL|MSC dose level 2|If no significant side effects are encountered at dose level 1, then subsequent subjects will receive four infusions of MSCs given twice weekly.
62568048|NCT02547428|EXPERIMENTAL|CTN SR First, Then Placebo|Participants received CTN SR tablets starting at a dose of 100 or 200 milligrams (mg) on Day 1. Dose was up titrated up to 800 mg daily dose for up to 3 weeks in Period 1. The dose was decreased based on safety and tolerability based on Investigator's discretion, followed by a washout Period of 1 week followed by matching-placebo for up to 3 weeks in Period 2. The most common total daily dose (TDD) was 400 mg/day.
62773402|NCT03298399|EXPERIMENTAL|MSC dose level 3|If dose level 2 is well tolerated, then subsequent subjects will receive six infusions MSCs given twice weekly.
62773403|NCT01496911|EXPERIMENTAL|Levocetirizine (5 mg)|
62773404|NCT01496911|ACTIVE_COMPARATOR|Hydroxyzine (50 mg)|
62773405|NCT01496911|PLACEBO_COMPARATOR|Placebo|
62773406|NCT00118430|EXPERIMENTAL|Stepped Care|Stepped care group
62773407|NCT00118430|ACTIVE_COMPARATOR|Usual Care|Treatment as usual group
62773408|NCT00118430|NO_INTERVENTION|No Treatment|Participants without depression group
62773409|NCT01120990|OTHER|All patients|All eligible patients in the study consist a single group and the same intervention is assigned to all of them.
62773410|NCT01506661|EXPERIMENTAL|Rheumatoid Arthritis|10 subjects with mild rheumatoid arthritis aged 50 years and older will be enrolled and will receive a single dose of Zostavax vaccine.
62773411|NCT01506661|ACTIVE_COMPARATOR|Healthy Subjects|10 healthy subjects aged 50 years or older who have not been previously immunized, will receive a single injection of Zostavax.
62773412|NCT00669201||1|healthy young volunteers Inclusion: age 18-40, Exclusion: wrist trauma/surgery
62183157|NCT00791739|EXPERIMENTAL|one arm study|
62183158|NCT00946205|EXPERIMENTAL|Laparoscopic anterior mesh rectopexy|
62183159|NCT00946205|ACTIVE_COMPARATOR|Laparoscopic posterior rectopexy|
62183160|NCT01148498|EXPERIMENTAL|Group 1|Older adults with mild Dementia Alzheimer's Type (DAT)
62735110|NCT01720589|EXPERIMENTAL|Melt (test oil)|Participants will consume a muffin containing 20 g of dietary fat provided by the test oil and their energy expenditure will be measure post-prandially for 6 hours. At the end of the measurement period, participants will consume a cookie containing 10 g of fat provided by the test oil and their food intake at an ad libitum meal will be measured 1 hour later.
62773413|NCT00669201||2|"patients with know osteoarthritis wrist changes according to pre-existing x-rays No age limits~exclusion: previous wrist surgery"
62773414|NCT00669201||3|Mixed group of 50 patients that perform routine MRI of the wrist for various indications
62773415|NCT01029041|EXPERIMENTAL|Strengthening exercise|This group does global strengthening exercise
62773416|NCT01029041|EXPERIMENTAL|Stretching exercise|This group does global stretching exercise
62773417|NCT01029041|NO_INTERVENTION|Control|This group does nor do any kind of exercise during the study
61997718|NCT03200925|NO_INTERVENTION|Group A - no video group|"Group A will be asked a short survey:~* their intention to practice skin to skin at the time of delivery~* if they participated in skin to skin in a previous pregnancy~* if they had any formal education about skin to skin~* if they did have formal education was it either~  * a.) Provided at a prenatal appointment,~ * b.) A formal class led by either a nurse or a lactation consultant.~We will also look at patient's medical record number, age, gestational age, any pregnancy complications, race, type of insurance, and the number of times the patient has been pregnant. We will also examine data that is already collected by this hospital after delivery regarding skin to skin. This includes gestational age in weeks at the time of delivery, 5 minute APGAR, delivery date/time, skin to skin initiation time, skin to skin end time, delivery to skin to skin duration (minutes), and skin to skin duration (minutes)."
62568049|NCT02547428|EXPERIMENTAL|Placebo First, Then CTN SR|Participants received matching-placebo for up to 3 weeks in Period 1, followed by a washout Period of 1 week, followed by CTN SR tablets starting at a dose of 100 or 200 mg on Day 1. Dose was up titrated up to 800 mg daily dose for up to 3 weeks in Period 2. The dose was decreased based on safety and tolerability based on Investigator's discretion. The most common TDD was 400 mg/day.
62773418|NCT06198686|EXPERIMENTAL|Sequence 1|A buccal formulation of Nalmefene 16 mg and a 1 mg intravenous dose of nalmefene injection, with a least 7 days washout period between dose
62773419|NCT06198686|EXPERIMENTAL|Sequence 2|A 1 mg intravenous dose of nalmefene injection, and a buccal formulation of Nalmefene 16 mg with a least 7 days washout period between dose
62773420|NCT01966445|EXPERIMENTAL|GSK2849330 Part 1|1 hour infusion administered intravenously at intervals of one week or more (escalating doses).
62773421|NCT01966445|EXPERIMENTAL|GSK2849330 Part 2|Intravenous infusion administered at the dose and schedule established in Part 1
62773422|NCT01990456|EXPERIMENTAL|PHASE 1: impact of tidal ventilation on VILI|In the first phase we will test whether administering a distending inspiratory pressure to produce tidal ventilation is superior to a strategy where only continuous positive airway pressure (CPAP) is applied for ventilation induced lung injury (VILI) mitigation, as assessed by its impact on biotrauma (serum cytokines) and physiologic measurements.
62773423|NCT01990456|EXPERIMENTAL|PHASE 2: impact of PEEP on VILI|In the second phase we will gain more insight as to whether a strategy that utilizes a PEEP level that correspond to best compliance is beneficial over Zero End-Expiratory Pressure (ZEEP). We will test the impact of both strategies on biotrauma (serum cytokines), physiologic parameters, and right ventricular function (transesophageal echocardiographic assessment).
62773424|NCT04921332|EXPERIMENTAL|Bright Light Therapy (BLT)|The intervention will consist of daily BLT sessions lasting 30 minutes at approximately 10AM (since many CF and COPD patients may not awaken until this time) starting on the day of admission through discharge for a goal of seven consecutive days. The intervention will use a 10,000-lux light box placed approximately 16-24 inches from the patient's face.
62773425|NCT02945644|PLACEBO_COMPARATOR|Placebo|pill filled with inert material
62183161|NCT01148498|EXPERIMENTAL|Group 2|Older adult controls with possible Alzheimer's Disease Pathology
62773426|NCT02945644|ACTIVE_COMPARATOR|Trazodone 50mg|
62773427|NCT02945644|ACTIVE_COMPARATOR|Trazodone 100mg|
61978522|NCT04826770||AZD/BNT/MOD|Subject receiving one dose of AZD 1222 (Vaxzevria®, Covishield®, ChadOx1 nCoV-19, Oxford University/Astra-Zeneca) followed by one dose of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as heterologous basic immunization and one dose of mRNA-1273 (Spikevax®, elasomeran (INN), Moderna) as booster vaccination
62568050|NCT06537362|NO_INTERVENTION|Control|During oscillometry measures, the subject's cheeks are manually supported by an expert (Gold Standard method)
62568051|NCT06537362|EXPERIMENTAL|Cheek Holder|During oscillometry measures, the subject's cheeks are supported by an integrated cheek support in the mouthpiece
62584754|NCT05021874|ACTIVE_COMPARATOR|Physiotherapeutic procedures:magneto-laser therapy|Magneto-laser therapy is a synergistic action of a slowly changing magnetic field generated by the Viofor JPS apparatus (Med \& Life, Poland) and a low-energy laser with infrared wavelength of 808 \[nm\] (max. power 300 mW) was applied. The dose was set to increase from 3,0 J/cm2 to 5,0 J/cm2 and the total dose applied per each patient from this subgroup was 40 J/cm2. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
62791497|NCT03047421||All patients included|For all patients scheduled for an anesthetic preoperative consultation, a comparison of accuracy of DES-OSA and P-SAP scores with PSG (polysomnography) will be performed.
62791498|NCT04182243|OTHER|Emergency Health Care Provider|Working in emergency health services in Northern Cyprus
61997719|NCT03200925|EXPERIMENTAL|Group B - video group|"Group B will be asked the same short survey as group A.~The patient would then immediately watch Jumping into Kangaroo Care, and then immediately take the post survey which would ask if they intended to practice skin to skin at the time of delivery.~We will also look at patient's medical record number, age, gestational age, any pregnancy complications, race, type of insurance, and the number of times the patient has been pregnant. We will also examine data that is already collected by this hospital after delivery regarding skin to skin. This includes gestational age in weeks at the time of delivery, 5 minute APGAR, delivery date/time, skin to skin initiation time, skin to skin end time, delivery to skin to skin duration (minutes), and skin to skin duration (minutes)."
61997720|NCT05175066|EXPERIMENTAL|Bisoprolol|40 patients who were given bisoprolol at a dose of 1.25 mg daily, and in the absence of clinical symptoms and heart rate above 60 and systolic blood pressure above 100, 1.25 mg was added to the therapeutic dose every 2 weeks to reach 5 mg daily.
62183162|NCT01148498|EXPERIMENTAL|Group 3|Older adult controls with no evidence of Alzheimer's Disease
62183163|NCT01148498|EXPERIMENTAL|Group 4|Younger subjects who are assumed to have no cognitive impairment
62392005|NCT02705859|OTHER|Single Arm|"This study is a Phase Ib/II open label, single arm, adaptive multi-centre trial.~Patients with HER2-positive, metastatic or incurable recurrent breast cancer, following disease progression during, or after, treatment with at least one systemic treatment regimen in the metastatic or recurrent setting, will be treated with copanlisib (at 30, 45 or 60 mg flat dosing IV weekly - depending on the maximum tolerated dose (MTD) determined in the Phase Ib part of the study) plus trastuzumab (4 mg/kg IV Cycle 1 Day 1 and then 2 mg/kg IV weekly starting from day 8)."
62773428|NCT04424693|ACTIVE_COMPARATOR|Tdap vaccinations at gestational week 28|Pregnant women entering into this clinical research study and signing informed consent at week 12 will be randomized to either receive Tdap vaccination at week 28 or week 36. Subjects receiving Tdap vaccination at week 28 will receive a placebo injection at week 36. Subject will be followed with routine standard of care throughout their pregnancy and have routine clinic visits from which study visits will include weeks 12, 20, 28, 36, and 2 weeks postpartum. Data will be collected at each of these visits with special attention to the development of preeclampsia and fetal health
62773429|NCT04424693|ACTIVE_COMPARATOR|Tdap vaccinations at gestational week 36|Pregnant women entering into this clinical research study and signing informed consent at week 12 will be randomized to either receive Tdap vaccination at week 28 or week 36. Subjects receiving Tdap vaccination at week 36 will receive a placebo injection at week 28. Subjects will be followed with routine standard of care throughout their pregnancy and have routine clinic visits from which study visits will include weeks 12, 20, 28, 36, and 2 weeks postpartum. Data will be collected at each of these visits with special attention to the development of preeclampsia and fetal health
61997721|NCT05175066|PLACEBO_COMPARATOR|Placebo|Two placebo tablets in similar shape and color to bisoprolol were given on a daily basis to each of the 40patients as the control group.
62183164|NCT01814436|EXPERIMENTAL|scaffold-free SHED-derived pellet|
62773430|NCT03999086||Control Group|Traditional evaluation/standard-of-care evaluation of patients undergoing multi-level spinal fusion surgery. These patients will receive point-of-care laboratory testing.
62773431|NCT03999086||Intervention arm|Utilization of TEG for decision-making regarding intra-operative transfusion in major spinal reconstruction surgery.
62183165|NCT00077597|EXPERIMENTAL|1|
62183166|NCT00077597|ACTIVE_COMPARATOR|2|
62183167|NCT02822417||patients after general anesthesia|Laparoscopic surgery, orthopedics surgery or open surgery patients after general anesthesia
62183168|NCT05246384|EXPERIMENTAL|Part I (dose escalation) RP7214 + Azacitidine|Participants will receive RP7214 orally in combination with Azacitidine in a 28-day cycle. The dose levels will be escalated until MTD/a recommended Phase 2 dose (RP2D) has been identified.
62183169|NCT05246384|EXPERIMENTAL|Part II (dose expansion) RP7214 + Azacitidine|Participants will receive RP7214 orally at the MTD/RP2D in combination with Azacitidine in a 28-day cycle.
61997722|NCT05466019|EXPERIMENTAL|Toripalimab combined with FLOT regimen|The enrolled patients will receive 3 cycles of FLOT regimen +Toripalimab treatment before surgery, and every 2 weeks is a treatment cycle (Q2W). After completing the 3 cycles of treatment, the patient undergoes surgical resection.Toripalimab combined with FLOT regimen were maintained for 4 cycles after surgery.
62392006|NCT03137212|EXPERIMENTAL|A group|STEMI patients first are given thrombolysis and then transfer to PCI center to be treated by PCI 3-6 hours after thrombolysis if the thrombolysis is successful. if the thrombolysis is not successful, patients will be treated by PCI immediately.
62791499|NCT03403439|EXPERIMENTAL|All Subjects|Reference Treatment - BI 1015550 alone followed by Test Treatment (itraconazole + BI 1015550)
61997723|NCT02040610|ACTIVE_COMPARATOR|Low Risk Prostate Cancer|Hypofractionated Proton Therapy 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks
61997724|NCT02040610|ACTIVE_COMPARATOR|Intermediate Risk Prostate Cancer|Hypofractionated Proton Therapy 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks
61997725|NCT05605340|EXPERIMENTAL|Intervention|Meal delivery intervention with brief behavioral support.
61997726|NCT01027091||patients with positive slope|patients with positive slope in the levels of free serum calcium levels between 6th and 12th postoperative hour
62183170|NCT05910645||Dental Residents in pediatric department|
62392007|NCT03137212|EXPERIMENTAL|B group|STEMI patients first are given thrombolysis and then transfer to PCI center to be treated by PCI 6-24 hours after thrombolysis if the thrombolysis is successful. if the thrombolysis is not successful, patients will be treated by PCI immediately.
62568052|NCT06116279|EXPERIMENTAL|Insertion of electrode during planned neurosurgery for epilepsy|During the surgical procedure, following exposure of the brain via a craniotomy, the novel electrodes will be inserted into tissue planned for resection. This will be targeted using the existing neuronavigation software that is being used during the surgery and may be augmented by intraoperative ultrasound, also a common adjunct used in these surgeries. Following insertion of the electrode, the cables will be connected to a specialised (portable) amplifier inside the operating theatre and 15 minutes of data will be recoded. The electrodes will then be removed and the surgical resection will then proceed as planned. The content of the recordings will not be available in real-time and will not be used to inform or change the surgical resection plan in any way.
62568053|NCT01269216|ACTIVE_COMPARATOR|5-FU with leucovorin|
62568054|NCT01269216|ACTIVE_COMPARATOR|TS-1 with Irinotecan|
62568055|NCT03472430|ACTIVE_COMPARATOR|Treatment group|Transcutaneous electrical nerve stimulation machine, start 5 minutes before start of oocyte retrieval and stop 5 minutes after removal of oocyte retrieval needle
62568056|NCT03472430|SHAM_COMPARATOR|Placebo group|TENS machine with electrodes not emitting any impulses, start 5 minutes before start of oocyte retrieval and stop 5 minutes after removal of oocyte retrieval needle
62568057|NCT04722068|EXPERIMENTAL|Volunteers with known HoFH and particpated in R1500-CL-1331 clinical trial|
62791500|NCT05690048|EXPERIMENTAL|Vancomycin + A/B + FMT|"1. Atezolizumab 1200mg i.v. \& Bevacizumab 15mg/kg body weight i.v. (A/B) as standard of care (SOC).~2. Vancomycin orally (125 mg 4xd, day -3 to 0) for reduction of original patient gut microbiota.~3. Fecal microbiota transfer (FMT) via capsule (50 g of fecal matter) on day 0 and day 21."
62392008|NCT00247052|ACTIVE_COMPARATOR|diclofenac|diclofenac
62392009|NCT00247052|PLACEBO_COMPARATOR|2|
62568058|NCT01753310|ACTIVE_COMPARATOR|Dysport®|Dysport® (intramuscular injection), between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
62568059|NCT01753310|PLACEBO_COMPARATOR|Placebo|Placebo, up to 2mL
62568060|NCT02818452|EXPERIMENTAL|Oatmeal containing beta-glucan|27 g oatmeal
62791501|NCT05690048|PLACEBO_COMPARATOR|Placebo Vancomycin + A/B + Placebo FMT|"1. Atezolizumab 1200mg i.v. \& Bevacizumab 15mg/kg body weight i.v. (A/B) as standard of care (SOC).~2. Placebo Vancomycin orally (125 mg 4xd, day -3 to 0) for reduction of original patient gut microbiota.~3. Placebo Fecal microbiota transfer (FMT) via capsule (50 g of fecal matter) on day 0 and day 21."
62791502|NCT06010784|EXPERIMENTAL|Intervention: After-school program + family support|
62791503|NCT06010784|ACTIVE_COMPARATOR|Control: After-school program only|
62791504|NCT05921565|EXPERIMENTAL|Single Behavioral Arm|Everyone in the study will receive the same type of treatment. They will all receive a treatment period that will last for 8 weeks. All participants will be given a 3% total weight loss goal, a daily calorie goal ranging from 1200-2000 kcal/day based on body weight, and a daily fat goal based on 25% of total daily calories from fat, and an option to stop their food/energy intake at 6pm every day without altering any other meal times. .Participants will also be asked to use two meal replacements per day. Participants will also be given a physical activity goal of 100 minutes per week.
62791505|NCT01103388|EXPERIMENTAL|Rituximab|
62791506|NCT01103388|NO_INTERVENTION|No Rituximbab|
62791507|NCT00213265|ACTIVE_COMPARATOR|1|
62791508|NCT00213265|EXPERIMENTAL|2|
62791509|NCT02223715||CDI|
62791510|NCT03000855|ACTIVE_COMPARATOR|ECDS|EUS-guided choledocho-duodenostomy
62791511|NCT03000855|ACTIVE_COMPARATOR|ERCP with CSEMS|Endoscopic retrograde cholangiopancreatography with covered metallic stent
62791512|NCT04474275||Study group 1|Primiparous women who gave birth with ceserean section
62791513|NCT04474275||Study group 2|Primiparous women who gave birth with vaginal route delivery without episiotomy
62791514|NCT04474275||Study group 3|Primiparous women who gave birth with vaginal route delivery with episiotomy
62773432|NCT02319135|ACTIVE_COMPARATOR|fludarabine cytarabine|"Priming with daily administration of subcutaneous G-CSF (lenograstim or filgrastim 5 mcg /kg / day, days -1, 1 and 2) (not given if hyperleukocytosis\> 25 x 109/l), followed by:~* Oral fludarabine (40 mg/m2/day, days 1 to 5) and subcutaneous cytarabine (75mg/m2/day, days 1 to 5) (FLUGA scheme) (fludarabine and cytarabine only days 1 to 4 if age ≥75 years), OR~* Fludarabine (25 mg/m2/day) and cytarabine (75 mg/m2/day infusion of 6 hours) on their intravenous formulations if the patient is hospitalized (patients with hyperleukocytosis or other unfavourable conditions).~Treatment cycles every 28 days"
62773433|NCT02319135|EXPERIMENTAL|Azacitidine|Subcutaneous Azacitidine 75 mg/m2/day, days 1 to 7. Treatment cycles every 28 days.
62183171|NCT05910645||Dental Residents in conservative department|
62183172|NCT04157023|OTHER|Medical Students|Simulator training of 7 patient cases adapted to medical students.
62183173|NCT04157023|OTHER|Ophthalmologist|Simulator training of 7 patient cases adapted to ophthalmologists.
62183174|NCT04157023|OTHER|Neurologist/Neurosurgeon/Neonatologist|Simulator training of 7 patient cases adapted to neurologists, neurosurgeons and neonatologists.
62183175|NCT03908593|ACTIVE_COMPARATOR|One month of therapy|Pantoprazole, 40mg, tablet, oral, once daily for 1 month
62183176|NCT03908593|EXPERIMENTAL|Twelve months of therapy|Pantoprazole, 40mg, tablet, oral, once daily for 12 months
62183177|NCT04322760|ACTIVE_COMPARATOR|Group A (control group)|Patients in each received 10 ml 0.5 % bupivacaine and 1µg/kg dexmedetomidine diluted in 10 ml saline injected intra-articularly without lidocaine patch
62183178|NCT04322760|EXPERIMENTAL|Group B|Patients in each received 10 ml 0.5 % bupivacaine and 1µg/kg dexmedetomidine diluted in 10 ml saline injected intra-articularly with a patch of lidocaine 5% was applied to the skin
62183179|NCT05630378|EXPERIMENTAL|Treatment group|"The treatment group has 11 visits in the outpatient clinic of integrative medicine and naturopathy. Additional they fill in a diary and wear a pedometer during the day. Diary and pedometer continue to week 15. In week 12 a video conference with the treatment-group takes place. During week 14+15 a qualitative telephone interview is set.~Patients fill in questionnaires before the start of the outpatient clinic and directly afterwards (week 11)."
62183180|NCT05630378|OTHER|Waiting group|Parallel to the treatment group the waiting group receives no intervention, but fills in a diary and wear a pedometer during the day. Their diary and pedometer continue only to week 11. No additional interventions (refresher; video conference; interview) take place. Patients fill in questionnaires before the start of the waiting phase, parallel to the start of the outpatient clinic and directly after its end (week 11).
62183181|NCT02028247|EXPERIMENTAL|Personalized Cognitive-behavioral therapy|Personalized Cognitive-behavioral therapy involves 16 weekly individual therapy sessions, up to 90 minutes each, based on a treatment protocol that has been designed specifically for youth with high-functioning autism spectrum disorders.
62183182|NCT02028247|ACTIVE_COMPARATOR|Standard Practice Cognitive-behavioral therapy|Standard Practice Cognitive-behavioral therapy involves 16 weekly individual therapy sessions, up to 60 minutes each, based on a treatment protocol that represent the standard practice psychotherapy for anxiety that has been found to be effective in multiple trials in youngsters without autism spectrum disorders.
62183183|NCT02028247|OTHER|Treatment as Usual|Participants randomized to the TAU condition will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions) for a 16-week period. Treatment changes (e.g., medication increase, starting psychotherapy in community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
62183184|NCT02673307|NO_INTERVENTION|Controle|The volunteer does not chew gum during the study period
62183185|NCT02673307|EXPERIMENTAL|Chewing gum|The volunteer chews gum during the first 45 min after ingestion of 250 ml water
62183186|NCT05009381|EXPERIMENTAL|Treatment group|Treatment group will receive STYLAGE® XXL at enrollment with an optional touch up injection 30 days later
62568061|NCT02818452|EXPERIMENTAL|Oatmeal containing beta-glucan + OatWell28XF Intervention 1|27.72g oatmeal
62568062|NCT02818452|EXPERIMENTAL|Oatmeal containing beta-glucan + OatWell28XF Intervention 2|28.43g oatmeal
62568063|NCT02818452|EXPERIMENTAL|Oatmeal containing beta-glucan + OatWell28XF Intervention 3|29.86g oatmeal
62568064|NCT02818452|EXPERIMENTAL|Oatmeal containing beta-glucan + OatWell28XF Intervention 4|32.72g oatmeal
62568065|NCT02818452|PLACEBO_COMPARATOR|Hot Cereal - Cream of Rice|20g oatmeal
62791515|NCT04474275||Control group|Nulliparous women
62183187|NCT05009381|EXPERIMENTAL|control group|Control group will not be treated at enrollment visit. Subjects will receive STYLAGE® XXL at visit 6 months after randomization, if they are still eligible for chin augmentation with an optional touch up injection 30 days later.
62773434|NCT03002272||TAVR|This observational study will enroll subjects that underwent TAVR more than 3 years ago.
62773435|NCT03002272||SAVR|Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
62773436|NCT04797962|EXPERIMENTAL|Intervention|dedicated case management
62773437|NCT04797962|NO_INTERVENTION|Usual care|usual care
62773438|NCT02265315|SHAM_COMPARATOR|LSVT +sham TMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS)
62773439|NCT02265315|ACTIVE_COMPARATOR|LSVT +left rTMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS) applied to left side of head
61997727|NCT01027091||patients with negative or no slope|patients with negative or no slope in the levels of free serum calcium levels between 6th and 12th postoperative hour.
62183188|NCT04240028||Individuals with prefrailty|"This is defined as a co-existing prefrailty using the Fried criteria. Frailty defined by the CHS index as proposed by Fried et al. will be identified by the presence of ≥ 3 of the following 5 components: 1) Shrinking as identified by an unintentional weight loss of ≥ 5% between two assessments, 2) Weakness as identified by a maximal grip strength in the lowest quintile stratified by body mass index quartile; 3) Poor energy as identified by an answer of no to the question Do you feel full of energy? from the 30-item Geriatric Depression Scale; 4) Slowness as identified by an average walk speed in the lowest quintile stratified by median standing height, and 5) Low physical activity level as identified by a PASE score in the lowest quintile. Participants with none of the above components will be considered to be vigorous and those with 1 or 2 components will be considered to be in a prefrail stage."
62773440|NCT02265315|ACTIVE_COMPARATOR|LSVT + right rTMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS) applied to right side of brain
62773441|NCT00849862|EXPERIMENTAL|Levetiracetam|Levetiracetam 750 mg Tablet (test) dosed in first period followed by Keppra 750 mg Tablet (reference) dosed in second period
62773442|NCT00849862|ACTIVE_COMPARATOR|Keppra®|Keppra® 750 mg Tablet (reference) dosed in first period followed by Levetiracetam 750 mg Tablet (test) dosed in second period
62773443|NCT03834220|EXPERIMENTAL|Cohort 1: Debio 1347 (Biliary Tract Cancer)|Participants with biliary tract cancer were included in this cohort to receive Debio 1347 80 milligrams (mg) tablets, orally, once daily (QD), from Day 1 to Day 28 in 28-day cycles until the occurrence of disease progression or unacceptable toxicity (up to a median duration of 20 weeks).
62773444|NCT03834220|EXPERIMENTAL|Cohort 2: Debio 1347 (Urothelial Cancer)|Participants with urothelial cancer were included in this cohort to receive Debio 1347 80 mg tablets, orally, QD, from Day 1 to Day 28 in 28-day cycles until the occurrence of disease progression or unacceptable toxicity (up to a median duration of 5.86 weeks).
62773445|NCT03834220|EXPERIMENTAL|Cohort 3: Debio 1347 (All Other Solid Tumor Histologies)|Participants with all other solid tumor histologies were included in this cohort to receive Debio 1347 80 mg tablets, orally, QD, from Day 1 to Day 28 in 28-day cycles until the occurrence of disease progression or unacceptable toxicity (up to a median duration of 8.14 weeks).
61997728|NCT03976427|EXPERIMENTAL|Guided Imagery|Participants will listen to a guided imagery recording
62773446|NCT03460912||All participants|
62773447|NCT03572790|EXPERIMENTAL|Prucalopride|
62773448|NCT03572790|PLACEBO_COMPARATOR|Placebo|
62773449|NCT04080856||Participants with endometriosis|Premenopausal participants with endometriosis receiving elagolix in real-world setting
61997729|NCT06227507|EXPERIMENTAL|No icon|"Participants will be shown 3 frozen meals at once; each product will be high in 1, 2, or 3 nutrients of concern (added sugar, sodium, and/or saturated fat) and will be labeled as such with a rectangular high in front-of-package label. The label will solely contain high in and nutrient text with no icon."
61997730|NCT06227507|EXPERIMENTAL|Magnifying glass|"Participants will be shown 3 frozen meals at once; each product will be high in 1, 2, or 3 nutrients of concern (added sugar, sodium, and/or saturated fat) and will be labeled as such with a rectangular high in front-of-package label. The label will contain high in and nutrient text, along with a magnifying glass icon."
62773450|NCT01252524|PLACEBO_COMPARATOR|Placebo|A placebo tablet PO TID before each meal with 8 oz of water for 6 months.
62773451|NCT01252524|EXPERIMENTAL|Calcium polycarbophil|Calcium polycarbophil 625 mg PO TID before each meal with 8 oz of water for 6 months
62773452|NCT05269030|EXPERIMENTAL|Case group|The patients will receive ivermectin nasal drops
62392010|NCT03172026|EXPERIMENTAL|Maraviroc + Augmented Rehabilitation|Participants will take Maraviroc 300 mg daily for 60 days, plus receive rehabilitation therapy as prescribed by the doctors and via telerehabilitation.
62568066|NCT05989256|EXPERIMENTAL|experimental hypoglycemia risk score is applied on a service which has already implemented EndoTool|Service where the experimental hypoglycemia risk score is applied on a service which has already implemented EndoTool
61997731|NCT06227507|EXPERIMENTAL|Exclamation Mark|"Participants will be shown 3 frozen meals at once; each product will be high in 1, 2, or 3 nutrients of concern (added sugar, sodium, and/or saturated fat) and will be labeled as such with a rectangular high in front-of-package label. The label will contain high in and nutrient text, along with an exclamation mark icon."
62568067|NCT05989256|ACTIVE_COMPARATOR|Service where EndoTool is applied without the experimental hypoglycemia risk score|Service where EndoTool is applied without our experimental hypoglycemia risk score
61978523|NCT04826770||Control/validation group|"Control samples for the validation of the used methods from the pre-SARS-CoV-2 era were transferred from the study Blood Donations from Healthy Blood Donors to Investigate Circannual Variations in Tryptophan Metabolism and Adaptive Immune Response to Bacterial Infectious Agents (in short TRP study). Subjects had not received any SARS-CoV-2 vaccination at that time. Remaining plasma samples were transferred to the AICOVI study."
62392011|NCT03172026|PLACEBO_COMPARATOR|Placebo + Augmented Rehabilitation|Participants will take placebo 300 mg daily for 60 days, plus receive rehabilitation therapy as prescribed by the doctors and via telerehabilitation.
62392012|NCT02490111|EXPERIMENTAL|DWJ1319 300 mg BID|DWJ1319 300 mg, orally, twice daily (BID) for up to 12 months
62392013|NCT02490111|EXPERIMENTAL|DWJ1319 300 mg QD|DWJ1319 300 mg, orally, once daily (QD), and DWJ1319 placebo-matching capsules, orally, once daily for up to 12 months
62773453|NCT05269030|ACTIVE_COMPARATOR|Control group|The patients will receive local steroid spray
62773454|NCT00678548|EXPERIMENTAL|guided imagery|CD
62773455|NCT00678548|ACTIVE_COMPARATOR|pain diary|Pain diary
62773456|NCT01257035||18F-FAZA-PET/CT|
62773457|NCT02437084|OTHER|Individuals without diabetes eligible to receive statin therapy|Eligible participants will receive 40 mg of atorvastatin
62773458|NCT02910102|OTHER|Sequence AB|RVT-101 35 mg in Period II and Placebo in Period IV
62773459|NCT02910102|OTHER|Sequence BA|Placebo in Period II and RVT-101 35 mg in Period IV
62568068|NCT05989256|ACTIVE_COMPARATOR|Standard of care glucose management|Service which has not yet implemented EndoTool - providers adjusting insulin and consulting the Glucose Management Team at their discretion
62568069|NCT00754104|EXPERIMENTAL|A|
62568070|NCT06453668|EXPERIMENTAL|Treatment|TCD601 (siplizumab) administered with the contemporary standard of care regimen.
62568071|NCT02641093|EXPERIMENTAL|Pembrolizumab|Pembrolizumab in combination with standard of care surgery followed by radiation therapy with or without cisplatin
62568072|NCT03859596||MGB/OAGB|Consequent group of patients who underwent MGB/OAGB
62568073|NCT05059873|EXPERIMENTAL|Systemic corticosteroid group|Patients will receive Oral prednisone 40mg/day for five consecutive days in addition to standard treatment during emergency admission or hospitalization.
62568074|NCT05059873|PLACEBO_COMPARATOR|Control group|Participating patients will receive an oral placebo of 40mg/day for five consecutive days in addition to standard treatment.
62568075|NCT03863782||Sarcoid uveitis|The cohort is composed by patients diagnosed or treated for sarcoid uveitis in the departement for Internal Medicine, Croix Rousse Hospital, Lyon, France.
61997732|NCT06227507|EXPERIMENTAL|Exclamation Mark with multiple labels|"Participants will be shown 3 frozen meals at once; each product will be high in 1, 2, or 3 nutrients of concern (added sugar, sodium, and/or saturated fat) and will be labeled as such with 1, 2, or 3 rectangular high in front-of-package labels, one for each specific nutrient of concern. Each label will contain high in and nutrient text, along with an exclamation mark icon."
62183189|NCT04240028||Individuals with cognitive-prefrailty|"A combination of prefrailty stage using Fried criteria and subjective cognitive impairment (SCI).~The IANA/IAGG consensus defines cognitive frailty as CDR = 0.5 and frailty by the Fried criteria.SCI will be defined using a proxy for subjective cognitive complaint (i.e. memory complaint) and following the procedure used in previous multicenter prevalence studies on MCR syndrome. Memory complaint used to define MCR syndrome was based on standardized memory loss question on the 15-item or 30-item Geriatric Depression Scale (GDS; Do you feel you have more problems with memory than most?). Memory complaint in our study will be elicited from this item of 30-item GDS."
62214563|NCT00539435|ACTIVE_COMPARATOR|1|Diabetic patients will complete cardiac quality of life questionnaires at baseline and monthly thereafter to monitor and assess progress with complications resulting from their heart disease. Comparisons will be performed on carotid ultrasounds,echocardiograms and lab values performed at baseline and every six months and medication information collected at weekly Pulsatile Intravenous Insulin treatment sessions
62568076|NCT01017874|EXPERIMENTAL|Pemetrexed + Cisplatin + Gefitinib|
62568077|NCT01017874|ACTIVE_COMPARATOR|Gefitinib|
62791516|NCT00246701|ACTIVE_COMPARATOR|Simvastatin|Simvastatin + placebo
62214564|NCT06611332|EXPERIMENTAL|Electroacupuncture|
62214565|NCT06611332|SHAM_COMPARATOR|Sham electroacupuncture|
62392014|NCT02490111|PLACEBO_COMPARATOR|Placebo|Placebo, orally, twice daily (BID) for up to 12 months
62392015|NCT01306682|ACTIVE_COMPARATOR|Trivalent Influenza vaccine|0.5ml of TIV will be administered into deltoid muscle of non dominant arm
62392016|NCT01306682|PLACEBO_COMPARATOR|Normal saline|0.5ml of normal saline administered into deltoid muscle of non dominant arm
62392017|NCT01159665|EXPERIMENTAL|PPV 5-30 minutes after injection|Primary Pars Plana Vitrectomy 5 to 30 minutes after 125µg of ocriplasmin intravitreal injection
62392018|NCT01159665|EXPERIMENTAL|PPV 31-60 minutes after injection|Primary Pars Plana Vitrectomy 31 to 60 minutes after 125µg of ocriplasmin intravitreal injection
62392019|NCT01159665|EXPERIMENTAL|PPV 2-4 hours after injection|Primary Pars Plana Vitrectomy 2 to 4 hours after 125µg of ocriplasmin intravitreal injection
62392020|NCT01159665|EXPERIMENTAL|PPV 24 hours (+2 hours) after injection|Primary Pars Plana Vitrectomy 24 hours (+2 hours)after 125µg of ocriplasmin intravitreal injection
61978524|NCT01585428|EXPERIMENTAL|Cervical|Patients will receive a non-myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of Young tumor infiltrating lymphocytes (TIL) plus high dose IV aldesleukin.
62392021|NCT01159665|EXPERIMENTAL|PPV 7 days (+1 day) after injection|Primary Pars Plana Vitrectomy 7 days (+1 day)after 125µg of ocriplasmin intravitreal injection
62392022|NCT01159665|NO_INTERVENTION|PPV without injection|Control Arm, no ocriplasmin intravitreal injection
62392023|NCT05541380||Cohort A|patients who were pathologically (histologically) diagnosed as papillary carcinoma (PTC). They are in advanced stage and need systemic therapies. These patients may be unresectable, recurrent, persistent, or metastatic disease with RAI refractory or ineligible and need systemic therapies.
62392024|NCT05541380||Cohort B|patients who were pathologically diagnosed as DTC other than PTC, which includes follicular carcinoma, Hurthle cell carcinoma, and poorly differentiated carcinoma. The patients are in advanced stage and need systemic therapies. These patients may be unresectable, recurrent, persistent, or metastatic disease with RAI refractory or ineligible and need systemic therapies.
62392025|NCT05541380||Cohort C|patients who were pathologically diagnosed as medullary thyroid cancer (MTC) with persistent disease.
62392026|NCT05541380||Cohort D|patients who were pathologically diagnosed as anaplastic thyroid cancer (ATC).
62392027|NCT05541380||Cohort E|"the patients who had performed large scale NGS oncopanel test previously and fulfil with the criteria in cohort A, B, C, or D.~The patients must meet all the inclusion criteria and none of the exclusion criteria in each cohort."
62392028|NCT06432582||cACLD|Patients with compensated advanced chronic liver disease (cACLD) regardless of etiology
62392029|NCT03471494||Breast cancer|
62392030|NCT03471494||Gastric cancer|
62392031|NCT03471494||Colon cancer|
62392032|NCT04762420||Sugammadex dose as suggested by senior anaesthesiologists (SSD) based on clinical experience.|
62392033|NCT04762420||Dose of Sugammadex determined by quantitative monitoring (QSD).|
62392034|NCT06099860|EXPERIMENTAL|Group A|KBT Group
62392035|NCT06099860|EXPERIMENTAL|Group B|BT Group
62392036|NCT02207127||MRI, DISE, and Surgery|All participants will undergo MRI and DISE prior to undergoing surgical treatment of obstructive sleep apnea.
62392037|NCT04148976|PLACEBO_COMPARATOR|Placebo (P)|The placebo consisted of 30g of calcium caseinate, 30g of maltodextrin, and 0.2g of flavoring. The placebo was provided in a dehydrated form in a packet containing 30g each provided twice a day. The content of each packet was dissolved in 250ml of water.
61997733|NCT06227507|EXPERIMENTAL|Exclamation Mark with Black Background|"Participants will be shown 3 frozen meals at once; each product will be high in 1, 2, or 3 nutrients of concern (added sugar, sodium, and/or saturated fat) and will be labeled as such with a rectangular high in front-of-package label. The label will contain high in and nutrient text, along with an exclamation mark icon. The background of the high in text will be black, and the high in text will be white."
61997734|NCT04233970|EXPERIMENTAL|Intervention group|Participants randomized to the intervention group will receive access to the multi-component, web-based intervention programme. The intervention programme will be developed in line with principles of patient empowerment and based on the Theory of Planned Behaviour.
62773460|NCT04374058||Two Times|The treatment group consists of selected patients that, based on their mean ultrafiltration rate, are switched from thrice-weekly to twice-weekly hemodialysis sessions
62773461|NCT04374058||Three times|Usual thrice-weekly hemodialysis schedule
62773462|NCT04761848|EXPERIMENTAL|Cilostazol|
62773463|NCT04761848|PLACEBO_COMPARATOR|Placebo|
61997735|NCT04233970|ACTIVE_COMPARATOR|Control group|Participants randomized to the control group will receive access to the web-based control programme with optimized standard care.
62773464|NCT06431230|EXPERIMENTAL|Standard HIIT Experimental Group (SH-EG)|SH-EG - Standard HIIT Experimental Group, participants who will perform typical high-intensity interval training
61997736|NCT01861496|EXPERIMENTAL|LiPlaCis|Dose escalation of LiPlaCis - a liposomal formulation of cisplatin will be administered intravenously in cycles every 3 weeks on day 1, day 8. Upon the investigator's judgement the patient may continue treatment for more than 3 cycles when benefiting from the study drug.
61997737|NCT04501731||Young PFT survivors|
61997738|NCT04501731||Age-matching controls|
61997739|NCT00547703|ACTIVE_COMPARATOR|Nortriptyline|Patients in this group will receive Nortriptyline 25mg at night for 8 weeks.
61997740|NCT00547703|PLACEBO_COMPARATOR|Sugar pill|Patients in this group will receive an identical placebo capsule at night for 8 weeks.
61997741|NCT03149237|NO_INTERVENTION|Standard of Care|The 12 clinics randomized to the control arm will continue to provide standard of care (SOC) EMTCT services that include: standard HoPS male engagement (male invitation to ANC services and couples HIV testing), opt-out rapid HIV testing of all pregnant women attending ANC, HIV-specific counseling and support for all women who test positive, provision of cotrimoxazole prophylaxis, and universal ART, as per option B+ guidelines.
62183190|NCT04240028||Individuals with MCR|The diagnosis of MCR syndrome will be made following the criteria of Verghese et al. 5: a combination of subjective cognitive complaint, in particular of memory complaint, with the presence of an objective slow gait and the absence of dementia or mobility disability. MCR syndrome will be defined at baseline assessment and each year of follow-up period. Slow gait speed will be defined as gait speed that is one standard deviation (SD) or more below age-and sex-appropriate mean values established in the present cohort like in previous studies. The mean value and SD of female and male will be determined separately. Gait speed was determined from the 3-meter walking test using the best time of the two trials recorded and expressed as meters per second.
62773465|NCT06431230|NO_INTERVENTION|Standard HIIT control group (SH-CG)|SH-CG - Standard HIIT Control Group, participants that will not perform the HIIT cycles
62183191|NCT00237211|EXPERIMENTAL|Letrozole|
62183192|NCT05763654||Linovera emulsion|No intervention. Routine clinical practice.
62392038|NCT04148976|EXPERIMENTAL|Dietary Portfolio (DP)|The DP included 25g of soy protein, 14g of dehydrated nopal,14g of oats, 4g of chia seeds, 4g of inulin, and 0.15g of flavoring. The DP was provided in a dehydrated form in a packet containing 30g each. The content of each packet was dissolved in 250ml of water.
62392039|NCT06313567|EXPERIMENTAL|Metronomic capecitabine|Low-dose capecitabine maintenance (500 mg/m2 body surface area twice daily for 1 year) after completion of standard adjuvant chemotherapy,
62392040|NCT06313567|ACTIVE_COMPARATOR|Standard therapy group|Observation after completion of standard adjuvant chemotherapy,
62392041|NCT04186754|EXPERIMENTAL|Comprehensive functional care plan|"The intervention will be carried out thanks to the reeducation to the effort carried out in the individuals, which will have the following interventions:~The treatment should be carried out INDIVIDUALIZED, in the hospital room or in a conditioned room, in sessions of approximately 30 minutes and on a daily basis. Carried out by professionals in the disciplines of nursing and occupational therapy."
62773466|NCT06431230|EXPERIMENTAL|Plyometric HIIT Experimental Group (PH-EG)|PH-EG - Plyometric HIIT Experimental Group, participants who will perform plyometric high-intensity interval training
62773467|NCT06431230|NO_INTERVENTION|Plyometric HIIT Control Group (PH-CG)|PH-CG - Plyometric HIIT Control Group, participants that will not perform the HIIT cycles
62773468|NCT03517462|EXPERIMENTAL|Ivermectin|Single dose directly observed treatment with Ivermectin 3Mg Tab (150 ug/kg) delivered orally.
62773469|NCT00000932||A|Participants currently enrolled in or currently being followed in an ongoing qualifying study. Qualifying studies can be found in the protocol.
62773470|NCT00000932||B|Participants previously enrolled in but not currently being followed in a qualifying study. Qualifying studies can be found in the protocol.
62773471|NCT00000932||C|Antiretroviral-naive participants not enrolling in a qualifying study (i.e., patients starting treatment outside the first study or patients deferring treatment)
62773472|NCT02628548|EXPERIMENTAL|Cognitive training program 1|This 8-week program will meet once per week for 1.5 hours. Participants will be trained in performing various cognition enhancing techniques at each class, and will practice these techniques both in class and at home each day for 45 minutes.
62773473|NCT02628548|EXPERIMENTAL|Cognitive training program 2|This 8-week program will meet once per week for 1.5 hours. Participants will be trained in performing various cognition enhancing techniques at each class, and will practice these techniques both in class and at home each day for 45 minutes.
62773474|NCT01774188||Intraocular pressure, EECP, no glaucoma|To examine no glaucoma patients' intraocular pressure before and after the treatment of Enhanced Extracorporeal Counterpulsation. EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks
62773475|NCT01774188||intraocular pressure, EECP, glaucoma|To examine glaucoma patients' intraocular pressure before and after the treatment of Enhanced Extracorporeal Counterpulsation. EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks.
62791517|NCT00246701|EXPERIMENTAL|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
62568078|NCT02141880||Treatment|All subjects will be under the same protocol which is eating and drinking on one afternoon.
62568079|NCT03948529|EXPERIMENTAL|eltrombopag|Eligible patients will receive the investigational drug eltrombopag
62568080|NCT04186793|EXPERIMENTAL|Guided Grocery Shopping|Participants in this study arm will receive a guided grocery shopping intervention for four weeks.
62773476|NCT00881504|EXPERIMENTAL|"FOLFOX6 and Bevacizumab"|"Intervention = bevacizumab in combination with chemotherapy~Treatment of biliary system carcinoma using Bevacizumab in combination with modified FOLFOX6."
62773477|NCT04851756|EXPERIMENTAL|CRet Group|30 min CRet with F.M on the rectus femoris and gastrocnemius medialis and lateralis
62773478|NCT04851756|SHAM_COMPARATOR|CRet Sham Group|30 min CRet with F.M on the rectus femoris and gastrocnemius medialis and lateralis with turned on CRet device at power 0
62773479|NCT01893736|NO_INTERVENTION|Control|In-hospital usual care consists of routine intrapartum and postnatal obstetric care. No extra intervention will be provided by research team.
62773480|NCT01893736|EXPERIMENTAL|In-hospital professional support|"The participants in in-hospital professional support arm will receive three 30-minute one-to-one hands-on breastfeeding counseling sessions during postpartum hospitalization."
62773481|NCT01893736|EXPERIMENTAL|Postpartum telephone follow-up support|"Participants in postpartum telephone follow-up support arm will receive telephone support in the first 4 weeks postpartum."
62773482|NCT01895309|EXPERIMENTAL|SB4 (proposed biosimilar to etanercept)|SB4 50 mg/week via subcutaneous injection
62773483|NCT01895309|ACTIVE_COMPARATOR|Enbrel (etanercept)|Enbrel 50 mg/week via subcutaneous injection
62773484|NCT01508260|EXPERIMENTAL|Pilot Phase Aquapheresis|The first portion of this study is an open label pilot experience to evaluate the safety of aquapheresis in leukemia patients with severe fluid overload non-responsive to diuretics. A total of 10 patients will be treated.
62392042|NCT04186754|ACTIVE_COMPARATOR|Traditional intervention without rehabilitation|"* Nursing care.~* Medical care.~* Spiritual attention."
62392043|NCT00816543|EXPERIMENTAL|1|3 cycles of neoadjuvant chemotherapy of Docetaxel, Oxaliplatin and S-1. Surgery 5 to 6 weeks after completion of the chemotherapy.
62773485|NCT01508260|EXPERIMENTAL|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. About 6 teaspoons of blood will flow through the blood circuit, and the excess fluid will slowly be collected in the collection bag. The exact length of time of aquapheresis treatment is determined by how much fluid needs to be removed and how fast it can be removed. The average treatment is about 24 hours but can extend up to 7 days. About 6 liters or 13 pounds will be removed.
62773486|NCT01508260|ACTIVE_COMPARATOR|Diuretics|Furosemide by vein over about 15 minutes every 8 hours or by vein as a continuous (non-stop) infusion.
62392044|NCT05346731|ACTIVE_COMPARATOR|Control group|"1. Weight category 30-40 kg will receive: dexamethasone (5 mg/m2), ondansetron (0.15 mg/kg), aprepitant (80 mg)~2. Weight category \> 40 kg will receive:~dexamethasone (5 mg/m2), ondansetron (0.15 mg/kg), aprepitant (125 mg) Note: aprepitant at a dose of 80 mg/day. applied for another 2 days, regardless of the number of days of chemotherapy."
62568081|NCT04186793|EXPERIMENTAL|Diet Provision Group|"Participants in this study arm will be provided with a diet low in free sugars. This intervention replaces the habitual diet with a low free sugars diet (goal of \<3% of total calories)."
62773487|NCT02869698|EXPERIMENTAL|Evaluation of cognitive functions by Spectral Dynamic Imaging|Evaluation of cognitive functions by SDI will be conducted during the exploration SEEG (which usually lasts from 1 to 3 weeks), and started a few days after implantation of intracranial electrodes
62773488|NCT01833000|OTHER|newborn suspected to suffer from necrotizing enterolitis|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler
61997742|NCT03149237|EXPERIMENTAL|Couples-based Services|The 12 clinics randomly assigned to the intervention arm will receive a combination of community and clinical EMTCT services, including: (1) ANC-based couples HIV testing, couples-based treatment enrollment, and clinical care for sero-concordant HIV+ expectant couples; (2) couple-centered treatment in the post-partum period at the EID clinic; (3) couples-based education and skills building during the ANC and post-partum period; and (4) treatment continuity support by expert-patient (peer) navigators selected among couples who have successfully navigated EMTCT.
62773489|NCT04896372|EXPERIMENTAL|ACT intervention|The ACT condition (comprehensive of standard care) comprises a three-week in-hospital multidisciplinary rehabilitation program for weight loss and a psychological intervention based on ACT combined with a standard psychological assessment and support to the hospitalization.
62392045|NCT05346731|EXPERIMENTAL|Olanzapine|"1. Weight category 30-40 kg will receive:~   dexamethasone (5 mg/m2), ondansetron (0.15 mg/kg), aprepitant (80 mg), olanzapine (2.5 mg)~2. Weight category \> 40 kg will receive: dexamethasone (5 mg/m2), ondansetron (0.15 mg/kg), aprepitant (125 mg), olanzapine (2.5 mg for \<55 kg, 5 mg for \>55 kg) Note: aprepitant at a dose of 80 mg/day. applied for another 2 days, regardless of the number of days of chemotherapy."
62392046|NCT05396196|ACTIVE_COMPARATOR|Pre-Tape|
62392047|NCT05396196|EXPERIMENTAL|With Tape 1|
62392048|NCT05396196|EXPERIMENTAL|With Tape 2|
62392049|NCT05396196|EXPERIMENTAL|Post-Tape|
62392050|NCT06306417|EXPERIMENTAL|Experimental group|acupuncture
62392051|NCT06306417|SHAM_COMPARATOR|control group|sham acupuncture
62568082|NCT03189095|EXPERIMENTAL|Intervention|
62568083|NCT03189095|NO_INTERVENTION|Wait-List Control|
62568084|NCT03995485|EXPERIMENTAL|KW-136+SOF|Treatment-naive and experienced subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
62568085|NCT05087264|EXPERIMENTAL|Indocyanine green injection|43 cases received preoperative intravenous injection of indocyanine green and radical resection of q-mc1 cervical cancer under pelvic autonomic nerve fluorescence development
62568086|NCT05087264|NO_INTERVENTION|Not Indocyanine green injection|43 cases underwent routine surgery，not indocyanine green injection
62568087|NCT06390904|EXPERIMENTAL|Obese EAH group|"This group including 29 EAH cases. Interventional Study Model was Simon two-stage optimal design. Eleven patients were needed for the first stage, and if eight or more patients achieved CR at 28 weeks, the trial can enter into the second stage.~Then every 12 to 16 weeks, an hysteroscope will be used to evaluate the endometrial condition, and the pathological findings will be recorded."
61997743|NCT03331796|EXPERIMENTAL|Active rTMS (Bilateral DLPFC)|One-third of participants will receive active rTMS to the right and left dorsolateral prefrontal cortex (DLPFC).
62773490|NCT04896372|OTHER|Standard care|The TAU comprises a three-week in-hospital multidisciplinary rehabilitation program for weight loss and the standard psychological assessment and support to the hospitalization
62392052|NCT02809963|ACTIVE_COMPARATOR|Eplerenone|Eplerenone 50 mg tablets. 2-4 tablets once daily for 26 weeks
62392053|NCT02809963|PLACEBO_COMPARATOR|placebo|sugar pill manufactured to mimic Eplerenone 50 mg tablet. 2-4 tablets once daily for 26 weeks.
61997744|NCT03331796|EXPERIMENTAL|Active rTMS (Bilateral LPC)|One-third of participants will receive active rTMS to the right and left lateral parietal cortex (LPC).
62773491|NCT04943120|EXPERIMENTAL|"Snow-Plow technique"|In class II cavities, application of X-tra Base bulk fill flowable composite (VOCO) in 1 mm thickness without curing followed by X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. Polymerization as one unit for 20 seconds.
62183193|NCT06091137||Non-appendectomy controls|
62773492|NCT04943120|ACTIVE_COMPARATOR|Bulk Fill technique|In class II cavities, application of 4 mm increment of X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. then the restoration id fully polymerized.
62773493|NCT04354272||Questionnaire|
62773494|NCT00605891|EXPERIMENTAL|A|carmoterol (CHF 4226) 1.0 μg once a day, in the morning
62183194|NCT06091137||Appendectomy cases|
62183195|NCT05008263||Patients with viral chronic liver disease at primary diagnosis|Patients with primary diagnosis of viral hepatitis B and hepatitis C who was referred for liver biopsy. All patients underwent liver shear wave elastography and dynamic liver scintigraphy evaluating liver physical and functional changes shortly prior to liver biopsy procedure.
62183196|NCT05974683|PLACEBO_COMPARATOR|Basic Maintenance Treatment|Continue use of current basic maintenance treatment of IgG4-RD plus placebo, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
62773495|NCT00605891|EXPERIMENTAL|B|carmoterol (CHF 4226) 2.0 μg once a day, in the morning
62773496|NCT00605891|EXPERIMENTAL|C|carmoterol (CHF 4226) 4.0 μg once a day, in the morning
62773497|NCT00605891|PLACEBO_COMPARATOR|D|Placebo once a day, in the morning
62773498|NCT00605891|ACTIVE_COMPARATOR|E|Salmeterol 50 μg BID, in the morning and in the evening
62773499|NCT02502981|EXPERIMENTAL|CKD stage 2 & 3|"Patients with CKD stage 2 \& 3 (eGFR 30-89ml/min/1.73m2) will be randomly assigned to receive either spironolactone or chlortalidone in a PROBE design.~Subjects will undergo cardiac MRI, carotid femoral pulse wave velocity, 24 hour ambulatory blood pressure monitoring, blood tests for renal function and spot urine analysis for proteinuria (albumin:creatinine ratio) at baseline and after 40 weeks of allocated treatment. Additional blood tests for renal function and potassium level will be assessed at week 1,2,4,8 and 20."
62773500|NCT01997190|EXPERIMENTAL|Study Arm|AdV-tk + valacyclovir
62773501|NCT06542991|EXPERIMENTAL|rTMS group|On the basis of drug treatment, a course of TBS treatment is performed for 7 days.
62773502|NCT02460341|EXPERIMENTAL|ondansetron-8|Single dose of 8 mg ondansetron (crossover with single dose of placebo)
62773503|NCT02460341|EXPERIMENTAL|ondansetron-16|Single dose of 16 mg ondansetron (crossover with single dose of placebo)
62773504|NCT02460341|EXPERIMENTAL|ondansetron-24|Single dose of 24 mg ondansetron (crossover with single dose of placebo)
62392054|NCT01941472|EXPERIMENTAL|Septic shock|Adult patients (at least 18 years of age) with refractory hypotension secondary to sepsis who, at the discretion of treating physicians, required fluid challenge in the presence of invasive hemodynamic monitoring. Refractory hypotension was defined as need of vasopressors to maintain systolic blood pressure (SBP) no less than 90 mmHg despite adequate fluid resuscitation.
61997745|NCT03331796|PLACEBO_COMPARATOR|Placebo rTMS (Inactive)|One-third of participants will receive placebo/inactive rTMS, either to the DLPFC or the LPC. Those receiving placebo rTMS will serve as the control group.
61997746|NCT02769702|EXPERIMENTAL|Intervention|Acthar 80 IU SC twice w eek
62183197|NCT05974683|ACTIVE_COMPARATOR|Enhancement Treatment|Use low dose mycophenolate mofetil (0.5g per day) as an add-on therapy of current basic maintenance treatment of IgG4-RD, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
62183198|NCT00552513|OTHER|Early Coronary Intervention|Coronary angiography and intervention (either percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\] surgery) as soon as possible (within 24 hours of randomisation).
62392055|NCT05948800|EXPERIMENTAL|Spraying group|The first group will use an isotonic seawater solution as a nasal spray for 10 days. The group with the isotonic seawater solution applied as a nasal spray will use it at least three times a day, and necessarily before exercise (about 20 minutes before).
62392056|NCT05948800|NO_INTERVENTION|Non-spraying group|The control group will not use such a solution.
62392057|NCT02033486|EXPERIMENTAL|TOBI + DBT|TOBI + DBT of women presenting for breast imaging.
62773505|NCT06212830|ACTIVE_COMPARATOR|Gabapentin|"This group will receive a combination of drugs including:~Gabapentin, NSAIDS and Paracetamol."
62773506|NCT06212830|ACTIVE_COMPARATOR|Targin|"This group will receive a combination of drugs including:~Targin, NSAIDS and Paracetamol."
62773507|NCT06212830|ACTIVE_COMPARATOR|Control|"This group will receive a combination of drugs including:~NSAIDS and Paracetamol."
62773508|NCT02139670||pregnant womens|
62773509|NCT03652519|EXPERIMENTAL|High-intensity Interval Training (HIIT)|Participants of the HIIT group will exercise three times per week over a period of three weeks (inpatient rehabilitation) on a cycle ergometer. Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Each exercise session will last 30 minutes and will be started and finalized with three minutes at low intensity (50% HRmax, warm-up / cool-down). During each exercise session, participants of the HIIT group will perform 5x one-and-a-half Minute high-intensive exercise bouts at 95-100% of their HRmax followed by active breaks of unloaded pedalling over 2 minutes with the aim to achieve 60% HRmax.
62791518|NCT02246426|EXPERIMENTAL|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 40 treatment sessions, 3-5 times weekly, 45-60 minutes per session.
62791519|NCT02246426|ACTIVE_COMPARATOR|Active Comparator|Commercially available computerized training requiring a total maximum of 40 treatment sessions, 3-5 times weekly, 45-60 minutes per session.
61997747|NCT04568122|EXPERIMENTAL|Saliva test|Participants perform each test assay, noting the results for comparison by technician, and completing survey questionnaires.
61997748|NCT06407466|EXPERIMENTAL|taping|kinesiotape
62568088|NCT02219880|PLACEBO_COMPARATOR|Placebo|Inert tablets matched for colour, size and consistency to active arm treatment. Both treatment arm tablets will match in appearance, and neither participants nor the trial clinicians will know what they are taking.
61997749|NCT06407466|EXPERIMENTAL|mobilization|instrument-assisted soft tissue mobilization
61997750|NCT06407466|ACTIVE_COMPARATOR|control|Those who did not receive any intervention
61997751|NCT00414804|ACTIVE_COMPARATOR|Spinal Cord Stimulation (SCS) Group|Spinal Cord Stimulation (SCS) Treatment Group
62568089|NCT02219880|EXPERIMENTAL|Kava - standardised 240mg kavalactones|Standardised 240mg kavalactones per day - fixed dose regime of two tablets of kava twice per day
62568090|NCT03194633||Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)|Male and female patients with a diagnosis of CKD and hypertension (age, 18-70 years) was enrolled.
62568091|NCT03390023||Hispanic Women|Hispanic women who have been pregnant within the past 5 years.
62568092|NCT03390023||Close Family Member|Close family member of participants in Group 1 - Hispanic Women.
62568093|NCT05222932|EXPERIMENTAL|TILT-123 and avelumab|"Patients will receive multiple administrations of TILT-123 and avelumab.~Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level."
62568094|NCT01074801|ACTIVE_COMPARATOR|Closed-loop|Subcutaneous insulin delivery to be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
62568095|NCT01074801|ACTIVE_COMPARATOR|Control arm|Subcutaneous insulin delivery to be administered according the standard insulin pump settings
62568096|NCT02356939|EXPERIMENTAL|Intraductal stent (IST)|"For intervention : intraductal removable stent In the IST group, the surgeon will place the IST in the bile duct, which is a custom-made segment (2 cm) of a 8 French T-tube. The stent is inserted in the biliary duct without suture fixation.~In the IST group, an endoscopic retrograde cholangio-pancreatography (ERCP) with sphincterotomy will be planned between the 4th and the 6th month post-transplantation."
62568097|NCT02356939|EXPERIMENTAL|Without intraductal stent (no IST)|For intervention : stent extraction by endoscopic retrograde cholangio-pancreatography (ERCP) Each center will perform its habitual postoperative follow up.
62568098|NCT05736757|NO_INTERVENTION|Control group|Control group (no tissue fibrinogen activator)
62568099|NCT05736757|EXPERIMENTAL|Drug group|Drug group (injection of 50 ug tissue fibrinogen activator into the suprachoroidal cavity or subretinal space )
62568100|NCT00937274|EXPERIMENTAL|Test product|
62773510|NCT03652519|ACTIVE_COMPARATOR|Moderate Continous Training (ST)|Participants of the ST group will exercise three times per week over a period of three weeks (inpatient rehabilitation) on a cycle ergometer. Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Each exercise session will last 30 minutes and will be started and finalized with three minutes at low intensity (50% HRmax, warm-up / cool-down). During each exercise session, participants of the ST group will exercise 30 minutes continuously at 65% of HRmax. This moderate continous training program represents the standard care at the local rehabilitation clinic.
62773511|NCT04088526|EXPERIMENTAL|intervention group|Through the effective intervention of risk factors for death in patients with dialysis, the effect of mortality of peri-dialysis patients was observed.
62773512|NCT04193774|PLACEBO_COMPARATOR|Drop of artificial tears|A drop op Thealoz duo
62773513|NCT04193774|ACTIVE_COMPARATOR|Drop op anesthetic|A drop of oxybuprocaïne
62791520|NCT05504044|OTHER|Control: Glucose|50 g glucose dissolved in 250 mL water
62791521|NCT05504044|OTHER|Control: Bread|91.4 g white bread
62791522|NCT05504044|EXPERIMENTAL|Bread and Almond paste|88.7 g white bread and 15 g almond paste
61997752|NCT00414804|ACTIVE_COMPARATOR|Nerve Blocks and PT|
61997753|NCT06087965|EXPERIMENTAL|Fingolimod group|0.5mg/day oral fingolimod over a course of 3 consecutive days
62183199|NCT00552513|OTHER|Delayed Coronary Intervention|Delayed intervention: Coronary angiography and intervention (either percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\] surgery) any time after 36 hours after randomisation.
62214566|NCT06086600|EXPERIMENTAL|Instrument Assisted Soft Tissue Mobilization|"Graston tool on gastrocnemius and soleus muscle. Conventional treatment will include~* Hot pack for 10-15 min (calf muscles)~* Stretching exercises of gastro-soleus (10reps x 2Sets).~* Post session : Cold pack for 5 minutes (calf muscles)"
62568101|NCT00937274|ACTIVE_COMPARATOR|Commercial product|
62568102|NCT00937274|PLACEBO_COMPARATOR|Standard care|
62568103|NCT01311271|SHAM_COMPARATOR|Sham rTMS-Sham rTMS|Sham rTMS for 2 weeks
62568104|NCT01311271|EXPERIMENTAL|Sham rTMS-Real rTMS|Sham rTMS in the first week and real rTMS in the second week
62568105|NCT01311271|EXPERIMENTAL|Real rTMS-Real rTMS|Real rTMS for 2 weeks
62568106|NCT03283657|EXPERIMENTAL|DiRECT|DiRECT consists of the following components that will be delivered by medical assistants before patients' routinely scheduled office visits: 1) a prediabetes decision aid focused on type 2 diabetes (T2D) risk and treatment options for preventing T2D; 2) a 'think aloud' exercise; and 3) formulating a preliminary treatment plan for T2D prevention.
62568107|NCT03283657|ACTIVE_COMPARATOR|Usual Care (UC)|Participants randomized to standard care will receive routine medical care without the medical assistant delivered DiRECT intervention.
61997754|NCT06087965|NO_INTERVENTION|Control group|No fingolimod will be administered.
61997755|NCT01800617|EXPERIMENTAL|Liothyronine, Sodium|
61997756|NCT00436943||A|Smokers
61997757|NCT00820001|EXPERIMENTAL|Acute Treatment Protocol Booster|Child participants in this arm were initial participants enrolled in the parent study and randomized to receive the specialty treatment from study clinicians in either the clinic or community setting. In this continuation study, the participants were enrolled at the 36 month assessment and randomized to participate in the booster dose of treatment. The treatment provided in this arm includes specific booster treatment based on the 8 modules of the initial treatment study. Saliva samples were also collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
61997758|NCT00820001|EXPERIMENTAL|Acute Treatment Protocol No-Booster|Child participants in this arm were initial participants enrolled in the parent study and randomized to receive the specialty treatment from study clinicians in either the clinic or community setting. In this continuation study, the participants were enrolled at the 36 month assessment and randomized to participate in assessments only thus not receiving any additional booster treatment. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
61997759|NCT00820001|ACTIVE_COMPARATOR|Treatment As Usual|Child participants in this arm were initial participants enrolled in the parent study in the clinically referred Treatment As Usual comparison group. These participants were initially enrolled in treatment services with identified providers and received treatment services as provided in that community agency. In this continuation study, the participants were enrolled at the 36 month assessment and participated in the ongoing follow-up assessments only. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
62183200|NCT04332432|EXPERIMENTAL|belapectin|"Single dose of 4 mg/kg of lean body mass (LBM) belapectin solution for injection administered intravenously (infused over approximately 60 minutes).~Group 1: 16 matched healthy subjects with normal hepatic function~Group 2: 8 subjects with mild hepatic impairment (Child-Pugh Class A \[4 x subjects with a score of 5 and 4 x subjects with a score of 6\])~Group 3: 8 subjects with moderate hepatic impairment (Child-Pugh Class B \[score of 7 to 9\])~Group 4: 8 subjects with severe hepatic impairment (Child-Pugh Class C \[score of 10 to 14\])."
62183201|NCT03195049|EXPERIMENTAL|blood group|blood is collected for maternal and infant blood group,complete blood count,before, during and after the procedure of exchange transfusion .
62183202|NCT03195049|EXPERIMENTAL|serum bilirubin estimation|estimation of serum bilirubin before, during and after the procedure of exchange transfusion .
62392058|NCT02766699|EXPERIMENTAL|EGFR(V)-EDV-Dox|EGFR(V)-EDV-Dox administered via 20 minute intravenous infusion once a week for seven weeks (1 Cycle). Subjects will receive one of two dose levels: 5 x 10\^9 or 8 x 10\^9. All subjects will undergo an adapted dose escalation regime in the first cycle of treatment. For subsequent cycles all doses will be administered at full strength (5x10\^9 or 8x10\^9 EGFR(V)-EDV-Dox). Subjects may receive further cycles of treatment if the tumor remains stable or is responding, and/or they are deriving clinical benefit from the therapy and are tolerating treatment.
62392059|NCT01815996||Pregnant Women|"Females between the age of 18-80 who are pregnant~One time blood draw to look at patient's DNA"
62392060|NCT01815996||Pulmonary Embolism Patients|"Male and Female patients that have suffered a pulmonary embolism within the past 48 hours~One time blood draw to look at patient's DNA"
62568108|NCT04408729|EXPERIMENTAL|PrEP My Way intervention|PrEP My Way is an intervention that involves peer-delivery of a kit containing PrEP and other sexual health services. Participants will be offered PrEP if HIV-negative per a point-of-care test, pregnancy testing, vaginal swabs for gonorrhea and chlamydia testing, condoms, and/or self-injection medroxyprogesterone, as desired.
62568109|NCT04408729|NO_INTERVENTION|Control|These participants will continue to receive PrEP at the clinic.
62568110|NCT04384003|ACTIVE_COMPARATOR|Shear Wave Ultrasound Elastography|Shear Wave Ultrasound Elastography (SWUE, AplioTM 300 Platinum, Toshiba Medical System Corp, Japan, 6I) to examine the morphology and mechanical properties (μ = ρVs2, μ is the shear modulus of the tissue, ρ is the density of muscle (1000 kg m-3), Young's modulus )
62568111|NCT04384003|ACTIVE_COMPARATOR|The 3-D Motion Analysis|An optoelectronic-based 3D motion analysis system, including cameras, force plates, and an EMG system will be used in this study. A lower limb model (pelvis included) will be established through commercial motion analysis software (VICON Corp, UK). We will use this model to measure joint kinematics, joint kinetics, and ground reaction forces during functional activities, such as level walking.
62568112|NCT04384003|ACTIVE_COMPARATOR|EMG acquisition system|Electromyographic signals measures will be focused on the Abductor Hallucis (AbdH), Peroneus Longus (PL) and Previous Brevis (PB), Gluteus Medius (Glut Med), and Gluteus Maximus (Glut Max). In order to reduce the cross-talk of other muscles in the foot, a miniature wireless surface EMG sensor (TrignoTM Mini Sensor, Delsys Inc. USA) will be used after confirmation of our previous research results.
62773514|NCT03688243||Cohort 1 'IMPACT Cohort'|Subjects with intermediate AMD in both eyes, and at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR subjects with AMD (early or intermediate) diagnosed in one eye and exudative AMD diagnosed in the fellow eye will undergo SS-OCT imaging every 3 months for 2 years
61997760|NCT00820001|OTHER|No Intervention Healthy Comparison|The Healthy Control subjects enrolled initially in the parent study are incorporated in a related project designed to evaluate the role of biological measures in differentiating antisocial and normal children. All Healthy Control participants were initially matched to cases in the clinical sample (both the acute treatment and the clinically referred Treatment as Usual).
62183203|NCT04186052|EXPERIMENTAL|BCMA CAR-T cells Infusion|
62183204|NCT00623363|ACTIVE_COMPARATOR|piclozotan|Participants will be randomized to receive two 12-hour intravenous (IV) infusions of piclozotan administered at a plasma level of 30 ng/mL over 2 inpatient days.
62392061|NCT01815996||Myocardial Patients|"Male and Female patients who have myocardial infarction in the past 48 hours.~One time blood draw to look at patient's DNA"
62392062|NCT01815996||Autoimmune Patients|"Male and Female patients that have been diagnosed with an Autoimmune disease~One time blood draw to look at patient's DNA"
62392063|NCT01815996||Healthy Controls|"Self-declared healthy adults (men and women).~One time blood draw to look at patient's DNA"
62392064|NCT02361307|PLACEBO_COMPARATOR|conventional ADL training|The control group receive the conventional ADL training programme
62392065|NCT02361307|ACTIVE_COMPARATOR|seamless ADL training|The experimental group receive the seamless ADL training programme which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training.
62392066|NCT03658031|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10mg per/day in prediabetes cases with MI before breakfast
62392067|NCT03658031|NO_INTERVENTION|Placebo|Antiplatelet, ACEI and Betablockers
62392068|NCT02978339|EXPERIMENTAL|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
62568113|NCT04384003|ACTIVE_COMPARATOR|Foot intrinsic muscle assessment and training device|"Schematic diagram of the novel modified foot intrinsic muscle (FIM) assessment and training device, which consists of one controller unit (signal generators, amplifier and A/D converter; signal generators provide noise-enhanced vibration to facilitate the muscle activation), 2 voice coil motor \& server, 2 optical rulers, 2 rail scale, and 7 load cells.~The main concept for this design is to provide the quantitative assessment of the foot intrinsic muscles and facilitation of intrinsic muscles of the fool during functional sporting activities such single-leg-standing and kicking."
61997761|NCT02559869||Amyotrophic Lateral Sclerosis (ALS)|Subjects will be diagnosed with possible, probable, probable-lab supported, or definite ALS.
62183205|NCT00623363|PLACEBO_COMPARATOR|0.9 % sodium chloride (normal saline)|Participants will be randomized to receive two 12-hour intravenous (IV) infusions of 0.9 % sodium chloride (normal saline) administered at a plasma level of 30 ng/mL over 2 inpatient days.
62392069|NCT03703609|EXPERIMENTAL|Tele-yoga|Intervention of doing medical yoga at home (tele-yoga) using (1) an online videoconference system (zoom) for particpating in group-yogaled by a live yoga instructor for 60 minutes twice a week and (2) daily individual yoga for a minimum of 10 minutes using a yoga-app. Participants are provided with a tablet with conference system zoom and yoga app for 12 weeks
62392070|NCT03703609|NO_INTERVENTION|Individual physical activty advice|The active control group will receive advice to be physically active that corresponds to the intervention group in time and effort, equivalent to 60 minutes for 2 days a week and a minimum of 10 minutes for 5 days a week. To compensate for the extra attention received by the intervention group by the instructor via tele-yoga group, the participants in the activecontrol group's patients will be dialed or have SMS contact (the participant chooses a type of contact) with a physiotherapist or nurse after 2, 4, 8 and 12 weeks.
62568114|NCT00751062|ACTIVE_COMPARATOR|Timolol|
62773515|NCT03688243||Cohort 2 'SWAGGER Cohort'|Subjects with GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye will undergo SS-OCT imaging every 3 months for 2 years
62773516|NCT03688243||Cohort 3|Subjects with GA enrolled in another trial
62773517|NCT00843154|EXPERIMENTAL|Candesartan QD|
62773518|NCT00843154|ACTIVE_COMPARATOR|Standard chronic heart disease therapy|
61997762|NCT02559869||Healthy Controls|Subjects with no known neurological disorder.
62392071|NCT05460728|EXPERIMENTAL|Dry needling|
62568115|NCT00751062|EXPERIMENTAL|PhXA41|
62568116|NCT05639049|EXPERIMENTAL|Enova GF3|Patient will receive the monofocal IOL in one eye during cataract surgery
62568117|NCT05639049|EXPERIMENTAL|Tecnis 1-piece ZCB00|Patient will receive the monofocal IOL in one eye during cataract surgery
62773519|NCT06026501|EXPERIMENTAL|PE0116+PE0105|PE0116 injection will be given 1mg/kg or 2mg/kg every three weeks and PE0105 injection will be given 3mg/kg every threee weeks until there appears evidence of progressive disease, intolerable toxicity, or the patient discontinues from the study treatment for other reasons.
62773520|NCT01441466||Group without isolation|Patients in this arm are nursed together (in the same room) independent of viral agent.
61997763|NCT02697162|EXPERIMENTAL|Antiseptic-coated catheter|Hydrophilic intermittent urinary catheter coated with octenidine chloride
61997764|NCT02697162|PLACEBO_COMPARATOR|Hydrophilic catheter|Hydrophilic intermittent urinary catheter
61997765|NCT04892238||Treatment-naïve|Subjects without previous experience of treatment provided for H.pylori infection
61997766|NCT04892238||treatment experienced|Subjects who were previously tested positive for H.pylori infection and who were treated for H.pylori infection with at least 2 antibiotics in combination with proton pump inhibitor not less than 6 weeks before the 13C-urea breath test
61997767|NCT04382911|EXPERIMENTAL|18F-fluoroestradiol PET / MRI|All enrolled subjects will receive the tracer and then have a PET/MRI scan.
62568118|NCT00473317|EXPERIMENTAL|1|All subjects in this study will be in the active arm
62773521|NCT01441466||group with isolation|Patients in this arm are nursed separately until the test result of the PCR (polymerase chain reaction) for viral agents is known (within 24-48 hrs). RS-positive patients are nursed separately (separate room) from RS-negative patients
62773522|NCT01501994|EXPERIMENTAL|Walking workstation, counseling, accelerometry feedback|2 week baseline: accelerometer with no feedback 12 experimental: Use of the walking workstation, counseling on increasing activity levels, feedback from the accelerometer 12 week crossover: Feedback from accelerometer, no counseling or walking workstation
62183206|NCT05985902|ACTIVE_COMPARATOR|Control Group|Core stabilization exercise training will be given to the control group for 12 weeks, 7 days a week, for 60 minutes. Core stabilization exercises will be applied to this group under the supervision of a physiotherapist for 2 days in our unit, while home-based core stabilization exercise training will be given on other days of the week.
62392072|NCT00204568|ACTIVE_COMPARATOR|1|Adriamycin mono
62392073|NCT00204568|EXPERIMENTAL|2|Trofosfamide
62392074|NCT04614142|EXPERIMENTAL|Experimental: Glecaprevir/pibrentasvir for HCV+ kidney transplant recipient|"Glecaprevir (100mg) / pibrentasvir (40mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor.~Subject will receive first dose on day 3 (+/- 2 days) post-kideny transplantation and continue daily for 8 weeks."
62392075|NCT04469309|EXPERIMENTAL|Group I|Group I will receive Brandoff Exercises
62392076|NCT04469309|ACTIVE_COMPARATOR|Group II|Group II will receive Somersault exercises
62568119|NCT04471194|EXPERIMENTAL|Self-Sampling Intervention|Participants in this group will receive cervical and colorectal cancer self-sampling kits, instructions for completing the self-sampling kits, and educational materials about cervical and colorectal cancer.
62568120|NCT04471194|NO_INTERVENTION|Control|Participants in this group will receive a standardized letter informing them that they are out-of-date for both cervical and colorectal cancer screenings and should schedule an appointment with their provider to receive these screenings.
62568121|NCT01120184|EXPERIMENTAL|Trastuzumab + Taxane (docetaxel or paclitaxel)|
62568122|NCT01120184|EXPERIMENTAL|Trastuzumab emtansine + pertuzumab|
62568123|NCT01120184|EXPERIMENTAL|Trastuzumab emtansine + pertuzumab placebo|
62568124|NCT04273347||patient with brain trauma|all patient with brain trauma in intensive care unit
62568125|NCT04273347||patient with spinal cord injury|all patient with spinal cord injury in intensive care unit
62568126|NCT02637882|EXPERIMENTAL|First intervention (ear plug)|"Other: ear plug~Other Name: eastnova ear plug"
62568127|NCT02637882|OTHER|Second intervention (eye mask)|"Other: eye mask~The patients will receive the second intervention (eye mask) in the second night (N2) from 9 pm to 6 am.~Other Name: Sleeping mask"
62568128|NCT02637882|OTHER|Ear plug and eye mask|The patients will receive the mixed intervention (eye mask) and (ear plug ) in the first night (N1) from 9 pm to 6 am.
62568129|NCT01240681|OTHER|FLT PET and BOLD MRI scan|All subjects will have the study intervention of FLT PET and BOLD MRI at baseline and after the first cycle of chemotherapy
62568130|NCT01080638|EXPERIMENTAL|Abciximab IC bolus|After CAG, For patients with undergoing percutaneous coronary intervention, intracoronary only or intravenous bolus abciximab(0.25mg/kg body weight) administration with intravenous bolus group has subsequent 12-hours continuous infusion at a dose 0.125ug/kg per minute (maximum: 10ug/min)
62568131|NCT01080638|ACTIVE_COMPARATOR|Abciximab IV bolus and 12hr continuous|
62568132|NCT05760989|EXPERIMENTAL|Treatment with the Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System|
62568133|NCT06574854|EXPERIMENTAL|DSW|Descending Stair Walking
62568134|NCT06574854|ACTIVE_COMPARATOR|ASW|Ascending Stair Walking
61997768|NCT05583396|OTHER|Acute exercise|Pulmonary diffusing capacity using the DLCO/NO technique is assessed at rest and during exercise (60% of maximal workload on a bicycle ergometer)
62568135|NCT01954056|ACTIVE_COMPARATOR|Hydrocortisone|hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line
62568136|NCT01954056|PLACEBO_COMPARATOR|Placebo|Saline placebo
62568137|NCT05851807||Patints with COVID-19 History|Patients with infected with COVID-19 in any time.
62568138|NCT05851807||Patints without COVID-19 History|Patients without COVID-19 history.
62568139|NCT04996914|EXPERIMENTAL|TACE+SBRT.|If a patient is eligible to participate in the project according to the in- and exclusion criteria, the patient will assigned to 1-2 sessions of TACE followed by SBRT within one month from last TACE session .
62568140|NCT00086177|ACTIVE_COMPARATOR|1|Progesterone 8% vaginal gel
62568141|NCT00086177|PLACEBO_COMPARATOR|2|Placebo Vaginal Gel
62568142|NCT01734005|EXPERIMENTAL|Red Ginseng|
62568143|NCT01734005|PLACEBO_COMPARATOR|Placebo|
62568144|NCT00749073|OTHER|Percutaneous Lumbar Decompression procedure|mild percutaneous lumbar decompression procedure
62568145|NCT00864929||1|Appropriate antimicrobial treatment
62568146|NCT00864929||2|Inappropriate antimicrobial treatment
62568147|NCT06576817|EXPERIMENTAL|Lower extremity and upper extremity exercise|Exercises in the circuit (8 total) will focus on the lower extremity (4) and upper extremity (4)
62568148|NCT06576817|ACTIVE_COMPARATOR|Lower extremity exercise|Exercises in the circuit (8 total) will focus on the lower extremity (4) alone.
62568149|NCT03068234|EXPERIMENTAL|Pirfenidone group|The subjects will receive pirfenidone from 200mg three times a day, oral administrated, with low dose steroids.
62568150|NCT03068234|PLACEBO_COMPARATOR|Control group|The subjects will receive placebo within first 24-week, and pirfenidone 200mg three times a day for the second 24-week, with low dose steroids.
62568151|NCT02376712||Pre-renal AKI|"Three definitions of pre-renal AKI will be used separately:~1. Hemodynamic instability (any sign of tissue hypoperfusion) on AKI identification, and AKI recovery in 24-72 hours following hemodynamic stabilization.~2. AKI recovery in less than 72 hours after AKI identification.~3. Decreased renal blood flow measured by transesophageal echocardiography (TEE)."
62791523|NCT05504044|EXPERIMENTAL|Bread, Almond paste and Inulin|88.7 g white bread, 15 g almond paste and 4 g inulin
61997769|NCT02366832|EXPERIMENTAL|Cryoablation|Amputee subjects experiencing phantom limb syndrome (PLS) will receive cryoablation
61997770|NCT03461224||MARA-1: accelerated hypofractionated RT|A forward planned IMRT technique was used and the prescribed dose to the breast was 40 Gy in 16 fx with a concomitant boost of 4 Gy.
62568152|NCT02376712||Renal AKI|"Three definitions of renal AKI will be used separately:~1. Hemodynamically stable at AKI identification; or hemodynamically instability (any sign of tissue hypoperfusion) on AKI identification, and AKI persistence in 24-72 hours following hemodynamic stabilization.~2. AKI persistence 72 hours after AKI identification.~3. Normal or increased renal blood flow measured by TEE."
62568153|NCT06574152|EXPERIMENTAL|EMS and PBM treatment|Photobiomodulation (PBM) therapy will be performed using a 660 nm diode laser (SiroLaser Advance Plus, Dentsply Sirona Inc, Charlotte, North Carolina, USA) following the outline of the incision flap in a contact mode. Each site will be irradiated for 25 seconds with an energy density of 10 J/cm2 (irradiation mode).
62568154|NCT06574152|SHAM_COMPARATOR|EMS and PBM sham treatment|The laser tip will be placed following the outline of the incision flap in a contact mode but without activating it (no irradiation).
62568155|NCT04735523||Warfarin|Reference group
62568156|NCT04735523||Dabigatran|Exposure group
62791524|NCT05504044|EXPERIMENTAL|Bread, Low dose almond paste and Inulin|89.6 g white bread, 10 g almond paste and 3.8 g inulin
62568157|NCT01297517|EXPERIMENTAL|Brinzolamide/Brimonidine|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, one drop instilled in each eye three times a day for 3 months
62568158|NCT01297517|ACTIVE_COMPARATOR|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, one drop instilled in each eye three times a day for 3 months
61997771|NCT03461224||CG: conventional fractionated RT|In the CG, the whole breast received 50.4 Gy in 28 fractions (fx) delivered with 3D-RT, followed by a sequential boost on the tumour bed of 10 Gy in 4 fx delivered with electrons
62568159|NCT01297517|ACTIVE_COMPARATOR|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, one drop instilled in each eye three times a day for 3 months
62773523|NCT01501994|OTHER|Control then crossover|2 week baseline: accelerometer with no feedback 12 week control period: accelerometer with no feedback 12 week crossover period: accelerometer with feedback, counseling on increasing activity, and use of a walking workstation
62773524|NCT02133976|ACTIVE_COMPARATOR|cognitive therapy|Cognitive therapy will be delivered to decrease pain interference
62773525|NCT02133976|ACTIVE_COMPARATOR|mindfulness training|Mindfulness training will be delivered to decrease pain interference
62773526|NCT02133976|ACTIVE_COMPARATOR|behavior therapy|Behavior therapy will be delivered to decrease pain interference
62773527|NCT02133976|ACTIVE_COMPARATOR|treatment as usual|Subjects will engage in their usual care for low back pain.
62773528|NCT04487457||Cancer|Patients receiving chemotherapy alone after immunotherapy for NSCLC or bladder cancer or ENT cancer
62773529|NCT00490776|EXPERIMENTAL|Panobinostat 20 mg|Participants received panobinostat, 20 milligrams (mg), capsules, orally, thrice weekly on alternate Days 1, 3, and 5 per week of a 28-day treatment cycle until unacceptable toxicity, disease progression, and/or physician's discretion to discontinue the treatment.
62773530|NCT03327168|ACTIVE_COMPARATOR|Adenosine|Perfusion is measured using PET/CT during intravenous infusion (0.14 mg/kg/min) of adenosine.
62773531|NCT03327168|NO_INTERVENTION|Room temperature|Perfusion and A2A receptor density is measured using PET/CT in resting room temperature conditions.
62773532|NCT03327168|EXPERIMENTAL|Cold exposure|Perfusion and A2A receptor density is measured using PET/CT during controlled cold exposure.
62773533|NCT02513316||Study I (AF)|Prospective cohort study of patients anticoagulated after cardioembolic stroke started on best practice oral anticoagulant (without prior use) for presumed cardioembolic ischaemic stroke due to non-valvular AF with follow up for the occurrence of ICH, ischaemic stroke and cognitive function for an average of two years. Our main baseline exposures (risk factors of interest) are the presence of CMBs on MRI, and genetic polymorphisms in candidate genes with potential functional relevance to ICH risk.
62773534|NCT02513316||Study II (ICH)|Observational and genetics study of intracerebral haemorrhage Patients with ICH (non anticoagulant-related ICH cases and anticoagulant-related ICH cases).
62773535|NCT01976143|EXPERIMENTAL|NKTR-102|A single 90 minute IV infusion of 220 mg/m2 NKTR-102
62773536|NCT02693379|EXPERIMENTAL|D-VIA|HPV high risk-positive (16, 18, 45, 31, 33, 35, 39, 51, 52, 56, 58, 59, 66, 68) women had a cervical examination using acetic acid (VIA) application and visual inspection.
62773537|NCT03737331|EXPERIMENTAL|Fractal visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be fractal (i.e., pink noise). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
62773538|NCT03737331|ACTIVE_COMPARATOR|Periodic visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be periodic (i.e., invariant). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
62773539|NCT03737331|SHAM_COMPARATOR|Random visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be random (i.e., white noise). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
62773540|NCT03737331|NO_INTERVENTION|Control|Natural walking.
62773541|NCT04259684|EXPERIMENTAL|gNO Group|Participants in the treatment group will receive gNO added to the oxygenator gas flow at 20 ppm throughout the duration of cardiopulmonary bypass.
62773542|NCT04259684|NO_INTERVENTION|Control Group|Participants in the control group will receive standard conduction of cardiopulmonary bypass.
62773543|NCT06533930||MS|(patients with multiple sclerosis)
62773544|NCT06533930||Control|(healthy volunteers)
61997772|NCT01067404||2008-09 study TIV recipients|Infants and toddlers who participated in earlier clinical trial (TITRE) to evaluate dosing (0.25mL versus 0.5mL) of trivalent influenza vaccine (TIV)
62568160|NCT06424613||Lithium Group|
62568161|NCT06424613||Non-lithium Group|
62568162|NCT03102346|EXPERIMENTAL|Home-based Cardiac Rehabilitation group|remote instructed exercise training at home
62568163|NCT03102346|NO_INTERVENTION|routine group|no instructed exercise training
62568164|NCT05697497|EXPERIMENTAL|Immediate start group with gait cadence assessment|This group will wear an activPAL device for 10 days prior to their baseline assessment and for 10 days after their week 12 assessment. The exercise intervention consists of a 2.5 to 3.5 minute daily routine that includes 2 upper body and 2 lower body exercises.
62568165|NCT05697497|EXPERIMENTAL|Immediate start group without gait cadence assessment|The exercise intervention consists of a 2.5 to 3.5 minute daily routine that includes 2 upper body and 2 lower body exercises.
62773545|NCT03214731|EXPERIMENTAL|low dose Art|25mg bid Artesunate and standard of care was given to patients
62773546|NCT03214731|EXPERIMENTAL|high dose Art|50mg bid Artesunate and standard of care was given to patients
62773547|NCT03214731|PLACEBO_COMPARATOR|placebo|Placebo and standard of care was given to patients
62773548|NCT00727558|ACTIVE_COMPARATOR|narafilcon A|spherical soft contact lens worn as a daily disposable modality for one week
62773549|NCT00727558|ACTIVE_COMPARATOR|nelfilcon A|spherical soft contact lens worn as a daily disposable modality for one week
61997773|NCT05949190|EXPERIMENTAL|M-RUSF+ (Maternal Ready-to-Use Supplementary Food + DHA/EPA/choline) and CBT|"Factorial 1. A daily dose of 500mg DHA, 500mg EPA, and 550mg choline will be added to the maternal balanced energy-protein RUSF. One sachet (daily dose) will provide 520 Kcal, 18g protein, and the same quantities of micronutrients as the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) for women. M-RUSF+ will be vacuum sealed and packaged in foil sachets containing 100g of food.~Factorial 2. Among participants randomized to receive M-RUSF+ vs. M-RUSF, those who develop ante- or postpartum depression will receive 6 sessions of CBT adopted for use in illiterate populations will be provided."
61997774|NCT05949190|EXPERIMENTAL|M-RUSF+ (Maternal Ready-to-Use Supplementary Food + DHA/EPA/choline) and no CBT|"Factorial 1. A daily dose of 500mg DHA, 500mg EPA, and 550mg choline will be added to the maternal balanced energy-protein RUSF. One sachet (daily dose) will provide 520 Kcal, 18g protein, and the same quantities of micronutrients as the UNICEF/World Health Organization/United Nations multiple micronutrient supplement for pregnant/lactating women. M-RUSF+ will be vacuum sealed and packaged in foil sachets containing 100g of food.~Factorial 2. Participants who develop ante- or postpartum depression will not receive CBT."
61997775|NCT05949190|EXPERIMENTAL|M-RUSF (Maternal Ready-to-use Supplementary Food without DHA/EPA/choline and CBT|"Factorial 1. M-RUSF will be similar to M-RUSF+, except it will not contain added DHA or EPA, and will only contain 5mg of added choline to help with flavor masking. One sachet (daily dose) will provide 520 Kcal, 18g protein, and the same quantities of micronutrients as the UNIMMAP for pregnant/lactating women. M-RUSF+ will be vacuum sealed and packaged in foil sachets containing 100g of food.~Factorial 2. Participants who develop ante- or postpartum depression will receive 6 sessions of CBT adopted for use in illiterate populations will be provided."
62773550|NCT01416623|EXPERIMENTAL|Henatinib|Henatinib either at 12.5,25,37.5,50,62.5,75,87.5 or 100 mg, p.o. once daily
62773551|NCT00794066||1|TIA
62773552|NCT00794066||2|Ischemic stroke
62183207|NCT05985902|EXPERIMENTAL|Training Group|After the first evaluation, the training group will be given Schroth exercise training for 12 weeks, 7 days a week, for 60 minutes. This group will be given Schroth exercises under the supervision of a physiotherapist for 2 days in our unit, while home-based Schroth exercise training will be given on other days of the week.
62183208|NCT01498562|EXPERIMENTAL|Gefitinib plus Nimotuzumab|Combination therapy group: Gefitinib(250mg daily) and Nimotuzumab (200mg weekly)
62183209|NCT01498562|ACTIVE_COMPARATOR|Gefitinib alone|Mono-therapy group: Gefitinib(250mg daily)
62392077|NCT01766024|EXPERIMENTAL|BCD-033 → Rebif|Volunteers in this group initially will receive a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the reference drug Rebif® (interferon beta-1a) at a dose of 44 µg.
62773553|NCT00794066||3|Hemorrhagic stroke
62773554|NCT03664765|ACTIVE_COMPARATOR|Intervention exercise arm|daily oropharyngeal and respiratory muscle exercises
62183210|NCT01903369||Elective orthopaedic surgery patients|All patients presenting for elective orthopaedic surgery \>16 years of age.
62183211|NCT04169451|EXPERIMENTAL|letrozole group|Women will be given IUI treatment with ovarian stimulation with letrozole 5mg/day starting from day 3 of menstrual cycle for 5 days.
62183212|NCT04169451|NO_INTERVENTION|natural cycle group|Women will be given IUI treatment without ovarian stimulation.
62183213|NCT03886597|EXPERIMENTAL|60 Arbequina Table Olives|Pharmacokinetics Study
62183214|NCT03886597|EXPERIMENTAL|120 Arbequina Table Olives|Pharmacokinetics Study
62183215|NCT03886597|EXPERIMENTAL|60 Table Olives|Table Olives Nutritional Intervention
62183216|NCT03886597|NO_INTERVENTION|Control|Control of Table Olives Nutritional Intervention
62183217|NCT03120598|ACTIVE_COMPARATOR|ATTC strategy|Behavioral: Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
62214567|NCT06086600|ACTIVE_COMPARATOR|Dynamic oscillatory stretch technique|"Dynamic oscillatory stretch technique on gastrocnemius and soleus muscle10reps x2 second hold oscillation x 3 sets.~Conventional treatment will include~* Hot pack for 10-15 min (calf muscles)~* Stretching exercises of gastro-soleus (10reps x 2 Sets).~* Post session : Cold pack for 5 minutes (calf Muscles"
62392078|NCT01766024|EXPERIMENTAL|Rebif → BCD-033|Volunteers in this group initially will receive a single sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg.
62773555|NCT03664765|SHAM_COMPARATOR|Control arm|Daily sham exercises
62773556|NCT01862367||rFXIII|
62773557|NCT04877769|EXPERIMENTAL|AT-527 Group A|n=8
62773558|NCT04877769|EXPERIMENTAL|AT-527 Group B|n=8
62773559|NCT04877769|EXPERIMENTAL|AT-527 Group C|n=8
62773560|NCT05650853|EXPERIMENTAL|Study intervention|Transrectal ultrasound and Urethroscopy
62773561|NCT04755452|EXPERIMENTAL|Low Intra-abdominal pressure|Intra-abdominal pressure will be set at 7 mm Hg during the procedure.
62773562|NCT04755452|ACTIVE_COMPARATOR|High (standard) intra-abdominal pressure|Intra-abdominal pressure will be set at 12 mm Hg during the procedure.
62773563|NCT06174909|EXPERIMENTAL|Calcium Hydroxide|"Calcium hydroxide has antimicrobial properties and tissue altering effect,used into root canals for the purpose of inhibiting coronal invasion of bacteria from the oral cavity."
62773564|NCT06174909|ACTIVE_COMPARATOR|Triple antibiotic Paste|"Triple antibiotic paste is combination of ciprofloxcin,metronidazole,and minocycline,used into root canals for the purpose of inhibiting coronal invasion of bacteria from the oral cavity."
62773565|NCT01577342|ACTIVE_COMPARATOR|Moxifloxacin 0.5%|1 drop four times daily for 3 days in affected eye post intravitreal injection
61997776|NCT05949190|EXPERIMENTAL|M-RUSF (Maternal Ready-to-use Supplementary Food without DHA/EPA/choline and no CBT|"Factorial 1. M-RUSF will be similar to M-RUSF+, except it will not contain added DHA or EPA, and will only contain 5mg of added choline to help with flavor masking. One sachet (daily dose) will provide 520 Kcal, 18g protein, and the same quantities of micronutrients as the UNIMMAP for pregnant/lactating women. M-RUSF+ will be vacuum sealed and packaged in foil sachets containing 100g of food.~Factorial 2. Participants who develop ante- or postpartum depression will not receive CBT."
61997777|NCT03100708||Patient with peritoneal carcinomatosis|Patient with peritoneal carcinomatosis and the Indication for local therapy. The Clinics tumor-board advice is needed.
61997778|NCT00072150|EXPERIMENTAL|Treatment (bortezomib)|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients with a solitary site of disease (i.e., lung or nodal metastases) and who have a partial response (PR) may be considered for surgical resection. Patients with a PR with residual disease after salvage surgery are eligible to continue study therapy. Patients who achieve a complete response, either through resection or bortezomib therapy, receive 2 additional courses of study therapy."
61997779|NCT04431791||Regorafenib|
62773566|NCT01577342|NO_INTERVENTION|No antibiotic use|
62773567|NCT03679455|EXPERIMENTAL|Treatment arm|Obinutuzumab (RO5072759) 25 MG/ML; Obinutuzumab will be administered by iv. infusion as an absolute (flat) dose of 1000 mg.
62773568|NCT03975569|EXPERIMENTAL|vulvovaginitis patients- lactobacillus gel|Daily use of vaginal gel containing lactobacilli by patients. Probiotic vaginal gel.
62773569|NCT04097977|EXPERIMENTAL|Intervention: RENEW in a psychiatric ward|Intervention The RENEW-S intervention consists of two key elements: collaborative networking and a youth group that will form the basis of real user involvement.
62773570|NCT04097977|NO_INTERVENTION|Conventional clinical practice in a psychiatric standard ward|The comparison group patients were admitted to a standard psychiatric ward that offered conventional care.
62773571|NCT04809155|EXPERIMENTAL|Girl2Girl|Girls receive text messages that address the information, motivation, and behavioral skills components need to prevent unwanted pregnancy.
62773572|NCT04809155|NO_INTERVENTION|Control - Healthy lifestyle|Girls receive text messages about a 'healthy lifestyle', including healthy social media use and self-esteem.
62773573|NCT04891185|EXPERIMENTAL|Primary Debulking Surgery|
61997780|NCT04431791||Fruquintinib|
62773574|NCT04891185|EXPERIMENTAL|Interval Debulking Surgery|
62773575|NCT00649831|ACTIVE_COMPARATOR|Group 2|
62773576|NCT00649831|ACTIVE_COMPARATOR|Group 1|
62773577|NCT01269502|EXPERIMENTAL|Skin temperature measurement|Regular measurement of skin temperature on feet for one year
62773578|NCT01269502|ACTIVE_COMPARATOR|Active control|Daily inspection of feet for one year
62773579|NCT05508893|OTHER|CT Angiography|Coronary CT Angiography will be performed on all individuals
62773580|NCT05508893|OTHER|Exercise stress test|An bicycle exercise stress test will be performed on all individuals
62773581|NCT03852979|EXPERIMENTAL|neo-adjuvant chemotherapy|The patients are given weekly paclitaxel 80 mg/m2 + carboplatin AUC=2 (or AUC=6 per three weeks) during 12 weeks/4 courses followed by conization if tumor size is reduced to \<2 cm
62773582|NCT05318820|EXPERIMENTAL|HMPL-523-TRR|Three cycle dose: TRR Test product: HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Co., Ltd.; Reference product: HMPL-523 Tablets manufactured by WuXi STA
62392079|NCT04411316|EXPERIMENTAL|Pharmacomechanical thrombolysis plus anticoagulation|"This group of patients will receive Pharmacomechanical catheter-directed thrombolysis (PCDT) plus Anticoagulation.~PCDT will be AngioJet along with alteplase. Anticoagulation will be heparin only"
62568166|NCT05697497|NO_INTERVENTION|Delayed-treatment control group with gait cadence assessment|This group will wear an activPAL device for 10 days prior to their baseline assessment and for 10 days after their week 12 assessment. The exercise intervention consists of a 2.5 to 3.5 minute daily routine that includes 2 upper body and 2 lower body exercises. Participants in the this arm will not start the exercise intervention until the day after the week 12 assessment.
62568167|NCT05697497|NO_INTERVENTION|Delayed-treatment control group without gait cadence assessment|The exercise intervention consists of a 2.5 to 3.5 minute daily routine that includes 2 upper body and 2 lower body exercises. Participants in the this arm will not start the exercise intervention until the day after the week 12 assessment.
62568168|NCT03693131|EXPERIMENTAL|MND-2119 2 g|MND-2119 2 g, orally, once daily after breakfast for 12 weeks.
62773583|NCT05318820|EXPERIMENTAL|HMPL-523-RTR|Three cycle dose:RTR Test product: HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Co., Ltd.; Reference product: HMPL-523 Tablets manufactured by WuXi STA
62773584|NCT05318820|EXPERIMENTAL|HMPL-523-RRT|Three cycle dose:RRT Test product: HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Co., Ltd.; Reference product: HMPL-523 Tablets manufactured by WuXi STA
62773585|NCT06001619|EXPERIMENTAL|Prostatic hyperplasia|Inclusion criteria for the BPH cohort includes clinical decision to initiate treatment of benign prostate hyperplasia (BPH) with 5-alpha-reductase inhibitors (finasteride, dutasteride, or combination of dutasteride and tamsulosin). Before starting the medication, size of the prostate has been measured with TRUS (transrectal ultrasound). The BPH cohort will include a total of 50 subjects and the study samples (gut microbiota, metabolite sampling) will be collected prior the start of the 5-alpha- reductase inhibitors and after 2 months of medical therapy. At this stage, PSA is determined from blood sample and the size of the prostate is measured with transrectal ultrasound (TRUS). In addition, after 6 months, PSA and prostate size measurements are repeated.
62791525|NCT04054076|EXPERIMENTAL|Prefabricated insoles|Prefabricated insoles with support in medial arch and metatarsal pad. A 2 mm top layer of cushioned material.
62791526|NCT04054076|EXPERIMENTAL|Custom-made insoles soft|Custom-made insoles formed over an individual cast positive. 35 shore of hardness in material Ethyl Vinyl Acetate.
61997781|NCT02727348|EXPERIMENTAL|Sciatic block with or without femoral block|Sciatic block with or without femoral block performed on the patient with 3mg/kg of ropivacaine
61997782|NCT02727348|ACTIVE_COMPARATOR|Spinal anaesthesia|Spinal anaesthesia will be performed on the patient with heavy marcaine 0.5% up to 3mls
62568169|NCT03693131|EXPERIMENTAL|MND-2119 4 g|MND-2119 4 g, orally, once daily after breakfast for 12 weeks.
61997783|NCT06390228||Major hepatectomy|Major hepatectomy was defined as the removal of four or more Couinaud's liver segments.
61997784|NCT06390228||Minor hepatectomy|Minor hepatectomy was defined as the removal of three or fewer Couinaud's segments.
62392080|NCT04411316|ACTIVE_COMPARATOR|Anticoagulation|This group of patients will receive standard anticoagulation only. Anticoagulation will be Heparin only
62568170|NCT03693131|ACTIVE_COMPARATOR|EPADEL CAPSULES 300 1.8 g|EPADEL CAPSULES 300 0.9 g, orally, twice daily after breakfast and dinner for 12 weeks.
62568171|NCT03693131|ACTIVE_COMPARATOR|EPADEL CAPSULES 300 2.7 g|EPADEL CAPSULES 300 0.9 g, orally, three-times daily after each meal for 12 weeks.
61997785|NCT05351346|EXPERIMENTAL|R-CHOP-X|Patients in R-CHOP-X group will receive rituximab 375 mg/m² IV on day 1, cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 2, and prednisone 100 mg/day PO on days 2-6 of every 21-day cycle for the first cycle. For the remaining 5 cycles, they will receive orelabrutinib 150 mg/day PO on days 1-21, or lenalidomide 25 mg/day PO on days 2-11, or decitabine 10 mg/m² IV on days -5 to -1 followed by standard R-CHOP of every 21-day cycle.
61997786|NCT05351346|ACTIVE_COMPARATOR|R-CHOP|Patients in R-CHOP group will receive rituximab 375 mg/m² IV on day 1, cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² iv, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 2, and prednisone 100 mg/day PO on days 2-6 of every 21-day cycle for 6 cycles.
61997787|NCT01619670|NO_INTERVENTION|no intervention|standard wound care
61997788|NCT01619670|ACTIVE_COMPARATOR|Apligraf|non adhesive layer with apligraf
61997789|NCT06447090|EXPERIMENTAL|VMAC+DLI|"VMAC regimen :~Veneclatra (VEN) 400 mg/d (reduced to 100 mg when combined with an azole), d1-7; Mitoxantrone Liposomal 30 mg/m2, d1; Cytosine arabinoside(Ara-C) 100 mg/m2/d, d1-7; Cyclophosphamide (CTX) 400 mg/m2/d, d2, 5); After 1 day of rest, cryopreserved donor stem cells MNC1-2X10\^8 /kg infusion, add low-dose (25 mg Bid) and short-course treatment (stop 2-3 weeks after DLI) oral cyclosporine (CSA) to prevent graft-versus-host disease (GVHD) 3 days before cryopreserved stem cell infusion."
61997790|NCT02438748||Patients|Individuals undergoing Repetitive Transcranial Magnetic Stimulation treatment for major depressive disorder.
61997791|NCT02438748||Controls|Healthy age-, and sex-matched control individuals.
61997792|NCT03934528|EXPERIMENTAL|Pilot Study|
62392081|NCT06177145|EXPERIMENTAL|experimental|This study was carried out with the immigrant women living in Akdağmadeni district of Yozgat province. Trainings and measurement tools in the HASCV-R programme was implemented in the training centres in the neighbourhoods where immigrant women lived with the support of Akdağmadeni Lausanne Immigrants Association.
61997793|NCT02165358||Patients|Patients verified with either becker muscular dystrophy or limb-girdle muscular dystrophy type 2I
61997794|NCT02165358||Controls|Healthy controls matched for age and gender.
61997795|NCT00898976||Group I|Immunohistochemistry is performed on tumor samples to analyze the following molecular markers: estrogen receptor, progesterone receptor, c-erbB2, p53, Ki-67, Bcl-2, Bax, cyclin D-1, and insulin-like growth factor-1R. PROJECTED ACCRUAL: A total of 300 tissue samples (150 from Native American women and 150 from Caucasian women) will be accrued for this study.
61997796|NCT00981032|EXPERIMENTAL|Pre-visit Summary|Patients in this arm will receive a pre-visit summary prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
61997797|NCT00981032|EXPERIMENTAL|Clinical Decision Sharing Tool|Patients in this arm will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
61997798|NCT03666169||Whole Cohort|UK Citizens, aged 18-65 years
61997799|NCT04517916||Zephyr Valve treatment|Patients undergoing the Zephyr Valve treatment for emphysema/COPD
61997800|NCT01664013|EXPERIMENTAL|Neuronox|Neuronox® is a botulinum toxin type A (BoNT/A) product developed by Medytox Inc. (Medytox) of Korea. Neuronox® was first approved by the Korean Food and Drug Administration in 2006, and by Thai Food and Drug Administration in 2008.
61997801|NCT00735371|ACTIVE_COMPARATOR|Lisdexamfetamine Dimesylate (LDX) 30 mg|
61997802|NCT00735371|ACTIVE_COMPARATOR|LDX 50 mg|
62183218|NCT03120598|EXPERIMENTAL|ISF strategy|Behavioral: Implementation \& Sustainment Facilitation (ISF) strategy: An organization-focused strategy that includes 7 discrete strategies (e.g., use of an implementation advisor, organize implementation team meetings, conduct cyclical small tests of change) and Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
62392082|NCT06177145|NO_INTERVENTION|control|
62568172|NCT05258305|OTHER|Augmentation|Subjects undergoing an aesthetic fat grafting procedure to the breast with or without a breast implant.
61997803|NCT00735371|ACTIVE_COMPARATOR|LDX 70 mg|
61997804|NCT00735371|PLACEBO_COMPARATOR|Placebo|
61997805|NCT02385799|PLACEBO_COMPARATOR|Sertraline Liquid Placebo|The placebo will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid placebo once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid placebo once per day for a period of six months.
62214568|NCT03782675|SHAM_COMPARATOR|Control|In the control arm, the ABS device will be placed as usual on the patient, but the airflow will NOT be activated. Only the technician in the room will be aware whether the device the device is turned on or not.
62214569|NCT03782675|EXPERIMENTAL|Air Barrier System|In the experimental (interventional) arm, the ABS device will be placed as usual on the patient, and the airflow will be activated. Only the technician in the room will be aware whether the device is turned on or not.
62773586|NCT06001619|EXPERIMENTAL|Prostatic cancer|Inclusion criteria for the cancer cohort include a clinical decision to initiate PCa treatment with androgen deprivation therapy (ADT) with LHRH antagonist (degarelix). This may include either treatment of a metastatic disease with definite ADT or adjuvant ADT to external beam radiation of the prostate. The cancer cohort will include a total of 50 subjects and the study samples (gut microbiota, metabolite sampling) will be collected prior the start of the ADT and after 2 months of medical therapy. In addition, after 2 and 6 months, PSA measurement is repeated.
62773587|NCT05216627||PSOM staff, trainees, or faculty who participate in the point of care testing|The cohort will be offered access to a self-administered saliva-based viral test is a small funnel and a tube in which participants will put their saliva into. When they are ready to self-collect their saliva sample, they will be instructed to not eat or drink for 30 minutes prior to collecting their saliva and to collect saliva in an isolated room. We will evaluate the implementation of this viral test.
62773588|NCT05845463|EXPERIMENTAL|Endoscopists with AI feedback|This will be the group of endoscopists who will have AI feedback during the endoscopy
62392083|NCT01277458||Non white HIV positive men who have sex with men|
61997806|NCT02385799|ACTIVE_COMPARATOR|Sertraline Active Medication|Liquid sertraline (20 mg/cc) will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid sertraline once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid sertraline once per day for a period of six months.
61997807|NCT03948373|EXPERIMENTAL|CPAP treatment|Group of patients who will receive CPAP treatment
62214570|NCT05711602|EXPERIMENTAL|Pilates group|This group receives physical training based on pilates exercises
62773589|NCT05845463|ACTIVE_COMPARATOR|Endoscopists without AI feedback|This will be the group of endoscopists without AI feedback during the endoscopy to assess their baseline site detection rate. Both arms will cross over to see if AI improves endoscopy quality and if its removal decreases quality.
62773590|NCT00768482|EXPERIMENTAL|Probuphine|Patients are first inducted on SL BPN, and then switched to 4 Probuphine implants
62214571|NCT05711602|NO_INTERVENTION|No intervention group|This group does not receive any treatment
62392084|NCT05654740|EXPERIMENTAL|Virtual Reality experiences|Virtual Reality experiences are offered regularly
62773591|NCT00940784|EXPERIMENTAL|Clopidogrel|Subjects will be randomized to clopidogrel (oral-75 mg per day) in addition to low dose aspirin and hydroxyurea
62773592|NCT00940784|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized placebo in addition to low dose aspirin and hydroxyurea
62773593|NCT02859896|EXPERIMENTAL|Hectorol|Hectorol (Doxercalciferol) will be administered orally two to three times weekly dependent on patient age. A dose titration scheme is used to individualize the dose to the patient's iPTH management.
62773594|NCT02859896|ACTIVE_COMPARATOR|Rocaltrol|Rocaltrol (Calcitriol) will be administered orally seven days/week. A dose titration scheme is used to individualize the dose to the patient's iPTH management.
62773595|NCT04216407|EXPERIMENTAL|Remote Ischemic Preconditioning|Short-term tourniquet on to the lower extremity before surgery
62773596|NCT04216407|NO_INTERVENTION|Control|No intervention
62773597|NCT04738630|EXPERIMENTAL|Experimental: HX008|Participants will receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)
62392085|NCT05654740|NO_INTERVENTION|No Virtual Reality|Virtual Reality experiences are not offered
62773598|NCT02186704||ICD with DX system|Implantable cardioverter-defibrillator recipients with DX system
62773599|NCT02186704||Dual chamber ICD|Dual chamber implantable-cardioverter-defibrillator recipients (retrospective cohort from IMPACT study)
62773600|NCT02186704||Single chamber ICD|Single chamber implantable cardioverter-defibrillator recipients (retrospective cohort from Cornell registry)
62773601|NCT04861428|EXPERIMENTAL|IQOS / Smoking as usual|Two weeks of IQOS, followed by two weeks of cigarette smoking as usual.
62773602|NCT04861428|ACTIVE_COMPARATOR|Smoking as usual / IQOS|Two weeks of cigarette smoking as usual, followed by two weeks of IQOS.
62773603|NCT02027753|EXPERIMENTAL|Insulin glargine and Oral anti diabetic treatment(s)|"1. Insulin glargine: Lantus~   * Add basal insulin: starting with 0.2 U/kg/day or 10 U/day~  * Adjust insulin glargine dose according to Fasting blood glucose~2. Oral Anti Diabetic treatment(s): DPP-4 inhibitors and Metformin plus or minus Sulphonylurea - Only Sulphonylurea can either be omitted or reduced at the physician's discretion."
62773604|NCT01853956|EXPERIMENTAL|A (reference)/ B (test)|initial administration of reference and cross-over to test
62773605|NCT01853956|EXPERIMENTAL|B (test)/ A (reference)|initial administration of test and cross-over to reference
62568173|NCT05258305|OTHER|Reconstruction|Subjects undergoing reconstructive fat grafting procedure to the breast with or without a breast implant.
62773606|NCT00552409|EXPERIMENTAL|Cholecalciferol|
62773607|NCT00552409|PLACEBO_COMPARATOR|Placebo|
62773608|NCT01416480|EXPERIMENTAL|Theobromine|Theobromine capsule 300mg
62773609|NCT01416480|ACTIVE_COMPARATOR|levodropropizine|levodropropizine syrup
62773610|NCT03873623||Kidney Transplant Recipients|
62773611|NCT04607460|EXPERIMENTAL|EMG-Biofeedback for Lower Back Pain|Participants will receive a JOGO Digital Therapeutics EMG Biofeedback device and a software installed on a tablet or smart phone. During the 8 weekly sessions participants will be instructed on how to use the device by a trained biofeedback instructor.
62773612|NCT04607460|NO_INTERVENTION|Treatment as usual (Lower Back Pain)|Participants in this group will receive no active treatment.
62773613|NCT04607460|EXPERIMENTAL|EMG-Biofeedback for Persistent Post-Mastectomy Pain|Participants will receive a JOGO Digital Therapeutics EMG Biofeedback device and a software installed on a tablet or smart phone. During the 4 weekly sessions participants will be instructed on how to use the device by a trained biofeedback instructor ahead of their mastectomy.
62183219|NCT05967078|EXPERIMENTAL|Test group|The device under investigation is the ExerCube training software licence provided by Sphery (https://sphery.ch/exercube/). The ExerCube training software licence is an exergame training product that includes immersive mixed-reality training programs (or video games) for patients. Depending on the patient's training requirements, the therapists can choose from the training program repertoire. The ExerCube supporting material for safety consisting of a harness and an over-head gantry system ensures a safe training environment and prevents patients from falling.
62183220|NCT03477409||Neonatal intensive care patients|The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
62183221|NCT05663164|EXPERIMENTAL|Experimental: Vitamin B1|Vitamin B1 (thiamine) 100mg every 6 hours x 3-days
62183222|NCT05663164|PLACEBO_COMPARATOR|Drug: Normal saline|Normal saline (0.9% NaCl solution) volume to match all components
62183223|NCT01215578|EXPERIMENTAL|patient treated|patient who receive sunitinib (SUTENT)
62183224|NCT02792647|PLACEBO_COMPARATOR|Placebo|Placebo
62183225|NCT02792647|EXPERIMENTAL|Experimental: IX-01|2 different dose groups 1,600 mg and 2,400 mg of IX-01 oral aqueous dispersion, administered once daily for 10 days
62183226|NCT02152254|ACTIVE_COMPARATOR|Arm A: Targeted Therapy|Personalized treatment, targeted therapy against the alteration based on molecular profiling.
62183227|NCT02152254|EXPERIMENTAL|Arm B: Standard-of-Care Therapy|Standard-of-Care treatment not selected on basis of alteration analysis.
62183228|NCT02561078|EXPERIMENTAL|Human regular U-500 insulin administered by CSII|Human regular U-500 insulin administered by CSII and titrated based on blood glucose readings for 26 weeks with a 2-week MDI lead-in.
62183229|NCT02561078|ACTIVE_COMPARATOR|Human regular U-500 insulin administered by MDI|Human regular U-500 insulin administered subcutaneously (SC) by MDI three times a day and titrated based on blood glucose readings for 26 weeks.
62183230|NCT06067022||Study Group|"42 patients with diabetic foot ulcers were included. For patients in this group, regarding diabetic foot; Sensory assessment, ulcer area and depth measurement, and diabetes management information were measured.~Apart from these evaluations, quality of life, pain, mandibular function and oropharyngeal swallowing problems were evaluated."
62183231|NCT06067022||Control Group|42 patients without diabetes were included. Patients in this group were evaluated for general health and quality of life, pain, mandibular function and oropharyngeal swallowing problems.
62183232|NCT01633138|ACTIVE_COMPARATOR|CRT-S|Cognitive Remediation Therapy - Standard
62183233|NCT01633138|EXPERIMENTAL|CRT-CM|Cognitive Remediation Therapy plus Contingency Management
62183234|NCT04131673||African Americans with MS|African American patients seen in the University of Kentucky's Multiple Sclerosis Clinic between the ages of 18 and 80 who have been diagnosed with MS
62183235|NCT04926441||Students from 8 European Universities, regardless of field of study and academic year|At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
62183236|NCT00869271|EXPERIMENTAL|1|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.
62183237|NCT00869271|ACTIVE_COMPARATOR|2|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle.
62183238|NCT06215287||Exjade Prescribers/HCP receiving Educational Materials|HCPs prescribing Exjade in the EU/EEA provided with Exjade Educational Materials
62183239|NCT03090971|EXPERIMENTAL|Cutaneous neurofibromas|Each subject will have two treatment neurofibromas and two control neurofibromas. Following microporation, the two treatment neurofibromas will be treated with topical diclofenac while the two control neurofibromas will be treated with topical saline.
62183240|NCT01278615|EXPERIMENTAL|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity
62183241|NCT01340300|ACTIVE_COMPARATOR|Exercise training|Exercise training with exercise physiologist
62183242|NCT01340300|ACTIVE_COMPARATOR|Exercise training with metformin|Exercise training with exercise physiologist with oral metformin
62183243|NCT01340300|ACTIVE_COMPARATOR|Metformin|Metformin
62183244|NCT01340300|ACTIVE_COMPARATOR|Control|Educational information
61997808|NCT03948373|NO_INTERVENTION|Conservative measures|Patients who will receive conservative treatment based on hygienic-dietetic measures
61997809|NCT01574703|EXPERIMENTAL|placebo|
62183245|NCT01470729||Spinocerebellar Ataxia type 1 (SCA1)|Spinocerebellar Ataxia type 1 (SCA1)
62183246|NCT01470729||Spinocerebellar Ataxia type 2 (SCA2)|Spinocerebellar Ataxia type 2 (SCA2)
62183247|NCT01470729||Spinocerebellar Ataxia type 3 (SCA3)|Spinocerebellar Ataxia type 3 (SCA3)
62183248|NCT01470729||Spinocerebellar Ataxia type 7 (SCA7)|Spinocerebellar Ataxia type 7 (SCA7)
62183249|NCT00740870|EXPERIMENTAL|Melody TPV Implant|Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.
62183250|NCT00990262||Acute Chest Pain|Patients who presented to the emergency department with acute chest pain, with negative initial biomarkers and normal or non-ischemic ECG
62183251|NCT00951171|EXPERIMENTAL|Cervical occulsion|Insemination Eliptosphere catheter filled with 1cc of air for 15 minutes. H/S Eliptosphere by Copper surgical (U.S. Patent No. 5,624,399)
62183252|NCT00951171|ACTIVE_COMPARATOR|Standard IUI|Insemination with TOmcat catheter
62183253|NCT01264887|EXPERIMENTAL|Tapentadol Prolonged Release|Participants allocated to this treatment arm can be flexibly dosed between 100 to 250 mg tapentadol twice daily (50 and 100 mg tablets to be dispensed).
62183254|NCT04486313|ACTIVE_COMPARATOR|Nitazoxanide|Two nitazoxanide 300 mg tablets orally twice daily for 5 days
62183255|NCT04486313|PLACEBO_COMPARATOR|Placebo|Two placebo tablets orally twice daily for 5 days
62183256|NCT03638258|EXPERIMENTAL|Roflumilast Cream 0.3%|Roflumilast cream 0.3% topically applied QD for 12 weeks.
62183257|NCT03638258|EXPERIMENTAL|Roflumilast Cream 0.15%|Roflumilast cream 0.15% topically applied QD for 12 weeks.
62183258|NCT03638258|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle cream matched to roflumilast cream (containing only excipients of active cream) applied QD for 12 weeks.
62183259|NCT04765553|ACTIVE_COMPARATOR|emapalumab|emapalumab i.v infusion
62183260|NCT04765553|PLACEBO_COMPARATOR|Placebo|Saline i.v. infusion
62183261|NCT02886598||Firmagon®|Treatment according to standard clinical practice.
62183262|NCT00809913|EXPERIMENTAL|Short treatment|7 days of standard antibiotic treatment (preferably ciprofloxacin) followed by 7 days of placebo
62183263|NCT00809913|ACTIVE_COMPARATOR|Standard treatment|14 days of standard antibiotic treatment (initial b-lactam or fluoroquinolone followed by ciprofloxacin through the 8th till 14th day)
62183264|NCT03131349||column heading in tables|history examinations investigation:serum zinc and iron
62183265|NCT03131349||row heading in tables|history examinations investigation:serum zinc and iron
62183266|NCT00944892|EXPERIMENTAL|Dose 1|
62183267|NCT00944892|EXPERIMENTAL|Dose 2|
62183268|NCT00944892|EXPERIMENTAL|Dose 3|
62183269|NCT00944892|PLACEBO_COMPARATOR|Placebo|
62183270|NCT04344210|EXPERIMENTAL|Tele-Intervention|Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
62183271|NCT04344210|NO_INTERVENTION|Usual Care|Participants will receive the usual care
62183272|NCT03807453||Psoriasis Vulgaris patients-Lesion|
62568174|NCT06509737|EXPERIMENTAL|SOCIAL MEDIA TRAINING INTERVENTION GROUP|"Life with Food Allergy Training will be held in 3 face-to-face sessions for the 1st intervention group, and the session titles are determined as follows.~1st Education: Introduction to food allergy, general information 2.Education: Food allergy management, food allergy in school and social environment-use of social support resources 3. Education: Treatment of food allergy, use of adrenaline autoinjectors"
62568175|NCT06509737|EXPERIMENTAL|CLASSİC FACE TO FACE EDUCATİON GROUP|Life with food allergy training; The 2nd Intervention Group will share videos created by the trainer with the same training content and visuals as the face-to-face training group on the instagram page to be created on social media. At the same time, it is planned to share posts created from the training content on the actively used page. The participant parents will be ensured to follow the page actively, it will be confirmed that they see the posts by liking them and the follow-up will be done by the researcher.
62183273|NCT03807453||Psoriasis Vulgaris patients-Lesion free|
62183274|NCT03807453||Seborrheic Dermatitis-Lesion|
62183275|NCT03807453||Seborrheic Dermatitis-Lesion free|
62183276|NCT03807453||Control Group|
62183277|NCT04262297||Prosthesis users|Prosthesis users with transtibial amputation
62584755|NCT05021874|ACTIVE_COMPARATOR|Physiotherapeutic procedures: manual therapy of soft tissues|Manual therapy of soft tissues will include: post-isometric relaxation of the masseter, cellular and tissue mobilization with Kibler fold, masseter trigger point therapy. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
62183278|NCT04262297||Able-bodied Controls|Prosthesis users' age-, sex- and dominancy-matched healthy controls
62183279|NCT02925234|EXPERIMENTAL|Panitumumab|Panitumumab for patients with a molecular tumor profile that can potentially be targeted by Panitumumab.
62183280|NCT02925234|EXPERIMENTAL|Olaparib|Olaparib for patients with a molecular tumor profile that can potentially be targeted by Olaparib.
62183281|NCT02925234|EXPERIMENTAL|Dabrafenib|Dabrafenib for patients with a molecular tumor profile that can potentially be targeted by Dabrafenib.
61997810|NCT01574703|EXPERIMENTAL|varenicline|
61997811|NCT01574703|EXPERIMENTAL|bupropion|
61997812|NCT01574703|EXPERIMENTAL|Nicotine Replacement Therapy Patch|
62183282|NCT02925234|EXPERIMENTAL|Nilotinib|Nilotinib for patients with a molecular tumor profile that can potentially be targeted by nilotinib.
62183283|NCT02925234|EXPERIMENTAL|Trametinib|Trametinib for patients with a molecular tumor profile that can potentially be targeted by trametinib.
62183284|NCT02925234|EXPERIMENTAL|Erlotinib|Erlotinib for patients with a molecular tumor profile that can potentially be targeted by erlotinib.
62183285|NCT02925234|EXPERIMENTAL|Trastuzumab & Pertuzumab (combination)|Trastuzumab and Pertuzumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab and Pertuzumab.
62183286|NCT02925234|EXPERIMENTAL|Vemurafenib & Cobimetinib (combination)|Vemurafenib and Cobimetinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Vemurafenib and Cobimetinib.
62183287|NCT02925234|EXPERIMENTAL|Vismodegib|Vismodegib for patients with a molecular tumor profile that can potentially be targeted by vismodegib.
62183288|NCT02925234|EXPERIMENTAL|Regorafenib|Regorafenib for patients with a molecular tumor profile that can potentially be targeted by regorafenib.
62183289|NCT02925234|EXPERIMENTAL|Nivolumab|Nivolumab for patients with a molecular tumor profile that can potentially be targeted by nivolumab.
62183290|NCT02925234|EXPERIMENTAL|Afatinib|Afatinib for patients with a molecular tumor profile that can potentially be targeted by Afatinib.
62183291|NCT02925234|EXPERIMENTAL|Dabrafenib & trametinib (combination)|Dabrafenib and trametinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Dabrafenib and trametinib.
62183292|NCT02925234|EXPERIMENTAL|Ribociclib|Ribociclib for patients with a molecular tumor profile that can potentially be targeted by Ribociclib.
62183293|NCT02925234|EXPERIMENTAL|Lenvatinib|Lenvatinib for patients with a molecular tumor profile that can potentially be targeted by Lenvatinib.
62183294|NCT02925234|EXPERIMENTAL|Pembrolizumab|Pembrolizumab for patients with a molecular tumor profile that can potentially be targeted by Pembrolizumab.
61997813|NCT05339607|EXPERIMENTAL|Intervention|
61997814|NCT04061200|ACTIVE_COMPARATOR|Semaglutide 1,34 mg/ml|Semaglutide 1,34 mg/ml (solution for subcutaneous injection in pre-filled pen-injector). At randomisation, the participants start with doses of 0.25 mg/week for 4 weeks, then escalate to doses of 0.5 mg/week for 4 weeks, and thereafter escalate to 1.0 mg/week if tolerated until 52 weeks of total treatment.
61997815|NCT04061200|PLACEBO_COMPARATOR|Placebo 1,34 mg/ml|Placebo 1,34 mg/ml (solution for subcutaneous injection in pre-filled pen-injector). At randomisation, the participants start with doses of 0.25 mg/week for 4 weeks, then escalate to doses of 0.5 mg/week for 4 weeks, and thereafter escalate to 1.0 mg/week if tolerated until 52 weeks of total treatment.
61997816|NCT01660893|EXPERIMENTAL|Kovacaine Mist, 3 sprays unilateral|Tetracaine HCl 3% and oxymetazoline HCl 0.05%
61997817|NCT01660893|EXPERIMENTAL|Tetracaine Only, 3 sprays unilateral|Tetracaine HCl 3%
61997818|NCT01660893|PLACEBO_COMPARATOR|Placebo, 3 sprays unilateral|Placebo
62568176|NCT01050933|EXPERIMENTAL|Carbon Monoxide|Healthy volunteers will receive 250 ppm of carbon monoxide by face mask. This dose will be administered for 1 hour with continuous COHb monitoring. At baseline and at each half hour time point, a blood sample will be drawn to be analyzed by the gas chromatograph. After 1 hour, the volunteer will be excused and asked to return in 4 hours and this procedure repeated. At any point, if the COHb level reaches 10%, administration of CO will be terminated.
61997819|NCT04415606|EXPERIMENTAL|QuikClot Control+|QuikClot Control+
62568177|NCT02042989|EXPERIMENTAL|MLN9708 and Vorinostat|"Dose Escalation Phase: Starting Dose of MLN9708 3 mg by mouth on day 1, 8 and 15. Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.~Dose Expansion Phase Starting Doses of MLN9708 and Vorinostat: Maximum tolerated dose from Dose Escalation Phase."
62568178|NCT00483444|NO_INTERVENTION|2|Control group were recruited in the emergency department after concussion and received standard care as directed by the ED physician and PCP.
62568179|NCT00483444|EXPERIMENTAL|1|Persons with concussion recruited in the emergency department received 5-6 scheduled telephone counseling calls focused on symptom management and self-management.
62773614|NCT04607460|NO_INTERVENTION|Treatment as usual (Persistent Post-Mastectomy Pain)|Participants in this group will receive no active treatment.
62773615|NCT04607460|EXPERIMENTAL|EMG-Biofeedback for Migraine|Participants will receive a JOGO Digital Therapeutics EMG Biofeedback device and a software installed on a tablet or smart phone. During the 6 weekly sessions participants will be instructed on how to use the device by a trained biofeedback instructor.
61997820|NCT04415606|PLACEBO_COMPARATOR|Standard gauze|Standard gauze per standard of care
61997821|NCT06264388|EXPERIMENTAL|DB107-RRV and DB107-FC Group|Patients will receive DB107-RRV during the tumor resection/biopsy procedure. Approximately 6 weeks after surgery, patients will start drug therapy with a 7-day oral regimen of 220 mg/kg/day DB107-FC, which is to be self-administered. This 7-day regimen, which is considered one cycle of treatment, is to be repeated every 6 weeks for up to 12 months. Patients will undergo follow up procedures for at least 5 years after last DB107-RRV treatment.
61997822|NCT01914666|EXPERIMENTAL|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. Tapering week doses of 40 mg for first week and 20 mg for second week.
61997823|NCT06165796||previous LASIK group|
61997824|NCT06165796||previous non-LASIK group|
61997825|NCT04488029|EXPERIMENTAL|Experimental Group|At the start of the study, subjects will be provided with a tablet with videoconferencing software and the PCT app pre-installed. Research staff will remotely setup a PCT account for the subjects, and provide instructions for logging into the PCT application. During the treatment period, patients will be instructed to use PCT for at least 30 minutes a day and at least 5 days a week. Performance data (accuracy and latency) will be reported by the PCT software to the treating clinician and will be used to modify task assignment over time. PCT tracks usage of the program so that research staff can access automated reporting of subject use to monitor participant adherence to the treatment program.
61997826|NCT04488029|ACTIVE_COMPARATOR|Control Group 1 [Conventional Workbook Therapy]|At the start of the study, subjects will be provided with a tablet with videoconferencing software and the PCT app pre-installed. Subjects in the control group will be told they will have access to 3-months of PCT after their participation in the study has concluded. Subjects in this group will be provided with a standard regime of paper workbooks and instructions to complete approximately 30 minutes a day at least 5 days a week.
62568180|NCT03425591||Cohort 1: Chronic Lymphocytic Leukemia (CLL) Participants|Participants with confirmed diagnosis of CLL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 1. The primary data source for this observational study will be the medical records of each enrolled participant.
62568181|NCT03425591||Cohort 2: Mantle-Cell Lymphoma (MCL) Participants|Participants with confirmed diagnosis of MCL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 2. The primary data source for this observational study will be the medical records of each enrolled participant.
62392086|NCT02624713|OTHER|Retrospective Random Controlled Research|"In the controlled retrospective follow up, (not random) 44 families participated with their 81 children and siblings. The intervention group included 18 families who participated in the Maccabi Active program (obesity treatment) in the years 2012-2013 in the northern district, with their 24 children (18 overweight children and 6 siblings). The control group included 26 families with their 57 children (27 children who had been overweight or obese in the years 2012-2013 when they were 8-14 years old and their 30 siblings). These families did not take part in a family based treatment for their overweight child. The parameters were measured at one set point time. All participants from both the control and research groups were evaluated at the follow-up and the data collected at follow-up is being reported collectively for the Retrospective Controlled Research branch."
61997827|NCT04150224|EXPERIMENTAL|Cohort 1 (C1A), PBTZ169|Two doses of PBTZ169: 640 mg OD fasted and 640 mg OD after meal. Wash-out period ≥6 days.
62392087|NCT02624713|OTHER|The Prospective study|The Prospective study had only an intervention group (obesity treatment). Forty-two families took part in this study, with 78 children: 48 overweight children and 30 siblings . The parameters were measured in three different times. Before the program (time 1), at the end of the program (after 6 months - time 2) and 8 months after completing the program (time 3).
62392088|NCT01791543|EXPERIMENTAL|Intramural Needle Catheter Ablation|Ablation of Ventricular Tachycardia with Intramural Needle Ablation Catheter
62392089|NCT05604482|EXPERIMENTAL|CXCR4-PET experimental group|In addition to the current standard of imaging in GCA, using FDG-PET/CT, participants receive CXCR4-PET.
62392090|NCT03193281|OTHER|Dasatinib|"All patients will begin the study on dasatinib treatment (Sprycel® 100mg once daily oral administration). Those who reach MR3.0 at 12 months (end of Study Stage 1) and achieve a confirmed result at 13 months, will switch to imatinib treatment (Imatinib-AFT 400mg once daily oral administration) for the next 24 months (Study Stage 2).~Patients who do not achieve a confirmed MR3.0 result at 13 months will not be eligible to switch to imatinib treatment and will remain on dasatinib treatment, as per Study Stage 1.~Patients will be assessed on a 3-monthly basis throughout the study. Those who discontinue dasatinib treatment during the study for reasons other than the planned treatment switch to imatinib at 13 months, will also be followed up every 3 months."
62392091|NCT05666466||case group|age between 12 to 50 disproportionate SRS to PTA level presence of OAE presence of CM Normal MRI and CT
62392092|NCT05666466||control group|age and sex matched to study group Normal hearing sensitivity and excellent speech discrimination no CAPD
62392093|NCT00715780||A|
62392094|NCT03950271|EXPERIMENTAL|SHR-1210+ Trastuzumab + Oxaliplatin + Capecitabine|trastuzumab + SHR-1210 + capecitabine + oxaliplatin for neoadjuvant chemotherapy 4-cycle.Then D2 radical surgery. The patients continued to receive capecitabine plus oxaliplatin for adjuvant therapy, and the total number of chemotherapy cycles was 8 cycles.
62392095|NCT02048501|OTHER|Weight Regain|The weight regain group will include 20 subjects who underwent Roux-en-Y gastric bypass (RYGB) with a follow up of at least 2 years and have experienced excess weight loss (EWL) of at least 50% at 12 (+ 2) months post-operatively and regained at least 15% of the post-operative nadir weight.
62392096|NCT02048501|OTHER|Sustained Weight Loss (SWL)|The sustained weight loss group will include 20 subjects who underwent Roux-en-Y gastric bypass (RYGB) with a follow up of at least 2 years and have experienced excess weight loss (EWL) of at least 50% at 12 (+ 2) months post-operatively and have regained less than 15% of the post-operative nadir weight.
62392097|NCT01639846|EXPERIMENTAL|RX-10045 active arm|RX-10045 Ophthalmic Solution, 0.09%
62392098|NCT01639846|PLACEBO_COMPARATOR|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution
62392099|NCT03752502|EXPERIMENTAL|Cerebral stimulation|"Active transcranial direct current stimulation~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
62392100|NCT03752502|EXPERIMENTAL|Combined stimulation|"Active transcranial direct current stimulation combined with active peripheral electrical stimulation (PES)~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~PES: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
62392101|NCT03752502|SHAM_COMPARATOR|Sham cerebral stimulation|"Sham transcranial direct current stimulation combined with active peripheral electrical stimulation (PES)~tDCS: 20 minutes (30s ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
62392102|NCT03752502|EXPERIMENTAL|Peripheral stimulation|"Active peripheral electrical stimulation (PES).~PES: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
62773616|NCT04607460|NO_INTERVENTION|Treatment as usual (Migraine)|Participants in this group will receive no active treatment.
62773617|NCT06382935|EXPERIMENTAL|MINST non surgical periodontal treatment|Periodontitis patients treated by means of MINST. Patients were treated with non-surgical MINST periodontal treatment in a single session.
62773618|NCT06382935|ACTIVE_COMPARATOR|Q-SI non surgical periodontal treatment|Periodontitis patients treated by means of Q-SI. Patients were treated with non-surgical quadrantwise periodontal treatment in 4 sessions, 1 session per week.
61978525|NCT01585428|EXPERIMENTAL|NonCervical|Patients will receive a non-myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of Young tumor infiltrating lymphocytes (TIL) plus high dose IV aldesleukin
61978526|NCT02062034|EXPERIMENTAL|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
61997828|NCT04150224|EXPERIMENTAL|Cohort 1 (C1B), PBTZ169|Two doses of PBTZ169: 640 mg OD after meal and 640 OD mg fasted. Wash-out period ≥6 days.
61997829|NCT04150224|EXPERIMENTAL|Cohort 2 (C2), PBTZ169|Single dose of PBTZ169: 960 mg fasted
61997830|NCT04150224|EXPERIMENTAL|Cohort 3 (C3), PBTZ169|Two doses of PBTZ169: 640 mg twice a day (fasted) with a 12-hour interval; total daily dose - 1280 mg
61997831|NCT04150224|EXPERIMENTAL|Cohort 4 (C4), PBTZ169|Single dose of PBTZ169: 1280 mg fasted
61997832|NCT04150224|EXPERIMENTAL|Cohort 5 (C5), PBTZ169|Multiple administration of PBTZ169: 1280 mg once a day after meal for 14 days
62773619|NCT01676623|ACTIVE_COMPARATOR|Comparison area, only standard government services|This intervention arm will receive the standard government services offered at CHCs all over Vietnam. In addition, participants in this arm will be exposed to the nationwide mass media campaign.
61977749|NCT05464160|EXPERIMENTAL|G-FMV (Group Focal Muscular Vibration)|"Patients allocated in the G-FMV, in addition to conventional rehabilitation treatment, will be treated for 3 weeks with FMV, applied to the upper and/or lower limb, depending on the clinical status.~The G-FMV will perform the treatment at a frequency of 7 times per week for 3 weeks (21 total applications), using the EVM EVO medical device (Endomedica, Italy), applying an intensity of 100 Hz for a total of 23 minutes. Specifically, four different trains of stimulation lasting 5 minutes each will be performed, interspersed with 1 minute of rest (20 minutes of treatment + 3 minutes of rest). FMV will be applied on agonist (major spasticity) muscles of the lower limb and/or upper limb, either single-district or multiple-district, according to clinical evidence of intervention. Stimulation will be conducted in a stand-alone session as an adjunctive modality to the rehabilitation project of physiotherapy and occupational therapy."
61997833|NCT02644707|EXPERIMENTAL|L-selenomethionine|A group randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months
61997834|NCT02644707|PLACEBO_COMPARATOR|Placebo|A group randomized to receive placebo (control group) for 6 months
61997835|NCT01261858|EXPERIMENTAL|Stainless steel and Kryptonite|Sternal closure with stainless steel and kryptonite
61997836|NCT01261858|ACTIVE_COMPARATOR|Stainless steel|Sternal closure with only stainless steel
61997837|NCT03892811||Infants referred for swallow study|"This is a within-subjects intervention study where each infant in the study will receive all three conditions.~The three study conditions are bottle-feeding with 1) Dr. Brown's Ultra-Preemie bottle nipple, 2) Dr. Brown's Preemie bottle nipple, and 3) Dr. Brown's Level 1 bottle nipple."
61997838|NCT05054738|EXPERIMENTAL|Combined Recovery Program (CRP)+Treatment-as-usual (TAU)|Combined Recovery Program (CRP) is a six-session motivational enhancement and daily living skills therapy workshop provided while on the inpatient unit. Attendance of CRP will be in addition to Treatment as Usual (TAU), that is, standard inpatient programming.
61997839|NCT05054738|ACTIVE_COMPARATOR|CRP+ Stable & Able (S&A)+TAU|Combined Recovery Program (CRP) a six-session motivational enhancement and daily living skills therapy workshop provided while on the inpatient unit, plus a home telehealth program (Stable \& Able) which begins on day 1 of hospital discharge. Attendance of CRP and S\&A will be in addition to TAU, that is, standard inpatient programming.
61997840|NCT05054738|NO_INTERVENTION|Treatment-as-usual only (TAU):|TAU will only receive the usual care on the inpatient unit including medical and medication management.
62183295|NCT02925234|EXPERIMENTAL|Durvalumab|Durvalumab for patients with a molecular tumor profile that can potentially be targeted by Durvalumab.
62392103|NCT01618929|ACTIVE_COMPARATOR|asthma with food allergy|The study will be performed in 2 groups of patients (Patients with and without food allergy) parallel to each other at the same time and within each group the patients will take montelukast and placebo (one after another in a double-blind design).
62392104|NCT01618929|ACTIVE_COMPARATOR|asthma without food allergy|The study will be performed in 2 groups of patients (Patients with and without food allergy) parallel to each other at the same time and within each group the patients will take montelukast and placebo (one after another in a double-blind design)
61997841|NCT01790334||Spontenous Ventilation (Group S)|ultrasonography of Right internal jugular vein
61997842|NCT01790334||Pressure control Ventilation (Group P)|ultrasonography of Right internal jugular vein
62392105|NCT01352923||peripheral blood|healthy voluntary donors
62392106|NCT01287403|PLACEBO_COMPARATOR|Refined wheat flour|A negative control flour to serve as a reference.
62392107|NCT01287403|ACTIVE_COMPARATOR|Esterase wholegrain wheat flour|Wholegrain wheat flour treated with esterases to release phenolics (positive control for phenolic acids)
62392108|NCT01287403|EXPERIMENTAL|Wholegrain wheat flour|Flour with unknown response
62392109|NCT01287403|EXPERIMENTAL|Liquid whole grain wheat flour|Test flour with unknown response.
62773620|NCT01676623|EXPERIMENTAL|A&T Franchise|In this arm, the 20 CHCs will offer Alive \& Thrive branded franchise services with enhanced quality of IYCF counseling through interpersonal contact between health workers at the commune level and clients who use the commune health services. In addition, the clients could also be exposed to the mass media campaign.
61997843|NCT01790334||Volume control ventilation (Group V)|ultrasonography of Right internal jugular vein
62183296|NCT02925234|EXPERIMENTAL|Rucaparib|Rucaparib for patients with a molecular tumor profile that can potentially be targeted by Rucaparib.
62183297|NCT02925234|EXPERIMENTAL|Axitinib|Axitinib for patients with a molecular tumor profile that can potentially be targeted by Axitinib.
62392110|NCT01287403|EXPERIMENTAL|Wholegrain barley flour|Test flour with unknown response.
62773621|NCT06172946|EXPERIMENTAL|INSPIRATORY MUSCLE TRAINING|"Power Breathe:~(3times/week for 8 weeks) The patient should inhale and exhale through the mouthpiece 30 times maximum. The training load is adjustable and should be set at a level appropriate for the patient to effectively train the inspiratory muscles. (Lázaro et al., 2021)"
62773622|NCT06172946|ACTIVE_COMPARATOR|TRANSCUTANEOUS ELECTRICAL DIAPHRAGMATIC STIMULATION|"Transcutaneous electrical Diaphragmatic Stimulation(TEDS):~(3times/week for 8 weeks) During each session, rectangular electrodes were placed on the parasternal region beside the xiphoid process; the sixth and seventh intercostal spaces in line with the mid-axillary line. The electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. TEDS intensity was gradually increased until visible muscle contraction was observed. (Hsin et al., 2022)"
62773623|NCT06124820|EXPERIMENTAL|Treatment Arm|Intravaginal micro-ablative fractional CO2 laser technology Deka SmartXide Touch C60 (MonaLisa Touch) will be administered intravaginally over a course of 5 cycles
62183298|NCT02925234|EXPERIMENTAL|Palbociclib|Palbociclib for patients with a molecular tumor profile that can potentially be targeted by Palbociclib.
62183299|NCT02925234|EXPERIMENTAL|Crizotinib|Crizotinib for patients with a molecular tumor profile that can potentially be targeted by Crizotinib.
62392111|NCT01287403|EXPERIMENTAL|Liquid wholegrain barley flour|Test flour with unknown response.
62392112|NCT05089773||group 1|The only group in this retrospective study includes patients diagnosed with transposition of the great arteries receiving arterial switch operation in children's hospital of fudan university and shanghai children's medical center.
62392113|NCT04241705|ACTIVE_COMPARATOR|Control arm|The control arm will provide optimized malaria control interventions that includes strengthened surveillance systems and commodities management, scale-up of vector control and case management services.
62392114|NCT04241705|ACTIVE_COMPARATOR|Reactive Case Detection (RCD) arm|Optimized malaria control interventions as in the control arm. In addition, following identification of microscopy or RDT positive, passively-detected index cases at the health post or health center; individuals who reside within a 100-meter radius of the index case will receive diagnosis for malaria using a conventional RDT. Positive individuals will receive treatment and follow-up as per the national treatment guidelines. 14 days of primaquine (PQ) will only be administered to those found to be normal upon G6PD testing. Additional procedures will include the collection of a dried blood spot.
62392115|NCT04241705|EXPERIMENTAL|Targeted Mass Drug Administration (tMDA) arm|Optimized malaria control interventions as in the control arm. In addition, following identification of microscopy or RDT positive index cases at the health post or health center, all eligible individuals who reside within a 100-meter radius of the index case will receive presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ) (0.25mg/kg daily). 14 days of primaquine (PQ) will only be administered to those found to be normal upon G6PD testing.
62568182|NCT04856267||Systemic AL Amyloidosis study cohort|"Eligible patients will undergo subcutaneous implantation of a cardiac monitor device (Brand name - LINQ device, Medtronic - referred to in the application as implantable loop recorder or ILR)"
62568183|NCT02792712|EXPERIMENTAL|STEMI_MRI_Ticagrelor|A Magnetic Resonance Imaging Study in myocardial salvage in patients with ST-Elevation myocardial infarction (STEMI) undergoing pRimary percutaneous coronary intervention - Ticagrelor Arm
61978527|NCT02062034|EXPERIMENTAL|Combined antioxidant therapy|(1mg copper + 20mg zinc + 180mg vitamin C + 30mg vitamin E + 1mg zeaxanthin + 4mg astaxanthin + 10mg lutein) daily of oral antioxidant combined therapy for 24 weeks
61997844|NCT00323414|ACTIVE_COMPARATOR|Polyunsaturated fatty acid (Opti-EPA)|Polyunsaturated fatty acid will consist of purified EPA:DHA (360 mg EPA and 240 mg DHA) 6 gelcaps-3 capsules by mouth 2x per day x 48 weeks
61997845|NCT00323414|PLACEBO_COMPARATOR|Placebo|Gelcaps containing corn oil as placebo 6 capsules 3 capsules by mouth 2 x per day for 48 weeks
61997846|NCT02530424|EXPERIMENTAL|Trast-pert-palbo-fulve|Patients will receive an association of drugs (trastuzumab, pertuzumab, palbociclib plus or minus fulvestrant) as neoadjuvant chemotherapy. Definitive surgery will be performed not earlier than 14 days and not later than 28 days after the last dose of any of the drugs in the combination. After completion of surgical treatment patients will receive irradiation as locally acceptable.
61997847|NCT04904185|OTHER|Part A|Six patients will be included in Part A. After inclusion 300 mL blood will be drawn from the patients for the production of the MASE-T cell product. Four days prior to MASE-T infusion the patient will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m2/day i.v. on day -4, -3, -2 and fludarabine 30 mg/m2/day i.v. on day -4, -3) followed by i.v. infusion of the MASE-T product on day 0.
61997848|NCT04904185|OTHER|Part B|Six patients will be includede in Part B. After inclusion 300 mL blood will be drawn from the patients for the production of the MASE-T cell product. Four days prior to MASE-T infusion the patient will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m2/day i.v. on day -4, -3, -2 and fludarabine 30 mg/m2/day i.v on day -4, -3) followed by i.v infusion of the MASE-T product on day 0. Pembrolizumab 2 mg/kg will be administered on day -1 and day +21.
62392116|NCT05162495|EXPERIMENTAL|Arm A|Requiring a diagnostic or screening RT-PCR test for COVID-19.
62392117|NCT05162495|EXPERIMENTAL|Arm B|Positive to COVID-19 in RT-PCR test performed up to 48 hours before screening.
62392118|NCT02039687|EXPERIMENTAL|1 mg per day ARA 290|1 mg ARA 290 administered subcutaneously for 28 consecutive days
62392119|NCT02039687|EXPERIMENTAL|4 mg per day ARA 290|4 mg ARA 290 administered subcutaneously for 28 consecutive days
61997849|NCT04069403|EXPERIMENTAL|Intervention Arm- Automated Reports|Receives automated reports on prescription patterns monthly
61997850|NCT04069403|NO_INTERVENTION|Control Arm: Usual clinical education and feedback|Receive no reports
62183300|NCT02925234|EXPERIMENTAL|Sunitinib|Sunitinib for patients with a molecular tumor profile that can potentially be targeted by Sunitinib.
62568184|NCT02792712|ACTIVE_COMPARATOR|STEMI_MRI_Clopidogrel|A Magnetic Resonance Imaging Study in myocardial salvage in patients with ST-Elevation myocardial infarction (STEMI) undergoing pRimary percutaneous coronary intervention - Clopidogrel Arm
62568185|NCT01496001|EXPERIMENTAL|Cohort|
62568186|NCT01992627|EXPERIMENTAL|High Intensity Laser Therapy|High Intensity Laser Therapy (HILTERAPIA HIRO 3.O)will be used among diagnosed patients with elbow epicondylosis. A five minutes duration of HILTERAPIA HIRO 3.0 along the epicondyle area in a targeted manner will be use on the initial treatment, one week after the initial treatment, two weeks after the initial treatment and four weeks after the initial treatment thereafter.
62584756|NCT01137929||With APN, With VUR, With Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will also have VUR by VCUG and a renal scar on follow-up DMSA renal scan.
62773624|NCT06124820|SHAM_COMPARATOR|Control Arm|Sham treatment -Participants receiving sham treatment will have the probes advanced in the same manner without the use of a laser energy device.
62773625|NCT00708734|EXPERIMENTAL|Arm 1|functional exercise training
62773626|NCT01220180||Epilepsy|
61978528|NCT02062034|PLACEBO_COMPARATOR|Placebo|Placebo. 100mg daily oral intake for 24 weeks
61978529|NCT03582202|ACTIVE_COMPARATOR|Dietetic service|Nutritional assessment and therapy by dietitian throughout the hospital stay
61997851|NCT06306456|EXPERIMENTAL|'GH21+Osimertinib'Group|GH21 Capsules Combined with Osimertinib Mesylate Tablets
62183301|NCT02925234|EXPERIMENTAL|Cabozantinib|Cabozantinib for patients with a molecular tumor profile that can potentially be targeted by Cabozantinib.
62183302|NCT02925234|EXPERIMENTAL|Abemaciclib|Abemaciclib for patients with a molecular tumor profile that can potentially be targeted by Abemaciclib.
62183303|NCT02925234|EXPERIMENTAL|Alectinib|Alectinib for patients with a molecular tumor profile that can potentially be targeted by Alectinib.
62392120|NCT02039687|EXPERIMENTAL|8 mg per day ARA 290|8 mg ARA 290 administered subcutaneously for 28 consecutive days
62773627|NCT01220180||Neuropathic Pain|
62773628|NCT01220180||Fibromyalgia|
62773629|NCT02706379|EXPERIMENTAL|Local cerebral oxygen saturation|use NIRS technical to detect local cerebral oxygen saturation of both sides of brain
62568187|NCT00396656|EXPERIMENTAL|Valsartan followed by atenolol + hydrochlorothiazide (HCTZ)|"After a 2-week washout period, patients were treated with valsartan for 20 weeks followed by one week in which it was tapered off. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. The valsartan dose was then tapered off to 80 mg for one week. Patients took valsartan film coated tablets orally once a day (od) in the morning.~After a second 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning."
62183304|NCT02925234|EXPERIMENTAL|Atezolizumab/bevacizumab|Atezolizumab and bevacizumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Atezolizumab and bevacizumab.
62183305|NCT02925234|EXPERIMENTAL|Ipilimumab/nivolumab|Ipilimumab and nivolumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Ipilimumab and nivolumab.
62392121|NCT02039687|PLACEBO_COMPARATOR|placebo|1 mL placebo administered subcutaneously for 28 consecutive days
62392122|NCT05130736|EXPERIMENTAL|Robot|Patients treated using a rehabilitation robot
62392123|NCT05130736|ACTIVE_COMPARATOR|Control|Patients receiving traditional rehabilitation treatment (robot used only as assessment tool)
62392124|NCT00918489|EXPERIMENTAL|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
62392125|NCT06419023|EXPERIMENTAL|Exercises group (EG)|The exercise group (EG) participated in supervised physical activity intervention using the Pilates Method (exercises on the mat, 60min each session, 2 sessions each week over 12 weeks) were administered by certified Pilates teacher.
62392126|NCT06419023|NO_INTERVENTION|Usual-Care Group (U-CG)|Patients in the U-CG were instructed to continue with their usual activities: a) to avoid changing their diet habits during intervention; b) being physically active as usual.
62392127|NCT05981560|EXPERIMENTAL|Closed Chain Exercise|closed chain exercise plan given to the participant of this group
62392128|NCT05981560|EXPERIMENTAL|Neuromuscular Training Exercise|Neuromuscular training plan given to the participants of this group
62392129|NCT04692285|ACTIVE_COMPARATOR|Patients with focal dystonia treatment first placebo second|Zolpidem 5 mg single dose
61978530|NCT03582202|PLACEBO_COMPARATOR|standard care|Nutritional handling by nurses supported by a dietician if needed
62183306|NCT02925234|EXPERIMENTAL|Entrectinib|Entrectinib for patients with a molecular tumor profile that can potentially be targeted by entrectinib.
62183307|NCT02925234|EXPERIMENTAL|Talazoparib|Talazoparib for patients with a molecular tumor profile that can potentially be targeted by talazoparib.
62183308|NCT02925234|EXPERIMENTAL|dacomitinib|Dacomitinib for patients with a molecular tumor profile that can potentially be targeted by dacomitinib.
62392130|NCT04692285|PLACEBO_COMPARATOR|Patients with focal dystonia placebo first treatment second|Placebo 5 mg single dose
62584757|NCT01137929||With APN, With VUR, Without Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will also have VUR by VCUG and NO renal scar on follow-up DMSA renal scan.
62584758|NCT01137929||With APN, without VUR, with Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan but who will NOT have VUR by VCUG; however they will have a renal scar on follow-up DMSA renal scan.
62773630|NCT01942070|EXPERIMENTAL|Bioresorbable vascular scaffold|Bioresorbable vascular scaffold (BVS)
62183309|NCT02925234|EXPERIMENTAL|Lorlatinib|Lorlatinib for patients with a molecular tumor profile that can potentially be targeted by lorlatinib.
62392131|NCT03077646|EXPERIMENTAL|Be SMART alone|Parents/guardians in this study group will watch a 5.5 minute Be SMART video and receive the handouts reviewing the information.
62392132|NCT03077646|EXPERIMENTAL|Be SMART + MD review|Parents/guardians in this study group will watch a 5.5 minute Be SMART video and receive the handouts reviewing the information and will also have an MD review the information (via a checklist to standardize the MD review).
62392133|NCT03077646|ACTIVE_COMPARATOR|Control: TSE materials|"Parents/guardians in this study group will watch a video Kids and Smoke Don't Mix and receive handouts reviewing information on tobacco smoke exposure (TSE)."
62392134|NCT01384513|EXPERIMENTAL|Treatment (Allogeneic PBSCT)|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 60 minutes on days -11 to -8 and busulfan IV over 3 hours on days -10 to -9. Patients undergo TBI on day -6. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients undergo DLI on day -6 and CD-34+ allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID on days -1 to 28."
62392135|NCT04406324||SARS-CoV-2 patients|Patients infected by SARS-CoV-2
62183310|NCT02925234|EXPERIMENTAL|Erdafitinib|Erdafitinib for patients with a molecular tumor profile that can potentially be targeted by erdafitinib.
62183311|NCT02925234|EXPERIMENTAL|Alpelisib|Alpelisib for patients with a molecular tumor profile that can potentially be targeted by alpelisib.
62392136|NCT03778281|EXPERIMENTAL|Baclofen group|Treatment of Chemotherapy-related Hiccups With Baclofen
62392137|NCT03778281|OTHER|Methoxyclopramide group|Treatment of Chemotherapy-related Hiccups With Methoxyclopramide
62392138|NCT03778281|EXPERIMENTAL|Baclofen group 2|After 3 days, if the metoclopramide treatment is ineffective, it will cross into the baclofen group 2.
62392139|NCT03778281|OTHER|Methoxyclopramide group 2|After 3 days, if the baclofen treatment is ineffective, it will cross into the metoclopramide group 2.
62392140|NCT04198376|EXPERIMENTAL|The Laterally Closed Tunnel Technique with SCTG|Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes. Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures
62392141|NCT04198376|EXPERIMENTAL|Modified Coronally Advanced Tunnel Technique with SCTG.|In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator .A second surgical site will be prepared to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site. After sutures are slid through each tunnelled interdental area the needle will be pushed through the CTG before it is guided back through the undermined tissues.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingival papillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.
62392142|NCT00988910||Group 1|
62392143|NCT00988910||Group 2|
62392144|NCT00759551|EXPERIMENTAL|Azilsartan 2.5 mg QD|
62392145|NCT00759551|EXPERIMENTAL|Azilsartan 5 mg QD|
62392146|NCT00759551|EXPERIMENTAL|Azilsartan 10 mg QD|
62392147|NCT00759551|EXPERIMENTAL|Azilsartan 20 mg QD|
62183312|NCT02925234|EXPERIMENTAL|Niraparib|Niraparib for patients with a molecular tumor profile that can potentially be targeted by niraparib.
62392148|NCT00759551|EXPERIMENTAL|Azilsartan 40 mg QD|
62392149|NCT00759551|PLACEBO_COMPARATOR|Placebo QD|
62392150|NCT00759551|ACTIVE_COMPARATOR|Olmesartan 20 mg QD|
62392151|NCT02592980|EXPERIMENTAL|Traditional anticoagulation|For the Traditional Anticoagulation group, the physician will adjust the dose according to the current INR value based on current guidelines
62392152|NCT02592980|EXPERIMENTAL|Pharmacogenetic anticoagulation|For the Pharmacogenetic Anticoagulation group, the dose will be prescribed based on data from each patient applied in a pharmacogenetic algorithm. In some cases, used algorithm may provide a counter-intuitive dose, i.e., a dose that is not adequate for adjusting the current patient' INR (for example, a higher dose for a patient that already has a high INR). In these cases, the physician will adjust the dose following clinical criteria based on published guidelines
62392153|NCT02174952|EXPERIMENTAL|TAU+SH|Families allocated to receive their usual treatment + self-help (TAU+SH) will receive 12 weeks of a self-help version of the New Forest Parenting Programme in addition to the usual treatment they are receiving from their clinician. They will also receive an introductory DVD aimed at highlighting key components of the intervention.
62392154|NCT02174952|NO_INTERVENTION|TAU|Families in the Treatment as Usual (TAU) condition will receive nothing additional to the treatment offered by their paediatrician or Child \& Adolescent Mental Health Services (CAMHS) during the trial phase. Families in the TAU condition will be offered the self-help manual at the end of the trial.
62773631|NCT01942070|ACTIVE_COMPARATOR|Everolimus-eluting stent|Durable polymer everolimus-eluting metallic stent (EES)
62183313|NCT02925234|EXPERIMENTAL|Pemigatinib|Pemigatinib for patients with a molecular tumor profile that can potentially be targeted by pemigatinib.
62183314|NCT02925234|EXPERIMENTAL|Selpercatinib|Selpercatinib for patients with a molecular tumor profile that can potentially be targeted by selpercatinib.
62584759|NCT01137929||With APN, Without VUR, Without Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will NOT have VUR by VCUG, NOR will they have a renal scar on follow-up DMSA renal scan.
62791527|NCT04054076|EXPERIMENTAL|Custom-made hard|Custom-made insoles formed over an individual cast positive. 55 shore of hardness in material Ethyl Vinyl Acetate.
62392155|NCT02887508|EXPERIMENTAL|HINTS Intervention|The HINTS intervention consisted of an online four-session group intervention for 45 minutes, twice a week for two weeks. In each session, facilitators presented information, motivational skills, and behavioral skills related to a specific topic relevant to online partner seeking and transmission risk reduction, including Internet safety and communication, condom negotiation, and serostatus disclosure.
62183315|NCT02925234|EXPERIMENTAL|Tepotinib|Tepotinib for patients with a molecular tumor profile that can potentially be targeted by tepotinib.
61997852|NCT05222061|ACTIVE_COMPARATOR|provisional-stenting group|Provisional stenting will be performed according to european bifurcation club consensus. MB and SB predilatation will be at the operator's discretion. A stent is delivered in the main vessel and positioned across the bifurcation. POT is mandatotary. In case of dissection impeding the flow in the SB or acute coronary closure after MB atenting a SB stenting using a DES was allowed. Dual-stent techniques will be performed according to the recommendation of the EBC consensus.
62183316|NCT01325597|EXPERIMENTAL|Combined training|Training with functional electrical stimulation added by inspiratory muscle training.
62183317|NCT01325597|EXPERIMENTAL|Electrical stimulation|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks
62183318|NCT01325597|EXPERIMENTAL|Inspiratory muscle training|IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure
62183319|NCT01325597|NO_INTERVENTION|Control group|No intervention.
62183320|NCT03397238||Non-metastatic TC|blood withdrawal, bone marrow aspiration
62183321|NCT03397238||Metastatic TC|blood withdrawal, bone marrow aspiration
62183322|NCT03397238||MNG surgery|blood withdrawal, bone marrow aspiration
62183323|NCT03397238||MNG RAI treatment|blood withdrawal
62183324|NCT03397238||Healthy volunteers|blood withdrawal
62183325|NCT04706793|EXPERIMENTAL|Etrasimod 2 mg|
62183326|NCT04706793|PLACEBO_COMPARATOR|Placebo|
62183327|NCT04991688|EXPERIMENTAL|BOTOX-A|
62392156|NCT02887508|ACTIVE_COMPARATOR|Healthy Living Control|The Healthy Living Control condition consisted of an online four-session group intervention for 45 minutes, twice a week for two weeks. In each session, facilitators presented information, motivational skills, and behavioral skills to address non-sexual health-related topics particularly relevant to individuals living with HIV, such as nutrition, healthy eating, portion control, exercise and staying active, and stress reduction.
62183328|NCT01310712|EXPERIMENTAL|oxybutynin|patients will receive in the end of the treatment, 10 mg of oxybutynin a day
62183329|NCT01310712|PLACEBO_COMPARATOR|Placebo|Placebo
62791528|NCT04054076|NO_INTERVENTION|Control group|No intervention with therapeutic insoles and/or shoes.
62183330|NCT01434537||SCAN|Venepuncture performed with support of the AccuVein 300 vein scanner.
62791529|NCT00590863|ACTIVE_COMPARATOR|SSRI + placebo|Participants will take escitalopram plus placebo.
62791530|NCT00590863|ACTIVE_COMPARATOR|Escitalopram + Bupropion SR|Participants will take escitalopram + bupropion-SR.
62791531|NCT00590863|ACTIVE_COMPARATOR|Venlafaxine XR + Mirtazapine|Participants will take venlafaxine-XR + mirtazapine.
62183331|NCT01434537||NO_SCAN|Venepuncture without support of the vein scanner.
62183332|NCT05367206|EXPERIMENTAL|NAC plus RCT|two circles of NAC with albumin-bound paclitaxel and carboplatin followed by standard chemoradiation with weekly cisplatin plus pelvic radiation
62183333|NCT05367206|NO_INTERVENTION|RCT|standard chemoradiation with weekly cispatin plus pelvic radiation
62183334|NCT00983892|EXPERIMENTAL|CarePartners+|Patients receive automated telephonic symptom assessment and symptom management advice; caregivers receive the intervention (Intervention = access to a caregiver Web site that updates them on patient's symptoms and provides tailored problem solving advice).
62183335|NCT00983892|NO_INTERVENTION|CarePartners-|Patients receive automated telephonic symptom assessment and symptom management advice; caregivers receive nothing (i.e. no access to the caregiver website, or 'intervention').
62183336|NCT00620633|EXPERIMENTAL|1|Patients with leukemia or myelodysplastic syndrome (MDS) who, following an HLA-matched allogeneic hematopoietic cell transplant, have relapsed with leukemia as demonstrated morphologically on peripheral blood smear or bone marrow aspirate
62183337|NCT02377011|EXPERIMENTAL|PS CBT|"Problem solving cognitive behaviour therapy (PS CBT) will be delivered remotely by means of telephone or video calling by a cognitive behaviour therapist in addition to their usual care.~The duration of the intervention will be 10 sessions. Research measures will be completed at baseline, 3,6,9 and 12 months"
62183338|NCT02377011|NO_INTERVENTION|Treatment as Usual|Participants will not receive any CBT therapy in addition to their usual care. Research measures will be completed at baseline,3,6,9 and 12 months.
62183339|NCT02860299|EXPERIMENTAL|Citrate lock|
62183340|NCT02860299|ACTIVE_COMPARATOR|Heparin lock|
62183341|NCT02780102|EXPERIMENTAL|Cognitive-Motor Rehabilitation|Cognitive-Motor Rehabilitation (CMR): 20 sixty-minute sessions of cognitive-motor rehabilitation
62183342|NCT02780102|EXPERIMENTAL|Ritalin|2 to 3 doses of 10 mg Ritalin tablets per day during 8 week.
62183343|NCT02780102|ACTIVE_COMPARATOR|Active Control|Active Control group simultaneously received 20 sixty-minute sessions of low dose cognitive-motor exercises
62183344|NCT03991988|EXPERIMENTAL|Montelukast Group|Montelukast (10, 20, or 40 mg)
62183345|NCT03991988|PLACEBO_COMPARATOR|Placebo Group|Matched placebo pill
62183346|NCT04716218|PLACEBO_COMPARATOR|neutral position|The initial percentage of glottic opening (POGO) by laryngoscopy was recorded in the ramped position. Thereafter, a second POGO (laryngeal view) was scored in the neutral position and then intubation was performed.
62183347|NCT04716218|EXPERIMENTAL|back up head elevated position|The initial POGO was recorded in the neutral position. The second POGO was scored in the ramped position and then the trachea was intubated.
62214572|NCT01888900|EXPERIMENTAL|Hepatitis C Virus Genotype 1A with QUAD|Subjects will be started on combination therapy with asunaprevir, daclatasvir, peginterferon alfa-2a and ribavirin for 24 weeks.
62791532|NCT03793361|EXPERIMENTAL|Arm A|Regorafenib
62791533|NCT03793361|PLACEBO_COMPARATOR|Arm B|Placebo
61997853|NCT05222061|EXPERIMENTAL|DCB group|"Coronary guidewires should be passed to the MB and SB, respectively. Lesion preparation of the main branch should be undertaken as considered necessary. Lesion preparation of the side branch is mandatorary. If the angiographic result will be good after predilatation (residual stenosis \< 30%), drug-eluting stent will implanted in the main branch of the bifurcation site (the stent diameter should be choosen based on the diameter of the distal MB). A kissing with conventional balloons should be performed in the MB and SB. Reapet kissing with drug-coated balloonin the SB and conventional balloon in MB (30 seconds at low pressure (8-10 bar) should be performed. The DCB diameter was again 0.8-1.0 of the vessel diameter.~In case of dissection impeding the flow in the SB or acute coronary closure after DCB application a SB stenting using a DES was allowed. Dual-stent techniques will be performed according to the recommendation of the EBC consensus."
61997854|NCT05417932|EXPERIMENTAL|SCG101|"This is a single arm study.~Patients will receive infusion and will be observed for dose limiting toxicity (DLT) over a 28-day period, and thereafter enter the progression free survival observation period and continuous long term survival follow up at time of disease progression."
61997855|NCT01404091|EXPERIMENTAL|Cohort 1: 40 milligram (mg) LY2940094|"40 mg LY2940094 was administered orally, one time only (it was originally expected that 100 mg LY2940094 would be administered).~If the receptor occupancy (RO) for a given dose is lower than 50%, (time to maximum concentration \[tmax\] or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
62183348|NCT05431998|EXPERIMENTAL|The use of demineralized autogenous tooth graft in the jumping gap of the immediate implant|The participant's own freshly extracted tooth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries, or restorations (if present) and have their crown decapitated, using a high-speed fine finishing stone and saline irrigation. The pulp chamber and root pulp will be cleaned by split opening the root and cleaning it out using a high-speed diamond bur. Subsequently, teeth will be ground, and demineralized using a hand bone mill (Gold Bone Mill, MCT Bio, Korea). Then the particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid (Chemajet Chemicals, Egypt) for 30 min then washed twice in saline and dried with sterile gauze. Then it will be used as a graft for the bone defect around the immediately placed implant.
62183349|NCT05431998|ACTIVE_COMPARATOR|The use of autogenous bone graft in the jumping gap of the immediate implant|A horizontal vestibular incision will be placed below the mucogingival junction and a mucoperiosteal flap will be reflected then autogenous bone particles will be collected from the participants using Automatic Bone Collector Bur (ACM Bur) by NeoBiotch, from the mandibular retro-molar region, speed 300rpm, torque 30Ncm, with irrigation.
62183350|NCT02802150|ACTIVE_COMPARATOR|Zanthoxylum schinifolium seed Oil|Zanthoxylum schinifolium seed Oil 100% (4g/day)
62183351|NCT02802150|PLACEBO_COMPARATOR|soy bean oil|soy bean oil 99.9%, edible dyes 0.01% (4g/day)
62392157|NCT03324282|EXPERIMENTAL|Arm A: GC + avelumab group|
62392158|NCT03324282|ACTIVE_COMPARATOR|Arm B: GC group|
62392159|NCT00275834|EXPERIMENTAL|A|Zonisamide 400 mg
62392160|NCT00275834|EXPERIMENTAL|B|Zonisamide 200 mg
62392161|NCT00275834|PLACEBO_COMPARATOR|C|matching placebo
62392162|NCT00218439|EXPERIMENTAL|1|Active medication for 4 weeks followed by placebo for 4 weeks
62392163|NCT00218439|EXPERIMENTAL|2|Placebo for 4 weeks followed by active for 4 weeks
62584760|NCT01137929||Without APN, With VUR|This group of children who present with a febrile UTI will be found NOT to have APN on DMSA renal scan and will also have VUR by VCUG. They will not undergo a second DMSA scan since the first one is normal.
62392164|NCT03511222|EXPERIMENTAL|Dose Escalation: Vorolanib + Nivolumab|"* Vorolanib is an oral drug which will be administered daily on an outpatient basis at the assigned dose level.~* Patients receiving nivolumab will get it on an outpatient basis as a 30-minute intravenous infusion at a dose of 480 mg on Day 1 of each 28-day cycle~* In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
62392165|NCT03511222|EXPERIMENTAL|Dose Escalation: Vorolanib + Pembrolizumab|"* Vorolanib is an oral drug which will be administered daily on an outpatient basis at the assigned dose level~* Patients receiving pembrolizumab will get it on an outpatient basis as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 200 mg on Day 1 of each 21-day cycle~* In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
62183352|NCT04584502|EXPERIMENTAL|Intervention as adjunct to Treatment as Usual|Participants will attend via Zoom an 8-session group-based yoga-mindfulness intervention offered over the course of approximately 10 consecutive weeks. Participants will also be asked to use a mobile companion app once a week during the intervention period. All intervention participants also receive treatment as usual for OUD at the partner practice, which includes medication for OUD, individual and/or group counseling, and case management.
62183353|NCT04584502|NO_INTERVENTION|Treatment as Usual|Participants receive treatment as usual for OUD at the partner practice, which includes medication for OUD, individual and/or group counseling, and case management.
62183354|NCT01773876|ACTIVE_COMPARATOR|Micafungin|MYCAMINE 100 mg intravenous an injection of 24 hours
62183355|NCT01773876|PLACEBO_COMPARATOR|PLACEBO|0.9% sodium chlorides 100ml infusion
62183356|NCT05768269||Cellular Therapy|Participants who have previously received an induced pluripotent stem cell (iPSC)-derived, ex vivo genome edited cellular therapy product in an eligible Century-sponsored index trial will be enrolled in this study for up to 180 months following the last treatment with a cellular therapy product in an eligible index trial.
62183357|NCT03014817|EXPERIMENTAL|Ultrasonically activated scalpel|Dissection with ultrasonically activated scalpel. Direction of dissection undecided but by experience most naturally fundus first.
62183358|NCT03014817|ACTIVE_COMPARATOR|Electrocautery|Dissection with electrocautery. Direction of dissection undecided but by experience most naturally cystic duct first.
62392166|NCT03511222|EXPERIMENTAL|Vorolanib + Nivolumab (Small Cell Lung Cancer)|"* Vorolanib is an oral drug which will be administered daily on an outpatient basis at 300 mg daily~* Patients receiving nivolumab will get it on an outpatient basis as a 30-minute intravenous infusion at a dose of 480 mg on Day 1 of each 28-day cycle~* In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
62392167|NCT02384096|ACTIVE_COMPARATOR|Conventional Programming, then Advanced Programming|Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received conventional single source programming followed by Precision Spectra SCS System advanced programming.
62392168|NCT02384096|ACTIVE_COMPARATOR|Advanced Programming, then Conventional Programming|Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received Precision Spectra SCS System advanced programming followed by conventional single source programming.
62392169|NCT03031613|EXPERIMENTAL|PEEP group|Application of 5 cmH2O PEEP during mechanical ventilation
62392170|NCT03031613|ACTIVE_COMPARATOR|ZEEP group|No application of PEEP during mechanical ventilation
62183359|NCT04922645|EXPERIMENTAL|Ferric citrate (commercially available, Auryxia)|Ferric citrate, (commercially available Auryxia), supplied as tablets for oral administration containing 1 gram ferric citrate (210 milligrams of ferric iron). Administered orally with meals or snacks.
62183360|NCT04922645|ACTIVE_COMPARATOR|Standard of care phosphate lowering therapy|Non-Auryxia phosphate-lowering therapy administered as standard of care.
62183361|NCT00424554|EXPERIMENTAL|Temozolomide treatment|
62183362|NCT00424554|NO_INTERVENTION|No treatment|
62183363|NCT04680793|OTHER|EDS Patients|No intervention during the control period (9 weeks) and then experimental during the rehabilitation stage (9 weeks).
62183364|NCT02007811|EXPERIMENTAL|allogeneic donor derived B-lymphocytes|
62183365|NCT04648098|EXPERIMENTAL|Experimental: Intervention group|Discharge training and telephone counseling
62183366|NCT04648098|NO_INTERVENTION|No Intervention: Control Group|Routine care
61997856|NCT01404091|EXPERIMENTAL|Cohort 2: 10 mg LY2940094|"The dose levels for subjects in Cohort 2 will be defined based on the results of the receptor occupancy (RO) data of previous cohort and the ongoing review of safety data. This dose was determined to be 10 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
61997857|NCT01404091|EXPERIMENTAL|Cohort 3: 4 mg LY2940094|"The dose levels for subjects in Cohort 3 will be defined based on the results of the receptor occupancy (RO) data of previous cohort(s) and the ongoing review of safety data. This dose was determined to be 4 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
61997858|NCT01404091|EXPERIMENTAL|Cohort 4: 20 mg LY2940094|"The dose levels for subjects in Cohort 4 will be defined based on the results of the receptor occupancy (RO) data of previous cohort(s) and the ongoing review of safety data. This dose was determined to be 20 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
62183367|NCT02660268|EXPERIMENTAL|Clinical pathway|Patients in the experimental group will be followed according to the clinical pathway
62183368|NCT02660268|NO_INTERVENTION|Control|Patients in the control group will receive standard care
62183369|NCT02100683||PDA Coil|Patients age 6 months to 21 years weighing \> 5kg with an angiographically confirmed PDA with a minimum diameter of \< 4 mm.
62183370|NCT02136771|ACTIVE_COMPARATOR|Vitamin D3|The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3; producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks
62183371|NCT02136771|PLACEBO_COMPARATOR|Placebo|Oily drops as placebo
62392171|NCT02554721|EXPERIMENTAL|Group 1 (CYP2C19 Wild Type)|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Acetylsalicylic acid 100 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Acetylsalicylic acid 100mg once daily for 1 week (Days 22-28)
62392172|NCT02554721|EXPERIMENTAL|Group 2 (CYP2C19 Wild Type)|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
61997859|NCT05527431|ACTIVE_COMPARATOR|high flow nasal cannula|
61997860|NCT05527431|ACTIVE_COMPARATOR|noninvasive mechanical ventilation|
61997861|NCT02485106|ACTIVE_COMPARATOR|Rifaximin group|Corticosteroid or Pentoxifylline for 28 days Rifaximin 400mg tid for 28 days
61997862|NCT02485106|ACTIVE_COMPARATOR|Control group|Corticosteroid or Pentoxifylline for 28 days
62183372|NCT02929719|EXPERIMENTAL|Test Gel 5%|Topical, twice daily on the face for 84 days.
62183373|NCT02929719|ACTIVE_COMPARATOR|ACZONE Gel 5%|Topical, twice daily on the face for 84 days
62183374|NCT02929719|PLACEBO_COMPARATOR|Placebo Gel|Topical, twice daily on the face for 84 days
62183375|NCT06302725|EXPERIMENTAL|Vaginal self sampling detecting HPV|
62183376|NCT04134715|EXPERIMENTAL|PF-06826647 alone then OC alone then OC+PF-06826647|In Period 1 (Period 1 is 2 days), participants will receive a single dose of PF-06826647 600 mg on Day 1. Period 2 (Period 2 is 14 days) will immediately follow Period 1 without any washout. In Period 2, the participants will receive OC in the form of 1 PORTIA (30 µg EE and 150 µg LN) or equivalent tablet, orally starting from Period 2 Day 1 until Period 3-Day 16 (Period 3 is 17 Days). Period 3 will immediately follow Period 2 with no washout. In Period 3 on Day 1, the participants will receive a single dose of PF-06826647 600 mg. On Day 2 in Period 3, PF-06826647 will not be dosed. From Day 3, the participants will receive PF-06826647 600 mg QD for 14 days followed by OC in the form of 1 PORTIA (EE and LN) or equivalent tablet.
62183377|NCT05101915|EXPERIMENTAL|Interventional|Single arm trial involving all patients receiving IMP
62214573|NCT01888900|EXPERIMENTAL|Hepatitis C Virus Genotype 1B with DUAL|Subjects will receive combination therapy with asunaprevir and daclatasvir alone for 24 weeks and undergo paired liver biopsies, pre-treatment and either at 2 or 4 weeks after starting therapy.
62183378|NCT05802914|EXPERIMENTAL|Exosuit|Exosuit refers to a soft active back exosuit. Participants in the exosuit arm will be fitted to a personal back exosuit device. Participants will be trained on how to use the device (retrieval, donning, powering up, mode switching, and doffing). Participants will be instructed to use the device at work, emphasizing they wear it whenever it seems practical (e.g. lifting) for as long as it remains comfortable. Associates from Verve Motion will check in with exosuit participants to address comfort issues and help participants integrate the exosuit into their workday.
62183379|NCT05802914|NO_INTERVENTION|Control|Control participants will not be assigned a back exosuit. Participants in the control group will perform workplace tasks as normal, completing study surveys at baseline and monthly for 4 months that are identical to exosuit group.
62183380|NCT03443011|EXPERIMENTAL|participants|All participants will be examined with both CT techniques. First a low dose CT without intravenous contrast followed by the standard method, a full dose CT with intravenous contrast
62183381|NCT05479188|ACTIVE_COMPARATOR|Minimal Invasive Extracorporeal Circulation (MiECC)|Patients undergoing cardiac surgery with Minimal Invasive Extracorporeal Circulation.
62183382|NCT05479188|ACTIVE_COMPARATOR|Conventional cardiopulmonary Bypass (cCPB)|Patients undergoing cardiac surgery with conventional cardiopulmonary bypass.
62183383|NCT02477449|EXPERIMENTAL|low dose group|8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS; All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
62183384|NCT02477449|EXPERIMENTAL|mid dose group|12 subjects in 0.5ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
62183385|NCT02477449|EXPERIMENTAL|high dose group|12 subjects in 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
62183386|NCT04332679|ACTIVE_COMPARATOR|Group A - control group|20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
62183387|NCT04332679|EXPERIMENTAL|Group B - Test group|20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
61997863|NCT02812758||patients|All sedated, intubated, mechanically ventilated adult patients admitted for elective cardiac surgery, monitored for sedation depth (with the BIS) and for preload dependence indices (SVV, PPV and PVI) transthoracic echocardiography
62183388|NCT05051215||Control group|40 healthy volunteers were included in the healthy control group
62183389|NCT05051215||NPM group|60 patients of NPM (30 PCM and 30 GM)were included
62183390|NCT03065608||Study Group|The study group included 36 patients with pain form of dysfunction.
61997864|NCT01358227|EXPERIMENTAL|PR104|
61997865|NCT02394080|EXPERIMENTAL|Photodynamic Bone Stabilization System (PBSS)|The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.
61997866|NCT03657888|EXPERIMENTAL|Family Club Denmark (FCD)|Participation in FCD
62183391|NCT03065608||Control Group|The control group consisted of 36 patients with painless form of disorder.
62183392|NCT03462537|EXPERIMENTAL|Experimental group 1|This group performed aerobic exercise just after low level laser therapy in the abdominal region with eight electrodes distributed in line.
61997867|NCT03657888|OTHER|Wait-list|Wait-list control
61997868|NCT04594850|NO_INTERVENTION|Placebo-Control group|Single intracavernous injection of Placebo Oral PDE5-inhibitor can take daily and on demand.
62183393|NCT03462537|EXPERIMENTAL|Experimental group 2|This group performed aerobic exercise just after low level laser therapy in the abdominal region with eight electrodes distributed in line, but low level laser therapy device was switched off.
62773632|NCT03156439|EXPERIMENTAL|BIS-001 ER|The subjects will be dosed twice daily (BID); in an on-site setting at dose initiation and at times of dose escalation to evaluate safety, and for specimen collection for routine laboratory and pharmacokinetic analysis. Subjects will be discharged and compliance of BID dosing will be monitored via twice daily phone calls by site staff. The initial dose will be 0.5mg BID with a dose escalation every 2-3 days until a maximum tolerated dose is observed or a maximum of 2.5mg BID dose is obtained.
62183394|NCT03462537|PLACEBO_COMPARATOR|Placebo group|Low level laser therapy without power. This group performed the low level laser therapy protocol, but low level laser therapy device was switched off.
62183395|NCT02176382|ACTIVE_COMPARATOR|Standard dose teriparatide|teriparatide daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15
62183396|NCT02176382|ACTIVE_COMPARATOR|High dose teriparatide|teriparatide alternate dose daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15
62183397|NCT00099203|EXPERIMENTAL|1|
62183398|NCT00099203|ACTIVE_COMPARATOR|2|
62183399|NCT03080662|SHAM_COMPARATOR|Sham valve (Placebo)|Sham Inspiratory valve (without resistance)
62773633|NCT02760810|EXPERIMENTAL|narafilcon A|Subjects who are new contact lens wearers (neophytes) between the ages of 18-45 will be dispensed the Test Lens and evaluated over a period of 2 weeks.
62773634|NCT02737150|ACTIVE_COMPARATOR|Self-expandable valve under local anesthesia|CoreValve Evolut R valve under local anesthesia with conscious sedation
62773635|NCT02737150|ACTIVE_COMPARATOR|Self-expandable valve under general anesthesia|CoreValve Evolut R valve under general anesthesia
62773636|NCT02737150|ACTIVE_COMPARATOR|Balloon-expandable valve under local anesthesia|Edwards Sapien 3 valve under local anesthesia with conscious sedation
62773637|NCT02737150|ACTIVE_COMPARATOR|Balloon-expandable valve under general anesthesia|Edwards Sapien 3 valve under under general anesthesia
62773638|NCT04458415|EXPERIMENTAL|TPR Arm|Surgeon will use the Traxi Panniculus Retractor to retract the panniculus during cesarean section.
62183400|NCT03080662|EXPERIMENTAL|Intervention|Inspiratory valve with increase resistance
62183401|NCT03599336|OTHER|Nonoperative Treatment|Subjects will have nonoperative treatment to treat proximal humerus fracture that is broken into 3 or 4 parts.
62183402|NCT03599336|OTHER|Operative Course for rTSA|Subjects will have shoulder replacement surgery to treat proximal humerus fracture that is broken into 3 or 4 parts.
62773639|NCT04458415|ACTIVE_COMPARATOR|Silk Tape Arm|Surgeon will use silk tape to retract the panniculus during cesarean section.
62773640|NCT05503056|EXPERIMENTAL|Intervention|Engage in six art therapy sessions
62773641|NCT05503056|PLACEBO_COMPARATOR|Control|Engage in usual activities
62183403|NCT04038320||HCV infected patients|All HCV infected confirmed by HCV RNA,
62183404|NCT02669407|EXPERIMENTAL|Regional nerve anesthesia|Regional nerve anesthesia of splanchnic nerve
62183405|NCT03211377||neoadjuvant therapy group|Preoperation chemotherapy treatment for patients up to four cycles
62183406|NCT03211377||adjuvant therapy|Postoperation chemotherapy treatment for patients up to six cycles
62183407|NCT03211377||Perioperative therapy|Preoperation chemotherapy treatment for patients up to four cycles and postoperation chemotherapy up to six cycles
62183408|NCT03023202||PMMTB|"This study of the PMMTB will include all patients \>= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor.~All standard of care functions will be performed by standard procedures."
62183409|NCT02050698|ACTIVE_COMPARATOR|short leg walking cast|After 1 weeks of immobilization in a short leg posterior splint, patient is allowed protected weightbearing in a short leg walking cast
62183410|NCT02050698|EXPERIMENTAL|hard-soled shoe|After 1 weeks of immobilization in a short leg posterior splint, patient is allowed tolerable weightbearing in a hard-soled shoe
62183411|NCT04921878|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection|"Dose-escalation phase: Patients will receive mitoxantrone hydrochloride liposome injection followed by a 3-week DLT observation period. The initial dose of mitoxantrone hydrochloride liposome injection will be set as 24 mg/m2, and then the dose is sequentially escalated to 30 mg/m2, 36 mg/m2 and 40 mg/m2.~Dose-expansion phase: After DLT observation, two to four dose cohorts will be selected for dose-expansion to further evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection."
62183412|NCT03589300|OTHER|Persona TM Tibia subjects|Subjects that receive the Persona TM Tibia implant
62183413|NCT05043883|EXPERIMENTAL|Single Group|Index EP Procedure: Ablation of atrial fibrillation
62183414|NCT06064045|EXPERIMENTAL|Intervention arm|The intervention entails boosting the quantity and frequency of simulation-based team training within the intervention group. Additionally, measures to enhance and support simulation will be introduced within the intervention group.
62183415|NCT06064045|NO_INTERVENTION|Control arm|Performing simulation as usual
62183416|NCT04540562|EXPERIMENTAL|Intervention|The COPD app consisted of an 8 week self-management program. The app had three views: timeline, information page, and contact page. The timeline was classified in 8 weeks, and each week included the lung exacerbation plan, daily and extra medication, information and education and questionnaires. The first week also included a video of a pulmonologist explaining the purpose of the app and additional information about the functionalities of the COPD app. A video consultation was planned after after 4 weeks and a face-to-face consultation after 8 weeks.
62183417|NCT00917462|EXPERIMENTAL|Sorafenib|Sorafenib for patients with metastatic or recurrent esophageal and gastroesophageal junction cancer.
62183418|NCT04590950||Single-group study|Severe haemophilia B patients substituted with eftrenonacog-alfa
62773642|NCT06147583|EXPERIMENTAL|Insulin pump fault simulation|Collection of patients data during outpatient use of AID (automated insulin delivery); Inpatient simulation of insulin pump faults by suspension of insulin administration.
62183419|NCT04963946|EXPERIMENTAL|watch and monitor|After 18 months of acalabrutinib treatment, patients will stop acalabrutinib treatment for watch and monitor until month 60. If progression disease, patients will be re-treated with ACA at the last received dose after central reviewing of treatment criteria.
62183420|NCT04963946|ACTIVE_COMPARATOR|Acalabrutinib|After 18 months of acalabrutinib treatment, patients will continue acalabrutinib treatment until month 60. If progression disease or unacceptable toxicity, patients will receive next line therapy at the discretion of their physicians and according to iwCLL 2018 criteria
62183421|NCT02928471||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks.
62773643|NCT05906355|EXPERIMENTAL|Group A（wearable filtrating artificial Kidney+traditional hemodialysis）|Group A was isolated ultrafiltration with wearable filtrating artificial Kidney Device first, and then with traditional hemodialysis machine.
62183422|NCT02543788|OTHER|patients|patients with chronic optic neuropathy in multiple sclerosis
62183423|NCT02543788|OTHER|Controls|healthy volunteers
62183424|NCT01543334||Patients|Patients with a vein or artery catheter and who are being administered antibiotics. The latter can be of the following: Amoxicillin-clavulanic acid, ampicillin, piperacillin-tazobactam, penicillin G, flucloxacillin, dicloxacillin, cloxacillin, cefazolin, ceftazidime, ceftriaxone, cefepime, meropenem, imipenem, doripenem, ertapenem; Vancomycin, teicoplanin. (see inclusion/exclusion criteria).
62183425|NCT04187430||Retrospective group|
62183426|NCT04187430||Prospective group|
62183427|NCT03234998|EXPERIMENTAL|motor-cognitive dual-task training|Participants in the motor-cognitive dual-task training group will participate in 12-session programs administered for 60 minutes each session, 3 times per week for 4 weeks.
62183428|NCT03234998|ACTIVE_COMPARATOR|cognitive dual-task training|Participants in the cognitive dual-task training group will also participate in a 12-session program conducted 60 minutes per session, 3 days a week, for a total of 4 weeks.
62183429|NCT02781298|EXPERIMENTAL|New Infant Cereal|amount ingested according to pediatricians recommendations
62183430|NCT02781298|ACTIVE_COMPARATOR|Multicereals Infant Cereal|amount ingested according to pediatricians recommendations
62183431|NCT02972814||Thoracic pain|Patients presenting to the emergency room with thoracic pain probably due to a non-STEMI
62183432|NCT03197077|EXPERIMENTAL|Elonva|A single injection of 100 microgram corifollitropin alfa. Oocyte retrieval on day five after corifollitropin alfa injection.
62183433|NCT03197077|ACTIVE_COMPARATOR|Puregon|Three daily injections of 150 IU follitropin beta. Oocyte retrieval on day five after the first follitropin beta injection.
62183434|NCT01510132|EXPERIMENTAL|Travacom|Travoprost/timolol fixed combination self-administered at the rate of 1 drop per eye, one time a day, at approximately 8 a.m. each day for 8 weeks.
62183435|NCT01461005|EXPERIMENTAL|Dynamic Stabilization System|Dynamic Stabilization System (DSS) System
62183436|NCT06231563|EXPERIMENTAL|Ketamine|intravenous ketamine infusion 0.5 mg/kg
62392173|NCT02554721|EXPERIMENTAL|Group 3 (CYP2C19 heterozygous (*1/*2) )|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
62392174|NCT02554721|EXPERIMENTAL|Group 4 (CYP2C19 homozygous (*2/*2))|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
62773644|NCT05906355|EXPERIMENTAL|Group B（traditional hemodialysis+wearable filtrating artificial Kidney）|Group B was isolated ultrafiltration with traditional dialysis machine first, and then with wearable filtrating artificial Kidney Device.
62183437|NCT06231563|PLACEBO_COMPARATOR|Remimazolam|intravenous remimazolam infusion 0.25 mg/kg
62183438|NCT01635543||Crohn's Disease with peri-anal fistulas|Identifying Crohn's Disease patients with peri-anal fistulas and suffering from sexual dysfunction.
62183439|NCT02121743|EXPERIMENTAL|Strattice|a strattice (10 x 10) will be used during the surgery, prior to the colostomy's conception
62183440|NCT02121743|PLACEBO_COMPARATOR|No strattice|the colostomy is not reinforced with a mesh
62183441|NCT02351713|EXPERIMENTAL|Threshold based method|Exercise Week 1 Heart rate (HR) \< first ventilatory threshold (VT1) 3 days 20 min/day Week 2 HR \< VT1 4 days 25 min/day Week 3 HR \< VT1 4 days 30 min/day Week 4 HR \< VT1 5 days 30 min/day Week 5-6 HR ≥ VT1 to \< second ventilatory threshold (VT2) 5 days 30 min/day Weeks 7-8 HR ≥ VT1 to \< VT2 5 days 30 min/day Weeks 9-12 HR ≥ VT2 5 days 30 min/day
62183442|NCT02351713|EXPERIMENTAL|Relative percent method|Exercise Week 1 40-45% heart rate reserve 3 days 20 min/day Week 2 40-45% heart rate reserve 4 days 25 min/day Week 3 40-45% heart rate reserve 4 days 30 min/day Week 4 40-45% heart rate reserve 5 days 30 min/day Week 5-6 50-55% heart rate reserve 5 days 30 min/day Weeks 7-8 50-55% heart rate reserve 5 days 30min/day Weeks 9-12 60-65% heart rate reserve 5 days 30 min/day
62392175|NCT00974727|EXPERIMENTAL|Gardening Program|
62392176|NCT00974727|NO_INTERVENTION|Control|Subjects received the standard of care for the summer.
62392177|NCT04060758|EXPERIMENTAL|14.7 mcg (single dose)|PA5108 Latanoprost FA SR Ocular Implant which releases 14.7 mcg.
62392178|NCT04060758|EXPERIMENTAL|26.6 mcg (single dose)|PA5108 Latanoprost FA SR Ocular Implant which releases 26.6 mcg.
62392179|NCT04060758|EXPERIMENTAL|35.5 mcg (single dose)|PA5108 Latanoprost FA SR Ocular Implant which releases 35.5 mcg.
62568188|NCT00396656|EXPERIMENTAL|Atenolol + hydrochlorothiazide (HCTZ) followed by valsartan|"After a 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks followed by one week in which atenolol was tapered off and HCTZ was discontinued. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning.~After a second 2-week washout period, patients were treated with valsartan for 20 weeks. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. Patients took valsartan film coated tablets orally once a day (od) in the morning."
62773645|NCT05954299||Normal|Participants and donor samples without disease (ex: non-cancer)
62773646|NCT05954299||Disease state or condition|Participants and donor samples with known disease or condition (ex: cancer)
62773647|NCT04041245||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
62773648|NCT04041245||Healthy group|This group will include 40 healthy volunteers.
62773649|NCT03765203|ACTIVE_COMPARATOR|Control|Control participants will care for the same set of CPV patients as the intervention arm, but will not have knowledge of or access to Natera's dd-cfDNA test results. Investigators will compare control participants' clinical recommendations to those in the intervention arm.
62183443|NCT02351713|NO_INTERVENTION|Control|Non-exercise control group
62183444|NCT01674517|EXPERIMENTAL|Montelukast sodium|Montelukast sodium chewable tablets 4mg and 5mg of Dr. Reddy's Laboratories Limited
62183445|NCT01674517|ACTIVE_COMPARATOR|SINGULAIR®|SINGULAIR®(containing Montelukast sodium) chewable tablets 4mg and 5mg of Merck Sharp \& Dohme Ltd., USA
62183446|NCT02916706|EXPERIMENTAL|Teneligliptin 20mg|Teneligliptin (20mg once daily) for 24 weeks
62183447|NCT02916706|PLACEBO_COMPARATOR|Placebo|Placebo for 24 weeks
62183448|NCT04811898|EXPERIMENTAL|Experimental single arm|Single group with 5 dose escalation for each cohort (0,5 mg/kg; 1 mg/kg; 2 mg/kg; 3 mg/kg; 5 mg/kg)
62392180|NCT04060758|EXPERIMENTAL|14.7 mcg (repeat dose)|Repeat dose of PA5108 Latanoprost FA SR Ocular Implant which releases 14.7 mcg.
62392181|NCT04064047|ACTIVE_COMPARATOR|External Anal application - 5 minutes exposure|Anal application of lidocaine cream 5% for 5 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
62392182|NCT04064047|ACTIVE_COMPARATOR|External Anal application - 10 minutes exposure|Anal application of lidocaine cream 5% for 10 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
62392183|NCT04064047|ACTIVE_COMPARATOR|External Anal application - 20 minutes exposure|Anal application of lidocaine cream 5% for 20 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
62773650|NCT03765203|EXPERIMENTAL|Intervention|Intervention participants will care for the same set of CPV patients as the control arm, but will be educated on and given access to Natera's dd-cfDNA test results. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
62773651|NCT04506333|EXPERIMENTAL|Small Cuff|"Participants with an upper-arm circumference of 6.3-9.4 may be placed in the small cuff arm."
62773652|NCT04506333|EXPERIMENTAL|Medium Cuff|"Participants with an upper-arm circumference of 9.0-14.6 may be placed in the medium cuff arm."
62392184|NCT04064047|ACTIVE_COMPARATOR|External Anal plus intrarectal - 5 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 5 minutes before probe insertion.~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
62791534|NCT03018639||Dialectical Behavior Therapy|The program's purpose is to help patients achieve the following therapeutic goals: (1) reduction of suicidal behaviors, (2) reduction of therapy-interfering behaviors, and (3) other risky or destabilizing behaviors. Standard DBT aims to achieve these goals by (1) conveying behavioral capabilities (skills), (2) motivation for applying these skills, (3) generalization of learned skills to the patient's natural environment, (4) structuring the treatment environment to reinforce functional behavior, and (5) conveying therapeutic resources and motivation to effectively treat patients with BPD.
61997869|NCT04594850|EXPERIMENTAL|Injection group: Cellgram-ED|Single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take daily and on demand.
62183449|NCT06276764||Patients with a documented history of IPMN|Patients with a documented history of IPMN by any imaging method will undergo the LINFU® procedure.
62183450|NCT00678977|EXPERIMENTAL|Arm A|"Dose Escalation - Patients will be entered into dose cohorts of three patients. Each cohort will be assigned to a dose level for the duration of the study. There will be no intra-patient dose-escalation. The starting dose will be 400 mg daily of pazopanib, and 1000 mg/m2 gemcitabine. Intermediate dose levels may also be explored. Intravenous gemcitabine will be given on Day 1 and 8 of Cycle 1 and each subsequent cycle.~Cohort expansion phase - patients will receive gemcitabine alone, at the OTR dose starting on Day 1 of Cycle 1. Pazopanib will be administered at the OTR beginning on Day 2 Cycle 1 after the last blood sample for gemcitabine analysis is collected, and pazopanib administration will continue for the duration of the study. Patients will return to the clinic on Day 8 of Cycle 1 for simultaneous administration of gemcitabine and pazopanib. On Day 1 of Cycle 2 patients will receive the simultaneous administration of gemcitabine and pazopanib"
61997870|NCT05242081|EXPERIMENTAL|S-ketamine|
61997871|NCT05242081|ACTIVE_COMPARATOR|Sufentanil|
61997872|NCT04699331|EXPERIMENTAL|Individualized stimulation group|Patients receive five sessions of individualized stimulation obtained from brain image-based transcranial direct stimulation simulation. The simulator generates the electrode's location on the scalp.
61997873|NCT04699331|ACTIVE_COMPARATOR|Conventional stimulation group|Patients receive five sessions of conventional stimulation with electrodes over C3 and C4 based on the 10-20 system.
61997874|NCT04699331|SHAM_COMPARATOR|Sham stimulation group|Patients receive five sessions of sham stimulation with electrodes over C3 and C4 based on the 10-20 system.
62392185|NCT04064047|ACTIVE_COMPARATOR|External Anal plus intrarectal - 10 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 10 minutes before probe insertion.~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
62392186|NCT04064047|ACTIVE_COMPARATOR|External Anal plus intrarectal - 20 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 20 minutes before probe insertion.~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
62392187|NCT04064047|SHAM_COMPARATOR|Control group|No anal application of lidocaine cream prior to probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
61997875|NCT05865288|EXPERIMENTAL|Oxytocin|24IU (12IU\*2) of Oxytocin, Sorbitol, Benzyl, alcohol glycerol, distilled water.
61997876|NCT05865288|PLACEBO_COMPARATOR|Placebo|24IU (12IU\*2) of Sorbitol, Benzyl, alcohol glycerol, distilled water.
61997877|NCT02149342|EXPERIMENTAL|HAL cream and MAL cream|0.2% HAL (Hexvix, Photocure) mixed with Unguentum M (Allmiral) and MAL (Metvix, Galderma) used in a randomized split-face design
61997878|NCT04728269|EXPERIMENTAL|Lactibiane topic AD|Cosmetical product Lactibiane Topic AD
61997879|NCT04728269|PLACEBO_COMPARATOR|Placebo|Placebo made with the same base as the cosmetical product
61997880|NCT03995381|EXPERIMENTAL|DAs group|Shared decision making using decision aids
61997881|NCT03995381|NO_INTERVENTION|Control group|Standard oral explanation guided with booklets
61997882|NCT05817929|EXPERIMENTAL|cardiac surgery|
62791535|NCT03357016|EXPERIMENTAL|High Intensity Interval Training program (HIIT)|Subjects perform three sessions of training during 12 weeks: 35 min at 50% maximal aerobic power on bicycle.
61997883|NCT04308317|EXPERIMENTAL|Tetrandrine Cohort|"After the subjects were enrolled, they were given Tetrandrine 60mg QD for a course of 1 week(Take 6 days, stop using for 1 day)"
61997884|NCT04308317|NO_INTERVENTION|Control Cohort|Treatment according to standard protocols without intervention
61997885|NCT02421133|EXPERIMENTAL|Transitional care program.|The transitional care program from hospital to home will be implemented at three steps: during the patient's stay in hospital, the day of the discharge and during 4 weeks after discharge.
61997886|NCT02421133|OTHER|standard care program|No intervention liable to affect the care provided to the patients, the organization of care or the practices of health care professionals will be implemented during the control period (time steps without intervention).
61997887|NCT01574352|EXPERIMENTAL|Intervention camp|Children's behavior are controlled each week day for six weeks, and children participate in three hours of physical activity every day
61997888|NCT01574352|EXPERIMENTAL|Small intervention|Children are only informed of healthy behavior
61997889|NCT03750981|OTHER|A 12-week pilot intervention study introducing a high-intensi|
61997890|NCT01630330|ACTIVE_COMPARATOR|Contact Force Known|Ablation with contact force data known
62392188|NCT05455060|EXPERIMENTAL|Chinese herbal formula (CHF)|The patients in CHF group will take CHF capsules, 12 capsules (6 gm) twice a day, total 12 gm a day for 12 weeks, and the dosage will be modified according to patients' body weight. (3gm BID for 20kg≦BW\<40kg; 1.5gm BID for BW\<20kg)
62392189|NCT05455060|PLACEBO_COMPARATOR|Control|The patients in control group will take the placebo capsules, which has the similar look, smell, and taste. The dosage, frequency, and duration are the same as CHF group, in which 12 capsules (6 gm) twice a day, total 12 gm a day for 12 weeks, and the dosage will be modified according to patients' body weight. (3gm BID for 20kg≦BW\<40kg; 1.5gm BID for BW\<20kg)
62568189|NCT03089723|EXPERIMENTAL|Lavage with Saline (LS)|"Under sterile conditions, the 1st carpometacarpal (CMC) will be locally anesthetized with ropivacaine and will be submitted to joint lavage with physiologic saline solution 2 to 5 mL (injection with a 30x8 needle and drained with the same needle after removal of the syringe. After emptying of the joint, 1mL saline solution will be injected.~Patients will ask to answer Visual Analog Scale (VAS) questionnaire, Range of Motion (ROM), Quick DASH, Sollerman Test, and functional grip strength (palmar grip strength, lateral grip strength and pulp-pulp pinch strength) evaluations immediately prior to the procedure and after 1, 3 and 6 months of each joint."
62791536|NCT03357016|EXPERIMENTAL|Moderate Intensity Continuous Training program (MICT)|Subjects perform three sessions of training during 12 weeks: repeated cycles of sprinting for 8s and pedaling slowly for 12s (between 20 and 30 rpm) for a maximum of 60 repeats per session.
61997891|NCT01630330|EXPERIMENTAL|Contact Force Not Known|Contact Force data unavailable during ablation
61997892|NCT03588364|EXPERIMENTAL|Osteopathic Manipulation|Twelve weekly sessions using the techniques of osteopathy in the cranial field.
61997893|NCT03588364|NO_INTERVENTION|Waitlist Control|Six-week waiting period.
61997894|NCT02108821|EXPERIMENTAL|Fecal Microbiome Transplantation|Fecal Microbiome Transplantation will be done at the time of EGD and colonoscopy. A parent or sibling or a healthy relative will be tested for several infections like hepatitis, H. Pylori, HIV, syphilis, ova and parasites, culture and C.diff. They will fill out a donor questionnaire used for blood donors prior to the sample collection. After eligibility criteria have been met, appropriate consent has been obtained, and the screening labs have been assessed, the fecal transplant procedure will take place in the procedure center at Children's Hospital of Pittsburgh. Fresh stool sample will be obtained from the donor. The fecal sample will be prepared for transplantation in a designated area in the procedure center. Frequency: once. Duration: Approximately 1 hour
61997895|NCT00210314|ACTIVE_COMPARATOR|High-dose methotrexate alone|
61997896|NCT00210314|EXPERIMENTAL|High-dose methotrexate associated with high dose cytarabine|
62214574|NCT06609837||Usability and Validity Group|In order to evaluate the usability of the 30SST, the validity of the test will be examined. In order to determine its validity in assessing functional capacity, the correlation of 6 MWT and 10SCT will be examined.
62568190|NCT03089723|EXPERIMENTAL|Lavage with Osteonil® Mini (LO)|"Under sterile conditions, the 1st carpometacarpal (CMC) will be locally anesthetized with ropivacaine and will be submitted to lavage with physiologic saline solution and Osteonil® Mini 1mL of 10mg will be injected in the 1st CMC joint.~Patients will ask to answer Visual Analog Scale (VAS) questionnaire, Range of Motion (ROM), Quick DASH, Sollerman Test, and functional grip strength (palmar grip strength, lateral grip strength and pulp-pulp pinch strength) evaluations immediately prior to the procedure and after 1, 3 and 6 months of each joint."
61997897|NCT04122573||Acute chest pain|The population in this study are characterized by acute chest pain as the first symptom for consultation within 24 hours.
61997898|NCT00722319||A|Patients on long-term oral anticoagulation who are submitted to PCI-S because of acute coronary syndrome or stable angina. No further groups nor interventions are anticipated since the study is observational
61997899|NCT01133769||Surgical vs Non surgical|This is an open, prospective, randomized, dual arm, parallel group clinical study of open reduction and internal fixation (ORIF) or intramedullary nail (IMN) versus non operative treatment for clavicle fracture in polytrauma patients with associated chest injury, with or without additional injuries to the head, abdomen, pelvis and extremities.
61997900|NCT00763074|PLACEBO_COMPARATOR|Control|Conventional education of life style intervention for type 2 diabetes
61997901|NCT00763074|ACTIVE_COMPARATOR|Diet|Dietary calorie restriction
62392190|NCT03647098||Cohorts 1|Non-small cell lung cancer patients with KRAS mutation were treated with chemotherapy.
62392191|NCT03647098||Cohorts 2|Non-small cell lung cancer patients with KRAS mutation were treated with chemotherapy plus Immune checkpoint inhibitors.
62392192|NCT03647098||Cohorts 3|Non-small cell lung cancer patients with KRAS mutation were treated with chemotherapy, Immune checkpoint inhibitors plus bevacizumab.
62791537|NCT03357016|EXPERIMENTAL|HIIT + Resistance Training program (RT)|Subjects perform three sessions of training during 12 weeks: Each subject performed HIIT protocol and then a single set of 8 exercises with 1 ou 2min resting period between exercises. Each set consisted of 8-12 repetitions at about 80% maximum repetition.
62392193|NCT03647098||Cohorts 4|Non-small cell lung cancer patients with KRAS mutation were treated from clinical trials.
62392194|NCT03647098||Cohorts 5|Non-small cell lung cancer patients with KRAS mutation were not treated for anything.
62392195|NCT05874895|EXPERIMENTAL|Manual Lymphatic Drainage|In addition to usual care, daily manual lymphatic drainage will be performed for five consecutive days. After this period.
62392196|NCT05874895|ACTIVE_COMPARATOR|Usual Care|Usual care for patients with septic shock will be provided.
62392197|NCT01270139|EXPERIMENTAL|Nano group|60 patients in Nano group were treated with transplantation of nanoparticles (NP), particularly with a bioengineered patch that was grown with allogenous stem cells pre-cultivated in the medium with NP. After the admission, patients were examined with QCA, and allocated to the trial. The implantation of the patch onto the artery was undergone by the minimally invasive cardiac surgery (MICS CABG) with fixation of the graft to the epicardial myocardium. MICS CABG implies a beating-heart multi-vessel heart surgery performed through several small incisions under direct vision through an anterolateral mini-thoracotomy in the 4th-6th intercostal spaces. The patients can expect high quality of life resuming all everyday activities within a few weeks of their operation. NP were activated with NIR laser at 7 days after the intervention. Patients were treated with bolus of bivalirudin on the day of NP detonation.
62568191|NCT03448419|EXPERIMENTAL|Empagliflozin|
62568192|NCT03448419|PLACEBO_COMPARATOR|Placebo|
62568193|NCT04903015|EXPERIMENTAL|professional Soccer players|
62568194|NCT04903015|ACTIVE_COMPARATOR|athletes not exposed to head injuries.|
62568195|NCT02169271|EXPERIMENTAL|Arm I (acetylsalicylic acid)|Patients receive acetylsalicylic acid PO QD for 12 months.
62568196|NCT02169271|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD for 12 months.
61997902|NCT00763074|ACTIVE_COMPARATOR|Exercise|Encourage to increase exercise amount: more than 60min's of exercise with moderate activity level two times per day
61997903|NCT00763074|ACTIVE_COMPARATOR|Diet and exercise|Intervention for both of exercise and diet
61997904|NCT00922571|EXPERIMENTAL|FS Laser Surgery|For femtosecond laser-assisted cataract surgery (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the OptiMedica Catalys™ Precision Laser System (Catalys System)
61997905|NCT04549220||Delivery (Birth) Cohort|All women greater than or equal (≥) to 18 years of age and emancipated minors aged between 14 and 17 years of age delivering a live infant or stillbirth at Kawempe Referral Hospital over a 6-month pilot phase will be invited to participate in the study until a sample size of at least 5000-6000 women is achieved.
61997906|NCT04549220||Active Surveillance Cohort|This is expected to improve capacity for managing and investigating infants \<3 months of age presenting with suspected sepsis at Kawempe Neonatal Intensive Care Unit (NICU), Postnatal Ward, and Acute Paediatric Wards and Mulago Hospital Paediatric Acute Care Unit, through provision of supplies for blood culture, CSF culture and nasopharyngeal swabs. Mothers/caretakers of Neonates that are diagnosed with GBS through this active case surveillance will be invited to participate in the study and will be enrolled following written informed consent.
61997907|NCT00786695|PLACEBO_COMPARATOR|Placebo|Identical looking Placebo
61997908|NCT00786695|EXPERIMENTAL|esomeprazole|esomeprazole (40 mg o d) for 14 days
61997909|NCT03424837|EXPERIMENTAL|Intervention Arm: SoC (standard of care) and ASCENT|Health care per institutional standard plus ASCENT via the TrueNTH website.
61997910|NCT03424837|NO_INTERVENTION|Control Arm: SoC and TrueNRH|Health care per institutional standard, plus access to the public information on the TrueNTH website; such as the symptom tracker, exercise \& diet, and lived experiences modules.
61997911|NCT00508742|EXPERIMENTAL|1|13 valent pneumococcal conjugate vaccine
61997912|NCT00508742|ACTIVE_COMPARATOR|2|7 valent pneumococcal conjugate vaccine
61997913|NCT04411433|EXPERIMENTAL|Favipiravir (3200 mg + 1200 mg)|"Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
62183451|NCT00678977|EXPERIMENTAL|Arm B|"Dose Escalation - Patients will be entered into dose cohorts of three patients. Each cohort will be assigned to a dose level for the duration of the study. There will be no intra-patient dose-escalation. The starting dose will be 400 mg daily of pazopanib, 1000 mg/m2 gemcitabine and 60 mg/m2 cisplatin. Doses of gemcitabine may range from 600 to 1250 mg/m2. Doses of cisplatin may range from 60 to 80 mg/m2. Intermediate dose levels may also be explored. Pazopanib administered starting on Day 1 of Cycle 1, gemcitabine co-administration on Day 1 and 8, and cisplatin on Day 1 in each 21-day cycle.~Cohort expansion - patients will receive gemcitabine and cisplatin alone, at the OTR doses, starting on Day 1 of Cycle 1. Pazopanib will be administered at the OTR dose beginning on Day 2 of Cycle 1, and pazopanib administration will continue for the duration of the study. Patients will return to the clinic on Day 8 of Cycle 1 for simultaneous administration of gemcitabine and pazopanib"
62183452|NCT02960945|EXPERIMENTAL|CTP-543|Tablet, single oral dose
62183453|NCT02960945|ACTIVE_COMPARATOR|Jakafi|Tablet, single oral dose
62183454|NCT03686618|NO_INTERVENTION|Cohort X|no secretin administered. All observations
62568197|NCT00771576||A. Healthy Controls|subjects w/ predicted normal BCM (healthy, normalweight, nondiabetic individuals who have stimulated insulin and cpeptide levels within the normal range);
62183455|NCT03686618|ACTIVE_COMPARATOR|Cohort 1|32 mcg (\<50kg) or 40 mcg (≥50kg) secretin two times a day (40 mcg; q 12 hrs)
62183456|NCT03686618|ACTIVE_COMPARATOR|Cohort 2|32 mcg (\<50kg) or 40 mcg (≥50kg) secretin four times a day (40 mcg; q 6 hrs)
62183457|NCT03686618|ACTIVE_COMPARATOR|Cohort 3|32 mcg (\<50kg) or 40 mcg (≥50kg) secretin six times a day (40 mcg; q 4 hrs)
62568198|NCT00771576||B. Longstanding T1D|subjects with predicted reduced beta cell mass (subjects with established T1DM who have low or not measurable stimulated insulin and c peptide levels);
62183458|NCT01181037||100 patients, displaced subcapital fracture, T.A.N nail.|100 patients sustained a displaced femoral subcapital fracture, that were operated on with closed reduction and internal fixation with TAN nail.
62392198|NCT01270139|ACTIVE_COMPARATOR|Ferro group|60 patients in Ferro group were managed with transplantation of iron-bearing nanoparticles (NP), particularly with intracoronary infusion of allogenous stem cells or CD68 targeted micro-bubbles pre-cultivated in the medium with iron-bearing NP. Cells and/ or micro-bubbles were infused with QCA- and IVUS-guidance to the target coronary artery via micro-catheter on the day of admission. The destruction of CD68 targeted micro-bubbles was obtained by using a Sonos 5500 machine with an S3 transducer operating in ultraharmonic mode (transmit, 1.3MHz/ receive, 3.6 MHz) with a mechanical index of 1.5 and a depth of 4 cm. The AXIOM Artis dBC (Siemens) magnetic navigation system was used for precise delivery of NP to the atheroma through two permanent computer-controlled external magnets generating a navigational magnetic field of 0.08 Tesla in any direction. NP were detonated with NIR laser under the protection of anti-platelet therapy.
62392199|NCT01270139|OTHER|Stenting control|In case of control group (stenting control), XIENCE V stent was implanted to 60 patients. Patients with a single de novo native coronary stenosis of less than 12 mm lesion length, more than 50% stenosis and reference diameter of 3.0 mm as assessed by online QCA were stented by a single stent of 3.0 x 18 mm. The procedure of implantation had to be performed according to common interventional practices including the administration of intracoronary nitroglycerine 0.2 mg of glycerol trinitrate or isosorbide dinitrate and intra-arterial heparin (50-100 U/kg body weight). Predilation with a conventional balloon catheter was recommended before DES deployment according to the manufacturer's recommendation. The protocol recommended the study stent should cover 2 mm of non-diseased tissue on either side of the target lesion. Postdilatation was allowed with a balloon that was shorter than was the study device.
62392200|NCT01787019|EXPERIMENTAL|30 weeks|initiation of oral feedings at 30 weeks
62773653|NCT04506333|EXPERIMENTAL|Lage Cuff|"Participants with an upper-arm circumference of 12.2-17.7 may be placed in the large cuff arm.~The large cuff arm will use an adaptive study design. Per the AAMI/ESH/ISO standards, at least 1/6 of participants must fall into each cuff size arm for that cuff size, and of the participants assigned to each cuff size, at least 40% of those must fall in the upper and lower half of the cuff's size range. However, we do not anticipate many participants in our age range falling in the upper half of the large cuff size range (upper arm circumference \> 14.95).~Because of this, our plan is to validate the large cuff, but if enrolling a patient with a large cuff would require additional patients be enrolled to reach 1/6 of the total sample, the large cuff will be dropped from consideration and the validation completed with only the small and medium cuffs."
62773654|NCT05184933|EXPERIMENTAL|Dipping vs non-dipping HTN|"Participants will wear an ambulatory blood pressure monitor (SpaceLabs, Inc.) which will take their blood pressure in 20-30-minute intervals for 24-48 hours to determine blood pressure dipping status.~All participants in this arm will complete the experiments in this order:~1. At-home polysomnography;~2. Constant Routine protocol;~3. Rested Wakefulness Trial AND Overnight Sleep Trial (Randomized crossover);~4. Sleep Regularization Trial"
62392201|NCT01787019|ACTIVE_COMPARATOR|33 weeks|initiation of oral feedings at 33 weeks
62392202|NCT05627999||patients candidate to the haemorrhoidal artery embolization|Consecutive patients assessed at the Division of General Surgery 1, Treviso Regional Hospital, from October to December 2021 and candidate to the haemorrhoidal artery embolization were included in the study. Indications to the procedure were symptomatic hemorrhoidal disease (French bleeding score \[FBS\] \> 4), Goligher's classification score II or III, age \>18 years, failure of non-operative management (change life style, dietary modification, supplemental fibers for constipation, over-the-counter treatments). Signed informed and research consents were obtained. Exclusion criteria were age \< 18 years, Goligher prolapse score IV, pregnancy, previous haemorrhoidal surgery, inflammatory bowel disease. Use of anticoagulant or antiaggregant was not considered an exclusion criteria \[stecca\].
62773655|NCT02478255|ACTIVE_COMPARATOR|Patients scheduled to undergo Radiation Therapy (RT)|Patients scheduled to undergo Radiation Therapy (RT) for lung cancer, or other malignancies such as breast cancer or lymphoma that involve significant irradiation of the thoracic cavity.
62773656|NCT02478255|ACTIVE_COMPARATOR|Healthy volunteers|
62773657|NCT03332160|ACTIVE_COMPARATOR|Standard of Care|Standard home lymphedema care
62773658|NCT03332160|EXPERIMENTAL|Flexitouch head and neck lymphedema treatment system|Daily treatment with Flexitouch® pneumatic compression device for treatment of head and neck lymphedema and standard home lymphedema care
62183459|NCT01181037||100 patients, displaced subcapital fracture, Bipolar H.A..|
62183460|NCT02194829|EXPERIMENTAL|Arm A|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Patients also receive WEE1 inhibitor AZD1775 PO daily on days 1, 2, 8, 9, 15, and 16.
62183461|NCT02194829|EXPERIMENTAL|Arm B|Patients receive paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, and WEE1 inhibitor AZD1775 as in Arm A.
62183462|NCT04626986|EXPERIMENTAL|microwave ablation|Microwave ablation（MWA）refers to all electromagnetic methods of inducing tumor destruction by using devices with frequencies greater than or equal to 900MHz. The rotation of dipole molecules accounts for most of the heat generated during MWA. Water molecules as dipoles attempt to continuously reorient at the same rate in microwave's oscillating electric field. As a result of microwave transmission, the water molecules flip back and forth billions of times a second. The vigorous movement of water molecules produce friction and heat, thus inducing cellular death via coagulation necrosis. The microwave unit (KY-2000, Kangyou Medical, Nanjing, China) is capable of producing 100 Watts of power at 2450 MHz.The needle antenna has a diameter of 1.6 mm (16G) and a length of 10 cm. The active tip length is 3mm and 5mm.
62392203|NCT04675437|EXPERIMENTAL|Frail patients (CABG, HF or mini-AVR)|12-weeks cardiac exercise program (3 sessions per week) consisting of aerobic exercises (ergometer, treadmill and arm ergometer).
62392204|NCT03103724|EXPERIMENTAL|Enzalutamide|All subjects will receive open label enzalutamide 160 mg (4 x 40 mg capsules), orally once daily.
62392205|NCT01419223||Consent to participate (Group 1)|Active military and veterans who consent to participate in an INTRuST PTSD or TBI research trial.
62392206|NCT01419223||Decline to participate (Group 2)|Active military and veterans who decline to participate in an INTRuST PTSD or TBI research trial.
62568199|NCT00771576||C. Obese Subjects|subjects with predicted increased beta cell mass (euglycemic obese subjects with fasting hyperinsulinemia).
62773659|NCT00536952|EXPERIMENTAL|Arm 1|Pulmozyme
62773660|NCT00536952|PLACEBO_COMPARATOR|Arm 2|Placebo
62773661|NCT03744520|EXPERIMENTAL|ESP block group|The patients who had paravertebral interfacial plane block for postoperative analgesia
62773662|NCT02686502|NO_INTERVENTION|Mode 1|Current guidelines. Subjects attending the examinations and the tests but not participating the individualized intervention. The subjects will receive general guidance on healthy exercise and diet.
62773663|NCT02686502|ACTIVE_COMPARATOR|Mode 2|Individualized lifestyle intervention. Exercise intervention will be based on submaximal ergometer test (estimated VO2max), clinical status, personal goals and preferences. Intervention also includes diet counseling, multiprofessional team support, peer support and use of mobile health applications.
62392207|NCT02312934|EXPERIMENTAL|Transdermal Nicotine|"Nicotine will be delivered by a transdermal patch delivery system for topical application. Each patch will contain approximately 1.75mg nicotine/cm2, and releases 7, and 14mg of nicotine, respectively, over 24 hours. Patches will be applied for 16 hours per day. Participants will be titrated over the course of the 6-week treatment period in order to avoid initial side effects as follows:~Week 1: ½ 7 mg patch per day, Week 2: 7 mg patch per day, Weeks 3-4: ¾ 14 mg patch per day, Weeks 5-6: 14 mg per day, Weeks 7-8: Treatment withdrawal"
62183463|NCT04626986|ACTIVE_COMPARATOR|breast conserving surgery|Breast-conserving surgery refers to the removal of the primary tumor and adjacent breast tissue, supplemented by postoperative radiotherapy.Its principle is to remove the primary tumor completely while meet patient's cosmetic satisfaction.The combined treatment of early breast cancer with radiotherapy and chemotherapy is the same as radical surgery or modified radical surgery in terms of local and regional control rate and long-term survival rate. Breast conserving surgery and postoperative comprehensive treatment have become one of the main methods for the treatment of early breast cancer.
62183464|NCT04311190|EXPERIMENTAL|ICU A|Family members' involvement in the care of their beloved one
62183465|NCT04311190|NO_INTERVENTION|ICU B|Standard care
62183466|NCT05376904|EXPERIMENTAL|HR18034 dose 1|
62183467|NCT05376904|EXPERIMENTAL|HR18034 dose 2|
62773664|NCT02686502|ACTIVE_COMPARATOR|Mode 3|Highly individual lifestyle intervention. In addition to Mode 2 arm intervention optimal intensity zones and volumes for individual exercise training will be determined based on advanced cardiopulmonary exercise test.
62773665|NCT02606357|EXPERIMENTAL|HOE901|HOE901 administered subcutaneously once a day in the evening, at dinner, or at bedtime with titration based on FPG levels
62773666|NCT02561559||Lung metastasis from soft-tissue sarcoma|Lung metastases from soft-tissue sarcoma
62773667|NCT00006094|EXPERIMENTAL|Treatment (oxaliplatin, fluorouracil, EBRT)|Patients receive oxaliplatin IV over 1 hour on day 1, fluorouracil IV continuously on days 1-7, and radiotherapy on days 1-5. Treatment repeats weekly for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
62773668|NCT05819619|ACTIVE_COMPARATOR|Standard of care|Administration of ibuprofen or ondansetron only when experiencing pain or nausea respectively post misoprostol administration.
62773669|NCT05819619|EXPERIMENTAL|Prophylactic use|Administration of ibuprofen and ondansetron at the time of misoprostol administration.
62183468|NCT05376904|EXPERIMENTAL|HR18034 dose 3|
62183469|NCT05376904|ACTIVE_COMPARATOR|ropivacaine HCl|
62183470|NCT02108847|EXPERIMENTAL|Fascia Iliaca Block - Ropivacaine|Ultrasound guided fascia iliaca block performed preoperatively with 40 mL of 0.2% ropivacaine.
62773670|NCT05521438|EXPERIMENTAL|QRX003-2% QAM|Subjects will apply test article once daily in the morning (QAM) for 12 weeks
62773671|NCT05521438|EXPERIMENTAL|QRX003-4% QAM|Subjects will apply test article once daily in the morning (QAM) for 12 weeks
62773672|NCT05521438|EXPERIMENTAL|Vehicle Lotion|Subjects will apply test article once daily in the morning (QAM) for 12 weeks
62773673|NCT05521438|EXPERIMENTAL|QRX003-4% BID|Subjects will apply test article twice daily BID for 12 weeks
62773674|NCT02641717|EXPERIMENTAL|All subjects|All patients enrolled in this study will self-collect a vaginal swab (experimental) then have a physician collected vaginal swab (gold standard)
62183471|NCT02108847|SHAM_COMPARATOR|Fascia Iliaca Block - Saline|Ultrasound guided fascia iliaca block performed preoperatively with 40 mL of Saline.
62183472|NCT03245619|EXPERIMENTAL|Subjects receiving GSK3335065 (Cohorts 1 to 8) in Part A|Male subjects will be assigned to Cohorts 1 to 8. In each cohort, six subjects will be randomized to receive alternating and escalated doses of GSK3335065.
62773675|NCT04237246|EXPERIMENTAL|Once daily Tacrolimus (Advegraf)|
62773676|NCT05976009|EXPERIMENTAL|active rTMS treatment|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
62791538|NCT05610527|ACTIVE_COMPARATOR|Hormonal contraception users|Females with inflammatory bowel disease who use hormonal contraception (combination oral contraceptives, the etonogestrel implant, or the levonorgestrel intrauterine device)
62183473|NCT03245619|EXPERIMENTAL|Subjects receiving Placebo (Cohorts 1 to 8) in Part A|Male subjects will be assigned to Cohort 1 and 2. In each cohort, two subjects will be randomized to receive placebo.
62183474|NCT03245619|EXPERIMENTAL|Subjects receiving GSK3335065 (Cohort 9 to 12) in Part B|Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, six subjects will be randomized to receive GSK3335065. In all cohorts each dose level will consist of an IV bolus on Day 1 subsequently followed by a continuous IV infusion for seven days.
62183475|NCT03245619|EXPERIMENTAL|Subjects receiving Placebo (Cohort 9 to 12) in Part B|Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, two subjects will be randomized to receive placebo.
62183476|NCT03245619|EXPERIMENTAL|Subjects receiving GSK3335065 (Cohort 13) in Part C|WONCBP will be assigned to cohort 13. Six subjects will be randomized to receive a single IV dose of GSK3335065.
62183477|NCT03245619|EXPERIMENTAL|Subjects receiving Placebo (Cohort 13) in Part C|WONCBP will be assigned to cohort 13. Two subjects will be randomized to receive placebo.
62183478|NCT03245619|EXPERIMENTAL|Subjects receiving GSK3335065 (Cohort 14) in Part C|WONCBP will be assigned to cohort 14. Six subjects will be randomized to receive a continuous IV infusion over 7 days of GSK3335065.
62183479|NCT03245619|EXPERIMENTAL|Subjects receiving Placebo (Cohort 14) in Part C|WONCBP will be assigned to cohort 14. Two subjects will be randomized to receive placebo.
62183480|NCT03774212|EXPERIMENTAL|Group A|On study night 1, participants will receive standard care (no headphones provided). On study night 2, these patients will wear Active Noise Cancelling headphones playing white noise.
62183481|NCT03774212|EXPERIMENTAL|Group B|Patients will spend night 1 wearing Active Noise Cancelling headphones playing white noise. On Study night 2, these patients will receive standard care (no headphones provided).
62183482|NCT04737421||Group 1 (G1): NobelActive TiUltra implants (3.0, NP, RP, WP)|Subjects will be enrolled into Group 1 and treated with NobelActive TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
62392208|NCT02312934|PLACEBO_COMPARATOR|Placebo|"Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.~Week 1: ½ 7 mg patch per day, Week 2: 7 mg patch per day, Weeks 3-4: ¾ 14 mg patch per day, Weeks 5-6: 14 mg per day, Weeks 7-8: Treatment withdrawal"
62392209|NCT06049511|EXPERIMENTAL|intervention group|An oral self-care protocol, grounded in Orem's Self-Care Deficit theory and incorporating self-care behaviors, was implemented for the patients in the treatment group. The protocol consisted of several components, including the assessment of oral mucositis by the researcher and self-assessment of the oral cavity by the patients. It also involved oral care, teaching proper tooth brushing techniques, providing written materials, supplying an oral care kit, and offering patient and family education.
62392210|NCT06049511|OTHER|control group|The control group consisted of a total of 30 patients who met the selection criteria, willingly participated in the study, and were randomly assigned based on a predetermined randomization list. In the control group, the investigator did not administer any specific oral care intervention. Instead, the patients received standard nursing care provided at the clinic to prevent oral mucositis. Moreover, all patients in the control group were given the same mouthwashes (Benzydamine and Mycostatin) as those in the treatment group. However, the frequency and timing of oral care varied among the nurses in the clinic due to differences in work load and individual experience.
62392211|NCT03051906|EXPERIMENTAL|Experimental|Durvalumab, Cetuximab and Radiotherapy followed by adjuvant Durvalumab (6 months)
62392212|NCT05150392|EXPERIMENTAL|Booster immunization 1 year after primary immunization|Subjects C0001-C0400 except C0243 received 1 dose of booster immunization 1 year after primary immunization.
62392213|NCT05150392|EXPERIMENTAL|Booster immunization 2 year after primary immunization|Subjects C0401-C0800 except C0556 received 1 dose of booster immunization 2 years after primary immunization.
62392214|NCT05150392|EXPERIMENTAL|Booster immunization 3 year after primary immunization|Subjects C0801-C1197 received 1 dose of booster immunization 3 years after primary immunization.
62183483|NCT04737421||Group 2 (G2): NobelParallel CC TiUltra implants (NP, RP; WP)|Subjects will be enrolled into Group 1 and treated with NobelParallel CC TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
62392215|NCT02956408|ACTIVE_COMPARATOR|Conventional|Patients in this arm will be prescribed Vitamin D3 2000 IU once a day
62392216|NCT02956408|EXPERIMENTAL|High Dose|Patients in this arm will be prescribed Vitamin D3 6000 IU once a day
62392217|NCT02693405|EXPERIMENTAL|child and adult survivors of brain tumor|"Executive functions and social cognition will be assessed using cognitive (Stroop task, Modified Card Sorting Task, Digit spans) and behavioral (BRIEF for childrens and BRIEF-A for adults) tests.~Quality of life will be assessed by questionaires (SF-36, QLQC30-BN20 for adults and Peds-Ql for childrens)"
62183484|NCT04737421||Group 3 (G3): NobelReplace CC TiUltra implants (NP, RP)|Subjects will be enrolled into Group 1 and treated with NobelReplace CC TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
62183485|NCT04737421||Group 4 (G4): Nobel Biocare N1 TiUltra TCC implants (NP, RP)|Subjects will be enrolled into Group 1 and treated with Nobel Biocare N1 TiUltra TCC implants , only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
62183486|NCT01828359|EXPERIMENTAL|Amosartan® tab|Amlodipine 5mg /Losartan 100mg
62183487|NCT01828359|ACTIVE_COMPARATOR|Cozaar® plus pro tab|Losartan 100mg/ HCTZ 12.5mg
62183488|NCT05962515||1|All patients in group 1 (n:22) had DN treatment applied to the piriformis muscle once a week for a total of 3 times under US guidance.
62183489|NCT05962515||2|All patients in group 2(n:22) had exercise programme for 3 weeks.
61997914|NCT04411433|EXPERIMENTAL|Favipiravir (3600 mg + 1600 mg)|"Dosage and method of administration: in a regimen of 2x1800 mg (oral) loading dose on day-1 followed by 1600 mg maintenance dose (2x800 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
62568200|NCT04148586|EXPERIMENTAL|One week Whole Breast Irradiation|WBI: 27 Gy/5 fractions/1 week. 5.4 Gy /fraction ± boost to tumor bed 5.4 Gy/ 1 fraction, 2 days after the end of WBI.
61997915|NCT04411433|EXPERIMENTAL|Favipiravir combined with Hydroxychloroquine|"Hydroxychloroquine Dosage and method of administration: in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
61997916|NCT04411433|EXPERIMENTAL|Favipiravir combined with Azithromycin|"Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
61997917|NCT04411433|ACTIVE_COMPARATOR|Hydroxychloroquine|"Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (200 mg oral 2 times daily) on day-2 to day-5 (5 days in total).~Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (200 mg oral 2 times daily) throughout 5 days (5 days in total)."
62183490|NCT05925062|EXPERIMENTAL|QActual|QActual is a phone-based app that offers peer-to-peer support, tracks mental wellness self-assessments, and provides support to users who are in crisis.
62183491|NCT05925062|NO_INTERVENTION|Control Arm - Subjects not using App|No intervention
62183492|NCT06260241|OTHER|With Traction Dressing|Traction dressing will be applied to patients after phalloplasty for 24 hours.
62183493|NCT06260241|OTHER|Without Traction Dressing|No traction dressing will be applied to patients after phalloplasty for 24 hours.
62183494|NCT00975013||Bone Density Study Group|Morbidly obese, (BMI \>40 kg/m2, or 35 kg/m2 with comorbidities) female patients who have given consent to undergo additional testing including bone densitometry, and lab testing preoperatively and at 6 and 12 months after undergoing elective laparoscopic roux-en-Y gastric bypass.
62183495|NCT01711346|EXPERIMENTAL|S303 Red Blood Cells (RBCs)|Participants will be assigned to S303 Red Blood Cells (RBCs) and then to Conventional, Untreated Red Blood Cells (RBCs).
62183496|NCT01711346|ACTIVE_COMPARATOR|Conventional, Untreated Red Blood Cells (RBCs)|Participants will be assigned to Conventional, Untreated Red Blood Cells (RBCs) and then to S303 Red Blood Cells (RBCs).
62183497|NCT00806637|EXPERIMENTAL|1|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
62183498|NCT00806637|ACTIVE_COMPARATOR|2|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
62183499|NCT02051569|EXPERIMENTAL|Tryptophan first|Tryptophan is given for the first 14 days, 6 times 500mg per day. Placebo is given 6 times per day for the second 14 days.
62183500|NCT02051569|EXPERIMENTAL|Tryptophan second|Placebo is given 6 times per day for the first 14 days. Tryptophan is given for the second 14 days, 6 times 500mg per day.
62183501|NCT03862261|NO_INTERVENTION|Standard-of-Care|Pediatric TB services based on current routine approach (national standard of care)
62183502|NCT03862261|EXPERIMENTAL|Intervention|Integrated pediatric TB services
62183503|NCT01031849|EXPERIMENTAL|Kaletra, all patients|Patients will change actual treament for monotherapy LPV/r. They only will take Kaletra 2/day
62183504|NCT01004029|PLACEBO_COMPARATOR|Vehicle|Castor Oil
62183505|NCT01004029|ACTIVE_COMPARATOR|Hydroxyprogesterone Caproate Injection (HPC), 250 mg/mL|HPC 250 mg/mL in oil
62568201|NCT04148586|EXPERIMENTAL|Once weekly Whole Breast Irradiation|WBI: 28.5 Gy/ 5 fractions/ 5 weeks. 5.7 Gy/fraction ± boost to tumor bed 5.7 Gy/ 1 fraction, one week after the end of WBI. WBI is given on the same day each week.
62392218|NCT02693405|EXPERIMENTAL|healthy controls|"Executive functions and social cognition will be assessed using cognitive (Stroop task, Modified Card Sorting Task, Digit spans) and behavioral (BRIEF for childrens and BRIEF-A for adults) tests.~Quality of life will be assessed by questionaires (SF-36, QLQC30-BN20 for adults and Peds-Ql for childrens)"
62392219|NCT05663775|EXPERIMENTAL|Prophylactic Mesalamine in combination of Immunotherapy (Nivolumab/Ipilimumab)|Participants will receive 500mg of Mesalamine QID (four times a day) in combination with standard of care Immunotherapy
62392220|NCT01283724|EXPERIMENTAL|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
62392221|NCT03338608|EXPERIMENTAL|Vertical Platysma Incision|Patients in this arm who have anterior cervical decompression and fusion will receive the vertical platysma incision.
62392222|NCT03338608|EXPERIMENTAL|Transverse Platysma Incision|Patients in this arm who have anterior cervical decompression and fusion will receive the transverse platysma incision.
62392223|NCT00052013|EXPERIMENTAL|PTK787/ZK 222584|
62392224|NCT03290196|OTHER|EXPAREL 1.3 % in 20 ML Injection|"EXPAREL (bupivacaine liposome injectable suspension, 20 mL single use vial, 1.3% \[13.3 mg/mL\]) is a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. EXPAREL dosage is based on the following factors:~* size of surgical site~* volume required to cover the area~* individual patient factors that may impact the safety of an amide local anesthetic~* maximum doe of 266 mg (20 mL)"
62392225|NCT00575458||1|Static Splint
62568202|NCT04148586|ACTIVE_COMPARATOR|3 weeks Whole Breast Irradiation|WBI: 40.05 Gy/ 15 fractions/ 3 weeks. 2.67 Gy/ fraction ± boost to tumor bed 10 Gy/ 4 fraction / 4 days after the end of WBI
62020877|NCT04497441||Netizens|Internet users in Al Qassim province region are the target study population for this study. This Cross sectional study utilizes an electronic google form to get responses from netizens of Al Qassim province of Saudi Arabia regarding the perception of COVID-19 information and information sources. All the questions in the survey are compulsory answerable questions. The settings in the google form are set so that a single respondent can limit the survey response to single time. The Google form link is shared to the netizens of Al Qassim province across relevant Social media platforms.
62392226|NCT00575458||2|Dynamic Splint
62392227|NCT01955642||AVC|Patients with non-cardioembolic AIC requiring initiation of treatment with clopidogrel as usual indications
62392228|NCT02874222||Caucasian|surveys completed by subject n=600, nationally
62392229|NCT02874222||African-American|surveys completed by subject n=200, nationally
62392230|NCT02874222||Asian|surveys completed by subject n=200, nationally
62392231|NCT02974452||Group I: Older adults|healthy subjects older than 68 years old whose shoulder muscle are measured by surface electromyography
62568203|NCT04119869|EXPERIMENTAL|iaya Smart Phone Application|"* Pre-study evaluation~* Access to the smartphone intervention over the course of 12 weeks~* Post-study evaluation and interview"
62584761|NCT01137929||Without APN, Without VUR|This group of children who present with a febrile UTI will be found NOT to have APN on DMSA renal scan and will also NOT have VUR by VCUG, NOR a renal scar on follow-up DMSA renal scan.
62584762|NCT04838457|EXPERIMENTAL|ACME-TM|Participants will obtain 4 sessions of telehealth cognitive behavioral therapy (CBT) focused on reducing alcohol misuse. Participants will receive a 5th telehealth coaching call to develop a plan for ensuing treatment regarding their elevated cardiovascular risk factors. Participants will then receive daily texts for one month aimed at helping them decrease these cardiovascular risk factors.
62392232|NCT02974452||Group II: Adults|healthy subjects 43 to 67 years old, whose shoulder muscle are measured by surface electromyography
62392233|NCT02974452||Group III: Young adults|healthy subjects 20 to 42 years old, whose shoulder muscle are measured by surface electromyography
62392234|NCT05057000|EXPERIMENTAL|Group A|DIET PROGRAM IN ADDITION TO AEROBIC EXRCISES
62392235|NCT05057000|OTHER|Group B|DIET PROGRAM
62392236|NCT00237146|EXPERIMENTAL|Zoledronic Acid|
62584763|NCT06682455||Patients with diagnosed intermediate age-related macular degeneration|
62183506|NCT04260464|EXPERIMENTAL|PF-06700841 Severe Renal Impairment|This arm includes participants with severe renal impairment who will receive a single oral dose of 30 mg PF-06700841 on Day 1
62183507|NCT04260464|EXPERIMENTAL|PF-06700841 Normal Renal Function|This arm includes participants with normal renal function who will receive a single oral dose of 30 mg PF-06700841 on Day 1
62183508|NCT04260464|EXPERIMENTAL|PF-06700841 Moderate Renal Impairment|This arm includes participants with moderate renal impairment who will receive a single oral dose of 30 mg PF-06700841 on Day 1
62183509|NCT04260464|EXPERIMENTAL|PF-06700841 Mild Renal Impairment|This arm includes participants with mild renal impairment who will receive a single oral dose of 30 mg PF-06700841 on Day 1
62183510|NCT00610805|EXPERIMENTAL|1|Participants randomized to this arm (n=15) will be followed by Preventive Cardiology and will have appropriate goal oriented interventions on their risk factor levels for 2 years.
62183511|NCT00610805|OTHER|2|Participants randomized to this arm (n=15) will receive usual care. The PI will send a letter of all testing results to their primary care physician. No standard care will be withheld.
62183512|NCT01353950||Adult Cystic Fibrosis Patients|Adults with Cystic Fibrosis will be followed longitudinally for 2 years
62568204|NCT02630173|EXPERIMENTAL|Non vital teeth with apical radiolucency|Endodontic treatment was performed in non vital teeth with periapical radiolucency. Local anesthesia was provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation was done.Using 3 % sodium hypochlorite, canal negotiation was done \& apical patency was achieved with #10 or #15K-files. Coronal flaring with # 2 and #3 Gates-Glidden drills was done.Calcium hydroxide was filled in the canals with the help of a lentulo spiral.At the second appointment,calcium hydroxide paste was removed and copious irrigation with 3% sodium hypochlorite was followed by 5.0 mL 17% ethylenediaminetetraacetic acid with a final rinse of 5.0 mL of 3% sodium hypochlorite. The canals were obturated with gutta-percha and ZOE sealer.
62020878|NCT05739058|EXPERIMENTAL|Low Exposure to Violet-Blue Light|ID 1-7 are assigned to the low dosage group
62020879|NCT05739058|EXPERIMENTAL|Medium Exposure to Violet-Blue Light|ID 8-15 are assigned to the medium dosage group
62020880|NCT05739058|EXPERIMENTAL|High Exposure to Violet-Blue Light|ID 16-22 are assigned to the high dosage group
62020881|NCT00881725|EXPERIMENTAL|Metformin|500mg t.i.d. for 4-12 weeks prior to Radical Prostatectomy
62020882|NCT02709967|ACTIVE_COMPARATOR|Material support|Writing materials
62020883|NCT02709967|EXPERIMENTAL|Economic support|Writing materials and economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9).
62020884|NCT02709967|EXPERIMENTAL|Combined intervention|Writing materials, economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9) and community dialogue (youth club meetings, community and parent meetings)
62020885|NCT01952340|EXPERIMENTAL|Flaxseed|30 grams of milled flaxseed on its own or baked into food products (ie: bagels, muffins, and snack bars)
62020886|NCT01952340|PLACEBO_COMPARATOR|Wheat/Mixed Dietary Oils|A combination of wheat, pecans, and/or mixed dietary oils on its own or baked into food products (ie: bagels, muffins, and snack bars)
62020887|NCT02175446|EXPERIMENTAL|Experimental1|"Bevacizumab and eribulin~In this study all patients will receive:~* Eribulin 1.23 mg/m2 on days 1, 8 every 3 weeks intravenously~* Bevacizumab 15 mg/kg every 3 weeks intravenously or Bevacizumab 10 mg/kg every 2 weeks intravenously"
62020888|NCT05605470|EXPERIMENTAL|Part A: Arm 1 (1 dose of ChulaCov19 BNA159 vaccine)|Participants will be randomized to receive ChulaCov19 BNA159 vaccine (50 mcg) given by IM (n=55)
62020889|NCT05605470|ACTIVE_COMPARATOR|Part A: Arm 2 (one dose of active comparator vaccine)|Participants will be randomized to receive Comirnaty® (Pfizer/BNT) vaccine (30 mcg) given by IM (n=25)
62020890|NCT05605470|EXPERIMENTAL|Part B: Arm 3 (one dose of COMVIGEN vaccine)|Participants will be randomized to receive ChulaCov19 BNA159.2 (COMVIGEN) vaccine (50 mcg) given by IM (n=70)
62020891|NCT04640051||LAAO group|Patients scheduled for LAAO with Amplatzer Amulet (Abbott) and for whom a 3D in silico simulation by FEops HEARTguide is available and reviewed before implantation
62020892|NCT01366833|ACTIVE_COMPARATOR|Self-expanding stent alone|All patients in Arm A will receive self-expanding stent alone
62020893|NCT01366833|EXPERIMENTAL|Brachytherapy and Stent therapy|
62020894|NCT02094989||diagnostic|
62020895|NCT02054962||Elderly|The investigators intend to asses the effect of fear of movement, PTSD symptoms, and physical activity on persistent pain and functional decline.
62020896|NCT02879838||Occupational Asthma|
62020897|NCT02879838||Work Aggravated Asthma|
62020898|NCT02879838||Non-Work-Related Asthma|
62020899|NCT04680377||Participants receiving standard of care durvalumab|Prior to receiving treatment participants will have samples taken from three different sources to test the microbiome bacteria to determine if it will help predict toxicity to the treatment
62020900|NCT01231711|EXPERIMENTAL|Vets Prevail|N=50. Participants were recent veterans (deployed after September 11, 2001) of operations in Iraq and Afghanistan who were experiencing depression/distress symptoms at the time of screening (CES-D \> 8) but who were not considered to be inappropriate for a health promotion intervention (CES-D \> 35 indicating severe depressed mood or exhibiting self-harm risk).
61997918|NCT04411433|ACTIVE_COMPARATOR|Hydroxychloroquine combined with Azithromycin|"Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total)."
62183513|NCT04800783|OTHER|Swallowing disorders cohort|All included patients will undergo an ultrasound assessment of the oral and laryngeal structures involved in the swallowing process.
62183514|NCT03553290|SHAM_COMPARATOR|control|Mechanical debridement alone
62183515|NCT03553290|ACTIVE_COMPARATOR|lower-level laser Therapy|"Mechanical debridement with lower-level laser therapy~Device: A.R.C. FOX Laser-FOX Q-810nm Mechanical debridement with lower-level laser therapy"
62183516|NCT01320644||vaginal mesh placement|
62183517|NCT02114983||first episode of suspected DVT of the lower limbs|patients with first suspected episode of DVT of the lower limbs
62183518|NCT05660330|EXPERIMENTAL|Holistic semi-tailormade well-being (intervention) group|They receive the holistic semi-tailormade intervention, consisting of training and workshops in three well-being domains: psychosocial, ergonomic and lifestyle. In addition to this intervention, they still receive their standard interventions
62183519|NCT05660330|NO_INTERVENTION|Standard well-being (control) group|At first, they receive standard well-being interventions. After six or twelve months, this group can participate in the holistic semi-tailormade well-being intervention.
62183520|NCT02332200||Early referral to therapy|Patients with a confirmed diagnosis of spondylolysis or spondylolisthesis whose physicians median referral to physical therapy time is less than or equal to 10 weeks.
62183521|NCT02332200||Later referral to therapy|Patients with a confirmed diagnosis of spondylolysis or spondylolisthesis whose physicians median referral to physical therapy time is \>10 weeks.
62183522|NCT02415283||HCC positive|¹³C-Octanoate Breath Test in 50 MRI proven HCC positive patients
62183523|NCT02415283||HCC negative|¹³C-Octanoate Breath Test in 50 MRI proven HCC negative patients
62183524|NCT03158129|EXPERIMENTAL|Arm A (nivolumab)|Participants receive nivolumab IV over 60 minutes on days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity.
62183525|NCT03158129|EXPERIMENTAL|Arm B (nivolumab, ipilimumab)|Participants receive nivolumab as in Arm A and receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity.
62183526|NCT03158129|EXPERIMENTAL|Arm C (nivolumab, cisplatin, docetaxel, pemetrexed)|Patients receive nivolumab IV over 30 minutes and cisplatin IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.
62183527|NCT03158129|EXPERIMENTAL|Arm D (ipilimumab, nivolumab, chemotherapy)|Patients receive ipilimumab IV over 90 minutes on day 1, nivolumab IV over 30 minutes on days 1, 22, and 43, and cisplatin (or carboplatin) IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.
62410011|NCT06653374||Neonatal Morbidity and Mortality Cohort|This cohort includes all live-born neonates delivered at the Isidro Ayora Obstetric-Gynecologic Hospital between January 2008 and December 2022. The study focuses on evaluating the influence of various perinatal and neonatal conditions on morbidity and mortality outcomes. Interventions of interest include obstetric management strategies (e.g., use of antenatal corticosteroids, mode of delivery), neonatal resuscitation protocols, NICU admission criteria, and the implementation of specific neonatal care practices such as early surfactant administration, infection control measures, and nutritional support.
62183528|NCT01328210|EXPERIMENTAL|blood letting|Blood letting was performed immediately after baseline assessment and after 4 weeks. First blood removal consisted of 400ml, second blood removal was tailored according to subsequent serum ferritin levels between 300- 400 ml.
62183529|NCT01328210|NO_INTERVENTION|waiting list control|This group received no specific treatment but was offered treatment after termination of the 6-week study phase
62183530|NCT00847132|EXPERIMENTAL|Collaborative Care|Collaborative Care Treatment: A study care manager provides depression education, consults with study psychiatrist to develop individualized treatment recommendations, and collaborates with patient and medical team to implement those recommendations
62183531|NCT00847132|ACTIVE_COMPARATOR|Usual Care|Usual Care Treatment: Primary medical providers are informed that the patient has depression and that treatment is recommended.
62183532|NCT04582747||Major abdominal Surgery patients|Major Abdominal Surgery Patients
62183533|NCT03949712|EXPERIMENTAL|Right motor cortex (M1) tSMS|tSMS will be applied to the right motor cortex for 30 minutes.
62183534|NCT03949712|EXPERIMENTAL|Left motor cortex (M1) tSMS|tSMS will be applied to the left motor cortex for 30 minutes.
62183535|NCT03949712|SHAM_COMPARATOR|Sham tSMS|Sham tSMS will be applied to the left or right motor cortex (randomized) for 30 minutes.
61997919|NCT04472936|ACTIVE_COMPARATOR|Group A|Double venous femoral access will be obtained. A duodecapolar catheter placed around tricuspid annulus will be used to prove isthmus block after CTI ablation.
61997920|NCT04472936|EXPERIMENTAL|Group B|Ablation will be performed similar as described in the Group A. After the ablation line is over, PRI on the surface ECG will be used to prove isthmus block after CTI ablation.
62183536|NCT03669198|ACTIVE_COMPARATOR|NT-pro BNP group|Subjects who be included in NT-pro BNP group examined NT-pro BNP in the ED to determine the baseline level and prior to discharge for determine the percent decline from baseline level. Patients in the NT-pro BNP group can be discharged if the NT-pro BNP level decreased ≥ 30% from baseline. If the target percent decline is not met, we will do intensification of therapy according to the algorithm
62773677|NCT04863690|EXPERIMENTAL|Sleep Intervention System - No Coaching|Participants will be asked to use either the Muse Mind Meditation, Muse Sleep Journeys, Go to Sleep Soundscapes or Go to Sleep Guidance each evening as part of their bedtime routine to help them prepare to sleep. In addition, participants may use any part of the Muse App (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations), as often as they like to help them fall asleep, go back to sleep, or as a meditation practice during the daytime. All Participants will also be asked to do the Muse Mind meditation for a minimum of 5 minutes per day, a minimum of 5 days per week, for 6 weeks.
62773678|NCT04863690|EXPERIMENTAL|Sleep Intervention System - Plus Digital Coaching|The procedure will be identical to Group 1 above, but in addition, all participants will also work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation.
62773679|NCT04863690|EXPERIMENTAL|Sleep Intervention System - Plus Digital Coaching plus Human Coaching|The procedure will be identical to Group 2 above, but in addition, all participants will be asked to join regular online coaching sessions. Participants will be divided into 9 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness, and how to use Muse and how to support sleep. Coaching will take place virtually using Interaxon's Zoom account. Throughout the coaching, all participants will be referred to via their first names or their anonymized login names. In addition, for any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours.
61997921|NCT03821012||CSCAP-1|STEMI with symptom onset within 12 h regardless of whether receiving reperfusion or symptom onset within 12-24 h of needing PPCI
61997922|NCT03821012||CSCAP-2|STEMI patients with symptom onset within 30 days
62183537|NCT03669198|NO_INTERVENTION|Control group|Patients in the control group were managed based on clinical judgment without use of NT-pro BNP testing. In the control group, the decision whether patient can be discharged or not was determined by cardiologist in charge of the patient based on clinical assessment.
62183538|NCT04969276|EXPERIMENTAL|Group 1: Fluzone High-Dose (HD) Quadrivalent Influenza Vaccine and COVID-19 Vaccine|Participants received an injection of 0.7 milliliters (mL), fluzone HD quadrivalent influenza vaccine, co-administered with 0.5 mL COVID-19 vaccine, intramuscularly (IM) on Day 1.
62410012|NCT05229783|EXPERIMENTAL|Electronic chromoendoscopy|High-resolution endoscopy combined with virtual chromoendocopy to detect esophageal displasic lesions
62410013|NCT05229783|ACTIVE_COMPARATOR|White light endoscopy with Seattle protocol|White light endoscopy to detect esophageal displasic lesions, and then systemic quadrantic biopsies every 2 centimeters from the esogastric junction to the top of the Barett's esophagus (Seattle protocol)
62410014|NCT04151316|EXPERIMENTAL|vertical group|
62392237|NCT05973565|EXPERIMENTAL|synchronous learning format|Volunteers will be asked to attend synchronous learning format MSK Training. The exercise protocol has a duration of 45 minutes of rhythmic training and includes sections of warming-up, stretching, breathing, movement combinations, a dance sequence and recovery. Each exercise is accompanied with music that provides a clear and predictable rhythm. More specifically, the beat or rhythm of the music is used as a guide for the timing and duration of specific movements, allowing people with PD to coordinate their movements with the music. Simple values are going to be introduced such as whole notes, half notes and quarter notes; clapping and tapping, breathing and sounds. Class will be accompanied by recorded classical piano music, to meet the needs of synchronous learning format and asynchronous remote video-based format. The intensity of the class is moderate approximately 3 MET. The instructor is an experienced dance teacher in musicokinetic education.
62773680|NCT04863690|NO_INTERVENTION|Control|The participants in the control group will receive a Muse Device, which they will be free to keep at the end of the study. They will be asked not to open and/or use the Muse device until the entire study is complete. On day 1 of the Study, they will complete the Cambridge Brain Sciences online cognitive assessment battery), plus a longer questionnaire about stress levels, workplace wellness, quality of life, mindfulness and (depending on group), sleep quality. At the completion of the study controls will be offered optional, free group coaching sessions if they complete the study requirements.
62392238|NCT05973565|EXPERIMENTAL|Asynchronous remote video-based format|"Volunteers will be asked to attend asynchronous remote video-based format MSK Training.~The exercise protocol is the same as the synchronous format but delivered via a video-based format"
62773681|NCT06191575||Observational (7T MRI, cognitive assessment, blood collection)|Patients undergo 7T MRI over 1-2 hours at baseline and at 12 months after baseline. Patients also undergo a proctored cognitive assessment over approximately 1 hour prior to each MRI. Additionally, patients undergo blood sample collection at screening and at 12 months after baseline MRI.
62773682|NCT05701566|EXPERIMENTAL|virtual reality group|unsedated colonoscopy using virtual reality headset.
62392239|NCT05973565|NO_INTERVENTION|Control|Volunteers will not be asked to sit quietly for a 45-minute period
62773683|NCT05701566|ACTIVE_COMPARATOR|colonoscopy with standard sedation|standard sedated colonoscopy.
62773684|NCT03300778|EXPERIMENTAL|aerobic exercise|Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
62773685|NCT03300778|PLACEBO_COMPARATOR|Placebo controlled group|6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
62773686|NCT00110461|ACTIVE_COMPARATOR|1|Aripiprazole 10 mg tablet
62773687|NCT00110461|ACTIVE_COMPARATOR|2|Aripiprazole 30 mg tablet
62773688|NCT00110461|PLACEBO_COMPARATOR|3|Placebo
62773689|NCT01436266|ACTIVE_COMPARATOR|Misoprostol|400 mcg buccally 2 hours prior to procedure
62773690|NCT01436266|PLACEBO_COMPARATOR|Placebo (Folic acid)|Two 1-mg tablets buccally 2 hours prior to procedure
62773691|NCT00709410|EXPERIMENTAL|1|This is a single arm study. All consenting, eligible participants will receive the oral cholera vaccine.
62773692|NCT04124003|EXPERIMENTAL|rosuvastatin + BMS-963272|
61997923|NCT03821012||CSCAP-3|STEMI patients with symptom onset within 30 days
61997924|NCT00960518|PLACEBO_COMPARATOR|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
62773693|NCT02407782|EXPERIMENTAL|Ivermectin|
62773694|NCT02407782|EXPERIMENTAL|Permethrin|
61997925|NCT00960518|EXPERIMENTAL|TACE+adefovir|patients received adefovir, at a dose of 10 mg daily after TACE treatment, for 48 weeks
61997926|NCT05058313|EXPERIMENTAL|Postmenopausal patients|
62392240|NCT00125138|EXPERIMENTAL|Melperone HCl - 20 mg|
62392241|NCT00125138|EXPERIMENTAL|Melperone HCl - 40 mg|
62392242|NCT00125138|EXPERIMENTAL|Melperone HCl - 60 mg|
62392243|NCT00125138|PLACEBO_COMPARATOR|Placebo|
62410015|NCT04151316|EXPERIMENTAL|horizontal group|
62773695|NCT00747409|ACTIVE_COMPARATOR|Hum|use of human regular insulin and NPH insulin
62773696|NCT00747409|ACTIVE_COMPARATOR|Ana|use of insulin aspart and insulin detemir
62773697|NCT01657708|OTHER|Shared Desicion Making Model|
62773698|NCT02182271|EXPERIMENTAL|BI 201335 ZW - single rising dose|
62773699|NCT02182271|PLACEBO_COMPARATOR|Placebo|
62773700|NCT01705912|EXPERIMENTAL|Training|Complete intervention i.e. basic intervention + individual training program.
62773701|NCT01705912|ACTIVE_COMPARATOR|Control|Basic intervention.
62773702|NCT03583736|ACTIVE_COMPARATOR|Rapid first contact virtual visit|Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed. Subjects will be randomized after accepting offer of a virtual visit.
62773703|NCT03583736|PLACEBO_COMPARATOR|First contact in person office visit|Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed. Subjects will be randomized after accepting offer of a virtual visit.
62773704|NCT00436592|EXPERIMENTAL|1|
62773705|NCT06444126||Initial Febrile Seizures|The initial cohort included children hospitalized with their first febrile seizure
62773706|NCT02582047|ACTIVE_COMPARATOR|Influenza vaccination with PPV23|concomitant vaccination with trivalent inactivated influenza vaccine and 23-valent polysaccharide pneumococcal vaccine
62773707|NCT02582047|ACTIVE_COMPARATOR|Influenza vaccination with PCV13|concomitant vaccination with trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine
61997927|NCT03385252|EXPERIMENTAL|Egg Group|Egg Intervention: Provision of eggs to caregivers of enrolled infants, with instructions to prepare and feed one egg to the infant each day for 6 months time. Households will be visited twice weekly to provide eggs and monitor intake.
62183539|NCT04969276|ACTIVE_COMPARATOR|Group 2: Fluzone HD Quadrivalent Influenza Vaccine|Participants received a single injection of 0.7 mL fluzone HD quadrivalent influenza vaccine, IM on Day 1.
62183540|NCT04969276|ACTIVE_COMPARATOR|Group 3: COVID-19 Vaccine|Participants received a single injection of 0.5 mL COVID-19 mRNA Vaccine, IM on Day 1.
62183541|NCT00867100|PLACEBO_COMPARATOR|Placebo|Placebo treatment
62183542|NCT00867100|EXPERIMENTAL|140 mg SC|140 mg SC PsO
62392244|NCT02978404|EXPERIMENTAL|Radiosurgery and Nivolumab|"Interventions: Nivolumab (240mg IV q2week or 480mg IV q4week) and Radiosurgery (15-20 Gray (Gy) in 1 fraction)~Upon entering this trial, patients with metastatic brain disease(s) will receive Nivolumab. One to 2 week after receiving the first dose of Nivolumab, radiosurgery will be delivered at doses ranging from 15 to 20 Gy in 1 fraction to the brain metastases to a maximum volume of 10 cubic centimeter."
62773708|NCT05760534|EXPERIMENTAL|Ideal body weight group|
61997928|NCT03385252|ACTIVE_COMPARATOR|Control Group|Control Group: Caregivers will receive a food basket at the end of the study. Throughout the trial, households will be visited twice weekly and asked about food intake.
61997929|NCT02946060|SHAM_COMPARATOR|Usual Care|Participants in this intervention will receive the minimal standard of care provided at the Cardiac Rehabilitation and Prevention Program at Toronto Rehabilitation Institute. Participants will receive an iPod with a silent track or white noise.
61997930|NCT02946060|ACTIVE_COMPARATOR|Audiobooks|Participants in this arm will receive iPods with Audiobooks based on their preferred genres.
62183543|NCT00867100|ACTIVE_COMPARATOR|350 mg SC|350 mg SC PsO
62773709|NCT05760534|ACTIVE_COMPARATOR|Total body weight group|
62183544|NCT00867100|EXPERIMENTAL|700 mg IV|700 mg IV PsO
62183545|NCT01056263||Non-Interventional Study|Subjects participating in this observational study originally participated in study A4061012 \[NCT00076011\], and may have also have participated in study A4061008 \[NCT00828919\].
62773710|NCT01286103|EXPERIMENTAL|001|Canagliflozin 300 mg once daily and 150 mg twice daily Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
62183546|NCT05716776||Group 1 short axial length (AL)|Axial length less than 21
62183547|NCT05716776||Group 2 average axial length (AL)|Axial length 21-24
62183548|NCT05716776||Group 3 long axial length (AL)|Axial length more than 24
62183549|NCT04708483|EXPERIMENTAL|Malignant thoracic tumoral pathology.|Patients suffering from primary malignant thoracic tumoral pathology or second line patients having had a therapy pause of at least 6 weeks.
62183550|NCT01982786|ACTIVE_COMPARATOR|Arm 1|IGRT\* 60 Gy in 20 fractions OR IGRT 78 Gy in 39 fractions
62183551|NCT01982786|ACTIVE_COMPARATOR|Arm 2|"IGRT 37.5 Gy in 15 fractions~+ HDR brachytherapy boost 15 Gy"
62183552|NCT02809807|EXPERIMENTAL|Baseline|Without a gas mask. We measure baseline respiratory index, parameters and the comfort.
62392245|NCT03193918|EXPERIMENTAL|Crenolanib combined with ramucirumab/paclitaxel|
62392246|NCT01883596|EXPERIMENTAL|0.12% Chlorhexidine|Bexident® (0.12% chlorhexidine) solution, applied topically, every 8 hrs.
62773711|NCT01286103|EXPERIMENTAL|002|Canagliflozin 100 mg once daily and 50 mg twice daily Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
62773712|NCT02626390|EXPERIMENTAL|Implicit Learning|Physiotherapy delivered based on implicit treatment guidance - achieved primarily by reducing the frequency of verbal coaching statements and promoting an external focus of attention.
62773713|NCT02626390|ACTIVE_COMPARATOR|Explicit Learning|Physiotherapy delivered based on explicit treatment guidance - achieved primarily by giving frequent verbal coaching statements and promoting an internal focus of attention.
62773714|NCT05329207|EXPERIMENTAL|(Intervention group) Hearing impaired adolescent experimental group|Hearing Impaired Adolescent Group implemented Web-Based Adolescent Health Promotion Education Program
61997931|NCT02946060|EXPERIMENTAL|Tempo-pace Synchronized Playlists|Participants in this arm will receive audio playlists synchronized to their exercise pace. Rhythmic enhancements will be added to the playlists during either month 2 or month 3 of the study.
62773715|NCT05329207|NO_INTERVENTION|(Control group) Hearing impaired adolescent control Group|Hearing Impaired Adolescent Group that did not apply Web-Based Adolescent Health Promotion Education Program
62773716|NCT05026853|EXPERIMENTAL|PRO Integration into Clinical Practice|PRO scores will be shared with patients and healthcare providers (HCPs) via an emailed report card
61997932|NCT03867513||mTBI cases|Those diagnosed with mild traumatic brain injury (mTBI) without abnormality on standard brain structural imaging, LOC ≤30mins, amnesia for ≤24hours, GCS ≥13 at all times and recovery to GCS 15 within 24hours)
61997933|NCT03867513||Acute trauma controls|Non-head trauma controls matched for age and sex with the mTBI group
61997934|NCT05320991|PLACEBO_COMPARATOR|Placebo|Participants receive a saline-solution intravenously
61997935|NCT05320991|EXPERIMENTAL|Ketamine|Participants receive ketamine (Plasma-level 100 ng/ml with an initial bolus administered as a 2 mg/ml solution)
61997936|NCT02617550|EXPERIMENTAL|Vericiguat + Nitroglycerin|Co-administration of vericiguat and nitroglycerin
61997937|NCT02617550|PLACEBO_COMPARATOR|Placebo + Nitroglycerin|Aministration of matching placebo and nitroglycerin.
61997938|NCT04021264|ACTIVE_COMPARATOR|PRE-GA|14 mL injection of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil before the start of surgery and 14 ml of 5% dextrose at the end of surgery into the epidural catheter
61997939|NCT04021264|SHAM_COMPARATOR|POST-GA|14 mL injection of 5% dextrose before the start of surgery and 14 ml of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil at the end of surgery into the epidural catheter
62183553|NCT02809807|EXPERIMENTAL|Assessment with gas mask and canister A|With a gas mask, the measurement have been done with a high resistive canister. We measure baseline respiratory index, parameters and the comfort. These would serve for conduction comparison with the baseline.
61997940|NCT01358617||Biomarker analysis|Archived tissue microarray samples are analyzed for ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) expression by UCHL1 monoclonal antibody and peroxidase technique.
61997941|NCT04871295|NO_INTERVENTION|Wait List|
61997942|NCT04871295|EXPERIMENTAL|Noom Healthy Weight|
61997943|NCT03495882|EXPERIMENTAL|AGEN1884 + AGEN2034|AGEN1884 in combination with AGEN2034 in subjects with Subjects with Metastatic or Locally Advanced Solid Tumors, and Expansion into Select Solid Tumors (cervical)
62183554|NCT02809807|EXPERIMENTAL|Assessment with gas mask and canister B|With a gas mask, the measurement have been done with a low resistive canister. We measure baseline respiratory index, parameters and the comfort. These would serve for conduction comparison with the baseline.
61997944|NCT05358275|EXPERIMENTAL|study group|Guided lid surgery is performed to reduce the loss of bone post operative
61997945|NCT05358275|ACTIVE_COMPARATOR|control group|The patient will receive active ordinary treatment for removal of odontogenic cysts
61997946|NCT00829296|EXPERIMENTAL|nebivolol|Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
61997947|NCT00829296|ACTIVE_COMPARATOR|Metoprolol|Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
61997948|NCT01459172|EXPERIMENTAL|Limonene intervention|
61997949|NCT03055000|EXPERIMENTAL|AGS-v|AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
61997950|NCT03055000|EXPERIMENTAL|AGS-v with adjuvant|ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL)on Day 0 and on Day 21
61997951|NCT03055000|PLACEBO_COMPARATOR|Placebo|WFI (0.5mL) on Day 0 and Day 21
61997952|NCT05833620||Symptomatic patients|Adult patients (≥ 18 years old) with hereditary angioedema with C1INH deficiency (HAE-C1INH) from different regions of Spain will be included. Patients included in the study will be divided into two groups: a) symptomatic, which will be those who present symptoms compatible with HAE-C1INH and who have a confirmed diagnosis
62020901|NCT00987298||Visceral fat mass|The study population will include adult men and women, ages 18 to 90 years. All subjects will be recruited at Oregon Health and Science University (OHSU). Subjects will represent a wide range of BMI values (18.5 - 40 kg/m2).
62773717|NCT05026853|NO_INTERVENTION|Usual Care|Patients and HCPs will not receive an emailed PROMIS score report. PROMIS scores, however, will be available in the EMR as usual.
62773718|NCT00694304|EXPERIMENTAL|Vortioxetine|
61997953|NCT05833620||Asymptomatic patients|Asymptomatic patients, which will be those with a C1INH deficiency and who have not developed symptoms of HAE. Asymptomatic patients must be at least 22 years old and meet the same criteria than those symptomatic, except for the presence of symptoms consistent with HAE-C1INH
61997954|NCT05409235|EXPERIMENTAL|OTT166 Cohort 1|Participants will receive OTT166 5% twice a day (BID) for 24 weeks
61997955|NCT05409235|EXPERIMENTAL|OTT166 Cohort 2|Participants will receive OTT166 5% four times a day (QID) for 24 weeks
61997956|NCT05409235|PLACEBO_COMPARATOR|Vehicle control Cohort 1|Participants will receive vehicle control BID for 24 weeks
61997957|NCT05409235|PLACEBO_COMPARATOR|Vehicle control Cohort 2|Participants will receive vehicle control QID for 24 weeks
61997958|NCT03093675|EXPERIMENTAL|TELELAP ALF-X Robotic Surgical System|The patients will undergo surgical procedures using the innovative TELELAP ALF-X robotic system.
61997959|NCT01819805||Patients taking tramadol hydrochloride and acetaminophen|
61997960|NCT05199480|EXPERIMENTAL|E-cigarette liquid type 1|Participants will be instructed to use at least one study product daily in place of their own e-cigarettes during the intervention period.
61997961|NCT05199480|ACTIVE_COMPARATOR|E-cigarettes liquid type 2|Participants will be instructed to use at least one study product daily in place of their own e-cigarettes during the intervention period.
61997962|NCT05199480|NO_INTERVENTION|No e-cigarettes|No e-cigarette use
61997963|NCT02181556|EXPERIMENTAL|FOLFIRI + Aflibercept|FOLFIRI and aflibercept (4 mg/m²) each 14 days until progression of disease
61997964|NCT04484272|ACTIVE_COMPARATOR|Control Group|(Self-monitoring of pain, stress, and opioid use + alerts/reminders). During efficacy trial (Weeks 1-8), patients will monitor their stress, pain, and opioid use daily. We will send system-generated alerts/reminders every 24 hours to patients via phone call, text, or email to facilitate data entry. During the long-term period (months 3-6), patients will continue to monitor their stress, pain, and opioid use daily and receive only system generated alerts/reminders via messaging service or staff cell phone.
61997965|NCT04484272|EXPERIMENTAL|Experimental Group|(Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS \[three video banks of RDE + Support\]). Self-monitoring, using video banks, and getting support elements comprise the YCWS intervention. The YCWS App is comprised of three tabs displayed across the top of the screen, namely, self-monitoring, video banks, and support. During the short-term trial (Weeks 1-8), patients will monitor their stress and pain daily and have access to three video banks from which to choose their daily intervention. We will send automated system-generated alerts/reminders every 24 hours to experimental group patients via phone call, text, or email to facilitate intervention use. During the long-term period (months 3-6), only system-generated alerts/reminders will be available.
61997966|NCT02605668|EXPERIMENTAL|Intensified Psychological Intervention|Intensified psychological intervention (Cognitive Behavioral Therapy), based on optimized extinction learning
61997967|NCT02605668|ACTIVE_COMPARATOR|Treatment As Usual|Standard intervention (Cognitive Behavioral Therapy) without optimized extinction learning
61997968|NCT00337103|EXPERIMENTAL|1|
61997969|NCT00337103|ACTIVE_COMPARATOR|2|
61997970|NCT04814290||living liver donors|cases already underwent hepatectomy for living-donor liver transplantation.
61997971|NCT04814290||matched controls|healthy persons who attended the preoperative clinic while preparing for donation but were rejected because of an ABO blood group mismatch.
61997972|NCT00945984||LESS|Patients who underwent LESS radical nephrectomy
62392247|NCT01883596|PLACEBO_COMPARATOR|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
61997973|NCT00945984||Conventional laparoscopy|Patients who underwent conventional laparoscopic radical nephrectomy
62392248|NCT02789761|ACTIVE_COMPARATOR|High-flavanol milk chocolate|Bi-daily consumption of 12 g portion of a high-flavanol milk chocolate containing approximately 35 mg of (-)-epicatechin for 2-weeks (14 days)
61997974|NCT05604560|EXPERIMENTAL|Arm A - Tislelizumab and SX-682|
62392249|NCT02789761|PLACEBO_COMPARATOR|Low-flavanol milk chocolate|Bi-daily consumption of 12 g portion of a low-flavanol milk chocolate containing approximately \<1 mg of (-)-epicatechin for 2-weeks (14 days)
62392250|NCT05814744|SHAM_COMPARATOR|Group (A)|bupivacaine 0.25% only
62392251|NCT05814744|ACTIVE_COMPARATOR|Group (B)|bupivacaine 0.25% and dexmedetomidine
62392252|NCT02441517|EXPERIMENTAL|Enzalutamide|Participants received 160 mg enzalutamide orally once daily until radiographic or clinical progression, or unacceptable toxicity.
61997975|NCT04175093||Mild persistent asthma|• Group I, patients with mild persistent asthma.
61997976|NCT04175093||Moderate persistent asthma|• Group II, patients with moderate persistent asthma.
61997977|NCT04175093||Severe persistent asthma|• Group III ,patients with severe persistent asthma.
61997978|NCT03350503|EXPERIMENTAL|Acrysof IQ Toric A-code IOL|IOL implanted during cataract surgery
61997979|NCT00769847||Sagittal synostosis|Male and female infants from 1-6 months of age with isolated, single suture sagittal craniosynostosis.
62183555|NCT03489499||All patients|Patients undergoing elective surgery with anesthesia
62183556|NCT04698798|EXPERIMENTAL|Skeletal muscle wasting|investigating acute skeletal muscle wasting in patients infected with SARS-CoV-2 and admitted to the ICU
62392253|NCT02391649|EXPERIMENTAL|Self-learning program|The participants in the Problem-solving Based Self-learning Program will complete the self-help and problem-solving manual developed by the research team for caregivers of people with psychotic disorders over 20 weeks. In addition to the orientation, understanding about psychosis and its care and final review sessions (4 sessions in 3 weeks) facilitated by the research nurse, the caregivers will work independently through the modules over 15-17 weeks.
61997980|NCT02829593|EXPERIMENTAL|type 1 diabetes|type 1 diabetes \>5 years duration
61997981|NCT02829593|PLACEBO_COMPARATOR|healthy controls|
61997982|NCT00283439|EXPERIMENTAL|Single Arm: AMG 531 Dose-Escalating Cohort Study|
61997983|NCT00706641|EXPERIMENTAL|Experimental: Neoadjuvant Dasatinib + Radical Cystectomy|Dasatinib 100 mg PO qd x 4 weeks followed by radical cystectomy 8-24 hours post last administered dasatinib dose
61997984|NCT00908960|EXPERIMENTAL|High TFMP: Enoxaparin|Patients received enoxaparin 40 mg subcutaneously once daily for 2 months (60 days).Only patients with high TFMP status at baseline were randomized to treatment or observation.
61997985|NCT00908960|NO_INTERVENTION|High TFMP: Observation|Patients undergo observation until evaluation with a lower extremity ultrasound at 2 months (day 60). Only patients with high TFMP status at baseline were randomized to treatment or observation.
61997986|NCT00908960|NO_INTERVENTION|Low TFMP: Observation|Patients undergo observation until evaluation with a lower extremity ultrasound at 2 months (day 60). Patients with low TFMP status at baseline were directly assigned to observation.
62183557|NCT01140282|ACTIVE_COMPARATOR|Arm I (Control)|Patients refrain from increasing physical activity levels for 16 weeks.
62392254|NCT02391649|ACTIVE_COMPARATOR|Psycho-education (in Phase 2)|Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the psychoeducation group, which is guided by a validated treatment protocol based on the research team's and McFarlane and his colleagues' psychoeducation programs for psychosis. The program consists of 12 two-hour sessions held weekly/biweekly (similar to the self-learning program, completed in 5 months), with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and ''review and future plan'.
62392255|NCT02391649|NO_INTERVENTION|Routine community care|Participants in the control group (and treatment groups) will receive routine psychiatric outpatient and family services.
62392256|NCT05463146|EXPERIMENTAL|Deep breathing excercises|Deep breathing is known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
62392257|NCT05463146|EXPERIMENTAL|Deep breathing excercise and progressive muscle relaxation|PMR involves participants actively contracting muscles to create tension and progressively releasing it. This routine is repeated until participants acquire complete relaxation
62392258|NCT02980211|EXPERIMENTAL|Tooth Extraction and Graft Dehisced Socket|Treatment of dehiscence defects at the time of tooth extraction using a minimally-invasive GBR technique that involves the application of a particulate bone allograft and a non-resorbable PTFE membrane.
62392259|NCT03241134|EXPERIMENTAL|Dry needling|A single dry needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into skin surface, fascia, into the muscle tissue at the MTrP location, and will move the needle up and down in multiple directions. In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct.
62773719|NCT01067365|EXPERIMENTAL|12.5 mg Androxal|12.5 mg Androxal daily
62773720|NCT01067365|EXPERIMENTAL|25 mg Androxal|25 mg Androxal daily
62773721|NCT03890367|EXPERIMENTAL|Group 1: MenACYW Conjugate Vaccine|Healthy, toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
62773722|NCT03890367|ACTIVE_COMPARATOR|Group 2: Nimenrix® Vaccine|Healthy, toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
61997987|NCT04321304|SHAM_COMPARATOR|Sham|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (2 mA) for the 30 seconds at the beginning and the end of the trial, but stays at 0 mA in the intervening time.
61997988|NCT04321304|EXPERIMENTAL|2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
62183558|NCT01140282|EXPERIMENTAL|Arm II (Exercise)|Patients participate in supervised exercise sessions over 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30-45 minutes once weekly for 16 weeks.
62183559|NCT02815059|EXPERIMENTAL|Ibrutinib, Dasatinib and prednisone, all patients|
62183560|NCT01324739|ACTIVE_COMPARATOR|B-type natriuretic peptide|the effect of B-type natriuretic peptide on glucose metabolism will be compared with placebo during an intravenous glocose tolerance test
62183561|NCT01324739|PLACEBO_COMPARATOR|Placebo|comparison of the effect of b-type natriuretic peptide on glucose metabolism and placebo
62392260|NCT03241134|SHAM_COMPARATOR|Sham needling|A single sham needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated.
62392261|NCT02477215|EXPERIMENTAL|MLN9708, Bendamustine and Dexamethasone Dose Escalation|"Ixazomib 4 mg, days 1, 8, 15.~Dexamethasone 40 mg oral weekly.~Bendamustine dose levels: 70 mg/m\^2, 80mg/m\^2, or 90 mg/m\^2 given on days 1 and 2"
62773723|NCT03890367|ACTIVE_COMPARATOR|Group 3: NeisVac-C® Vaccine|Healthy, toddlers aged 12 to 23 months received a single dose of NeisVac-C® vaccine on Day 0.
62773724|NCT01171209|EXPERIMENTAL|IFN-alfa|One single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c.
62773725|NCT01171209|EXPERIMENTAL|Interferon-beta|One single injection of IFN-beta followed by blood test for MxA9.12 hours after injection
62773726|NCT05840588|EXPERIMENTAL|Probiotic Bifidobacterium breve PRL2020|Patients in this arm will receive Probiotic Bifidobacterium breve PRL2020 (20 billion CFU) 2 sticks/day for 10 days in addition to the antibiotic Amoxicillin or Amoxicillin/Clavulanic acid.
62773727|NCT05840588|ACTIVE_COMPARATOR|Control|Patients in this arm will receive only antibiotic Amoxicillin or Amoxicillin/Clavulanic acid.
62773728|NCT06303895|EXPERIMENTAL|routine treatment+swallowing rehabilitation training+acupuncture therapy|The group was given routine treatment and swallowing rehabilitation training. Moreover, the experimental group was given acupuncture therapy.
62773729|NCT06303895|ACTIVE_COMPARATOR|routine treatment+swallowing rehabilitation training|The control was given routine treatment and swallowing rehabilitation training
62773730|NCT02092766|EXPERIMENTAL|IV artesunate|Intravenous artesunate 2.4 mg/kg body weight STAT, then 2.4 mg/kg at 12, 24, 48 and 72 hours (5 doses total)
62773731|NCT02092766|ACTIVE_COMPARATOR|IV quinine|Intravenous quinine dihydrochloride 20 mg salt/kg body weight loading dose over 4 hours, then 10 mg/kg over 2 hours 8 hourly until 72 hours (9 doses total)
61997989|NCT04321304|EXPERIMENTAL|4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
61997990|NCT00107458|EXPERIMENTAL|Treatment 1|VPA Target Trough Concentration 75-100 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid
62392262|NCT02477215|EXPERIMENTAL|MLN9708, Bendamustine and Dexamethasone MTD|"Ixazomib 4 mg, days 1, 8, 15.~Dexamethasone 40 mg oral weekly.~Bendamustine dose levels: MTD given on days 1 and 2"
62410016|NCT01589016||PUL (pregnancy of unknown location),|
62773732|NCT00772681|EXPERIMENTAL|1|
62773733|NCT03380052||Gastric cancer|Patients who were diagnosed with gastric cancer
62773734|NCT03380052||Control|Healthy participants or benign disease patients such as benign gastric ulcers, duodenal ulcers, reflux esophagitis, or non-erosive reflux disease
62773735|NCT00169221|ACTIVE_COMPARATOR|postop chemoradio with cisplatin|postoperative chemoradiotherapy with cisplatin
62773736|NCT00169221|EXPERIMENTAL|postop chemoradio (cisplatin)+gefitinib|postoperative chemoradiotherapy with cisplatin + gefitinib
62773737|NCT05031078|EXPERIMENTAL|Group 1: Lymph node sampling at D-30 to D0, D14 and D30|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180.~Group 1 will have lymph node sampling done D-30 to D0, D14 and D30. Bone marrow sampling will be done for all groups at D730."
62773738|NCT05031078|EXPERIMENTAL|Group 2: Lymph node sampling at D60, D74 and D90|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180.~Group 2 will have lymph node sampling done at D60, D74 and D90. Bone marrow sampling will be done for all groups at D730."
62773739|NCT05031078|EXPERIMENTAL|Group 3: Lymph node sampling at D180, D194 and D210|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180.~Group 3 will have lymph node sampling D180, D194 and D210. Bone marrow sampling will be done for all groups at D730."
62183562|NCT01644188|EXPERIMENTAL|Alirocumab 75 /up to 150 mg Q2W|Alirocumab 75 mg every 2 weeks (Q2W) and oral placebo capsule for ezetimibe daily added to stable Lipid Modifying Therapy (LMT) for 104 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C level ≥70 mg/dL (1.81 mmol/L) at Week 8.
62392263|NCT01189396|EXPERIMENTAL|T|Four doses of A006 taken in 30 minute intervals. Doses will have an escalating number of inhalations (1, 1, 2, and 4 inhalations). Total cumulative Albuterol dose at 90 minutes is 1440 mcg.
62392264|NCT01189396|ACTIVE_COMPARATOR|R|Four doses of Proventil-HFA taken in 30 minute intervals. Doses will have an escalating number of inhalations (2, 2, 4, and 8 inhalations). Total cumulative Albuterol dose at 90 minutes is 1440 mcg.
62392265|NCT01189396|PLACEBO_COMPARATOR|P|Four doses of Placebo DPI taken in 30 minute intervals. Doses will have an escalating number of inhalations (1, 1, 2, and 4 inhalations). Total cumulative Albuterol dose at 90 minutes is 0 mcg.
62568205|NCT02630173|ACTIVE_COMPARATOR|Vital teeth|Only scaling and root planing will be done in contralateral vital tooth with pocket depth \>5mm .Non surgical periodontal treatment in the form of scaling and root planing was provided in minimum of two sessions using ultrasonic scaler (Satelec P5 Booster Suprasson) and hand instruments (Hu-friedy scalers and curettes).
62392266|NCT04449874|EXPERIMENTAL|Arm A: Dose-escalation (Stage I), Dose Expansion (Stage II)|"Participants in Stage I will receive GDC-6036 administered orally once daily (PO QD). The dose will be increased in successive cohorts until a study-specific threshold is reached.~Participants with select solid tumors will be treated with GDC-6036 PO QD in Stage II."
62392267|NCT04449874|EXPERIMENTAL|Arm B: GDC-6036 + Atezolizumab (Stage I and Stage II)|Participants with non-small cell lung cancer will receive GDC-6036 in combination with atezolizumab.
62392268|NCT04449874|EXPERIMENTAL|Arm C: GDC-6036 + Cetuximab (Stage I and Stage II)|Participants with colorectal cancer will receive GDC-6036 in combination with cetuximab.
62392269|NCT04449874|EXPERIMENTAL|Arm D: GDC-6036 + Bevacizumab (Stage I and Stage II)|Participants with solid tumors will receive GDC-6036 in combination with bevacizumab.
62392270|NCT04449874|EXPERIMENTAL|Arm E: GDC-6036 + Erlotinib (Stage I and Stage II)|Participants with non-small cell lung cancer will receive GDC-6036 in combination with erlotinib.
62392271|NCT04449874|EXPERIMENTAL|Arm F: GDC-6036 + GDC-1971 (Stage I and Stage II)|"Participants with solid tumors will receive GDC-6036 in combination with GDC-1971 PO in Stage I.~Participants with select solid tumors will be treated with GDC-6036 in combination with GDC-1971 PO in Stage II."
62392272|NCT04449874|EXPERIMENTAL|Arm G: GDC-6036 + Inavolisib (Stage I and Stage II)|"Participants with solid tumors will receive GDC-6036 in combination with inavolisib PO in Stage I.~Participants with select solid tumors will be treated with GDC-6036 in combination with inavolisib PO in Stage II."
62392273|NCT05386368|OTHER|Right receives ReCell (A)|Right perioral area of face receives ReCell/ Left receives saline
62392274|NCT05386368|OTHER|Left receives ReCell (B)|Left perioral area of face receives ReCell/ Right receives saline
62568206|NCT03208166|EXPERIMENTAL|Ischemic Conditioning|Doctormate device is used daily.
62568207|NCT03208166|OTHER|Usual Care|Standard medical care.
62568208|NCT03280524|PLACEBO_COMPARATOR|Control Group|Control Group will receive self-care guidelines with feet
62568209|NCT03280524|EXPERIMENTAL|Treatment Group|Treatment will receive self-care guidelines with feet and 12 sessions of foot reflexology
62773740|NCT03918707||Prospective|The prospective group will consist of approximately 15 evaluable patients who will undergo rWGS sequencing in addition to standard of care genetic testing. Subjects in this study will be drawn from children admitted to the NICU at OSF HealthCare Children's Hospital of Illinois who meet inclusion criteria.
62773741|NCT03918707||Historical Control|The historical control group will consist of patients admitted to the NICU between January 1, 2016 and December 31, 2018 who received genetic testing at less than 4 months of age and fulfil eligibility criteria.
62773742|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 1|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is \<350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is \<350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~Assigned Intervention: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
61997991|NCT00107458|EXPERIMENTAL|Treatment 10|VPA Target Trough Concentration 100-150 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid
61997992|NCT00107458|EXPERIMENTAL|Treatment 20|VPA Target Trough Concentration 150-200 mcg/mL
61997993|NCT05318144||PCR (-) symptomatic|control group, pregnant women with negative COVID-19 Polymerase Chain Reaction (PCR) test
62183563|NCT01644188|ACTIVE_COMPARATOR|Ezetimibe 10 mg|Ezetimibe 10 mg capsule daily and subcutaneous placebo for alirocumab Q2W added to stable LMT for 104 weeks.
62392275|NCT05519189|ACTIVE_COMPARATOR|Peri-anal infiltration of Ropivacaine|
62392276|NCT05519189|EXPERIMENTAL|Failure to perform peri-anal ropivacaine infiltration|
62392277|NCT04592822|EXPERIMENTAL|Treatment T|30 minutes after the start of a standard breakfast, subjects will take one straw of WD-1602 Dabigatran Etexilate Mesylate Granules (150 mg) in 100 mL water as oral administration.
62392278|NCT04592822|ACTIVE_COMPARATOR|Treatment R|30 minutes after the start of a standard breakfast, subjects will receive a single Pradaxa® 150 mg capsule swallowed with 240 mL water as oral administration.
62410017|NCT01589016||EP ( ectopic pregnancies P)|
62410018|NCT01589016||IUP-singleton intrauterine pregnancies|
62410019|NCT04286438|EXPERIMENTAL|Bentracimab (PB2452) Infusion - Open Label Active Drug|Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration. For patients with uncontrolled major or life-threatening bleeding or in need of urgent surgery or invasive procedure.
62568210|NCT06047730||multi-port laparoscopic surgery|
62568211|NCT06047730||transumbilical laparoendoscopic single-site surgery|
62183564|NCT02759926|ACTIVE_COMPARATOR|Denatonium benzoate intragastric|1 µmol/kg bodyweight (10mM) was administered as a bolus into the stomach through a nasogastric feeding tube.
62183565|NCT02759926|ACTIVE_COMPARATOR|Quinine hydrochloride intragastric|10 µmol/kg bodyweight (100mM) was administered as a bolus into the stomach through a nasogastric feeding tube.
62183566|NCT02759926|PLACEBO_COMPARATOR|Tap water intragastric|An equal amount of tap water was administered as a bolus into the stomach through a nasogastric feeding tube.
62183567|NCT02759926|ACTIVE_COMPARATOR|Denatonium benzoate intraduodenal|1 µmol/kg bodyweight (10mM) was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
62183568|NCT02759926|ACTIVE_COMPARATOR|Quinine hydrochloride intraduodenal|10 µmol/kg bodyweight (100mM) was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
62773743|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 2|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is \<350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and \<500 ng/dL, adjust dose to 633 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62183569|NCT02759926|PLACEBO_COMPARATOR|Tap water intraduodenal|An equal amount of tap water was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
62183570|NCT02690493|ACTIVE_COMPARATOR|Acupuncture Only|Patients will be treated with acupuncture only.
62392279|NCT06022627|EXPERIMENTAL|Pranayam Yoga Group|It was planned to use a simple random sampling method among individuals who met the research inclusion criteria and agreed to participate voluntarily in the study. During randomization; Patients in the study and control groups will be determined using the random.org site. While the routine treatment of the patients in the study group continues, 20 minutes of pranayama yoga training will be given by the yoga instructor to the patient and his relatives, and it is planned that the patient will practice pranayama yoga, which is taught for 20 minutes every day for 21 days. Patients or their relatives will be called every morning by phone or video communication will be made online and pranayama yoga will be provided. In addition, a training booklet describing pranayama yoga exercises in detail, a training video and a 21-day checklist of doing yoga will be given to the patients. function test will be done and checklists will be taken back from patients.
62773744|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 3|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is \<350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 570 mg (TU) TSX-011 twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62773745|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 4|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is \<350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is \>800 ng/dL, decrease to 507 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62791539|NCT05610527|OTHER|Naturally cycling participants|Females with inflammatory bowel disease who do not use hormonal contraception and have regular menstrual cycles (self or partner permanent contraception, copper IUD, abstinence, barrier methods, and fertility awareness methods)
62791540|NCT01048658|ACTIVE_COMPARATOR|Sevoflurane|Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
62791541|NCT01048658|PLACEBO_COMPARATOR|No Sevoflurane|Subject receives standard of care drug regimens for anesthesia with this procedure.
62183571|NCT02690493|ACTIVE_COMPARATOR|Functional Taping Only|Patients will be treated with taping only.
62568212|NCT06047730||vaginal natural orifice transluminal endoscopic surgery|
61977750|NCT05464160|ACTIVE_COMPARATOR|G-CON (Group Conventional)|"Patients allocated in the G-CONwill be treated for 3 weeks by specific conventional rehabilitation based on the clinical status.~The G-CON will carry out the normal physiotherapy and occupational therapy rehabilitation treatment, as per the rehabilitation project, for an equal total treatment time to the G-FMV. Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc...)"
61997994|NCT05318144||PCR (+) asymptomatic|Pregnant women who have a positive COVID-19 PCR test and have had the infection without symptoms
61997995|NCT05318144||PCR (+) mild-moderate|Pregnant women with positive COVID-19 PCR test and mild to moderate symptoms and inpatient treatment
61997996|NCT05318144||PCR (+) severe COVID-19|Pregnant women with positive COVID-19 PCR test and severe symptoms
61997997|NCT02609022|EXPERIMENTAL|CV-MG01|The therapeutic vaccine candidate, CV-MG01 comprises two short synthetic peptides separately conjugated to a carrier protein for the potential treatment of myasthenia gravis
62183572|NCT02690493|EXPERIMENTAL|Acupuncture and Functional Taping|Patients will be treated with both acupuncture and taping at the same session.
62183573|NCT03128528|PLACEBO_COMPARATOR|Placebo Oral Tablet|Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.
62183574|NCT03128528|ACTIVE_COMPARATOR|Empagliflozin|Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.
62183575|NCT03866447|ACTIVE_COMPARATOR|vitamin D versus placebo|This group will be treated by topical Vitamin D analogue (Calcipotriol) versus placebo (panthenol).split face.half of the face will be treated by vitamin d and the other by placebo(panthenol)
62183576|NCT03866447|ACTIVE_COMPARATOR|Adapalene versus placebo|this group will be treated by topical Adapalene (0.1%) versus versus placebo (panthenol).split face.half of the face will be treated by vitamin d and the other by placebo(panthenol)
62568213|NCT04291183|EXPERIMENTAL|elderly people to undergo hortic culture therapy|Horticultural Therapy will be applied to the elderly in the experimental group in the form of two days a week visit for eight weeks. Flower and vegetable seedlings suitable for the season will be planted in the garden with the elderly. The elderly will be asked to take care of the plants they planted every day (irrigation and collecting extra herbs) and the elderly people will be observed by doing these processes twice a week
61997998|NCT02609022|PLACEBO_COMPARATOR|Placebo|Aluminium hydroxide adjuvant alone
62183577|NCT02833623|EXPERIMENTAL|Short-message-based Re-education group|"Patients receive oral and written education before H. pylori eradication therapy at first, then they receive short message re-education twice per day during therapy.~Both the content of the oral and written education and the short message re-education are same."
62392280|NCT06022627|NO_INTERVENTION|Non-Pranayama Yoga Group|The routine treatment of the control group will continue and any intervention will not be applied. After the data collection process of the study is completed, paranayama yoga training will be given to the patients in the control group and they will be advised to do it regularly for at least 21 days.
62392281|NCT04279041|EXPERIMENTAL|Fanta and Zunba rotatory files|Fanta and Zunba rotatory files
62392282|NCT04279041|ACTIVE_COMPARATOR|manual K-files|manual K-files
62392283|NCT00656136|PLACEBO_COMPARATOR|Placebo|Patients receive placebo once daily
62568214|NCT04291183|NO_INTERVENTION|elderly people who will not receive horticultural therapy|pre-test data forms will be applied to the control group. Post-test data forms will be reapplied after 8 weeks
62568215|NCT00318474|ACTIVE_COMPARATOR|Mycophenolate Mofetil (MMF)|Dose is based on body size (between 25mg/kg/day and 36mg/kg/day with a maximum dose 1gm BID; initial dose to be used in the first 2 weeks of therapy will be approximately 1/2-2/3 of the full dose). Route of administration is oral. Frequency is daily. MMF will be administered up to 12 months.
62568216|NCT00318474|PLACEBO_COMPARATOR|MMF Placebo|Subjects receive MMF placebo.
62568217|NCT05251896|EXPERIMENTAL|Plasma-free procedure|Use albumin solution, lactated Ringer's solution, normal saline as replacement fluid
62568218|NCT02809313|EXPERIMENTAL|Treatment Gingivitis with Probiotic|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral hygiene instruction) and adjunct probiotic containing one sachet Lactobacillus rhamnosus per day during 3 month
62568219|NCT02809313|PLACEBO_COMPARATOR|Treatment Gingivitis conventional|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral hygiene instruction) and adjunct placebo containing one sachet placebo (talc power) per day during 3 month
62568220|NCT03444311|ACTIVE_COMPARATOR|A: 1 dosis|1 dosis (3E+09 cfu/day + 6 g of fiber/day)
62568221|NCT03444311|ACTIVE_COMPARATOR|B: 2 dosis|2 dosis (3E+09 cfu/day + 12 g of fiber/day)
62568222|NCT00954811|ACTIVE_COMPARATOR|HCG for ovulation triggering and luteal progesterone|conventional triggering with HCG and conventional luteal support with progesterone
62568223|NCT00954811|EXPERIMENTAL|Agonist triggering and rec-LH luteal support plus progesterone|new method of triggering with GnRH-agonist and proof of concept intervention with novel way of luteal support with rec-LH plus the usual co-treatment with progesterone
62183578|NCT02833623|ACTIVE_COMPARATOR|conventional education group|Patients only receive oral and written education before H. pylori eradication therapy.
62392284|NCT00656136|EXPERIMENTAL|BIBW 2992|Patients receive BIBW 2992 tablets once daily
62392285|NCT01824732||Allergic group|All patients who used Tanreqing Injection have anaphylaxis.
62392286|NCT01824732||Control group|All patients who used Tanreqing Injection don't have anaphylaxis.One allergic group patient should matched four control group patients.
62392287|NCT03811899|EXPERIMENTAL|18F-DCFPyL PET/CT imaging|We will use technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data is gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.
62392288|NCT03527875|EXPERIMENTAL|PTBD group|Percutaneous Transhepatic Biliary Drainage
62568224|NCT01888172|EXPERIMENTAL|Weight Watchers Online|
62568225|NCT01888172|EXPERIMENTAL|Weight Watchers Online + ActiveLink|
62568226|NCT01888172|ACTIVE_COMPARATOR|Internet Delivered Eating and Activity Program|
62568227|NCT05042999|EXPERIMENTAL|Virtual Reality Goggles|Patients randomized to the intervention group will undergo their procedure as standard of care but will wear the Oculus Go Goggles and experience a virtual reality simulation. The simulation is a non-interactive polar theme video.
62568228|NCT05042999|NO_INTERVENTION|Control|Patients randomized to the control group will undergo their procedure as standard of care without the use of virtual reality goggles.
62568229|NCT04393519||Prospective|Prospective cohort that received TIPS from 05/12/2020 onwards
61977751|NCT03241355|ACTIVE_COMPARATOR|prebiotic inulin-type fructan|
61977752|NCT03241355|PLACEBO_COMPARATOR|placebo maltodextrin|
61997999|NCT01297868||exercise group|
62183579|NCT00545571|EXPERIMENTAL|Mircera in Renal Anemia|Participants will receive intravenous Mircera every 4 weeks for a total of 52 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
62392289|NCT03527875|EXPERIMENTAL|ENBD group|Endoscopic Nasobiliary Biliary Drainage
62392290|NCT03527875|EXPERIMENTAL|EBS group|Endoscopic Biliary Stenting
62392291|NCT03527875|NO_INTERVENTION|Without PBD group|receive surgery without PBD
62392292|NCT01003691|EXPERIMENTAL|Arm 1|
62392293|NCT05645939||Patients diagnosed with HCMP during study period|Patients newly diagnosed with HCMP between January 2015 and December 2020
62020902|NCT05003921|EXPERIMENTAL|Treatment Group|three intrathecal injections of 50 million cells at two-month intervals.
62568230|NCT06118931|EXPERIMENTAL|Early (7:00-16:00h) TRE|Participants will be asked to eat ad libitum between the hours of 7:00 - 16:00 each day for seven days, and then only drink water or other no calorie beverages for the rest of the day. On the 8th day, they will consume one meal replacement beverage at 7:00 and be instructed to not consume anything else for two hours. After the two hours they will be instructed to return to their normal baseline eating habits.
62773746|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 5|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and \<500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is \<350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62773747|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 6|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and \<500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and \<500 ng/dL, adjust dose to 507 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62773748|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 7|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and \<500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 443 mg (TU) TSX-011 twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62773749|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 8|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and \<500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is \>800 ng/dL, decrease dose to 380 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62773750|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 9|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is \<350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62183580|NCT01779453|EXPERIMENTAL|ETC-1002|ETC-1002 treatment group, oral once daily
62392294|NCT02451137|EXPERIMENTAL|Toujeo|Toujeo® (Insulin glargine, 300 units per millilitre \[U/mL\]) subcutaneous (SC) injection once daily up to Month 12, with or without available participant support program.
62773751|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 10|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and \<500 ng/dL, increase dose to 443 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62773752|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 11|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 380 mg (TU) TSX-011 twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
61998000|NCT02075944|EXPERIMENTAL|High intensity aerobic exercise|30 minutes of high intensity aerobic exercise 3 times a weeks for 9 weeks - incorporation interval training
62020903|NCT02467777|ACTIVE_COMPARATOR|Forced Air|Bair Hugger
62183581|NCT01779453|PLACEBO_COMPARATOR|Placebo|Placebo treatment group, oral once daily
62392295|NCT02451137|ACTIVE_COMPARATOR|Standard of Care|Lantus® (Insulin glargine, 100 U/mL) SC injection administered once daily; or Levemir® (Insulin detemir) SC injection administered either once or twice daily up to Month 12, with or without available participant support program.
62392296|NCT02319798|ACTIVE_COMPARATOR|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital as usual.
62392297|NCT02319798|EXPERIMENTAL|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
62392298|NCT04235959|PLACEBO_COMPARATOR|Placebo|Participants received placebo once weekly (QW) subcutaneously (SC).
62568231|NCT06118931|EXPERIMENTAL|Mid (9:30-18:30h) TRE|Participants will be asked to eat ad libitum between the hours of 9:30 - 18:30 each day for seven days, and then only drink water or other no calorie beverages for the rest of the day. On the 8th day, they will consume one meal replacement beverage at 9:30 and be instructed to not consume anything else for two hours. After the two hours they will be instructed to return to their normal baseline eating habits.
62020904|NCT02467777|ACTIVE_COMPARATOR|Conductive Warming|VitaHeat
62020905|NCT01055743|EXPERIMENTAL|Radical resection + Fluorouracil Implants|
62020906|NCT01055743|ACTIVE_COMPARATOR|Radical resection|
62020907|NCT00969891||AML patients in induction treatment|
62020908|NCT02241226|EXPERIMENTAL|Perfect health course|Perfect health course at the Chopra Center for Wellbeing
62020909|NCT02241226|NO_INTERVENTION|Resort group|Resort group at the La Costa resort
62020910|NCT03779386|EXPERIMENTAL|Music during labor and delivery|Music during labor and delivery
61998001|NCT02075944|EXPERIMENTAL|Low intensity aerobic exercise|30 minutes of low intensity aerobic exercise 3 times a weeks for 9 weeks
61998002|NCT02075944|NO_INTERVENTION|Control|No intervention. Participants are told not to make any changes in their everyday life
61998003|NCT05130203|EXPERIMENTAL|MouvMat Exergaming|Older adults in the intervention group will participate in a 6-week, 3 times per week, 45 minutes per session exercise program involving use of the MouvMat. Each resident from the intervention group will engage with the exergame supervised by a qualified and trained RA. Each intervention session will involve groups of 4-5 participants, with participants taking turns. An RA blinded to participants' condition will collect the outcome data.
62392299|NCT04235959|EXPERIMENTAL|Tirzepatide - Cohort 1 (2.5 to 10 Milligram (mg)) and Cohort 2 (2.5 to 15 mg)|"Participants in Cohort 1 received weekly SC doses of tirzepatide with titration regimen starting from 2.5 mg for Weeks 0 through 3 followed by 5 mg for Weeks 4 through 7, 7.5 mg for Weeks 8 through 11, and 10 mg for Weeks 12 through 15.~Participants in Cohort 2 received weekly SC doses of tirzepatide with titration regimen starting from 2.5 mg for Weeks 0 through 3 followed by 5 mg for Weeks 4 through 7, 7.5 mg for Weeks 8 through 11, and 10 mg for Weeks 12 through 15, 12.5 mg for Weeks 16 through 19, and 15 mg for Weeks 20 through 23."
62392300|NCT04993183|EXPERIMENTAL|3-day PLUS Convention|Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, service-learning seminar, disability simulation workshop, and two community contact sessions.
62392301|NCT04040725|EXPERIMENTAL|Rogaratinib|"* Rogaratinib is administered orally twice daily~* Rogaratinib is held for 72 hours before cystoscopy/TURBT and if no complications are seen, treatment is resumed 24 hours after the TURBT"
62392302|NCT02078674|EXPERIMENTAL|Group A|Placebo
62392303|NCT02078674|EXPERIMENTAL|Group B|High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 and Day 21
62392304|NCT02078674|EXPERIMENTAL|Group C|High dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
62392305|NCT02078674|EXPERIMENTAL|Group D|Intermediate dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
62392306|NCT02078674|EXPERIMENTAL|Group E|Low dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
62773753|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 12|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is \>800 ng/dL, decrease TSX-011 dose to 317 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62773754|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 13|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is \>800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is \<350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62773755|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 14|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is \>800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and \<500 ng/dL, increase dose to 380 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62392307|NCT02078674|EXPERIMENTAL|Group F|High dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
62392308|NCT02078674|EXPERIMENTAL|Group G|Intermediate dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
62392309|NCT02078674|EXPERIMENTAL|Group H|Low dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
62392310|NCT03223025|EXPERIMENTAL|CinnaTropin®, Then Nordilet®|CinnaTropin® was administered with 0.03 mg/kg daily subcutaneous injections for three months. After that, the participants received 0.03 mg/kg daily subcutaneous injections of Nordilet® for three months.
62392311|NCT03223025|ACTIVE_COMPARATOR|Nordilet®, Then CinnaTropin®|Nordilet® was administered with 0.03 mg/kg daily subcutaneous injections for three months. After that, the participants received 0.03 mg/kg daily subcutaneous injections of CinnaTropin® for three months.
62392312|NCT03552172||Prescription physical activity|
62392313|NCT03552172||No prescription for physical activity or suspension|
62392314|NCT05960006||Ceftriaxone|Patiënts with liver cirrhosis receiving ceftriaxone treatment.
62392315|NCT02043704|EXPERIMENTAL|IV Acetaminophen|Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
62791542|NCT06040944||Exposure 1|Schizophrenic patients that have been taking antipsychotic drugs inducing hyperprolactinemia (FGAs and the SGAs; amisulpride, risperidone and paliperidone) for at least 1 year
62392316|NCT02043704|PLACEBO_COMPARATOR|Saline|Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
62773756|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 15|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is \>800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 317 mg (TU) TSX-011 twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62773757|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 16|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is \>800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is \>800 ng/dL, decrease dose to 253 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62773758|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 17|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is \>800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is \<350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62773759|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 18|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is \>800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.~Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and \<500 ng/dL, dose adjust subjects on once-daily dosing from 507 mg TU daily to 570 mg TU daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62773760|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 19|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is \>800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.~Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose of 507 mg TU daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62791543|NCT06040944||Exposure 2|Schizophrenic patients that have been taking antipsychotics sparing hyperprolactinemia (In SGAs; clozapine, quetiapine, olanzapine, ziprasidone and aripiprazole) for at least 1 year
62392317|NCT05405738||normal group|
62392318|NCT05405738||2flap palatoplasty group|
61998004|NCT05130203|OTHER|Standard Recreational Programming|A control group will meet on a similar schedule as the MouvMat group for standard recreational programming conducted by onsite recreational therapists. The same RA from the experimental group will collect outcome measurements from control group participants.
62392319|NCT05405738||Furlow with buccinator group|
62392320|NCT01365182|EXPERIMENTAL|BF+SUPPORT|a 60-minute session of biofeedback (BF) training in pelvic floor muscle exercises plus 6 biweekly peer support group sessions during 3 months to learn symptom self- management skills
62791544|NCT06040944||Non exposure (basline)|Newly diagnosed schizophrenic patients and/ or patients did not receive any psychiatric treatment for at least 1 year
62183582|NCT01765790|EXPERIMENTAL|Malignant Solid Tumor (Arm 1)|"Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 5 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -\> 2. Safety data review. If dose escalation permissible -\> 3. Next dose group -\> 4. Safety data review, etc.~Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s)."
62183583|NCT01765790|EXPERIMENTAL|Metastatic Adenocarcinoma of the Colon or Rectum (Arm 2)|"Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 3 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -\> 2. Safety data review. If dose escalation permissible -\> 3. Next dose group -\> 4. Safety data review, etc.~Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s)."
62183584|NCT00746109|PLACEBO_COMPARATOR|NOPACKING|The comparison group will undergo a routine incision and drainage procedure but will not have packing placed inside the abscess cavity.
62183585|NCT00746109|EXPERIMENTAL|PACKING|This group will receive wound packing as per usual protocol
62392321|NCT01365182|EXPERIMENTAL|BF+PHONE|a 60-minute session of biofeedback (BF) training in pelvic floor muscle exercises plus 6 biweekly individual telephone contact with a therapist during 3 months to learn symptom self- management skills
62392322|NCT01365182|NO_INTERVENTION|Usual Care|Subjects continued receiving usual care without receiving any intervention training sessions
62392323|NCT01377194|EXPERIMENTAL|1|40mg Levomilnacipran ER
62392324|NCT01377194|EXPERIMENTAL|2|80mg of Levomilnacipran ER
62392325|NCT01377194|PLACEBO_COMPARATOR|3|Placebo
62392326|NCT04189198|EXPERIMENTAL|Articaine group|Patients in this group are assigned to recieve 30 ml of Articaine 2%
62392327|NCT04189198|EXPERIMENTAL|Bupivacaine|Patients in this group are assigned to recieve 30 ml of bupivacaine 0.5%
62392328|NCT04250246|EXPERIMENTAL|Ipilimuamb plus nivoluamb plus guadecitabine|ipilimumab plus nivolumab combined with guadecitabine
62568232|NCT06118931|EXPERIMENTAL|Late (12:00-21:00h) TRE|Participants will be asked to eat ad libitum between the hours of 12:00 - 21:00 each day for seven days, and then only drink water or other no calorie beverages for the rest of the day. On the 8th day, they will consume one meal replacement beverage at 12:00 and be instructed to not consume anything else for two hours. After the two hours they will be instructed to return to their normal baseline eating habits.
62568233|NCT06118931|NO_INTERVENTION|Control|During the first week of the study, participants will be asked to eat as they normally do, and to not make any changes regarding when they are stopping or starting eating.
61998005|NCT04138875|ACTIVE_COMPARATOR|Low Risk|Low risk patients (those in complete response (CR) after induction) will receive rituximab (375mg/m2) and brentuximab vedotin (1.8mg/m2) on day 1 of 21 day cycles, for 4 cycles.
62183586|NCT00749359|EXPERIMENTAL|open label treatment|On each treatment period, subjects will receive controlled release paroxetine 37.5 milligram (mg) on Day 1.
62183587|NCT01755910||Left thoaracic paravertebral block|Surgery in the left breast under left thoracic paravertebral block and HRV
62183588|NCT01755910||Right thoracic paravertebral block and HRV|Surgery in the right breast under right thoracic paravertebral block and HRV
62392329|NCT04250246|ACTIVE_COMPARATOR|Ipilimumab plus nivolumab|Ipilimumab plus nivolumab
62392330|NCT00876291|PLACEBO_COMPARATOR|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
62392331|NCT00876291|ACTIVE_COMPARATOR|Probiotic|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
62183589|NCT03818243|EXPERIMENTAL|RLS-|patients with Parkinson disease without RLS
62183590|NCT03818243|EXPERIMENTAL|RLS+|patients with Parkinson disease with RLS
62183591|NCT03854019|EXPERIMENTAL|Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg), then Placebo|Dextromethorphan/quinidine (DM/Q) 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.
62183592|NCT03854019|PLACEBO_COMPARATOR|Placebo, then Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)|Placebo one capsule once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
62392332|NCT04809142|EXPERIMENTAL|TQB2450+Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
62568234|NCT02646995|EXPERIMENTAL|Active|modified lipid formulation
62568235|NCT02646995|ACTIVE_COMPARATOR|Control|fish oil
62568236|NCT01770769|ACTIVE_COMPARATOR|Internal fixation - standard treatment|Internal fixation with two parallel cancellous screws (Hip Pins(R)) Current standard treatment
62791545|NCT06458985|EXPERIMENTAL|Disclosing Recovery|Participants complete a one-hour disclosure intervention for people in treatment for opioid use disorder. The intervention is facilitated by a workbook and accompanying worksheet.
62183593|NCT02226497|ACTIVE_COMPARATOR|Arm I (standard outpatient supportive care)|Patients receive standard outpatient supportive care after completion of chemotherapy.
61998006|NCT04138875|ACTIVE_COMPARATOR|High Risk|High risk patients (those who do not achieve a CR after induction), will receive rituximab (375mg/m2) and brentuximab vedotin (1.8mg/m2) on day 1 and bendamustine (90mg/m2) on day 1-2 of 21 day cycles for up to 8 cycles. Interim imaging will be performed in cycle 4 (days 14-21) and patients achieving CR will receive additional 2 cycles for a total of 6, patients achieving partial response (PR) will receive 4 additional cycles.
61998007|NCT02611622|ACTIVE_COMPARATOR|Arm 1: Control|"* Participants will be presented with envelopes labeled with a unique block-randomization code and asked to pick one~* Once the participant selects an envelope, the research coordinator will verify whether the code assigns the patient to the control or the intervention group, without the knowledge of the otolaryngologist who will be blinded to participant randomization at this point.~* Participants in the control group will proceed to filling out Demographic Survey and Patient Satisfaction Survey~* Once completed, they will be given the opportunity to discuss any further questions or concerns about their thyroid condition with their otolaryngologist"
62392333|NCT04809142|ACTIVE_COMPARATOR|Chemotherapy|Capecitabine tablets combined with oxaliplatin injection or gemcitabine hydrochloride injection. Each cycle is 3 weeks.
62773761|NCT03335254|EXPERIMENTAL|Dose-Escalating Arm 20|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is \>800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.~Period 3, Day 26-30: Once Daily Dose If Period 3, Day 19 total testosterone is \>800 ng/dL, decrease dose to 380 mg TU daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
62773762|NCT03339973|EXPERIMENTAL|allo-APZ2-PAOD|20-30 intramuscular injections, single dose of allo-APZ2-PAOD, 150 - 225 x 10\^6 cells per patient (depending on length of lower leg)
62773763|NCT03339973|PLACEBO_COMPARATOR|Placebo|20-30 intramuscular injections, vehicle solution (depending on length of lower leg)
62773764|NCT00665769|PLACEBO_COMPARATOR|Hypercapnia|Hypercapnic ventilation. The goal will be to maintain transcutaneous CO2 55 mm Hg (50-60 mm Hg) during the first week of life, or until extubation. A written, laminated hypercapnic ventilator algorithm will be placed at the bedside.
62773765|NCT00665769|ACTIVE_COMPARATOR|Normocapnia|Normocapnic ventilation. The goal will be to maintain transcutaenous CO2 40 mm Hg (35-45 mm Hg) during the first week of life, or until extubation. A written, laminated normocapnic ventilator algorithm will be placed at the bedside.
62773766|NCT04329494|EXPERIMENTAL|Arm I (PIPAC, doxorubicin, cisplatin)|Patients with ovarian, uterine, or gastric cancer, undergo PIPAC with doxorubicin IP, followed by cisplatin IP. Treatment repeats every 4-6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
62773767|NCT04329494|EXPERIMENTAL|Arm II (PIPAC, oxaliplatin, leucovorin, fluorouracil)|Patients with colorectal or appendiceal cancer undergo PIPAC with oxaliplatin IP. For cycles 2 and 3, patients receive leucovorin IV over 10 minutes and fluorouracil IV over 15 minutes 1-24 hours before undergoing PIPAC. Treatment repeats every 4-6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
62773768|NCT04329494|EXPERIMENTAL|Arm III (PIPAC, mitomycin, FOLFIRI)|Patients with colorectal or appendiceal cancer who have undergo at least 4 months (or 8 cycles) of first-line standard of care chemotherapy but have not progressed on second line chemotherapy undergo PIPAC with mitomycin IP. Patients also receive standard of care irinotecan IV over 90 on day 1, leucovorin IV over 30 minutes on day 1, and fluorouracil IV on days 1-2 during weeks 2, 4, 8, 10, 14 and 16. Treatment repeats every 4-6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
62773769|NCT04617015|EXPERIMENTAL|Ipratropium bromide|All subjects will receive ipratropium bromide HFA and will have spirometry performed before and after ipratropium.
62773770|NCT01601210|PLACEBO_COMPARATOR|Placebo|
62773771|NCT01601210|ACTIVE_COMPARATOR|2 grams of creatine|
62020911|NCT03779386|NO_INTERVENTION|No music during labor and delivery|No music during labor and delivery
62020912|NCT01636310|ACTIVE_COMPARATOR|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
62020913|NCT01636310|ACTIVE_COMPARATOR|Female Smokers (Early Follicular Phase; cycle days 4-8)|
62020914|NCT01223664|ACTIVE_COMPARATOR|Group A(conserved therapy )|Thirty of the enrolled patients were assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
62020915|NCT01223664|EXPERIMENTAL|Group B (BMSC Transplantion)|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation
62020916|NCT05097339||Patients with type 1 diabetes|Patients with type 1 diabetes perform a morning Symptom Limited Maximal Exercise Test (CPET) or a 60-minute morning Aerobic Test (AEX) at 60% VO2peak
62020917|NCT02819726|EXPERIMENTAL|SAIT101|In Part A, each patient will receive one course of two 1000 mg SAIT101 infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (\<50% improvement from Baseline in swollen and tender joint count at Week 24) will be eligible for a further course of two 1000 mg infusions of SAIT101 on Week 24 and Week 26.
62020918|NCT02819726|ACTIVE_COMPARATOR|Rituxan|In Part A, each patient will receive one course of two 1000 mg Rituxan infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (\<50% improvement from Baseline in swollen and tender joint count at Week 24) will be randomised in a 1:1 ratio to receive Rituxan or SAIT101 10000 mg infusions on Week 24 and Week 26.
62020919|NCT02819726|ACTIVE_COMPARATOR|MabThera|In Part A, each patient will receive one course of two 1000 mg MabThera infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (\<50% improvement from Baseline in swollen and tender joint count at Week 24) will be eligible for a further course of two 1000 mg infusions of MabThera on Week 24 and Week 26.
62020920|NCT03793101||BiMICS 1.4|Group 1.4 - Patients operated with 1.4 mm BiMICS technique
62020921|NCT03793101||BiMICS 1.8|Group 1.8 - Patients operated with 1.8 mm BiMICS technique
62020922|NCT05969353|SHAM_COMPARATOR|sham controlled arm|
62020923|NCT05969353|ACTIVE_COMPARATOR|battlefield acupunture|
62183594|NCT02226497|EXPERIMENTAL|Arm II (home telemonitoring device)|Patients receive standard outpatient supportive care as in Arm I and use the home telemonitoring device for the duration of chemotherapy-induced cytopenia (up to 3-4 weeks).
62392334|NCT01866891|EXPERIMENTAL|single arm|
62392335|NCT00641017|EXPERIMENTAL|1 and 2 - Adults|One immunization of 1x10\^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
62392336|NCT00641017|EXPERIMENTAL|3A - Seropositive Children|One immunization of 1x10\^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
62183595|NCT03596463||Group A|Patients treated according to suggestions of tumor board
62392337|NCT00641017|PLACEBO_COMPARATOR|3B - Seropositive Children|One dose of 1x10\^6 TCID50 rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
62773772|NCT01601210|ACTIVE_COMPARATOR|4 grams of creatine|
62773773|NCT01601210|ACTIVE_COMPARATOR|10 grams of creatine|
62773774|NCT06213181|NO_INTERVENTION|Control Group|Participants assigned to this group will receive general advice about the positive effects of regular physical activity. They will be given a guide of physical exercise recommendations, according to the World Health Organization for people over 65 years of age.
62773775|NCT06213181|EXPERIMENTAL|Mindfulness intervention|Participants assigned to this group will receive a mindfulness-based intervention for eight weeks with a weekly session lasting two hours per session. It is an experimental and interactive program that includes conscious movements, meditation, practical activities on attention in the present moment and the search for strategies to face complex situations from the collective and individual level. Participants will carry out daily practices at home during the week with the resources shared in each session.
62773776|NCT04070495|EXPERIMENTAL|Clarithromycin|
62773777|NCT04070495|EXPERIMENTAL|Rifampicin|
62773778|NCT05635474|EXPERIMENTAL|dietary supplement|According to the 2018 statistics of the American Association of Liver Diseases, about 25% of the world's population has non-alcoholic fatty liver disease. Bacillus coagulans does not exist in intestinal microbiota, because it has characteristics of spore production and lactobacillus lactic acid production, and has the ability to maintain the health of intestinal bacteria, acid and alkali resistance, With the advantages of high temperature resistance and high stability, it is currently one of the commonly used probiotic strains. Clinical studies have shown that after intervention of a single Bacillus coagulans strain in patients with non-alcoholic fatty liver disease, the problem of liver fat accumulation and inflammation can be significantly improved, so supplementing Bacillus coagulans TCI711 probiotics isolated from apples may improve Functions of liver and gut microbiota in patients with nonalcoholic fatty liver disease.
62773779|NCT05635474|PLACEBO_COMPARATOR|placebo|The placebo was also given in the form of capsules, the main ingredients were maltodextrin, silicon dioxide and magnesium stearate
62773780|NCT01522261|ACTIVE_COMPARATOR|Mechanical Bowel Prep|Patients randomized to complete a Mechanical Bowel Prep. (complete bowel cleansing) and fleet enemas prior to surgery.
62773781|NCT01522261|ACTIVE_COMPARATOR|No Mechanical Bowel Prep.|Patients randomized to complete two fleets enemas only prior to surgery.
62773782|NCT05412628|EXPERIMENTAL|Esophageal cancer group|patients aged ≥ 20 years with esophageal cancer
62392338|NCT00641017|EXPERIMENTAL|4A - Seronegative Infants and Children|One immunization of 1x10\^5 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
62773783|NCT05412628|EXPERIMENTAL|Oropharyngeal cancer group|patients aged ≥ 20 years with oropharyngeal cancer
62773784|NCT05412628|EXPERIMENTAL|Synchronous cancer group|patients aged ≥ 20 years with synchronous oropharyngeal cancer and esophageal cancer
62183596|NCT03596463||Group B|Patients not treated according to suggestions of tumor board
62183597|NCT04608136|EXPERIMENTAL|Yolk ketogenic diet|consume carbohydrate \< 10% and 3 whole eggs supplement per day in 12 weeks
62183598|NCT04608136|EXPERIMENTAL|White ketogenic diet|consume carbohydrate \< 10% and 6 white eggs supplement per day in 12 weeks
62183599|NCT04608136|ACTIVE_COMPARATOR|Control group|decrease consumption of diet from typical (decreased energy 20%) but consume carbohydrate in normal level
62183600|NCT01316965|EXPERIMENTAL|multifaceted prevention program|
62183601|NCT01316965|NO_INTERVENTION|usual care|
62183602|NCT04874623|EXPERIMENTAL|CDI|
62392339|NCT00641017|PLACEBO_COMPARATOR|4B - Seronegative Infants and Children|One dose of 1x10\^5 TCID50 rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
62773785|NCT05412628|PLACEBO_COMPARATOR|Control group|patients aged ≥ 20 years with symptoms of dysphagia without cancer
62773786|NCT03821194|EXPERIMENTAL|Gua sha group|do gua sha for the subjects
62773787|NCT03821194|ACTIVE_COMPARATOR|control group|give hot pack for the subjects
62183603|NCT01690923|EXPERIMENTAL|Nasal Mask First, then Pillows Mask|"Nasal mask is used for 7 nights, then followed by Pillows mask for 7 nights.~\[Nasal mask=Mirage Activa, Micro, FX; Pillows mask=Swift FX\]"
62773788|NCT05518708|EXPERIMENTAL|BI 3032950 treatment group - part A|
62773789|NCT05518708|EXPERIMENTAL|BI 3032950 treatment group - part B|
62773790|NCT05518708|PLACEBO_COMPARATOR|Placebo group|
61998008|NCT02611622|EXPERIMENTAL|Arm 2: LUMA ENT™|"* Participants will be presented with envelopes labeled with a unique block-randomization code and asked to pick one~* Once the participant selects an envelope, the research coordinator will verify whether the code assigns the patient to the control or the intervention group, without the knowledge of the otolaryngologist who will be blinded to participant randomization at this point.~* Participants in the intervention group will proceed to viewing the LUMA ENT™ videos pertinent to their thyroid condition using either of the two iPADS (the videos should not last longer than 10 minutes)~* Once video viewing is complete, participants will be given the opportunity to discuss any further questions or concerns about their thyroid condition with their otolaryngologist, especially as relates to questions that arise as a result of viewing the video~* Subsequently, the participants will proceed to filling out Demographic Survey and Patient Satisfaction Survey"
61998009|NCT03219697|EXPERIMENTAL|Parenting education program|"8 weeks of group parenting education sessions followed by two optional booster sessions.~2 public health nurse home/virtual visits and 4 coaching calls over a period of 6 months."
61998010|NCT03219697|NO_INTERVENTION|Control|Receive regular health care
62183604|NCT01690923|EXPERIMENTAL|Pillows Mask, then Nasal Mask|Pillows mask for 7 nights, then followed by Nasal mask is used for 7 nights. \[Nasal mask=MMirage Activa, Micro, FX; Pillows mask=Swift FX\]
62568237|NCT01770769|EXPERIMENTAL|Hemi - arthroplasty|cemented Hemi - arthroplasty (Exeter(R)) modular system V40 by Stryker. Refobacin cement.
62773791|NCT03824093|ACTIVE_COMPARATOR|AFIX Only|Practices enrolled in the AFIX only arm will receive an in-person AFIX consultation that includes assessment of current HPV vaccination rates and feedback on strategies to increase vaccination rates.
62773792|NCT03824093|ACTIVE_COMPARATOR|AFIX+ Provider Communication Training|Practices enrolled in the AFIX+ Provider Training arm will receive an in-person AFIX consultation along with a brief communication training for providers and poster and brochure displays in clinic waiting and exam rooms.
62773793|NCT02974569||C-SCAT|C-SCAT arm: Completes and uses Computerized Symptom Capture Tool (C-SCAT) during visit with provider for two clinic visits.
61998011|NCT02009410|EXPERIMENTAL|Creon|
61998012|NCT02009410|PLACEBO_COMPARATOR|Placebo|
62183605|NCT02345915|OTHER|Young adult acute leukemia-survivor|
62773794|NCT00687102|EXPERIMENTAL|Star participants assigned to Tamoxifen|Participants in the parent study, STAR assigned to Tamoxifen who were 65 or older at time of enrollment.
62773795|NCT00687102|EXPERIMENTAL|Star participants assigned to Raloxifene|Participants in the parent study, STAR assigned to Raloxifene who were 65 or older at time of enrollment.
62773796|NCT05658380|ACTIVE_COMPARATOR|atropine|
62773797|NCT05658380|PLACEBO_COMPARATOR|normal saline|
62773798|NCT03305393|OTHER|Adaptiv CRT|Adaptiv CRT algorithm in Medtronic FDA approved CRT devices to be programmed as ON at 6 month follow-up visit
62183606|NCT04409522|EXPERIMENTAL|Test Group|Participants in this group, in addition to receiving the usual treatment of COVID-19, will receive a 9 mg dose of melatonin for seven to ten nights.
62183607|NCT04409522|ACTIVE_COMPARATOR|Control Group|Participants in this group will receive the usual treatment of COVID-19
62183608|NCT01743521|EXPERIMENTAL|Group A - 8 weeks total therapy|8 weeks total therapy of TPV/PEG-IFN/RBV if undetectable HCV RNA after 2 weeks of therapy
62183609|NCT01743521|EXPERIMENTAL|Group B - 12 weeks total therapy|12 weeks total therapy of TPV/PEG-IFN/RBV if undetectable HCV RNA after 4 weeks of therapy
62183610|NCT01743521|EXPERIMENTAL|Group C - 24 weeks total therapy|24 weeks total therapy - TPV/PEG-IFN/RBV for 12 weeks + PEG-IFN/RBV for 12 weeks if undetectable HCV RNA after 8 weeks of therapy
62183611|NCT05036525|EXPERIMENTAL|use HANBIO BarriGel|
62183612|NCT05036525|NO_INTERVENTION|No anti-adhesive product|
62568238|NCT04494490|NO_INTERVENTION|Usual Care Condition|"During the usual care condition the therapists will be instructed to act as usual, that is, to read the guidelines on low back pain if they have read previous published guidelines and not read these guidelines if they have not read any other guidelines."
62773799|NCT05481047|EXPERIMENTAL|prevention|investigator will prevent intraoperative arterial hypotension based on HPI index
62773800|NCT05481047|NO_INTERVENTION|treatment|investigators will treat intraoperative arterial hypotension based on standard hemodynamic parameters
62773801|NCT01705834||Arthritis patients|Patients with Rheumatoid Arthritis
62773802|NCT00671437|EXPERIMENTAL|Arm 1|"Whole body FDG-PET/CT scan and CT scan of neck and chest (within 28 days of Day 1)~Cetuximab 400 mg/m2 intravenously (IV) over 2 hours on day 1 and 250 mg/m2 IV over 1 hour on days 8, 15, 22, 29, 36, 43, and 50.~Whole Body FDG-PET/CT scan and CT scan of neck and chest on Day 57 (prior to cetuximab infusion)~Cetuximab 250 mg/m2 IV over 1 hour on Day 57~Cetuximab 250 mg/m2 IV over 1 hour weekly until progressive disease"
62773803|NCT02231385|EXPERIMENTAL|Acetic Acid|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
62392340|NCT00641017|EXPERIMENTAL|5A - Seronegative Infants and Children|One immunization of 1x10\^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
62773804|NCT02231385|NO_INTERVENTION|Control Group|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
62773805|NCT00141115|EXPERIMENTAL|Levetiracetam|Levetiracetam 1500 mg BID
62773806|NCT06547515||Sleeve gastrectomy - Men|n = 39 men with obesity undergoing sleeve gastrectomy
61998013|NCT03412916|EXPERIMENTAL|GetActive|The GetActive program uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The GetActive sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal \& coping, and growth enhancement). The format is a 10-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions.
61998014|NCT03412916|EXPERIMENTAL|GetActive with Fitbit|The GetActive with Fitbit is identical to that of the p3RP with the addition of a digital monitoring device (i.e., Fitbit) for recording of physical activity.
61998015|NCT04914728|EXPERIMENTAL|mini-invasive lumbar arthrodesis|"The patient will be admitted to the hospital on the morning of the surgery, operated on the same morning by either the posterior or anterior mini-invasive approach.~The choice of the approach depends on the specificity of the pathology leading to the arthrodesis procedure and the surgeon's experience. It is the surgeon who decides this in agreement with the patient. The patient will be discharged in the evening after agreement of the anaesthetist and the surgeon."
62392341|NCT00641017|PLACEBO_COMPARATOR|5B - Seronegative Infants and Children|One dose of rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
62392342|NCT06107348||Immune Disorder|
62392343|NCT05162599|EXPERIMENTAL|Diagnostic study, experimental evaluative cross-sectional study|Evaluate the performance of the Cardiags Trimod medical device, compared to a reference examination, echocardiography, for the detection of heart murmurs Verification of the performance of the Cardiags Trimod medical device compared to a reference examination (ECG, Cardiologist interpretation) for the detection of rythm abnormalities Verification of the repeatability of measurements Verification of safety and suitability for use Verification of acceptability
62392344|NCT03604016|EXPERIMENTAL|Besifovir dipivoxil+L-carnitine|Besifovir dipivoxil 150 mg and L-carnitine 330 mg
62392345|NCT03604016|ACTIVE_COMPARATOR|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
62392346|NCT02094131|EXPERIMENTAL|Cliniflo group (CG)|Training using flow-oriented incentive spirometry Cliniflo
62568239|NCT04494490|ACTIVE_COMPARATOR|CPG+PIPT Condition|An active Clinical Practice Guidelines (CPG) implementation strategy will be utilized with an education component in Psychologically Informed Physical Therapy (PIPT) with peer opinion leaders and a monthly audit/feedback on CPG adherence rates and patient outcomes
62773807|NCT06547515||Sleeve gastrectomy - Premenopausal women|n = 39 premenopausal women with obesity undergoing sleeve gastrectomy
62773808|NCT06547515||Sleeve gastrectomy - Postmenopausal women|n = 39 postmenopausal women with obesity undergoing sleeve gastrectomy
62773809|NCT06547515||Obese non-surgical group|n = 39 (13 men, 13 premenopausal and 13 postmenopausal women) obese non-surgical individuals
62773810|NCT02831322|EXPERIMENTAL|radial artery occlusion|Radial artery occlusion was the absence of a flow signal by Doppler ultrasound examination.
62773811|NCT02831322|OTHER|radial artery normal|Radial artery normal was blood flow signal by Doppler ultrasound
62773812|NCT02373514|ACTIVE_COMPARATOR|Paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with rapid infusion
62773813|NCT02373514|ACTIVE_COMPARATOR|Dexketoprofen|Intravenous 50 mg dexketoprofen in 100 ml saline with rapid infusion
62773814|NCT03716752|ACTIVE_COMPARATOR|bone graft and collagen barrier|peridoontal regeneration using bone graft and collagen barrier as treatment of vertical bony defects with recession defect
62392347|NCT02094131|EXPERIMENTAL|Voldyne group (VG)|Training using volume-oriented incentive spirometry Voldyne
62392348|NCT02094131|NO_INTERVENTION|Control group (CONG)|No intervention. Assessment and reassessment after 5 weeks.
62392349|NCT01234662|ACTIVE_COMPARATOR|Group 1|Spinal anesthesia + intrathecal opioid bolus (SPA)
62392350|NCT01234662|ACTIVE_COMPARATOR|Group 2|CSE + epidural opioid bolus (CSE)
62392351|NCT01234662|EXPERIMENTAL|Group 3|CSE + continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs (CSEPCEA)
62392352|NCT02632097|EXPERIMENTAL|Histoacryl|Intervention: Lichtenstein Hernioplasty with Histoacryl™(cyanoacrylate glue 0.5 ml) for mesh fixation (Optilene™ mesh 60 g/m2 (B. Braun))
62773815|NCT03716752|EXPERIMENTAL|Modified connective tissue graft wall with wing technique|peridoontal regeneration using bone graft and modified connective tissue graft wall with wing as treatment of vertical bony defects with recession defect
62773816|NCT03247725|ACTIVE_COMPARATOR|Treatment as usual (waiting list)|Patients at this condition will receive the usual medical treatment at the pain unit, but they will not be monitored daily using the app.
62773817|NCT03247725|EXPERIMENTAL|Treatment as usual + app (without alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Because alarms will not be generated, physicians will not know if an undesired event is occuring despite the app is actually collecting data.
62773818|NCT03247725|EXPERIMENTAL|Treatment as usual + app (with alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
61998016|NCT02042924|EXPERIMENTAL|Imaging studies|Subjects will have a FLT PET/CT and a MRI prior to starting the preparative regimen for transplant and another of each scan 100 days after transplant.
62568240|NCT01296776|ACTIVE_COMPARATOR|whole-body electromyostimulation|20 min of whole-body electromyostimulation with sequences of 6 sec of current and 4 sec at 85 Hz performed during low-intensity/low amplitude movements. 3 sessions / 14 days for 12 months
62183613|NCT00526097|EXPERIMENTAL|Bisacodyl 5 mg x 2 once daily|patient to receive two enteric-coated tablets containing 5 mg bisacodyl
62773819|NCT05749393|EXPERIMENTAL|Low-dose group|The initial dose was 50U/kg intravenous injection, and the dosage was halved by intravenous injection every 1 hour to the minimum 1000u/h. The medication will be discontinued at the end of the procedure.
62773820|NCT05749393|EXPERIMENTAL|High-dose group|The initial dose was 70U/kg intravenous injection, and the dosage was halved by intravenous injection every 1 hour to the minimum 1000u/h. The medication will be discontinued at the end of the procedure.
62773821|NCT02561221|EXPERIMENTAL|Lifestyle Counseling|Patients in the Lifestyle Counseling Arm attended weekly (16 in-person) sessions in the first six months, followed by monthly sessions for the remaining 18 months. The behavioral intervention was delivered by a trained health coach embedded in the primary care clinic. Primary Care Practitioners in the experimental arm received a series of webinars on obesity science to help them manage and treat patients with obesity.
62773822|NCT02561221|NO_INTERVENTION|Usual Care|Patients assigned to the usual care arm continued to interact with their Primary Care Practitioners according to their usual schedule, and received a series of newsletters on topics of interest, including importance of sleep for health, brain and memory health, goal setting, smoking cessation, etc. Primary Care Practitioners in the usual care arm received a webinar describing the current Centers for Medicare and Medicaid (CMS) approach to reimbursing for obesity treatment, and a reminder informational brochure was sent to the Primary Care Practitioners each year.
61998017|NCT04268420|ACTIVE_COMPARATOR|"Part A - Low Dose"|"Part A vaccinees in the low dose arm will receive the lower dosing (20 μg FMP013 per 0.5 mL ALFQ) approximately 2 weeks prior to each vaccination. Vaccination to be delivered on 0,1,2 month."
62773823|NCT04594928|EXPERIMENTAL|GLPG3667 Dose A|Daily doses of GLPG3667 for 4 weeks.
61998018|NCT04268420|ACTIVE_COMPARATOR|"Part A - High Dose"|"Part A vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,2 month."
62183614|NCT00526097|PLACEBO_COMPARATOR|Placebo|patient to receive two placebo-to-match enteric-coated tablets 5 mg bisacodyl
62183615|NCT05729204|EXPERIMENTAL|Hypertonic seawater group|Patients that will receive nasal irrigations with hypertonic (2.3% NaCl) seawater solution containing brown algae (Undaria pinnatifida) and blue-green algae (Spirulina platensis) as well as essential oils of Eucalyptus globulus and Mentha spicata, and Thymus vulgaris extract (Sinomarin® Plus Algae Cold \& Flu Relief, Gerolymatos International SA, Krioneri, Greece)
62183616|NCT05729204|NO_INTERVENTION|control group|Patients that will not perform nasal irrigations
62183617|NCT03480295|EXPERIMENTAL|HA0.4%+TAU0.5%|Patients had to administer 4 drops/day of an ophthalmic solution containing hyaluronic acid 0.4% and taurine 0.5% in addition to the ongoing glaucoma treatment
62392353|NCT02632097|EXPERIMENTAL|Suture|Intervention: Lichtenstein Hernioplasty with Sutures (polypropylene 2/0) to fix the Optilene™ mesh 60 g/m2 (B. Braun)
61998019|NCT04268420|ACTIVE_COMPARATOR|"Part B - Standard Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 4,5,6 month."
62183618|NCT03480295|ACTIVE_COMPARATOR|HA0.2%|Patients took 4 drops/day of an ophthalmic solution containing hyaluronic acid 0.2%
61998020|NCT04268420|ACTIVE_COMPARATOR|"Part B - Delayed Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,6 month."
62773824|NCT04594928|EXPERIMENTAL|GLPG3667 Dose B|Daily doses of GLPG3667 for 4 weeks.
62392354|NCT02254616|EXPERIMENTAL|Mirror therapy with tDCS|Functional training will consist of unilateral and bilateral functional tasks in daily living, and last for 30 minutes. Some examples are mopping the table by using the affected hand or scooping beans from a bowl with one hand while the other hand stabilizes the bowl. The principles of part-task practice and whole-task practice will be applied based on the participant's performance level.Functional training will consist of unilateral and bilateral functional tasks in daily living, and last for 30 minutes. Some examples are mopping the table by using the affected hand or scooping beans from a bowl with one hand while the other hand stabilizes the bowl. The principles of part-task practice and whole-task practice will be applied based on the participant's performance level.
62773825|NCT04594928|PLACEBO_COMPARATOR|Placebo|Placebo to match will be administered as capsules for daily oral use.
62773826|NCT01177969|EXPERIMENTAL|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
62773827|NCT01177969|PLACEBO_COMPARATOR|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
61998021|NCT04268420|ACTIVE_COMPARATOR|"Part B - Delayed Fractional Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,6 month."
61998022|NCT04268420|NO_INTERVENTION|Control|Up to 6 subjects will be enrolled (defined as receiving malaria challenge) later in the trial to serve as challenge controls. Additional subjects may be recruited as alternates to ensure that 6 control subjects undergo the challenge. Any alternates not challenged will be released from the study at day of challenge.
62183619|NCT01895049|ACTIVE_COMPARATOR|Mycophenolate sodium|Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium, and late introduction of tacrolimus
61998023|NCT00254995||Menactra Vaccine Recipients|Participants who received Menactra vaccine as part of routine medical care during the study period in Kaiser Permanente.
61998024|NCT00254995||Age-Matched Control|Each individual receiving Menactra vaccine served as their own control for evaluation of acute (Days 0-30) events (short-term surveillance). For the 6-month (long-term) surveillance, for each person receiving Menactra vaccine, a control matched on age (± 1 year), sex, and month of vaccination was selected who received a received tetanus and diphtheria toxoids (Td), hepatitis A, hepatitis B, or hepatitis A/hepatitis B combination vaccine as part of routine medical care during the same month 1 year earlier in Kaiser Permanente
61998025|NCT05268861|EXPERIMENTAL|Training with EA feedback|Subjects will undergo training with the EA-VR game that includes a 15 degree elbow flexion error.
61998026|NCT05268861|SHAM_COMPARATOR|Training without EA feedback|Subjects will undergo training with the EA-VR game that does not include EA feedback.
62183620|NCT01895049|EXPERIMENTAL|Everolimus|Induction therapy with Thymoglobulin, prednisone, everolimus, and late introduction of tacrolimus.
62392355|NCT02254616|ACTIVE_COMPARATOR|Mirror Therapy|The MT only group will receive a 60-minute MT per session followed by a 30-minute functional training. Participant will go through the same protocol as that for the MT+tDCS and MT+sham tDCS groups with no tDCS presented in setting. This group is for evaluating placebo effect of the present of tDCS application.
62392356|NCT02254616|ACTIVE_COMPARATOR|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training. During the 60-mimute conventional training, interventions will include passive range of movement and muscle tone normalization techniques of the affected arm, and gross motor training (e.g., shoulder ladder activity), fine motor training (e.g., grasping cones), and muscle strength training in a unilateral and bilateral manners. During the 30-minute functional training, the same principles to those in the MT groups will be applied.
62773828|NCT03907033|ACTIVE_COMPARATOR|Standard Bupivacaine|Patients in the control group will receive 0.25% bupivacaine hydrochloride (bupivacaine HCl). 10cc will be injected bilaterally into each uterosacral ligament prior to the colpotomy incision. After entry into the posterior cul-de-sac, an additional 10cc of will be injected bilaterally into the deeper uterosacral ligaments.
62773829|NCT03907033|EXPERIMENTAL|Liposomal Bupivacaine|Patients in the study group will receive a mixture of 0.5% bupivacaine HCl and liposomal bupivacaine in 1:1 ratio. 10cc of the mixture will be injected bilaterally into each uterosacral ligament prior to the colpotomy incision. After entry into the posterior cul-de-sac, an additional 10cc will be injected bilaterally into the deeper uterosacral ligaments
62773830|NCT04999527|EXPERIMENTAL|Healthy Volunteer: Single Ascending Dose of DISC-0974|Single Intravenous (IV) or Subcutaneous (SC) ascending dose in healthy volunteers
61998027|NCT03202004|EXPERIMENTAL|GSK2894512 1% cream group|Subjects will apply a thin layer of GSK2894512 1% (10 milligrams per gram \[mg/g\]) topical cream once daily to all psoriasis lesions for 12 weeks. The study staff will instruct subjects on proper topical application of cream.
62392357|NCT02254616|ACTIVE_COMPARATOR|Mirror Therapy with sham-tDCS|Functional training will consist of unilateral and bilateral functional tasks in daily living, and last for 30 minutes. Some examples are mopping the table by using the affected hand or scooping beans from a bowl with one hand while the other hand stabilizes the bowl. The principles of part-task practice and whole-task practice will be applied based on the participant's performance level.
62773831|NCT04999527|EXPERIMENTAL|Healthy Volunteer: Single Ascending Dose of Placebo|Single Intravenous (IV) or Subcutaneous (SC) ascending dose in healthy volunteers
62773832|NCT00541346|EXPERIMENTAL|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
62773833|NCT02189278|EXPERIMENTAL|Psychosocial Intervention|Telephone-based psychosocial intervention involving six telephone encounters. Each encounter focuses on teaching skills for improving adherence and overcoming barriers to obtaining recommended surveillance.
62773834|NCT02189278|NO_INTERVENTION|Treatment as usual|Treatment as usual control.
62392358|NCT05025306|NO_INTERVENTION|control group|only atraumatic extractions were done, honey was not applied
62392359|NCT05025306|EXPERIMENTAL|experimental group|ziziphus honey was applied into the sockets after tooth extractions in experimental group
62568241|NCT01296776|PLACEBO_COMPARATOR|wellness control group|Low intensity, low frequency exercise that focus on well being. 1 session/week for 10 weeks. 10 blocks of exercise with intermittent periods of 100 weeks of rest
62568242|NCT01737632|EXPERIMENTAL|Multidimensional Family Therapy (MDFT)|MDFT is an intensive, in-home family-based drug abuse treatment for adolescent substance abusers. MDFT views family factors in their context -in terms of the network (individual, familial, peer, community) or multiplicity of influences on drug use and change.
62773835|NCT02458183|EXPERIMENTAL|DTaP-IPV combination vaccine|Dosage and administration: A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of right thigh at the age of 2, 4, and 6 months
62773836|NCT02458183|ACTIVE_COMPARATOR|DTaP vaccine and IPV vaccine|"Product name: : Boryung DTaP Vaccine Inj. (Prefilled syringe) (Absorbed diphtheria, tetanus toxoid, and purified pertussis combination vaccine) Dosage and administration: A 0.5-mL dose is administered 3 times intramuscularly in the anterolateral aspect of right thigh at the age of 2, 4, and 6 months.~Product name: IPVAX INJ. PREFILLED SYRINGE INJ. Dosage and administration: A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of left thigh at the age of 2, 4, and 6 months."
62392360|NCT01354834||hMG|
62392361|NCT02847364|EXPERIMENTAL|Chewing gum group|The patients will be asked to chew on a regular chewing gum starting morning of post-operative day 1 until the first bowel movement.
62392362|NCT02847364|NO_INTERVENTION|Control group|These patients will not be offered any food/beverage orally. Patients will be asked not to eat or chew anything till the first bowel movement.
62392363|NCT01693991|EXPERIMENTAL|Meaning-Making intervention (MMi)|Patients in this arm will be receiving the Meaning-Making intervention (MMi) as per intervention manual (Lee, 2006).
62410020|NCT03039686|EXPERIMENTAL|RO7239361 Low Dose|Participants received low dose RO7239361 SC on specified days of the 48-week DB period. Following the DB period participants received low dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
62773837|NCT03936751|ACTIVE_COMPARATOR|CPAP|Continuous positive airway pressure
62773838|NCT03936751|SHAM_COMPARATOR|Nasal strips|Nasal Strips
61998028|NCT03202004|PLACEBO_COMPARATOR|Vehicle cream group|Subjects will apply a thin layer of vehicle cream once daily to all psoriasis lesions for 12 weeks. The study staff will instruct subjects on proper topical application of cream.
61998029|NCT03175094|EXPERIMENTAL|Holistic Health Recovery Program for HIV+ Intervention|
61998030|NCT03175094|NO_INTERVENTION|Control|
62568243|NCT01737632|OTHER|Adolescent Residential Treatment|"The Adolescent Treatment Program (ATP) is a residential dual diagnosed substance abuse treatment program that is staff secure. It is based on a social learning approach which emphasizes positive reinforcement for appropriate coping behavior and social skills, and incorporates a levels system which allocates privileges and responsibilities according to the individual's behavioral capacities."
62568244|NCT04005404|EXPERIMENTAL|intertrochanteric femoral fractures|geriatric patients with intertrochanteric femoral fracture who have consented to the study intervention
62568245|NCT04005404|EXPERIMENTAL|neck femur fractures|geriatric patients with neck of femur fracture who have consented to the study intervention
62773839|NCT06034353|ACTIVE_COMPARATOR|Basic group|Lifestyle Modifications: General education about healthy life style and diet. Education : general awareness about disease and medication Pill Planner: Pill planner will be provided to keep them adherent to their medication Counselling: Counsel the patients about there medication dosage, frequency and appropriate time.
62791546|NCT06458985|NO_INTERVENTION|Waitlist Comparator|Participants do not complete the disclosure intervention at their baseline appointment. They are given the opportunity to complete the disclosure intervention at their final appointment.
62568246|NCT04005404|EXPERIMENTAL|subtrochanteric femoral fractures|geriatric patients with subtrochanteric femoral fracture who have consented to the study intervention
62568247|NCT05020158|EXPERIMENTAL|Family Talk intervention|FTI entails six meetings, with intervals of 1-2 weeks between meetings. Meetings 1-2 include only the parent(s) and focus on their experiences of the situation, as well as the consequences of the diagnosis for each family member. The parent(s) will formulate the goal of the intervention. Meeting 3: Interviews will be held with each child and includes the child's life situation. Meeting 4 includes the parent(s) and focuses on planning the family meeting. The children's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5 is a family meeting and consists of questions and issues raised earlier by the family members. Meeting 6 is a follow-up with all family members. The meeting is guided by the family members' needs, e.g., regarding communication and parenting. If the intervention is interrupted unexpectedly and cannot be finished as scheduled due to extraordinary circumstances, extra meetings are available (Meetings 7-11).
62568248|NCT01665560||Smokers--Currently Smoking|Individuals that are right handed, and not claustrophobic were recruited. This same group was used for the smoking-group and refrain from smoking was evaluated by CO2 evaluation. To be classified as smokers, they had to report smoking 3-10 cigarettes daily for at least the last year and have a carbon monoxide reading of CO \>10 ppm.
61998031|NCT01466946||semi-structured interviews|A qualitative study of MSKCC lung cancer patients of Hispanic/Latino descent by collecting retrospective patient narratives to understand the processes that led them to seek medical help when they did, their experiences in seeking and receiving medical guidance, as well as their decisions regarding lung cancer treatment. In addition, we will explore how these patients' representations of lung cancer with its associated risk factors and symptoms affected their treatment decisions.
61998032|NCT03676530|NO_INTERVENTION|Relative Rest (Control)|Male/Female Military Trainees with symptoms consistent with Tibial Stress Syndrome. No compression. Standard of care therapy includes relative extremity rest, stretches and graduated run program.
61998033|NCT03676530|EXPERIMENTAL|Compression Garments|Male/Female Military Trainees with symptoms consistent with Tibial Stress Syndrome. Standard of care therapy includes compression garments worn, stretches and graduated run program.
61998034|NCT01991119|ACTIVE_COMPARATOR|Propafenone|Propafenone group
61998035|NCT01991119|ACTIVE_COMPARATOR|Dronedarone|Dronedarone group
61998036|NCT03445624||patient on traditional therapy|Drug: steroid,5ASA , immuran for assesment the outcome of therapy in inflammatory bowel disease steroid(40- 60mg tablet),5ASA(pentasa 3-4gm tablet),azathioprin (immuran 100 mg tablet)
62392364|NCT01693991|PLACEBO_COMPARATOR|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
62773840|NCT06034353|EXPERIMENTAL|Advanced|Lifestyle Modifications: Specific education on keto-diet, yoga and meditation Education : Specific disease education targeting medication adverse drug reaction (ADR), seizure chart management Pill Planner: Pill planner will also be provided to this group Counselling: Cognitive Behavioral therapy will be provided
62392365|NCT01693991|NO_INTERVENTION|Control Group|Patients in this group will only be receiving treatment as usual.
62392366|NCT03429569|SHAM_COMPARATOR|accelerated conventional technique|"Pachymetry greater than 400μm~Topographic criteria for keratoconus evolution:~Variation over a 6-month period of the following changes:~An increase equal to or greater than 1D of maximum keratometry (Kmax) And / or an increase in mean keratometry (Kmean) greater than or equal to 0.75D And / or an increase in the difference between the meridian and the most arched and the least arched (Kmax-Kmin) greater than or equal to 0.75D And / or a decrease in the central thickness greater than or equal to 2% Criteria of non-inclusion Age under 18 Ectasies post LASIK Pregnant women breastfeeding Major corneal opacities Absence of consent to participation in the study No affiliation to Social Security or State Medical Aid (AME) or Universal Medical Coverage (CMU)"
62773841|NCT01560455|ACTIVE_COMPARATOR|single stent|single stent
62568249|NCT01665560||Non-Smoker|Healthy individuals meeting the inclusion criteria who claim to not smoke. This is confirmed w/ CO testing.
62568250|NCT01660750|EXPERIMENTAL|Carfilzomib, Cyclophosphamide, Dexamethasone|All eligible subjects will receive Carfilzomib, Cyclophosphamide, and Dexamethasone.
62773842|NCT01560455|ACTIVE_COMPARATOR|dual stent|dual stent (culotte)
62773843|NCT01570049|EXPERIMENTAL|Bendamustine|Dose of 120 mg/m2/day on Day 1 and Day 2 of each treatment cycle (every 21 days), to a maximum of 8 cycles.
62773844|NCT03497364|EXPERIMENTAL|Bupivacaine group|Pregnant women received combined spinal-epidural anesthesia by injecting bupivacaine. The dose of bupivacaine depended on height of subjects.
62773845|NCT03497364|EXPERIMENTAL|Ropivacaine group|Pregnant women received combined spinal-epidural anesthesia by injecting ropivacaine. The dose of ropivacaine depended on height of subjects).
61998037|NCT03445624||patient on infliximab|drug : infliximab (5mglkg intravenous)for the first dose,the second dose after 2 weeks the third dose after 6 weeks then every 2 months
61998038|NCT04188262|EXPERIMENTAL|NVS Therapy|NVS Therapy will be delivered to de novo lesions in Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) during PTA in patients with symptomatic peripheral artery disease.
61998039|NCT00639834|EXPERIMENTAL|1|Active MDX-1342 given in combination with Methotrexate
61998040|NCT01578928|EXPERIMENTAL|SOM230|subjects with varying degrees of renal impairment along with subjects without renal impairment
61998041|NCT01315769||non pregnant nulliparous|Group 1
61998042|NCT01315769||primiparous women|Group 2
61998043|NCT01180270||Cervical dystonia|"patients suffering from cervical dystonia~under routine botulinum toxin treatment"
61998044|NCT01180270||healthy volunteers|control group
61998045|NCT04498793|EXPERIMENTAL|PD-1 group|"Participants receive tislelizumab every 3 weeks (Q3W) + nab-paclitaxel weekly x 4 cycles, followed by tislelizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 14 cycles of tislelizumab Q3W plus capecitabine (TNBC subtype) or endocrine therapy (Luminal subtype) as adjuvant therapy post-surgery.~Each cycle is 21 days."
61998046|NCT04498793|ACTIVE_COMPARATOR|Control group|"Participants receive nab-paclitaxel weekly x 4 cycles followed by (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by capecitabine (TNBC subtype) or endocrine therapy (Luminal subtype) as adjuvant therapy post-surgery.~Each cycle is 21 days."
61998047|NCT02581774||term isolated oligohydramnios|Labor Monitoring and normal delivery tracking
61998048|NCT02581774||prolonged pregnancies|Labor Monitoring and normal delivery tracking
61998049|NCT01908569|ACTIVE_COMPARATOR|NO MACS + Time-lapse technology|The sperm capacitation will be performed through a density gradient. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).
61998050|NCT01908569|EXPERIMENTAL|MACS + time-lapse technology|The sperm capacitation will be performed through a density gradient. After that, it will be subjected to the MACS technique in order to select the non-apoptotic spermatozoids. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).
61998051|NCT00754416||S.E.S prosthesis|Consecutive series of patients with a S.E.S prosthesis.
61998052|NCT04332328||Ulcerative patients|
61998053|NCT04332328||Non ulcerative patients|
61998054|NCT00779012|EXPERIMENTAL|Remicade|
61998055|NCT06183359|EXPERIMENTAL|The group Self-Identification Program (SIP)|"The Self-Identification Program (SIP) is a third level of third wave CBT.~It targets a correct self-identification through the of the following skills :~* understand the nature and functioning of one's own mind (=conscious power, what allows the appearance of experiences);~* learn to identify with the characteristics of the mind : to provide soothing (session 1), reassuring power (session 2), benevolent power (session 3), discerning power (session 4), prioritizing power (session 5), acting power (session 6), creative power (session 7), liberating power (session 8)~* live better with your emotions and moods (and their dysregulation);~* develop more respectful communication for oneself and others"
61998056|NCT06183359|OTHER|The group Acceptance and Commitment Therapy (ACT)|"The Acceptance and Commitment Therapy (ACT) is a first level of third wave CBT.~It targets the development of the following skills, consistent with the content of programs validated in the domain :~* decision-making tool (matrix (session 1));~* flexibility skills: defusion (session 2), Self as context (session 4), acceptance (session 4), contact with the present moment (session 5), values (session 6), valued actions (session 7), toolkit skills (session 8)."
62183621|NCT00885326|OTHER|Treatment|"Bevacizumab: Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.~Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).~Zoledronic acid will be administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first."
62392367|NCT03429569|SHAM_COMPARATOR|iontophoresis|"Pachymetry greater than 400μm~Topographic criteria for keratoconus evolution:~Variation over a 6-month period of the following changes:~An increase equal to or greater than 1D of maximum keratometry (Kmax) And / or an increase in mean keratometry (Kmean) greater than or equal to 0.75D And / or an increase in the difference between the meridian and the most arched and the least arched (Kmax-Kmin) greater than or equal to 0.75D And / or a decrease in the central thickness greater than or equal to 2% Criteria of non-inclusion Age under 18 Ectasies post LASIK Pregnant women breastfeeding Major corneal opacities Absence of consent to participation in the study No affiliation to Social Security or State Medical Aid (AME) or Universal Medical Coverage (CMU)"
62773846|NCT03497364|NO_INTERVENTION|Control group|Pregnant women received combined spinal-epidural anesthesia by injecting bupivacaine. 2ml bupivacaine (0.75% bupivacaine (2 ml) + cerebrospinal fluid (1 ml)) was injection for all subjects.
62392368|NCT04640792|NO_INTERVENTION|Common Colonoscopy (Group A)|Patients will be examined with Conventional Colonoscopy (CC)
62392369|NCT04640792|EXPERIMENTAL|Magentiq Eye Assisted Colonoscopy (Group B)|Patients will be examined with Magentiq Eye Assisted Colonoscopy (MEAC)
62568251|NCT02409199|EXPERIMENTAL|apatinib|Apatinib 850 mg qd po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62568252|NCT02409199|ACTIVE_COMPARATOR|Docetaxel|Docetaxel 60mg/m2 ivgtt every 3 weeks, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62773847|NCT00953563|NO_INTERVENTION|compression therapy|
62773848|NCT00953563|ACTIVE_COMPARATOR|Biologic with compression therapy|
62773849|NCT04021212||Patients with pituitary adenomas resection|Patients suffers from pituitary adenomas and undergo transsphenoidal surgery for at least once
61998057|NCT06415643|EXPERIMENTAL|Transplantation group|transplantation group
61998058|NCT05040633|EXPERIMENTAL|Low Level Laser Therapy + standard exercise therapy|This group of participants will first receive the standard therapy of strengthening and stretching exercises followed by the Low Lever Laser Therapy.
62791547|NCT01756404|EXPERIMENTAL|Cohort 1|Each volunteer will receive a total daily dose of 30 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
62773850|NCT05670132|EXPERIMENTAL|Neurocardiac rehabilitation program|"The home-based neuro-cardiac rehabilitation program will consist of weekly sessions of neuro-cardiac training during 12 weeks at home.~* The physical activity training consists of two 1-hour sessions of adapted physical activities per week supervised by an APA educator or equal. One weekly session is held in person, at home, and the second one in videoconference. All training sessions follow the same scheme with 30 minutes of bicycle training, adapted from high-intensity training (30-33), and 30 minutes of free adapted physical activities~* The neuropsychological component will consist of 2 home-based weekly 25-minute sessions of computerized cognitive training via the new platform of CogMed (standard format) for the patient and 1 weekly 30/45-min teleconsultation session of neuropsychological feedback on every-day life emotional regulation and executive functioning applied to school and family life for either the parent (for ages 17 and younger) or young adults with CHD."
61998059|NCT05040633|SHAM_COMPARATOR|Sham Low Level Laser Therapy + standard exercise therapy|This group of participants will first receive the standard therapy of strengthening and stretching exercises followed by a sham Low Level Laser Therapy (LLLT). The laser equipment will be deactivated and not switched on.
62773851|NCT05670132|ACTIVE_COMPARATOR|Standard of care|The control group will follow European recommendations for cardiology care (standard of care) without introducing any additional interventions for research purposes at the exception of primary (HRQoL questionnaires) and secondary outcomes
62773852|NCT00510978|ACTIVE_COMPARATOR|1|Bifidobacterium infantis 35624
62773853|NCT00510978|ACTIVE_COMPARATOR|2|Lactobacillus salivarius UCC118
62773854|NCT00510978|PLACEBO_COMPARATOR|3|Placebo
62773855|NCT06267066|ACTIVE_COMPARATOR|Topical Corticosteroids|Patients will be prescribed topical steroids cream twice daily and topical emollient once daily for 3 months.
61998060|NCT05040633|ACTIVE_COMPARATOR|Standard Exercise Therapy|Trial participants in this group will only receive the standard exercise therapy. The exercise therapy will consist of strengthening and stretching exercises.
61998061|NCT04505891|NO_INTERVENTION|Usual care|
61998062|NCT04505891|ACTIVE_COMPARATOR|Education alone|
62773856|NCT06267066|ACTIVE_COMPARATOR|Fractional carbon dioxide|Patients will receive 3 monthly laser sessions, in addition to the use of topical emollients only once daily in between the sessions.
62773857|NCT06267066|ACTIVE_COMPARATOR|Combined topical corticosteroids and Laser|Patients will receive 3 monthly laser sessions, in addition to topical steroids twice daily and topical emollient once daily in between the sessions.
62773858|NCT01799434|EXPERIMENTAL|Exercise|All participants had to run 20min on their individual anaerobic threshold
62773859|NCT04198675|ACTIVE_COMPARATOR|Supervised EMG Biofeedback Exercise Training Group|Frequency: 3/week Duration:6 weeks Dosage: Tolerable intensity-dependent increase in exercises program.
62773860|NCT04198675|ACTIVE_COMPARATOR|Home-Based Exercise Training Group|Frequency: 3/week Duration:6 weeks Dosage: Tolerable intensity-dependent increase in exercises program.
62773861|NCT04198675|SHAM_COMPARATOR|Posture Training/Ergonomic Regulations Group|1 session, no further intervention until second evaluation for 6 weeks.
62773862|NCT02270593||Placenta previa|first; maternal serum, fetal membranes (placenta) and maternal myometrial samples will be investigated for ADAMTS, Proteoglycans and oxidative/antioxidative enzyme status levels in patients with placental invasion anomalies Placenta Previa totalis by ELISA, western blot, immunohystochemistry and PCR (polymerase chain reaction).
62773863|NCT02636712||ImageReady™ MR Conditional Pacing System|"1. Subject must have the ImageReady™ System as their initial (de novo) pacing system implant~2. Subject has a Class I or II indication for implantation of a pacemaker according to the CSPE guidelines"
61998063|NCT04505891|ACTIVE_COMPARATOR|Education and follow-up|
61998064|NCT02022228|EXPERIMENTAL|0.2mg triptorelin and 500 IU hCG|Patients were triggered with 0.2mg triptorelin and 500 IU hCG
61998065|NCT02022228|EXPERIMENTAL|0.2mg triptorelin and 1000 IU hCG|Patients were triggered with 0.2mg triptorelin and 1000 IU hCG
61998066|NCT00836875|EXPERIMENTAL|1|Children from 2 to 17 years who have possible, probable or proven invasive aspergillosis, or other rare mold infection (eg, Scedosporium and Fusarium).
61998067|NCT05235191|EXPERIMENTAL|methadone|In this arm patients will take methadone 5mg
61998068|NCT05235191|PLACEBO_COMPARATOR|placebo|In this arm patients will take placebo tablets (the same number, color and physical aspects as the methadone tablets).
62183622|NCT04596098||Group A|Patient hospitalized in Grenoble University Hospital for CoViD19. Patient not previously followed in Grenoble University Hospital for a chronic disease.
62183623|NCT04596098||Group B|Patient hospitalized in Grenoble University Hospital for CoViD19. Patient followed in Grenoble University Hospital for a chronic disease.
62183624|NCT00867178|EXPERIMENTAL|Treatment (vorinostat, isotretinoin, chemotherapy)|See Detailed Description
61998069|NCT03438890|EXPERIMENTAL|Warm saline group|In subjects allocated to the warm saline group, a thermos flask, which was filled with heated sterile water, was used. A 1000 ml bottle of sterile water was heated to 60 ˚C in a stove for an hour at minimum. Just before introducing into the abdominal cavity, the laparoscope was placed into the thermos flask for 30 seconds at minimum . After each incidence of laparoscopic lens fogging (LLF), the scope was briefly inserted into the thermos flask about 10 seconds, and was then wrapped gauze around the lens before abdominal reinsertion.
61998070|NCT03438890|EXPERIMENTAL|anti-fog agent group|In the anti-fog agent group, Ultra-Stop TM (Sigmaphrarm, Vienna, Austria), which is a commercial anti-fogging solution containing alcohol, surfactant, and water for medical optical devices, was used. Wiping the lens with gauze soaked in Ultra-Stop TM and allowing the surfactant to act for 5 seconds, the laparoscope was introduced into the abdominal cavity. After each laparoscopic lens fogging (LLF), the scope was removed from the abdomen and cleaned using the same corresponding method.
61998071|NCT03438890|EXPERIMENTAL|chlorhexidine group|In the chlorhexidine group, the lens was wiped with gauze soaked in 4% chlorhexidine detergent solution (Firson, Cheonan, Korea) for 5 seconds before introducing into the abdominal cavity, and chlorhexidine was reapplied on the lens at the occurrence of laparoscopic lens fogging (LLF).
61998072|NCT03438890|NO_INTERVENTION|control group|In the control group, the lens was not wiped gauze or applied any solution before use of the laparoscope. When occurred the event of each laparoscopic lens fogging (LLF) that splatter of irrigation fluid, blood, and body fluids affected visual clearance, the laparoscopic lens was manually rubbed with clean gauze by a scrub nurse.
61998073|NCT04642729|OTHER|ReLex Smile surgery|The myopic lenticule after Relex Smile surgery is put into BBS solution for 10 min. Under topical anesthesia, Using VisuMax Femtosecond Laser.
62183625|NCT05559983|EXPERIMENTAL|OSP:rTTHc Cholera Conjugate Vaccine|2 doses @0.5 mL of test vaccine administered intramuscularly in deltoid region at 4 weeks apart
62183626|NCT05559983|EXPERIMENTAL|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant|2 doses @0.5 mL of test vaccine administered intramuscularly in deltoid region at 4 weeks apart
62183627|NCT05559983|PLACEBO_COMPARATOR|Placebo|2 doses @0.5 mL of Sterile 0.9% sodium chloride administered intramuscularly in deltoid region at 4 weeks apart
62773864|NCT02472236|EXPERIMENTAL|Digoxin and PEX168(200µg)|Digoxin: 0.5mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
62183628|NCT04442347|EXPERIMENTAL|ARCT-810|Ascending single doses of ARCT-810 administered intravenously
62183629|NCT04442347|PLACEBO_COMPARATOR|Placebo|Single doses of 0.9% Saline administered intravenously
62183630|NCT00841230|PLACEBO_COMPARATOR|Lactose placebo|1x/day
62183631|NCT00841230|EXPERIMENTAL|Deanxit|
62183632|NCT02438371|ACTIVE_COMPARATOR|Nifedipine|Participants will receive nifedipine 10 mg orally every 20 minutes for 3 doses, then nifedipine 10 mg every 6 hours for a total of 48 hours.
62568253|NCT04350125|EXPERIMENTAL|Platelet Rich Plasma Treatment|Male subjects diagnosed with Erectile Dysfunction (ED) will receive platelet rich plasma injections.
62773865|NCT06416254|ACTIVE_COMPARATOR|Fibre-enriched|During the fibre-enriched arm, participants will receive the fibre-rich diet containing fibre-enriched foods provided through a full meal plan to be consumed throughout the day.
62773866|NCT06416254|PLACEBO_COMPARATOR|Control|During the control arm, participants will receive a non-fibre enriched diet consisting of matched control foods provided through a full meal plan otherwise identical to the fibre-enriched arm.
62183633|NCT02438371|ACTIVE_COMPARATOR|Nifedipine plus Indomethacin|Participants will receive will receive nifedipine 10 mg orally every 20 minutes for 3 doses, then nifedipine 10 mg every 6 hours for a total of 48 hours, as well as indomethacin 100 mg orally, then indomethacin 50 mg orally every 6 hours for a total of 48 hours.
62183634|NCT05680324|ACTIVE_COMPARATOR|Abdominoplasty with Monsplasty|
62183635|NCT05680324|ACTIVE_COMPARATOR|Abdominoplasty without monsplasty|
62183636|NCT04724096||Non-patient volunteers|5 non-patient volunteers for testing of protocol to allow for the ascertaining of good quality data prior to the scanning of patients.
62183637|NCT04724096||Patients|50 patients to be scanned with the oxygen enhanced MRI scan protocol prior to definitive curative intent therapy.
62183638|NCT04482192|ACTIVE_COMPARATOR|Thoracic paravertebral block group|Continuous thoracic paravertebral block with 1% lidocaine infusion for 3 postoperative days through a paravertebral catheter inserted intraoperatively by the surgeon.
62183639|NCT04482192|ACTIVE_COMPARATOR|Systemic analgesia group|patients in this group will receive paracetamol and ketorolac by intravenous infusion every 6 hours for 3 postoperative days
62183640|NCT02468908|EXPERIMENTAL|Molgramostim nebuliser solution, inhaled|Single dose 150, 300 and 600 ug, multiple dose 300 and 600 ug for 6 days
62183641|NCT02468908|PLACEBO_COMPARATOR|Nebuliser solution, inhaled|Inhaled nebuliser solution
62183642|NCT06360705|EXPERIMENTAL|Exploratory Open Label|Experimental: StrataMGT
62183643|NCT03181919|EXPERIMENTAL|Step Up group|includes females taking Letrozole 5 mg tablets in a step-up protocol 5 mg in day one, 7.5 in day 2, 10 mg in days 3, 12.5 mg in day 4 and 15 in day 5 started in day 3 to day 7 of menstrual cycle.
62183644|NCT03181919|NO_INTERVENTION|Control group|includes females taking Letrozole 5 mg tab orally once daily started in day 3 to day 7 of menstrual cycle.
62183645|NCT00103532|EXPERIMENTAL|Healthy Choices - Motivational Enhancement Intervention|Motivational enhancement intervention
62183646|NCT00103532|ACTIVE_COMPARATOR|Standard Care|Standard care/individualized referrals
62773867|NCT04113551||Cohort T1: Methylphenidate (MPH) (Concerta)|Analysis of data will be performed for participants who have had first exposure of MPH (Concerta) and who were never exposed to MPH (Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
62773868|NCT04113551||Cohort T2: MPH (Ritalin)|Analysis of data will be performed for participants who have had first exposure of MPH (Ritalin) and who were never exposed to MPH (Concerta) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
62773869|NCT04113551||Cohort T3: MPH (Concerta and Ritalin)|Analysis of data will be performed for participants who have had exposure to Concerta and Ritalin during the time in the cohort between 1 January 2013 and 30 September 2018 and has continuous observation of at least 30 days prior to the exposures.
62183647|NCT05142839|EXPERIMENTAL|EUS-CD|EUS-guided choledochoduodenostomy
61998074|NCT04642729|OTHER|fresh corneal lenticule implantation|Using VisuMax Femtosecond Laser we make intrastromal pocket incision 2-3 mm in periphery of cornea (Because the macular dystrophy is in the center more progressive) and 150 µm deep to put fresh corneal lenticule. After one month using VisuMax we create a flap using autologous serum with purpose to remove more dead keratocytes and adding live keratocytes with aim to regenerate the metabolism of cornea.
61998075|NCT00489853|EXPERIMENTAL|Symbicort then Formoterol then Placebo|Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
62773870|NCT04113551||Cohort T4: Atomoxetine (ATO)|Analysis of data will be performed for participants who have had first exposure of ATO between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
61998076|NCT00489853|EXPERIMENTAL|Formoterol then Symbicort then Placebo|Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
62183648|NCT05142839|EXPERIMENTAL|EUS-GEA|EUS-guided gastroenterostomy
62183649|NCT01947517||Parasol Punctal Occluder Group|Randomized to receive Brand A punctal plugs
62183650|NCT01947517||Superflex Punctal Occluder Group|Randomized to receive Group B punctal plugs
62392370|NCT04901702|ACTIVE_COMPARATOR|(Arm A) ONI plus TAL|The phase I/II study will evaluate a treatment regimen; nanoliposomal irinotecan (nal-IRN, Onivyde) plus talazoparib (TAL)
61998077|NCT00489853|PLACEBO_COMPARATOR|Placebo then Formoterol then Symbicort|Placebo, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily
61998078|NCT01453842|EXPERIMENTAL|Diet oil|
61998079|NCT01453842|ACTIVE_COMPARATOR|Olive oil|
61998080|NCT01453842|PLACEBO_COMPARATOR|Carrot|
61998081|NCT02150655|EXPERIMENTAL|Probiotic|Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 oral capsules
61998082|NCT02150655|PLACEBO_COMPARATOR|Placebo|Sugar pill
61998083|NCT02102633|EXPERIMENTAL|Dabigatran|Dabigatran 150 mg orally
61998084|NCT02102633|EXPERIMENTAL|Dabigatran + Bosutinib|Dabigatran 150 mg co-administered with Bosutinib 500 mg orally
61998085|NCT02265978|EXPERIMENTAL|CopeSmart|
62568254|NCT03584334|OTHER|18FDG PET|Diagnostic performance of 18FDG PET for identification of early tumor escape to immunotherapy in patients with unresectable melanoma or Broncho-Pulmonary Carcinoma No to Advanced or Metastatic Small Cells
61998086|NCT02265978|NO_INTERVENTION|Control|
61998087|NCT04518007|ACTIVE_COMPARATOR|hyperbaric oxygen therapy (HBOT) active treatment|The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes, of 100% oxygen at 2 ATA and 5-minute air breaks every 20 minutes.
61998088|NCT04518007|SHAM_COMPARATOR|hyperbaric oxygen therapy (HBOT) sham treatment|All the conditions provided in the HBOT intervention will be provided in the sham intervention. However, in contrast to the HBOT, where the pressure will go up to 2 ATA, in the sham condition the pressure will go up to 1.1 ATA during the first five minutes of the session with noise of circulating air, and then decrease slowly during the next half hour to 1.0 ATA and the oxygen level will be 21% The initial 1.1 ATA level will provide a minimal pressure sensation in the ears, with the same nurse advice on pumping the ears. In the last five minutes of the session, the air will be circulated again with its related noises. Sham and HBOT sessions will never be adjacent, so subjects from the two groups cannot meet and discuss the session and its effects.
62568255|NCT04740710|ACTIVE_COMPARATOR|Standard Breathing and Attention Training|The standard breathing and attention training (BAT) includes guided instructions on deep breathing and relaxation. Participants will practice standard BAT once a day for 15 minutes for 5 days in a row.
61998089|NCT05766306|EXPERIMENTAL|Probiotic|Participants will be randomized to receive the probiotic blend for 56 days.
61998090|NCT05766306|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive the placebo for 56 days
61998091|NCT03499392|OTHER|psychological investigation|
61998092|NCT01070316|EXPERIMENTAL|Everolimus|Subjects will be administered study drug if they meet study criteria after 4 weeks of baseline phase. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily.
61998093|NCT01418209|ACTIVE_COMPARATOR|Low-dose 17-ß-estradiol with progesterone taper|
61998094|NCT01418209|ACTIVE_COMPARATOR|Venlafaxine XR|
61998095|NCT01418209|PLACEBO_COMPARATOR|Placebo|
61998096|NCT03950284|EXPERIMENTAL|immediate loading with all on four technique in FFF|immediately loaded dental implants with the all-on-four technique in free vascularized fibular grafts
62183651|NCT03626077|ACTIVE_COMPARATOR|group A|Group (A) physical therapy program for 60 minutes per session, three times a week for three consecutive months
61998097|NCT01090726|EXPERIMENTAL|Storz videolaryngoscope|Macintosh overview followed by Airtraq overview followed by Storz videolaryngoscope overview and intubation.
61998098|NCT01090726|ACTIVE_COMPARATOR|Airtraq|Macintosh overview followed by Storz videolaryngoscope overview followed by Airtraq overview and intubation.
61998099|NCT02694419||obese/PCO|Women with PCOS who are overweight\\obese with BMI ≥ 25 kg/m2.
61998100|NCT02694419||normal weight/PCO|Women with PCOS who are normal weight with BMI \< 25 kg/m2.
61998101|NCT02694419||Obese/fertile|Fertile regularly menstruating women with at least one previous spontaneous pregnancy who are overweight\\obese with BMI ≥ 25 kg/m2.
61998102|NCT02694419||normal weight/fertile|Fertile regularly menstruating women with at least one previous spontaneous pregnancy who are normal weight with BMI \< 25 kg/m2.
61998103|NCT04977258|ACTIVE_COMPARATOR|Control group|Only treadmill aerobic exercise with 60 min recovery in supine position.
61998104|NCT04977258|EXPERIMENTAL|Controlled hydration group|Treadmill aerobic exercise with 60 min recovery in supine position, with mineral water predetermined intake.
61998105|NCT04977258|EXPERIMENTAL|Ad Libitum hydration group|Treadmill aerobic exercise with 60 min recovery in supine position, with mineral water intake in an uncontrolled manner.
61998106|NCT03019692||enrolled babies with neonatal intracranial bleed|all babies who suffered from intra cranial or intraventricular bleed during neonatal period
61998107|NCT05888168||POAF|This group will consist of patients who have developed postoperative atrillary fibrillation (POAF) after undergoing coronary artery bypass grafting (CABG).
61998108|NCT05888168||Non-POAF|This group will consist of patients who have not developed postoperative atrillary fibrillation (POAF) after undergoing coronary artery bypass grafting (CABG).
62183652|NCT03626077|ACTIVE_COMPARATOR|group B|Group (B) E-Link Upper Limb Exerciser (augmented biofeedback training)for 60 minutes per session, three times a week for three consecutive months
62568256|NCT04740710|EXPERIMENTAL|Focused Breathing and Attention Training|The focused BAT is similar to the standard BAT in most ways but includes extra instructions to help focus and alter breathing patterns. Participants will practice focused BAT once a day for 15 minutes for 5 days in a row.
61998109|NCT04818359|EXPERIMENTAL|Interventional Arm|Supervised exercise program: MoviS Training. Lifestyle (nutrition and exercise) counseling based on WCRF 2018 recommendations; psychological well-being counseling which comprises evaluation for anxiety and depression.
61998110|NCT04818359|NO_INTERVENTION|Control Arm|Lifestyle (nutrition and exercise) counseling based on WCRF 2018 recommendations; psychological well-being counseling which comprises evaluation for anxiety and depression.
61998111|NCT02811939|EXPERIMENTAL|Active THC and Placebo Pregnenolone|
61998112|NCT02811939|EXPERIMENTAL|Active THC and Active Pregnenolone|
61998113|NCT02811939|EXPERIMENTAL|Placebo THC and Active Pregnenolone|
61998114|NCT02811939|PLACEBO_COMPARATOR|Placebo THC and Placebo Pregnenolone|
61998115|NCT01421784|OTHER|Cine-MRI|Rapid Cine-MRI
61998116|NCT02752191|ACTIVE_COMPARATOR|Ferumoxytol|Ferumoxytol, 4mg/kg of body weight, one time infusion of several minutes
61998117|NCT02752191|ACTIVE_COMPARATOR|gadofosveset|gadofosveset, 0.03mmol/kg, one time bolus injection
61998118|NCT03002051|EXPERIMENTAL|EUS guided drainage|Patients suffering from the conditions in focus would receive EUS guided drainage with the lumen apposing stent
61998119|NCT01443247|EXPERIMENTAL|platelet support + anti-d|
61998120|NCT01443247|NO_INTERVENTION|platelet support|
61998121|NCT04054687|EXPERIMENTAL|TXA|Research participants in the experimental group will receive one dose of 100mg/mL TXA soaked in a cotton pledget in the bleeding nare for a total of 15 minutes.
61998122|NCT04054687|PLACEBO_COMPARATOR|Saline|Research participants in the placebo group will receive one dose of normal saline (0.9%) soaked in a cotton pledget in the bleeding nare for a total of 15 minutes.
61998123|NCT03464864|EXPERIMENTAL|Treprostinil Inhalation Powder 30 mcg|
61998124|NCT03464864|EXPERIMENTAL|Treprostinil Inhalation Powder 60 mcg|
61998125|NCT03464864|EXPERIMENTAL|Treprostinil Inhalation Powder 90 mcg|
61998126|NCT03464864|EXPERIMENTAL|Treprostinil Inhalation Powder 120 mcg|
61998127|NCT03464864|EXPERIMENTAL|Treprostinil Inhalation Powder 150 mcg|
61998128|NCT03464864|EXPERIMENTAL|Treprostinil Inhalation Powder 180 mcg|
62735111|NCT01720589|ACTIVE_COMPARATOR|Corn oil (control)|Participants will consume a muffin containing 20 g of dietary fat provided by the control oil and their energy expenditure will be measure post-prandially for 6 hours. At the end of the measurement period, participants will consume a cookie containing 10 g of fat provided by the control oil and their food intake at an ad libitum meal will be measured 1 hour later.
61998129|NCT03464864|EXPERIMENTAL|Treprostinil Inhalation Powder 240 mcg|
61998130|NCT03464864|EXPERIMENTAL|Treprostinil Inhalation Powder 300 mcg|
61998131|NCT04211337|EXPERIMENTAL|Selpercatinib - Treatment A (TRT A)|"160 milligrams Selpercatinib administered orally (PO) twice daily (BID).~Adolescent Dose: 92 milligrams per square meter (mg/m2) BID (not to exceed 160 mg BID)."
61998132|NCT04211337|ACTIVE_COMPARATOR|Cabozantinib or Vandetanib - Treatment B (TRT B)|"140 mg Cabozantinib administered orally daily (QD) or 300 mg Vandetanib administered orally QD per physician choice.~Cabozantinib Adolescent Dose: 40 mg/m2.~Vandetanib Adolescent Dose:~* 0.7 - \<0.9 - 100 mg every other day (QOD)~* 0.9 - \<1.2 - 100 mg QD~* 1.2 - \<1.6 - 7-day schedule 100 mg - 200 mg - 100 mg - 200 mg - 100 mg - 200 mg - 100 mg~* ≥1.6 - 200 QD"
61998133|NCT04139928|EXPERIMENTAL|Picometer-ionic form of magnesium chloride|
61998134|NCT04139928|ACTIVE_COMPARATOR|Magnesium citrate or magnesium oxide|
61998135|NCT04139928|PLACEBO_COMPARATOR|Placebo|
62183653|NCT03626077|EXPERIMENTAL|group C|group (C) physical therapy program and E-Link Upper Limb Exerciser
61998136|NCT02821962|EXPERIMENTAL|Sedentary prompts (VTAP)|Participants will complete supervised exercise sessions as part of cardiac rehabilitation programming on-site twice weekly for a total of 8 weeks. Participants will also be provided with a VTAP (activPAL3 VT) monitor to wear during waking hours for weeks 1 through 7 of cardiac rehabilitation. The VTAP will alert participants when they have been sedentary for 30 consecutive minutes.
61998137|NCT02821962|NO_INTERVENTION|Usual care|Participants will complete supervised exercise sessions as part of cardiac rehabilitation programming on-site twice weekly for a total of 8 weeks.
61998138|NCT00545857|EXPERIMENTAL|Pioglitazone|
61998139|NCT00545857|PLACEBO_COMPARATOR|Placebo control|
61998140|NCT04950777|NO_INTERVENTION|standard of care|
61998141|NCT04950777|EXPERIMENTAL|patient education|The intervention group will receive the patient education document with their questionnaire, randomization will occur by the study team prior to subject visits. The patient education will be designed to address and investigate the four domains of physical literacy including, knowledge and understanding, motivation and confidence, daily behavior, and physical competence, (i.e., referral based training/PT (passive), self-motivated/directed exercise choice (speaks to child ownership/motivation), simple play outside 60 minutes/day (middle)).
61998142|NCT04842539|EXPERIMENTAL|FMT Arm|FMT Arm:30 grams stool homogenized with 100 mL normal saline and filtered administered a single time via nasojejunal tube.
61998143|NCT04842539|OTHER|Standard of care (SOC) Arm|Standard of care treatment with nutritional supplementation and other supportive care
61998144|NCT01625975||Growth modulation with Eight plate|Pediatric patients undergoing growth modulation with the Eight plate system
62183654|NCT01305473||Sepramesh Group|
61998145|NCT04965194|EXPERIMENTAL|Erector spinae plane block (ESPB)|20 ml of 0.25% bupivacaine will be administered to perform ESP block on each side
62773871|NCT04113551||Cohort T5: Guanfacine (GFC)|Analysis of data will be performed for participants who have had first exposure of GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
62773872|NCT04113551||Cohort T6: MPH (Concerta and Ritalin), ATO, or GFC|Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin), ATO, or GFC first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.
61998146|NCT04965194|EXPERIMENTAL|Quadratus lumborum plane block (QLPB)|The injectate (20ml of bupivacaine 0.25%) should ideally spread from the injection site inside the fascial plane between the QL and psoas major muscles to the thoracic paravertebral space with a goal to accomplish segmental somatic and visceral analgesia from T4 to L1.
61998147|NCT04965194|PLACEBO_COMPARATOR|Control group|patients received no regional block
62183655|NCT01888627|EXPERIMENTAL|Integrated care|The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
62773873|NCT04113551||Cohort T7: MPH (Concerta or Ritalin)|Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin) first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior. These are the first exposure to any MPH among the participants with who had some exposure to MPH.
62773874|NCT04113551||Cohort T8: MPH (Concerta) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta) and were never exposed to MPH (Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
62183656|NCT03855176|ACTIVE_COMPARATOR|1-dose group|Provide 1 booster dose of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.
62183657|NCT03855176|EXPERIMENTAL|2-dose group|Provide 2 booster doses of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.
61998148|NCT04595864|EXPERIMENTAL|treatment group|Transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
61998149|NCT04595864|NO_INTERVENTION|control group|no neo-adjuvant treatment before operation
61998150|NCT02327923|ACTIVE_COMPARATOR|Lidocaine|Intravenous bolus administration of lidocaine at the time of induction followed by infusion till the last suture.
61998151|NCT02327923|ACTIVE_COMPARATOR|Esmolol|Intravenous bolus administration of esmolol at the time of induction followed by infusion till the last suture.
61998152|NCT02279186|ACTIVE_COMPARATOR|group A|receiving tranexamic acid
62183658|NCT02716298|ACTIVE_COMPARATOR|fanfilcon A|Study participants are randomized to wear fanfilcon A lens during the crossover study
62183659|NCT02716298|ACTIVE_COMPARATOR|lotrafilcon B|Study participants are randomized to wear lotrafilcon B lens during the crossover study.
62392371|NCT04901702|ACTIVE_COMPARATOR|(Arm B) ONI plus TMZ|The phase I/II study will evaluate a treatment regimen; Onivyde (ONI) plus temozolomide (TMZ)
62773875|NCT04113551||Cohort T9: MPH (Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Ritalin) and were never exposed to MPH (Concerta) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
62773876|NCT04113551||Cohort T10: ATO All Exposures|Analysis of data will be performed for participants who have had all exposures of ATO between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
62773877|NCT04113551||Cohort T11: GFC All Exposures|Analysis of data will be performed for participants who have had all exposures of GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
62568257|NCT03174535||Exposure group|The exposure group was the patients who were treated with Qilong capsules (QLC). The willingness of the patients and the objective judgment of the clinician were comprehensively considered to decide whether to use QLC for intervention. Patients who chose to use QLC for intervention would take it immediately after being deemed eligible for enrollment. The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks. QLC was produced by Jining Huaneng Pharmaceutical Factory Co., Ltd. All participants in the exposure groups received the standard level of CT provided by clinicians according to the clinical diagnosis and treatment guidelines for IS, including antiplatelet aggregation drugs, antihypertensive drugs, hypoglycemic drugs, and lipid-lowering drugs.
62183660|NCT05397210||Infinity-Lock™ Button System|Participants diagnosed with acute or chronic Grade Ill-VI ACJ dislocation who require treatment with an Infinity-Lock Button System who meet the inclusion criteria and none of the exclusion criteria.
62183661|NCT00607061|OTHER|1|Full term newborn babies with gestational age \> 37 weeks of amenorrhea and weight of birth \> tenth percentile.
62183662|NCT00607061|OTHER|2|Low birth weight newborn babies (gestational age \< 32 weeks of amenorrhea and/or weight of birth \< 1500 g and/or weight of birth \< third percentile for their gestational age.
61998153|NCT02279186|NO_INTERVENTION|group B|does not receive tranexamic acid
61998154|NCT03718611|EXPERIMENTAL|Sequence 1|BR900A - Wash out - BR9001
61998155|NCT03718611|EXPERIMENTAL|Sequence 2|BR9001 - Wash out - BR900A
62183663|NCT00607061|OTHER|3|Full term newborn babies (gestational age \> 37 weeks of amenorrhea and weight of birth \> tenth percentile).
62183664|NCT03900429|PLACEBO_COMPARATOR|Matching Placebo|Placebo Daily
62183665|NCT03900429|ACTIVE_COMPARATOR|80 mg MGL-3196|80 mg daily
62392372|NCT04501991||Patients with Type 2 Diabetes|Patients with type 2 diabetes and a scheduled visit during the lockdown for COVID-19
62392373|NCT00081900|EXPERIMENTAL|DENSPM|
62392374|NCT03190304|ACTIVE_COMPARATOR|Enalapril|Enalapril at a dose of 10 mg twice daily for 6 months
62392375|NCT03190304|EXPERIMENTAL|Neprilysin (LCZ696)|LCZ696 at a dose of 200 mg twice daily for 6 months
62392376|NCT01821001|EXPERIMENTAL|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
62392377|NCT02769988||Project SHARE|
62392378|NCT03017131|EXPERIMENTAL|Treatment (decitabine, genetically modified T cells)|COURSE 1: Patients receive decitabine IV daily over 1 hour on days -8 to -6, cyclophosphamide IV over 2 hours on days -4 and -3, and genetically engineered NY-ESO-1-specific T lymphocytes IV and IP on day 0. Patients also receive aldesleukin SC BID on days 1-14..
62392379|NCT03941652||Women with gestational diabetes without a prior GDM|The investigators will evaluate the usability of the sensors and define what features the application should have and how the data should be presented to the users. Participants (n=up to 10) use the sensors for one week and fill out logbooks for physical activity, sleep and diet. Participants fill questionnaires before and after the usage period, and take part in semi-structured interview.
62392380|NCT03941652||Women with gestational diabetes with or without a prior GDM|The investigators define major usability issues with different versions of functional prototypes of eMOM GDM application developed in the project before moving to phase 2 of the study. GDM women (n=up to 12) will use the available version of the application for one week, and afterward the participants with GDM will take part in semi-structured interview.
62392381|NCT03941652||General pregnant women|The investigators will define major usability issues with different versions of functional prototypes of eMOM GDM application developed in the project before moving to phase 2 of the study. General pregnant women (n=up to 30) will use the available version of the application for one week, and afterward the general pregnant women will fill out a web form of usability of the application after the application week.
62392382|NCT03941652||Health care professionals|Nurses/midwifes (n=up to 15) will be interviewed for collecting user requirements for the professional eMOM GDM application in semi-structured interviews. Also the usability of the user interface prototypes will be evaluated using cognitive walkthrough.
62392383|NCT04570124|EXPERIMENTAL|Remote Surveillance|Women will use the home blood pressure monitoring device to record their blood pressure everyday for the first postpartum week, and then weekly until postpartum week 6.
62392384|NCT03143465|EXPERIMENTAL|CGRP|
62392385|NCT03143465|EXPERIMENTAL|Sildenafil|
62392386|NCT03143465|PLACEBO_COMPARATOR|Placebo|
62392387|NCT01096758||PKU patients|
62392388|NCT01096758||healthy controls|
62392389|NCT04545645|ACTIVE_COMPARATOR|Neural Stress Provoked by the Median Nerve|
61998156|NCT04982666|EXPERIMENTAL|Whole-Food, Plant-Based Diet Group|Subjects with a known diagnosis of Crohn's disease will follow a whole-food, plant-based diet for a total of 12 weeks
61998157|NCT04982666|ACTIVE_COMPARATOR|FODMAP Diet|Subjects with a known diagnosis of Crohn's disease will follow a FODMAP diet for a total of 12 weeks
61998158|NCT02082210|EXPERIMENTAL|Emibetuzumab + Ramucirumab (Part A)|Part A: Dose escalation (750mg, 2000mg) of Emibetuzumab administered intravenously (IV), on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
61998159|NCT02082210|EXPERIMENTAL|Emibetuzumab + Ramucirumab (Part B)|Part B: Recommended 750mg Emibetuzumab dose from Part A to be administered IV, on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
61998160|NCT01268384|EXPERIMENTAL|FDR_GX|Fixed dose rate gemcitabine plus capecitabine every 3 weeks for 3-9 cycles
61998161|NCT05747144||Macular hole|Patients affected by macular hole.
61998162|NCT05747144||Epiretinal membranes|Patients affected by epiretinal membrane.
61998163|NCT05747144||Retinal detachment|Patients affected by retinal detachment.
62183666|NCT03900429|ACTIVE_COMPARATOR|100 mg MGL-3196|100 mg daily
62183667|NCT02575950|EXPERIMENTAL|LEO43204 0,018%|Experimental drug
62183668|NCT02575950|PLACEBO_COMPARATOR|Vehicle|Placebo
62183669|NCT06009172|EXPERIMENTAL|APA group|
62183670|NCT06009172|NO_INTERVENTION|Control group|
62183671|NCT02541942|OTHER|Collection of specimen|
62392390|NCT04545645|EXPERIMENTAL|Neural stress provocation with cognitive auditory distraction|
62392391|NCT04545645|EXPERIMENTAL|Providing neural stress with a motor distraction|
62183672|NCT04137718||Rare driver gene mutation-positive|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a rare driver gene mutation positive.
62392392|NCT04545645|EXPERIMENTAL|Neural stress provocation with both distractions|
62392393|NCT00002624|EXPERIMENTAL|Radiotherapy + surgery|"Patients begin radiotherapy 2-8 weeks postoperatively. Patients with complete resection undergo radiotherapy 5 days a week for 5.6 weeks. Patients with incomplete resection undergo radiotherapy 5 days a week for 6.6 weeks.~Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter."
62392394|NCT05000034|EXPERIMENTAL|Patients|
62392395|NCT02395445|ACTIVE_COMPARATOR|Totaltrack|Indirect laryngoscopy
62392396|NCT02395445|ACTIVE_COMPARATOR|Macintosh Laryngoscope|Direct laryngoscopy
62568258|NCT03174535||Non-exposure group|The non-exposure group was the patients who did not take QLC. All participants in the non-exposure groups received the standard level of CT provided by clinicians according to the clinical diagnosis and treatment guidelines for IS, including antiplatelet aggregation drugs, antihypertensive drugs, hypoglycemic drugs, and lipid-lowering drugs.
62568259|NCT06536387|EXPERIMENTAL|Storytelling Through Music|Storytelling Through Music is a six-week intervention that utilizes storytelling, reflective writing, self-care skills, and song-writing. The intervention will be administered in small groups of 4-6 participants/group and with a hybrid approach. The writing workshops will occur online, and the share circle (stories and songs shared with the group) will occur in person. The group sizes will be kept small to ensure that each participant has adequate time to share their writing during the group sessions.
62392397|NCT02119559|OTHER|CTC assay, Cetuximab|Detection \& characterization of viable CTC in the peripheral blood.
62392398|NCT05370300||Controls: Patients with negative screening MMG|Patients presenting to Duke Radiology for routine screening mammogram will be screened for eligibility as negative controls. Study enrollment for negative controls presumes that patients do not receive their screening mammography results immediately. Patients will be approached on the day of their first new patient visit to the Duke Cancer Center. If they are willing, they will be consented in clinic, and directed down to the lab for their first blood draw.
62392399|NCT05370300||Cases: Patients with known cancer diagnosis|Patients presenting to the Duke Cancer Center for evaluation by Medical or Surgical Oncology of a newly diagnosed breast cancer will be screened for study eligibility and approached, enrolled, and consented accordingly. Patients will be approached on the day of their first new patient visit to the Duke Cancer Center. If they are willing, they will be consented in clinic, and directed down to the lab for their first blood draw.
62734575|NCT04347512|EXPERIMENTAL|Hydroxychloroquine and Azithromycin|"Hydroxychloroquine is given for 5 days, with a loading dose of 400 mg qd at D1, and 200 mg qd for the next 4 days (D2-D5).~Azithromycin is given for 5 days, with a loading dose of 500 mg at D1, and 250 mg for the next 4 days.~Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc) In case of moderate renal failure (glomerular filtration rate between 30 and 60 mL/min/m²), hydroxychloroquine dosage are lowered by half."
62734576|NCT00861172|EXPERIMENTAL|1|
62392400|NCT03808194|ACTIVE_COMPARATOR|Optimized ART linkage package|Participants in this arm will receive a clinic referral card and text messages to support linkage to ART.
62392401|NCT03808194|EXPERIMENTAL|Conditional lottery incentive|Participants in this arm will receive a clinic referral card and text messages to support linkage to ART and will be entered into a lottery each time they meet the following conditions: visited the clinic by month 1, initiated treatment by month 3, and achieved viral suppression by month 6
61998164|NCT05747144||Macular dystrophies|Patients affected by macular dystrophies.
61998165|NCT00649337|EXPERIMENTAL|1|Adjunct screening with sonocine
62183673|NCT04137718||Rare driver gene mutation-negative|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction(PCR)panel kit in the hospital requires the use of tissue samples and the results show a rare driver gene mutation negative.
62392402|NCT04946916|EXPERIMENTAL|Participant with psychiatric condition without cognitive impairment|In the psychiatric condition group without cognitive impairment will be included participants with schizophrenia or bipolar disorder according to DSM V criteria.
62773878|NCT04113551||Cohort T12:MPH(Concerta and Ritalin),ATO,orGFC All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin), ATO, or GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.
62773879|NCT04113551||Cohort T13: MPH (Concerta or Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta or Ritalin).
62392403|NCT04946916|EXPERIMENTAL|Participant with psychiatric condition with cognitive impairment|In the psychiatric condition group with cognitive impairment will be included participants with schizophrenia or bipolar disorder according to DSM V criteria. To date, there are no clinical criteria for defining the dementia evolution of psychiatric disorders. The diagnosis of psychiatric disorder with cognitive involution is often made on the basis of subjective criteria or on the appreciation of health care teams. In the present study, cognitive involution will be defined by the occurrence of cognitive deterioration objectified by disturbed neuropsychological tests and the occurrence of progressive behavioral changes contrasting with the person's previous state and reported by the care team, a member of the family or by the patient himself. Cognitive involution must be accompanied by a decrease in autonomy with respect to the person's previous abilities.
62392404|NCT04946916|EXPERIMENTAL|Patients with biological Alzheimer's disease|Alzheimer's disease with frontal, amnestic, language, and visual presentation with typical Alzheimer CSF according to the 2011 NIA-AA diagnostic criteria.
62392405|NCT04946916|EXPERIMENTAL|Patient with fronto-temporal dementia|Probable or definite Fronto-temporal dementia, mostly behavioral variant of FTD (according to the diagnostic criteria for FTDb of Rascovsky, 2011) but Semantic Disease, Primary Progressive Non-Fluent Aphasia, Progressive Supra-Nuclear Palsy-DFT will be accepted if behavioral onset.
62392406|NCT04247802|EXPERIMENTAL|Backwards Walking (BW) programme|This group will undertake a routine course of one to one out-patient physiotherapy which will include a BW programme. The BW programme will be prescribed by a physiotherapist and the participant will carry it out, along with other prescribed exercises, in their own home. Each participant will initially be prescribed a 5 minute BW programme to be completed once a day. The length of the BW programme and intensity will be progressed or regressed as deemed appropriate by the treating clinician with the aim for patients to achieve at least 10 minutes of BW every day of the week.
62392407|NCT04247802|ACTIVE_COMPARATOR|Usual Care|This group will undertake a routine course of one to one out-patient physiotherapy over 12 weeks. To allow comparison between the two groups the control group will also have up to four review appointments where their home exercise programme can be progressed or regressed. The physiotherapy treatments will be not be restricted (apart from no BW programme) to allow for a pragmatic approach based on the treating clinician's clinical judgement, however their content will be recorded on treatment logs.
62392408|NCT01134458|NO_INTERVENTION|Control|Receive primary care and management of CVD according to the discretion of their primary care provider. They will also receive generic educational information concerning CVD at baseline and at study end (at their request). We will collect outcomes at baseline and 3-months.
62392409|NCT01134458|EXPERIMENTAL|Web-based Intervention|Given current risk assessment for CVD based on Health Dialog Cardiac Risk Calculator, recommendations for behavior change, and Health Dialog's Living with Coronary Heart Disease. Can change initial patient risk information provided by the Risk Calculator during the initial visit, noting what they are will work on during the study. Sent monthly email reminders to log onto the system to choose that months' behavioral modules. Given a choice of at least 2 health behavior modules per month (smoking cessation, exercise, diet, and weight) to improve their CVD risk. Information on risk, CVD knowledge, medication management and side effects will be provided to all participants. It will also provide tailored information to help the individual initiate and maintain these behaviors.
62392410|NCT03803956|ACTIVE_COMPARATOR|Active PBMT|Application of PBMT (Photobiomodulation Therapy) with a total dose of 850 Joules.
62392411|NCT03803956|PLACEBO_COMPARATOR|Placebo PBMT|Application of placebo PBMT (Photobiomodulation Therapy) without any dose (0 Joule).
62568260|NCT03466684|EXPERIMENTAL|BIA-directed fluid resuscitation|After the achievement of CVP, MAP and ScvO2 goals, if hyperhydration (HL \> 74.3%) was found, then the following fluid management was applied with each passing 6h. If HL was above 87% (severe level), fluid infusion was restricted, a furosemide drip was used, and CRRT was initiated with an ultrafiltration rate when patients were failure or inadequate response to above diuretic therapy that gave a net negative fluid balance of at least 1500 ml during the next 6h. If HL was 81%-87% (moderate level), above methods were used to trigger a net negative fluid balance (about 1000 ml) for the next 6h. Similarly, If HL was 74.3%-81% (mild level), a net negative fluid balance of about 500 ml would be achieved during the next 6h of ICU hospitalization. If HL was blow 71%, a state of dehydration, CVP, MAP, and ScvO2 was maintained as above during ICU resuscitation.
62791548|NCT01756404|EXPERIMENTAL|Cohort 2|Each volunteer will receive a total daily dose of 100 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
62791549|NCT01756404|EXPERIMENTAL|Cohort 3|Each volunteer will receive a total daily dose of 300 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
62392412|NCT01769846|EXPERIMENTAL|Early Mobilization protocol|Early Mobilization protocol: Patients in the treatment group additionally received a progressive cycling exercise session 7 days a week, until the last day of ICU stay, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH \& Co. KG, Betzenweiler, Germany). Cycling exercise will be realized during 30 consecutive minutes, initially in continuos and passive (classified patients with RASS - 4) exercise, at a fixed pedaling rate of 20 cycles/min and after in actively (classified patients with RASS 0), with an exercise intensity of 3-5 on the Borg rate of perceived exertion scale.
62392413|NCT01769846|NO_INTERVENTION|Control group|Group will undergo usual mobilization per standard ICU care. Conventional physical and respiratory therapy were provided by the ICU physical therapists twice daily, for approximately 30 min, 7 days per week. The protocol included vibrocompression maneuvers; lung hyperinflation by the mechanical ventilator; and tracheal aspiration, when necessary; as well as passive and active-assisted motor exercises for arms and legs, depending on the clinical course of patients.
62392414|NCT02285699|OTHER|SSRI treatment|The intervention only applies to Phase II of the proposed study. Individuals in the OCD group will be offered 12-weeks of standard SSRI treatment ti determine whether 12-weeks of treatment results in a change of the gut microbiota/inflammatory markers.
62392415|NCT05821998|EXPERIMENTAL|Thoracic block technique and designed chest physical therapy program|Manual compression on healthy lung for 20 seconds and rest for 20 seconds, total time 20 minutes and percussion, vibration and modified postural drainage on session time for 35 minutes every day for ten days
62392416|NCT05821998|ACTIVE_COMPARATOR|Designed chest physical therapy program|Percussion, vibration and modified postural drainage for 30 minutes every day for ten days
62392417|NCT01616173|ACTIVE_COMPARATOR|Perineural Dexamethasone|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine and perineural dexamethasone 8mg/2mL, and 50mL IV normal saline infusion
62392418|NCT01616173|ACTIVE_COMPARATOR|Intravenous Dexamethasone|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine with saline and IV dexamethsone 8mg in 50mL infusion
62392419|NCT01616173|PLACEBO_COMPARATOR|No Perioperative Steroids|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine with saline and 50mL infusion
62392420|NCT03549546|OTHER|Patients undergoing lung cancer surgery|Patients undergoing lung cancer surgery will be included. Blood samples will be collected.
62410021|NCT03039686|EXPERIMENTAL|RO7239361 High Dose|Participants received high dose RO7239361 SC on specified days of the 48-week DB period. Following the DB period participants received high dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
62568261|NCT03466684|ACTIVE_COMPARATOR|Traditional fluid resuscitation|A timely restricted intravenous fluid regimen or dehydration therapy was implemented by two senior clinicians according to cumulative fluid balance recording and hemodynamic condition such as heart rate, blood pressure, central venous pressure, mean arterial pressure, urine output and body weight change.
62568262|NCT04121819|EXPERIMENTAL|AraC|cytarabine 100mg/m2 d1-5 subcutaneous
62568263|NCT04451057|EXPERIMENTAL|high flow nasal nasal cannula|Patients allocated for this arm are received high flow nasal cannula therapy after extubation.
62568264|NCT04451057|ACTIVE_COMPARATOR|low flow nasal cannula|Patients allocated for this arm are received conventional oxygen therapy after extubation.
62791550|NCT01756404|EXPERIMENTAL|Cohort 4|Each volunteer will receive a total daily dose of 600 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
62791551|NCT01756404|EXPERIMENTAL|Cohort 5|Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) twice daily (600 mg total daily dose) or placebo (inactive medication) twice daily on Days 1 through 14.
62791552|NCT00917618|ACTIVE_COMPARATOR|Exercise intervention|Patients began the exercise intervention after randomization for 12 weeks
62791553|NCT00917618|PLACEBO_COMPARATOR|Control|Patients were asked not to change their baseline exercise program
62791554|NCT03648515||Malocclusion patients|"Patients with different types of malocclusion will be included. Plaster models will be fabricated after pouring the impressions with hard gypsum.~Then, digital images of the dental arches of each patient will be taken using a dedicated camera with very high resolution. Finally, digital images of models that were poured with gypsum will be taken also with the same camera and in the same conditions."
62791555|NCT06411236||middle and old group|"A total of 15 middle-aged and elderly subjects were selected. Resting state detection: After entering the NIR assessment room, the subjects sat comfortably for 5 minutes, and then wore fNIRS headcaps. The subjects were asked to sit quietly and avoid moving and thinking for 30 seconds.~Task state detection: Subjects entered the NIR assessment room, sat comfortably for 5 minutes, and then wore fNIRS headcaps. After resting for 30 seconds, the subjects were asked to swallow, swallow saliva for 20 seconds, rest for 20 seconds, and repeat three times."
62791556|NCT06411236||young group|"A total of 15 young subjects were selected. Resting state detection: After entering the NIR assessment room, the subjects sat comfortably for 5 minutes, and then wore fNIRS headcaps. The subjects were asked to sit quietly and avoid moving and thinking for 30 seconds.~Task state detection: Subjects entered the NIR assessment room, sat comfortably for 5 minutes, and then wore fNIRS headcaps. After resting for 30 seconds, the subjects were asked to swallow, swallow saliva for 20 seconds, rest for 20 seconds, and repeat three times."
62791557|NCT06225687|EXPERIMENTAL|Heat Application|Heat will be applied to the abdominal/lumbar area for 15 minutes.
62773880|NCT04113551||Cohort T14: MPH (Concerta and Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta and Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta) during the study period and to an exposure to MPH (Ritalin) during the study period.
62568265|NCT05903469|EXPERIMENTAL|Patient with explicit suicidal ideation and suicide attempt|
62410022|NCT03039686|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo solution subcutaneously (SC) on specified days of the 48-week double-blind (DB) period. Following the DB period participants received low dose or high dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
62773881|NCT00710463||Control group|patients receive a hospital based comprehensive pulmonary rehabilitation programme, including endurance training, physiotherapy, medical therapy, and long term oxygen treatment when indicated.
62773882|NCT00710463||NIV treatment group|patients receive a hospital based comprehensive pulmonary rehabilitation programme, including endurance training, physiotherapy, medical therapy, and long term oxygen treatment when indicated, plus newly introduced nocturnal non invasive ventilation.
62791558|NCT06225687|NO_INTERVENTION|Control Group|No intervention will be made.
62183674|NCT01447199||Gene Mutation|Group with increased risk for developing colorectal and/or other cancers as the result of an inherited gene mutation, family history of cancer, or an early age of cancer onset.
62183675|NCT01447199||No Cancer History|Group with little/no personal or family history of cancer.
62183676|NCT01447199||Spouses|Spouses of those who may have an increased risk for developing colorectal and/or other cancers as the result of an inherited gene mutation, family history of cancer, or an early age of cancer onset, or little/no personal or family history of cancer.
62183677|NCT05995093||non-DIC group|
62183678|NCT05995093||pre-DIC group|
62183679|NCT05995093||overt-DIC group|
62183680|NCT05995093||DIC group|
62183681|NCT00809679|EXPERIMENTAL|T-62 100 mg bid|
62183682|NCT00809679|EXPERIMENTAL|T-62 200 mg bid|
62183683|NCT00809679|PLACEBO_COMPARATOR|Placebo|
62183684|NCT00726713|EXPERIMENTAL|1|Metanx
62183685|NCT00726713|PLACEBO_COMPARATOR|2|Placebo
62183686|NCT02080377|ACTIVE_COMPARATOR|Current Standard Care|Insulin + Metformin
62183687|NCT02080377|ACTIVE_COMPARATOR|Treatment|Glibenclamide + Metformin
62183688|NCT00350298|EXPERIMENTAL|GS-CDA1/MDX-1388|Biological: GS-CDA1/MDX-1388 One Intravenous dose
62183689|NCT00350298|PLACEBO_COMPARATOR|Placebo|Biological: normal saline (0.9% sodium chloride) One Intravenous dose
62183690|NCT01662037|EXPERIMENTAL|Bosentan group|Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
62410023|NCT03907709||First Responders in In-Home Addiction Treatment Program|- First responders (individual who does or has worked as a police officer, fire fighter, corrections officer, military police, emergency medical technician, paramedic, parole or probation officer)
62568266|NCT05903469|EXPERIMENTAL|Patient with explicit suicidal ideation without suicide attempt|
62568267|NCT05903469|ACTIVE_COMPARATOR|Patient without explicit suicidal ideation|
62568268|NCT04100980||Chronic UTI|Patients who have been diagnosed with chronic urinary tract infections (UTI).
61998166|NCT02702401|EXPERIMENTAL|Pembrolizumab+Best Supportive Care|Participants receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).
61998167|NCT02702401|PLACEBO_COMPARATOR|Placebo+Best Supportive Care|Participants receive a placebo IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC.
62183691|NCT01662037|NO_INTERVENTION|Routinely group|Routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
62183692|NCT01588366|PLACEBO_COMPARATOR|Placebo|Part A and B - Up to 4 capsules of placebo administered orally once a day for 28 days.
62183693|NCT01588366|EXPERIMENTAL|15 mg LY2409021|Part B - 1 capsule of 15 mg LY2409021 orally once a day for 28 days. (Arm added in September, 2012, per protocol amendment.)
62568269|NCT02632929||Diabetic Foot Ulcers at Amputation Risk|Patients at high risk for limb amputation from a diabetic foot ulcer will be treated with comprehensive, interdisciplinary approach (usual care) in combination with early application of advanced therapy; dehydrated human amniotic membrane allografts (AMNIOEXCEL®, Derma Science, Princeton, New Jersey).
61998168|NCT05365438|EXPERIMENTAL|Atmeg with Omethyl Cutielet|Atmeg: 2 capsules daily (1 capsule containes atorvastatin 10 mg and Omega-3 1000 mg) Omethyl Cutielet: Omega-3 2000mg (920mg as EPA ethyl ester, 760mg as DHA ethyl ester) once daily
61998169|NCT05365438|ACTIVE_COMPARATOR|Atmeg|Atmeg: 2 capsules daily (1 capsule containes atorvastatin 10 mg and Omega-3 1000 mg)
61998170|NCT05365438|ACTIVE_COMPARATOR|ezetimibe/atorvastatin 10/20|1 tablet once daily (atorvastatin 20mg with ezetimibe 10mg)
61998171|NCT02048020|EXPERIMENTAL|Treatment (paclitaxel, carboplatin, IMRT)|"INDUCTION: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~CHEMORADIOTHERAPY: At least 2 weeks after completion of induction chemotherapy, patients receive paclitaxel IV over 1 hour weekly and undergo IMRT daily 5 days a week for 5.5 weeks in the absence of disease progression or unacceptable toxicity."
61998172|NCT00554671|EXPERIMENTAL|Pharmacist-led Group Visits|Algorithm driven medication titration, Behavioral: Monitoring, Behavioral: Group support, Behavioral: Self efficacy
62183694|NCT01588366|EXPERIMENTAL|60 mg LY2409021|Part A - 4 capsules of 15 mg LY2409021 administered orally once a day for 28 days.
62183695|NCT02174614|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
62183696|NCT02174614|EXPERIMENTAL|TAU plus Rapid Abstinence Initiation (RAI)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment
62183697|NCT02174614|EXPERIMENTAL|TAU plus RAI plus Cognitive Control Training (CCT)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized games 3 times per week for the first 4 weeks.
62183698|NCT06356623||patients with PONV|
62183699|NCT06356623||patients without PONV|
62183700|NCT06478407||Diabetic retinopathy screening group|Diabetes patients in the community to accept unified eye test, confirm whether patients with diabetic retinopathy
62183701|NCT00694798|EXPERIMENTAL|Mw|All enrolled patients to receive Mycobacterium w
62183702|NCT01216059|EXPERIMENTAL|Intervention group|Subjects will receive daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study.
62183703|NCT01216059|NO_INTERVENTION|Control Group|Subjects will receive a weekly text message reminder about pop-culture, sports or weather.
62183704|NCT02924350|EXPERIMENTAL|Test dentifrice containing stannous fluoride|All the participants in the test arm applied test dentifrice on their two test teeth using their finger, followed by brushing these test teeth, followed by brushing the whole mouth using test dentifrice. Participants brushed their teeth for 3 days twice daily (morning /evening).
62183705|NCT02924350|ACTIVE_COMPARATOR|Control dentifrice containing sodium monofluorophosphate|All the participants in the control arm applied control dentifrice on their two test teeth using their finger, followed by brushing these test teeth, followed by brushing the whole mouth using control dentifrice. Participants brushed their teeth for 3 days twice daily (morning /evening).
62568270|NCT00642564||001|
62568271|NCT02572570|EXPERIMENTAL|Posterior Composite Resin Restoration|Participants will receive two commercially available tooth-colored restorative materials used for direct restoration as per manufacturer's instructions.
62568272|NCT03126968|EXPERIMENTAL|Prophylactic topical epinephrine|Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical epinephrine in a blinded manner prior to performance of transbronchial lung biopsy.
62735112|NCT01846299|EXPERIMENTAL|Ranibizumab|A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
61998173|NCT00554671|NO_INTERVENTION|Usual Care|Patient continues on usual care for diabetes
61998174|NCT04208906|EXPERIMENTAL|Children with congenital cardiac disease|Pediatric patients aged \< 7 years undergoing cardiac surgery
61998175|NCT06325150|EXPERIMENTAL|Light glasses type 1|Experimental light emitting glasses.
61998176|NCT06325150|PLACEBO_COMPARATOR|Light glasses type 2|Placebo light emitting glasses
61998177|NCT06325150|NO_INTERVENTION|No glasses control|No glasses control group
62392421|NCT05322694||Acute respiratory infections|"Participants will be recruited according to their symptoms when presenting to the emergency room. They can be included either in the acute respiratory infection group or acute infectious diarrhea group or both.~Immediately after triage, eligible patients will be approached by research personnel (nurse or other professional authorized to perform the sampling and techniques required for the study) and enrolled after consent has been obtained. Once the study procedures are completed, participants will follow the care pathway that they would normally follow without the research project. The results of the clinical decision rule (molecular test and risk stratification tool) will not be disclosed to the treating team or the patient."
61998178|NCT00273728|ACTIVE_COMPARATOR|HES, Septic shock, resuscitation|study group with HES 6%
61998179|NCT03366350|EXPERIMENTAL|Consolidative allo-HSCT following CAR-T therapy|Patients who had achieved MRD-negative complete remissions through CAR-T therapy (NCT02965092) will, on their own accord, receive allo-HSCT if there are no previous HSCT, contraindications, and other restrictions.
61998180|NCT00314366|ACTIVE_COMPARATOR|Stem Cell Therapy|Subjects are randomized to receive Stem Cell Therapy (treatment) at the time of enrollment where cells are delivered after NOGA mapping and cells injected with the Myostar catheter.
61998181|NCT00314366|PLACEBO_COMPARATOR|Control|"Placebo patients will receive injections of plasma (control) instead of stem cells. Placebo patients are able to crossover and receive active treatment at 6 months if they meet the criteria.~At 6 months, subject is offered stem cell therapy and then followed for 12 months."
61998182|NCT00717769|EXPERIMENTAL|SUN13834|
61998183|NCT00717769|PLACEBO_COMPARATOR|Placebo|
61998184|NCT04262895|EXPERIMENTAL|TTI-0102 2 mg/day|TTI-0102 2 mg/day
61998185|NCT04262895|EXPERIMENTAL|TTI-0102 4 mg/day|TTI-0102 4 mg/day
61998186|NCT04262895|PLACEBO_COMPARATOR|Placebo|Placebo
61998187|NCT01232296|EXPERIMENTAL|TKI258|capsule
61998188|NCT01232296|EXPERIMENTAL|Sorafenib|tablet
61998189|NCT05377021|ACTIVE_COMPARATOR|"Diet group"|
61998190|NCT05377021|EXPERIMENTAL|"Diet and exercise combination group"|
62183706|NCT04119440|EXPERIMENTAL|Low Dose|Vaccination with 2x10\^7 PFU MVA-MERS-S_DF1. Vaccinations will be administered at days 0, 28 or 56, and 336.
62183707|NCT04119440|EXPERIMENTAL|High Dose|Vaccination with 2x10\^8 PFU MVA-MERS-S_DF1. Vaccinations will be administered at days 0, 28 or 56, and 336.
62773883|NCT03259815|EXPERIMENTAL|PIOS Intervention Group|"Operator-blinded pre and post-PCI coronary physiology measurements will be recorded. If FFR is \<0.90, the result will be disclosed to the operator and a hyperaemic pressure wire pullback will be performed during a standard peripheral intravenous adenosine infusion (140mcg/kg/min).~The operator will then follow the PIOS protocol to attempt to obtain the target optimal post-PCI FFR result."
62773884|NCT03259815|ACTIVE_COMPARATOR|Control Group|Operator-blinded pre and post-PCI coronary physiology measurements will be recorded and the angiographically defined result will be accepted.
62183708|NCT04119440|PLACEBO_COMPARATOR|Placebo|Injection with placebo. Injections will be administered at days 0, 28 or 56, and 336.
62773885|NCT03806075|EXPERIMENTAL|Peutz-Jeghers patients|All Peutz-Jeghers patients meet the clinical criteria
62773886|NCT03806075|PLACEBO_COMPARATOR|Health persons|Those without Peutz-Jeghers syndrome
62773887|NCT02399514|OTHER|RePneum coils|Patients who needed lung volume reduction with RePneum coils
62773888|NCT01165970|ACTIVE_COMPARATOR|Glandosane|After in situ exposition the enamel and dentin samples will demineralize with Glandosane.
62773889|NCT01165970|EXPERIMENTAL|Saliva natura|After in situ exposition the enamel and dentin samples will remineralize with Saliva natura
62773890|NCT03187223|ACTIVE_COMPARATOR|Arm A (Mel)|Melphalan 100mg/m2/day iv days -2 and -1
62773891|NCT03187223|EXPERIMENTAL|Arm B (BenMel)|Melphalan 100mg/m2/day iv days -2 and -1 Bendamustine 200mg/m2/day iv days -4 and -3
62773892|NCT02238093||Dialysis Patients|End-stage renal disease patients undergoing dialysis at the Hillel Yaffe Medical Center.
62773893|NCT01310829||Virtual Reality|Board-eligible or board-certified genetic counselors and students evaluate a virtual reality-based intervention using questionnaires and physiological measurements.
62773894|NCT03083145|ACTIVE_COMPARATOR|Educational Messaging|Whey protein beverage and pea protein beverages administered in a randomized order with a one- to two-week washout period between beverages.
62773895|NCT03083145|ACTIVE_COMPARATOR|No Messaging|Whey protein beverage and pea protein beverages administered in a randomized order with a one- to two-week washout period between beverages.
62773896|NCT04309058|EXPERIMENTAL|Vitamin D drops|This group of patients are going to supplemented with Vitamin D drops 400IU / d orally.
62773897|NCT04309058|NO_INTERVENTION|Control|The other group do not interfere.
62773898|NCT01912690|PLACEBO_COMPARATOR|standard of care|
62773899|NCT01912690|ACTIVE_COMPARATOR|aerobic training only|
62773900|NCT01912690|ACTIVE_COMPARATOR|Aerobic and strength training|
62773901|NCT04345172|ACTIVE_COMPARATOR|a lacrimal dilator group (Group LD)|The patients allocated to receive STB performed with a lacrimal dilator
62183709|NCT02646722||No pain|patients show no pain on rocuronium injection
62183710|NCT02646722||mild pain|patients move a hand only on rocuronium injection
62183711|NCT02646722||moderate pain|patients move a arm on rocuronium injection
62183712|NCT02646722||severe pain|patients show generalized movement because of pain
62183713|NCT03492710|EXPERIMENTAL|IGIV-SN|Immunoglobulin, Supplied in 5g (100mL) and/or 10g (200mL)
62773902|NCT04345172|ACTIVE_COMPARATOR|a Wescott scissors (Group WS)|The patients allocated to receive STB performed with a Wescott scissors
62773903|NCT05928416||SLA group|300 patients
62773904|NCT05928416||Control group|300 patients
62773905|NCT04046250|EXPERIMENTAL|TK112690|TK112690 treatment
62773906|NCT04046250|PLACEBO_COMPARATOR|Placebo|TK112690 formulation
62773907|NCT04147546|EXPERIMENTAL|Intervention arm|"A full course of dihydroartemisinin-piperaquine (DP) over 3 days. The first dose of DP will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home.~At each ANC visit, study nurses will perform an HS-RDT for participants in this arm. Reminders will be sent in this group in order to improve IPTp-SP uptake"
62773908|NCT04147546|NO_INTERVENTION|Control arm|"A full course of artemether-lumefantrine (AL) over 3 days. The first dose of AL will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home.~At each ANC visit, study nurses will perform a conventional RDT for participants in this arm if the participant have symptoms suggestive of malaria. No reminder will be sent"
62773909|NCT01326832||Primoris|50 patients included in RSA cohort of total of 350 anticipated Primoris cases
62773910|NCT01666106||Subjects with cancer and ONJ|Subjects with cancer and positively adjudicated ONJ
62773911|NCT03871972|EXPERIMENTAL|UCB injection group|This pilot study includes only 2 subjects who are enrolled by invitation. Both subjects are included in this single arm.
62773912|NCT01549873|ACTIVE_COMPARATOR|Total intravenous anesthesia (TIVA)|
62773913|NCT01549873|ACTIVE_COMPARATOR|Inhaled anesthesia|
62773914|NCT03610373|EXPERIMENTAL|Shared Decision Making|In this arm, parents and children will participate in a shared decision-making protocol with the clinician to plan their treatment. The treatment options available are established, evidence-based treatment techniques. The shared decision-making protocol was developed for this research project.
62773915|NCT03610373|ACTIVE_COMPARATOR|Clinician Guided|In this arm, the clinician will plan the treatment in consultation with their supervisor, and share the treatment plan with the parent and child. The parent and child will have the opportunity to ask questions about the treatment plan (and, if they do not agree, reject the treatment plan), but they are not actively involved in making each decision. This is more typical of usual care.
62773916|NCT04460846|ACTIVE_COMPARATOR|Alkaline water|Participants will consume 1.5 liters per day
62773917|NCT04460846|PLACEBO_COMPARATOR|Reverse osmosis water|Participants will consume 1.5 liters per day
62773918|NCT02774655|EXPERIMENTAL|PAI APP|personal activity index application
62773919|NCT02774655|ACTIVE_COMPARATOR|FitBit APP|
61998191|NCT06095466||Cirrhotic cardiomyopathy|Cirrhotic cardiomyopathy, among a broad spectrum of cardiac complications in cirrhosis, is characterized by systolic and diastolic cardiac dysfunction and electrocardiographic changes. However, it is seen more in NASH related cirrhotic patients, who have an additional risk of developing cardiac complications. Cirrhosis contributes to a including cirrhotic cardiomyopathy owing to various pathological conditions interlinked at the cellular and molecular level. A hyperdynamic circulatory state caused due to excessive release of vasodilators in a pro-inflammatory condition of cirrhosis, along with negative-inotropic pathways contributes to the development of a compromised cardiac function. Electrocardiography, 2D echocardiography with tissue Doppler or speckle tracking are the routine diagnostic tests used to diagnose CCM.
62773920|NCT03990506|EXPERIMENTAL|Epi-on PiXL|Photorefractive intrastromal corneal crosslinking without epithelium debridement during humidified high oxygen flow.
61998192|NCT05180435|EXPERIMENTAL|Family Meals|Have at least 5 dinners per week.
62773921|NCT03990506|ACTIVE_COMPARATOR|Epi-off PiXL|Photorefractive intrastromal corneal crosslinking with epithelium debridement.
61998193|NCT05180435|ACTIVE_COMPARATOR|Standard|Consume the recommended amounts of fruits and vegetables.
61998194|NCT04903236||Non-patient healthy volunteer|Undertake MR Imaging to enable development of sequences.
62392422|NCT05322694||Acute infectious diarrhea|"Participants will be recruited according to their symptoms when presenting to the emergency room. They can be included either in the acute respiratory infection group or acute infectious diarrhea group or both.~Immediately after triage, eligible patients will be approached by research personnel (nurse or other professional authorized to perform the sampling and techniques required for the study) and enrolled after consent has been obtained. Once the study procedures are completed, participants will follow the care pathway that they would normally follow without the research project. The results of the clinical decision rule (molecular test and risk stratification tool) will not be disclosed to the treating team or the patient."
62392423|NCT03809702|ACTIVE_COMPARATOR|Pregabalin group|Group 1: Pregabalin tablet 75 mg orally twice daily for 4 weeks will be given to the subjects in this group along with other routine treatment Here, the intervention is administration of Pregabalin tablet 75 mg
62392424|NCT03809702|PLACEBO_COMPARATOR|Placebo group|Group 2: Placebo tablet twice daily for 4 weeks will be given to the subjects in this group along with other routine treatment
62392425|NCT00963040|EXPERIMENTAL|Syntocinon® TI-004 protocol|Treated group
62392426|NCT00963040|PLACEBO_COMPARATOR|Sterile water TI-004 protocol|Placebo group
62392427|NCT00963040|EXPERIMENTAL|Syntocinon® TI-005 protocol|
62773922|NCT05288140|NO_INTERVENTION|usual ICU practice|The patient's evolution is reported verbally to the family.
62392428|NCT00963040|PLACEBO_COMPARATOR|Sterile water TI-005 protocol|
62773923|NCT05288140|EXPERIMENTAL|ICU diary|Made a diary
62773924|NCT05611502|EXPERIMENTAL|TMS A|TMS administered over right frontal eye field at 10 Hz, 110% of MT, 60 x 5 sec trains, 25 sec ITI
62773925|NCT05611502|ACTIVE_COMPARATOR|TMS B|TMS administered over right frontal eye field at 1 Hz, 110% of MT, 7 x 225 sec trains, 30 sec ITI
62773926|NCT06543680|ACTIVE_COMPARATOR|Resin Modified Glass Ionomer cement|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
62773927|NCT06543680|PLACEBO_COMPARATOR|Self-Adhesive flowable composite|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
62773928|NCT06543680|PLACEBO_COMPARATOR|Self-Adhesive composite hybrid|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
62773929|NCT05176756|ACTIVE_COMPARATOR|Attention Control|In addition to using a wearable device, participants in this arm will receive a daily notification of their step count from the previous day. This notification serves as an 'attention control' and allows us to better isolate the impact of the gamification with social support. It may also help to reduce differential attrition across arms.
61998195|NCT04903236||Patient|Provide weekly blood and urine samples during period of radiotherapy as well as additional MR images.
62392429|NCT03698032|ACTIVE_COMPARATOR|Water Arm|Participants will consume water only as the intervention
62392430|NCT03698032|ACTIVE_COMPARATOR|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
61998196|NCT04492891|EXPERIMENTAL|Arm A Cyclosporine|Neoral, N=50 Patients 2.5 mg/kg PO BID 7 days
61998197|NCT04492891|OTHER|Arm B Standard of Care|Standard of Care Treatment, N= 25 Patients 7 days
61998198|NCT02312232|EXPERIMENTAL|Levodopa formulation A|Levodopa formulation A together with ODM-104 100 mg and carbidopa
61998199|NCT02312232|EXPERIMENTAL|levodopa formulation B|levodopa formulation B together with ODM-104 100 mg and carbidopa
62791559|NCT06552637|EXPERIMENTAL|Device and Medical Management|"* Subjects will be implanted with the VisONE System programmed to deliver SDS (Therapy On) and receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association \[AHA\] / American College of Cardiology \[ACC\] guidelines) including those drugs to be determined by the subject's physician~* Assigned Interventions:~  * Device: VisONE System (SDS)~ * Drug: Medical Management"
61998200|NCT02312232|EXPERIMENTAL|levodopa formulation C|levodopa formulation C together with ODM-104 100 mg and carbidopa
61998201|NCT02312232|ACTIVE_COMPARATOR|Sinemet IR 100/25 mg|Sinemet IR 100/25 mg together with ODM-104 100 mg
62183714|NCT06417944||Schroth group (Group 1)|"Patients aged 10-18 years who are diagnosed with scoliosis and given 10 sessions of schroth exercises, either outpatient or inpatient.~Scoliosis study forms consisting of clinical and radiological measurements of patients aged 10-18 years who applied to the outpatient clinic with spine deformity will be filled in in detail."
62183715|NCT06417944||Control group (Group 2)|Patients aged 10-18 years who are diagnosed with scoliosis and given home exercise Scoliosis study forms consisting of clinical and radiological measurements of patients aged 10-18 years who applied to the outpatient clinic with spine deformity will be filled in in detail.
62773930|NCT05176756|EXPERIMENTAL|Gamification and Social Support|Participants in this arm will receive the same devices and daily messaging as control. They will also be entered into a game designed using behavioral economic principles for 6 months. This intervention has been adapted from our prior successful pilot studies. The game runs automatically and does not require any effort on the part of the participant to 'play' the game other than to strive for physical activity goals. Participants in this arm will also select a family member or friend who will serve as a support partner to encourage the participant to meet their step goals. The gamification and social support interventions will end after 6 months at which point participants will receive the same treatment as the attention control arm for the 3-month follow-up period.
61998202|NCT02312232|ACTIVE_COMPARATOR|Half Sinemet CR 100/25 mg|Half Sinemet CR 100/25 mg together with ODM-104 100 mg
62183716|NCT02647788|ACTIVE_COMPARATOR|Acetaminophen/Ibuprofen|Group 1: Acetaminophen 650 mg; Ibuprofen 400 mg
62773931|NCT05484323|EXPERIMENTAL|Glucose as reference food|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
62773932|NCT05484323|EXPERIMENTAL|White bread|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
62773933|NCT05484323|EXPERIMENTAL|Cookie containing 0 g spirulina|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
62791560|NCT06552637|SHAM_COMPARATOR|Medical Management|"* Subjects will be implanted with the VisONE System programmed not to deliver SDS (Therapy Off) and receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association \[AHA\] / American College of Cardiology \[ACC\] guidelines) including those drugs to be determined by the subject's physician~* Assigned Interventions:~  * Drug: Medical Management"
61998203|NCT00480779|OTHER|GLB Group|The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study choose traditional GLB face-to-face group delivery or delivery via DVD. Group members met weekly and completed the program over a 12-15 week period. The face-to-face group meetings were led by a trained lifestyle coach, and participants were encouraged to self-monitor their eating and physical activity behaviors. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
62183717|NCT02647788|ACTIVE_COMPARATOR|Acetaminophen/Codeine|Group 2: Acetaminophen 300mg, Codeine 30 mg
62183718|NCT00865852|EXPERIMENTAL|A|Metformin HCl 750 mg Extender Release tablets, single dose
62183719|NCT00865852|ACTIVE_COMPARATOR|B|GLUCOPHAGE® XR 750 mg tablets, single dose
62183720|NCT06402578|NO_INTERVENTION|Control Group,|Control Group, will be issued with a smartwatch that is paired with a freely accessible App called Alexia® to record their PA. They will be asked to carry on with their daily activity and to record when they do any of their own physical activities that they do themselves routinely on an everyday basis during the 12 week study. They will not receive a 12 week PA programme.
62183721|NCT06402578|EXPERIMENTAL|Intervention 1|Intervention 1, will be provided with a 12 week PA programme and asked to record their PA while they follow the programme during the 12 week study.
62183722|NCT06402578|EXPERIMENTAL|Intervention 2|Intervention 2, will also be provided with the same 12 week PA program and asked to record their PA while they follow the programme during the 12 week study. The participants in this group will also get support from a physical activity professional (PAP) who will be monitoring their 12 week journey. The PAP will be prompting the participant with weekly information as to why they are doing these exercises as well as supporting the participants to continue their programme as soon as non-adherence to the exercise program becomes apparent during the 12 week study.
62183723|NCT04753944|ACTIVE_COMPARATOR|Probiotic group|Patients will be introduced for 5 weeks with probiotic therapy (in the study group). They will take Ecologic®Barrier (Winclove Probiotics BV, Amsterdam, The Netherlands), consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58. The probiotic dose is going to be 4 capsules daily (one capsule contains 500 million CFUs of living probiotic strains). The treatment will be administered two times a day, during breakfast and supper. The probiotic formula will be Provided by polish distributor of Winclove products, namely Sanprobi sp. z o. o. sp. k
62392431|NCT03698032|ACTIVE_COMPARATOR|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
62392432|NCT04944121|EXPERIMENTAL|RSLV-132|RSLV-132 is an enzymatically active ribonuclease designed to digest the ribonucleic acid contained in autoantibodies and immune complexes and thereby render them biologically inert. A dose of 10 mg/kg will be administered by intravenous infusion on Days: 1, 8, 15, 29, 43, and 57
62392433|NCT04944121|PLACEBO_COMPARATOR|Placebo|Sodium chloride 0.9% will be administered by intravenous infusion on Days: 1, 8, 15, 29, 43, and 57
62392434|NCT06446297||Generational X|"Date of Birth (DOB) categorisation of Generation X: 1st January 1965 - 31st December 1980.~PGDiTs recruited from the local hospital will be stratified into generational groups according to their date of birth. The investigators anticipate on having approximately two focus groups per generation."
62392435|NCT06446297||Generation Y|DOB categorisation of Generation Y: 1st January 1981 - 31st December 1995. PGDiTs recruited from the local hospital will be stratified into generational groups according to their date of birth. The investigators anticipate on having approximately two focus groups per generation.
62392436|NCT06446297||Generation Z|DOB categorisation of Generation Z: 1st January 1996 - 31st December 2010. PGDiTs recruited from the local hospital will be stratified into generational groups according to their date of birth. The investigators anticipate on having approximately two focus groups per generation.
62392437|NCT05011240|EXPERIMENTAL|Paediatric Autism Communication Therapy (PACT) Intervention plus Community Assistance as Usual|Participants will receive 12 sessions over 5 months of Paediatric Autism Communication Therapy (PACT).
62392438|NCT05011240|ACTIVE_COMPARATOR|Community support as usual plus psychoeducation (Control)|Participants in the Control group will receive psycho-educational support via monthly sessions led by researchers with experience in child development. In each session, a presentation will be delivered to provide parents with information about child development and environmental factors that contribute to healthy child development, including sensitive parenting styles, frequent positive social interactions between parents and children and cognitive stimulation. The presentations will be followed by group discussions. Children will also continue to receive Community Assistance as Usual via their normal early education centers. These centers offer daily activities designed to promote children's learning, autonomy, movement, integration and socialization. Children attend their educational center five days per week between the hours of 8am and 5pm.
62392439|NCT05677841|EXPERIMENTAL|Exercise group|Exercise group will be given spinal stabilization exercises focusing on the pelvic floor and lifestyle reccommendations
62392440|NCT05677841|ACTIVE_COMPARATOR|Control group|Control group will be given lifestyle recommendations
62392441|NCT04090294|EXPERIMENTAL|Roflumilast -non roflumilast|"35 patients will receive Roflumilast for three months and improvement regarding dyspnea scales , Pulmonary function Test , Six minutes walking test and bronchectasis severity index (FACED) score pre and post therapy will be assessed.~patients will receive Roflumilast 500 Mcg. Tablet Once daily for Three months and then base line assessment will be repeated to evaluate improvement."
62392442|NCT05093660||Patients with acute appendicitis|Patients with acute appendicitis, after surgery and with pathohistological specimen confirmation.
62392443|NCT05093660||Patients without acute appendicitis|Patients without acute appendicitis, after laboratory, clinical and/or radiological exclusion of acute admittance.
62392444|NCT00280059|EXPERIMENTAL|1|
62568273|NCT03126968|PLACEBO_COMPARATOR|Placebo|Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical placebo in the form of normal saline in a blinded manner prior to performance of transbronchial lung biopsy.
62183724|NCT04753944|PLACEBO_COMPARATOR|Placebo group|Patients will be introduced for 5 weeks with placebo that consist of maize starch, maltodextrins and vegetable protein. The placebo dose is going to be 4 capsules daily (one capsule). The treatment will be administered two times a day, during breakfast and supper.
62183725|NCT05092477|EXPERIMENTAL|Integrated Intervention|4 intervention sessions over 6 months using an educational and counseling intervention developed by the study team.
62183726|NCT05092477|ACTIVE_COMPARATOR|Control|Attention Control group - Supportive counseling for DM management
62392445|NCT00280059|ACTIVE_COMPARATOR|2|
62568274|NCT03070600|ACTIVE_COMPARATOR|Universal PrEP Counselling|All enrolled women receiving antenatal care at facilities assigned to Universal PrEP arm will receive standardized HIV risk counseling and then self-select whether they want to use PrEP.
62568275|NCT03070600|EXPERIMENTAL|Targeted PrEP Clinics|All enrolled women receiving antenatal care at facilities assigned to the Targeted PrEP arm will be assessed for HIV-risk prior to receiving targeted PrEP counseling.
62791561|NCT05916469||Bleeding disorder using LNG-IUD|Adolescents and young adults ages 10-24 with diagnosed bleeding disorder planning use of LNG-IUD.
62183727|NCT03740477|EXPERIMENTAL|Intrevention|Eligible participants will receive a 30-second smartphone-based ECG
62183728|NCT05379790|EXPERIMENTAL|Intraperitoneal irinotecan 50 mg + CAPOX|Intraperitoneal irinotecan, dose level 1 50 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
62183729|NCT05379790|EXPERIMENTAL|Intraperitoneal irinotecan 75 mg + CAPOX|Intraperitoneal irinotecan, dose level 2 75 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
62183730|NCT05379790|EXPERIMENTAL|Intraperitoneal irinotecan 100 mg + CAPOX|Intraperitoneal irinotecan, dose level 3 100 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
62183731|NCT05379790|EXPERIMENTAL|Intraperitoneal irinotecan 150 mg + CAPOX|Intraperitoneal irinotecan, dose level 4 150 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
62183732|NCT05379790|EXPERIMENTAL|Intraperitoneal irinotecan 200 mg + CAPOX|Intraperitoneal irinotecan, dose level 5 200 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
62183733|NCT05379790|EXPERIMENTAL|Intraperitoneal irinotecan 250 mg + CAPOX|Intraperitoneal irinotecan, dose level 6 250 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
62183734|NCT04315116|EXPERIMENTAL|Treament|Subjects receiving a single oral dose of pyrotinib maleate and wash-out for 6 days, then receiving Loperamide 4 mg bid from day 7 to day 13, with a single oral dose of pyrotinib maleate coadministered on day 10 .
62183735|NCT03669328||Group 1|patients of 2016, June with locoregional anesthesia
62791562|NCT05916469||Non-bleeding disorder using LNG-IUD|Adolescents and young adults ages 10-24 without diagnosed bleeding disorder planning use of LNG-IUD.
62791563|NCT05916469||Bleeding disorder using NETA|Adolescents and young adults ages 10-24 with diagnosed bleeding disorder planning use of NETA.
62791564|NCT05751369|ACTIVE_COMPARATOR|Education Only|Treatment as usual with brief videos and weblink
62183736|NCT03669328||Group 2|patients of 2018, June with locoregional anesthesia
62183737|NCT01884220||Patients with Disease|Patients with Wolman disease (WD), Cholesteryl Ester Storage Disease (CESD), or Lysosomal acid lipase (LAL) deficiency.
62183738|NCT04727359||FIT64b model project|Patients being treated in FIT64b model project at UKT
62183739|NCT04727359||Standard care|Patients being treated in standard care (control hospitals)
62183740|NCT04114097|EXPERIMENTAL|Betamethasone-17-valerat + placebo ointment|"Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing corticosteroid (Betnovate, betamethasone dipropionate ointment 0.1%) and placebo"
62183741|NCT04114097|ACTIVE_COMPARATOR|Tacrolimus ointment|"Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing calcineurin inhibitor (Protopic, tacrolimus ointment 0.1%)"
62183742|NCT05026489||G6PD Deficiency|In the laboratory of the First Affiliated Hospital of Xi 'an Jiaotong University, tetrazolazole-blue quantitative method will be used to detect G6PD. According to the normal range of the tetrazole-blue quantitative method (6.8-20.5NBT), adults with G6PD activity \< 6.8NBT were positive, and G6PD deficiency is confirmed.
62183743|NCT05026489||Normal|The G6PD activity ranged from 6.8 to 20.5 NBT and the G6PD activity is normal.
62183744|NCT01687868|EXPERIMENTAL|dexmedetomidine continuous infusion|
62183745|NCT02367105|ACTIVE_COMPARATOR|Testosterone plus Lifestyle Therapy|Testosterone replacement in combination with behavioral diet to induce \~10% weight loss + supervised aerobic and exercise training
62183746|NCT02367105|PLACEBO_COMPARATOR|Placebo plus Lifestyle Therapy|Placebo in combination with behavioral diet to induce \~10% weight loss and supervised aerobic and exercise training
62392446|NCT04790214|EXPERIMENTAL|Stable CHF patients|Stable CHF patients on stage II/III based on the New York Heart Failure classification
62392447|NCT03547674|ACTIVE_COMPARATOR|barefoot|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
62392448|NCT03547674|ACTIVE_COMPARATOR|shoes only|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
62392449|NCT03547674|ACTIVE_COMPARATOR|untuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
62392450|NCT03547674|EXPERIMENTAL|tuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
62392451|NCT04647708|EXPERIMENTAL|Part A (Cohort 1): M5049 Dose A|
62392452|NCT04647708|EXPERIMENTAL|Part A (Cohort 2): M5049 Dose B|
62392453|NCT04647708|EXPERIMENTAL|Part A (Cohort 3): M5049 Dose C|
62392454|NCT04647708|EXPERIMENTAL|Part A (Cohort 4): M5049 Dose D|
62392455|NCT04647708|PLACEBO_COMPARATOR|Part A: Placebo|
62392456|NCT04647708|EXPERIMENTAL|Part B (Cohort 5): M5049 Dose E|
62392457|NCT04647708|PLACEBO_COMPARATOR|Part B: Placebo|
62392458|NCT03451058||Mild TBI Group|History of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
62392459|NCT03451058||Moderate to Severe TBI Group|History of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
62392460|NCT03451058||Healthy Controls|No history of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
62392461|NCT05737108|EXPERIMENTAL|Group A-test samples|This group will be given test bilberry capsule for 30 days and then have a washout period for 20 days.
62392462|NCT05737108|PLACEBO_COMPARATOR|Group A-placebo|This group will be given placebo for 30 days and then have a washout period for 20 days.
62392463|NCT02861521|EXPERIMENTAL|Corrective shoe lift|Participants will be given an external shoe lift to correct post-operative leg length discrepancy (LLD).
62568276|NCT00778219||A|Patients needing intubation of single lumen tracheal tube and performed using laryngoscope
62392464|NCT02861521|SHAM_COMPARATOR|Sham shoe intervention|Participants will be given a sham shoe intervention that does not correct post-operative leg length discrepancy.
62392465|NCT01867996|EXPERIMENTAL|Retosiban and EFZ|All subjects will receive on Day 1, a 6 mg bolus of retosiban for 5 min, followed by a 6 mg/hr infusion for 12 hrs. On Day 2 a washout day will occur. On Days 3-17, subjects will receive EFZ 600 mg OD dose of in the evening. On Day 18, subjects will receive a 6 mg bolus of retosiban for 5 mins, followed by a 6 mg/hr infusion for 12 hrs plus a 600 mg dose of EFZ.
62392466|NCT04095611|EXPERIMENTAL|SPAIRE|hemiarthroplasty surgery, the muscle-sparing modification of the posterior approach (SPAIRE).
62392467|NCT04095611|ACTIVE_COMPARATOR|LATERAL|hemiarthroplasty surgery, the standard lateral approach
62392468|NCT01559142|ACTIVE_COMPARATOR|IFX TG|
62392469|NCT01559142|ACTIVE_COMPARATOR|IFX alone|
62392470|NCT03839446|EXPERIMENTAL|mitoxantrone + etoposide + gemtuzumab ozogamicin|10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6
62392471|NCT03741257|ACTIVE_COMPARATOR|Group A|Received Hypertonic saline 3% as resuscitation fluid.
62392472|NCT03741257|ACTIVE_COMPARATOR|Group B|Received Hypertonic saline 1.8% as resuscitation
62568277|NCT00778219||B|Patients needing intubation of single lumen tracheal tube and performed using lightwand
62568278|NCT00778219||C|Patients needing intubation of double lumen endobronchial cath and performed using laryngoscope
62568279|NCT03609385||Stroke patients with elevated troponin|Patients with acute ischemic stroke (confirmed by cerebral imaging) and cardiac troponin values \> 52 ng/l or troponin values \> 14 ng/l and dynamic change \> 20% will undergo coronary angiography
62773934|NCT05484323|EXPERIMENTAL|Cookie containing 2.5 g spirulina|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
62773935|NCT02886871|EXPERIMENTAL|Personalized Steps Goal|Step Goal Delivery by Smartphone
62392473|NCT05469451|EXPERIMENTAL|Group 1: irradiated with low power laser (940nm)|Irradiated with a low power density laser of 940 (nm), 100 megawatt, which will be calibrated and the result of the calibration will be checked with the use of the power meter. The equipment used will be a diode laser (BIOLASE™), the area to be irradiated will be the anterior segment of the lower arch, each tooth will be irradiated for a time of 10 seconds on the vestibular surfaces of the teeth and 10 seconds on the lingual surfaces of the teeth, both at gingival level and at apical level in scanning mode.
62568280|NCT04968535|EXPERIMENTAL|Therapy|Patients receiving suprathreshold electrotherapy in weekly intervals for a Duration of 30 min each. Device calibration with determination of the individual threshold was performed prior to the application of electrical current.
62568281|NCT04968535|SHAM_COMPARATOR|Control|Patients receiving device calibration without consequent electrotherapy.
62568282|NCT04968535|NO_INTERVENTION|Control of control|Patients lay on the mat without receiving device calibration nor electrotherapy.
62773936|NCT02886871|ACTIVE_COMPARATOR|Constant Steps Goal|Step Goal Delivery by Smartphone
62392474|NCT05469451|PLACEBO_COMPARATOR|Group 2: Simulated that they were irradiated.|Group 2: it was simulated that they were irradiated.
62568283|NCT06189300|EXPERIMENTAL|Virtual Glasses|Training and consultancy will be provided
62568284|NCT06189300|NO_INTERVENTION|Control|Standard care will be given
62568285|NCT04298970|ACTIVE_COMPARATOR|Intervention|Consuming a product containing 35-40 gram of freeze dried kale a day.
62568286|NCT04298970|PLACEBO_COMPARATOR|Placebo|Consuming a placebo product.
62568287|NCT02755467|EXPERIMENTAL|Laser treatment|Each subject will receive a 532 nm KTP laser treatment for their spider angioma(s).
61998204|NCT00480779|OTHER|GLB DVD|The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study choose traditional GLB face-to-face group delivery or delivery via DVD. Those who took part via DVD received an overview of the GLB program at the first session, as well as the materials needed for the program. They subsequently watched one session of the program each week, and received a telephone call from a trained lifestyle coach each week to review weight, physical activity minutes and questions/concerns regarding the program. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
62183747|NCT04271046|EXPERIMENTAL|Experimental Group- STAR-C-VTF|"This study will use a parallel, two-arm randomized trial design. Participants will be 100 Person-with-Dementia-Caregiver dyads in which the person with dementia lives at home and recently filled a new prescription for antipsychotic medication. The experimental intervention will combine three elements:~* self-directed learning in which the caregiver will receive training materials delivered electronically through a web-based learning portal;~* one orientation phone visit with a coach;~* ongoing support from the coach via telephone and secure messaging in the web-portal.~Participants will complete self-report assessments at baseline, 8-weeks post-enrollment, and 6 months post-enrollment. Automated medication and primary care utilization data will be collected throughout the 6 month study period."
61998205|NCT00218517|EXPERIMENTAL|1|
62183748|NCT04271046|ACTIVE_COMPARATOR|Control|"One orientation phone visit with a coach. Participants in the control condition will receive mailed material from the Alzheimer's Association, web links and template secure messages.~Participants will complete self-report assessments at baseline, 8-weeks post-enrollment, and 6 months post-enrollment. Automated medication and primary care utilization data will be collected throughout the 6 month study period."
61998206|NCT00218517|PLACEBO_COMPARATOR|2|
61998207|NCT03662438|OTHER|Study Participants|"This is a self-controlled study where participants will serve as their own controls. All participants will be enrolled into a 10 week home-based physiotherapy program which will include a total of 2 home visits by a physiotherapist at the start and midpoint of the program. Participants will also receive weekly telephone calls by a research coordinator to provide encouragement for patient on the programme and enquire about compliance to the home exercise regimen and safety (e.g. falls and healthcare utilisation).~Patients will also be prescribed a lightweight portable oxygen concentrator to facilitate exercise therapy and mobility in the community. They will receive familiarisation and training in its usage as part of the home-based physiotherapy program."
61998208|NCT00577512|EXPERIMENTAL|HD DTPACE|DTPACE
61998209|NCT06096415|EXPERIMENTAL|Experimental: ABX-101 1mg|"Participants will be screened, enrolled and receive the assigned treatment within 12 hours of the primary TBI insult (or estimated less than 12 hours if the exact time is unknown).~Enrolled participants will be stratified 1:1 (in each arm) by GCS score (GCS 4-8 in one group and GCS 9 - 12 in the other).~The treatment period, which involves 6 hourly, i.e., quarter in die (QID), ABX 101 (1 mg OR 2 mg) intramuscular injections, is seven days."
61998210|NCT06096415|EXPERIMENTAL|Experimental: ABX-101 2mg|"Participants will be screened, enrolled and receive the assigned treatment within 12 hours of the primary TBI insult (or estimated less than 12 hours if the exact time is unknown).~Enrolled participants will be stratified 1:1 (in each arm) by GCS score (GCS 4-8 in one group and GCS 9 - 12 in the other).~The treatment period, which involves 6 hourly, i.e., quarter in die (QID), ABX 101 (1 mg OR 2 mg) intramuscular injections, is seven days."
61998211|NCT06096415|PLACEBO_COMPARATOR|Placebo Comparator: Saline|Placebo to the ABX-101 will be administered to patients.
61998212|NCT01102413|EXPERIMENTAL|Monofer|Injections or infusions
61998213|NCT01102413|ACTIVE_COMPARATOR|Iron Sulphate|Oral intake
62183749|NCT01621789|EXPERIMENTAL|dye of lutein, zeaxanthin, trypan blue|during the surgery will be evaluated if the dye is suitable for dyeing anterior lens capsule
62568288|NCT01729078|EXPERIMENTAL|high fat ( MUFA) diet|intervention using high fat diet.
62568289|NCT01729078|EXPERIMENTAL|high carb/high fiber|diet using high carb-high fiber with dry beans
61998214|NCT05374265|NO_INTERVENTION|Registry|Patients with non-viable myocardium will be treated with standard clinical care.
61998215|NCT05374265|OTHER|OMT with revascularization|Patients with viable myocadium will be randomised to OMT with revascularization. PCI will be performed according to standard techniques using newer generation drug eluting stents. All patients will receive dual anti-platelet treatment for 12 months, or as per local practice guidelines.
61998216|NCT05374265|OTHER|OMT alone|Patients with viable myocardium will be radomised to OMT alone. PCI will be performed according to standard techniques using newer generation drug eluting stents. All patients will receive dual anti-platelet treatment for 12 months, or as per local practice guidelines.
61998217|NCT02418468|EXPERIMENTAL|Placebo|Matching placebo indacaterol capsules for inhalation once daily delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
61998218|NCT02418468|EXPERIMENTAL|Indacaterol 150 mcg|Indacaterol 150 mcg capsules for inhalation once daily delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
61998219|NCT05233566|EXPERIMENTAL|Ketamine Arm|Following surgery and extubation, patients will receive ketamine 0.5 mg/kg over 10 minutes followed by an infusion of 0.3 mg/kg/h for 2 hours 50 minutes.
61998220|NCT05233566|PLACEBO_COMPARATOR|Control Arm|Following surgery and extubation, patients will receive normal saline at an equal rate to that used in the ketamine arm.
62183750|NCT00639314|EXPERIMENTAL|1|In PpPD, the proximal duodenum was divided 3-4cm distal to the pylorus ring
62183751|NCT00639314|ACTIVE_COMPARATOR|2|In PrPD, the stomach is divided just above the pylorus ring. the nearly total stomach more than 95% was preserved.
62183752|NCT03728959|EXPERIMENTAL|Liquid meal (Nutridrink)|Liquid meal (Nutridrink)
62183753|NCT03728959|EXPERIMENTAL|GIP|Glucose-dependent insulinotropic polypeptide
62183754|NCT03728959|EXPERIMENTAL|GLP-2|Glucagon-like peptide-2
62183755|NCT03728959|EXPERIMENTAL|Placebo (saline)|Placebo (saline)
62392475|NCT05551182|EXPERIMENTAL|Nicergoline low dose|Nicergoline 10 mg bid (20 mg/day)
62392476|NCT05551182|EXPERIMENTAL|Nicergoline high dose|Nicergoline 30 mg bid (60 mg/day)
62183756|NCT03629899|EXPERIMENTAL|RETINA IMPLANT Alpha AMS|"After implantation surgery, every single sub-test will be performed with randomized implant activation (ON or OFF). During every trial of each sub-test there will be a study coordinator and a technician. The study coordinator will have a set randomization examination schedule while the technician will record patient response without knowledge of the randomization examination schedule. The patient, technician and investigator will all be masked to the testing conditions."
62183757|NCT03469492|ACTIVE_COMPARATOR|type 2 diabetes mellitus|Subjects with type 2 diabetes on insulin.
62183758|NCT03469492|ACTIVE_COMPARATOR|type 1 diabetes mellitus|Subjects with type 1 diabetes on insulin.
62183759|NCT01795859|EXPERIMENTAL|SD-809 ER Tablets|SD-809 ER tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white). All are administered three times a day, with the 6 mg final dose is placebo.
62183760|NCT01795859|EXPERIMENTAL|SD-809 Tablets|SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white). All are administered three times a day, with the 6 mg final dose is placebo.
62183761|NCT00947141|EXPERIMENTAL|Group A|"Group A: (low level infection) has 2 arms:~1. Start treatment when 2 consecutive levels CMV PCR \>200copies / ml~2. Monitor (Treatment starts when CMV PCR \>3,000 copies / ml (current site clinical protocol))"
62568290|NCT01729078|EXPERIMENTAL|high carb/low fat|Habitual diet
62568291|NCT01576679|EXPERIMENTAL|tPA|tissue Plasminogen Activator
62183762|NCT00947141|EXPERIMENTAL|Group B|"Group B: (patients receiving pre-emptive therapy) has 2 arms:~1. Stop treatment when 2 levels CMV PCR \<3,000 copies / ml~2. Monitor (Treatment stops when there are 2 consecutive levels of CMV PCR \<200 copies / ml (current site clinical protocol))"
62183763|NCT01951521|EXPERIMENTAL|Boost|Boost radiation consists of 5 fractions of 3 Gy (total 15 Gy) delivered to the tumor (Gross Tumor Volume) additional to standard chemoradiation of 50 Gy with Capecitabine.
62183764|NCT01951521|NO_INTERVENTION|Standard chemoradiation|Standard chemoradiation consisting of 25 x 2 Gy (total 50 Gy) with Capecitabine.
62183765|NCT06172114|ACTIVE_COMPARATOR|Control group (C)|Xenograft + resorbable collagen membrane
62183766|NCT06172114|EXPERIMENTAL|Test group (T)|Xenograft combined with L-PRF + resorbable collagen membrane
62568292|NCT01576679|PLACEBO_COMPARATOR|Placebo|Saline
62392477|NCT04769258||Patients with IBD treated with immunomodulatory drugs|
62183767|NCT04429035|EXPERIMENTAL|Vitamin K2|Participants receive Vitamin K2 (Menaquinone) 100mcg tablet orally 3 times daily for 12 months.
62183768|NCT04429035|PLACEBO_COMPARATOR|Placebo|Participants receive Vitamin K2 (Menaquinone) placebo tablet matching Vitamin K2 (Menaquinone) orally 3 times daily for 12 months.
62183769|NCT03587779|EXPERIMENTAL|Sevoflurane|Anesthesia is maintained with sevoflurane.
62183770|NCT03587779|EXPERIMENTAL|Desflurane|Anesthesia is maintained with desflurane.
62392478|NCT04769258||Patients with IBD not treated with the immunomodulatory drugs|
62392479|NCT03824574|EXPERIMENTAL|Treatment arm|Subjects receiving the clear mandibular advancement appliance
62392480|NCT01540721|EXPERIMENTAL|Experimental paracetamol formulation|Experimental formulation
62392481|NCT01540721|ACTIVE_COMPARATOR|Marketed paracetamol|Marketed formulation
62392482|NCT02418000|EXPERIMENTAL|E6201 240 mg/m^2 IV weekly|E6201 240 mg/m\^2 administered IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle)
62392483|NCT02418000|EXPERIMENTAL|E6201 320 mg/m^2 IV weekly|E6201 320 mg/m\^2 administered IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle)
62392484|NCT02418000|EXPERIMENTAL|E6201 160 mg/m^2 IV twice weekly|E6201 160 mg/m\^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle)
62392485|NCT02418000|EXPERIMENTAL|E6201 240 mg/m^2 IV twice weekly|E6201 240 mg/m\^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle)
62392486|NCT02418000|EXPERIMENTAL|E6201 320 mg/m^2 IV twice weekly|E6201 320 mg/m\^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22, and 25, repeated every 28 days (= 1 cycle)
62392487|NCT04046289||Low Calcium|low calcium milk of 180 ml, twice daily for 24 weeks
62392488|NCT04046289||Regular Calcium|regular calcium milk of 180 ml, twice daily for 24 weeks
62392489|NCT04046289||Probiotic 1|regular calcium milk of 180 ml + probiotic, twice daily for 24 weeks
62392490|NCT04046289||Probiotic 2|regular calcium milk of 180 ml + probiotic, twice daily for 24 weeks
62392491|NCT02347345|ACTIVE_COMPARATOR|Active injection drug use (IDU)|In active IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
62392492|NCT02347345|ACTIVE_COMPARATOR|Former injection drug use (former IDU)|In former IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
62392493|NCT02347345|NO_INTERVENTION|Healthy volunteers|HIV, HCV and HBV negative, never injected drugs, no recreational drugs for at least 2 years (does not include marijuana) and negative urine screen for opiates at the screening visit.
61998221|NCT04134000|EXPERIMENTAL|Atezolizumab + BCG|"Ten patient will be enrolled in first cohort, starting on level 0 (DL 0) receiving BCG 1 instillation per week and Atezolizumab 1200 mg IV every three weeks (q3w).~The next level of dose in case is necessary is BCG 1/2 instillation per week and Atezolizumab 1200 mg IV every three weeks (q3w)"
62183771|NCT05153330|EXPERIMENTAL|Dose Escalation Phase|"Experimental: ARM A:~Study participants who are not receiving a moderate or strong CYP3A4 inhibitor.~Dose Escalation Phase:~* Cohort 1: Participants with acute leukemia~* Cohort 2: Participants with diffuse large B-cell lymphoma~* Cohort 3: Participants with multiple myeloma~* Cohort 4: Participants with chronic lymphocytic leukemia/ small lymphocytic lymphoma~Participants will receive escalating dose BMF-219 orally once per day to identify the OBD/RP2D (Optimal Biologic Dose/Recommended Ph2 Dose).~Dose Expansion Phase:~Cohorts 1, 2, 3, and 4 will receive BMF-219 at the OBD/ RP2D to further assess the safety/ efficacy of the investigational drug."
61998222|NCT03430804||Single gruop320 parturients|Measurement of cervical length and digital examination of Bishop score in 320 women undergoing induction of labour will be carried out in ain shams university maternity hospital.
61998223|NCT00016952|EXPERIMENTAL|irinotecan|"Prior oxaliplatin-based chemotherapy: Patients receive irinotecan IV over 90 minutes on day 1. Treatment repeats every 3 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a confirmed complete response for 2 consecutive courses may discontinue treatment at investigator's discretion.~Quality of life is assessed at baseline, approximately every 6 weeks during treatment, and then after the last course of treatment.~Patients are followed every 3 months for 5 years."
61998224|NCT00016952|EXPERIMENTAL|leucovorin + fluorouracil|"Prior to irinotecan and oxaliplatin combination chemotherapy: Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV continuously on days 1 and 2. Treatment repeats every 2 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a confirmed complete response for 2 consecutive courses may discontinue treatment at investigator's discretion.~Quality of life is assessed at baseline, approximately every 6 weeks during treatment, and then after the last course of treatment.~Patients are followed every 3 months for 5 years."
61998225|NCT01393769|EXPERIMENTAL|Melphalan|Intra-arterial chemotherapy with melphalan, via direct administration by catheterization of the ophthalmic artery. Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume: a)3 mg for patients under 10 kg and tumour volume size under 1,5 cm3; b)5 mg for patients over 10 kg and tumour volume over 1,5 cm3; c)4 mg in all other situations(tumour volume over 1,5 cm3 in patients under 10 kg or tumour volume under 1,5 cm3 in patients over 10 kg).
61998226|NCT04742569||Cohort 1- Exposed/Early Symptomatic|"The population identified for this study includes subjects who request COVID-19 testing in response to a concern for recent COVID-19 exposure and/or concern of COVID-19-like related symptoms. We will recruit and enroll patients through public facing websites, clinic and pharmacy vaccination schedules and on-site vaccination marketing.~For the population with recent COVID-19 exposure and/or concern of COVID-19-like related symptoms, population identification includes subjects who visit eTrueNorth's https://www.doineedacovid19test.com/ website where subjects have access to over 7,500 testing site locations across the nation. Otherwise, individuals seeking COVID-19 testing will be directed to the ClinOne, Inc. website for information regarding the Wearable Diagnostic for Detection of COVID-19 Infection study contact information for study participation, enrollment into the study using eConsent, and will receive a BioSticker wearable kit by express mail the next day."
61998227|NCT04742569||CoHort 2- Pfizer or Moderna Vaccine|Secondly, the other population identified for this study includes subjects who are scheduled for the first and second dose of the mRNA-based Pfizer/BioNTech and Moderna vaccine series. For the population seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series, we will recruit and enroll patients through public-facing websites, clinic, and pharmacy vaccination schedules, and on-site vaccination marketing
61998228|NCT02583581|EXPERIMENTAL|Participants diagnosed with migraine|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv)
62392494|NCT02190396||Group 1|Placental calcification of Grade 3
62392495|NCT02190396||Group 2|No placental calcification noted, the control group.
62392496|NCT05896800|EXPERIMENTAL|Low concentration group|inhaled nitric oxide (iNO) 10ppm，≥2 hours/day for 7 days
62392497|NCT05896800|EXPERIMENTAL|High concentration group|iNO 40ppm，≥2 hours/day for 7 days
62392498|NCT01211795|ACTIVE_COMPARATOR|Topical Ketoprofen gel|
62392499|NCT01211795|PLACEBO_COMPARATOR|Placebo gel|
62392500|NCT05364203|NO_INTERVENTION|no intervention|Injections were done as usual without mask.
62392501|NCT05364203|ACTIVE_COMPARATOR|Comparator|Injections are made as in standard practice. The virtual reality headset is added to the patient. In this case, there is no image or sound. The mask is off.
62392502|NCT05364203|EXPERIMENTAL|Intervention|Injections are made as in standard practice. We add the virtual reality mask with the image and the sound.
62392503|NCT06252831|EXPERIMENTAL|Healthy volunteers|1 sachet (1 g) take 2 times a day with an interval of 12 hours. The duration of taking the medicine is 7 days. The study is carried out on an outpatient basis. The total duration of each subject's participation in the clinical trial is no more than 21±1 days.
62568293|NCT04347369||Observed group|The patients who were detected COVID-19 disease by RT-PCR and CT imaging.
62568294|NCT04332900|NO_INTERVENTION|Control condition|In this condition there will not be any application of therapeutic approach.
62568295|NCT04332900|EXPERIMENTAL|Intervention proximal condition|The proximal therapeutic approach will be the SERF strap (S.E.R.F. strap; DonJoy Orthopedics, Inc., vista, CA).
62791565|NCT05751369|EXPERIMENTAL|TECW+|Education plus motivational enhancement
62183772|NCT05153330|EXPERIMENTAL|Dose Expansion|"Experimental: ARM B:~Study participants who are receiving a moderate or strong CYP3A4 inhibitor.~Dose Escalation Phase:~• Cohort 1: Participants with acute leukemia will receive escalating dose BMF-219 orally to identify the OBD/ RP2D (Optimal Biologic Dose/Recommended Ph2 Dose).~Dose Expansion Phase:~Cohort 1 will receive BMF-219 at the OBD/ RP2D to further assess the safety and efficacy of the investigational drug."
61998229|NCT01924169|EXPERIMENTAL|Lenalidomide|Lenalidomide administered at the dose of 5 mg/day on Monday, Wednesday and Friday for 3 months. If Immunoglobulin G (IgG) levels improve by at least 25% of baseline, lenalidomide administration continued for 3 months on, and 3 months off for 2 years. If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years. Seasonal influenza vaccination (Trivalent Influenza Vaccine, Fluzone High Dose) administered yearly, during the fall/winter season and pneumococcal immunization (Pneumococcal Polysaccharide Vaccine, Pneumovax) administered once between month 6 and month 21.
61998230|NCT03709537|EXPERIMENTAL|Mental Health Peer Workforce Support|Sites assigned to this group will engage in Co-Learning Collaborative, several trainings, and the creation of Implementation Teams--all part of the intervention and designed to support their peer workforce.
61998231|NCT03709537|NO_INTERVENTION|Control Group|Sites assigned to this group will continue practice as usual and not receive any additional peer worker training or technical assistance.
62183773|NCT03447574|EXPERIMENTAL|Aim 1|The ethanol dilution is, in essence, a non-invasive dilution method. It is of interest because of how ethanol readily dissolves itself exclusively into the water space of the body\[4\], is non-toxic in reasonable concentrations, is metabolized in a 0th order reaction above concentrations of 0.015 g/dL\[4\], and there are non-invasive methods for determining blood alcohol concentration\[5, 6\]. Thus, by drinking a known amount of ethanol, total body water can be calculated after a few hours of periodic breathalyzer analyses. Ethanol has been validated against deuterium oxide, the invasive gold standard for determining total body water\[4\]. The ethanol dose will be 0.5g/kg body weight.
62183774|NCT03447574|ACTIVE_COMPARATOR|Aim 2|30mL/kg body weight of saline will be rapidly infused after the baseline measurements completed in Aim 1. Non-invasive methods for fluid volume determination (CO-pulse-oximetry, ethanol breathalyzer, BIS) will be conducted and change from baseline calculated. To determine if non-invasive fluid volume techniques can accurately determine fluid changes in healthy participants.Non-invasive methods for fluid volume determination (CO-pulse-oximetry, ethanol breathalyzer, BIS) will be conducted and change from baseline calculated.
62183775|NCT01454388|ACTIVE_COMPARATOR|PEG plus breakfast|patients are allowed to have a low residue breakfast the day prior to colonoscopy
62183776|NCT01454388|NO_INTERVENTION|PEG without breakfast|
62183777|NCT01454388|ACTIVE_COMPARATOR|picosalax plus breakfast|patients are allowed to have a low residue breakfast the day prior to colonoscopy
62183778|NCT01454388|NO_INTERVENTION|picosalax without breakfast|
62183779|NCT01551069|ACTIVE_COMPARATOR|HCQ|HCQ 200\~400mg, once daily, oral administration
62392504|NCT02107781||Patients with open abdomen|Patients in a critical care unit with abdomen that was not closed during initial operation \& will have intra-abdominal pressure monitoring using the AbViser abdominal compartment pressure measuring device.
62392505|NCT01251666|OTHER|Magstream + Oc Sensor + Hemoccult II|"Each patient will perform all three tests:~* Magstream: 2 samples (each on a different stool)~* OC Sensor: 2 samples (each on a different stool)~* Hemoccult II: 6 samples (2 samples per stool, on 3 different stools)~Each test will be considered as positive if at least one sample is positive (cutoff for Magstream 55 ng/ml and for OC Sensor 150 ng/ml).~Screening will be considered as positive if at least one of the three tests is positive, leading to a colonoscopy"
62392506|NCT01579994|EXPERIMENTAL|Ganetespib (STA-9090) and crizotinib|This protocol is a phase I single arm, open label, single institution study of crizotinib and ganetespib (STA-9090) in patients with ALK+ advanced NSCLC who are crizotinib naïve.
62392507|NCT00630760|EXPERIMENTAL|1|NRX 194204 capsules in escalating doses, starting at 3mg/m2.
62183780|NCT01551069|OTHER|Placebo|HCQ-placebo, once daily, oral administration
62392508|NCT02938858||ATRA-chimio|according to usual practice center
62392509|NCT02938858||ATRA-ATO|according to usual practice center
62392510|NCT02567721||Study Cohort|Subjects who will receive influenza vaccination between 1 September 2015 and 30 November 2015 in the 9 GP practices from who clinical data routinely collected as part of clinical consultations in primary care will be extracted.
62392511|NCT05129618|ACTIVE_COMPARATOR|Product Tolerability Arm|active product: MHS 1031 Panosyl-isomaltooligosaccharides liquid 1 g (1.4 ml) per day
62392512|NCT05129618|PLACEBO_COMPARATOR|Placebo Tolerability Arm|Placebo liquid 1 g (1.4 ml) per day
62392513|NCT01219959|ACTIVE_COMPARATOR|Non-glucose Sparing|Dianeal only
62392514|NCT01219959|EXPERIMENTAL|Glucose Sparing|Dianeal, Extraneal, Nutrineal
61998232|NCT02845752|ACTIVE_COMPARATOR|Stiolto Respimat|Two actuations of Stiolto Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
61998233|NCT02845752|PLACEBO_COMPARATOR|Placebo Respimat|Two actuations of Placebo Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
62392515|NCT05503043|EXPERIMENTAL|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the first hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
62392516|NCT05503043|PLACEBO_COMPARATOR|Normal saline|Normal saline administered as a bolus and an infusion with identical volume and rate changes as the treatment group.
61998234|NCT04339400|EXPERIMENTAL|TQ05105 Tablet|TQ05105 tablet 5mg administered orally once. Then TQ05105 tablet administered orally, twice daily in 28-day cycle after 3 days of first administration.
62183781|NCT00771095|ACTIVE_COMPARATOR|Control (available) podcast|
62183782|NCT00771095|EXPERIMENTAL|Enhanced podcast|
61998235|NCT03468881||Breast cancer radiation therapy|Observation over a period of all treatment sessions for radiotherapy.
62183783|NCT02892201|EXPERIMENTAL|All subjects|"for patients with squamous cell carcinoma of the head and neck who have residual disease following definitive therapy with radiation~Pembrolizumab will be given at a constant dose of 200 mg every three weeks, for four cycles. Patients with resectable disease can then go on to surgery, and patients with unresectable disease can continue on pembrolizumab until progression or for up to 1 year."
62183784|NCT00470405|EXPERIMENTAL|Therapeutic Intervention|
62183785|NCT00444262|ACTIVE_COMPARATOR|1|conventional treatment
62183786|NCT00444262|EXPERIMENTAL|2|stroke volume optimisation
62183787|NCT01301703|ACTIVE_COMPARATOR|Tdap vaccination|Patients and controls will be vaccinated with BOOSTRIX (Tdap vaccine)
62183788|NCT04999605|EXPERIMENTAL|AK112|AK112 injection
62183789|NCT05130346|EXPERIMENTAL|Mindfulness Based Stress Reduction (MBSR)|
62183790|NCT05130346|NO_INTERVENTION|Standard of Care (SOC)|
62183791|NCT06168162|EXPERIMENTAL|titrate PEEP|individulaized PEEP starting 7cmH2O titrated to best static compliance (Cstat) ranging from 50 -100 cmH2O
62183792|NCT06168162|ACTIVE_COMPARATOR|standard|standard PEEP of 5 cmH2O
62183793|NCT04328103||Cognitive Behavior Therapy (CBT)|Following established procedures at the Depression Evaluation Service (DES) at New York State Psychiatri Institute (NYSPI), 12 sessions of individual manual-driven CBT (Emery, 2000) will be conducted by highly trained master degree clinicians.
62183794|NCT04328103||Nonspecific Supportive Therapy (PBO)|As a non-CBT intervention that includes warmth, genuineness and empathy (Linde et al., 2011), nonspecific supportive therapy (PBO) will be administered in a parallel format to CBT, also consisting of 12 individual sessions.
62183795|NCT04869813||Heart failure patients|"Inclusion criteria:~* Age \> or = 40 yrs~* Stable chronic heart failure~* Systolic dysfunction determined by cardiac MRI with left ventricle ejection fraction 40% or less~Exclusion criteria:~• Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease~Contraindications to MRI such as:~* Heart pacemaker/defibrillator~* Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires~* Cochlear implant or other ear implants~* Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity)~* Programmable shunt~* Aneurysm clips and coils~* Stents • Filters (for example, blood clot filters)~* Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)"
62183796|NCT04869813||Healthy volunteers (Controls)|"Inclusion criteria:~* Age \> or = 40 yrs~* No diagnosed heart failure or sarcopenia~Exclusion criteria~• Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease~Contraindications to MRI such as:~* Heart pacemaker/defibrillator~* Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires~* Cochlear implant or other ear implants~* Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity)~* Programmable shunt~* Aneurysm clips and coils~* Stents~* Filters (for example, blood clot filters)~* Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)"
62183797|NCT04166110|ACTIVE_COMPARATOR|Physician's prescription|Antibiotic treatment duration according to physician, following the French national guidelines: 7 to 14 days.
62183798|NCT04166110|EXPERIMENTAL|Duration according to stability|"Antibiotic treatment duration is variable. Interruption of treatment is based on the patient reaching stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure ≥ 90mmHg, oxygen saturation ≥ 90%).~Minimum of duration of antibiotic treatment: 3 days."
62183799|NCT02194842|ACTIVE_COMPARATOR|Enzalutamide|Enzalutamide will be given at a dose of 160 mg daily
62568296|NCT04332900|EXPERIMENTAL|Intervention distal condition|The distal therapeutic approach will be a pair of foot orthoses with semi-rigid arch support and medial elevation at the forefoot and at the rearfoot by 7° each (Propulsão Produtos Biomecânicos, Minas Gerais, Brazil).
62568297|NCT01854190||Resistant hypertension|"Patients with uncontrolled blood pressure despite 3 medications, including diuretic.~Endothelial function assessed by peripheral arterial tonometry (PAT) by EndoPAT and the OSA diagnosis also through PAT, using the portable device WatchPAT."
62568298|NCT01854190||Controlled hypertension|Patients with controlled blood pressure by medications. These drugs are the same used in both groups.
62568299|NCT00891059||Placebo Diskus Inhaler|
62183800|NCT02194842|EXPERIMENTAL|Enzalutamide and Ra223|Ra223 will be administered 55kBq/kg standard dose monthly for 6 months and given in combination with enzalutamide at a dose of 160 mg daily.
62183801|NCT02239861|EXPERIMENTAL|TAA-Specific CTLs|"4 different dosing schedules will be evaluated. 2 to 4 patients will be evaluated on each dosing schedule. The first 2 patients on each dose level will be staggered by 4 weeks (which starts when the first infusion is given, Day 0). No subjects between the ages of 2-18 will be enrolled to a dose level on this protocol, until an adult has been enrolled to and treated on that dose level on one of the protocols being conducted under this same IND. Each patient will receive 2 injections at the same dose,14 days apart: The expected volume of infusion will be 1 to 10 cc.~Dose Level One:~Day 0 and 14: 5 x 10\^6 cells/m\^2~Dose Level Two:~Day 0 and 14: 1 x 10\^7 cells/m\^2~Dose Level Three:~Day 0 and 14: 2 x 10\^7 cells/m\^2~Dose Level Four:~Day 0 and 14: 4 x 10\^7 cells/m\^2"
62392517|NCT02939508|EXPERIMENTAL|Colon originated|A history of colon (-innervating) nerve damage, moderate or more severe edema; and without a history of colon (-innervating) nerve damage, with mild or severe edema of colonic wall on CT.
62568300|NCT05787717|EXPERIMENTAL|Parental presence|Parents are present and active in the care of their child until general anesthesia has been established in the operating room
62392518|NCT02939508|ACTIVE_COMPARATOR|Non-colon originated|"NCOG met one of the two following criteria:~1. History of nerve damage that could affect colon movement (colon \[-innervating\] nerve damage), such as pelvic or retroperitoneal operation, spine injury, or cerebral lesion; and non-existing or mild edema of colonic wall on abdominal CT;~2. Absence of history of colon(-innervating) nerve damage, with no obvious change in the colonic wall visible on the CT scan."
62773937|NCT04712552||Stereotactic robot-guided deep brain stimulation procedure|Patients requiring a stereotactic robot-guided deep brain stimulation procedure (Parkinson's disease, disabling tremor, dystonia)
62773938|NCT03909451|EXPERIMENTAL|Dose 1|Sotagliflozin dose 1, once daily for 8 days
61998236|NCT02533271|EXPERIMENTAL|TNT group|The intervention of TNT group is Short-course radiotherapy with neoadjuvant chemotherapy, which consists of a short-course radiotherapy (SCRT, 5 Gy x 5 alone), then after 7-10 days of radiotherapy completed, patients will receive neoadjuvant chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are prescribed preoperatively, then followed by a total mesorectal excision(TME) and postoperative adjuvant chemotherapy. If patients are eligible for postoperative chemotherapy this should consist of at least 2 cycles, which are the same as neoadjuvant chemotherapy.
62183802|NCT02804399|EXPERIMENTAL|all subjects|subjects will receive a 100 mg single oral dose of PF-06463922 followed by a 100 mg single dose of PF-06463922 combined with 600 mg QD dose of rifampin with at least 10 days of washout period between two PF-06463922 doses.
62183803|NCT05266898|EXPERIMENTAL|Gardasil-9 recipients|Participants receive 3-dose Gardasil-9 vaccine series.
62183804|NCT00661713|EXPERIMENTAL|rMenB06|Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and two injections of placebo (at month 1, month 2). A second injection of rMenB+OMV NZ vaccine was given later (month 6).
62392519|NCT01905241|EXPERIMENTAL|Anatomic TSA using RTI|During Anatomic Total Shoulder Arthroplasty (TSA), the surgeon will have use of the SmartBone and the bone cement mold made from the SmartBone (the RTI) to transfer the preoperative plan for glenoid implant positioning to the patient's anatomy.
62568301|NCT05787717|NO_INTERVENTION|Control|Parents leave their infant in the holding area of the operating rooms
62568302|NCT05470699|EXPERIMENTAL|Diagnostic ([18F]-DCFPyL PET-CT, X1 RMRS PET-CT)|Patients receive \[18F\]-DCFPyL IV and undergo \[18F\]-DCFPyL PET-CT over 30 minutes per SOC. Patients with PET avid lesions then undergo a X1 RMRS PET-CT imaging-only session within 120 minutes of injection over 20-35 minutes.
62568303|NCT00080756|EXPERIMENTAL|Group 1 (planned risk reduction mastectomy)|Patients receive deslorelin, estradiol, and testosterone intranasally QD for 6 months. Patients then undergo planned risk reduction mastectomy.
62568304|NCT00080756|ACTIVE_COMPARATOR|Group 2 (continued survaillance)|Patients receive deslorelin, estradiol, and testosterone intranasally QD for 10 months. Patients then undergo continued surveillance through 10 months.
62773939|NCT03909451|EXPERIMENTAL|Dose 2|Sotagliflozin dose 2, once daily for 8 days
62773940|NCT03909451|PLACEBO_COMPARATOR|Placebo|Placebo, once daily for 8 days
62773941|NCT01302054|EXPERIMENTAL|Fesoterodine|
62773942|NCT01302054|PLACEBO_COMPARATOR|Placebo|
62773943|NCT00483041|EXPERIMENTAL|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
62773944|NCT00483041|PLACEBO_COMPARATOR|PLACEBO|Placebo administered as a single intravenous infusion
62773945|NCT02593656|EXPERIMENTAL|High Protein|Ingestion of 2.0 grams of protein per kilogram of body weight per day combined with exercise training
61998237|NCT02533271|OTHER|CRT group|The intervention of CRT group is long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively, followed by a total mesorectal excision(TME) and then postoperative adjuvant chemotherapy. The radiotherapy is given in combination with capecitabine in a dose of 825 mg/m2 twice daily on days when radiotherapy, excluding weekends. If patients are eligible for postoperative chemotherapy this should consist of at least 6 cycles of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once every 3 weeks.
61998238|NCT02346084|EXPERIMENTAL|Female Participants - Arms 1A through 9A|"Female Participants 9 Arms (1A through 9A) 3 Product Sequences~Product Sequence 1 Rx1- MVC tablet PO Rx2- MVC 1% gel PR Rx3- MVC 1% gel PV~Product Sequence 2 Rx1- MVC 1% gel PR Rx2- MVC 1% gel PV Rx3- MVC tablet PO~Product Sequence 3 Rx1- MVC 1% gel PV Rx2- MVC tablet PO Rx3- MVC 1% gel PR~3 Biopsy Schedules D8- (\~2-hr after the 8th dose) D9- (\~24-hr after the 8th dose) D10- (\~48-hr after the 8th dose)"
62183805|NCT00661713|EXPERIMENTAL|rMenB0|Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and three injections of placebo (month 1, month 2 and month 6).
62392520|NCT05485194|NO_INTERVENTION|Unassisted healing|The extraction sockets in the non-intervention group will be filled with blood clots only.
62568305|NCT04565145|EXPERIMENTAL|Kava Pharmacokinetics Group|75 mg kava dietary supplement capsules per day for one week.
62773946|NCT02593656|ACTIVE_COMPARATOR|Normal Protein|Ingestion of 1.0 gram of protein per kilogram of body weight per day combined with exercise training
62183806|NCT00661713|EXPERIMENTAL|rMenB016|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).
62392521|NCT05485194|EXPERIMENTAL|Titanium bone screw (TBS)|One titanium bone screw (TBS) will be placed over the labial/buccal plate of the extraction socket in the TBS group on the same day of the extraction.
62568306|NCT04565145|PLACEBO_COMPARATOR|Placebo|Three placebo capsule per day for one week
62568307|NCT06255119|ACTIVE_COMPARATOR|Active VR Group|Participants received the active virtual therapy intervention.
62773947|NCT01838018||PKAN|This group consists of individuals diagnosed with PKAN using a combination of MRI and PANK2 gene sequencing.
62773948|NCT01838018||Healthy volunteers|This is a control group of healthy volunteers, matched with the PKAN group for age and sex.
62183807|NCT00661713|EXPERIMENTAL|rMenB01|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and two injection of placebo (at month 2 and month 6).
62773949|NCT01308229|EXPERIMENTAL|Nile PAX®|
62183808|NCT00661713|EXPERIMENTAL|rMenB026|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).
62183809|NCT00661713|EXPERIMENTAL|rMenB02|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and two injections of placebo (at month 1 and month 6).
62183810|NCT00661713|EXPERIMENTAL|rMenB012|Subjects received three injections of rMenB+OMV NZ vaccine (at month 0, month 1 and month 2) and one injection of placebo later (at month 6).
62183811|NCT00661713|EXPERIMENTAL|rMenB6|Subjects received three injections of placebo(at month 0, month 1 and month 2) and one injection of rMenB+OMV NZ vaccine(at month 6).
62568308|NCT06255119|NO_INTERVENTION|Control Group|A group of patients concurrently on the ATS unit, otherwise eligible to participate in the study who did not enroll, and did not receive an intervention.
62773950|NCT05251038|EXPERIMENTAL|Experimental Group|"Patients will either receive a combination of:~Sotorasib + Liposomal Irinotecan (nal-IRI) + 5 Fluorouracil (5FU) + Leucovorin (LV)~OR~Sotorasib + Gemcitabine (GEM) + Nab-paclitaxel~\*The combination of therapy received is based on the participants prior therapy and of the discretion of their treating physician"
62773951|NCT05230485|EXPERIMENTAL|Higher CPAP|CPAP level will be 2 cmH2O higher than pre-extubation measured mean airway pressure
62392522|NCT05485194|ACTIVE_COMPARATOR|Alveolar ridge preservation (ARP)|The extraction socket will be filled with mineralized ground cortical allograft up to the level of the buccal and lingual/palatal bony plates. A resorbable membrane will be trimmed and adapted to cover the grafting material. The flaps will be secured with a monofilament suture.
62392523|NCT05932420|PLACEBO_COMPARATOR|Control group|Placebo is provided
62392524|NCT05932420|EXPERIMENTAL|Experimental groep|Ketone ester is provided
62392525|NCT00938743|ACTIVE_COMPARATOR|Atomoxetine|Treatment with a final dosis of 40-80mg atomoxetine daily
62392526|NCT00938743|NO_INTERVENTION|Waiting list|
62568309|NCT00384462||1|Premature Infants (32-35 wks. GA) who are less than six months of age at start of RSV season and followed until May of the following year.
62568310|NCT00384462||2|Premature newborns (32-35 wks. GA) who are born during the current RSV season and discharged from the hospital after 01 Dec and followed until May of the next year.
62392527|NCT04462731|EXPERIMENTAL|Obturation technique: WVT|Warm vertical compaction technique (WVT): Teeth filled with AH Plus Jet Root Canal Sealer were filled with .04 taper gutta-percha points by WVT. The sealer was introduced with the master cone. The depth of heated plugger was within 3-5 mm of WL in the WVT group, and the remaining canal space was backfilled with additional sealer and thermoplasticized gutta-percha.
62773952|NCT05230485|ACTIVE_COMPARATOR|Equivalent CPAP|CPAP level will be equal to the pre-extubation measured mean airway pressure
62773953|NCT05943197|EXPERIMENTAL|20 patients with zirconia|patients who will receive crowns from zirconia
62773954|NCT05943197|EXPERIMENTAL|20 e-max patients|patients who will receive crowns from e-max
62773955|NCT05943197|EXPERIMENTAL|20 patients Cobalt-chromium alloy|patients who will receive crowns from Cobalt-chromium alloy
62773956|NCT05943197|EXPERIMENTAL|20 patients metal-ceramics|patients who will receive crowns from metal-ceramics
62773957|NCT00076349|EXPERIMENTAL|1|open-label, single arm, clinical trial of bendamustine (SDX-105) plus rituximab
62773958|NCT01278407|PLACEBO_COMPARATOR|Placebo - Confirmatory Phase|Participants received donepezil matched placebo tablets orally, once daily for 12 weeks in the confirmatory phase.
62773959|NCT01278407|EXPERIMENTAL|Donepezil 5 mg - Confirmatory Phase|Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 10 weeks in the confirmatory phase.
62773960|NCT01278407|EXPERIMENTAL|Donepezil 10 mg - Confirmatory Phase|Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 4 weeks. Thereafter, the dose was increased to 10 mg for 6 weeks in the confirmatory phase.
62773961|NCT01278407|EXPERIMENTAL|Placebo to Donepezil (5 +10 mg) - Extension Phase|Participants previously receiving donepezil matched placebo up to Week 12 in the Confirmatory Phase, continued placebo until Week 16 (at the beginning of the Extension Phase). Participants received 3 mg of donepezil, and the dose was then increased to 5 mg at Week 18 and to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.
62773962|NCT01278407|EXPERIMENTAL|Donepezil (5 +10 mg) - Extension Phase|Participants previously receiving donepezil (5 mg or 10 mg) up to Week 12 in the Confirmatory Phase, maintained allocated treatment and dosages until Week 24. In the 5 mg group of the Confirmatory Phase, the dose was increased to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.
62773963|NCT04107441|EXPERIMENTAL|Part 1 arm|Ten healthy participants will receive one orally disintegrating tablet (ODT) with 5 mg, 10 mg, 20 mg or 40 mg AX-8 twice daily (8 hours apart, i.e. at 0 hour and +8 hours), during the treatment day (Day 1) of treatment periods 1, 2, 3 or 4, respectively.
62773964|NCT04107441|EXPERIMENTAL|Part 2 arm|Ten healthy participants will receive one orally disintegrating tablet (ODT) with 5 mg AX-8 and one ODT with 40 mg AX-8 8 hours later (i.e. at 0 hour and +8 hours), during the treatment day (Day 1) of the treatment period.
62773965|NCT02166541|EXPERIMENTAL|INRS with BCSK|"Intensive Neurophysiological Rehabilitation System (INRS) including the Biomechanical correction of the spine according to Kozyavkin (BCSK).~The daily treatment for about 2 hours are in general equal for all children except for the type of spinal manipulation. Duration of all treatment will be noted in a Treatment Diary."
61998239|NCT02346084|EXPERIMENTAL|Male Participants - Arms 1B through 4B|"Male Participants 4 Arms (1B through 4B) 2 Product Sequences 2 biopsy schedules~Product Sequence 1 Rx1- MVC tablet PO Rx2- MVC 1% gel PR~Product Sequence 2 Rx1- MVC 1% gel PR Rx2- MVC tablet PO~Biopsy Schedule D8- (\~2-hr after the 8th dose) D10- (\~48-hr after the 8th dose)"
62392528|NCT04462731|ACTIVE_COMPARATOR|Obturation technique: SBT|Sealer-based filling technique (SBT): Teeth filled with SBT were obturated with EndoSequence BC Sealer by injecting the sealer into the coronal third of each canal. Size 30 Lentulo spiral coated with additional sealer was introduced 3 mm short of WL depth at 300rpm. Bioceramic coated gutta-percha was dipped in BC sealer and introduced into the canal to WL. A heated plugger was used to sear the gutta-percha point at each orifice.
62392529|NCT03607968||All women in this study|All women with POP and concomitant overt or occult USI, who underwent the novel anterior TVM surgeries, were enrolled in this study. Medical records, including urodynamic studies, questionnaires and 3-day bladder diaries, were retrospectively reviewed. Linear regress analysis was used to identify factors that were responsible for the changes in pad weights from baseline \[i.e., 100 \* (postoperative pad weight - baseline pad weight)/baseline pad weight\].
62568311|NCT01878552||ARDS|Mechanically ventilated patients with Acute Respiratory Distress Syndrome
62791566|NCT00078247|EXPERIMENTAL|1|Participants will receive 6 months of ARV therapy and treatment for TB
61998240|NCT04082988|OTHER|Nivolumab|"Nivolumab treatment according to label: 3 mg/kg nivolumab IV Q2W, 240mg Q2W or 480mg Q4W as an IV infusion until disease progression or unacceptable toxicity.~FDG PET-CT will be performed at baseline and between 7 and 14 days after treatment initiation"
62183812|NCT02420405|PLACEBO_COMPARATOR|Routine gene testing|Routine gene testing of EGFR, ROS1 and ALK will be performed on those diagnosed with nonsquamous NSCLC.
61998241|NCT02781636|EXPERIMENTAL|Chronic Tibial Implant Arm|StimGuard Protect System (Chronic Tibial Nerve Stimulation) Implant Procedure. Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
62183813|NCT02420405|EXPERIMENTAL|Next-generation sequencing|Routine gene testing was performed in those diagnosed with nonsquamous NSCLC. NGS will be performed on these that have adequate rest tissues.
62183814|NCT06486584|EXPERIMENTAL|Contingency Management|"Meet weekly for 30 minutes with their case manager to discuss progress on life goals ($10) and for having seven days with no disruptive behaviors (or trouble-free days) per week at each visit, they will receive an additional baseline payment of $20, increasing with continued success in subsequent weeks by $1 per week."
62183815|NCT06428877||Patients who underwent EVAR with ACS Gore excluder.|Patients who underwent EVAR with ACS Gore excluder. Only patients with proximal neck angulation superior to 60 degrees will be considered.
62183816|NCT04067908|EXPERIMENTAL|woman giving birth prematurely|Proteome: by liquid chromatography coupled with tandem mass spectrometry. Fibronectin: by vaginal sampling. Ultrasound of the cervix. Cytokines: ELISA kit of a panel of several cytokines.
62183817|NCT01287845|EXPERIMENTAL|Arm 1|
62392530|NCT00074399|EXPERIMENTAL|1|Participants will receive nevirapine for 6 weeks
62392531|NCT00074399|PLACEBO_COMPARATOR|2|Participants will receive nevirapine placebo for 6 weeks
62392532|NCT04679064|ACTIVE_COMPARATOR|Phisician's choice of standard chemotherapy|"Chemotherapy at physician's choice between Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 Gemcitabine 1000 mg/mq d 1,8,15 q 28 Topotecan 1.25 mg/mq day 1-5 q 21~+/- Bevacizumab at defined scehedule"
62568312|NCT06069219||Adult patients received epidural sufentanil during and after abdominal surgery|All patients were premedicated with oral midazolam 7,5 mg and then they were induced into general endotracheal anesthesia according to a standardized protocol, with propofol 1-3 mg/kg, fentanyl 1-2 ug/kg and rocuronium bromide 0.6 mg/kg. Anaesthesia was continued with sevoflurane or desflurane MAC 1 to maintain mean arterial pressure with a value of +/- 20% of the original value. The epidural sufentanil infusion was started with bolus during anesthesia and continued after surgery as long as was necessary.
62568313|NCT01873846|EXPERIMENTAL|Silicone Hydrogel Contact Lens|Contact lenses to be worn in each eye on a daily wear basis for 2 weeks. Participants will be provided with Bausch + Lomb Biotrue® multi-purpose solution and contact lens cases for daily rinsing, cleaning, disinfecting, and storing their lenses.
62568314|NCT04812041||Intensive care unit delirium|Covid-19 patients in ICU are screened for delirium and rated the severity with CAM-ICU 7 scores.
62568315|NCT01400490|PLACEBO_COMPARATOR|Olive Oil 6 grams/day|
62568316|NCT01400490|ACTIVE_COMPARATOR|DHA 1800 mg/day|
62568317|NCT01400490|ACTIVE_COMPARATOR|EPA 1800 mg/day|
62568318|NCT01400490|ACTIVE_COMPARATOR|Fish Oil with EPA 1800 mg/day and DHA 1200 mg/day|
62568319|NCT06481293|EXPERIMENTAL|Group 1|Group 1 received diode laser therapy
62568320|NCT06481293|EXPERIMENTAL|group 2|Group 2 received topical application of aveogl dressing
62568321|NCT05428683|OTHER|prophylactic measures against post-operative inflammations|Usage of triamcinolone and moxifloxacin combination to be injected intravitreally by using 30 G needle.
62568322|NCT05258318|ACTIVE_COMPARATOR|DR crush technique|
61998242|NCT02000375|EXPERIMENTAL|DHEA|Daily oral administration of DHEA at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
62183818|NCT01287845|EXPERIMENTAL|Arm 2|
62568323|NCT05258318|EXPERIMENTAL|DK crush technique|
62568324|NCT05224739||Patients who underwent MILR from January 1, 2000 to December 31, 2020|Hospital of patients who underwent MILR from January 1, 2000 to December 31, 2020.
62568325|NCT03602378||Parents of children with disability|parents of children with developmental disabilities (Down syndrome, autism spectrum disorder, pervasive developmental disorder, cerebral palsy), age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
62568326|NCT03602378||Parents of children with chronic disease|parents of children chronic disease (diabetes mellitus type 1, epilepsy, asthma), age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
62568327|NCT03602378||Parents of healthy children|parents of healthy children, age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
62568328|NCT03252977|EXPERIMENTAL|Tailored group|Tailored regimen of IV PCA according to pain sensitivity The regimen of IV PCA will be determined according to preoperative pain sensitivity of patients. Pressure pain threshold will be measured preoperatively in these patients using pressure algometer. Patients with low pain threshold will use high dose IV PCA containing fentanyl 1500mcg, while patients with high pain threshold will use low dose IV PCA containing fentanyl 1000mcg.
62791567|NCT00078247|EXPERIMENTAL|2|Participants will not receive ARV therapy until CD4 counts drop below 250 cells/mm3. All participants will receive treatment for TB.
62183819|NCT01752764|EXPERIMENTAL|Test product|Test product: Salad with high dosage fat
62183820|NCT01752764|OTHER|Control product|Control product: Salad with low dosage fat
62392533|NCT04679064|EXPERIMENTAL|Niraparib+Dostarlimab|Dostarlimab 500 mg q 3W for the fist 4 cycles, 1000 mg q 6W thereafter + Niraparib 300 mg or 200 mg if platelet count \<150,000 /μL and/or body weight \<77kg QD po q 28
62773966|NCT02166541|SHAM_COMPARATOR|INRS with traditional spinal manipulation|"Intensive Neurophysiological Rehabilitation System (INRS) including spinal manipulation by the traditional technique.~The daily treatment for about 2 hours are in general equal for all children except for the type of spinal manipulation. Duration of all treatment will be noted in a Treatment Diary."
62183821|NCT06345326|EXPERIMENTAL|Repeated greater occipital nerve block|In this arm, all the participiants will receive ultrasound guided greater occipital nerve block for a week, for 4 weeks with ultrasound guidiance at the level C2
62568329|NCT03252977|SHAM_COMPARATOR|control group|Regimen of IV PCA without considering pain sensitivity The regimen of IV PCA will be determined according to experimental group patient assignments. Pressure pain threshold will not be measured in these patients. Patients will use IV PCA with fentanyl 1000mcg or fentanyl 1500mcg. The determination will be paired to assignment of experimental group.
62568330|NCT02617160|EXPERIMENTAL|MD Logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
62773967|NCT02166541|EXPERIMENTAL|Total population|All participants (i.e., both arms described above INRS with BCSK or traditional spinal manipulation)
62773968|NCT00821912|EXPERIMENTAL|Taxotere Xeloda|"Taxotere i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule.~Xeloda orally day 1-14 every 3 weeks."
62183822|NCT06345326|EXPERIMENTAL|Greater occipital nerve pulse radiofrequency|In this arm, all the participiants will receive ultrasound guided greater occipital nerve pulse radiofrequency with ultrasound guidiance at the level C2
62183823|NCT02950181|EXPERIMENTAL|Specific Aim|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
62183824|NCT04351945||Blood test|Patients will have a blood test to define hormone levels.
62183825|NCT02085473|ACTIVE_COMPARATOR|Cohort 1|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'W' mL/min.
62773969|NCT05017818||Treated and untreated subjects with TK2 deficiency|Two TK2 deficiency groups. (1) Subjects treated with chemical-grade dCMP/dTMP, dC/dT, and/or MT1621 outside of a Modis sponsored study. (2) Subjects not treated with chemical-grade dCMP/dTMP, dC/dT, and/or MT1621 outside of a Modis sponsored study.
62791568|NCT05498519|EXPERIMENTAL|Dose-escalation and Dose-expansion|SY-4798 will be given orally in ascending doses (escalation cohort) until the DLT or RP2D is reached. In dose-expansion phase, preliminary anti-tumor activity will be assessed in FGF19+ advanced tumor.
62183826|NCT02085473|EXPERIMENTAL|Cohort 2|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'X' mL/min.
62392534|NCT03629405|NO_INTERVENTION|A - Negative control (untreated) for product C|On the forearms four test areas were located, which were labeled from A-D. Test area A contralateral to product C
62392535|NCT03629405|NO_INTERVENTION|B - Negative control (untreated) for product D|On the forearms four test areas were located, which were labeled from A-D. Test area B contralateral to product D
62392536|NCT03629405|EXPERIMENTAL|C - Cosmetic Product WO 3741 with pH 4|On the forearms four test areas were located, which were labeled from A-D. Test area C on the same arm like product D.
62392537|NCT03629405|EXPERIMENTAL|D - Cosmetic Product WO 4081-1 with pH 5.8|On the forearms four test areas were located, which were labeled from A-D.
62392538|NCT05768113||Covixyl-V ELAH|No formal sample size calculation was performed. A total of 30 patients were enrolled and considered as sufficient sample size to compare the estimates of tests treatment with reference treatment
62392539|NCT05768113||Placebo|No formal sample size calculation was performed. A total of 30 patients were enrolled and considered as sufficient sample size to compare the estimates of tests treatment with reference treatment. This one is Placebo
62392540|NCT06261658|EXPERIMENTAL|Study group|Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
62392541|NCT05657379|EXPERIMENTAL|Product X moisturizer|Participants will used Product X moisturizer twice daily for 8 weeks
62568331|NCT02617160|ACTIVE_COMPARATOR|Control Group-Medical guided recommendations|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice
62773970|NCT03392870|EXPERIMENTAL|TAVA-ACTIVE|Integrative interventional programme. It involves high-frequency multidisciplinary intervention: nursing, psychology, psychiatry and social services. A psychotherapeutic group would be offered to those patients with an intelligence quotient\>70, verbal communication and no behavioural alterations.
62773971|NCT03392870|ACTIVE_COMPARATOR|CONTROL|As usual
62773972|NCT04956588|EXPERIMENTAL|experimental group|
62773973|NCT04956588|ACTIVE_COMPARATOR|control group|
62773974|NCT05808010|EXPERIMENTAL|Mononuclear cells+Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules|
62392542|NCT02569398|EXPERIMENTAL|Group 1|Participants will receive one atabecestat, 5 milligram (mg) tablet orally once daily up to 54 months.
62392543|NCT02569398|EXPERIMENTAL|Group 2|Participants will receive one atabecestat, 25 mg tablet orally once daily up to 54 months.
62392544|NCT02569398|EXPERIMENTAL|Group 3|Participants will receive one matching placebo tablet orally once daily up to 54 months.
62392545|NCT02020681|EXPERIMENTAL|Curodont Repair|Single application of Curodont Repair on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.
62392546|NCT02020681|PLACEBO_COMPARATOR|Placebo|Single application of Placebo on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.
62392547|NCT03475173|EXPERIMENTAL|Laser Speckle Blood Flow Group|
62392548|NCT05950399|EXPERIMENTAL|Group I (resting and/or stress echocardiography)|Patients choose to undergo either a resting echocardiography performed before and after delivery of a cancer therapeutic agent and months 3, 6, 9 and 12 or up to 5 low intensity stress echocardiography over 25 minutes performed depending on where they are at in the course of their cancer therapy and/or cardiac rehabilitation program at baseline and/or months 3, 6, 9 and 12 after starting cancer therapy.
62392549|NCT05950399|ACTIVE_COMPARATOR|Group II (stress echocardiography)|Participants undergo low intensity stress echocardiography over 25 minutes at baseline and may undergo a second one at least 24 hours later.
62392550|NCT03982069|ACTIVE_COMPARATOR|FluMist live attenuated influenza vaccine|Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally
62392551|NCT03982069|ACTIVE_COMPARATOR|Flucelvax inactivated influenza vaccine|Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly
62568332|NCT06126913|NO_INTERVENTION|Standard of Care|At sites randomized to standard care, participants newly diagnosed will receive facility-based care per Uganda Ministry of Health (MoH) protocols
62568333|NCT06126913|EXPERIMENTAL|Community Antiretroviral Therapy|Newly diagnosed individuals (diagnosed in the prior 6 months) at intervention sites will be offered community ART delivery on a rolling basis during the enrollment window, initiating individuals into groups as close to their date of diagnosis as possible. Newly enrolled individuals will join existing community ART delivery groups, or when a new group is needed based on group size or geographic location, a new group will be formed.
62773975|NCT05808010|EXPERIMENTAL|Mononuclear cells|Mononuclear cells are obtained from umbilical cord blood by density gradient centrifugation
62392552|NCT05744466||Cohort 1|Participants that have initiated deucravacitinib
62392553|NCT05744466||Cohort 2|Participants that have initiated apremilast
62392554|NCT02564627|EXPERIMENTAL|Self-applied patch|The patients will use a self-applied patch weekly for PENS of dermatome T6. A 1200 Kcal/day diet will be also prescribed.
62773976|NCT05808010|ACTIVE_COMPARATOR|Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules|Weifuchun is a kind of edible Chinese herbal prescription
62773977|NCT02965885|EXPERIMENTAL|TAS-116|
62773978|NCT06097546||Breast cancer patients|Newly diagnosed patients with breast cancer
62773979|NCT06097546||Benign lesions|Diagnosed patients with benign breast lesions
62773980|NCT06097546||Control|apparently healthy individuals with matched age and sex
62773981|NCT01196962|EXPERIMENTAL|Internal jugular vein|
62773982|NCT04372459|EXPERIMENTAL|Online integrated and stepped psychosocial care|A group of breast cancer survivors will be randomly allocated (1:1 allocation) to the online integrated and stepped psychosocial care group
62773983|NCT04372459|EXPERIMENTAL|Usual psychosocial care|A group of breast cancer survivors will be randomly allocated (1:1 allocation) to the usual psychosocial care group
62773984|NCT00685737|ACTIVE_COMPARATOR|1|1-MNA-Low Dose
62773985|NCT00685737|ACTIVE_COMPARATOR|2|1-MNA-High Dose
62773986|NCT00685737|PLACEBO_COMPARATOR|3|Placebo
62773987|NCT03787992|EXPERIMENTAL|Alflutinib Mesylate (AST2818) +placebo|AST2818 (80 mg or 40 mg orally, once daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule
62183827|NCT02085473|EXPERIMENTAL|Cohort 3|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'Y' mL/min.
62183828|NCT02085473|EXPERIMENTAL|Cohort 4|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'Z' mL/min.
62183829|NCT01187745||suspect kidney stones|Patients presenting with flank abdominal pain
62568334|NCT05516485|EXPERIMENTAL|Diagnostic (MRE, tumor grading)|Patients undergo MRE scan over 25 minutes before surgery at the time of standard of care pre-operative MRI scan. On the day of surgery, the surgeon grades and records tumor consistency/stiffness during the operation and afterwards.
62568335|NCT02109627|EXPERIMENTAL|Ficlatuzumab, Cytarabine|"Ficlatuzumab 5-20 mg/kg; intravenous; Days 0, 14, 28, 42; Number of cycles: until progression or unacceptable toxicity develops.~Cytarabine 2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops."
62773988|NCT03787992|ACTIVE_COMPARATOR|Gefitinib + placebo AST2818|Gefitinib (250 mg orally, once daily) + placebo AST2818 (80 mg or 40 mg orally, once daily), in accordance with the randomisation schedule.
62773989|NCT03508232|PLACEBO_COMPARATOR|Placebo control|Two placebo capsules upon enrollment, followed by one placebo capsule p.o. every 12 hours for 7 days
62773990|NCT03508232|EXPERIMENTAL|Doxycycline hyclate|Two 100mg doxycycline capsules (200 mg) p.o. upon enrollment, followed by one 100 mg capsule p.o. every 12 hours for 7 days
62773991|NCT02784769|EXPERIMENTAL|aneurysm diameter of below 75 mm|
62773992|NCT02784769|EXPERIMENTAL|aneurysm diameter above 75 mm|
62773993|NCT02797496|EXPERIMENTAL|Asymmetric Motor Strengthening|
62773994|NCT02797496|ACTIVE_COMPARATOR|Conventional Therapy|
62773995|NCT04664647||Patients with CCPD|"Inclusion criteria：~1. Criteria for central nervous system involvement: T2 high-signal intensity lesions in the brain, or spinal cord on MRI, or visual-evoked potentials(VEPs) abnormalities.~2. Criteria for peripheral nervous system involvement: conduction delay, conduction block, temporal dispersion or F-wave abnormalities, suggesting peripheral demyelinating neuropathy regarding nerve conduction studies (NCS). In the present study, it was compulsory for at least two nerves between the median, ulnar, tibial and peroneal nerves to have abnormal findings indicating demyelination.~Exclusion criterion:~Secondary demyelinating diseases or changes."
62773996|NCT06584084|EXPERIMENTAL|Muscle electrophysiological signals recording|Recording of electrophysiological signals of muscles with a WPM-SEMG prototype
62773997|NCT03507075|ACTIVE_COMPARATOR|Contingent|The Contingent group will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner.
62773998|NCT03507075|SHAM_COMPARATOR|Noncontingent|The Noncontingent group will receive payments each day they successfully provide samples independent of the alcohol content of those samples.
62773999|NCT01286363||Brachyfacial|Subjects with a horizontal facial growth pattern
62774000|NCT01286363||Mesofacial|Subjects with a balanced facial growth pattern
62774001|NCT01286363||Dolichofacial|Subjects with a vertical facial growth pattern
62774002|NCT02023047|EXPERIMENTAL|Once daily|Nifedipine 12 mg Once daily
62774003|NCT02023047|EXPERIMENTAL|Twice Daily|Nifedipine 12 mg twice daily
62774004|NCT05901103|ACTIVE_COMPARATOR|SPSIPB|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle. PCA device was also performed to this group with the same protocol which was detailed in control arm.
62774005|NCT05901103|NO_INTERVENTION|Control|Control group patients were not subjected to any block or local infiltration anesthesia (local anesthetic administration around the incision). Their postoperative pain was relieved with tramadol (intravenous analgesic drug) administration by using patient-controlled analgesia (PCA) device. Patient-controlled analgesia was achieved with tramadol hydrochloride at a concentration of 4 mg per 1 ml with the PCA device. The PCA device was configured to administer the patients boluses of 10 mg tramadol hydrochloride with a lockout time of 20 minutes, allowing a maximum of 4 pushes per hour. The total dose was standardized for all patients with a maximum daily dose of 400 mg and a maximum dose of 100 mg tramadol hydrochloride every 6 hours.
62774006|NCT04524624|EXPERIMENTAL|AI-based CDSS|"1. Automatically identifying acute ischemic stroke lesions on DWI.~2. Classification of stroke subtypes and mechanisms.~3. Evidence-based alerts and guidelines for early stroke management.~4. Guideline-recommended secondary stroke prevention strategies."
62774007|NCT04524624|NO_INTERVENTION|Usual Care|Usual Care
62183830|NCT01448369|ACTIVE_COMPARATOR|EyeGiene|EyeGiene (Eyedetec Medical Inc., US) is a self-contained, convenient warm compress system for the eyes. The system is composed of a reusable eye mask and one time use warmers that are inserted into the eye mask. The warming units are activated by squeezing just prior use and deliver 40°C heat for up to 5 minutes within 30-60 seconds.
62392555|NCT02564627|ACTIVE_COMPARATOR|Conventional procedure|The patient will attend weekly the Outpatient Clinic for receiving the PENS of dermatome T6. The procedure will be performed by the Medicine Doctor. A 1200 Kcal/day diet will be also prescribed.
62568336|NCT02801617|EXPERIMENTAL|Sequence 1 (PRO-067)|"study subjects will be allocated to receive PRO-067 QD for 30 days, after which they will be crossed over to the other medication (GAAP Ofteno®) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.~Washout period: 21 hours"
62568337|NCT02801617|ACTIVE_COMPARATOR|Sequence 2 (GAAP Ofteno®)|"study subjects will be allocated to receive GAAP Ofteno® QD for 30 days, after which they will be crossed over to the other medication (PRO-067) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.~Washout period: 21 hours"
62568338|NCT02533440|EXPERIMENTAL|EXPAREL and Local Anesthetics|In the experimental group, patients will receive EXPAREL and local anesthetics, and will be prescribed opioid and non-opioid analgesics (for use only if in pain).
62774008|NCT03377933|EXPERIMENTAL|probiotics and quadruple therapy|Patients are given two-week compound Lactobacillus acidophilus probiotic (1 g t.i.d.), followed by a quadruple antibiotic regimen (esomeprazole \[20 mg b.i.d.\] + bismuth potassium citrate \[220 mg b.i.d.\] + tetracycline \[750 mg b.i.d.\] + furazolidone \[100 mg b.i.d.\]) for 10 days as rescue therapy.Meanwhile perform endoscopy and take gastric mucosa specimens for gene sequencing before and after the application of probiotic.
62392556|NCT02564627|OTHER|1200 Kcal/day diet|A 1200 Kcal/day diet will be also prescribed.
62392557|NCT05413655|EXPERIMENTAL|1000 mg|The recruited patient randomly assigned to this arm will take 1000 mg EX039 per day
62392558|NCT05413655|EXPERIMENTAL|750 mg|The recruited patient randomly assigned to this arm will take 750 mg EX039 per day
62392559|NCT05413655|PLACEBO_COMPARATOR|placebo|The recruited patient randomly assigned to this arm will take placebo per day
62392560|NCT03984682|EXPERIMENTAL|Experimental group|Patients will benefit from regular care + Joint Crisis Plan
62392561|NCT03984682|NO_INTERVENTION|Control group|Patients will benefit from regular care
62392562|NCT01319539|EXPERIMENTAL|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy (therapeutic conventional surgery) on day 0. Patient samples will be processed for pharmacological study and laboratory biomarker analysis.
62392563|NCT00121485|EXPERIMENTAL|HeartMate II|Implantation of HeartMate II LVAS
62392564|NCT00121485|ACTIVE_COMPARATOR|HeartMate XVE|Implantation of HeartMate XVE LVAS
62392565|NCT02931357|EXPERIMENTAL|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day.
62392566|NCT02931357|ACTIVE_COMPARATOR|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
62392567|NCT01757821|EXPERIMENTAL|6-Hz Priming|real 6-Hz primed low-frequency rTMS
62392568|NCT01757821|SHAM_COMPARATOR|Sham 6-Hz Priming|Sham 6-Hz Primed low-frequency rTMS
62392569|NCT01757821|ACTIVE_COMPARATOR|Real 1-Hz rTMS only|real 1-Hz rTMS only
62392570|NCT05099458|EXPERIMENTAL|Hepatitis B|
62392571|NCT00156962|ACTIVE_COMPARATOR|Epoetin alfa RB|
62392572|NCT00156962|EXPERIMENTAL|Epoetin alfa DT|
62392573|NCT03400228|EXPERIMENTAL|Protics|Patients in the intervention group were to drink 2 sachets of 1g of probiotic daily for 24 weeks
62392574|NCT03400228|PLACEBO_COMPARATOR|Placebo|Patients in the intervention group were to drink 2 sachets of 1g of maltodextrin daily for 24 weeks
62392575|NCT04418908|ACTIVE_COMPARATOR|GnRHant + E2|Participants in this arm received GnRHant and a transdermal estradiol patch (0.075 mg/day) for a period of 1 week.
62392576|NCT04418908|PLACEBO_COMPARATOR|GnRHant + PL|Participants in this arm received GnRHant and a placebo patch for a period of 1 week.
62392577|NCT05659342|EXPERIMENTAL|ELDOA Technique|ELDOA positions (hold for 1 minute, 3 alternative days for 4 weeks). Hot pack (10-15 minutes) McKenzie extension Exercises
62392578|NCT05659342|EXPERIMENTAL|Mechanical Lumbar Traction|"Mechanical Lumbar Traction (50% of body weight was applied, in supine position, the hip and knee at 90- degree flexion, and the legs were supported.~Hot pack (10-15 minutes) McKenzie extension Exercises"
62392579|NCT05818475|ACTIVE_COMPARATOR|Angiography-guided PCI|Patients will receive PCI of all lesions with at least 50% diameter stenosis at visual estimation. PCI plan and assessment of PCI results will be based on angiography.
62392580|NCT05818475|EXPERIMENTAL|Angiography-derived FFR PCI indication and planning|Patients will receive PCI of all lesions with at least 50% diameter stenosis and positive angiography-derived FFR value (≤0.80). PCI planning will be based on the pullback curve obtained by angiography-derived FFR to obtain an optimal post-PCI physiology.
62392581|NCT01211860|EXPERIMENTAL|DCCR Treatment|DCCR Treatment 290 mg diazoxide choline
62392582|NCT04477564||Unprovoked proximal deep vein thrombosis|
62392583|NCT04477564||Provoked distal deep vein thrombosis|
62774009|NCT02264548|EXPERIMENTAL|Arm 1|Radiation: Radio-Ablation
62774010|NCT00619099|EXPERIMENTAL|1|
62392584|NCT04477564||age-matched control group with no history of vein thrombosis|
62392585|NCT00265876|EXPERIMENTAL|AZD0530 + Gemcitabine|
62392586|NCT04710459|ACTIVE_COMPARATOR|Group 1|it included 30 patients, they were subjected to chemoradiotherapy plus endobronchial cryotherapy.
62392587|NCT04710459|NO_INTERVENTION|Group 2|it included include 30 patients, they were subjected to chemoradiotherapy.
62392588|NCT00486720|EXPERIMENTAL|1|vorinostat 400 mg
62392589|NCT00486720|EXPERIMENTAL|2|vorinostat 200 mg
62392590|NCT01052558|ACTIVE_COMPARATOR|Cataract Surgery Only|
62392591|NCT01052558|EXPERIMENTAL|Treatment with Cataract Surgery & Stents|Ab interno trabecular micro-bypass stent surgery
62392592|NCT03431246|EXPERIMENTAL|Gardasil and Gardasil-9|
62568339|NCT02533440|ACTIVE_COMPARATOR|Oral Opioid and Local Anesthetics|In the control group, patients will receive local anesthetics at the time of surgery and oral opioid or non-opioid analgesics (for use only if in pain).
62392593|NCT01411059|EXPERIMENTAL|yoga|32 weeks of yoga training
62392594|NCT01526343|EXPERIMENTAL|Reveal XT|
62568340|NCT03326570||Bronchoscopy Data Collection|Medical information collected after bronchoscopy for up to 2 years.
62568341|NCT05350618||Asymptomatic controls|A single transperineal ultrasound assessment session will be conducted by two independent physiotherapists with an expertise in pelvic floor rehabilitation
62568342|NCT05350618||Women with provoked vestibulodynia|A single transperineal ultrasound assessment session will be conducted by one physiotherapist with an expertise in pelvic floor rehabilitation
62568343|NCT04021914|EXPERIMENTAL|EnChroma glasses|EnChroma products improve brightness and color purity of primary colors for CVD people. Each participant with CVD will be provided EnChroma products to use indoors over the course of two weeks in the emergency department, educational settings, and in their personal life.
62568344|NCT05858788|EXPERIMENTAL|SAR441566|Participants will receive single ascending doses of SAR441566 on day 1 of each 8-12-day cycle
62568345|NCT00813150|EXPERIMENTAL|Vd (bortezomib + dexamethasone)|"Participants received bortezomib at a dose of 1.3 mg/m² body surface area (BSA) for eight 3-week cycles. Within each cycle it was administered twice weekly (on Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 through 21). They received single oral doses of 20 mg dexamethasone on Days~1 and 2, 4 and 5, 8 and 9, and 11 and 12 of each cycle."
62568346|NCT00813150|ACTIVE_COMPARATOR|Vcd (bortezomib + low-dose dexamethasone + cyclophosphamide)|Participants received bortezomib at a dose of 1.3 mg/m² body surface area (BSA) for eight 3-week cycles. Within each cycle it was administered twice weekly (on Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 through 21). They received single oral doses of 20 mg dexamethasone on Days 1 and 2, 4 and 5, 8 and 9, and 11 and 12 of each cycle and single oral doses of 50 mg cyclophosphamide on a once daily basis from Day 1, Cycle 1 continuously until Day 21, Cycle 8.
62568347|NCT03708328|EXPERIMENTAL|Dose Escalation Part A: Once Every 2 Weeks (Q2W)|Lomvastomig will be administered in treatment cycles once every 2 weeks (Q2W). Dose escalation will be carried out according to a modified continual reassessment method (mCRM) with escalation with overdose control (EWOC) design.
62568348|NCT03708328|EXPERIMENTAL|Expansion Part B1: Metastatic Melanoma Cohort|This cohort will comprise participants with checkpoint inhibitor (CPI) experienced, second line and beyond metastatic melanoma. The starting dose of lomvastomig for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
62392595|NCT02173158|EXPERIMENTAL|lomitapide|Maximum tolerated dose of lomitapide (up to 60mg/day) in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.
62392596|NCT04212026|EXPERIMENTAL|Nivolumab|"Nivolumab treatment will be given every 2 weeks at a standard flat dose of 240 mg for a total of 5 doses, and the IRE procedure will be performed using the standard setting to ablate tumors at the level of the liver that is well tolerated by the patients. Two weeks after the last dose of nivolumab (Week 8), radiological restaging will be performed (=Week 10)."
62392597|NCT00479973|ACTIVE_COMPARATOR|Cinnamonforce|Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.
62392598|NCT00479973|PLACEBO_COMPARATOR|Placebo|
62392599|NCT02218424|EXPERIMENTAL|Magnesium|Intravenous magnesium. After IV placed intraoperatively, a bolus dose of magnesium 30 mg/kg is given over 15 minutes, followed by a continuous infusion of magnesium at 10 mg/kg/hr until the completion of the procedure.
62392600|NCT02218424|PLACEBO_COMPARATOR|Placebo infusion|Intravenous normal saline will be given as placebo. An equal amount of volume normal saline will be given intravenously as the control group.
62392601|NCT05147766|EXPERIMENTAL|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
62568349|NCT03708328|EXPERIMENTAL|Expansion Part B2: NSCLC Cohort 1|This cohort will comprise participants with CPI and platinum experienced, second or third line PD-L1 positive non-small cell lung cancer (NSCLC). The starting dose of lomvastomig for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
62392602|NCT05071742||IBD group|According to the consensus opinions on diagnosis and Treatment of Inflammatory Bowel Disease (Beijing, 2018) formulated by Chinese Society of Gastroenterology, Chinese Medical Association The diagnosis of IBD was confirmed by clinical, laboratory, radiographic, digestive endoscopy and histopathological examination.
62392603|NCT05071742||control group|During the same period, healthy subjects were collected from the physical examination center of our hospital as subjects of the normal control group. Infectious diarrhea, ischemic bowel disease, radiation enteritis, gastrointestinal tumor, diabetes, systemic lupus erythematosus, rheumatoid arthritis and autoimmune thyroiditis were excluded from all clinical examinations before inclusion.
62392604|NCT02549261|EXPERIMENTAL|the tolerance trial of treatment|nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
62392605|NCT02549261|EXPERIMENTAL|A|nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
62392606|NCT02549261|PLACEBO_COMPARATOR|B|chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
62392607|NCT00952146|EXPERIMENTAL|Transgastric peritoneoscopy|Only one arm, feasibility study
62392608|NCT04350034|EXPERIMENTAL|Xbox training group|The study group received Xbox training plus routine physical therapy protocol treatment. The dose of Xbox training was 50 min, three times a week for 12 weeks, using the Xbox gaming system (Xbox 360 Kinect console; Microsoft Inc., Redmond, Washington, USA).
62392609|NCT04350034|PLACEBO_COMPARATOR|Control group|patients participated in a routine physical therapy protocol (RPTP) including joint range of motion exercises (ROM), muscle stretching technique, splinting, daily walking, and ADL training.
62392610|NCT05631873|EXPERIMENTAL|Intervention|
62392611|NCT05631873|NO_INTERVENTION|Control|
62392612|NCT06430008||lipid pneumonia|
62392613|NCT06430008||cough|
62392614|NCT06430008||cryptogenic organizing pneumonia|
62392615|NCT06430008||pulmonary alveolar proteinosis|
62392616|NCT06430008||bacterial pneumonia|
62392617|NCT06430008||fungal pneumonia|
62392618|NCT06430008||pulmonary edema|
62392619|NCT06430008||mucinous adenocarcinoma of the lung|
62392620|NCT03377218|NO_INTERVENTION|Control|Without additional iodine supplementation.
62392621|NCT03377218|EXPERIMENTAL|Iodine|Receiving iodine.
62392622|NCT03377218|EXPERIMENTAL|Iodine + Selenium|Receiving iodine and selenium.
62392623|NCT04079699|EXPERIMENTAL|Liquid Biopsy|"Experimental arm where the liquid biopsy decides whether to perform an prostate biopsy or not"
62392624|NCT04079699|OTHER|Standard Biopsy|Standard arm, where every patient receives a standard prostate biopsy
62568350|NCT03708328|EXPERIMENTAL|Expansion Part B3: NSCLC Cohort 2|This cohort will comprise participants with PD-L1 high, cancer immunotherapy (CIT) naïve first line NSCLC. The starting dose of lomvastomig for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
62392625|NCT01298011|EXPERIMENTAL|Gemcitabine & Abraxane Pancreatic Cancer|
62392626|NCT03188458|OTHER|Second and third trimester Group|This study group will include infants whose mothers have received Boostrix during the second (21-27 weeks) and third trimester (above 28 weeks) of their pregnancy, as per routine practice.
62392627|NCT04884009|EXPERIMENTAL|SHR-1701+ Famitinib|
62392628|NCT04884009|EXPERIMENTAL|SHR-1701|
62392629|NCT01681004|EXPERIMENTAL|iFuse Implant System|Surgical placement of iFuse implants in the affected SI joint
62392630|NCT01681004|ACTIVE_COMPARATOR|Non-Surgical Management|Medications, SI joint injection, physical therapy and RF ablation of SI joint
62392631|NCT03092076|EXPERIMENTAL|Pharmacokinetics|The pharmacokinetics characteristic of ticagrelor in healthy Chinese is investigated to provide the basis for its efficacy and safety of clinical treatment.
62392632|NCT03092076|EXPERIMENTAL|Antiplatelet effects|The antiplatelet effects of ticagrelor in healthy Chinese is investigated to provide the basis for its efficacy and safety of clinical treatment.
62392633|NCT03092076|NO_INTERVENTION|The impact of genotype|The recovery time of platelet function following the administration of ticagrelor is widely varied that genetic variants maybe an underlying factor.The impact of genotype on pharmacokinetic parameters and ADP of ticagrelor is compared among different genotypes.
62392634|NCT00174460|ACTIVE_COMPARATOR|Treatment Arm|
62392635|NCT00174460|NO_INTERVENTION|Control Arm|
62392636|NCT02255942|EXPERIMENTAL|Iron fortified rice|Administration of iron fortified rice to all subjects; subjects will act as their own controls and each subject will receive all foreseen treatments/interventions.
62392637|NCT02604134|OTHER|conventional treatment group|The child will receive a prophylaxis and fluoride varnish. Parents will fill out a parent and a child questionnaire.
62392638|NCT02604134|OTHER|Silver Nitrate group|The child will receive a prophylaxis, then silver nitrate and then fluoride varnish. Parents will fill out a parent and a child questionnaire.
62392639|NCT03328741|EXPERIMENTAL|Joint Academy|Online osteoarthritis treatment
62392640|NCT03328741|ACTIVE_COMPARATOR|The BOA program|Face-to-face osteoarthritis treatment
62392641|NCT01967992|ACTIVE_COMPARATOR|American Diabetes Association recommended diet|"Participants in the American Diabetes Association (ADA) diet group will receive standard ADA advice. The diet includes high-fiber foods (such as vegetables, fruits, whole grains, and legumes), low-fat dairy products, fresh fish, and foods low in saturated fat. They will be asked to use the plate method to guide their nutritional choices."
62568351|NCT03708328|EXPERIMENTAL|Expansion Part B4: SCLC Cohort|This cohort will comprise participants with CPI naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to, standard therapy. The starting dose of lomvastomig for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
62568352|NCT03708328|EXPERIMENTAL|Expansion Part B5: ESCC Cohort|This cohort will comprise participants with CPI-naïve esophageal squamous cell carcinoma (ESCC). The starting dose of lomvastomig for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
62774011|NCT00619099|EXPERIMENTAL|2|
61998243|NCT03696433|EXPERIMENTAL|Low- then high-salt diet|10 subjects will be enrolled and each will undergo study procedures at 4 separate visits. Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets. After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: low-salt diet, then washout consisting of the subject's typical diet, then high-salt diet. Each dietary or washout period lasts for 7 days, and study visits will occur after each period.
61998244|NCT03696433|EXPERIMENTAL|High- then low-salt diet|10 subjects will be enrolled and each will undergo study procedures at 4 separate visits. Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets. After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: high-salt diet, then washout consisting of the subject's typical diet, then low-salt diet. Each dietary or washout period lasts for 7 days, and study visits will occur after each period.
61998245|NCT00582933|EXPERIMENTAL|1|25 research participants with HLA Identical Related Donor using PBSC, 6 with BMT
61998246|NCT00582933|EXPERIMENTAL|2|70 research participants with HLA-Matched Unrelated Donor using PBSC, 17 with BMT
62392642|NCT01967992|EXPERIMENTAL|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate, ketogenic diet: carbohydrate intake 20-35 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
62392643|NCT05184868|EXPERIMENTAL|AT247|0.02 U/Kg/H Basal via continuous subcutaneous infusion with 2 bolus 0.15 U/Kg doses in a glucose clamp for one 3-day period
62392644|NCT05184868|ACTIVE_COMPARATOR|NovoLog®|0.02 U/Kg/H Basal via continuous subcutaneous infusion with 2 bolus 0.15 U/Kg doses in a glucose clamp for one 3-day period
62774012|NCT03677297|EXPERIMENTAL|ROSUVASTATIN|1.2% Rosuvastatin Gel. Insertion in infrabony defects once
62774013|NCT03677297|PLACEBO_COMPARATOR|placebo|No intervention used on control site
62774014|NCT03883087|EXPERIMENTAL|HQP1351|
62774015|NCT02396394|EXPERIMENTAL|Two-Step Adherence Feedback|Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is \<95%.
62183831|NCT01448369|ACTIVE_COMPARATOR|Blephasteam|Blephasteam (Spectrum Théa, France) is an eyelid warming device that can be conveniently used at home. The goggles provide standardised heat of about 38 degrees to liquefy lipids and also humidify the chambers with mineral water to ensure optimal moisture levels.
62774016|NCT01862549|EXPERIMENTAL|DBT for children|Dialectical Behavior Therapy for children is a 32 session intervention (it consists of 2 pre-treatment sessions and 30 treatment sessions; treatment sessions are to be delivered in 32 weeks total) with once per week meetings, including 30 min. individual child therapy, 20 min. meeting with a caregiver and 40 min. of skills training with both.
62791569|NCT05096689|EXPERIMENTAL|Non-operative|Non-operative treatment of lateral humeral condyle fractures
61998247|NCT00582933|EXPERIMENTAL|3|25 research participants with HLA-Mismatched Related Donor using PBSC, no BMT
61998248|NCT02167256|EXPERIMENTAL|AZD0530 100mg daily|Patients in the experimental group (50%) will be started on this dose. After 2 weeks, patients with a plasma drug level of \<100ng/ml will receive 125mg AZD0530 daily and remain in the same experimental group as patient receiving 100mg daily.
61998249|NCT02167256|PLACEBO_COMPARATOR|AZD0530 Placebo|50% of patients will receive placebo treatment for the duration of the study,
61998250|NCT05970432|EXPERIMENTAL|TQH2722 injection 300mg-150mg|Participants received subcutaneous injection of 300 mg TQH2722 injection + 600 mg placebo on day 1, followed by subcutaneous injection of 150 mg TQH2722 injection + 300 mg placebo on days 15, 29, 43, 57, 71, 85, 99.
62183832|NCT01448369|PLACEBO_COMPARATOR|Control- Hot Compress|The participants in this group will be using warm compresses with a hot towel.
62183833|NCT00854971|NO_INTERVENTION|control|Oxaliplatin infusion (85mg/m2) on days 1 and 15 (every 2 weeks) 5-FU bolus + infusions (400 mg/m2) on days 1, 2, 15 and 16 LV infusions (200 mg/m2) on days 1, 2, 15 and 16
62183834|NCT00854971|ACTIVE_COMPARATOR|Active|FOLFOX-4 regimen + Infusion of TKCell(autologous activated lymphocyte) over 2x10\^9 cells, IV route, 7 times
62183835|NCT02840916|EXPERIMENTAL|verum laser acupuncture|verum laser acupuncture
62183836|NCT02840916|SHAM_COMPARATOR|sham laser acupuncture|sham laser acupuncture (no laser output)
62183837|NCT02196311||Supracondylar humerus fractures|We are looking to compare open reduction internal fixation versus circular external fixation for supracondylar humerus fractures.
62183838|NCT02997683|EXPERIMENTAL|3-month home based training on whole body vibration platform|This Group will receive a training device to perform their given exercises on
62183839|NCT02997683|PLACEBO_COMPARATOR|3-month home based training on floor|This Group will perform their given exercises at home on the floor
62183840|NCT05188625|NO_INTERVENTION|Control arm|This group will receive the standard care of face-to-face dietitian counselling sessions.
62183841|NCT05188625|EXPERIMENTAL|Intervention arm|This group will receive online self-paced dietary education, and followed up by telehealth video consultation with dietitian for dietary counselling.
62183842|NCT02128698|EXPERIMENTAL|Protein and computer-assisted exercise|Patient group which takes daily protein supplements and is advised to do exercise 4 times per week by using Nintendo Wii Balance Board and Wii Fit Plus Software during 6 months after bariatric surgery.
62183843|NCT02128698|PLACEBO_COMPARATOR|Placebo and computer-assisted exercise|Patient group which takes daily control product and is advised to do exercise 4 times per week by using Nintendo Wii Balance Board and Wii Fit Plus Software during 6 months after bariatric surgery.
62183844|NCT02128698|ACTIVE_COMPARATOR|Protein and usual exercise|Patient group which takes daily protein supplements and is advised to do exercise 4 times per week by using written exercise instructions during 6 months after bariatric surgery.
62183845|NCT02128698|ACTIVE_COMPARATOR|Placebo and usual exercise|Patient group which takes daily control product and is advised to do exercise 4 times per week by using written exercise instructions during 6 months after bariatric surgery.
62183846|NCT02425241|EXPERIMENTAL|CPHPC|"CPHPC infusion over 26 hours to deplete SAP at weeks 0,4 and 8. pSG2.HIVconsv DNA vaccine 4 mg at weeks 0, 4 and 8 after 24 hours of CPHPC infusion.~ChAdV63.HIVconsv booster vaccine 5 x 10\^10 vp at week 12. MVA.HIVconsv booster vaccine 2 x 10\^8 pfu at week 20"
62183847|NCT02425241|PLACEBO_COMPARATOR|0.9% w/v saline solution|"Placebo (normal saline) infusion over 26 hours at weeks 0,4 and 8. pSG2.HIVconsv DNA vaccine 4 mg at weeks 0, 4 and 8 after 24 hours of placebo infusion.~ChAdV63.HIVconsv booster vaccine 5 x 10\^10 vp at week 12. MVA.HIVconsv booster vaccine 2 x 10\^8 pfu at week 20"
62183848|NCT02973802|EXPERIMENTAL|ATX-GD-59 treatment|An upward titration over five dose levels (25, 50, 100, 400 and 800 micrograms) followed by 5 doses of 800 micrograms of ATX-GD-59 will be administered two weeks apart by intradermal injection.
62183849|NCT00895388|OTHER|Structured Rehabilitation program|
62183850|NCT00895388|NO_INTERVENTION|Controls|
62183851|NCT05708300||chronic rhinosinusitis with nasal polyps with bronchial asthma|Patients with chronic rhinosinusitis with nasal polyps with bronchial asthma will be administered Mepolizumab (100 MG), subcutaneusly every 30 days
62774017|NCT01862549|ACTIVE_COMPARATOR|Treatment as Usual|Children in active comparison conditions will receive Treatment as Usual (TAU) that primarily consists of 32 weekly sessions of supportive individual psychotherapy and adjunctive family interventions. Individual therapy included cognitive behavioral skills training (e.g., psychoeducation, cognitive modifications, thought blocking) and non-directive supportive therapy. Family therapy includes parenting skills training (e.g., limit setting, reinforcement techniques), structuring household environment, and safety planning.
62183852|NCT05708300||chronic rhinosinusitis with nasal polyps without bronchial asthma|Patients with chronic rhinosinusitis with nasal polyps without bronchial asthma will be administered Mepolizumab (100 MG), subcutaneusly every 30 days
62183853|NCT03009019|EXPERIMENTAL|DFN-15 Active|DFN-15 Active
62183854|NCT03009019|PLACEBO_COMPARATOR|DFN-15 Placebo|DFN-15 Placebo
62183855|NCT05162898|EXPERIMENTAL|GROUP 1|
62183856|NCT04205656|EXPERIMENTAL|Leukocyte-Poor Platelet Rich Plasma (LP-PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.
62183857|NCT04205656|EXPERIMENTAL|Bone Marrow Concentrate (BMC)|Participants will have a knee injected with BMC stem cells harvested from the iliac crest
62183858|NCT04205656|PLACEBO_COMPARATOR|Control|Patients randomized in the placebo arm will undergo their standard of care treatment and will not receive LP-PRP or BMC.
62183859|NCT05623371|EXPERIMENTAL|Treatment group|Leadership training comprising 5 modules and group exercises
62183860|NCT05623371|OTHER|Control group|Active control group receiving the offer of a webinar and written material
62183861|NCT02007395||colonoscopy population|
62774018|NCT03974295|EXPERIMENTAL|Intercourse Group|unlimited unprotected vaginal intercourse starting 24 hours after the frozen embryo transfer
62183862|NCT06284434|EXPERIMENTAL|LB Treatment Arm|Patients on the treatment arm will receive liposomal bupivacaine mixed with epinephrine (ratio of 1:100,000), which is not considered the standard of care.
62183863|NCT06284434|ACTIVE_COMPARATOR|Bupivacaine Control Arm|Patients on the control arm will follow the current standard of care, which is traditional bupivacaine mixed with epinephrine (1:100,000).
62183864|NCT05095324||control|the infection patients who didn't have organ failure according to the SOFA score: 1. respiratory system: PaO2/FiO2≥\<400 mmHg; 2. MAP≥70mmHg; 3. Liver: Bilirubin\<1.2mg/dL; 4. Renal system: Creatinine\<1.2mg/dL or Urine output≥500ml/d; 5. Platelets≥150×10\^9/L; 6. nervous system:Glasgow coma score=15.
62183865|NCT05095324||organ failure|the patients who had sepsis in follow up period: 1. respiratory system:PaO2/FiO2\<400mmHg; 2. Circulation: MAP\<70mmHg or administration of vasopressors required; 3. Liver: Bilirubin≥1.2mg/dL; 4. Renal system: Creatinine≥1.2mg/dL or Urine output\<500ml/d; 5. Coagulation: Platelets\<150×10\^9/L; 6. nervous system: Glasgow coma score \<15.
62183866|NCT03269747|ACTIVE_COMPARATOR|Prednisone|Prednisone 40 mg daily for 7 days
62183867|NCT03269747|PLACEBO_COMPARATOR|Placebo|Placebo daily for 7 days
62183868|NCT04014790|EXPERIMENTAL|RGI-2001|Subjects will be administered RGI 2001 in combination with standard of care treatment
62183869|NCT02510053|OTHER|Patients With IFI in ICU|40 patients receive Caspofungin for an Invasive Fungal Infection(IFI) in the Intensive Car will be recruited
62183870|NCT06069453|EXPERIMENTAL|Group A|Solution containing Hyaluronic Acid (HA) sodium salt and Hydeal-D
62183871|NCT06069453|NO_INTERVENTION|Group B|standard management according to institutional protocol
62183872|NCT04683770||HR + / HER2 - advanced breast cancer|
62183873|NCT04322812|ACTIVE_COMPARATOR|Active PBMT|Active PBMT applied three times a week (interval of 48 hours approximately), for three consecutive weeks, totalling nine treatment sessions.
62183874|NCT04322812|PLACEBO_COMPARATOR|Placebo PBMT|Placebo PBMT applied three times a week (interval of 48 hours approximately), for three consecutive weeks, totalling nine treatment sessions.
62183875|NCT02901236|ACTIVE_COMPARATOR|Mitomycin C|Standard Guarded Trabeculectomy will be performed. In this arm 0.02% of mitomycin C (Kyowa, Japan) will be applied on bare sclera under the conjunctiva for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
62183876|NCT02901236|ACTIVE_COMPARATOR|Bevacizumab|Standard Guarded Trabeculectomy will be performed. In this arm at the end of the case and after conjunctival closure 1.25mg of bevacizumab (Avastin; Genentech, San Francisco, CA) will be injected into the the anterior chamber through a paracentesis.
62183877|NCT06315101||Lenvatinib combined with Chinese Herbal Medicine|
62183878|NCT02627768||Cohort 1: Ustekinumab Treatment|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy.
62183879|NCT02627768||Cohort 2: TNFi Treatment|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy.
62183880|NCT04947436|ACTIVE_COMPARATOR|High Frequency Chest Wall Oscillation|
62183881|NCT04947436|ACTIVE_COMPARATOR|Mechanical insufflation/ exsufflation|
62183882|NCT04947436|ACTIVE_COMPARATOR|High Frequency Chest Wall Oscillation and Mechanical insufflation/ exsufflation|
62183883|NCT06190288|EXPERIMENTAL|Intervention group|The intervention includes five core elements provided by a multiprofessional team: (1) continuous support for patients and caregivers; (2) care coordination with primary care providers;(3) visits at patients' homes; (4) medication- and self-management with patients and caregivers; and (5) proactive advanced care planning. Patients will receive specialized support including home visits up to 90 days after hospital discharge.
62183884|NCT04749498|ACTIVE_COMPARATOR|White Bread|White bread with a standard test breakfast
62392645|NCT05184868|ACTIVE_COMPARATOR|Fiasp®|0.02 U/Kg/H Basal via continuous subcutaneous infusion with 2 bolus 0.15 U/Kg doses in a glucose clamp for one 3-day period
62183885|NCT04749498|ACTIVE_COMPARATOR|Whole Wheat Bread|Whole wheat bread with a standard test breakfast
62392646|NCT00516217|EXPERIMENTAL|Galaximab|Induction: 500 mg/m\^2 by IV over 60 minutes days 1, 8, 15 \& 22 Extended Induction: 500 mg/m\^2 by IV every 4 weeks until disease progression or unacceptable toxicity
62410024|NCT06650956|EXPERIMENTAL|Intervention district|The intervention provides HPV vaccinations to girls aged 10-13 and sexual and reproductive health (SRH) services to boys and girls aged 10-13 through three service delivery touch points: schools, health facilities, and community outreach. The vaccine in the intervention is a single dose of recombinant Human Papilloma virus quadrivalent types, 6, 11, 16, and 18. Schools will provide vaccinations and comprehensive sexuality education (CSE) sessions. Health facilities offer vaccinations and SRH education service. Community outreach delivers the integrated package to out-of-school girls and boys.
62774019|NCT03974295|NO_INTERVENTION|Pelvic Rest Group|pelvic rest after frozen embryo transfer until positive pregnancy test
62774020|NCT00877370|EXPERIMENTAL|ertapenem|subjects will receive ertapenem while receiving CVVHD
62183886|NCT04749498|EXPERIMENTAL|Barley Bread|Barley bread with a standard test breakfast
62183887|NCT04749498|EXPERIMENTAL|Oat Bread|Oat bread with a standard test breakfast
62183888|NCT04403906|EXPERIMENTAL|PCL Rapid Antigen Test arm|Single arm trial design. Only patients undergoing standard clinical testing (SARS-CoV-2 PCR test) and consenting for additional testing with the PCL rapid antigen test will be included
62183889|NCT03248141||Hemophilia B|real world administration patterns and resource utilization implications
62183890|NCT03248141||Hemophilia A|real world administration patterns and resource utilization implications
62183891|NCT02360800|EXPERIMENTAL|TISSEEL|Spray Fibrin Sealant
62183892|NCT02360800|ACTIVE_COMPARATOR|CONTROL|Traditional hemostasis and chest closure routine
62183893|NCT03289702|EXPERIMENTAL|CORETOX®|
62183894|NCT03289702|ACTIVE_COMPARATOR|BOTOX®|
62183895|NCT04784455|EXPERIMENTAL|nomacopan (rVA576)|The study population will consist of paediatric patients who have undergone allogeneic or autologous HSCT and develop HSCT-TMA within a year of HSCT
62183896|NCT04049370||"Retrospective data collection of the actual state"|"Retrospective data collection of the actual state 6 months prior to August 2019."
61998251|NCT05970432|EXPERIMENTAL|TQH2722 injection 600mg-300mg|Participants received subcutaneous injection of 600 mg TQH2722 injection + 300 mg placebo on day 1, followed by subcutaneous injection of 300 mg TQH2722 injection + 150 mg placebo on days 15, 29, 43, 57, 71, 85, 99.
62183897|NCT04049370||Prospective data collection|Prospective data collection after implementation of the quality assurance measure for another 6 months (SOP as clinical decision tool into the electronic database of the CPU).
62392647|NCT02716207|EXPERIMENTAL|Maximal tolerated dose with CyberKnife|SBRT will be delivered in 5 fractions within 1 to 2 weeks by the following schedule: Doses of 7 Gy, 7.5 Gy, 8 Gy, 8.5 Gy, 9 Gy, 9.5 Gy x 5 with BED10 in correspondence to 59.5 Gy, 65.6 Gy, 72 Gy, 78.6 Gy, 85.5 Gy, 92.6 Gy respectively while meeting with normal tissue constraints. A minimum of three patients will be included for each dosage level. And an interval is four weeks between each dose level. In case patient presents III/IV GI toxicity, three additional patients will be included at the same dose level. The Maximal Tolerated Dose will be defined as the dose for which at least 2 patients in 3, or at least 3 patients in 9, will present with a limiting toxicity.
62183898|NCT05234775|EXPERIMENTAL|LIB003 (lerodalcibep) Process 1|300 mg LIB003 Process 1 drug product administered SC
62183899|NCT05234775|ACTIVE_COMPARATOR|LIB003 (lerodalcibep) Process 2|300 mg LIB003 Process 2 drug product administered SC
62392648|NCT00809549|PLACEBO_COMPARATOR|Normal Saline|
62392649|NCT00809549|EXPERIMENTAL|Filgrastim|
62392650|NCT03826849|NO_INTERVENTION|Waitlist Control|Assessment only condition for all 12 weeks of participation.
62392651|NCT03826849|EXPERIMENTAL|Insomnia Coach|Intervention condition that involves use of the Insomnia Coach app for 6 weeks.
62392652|NCT01110603|EXPERIMENTAL|MK-4827 + carboplatin|
62392653|NCT01110603|EXPERIMENTAL|MK-4827 + carboplatin/paclitaxel|
62392654|NCT01110603|EXPERIMENTAL|MK-4827 + carboplatin/liposomal doxorubicin|
62392655|NCT01712529|EXPERIMENTAL|Supervised physical exercise|Walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
62774021|NCT02924012|EXPERIMENTAL|active video game|An active game session lasting 40 minutes
62774022|NCT02924012|OTHER|sedentary video game|An sedentary game session lasting 40 minutes
62774023|NCT02924012|OTHER|walking|An walking lasting 40 minutes
62774024|NCT01443507|EXPERIMENTAL|high intensity long interval|A group training four by four minutes interval at 90-95% of maximal heart rate dispersed by three minutes active pauses at 70% of maximal heart rate.
61998252|NCT05970432|EXPERIMENTAL|TQH2722 injection 900mg-450mg|Participants received subcutaneous injection of 900 mg TQH2722 injection on day 1, followed by subcutaneous injection of 450 mg TQH2722 injection on days 15, 29, 43, 57, 71, 85, 99.
61998253|NCT05970432|PLACEBO_COMPARATOR|TQH2722 injection matching Placebo|Subjects received 900mg placebo injection subcutaneously on day 1, followed by 450mg placebo injection on days 15, 29, 43, 57, 71, 85, 99.
61998254|NCT02239536|EXPERIMENTAL|Hot snare polypectomy|Intervention: Procedure: removal of eligible polyps using hot snare polypectomy technique
61998255|NCT02239536|EXPERIMENTAL|Hot snare polypectomy(saline injection)|Intervention: Procedure: removal of eligible polyps using hot snare polypectomy after saline injection technique
61998256|NCT02660918|EXPERIMENTAL|Treatment|Women undergoing endometrial ablation that meet the eligibility criterial will receive a standardized paracervical injection of Bupivacaine 20 mL 0.25% at the completion of the procedure.
61998257|NCT02660918|PLACEBO_COMPARATOR|Control|Women undergoing endometrial ablation that meet the eligibility criterial will receive an equal volume standardized paracervical injection of Normal Saline at the completion of the procedure.
61998258|NCT06296667|EXPERIMENTAL|group1: vertical/ vertical|participant posture: The thoracic block is vertically aligned over the pelvic block.The angle of the thoracic block is vertical in the sagittal plane allowing for the dome of the diaphragm to rest on top of the abdomen.Vertical force transfers through the musculoskeletal system through the mid-foot and into the standing surface causing no shifts in postural alignment.
61998259|NCT06296667|EXPERIMENTAL|group 2: vertical/ posterior|participant posture: The thoracic block is vertically aligned over the pelvic block but is posteriorly tipped in the sagittal plane.Vertical force leads to an accentuated extension in the thoracolumbar and lumbar regions with decreased ability to sustain vertical forces.
61998260|NCT06296667|EXPERIMENTAL|group 3: posterior/ posterior|participant posture: The thoracic block is aligned posterior to the pelvic block and is posteriorly tipped in the sagittal plane. Vertical force leads to an accentuated extension in the lower lumbar region with a forward shear of the pelvis and decreased ability to sustain vertical forces.
61998261|NCT06296667|EXPERIMENTAL|group 4: posterior/ anterior|participant posture: The thoracic block is aligned posterior to the pelvic block and is anteriorly tipped in the sagittal plane. Vertical force leads to a slight flexion in the thoracic and lumbar regions with a forward shear of the pelvis and decreased ability to sustain vertical force.
61998262|NCT06296667|EXPERIMENTAL|group 5:anterior/ posterior|participant posture: The thoracic block is aligned anterior to the pelvic block and is posteriorly tipped in the sagittal plane. Vertical force leads to extension in the mid and lower lumbar regions with a posterior shear of the pelvis and decreased ability to sustain vertical forces.
62392656|NCT01712529|NO_INTERVENTION|No supervised physical exercise|No intervention for 16 weeks
62392657|NCT05773885|EXPERIMENTAL|Experimental Group (EG)|The Experimental Group (EG) will carry out 30 sessions (3-5 days/week, for 6-10 weeks) of motor, speech, and cognitive rehabilitation exercises using the VRRS Tablet home TR system (Khymeia srl, Noventa Padovana, Italy).
62774025|NCT01443507|EXPERIMENTAL|long duration at moderate training|a continuous training group exercising at 70% of maximal heart rate for 90 minutes.
62774026|NCT04721665||SLD patients|No intervention
62774027|NCT00056446|EXPERIMENTAL|1|Oxaliplatin/5-FU/LV and PTK787/ZK 222584
62774028|NCT00056446|PLACEBO_COMPARATOR|2|Oxaliplatin/5-FU/LV and placebo
62774029|NCT03693781|ACTIVE_COMPARATOR|Colchicine 0.01mg/kg/day + Riluzole 100 mg|Oral colchicine will be administered at fast, at specified dose pro kilograms for 30 weeks, while taking Riluzole 100 mg/day
62774030|NCT03693781|ACTIVE_COMPARATOR|Colchicine 0.005 mg/kg/day + Riluzole 100 mg|Oral colchicine will be administered at fast, at specified dose pro kilograms for 30 weeks, while taking Riluzole 100 mg/day
62774031|NCT03693781|PLACEBO_COMPARATOR|Placebo + Riluzole 100 mg|Placebo pills will be administered at fast, while taking Riluzole 100 mg/day
62774032|NCT02622646||Well controlled patients|Patients with an adequate disease control with the routine clinical practice (AJBR≤2, non-severe ABR≤5 and severe ABR≤2) (Ministerio de Sanidad, Servicios Sociales e Igualdad. Gobierno de España; 2012)
62183900|NCT05160311|OTHER|Optimized Medical Treatment (OMT)|The patient considered non-viable by MRI and randomized to Optimized Medical Treatment (OMT) will be treated according to Optimized Medical Treatment guidelines for Coronary Artery Disease (CAD)
62183901|NCT05160311|EXPERIMENTAL|Angioplasty (PCI) and Optimized Medical Treatment (OMT)|The patient considered non-viable and randomized to Coronary Angioplasty will be treated with drug-eluting stent (PCI) and Optimized Medical Treatment (OMT)
62183902|NCT06168422||DES Group|All lesions in these patients were treated with DES
62183903|NCT06168422||DES+DCB Group|These patients were treated using a combination of DES and DCB
62183904|NCT06168422||DCB Group|All lesions in these patients were treated with DCB
62183905|NCT06258733|EXPERIMENTAL|Lay-led FL workshops|Community lay leaders who underwent training in a manualized program will disseminate the workshop to women in their communities through engaging visual and game-based tools.
62183906|NCT06258733|EXPERIMENTAL|Expert-led FL workshops|Trained health experts will disseminate the same manualized program in community groups recruited by research staff to match lay-led groups.
62183907|NCT00592462||Whole Body MRI|
62183908|NCT03980990|EXPERIMENTAL|Metformin Continuation|Patients undergoing angiography will continue their metformin without interruption at their next scheduled dose following angiography.
62183909|NCT03980990|NO_INTERVENTION|Metformin Interruption|Patients undergoing angiography will interrupt their metformin for 48 hours post angiography.
62183910|NCT01152476|ACTIVE_COMPARATOR|group SR|
62392658|NCT05773885|ACTIVE_COMPARATOR|Control Group (CG)|The Control Group (CG) will carry out 30 sessions (3-5 days/week, for 6-10 weeks) of conventional rehabilitation treatments (including physiotherapy, occupational therapy, speech therapy, psychotherapy) without the use of any technological devices.
62774033|NCT02622646||Poor controlled patients|Patients with poor disease control, based on the international guidelines: AJBR\>2, ABR\>2 for severe BE or ABR \>5 for non-severe BE
62774034|NCT04357977||Covid +|Laboratory obtained Covid+ specimen results will be compared to saliva specimen
62774035|NCT05578378|EXPERIMENTAL|CLAG arm|Cladribine (5 mg/m2)should be intravenous use on day 1-5, granulocyte colony-stimulating factor will be hypodermic injection using 300 μg per day on days 0-5,cytarabine (1.5 mg/m2) every 12 hours, intravenous infusion on day1-5,4 weeks per cycle.
61998263|NCT06296667|EXPERIMENTAL|group 6: anterior/ anterior|participant posture: The thoracic block is aligned anterior to the pelvic block and is anteriorly tipped in the sagittal plane. Vertical force leads to an overall flexion of the trunk and decreased ability to sustain vertical forces
62183911|NCT01152476|ACTIVE_COMPARATOR|group S|
62183912|NCT01808898|EXPERIMENTAL|Local anaesthetic|2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
62183913|NCT01808898|PLACEBO_COMPARATOR|Saline|2mls of Normal Saline solution in a 5ml syringe
62183914|NCT01579721|EXPERIMENTAL|SILS-group|20 patients undergoing Single Incision Laparoscopic Surgery
62183915|NCT01579721|NO_INTERVENTION|CLS-group|20 patients undergoing Conventional Laparoscopic Surgery for rectal cancer
62183916|NCT04889859|ACTIVE_COMPARATOR|long RL group|long Roux limb Roux-en-Y reconstruction
62392659|NCT00585676||Diabetic|Patients with Diabetes
62392660|NCT00585676||Abnormal glucose level|Patients who were screened and had abnormal blood glucose levels
62392661|NCT00585676||Control|Non-diabetic (normal glucose screening)
62774036|NCT05578378|ACTIVE_COMPARATOR|Control arm|"Patients in the control arm received the investigator's choice of one of the following three regimens:~1. FLAG:Fludarabine(30mg/m2)should be intravenous use on day 1-5, granulocyte colony-stimulating factor will be hypodermic injection using 300 μg per day on days 0-5,cytarabine (1.5 mg/m2) every 12 hours, intravenous infusion on day1-5,4 weeks per cycle.~2. a high-dose cytosine arabinoside-based regimen;~3. a high-dose methotrexate-based regimen"
62774037|NCT02383641||Observation|Patients with Wolman disease or high-grade suspicion for Wolman disease
62791570|NCT01909089|EXPERIMENTAL|Chloroprocaine|Up-down sequential allocation.
62183917|NCT04889859|EXPERIMENTAL|long BPL group|long biliopancreatic limb Roux-en-Y reconstruction
62183918|NCT05218746|EXPERIMENTAL|Serratus anterior block|Regional analgesic block of anterolateral chest wall
62183919|NCT05218746|EXPERIMENTAL|Erector spinae block|Regional analgesic block for the whole chest wall
62183920|NCT02282306|OTHER|TTIP-PRO|"Patients who have experienced an OOD in the past 8 months will be eligible to receive TTIP-PRO. A letter about the study will be sent to those patients. Interested patients will call the UC Health staff working on this study. The intervention entails administering the Personal Opioid-Overdose Risk Survey and the Opioid Overdose and Treatment Awareness Survey to the patient. The TTIP-PRO computer program uses the information to generate the Personal Feedback Report, which is used by the Peer Interventionist to provide the intervention. The TTIP-PRO computer program also creates the Personal Risk Factors Report which is mailed to the participant with some other helpful information."
62183921|NCT05274425||Enerzair 150/50/80 μg|Enerzair inhalation capsule (indacaterol acetate/glycopyrronium bromide/mometasone furoate; 150/50/80 μg) via Breezhaler
62183922|NCT05274425||Enerzair 150/50/160 μg|Enerzair inhalation capsule (indacaterol acetate/glycopyrronium bromide/mometasone furoate; 150/50/160 μg) via Breezhaler,
62183923|NCT05918393|OTHER|Functional communication training (FCT)|During FCT, signaled intervals of reinforcement (i.e., the functional reinforcer is available contingent on communication) and extinction (i.e., the functional reinforcer is unavailable and thus both severe destructive behavior (SDB) and communication are on extinction) will be alternated within a single session. During the treatment-challenge evaluation, SDB will remain on extinction throughout and all communication responses will be reinforced on an FR-1 schedule during the signaled reinforcement intervals.
62183924|NCT05105568|EXPERIMENTAL|Process-based therapy|
62392662|NCT01822886|EXPERIMENTAL|Romidepsin, Gemcitabine|Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD (progression disease)
62568353|NCT01537926|EXPERIMENTAL|N-acetylcysteine (NAC)|N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days
62774038|NCT02147769||Preterm infants monitored with NIRS|All infants enrolled in the study will be monitored with cerebral near-infrared spectroscopy (NIRS monitoring) to measure cerebral oxygenation levels in the first 96 hours of life. Mean arterial blood pressure will simultaneously be monitored.
62774039|NCT00126984|EXPERIMENTAL|Group A|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation A
62774040|NCT00126984|EXPERIMENTAL|Group B|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation B
62774041|NCT00126984|EXPERIMENTAL|Group C|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation C
62392663|NCT03931629|ACTIVE_COMPARATOR|CONVENTIONAL PHACO|In Phase I, one of the three surgeons operated the LensX®, another performed the FLACS surgery (FLACS I) in one operating room (OR1), while the third surgeon performed the conventional phacoemulsification procedure (MANUAL) in another operating room (OR2). On subsequent days, the surgeons rotated between LensX®, FLACS and MANUAL surgery
62774042|NCT00126984|EXPERIMENTAL|Group D|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation D
62774043|NCT00126984|ACTIVE_COMPARATOR|Group E|Subjects of 12-14 months of age who will receive Meningitec and subjects of 3-5 years of age who will receive Mencevax ACWY.
62774044|NCT05066308|EXPERIMENTAL|Cannabidiol (CBD)|The recommended starting dosage is 2.5mg/kg taken twice daily. The titration schedule recommended in the EPIDIOLEX label will be followed, with 2.5 mg/kg twice daily in week 1, 5 mg/kg twice daily in week 2, 7.5 mg/kg twice daily in week 3, and 10 mg/kg twice daily in week 4 with the second PET scan conducted after one week at the maximum labeled dose. Any participant not tolerating a given dose can either go back down to the next lowest dose or delay uptitration at any week in the protocol. Participants will be instructed to take Epidiolex with a meal rather than in a fasted state. Participants will be treated for 4 weeks in total.
62774045|NCT05066308|PLACEBO_COMPARATOR|Placebo|The placebo will be taken at identical doses to the active drug condition.
62774046|NCT02263911|EXPERIMENTAL|Baricitinib Test Treatment 1 (T1)|Single oral dose of 2 × 4 milligram (mg) baricitinib commercial formulation tablet fasted on Day 1 in one of five periods.
62774047|NCT02263911|EXPERIMENTAL|Baricitinib Reference Treatment 1 (R1)|Single oral dose of 1 × 8 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods.
62774048|NCT02263911|EXPERIMENTAL|Baricitinib Test Treatment 2 (T2)|Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet fasted on Day 1 in one of five periods.
62774049|NCT02263911|EXPERIMENTAL|Baricitinib Reference Treatment 2 (R2)|Single oral dose of 1 × 4 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods.
62774050|NCT02263911|EXPERIMENTAL|Baricitinib Test Treatment 2 with Meal (T2F)|Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet after food intake on Day 1 in one of five periods.
62774051|NCT01055678|EXPERIMENTAL|All Patients|Single arm study analyzing tumor hypoxia after EF5 injection
62774052|NCT03853564|EXPERIMENTAL|Video-Feedback Group (VFG)|Dyads of mothers and their infant with developmental disability who are exposed to the video-feedback intervention focused on different domains of mother-infant quality of interaction (number of sessions: 6).
62774053|NCT03853564|SHAM_COMPARATOR|Phone-Call Group (PCG)|Dyads of mothers and their infant with developmental disability who are not exposed to the video-feedback intervention, instead they receive phone calls focused on obtaining descriptions of different domains of infant behavioral development (number of sessions: 6)
62774054|NCT02048033|ACTIVE_COMPARATOR|Arm with Apollo Endosurgery OverStitch technical|
62774055|NCT02048033|PLACEBO_COMPARATOR|Arm without Apollo Endosurgery OverStitch technical|
62774056|NCT01424566|EXPERIMENTAL|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 2 or 7 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligrams \[mg\]/milliliter \[mL\]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%)flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
62774057|NCT01424566|PLACEBO_COMPARATOR|Placebo (GA-0034)|Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorings.
61998264|NCT04249804|EXPERIMENTAL|Intrathecal Mg group|45 patients will receive 50 mg intrathecal MgSo4 added to 0.5% hyperbaric bupivacaine
62774058|NCT02575703|EXPERIMENTAL|[¹⁴C]-LY3023414|Single oral dose of \[¹⁴C\]-LY3023414 administered on Day 1
62774059|NCT00867555|EXPERIMENTAL|EGCG|"Double blind randomized, placebo-controlled cross-over design with two arms:~* the green tea extract TEAVIGO, high in EGCG and~* placebo"
62774060|NCT00867555|PLACEBO_COMPARATOR|placebo|
62774061|NCT02166827|ACTIVE_COMPARATOR|NeuroAD|NeuroAd Treatment, synchronized TMS and cognitive training stimulation
62774062|NCT02166827|SHAM_COMPARATOR|Sham TMS+Cog|Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
62774063|NCT03243175|EXPERIMENTAL|Direct Oral Anticoagulant (DOAC)|Apixaban 5MG twice daily
61998265|NCT04249804|EXPERIMENTAL|IV Mg infusion group|45 patients will receive IV magnesium sulfate 50 mg/kg in 100 mL isotonic saline over 20 min as a bolus then 2 mg/kg/h infusion using a separate infusion set after administering spinal anesthesia
62774064|NCT03243175|EXPERIMENTAL|Left Atrial Appendage Closure (LAAC)|Devices will be chosen by local teams.
62774065|NCT03243175|NO_INTERVENTION|Control|avoiding anticoagulation and LAAC during the entire study period The standard clinical practice without OAC may include: antiplatelet drug (in case of comorbidities such as coronary heart disease) or no antithrombotic drug
62774066|NCT02127177|EXPERIMENTAL|Cpap|
62774067|NCT02127177|NO_INTERVENTION|No Cpap|
62774068|NCT02967601||Elective Cesarean Section|
62774069|NCT05732883|EXPERIMENTAL|Dexamethasone group|One dose of 8mg in 2ml Dexamethasone will be given
62774070|NCT05732883|PLACEBO_COMPARATOR|Placebo group|One dose of 2ml 0.9% Normal saline will be given
62774071|NCT03948919|ACTIVE_COMPARATOR|FMT Treatment|Fecal microbiota - 1.0-3.0 x 10\^11 CFU / day (2 capsules per day for 8 weeks).
61998266|NCT04249804|NO_INTERVENTION|control|0.5% heavy bupivacaine in the spinal with no additives
61998267|NCT00417794|ACTIVE_COMPARATOR|1|Atomoxetine HCL (Strattera)
61998268|NCT00417794|PLACEBO_COMPARATOR|2|
61998269|NCT04275596|ACTIVE_COMPARATOR|2QR complex|Patients who undergo anal surgery will apply 2QR complex topical agent on the wound until healing
61998270|NCT04275596|ACTIVE_COMPARATOR|Placebo|Patients who undergo anal surgery will apply placebo cream on the wound until healing
62392664|NCT03931629|ACTIVE_COMPARATOR|FEMTOSECONDLASER (FLACS)|In Phase I, one of the three surgeons operated the LensX®, another performed the FLACS surgery (FLACS I) in one operating room (OR1), while the third surgeon performed the conventional phacoemulsification procedure (MANUAL) in another operating room (OR2). On subsequent days, the surgeons rotated between LensX®, FLACS and MANUAL surgery
62392665|NCT01994070|ACTIVE_COMPARATOR|Electrical-first|"Patients in atrial fibrillation for less than 48 hours will be administered procedural sedation and analgesia and an electrical current applied across their chest (cardioversion) to attempt conversion to normal sinus rhythm. If this does not succeed, they will be given intravenous procainamide (chemical cardioversion). If procainamide is required, physicians will be informed as follows: 50% of patients convert to normal sinus rhythm within one hour and 90% of patients convert within two hours. Physicians can then proceed at their discretion."
62774072|NCT03948919|PLACEBO_COMPARATOR|Placebo|The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product. Two capsules taken daily for 8 weeks.
62183925|NCT03771222|EXPERIMENTAL|Prophylactic DLI|The scheduled time of the first prophylactic DLI was +30 \~ +60 days after transplantation for HLA-matched sibling donors (MSD)-PBSCT recipients and +60 \~ +90 days after transplantation for HLA-haploidentical sibling donors (HID)-PBSCT recipients.
62183926|NCT03771222|NO_INTERVENTION|No prophylactic DLI|
62774073|NCT03048604|EXPERIMENTAL|Genio(TM) system therapy|
62774074|NCT01338584|EXPERIMENTAL|Pelvic floor muscle training, post prostatectomy|Pelvic floor muscle training will be taught on the day of admission
62774075|NCT06277648|NO_INTERVENTION|Control|All patients received standard spinal anaesthesia procedures with multimodal pain protocol postoperatively.
62774076|NCT06277648|EXPERIMENTAL|PENG block|All patients received standard spinal anaesthesia procedures with PENG block postoperatively.
62774077|NCT06277648|EXPERIMENTAL|SIFI block|All patients received standard spinal anaesthesia procedures with SIFIB postoperatively.
62774078|NCT05718037|EXPERIMENTAL|LY|Young adult subjects received low dose of BV211
62774079|NCT05718037|EXPERIMENTAL|HY|Young adult subjects received high dose of BV211
62774080|NCT05718037|PLACEBO_COMPARATOR|Placebo|Young adult subjects received placebo
62774081|NCT05718037|EXPERIMENTAL|LO|Old adult subjects received low dose of BV211
62774082|NCT05718037|EXPERIMENTAL|HO|Old adult subjects received high dose of BV211
62774083|NCT05718037|ACTIVE_COMPARATOR|Control Vaccine|Old adult subjects received control vaccine
61998271|NCT04729166|EXPERIMENTAL|Study group|The study group were provided with education with structured educational material and followed in this study, in addition to the usual care provided by healthcare professionals.
61998272|NCT04729166|NO_INTERVENTION|Control group|Control group was int the usual care.
61998273|NCT05296603|EXPERIMENTAL|Cohort A|Duration of response time less than 3 months
62774084|NCT01760590|EXPERIMENTAL|Manual Manipulation|Patients will be randomized to receive a thrust manipulation
62774085|NCT01760590|EXPERIMENTAL|Manual Mobilization|Patients will be randomized to receive mobilization
62774086|NCT02821364|OTHER|Advanced Life Support|ALS providers are trained and able to perform certain procedures such as intubation with endotracheal tubes and placement of intravenous catheters. Endotracheal intubation is often performed by pre-hospital providers in critically ill trauma patients because it is believed that it allows for protection of the airway and better delivery of oxygen. However, most studies actually show that intubation does not provide a survival advantage to this patient population and actually could result in worse outcomes. Intravenous catheter placement and administration of intravenous fluids is also routinely performed however, studies have shown that it is also not helpful.
62774087|NCT02821364|NO_INTERVENTION|Basic Life Support|Subjects randomized to the study group will receive basic life support (BLS) level care. This means that pre-hospital procedures such as endotracheal intubation and intravenous fluid administration will not be carried out. However, passive oxygen and needle thoracostomy, if required for tension pneumothorax, will be permitted if medically necessary.
62774088|NCT00772109|EXPERIMENTAL|Fluzone Intradermal Vaccine Lot 1|Participants will receive a dose of Influenza intradermal vaccine Lot 1
61998274|NCT05296603|EXPERIMENTAL|Cohort B|Duration of response time between 3 and 6 months
61998275|NCT05296603|EXPERIMENTAL|Cohort C|Duration of response time more than 6 months
61998276|NCT02371707|EXPERIMENTAL|Idalopirdine 60 mg formulation A (test)|
61998277|NCT02371707|EXPERIMENTAL|Idalopirdine 60 mg formulation B (reference)|
61998278|NCT01466270|EXPERIMENTAL|Arm I|Patients receive donepezil hydrochloride PO QD.
61998279|NCT01466270|PLACEBO_COMPARATOR|Arm II|Patients receive placebo PO QD.
61998280|NCT04165668||Dispatched lay responders|Nearby mobile phone located and dispatched lay responders who reached the place of the suspected OHCA before EMS and first responders (fire and police services).
61998281|NCT04165668||Non-dispatched lay responders|Nearby mobile phone located lay responders who have neither actively, nor technically responded due to either human or technical factors.
61998282|NCT06182358|EXPERIMENTAL|Active Treatment|XDEMVY (lotilaner ophthalmic solution) 0.25%, administered topically twice a day for approximately 43 days
62183927|NCT04956614|EXPERIMENTAL|suture of Achilles tendon without immobilisation|
62183928|NCT04956614|EXPERIMENTAL|suture of Achilles tendon with immobilisation|
62183929|NCT00966030|EXPERIMENTAL|1|MK0974 Tablet
62183930|NCT00966030|ACTIVE_COMPARATOR|2|MK0974 Liquid filled capsule
62183931|NCT03008304|EXPERIMENTAL|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
61998283|NCT06182358|PLACEBO_COMPARATOR|Control|Vehicle of XDEMVY ophthalmic solution, administered topically twice a day for approximately 43 days
61998284|NCT05692661|EXPERIMENTAL|proton plus carbon ion radiotherapy|CTV1: whole breast, proton therapy. CTVboost: Tumor bed, carbon ion dose escalation study with four dose levels.
61998285|NCT02123199||Indacaterol/QAB149|Patients treated with Indacaterol for COPD prior to enrollment in study
61998286|NCT06325033||Patients age ≥ 18 - <65 and BMI <30|Adult patients for procedural sedation in the University Medical Center Groningen (UMCG) between 01-01-2024 and 01-01-2025.
61998287|NCT06325033||Patients age ≥ 18 - <65 and BMI ≥ 30|Adult patients for procedural sedation in the UMCG between 01-01-2024 and 01-01-2025.
61998288|NCT06325033||Patients age ≥ 65 and over|Adult patients for procedural sedation in the UMCG between 01-01-2024 and 01-01-2025.
62183932|NCT03008304|NO_INTERVENTION|Control group|In this group, the patients will receive no special treatment. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62183933|NCT02576327|EXPERIMENTAL|Aprepitant Arm|Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）+ Aprepitant125mg（Day1-2）、80mg（Day3-6）
62183934|NCT02576327|ACTIVE_COMPARATOR|Control Arm|Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）
62183935|NCT03752242|EXPERIMENTAL|BMX-010 0.03%|Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Acne of the face.
61998289|NCT05149417|PLACEBO_COMPARATOR|Standard group|Patients enrolled in this group were discharged and they didn't undergo any intervention within the treatment period.
61998290|NCT05149417|ACTIVE_COMPARATOR|SMS group|patients received SMS at day 2 , day 4 and day 7 after emergency departement discharge to remind them to take their treatment .
61998291|NCT05149417|ACTIVE_COMPARATOR|telemonitoring group|Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.
61998292|NCT03621878|ACTIVE_COMPARATOR|Control group|Patients in this group had 6 sessions in 2 weeks of Transcutaneous Electric Nerve Stimulation (TENS).
61998293|NCT03621878|EXPERIMENTAL|Tensioner Group|Patients in this group had 6 sessions in 2 weeks of TENS combined with neural mobilization exercises (Tensioner technique).
61998294|NCT03621878|EXPERIMENTAL|Slider Group|Patients in this group had 6 sessions in 2 weeks of TENS combined with neural mobilization exercises (Slider technique).
61998295|NCT06311890|EXPERIMENTAL|photosensitizer group|Subjects will receive a photodynamic therapy with chlorin-e6 after acne removal surgery.Each subject will receive three treatments, two weeks (±3 days) intervals.
61998296|NCT06311890|PLACEBO_COMPARATOR|photosensitizer-placebo group|Subjects will receive a red light exposure treatment with chlorin-e6 placebo after acne removal surgery.Each subject will receive three treatments, two weeks (±3 days) intervals.
61998297|NCT02420028|EXPERIMENTAL|OptiVein IV catheter|Insertion of an IV catheter into the patient's vein, defined as placement of the catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
62183936|NCT03540290|ACTIVE_COMPARATOR|Mechanical instrumentation and oral hygiene instructions|
62183937|NCT03540290|EXPERIMENTAL|Modification of the implant supported prostheses|
62183938|NCT05209724|EXPERIMENTAL|Provider Supervised|Digital monitoring system with provider supervision
62774089|NCT00772109|EXPERIMENTAL|Fluzone Intradermal Vaccine Lot 2|Participants will receive a dose of Influenza intradermal vaccine Lot 2
61998298|NCT02420028|ACTIVE_COMPARATOR|Vasofix Certo IV catheter|Insertion of an IV catheter into the patient's vein, defined as placement of the catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
62183939|NCT05209724|NO_INTERVENTION|Self Supervised|Digital monitoring system without provider supervision
62183940|NCT00746785|EXPERIMENTAL|2.5 mg Olanzapine|"2.5 mg Olanzapine~1x per day for 12 weeks."
62183941|NCT00746785|ACTIVE_COMPARATOR|5mg Olanzapine|"5 mg Olanzapine~1x per day for 12 weeks."
61998299|NCT05984355||People aged 65 and over|
61998300|NCT05984355||Naturals caregivers|
62183942|NCT00746785|PLACEBO_COMPARATOR|Placebo|"Placebo~1x per day for 12 weeks."
62183943|NCT02594410|EXPERIMENTAL|Treatment|patients receiving renal artery stenting and anti-hypertension drug for renal artery atherosclerosis
62774090|NCT00772109|EXPERIMENTAL|Fluzone Intradermal Vaccine Lot 3|Participants will receive a dose of Influenza intradermal vaccine Lot 3
61998301|NCT05984355||Professionals|
61998302|NCT05808712||Translation and validation design|"To translate the English version of The Supportive Care Needs Survey-short form (SCNS-SF34) questionnaire into Swedish and to test the reliability and validity.~Design: Translation and validation design~A multicenter national validation study, in three university hospital in Sweden. Consecutive sampling procedure during a one-year period (2023), to evaluate internal consistency and test-retest reliability of the SCNS-SF34 in Swedish. Number is calculated to be 300 patients, and test-rest (reliability) in 50 patients. Inclusion criteria = \>18 years, cancer patients with different gastrointestinal cancer diagnosis. Exclusion criteria= not able to answer a questionnaire in Swedish.~Demographical and clinical data will be collected using a case report form. The survey will be distributed to patients via a web-based questionnaire or paper and pen questionnaire procedure."
62183944|NCT04475237||Healthy mandibles|Belgian adults (between 20 and 60 years old), 50/50 male/female, with no major mandibular problems/deformities
62183945|NCT02282423|EXPERIMENTAL|Lean Controls|"Lean controls will have BMI of 25 or less, gender specific normal body fat, and not be taking any medication that affects glucose metabolism.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
62183946|NCT02282423|EXPERIMENTAL|Obese, Non-diabetic|"Obese nondiabetics will have a BMI between 30-50 and not be taking any medication that affects glucose metabolism.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
62183947|NCT02282423|EXPERIMENTAL|Diabetic|"Diabetic patients will have a BMI between 30-50. We will recruit patients with mild or newly diagnosed type 2 diabetes who are treated with diet, sulfonylureas, or other drugs working through enhanced insulin secretion. Patients taking metformin or TZDs will not be recruited due to the effects of those drugs on insulin action.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
62568354|NCT01537926|PLACEBO_COMPARATOR|Placebo|Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.
62183948|NCT02282423|EXPERIMENTAL|Non-diabetic|"Patients will be nondiabetic, although we will include patients with impaired glucose tolerance. Patients will meet criteria for treatment with fibrates to lower plasma triglyceride concentrations (triglyceride\>300 mg/dl for nondiabetics, 250 mg/dl for patients with impaired glucose tolerance). We will aim at recruiting equal numbers of men and women. All participants will be between the ages of 30 and 59. Patients will have a BMI of 25-50 and not be taking any other medication that affects glucose metabolism. All participants will be sedentary (not reporting more than 10 minutes per day of light to vigorous leisure time physical activity.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
62183949|NCT04957329|ACTIVE_COMPARATOR|BAK-preserved|Xalatan eye drop
62183950|NCT04957329|ACTIVE_COMPARATOR|Preservative-free|Monoprost eye drop
62183951|NCT05394090|EXPERIMENTAL|saliva-stimulated group|In approximately 50 randomly selected patients (group 1), from the second day of admission until the end of hospitalization, a 15-minute manual stimulation of the submandibular and sublingual bib was performed internally and externally. In addition, oral hygiene was performed in patients, taking into account the tongue and cheeks.
62183952|NCT05394090|NO_INTERVENTION|the group in which the saliva was not stimulated|There was no saliva in the group of 50 patients
62183953|NCT01638845|ACTIVE_COMPARATOR|continuous perineural catheter|
62183954|NCT01638845|NO_INTERVENTION|Control|
62183955|NCT05154708||Patient Group - Phase 1|15 to 30 patients are expected in Phase 1 for the identification of needs and expectations in relation to a systematic electronic assessment of symptoms by the patients themselves
62183956|NCT05154708||Health Professionals Group - Phase 1|15 to 30 healthcare professionals are expected to participate in Phase 1 regarding the identification of needs and expectations in relation to a systematic electronic assessment of symptoms by the patients themselves
62183957|NCT05154708||Patient Group - Phase 2|50 à 60 patients were expected to test a systematic electronic assessment
62183958|NCT04422977|OTHER|CoVID exposure|
62392666|NCT01994070|ACTIVE_COMPARATOR|Chemical-first|"Patients in atrial fibrillation for less than 48 hours will be administered intravenous procainamide (chemical cardioversion) to attempt conversion to normal sinus rhythm. If procainamide is required, physicians will be informed as follows: 50% of patients convert to normal sinus rhythm within one hour and 90% of patients convert within two hours. Physicians can then proceed at their discretion. If this does not succeed, patients will be administered procedural sedation and analgesia and an electrical current applied across their chest (electrical cardioversion) to attempt conversion to normal sinus rhythm."
62392667|NCT01951833||Cystic fibrosis (Ecomedics vs NDD)|No treatment, observational
62392668|NCT01951833||Healthy (Ecomedics vs NDD)|"Free of respiratory symptoms for at least two weeks and will not have any chronic or recurrent chest problem.~No treatment, observational"
62392669|NCT05158127|EXPERIMENTAL|Treatment Group (AlloRx)|intravenous infusion and intralesional injection of 100 million cells
62392670|NCT02104232|EXPERIMENTAL|THPP-I|TPs in the THPP-I group receive, in addition to enhanced usual care (EUC), between 6 to 14 sessions of THPP (simple cognitive behaviour therapy) starting from their recruitment in the second/ third trimester until up to 6 months after child birth. Sessions will be delivered by peers on an individual basis at a location of convenience to the TPs.
62392671|NCT02104232|OTHER|Enhanced usual care (EUC)|Enhanced usual care (EUC) will comprise communicating the results of the screening to the mother through an information sheet on self-care for mental health, communicating the results to the mother's gynaecologist, providing the gynaecologist with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
62568355|NCT05220982|EXPERIMENTAL|Conversation Training Therapy|
62774091|NCT00772109|ACTIVE_COMPARATOR|Fluzone Intramuscular Vaccine|Participants will receive a dose of influenza intramuscular vaccine
62774092|NCT04648514|ACTIVE_COMPARATOR|Using of bone osteotomes for closed sinus lifting|Using of summers' osteotome technique by bone osteotomes for closed sinus lifting then evaluation the amount of bone height gain will be done radiographically (by panorama and CBCT) after implant placement in posterior edentulous maxilla .
62774093|NCT04648514|ACTIVE_COMPARATOR|Patient satisfaction evaluation after using bone osteotomes|Evaluation of patient satisfaction numerically will be done after using summers' osteotome technique by bone osteotomes for closed sinus lifting in posterior edentulous maxilla
62774094|NCT03484390|EXPERIMENTAL|Mindfulness-based stress reduction|The MBSR program is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 120 minute sessions, once per week for eight weeks.
62774095|NCT03484390|ACTIVE_COMPARATOR|Wellness Group|The Wellness control group uses a health education manual that provides information on various aspects of health, including diet, physical activity, sleep, stress management, and communication. The manual is used during weekly check-in phone calls for an 8-week period.
62774096|NCT06150794|ACTIVE_COMPARATOR|MTX alone (arm 1)|"Participants will receive intra-matrical methotrexate injection in the affected fingers of both hands, once a month for 3 months.~Comparison arms represent right hand (MTX+EL) and left hand (MTX alone) in the same participants."
62774097|NCT06150794|ACTIVE_COMPARATOR|MTX + EL (arm 2)|"Participants will receive excimer laser treatment in the affected fingers of the right hand only, in addition to treatment with methotrexate injection the same participants are receiving in the same hand.~Excimer laser will be applied twice weekly for 3 months.~Comparison arms represent right hand (MTX+EL) and left hand (MTX alone) in the same participants."
61998303|NCT04912921|EXPERIMENTAL|palmitoylethanolamide|Levagen
61998304|NCT04912921|PLACEBO_COMPARATOR|Placebo|microcrystalline cellulose
61998305|NCT04912921|EXPERIMENTAL|HydroCurc|curcumin
61998306|NCT04912921|PLACEBO_COMPARATOR|Control|microcrystalline cellulose
61998307|NCT00938028||Microbiome, Metabolome, Stool, Toddler|healthy infant stool samples
62183959|NCT02582385||Amyotrophic lateral sclerosis (ALS)|Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from patients who died with an amyotrophic lateral sclerosis.
62183960|NCT02582385||Control|Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from one non-ALS case.
62183961|NCT04173702|EXPERIMENTAL|Healthy Group|Postural sway and stability limits in assessment of healthy individuals
62774098|NCT01073007|EXPERIMENTAL|Simvastatin|Simvastatin 40 mg daily for 3 months.
62774099|NCT01073007|PLACEBO_COMPARATOR|Placebo|
61998308|NCT02738125||Subjects starting/ receiving adalimumab|Subjects starting/ receiving Adalimumab for UC
61998309|NCT03212625|EXPERIMENTAL|Urea cream 20%|144 patients spread urea cream (urea 20%)
61998310|NCT03212625|PLACEBO_COMPARATOR|Placebo|144 patients spread placebo cream (urea 0%)
61998311|NCT05583903|EXPERIMENTAL|Virtual Reality Software Usability in Healthy Volunteers Age 18-35 Years|Healthy volunteers between the ages of 18 and 35 years will utilize the ReCognition virtual reality software
62392672|NCT02115568||Long-term safety follow-up|To be eligible, subjects must have actively participated in a Juventas (JVS-100) sponsored trial under IND 14203.
62392673|NCT00777439|OTHER|Domperidone|All eligible subjects will receive domperidone in an open label, single group assignment.
62392674|NCT01551043|EXPERIMENTAL|Arm 1|
62392675|NCT00409565|EXPERIMENTAL|Cetuximab plus bevacizumab|Cetuximab plus bevacizumab
62774100|NCT02438813||All Enrolled Participants|All enrolled participants who signed informed consent whether or not they elected to receive treatment as per standard of care in clinical practice for submental fat (SMF). Treatments for SMF included: ATX1-101, Surgical Procedures, Laser Liposuction, Energy Devices or Other Treatments.
62774101|NCT01778426||Patients with Medtronic neurostimulator|Patients suffering from chronic neuropathic pain syndrome implanted (first implant or replacements) with a Medtronic neurostimulator.
62774102|NCT02816619|EXPERIMENTAL|APA+|APA + : patients will beneficiate of Personalized Physical Activity coaching program during 3 months (1 hour, twice by week, during 3 months)
62774103|NCT02816619|OTHER|APA-|APA- : patients will do free practice of physical activity during 3 months.
61998312|NCT05583903|EXPERIMENTAL|Virtual Reality Software Usability in Healthy Volunteers Age 60 or Greater Years|Healthy volunteers 60 years of age and older will utilize the ReCognition virtual reality software
62392676|NCT06111755|ACTIVE_COMPARATOR|SmokefreeTXT|Daily smokers for at least 6 months who report an interest in quitting will be randomized to receive the National Cancer Institute's SmokefreeTXT.
62392677|NCT06111755|EXPERIMENTAL|SmokefreeTXT + smartband|Daily smokers for at least 6 months who report an interest in quitting will be randomized to receive the National Cancer Institute's SmokefreeTXT + smartband.
62392678|NCT02746276|OTHER|Ceftriaxone and metronidazole|Pharmacokinetic study of ceftriaxone and metronidazole in malnourished children
62392679|NCT04533932||Elastography|
62568356|NCT05220982|EXPERIMENTAL|Global Voice Prevention and Therapy Model|
62568357|NCT05220982|EXPERIMENTAL|Modified Conversation Training Therapy|
62774104|NCT02168517||Group I|Overweight osteoarthritis patients
62774105|NCT02168517||Group II|Normal weight osteoarthritis patients.
62774106|NCT02168517||Group III|Overweight healthy men.
62774107|NCT02168517||Group IV|Normal weight healthy men.
62568358|NCT05220982|EXPERIMENTAL|Modified Global Voice Prevention and Therapy Model|
62774108|NCT03683888|EXPERIMENTAL|Healthsnap|50 patients will receive HealthSnap assessment in addition to their current treatment regardless of their participation into the study
62774109|NCT03683888|ACTIVE_COMPARATOR|Diet|50 patients will receive standard of care dietary counselling in addition to their current treatment regardless of their participation into the study
61998313|NCT01893424|ACTIVE_COMPARATOR|Sativex buccal spray|volunteers will receive a single dose of 8 actuations of Sativex® which will be administrated within 1-2 min by the study physician. The dose of THC and CBD to be administered is the following: THC 21.6 mg and CBD 20 mg. Sativex® actuations will be directed sublingually and at the buccal mucosa.
62568359|NCT00722358|ACTIVE_COMPARATOR|BMS-650032|
62568360|NCT00722358|PLACEBO_COMPARATOR|Placebo|
62734577|NCT02463708||BHL COTP Caregivers|Caregivers participate in the BHL COTP, which provides support, education, and care management services from a Behavioral Health Provider (BHP) in addition to the Telehealth Education Program (TEP), a manualized program that consists of various modules that seek to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
62774110|NCT02215343|EXPERIMENTAL|High fibre diet (wheat bran extract)|
62774111|NCT02215343|EXPERIMENTAL|High PUFA diet (fish oil supplement)|
62774112|NCT01984450|ACTIVE_COMPARATOR|ACIC|The patients in this group will be treated by the ACIC technique, which uses autologous collagen to regenerate articular cartilage. ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation.
61998314|NCT01893424|EXPERIMENTAL|CBD-THC-Piperine-PNL capsule|12 volunteers will receive a single oral dose of THC:CBD P-PNL capsule with 200 mL of water. The dose of THC and CBD to be administered is the same as in the Sativex arm: THC 21.6 mg and CBD 20 mg.
61998315|NCT01457495|EXPERIMENTAL|DTPa 1 Group|
61998316|NCT01457495|ACTIVE_COMPARATOR|DTPa 2 Group|
62774113|NCT01984450|ACTIVE_COMPARATOR|MCIC|The patients in this group will be treated by the MCIC technique, which uses concentrated BMAC to regenerate articular cartilage. MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation.
62774114|NCT06484361|EXPERIMENTAL|Arm 1|Dual tracer PET/MRI
61998317|NCT02018289|EXPERIMENTAL|Triclosan|Suture of the abdominal wall with triclosan coated suture
61998318|NCT02018289|SHAM_COMPARATOR|No triclosan|Suture of the abdominal wall with the same suture, but without triclosan
61998319|NCT03818516|EXPERIMENTAL|Oral Glucose Tolerance Test (OGTT)|Medically stable participants with schizophrenia and a range of insulin resistance will have an oral glucose tolerance test.
61998320|NCT03508856|EXPERIMENTAL|Picato 0.015% gel|Picato 0.015% gel, is a topical treatment for actinic ketatoses.
61998321|NCT00651027|EXPERIMENTAL|A|
61998322|NCT00651027|EXPERIMENTAL|B|
61998323|NCT00651027|EXPERIMENTAL|C|200 mg
61998324|NCT05157932|EXPERIMENTAL|Talk Test|Virtual Cardiac Rehab + Exercise prescription based on the Talk test.
61998325|NCT05157932|EXPERIMENTAL|Cardiopulmonary Exercise Test|Virtual Cardiac Rehab + Exercise prescription based on the CPET results.
62774115|NCT06221787|PLACEBO_COMPARATOR|1565 nm non-ablative fractional laser combined with normal saline|The treatment parameters were adjusted according to each patient's age, skin color, surface area of affected skin, location of melasma, and skin type.After the scanning, infusing with normal saline in the entire face.
61998326|NCT01617603|EXPERIMENTAL|High polyphenol milk chocolate|High polyphenol milk chocolate containing approximately 1 mg/g of epicatechin
62568361|NCT05880875|EXPERIMENTAL|Reflective Supervision Enhancement|The Reflective Supervision enhancement is a professional development series for supervisors of state pre-kindergarten programs that is designed to build skills in using Reflective Supervision with teachers. The goal of the Reflective Supervision enhancement is to provide supervisors with foundational knowledge in Reflective Practice and Supervision and increase their use of Reflective Supervision principles and practices within their work. The series consists of a day-long foundational training and nine skills-focused workshops. Supervisors are expected to receive 8 hours of foundational training prior to the start of the academic year, and nine 2-hour monthly small groups over the course of the academic year.
62774116|NCT06221787|EXPERIMENTAL|microneedles combined with hUCMSC-Exos|The hUCMSC-Exos were applied while rolling a microneedle roller in the entire face.
61998327|NCT01617603|ACTIVE_COMPARATOR|Nestle Noir 70 % chocolate|Nestle Noir 70 % chocolate containing approximately 1 mg/g of epicatechin
61998328|NCT01617603|PLACEBO_COMPARATOR|Low polyphenol milk|Low polyphenol milk control (matched to product 1 as closely as possible for milk content, carbohydrate, fat and calories, made from cocoa butter, sugar, milk powder and small amount of cocoa liquor to improve taste, giving approximately 0.05mg/g epicatechin.
62568362|NCT05880875|NO_INTERVENTION|Business-As-Usual Waitlist Control|Supervisors in the business-as-usual waitlist control condition will supervise teachers as-per-usual (i.e., using standard administrative supervision), and will be eligible for the typical array of professional development opportunities that may be offered to them. These supervisors will receive the Reflective Supervision enhancement the following academic year.
62568363|NCT06349993|EXPERIMENTAL|Digital Intervention|
62568364|NCT06349993|ACTIVE_COMPARATOR|Health Education|
62568365|NCT02711696|ACTIVE_COMPARATOR|A, GCED cohort|GCED, Gluten Contamination Elimination Diet
62568366|NCT02711696|NO_INTERVENTION|B, time cohort|Cohort B consisted of patients on long term follow-up that accepted a repeated biopsies 60 or more months later the first control biopsy.
62568367|NCT01575951|EXPERIMENTAL|All patients|All participants enrolled.
62568368|NCT05872204|EXPERIMENTAL|Abemaciclib and letrozole|Participants received abemaciclib 150 mg tablet orally twice daily and letrozole tablet 2.5 mg orally once daily until disease progression, unacceptable adverse event(s) or death.
62568369|NCT03690128|ACTIVE_COMPARATOR|Control Arm - standard EWS procedure|Standard use of the current implement Early Warning System, based on the principles of the National Early Warning Score and with a standard escalation protocol.
62568370|NCT03690128|ACTIVE_COMPARATOR|Intervention Arm - I-EWS|"Implementation of Individual Early Warning Score (I-EWS) with a systematic clinical assessment with a standard escalation protocol as intervention 7 parameters (Respiration rate, pulse, saturation, systolic blood pressure, consciousness, temperature, Oxygen) are registered , an aggregated score is generated. In the electronic patient journal (Sundhedsplatformen), the nursing staff is asked to reevaluate the aggregated score based on their clinical assessment of the patient. The aggregated score can be upgraded with up to 6 points and downgraded with up to 4.~This new I-EWS score interacts with the standard escalation protocol which defines the observation frequency and relevant clinical actions."
62774117|NCT06221787|EXPERIMENTAL|1565 nm non-ablative fractional laser combined with hUCMSC-Exos|The treatment parameters were adjusted according to each patient's age, skin color, surface area of affected skin, location of melasma, and skin type.After the scanning, infusing with hUCMSC-Exos in the entire face.
62774118|NCT06221787|EXPERIMENTAL|PBASM combined with hUCMSC-Exos|4-5 levels of intensity were used, rolling each area for 8-10 min before applying the hUCMSC-Exos in the entire face.
62774119|NCT06054256|EXPERIMENTAL|Group CBT-I|The group CBT-I will receive 6-session group-based CBT-I.
61998329|NCT03416400||Immature oocytes vitrified before In Vitro Maturation|Immature oocytes were vitrified using closed system vitrification. After warming, they were cultured during 36 hours in IVM medium and fixed for cellular analysis
62214575|NCT03046108|ACTIVE_COMPARATOR|blind injection of Morton neuroma|"Percoutaneous blind injection in Morton neuroma by subcutaneous needle group 1 are going to be injected by an experimented orthopaedic surgeon based on anatomic landmark. There is no internal control of the needle placement.~Mixture of 1 cc of 2% mepivacaine (Mepivacaina Normon 2%® )+ 40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected.~Up to 4 injections are allow in the first three months of follow-up"
62568371|NCT04711590||Successful extubation|The patients pass the spontaneous breathing trial and are successful extubated without reintubation within 72 hours. .
62568372|NCT04711590||Failed extubation|The patients pass the spontaneous breathing trial and are successful extubated with reintubation within 72 hours. .
62568373|NCT00765336|ACTIVE_COMPARATOR|Minocycline Extended-Release Tablets|
62568374|NCT00765336|PLACEBO_COMPARATOR|Placebo|
62774120|NCT06054256|EXPERIMENTAL|App-based CBT-I|The app-based CBT-I group will receive 6-session CBT-I via smartphone.
62791571|NCT00849849||Postpartum GDM OGTT|200 women with prior GDM in their index pregnancies will undergo postpartum screening assessment. This program will follow these women who are at a high risk of developing DM2 after delivery for 1 year.
62791572|NCT00719680|EXPERIMENTAL|IgPro20|The IgPro20 dose will be the same as in the previous pivotal study ZLB04_009CR (NCT00419341) infused subcutaneously weekly or twice a week (in the latter case, half of a weekly dose will be used)
62774121|NCT06054256|SHAM_COMPARATOR|Health-related psychoeducation control|The control group will receive group-based health-related psychoeducation, a format that has been adopted in the previous research, in order to provide the credibility of the intervention to the participants, and to control for the potential effects of attention and nonspecific components, e.g., receiving health-related information, expectations of benefit. It will also consist of 6 weekly sessions which contain education on healthy diet, exercise habits, sleep hygiene and self-care specific to pregnancy, but will not include any active therapeutic components of CBT-I.
62774122|NCT05474222|EXPERIMENTAL|Horizon Eagle Fatherhood Programming - classroom instruction|The intervention (the Horizon Eagle Fatherhood Programming) is an intensive 40-hour classroom-based program taught by project staff. This instruction addresses topics such as Fatherhood Development, Relationship Enhancement, and Financial Literacy, and features the 24/7 Dad curriculum as part of the instruction. Intervention participants and control participants will have an opportunity to participate in case management services and workforce training.
61998330|NCT03416400||Immature oocytes cultured in vitro before vitrification|Immature oocytes were cultured in vitro in IVM medium during 36 hours. After IVM, they were vitrified. After warming, they were fixed for cellular analysis.
61998331|NCT03416400||Fresh oocytes|Immature oocytes were cultured in vitro in IVM medium during 36 hours and subsequently, fixed for cellular analysis.
61998332|NCT00358462|ACTIVE_COMPARATOR|Active azithromycin+placebo doxycycline|Active azithromycin (1g) and placebo doxycycline
61998333|NCT00358462|ACTIVE_COMPARATOR|Active doxycycline+placebo azithromycin|Active doxycycline and placebo azithromycin
62183962|NCT03747614|EXPERIMENTAL|Dry eye group|The recruitment of subjects met the criteria of DEWS. Each subject received treatment based on increasing severity according to the expert consensus for the treatment of DE inflammation. For moderate levels of severity, topical anti-inflammatory agents (0.1% Fluorometholone) were administered twice daily and then gradually less frequently until inflammation was controlled. For severe DE, the approach was similar to that of the moderate level but with an increased concentration and treatment frequency of the anti-inflammatory agents (0.1% Fluorometholone, 4 times daily). Topical 0.05% tacrolimus twice daily when DE was extremely severe. Functional Slit-Lamp Biomicroscopy were administrated to collected data from this group.
62183963|NCT03747614|EXPERIMENTAL|Control group|Normal health subject without drug intervention, Functional Slit-Lamp Biomicroscopy were administrated to collected data from this group.
62183964|NCT00436956|EXPERIMENTAL|AZD2171 in Prostate Cancer|Cohort 1 (n=35) received 20 mg AZD2171 (Cediranib) orally daily. Cohort 2 (n=23) received prednisone 10 mg orally daily with 20 mg AZD2171.
62568375|NCT02703467||Healthy|Healthy subjects will have no significant medical history and no previous history of asthma or other serious illnesses. They should be non-smokers. The investigators willl measure spirometry and ensure that the values lie within the normal predicted range.
62568376|NCT02703467||Asthmatics|Patients diagnosed as having asthma will be recruited from Royal Brompton Hospital Asthma Clinics. These patients will have a range of severity of asthma ranging from mild-moderate to severe asthma patients. The diagnosis of asthma is ascertained as described in the inclusion criteria.
62568377|NCT03845660|NO_INTERVENTION|Usual Care|Providers taking care of patients randomized to this arm will have no alert related to the patients prognosis.
62568378|NCT03845660|EXPERIMENTAL|Electronic Alert|"Patients randomized to the intervention will have an alert of their prognosis based on the best available prognostic models for inpatient and 1-year mortality generated with information from their electronic health record, which will consist of a pop-up when the provider accesses a patient record to enter a progress note after the definitions for inclusions into the study have been registered."
62568379|NCT02513160|EXPERIMENTAL|Beclomethasone dipropionate BAI 320|"Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) at 320 mcg/day (40 mcg/inhalation, 4 inhalations twice daily)~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
62568380|NCT02513160|EXPERIMENTAL|Beclomethasone dipropionate BAI 640|"Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) at 640 mcg/day (80 mcg/inhalation, 4 inhalations twice daily)~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
61998334|NCT03522181|PLACEBO_COMPARATOR|control group|saline
61998335|NCT03522181|EXPERIMENTAL|GIK group|glucose-Insulin-Potassium(GIK) infusion
61998336|NCT01561066|SHAM_COMPARATOR|conservative therapy|Conservative therapy includes orrection of electrolytic disturbances, suppression of gastric/intestinal secretion with octreotide, nutritional support.
61998337|NCT01561066|ACTIVE_COMPARATOR|Application of autologous PRFG|The application of the glues through the external opening of the fistula was controlled by the drainage tube, which was based on fistulography to assure total occlusion of the internal hole. To allow the adhesion of the fibrin glues patch, all fistulous tracts were debrided to produce a smooth surface. At the time of procedures, the two components were mixed together to yield a gelatinous substance. After the FG was instilled, any redundant glue was removed from the external openings.
62183965|NCT00581464|ACTIVE_COMPARATOR|1|
62183966|NCT00581464|ACTIVE_COMPARATOR|2|
62183967|NCT01852032|EXPERIMENTAL|Breast cancer Patients|Tomosynthesis Breast Scanning is done and breast CT Scanning is done.
62183968|NCT05364034|EXPERIMENTAL|Urban Afforestation Group|Participants will perform an afforestation activity with a duration of 90 minutes.
62183969|NCT04560062||Population in Quito|576 randomly chosen patients with diabetes in District 17D06, Quito (Ecuador)
62183970|NCT04560062||Population in Esmeraldas|576 randomly chosen patients with diabetes in Eloy Alfaro District, Esmeraldas (Ecuador)
61998338|NCT00301249||Family Investigation of Nephropathy and Diabetes (FIND)|Individuals with diabetic nephropathy, their parents, and selected siblings
62392680|NCT03152643|EXPERIMENTAL|blastocyst-stage embryo transfer group|For subjects assigned to blastocyst-stage (D5/D6) embryo transfer group, all embryos will be cultured to D5 or D6. 1 blastocysts of the best quality will be transferred in fresh cycle on D5 or D6 after oocyte retrieval (D5 embryo will be the prior choice). The surplus embryos, if any, will be vitrified for future FET in case the fresh cycle does not result in a live birth. If a patient is at a high risk of OHSS, all embryos on D5 or D6 can be cryopreserved with vitrification for patient's safety. The FET cycle will be initiated on the second menstrual cycle after oocyte retrieval.
62392681|NCT03152643|EXPERIMENTAL|cleavage-stage embryo transfer group|For subjects assigned to the cleavage-stage (D2/3) embryo transfer group, 1 cleavage embryos of the best quality will be transferred in fresh cycle on Day 2/3 after oocyte retrieval. The surplus embryos, if any, will be vitrified for future FET if the fresh cycle does not result in a live birth. If a patient is at a high risk of OHSS, all embryos on Day 2/3 are allowed to be cryopreserved with vitrification for patient's safety. The FET cycle will be initiated on the second menstrual cycle after oocyte retrieval.
62392682|NCT03329053|EXPERIMENTAL|Experimental group|Patients randomized into the experimental group will undergo behavioural counselling. During the 30-minute long consultation patients will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support system EXPERT tool.
62568381|NCT02513160|ACTIVE_COMPARATOR|Beclomethasone dipropionate MDI 320|"Beclomethasone dipropionate Metered Dose Inhaler (MDI) 320 mcg/day (40 mcg/inhalation, 4 inhalations twice daily)~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
62774123|NCT05474222|NO_INTERVENTION|Control|The control group does not receive any part of the classroom instruction that the intervention group receives. Like the intervention group, however, the control group does have access to case management and workforce training.
61998339|NCT00301249||African American MALD|Case-control study of African American patients with nephropathy (cases) and their spouses (controls) unaffected by diabetes and nephropathy; offspring were genotyped when available to provide haplotype data.
62392683|NCT03329053|ACTIVE_COMPARATOR|Control group|Patients randomized into the control group will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, also in the domain of recommendations for physical activities.
62568382|NCT02513160|PLACEBO_COMPARATOR|Placebo|"Pooled breath-actuated inhaler (BAI) or metered-dose inhaler (MDI) placebo groups. Participants were instructed to take 4 inhalations twice daily for 6 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
62774124|NCT02145598|EXPERIMENTAL|Lenalidomide|Lenalidomide 10mg/day
62774125|NCT02145598|PLACEBO_COMPARATOR|Placebo|Placebo
61998340|NCT00301249||Mexican American MALD|Case-control study of unrelated individuals of Mexican American heritage in which both cases and controls had diabetes, but only the case had nephropathy
61998341|NCT03951922|EXPERIMENTAL|Therapeutic Horticulture Group|The therapeutic horticulture group will participate in a 6-week horticulture program meeting twice a week for an hour led by an occupational therapist incorporating plant-based activities and education on pain management techniques at a community farm.
61998342|NCT01034410|ACTIVE_COMPARATOR|Control|cytarabine 2g/m2 bid Days 4-7
61998343|NCT01034410|EXPERIMENTAL|AS1411-40|AS1411 40mg/kg/day d1-7 plus cytarabine 2g/m2 bid days 4-7
62774126|NCT01822613|EXPERIMENTAL|LJM716-BYL719 arm|approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the LJM716-BYL719 combination arm to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).
62791573|NCT05527821|EXPERIMENTAL|Surufatinib Combined With Sintilimab and SCRT|
62791574|NCT03470207|NO_INTERVENTION|Post-Intervention Cohort (Aim 1)|This arm will not have the intervention of the implementation of the structured post-pulmonary embolism follow up protocol that is outlined in Aim 1.
61998344|NCT01034410|EXPERIMENTAL|AS1411-80|AS1411 80mg/kg/day d1-7, cytarabine 2g/m2 bid days 4- 7/ bid d4-7
61998345|NCT03672435||proparacaine|Received topical proparacaine 0.5% with routine antibiotic-steroid ointment in operative eye(s) following strabismus surgery
61998346|NCT03672435||No proparacaine|Received no topical proparacaine 0.5% but did receive routine antibiotic-steroid ointment in the operative eye(s) following strabismus surgery
61998347|NCT06402188|EXPERIMENTAL|ColoSeal ICD Device Treatment Arm|Subjects will undergo transanal placement of the ICD Device.
61998348|NCT01746784|EXPERIMENTAL|N6022|Subjects randomized to study drug will receive N6022 by intravenous infusion once per day for 7 days
61998349|NCT01746784|PLACEBO_COMPARATOR|Normal saline|Subjects randomized to placebo will receive normal saline administered intravenously using the same volume as the active drug group
61998350|NCT02544529|EXPERIMENTAL|Echothiophate Iodide|Echothiophate Iodide 0.03% one drop to each eye three times per week for 18 weeks
61998351|NCT02544529|PLACEBO_COMPARATOR|Carboxymethylcellulose Sodium (0.5%)|Carboxymethylcellulose Sodium (0.5%) one drop to each eye three times per week for 18 weeks
61998352|NCT03865329|EXPERIMENTAL|Intervention- Home Pulmonary Rehabilitation|Participants will be offered a Home-based pulmonary rehabilitation program with health coaching.
61998353|NCT03299842|EXPERIMENTAL|ZX008|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
62392684|NCT02933333|EXPERIMENTAL|GM-CSF|Eligible patients received subcutaneous GM-CSF 5 μg/kg per day when the first time of absolute neutrophil count \[ANC\] \<1.5\*10\^9/L after chemotherapy. GM-CSF is given daily for at least 5 days and continued until the ANC reached 1.5\*10\^9/L for two consecutive days.
62392685|NCT02933333|EXPERIMENTAL|G-CSF|Eligible patients received subcutaneous G-CSF 5 μg/kg per day when the first time of absolute neutrophil count \[ANC\] \<1.5\*10\^9/L after chemotherapy. G-CSF is given daily for at least 5 days and continued until the ANC reached 1.5\*10\^9/L for two consecutive days.
62392686|NCT02933333|EXPERIMENTAL|G-CSF + GM-CSF|Eligible patients received subcutaneous a combination of GM-CSF 5 μg/kg per day and G-CSF 5 μg/kg per day when the first time of absolute neutrophil count \[ANC\] \<1.5\*10\^9/L after chemotherapy. GM-CSF and G-CSF are given daily for at least 5 days and continued until the ANC reached 1.5\*10\^9/L for two consecutive days.
62392687|NCT01496391||Healthy Participants|eGFR ≥60 ml/min/1.73m\^2, healthy prospective kidney donor
62392688|NCT01496391||Moderate Renal Function Impairment|eGFR 30-59 ml/minute/1.73m\^2
62392689|NCT01496391||Severe Renal Function Impairment|eGFR \<30 mL/minute/1.73m\^2
62392690|NCT02079077|OTHER|Acetylsalicylic Acid (ASA)|ASA 81 mg. p.o. daily for two months
62392691|NCT02079077|OTHER|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. o.d. p.o. for two months.
62568383|NCT03538730|NO_INTERVENTION|Attention Control|Similar to previous narrative and memory interventions, parents in the control group will receive instructions from a researcher for 20 minutes on how to engage in child-directed play. Importantly, they will not talk about pain or the past surgery experience.
62568384|NCT03538730|EXPERIMENTAL|Memory Reframing Intervention|Parents in the intervention group will spend 20 minutes with a researcher and receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods.
62774127|NCT01822613|ACTIVE_COMPARATOR|Paclitaxel, Docetaxel or Irinotecan arm|approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the Paclitaxel, Docetaxel or Irinotecan arm (physician's choice arm) to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the LJM716-BYL719 combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).
61998354|NCT01076829|ACTIVE_COMPARATOR|Spice patty|hamburger meat cooked with spice mixture
61998355|NCT01076829|PLACEBO_COMPARATOR|salt patty|Subjects consume salt containing hamburger meat
62392692|NCT02626078||observation and interview of residents|residents will be observed over lunch and an interview will be held with each resident after lunch
62392693|NCT00960323|ACTIVE_COMPARATOR|Colchicine Alone|baseline colchicine pharmacokinetics
62392694|NCT00960323|EXPERIMENTAL|Colchicine with Atorvastatin|Colchicine pharmacokinetics in the presence of atorvastatin at steady state.
62568385|NCT06163664|EXPERIMENTAL|Intervention|Intervention with 1 week use of ChatGPT
62392695|NCT03303144|EXPERIMENTAL|Triferic via Hemodialysate|Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic over 4 hrs at one hemodialysis session.
62568386|NCT06163664|ACTIVE_COMPARATOR|Delayed control|No ChatGPT use for 1 week and intervention after 1 week
62568387|NCT02639624|EXPERIMENTAL|Low bicarbonate dialysate First|Dialysis with low bicarbonate dialysate (expected normal for an adult \~24 mEq) for the first half of dialysis then switched over to normal bicarbonate dialysate for the second half.
62568388|NCT02639624|ACTIVE_COMPARATOR|Normal bicarbonate dialysate First|Dialysis with normal (37 mEq) for the first half of dialysis then switched over to low bicarbonate dialysate
62774128|NCT04006392|EXPERIMENTAL|Erchonia FX-635|The Erchonia FX-635 is administered to the foot 12 times over 6 weeks (2 times each week) for 15 minutes per foot.
62392696|NCT03303144|EXPERIMENTAL|Triferic via IV infusion( pre-dialyzer)|Patients will receive a single 6.5-mg dose of Triferic iron administered IV over 3 hrs during hemodialysis via arterial blood line (pre-dialyzer)
62774129|NCT04006392|SHAM_COMPARATOR|Placebo Laser|Noise and appearance of output is the same but no active therapy applied. Treatment administration procedure is the same as with the experimental arm.
62774130|NCT01720979||Patients with traumatic injuries|Children that were admitted to the hospital after traumatic injuries to body parts below the clavicles (traumatic control injury) and children that were admitted to the hospital after traumatic brain injury as diagnosed by a physician (TBI).
61998356|NCT02212821|PLACEBO_COMPARATOR|Placebo|intravenous infusion
62392697|NCT03303144|EXPERIMENTAL|Triferic via IV infusion (post-dialyzer)|Patients will receive a single 6.5-mg dose of Triferic iron administered IV over 3 hrs during hemodialysis via venous blood line (post-dialyzer)
62392698|NCT04146259||group A|Control
62392699|NCT04146259||Group B|Post-surgical hypoparathyroidism
62392700|NCT05637827||children with hyperopia|The refractive error and axial length of eye were observed
61998357|NCT02212821|EXPERIMENTAL|Erythromycin|intravenous infusion
61998358|NCT01567969|EXPERIMENTAL|IICAPS|Provision of Intensive In-home Child and Adolescent Psychiatric Service, a six to seven month family-focused in-home psychiatric intervention.
62392701|NCT05637827||children with emmetropia|The refractive error and axial length of eye were observed
62392702|NCT05637827||children with myopia|The refractive error and axial length of eye were observed
62568389|NCT00841113|EXPERIMENTAL|1 Abarelix|Investigative drug
62568390|NCT00841113|ACTIVE_COMPARATOR|2 Goserelin plus bicalutamide|Standard therapy
62392703|NCT04853368|EXPERIMENTAL|F508del Homozygous Cystic Fibrosis (CF) Participants|F508del homozygous cystic fibrosis (CF) participants receive galicaftor/navocaftor dual combination (28 days) followed by galicaftor/navocaftor/ABBV-119 triple combination therapy (28 days).
62392704|NCT04853368|EXPERIMENTAL|F508del Heterozygous CF Participants (Active Drug Group)|F508del heterozygous CF participants receive galicaftor/navocaftor/ABBV-119 combination therapy (28 days).
62392705|NCT04853368|PLACEBO_COMPARATOR|F508del Heterozygous CF Participants (Placebo Group)|F508del heterozygous CF participants receive placebo (28 days).
61998359|NCT01567969|ACTIVE_COMPARATOR|Home-based CTC|Provision of Home-based Child Treatment Coordination, a six to seven month child-focused case management service with monthly in-home visits with the child's parent/legal guardian.
61998360|NCT00697346|EXPERIMENTAL|Part 1: PIC Dose Escalation|Alisertib 25 or 35 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 21 days followed by a 7-day recovery period in 28-day cycles or alisertib 35, 45, 65 or 90 mg PIC, orally, (QD for 14 days followed by a 14-day recovery period in 28-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 14 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose), followed by their respective dosage assignment.
62183971|NCT03752255|EXPERIMENTAL|Anxiety measurement method|Before the operation, patients in the experimental group will fill the anxiety scales (DAS and STAI). Then patients will watch a video about impacted tooth. This video will include the complications that patients may face and what should be done after the procedure. After the watching the video, patients will fill the both DAS and STAI.
62183972|NCT03752255|PLACEBO_COMPARATOR|Control|Before the operation, patients in the experimental group will fill the anxiety scales (DAS and STAI). The verbal information in detail will be given to the patients by the surgeon.This verbal information will include the complications that patients may face and what should be done after the procedure.
62183973|NCT05423431||Radiation with Hydrogel Spacer|Males at least 18 years of age, who underwent radiation therapy with a hydrogel spacer in place.
62183974|NCT01633476|ACTIVE_COMPARATOR|Valaciclovir|Active treatment with valaciclovir
62183975|NCT01633476|NO_INTERVENTION|No additional treatment|No additional treatment
62183976|NCT02884492|EXPERIMENTAL|Cognitive impairment|Adults with Alzheimer's disease, preclinical Alzheimer's disease or impairment due to suspected non-Alzheimer's disease pathophysiology will receive 18F-THK- 5351 and/or lumbar puncture (optional).
62183977|NCT02884492|ACTIVE_COMPARATOR|No cognitive impairment|Normal aging adults will receive 18F-THK- 5351 and/or lumbar puncture (optional).
62183978|NCT01974453||Right transradial|Procedures performed through right transradial approach
62392706|NCT04853368|EXPERIMENTAL|F508del Homozygous and Heterozygous CF Participants|F508del homozygous and heterozygous CF participants receive galicaftor/navocaftor/ABBV-576 triple combination therapy for 28 days.
62392707|NCT01467531|EXPERIMENTAL|Cohort 1|Period 1 Treatment A = Dolutegravir 50mg q24h x 5 days; Period 2 Treatment B = Rilpivirine 25mg q24h x 11; Period 3 Dolutegravir 50mg q24h + Rilpivirine q24h x 5 days
62392708|NCT01467531|EXPERIMENTAL|Cohort 2|Period 1 Treatment A = GSK1265744 30mg q24h x 12 days; Period 2 Treatment B = Rilpivirine 25mg q24h x 12; Period 3 GSK1265744 30mg q24h + Rilpivirine q24h x 12 days
62392709|NCT00518167|EXPERIMENTAL|1|Intensive lifestyle intervention
61998361|NCT00697346|EXPERIMENTAL|Part 1: ECT Dose Escalation|Alisertib 40 mg, Enteric-coated Tablet (ECT) formulation, orally, QD for 14 days followed by a 14-day recovery period in 28-day cycles, or alisertib 30, 40 or 50 mg ECT, orally BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 15 cycles).
62183979|NCT01974453||Left transradial|Procedures performed through left transradial approach
62183980|NCT01974453||Femoral|Procedures performed through transfemoral approach
62392710|NCT00518167|NO_INTERVENTION|2|Standard counselling at baseline
62392711|NCT00948896|EXPERIMENTAL|1|
62392712|NCT00948896|EXPERIMENTAL|2|
62183981|NCT02210208|EXPERIMENTAL|Mepitel® Ag|A dressing device used for surgical burn wounds with skin graft.
62183982|NCT02210208|EXPERIMENTAL|Mepilex® Transfer Ag|Donor site dressing device in the very same patient.
62183983|NCT04195932|EXPERIMENTAL|Exercise|6 moths of supervised moderate intensity aerobic and resistive exercise training
62392713|NCT00948896|EXPERIMENTAL|3|
62183984|NCT05072262|ACTIVE_COMPARATOR|Control (dexamethasone only)|Topical dexamethasone 1 mg/ml (Spersadex) started the day after surgery
62183985|NCT05072262|EXPERIMENTAL|Study group (NSAIDs and dexamethasone)|Topical nepafenac (Nevanac) 3 mg/ml and dexamethasone 1 mg/ml (Spersadex) started the day after surgery.
62183986|NCT01157351|EXPERIMENTAL|001|paliperidone palmitate 78 117 156 or 234 mg monthly injection for 15 months
62183987|NCT01157351|ACTIVE_COMPARATOR|002|aripiprazole flexible dosing as prescribed by the study doctor for 15 months
62183988|NCT01157351|ACTIVE_COMPARATOR|003|haloperidole flexible dosing as prescribed by the study doctor for 15 months
62183989|NCT01157351|ACTIVE_COMPARATOR|004|olanzapine flexible dosing as prescribed by the study doctor for 15 months
62183990|NCT01157351|ACTIVE_COMPARATOR|005|paliperidone flexible dosing as prescribed by the study doctor for 15 months
62392714|NCT00948896|NO_INTERVENTION|4|
62392715|NCT01005966|OTHER|Run in|Placebo
62392716|NCT01005966|EXPERIMENTAL|Sodium Fluoride Toothpaste|Sodium fluoride toothpaste
62392717|NCT01005966|ACTIVE_COMPARATOR|Amine Fluoride Toothpaste|Amine Fluoride
62392718|NCT01005966|OTHER|675ppmf toothpaste|Dose response
62392719|NCT01005966|ACTIVE_COMPARATOR|Sodium monofluorophosphate/sodium fluoride Toothpaste|Sodium monofluorophosphate/sodium fluoride Toothpaste
62392720|NCT01005966|PLACEBO_COMPARATOR|0 ppmf toothpaste|
62392721|NCT03570658|EXPERIMENTAL|Single-Ascending Dose (SAD)|Participants will receive a single dose of RO7049389.
62392722|NCT03570658|EXPERIMENTAL|Multiple-Ascending Dose (MAD)|Participants will receive multiple doses of RO7049389.
62392723|NCT03570658|PLACEBO_COMPARATOR|Placebo|Participants will receive either a single dose (SAD cohorts) or multiple doses (MAD cohorts) of placebo matched to RO7049389.
62392724|NCT01478542|ACTIVE_COMPARATOR|Favourable Prognosis F-A - Recruitment completed|Induction therapy with 4 cycles of R-CHOP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm \[max. 2mg absolute\], Predniso\[lo\]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2 additional cycles of R-CHOP-14 + 2xR plus additional involved-site radiotherapy, if FDG-PET negative only 4xR without radiotherapy.
62392725|NCT01478542|EXPERIMENTAL|Favourable F-B - Arm Closed|Induction therapy with 4 cycles of R-CHLIP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, liposomal Vincristine 1,4 mg/sqm (max. 2mg absolute), Predniso\[lo\]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2 additional cycles of R-CHLIP-14 + 2xR plus additional involved-site radiotherapy, if FDG-PET negative only 4xR without radiotherapy.
62392726|NCT01478542|ACTIVE_COMPARATOR|Less Favourable LF-A - Recruitment completed|Induction therapy with 6 cycles of R-CHOP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm \[max. 2mg absolute\], Predniso\[lo\]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2xR plus additional radiotherapy to the initial bulky region, if FDG-PET negative only 2xR without radiotherapy. After 3xR-CHOP-14 an interim restaging will be performed.
62392727|NCT01478542|EXPERIMENTAL|Less Favourable LF-B - Recruitment completed|Induction therapy with 6 cycles of R-CHLIP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, liposomal Vincristine 1,67 mg/sqm \[uncapped\], , Predniso\[lo\]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2xR plus additional radiotherapy to the initial bulky region, if FDG-PET negative only 2xR without radiotherapy. After 3xR-CHLIP-14 an interim restaging will be performed. Recruitment completed.
62392728|NCT01478542|EXPERIMENTAL|Less Favourable LF-C - Recruitment completed|Induction therapy with 6 cycles of CHOP-14 (Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm \[max. 2mg absolute\], Predniso\[lo\]ne 100mg/d d1-5) combined with an optimized Rituximab-schedule (375 mg/sqm, d-4, d-1, d1, d4, d14, d28, d42, d56, d91, d126, d175, d238) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive additional radiotherapy to the initial bulky region, if FDG-PET negative omission of radiotherapy. After 3x CHOP-14 an interim restaging will be performed. Recruitment completed.
62392729|NCT01478542|EXPERIMENTAL|Less Favourable LF-D - Recruitment completed|Induction therapy with 6 cycles of CHLIP-14 (Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, 1,67 mg/sqm \[uncapped\], , Predniso\[lo\]ne 100mg/d d1-5) combined with an optimised Rituximab-schedule (375 mg/sqm, d-4, d-1, d1, d4, d14, d28, d42, d56, d91, d126, d175, d238) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive additional radiotherapy to the initial bulky region, if FDG-PET negative omission of radiotherapy. After 3x CHLIP-14 an interim restaging will be performed. Recruitment completed.
62392730|NCT03104270|EXPERIMENTAL|Elo Pom Car and Dex|"Drug dosing and administration:~All drugs are administered on a 28-day cycle.~Elotuzumab: 10 mg/kg IV on Days 1,8,15 and 22 Cycles 1 and 2. 20 mg/kg on Day 1 of Cycles 3 and beyond.~Pomalidomide: 3 mg PO on days 1-21~Carfilzomib: 20 mg/m2 IV on days 1 of cycle 1. 56 mg/m2 IV on days 8 and 15 of cycle 1 and Days 1, 8 and 15 of the remaining seven cycles.~Dexamethasone: On days 1,8,15,22 of Cycle 1-2 and day 1 of Cycle 3 and every day 1 thereafter, pre-treatment with 28 mg PO 3-24 hours prior to the start of ELO. On days 8,15,22 of Cycle 3 and beyond, 40mg of DEX PO or IV. On Day 8 and 15 of Cycle 3 and beyond, pre-treatment with DEX 40mg PO or IV at least 30 min and no more than 4 hours prior to the start of CFZ."
62392731|NCT02800096|ACTIVE_COMPARATOR|Gambling Internet intervention|The gambling only Internet intervention (G-only) will consist of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
62568391|NCT01173523|EXPERIMENTAL|Cohort A: STA-9090|Once weekly IV dosing of STA-9090 200mg/m2 was given weeks 1, 2, and 3 of a 4-week cycle. Participants received treatment until evidence of progressive disease or unacceptable toxicity. Participants were stratified at baseline into 2 distinct prognostic groups. Cohort A participants had relapsed \> 60 days following initial chemotherapy completion.
62568392|NCT01173523|EXPERIMENTAL|Cohort B: STA-9090|Once weekly IV dosing of STA-9090 200mg/m2 was given weeks 1, 2, and 3 of a 4-week cycle. Participants received treatment until evidence of progressive disease or unacceptable toxicity. Participants were stratified at baseline into 2 distinct prognostic groups. Cohort B participants had not responded or had relapsed \</= 60 days from the completion of initial chemotherapy.
62568393|NCT03096938|PLACEBO_COMPARATOR|Normal screening group|patients receive the routine screening examination
62568394|NCT03096938|EXPERIMENTAL|methylation markers screening group|patients receive the methylation markers screening
62568395|NCT04424043|EXPERIMENTAL|neo-TACE-HAIC with surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
62568396|NCT04424043|ACTIVE_COMPARATOR|surgery alone|hepatic resection remove the liver tumors
62568397|NCT03894826|EXPERIMENTAL|TREATMENT|Participants will be administered 230 mg/m2/day of oral Vorinostat \[100 mg tablets\] in addition to standard of care anti-seizure medication for a duration of 6 weeks.
62568398|NCT00770783|EXPERIMENTAL|Magnetic Seizure Therapy (MST)|
62568399|NCT00770783|ACTIVE_COMPARATOR|Electroconvulsive Therapy (ECT)|
62568400|NCT05006079|PLACEBO_COMPARATOR|Placebo drug|Lactose, administered both at 9:30 am and 12:00 pm
61998362|NCT00697346|EXPERIMENTAL|Part 2: PTCL|Participants with peripheral T-cell lymphoma (PTCL) received alisertib 50 mg ECT, orally, BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).
61998363|NCT01188577|EXPERIMENTAL|Epinephrine Inhalation Aerosol, HFA|Experimental treatment of 10 inhalations of 125 mcg epinephrine base propelled by HFA 134a
61998364|NCT01188577|ACTIVE_COMPARATOR|Epinephrine Inhalation Aerosol, CFC|Epinephrine Inhalation Aerosol, CFC propelled, 220 mcg/inhalation , 10 inhalations
62568401|NCT05006079|ACTIVE_COMPARATOR|Morphine alone|15mg immediate-release oral morphine, administered both at 9:30 am and 12:00 pm
62183991|NCT01157351|ACTIVE_COMPARATOR|006|perphenazine flexible dosing as prescribed by the study doctor for 15 months
62774131|NCT02160145|EXPERIMENTAL|Tolvaptan|Tolvaptan (OPC-41061)
62392732|NCT02800096|EXPERIMENTAL|Gambling Internet intervention + MoodGYM|The G+MH intervention condition will consist of the G-only intervention and an online intervention for depression and anxiety. The mental health intervention chosen is MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
62392733|NCT03260699|NO_INTERVENTION|Control group|Subjects will receive two out-patient physical therapy (PT) visits per week for 2 weeks, followed by additional PT visits at clinician's discretion after TKA.
62392734|NCT03260699|EXPERIMENTAL|Bracing group|Subjects will be fitted with the Ongoing Care Solutions, Inc (OCSI) Rehabilitator brace prior to surgery. This brace will be worn for 6 weeks before surgery. The brace will be worn again after surgery \~10 days after surgery or when staples are removed until the end of the study. Participants will also have two PT visits per week for 2 weeks, followed by additional PT visits at clinician's discretion.
62392735|NCT00911508|ACTIVE_COMPARATOR|Left Atrial Ablation|Pulmonary vein isolation using a circumferential ablative approach in the left atrium. Ablation may be performed using circular mapping catheter-guided ablation, antral isolation using a circular guided approach, or wide area circumferential ablation.
62392736|NCT00911508|ACTIVE_COMPARATOR|Rate or Rhythm Control Therapy|Current state-of-the-art drug therapy for atrial fibrillation (rate control or rhythm control). Treating physicians will be encouraged to follow the American College of Cardiology / American Heart Association / European Society of Cardiology Atrial Fibrillation Guidelines with regard to drug therapy for atrial fibrillation. The specific choice of rate control versus rhythm control drug therapy and the specific drugs to be used will ultimately be left to the discretion of the treating physician.
62392737|NCT05597852|EXPERIMENTAL|Study Arm|All patients with local recurrence of prostate cancer post irradiation will undergo placement of a hydrogel spacer between the prostate and rectum, in an effort to decrease toxicity and improve patient's bowel quality of life prior to SABR.
62392738|NCT01866280|EXPERIMENTAL|Normal sleep Normal meals|Normal sleep/Normal meal times
62392739|NCT01866280|EXPERIMENTAL|Normal sleep Late meals|Normal sleep/Late meal times
62183992|NCT01157351|ACTIVE_COMPARATOR|007|quetiapine flexible dosing as prescribed by the study doctor for 15 months
62392740|NCT01866280|EXPERIMENTAL|Late sleep Late meals|Late sleep/Late meal times
62392741|NCT01866280|EXPERIMENTAL|Late sleep Normal meals|Late sleep/Normal meal times
62568402|NCT05006079|ACTIVE_COMPARATOR|Alprazolam alone|0.25mg oral alprazolam, administered at both 9:30 am and 12:00 pm
62183993|NCT01157351|ACTIVE_COMPARATOR|008|risperidone flexible dosing as prescribed by the study doctor for 15 months
62183994|NCT01699698|EXPERIMENTAL|Test subject|
62183995|NCT05313906|EXPERIMENTAL|exprimental group|RC48 plus AK105 and cisplatin
62183996|NCT02920255||Electronic Caliper Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with electronic calipers.
62183997|NCT02920255||Conventional Caliper Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with conventional calipers.
62183998|NCT02920255||X-ray Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with x-rays.
62183999|NCT06142981|EXPERIMENTAL|Experimental group|Patients will receive three PRP sessions, where the patients received intravenous injections at four acupuncture points (stomach 36 and GB 34 on both sides) at the 1st, 2nd, and 3rd month.
62184000|NCT01855477|OTHER|Histological biopsy procedure|This is a multicenter study combining histological biopsy of tumor material with DNA sequencing using Next Generation Sequencing (NGS) platform. The study aims to obtain a more accurate pre-treatment stratification of cancer patients by obtaining fresh tumor biopsies for next-generation sequencing to obtain a mutational profile.
62184001|NCT04869150||those with myocardial bridges|
62392742|NCT05633394|EXPERIMENTAL|AtaCor EV Temporary Pacing Lead System|Subjects implanted with the AtaCor StealthTrac Lead Model AC-101400
62568403|NCT05006079|ACTIVE_COMPARATOR|Morphine then alprazolam|15mg oral morphine administered at 9:30 am, then 0.25mg oral alprazolam administered at 12:00 pm
62184002|NCT04869150||those without myocardial bridges|
62184003|NCT05806606|EXPERIMENTAL|Dyadic Empowerment-based Heart Failure program (De-HF)|The 16-week De-HF Program is delivered on a dyadic basis. The program consists of three core elements: i) joint dyadic interview in a home visit (1st-2nd week), ii) five ICT-enhanced empowerment-based modules (3rd-12th week; 2 sessions/ each module), and iii) post-module telephone follow-up (13th-16th week). The overall aim of the dyadic interview is to understand their usual pattern of collaboration, deficits, strengths and competing concerns in disease management. This is followed by the empowerment modules with the purpose to help the care dyads to get a consensus in disease interpretation (1st session: Perceptual and Cognitive Empowerment Session) and develop collaborative goal attainment process (2nd Session: Collaborative Gaol-Setting Process). This will be followed by two bi-weekly telephone calls to the care dyads using a speaker phone to monitor their level of goal attainment for the five modules, and to give further advice and counselling.
62568404|NCT05006079|ACTIVE_COMPARATOR|Alprazolam then morphine|0.25mg oral alprazolam administered at 9:30 am, then 15mg oral morphine administered at 12:00 pm
62568405|NCT05006079|ACTIVE_COMPARATOR|Morphine+alprazolam simultaneously|morphine 15mg + 0.25mg alprazolam at 9:30 am, then morphine 15mg + 0.25mg alprazolam at 12:00 pm
62568406|NCT00490750|ACTIVE_COMPARATOR|Laparoscopic Dor fundoplication|Heller myotomy followed by Dor fundoplication
62214576|NCT03046108|ACTIVE_COMPARATOR|blind injection of Mepivacaine|"1 cc of 2% mepivacaine (Mepivacaina Normon 2%® )+ 40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected.~Up to 4 injections are allow in the first three months of follow-up"
62392743|NCT01080157||Volunteers 18+, at risk for diabetes|
62392744|NCT00631228||1|The group will be monitored to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
62392745|NCT06076174|EXPERIMENTAL|Tele-rehab|6-week home-based exercise programme, will be monitored via the software that records each session so the therapist can review
62392746|NCT06076174|ACTIVE_COMPARATOR|Conventional|6-week home-based exercise programme, will have written instructions on paper to follow through by participant themselves
62392747|NCT03688841|EXPERIMENTAL|Bridged V.A.C.® with compression therapy|A vacuum assisted closure device will be placed on the ulcer. A compression dressing will be placed over the V.A.C.® device
62184004|NCT05806606|ACTIVE_COMPARATOR|Dyadic education program|The 16-week HF education program comprises a home visit, five bi-weekly online training sessions, and the subsequent telephone follow-up for the care dyads. The nurse will first assess how they manage HF in terms of medication compliance, fluid and dietary control, symptom monitoring and responses in a home visit and clarify their major misconceptions in self-care. This will be followed by five bi-weekly online education sessions on the same topics as the empowerment modules in the De-HF program.
62184005|NCT01409122|EXPERIMENTAL|Part A Multiple Dose|Ascending multiple dose administration (every 8 hours, \[Q8H\]) of AIR001 or placebo for 16 consecutive doses
62184006|NCT01409122|EXPERIMENTAL|Part B Single Dose with Sildenafil|Single escalating doses of AIR001 or placebo (Q8H, Day 4-6) administered in combination with steady-state sildenafil administration (Q8H, Days 1-6)
62184007|NCT01409122|EXPERIMENTAL|Part C, administration of AIR001 to patients with PAH|Four doses of AIR001 will be administered via nebulization to patients with PAH.
62184008|NCT01409122|EXPERIMENTAL|Part D, device crossover study|PK, safety and tolerability of single doses of AIR001 administered in a randomized order with three different nebulizers.
62184009|NCT05216198||TIA patients|Diagnostic of TIA by the exams performed in the emergencies of CHUGA.
62184010|NCT05913869|EXPERIMENTAL|Online MBSR 1|received modified online 8-week group-based MBSR intervention delivered by a UMASS trained MBSR instructor
62184011|NCT05913869|ACTIVE_COMPARATOR|Waitlist control|On a waiting list to receive the identical intervention as the treatment group after the active treatment group completes.
62184012|NCT03903835|ACTIVE_COMPARATOR|Control: Standard Care|Randomization between assignment to the control arm or the biomarker driven arm will be stratified on biomarker signatures, previous treatment, and fraction of ctDNA and will therefore occur after the results from the ctDNA profiling is obtained. Patients in the control arm will receive standard of care following national guidelines.
62184013|NCT03903835|EXPERIMENTAL|Treatment 1 in mHSPC: AR signalling inhibitors (ARSi)|Assignments to therapy in the biomarker driven arms will be done on the basis of the biomarker signature using the current information about the efficacy of the various regimens for that signature. Information from previous studies may be incorporated in the randomization at study onset if such reliable data exists. Specifically, patients with an intact androgen receptor (AR) and without TP53 mutations will have increased chance of being randomized to treatment with ARSi.
62184014|NCT03903835|EXPERIMENTAL|Treatment 2 in mHSPC: taxane-based chemotherapy in combination with ARSi|Patients with TP53 mutations and TMPRSS2-ERG gene fusions will have an increased chance of being randomised to treatment with chemotherapy plus an ARSi.
62568407|NCT00490750|ACTIVE_COMPARATOR|Laparoscopic Toupet fundoplication|Heller myotomy followed by Toupet fundoplication
62568408|NCT00111605|EXPERIMENTAL|1|HIV gag DNA vaccine or placebo on Days 0, 28, and 84
61998365|NCT05098535|EXPERIMENTAL|Visual Aid + Scripted Risk Discussion|This will involve the group of patients randomized to receive their perioperative risk discussion supplemented with the use of a visual aid in addition to a scripted discussion of their personalized perioperative risk of myocardial injury (MINS) during their consultation with an anesthesiologist in the PSS clinic.
62568409|NCT00111605|EXPERIMENTAL|2|HIV gag DNA vaccine plus 100 mcg of IL-12 or placebo on Days 0, 28, and 84
61998366|NCT05098535|ACTIVE_COMPARATOR|Scripted Risk Discussion|This will involve a group of patients randomized to receive a scripted discussion of their personalized perioperative risk of myocardial injury (MINS) during their consultation with an anesthesiologist in the PSS clinic.
61998367|NCT04847674|EXPERIMENTAL|TEV-53275 Dose A|
61998368|NCT04847674|EXPERIMENTAL|TEV-53275 Dose B|
61998369|NCT04847674|PLACEBO_COMPARATOR|Placebo|
61998370|NCT04388943||1|
61998371|NCT01434524|NO_INTERVENTION|Control|normal dietary
61998372|NCT01434524|NO_INTERVENTION|LIVACT|The present study used LIVACT for preoperative supplementation, commencing two weeks prior to surgery, and continuing for at least 6 months postoperatively with careful monitoring of compliance.
61998373|NCT00782262|OTHER|Group 1 (n=20)|BP \< 140/90, no diabetes mellitus and fasting glucose \< 5.5
61998374|NCT00782262|OTHER|Group 2 (n=20)|BP \> 140/100, no diabetes mellitus and fasting glucose \< 5.5
61998375|NCT00782262|OTHER|Group 3 (n=20)|BP \<140/100, no diabetes mellitus, fasting glucose 5.5 - 6.9
61998376|NCT03880721||Good prognosis|
61998377|NCT03880721||Poor prognosis|
61998378|NCT03880721||Recurrence|
61998379|NCT03880721||Not Recurrence|
61998380|NCT03880721||Survival|
61998381|NCT03880721||Death|
61998382|NCT01434290|EXPERIMENTAL|5 Fractions|36.25 Gy IMRT in 5 fractions over two and a half weeks
61998383|NCT01434290|EXPERIMENTAL|12 Fractions|51.6 Gy IMRT in 12 fractions over two and a half weeks
61998384|NCT01339390|EXPERIMENTAL|Arm 1: MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE! program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
62568410|NCT00111605|EXPERIMENTAL|3|HIV gag DNA vaccine plus 500 mcg of IL-12 or placebo on Days 0, 28, and 84
61998385|NCT01339390|ACTIVE_COMPARATOR|Arm 2: MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the primary care provider (PCP) to determine if the person would benefit from a weight loss program, and to refer them to MOVE! if they and the patient agree that it would be beneficial. The MOVE! program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
61998386|NCT05680922|EXPERIMENTAL|Experimental LB2102|DLL3-Directed Chimeric Antigen Receptor T-cells (CAR T)
61998387|NCT02072967||Ribomustin and rituximab|
61998388|NCT02857010|EXPERIMENTAL|Allogenic Mesenchymal stem cells|Intravenous allogenic bone marrow derived mesenchymal stem cells: 4 doses of 2 x 106/kg administered on days 1, 4, 11 and 18
61998389|NCT02857010|PLACEBO_COMPARATOR|Placebo|Solution without cells on days 1, 4, 11 and 18
61998390|NCT00654069|PLACEBO_COMPARATOR|Placebo|Tablet
61998391|NCT00654069|ACTIVE_COMPARATOR|Acurox 5/30mg|Oxycodone HCl 5mg/Niacin 30mg tablet
61998392|NCT00654069|PLACEBO_COMPARATOR|Acurox 7.5/30|Oxycodone HCl 7.5mg/Niacin 30mg tablet
62392748|NCT03688841|ACTIVE_COMPARATOR|Conventional compression therapy|A Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings will be applied and changed once to three times per week (dependant on exudate).
62774132|NCT02160145|PLACEBO_COMPARATOR|Placebo|Placebo
62184015|NCT03903835|EXPERIMENTAL|Treatment 3 in mHSPC: Poly ADP Ribose Polymerase (PARP) inhibitor|DNA-repair deficient patients will have an increased chance of receiving PARP inhibitors at study onset.
62392749|NCT04282811||cohort group|Patients who have received at least one dose of venetoclax
62392750|NCT04652609|EXPERIMENTAL|PRESIONA|An adapted therapeutic exercise program using blood flow restriction cuff perfomed during chemotherapy treatment. 24-36 sessions of 1 hour multimodal components: aerobic, strength and fascial release exercises. Frequency will be adapted to the recovery status of each patient.
62392751|NCT04652609|NO_INTERVENTION|Control group|Patients undergoing usual medical treatment
62392752|NCT03584412|EXPERIMENTAL|ACT OPEN|Acceptance and Commitment Therapy Online for Painful Peripheral Neuropathy (ACT OPEN).
62392753|NCT03584412|OTHER|Waiting List Control|Participants in this condition will not receive any change to their usual treatment for a period of 5 months, after which they will be given access to complete the ACT OPEN treatment.
62392754|NCT00984958|OTHER|Bulkamid|Injection with Bulkamid
62774133|NCT05350189||Gadavist Single-dose vial|Data will be collected from contrast-enhanced Magnetic Resonance Imaging (MRI) using Gadavist from a single-dose vial of 7.5 or 10 or 15 milliliters (mL).
62774134|NCT05350189||Gadavist IBP|Data will be collected from contrast-enhanced MRI using Gadavist from an IBP of either 30 or 65 milliliters (mL), and from Gadavist via a single-dose vial due to insufficient product remaining in an IBP during the IBP cohort.
62184016|NCT03903835|EXPERIMENTAL|Treatment 1 in mCRPC: AR signalling inhibitors (ARSi)|Specifically, patients with an intact androgen receptor (AR) and without TP53 mutations will have increased chance of being randomized to treatment with ARSi.
62184017|NCT03903835|EXPERIMENTAL|Treatment 2 in mCRPC: Poly ADP Ribose Polymerase (PARP) inhibitor|DNA-repair deficient patients will have an increased chance of receiving PARP inhibitors at study onset.
62184018|NCT03903835|EXPERIMENTAL|Treatment 3 in mCRPC: selective AKT Inhibitor|Patients with alterations in the PI3K pathway will have an increased chance of receiving the combination treatment with Capivasertib plus Docetaxel.
62184019|NCT03903835|EXPERIMENTAL|Treatment 4 in mCRPC: Carboplatin|Only patients with DNA-repair deficiency will be treated with Carboplatin as second line treatment in the castration-resistant phase of ProBio.
62184020|NCT03445117|EXPERIMENTAL|Intervention|Clinics assigned to the intervention arm will receive an educational intervention. This comprises posters on vaccination to be put up in the clinic, as well as a flyer which will be handed out by the clinic assistants to all patients 65 years and above, at the point of registration. The poster and flyer content will provide simple messaging to encourage patients to receive influenza and pneumococcal vaccinations and inform them of available healthcare subsidies.
62184021|NCT03445117|NO_INTERVENTION|Control|Clinics assigned to control arm will run as per their normal operations and not have the interventions implemented.
62184022|NCT03887247|ACTIVE_COMPARATOR|E-Mail Alert|Send email to the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager.
62184023|NCT03887247|NO_INTERVENTION|As-Usual|As-usual (no email) approach.
62184024|NCT04981353|ACTIVE_COMPARATOR|group 1|:(group 1) will be putted in sitting position and disinfecting her back. A real-time high-frequency linear ultrasound will be used to do the thoracic (ESP) at the level of T11 by visualizing the transverse process of T11 thoracic vertebrae and erector spinae muscle and injecting a 20 ml of bupivacaine 0.25% bilaterally using an in-plane technique, a 20-gauge, 70-mm needle (Tuoren, Henan, China) will be advanced into the plane below (ESM) after injecting lidocaine 1% 2ml at the site of injection, Needle will be advanced with a cranial to caudal direction
62184025|NCT04981353|ACTIVE_COMPARATOR|group 2|(group 2) patients will receive pethidine 25mg doses if NRS \>4.
62568411|NCT00111605|EXPERIMENTAL|4|HIV gag DNA vaccine plus 1,500 mcg of IL-12 or placebo on Days 0, 28, and 84
62184026|NCT02850718|EXPERIMENTAL|Period 1: Sublingual wafer|Subjects receive receive a single dose of 50 mg sublingual sildenafil followed by plasma sampling for 14 hours.
62184027|NCT02850718|ACTIVE_COMPARATOR|Period 2: Oral comparator|Subjects receive a single dose of 50 mg oral sildenafil (Viagra) followed by plasma sampling for 14 hours.
62214577|NCT03046108|ACTIVE_COMPARATOR|blind injection of Triamcinolone|40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected. Up to 4 injections are allow in the first three months of follow-up
62774135|NCT02372422|EXPERIMENTAL|Transvaginal Cervical Length Group|Clinicians managing the patients were aware of the transvaginal cervical length ultrasound measurements.
62774136|NCT02372422|OTHER|Routine Care|Clinicians managing the patients were not aware of any transvaginal cervical length ultrasound measurements.
62774137|NCT04770844||premature child|300 premature child will be included. They will have three acquisitions during hospitalization.
62392755|NCT00984958|OTHER|expectance|The expectance arm will after 2 month have the same treatment as the treatment arm
62392756|NCT04959162|EXPERIMENTAL|E-learning preparation|Will receive e-learning prior to a hands-on course in musculoskeletal ultrasound
62392757|NCT04959162|ACTIVE_COMPARATOR|Conventional preparation|Will receive standard information (time, place etc) prior to a hands-on course in musculoskeletal ultrasound
62392758|NCT05461404|EXPERIMENTAL|Emollient arm|Infants will receive gentle, hygienic whole-body massage by trained nurses (not parents or other family members) with 3g of SSO per kg of body weight - a dose sufficient to saturate the skin - three times daily for the first 14 days and twice daily thereafter during the duration of their stay in the hospital until death, discharge or through day 28 after birth.
62568412|NCT00111605|EXPERIMENTAL|5|HIV gag DNA vaccine or placebo on Days 0, 28, 84, 168, and 273
61998393|NCT02528916||Primary Knee Arthroplasty Patients|Patients who consented, met inclusion and exclusion criteria, had plasma and synovial fluid samples drawn as described in the included protocol. No interventions were completed. No changes to standard of care treatment completed.
62184028|NCT06055803|EXPERIMENTAL|Health Behavior Program|Each participant will have an individualized assessment with plan and goals set at the program intake visit. Program components will include: Physical Activity, Nutrition, Emotional Well-being, Cardiovascular Risk, Survivorship, and other items individualized to the participant as needed (e.g., tobacco cessation). The 12-week program will alternate between group and individual sessions each week. Individualized plans will be reviewed every two weeks at the participant individual sessions.
62184029|NCT06031961|ACTIVE_COMPARATOR|1st group: Melatonin group|All children in this group have to receive 0.5 mg/kg of melatonin(maximum dose 20 mg) which will be administered orally on the night before surgery ( at 12 am) and immediately before 30 minutes before entering the catheterization room.
62184030|NCT06031961|PLACEBO_COMPARATOR|2nd group: Placebo group|All children in this group have to receive a placebo which will be administered orally on the night before surgery and immediately before 30 minutes before entering the catheterization room.
62184031|NCT05661669|EXPERIMENTAL|Ketamine|This arm will receive ketamine (n=25)
62184032|NCT05661669|PLACEBO_COMPARATOR|Placebo|This arm will receive the saline placebo (n=25)
62184033|NCT00238953|EXPERIMENTAL|EC MPS|
62184034|NCT05177783|EXPERIMENTAL|Tuune|Participants complete the Tuune contraceptive decision aid health questionnaire.
62184035|NCT05177783|ACTIVE_COMPARATOR|Control|Participants complete a standard physician intake health questionnaire.
62184036|NCT06348264|EXPERIMENTAL|Rezvilutamide plus LHRHa|Participants will receive rezvilutamide in combination with a LHRHa for up to 2 years.
62184037|NCT04026399|EXPERIMENTAL|stimulation + therapy|The participant receives stimulation and home therapy.
62184038|NCT04026399|SHAM_COMPARATOR|no stimulation + therapy|The participant receives no stimulation and receives home therapy.
62184039|NCT00002721|EXPERIMENTAL|Prostate cancer patients|Prostate cancer patients that have not responded to hormon therapy
62184040|NCT06210061|ACTIVE_COMPARATOR|Group A (Propofol-Fentanyl)|Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery. Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation.
62184041|NCT06210061|EXPERIMENTAL|Group B (Propofol-Fentanyl-Dexmedetomidine)|"Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery.~In addition patients will receive Dexmedetomidine (0.5ug.kg) loading dose infused over 10 mins followed by a constant infusion rate of (0.2ug/kg/hr). Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation."
62392759|NCT05461404|NO_INTERVENTION|Control arm|Infants in the control group will receive the standard of care for infants in the neonatal care unit, which does not include use of topical emollients or massage (i.e., family members will not be allowed to apply skin care products to their infants), or other particular measures to prevent skin breakdown or to modulate skin barrier function.
62392760|NCT02298790|EXPERIMENTAL|Early Meals|Meals are eaten early in the wake episode
61998394|NCT05550051|ACTIVE_COMPARATOR|lignocaine nebulization before awake nasal fiberoptic intubation|Patients will have lignocaine nebulization by using 3 ml of lignocaine 2%, with O2 flow rate 10 l/min to deliver 60 mg lignocaine, of which about 25% is absorbed, and patients were encouraged to inhale deeply to facilitate further delivery of the anesthetic in their airway. After finishing the nebulization setting the patient will be asked about facial, nasal, and oral numbness if no numbness, the patient will have another nebulization setting.
62184042|NCT06210061|EXPERIMENTAL|Group C (Propofol-Fentanyl-Sevoflurane)|"Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery.~In addition the anesthesia will be maintained with inhalational anesthesia of 50% oxygen , 50% air plus sevoflurane concentration adjusted to keep BIS between 40 \& 50 . Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation"
62184043|NCT05928299||Durable Clinical Benefit|PFS≥ 6 months
62184044|NCT05928299||Non-durable Clinical Benefit|PFS\< 6 months
62184045|NCT05380141||Patients|Patients, children and adolescents referred to the chronic pain consultation of Necker Hospital with identification of school absenteeism or dropping out and having been the victim of school bullying.
62392761|NCT02298790|EXPERIMENTAL|Late Meals|Meals are eaten late in the wake episode
62392762|NCT01622842||Bioimpedance|8 females and 8 males BMI from 19 to 46 SBP from 119 to 182
62392763|NCT01347515|PLACEBO_COMPARATOR|FOO250|FOO250 ppm, the standard virgin olive oil
62392764|NCT01347515|ACTIVE_COMPARATOR|FOO500|Olive oil enriched with its own broad-spectrum phenolic compounds; FOO500 ppm
62392765|NCT01347515|ACTIVE_COMPARATOR|FOO750|Olive oil enriched with its own broad-spectra phenolic compounds; FOO750 ppm
62392766|NCT01136759|PLACEBO_COMPARATOR|Pregnancy cohort, placebo|Pregnant women will receive placebo gel.
62392767|NCT01136759|EXPERIMENTAL|Lactation cohort, tenofovir gel|Lactating mothers will receive tenofovir gel.
62392768|NCT01136759|EXPERIMENTAL|Pregnancy cohort, tenofovir gel|Pregnant women will receive tenofovir gel.
62392769|NCT06471686|EXPERIMENTAL|Acamprosate|The intervention group was assigned to acamprosate 666 mg oral tablets three times daily in addition to routine medical care for 14 weeks. Once assigned to this group, participants underwent a medication reconciliation with a transplant pharmacist to ensure there were no drug-drug interactions and answer questions regarding the medication. The medication prescription was then sent by the principal investigator (HH) to the patient preferred pharmacy. The research assistants (KL and JA) would confirm that the medication was obtained. They then underwent weekly telemedicine visits with a research member for 14 weeks and filled out self-report surveys to evaluate cravings, alcohol use, and side effects
62392770|NCT06471686|NO_INTERVENTION|Standard of Care|The control group continued with what was considered routine medical care as indicated by their medical condition including frequency of clinic visits (ranging from 1-6 months dependent on time from transplant), frequency of laboratory draws (ranging from twice monthly to biannually dependent on time from transplant), and adjustment of LT related medications (i.e. immunosuppression and prophylaxis against communicable disease). They also underwent weekly telemedicine visits with a research member for 14 weeks and filled out self-report surveys to evaluate cravings, alcohol use, and side effects
62392771|NCT05588622|EXPERIMENTAL|Treatment Group|This single-arm study will enroll all 20 participants in the Meru Health Program.
62392772|NCT02405273|EXPERIMENTAL|Interventional Group|Pulmonary rehabilitation
62392773|NCT02405273|ACTIVE_COMPARATOR|Control Group|Standard Care
62392774|NCT03449342|EXPERIMENTAL|Turoctocog alfa|Previously treated moderate or severe haemophilia A patients will receive routine prophylaxis treatment and treatment of bleeding episodes.
62392775|NCT03740724|EXPERIMENTAL|FCX-013 + veledimex|Following the injection of FCX-013, subjects will initiate a 14-day course of veledimex to be taken orally daily
61998395|NCT05550051|ACTIVE_COMPARATOR|Upper airway block before awake nasal fiberoptic intubation|"Upper airway block by using about lignocaine 2%, the block will be performed by:~1. Bilateral superior laryngeal nerve block and will be performed by slight neck extension to identify the hyoid bone. Insert the needle laterally aiming at the greater cornu, and after hitting the bone, it will slide inferiorly, and 2 mL of 2% lignocaine will be injected blocking both the internal and the external branches of the superior laryngeal nerve.~2. Trans tracheal instillation for recurrent laryngeal nerve block and will be performed by extending the neck to identify the midline and palpate the cricoid cartilage. The cricothyroid membrane lies above the cricoid cartilage. A needle will be inserted in the cricothyroid membrane while aspirating and once air bubbles appears, 5ml of 4% lignocaine will be injected resulting in cough and dispersing of the LA, blocking the nerve."
62392776|NCT01072175|EXPERIMENTAL|Arm Part A|Day 1: GSK2118436 75mg; Day 2 through Day 16: GSK1120212 2mg; Day 15: GSK2118436 75mg +GSK1120212 2mg Drug-drug interaction
61998396|NCT04187196|EXPERIMENTAL|Sedation with propofol group|Participants in this group will be randomized to sedation with bolus dosing of propofol for cardioversion.
61998397|NCT04187196|EXPERIMENTAL|Sedation with methohexital group|Participants in this group will be randomized to sedation with bolus dosing of methohexital for cardioversion.
61998398|NCT01159964|EXPERIMENTAL|Cohort 1|Subjects will receive investigational dose-level A (different from dose-levels B and C). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
61998399|NCT01159964|EXPERIMENTAL|Cohort 2|Subjects will receive investigational dose-level B (different from dose-levels A and C). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
61998400|NCT01159964|EXPERIMENTAL|Cohort 3|Subjects will receive investigational dose-level C (different from dose-levels A and B). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
61998401|NCT06406127|EXPERIMENTAL|Chemotherapy + Alpha Lipoic Acid|will receive chemotherapy (paclitaxel for 12 weeks) + Alpha Lipoic Acid for 14 weeks (one week before the start of paclitaxel and continue for one week after the end of paclitaxel).
61998402|NCT06406127|NO_INTERVENTION|Chemotherapy only|will receive chemotherapy only (paclitaxel for 12 weeks).
62392777|NCT01072175|EXPERIMENTAL|Arm Part B|GSK2118436 + GSK1120212 Dose escalation to a maximum tolerated combination dose
62392778|NCT01072175|EXPERIMENTAL|Arm Part C|GSK2118436 + GSK1120212 cohort expansion for safety and efficacy
62392779|NCT00491062|ACTIVE_COMPARATOR|Control|
62392780|NCT00491062|EXPERIMENTAL|Parkinson stade 1|
62392781|NCT00491062|EXPERIMENTAL|Parkinson stade2|
62392782|NCT00491062|EXPERIMENTAL|Parkinson stade 3|
62392783|NCT05008627||Doffing PPE with verbal instructions and monitor|The subject will remove the PPE according to verbal instructions by a monitor
62184046|NCT01391676||Trabeculectomy|glaucoma patients undergoing trabeculectomy with mitomycin c 0,02%
62184047|NCT02261298|EXPERIMENTAL|ONO-4538 1mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 1mg/kg, 3 times once every 2 weeks in each 6-week cycle
62184048|NCT02261298|EXPERIMENTAL|ONO-4538 3mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 3mg/kg, 3 times once every 2 weeks in each 6-week cycle
62184049|NCT02261298|EXPERIMENTAL|ONO-4538 10mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 10mg/kg, 3 times once every 2 weeks in each 6-week cycle
62184050|NCT04122482|EXPERIMENTAL|Intervention Group|In this arm, participants will be given access to the course material shortly after eligibility criteria is confirmed. They will be asked to complete post-measures questionnaires at 4 weeks and 8 weeks following completion of the course material.
62184051|NCT04122482|EXPERIMENTAL|Wait-list Control|In this arm, participants will be given access to the course material 8 weeks following confirmation of their eligibility. During, the 8-week waiting period they will be asked to complete questionnaires at 4 weeks and 8 weeks. At 8 weeks they will be given access to the course material and will be asked to complete the same questionnaires 4- and 8-weeks following completion of the course material.
62184052|NCT02419963|OTHER|IBS-D patients|Subjects on this arm will have an endoscopy for tissue biopsy, and provide blood samples and stool samples.
62184053|NCT02419963|OTHER|Healthy Controls|Subjects on this arm will have an endoscopy for tissue biopsy, and provide blood samples and stool samples.
62184054|NCT04469790|NO_INTERVENTION|SIT|Continuous sitting for 3 hours
62184055|NCT04469790|EXPERIMENTAL|SIT+WALK|Interrupt sitting with 3-minutes of moderate-intensity walking every 30 minutes for 3 hours
62184056|NCT04469790|EXPERIMENTAL|EX|Perform 18 consecutive minutes of moderate-intensity walking, then sit for the remaining time
62184057|NCT04546022|OTHER|GSP measurement|For the GSP measurement, subjects will be Intravenous administered with 1.25 ml/kg G.S.P. solution (400 mg/ml of galactose) to subjects after I.V. G.SP. solution within 3 to 5 minutes. Sixty minutes after- G.S.P. solution, a sample of 0.5 ml of whole blood will be taken from subject's finger for the determination of GSP value.
62184058|NCT05000632|EXPERIMENTAL|Smoke Free SafeCare (SFSC)|Providers randomized to this group will receive additional SFSC training and will disseminate SFSC program to families who report having a smoker in the home.
62184059|NCT05000632|ACTIVE_COMPARATOR|Standard SafeCare|Providers randomized to this group will disseminate the Standard SafeCare program to families who report having a smoker in the home.
62184060|NCT00358982|EXPERIMENTAL|1|
62392784|NCT05008627||Doffing PPE without verbal instructions|The subject will remove the PPE independently without a monitor
62568413|NCT00111605|EXPERIMENTAL|6|HIV gag DNA vaccine plus IL-12 or placebo on Days 0, 28, and 84 plus CTL MEP/RC529-SE/GM-SCF booster vaccine on Days 168 and 273
62568414|NCT00111605|EXPERIMENTAL|7|HIV gag DNA vaccine plus IL-12 DNA adjuvant or placebo on Days 0 and 84
62568415|NCT05048901|EXPERIMENTAL|Cabozantinib and Lanreotide|Oral cabozantinib 40-60 mg/day and lanreotide 120mg deep subcutaneous injection (SC) in day 1 every 4 weeks.
62568416|NCT04102267|EXPERIMENTAL|Liposomal bupivacaine injection (Group 1)|Liposomal bupivacaine 266 mg via injection
62568417|NCT04102267|EXPERIMENTAL|Bupivacaine HCl continuous infusion (Group 2)|Bupivacaine HCl 300 mg via continuous infusion
62568418|NCT03376789|ACTIVE_COMPARATOR|MYL-1501D (Process V Product)|MYL-1501D (Process V Product)
62184061|NCT04697368|EXPERIMENTAL|Experimental Group (EG)|The experimental group (EG), in addition to the standard treatment, will perform one session per day, each lasting 40 minutes, with the Armeo Power robotic system for upper limb rehabilitation. Each subject will perform a total of 25 ± 3 treatment sessions with a frequency of 5 times a week for 5 weeks.
62184062|NCT04697368|ACTIVE_COMPARATOR|Control Group (CG)|The control group (CG), in addition to the standard routine rehabilitation treatment, will follow 40 minutes of conventional upper limb rehabilitation. Each subject will perform a total of 25 ± 3 conventional upper limb treatment sessions with a frequency of 5 times a week for 5 weeks.
62184063|NCT01217619|EXPERIMENTAL|Erlotinib|Single-arm
62184064|NCT04061070|SHAM_COMPARATOR|No Intervention with the mix threalose plus polyphenols|The patients allocated in this arm will not treated with a mix of threalose plus polyphenols
62184065|NCT04061070|ACTIVE_COMPARATOR|Intervention with the mix threalose plus polyhenols|The patients allocated in this arm will treated with a mix of threalose plus polyphenols
62184066|NCT05471440|ACTIVE_COMPARATOR|Direct boost mRNA|Participants will be randomised into a direct boost group (DB; i.e end of August) or a post-poned boost group (PPB; i.e 3-4 months later) group after stratification for priming (mRNA versus Janssen). The immune response will be measured at start of the study (visit 1, all participants) and 0, 7, 28 and 84 days after boost.
62184067|NCT05471440|ACTIVE_COMPARATOR|Direct boost adeno|Participants will be randomised into a direct boost group (DB; i.e end of August) or a post-poned boost group (PPB; i.e 3-4 months later) group after stratification for priming (mRNA versus Janssen). The immune response will be measured at start of the study (visit 1, all participants) and 0, 7, 28 and 84 days after boost.
62392785|NCT03751462|EXPERIMENTAL|Pseudoexfoliation syndrome|Patients with pseudoexfoliation syndrome or traumatic cataract will be examined using the Purkinjemeter device concerning IOL wobble, tilt and decentration
62568419|NCT03376789|ACTIVE_COMPARATOR|MYL-1501D (Process VI Product)|MYL-1501D (Process VI Product)
62568420|NCT02116127|EXPERIMENTAL|Active tDCS|The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
62392786|NCT03563807|EXPERIMENTAL|Golf|Group golf lessons will be led by professional golf instructors.
62392787|NCT03563807|ACTIVE_COMPARATOR|Tai Chi|Group Tai Chi classes led by a certified Tai Chi instructor.
61998403|NCT05126927|EXPERIMENTAL|68Ga-NODAGA-SNA006|A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors
61998404|NCT02006277|EXPERIMENTAL|Cohort 1|Cohort 1 will be an open label, randomized, 4 period, 4 treatment, 4 sequence, cross over sensory evaluation of three new prototype formulations (75 mg dose of crizotinib as prototypes 0.529 mg/mg, 0.470 mg/mg and 0.420 mg/mg Microspheres) and OS (75 mg dose of crizotinib)via use of a Crizotinib Taste Assessment - Questionnaire for Cohort 1 in healthy adults.
61998405|NCT02006277|EXPERIMENTAL|Cohort 2|This cohort will be an open label, randomized, 5 period, 5 treatment, 4 sequence, cross over single dose bioavailability study employing administration of four crizotinib formulations Treatments E, F, G and H (Crizotinib 250 mg dose Formulated Capsule and 250 mg dose crizotinib as prototypes 0.529 mg/mg, 0.470 mg/mg and 0.420 mg/mg Microspheres, respectively) in the fasted state to healthy adult subjects (Periods 1-4). In addition, Treatment I (250 mg dose of crizotinib OS) will be administered at Period 5, for a taste evaluation only (no pharmacokinetic (PK) sample collection after the dose), in the period immediately following the completion of Period 4 of Cohort 2. A Crizotinib Taste Assessment - Questionnaire for Cohort 2 will be filled by all subjects.
61998406|NCT03863613|ACTIVE_COMPARATOR|Pessary group|A soft, flexible, silicone pessary, purchased from the manufacturer (Arabin®, Dr Arabin GmbH \& Co KG, Germany) will be inserted through the vagina, upward around the cervix by 4 senior clinicians, who had experienced with pessary used, within one week of randomisation. Size of the pessary will be determined at the time of speculum inspection.
61998407|NCT03863613|ACTIVE_COMPARATOR|Cerclage group|Women will be receiving the cervical cerclage according to local protocol, within a week after randomisation. 3 senior clinicians who had experienced with cerclage, will perform cerclage, using Mc Donald technique, under spinal anaesthesia.
61998408|NCT03863613|ACTIVE_COMPARATOR|Pessary plus progesterone group|400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the pessary that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
61998409|NCT03863613|ACTIVE_COMPARATOR|Cerclage plus progesterone group|400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the cerclage that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
61998410|NCT03126994|EXPERIMENTAL|PhysioWave Cardiovascular Analyzer|The Experimental Device is the PhysioWave Cardiovascular Analyzer, which will be used to measure Pulse Wave Velocity, Pulse Rate, Body Weight, and BMI. This will be compared to FDA-cleared devices to determine equivalence: AtCor XCEL PWA \& PWV to measure Pulse Wave Velocity and Pulse rate, and Detecto SOLO to measure Body Weight and BMI.
61998411|NCT02540954|EXPERIMENTAL|Aflibercept extended dosing|Aflibercept was administered 2mg per injection intravitreal (IVT) in the study eye in Aflibercept extended dosing. Flexible dosing interval is ≥ 8 weeks (no upper limit) based on visual and anatomic outcomes as judged by the investigator. When/if visual and anatomical outcomes indicated that the disease had re-activated, the treatment interval reverted to the last treatment interval in which the disease was inactive (ie, no signs of exudation were observed).
61998412|NCT02540954|ACTIVE_COMPARATOR|Aflibercept 2Q8 (2 mg aflibercept administered every 8 weeks)|Aflibercept was administered 2mg per injection IVT in the study eye in Aflibercept 2Q8. Fixed dosing interval is 8 weeks (±3 days), modification of the treatment interval was not allowed.
62020924|NCT02061631|EXPERIMENTAL|Docetaxel, Cisplatin|"Induction:One-hour intravenous infusion of docetaxel at 75 mg/m2 followed by a 30 minute intravenous infusion of cisplatin at 75 mg/m2. All patients to be pre-medicated with oral dexamethasone at 8 mg twice daily for 3 days, commencing one day before docetaxel infusion. All patients will be premedicated with intravenous dexamethasone 20 mg to be administered before cisplatin infusion. Docetaxel and cisplatin treatments to be repeated every 21 days for three cycles.~Chemoradiotherapy (CRT): Cisplatin to be administered by 30 minutes intravenous infusion at a dose of 30 mg/m2 weekly starting concomitantly with conventional radiotherapy for a period of 6 weeks. Intravenous cisplatin to be continued for four weeks.~Radiotherapy: Gross disease dose will be 60 Gy/30 fractions and sub clinical dose 45-50 Gy/30 fractions."
62392788|NCT05433116|OTHER|pembrolizumab + lenvatinib|combined pembrolizumab (200mg q3w) and lenvatinib treatment (20mg once daily)
62392789|NCT05433116|OTHER|pembrolizumab|pembrolizumab (200mg q3w)
62392790|NCT04675034|EXPERIMENTAL|Cohort 1|Dose A: MEDI7352 Q2W
62392791|NCT04675034|EXPERIMENTAL|Cohort 2|Dose B: MEDI7352 Q2W
62392792|NCT04675034|EXPERIMENTAL|Cohort 3|Dose C: MEDI7352 Q2W
62392793|NCT04675034|EXPERIMENTAL|Cohort 4|Dose D: MEDI7352 Q2W
62392794|NCT04675034|PLACEBO_COMPARATOR|Cohort 5:|Placebo to match MEDI7352 Q2W
62392795|NCT01928758|EXPERIMENTAL|Reduced Nicotine Content Cigarettes|The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 7.4, 3.3, 1.4, 0.7 and 0.2 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks
62392796|NCT01928758|PLACEBO_COMPARATOR|Usual Nicotine Content Cigarettes|Research cigarettes with a usual nicotine content (around 11.6mg per cigarette)
62392797|NCT00883896|PLACEBO_COMPARATOR|Arm 1|Part 1: Placebo
62392798|NCT00883896|EXPERIMENTAL|Arm 2|Part 1: 100 mg ILV-094 SC Q4W
62392799|NCT00883896|EXPERIMENTAL|Arm 3|Part 1: 100 mg ILV-094 SC Q2W
62568421|NCT02116127|SHAM_COMPARATOR|Sham tDCS|The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
62774138|NCT03489512|EXPERIMENTAL|A (Chloraprep)|2% chlorhexidine gluconate with 70% isopropyl alcohol with a sterile 3ml single dose applicator. Use for the preparation of the skin before insertion of the central venous catheters and at each dressing change.
62774139|NCT03489512|ACTIVE_COMPARATOR|B (Clorhexidine 2%)|2% aqueous base chlorhexidine (10 ml single dose containers). Use for the preparation of the skin before insertion of the central venous catheters and at each dressing change.
62774140|NCT03691363|EXPERIMENTAL|M-STEP|Mobile exercise intervention
62774141|NCT06299176|EXPERIMENTAL|Whole Heart Radiation Therapy|Whole heart radiotherapy, 5 Gy in 1 fraction
62774142|NCT03565237|EXPERIMENTAL|All Study Participants|Study participants with Hemophilia B in India receiving Rixubis
62791575|NCT03470207|EXPERIMENTAL|Pre-Intervention Cohort (Aim 3)|This arm will have the intervention of the implementation of the structured post-pulmonary embolism follow up protocol that is outlined in Aim 1.
62791576|NCT01429701|EXPERIMENTAL|Test association cream|polymyxin B sulphate + prednisolone + benzocaine + clioquinol
62392800|NCT00883896|PLACEBO_COMPARATOR|Arm 4|
62392801|NCT00883896|EXPERIMENTAL|Arm 5|Part 2: 200 mg ILV-094 SC Q2W
62392802|NCT02063802|ACTIVE_COMPARATOR|metformin and healthy habits program|1 gr per day. (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
62392803|NCT02063802|EXPERIMENTAL|Conjugated Linoleic Acid and healthy habits|Total dose: 3gr per day (500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner by mouth for four months.
62392804|NCT02063802|PLACEBO_COMPARATOR|Placebo and healthy habits program|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months.
62392805|NCT00711009|ACTIVE_COMPARATOR|LPV/r + FTC/TDF|lopinavir/ritonavir 400/100 milligram (mg) tablet twice-daily + co-formulated emtricitabine/tenofovir disoproxil fumarate 200/300 mg once-daily
62392806|NCT00711009|EXPERIMENTAL|LPV/r + RAL|lopinavir/ritonavir 400/100 mg tablet twice-daily + raltegravir 400 mg twice-daily
62568422|NCT05482113|ACTIVE_COMPARATOR|Control - Standard Bupivacaine|After proper positioning and local infiltration, a linear high-frequency ultrasound transducer will be placed on the anteromedial aspect of the neck, approximately 2 cm above the clavicle, and the interscalene brachial plexus will be identified between the anterior and middle scalene muscles. After sterile preparation of the skin, a 22-gauge needle will be inserted in-plane from the lateral aspect of the transducer and directed through the middle scalene muscle. The needle will be advanced until the tip is observed just lateral to the brachial plexus sheath. After negative aspiration, 20mL of 0.5% bupivacaine will be injected in 5mL increments, followed by 20mL of 0.25% bupivacaine injected in 5mL increments. The injection will be administered slowly with periodic aspiration, with the needle being adjusted using ultrasound guidance as the ISB is injected to surround the brachial plexus trunks (upper, middle and lower) that are seen at the interscalene level of injection.
62735113|NCT01846299|SHAM_COMPARATOR|Sham control|Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At month 1, if treatment was needed, sham was administered. At month 2, participants switched to open-label ranibizumab on an as needed basis.
62735114|NCT03789656|EXPERIMENTAL|Paltusotine|
62735115|NCT00902850|EXPERIMENTAL|SofLens Daily Disposable|SofLens Daily Disposable Lenses
62020925|NCT03806738|EXPERIMENTAL|Shared Decision Making Questionnaire|"* Patients randomized to the intervention arm will receive the intervention-specific Carevive questionnaire, which includes standard questions with additional decision-making questions. These surveys will be repeated every 6 months until the patient has received a TP.~* One month or at the next visit following the decision, the patient will be asked to complete a research survey using REDCap."
62392807|NCT02101216|EXPERIMENTAL|Pharmacokinetics of low dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 50 mg (1 tablets) to 6 subjects
62735116|NCT00902850|ACTIVE_COMPARATOR|Marketed 1 Day Contact Lens|Marketed 1 Day Contact Lens
62735117|NCT06017960|EXPERIMENTAL|Dry needling group|Dry needling + usual care. Subjects will receive a total of 4 sessions of ultrasound-guided dry needling over 4 weeks, one per week.
62392808|NCT02101216|EXPERIMENTAL|Pharmacokinetics medium dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 100 mg (2 tablets) to 6 subjects
62392809|NCT02101216|EXPERIMENTAL|Pharmacokinetics of high dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 200 mg (4 tablets) to 6 subjects
62392810|NCT02101216|EXPERIMENTAL|Bioequivalence of Prurisol (350 mg)|Single dose of Prurisol™ 350 mg (7 x 50 mg tablets)
62735118|NCT06017960|SHAM_COMPARATOR|Control group|Sham or simulated dry needling. + usual care. Subjects will receive a total of 4 sessions of sham ultrasound-guided dry needling over 4 weeks, one per week.
62735119|NCT06436014|EXPERIMENTAL|Total Knee Replacement VR Intervention Group|"Pre-Test + Intervention + Post-Test) (Participants who underwent total knee replacement Participants who underwent total knee replacement surgery and received a pre-test, followed by VR intervention.Participants in this group are initially assessed with VAS and Beck Anxiety Scale.~Subsequently, VR intervention is administered to this group. After the intervention, participants are reassessed with VAS and Beck Anxiety Scale."
62392811|NCT02101216|ACTIVE_COMPARATOR|Bioequivalence of Ziagen (300 mg)|Single dose of Ziagen 300 mg (1 x 300mg tablet)
62392812|NCT04387396|EXPERIMENTAL|Physiotherapy|Exercise intervention will be applied to this arm.
62392813|NCT04387396|NO_INTERVENTION|Control|No intervention will be made to this arm, only evaluations will be made.
62735120|NCT06436014|NO_INTERVENTION|Total Knee Replacement Control Group|Pre-Test (Participants who underwent total knee replacement surgery and received only a pre-test).Participants in this group are initially assessed with VAS and Beck Anxiety Scale.
62735121|NCT06436014|EXPERIMENTAL|Hysterectomy VR Intervention Group|Pre-Test + Intervention + Post-Test) Participants who underwent hysterectomy surgery and received a pre-test, followed by VR intervention.Participants in this group are initially assessed with a pre-test, followed by VR intervention.
62392814|NCT05929872|EXPERIMENTAL|Experimental group|The experimental group receives strategic memory training plus non-invasive brain stimulation (ACTIVE tDCS).
62184068|NCT05471440|ACTIVE_COMPARATOR|Post-poned boost mRNA|Participants will be randomised into a direct boost group (DB; i.e end of August) or a post-poned boost group (PPB; i.e 3-4 months later) group after stratification for priming (mRNA versus Janssen). The immune response will be measured at start of the study (visit 1, all participants) and 0, 7, 28 and 84 days after boost.
62392815|NCT05929872|SHAM_COMPARATOR|Control Group|The control group receives strategic memory training plus sham non-invasive brain stimulation (SHAM tDCS).
62392816|NCT01233284|EXPERIMENTAL|tiotropium low dose once daily|once daily, delivered by the Respimat® inhaler
62568423|NCT05482113|EXPERIMENTAL|Experimental - Liposomal Bupivacaine (Exparel)|After proper positioning and local infiltration, a linear high-frequency ultrasound transducer will be placed on the anteromedial aspect of the neck, approximately 2 cm above the clavicle, and the interscalene brachial plexus will be identified between the anterior and middle scalene muscles. After sterile preparation of the skin, a 22-gauge needle will be inserted in-plane from the lateral aspect of the transducer and directed through the middle scalene muscle. The needle will be advanced until the tip is observed just lateral to the brachial plexus sheath. After negative aspiration, 20mL of 0.5% bupivacaine will be injected in 5mL increments, followed by 20mL of Exparel injected in 5mL increments. The injection will be administered slowly with periodic aspiration, with the needle being adjusted using ultrasound guidance as the ISB is injected to surround the brachial plexus trunks (upper, middle and lower) that are seen at the interscalene level of injection.
62184069|NCT05471440|ACTIVE_COMPARATOR|Post-poned boost adeno|Participants will be randomised into a direct boost group (DB; i.e end of August) or a post-poned boost group (PPB; i.e 3-4 months later) group after stratification for priming (mRNA versus Janssen). The immune response will be measured at start of the study (visit 1, all participants) and 0, 7, 28 and 84 days after boost.
62774143|NCT04171232|ACTIVE_COMPARATOR|Balance It (Group 1)|Children with spastic hemiplegic cerebral palsy were assessed by Manual Muscle Testing (MMT) to determine the muscle power/strength, Goniometer to determine the Range of Motion (ROM), Disability of Arms, Shoulders, and Hand (DASH) questionnaire to assess the function of upper extremity, and Pediatric Balance Scale to determine the body balance and were assigned in the Balance It group. Each subject in first group would complete 8 weeks of augmented reality(AR) therapy sessions which would be aimed to improve the muscle power/strength, range of motion, balance and function. Each subject would be evaluated before their first AR therapy session (pre- interventionally) and after their last AR therapy session (post-interventionally) for changes in muscle power, ROM, upper extremity function and balance.
62020926|NCT03806738|OTHER|Standard of Care Questionnaire|"* Patients randomized to standard of care will receive the standard-of-care Carevive questionnaire used to generate TPs at time of enrollment and then every 6 months for patients with MBC who have not made a treatment decision until a treatment decision is made.~* One month or at the next visit following the decision, the patient will be asked to complete a post-treatment survey using REDCap."
62184070|NCT05090605||Experimental group:|Patients with breast cancer
62184071|NCT05090605||Control group|Patients without breast cancer
62392817|NCT01233284|EXPERIMENTAL|tiotropium medium dose once daily|once daily, delivered by the Respimat® inhaler
62392818|NCT01233284|EXPERIMENTAL|tiotropium high dose once daily|once daily, delivered by the Respimat® inhaler
62392819|NCT01233284|PLACEBO_COMPARATOR|Placebo once daily|once daily, delivered by the Respimat® inhaler
62392820|NCT05596864||Experimental group|Patients with gastric cancer underwent contrast-enhanced CT scan and gastric filling ultrasound, respectively.
62568424|NCT03963492|ACTIVE_COMPARATOR|Continuous Walking|Participants in the Continuous Walking (CONT) arm will undergo training 2x/week for 6 weeks for a total plan of 12 training sessions. The intervention for the CONT group will be to complete a 6-minute long walk without rest breaks
62735122|NCT06436014|NO_INTERVENTION|Hysterectomy Control Group|Participants who underwent hysterectomy surgery and received only a pre-test).Participants are assessed only with VAS and Beck Anxiety Scale after the intervention period.
62791577|NCT01429701|ACTIVE_COMPARATOR|Comparative association cream|betamethasone + gentamicin + tolnaftato + clioquinol
62735123|NCT04351607|EXPERIMENTAL|Verum|oral dose of 2 x 30mg (=60mg) Oleovital® Eisen Forte p.o. per day over a limited intake of 3-6 weeks due to increased physiological iron demand
62184072|NCT03677245|EXPERIMENTAL|Balance Biking|Strider Balance Bike riding for 5 days following the Strider Learn to Ride Curriculum
62184073|NCT00875277|EXPERIMENTAL|LEO 29102 cream|LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks
62020927|NCT00648479|EXPERIMENTAL|1|
62184074|NCT00875277|PLACEBO_COMPARATOR|LEO 29102 Cream Vehicle|LEO 29102 cream vehicle applied topically twice daily for 4 weeks.
62184075|NCT00875277|EXPERIMENTAL|Betamethasone Dipropionate Cream|Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.
62184076|NCT00875277|EXPERIMENTAL|LEO 29102 Plus Calcipotriol Cream|LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.
62184077|NCT00875277|EXPERIMENTAL|LEO 29102 Plus Betamethasone Dipropionate|LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.
62735124|NCT04351607|NO_INTERVENTION|Control group|no intervention
62735125|NCT04351607|OTHER|Patient with menstral bleeding - subcollective A|verum or control
62735126|NCT04351607|OTHER|Patient without menstral bleeding - subcollective B|verum or control
62735127|NCT03260855|OTHER|Lymphoma survivorship|This present study is based on an interventional (with an analysis of human blood sample) and on the use of different Questionnaires/Scales.
61998413|NCT04036942|ACTIVE_COMPARATOR|Hybrid argon plasma.|"After diagnostic endoscopy investigators will proceed to use argon plasma probe for marking 270 grades around the esophagogastric junction preserving part of the mucosa towards the greater curvature, then investigators will use the jet included in the argon plasma probe with effect 20 to 40 system for the injection of the background submucosa in the marking area, applying 0.9% saline solution with methylene blue, to achieve adequate Submucosal elevation for application or argon plasma with high voltages (100 watts, 1.5 liters / min) using forced coagulation mode, applying plasma argon to 1cm above the Z line in the esophageal mucosa and 2cm below it towards the gastric mucosa, argon will be applied until a carbonization effect of the mucosa is achieved, once the application of the therapy is performed mucosal lavage and immersion technique to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications"
62774144|NCT04171232|ACTIVE_COMPARATOR|Bubble Pop (Group 2)|Children with hemiplegic cerebral palsy were assessed by Manual Muscle Testing (MMT) to determine the muscle power/strength, Goniometer to determine the Range of Motion (ROM), Disability of Arms, Shoulders, and Hand (DASH) questionnaire to assess the function of upper extremity, and Pediatric Balance Scale to determine the body balance and were assigned in the Bubble Pop group. Each subject in second group would complete 8 weeks of augmented reality(AR) therapy sessions which would be aimed to improve the muscle power/strength, range of motion, balance and function. . Each subject would be evaluated before their first AR therapy session (pre- interventionally) and after their last AR therapy session (post-interventionally) for changes in muscle power, ROM, upper extremity function and balance.
62020928|NCT00648479|ACTIVE_COMPARATOR|2|
62020929|NCT03663413||BIS|Monitored with BIS (bispectral index) monitor in addition to other conventional monitors of blood pressure, ECG, oxygen saturation and anesthetic agent concentration.
62184078|NCT00875277|ACTIVE_COMPARATOR|Daivobet® Ointment|Daivobet® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.
62184079|NCT00228631||Sickle Cell Disease Bone Marrow Transplant|Sickle Cell Disease Bone Marrow Transplant candidates
62184080|NCT03962764||Community|Community fathers include fathers who are recruited through community partners and self-referrals. Only fathers 18 years of age and older are included in program analysis
62184081|NCT01777126|ACTIVE_COMPARATOR|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
62184082|NCT01777126|EXPERIMENTAL|Oral Nutrition Protocol (ONP) group|Oral intake was increased progressively with oral fluids and easily digestible food, independent of bowel movements. The corresponding energy content from the meals and oral fluids were calculated. Fortimel Jucy®, 200 ml containing 300 kcal, was used as the formulary energy sip. Extra fluids, up to two liter per day, were given intravenously, at the discretion of the treating physician. If the patient tolerated the ONP well, the oral intake was considered equal in terms of calories as the corresponding oral meal in the ONP. From the sixth day, the patient was allowed to eat at will. Only if oral intake remained insufficient after 5 days, which was left to the opinion of the treating physician, PN could be initiated in this group.
62184083|NCT01383239|ACTIVE_COMPARATOR|Immediate postoperative therapy|Patients will be randomized into one of two groups: immediate postoperative therapy versus 6-week delay
62392821|NCT04166721|EXPERIMENTAL|DKN-01 and atezolizumab|"DKN-01 is an intravenous medication which will be given at a variable dose during the Phase IIA safety run in phase of the trial (150mg, 300mg or 600mg IV q14d).~During the Phase IIB efficacy phase of the trial patients will be treated with DKN-01 at the safe and tolerated combination dose identified during the Phase IIA safety run in phase.~Atezolizumab is a monoclonal antibody which is given via an intravenous infusion at a dose of 840mg on the first day of a two week cycle. (Day 1 q 14d) from cycle 2 onwards.~In the first cycle of treatment, patients will be treated with only DKN-01, and following this they will be treated with both DKN-01 and atezolizumab"
62392822|NCT03914131|EXPERIMENTAL|study group|"Introduction period: 2 weeks, time window (±2 days). Dosage regimen: Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.~The treatment period: 12 weeks, time window (±4 days). Dosage regimen:Take Xinnaoning Capsule 3 tablets per time, 3 times per day, orally, after meals.~Dosage form:Capsule"
62791578|NCT04886778|EXPERIMENTAL|Group A or Trial group|Group A was treated with a 12-week low-carbohydrate diet combined with probiotic compound preparations.
62020930|NCT03663413||Narcotrend|Monitored with Narcotrend monitor in addition to other conventional monitors of blood pressure, ECG, oxygen saturation and anesthetic agent concentration.
62020931|NCT06328699|EXPERIMENTAL|Arm I (Chaplain delivered compassion meditation)|Patients receive chaplain led compassionate centered spiritual health sessions over 30 minutes, twice per week for up to 2 weeks.
62184084|NCT01383239|ACTIVE_COMPARATOR|postoperative therapy delayed for 6 weeks|Patients will be randomized into one of two groups: immediate postoperative therapy versus 6-week delay.
62184085|NCT02838784|EXPERIMENTAL|Artacent Human Amniotic Membrane|Patients randomized to the Artacent group will receive standard of care (off-loading with a removable cast walker and non-adherent dressings in addition to debridement and use of moisture retentive dressing) and the application of the Artacent amniotic allograft once every two weeks for up to 5 applications or until the ulcer has healed.
62184086|NCT02838784|ACTIVE_COMPARATOR|Lower Extremity Ulcer Standard of Care|Patients randomized to standard of care will receive off-loading with a removable cast walker and non-adherent dressings (e.g. Adaptic) in addition to debridement and use of moisture retentive dressings. An outer dressing will also be applied.
62184087|NCT05005325|ACTIVE_COMPARATOR|Experimental group(Male)|Participants will be included in the study after screening from inclusion criteria. Each participant will perform FMS during a single session before competition as pre testing. It consists of 7 movement tasks and 3 clearance screens. Movement task will include deep squat, hurdle step, inline lunge, shoulder mobility, active straight-leg raise, trunk stability push-up and rotary stability. Five of the 7 tasks (hurdle step, inline lunge, shoulder mobility, active straight-leg raise and rotary stability) will be performed on both right and left sides. In addition to these, 3 clearance screen will assess the presence of pain with shoulder internal rotation/flexion, end range spinal flexion and end range spinal extension. Participants will be instructed for each task performance and will perform 3 attempts for each task.
62735128|NCT04920071||Control|150 healthy control participants
62735129|NCT04920071||AMD Cohort high-contrast VA group i|Better than 0.4 logMAR
62568425|NCT03963492|EXPERIMENTAL|Interval Walking|Participants in the Interval Walking (INT) arm will undergo training 2x/week for 6 weeks for a total plan of 12 training sessions. The intervention for the (INT) group will be to complete three 2-minute-long walks with 2-minute seated rest breaks between each walk
62774145|NCT04171232|ACTIVE_COMPARATOR|Scoop'd (Group 3)|Children with hemiplegic cerebral palsy were assessed by Manual Muscle Testing (MMT) to determine the muscle power/strength, Goniometer to determine the Range of Motion (ROM), Disability of Arms, Shoulders, and Hand (DASH) questionnaire to assess the function of upper extremity, and Pediatric Balance Scale to determine the body balance and were assigned in the Scoop'd group. Each subject in third group would complete 8 weeks of augmented reality(AR) therapy sessions which would be aimed to improve the muscle power/strength, range of motion, balance and function. . Each subject would be evaluated before their first AR therapy session (pre- interventionally) and after their last AR therapy session (post-interventionally) for changes in muscle power, ROM, upper extremity function and balance
62214578|NCT03046108|EXPERIMENTAL|ultrasound guided injection|US guided injection in Morton neuroma by subcutaneous needle. group 2 are going to be injected by an experimented musculoskeletal radiologist under ultrasound guidance. There is internal control of needle placement by ultrasound.
62568426|NCT02632266|ACTIVE_COMPARATOR|Powder HMF|Once patient has reached 80ml/kg/day of enteral feedings, 1 pack of powder HMF will be added to 50 ml of human or donor breast milk, then increased to a maximum of 2 packs for 50 ml following the unit feeding advancement protocol and this will be continued up until 48 hours prior to discharge.
62735130|NCT04920071||AMD Cohort high-contrast VA group ii|0.4-0.6 logMAR
62214579|NCT03046108|EXPERIMENTAL|guided injection of mepivacaine|"2% mepivacaine (Mepivacaina Normon 2%® ) in each of the web spaces affected with Morton neuroma is injected.~Up to 4 injections are allow in the first three months of follow-up"
62735131|NCT04920071||AMD Cohort high-contrast VA group iii|0.6-0.8 logMAR
62735132|NCT04920071||AMD Cohort high-contrast VA group iv|0.8-1.0 logMAR
62184088|NCT05005325|EXPERIMENTAL|Experimental group(Female)|Participants will be included in the study after screening from inclusion criteria. Each participant will perform FMS during a single session before competition as pre testing. It consists of 7 movement tasks and 3 clearance screens. Movement task will include deep squat, hurdle step, inline lunge, shoulder mobility, active straight-leg raise, trunk stability push-up and rotary stability. Five of the 7 tasks (hurdle step, inline lunge, shoulder mobility, active straight-leg raise and rotary stability) will be performed on both right and left sides. In addition to these, 3 clearance screen will assess the presence of pain with shoulder internal rotation/flexion, end range spinal flexion and end range spinal extension. Participants will be instructed for each task performance and will perform 3 attempts for each task.
62184089|NCT06108453|EXPERIMENTAL|Methotrexate|
62184090|NCT06108453|EXPERIMENTAL|Methotrexate + Rifampicin|Methotrexate + Rifampicin
62568427|NCT02632266|ACTIVE_COMPARATOR|Liquid HMF|Once patient has reached 80ml/kg/day of enteral feedings, researchers will add 1 packet (5 ml) of liquid HMF to 50 ml of human or donor breast milk, then increase to 2 packs to 50 ml following the unit feeding protocol and this will be continued up until 48 hours prior to discharge.
62568428|NCT04351919|EXPERIMENTAL|HCQ Arm|
62568429|NCT04903639||obese COPD|COPD patient with BMI more than 30
62568430|NCT04903639||non obese COPD|COPD patient with BMI less than 30
62568431|NCT02915770|EXPERIMENTAL|participants receive cholangiojejunostomy|participants will receive hepatectomy、cholangiojejunostomy and T-tube Drainage
62568432|NCT02915770|ACTIVE_COMPARATOR|participants receive no cholangiojejunostomy|participants will receive hepatectomy and T-tube Drainage
62568433|NCT05670665||Non-exposed|Low-risk, singleton pregnancies.
62568434|NCT05670665||Exposed|Singleton pregnancies that are admitted to hospital due to threatened preterm labor or preterm premature rupture of membranes.
62568435|NCT02172664|ACTIVE_COMPARATOR|Adhese Universal with self etch enamel etching|patients will receive one restoration on randomly selected study tooth utilizing the self-etch universal adhesive (Adhese Universal, Ivoclar Vivadent) with no separate enamel etching
62568436|NCT02172664|EXPERIMENTAL|selective etch protocol followed by Adhese Universal|patients will receive one restoration on randomly selected study tooth utilizing a 37% phosphoric acid solution followed by application of self-etch universal adhesive (Adhese Universal, Ivoclar Vivadent)
62568437|NCT02907177|EXPERIMENTAL|Ponesimod|Ponesimod
62568438|NCT02907177|PLACEBO_COMPARATOR|Placebo|Placebo
62568439|NCT05061693|EXPERIMENTAL|INCB054707 Dose A|Participants will receive INCB054707 Dose A for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
62568440|NCT05061693|EXPERIMENTAL|INCB054707 Dose B|Participants will receive INCB054707 Dose B for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
62568441|NCT05061693|EXPERIMENTAL|INCB054707 Dose C|Participants will receive INCB054707 Dose C for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
62568442|NCT05061693|PLACEBO_COMPARATOR|Placebo followed by INCB054707 Dose B or C|Participants will receive placebo for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
62568443|NCT03543748|EXPERIMENTAL|TMS|The Transcranial Magnetic Stimulation course consisted of daily sessions of 2,000 stimuli for the left DLPFC (50 trains of 40 stimuli at 10 Hz for 10 days),
62568444|NCT03543748|SHAM_COMPARATOR|SHAM|The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field.
62568445|NCT05616195||3D printed bone prosthesis replacement surgery|Patients undergoing 3D-printed bone prosthesis replacement surgery
62568446|NCT00302848||Users of Drospirenone (DRSP)|
62568447|NCT00302848||Users of Levonorgestrel (LNG)|
62392823|NCT03914131|PLACEBO_COMPARATOR|control group|"Introduction period: 2 weeks, time window (±2 days). Dosage regimen: Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.~The treatment period: 12 weeks, time window (±4 days). Dosage regimen:Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.~Dosage form:Capsule"
62184091|NCT05864118|EXPERIMENTAL|Saliva passive drool|Participant is asked to spit saliva, through a straw, into a micro centrifuge tube. This specimen will undergo respiratory pathogen panel PCR testing and COVID-19 antibody testing.
62184092|NCT05864118|EXPERIMENTAL|Oral Capsule saliva|Participant is asked to chew on a study device (Oral Capsule) with their molar teeth which will draw saliva into the device's internal specimen chamber. This specimen will undergo respiratory pathogen panel PCR testing and COVID-19 antibody testing.
62184093|NCT05864118|EXPERIMENTAL|NP saline wash by study device|Participant will receive a nasopharyngeal wash with sterile saline. The irrigation saline is recollected into the device's internal specimen chamber. This specimen will undergo respiratory pathogen panel PCR testing and COVID-19 antibody testing.
62184094|NCT05864118|EXPERIMENTAL|Blood by standard finger stick method|Participant is asked to provide approximately 60 uL of blood via a capillary finger stick. This specimen will undergo COVID-19 antibody testing.
62184095|NCT01394549||Cardiology|The study includes all patients hospitalized for acute coronary syndrome during the week selected and who agreed to participate in the study.
62184096|NCT02876029|OTHER|Reference|White wheat bread
62184097|NCT02876029|OTHER|Test product|Pasta
62184098|NCT04805957|EXPERIMENTAL|Treatment|All subjects will receive 1.47umol/kg/day sulforaphane for 12 weeks. Pills are taken once a say with a meal.
62184099|NCT05584722||Idiopathic or Heritable Pulmonary Arterial Hypertension|Patients diagnosed with pulmonary arterial hypertension, either idiopathic or heritable, defined according to standard criteria.
62184100|NCT05584722||Unaffected Mutation Carriers|Healthy participants with a known BMPR2 gene mutation and normal pulmonary pressure and RV function on echo.
62184101|NCT05584722||Healthy Controls|Healthy individuals without cardiopulmonary disease
62184102|NCT03927690|EXPERIMENTAL|LKA651|LKA651 Intravitreal injection
62184103|NCT03927690|EXPERIMENTAL|LKA651 + Lucentis|LKA651 + Lucentis Intravitreal injection
62184104|NCT03927690|ACTIVE_COMPARATOR|Lucentis|Lucentis Intravitreal injection
62184105|NCT03065998|ACTIVE_COMPARATOR|Drug-A|opripramol 150 mg per day (3\*50) Opipramol is a selective agonist for sigma-1 receptor. It is clinically used as an antidepressant and anxiolytic agent.
62184106|NCT03065998|ACTIVE_COMPARATOR|Drug-B|baclofen 90 mg per day (3\*30) Baclofen is a GABAb-1 antagonist and has shown partial efficacy in suppressing withdrawal symptoms in alcohol addicts and cocaine.
62184107|NCT00835510|EXPERIMENTAL|Butenafine cream 1% (Taro)|Butenafine cream manufactured by Taro applied for 7 days
62184108|NCT00835510|ACTIVE_COMPARATOR|Lotrimin Ultra (butenafine) 1%|Lotrimin Ultra (butenafine) applied for 7 days
62184109|NCT00835510|PLACEBO_COMPARATOR|Vehicle|Butenafine vehicle applied for 7 days
62184110|NCT04711486|EXPERIMENTAL|Contraloid acetate|"300 mg Contraloid/participant administered orally (for 28 days) as a single daily dose.~Other Name: PRI-002"
62020932|NCT06328699|ACTIVE_COMPARATOR|Arm II (Traditional chaplain consultation)|Patients receive a traditional chaplain consultation and care upon request, per standard of care.
62184111|NCT04711486|PLACEBO_COMPARATOR|Placebo|300 mg Placebo (Microcrystalline cellulose)/participant administered orally (for 28 days) as a single daily dose.
62392824|NCT02996981||Cranberry group|Patients underwent pelvic floor gynecologic surgery performed by a physician at Cincinnati Urogynecology Associates, TriHealth Inc between April 2016 and September 2016 and discharged home with an indwelling urinary catheter following the surgery. This group of people had cranberry juice capsules prescribed.
62392825|NCT02996981||No cranberry group|Patients underwent pelvic floor gynecologic surgery performed by a physician at Cincinnati Urogynecology Associates, TriHealth Inc between April 2015 and September 2015. This group of people did not have cranberry juice capsules prescribed.
62392826|NCT05702840|EXPERIMENTAL|Resistance exercise training + weight loss group (RT+WL)|Participants (WL-RT) will be provided with a resistance exercise booklet containing instructions for exercises and links to demonstration videos. A demonstration and explanation of the exercises will be given at the beginning of the intervention, alongside a discussion of the principles of the programme such as starting level and progression. We will ask participants to perform the resistance exercises for 12-week period. Participants will be asked to perform exercises 3 times a week (3 sets reaching the RPE scale between 8 - 10 out of 10 (4-6 out of 10 in the first week)) for the intervention period. The exercises will include press-ups, band lateral raises, band seated low row, squat, lunge and calf raise.
62568448|NCT00302848||Users of other oral contraceptives (OCs)|
62020933|NCT03041610|EXPERIMENTAL|Walking intervention|
62184112|NCT03296566|EXPERIMENTAL|Patient Liaison Intervention|The participants randomized to the intervention group will be exposed to the patient liaison in receiving their colposcopy report results and recommendations. Rather than receive results from their referring/family physician, an experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients.
62214580|NCT03046108|EXPERIMENTAL|guided injection of Triamcinolone|40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected. Up to 4 injections are allow in the first three months of follow-up
62214581|NCT02773563||EUS with CO2 insufflation|Patients undergoing EUS with CO2 insufflation
62214582|NCT02773563||EUS with air insufflation|Patients undergoing EUS with air insufflation
62020934|NCT03041610|NO_INTERVENTION|Control|
62020935|NCT02744924|EXPERIMENTAL|Physical activity intervention|Participants undergo the community-based physical activity promotion (see Intervention)
62020936|NCT04473404|EXPERIMENTAL|Probiotic - low dose|Powdered probiotic with a carrier.
62392827|NCT05702840|EXPERIMENTAL|Weight loss only group (WL)|All participants (WL and WL-RT) will be provided with vouchers to access the weight watchers weight loss programme for a 12-week period. Weight Watchers is a commercially available programme and participants will set an initial goal to lose 5kg of body mass. If 5kg weight loss is achieved then the participant can chose further weight loss goals, as long as it would result in a body mass in the weight watchers healthy weight range (https://www.weightwatchers.com/uk/weight-loss/programme/tools/healthy-weight-chart).This plan works on the basis of an individualised points plan that can then be used by the participant to select foods/meals to consume throughout the day.
62392828|NCT04390620||MUCODA|DAFILON - sterile, monofilament, non-absorbable surgical suture material produced from Polyamide
62392829|NCT05515887|EXPERIMENTAL|Shenqu Xiaoshi Oral liquid|Shenqu Xiaoshi Oral liquid will be taken orally.
62214583|NCT03037853||Healthy volunteers|Healthy volunteers
62214584|NCT03972150|EXPERIMENTAL|Part I: BI 836880 alone|Part I followed by Part II
62214585|NCT03972150|EXPERIMENTAL|Part II: BI 836880 and BI 754091|
62214586|NCT04079751|ACTIVE_COMPARATOR|Neutral Mechanical Alignment|Total knee arthroplasty: Neutral Mechanical Alignment vs Anatomical Alignment
62214587|NCT04079751|ACTIVE_COMPARATOR|Anatomical Alignment|Total knee arthroplasty: Neutral Mechanical Alignment vs Anatomical Alignment
62214588|NCT00721591||A|Subjects opting for treatment with unfractionated heparin
62214589|NCT00721591||B|Subjects opting for treatment with low molecular weight heparin
62214590|NCT02907229|EXPERIMENTAL|Treatment group|neuroendovascular therapy(NCVC-CS1)
62214591|NCT00307684|EXPERIMENTAL|001|open label PR OROS methylphenidate Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
62214592|NCT00307684|EXPERIMENTAL|002|double blind PR OROS methylphenidate 18 36 54 72 or 90 mg/day once daily for 4 weeks
62214593|NCT00307684|PLACEBO_COMPARATOR|003|double blind placebo matching placebo tablets once daily for 4 weeks
62214594|NCT01080716|EXPERIMENTAL|Part 1/Arm 1 of Study: WRSS1 vaccine|WRSS1 is a live attenuated S. sonnei vaccine candidate derived from the Mosely strain of S.sonnei
62214595|NCT01080716|PLACEBO_COMPARATOR|Part 1/Arm 2 of Study: Placebo vaccine|Placebo
62214596|NCT01080716|EXPERIMENTAL|Part 2/Arm 1 of Study: S. sonnei 53G|10 volunteers from Study Arm 1/Part 1 (WRSS1 vaccine) plus 4 alternates from Arm 1/Part 1 are given 53G S. sonnei
62214597|NCT01080716|ACTIVE_COMPARATOR|Part 2/Arm 2 of Study: S sonnei 53G|10 subjects (naïve controls) plus 4 alternates are give 53G S sonnei
62214598|NCT02930226|EXPERIMENTAL|1 unit FDP-CPD|Subjects are to have sufficient plasma withdrawn during a single WB collection visit to allow re-infusion with 1 unit of autologous FDP-CPD
62214599|NCT02930226|EXPERIMENTAL|Reinfusion 1 unit FDP-ACD|Subjects are to have sufficient plasma withdrawn during 1 plasmapheresis collection visit to allow re-infusion with 1 unit of autologous FDP-ACD
62214600|NCT02930226|EXPERIMENTAL|Reinfusion 2 units FDP-CPD|Subjects are to have sufficient plasma withdrawn during 2 separate WB collection visits to allow re-infusion with 2 units of autologous FDP-CPD
62214601|NCT02930226|EXPERIMENTAL|Reinfusion 2 units FDP-ACD|Subjects are to have sufficient plasma withdrawn during 1 plasmapheresis collection to allow re-infusion with 2 units of autologous FDP-ACD
62214602|NCT02930226|ACTIVE_COMPARATOR|Reinfusion 3 units FDP, 3 units FFP (1st)|Subjects plasma withdrawn during 2 or 3 plasmapheresis collections to allow re-infusion with 3 units of autologous FDP-ACD and 3 units of autologous control FFP. Subjects will receive in total 6 units over the course of 2 infusion visits. Subjects are to be randomized to treatment schedule arms that dictate the sequence for infusing FDP-ACD and FFP across the 2 infusion visits
62214603|NCT02930226|ACTIVE_COMPARATOR|Reinfusion 3 units FDP, 3 units FFP (2nd)|Subjects plasma withdrawn during 2 or 3 plasmapheresis collections to allow re-infusion with 3 units of autologous FDP-ACD and 3 units of autologous control FFP. Subjects will receive in total 6 units over the course of 2 infusion visits. Subjects are to be randomized to treatment schedule arms that dictate the sequence for infusing FDP-ACD and FFP across the 2 infusion visits
62214604|NCT05094024|ACTIVE_COMPARATOR|Central kitchen-prepared MDCF-2 arm|Children randomized to this arm will receive 25gm of kitchen-prepared version of MDCF-2 twice daily.
62214605|NCT05094024|EXPERIMENTAL|Ready-to-use supplementary food (RUSF) arm|Children randomized to this arm will receive 25g RUSF twice daily.
62214606|NCT05094024|EXPERIMENTAL|Freshly reconstituted MDCF-2 ingredients|Children randomized to this arm will receive individually packaged MDCF-2 ingredients, combined into 21.72g servings provided twice daily.
62214607|NCT05094024|EXPERIMENTAL|MDCF-2 shelf-stable foil pouch prototype with green banana powder|Children randomized to this arm will receive 21.77gm of shelf-stable foil pouch prototype with green banana powder twice daily.
62214608|NCT05094024|EXPERIMENTAL|MDCF-2 shelf-stable foil pouch prototype with sweet potato|Children randomized to this arm will receive 23.34gm of MDCF prototype with sweet potato twice daily.
62214609|NCT02720302|EXPERIMENTAL|SOFT|"All Children have their first and their last consultation at The Child Obesity Unit.~The investigators use Standardized Obesity Family Therapy SOFT as described by Nowicka \& Flodmark (1-3). The intervention use psychological techniques developed in systemic family therapy applied on advice regarding exercise and diet as well as behavioural Life style Changes.~At each consultation with the overweight child and his/her biological parents there are two therapists present."
62392830|NCT02457130|EXPERIMENTAL|Group A|"After providing written informed consent, eligible subjects will be randomized in a 1:1 fashion to group A or B.~Ticagrelor (180-mg loading dose the first day followed by 90-mg b.i.d. maintenance dose) for one week; washout period of 2-4 weeks; crossover to clopidogrel (600-mg loading dose the first day followed by 75-mg daily maintenance dose) for one-week."
62392831|NCT02457130|EXPERIMENTAL|Group B|"After providing written informed consent, eligible subjects will be randomized in a 1:1 fashion to group A or B.~Clopidogrel (600-mg loading dose the first day followed by 75-mg daily maintenance dose) for one-week; washout period of 2-4 weeks; crossover to ticagrelor (180-mg loading dose the first day followed by 90-mg b.i.d. maintenance dose) for one week."
62392832|NCT04643158|EXPERIMENTAL|Part 1 and Part 2: AZD1402 Dose 1|Randomised participants will receive oral inhalation of AZD1402 Dose 1 via DPI.
62392833|NCT04643158|EXPERIMENTAL|Part 1 and Part 2: AZD1402 Dose 2|Randomised participants will receive oral inhalation of AZD1402 Dose 2 via DPI.
62392834|NCT04643158|EXPERIMENTAL|Part 1: AZD1402 Dose 3|Randomised participants will receive oral inhalation of AZD1402 Dose 3 via DPI.
62392835|NCT04643158|PLACEBO_COMPARATOR|Part 1 and Part 2: Placebo|Randomised participants will receive oral inhalation of matching placebo via DPI.
62392836|NCT00490828|PLACEBO_COMPARATOR|A|
62392837|NCT00490828|ACTIVE_COMPARATOR|B|Stress doses of hydrocortisone
62392838|NCT00734916|ACTIVE_COMPARATOR|1|Omegaven 10%
62392839|NCT00734916|ACTIVE_COMPARATOR|2|Intralipid 10%
62392840|NCT00734916|PLACEBO_COMPARATOR|3|Placebo
62392841|NCT01087944|EXPERIMENTAL|1|"Peginterferon via auto-injector device.~All participants will receive Peginterferon in a cross-over design."
62392842|NCT01087944|ACTIVE_COMPARATOR|2|"Peginterferon via pre-filled syringe.~All participants will receive Peginterferon in a cross-over design."
62392843|NCT05618769|EXPERIMENTAL|Intervention (LONG LOVE Framework)|"Consists of participants born in Franciscus Gasthuis (FG) and/or Vlietland (FV) and will be allocated to the intervention group, receiving additional (in addition to current standard of care) follow-up in accordance with our newly developed framework to identify modi able influencing factors compromising pulmonary health using validated questionnaires, weekly monitoring of respiratory symptoms as reported by parents using an app, in- and outdoor air quality measurements and non-invasive pulmonary function measurements based on impedance pneumatography.~In case of any modi able influencing factors, appropriate lifestyle and/or medical interventions will be undertaken."
62392844|NCT05618769|NO_INTERVENTION|Control|"Consist of participants born in Maasstad Ziekenhuis (MSZ) and Albert Schweitzer Ziekenhuis (ASZ) and will receive standard of care follow-up.~Parents are requested to provide informed consent for the registration of outcome measurements and requested to complete validated questionnaires. Data on utilization of medical services will be inquired to avoid recall bias."
62392845|NCT01883362|EXPERIMENTAL|Standard of Care with Midostaurin|Patients received standard of care in the post stem cell transplant (SCT) setting in addition to Midostaurin 50mg twice a day for 12 months (cycles).
62392846|NCT01883362|ACTIVE_COMPARATOR|Standard of Care|Patients received standard of care alone in the post SCT setting
62392847|NCT01599091||Fibroblast's donors|Patients undergoing tooth extraction will be asked permission to use the anyway extracted teeth and gingiva in order to harvest fibroblasts for further basic research.
62392848|NCT05961124|EXPERIMENTAL|Single arm- Niraparib|Oral niraparib will be administered in a dose escalation design where patients will start at a dose of 100 mg PO daily for the first two cycles, then 200 mg PO daily for the third and fourth cycle. Patients will remain on the individualized dose until either they experience an adverse event and require a dose reduction or they have disease progression.
62020937|NCT04473404|EXPERIMENTAL|Probiotic - high dose|Powdered probiotic with a carrier.
62392849|NCT02493829|EXPERIMENTAL|AML Cell Vaccine|
62020938|NCT04473404|PLACEBO_COMPARATOR|Placebo|Carrier only.
62392850|NCT05457712|EXPERIMENTAL|Intervention group|In the first evaluation and after the patient's consent, a standardized complementary questionnaire will be applied, with demographic and clinical information. The nutritionist will carry out the anthropometric assessment, questionnaires and application of the protocol for this group. The energy and protein value of the prescribed diet will be followed according to the original protocol considering plans A, B or C, via a hypercaloric formula with a caloric density of 1kcal/ ml for infants starting 60 days preoperatively. The return for nutritional monitoring will take place after evaluation: weekly, biweekly or monthly.
62392851|NCT05457712|OTHER|Control group|In the first evaluation and after the patient's consent, a standardized complementary questionnaire will be applied, with demographic and clinical information. The nutritionist will carry out the anthropometric assessment and questionnaires. Afterwards, they will be evaluated through the standard nutritional protocol of the nutrition clinic of the Institute of Cardiology and Children's Hospital Santo Antonio of Porto Alegre, whose standard nutritional prescription is a polymeric formula with a caloric density of 0.67 kcal/ml. Nutritional monitoring will take place through telephone contact for information on the baby's clinical data and in person before the surgery is performed.
62392852|NCT04622059|EXPERIMENTAL|acoustic stimulation|Fetuses in the group A (n=105) received an acoustic stimulation
62392853|NCT04622059|NO_INTERVENTION|no acoustic stimulation|Fetuses in the group B (n=105) no intervention was performed
62392854|NCT01658527|EXPERIMENTAL|Orteronel, 300 mg twice daily|
62392855|NCT01658527|ACTIVE_COMPARATOR|Bicalutamide 50 mg per day|
62392856|NCT01115205|EXPERIMENTAL|Supervised walking groups|Patients included in walking groups, under the supervision of a qualified personal trainer.
62392857|NCT01115205|ACTIVE_COMPARATOR|Controls|Patients receiving the standard counselling procedures of the Verona Diabetic Clinic.
62568449|NCT01643577|ACTIVE_COMPARATOR|Acupuncture protocol for gastroparesis|Patients randomized to this arm will receive an acupuncture protocol that with points designed to treat gastroparesis
62020939|NCT00664612|EXPERIMENTAL|1|Air Traq then Macintosh
62020940|NCT00664612|EXPERIMENTAL|2|Macintosh then AirTraq
62020941|NCT03650881|EXPERIMENTAL|Neutrogena ® Light Therapy Acne Mask (MASK)|Over-the-counter powered light-based device for the treatment of acne
62020942|NCT03650881|ACTIVE_COMPARATOR|Topical benzoyl peroxide 2.5% gel and OTC adapalene|Over-the-counter medication for the treatment of acne + 0.1% Adepalene Gel
62020943|NCT00761839|EXPERIMENTAL|Arm 1|These patients receive the experimental intervention--the after-care summary.
62392858|NCT04084210|ACTIVE_COMPARATOR|Juul + Active Patch in Wk 1 and Placebo Patch in Wk 2|Participants will be given Juul e-cigarettes for four weeks; in Switch Week 1, participants also will use active nicotine patches; in Switch Week 2, participants will use placebo patches.
62392859|NCT04084210|ACTIVE_COMPARATOR|Juul + Placebo Patch in Wk 1 and Active Patch in Wk 2|Participants will be given Juul e-cigarettes for four weeks; in Switch Week 1, participants also will use placebo patches; in Switch Week 2, participants will use active nicotine patches.
62392860|NCT04084210|ACTIVE_COMPARATOR|VLNC + Active Patch in Wk 1 and Placebo Patch in Wk 2|Participants will be given very low nicotine cigarettes (VLNCs) for four weeks; in Switch Week 1, participants also will use active nicotine patches; in Switch Week 2, participants will use placebo patches.
62392861|NCT04084210|ACTIVE_COMPARATOR|VLNC + Placebo Patch in Wk 1 and Active Patch in Wk 2|Participants will be given very low nicotine cigarettes (VLNCs) for four weeks; in Switch Week 1, participants also will use placebo patches; in Switch Week 2, participants will use active nicotine patches.
62392862|NCT04084210|OTHER|No Product + Active Patch in Wk 1 and Placebo Patch in Wk 2|Participants will be given no alternative nicotine delivery products but in Switch Week 1, participants will use active nicotine patches; in Switch Week 2, participants will use placebo patches.
62392863|NCT04084210|OTHER|No Product + Placebo Patch in Wk 1 and Active Patch in Wk 2|Participants will be given no alternative nicotine delivery products for two weeks but in Switch Week 1 participants will use placebo patches; in Switch Week 2, participants will use active nicotine patches.
62392864|NCT00003824|EXPERIMENTAL|cipro|ciprofloxacin
62392865|NCT00003824|EXPERIMENTAL|ceph|cephalexin
62392866|NCT04419220||Observational|Doppler Ultrasound will be performed in all subjects.
62392867|NCT02978300|ACTIVE_COMPARATOR|NIV/HFNC group|Continuous NIV for at least 4 hours until clinical improvement then intermittent 1-hour sessions for a minimal duration of 12 hours a day. Between NIV sessions HFNC will be delivered as in the HFNC group.
62392868|NCT02978300|EXPERIMENTAL|HFNC group|Continuous HFNC alone 24h/24 until weaning or intubation.
62568450|NCT01643577|PLACEBO_COMPARATOR|Acupuncture for musculoskeletal pain|Patients randomized to this arm will receive acupuncture therapy consisting of points designed to treat musculoskeletal pain.
62568451|NCT02818933||Aim 1|This group follows a crossover design where adolescents 12-17 years old (n=10) complete a diet recall using one of the two methods (interviewer-administered vs web-based), and then does another diet recall using the other method about a week later. Participants are randomly assigned to the order in which they complete each method of diet recall.
62568452|NCT02818933||Aim 2, interviewer-administered recall|This group of adolescents 12-17 years old (n=10) completes an interviewer-administered diet recall once a week for 6 weeks.
62392869|NCT02318082|EXPERIMENTAL|Interleukin-2 (IL-2)|Interleukin-2: Each participant will receive daily subcutaneous IL-2 for self-administration per cycle. Each participant will start at Dose Level A. In the abscence of DLTs or severe non-DLT adverse events, participants will have daily SC IL-2 dose-escalated at Week 2 (to dose level B) and at Week 4 (to Dose Level C), and continue on their maximum tolerated dose (MTD) IL-2 for 4 weeks total.
62392870|NCT06245850|EXPERIMENTAL|Baduanjin Group|
62392871|NCT06245850|ACTIVE_COMPARATOR|REBTgroup|
62392872|NCT05870358|NO_INTERVENTION|fmSRP|27 patients with diabetic periodontitis underwent full mouth scaling and root planning (fmSRP) alone
62392873|NCT05870358|ACTIVE_COMPARATOR|fmSRP-mel|28 patients with diabetic periodontitis were administered systemic melatonin tablets (6 mg daily, for 30 days) immediately after fmSRP.
62392874|NCT05649020|OTHER|Prilocaine dose|to determine the ED50 and ED90 of intrathecal HP for patients undergoing undergoing ambulatory MRI/ultrasound fusión prostate biopsy.
62392875|NCT03110172|ACTIVE_COMPARATOR|KSS scale|Knee Society Score with Duloxetine Hydrochloride
62392876|NCT03110172|ACTIVE_COMPARATOR|HAMD-17 scale|Hamilton Depression Score with Duloxetine Hydrochloride
62568453|NCT02818933||Aim 2, web-based recall|This group of adolescents 12-17 years old (n=10) completes a web-based self-administered diet recall once a week for 6 weeks.
62392877|NCT03110172|ACTIVE_COMPARATOR|SF-36 scale|Medical Outcomes Study Short Form-36 score with Duloxetine Hydrochloride
62392878|NCT03110172|ACTIVE_COMPARATOR|WOMAC scale|Western Ontario and McMaster Universities Index with Duloxetine Hydrochloride
62392879|NCT04382066|EXPERIMENTAL|Experimental 1|Plitidepsin 1.5 mg / day x 3 consecutive days
62392880|NCT04382066|EXPERIMENTAL|Experimental 2|Plitidepsin 2.0 mg / day x 3 consecutive days
62392881|NCT04382066|EXPERIMENTAL|Experimental 3|Plitidepsin 2.5 mg / day x 3 consecutive days
62392882|NCT04536142||Brain tumors|Subjects with operable supratentorial brain tumors
62392883|NCT04536142||Healthy subjects|Healthy subjects
62568454|NCT04084223|EXPERIMENTAL|Active RA patients group|"64 active RA patients (DAS28\>3,2 AND presence of ≥2 US synovitis with Power-Doppler≥2) with an inadequate response to methotrexate (MTX) starting a treatment with JAKi (tofacitinib ou baricitinib) will be evaluated at baseline, 1, 3 and 6 months in 5 centres.~A clinical joint assessment will be performed and CRP will be tested to calculate DAS28-CRP. Several PROs will be completed: RAPID3, HAQ, pain, and patient global assessment of disease activity on a VAS.~An US exam on 40 joints and 12 tendons will be performed by an independent investigator, looking for synovitis and tenosynovitis with B-Mode and Power Doppler. A Global US score (GLOESS) will be collected at each visit."
62568455|NCT04446169||SARS-CoV 2 Patients|Patients with previous nasopharyngeal swab positive for SARS-CoV-2, subsequently negativeized in two detections
62392884|NCT03301168|EXPERIMENTAL|BPX-501 T cells and Rimiducid|"TCR alpha beta depleted graft infusion with addback of BPX-501 T cells.~Rimiducid: Dimerizer drug administered to subjects who present with Grade I-IV acute GVHD with inadequate response to steroids within 48 hours of treatment or mild to severe chronic GVHD with inadequate response to steroids within 7 days of treatment."
62392885|NCT06018402|ACTIVE_COMPARATOR|physical therapy|The physical therapy program is planned as a total of 15 sessions in the lumbar region, each session consisting of TENS (50-100 Hz stimulation frequency, 200 µs pulse duration, intensity is increased as much as the patient could tolerate, 20 minutes in total), hotpack (to be placed on the painful area, 20 minutes), US (1 mHz frequency, 10 minutes, 1.5 watt/cm2 intensity)
62392886|NCT06018402|ACTIVE_COMPARATOR|physical therapy + espb|"same physical therapy program, in addition Ultrasound-guided lumbar ESPB is performed using an in-line cephalic approach, and after contacting the corner of the L3 transverse process, a small dose of saline is injected into the fascial space between the L3 transverse process and the erector spinae muscles to lift off the fascia. After verification, a mixture of 20 mL of 1% lidocaine and 3 mg betamethasone is administered for unilateral injection. The procedure is performed bilaterally."
62392887|NCT02605720|EXPERIMENTAL|Dihydroartemisinin-piperaquine|
62392888|NCT03014700|ACTIVE_COMPARATOR|Cryoprecipitate Arm|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
62392889|NCT03014700|ACTIVE_COMPARATOR|Fibrinogen Concentrate Arm|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
62392890|NCT03400202||Group A: Dark Circles None|Group A includes participants with Dark Circle Severity Scale score 0 (None). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
62392891|NCT03400202||Group B: Dark Circles Mild|Group B includes participants with Dark Circle Severity Scale score 1 to 3 (Mild). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
62392892|NCT03400202||Group C: Dark Circles Moderate|Group C includes participants with Dark Circle Severity Scale score 4 to 6 (Moderate). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
62568456|NCT02644668|PLACEBO_COMPARATOR|Placebo|Patients randomized to this treatment arm will receive a placebo suspension twice daily for 8 weeks.
62184113|NCT03296566|NO_INTERVENTION|Control|The control group will receive the standard of care for colposcopy results reporting via their referring physician. Following their colposcopy visit, control patients are given a slip of paper reminding them to call their family/referring physician for their colposcopy results in three weeks if they have not yet been contacted. Upon receipt of the final pathology, colposcopy reports are prepared by the colposcopists and forwarded to family/referring physicians typically within 2-3 weeks of the visit. Patients then receive the results of their colposcopy report from their family/referring physician by whatever method of communication preferred by that provider.
62184114|NCT05585177|EXPERIMENTAL|Growth hormone pretreatment+IVF/ICSI|After 3 months of Growth hormone treatment (2 units daily), IVF/ICSI was performed
62184115|NCT05585177|NO_INTERVENTION|IVF/ICSI|IVF/ICSI was performed
62184116|NCT05980962|ACTIVE_COMPARATOR|Group 1 (Anteriorization group)|Symmetrical Anteriorization of the inferior oblique muscle
62184117|NCT05980962|EXPERIMENTAL|Group 2 (Resction group)|Asymmetrical Anteriorization of the inferior oblique muscle, where an additional resection of the inferior oblique was done for the eye with the larger deviation
62184118|NCT04578587|ACTIVE_COMPARATOR|Rater 1|Rater 1
62184119|NCT04578587|ACTIVE_COMPARATOR|Rater 2|Rater 2
62184120|NCT01454232|OTHER|gastric surgery|obese patients addressed for gastric surgery
62184121|NCT01454232|ACTIVE_COMPARATOR|lean healthy subjects evaluated once|lean healthy subjects evaluated once
62184122|NCT02620956|ACTIVE_COMPARATOR|obese nebulizer|would be used to inhale an aerosol with technetium labeled diethylenetriaminepente-acetic acid (99mTc - DTPA) with an activity of 1 mCi in a total dose volume with normal saline of 2,5 ml and heliox using a vibrating mesh inhaler.
62184123|NCT02620956|EXPERIMENTAL|asthmatic obese nebulizer|would be used to inhale an aerosol with technetium labeled diethylenetriaminepente-acetic acid (99mTc - DTPA) with an activity of 1 mCi in a total dose volume with normal saline of 2,5 ml and heliox using a vibrating mesh inhaler.
62184124|NCT01264445|EXPERIMENTAL|Group A|Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.
62184125|NCT01264445|EXPERIMENTAL|Group B|Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.
62184126|NCT01264445|EXPERIMENTAL|Group C|Ad35-GRIN investigational HIV vaccine at Month 0 followed by Adjuvanted GSK investigational HIV vaccine at Months 3 and 4.
62184127|NCT01264445|EXPERIMENTAL|Group D|Adjuvanted GSK investigational HIV vaccine and Ad35-GRIN investigational HIV vaccine co-administered (simultaneous administration with separate injections)at Months 0, 1, and 4.
62568457|NCT02644668|EXPERIMENTAL|Reldesemtiv 150 mg twice daily|Patient randomized to this treatment arm will receive reldesemtiv suspension at a dose of 150 mg, twice daily for 8 weeks.
62774146|NCT05095415|ACTIVE_COMPARATOR|Typical Pre-operative Experience|Participants will be be placed in appropriate subgroups based upon their diagnosis and surgical intervention. Subgroups include: CMC Arthroplasty, ORIF of the Distal Radius, and Flexor/Extensor Tendon Repairs.
62184128|NCT03564834|EXPERIMENTAL|Laparoscopic gastrectomy|A standard laparoscopic gastrectomy with D2 lymphadenectomy will be performed by two experienced surgeons, according to the Japanese Gastric Cancer Treatment Guidelines 2014 (version 4) and the Japanese Classification of Gastric Carcinoma (3rd English edition).
62184129|NCT03564834|ACTIVE_COMPARATOR|Open gastrectomy|A standard open gastrectomy with D2 lymphadenectomy will be performed by two experienced surgeons, according to the Japanese Gastric Cancer Treatment Guidelines 2014 (version 4) and the Japanese Classification of Gastric Carcinoma (3rd English edition).
62184130|NCT04582669|PLACEBO_COMPARATOR|Sodium Chloride 0.9%|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of sodium chloride 0.9% in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
62184131|NCT04582669|ACTIVE_COMPARATOR|Intralesional Triamcinolone 10 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 10 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
62568458|NCT02644668|EXPERIMENTAL|Reldesemtiv 450 mg twice daily|Patients randomized to this treatment arm will receive reldesemtiv suspension at a dose of 450 mg, twice daily for 8 weeks.
62184132|NCT04582669|EXPERIMENTAL|Intralesional Triamcinolone 20 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 20 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
62184133|NCT04582669|EXPERIMENTAL|Intralesional Triamcinolone 40 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 40 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
62184134|NCT02239081|EXPERIMENTAL|CTP-730, 5 mg|oral suspension, once daily.
62184135|NCT02239081|EXPERIMENTAL|CTP-730, 10 mg|Oral Suspension, once daily.
62184136|NCT02239081|EXPERIMENTAL|CTP-730, 20 mg|Oral Suspension, once daily.
62184137|NCT02239081|EXPERIMENTAL|CTP-730, 30 mg|Oral Suspension, once daily.
61998414|NCT04036942|ACTIVE_COMPARATOR|Band mucosectomy|After diagnostic endoscopy investigators will proceed to use the tip of a polypectomy snare for marking 270 grades around the esophagogastric junction preserving part of the mucosa towards the greater curvature, then investigators will perform submucosal elevation with the injection of 0.9% saline with carmine indigo and adrenaline 1:10000, after adequate submucosal elevation investigators will proceed with the help of a band ligation cap to suction and release the elastic band in the previously marked and elevated tissue, proceeding to resect the previously ligated tissue with polypectomy loop below the elastic band with forced coagulation (Effect 2, 40 W), until the marked mucosa is completely resected (average used of 5 elastic bands, reviewing the work area for complications like bleeding or perforation.
61998415|NCT02633956|EXPERIMENTAL|5 mg Obeticholic Acid|5 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
61998416|NCT02633956|EXPERIMENTAL|10 mg Obeticholic Acid|10 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
62184138|NCT02239081|EXPERIMENTAL|CTP-730, 40 mg|Oral Suspension, once daily.
62184139|NCT02239081|EXPERIMENTAL|CTP-730, 50 mg|Oral Suspension, once daily.
62184140|NCT02239081|EXPERIMENTAL|CTP-730, 60 mg|Oral Suspension, once daily.
62184141|NCT02680197|EXPERIMENTAL|CHF5259 12.5 μg total daily dose|"CHF5259 or Placebo administration:~Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 6.25μg + 1 puff of CHF5259 DPI matched placebo twice a day~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
62184142|NCT02680197|EXPERIMENTAL|CHF5259 25 μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 6.25μg + 1 puff of CHF5259 DPI 6.25μg twice a day~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
62184143|NCT02680197|EXPERIMENTAL|CHF5259 50 μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 12.5 μg + 1 puff of CHF5259 DPI 12.5 μg twice a day~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
62184144|NCT02680197|EXPERIMENTAL|CHF5259 100μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment :1 puff of CHF5259 DPI 25 μg + 1 puff of CHF5259 DPI 25 μg twice a day~Interventions :~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
62184145|NCT02680197|PLACEBO_COMPARATOR|CHF5259 matched Placebo BID|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 2 puffs of CHF5259 DPI matched placebo twice a day~Interventions :~Day 1 : pre-dose spirometry, serial spirometry, haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
62184146|NCT05084599|PLACEBO_COMPARATOR|left-tilt group|After spinal anesthesia, the patient was placed in a 15° left position until the fetus was delivered, and metaraminol was given at an initial rate of 2.00μg/kg/min throughout the process.
62184147|NCT05084599|EXPERIMENTAL|supine group|After spinal anesthesia, the patient was placed in a supine position until the fetus was delivered, and metaraminol was given at an initial rate of 2.7μg/kg/min throughout the process.
62184148|NCT03232034|PLACEBO_COMPARATOR|Calcium Citrate|Calcium citrate (1000 mg calcium) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
61998417|NCT02633956|EXPERIMENTAL|25 mg Obeticholic Acid|25 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
61998418|NCT02633956|PLACEBO_COMPARATOR|Placebo|One tablet daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
62774147|NCT05095415|EXPERIMENTAL|Occupational Therapy Consult Experience|Participants will be be placed in appropriate subgroups based upon their diagnosis and surgical intervention. Subgroups include: CMC Arthroplasty, ORIF of the Distal Radius, and Flexor/Extensor Tendon Repairs.
62774148|NCT04816318||Social and public health measures against COVID-19|Public Health and Social measures against COVID-19. This group refers to the population exposed to public health and social measures against COVID-19
62184149|NCT03232034|ACTIVE_COMPARATOR|Milk Mineral Supplement|Milk mineral supplement (equating to 1000 mg calcium) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
62184150|NCT03232034|EXPERIMENTAL|Milk mineral supplement plus Whey Protein Hydrolysate|Milk mineral supplement (equating to 1000 mg calcium) plus whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
61998419|NCT03766178|EXPERIMENTAL|Nimotuzumab + SHR-1210|Nimotuzumab + SHR-1210
61998420|NCT03764722|EXPERIMENTAL|Levosimendan|
62184151|NCT02550912|ACTIVE_COMPARATOR|Vitamin D group|Patients will receive vitamin D drug with generic name: V drops manufactured by Medical Union Pharmaceuticals, Egypt Dosage form: liquid drops Dosage, frequency, and Duration:1000 international units per day for 3 months then 1000 international units per 25 pounds per day for another 3 months.
62392893|NCT03400202||Group D: Dark Circles Severe|Group D includes participants with Dark Circle Severity Scale score 7 to 9 (Severe). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
62392894|NCT06401902||Diabetics|Diabetics patients who underwent internal carotid artery surgery
62392895|NCT06401902||Nondiabetics|Nondiabetics patients who underwent internal carotid artery surgery
62392896|NCT04696601|EXPERIMENTAL|Olfactory test|The result of the olfactory test will be compared to the result of the RT-PCR test.
62774149|NCT04816318||Control|The comparator is the pre-intervention period
62774150|NCT05035433|EXPERIMENTAL|First lithotripsy and then EPBD|After successful selective bile duct intubation, contrast agent was injected to measure the thickness of the bile duct and the size of bile duct stones under fluoroscopy. For those meeting the inclusion criteria, sphincterotomy was performed first.Papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken line to suitable size after the switch to expanding balloon EPBD and further kidney stones, papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken balloon to suitable size after the switch to expansion, expansion size 10-12 mm, according to the lower bile duct diameter, expansion time of 30 seconds.Then, the stones were removed with a net basket or balloon, and the nasobiliary duct was placed to end the operation.
61998421|NCT03929965|EXPERIMENTAL|advanced solid tumors with FGFR alteration|
61998422|NCT01408186|ACTIVE_COMPARATOR|Rabeprazole|Tablet 20mg daily for 12 months
61998423|NCT01408186|ACTIVE_COMPARATOR|Famotidine|Tablet 40mg daily for 12 months
62184152|NCT02550912|PLACEBO_COMPARATOR|Placebo group|Patients will receive glucose syrup same taste and color as vitamin D3 drops with same dosage regimen to vitamin D group.
62392897|NCT00412555|EXPERIMENTAL|1|
62392898|NCT03955068|OTHER|Strict Classic Ketogenic Diet Arm|The classic ketogenic diet is individually calculated for each patient based on age, weight, and nutritional needs. The diet is typically administered from a 2:1 to 4:1 ratio; this means 2 to 4 parts of fat to 1 part of both protein (calculated based on RDA and whatever remaining portion of carbohydrates. The basis of calculations is first on the amount of required protein needed to meet RDA to insure adequate growth. Fine tuning of ketogenic diet therapy is based on serum beta-hydroxybutyrate levels (target levels of 3.5-6.5 mmol/L), tolerance of the diet, and response to treatment.
62392899|NCT05894187|NO_INTERVENTION|Control group (no video)|Children in this group will not receive a link to view an informational animated prior to their surgery date
62392900|NCT05894187|EXPERIMENTAL|Intervention group ( video)|Children in this group will receive a link to view an informational animated video 3 nights prior to their surgery date.
61998424|NCT04498962|EXPERIMENTAL|chronic stable angina|Experimental: the patient who have the syndrome of intermingled phlegm and blood stasis with chronic stable angina will be treated by Danzhu Fuyuan Granule in addtion to routine care
61998425|NCT04498962|EXPERIMENTAL|Vascular Dementia|Experimental: the patient who have the syndrome of intermingled phlegm and blood stasis with Vascular Dementia will be treated by Danzhu Fuyuan Granule in addtion to routine care
61998426|NCT04498962|EXPERIMENTAL|Idiopathic Membranous Nephropathy|Experimental: the patient who have the syndrome of intermingled phlegm and blood stasis with Idiopathic Membranous Nephropathy will be treated by Danzhu Fuyuan Granule in addtion to routine care
61998427|NCT04498962|NO_INTERVENTION|Healthy population|Comparator: Healthy population with no treatment
62020944|NCT00761839|ACTIVE_COMPARATOR|Arm 2|These patients are the control group and receive usual care.
62392901|NCT03581708||advanced lung cancer|Patients diagnosed with advanced lung cancer
62392902|NCT05853835|EXPERIMENTAL|Cohort-1|First dose of SAD cohort (6 treatment + 2 placebo)
62392903|NCT05853835|EXPERIMENTAL|Cohort-2|Second dose of SAD cohort (6 treatment + 2 placebo)
62392904|NCT05853835|EXPERIMENTAL|Cohort-3|Third dose of SAD cohort (6 treatment + 2 placebo)
62392905|NCT05853835|EXPERIMENTAL|Cohort-4|Fourth dose of SAD cohort (6 treatment + 2 placebo)
62392906|NCT05853835|EXPERIMENTAL|Cohort-5|Fifth dose of SAD cohort (6 treatment + 2 placebo)
62774151|NCT05035433|EXPERIMENTAL|First EPBD and then lithotripsy|After puncture of the papillary sphincter, the guide wire was indwelled in the bile duct, and the columnar dilating balloon was inserted in exchange. The dilation size was 10-12mm, and the dilation time was 30 seconds according to the diameter of the lower end of the bile duct.At the end of the expansion, the stones were broken to a suitable size using a one-piece gravel net basket.The calculi were removed by using a stone net basket or balloon, and the nasobiliary duct was placed to end the operation.
62774152|NCT04204356|EXPERIMENTAL|tDCS group|Participants randomly allocated to this group using a random number generator will receive a once weekly, 6-week block of language treatment with active tDCS.
62392907|NCT05853835|EXPERIMENTAL|Cohort-6|Sixth dose of SAD cohort (6 treatment + 2 placebo)
62392908|NCT05853835|EXPERIMENTAL|Cohort-7|First dose of MAD cohort (6 treatment + 2 placebo)
62774153|NCT04204356|SHAM_COMPARATOR|Sham group|Participants randomly allocated to this group using a random number generator will receive a once weekly, 6-week block of language treatment without active tDCS (sham)
62774154|NCT03979599|ACTIVE_COMPARATOR|magnesium sulphate& levobupivacaine|Levobupivacaine add to magnisum sulphate
62774155|NCT03979599|PLACEBO_COMPARATOR|levobupivacaine|levobupivacaine
62774156|NCT04135846|EXPERIMENTAL|doxazosin|16 mg, or maximum tolerated dose (MTD)
61998428|NCT01891851|EXPERIMENTAL|TMC435350 / Ritonavir|TMC435350 2 capsules of 100-mg twice daily / Ritonavir one 100-mg capsule twice daily
61998429|NCT05510869|EXPERIMENTAL|B-MICS 1.4 mm|bimanual 1.4 mm cataract surgery (B-MICS)
62184153|NCT03913689||StimRouter Neuromodulation System|Implant of the Bioness StimRouter Neuromodulation System in subjects with chronic pain of peripheral nerve origin
62392909|NCT05853835|EXPERIMENTAL|Cohort 8|Second dose of MAD cohort (6 treatment + 2 placebo)
62392910|NCT05853835|EXPERIMENTAL|Cohort 9|Third dose of MAD cohort (6 treatment + 2 placebo)
62392911|NCT06021028|EXPERIMENTAL|Beautifil II Resin composite|Giomer restorative
62392912|NCT06021028|ACTIVE_COMPARATOR|Neo Spectra resin composite|Nano-hybrid resin composite
62774157|NCT04135846|PLACEBO_COMPARATOR|placebo|matching placebo
62774158|NCT01814670|EXPERIMENTAL|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
62774159|NCT06014281|EXPERIMENTAL|Meditation group|"Baseline to week 8:~Subjects will be trained to meditate for 10 minutes daily, and several measures (questionnaires, cognitive tests, and physiological measurements) will be obtained to assess the efficacy of daily meditation practice on mental health and well being. Focused-attention meditation technique will be used to train participants. Specifically the SOS meditation technique will be employed.~Week 8 to week 16:~Subjects will self report if they choose to continue SOS meditation and several measures (questionnaires, cognitive tests, and physiological measurements) will be obtained to assess the impact of continued meditation practice on mental health and well being."
62791579|NCT04886778|PLACEBO_COMPARATOR|Group B or Placebo control group|Group B was treated as a control group with a 12-week low-carbohydrate diet combined with placebo treatment.
62392913|NCT00854776|ACTIVE_COMPARATOR|1|Upper GI tract symptoms are evaluated. Patients are asked to report to gastroenterologist if they have persistent ulcer symptoms and to report to the emergency room if they have evidence of GI bleeding or ulcer complications (melena, hematemesis, or sudden onset of severe epigastric pain). Endoscopy will be undergone to document any gastroduodenal ulcers with or without ulcer complications. If the hemoglobin level has decreased by 2g/dL or more, or stool check shows occult blood at each visit, endoscopy will be undergone to check the presence of gastroduodenal ulcers with or without bleeding. Patients without persistent ulcer symptoms or without evidence of ulcer complications will be invited to undergone scheduled endoscopy at the 3-month end of follow-up in each subjective.
62392914|NCT00854776|PLACEBO_COMPARATOR|2|Upper GI tract symptoms are evaluated at each visit. Patients are asked to report to gastroenterologist if they have persistent ulcer symptoms and to report to the emergency room if they have evidence of GI bleeding or ulcer complications (melena, hematemesis, or sudden onset of severe epigastric pain). Endoscopy will be undergone to document any gastroduodenal ulcers with or without ulcer complications. An ulcer is defined as a circumscribed mucosal break at least 3 mm in diameter. If the hemoglobin level has decreased by 2g/dL or more, or stool check shows occult blood at each visit, endoscopy will be undergone to check the presence of gastroduodenal ulcers with or without bleeding. Patients without persistent ulcer symptoms or without evidence of ulcer complications will be invited to undergone scheduled endoscopy at the 3-month end of follow-up in each subjective.
62392915|NCT02808299||all the antigen and antibody of HBV are negative|Hepatitis B Virus surface antigen (HBsAg), Hepatitis B Virus surface antibody (HBsAb), Hepatitis B Virus e antigen (HBeAg), Hepatitis B Virus e antibody (HBeAb), Hepatitis B Virus core antibody (HBcAb) are all negative.
62392916|NCT02808299||HBV infection history|One or more of HBsAb,HBeAb, HBcAb are positive, while HBsAg and HBeAg are negative. If only HBsAb is positive, the history of HBV vaccination need to be excluded.
61998430|NCT05510869|ACTIVE_COMPARATOR|C-MICS 1.8 mm|coaxial 1.8 mm cataract surgery (C-MICS)
62184154|NCT01337375|EXPERIMENTAL|A/B|
62184155|NCT01337375|EXPERIMENTAL|C/D|
62184156|NCT05780216|EXPERIMENTAL|DMT and harmine|"This arm comprises the following interventions:~* Mindfulness Intervention in the course of the meditation group retreat~* Administration of DMT + harmine (moderate-high dose)"
62392917|NCT02808299||HBV carriers|One or two of HBsAg and HBeAg are positive, accompanied by any HBV antibody is positive or not.
62791580|NCT01356459|EXPERIMENTAL|Intervention|Patients in this arm will have Mepilex dressings applied to their sacrum and heels
62791581|NCT01356459|NO_INTERVENTION|Control|Patients in this arm will have standard care
62791582|NCT05741398|EXPERIMENTAL|Demaod VR system tratment|Non-invasive light pulse generated by a non-contacting device for treating the symptoms of dry eyes and MDG.
62774160|NCT06014281|EXPERIMENTAL|Waitlist control|"Baseline to week 8:~Subjects will be place in a control group which receives no intervention. However, several measures (questionnaires, cognitive tests, and physiological measurements) will be obtained to assess baseline mental health and well being scores.~Week 8 to week 16:~Subjects will be trained to meditate for 10 minutes daily, and several measures (questionnaires, cognitive tests, and physiological measurements) will be obtained to assess the efficacy of daily meditation practice on mental health and well being. Focused-attention meditation technique will be used to train participants. Specifically the SOS meditation technique will be employed."
62184157|NCT05780216|PLACEBO_COMPARATOR|Placebo|"This arm comprises the following interventions:~* Mindfulness Intervention in the course of the meditation group retreat~* Administration of Placebo"
62184158|NCT04300153|EXPERIMENTAL|ESP Group|At the end of the skin closure, patients will be positioned in lateral decubitis and unilateral ESP block will be performed with single injection of 30 ml 0.25% bupivacaine at the level of T12 transverse process. All patients will receive intravenous (iv) paracetamol 1000 mg at the arrival to the recovery room. The dosage will be repeated at every 8-hours interval.
62184159|NCT04300153|SHAM_COMPARATOR|Control Group|At the end of the skin closure, patients will be positioned in lateral decubitis and unilateral ESP block will be performed with single injection of 30 ml normal saline at the level of T12 transverse process. All patients will receive intravenous (iv) paracetamol 1000 mg at the arrival to the recovery room. The dosage will be repeated at every 8-hours interval.
62184160|NCT01243411|EXPERIMENTAL|AA4500|collagenase clostridium histolyticum
62184161|NCT03679897|EXPERIMENTAL|Ropivacaine group|BPB with 0.375% ropivacaine solution
62184162|NCT03679897|ACTIVE_COMPARATOR|Levobupivacaine group|BPB with 0.25% levobupivacaine solution
62184163|NCT03668171|EXPERIMENTAL|MSC group|mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2 weeks
62184164|NCT03668171|PLACEBO_COMPARATOR|control|placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 1, 2
62184165|NCT03344016|NO_INTERVENTION|Standard care follow-up group|Patients will receive an information leaflet (see appendix), which advises on recommended routine follow-up according to international guidelines.
62184166|NCT03344016|ACTIVE_COMPARATOR|Special care follow-up group|In addition to the information leaflet patients will be actively contacted by the clinical center to increase the likelihood that patients meet recommended follow-up schedules.
62184167|NCT03304613|ACTIVE_COMPARATOR|Standard Web-based Cognitive Behavioral Therapy (e-CBT)|"Patients randomized to e-CBT will undergo Standard Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management Program and meet with a study medical assistant (MA) for an orientation session. The MA provides an overview of the program, explains the rationale for treatment, and directs them to the FibroGuide website. FibroGuide features the CBT modules that will be used by both groups. Patients will complete one module per week. Materials needed for the 8-week intervention including the instructions for each activity and forms for the written aspects of an activity (worksheets) will be provided in the first visit and available online. The FibroGuide website evolved from the evidence-based website Living Well with Fibromyalgia that has established efficacy for improving functional status and reducing pain."
62184168|NCT03304613|EXPERIMENTAL|Resilience-Enhanced web-based CBT Program|"Patients randomized to PRISM will undergo Promoting Resilience through Innovative Self-Management (PRISM) and meet with the MA for an orientation session. The MA describes the program, explains the rationale for treatment, and directs them to the FibroGuide and PRISM websites. Materials and worksheets are provided in the first visit and available online. The e-CBT elements retained are the core elements of CBT for pain, while the resilience-based activities capitalize on the best practices for positive activities interventions including having multiple overlapping activities, making favored activities standard practice beyond the study and having a coaching component."
62184169|NCT03304613|NO_INTERVENTION|Usual Care|Patients randomized to the usual care only group will have no contact with the study MAs. Usual care patients return for the same follow-up assessments (and electronic medical record review) at 8 weeks and at 6 and 12 months. Whereas major surgery including surgeries for pain, are exclusion criteria, spine and pain injections will be permitted.
62392918|NCT02434666|EXPERIMENTAL|CPC-201|
62774161|NCT05979168|EXPERIMENTAL|Intervention arm|Hypertensive patients with uncontrolled BP in the intervention group will receive mobile phone text messages in the Nepali language and accept the phone call from the trained research nurse on their given mobile. They will also get the opportunity to ask questions and clarification during the phone call. However, text messaging would be only one way.
62184170|NCT01355107||chronic hcv, no liver cirrhosis, no HCC|patients with chronic hepatitis c- infection: no cirrhosis of the liver (= Desmet IV), no HCC - suspected lesion in the liver
62184171|NCT01355107||chronic hcv, liver cirrhosis, no HCC|patients with hcv- associated cirrhosis of the liver, but with no HCC - suspected lesions in the liver
62184172|NCT01355107||hcv-infection, HCC|patients with hcv- associated HCC
62392919|NCT05384756|EXPERIMENTAL|Treatment (TMLI, alemtuzumab)|Patients receive alemtuzumab IV over 4 hours QD on days -7 to -3. Patients undergo TMLI BID on day -2. Patients also undergo HCT on day 0 and receive sirolimus on day -1 and day 0.
62392920|NCT05177861|OTHER|Electromyelography|EMG will be performed only once to determine the ulnar nerve entrapment site in patients.
62184173|NCT04317261|EXPERIMENTAL|Hematuria patients|
62184174|NCT00863798|EXPERIMENTAL|Desvenlafaxine succinate sustained release 10 mg|
62184175|NCT00863798|EXPERIMENTAL|Desvenlafaxine succinate sustained release 50 mg|
62184176|NCT00863798|PLACEBO_COMPARATOR|Placebo|
62184177|NCT04444219|OTHER|Breakfast meal_1|100 g white bread, 40 g yellow cheese and Κing Oyster mushrooms (test meal)
61998431|NCT05510869|ACTIVE_COMPARATOR|C-SICS 2.4 mm|coaxial 2.4 mm small incision cataract surgery (C-SICS)
61998432|NCT03516669|OTHER|Intraluminal Clarithromycin eradication|20 Patients receive intraluminal Clarithromycin eradication of H. pylori.
62184178|NCT04444219|OTHER|Breakfast meal_2|100 g white bread, 40 g yellow cheese and 6-7 cherry tomatoes (control meal)
62184179|NCT04330378||Hospital-at-home|All patients who are enrolled into the NUHS@Home Programme will be recruited into this arm. Patients will be sent home via ambulance, where they will be reviewed by a NUHS@Home nurse. Intravenous therapies, pillboxes for medication, remote monitoring software, and telecommunication tools will be set up as indicated. NUHS@Home doctors will visit at least once daily, and nurses at least twice daily as required. Therapists will conduct home visits as necessary. The NUHS@Home team is available 24/7. When conventional discharge criteria are met, the patient will be discharged. The NUHS@Home clinical team will be under clinical governance of Division of Advanced Internal Medicine at NUH and patients will be considered 'inpatients' throughout the treatment period.
62184180|NCT04330378||Usual in-hospital care|Patients who would otherwise be eligible for NUHS@Home but are not able to be enrolled due to capacity will be recruited into this arm. They will receive usual care in the wards that they are already in until they are discharged.
62184181|NCT04330378||Rejected cohort|Patients who were offered but declined enrolments inot the NUHS@Home programme will be approached for consent to be in the rejected cohort. There will be no change to the patient's clinical management.
62392921|NCT04491591|EXPERIMENTAL|BREASTChoice|"* After consent, the participant will be randomized~* Depending on the clinic work-flow, the patient will be sent the link to the BREASTChoice tool by email or MyChart message~  * 1) prior to their visit with the surgeon;~ * 2) at the time of their visit with the surgeon;~ * 3) after the surgeon appointment~* Will receive an online survey to complete after viewing the BREASTChoice tool assessing socio-demographics, knowledge, health literacy, decisional conflict, patient engagement, health-related quality of life, preferred decision role, and usability of the website.~* Will pull from the electronic medical record breast cancer diagnosis stage, previous breast cancer surgery and participants' reconstruction decision after enrollment."
62568459|NCT03950414|EXPERIMENTAL|Tier 1|3 participants enrolled at dose level 5x10\^3 cells/kg of CMV viral specific T-cells
62568460|NCT03320343||Patients recruited for pelvic imaging examination|
62568461|NCT05917535|EXPERIMENTAL|Intervention group|Patients offered mentalizing course supplemental to treatment as usual
62568462|NCT05917535|NO_INTERVENTION|Control|Control group - treatment as usual.
61998433|NCT03516669|OTHER|Oral standard triple therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor and two antibiotics ( amoxicillin, and clarithromycin) for 14 days.
61998434|NCT01358318|PLACEBO_COMPARATOR|Control|
62184182|NCT03840109||All Participants|All participants will take an online questionnaire which includes their evaluation of one of 18 different emotional support messages randomly assigned through the Qualtrics survey system. The participants answer a series of closed ended scales regarding quality of the support message, supporter's competence, amount of emotional improvement they experienced after reading the message, and likelihood to seek support from the person writing the message.
62184183|NCT04580498|EXPERIMENTAL|Treatment group A|SHR-1701+Paclitaxel+carboplatin
62568463|NCT01709487|EXPERIMENTAL|HIPEC surgery with chemotherapy|"* 3 courses of pre-operative chemotherapy: carboplatin AUC = 5 IV + paclitaxel 175 mg/m2 IV every 3 weeks~* Debulking surgery~* HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery~* 3 courses of post-operative chemotherapy: carboplatin AUC = 5 IV + paclitaxel 175 mg/m2 IV every 3 weeks"
62568464|NCT05552248||Orthosis group 1|Use of LumbarBelt Soft 300 device during sport practice (for 12 weeks)
61998435|NCT01358318|EXPERIMENTAL|Soy Protein|
62184184|NCT04580498|EXPERIMENTAL|Treatment group B|SHR-1701
62568465|NCT05552248||Control group 1|Control group of the LumbarBelt Soft 300 group - no medical device used during sport practice (for 12 weeks)
62568466|NCT05552248||Orthosis group 2|Use of LumbarBelt Mid 500 device during sport practice (for 12 weeks)
62568467|NCT05552248||Control group 2|Control group of the LumbarBelt Mid 500 group - no medical device used during sport practice (for 12 weeks)
62568468|NCT06286774|EXPERIMENTAL|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for five (5) weeks.
62568469|NCT06286774|NO_INTERVENTION|Waitlist control|Control participants will receive CBT-I at the end of the study.
62734578|NCT05068505|EXPERIMENTAL|Community health worker delivered multicomponent intervention|The study will employ a closed cohort stepped wedge cluster randomized design. There will be a sequential crossover of clusters from the control to the intervention arms and the order of the cross over will be randomly determined. This study will be conducted in 21 clusters within Nakaseke district. Each cluster will consist of 4-5 villages. We plan to rollout the intervention in three clusters per month.
61998436|NCT01358318|EXPERIMENTAL|Soy Fiber|
61998437|NCT01358318|EXPERIMENTAL|Soy Protein and Soy Fiber|
61998438|NCT05626946||Nursing Home resident from Grand Nancy area with Advanced Practice Nurse intervention|Patients aged 75 years and over, resident in Nursing Home at the time of inclusion, and received at least once in the emergency room of the Nancy Hospital during the period concerned. Inclusion in the group with IPA intervention for Nursing Home residents of the Grand Nancy area where the Advanced Practice Nurse is authorised to intervene.
61998439|NCT05626946||Nursing Home resident outside Grand Nancy area without Advanced Practice Nurse intervention|Patients aged 75 years and over, resident in Nursing Home at the time of inclusion, and received at least once in the emergency room of the Nancy Hospital during the period concerned. Inclusion in the control group for Nursing Home residents outside the Grand Nancy area without the Advanced Practice Nurse intervention.
61998440|NCT04648865|EXPERIMENTAL|LY3537031|LY3537031 administered subcutaneously (SC).
61998441|NCT04648865|PLACEBO_COMPARATOR|Placebo|Placebo administered SC.
61998442|NCT00794196|NO_INTERVENTION|Usual Care|The control group will be receiving usual medical and pharmaceutical care.
61998443|NCT00794196|EXPERIMENTAL|Intervention Group|Intervention group will be receiving usual medical and pharmaceutical care plus a pharmaceutical support program.
61998444|NCT06290310||mechanically ventilated patients|Invasively or non-invasively ventilated patients.
61998445|NCT02623803|ACTIVE_COMPARATOR|Treatment group|lidocaine infusion will be initiated at the time of anesthesia induction in the operating room. Dosage 1.5mg/kg/hour. Continuous infusion until patient meets discharge criteria in recovery room.
62184185|NCT03192969|EXPERIMENTAL|Abatacept Combination Therapy|Abatacept subcutaneous injection (125 mg/mL prefilled syringe weekly) in combination with glucocorticoid therapy (up to 28-week taper of oral prednisone daily)
62184186|NCT03192969|PLACEBO_COMPARATOR|Placebo Monotherapy- 28 Weeks|Glucocorticoid therapy (28-week taper of oral prednisone daily) in combination with placebo subcutaneous injection (1 mL pre-filled syringe weekly)
62184187|NCT03192969|PLACEBO_COMPARATOR|Placebo Monotherapy- 52 Weeks|Glucocorticoid therapy (52 week taper of oral prednisone daily) in combination with subcutaneous placebo weekly
62392922|NCT04491591|ACTIVE_COMPARATOR|Attention Control Website|"* After consent, the participant will be randomized~* Depending on the clinic work-flow, the patient will be sent the link to the website by email or MyChart message~  * 1) prior to their visit with the surgeon;~ * 2) at the time of their visit with the surgeon;~ * 3) after the surgeon appointment~* Will receive an online survey to complete after viewing the website assessing socio-demographics, knowledge, preferences, health literacy, decisional conflict, measure of patient engagement, health-related quality of life, preferred decision role, consult time, and usability of the website.~* Will pull from the electronic medical record breast cancer diagnosis stage, previous breast cancer surgery and participants' reconstruction decision after enrollment."
62392923|NCT04491591|EXPERIMENTAL|Clinicians|"* Will receive a brief virtual training on how BREASTChoice functions and the features, including placement of the patient tool summary in the electronic health record~* Will complete pre-post trial survey about shared decision making"
62392924|NCT01756846|OTHER|usual care|Daily practice of the cardiologist or attending emergency doctor, in order to diagnose a patient with chest pain. In this period attending doctors assess the risk of a patient with chest pain, based on his/hers experience and various criteria (for example described in European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, without a formal risk score).
61998446|NCT02623803|PLACEBO_COMPARATOR|Control group|placebo infusion (D5W) will be initiated at the time of anesthesia induction in the operating room. Continuous infusion until patient meets discharge criteria in recovery room.
61998447|NCT05092893||Children with Developmental Coordination Disorder|"INCLUSION:~* Confirmed diagnosis of DCD~* Comorbidities are allowed (f.e. ASD, ADHD, ADD,...)~EXCLUSION:~o Any other neurodevelopmental disorder which might affect motor development (f.e. CP)."
62392925|NCT01756846|OTHER|use of HEART risk score|see intervention
62392926|NCT02505945|ACTIVE_COMPARATOR|Control Arm|Double-dose PPI \[Omeprazole 20 mg BID (twice a day)\]
61998448|NCT02920983|ACTIVE_COMPARATOR|somofilcon A|Subjects are randomized to wear somofilcon A for one week during the cross over study.
61998449|NCT02920983|ACTIVE_COMPARATOR|nelfilcon A II 2|Subjects are randomized to wear nelfilcon A II 2 for one week during the cross over study.
61998450|NCT02920983|ACTIVE_COMPARATOR|omafilcon A ll 2|Subjects are randomized to wear omafilcon A ll 2 for one week during the cross over study.
61998451|NCT03296306|ACTIVE_COMPARATOR|6 cycles arm|Patients without evidence of disease progression or unacceptable toxicities after completion of two or four treatment cycles of cisplatin based chemotherapy (GP, GP-S, MVAC, HD-MVAC with GCSF) were randomly assigned to receive additional two to four cycles of chemotherapy (totally six cycles)
61998452|NCT03296306|EXPERIMENTAL|4 cycles arm|Patients without evidence of disease progression or unacceptable toxicities after completion of two or four treatment cycles of cisplatin based chemotherapy (GP, GP-S, MVAC, HD-MVAC with GCSF) were randomly assigned to receive additional zero to two cycles of chemotherapy (totally four cycles)
62392927|NCT02505945|ACTIVE_COMPARATOR|Treatment Arm|LINX Reflux Management System
62020945|NCT03965052|EXPERIMENTAL|PRO-179|Dosage: 1 drop every 24 hours, at night, in both eyes.
62184188|NCT01875341|ACTIVE_COMPARATOR|Active treatment with NCPAP|This group will receive treatment with NCPAP, Nasal Continuous Positive Airway Pressure for 6 weeks. Nasal Continuous Positive Airway Pressures will be increased until apneas \& hypopneas are prevented during all sleep stages.
62392928|NCT02061020|EXPERIMENTAL|Sequence 1|"1. THC containing cigarettes 10mg~2. THC containing cigarettes 30mg~3. Placebo"
62392929|NCT02061020|EXPERIMENTAL|Sequence 2|"1. THC containing cigarettes 30mg~2. Placebo~3. THC containing cigarettes 10mg"
62392930|NCT02061020|EXPERIMENTAL|Sequence 3|"1. Placebo~2. THC containing cigarettes 10mg~3. THC containing cigarettes 30mg"
62392931|NCT00579059|OTHER|1|Maxim® Pop-Top® Tibia
62392932|NCT00579059|OTHER|2|Maxim® Regular Tibia
62392933|NCT04391894|EXPERIMENTAL|ECF843 0.45 mg/mL TID or vehicle (Part 1)|ECF843 0.45 mg/mL TID or vehicle (Part 1)
61998453|NCT03561857|EXPERIMENTAL|Confocal Laser Endomicroscopy|All included patients will undergo probe-based Confocal Laser Endomicroscopy during Robotic-Assisted Radical Prostatectomy (RARP) or Laparoscopic Radical Prostatectomy (LRP)
61998454|NCT01485315|ACTIVE_COMPARATOR|Liberal blood transfusion|Blood transfusion at haemoglobin 9.0 g/dl (5.6 mM) or less
61998455|NCT01485315|ACTIVE_COMPARATOR|Restrictive blood transfusion|Blood transfusion at haemoglobin 7.0 g/dl (4.3 mM) or less
62184189|NCT01875341|SHAM_COMPARATOR|Sub- active treatment with NCPAP|This group will receive treatment with Nasal Continuous Positive Airway Pressure at sub-therapeutic levels for 6 weeks. Patients will be taught how to use NCPAP in the sleep lab. Pressures will be left unchanged at the lowest possible value for the NCPAP device. After completion of treatment patients will be provided usual NCPAP therapy.
62184190|NCT05972798|EXPERIMENTAL|Omega-3 fatty acids|"1. Age \> 60 years.~2. Previous major depressive disorder (MDD), single or recurrent.~3. Mood is relatively stable for at least 3 weeks and the score of 17-item Hamilton Depression Rating Scale (HAMD-17) less than 10"
62184191|NCT05972798|PLACEBO_COMPARATOR|Soybean oil|"1. Age \> 60 years.~2. Previous major depressive disorder (MDD), single or recurrent.~3. Mood is relatively stable for at least 3 weeks and the score of 17-item Hamilton Depression Rating Scale (HAMD-17) less than 10"
62392934|NCT04391894|EXPERIMENTAL|ECF843 0.15 mg/mL TID or vehicle (Part 1)|ECF843 0.15 mg/mL TID or vehicle (Part 1)
62392935|NCT04391894|PLACEBO_COMPARATOR|ECF843 vehicle TID (Part 1)|ECF843 vehicle TID (Part 1)
62392936|NCT04391894|EXPERIMENTAL|ECF843 0.15 mg/mL BID or vehicle (Part 1)|ECF843 0.15 mg/mL BID or vehicle (Part 1)
62392937|NCT04391894|PLACEBO_COMPARATOR|ECF843 vehicle BID (Part 1)|ECF843 vehicle BID (Part 1)
61998456|NCT02170584|EXPERIMENTAL|BIBR 953 ZW IV|
62184192|NCT00889837|EXPERIMENTAL|Inhaled Loxapine|Staccato Loxapine, 10 mg doses x 2, 10 hours apart
62184193|NCT00889837|PLACEBO_COMPARATOR|Inhaled Placebo|Staccato Placebo,inhalations x 2, 10 hours apart
62184194|NCT01882478||failure to respond to RF ablation|patients undergoing endoscopic RF ablation therapy with persistent BE with HGD or IMCA despite 2 or more serial RF ablation treatment sessions
62184195|NCT00156923|EXPERIMENTAL|Medisorb naltrexone 380 mg|
62184196|NCT00156923|EXPERIMENTAL|Medisorb naltrexone 190 mg|
62184197|NCT03102866|ACTIVE_COMPARATOR|Arm I (usual care)|Patients receive usual care for 6 weeks during radiation therapy and for 12 weeks after completion of radiation therapy.
62184198|NCT03102866|EXPERIMENTAL|Arm II (aerobic and strength training exercise)|Patients undergo a supervised aerobic and strength training exercise session over 40-60 minutes 3 times weekly for 6 weeks during radiation therapy and for 12 weeks after completion of radiation therapy.
62184199|NCT04587986|EXPERIMENTAL|Abdominal Toning and Reduction of Subcutaneous Fat|The treatment administration phase will consist of three (3) treatments, delivered once a week. The applicator of BTL-703 will be applied over the umbilicus. The active group will receive treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold. The device will induce visible muscle contractions along with heating of the subcutaneous fat.
62184200|NCT04587986|SHAM_COMPARATOR|Sham control|The treatment administration phase will also consist of three (3) treatments, delivered once a week. The sham group will receive a treatment with the intensities of the magnetic field and radiofrequency energy set to 5% of the maximum device output.
62184201|NCT02722655||Type 1 diabetes mellitus|Sudden onset of symptoms and non-overweight/obese
62184202|NCT02722655||Type 2 diabetes mellitus|Insidious onset of symptoms and overweight/obese
62791583|NCT01267305|ACTIVE_COMPARATOR|lung lmwh1|use LMWH once daily after lung resection
61998457|NCT02170584|ACTIVE_COMPARATOR|BIBR 1048 MS oral solution|
61998458|NCT02170584|EXPERIMENTAL|BIBR 1048 MS tablet|
61998459|NCT02170584|PLACEBO_COMPARATOR|BIBR 953 ZW IV Placebo|
61998460|NCT05961566|NO_INTERVENTION|Control|Individuals with no addition of intervention (collagen matrix) after harvesting from the palate for a subepithelial connective tissue graft.
61998461|NCT05961566|EXPERIMENTAL|Collagen Matrix|Individuals with the addition of the intervention (collagen matrix) after harvesting form the palate for a subepithelial connective tissue graft.
62392938|NCT03860870|EXPERIMENTAL|Clenbuterol|Subjects ingest 80 micrograms of clenbuterol tablets
62392939|NCT03860870|PLACEBO_COMPARATOR|Placebo|Subjects ingest placebo tablets
62392940|NCT01347359|EXPERIMENTAL|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, either face-to-face or by telephone.
62392941|NCT01347359|ACTIVE_COMPARATOR|Control - Standard of care|"Standard of care is at the discretion of the treating rheumatologist."
62392942|NCT04997512|NO_INTERVENTION|Standard of care|Participants are returned to the care of their usual diabetes care provider following randomisation. They will donate blood and urine samples as well as completing diabetes specific questionnaires at 0 and 6 months. They will also wear a blinded glucose sensor (freestyle Libre PRO) for a two week period at month 6.
62734579|NCT05068505|NO_INTERVENTION|Control|All clusters will be observed under both the intervention and control arm through sequential crossover.
62791584|NCT01267305|EXPERIMENTAL|lung lmwh2|use LMWH twice daily after lung resection
61998462|NCT02467101|EXPERIMENTAL|Corticosteroid/Saline|"Corticosteroid/Saline~Patients with diagnosis of frontal fibrosing alopecia are included in the study. The diagnosis is based on the clinical findings of frontal and temporoparietal hairline recession with loss of follicular ostia.~In the same patient, intralesional triamcinolone acetone will be injected to half-head (in the active border of hairline) and in the other half-head the patient will be injected with saline solution (placebo).~The intralesional triamcinolone acetone (40 mg/ml)l) of 0,1 mL/1cm, is given along the frontal and frontoparietal hairline every 4 weeks (3 sessions).~This study includes 4 visits: 3 visits of treatment (with 1-month interval) and 1 visit of follow-up (month 6)."
61998463|NCT03876730||Study group|3-18 aged children with cerebral palsy
62392943|NCT04997512|EXPERIMENTAL|Intervention arm|Participants will be randomised at baseline. They will provide blood and urine samples at months 0 and 6 as well as fill in diabetes specific questionnaires. They will receive education surrounding hypoglycaemia at baseline from a diabetes specialist nurse. They will wear a freestyle libre device which is changed every two weeks for a period of 6 months. At weeks 2,4,12 and 24 they will have their diabetes medication adjusted by the diabetes specialist nurse/diabetes doctor according to their blood glucose profiles, analysed from the data generated by freestyle libre.
62392944|NCT04210141|ACTIVE_COMPARATOR|Standard of care|Patients will receive an initial antivenom dose of 80mL lyophilized BPI viper antivenom, as per current national guidelines
62774162|NCT05979168|NO_INTERVENTION|Control arm|The control arm will receive the usual routine maintenance. In Nepal, hypertensive patients usually receive a prescription of antihypertensive medicine and advise for follow-up as the standard care. In addition, a pamphlet containing information about hypertension and required behavior modifications will be provided to all study participants, including the control arm.
62774163|NCT04293302||Brain abnormality|Newborn who had any gestational brain sonographic abnormality
62774164|NCT04293302||No brain abnormality|Newborn who did not have any gestational brain sonographic abnormality
62774165|NCT02789592|EXPERIMENTAL|Group 1|Phase 1: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
62774166|NCT02789592|EXPERIMENTAL|Group 2|Phase 1: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
62774167|NCT02789592|EXPERIMENTAL|Group 3|Phase 1: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks
62774168|NCT02789592|EXPERIMENTAL|Group 4|Phase 1: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks
61998464|NCT02393963|EXPERIMENTAL|Tranexamic Acid|Intra-articular administration of low dose Tranexamic acid
61998465|NCT02393963|PLACEBO_COMPARATOR|Placebo|Sodium Chloride
62020946|NCT03965052|ACTIVE_COMPARATOR|Travatan®|Dosage: 1 drop every 24 hours, at night, in both eyes.
62184203|NCT02722655||Type 1.5 diabetes mellitus|Overlap of type 1 and type2 diabetes mellitus clinical characteristics
62184204|NCT02722655||Other types of diabetes mellitus|According American Diabetes Association criteria
62392945|NCT04210141|EXPERIMENTAL|Adaptive arm|Patients will receive an initial dose of lyophilized BPI viper antivenom determined by the adaptive model.
62392946|NCT06254794|EXPERIMENTAL|Blood flow restriction group|The study group will undergo normal Achilles tendon rupture reconstruction rehab modified by use of a tourniquet for blood flow restriction during selected exercises.
62392947|NCT06254794|OTHER|Standard of Care (control) group|The control group will undergo the normal Achilles tendon rupture reconstruction rehab protocol as determined by Drs. Varner and McCulloch.
62392948|NCT02052180|EXPERIMENTAL|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
62774169|NCT02789592|EXPERIMENTAL|Group 5|Phase 1: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
62774170|NCT02789592|EXPERIMENTAL|Group 6|Phase 1: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
62392949|NCT02052180|ACTIVE_COMPARATOR|Control|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
62392950|NCT03846856||Ovarian cancer patients|Biopsy will be taken from ovarian cancer patients and sent to laboratory for analysis
62791585|NCT01267305|EXPERIMENTAL|lung Fondaparinux|use Fondaparinux once daily after lung resection
61998466|NCT03984695|NO_INTERVENTION|Control|"* 15 minute discharge planning session with health educator~* Health education booklet containing SHE-Women intervention content in print form(N\~100)~* access to health educator via text message"
62184205|NCT03247738|EXPERIMENTAL|Cangrelor|Cangrelor will be administered as 30 μg/kg bolus followed by 4 μg/kg/min infusion for 2 hours
62184206|NCT03247738|PLACEBO_COMPARATOR|Placebo|Normal saline bolus and infusion for 2 hours
62184207|NCT06366503|EXPERIMENTAL|Split-Face Application of Active (Experimental)|"Active (Experimental) Post-Procedure Cream~Dosage Form: reverse emulsion (water in oil) cream containing bioactive ingredients, botanical actives, peptides, and antioxidants.~Frequency of Dosage: Three times daily (morning, afternoon, and evening). Subjects were asked to apply face (including upper eyelid), jawline, and neck. The product was labelled with Right or Left depending on split-face randomization.~Study duration: 28 days. Active Post-Procedure Cream duration 14-days."
62184208|NCT06366503|ACTIVE_COMPARATOR|Split-Face Application of Comparator|"COMPARATOR:~Dosage Form: anhydrous formulation.~Comparator Anhydrous Formulation Frequency of Dosage: Three times daily (morning, afternoon, and evening). Subjects were asked to apply on the face (including upper eyelid), jawline, and neck. The product was labelled with Right or Left depending on split-face randomization.~Study duration: 28 days. Comparator duration 14-days."
62568470|NCT06230926||Parkinson's Disease Group|The study will be conducted in collaboration with Gazi University Faculty of Health Sciences and Niğde Ömer Halisdemir University. The study data will be obtained from individuals diagnosed with PD admitted to the Neurology Outpatient Clinic of Niğde Ömer Halisdemir University Training and Research Hospital. Necessary permissions were obtained from all institutions and questionnaire developers. Since at least 5-10 times the number of items in the questionnaire (7 items) must include at least 5-10 times the number of participants in order to perform factor analysis, a pretest of the questionnaire will be applied to individuals with PD with at least 35-70 participants.
62020947|NCT00423436|EXPERIMENTAL|IVR Assessment Plus Triage|Interactive Voice Response Telephone System (IVR) Plus Triage (Participants report symptoms to telephone system and doctor/nurse notified when symptom is severe) + Questionnaire
62020948|NCT00423436|EXPERIMENTAL|IVR Assessment Only|IVR (Phone calls twice weekly) + Questionnaire
61998467|NCT03984695|EXPERIMENTAL|Intervention|"Deliver text-Web intervention to (N \~100) women~Researchers will deliver the integrated, multimedia electronic women's health literacy intervention arm of SHEWomen in text-Web format for individuals recently released from jail. Two health educators will be responsible for delivering content to participants, with an estimated contact time of \~10 hours pushed to participants over approximately a 5-day period."
62184209|NCT05203809||Observation group|Group of participants wearing continuous temperature monitoring device
62184210|NCT02983877|EXPERIMENTAL|iTAB-CV|"In the Individualized Texting for Adherence Building-CV (iTAB-CV) Stage 1, participants will receive alternating daily texts with educational and motivational content on treatment for high blood pressure and bipolar disorder, and a daily mood rating request to both monitor their mood and to determine adherence to iTAB-CV intervention. Stage 1 will last one month.~In the Individualized Texting for Adherence Building-CV (iTAB-CV) Stage 2, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from Stage 1. Stage 2 will last one month."
62184211|NCT01494545|EXPERIMENTAL|Delefilcon A|Delefilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for two weeks. A new pair was inserted each day.
62184212|NCT00458393|EXPERIMENTAL|TDF/FTC|Drug. Daily oral tablet of co-formulated 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate (TDF/FTC).
62774171|NCT04855383|EXPERIMENTAL|The group of frozen embryo transfer with intramuscular injection of human chorionic gonadotropin.|In this group, endometrial preparation for embryo transfer will be through the standard protocol using a gonadotropin-releasing hormone agonist. Patients receive 5,000 IU of human chorionic gonadotropin by intramuscular injection, 72 hours before embryo transfer, on the day of embryo transfer, and 72 hours after embryo transfer.
62184213|NCT00458393|PLACEBO_COMPARATOR|Placebo|Drug. Daily oral placebo
62184214|NCT05932706|ACTIVE_COMPARATOR|real stimulation|The central electrode was placed over F3, with return electrodes at Fp1, Fz, F7 and C3. Fourteen 2-mA sessions (ramp-up and ramp-down periods of 15 and 15 seconds, respectively) were applied for 30 minutes per session, twice daily over 7 consecutive days, and the stimulus frequency was set as IAF.
62184215|NCT05932706|SHAM_COMPARATOR|sham stimulation|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15 and 15 s); no current was delivered during the 30-minute intervention. Participants will receive sham tACS twice daily for two weeks.
61998468|NCT04441333|EXPERIMENTAL|AspivixTM cervical vacuum tenaculum|Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum.
61998469|NCT02146482|NO_INTERVENTION|Control|Did not receive an intervention during the active portion of the study (i.e. 12 weeks). After the active portion of the study, this group was given a sit-stand computer workstation.
61998470|NCT02146482|EXPERIMENTAL|Sit-stand computer workstation|Given a sit-stand computer workstation to use at their place of work
61998471|NCT00855309|EXPERIMENTAL|Arm I|Patients receive weight-based IV acyclovir sodium every 8 or 12 hours.
62184216|NCT03484299|OTHER|Treatment|Irreversible electroporation and treatment with either FOLFIRINOX or Gemcitabine (based upon which chemotherapy regimen received prior to IRE)
62568471|NCT05565118|EXPERIMENTAL|Standard Surgical Treatment + Intraoperative Electrocorticography|Each participant will undergo intraoperative electrocorticography (ECOG) through subdural grid (SDG) and depth electrode (DE) via FDA-cleared, standardized, brain recording technology. During this surgery, participants will also undergo a tissue biopsy at recording sites for correlation to neural recording data.
62568472|NCT03335475|ACTIVE_COMPARATOR|Fitbit Only|In the Fitbit Only arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, and a Fitbit. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
62568473|NCT03335475|EXPERIMENTAL|Fitbit + Coaching Sessions|In the Fitbit + Coaching Sessions arm, participant will receive their exercise prescription, as devised from their baseline exercise stress test results, a Fitbit, and will have 8 sessions with a coach (interventionist) over the course of 20 weeks. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
62568474|NCT01999556||Patient|Specimen Collection
62568475|NCT01999556||Relative|Specimen Collection
62568476|NCT03187730|ACTIVE_COMPARATOR|Intervention Arm|
62568477|NCT03187730|PLACEBO_COMPARATOR|Waitlist Control|
62184217|NCT01657877|EXPERIMENTAL|CSP/SMFP Dentifrice|Dentifrice containing high fluoride content as SMFP and CSP
62184218|NCT01657877|ACTIVE_COMPARATOR|SMFP Dentifrice Prototype 1|Dentifrice containing high fluoride content as SMFP and no CSP
62184219|NCT01657877|ACTIVE_COMPARATOR|SMFP Dentifrice Prototype 2|Dentifrice containing low fluoride content as SMFP and no CSP
62184220|NCT01657877|ACTIVE_COMPARATOR|CSP Dentifrice|Dentifrice containing CSP but no fluoride
62184221|NCT01657877|PLACEBO_COMPARATOR|Placebo Dentifrice|Dentifrice containing no CSP and no fluoride
62184222|NCT03758794|ACTIVE_COMPARATOR|interactive lecture module|interactive lecture
62568478|NCT02742493|EXPERIMENTAL|0.028 bonded to canines|lower fixed canine and canine retainer and upper removable Hawley (Intervention A)
62568479|NCT02742493|EXPERIMENTAL|0.027 7-strand bonded to all 6|lower fixed canine to canine retainer and upper removable Hawley (Intervention B)
62568480|NCT02742493|ACTIVE_COMPARATOR|removable Hawley-type|lower hawley-type and upper hawley removable retainer (Control)
62568481|NCT03489668|ACTIVE_COMPARATOR|PCOS|Metformin administration 1500mg/day
62568482|NCT03489668|NO_INTERVENTION|Control|
62774172|NCT04855383|NO_INTERVENTION|The group of frozen embryo transfer without intramuscular injection of human chorionic gonadotropin.|In this group, endometrial preparation for embryo transfer will be through the standard protocol using a gonadotropin-releasing hormone agonist. Embryo transfer will be done without human chorionic gonadotropin intramuscular injection.
62568483|NCT02746965|EXPERIMENTAL|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
61998472|NCT00855309|EXPERIMENTAL|Arm II|Patients receive low-dose IV acyclovir sodium every 8 or 12 hours.
62184223|NCT03758794|ACTIVE_COMPARATOR|online educational module|online educational using a special link
62184224|NCT05248698|EXPERIMENTAL|group 1|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, plus Mediterranean Diet for 6 months
62392951|NCT02874755|EXPERIMENTAL|Tuberculosis Program (PPIA)|Half of the 300 participants were randomly selected to be sensitized and engaged into the program, and subsequently to receive the benefits of the PPIA intervention. Providers in the PPIA arm if networked into the program will receive the benefits of the program, including but not limited to: ability to provide presumptive TB patients and TB cases vouchers for free and/or subsidized diagnostic testing and referrals to providers for free first line anti-TB treatment (TB cases only); reimbursements for subsidized tests; training opportunities, and access to a referral network.
62392952|NCT02874755|NO_INTERVENTION|No Tuberculosis Program (Non-PPIA)|The remaining half of the sample in Mumbai selected randomly will be phased into the program at least a year after the PPIA arm. However, during the year of the study, they will not be networked into the program.
62392953|NCT00584428|EXPERIMENTAL|1|
62392954|NCT00440362|ACTIVE_COMPARATOR|T1|
61998473|NCT06267235|EXPERIMENTAL|Acute meal test|acute intake of a low protein, high carbohydrate diet. No drug intervention
61998474|NCT06267235|EXPERIMENTAL|Chronic low protein, high carbohydrate diet|Low protein, high carbohydrate diet and habitual diet. No drug intervention
62568484|NCT02746965|ACTIVE_COMPARATOR|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
62568485|NCT05894005|ACTIVE_COMPARATOR|Group A|"VR - Route 1: Students will be first taken to the anesthesia lounge. Here the students will receive VR instructions on how to navigate Route 1 (i.e. they will watch a 360-degree immersive video using Oculus VR headset). Then the students will be assessed with an observed walkthrough of Route 1.~Traditional - Route 2: After completing the Route 1 walkthrough, the same group will be given traditional instructions (2D video) on navigating Route 2, followed by an observed walkthrough of Route 2."
62568486|NCT05894005|ACTIVE_COMPARATOR|Group B|"Traditional - Route 1: Students will be first taken to the anesthesia lounge. Here the students will receive traditional instructions (2D video) on how to navigate Route 1. Then the students will be assessed with an observed walkthrough of Route 1.~VR - Route 2: After completing the Route 1 walkthrough, the same group will be given VR instructions on how to navigate Route 2, followed by an observed walkthrough of Route 2."
62774173|NCT00892138|EXPERIMENTAL|Mindfulness training|Mindfulness training
61998475|NCT06267235|EXPERIMENTAL|Low protein , high fat diet|Low protein, high fat diet and habitual diet. No drug intervention
61998476|NCT03395366|ACTIVE_COMPARATOR|Group 1|Multifaceted Educational / Cognitive Behavioral Intervention
61998477|NCT03395366|NO_INTERVENTION|Group 2|Standard of Care + Dialysis Education without the Cognitive Behavioral component
61998478|NCT04725435|EXPERIMENTAL|Kangaroo care|"No Intervention: Standard care The control group will be followed by infants using nesting in the incubator. It will be followed for 60 minutes without any action or application.~Experimental: Kangaroo care The mother kangaroo will care for at least 60 minutes."
61998479|NCT04725435|EXPERIMENTAL|Facilitated tucking position|"No Intervention: Standard care In the Control Group, the heel stick procedure will be performed in the infants own bed as in the clinical routine.~Experimental 1: Manual Facilitated Tucking Position, infants will be given a manual facilitated tucking position during the heel stick procedure.~Experimental 2: Facilitated Tucking Position, with the Nesting Bed (Tortoise Neo Bed), the facilitated tucking position will be given by the clinic nurse with the nesting bed during the heel stick collection procedure."
61998480|NCT01076985||Lopinavir/ritonavir group|All pregnant women in this noninterventional, post-marketing observational study, who were prescribed lopinavir/ritonavir (Kaletra) in accordance with the local Prescribing Information for the treatment of HIV infection.
62184225|NCT05248698|ACTIVE_COMPARATOR|group 2|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, for 6 months
62392955|NCT00440362|ACTIVE_COMPARATOR|T2|
62392956|NCT00440362|ACTIVE_COMPARATOR|T3|
62568487|NCT04432610|EXPERIMENTAL|Bisoprolol first, Nebivolol Second|In this arm, patient will first receive bisoprolol, and after 1 week washout period, nebivolol
62184226|NCT01963715|EXPERIMENTAL|EGFR+ Solid Tumor|EGFR+ Solid Tumor
62184227|NCT03420898||1|General Medicine in Hospital Unit 70 Bed. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
62184228|NCT03420898||2|General Medicine in Hospital 38 Bed Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
62184229|NCT03420898||3|Cardiovascular Surgery in Hospital Unit 36 bed. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
62184230|NCT03420898||4|General Surgery in Hospital 24 bed Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
62184231|NCT03420898||5|Cardiac 36-bed in Hospital Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
62568488|NCT04432610|EXPERIMENTAL|Nebivolol first, Bisoprolol second|In this arm, patient will first receive nebivolol, and after 1 week washout period, bisoprolol
62734580|NCT03873298|EXPERIMENTAL|COPD|Each participant will undergo two six minute walk tests and the results will be compared within each subject.
62392957|NCT00440362|ACTIVE_COMPARATOR|T4|
62392958|NCT00440362|ACTIVE_COMPARATOR|T5|
62392959|NCT00440362|ACTIVE_COMPARATOR|T6|
62568489|NCT03308097|EXPERIMENTAL|PrEP Mobile Messaging Intervention|Participants from the STI/HIV testing clinic will receive Enhanced Standard of Care (described below) plus texted messages with the intervention content and follow-up questions over the next 4 weeks on their cell phones. Participants will receive approximately 8-16 interactive text messages with links to web content. Texts will be sent twice a week over the next 4 weeks. Participants will return for 2 more appointments over the next couple of months to fill out questionnaires.
62734581|NCT03873298|EXPERIMENTAL|IPF|Each participant will undergo two six minute walk tests and the results will be compared within each subject.
62020949|NCT01853449|EXPERIMENTAL|CWS+Fentanyl Citrate (250 mcg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
62392960|NCT00440362|ACTIVE_COMPARATOR|T7|
62392961|NCT00440362|ACTIVE_COMPARATOR|T8|
62392962|NCT00440362|PLACEBO_COMPARATOR|C1|
62392963|NCT00440362|PLACEBO_COMPARATOR|C2|
62392964|NCT00440362|PLACEBO_COMPARATOR|C3|
62392965|NCT00440362|PLACEBO_COMPARATOR|C4|
62392966|NCT01432470|EXPERIMENTAL|Oxytocin, Intravaginal administration|
62392967|NCT01432470|PLACEBO_COMPARATOR|Placebo, Intravaginal administration|
62392968|NCT04369443|NO_INTERVENTION|MANH|
62392969|NCT04369443|EXPERIMENTAL|LANH|
62392970|NCT03573921|EXPERIMENTAL|Gastrografin Arm|Patients will receive a single dose of undiluted Gastrografin via the nasogastric tube at 24 hours after admission for small bowel obstruction. The dose of Gastrografin will be proportional to the patient's weight and age and will be based off of the recommendations from the drug manufacturer. Dosages will range from 30 ml for infants to children less than 5 years old and 60 ml for children 5-18 years and will not be diluted.
61998481|NCT01482767|EXPERIMENTAL|HCV Treatment-Naive (Group A)|Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV). Among non-cirrhotics, the Week 8 HCV RNA was used to determine total duration of therapy. Those who had undetectable HCV RNA at Week 8 completed therapy at Week 28. Those with detectable HCV RNA at Week 8 received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
62774174|NCT00892138|NO_INTERVENTION|Control|Study program as usual
61998482|NCT01482767|EXPERIMENTAL|HCV Treatment-Experienced (Group B)|Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV), and non-cirrhotics received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
61998483|NCT05111366|EXPERIMENTAL|TQB2450 injection combined with Anlotinib hydrochloride capsules|
62184232|NCT03420898||6|General Medicine 26 Bed in Hospital Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
62392971|NCT03573921|EXPERIMENTAL|Control Arm|Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after admission for small bowel obstruction. The volume of saline solution will be proportional to the volume of Gastrografin patients of similar weight and age would receive.
61998484|NCT03996200|EXPERIMENTAL|MINIject CS627 implant|MINIject 627 implant is used to reduce intra-ocular pressure in the eye. It is implanted through a minimally-invasive glaucoma surgical intervention in a stand alone procedure.
61998485|NCT02353767||Cases|Presence of metabolic syndrome according to the International Diabetes Foundation (IDF)
61998486|NCT02353767||Controls|"* age ± 7 years from cases~* duration of HIV-1 infection ± 3 years from cases~* HIV-1 viral load matched to cases according to 3 thresholds: 50 - 500, 501 - 1000 or \> 1000 copies/mL"
61998487|NCT04213898|EXPERIMENTAL|SHR-1210+Albumin-bound paclitaxel+Epirubicin|Neoadjuvant therapy：SHR-1210+Albumin-bound paclitaxel+Epirubicin
62392972|NCT05852002|EXPERIMENTAL|35 kDa hyaluronan fragment injection|35kDa hyaluronan fragment was produced by using hyaluronidase PH20 to cleave 1600kDa hyaluronan ( HA1600 ). Batch number of 35 kDa hyaluronan fragment injection is L20200708MP07707,and the injection was approved by Ministry of Health, Mongolia.
62734582|NCT03504488|EXPERIMENTAL|Monotherapy - CAB-ROR2-ADC (BA3021) alone|BA3021 alone Q2W dosing regimen
62734583|NCT03504488|EXPERIMENTAL|Combination Therapy|CAB-ROR2-ADC (BA3021) with PD-1 inhibitor
61998488|NCT01909661|EXPERIMENTAL|Damira/Celia peptide hydrolyzed casein|Extensively Hydrolyzed (EH)casein infant formula
61998489|NCT01909661|EXPERIMENTAL|Picot riz/Celia rice/Sanutri arroz|Picot riz/Celia rice/Sanutri arroz Extensively Hydrolyzed (EH) rice protein infant formula
61998490|NCT01110421|EXPERIMENTAL|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose) will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
61998491|NCT01110421|EXPERIMENTAL|Cefepime|Cefepime 50 mg/kg per dose (up to 2 g/dose) will be administered every 8 hours as 30-minutes IV (at least 3 days of IV cefepime only or IV cefipime followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
61998492|NCT03844126|EXPERIMENTAL|Patients attending the classes|The patients attending the transition classes will receive a survey to assess transition preparedness before and after attending the class.
62392973|NCT00749866|ACTIVE_COMPARATOR|1|Nebulised Gentamicin
62392974|NCT00749866|PLACEBO_COMPARATOR|2|Nebulised 0.9% Saline
62392975|NCT04033718|EXPERIMENTAL|Inpatient lab bundling plus navigation|Testing for CD4 count, tuberculosis, cryptococcus, and HIV RNA with samples collected in a bundle-type approach. Additional inpatient support from a patient navigator
62392976|NCT04033718|EXPERIMENTAL|Inpatient lab bundling alone|Testing for CD4 count, tuberculosis, cryptococcus, and HIV RNA with samples collected in a bundle-type approach.
62734584|NCT06521827|EXPERIMENTAL|short course radiotherapy|patients with metastatic rectal cancer will receive short course of radiotherapy befor staring chemotherapy
62774175|NCT04556422|ACTIVE_COMPARATOR|Sauna alone|Sauna exposure for 30 minutes
62774176|NCT04556422|EXPERIMENTAL|Exercise and Sauna|Cycling exercise for 15 minutes followed by sauna for 15 minutes
62774177|NCT01825941|ACTIVE_COMPARATOR|Metoclopramide + Diphenhydramine|Metoclopramide 10 milligrams + Diphenhydramine 50 milligrams, administered as an intravenous drip over 15 minutes
62774178|NCT01825941|PLACEBO_COMPARATOR|Metoclopramide + placebo|Metoclopramide 10mg + placebo, administered intravenously over 15 minutes
62735133|NCT05527782|EXPERIMENTAL|induction mTPF|"1. 4 CYCLES OF INDUCTION mTPF: Docetaxel 40 mg/m2 iv day 1, Cisplatin 40 mg/m2 iv day 1, Leucovorin 400 mg/m2 iv followed by Fluorouracil (5FU) bolus 400 mg/m2 iv day 1, 5FU 1000 mg/m2 iv day 1-2, q2w. Primary neutropenic fever prophylaxis with GCSFs x 3 days~2. CONCURRENT CHEMORADIOTHERAPY WITH 2 CYCLES OF CISPLATIN 100mg/m2 iv q3w"
62774179|NCT00867906|OTHER|Cohort 1|Asthmatics using salbutamol only, subjects to receive either Cat-PAD or placebo comparator
62774180|NCT00867906|OTHER|Cohort 2|Asthmatics using inhaled corticosteroid, subjects to receive either Cat-PAD or placebo comparator
62774181|NCT00867906|OTHER|Cohort 3|Asthmatics using inhaled corticosteroid and LABA, subjects to receive either Cat-PAD or placebo comparator
62774182|NCT04857411|EXPERIMENTAL|Participant 'Buddies'|Participants will have an 8-week program initiation phase followed by a maintenance phase through 6-months, supported by Ambassadors.
62774183|NCT03139617|ACTIVE_COMPARATOR|Fascia Iliaca Compartment Block (FICB)|fascia iliaca compartment block is done using a blind technique with a blunt size 24 Gauge (G) needle. The technique is based upon the anatomical landmark and once located the space local anaesthetic ropivacaine 0.375% will be given based on the body weight.
62774184|NCT03139617|EXPERIMENTAL|3 in 1 femoral block (FNB)|Ultrasound guided femoral 3 in 1 block using insulated stimulating needle 22 Gauge (G). Ropivacaine 0.375% as per ideal body weight.
62774185|NCT00256516|EXPERIMENTAL|Eco-Atkins diet|
62774186|NCT00256516|ACTIVE_COMPARATOR|NCEP diet|
62774187|NCT03323866|ACTIVE_COMPARATOR|Mometasone nasal spray|Mometasone nasal spray 50 mcg/dose, 2 sprays/nostril twice daily x 3 months Patients will also be taking Sinus Rinse once daily throughout the study period
61998493|NCT05411822|EXPERIMENTAL|Lighting Intervention Blue|Blue light (λmax = 451 nm) on and off axis
62774188|NCT03323866|EXPERIMENTAL|Budesonide irrigation|2 cc budesonide nebule (0,5 mg/cc) incorporated to 240 of saline water (Sinus Rinse) to be taken on a daily basis x 3 months
62774189|NCT06338202||Patients treated with mavacamten|Patients with symptomatic obstructive hypertrophic cardiomyopathy (NYHA functional class II-III) who receive mavacamten as part of routine clinical care
62774190|NCT05633966|EXPERIMENTAL|Kisspeptin pump|SC administration of kisspeptin for two weeks (pulsatile)
62774191|NCT05273541|EXPERIMENTAL|Prime-boost vaccination|Patients in the experimental group need to accept the prime-boost vaccination regimen
62774192|NCT01897090|EXPERIMENTAL|Elimination Diet|"thirty (30) patients will be on the Crohn's Disease Diet (primarily an anti-inflammatory diet that is an elimination diet - gluten-free, casein-free based with limited carbohydrate)"
62774193|NCT01897090|ACTIVE_COMPARATOR|Dietary Guidelines for Americans|The DASH eating plan is based on 1,600, 2,000, 2,600 and 3,100 calories.
62774194|NCT05950620||Intervention|Pediatric patients with obesity or in need of weight management for unwanted weight gain.
62774195|NCT05950620||Controls|Historic controls matched to the Intervention group on age, sex, and BMI percentile.
62774196|NCT04365933|EXPERIMENTAL|Arm 1|EYP001a Dose A QD + ETV 0.5 mg QD + peg-IFN dosed per body surface area (180 µg, 135 µg or 90 µg) QW
62568490|NCT03308097|ACTIVE_COMPARATOR|Enhanced Standard of Care|As part of the enhanced standard of care, participants seen in the STI/HIV testing clinic are given feedback regarding PrEP eligibility and current risk behaviors. Participants are also given an informational handout about PrEP, shown a brief video, and given contact information for the PrEP Clinic Care Coordinator. Participants will return for 2 more visits over the next couple months to fill out questionnaires.
62774197|NCT04365933|EXPERIMENTAL|Arm 2|EYP001a Dose A QD + peg-IFN dosed per body surface area (180 µg, 135 µg or 90 µg) QW
62774198|NCT01295424||Single group study|
62774199|NCT05231707|EXPERIMENTAL|Intervention|For couples who are prevalent sero-discordant, this will be a CHTC session. For couples who are prevalent concordant HIV-positive, the first visit will be the first Partner Steps session. For couples in which one or both do not know their sero-status or have not tested for HIV in the past 12 months, the first session will be a CHTC session.
61998494|NCT05411822|EXPERIMENTAL|Lighting Intervention Green|Green light (λmax = 522 nm) on and off axis
61998495|NCT06382233||Babies with unilateral UPJO|Children aged 0-5 years with unilateral UPJO. Unilateral UPJO will be defined as an hydronephrosis needing of surgical correction on the basis of at least 2 of the following criteria: APDP ≥ 30 mm, SRF less than 40% at the Mag3S, SRF with delta \> 10% at follow-up Mag3S compared with the first Mag3S, delayed wash-out following diuretic administration, progressive increase of the APDP at follow-up kidney ultrasounds, 4th degree hydronephrosis.
61998496|NCT06382233||Controls of babies with unilateral UPJO|Children aged 0-5 years needing of surgical correction for hernia, hydrocele, phimosis or cryptorchidism.
61998497|NCT00009919|EXPERIMENTAL|Treatment (semaxanib)|Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues every 6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with CR receive an additional 6 months of therapy after achieving CR.
61998498|NCT01234545||A|
62020950|NCT01853449|PLACEBO_COMPARATOR|CWS+0.9% saline placebo|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
62184233|NCT04031573|EXPERIMENTAL|Ivabradine (Low)|
62184234|NCT04031573|EXPERIMENTAL|Ivabradine (High)|
62774200|NCT05231707|ACTIVE_COMPARATOR|Attention Matched Control|Participants in the control group will receive an intervention, with the same number of sessions as couples of the same sero-status in the intervention condition, delivered via one-on-one couples counseling sessions (i.e., one couple with one counselor).
62774201|NCT05546671||Strong grippers|
62774202|NCT05546671||Weak grippers|
62774203|NCT06465745|EXPERIMENTAL|Primary Cohort|Designed to evaluate the safety and performance of the AltaValve System for the treatment of moderate-to-severe or severe MR in a targeted patient population without at least moderate mitral annular calcification (MAC).
62774204|NCT06465745|EXPERIMENTAL|Mitral Annular Calcification Cohort (MAC)|Designed to evaluate the safety and performance of the AltaValve System for the treatment of moderate-to-severe or severe MR in a targeted patient population with moderate to severe MAC.
62791586|NCT01267305|ACTIVE_COMPARATOR|eso lmwh1|use LMWH once daily after esophagectomy
62392977|NCT03606265|EXPERIMENTAL|App+Web|Treatment as usual + app Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
62392978|NCT03606265|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual (waiting list) Patients at this condition will receive the usual medical treatment at the pain unit, but they will not be monitored daily using the app.
62392979|NCT02487524|OTHER|Nerve resection with pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
62392980|NCT02487524|OTHER|Nerve resection without pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
62392981|NCT02487524|OTHER|No nerve resection but pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
62392982|NCT02503956|EXPERIMENTAL|Treated group|Patients treated with perforated punctal plugs
61998499|NCT04985851|EXPERIMENTAL|maintenance treatment durvalumab + anlotinib|"Durvalumab 1500 mg monotherapy will be continued q4w. Anlotinib will be administered according to prescribing information in general use. The dose is 12mg, QD, PO, 14 days-on and 7 days-off.~* N.B. If a patient's weight falls to 30 kg or below (≤30 kg) the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab until the weight improves to \>30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500 mg.~* Anlotinib is available at three dose levels, 12 mg, 10 mg, and 8 mg. Dose reduction may take place whenever toxicity that is not controlled with optimal supportive care is noted during the study. If a subject subsequently tolerates treatment well at that level in the judgment of the investigator, the dose may be increased to the next dose level. If a subject cannot tolerate treatment after dose reduction to 8 mg, treatment will be discontinued"
61998500|NCT04985851|ACTIVE_COMPARATOR|maintenance treatment durvalumab|Durvalumab 1500 mg monotherapy will be continued q4w.
61998501|NCT01332942|PLACEBO_COMPARATOR|Placebo|
61998502|NCT01332942|EXPERIMENTAL|Molidustat (BAY85-3934) 5 mg|
62392983|NCT02503956|ACTIVE_COMPARATOR|Comparison group|Comparison group treated with standard of care - Lacrimal intubation with Crawford lacrimal tube
62392984|NCT06177925|EXPERIMENTAL|Treatment (Adebrelimab, chemotherapy, radiation therapy)|Participants will receive Adebrelimab intravenously in combination with carboplatin /Cisplatin and etoposide during the induction phase (2 Cycles ). Thereafter, participants will receive concurrent chemoradiotherapy(thoracic radiation therapy and SBRT for metastases,combination with carboplatin /Cisplatin and etoposide for 1-2 Cycles).Then participants will receive Adebrelimab combination with carboplatin /Cisplatin and etoposide for 1-2 Cycles,followed by Adebrelimab maintenance until persistent radiographic PD, intolerable toxicity or withdrawal of consent during the maintenance phase.
62392985|NCT01189201|EXPERIMENTAL|BI 10773/linagliptin FDC SID|medium single dose ofBI 10773/linagliptin FDC (Formulation A1)
62392986|NCT01189201|EXPERIMENTAL|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
62392987|NCT01189201|EXPERIMENTAL|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
62392988|NCT01189201|EXPERIMENTAL|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
62392989|NCT00573352|OTHER|1|Far infrared radiation
62392990|NCT05210959||Preterm or term born infants|Premature or term born infants between the aged 3-18 months were recruited in this study.
62392991|NCT00697242|EXPERIMENTAL|Group A|
62392992|NCT00697242|EXPERIMENTAL|Group B|
62392993|NCT00697242|EXPERIMENTAL|Group C|
62392994|NCT00697242|ACTIVE_COMPARATOR|Group D|
62392995|NCT00697242|EXPERIMENTAL|Group E|
62392996|NCT04337463|EXPERIMENTAL|ATG-008 and Toripalimab|Toripalimab will be combined with ATG-008.
62392997|NCT05577572|EXPERIMENTAL|Probiotics packets|Probiotics contains 450 billion colony-forming units per packet. The compositions are maltose, lactic acid bacteria and bifidobacteria blend, cornstarch, silicon dioxide.
62392998|NCT05577572|PLACEBO_COMPARATOR|Placebo packets|The compositions are maltodextrin, silicon dioxide, sucralose
62392999|NCT05941494|EXPERIMENTAL|Propofol-based anesthetic maintenance with phenylephrine used as the vasopressor|Propofol-based anesthetic maintenance with phenylephrine used as the vasopressor. Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min. Patient will receive phenylephrine infusion as the primary vasopressor of choice. The typical dose of phenylephrine infusion is 10-40 mcg/min (dilution 100 mcg/ml).
62393000|NCT05941494|EXPERIMENTAL|Propofol-based anesthetic maintenance with ephedrine used as the vasopressor|Propofol-based anesthetic maintenance with ephedrine used as the vasopressor. Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min. The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).
62393001|NCT05941494|EXPERIMENTAL|Sevoflurane-based anesthetic maintenance with phenylephrine used as the vasopressor|"Sevoflurane-based anesthetic maintenance with phenylephrine used as the vasopressor.~Patient's anesthesia will be maintained with 1 MAC of sevoflurane during surgery. Patient will receive phenylephrine infusion as the primary vasopressor of choice. The typical dose of phenylephrine infusion is 10-40 mcg/min (dilution 100 mcg/ml)."
62735134|NCT00656058|EXPERIMENTAL|Montelukast to Treat Bronchiolitis Obliterans|Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.
62774205|NCT04476875|ACTIVE_COMPARATOR|Open outpatient clinic programme (OOCP)|OOCP patients had no scheduled appointments but were allowed acute appointments with their rheumatologist, and had access to nurse-led consultations and telephone helpline.
61998503|NCT01332942|EXPERIMENTAL|Molidustat (BAY85-3934) 10 mg|
61998504|NCT01332942|EXPERIMENTAL|Molidustat (BAY85-3934) 25 mg|
61998505|NCT01332942|EXPERIMENTAL|Molidustat (BAY85-3934) 50 mg|
61998506|NCT01332942|EXPERIMENTAL|Molidustat (BAY85-3934) 75 mg|
61998507|NCT00364780|EXPERIMENTAL|1|Patients received XL647 at an intermittent dosing schedule receiving drug for 5 days followed by 9 days without drug.
61998508|NCT00364780|EXPERIMENTAL|2|Patients received drug at a daily dosing schedule
61998509|NCT01638962|EXPERIMENTAL|NEMEX|NEuroMuscular EXercise
61998510|NCT01638962|ACTIVE_COMPARATOR|PHARMA|PHARMAcological pain relief
61998511|NCT00526058|OTHER|A (Secura then Futura)|The Group Randomized first to the approved Plasmat® Secura apheresis system and then to the Plasmat® Futura apheresis system.
62774206|NCT04476875|NO_INTERVENTION|Traditional scheduled routine follow up (TSRF)|Appointments for the TSRF group were scheduled according to routine procedures.
61998512|NCT00526058|OTHER|B (Futura then Secura)|The Group Randomized first to the approved Plasmat® Futura apheresis system and then to the Plasmat® Secura apheresis system.
62568491|NCT03025529|EXPERIMENTAL|Active Cerebellar rTMS|Cerebellar rTMS will be carried out in ET subjects using a MagPro stimulator with a double cone coil at 1Hz (1 pulse every second) for 3 minutes on the left and 3 minutes on the right, at the cerebellar location indicated by resting state functional connectivity MRI analysis. Subjects with ET will undergo 5 consecutive daily sessions of cerebellar rTMS at either the connectivity map generated target or sham rTMS and then crossover to the other target after 2 weeks. Subjects will be blinded to the treatment order assignment. The intensity of the stimulation will be determined as 90% of the resting motor threshold, to be determined at the beginning of the first visit.
61998513|NCT03388190|ACTIVE_COMPARATOR|Control Arm|The control arm will consist of intermittent treatment with the Nordic FLOX regimen in terms of 8 cycles before break until disease progression, when therapy is reintroduced and administered for another 8 cycles before a new break. This schedule will be continued until progressive disease on ongoing therapy (PFS), intolerable toxicity, withdrawal of consent, or death, whichever occurs first.
61998514|NCT03388190|EXPERIMENTAL|Experimental Arm|The experimental arm will consist of repeat 2 cycles of the Nordic FLOX regimen followed by 2 cycles of nivolumab for a total of 8 individual cycles before break until disease progression, when therapy is reintroduced and administered for another total of 8 individual cycles before a new break. This schedule will be continued until progressive disease on ongoing therapy (PFS), intolerable toxicity, withdrawal of consent, or death, whichever occurs first.
61998515|NCT02815748|OTHER|SP2086|SP2086 was taken only one time at 100mg dose in health volunteers
61998516|NCT04246385|EXPERIMENTAL|Allocated to intervention|Participants will participate in a one on one session to complete their COPM and set their goal for the group. Participants will participate in 6 group sessions focusing on the CO-OP approach.
61998517|NCT04246385|NO_INTERVENTION|Allocated to control|"The control group will receive usual care occupational therapy including a mix of individual sessions and occupational therapy groups that do not include the CO-OP group."
61998518|NCT06469255|EXPERIMENTAL|Ketogenic Diet Intervention|4 weeks low calorie Ketogenic Diet intervention
62774207|NCT02880917|ACTIVE_COMPARATOR|Cognitive training + tDCs-Active|tDCs active left dorsolateral prefrontal cortex (2mA,20 min) and Cognitive training (20min) at the same time.
62774208|NCT02880917|SHAM_COMPARATOR|Cognitive training+ tDCs-Sham|tDCs Sham dorsolateral prefrontal cortex ((2mA,20 min) and Cognitive training (20min) at the same time.
62774209|NCT03881904|ACTIVE_COMPARATOR|OCP Group|This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will receive 0.075mg gestodene/0.03mg ethinylestradiol (Gynera®, Bayer Schering Pharma AG, Germany) from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.
61998519|NCT00679575||1|Cases : Patients with a first myocardial infarction
61998520|NCT00679575||2|Referents : Patients recruited by a GP during a routine consultation
61998521|NCT03898765|EXPERIMENTAL|Experimental：Dry blood spot screening|
61998522|NCT00397982|EXPERIMENTAL|Treatment (enzyme inhibitor, monoclonal antibody)|Patients receive temsirolimus IV over 30 minutes on days 1 and 8 and bevacizumab IV over 30-90 minutes on day 8. Treatment repeats every 14 days for a maximum of 26 courses in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection on day 9 of course 2.
61998523|NCT05492396||Standard gluteus medius repair|Subjects will all undergo standard gluteus medius repair that includes augmentation with the biointegrative implant.
61998524|NCT01504321|ACTIVE_COMPARATOR|Active|
61998525|NCT01504321|PLACEBO_COMPARATOR|Placebo|
61998526|NCT03377777||Infants|Outwardly healthy male and female infants at 6-7 months or 12-13 months. No intervention.
61998527|NCT01552772|EXPERIMENTAL|Aripiprazole IM Depot|
62184235|NCT04031573|PLACEBO_COMPARATOR|Control|
62568492|NCT03025529|SHAM_COMPARATOR|Sham Cerebellar rTMS|In sham rTMS, the same parameters and procedures as Treatment Procedures 4-8 will be used, except that the coil will be angled 90 degrees from the scalp, resting on one wing of the coil.
62735135|NCT01557101|OTHER|COLON CAPSULE ENDOSCOPY|
62735136|NCT01557101|OTHER|OPTICAL COLONOSCOPY|
61998528|NCT06406738|EXPERIMENTAL|High Reality Simulator|Newborn first-care training will be given by the responsible investigator, and then one of the groups will be allocated by randomization. Using High Reality Simulator will perform Newborn first-care. These trainings will first be in the form of the instructor responsible for the groups demonstrating the application, and then the students will apply it one by one.
61998529|NCT06406738|NO_INTERVENTION|control group|Using model will perform Newborn first-care. These trainings will first be in the form of the instructor responsible for the groups demonstrating the application, and then the students will apply it one by one.
61998530|NCT04270981|EXPERIMENTAL|[14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250|single administration of 960 mg (4 × 240 mg capsules) acoziborole in oral and fasted condition
61998531|NCT02362165|EXPERIMENTAL|CyBorD regimen|this arm will receive cyclophosphamide (500mg/d,once-weekly),bortezomib(1.3mg/㎡，once-weekly,subcutaneous injection), and dexamethasone (40mg/d,once-weekly)(CyBorD) as induction therapy.
61998532|NCT02362165|ACTIVE_COMPARATOR|PAD regimen|this arm will receive bortezomib(1.3mg/㎡，once-weekly,subcutaneous injection), dexamethasone (40mg/d,once-weekly), and doxorubicin (9mg/㎡，d1-4)(PAD) as induction therapy.
61998533|NCT02789176||Outpatient Enrollees|This is a cohort of 150 subjects who were previously enrolled in the Neonatal Seizure Registry, a multi-center association of institutions across the United States, They were contacted to participate in the study after discharge from the Neonatal Intensive Care Unit (NICU) but prior to the prospective follow up. They were asked to take part in all prospective follow up surveys at 12, 18, \& 24 months of age.
62393002|NCT05941494|EXPERIMENTAL|Sevoflurane-based anesthetic maintenance with ephedrine used as the vasopressor|Sevoflurane-based anesthetic maintenance with ephedrine used as the vasopressor. Patient's anesthesia will be maintained with 1 MAC of sevoflurane during surgery. The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).
62184236|NCT03139305|ACTIVE_COMPARATOR|Glucagon Low Dose|
62184237|NCT03139305|ACTIVE_COMPARATOR|Glucagon High Dose|
61998534|NCT02789176||NICU Enrollees|This is a cohort of 150 subjects who were enrolled in the study prior to discharge from the NICU. They were asked to complete surveys prior to discharge from the NICU, returned to the hospital for a 1 hour EEG to monitor brain activity between 2-4 months of age, \& completed the follow surveys at 12, 18, \& 24 months of age.
61998535|NCT01129141|EXPERIMENTAL|Tele-PTM|Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
62184238|NCT03139305|PLACEBO_COMPARATOR|Placebo|
61998536|NCT01129141|OTHER|Wait List Control|Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
61998537|NCT02121691|EXPERIMENTAL|Walk by Faith|Intervention arm
62184239|NCT03119688|OTHER|Test product|0.09 milliliters (ml) of the cleanser (test product) will be applied on the allocated site on forearm topically.
62184240|NCT03119688|OTHER|Positive Control|Soap bar (positive control) will be applied on the allocated site on forearm by topical dermal administration of towel moistened with sterile water that had been rubbed onto the 100 g bar of soap for 6 seconds to generate a lather.
62184241|NCT03119688|OTHER|Negative Control|0.09 ml of sterile water (Reference Product) will be applied on the allocated site on forearm topically.
61998538|NCT02121691|NO_INTERVENTION|Comparison|Non-intervention arm
62184242|NCT03119688|OTHER|No Treatment|An area of the forearm that remained unwashed and was included in the study as a reference for the treated areas.
62184243|NCT05752045|OTHER|Diabetic patient group assessed for multiple eye diseases|Each patient eye disease status will be assessed by expert readers so to provide ground truth against which algorithms performances will be assessed
62184244|NCT01068106|ACTIVE_COMPARATOR|BPLES|Biodegradable polymer limus-eluting stents
62184245|NCT01068106|ACTIVE_COMPARATOR|PPLES|Permanent polymer limus-eluting stent
62184246|NCT05821686|EXPERIMENTAL|Intervention Arm|Intralesional IL-2 therapy x 4 weeks between initial consultation and planned surgery
62184247|NCT03286309|EXPERIMENTAL|EMG-driven soft robot hand|subjects will receive EMG-driven soft robot hand system.
62184248|NCT03286309|PLACEBO_COMPARATOR|sham group|subjects will receive passive pre-programmed soft robot hand system.
62184249|NCT02390661|NO_INTERVENTION|No drain|Control group
62184250|NCT02390661|EXPERIMENTAL|Penrose drain placement|Placement of a penrose drain after irradiation catheter is removed
62184251|NCT04969809|EXPERIMENTAL|Patients on diet|We will invite approximately 50 adult patients with PKU who were or are still being managed in the PPB clinic of the Pediatric Clinic of the University Medical Center Ljubljana. It is estimated that half of the patients still fully or at least partially follow the dietary treatment.
62393003|NCT00745004|EXPERIMENTAL|1|Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days.
62393004|NCT00745004|PLACEBO_COMPARATOR|2|Placebo 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days.
62184252|NCT04969809|EXPERIMENTAL|patients without diet|Half of the patients have abandoned the diet treatment and mostly no longer come for outpatient examinations.
62393005|NCT04476641|EXPERIMENTAL|DC-CIK|
62184253|NCT04590872|EXPERIMENTAL|Autologous Tolerogenic Dendritic Cell with Proinsulin Peptide (PIpepTolDC)|After completion of leukapheresis, patients receive a prime dose of PIpepTolDC intradermally (ID) on Day 0, followed by a boost dose of PIpepTolDC ID on Day 28.
61998539|NCT01436279|EXPERIMENTAL|Mifepristone + misoprostol|Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure
62184254|NCT02934945|OTHER|patients with CVA(CVA group)|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for six months
62393006|NCT05658133|OTHER|Survey for student athletes|15 to 20 minute online questionnaire completed using Qualtrics
62568493|NCT03025529|NO_INTERVENTION|Healthy control pilot|This pilot phase is done to assess feasibility of obtaining MRI and cerebellocortical inhibition measures in healthy control subjects.
61998540|NCT01436279|ACTIVE_COMPARATOR|Osmotic dilators|Placed 20-24 hours prior to procedure
61998541|NCT03852797|ACTIVE_COMPARATOR|Ketamine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ketamine (from 10 -7M to 10 -4M)
61998542|NCT03852797|ACTIVE_COMPARATOR|Ketamine + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of ketamine (from 10 -7M to 10 -4M)
62393007|NCT05658133|OTHER|Survey for influencers of student athletes|15 to 20 minute online questionnaire completed using Qualtrics
61998543|NCT03852797|ACTIVE_COMPARATOR|Propofol|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of propofol (from 10 -7M to 10 -4M)
62393008|NCT02443558|EXPERIMENTAL|Complete Injury|"Patients suffering from complete injury at the cervical spinal cord level (ASIA Impairment Scale A).~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms."
62393009|NCT02443558|EXPERIMENTAL|Incomplete Injury|"Patients suffering from incomplete injury at the cervical spinal cord level (ASIA Impairment Scale B,C,D,E).~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
61998544|NCT03852797|ACTIVE_COMPARATOR|Propofol + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of propofol (from 10 -7M to 10 -4M)
61998545|NCT03852797|ACTIVE_COMPARATOR|Etomidate|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of etomidate (from 10 -7M to 10 -4M)
62393010|NCT02443558|ACTIVE_COMPARATOR|Non-cervical injury|"Patients suffering from complete or incomplete injury of the spinal cord at a level other than the cervical (thoracic or lumbar).~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
62568494|NCT04565197|EXPERIMENTAL|Group intervene with convalescent plasma|"Review effect of Plasma therapy as clinical trial among hospitalized patients with COVID-19 infection.~Transfuse 2 aliquots of plasma (200 mL x 2) per patient.~* Transfuse first aliquot for 2-3 hours (\~1.4 to 2 mL/min)~* Transfuse second aliquot at same rate 2 hours after completion of first aliquot"
62568495|NCT00716781||1 (first year)|Asymptomatic infants born to GBS-positive mothers or to mothers with risk factors and incomplete prophylaxis were managed according to the CDC protocol. Blood cultures and CBC were performed and the infant was observed for 48 hours. Participating hospital were free to perform any additional test, such as CRP, MiniESR, etc
62735137|NCT05050968|EXPERIMENTAL|Adapted Physical Activity Group|Patients will follow a 3-month physical activity program 3 times a week between V1 and V2. Then, between V2 and V3, no APA program will be offered to both groups.
62184255|NCT02934945|OTHER|patients with TA(TA group)|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for six months
62184256|NCT04667715|ACTIVE_COMPARATOR|Exablate Test Arm|Subjects will undergo ExAblate BBBD prior to their standard of care tumor removal
62184257|NCT04667715|NO_INTERVENTION|Control Test Arm|Subjects will undergo their standard of care tumor removal
62568496|NCT00716781||2 (second year)|Asymptomatic infants born to GBS-positive mothers or to mothers with risk factors and incomplete prophylaxis were managed with clinical observation only. Clinical surveillance was based on 3 signs: 1. Skin appearance (pink, pale, mottled, cyanotic); 2. Respiratory rate (\>50 or \<50 breaths per minute); 3. Dyspnea (Yes / No)
62568497|NCT03357523|EXPERIMENTAL|Red LED|Light emitting diodes, 633 nm, 70 mW/cm2, Omnilux new-U (Red LED) (Photomedex, Horsham, PA, USA); RESPeRATE; Heating bag
62184258|NCT02949232|EXPERIMENTAL|Prednisolone|Prednisolone will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following treatment guidelines for Inflammatory Bowel Diseases (2008).
62184259|NCT02949232|PLACEBO_COMPARATOR|Placebo Oral Tablet|Placebo will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following the treatment schedule of the experimental arm
61998546|NCT03852797|ACTIVE_COMPARATOR|Etomidate + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of etomidate (from 10 -7M to 10 -4M)
62568498|NCT03357523|ACTIVE_COMPARATOR|Near Infrared LED|Light emitting diodes, 830 nm, 55 mW/ cm2, Omnilux new-U (Near infrared LED) (Photomedex, Horsham, PA, USA); RESPeRATE metronome; Heating bag
62568499|NCT03662802||ECG Data|Coded data including; wavelengths, amplitude, intervals, timing, frequence
62568500|NCT02790099|EXPERIMENTAL|Rectus sheath block only|Patient will be given surgical rectus sheath block postoperatively with 40ml of bupivacaine (2.5mg/mL) and 0.1ml of normal saline will be injected intrathecally at time of spinal anaesthesia.
62774210|NCT03881904|NO_INTERVENTION|Control Group|This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will start GnRH antagonist COH directly without OCP pretreatment.
62568501|NCT02790099|ACTIVE_COMPARATOR|Intrathecal morphine group|0.1mg preservative free morphine will be injected intrathecally at time of spinal anesthesia and 40ml of normal saline will be injected as rectus sheath block.
61998547|NCT03302481|EXPERIMENTAL|Experimental Group|the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
61998548|NCT04667403|EXPERIMENTAL|Telemedicine|"Pain is monitored, from the patient's home, using a computer application accessible from a smartphone or a computer with internet access.~This application will allow the patient to describe his or her pain by means of a self-questionnaire. Healthcare professionals (nurse coordinator, pain specialist and oncologist) will thus be able to remotely interpret the data collected, enabling them to provide patients with a rapid response to adapt their pain treatment without the patient having to travel to the establishment."
61998549|NCT02188576|EXPERIMENTAL|high dose TXA|"High dose TXA is the intervention.~A higher dose of tranexamic acid will be given to this arm as follows:~50 mg/kg loading dose and 5 mg/kg/h infusion"
61998550|NCT02188576|EXPERIMENTAL|Low Dose TXA|"Low dose TXA is the intervention.~A lower dose of TXa will be given as follows:~10 mg/kg loading dose and 5 mg/kg/h infusion"
62568502|NCT02790099|ACTIVE_COMPARATOR|Both intervention|Patient will be given 0.1mg preservative free morphine intrathecally at time of spinal anaesthesia and surgical rectus sheath block with 40ml of bupivacaine (2.5mg/ml).
62568503|NCT01720862||Episodic migraineurs|Those with migraines \>2 and \< 12 times per month.
62568504|NCT01720862||Chronic migraineurs|Those with migraines greater than 14 days per month.
62568505|NCT01720862||Controls|Those without headaches other than occasional hangover, cold, flu headaches.
62568506|NCT03004781|NO_INTERVENTION|Waiting-list|8-week period without intervention, N=45
62568507|NCT03004781|EXPERIMENTAL|self-efficacy|8-week group-based parenting program on self-efficacy beliefs, N=19
62568508|NCT03004781|EXPERIMENTAL|self-efficacy/emotion coaching|8-week group-based parenting program on self-efficacy beliefs and emotion coaching practice, N=26
62568509|NCT00782626|EXPERIMENTAL|everolimus|Patients rcvd oral everolimus 5.0 mg/m2/day for a 28-day treatment course up to a total of 12 courses (48 weeks) if a patient had stable disease except if toxicity was unacceptable. Two dose reductions were permitted (3.0 5.0 mg/m2/day and 2.0 mg/m2/day).
62568510|NCT04126538|EXPERIMENTAL|Patient group|Patients with chronic kidney disease take pirfenidone capsule 400mg once orally
62568511|NCT04126538|EXPERIMENTAL|Control group|Healthy subjects take pirfenidone capsule 400mg once orally
62568512|NCT05352620|EXPERIMENTAL|Implant assisted maxillary overdenture|Horseshoe Maxillary Complete overdenture construction (Stabilizing and connecting the Smart Box housing)
62568513|NCT04709146|OTHER|Recovered Covid-19 patients|Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.
62568514|NCT04709146|OTHER|Healthy Control|Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.
62020951|NCT01853449|ACTIVE_COMPARATOR|No CWS+Fentanyl Citrate (250 mcg)|No chest wall strapping (unloaded control) + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
62568515|NCT03889418|ACTIVE_COMPARATOR|Electronic medical recorded clinical decision support|Usual care only
61998551|NCT02464202|EXPERIMENTAL|stereolithography tooth replica|stereolithographic tooth replica used as a guide for tooth autotransplantation decreases extra-alveolar time and reduces trauma to periodontal ligament tissue therefore increasing the success rate after transplantation
61998552|NCT05716828|EXPERIMENTAL|Balint group|Participants in the Balint group completed Balint training for a period of three months.
62393011|NCT02443558|ACTIVE_COMPARATOR|Healthy participants|"Healthy participants, age and sex matched to those of the other Arms.~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
62774211|NCT01858753|EXPERIMENTAL|Autologous fibroblasts|Autologous fibroblasts grown in culture from skin biopsy taken from patient. The cells will be injected into the scars to be treated.
62774212|NCT01858753|PLACEBO_COMPARATOR|Sterile saline|Sterile saline will be injected into the scar to be evaluated.
62393012|NCT03575741||Patients|After suffering from a concussion patients will be investigated 48 h, 72 h, 120 h, 360 h and 720 h after sustaining the injury. Postural control will be measured using 7 different easy balance tests.
62393013|NCT03575741||Control|Healthy children will be measured in the very same way to collect data of possible matched controls.
62393014|NCT05132751|EXPERIMENTAL|Group A|Machine Learning Ventilator Decision System Ventilation
62393015|NCT05132751|ACTIVE_COMPARATOR|Group B|Standard Controlled Ventilation
62393016|NCT04185766|PLACEBO_COMPARATOR|Placebo (0,5 ml/Kg)|
61998553|NCT05716828|NO_INTERVENTION|non-Balint group|
61998554|NCT03060434|ACTIVE_COMPARATOR|Control|Ibuprofen
61998555|NCT03060434|EXPERIMENTAL|Pentoxifylline|Pentoxifylline oral tablets
61998556|NCT01552538|EXPERIMENTAL|Cyberonics VNS System|Continued stimulation w/Cyberonics VNS
62020952|NCT01853449|PLACEBO_COMPARATOR|No CWS+0.9% saline placebo|No chest wall strapping (unloaded control) + single-dose inhalation of 0.9% saline placebo
62393017|NCT04185766|PLACEBO_COMPARATOR|Placebo (1 ml/Kg)|
62020953|NCT03554122|ACTIVE_COMPARATOR|Shotblocker Group|Patients spinal injections were performed with Shotblocker placed onto injection site
62393018|NCT04185766|EXPERIMENTAL|Destrogel (0,5 ml/Kg)|
62393019|NCT04185766|EXPERIMENTAL|Destrogel (1 ml/Kg)|
62393020|NCT01728870|EXPERIMENTAL|Unique Diet+Partial Enteral Nutrition|"Unique Diet+Partial Enteral Nutrition (PEN): This group will receive as follows:~Weeks 1-6: 50% of dietary needs from PEN (Modulen, Nestle) and 50% from a limited whole food diet.~Weeks 7-12: 25% of dietary needs from PEN (Modulen, Nestle) and 75% from a limited whole food diet."
62393021|NCT01728870|ACTIVE_COMPARATOR|Exclusive Enteral Nutrition (Modulen)|"Exclusive Enteral Nutrition(EEN): This group will receive as follows:~Weeks 1-6: EEN(100% of dietary needs from Modulen) Weeks 7-12: 25% of dietary needs from Modulen and 75% from a free diet."
62393022|NCT02404792|ACTIVE_COMPARATOR|HIV-uninfected|HIV-uninfected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
62735138|NCT05050968|NO_INTERVENTION|Control group|Patients will receive standard hospital management
62735139|NCT01999244|EXPERIMENTAL|SC|Self-guided self-monitoring condition. Participants will receive standard self-monitoring tools and information on weight regulation.
62735140|NCT01999244|EXPERIMENTAL|TECH|Technology condition. Participants will receive self-monitoring technology and information regarding weight regulation.
62735141|NCT01999244|EXPERIMENTAL|TECH+INT|Technology plus interventionist contact arm. Participants will receive self-monitoring technology, information regarding weight regulation, and interventionist contact via telephone.
62735142|NCT06093542|EXPERIMENTAL|AZD7503|Participants will subcutaneously receive AZD7503.
62774213|NCT01964677|EXPERIMENTAL|MR-HIFU of painful bone metastases|
62774214|NCT03316950|EXPERIMENTAL|IntraGen RF|Patients will undergo treatment with radiofrequency device, using the device's standard protocol. Patients will have 3 treatments space one month apart. Each treatment will be a total of 20 minutes for internal treatment only. Prior to treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
62774215|NCT03316950|EXPERIMENTAL|DiVA|Patients randomized into the DiVA treatment group will receive treatment per DiVA protocol. Patients will have a total of 3 treatments, space 1 month apart. Each treatment will last approximately 10 minutes. Prior to treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
62774216|NCT03316950|SHAM_COMPARATOR|Placebo Arm|"Patients randomized into the Placebo arm will include participants from the DiVa PlaceboGroup and IntraGen Placebo Group combined and will receive treatment based on the DiVA Sham and IntraGen Sham protocols.~DiVa Placebo: patients will undergo a three-part placebo treatment, spaced 1 month apart (+/- 10 days) of the vulvovaginal area. The vaginal HFL handpiece will be inserted into the vaginal canal but sub-therapeutic energy will not be delivered to the tissue.~IntraGen Placebo: patients will undergo a three-part placebo treatment, space 1 month apart (+/- 10 days) of the vulvovaginal area. This will be achieved through application of the probe, but with applying sub-therapeutic energy to the tissue."
61998557|NCT04126291|EXPERIMENTAL|Evaluation of whiteboard videos|Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived change in self-efficacy/ confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
61998558|NCT03164070||Patients with osteoarthritis|Patients with medium and large joint osteoarthritis
61998559|NCT03164070||Control group|Control group of healthy persons
61998560|NCT03339609||Immediate uroflow/EMG testing|Participants performed two direct repetitions of uroflowmetry in combination with EMG.
61998561|NCT03339609||uroflow measurement beforehand|Participants performed a preceding measurement of isolated uroflowmetry, followed by two randomized measurements of either isolated uroflowmetry or uroflowmetry with EMG.
61998562|NCT03703635|EXPERIMENTAL|Intracranial balloon angioplasty and aggressive medical management|All the participants in this group will be given Intracranial balloon angioplasty and aggressive medical management.
62568516|NCT03889418|ACTIVE_COMPARATOR|stepped opioid collaborative care model|Usual care AND collaborative care with behavioral health integration
61998563|NCT03703635|EXPERIMENTAL|Aggressive Medical management|All the participants in this group will be given aggressive medical management alone.
62393023|NCT02404792|EXPERIMENTAL|HIV-infected|HIV-infected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
62568517|NCT04756726|EXPERIMENTAL|Phase 1: Arm A - cemsidomide|Participants with r/r NHL or r/r MM will be treated with oral cemsidomide as a single agent administered at different dosages and dosing schedules.
62568518|NCT04756726|EXPERIMENTAL|Phase 1: Arm B1 - cemsidomide|Participants with r/r MM will be treated with escalating doses of oral cemsidomide as a single agent administered at different dosages and dosing schedules in each cohort, until the determination of maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) or Sponsor discretion.
62568519|NCT04756726|EXPERIMENTAL|Phase 1: Arm B2 - cemsidomide in combination with dexamethasone|Participants with r/r MM will be treated with escalating doses of oral cemsidomide in combination with a fixed dose of oral dexamethasone in each cohort
61998564|NCT00694967|ACTIVE_COMPARATOR|1|McDonald cerclage
62735143|NCT06093542|PLACEBO_COMPARATOR|Placebo|Participants will subcutaneously receive placebo.
62774217|NCT03316950|EXPERIMENTAL|Dual Treatment|Patients previously randomized into the DiVA Sham and IntraGen Sham groups will be placed in the Dual Treatment group. Patients will have a total of 3 dual treatments, spaced 1 month apart. Each treatment will last approximately 20 minutes. Prior to dual treatments, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken at follow up visits.
62774218|NCT01922843|EXPERIMENTAL|DP001|DP001 softgel capsules, 440 ng taken orally three times weekly after dialysis for 12 weeks
62393024|NCT04424758|EXPERIMENTAL|Intervention group|Receives information about mammography screening through a video. The video was developed with the goal of informing about mammography screening in a societal perspective using best available evidence.
62393025|NCT04424758|PLACEBO_COMPARATOR|Control group|Receives information about energy systems through a video. The video does not contain any information related to mammography screening.
62393026|NCT06035341|EXPERIMENTAL|Treatment Group|Participants in this group will be received orofacial manual therapy as treatment. The number of participants is planned to be 23.
62393027|NCT02303470|EXPERIMENTAL|Vigorous Exercise|High-intensity interval training for 15 minutes daily, 5 days per week for 8 weeks
62393028|NCT02303470|EXPERIMENTAL|Moderate Exercise|Brisk walking for 30 minutes daily, 5 days per week for 8 weeks
62393029|NCT02382419|EXPERIMENTAL|Arm I (carrageenan-containing gel)|Participants apply carrageenan-containing gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.
62393030|NCT02382419|PLACEBO_COMPARATOR|Arm II (placebo gel)|Participants apply placebo gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.
62568520|NCT04756726|EXPERIMENTAL|Phase 1: Arm C - cemsidomide|Participants with r/r NHL will be treated with escalating doses of oral cemsidomide single agent administered according to different dosing schedules in each cohort
62393031|NCT03244280|OTHER|MOB015B|
62393032|NCT03521089|ACTIVE_COMPARATOR|Active tDCS|Active tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The active tDCS intervention include stimulation for 15 minutes at 1mA. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
62393033|NCT03521089|SHAM_COMPARATOR|Sham tDCS|Sham tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The sham tDCS intervention lasts for 15 minutes. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
62393034|NCT04235673|EXPERIMENTAL|melatonin|melatonin oral drops; 3 mg/kg/day for 15 days
62568521|NCT04756726|EXPERIMENTAL|Phase 2: Arm 1 - cemsidomide|Participants with r/r MM will be treated with oral cemsidomide single agent
62568522|NCT04756726|EXPERIMENTAL|Phase 2: Arm 2 - cemsidomide in combination with dexamethasone|Participants with r/r MM treated with oral cemsidomide in combination with oral dexamethasone
62774219|NCT01922843|PLACEBO_COMPARATOR|Placebo|Placebo softgel capsules, taken orally three times weekly after dialysis for 12 weeks
61998565|NCT00694967|ACTIVE_COMPARATOR|2|17 hydroxyprogesterone caproate
62393035|NCT04235673|PLACEBO_COMPARATOR|placebo|oral drops manufactured to mimic melatonin
62393036|NCT01990417|EXPERIMENTAL|Passive stretching|After evaluation, the participants were randomly divided into four groups: A, B, C and D. Group A. stretched before and after workout ; group B stretched only before workout; group C stretched only after workout; and group D did not stretch at all.
62393037|NCT03715127|PLACEBO_COMPARATOR|Placebo|one oral dose of 100% mannitol (placebo)
62393038|NCT03715127|ACTIVE_COMPARATOR|Psilocybin|one oral dose of 0.215mg/kg psilocybin (verum)
62393039|NCT05600842||De-escalated radiotherapy|
62568523|NCT04756726|EXPERIMENTAL|Phase 2: Arm 3 - cemsidomide|Participants with r/r mantle cell lymphoma (MCL) treated with oral CFT7455
62774220|NCT03519594||Embolization group|The group that underwent embolization after pelvic injury.
62774221|NCT03519594||Non-embolization group|The observed group of pelvic injuries without embolization
62774222|NCT06422637|EXPERIMENTAL|Intervention group|By collecting 2,972 peripheral blood samples from a natural population baseline, a comprehensive analysis of the fragmentomic characteristics of cfDNA was conducted based on whole-genome sequencing (WGS) of plasma cfDNA.
62774223|NCT06422637|NO_INTERVENTION|control group|2972 individuals were enrolled from the general population for routine LDCT screening.
61998566|NCT05414643||At- risk group (SCAI stages A, B)|Patients who had a SCAI stage A or B at any point during their stay at the New Brunswick Heart Centre, Saint John Regional Hospital. This group was compared with the cardiogenic shock group only for preliminary analysis.
61998567|NCT05414643||Cardiogenic shock group (SCAI stages C-E)|Patients who had a SCAI (Society for Cardiovascular Angiography and Interventions) stage C-E at any point during their stay at the New Brunswick Heart Centre, Saint John Regional Hospital. This group was used for all subsequent analyses.
61998568|NCT01524770|ACTIVE_COMPARATOR|Manual syringe|Dulaglutide: Single dose of 1.5 milligrams (mg) dulaglutide administered subcutaneously (SC) by manual syringe in one of two study periods separated by a 28-day minimum washout period.
61998569|NCT01524770|EXPERIMENTAL|Auto-injector|Dulaglutide: Single dose of 1.5 milligrams (mg) dulaglutide administered subcutaneously (SC) by auto-injector in one of two study periods separated by a minimum 28-day washout period
61998570|NCT04582851||Postgraduate students|prevalence of TMD among postgraduate students.
61998571|NCT06022016|EXPERIMENTAL|Index case or related|
61998572|NCT01467232|EXPERIMENTAL|Autologous CD133+ Stem Cells|Autologous CD133+ stem cells
61998573|NCT01467232|PLACEBO_COMPARATOR|Saline solution containing autologous plasma|Saline solution containing autologous plasma without CD133+ (indistinguishable from the autologous CD133+ stem cells)
61998574|NCT00439556|EXPERIMENTAL|Treatment (chemotherapy, transplant, filgrastim, tacrolimus)|See Detailed Description
62774224|NCT01869660|EXPERIMENTAL|Shared Decision Making|The present SDM intervention is based on principles derived from previous randomized controlled trials of SDMs. SDM meetings comprise at least 4 weekly 20 minutes sessions. Meetings have at least three professionals: a case manager (psychiatrists or nurses), a primary doctor, and a nurse/social worker. The focus of the meeting is to empower patients to discuss their attitudes and preferences toward treatments.
62020954|NCT03554122|PLACEBO_COMPARATOR|Placebo Group|Patients spinal injections were performed without Shotblocker
62774225|NCT01869660|NO_INTERVENTION|Usual Care|Patients with no special program about decision making.
62774226|NCT04025177|EXPERIMENTAL|Neonates with an open PDA|Neonates born between 23 (0/7) and 26 (6/7) weeks gestational age with an open PDA, according to clinical protocol criteria, and no contraindication to the use of indomethacin.
62774227|NCT01699711|ACTIVE_COMPARATOR|Dietary Supplement: Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
61998575|NCT02965612|EXPERIMENTAL|ITS with Injex|For Each patient, at each monthly vaccination session and randomly in alternate mode, will be administered two vaccine doses of 0.25 ml each at 20 minutes from one another in the two arms, in an alternating manner via Injex and via subcutaneous.
62184260|NCT04100837||transportal group|swabs will be obtained from subcutaneous tissue at antromedial portal track in transportal technique (femoral tunnel drilling) , before and after the instrumentation and femoral screw insertion, a control sample will be taken at antrolateral track in both techniques, then samples will be sended to the lab to be studied.
62393040|NCT00579514|ACTIVE_COMPARATOR|1|"All incident second primary cancers of colon, breast, bladder, kidney, prostate, ovarian cancer lung cancer and lymphoid cancer diagnosed between 1999 and present will be included in the secondary design to compare second primary cancer cases and first primary controls."
62393041|NCT00579514|PLACEBO_COMPARATOR|2|Controls will be volunteer blood donors from the New York Blood Center as well as normal volunteers from other AMDeC sites.
62393042|NCT00972309|EXPERIMENTAL|Cohort 1: T-cell receptor alternate reading frame protein (TARP)|TARP peptides
62393043|NCT00972309|EXPERIMENTAL|Cohort: 2 -T-cell receptor alternate reading frame protein (TARP)|TARP dendritic cells
62393044|NCT05637086|EXPERIMENTAL|Control Group|This group will receive 100 mg of phenytoin 3 times daily for 6 months.
62774228|NCT01699711|PLACEBO_COMPARATOR|Placebo|No active treatment is given.
62791587|NCT01267305|EXPERIMENTAL|eso lmwh2|use LMWH twice daily after esophagectomy
62791588|NCT01267305|EXPERIMENTAL|eso Fondaparinux|use Fondaparinux once daily after esophagectomy
61998576|NCT02965612|ACTIVE_COMPARATOR|SCIT: ITS via subcutaneous|For Each patient, at each monthly vaccination session and randomly in alternate mode, will be administered two vaccine doses of 0.25 ml each at 20 minutes from one another in the two arms, in an alternating manner via Injex and via subcutaneous.
61998577|NCT05909371|EXPERIMENTAL|Classical physiotheraphy|The Program Applied to the Classical Physiotherapy Group The Warm-Up The postural exercises Short Breathing exercises Strengthening exercises Don't sit up Daily Balance exercises Walking exercises Pre-cooling exercise An individual-specific standardized exercise program suitable for clinical characteristics will be applied to patients with a maximum of 1 set of 8-12 repetitions for 30-45 minutes for each exercise (Modified Borg scale 4-6 or maximum heart rate 60-70%).
62184261|NCT04100837||transtibial group|swabs will be obtained from subcutaneous tissue at antromedial portal track in transtibial technique (femoral tunnel drilling), before and after the instrumentation and femoral screw insertion, a control sample will be taken at antrolateral track in both techniques, then samples will be sended to the lab to be studied.
62184262|NCT04331132|PLACEBO_COMPARATOR|Conventional diuretic group|The conventional furosemide treatment will follow the modified 2019 Position Statement from the ESC Heart Failure Association
62184263|NCT04331132|ACTIVE_COMPARATOR|Vasopressin-2 antagonist group|Tolvaptan 15mg once daily for 2 days will be added-on the furosemide strategy based on the modified 2019 Position Statement from the ESC Heart Failure Association
62791589|NCT02121249|EXPERIMENTAL|Robot assisted pedicle screw fixation|posterior lumbar interbody fusion using Robot assisted pedicle screw fixation (Renaissance, Mazor Robotics Ltd, Caesare, Israel)
62184264|NCT01722786||DOA|"Expected number of patients estimated by study duration~N= 90 patients treated with direct oral anticoagulants (DOA) with acute bleeding~N= 40 patients treated with direct oral anticoagulants (DOA) with urgent surgical intervention"
62184265|NCT01722786||VKA|"Expected number of patients estimated by study duration~N= 90 treated with vitamin K antagonists (VKA) with acute bleeding~N= 40 patients treated with vitamin K antagonists (VKA) with urgent surgical intervention"
62184266|NCT04917263||Retrospective|
62184267|NCT04917263||Prospective|
62393045|NCT05637086|ACTIVE_COMPARATOR|Pentoxifylline group|This group will receive 100 mg of phenytoin 3 times daily plus pentoxifylline 400 mg two times daily for 6 months
62393046|NCT05637086|ACTIVE_COMPARATOR|Celecoxib group|This group will receive 100 mg of phenytoin 3 times daily plus celecoxib 200 mg once daily for 6 months
62393047|NCT04563845|PLACEBO_COMPARATOR|Part 1: Participants receiving placebo|Participants will receive a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
62184268|NCT01438762|ACTIVE_COMPARATOR|Information and patient education|All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.
62214610|NCT02720302|EXPERIMENTAL|TeleSOFT|"The same method Lifestyle intervention SOFT is used. The only difference is that the communication in the second, third (and fourth) visit is made by use of video on distance. The investigators use Standardized Obesity Family Therapy SOFT as described by Nowicka \& Flodmark (1-3)."
62393048|NCT04563845|EXPERIMENTAL|Part 1: Participants receiving GSK3640254 500 milligrams (mg)|Participants will receive a single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.
62568524|NCT04756726|EXPERIMENTAL|Phase 2: Arm 4 - CFT7455|Participants with r/r peripheral T-cell lymphoma (PTCL) treated with oral cemsidomide single agent
62184269|NCT01438762|ACTIVE_COMPARATOR|Information, education and physiotherapy|"Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking.~In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas."
61998578|NCT05909371|EXPERIMENTAL|Motor cognitive exercise group|"The Program to be Applied in addition to the Physiotherapy Program to the Motor-cognitive Exercise Group .Remembering the word. Color/week/month/animal names counting/// girls boy names counting/// Country City names counting.~from 50 back to 2 bad, 3 er,// counting from 50 back to 4 er//counting from 100 back to 2 bad 2 bad 3 er 3 er and simple arithmetic problems with single digits.~Counting the months of the year// Counting the months of the year starting from any month// Counting the months of the year and 30 31 days."
61998579|NCT05724849|EXPERIMENTAL|Venlafaxine|"Patients who screen negative or meet criteria for mild MDD are eligible for the randomized control trial (RCT) portion of this study in which patients are randomized into either the intervention (venlafaxine) arm or placebo. Participants randomized into the intervention group will be prescribed a starting dose of venlafaxine immediate release (IR) 75mg once daily. The dosing will be increased at the following rate:~Week 1: 75mg in AM~Week 2: 75mg BID~Week 3: 150mg in AM, 75mg in PM~Week 4: 150mg BID~For patients with hepatic impairment, severe renal impairment, or end stage kidney disease, the starting dose is 37.5 mg once daily, increased by increments of 37.5 mg per day to reach a maximum of 187.5 mg per day, given in two divided doses."
61998580|NCT05724849|PLACEBO_COMPARATOR|Placebo|Patients who screen negative or meet criteria for mild MDD are eligible for the randomized control trial (RCT) portion of this study in which patients are randomized into either the intervention (venlafaxine) arm or placebo. Participants randomized to the placebo group will receive a placebo capsule with the same dosing schedule as the intervention group.
61998581|NCT05724849|OTHER|Observation|Patients who screen positive for moderate, moderately-severe, or severe MDD are excluded from the RCT and will be enrolled in the study as an observation cohort. These patients will be offered initiation of venlafaxine and will be referred to our collaborating oncologic psychiatrist. Patients in cohort B will still complete the same patient-reported outcome measures (PROMs) as patients in cohort A, allowing us to collect data and better understand what effects venlafaxine has on patients who are already diagnosed with depression at the start of treatment for HNC.
61998582|NCT03696524|EXPERIMENTAL|Intervention Group|This group will receive placement of a tunneled pleural catheter to drain their recurrent, chronic, and symptomatic pleural effusion in addition to their usual medication therapy.
61998583|NCT03696524|NO_INTERVENTION|Usual Care|The control group will continue with medical therapy by their referring physician and serial thoracenteses when clinically appropriate.
61998584|NCT06162286|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin IV/PO
61998585|NCT06162286|EXPERIMENTAL|Omadacycline|Omadacycline IV/PO
61998586|NCT03003975|ACTIVE_COMPARATOR|PVI by single cryoballoon application|"A single cryoballoon application for pulmonary vein isolation will be guided by a Multipolar Recording Catheter (Achieve Mapping Catheter), passed through the inner lumen of the cryoablation catheter. A single application of 4 minutes will be used per vein guided by recording of loss of electrograms and by a defined drop of temperature within 2 minutes application. If a stable position with adequate occlusion of the vein the Achieve catheter should be located proximally for evaluation of entrance block during application, but can be advanced deeper for stability and then retracted to the ostium to evaluate vein isolation (entrance block).~If the vein then is isolated after a single application, the operator can move on to the next vein."
61998587|NCT03003975|ACTIVE_COMPARATOR|PVI by 2 cryo applications|Cryoballoon ablation with a conventional guidewire passed through the inner lumen of the catheter for stability will be used. Ablation will be performed with 2 consecutive applications for 4 minutes each in each vein guided by degree of occlusion and temperature drop at the discretion of the physician.
62393049|NCT04563845|EXPERIMENTAL|Part 2: Main QTc Study|Participants will be randomized to 1:1:1:1 ratio to receive Treatment T- Therapeutic dose of GSK3640254 (100 mg QD) on Days 1 through 7 or Treatment ST- Supratherapeutic dose of GSK3640254 (to be determined from Part 1) on Days 1 through 7 or Treatment P- Placebo for GSK3640254 on Days 1 through 7 or Treatment M- Moxifloxacin (GSK3640254 placebo Days 1 through 6 and a single dose of Moxifloxacin \[400 mg\] on Day 7 in 4 treatment periods. There will be at least 7 days wash out period between each period.
62393050|NCT02114736|EXPERIMENTAL|Rectus femoris tenotomy|Surgical release of the proximal tendon of the rectus femoris
62393051|NCT02114736|ACTIVE_COMPARATOR|Botulinum toxin in the rectus femoris muscle|Botulinum toxin (200U Botox) injection in the rectus femoris muscle
62393052|NCT03375866|ACTIVE_COMPARATOR|Pretzels|
62774229|NCT01009086|EXPERIMENTAL|Placebo|Participants will receive subcutaneous (SC) injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants will cross over to receive SC injections of ustekinumab 45 mg at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 88. If early escape, SC injections of 45 mg ustekinumab will be given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 88. For participants entering early escape, a SC placebo injection will be given at Week 24 to maintain the blind.
61998588|NCT03974230||Patients with Fuchs Endothelial Corneal Dystrophy (FECD)|Patients with Fuchs Endothelial Corneal Dystrophy (FECD). They will have a collection of datas and a blood sample.
62393053|NCT03375866|EXPERIMENTAL|Mixed nuts|
62774230|NCT01009086|EXPERIMENTAL|Ustekinumab 45 mg|Participants will receive SC injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, SC injections of 90 mg ustekinumab will be given at Week 16 and every 12 weeks thereafter with the last dose at Week 88. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
62774231|NCT01009086|EXPERIMENTAL|Ustekinumab 90 mg|Participants will receive SC injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, the same dosage schedule will continue. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
62791590|NCT02121249|ACTIVE_COMPARATOR|Free hand technique|using Free hand technique, posterior lumbar interbody fusion (No specific device)
61998589|NCT03974230||Control group|Witness will be included in control group. They will have a blood sample and slit lamp examination.
61998590|NCT04027166|EXPERIMENTAL|administration immediate|Methadone will be administered prior to study procedures
61998591|NCT04027166|EXPERIMENTAL|administration delayed|Methadone will be held for four hours until the end of all study procedures.
62184270|NCT01438762|NO_INTERVENTION|Observational cohort|Those who do not wish to participate in the randomization procedure will be followed through an observational cohort. The observational cohort will be followed at the same time-points and they will be asked which treatment they have received.
62393054|NCT01103661|OTHER|Numeris-AF Guided Coagulation System|
62393055|NCT00821886|EXPERIMENTAL|Ixabepilone/Trastuzumab/Carboplatin|Neoadjuvant treatment with Ixabepilone, Trastuzumab and Carboplatin, followed by surgery, peri-operative treatment and post-operative (adjuvant) treatment if patient deemed to be a surgical candidate
62393056|NCT02581657|EXPERIMENTAL|PE0139 Injection|PE0139 Subcutaneous Injection - 6 weekly doses
62393057|NCT02581657|PLACEBO_COMPARATOR|Placebo Injection|Placebo Subcutaneous Injection - 6 weekly doses
62735144|NCT02089009|OTHER|Group 1 Standard Population|Retinal Imaging, vessel measurements, vessel changes of a population of a female health hospital
61998592|NCT00881192|NO_INTERVENTION|Control|No preoperative IABP; if needed, postoperative IABP placement
61998593|NCT00881192|ACTIVE_COMPARATOR|IABP|Preoperative IABP placement
61998594|NCT03689361|OTHER|with migraine aura.|patient with migraine aura detected by MRI, then MRI control 3 month after
62735145|NCT02089009|OTHER|Group 2 Pregnant Population|Change in vessel diameter at perinatal visits with retinal imaging (Retinal Imaging, vessel measurements, vessel changes)
62735146|NCT04247893|ACTIVE_COMPARATOR|Exercises with blood flow restriction|Exercise: 10 minutes of heating on a treadmill without changing the inclination and adopting a standardized speed; Supine bridge, Supine unilateral bridge, Flexion of the hip with the knee extended, Knee extension, volunteer in sedation; Prone knee flexion; Squat on the wall associated with isometric contraction; Abduction of the hip, lateral rotation and knee extension in lateral decubitus associated with isometric contraction; Abduction, lateral rotation of the hip, slight knee and hip flexion performing abduction with the feet together: associated with isometric contraction; Abduction of the hip in orthostatic associated with isometric contraction.Device: The blood flow restriction in mmHg will be performed using a vascular occlusion training manometer, positioned in the thigh inguinal region and inflated to the point where the auscultatory pulse of the tibial artery is interrupted.
62735147|NCT04247893|EXPERIMENTAL|Exercises with blood flow restriction + photobiomodulation|Exercise: 10 minutes of heating on a treadmill without changing the inclination and adopting a standardized speed; Supine bridge, Supine unilateral bridge, Flexion of the hip with the knee extended, Knee extension, volunteer in sedation; Prone knee flexion; Squat on the wall associated with isometric contraction; Abduction of the hip, lateral rotation and knee extension in lateral decubitus associated with isometric contraction; Abduction, lateral rotation of the hip, slight knee and hip flexion performing abduction with the feet together: associated with isometric contraction; Abduction of the hip in orthostatic associated with isometric contraction.Devices: The blood flow restriction in mmHg will be performed using a vascular occlusion training manometer, positioned in the thigh inguinal region and inflated to the point where the auscultatory pulse of the tibial artery is interrupted.Photobiomodulation a mesh composed of multiple diodes containing 50 Infrared LEDs.
61998595|NCT03689361|OTHER|without migraine aura|patient without migraine aura detected by MRI, then telephone consultation 3 month after
62774232|NCT05890482|EXPERIMENTAL|Islamic Trauma Healing (ITH)|A lay-led, six-session group intervention that combines empirically supported exposure-based and cognitive restructuring techniques with Islamic principles.
62774233|NCT05890482|OTHER|Wait List/Delayed (ITH)|Six week waitlist condition and then crossed-over to six weeks of the ITH intervention
62774234|NCT04635813||Group 1 - COVID group|Patients that underwent surgery during COVID-19 pandemic
61998596|NCT05067933|EXPERIMENTAL|Part 1 Cohort 1a (Naïve, low dose, young adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who are vaccine naïve
61998597|NCT05067933|EXPERIMENTAL|Part 1 Cohort 1b (Naïve, high dose, young adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who are vaccine naïve
61998598|NCT05067933|EXPERIMENTAL|Part 1 Cohort 1c (Naïve, low dose, older adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who are vaccine naïve
61998599|NCT05067933|EXPERIMENTAL|Part 1 Cohort 1d (Naïve, high dose, older adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who are vaccine naïve
61998600|NCT05067933|EXPERIMENTAL|Part 1 Cohort 2a (Prior vaccinated, low dose, young adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who have received prior vaccinations with an mRNA vaccine
61998601|NCT05067933|EXPERIMENTAL|Part 1 Cohort 2b (Prior vaccinated, high dose, young adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who have received prior vaccinations with an mRNA vaccine
62184271|NCT05523856||New Treatment Modalities Cohort|A consecutive sample of clinically localized prostate cancer patients treated with active surveillance, robot-assisted radical prostatectomy, intensity-modulated radiotherapy, or real-time brachytherapy in 18 Spanish hospitals.
62184272|NCT05997459|EXPERIMENTAL|experimental group|
62393058|NCT01610752|EXPERIMENTAL|SmartMoms-Clinic|If picked for this group, you will attend study meetings with a weight management counselor. During the second trimester study meetings occur 4 times per month. During the third trimester you will attend study meetings 2 times per month. These meetings will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
62393059|NCT01610752|EXPERIMENTAL|SmartMoms-Phone|If picked for this group, you will have two individual sessions with a weight management counselor. At the first session, you will receive a scale and other technology to help manage your weight during pregnancy. Each week you will receive information from a weight management counselor via a Smartphone (you can use your own Smartphone or one will be provided to you). The information will cover topics to help manage your weight during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to measure your body weight (using a scale we will provide) as well as monitor your food intake and exercise habits with the Smartphone.
62774235|NCT04635813||Group 2 - control group|Patients that underwent surgery during 2019
62774236|NCT05157139|NO_INTERVENTION|Control|Patients receiving only standard care
62774237|NCT05157139|ACTIVE_COMPARATOR|Intervention (low dose)|Two capsules twice daily for 3 days then one capsule twice daily for 2 days
62774238|NCT05157139|ACTIVE_COMPARATOR|Intervention (high dose)|two capsules three times daily for 3 days, followed by one capsule three times daily for 4 days
62774239|NCT01304407|OTHER|RTS Subjects, Calcium Isotope|Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.
61998602|NCT05067933|EXPERIMENTAL|Part 1 Cohort 2c (Prior vaccinated, low dose, older adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who have received prior vaccinations with an mRNA vaccine
62184273|NCT04171934||Adults|Subjects 22+ years of age
62184274|NCT04171934||Pediatric|Subjects less than 22 years of age
62184275|NCT02794714|EXPERIMENTAL|deep neuromuscular blockade|Rocuronium will be administered to achieve PTC 1-2 throughout surgery.
62184276|NCT02794714|ACTIVE_COMPARATOR|moderate neuromuscular blockade|Rocuronium will be administered to achieve TOFC 2 throughout surgery
62774240|NCT01579630|EXPERIMENTAL|Pemetrexed 500mg/m2 iv|
62774241|NCT01579630|EXPERIMENTAL|Pemetrexed 500 mg/m2 i.v. and Gefitinib 250 mg|
62774242|NCT00771615|EXPERIMENTAL|A/turkey H5N1 influenza Formulation A Group|Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62774243|NCT00771615|EXPERIMENTAL|A/turkey H5N1 influenza Formulation B1 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62774244|NCT00771615|EXPERIMENTAL|A/turkey H5N1 influenza Formulation B2 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62774245|NCT00771615|EXPERIMENTAL|A/turkey H5N1 influenza Formulation C1 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62791591|NCT03579277|ACTIVE_COMPARATOR|Radial forearm free flap|Subjects in this arm will receive a radial forearm free flap.
62791592|NCT03579277|ACTIVE_COMPARATOR|Ulnar forearm free flap|Subjects in this arm will receive an ulnar forearm free flap.
61998603|NCT05067933|EXPERIMENTAL|Part 1 Cohort 2d (Prior vaccinated, high dose, older adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who have received prior vaccinations with an mRNA vaccine
61998604|NCT05067933|EXPERIMENTAL|Part 2 Healthy Adults: Active vaccine|Repeat dose vaccinations with VXA-CoV2-1.1-S at dose selected from Part 1 in healthy male and female adult volunteers 18 to 75 years old
61998605|NCT05067933|PLACEBO_COMPARATOR|Part 2 Healthy Adults: Placebo control|Repeat dose administration with matching placebo tablets in healthy male and female adult volunteers 18 to 75 years old
61998606|NCT03624621|EXPERIMENTAL|Functional Remediation + CCT|12 sessions (1 per week) of group functional remediation program (90 min/session) plus 20 min of tailored computerized cognitive training (CCT)
62568525|NCT02007681|EXPERIMENTAL|Lifestyle change|One 5-10 minute break per hour during the work day using a software that alert the participant, and perform 6000 steps above the baseline number of steps/day (previously evaluated), by adopting several domain specific strategies, during 7 days.
62184277|NCT02271022||Cohort 1|"Patients (≥18 years of age) with a working diagnosis of NSTEMI and treatment with an OAP agent (ticagrelor, clopidogrel, or prasugrel) either in the ED, or in any case within the timeframe that emergency physicians consider to be upstream-within the first 72 hours of care and at least 4 hours before diagnostic angiography. In addition, only those patients who undergo a diagnostic coronary angiography within 72 hours of ED arrival will be eligible for UPSTREAM."
62184278|NCT02038998|SHAM_COMPARATOR|Static group|Control group. They will receive the standard care provided by the protocols of the ictus unit. They will lay on the Exer-Rest® TL device but the acceleration will NOT be connected.
62774246|NCT00771615|EXPERIMENTAL|A/turkey H5N1 influenza Formulation C2 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
61998607|NCT03624621|PLACEBO_COMPARATOR|Psychoeducation + Online Games|12 sessions (1 per week) of psychoeducation for major depression (90 min/session) plus 20 min of playing freely with online games (pre-selected by investigators)
62184279|NCT02038998|EXPERIMENTAL|Single pGz intervention|In addition to the standard care established in the ictus unit, these patients will receive a single exposure to pGz on the Exer-Rest® TL, for 3 hours, during the first day of their stay in the hospital.
62184280|NCT02038998|EXPERIMENTAL|Multiple pGz interventions|In addition to the standard care, these patients will be exposed to 45 minutes of pGz, on the Exer-Rest® TL, every day during their first week in the Hospital.
62184281|NCT05197114|EXPERIMENTAL|Intervention|There will be one arm to the study, and all participants will be receiving the intervention.
62393060|NCT01610752|NO_INTERVENTION|Physician Directed|If picked for this group, you will receive weight management advice from your physician's office.
62393061|NCT00944762|EXPERIMENTAL|Ecosystem Focused Therapy (EFT)|Participants will receive EFT.
62393062|NCT00944762|ACTIVE_COMPARATOR|Education in stroke and depression|Participants will receive education in stroke and depression.
62568526|NCT02007681|NO_INTERVENTION|Control|Regular free week with no changes performed
62568527|NCT06080035|EXPERIMENTAL|Topical Cetyl Tranexamate Mesylate|Product will be used on the face twice daily in the morning and in the evening for 2 weeks.
62568528|NCT03019237|EXPERIMENTAL|intranasal anti-IgE|Anti-IgE (Xolair) will be freshly diluted in sterile 0.9% sodium chloride solution (438 μg/ml) and will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
62774247|NCT00771615|EXPERIMENTAL|A/turkey H5N1 influenza Formulation D1 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62774248|NCT00771615|EXPERIMENTAL|A/turkey H5N1 influenza Formulation D2 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
61998608|NCT03624621|NO_INTERVENTION|Treatment as usual|Usual intervention supervised by their psychiatrist
61998609|NCT06031571|EXPERIMENTAL|group A|group A (will receive cupping massage technique in addition to traditional exercises)
61998610|NCT06031571|EXPERIMENTAL|Group B|group B (will receive myofascial release technique in addition to traditional exercises)
61998611|NCT00386256|EXPERIMENTAL|Health Buddy outpatient|Received home telehealth monitoring by Health Buddy
61998612|NCT00386256|EXPERIMENTAL|Telephone outpatient|
61998613|NCT00386256|EXPERIMENTAL|health buddy inpatient|
61998614|NCT00386256|EXPERIMENTAL|telephone inpatient|
61998615|NCT04890392|EXPERIMENTAL|PD-1 with SOX|S-1: 40\~60mg Bid，d1\~14, q3w Oxaliplatin：130mg/m2，iv drip for 2h，d1, q3w PD-1（Tislelizumab）:200mg,iv drip for at least 1h,d1,q3w
61998616|NCT00571129|ACTIVE_COMPARATOR|with tubes or mitomycin|After DCR bicanalicular tubes were inserted After re-DCR mitomycin in cottonpads were placed into rhinostoma for 5 minutes
61998617|NCT00571129|ACTIVE_COMPARATOR|without tubes or mitomycin|After DCR no tubes were inserted After re-DCR no mitomycin was used
61998618|NCT02315235|ACTIVE_COMPARATOR|control|The operator inject normal saline(control) to thirty site of the other side leg of active comparator. The volume of one site injection is 0.5 ml. The depth of needle injection would be 1.5cm.
62393063|NCT01425268|EXPERIMENTAL|AeroForm Tissue Expansion|AeroForm Tissue Expansion inflation with carbon dioxide by remote control
62568529|NCT03019237|ACTIVE_COMPARATOR|intranasal allergen|GMP produced rBet v 1 will be freshly diluted in sterile 0.9% sodium chloride solution (50 μg/ml) and will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
62393064|NCT01425268|ACTIVE_COMPARATOR|Saline Tissue Expansion|Saline Tissue Expansion inflated by needle injections of saline
62568530|NCT03019237|PLACEBO_COMPARATOR|intranasal saline|Sterile 0.9% sodium chloride solution will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
62184282|NCT05651113||Positive NBS for SCID|Parents whose baby was referred to an immunologist due their SCID screening result (minimum n= 10-25)
62184283|NCT05651113||Normal NBS result|Parents who received a normal screening result (minimum n=10-25)
62568531|NCT04079647||Patient with endocrinopathy after immunotherapy|Patient with endocrinopathy after immunotherapy
62568532|NCT02594553|EXPERIMENTAL|Intervention|All GPs working at the participating GP out-of-hours centres that are in the intervention group will use the GP-parent information-exchange tool (interactive booklet).
62568533|NCT02594553|NO_INTERVENTION|Control|All GPs working at the participating GP out-of-hours centres that are in the control group will provide care as usual.
62568534|NCT02838823|EXPERIMENTAL|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
62568535|NCT05386459||Main|Ingaron (INN: recombinant human interferon gamma, lyophilizate for solution preparation for intramuscular and subcutaneous administration 500,000 IU) 1 subcutaneous injection 1 time per day (in the morning) daily for 5 days (5 injections in total) against the background of basic antibacterial and symptomatic therapy
62184284|NCT05651113||False positive NBS result|Parents who have received a false positive result elsewhere in screening (minimum n=2-10)
62184285|NCT05651113||CFSPID Designation|Parents who received a CFSPID result (minimum n=\~10)
62184286|NCT05651113||SCID via family history or clinical presentation|Parents whose baby was identified with SCID due to family history or clinical presentation (minimum n=10)
62184287|NCT05651113||Parents whose babies have died|Parents who have received an abnormal screening result (T cell receptor excision circles (TRECs) or who were identified with SCID due to family history or clinical presentation and whose baby has subsequently died (n=\~10)
62184288|NCT06446271||Gene positive participants (personal history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant)|"Pathogenic and likely pathogenic variants defined by American College of Medical Genetics guidelines.~Expected recruitment of: 300 TTN, 300 MYBPC3, up to 50 LMNA, up to 50 FLNC and up to 50 DSP"
62184289|NCT06446271||Gene negative controls (family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant)|Expected recruitment of 50 patients.
62184290|NCT02209610|OTHER|Patients With Heart Failure: Neuromuscular Abnormalities|Patients with Heart Failure
62393065|NCT00526760|EXPERIMENTAL|Dexmedetomidine|
62568536|NCT05386459||Control|Only basic antibacterial and symptomatic therapy. The use of the study drug was carried out on the basis of the decision of the medical commission with the execution of the protocol and primary medical documentation of the patient
62568537|NCT03411031|ACTIVE_COMPARATOR|A: Elotuzumab + Lenalidomide at 25 mg|"Elotuzumab 10 mg/kg intravenously (IV) weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab.~Lenalidomide 25 mg by mouth (PO) daily days 1-21 out of a 28-day schedule."
62184291|NCT02209610|OTHER|Health Control Subjects and Neuromuscular Function|Health Control Subjects
62184292|NCT03765164|ACTIVE_COMPARATOR|Control|Control participants will care for the same set of CPV patients as the intervention arm, but will not have knowledge of or access to GlycoMark 1,5-AG test results. Investigators will compare control participants' clinical recommendations to those in the intervention arm.
62184293|NCT03765164|EXPERIMENTAL|Intervention|Intervention participants will care for the same set of CPV patients as the control arm, but will be educated on and given access to GlycoMark 1,5-AG test results. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
62393066|NCT06347146|EXPERIMENTAL|Standard implementation strategy condition|The Standard Implementation strategy condition is one that has been applied in our prior randomized controlled trials (RCTs). In applying this strategy, the investigators will meet with both non-governmental organizations (NGO) and school staff to gauge NGOs interest in partnering on study implementation and describe roles and responsibilities.
62184294|NCT04311047|EXPERIMENTAL|USPIO-enhanced MRI|Ferumoxtran-10 contrast will be intravenously administered 24-36 before performing an MRI scan. The MRI scan will be discussed with the surgeon prior to resection. Findings on MRI will be compared to pathology.
62393067|NCT06347146|EXPERIMENTAL|Enhanced Implementation strategy condition|The Enhanced Implementation strategy condition will be developed using Implementation Mapping, a systematic protocol for developing implementation strategies using theory, evidence, and stakeholder input. This will ensure that known determinants of implementation, scale-up, and sustainment are addressed by strategies designed collaboratively with the community partners from a public-private partnership of government-funded public schools and non-government organizations (NGOs).
62393068|NCT03366649|OTHER|UMA (Group 1)|Participants in the UMA group will receive an undersizing mitral annuloplasty (UMA).
62393069|NCT03366649|OTHER|UMA + PMA (Group 2)|Participants in the UMA + PMA group will receive an undersizing mitral annuloplasty (UMA) with papillary muscle approximation (PMA).
62393070|NCT03366649|NO_INTERVENTION|Retrospectively identified patients|Retrospectively identified patients, who already underwent the standard of care surgery for the lesion of interest at Emory, within 6 months (± 1 month) after the date of their surgery, and are suitable for recruitment to the study for their post-operative research.
62774249|NCT00771615|EXPERIMENTAL|A/turkey H5N1 influenza Formulation E1 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62774250|NCT00771615|EXPERIMENTAL|A/turkey H5N1 influenza Formulation E2 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62774251|NCT00504374||Symptoms Questionnaire|Patients with lung cancer.
62774252|NCT05271331|EXPERIMENTAL|ESP block|Patient will receive ESP block one level above surgery with ropivacaine 0.35% 20 ml per side Patient will receive preoperative wound infiltration with Saline 40 ml
62184295|NCT03723122|EXPERIMENTAL|DCRI program|Patient-caregiver dyads will immediately attend the Dyadic communication reinforcement intervention. For both groups, first assessment time take place just after the enrollment, before the randomization. For this group, second assessment time take place 2 weeks post-intervention. Pre-post assessments consist in self-reported scales assessing emotional distress, individual coping, cancer-related dyadic communication frequency, satisfaction, self-efficacy and coping.
62184296|NCT03723122|NO_INTERVENTION|Waiting List|Patient-caregiver dyads are in a waiting condition for 6 weeks. They will attend the Intervention after the second assessment time if they want to. For both group, first assessment time take place just after the enrollment, before the randomization. For this group, second assessment time take place 6 weeks after first assessment time. First and second assessment consist in self-reported scales assessing emotional distress, individual coping, cancer-related dyadic communication frequency, satisfaction, self-efficacy and coping.
62184297|NCT02560389|PLACEBO_COMPARATOR|Placebo|Placebo administered in pill form once by mouth
62184298|NCT02560389|ACTIVE_COMPARATOR|100mg L-DOPA|100mg levodopa administered in pill form once by mouth
62774253|NCT05271331|ACTIVE_COMPARATOR|Wound infiltration|Patient will receive ESP block one level above surgery with Saline 20 ml per side Patient will receive preoperative wound infiltration with ropivacaine 0.35% 40 ml
62774254|NCT00884832|EXPERIMENTAL|Oral Clonidine|Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
62184299|NCT02560389|ACTIVE_COMPARATOR|200mg L-DOPA|200mg levodopa administered in pill form once by mouth
62184300|NCT02484547|EXPERIMENTAL|Low Dose|Monthly intravenous (IV) infusions
62184301|NCT02484547|EXPERIMENTAL|High Dose|Monthly intravenous (IV) infusions
62184302|NCT00027703|EXPERIMENTAL|Arm I|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-60 minutes (beginning after gemcitabine infusion) and bevacizumab IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), complete response (CR), or partial response (PR) after the sixth course may receive bevacizumab as a single agent once every 3 weeks in the absence of disease progression or unacceptable toxicity.
62184303|NCT00027703|EXPERIMENTAL|Arm II|Patients receive gemcitabine and cisplatin as in arm I and placebo IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats as in arm I. Patients who achieve SD, CR, or PR after the sixth course may receive placebo as a single agent once every 3 weeks in the absence of disease progression.
62393071|NCT01031784|EXPERIMENTAL|Holmium-166 microspheres, intra-arterial|intra-arterial administration of holmium-166 microspheres in the liver
62393072|NCT01000233|ACTIVE_COMPARATOR|Phytine (Phytate)|300 mg tid\* 24 months
62393073|NCT01000233|PLACEBO_COMPARATOR|Placebo|
62393074|NCT00727662|EXPERIMENTAL|1|Yoga
62568538|NCT03411031|ACTIVE_COMPARATOR|B: Elotuzumab + Lenalidomide at 10 mg|"Elotuzumab 10 mg/kg IV weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab.~Lenalidomide 10 mg PO daily days 1-21 out of a 28-day schedule."
62568539|NCT05408299||Immunocompetent|100 healthy persons not suffering of any systemic diseases or malignancy of whatever nature.
62774255|NCT00884832|PLACEBO_COMPARATOR|Oral Placebo|Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
62774256|NCT03083184|EXPERIMENTAL|Intervention group|Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).
62774257|NCT03083184|OTHER|control group|Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).
62774258|NCT05587374|EXPERIMENTAL|Cadonilimab arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 \& 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Cadonilimab 10mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 14 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.
62774259|NCT05587374|ACTIVE_COMPARATOR|Chemoradiation arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 \& 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT.
62774260|NCT05245188|EXPERIMENTAL|Experimental Product 1|Consumption of 200 ml of product 1. Subjects will take this amount only on the day of the visit that they are to consume this product.
62393075|NCT00727662|ACTIVE_COMPARATOR|2|A Wellness Seminar series
62393076|NCT03528811|OTHER|Five points test of Tongji university|"We established the evaluatation and follow-up system of diabetes vascular disease based on the method called Five points test of Tongji university ."
62568540|NCT05408299||Immunocompromised|100 B thalassemia splenectomised patients.
61998619|NCT02315235|ACTIVE_COMPARATOR|stem cell (mononuclear cell)|The stem cell (mononuclear cell) is injected to thirty site of one side leg in operating room after general anesthesia. The volume of one site injection is 0.5 to 1.0 ml. The depth of needle injection would be 1.5cm.
62184304|NCT00741208|OTHER|1|Patients randomized to receive soy isoflavone twice daily for 2 weeks. Patients will cross-over and receive placebo medication for 2 weeks later in the study
62393077|NCT05447299||Typically developing children|Reference group of typically developing children
62393078|NCT05447299||Cerebral palsy group|Children with a diagnosis of cerebral palsy
62393079|NCT02445768|EXPERIMENTAL|Cognitive multisensory rehabilitation|The treatment group will receive the cognitive multisensory rehabilitation that uses motor imagery and sensory discrimination exercises
62774261|NCT05245188|EXPERIMENTAL|Experimental Product 2|Consumption of 200 ml of product 2. Subjects will take this amount only on the day of the visit that they are to consume this product.
62774262|NCT05245188|EXPERIMENTAL|Experimental Product 3|Consumption of 200 ml of product 3. Subjects will take this amount only on the day of the visit that they are to consume this product.
61998620|NCT03851016|EXPERIMENTAL|Life Story Book Intervention First, Then Usual Care|Participants first received the Life Story Book Intervention once a week for 3 weeks. After a washout period of 1 week, they then received the Usual Care Intervention for 3 weeks. Posttests were then conducted for 1 week.
61998621|NCT03851016|EXPERIMENTAL|Usual Care First, Then Life Story Book Intervention|Participants first received the Usual Care Intervention for 3 weeks. After a washout period of 1 week, they then received the Life Story Book Intervention once a week for 3 weeks. Posttests were then conducted for 1 week.
61998622|NCT06221228|NO_INTERVENTION|Conventional Training (CT):|Usual care in the clinical practice: Pre-dialysis training class
61998623|NCT06221228|EXPERIMENTAL|Audio-visual assisted Flipped Classroom pre-dialysis training|The audio-visual assisted Flipped Classroom (FC) CAPD Training Programme is a one-week individual intervention, which consists of five sessions (8-hours each). Pre-class audio-visual tutorials will be provided for self-study prior to F2F sessions. Six instructional videos, each dedicated to a specific procedure, are accessible for preview and repeated viewing as needed. Such flexibility allows the patients to revise at their own preferred time and pace. The four videos are (1) CAPD preparation and hand washing, (2) CAPD bag exchange procedure (Ultrabag or Balance systems), (3) Trouble shooting, and (4) Addressing contamination, (5) Detecting peritonitis, and (6) Exit site care. Participants will be asked to take note of any issues or difficulties they encounter while watching the video. A CAPD education booklet will be prepared and distributed to the patients at the beginning of the F2F training session. Take-home exercises will allow participants to revise the materials covered.
62020955|NCT01496352|EXPERIMENTAL|DFA-02|Progressive cohorts of 10 subjects (8 active, 2 placebo) receiving 10, 20 , 30 or 40 mL of DFA-02 or matching placebo.
62020956|NCT01496352|PLACEBO_COMPARATOR|DFA-02 placebo|
62184305|NCT00741208|OTHER|2|Patients randomized to receive placebo medication twice daily for 2 weeks. Patients will cross-over and receive soy isoflavone for 2 weeks later in the study
62393080|NCT04278846|EXPERIMENTAL|DepoFoam bupivacaine|local anesthetic
62393081|NCT04278846|ACTIVE_COMPARATOR|Bupivacaine hydrochloride (HCl)|local anesthetic
62393082|NCT04129736|OTHER|Teriflunomide 14 mg tablets|Single arm
62774263|NCT05245188|EXPERIMENTAL|Experimental Product 4|Consumption of 200 ml of product 4. Subjects will take this amount only on the day of the visit that they are to consume this product.
62774264|NCT01608373|ACTIVE_COMPARATOR|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
62393083|NCT03924960|EXPERIMENTAL|High-intensity interval training|Participants in this group will perform a 20-25 minutes of aerobic exercise with a maximum capacity of 3-4 minutes (HRmax 80-95%) and active recovery for 3-4 minutes (HRmax 30-50%), five exercise sessions per week for 6 weeks.
62393084|NCT03924960|ACTIVE_COMPARATOR|Moderate-intensity continuous training|Participants in this group will perform a 30-45 minute ergometric cycling exercise at 65-70% of the measured maximum heart rate (HRmax), five exercise sessions per week for 6 weeks.
62393085|NCT03924960|OTHER|Control|Usual care control group
62393086|NCT04135300|EXPERIMENTAL|Arm of BBM-H901|Subjects will be dosed with single dose of BBM-H901 at 5x10·12 vg/kg via intravenous infusion.
62568541|NCT01387087|EXPERIMENTAL|Group A|Lowest dose, all males, fasting
62774265|NCT01608373|ACTIVE_COMPARATOR|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc.
62774266|NCT01608373|PLACEBO_COMPARATOR|Intravenous normal saline group|The patients in Group C (placebo control group) received normal saline intravenous injection
61998624|NCT04156815|ACTIVE_COMPARATOR|1,565nm NAFL only group|Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas. A facial sheet mask (skin repair dressing, Panion \& BF Biotech Inc, Zhuhai, China) was used to clean the face after laser treatment, and the face was cooled by air cooler for 10 minutes. The patients received three treatment sessions with a 6-week interval between each session.
62184306|NCT04741737|EXPERIMENTAL|reSLNB arm|repeat SLNB procedure is performed in when the patient is diagnosed with ipsilateral breast tumor recurrence, who had undergone partial mastectomy and sentinel lymph node biopsy for primary operation.
62184307|NCT03200236|EXPERIMENTAL|Intensive Telephone Counseling|This arm provides a multi-faceted, 8-session intensive telephone counseling (ITC) protocol, tailored on lung cancer screening results, with 8-weeks of free nicotine replacement patches provided (Nicoderm patch, 21mg, 14mg, and 7mg) and primary care engagement.
62184308|NCT03200236|ACTIVE_COMPARATOR|Usual Care|This arm provides a multi-faceted, 3-session usual care telephone counseling (UC) protocol, with 2-weeks of free nicotine replacement patches provided (Nicoderm patch, 21mg, 14mg, and 7mg) and primary care engagement.
61998625|NCT04156815|ACTIVE_COMPARATOR|Oral isotretinoin only group|Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
62184309|NCT04338906|EXPERIMENTAL|Camostat + Hydroxychloroquine|Subjects will receive Camostat (400 mg tid) + hydroxychloroquine (400 mg bid day1, 200 mg bid d2-d7)
62184310|NCT04338906|ACTIVE_COMPARATOR|Placebo + Hydroxychloroquine|Subjects will receive placebo (tid) + hydroxychloroquine (400 mg bid day1, 200 mg bid d2-d7)
62774267|NCT04785599|EXPERIMENTAL|Group EC1: Exercices, informative talk|Group EC1 carried out the conventional prevention program consisting of an informative talk and an exercise program
62393087|NCT05734534|EXPERIMENTAL|BFR-ST and BFR-HIT|Participants will be allocated to a BFR intervention including resistance training and high-intensity intervals performed on a bicycle ergometer, both performed with BFR.
62393088|NCT05734534|ACTIVE_COMPARATOR|HL-ST and HIT|Participants will be allocated to heavy load resistance training and high-intensity intervals performed on a bicycle ergometer, both performed without BFR
62393089|NCT05734534|EXPERIMENTAL|BFR-P|Participants with COPD experiencing an acute exacerbation of their COPD requiring hospitalization will be allocated to application of BFR twice daily throughout their hospitalization. Participants are resting in a supine position throughout the application of BFR.
62393090|NCT05734534|EXPERIMENTAL|BFR-NMES|Participants with COPD experiencing an acute exacerbation of their COPD requiring hospitalization will be allocated to application of BFR with neuromuscular electrical stimulation (BFR-NMES) twice daily throughout their hospitalization. Participants are resting in a supine position throughout the application of BFR-NMES.
62774268|NCT04785599|EXPERIMENTAL|Group ECCP2: Exercices, informative talk, compression garment|Group ECCP2 carried out the same program but with the addition of a prophylactic compression garment
61998626|NCT04156815|ACTIVE_COMPARATOR|Double therapy group|The patients first received 2-4 weeks of oral isotretinoin medication (1mg/kg/d), followed by 1565nm M22-ResurFx NAFL treatment. Subjects were then given isotretinoin with a dosage of 0.5 mg/kg/d for the next 12-14 weeks. Laser treatment parameters and procedures were as same as in the group one above.
62393091|NCT05734534|ACTIVE_COMPARATOR|Control group|Participants with COPD experiencing an acute exacerbation of their COPD requiring hospitalization will allocated to usual care, consisting of daily physiotherapy sessions.
62568542|NCT01387087|EXPERIMENTAL|Group B|Second lowest dose, all males, fasting
62774269|NCT05701046||Anterior and oblique interbody fusion (ALIF, OLIF + Posterior fixation (open or MIS) or stand-alone)|
62774270|NCT05701046||Posterior interbody fusion (TLIF or PLIF) (open or MIS)|
62774271|NCT06506929|EXPERIMENTAL|Task specific Physical Therapy|Participants will received task specific physical therapy for 1 hour, twice a week for 6 weeks
62774272|NCT05423912|EXPERIMENTAL|Couple in Control Program for Persons with Mild Cognitive Impairment (MCI)|Persons with MCI participating in the Couple in Control (CiC) Program.
62184311|NCT03414047|EXPERIMENTAL|Prexasertib Cohort 1|Participants received 105 milligram per square meter (mg/m²) prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, breast cancer susceptibility gene (BRCA) negative and have received ≥3 lines of prior therapy.
62184312|NCT03414047|EXPERIMENTAL|Prexasertib Cohort 2|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, BRCA negative and have received \<3 lines of prior therapy.
62184313|NCT03414047|EXPERIMENTAL|Prexasertib Cohort 3|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, BRCA positive and received a prior poly ADP ribose polymerase (PARP) inhibitor.
62568543|NCT01387087|EXPERIMENTAL|Group C|Third lowest dose, all males, fasting
62774273|NCT05423912|EXPERIMENTAL|Couple in Control Program for Care Partners of MCI Participants|Care partners participating in the Couple in Control (CiC) Program with the MCI participant they care for.
62774274|NCT05604963|ACTIVE_COMPARATOR|Group 1: Two-stage Completion Thyroidectomy|Patients randomised to this arm will undergo a 2nd operation to remove the remaining thyroid lobe.
62774275|NCT05604963|NO_INTERVENTION|Group 1: Surveillance|Patients randomised to this arm will have no 2nd surgery and proceed directly to follow-up visits.
62774276|NCT05604963|EXPERIMENTAL|Group 2: Hemi-thyroidectomy|Patients randomised to this arm will have a single HT operation to remove thyroid lobe with the tumour.
61998627|NCT04156815|EXPERIMENTAL|Triple therapy group|The patients received the same treatments as the subjects in group (3) with additional PBT. At the end point of each session of laser treatment, an acupuncture practitioner performed a PBT in the areas within 1.5 cm radius of the five facial acupoints (Yintang, Zhukong, Sun, Yingxiang, Cuanzhu) (Figure 1). These areas usually appeared intensive erythema. A facial sheet mask was used to clean the face after PBT, and the face was cooled by air cooler for 10 minutes.
61998628|NCT01541930|EXPERIMENTAL|GK567|GK567: Metronidazole Gel 0.75% Once or twice daily, for 14 days, up to 30g
62184314|NCT03414047|EXPERIMENTAL|Prexasertib Cohort 4|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum refractory disease, BRCA positive or negative, no restriction on number of lines of prior therapy.
62393092|NCT01379599|EXPERIMENTAL|Brief motivation intervention|Brief motivation intervention was implemented with enrollees identified with heroin and cocaine use who were allocated to the experimental group. The aim was to test the ability of a peer-delivered intervention to reduce risk of HIV and STIs related to sexual behaviors (condom use and sex while high on drugs.
62774277|NCT05604963|ACTIVE_COMPARATOR|Group 2: Total Thyroidectomy|Patients randomised to this arm will have a single TT operation to remove the entire thyroid gland.
62774278|NCT06507475||Semaglutide|Participants diagnosed with type 2 diabetes (T2D) who had initiated once-daily oral semaglutide during the target selection period of April 2022 to December 2023 and have not previously been treated with injectable glucose-lowering medication in routine clinical practice.
62774279|NCT03020017|EXPERIMENTAL|Treatment (NU-0129)|Patients receive NU-0129 IV over 20-50 minutes and undergo standard of care tumor resection within 8-48 hours.
61998629|NCT01307566|EXPERIMENTAL|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure (CPAP)
61998630|NCT04078776||Lean Individuals|waist circumference ≤94 cm (men) and 80 cm (women) and BMI ≥ 21.0 kg/m2
61998631|NCT04078776||Obese Individuals|waist circumference ≥102cm (men) and 88 cm (women) and BMI ≥ 30.0kg/m2
61998632|NCT05668065|EXPERIMENTAL|CoronaVac/CoronaVac|Biological: Coronavac Two doses at 21-day +/- 3 days. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.
61998633|NCT05668065|ACTIVE_COMPARATOR|CoronaVac/BNT162b2|"Biological: CoronaVac/BNT162b2 First dose of Coronavac. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.~Second dose of BNT162b2 at 21-day +/- 3 days. Each dose of the Pfizer-BioNTech COVID-19 Vaccine is 0.3 ml. Each prefilled syringe contains 30 mcg of a nucleoside-modified messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2."
61998634|NCT00874068|ACTIVE_COMPARATOR|Standard vegetable oil formula|
62393093|NCT01379599|NO_INTERVENTION|control group|Care as usual.
62393094|NCT02291068|OTHER|psychotherapy treatment|3 months long (12 sessions) dynamic psychotherapy.
61998635|NCT00874068|ACTIVE_COMPARATOR|InFat|
62393095|NCT03797781|EXPERIMENTAL|High protein|
62774280|NCT03336385|PLACEBO_COMPARATOR|Placebo|Maltodextrin 12 gram used as placebo
62774281|NCT03336385|ACTIVE_COMPARATOR|Naxus|Naxus contains the wheat-derived prebiotic fibre Arabinoxylan
61998636|NCT00874068|NO_INTERVENTION|Breast-fed|
62184315|NCT01939951|ACTIVE_COMPARATOR|Activation Energy Serum|Activation Energy Serum 7 or 21 drops twice daily for 4 weeks
62184316|NCT01939951|PLACEBO_COMPARATOR|Placebo|sugar pill
62393096|NCT03797781|EXPERIMENTAL|Low protein|
61998637|NCT04123496|EXPERIMENTAL|Dose 1|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is 5 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62020957|NCT01371318|EXPERIMENTAL|OWEMR|Medical centers will be randomized to use the Online Wound Electronic Medical Record to enhance care of patients with diabetic foot ulcers
62184317|NCT05804682||Patients that underwent fascial dissection for N1b papillary thyroid cancer|
62184318|NCT05804682||Patients that underwent ftandard dissection for N1b papillary thyroid cancer|
62184319|NCT01031797||High SLEDAS|High SLE disease activity score
62184320|NCT01031797||Low SLEDAS|SLE patient with low score
62184321|NCT03430050|ACTIVE_COMPARATOR|Progesterone|Prometrium 200mg. Take one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
62393097|NCT03797781|EXPERIMENTAL|Minimum protein|
62393098|NCT01205399||AlloMax Surgical Graft Group|
62568544|NCT01387087|EXPERIMENTAL|Group D|Middle dose, all males, fasting
62568545|NCT01387087|EXPERIMENTAL|Group E|Third lowest dose, all females, fasting
62774282|NCT03336385|ACTIVE_COMPARATOR|Oatwell|Oatwell contains an oat-derived prebiotic beta-glucan fibre
62774283|NCT03514563||Group A|MRI imaging, Optical scan and 3D photography for patients with Class I (non-skeletal) malocclusion with no facial asymmetry or other pathology.
62774284|NCT03514563||Group B|MRI imaging, Optical scan and 3D photography for patients with Class III (skeletal-based) malocclusion with maxillary deficiency and normal vertical facial relationships, with no facial asymmetry or other pathology
62774285|NCT03514563||Group C|MRI imaging, Optical scan and 3D photography for patients with Cleft lip and/or palate and a Class III malocclusion and no other pathology
61998638|NCT04123496|EXPERIMENTAL|Dose 2|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is 10 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
61998639|NCT04123496|EXPERIMENTAL|Dose 3|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 3 is 15 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
61998640|NCT04123496|EXPERIMENTAL|Dose 4|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 4 is 20 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
61998641|NCT04123496|EXPERIMENTAL|Dose 5|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 5 is 25 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
61998642|NCT04123496|EXPERIMENTAL|Dose 6|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 6 is 30 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
61998643|NCT04123496|EXPERIMENTAL|Dose 7|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 7 is 35 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
61998644|NCT04123496|EXPERIMENTAL|Dose 8|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 8 is 40 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
61998645|NCT04123496|EXPERIMENTAL|Dose 9|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 9 is 45 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
61998646|NCT04123496|EXPERIMENTAL|Dose 10|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 10 is 50 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
61998647|NCT03669445|EXPERIMENTAL|four drugs combination|21-day cycles induction, then 28-day cycles consolidation and maintenance with Lenalidomide, Ixazomib, and Dexamethasone Plus Daratumumab
61998648|NCT02871128|EXPERIMENTAL|Natureheme-iron|Subjects receive 2 capsules per day containing either 1000 mg Fe.
62184322|NCT03430050|PLACEBO_COMPARATOR|Placebo|Placebo. ake one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
62184323|NCT06339749||Main study objective Groups: normotensive group|Main study objective Groups: normotensive group
61998649|NCT02871128|PLACEBO_COMPARATOR|Placebo|Subjects receive 2 capsules per day containing starch placebo of similar appearance.
61998650|NCT02871128|ACTIVE_COMPARATOR|supplement|Subjects receive 1 capsule per day containing either 100 mg Fe.
61998651|NCT02448875|ACTIVE_COMPARATOR|CyPass|CyPass Micro-Stent without adjunct viscoelastic implanted in the study eye
62184324|NCT06339749||Main study objective Groups: Stage 1 hypertension group|Main study objective Groups: Stage 1 hypertension group
62184325|NCT06339749||Secondary objective grouping: Stage 1 hypertension low-risk group|Secondary objective grouping: Stage 1 hypertension low-risk group
62774286|NCT03297125||Eligible Subjects|All enrolled subjects undergoing Optune therapy.
61998652|NCT02448875|EXPERIMENTAL|CyPass30|CyPass Micro-Stent implantation followed by targeted delivery of 30 μl ophthalmic viscoelastic
61998653|NCT02448875|EXPERIMENTAL|CyPass60|CyPass Micro-Stent implantation followed by targeted delivery of 60 μl ophthalmic viscoelastic
62184326|NCT06339749||Secondary objective grouping: Stage 1 hypertension high-risk group|Secondary objective grouping: Stage 1 hypertension high-risk group
62184327|NCT05913986|EXPERIMENTAL|Alpha-lipoic acid and y silybum marianum|LUDLEV®300 mg/46.2 mg once day
62184328|NCT05913986|PLACEBO_COMPARATOR|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
62184329|NCT01605656||Focus Groups + Interviews + Questionnaires|HIV-positive women recruited from the population of individuals seeking care at Thomas Street Health Center (TSHC) of the Harris County Hospital District (HCHD).
62184330|NCT01387815||Topical/Traditional Systemic Agent|Participants who initiated treatment with a new topical agent that was not used before or already being treated with topical agent and not responding, thereby requiring a change of treatment type, frequency, or dose and all participants who initiated treatment with a new systemic agent that was not used before alone or in combination with topical agents.
62184331|NCT01387815||Adalimumab|Participants treated with adalimumab alone or in combination with topical agents.
62184332|NCT05483114|ACTIVE_COMPARATOR|Polyvinylsiloxane|Accuracy of indirect bonding of self-ligating brackets made with polyvinylsiloxane transfers
62774287|NCT01981681|EXPERIMENTAL|Cohort 1 Experimental Arm|
61998654|NCT01990677|ACTIVE_COMPARATOR|25mg Eplerenone- Chronic CSCR Diagnosis|Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 58 days. Throughout the 58 day treatment period dosage will be adjusted. The adjustment will be based on serum potassium and creatine levels from blood draws done at Day 12 and Day 33. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or reduced to placebo, one time, each day.
61998655|NCT01990677|PLACEBO_COMPARATOR|Placebo- Chronic CSCR Diagnosis|Dosing will begin with placebo and will stay as placebo throughout the study. The placebo pills will be taken orally, once daily, for 58 days. The placebo pills will be compounded to be of similar composition to the eplerenone tablets, without the active ingredient.
61998656|NCT01990677|ACTIVE_COMPARATOR|25mg Eplerenone- Acute CSCR Diagnosis|Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 28 days. Throughout the 28 day treatment period, dosage will be adjusted based on serum potassium and creatine levels from blood draws done on Day 12. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or reduced to placebo, one time, each day.
61998657|NCT01990677|ACTIVE_COMPARATOR|Placebo- Acute CSCR Diagnosis.|Dosing will begin with placebo and will stay as placebo throughout the study. The placebo pills will be taken orally, once daily, for 28 days. The placebo pills will be compounded to be of similar composition to the eplerenone tablets, without the active ingredient.
62774288|NCT01981681|EXPERIMENTAL|Cohort 2 Experimental Arm|
62774289|NCT01981681|EXPERIMENTAL|Cohort 3 Experimental Arm|
61998658|NCT02248090|EXPERIMENTAL|AZD9496|AZD9496 dose escalation and expansion(s)
61998659|NCT01332136||Endoscopic sinus surgery|Patients electing endoscopic sinus surgery for chronic rhinosinusitis
61998660|NCT01332136||Medical management|Continued medical management for symptoms of chronic rhinosinusitis
61998661|NCT05992792|EXPERIMENTAL|App Salud Responde|"Subjects register in the Salud Responde (SR) app services de platform"
61998662|NCT05992792|EXPERIMENTAL|SMS Salud Responde|Subjects register in SR SMS services platform
62184333|NCT05483114|ACTIVE_COMPARATOR|Thermal glue|Accuracy of indirect bonding of self-ligating brackets made with thermal glue transfers
62393099|NCT05223764||Fertility preservation population|all women who underwent oocyte cryopreservation cycles for oncological purposes from January 2001 to December 2017 at Fertility Center of Humanitas Research Hospital, Rozzano (Milano), Italy
61998663|NCT05992792|EXPERIMENTAL|Internet|Subjects users with internet in their mobile phone
61998664|NCT05992792|EXPERIMENTAL|Whitout internet|Subjects whitout internet to recibe message by SMS
61998665|NCT05715567||Patients with COVID-19|
61998666|NCT05715567||Patients without COVID-19|
61998667|NCT04503564|EXPERIMENTAL|Achilles Infusion Set|Coil-reinforced soft polymer indwelling cannula
61998668|NCT05735288||Haemodialysis patients|Haemodialysis patients attending haemodialysis in an outpatient setting in Beaumont Hospital, Ireland.
61998669|NCT00774631|EXPERIMENTAL|Hypothermia|mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming
62393100|NCT05727696|ACTIVE_COMPARATOR|radial shortening|
61998670|NCT00774631|ACTIVE_COMPARATOR|No hypothermia|no hypothermia, according to local recommendations and guidelines of medical societies and literature
61998671|NCT02911675||Standard of Care Group|Study Group 1: Standard EVD/IVC management with therapeutic CSF drainage as appropriate and hourly EVD/IVC ICP measurements per standard of care with simultaneous IPM/Camino ICP measurements collected.
61998672|NCT02911675||Experimental Group|Study Group 2: Therapeutic CSF drainage as appropriate, with EVD/IVC closure and ICP assessment approximately every 12 hours with simultaneous IPM/Camino ICP measurements collected.
61998673|NCT02072291|EXPERIMENTAL|Nifedipine|Nifedipine 5mg single dose
62393101|NCT05727696|ACTIVE_COMPARATOR|capitate shortening|
62393102|NCT03154424|PLACEBO_COMPARATOR|Bridging (control group)|External fixation in treatment the distal radius fracture
62393103|NCT03154424|ACTIVE_COMPARATOR|Nonbridging (tested group)|External fixation in treatment the distal radius fracture improve grip strength?
62393104|NCT05029102|EXPERIMENTAL|TAS-102 and Anlotinib|TAS-102: 35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle Anlotinib: 10mg，per oral，once daily，days 1-14 of each 21-day cycle
62393105|NCT03243318||Presence of motor evoked potentials|Those patients with Shoulder Abduction and Finger Extension (SAFE) score \<8/10 with the presence of motor evoked potentials elicited by TMS over the ipsilesional motor cortex
61998674|NCT02072291|PLACEBO_COMPARATOR|Placebo|
62184334|NCT00809341|ACTIVE_COMPARATOR|PET Negative|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or an equivalent anthracycline-containing regimen for 3 cycles, followed by PET scan. Participants with a negative PET scan will complete their chemotherapy regimen as prescribed by their oncologist.
62184335|NCT00809341|ACTIVE_COMPARATOR|PET Positive|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or an equivalent anthracycline-containing regimen for 3 cycles, followed by PET scan. Participants with a positive PET scan will receive two cycles of R-ICE (rituximab, ifosfamide, carboplatin, etoposide) followed by HiCy (high-dose cyclophosphamide).
62184336|NCT05807425|EXPERIMENTAL|Polidocanol foam sclerotherapy|A cohort of cirrhotic patients with hemorrhoidal disease will be treated with polidocanol foam sclerotherapy.
62393106|NCT03243318||absence of motor evoked potentials|Those patients with Shoulder Abduction and Finger Extension (SAFE) score \<8/10 with the absence of motor evoked potentials elicited by TMS over the ipsilesional motor cortex
62774290|NCT01981681|PLACEBO_COMPARATOR|Cohort 3 Placebo Arm|
62774291|NCT01981681|EXPERIMENTAL|Cohort 4 Experimental Arm|
62774292|NCT01981681|PLACEBO_COMPARATOR|Cohort 4 Placebo Arm|
61998675|NCT05388942|EXPERIMENTAL|Virtual reality hypnosis (VRH)|
61998676|NCT05388942|ACTIVE_COMPARATOR|Nitrous oxide (NO)|
61998677|NCT00003256|EXPERIMENTAL|Arm I|Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects may receive a dose escalation.
61998678|NCT04460222|EXPERIMENTAL|Rotational Thromboelastometry (ROTEM)|To prevent bleeding during invasive procedure, cirrhotic children in the ROTEM group will receive prophylactic transfusion based on the following protocol:- EXTEM CT \> 80 sec - FFP will be transfused at 15 ml/kg MCF \< 35 mm- Platelet will be transfused at 10 ml/kg FIBTEM MCF \< 7 mm- Cryoprecipitate will be transfused at 5 ml/kg
62393107|NCT03970330|EXPERIMENTAL|Low-Dose Naltrexone|12-week intervention period of 4.5 mg daily naltrexone in combination with standard treatment of 5-15 mg daily norethindrone acetate
62393108|NCT03970330|PLACEBO_COMPARATOR|Placebo|12-week intervention period of daily placebo in combination with standard treatment of 5-15 mg daily norethindrone acetate
61998679|NCT04460222|ACTIVE_COMPARATOR|Conventional Transfusion|"To prevent bleeding during the procedure, cirrhotic children in the conventional group will receive prophylactic transfusion if either FFP, Platelet or Cryoprecipitate is deranged based on the following protocol~* If INR: 1.5 - 2.5 FFP will be transfused at 10 ml/kg~* If Platelet Count is 20,000/mm3-50,000/mm3 Platelet will be transfused at 10 ml/kg~* If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg"
61998680|NCT01143090|EXPERIMENTAL|Open Label|Subjects will continue on treatment with the same dose of lurasidone flexible dosing - 40 mg to 12 mg once daily taken orallay at endpoint of the D1050289 ( NCT01143077) core study.
62774293|NCT02841241|EXPERIMENTAL|Esmolol|Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
62184337|NCT00508274|EXPERIMENTAL|lapatinib in combination with capecitabine|daily oral lapatinib (1250 mg/day) in combination with capecitabine (2000mg/m2/day on days1-14 every 21 days)
62184338|NCT04281693|EXPERIMENTAL|Screening participants|
62393109|NCT00389909|ACTIVE_COMPARATOR|1|Treatment based on patient weight;
62393110|NCT00389909|ACTIVE_COMPARATOR|2|Treatment based on a chart taking into account weight, age and gender
62393111|NCT06046937|EXPERIMENTAL|Monolaurin Ointment|treatment arm
62393112|NCT06046937|ACTIVE_COMPARATOR|Mupirocin Ointment|control drug
62568546|NCT01387087|EXPERIMENTAL|Group F|Third highest dose, all males, fasting then fed
62568547|NCT01387087|EXPERIMENTAL|Group G|Second highest dose, all males, fasting
61998681|NCT02959281|EXPERIMENTAL|Hemodynamic data available|Providing caring physicians with hemodynamic variables measured using the NICAS system.
61998682|NCT02959281|NO_INTERVENTION|Hemodynamic data not available|Hemodynamic variables measured using the NICAS system will not be provided to the caring physicians.
62568548|NCT01387087|EXPERIMENTAL|Group H|Highest dose, all males, fasting
62568549|NCT01387087|EXPERIMENTAL|Group I|Second highest dose, all females, fasting
61998683|NCT03125512|EXPERIMENTAL|Night Shift positional device|Randomized to Night shift positional therapy first for 8 weeks, followed by CPAP for 8 weeks, with a 1 week washout period.
62184339|NCT04400799|EXPERIMENTAL|Test Group|Enoxaparin (Clexane®) will be given at the recommended dose of 4,000 IU antiXa activity (40 mg/0.4 ml) once daily by SC injection for 14 days.
62184340|NCT04400799|NO_INTERVENTION|Control Group|No study drug
62184341|NCT01419938|ACTIVE_COMPARATOR|Light therapy for two weeks|
62393113|NCT03726840|NO_INTERVENTION|Driving performance no fragrance|healthy young (ages 24-35 years) and older (ages 60-85 years) with no fragrance
62393114|NCT03726840|EXPERIMENTAL|Driving performance Fragrance|healthy young (ages 24-35 years) and older (ages 60-85 years) with fragrance
62393115|NCT05497570|ACTIVE_COMPARATOR|Tenoxicam|The Tenoxicam group (n:16) received both arthrocentesis and a 2-ml injection of tenoxicam (Oksamen-L, Mustafa Nevzat İlaç Sanayi, Istanbul, Turkey) to the temporomandibular joint.
62393116|NCT05497570|ACTIVE_COMPARATOR|Control|Only arthrocentesis was given to patients in the control group
62393117|NCT02756182|EXPERIMENTAL|Urodynamics with AC and WP|Patients underwent a conventional urodynamics study utilizing a single catheter technique
62393118|NCT00971100|EXPERIMENTAL|low dose of antigen + low dose of adjuvant|
62393119|NCT00971100|EXPERIMENTAL|high dose of antigen + high dose of adjuvant|
62393120|NCT00971100|EXPERIMENTAL|high dose of antigen|
62568550|NCT01387087|PLACEBO_COMPARATOR|Placebo Group A|all male, fasting
62568551|NCT01387087|PLACEBO_COMPARATOR|Placebo Group B|all male, fasting then fed
62568552|NCT01387087|PLACEBO_COMPARATOR|Placebo Group C|all female, fasting
62568553|NCT04005430|EXPERIMENTAL|Phase 1|Phase I open label study
62774294|NCT03550768||MDP|ERCP was performed by trainees or trainers. Before the cannulation, the photo of major duodenal papilla will be taken carefully to evaluate its size, morphology, orientation and location. All patients initially received wire-guided cannulation with a sphincterotome, If cannulation failed, precut sphincterotomy or the double-wire technique was performed when appropriate. Therapeutic manipulation (eg, sphincterotomy, balloon dilation, stone extraction, and stenting) was done when appropriate. Pancreatic duct stent placement was performed at the discretion of the endoscopists.
62774295|NCT04491760|EXPERIMENTAL|Inspiratory muscle training|Inspiratory muscle training (IMT) will be perform for 15 minutes each time, twice a day, training every day from 12h to 24h after primary percutaneous coronary intervention (PCI) to 30 days since randomized.
62184342|NCT01419938|ACTIVE_COMPARATOR|Light therapy and CBT|Two weeks of light therapy and after that 4 weeks of Cognitive behaviour therapy (CBT)
62774296|NCT04491760|NO_INTERVENTION|Control group|Participants will receive standard care according to the current guideline and clinical practice after primary PCI.
62774297|NCT05771038|ACTIVE_COMPARATOR|sodium alendronate group|prepared sodium alendronate gel will be placed in defective extraction sockets.
62774298|NCT05771038|ACTIVE_COMPARATOR|stickybone group|20cc of venous blood is collected from the patient's forearm into silica-coated tube (10 ml) and 1 non coated vacutainer. Blood will be used to make injectable prf by spinning in centrifuge(2400-2700) for 2 minutes to produce autologous fibrin glue and then for 12 minutes+/- 2 minutes to obtain the concentrated growth factor layer. and sticky bone will be prepared then inserted into the socket.
62568554|NCT03074825|EXPERIMENTAL|chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
62774299|NCT03030339||Group 1: High VA intake, recent VAS|Children who are exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake
62774300|NCT03030339||Group 2: High VA intake|Children who are exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
62774301|NCT03030339||Group 3: Low/adequate VA intake|Children who are not exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
62774302|NCT05095168|EXPERIMENTAL|Single Ascending Dose (SAD)|In the SAD arm subjects will be sequentially included in one of up to six cohorts (dose levels). Additional subjects may be added in any cohort if necessary.
62774303|NCT05095168|PLACEBO_COMPARATOR|placebo|In the SAD arm subjects will be sequentially included in one of up to six cohorts (dose levels). In higher dose levels, subjects will be randomized to receive the treatment or placebo.
62774304|NCT02149017|EXPERIMENTAL|SNUBH-NM-333(18F), Safety, Efficacy|10 young controls, 10 cognitively normal elderly, and 10 Alzheimer's disease patients
62774305|NCT02133365|ACTIVE_COMPARATOR|Mindfulness and Interoceptive Exposure|Atrial fibrillation patients will receive 4-5 manualized, individualized sessions of Mindfulness and Interoceptive Exposure.
62774306|NCT02133365|NO_INTERVENTION|Medical care as usual|Atrial fibrillation patients will receive medical and cardiac care as usual.
62774307|NCT03468322|EXPERIMENTAL|AC-203 1% ointment|AC-203 1% ointment, QD
62774308|NCT03468322|PLACEBO_COMPARATOR|Vehicle ointment|Vehicle ointment, QD
62774309|NCT02125565|EXPERIMENTAL|Local Anaesthesia|These subjects received an injection of lidocaine 1% 2ml subcutaneously prior to arterial puncture
62774310|NCT02125565|NO_INTERVENTION|No Local Anaesthesia|Patients underwent arterial puncture directly with NO prior anaesthesia
62774311|NCT01013311||Cardiac Sarcoidosis|Patients with Cardiac Sarcoidosis who had an ICD implanted
62774312|NCT03908476|EXPERIMENTAL|Subjects using BurstDR SCS systems|Spinal cord stimulation with a Burst waveform.
61998684|NCT03125512|ACTIVE_COMPARATOR|Continuous positive airway pressure|Randomized to CPAP first for 8 weeks, followed by positional therapy for 8 weeks, with a 1 week washout period.
62184343|NCT04815343|EXPERIMENTAL|Bilateral users|two implant systemswith two sound processors
62184344|NCT04815343|EXPERIMENTAL|Bimodal user|with one sound processor and one hearing aid
62184345|NCT02605278|EXPERIMENTAL|Clinical program for pain and depression|Structured program with integrated management for depression and chronic musculoskeletal pain with three main components: 1) Optimized care of major depression on the basis of a Clinical Guideline 2) Care Management, and 3) Group psychoeducational intervention.
61998685|NCT04552938||Patients underwent supermicrosurgical LVA|Patients underwent supermicrosurgical LVA between June 2018 and May 2019.
62184346|NCT02605278|ACTIVE_COMPARATOR|Control|Care as usual
62184347|NCT00589836||Cardiac Pathologies|Patients with cardiomyopathy, ischemic heart disease, will have tissue Doppler echocardiograms performed
62184348|NCT06023810|EXPERIMENTAL|experimental|Watson's human care theory-based motivational interviewing method
62568555|NCT03578432|EXPERIMENTAL|Supportive care (everolimus, saliva output testing)|Participants receive everolimus PO QD for 5 days beginning 2 weeks after radiation treatment. Participants also undergo saliva output testing at baseline prior to radiation or chemoradiation treatment, after 3 weeks of RT/chemoRT, after 6 weeks of RT/chemoRT, prior to everolimus administration, at completion of the 5 day everolimus course, and at 1, 3, and 6 months after the completion of radiation or chemoradiation therapy.
62774313|NCT03908476|EXPERIMENTAL|Subjects using DRG systems|Dorsal root ganglion stimulation.
62774314|NCT00594594|EXPERIMENTAL|1|Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
62184349|NCT06023810|NO_INTERVENTION|control|
62393121|NCT04632316|EXPERIMENTAL|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
62568556|NCT03155464|OTHER|Group 1|"Order of two elements of surgical procedure: patients in group 1 will receive sympathectomy prior to bypass during the surgical procedure.~Indocyanine Green (ICG) will be used in both groups."
62774315|NCT03403309|EXPERIMENTAL|Inosine 5'-monophosphate arm|Subjects are treated with inosine 5'-monophosphate to increase serum uric acid level.
62774316|NCT03403309|PLACEBO_COMPARATOR|Placebo arm|Subjects are treated with placebo not to increase serum uric acid level.
62774317|NCT01235299||Healthy subjects|
62774318|NCT01235299||Subjects suffering from Diabetes mellitus|
62774319|NCT01235299||Subjects suffering from peripheral arterial occlusive disease|
62774320|NCT03519061|EXPERIMENTAL|Treatment|This is the group of enrollees who receive budesonide
62774321|NCT05533710|EXPERIMENTAL|Group A : erector spinae block.|patients will receive bilateral ultrasound guided erector spinae block.
62774322|NCT05533710|EXPERIMENTAL|Group B : transversus abdominis plane block.|patients will receive bilateral ultrasound guided transversus abdominis plane block.
62774323|NCT05298800|EXPERIMENTAL|COVID-19 and QIV|
61998686|NCT02908724||ERT receiving patients|Patients that were receiving specific treatment for FD (ERT, enzyme replacement therapy, Fabrazyme or Replagal) during the observational time (n= 47).
61998687|NCT02908724||non-ERT receiving patients|Patients that were not receiving specific treatment for FD (ERT, enzyme replacement therapy, Fabrazyme or Replagal) during the observational time (n= 19).
62774324|NCT05298800|EXPERIMENTAL|COVID-19 and PPV23|
62774325|NCT05298800|EXPERIMENTAL|COVID-19|
62774326|NCT03399955|EXPERIMENTAL|Arm 1: Paromomycin + Miltefosine|Paromomycin 20 mg/kg/d IM for 14 days combined with Miltefosine allometric BID PO dosing for 42 days
62774327|NCT03399955|EXPERIMENTAL|Arm 2: Ambisome + Miltefosine|AmBisome® 5mg/kg/d IV infusion at D1, D3, D5 and D7 (20 mg/kg total dose) combined with Miltefosine allometric BID PO dosing for 28 days
62774328|NCT00658190||1|Women obtaining routine Pap tests for cervical cancer screening
62774329|NCT04081272||G6PD-normal|Donated blood from G6PD-normal subjects
62774330|NCT04081272||G6PD-deficient|Donated blood from G6PD-deficient subjects
61998688|NCT00698269||A|
61998689|NCT00698269||B|
61998690|NCT00698269||C|
61998691|NCT01384435|EXPERIMENTAL|KPS-0373, lowest dose|
61998692|NCT01384435|EXPERIMENTAL|KPS-0373, 2nd lowest dose|
61998693|NCT01384435|EXPERIMENTAL|KPS-0373, 2nd highest dose|
61998694|NCT01384435|EXPERIMENTAL|KPS-0373, highest dose|
61998695|NCT01384435|PLACEBO_COMPARATOR|Placebo|
61998696|NCT04334460|ACTIVE_COMPARATOR|Active (BLD-2660) Group|
61998697|NCT04334460|PLACEBO_COMPARATOR|Placebo Group|
61998698|NCT01073865|EXPERIMENTAL|1|"Zoladex 10.8 mg (goserelin acetate) will be injected once every 12 weeks (± 7 days).~One oral tamoxifen 20 mg tablet also will be taken daily"
61998699|NCT01073865|ACTIVE_COMPARATOR|2|Zoladex 3.6 mg (goserelin acetate) will be injected once every 4 weeks (± 7 days). One oral tamoxifen 20 mg tablet will also be taken daily.
61998700|NCT03266068||Post Infectious IBS Case|Subjects who have suffered from acute bacterial gastroenteritis within last two years and have developed some symptoms that might be suggestive of post-infectious irritable bowel syndrome (IBS). Subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
62020958|NCT01371318|NO_INTERVENTION|Standard of Care|Medical/wound centers will be randomized to continue routine care of patients with diabetic foot ulcers
62020959|NCT00910481|EXPERIMENTAL|Elective IABP Insertion|
62020960|NCT00910481|NO_INTERVENTION|No Planned IABP Insertion|
61998701|NCT03266068||Post Infectious with no IBS Control|Subjects who have suffered from acute bacterial gastroenteritis within last two years and have not developed symptoms suggestive of post-infectious irritable bowel syndrome (IBS). Subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
61998702|NCT03266068||Healthy Control|Healthy volunteers; subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
62184350|NCT06124976|EXPERIMENTAL|ST-02|ST-02 is a new gemcitabine formulation for instillation into the upper urinary tract. Eligible participants will be enrolled and receive ST-02 once weekly for six weeks in a retrograde or antegrade fashion at the discretion of the treating urologist.
62774331|NCT00300365|EXPERIMENTAL|Active Pioglitazone + Open-Label Niacin|Intervention: Pioglitazone, initially 30mg, then titrated to 45mg + niacin ER 2.0 g/day + aspirin 325 mg/day
62774332|NCT00300365|PLACEBO_COMPARATOR|Placebo +Open-Label Niacin|Intervention: Pioglitazone Placebo + 2.0 g/day Open-Label Niacin + 325 mg/day Aspirin
62184351|NCT06250088|ACTIVE_COMPARATOR|Emdogain (EMD)|
62184352|NCT06250088|SHAM_COMPARATOR|Control|
62184353|NCT05074771|EXPERIMENTAL|ARC intellicare|"Study participants will use ARC intellicare at home, to carry out usability tests and a collection of useful data in order to optimise the system. After enrolment and training session, patients will receive an ARC unit to be used autonomously for the following 30 days.~45 minutes 5 days / week for 4 weeks of personalized training will be carried out by the enrolled subjects: 4 weekly sessions will be unsupervised, while one will be supervised remotely by a therapist in telepresence, thanks to the integrated audio-video channel."
62184354|NCT03647384|EXPERIMENTAL|Intervention|In this arm, patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
62774333|NCT01158690|EXPERIMENTAL|resource card group|The intervention group will receive an envelope with a gift voucher and a resource card (wallet size card with on the one side safety measures and on the other side contact details of resources for violence).
61998703|NCT05321862|EXPERIMENTAL|[68Ga]Ga-PentixaFor|
61998704|NCT06080152|EXPERIMENTAL|1|1. 12 patients get an A-linker 3 months before surgery (knee arthroplasty)
61998705|NCT06080152|NO_INTERVENTION|2|2. 12 patients use a walker 3 months before surgery (knee arthroplasty)
62184355|NCT03647384|ACTIVE_COMPARATOR|Control|In this arm, patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
62568557|NCT03155464|OTHER|Group 2|"Order of two elements of surgical procedure: Patients in group 2 will receive bypass prior to sympathectomy during the surgical procedure.~Indocyanine Green (ICG) will be used in both groups."
62568558|NCT01945840|ACTIVE_COMPARATOR|Roux en Y Gastric Bypass|Participants will be those already scheduled to undergo Roux en Y Gastric Bypass Surgery
61998706|NCT05927753|EXPERIMENTAL|Test lens. Deseyne Daily Disposable Contact Lens|Test contact lens to be worn as a daily disposable soft (hydrophilic) contact lens, to be discarded daily. Individual new lens placed daily for a period of 90 consecutive days, bilaterally. Follow-up visits are 1 week, 1 month, 2 months, and 3 months after dispensing.
61998707|NCT05927753|ACTIVE_COMPARATOR|Control lens. 1-Day Acuvue Moist Daily Disposable Contact Lens|Control lens to be worn as a daily disposable soft (hydrophilic) contact lens, to be discarded daily, Individual new lens placed daily for a period of 90 consecutive days, bilaterally. Follow-up visits are 1 week, 1 month, 2 months, and 3 months after dispensing.
62020961|NCT05818449|EXPERIMENTAL|DigiNet group|The intervention group will receive the DigiNet intervention.
62184356|NCT05330052|EXPERIMENTAL|Agilik|The participant will be provided custom knee orthoses (the Agilik) to trial in this study
62568559|NCT01945840|EXPERIMENTAL|Gut hormone infusion|"Infusion of three gut hormones (GLP-1, PYY and oxyntomodulin) subcutaneously for 4 weeks as below:~* Combination of GLP-1/OXM/PYY (GOP)~* Single GLP-1~* Single OXM~* Single PYY~* Combination of GLP-1 and OXM~* Combination of GLP-1 and PYY~* Combination of OXM and PYY"
62774334|NCT01158690|ACTIVE_COMPARATOR|control group|The control group will receive the same envelop with a gift voucher and a letter of thanks.
62020962|NCT05818449|NO_INTERVENTION|Comparison group|The comparison group will receive usual care.
62020963|NCT05421598|EXPERIMENTAL|Amlitelimab dose level 1|Initial loading dose of amlitelimab on Day 1, followed by one injection of amlitelimab dose level 1 every 4 weeks (Q4W) until Week 20 (inclusive) and every 12 weeks (Q12W) starting from Week 24 and thereafter.
62020964|NCT05421598|EXPERIMENTAL|Amlitelimab dose level 2|Initial loading dose of amlitelimab on Day 1, followed by one injection of amlitelimab dose level 2 Q4W until Week 20 (inclusive) and Q12W starting from Week 24 and thereafter.
62184357|NCT01019798|EXPERIMENTAL|open label|
62184358|NCT05629143|OTHER|Intermittent deprescribing strategy|Classical approach for deprescribing of PPI based on Belgian Guidelines. In this study arm, the patients will keep the intake of their PPI but will decrease the use of PPI using a scheme where the PPI dose in reduced intermittently for one month. After one month in the intermittent deprescribing scheme, the patients will stop the use of PPI.
62184359|NCT05629143|OTHER|On-demand deprescribing strategy|In this study arm, the patients will keep the intake of their PPI but will decrease the use of PPI in an on-demand bases for one month. The patient will only take the PPI when strictly needed because of symptoms. After one month in the on-demand PPI use, the patients will stop the use of PPI.
62184360|NCT05629143|OTHER|Replacement of PPI with alginate therapy|In this study arm, the patient will stop the intake of the PPI band replace it with the use of an alginate for one month. After one month, the patient will stop the use of alginates.
62568560|NCT01945840|PLACEBO_COMPARATOR|Placebo infusion|Saline infusion given subcutaneously for 4 weeks.
62568561|NCT01945840|ACTIVE_COMPARATOR|Very low calorie diet|Participants will be asked to follow a very low calorie diet for 4 weeks.
62774335|NCT04593407|ACTIVE_COMPARATOR|Endoscopic Mucosal Resection (EMR):|Piecemeal EMR is a conventional endoscopic resection technique. A submucosal injection of a large volume of a solution (normal saline or other) with or without dilute epinephrine (1/10,000) with or without indigo carmine is performed. Then, sequential piecemeal resection is performed with use of a combination of stiff-type snares. At the end of the procedure when macroscopically visible adenoma has been totally resected, a snare tip soft coagulation (STSC) of the margin of the scar is performed to eliminate non visible residual neoplastic tissue. This procedure is quicker and safer than ESD but led to more recurrent disease (around 20% with the standard technique but recently reduced to 5% after the introduction of STSC)
62568562|NCT02856932|EXPERIMENTAL|Glass Ionomer with Glass Hybrid technology|Intervention
62774336|NCT04593407|EXPERIMENTAL|: Endoscopic Submucosal Dissection (ESD):|ESD is a newer resection technique that allows en bloc resection for large LSLs. A submucosal injection is also needed but, in this case, different endo-knives are used to achieve the resection instead of diathermic snares. The en bloc resection allows a more precise pathological analysis and the risk of recurrence is lower (\<2%) when margins are tumor-free.
62774337|NCT01178424|EXPERIMENTAL|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of mindfulness skills taught in the program.
62774338|NCT01178424|ACTIVE_COMPARATOR|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
62774339|NCT01423916|ACTIVE_COMPARATOR|Arm 1 (OPC-34712, placebo)|Arm 1 will be administered 4 mg OPC-34712 once daily (QD) for 11 days and OPC-34712 placebo for 1 day.
62774340|NCT01423916|ACTIVE_COMPARATOR|Arm 2 (OPC-34712, placebo)|Arm 2 will be administered 12 mg OPC-34712 QD for 11 days and OPC-34712 placebo for 1 day.
62774341|NCT01423916|ACTIVE_COMPARATOR|Arm 3 (moxifloxacin, placebo)|Arm 3 will be administered 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for 1 day and OPC-34712 placebo QD for 11 days.
62774342|NCT01423916|ACTIVE_COMPARATOR|Arm 4 (moxifloxacin, placebo)|Arm 4 will be administered OPC-34712 placebo QD for 11 days and 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for one day.
62774343|NCT00701805|EXPERIMENTAL|Paricalcitol 2 µg ± 1 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
62774344|NCT00701805|EXPERIMENTAL|Paricalcitol 2 µg ± 2 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
62184361|NCT05419310|EXPERIMENTAL|Group A1|Rehabilitation based on core strengthening exercises associated with the application of REAL elastic taping
62184362|NCT05419310|SHAM_COMPARATOR|Group A2|Rehabilitation based on core strengthening exercises, associated with the application of SHAM elastic taping - sham comparator to group A1
62184363|NCT05419310|EXPERIMENTAL|Group A3|rehabilitation based on exercises for core strengthening
62184364|NCT05419310|ACTIVE_COMPARATOR|Group B|The intervention group B will perform rehabilitation treatment with a structured protocol based on rehabilitation pilates. Comparator to Group A3
62184365|NCT04492137|EXPERIMENTAL|Ultra Early NKF group|Patients submitted to Ultra early NKF in a consecutive fashion by an expert endoscopist
62393122|NCT05503758||Group A|9 participants have exposed to midline epidural anaesthesia for cesarean delivery.
62568563|NCT02856932|ACTIVE_COMPARATOR|Conventional high viscosity Glass Ionomer|Comparator
62568564|NCT05596929|NO_INTERVENTION|Control|
62568565|NCT05596929|EXPERIMENTAL|Experimental|
61998708|NCT02809430|EXPERIMENTAL|CPAP intervention|Participants will receive 3 nights of auto-CPAP in order to identify those with OSA using flow resistance detected by the device. After 3 nights, those without apparent OSA or with central apnea, and those who simply do not tolerate CPAP will be excluded from the study. An intensive CPAP adherence protocol (iCAP) will be initiated, including collaborative care with rehabilitation nurses, the study's sleep technologist and overnight respiratory therapists. After the run-in period, the sleep technologist will meet at least twice weekly with CPAP-tolerant participants during their rehabilitation stay for further OSA education and encouragement with a target adherence of 4 hours per night. Participants diagnosed with OSA by the device and tolerant will continue CPAP therapy during rehabilitation and at home for a treatment period of 3 months. Adherence will be downloaded remotely from participant's machines to encourage adherence to treatment and troubleshoot any problems with the device.
61998709|NCT06226727|EXPERIMENTAL|Sequence Group A|"The investigational products will be administered according to the treatment groups assigned to each sequence group in Period 1\~4.~\*Sequence Group A \[Period 1, 3\] Co-administration of BR1019-1(R1) and BR1019-2(R2). \[Period 2, 4\] Administration of BR1019(T)"
61998710|NCT06226727|EXPERIMENTAL|Sequence Group B|"The investigational products will be administered according to the treatment groups assigned to each sequence group in Period 1\~4.~\*Sequence Group B \[Period 1, 3\] Administration of BR1019(T) \[Period 2, 4\] Co-administration of BR1019-1(R1) and BR1019-2(R2)."
62184366|NCT04492137|NO_INTERVENTION|Standard cannulation techniques group (including double-guidewire-assisted cannulation)|Patients submitted to standard cannulation techniques (including double-guidewire-assisted cannulation) in a consecutive fashion by an expert endoscopist
62184367|NCT01476813|EXPERIMENTAL|Glyco 25|BDP/FF (400/24 daily)+ Glyco 25µg daily
62184368|NCT01476813|EXPERIMENTAL|Glyco 50|BDP/FF (400/24 daily)+ Glyco 50 µg daily
62184369|NCT01476813|EXPERIMENTAL|Glyco 100|BDP/FF (400/24 daily)+ Glyco 100µg daily
62184370|NCT01476813|ACTIVE_COMPARATOR|BDP/FF 400/24|BDP/FF 400/24
62184371|NCT00548756|EXPERIMENTAL|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy
62184372|NCT00548756|OTHER|Observation|Observation
62184373|NCT03789812|ACTIVE_COMPARATOR|Manual Toothbrush with Superfloss|Patients in this group will receive Manual Toothbrush (Oral B) and Superfloss (Oral B) and will be instructed to use them three times a day.
62184374|NCT03789812|EXPERIMENTAL|Electric Toothbrush with Superfloss|Patients in this group will receive Electric Toothbrush (JETPIK) and Superfloss (Oral B) and will be instructed to use them three times a day.
62184375|NCT03789812|EXPERIMENTAL|Manual Toothbrush with Water Flosser|Patient in this group will receive Manual Toothbrush and Dental Water Jet and will be instructed to use them three times a day.
62184376|NCT03789812|EXPERIMENTAL|Electric Toothbrush with Water Flosser|Patient in this group will receive Electric tooth brush (JETPIK) and water flosser and will be instructed to use them three times a day.
62184377|NCT01785147|EXPERIMENTAL|BP1.4979 3mg|BP1.4979 3mg during 3 months
62774345|NCT00701805|EXPERIMENTAL|Paricalcitol 4 µg ± 1 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
62774346|NCT00701805|EXPERIMENTAL|Paricalcitol 4 µg ± 2 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
62774347|NCT01816555|EXPERIMENTAL|Vitamin D- Normal Level at Screening|Subjects will have surgery as their initial breast therapy. If subjects have a normal level of Vitamin D(25-hydroxyVit D 30-100ng/mL), they will be assigned to this group.
62184378|NCT01785147|EXPERIMENTAL|BP1.4979 10mg|BP1.4979 10mg during 3 months
62184379|NCT01785147|EXPERIMENTAL|BP1.4979 15mg|BP1.4979 15mg during 3 months
62184380|NCT01785147|PLACEBO_COMPARATOR|Placebo|Placebo during 3 months
62184381|NCT06385041|NO_INTERVENTION|Control group|Physical training program will include: dosed aerobic training program on cycle ergometers (6 days/week, for 10-30 minutes, 30-50% watts or 30-50% HRmax). The training program consists individually according to the person state of health and respiratory muscle training (7 days/week, for 15 minutes).
62184382|NCT06385041|EXPERIMENTAL|Intervention group 1|Physical training program will include: dosed aerobic training program on cycle ergometers and respiratory muscle trainings as in control group. Also patients will get an individualized exercise program for frailty syndrome, which will include strength exercises (with elastic resistance bands and weights) and balance training (unstable surfaces) 3 times/week 30-45 minutes.
62393123|NCT05503758||Group B|22 participants have exposed to midline spinal anaesthesia for cesarean delivery.
62184383|NCT06385041|EXPERIMENTAL|Intervention group 2|Physical training program will include: dosed aerobic training program on cycle ergometers and respiratory muscle trainings as in control group. Also patients will get an individualized program for frailty syndrome, with the help of interactive technologies 3 times/week. 30-45 minutes (gait training with Biodex GaitTrainerTM3 with visual and audio feedback, Zebris FDM-T, with the help of which virtual barriers are created, thus simulating real environment for the patient, while performing a cognitive task, for balance training we will use a computerized Biodex board. For strength training we will use equipment HUR based on pneumatic (air pressure) technology.
62184384|NCT01592084||lipid lowering therapy|those with lipid lowering therapy those without lipid lowering therapy
62184385|NCT04505475||Direct oral anticoagulants|Patients taking dabigatran, ravaroxaban or apixaban
62184386|NCT04505475||Vitamin K antagonists|Patients taking acenocoumarol with therapeutic INR levels (2.0-3.5)
62184387|NCT04266353|EXPERIMENTAL|Single arm|Participants with receive resveratrol at 150 mg daily for 6 weeks
62184388|NCT06220812|EXPERIMENTAL|study group A|20 children will receive designed physical therapy program in addition to low level laser
62184389|NCT06220812|EXPERIMENTAL|study group B|20 children will receive designed physical therapy program in addition to pulsed electromagnetic field .
62774348|NCT01816555|EXPERIMENTAL|Vitamin D- Insufficient or Deficient Level at Screening|Subjects will have surgery as their initial breast therapy. If subjects are insufficient (25-hydroxy Vit D 21-29 ng/mL)or deficient (25-hydroxyVit D \<20ng/mL) Vitamin D levels, they will be assigned to this group.
62774349|NCT03922165||DS peds eligible for Adenotonsillectomy|Dyads of caregivers and children with DS aged 3-13 years diagnosed with SDB and referred for treatment with adenotonsillectomy.
62184390|NCT02759796|PLACEBO_COMPARATOR|Clinical assessment of flap perfusion|Tailoring the flap according to clinical assessment of flap perfusion
61998711|NCT02825069|EXPERIMENTAL|Intervention group|Early introduction of solid foods starting at the age of 4 months, with foodstuff from all major groups in diet by the age of 6 months (vegetables and fruits, wheat and other grains, meat, fish, egg, dairy products). Babies presenting with mild symptoms are encouraged to continue the symptom-eliciting food.
62184391|NCT02759796|EXPERIMENTAL|Angiography assessment of flap perfusion|Tailoring the flap according to ICG Angiography assessment of flap perfusion
62184392|NCT03246347|EXPERIMENTAL|Single Arm|Docetaxel + Enzalutamide + Androgen Deprivation Therapy
62184393|NCT01648595|EXPERIMENTAL|Fentanyl|In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour. In control group was not intervention.
62184394|NCT01648595|NO_INTERVENTION|Without Fentanyl|The control group did not receive Fentanyl.
62184395|NCT02783053|OTHER|Metformin use|The investigators compare the use of metformin vs no metformin
62184396|NCT02783053|NO_INTERVENTION|Lean or Obese|The investigators compare the effect of metformin on 18F-FDG uptake between lean and obese men.
62184397|NCT00636662||all|any patient exhibiting symptoms of influenza
62184398|NCT02762305|EXPERIMENTAL|RSVP Bone Builder group exercise|A group of older adults who are participating in the RSVP Bone Builder group exercise.
62184399|NCT01405677|EXPERIMENTAL|Epaxal 0.25 mL|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
62184400|NCT01405677|ACTIVE_COMPARATOR|Epaxal 0.5 mL|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
62184401|NCT01405677|ACTIVE_COMPARATOR|Havrix Junior|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
62184402|NCT02115919|EXPERIMENTAL|Cohort A|Cohort A participants will undergo perilesional Multikine injections (200IU) once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.
62774350|NCT00931801|EXPERIMENTAL|Intervention Arm No.1|
61998712|NCT02825069|NO_INTERVENTION|Control group|Families are advised to follow the official Finnish Nutrition Recommendations, including exclusive breastfeeding until the age of 6 months.
61998713|NCT04219865|ACTIVE_COMPARATOR|Compound Edaravone|10 mL per vial (containing edaravone 10 mg and 2-aminoethanesulfonic acid 200 mg)
61998714|NCT04219865|PLACEBO_COMPARATOR|Placebo|10 mL per vial
62184403|NCT02115919|EXPERIMENTAL|Cohort B|Cohort B participants will undergo perilesional Multikine injections 400IU once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.
62393124|NCT05503758||Group C|10 participants underwent general anesthesia for cesarean delivery.
62774351|NCT00931801|EXPERIMENTAL|Intervention Arm No.2|
62774352|NCT00931801|ACTIVE_COMPARATOR|Control Arm|Continue baseline regimen
62774353|NCT04450329|EXPERIMENTAL|SB15 (Proposed aflibercept biosimilar)|Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
62791593|NCT05590507|EXPERIMENTAL|Group A/Intervention|Subjects will use mindfulness audio recordings along with their physical activity, and will receive a weekly health coaching phone call along with supplemental educational materials.
61998715|NCT03726177|ACTIVE_COMPARATOR|aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
62184404|NCT05482490|EXPERIMENTAL|IFCDPprotocol|Patients subjected to the novel implant-supported fixed complete dental prostheses maintenance protocol
62184405|NCT01576913|ACTIVE_COMPARATOR|Music pacing|Exercise testing with music pacing
62184406|NCT01576913|NO_INTERVENTION|No music pacing|Exercise testing without music pacing
62184407|NCT04481646||1|Patients admitted to hospital with COVID-19 symptoms will be approached to undertake a face mask sample and nasopharyngeal swab at two time points 12 hours apart on a single day whilst in hospital. Medical records will be accessed for basic clinical, demographic and microbiological data.
62393125|NCT05503758||Group D|22 participants were in the control group (no previous pregnancy or anaesthesia).
62393126|NCT03734601|EXPERIMENTAL|TBI+TLI|TBI, single exposure on Day -1, 80 centigray (cGy) in addition to total lymphoid irradiation (TLI, 120 cGy/day for 9 days, weekends excluded) and anti-thymocyte globulin (ATG) 1.5 mg/kg (conditioning regimen)
62774354|NCT04450329|ACTIVE_COMPARATOR|Eylea (Aflibercept)|"Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.~At Week 32, subjects in Eylea group will re-randomized into SB15 or Eylea group. After re-randomization, subjects transited to SB15 group will receive SB15 2 mg (0.05 mL) once every 8 weeks until Week 48 and subjects remaining in Eylea group will continue to receive Eylea 2 mg (0.05 mL) once every 8 weeks until Week 48."
62774355|NCT00556270||Matrix II|
62184408|NCT04481646||2|Healthcare workers who have report COVID-19 symptoms will be asked to undertake a face mask sample and nasophayngeal swab on days 1,3,5,7,10,14 and 21 of the study, for part of which they will be quarantined at home.During this time they will complete a simple symptom diary. Medical records will be accessed for basic clinical, demographic and microbiological data.
62774356|NCT05985096|EXPERIMENTAL|Virtual Reality Group|"Adequate physical activity not only reduces depression, but also prevents the neural dysfunction that can occur as a result of depression. However, the level of physical activity among young people is not sufficient. Based on this fact, we believe that it is necessary to use 3D virtual reality applications to increase physical activity levels and exercise motivation.~The aim of our study is to investigate the effect of virtual reality training on balance, depression, anxiety and stress parameters in healthy young people."
62774357|NCT05985096|NO_INTERVENTION|Control Group|The control group will perform individual exercise. The physical activity will be monitored with video recordings.
62774358|NCT01657760|PLACEBO_COMPARATOR|placebo|Intravenous saline control, in a double-blind, crossover study, with infusion days at least 2 weeks apart.
62774359|NCT01657760|ACTIVE_COMPARATOR|citalopram infusion|40 mg citalopram in 250 ml saline infused over 1 hour, in a double-blind, crossover study, with infusion days at least 2 weeks apart.
62774360|NCT01919216|ACTIVE_COMPARATOR|Open Track|Open treatment with 20mg of citalopram, increased to 40mg if depression has not remitted at week 4.
62774361|NCT01919216|PLACEBO_COMPARATOR|Placebo Track|Blinded treatment with either citalopram 20mg or placebo, increased to citalopram 40mg or placebo at week 4 if depression has not remitted.
62774362|NCT02964585|ACTIVE_COMPARATOR|Active Arm|100 mg of Canagliflozin for 16 weeks
62184409|NCT04481646||3|Healthcare workers from different areas of the hospital will be approached as part of a screening programme. They will be asked to undertake a single face mask and swab sample. Basic clinical and environmental data will be collected about each participant so they exposure risk can be stratified.
62393127|NCT03436212|OTHER|Continuous Glucose Monitoring (CGM)|DEXCOMG4 device for 14 days
62393128|NCT06452680|EXPERIMENTAL|Preservation group|In the preservation group, the IPL was untouched
62393129|NCT06452680|NO_INTERVENTION|Dissection group|In the dissection group, the IPL was commonly dissected until the inferior pulmonary vein was exposed
62774363|NCT02964585|PLACEBO_COMPARATOR|Placebo Arm|Placebo for 16 weeks
62774364|NCT01543776|ACTIVE_COMPARATOR|Arm I (fasting)|Patients receive abiraterone acetate PO daily first thing in morning after an overnight fast of at least 8 hours.
62774365|NCT01543776|EXPERIMENTAL|Arm II (fed)|Patients receive abiraterone acetate PO daily within 30 minutes of a conventional low-fat breakfast.
62774366|NCT06065592|ACTIVE_COMPARATOR|Non-Carriers of Targeted Gene-Related Polymorphisms (GRPs) in Cancer Patients|Cancer patients without any incidence of thromboembolism will be included if they are non-carriers of the targeted gene-related polymorphism (GRP).
62774367|NCT06065592|ACTIVE_COMPARATOR|Carriers of Targeted GRPs in Cancer Patients|Cancer patients without any incidence of thromboembolism will be included if they are carriers of the targeted gene-related polymorphism.
62774368|NCT06065592|EXPERIMENTAL|Carriers of Targeted GRPs in Cancer-Associated Thromboembolism Patients|Cancer patients with incidence of thromboembolism will be included if they are carriers of the targeted gene-related polymorphism.
62774369|NCT06065592|EXPERIMENTAL|Carriers of Targeted GRPs in Cancer-Associated Thromboembolism Patients Treated with Palbociclib|Cancer patients with incidence of thromboembolism will be included if they are carriers of the targeted gene-related polymorphism and will be subjected to Palbociclib treatment.
62774370|NCT06065592|EXPERIMENTAL|Carriers of Targeted GRPs in Cancer-Associated Thromboembolism Treated with Anti-Coagulant|Cancer patients with incidence of thromboembolism will be included if they are carriers of the targeted gene-related polymorphism and will be subjected to anti-coagulant treatment.
62774371|NCT05883254||Control group|Normal individuals
62791594|NCT05590507|NO_INTERVENTION|Group B/Control|Subjects will receive education materials on healthy habits for increasing physical activity based on the National Institutes of Health, and bi-weekly check-in phone call.
62184410|NCT05720377|EXPERIMENTAL|Obese, receives access to exercise phone application|obese, receives access to exercise phone application and interval contact by health provider in between clinic visits , receives continuous glucose monitor
62184411|NCT05720377|NO_INTERVENTION|Obese, no intervention|obese, receives continuous glucose monitor
62184412|NCT05720377|EXPERIMENTAL|Prediabetes, receives access to exercise phone application|prediabetes receives access to exercise phone application and interval contact by health provider in between clinic visit, receives continuous glucose monitor
62184413|NCT05720377|NO_INTERVENTION|Prediabetes, no intervention|prediabetes, receives continuous glucose monitor
62393130|NCT01273012|PLACEBO_COMPARATOR|Placebo|The group of patients treated with placebo.
62393131|NCT01273012|EXPERIMENTAL|Infloran|The group of patients treated with Infloran.
61998716|NCT03726177|ACTIVE_COMPARATOR|aspirin 81 mg plus placebo|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first plus placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
61998717|NCT00247728|NO_INTERVENTION|Untreated Control|Untreated control arm
62184414|NCT05720377|EXPERIMENTAL|Type 2 diabetes, receives access to exercise phone application|prediabetes receives access to exercise phone application and interval contact by health provider in between clinic visit, receives continuous glucose monitor
61998718|NCT00247728|EXPERIMENTAL|160 mg PI-88/Day|PI-88 160 mg/day SC injection
61998719|NCT00247728|EXPERIMENTAL|250 mg PI-88/Day|PI-88 250 mg/day SC injection
61998720|NCT05039346||Brain Tumor|Patients who are diagnosed with a high grade glioma that is progressive and therapy resistance. Patients will have a KPS of 60 or less.
61998721|NCT05039346||Care Giver|"Should a patient be unable to answer, the care giver will step in and provide surrogate answers.~Additionally, at four weeks following the patient's death, the patient's care giver will be interviewed by utilizing a validated questionnaire."
61998722|NCT04223882|EXPERIMENTAL|Group Intervention- Management of stress|Patients in the intervention group will receive usual medical care and more stress management intervention. Stress management with cognitive behavioral techniques will be implemented one month after hospital discharge in the intervention group. Group sessions will be held between 6-9 people. There will be 3 1-hour meetings for 3 weeks. The intervention will be performed by psychologist.
61998723|NCT04223882|ACTIVE_COMPARATOR|Group Control|Patients in the control group will receive usual medical care.
61998724|NCT03950128|EXPERIMENTAL|Mindfulness-Based Skills Training|This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The intervention is given over the course of three 50-minute sessions with homework between sessions.
61998725|NCT03950128|ACTIVE_COMPARATOR|Psychoeducational|This intervention is based on the Love is Not Abuse (LINA) Curriculum (Liz Claiborne Education Development Center (n.d.)). It was adapted to be given over the course of three 50-minute sessions.
61998726|NCT02103829|ACTIVE_COMPARATOR|Condition #1|Condition #1 will consist of Brief Intervention #1, a brief online suggestion that takes less than 1 minute to complete.
61998727|NCT02103829|EXPERIMENTAL|Condition #2|Condition #2 will consist of Brief Intervention #1 and Brief Intervention #2 that together take less than a minute to complete.
61998728|NCT02103829|EXPERIMENTAL|Condition #3|Condition #3 will consist of Brief Intervention #1 and Brief Intervention #3, which, together, will take less than 8 minutes to complete.
61998729|NCT02103829|EXPERIMENTAL|Condition #4|Condition #4 will consist of Brief Intervention #1, Brief Intervention #2, and Brief Intervention #3, which, together, will take less than 8 minutes to complete.
61998730|NCT04257812||Ceftolozane-Tazobactam cohort|Patients older than 18 years old that are hospitalised in the Virgen Macarena University Hospital that are being treated with Ceftolozane-Tazobactam in empiric or targeted treatment.
62184415|NCT05720377|NO_INTERVENTION|Type 2 diabetes, no intervention|Type 2 diabetes, receives continuous glucose monitor
62184416|NCT03371823|OTHER|Normotensive|Normotensive PMW will complete an experimental visit to assess vascular function. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visit to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
62184417|NCT03371823|EXPERIMENTAL|Hypertensives|Hypertensive women will be tested at baseline and then administered Losartan 50 mg once a day at night for 14 days. Vascular function is measured at baseline and again after 2 weeks of losartan. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visits to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
61998731|NCT02318693|EXPERIMENTAL|Sitagliptin 50 mg|Sitagliptin 50 mg administered orally once daily before breakfast for 14 days.
61998732|NCT02318693|ACTIVE_COMPARATOR|Glibenclamide 2.50 mg TDD|Glibenclamide 1.25 mg administered orally twice daily (2.5 mg TDD) for 14 days. TDD = Total daily dose.
61998733|NCT02794272|EXPERIMENTAL|Anodal tDCS|Anodal stimulation during resting state fMRI
61998734|NCT02794272|EXPERIMENTAL|Cathodal tDCS|Cathodal stimulation during resting state fMRI
61998735|NCT02794272|SHAM_COMPARATOR|sham tDCS|Sham stimulation during resting state fMRI
62184418|NCT04142411|EXPERIMENTAL|Insulin and Sodium Hyaluronate Ultrasound guided injection|Subjects will receive Ultrasound guided injection of 10 IU of crystalline insulin and 20 mg of Sodium Hyaluronate
62184419|NCT04142411|ACTIVE_COMPARATOR|Insulin Ultrasound guided injection|Subjects will receive Ultrasound guided injection of 10 IU of crystalline insulin
61998736|NCT01112293|EXPERIMENTAL|Investigational drug infusion-for safety and effectiveness|Phase II, Single-Arm, Multi-Site study. All subjects will receive the investigational agent, GC1008 in 3 week cycles of treatment
61998737|NCT04022135|ACTIVE_COMPARATOR|Folic acid|0.6 mg/day
61998738|NCT04022135|EXPERIMENTAL|(6S)-5-methyltetrahydrofolic acid (Metafolin)|0.625 mg/d (an equimolar dose to folic acid)
61998739|NCT04377607||Group OP|outpatients with asymptomatic or uncomplicated or mild pneumonia
61998740|NCT04377607||Group H|hospitalized patients
62774372|NCT05883254||thalassemia intermedia patients and sickle cell disease patients|"1. Inclusion criteria~   * Patients with sickle cell anemia and β-thalassemia intermedia.~  * Patients are of both sexes (males and females) at any age.~2. Exclusion criteria:~   * Patients with any other type of haemolytic anaemias.~  * Patients on Hydroxyurea therapy."
61998741|NCT04377607||Group IC|patients admitted to intensive care unit
61998742|NCT03921060|NO_INTERVENTION|Main Study|Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan (if not completed as standard of care within 6 months prior to research visit), micro CT, and blood collection.
61998743|NCT03921060|EXPERIMENTAL|Denosomab Sub-study|Approximately 10 subjects with CF that have completed the main study and have results which indicate bone disease are eligible to participate in the sub study. Subjects who consent will receive treatment with denosumab (60 mg/ml via subcutaneous injection in the upper arm, upper thigh, or abdomen every 6 months) for up to 5 years. These subjects will be asked to return every 6 months for injections and annually (+/- 6 months) for up to 5 years for a DEXA scan, micro CT, and blood collection.
61998744|NCT01095588|EXPERIMENTAL|Avanafil|
61998745|NCT01095588|PLACEBO_COMPARATOR|Placebo|
61998746|NCT02866838|EXPERIMENTAL|Tranexamic acid|Intravenous tranexamic acid: 1g loading dose given as 100 mls infusion over 10 minutes, followed by another 1g in 250 mls infused over 8 hours.
61998747|NCT02866838|PLACEBO_COMPARATOR|Placebo|Saline 0.9% given in identical dosage as experimental
61998748|NCT04792112|EXPERIMENTAL|Guideline + decision support tool|A decision support tool summarizing harms and benefits of late preterm antenatal corticosteroids will be integrated into the clinical practice guideline available to clinicians in the hospitals in the experimental arm.
61998749|NCT04792112|NO_INTERVENTION|Guideline only|Clinicians in the hospitals in the 'no-intervention' arm will have access to the standard guideline only (without the integrated decision support tool).
61998750|NCT01195805|ACTIVE_COMPARATOR|Amiloride|
61998751|NCT01195805|ACTIVE_COMPARATOR|Spironolactone|
62774373|NCT00991406|EXPERIMENTAL|Arm 1: FES|Case-control study: pre- and post-stimulation (FES).
62774374|NCT05726474|EXPERIMENTAL|Combined exercise|
62774375|NCT05726474|EXPERIMENTAL|High interval training|
62774376|NCT05726474|NO_INTERVENTION|Usual care|
62774377|NCT06356688|EXPERIMENTAL|paclitaxel polymer micelles and cisplatin combined with Camrelizumab|
62774378|NCT03933176|EXPERIMENTAL|Simplified restorative procedure|After selective carious tissue removal, the universal adhesive (Adper Universal; 3M ESPE, St. Paul, MN, EUA) will be applied on the cavity walls. The cavity will be restored using a single increment of Filtek One Bulk Fill (3M ESPE, St. Paul, MN, EUA).
61998752|NCT01195805|PLACEBO_COMPARATOR|Placebo|1 tablet twice a day for 28 days
61998753|NCT03584269|EXPERIMENTAL|NIV Device + LTOT|administration of ventilary support, without using an invasive artificial airway
61998754|NCT03584269|ACTIVE_COMPARATOR|LTOT|standard treatment, without NIV
61998755|NCT00706836|ACTIVE_COMPARATOR|Pregabalin 50 mg|Pregabalin oral tablets (50 mg)
61998756|NCT00706836|ACTIVE_COMPARATOR|Pregabalin 200 mg|Pregabalin oral tablets (200 mg)
61998757|NCT00706836|PLACEBO_COMPARATOR|Placebo|Placebo
61998758|NCT03711162|EXPERIMENTAL|GLPG1690 600 mg|Participants received GLPG1690 (ziritaxestat) 600 mg, film-coated tablets orally once daily (mean GLPG1690 exposure was up to 325.3 days) in addition to local standard of care. Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
61998759|NCT03711162|EXPERIMENTAL|GLPG1690 200 mg|Participants received GLPG1690 (ziritaxestat) 200 mg as film-coated tablet for oral use once daily (mean GLPG1690 exposure was up to 356.0 days) in addition to local standard of care. Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
62184420|NCT04142411|ACTIVE_COMPARATOR|Sodium Hyaluronate Ultrasound guided injection|Subjects will receive Ultrasound guided injection of 20 mg of Sodium Hyaluronate
62184421|NCT04021225|ACTIVE_COMPARATOR|Ectoin® Allergy Eye Drops 2%|"20 Patients:~- Ectoin® Allergy Eye Drops 2% (bitop AG)"
62184422|NCT04021225|ACTIVE_COMPARATOR|Ectoin® Eye Spray Colloidal|"20 Patients:~-Ectoin® Eye Spray Colloidal (bitop AG)"
62184423|NCT04021225|ACTIVE_COMPARATOR|Tears Again® Eye Spray|"20 Patients:~- Tears Again® Eye Spray (Optima Pharmazeutische GmbH)"
62393132|NCT02114346|EXPERIMENTAL|Atorvastatin|Patients in the atorvastatin group receive 80 mg atorvastatin (2 x atorvastatin 40 mg tablets) once daily from 24 hours before to 48 hours after administration of contrast material.
62393133|NCT02114346|PLACEBO_COMPARATOR|Placebo|Patients in the placebo group receive 2 placebo tablets once daily from 24 hours before to 48 hours after administration of contrast material.
62393134|NCT06417658|EXPERIMENTAL|Endoscopic Supraorbital Eyebrow Craniotomy|his minimally invasive neurosurgical procedure accesses brain tumors by making a small incision within the eyebrow, providing access to pathologies of the anterior skull base. Compared to traditional frontal craniotomy, this approach aims to minimize tissue disruption, potentially reducing postoperative complications and improving cosmetic outcomes. The procedure involves precise surgical techniques guided by endoscopic visualization, allowing for targeted tumor resection while preserving surrounding healthy tissue. Additionally, the use of smaller incisions may lead to reduced scarring and faster recovery times compared to conventional approaches.
62774379|NCT03933176|ACTIVE_COMPARATOR|Control|A thin layer of resin-modified glass ionomer (Ionoseal (Voco America Inc., Briarcliff Manor, NY, EUA) will be placed on the pulpal floor of the cavity. Then, the adhesive and composite will be used following the same directions defined for the experimental condition.
62774380|NCT03602859|PLACEBO_COMPARATOR|Participants receiving SOC+placebo|Participants in this arm will receive SOC (carboplatin+paclitaxel+/-bevacizumab) in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment with dostarlimab placebo from cycles 2 to 6 and maintenance treatment of +/-bevacizumab along with niraparib placebo and dostarlimab placebo
62774381|NCT03602859|ACTIVE_COMPARATOR|Participants receiving SOC+niraparib|Participants in this arm will receive SOC in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment dostarlimab placebo from cycles 2 to 6 and maintenance treatment of +/- bevacizumab with niraparib and dostarlimab placebo
62774382|NCT03602859|EXPERIMENTAL|Participants receiving SOC+dostarlimab+niraparib|Participants in this arm will receive SOC in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment dostarlimab, and maintenance treatment of +/-bevacizumab with niraparib and dostarlimab
62774383|NCT04552288|EXPERIMENTAL|Participants with eosinophil-related cutaneous events|Study participants will have grade 2/3 eosinophil-related cutaneous adverse events
62020965|NCT05421598|EXPERIMENTAL|Amlitelimab dose level 3|Initial loading dose of amlitelimab on Day 1, followed by one injection of amlitelimab dose level 3 Q4W until Week 20 (inclusive) and Q12W starting from Week 24 and thereafter.
62184424|NCT00004445|EXPERIMENTAL|Implanted Neuroprosthesis|"Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.~Interventions include:~Procedure/Surgery Rehabilitation/Exercise~Device includes:~IRS-8 Stimulating Electrodes External Controller"
62184425|NCT04567810|EXPERIMENTAL|Part A: 2 mg preparation|Participants receive a single 2 mg dose of anti-SARS-CoV-2 IgY.
62184426|NCT04567810|EXPERIMENTAL|Part A: 4 mg preparation|Participants receive a single 4 mg dose of anti-SARS-CoV-2 IgY.
62184427|NCT04567810|EXPERIMENTAL|Part A: 8 mg preparation|Participants receive a single 8 mg dose of anti-SARS-CoV-2 IgY.
62184428|NCT04567810|PLACEBO_COMPARATOR|Part A: placebo preparation|Participants receive placebo matching anti-SARS-CoV-2 IgY.
62184429|NCT04567810|EXPERIMENTAL|Part B: 6 mg total daily dose|Participants receive a 2 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.
62184430|NCT04567810|EXPERIMENTAL|Part B: 12 mg total daily dose|Participants receive a 4 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.
62184431|NCT04567810|EXPERIMENTAL|Part B: 24 mg total daily dose|Participants receive a 8 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.
62184432|NCT04567810|PLACEBO_COMPARATOR|Part B: 0 mg total daily dose|Participants receive placebo matching anti-SARS-CoV-2 IgY three times daily for 14 days.
61998760|NCT03711162|PLACEBO_COMPARATOR|Placebo|Participants received GLPG1690 (ziritaxestat) matching placebo tablets for oral use once daily (mean GLPG1690 exposure was up to 353.4 days) in addition to local standard of care. Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
62568566|NCT01144702|EXPERIMENTAL|artesunate & mefloquine combination|ASMQ will be administered to individuals with uncomplicated malaria by P. falciparum according to the dose regimen for age and weight, standardized (Farmanguinhos, Ministry of Health). For patients in the range of 5 to \<18kg (6 months to 5 years old), will be offered treatment in the pediatric presentation of Artesunate+Mefloquine 25 +50 mg (5 to \<9 kg = 1 tablet once daily for 3 days, 9 to \<18 kg = 2 tablets once daily for 3 days). To study subject aged 18 or more kilos (six years or more years old) will be given the combination of Artesunate + Mefloquine presentation ASMQ 100 +200 mg (18 to 29 kg = 1 tablet once daily for 3 days, 30 kg or more = 2 tablets once daily for 3 days). Clinically and biochemically monitoring will be done for 42 days.
62568567|NCT01109485|EXPERIMENTAL|Olopatadine|Olopatadine hydrochloride ophthalmic solution 0.1%
62568568|NCT03757065||Systemic Lupus Erythematosus|
62568569|NCT03757065||Sjogren's Syndrome|
62568570|NCT03757065||Multiple Sclerosis|
62568571|NCT03757065||Systemic Sclerosis|
62568572|NCT03757065||Crohn's Disease|
62568573|NCT03757065||Ulcerative Colitis|
62568574|NCT03757065||Inflammatory Myositis|
62568575|NCT01376999|EXPERIMENTAL|Step Down|Step Down: We begin the COS (controlled ovarian stimulation) with 150 IU of FSH-r until 7th day of stimulation. This day we make an adjustment reducing the dose if necessary.
62568576|NCT01376999|ACTIVE_COMPARATOR|Step Up|Step up: We begin the COS (controlled ovarian stimulation) with 75 IU of FSH-r until 7th day of stimulation.This day we make an adjustment increasing the dose if necessary.
62568577|NCT05212610|EXPERIMENTAL|Pfizer-BioNTech mRNA COVID-19 vaccine|Subject will receive an initial or additional dose of the Pfizer-BioNTech (Comirnaty) mRNA COVID-19 vaccine
62568578|NCT05046912|EXPERIMENTAL|Clinical|Clinical participants with a primary diagnosis of psychosis or related disorder.
62568579|NCT05046912|ACTIVE_COMPARATOR|Non-clinical|Non-clinical participants with no mental health diagnoses.
62774384|NCT01344720|ACTIVE_COMPARATOR|etoricoxib|etoricoxib up to 60mg/day as monotherapy
61998761|NCT04124107|EXPERIMENTAL|Prostate biopsy with 68Ga-PSMA PET/MRI|Both targeted biopsy and 12-core systematic biopsy with positive 68Ga-PSMA PET/MRI
62020966|NCT05421598|PLACEBO_COMPARATOR|Placebo|Initial loading dose of amlitelimab matching placebo on Day 1, followed by one injection of amlitelimab matching placebo Q4W until Week 20 (inclusive) and Q12W starting from Week 24 and thereafter.
62020967|NCT04192097|NO_INTERVENTION|Traditional teaching|No specific curriculum about professionalism
62568580|NCT01697072|EXPERIMENTAL|Rilotumumab|Rilotumumab (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
62568581|NCT01697072|PLACEBO_COMPARATOR|Placebo|Rilotumumab-placebo (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
62568582|NCT00347958|EXPERIMENTAL|Adacel vaccine group|Participants 15 to 69 years of age who received a dose of Adacel vaccine in one of three previous studies (Td501, or Td502, or Td505), revaccinated in Study Td518.
62568583|NCT02985580|ACTIVE_COMPARATOR|Blueberry|Blueberry concentrate consumed daily for 12 weeks.
62568584|NCT02985580|PLACEBO_COMPARATOR|Placebo|Placebo concentrate consumed daily for 12 weeks.
62568585|NCT02943954|OTHER|Angiography guided PCI|Revascularisation of non-culprit lesions guided by PCI
62568586|NCT02943954|OTHER|FFR guided PCI|Revascularisation of non-culprit lesions guided by FFR measurement
62568587|NCT00223041|NO_INTERVENTION|A (therapy with fluvastatin 80mg retard)|kidney transplants receive in addition fluvastatin 80mg retard for 3 years
62568588|NCT00223041|PLACEBO_COMPARATOR|B|no therapy with fluvastatin
62568589|NCT01411800|EXPERIMENTAL|Treatment A|500 mg LX1033, capsules administered two times per day orally
62568590|NCT01411800|EXPERIMENTAL|Treatment B|500 mg LX1033, tablets administered two times per day orally
62774385|NCT01344720|ACTIVE_COMPARATOR|etoricoxib plus controlled-release oxycodone|combination treatment of etoricoxib (30 mg/day) plus controlled-release oxycodone (10 mg/day)
62774386|NCT02666612|OTHER|Patients with metastatic cancer|
62774387|NCT00758641|EXPERIMENTAL|L-PRP Injection|L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
62774388|NCT00758641|ACTIVE_COMPARATOR|Steroid Injection|Corticosteroid injections
62774389|NCT02180477|EXPERIMENTAL|UHAC 62 XX TF1 tablet|
62774390|NCT02180477|EXPERIMENTAL|UHAC 62 XX TF2 tablet|
62774391|NCT02180477|ACTIVE_COMPARATOR|UHAC 62 XX capsule|
62774392|NCT00907166|EXPERIMENTAL|Phase I, Arm A|CPI-613 + Gemcitabine
62774393|NCT00907166|EXPERIMENTAL|Phase II, Arm A|CPI-613 + Gemcitabine
62774394|NCT00907166|ACTIVE_COMPARATOR|Phase II, Arm B|Gemcitabine
62774395|NCT05296993|EXPERIMENTAL|Extracts|The ingredients found in these serums are all naturally occurring ingredients extracted from a variety of plant species: Pinetonal, Thyvolve, Telogenic, Sentophagy, Inflasolve, Stemegenis, and CMEnhance
62774396|NCT04572750|EXPERIMENTAL|EMPOWER-ED|Individuals will be given access on their preferred platform to an electronic self-help app focused on reducing benzodiazepine use
62774397|NCT04572750|NO_INTERVENTION|Control|Individuals will be provided care as usual
62774398|NCT01276002|NO_INTERVENTION|No stenting|Control group, no stenting of the pancreatic duct in case of a disrupted duct
62774399|NCT01276002|ACTIVE_COMPARATOR|Pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting in this arm
62774400|NCT01761500|OTHER|Modified BFM-90 protocol|Using the Modified BFM-90 protocol to treat Chinese children and adolescents with NHL
62774401|NCT05827315||Thoracic surgery cohort|35 patients undergoing thoracic surgery with lung resection and one lung ventilation under primarily general anaesthesia.
61998762|NCT04066426|EXPERIMENTAL|naproxen sodium+codeine phosphate|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Codeine phosphate is an opioid analgesic which has similar applications to those of morphine. However, it is significantly less potent as an analgesic and has only mild sedative effects. The drug's principal site of action is at the µ-opioid receptors (MOR) which are distributed in the central nervous system. Peak effect is reached within 2 hours and analgesic action continues for approximately 4 hours. Naproxen sodium (550 mg)+codeine phosphate (30 mg) was used twice daily in this study.
62774402|NCT05827315||Upper gastrointestinal surgery cohort|35 patients undergoing upper gastrointestinal surgery with one lung ventilation under primarily general anaesthesia.
62774403|NCT05827315||Colorectal surgery cohort|35 patients undergoing elective colorectal surgery under primarily general anaesthesia.
62774404|NCT05827315||Vascular surgery cohort|35 patients undergoing elective open abdominal aortic surgery under primarily general anaesthesia.
61998763|NCT04066426|EXPERIMENTAL|naproxen sodium+dexamethasone|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Naproxen sodium (550 mg) was used twice daily + dexamethasone (8 mg) was used once daily in this study.
62020968|NCT04192097|EXPERIMENTAL|Professionalism curriculum|Traditional teaching + professionalism curriculum
62020969|NCT04946513||Group 1|Patients with femoroacetabular impingement syndrome and underwent hip arthroscopy。
62774405|NCT05827315||Orthopaedic surgery cohort|35 patients undergoing elective primary hip or knee arthroplasty under spinal anaesthesia +/- sedation.
62774406|NCT04650425|EXPERIMENTAL|Intervention group|Each participant will undergo one or two sessions, consisting of cognitive tasks, video-EEG recording and administering of questionnaires.
62774407|NCT05737719||Prehab|Patients awaiting a knee surgical procedure, and after the surgery
62020970|NCT03455075|EXPERIMENTAL|Lower DMAU + LNG|DMAU 100 mg + LNG 30 mcg administered orally in capsules.
62020971|NCT03455075|EXPERIMENTAL|Middle DMAU + LNG|DMAU 200 mg + LNG 30 mcg administered orally in capsules.
62774408|NCT05737719||Control|Patients after the surgery
62020972|NCT03455075|EXPERIMENTAL|Middle DMAU + Placebo|DMAU 200 mg + placebo administered orally in capsules.
62774409|NCT00154882|EXPERIMENTAL|A|
62774410|NCT02160691|EXPERIMENTAL|Anxiety Meter|The Anxiety Meter (experimental) group will receive a real-time display of physiological arousal on the Anxiety Meter during the intervention period in visit #4.
62774411|NCT02160691|NO_INTERVENTION|No Anxiety Meter|The control group will have the Anxiety Meter during the intervention period, but the marker will not move.
62774412|NCT03708666|OTHER|Telemonitoring of blood pressure|Patients measure their blood pressure and register their results on the app or website.
62791595|NCT05267119||Hijab|Women wearing hijab whose scalp sample was taken for microbiome analysis
62020973|NCT03455075|EXPERIMENTAL|Higher DMAU + Placebo|DMAU 400 mg + placebo administered orally in capsules.
62020974|NCT03455075|PLACEBO_COMPARATOR|Placebo|Placebo administered orally capsules.
62020975|NCT01719965||Health Workers|"* Worked in SMRU for at least 6 months~* Clinic assistants, medics or home visitors"
62020976|NCT01719965||Researchers|"* Worked in SMRU for at least 6 months~* Physician or scientist"
62020977|NCT01719965||CAB members|- Member of the CAB for at least 3 months
62020978|NCT01719965||Community members|- Lived in the border area (area served by SMRU or Mae Sot) for at least 6 months
62020979|NCT01719965||Research subjects|- Participants who are currently enrolled in an SMRU study
61998764|NCT04066426|EXPERIMENTAL|naproxen sodium|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Naproxen sodium (550 mg) was used twice daily in this study.
62568591|NCT04029584|EXPERIMENTAL|Fluvastatin Alone First, Then Fluvastatin +IV Rifampin 600 mg|"The effect of rifampin on the pharmacokinetics of fluvastatin will be studied in healthy volunteers with or without hepatic induction in a randomized, unblinded, crossover clinical trial.~For uninduced periods, subjects will be randomized to receive one oral dose of fluvastatin (Lescol®) 20mg capsule first. Separated by one day of washout, they then receive one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline.~Before starting hepatic induced period, subjects will have a washout for greater than one week.~To induce hepatic enzyme and transporter, Subjects will be pretreated with 5 days with 600mg oral rifampin. Subjects will be then randomized first to receive a single dose of fluvastatin 20mg. Separated by one day of washout, subject will then receive one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg."
62184433|NCT05100810||Angelman syndrome patients|This study will comprehensively evaluate the natural clinical progression of the disease using scales and questionnaires for the assessment of motor function and global development, movement monitoring devices (ActiMyo), and by collecting sleep and seizure diaries. In addition, proteomic analysis and electroencephalography (EEG) recordings will be collected to identify biomarkers that will indicate improvements in disease outcome following treatment.
62184434|NCT04668521||COHORT A|Women with a pelvic mass, symptomatic or asymptomatic.
62184435|NCT04668521||COHORT B|Women diagnosed with a pelvis mass undergoing genetic testing through our commercial offering.
62184436|NCT04668521||COHORT C|Subject must not have an identifiable adnexal mass and may, or may not, have a family history or a known familial genetic abnormality (germ line or identified in family cancer i.e. somatic DNA mutation) associated with ovarian cancer.
62393135|NCT06417658|ACTIVE_COMPARATOR|Conventional Frontal Craniotomy|This arm represents the standard surgical approach for treating frontal skull base lesions. In this arm, surgeons perform the craniotomy through a conventional frontal approach rather than the endoscopic supraorbital eyebrow approach. This arm serves as the comparator against the experimental arm to evaluate the differences in cosmetic outcomes, scar assessment, and complications between the two surgical techniques.
62393136|NCT04954560|ACTIVE_COMPARATOR|losartan|Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
62393137|NCT04954560|ACTIVE_COMPARATOR|eprosartan|Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
62393138|NCT00051246|ACTIVE_COMPARATOR|1 M-ITG|Mother-infant group psychotherapy
62393139|NCT00051246|ACTIVE_COMPARATOR|2 - IPT|Individual interpersonal psychotherapy
61998765|NCT04066426|ACTIVE_COMPARATOR|paracetamol|Paracetamol is a mild analgesic and antipyretic, and is recommended for the treatment of most painful and febrile conditions, for example, headache including migraine, toothache, neuralgia, colds and influenza, sore throat, backache, rheumatic pain and dysmenorrhoea.
62393140|NCT03534089|PLACEBO_COMPARATOR|Standard infant fomula|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with standard infant formula (without lactoferrin supplementation)
62393141|NCT03534089|EXPERIMENTAL|Low level LF infant formula group|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with infant formula supplemented with low level of lactoferrin (38mg/100g). Lactoferrin:38mg/100g
62774413|NCT03038854|EXPERIMENTAL|Test GUM|This group will drink a test toddler growing up milk (GUM) with higher amounts of key nutrients
62774414|NCT03038854|ACTIVE_COMPARATOR|Standard GUM|This group will drink a standard toddler growing up milk (GUM)
62774415|NCT03038854|PLACEBO_COMPARATOR|Comparator Group|This group will drink liquid full fat cows' milk
62774416|NCT03038854|NO_INTERVENTION|Population Group|This group will eat and drink their usual foods with no interventions.
61998766|NCT02437565|ACTIVE_COMPARATOR|Control|Placement of stainless steel crown under general anesthesia without the use of an occlusal template
62184437|NCT01748045|EXPERIMENTAL|inhaled Nitric Oxide|iNO to start at 20 parts per million (ppm) for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.
62393142|NCT03534089|EXPERIMENTAL|High level LF infant formula group|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with infant formula supplemented with high level of lactoferrin (76mg/100g)
62393143|NCT04784559|EXPERIMENTAL|Plitidepsin 1.5 mg arm|Patients will receive plitidepsin 1.5 mg/day intravenous (IV) in addition to dexamethasone on days 1 to 3.
62393144|NCT04784559|EXPERIMENTAL|Plitidepsin 2.5 mg arm|Patients will receive plitidepsin 2.5 mg/day IV in addition to dexamethasone on days 1 to 3.
61998767|NCT02437565|EXPERIMENTAL|Impression|Placement of stainless steel crown under general anesthesia with the use of an occlusal template prepared after making an impression of the teeth using a fast setting polyvinyl siloxane material
61998768|NCT01336686|EXPERIMENTAL|Arhalofenate 400 mg|
61998769|NCT01336686|EXPERIMENTAL|Arhalofenate 600 mg|
61998770|NCT01336686|PLACEBO_COMPARATOR|Placebo|
62393145|NCT04784559|ACTIVE_COMPARATOR|Control arm|Patients will receive dexamethasone IV on Days 1 to 3. Additionally, in accordance with local treatment guidelines, patients in this group may receive a regulatory-approved antiviral treatment.
62393146|NCT06437223|EXPERIMENTAL|Experimental|IFX-LC001 Tonabersat tablets 40mg tablets or placebo Take two tablets once per day
62393147|NCT06437223|PLACEBO_COMPARATOR|Placebo|IFX-LC001Tonabersat tablets 40mg tablets or placebo Take two tablets once per day
61998771|NCT01335958|EXPERIMENTAL|A|
61998772|NCT04874337|EXPERIMENTAL|Experimental group|Disaster nursing and management training will be given to students using Jenning's Disaster Nursing and Management Model.
61998773|NCT04874337|NO_INTERVENTION|Control Group|
61998774|NCT04345952|EXPERIMENTAL|Calm Meditation|Participants in the Calm group will be asked to use the Calm app ad libitum during their time spent receiving chemotherapy at the Mays Cancer Center (\~2 hours) and while at home between treatment cycles ad libitum. Participation will be measured during the entire intervention using internal tracking systems within the app (i.e., # of times logged in, type of meditation accessed, time spent meditating, date and time of meditation accessed). This data will be provided to us through data coordinator of the app.
62393148|NCT02112396|EXPERIMENTAL|Immediate Intervention|Subjects receive 12 sessions of Community Reinforcement and Family Training (CRAFT) immediately after study inclusion
62393149|NCT02112396|OTHER|Waiting list group|Waiting list group members receive the Community Reinforcement and Family Training CRAFT intervention after the first follow-up (3 months post study inclusion)
62393150|NCT04667611||Mild|
62393151|NCT04667611||Moderate|
62393152|NCT04667611||Severe|
61998775|NCT04345952|NO_INTERVENTION|Usual Care|The usual care control group will not be offered anything to listen to during their chemotherapy treatment cycles or when they are between chemotherapy treatment cycles. They will receive their treatment as intended without any additional intervention.
61998776|NCT03534856|EXPERIMENTAL|Mindfulness meditation|Two weeks of short, daily guided mindfulness meditations were provided.
61998777|NCT02012127||Acromegalic patients|
61998778|NCT01857063|EXPERIMENTAL|Montelukast/Placebo|Participants receive montelukast 5 mg chewable tablets for 7 days during Period 1 and receive placebo chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.
62020980|NCT05806697|OTHER|All participants|
62393153|NCT02557269|ACTIVE_COMPARATOR|Group HPMC|Hydroxyl-propyl-methyl-cellulose (HPMC) powder added immediately after other intranasal treatment options
62393154|NCT02557269|PLACEBO_COMPARATOR|Group Placebo|Lactose powder (placebo) added immediately after other intranasal treatment options
62393155|NCT02557269|OTHER|Group Immunotherapy|Immunotherapy group with grass allergens sublingually (Staloral #688) and rescue medication
62393156|NCT03609775|EXPERIMENTAL|Treatment A (ethanol + ACT-541468)|5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of ACT-541468 (50 mg)
62774417|NCT03834935|EXPERIMENTAL|Pim|20 patients receiving topical Elidel (pimecrolimus 1%) bid on the affected area for 9 weeks.Sunscreens will not be indicated, and hygienic habits will not be changed.
62393157|NCT03609775|EXPERIMENTAL|Treatment B (ethanol placebo + ACT-541468)|5 h i.v. placebo clamp in combination with a single oral dose of ACT-541468 (50 mg)
62393158|NCT03609775|EXPERIMENTAL|Treatment C (ethanol + ACT-541468 placebo)|5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of matching ACT-541468 placebo
62393159|NCT03609775|EXPERIMENTAL|Treatment D (ethanol placebo + ACT-541468 placebo)|5 h i.v. placebo clamp in combination with a single oral dose of matching ACT-541468 placebo
62393160|NCT03809260|EXPERIMENTAL|Part 1|Metformin/Vancomycin
62393161|NCT03809260|EXPERIMENTAL|Part 2|Metformin
62393162|NCT01920165||Full cohort|The population at risk for each time point is the number of children living in England aged 0-14 year
62774418|NCT03834935|PLACEBO_COMPARATOR|Pl|20 patients receiving placebo (control group), cold cream bid on the affected area for 9 weeks.Sunscreens will not be indicated, and hygienic habits will not be changed.
62774419|NCT01501552|NO_INTERVENTION|Treatment as usual|In the no-intervention treatment as usual group, a package, containing a summary card of the national guideline recommendation, will be delivered to each provider unit without demonstration. In Poland, the summary card will be adapted from the PHEPA guidelines (ref) for the purposes of this trial. The treatment as usual group will be requested to screen and offer person-to-person SBI at the PHCU.
62774420|NCT01501552|EXPERIMENTAL|Training & support (T&S)|The T\&S only group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
62791596|NCT05267119||No hijab|Women not wearing hijab whose scalp sample was taken for microbiome analysis
62791597|NCT02262702||Extended Release Paracetamol|Participants prescribed with extended release paracetamol tablet containing 665 mg paracetamol.
62791598|NCT02262702||Standard Paracetamol|Participants prescribed with standard paracetamol tablet containing 500 mg paracetamol.
62393163|NCT01148108|EXPERIMENTAL|Mantle Cell Lymphoma|Patients with relapsed or refractory mantle cell lymphoma
62791599|NCT06473792|NO_INTERVENTION|Colgate Maximum Cavity Protection (Control)|Participants will be advised to use regular toothpaste twice a day for 3 weeks after the bonding. A regular toothpaste and a standard brushing technique will be conveyed to all the participants.
62791600|NCT06473792|EXPERIMENTAL|Probiotic Toothpaste Group|Participants will be advised to use a Probiotic toothpaste twice a day for 3 weeks after the bonding. A probiotic toothpaste and a standard brushing technique will be conveyed to all the participants.
62393164|NCT01148108|EXPERIMENTAL|Diffuse Large B Cell Lymphoma|Patients with relapsed or refractory diffuse large B cell lymphoma
62393165|NCT01148108|EXPERIMENTAL|Multiple Myeloma|Patients with relapsed or refractory multiple myeloma
62393166|NCT04203082|EXPERIMENTAL|Exposure Intervention|Participants randomized to receive the Exposure Intervention will be scheduled to come to clinic for a 1-hour session for the intervention. During this time, they will receive psychoeducation and behavioral exposure to the Cesarean section procedure.
62393167|NCT04203082|OTHER|Usual Care|Participants randomized to the Care as Usual condition will receive the typical standard of care that is offered in the center. This involves the anesthesiologist meeting with the patient during a delivery planning meeting to provide patients with the opportunity to review anesthetic technique and ask questions.
62393168|NCT06090461||naltrexone 8mg and bupropion 90mg extended-release oral tablet (NB)|A total daily dosage of two NB 8 mg/90 mg tablets twice daily (32 mg/ 360 mg) is reached at the start of Week 4, following titration.
62393169|NCT06090461||lorcaserin|A total of one 10 mg tablet administered orally twice daily; or one 20 mg tablet administered orally once daily.
62393170|NCT05038007|ACTIVE_COMPARATOR|Control|Bupivacaine Hydrochloride in perioperative intercostal blockades
62393171|NCT05038007|EXPERIMENTAL|Intervention|Liposomal bupivacaine in perioperative intercostal blockades
62393172|NCT03993002|ACTIVE_COMPARATOR|Normoxia with Normocarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.~PaO2 \< 100 (FiO2 \>= 21%) PaCO2 of 30-40"
62393173|NCT03993002|ACTIVE_COMPARATOR|Normoxia with Hypercarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.~PaO2 \< 100 (FiO2 \>= 21%) PaCO2 of 50-60"
62393174|NCT03993002|ACTIVE_COMPARATOR|Hyperoxia with Normocarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.~PaO2 \> 250 (FiO2 \>= 70%) PaCO2 of 30-40"
62393175|NCT03993002|ACTIVE_COMPARATOR|Hyperoxia with Hypercarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.~PaO2 \> 250 (FiO2 \>= 70%) PaCO2 of 50-60"
62393176|NCT04264949|EXPERIMENTAL|group application (GA)|"benefit from conventional care in a rehabilitation center, therapeutic education program and education in the use of the smartphone application mon coach dos"
62393177|NCT04264949|ACTIVE_COMPARATOR|Groupe conventional care (GCC)|benefit from conventional care in a rehabilitation center and therapeutic education program
62393178|NCT03767309|EXPERIMENTAL|Test group|SCTG will be harvested from the palate in the intervention group (coronally advanced flap and abrasively de-epithelialized free gingival graft)
62393179|NCT03767309|ACTIVE_COMPARATOR|Control group|SCTG will be harvested from the palate using Zucchilli's technique (zucchelli, 2010) in the control group (coronally advanced flap and conventionally de-epithelialized free gingival graft)
62393180|NCT06381024|NO_INTERVENTION|Standard of care group|Standard of care
62393181|NCT06381024|EXPERIMENTAL|Standard of care with Cureety group|In-person care with remote patient monitoring with the Cureety application
62393182|NCT03229512|EXPERIMENTAL|Intervention|Topical 1% Sildenafil Cream
62393183|NCT03954054||Former therapeutic education participants|Semi-structured interviews with people who already completed the TPE programme
62393184|NCT03954054||Intervention group (current therapeutic education participants)|"A face-to-face interview and a telephone interview at treatment initiation (M0) and 6 months after programme initiation (M6)~Administration of socio-economic questionnaires and a Brief Evaluation of Alcohol-Related Neuropsychological Impairment (BEARNI) before, and 6 months after inclusion in the therapeutic education programme."
62393185|NCT03954054||Control AUD (Alcohol Use Disorder) patients|"A face-to-face interview and a telephone interview at treatment initiation (M0) and 6 months after programme initiation (M6)~Administration of socio-economic questionnaires and a Brief Evaluation of Alcohol-Related Neuropsychological Impairment (BEARNI) before, and 6 months after inclusion in the therapeutic education programme."
62393186|NCT02627157||myopia patients|20 to 40 years of age and have myopia with a spherical equivalent (SE) between 0.00 and -11.00 diopters (D)
62393187|NCT04867668|EXPERIMENTAL|Digital intervention|Participants will be randomized to receive variable levels of exposure (including no exposure control) of digital anti-vaping and anti-smoking messages. We will evaluate the effects of experimental condition and exposure on outcomes (tobacco product use).
62393188|NCT04867668|NO_INTERVENTION|Control|No exposure control condition
62393189|NCT03131856|EXPERIMENTAL|Nutritional intervention programme|An individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks).
62393190|NCT03131856|NO_INTERVENTION|Usual care|Usual care which means no individual dietary plan and no nutrition follow-up visits after discharge.
61998779|NCT01857063|EXPERIMENTAL|Placebo/Montelukast|Participants receive placebo chewable tablets for 7 days during Period 1 and receive montelukast 5 mg chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.
61998780|NCT00882531|EXPERIMENTAL|Isotretinoin|
62184438|NCT01748045|PLACEBO_COMPARATOR|Nitrogen Gas|Placebo gas will be adjusted the same as study gas: to start at 20ppm for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.
62774421|NCT01501552|EXPERIMENTAL|Financial incentive|The financial incentive only group will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
62184439|NCT02057575|EXPERIMENTAL|PG324 Ophthalmic Solution 0.01%|Netarsudil 0.01%, Latanoprost 0.005% fixed combination ophthalmic solution
62184440|NCT02057575|EXPERIMENTAL|PG324 Ophthalmic Solution 0.02%|Netarsudil 0.02%, Latanoprost 0.005% fixed combination ophthalmic solution
62184441|NCT02057575|ACTIVE_COMPARATOR|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|Netarsudil 0.02% ophthalmic solution
62393191|NCT01723527|EXPERIMENTAL|Therapeutic Workplace|Participants assigned to this condition will receive the standard services and requirements for diversion as described for the usual care group, and will also be eligible to attend the three-phase Therapeutic Workplace (TW) intervention. All phases of this intervention include employment-based drug abstinence reinforcement contingencies. Under these contingencies, participants can work and earn wages or wage subsidies contingent upon drug abstinence as verified by urinalysis. Phase 1 of the TW intervention is expected to increase cocaine abstinence and to prepare participants for employment. Phase 2 of the TW intervention is expected to maintain abstinence while participants are employed in an onsite model workplace. Phase 3 is designed to increase employment in community jobs and to maintain abstinence while participants are employed in offsite community workplaces.
62393192|NCT01723527|ACTIVE_COMPARATOR|Diversion to treatment (Usual Care)|Participants in this condition will be offered the standard treatment services available in community methadone and buprenorphine programs, including medication (methadone or buprenorphine, respectively), counseling services, HIV testing, and case management. All services will be provided in the treatment clinics. There are a number of clinics within easy walking distance from the research site, and others throughout the city that are reachable by public transportation from the research site. In addition, all participants will receive referrals to the Re-Entry Center, a One-Stop Career Center tailored to the needs of offenders, at all intake and monthly assessments. As mentioned in detail above, participants will be required by the court to stay enrolled in treatment for 90 days. It is important to note that all diverted individuals will receive these services and requirements, independent of whether they agree to participate in the pilot study.
62184442|NCT02057575|ACTIVE_COMPARATOR|Latanoprost Ophthalmic Solution 0.005%|Latanoprost 0.005% ophthalmic solution
62393193|NCT05257876|EXPERIMENTAL|Intervention group|Participants in the intervention group will receive breathing exercise training, pain information booklet, and usual care.
62584764|NCT04637581|EXPERIMENTAL|Wraparound|Wraparound is a 12-month intervention including a family-centered discovery process to identify values, needs, and strengths to help the family be successful in reaching family functioning and parental recovery goals; weekly or twice weekly family meetings with the Wraparound coordinator; intensive care coordination among systems and providers (substance use disorder, mental health, schools, pediatrics, homeless shelters, etc.); and bi-monthly family-centered team meetings (including the family's natural and professional supports) to discuss strategies, progress and continued needs. Wraparound coordinators (2) work with up to 10 families at a time and receive extensive training (including observation) and supervision by expert trainers at University of New Hampshire.
62774422|NCT01501552|EXPERIMENTAL|E-SBI|The e-SBI (online screening and brief intervention)only group are expected to refer identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
62774423|NCT01501552|EXPERIMENTAL|T&S and financial incentive|The T\&S and financial incentive group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. Also, they will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
62791601|NCT02764658|EXPERIMENTAL|Pulmonary recovery on the AECOPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in AECOPD Patients
61998781|NCT00882531|PLACEBO_COMPARATOR|placebo|
61998782|NCT00556855|EXPERIMENTAL|A|applied on one hand
61998783|NCT00556855|PLACEBO_COMPARATOR|B|applied on the other hand
62020981|NCT05601531|EXPERIMENTAL|Autologous Tooth Root+Vit.D3+Bone graft|Placement of bone graft and local administration of Vit.D3, and placement of autologous root slices
62184443|NCT04378647|ACTIVE_COMPARATOR|Induction ESHAP|3 Cycles ESHAP ( 21 days) : Etoposide \[40 mg/m2/ day IV, D1-4\], Solumedrol \[250 mg/day IV, D1-4\], High dose Ara-C \[2 g/m2 IV, D5\] Cisplatinum \[25 mg/m2/day IV, D1-4\]
62184444|NCT04378647|EXPERIMENTAL|Induction BV-ESHAP|3 Cycles of Brentuximab VEedotin + ESHAP ( 21 days) : Etoposide \[40 mg/m2/ day IV, D1-4\], Solumedrol \[250 mg/day IV, D1-4\], High dose Ara-C \[2 g/m2 IV, D5\] Cisplatinum \[25 mg/m2/day IV, D1-4\] Brentuximab Vedotin \[1.8 mg/kg IV, D1\]
62184445|NCT03530436|OTHER|Native turmeric extract|6 capsules of native curcumin (207 mg curcumin)
62184446|NCT03530436|EXPERIMENTAL|Native turmeric extract with 7-9% volatile turmeric oils|6 capsules of the formulation; dosage normalized to 207 mg curcumin
62184447|NCT03530436|EXPERIMENTAL|Turmeric extract plus mixture of phytochemicals|6 capsules of the formulation; dosage normalized to 207 mg curcumin
61998784|NCT05973916|EXPERIMENTAL|Comprehensive intervention|"Cleaning of patients' rooms will be subjected to a comprehensive intervention, consisting of: 1) a patient's unit commando team for daily and for terminal cleaning, 2) all lights in patients' room are VYV led lights, and 3) in each room, a QleanAir Scandinavia® filtering machine will be placed."
61998785|NCT05973916|NO_INTERVENTION|Common Practice|"Patients' rooms will be cleaned and disinfected according to the current common practice as detailed below."
61998786|NCT03742141|EXPERIMENTAL|Intraoperative Video Laryngoscopy|Participants undergoing neck procedures
62774424|NCT01501552|EXPERIMENTAL|T&S and e-SBI|The T\&S and e-SBI group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call was offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) was offered. Also this group is expected to refer identified at-risk patients to an approved e-SBI (online screening and brief intervention) programme, which will either be country specific (where these exist) or based on the WHO e-SBI programme (Poland).
62774425|NCT01501552|EXPERIMENTAL|Financial incentive and e-SBI|The financial incentive and e-SBI (online screening and brief intervention) group will be paid for screening and referral performance instead of actual delivery of e-SBI by themselves as in line with the e-SBI only group, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
62774426|NCT01501552|EXPERIMENTAL|T&S, financial incentive and e-SBI|The T\&S, financial incentive and e-SBI (online screening and brief intervention) group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Also, they are expected to offer screening at the PHCU and to refer screen positive patients to e-SBI programmes. Additionally, they will be paid for screening and referral performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
62774427|NCT03914677|EXPERIMENTAL|Mecamylamine Oral Tablet|Initial dose - mecamylamine 2.5 mg tablet po 3 hours prior to provocative testing; subsequent dose escalations as needed, to 5 mg and then 7.5 mg, using the same testing methodology.
61998787|NCT04116710|EXPERIMENTAL|Phase 1: HS-130 + HS-110 (viagenpumatucel-L)|Patients will receive a combination of intradermal HS-130 and HS-110 once every 14 days. The dose levels will be determined by the starting dose and the escalation steps outlined in the protocol.
61998788|NCT03167762|EXPERIMENTAL|Study group|
61998789|NCT00651521||1|CKD stage 1 patients
61998790|NCT00651521||2|CKD stage 2 patients
61998791|NCT00651521||3|CKD stage 3a patients
61998792|NCT00651521||4|CKD stage 3b patients
62184448|NCT03530436|EXPERIMENTAL|Cyclodextrin complex of curcuminoids|6 capsules of the formulation; dosage normalized to 207 mg curcumin
61998793|NCT00651521||5|CKD stage 4 patients
61998794|NCT00651521||6|CKD stage 5 patients
61998795|NCT06267612|EXPERIMENTAL|Corheart 6 LVAS|Corheart 6 Left Ventricular Assist System (Corheart 6 LVAS) to be used on patients with advanced heart failure.
61998796|NCT00994331|ACTIVE_COMPARATOR|Group A-CT Coregistration|5 subjects with CT co-registration in a magnetically navigated PCI (Group A)
61998797|NCT00994331|ACTIVE_COMPARATOR|Group B-Angiographic|5 subjects with angiographic co-registration in a magnetically navigated PCI (Group B)
61998798|NCT00994331|ACTIVE_COMPARATOR|Group C-Standard Angiography|5 subjects with standard angiography in a conventional PCI (Group C)
61998799|NCT02213211|EXPERIMENTAL|Diagnosis and treatment of malaria|"School-based diagnosis and treatment of uncomplicated malaria using malaria RDTs and Artemether lumefantrine as part of Learner Treatment Kits (LTK) used by teachers.~Drug: Artemether lumefantrine (artemisinin-based combination therapy \[ACT\], Coartem). Three-day doses of 20mg/120mg, 40mg/240mg, 60mg/360mg and 80mg/480mg Coartem are provided, according to weight, upon a positive rapid diagnostic test (RDT) result."
61998800|NCT02213211|NO_INTERVENTION|No intervention|No intervention provided
61998801|NCT04594395||Healthy volunteers|Any adult aged 18 to 65 years of age living in Phnom Penh that is sufficiently healthy and willing to undergo fingerstick by the mobile unit for SARS-CoV-2 ELISA assays.
61998802|NCT04594395||Household contacts|Adult relatives of the healthy volunteers.
61998803|NCT01403038|EXPERIMENTAL|Elagolix Dose Regimen 1|Elagolix Dose regimen 1 for 84 days
61998804|NCT01403038|EXPERIMENTAL|Elagolix Dose Regimen 2|Elagolix Dose Regimen 2 for 84 days
62184449|NCT03530436|EXPERIMENTAL|Turmeric oleoresin|6 capsules of the formulation; dosage normalized to 207 mg curcumin
62184450|NCT03530436|EXPERIMENTAL|Liposomal curcumin|6 capsules of the formulation; dosage normalized to 207 mg curcumin
62568592|NCT04029584|EXPERIMENTAL|Fluvastatin +IV Rifampin 600 mg First, Then Fluvastatin Alone|"The effect of rifampin on the disposition of fluvastatin will be studied in healthy volunteers with or without hepatic induction in a randomized, unblinded, crossover clinical trial.~For uninduced periods, subjects will be randomized to first receive one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline.Separated by one day of washout, subjects will be then receive a single dose of fluvastatin (Lescol®) 20mg capsule.~Before starting induction periods, subjects will have a washout greater than one week.~To induce hepatic enzyme and transporter, subjects will be pretreated with 5 days with 600mg oral rifampin. subjects will be randomized to receive first one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg. Separated by one day of washout, subject will then receive one oral dose of fluvastatin 20mg."
62568593|NCT02323425|EXPERIMENTAL|Remote Ischemic Postconditioning|remote ischemic postconditioning（RIPC） treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation twice a day for the total of 180 consecutive days.
62568594|NCT02323425|NO_INTERVENTION|Control|Patients in control group will receive foundation treatment. Foundation treatment: including blood vessel expansion、free radical elimination etc during acute phase and aspirin (100-300 mg/d), and atorvastatin (20 mg/d) till the end of the study (180 consecutive days).
62184451|NCT03530436|EXPERIMENTAL|Phytosomal curcumin|6 capsules of the formulation; dosage normalized to 207 mg curcumin
62568595|NCT03898167|ACTIVE_COMPARATOR|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator on behalf of Harris Health System.
62774428|NCT04108806|EXPERIMENTAL|Endovascular therapy|Outcome of endovascular therapy on PAC
62774429|NCT00575874|EXPERIMENTAL|1|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
62774430|NCT00575874|EXPERIMENTAL|2|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
62184452|NCT03530436|EXPERIMENTAL|Micellar turmeric extract|6 capsules of the formulation; dosage normalized to 207 mg curcumin
62184453|NCT04686682|EXPERIMENTAL|JAB-8263 Part1|Monotherapy, dose escalation
62184454|NCT04686682|EXPERIMENTAL|JAB-8263 Part 2|Monotherapy, dose expansion
62184455|NCT06034899|EXPERIMENTAL|Part 1: BMS-986196 Dose 1 (Treatment A)|
62568596|NCT03898167|EXPERIMENTAL|Mailed HPV Self-Sampling Kit|Participants receive a scripted telephone recall from a patient navigator on behalf of Harris Health System and receive a mailed HPV self-sampling kit with a pre-paid return envelope.
62568597|NCT03898167|EXPERIMENTAL|Mailed HPV Self-Sampling Kit + Patient Navigation|Participants receive a scripted telephone recall and mailed self-sampling kit with a pre-paid return envelope. Within 3-5 days of the kit's mail-out, participants will receive a telephone call from a patient navigator to provide one-on-one education.
62568598|NCT04677777|EXPERIMENTAL|PP-007 along with Standard of care (SOC)|The study has only single arm, wherein, patients will receive two doses of PP-007 (24 ± 6 hours apart), along with the Standard-of-care (SOC) as per the site's medical practice. SOC is defined as Intravenous thrombolysis (IVT) or Mechanical Thrombectomy (MT) or both (IVT+MT).
62568599|NCT04841395||PE|Premature ejaculation group
62568600|NCT04841395||CG|Control group (Healthy subjects)
62568601|NCT01611727|EXPERIMENTAL|Cisplatin|
62568602|NCT02507739|OTHER|possibility to walk during labor|possibility to walk during labor
62568603|NCT02507739|OTHER|no possibility to walk during labor|no possibility to walk during labor
62568604|NCT04723446|EXPERIMENTAL|Group 1 (test group; n= up to 10 patients) - 0.2 % Chlorhexidine digluconate|Participants will be instructed to rinse their mouth with 10 ml of Corsodyl® Alcohol free mouthwash for 1 minute.
62568605|NCT04723446|EXPERIMENTAL|Group 2 (test group; n= up to 10 patients) - 1.5% Hydrogen peroxide|Participants will be instructed to rinse their mouth with 10 ml of Colgate® Peroxyl mouthwash for 1 minute.
62774431|NCT00575874|EXPERIMENTAL|3|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
62774432|NCT00575874|ACTIVE_COMPARATOR|4|30 mg pioglitazone HCl capsules once daily for 12 weeks
61998805|NCT01403038|EXPERIMENTAL|Elagolix Dose Regimen 3|Elagolix Dose Regimen 3 for 84 days
62184456|NCT06034899|EXPERIMENTAL|Part 1: BMS-986196 Dose 1 (Treatment B)|
62184457|NCT06034899|EXPERIMENTAL|Part 2: BMS-986196 Dose 2 (Treatment A)|
62184458|NCT06034899|EXPERIMENTAL|Part 2: BMS-986196 Dose 2 (Treatment B)|
62184459|NCT06545409|EXPERIMENTAL|SPSIP group|Patients in this group will be treated with the Serratus Posterior Superior Intercostal Plane Block, administered under ultrasound guidance 15 minutes before surgery in the operating room. The block will be performed by administering 30 ml of 0.25% bupivacaine.
62184460|NCT06545409|PLACEBO_COMPARATOR|Placebo group|Patients in this group will be treated with the Serratus Posterior Superior Intercostal Plane Block, administered under ultrasound guidance 15 minutes before surgery in the operating room. The block will be performed using 30 ml of a placebo solution without an active ingredient (0.9% NaCl)
62774433|NCT00575874|PLACEBO_COMPARATOR|5|Matching rivoglitazone HCL placebo tablets and/or matching pioglitazone HCL placebo capsules
62774434|NCT06475040|EXPERIMENTAL|Open-label aiTBS to novel right dmPFC TMS anxiety target|
61998806|NCT01403038|EXPERIMENTAL|Elagolix Dose Regimen 4|"Elagolix Dose Regimen 4 for 84 days~Additional Dose Regimens may be added and will be administered for 84 days."
61998807|NCT01403038|EXPERIMENTAL|Elagolix Dose Regimen 5|Elagolix Dose Regimen 5 for 84 days
61998808|NCT01403038|EXPERIMENTAL|Elagolix Dose Regimen 6|Elagolix Dose Regimen 6 for 84 days
61998809|NCT01403038|EXPERIMENTAL|Elagolix Dose Regimen 7|Elagolix Dose Regimen 7 for 84 days
61998810|NCT02153866|PLACEBO_COMPARATOR|rotavirus|vaccinate one dose rotavirus vaccine for each of 700 participants aged 8\~9months
61998811|NCT02153866|PLACEBO_COMPARATOR|measles-rubella|vaccinate one dose measles-rubella vaccine for each of 350 participants aged 8\~9 months.
61998812|NCT02153866|PLACEBO_COMPARATOR|measles-mumps-rubella|vaccinate one dose measles-mumps-rubella vaccine for each of 350 participants aged 8\~9 months.
62184461|NCT02645539|EXPERIMENTAL|Single Arm|All patients are treated with the intravascular ventricular assist system (iVAS).
62184462|NCT01041989|NO_INTERVENTION|Standard health counseling at baseline|
61998813|NCT02153866|EXPERIMENTAL|rotavirus, measles-rubella|simultaneously vaccinate one dose rotavirus vaccine and one dose measles-rubella vaccine for each of 700 participants aged 8\~9 months.
62184463|NCT01041989|EXPERIMENTAL|Lifestyle counseling|Multi-domain lifestyle counseling including nutritional guidance, increased physical activity, cognitive training, increased social activity and intensive monitoring of vascular and metabolic risk factors.
62184464|NCT02947841|PLACEBO_COMPARATOR|Placebo|In the placebo cohort, subjects will alternate their DBS parameters between group A and group B every week for 12 weeks, but they will be blinded to the fact that their group A and group B are equivalent.
62184465|NCT02947841|ACTIVE_COMPARATOR|Treatment|In the treatment cohort, subjects will alternate their DBS parameters between group A and group B every week for 12 weeks.
62184466|NCT01850823|PLACEBO_COMPARATOR|placebo|Placebo
62184467|NCT01850823|ACTIVE_COMPARATOR|NASONEX® Nasal Spray (Schering Corporation)|Mometasone Nasal spray
62184468|NCT01850823|EXPERIMENTAL|Mometasone Nasal Spray (Watson Laboratories, Inc)|Mometasone Nasal spray
62184469|NCT02988349|ACTIVE_COMPARATOR|Caries-free subjects|Subjects will use Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks,.
62184470|NCT02988349|EXPERIMENTAL|Caries-active subjects|Subjects will use Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks,.
62184471|NCT04429802|PLACEBO_COMPARATOR|Placebo|Placebo is an opaque empty gel capsule obtained from the UZ Gasthuisberg pharmacy. These capsules are composed of 100% gelatine that will rapidly dissolve (disintegration time is 15 minutes) in the stomach without affecting the gastric motor function.
62184472|NCT04429802|EXPERIMENTAL|Prucalopride|2 mg, Resolor®, Shire, Belgium Prucalopride (2 mg) is rapidly absorbed; after a single oral dose of 2 mg Cmax was attained in 2-3 hours. The absolute oral bioavailability is \>90%. Concomitant intake of food does not influence the oral bioavailability of prucalopride.
62184473|NCT03416569|EXPERIMENTAL|Nicotine-Prazosin Interaction Study|Over four test days, each participant will be tested with placebo, nicotine alone, prazosin alone, and nicotine + prazosin, in a double-blind sequence.
62184474|NCT02569632|EXPERIMENTAL|Open Label: MenB-FHbp|Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)
62184475|NCT00607178|EXPERIMENTAL|Influenza vaccine|Enrolled patients who are randomly assigned to receive influenza vaccine
61998814|NCT02153866|EXPERIMENTAL|rotavirus, measles-mumps-rubella|simultaneously vaccinate one dose rotavirus vaccine and one dose measles-mumps-rubella vaccine for each of 700 participants aged 8\~9 months.
61998815|NCT02980965|EXPERIMENTAL|neoadjuvant chemo-endocrine therapy|In the experimental arm, patients received concurrent chemotherapy (fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles) with endocrine therapy (letrozole with or without leuprorelin) as a neoadjuvant treatment
61998816|NCT02980965|ACTIVE_COMPARATOR|neoadjuvant chemotherapy alone|In the control group, patients received neoadjuvant chemotherapy alone (fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles)
61998817|NCT02449239|EXPERIMENTAL|Vicinium|"Induction - 30 mg of Vicinium in 50 mL of saline administered twice weekly (BIW) for 6 weeks followed by once weekly for 6 weeks, for a total of 12 weeks.~Maintenance - 30 mg of Vicinium in 50 mL of saline administered once weekly every other week for up to 104 weeks."
61998818|NCT01920815||Beta blocker therapy|Cohort will consist of those actively taking any beta blocker medication. Observation only.
61998819|NCT01920815||ARB therapy|Cohort will consist of those actively taking any angiotensin receptor blocker medication. Observation only.
61998820|NCT01920815||No therapy|Cohort will consist of those not taking either beta blocker nor angiotensin receptor blocker. Observation only.
61998821|NCT02848976||IA group|EDSS (Expanded Disability Status Scale) below 6 with RE
61998822|NCT02848976||IB group|EDSS (Expanded Disability Status Scale) below 6 with no RE
61998823|NCT02848976||IIA group|EDSS (Expanded Disability Status Scale) betwin 6 and 8 with RE
61998824|NCT02848976||IIB group|EDSS (Expanded Disability Status Scale) below 6 with RE
61998825|NCT00515307|EXPERIMENTAL|A|
61998826|NCT05370664||Female COPD|
61998827|NCT05370664||Male COPD|
61998828|NCT00832351|EXPERIMENTAL|1|Early mobilisation within 24 hours after admittance to hospital
62184476|NCT00607178|PLACEBO_COMPARATOR|Placebo|Enrolled patients who are randomly assigned to receive placebo of influenza vaccine
62184477|NCT04148118|EXPERIMENTAL|NE+50µg rPA - sprayer|
62184478|NCT04148118|EXPERIMENTAL|NE+50µg rPA - pipette|
62184479|NCT04148118|EXPERIMENTAL|NE+100µg rPA - sprayer|
62184480|NCT04148118|EXPERIMENTAL|NE+100µg rPA - pipette|
62184481|NCT04148118|PLACEBO_COMPARATOR|Saline - sprayer|
62184482|NCT04148118|PLACEBO_COMPARATOR|Saline - pipette|
62184483|NCT04148118|ACTIVE_COMPARATOR|BioThrax - SC|
61998829|NCT00832351|NO_INTERVENTION|2|Mobilisation after 24 but within 48 hours from admittance to hospital
62184484|NCT05144685|EXPERIMENTAL|Experimental App + Treatment as Usual|This intervention will be for the treatment group
62774435|NCT05235724||Subset of study-OBS15333 patients|As a sub-study of the OBS15333 pediatric AD registry (PEDISTAD), all participants in this study will be receiving standard care of therapies for moderate to severe AD.
61998830|NCT02777125|ACTIVE_COMPARATOR|Albuterol by Metered Dose Inhaler|Albuterol administered via MDI and spacer device with weight and severity based dosing. For weight less than 20 kg: mild and moderate disease 540mcg of albuterol per dose. For weight greater than or equal to 20 kg: mild disease 540 mcg of albuterol per dose and moderate disease 1080 mcg of albuterol per dose.
61998831|NCT02777125|ACTIVE_COMPARATOR|Albuterol Breath Actuated Nebulizer|Subjects randomized to BAN were evaluated for proper breath actuation technique. For subjects unable to coordinate breath actuation, the RT attached an appropriately sized mask to the device, changed the setting to continuous nebulization and returned upon completion of the treatment. Albuterol dosing was based upon the subject's weight and presenting symptom severity. Children presenting in the mild and moderate severity category weighing less than 20kg, received 2500mcg of albuterol. Children weighing more than 20kg, received 2500mcg of albuterol if their presentation met mild severity criteria, or 5000mcg if they met moderate criteria.
61998832|NCT04242108||Angle closure group|
62774436|NCT00348894|EXPERIMENTAL|Open Treatment|\[S,S\]-reboxetine
62774437|NCT00348894|OTHER|Standard Care|Standard Care
62774438|NCT04903366||Chronic wound|Any chronic wound, for greater than 30 days with minimal improvement
62774439|NCT04903366||Glaucoma|Any diagnosis of glaucoma and active prescription of timolol drops
62774440|NCT02999152|EXPERIMENTAL|Total Body Irradiation|Patient suffering from a malignant blood disease that requires a total body radiation, without (or prior to) a concomitant chemotherapy, according to the following protocol: 2x2 Gray per day, for 3 days. Blood and urines samples will be performed at days 0, 1, 2 and 3 of the treatment plan.
62774441|NCT02999152|EXPERIMENTAL|Partial Body Irradiation|Patient with at least one bone metastasis localized at the pelvis and requiring partial body radiation therapy without associated chemotherapy, according to the following protocol: 4 Gray per day for 5 days will perform blood and urines samples at days 0, 1, 2 and 3 after the beginning of the radiation treatment.
62774442|NCT03331523|EXPERIMENTAL|Calcipotriene/betamethasone dipropionate|
62774443|NCT03331523|ACTIVE_COMPARATOR|Taclonex®|
62774444|NCT03331523|PLACEBO_COMPARATOR|Placebo|
62774445|NCT02943616|EXPERIMENTAL|Absorb BVS|Subjects receiving Absorb GT1 Bioresorbable Vascular Scaffold (BVS).
62774446|NCT00688272|EXPERIMENTAL|Arm 1|Eltrombopag 75 mg QD x 6 days
61998833|NCT04242108||Open angle group|
61998834|NCT04242108||Peripheral synechia (PAS) group|
61998835|NCT04242108||Non-peripheral synechia (PAS) group|
61998836|NCT01050738|ACTIVE_COMPARATOR|Intracapsulare position|
61998837|NCT01050738|ACTIVE_COMPARATOR|Extracapsulare position|
61998838|NCT06344819|EXPERIMENTAL|Acupuncture|
62774447|NCT00688272|ACTIVE_COMPARATOR|Arm 2|Ciprofloxicin 500mg BID x 6 days
62774448|NCT00688272|PLACEBO_COMPARATOR|Arm 3|Placebo QD x 6 days
62774449|NCT01704456|EXPERIMENTAL|Mindfulness-based cognitive therapy (MBCT)|Women in the MBCT Group Treatment arm will receive the treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
61998839|NCT06344819|SHAM_COMPARATOR|Sham Acupuncture|
61998840|NCT01435291|EXPERIMENTAL|Advagraf|
61998841|NCT01435291|ACTIVE_COMPARATOR|Prograf|
61998842|NCT03907683|EXPERIMENTAL|Random Messaging|Participants receive 0-5 messages/day from the Random AIM app. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages are selected randomly from three content domains: Move More (40%), Sit Less (40%), and Inspirational Quotes Unrelated to Movement (20%). Half of the messages are accompanied by images. Message selection and timing are determined randomly each night for the following day.
62020982|NCT05601531|EXPERIMENTAL|Autologous Tooth Root+ Bone graft|Placement of bone graft without local administration of Vit.D3 and placement of autogenous root slices
62020983|NCT05601531|EXPERIMENTAL|Bone graft|Only bone graft materials were placed, no local administration of Vit.D3, and no autologous root slices were placed
62020984|NCT05601531|NO_INTERVENTION|Natural healing|After the wound healed naturally, no bone graft material was filled, and Vit.D3 was not administered locally, and autologous tooth root slices were not placed.
62020985|NCT01888315|EXPERIMENTAL|Catheter-based renal denervation|"One procedure will be performed using one of the CE-marked devices for renal denervation:~Device: Renal denervation with Symplicity Flex Medtronic/Ardian Device: Renal denervation with EnligHTN St. Jude Medical Device: Renal denervation with Paradise Recor Device: Renal denervation with V2 Vessix"
62020986|NCT01888315|NO_INTERVENTION|Medical therapy|Best medical therapy using guideline recommended drugs in each disease state.
62020987|NCT00087074|EXPERIMENTAL|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses beyond CR.
62020988|NCT05194410|EXPERIMENTAL|Intervention|6 months of virtual, team-based exercise
62020989|NCT05194410|OTHER|Control|3 months of usual exercise and then 3 months of virtual, team-based exercise
62568606|NCT04723446|EXPERIMENTAL|Group 3 (test group; n= up to 10 patients) - Cetylpyridinium chloride|Participants will be instructed to rinse their mouth with 10 ml of Oral-B® Gum \& Enamel Care mouthwashes for 1 minute.
62568607|NCT04723446|EXPERIMENTAL|Group 4 (control group; n= up to 10 patients) - No rinsing|Patients will be instructed to not rinse their mouth with any solution, not even water.
62568608|NCT04692311|EXPERIMENTAL|Persons with central nervous system diseases|Persons with central nervous system diseases received additional training with i-ACT during 6 weeks. After final training, a semi-structured interview was performed. And at six weeks follow-up, a final assessment took place.
62568609|NCT04692311|OTHER|Occupational therapists|Occupational therapists were invited to a semi-structured interview to gather information about their professional opinion regarding i-ACT.
62568610|NCT04227223|EXPERIMENTAL|Study Group|Study Group - 36 patients with chronic Low-Back Pain with opioids pharmacotherapy
62774450|NCT01704456|EXPERIMENTAL|Cognitive Behavioural Therapy (CBT)|Women in the CBT Group Treatment arm will receive the treatment in small group format (8-9 women). Each session will be 2.25 hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
61998843|NCT00842348|EXPERIMENTAL|Lanreotide (Autogel formulation)|Patients from the preceding DB study (Study 726) were treated with open label lanreotide Autogel 120 mg by deep subcutaneous injections every 28 days. Patients were included if they had been treated with lanreotide (Autogel formulation) or placebo in DB Study 726 and had stable disease at the end of the 96-week treatment period, or if they had received placebo and had disease progression at any time during Study 726. Safety data were based on the safety population patients who received lanreotide in Study 729). The main efficacy analysis was based on the ITT population (patients randomised in Study 726 regardless of whether they continued into Study 729).
61998844|NCT01914224|EXPERIMENTAL|Group 1|dietary education of low sodium and high potassium consumption
61998845|NCT01914224|ACTIVE_COMPARATOR|Group 2|dietary education of low sodium consumption only
61998846|NCT01505686|EXPERIMENTAL|study group|All patients in this study have MRI scan prior to hernia repair surgery. If inflammatory changes are present, the scan is repeated 6 months after surgery. If not, the scan is performed only if the patient has pain problems at 6 months.
61998847|NCT01544530|EXPERIMENTAL|Hypothermia (32-33 degree C)|Following randomization, hypothermia will be induced by a combination of cold isotonic fluid and sustained until organ procurement by a central venous catheter
61998848|NCT01544530|NO_INTERVENTION|Normothermia (36.5 - 37.5 degree C)|Normothermia will be maintained until organ procurement as per current standard of care
61998849|NCT04185233|EXPERIMENTAL|iPad distraction|"Children of this group will receive the iPad when the nurse will prepare the material for the venous track. They will choose a game adapted to their age and will be able to play it during all the procedure time.~Intervention : game on iPad"
61998850|NCT04185233|ACTIVE_COMPARATOR|Nitrous Oxide|"Children of this group will receive the Nitrous Oxide 3 minutes before the intervention (venous track). They will keep the mask during all the procedure time.~Intervention : Nitrous Oxide"
62568611|NCT04227223|ACTIVE_COMPARATOR|Control Group|Control Group - 14 patients, healthy volunteers.
62568612|NCT06155929|OTHER|Flight|The intervention is the flight to turkey and home to Denmark again.
62568613|NCT06461026|EXPERIMENTAL|150 mg of L9LS|Participants will receive a dose of 150 mg of L9LS.
61998851|NCT00739752|EXPERIMENTAL|Non-Framed-Offered|Non-Framed, Information Only Condition. Vaccine Offered.
61998852|NCT00739752|EXPERIMENTAL|Non-Framed-Recommended|Non-Framed, Information Only Condition. Vaccine Recommended.
61998853|NCT00739752|EXPERIMENTAL|Gain-Framed-Offered|Gain-Framed Intervention emphasizes the benefits associated with receiving HBV vaccine. Vaccine Offered.
61998854|NCT00739752|EXPERIMENTAL|Gain-Framed-Recommended|Gain-Framed Intervention emphasizes the benefits associated with receiving HBV vaccine. Vaccine Recommended.
61998855|NCT00739752|EXPERIMENTAL|Loss-Framed-Offered|Loss-Framed Intervention emphasizes the risks associated with not receiving HBV vaccine. Vaccine Offered.
62568614|NCT06461026|PLACEBO_COMPARATOR|Placebo (normal saline)|Participants will receive placebo of Normal Saline for comparison.
62568615|NCT01287559||Subjects with NEC|Infants in which a possible diagnosis of NEC is suspected
62568616|NCT01287559||Control Infants|Age-matched and illness-severity matched to NEC subjects, controls are infants NOT suspected of having NEC.
62568617|NCT04191525|EXPERIMENTAL|BPL-1 Probiotic capsules|BPL-1 Probiotic 1 capsule/day
62568618|NCT04191525|PLACEBO_COMPARATOR|Placebo|1 capsule/day
62568619|NCT02627664||observational study|natural history of non dopaminergic signs
62568620|NCT01353599|EXPERIMENTAL|Asmanex|Study participants will receive inhaled Mometasone Furoate (Asmanex) 220mcg once daily for 8 weeks.
62774451|NCT04082286|EXPERIMENTAL|Radioimmunotherapy|Children affected by high risk malignant disorders will be receiving increasing infused activity of a radio-immune conjugated antibody as part of their conditioning regimen prior to alleogeneic stem cell transplantation
62774452|NCT04842305||G1: Control group|SARS-CoV-2 naïve persons who have neither been vaccinated nor have had COVID-19 (controls)
62774453|NCT04842305||G2: COVID-19 infected|Persons who have had COVID-19
62774454|NCT04842305||G3: COVID-19 vaccinated|Persons who have been vaccinated with Pfizer-BioNTech BNT162b2, Moderna mRNA-1273 or AstraZeneca ChAdOx1-S
62774455|NCT04842305||G4: COVID-19 infected and vaccinated|Individuals who have been infected with COVID-19 and subsequently been vaccinated
62774456|NCT03342092||Questionnaire|Questionnaires distributed to the families 15 days before child's medical consultation
61998856|NCT00739752|EXPERIMENTAL|Loss-Framed-Recommended|Loss-Framed Intervention emphasizes the risks associated with not receiving HBV vaccine. Vaccine Recommended.
61998857|NCT04733963|EXPERIMENTAL|Arm A|Maintenance therapy with Fruquintinib Plus Capecitabine
61998858|NCT04733963|ACTIVE_COMPARATOR|Arm B|Maintenance therapy with Bevacizumab Plus Capecitabine
61998859|NCT00983216|ACTIVE_COMPARATOR|Colchicine alone|-baseline colchicine pharmacokinetics
61998860|NCT00983216|EXPERIMENTAL|Colchicine with Steady-State Ketoconazole|-colchicine pharmacokinetics in presence of steady-state ketoconazole
61998861|NCT02347566|EXPERIMENTAL|Physical activity enhancing programme|Usual care + physical activity enhancing programme (PAEP) (Study group, \[S\]), which includes both pulmonary rehabilitation programme plus the PAEP using an activity monitor (DirectLife) with set targets of physical activity levels to stimulate and increase physical activity in daily life.
61998862|NCT02347566|OTHER|Control|Usual care (control, \[C\]) that includes only the pulmonary rehabilitation programme with the use of an activity monitor (DirectLife) in daily routine without any feedback or incentive to increase physical activity in daily life.
62568621|NCT03904251|EXPERIMENTAL|Treatment (CPX-351, gemtuzumab ozogamicin)|"INDUCTION: Patients receive liposome-encapsulated daunorubicin 44mg/m2 - cytarabine 100mg/m2 IV over 90 minutes on days 1, 3, and 5, and gemtuzumab ozogamicin 3 mg/m2 (max 4.5 mg) IV over 120 minutes on day 7, or days 4 and 7, or days 1, 4, and 7 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi receive consolidation therapy at the discretion of the treating physician and/or proceed to allogeneic HSCT."
61998863|NCT00664716|PLACEBO_COMPARATOR|Placebo|subcutaneous administration of placebo given for 12 weeks
62774457|NCT06347939||All the patients undergo the same procedure|All the patients undergo the same procedure and every patient's own samples are compared to each other.
62774458|NCT02785419|EXPERIMENTAL|Arm Training with Action Selection|Task-oriented, functional arm training with the addition of action selection cues to practice. All participants receive the same arm training intervention.
62774459|NCT02580786|EXPERIMENTAL|Breastfeeding peer support|Internet-based breastfeeding peer-support group in social media (Facebook). The mothers are allowed to use the group based on their individual needs from the recruitment to the first birthday of their child. Peer support is provided by three voluntary mothers. The mothers can discuss breastfeeding-related issues and ask questions. A midwife will moderate the group.
62774460|NCT02580786|NO_INTERVENTION|Routine breastfeeding support|Routine breastfeeding support provided in the hospital and in the maternal and child health clinics
62774461|NCT06175169|ACTIVE_COMPARATOR|IA model|A fully automated diagnostic framework based on 3D-CNN model to predict non-appendicitis, simple and complicated appendicitis
62774462|NCT06175169|NO_INTERVENTION|Non-radiologist|Ten non-radiologists participated in this study. CT image same to IA model was allocated to radiologist randomly.
62791602|NCT02764658|OTHER|Routine care on the AECOPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in AECOPD Patients
61998864|NCT00664716|EXPERIMENTAL|One Dose|BG9924 - dosage level administered as per Biogen Idec protocol
61998865|NCT00664716|EXPERIMENTAL|Second Dose|BG9924 - dosage level administered as per Biogen Idec protocol
61998866|NCT00664716|EXPERIMENTAL|Third Dose|BG9924 - dosage level administered as per Biogen Idec protocol
61998867|NCT00664716|EXPERIMENTAL|Fourth Dose|BG9924 - dosage level administered as per Biogen Idec protocol
61998868|NCT00664716|EXPERIMENTAL|Fifth Dose|BG9924 - dosage level administered as per Biogen Idec protocol
61998869|NCT01397175|ACTIVE_COMPARATOR|Biolimus-eluting stent|Biomatrix stent, Biosensors, USA Biomatrix Flex stent, Biosensors, USA
61998870|NCT01397175|ACTIVE_COMPARATOR|Everolimus-eluting stent|Xience Prime stent, Abbott, USA Xience V stent, Abbott, USA
62568622|NCT05510479||OdySight vs Standardized methods|All patients perform Visual Acuity testing through OdySight and according to standard practice
61998871|NCT01397175|ACTIVE_COMPARATOR|Zotarolimus-eluting stent|Endeavor resolute, Medtronic, USA Endeavor resolute integrity, Medtronic, USA
61998872|NCT01515969|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD. Starting on day 15, patients also receive dovitinib lactate PO QD on days 1-5 of each week. Treatment continues in the absence of disease progression or unacceptable toxicity.
62020990|NCT05306652|EXPERIMENTAL|A - Home based supervised physical exercise|patients will have a home-based physical activity prescription
62393194|NCT05257876|NO_INTERVENTION|Control group|Participants in the control group will receive pain information booklet and usual care.
61998873|NCT03323528|ACTIVE_COMPARATOR|Dorithricin|"Dorithricin throat lozenges is a fixed combination of three active substances: Benzalkonium Chloride-Benzocaine Topical plus tyrothricin. Lozenge has to be sucked slowly until it fully dissolves in the mouth and dosed up to 8 lozenges per day. Test product without mint oil.~Intervention: The initial dose is administered at the study site. Patients administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
62568623|NCT05037201|NO_INTERVENTION|Usual care|The control arm will receive usual health system messaging about the importance and deadlines for receiving COVID-19 vaccination.
61998874|NCT03323528|PLACEBO_COMPARATOR|Placebo|"Placebo Oral Tablet is taken orally. Placebo consists of a lozenge with matched appearance and the same excipients as those of the Dorithricin lozenge. The initial dose (2 lozenges simultaneously) is administered at the study site.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
61998875|NCT05357872|EXPERIMENTAL|BIS 40-50 Group|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50
62791603|NCT02764658|OTHER|Routine care on the stable COPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in stabel COPD Patients
62791604|NCT02748395|PLACEBO_COMPARATOR|Placebo|Injection of 3.5mL of normal saline into the point of maximal tenderness in the abdomen
62791605|NCT02748395|EXPERIMENTAL|Treatment|Injection of 20mg triamcinolone and 1% lidocaine into the point of maximal tenderness in the abdomen
61998876|NCT05357872|EXPERIMENTAL|BIS 50-60 Group|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 50-60 during the operation.
61998877|NCT01679275||measuring cerebral oxygenation|NIRS: Measurement of cerebral oxygenation using Near Infrared Spectroscopy (NIRS) during the pre-operative phase in neonates with congenital heart disease.
62393195|NCT01247467||Breast Tumor|Breast Tumor Blocks
62568624|NCT05037201|EXPERIMENTAL|Text message|The intervention arm will receive a text message stating that the vaccine is reserved for them on a specific date. They will have the ability to reschedule to a different day, opt-out of this text messaging intervention, or if previously vaccinated they can upload documentation to the Ascension website.
62791606|NCT03785158|ACTIVE_COMPARATOR|Melatonin|3 mg of liquid melatonin by oral route for 8 days. The 1st dose will be given 1-2 hours prior to the surgery, followed by bed time doses (between 7-9 pm) given on postoperative day (POD) 1 until discharge or for the first 7 days.
62791607|NCT03785158|PLACEBO_COMPARATOR|Placebo Group|Similar looking/tasting 3 mg (5 ml) placebo syrup administered preoperatively by oral route and for the next 7 days or until discharge. The 1st dose will be given 1-2 hours prior to the surgery, followed by bed time doses (between 7-9 pm) given on postoperative day (POD) 1 until discharge or for the first 7 days.
62791608|NCT01294969|EXPERIMENTAL|AL-4943A|One drop per day in both eyes
62791609|NCT02253953|EXPERIMENTAL|D1|
62791610|NCT02253953|EXPERIMENTAL|D2|
62791611|NCT02253953|EXPERIMENTAL|D3|
62791612|NCT02253953|EXPERIMENTAL|D4|
62791613|NCT02253953|EXPERIMENTAL|D5|
62791614|NCT02253953|EXPERIMENTAL|D6|
62791615|NCT02253953|EXPERIMENTAL|D7|
62791616|NCT02253953|EXPERIMENTAL|D8|
62791617|NCT02253953|EXPERIMENTAL|D10|
62791618|NCT02253953|PLACEBO_COMPARATOR|Placebo|for D3 - D10
62791619|NCT00668811|EXPERIMENTAL|Treatment Arm - Sutent|Sutent 37.5 mg/day will be given orally.
62791620|NCT01053988|EXPERIMENTAL|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
62791621|NCT01053988|EXPERIMENTAL|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
62791622|NCT01053988|EXPERIMENTAL|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
62791623|NCT01053988|PLACEBO_COMPARATOR|Placebo|Placebo
62791624|NCT01053988|EXPERIMENTAL|FF/GW642444 Inhalation Pwdr|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
62791625|NCT02056093|EXPERIMENTAL|Intubated patients|Intubated patients: The three modes (PSV, PAV, NAVA) will be applied in random order to each mechanically ventilated patient included in the study.
62791626|NCT00952081|EXPERIMENTAL|clevidipine,brain tumor,hypertension|21 or older, Clevidipine in brain tumor resection, epilepsy focus resection during acute hypertension under general anesthesia
62791627|NCT05594407|ACTIVE_COMPARATOR|dexmedetomidine-ketamine-lidocaine (DKL) group|combination of dexmedetomidine, ketamine and lidocaine in one syringe
61998878|NCT03080961|EXPERIMENTAL|Before and after VIBLOK|The degree to which HSV-2 is blocked by the VIBLOK cream is determined by comparing the amount of HSV in the external genital area before and after application of the cream. So participants are their own control.
61998879|NCT04322396|PLACEBO_COMPARATOR|Control|"This arm will receive standard care and placebo in 15 days.~Azithromycin placebo:~Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1~Hydroxychloroquine placebo:~Day 1-15: 200 mg x 2"
61998880|NCT04322396|ACTIVE_COMPARATOR|Intervention|"This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.~Azithromycin:~Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1~Hydroxychloroquine:~Day 1-15: 200 mg x 2"
61998881|NCT03618264|EXPERIMENTAL|Dexamethasone plus Ropivacaine group|Participates received peri-incisional scalp infiltration of a miscible liquid of dexamethasone and ropivacaine. The local infiltration miscible liquid containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter
61998882|NCT03618264|ACTIVE_COMPARATOR|Ropivacaine group|Participates received peri-incisional scalp infiltration of 5mg/mL ropivacaine.
62020991|NCT05306652|ACTIVE_COMPARATOR|B- Unsupervised physical exercise|patients will receive a physical activity counselling, without a real prescription and supervision
62020992|NCT03434717|EXPERIMENTAL|Control (high distress)|Control group receiving care as usual
62020993|NCT03434717|EXPERIMENTAL|Individualised rehabilitation|"Patients with high distress receive the intervention individualized rehabilitation including evaluation of individual needs and based on that physical, psychological or social interventions to promote rehabilitation."
62184485|NCT05144685|EXPERIMENTAL|Other App + Treatment as Usual|This intervention will be for the control group
62184486|NCT04795206||Cohort 1: Main Cohort|All eligible participants with CHM in IRIS Registry will be included.
62774463|NCT00569868|EXPERIMENTAL|Velcade|"Treatment on this study will last 2 cycles. Each cycle consists of 3 weeks, or 21 days. After you have gone off study, you will be followed every three months for approximately 2 years.~Each cycle will consist of 3 weeks (21 days) according to the schedule below.~DRUG ROUTE DOSE DAYS Velcade IV 1.3 mg/m2 1,4,8, and 11 This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a two cycles."
62774464|NCT02903043||COPD patients|Quadriceps biopsies will be done. No drug administration.
62774465|NCT02903043||Healthy controls|Quadriceps biopsies will be done. No drug administration.
62774466|NCT06110000|EXPERIMENTAL|pragmatic set of interventions|"The pragmatic set included 6 interventions as follows.~1. Pragmatic posterior capsular stretch (PPCS)~2. Serratus anterior stretch (SAS)~3. Rotator cuff facilitation (RCF)~4. Acromioclavicular joint mobilization~5. Pectoralis minor stretch~6. Thoracic manipulation"
62774467|NCT06110000|PLACEBO_COMPARATOR|scapular strengthening exercises|"Scapular strengthening exercises will be individualised focusing on Serratus anterior, trapezius, Levator scapulae, Rhomboids.~Serratus anterior;~* Dynamic hug~* Scaption with external rotation~* Diagonal PNF (shoulder flexion, horizontal flexion, external rotation),~Trapezius - Upper trapezius:~* Unilateral shoulder shrug,~* Rowing,~* Forward shoulder flexion,~* Shoulder abduction in scapular plane above 120 degrees.~Middle trapezius:~* Prone shoulder horizontal abduction~* Scaption, horizontal abduction with external rotation~Lower trapezius:~* Unilateral scapular retraction,~* Prone bilateral shoulder external rotation at 90 degrees of abduction,~* Prone shoulder abduction.~Levator Scapulae:~* Horizontal abduction with shrug,~* Horizontal abduction with ER,~* Prone shoulder extension.~Rhomboids:~* ER at 90° of abduction,~* ER at 0° of abduction,~* Horizontal abduction,~* Shoulder extension,"
62774468|NCT00819117|ACTIVE_COMPARATOR|Transvenous Lead (TVN CRT)|Control group: resynchronization via a transvenous left ventricular lead (TVN CRT)
62774469|NCT00819117|EXPERIMENTAL|Epicardial Lead (EPI CRT)|Treatment group: resynchronization via an epicardial left ventricular lead (EPI CRT)
62774470|NCT01993563|EXPERIMENTAL|Graded Motor Imagery|
62774471|NCT01993563|ACTIVE_COMPARATOR|Standard treatment|
62774472|NCT02266576|ACTIVE_COMPARATOR|Standard Diabetes Prevention Program (DPP)|Participants receive Standard DPP over the course of 20 weeks.
62774473|NCT02266576|EXPERIMENTAL|Enhanced DPP|Participants receive Standard DPP plus Enhanced DPP over the course of 20 weeks.
62774474|NCT06280885|EXPERIMENTAL|FIERCE Programme|"The FIERCE programme will consist of an aerobic and resistance exercise program delivered for the duration of chemotherapy.~Exercise will be prescribed with the aim of achieving an overall exercise volume over the course of a chemotherapy cycle. The total volume of exercise prescribed in each cycle will be targeted towards achieving the exercise guidelines for cancer survivors which recommends 90 minutes of aerobic activity per week, in addition to resistance exercise at least two times per week.~Exercise intensity will be autoregulated by participants based on how they are feeling on a given day. Participants will be given a choice of exercising at low, moderate, or higher intensity based on how BORG rating of perceived exertion (RPE) scale.~Weekly check ins will be made to each participant over the phone by an exercise physiologist for goal setting. Participants will also be given a pedometer to monitor daily physical activity levels."
62020994|NCT03434717|EXPERIMENTAL|Control group (low distress)|Control group receiving care as usual
61998883|NCT02692677|EXPERIMENTAL|JNJ-42756493|Each participant will receive a single oral dose of 12 milligram (mg) of unlabeled JNJ-42756493 admixed with 14C JNJ-42756493 at Pre-dose,0.5,1,2,3,4,8,12 hour post-dose(pd) on Day 1;24,36 h pd on Day 2;48 h pd on Day 3,72 h pd on Day 4; 96 h pd on Day 5;192 h pd on Day 9,216 h pd on Day 10,240 h pd on Day 11,264 h pd on Day 12,288 h pd on Day 13 and 312 h pd on Day 14
61998884|NCT04270825|EXPERIMENTAL|CBT with IPT|Group CBT with IPT will consist of 20 weekly two-hour sessions and has been developed for the proposed study based on the protocols for group CBT for HD and group IPT. Treatment includes strategies from CBT, including cognitive restructuring, behavioral exposures, and organizational strategies, as well as strategies from IPT, including role-play, interpersonal skills building, communication analysis, and decision analysis.
61998885|NCT04065789|EXPERIMENTAL|Carfilzomib,Daratumumab,revlimid and dexamethasone|Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone
62774475|NCT06280885|ACTIVE_COMPARATOR|Pedometer programme|Participants randomized to the pedometer programme will receive individualised advice about exercising during chemotherapy and will also receive a pedometer to encourage daily activity. Participant in both groups will receive a personal exercise consultation to identify their individual needs and understand their exercise preferences.
62774476|NCT02419820|EXPERIMENTAL|APD791 10mg single dose|APD791 10mg single dose
62774477|NCT02419820|EXPERIMENTAL|APD791 20mg single dose|APD791 20mg single dose
62774478|NCT02419820|EXPERIMENTAL|APD791 40mg single dose|APD791 40mg single dose
62774479|NCT02419820|EXPERIMENTAL|APD791 10mg|APD791 10mg single dose + Aspirin + Clopidogrel
62774480|NCT02419820|EXPERIMENTAL|APD791 20mg|APD791 20mg single dose + Aspirin + Clopidogrel
62774481|NCT02419820|EXPERIMENTAL|APD791 40mg|APD791 40mg single dose + Aspirin + Clopidogrel
62774482|NCT02419820|EXPERIMENTAL|APD791 80mg|APD791 80mg single dose + Aspirin + Clopidogrel
62774483|NCT02419820|EXPERIMENTAL|APD791 160mg|APD791 160mg single dose + Aspirin + Clopidogrel
62774484|NCT02419820|EXPERIMENTAL|APD791 240mg|APD791 240mg single dose + Aspirin + Clopidogrel
62774485|NCT02419820|EXPERIMENTAL|APD791 320mg|APD791 320mg single dose + Aspirin + Clopidogrel
62774486|NCT02419820|PLACEBO_COMPARATOR|APD791 Placebo|APD791 placebo for single dose + Aspirin + Clopidogrel
61998886|NCT05245422|ACTIVE_COMPARATOR|Cow's milk intact protein infant formula|Control
61998887|NCT05245422|EXPERIMENTAL|Partially hydrolyzed cow's milk protein infant formula|Investigational
61998888|NCT00499096|EXPERIMENTAL|Chronic Care Model for Bipolar Disorder|An intervention group of patients with bipolar disorder and 1 or more risk factor for cardiovascular disease; group will receive self-management group sessions, followed by phone contacts by the Care Manager. This is the chronic care model for bipolar disorder
61998889|NCT00499096|NO_INTERVENTION|Enhanced Usual Care|A group of patients with bipolar disorder and one or more risk factors for cardiovascular disease will be randomized to receive enhanced usual care. This group will receive usual care, plus mailings on wellness topics (attention control), and their providers will receive information on guideline concordant care.
62184487|NCT04795206||Cohort 2: Trial-Matched Cohort|Only male participants with CHM from Cohort 1 to match Biogen's IST study population using propensity score matching will be included.
62184488|NCT02062645|EXPERIMENTAL|amlodipine/valsartan|All patients will receive amlodipine/valsartan 5/160 mg daily in screening and up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (day 30) if their hypertension can not be controlled. The duration of treatment period is 8 weeks.
62184489|NCT03058380||Stated-Preferences Evaluation Group|A stated-preferences evaluation instrument will be provided to participants with knee pain in the Stated-Preferences Evaluation Group. The instrument will measure patient preferences for total knee replacement versus unicompartmental knee replacement.
62774487|NCT02419820|EXPERIMENTAL|APD791 2mg MD|APD791 2mg multiple dose + Aspirin + Clopidogrel
62774488|NCT02419820|EXPERIMENTAL|APD791 5mg MD|APD791 5mg multiple dose + Aspirin + Clopidogrel
62774489|NCT02419820|EXPERIMENTAL|APD791 10mg MD|APD791 10mg multiple dose + Aspirin + Clopidogrel
62774490|NCT02419820|EXPERIMENTAL|APD791 20mg MD|APD791 placebo for multiple dose + Aspirin + Clopidogrel
62774491|NCT02419820|PLACEBO_COMPARATOR|APD791 placebo MD|APD791 placebo for multiple dose + Aspirin + Clopidogrel
62774492|NCT01949519|EXPERIMENTAL|Docetaxel and Lycopene|
62774493|NCT06102109|ACTIVE_COMPARATOR|Yamane Arm|Scleral IOL fixation using the Yamane technique. A 3 piece IOL (Kowa Avansee Preset) gets fixated in the sclera.
62774494|NCT06102109|ACTIVE_COMPARATOR|"4-flanged Arm"|Scleral IOL fixation using the 4 flanged technique. A 4 loop haptic IOL (Physiol Micropure 123) gets fixated in the sclera using 6.0 polypropylene suture
62774495|NCT04365452|EXPERIMENTAL|Invia Motion Arm|
62774496|NCT03688100|ACTIVE_COMPARATOR|Patients: Medication Management (MEDS)|The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
62774497|NCT03688100|ACTIVE_COMPARATOR|Patients: Behavioral Activation Therapy (BA)|BA is an evidence-based psychotherapy with more than 25 randomized trials showing effectiveness in depression. The therapy group will consist of an introductory in person 50-minute treatment session, followed by 12 weekly telephone 50-minute outpatient treatment sessions, then 3 monthly telephone 50-minute outpatient maintenance sessions. A typical BA session will last 50 minutes and include a review of the previous session and completed daily monitoring record forms, an in-depth discussion of life areas and value, and verbal reinforcement of activity engagement.
61998890|NCT01052545|EXPERIMENTAL|Arm 1- Intervention: Audit-Feedback|Baseline surveillance for the clinical outcomes will begin in year 1 at the intervention site and continue for all 3 years of the project. Guideline distribution will begin in year 2 and continue throughout the project. Audit-feedback will occur during year 2 of the study at the intervention site. Feedback will be delivered to individual health care providers at the intervention site during year 2.Unit-level audit feedback will be delivered at the intervention site during years 2 and 3 of the study. Provider surveys of knowledge and attitudes concerning the ABU guidelines will be administered at the intervention site in years 2 and 3 of the project.
61998891|NCT01052545|NO_INTERVENTION|Arm 2- Control|At the control site, baseline surveillance for the clinical outcomes will begin in year 1 at the and continue for all 3 years of the project. Guideline distribution will begin in year 2 and continue throughout the project. Audit-feedback will not occur at the control site. Provider surveys of knowledge and attitudes concerning the ABU guidelines will be administered at the control site in year 3 of the project.
61998892|NCT04269967||Tele-rehabilitation|Patients who choose tele-rehabilitation
61998893|NCT04269967||Usual care|Patients who choose usual (rehabilitation) care
61998894|NCT04560634||Normal Diastolic Function|Diastolic Function within normal values (defined in terms of E wave and A wave velocity and Deceleration Time according to the American Society of Echocardiography and the European Association of Echocardiography)
61998895|NCT04560634||Impaired Diastolic Function|Diastolic Function with pseudonormal pattern or impaired values (defined in terms of E wave and A wave velocity and Deceleration Time according to the American Society of Echocardiography and the European Association of Echocardiography)
61998896|NCT05983497|EXPERIMENTAL|Experimental: Self-care skill Education|A total of 112 Participants will be assigned to the experimental group. Self-care skill educational intervention is administered to all the participants.
61998897|NCT05983497|NO_INTERVENTION|No Intervention:|A total of 112 Participants will be assigned to the control group.No intervention will be received
61998898|NCT01637350||Subtotal gastrectomy , BillrothⅠ|
61998899|NCT01637350||Subtotal gastrectomy , BillrothⅡ|
62184490|NCT04206709|EXPERIMENTAL|aerobic effort|Active upper limbs pedaling
62184491|NCT04206709|SHAM_COMPARATOR|passive pedaling|passive pedaling
62184492|NCT00151827|EXPERIMENTAL|Olmesartan medoxomil|Olmesartan oral tablets 20 mg or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
62568625|NCT03278223|ACTIVE_COMPARATOR|Test solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.
62568626|NCT03278223|ACTIVE_COMPARATOR|Control solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.
62774498|NCT03688100|NO_INTERVENTION|Caregivers: Medication Management (MEDS)|Caregivers of patients receiving the the above described Medication Management (MEDS) intervention were monitored for caregiver burden at 3, 6, and 12 months.
62774499|NCT03688100|NO_INTERVENTION|Caregivers: Behavioral Activation Psychotherapy (BA)|Caregivers of patients receiving the the above described Behavioral Activation Psychotherapy (BA) intervention were monitored for caregiver burden at 3, 6, and 12 months.
62774500|NCT03586115||Patients with Hereditary telangectasia|In addition to all laboratory analyses and imaging studies required to evaluate the disease, hepatic elastometry and critical flicker frequency assessment will be performed.
62774501|NCT01067469|EXPERIMENTAL|Standard Dose Bevacizumab|Bevacizumab 10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
62774502|NCT01067469|EXPERIMENTAL|Low Dose Bevacizumab + Lomustine|Bevacizumab 5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle. Lomustine starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
62774503|NCT05463263|EXPERIMENTAL|Phase 1 (Part 1, Dose Escalation)|Up to 5 dose levels with STP938 administered as oral monotherapy
62774504|NCT05463263|EXPERIMENTAL|Phase 2 (Part 2; expansion)|At defined dose level(s) with STP938 administered as oral monotherapy
62774505|NCT03044808|EXPERIMENTAL|Lidocain|Patient gets the experimental treatment with IV lidocain 0,5mg/ml, 1,5mg/kg bolus before induction of anesthesia, after that infusion of 1,5mg/kg/h is started and continued until 2 hours after end of surgery.
62774506|NCT03044808|PLACEBO_COMPARATOR|Control|Patients get the same amount in ml and duration as if it was the experimental arm. Only in this arm it is isotonic saline instead.
62774507|NCT00328250|EXPERIMENTAL|1|Participants will receive the online CBT intervention immediately and will use the online program for 8 weeks
62774508|NCT00328250|ACTIVE_COMPARATOR|2|Participants will receive the online CBT intervention after a 4-month waiting period
62774509|NCT05296031|ACTIVE_COMPARATOR|Drug Eluting Stent (DES)|Drug Eluting Stent (DES). Zilver PTX.
61998900|NCT01637350||total gastrectomy, jejunal interposition|
61998901|NCT01637350||total gastrectomy , Roux-en-Y|
61998902|NCT04206293|EXPERIMENTAL|Juvéderm® VOLITE|Participants received Juvéderm® VOLITE, intradermal injection on a zone of 8 centimeter (cm) x 4 cm (32 cm\^2) of the volar left forearm on Day 0. The dose to be injected was decided by the investigator as per the Directions for Use. A maximum of 1 milliliter (mL) was injected on the zone treated.
61998903|NCT02203812|EXPERIMENTAL|Probiotic Arm|L. brevis CD2 Lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). Each lozenge contains at least 1 billion colony forming units of Lactobacillus brevis CD2.
62184493|NCT00151827|EXPERIMENTAL|Losartan|Losartan over encapsulated tablets 50 mg and 100 mg plus olmesartan placebo.
62184494|NCT05590143|EXPERIMENTAL|Intervention|Dapagliflozin 10 mg
62184495|NCT05590143|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62184496|NCT02603705|EXPERIMENTAL|Oxycodone extended-release|Egalet abuse-deterrent, extended-release oxycodone tablet
62568627|NCT02839304|EXPERIMENTAL|Catheter Ablation Treatment|Cryoablation System: Atrial Fibrillation Ablation
62568628|NCT00507455|PLACEBO_COMPARATOR|Placebo|Participants received once daily, oral doses of placebo matching solifenacin succinate and tamsulosin tablets for 12 weeks.
62774510|NCT05296031|PLACEBO_COMPARATOR|Bare Metal Stent (BMS)|Bare Metal Stent (BMS). Zilver Flex
62791628|NCT05594407|ACTIVE_COMPARATOR|remifentanil group|syringe of remifentanil
62774511|NCT02477553|EXPERIMENTAL|Quantitative|"Subjects view:~1. A computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy and stool testing. Includes excerpts from a video from the American Cancer Society.~2. Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting and dying from CRC, (b) the reduction in morbidity and mortality provided by colonoscopy and stool tests, (c) the sensitivity of colonoscopy and stool tests for finding cancer, (d) the false negative values of colonoscopy and stool tests for finding cancer, (e) the risk of heavy bleeding or colon injury from colonoscopy, and (f) the chance of having a positive stool test."
62774512|NCT02477553|ACTIVE_COMPARATOR|Verbal|"Subjects view:~1. A computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy and stool testing. Includes excerpts from a video from the American Cancer Society.~2. Computer-based presentation providing verbal information regarding (a) the lifetime average probability of getting and dying from CRC, (b) the reduction in morbidity and mortality provided by colonoscopy and stool tests, (c) the sensitivity of colonoscopy and stool tests for finding cancer, (d) the false negative values of colonoscopy and stool tests for finding cancer, (e) the risk of heavy bleeding or colon injury from colonoscopy, and (f) the chance of having a positive stool test."
62774513|NCT01191346||3T MRI|Patients receiving 3T MRI
62774514|NCT05611814|SHAM_COMPARATOR|Sham treatment|The sham maneuver treatment addressed soft tissue tension, restriction of motion, and tenderness of the lower thoracic and lumbar regions.
62774515|NCT05611814|EXPERIMENTAL|Experimental Osteopathic Manipulative Treatment|The sham maneuver treatment addressed soft tissue tension, restriction of motion, and tenderness of the cervical region (targeted anatomical structures).
62774516|NCT05728281|OTHER|Resumption of sexual intercourse recommended 4 weeks after hysterectomy|
62774517|NCT05728281|OTHER|Resumption of sexual intercourse recommended 8 weeks after hysterectomy|
62184497|NCT05256745|EXPERIMENTAL|Cohort 1: TTP488 (Azeliragon) co-administered with dose dense paclitaxel (ddAC/ddT)|Cohort 1: On day 7 of cycle 3, twelve capsules of azeliragon taken daily for 6 days, and then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 4 Day 2 (C4D2).
62791629|NCT01794260|PLACEBO_COMPARATOR|Placebo cream|Placebo cream
62791630|NCT01794260|EXPERIMENTAL|Plai cream|Cream from Zingiber cassumunar Roxb. extract
62215277|NCT02423278|EXPERIMENTAL|D2 Lymphadenectomy|"This is the control group in which a classic surgical procedure for gastric cancer is performed.~Under this arm, main therapeutic measures are included as follows:~* three-cycle SOX chemo regimen (S-1+Oxaliplatin) as neoadjuvant chemotherapy~* radical gastrectomy plus D2 lymphadenectomy (Without para-aortic lymph nodes dissection)~* five-cycle SOX chemo as adjuvant chemotherapy~* five-year follow-up program to evaluate the prognosis."
62791631|NCT03332836|EXPERIMENTAL|Cohort 1|Single dose subcutaneous administration (Dose A)
61998904|NCT02203812|PLACEBO_COMPARATOR|Placebo Arm|Placebo lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). The placebo lozenge contains all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2).
61998905|NCT03026621|PLACEBO_COMPARATOR|Placebo|This will be an herbal tea the looks similar to the control.
61998906|NCT03026621|EXPERIMENTAL|Lignite Extract|This will be the Restore gut supplement
61998907|NCT02620098|EXPERIMENTAL|Size Matters Handwriting Program|All participants were receiving educational support in the form of IEP and/or RtI tier 2 interventions, and were participating in a support classroom where those services where being delivered. The intervention group consisted of 23 kindergarten students comprising all students in two kindergarten support classrooms, one in each of two neighboring schools. All students in the group received the Size Matters Handwriting Program.
61998908|NCT02620098|NO_INTERVENTION|Control|All participants were receiving educational support in the form of IEP and/or RtI tier 2 interventions, and were participating in a support classroom where those services where being delivered. The control group consisted of 12 kindergarteners comprising all students in a kindergarten support classroom at a third school. They received no additional interventions.
62184498|NCT05256745|EXPERIMENTAL|Cohort 2: TTP488 (Azeliragon) co-administered with TC|"TC: docetaxel and cyclophosphamide~Cohort 2a (6 cycles): Cycle 5 Day 14 (C5D14), take twelve capsules of azeliragon daily for 6 days, then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 6 Day 2 (C6D2).~Cohort 2b (4 cycles): Cycle 3 Day 14 (C3D14), take twelve capsules of azeliragon daily for 6 days, then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 4 Day 2 (C4D2)."
62184499|NCT05256745|EXPERIMENTAL|Cohort 3: TTP488 (Azeliragon) co-administered with TCHP|TCHP: docetaxel, carboplatin, trastuzumab, and pertuzumab Cohort 3: Cycle 5 Day 14 (C5D14), take twelve capsules of azeliragon daily for 6 days, then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 6 Day 2 (C6D2).
62184500|NCT05256745|EXPERIMENTAL|Cohort 4: TTP488 (Azeliragon) co-administered with chemotherapy regimen that includes ddAC|"given at the end of the chemotherapy plan \[can include: (1)weekly carboplatin + paclitaxel + pembrolizumab followed by pembrolizumab + dose dense doxorubicin and cyclophosphamide; (2) weekly carboplatin + paclitaxel followed by dose dense doxorubicin and cyclophosphamide; (3) weekly or dose dense paclitaxel followed by dose dense doxorubicin and cyclophosphamide\]~Cohort 4: On day 7 of cycle 3, twelve capsules of azeliragon taken daily for 6 days, and then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 4 Day 2 (C4D2)."
62184501|NCT05971628|EXPERIMENTAL|Liver transplantation with the RAPID procedure|Liver transplantation for hepatocellular carcinoma according to the RAPID protocol. This protocol is an auxiliary liver transplantation of a partial graft with total hepatectomy in two stages (2 successive operations).
62568629|NCT00507455|EXPERIMENTAL|6 mg Solifenacin + 0.4 mg Tamsulosin|Participants received once daily, oral doses of 6 mg solifenacin succinate and 0.4 mg tamsulosin tablets for 12 weeks.
62568630|NCT00507455|EXPERIMENTAL|9 mg Solifenacin + 0.4 mg Tamsulosin|Participants received once daily, oral doses of 9 mg solifenacin succinate and 0.4 mg tamsulosin tablets for 12 weeks.
62774518|NCT02068872|EXPERIMENTAL|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of \> 40 or \> 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
62215278|NCT03635723||Surgical|Having undergone a procedure in hospital
62568631|NCT01265108|EXPERIMENTAL|Intravenous iron sucrose|Infusion of 200 mg iron sucrose (Venofer) in 100 ml normal (0.9%) saline.
62774519|NCT01804309||Early breast cancer patients|Clinical stage T1-2 N0M0 primary unilateral invasive breast cancer patients
62774520|NCT02029794|EXPERIMENTAL|HPV Self-collection|Subjects will self-collect a cervical-vaginal sample. One time use.
61998909|NCT00799968|ACTIVE_COMPARATOR|Group 1|UK-12h group
61998910|NCT00799968|EXPERIMENTAL|Group 2|UK-2h group
62568632|NCT01265108|PLACEBO_COMPARATOR|Intravenous normal saline|Infusion of 100 ml normal (0.9%) saline.
62791632|NCT03332836|EXPERIMENTAL|Cohort 2|Single dose subcutaneous administration (Dose B)
62791633|NCT03332836|EXPERIMENTAL|Cohort 3|Single dose subcutaneous administration (Dose C)
61998911|NCT05193474|NO_INTERVENTION|Refuse to integrate palliative care into usual care.|Usual ESRD care team
61998912|NCT05193474|EXPERIMENTAL|Agree to integrate palliative care into usual care.|Usual ESRD care + combined palliative care team
61998913|NCT02334228|EXPERIMENTAL|In SHAPE Lifestyles|In SHAPE Lifestyle is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
61998914|NCT02334228|ACTIVE_COMPARATOR|Health Club Membership and Education|Fitness club membership with education in using the exercise equipment.
61998915|NCT04023877|EXPERIMENTAL|E2027|Participants will receive approximately 130 microcurie (μCi) of \[14C\]E2027 as a single 50 milligram (mg) (free base), capsule, orally on Day 1.
62393196|NCT03999203|ACTIVE_COMPARATOR|A - T2 High Severe Asthmatics|"Severe asthmatic patients with eosinophil count ≥ 0.15x10\^9/mL andhigh FeNO levels ≥20 ppb.~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
62774521|NCT02029794|ACTIVE_COMPARATOR|VIA arm|Standard of care in Uganda is visual inspection with acetic acid (VIA). Women randomized to this arm will undergo the following: Cervix examined by clinician using speculum and light source. Cervix then sprayed with 3-5% acetic acid, and then lesions described one minute after application of acetic acid. VIA negative no acetowhite lesions detected; positive is when dense aceto-white lesions are seen touching squamocolumnar junction
61998916|NCT01569529||No ad exposure|Young adults, who enroll in the cessation program, one month prior to presenting the online advertisements (intervention).
61998917|NCT01569529||Ad exposure|Young Adults, who register for the cessation program, by clicking through the online advertisements (intervention).
61998918|NCT05878548|EXPERIMENTAL|fixation with Wagner technique and Telescoping nail|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture
61998919|NCT01433432|ACTIVE_COMPARATOR|Purinethol|Subjects who previously received 12 weeks of Purinethol (at 1-1.5 mg/kg)in the original study will now receive 80 mg DR-6MP (2 x 40 mg tablets) once dailyh, in the evening, for an additional 12 weeks
61998920|NCT01433432|EXPERIMENTAL|Test Drug|Subjects who previously received test drug (80 mg DR-6MP) for 12 weeks in the original study, will continue to receive 80 mg DR-6MP (2 x 40 mg tablets) once daily, in the evening, for an additional 12 weeks
61998921|NCT04254614|EXPERIMENTAL|Personalised mobile application for IBD patients|This is a cohort study with a 1 arm intervention group, without a control group. Patients included in this study will be invited to use a mobile application. The content and functionalities of this application are described in the intervention section.
61998922|NCT06331793|EXPERIMENTAL|Active AlgoCare|An active AlgoCare device (that emits a pulsed radio frequency electromagnetic field at 27.1 MHz) will be placed over the surgical dressing using a plaster or bandage for six days.
61998923|NCT06331793|PLACEBO_COMPARATOR|Non-active AlgoCare|A non-active AlgoCare device (that doesn't emit pulsed radio frequency electromagnetic field) will be placed over the surgical dressing using a plaster or bandage for six days.
62774522|NCT06095167|EXPERIMENTAL|The immunotherapy and induction chemotherapy plus RT alone group|Patients receive Anti-PD-1 Antibody, gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for three cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT) alone.
61998924|NCT00950534|EXPERIMENTAL|General Practitioner initiation with insulin glargine|Patients will be prescribed insulin glargine by their Investigator and they will be taught how to administer insulin glargine according to Australian guidelines. Patients will be treated for 24 weeks.
61998925|NCT00950534|ACTIVE_COMPARATOR|Usual standard of care|Patients will be treated by their Investigator with the usual standard of care for 24 weeks (e.g., OAD dose titration, addition of a second or third OAD, or referral to an endocrinologist)
61998926|NCT03365674|EXPERIMENTAL|Vibration group|Vibrator head was applied (100Hz) on the popliteal fossa, during the trigger point injection
62393197|NCT03999203|ACTIVE_COMPARATOR|B - T2 Low Severe Asthmatics|"Severe asthmatic patients with eosinophil count ≤ 0.15x10\^9/mL and low FeNO levels \<20 ppb.~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
62393198|NCT03999203|ACTIVE_COMPARATOR|C - Mild/Moderate Asthmatics|mild/moderate severe asthmatics (defined as step 2/3 using the GINA classification of severity) recruited from general respiratory clinics in the Belfast HSC Trust Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling
62774523|NCT06095167|ACTIVE_COMPARATOR|The immunotherapy and induction chemotherapy plus CCRT group|Patients receive Anti-PD-1 Antibody, gemcitabine (1000 mg/m² d1,8) , cisplatin (80mg/m² d1) every 3 weeks for three cycles and cisplatin 80-100 mg/m² every 3 weeks for 2 cycles, concurrently with intensity-modulated radiotherapy (IMRT)
62791634|NCT01636986|EXPERIMENTAL|DT1|Delefilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 4 weeks
62184502|NCT05971628|NO_INTERVENTION|Comparator group with standard liver transplantation (whole graft)|Orthotopic liver transplantation with whole organ from deceased donor for hepatocellular carcinoma. Data will be provided by Biomedicine Agency, following pairing rules.
62393199|NCT03999203|ACTIVE_COMPARATOR|D - T2 Intermediate|"Severe asthmatic patients with eosinophil count ≥ 0.15x10\^9/mL OR high FeNO levels ≥20 ppb.~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
62774524|NCT03350555|EXPERIMENTAL|ERCP with additioned endoscopy|This arm will include participants undergoing ERCP with assistance of additioned endoscopy.
62774525|NCT03350555|NO_INTERVENTION|ERCP without additioned endoscopy|This arm will include participants undergoing ERCP without assistance of additioned endoscopy as negative controls.
62774526|NCT01252979|EXPERIMENTAL|Medium Chain Triglyceride|
62774527|NCT04892108|EXPERIMENTAL|Group STARR|Patients undergoing transanal prolassectomy with mechanical stapler (STARR: Stapled Trans Anal Rectal Resection) randomly
62774528|NCT04892108|EXPERIMENTAL|Group LVR|Patients undergoing Laparoscopic suspensory correction of rectal prolapse by ventral rectopexy with biological prosthesis (LVR) randomly
62774529|NCT05178862|EXPERIMENTAL|IV echinocandin followed by oral ibrexafungerp (SCY-078)|
62774530|NCT05178862|ACTIVE_COMPARATOR|IV echinocandin followed by oral fluconazole|
62774531|NCT03169257|EXPERIMENTAL|OB|Obese subjects according to the International Obesity Task Force (IOTF) criteria aged 6 to 16 years. OB subjects will undergo for 12 months an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes.
62774532|NCT03169257|NO_INTERVENTION|NW|Normal weight subjects according to the International Obesity Task Force (IOTF) criteria aged 6 to 16 years and age, sex and pubertal status matched with the OB group
62774533|NCT03762798|EXPERIMENTAL|Treatment|All participants will receive the Bridge device.
62184503|NCT01516853||Patient Group|Subjects with known or suspected iron overload will undergo serum iron measurements and a non-contrast MRI scan.
62393200|NCT06412471|EXPERIMENTAL|Arm 1|dose level 1 of SSGJ-707 combined with chemotherapy
62393201|NCT06412471|EXPERIMENTAL|Arm 2|dose level 2 of SSGJ-707 combined with chemotherapy
62774534|NCT04214678|EXPERIMENTAL|Underwater clip closure|The post-resection defect is closed using endoscopic clips with underwater technique
62774535|NCT04214678|ACTIVE_COMPARATOR|Conventional clip closure|The post-resection defect is closed using endoscopic clips with conventional gas insufflation (CO2)
62393202|NCT06412471|EXPERIMENTAL|Arm 3|dose level 3 of SSGJ-707 combined with chemotherapy
62774536|NCT00598325|EXPERIMENTAL|NicVAX|
62774537|NCT00598325|EXPERIMENTAL|NicVAX Lot 2|2nd cohort receives a different lot of vaccine from the 1st cohort
62184504|NCT01516853||Control Group|Subjects with no known history of iron overload or liver disease will undergo a serum iron measurement and a non-contrast MRI scan.
62184505|NCT04674878|EXPERIMENTAL|MET group|METs for accessory muscles of respiration including sternocleidomastoid, scalenes and trapezius given thrice a week for 8 weeks.
62774538|NCT04826016|EXPERIMENTAL|PHASE Ib - ARM A: POL6326 (balixafortide) + eribulin|On day 1 and 8 of each 21-day cycle (+/- 1 day) fixed eribulin dose of 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate) combined with increasing doses of POL6326 (balixafortide) starting at a dose of 11 mg/Kg will be administered both intravenously. POL6326 (balixafortide) will be administered following a biphasic regimen (0,5 mg/Kg of POL6326 (balixafortide) dose during the first 30 min of treatment, the remaining dose during the following 3 h and 30 min for a total of 4h. Eribulin will be administered within 45 min after the end of the POL6326 (balixafortide) infusion over 2 to 5 min. Up to 4 additional cohorts may be introduced
62774539|NCT04826016|EXPERIMENTAL|PHASE Ib - ARM B: POL6326 (balixafortide) + nab-paclitaxel|On day 1, 8 and 15 of each 28-day cycle (+/- 1 day) fixed nab-paclitaxel dose of 100 mg/m2 combined with increasing doses of POL6326 (balixafortide) starting at a dose of 5.5 mg/Kg will be administered both intravenously. POL6326 (balixafortide) will be administered following a biphasic regimen (0,5 mg/Kg of POL6326 (balixafortide) dose during the first 30 min of treatment, the remaining dose during the following 3 h and 30 min for a total of 4h. Nab-paclitaxel will be administered within 45 min after the end of the POL6326 (balixafortide) infusion over 30 min. Up to 5 additional cohorts may be introduced
62215279|NCT05406167||Stereotactic Body Radiotherapy [SBRT]|Patients treated with Reflexion X1 with SBRT as the standard of care
62774540|NCT04826016|EXPERIMENTAL|PHASE 2 - ARM A: POL6326 (balixafortide) + eribulin|MTD/RDP2 POL6326 (balixafortide) (from arm A phase Ib) will be administered over 4h intravenous infusion (biphasic regimen as detailed above/ phase Ib) followed by 1.4 mg/m2 eribulin over 5 min Intravenous infusion on days 1 and 8 in 21-day cycles (+/- 1 day).
61998927|NCT03365674|PLACEBO_COMPARATOR|Placebo group|In placebo group, vibrator head was applied with switch-off sate, during the trigger point injection
61998928|NCT04655716|EXPERIMENTAL|Sodium bicarbonate|Intravenous sodium bicarbonate infusion
61998929|NCT04655716|NO_INTERVENTION|Standard care|Standard of care by the clinical team
61998930|NCT03904706|EXPERIMENTAL|Audits only|"Formalized audit teams with monthly meetings at each facility.~Audit Intervention phases:~1. Identification of facility leadership (i.e physicians or leading health care providers) to be trained on best practices in obstetric and perinatal care in the implementation of the audits.~2. Training of identified audit leaders (main investigator is typically a physician)~   a. 5-day training workshop to include: i. Day 1: maternal death and near misses, perinatal, neonatal deaths and morbidity outcomes ii. Day 2: 'Three-delay' framework and identifying modifiable factors iii. Day 3: data collection and setting up the audit system iv. Days 4-5: mentoring on the identification of the audit teams and initiating audit implementation~3. Creating audit team (composed of at least two obstetricians, 2 pediatricians plus the main investigator)~4. Establishing and launching the audit cycle (monthly meetings)~5. Annual re-certification of audit leaders"
62774541|NCT04826016|EXPERIMENTAL|PHASE 2 - ARM B: POL6326 (balixafortide) + nab-paclitaxel|MTD/RDP2 POL6326 (balixafortide) (from arm B phase Ib) will be administered over 4h intravenous infusion (biphasic regimen as detailed above/ phase Ib) followed by 100 mg/m2 nab-paclitaxel over 30 min Intravenous infusion on days 1, 8 and 15 in 28-day cycles (+/- 1 day).
61998931|NCT03904706|EXPERIMENTAL|Audits with community feedback|This intervention will implement the audits as described in arm 1; however, key community representatives (approximately 3-5 members) will be identified to attend monthly follow-up meetings with audit team leaders to discuss the community aspects (phase one and two-delays) that could have prevented the death, near miss or severe adverse outcome. Information regarding the cause(s) of death in the community will be collected by the LHW or CMW, who reports to the health facility on a monthly basis.
61998932|NCT03904706|NO_INTERVENTION|Control|Monthly outcome data will be collected from health facilities where no audits will be conducted. Data from this group will help evaluate the effectiveness of the intervention arms on perinatal and neonatal mortality.
61998933|NCT01914484|EXPERIMENTAL|Nilotinib with Ruxolitinib|"Nilotinib: Given that recommended dose of Nilotinib for imatinib failed CML patients is 400mg twice daily, Nilotinib dose will remain fixed at 400mg bid throughout the cycles.~Ruxolitinib: In the phase I part of the study, dose escalation will follow a 3+3 study design. Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose. Ruxolitinib will be given at one of 3 fixed dose levels for the duration of their treatment, either 10mg twice daily, 15mg twice daily or 20mg twice daily."
61998934|NCT02409836|ACTIVE_COMPARATOR|Crest Cavity Protection|Marketed Dentifrice
61998935|NCT02409836|ACTIVE_COMPARATOR|Crest for Kids Hawaiian Punch Paste|Marketed Dentifrice
62774542|NCT03972956||Colorectal cancer or gastric cancer patient|Patients suffering from CRC or gastric cancer scheduled to have surgical resection of colon/rectum or stomach.
62774543|NCT03972956||Non-malignant disease patient|Patients suffering from non-malignant disease scheduled to have surgery.
62568633|NCT06236789||Castration-resistant prostate cancer patients treated with ifosfamide/mesna|
62774544|NCT00787501|ACTIVE_COMPARATOR|SSRIs|Selective Serotonin Reuptake Inhibitors
62774545|NCT00787501|ACTIVE_COMPARATOR|CBT|Cognitive Behavior Therapy
62774546|NCT05830877|EXPERIMENTAL|the acupuncture group|the patients included in this arm will recept the Tiaoshen acupuncture.
62774547|NCT05830877|ACTIVE_COMPARATOR|the placebo acupuncture group|Subjects in the placebo acupuncture group will receive non-insertive acupuncture using the sham needle supported by the Park device, and the selected acupoints is the same as the acupuncture group.
62774548|NCT03437707|PLACEBO_COMPARATOR|placebo|250 ml saline will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
62791635|NCT01636986|ACTIVE_COMPARATOR|1DAVM|Etafilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 4 weeks
62791636|NCT04561440||molecular karyotyping|
62774549|NCT03437707|ACTIVE_COMPARATOR|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
62774550|NCT03437707|ACTIVE_COMPARATOR|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
62774551|NCT00254891|EXPERIMENTAL|A|Standard of care chemotherapy plus experiment intervention (PF-3512676)
62774552|NCT00254891|ACTIVE_COMPARATOR|B|Standard of care chemotherapy
62774553|NCT04721548|PLACEBO_COMPARATOR|Minoxidil´s Placebo|The recommended dosage is 1 ml of the solution twice a day (morning and evening).
62774554|NCT04721548|EXPERIMENTAL|Topical Minoxidil 5%|The recommended dosage is 1 ml of the solution twice a day (morning and evening).
62774555|NCT03897595||Mpact cup|Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
62774556|NCT01032824|EXPERIMENTAL|Intervention|Individual telephone counseling intervention.
62774557|NCT01032824|OTHER|Group Arm|Attention-matched comparison arm
62774558|NCT01032824|OTHER|Book Arm|Information-matched control arm.
62774559|NCT03874039||Healthy Adults|Healthy adults with no prior diagnosis of atopic dermatitis
62774560|NCT03874039||Atopic Dermatitis|Adults with prior diagnosis of Atopic Dermatitis from board certified dermatologist
62774561|NCT01265303|OTHER|Catheter ablation|
62774562|NCT01265303|OTHER|Pacemaker implantation|
62774563|NCT01265303|OTHER|Pharmacotherapy|
62774564|NCT02870088|ACTIVE_COMPARATOR|Prolonged Sitting|Participants sat on a chair during the trial.
62774565|NCT02870088|EXPERIMENTAL|Breaking Sitting|Participants walked regularly during the trial.
62774566|NCT04876612|PLACEBO_COMPARATOR|Patients who received placebo after transforminal epidural steroid injection|Patients who took placebo for 12 weeks after TFESI
62774567|NCT04876612|EXPERIMENTAL|Patients who received limaprost (Opalmon®) after transforaminal epidural steroid injection|Patients who took limaprost (Opalmon®) for 12 weeks after TFESI
62774568|NCT06100874|EXPERIMENTAL|Sacituzumab Govitecan + Trastuzumab (or Biosimilar)|"Participants will complete the following:~* Baseline visit with assessments.~* CT or MRI scans every 9 weeks for 27 weeks and then every 12 weeks.~* Echocardiogram or MUGA scan every 12 weeks for 24 weeks and then every 16 weeks.~* Cycle 1 through Cycle 2:~  * Days 1 and 8 of 21 day cycle: Predetermined dose of Sacituzumab govitecan 1x daily.~ * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab either intravenously or subcutaneously 1x daily.~* Cycle 2:~  * Day 1: Optional tumor biopsy~ * Days 1 and 8 of 21 day cycle: Predetermined dose of Sacituzumab govitecan 1x daily.~ * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab either intravenously or subcutaneously 1x daily.~* Cycle 3 through End of Treatment:~  * Days 1 and 8 of 21 day cycle: Predetermined dose of Sacituzumab govitecan 1x daily.~ * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab either intravenously or subcutaneously 1x daily.~* End of treatment:~  * Follow up visits every 6 months."
62774569|NCT05087719|EXPERIMENTAL|experimental group|The patients in the experimental group will get the hot pack initially for 15 minutes .Then for proprioception training of graphesthesia for 15 mints, therapist repeatedly draw some letter, figures, digit, shapes ,alphabets on the palm of hand/digits of patient.For Stereognosis therapist command the patient to close his or her eyes, then on affected hand put some different kinds of objects and shapes then ask the patient to identify that object, the object might be of any kind like a key, rubber a block or a coin etc. Total time for stereognosis was 15 minutes. For motor training patients were guided by the therapist to use his or her affected hand more. Then patient practiced some task like drawing writing his or her name, folding the towel or a paper, eating something with different speed, picking small objects like nails and put them in to small boxes, organize the cards etc. This training session required 15 minutes.
62774570|NCT05087719|ACTIVE_COMPARATOR|conventional treatment|baseline treatment of hot pack for 15 minutes will be given.The patients in this group will get muscle strengthening exercise of the hand, Range of motion, and stretching of the hand muscles, 3 sets of 8 repetitions were given to the patient, gap of 2 minutes will be given between regimes. For 20 minutes this session will be given to patient by the therapist.
62774571|NCT04421209|EXPERIMENTAL|Propranolol treatment|"Subjects randomized to the propranolol treatment arm will be administered propranolol 40mg BID for three days prior to surgery, 40mg BID the day of surgery and on post-operative days 1 and 2. Subjects and researchers will be blinded and will not know if propranolol or placebo control is administered.~Patients will be evaluated for opioid usend pain scores at 24 hrs, 48 hrs, 1 week, 4 weeks, and 12 weeks post-op.~Blood will also be obtained pre-operatively, 8 hours and 24 hours post-operatively to measure the level of inflammatory markers. We will use these samples to evaluate if treatment with propranolol decreases the levels of inflammatory markers, and if this correlates to decreased opioid use and pain scores post-operatively.~All other pre-, intra-, and post-operative interventions will be equivalent between the experimental and placebo groups, and this study's interventions will not affect surgical management."
62774572|NCT04421209|PLACEBO_COMPARATOR|Placebo|"Subjects randomized to the placebo treatment arm will be administered placebo tablets with the same schedule as propranolol in the experimental arm. Subjects and researchers will be blinded and will not know if propranolol or placebo control is administered.~Patients will be evaluated for opioid use and pain scores at 24 hrs, 48 hrs, 1 week, 4 weeks, and 12 weeks post-op.~Blood will also be obtained pre-operatively, 8 hours and 24 hours post-operatively to measure the level of inflammatory markers. We will use these samples to evaluate if treatment with propranolol decreases the levels of inflammatory markers compared to placebo, and if this correlates to decreased opioid use and pain scores post-operatively.~All other pre-, intra-, and post-operative interventions will be equivalent between the experimental and placebo groups, and this study's interventions will not affect surgical management."
62791637|NCT04561440||cytogenic karyotyping|
61998936|NCT02409836|ACTIVE_COMPARATOR|Crest for Kids Bubble Gum Paste|Marketed Dentifrice
61998937|NCT03007394|ACTIVE_COMPARATOR|Lorcaserin|10 mg capsule by mouth, twice a day, for 13 weeks
61998938|NCT03007394|PLACEBO_COMPARATOR|Placebo Oral Capsule|10 mg placebo capsule, twice a day, for 13 weeks
61998939|NCT02818595|EXPERIMENTAL|Normal children|Every child meet the age criteria and without ductus arteriosus persistence ultrasound or detectable neurological disorders after clinical, neurophysiological and radiological
62774573|NCT01639755|EXPERIMENTAL|All Participants|Al participants who had new texture shaped breast implants surgically implanted.
62774574|NCT05808517|EXPERIMENTAL|TC plus rTMS group|Participants received 12 one-hour sessions over 4 weeks (three times per week with a day between sessions). Each session of rTMS consisted of a sequence of three stimulation pulses per string with a string interval of 1 s (total 500 strings, total 1,500 stimulation pulses, and total stimulation time of 30 mins per session). After subjects finished each rTMS session, they immediately attended the TC class together with the participants in the TC-alone group.
61998940|NCT02818595|EXPERIMENTAL|Abnormal children|Every child meet the criteria of age and having a detectable neurological disease after clinical, neurophysiological and radiological as intraventricular hemorrhage .
62184506|NCT04674878|ACTIVE_COMPARATOR|Breathing exercise group|Diaphragmatic breathing, pursed lip breathing and diaphragmatic breathing with resistance given thrice a week for 8 weeks.
62184507|NCT01138371||Familial hypercholesterolemia|"* Heterozygous FH with documented CAD and LDL-C ≥ 200 mg/dL (Documented CAD may be represented as: Lesion(s) on coronary angiography, history of myocardial infarction, CABG, PTCA, progressive angina demonstrated by stress testing, history of other revascularization procedure)~* Homozygous FH and LDL-C \> 500 mg/dL~* Heterozygous FH and LDL-C ≥ 300 mg/dL~* On stable LDL apheresis therapy for at least 6 months"
62774575|NCT05808517|ACTIVE_COMPARATOR|TC-alone group|Participants underwent a 4-week intervention program consisting of simplified Yang style 12-Form Easy TC given as 1-hour sessions, three times per week. Each session included 5 to 10 minutes of warm-up exercise, 45 minutes of TC practice, and 5 to 10 minutes of cool-down exercise. The TC intervention was conducted in a small group format (i.e., 6-8) led by a trained TC instructor.
62774576|NCT05808517|NO_INTERVENTION|Treat-as-usual control group|Participants in the TAU control group received treatments as usual for 4 weeks. No additional sleep intervention was provided. All participants were required to complete the subjective and objective assessments.
62774577|NCT03053869|EXPERIMENTAL|Benzodiazepine - Limited use strategy|"1. No routine use of any intraoperative benzodiazepines.~2. Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~3. Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
62774578|NCT03053869|ACTIVE_COMPARATOR|Benzodiazepine - Ad libitum strategy|"1. Administration of some benzodiazepine to most patients undergoing cardiac surgery.~2. Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
61998941|NCT03023488|EXPERIMENTAL|Flexible ureteroscopy arm|the findings of patients undergoing flexible ureteroscopy + laser lithotripsy for renal stones according to EAU Guidelines Doppler Ultrasound examination has been performed in the pre-operative and post-operative periods
61998942|NCT05572619||Positive group|A patient diagnosed with large vessel occlusion after a non-contrast CT, CT perfusion and CT angiography
62215280|NCT05406167||Intensity -Modulated Radiation Therapy [IMRT]|Patients treated with Reflexion X1 with IMRT as the standard of care
62393203|NCT06412471|EXPERIMENTAL|Arm 4|PD-1/L1 combined with chemotherapy
62393204|NCT06412471|EXPERIMENTAL|Arm 5|dose level 1 of SSGJ-707 combined with chemotherapy
61998943|NCT05572619||Negative group|A normal person or a patient not diagnosed with intracranial haemorrhage after a non-contrast CT, CT perfusion and CT angiography
62215281|NCT05406167||Biology-guided Radiotherapy [BgRT]|Patients treated with Reflexion X1 with BgRT as the standard of care
62393205|NCT06412471|EXPERIMENTAL|Arm 6|dose level 2 of SSGJ-707 combined with chemotherapy
62184508|NCT03018223|EXPERIMENTAL|Conditioning/HCT/GVHD Prophylaxis|"Pre-HCT Conditioning, HCT, GVHD Prophylaxis.~1. Conditioning regimen: To reduce heterogeneity, two commonly used myeloablative (MAC) and reduced intensity (RIC) regimens are permitted on this trial. Myeloablative conditioning: fludarabine, busulfan. Reduced intensity conditioning: fludarabine, cyclophosphamide, total body irradiation.~2. Peripheral blood hematopoietic cell transplantation~3. Graft vs. Host Disease (GVHD) prevention treatment: cyclophosphamide, mycophenolate mofetil, sirolimus.~4. Growth factor support: G-CSF"
62184509|NCT00365547|EXPERIMENTAL|Patients Treated With Topotecan and Avastin in NSCLC|Weekly topotecan hydrochloride and bi-weekly Avastin (bevacizumab) in patients with non-small cell lung cancer (NSCLC) who have failed prior systemic chemotherapy.
62184510|NCT03619889|SHAM_COMPARATOR|Sham simulation group|A simulation of the pressure release technique, applying a soft pressure or contact in the same muscles sites or trigger points than in the intervention group.
62184511|NCT03619889|EXPERIMENTAL|Pressure release technique group|The release pressure technique is applied in the trigger points of masticatory and neck muscles (upper trapezius, sternal and clavicular sternocleidomastoid, deep and superficial masseter, posterior, medium and anterior temporalis.
62184512|NCT03121495|ACTIVE_COMPARATOR|Second forward view exam|During withdrawal, the colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed.
62184513|NCT03121495|NO_INTERVENTION|Conventional withdrawal exam|No intervention additional to the conventional withdrawal examination during withdrawal
62184514|NCT04297072||Rivaroxaban|Participants in this group administered oral anticoagulant Rivaroxaban
62393206|NCT06412471|EXPERIMENTAL|Arm 7|dose level 3 of SSGJ-707 combined with chemotherapy
62393207|NCT06412471|EXPERIMENTAL|Arm 8|Selected dose of SSGJ-707 combined with chemotherapy
62774579|NCT04057690||MCA ischemia without malignant edema|MCA ischemia without malignant edema
62393208|NCT06412471|EXPERIMENTAL|Arm 9|Selected dose of SSGJ-707 combined with chemotherapy
62774580|NCT04057690||MCA ischemia with malignant edema|MCA ischemia without malignant edema w/o surgical treatment
62774581|NCT01851785|NO_INTERVENTION|Attention control|Subjects randomized to the attention control arm will receive an educational program (an NIH-developed booklet) that summarizes how to live with knee OA but does not specifically mention joint replacement. This booklet provides information about OA, examples of exercises one could do to improve pain and reduce stiffness, types of non-drug pain relief such as massage, and information about various medications. The interventionist will give the participant the booklet and describe what can be found inside. They are also encouraged to ask their doctor any questions they may have about the information in the booklet or questions they may have about their OA. The purpose of this educational program is to provide a tangible clinical incentive to the control group for participating in this additional component of the study.
62774582|NCT01851785|EXPERIMENTAL|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
62774583|NCT03861156|EXPERIMENTAL|D-0316|Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
62774584|NCT05794828|EXPERIMENTAL|Erector Spinae Plane Block (ESP) administration|Patients with the listed diagnoses will be offered and then consented for an ESPB under ultrasound guidance.
62774585|NCT02266212|ACTIVE_COMPARATOR|Smoke|Fagerstrom test for nicotine dependence
62774586|NCT02266212|ACTIVE_COMPARATOR|Pain|pain during post-operation Day1 to Day4
62774587|NCT02266212|ACTIVE_COMPARATOR|Morphine|Morphine consumption during post-operation Day1 to Day4
62184515|NCT04297072||Vitamin-K antagonists (VKAs)|Participants in this group administered oral anticoagulants VKAs
62184516|NCT03585686|EXPERIMENTAL|vemurafenib|vemurafenib, Cytarabine, 2-chlorodeoxyadenosine
62184517|NCT03618836||Cases. Preterm Births|Microbiological and biological patterns on vaginal samples in the first trimester of pregnancy among spontaneous preterm births between 22 and 36 weeks
62393209|NCT06412471|EXPERIMENTAL|Arm 10|PD-1/L1 combined with chemotherapy
62393210|NCT06195033|EXPERIMENTAL|AI-guided surgical protocol group|
62184518|NCT03618836||Controls. Term Births|Microbiological and biological patterns on vaginal samples in the first trimester of pregnancy among deliveries over ≥ 37 weeks
62393211|NCT06195033|NO_INTERVENTION|traditional surgical protocol group|
62393212|NCT01265719||Latanoprost-treatment group|
62393213|NCT01265719||Non-topical prostaglandin analogue treatment group|
62393214|NCT00081276|EXPERIMENTAL|Treatment (triapine and cisplatin)|Patients receive 3-AP IV over 2 hours on days 1-4 and cisplatin IV over 1 hour on days 2 and 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62393215|NCT03462628|EXPERIMENTAL|Study Group|PVI with additional low-voltage substrate modification
62393216|NCT03462628|ACTIVE_COMPARATOR|Control Group|PVI only
62393217|NCT02551900|EXPERIMENTAL|Warm water exercise & Cold water exercise|
62393218|NCT02551900|ACTIVE_COMPARATOR|Warm water exercise & Land cycling exercise|
62184519|NCT03717077|EXPERIMENTAL|Learned resourcefulness intervention|The learned resourcefulness program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
62184520|NCT03717077|NO_INTERVENTION|Usual home care service|The control group maintains home care service
62184521|NCT00371995|EXPERIMENTAL|1|"Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)"
62393219|NCT01743781|EXPERIMENTAL|intervention group|view a 10-minute informational video about comprehensive eye examination
62568634|NCT02791919|EXPERIMENTAL|Treatment (AZD1775, FLAG chemotherapy)|Patients receive filgrastim IV or SC daily, fludarabine intravenously IV over 30 minutes, cytarabine IV over 1-3 hours and wee1 kinase inhibitor AZD1775 PO on days 1-5. Patients who meet criteria for CR, CRp or PR may receive a second course of therapy. Courses repeat every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62774588|NCT05714137|EXPERIMENTAL|Proximal massage and fist clenching|The experimental group of 36 patients underwent proximal massage and fist clenching after IV insertion. Proximal massage: For a total of 5 to 10 minutes, twice daily for 4 days, between 30 seconds- 1 minute in sessions of approximately 20 strokes, a light massage is administered utilizing the palm surfaces of the fingers. Fist Clenching : Under the researcher's supervision, participants in the activity known as palm fisting squeeze a soft palm ball 20 times in each of twice a day for four days, lasting between 30 seconds - 1 minute. The Peripheral Venous Catheter-Related Phlebitis Risk Scale, the Phlebitis Diagnostic Scale, and the Patient Information Form were employed right after following PVC (0. hour). The Phlebitis Diagnostic Scale was used for 96 hours to assess the patient's vascular access at the 24th, 48th, 72nd, and 96th hours.
62774589|NCT05714137|NO_INTERVENTION|Standard care for PVC|The standard care group of 36 patients received typical nursing PVC care. Standard nurse PVC care: Only standard PVC care and follow-up were provided. It was carefully avoided that the patients would interact with one another or be in the same patient room. The Peripheral Venous Catheter-Related Phlebitis Risk Scale, the Phlebitis Diagnostic Scale, and the Patient Information Form were employed right after following PVC (0. hour). The Phlebitis Diagnostic Scale was used for 96 hours to assess the patient's vascular access at the 24th, 48th, 72nd, and 96th hours.
62568635|NCT03249012|EXPERIMENTAL|Empiric calcium and calcitriol repletion group|All patients in this group will receive post-operative calcium carbonate and calcitriol.
62184522|NCT03418493|EXPERIMENTAL|LY3316531 (Part A)|Participants received single doses of 3 milligrams (mg), 15 mg, 75 mg, 300 mg, 900 mg, or 2000 mg LY3316531 administered Intravenously (IV), or 300 mg LY3316531 administered Subcutaneously (SC).
62184523|NCT03418493|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo matching LY3316531 administered IV.
62184524|NCT03418493|EXPERIMENTAL|LY3316531 (Part B)|Participants received 3 doses of 2000 mg LY3316531 administered IV (1 dose every 4 weeks).
62184525|NCT03418493|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo matching LY3316531 administered IV.
62184526|NCT03418493|EXPERIMENTAL|LY3316531 (Part C)|Participants with psoriasis received single doses of 300 mg LY3316531 administered IV.
62184527|NCT02011217|EXPERIMENTAL|Rye crisp bread A|
62184528|NCT02011217|EXPERIMENTAL|Rye crisp bread B|
62568636|NCT03249012|EXPERIMENTAL|PTH based repletion group|Patients in this group will be prescribed calcium carbonate and calcitriol based on their post-operative PTH.
62568637|NCT03977870||patients with Venous thromboembolism (VTE)|
62184529|NCT02011217|EXPERIMENTAL|Wheat crisp bread C|
62393220|NCT01743781|NO_INTERVENTION|control group|No intervention
62393221|NCT03834857|OTHER|single|Implantation of Stentrode device
62774590|NCT05701436|EXPERIMENTAL|the test group|The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on 3D-HDRA results. Precise transarterial chemoembolization at 1-month intervals for 4 months after surgery.
62774591|NCT05701436|ACTIVE_COMPARATOR|the control group|The control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization. Empirical transarterial chemoembolization at 1-month intervals for 4 months after surgery.
61998944|NCT00002882|EXPERIMENTAL|IFN-A Therapy Schedule A|Schedule A: IV Interferon alfa-2b (IFN-A) induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.
61998945|NCT00002882|EXPERIMENTAL|IFN-A Therapy Schedule B|Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks.
62568638|NCT01610089|EXPERIMENTAL|stable isotope infusion|Infusion of isotopes \[15N2-ureido\] arginine, \[5-13C,4, 4, 5, 5-D4\] citrulline, \[15N\]citrulline, 15N sodium nitrate and \[15N\]\[18O3\] potassium nitrate,\[18O\]\[13C\]urea.
62568639|NCT02149979|EXPERIMENTAL|Temperature Controlled Laser Soldering|Efficacy and safety of Temperature Controlled Laser Soldered wound incisions closure
62774592|NCT02603848|EXPERIMENTAL|Ibuprofen suspension|Ibuprofen suspension (Advil) will be administered orally at a dose of 10mg/kg every 6 hours for 72 hours post-surgery.
62774593|NCT02603848|ACTIVE_COMPARATOR|Morphine Sulfate suspension|Morphine sulfate suspension will be administered orally at a dose of 0.02 - 0.04 mg/kg every 6 hours for 72 hours post-surgery.
62774594|NCT06284330|NO_INTERVENTION|Standard of care cascade testing|Standard of care cascade genetic testing
62774595|NCT06284330|EXPERIMENTAL|Choice architecture cascade testing|Direct mailed genetic testing kit to probands' relatives.
62774596|NCT01890668|EXPERIMENTAL|Osteopathic Manipulative Treatment|Randomization and first OMT will take place at discharge (Day 3); second osteopathic therapy will be performed by the same osteopath practitioner at Day10.
62774597|NCT01890668|PLACEBO_COMPARATOR|Control group|Control group consists in classical medical and paramedical breastfeeding support. OMT on the newborn will be realized by osteopath dissimulated behind a screen. Placebo OMT consists to mimic, without the knowledge of parents, osteopathic techniques on a dolly.
61998946|NCT00002882|EXPERIMENTAL|Adjuvant Biochemotherapy|Cisplatin IV Days 1-4; Vinblastine IVPB Days 1-4; Dacarbazine (DTIC) IVPB on Day 1; IFN-A is given subcutaneously on days 1-5; IL-2 continuous infusion for 96 hours on Days 1-4. Each course repeated every 21 days for 4 courses.
61998947|NCT00838565|PLACEBO_COMPARATOR|Placebo|
61998948|NCT00838565|EXPERIMENTAL|PF-04236921|
62568640|NCT03699618||Anti-VEGF injection only|Patients who will receive monthly intravitreal anti-VEGF injection for 12 months, followed by anti-VEGF at standard of care treatment interval during months 12-24
62774598|NCT06246812|EXPERIMENTAL|DFFC Group|Students who participated in the 2022 DFFC
62184530|NCT06145789||standing powered wheelchair|standing powered wheelchair evaluation
62184531|NCT02743988|EXPERIMENTAL|Low target range|Low oxygen saturation target range: SpO2 85-89%
62184532|NCT02743988|ACTIVE_COMPARATOR|High target range|High oxygen saturation target range: SpO2 91-95%
61998949|NCT01387321|EXPERIMENTAL|BYL719|
62184533|NCT00739609|EXPERIMENTAL|1|
62184534|NCT03916822||ABMR|Biopsy-proven ABMR-Banff criteria, with or without Complement binding donor-specific anti-HLA antibodies
62568641|NCT03699618||Hemorrhage displacement + Anti-VEGF|Hemorrhage displacement (at investigators' discretion) followed by monthly intravitreal anti-VEGF injections for 12 months, and standard of care treatment interval during months 12-24
62568642|NCT04562350|EXPERIMENTAL|Intervention group|A sample of students aged 12 to 16 years from middle school and high school in the sanitary region of Anoia in the course of 2020-21.
62568643|NCT04562350|NO_INTERVENTION|Control group|A sample of students aged 12 to 16 years from middle school and high school in the sanitary region of Osona in the course of 2020-21.
62184535|NCT03916822||TCMR|Biopsy-proven TCMR-Banff 1A, 1B, 2 and 3
62184536|NCT03916822||No Rejection|Biopsy-proven, or clinical criteria
62184537|NCT04021082|EXPERIMENTAL|Cohort A|Cerdulatinib dosing of patients with Peripherial T-Cell Lymphoma (PTCL) not otherwise specified (NOS); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
62184538|NCT04021082|EXPERIMENTAL|Cohort B|Cerdulatinb dosing of patients with nodal lymphomas of T follicular helper (TFH) phenotype origin, including angioimmunoblastic T cell lymphoma (AITL), follicular T-cell lymphoma (FTCL), and nodal PTCL with TFH phenotype; Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
62184539|NCT04021082|EXPERIMENTAL|Cohort C|Cerdulatinb dosing of patients with Anaplastic large cell lymphoma (ALCL) (anaplastic lymphoma kinase positive \[ALK+\] and negative \[ALK-\]); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
62184540|NCT04021082|EXPERIMENTAL|Cohort D|Other rare types of extranodal non-cutaneous aggressive PTCL, including hepatosplenic T-cell lymphoma (HSTCL), enteropathy-associated T-cell lymphoma (EATL type I), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL, EATL type II), and extranodal NK/T-cell lymphoma (nasal type); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
61998950|NCT01346267|EXPERIMENTAL|Arm I- Real Acupressure bands|Patients wear Sea-Band acupressure wristbands on each wrist beginning approximately 30 minutes prior to the first cisplatin-containing chemotherapy course and continually for 24 hours after the last chemotherapy dose (acute phase), and for a maximum of 7 days or until the next chemotherapy course starts (delayed phase). Patients are allowed to take bands off intermittently (up to 4 times a day, for no more than 15 minutes each time) to relieve pressure or to bathe. Patients also receive standard of care anti-emetic prophylaxis comprising granisetron, ondansetron, or dexamethasone during chemotherapy according to institutional or physician preference.
62774599|NCT06246812|EXPERIMENTAL|DFFC + Text Group|Students who participated in the 2022 DFFC and received text messages
62774600|NCT06246812|NO_INTERVENTION|Control Group|Students who did not participate in the 2022 DFFC
62774601|NCT03370562|ACTIVE_COMPARATOR|Dexmedetomidine|Patient will receive 10 mcg of dexmedetomidine in 5 ml of normal saline, administered by slow intravenous injection
62774602|NCT03370562|PLACEBO_COMPARATOR|Placebo|Patient will receive 5 ml of normal saline, administered by slow intravenous injection
62774603|NCT05098509|ACTIVE_COMPARATOR|RAD011 40 milligrams per kilogram (mg/kg)|Participants were administered 40 mg/kg of RAD011 orally daily with food.
62774604|NCT05098509|ACTIVE_COMPARATOR|RAD011 20 mg/kg|Participants were administered 20 mg/kg of RAD011 orally daily with food.
62774605|NCT05098509|ACTIVE_COMPARATOR|RAD011 10 mg/kg|Participants were administered 10 mg/kg of RAD011 orally daily with food.
62774606|NCT05098509|PLACEBO_COMPARATOR|Placebo|Participants were administered a placebo matching to RAD011, orally daily with food.
61998951|NCT01346267|SHAM_COMPARATOR|Arm II- Placebo Acupressure Bands|Patients wear placebo wristbands on each wrist and receive standard of care anti-emetic prophylaxis during chemotherapy as patients in arm I.
62774607|NCT04394650|EXPERIMENTAL|CC-98633|Subjects will receive CC-98633 following 3 consecutive doses of lymphodepleting chemotherapy (fludarabine and cyclophosphamide).
62184541|NCT02525081|EXPERIMENTAL|ACE-inhibitor|"In both the placebo and Ramipril group medication will start with either 2,5 mg (Blood Pressure\<130) or 5 mg (Blood Pressure\>130) daily. After 2-3 weeks the dose is doubled to 5 mg or 10 mg unless blood pressure is below 115 mmHg. If blood pressure continues to be higher than 115 mmHg for patients up titrated to 5 mg treatment dose will be doubled to 10 mg at the third visit.~Patients taking a dose of~* 2,5 mg will take a half tablet a day~* 5 mg will take one whole tablet a day~* 10 mg will take two tablets a day"
62215282|NCT05198102|EXPERIMENTAL|Investigational vaccine group|Recombinant novel coronavirus vaccine (CHO cells) injection, Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose.
62774608|NCT01848470|EXPERIMENTAL|E1. CG400549 640mg|CG400549 640mg BID on Day 1-5 and QD on Day 6 in the fed-state
62774609|NCT01848470|EXPERIMENTAL|E2: CG400549 320mg|CG400549 320mg QD on Day 1-5 in the fed-state.
62774610|NCT01848470|EXPERIMENTAL|E3: CG400549 640mg|CG400549 640mg QD on Day 1-5 in the fed-state.
61998952|NCT04415099|EXPERIMENTAL|One group|Only one group was assessed before and after performing muscle fatigue protocol.
61998953|NCT06442735|EXPERIMENTAL|Intrapartum ultrasound|IPUS group women were performed pelvic examination at admission and every 2 to 4 hours during the first stage of labor and at least hourly during the second stage by intrapartum ultrasound.
62774611|NCT01848470|EXPERIMENTAL|E4: CG400549 960mg|CG400549 960mg QD on Day 1-5 in the fed-state.
62774612|NCT01848470|PLACEBO_COMPARATOR|P1 Placebo|Placebo 640mg BID on Day 1-5 and QD on Day 6 in the fed-state
62774613|NCT01848470|PLACEBO_COMPARATOR|P2: Placebo 320mg|Placebo 320mg QD on Day 1-5 in the fed-state
62774614|NCT01848470|PLACEBO_COMPARATOR|P3 Placebo 640mg|Placebo 640mg QD on Day 1-5 in the fed-state.
62774615|NCT01848470|PLACEBO_COMPARATOR|P4: Placebo 960mg|Placebo 960mg QD on Day 1-5 in the fed-state.
62774616|NCT00901810|ACTIVE_COMPARATOR|Apex Locator|Working length for cleaning and shaping of the canal is measured by Electronic Apex Locator in this group.
62774617|NCT00901810|ACTIVE_COMPARATOR|Radiography|Working length for cleaning and shaping of the canal is measured by Radiography in this group.
62774618|NCT06285123||Responders|
62774619|NCT06285123||Non-Responders REP|
62774620|NCT06285123||Non-Responders REP/Facillitation|
61998954|NCT06442735|ACTIVE_COMPARATOR|Vaginal examination|VE group women were performed pelvic examination at admission and every 2 to 4 hours during the first stage of labor and at least hourly during the second stage by vaginal examination.
61998955|NCT05005390|EXPERIMENTAL|TTIP ventilation, then mask ventilation|Subjects will first be ventilated with the TTIP technique. If the subjects are adequately ventilated, as defined by carbon dioxide measured during exhalation in at least one of the first three consecutive breaths, ventilation will continue until completion of 10 breaths, for 1 min (Step 1). Subjects will then be ventilated with mask ventilation (Step 2). In Step 1, if ventilation fails with the TTIP technique for all of the first three consecutive breaths, the subject will be crossed over to the mask ventilation. If ventilation fails again with all the first three consecutive breaths after crossover, the study will be terminated. The routine care is resumed including tracheal intubation or laryngeal mask airway (LMA) insertion.
61998956|NCT05005390|ACTIVE_COMPARATOR|Mask ventilation, then TTIP ventilation|Subjects will first be ventilated with the mask technique. If the subjects are adequately ventilated, as defined by carbon dioxide measured during exhalation in at least one of the first three consecutive breaths, ventilation will continue until completion of 10 breaths, for 1 min (Step 1). Subjects will then be ventilated with TTIP technique (Step 2). In Step 1, if ventilation fails for all of the first three consecutive breaths, the subject will be crossed over to the TTIP ventilation. If ventilation fails again with all the first three consecutive breaths after crossover, the study will be terminated. The routine care is resumed including tracheal intubation or LMA insertion.
61998957|NCT03010410||Influenza/respiratory virus pts <65 yrs|Patients with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses
61998958|NCT03010410||Influenza/respiratory virus pts ≥ 65 yrs|Patients with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses
61998959|NCT03010410||Sepsis/septic shock patients < 65 yrs|Sepsis and septic shock patients
61998960|NCT03010410||Sepsis/septic shock patients ≥ 65 yrs|sepsis and septic shock patients
61998961|NCT05658744|EXPERIMENTAL|Video group|Insulin administration video was shown to 52 patients with diabetes using insulin. The video was sent to the patients' mobile phones
62184542|NCT02525081|PLACEBO_COMPARATOR|Placebo|"In both the placebo and Ramipril group medication will start with either 2,5 mg (Blood Pressure\<130) or 5 mg (Blood Pressure\>130) daily. After 2-3 weeks the dose is doubled to 5 mg or 10 mg unless blood pressure is below 115 mmHg. If blood pressure continues to be higher than 115 mmHg for patients up titrated to 5 mg treatment dose will be doubled to 10 mg at the third visit.~Patients taking a dose of~* 2,5 mg will take a half tablet a day~* 5 mg will take one whole tablet a day~* 10 mg will take two tablets a day"
62215283|NCT00550589|EXPERIMENTAL|Cidofovir|1.0% topical cidofovir cream
62215284|NCT00481624|EXPERIMENTAL|Epoetin Alfa plus Iron|
61998962|NCT05658744|EXPERIMENTAL|Brochure group|Insulin administration leaflet was given to 42 patients with diabetes using insulin. Patients read the brochure aloud
61998963|NCT04106310|ACTIVE_COMPARATOR|Theranova|Patients will be receiving hemodialysis using Theranova dialyzer. The other hemodialysis parameters are kept the same.
62215285|NCT04521348|EXPERIMENTAL|RAIR-DTC arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
62393222|NCT01446835|EXPERIMENTAL|nelfilcon A|Nelfilcon A printed contact lens randomly assigned to one eye, with etafilcon A printed contact lens assigned to the fellow eye for contralateral wear. Lenses will be worn for 20 minutes.
62393223|NCT01446835|ACTIVE_COMPARATOR|etafilcon A|Etafilcon A printed contact lens randomly assigned to one eye, with nelfilcon A printed contact lens assigned to the fellow eye for contralateral wear.
62393224|NCT06241131|EXPERIMENTAL|desflurane with remifentanil anesthesia|Subjects were randomly assigned to the experimental group。In this group, desflurane was inhaled at a starting concentration of 1 MAC (Minimal Alveolar Concentration), and remifentanil 0.1 μg/kg/min was continuously pumped intravenously.
62393225|NCT06241131|ACTIVE_COMPARATOR|sevoflurane with remifentanil anesthesia|Subjects were randomly assigned to the active comparator group。In this group, sevoflurane was inhaled at a starting concentration of 1 MAC, and remifentanil 0.1 μg/kg/min was continuously pumped intravenously.
62393226|NCT01180452|OTHER|Single group open label|Prospective Cohort
62393227|NCT00843128|EXPERIMENTAL|1: RAGT|Following randomization, 20 patients will be treated with RAGT, 12 sessions over three weeks
62774621|NCT05653817|EXPERIMENTAL|Advanced or metastatic cholangiocarcinoma|A multicenter clinical study of carralizumab combined with albumin paclitaxel and apatinib mesylate in the second-line treatment of advanced or metastatic cholangiocarcinoma.Albumin-bound paclitaxel 125 mg/m2 d1,8; Carrilizumab 200mg Q3W d1; Apatinib mesylate tablet treatment: 250mg orally, once a day, continuous administration. Treatment continued or was evaluated every 2 cycles until disease progression or toxic side effects of patient intolerance to the treatment regimen.
62774622|NCT03436823|EXPERIMENTAL|R.TMS + nurse semi-structured interview|Repeated Transcranial Magnetic Stimulation sessions associated with nurse semi-structured interview
62774623|NCT03436823|SHAM_COMPARATOR|R.TMS + Music & Relaxation|Repeated Transcranial Magnetic Stimulation sessions associated with music listening \& relaxation with eyes closed
62774624|NCT01477112|EXPERIMENTAL|Supplemented Diabetics (DB)|Diabetics supplemented with betacarotene for 45 days
61998964|NCT04106310|ACTIVE_COMPARATOR|High-flux|Patients will be receiving hemodialysis using a high-flux dialyzer. The other hemodialysis parameters are kept the same
62020995|NCT03574454|OTHER|Phase 1 - Mixed Scan Data Training Set|Machine learning (ML): A mixed data set of 200 WB-MRI scans comprising scans obtained from 40 healthy volunteers (scanned for the purposes of the study), 40 previously acquired inactive myeloma WB-MRI scans and 120 previously acquired active myeloma WB-MRI scans, in which machine learning and convolutional neural networks will be trained to recognise healthy marrow, treated inactive previous myeloma and active myeloma. An algorithm will be developed for testing in phase 2.
62393228|NCT00843128|ACTIVE_COMPARATOR|2: Control|The control group will be treated by CWT, 12 sessions in three weeks.
62393229|NCT00553319|PLACEBO_COMPARATOR|Placebo|Placebo
62774625|NCT01477112|EXPERIMENTAL|Unsupplemented Diabetics (DS)|Diabetics without betacarotene supplementation
62774626|NCT01477112|ACTIVE_COMPARATOR|Supplemented Controls (CB)|Controls supplemented with betacarotene for 45 days
62774627|NCT01477112|ACTIVE_COMPARATOR|Unsupplemented Controls (CS)|Controls without betacarotene supplementation
62393230|NCT00553319|EXPERIMENTAL|Adderall-XR 60 mg|Adderall-XR 60 mg
62393231|NCT00553319|EXPERIMENTAL|Adderall-XR 80 mg|Adderall-XR 80 mg
62393232|NCT01539616|EXPERIMENTAL|ZYH7 4mg|ZYH7 4mg
62393233|NCT01539616|EXPERIMENTAL|ZYH7 8mg|ZYH7 8mg
62393234|NCT01539616|EXPERIMENTAL|ZYH7 16mg|ZYH7 16mg
62393235|NCT01539616|ACTIVE_COMPARATOR|Fenofibrate 160mg|Fenofibrate 160mg
62393236|NCT02136719|ACTIVE_COMPARATOR|Group A|bimanual uterine compression immediately after delivery of placenta for 5 minutes in 260 women
62393237|NCT02136719|NO_INTERVENTION|Group B|no intervention (260 women).
62393238|NCT03938857|PLACEBO_COMPARATOR|Fen. SOC+saline placebo (bolus+infusion)|Fentanyl standard of care (SOC) titrated to sedation + saline placebo (bolus + infusion)
62393239|NCT03938857|ACTIVE_COMPARATOR|Fen. SOC+Dex.(.5mcg/kg + .25mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.2mcg/kg/hr infusion)
62393240|NCT03938857|ACTIVE_COMPARATOR|Fen. SOC+Dex.(.5mcg/kg + .5mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.5mcg/kg/hr infusion)
62393241|NCT03938857|ACTIVE_COMPARATOR|Fen. SOC+Dex.(.5mcg/kg + .75mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.7mcg/kg/hr infusion)
62774628|NCT00946907|ACTIVE_COMPARATOR|aspirin|
62774629|NCT00946907|PLACEBO_COMPARATOR|placebo|
62774630|NCT00054028|EXPERIMENTAL|Treatment (suramin and paclitaxel)|"PHASE I: Patients receive low-dose suramin IV over 30 minutes and paclitaxel IV over 1 hour once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive adjusted doses of suramin until a target dose is determined. The suramin target dose is defined as the dose at which at least 5 of 6 patients achieve the target plasma concentration of 10-50 uM over the duration when paclitaxel levels are therapeutic.~PHASE II: Patients receive paclitaxel in combination with the target dose of suramin as above."
62774631|NCT05607706|NO_INTERVENTION|Control|families were not allowed to enter the NICU
62774632|NCT05607706|ACTIVE_COMPARATOR|Maternal Odor|Babies compared only to the mother's odor
62774633|NCT05607706|ACTIVE_COMPARATOR|Kangaroo care|Babies given kangaroo care
62774634|NCT03271905|EXPERIMENTAL|Pressure-controled-ventilation (PCV)|Nebulization during mechanical ventilation on a pressure controled ventilation mode.
61998965|NCT00581958||Patients undergoing HSCT|Research subjects will have blood and/or urine sampled at three time points in the Department of Radiation Oncology. Participating patients will have at least a total two samples collected at each time point. The first sampling will occur before the first TBI treatment is given. The second sampling will occur before the second TBI treatment, usually 3 to 8 hours after the first treatment (in the case of multifraction TBI). If a patient is being treated with single fraction TBI, then the second sampling will occur approximately 3-8 hours after the first TBI treatment. The third and final sampling will occur at the next morning blood draw, prior to the fourth TBI treatment (in the case of multifraction TBI), 24 hours after the first TBI treatment.
61998966|NCT02346136|EXPERIMENTAL|Tai Chi|This arm will receive a 6-month Tai Chi training intervention. Tai Chi training will include gentle dynamic stretching and strengthening, slow integrated movements, efficient posture, heightened body awareness and inner focus, active relaxation of body and mind, mindful diaphragmatic breathing, and healing imagery and intention. Participants will be asked to complete two formal group classes each week for at least 6 months, led by senior Tai Chi instructors. Additionally, participants will be given practice Digital Versatile Disc (DVD), DVD players if necessary, and instructions for daily home practice a minimum of 20 minutes on 3 non-class days each week.
61998967|NCT02346136|ACTIVE_COMPARATOR|Educational Control|This arm will receive a 6-month educational control intervention. Participants will attend monthly educational group sessions within a common area of each housing facility. Sessions will be led by research personnel and include material from Patient Education Forms (PEFs) produced by the American Geriatric Society. Sessions will be semi-structured and contain approximately 30 minutes of lecture and 30 minutes of group discussion.
61998968|NCT06197568|EXPERIMENTAL|Weekly 0.1 μg AZU-101|Weekly 0.1 μg vaginal dose of AZU-101
62774635|NCT03271905|EXPERIMENTAL|PCV and high PEEP|Nebulization during mechanical ventilation on a pressure controled ventilation mode and PEEP = 15 cmH2O.
62774636|NCT03271905|EXPERIMENTAL|Pressure suport ventilation (PSV)|Nebulization during mechanical ventilation on a pressure suport ventilation mode.
61998969|NCT06197568|EXPERIMENTAL|Weekly 0.5 μg AZU-101|Weekly 0.5 μg vaginal dose of AZU-101
61998970|NCT06197568|EXPERIMENTAL|Weekly 1 μg AZU-101|Weekly 1 μg vaginal dose of AZU-101
62774637|NCT01909765|ACTIVE_COMPARATOR|Dorsal slite|Skin and mucosa insicion made together
61998971|NCT06197568|EXPERIMENTAL|Twice-weekly 0.1 μg AZU-101|Twice-weekly 0.1 μg vaginal dose of AZU-101
61998972|NCT06197568|EXPERIMENTAL|Twice-weekly 0.5 μg AZU-101|Twice-weekly 0.5 μg vaginal dose of AZU-101
62774638|NCT01909765|EXPERIMENTAL|Double incision|Skin and mucosa incision made separately
62774639|NCT02355444|EXPERIMENTAL|High-dose blackberry polyphenol beverage|Each participant will consume a blackberry beverage with high-dose blackberry polyphenols (250mL/day for 6 weeks).
62774640|NCT02355444|PLACEBO_COMPARATOR|Low-dose blackberry polyphenol beverage|Each participant will consume a blackberry beverage with minimal blackberry polyphenols (250mL/day for 6 weeks).
62774641|NCT04268745|EXPERIMENTAL|Virtual Reality|Progressive immersive training with the virtual reality app Scenes: start from most salient to the patient, eventually do all Duration: start at 60 seconds, increase over time up to 3 minutes per scene Complexity: start minimal, gradually increase up to most complex Tasks: standing with diverse base of support (BOS), head turns (progress with speed, planes); stepping, turning 8 weeks, 1 visit per week, 30 minutes long In home: Gait and balance exercises, No exercises with eyes closed, 8 weeks, 6 times per week, twice per day, 10 minutes long
62774642|NCT04268745|ACTIVE_COMPARATOR|Traditional Vestibular Rehabilitation|"Progressive gait, gaze stability and balance exercises Gait: walking with head turns, progress with range, speed and planes of head movement; change of walking BOS: wide, normal, tandem Gaze: focus on a target while moving head side to side / up down. Progress with speed, duration, busier background, standing to walking.~Balance: standing balance tasks, progress with BOS (wide to narrow to tandem), support surface, eyes closed, duration, head turns.~8 weeks, 1 visit per week, 30 minutes long In home: Gait, gaze stability and balance exercises, including exercises with eyes closed, 8 weeks, 6 times per week, twice per day, 10 minutes long"
62393242|NCT06510023|EXPERIMENTAL|Individuals with Acquired Brain Injury|Measuring the effect of three different types of rewards (one dollar, one penny, and no reward) on performance in a cognitive test.
62774643|NCT06013189||Group 1|Sweep Gas Flow did not changed (1.35 L/m2/min)
62774644|NCT06013189||Group 2|Sweep Gas Flow decreased during rewarming (1.2 L/m2/min)
62774645|NCT06013189||Group 3|Sweep Gas Flow decreased during rewarming (1 L/m2/min)
61998973|NCT02994862|EXPERIMENTAL|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
61998974|NCT02994862|ACTIVE_COMPARATOR|Conventional Bonding|Normal Bonding Method
61998975|NCT03166280||hepatitisC-pre-ttt|Naïve HCV Patients (\>18Y) coming to National Committee for control of viral hepatitis before receiving their treatment
61998976|NCT03166280||hepatitis C-ttt|Naïve HCV Patients (\>18Y) coming to National Committee for control of viral hepatitis- 12 weeks after stoppage their treatment of sofosbuvir 400 mg/day plus Daclatasvir 60 mg/day for 12 weeks.
62393243|NCT06510023|OTHER|Non-impaired controls|Measuring the effect of three different types of rewards (one dollar, one penny, and no reward) on performance in a cognitive test.
62774646|NCT04382417||Covid-19|Patients with verified or highly suggestive Covid-19 diagnosis and Intensive Care treatment.
61998977|NCT04844554|EXPERIMENTAL|Group 1 - 3.0 mA active HD-tDCS|HD-tDCS with 3.0 milliamperes (mA) of intensitive
61998978|NCT04844554|EXPERIMENTAL|Group 2 - Sham HD-tDCS|Sham HD-tDCS
61998979|NCT00414388|EXPERIMENTAL|Single agent Sorafenib|Oral Single agent Sorafenib 400mg twice daily
61998980|NCT01091792|EXPERIMENTAL|Bevacizumab|Bevacizumab + temozolomide + radiotherapy followed by adjuvant bevacizumab + temozolomide
62774647|NCT02249468||Mild and Moderate Alzheimer's Disease|
62774648|NCT02249468||Cognitively intact healthy people|
61998981|NCT04952220||native septic arthritis of the knee|"Describe the ultrasound abnormalities observed at D0, D10 or before surgery, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee:~thickness and vascularity of the synovial membrane, existence and measurement of joint effusion existence of articular partitioning, erosions and adjacent soft tissue involvement (muscle abscess, cellulitis)"
61998982|NCT04499079|NO_INTERVENTION|Probation Referral Practice as Usual|Data are collected regarding standard probation practice and outcomes before implementation of the Learning Health System.
61998983|NCT04499079|EXPERIMENTAL|Learning Health System|Participating counties receive a system-level intervention, a Learning Health System, designed to improve youth connection to substance use treatment.
62774649|NCT02610803||Patients with ischemic stroke|Patients admitted with ischemic stroke from August 2008 to April 2011 (Retrospectively defined).
61998984|NCT02190799|EXPERIMENTAL|Convalescent plasma|Enrolled patients will receive 2 units of the convalescent plasma after meeting the eligibility criteria
61998985|NCT01469286|ACTIVE_COMPARATOR|TEA|Needleless electroacupuncture at ST36 and PC6
62774650|NCT00172042|EXPERIMENTAL|Zoledronic acid|Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 to 4 weeks for 24 months. Dosage was adjusted for participants with mild or moderate renal impairment.
62774651|NCT00172042|OTHER|Control|No investigational treatment. If a participant developed bone metastases, treatment was started with Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 to 4 weeks until 24 months from the date of study entry had elapsed.
62774652|NCT04919837|EXPERIMENTAL|Algorithm assisted group|Patients receive assisting devices fitting services from human doctors assisted by the machine learning model
62774653|NCT04919837|EXPERIMENTAL|Human doctor group|Patients receive assisting devices fitting services from humanr doctors
61998986|NCT01469286|PLACEBO_COMPARATOR|Sham-TEA|Needleless acupuncture at sham-points
61998987|NCT04736238|EXPERIMENTAL|Trial group|The patients who receive arthroscopic surgery.
61998988|NCT04736238|OTHER|Control group|The patients who receive BrostrÖm surgery.
61998989|NCT01290848|EXPERIMENTAL|Township of Uxbridge|The Take TIME for Your Child's Health campaign will target parents and caregivers of children up to 8 years of age.
61998990|NCT01290848|NO_INTERVENTION|Township of Guelph/Ermosa|For a control group the investigators have selected a community that is similar in size, household composition, population density, distance from Toronto and economic status to the Township of Uxbridge.
61998991|NCT00531843|EXPERIMENTAL|1A|Patients at high risk for venous thromboembolism (criteria: age\>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with Abbreviated Injury Scale (AIS) \>=3). These patients will receive fondaparinux 2.5mg via subcutaneous administration (SubQ) daily.
62393244|NCT05401708||DM Naïve|a new patient without a history of DM medication
62393245|NCT05277805||EMPOWER-UP participants|People with cancer, diabetes, or mental disorders answering the EMPOWER-UP questionnaire
62568644|NCT01199627|EXPERIMENTAL|A|"Group A: 1st dose 15mg/kg of TXA (tranexamic acid) in 100ml saline 0.9% after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
62568645|NCT01199627|EXPERIMENTAL|B|"Group B: 1st dose: 10mg/kg of TXA (tranexamic acid) in 100ml 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes of 10mg/kg of TXA in 100ml saline 0.9% at three hours after the first administration."
62393246|NCT00759499||Debridement|The intent of this protocol is to salvage wound material that is normally destined for destruction, so it can be used in wound-related scientific studies. This clinical wound material can be studied in order to better understand the molecular, cellular, or ecological components of the wound system. These studies may be able to provide important insights into the keys of wound healing, wound persistence, or wound deterioration.
62568646|NCT01199627|PLACEBO_COMPARATOR|C|Placebo
62568647|NCT05885763|EXPERIMENTAL|1-week, single arm, open label treatment phase|
62568648|NCT01648868|EXPERIMENTAL|Excitatory effects of rTMS|Study excitatory effects of rTMS applied to the STS in patients with autism
62774654|NCT03802045|EXPERIMENTAL|Low frequency EA|"25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 2Hz; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm)."
62791638|NCT03776201|EXPERIMENTAL|Internal Focus|"The internal focus group will receive 20 minutes of balance training 2 times per week. All training sessions will include a 5-minute walking warm-up, a 20-minute balance training program, and a 5-minute walking cool-down. The balance training will use a 30 wobble board with five bases ranging from 1 (easy) to 3 (very difficult). 20 trials of balance practice for 30-second intervals with 30-second breaks in between trials will be used every day. The Internal Focus group will be reminded to focus their attention internally via the prompt keep your feet as level as possible prior to each balance trial. To monitor whether the experimental groups are focusing as asked and to what extent, a compliance check that has been used in similar attentional focus literature will be used."
62215286|NCT04521348|EXPERIMENTAL|MTC arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
62393247|NCT02098291|EXPERIMENTAL|G17DT|
62393248|NCT00764465|ACTIVE_COMPARATOR|Group A|Period 1-Maraviroc 300mg BID Period 2- Fosamprenavir 1400mg BID Period 3- Fosamprenavir 1400mg BID + Maraviroc 300mg BID
62393249|NCT00764465|ACTIVE_COMPARATOR|Group B|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg BID + Maraviroc 300mg BID Period 3-Fosamprenavir 1400mg BID
62393250|NCT00764465|ACTIVE_COMPARATOR|Group C|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Maraviroc 300mg BID
62393251|NCT00764465|ACTIVE_COMPARATOR|Group D|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Maraviroc 300mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID
62393252|NCT00764465|ACTIVE_COMPARATOR|Group E|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3- Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Maraviroc 300mg BID
62393253|NCT00764465|ACTIVE_COMPARATOR|Group F|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Maraviroc 300mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
62568649|NCT01648868|ACTIVE_COMPARATOR|Inhibitory effects of rTMS|Study inhibitory effects of rTMS applied to the STS in healthy controls
62568650|NCT01778530|EXPERIMENTAL|TRC105 for Recurrent Glioblastoma|
62568651|NCT04016129|EXPERIMENTAL|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR|Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies
62568652|NCT05953519|EXPERIMENTAL|Unified Protocol intervention|The Unified Protocol consists of 12-weeks, virtual, group sessions focused on reducing depression and anxiety through: (1) Increasing emotional awareness; (2) Cognitive restructuring against dysfunctional beliefs; (3) Changing action tendencies associated with disordered emotions; (4) Preventing emotional avoidance and utilizing emotion exposure techniques; (5) Providing mutual help among group members; and (6) Providing opportunities for corrective experiences.
62568653|NCT05953519|NO_INTERVENTION|Control group|The control group will not receive any intervention and will complete the same baseline and follow-up assessments.
62568654|NCT00698633||M2a- Taper™ Hip System|M2a- Taper™ Hip System
62568655|NCT01018927||Additional MRI images|Prospective review of 100 CMR studies performed on multiple myeloma patients referred for cardiac evaluation by MRI. Three additional MRI images will be performed to determine the role of cardiac MR (CMR) in detecting features of early myocardial infiltration
62568656|NCT01583062|ACTIVE_COMPARATOR|1|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
62568657|NCT01583062|PLACEBO_COMPARATOR|2|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
62568658|NCT02892955|EXPERIMENTAL|HeartMate 3 LVAS (HM3 LVAS)|The study was a single-arm, prospective, multi-center, study for continued evaluation of safety and clinical performance of the HM3 LVAS.
62568659|NCT05984901|OTHER|The CAVA Multicentre Dizziness Trial (CAVA2)|CAVA 2 is a single arm study testing a diagnostic device to diagnose different inner-ear conditions appraised by calculating values for sensitivity and specificity. Head and eye movements recorded by the CAVA device will enable the computer algorithms (to be developed) to differentiate between the three target conditions.
62568660|NCT03355274|EXPERIMENTAL|Patients|Patients suspected of thoracic outlet syndrome Transcutaneous oximetry during upper arm manoeuvers
62393254|NCT05578664|EXPERIMENTAL|ARM A|Pembrolizumab will be administered at flat dose of 400 mg IV every six weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RadioTherapy, RT) from day 21 of cycle 1 to day 42 of cycle 1.
62774655|NCT03802045|EXPERIMENTAL|High frequency EA|"25 participants will receive 25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 100Hz; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm).~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
62774656|NCT03802045|EXPERIMENTAL|Alternating frequency EA|"25 participants will receive 25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 100Hz and 2Hz for 3 seconds each; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm).~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
61998992|NCT00531843|ACTIVE_COMPARATOR|1B|Patients at high risk for venous thromboembolism (criteria: age\>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with AIS \>=3) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure with creatine clearance \<30 mL/min, head injury with head AIS \>=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression.
62393255|NCT05578664|ACTIVE_COMPARATOR|ARM B|Local therapy alone (tumor resection or definitive RadioTherapy, RT) within 42 days from randomization.
62568661|NCT03355274|SHAM_COMPARATOR|controls|healthy asymptomatic subjects Transcutaneous oximetry during upper arm manoeuvers
62568662|NCT05044611|EXPERIMENTAL|Amiloride|the experimental arm will receive 5mg of amiloride twice daily during 2 months
62568663|NCT05044611|PLACEBO_COMPARATOR|Placebo|the control arm will receive a placebo twice daily during 2 months
61998993|NCT00531843|EXPERIMENTAL|2A|Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days \>3, 2 or more high risk factors). These patients will receive fondaparinux 2.5mg SubQ daily and mechanical compression.
62568664|NCT06465862|EXPERIMENTAL|TruTag System|Participants will operate the TruTag system daily to record their adherence to TruTag-tagged Biktarvy for 90 days.
62568665|NCT05504980|EXPERIMENTAL|İntervention group|Patients in the intervention group will be given 30 degrees right lateral, supine, and 30 degrees left lateral positions, 1 hour apart, respectively.
62568666|NCT05504980|NO_INTERVENTION|Control group|Patients in the control group will be given 30 degrees right lateral, supine and 30 degrees left lateral positions, respectively, at 2 hour intervals according to the hospital routine practice.
62393256|NCT05712343|EXPERIMENTAL|valacyclovir group|"Patients (N=20) in the valacyclovir group will be received, at baseline, periodontal scaling + valacyclovir (500 mg, 3 times a day for 3 days) (Valacyclovir group)."
62774657|NCT03802045|ACTIVE_COMPARATOR|Control Group|"25 participants will follow exactly the same protocol as the experimental groups, however they will not undergo electrical stimulation, as the acupuncturist will activate channels that are not connected to the patient.~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
62774658|NCT03802045|PLACEBO_COMPARATOR|Placebo Group|"25 participants will will follow exactly the same protocol as the experimental groups, however an adhesive moxa (Dong Yang®) will be placed on each acupoint and the needle will be inserted over it, so that the participant only feels the needle prick, but without perforation of the skin and the deQi sensation. In addition, as in the control group, the electrodes will be connected to the needles, however, no electrical current will be applied.~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
61998994|NCT00531843|ACTIVE_COMPARATOR|2B|Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days \>3, 2 or more high risk factors) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure creatine clearance \<30 mL/min, head injury with head AIS \>=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression and possibly temporary inferior vena cava (IVC) filter(as determined by the patient's care givers).
61998995|NCT01538186||PCI without treating the side branch|
62393257|NCT05712343|ACTIVE_COMPARATOR|Control group|"Patients (N=20) in the control group will receive, at baseline, periodontal scaling + placebo medication, three times a day for 3 days (Control group)."
62393258|NCT03231059||Experimental treatment strategy|All patients in the treatment group received acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy
62393259|NCT03231059||Reference treatment strategy|"Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and ticagrelor for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy."
62568667|NCT05999201|EXPERIMENTAL|craniocervical neural mobilization|the patients will receive craniocervical neural mobilization and a selected physiotherapy program twice a week for four weeks
62568668|NCT05999201|ACTIVE_COMPARATOR|selected physiotherapy program|the patients will receive a selected physiotherapy program twice a week for four weeks
62568669|NCT05721014|EXPERIMENTAL|OsteoStrong|Training following the OsteoStrong-method.
62774659|NCT01612208||Distal femur fractures|(AO/OTA types 33-A and 33-C)
62774660|NCT00440830|EXPERIMENTAL|Smokers-nicotine|Smokers who were treated with nicotine
62774661|NCT00440830|EXPERIMENTAL|Nonsmokers-nicotine|Nonsmokers who were treated with nicotine
62774662|NCT00440830|PLACEBO_COMPARATOR|Smokers-placebo|Smokers who were treated with placebo
62774663|NCT00440830|PLACEBO_COMPARATOR|Nonsmokers-placebo|Nonsmokers who were treated with placebo
61998996|NCT01538186||PCI with treating the side branch|
61998997|NCT04675320||First-line epithelial ovarian cancer (30 patients)|Maintenance treatment of adult patients with newly diagnosed advanced epithelial ovarian, fallopian tube or primary peritoneal cancer (FIGO stages III and IV) with or without BRCA1/2 mutation who have had a partial or complete response to first-line platinum-based chemotherapy.
62568670|NCT05721014|ACTIVE_COMPARATOR|Individually Adapted and Combined Physical Training|Training based on current recommendations on exercise for people with osteoporosis.
61998998|NCT04675320||Recurrent epithelial ovarian cancer (20 patients)|Single-agent maintenance treatment of adult patients with primary, recurrent, platinum-sensitive epithelial ovarian, fallopian tube or peritoneal cancer who have responded (completely or partially) to platinum-based chemotherapy.
61998999|NCT04796831|EXPERIMENTAL|All Participants|Participants who will receive a single, oral dose of 60 mg quizartinib and a single, IV administration of 50 μg 14C-quizartinib solution for infusion at 4 hours post-oral dosing.
62774664|NCT05685056|NO_INTERVENTION|Control group|The control group will receive no intervention, and will be receiving only text reminders regarding the study, the following visits and study logistics in order to limit dropout rate.
62774665|NCT05685056|EXPERIMENTAL|Intervention group|Intervention will happen with weekly text messages during the study period, focusing on pregnancy nutrition and iodine rich foods. The texts will be based on the taxonomy of behavior change techniques used in interventions, the nudge theory and will be covering themes identified on our previous research.
62774666|NCT00634790|ACTIVE_COMPARATOR|alprazolam group|
62774667|NCT01700010|EXPERIMENTAL|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
62568671|NCT04403230|EXPERIMENTAL|Clinical behaviour on teeth prepared without finish line|Evaluate the clinical behavior of restorations placed on teeth prepared without finish line, monitoring periodontal status as well as the prostheses to assess stability and treatment predictability.
61999000|NCT02976896|EXPERIMENTAL|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
61999001|NCT04400279|EXPERIMENTAL|Yoga Exercise group|Using the Down Dog app, this group will be given access to an at-home personalized yoga practice, unique every time the participants complete it. Asked to complete yoga practice 4 times per week for 6 weeks. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
62393260|NCT02607904|EXPERIMENTAL|GWP42003-P|"Administered orally, twice daily (morning and evening), commencing with titration of 100 mg/mL GWP42003-P to 20 mg/kg/day over 10 days in a blinded manner (i.e., only participants taking placebo in the blinded phase will up-titrate; doses will remain unchanged for those taking GWP42003-P in the blinded phase).~Participants remain on the maintenance dose for the remainder of the 48-week treatment period, until early withdrawal or at an early study conclusion date defined by the sponsor. However, investigators may subsequently decrease or increase the participant's dose (to a maximum of 30 mg/kg/day) until the optimum dose is found.~Dosing is tapered (10% each day) for participants who do not immediately continue to use GWP42003-P once market authorization is granted, or for those who withdraw early."
62393261|NCT05066906|EXPERIMENTAL|Use of Identifor and Companion+referral to employment agencies|This group will use the Identifor tool and Companion app for a period of 6 months. They will also receive standard referral to employment agencies.
62393262|NCT05066906|ACTIVE_COMPARATOR|Referral to employment agencies|This group will not use the Identifor tool and Companion app. They will only receive standard referral to employment agencies.
62393263|NCT03039699|EXPERIMENTAL|Ergoferon|Tablet for oral use. Dose per administration - 1 tablet per intake (outside a meal/feeding). Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.
62393264|NCT03039699|PLACEBO_COMPARATOR|Placebo|Tablet for oral use. Dose per administration - 1 tablet per intake (outside a meal/feeding). Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.
62393265|NCT06278181||Type 2 diabetes|Individuals with type 2 diabetes followed by the diabetes clinic at Limbe hospital
62393266|NCT06278181||Diabetes free|Community controls without diabetes, referred by the patients with diabetes. The unexposed individuals referred should have approximately the same age, be of same sex and health cathment area as the exposed individual
62393267|NCT04650932|EXPERIMENTAL|Sustained Dual Frequency, Dual Region, Stimulation|
61999002|NCT04400279|EXPERIMENTAL|High Intensity Interval Training group|Using the Down Dog app, this group will be given access to at-home bodyweight high intensity interval training (HIIT) workouts. Asked to complete these HIIT workouts 4 times per week for 6 weeks. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
62393268|NCT03792230|EXPERIMENTAL|Video|This group received educatıon via video material
62393269|NCT03792230|EXPERIMENTAL|Brochure|This group received education via written material (brochure)
62393270|NCT03792230|NO_INTERVENTION|Control|This group received standart clinical education
62774668|NCT03239015|EXPERIMENTAL|Targeted Drug Therapy Group|All recruited patients with druggable molecular event will be treated with corresponding targeted drug including Gefitinib/Erlotinib/Afatinib, Trastuzumab, Oxazolidine, Olaparib, Everolimus, Cabozantinib, Vemurafenib/Dabrafenib, and Palbociclib. If no durggable target, PD-1/L1 inhibitor plus anti-angiogenic agent was used.
62774669|NCT06128122|EXPERIMENTAL|Dextrose injection intraarticularly and in subcutaneous tissue with timed dextrose measurements|"Step One: Injection of 30 ml of D12.5% in the knee anteromedially with knee flexed. Placement of IV catheter into the suprapatellar pouch, and secure catheter. Withdraw and analyze samples for dextrose levels at 15-minute intervals. If catheter fails, aspirate directly from suprapatellar pouch.~Step Two: Inject 1-3 ml of D5W into interstitial space about a functioning Dexcom G7 sensor. Measure dextrose levels every 5 minutes on a Dexcom receiver."
62774670|NCT00659503|ACTIVE_COMPARATOR|1|Ciclesonide 200µg
62774671|NCT00659503|PLACEBO_COMPARATOR|2|Placebo
62774672|NCT05115513|EXPERIMENTAL|Placebo Marijuana|Placebo Marijuana will be administered.
62774673|NCT05115513|EXPERIMENTAL|Medium THC Marijuana|Medium THC marijuana will be administered.
62774674|NCT05891158|EXPERIMENTAL|Arm 1, Mild HI: Fazirsiran 200 mg|Participants with mild hepatic impairment (HI) will receive fazirsiran 200 milligrams (mg) subcutaneous (SC) injection on Day 1.
62774675|NCT05891158|EXPERIMENTAL|Arm 2, Moderate HI: Fazirsiran 200 mg|Participants with moderate HI will receive fazirsiran 200 mg SC injection on Day 1. The dose may be modified after review of available safety and PK data by the sponsor study team in consultation with the investigator.
61999003|NCT04400279|EXPERIMENTAL|Combination Yoga & HIIT group|Using the Down Dog app, this group will be given access to both the unique yoga practice and bodyweight HIIT workouts. Asked to complete 2 yoga and 2 HIIT workouts per week. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
61999004|NCT04400279|NO_INTERVENTION|Control group|This group will be maintaining their pre-study activity levels for the first 6 weeks of the study. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. Then the participants will be given access to all the Down Dog apps (both yoga and HIIT included) to use as the participants please for the following 6 weeks. A final wellbeing and health survey at the end of the second 6 weeks will be administered.
61999005|NCT02423941|EXPERIMENTAL|Retrograde reperfusion|During the transplant procedure the liver is initially reperfused retrogradely via hepatic veins. Venting of 300 ml blood is allowed via donor portal vein. After completion the portal vein anastomosis and retrograde venting of another 100 ml blood the antegrade portal reperfusion is performed.
61999006|NCT02423941|ACTIVE_COMPARATOR|Antegrade reperfusion|During the transplant procedure the liver is reperfused conventionally, antegradely via portal vein after completion of caval and portal anastomoses. Venting of 300 ml blood is allowed via tube placed in infrahepatiс caval anastomosis before unclamping the vena cava.
61999007|NCT00393679|EXPERIMENTAL|1|AS-AQ
61999008|NCT00393679|EXPERIMENTAL|2|"DHAPQ~TO BE NOTED: since the batches of the study drug DHAPQ expire at the end of October 2008, and because of the unavailability of a new batch of DHAPQ from the manufacturer, the recruitment in the DHAPQ arm had to be discontinued on 30th October 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities."
62774676|NCT05891158|EXPERIMENTAL|Arm 3, Severe HI: Fazirsiran 200 mg|Participants with severe HI will receive fazirsiran 200 mg SC injection on Day 1. The dose may be modified after review of available safety and PK data by the sponsor study team in consultation with the investigator.
61999009|NCT00393679|EXPERIMENTAL|3|AL
61999010|NCT00393679|EXPERIMENTAL|4|"Lapdap + AS~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008."
62184543|NCT03464383|EXPERIMENTAL|Epileptologist-Driven Treatment|The intervention will consist of initiating a chronic care management plan in the epilepsy clinic and an initial prescription from the epileptologist for escitalopram 10mg daily. Escitalopram dose adjustment will be made based on biweekly repeated screening of anxiety and depression symptoms, as well as side effects identified on biweekly telephone calls or the 6-week advanced practice provider (APP) follow up visit. Escitalopram dose may be titrated up to a maximum of 20mg daily in 5-10mg increments every 2 weeks for treatment effect, or titrated down to 5mg if needed for adverse effects. If a participant is unable to tolerate escitalopram, then venlafaxine XR 37.5mg will be substituted, to be titrated in a similar manner biweekly based on side effects and anxiety and depression symptoms (with 37.5-75mg increment dose changes and maximum dose of 225mg daily).
62184544|NCT03464383|ACTIVE_COMPARATOR|Standard of Care|A psychiatry referral order placed by epileptologist under typical care circumstances (internal or external referral based on the participant's geographic preferences). Internal referrals will be processed by current clinic/institutional protocols. External referral orders will be printed and provided to the patient along with brief instructions on how to find a provider covered by the patient's insurance.
62393271|NCT03478631|EXPERIMENTAL|High Nitrate Dehydrated Vegetables|Participants are given high-nitrate dehydrated vegetable powders contained in opaque sachets. Participants are advised to consume three sachets per day, over the course of three meals, for 16 weeks.
61999011|NCT03455465||No intervention|Patients in this arm will not be approached by community health workers during their visit to the Emergency Department.
61999012|NCT03455465||Community Health Worker Program|Participants in this group will be approached by a community health worker during their visit to the Emergency Department with the goal of enrolling them in a comprehensive post-discharge program.
61999013|NCT04856033|EXPERIMENTAL|TM|Transcendental Mediation
61999014|NCT04856033|ACTIVE_COMPARATOR|PCT|Present Centered Therapy
62184545|NCT03464383|OTHER|Survey Arm|This option will be offered to individuals who are found to have anxiety or depression symptoms on screening but who are found to be ineligible for intervention arms of the study, or those who are eligible for the intervention arm but decline to participate in the intervention.
62184546|NCT01430117|EXPERIMENTAL|1|"Poa pratensis allergen extract at 4 different concentrations.~Positive control.~Negative control."
62393272|NCT03478631|ACTIVE_COMPARATOR|Low-Nitrate Dehydrated Vegetables|Participants are given low-nitrate dehydrated vegetable powders contained in three opaque sachets. Participants are advised to consume three sachets per day, over the course of three meals, for 16 weeks.
62393273|NCT02206776|PLACEBO_COMPARATOR|Midazolam|A single dose of intranasal midazolam up to 4 mg
62393274|NCT02206776|EXPERIMENTAL|Ketamine|A single dose of intranasal ketamine up to 50 mg
62393275|NCT04020042|EXPERIMENTAL|Ultrasound imaging guidance|Determination of epidural needle site by using ultrasound guidance
61999015|NCT02569671|OTHER|Immediate Placement - Test|Straumann Bone Level Tapered Implant - Immediate Placement - Implant is placed at the time of tooth extraction to replace a single tooth.
61999016|NCT02569671|OTHER|Delayed Placement - Control|Straumann Bone Level Tapered Implant - Delayed Placement - Implant is placed after 16-18 weeks of healing to replace a single tooth.
61999017|NCT00712296|EXPERIMENTAL|ASHMI 4|ASHMI 4 capsules twice a day
61999018|NCT00712296|EXPERIMENTAL|ASHMI 12|ASHMI 12 capsules twice a day
61999019|NCT00712296|PLACEBO_COMPARATOR|Placebo|Placebo 6 capsules twice a day
62393276|NCT04020042|ACTIVE_COMPARATOR|Traditional landmark palpation|Depermination of epidural needle site by using traditional landmark method
62393277|NCT02904317||Misprostol vaginal insert for labour induction|69 patients matching the inclusion criteria and received MVI for labour induction
61999020|NCT04453917|EXPERIMENTAL|Patients with active PML|Patients with neurological symptoms (\< 3 months) with brain MRI lesions suggestive of PML and positive PCR in cerebrospinal fluid for JCV
61999021|NCT04619056|EXPERIMENTAL|Cohort 1|CEB-01 with total SN-38 dose: 9 mg
61999022|NCT04619056|EXPERIMENTAL|Cohort 2|CEB-01 with total SN-38 dose: 18 mg
61999023|NCT04619056|EXPERIMENTAL|Cohort 3|CEB-01 with total SN-38 dose: 36 mg
61999024|NCT02201303|EXPERIMENTAL|Part 1|Blood sample will be collected from the RSV-infected children \<2 years and healthy adults participants. Escalating concentrations of CXCL1 will be added to whole blood in vitro and CD11b up regulation on peripheral blood neutrophils will be analyzed
61999025|NCT02201303|EXPERIMENTAL|Part 2|Blood sample will be collected from the RSV-infected children \<2 years and healthy adults participants. Escalating concentrations of danirixin will be added to whole blood in vitro with a fixed concentration of CXCL1 to determine inhibition of CD11b expression on peripheral blood neutrophils
62393278|NCT02904317||Oral misoprostol for labour induction|69 patients matching the inclusion criteria and received OM for labour induction
62393279|NCT00372073|ACTIVE_COMPARATOR|Arm 1 with seliciclib|Oral seliciclib at 1200mg b.i.d. for 3 consecutive days as an outpatient beginning on day 1 every 2 weeks for 3 cycles as run-in. Patients (randomized) continue on treatment if derived clinical benefit during run-in period.
61999026|NCT03696654|NO_INTERVENTION|Before treatment|
61999027|NCT03696654|ACTIVE_COMPARATOR|After treatment|
61999028|NCT05558293|PLACEBO_COMPARATOR|Periodontitis quadrant Scaling root planing|Patients undergo non surgical quadrant scaling and root planing performed per quadrant
61999029|NCT05558293|ACTIVE_COMPARATOR|Periodontitis full mouth scaling root planing|Patients undergo non surgical full mouth scaling and root planing
61999030|NCT00991575||Diabetes, type 1|
61999031|NCT06330194|ACTIVE_COMPARATOR|Intervention Group|2nd Generation Automated Insulin Delivery system (Medtronic MiniMed 780G)
61999032|NCT06330194|NO_INTERVENTION|Control Group|Usual care consisting of participants current insulin-treatment (either multiple daily injection with insulin or traditional insulin pump therapy with manual determination of insulin dosing) and real-time CGM if already used.
61999033|NCT03012386|EXPERIMENTAL|Sildenafil citrate|Sildenafil citrate 20 mg three times a day
62393280|NCT00372073|PLACEBO_COMPARATOR|Arm 2 with placebo control|Randomized to placebo after run-in period.
62393281|NCT04748731|EXPERIMENTAL|Experimental Group. Video-feedback intervention.|A weekly online brief intervention using video-feedback and psycho-educational materials on early parenting (detailed description of the intervention on section 5).
62393282|NCT04748731|OTHER|Control Group. Psycho-educational intervention|They will receive weekly information on parenting in the 1st year of life. They will have direct contact (via WhatsApp) with a child psychologist to ask questions about the material and to refer to specialized support if needed.
61999034|NCT00347152|ACTIVE_COMPARATOR|2|Slow Progressive Divalproex DR to Divalproex ER switch
61999035|NCT00347152|ACTIVE_COMPARATOR|1|Immediate, Progressive Divalproex DR to Divalproex ER switch
61999036|NCT06328790||Functional Motor Disorder rehabilitation group (FMD)|Patients with FMD (subject to current diagnostic criteria) will undergo experiment 3.
61999037|NCT06328790||Healthy Controls group (HC)|Healthy subjects at least 18 years old will undergo experiment 1.
61999038|NCT06328790||"Organic Motor Disorders group"|"Patients with organic motor disorders (weakness due to peripheral neuromuscular disorders, essential tremor, or idiopathic adult-onset dystonia, all according to current diagnostic criteria) will undergo experiment 2."
61999039|NCT06328790||Functional Motor Disorder group (FMD)|Patients with FMD (subject to current diagnostic criteria) will undergo experiment 1.
61999040|NCT03069625|EXPERIMENTAL|Sit-to-stand test|Children and adolescents will perform 2 STS tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
61999041|NCT03069625|ACTIVE_COMPARATOR|6-Minute Walk Test|Children and adolescents will perform 2 6MWT tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
61999042|NCT06321874|EXPERIMENTAL|Normobaric Oxygen Paradox (NOP) group|The NOP group received 60% oxygen for two hours on days 1, 3, and 5 post-surgery using a venti-mask.
61999043|NCT06321874|NO_INTERVENTION|Control (CTR) group|The CTR group did not receive oxygen therapy during the post-operatory period starting from day 1.
61999044|NCT02196285|EXPERIMENTAL|Double viral vaccine (MR)|Measles and rubella vaccine
61999045|NCT06474494|EXPERIMENTAL|Experimental: Experimental group 1|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying double layer of Scotchbond Universal Plus adhesive applied as etch-and-rinse mode
62184547|NCT02137577|EXPERIMENTAL|DEB catheter|use DEB catheter(trade name: Lotus/Tulip) to treat the stenosis or occlusion in below popliteal artery of experimental arm
62184548|NCT02137577|ACTIVE_COMPARATOR|common PTA balloon catheter|use common PTA balloon catheter(trade name:Amphirion Deep) to treat stenosis or occlusion in below popliteal artery of control group
62184549|NCT02396446||Intervention group|Inpatients at CSMC whose abdominal acoustic sounds will be measured using the AbStats device.
62184550|NCT03634306|ACTIVE_COMPARATOR|ARM 1|Laparoscopic hysterectomy with use of the Ultravision System
62568672|NCT02720328|OTHER|DOAC-treated patients|Concerning patients taking DOACs, blood samples are drawn to evaluate DOAC plasma concentration. One EDTA tube is also drawn to extract DNA and determine the genetic profile of genes involved in the metabolism of DOACs. The aim will be to assess if genetic determinants can explain the observed interindividual variability in plasma concentrations.
62774677|NCT05891158|EXPERIMENTAL|Arm 4, Normal Hepatic Function: Fazirsiran 200 mg|Participants with normal hepatic function will receive fazirsiran 200 mg SC injection on Day 1. The dose may be modified after review of available safety and PK data by the sponsor study team in consultation with the investigator.
62774678|NCT04212689|ACTIVE_COMPARATOR|Control Group|Number of participants in this group is anticipated to be 20. Conventional physiotherapy and rehabilitation methods will be applied to this group. Physiotherapy approaches include stretching exercises, neurodevelopmental approaches, static positioning, strengthening exercises, Transcutaneous Electrical Nerve Stimulation (TENS), hydrotherapy, cryotherapy.
62774679|NCT04212689|ACTIVE_COMPARATOR|Study Group|Number of participants in this group is anticipated to be 20. Participants in this group will be receiving conventional physiotherapy and rehabilitation methods and 10 minutes of exercise with the game-based virtual reality system (USE-IT). In the USE-IT system two games will be played for 5 minutes each.
62184551|NCT03634306|PLACEBO_COMPARATOR|ARM 2|Laparoscopic Hysterectomy per Standard of Care/no Ultravision System
62184552|NCT03634306|ACTIVE_COMPARATOR|ARM 3|Laparoscopic myomectomy with use of the Ultravision System.
62184553|NCT03600649|EXPERIMENTAL|Myxoid Liposarcoma|Twice-daily administration of oral seclidemstat
62774680|NCT01943006|EXPERIMENTAL|Hirudoid cream|"Patient treated with Hirudoid cream 0.3% Mucopolysaccharide polysulfate~Twice daily"
62774681|NCT01943006|PLACEBO_COMPARATOR|Placebo|"Patients treated with placebo cream without active substance~Twice daily"
62774682|NCT02939768|EXPERIMENTAL|Exercise training protocols|Participants will be randomized in one of three groups: HIIT, ST or ST combined with HIIT (ST+HIIT). Each training protocol will last 10 weeks, being the initial two weeks designed to participants' gradual adaptations to respective training protocol, with sessions performed three times per week in non-consecutive days.
62774683|NCT02939768|NO_INTERVENTION|Control period|Before interventions (exercise training protocols), all participants will participate of a control period lasting one month, where participants will be encouraged to maintain their habitual lifestyle and usual diet habits.
62774684|NCT00447122|EXPERIMENTAL|treatment 1|Gemcitabine 1000mg/m2 with lapatinib 1000mg/d weekly x 3 weeks
62184554|NCT03600649|EXPERIMENTAL|Sarcomas with FET-family translocations, including demoplastic small round cell tumors|Twice-daily administration of oral seclidemstat
62184555|NCT03600649|EXPERIMENTAL|Ewing sarcoma, combination therapy|Twice daily administration of seclidemstat in combination with cyclophosphamide and topotecan
62184556|NCT04455607|EXPERIMENTAL|experimental group|Random perturbation training
62184557|NCT04455607|ACTIVE_COMPARATOR|control group|Block perturbation training
62184558|NCT00003597|EXPERIMENTAL|Cohort 1|Chemotherapy days 0-4, G-CSF (5 μg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). rhTPO began on the last day of ICE (Ifosfamide, Carboplatin and Etoposide) chemotherapy (Day 4) and subsequent doses will be administered on Days 6, 8, 10 and 12 (5 doses total). The initial dose of rhTPO was 1.2 μg/kg/dose and was subsequently escalated to 2.4 and 3.6 μg/kg/dose as tolerated. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one only).
62184559|NCT00003597|EXPERIMENTAL|Cohort 2|"Chemotherapy days 0-4, G-CSF (5 μg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). The dose of rhTPO 1.2 μg/kg/dose and subsequently escalated to 2.4 and 3.6 μg/kg/dose as tolerated. Patients assigned to Cohort II will receive pre-chemotherapy rhTPO at 3.6 μg/kg/dose on Days -5, -3, -1, and post-chemotherapy rhTPO on Days +4, +6, and +8 (6 doses total. Subsequent courses of chemotherapy will begin as soon as the ANC recovers to~≥ 1,000/μL and the platelet count to ≥ 100,000/μL between days 21 and 35. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one nly). For the second cohort, full data collection will occur for cycles one and two and limited data collection for cycles 3, 4, 5, and 6."
62184560|NCT05781009|ACTIVE_COMPARATOR|patients receiving 300mg PREG|Patients randomly assigned to receive 300mg of pregnenolone (PREG) daily.
62184561|NCT05781009|PLACEBO_COMPARATOR|placebo|Patients randomly assigned to receive a placebo daily.
62393283|NCT00983125|EXPERIMENTAL|clonidine|
62393284|NCT00983125|OTHER|no clonidine|
62393285|NCT02944058|ACTIVE_COMPARATOR|Philos plate|Intervention is surgery with Philos plate
62568673|NCT00917748|EXPERIMENTAL|1|docetaxel chemotherapy + modafinil 100 mg capsules
62568674|NCT00917748|PLACEBO_COMPARATOR|2|docetaxel chemotherapy + placebo (lactose) capsules (matched to modafinil drug)
62214611|NCT02145559|EXPERIMENTAL|Metformin XR|All eligible patients with histologically-confirmed advanced solid tumors will be started on sirolimus (3 mg daily) alone for the first 7 days. On day 8, patients will recieve metformin XR (500 mg daily with the evening meal)(through day 21). On day 15, patients randomized to metformin XR will have their dose increased to 1000 mg daily if there is no grade ≥ 2 toxicity due to metformin XR. Patients who develop grade 2 toxicity due to metformin will be maintained on metformin XR 500 mg daily for the rest of the study, while patients who develop \> grade 2 toxicity will be taken off study. From day 22 onwards, all patients will be on combination of sirolimus and metformin.
62393286|NCT02944058|ACTIVE_COMPARATOR|Multiloc nail|Intervention is surgery with Multiloc nail
62393287|NCT01006785|EXPERIMENTAL|Treatment I|DLBS1425 150 mg three times daily
62393288|NCT01006785|EXPERIMENTAL|Treatment II|DLBS1425 300 mg three times daily
62393289|NCT03898882||BMI 20 - 29.9 kg/m2|
62393290|NCT03898882||BMI > 30 kg/m2|
62568675|NCT02537613|EXPERIMENTAL|Arm A- obinutuzumab -> ibrutinib|Participants enrolled in Arm A will receive obinutuzumab weekly starting cycle 1, and will receive obinutuzumab monthly during cycles 2-6. Participants will begin to take ibrutinib daily starting cycle 2 and will continue with daily ibrutinib until the end of treatment.
62393291|NCT03728647|EXPERIMENTAL|multimedia health education|The program (flat touch computer) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, complications, and experience sharing of insulin injection by a patient group. Technology: steps of insulin injection skills and complete technology demonstration . The program contents were organized using a unit-based piecemeal teaching approach. Participants could adjust their learning pace according to individual situations and could practice injection skills using an injection mold during hospitalization. A diabetes educator has assessed the learning outcome of each participant after intervention. At the day of discharge from hospital, each participant would acquire a copy of the multimedia health education compact disc.
62393292|NCT03728647|ACTIVE_COMPARATOR|regular health education|The regular (traditional) education program (a diabetes educator) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, and complications. Technology: steps of insulin injection skills and complete technology demonstration.
62393293|NCT04391192|EXPERIMENTAL|Participants|All participants will be given the phone number and encouraged to call any time they plan to use substances alone
62568676|NCT02537613|EXPERIMENTAL|Arm B- ibrutinib -> obinutuzumab|Participants enrolled in Arm B will begin to take ibrutinib daily starting cycle 1 and will continue with daily ibrutinib until the end of treatment. Participants will begin to receive obinutuzumab weekly starting cycle 2, and will receive obinutuzumab monthly during cycles 3-7
62568677|NCT02537613|EXPERIMENTAL|Arm C- obinutuzumab/ibrutinib|Participants enrolled in Arm C will begin to take ibrutinib daily starting cycle 1 and will continue with daily ibrutinib until the end of treatment. At the same time, participants will begin to receive obinutuzumab weekly starting cycle 1, and will receive obinutuzumab monthly during cycles 2-6.
62568678|NCT05846100|PLACEBO_COMPARATOR|standard group|Fictional ultrasound identification Screen device shut down Intervertebral space identified using the standard palpation
62184562|NCT00469859|EXPERIMENTAL|Group 1 (Lestaurtinib dose 50 mg/m2|"DOSE-FINDING PHASE:~COURSE 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2. Cohorts of 6 patients receive escalating doses of lestaurtinib until a TBAD is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by PIA assay.~COURSE 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Continued (see detailed description)"
62214612|NCT02145559|ACTIVE_COMPARATOR|Delayed Metformin|All eligible patients with histologically-confirmed advanced solid tumors will be started on sirolimus (3 mg daily) alone for the first 7 days. On day 8, patients will be randomized to receive no metformin for two weeks (through day 21). From day 22 onwards, all patients will be on combination of sirolimus and metformin. Patients who were initially not randomized to metformin XR will begin taking it at 500 mg daily with an evening meal and titrated up to 1000 mg daily after one week, as above. Each cycle will be 4 weeks.
62214613|NCT03674359||Cohort|Patients hospitalized in intensive care, meeting the inclusion criteria. BDG analysis
62393294|NCT04384120|EXPERIMENTAL|Rotator Cuff Rehabilitation Using BFR|"Patients with rotator cuff tears who plan for either nonoperative treatment with physical therapy or operative treatment with arthroscopic rotator cuff repair (RCR) surgery will be randomized to undergo rehabilitation using blood flow restriction cuffs.~1. Patients who elect for nonoperative treatment of their rotator cuff tear will undergo traditional therapy using blood flow restriction cuffs.~2. Patients who elect for RCR will undergo preoperative and postoperative traditional therapy using blood flow restriction cuffs."
62568679|NCT05846100|ACTIVE_COMPARATOR|ultrasound group|pre-puncture ultrasound-guided neuraxial anesthesia group
62568680|NCT04024969||Clinically isolated syndrome|Those presenting for diagnositic evaluation of multiple sclerosis, not currently meeting the 2017 McDonald criteria.
62568681|NCT01047059|EXPERIMENTAL|Trial Intervention|150mg Erlotinib daily, 15mg/kg b.w. Bevacizumab on d1, d22, d43 as medication FDG-PET, FLT-PET and DCE-MRI as diagnostical tools
62568682|NCT00932308|ACTIVE_COMPARATOR|1|Western-style, high-fat, low-calcium diet (WD)
62568683|NCT00932308|ACTIVE_COMPARATOR|2|Prudent, low-fat, calcium sufficient diet (PD)
62568684|NCT03768908|ACTIVE_COMPARATOR|Treatment with artesunate + amodiaquine|Co-administration of a daily dose of artesunate (Arsumax) 4mg/kg and amodiaquine (Flavoquine) 10mg/kg for 3 days, under direct observation. Children \<12months \<10kg: artesunate (Arsumax) 50mg - 0.5tab/day + amodiaquine (Flavoquine) 153mg - 0.5tab/day; Children 12-59months 10-20kg: artesunate (Arsumax) 50mg - 1 tab/day + amodiaquine (Flavoquine) 153mg 1 tab/day.
62568685|NCT03768908|ACTIVE_COMPARATOR|Treatment with artemether-lumefantrine (Coartem®)|Artemether-lumefantrine (Coartem®) - artemether 1.3mg/kg + lumefantrine 4mg/kg administered twice daily, both doses under direct observation either in the clinic or in the patient's home. Children \<60 months, 5-14kg: 1 tab/dose; Children \<60 months \>14kg: 2 tabs/dose.
62568686|NCT06400186|EXPERIMENTAL|Biomechanical Response to Balance Challenging Environments|Aim 1 will determine how people with chronic stroke (PwCS) adapt their gait in response to different balance challenging environments. For Aim 1, the investigators will conduct a single-session cross sectional study to assess gait patterns during and immediately following walking practiced in balance challenging environments. PwCS will perform treadmill walking in a natural unmodified environment, and in two balance-challenging environments that will include a Movement Amplification Environment (MAE), and an unpredictable lateral perturbation environment. All enrolled participants will undergo clinical outcome measure assessments to identify baseline function. In addition, all participants in Aim 1 will undergo biomechanical testing while walking in each of the three environments to assess changes in their walking patterns.
62774685|NCT00447122|EXPERIMENTAL|treatment 2|Gemcitabine 1000mg/m2 with lapatinib 1500mg/d weekly X 3 weeks
61999046|NCT06474494|EXPERIMENTAL|Experimental group 2|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying double layer of Scotchbond Universal Plus adhesive applied as selective enamel etching mode
61999047|NCT06474494|ACTIVE_COMPARATOR|Control group 1|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying one layer of Scotchbond Universal Plus adhesive applied as etch-and-rinse mode
61999048|NCT06474494|ACTIVE_COMPARATOR|Control group 2|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying one layer of Scotchbond Universal Plus adhesive applied as selective enamel etching mode
61999049|NCT01660828|ACTIVE_COMPARATOR|Intensive cycling test preceded by RIPC|Intensive cycling test preceded by a RIPC protocol.
61999050|NCT01660828|NO_INTERVENTION|No intervention/ RIPC|Intensive cycling test not preceded by a RIPC protocol.
62774686|NCT00447122|EXPERIMENTAL|treatment 3|gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 on days 1 and 14 of a 28-day cycle with lapatinib 1000 mg/d
61999051|NCT05148312|EXPERIMENTAL|AQ001S 0.125 mg/2mL single-dose|AQ001S 0.125 mg/2 ml (budesonide 0.125 mg/2 ml inhalation solution) single-dose administered by nebulization.
61999052|NCT05148312|EXPERIMENTAL|AQ001S 0.250 mg/2mL single-dose|AQ001S 0.250 mg/2 ml (budesonide 0.250 mg/2 ml inhalation solution) single-dose administered by nebulization.
61999053|NCT05148312|EXPERIMENTAL|AQ001S 0.500 mg/2mL single-dose|AQ001S 0.500 mg/2 ml (budesonide 0.500 mg/2 ml inhalation solution) single-dose administered by nebulization.
61999054|NCT05148312|ACTIVE_COMPARATOR|Budesonide inhalation suspension 1.0 mg/2 ml single-dose|Pulmicort Respules® 1.0 mg/2 ml is a budesonide inhalation suspension administered by nebulization.
61999055|NCT01744327||Chronic Plaque type psoriasis|Patients with plaque type psoriasis
61999056|NCT02142686|ACTIVE_COMPARATOR|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm.
62393295|NCT04384120|ACTIVE_COMPARATOR|Rotator Cuff Rehabilitation Without BFR|"Patients with rotator cuff tears who plan for either nonoperative treatment with physical therapy or operative treatment with arthroscopic rotator cuff repair (RCR) surgery will be randomized to undergo rehabilitation without using blood flow restriction cuffs.~1. Patients who elect for nonoperative treatment of their rotator cuff tear will undergo traditional therapy without using blood flow restriction cuffs.~2. Patients who elect for RCR will undergo preoperative and postoperative traditional therapy without using blood flow restriction cuffs."
62774687|NCT00447122|EXPERIMENTAL|treatment 4|gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 on days 1 and 14 of a 28-day cycle with lapatinib 1500 mg/d
62774688|NCT02345330|EXPERIMENTAL|Tavokinogene Telseplasmid (tavo) Electroporation (EP)|Participants received tavo intratumorally followed immediately by electroporation (EP) on Days 1, 8, and 15 in a 6-week cycle for up to 9 cycles.
62774689|NCT04303299|EXPERIMENTAL|Oseltamivir plus Chloroquine in Mild COVID19|Oseltamivir 300mg ( or 4-6 mg/kg) per day plus Hydroxychloroquine 800 mg per day In mild COVID19
62774690|NCT04303299|EXPERIMENTAL|Darunavir and Ritonavir plus oseltamivir|Darunavir 400 mg every 8 hours Ritonavir 200 mg (or 2.5 mg/kg ) per day plus plus Oseltamivir 300mg ( or 4-6 mg/kg) per day plus Hydroxychloroquine 400mg per day in Mild COVID19
61999057|NCT02142686|ACTIVE_COMPARATOR|Filling pressure 50.|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg in this group
61999058|NCT02142686|ACTIVE_COMPARATOR|illing pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm Hg.
61999059|NCT05057416|EXPERIMENTAL|High Intensity Interval Training (HIIT) Protocol|Participants in the HIIT group will start with a 2.5-minute warm-up at about 30% VO2 max. The participants will then complete 3 running bouts at 80-90% VO2 max. Each running bout will be separated by 2 minutes of active rest where the participants will walk at 50% VO2 max. The total exercise time of this protocol will be 15 minutes. Finally, the participants will finish with a 2.5 min cool-down where they will walk at a light intensity of 30% VO2 max, for a total exercise duration of 20 minutes.
62774691|NCT04303299|EXPERIMENTAL|Lopinavir and Ritonavir plus Oseltamivir in mild COVID19|Lopinavir 800 mg ( or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg ( or 4-6 mg /kg ) per day In mild COVID19
62774692|NCT04303299|EXPERIMENTAL|Lopinavir and Ritonavir Oseltamivir moderate to severe COVID19|Lopinavir 800 mg ( or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg ( or 4-6 mg /kg ) per day In moderate to critically ill COVID19
62774693|NCT04303299|EXPERIMENTAL|Favipiravir lopinavir /Ritonavir for mod. To severe|Lopinavir 800 mg (or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Favipiravir 2400 mg, 2400 mg, and 1200 mg every 8 h on day 1, and a maintenance dose of 1200 mg twice a day in Mild COVID19 In moderate to critically ill COVID19
62214614|NCT04289051|EXPERIMENTAL|HYDRAL Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
62393296|NCT00758576|EXPERIMENTAL|SN6AD1|AcrySof ReSTOR Model SN6AD1 Intraocular Lens
62393297|NCT02383966|EXPERIMENTAL|Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil|
62393298|NCT02383966|ACTIVE_COMPARATOR|Cisplatin/Carboplatin + 5-Flurouracil|
62774694|NCT04303299|EXPERIMENTAL|Darunavir /ritonavir oseltamivir chloroquine mod-severe|Darunavir 400 mg every 8 hours Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg (or 4-6 mg /kg ) per day plus Hydroxychloroquine 400 mg per day In moderate to critically ill COVID19
62774695|NCT04303299|EXPERIMENTAL|Darunavir /ritonavir favipiravir chloroquine mod-severe|Darunavir 400 mg every 8 hours Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Favipiravir 2400 mg, 2400 mg, and 1200 mg every 8 h on day 1, and a maintenance dose of 1200 mg twice a day plus Hydroxychloroquine 400 mg per day In moderate to critically ill COVID19
61999060|NCT05057416|EXPERIMENTAL|Sprint Interval Training (SIT) Protocol|Participants in the Sprint Interval Training group will perform a 2.5-minute warm up at a VO2 max of 30%. Next, the participants will perform 6 all-out sprints at 150-200% of VO2 max, separated by 2-minute active rests at 50% VO2 max. The total exercise time of the SIT protocol is about 14 minutes. Finally, the participants will perform a walking cool-down of 3.5 minutes at 30% VO2 max, for a total exercise duration of 20 minutes.
61999061|NCT05057416|EXPERIMENTAL|Moderate Intensity Continuous Training (MICT)Protocol|Participants in the Moderate Intensity Continuous Training group will first be warming up for 2.5 minutes at a VO2 max of 30%. After the warm up, participants will be running for 15 minutes at 45-60% of VO2 max. Finally, the participants will perform a 2.5-minute cool-down at 30% VO2 max, for a total exercise duration of 20 minutes.
61999062|NCT01935765|EXPERIMENTAL|Diabetes people|99 Type 1 diabetic patients aged 18 to 60 years, diagnosed since at least a year
61999063|NCT01935765|EXPERIMENTAL|healthy volunteers (controll group)|46 healthy volunteers matched by age, gender and body mass index
61999064|NCT04689256|EXPERIMENTAL|MR-010 walking therapy|Subjects will use the MR-010 three times a week for 30 minutes per session for 90 days. Subjects will undergo a 10-meter walk test bi-weekly and at 45 and 90 days.
61999065|NCT04689256|NO_INTERVENTION|Standard of Care|Subjects will undergo a 10-meter walk test bi-weekly for 90 days and at 45 and 90 days
62393299|NCT05492552|NO_INTERVENTION|Non-COVID participants|
62393300|NCT05492552|EXPERIMENTAL|COVID participants in intervention|The intervention group will attend the laboratory for baseline testing and complete a week of usual daily activity. Following this week they will then be guided to increase their daily step count by 2,000 and supported through weekly telephone calls.
61999066|NCT03437200|EXPERIMENTAL|Arm A: Chemoradiation + Nivolumab|"All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX followed by 3 cycles of 2 weeks of FOLFOX without RT.~Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year."
61999067|NCT03437200|EXPERIMENTAL|Arm B: Chemoradiation + Nivolumab + Ipilimumab|Same as arm A + induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year
61999068|NCT03215134|EXPERIMENTAL|Self-criticism intervention|6 weekly face to face therapy sessions (1st assessment an intervention session of 60 to 90 minutes; sessions 2-5 are 60 minutes each) and a 2 month follow-up telephone call of upto 30 minutes.
62393301|NCT05492552|NO_INTERVENTION|COVID participants assigned to usual daily activity|
62774696|NCT04303299|NO_INTERVENTION|Conventional Qurantine|Patient who unwilling to treatment and willing to quarantine in mild COVID19
62774697|NCT03197909||Healthy subjects|Determination of pro-inflammatory plasma factors at Healthy subjects aged from 35 to 85 years old
62774698|NCT03197909||COPD patients|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old
62774699|NCT01614171|EXPERIMENTAL|Growth hormone therapy|Growth hormone treatment for 6 months
62214615|NCT04289051|ACTIVE_COMPARATOR|BIOTENE® Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
62393302|NCT06241495|EXPERIMENTAL|Aromatherapy|
62393303|NCT06241495|PLACEBO_COMPARATOR|Control Group|
62393304|NCT03260543|EXPERIMENTAL|fermented ginseng powder|tablets (2 tablets/day, 125 mg \& 500 mg/day) for 12 weeks.
62393305|NCT03260543|PLACEBO_COMPARATOR|Placebo|Placebo for 12 weeks.
62393306|NCT00490815|EXPERIMENTAL|1|
62393307|NCT00490815|EXPERIMENTAL|2|
62774700|NCT03968185||Interfascial infiltration|Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.
62774701|NCT03968185||Standard medical treatment|Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.
62774702|NCT05822050|EXPERIMENTAL|Low risk group|10 patients. Selinexor 60mg QW Oral 21days/cycle
62774703|NCT05822050|EXPERIMENTAL|Medium/High risk group|10 patients. Selinexor 60mg QW Oral with Chemotherapy 21days/cycle
62774704|NCT03067376|EXPERIMENTAL|[14C]-CORT125134|Two capsules each containing 125 milligrams (mg) \[14C\]-CORT125134 administered to each participant on 1 occasion
62774705|NCT05173701|EXPERIMENTAL|Probiotics|Administration of a mixture of probiotics once daily for three months
62774706|NCT05173701|PLACEBO_COMPARATOR|Placebo|Administration of a placebo (maltodextrin) once daily for three months
62774707|NCT03836677|EXPERIMENTAL|BGF-GFF|Subject first treated with Budesonide/Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Glycopyrronium/Formoterol Fumarate
62774708|NCT03836677|EXPERIMENTAL|GFF-BGF|Subject first treated with Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Budesonide/Glycopyrronium/Formoterol Fumarate
62774709|NCT05124379|OTHER|Hemoclin Gel|
62774710|NCT02073669|OTHER|Second generation immigrants from high TB incidence countries|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA).
61999069|NCT05009758|ACTIVE_COMPARATOR|T2-high asthma with nasal polyps|"* FeNO \> 25 ppB~* Had either two times \>= 250 eosinophils /µl measured in the blood OR one measurement of blood eosinophils \>= 250 cells/µl (one of the two measurements at the screening visit) and/or one measurement of sputum eosinophils \> 2% within the last 12 months~* Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and CRSwNP Guidelines)~* Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 5 half-lives or at least 3 months have passed"
61999070|NCT05009758|ACTIVE_COMPARATOR|T2-high asthma without nasal polyps|"* FeNO \> 25 ppB~* Had either two times \>= 250 eosinophils /µl measured in the blood OR one measurement of blood eosinophils \>= 250 cells/µl (one of the two measurements at the screening visit) and/or one measurement of sputum eosinophils \> 2% within the last 12 months~* Absence of NP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and CRSwNP Guidelines)~* Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 5 half-lives or at least 3 months have passed"
62393308|NCT02967393|ACTIVE_COMPARATOR|IIV4|0.5 mL intramuscular injection
62393309|NCT02967393|ACTIVE_COMPARATOR|cc IIV4|0.5 mL intramuscular injection
62393310|NCT00324519|ACTIVE_COMPARATOR|Misoprostol Drug|This is the misoprostol drug.
62393311|NCT00324519|EXPERIMENTAL|The Foley Bulb|This is the experimental portion to test the Foley Bulb.
62774711|NCT02073669|OTHER|Native Israelis|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA).
62774712|NCT03496766|EXPERIMENTAL|Experimental Arm|Tipifarnib 600 mg, po, bid daily on days 1-7 and 15-21 of 28-day treatment cycles for up to 24 months
62774713|NCT00958737|EXPERIMENTAL|Arm I|"Patients receive modified FOLFOX 6 comprising oxaliplatin IV 85 mg/m² over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1. Treatment repeats every 14 days for 6 courses (3 months).~Patients receive CAPOX comprising oxaliplatin IV 130 mg/m² over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which will be administered orally at a dose of 1000 mg/m2 twice-daily (equivalent to a total daily dose of 2000 mg/m2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment)"
62214616|NCT04289051|PLACEBO_COMPARATOR|Placebo Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
62393312|NCT03063515|NO_INTERVENTION|IVGTT without pyridostigmine|An intravenous glucose tolerance test (IVGTT) will be performed without any medication for baseline comparison.
62393313|NCT03063515|ACTIVE_COMPARATOR|IVGTT with pyridostigmine|An IVGTT will be performed 2 hours after taking one single dose of pyridostigmine 60 mg
62393314|NCT03856242|NO_INTERVENTION|No intervention|It included the patients in whom during urination certain changes in HM were registered. The Group 1 patients' age varied from 63 to 79 years (mean 68.6±4.94 years). Nearly all except two patients (cardiac background of these patients did not require medical or surgical correction) from this group received cardiotropic therapy which did not change during one-month follow-up.
62393315|NCT03856242|ACTIVE_COMPARATOR|Tamsulosin|This group enrolled 28 patients in whom primary HM detected certain alterations (VE, SVE, ST segment depression) which did not coincide with the act of urination. The age of patients was from 57 to 81 years (mean 71.3±1.1 years). In order to improve impaired urination were also received Tamsulosin at a dose of 0.4 mg once daily (in the morning) for the whole period of follow up and treatment. Tamsulosin Oral Capsule.
62393316|NCT03856242|ACTIVE_COMPARATOR|TURP|This group was composed of patients for whom after examination for symptoms of IHD and LUTS/BPH a decision was made on the necessity to perform operative treatment of BPH. TURP operation was indicated due to pronounced urination disorders which were most important amongst the patient's complaints. The patients' age varied from 59 to 77 years (mean 67.5±2.1 years).
62393317|NCT04460495|EXPERIMENTAL|Feasibility (ASL,pH-Weighted amine CEST, O2-Weighted SAGE-EPI)|Participants undergo ASL perfusion, pH-weighted amine CEST, and oxygen-weighted SAGE-EPI , while breathing normal room air (21% oxygen). Patients then undergo another ASL perfusion, pH-weighted amine CEST, and oxygen-weighted SAGE-EPI while breathing medical grade air (100% oxygen). Total ASL perfusion, pH-weighted amine CEST, and oxygen-weighted SAGE-EPI imaging scan time is 60 minutes.
62568687|NCT06400186|EXPERIMENTAL|Heart Rate Response to Balance Challenging Environments|Aim 2 is a feasibility study to determine if high intensity gait training can be achieved within a MAE. For Aim 2, the investigators will employ a two-way cross over study design consisting of two gait training sessions (one in a natural unmodified environment and the other in a MAE). The investigators will examine cardiovascular response, perceived exertion, and gait characteristics (speed, number of steps) to quantify if the MAE impacts training intensity. All enrolled participants will undergo clinical outcome measure assessments. In addition, all participants for Aim 2, heart rate (HR), rate of perceived exertion (RPE), number of steps taken during the training sessions, and walking speeds will be recorded.
62568688|NCT06104020|ACTIVE_COMPARATOR|Restrictive fluid group (RG)|The restrictive fluid group (RG) aims to achieve a net zero fluid balance and involves a 2 mL/kg bolus at anesthesia induction, followed by an intraoperative crystalloid infusion at a rate of 4 mL/kg/hr.
62774714|NCT00958737|EXPERIMENTAL|Arm II|Patients receive modified FOLFOX 6 or CAPOX as in arm I. Treatment repeats every 14 days for 12 courses (6 months)or regarding CAPOX every 21 days for 8 courses (6 month).
62774715|NCT02971150|EXPERIMENTAL|BBTI|Participants will receive Brief Behavioral Treatment for Insomnia (BBTI). This will be administered over the course of 4 weeks. BBTI is based on the concepts of sleep restriction and stimulus control. The first and third session are in person and the 2 and 4th session are conducted over the phone. Throughout the treatment, participants will complete daily sleep dairies. After 4 weeks of treatment, participants randomized to this group will cross over to the no intervention group and will be called once a week to assess mood and sleep symptoms.
62774716|NCT02971150|NO_INTERVENTION|Control|Participants will not receive treatment. They will be contacted by phone once a week to complete assessments of mood and sleep. After 4 weeks, they will cross over to the experimental BBTI group.
62774717|NCT02517372|ACTIVE_COMPARATOR|Cohorte 1|"Low dose pemirolast sodium (CRD007) given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
62774718|NCT02517372|ACTIVE_COMPARATOR|Cohorte 2|"Medium dose CRD007 given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
62774719|NCT02517372|ACTIVE_COMPARATOR|Cohorte 3|"High dose CRD007 given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
62774720|NCT00129467|EXPERIMENTAL|methylphenidate + SSRI|During the 18-day blind treatment period, subjects will be prescribed methylphenidate 5-10 mg twice per day and selective serotonin reuptake inhibitor (SSRI). Subjects already receiving a SSRI when they begin the study, will continue on the recommended dose of that SSRI; subjects not receiving a SSRI will be prescribed 10-20 mg per day Citalopram. Subjects who respond to methylphenidate treatment will have the option of continuing on methylphenidate, up to 15 mg bid, and an antidepressant in the 6 week open label portion of the study.
62774721|NCT00129467|PLACEBO_COMPARATOR|Placebo + SSRI|During the 18-day blind treatment period, subjects will be prescribed placebo 1-2 capsules twice per day and selective serotonin reuptake inhibitor (SSRI). Subjects already receiving a SSRI when they begin the study, will continue on the recommended dose of that SSRI; subjects not receiving a SSRI will be prescribed 10-20 mg per day Citalopram.
62774722|NCT01471210|EXPERIMENTAL|Part 1 : Urelumab (BMS-663513) Dose escalation|Urelumab (BMS-663513) solution administered intravenously on specified days
62774723|NCT01471210|EXPERIMENTAL|Part 2 : Urelumab (BMS-663513) Cohort Expansion|Urelumab (BMS-663513) solution administered intravenously on specified days
62774724|NCT01471210|EXPERIMENTAL|Part 3:Urelumab (BMS-663513) Tumor-specific Cohort Expansions|Enrollment of subjects of three specific tumor types \[(colorectal cancer (CRC), head and neck squamous cell carcinoma (SCCHN), and B-Cell non-Hodgkin's lymphoma (B-NHL)\] who will be treated at the Maximum Tolerated Dose (MTD) (or highest dose tested)
62774725|NCT01471210|EXPERIMENTAL|Part 4:Urelumab (BMS-663513) Cohort Expansion in B-NHL|Arm A and Arm B: Urelumab (BMS-663513) liquid administered intravenously on specified days exploring q3w and q6w dosing regimen
62774726|NCT05024136|ACTIVE_COMPARATOR|Placebo|Subjects take 30 mins aromatherapy of Limon essential oil per time, a total of 3 times for the month.
62774727|NCT05024136|EXPERIMENTAL|Experimental|Subjects take 30 mins aromatherapy of vetiver essential oil per time, a total of 3 times for the month.
62774728|NCT02830620|OTHER|groupe1|cancer of the pancreas WITH syndrome of anorexia-cachexie Dosage of chimiokines
62774729|NCT02830620|OTHER|groupe2|cancer of the pancreas WITHOUT syndrome of anorexia-cachexie Dosage of chimiokines
62774730|NCT02830620|OTHER|groupe3|pure food limitation typifies restrictive anorexia nervosa Dosage of chimiokines
62774731|NCT02830620|OTHER|groupe4|unhurt individual of any appetite-suppressing evolutionary disease and cachectisante Dosage of chimiokines
62774732|NCT05633264||Cohort 1|Psoriasis (PsO) participants who initiate treatment with Deucravacitinib.
62774733|NCT02713659|EXPERIMENTAL|Early Literacy Promotion|Parents and children randomized to the Early Literacy Promotion arm.
62774734|NCT02713659|ACTIVE_COMPARATOR|Standard Literacy Promotion|Parents and children randomized to the Standard Literacy Promotion arm.
62774735|NCT04787991|EXPERIMENTAL|Cohort A: Nivolumab + Ipilimumab + nP/gem|
62215287|NCT04521348|EXPERIMENTAL|ATC arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
62568689|NCT06104020|ACTIVE_COMPARATOR|liberal group (LG)|The liberal group (LG) will receive a 10 mL/kg bolus at anesthesia induction, followed by an intraoperative crystalloid infusion at a rate of 8 mL/kg/hr \[12, 13\].
62215288|NCT04521348|EXPERIMENTAL|DTC unsuitable for RAI arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
62184563|NCT00469859|EXPERIMENTAL|Group 2 (Lestaurtinib: Dose 62.5 mg/m2|"DOSE-FINDING PHASE:~COURSE 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2. Cohorts of 6 patients receive escalating doses of lestaurtinib until a TBAD is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by PIA assay.~COURSE 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Continued (see detailed description)"
62184564|NCT04875897|EXPERIMENTAL|treatment with keepMED PAP device|Therapy night is performed with the keepMED PAP during a polysomnography in the sleep lab
62184565|NCT03984175|EXPERIMENTAL|Patients with ARDS at three Intermountain tertiary hospitals|
62184566|NCT00078728|EXPERIMENTAL|Family-based anxiety prevention program|Participants will complete an 8 session (1 session/week), cognitive behavioral therapy-based, family prevention program to be administered by a trained clinician, after randomization to the study. The prevention program will include 3 booster sessions that take place after the first 8 sessions.
62184567|NCT00078728|ACTIVE_COMPARATOR|Evaluation only|Waitlist control group. Participants in this group will receive general information (in the form of a printed packet) about anxiety after randomization to the study. Families in this group will complete all study evaluations and will then be offered the option of participating in the prevention program. Families who accept will begin the prevention sessions and will receive the same CBT-based, family-based prevention program as the other treatment arm.
62184568|NCT03062345|EXPERIMENTAL|Single-User Mode first, Multi-User Mode second|
62393318|NCT01012765|EXPERIMENTAL|Indacaterol - placebo - tiotropium|In treatment period 1, patients received indacaterol 150µg once daily; in treatment period 2, patients received placebo to indacaterol once daily; in treatment period 3, patients received tiotropium 18µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
62393319|NCT01012765|EXPERIMENTAL|Placebo - Tiotropium - Indacaterol|In treatment period 1, patients received placebo to indacaterol once daily; in treatment period 2, patients received tiotropium 18µg once daily; in treatment period 3, patients received indacaterol 150µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
62393320|NCT01012765|EXPERIMENTAL|Tiotropium - indacaterol - placebo|In treatment period 1, patients received tiotropium 18µg once daily; in treatment period 2, patients received indacaterol 150µg once daily; in treatment period 3, patients received placebo to indacaterol once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
62774736|NCT04787991|EXPERIMENTAL|Cohort B: Hydroxychloroquine + Ipilimumab + nP/gem|
62774737|NCT04787991|EXPERIMENTAL|Cohort C: NG-350A + Ipilimumab + nP/gem|
62184569|NCT03062345|EXPERIMENTAL|Multi-User Mode first, Single-User Mode second|
62184570|NCT02089412|EXPERIMENTAL|E2006: fed conditions|E2006 10-mg will be administered as a single dose under fed treatment conditions.
62184571|NCT02089412|EXPERIMENTAL|E2006: fasted conditions|E2006 10-mg will be administered as a single dose under fasted treatment conditions.
62774738|NCT00438594|NO_INTERVENTION|Control group|Control group
62774739|NCT00438594|EXPERIMENTAL|Paraprofessional home visits|home visitation by Paraprofessional
62774740|NCT00438594|EXPERIMENTAL|Nurse home visits|home visitation by Nurse
62774741|NCT03189836|EXPERIMENTAL|ACTR707 in combination with rituximab|
62774742|NCT05755659|EXPERIMENTAL|Tumor chemotherapy patients|To evaluate the safety of Fosaprepitant Dimeglumine for injection in the prevention of nausea and vomiting caused by tumor chemotherapy drugs
61999071|NCT05009758|ACTIVE_COMPARATOR|CRSwNP in absence of asthma|"* Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and Nasal Polyps Guidelines26~* Evidence of Type 2 inflammation: blood eosinophils \>= 250 cells/µl measured in the blood OR total IgE \>100 kU/L26 at the screening visit~* Absence of asthma and N-ERD~* Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 5 half-lives or at least 3 months have passed"
61999072|NCT02703571|EXPERIMENTAL|Advanced or metastatic solid tumors|Patients in the Phase I portion of the study who have advanced or metastatic solid tumors
62214617|NCT00555594|ACTIVE_COMPARATOR|A|Patients with corneal neovascularization of infectious etiology, steroid reactors, and know glaucoma or glaucoma suspects. They received one dose of 0.1cc of subconjunctival Bevacizumab (Avastin™ Genentech, Inc, USA) in bulbar conjunctiva, 2 mm from the limbus, according to the location of the vessels.
62774743|NCT02492282|EXPERIMENTAL|Closed-Loop|This group includes patients with randomization process be assigned to closed loop intravenous anesthesia; the system evaluates, feeds and acts according to the patient's bispectral index, excluding the anesthesiologist. This system use a variable control of specific therapeutic effect; a target value for this variable (set point); an actuator control (infusion pump), a system (patient) and a control algorithm.
62774744|NCT02492282|ACTIVE_COMPARATOR|Open-Loop|This group includes patients with the randomization process are assigned to open loop in which the application of anesthetics is exclusively with pharmacokinetic parameters using TCI and employs mathematical models drug. For propofol used Schneider model and Minto model for remifentanil based on effective site concentration. Changes will be made by the anesthesiologist according to his criteria, trying to keep the BIS range of 40 and 60.
62393321|NCT01012765|EXPERIMENTAL|Placebo - indacaterol - tiotropium|In treatment period 1, patients received placebo to indacaterol once daily; in treatment period 2, patients received indacaterol 150µg once daily; in treatment period 3, patients received tiotropium 18µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
62393322|NCT01012765|EXPERIMENTAL|Indacaterol - tiotropium - placebo|In treatment period 1, patients received indacaterol 150µg once daily; in treatment period 2, patients received tiotropium 18µg once daily; in treatment period 3, patients received placebo to indacaterol once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
61999073|NCT04594096|EXPERIMENTAL|Immediate Intervention Arm|"Observation periods will be from 4 days post last administration of chemotherapy until the next chemotherapy administration.~All patients will undergo an initial observation period that will span two chemotherapy cycles and will be receiving clinical care as usual determined by the primary oncology team.~Patients enrolled on the immediate arm will start the intervention (telehealth visits) in Time Period 2 (following chemotherapy cycles 3 and 4). During Time Period 3 (following chemotherapy cycles 5 and 6), this arm will resume clinical care as usual."
62393323|NCT01012765|EXPERIMENTAL|Tiotropium - placebo - indacaterol|In treatment period 1, patients received tiotropium 18µg once daily; in treatment period 2, patients received placebo to indacaterol once daily; in treatment period 3, patients received indacaterol 150µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
62393324|NCT06493617|EXPERIMENTAL|Control Group|received a standard physical therapy program of nerve glide, hand strengthening exercise and mobilization
62774745|NCT02895945|EXPERIMENTAL|BAX 802 in Surgery|Participants who are undergoing major or minor elective surgical, dental, or other invasive procedures.
61999074|NCT04594096|EXPERIMENTAL|Delayed Intervention Arm|"Observation periods will be from 4 days post last administration of chemotherapy until the next chemotherapy administration.~All patients will undergo an initial observation period that will span two chemotherapy cycles and will be receiving clinical care as usual determined by the primary oncology team.~Patients enrolled on the delayed arm will receive clinical care as usual during Time Period 2 (following chemotherapy cycles 3 and 4). During Time Period 3 (following chemotherapy cycles 5 and 6), this arm will start the intervention (telehealth visits)."
62215289|NCT01010347|ACTIVE_COMPARATOR|Splint|Preformed velcro volar splints are compared to traditional circumferential casting.
62215290|NCT01010347|PLACEBO_COMPARATOR|Cast|The circumferential cast is the standard of treatment against which the splint is compared.
62774746|NCT01147848|EXPERIMENTAL|Fluticasone furoate/Vilanterol (GW642444)|Fluticasone furoate/vilanterol inhalation powder once daily + placebo inhalation powder twice daily for 24 weeks
61999075|NCT00064246|EXPERIMENTAL|Treatment (rituximab, yttrium Y 90 ibritumomab tiuxetan)|"Phase I: Patients receive rituximab IV and indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo 2 (or 3 if needed) imaging scans between days 1-6. In the absence of altered biodistribution, patients receive rituximab IV followed within 4 hours by IDEC-Y2B8 IV over 10 minutes on day 8.~Phase II: Patients receive treatment as in phase I at the MTD of IDEC-Y2B8. Patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 2 years."
61999076|NCT01465464|EXPERIMENTAL|Orantinib|
61999077|NCT01465464|PLACEBO_COMPARATOR|Placebo|
61999078|NCT02643251|EXPERIMENTAL|Clonidine Hydrochloride Topical Gel,0.1%|Clonidine Hydrochloride Topical Gel,0.1%
61999079|NCT02643251|PLACEBO_COMPARATOR|Clonidine Hydrochloride Gel Comparator|Clonidine Hydrochloride Gel Comparator
62774747|NCT01147848|ACTIVE_COMPARATOR|Fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol inhalation powder twice daily + placebo inhalation powder once daily for 24 weeks
62774748|NCT04022980|EXPERIMENTAL|Stage 1|Safety Run-In
62774749|NCT04022980|EXPERIMENTAL|Stage 2|Expansion Cohort
61999080|NCT00086580|EXPERIMENTAL|Combination Arm (FluCAM)|
61999081|NCT00086580|ACTIVE_COMPARATOR|Fludarabine Alone|
61999082|NCT05091528|EXPERIMENTAL|SBT6050 + T-DXd (5.4 mg/kg)|SBT6050 plus trastuzumab deruxtecan
61999083|NCT05091528|EXPERIMENTAL|SBT6050 + T-DXd (6.4 mg/kg)|SBT6050 plus trastuzumab deruxtecan
61999084|NCT05091528|EXPERIMENTAL|SBT6050 + Tucatinib + Trastuzumab + Capecitabine|SBT6050 plus tucatinib, trastuzumab, and capecitabine
61999085|NCT05091528|EXPERIMENTAL|SBT6050 + Tucatinib + Trastuzumab|SBT6050 plus tucatinib and trastuzumab
62393325|NCT06493617|EXPERIMENTAL|Study Group|received a cervical mobilization in addition to the standard physical therapy program for 12 sessions
62393326|NCT03887143||Arterial ischemic stroke in patients less than 18 years old|"Patients \< 18 years old~* Suspected or confirmed cerebral infarction~* With recanalization treatment in the acute phase: intra-venous thrombolysis +/- intra-arterial thrombolysis +/- thrombectomy~* Patients treated between January 2015, 1st and May 2018, 31st"
62393327|NCT04226209|EXPERIMENTAL|PSSE|Physiotherapeutic Scoliosis-Specific Exercises PSSE group will receive corrective exercise for scoliosis
62774750|NCT06254924|EXPERIMENTAL|QI App Users|Participants will be asked to use the QI App once per day for 5-10 minutes per day for 6 weeks.
62774751|NCT06254924|EXPERIMENTAL|Parents/Guardians of QI App Users|Parents/guardians of QI App users will be aware that their child is using the QI App once per day for 5-10 minutes per day for 6 weeks.
61999086|NCT04409821|EXPERIMENTAL|Tele-delivered psychological intervention|Weekly tele-delivered psychological intervention
61999087|NCT00578500|ACTIVE_COMPARATOR|OCCT|Patients referred to ovarian cryopreservation.
61999088|NCT05207124||Botulinum toxin injection group|onabotulinumtoxinA
61999089|NCT01652716|EXPERIMENTAL|Exenatide once weekly suspension|Exenatide suspension 2 mg weekly subcutaneous injection
61999090|NCT01652716|ACTIVE_COMPARATOR|Exenatide twice daily (BID)|Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks
61999091|NCT02884089|PLACEBO_COMPARATOR|Placebo + Metformin|Single dose of placebo administered orally followed by a single dose of metformin administered orally in one of four study periods.
61999092|NCT02884089|EXPERIMENTAL|Abemaciclib + Metformin|Single dose of abemaciclib administered orally followed by a single dose of metformin administered orally in one of four study periods.
61999093|NCT02884089|PLACEBO_COMPARATOR|Placebo + Iohexol|Single dose of placebo administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
61999094|NCT02884089|EXPERIMENTAL|Abemaciclib + Iohexol|Single dose of abemaciclib administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
61999095|NCT04055857||NIID|NIID patients
61999096|NCT04055857||HC|healthy control
61999097|NCT06430619||Patients diagnosed with Acute Respiratory Distress Syndrome (ARDS) according to Berlin criteria|The oxygenation indexes of the patients will be measured and the effectiveness of these indexes in diagnosing ARDS will be compared.
61999098|NCT03925324|EXPERIMENTAL|Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.
61999099|NCT03925324|PLACEBO_COMPARATOR|Placebo|Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.
62215291|NCT04556903|EXPERIMENTAL|Bilateral Arm Training|Bilateral Arm Training
62215292|NCT04556903|ACTIVE_COMPARATOR|modified constrained induce movement therapy|modified constrained induce movement therapy
62215293|NCT01579279|EXPERIMENTAL|ABT-652 6 mg|ABT-652 capsules - twice daily
61999100|NCT02953899|EXPERIMENTAL|Contingency Management|This is a treatment where participants earn points for treatment attendance and for providing evidence of gambling abstinence. These points are added to study accounts that can be redeemed for goods and services available at a variety of on-line businesses (e.g., Amazon, Walmart, etc.). Submission of evidence of gambling behaviour or non-attendance at an on-line counselling session re-sets subsequent points to the starting level. The CM procedure is implemented as part of the CBT counselling session.
61999101|NCT02953899|ACTIVE_COMPARATOR|Cognitive Behavioural Therapy|"CBT is currently considered best practice for the treatment of problem gambling, as noted in the National Health and Medical Research Council (Australia) endorsed Clinical Guidelines for problem and pathological gambling treatment (Problem Gambling Research and Treatment Centre, 2011). CBT is typically a semi-structured approach for delivering cognitive behavioural therapy addressing the participant's experiences, thoughts, and emotions relating to their gambling and substance use. Techniques include psychoeducation, behavioural interventions, and cognitive strategies. Participants are expected to attend on-line counselling sessions three times a week for approximately 12 weeks. All participants will receive individual counselling from an experienced counsellor/therapist."
61999102|NCT02619409|PLACEBO_COMPARATOR|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
61999103|NCT02619409|ACTIVE_COMPARATOR|EPI25 group|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
62393328|NCT04226209|NO_INTERVENTION|Control|Control group will be taken to the queue list.
61999104|NCT02619409|ACTIVE_COMPARATOR|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc.
61999105|NCT02619409|ACTIVE_COMPARATOR|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075 cc, and sterile saline 0.025%.
61999106|NCT02619409|ACTIVE_COMPARATOR|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc
61999107|NCT03450707|EXPERIMENTAL|Thiamine|Patients randomized to the thiamine arm will receive thiamine 500mg in 100mL of normal saline intravenously every 12 hours for 5 doses. Patients will be connected to a noninvasive monitor for measurement of global oxygen consumption (VO2) for at least 48 hours or until extubated, whichever comes first. Blood will be drawn at 0,6,12,24,72 and 168 hours for measurement of lactate, thiamine level, pyruvate dehydrogenase, NSE, S100 and other markers of organ injury. CPC-E score will be assessed prior to hospital discharge and at 30 and 90 days to evaluate differences in neurologic and functional impairment.
61999108|NCT03450707|PLACEBO_COMPARATOR|Placebo|Patients randomized to placebo will receive 100mL normal saline intravenously every 12 hours for 5 doses. All other aspects of the protocol will be the same as in the experimental arm. Patients will be connected to a noninvasive monitor for measurement of global oxygen consumption (VO2) for at least 48 hours or until extubated, whichever comes first. Blood will be drawn at 0,6,12,24,72 and 168 hours for measurement of lactate, thiamine level, pyruvate dehydrogenase, NSE, S100 and other markers of organ injury. CPC-E score will be assessed prior to hospital discharge and at 30 and 90 days to evaluate differences in neurologic and functional impairment.
61999109|NCT03761732|EXPERIMENTAL|PTSD lay-led group treatment program|The group will go through the Islamic Trauma Healing Program
61999110|NCT02150668|EXPERIMENTAL|HOPS Intervention|School counselors deliver HOPS intervention to students during the school day. This includes 16, 20-minute sessions with the student and two joint family meetings.
61999111|NCT02150668|ACTIVE_COMPARATOR|HSI Intervention|School counselors deliver the HSI intervention which focuses on improving focus and efficiency of work completion. This consists of 16, 20-minute sessions, with the student and two joint family meetings.
61999112|NCT05826964|EXPERIMENTAL|Step 2 Arm 1: No Modification of Therapy|"Participants in Step 2 Arm 1 will first undergo ctDNA monitoring in Step 1, providing blood samples for ctDNA testing at the following timepoints until a rise in ctDNA leading to a ratio (ctDNA result at time of assessment/ctDNA level at baseline) greater than (\>) 1 occurs:~* Cycle 1 day 1 (C1D1),~* Day 30 (D30) post-treatment initiation (±3 days),~* Day 60 (D60) post-treatment initiation (±3 days), and then~* every 8-9 weeks (±1 week).~Participants will have no change in standard of care therapy administered in Step 1."
61999113|NCT05826964|EXPERIMENTAL|Step 2 Arm 2: Early Switch in Therapy|"Participants in Step 2 Arm 2 undergo an early switch in standard of care therapy received in Step 1:~* From AI+CDK4/6i in Step 1 to one of the following alternate endocrine therapies (ET) or chemotherapy:~  * SERD+CDK4/6i~ * mTOR Inhibitor + AI~ * mTOR Inhibitor+SERD~ * mTOR inhibitor + Selective estrogen receptor modulator~ * PI3K inhibitor + SERD~ * oral SERD~ * Chemotherapy~* From SERD+CDK4/6i in Step 1 to one of the following alternate ET or chemotherapy:~  * mTOR Inhibitor + AI~ * mTOR Inhibitor+SERD~ * mTOR inhibitor + Selective estrogen receptor modulator~ * PI3K inhibitor + AI~ * PI3K inhibitor + SERD~ * oral SERD~ * Chemotherapy~Participants will receive this therapy for approximately 14 months."
62214618|NCT00555594|ACTIVE_COMPARATOR|B|Patients with corneal neovascularization of any cause except for infectious disease. Patients of this group received one application of 0.1cc of subconjunctival Bevacizumab™ + 0.1cc of triamcinolone acetonide (ATLC; Grin laboratories, México city) in bulbar conjunctiva, 2 mm from de limbus, according to the location of the vessels.
62215294|NCT01579279|EXPERIMENTAL|ABT-652 12 mg|ABT-652 capsules twice daily
62393329|NCT05689645|EXPERIMENTAL|F573 for injection groups|"The first 16 patients with liver injury were given doses of 0.5, 1.0 and 2.0 mg/kg,2 mL intramuscular injection (IM), once a day for 7 days,and the subsequent 9 patients with CHB were given doses of 2 mL intramuscular injection (IM), once a day for 7 days, according to the results of the efficacy and safety trials of the first 16 patients. The dosage of the second stage was determined according to the results of efficacy and safety trials of the the first stage . The dosage volume was 2 mL by intramuscular injection (IM), once a day for 14 days.The dosage of the third stage was determined according to the results of the first and second stage efficacy and safety trials. The dosage volume was 2 mL and intramuscular injection (IM) was administered once a day for 28 consecutive days.~The dosage of the above three stages of administration was calculated according to the weight of the most recent visit."
62568690|NCT02332226|EXPERIMENTAL|Representational approach|Four sessions with a nurse. For each session, the parent identifies an area where he/she needs more information. The nurse and the parent jointly survey the parent's knowledge of the area and discusses consequences of knowledge gaps or misunderstandings. Then, new information is introduced and benefits from the new information is discussed.
62568691|NCT02332226|NO_INTERVENTION|Control|Standard care as per ward protocol.
61999114|NCT05826964|EXPERIMENTAL|Step 3: Optional Treatment for Patients in Arm 1|Optional for participants who were randomized to Step 2 Arm 1 and experience clinical progression. Participants may change from their AI+CDK4/6i to SERD+CDK4/6i, or from SERD+CDK4/6i treatment to alternative endocrine therapy or chemotherapy. Therapy options for Step 3 are the same as listed for participants randomized to Step 2 Arm 2 and is administered standard of care. For those patients who decline to crossover into Step 3, further treatment and disease management will occur at their treating physician's discretion.
61999115|NCT05137873||Surgery before 6 months of age|Babies with heart disease surgery, great vessels transposition surgery type before 6 months of age
61999116|NCT02995291|PLACEBO_COMPARATOR|Control|1.7ml saline water
61999117|NCT02995291|EXPERIMENTAL|OraVerse|1.7ml OraVerse
62393330|NCT05689645|PLACEBO_COMPARATOR|Placebo Comparator|"1. The first stage: the first 16 patients with liver injury,and the subsequent 9 patients with CHB were treated with Sterilizing water for injection , the dose volume was 2 mL, intramuscular injection (IM), once a day for 7 consecutive days, Basic treatment: receiveDiammonium glycyrrhizate enteric-coated capsules at a dose of 150 mg 3 times a day.~2. The second stage: the dosage volume was 2 mL by intramuscular injection (IM) once a day for 14 days.Basic treatment: receiveDiammonium glycyrrhizate enteric-coated capsules at a dose of 150 mg 3 times a day.~3. The third stage: the Screen eligible subjects were treated with Sterilizing water for injection. The dose volume was 2 mL, intramuscular injection (IM), once a day for 28 consecutive days. Basic treatment: receive acetylcysteine injection at a dose of 8 g / d once a day."
62393331|NCT05416086|OTHER|iCLAS Cryoablation arm|all subjects will receive a cryoablation procedure with the iCLAS System and be followed up for 12-month
62393332|NCT02221804|EXPERIMENTAL|COPD - reduced activity levels|COPD patients who have voluntarily decreased their daily physical activity levels to no more than 1500 steps/day for 14 days.
62393333|NCT02221804|EXPERIMENTAL|Healthy - reduced activity levels|Healthy age-matched controls who have voluntarily decreased their daily physical activity levels to no more than 1500 steps/day for 14 days.
61999118|NCT00917891|PLACEBO_COMPARATOR|vehicle placebo gel|
61999119|NCT00917891|EXPERIMENTAL|dapivirine gel|
61999120|NCT01266668||Primary breast DLBCL|Primary breast DLBCL was defined as that involving single extranodal organ (i.e. breast) regardless of the status of nodal disease.
61999121|NCT01266668||Nodal DLBCL|The disease was only limited to the lymph nodes or lymphoid organs without extranodal organ involvements.
62215295|NCT01579279|EXPERIMENTAL|ABT-652 12 mg - 18 mg|ABT-652 capsules twice daily
62393334|NCT02221804|NO_INTERVENTION|COPD - unchanged activity levels|
62568692|NCT06576180||Neoadjuvant therapy+ Surgery group( Group A)|The patient was diagnosed with head and neck squamous cell carcinoma (stage I-IVA), untreated, and planned to undergo surgical treatment + combined chemotherapy and immunotherapy.
62774752|NCT06258096|EXPERIMENTAL|Photobiomodulation therapy (PBMT)|Patients will receive either PBMT or sham-PBMT during admission to the hospital. The oral cavity of the patients will be exposed to LED light using a new intra-oral device on the THOR Control Unit at the intensity of 50mW/m2 for 60 seconds per dose. Additionally, the perioral region will be exposed to LED light using an extra-oral device on the THOR Control Unit at the intensity of 50mW/m2 for 60 seconds per dose.
62774753|NCT06258096|SHAM_COMPARATOR|Sham-PBMT|Patients will receive either PBMT or sham-PBMT during admission to the hospital. The sham-PBMT is the placebo treatment and consists of light of the same colour (white light with a red filter), applied in the same way as in the experimental group.
62774754|NCT04036929|EXPERIMENTAL|Estrogen-bazedoxifene|Tablet, once daily for 6 months.
62774755|NCT04036929|PLACEBO_COMPARATOR|Placebo|Closely matched tablet, once daily for 6 months.
62774756|NCT00826670|EXPERIMENTAL|Topical decolonization|
62774757|NCT00826670|PLACEBO_COMPARATOR|Placebo|
62568693|NCT06576180||Direct surgery group (Group B)|The patient was diagnosed with head and neck squamous cell carcinoma (stage I-IVA), untreated, and planned to undergo surgery.
62774758|NCT02024126|EXPERIMENTAL|High dosage exercise therapy|The high-dosage exercise treatment will be conducted under supervision of experienced physiotherapists, and it follows an exercise protocol previously described as Medical Exercise Therapy, MET. The regimen contains different semi-global and local exercises for the knee. To be able to reach a high number of repetitions despite ongoing pain, the principle of de-loading (reducing weight) will be applied. The use of de-loading allows high number of repetitions nearly or entirely pain free. Later, as the patient improves and tolerates increased loading, the exercises are adapted to be more functional, using closed chain exercises without de-loading the body. Each of the exercises will be performed in 3 sets of 30 repetitions with 30-60s rest in between. Global exercises using a stationary bike will be performed three times during one treatment-session; first 20 minutes as global pain modulation, ten minutes in the middle of the treatment, and then ten minutes at the end of the treatment.
62774759|NCT02024126|ACTIVE_COMPARATOR|Lower dosage exercise therapy|Patients in the comparison-/control group will perform six exercises, of which, five will be in 2 sets of 10 repetitions combining local and semi-global exercises, again using the principle of de-loading. The five semi-global and local exercises are the same as performed in the MET-group, and the regimen will be supervised in the same manner as for the MET-group. The therapy starts with 10 minutes using a stationary bike, and the same principles will be applied as for the MET-group regarding grading and follow-up with exercises and adjusting the exercises so that they are performed close to pain-free.
62774760|NCT00684827|EXPERIMENTAL|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses).~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. An AeroChamber Plus spacer will be utilized for each dose"
62774761|NCT00684827|ACTIVE_COMPARATOR|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. An AeroChamber Plus spacer will be utilized for each dose.
62774762|NCT02533895|EXPERIMENTAL|Treatment with AV0113|"14 sarcoma and 7 non-sarcoma are treated with AV0113, an anti-tumour immune therapy with autologous DCs loaded with tumour cell lysates in order to establish the feasibility and safety of tumour vaccination.~Peripheral blood mononuclear cells (MNCs) are obtained from patients by leukocyte apheresis. Monocytes enriched by density gradient centrifugation from MNCs will be used to generate immature DCs. These immature DCs will be loaded with autologous tumour cell lysates obtained by needle biopsy or surgery prior to tumour vaccination. The antigen loaded immature DCs will then receive a final maturation stimulus transmitted by exposure to lipopolysaccharide and interferon-gamma. Maturation enables DCs to present antigen with high efficiency to T-lymphocytes."
62774763|NCT02533895|OTHER|Historic control|In order to be able to compare the survival data of 14 sarcoma patients treated with AV0113, 42 historic control sarcoma patients from the data base of the Department of Orthopaedics, Medical University Vienna, that will be matched for disease, recurrences, relapses etc. will be included into this study.
62774764|NCT04093986||Retrospective Chart Review|Medical record chart review of women seen previously for clinical care prior to June 20, 2019 at participating institutions with SCD and hydroxyurea exposure during gestation or lactation will be identified by healthcare providers.
62774765|NCT04093986||Participant Survey and Retrospective Chart Review|Participants providing their medical records without the assistance of a health care provider will be asked to complete a questionnaire through REDCap and will have the option to upload their deidentified medical records if they are available.
61999122|NCT03640676|SHAM_COMPARATOR|INP -10mmHg|In addition to standard medical treatment, patients will receive treatment with FlowOx, applying intermittent negative pressure of -10mmHg one hour in the morning and one hour in the evening at home for 12 weeks.
61999123|NCT03640676|ACTIVE_COMPARATOR|INP -40mmHg|In addition to standard medical treatment, patient swill receive treatment with FlowOx, applying intermittent negative pressure of -40mmHg one hour in the morning and one hour in the evening at home for 12 weeks.
62568694|NCT06576180||Healthy people (Group C)|Healthy people
61999124|NCT01583010|NO_INTERVENTION|Standard Treatment Group|Patients receiving ultrasound guided regional anaesthesia without using Advanced Needle Visualization Technology(R)
62568695|NCT03711708|EXPERIMENTAL|Zoloft Oral Solution|50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water.
62568696|NCT03711708|ACTIVE_COMPARATOR|Zoloft Tablets|Zoloft 50 mg tablet.
62568697|NCT03524417|EXPERIMENTAL|RIG injection|RIG injection on day 7
62214619|NCT01035359|ACTIVE_COMPARATOR|external fixation|Operation with external fixation and optional addition of k-wire
62393335|NCT02337816||Endometriosis|Patients will undergo laparoscopic surgery in order to treat endometriosis. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood, with the purpose to study metabolitis, will be collected before surgery.
62393336|NCT02337816||Controls|Patients will undergo laparoscopic surgery in order to treat benign gynecological diseases. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood,with the purpose to study metabolitis, will be collected before surgery.
62774766|NCT04246723|EXPERIMENTAL|Cohort A (Narlaprevir + Ritonavir + Sofosbuvir for 12 weeks)|"All of enrolled patients receive equal study therapy with Narlaprevir 200 mg Once a day (QD)/Ritonavir 100 mg QD/Sofosbuvir 400 mg QD orally for 12 weeks. Narlaprevir should be taken with ritonavir and food and should be taken at approximately the same morning time each day.~Sofosbuvir can be taken with or without meals."
62774767|NCT04246723|EXPERIMENTAL|Cohort B (Narlaprevir + Ritonavir + Sofosbuvir for 8 weeks)|"All of enrolled patients receive equal study therapy with Narlaprevir 200 mg QD (once daily)/Ritonavir 100 mg QD/Sofosbuvir 400 mg QD orally for 8 weeks. Narlaprevir should be taken with ritonavir and food and should be taken at approximately the same morning time each day.~Sofosbuvir can be taken with or without meals."
62774768|NCT03225924|EXPERIMENTAL|Experimental|Entospletinib + Rituximab + Cyclophosphamide + Doxorubicine + Vincristine + Prednisone
62774769|NCT00895453|ACTIVE_COMPARATOR|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid).
62774770|NCT00895453|ACTIVE_COMPARATOR|itraconazole + lactobacilli agent|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid). Additionally, Lactobacillus vaginal tablets monthly given through 6 days.
62774771|NCT00895453|ACTIVE_COMPARATOR|classic homeopathy (CH)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
62774772|NCT03946085|EXPERIMENTAL|Lumega-Z group|Participants assigned the study supplement Lumega-Z.
62774773|NCT03946085|ACTIVE_COMPARATOR|AREDS2 group|Participants assigned the AREDS2 supplement
62568698|NCT00855894|EXPERIMENTAL|Pertuzumab + erlotinib|Patients received pertuzumab 840 mg intravenously (IV) 1 time (loading dose) followed by 420 mg IV (maintenance dose) every 3 weeks (q3w) plus erlotinib 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.
62774774|NCT03946085|NO_INTERVENTION|Control|Participants are determined ocular normal after clinical examination and do not have retinal drusen.
61999125|NCT01583010|ACTIVE_COMPARATOR|ANV ® Group|Patients receiving ultrasound guided regional anaesthesia with using Advanced Needle Visualization Technology(R)
61999126|NCT04915404|EXPERIMENTAL|pK Assessment of Berubicin and its active metabolite|The first 18 patients will undergo a pK assessment of Berubicin and it's active metabolite Berubicinol during the dosing days of the first two cycles. After 18 patients are done n intern analysis will new performed.
61999127|NCT05314686||Technical validity of data transmitted remotely.|The first twenty participants will participate in the step of the study aimed at assessing the technical validity of data transmitted remotely from devices connected to the telerehabilitation system.
62393337|NCT04781127|EXPERIMENTAL|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
62393338|NCT04673760|EXPERIMENTAL|Arm 1: Structured specialized palliative home care|Eligible specialist palliative home care teams provide ambulant specialised palliative care as usual
62393339|NCT04673760|NO_INTERVENTION|Arm 2: No care of specialist palliative home care teams at study inclusion|No care from specialist palliative home care teams at study inclusion
62568699|NCT00925444|EXPERIMENTAL|FOREseal|
62568700|NCT00925444|ACTIVE_COMPARATOR|Stapling|
62774775|NCT06056856|ACTIVE_COMPARATOR|PSG group|The group of patients who will undergo penile skin graft substitituion of long anterior urethral stricture
62774776|NCT06056856|ACTIVE_COMPARATOR|BMG group|The group of patients who will undergo buccal mucosal graft substitituion of long anterior urethral stricture
62774777|NCT04477057|OTHER|one arm|one arm
62774778|NCT00812565|PLACEBO_COMPARATOR|Placebo every 2 weeks|Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).
61999128|NCT05314686||Clinical feasibility.|The last twenty participants will perform their pulmonary rehabilitation program at home using the telerehabilitation system over an eight-week period.
61999129|NCT01024543|SHAM_COMPARATOR|Placebo|Placebo
61999130|NCT01024543|EXPERIMENTAL|Angiotensin II|Angiotensin II
61999131|NCT01024543|ACTIVE_COMPARATOR|Phenylephrine|Phenylephrine
62393340|NCT06157970||Block Group|After intubation, the plastic part of the 18G angioket is placed transnasally into both nostrils in the supine position of the patients who will undergo sphenopalatine ganglion block, with the head in 15-20° extension and is advanced until it contacts the posterior mucosa. After contact, withdraw 1 mm and apply 0.5% bupivacaine 2 ml by dropping into the postnasal space within 1 minute.
62568701|NCT02699346|EXPERIMENTAL|HS-1000 recording|Eligible patients and healthy subjects will be enrolled into the study and HS-1000 headset portion of the device will be placed in their ears. HS-1000 monitoring intervals will last from 20 minutes continuously. Following completion of data collection, HS-1000 will be removed.
62568702|NCT02562001|EXPERIMENTAL|Outpatient active group|This group will receive active tDCS, combined with Lokomat gait training
62568703|NCT02562001|EXPERIMENTAL|Inpatient active group|This group will receive active tDCS, combined with Lokomat gait training
62568704|NCT02562001|EXPERIMENTAL|Outpatient placebo group|This group will receive placebo tDCS, combined with Lokomat gait training
62774779|NCT00812565|EXPERIMENTAL|0.1 g/kg octagam 10% every 2 weeks|Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).
62774780|NCT00812565|EXPERIMENTAL|0.25 g/kg octagam 10% every 2 weeks|Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).
62774781|NCT00812565|EXPERIMENTAL|0.4 g/kg octagam 10% every 2 weeks|Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).
62774782|NCT00812565|PLACEBO_COMPARATOR|Placebo every 4 weeks|Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).
62774783|NCT00812565|EXPERIMENTAL|0.2 g/kg octagam 10% every 4 weeks|Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).
62774784|NCT00812565|EXPERIMENTAL|0.5 g/kg octagam 10% every 4 weeks|Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).
62774785|NCT00812565|EXPERIMENTAL|0.8 g/kg octagam 10% every 4 weeks|Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).
62774786|NCT03131882|EXPERIMENTAL|Hyaluronic acid|Hyaluronic acid
62774787|NCT03131882|ACTIVE_COMPARATOR|Triamcinolone acetonide|10mg/ml Triamcinolone acetonide
62774788|NCT04364620|EXPERIMENTAL|Arm AB-16B5 and Docetaxel|AB-16B5 at a dose of 12 mg/kg once weekly on Days 1, 8 and 15 combined with docetaxel at a dose of 75 mg/m2 once every 3 weeks on Day 1.
62774789|NCT06407102|OTHER|Patient with programmed surgery|Patient programmed with surgery of meatotomy, septoplasty or turbinoplasty, or other programmed surgeries
62774790|NCT03134183|EXPERIMENTAL|Vaginal Misoprostol|Intervention is misoprostol versus placebo 400mcg misoprostol formulated within cocoa butter suppository
62774791|NCT03134183|EXPERIMENTAL|Buccal Misoprostol|Intervention is misoprostol versus placebo 400mcg misoprostol formulated within mint flavored powder
62774792|NCT03623009|EXPERIMENTAL|Intervention|An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
62774793|NCT03623009|SHAM_COMPARATOR|Control|The control arm will receive a neutral article prior to completing the assessment.
61999132|NCT02690675|EXPERIMENTAL|Intervention high-iron fortified milk|This group received a high dose of iron by formula milk (1.2mg/100mL) between 6 and 12 months of age.
61999133|NCT02690675|EXPERIMENTAL|Intervention low-iron fortified milk|This group received a low dose of iron by formula milk (0.4mg/100mL) between 6 and 12 months of age.
61999134|NCT00418691|ACTIVE_COMPARATOR|Immediate Release (IR) Methylphenidate|10 mg by mouth (PO) twice daily for 4 Weeks
61999135|NCT00418691|ACTIVE_COMPARATOR|Sustained Release (SR) Methylphenidate|200 mg PO once daily for 4 Weeks
61999136|NCT00418691|ACTIVE_COMPARATOR|Modafinil|18 mg PO once daily for 4 Weeks
61999137|NCT03839589|EXPERIMENTAL|MBSR-A|Intervention Mindfulness Condition: MBSR is a structured intervention delivered through an 8-week course. Mindful breathing, awareness, walking, and attention are core activities taught and practiced during and outside of the course.
61999138|NCT03839589|PLACEBO_COMPARATOR|Wait-listed MBSR-A|The MBSR-A Wait-listed group: This wait-listed group will be followed with the same outcome assessments as the MBSR- A immediate group but will receive no intervention until after outcomes from group 1 are collected at 3 months, when they will also receive the MBSR-A
61999139|NCT03525197|EXPERIMENTAL|Whey protein-based supplement|Participants in the experimental condition will consume a supplement containing Whey Protein Isolate (20g) and other ingredients
61999140|NCT03525197|ACTIVE_COMPARATOR|Collagen protein-based supplement|Participants in the experimental condition will consume a supplement containing Collagen protein (20g) and other ingredients
62393341|NCT06157970||Control Group|Group of patients who did not undergo sphenopalatine gangion block
62393342|NCT04143815|EXPERIMENTAL|MBA-P01 30U|Experimental group, Dose: 30U
62393343|NCT04143815|EXPERIMENTAL|MBA-P01 20U|Experimental group, Dose: 20U
62774794|NCT00837603|ACTIVE_COMPARATOR|Training|Ergometer Training
62774795|NCT00837603|NO_INTERVENTION|2|Counseling
62774796|NCT00518297|ACTIVE_COMPARATOR|1|
62774797|NCT00518297|ACTIVE_COMPARATOR|2|
62774798|NCT00518297|ACTIVE_COMPARATOR|3|
62774799|NCT05476523||Healthy Data Collection|As a part of the study, a group of up to 2000 healthy subjects will undergo a NeuraLight session including oculometric measurements and eye-tracking recordings using a novel software-based platform and an eye-tracking system (approx. 15 minutes). The oculometric evaluation will occur for every patient 1 time, and all subjects will be recruited over a period of 36 months. All assessments will be performed during a clinic visit unless authorized to be conducted remotely
62774800|NCT00514462|EXPERIMENTAL|A|low level laser instrument (Painless Light PL-830, Advanced Chips \& Products Crop., USA)
62774801|NCT00028574|ACTIVE_COMPARATOR|Gabapentin (28 days)|Oral Gabapentin 300 mg days 1-28
62774802|NCT00028574|ACTIVE_COMPARATOR|Gabapentin (7, 21)|Oral Gabapentin 300 mg once daily on days 1-7 days and twice daily days 8-28
62184572|NCT05168709|EXPERIMENTAL|Approved COVID-19 vaccination|The approved COVID-19 vaccination arm will receive the COMIRNATY™ (tozinameran - BNT162b2 \[mRNA\]) COVID-19 VACCINE. The dose, strength of the dose unit, dosing interval and dosing period of tozinameran used in this trial will be as approved by the Therapeutic Goods Administration (TGA) and recommended by the Australian Technical Advisory Group on Immunisation (ATAGI) for children aged 5 to \<12 years of age. The recommended dose of tozinameran for this age group is 10 µg (0.2 mL) and the recommended schedule is 2 doses, 8 weeks apart. Therefore two tozinameran doses of 10µg (0.2 mL) will be administered intramuscularly 8-weeks apart as part of this arm of the trial.
62774803|NCT00028574|ACTIVE_COMPARATOR|Gabapentin (7, 7, 14)|Oral Gabapentin 300 mg once daily on days 1-7, twice daily on days 8-14 and three times daily on days 15-28
62184573|NCT04761692|EXPERIMENTAL|Arm 1|This arm will include 5 churches who will receive all study activities in the Vaccine Education Promotion Management Plan
62184574|NCT04761692|EXPERIMENTAL|Arm 2|This arm will include 5 churches who will receive some study activities in the Vaccine Education Promotion Management Plan
62184575|NCT04761692|EXPERIMENTAL|Arm 3|This arm will include 5 churches who will receive all study activities in the Vaccine Education Promotion Management Plan following completion of Arm 1 and 2.
62184576|NCT05603065|ACTIVE_COMPARATOR|Chemotherapy|
62184577|NCT05603065|ACTIVE_COMPARATOR|Radiotherapy|
62184578|NCT05930808|EXPERIMENTAL|First Test Concor (Fasted), Then Reference Concor (Fasted)|Participants will receive a single oral dose of Test Concor tablet on Day 1 in treatment period 1 followed by single oral dose of reference Concor tablet on Day 8 in treatment period 2 under fasted condition. There will be separate washout period of 7 days between each treatment period.
62184579|NCT05930808|EXPERIMENTAL|First Reference Concor (Fasted), Then Test Concor (Fasted)|Participants will receive a single oral dose of Reference Concor tablet on Day 1 in treatment period 1 followed by single oral dose of Test Concor tablet on day 8 in treatment period 2 under fasted condition. There will be separate washout period of 7 days between each treatment period.
62184580|NCT05930808|EXPERIMENTAL|First Test Concor (Fed), Then Reference Concor (Fed)|Participants will receive a single oral dose of Test Concor tablet on Day 1 in treatment period 1 followed by a single oral dose of Reference Concor tablet on Day 8 in treatment period 2 under fed condition. There will be separate washout period of 7 days between each treatment period.
62184581|NCT05930808|EXPERIMENTAL|First Reference Concor (Fed), Then Test Concor (Fed)|Participants will receive a single oral dose of Reference Concor tablet on Day 1 in treatment period 1 followed by a single oral dose of Test Concor tablet on Day 8 in treatment period 2 under fed condition. There will be separate washout period of 7 days between each treatment period.
62393344|NCT04143815|EXPERIMENTAL|MBA-P01 10U|Experimental group, Dose: 10U
62393345|NCT04143815|PLACEBO_COMPARATOR|Placebo|Placebo group, Normal saline
62568705|NCT02562001|EXPERIMENTAL|Inpatient placebo group|This group will receive placebo tDCS, combined with Lokomat gait training
62774804|NCT00028574|PLACEBO_COMPARATOR|Placebo|"Oral Placebo 300 mg on one of the following schedules:~* once daily on days 1-28~* once daily on days 1-7, twice daily on days 8-28~* once daily on days 1-7, twice daily on days 8-14 and three times daily on days 15-28"
62568706|NCT01889329|EXPERIMENTAL|RUTF-1|Made from local food ingredients
62568707|NCT01889329|EXPERIMENTAL|RUTF-2|Made from local food ingredients
62774805|NCT00667667|ACTIVE_COMPARATOR|1|vertical vibration device (using Vibrafit whole body vibration platforms)
62184582|NCT02582398|EXPERIMENTAL|Light Therapy|One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.
62214620|NCT01035359|EXPERIMENTAL|Volar plate|Operation with a Synthes volar two column plate (TCP)
62214621|NCT05185934|ACTIVE_COMPARATOR|Food supplement Endocalyx|Thirty patients with COVID-19 infection will randomized to receive 4 capsules a day of the food supplement Endocalyx for 4 months.
62568708|NCT01889329|ACTIVE_COMPARATOR|Plumpynut|Made from peanut
62214622|NCT05185934|PLACEBO_COMPARATOR|Placebo|Thirty patients with COVID-19 infection will randomized to receive 4 capsules a day of the placebo for 4 months.
62214623|NCT05927662||Type 2|Patients with Roussouly type 2 sagittal profile
62214624|NCT05927662||Type 1,3,4|Patients with other Roussouly type sagittal profiles (1,3,4)
62214625|NCT01453543|EXPERIMENTAL|Deep transverse friction massage|Massage technique will be used.
62214626|NCT04948281||Infection Group|A group of joint infection patients after arthroscopic ACL reconstruction surgery , diagnose was made according to American CDC criteria of joint infection
62214627|NCT04948281||Control Group|A group of patients which were matched to infections group retrospectively one-to-three who did not sustain any kind of infection after ACL reconstruction.
62214628|NCT04224207|ACTIVE_COMPARATOR|Before application|RP patients with progressive visual acuity and visual field loss: before stem cell application.
62214629|NCT04224207|ACTIVE_COMPARATOR|After application|RP patients, after stem cell applications.
62215296|NCT01579279|PLACEBO_COMPARATOR|Placebo|Placebo capsules twice daily
62215297|NCT01579279|ACTIVE_COMPARATOR|Duloxetine|Duloxetine capsules once daily
61999141|NCT02806726|EXPERIMENTAL|iDesign 1.3-PRESBY|iDesign 1.3-PRESBY in one eye of subject (experimental) is used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
61999142|NCT02806726|ACTIVE_COMPARATOR|iDesign 1.3|iDesign 1.3 in one eye of subject (control) is used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
61999143|NCT00850395||1|Non-Interventional
61999144|NCT02197390|EXPERIMENTAL|Health Care plus Public Health|The Health Care intervention involves the implementation of an obesity care model within a Federally Qualified Health Center (FQHC) and includes a Family Wellness Program delivered by Community Health Workers (CHWs). The Public Health intervention involves working with early care and education centers, schools, community recreation organizations, and restaurants to promote four health behaviors: fruit and vegetable consumption, physical activity, water consumption, and quality sleep.
61999145|NCT02197390|EXPERIMENTAL|Health Care|The Health Care intervention involves the implementation of an obesity care model within a Federally Qualified Health Center (FQHC) and includes a Family Wellness Program delivered by Community Health Workers (CHWs).
61999146|NCT02197390|EXPERIMENTAL|Public Health|The Public Health intervention involves working with early care and education centers, schools, community recreation organizations, and restaurants to promote four health behaviors: fruit and vegetable consumption, physical activity, water consumption, and quality sleep.
61999147|NCT02197390|EXPERIMENTAL|Control|No intervention.
61999148|NCT03509038|EXPERIMENTAL|Urinary incontinence before bariatric surgery|All patients with urinary incontinence before bariatric surgery will be addressed for a urodynamic exam
61999149|NCT04571112|EXPERIMENTAL|NBM ON|"The post-surgical double-blind cross-over phase with randomization will follow once programming settings are determined. Under constant GPi DBS, patients will receive NBM DBS active or sham for 8 weeks followed by an 8-week cross-over.~The NBM ON arm will have constant NBM stimulation for 8 weeks."
61999150|NCT04571112|SHAM_COMPARATOR|NBM OFF|"The post-surgical double-blind cross-over phase with randomization will follow once programming settings are determined. Under constant GPi DBS, patients will receive NBM DBS active or sham for 8 weeks followed by an 8-week cross-over.~The NBM OFF arm will have NBM stimulation turned off for 8 weeks."
61999151|NCT01226719|EXPERIMENTAL|FOLFOXIRI+panitumumab regimen|"All patients will receive the FOLFOXIRI/panitumumab regimen, with drugs administered in the following order:~* Panitumumab~* Oxaliplatin~* Irinotecan~* Leucovorin~* 5-Fluorouracil"
61999152|NCT01637610||PPROM|All women presenting to assessment at the labour and delivery unit at RUH with suspected PPROM between 16+0 and 36+6 weeks gestation.
61999153|NCT03420703|ACTIVE_COMPARATOR|Block group|Erector espine plane block will be administrated to this group. An intravenous patient controlled analgesia device will be given to the patients postoperatively
61999154|NCT03420703|SHAM_COMPARATOR|control group|An intravenous patient controlled analgesia device will be given to the patients postoperatively
61999155|NCT04203550|ACTIVE_COMPARATOR|Irrigation group (IR)|A burr-hole craniostomy is performed and the dura is opened sharply and 10 ml of subdural exudate is aspired with blunt aspiration needle for a CSDH sample to be stored in -70℃ to be used for later analysis. Subdural space is irrigated by repeated rinsing with body temperature saline solution with a syringe and blunt needle until surgeon considers exudate to be clear. Minimum volume of irrigation will be 200 ml per operated side. The subdural drain is inserted 3-5 cm underneath the skull and parallel to it. The total volume of irrigation as well as the duration of operation is recorded.
61999156|NCT04203550|EXPERIMENTAL|No-Irrigation group (N-IR)|A burr-hole craniostomy is performed and a small incision to the dura is made and 10 ml of subdural exudate is aspired with blunt aspiration needle for a CSDH sample to be stored in -70℃ to be used for later analysis. The subdural drain is inserted approximately 3-5 cm underneath the skull and parallel to it. The duration of operation is recorded.
61999157|NCT06476223|EXPERIMENTAL|Artificial saliva containing cumin and ginger extract|The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
61999158|NCT06476223|PLACEBO_COMPARATOR|Placebo|The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
61999159|NCT00853177|EXPERIMENTAL|nitrous oxide|"N2O of 50% and 50% O2~MEOPA"
61999160|NCT00853177|ACTIVE_COMPARATOR|lidocaine|Injection solution 1%
61999161|NCT00412165|NO_INTERVENTION|usual care|Usual care arm receives standard physical activity, nutrition and weight loss information from their primary care provider. The study offers and pays for a series of weight management sessions provided by Rady's Children's Hospital and Health Center's Nutrition Dept.
61999162|NCT00412165|EXPERIMENTAL|Intervention - Web|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition.
62393346|NCT02195531|ACTIVE_COMPARATOR|Treatment|Participants will receive education and feedback tailored to the psychological profile of the receiving participant.
61999163|NCT00412165|EXPERIMENTAL|Intervention - Group|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition and has access to monthly group session with other teen and parent participants.
61999164|NCT00412165|EXPERIMENTAL|Intervention - Cell Phone|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition and are provided with cell phones to use during the program. The cell phone allows for the transfer of text messages from the study to the participant that are tailored to their health goals. In addition, self-monitoring and uploading capabilities to the program website are included.
62393347|NCT02195531|ACTIVE_COMPARATOR|Control Group|Participants will receive education inconsistent with their profile.
62568709|NCT00030901|ACTIVE_COMPARATOR|L-selenomethionine|L-selenomethionine (Selenium)one tablet by mouth daily for 3 years.
61999165|NCT03758911||bone marrow/blood stem cell donors|Participants underwent a one time semi-structured telephone interview to understand the perspectives of bone marrow/stem cell donors experience, including how family dynamics impacted participants' decision to donate and identifying unique supportive care needs of bone marrow/stem cell donors.
61999166|NCT04201561|EXPERIMENTAL|Experimental group|The patient will receive an intravenous selenium 2000 μg/40 ml dose just before chemotherapy begins every cycle (every 3 weeks for 6 cycles). Afterward, the same dose will be continued during the maintenance period if it is medically required or if the patient desires to do so.
61999167|NCT04201561|PLACEBO_COMPARATOR|Placebo group|The patient will receive an intravenous normal saline 40 ml dose just before chemotherapy begins every cycle (every 3 weeks for 6 cycles). Afterward, the same dose will be continued during the maintenance period if it is medically required or if the patient desires to do so.
61999168|NCT03289104|ACTIVE_COMPARATOR|Steel Wires|In this arm, patients will have their sternum closed with steel wires.
61999169|NCT03289104|EXPERIMENTAL|ZipFix Sternal Closure System (Plastic Cables)|In this arm, patients will have their sternum closed with the ZipFix system.
62568710|NCT00030901|PLACEBO_COMPARATOR|L-selenomethionine placebo|L-selenomethionine placebo one tablet by mouth daily for 3 years
62568711|NCT03801369|EXPERIMENTAL|Arm I (olaparib, durvalumab)|Patients receive olaparib PO BID on days 1-28 of each cycle and durvalumab intravenously (IV) over 1 hour on day 1 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, continue on therapy beyond the planned 13 cycles.
62568712|NCT03801369|EXPERIMENTAL|Arm II (olaparib, selumetinib)|Patients receive olaparib PO BID on days 1-28 of each cycle and selumetinib PO BID on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, continue on therapy beyond the planned 13 cycles.
62568713|NCT03801369|EXPERIMENTAL|Arm III (olaparib, capivasertib)|Patients receive olaparib PO BID on days 1-28 of each cycle and capivasertib PO BID 4 days on and 3 days off of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, continue on therapy beyond the planned 13 cycles.
62568714|NCT03801369|EXPERIMENTAL|Arm IV (ceralasertib)|Patients receive ceralasertib PO BID on days 1-14 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, continue on therapy beyond the planned 13 cycles.
62568715|NCT06081647|EXPERIMENTAL|the COMBO Endoscopy Oropharyngeal Airway Group|In this group, patients use the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
62568716|NCT06081647|ACTIVE_COMPARATOR|Regular Nasal Cannula Group|In this group, patients use the regular nasal cannula for oxygenation.
62568717|NCT04977427|ACTIVE_COMPARATOR|Prednisolone Arm|Standard post-cataract surgery therapy arm; acts as control in each patient.
62568718|NCT04977427|ACTIVE_COMPARATOR|Dextenza Arm|Investigational arm to compare the effectiveness of the Dextenza insert to standard therapy.
62568719|NCT05820529|OTHER|Effect of Adenotonsillectomy in velopharyngeal valve mechanism|We do adenotonsillectomy and show its effect in velopharyngeal valve
62184583|NCT02582398|PLACEBO_COMPARATOR|Placebo Light|The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (\<400nm or \>500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
62393348|NCT02195531|NO_INTERVENTION|Standard of care|Participants will not receive education or feedback.
62393349|NCT04584827||complication positive (up to 30 days after surgery)|"Complications:~* Moderate to severe intracerebral hemorrhage confirmed in a brain CT scan (Midline shift in brain imaging ≥ 3 mm),~* İntracranial hypertension requiring post op surgical drainage,~* Status epilepticus or seizures,~* The need for tracheal intubation or use of mechanical ventilation after surgery,~* Decrease in GKS,~* Unmanageable agitation that requires restriction or sedation,~* Need for respiratory failure and oxygen therapy,~* Unexpected serious motor deficit~* Died"
62568720|NCT05820529|OTHER|Effect of Adenoidectomy in velopharyngeal valve mechanism|We do adenoidectomy and show its effect in velopharyngeal valve
62568721|NCT05820529|OTHER|Effect of tonsillectomy in velopharyngeal valve mechanism|We do tonsillectomy and show its effect in velopharyngeal valve
62393350|NCT04584827||complication negative (up to 30 days after surgery)|No complications are seen within 30 days and the patient is healthy
62393351|NCT05131139|EXPERIMENTAL|Continuous Glucose Monitoring Device|Eversense 524 CGM System and ROME CGM System.
61999170|NCT02153775|EXPERIMENTAL|Progressive muscle relaxation|Progressive muscle relaxation: single 20-minutes session
61999171|NCT02153775|NO_INTERVENTION|Reading newspaper of the day|Reading newspaper of the day : single 20-minutes session
61999172|NCT02832869|EXPERIMENTAL|short message service|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
61999173|NCT02832869|EXPERIMENTAL|Wechat|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as Wechat based re-education by one investigator on the day before colonoscopy.
61999174|NCT02832869|NO_INTERVENTION|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
62184584|NCT06319651|EXPERIMENTAL|Experimental Group|"In addition to the routine Phase 1 cardiac rehabilitation, Resistance Exercises~* Extending thighs~* Closing thighs~* Opening thighs~* Bending thighs~* Bending ankles~* Ankle opening"
61999175|NCT02983006|EXPERIMENTAL|DS-8273a & Nivolumab|Patient groups (cohorts) will receive a single dose level of DS 8273a \& Nivolumab; DS 8273a will be increased in subsequent cohorts.
62184585|NCT06319651|ACTIVE_COMPARATOR|Routine Phase 1 cardiac rehabilitation|Routine Phase 1 cardiac rehabilitation only.
62184586|NCT03954288||chronic otitis media|patients with chronic otitis media without cholesteatoma
61999176|NCT01313429|EXPERIMENTAL|1|tumor cell vaccine administered with chemotherapy
62184587|NCT03954288||cholesteatoma|patients with chronic otitis media whose cholesteatoma
62568722|NCT04712344|EXPERIMENTAL|COVID-19 convalescent plasma|A total of three units of COVID-19 convalescent plasma administered on three separate occasions during Day 1 and Day 2 and standard treatment.
62568723|NCT04712344|NO_INTERVENTION|Standard treatment|Standard treatment.
62568724|NCT03319238||Patient cohort|Neuropathic pain patient taking ketamine
61999177|NCT01462669|OTHER|Treatment Period 1|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
61999178|NCT01462669|OTHER|Treatment Period 2|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
61999179|NCT01462669|OTHER|Treatment Period 3|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
61999180|NCT01462669|OTHER|Treatment Period 4|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
61999181|NCT02144740|OTHER|NWT-03, then placebo|4 weeks 2g NWT-03 followed by placebo , separated by a 4wk wash-out period
61999182|NCT02144740|OTHER|Placebo, then NWT-03|4 weeks placebo followed by 2g NWT-03, separated by a 4wk wash-out period
61999183|NCT00389116|EXPERIMENTAL|1|
62184588|NCT03954288||control|patients scheduled to operation with diagnosis of other causes
62184589|NCT05865171|EXPERIMENTAL|Cohort 1: Severe Renal Impairment|Participants will receive a single dose of IXP on Day 1.
62184590|NCT05865171|EXPERIMENTAL|Cohort 1: Healthy Participants|Participants will receive a single dose of IXP on Day 1.
62184591|NCT03945162|EXPERIMENTAL|0.7 mg/cm^2 Ruvidar® (TLD-1433) Bladder infusion and Photodynamic Therapy|A single instillation of Ruvidar® (TLD-1433) (at the therapeutic dose of 0.7 mg/cm\^2) will be infused intravesically into the bladder for approximately 60 minutes. PDT treatment is performed after Ruvidar® (TLD-1433) has been rinsed from the bladder. Two Study Treatments will be performed, a primary Study Treatment at Day 0 and a maintenance Study Treatment at Day 180.
62568725|NCT00789945|PLACEBO_COMPARATOR|Study Arm A|Study Arm A will be the primary control arm.
62568726|NCT00789945|EXPERIMENTAL|Study Arm B|Study Arm B will serve as the intervention arm.
62568727|NCT05776264|EXPERIMENTAL|Music Condition|3 self-selected music choices to be played during the study
62568728|NCT05776264|PLACEBO_COMPARATOR|Podcast Condition|One self-selected podcast choice to be played during the study
61999184|NCT00389116|PLACEBO_COMPARATOR|2|
62568729|NCT00228436|EXPERIMENTAL|Cohort 1|Peginesatide starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses.
62568730|NCT00228436|EXPERIMENTAL|Cohort 2|Peginesatide starting dose of 0.075 mg/kg administered SC Q4W for a total of 6 doses.
61999185|NCT00052845|EXPERIMENTAL|Combined chemotherapy|combination of 3 chemotherapy agents for hormone refractory prostate cancer
61999186|NCT05949138||ECG-Less Cardiac CT|Enrolled subjects will receive a clinically-indicated, diagnostic Cardiac CT with contrast. No ECG leads will be applied.
61999187|NCT01652391|EXPERIMENTAL|Anodal transcranial direct current stimulation|Anodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus
61999188|NCT01652391|SHAM_COMPARATOR|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
61999189|NCT06164132||Normal Weight group|Their BMI ranged from 18.5 to 24.9 kg/m2.
62568731|NCT00228436|EXPERIMENTAL|Cohort 3|Peginesatide starting dose of 0.025 mg/kg administered SC Q4W for a total of 6 doses.
62568732|NCT00228436|EXPERIMENTAL|Cohort 4|Peginesatide starting dose of 0.05 mg/kg administered intravenously (IV) Q4W for a total of 6 doses.
62568733|NCT00228436|EXPERIMENTAL|Cohort 5|Peginesatide starting dose of 0.025 mg/kg administered SC once every 2 weeks (Q2W) for a total of 12 doses.
62568734|NCT00228436|EXPERIMENTAL|Cohort 6|Peginesatide starting dose of 0.0375 mg/kg administered SC Q2W for a total of 12 doses.
62568735|NCT00228436|EXPERIMENTAL|Cohort 7|Peginesatide fixed starting dose of 4 mg administered SC Q4W for a total of 6 doses.
61999190|NCT06164132||Overweight group|Their BMI ranged from 25 to 29.9 kg/m2.
61999191|NCT06164132||Obese group|Their BMI was ≥ 30 kg/m2.
61999192|NCT05263427|EXPERIMENTAL|TOCONAUTE and gold standard : cardiotocograph|
61999193|NCT00004144|EXPERIMENTAL|bryostatin 1 & gemcitabine hydrochloride|
61999194|NCT01211028|OTHER|Autologous ASCs|Expanded autologous ASCs (Adipose Stroma/Stem Cells) Intramuscular dose of 100 million expanded cells.
62184592|NCT01458847|EXPERIMENTAL|Cohort I: 2% cis-UCA solution (50 ml)|
62184593|NCT01458847|EXPERIMENTAL|Cohort II: 4% cis-UCA solution (50 ml)|
62184594|NCT01458847|EXPERIMENTAL|Cohort III: 6% cis-UCA solution (50 ml)|
62184595|NCT00968006|EXPERIMENTAL|Treatment|Sitagliptin 100 mg once daily for 4 weeks
62568736|NCT00228436|EXPERIMENTAL|Cohort 8|Peginesatide fixed starting dose of 3 mg administered SC Q4W for a total of 6 doses.
62568737|NCT05138705|EXPERIMENTAL|Outcome|Quadrivalent influenza vaccine Participants randomized to receive two injections of 0.5 mL quadrivalent influenza vaccine at Day 0 and 28.
62568738|NCT03279822||Group|
62568739|NCT01164579|EXPERIMENTAL|Tofacitinib (CP 690,550) 10 mg BID plus MTX|
62184596|NCT00968006|NO_INTERVENTION|Control|No change in anti-diabetic treatment regimen for at least 4 weeks.
61999195|NCT03152370|EXPERIMENTAL|E7046 in combination with Long Course Chemoradiotherapy (LCRT)|Participants will receive once daily (QD) doses of E7046 (recommended Phase 2 dose \[RP2D\] determined in the Dose-Escalation part of the study) for 10 weeks, starting on Day 1, 14 days prior to initiation of the radiotherapy. LCRT will be initiated on Day 15 and will consist of a total of 45 Grays (GY) radiation administered in 1.8 GY daily doses delivered for 5 days (Monday to Friday) every week for 5 weeks. Capecitabine (825 milligrams per meters squared \[mg/m\^2\]) will be administered twice daily on the days of radiotherapy. Surgery will be performed 14 to 16 weeks from the first day of E7046 treatment.
62393352|NCT02784665|EXPERIMENTAL|577-MPL|"577nm micropulse laser(577-MPL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Multiple laser spots will be applied, covering the leakage area."
62393353|NCT02784665|ACTIVE_COMPARATOR|577-TL|"577nm Traditional laser(577-TL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Traditional laser spots will be applied, covering the leakage area."
62568740|NCT01164579|EXPERIMENTAL|Tofacitinib (CP-690,550) 10 mg BID, tablet plus placebo MTX|
62568741|NCT01164579|ACTIVE_COMPARATOR|Placebo tofacitinib (CP-690,55) plus MTX 10 mg/wk to 20 mg/wk|
62184597|NCT01743105|EXPERIMENTAL|Study population|"The study population consists of patients treated for acute respiratory distress in the emergency department at the Nîmes University Hospital. See inclusion and exclusion criteria.~Interventions: Diaphragm excursion measures 1, Diaphragm excursion measures 2"
62184598|NCT00026182|EXPERIMENTAL|Arm I (rituximab and recombinant interleukin-12)|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients receive interleukin-12 SC twice weekly beginning on day 2 and continuing until disease progression.
62184599|NCT00026182|EXPERIMENTAL|Arm II (rituximab and recombinant interleukin-12)|Patients receive rituximab as in arm I. Patients are evaluated at week 12. Patients with stable or progressive disease receive interleukin-12 SC twice weekly until disease progression or for 24 weeks. Patients with a complete or partial response after rituximab are monitored until disease progression and then begin interleukin-12 SC twice weekly until further disease progression.
62393354|NCT05946837|EXPERIMENTAL|Pneumatic Compression Therapy (PCT)|
62393355|NCT03554798|EXPERIMENTAL|nOPV2 Candidate 1 (monovalent oral poliovirus type1)|"Cohort A: IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1.~Cohort B: 6 weeks Infants vaccinated with 3 doses of bOPV and 1 dose of IPV, followed with 1 dose of candidate 1."
62393356|NCT03554798|EXPERIMENTAL|nOPV2 Candidate 2 (monovalent oral poliovirus type2)|"Cohort A: IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 2.~Cohort B: Infants vaccinated with 3 doses of bOPV and 1 dose of IPV, followed with 1 dose of candidate 2."
62393357|NCT03691831|ACTIVE_COMPARATOR|Active|A-101 45% (Topical solution, hydrogen peroxide 45%)
62774806|NCT00667667|ACTIVE_COMPARATOR|2|side-alternating vibration device (using Board 3000 whole body vibration platforms)
62774807|NCT00667667|SHAM_COMPARATOR|3|wellness-control group
62774808|NCT03549559|ACTIVE_COMPARATOR|Healthy Subjects|Healthy subjects will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.
62774809|NCT03549559|ACTIVE_COMPARATOR|Diabetes Patient Subjects|Patient subjects with diabetes will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.
62774810|NCT03549559|EXPERIMENTAL|Aortic Stenosis Patient Subjects|Patient subjects with aortic stenosis will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI before and after transcatheter valve replacement.
62774811|NCT03589222|EXPERIMENTAL|Selinexor, Daratumumab, Bortezomib and dexamethasone|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle plus dexamethasone 40 or 20 mg mg orally with each dose of selinexor in combination with daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter and bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9. Each cycle is of 4 weeks of duration
62774812|NCT03255746|EXPERIMENTAL|Sleep Enhancement|
62774813|NCT03255746|PLACEBO_COMPARATOR|Health Education|
62774814|NCT02402283|EXPERIMENTAL|Test Product|Metronidazole benzoate oral granules
62774815|NCT02402283|ACTIVE_COMPARATOR|Reference Product|Flagyl 400 mg Tablets
62184600|NCT04072445|EXPERIMENTAL|Treatment (trifluridine and tipiracil, irinotecan)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and irinotecan hydrochloride IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62184601|NCT02168283|EXPERIMENTAL|treatment arm|active fluid management includes 3 components: dietary counseling, diuretics, and intensive dialysis regimen
62184602|NCT02168283|ACTIVE_COMPARATOR|control arm|dietary counseling alone
62184603|NCT00805285|EXPERIMENTAL|Combination Oral Budesonide and Rectal Hydrocortisone|See intervention
62184604|NCT01043445|EXPERIMENTAL|GPR119 agonist, 2-oleoyl glycerol|2-oleoyl glycerol; 2g. and vehicle
62184605|NCT01043445|ACTIVE_COMPARATOR|Oleic acid|oleic acid; 3.2g and vehicle
62184606|NCT01043445|PLACEBO_COMPARATOR|Vehicle|5 ml. of glycerol and 5 ml 96% ethanol
62393358|NCT03691831|PLACEBO_COMPARATOR|Vehicle|Topical solution, isopropyl alcohol and water
62568742|NCT02075931|EXPERIMENTAL|Physical Activity Feedback|The physical activity feedback intervention will involve real-time physical activity monitoring using a device to provide activity feedback directly to patients in combination with patient group meetings held monthly during the 12 week intervention for the purposes of mutual support in attaining physical activity goals.
62568743|NCT02075931|ACTIVE_COMPARATOR|Control|The control represents the current standard of care post total knee arthroplasty.
62774816|NCT03793491||Patients having Parkinson's disease|Parkinson's patients presenting motor fluctuations and/or disabling dyskinesia and in need of the establishment of a second line treatment by subcutaneous apomorphine infusion or intrajejunal infusion of levodopa-carbidopa in the context of classical care of their Parkinson's disease. Patients will have TCI scale and PDQ-39 scale.
62568744|NCT01937611|EXPERIMENTAL|Dexmedetomidine|dexmedetomidine 1μg•kg-1
62568745|NCT01937611|ACTIVE_COMPARATOR|midazolam|midazolam 0.03 mg•kg-1
61999196|NCT03152370|EXPERIMENTAL|E7046 in combination with SCRT followed by chemotherapy|Participants will receive QD doses of E7046 (RP2D determined in the Dose-Escalation part of the study) for 10 weeks, starting on Day 1, 14 days prior to initiation of the radiotherapy. Short course radiotherapy (SCRT) will be initiated on Day 15 and will consist of a total of 25 Gy radiation administered in 5 Gy daily doses for 5 days (Monday to Friday) for 1 week. Ten days after the end of radiotherapy, 3 cycles of the modified folinic acid/5-FU/oxaliplatin (mFOLFOX-6) regimen will be administered every 2 weeks for 2 consecutive days. Surgery will be performed 14 to 16 weeks from the first day of E7046 treatment.
61999197|NCT05132621||Participants diagnosed with SLE|
61999198|NCT05132621||Participants diagnosed with IgA nephropathy|
61999199|NCT05132621||Healthy Participants|
61999200|NCT02646579|EXPERIMENTAL|Spinal and Peripheral Dry Needling|Participants will receive dry needling to the low back and painful areas in the leg.
62568746|NCT05068180|EXPERIMENTAL|Neuroleptanalgesia group|Droperidol 1.25 mg and fentanyl 0.025 mg (diluted with normal saline up to 5ml) is to be administrated intravenously 30 minutes before the end of the procedure.
61999201|NCT02646579|ACTIVE_COMPARATOR|Peripheral Dry Needling|Participants will receive dry needling to painful areas in the leg.
61999202|NCT03292081|EXPERIMENTAL|OFDI-guided PCI|
61999203|NCT03292081|ACTIVE_COMPARATOR|IVUS-guided PCI|
61999204|NCT06062043|EXPERIMENTAL|Brief ACT with CPP Education Group|The Brief Acceptance and Commitment Training (ACT) with Chronic Pelvic Pain (CPP) education Group will attend weekly 90-minute sessions for up to six weeks to learn new ways to respond to their pain and engage in meaningful activities.
61999205|NCT06062043|NO_INTERVENTION|Enhanced Treatment as Usual|The enhanced treatment as usual (TAU) condition will receive a letter with CPP-specific treatment resources and encouraged to consult with their VHA primary care clinicians for additional education and treatment options.
61999206|NCT03160963||Ages 18-29|Power testing 18-29 year old men and women
61999207|NCT03160963||Ages 30-39|Power testing 30-39 year old men and women
61999208|NCT03160963||Ages 40-49|Power testing 40-49 year old men and women
62568747|NCT05068180|PLACEBO_COMPARATOR|Control group|The same volume of normal saline is to be administrated intravenously 30 minutes before the end of the procedure.
62568748|NCT01166620||Patients with rheumatoid arthritis new to abatacept.|
62568749|NCT01166620||Patients with rheumatoid arthritis new to etanercept|
62568750|NCT01166620||Patients with rheumatoid arthritis new to adalimumab|
62568751|NCT01166620||Patients with rheumatoid arthritis new to infliximab|
62568752|NCT00937365|ACTIVE_COMPARATOR|Exercise|Specific strengthening exercises demonstrated to improve pregnancy-related low back pain are taught to participants of this arm. Additionally, each participant will be evaluated and additional exercises will be prescribed relevant to her particular needs. Study participants of this arm are asked to perform the exercises at home at least once a day. Exercise is recorded in a diary. Participants follow the same study visit schedule as the two other arms.
62568753|NCT00937365|EXPERIMENTAL|Spinal Manipulation|Women randomized to this arm will be evaluated for spinal subluxations and, if appropriate, treated with chiropractic manipulation. Type of manipulation is determined by presentation. Woman may be manipulated with high velocity low amplitude thrust, blocking, activator, or other appropriate means of manipulating.
62774817|NCT00908102|ACTIVE_COMPARATOR|BB|"Subjects received the back book booklet, which is an self-information booklet about managing low back symptoms.~Included in the Mild and Mild vs. NC interventions."
62774818|NCT00908102|EXPERIMENTAL|BB+A|"Subjects received a back book booklet and also oral advice based on the back book by the occupational health professional (OH Nurse or OH Physician in mild or moderate intervention, respectively).~Included in the Mild and Mild vs. NC interventions. Arm was also used as a control at the Moderate and Moderate vs. NC interventions."
62774819|NCT00908102|EXPERIMENTAL|DBC|A graded activity back school program was carried out in a physiotherapy out-patient clinic that consisted of one-hour session twice or three times per week, lasting for 12 weeks, supervised by a specially trained physiotherapist. Arm is included in the MOderate and Moderate vs. NC interventions.
61999209|NCT03160963||Ages 50-59|Power testing 50-59 year old men and women
61999210|NCT03160963||Ages 60-69|Power testing 60-69 year old men and women
61999211|NCT03160963||Ages 70-79|Power testing 70-79 year old men and women
61999212|NCT03160963||Ages 80+|Power testing men and women 80 years of age and above
61999213|NCT06323252|ACTIVE_COMPARATOR|Intervention group|Participants with hypetriglyceridemia will be subjected to nutritional counsel and the intake of 1 soft gel capsule daily for a total of 3 months.
61999214|NCT06323252|ACTIVE_COMPARATOR|Control group|Participants with hypetriglyceridemia will be subjected to nutritional counsel for a total of 3 months.
61999215|NCT04141280||Insomnia group|According to the inclusion and exclusion criteria, 150 patients with insomnia were selected, which were divided into five groups: liver stagnation fire syndrome, phlegm heat syndrome, yin deficiency fire dysfunction syndrome, heart spleen deficiency syndrome and heart deficiency biliary syndrome.
61999216|NCT04141280||Normal group|According to the inclusion and exclusion criteria, 30 normal people were selected.
61999217|NCT01654965|EXPERIMENTAL|Treatment (tivantinib, topotecan hydrochloride, pegfilgrastim)|Patients receive tivantinib PO BID on days 1-21, topotecan hydrochloride IV over 30 minutes on days 1-5, and pegfilgrastim SC on day 6. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61999218|NCT05164458|EXPERIMENTAL|IBI389|A dose escalation stage of IBI 389 monotherapy.
62184607|NCT00567983|ACTIVE_COMPARATOR|1.|
62184608|NCT00567983|PLACEBO_COMPARATOR|2.|
62774820|NCT00908102|EXPERIMENTAL|PMU|An intensive, multidisciplinary LBP rehabilitation program was carried out in a physical medicine out-patient unit at the local Central Hospital. The program included a 3-week pre-course of 1,5 hour session at 3 days per week, closely followed by a 3-week intensive rehabilitation course of 6.5 hours per day for 5 days per week. A personal graded activity training program was made for each subject and patients were later called for follow-up visit within 1 year of the initial course. Arm is included in the MOderate and Moderate vs. NC interventions.
62774821|NCT00908102|PLACEBO_COMPARATOR|NC|Natural course of low back pain
61999219|NCT05164458|EXPERIMENTAL|IBI 389 + sintilimab|A dose escalation stage of IBI 389 in combination with sintilimab.
61999220|NCT02953821|EXPERIMENTAL|Acthar Gel|Participants receive Acthar Gel every other day for 4 weeks, and then twice per week for 20 weeks
61999221|NCT02953821|PLACEBO_COMPARATOR|Placebo Gel|Participants receive Placebo Gel every other day for 4 weeks, and then twice per week for 20 weeks
61999222|NCT05709184|EXPERIMENTAL|Lyophilized fecal microbiome transfer (Lyo-FMT)|Vancomycin will be given orally in 125 mg capsules/solution 4 times daily for a total of 5 days (day 1 - initiation of therapy by the clinical team), followed by a loading dose of oral Lyo-FMT capsules on day 6 (15 capsules). On days 7-10, patients will receive 10 Lyo-FMT capsules per day. A total of 55 capsules, derived from \~30-40g of the original material, will be administered throughout 5 days. Prior to each Lyo-FMT administration, patients will be asked to fast for 8 hours. Bowel preparation or proton pump inhibitor use will not be required per protocol. The loading dose will be administered under medical supervision, while further dosing can be administered at the patient's home/institute, after training and guidance
61999223|NCT05709184|ACTIVE_COMPARATOR|Vancomycin monotherapy|Vancomycin will be given orally in 125 mg capsules/solution 4 times daily for a total of 10 days (day 1 - initiation of therapy by the clinical team, not from randomization).
62774822|NCT06303466||Danish Fabry Patients|Patients with a genetically-verified diagnosis of Fabry Disease.
62774823|NCT06334874|ACTIVE_COMPARATOR|intervention|
62774824|NCT06334874|PLACEBO_COMPARATOR|placebo|
62774825|NCT03583827|EXPERIMENTAL|Experimental Group|Experimental group patients will be submitted to conventional therapy for 30 minutes and training of the affected upper limb using virtual reality, which will last 20 minutes over twelve sessions (4 weeks).
62774826|NCT03583827|ACTIVE_COMPARATOR|Control Group|The control group will undergo 30 minutes of Conventional physical therapy in twelve sessions (4 weeks).
62774827|NCT00910169||inpatient treatment|naturalistic treatment no modification: observational study
62774828|NCT01722656|OTHER|Aflibercept|All subjects will receive aflibercept
61999224|NCT00938483|EXPERIMENTAL|Extensively hydrolyzed infant formula|New extensively hydrolyzed formula, NPS-202
62774829|NCT02258113|OTHER|LEA numbers, Pelli-Robson, Octopus|Comparable generally used method for measuring visual acuity, contrast sensitivity and visual field.
62774830|NCT03740568|OTHER|Normal Progesterone group|Progesterone level \>10.64 ng/mL on day 4 of progesterone supplementation
62774831|NCT03740568|EXPERIMENTAL|Low Progesterone group|Progesterone level \<10.64 ng/mL on day 4 of progesterone supplementation
62774832|NCT00067782|ACTIVE_COMPARATOR|1|
62774833|NCT00067782|ACTIVE_COMPARATOR|2|
62774834|NCT02348307|ACTIVE_COMPARATOR|FYU-981|
61999225|NCT00938483|ACTIVE_COMPARATOR|Infant formula - Extensively hydrolyzed Nutramigen Lipil|Currently marketed extensively hydrolyzed formula (Nutramigen Lipil)
61999226|NCT01332617|EXPERIMENTAL|Treatment with combination therapy|Treatment with combination therapy of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine, and Methylprednisolone.
61999227|NCT04679077|OTHER|Cytocam-IDF Imaging|All patients will undergo the same interventional test.
62184609|NCT04517942|EXPERIMENTAL|EVERYbody Project: Peer facilitator version|"This dissonance-based body image program was created from focus group feedback (Ciao, Ohls, \& Pringle, 2017) and piloted in an initial randomized-controlled trial. Based on the Body Project (Stice et al., 2006), it retains key dissonance activities while adapting exercises to have a more inclusive focus (e.g., expanding the gender focus, exploring diversity characteristics within appearance ideals, adjusting activities to be inclusive of diversity).~Around 10% of the original EVERYbody Project manual was modified to create the Peer Facilitator version for the current trial. Changes focused on adding individual exercises to draw out the critique of diversity in cultural ideals, refining prompts to be more suitable for peer facilitation, and flagging sections of the manual for more expert peer facilitation.~Peer facilitators received 16 hours of training on the EVERYbody Project manual and peer facilitation guidelines (e.g., group management, handling problems, etc.)."
62215298|NCT06139081|EXPERIMENTAL|Group A|Transnasal oxygen was administered by nasal catheter before gastroscopy, transoral oxygen was administered by nasal catheter during gastroscopy, and transnasal oxygen was administered by nasal catheter after withdrawal of gastroscope.
62774835|NCT02348307|PLACEBO_COMPARATOR|Placebo|
62774836|NCT03887858|EXPERIMENTAL|Reference/Test|"1. Period 1: Harnal-D Tab. 1T~2. Period 2: Chong Kun Dang Tamsulosin HCl Tab. 1T"
62774837|NCT03887858|EXPERIMENTAL|Test/Reference|"1. Period 1: Chong Kun Dang Tamsulosin HCl Tab. 1T~2. Period 2: Harnal-D Tab. 1T"
62774838|NCT06113536|EXPERIMENTAL|Ultrasonographic evaluation|Ultrasonographic evaluation for assessment of possible meniscal extrusion
61999228|NCT04110483|ACTIVE_COMPARATOR|TURBT|A step-by-step resection of a tumor. Firstly, visible tumor is resected, then resection continues to the apparently normal mucosa on the border of the tumor, than resection of the muscle layer at the base of the tumor is performed until normal muscle fibers are visible.
62184610|NCT04517942|ACTIVE_COMPARATOR|Video + Expressive Writing group|"Video + expressive writing groups were facilitated by a peer leader following a detailed script. This intervention was designed as an active but low-dissonance comparison condition. Participants viewed two separate documentary movies related to gender and/or appearance-related pressures (one during each session): (1) The Illusionists (2015 ), and (2) The Mask You Live In (2015). Participants engaged in a brief (10 minute) reflective writing exercise after each film. In order to keep dissonance low, participants were told that their reflections would not be shared with anyone and they were not turned in.~Peer facilitators received brief (1 hour) training on the video group manual."
62184611|NCT00715117|PLACEBO_COMPARATOR|Sugar pill|Subjects will receive placebo for for the first 8 weeks administered orally one time daily. After 8 weeks placebo treated subjects are then crossed over to active drug naltrexone 0.1 mg/kg not to exceed 4.5 mg PO once daily for an additional 8 weeks.
62184612|NCT00715117|EXPERIMENTAL|Naltrexone|Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally either in capsules or liquid blinded for 8 weeks followed by open-labeled naltrexone for an additional 8 weeks. Safety and toxicity will be compared to placebo. Also change in Crohn's activity index scores of naltrexone to placebo are compared.
62184613|NCT03373955||Immunotherapy,chemotherapy,radiotherapy|Pembrolizumab will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent.The peripheral blood will be collected at 3 weeks,2 months, 6 months,an average of 1 year
62184614|NCT05471804|PLACEBO_COMPARATOR|Placebo control|An inert tablet with the same physical appearance as the experimental intervention tablet
62184615|NCT05471804|EXPERIMENTAL|Zembrin|25 mg per day of Sceletium tortuosum extract (Zembrin®)
62568754|NCT00937365|EXPERIMENTAL|Neuroemotional technique (NET)|"Neuroemotional technique (NET) is a mind-body technique which combines elements of chiropractic medicine, Chinese medicine, and behavioral psychology. Muscle response testing, a form of functional neurology, and visceral somatic reflexes are used to ascertain whether the pain or dysfunction experienced by the participant has an emotional component. If an emotional component is present, it is identified and the original triggering occurrence is identified. The participant creates a snapshot of that original occurrence and while she holds that image in her mind spinal levels which innervate the associated organ are adjusted."
61999229|NCT04110483|EXPERIMENTAL|Tm-fiber ERBT|A circumferential incision around the tumor is made in the visually intact bladder mucosa. After that, the incision is continued deeper into the muscular layer. Than the surgeon resects the base of the tumor with the muscular layer using traction and incisions of the muscle fibers.
62184616|NCT01545557|EXPERIMENTAL|Hyaluronic acid dermal filler|One Emervel Volume injection at baseline and touch up injections 3 weeks after if needed
62393359|NCT01939015|ACTIVE_COMPARATOR|Standard titanium miniplate- single non compression miniplate|fixation will be perform by A single non compression miniplate with 4-hole 2-mm using 2-mm monocortical screws at superior border of the mandible according to ideal lines of osteosynthesis.
62184617|NCT03770052|EXPERIMENTAL|0.25mg robeglitazone add-on group|0.25mg robeglitazone once daily in patients with type 2 diabetes with inadequate control on metformin and DPP-4 inhibitor therapy
62393360|NCT01939015|EXPERIMENTAL|three dimensional titanium miniplate|3D curved strut miniplate\* (Universal Mandible System, Stryker-Lei binger, Freiburg, Germany) , installed and stabilized with monocortical screws. The 3D plate will be place in such a way that a horizontal bar is perpendicular and a vertical bar is parallel to the fracture line.
62393361|NCT01205568|EXPERIMENTAL|Patients with Resistant Pulmonary Artery Stenosis|Vessels with resistant PA stenosis were identified during catheterization and eligible vessels were randomized to Cutting Balloon or High Pressure Balloon Dilation
62184618|NCT03770052|ACTIVE_COMPARATOR|0.5mg robeglitazone add-on group|0.5mg robeglitazone once daily in patients with type 2 diabetes with inadequate control on metformin and DPP-4 inhibitor therapy
62393362|NCT01613209|EXPERIMENTAL|Olmesartan/Amlodipin fixed combination|
62568755|NCT05973539|EXPERIMENTAL|High carbohydrate, low fat diet|65% of energy is derived from carbohydrates, 20% from fat, and 15% from protein.
62568756|NCT05973539|EXPERIMENTAL|High fat, low carbohydrate diet|65% of energy is derived from fat, 20% from carbohydrates, and 15% from protein.
62774839|NCT05715515|EXPERIMENTAL|Nasal sampling/Testing (Self-Test) + Nasopharyngeal sampling/Testing (Professional Use)|"Lay users (self-tester or caregiver) will be provided with a Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test kit. Each lay user will collect one mid-turbinate nasal swab from both nostrils, perform and interpret the Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test. All procedures for testing and result interpretation, including sample collection and extraction will be conducted by the lay user following the Instructions for Use provided in the kit.~The first NP swab sample will be used to conduct a Panbio™ COVID- 19/FluA\&B Rapid Panel Professional Use test.~The second NP swab sample will be eluted in Universal Transport Medium (UTM) provided by Abbott/the Core Laboratory, labelled and stored, according to the laboratory manual. UTM samples will be shipped to the Core Laboratory for testing with RT-PCR protocols for Flu A, Flu B and SARS-CoV-2, according to the laboratory manual."
62774840|NCT04964596|ACTIVE_COMPARATOR|a colonoscopy as surveillance exam|patients will undergo Colonoscopy, finding will be documented. Findings of colonoscopy will be documented and treated according to the institutional standards. Study participation for patients ends after the colonoscopy and follow-up of pathology results and complication assessment.
62184619|NCT02980705|EXPERIMENTAL|SUNPG1622 I|SUNPG1622 I dose
62184620|NCT02980705|PLACEBO_COMPARATOR|Placebo|Placebo dose
62184621|NCT00983112|EXPERIMENTAL|Evicel|
62184622|NCT00983112|PLACEBO_COMPARATOR|Placebo|
62215299|NCT06139081|NO_INTERVENTION|Group B|Nasal catheter was used to give oxygen before, during and after withdrawal of gastroscope
62393363|NCT05868629||dabrafenib plus trametinib|patients treated with dabrafenib and trametinib
62568757|NCT06222164||Residual Specimens|Residual specimen/sample collection study where peripheral blood (PB), bone marrow (BM), genomic (gDNA), and/or formalin-fixed paraffin-embedded tissue (FFPE) specimens/samples are obtained from patient samples sent to LabPMM, LLC for clinical testing.
62184623|NCT01849445|ACTIVE_COMPARATOR|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
62184624|NCT01849445|ACTIVE_COMPARATOR|Home physiotherapy excercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
62184625|NCT04787432|EXPERIMENTAL|Intervention|"Experimental: SAFRAPP Intervention~Participants in this group will receive a 6-week SAFRAPP intervention, comprising of laughter yoga, health education and case management. SAFRAPP will be conducted on social media (Facebook and WhatsApp)."
62184626|NCT04787432|NO_INTERVENTION|Control Grup|The control group will not receive any intervention during the study. Participants in the control group will take the same program after the study is completed.
62184627|NCT01162447||PCO|Healthy control subjects and patients with polycystic ovarian syndrome will be recruited for the study.
62184628|NCT00878553|PLACEBO_COMPARATOR|Placebo|Two placebo tablets administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
62184629|NCT00878553|EXPERIMENTAL|10 mg SKP-1041|One 10 mg SKP-1041 controlled release zaleplon tablet plus one placebo tablet administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
62184630|NCT00878553|EXPERIMENTAL|15 mg SKP-1041|One 15 mg SKP-1041 controlled release zaleplon tablet plus one placebo tablet administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
62184631|NCT00878553|EXPERIMENTAL|20 mg SKP-1041|Two 10 mg SKP-1041 controlled release zaleplon tablets administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
62184632|NCT06287086|EXPERIMENTAL|BRL-101|BRL-101 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the BCL11A gene. Subjects will receive a single infusion of BRL-101.
62184633|NCT02135822|EXPERIMENTAL|nanoparticle albumin-bound paclitaxel, gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 and 8, in combination with gemcitabine which is given at 1000 mg/m2, on day 1 and 8, each 21-day cycle. Number of cycle: 6 cycles.
62184634|NCT04471649||Experimental|Patient with rheumatoid arthritis using hydroxychloroquine as a part of their treatment regimen.
62184635|NCT04471649||Active Comparator|Patient with rheumatoid arthritis not using hydroxychloroquine as a part of their treatment regimen
62184636|NCT00523952|EXPERIMENTAL|1|
62393364|NCT02973399|EXPERIMENTAL|SNX-5422 plus ibrutinib|Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule for 2 cycles after a CR or until the cancer progresses or the subject is unable to tolerate the therapy
62393365|NCT02577107|EXPERIMENTAL|Ranibizumab 0.5 mg|Three monthly injections of 0.5mg Ranibizumab
62393366|NCT02577107|ACTIVE_COMPARATOR|Conbercept 0.5 mg|Three monthly injections of 0.5mg Conbercept
61999230|NCT03123159||HBV Infected patients|chronic HBV patients who will undergo standard of care FDA approved antiviral therapy to treat HBV infections. Will have blood drawn to be tested using the DxN HBV Assay. Study is observational and results will not be used to manage patient care.
62393367|NCT06138912||Age|20-29, 30-39, 40-49, 50-59, 60-69, and 70-79
61999231|NCT01248299|EXPERIMENTAL|Chemotherapy plus best supportive care|Chemotherapy plus best supportive care with follow up at each cycle of the treatment with FU-CDDP; LV5FU2-CDDP; FOLFOX; TPF
61999232|NCT01248299|ACTIVE_COMPARATOR|Best supportive care|Best supportive care with follow up every 6 weeks
61999233|NCT05440292|EXPERIMENTAL|Hotspot-rTMS Group|rTMS stimulate on the hotspot of unaffected hemisphere
61999234|NCT05440292|EXPERIMENTAL|fMRI-rTMS Group|rTMS stimulate on the motor task activation poin (targeted by fMRI) of unaffected hemisphere
61999235|NCT04426617|EXPERIMENTAL|fentanyle|: patients will receive US guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25% \& fentanyl).
61999236|NCT04426617|EXPERIMENTAL|Midazolam|patients will receive us guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25% \& midazolam).
61999237|NCT04426617|PLACEBO_COMPARATOR|control|patients will receive us guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25%).
62184637|NCT04314388|EXPERIMENTAL|Intervention: Outdoor walking Rehabilitation Programme|Participants in the intervention will be provided with an exercise diary. This will include walking routes for the instructor led 3-month outdoor-walking rehabilitation programme. The exercise diary will also include home exercises for the participants to complete twice-per-week that will be explained in detail, using coaching points and images to support. As these exercises will be completed at home. Each exercise has four progressions ranging from easy to hard.
62184638|NCT04314388|OTHER|Control: The light Stretches Programme|The control group intervention will be a non-exercise intervention to avoid training effects. The control group will be asked to keep to their normal activities of daily living and given ten targeted active stretches for the upper and lower body three times per week at home. Participants in the control group will each be provided a booklet for the given stretches.
62184639|NCT04092049|EXPERIMENTAL|lollipop|
62184640|NCT04092049|NO_INTERVENTION|control|
62184641|NCT02830009|OTHER|Primary Hyperoxaluria patient|
62184642|NCT02830009|OTHER|Primary Hyperoxaluria patient's siblings|
62184643|NCT02830009|OTHER|Idiopathic hypercalciuria patients|
62184644|NCT02830009|OTHER|Healthy volunteers|
62184645|NCT04151472|EXPERIMENTAL|90mg Idebenone|Placebo by mouth, three times a day for 1 months； Idebenone 30mg table by mouth, three times a day for next 3 months
62393368|NCT06138912||sex|each group included 10 subjects
62184646|NCT04151472|EXPERIMENTAL|270mg Idebenone|Placebo by mouth, three times a day for 1 months； Idebenone 90mg table by mouth, three times a day for next 3 months
62184647|NCT04151472|PLACEBO_COMPARATOR|Placebo|Placebo by mouth, three times a day for 4 months
62184648|NCT02379793|EXPERIMENTAL|LEO 80185 gel, vehicle, liquid paraffin|Each subject has all 3 treatments applied topically at the same time. However, the location on which the treatments are applied is randomised in an investigator blinded manner.
62184649|NCT05632718|EXPERIMENTAL|Resistance group|16 weeks of resistance exercise-training.
62184650|NCT05632718|EXPERIMENTAL|Endurance group|16 weeks of endurance exercise-training.
62184651|NCT05632718|NO_INTERVENTION|Control group|Does not enrole in exercise-training programme.
62184652|NCT05887206||Patients treated by Belantamab Mafodotin|"patients treated by Belantamab Mafodotin with a refractory multiple myeloma and an ophthalmologic follow-up between January 2020 and February 2022 will be included.~Data will be collected for patients coming from multiple French centers which followed patients treated by Belantamab Mafodotin between January 2020 and February 2022. They will be obtained by contacting centers through an email sent with a secure mail address."
62184653|NCT04733898|EXPERIMENTAL|Social games|Participants in the social games group will be given access to an app with games that are either adaptations of well-known games or newly developed games, all designed to be played with just text messages and photos. A game is essentially a chat group with the people you invited to play that specific game with. Participants can play with their own network of family and friends, as well as other people in the same condition.
62184654|NCT04733898|ACTIVE_COMPARATOR|Non-personal games|Participants in the active control group will be given access to an app that offers 'non-personal games'. The portal will contain a subset of the social games, which have been adapted for non-personal play. This means that all aspects that make the games personal are removed and discouraged. The games that remain can still be played with others (family/friends and others in the same condition), but are designed not to elicit personal interaction. Participants are asked to play the games at least twice a week, but may play as often as they like.
62184655|NCT04733898|NO_INTERVENTION|Passive control|The passive control group will be given access to an app that contains no games. Similar to the other groups, the portal is used to complete the questionnaires. Use of other games, (gaming) apps or social media platforms is allowed in this group, as in the other groups. The only restriction they will not have access to the games offered in the social games and active control groups.
62184656|NCT05333822|EXPERIMENTAL|Bashan|a vegetable plant based compound drink add after three meals for 14 days
62393369|NCT02311660|EXPERIMENTAL|vagus nerve stimulation|Patients will have an implanted vagus nerve stimulation device.
62393370|NCT01363999|EXPERIMENTAL|A|RO5317116/F01 bilayer tablet
62393371|NCT01363999|EXPERIMENTAL|B|RO5317116/F03 bilayer tablet
62184657|NCT05333822|PLACEBO_COMPARATOR|Water|water as placebo
62184658|NCT00926380|EXPERIMENTAL|denosumab ONLY|
62184659|NCT00926380|EXPERIMENTAL|teriparatide (Forteo®) ONLY|
62184660|NCT00926380|EXPERIMENTAL|denosumab and teriparatide (Forteo®)|
62184661|NCT00251056|ACTIVE_COMPARATOR|1|
62184662|NCT00251056|ACTIVE_COMPARATOR|2|
62184663|NCT00251056|ACTIVE_COMPARATOR|3|
62184664|NCT00251056|ACTIVE_COMPARATOR|4|
62184665|NCT02806505|EXPERIMENTAL|Peginterferon alfa-2a 135 microgram (mcg)|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 135 mcg subcutaneously (SC) once weekly up to Week 48.
62184666|NCT02806505|EXPERIMENTAL|Peginterferon alfa-2a 90 mcg|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 90 mcg SC once weekly up to Week 48.
62184667|NCT03367910|EXPERIMENTAL|FMT for MDRO UTI|Participants with eligible MDRO UTIs will receive FMT (150mL of RBX2660) via enema.
62184668|NCT05060497||Covid patients|Participants who were treated in hospital with laboratory diagnosed Covid-19 requiring high flow oxygen, non invasive ventilation or intubation and have now recovered. They will be recruited 5-7 months post discharge from their local hospital Trust
62184669|NCT05060497||Healthy control volunteers|Participants who are otherwise healthy, who have not had Covid-19 infection and are age, gender, BMI and ethnicity matched to patients
62184670|NCT05559671|EXPERIMENTAL|HZ/su Vaccine, then Placebo|During the initial 24-week period (Period 1), participants will receive HZ/su injection at week 0 and week 8. During the second 24-week period (Period 2), participants will receive placebo saline injection at week 24 and week 32.
62184671|NCT05559671|EXPERIMENTAL|Placebo, then HZ/su Vaccine|During the initial 24-week period (Period 1), participants will receive placebo saline injection at week 0 and week 8. During the second 24-week period (Period 2), participants will receive HZ/su injection at week 24 and week 32.
62393372|NCT01363999|EXPERIMENTAL|C|RO5317116/F04 active-coated tablet
62393373|NCT01363999|EXPERIMENTAL|D|RO4607381/F49 tablet
62393374|NCT04797364|EXPERIMENTAL|Pharmacogenetic Testing|Pharmacogenetic testing panel (CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, NUDT15, SLCO1B1, TPMT, VKORC1)
62393375|NCT03222869||Laryngotracheal Stenosis|Patients with laryngotracheal stenosis will have pressure sensors placed proximal and distal to the stenosis. Pressure and air flow will be measured
62393376|NCT04151654|OTHER|assessment1|İt is assessment study. Assessment1 was evaluated for all test with and without footwear.
62568758|NCT01976429|OTHER|asymptomatic on flight/dive|individuals who experience no middle-ear problems on flying or diving
62393377|NCT04335929|EXPERIMENTAL|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
62393378|NCT05107557|EXPERIMENTAL|Experimental Group|The experimental group is also called the combined immunization group.260 participants will receive the first dose of COVID-19 vaccine and EV71 vaccine on day 0 and the second dose of COVID-19 vaccine and EV71 vaccine on day 28.
62393379|NCT05107557|ACTIVE_COMPARATOR|Control Group|The control group is also called the Non-combined immunization group.260 participants will receive the first dose of COVID-19 vaccine on day 0,the first dose of EV71 vaccine on day 14,the second dose of COVID-19 vaccine on day 28 and the second dose of EV71 vaccine on day 42.
62184672|NCT05060835||Breast Cancer|patients diagnosed with breast cancer at any stage.
62184673|NCT05060835||Prostate cancer|patients diagnosed with prostate cancer at any stage
62393380|NCT03831581|EXPERIMENTAL|Erector Spinae Plane Block|Patients with chest pain or upper abdomen underwent Erector Spinae Plane Block guided by ultrasound, bupivacaine 0.5% 20 ml was administered in the interfascial plane between the transverse process of T5 and the erector muscles of the spine, 60 minutes after dermatomes distribution was evaluated with pinprick and cold.
62393381|NCT03290274|EXPERIMENTAL|Deep brain stimulation (fornix)|Deep brain stimulation at fornix area
62393382|NCT03290274|EXPERIMENTAL|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation at Basal nucleus of Meynert
62568759|NCT01976429|OTHER|symptomatic on flying/diving|individuals who have experienced middle-ear problems on flying or diving
62184674|NCT04212975|EXPERIMENTAL|group 1|lavage by dextrose
62184675|NCT04757714|OTHER|COPD Patients|"Patients agreeing to participate in the study and meeting the inclusion and non-inclusion criteria will have:~* The high-resolution peripheral scanner (HRpQCT) of the tibia and radius~* a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)~* to complete:~  * a physical activity questionnaire (PHAS instrument)~ * a COPD quality of life questionnaire (St George Hospital)~* A search for sarcopenia by studying the strength of the grip (dynamometer)"
62184676|NCT04693910|EXPERIMENTAL|Multimedia information group|The experimental group received a weekly multimedia hormone therapy information program for 6 weeks.
62184677|NCT04693910|NO_INTERVENTION|Routine care group|The control group will receive routine care.
62393383|NCT03747497|EXPERIMENTAL|contezolid acefosamil|contezolid acefosamil 1500 mg IV x 1 dose, followed by 1000 mg IV q12h for at least 3 total IV doses, followed by 1300 mg PO q12h for 10 to 14 days
62393384|NCT03747497|ACTIVE_COMPARATOR|linezolid|linezolid 600 mg IV q12h for at least 3 total IV doses, followed by 600 mg PO q12h for 10 to 14 days
62393385|NCT02530580|EXPERIMENTAL|20 mg AZD7325|10 mg AZD7325 in orange capsule, Size 0, 2 capsules as a single oral dose
62393386|NCT02530580|PLACEBO_COMPARATOR|Placebo|10 mg Microcrystalline cellulose in orange capsule, Size 0, 2 capsules as a single oral dose
62393387|NCT01044095|ACTIVE_COMPARATOR|Autologous prime boost regimen 1|FluMist® live intranasal vaccine (LAIV) 0.2mL (0.1mL per nostril): 2 doses separated by 8 weeks (+/- 7 days)
62393388|NCT01044095|ACTIVE_COMPARATOR|Autologous prime boost regimen 2|Fluzone® inactivated seasonal influenza virus vaccine intramuscularly: 2 doses separated by 8 weeks (+7 days)
62393389|NCT01044095|EXPERIMENTAL|Heterologous prime boost regimen 1|FluMist® live, intranasal vaccine single dose, followed by Fluzone® inactivated influenza virus vaccine 8 weeks (+/-7 days) later
62393390|NCT01044095|EXPERIMENTAL|Heterologous prime boost regimen 2|Fluzone® inactivated seasonal influenza virus vaccine single dose, followed by FluMist® live, intranasal seasonal influenza vaccine 0.2mL 8 weeks (+/- 7 days) later
62393391|NCT00759993|EXPERIMENTAL|A,1|chromium piccolinate 1000mg
62393392|NCT00759993|PLACEBO_COMPARATOR|A,2|matching placebo
61999238|NCT03377712||Brachial Plexus Injury group|Patients who will be submitted to the surgical procedure and monitored for the repercussions of the surgery. Interventions: optoelectronic plethysmography, diaphragmatic ultrasound, postural evaluation, functional capacity, pain evaluation, function and quality of life
61999239|NCT03377712||Paired group|Healthy individuals who will be matched by sex and age with the group of patients who will effectively undergo the surgical process. Interventions: optoelectronic plethysmography, diaphragmatic ultrasound, postural evaluation and functional capacity.
62184678|NCT02928211|EXPERIMENTAL|Experimental|All subjects will receive the ointment and have scans with the Sapphire II device
62393393|NCT02119728|ACTIVE_COMPARATOR|Arm I (standard of care surgery)|Patients undergo standard of care surgery on day 1.
62393394|NCT02119728|EXPERIMENTAL|Arm II (HPPH, photodynamic therapy)|Patients receive HPPH IV over 1 hour on day 0. Approximately 24 hours later, patients undergo photodynamic therapy on day 1.
62184679|NCT04933981||interventional nursing home (INH).|regular, twice to three times weekly, and voluntary, i.e. non-mandatory, on-site testing for SARS-CoV-2 of HCW and visitors (INH)
62393395|NCT02440191|ACTIVE_COMPARATOR|3DCRT|conventional 3-dimensional conformal radiotherapy on the breast, 50.4 Gy/28 fx and tumor bed boost, 9 Gy/5 fx will be irradiated for 6.5 weeks.
62393396|NCT02440191|EXPERIMENTAL|IMRT (Intensity modulated radiotherapy)|"Intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) on the whole breast, 50.4 Gy/28 fx and tumor bed, 57.4 Gy/28 fx will be irradiated for 5.5 weeks.~Unlike 3DCRT, concomittant boost technique is used in the IMRT arm."
62393397|NCT03693846|EXPERIMENTAL|Nivolumab and Ipilimumab|Treatment will consist of Nivolumab 480mg every 4 weeks and Ipilimumab 1mg/kg every 8 weeks. Subjects will continue on study therapy until disease progression, unacceptable toxicity, withdrawal of consent, or 24 months of therapy.
62774841|NCT04964596|ACTIVE_COMPARATOR|undergoing a FIT as surveillance exam|if the FIT test is positive: patients will have subsequent colonoscopy within 3 months. Findings of FIT testing and if positive the colonoscopy will be documented and participation in the study will end after that. Findings of the FIT test and colonoscopy will be treated according to the institutional standards. If FIT test is negative patient will leave the study and will have a follow up with a colonoscopy or FIT test in 1 to 2 years outside of this study.
62184680|NCT04933981||control nursing home (CNH)|routine setting without frequent regular testing for SARS-CoV-2 (control nursing homes; CNH). Testing only performed by local health authorities upon medical indication, i.e. non-surveillance testing
62393398|NCT05102734||Topical nitroglycerin|A topical nitroglycerin solution will be applied to the area of interest
62393399|NCT03558230|EXPERIMENTAL|Vibration|The experimental group will receive the wrist stimulation during standardized Constraint-Induced Movement Therapy.
62393400|NCT03558230|PLACEBO_COMPARATOR|No Vibration|"The control group will wear the vibration device with no vibration during standardized Constraint-Induced Movement Therapy.~* The vibration device is a generic, commercially-available, vibrator, not particularly used for this peripheral skin stimulation purpose."
62568760|NCT00012376|EXPERIMENTAL|Treatment (bryostatin 1 and sargramostim)|Patients receive bryostatin 1 IV continuously and GM-CSF subcutaneously once daily on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with disease stabilization or improvement may continue treatment for up to 12 courses.
62568761|NCT04306731|EXPERIMENTAL|Interventional (Group M)|The group of patients given nanotechnology structured water magnalife
62568762|NCT04306731|ACTIVE_COMPARATOR|Control (Group T)|The group of patients given Trimethoprim
62568763|NCT04306731|PLACEBO_COMPARATOR|Placebo (Group O)|The group of patients given ordinary bottled drinking water
62774842|NCT04964596|ACTIVE_COMPARATOR|undergoing CT colonography as surveillance exam|If CTC is positive: patients will have subsequent colonoscopy within 3 months. Findings will be documented and participation in the study will end there. Findings of the colonoscopy will be addressed according to our institution's guidelines. If CTC is negative for polypoid lesions patient will leave the study and will have a follow up 5 years after with either a CTC or colonoscopy.
62774843|NCT06145958||No androgen deprivation|Those patients not given androgen deprivation therapy
62774844|NCT06145958||Short course androgen deprivation|Those patients given 6 months of androgen deprivation therapy
62774845|NCT06145958||Long course androgen deprivation|Those patients given 24 months of androgen deprivation therapy
61999240|NCT01105507|EXPERIMENTAL|canakinumab arm|
61999241|NCT06347081|PLACEBO_COMPARATOR|Placebo|Patients received standard medical care, nursing, physiotherapy, and a sham laser during the course of treatment
61999242|NCT06347081|ACTIVE_COMPARATOR|Laser group|Patients received 532 nm laser radiation in addition to standard medical care, nursing, and physiotherapy.
62184681|NCT04765410||Patients with solid pancreatic masses|Patients with solid pancreatic masses
62184682|NCT02192723|EXPERIMENTAL|Typical antipsychotic|Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day) for 8 weeks.
62184683|NCT02192723|ACTIVE_COMPARATOR|Risperidone|Risperidone, 2\~6mg/day, twice day, 8 weeks
62184684|NCT02192723|ACTIVE_COMPARATOR|Olanzapine|5\~20mg/day
62184685|NCT02192723|ACTIVE_COMPARATOR|Quetiapine|400\~750mg/day
62184686|NCT02192723|ACTIVE_COMPARATOR|Aripiprazole|Aripiprazole, 10\~30mg/day, twice per day, 8 weeks
62774846|NCT04311463|EXPERIMENTAL|Paroxetine hydrochloride followed by PAXIL|
62774847|NCT04311463|EXPERIMENTAL|PAXIL followed by paroxetine hydrochloride|
62774848|NCT04882787|EXPERIMENTAL|BTE hearing aid model|BTE or SP-BTE (super power) hearing aid fitting
62774849|NCT05055310||Normal elderly|normal cognitive group
62774850|NCT05055310||aMCI|amnestic mild cognitive impairment
62774851|NCT05055310||AD|Alzhiemer's disease
62774852|NCT02517320|EXPERIMENTAL|MT-3995 Low|
62774853|NCT02517320|EXPERIMENTAL|MT-3995 Middle|
62774854|NCT02517320|EXPERIMENTAL|MT-3995 High|
62774855|NCT02517320|PLACEBO_COMPARATOR|Placebo|
62774856|NCT04043078|OTHER|Exercise|Exercise and respiratory muscle training before surgery
62774857|NCT02209623||Pregnant Women receiving TDAP|
62774858|NCT05020002||Single biofluid collection|We will ask eligible volunteers to provide a single urine sample and undergo a single blood draw.
61999243|NCT06014073|EXPERIMENTAL|Patients with refractory or relapsed B-cell NHL|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, TRAC and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T.
61999244|NCT02350309|EXPERIMENTAL|Lemborexant 5 mg|Participants will receive a single, oral tablet formulation dose of lemborexant 5 mg within 5 minutes before bedtime.
61999245|NCT02350309|EXPERIMENTAL|Lemborexant 10 mg|Participants will receive a single, oral tablet formulation dose of lemborexant 10 mg within 5 minutes before bedtime.
61999246|NCT02350309|PLACEBO_COMPARATOR|Lemborexant-matched Placebo|Participants will receive a single, oral tablet formulation dose of lemborexant-matched placebo within 5 minutes before bedtime.
61999247|NCT02350309|ACTIVE_COMPARATOR|Flurazepam 30 mg|Participants will receive a single, oral capsule formulation dose of flurazepam 30 mg within 5 minutes before bedtime.
61999248|NCT01387204|EXPERIMENTAL|Single-Dose, 2 mg [14C]GSK1120212|A single 2 mg (2 mg/10mL) oral dose of \[14C\]GSK1120212 containing approximately 79 μCi of radioactivity will be delivered as a solution.
61999249|NCT02143570|EXPERIMENTAL|Darifenacin + Physiotherapy|Patients allocated to this group will receive Darifenacin 7.5mg daily in addition to physiotherapy for 12 weeks. This dose may be increased up to 7.5mg twice daily in follow-up visits in cases of refractory symptoms.
61999250|NCT02143570|ACTIVE_COMPARATOR|Physiotherapy|Patients allocated to this arm will receive a tailored pelvic floor exercise programme in addition to a matching placebo pill.
61999251|NCT00849368|EXPERIMENTAL|Azathioprine / Allopurinol|Single arm study: Dose escalations as described.
61999252|NCT03033017||HIV-infected on antiretroviral therapy 2 years|HIV-infected participants who have been on antiretroviral therapy (ART) for at least two years.
61999253|NCT04317248|EXPERIMENTAL|MSDCV immune therapy combined with radical surgery therapy|Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5\*10\^7 cells per time, total 6 times; Hepatocellular Carcinoma Radical surgery therapy: one time at a good operation time before the first time of MSDCV immune therapy
62184687|NCT02192723|ACTIVE_COMPARATOR|Ziprasidone|Ziprasidone, 80\~160mg/day, twice per day, 8 weeks
62774859|NCT05020002||Serial biofluid and muscle function testing|We will ask eligible volunteers to provide a urine sample, a blood sample, and undergo standard muscle function tests once every six months over a two-year period, and undergo pulmonary function tests and electrocardiogram once per year for two years.
62774860|NCT05020002||Biofluid and muscle tissue biopsy|We will ask eligible volunteers to provide a urine sample and undergo a muscle biopsy once.
62774861|NCT02095509|ACTIVE_COMPARATOR|Subcutaneous Enoxaparin|Subcutaneous enoxaparin 40 mg every 24 hours for three days
61999254|NCT04317248|NO_INTERVENTION|Radical surgery therapy|Hepatocellular Carcinoma Radical surgery therapy: one time at a good operation time
62184688|NCT01832454|OTHER|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
62184689|NCT04460729|EXPERIMENTAL|Cohort 1|Participants who are asymptomatic and without prior brain therapy
62184690|NCT04460729|EXPERIMENTAL|Cohort 2|Participants who are symptomatic with or without prior brain therapy or asymptomatic with prior brain therapy or with leptomeningeal disease
62184691|NCT05005286||Group A|Lactating women with vaginal infection during pregnancy as confirmed by past medical records
62184692|NCT05005286||Group B|Lactating women without any vaginal infection during pregnancy
62393401|NCT04435951||Group 1 (with TMJD)|Group 1, consists of 60 patients diagnosed with Temporomandibular Joint Dysfunction (TMJD) according to the Research Diagnostic Criteria for Temporomandibular Disorders by a specialist and experienced dentist in TMJD.
61999255|NCT04317248|EXPERIMENTAL|MSDCV immune therapy combined with TACE therapy|Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5\*10\^7 cells per time, total 6 times; Transcatheter Hepatic Arterial Chemoembolization (TACE) therapy: the first time of TACE therapy must perform before the first time of MSDCV immune therapy， then perform when necessary according to subjects condition
61999256|NCT04317248|NO_INTERVENTION|TACE therapy|Transcatheter Hepatic Arterial Chemoembolization (TACE) therapy: perform when necessary according to Subjects condition
62393402|NCT04435951||Group 2 (without TMJD)|Group 2, consists of 60 individuals who did not exhibit TMJD symptoms and have not TMJD diagnosis.
62184693|NCT03537378|EXPERIMENTAL|Hybrid APC Therapy Group|1) Patients are diagnosed as early central lung neoplasms (severe dysplasia, carcinoma in situ, microinvasive carcinoma，mucoepidermoid carcinoma.etc.) by inquiry of the first doctor, CT test, endoscopy and histopathology. Patients who meet inclusion/exclusion criteria are not suitable for or refuse surgery.
62184694|NCT02055456|EXPERIMENTAL|Nandrolone Decanoate|Nandrolone Decanoate intramuscularly administered, every two weeks, 5 mg/kg/dose
61999257|NCT04317248|EXPERIMENTAL|MSDCV immune therapy combined with targeted agents therapy|Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5\*10\^7 cells per time, total 6 times; Targeted agents therapy: Sorafenib or Lenvatinib. For Sorafenib: 0.4g twice daily; for Lenvatinib: 12mg/8mg per day according to subjects condition
61999258|NCT04317248|NO_INTERVENTION|Targeted agents therapy|Targeted agents therapy: Sorafenib or Lenvatinib. For Sorafenib: 0.4g twice daily; for Lenvatinib: 12mg/8mg per day according to subjects condition
61999259|NCT02915653|NO_INTERVENTION|Control|Control: not receiving any intervention
61999260|NCT02915653|EXPERIMENTAL|Intervention 1|Receiving educational materials on a new diagnostic service
61999261|NCT02915653|EXPERIMENTAL|Intervention 2|Receiving educational materials on a new diagnostic service
62184695|NCT00398723|EXPERIMENTAL|Vitiligo|adult patients (age 18 or greater) with extensive vitiligo warranting treatment with whole body NB-UVB
62393403|NCT00303602|EXPERIMENTAL|A|Sublingual orally disintegrating olanzapine (SODO)
62393404|NCT00303602|ACTIVE_COMPARATOR|B|Oral olanzapine
62393405|NCT02493712|EXPERIMENTAL|High dose|High dose, twice a day for 6 weeks.
62393406|NCT02493712|PLACEBO_COMPARATOR|Placebo: C|Placebo, twice a day
62393407|NCT02493712|EXPERIMENTAL|Low dose|Low dose, twice a day for 6 weeks
62393408|NCT03506165|EXPERIMENTAL|Rheumatoid Arthritis with Periodontitis|Rheumatoid Arthritis patients with Periodontitis diagnosed after oral examination then treated with Periodontal treatment
62393409|NCT03506165|NO_INTERVENTION|Rheumatoid without Periodontitis|Rheumatoid Arthritis patients without Periodontitis diagnosed after oral examination with. No interventions
61999262|NCT05626036|ACTIVE_COMPARATOR|Arthrex Tightrope|Syndesmosis fixation performed with Arthrex Tightrope device. This is a high-tension suture fixation with a button based anchor system.
61999263|NCT05626036|EXPERIMENTAL|Synthes Fibulink|Syndesmosis fixation performed with Synthes Fibulink device. This is a high-tension suture fixation with a screw based anchor system.
62184696|NCT02572115|ACTIVE_COMPARATOR|Intervention arm - jumped the line|"This arm is presented with the possibility to use the emergency access button that enables the patient to bypass the telephone waiting line. This arm represents the patients who choose to use the intervention."
62184697|NCT02572115|ACTIVE_COMPARATOR|Intervention arm - did not jump the line|"This arm is presented with the possibility to use the emergency access button that enables the patient to bypass the telephone waiting line. This arm represents the patients who got the option to use the intervention but DID NOT."
62184698|NCT02572115|NO_INTERVENTION|Control|This arm does not get the intervention.
62184699|NCT01607528|ACTIVE_COMPARATOR|Probiotic|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 10E9 cfu/g per day
62184700|NCT01607528|PLACEBO_COMPARATOR|Placebo|A similar looking and tasting powder
62184701|NCT04595942|ACTIVE_COMPARATOR|Midodrine|10 mg midodrine three times a day
62184702|NCT04595942|ACTIVE_COMPARATOR|Fludrocortisone|0.1 mg fludrocortisone two times a day
62184703|NCT04595942|OTHER|Lifestyle modification|Education, salt and water intake, counter-pressure maneuvers
62184704|NCT04673045|ACTIVE_COMPARATOR|Active neuromuscular electrical stimulation|This group will receive active NMES delivered the electrical current through electrodes inserted in saline-soaked sponges.
62184705|NCT04673045|SHAM_COMPARATOR|Sham neuromuscular electrical stimulation|This group will receive sham NMES
62393410|NCT01892046|EXPERIMENTAL|SNX-5422|Open label administration of SNX-5422 capsules every other day (QOD) for 21 days of a 28 day cycle. Dose escalation will be based on safety outcomes defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level. During the dose escalation phase, subjects will receive carboplatin and paclitaxel once every 21 days for a total of 4 courses. During the maintenance phase, SNX-5422 at the MTD will be dosed every other day (QOD) for 21 days of a 28 day cycle.
61999264|NCT01590407|EXPERIMENTAL|ALS-002200|
61999265|NCT01590407|PLACEBO_COMPARATOR|Placebo|
62184706|NCT05364645|EXPERIMENTAL|Arm A (carboplatin, pemetrexed, selpercatinib)|Patients receive carboplatin IV over 30 minutes and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also selpercatinib PO BID in the absence of disease progression or unacceptable toxicity.
62184707|NCT05364645|ACTIVE_COMPARATOR|Arm B (carboplatin, pemetrexed)|Patients receive carboplatin IV over 30 minutes and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62184708|NCT00640198|ACTIVE_COMPARATOR|Group 1 Memantine|Patients included in this group will receive memantine alone followed by memantine combined with intensive speech-language therapy.
62184709|NCT00640198|PLACEBO_COMPARATOR|Group 2|Patients included in this group will receive placebo alone followed by memantine combined with intensive speech-language therapy.
62184710|NCT05585736|OTHER|Cycloplegic refraction|All refractions were measured before and after cycloplegic addition to the eye.
62184711|NCT01382862|NO_INTERVENTION|Regular Care|Regular care for suspected stroke in Berlin consists of an ambulance with paramedics only, and neither computed tomography (CT) nor point-of-care diagnostics. In Berlin, emergency physicians are involved in prehospital care only in cases of special medical emergencies such as severe instability of vital parameters or loss of consciousness.
62184712|NCT01382862|ACTIVE_COMPARATOR|Stroke Emergency Unit Mobile (STEMO)|The STEMO is equipped with a CT-scanner, a point-of-care laboratory and the infrastructure for tele-radiological as well as videoconferencing support. STEMO is operated by a team of experienced neurologists (n=6, half-time positions, with additional formal training in emergency medicine according to the requirements of the Berlin Medical Board), paramedics of the fire brigade (n=3, two years formal training in emergency care) and radiology technicians (n=3, three years formal training in radiology assistance and three months formal training in emergency care).
62393411|NCT06169410|EXPERIMENTAL|ramucirumab combined with lobaplatin, S-1 and nab-paclitaxel|Patients will be given ramucirumab (8mg/kg), lobaplatin (30 mg/m2) and nab-paclitaxel (100mg/m2) by intravenous drip on the first day of each cycle, 3 weeks a cycle, together with oral S-1 (patients with a body surface area less than 1.25 m2, will give 40 mg each time; patients with a body surface area between 1.25 and 1.5 m2; will give 50 mg each time; patients with a body surface area greater than 1.5 m2, will give 60 mg each time), 2 weeks on and 1 week off.
62568764|NCT03125252|EXPERIMENTAL|Bundle|Specific action plan : ABCDE, complemented with care related to the nursing and paramedical role concerning the patient's environmental factors
62568765|NCT03125252|OTHER|Control|Standard paramedical and medical practices
62568766|NCT01034202|EXPERIMENTAL|Norditropin® SimpleXx® 0.02 mg/kg + NNC126-0083|
62568767|NCT01034202|EXPERIMENTAL|Norditropin® SimpleXx® 0.04 mg/kg + NNC126-0083|
62184713|NCT01530386|EXPERIMENTAL|Lacosamide|300 mg/day
62184714|NCT00832364|EXPERIMENTAL|1|U0279 and Injectable Biologic
62184715|NCT00832364|PLACEBO_COMPARATOR|2|Placebo and Injectable Biologic
62184716|NCT04131686||Control sites|Group of patients receiving standard treatment for symptomatic acute rhinosinusitis
62184717|NCT04131686||Test sites|Group of patients receiving NAC inhalation in addition to standard treatment for symptomatic acute rhinosinusitis
62184718|NCT03123302||Group 1|Epileptic patients who are sedated with a total dose of propofol 2 mg/kg and midazolam 0.1 mg/kg.
62184719|NCT03123302||Group 2|Epileptic patients who are sedated with a total dose of pentothal 4 mg/kg and midazolam 0.1 mg/kg.
62184720|NCT03123302||Group 3|Non-epileptic patients who are sedated with a total dose of propofol 1 mg/kg and ketamine 1 mg/kg.
62184721|NCT03123302||Group 4|Non-epileptic patients who are sedated with a total dose of midazolame 0.1 mg/kg and ketamine 1 mg/kg.
61999266|NCT04143451|ACTIVE_COMPARATOR|IQ|"Year 1: a single dose ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream~Year 2: randomised into 3 subgroups. Group IQ1: ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream Group IQ2: IM QIV (15 µg of hemagglutinin per strain with pre-treatment of the injected skin with aqueous cream. Group IQ3: ID normal saline vaccination with pre-treatment of the injected skin with imiquimod (Aldara) cream.~Year 3: IQ1 and IQ2 same treatment as second year. IQ3 same as first year."
61999267|NCT04143451|ACTIVE_COMPARATOR|IM|"Year 1: a single dose IM QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream~Year 2: randomised into 3 subgroups. Group IM1: IM QIV (15 µg of hemagglutinin per strain with pre-treatment of the injected skin with aqueous cream. Group IM2: ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream. Group IM3: IM normal saline vaccination with aqueous cream pretreatment.~Year 3: IM1 and IM2 same treatment as second year. IM3 same as first year."
61999268|NCT04143451|ACTIVE_COMPARATOR|HD|"Year 1: a single high-dose IM TIV (60 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream~Year 2: Group HD1: IM QIV (60 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream. Group HD2: IM normal saline vaccination with aqueous cream pretreatment.~Year 3: Group HD1 same treatment as second year. HD2 same as first year."
61999269|NCT02961699|EXPERIMENTAL|Transpose ® RT System|Adipose-derived stem cells (also known as stromal vascular fraction or SVF) will be injected subcutaneously around the rim of the wound bed following standard would debridement. The standard collagen dressing material will also be saturated with SVF after placement within the would itself. Normal (standard) dressing of wound will be placed over wound.
61999270|NCT02961699|ACTIVE_COMPARATOR|debridement/dressing of wound|Wound will be debrided and collagen dressing placed within wound bed as per standard of care. Standard dressing will cover wound. No adipose-derived stem cells (SVF) will be applied to control subject wounds.
61999271|NCT06039241||AD patients treated with dupilumab|Patients ≥6 years of age in whom dupilumab therapy was initiated to treat their severe AD (6-11 years) or moderate to severe AD (adult and adolescent patients ≥12 years of age) based on the patient's medical requirements and standards of best medical practice.
61999272|NCT01009099|EXPERIMENTAL|Arm 1|exercise training with breathing retraining
61999273|NCT01009099|ACTIVE_COMPARATOR|Arm 2|exercise training
61999274|NCT05243212|EXPERIMENTAL|'low' dose|The dose escalation stage will involve recruitment of 3 RRMM patients for 'low' dose (6 x 106 CAR-T cells/kg) CAR-T therapy. After 14 days of follow-up for each of the 3 subjects, the DSC will determine whether the next subject can be recruited. After 14 days follow-up for the 3rd subject, DSC will review data for the 3rd subject and consider the data for the first 3 subjects.
61999275|NCT05243212|EXPERIMENTAL|'high' dose|In the absence of dose limiting toxicities (DLTs), the DSC may recommend recruitment of 3 subjects to be treated with the 'high' dose (9x106 CAR-T cells/kg) CAR-T therapy, with similar staggering.
61999276|NCT00724516|EXPERIMENTAL|Novel Breast Compression Paddle|Women scheduled to undergo a breast mammography wire localization procedure will have a new breast compression paddle will be used Instead of using the regular wire localization mammography compression paddle.
61999277|NCT02235779|OTHER|Cryobiopsy|
61999278|NCT02366078|EXPERIMENTAL|Stress management|Participants will receive SMART traiing
61999279|NCT01113125|EXPERIMENTAL|Fucicort|
61999280|NCT01113125|PLACEBO_COMPARATOR|Fucidin|
61999281|NCT06132607|EXPERIMENTAL|Preoperative 3D lung reconstruction|Patients who were planned for an anatomical lung resection with preoperative 3D lung reconstruction.
61999282|NCT00615563||genotype test|
61999283|NCT00615563||combined phenotype/genotype test|
61999284|NCT03195959||PH-Patients|Patients with mean pulmonary artery pressure \>25mmHg and a pulmonary arterial wedge pressure \<15mmHg during right heart catheterisation, which are diagnosed as having pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
61999285|NCT03195959||Control group|Patients with clinically indicated right heart catheterisation (because of dyspnea or other signs of PH), but had no PH (no elevated mean pulmonary artery pressure (mPAP \<20mmHg)).
61999286|NCT05418452|EXPERIMENTAL|metformin|will receive split-crest technique by ultrasonic bone surgery with implant placement and PRF mixed with 1% metformin gel
61999287|NCT05418452|NO_INTERVENTION|control|will receive split-crest technique by ultrasonic bone surgery with implant placement without gap filling.
61999288|NCT01231581|EXPERIMENTAL|GSK1120212 plus Gemcitabine|GSK1120212 administered orally plus gemcitabine IV
61999289|NCT01231581|ACTIVE_COMPARATOR|Placebo plus Gemcitabine|Placebo administered orally plus gemcitabine IV
61999290|NCT02310178|OTHER|Group/Cohort|all of the current bariatric surgeries are allowed in this prospective cohort study
61999291|NCT01158222|EXPERIMENTAL|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 42 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
61999292|NCT00208377|OTHER|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
61999293|NCT04709666||Endsocopic Retrograde ColangioPancreatography (ERCP)|Endsocopic Retrograde ColangioPancreatography (ERCP)
61999294|NCT01556672|EXPERIMENTAL|adalimumab|All patients will receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
62393412|NCT06169410|ACTIVE_COMPARATOR|lobaplatin combined with S-1 and nab-paclitaxel|Patients will be given lobaplatin (30 mg/m2) and nab-paclitaxel (100mg/m2) by intravenous drip on the first day of each cycle, 3 weeks a cycle, together with oral S-1 (patients with a body surface area less than 1.25 m2, will give 40 mg each time; patients with a body surface area between 1.25 and 1.5 m2; will give 50 mg each time; patients with a body surface area greater than 1.5 m2, will give 60 mg each time), 2 weeks on and 1 week off.
62393413|NCT02203305|EXPERIMENTAL|Cochlear Implant|Cochlear implantation of the affected ear
61999295|NCT04618055|EXPERIMENTAL|NiTiDent Tuah Porous NiTi Dental Implants|
62184722|NCT01006889|EXPERIMENTAL|Exenatide (twice daily)|Patients with T2DM well-controlled on an intensified insulin regimen for the previous 6 months by the will have their insulin aspart discontinued and replaced for exenatide twice daily while continuing the bedtime detemir insulin. Safety and efficacy parameters will be measured before and after 6 months of treatment.
62184723|NCT01391429|EXPERIMENTAL|Video decision support tool|Video decision support tool for goals-of-care options
62393414|NCT02203305|OTHER|Control Group|A control group without the study intervention (cochlear implantation) will complete the test battery.
62393415|NCT02203305|EXPERIMENTAL|Cochlear Implant: Asymmetric hearing loss|Cochlear implantation of the poorer hearing ear
62393416|NCT04515602|EXPERIMENTAL|Part 1 Arm I (low/medium tumor burden)|Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
62393417|NCT04515602|ACTIVE_COMPARATOR|Part 1 Arm II (low/medium tumor burden)|Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
61999296|NCT04618055|ACTIVE_COMPARATOR|Control Implant|
61999297|NCT05705622|EXPERIMENTAL|Experimental intervention group|"Sociodemographic information, comorbidity, habits and disease information of the patients included in the experimental group were obtained through the Patient Diagnosis Form and recorded in the form. The patients were evaluated for oral mucositis by diagnosing the mouth. It was recorded in the World Health Organization Mucositis Evaluation Form, Oral Mucositis Risk Assessment Scale in Hematology Patients, Oral Mucous Membrane Evaluation and Follow-up Form. After the diagnosis of oral mucositis was made, a pre-test was performed using the Oral Mucositis Knowledge Level Evaluation Form to measure the oral mucositis knowledge level of the patients. Later, the patients included in the experimental group were given training on the evaluation, prevention, care and treatment of oral mucositis, and a training booklet was given for the benefit of the patients."
61999298|NCT05705622|NO_INTERVENTION|No intervention control group|The first follow-up of the patients included in the control group was made in the patient's room on the day of their admission to the bone marrow transplant unit. Sociodemographic information, comorbidity, habits and disease information of the patients were obtained through the Patient Diagnosis Form and recorded in the form. The patients were evaluated for oral mucositis by diagnosing the mouth. It was recorded in the World Health Organization Mucositis Evaluation Form, Oral Mucositis Risk Assessment Scale in Hematology Patients, Oral Mucous Membrane Evaluation and Follow-up Form. The patients in the control group were not given training on oral mucositis and the training booklet prepared by the researcher was not given.
61999299|NCT05653960||Subjects who undergo EMR or ESD|Subjects who undergo EMR or ESD for colorectal lesions
61999300|NCT02990793|ACTIVE_COMPARATOR|Active MeRT Treatment|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 5 weeks.
61999301|NCT02990793|SHAM_COMPARATOR|Sham MeRT Treatment|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 5 weeks.
61999302|NCT05595629|ACTIVE_COMPARATOR|Text-message based remote blood pressure monitoring|Women in this group will receive current standard of care: remote blood pressure monitoring via text message. Specifically, they will receive automatic blood pressure cuffs, instructions how to obtain their blood pressures and log them into our Electronic Medical Record, and contact information for the nurse practitioner and community health worker managing the program. The NP will respond via text message to each individual measurement with instructions as to next steps.
61999303|NCT05595629|EXPERIMENTAL|App-based remote blood pressure monitoring|Women in this group will receive a Bluetooth-enabled automatic blood pressure cuff that synchs automatically to a smartphone application that incorporates Artificial Intelligence to respond to each recorded measurements with recommended next steps and also document the measurement and response in a secure platform. This affiliated smartphone application will also contain education on hypertension management. Upon receipt of the blood pressure cuff, participants will be instructed to set up the program/app.
61999304|NCT01627613|EXPERIMENTAL|AP301|Treatment group
61999305|NCT01627613|PLACEBO_COMPARATOR|saline solution|Placebo group
61999306|NCT04708717|EXPERIMENTAL|Stimulation Rate|
62393418|NCT04515602|EXPERIMENTAL|Part 2 Arm I (high tumor burden)|Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
62393419|NCT04515602|ACTIVE_COMPARATOR|Part 2 Arm II (high tumor burden)|Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
61999307|NCT04708717|ACTIVE_COMPARATOR|Electrode Location|
61999308|NCT03608488|EXPERIMENTAL|Vitamin D<10 ng/ml; Vitamin D replacement|Vitamin D replacement (50.000 IU/per week, for 8 weeks)
62184724|NCT01391429|NO_INTERVENTION|Verbal description|Standard verbal description of goals-of-care options provided by an inpatient palliative care team
62184725|NCT03592004||Guangdong General Hospital|
62184726|NCT03592004||Cancer Hospital Chinese Academy Of Medical Sciences|
62184727|NCT03592004||Beijing Friendship Hospital|
62184728|NCT03592004||Yunnan Cancer Hospital|
62184729|NCT03592004||Liaoning Cancer Hospital|
62184730|NCT03592004||The First Hospital Of China Medical University|
62184731|NCT03592004||Affiliated Hospital Of Hebei University|
62184732|NCT03356964|ACTIVE_COMPARATOR|Control group|Follicle stimulating Hormone will be applied, starting from day 3 of the cycle, the dosage will be choosen between Gonal F 150 - 225 IU, according to the ovarian reserve parameters (13). The stimulation dosage will remain unchanged until the criteria for final oocyte maturation are met (≥ 3 follicles of ≥ 17 mm).
62184733|NCT03356964|EXPERIMENTAL|Study group|Follicle stimulating Hormone will be applied, starting from day 3 of the cycle, the dosage will be choosen between Gonal F 150 - 225 IU, according to the ovarian reserve parameters (LaMarca et al.). As soon as ≥ 3 follicle of a size of 14mm are seen, the stimulation dosage will be reduced daily by 12.5 IU recFSH until the criteria for final oocyte maturation are met (≥ 3 follicles of ≥ 17 mm).
62184734|NCT00805597|EXPERIMENTAL|radiotherapy|radiotherapy of 50Gy/25/f/5w to the ipsilateral chest wall and supraclavicular region
62393420|NCT04000412||CASE GROUP|patients with chronic infarction undergoing catheter ablation of ventricular arrhythmias
62393421|NCT01840332|EXPERIMENTAL|L-thyroxin|this is one arm study
62568768|NCT01034202|PLACEBO_COMPARATOR|Norditropin® SimpleXx® 0.02 mg/kg + placebo|
62568769|NCT01034202|PLACEBO_COMPARATOR|Norditropin® SimpleXx® 0.04 mg/kg + placebo|
62568770|NCT01034202|EXPERIMENTAL|NNC126-0083|
62568771|NCT01034202|PLACEBO_COMPARATOR|Placebo|
62393422|NCT03939429|EXPERIMENTAL|QPX2015|QPX2015, antibiotic
62393423|NCT03939429|PLACEBO_COMPARATOR|Placebo|Matched placebo
62393424|NCT02380599|EXPERIMENTAL|Experimental Group|Crossover assignment of mid-thoracic spinal manipulation, spinal mobilization, or sham ultrasound
62393425|NCT01461018|EXPERIMENTAL|IgPro20|
62393426|NCT06085690|NO_INTERVENTION|Existing central venous catheters in the hospital or ICU maintain routine care procedures|According to the hospital or ICU catheterization, maintenance and removal of central venous catheter routine care
62568772|NCT06065163|EXPERIMENTAL|Ultrasound Guided Treatment|Patients allocated to this will be guided (diuretic treatment) by ultrasound (VExUS) findings
62568773|NCT06065163|ACTIVE_COMPARATOR|Clinical Guided Treatment|Patients allocated to this will be guided (diuretic treatment) by clinical congestion score (CCS) findings
62568774|NCT01045811|EXPERIMENTAL|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
62568775|NCT01045811|ACTIVE_COMPARATOR|Stress management|Cognitive reconstructive strategies for stress management
62568776|NCT05879289|EXPERIMENTAL|Clinical Trial|36 participants using the product for 90 days. Aims to evaluate the clinical, subjective and instrumental usage
62568777|NCT04996901||derivation cohort|Data from Renmin Hospital of Wuhan University, The First College of Clinical Medical Science, China Three Gorges University, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Xiangyang No.1 People's Hospital，and Wuhan Third Hospital will be used as a derivation cohort.
62568778|NCT04996901||validation cohort|Data from The First Affiliated Hospital of Dalian Medical University and Jiangxi Provincial People's Hopital will be used as a derivation cohort.
62568779|NCT02907723|EXPERIMENTAL|Continuous Sleep Recording|Continuous Sleep Recording in Patients
62568780|NCT03870932|EXPERIMENTAL|Motor imagery rehabilitative group (MIG)|"All patients performed 10 treatment sessions, lasting 60 to 90 minutes, twice a week, in groups of three to four patients. The gold standard was to choose simple and safe exercises in order to encourage the patient to repeat the schedule at home. The exercises proposed in the MIG have been chosen respecting the following principles: slowness, painlessness, promoting attention, easy to imagine. The main purpose of motor imagery-based exercises was to bring the patient back to feeling and self-perceiving the execution of the movement. More than the quantity of repetition, the quality of the movement, free from pain, was important."
62568781|NCT03870932|ACTIVE_COMPARATOR|Control rehabilitative Group (CG)|The CG received a conventional rehabilitation protocol, based on ten 1-hour sessions, held twice a week (over a 5-week period), previously investigated as efficient in FM by the authors and published. The exercises included low-to-moderate impact aerobic training, walking in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes), for a total of 20 consecutive minutes, posture exercises for the back and proprioceptive exercises for the trunk, to improve axial stability. Each exercise was repeated 10 times (3 sets of 10), with a resting period of at least 3 minutes between sets. All sessions ended with stretching and diaphragmatic breathing exercises.
62184735|NCT00805597|ACTIVE_COMPARATOR|no radiotherapy|no radiotherapy
62393427|NCT06085690|EXPERIMENTAL|evidence-based intervention Plan for the Prevention of CRBSI in ICU patients|"On the basis of routine nursing, the evidence-based intervention Plan for the Prevention of CRBSI in ICU patients was implemented for intervention."
62393428|NCT03420846|EXPERIMENTAL|OCT Mapped arm|OCT is used to map the tumour margins as the first stage MMS estimate
62568782|NCT00648882|EXPERIMENTAL|1|LEVOTHYROXINE SODIUM TABLETS,USP 300 mcg;
62568783|NCT00648882|ACTIVE_COMPARATOR|2|SYNTHROID® 300 mcg Tablets
62774862|NCT02095509|ACTIVE_COMPARATOR|Intravenous Enoxaparin|40 mg enoxaparin daily as continuous intravenous infusion for three days (72 hours)
62774863|NCT02387008|ACTIVE_COMPARATOR|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
62184736|NCT01003171|EXPERIMENTAL|MCS-2|
62393429|NCT03420846|NO_INTERVENTION|Control arm|Standard MMS is performed
62393430|NCT04824599|ACTIVE_COMPARATOR|PECS+subcutaneus local anesthetic infiltration|Preoperative ultrasound-led PECS II blockade with ropivacaine 3,75mg/ml (2mg/kg). After surgery - wound infiltration by the surgeon with ropivacaine 2mg/ml (1mg/kg).
62393431|NCT04824599|ACTIVE_COMPARATOR|Local anesthetic infiltration|Prior to scrubbing surgeon infiltrates the thought incision area with ropivacaine 3,75/ml (1mg/kg). Perioperatively after removal of the tumor follows the deep infiltration of the wound with ropivacaine 3,75mg/ml (2mg/kg).
62393432|NCT03343665|EXPERIMENTAL|Nivolumab 40 mg|Experimental: Nivolumab Nivolumab 40 mg IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62393433|NCT05535803|EXPERIMENTAL|Patients with tracheal/laryngeal stenosis receiving standard treatment and stem cells|Patients with tracheal/laryngeal stenosis receiving standard surgical treatment and mesenchymal stem cells
62393434|NCT05535803|ACTIVE_COMPARATOR|Patients with tracheal/laryngeal stenosis receiving standard treatment|Patients with tracheal/laryngeal stenosis receiving standard surgical treatment
62568784|NCT02479620|ACTIVE_COMPARATOR|Dexamethasone Delivery|"Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe.~For Subjects randomized into the Dexamethasone Delivery arm, this protocol will utilize a 4 mg/mL preparation of Dexamethasone Sodium Phosphate Injection, USP. Each milliliter of the solution contains 4.37 mg of dexamethasone sodium phosphate equivalent to 4 mg of dexamethasone phosphate or 3.33 mg of dexamethasone. The total dose of Dexamethasone Sodium Phosphate Injection, USP will be diluted by 20% prior to infusion. This will result in a final concentration of 3.2 mg dexamethasone phosphate (3.5 mg dexamethasone sodium phosphate, or 2.67 mg dexamethasone) in each milliliter of solution."
61999309|NCT03608488|EXPERIMENTAL|Vitamin D<10 ng/ml; Vitamin D replacement and exercise|Vitamin D replacement (50.000 IU/per week, for 8 weeks) and Core and balance exercises for 8 weeks.
61999310|NCT03608488|EXPERIMENTAL|Vitamin D<10 ng/ml; exercise|Core and balance exercises for 8 weeks.
62393435|NCT04566016|EXPERIMENTAL|Regional anesthesia|Patients scheduled for lower limb arterial bypass surgery and allocated for treatment with spinal anesthesia associated with spontaneous ventilation (nasal cannula with supplemental oxygen - Group 1).
62393436|NCT04566016|ACTIVE_COMPARATOR|General anesthesia|Patients scheduled for lower limb arterial bypass surgery and allocated for treatment with general anesthesia under controlled mechanical ventilation (tidal volume 6 to 8 ml / kg of the predicted body weight and PEEP of 5 cmH2O - Group 2).
62393437|NCT03303352|EXPERIMENTAL|Fast Pass First, Slow Pass Second|"Each patient will receive 2 EUS FNA passes, 1 fast and 1 slow, with a 22 gauge EUS needle, with suction syringe, employing the fanning technique, 10 jabs for each pass.~A fast pass has an advancing mean acceleration jab (to movement) higher than 1 g, while a slow pass has an advancing mean acceleration jab of less than 1 g (where 1 g equals 9.8 m/s2). Both movements will have a slow fro withdrawal movement, from the point of maximum advance into the lesion to the lesion entry site.~For each patient, the passes order with be either done as fast pass first, slow pass second."
62393438|NCT03303352|EXPERIMENTAL|Slow Pass First - Fast Pass Second|"Each patient will receive 2 EUS FNA passes, 1 fast and 1 slow, with a 22 gauge EUS needle, with suction syringe, employing the fanning technique, 10 jabs for each pass.~A fast pass has an advancing mean acceleration jab (to movement) higher than 1 g, while a slow pass has an advancing mean acceleration jab of less than 1 g (where 1 g equals 9.8 m/s2). Both movements will have a slow fro withdrawal movement, from the point of maximum advance into the lesion to the lesion entry site.~For each patient, the passes order with be either done as slow pass first, fast pass second."
62393439|NCT05038397|EXPERIMENTAL|Therasphere|
62393440|NCT04025736|EXPERIMENTAL|Patients received Tranexamic acid|The patient was assigned as intervention group, TXA will be aspirated into a syringe. In TXA group, TXA 1000 mg (20 mL) was given intravenously 10 minutes before surgery.
62393441|NCT04025736|PLACEBO_COMPARATOR|Patients received same volume of saline|In the control group, the patient received 20ml saline intravenous also 10 min before surgery.
62393442|NCT03345927||high cardiovascular risk group|no intervention
62393443|NCT02643420|EXPERIMENTAL|Arm 1: SPI-2012 and Docetaxel + Cyclophosphamide (TC)|Participants received SPI-2012 13.2 milligram (mg)/0.6 milliliter (mL) (3.6 mg Granulocyte Colony-Stimulating Factor \[G-CSF\]) fixed-dose subcutaneous (SC) injection once per cycle on Day 2 of each cycle up to Cycle 4 (each cycle was 21 days), approximately 24-26 hours after TC chemotherapy administration. TC chemotherapy was administered on Day 1 of each cycle and included Docetaxel 75 mg/m\^2 intravenous (IV) infusion and Cyclophosphamide 600 mg/m\^2 IV infusion per institute's standard of care.
62393444|NCT02643420|EXPERIMENTAL|Arm 2: Pegfilgrastim and Docetaxel + Cyclophosphamide (TC)|Participants received pegfilgrastim 6 mg SC injection once per cycle on Day 2 of each cycle up to Cycle 4 (each cycle was 21 days), approximately 24-26 hours after TC chemotherapy administration. TC chemotherapy on Day 1 of each cycle included Docetaxel 75 mg/m\^2 IV infusion and Cyclophosphamide 600 mg/m\^2 IV infusion per institute's standard of care.
62393445|NCT04083287|ACTIVE_COMPARATOR|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
62568785|NCT02479620|NO_INTERVENTION|Control|"Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe.~Standard endovascular revascularization therapy consisting of atherectomy with or without angioplasty and with or without stent placement. No additional drug will be given to Subjects randomized to Control."
61999311|NCT03608488|ACTIVE_COMPARATOR|Vitamin D>30ng/ml; exercise|Core and balance exercises for 8 weeks.
61999312|NCT05254795|NO_INTERVENTION|Usual care recipients|
62184737|NCT00665223|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo capsule matching to ACR16 once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 26), placebo capsule will be taken twice daily as 2 separate doses.
62184738|NCT00665223|EXPERIMENTAL|ACR16 45 mg|Participants will receive ACR16 45 milligrams (mg) capsule orally once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 26), one ACR16 45 mg capsule and one placebo capsule will be taken as 2 separate doses.
61999313|NCT05254795|EXPERIMENTAL|Molecular tumor board intervention|
62184739|NCT00665223|EXPERIMENTAL|ACR16 90 mg|Participants will receive ACR16 45 mg capsule once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 26), ACR16 45 mg capsule will be taken twice daily as 2 separate doses (total dose: 90 mg)
61999314|NCT01557400|EXPERIMENTAL|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water, milk, fruit juice (except apple juice) fruit punch, or in semi-solid food (for example, yogurt, pudding, or applesauce). The dose level for ataluren will be 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening. Administration within 30 minutes after a meal will be recommended. Study drug dosing will be based on milligrams of drug per kilogram of body weight. Because of potential changes in participant body weight over time, weight-based dose adjustment can occur every 24 weeks as required. Study drug will be taken for up to 240 weeks.
61999315|NCT00333684|ACTIVE_COMPARATOR|receive bioalcamid at baseline|half subjects received bioalcamid at baseline
62774864|NCT02387008|ACTIVE_COMPARATOR|GUIDOR® membrane alone|horizontal bone augmentation with synthetic GUIDOR® membrane
62393446|NCT04083287|ACTIVE_COMPARATOR|Group I = ISCB group|In group I, ISCB will be performed with patients in the supin position. US probe will be placed in transverse plane at the level of cricoid cartilage. The prob will be moved laterally when the artery is visualized. The needle will be inserted in a medial-to-lateral direction after the brachial plexus between the scalen muscles is visualized. Then, 5 ml normal saline will be enjected for correction of the needle with in-plane technique. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
62568786|NCT04722042|OTHER|Default|The default frequency filters assigned by the clinical software
62568787|NCT04722042|EXPERIMENTAL|Place-based|Frequency filters adjusted to align with the cochlear place frequency
62568788|NCT05994339|EXPERIMENTAL|Radiotherapy Combined with Almonertinib|Radiotherapy was administered using Intensity-Modulated Radiation Therapy (IMRT) technique, with a prescribed dose of 60 Gy in 30 fractions. Almonertinib was orally administered at 110 mg per day, starting from the first day of radiotherapy and continued for 42 days until the completion of radiotherapy, followed by continuous medication until disease progression.
62568789|NCT05994339|ACTIVE_COMPARATOR|Radiotherapy Combined with Chemotherapy|Radiotherapy was administered using Intensity-Modulated Radiation Therapy (IMRT) technique, with a prescribed dose of 60 Gy in 30 fractions. Chemotherapy with paclitaxel at 135 mg/m2 and cisplatin at 70 mg/m2 was intravenously infused for two cycles during the 1st and 4th weeks. After the completion of radiotherapy, there was a rest period of 4 weeks, followed by continuation of the TP regimen for consolidation chemotherapy for 4 cycles.
62568790|NCT05644626|EXPERIMENTAL|Phase 1a: Dose Escalation|Part A: Increasing dose levels of BGB-B167 monotherapy; Part B: Increasing dose levels of BGB-B167 in combination with tislelizumab (BGB-A317)
62774865|NCT02387008|ACTIVE_COMPARATOR|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
62774866|NCT03009318|OTHER|MRS imaging and 11C-MET PET/CT|Each patient underwent both MRS and MET PET before surgery.
62774867|NCT01107613|EXPERIMENTAL|Intervention Arm|Opinion leader educational letter
62774868|NCT01107613|NO_INTERVENTION|Control/Standard Care|Regular care
62393447|NCT03077074|EXPERIMENTAL|Low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
62393448|NCT01041742|EXPERIMENTAL|OPCAB|
62568791|NCT05644626|EXPERIMENTAL|Phase 1b: Dose Expansion|BGB-B167 alone or in combination with tislelizumab (BGB-A317)
62774869|NCT06025409|EXPERIMENTAL|Experimental: Leuprorelin|Participants with body weight greater than or equal to (≥) 20 kilogram (kg) will receive the recommended dose of leuprorelin 11.25 milligram (mg), injection, subcutaneously, once every 3 months for 6 months. Participants with body weight less than (\<) 20 kg will receive leuprorelin 5.625 mg, injection, subcutaneously, once every 3 months for 6 months.
62774870|NCT04348396||Elderly patients affected by COVID-19|The group taken into consideration consists of elderly patients hospitalized with diagnosed COVID-19.
62774871|NCT04186507||Prelaminary group|To confirm that Li+ is detectable in sweat .
62774872|NCT04186507||Spectrophon LTD biosensors for Li+ detection in sweat|In this group will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat
61999316|NCT00333684|ACTIVE_COMPARATOR|Receive bioalcamid at 24 weeks|other half of subjets received bioalcamid at 24 weeks
61999317|NCT04138615|EXPERIMENTAL|Morphine|Morphine will be administered intravenously
61999318|NCT04138615|PLACEBO_COMPARATOR|Placebo|Saline will be administered intravenously
61999319|NCT01849211|OTHER|neuromuscular block|
61999320|NCT05190042|EXPERIMENTAL|Continuous suture group|"Surgical sutures were used to completely close the post-EMR/ESD mucosal/submucosal defects.~This group was set as a experimental group."
61999321|NCT05190042|ACTIVE_COMPARATOR|Clips group|Clips were used to completely close the post-EMR/ESD mucosal/submucosal defects. This group was set as a control group.
61999322|NCT06391879||VHL-related RCC cohort|This cohort incorporates subjects with VHL-related renal cell carcinoma.
62568792|NCT05505734|EXPERIMENTAL|PT027|Participants will receive Budesonide and Albuterol Sulfate Pressurised Inhalation Suspension 160/180 μg up to a maximum of 12 inhalations to max dose.
61999323|NCT02607514|EXPERIMENTAL|immediate yoga arm|participants will immediately start the 8-week hyperthermic yoga intervention
61999324|NCT02607514|OTHER|delayed yoga arm|participants will wait 8-weeks to start the 8-week hyperthermic yoga intervention
61999325|NCT03212963|EXPERIMENTAL|Halobetasol lotion treatment arm|All subjects will receive Halobetasol Topical Lotion, 0.05%.
62774873|NCT01502163|NO_INTERVENTION|Control|"* No prewarming~* Intraoperative forced air warming (Thermoflect™/Mistral Air™) (after induction of anaesthesia, before surgery starting)~* Passive insulation with Thermoflect™ material.~* All fluids administrated intraoperative will be warmed."
62774874|NCT01502163|ACTIVE_COMPARATOR|Group passive prewarming|"* Passive prewarming / insulation on nursery ward before transport to the OR (Thermoflect TSCI, Amersfoort, NL)~* Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.~* All fluids administrated intraoperative will be warmed."
61999326|NCT05585814|EXPERIMENTAL|Pembrolizumab+ Bevacizumab + CAPOX as neoadjuvant treatment for 4 cycles|"CapOx: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3 weeks for 4 cycles and Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 4 cycles;~Bevacizumab：Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 4 cycles;~Pembrolizumab：Pembrolizumab is given intravenously at 200 mg on day 1 every 3 weeks for 4 cycles"
62774875|NCT01502163|ACTIVE_COMPARATOR|Group Active prewarming|"* Active prewarming on nursery ward before transport to the OR (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)~* Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.~* All fluids administrated intraoperative will be warmed."
62184740|NCT01582503|EXPERIMENTAL|MEMP1972A 150 mg|
62568793|NCT05505734|EXPERIMENTAL|PT007|Participants will receive Albuterol Sulfate Pressurised Inhalation Suspension 180 μg up to a maximum of 12 inhalations to max dose.
62774876|NCT06124794|EXPERIMENTAL|PROTOXIN 100U (Clostridium botulinum toxin type A)|PROTOXIN will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL)
62568794|NCT05362188|EXPERIMENTAL|Topical Nicotinamide 2%|will receive topical nicotinamide 2%
62568795|NCT05362188|EXPERIMENTAL|Topical Nicotinamide 4%|will receive topical nicotinamide 4%
61999327|NCT05901727||HIV treatment survey participants|HIV treatment patients eligible to be enrolled in the patient survey
61999328|NCT05901727||Provider survey participants|HIV treatment providers eligible to be enrolled in the provider survey
61999329|NCT05901727||Time and motion observation participants|HIV treatment providers eligible to be enrolled in the time and motion observation study
62184741|NCT01582503|EXPERIMENTAL|MEMP1972A 300 mg|
62184742|NCT01582503|EXPERIMENTAL|MEMP1972A 450 mg|
62184743|NCT01582503|PLACEBO_COMPARATOR|Placebo|
62184744|NCT04429646|EXPERIMENTAL|LAMax left atrial appendage occluder|Intervention device, LAMax left atrial appendage closure system
62184745|NCT04429646|ACTIVE_COMPARATOR|Watchman (control)|Intervention device, Watchman® LAA Closure Device
62184746|NCT01860547|EXPERIMENTAL|bilberry|
62184747|NCT01860547|EXPERIMENTAL|sea buckthorn berry|
62184748|NCT01860547|EXPERIMENTAL|sea buckthorn phenolic extract|
62184749|NCT01860547|EXPERIMENTAL|sea buckthorn oil|
62184750|NCT04799847|EXPERIMENTAL|Catumaxomab|In the dose escalation phase, 2 dose levels of catumaxomab will be explored.
62184751|NCT00571896|EXPERIMENTAL|SennaS|This group of participants will receive SennaS to use after surgery.
62568796|NCT05362188|PLACEBO_COMPARATOR|Placebo|Subjects will receive only cream/gel base without API for control
62568797|NCT00907543|OTHER|Neoadjuvant Treatment|Preoperative chemotherapy/radiotherapy treatment
62774877|NCT04692142|ACTIVE_COMPARATOR|Passive online|Before L1, all students will be asked to complete a set of multiple-choice questions (MCQs), formative exam (i.e. pre-test). Following the test , the lecture will be delivered to the participants of PG using a passive online teaching format for 60 minutes (i.e., live-video streaming). After the lecture is completed, students will be asked to re-take the same pre-test exam and complete questionnaire regarding their experience with the teaching methods.
62791639|NCT03776201|EXPERIMENTAL|External Focus|"The external focus group will receive 20 minutes of balance training 2 times per week. All training sessions will include a 5-minute walking warm-up, a 20-minute balance training program, and a 5-minute walking cool-down. The balance training will use a 30 wobble board with five bases ranging from 1 (easy) to 3 (very difficult). 20 trials of balance practice for 30-second intervals with 30-second breaks in between trials will be used every day. The external focus group will be reminded to focus their attention externally via the prompt please keep the board as level as possible prior to each balance trial. To monitor whether the experimental groups are focusing as asked and to what extent, a compliance check that has been used in similar attentional focus literature will be used."
62791640|NCT03776201|NO_INTERVENTION|Control|The control group will not receive any balance training
62184752|NCT00571896|PLACEBO_COMPARATOR|Placebo|This group of participants will receive placebo pills to use after surgery.
61999330|NCT05901727||HIV testing survey participants|Individuals presenting for HIV testing eligible to be enrolled in the HIV testing survey
61999331|NCT01303575|EXPERIMENTAL|HIV, STI, and Pregnancy Prevention Curriculum|
61999332|NCT01303575|ACTIVE_COMPARATOR|Control curricula: Science Education|No sexual health elements
61999333|NCT06483971|OTHER|Oral Isotretinoin|
61999334|NCT06483971|EXPERIMENTAL|Antibiotics|
61999335|NCT06022185|EXPERIMENTAL|Experimental group|Web Based E-Health Literacy, Digital Literacy and Healthy Lifestyle Behaviors Training
61999336|NCT06022185|NO_INTERVENTION|Control Group|No action will be taken.
62568798|NCT00907543|EXPERIMENTAL|Adjuvant Treatment|Postoperative chemotherapy/radiotherapy treatment
61999337|NCT03031171|EXPERIMENTAL|Navigated: Screening patient navigation|Clinic patients who received navigation
61999338|NCT03031171|ACTIVE_COMPARATOR|Non-Navigated|Randomly matched sample of non-navigated clinic patients
62568799|NCT00789854|ACTIVE_COMPARATOR|Add-on Quetiapine XR+SSRI/Venlafaxine|"Selective serotonin reuptake inhibitors (SSRI) or Venlafaxine from previous therapy + add-on treatment with quetiapine XR, 300mg tablet once daily (od).~From previous anti-depressant treatment 64% of the patients had SSRI and 35% had Venlafaxine at baseline."
61999339|NCT03346122|EXPERIMENTAL|Cohort 1:JNJ-64991524 Dose Level (DL) 1 or Placebo(SAD Part 1)|Participants will receive a single oral dose (Dose level 1) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
61999340|NCT03346122|EXPERIMENTAL|Cohort 2: JNJ-64991524 DL 2 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 2) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
61999341|NCT03346122|EXPERIMENTAL|Cohort 3: JNJ-64991524 DL 3 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 3) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
61999342|NCT03346122|EXPERIMENTAL|Cohort 4:JNJ-64991524 DL 4 or Placebo (SAD Part 1:Fasted-Fed)|Participants will receive a single oral dose (Dose level 4) of either JNJ-64991524 or placebo capsules in a fasted condition on Day 1 and fed condition, on Day 7.
61999343|NCT03346122|EXPERIMENTAL|Cohort 5: JNJ-64991524 DL 5 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 5) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
61999344|NCT03346122|EXPERIMENTAL|Cohort 6: JNJ-64991524 DL 6 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 6) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
61999345|NCT03346122|EXPERIMENTAL|Cohort 1: JNJ-64991524 DL 7 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 7) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and pharmacokinetics (PK) from Part 1.
61999346|NCT03346122|EXPERIMENTAL|Cohort 2: JNJ-64991524 DL 8 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 8) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
61999347|NCT03346122|EXPERIMENTAL|Cohort 3: JNJ-64991524 DL 9 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 9) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
61999348|NCT03346122|EXPERIMENTAL|Cohort 4: JNJ-64991524 DL 6 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 6) of JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined by tolerability and PK from Part 1.
61999349|NCT00914615|EXPERIMENTAL|SBRT for liver mets from colorectal cancer|
61999350|NCT03674866||Patients with diabetes|Patients with type 1 diabetes and type 2 diabetes who received at least one prescription of insulin degludec (Tresiba®).
61999351|NCT01451775|EXPERIMENTAL|Treatment A|high dose of empagliflozin after overnight fasting for at least 10 h
61999352|NCT01451775|EXPERIMENTAL|Treatment B|high dose of empagliflozin after a standardised high fat breakfast
61999353|NCT01451775|EXPERIMENTAL|Treatment C|low dose empagliflozin after overnight fasting for at least 10 h
61999354|NCT01172743||Diabetes|Individuals with diabetes that fit eligibility criteria.
61999355|NCT01172743||Normal Control|Individuals without history of diabetes.
61999356|NCT04694807|EXPERIMENTAL|Group-based Cognitive Behavioural Therapy|A group delivered treatment format of CBTgrief (12 sessions).
61999357|NCT04694807|ACTIVE_COMPARATOR|Individually delivered Cognitive Behavioural Therapy|An individual delivered treatment format of CBTgrief (12 sessions).
61999358|NCT04887662|NO_INTERVENTION|Control|The control group will be asked to follow their usual diet, but will receive print materials about a diet for cardiovascular health.
62568800|NCT00789854|ACTIVE_COMPARATOR|Add-on Lithium+SSRI/Venlafaxine|"Selective serotonin reuptake inhibitors (SSRI) or venlafaxine from previous therapy + add-on treatment with lithium, approximately 900mg tablet once daily (od).~From previous anti-depressant treatment 67% of the patients had SSRI and 33% had Venlafaxine at baseline."
62568801|NCT00789854|ACTIVE_COMPARATOR|Monotherapy Quetiapine XR|Switch from previous treatment with SSRI or venlafaxine to quetiapine XR monotherapy, 300mg tablet once daily (od)
62184753|NCT00188721||1|Women with confirmed unilateral breast carcinoma or ductal carcinoma in situ (DCIS)
62774878|NCT04692142|EXPERIMENTAL|Flipped classroom|"Participants of FG will have an access to a recorded lecture. and they will be taught using an active teaching model known as flipped classroom model. In this model, participants will have 7 -day monitored remote access to the recorded L1. Similar to PG, completing the online pre-test formative exam will be preliminary requirement to access the published recorded L1.~At the expiry of remote access to the recorded lecture, participants from FG will be invited to attend post-lecture discussion sessions. To enhance the effectiveness of flipped classroom teaching method, the cohort of FG will be randomly, using computer generated randomisation, subdivided to two smaller groups in which each group will be consisted of half of the FG cohort. The same lecturer will moderate the discussions for each group separately. After the lecture is completed, students will be asked to re-take the same pre-test of L1 and complete questionnaire regarding their experience with the teaching methods."
62774879|NCT06412913||Patients in pediatric age (> 18 month and < 18 years) at the time of surgery|The full analysis set includes all paediatric patients who that have been treated for diaphyseal fractures of long bones with the MJ-FLEX the will be systematically consecutive screened at the centers.
62184754|NCT00188721||2|Women without radiological suspicious lesions, matched to cases by age (± 2.5 years), date of screening mammogram, and screening center.
62184755|NCT01304628|EXPERIMENTAL|PL-3994 (4 escalating doses)|
62184756|NCT01304628|PLACEBO_COMPARATOR|Placebo|
62184757|NCT03171935|EXPERIMENTAL|High-Flow Nasal Cannula Oxygenation|
62184758|NCT03171935|EXPERIMENTAL|Noninvasive Positive Pressure Ventilation|
62184759|NCT03171935|ACTIVE_COMPARATOR|Conventional Weaning|
62184760|NCT02416713|PLACEBO_COMPARATOR|Education Only (Control)|The Cellcontrol DriveID device will run completely in the background with no observable changes to cellphone functions while driving. During Week Four, participants will be presented educational materials on the dangers of distracted driving.
62184761|NCT02416713|EXPERIMENTAL|Opt-in Blocking|Participants will have to initiate Cellcontrol DriveID device when entering the vehicle; the blocking settings will be pre-set to block all calls and text messages when the car is in motion.
62774880|NCT03414294|EXPERIMENTAL|K-755 Part A (SAD)|
62774881|NCT03414294|PLACEBO_COMPARATOR|Placebo Part A (SAD)|
62774882|NCT03414294|EXPERIMENTAL|K-755 Part B (MAD)|
62774883|NCT03414294|PLACEBO_COMPARATOR|Placebo Part B (MAD)|
62184762|NCT02416713|EXPERIMENTAL|Opt-out Blocking|Cellcontrol DriveID device will automatically turn on when the teen begins driving and will be pre-set to block all calls and text messages when the car is in motion.
62184763|NCT02416713|EXPERIMENTAL|Opt-out Blocking with Notification|Cellcontrol DriveID device will automatically turn on when the teen begins driving and will be pre-set to block all calls and text messages when the car is in motion. If a participant overrides the blocking function, an email will be sent to a parent/guardian.
62774884|NCT03414294|EXPERIMENTAL|K-755 Part C (FE)|
62774885|NCT03414294|EXPERIMENTAL|K-755 Part D (FE)|
62774886|NCT03414294|EXPERIMENTAL|K-755 Part E (MAD)|
62774887|NCT03414294|PLACEBO_COMPARATOR|Placebo Part E (MAD)|
61999359|NCT04887662|EXPERIMENTAL|Fermented vegetable|The fermented vegetable group will be asked to consume 100 g of fermented vegetables per day, at least 5 days per week for 8 weeks.
61999360|NCT00793364|ACTIVE_COMPARATOR|Stanol ester|Stanol-ester administration group
61999361|NCT00793364|PLACEBO_COMPARATOR|Placebo spread|Placebo spread group
61999362|NCT00793364|OTHER|Mediterranean diet group|Mediterranean diet group
62184764|NCT04453163|EXPERIMENTAL|RAAC program|"If the patient is under the RAAC group, he/she will then be received in consultation by a RAAC specialist nurse, between the anesthesia / radiology consultation and the intervention. This RAAC nurse will explain the procedure and show him/her an information video on vertebroplasty. Information about managing anxiety and pain will also be provided. In addition, the day after the patient leaves the clinic, the RAAC nurse will call him/her to inquire."
62184765|NCT04453163|OTHER|Standard management program|"If the patient is under the control group, he/she will be taken care of according to the standard protocol after a surgery in percutaneous vertebroplasty. The patient will not have a consultation with the specialized nurse."
62184766|NCT04358536||COVID-19 Patients|"Single posteroanterior (or front-on) X-rays collected from COVID-19 patients"
62774888|NCT03806608|EXPERIMENTAL|Crestal|Implants were placed with the implant-abutment interface(IAI) at the level of the the alveolar ridge
61999363|NCT02282696|EXPERIMENTAL|cancer patients|Questionnaire, focus group participation
62184767|NCT04358536||Non COVID-19 Patients|"Single posteroanterior (or front-on) X-rays collected from subsets of non COVID-19 patients"
62184768|NCT02635386|EXPERIMENTAL|Exenatide once weekly (EQW )|EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks
62184769|NCT02635386|EXPERIMENTAL|Dapagliflozin (DAPA)|DAPA-10 mg oral pill once daily in am for 24 weeks
62184770|NCT02635386|EXPERIMENTAL|EQW plus DAPA|EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks
62184771|NCT02635386|EXPERIMENTAL|Dapagliflozin plus Glucophage (MET ER)|Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks
62184772|NCT02635386|ACTIVE_COMPARATOR|Phentermine /Topiramate (PHEN/ TPM) ER|Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks
62184773|NCT04617236|EXPERIMENTAL|Cultivando la Salud Educational Intervention|After completing eligibility and baseline surveys, Lay health workers delivered an educational intervention for breast and cervical cancer screening. This educational session was delivered in participants' home and lasted between 1-2 hours. Follow-up data was collected 4-6 months post educational session.
62184774|NCT04617236|NO_INTERVENTION|Control|No intervention was delivered. At baseline, participants completed eligibility and baseline surveys. Follow-up data was collected 4-6 months post-baseline survey.
61999364|NCT00003491|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
61999365|NCT02774681|EXPERIMENTAL|Treatment (palbociclib)|Patients receive palbociclib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with HER2 positive breast cancer may also receive trastuzumab IV over 30-90 minutes every 3 weeks.
61999366|NCT03856762|EXPERIMENTAL|Traditional Jiangnan diet|Subjects will be supplied with traditional Jiangnan diet and APP-based behavioral modification
61999367|NCT03856762|EXPERIMENTAL|Mediterranean diet|Subjects will be supplied with Mediterranean diet and APP-based behavioral modification
61999368|NCT03856762|EXPERIMENTAL|Current Shanghai diet|Subjects will be supplied with current Shanghai diet and APP-based behavioral modification
61999369|NCT04590495|ACTIVE_COMPARATOR|300 mg Cannabidiol (CBD) oil|
62184775|NCT02147782||control|Healthy people from physical examination centers are recruited as controls.
62393449|NCT04816942|EXPERIMENTAL|Convalescent Plasma|Patients receiving Two units of ABO compatible COVID-19 convalescent plasma will be administered.P
62393450|NCT00337935|EXPERIMENTAL|Epoetin Alfa|
62393451|NCT00337935|OTHER|Group 2|Standard treatment of anemia excluding use of erythropoetin stimulating agents (ESAs).
62393452|NCT01454895|EXPERIMENTAL|Interactive Web-based Info (IWI) & HPDs|Subjects will receive interactive Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing, as well as a mailed sample of various types of hearing protection devices.
62568802|NCT03547375|EXPERIMENTAL|treatment group|Apatinib 500mg/d po,28 days as one cycle
61999370|NCT04590495|PLACEBO_COMPARATOR|Placebo|
61999371|NCT04419116|EXPERIMENTAL|tibial preservation bone cut|tibial preservation bone cut following mobile bearing UKA
62184776|NCT02147782||CKD1|"1. with clinical one or more symptoms and signs of kidney injury listed as below：~   1. Urinary albumin ( urinary albumin excretion rate≥30 mg/24 h.albumin-creatinine ratio≥3mg/mmol)~  2. urinary sediments abnormality~  3. renal tubular lesions~  4. renal histological abnormalities~  5. abnormal structure showed by imaging~  6. history of renal transplantation~2. GFR≥90（ml/min/1.73m²)"
62184777|NCT02147782||CKD2|with clinical symptoms and signs of kidney injury, and 60\<=GFR\<=89（ml/min/1.73m²)
62184778|NCT02147782||CKD3|with clinical symptoms and signs of kidney injury, and 30\<=GFR\<=59（ml/min/1.73m²)
61999372|NCT04419116|EXPERIMENTAL|tibial conventional bone cut|tibial conventional bone cut following mobilebearing UKA
62184779|NCT02147782||CKD4|with clinical symptoms and signs of kidney injury, and 15\<=GFR\<=29（ml/min/1.73m²)
61999373|NCT00232908|EXPERIMENTAL|1|
62184780|NCT02147782||CKD5|with clinical symptoms and signs of kidney injury, and GFR\<15（ml/min/1.73m²)
62184781|NCT04744805||mask wear|
62184782|NCT04744805||dry eye|
62184783|NCT02780895|EXPERIMENTAL|Single Arm Study|stereotactic brain surgery of human stem cells (OK99)
62568803|NCT06344884|EXPERIMENTAL|Early Catheter Removal|Participants in this arm will be asked to remove their catheters POD1.
62568804|NCT06344884|NO_INTERVENTION|Standard Catheter Removal|Participants in this arm will be asked to remove their catheters POD3-4.
62568805|NCT02921685|EXPERIMENTAL|Monalizumab|Monalizumab treatment will be initiated 75 to 100 days after hematopoietic stem cells transplantation. Patients will receive a single dose of monalizumab by intravenous route over 1 hour.
62568806|NCT05182684|EXPERIMENTAL|Single arm|Electrocardiograms were measured by VP-100 for more than 6 hours and transmitted to a central server.
61999374|NCT02603809|PLACEBO_COMPARATOR|Placebo|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received placebo orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
61999375|NCT02603809|EXPERIMENTAL|Aprocitentan 5 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
61999376|NCT02603809|EXPERIMENTAL|Aprocitentan 10 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 10 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
62184784|NCT01803347|EXPERIMENTAL|ASC + fibrin glue|Intervention: drug: ASC + fibrin glue Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 100 million ASCs plus fibrin glue plus a deep curettage and closure of the internal orifice and evaluated after 16 weeks. If needed a second dose of 100 million ASCs plus fibrin glue will be applied then.
62184785|NCT01803347|ACTIVE_COMPARATOR|Fibrin glue|Intervention: fibrin glue Fibrin glue: Subjects will be treated with a dose fibrin glue plus a deep curettage and closure of the internal orifice, and evaluated after 16 weeks. If needed a second dose of fibrin glue will be applied then.
62184786|NCT06426147|EXPERIMENTAL|L-citrulline|1 or 2 sachets every 12 hours (200-300mg/kg/day depending on weight-band) for 28 days
62184787|NCT06426147|PLACEBO_COMPARATOR|Placebo|1 or 2 sachets every 12 hours (depending on weight-band) for 28 days
62184788|NCT04178447|EXPERIMENTAL|Group 1: ESRD subjects not on dialysis or severe RI|subjects with eGFR \<15 mL/min/1.73 m2) or (eGFR 15 to \<30 mL/min/1.73 m2)
62184789|NCT04178447|EXPERIMENTAL|Group 2: normal renal function|subjects with eGFR ≥90 mL/min/1.73 m2
62184790|NCT04178447|EXPERIMENTAL|Group 3: moderate RI|subjects with eGFR 30 to \<60 mL/min/1.73 m2
62774889|NCT03806608|EXPERIMENTAL|Subcrestal|Implants were placed with the implant-abutment interface(IAI) 1 mm below the level of the alveolar ridge
62774890|NCT02316886|EXPERIMENTAL|Coronary intervention|bioabsorbable vascular scaffolds (BVS) (early period) or everolimus-eluting stents (middle and late period) +Optimal Medical Treatment
62184791|NCT04178447|EXPERIMENTAL|Group 4: mild RI|subjects with eGFR 60 to \<90 mL/min/1.73 m2
62184792|NCT06144593|EXPERIMENTAL|Intermittent carbohydrate restriction|Four weeks of intermittent carbohydrate restriction: a dietary regime alternating between two days of restricting carbohydrate intake to 70-90 grams, while energy intake is ad libitum, from fat- and protein-containing foods, and two days of non-restricted diet.
62774891|NCT02316886|ACTIVE_COMPARATOR|Optimal Medical Treatment|Optimal Medical Treatment
62774892|NCT03034902|EXPERIMENTAL|Combined EEG and fNIRS|EEG is electroencephalography. fNIRS is functional near infrared spectroscopy. The EEG+NIRS recordings will be obtained via an extended EEG cap that is applied to the subject's head. Changes in neuronal activity and hemodynamics will be measured.
62774893|NCT02239965||Anaesthesia personnel|Anaesthesiologists and nurse anaesthetists
61999377|NCT02603809|EXPERIMENTAL|Aprocitentan 25 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 25 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
61999378|NCT02603809|EXPERIMENTAL|Aprocitentan 50 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 50 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
61999379|NCT02603809|ACTIVE_COMPARATOR|Lisinopril 20 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received lisinopril 20 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
61999380|NCT05410327|EXPERIMENTAL|Chokeberry consumption|Participants will be given 100ml of a water-infused chokeberry juice to consume twice per day for a period of 6 weeks.
62393453|NCT01454895|EXPERIMENTAL|Interactive Web-based Information (IWI)|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
61999381|NCT03108846|EXPERIMENTAL|Escitalopram|Escitalopram up to 15mg/day taken as 1-3 capsules each containing 5mg escitalopram once per day in the morning
61999382|NCT03108846|PLACEBO_COMPARATOR|Placebo|1-3 capsules each containing placebo only once per day in the morning
61999383|NCT05906862|EXPERIMENTAL|AMT-253 Dose Escalation|
61999384|NCT03517709|OTHER|Conventional|
61999385|NCT03517709|OTHER|Blood Pressure Monitor|
61999386|NCT02047799|ACTIVE_COMPARATOR|Calcitriol|A daily dose of 1000 IU of cholecalciferol (administered as 1 capsule of 25 μg each)
61999387|NCT02047799|PLACEBO_COMPARATOR|Control|A daily dose of placebo (administered as 1 capsule )
61999388|NCT06296303|EXPERIMENTAL|Pulsed electromagnetic therapy group|Patients in this group will receive Pulsed electromagnetic therapy + Conventional physical therapy
61999389|NCT06296303|EXPERIMENTAL|Ultrasound phonophoresis group|Patients in this group will receive Ultrasound phonophoresis + Conventional physical therapy
61999390|NCT06296303|ACTIVE_COMPARATOR|Control group|Patients in this group will receive Conventional physical therapy
62184793|NCT06144593|NO_INTERVENTION|Control arm|Four weeks of free-living with no dietary restrictions.
61999391|NCT01346384||intracuff pressure N2O|measured intracuff pressure of LT with N2o during operative period
61999392|NCT02214121|OTHER|Ticagrelor Dose 1a + Dose 2a|Part A: Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week repeated dosing Part B: Ticagrelor or placebo 4 weeks repeated dosing.
62393454|NCT01454895|EXPERIMENTAL|Static Web information (SWI) & HPDs|Subjects will receive static Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing, as well as a mailed sample of various types of hearing protection devices.
62393455|NCT01454895|ACTIVE_COMPARATOR|Static Web information only|Subjects will receive interactive Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing.
62393456|NCT01454895|EXPERIMENTAL|Hearing protection Devices only|Subjects will receive a mailed sample of various types of hearing protection devices.
62393457|NCT01454895|OTHER|Interactive Web-based information only|used for cases enrolling after achievement of study enrollment goal
62393458|NCT02514109||patient|Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuronopathy.
62393459|NCT02514109||control|Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuropathy excluding a neuronopathy.
62393460|NCT04076280|EXPERIMENTAL|SWAP Intervention|The participants are randomized using a table of random numbers pre-generated by a computer assigning them to the Sodium Watcher Program.
62393461|NCT04076280|ACTIVE_COMPARATOR|Usual Care|The participants are randomized using a table of random numbers pre-generated by a computer assigning them to the usual care group.
62393462|NCT00933543|EXPERIMENTAL|Visonac cream with PDT|Active treatment, Light dose 37 J/cm2.
62393463|NCT00933543|PLACEBO_COMPARATOR|Vehicle cream with PDT|Placebo treatment, Light dose 37 J/cm2.
62393464|NCT01403415|EXPERIMENTAL|Treatment (temsirolimus, combination chemotherapy)|Patients receive dexamethasone PO or IV on days 1-5 and 15-19; mitoxantrone hydrochloride IV over 30 minutes on days 1-2; temsirolimus IV over 30 minutes on days 1 and 8; vincristine sulfate IV on days 1, 8, 15, and 22; and pegaspargase IV over 1 hour on days 3 and 17. Some patients may also receive methotrexate IT up to 72 hours prior to or on day 1 and on day 8.
62393465|NCT04997291|EXPERIMENTAL|Dexrazoxane|
62393466|NCT00231959|PLACEBO_COMPARATOR|Sugar pill|Placebo
62393467|NCT00231959|EXPERIMENTAL|Pramipexole|
62393468|NCT01265927|EXPERIMENTAL|GRN163L + Trastuzumab|
62393469|NCT05886374|EXPERIMENTAL|HMPL-415S1|HMPL-415S1 will be administered orally once daily in 28 days treatment cycles
62774894|NCT02553538|EXPERIMENTAL|Patient Navigation Intervention|Participants randomized to the intervention arm were transferred to a navigator roster within the TopCare application for the 8-month study period. Navigators utilized TopCare to track these participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
62184794|NCT00498615|EXPERIMENTAL|Fasudil 80 mg|Subject is given a single dose of 80 mg of Fasudil ( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
62393470|NCT00005803|EXPERIMENTAL|Treatment (tandem transplantation)|See Detailed Description
62774895|NCT02553538|NO_INTERVENTION|Standard of Care - No Intervention|Participants randomized to the control arm received usual care within TopCare, which meant that clinicians and staff could elect to send the participant a reminder letter about their overdue cancer screening exams, reach out to schedule overdue exams, or document appropriate reasons for deferral or exclusion.
62184795|NCT00498615|EXPERIMENTAL|40 mg Fasudil|Subject is given a single dose of 40 mg of Fasudil ( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
62184796|NCT00498615|PLACEBO_COMPARATOR|placebo|Subject is given a single dose of placebo( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
62184797|NCT00069381|EXPERIMENTAL|study arm|
62393471|NCT01208376||unexplained chronic ALT elevation|Case patients: HIV-infected, unexplained chronic alanine aminotransferase (ALT) elevation
62393472|NCT01208376||always normal ALT|Control patients: HIV-infected, always normal ALT values
62393473|NCT03922945|EXPERIMENTAL|VI-0521 Mid Dose (Phentermine 7.5 mg +Topiramate 46 mg)|Weeks 1-2: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Weeks 3-56: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily
62393474|NCT03922945|EXPERIMENTAL|VI-0521 Top Dose (Phentermine 15 mg + Topiramate 92 mg)|Weeks 1-2: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Weeks 3-12: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily; Weeks 13-14: VI-0521 (Phentermine 11.25 mg + Topiramate 69 mg) oral capsule, once daily; Weeks 15-56: VI-0521 (Phentermine 15 mg + Topiramate 92 mg) oral capsule, once daily
62393475|NCT03922945|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo oral capsule, once daily for up to 56 weeks
62393476|NCT03263052||Tacrolimus XR|
62393477|NCT04447183|EXPERIMENTAL|Test group|The test group of patients who took thyroid hormone medicine and were euthyroid \[i.e. their thyroid stimulating hormone (TSH) levels are normal\], and received injections of Thyrogen (0.9 mg daily on two consecutive days) followed by oral radioiodine.
62393478|NCT04447183|EXPERIMENTAL|Control group|The control group of patients did not take thyroid hormone medicine so that they were hypothyroid (i.e. their TSH levels were high,TSH≥30mU/L), and were given oral radioiodine.
62393479|NCT06015269|EXPERIMENTAL|DC cells|Super DC Vaccine (DC)
62393480|NCT05158504|EXPERIMENTAL|Motivation|Motivational notifications were sent to the nurses in the motivational group (n=30) via SMS messages to their mobile phones at 07.00, 12.00 and 16.00 for 21 days. Like a good morning message that allows you to start the day with a beautiful energy (Example: Thank you for the hard and selfless work you do every day. We love and appreciate angels like you and you. Good morning). Motivational notifications sent to the participants were prepared each day to be different from the previous day. Data were obtained with the Individual Introduction Form, Job Satisfaction, Compassion Fatigue and Communication Skills Scale.
62393481|NCT05158504|NO_INTERVENTION|Control|Motivational notifications were not sent to the nurses in the control group (n=30) and they continued their routine work in the emergency room. only pretest and posttest were applied. Data were obtained with the Individual Introduction Form, Job Satisfaction, Compassion Fatigue and Communication Skills Scale.
62568807|NCT05578261|EXPERIMENTAL|Active|"All of the participants will accept one session iTBS over right Crus I/II. The total pulses of every session are 1200 pulses (600 pulses with 15 minutes interval)~\*iTBS = intermittent theta burst stimulation."
62393482|NCT03952416|NO_INTERVENTION|Standard of Care (SOC)|The control group for this study will receive rehabilitation therapy that is recommended and provided by the current healthcare structure. The SOC group will receive therapy only from four therapists who are not trained and supervised in EMR. These therapists will be monitored (videotaped or observed) but will not be not asked to do anything differently with their patients. The investigators recognize that spillover of therapist EMR training to untrained therapists is a concern. Thus, the investigators will ask therapists in the EMR group to agree not to share any of the training with non-trained therapists over the course of the study, and the investigators will provide free EMR training to the non-trained therapists once the treatment phase of the study is complete.
62568808|NCT00735813|EXPERIMENTAL|A|Tunneled central venous catheters locked with Taurolock
61999393|NCT02214121|OTHER|Ticagrelor Dose 1b + Dose 2b|Part A: Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week repeated dosing. Part B: Ticagrelor or placebo 4 weeks repeated dosing.
62184798|NCT04361968|EXPERIMENTAL|Animal-assisted placebo condition|Participants receive verbal information that they are receiving an analgesic cream. Additionally, and before getting the dog, participants will get a therapeutic rationale for the presence of the dog.
62184799|NCT04361968|EXPERIMENTAL|Placebo condition|Participants receive verbal information that they are receiving an analgesic cream.
62184800|NCT04361968|EXPERIMENTAL|Dog only condition|Before meeting the dog, participants will get a therapeutic rationale for the presence of the dog.
62184801|NCT04361968|OTHER|Control condition|Participants in this condition will receive no intervention.
62184802|NCT02424019|EXPERIMENTAL|ILUVIEN 0.19 MG|All patients will receive ILUVIEN (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg.
62184803|NCT04106570|EXPERIMENTAL|YOMH|Young obese metabolically healthy Description: Aged from 20 to 40 years old and with a glycemia \< 1g/l and a triglyceridemia \< 1,5g/l.
62184804|NCT04106570|EXPERIMENTAL|YOMD|"Young obese with metabolic disorders~Description: Aged from 20 to 40 years old and with a glycemia \> 1g/l and a triglyceridemia \> 1,5g/l."
62568809|NCT00735813|ACTIVE_COMPARATOR|B|Tunneled central venous catheter locked with heparin
62184805|NCT04106570|EXPERIMENTAL|MAOMH|"Middle-Age obese metabolically healthy~Description: Aged from 40 to 50 years old and with a glycemia \< 1g/l and a triglyceridemia \< 1,5g/l."
62184806|NCT04106570|EXPERIMENTAL|MAOMD|Middle-Age obese with metabolic disorders Description: Aged from 40 to 50 years old and with a glycemia \> 1g/l and a triglyceridemia \> 1,5g/l.
62184807|NCT04106570|EXPERIMENTAL|EOMH|"Elderly obese metabolically healthy~Description: Aged from 50 to 70 years old and with a glycemia \< 1g/l and a triglyceridemia \< 1,5g/l."
62184808|NCT04106570|EXPERIMENTAL|EOMD|"Elderly obese with metabolic disorders~Description: Aged from 50 to 70 years old and with a glycemia \> 1g/l and a triglyceridemia \> 1,5g/l."
62184809|NCT03747809||Patients with CIEDs having Remote Monitoring|
62184810|NCT03747809||Patients with CIEDs having no Remote Monitoring|
62184811|NCT02311777|ACTIVE_COMPARATOR|Pregabalin-ketamine|Pregabalin and ketamine will be given preoperative period
62184812|NCT02311777|PLACEBO_COMPARATOR|Placebo|Placebo will be given preoperative period
62184813|NCT06382389|EXPERIMENTAL|EMONO|Equimolar Mixture of Oxygen and Nitrous Oxide (50%O2 / 50%N2O) Active drug: Nitrous Oxide
62184814|NCT06382389|ACTIVE_COMPARATOR|medical air|Comparator : medical Air (78% N2 / 22% O2)
62184815|NCT00509405|PLACEBO_COMPARATOR|Potassium citrate|
62568810|NCT06576492|EXPERIMENTAL|Treated group|Application of RV4986A lotion associated with RD0057H shampoo (Extra Doux shampoo)
62568811|NCT06576492|OTHER|Control group|Application of RD0057H shampoo (Extra Doux shampoo)
62568812|NCT06048744|ACTIVE_COMPARATOR|external oblique intercostal block|"After induction of general anesthesia, external oblique intercostal blocks will be performed with patients positioned in the supine position with their ipsilateral arm abducted.~A 14-15 MHz linear ultrasound transducer (Sono-Site) was placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib.~30 ml of bupivacaine 0.25% will be administered incrementally. The drug will be injected after a negative aspiration into the plane deep to the external oblique muscle and superficial to the sixth and seventh ribs and their associated intercostal muscles."
62184816|NCT05964959|EXPERIMENTAL|Intervention|"In the intervention group, the nurse and participant will be using the Mouth Education Program (MEP) to discuss causes, consequences and interventions for dry mouth in a structured manner, ultimately leading to an appropriate, individual treatment plan.~The MEP is based on current clinical, national palliative care guidelines on dry mouth care."
62184817|NCT05964959|ACTIVE_COMPARATOR|Control|The control group will receive care as usual, provided by their trusted, treating clinicians and care teams. Questionnaires will be administered by researchers.
62184818|NCT02185898|ACTIVE_COMPARATOR|Leading U.S. tobacco-burning non-menthol cigarette|Leading U.S. non-menthol cigarette
62184819|NCT02185898|ACTIVE_COMPARATOR|Leading U.S. tobacco-burning menthol cigarette|Leading U.S. menthol cigarette
62184820|NCT02185898|EXPERIMENTAL|Electronic cigarette #1|VUSE® (menthol flavor, 29 mg nicotine)
62184821|NCT02185898|EXPERIMENTAL|Electronic cigarette #2|VUSE® (original flavor, 29 mg nicotine)
61999394|NCT02030171|ACTIVE_COMPARATOR|PLURIHOC|-Functionnal reeducation : in hospital, intensive, multidisciplinary.
61999395|NCT02030171|ACTIVE_COMPARATOR|KIPLURI|-Functionnal reeducation : ambulatory, no intensive multidisciplinary.
62184822|NCT02185898|EXPERIMENTAL|Electronic cigarette #3|VUSE® (original flavor, 14 mg nicotine)
62184823|NCT02185898|EXPERIMENTAL|U.S. Market-sample electronic cigarettes (two brands)|blu™ (any variety) and NJOY® (any variety)
62184824|NCT04198493|EXPERIMENTAL|Continuous Positive Airway Pressure(CPAP)|"Patients with CPAP treatment. Titration will be performed by polysomnography CPAP to determine the optimal treatment pressure.~This group will also be instructed in sleep hygiene and dietary counseling~Intervention:~Device: CPAP Other: Conservative treatment for OSA"
62184825|NCT04198493|ACTIVE_COMPARATOR|CONSERVATIVE TREATMENT for OSA|Sleep hygiene and dietary counseling. Sleep hygiene (regular sleep schedule, physical exercise) and dietary counseling Intervention: Other: Conservative treatment for OSA
62184826|NCT03042299|EXPERIMENTAL|TAK-536 Granules + TAK-536 Tablet|TAK-536 10 milligram (mg), granules (pediatric formulation), under fasted condition, orally, once on Day 1 of Intervention Period 1, followed by a Washout Period of at least 6 days, further followed by TAK-536 10 mg, tablet (commercial formulation), under fasted condition, orally, once on Day 1 of Intervention Period 2.
62393483|NCT03952416|EXPERIMENTAL|Enhanced Medical Rehabilitation (EMR)|Patients in the EMR group will also receive the recommended rehabilitation therapy, but they will receive therapy only from four therapists who are trained and supervised in EMR. The therapy sessions will follow EMR protocol. EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation.
62393484|NCT02786368|OTHER|Control group|For year one, this arm will receive no intervention. Usual agriculture production and income will be assessed monthly for one year. Additionally, every season (twice yearly), household food security and usual dietary intake of woman of reproductive age (WRA) and their child aged 6-59 mo will also be collected. After one year of implementation, this group will be offered the Enhanced Homestead Food Production package fully subsidized, as well as training on nutrition, WASH, gender and business/marketing.
62393485|NCT02786368|EXPERIMENTAL|EHFP group|Households will receive training and inputs for an Enhanced Homestead Food Production (EHFP) package. Participants will also receive educational components through inter-personal behavioural change communication on nutrition (Essential Nutrition Actions), Water Sanitation and Hygiene (WASH), gender, and business/marketing.
62568813|NCT06048744|ACTIVE_COMPARATOR|Erector Spine Block|After induction of general anesthesia, patients will be positioned in the lateral position . A linear ultrasound transducer will be placed on the midline to identify the T8 spinous process. From this position, the ultrasound transducer was moved 2-3 cm laterally to visualize the hyperechoic line of the T8 transverse process with its associated acoustic shadow inferiorly, and the overlying erector spinae muscle superiorly. 30 ml 0.25% bupivacaine will be injected.
62774896|NCT02772627|EXPERIMENTAL|Nebicapone 100 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
62184827|NCT03042299|EXPERIMENTAL|TAK-536 Tablet + TAK-536 Granules|TAK-536 10 mg, tablet (commercial formulation), under fasted condition, orally, once on Day 1 of Intervention Period 1, followed by a Washout Period of at least 6 days, further followed by TAK-536 10 mg, granules (pediatric formulation), under fasted condition, orally, once on Day 1 of Intervention Period 2.
62184828|NCT06364176|EXPERIMENTAL|Losartan|Losartan 25mg twice daily for one week followed by 50mg twice daily through week 12.
62184829|NCT06364176|PLACEBO_COMPARATOR|Placebo|Placebo twice daily through week 12
62184830|NCT03796208|EXPERIMENTAL|Tobacco Intervention|Participants in this group will be randomized to the Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC) intervention.
62393486|NCT05936801|EXPERIMENTAL|Anterior Chest Compression technique|"Baseline treatment given is percussion and vibration in side lying position. The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process. Inspiration is facilitated by the pressure on anterior chest, followed by a hold.~Just as the patient is instructed to cough, the therapist applies a quick force with both arms:~down and back on the upper chest and up and back on the lower chest or abdomen. 3 sessions in a wk would be given on alternate days"
62568814|NCT05799638||Heart Failure Patients who were tolerable to GDMT|Guideline-Directed Medication Treatment contains ACEI/ARB/ARNI, β blocker, SGLT2i and MRA. The patients in this group were tolerable to all the medications and accepted GDMT.
62774897|NCT02772627|EXPERIMENTAL|Nebicapone 200 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
62774898|NCT02772627|EXPERIMENTAL|Nebicapone 300 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
62774899|NCT01493856|ACTIVE_COMPARATOR|Rosuvastatin+Olmesartan|single dose of Rosuvastatin 20mg and olmesartan medoxomil(CS-866) 40mg
62774900|NCT01493856|EXPERIMENTAL|DWJ1276|Single dose of DWJ1276
62774901|NCT02288988|OTHER|GERD patients with Short Esophagus|Patients with True Short Esophagus diagnosed intra-operatively: The length of the intra-abdominal portion of the esophagus \< 2.5 cm measured intra-operatively using a combined endoscopic-laparoscopic method. Minimally invasive antireflux surgery was performed (Collis gastroplasty + Nissen fundoplication).
62184831|NCT03796208|ACTIVE_COMPARATOR|Treatment As Usual|Participants in this group will be randomized to tobacco treatment as usual.
62393487|NCT05936801|EXPERIMENTAL|Abdominal Thrust Technique|Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs.
62393488|NCT04946721||1.BMT Patients (Study)|Patients prior to receiving a bone marrow transplant will be recruited during their initial intake prior to their BM transplant through the PI's regularly scheduled appointment with these patients.
62393489|NCT04946721||2.Controls|Patients with no history of eye disease or cancer history
62774902|NCT01789606|EXPERIMENTAL|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|
62774903|NCT03961412|EXPERIMENTAL|family-based intervention + education materials|The participants will identify their accompanying influential person (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. Their accompanying influential person is eligible if they are (a) aged 18 or older and (b) willing to participate in the study.
62774904|NCT03961412|ACTIVE_COMPARATOR|women only intervention + education materials|Only the participants will attend the 1.5-2 hour face-to-face intervention on cervical cancer and screening.
62568815|NCT05799638||Heart Failure Patients who were intolerable to GDMT|The patients in this group were intolerable to one or more medication in GDMT due to hypotension, hyperkalemia or renal insufficiency.
62568816|NCT02344238|OTHER|Standard Capsules|Receive standard capsules (no ID cap technology) with compliance measured by self-report, pill count, and riboflavin measurement.
62184832|NCT04036253|ACTIVE_COMPARATOR|Eprex/Erypo|"Receive EPREX/ ERYPO® subcutaneously with an initial dose of 29 IU/ kg twice a week (2000 IU twice a week for 70 kg of weight), to be titrated according to the scheme that is summarized below.~There will be a follow - up of patients with visits to the site every two weeks during the first 12 weeks of dose titration that will be followed by 12 additional weeks of dose maintenance with visits every 4 weeks."
62184833|NCT04036253|EXPERIMENTAL|Hemax PFS|"receive HEMAX® PFS subcutaneously with an initial dose of 29 IU/ kg twice a week (2000 IU twice a week for 70 kg of weight), to be titrated according to the scheme that is summarized below.~There will be a follow - up of patients with visits to the site every two weeks during the first 12 weeks of dose titration that will be followed by 12 additional weeks of dose maintenance with visits every 4 weeks."
61999396|NCT02030171|ACTIVE_COMPARATOR|KIMONO|-Functionnal reeducation : ambulatory, low-intensity
61999397|NCT01006382||Adolescents and young adults with food allergy|Adolescents aged 13-21 years with a diagnosis of food allergy
62774905|NCT06175156|EXPERIMENTAL|Controlled analgesia/sedation (PCAS) group|Each group of patients is required to open the right upper limb venous access as a routine, take the left side lying position, and continuously inhale oxygen with a mask at a flow rate of 8L/min, while connecting various monitoring devices. During the pre anesthesia assessment, explain in detail to the patient the usage of the self-control pump and confirm that each patient can master it. Firstly, connect the self-control analgesic pump with a loading dose of 3 ml. Then, continuously pump in a mixture of propofol and remifentanil at a speed of 0.1 ml/kg/h. After the loading dose is completed, the examination can begin. During the operation, press the self-control handle according to the patient's sensation. Each press can quickly push 1ml of the medication, with a locking time of 1 minute.
62774906|NCT06175156|ACTIVE_COMPARATOR|Intravenous combined anesthesia group|Each group of patients is required to open the right upper limb venous access as a routine, take the left side lying position, and continuously inhale oxygen with a mask at a flow rate of 8L/min, while connecting various monitoring devices. Intravenous slow infusion of fentanyl 1 μ G/kg, midazolam 0.02mg/kg, slowly administer propofol 0.8-1mg/kg after 2 minutes (time greater than 60 seconds), and start the examination when the patient's consciousness disappears and they do not respond. During the surgery, propofol is interrupted to maintain the auditory evoked potential index (AAI) between 30-40.
62774907|NCT00391612|SHAM_COMPARATOR|2|subject receives optimal medical management, supervised pulmonary rehabilitation therapy and undergoes bronchoscopy but no stents are placed
61999398|NCT05093699|ACTIVE_COMPARATOR|Control Group|Arterial line placement via standard mechanism; utilization of a single-plane ultrasound probe
62184834|NCT04843384|EXPERIMENTAL|Reiki|"One of these methods, reiki, has roots which go back thousands of years. Modern reiki was rediscovered and introduced by Mikao Usui in Japan at the end of the 19th century. Reiki means universal life energy . The aim in reiki, in which healing energy is purposefully directed, is to provide restoration of unbalanced energy layers which might be the source of physical, emotional or psychological pain."
62393490|NCT00622310|EXPERIMENTAL|1 Exercise|Subjects in the EX group will perform supervised exercise 5 d/wk. Exercise will consist primarily of walking on an inclined motor-driven treadmill, but alternate activities will be permitted for 20% of the total exercise sessions (1 of 5 days). Exercise sessions will be preceded by a 5 min warm-up performed at a HR corresponding to 40% of VO2max. The initial exercise duration and intensity at baseline will be 20 minutes at an intensity that elicits a heart rate (HR) corresponding to 60% of VO2max. The target EE will be achieved by a gradual progression of exercise duration and intensity over the first 8 weeks of the exercise program. The target exercise intensity will be the workload corresponding to 75% of VO2max.
62568817|NCT02344238|OTHER|ID Capsules without Prompts|Receive ID capsules, with compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap.
62568818|NCT02344238|OTHER|ID Capsules with Prompts|Receive ID capsules, with compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap. This arm will also receive prompts (reminder calls and/or text messages) to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
62568819|NCT01277627|ACTIVE_COMPARATOR|Nevirapine|
61999399|NCT05093699|EXPERIMENTAL|Butterfly iQ+ ultrasound probe|Arterial line placement utilizing dual-plane, Butterfly iQ+ ultrasound probe
61999400|NCT05142683|ACTIVE_COMPARATOR|Treatment as Usual|Study involvement for all sites will begin in the TAU condition, which is the typical treatment at the participating community mental health agency. A range of treatments observed in our previous survey of sites will be on offer in these agencies, depending on the preferences and context of the local agency. In typical TAU in community mental health agencies, depressive symptoms and function are not systematically monitored via standardized rating scales. TAU may or may not include referral to psychotherapy and/or parent support. There are no prompts to prescribe specific medications, and/or internal and external referrals to treatment and other services, guided by local service standards.
62184835|NCT04843384|SHAM_COMPARATOR|Sham reiki|With the Sham Reiki patients, a nurse without reiki training performed Sham Reiki randomly for approximately, following a protocol which did not include the body's energy centers or chakras.
62184836|NCT04843384|NO_INTERVENTION|Control|The control group received no intervention beyond routine care.
62184837|NCT00263575|EXPERIMENTAL|sublingual fentanyl tablet|
62184838|NCT00776659||Observational|
62184839|NCT03359226|EXPERIMENTAL|Submandibular gland biopsy|No treatment is being used in this study. Study participants will have bilateral submandibular gland biopsies.
62568820|NCT01277627|ACTIVE_COMPARATOR|Non-nevirapine|
62568821|NCT02199431|EXPERIMENTAL|Lu AF1167 capsule 0.5 mg|Single oral dose (day 1)
62568822|NCT02199431|EXPERIMENTAL|Lu AF11167 0.5 mg capsule + itraconazole 200 mg capsule|Itraconazole administered once daily for 7 days (day 3-9); Lu AF11167 administered as a single dose on day 8
62774908|NCT00391612|EXPERIMENTAL|1|subject receives optimal medical management, supervised pulmonary rehabilitation therapy and undergoes bronchoscopy during which up to six Exhale drug-eluting stents are placed in the lungs
62774909|NCT04119102|EXPERIMENTAL|Open Label Duobrii|Duobrii QD
62393491|NCT00622310|EXPERIMENTAL|2 Walk|Subjects in the WALK group will also perform exercise 5 d/wk. Exercise will consist exclusively of walking on level grades, and will be prescribed in two equal duration bouts each day. Subjects in the WALK group will be individually prescribed a walking program based on the EE during moderate intensity walking. The target exercise intensity will be walking speeds corresponding 45% of VO2max.
62774910|NCT02411929|EXPERIMENTAL|Ertugliflozin|Period 1: Oral dose of 15 mg unlabeled ertugliflozin + intravenous (IV) dose of 100 µg 14\^C-labeled ertugliflozin containing approximately 400 nCi 14\^C. The 14\^C IV dose will be administered as an infusion over approximately 5 minutes starting at 55 minutes after the unlabeled oral dose. → Period 2: Oral dose 15 mg unlabeled ertugliflozin + oral dose of 100 µg 14\^C-labeled ertugliflozin containing approximately 400 nCi 14\^C. Both the unlabeled and 14\^C-ertugliflozin will be administered at the same time (no more than 5 minutes apart). Dosing in Periods 1 and 2 will be separated by a washout of at least 11 days.
62774911|NCT03855683|EXPERIMENTAL|Group therapy (Unified Protocol)|Participants experiencing stress, anxious, and/or depressive symptoms will receive 8 sessions of Unified Protocol for Emotional Disorders lasting for 90 minutes each. Includes psycho-education about (mal)adaptive emotion regulation, cognitive and behavioral tools to reduce symptoms of stress, anxiety, and/or depression.
62774912|NCT05042102|EXPERIMENTAL|Donepezil + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
62774913|NCT05042102|EXPERIMENTAL|Donepezil + Placebo CRT|Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
62774914|NCT05042102|EXPERIMENTAL|Placebo medication + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
61977753|NCT03683446||Laparoscopic Rectal Surgery|A minimally invasive surgery and specialized technique for performing surgery using smaller incisions (or ports) to enter into the abdomen or anus for a tubular instrument(trochar), and a special camera (laparoscope), which is passed through the trochars to visualize the colon. For abdominal entry, at the beginning of the procedure, the abdomen is inflated with carbon dioxide gas to provide a working and viewing space for the surgeon. For both, the laparoscope transmits images from the abdominal cavity or anus to high-resolution video monitors to allow the surgeon detailed images of the abdomen on the monitor.
62020996|NCT03574454|OTHER|Phase 2 - Mixed Scan Data Validation Set|Machine Learning (ML): A mixed data set of 353 WB-MRI scans as that comprising 50 healthy volunteers (scanned for the purposes of the study), and previously acquired scans from 303 myeloma patients, 100 of whom have inactive disease and 203 of whom have active myeloma. The scans will be read by radiologists in random order either with or without the support of for the detection of active myeloma. The diagnostic performance of the radiology reads with or without the machine learning support will be measured against an expert panel reference standard.
62184840|NCT04417400|EXPERIMENTAL|Intervention|Patients who received MUR at visit 1
62184841|NCT04417400|NO_INTERVENTION|Control|Patients received standard care and MUR after visit 2 (upon completion of the study)
62393492|NCT04151420||Adult IBD patients|
62393493|NCT02287831|EXPERIMENTAL|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
62393494|NCT02414100||Patient derived cancer cell lines|Patients receive gemcitabine hydrochloride IV qw 3/4 wk or gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV qw 3/4 wk in the absence of disease progression or recurrence per standard of care. Tissue and blood samples are collected for genetic analysis via sequencing.
62393495|NCT04586608|ACTIVE_COMPARATOR|active comparator|
62393496|NCT04586608|OTHER|soybean oil-based IVFE|soybean oil-based IVFE
62393497|NCT04192292|NO_INTERVENTION|No Treatment|No change to participants standard care
62568823|NCT02588612|EXPERIMENTAL|letetresgene autoleucel (GSK3377794)|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
62774915|NCT05042102|EXPERIMENTAL|Placebo medication + Placebo CRT|Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
62774916|NCT05153213|EXPERIMENTAL|Finger Lengths|Vernier caliper was used to determine the length of Index Finger to record Vertical Dimensions of Occlusion
62774917|NCT05153213|ACTIVE_COMPARATOR|Conventional method|Willis gauge was used to determine the Length from Base of the nose to Base of the chin to record Vertical Dimensions of Occlusion
62774918|NCT04877236|EXPERIMENTAL|Green Sun Medical Brace|This study only has one arm, administration of the Green Sun Medical Whisper Brace.
62774919|NCT01802307|EXPERIMENTAL|Focal Therapy|
62393498|NCT04192292|EXPERIMENTAL|Low dose sulphonylurea alone|Participants will be given a single dose of low dose sulphonylurea once daily for 14 days as a physiological stimulus. The sulphonylurea given in this study will be gliclazide 20mg orally once daily.
62393499|NCT04192292|EXPERIMENTAL|DPP4 inhibitor alone|Participants will be given a single dose of DPP4 inhibitor once daily for 14 days as a physiological stimulus. The DPP inhibitor given in this study will be sitagliption 100mg orally once daily.
62568824|NCT03903432|OTHER|45 participants, in one center - Assuta|Patients with chronic sinusitis who are scheduled to undergo ESS at Assuta will be recruited and patients will sign an informed consent form for performing MRI (new protocol-without gadolinium injection) in addition to the routine CT.
61999401|NCT05142683|EXPERIMENTAL|CARIBOU-2|"After the CARIBOU-1 pilot study, the Principal Investigator revised the ICP to render it more applicable to community settings as well as offer a second-line psychotherapy (Brief Psychosocial Intervention) for youth who do not engage with, or respond to, cognitive-behavioural therapy. The revised version is called the CARIBOU-2 intervention. The current iteration of the pathway involves a series of steps: (1) structured assessment, including safety assessment; (2) education on depression, sleep, exercise, and diet; (3) psychotherapy (with 1st line Cognitive Behavioural Therapy, 2nd line Brief Psychosocial Intervention); (4) a caregiver structured support group; (5) medication options (1st line fluoxetine, 2nd line sertraline); (6) team reviews every four weeks, (meeting with the youth and involved clinicians to review measures and discuss treatment changes); and, (7) discharge and follow-up planning."
61999402|NCT00804336|EXPERIMENTAL|Pasireotide and RAD001|RAD001 was administered orally as a once-daily dose. Pasireotide s.c. was self-administered s.c. twice daily for 4 weeks. If pasireotide s.c. was tolerated, patients received pasireotide LAR i.m. at the corresponding dose level. Pasireotide s.c. was continued for an additional 2 weeks after administration of pasireotide LAR until anticipated steady-state levels of pasireotide LAR were achieved. Pasireotide LAR was administered every 28 days. Cycles for everolimus and pasireotide LAR were repeated every 28 days.
61999403|NCT04028011||PSG and novel wearable device|75 patients will wear polysomnography at the same time as the Novel wearable device
61999404|NCT04028011||PG and novel wearable device|75 patients will wear polygraphy at the same time as the novel wearable device
61999405|NCT01467076|ACTIVE_COMPARATOR|Inhaled PGE1 (150 ng/kg/min)|150 ng/kg/min Inhaled PGE1
61999406|NCT01467076|PLACEBO_COMPARATOR|Aerosolized Normal Saline|Eligible infants will be randomly assigned to either IPGE1 \[150ng/kg/min\], IPGE1 \[300ng/kg/min\] or control group. Infants in the control group will receive the same volume of aerosolized saline and oxygen from the respirator.
62568825|NCT01630187|ACTIVE_COMPARATOR|Carbetocin 100 mcg|
62774920|NCT02040896||Group 1|All consecutive emergency department patients undergoing CT during study hours will be prospectively enrolled, except for those meeting pre-specified exclusion criteria.
61977754|NCT03683446||Open Rectal Surgery|Surgery performed through a single long incision (cut) in the abdomen (belly) to access the colon and/or the rectum.
61977755|NCT04645641|ACTIVE_COMPARATOR|CGM Users|Glucose challenge during clinic sessions to assess performance of CGM compared to comparator measurement.
61999407|NCT01467076|ACTIVE_COMPARATOR|Inhaled PGE1 (300 ng/kg/min)|300 ng/kg/min of Inhaled PGE1
61999408|NCT02227485|ACTIVE_COMPARATOR|Chlorhexidine (0.2%)|Chlorhexidine (0.2%) mouth rinse, 10 ml for 2 minutes every night for 2 weeks and tooth bleaching (one time) after using mouth rinse.
61999409|NCT02227485|EXPERIMENTAL|Punica granatum Pleniflora mouth rinse|Punica granatum Pleniflora (Golnaar) mouth rinse, 10 ml for 2 minutes every night for 2 weeks and tooth bleaching (one time) after using mouth rinse.
61999410|NCT05547321|EXPERIMENTAL|Monotherapy (OMTX705)|OMTX705 is administered as single agent.
61999411|NCT05547321|EXPERIMENTAL|Combination (OMTX705 + pembrolizumab)|OMTX705 is administered in combination with pembrolizumab.
61999412|NCT03561181|EXPERIMENTAL|High dose Group|Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
61999413|NCT03561181|EXPERIMENTAL|low dose Group|Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,5μg/dose
61999414|NCT03912727|EXPERIMENTAL|Alpha-lipoic acid|18 patients will receive alpha lipoic acid (thiotacidR) product with their standard therapy.
61999415|NCT03912727|PLACEBO_COMPARATOR|Control|18 patients will receive their standard therapy only.
61999416|NCT03367312|EXPERIMENTAL|Pulmonary Hypertension Patients on Inhaled Prostacyclin|10 subjects will Pulmonary Hypertension on a stable dose of Inhaled Prostacyclin for treatment of PH.
61999417|NCT02153944|EXPERIMENTAL|Behavioral: Drug challenge with methylphenidate|Participant received methylphenidate 20 mg orally during study visit
61999418|NCT02153944|PLACEBO_COMPARATOR|Behavioral: Drug challenge with placebo|Participant received placebo orally during study visit
61999419|NCT02153944|EXPERIMENTAL|Behavioral: Drug challenge with propranolol|Participants received propranolol 40mg orally during study visit
61999420|NCT02153944|EXPERIMENTAL|fMRI: Drug challenge with methylphenidate|Participant received methylphenidate 20 mg orally during study visit
62184842|NCT05327036||pregnant women with Single Umbilical Artery|pregnant women with Single Umbilical Artery
62774921|NCT04503824||Group IIa: 13 papular OLP|
62774922|NCT04503824||Group IIb: 13 atrophic OLP|
62774923|NCT04503824||Group IIc: 13 erosive OLP|
62184843|NCT05327036||pregnant women with Umbilical Artery Embolism|pregnant women with Umbilical Artery Embolism
62184844|NCT05327036||Normal pregnant women|Normal pregnant women without pregnancy complications
62184845|NCT01036243|EXPERIMENTAL|Test formula 1|Hydrolyzed formula with probiotics
62184846|NCT01036243|ACTIVE_COMPARATOR|test formula 2|acidified hydrolyzed formula.
62568826|NCT01630187|EXPERIMENTAL|Carbetocin 50 mcg|
62568827|NCT02363543|ACTIVE_COMPARATOR|Hyalomatrix|Sterile, single use, flexible, and conformable wound dressing comprised of a derivative of hyaluronic acid which acts as a three dimensional regenerative matrix.
62774924|NCT04503824||Group I: 13 healthy individuals|
62774925|NCT01059383|EXPERIMENTAL|VECAM 40/300|
62774926|NCT01059383|ACTIVE_COMPARATOR|Esomeprazole 20 mg|
62774927|NCT00513721||III|Prostate specimens with positive surgical margins.
62184847|NCT01036243|ACTIVE_COMPARATOR|Test formula 3|hydrolyzed formula without probiotics
62774928|NCT00859157||Group 1|Patients undergo standard mastectomy.
62774929|NCT00859157||Group 2|Patients undergo tumescent mastectomy.
62774930|NCT05875493|EXPERIMENTAL|A-JAB-21822|Dosing in the fasted state followed by fed dosing
62774931|NCT05875493|EXPERIMENTAL|B-JAB-21822|Dosing in the fed state followed by fasted dosing
61977756|NCT02680912|EXPERIMENTAL|Warm needle acupuncture|"Warm needle acupuncture (wenzhen; 温针) is where moxa cones are placed on the handle of the needle, after the needle has been inserted. Once lit, heat transmits along the shaft of the needle to the acupuncture point.~Moxa refers to the herb mugwort (Artemisia vulgaris) that is burnt to warm specific parts of the body, including acupuncture points."
61977757|NCT02680912|ACTIVE_COMPARATOR|Basic needle acupuncture|Basic needle acupuncture is the use of acupuncture needles alone, without other methods of stimulation.
62393500|NCT04192292|EXPERIMENTAL|Low dose sulphonylurea + DPP4 inhibitor|Participants will be given a single dose of low dose sulphonylurea once daily and a single dose of DPP4 inhibitor for 14 days as a physiological stimulus. The sulphonylurea given in this study will be gliclazide 20mg orally once daily and the DPP4 inhibitor will be sitagliptin orally100mg once daily.
62393501|NCT02301468|EXPERIMENTAL|Dry needling|Dry needling (experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained
62393502|NCT02301468|EXPERIMENTAL|Ischemic compression|Ischemic compression (experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
62774932|NCT01843270|EXPERIMENTAL|ideal body weight|LMA size based on ideal body weight
62774933|NCT01843270|EXPERIMENTAL|actual body weight|LMA size according to actual body weight
62774934|NCT01694836|EXPERIMENTAL|Depigoid Birch 5.000 DPP/ml|"Suspension for s.c. injection. Treatment schedule:~1. Build-up phase (1 day: 0,2 ml+0,3 ml at interval of 30 minutes)~2. Maintenance phase (3 years: 0,5 ml at intervals of 4-6 weeks)"
62774935|NCT01694836|PLACEBO_COMPARATOR|Placebo|"Suspension for s.c. injection. Treatment schedule:~1. Build-up phase (1 day: 0,2 ml+0,3 ml at interval of 30 minutes)~2. Maintenance phase (3 years: 0,5 ml at intervals of 4-6 weeks)"
62774936|NCT05017532|EXPERIMENTAL|Intervention|Intervention with RC2S+ that consists of 24 biweekly sessions
62774937|NCT00547521|EXPERIMENTAL|Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort|In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants were also administered a stable MTX dose of greater than or equal to 10 mg once weekly for at least 4 weeks prior to first injection of SC abatacept.
61977758|NCT03104595|EXPERIMENTAL|Cohort 1|EC-18 500 mg
61977759|NCT03104595|EXPERIMENTAL|Cohort 2|EC-18 1000 mg
61977760|NCT03104595|EXPERIMENTAL|Cohort 3|EC-18 1500 mg
62184848|NCT01036243|ACTIVE_COMPARATOR|reference product|standard infant formula
62184849|NCT00784745|EXPERIMENTAL|Dexamethasone|
62184850|NCT02759237||Patient Group|Patients identified for treatment of symptomatic aortic sten
62184851|NCT04008056||Patients undergoing chemotherapy|
62774938|NCT00547521|EXPERIMENTAL|SC Abatacept Monotherapy Cohort|In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants did not receive MTX at screening i.e., MTX naive, or discontinued MTX due to lack of efficacy or tolerability at least 4 weeks prior to first injection of SC abatacept.
62774939|NCT01517581||Malignant Disease with no visualized BAT|Children 18 years or younger who 1) had PET/CT scans with evidence of malignant disease but no metabolically active brown adipose tissue (BAT) at diagnosis and 2) were disease free within 1 year of diagnosis.
62774940|NCT02219503|EXPERIMENTAL|Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir|Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 12 weeks
62774941|NCT00979225|EXPERIMENTAL|Medication report|Medication reports delivered to providers at the point of care
62774942|NCT00979225|EXPERIMENTAL|Med. report plus care manager notices|Medication reports delivered to providers at the point of care and notices sent electronically to care managers
62774943|NCT00979225|NO_INTERVENTION|Control|
62774944|NCT05079477|ACTIVE_COMPARATOR|Calorie label|"Calorie label (control) will display a calories per package label on all beverages, not just sugary drinks. This is modeled after the American Beverage Association's current Clear on Calories labels. Additionally, all snack items will have a calories per serving label."
62774945|NCT05079477|EXPERIMENTAL|Sugar graphic warning label|"All products in this arm will also have calorie labels. Beverages with added sugar will also have sugar graphic warning labels with the text: WARNING: drinking beverages with added sugars contributes to obesity, diabetes, and tooth decay along with graphics depicting the amount of sugar in the beverage."
62774946|NCT02001584|EXPERIMENTAL|Healthy Volunteers|
61999421|NCT02153944|PLACEBO_COMPARATOR|fMRI: Drug challenge with placebo|Participant received placebo orally during study visit
62393503|NCT02264327|EXPERIMENTAL|MI Training + SIM|"Service Providers in all group will receive a free two-day Motivational Interviewing training. Service Providers in this group will also receive access and a brief introduction to the Motivational Interviewing Simulator (SIM). Sim is designed to help Service Providers practice, learn, maintain, and implement MI skills.~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
62774947|NCT02001584|EXPERIMENTAL|Obese, Otherwise Healthy Volunteers|
62774948|NCT00961194|PLACEBO_COMPARATOR|placebo|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
62774949|NCT00961194|EXPERIMENTAL|dose of ketamine tested = 0.35 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
62774950|NCT00961194|ACTIVE_COMPARATOR|dose of ketamine tested = 0.7 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
62393504|NCT02264327|ACTIVE_COMPARATOR|MI Training + MI eBook|"Service Providers in all group will receive a free two-day Motivational Interviewing training. Service Providers in this group will also receive a Motivational Interviewing eBook designed to help Service Providers learn, maintain, and implement MI skills.~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
62774951|NCT00961194|ACTIVE_COMPARATOR|dose of ketamine tested = 1.4 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
62774952|NCT00048100|EXPERIMENTAL|Apheresis + Transplant|Skin biopsy \& either a leukodepletion apheresis or an additional marrow aspiration prior to marrow or stem cell transplantation.
62393505|NCT02264327|ACTIVE_COMPARATOR|MI Training Only|"Service Providers in this group will only receive a free two-day Motivational Interviewing training.~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
62568828|NCT02363543|ACTIVE_COMPARATOR|Integra|Sterile, single use, wound care dressing comprised of a porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan
62568829|NCT00351468|EXPERIMENTAL|Eltrombopag|Open-label eltrombopag
62774953|NCT06459336|EXPERIMENTAL|Intensive constraint-induced movement therapy|intensive protocol of CIMT of total 36 hours will be given in a week
62774954|NCT06459336|EXPERIMENTAL|Distributed constraint-induced movement therapy|Distributed participants will total of 36 hours treatment for 8 weeks
62774955|NCT02966470||General surgery patient|General surgery patient admitted to the Section of General Surgery, Trauma, and Surgical Critical Care who are over 60.
61977761|NCT03104595|EXPERIMENTAL|Cohort 4|EC-18 2000 mg
61977762|NCT03104595|EXPERIMENTAL|Cohort 5|EC-18 3000 mg
61977763|NCT03104595|EXPERIMENTAL|Cohort 6|EC-18 4000 mg
61977764|NCT01835067|SHAM_COMPARATOR|Control Group (A)|Ranibizumab only (active control). Participants will receive a 'sham injection' to simulate C3F8 and/or tPA administration.
61999422|NCT01423448|EXPERIMENTAL|Bulletin board|Participants will be given access to the online bulletin board (intervention) for a 6 month period
62184852|NCT02835092|ACTIVE_COMPARATOR|Self-directed Control|
61999423|NCT01423448|NO_INTERVENTION|Control|After 6 months participants allocated to the control group will receive access to the intervention
62184853|NCT02835092|EXPERIMENTAL|Take Shape For Life Program|
62184854|NCT02835092|EXPERIMENTAL|Medifast Direct Program|
62568830|NCT02298153|EXPERIMENTAL|atezolizumab (MPDL3280A) + epacadostat (INCB024360)|atezolizumab (MPDL3280A) 1200 mg given every 3 weeks + epacadostat (INCB024360) 25 mg BID as starting dose, followed by dose escalations until MTD or PAD is identified
62568831|NCT03078764|EXPERIMENTAL|Patient Arm using mHealth|Patients with uncontrolled type 2 diabetes
62774956|NCT00837226||Study group-Bariatric procedure performed|
62393506|NCT03169127|EXPERIMENTAL|Experimental Group Ibuprofen 600mg|Two Hundred healthy volunteers underwent removal of one lower third molar, will be treated to control pain, swelling and trismus with ibuprofen 600mg. Therefore, these 200 patients will be genotyped and phenotyped for these genes and their postoperative records with all data collected will be compared with the haplotypes found in the Brazilian population.
62393507|NCT00157157|EXPERIMENTAL|Single Arm - All Participants|All subjects enrolled in the study who meet the eligibility criteria.
62393508|NCT00216112|EXPERIMENTAL|Investigational Treatment|Imatinib Mesylate + Docetaxel
62774957|NCT00837226||Control group: No bariatric procedures|
62774958|NCT03794674||MPI test group|50 eligible patients. Frailty level independently assessed by two reviewers based on the medical records and assessed by one research assistant based on bedside testing.
62774959|NCT00519662|EXPERIMENTAL|Dose escalating cohorts of SNS-314|Sequential groups, starting at a dose of 30 mg/m2, will be escalated according to identification of dose limiting toxicities against various criteria. Doses escalated by doubling the dose until the first observation of clinically significant Grade 2 or greater toxicity related to SNS-314 injection. Results in dosing increments of 67%, 50%, 40%, 33%, and subsequently 25% based on modified Fibonacci schema.
62774960|NCT02997982|EXPERIMENTAL|Valaciclovir treatment|Valaciclovir 500Mg Tablet
62774961|NCT01854268|EXPERIMENTAL|Healthy adults who receive capsaicin|Single treatment consisting of healthy adults.
62774962|NCT01438177|EXPERIMENTAL|Velcade+Cyclophosphamide+Chloroquine|"VELCADE given by intravenous push at 1.3 mg/m\^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.~Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.~Chloroquine given at 500 mg orally daily on days 1-14 and 22-35.~Each cycle is 42 days in length."
62774963|NCT06583577|EXPERIMENTAL|3D model simulator preoperative education|Participants will receive standard preoperative education regarding ostomy care enhanced by the hands on use of a the ostomy simulator.
62774964|NCT06583577|NO_INTERVENTION|Standard preoperative education|Participants will receive standard preoperative education.
62774965|NCT00870298|EXPERIMENTAL|computerized alert|An automatic electronic stop of the tmp/sulfa or warfarin order whenever a resident or nurse practitioner places an order for tmp/sulfa with an already active warfarin order, or when ordering both simultaneously
62774966|NCT00870298|OTHER|2 Current practice|Current practice of the pharmacist recommending cessation of concurrent warfarin and tmp/sulfa orders
62774967|NCT05529329|ACTIVE_COMPARATOR|Group (Z)|patients received zirconia restorations group
62774968|NCT05529329|EXPERIMENTAL|Group (EC)|patients received IPS E.max Cad restorations group
62774969|NCT02607228|EXPERIMENTAL|Alobresib Dose Escalation|Participants who have progressed on either abiraterone and/or enzalutamide will be enrolled to receive increasing doses of alobresib up to 9 mg to determine the MTD.
62774970|NCT02607228|EXPERIMENTAL|Alobresib + Enzalutamide Dose Escalation|Following a two week lead-in with enzalutamide once daily, participants who have progressed on abiraterone will receive less than or equal to MTD of alobresib in combination with enzalutamide 160 mg once daily. Based on observed pharmacokinetics (PK) interaction, toxicity, and tolerability observed in the single agent dose escalation, the dose of alobresib may be increased.
62774971|NCT02607228|EXPERIMENTAL|Alobresib Dose Expansion (Group 1)|Participants will receive a dose less than or equal to MTD of alobresib (based on safety, pharmacodynamics (PD), and tolerability).
61977765|NCT01835067|EXPERIMENTAL|C3F8 Only Group (B)|C3F8 given. Ranibizumab given as standard.
61977766|NCT01835067|EXPERIMENTAL|tPA and C3F8 Group (C)|Both C3F8 gas and tPA given. Ranibizumab given as standard.
61977767|NCT01835067|EXPERIMENTAL|tPA Only Group (D)|tPA given. Ranibizumab given as standard.
62568832|NCT03078764|EXPERIMENTAL|Community nurses|Nurses who receive mHealth report about patients in the patients' arm.
62568833|NCT04104633|OTHER|Patients with breast or colorectal cancer|10 patients with invasive breast carcinoma, not otherwise specified (NOS) (Stade I to III) and 10 patients with invasive colorectal adenocarcinoma (Stade I to III)
62774972|NCT02607228|EXPERIMENTAL|Alobresib + Enzalutamide Dose Expansion (Group 2)|Participants will receive a dose less than or equal to MTD of alobresib plus enzalutamide (based on safety, PD, and tolerability).
62568834|NCT00279461|EXPERIMENTAL|A,|Arm A: Vitamin D 2,000 units daily all in one capsule for 6 months
62774973|NCT02607228|EXPERIMENTAL|Alobresib + Enzalutamide Dose Expansion (Group 3)|Participants will receive alobresib plus enzalutamide (dose will be equivalent to the dose chosen for Group 2).
62774974|NCT04518488|ACTIVE_COMPARATOR|Prehabilitation group|The prehabilitation group will receive a set of exercises designed to strengthen both limbs. The exercises will be taught and illustrated by a trained physiotherapist and are to be done daily during the period prior to surgery. The participant will be coached and supported for the exercise program, twice a week during the pre-operative period.
62774975|NCT04518488|OTHER|Informational support group (control group)|The focus for participants in the Informational Support Group will be on needs for information and psychosocial support during the pre-operative period. The intervention will be in the form of telephone or video calls by a trained health professional. These calls will be scheduled twice a week during the pre-operative period.
62393509|NCT03176823|SHAM_COMPARATOR|Control Arm|"Control-arm patients will be treated with standard Best Practice management of traumatic brain injury, with the addition of sham-RIC. The sham intervention will use a purpose-built device which will visually and audibly mimic a functional RIC device, with the key distinction being non-inflation of the arm cuff with resultant non-occlusion and no induced ischemia. To mask patient enrollment, all patients in both study arms will have the arm and RIC device draped in an opaque sheet so that the extremity distal to the RIC device are not visible to medical staff during the period of intervention."
62393510|NCT03176823|EXPERIMENTAL|RIC Arm|The RIC treatment will be applied with a purpose-built commercial RIC device which will aid in standardizing dose and delivery. Therapeutic RIC will be provided by the CellAegis Technologies autoRIC device on an upper extremity. As with the control cohort, this cohort will undergo complete extremity draping.
62393511|NCT06050811|EXPERIMENTAL|Prebiotic supplement|5 g 2'-Fucosyllactose per day
62774976|NCT04238169|EXPERIMENTAL|SBRT+Toripalimab|"Immunotherapy：Toripalimab: 240 mg once every three weeks，Until progress of disease or investigators determine that clinical benefit is no longer available or there are intolerable toxicity.~SBRT：30-50Gy/5F（2-4 locations)."
62774977|NCT04238169|EXPERIMENTAL|SBRT+Bevacizumab+Toripalimab|"Immunotherapy：Toripalimab: 240 mg once every three weeks，Until progress of disease or investigators determine that clinical benefit is no longer available or there are intolerable toxicity.~SBRT：30-50 Grays(Gy) in 5 fractions（2-4 locations）. Bevacizumab：7.5mg/kg once every three weeks."
62184855|NCT02193659|EXPERIMENTAL|Cereals|For 30 days, participants in group 1 took cereals with omega-3 in the breakfast with diet, group 2 took cereals and diet, and group 3 only received the diet. The energy intake of the designed diet was similar into the three groups (ranging 1900-2000 Kcal per day).
62184856|NCT03995225|EXPERIMENTAL|Smokers|This study involves wearing a smartband to monitor, record and notify smokers of smoking events and deliver real-time brief mindfulness exercises by smartphone app. There is only one arm.
62184857|NCT03551431|EXPERIMENTAL|Video EEG with verbal suggestion|
62184858|NCT03551431|EXPERIMENTAL|video EEG with verbal suggestion and tuning fork|
62184859|NCT03551431|EXPERIMENTAL|video EEG with verbal suggestion and cotton swab|
62393512|NCT06050811|PLACEBO_COMPARATOR|Placebo|5 g maltodextrin per day
62393513|NCT02908594|EXPERIMENTAL|exercise group|Using the Medical Exercise Peddler 3000, Medi-Bike, Taiwan as an exercise tool. Exercise group received routine care and 3- months exercise. The exercise was performed during the first 2 hr of each haemodialysis session (30 min per session, 3 sessions per week for 3 months).
62393514|NCT02908594|NO_INTERVENTION|control group|The control group received routine care
62393515|NCT01013116|EXPERIMENTAL|modified allergen extract of house dust mites|
62393516|NCT01013116|PLACEBO_COMPARATOR|Placebo|
62393517|NCT02610790||Connected bracelet|Patients with a colorectal surgery planned will be included. Fifteen days before surgery, patients will have a connected bracelet permitting to quantify the number of steps and distance achieved each day before surgery.
62184860|NCT04991636|EXPERIMENTAL|Protocol|Each patient agreeing to participate in the study will be distributed in the protocol group and will receive an angioscan according to the protocol in pre-operative and at the usual post-operative check-up within 3 months after the operation. The usual procedure, foresees an angioscanner with injection of contrast product and the measurement of the images is performed during a deep breath. In order to obtain a complete respiratory cycle, the study procedure foresees in addition to the usual procedure, an image measurement during a deep exhalation.
62393518|NCT06509776||Population sample|Random subsample of all 17-18-year-old individuals in Denmark, i.e. live births from year 2006 and 2007.
62393519|NCT00130754|EXPERIMENTAL|1|Thymo
62393520|NCT00130754|NO_INTERVENTION|2|
62393521|NCT03844282||CArBON (baseline)|The RESCUE-RACER programme is formed of two studies; baseline (CArBON) and one post-injury (CARS). At baseline the larger CArBON study involves completion of a thorough single baseline neuroscientific assessment of healthy motorsport competitors including clinical, neuropsychological, neurocognitive, biomarker and vestibulo-ocular assessments, in addition to MRI of the brain.
62568835|NCT00279461|PLACEBO_COMPARATOR|B|Arm B: matching placebo one capsule daily for 6 months
62568836|NCT05630833|EXPERIMENTAL|Gepotidacin + Placebo|
62568837|NCT05630833|ACTIVE_COMPARATOR|Nitrofurantoin + Placebo|
62774978|NCT02189681|ACTIVE_COMPARATOR|Group C|Patients in this group underwent Conventional landmark guided midline spinal anaesthesia.
62774979|NCT02189681|EXPERIMENTAL|Group P|This group had pre-procedure ultrasound guided L5S1 paramedian spinal anaesthesia performed
62774980|NCT04288700|ACTIVE_COMPARATOR|Group A|
62774981|NCT04288700|ACTIVE_COMPARATOR|Group B|
62774982|NCT04288700|ACTIVE_COMPARATOR|Group C|
62774983|NCT04288700|ACTIVE_COMPARATOR|Group D|
62774984|NCT00098306|EXPERIMENTAL|1|
62774985|NCT00098306|EXPERIMENTAL|2|
62774986|NCT00098306|EXPERIMENTAL|3|
61999424|NCT02311751|ACTIVE_COMPARATOR|Active rTMS|"Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 25 simulation trains of 30 stimuli each (i.e., 750 stimuli) and an intertrain interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right dorsolateral prefrontal cortex (DLPFC). The order of bilateral stimulation (i.e. right then left or left than right) will be held constant for all 20 treatments.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
62184861|NCT02373917||study group|patient who in the biopsy showed lung cancer
62184862|NCT02373917||control group|patient who in the biopsy showed not to have lung cancer
62184863|NCT03112447|EXPERIMENTAL|absorbable cartilage nail Group|10 males and 7 females, ages 7-15 years (average, 11.8), and 3 patients with elbow dislocation, the fractures were fixed by absorbable cartilage nail
62184864|NCT03112447|ACTIVE_COMPARATOR|traditional Kirschner wire Group|10 males and 5 females, ages 8-14 years (average, 12.6), and 4 patients with elbow dislocation, the fractures were fixed by traditional Kirschner wires
62184865|NCT03751553|EXPERIMENTAL|obstetric gel group|they will have the standard care during labor and delivery with the vaginal application of the obstetrical gel.
62184866|NCT03751553|NO_INTERVENTION|no intervention group|they will receive the standard care during labor and delivery without the use of the obstetrical gel
62184867|NCT02923193|EXPERIMENTAL|Lithoplasty System followed by DCB|Shockwave Lithoplasty® Peripheral Lithoplasty System is a lithotripsy-enhanced, low-pressure balloon dilatation of calcified, stenotic peripheral arteries in patients who are candidates for percutaneous therapy. lithoplasty
62184868|NCT02923193|ACTIVE_COMPARATOR|Medtronic IN.PACT (DCB)|Medronic IN.PACT Drug Coated Balloon (DBS) is indicated for percutaneous transluminal angioplasty (PTA) in patients with obstructive disease of peripheral arteries, including patients with in-stent restenosis (ISR) and arteriovenous (AV) access to help maintain hemodialysis access in patients with end-stage renal disease.
62184869|NCT01068288|EXPERIMENTAL|Expectant Management|Expectant Management
62184870|NCT01068288|EXPERIMENTAL|Operative management|Operative management
62184871|NCT00755898|ACTIVE_COMPARATOR|1|Patients with a medical diagnosis of cancer appearing at outpatient clinics for treatment and/or monitoring of their disease status
62184872|NCT00755898|ACTIVE_COMPARATOR|2|Healthy adult volunteers
61999425|NCT02311751|SHAM_COMPARATOR|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
62184873|NCT04700475|EXPERIMENTAL|Laser group|Laser group composes of thirty patients who will receive low level laser three times a week, on alternate day (48h interval) Laser therapy will be initiated before the first radiotherapy session and ended after the last session, totaling 21 sessions
61999426|NCT05960396|EXPERIMENTAL|balanced diet|Carbohydrates 50% -65%, fats 20% -30%, and proteins 10% -15%.
61999427|NCT05960396|EXPERIMENTAL|Low-carbohydrate diet|Carbohydrates 20% -40%, fats 30% -45%, and proteins 30% -40%.
62184874|NCT04700475|OTHER|Control group|control group composes of thirty patients will be treated with 15mL of a 2% citric acid solution applied as a mouth rinse for 30 sec
62184875|NCT03949465|EXPERIMENTAL|Open label iTBS rTMS|Participants will receive repetitive transcranial magnetic stimulation (rTMS) as a treatment for depression
62184876|NCT00456378|EXPERIMENTAL|DIAM™ spinal stabilization system|Implantation of the DIAM Spinal Stabilization System
62184877|NCT00456378|ACTIVE_COMPARATOR|Conservative care|Conservative Care
62184878|NCT02101827||Hysteroscopic surgery|Women who received hysteroscopic surgeries or examinations
62184879|NCT03458728|EXPERIMENTAL|Dose escalation of BAY806946 in Phase 1|It is estimated that 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Safety and MTD/RP2D dose will be evaluated in 2 age groups (\< 1 year old and ≥ 1 year old).
62184880|NCT03458728|EXPERIMENTAL|Patients with Neuroblastoma in Phase 2|Recommended Phase 2 dose (RP2D) for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
62184881|NCT03458728|EXPERIMENTAL|Patients with Osteosarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
62184882|NCT03458728|EXPERIMENTAL|Patients with Rhabdomyosarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
62184883|NCT03458728|EXPERIMENTAL|Patients with Ewing sarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
62568838|NCT01476839|EXPERIMENTAL|Treatment (radiolabeled monoclonal antibody, chemotherapy)|"DOSIMETRY STUDY: Patients receive basiliximab IV and indium In 111 basiliximab IV on day -21. Patients undergo indium In 111 imaging scans daily. Patients with appropriate biodistribution continue on to treatment.~TREATMENT: Patients receive basiliximab IV and yttrium Y 90 basiliximab IV on day -14. Patients also receive BEAM chemotherapy comprising carmustine IV over 2 hours on days -7 and -6, etoposide IV BID over 4 hours and cytarabine IV over 2 hours BID on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic progenitor cell infusion on day 0."
62184884|NCT03455777|EXPERIMENTAL|AKCEA-ANGPTL3-LRX Dose 1|
62184885|NCT06226298|EXPERIMENTAL|Xiaxi|The experimental group will lie in the Xiaxi postural hammock for 10 minutes for 5 days.
62184886|NCT06226298|ACTIVE_COMPARATOR|Control|The control group will lie on a mat on the floor for 10 minutes, 5 days of intervention.
62184887|NCT02827578|EXPERIMENTAL|Tamsulosin + Solifenacin|Tamsulosin and Solifenacin
62184888|NCT02827578|ACTIVE_COMPARATOR|Tamsulosin + Solifenacin Placebo|Tamsulosin and Solifenacin placebo
62184889|NCT01728623|EXPERIMENTAL|E7080|
62184890|NCT04732247|EXPERIMENTAL|Oxytocin nasal spray|4x per day (QID) intranasal treatment with oxytocin (48 IU per dose)
62184891|NCT04732247|PLACEBO_COMPARATOR|Placebo nasal spray|4x per day (QID) intranasal treatment with placebo (identical to oxytocin nose spray minus the oxytocin)
62184892|NCT04665362|EXPERIMENTAL|M1-c6v1 combined with SHR-1210 and Apatinib|Single-arm
62393522|NCT03844282||CARS (exposure to a potentially concussive event)|The RESCUE-RACER programme has a single post-injury study; after involvement in a potentially concussive event sustained during motorsport, CARS serially repeats the CArBON assessment battery in the immediate post-concussion recovery period. CARS participants will under-go post-exposure neuroscientific assessments immediately after injury and then at one, two and three weeks post-injury. If symptoms persist beyond this time, a further two assessments at monthly intervals will be offered.
62393523|NCT05824273|EXPERIMENTAL|Tailored health communication intervention (LungTalk)|"Participants will receive the tailored health intervention LungTalk. LungTalk is a 10-15 minute long computer-tailored health communication and decision-making tool that is theoretically grounded in the Conceptual Model on Lung Cancer Screening Participation."
62184893|NCT00693433|EXPERIMENTAL|Treatment (enzyme inhibitor, chemotherapy)|Patients receive temsirolimus IV over 30 minutes once weekly on days 1, 8, 15, and 22 and oral dexamethasone once on days 1, 2, 8, 9, 15, 16, 22, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62184894|NCT04247269||Enteral formula standard|Children fed an intact protein formula
62184895|NCT04247269||Enteral formula semi-elemental|Children fed a semi-elemental protein formula
62184896|NCT06488638|EXPERIMENTAL|Group A|"Treatment period 1) nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days~Treatment period 2) placebo nitrate-depleted beetroot juice (70ml) twice a day for 3 days"
62184897|NCT06488638|PLACEBO_COMPARATOR|Group B|"Treatment period 1) placebo nitrate-depleted beetroot juice (70ml) twice a day for 3 days~Treatment period 2) nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days"
62393524|NCT05824273|ACTIVE_COMPARATOR|Non-tailored Intervention|Participants will receive non-tailored American Cancer Society (ACS) Lung Screening Informational Video as per standard of care. ACS Lung Screening Informational Video (ACS LSIV) is a non-tailored 5-minute video from the American Cancer Society about lung cancer screening designed for the lay individual.
62393525|NCT03429894|EXPERIMENTAL|Treatment|All patients will undergo imaging (angiography and IVUS) follow-up with approximately one-half of the patients returning for follow up at 9 months and approximately one-half returning for follow up at 12 months.
62393526|NCT04218942|EXPERIMENTAL|Prospective non randomised feasibility study|
62568839|NCT06338501|EXPERIMENTAL|Group Exercise|30 functional specific exercises for muaythai athletes. Nutrition Control HRV quantify.
62774987|NCT05774847||All healthy participants|Healthy participants will be recruited and assigned to different behavioral studies assessing the effect of the experimental manipulations of interest on decision-making metrics.
62774988|NCT00307866|EXPERIMENTAL|Arm 1|
62184898|NCT00477464|EXPERIMENTAL|Lapatinib+capecitabine|Lapatinib 1250mg once daily +capecitabine 2000mg/m\^2 twice daily (14 days out of 21 days)
62184899|NCT01939210|EXPERIMENTAL|Arm I (breathing training sessions)|Patients participate in 3 50-minute breathing training sessions, including a psycho-educational component and meditation-based breathing training, over 10 days. Patients then undergo 4D-CT on day 14 and undergo image-guided SBRT or standard radiation therapy 5 times a week for up to 5 fractions or 25 fractions, respectively.
62184900|NCT01939210|ACTIVE_COMPARATOR|Arm II (control)|Patients receive standard care over 10 days. Patients then undergo 4D-CT on day 14 and undergo image-guided SBRT or standard radiation therapy 5 times a week for up to 5 fractions or 25 fractions, respectively.
62184901|NCT02196077|EXPERIMENTAL|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
62184902|NCT02196077|EXPERIMENTAL|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI)160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
62184903|NCT02196077|EXPERIMENTAL|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
62184904|NCT02196077|EXPERIMENTAL|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
62184905|NCT02196077|EXPERIMENTAL|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
62184906|NCT00905359|ACTIVE_COMPARATOR|Aperius™ PercLID™ System|Aperius™ PercLID™ System arm. Patients randomized to this arm will undergo treatment with the Aperius™ PercLID™ System.
62184907|NCT00905359|ACTIVE_COMPARATOR|Standalone Decompressive Surgery|Patients randomized to this arm will receive Standalone Decompressive Surgery, defined as decompressive surgery without instrumentation or fusion.
62568840|NCT06468085|EXPERIMENTAL|Group A: The premixed Bioceramic NeoPUTTY® group|Cases will be evaluated clinically and radiographically to obtain baseline data. Local anesthesia will be administered and then rubber dam isolation will be performed. Pulpotomy procedure will be performed after hemostasis followed by covering pulp stump with Premixed Bioceramic NeoPUTTY® then final composite restoration will be applied.
62774989|NCT03238118|EXPERIMENTAL|Attention bias modification training|For attention-toward-positive, stimuli are colour-pictures of 16 angry and 16 happy faces (half female). Each happy face is presented 10 times, and each angry face presented 80 times across trials, balanced across the different positions in the 3 × 3 matrix. This yielded 160 training trials (two blocks of 80 trials). Children had to mouse-click on the happy face within the 3 × 3 matrix of angry faces as quickly and as accurately as possible. The matrix disappeared after the child mouse-clicked on the correct face and the next trial began.
62774990|NCT03238118|PLACEBO_COMPARATOR|Attention Control Training|For attention-training-control, stimuli are 20 colour-pictures of individual birds and flowers used in prior visual-search tasks with children. Children mouse-clicked on the bird presented amongst flowers as quickly and accurately as possible. Other task parameters were similar to the attention-toward-positive task (160 training trials). No performance feedback is given in either condition.
62774991|NCT03238118|PLACEBO_COMPARATOR|Psychoeducation|Psychoeducation is an intervention that is characterized by informing the participant of their irritability symptoms. The goal is to teach participants how to understand their symptoms, explain their treatment modalities, recognize signs that may lead to a possible crisis, and provide tips and strategies on how to deal with irritability.
62774992|NCT01297582|EXPERIMENTAL|E|
62774993|NCT01297582|PLACEBO_COMPARATOR|P|
62774994|NCT02478528|EXPERIMENTAL|Experimental|
62774995|NCT06524232|ACTIVE_COMPARATOR|Practice Facilitation Only|Practice Facilitation: Practices will receive up to 2 hours of direct practice facilitation services per month for 12 months.
62774996|NCT06524232|EXPERIMENTAL|Practice Facilitation + Learning Collaborative|"Practice Facilitation (PF): Practices will receive up to 2 hours of direct practice facilitation services per month for 12 months.~Learning Collaborative (LC): Virtual LC sessions will be held monthly and will include participants presenting anonymized cases to clinical experts, targeted brief didactics related to the content of the cases, and time for open discussion and Q\&A."
62774997|NCT06524232|EXPERIMENTAL|Practice Facilitation + Performance Incentives|"Practice Facilitation: Practices will receive up to 2 hours of direct practice facilitation services per month for 12 months.~Performance Incentives: Practices will receive a maximum total of $6,000 based on their performance during the 12-month implementation period. They will have the opportunity to receive up to $1,500 per quarter if they reach performance milestones for the quarter."
62774998|NCT06524232|EXPERIMENTAL|Practice Facilitation + Learning Collaborative + Performance Incentives|"Practice Facilitation: Practices will receive up to 2 hours of direct practice facilitation services per month for 12 months.~Learning Collaborative (LC): Virtual LC sessions will be held monthly and will include participants presenting anonymized cases to clinical experts, targeted brief didactics related to the content of the cases, and time for open discussion and Q\&A.~Performance Incentives: Practices will receive a maximum total of $6,000 based on their performance during the 12-month implementation period. They will have the opportunity to receive up to $1,500 per quarter if they reach performance milestones for the quarter."
62774999|NCT02257203|EXPERIMENTAL|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
62775000|NCT02257203|ACTIVE_COMPARATOR|Reading Education|Parents will receive an educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
62775001|NCT02516319|ACTIVE_COMPARATOR|Serial Blood Draws|Cohorts 3 and 4 - weight based doses of ICG dye followed by serial blood draws at 5, 10, 15 and 20 minutes post ICG injection.
62775002|NCT02516319|EXPERIMENTAL|Liver Funtion Test Dye Detection Monitor|All cohorts receive continuous LFT monitoring post ICG injection.
62775003|NCT01270256|ACTIVE_COMPARATOR|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
62775004|NCT01270256|PLACEBO_COMPARATOR|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
62775005|NCT02654938|EXPERIMENTAL|Mobilan (M-VM3)|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 2) treated with Investigational Drug Product
62184908|NCT01907945|EXPERIMENTAL|Intervention|Participant households in this arm are eligible for participation in the social network-based water treatment education program (referred to as the Microclinic Water Program). Participant households who do not enroll in the Microclinic Water Program receive household-based education identical to that of the 'comparison' arm.
62393527|NCT01975883||Spine surgical patients|Sequential patients scheduled for spine surgery, including degenerative, deformative, tumoral and traumatologic indications are eligible to participate. Exclusion criteria are the following : infection or history of infection of surgical site, past medical history of diabetes mellitus, defined as chronic glucose intolerance either insulin-dependent or non insulin-dependent at the time of operation, and patients with preoperative random BG levels greater than 126 mg/dl considering they could also represent undiagnosed diabetes
62393528|NCT03006549|EXPERIMENTAL|Emergency Manual|emergency manual present
62393529|NCT03006549|NO_INTERVENTION|No Emergency|NO emergency manual present
62393530|NCT01094821|EXPERIMENTAL|3 mg ATI-7505|3 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
62393531|NCT01094821|PLACEBO_COMPARATOR|Placebo|Placebo capsule three times daily for 9 days followed by transit scintigraphy
62568841|NCT06468085|EXPERIMENTAL|Group B: The Biodentine™ group|Cases will be evaluated clinically and radiographically to obtain baseline data. Local anesthesia will be administered and then rubber dam isolation will be performed. Pulpotomy procedure will be performed after hemostasis followed by covering pulp stump with Biodentine™ then final composite restoration will be applied.
62775006|NCT02654938|PLACEBO_COMPARATOR|Placebo|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 2) treated with Placebo (Glucose 5%)
62184909|NCT01907945|ACTIVE_COMPARATOR|Comparison|Participant households in this arm receive household drinking water treatment education at the household level.
62775007|NCT02237261|EXPERIMENTAL|Bendamustine, Bortezomib, Prednisone|Induction: Bortezomib: 1.3 mg/m2 subcutaneous for 7 days and Bendamustine: 90 mg/m2 intravenous for 2 days and in addition Prednison: : 60 mg/m2 per os for 4 days Consolidation: Bortezomib: 1.3 mg/m2 subcutaneous for 4 days and Bendamustine: 90 mg/m2 intravenous for 2 days and in addition Prednison 60 mg/m2 per os for 4 days
62775008|NCT06508008|EXPERIMENTAL|Intermittent negative pressure sputum suction through oral pharyngeal airway|(1) Insert the oropharyngeal airway parallel into the oral cavity; (2) Apply paraffin oil to the front end of the sputum suction tube; (3) The suction tube is inserted into the deep oral cavity through the middle lumen of the oropharyngeal airway; (4) Intermittent negative pressure for suction and suction of sputum
62775009|NCT06508008|NO_INTERVENTION|continuous negative pressure suction|(1) Use a tongue depressor to open the mouth; (2) Lubricating the front end of the sputum suction tube with paraffin oil; (3) Insert a suction tube into the oral cavity to aspirate phlegm.
62775010|NCT01850355|EXPERIMENTAL|Buspirone|Buspirone administered in tablets twice daily titrated to a maximum daily dose of 60mg for 8 weeks.
62775011|NCT03462381|EXPERIMENTAL|Protein|Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
62775012|NCT03462381|PLACEBO_COMPARATOR|Carbohydrate|Three endurance training sessions weekly with carbohydrate supplementation post-exercise and before sleep.
62775013|NCT01633177|ACTIVE_COMPARATOR|Vitamin D and Omega-3|
62775014|NCT01633177|ACTIVE_COMPARATOR|Vitamin D and Omega-3 placebo|
61999428|NCT01504724|EXPERIMENTAL|IVB group|Patients were treated with IVB injections approximately within 1 week before the first PRP. Then patients had PRP, which was done in three sessions at weeks 0, 1, and 2 according to ETDRS guidelines. The superior, inferior, and nasal and temporal areas were treated sequentially.
61999429|NCT01504724|NO_INTERVENTION|only PRP group|Patients had PRP, which was done in three sessions at weeks 0, 1, and 2 according to ETDRS guidelines. The superior, inferior, and nasal and temporal areas were treated sequentially.
61999430|NCT01064895||Active Cohort|Patients receiving the Benephit device and targeted renal therapy.
61999431|NCT00924911|EXPERIMENTAL|Part 1|A 4 way crossover of three GSK1322322 tablet formulations and GSK1322322 powder in bottle
62393532|NCT01094821|EXPERIMENTAL|10 mg ATI-7505|10 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
62775015|NCT01633177|ACTIVE_COMPARATOR|Vitamin D placebo and Omega-3|
62775016|NCT01633177|PLACEBO_COMPARATOR|Vitamin D placebo and Omega-3 placebo|
62775017|NCT05517694|EXPERIMENTAL|pelvic floor exercises, behavioral therapy and respiratory exercises group|Interventions of this group include pelvic floor exercises and behavioral therapy plus respiratory exercises for 8 weeks.
62775018|NCT05517694|ACTIVE_COMPARATOR|pelvic floor exercises and behavioral therapy group|Interventions of this group include pelvic floor exercises and behavioral therapy for 8 weeks.
62775019|NCT03574428|ACTIVE_COMPARATOR|Cohort 1|GNbAC1 36 mg/kg single i.v. dose or GNbAC1 placebo
62775020|NCT03574428|ACTIVE_COMPARATOR|Cohort 2|GNbAC1 60 mg/kg single i.v. dose or GNbAC1 placebo
62775021|NCT03574428|ACTIVE_COMPARATOR|Cohort 3|GNbAC1 85 mg/kg single i.v. dose or GNbAC1 placebo
62775022|NCT03574428|ACTIVE_COMPARATOR|Cohort 4|GNbAC1 110 mg/kg single i.v. dose or GNbAC1 placebo
62184910|NCT02914171|EXPERIMENTAL|Treatment arm|Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention using an add-on procedure delivering autologous bone marrow-derived mononuclear cells into the right ventricle.
62184911|NCT02914171|OTHER|Control arm|Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention without cell delivery.
62184912|NCT04115852||CON|Healthy Controls
62184913|NCT04115852||BED|Patients with Binge-Eating-Disorder
62184914|NCT03712449|EXPERIMENTAL|BELKYRA Treatment|"BELKYRA was injected into the subcutaneous fat for maximum of 6 treatments, 1 month apart from Month 0 to Month 5. Maximum dose did not exceed 100 milligrams (mg) \[10 milliliters (mL)\] in a single treatment.~SkinMedica products: (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 6 to Month 11.~Facial filler injectable treatment (JUVÉDERM VOLBELLA with Lidocaine and/or JUVÉDERM VOLIFT with Lidocaine and/or JUVÉDERM VOLUMA with Lidocaine and/or JUVÉDERM VOLITE with Lidocaine) from Month 6 to Month 8. The volume of filler injected at initial and touch-up treatments was determined by the investigator.~BOTOX Cosmetic 20 units (U) to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U total injected to forehead lines at Month 9 and Month 10."
62568842|NCT06468085|ACTIVE_COMPARATOR|Group C: the root canal treatment group|Root canal treatment will be performed to the control group followed by composite restoration.
62568843|NCT02045342|EXPERIMENTAL|Carbohydrate drink|Ingest 500ml (1g/kg) prior to metabolic measures.
62568844|NCT02045342|PLACEBO_COMPARATOR|Placebo|Ingest 500ml of placebo prior to metabolic measures.
62568845|NCT06297330|EXPERIMENTAL|Sleep intervention|One arm : All volunteers will receive a sleep management intervention.
62568846|NCT03574285|EXPERIMENTAL|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
62568847|NCT03574285|ACTIVE_COMPARATOR|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
62568848|NCT03328013||Women aged 25 to 33 years in 2017|"Women aged 25 to 33 years in 2017 and having performed an analyzed smear at the Brest University Hospital.~They are invited to fill out an online questionnaire asking them about :~* vaccine status against HPV~* if vaccinated, the name of the vaccine and the number of injection~* age of first sexual intercourse~* do they have a gynecological pathology"
62568849|NCT03648736||HOCM patients|selected for routine TASH procedure
62568850|NCT02463903|EXPERIMENTAL|Coping effectiveness Training (CET)|The intervention consists of Coping Effectiveness Training (CET), a manual-based group intervention based on a cognitive transactional theory of stress and coping. The purpose of CET is to improve skills to appraise stress, teach a number of techniques to cope with stress, and to give an opportunity to interact with other people with similar experiences of living with CHF. The CET program will, in this study, be modified for patients with CHF. The intervention consists of seven, 90-minute weekly sessions led by a nurse with a Masters degree in nursing science and extensive experience in heart failure care in collaboration with a professional psychologist. Each group consisted of 8 to 12 patients.
62215300|NCT04933773|EXPERIMENTAL|Set averaging times: 2-4 seconds and 8 seconds|SpO2 is measured by two pulse oximeters on one participant's hand (on the index finger and middle finger). One pulse oximeter is set to an averaging time of 2-4 seconds, the second pulse oximeter is set to an averaging time of 8 seconds.
62393533|NCT01094821|EXPERIMENTAL|20 mg ATI-7505|20 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
62775023|NCT04228094||TDApp1|This cohort will use TDApp1: an eHealth tool to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder
62775024|NCT06065891|OTHER|Resection of Paraartic lymph nodes|Single arm
62775025|NCT03779074|ACTIVE_COMPARATOR|10d bismuth quadruple therapy|rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days.
61999432|NCT00924911|EXPERIMENTAL|Part 2|A 3 way crossover of a GSK1322322 tablet with a high fat meal, with Ranitidine, and with Ranitidine and Vitamin C.
62393534|NCT00880711||1|Patient with advanced BC, already receiving Faslodex therapy
62568851|NCT02463903|NO_INTERVENTION|Control|The control group will receive standard health care and will not take part of the intervention.
62393535|NCT06049823|EXPERIMENTAL|Test1|half- (bottom 50% of socket filled with gelatin sponge and the top 50% of the socket filled with deproteinized bovine bone mineral mixed with collagen (DBBM-C)) then covered with a collagen membrane in tooth sockets
62568852|NCT01076673|EXPERIMENTAL|PBSC and Hyaluronic Acid|Peripheral blood stem cells and hyaluronic acid injections
62568853|NCT01076673|ACTIVE_COMPARATOR|Hyaluronic Acid|Hyaluronic Acid
62568854|NCT02802787|EXPERIMENTAL|Camp Discovery|One week activity based camp
62568855|NCT00832455|EXPERIMENTAL|Montelukast|
62568856|NCT02323373|EXPERIMENTAL|Topical group|Intervention: Tranexamic Acid - topical. Topical administration of a solution of 1.5 g of tranexamic acid (50 mg/ml, Transamin, Zydus Nikkho) diluted in 50 ml of saline (at 0.9%), sprayed over the operated area, covering it for 5 minutes, before the tourniquet release.
62568857|NCT02323373|ACTIVE_COMPARATOR|Intravenous group|Intervention: Tranexamic Acid - intravenous Intravenous injection of 20 mg/kg of tranexamic acid, diluted in 100 ml of saline at 0.9%, administered with anesthesia in 10 minutes.
62568858|NCT02323373|PLACEBO_COMPARATOR|Placebo|Intervention: intravenous injection of 100 ml of saline solution also administered with anesthesia in 10 minutes.
62568859|NCT06578429|EXPERIMENTAL|Active dTMS|Participants will receive 30 active dTMS treatments, administered 3 times per day over 10 consecutive business days. Each treatment visit will last approximately 30 minutes in total.
62568860|NCT06578429|SHAM_COMPARATOR|Sham dTMS|Participants will receive 30 sham dTMS sessions, administered 3 times per day over 10 consecutive business days. Each treatment visit will last approximately 30 minutes in total.
62775026|NCT03779074|EXPERIMENTAL|14d hybrid therapy|a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days.
62775027|NCT03779074|EXPERIMENTAL|14d high-dose dual therapy|rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
62568861|NCT04911777|EXPERIMENTAL|Pentarlandir™ UPPTA - High Dose|High dose of Pentarlandir™ UPPTA, q8h (over 3 hours postprandially)
61999433|NCT00843713|PLACEBO_COMPARATOR|Placebo|For subjects assigned to the placebo group, patients will take a matching placebo pill of 400 mg by mouth twice daily for 24 weeks in addition to taking their current HIV medication
61999434|NCT00843713|ACTIVE_COMPARATOR|Raltegravir|For subjects assigned to the active comparator group, they will receive raltegravir at 400 mg by mouth twice daily for 24 weeks in addition to continuing to take their current HIV medication
61999435|NCT04601688|EXPERIMENTAL|BRVO: Bevacizumab and intravitreal Dexamethasone|Participants with BRVO will receive a combination of Bevacizumab and intravitreal Dexamethasone.
61999436|NCT04601688|ACTIVE_COMPARATOR|BRVO: Bevacizumab|Participants with BRVO will receive Bevacizumab only.
61999437|NCT04916184|ACTIVE_COMPARATOR|aerobic exercise|effects on diastolic dysfunction in patients with stable chronic heart failure
61999438|NCT04916184|ACTIVE_COMPARATOR|Combined exercise|effects on diastolic dysfunction in patients with stable chronic heart failure
61999439|NCT03083496|ACTIVE_COMPARATOR|Potassium Oxalate 5%|Prophylaxis of the teeth; an application every 48 hours; 4 sessions
61999440|NCT03083496|ACTIVE_COMPARATOR|Potassium Oxalate 10%|Prophylaxis of the teeth; an application every 48 hours; 4 sessions
61999441|NCT02202447|EXPERIMENTAL|EC1169|"PART A AND B: EC0652 is in development as a radioimaging agent for PSMA-expressing tumors. All patients receive a baseline 99mTc-EC0652 SPECT/CT scan for PSMA expression prior to Cycle 1 Day 1.~PART A: EC1169 given as IV bolus QW on Weeks 1 and 2 of a 3 week cycle. Dose based on dose escalation plan starting with 0.2 mg/m2~PART B: EC1169 cohort 1 - taxane naive mCRPC patients that have progressed while receiving (or subsequent to receiving) abiraterone and/or enzalutamide but must not have previously received taxane-based systemic chemotherapy for mCRPC (previous treatment with six cycles of docetaxel for metastatic castration-sensitive prostate cancer (mCSPC) is permissible).~PART B: EC1169 cohort 2 - taxane exposed mCRPC patients who have progressed while receiving (or subsequent to receiving) abiraterone and/or enzalutamide and who have progressed subsequent to receiving \> 2 cycles of a taxane-based regimen for mCRPC."
62184915|NCT03712449|EXPERIMENTAL|Non-BELKYRA Treatment|"Participants who did not receive BELKYRA.~SkinMedica products: (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 0 to Month 5.~Facial filler injectable treatment (JUVÉDERM VOLBELLA with Lidocaine and/or JUVÉDERM VOLIFT with Lidocaine and/or JUVÉDERM VOLUMA with Lidocaine and/or JUVÉDERM VOLITE with Lidocaine) from Month 0 to Month 2. The volume of filler injected at initial and touch-up treatments was determined by the investigator.~BOTOX Cosmetic 20 units (U) to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U total injected to forehead lines at Month 3 and Month 4."
62393536|NCT06049823|EXPERIMENTAL|Test2|half- (bottom 50% of socket filled with gelatin sponge and the top 50% of the socket filled with deproteinized bovine bone mineral mixed with collagen (DBBM-C)) then covered with a nonresorbable membrane in tooth sockets
62568862|NCT04911777|EXPERIMENTAL|Pentarlandir™ UPPTA - Low Dose|Low dose of Pentarlandir™ UPPTA and placebo, q8h (over 3 hours postprandially)
62775028|NCT04367090|EXPERIMENTAL|Pyrotinib and docetaxel plus trastuzumab|
62775029|NCT01141478|ACTIVE_COMPARATOR|Proton Beam Radiotherapy plus Sorafenib|A combination of radiation therapy (proton) to kill tumor cells as well as Sorafenib which is a study drug administered to patients to stop tumor growth.
62184916|NCT03004586|EXPERIMENTAL|EBUS-TBNA:First Using a 25-Gauge Needle Then 22-gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by first using a 25-gauge needle, followed by a 22-gauge needle.
62393537|NCT06049823|EXPERIMENTAL|Control|full-grafting (DBBM-C+ Collagen membrane) in tooth sockets
62393538|NCT05597189|EXPERIMENTAL|Botanical extracts high dose|Consumption for 84 days. Subjects should consume two capsules half an hour before breakfast.
62393539|NCT05597189|EXPERIMENTAL|Botanical extracts low dose|Consumption for 84 days. Subjects should consume two capsules half an hour before breakfast.
62568863|NCT04911777|PLACEBO_COMPARATOR|Placebo|Pacebo, q8h (over 3 hours postprandially)
62568864|NCT05056259||newly diagnosed endometrial cancer|
62568865|NCT05056259||Recurrent cases of endometrial cancer|
62568866|NCT05984524|EXPERIMENTAL|Gamma|8-week music-based intervention with gamma lights
62775030|NCT01141478|ACTIVE_COMPARATOR|Sorafenib|Sorafenib is an oral pill taken daily to inhibit tumor growth at the cellular level.
62775031|NCT01467830|EXPERIMENTAL|absorbable sutures|patients attributed to that arm, undergoing surgery of Open Inguinal Hernia Repair With Mesh Fixation using absorbable sutures.
62775032|NCT01467830|OTHER|non absorbable sutures|patients attributed to that arm, undergoing surgery of Open Inguinal Hernia Repair With Mesh Fixation using non absorbable sutures,this is the method being considered the standard of care thus far.
62775033|NCT03824587|EXPERIMENTAL|Tenapanor 30 mg BID|"During the Double-Blind Treatment Period, subjects will receive tenapanor starting at a dose of 30 mg bid (three 10 mg tablets each time).~Investigators may decrease or increase the dose of study medication based on s-P levels and/or gastrointestinal (GI) tolerability in 10 mg increments to a minimum of 10 mg bid or a maximum of 30 mg bid at any time during the Double-Blind Treatment Period."
61977768|NCT03690115|EXPERIMENTAL|Experimental|Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
62393540|NCT05597189|PLACEBO_COMPARATOR|Control group|Consumption for 84 days. Subjects should consume two capsules half an hour before breakfast.
62568867|NCT05984524|PLACEBO_COMPARATOR|Control|8-week music-based intervention with control lights
62568868|NCT06396871||High risk - Liver Fibrosis|"1. FIB-4 score ≥ 1.3 AND~2. Fibroscan measurement ≥ 8kPa"
62568869|NCT06396871||Low risk - Liver Fibrosis|Fibroscan measurements \< 8kPa
62568870|NCT06396871||Steatotic Liver Disease|Diagnosis of steatosis in ultrasound AND CAP \> 275 dB/m
62568871|NCT06396871||No Steatotic Liver Disease|No steatosis in liver ultrasound AND CAP ≤ 275 dB/m
61999442|NCT02579746|EXPERIMENTAL|intervention|The intervention group received usual care plus the DASHNa-CC intervention.
61999443|NCT02579746|ACTIVE_COMPARATOR|control|The control group received usual care.
61999444|NCT03108248||ISP-TACE group|During the study period, a total of 44 patients with HCC with PVTT underwent the irradiation stent placement and TACE were included in the ISP-TACE group.
61999445|NCT03108248||TACE group|During the study period, a total of 82 patients with HCC with PVTT underwent TACE monotherapy were included in the ISP-TACE group.
61999446|NCT00684424||Outpatients with epilepsy|
61999447|NCT03922568||Density Gradient Centrifugation (DGC)|semen was layered over 50 % and 90% discontinuous Density Gradient layers in a 15ml conical tube, then centrifuged at 250 g for 8 min at room temperature. supernatant was aspirated and the resulted pellet was washed using Sperm wash media and centrifuged at 250 g for 8 min at room temperature. The final pellet was re suspended in residual volume
62775034|NCT03824587|PLACEBO_COMPARATOR|Placebo|same size, weight and appearance of experimental drug
61999448|NCT03922568||Physiological ICSI (PICSI)|Semen processing is done by double layer DGC method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Hyaluronan bound sperms are selected for oocyte injection
61999449|NCT03922568||Magnetic Activated Cell Sorting (MACS)|Semen processing is done by double layer DGC method. The resulted pellet is labeled with Annexin V microbeads followed by separation on MACS column, the eluted fraction contains non apoptotic sperms suitable for oocyte injection.
61999450|NCT01968018|EXPERIMENTAL|Tramadol HCI + acetaminophen|
62775035|NCT00731471|EXPERIMENTAL|1|12 Healthy adults infected with HIV
62775036|NCT00731471|EXPERIMENTAL|2|12 HIV+ adults on antiretroviral therapy
62775037|NCT06337708|EXPERIMENTAL|Smart Walk|Participants will receive a culturally tailored smartphone-delivered physical activity intervention.
62775038|NCT06337708|ACTIVE_COMPARATOR|Fitbit|Participants will receive a Fitbit Inspire 3 activity monitor.
62775039|NCT00955513|EXPERIMENTAL|diclofenac diethylamine gel 2.32% gel twice a day|drug
62775040|NCT00955513|EXPERIMENTAL|diclofenac diethylamine gel 2.32% gel three times a day|drug
62775041|NCT00955513|PLACEBO_COMPARATOR|placebo|placebo
62775042|NCT05407350||Crohns disease patients|Adult patients with moderately to severely active CD
62775043|NCT00123604|EXPERIMENTAL|Carvedilol|Carvedilol, orally, 25 mg, twice daily for five months
61999451|NCT01064791|EXPERIMENTAL|Arm 1|sotrastaurin (100mg bid) + tacrolimus + standard of care medications
62775044|NCT00123604|ACTIVE_COMPARATOR|Metoprolol|Metoprolol, orally, 200 mg, twice daily for five months.
62775045|NCT00619307|ACTIVE_COMPARATOR|Transition with prophylactic ibuprofen|
62775046|NCT00619307|ACTIVE_COMPARATOR|Transition with PRN ibuprofen|
61999452|NCT01064791|EXPERIMENTAL|Arm 2|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
61999453|NCT01064791|EXPERIMENTAL|Arm 3|sotrastaurin (300mg bid) + tacrolimus + standard of care medications
61999454|NCT01064791|ACTIVE_COMPARATOR|Arm 4|mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
62775047|NCT02212769|EXPERIMENTAL|A Group|1st oral administration of Losartan 50mg and 2nd oral administration of Losartan 50mg and DW1029M 1200mg
62775048|NCT02212769|EXPERIMENTAL|B Group|1st oral administration of DW1029M 1200mg and Losartan 50mg and 2nd oral administration of Losartan 50mg
62775049|NCT01649024|EXPERIMENTAL|single arm of Tremelimumab|Tremelimumab is administered at 15 mg/kg on day 1 every 12 weeks for 4 doses
62775050|NCT04732949|ACTIVE_COMPARATOR|SNG001|SNG001 via inhalation using Ultra device, once a day for 14 days
62775051|NCT04732949|PLACEBO_COMPARATOR|Placebo|Placebo via inhalation using Ultra device, once a day for 14 days
62775052|NCT01332747|EXPERIMENTAL|Safoof e Muhazzil in its conventional powder form|safoof e muhazzil in its conventional powder form 5 gms twice daily given orally
62775053|NCT01332747|EXPERIMENTAL|compressed tablet of safoof e muhazzil|compressed tablet of safoof e muhazzil is given in equivalent dose orally
62775054|NCT01332747|ACTIVE_COMPARATOR|atorvastatin|atorvastatin 10mg daily as a standard control
61999455|NCT04360577|EXPERIMENTAL|High-dose acupuncture|Acupuncture for 7 times every 3 weeks (one cycle of chemotherapy) for 9 weeks (3 cycles of chemotherapy)
62184917|NCT03004586|EXPERIMENTAL|EBUS-TBNA:First Using a 22-Gauge Needle Then 25-gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by first using a 22-gauge needle, followed by a 25-gauge needle.
62568872|NCT06396871||Diabetes|"1. HbA1c ≥ 6.5% OR/AND~2. Fasting Glucose \> 126 mg/dl OR/AND~3. Glucose at 120 min of OGTT \> 200 mg/dl AND/OR history of Diabetes, treated with at least one antidiabetic medication"
62184918|NCT02962414|EXPERIMENTAL|everolimus|everolimus, 2mg dispersible tablets
62184919|NCT04037345|EXPERIMENTAL|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10\^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
62568873|NCT06396871||Prediabetes|"1. HbA1c \>5.7 AND \<6.5% OR/AND~2. Fasting Glucose 100-125 mg/dl OR/AND~3. Glucose at 120 min of OGTT between 140-200 mg/dl"
62568874|NCT06396871||Normal glucose tolerance|"1. HbA1c \< 5.7% AND~2. Fasting glucose \< 100 mg/dl AND~3. Glucose at 120 min of OGTT \<140 mg/dl and no history of Diabetes"
62568875|NCT00077207|EXPERIMENTAL|Treatment (carboplatin, vincristine sulfate, temozolomide)|Induction therapy: Patients receive carboplatin IV (175/m2) over 1 hour on days 1, 8, 15, and 22; vincristine IV (1.5 mg/m2) on days 1, 8, 15, 22, 29, and 36; and oral temozolomide (200 mg/m2) on days 43-47. Four weeks after the completion of induction therapy, patients achieving stable or responding disease proceed to maintenance therapy. Maintenance therapy: Patients receive carboplatin (175/m2) and temozolomide (200 mg/m2) as in induction therapy and vincristine IV ((1.5 mg/m2) day 1 of weeks 10,11,12. Treatment repeats every 10 weeks for a total of 6 courses in the absence of disease progression.
62568876|NCT03105908|OTHER|Treatment|Internet delivered Acceptance and Commitment therapy, supported by a psychologist/psychology student under supervision.
62568877|NCT03105908|OTHER|Waiting list control condition|Participants receive no treatment for ten weeks, i.e. waiting list condition. Following post-assessment, the control condition receive unguided iACT (i.e. the same content and structure as iACT but without systematic therapist communication).
62568878|NCT03618394||Smoflipid|premature neonates receiving MCT/ω-3-PUFA-containing lipid emulsion
62568879|NCT03618394||Intralipid|premature neonates receiving Soybean Based lipid emulsion
62775055|NCT03942939|EXPERIMENTAL|A - TKA with short tourniquet time|50 arms: subjects will receive a tourniquet with a short tourniquet time during TKA surgery. Short tourniquet time is defined in this study as the release of the tourniquet after the initial exposure, resulting in a total tourniquet time of only 10-15 minutes.
62775056|NCT03942939|ACTIVE_COMPARATOR|B - TKA with tourniquet|50 arms: subjects will receive a tourniquet during TKA surgery.
62568880|NCT03432637|EXPERIMENTAL|SV|undergoing thoracoscopic lobectomy under spontaneous ventilation (SV)
62775057|NCT01363115|EXPERIMENTAL|OJ fortified with Ca and VitD|Regular OJ fortified with Calcium (350 mg/8 fluid oz serving) and Vitamin D3 (100 IU/8 fluid oz serving): one 8 fluid oz serving three times/day (treatment) in combination with nutritional counseling
62775058|NCT01363115|ACTIVE_COMPARATOR|OJ without VitD and Ca|Regular OJ without Calcium or Vitamin D3: one 8 fluid oz serving three times/day (control)
62775059|NCT00528996|PLACEBO_COMPARATOR|Placebo|Matching Placebo
61999456|NCT04360577|EXPERIMENTAL|Low-dose acupuncture|Acupuncture for 3 times every 3 weeks (one cycle of chemotherapy) for 9 weeks (3 cycles of chemotherapy)
61999457|NCT04360577|NO_INTERVENTION|Usual care|Chemotherapy without acupuncture
62184920|NCT04037345|EXPERIMENTAL|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10\^7 cells/2mL) ( 2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
62568881|NCT03432637|ACTIVE_COMPARATOR|SLV|undergoing thoracoscopic lobectomy under intubated anesthesia with single-lung mechanical ventilation(SLV)
62568882|NCT01047384|EXPERIMENTAL|Experimental|acupuncture-moxibustion therapy
62568883|NCT01047384|ACTIVE_COMPARATOR|Regular therapy|Regular therapy
62775060|NCT00528996|EXPERIMENTAL|BEA 2180 BR low dose|Low dose
62775061|NCT00528996|EXPERIMENTAL|BEA 2180 BR medium dose|Medium dose
62775062|NCT00528996|EXPERIMENTAL|BEA 2180 BR high dose|High dose
62184921|NCT04037345|EXPERIMENTAL|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10\^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
62184922|NCT06192030||Retrospective cohort|The cohort was retrospectively enrolled in The Sixth Affiliated Hospital, Sun Yat-sen University from August 2010 to August 2022. It is a training cohort.
62184923|NCT06192030||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is a validation cohort.
62775063|NCT00528996|EXPERIMENTAL|Tiotropium Bromide|Tiotropium Bromide
61999458|NCT00411619|EXPERIMENTAL|Everolimus|As this was a non-randomized, open-label, single arm study, all patients in the study received treatment with everolilmus
62393541|NCT02173015|NO_INTERVENTION|Low Fall Risk|"Individuals who have a functional reach greater than 8 and a unipedal stance time greater than 5 s."
62393542|NCT02173015|NO_INTERVENTION|High Fall Risk, No Training|"Individuals who have a functional reach of 8 or less OR a unipedal stance time of 5 s or less, but do not qualify for compensatory step training due to health concerns."
61999459|NCT04974775||Critically Ill|Critically ill patients and patients in need of post-operative intensive care.
61999460|NCT04974775||Cardiac Arrest|Cardiac Arrest according to the ICD-10 I469 diagnosis.
61999461|NCT04974775||Sepsis|Sepsis according to the sepsis-3 criteria.
61999462|NCT04974775||Covid-19|Critically ill patients with a positive Covid-19 test.
61999463|NCT04974775||Influenza|Critically ill patients with a positive influenza test.
61999464|NCT04974775||Trauma|Critically ill patients after a severe traumatic event.
62184924|NCT02621554|EXPERIMENTAL|resveratrol supplementation|Dietary Supplement: Resveratrol
62184925|NCT02621554|PLACEBO_COMPARATOR|placebo supplementation|Dietary Supplement: Placebo
62184926|NCT05342519|EXPERIMENTAL|Topical rapamycin 0.001%|Patients randomized to this arm of the study will apply 2 finger tip units (FTU) or 0.5 cc topical rapamycin 0.001% cream daily for 6 months
62393543|NCT02173015|EXPERIMENTAL|High Fall Risk, Training|"Individuals who have a functional reach of 8 or less OR a unipedal stance time of 5 s or less, and qualify for compensatory step training."
62393544|NCT00264693||P - A|Prophylactic Dosage, GFR \>= 60 mL/min/1.73m\^2
62393545|NCT00264693||P - B|Prophylactic Dosage, GFR 30-59 mL/min/1.73m\^2
62393546|NCT00264693||P - C|Prophylactic Dosage, GFR \< 30 mL/min/1.73m\^2
62393547|NCT00264693||P - CAPD|Prophylactic Dosage, CAPD
62393548|NCT00264693||T - A|Therapeutic Dosage, GFR \>= 60 mL/min/1.73m\^2
62393549|NCT00264693||T - B|Therapeutic Dosage, GFR 30-59 mL/min/1.73m\^2
62393550|NCT00264693||T - C|Therapeutic Dosage, GFR \< 30 mL/min/1.73m\^2
62393551|NCT00264693||T - CAPD|Therapeutic Dosage, CAPD
62393552|NCT03839316|ACTIVE_COMPARATOR|tDCS group|"Sixteen stroke patient receiving bihemispheric tDCS in addition to a conventional physiotherapy (PT) and occupational therapy (OT) program for five consecutive days per week for a three week period (a total of fifteen sessions).~The one hour long conventional PT sessions will include an upper extremity range of motion, strengthening and neurofacilitation exercise program. The one hour long OT sessions will include task specific exercises chosen according to the patient's functional status, including activities aimed at improving gross and fine motor function of the upper extremities.~The tDCS application will be applied at the beginning of each OT session and will be continued for a total of thirty minutes at 2 mA."
62393553|NCT03839316|SHAM_COMPARATOR|Sham group|Sixteen stroke patient receiving a conventional PT and OT program and sham tDCS for 5 consecutive days per week for a 3 week period ( a total of 15 sessions). The one hour long conventional PT and OT sessions will be the same as in the tDCS group. For sham tDCS, electrode application and positioning will be the same as the intervention group and will be applied at the beginning of each OT session as previously described. The current will initially be increased up to 2 mA, so to provide the typical initial tingling sensation, and slowly decreased over 30 seconds and consequently switched off. The electrodes will be removed after a total of thirty minutes.
62393554|NCT01631123|EXPERIMENTAL|Diet interventions|Sequential dietary intervention
62393555|NCT03987165|EXPERIMENTAL|Music Therapy|Music therapy by a certified music therapist will be delivered to infants over a period of 5 days. There will be two periods of data collection each day, one in the morning and one in the afternoon. Each baby will receive music therapy during one of these time points, with each baby serving as their own control during the second timepoint.
62568884|NCT01357317|ACTIVE_COMPARATOR|Lanthanum Carbonate|Lanthanum Carbonate: initial dose 500 mg TID with meals, titrated at monthly intervals in 500 mg increments or decrements, with goal of returning to normal the level of the abnormal baseline marker(s) of phosphorus homeostasis (serum phosphorus, PTH or TRP). Normality for this marker will be defined as serum phosphorus of 2.6-4.6 mg/dl, PTH of 10-65pg/ml and TRP\>=80%.
62775064|NCT02733965|OTHER|standard course|"The patients in the control group will have a classic course of treatment. They will receive -An educational assessment consisting on evaluating the patient's educational needs.~* Group workshops entitled Disease and drugs, Dietary and sports activity, Psychology Workshop during which the patient will be able to participate in order to get all the information he needs.~* Individual therapeutic education sessions to specifically and personally highlight certain non-pharmaceutical educational needs identified at the time of the educational assessment.~Moreover, in the control arm, a systematic short pharmaceutical interview with an average duration of 15 minutes will be proposed to patients at the initiation of treatment, at D15 after the prescription (considered as the date of inclusion) at M1 and then every 3 months (M3, M6, M9 and M12):"
62791641|NCT05936983||Patients with Bipolar disorder|Participants will be asked to fill out a structured questionnaire containing their sociodemographic characteristics. Then, Anthropometric Measurements, Eurofit test battery, Rapid Depressive Symptom Inventory-Self-Report Form and International physical activity questionnaire will be applied respectively.
62791642|NCT05936983||Patients with Schizophrenia group|Participants will be asked to fill out a structured questionnaire containing their sociodemographic characteristics. Then, Anthropometric Measurements, Eurofit test battery, Rapid Depressive Symptom Inventory-Self-Report Form and International physical activity questionnaire will be applied respectively.
62393556|NCT03987165|NO_INTERVENTION|Control|
62393557|NCT02617602|EXPERIMENTAL|Goal directed therapy|Based on transpulmonary thermodilution, hemodynamic management will be implemented to achieve predefined goals
62393558|NCT02617602|ACTIVE_COMPARATOR|Control|Conventional therapy
62393559|NCT04468100|EXPERIMENTAL|Tigerase®|Dornase alfa
62184927|NCT05342519|ACTIVE_COMPARATOR|Topical rapamycin 0.1%|Patients randomized to this arm of the study will apply 2 FTU (0.5 cc) topical rapamycin 0.1% cream daily for 6 months
62184928|NCT05342519|PLACEBO_COMPARATOR|Placebo|All patients will apply 2 FTU (0.5 cc) topical placebo cream daily for 6 months to the corresponding anatomic location on the opposite side of the body where the experimental drug is not being applied
62184929|NCT01438840|ACTIVE_COMPARATOR|Avatrombopag (Core Study)|Avatrombopag will be administered orally as 5 mg, 10 mg, 20 mg, 30 mg, or 40 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag, one daily and allowed to have their dose titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on their response to study drug.
62184930|NCT01438840|PLACEBO_COMPARATOR|Placebo (Core Study)|Placebo will be administered as 5 mg, 10 mg, 20 mg, 30 mg or 40 mg in a flexible dose design for 26 weeks. Placebo will be administered orally at a starting dose of 20 mg, once daily. Afterwards the dose can be titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on the participant's response to the study drug; placebo titration will be used to maintain the blind.
62184931|NCT01438840|EXPERIMENTAL|Avatrombopag (Open-Label Extension)|Participants who meet all eligibility criteria requirements of extension phase and who discontinue the core study because of lack of treatment effect will continue into the extension phase. Avatrombopag will be administered to participants who enter extension phase, with a starting dose of 20 mg avatrombopag, once daily for 76 weeks and undergo dose titration.
62184932|NCT00359047|EXPERIMENTAL|Documentation|Written educational material on osteoporosis for the participant and the physician.
62184933|NCT00359047|EXPERIMENTAL|Video|A 15-minute educational video on osteoporosis as well as written documentation on osteoporosis for the participant and the physician.
62393560|NCT04468100|ACTIVE_COMPARATOR|Pulmozyme®|Dornase alfa
62393561|NCT05237843|PLACEBO_COMPARATOR|Group A (control group)|"35 women in this group will receive only the standard treatment in the form of :~* low- dose aspirin (LDA) 81 mg/day orally (Jusprin® 81mg which manufactured by Future Pharmaceutical Company),~* LMWH (Enoxaparin, Clexane® which manufactured by SANOFI company) with a dose ( .5 mg/kg) subcutaneously injected/24 hr .~LDA ought to be begun before origination, while LMWH ought to be begun after confirmation of pregnancy by detecting fetal viability by ultrasound till age of viability (20wks)~-PLUS Placebo specially manufactured tablets in Ain shams faculty of pharmacy will start once known she is pregnan"
62184934|NCT04979247|EXPERIMENTAL|Oliceridine|Patients receive Oliceridine for pain control.
62184935|NCT00741468|EXPERIMENTAL|All subjects|Proellex 50 mg CYP1A2 probe CYP2C9 probe CYP2C19 probe CYP2D6 probe CYP3A4 probe
62184936|NCT02826798|EXPERIMENTAL|VBI-1501A: 0.5µg with adjuvant|0.5µg CMV vaccine with adjuvant
62184937|NCT02826798|EXPERIMENTAL|VBI-1501A: 1.0µg with adjuvant|1.0µg CMV vaccine with adjuvant
62393562|NCT05237843|EXPERIMENTAL|Group B ( Hydroxychloroquine group )|This group included 35 women who will administered Hydroxychloroquine 200 mg (Hydroquine® 200mg which fabricated by MinaPharm Company) one tablets / day once known she is pregnant in addition to the standard therapy (LMWH + LDA )
61977769|NCT06538337|EXPERIMENTAL|Hypofractionated External beam Radiotherapy|5 daily treatment sessions of MRI or CT-Guided Stereotactic Body Radiation Therapy (SBRT).
61977770|NCT01488539|EXPERIMENTAL|STAIR/NT|Patients will receive STAIR/NT treatment
62393563|NCT05237843|NO_INTERVENTION|Study Director|Only those directing the study know the treatment that each participant receives Placebo OR Hydroxychloroquin
62184938|NCT02826798|EXPERIMENTAL|VBI-1501A: 2.0 µg with adjuvant|2.0 µg CMV vaccine with adjuvant
62184939|NCT02826798|EXPERIMENTAL|VBI-1501: 1.0µg without adjuvant|1.0µg CMV vaccine without adjuvant
62184940|NCT02826798|PLACEBO_COMPARATOR|Placebo|Buffer/sucrose used for VBI-1501 suspension
62184941|NCT03055923||Asthma Patients|30 people who suffer from a confirmed diagnosis of asthma
62184942|NCT03055923||Chronic Obstructive Pulmonary Disease Patients|30 people who suffer from a confirmed diagnosis of COPD
62184943|NCT03055923||Healthy Controls|30 healthy volunteers who have no known diagnosis of Lung disease
62184944|NCT03046368|NO_INTERVENTION|Standard cover letter|"The group will receive a standard cover letter to the survey that is designed to have broad appeal:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark."
62393564|NCT03150706|EXPERIMENTAL|Avelumab|"The mismatch repair deficient or microsatellite instable, or POLE mutated metastatic colorectal cancer patients who were progressed after at least one prior systemic treatment for metastatic setting.~After checking the eligibility for the study entry, patients will be entered into the study treatment with avelumab monotherapy."
62393565|NCT03028649|EXPERIMENTAL|β-hydroxy-β-methylbutyrate (HMB)|"Group taking oral supplementation with calcium salt of β-hydroxy-β-methylbutyric acid produced by Olimp Laboratories. A single capsule contained 1250 mg Ca-HMB, which corresponds to 1000 mg of β-hydroxy-β-methylbutyrate.~Interventions:~The experimental procedure for each athlete included a 12-week HMB supplementation - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day.~Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced."
62393566|NCT03028649|PLACEBO_COMPARATOR|Placebo (maltodextrin)|"Group taking oral supplementation with placebo (maltodextrin). A single capsule contained 1000 mg of maltodextrin.~Interventions:~The experimental procedure for each athlete included a 12-week placebo administration - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day.~Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced."
62568885|NCT01357317|ACTIVE_COMPARATOR|Calcium Acetate|Calcium Acetate: initial dose 667 mg TID with meals, titrated at monthly intervals in 667 mg increments or decrements, with goal of returning to normal the level of the abnormal baseline marker(s) of phosphorus homeostasis. The maximum daily intake of elemental calcium should not exceed 1500 mg in order to comply w/recommendations from K-DOQI \[5\](this is approximately equal to three 667mg tablets of calcium acetate TID).
62568886|NCT01357317|ACTIVE_COMPARATOR|Dietary instructions|Dietary instructions consisting of pamphlets describing foods high in phosphorus and consultation with a renal dietitian if necessary, with the goal of return to normal the level of the abnormal marker of phosphorus homeostasis. Rescue therapy with a phosphorus binder of the treating physician's choice will be allowed in patients who fail to normalize elevated baseline serum phosphorus levels after 3 months following dietary instructions.
62184945|NCT03046368|EXPERIMENTAL|Targeted cover letter 1|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and sleep problems."
62184946|NCT03046368|EXPERIMENTAL|Targeted cover letter 2|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and contact to family and friends."
62184947|NCT03046368|EXPERIMENTAL|Targeted cover letter 3|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and sex"
62184948|NCT03046368|EXPERIMENTAL|Targeted cover letter 4|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sleep problems and contact to family and friends."
62184949|NCT03046368|EXPERIMENTAL|Targeted cover letter 5|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sleep problems and sex."
62184950|NCT03046368|EXPERIMENTAL|Targeted cover letter 6|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sex and contact to family and friends."
62184951|NCT03046368|EXPERIMENTAL|Targeted cover letter 7|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, sleep problems and contact to family and friends."
62184952|NCT03046368|EXPERIMENTAL|Targeted cover letter 8|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, sleep problems and alcohol."
62184953|NCT03046368|EXPERIMENTAL|Targeted cover letter 9|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, alcohol and contact to family and friends."
62215301|NCT04933773|EXPERIMENTAL|Set averaging times: 8 seconds and 16 seconds|SpO2 is measured by two pulse oximeters on one participant's hand (on the index finger and middle finger). One pulse oximeter is set to an averaging time of 8 seconds, the second pulse oximeter is set to an averaging time of 16 seconds.
61977771|NCT01488539|OTHER|Treatment as Usual (TAU)|Patients will receive Treatment as Usual (TAU)
61999465|NCT04974775||Healthy controls|Healthy at the time of blood sampling
61999466|NCT03790826|EXPERIMENTAL|Cystoscopic Inspection|"Comparison of bladder damage with traditional Foley catheter and the Kohli Atraumatic catheter.~Interventions: cystoscopy"
61999467|NCT02967250|EXPERIMENTAL|Ursodeoxycholic acid treatment|Each subject will receive UDCA intervention for six weeks.
61999468|NCT04817228|EXPERIMENTAL|EX-02 Gel|The powder of EX-02 (8.1 g in each unit) should be reconstituted with 20 g sterile water for injection (WFI) to obtain 5% EX-02. EX-02 5% gel will be topically applied on a wound surface of up to 80 cm2 for 24±3 hours, up to 8 consecutive applications
61999469|NCT03821558|ACTIVE_COMPARATOR|Interval training group|Patients to be randomized to the 'interval training group' will have exercise training sessions 3 times per week for a period of 12 weeks. During training, they will undergo interval exercise series composed of high-intensity intervals (80-90% of peak exercise performance) and low-intensity intervals (60-70% of peak exercise performance).
62184954|NCT03046368|EXPERIMENTAL|Targeted cover letter 10|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as alcohol, sleep problem and contact to family and friends."
62568887|NCT04511013|EXPERIMENTAL|Arm I (encorafenib, binimetinib, nivolumab)|Patients receive encorafenib PO QD on days 1-28, binimetinib PO BID on days 1-28, and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62393567|NCT03081858|EXPERIMENTAL|TSD-001 Administration Part 1, Cohort 1|Part 1, Cohort 1: For the first 3 subjects enrolled, the initial dose will be 10 mg in Sterile Water for Injection (SWFI). TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If Dose Limiting Toxicity(DLT) does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (25, 50, 75, 100, 150 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged \[greater than 14 days\] grade 2 toxicity) is observed.
62568888|NCT04511013|EXPERIMENTAL|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV on day 1 of all cycles and ipilimumab IV over 30 minutes on day 1 of cycles 1-4. Cycles repeat every 21 days for 4 cycles and then every 28 days in the absence of disease progression or unacceptable toxicity.
62568889|NCT04417855||LDH|Group of symptomatic individuals with LDH confirmed in MRI.
62568890|NCT04417855||Control|Group of asymptomatic individuals with no LDH.
62568891|NCT01294241|EXPERIMENTAL|Oleogel-S10|The eligible wound (half) was topically treated with Oleogel-S10 and covered with a non-adhesive wound dressing (Mepilex®) on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
62775065|NCT02733965|OTHER|Long Pharmaceutical Consultations|The patients will receive the same course of treatment as in the control group, including the D0 short pharmaceutical interview, with the same prerogatives of acceptance or rejection of participation in the TPE program. Short pharmaceutical interviews from D15 to M12 will be replaced by long pharmaceutical consultations of 30 to 60 minutes. The latter consisting in a full clinical medication review and incorporating the pedagogic aspects addressed in the short pharmaceutical interviews but for all therapeutic drugs taken by the patient. Additional consultations are possible on the request of the oncologist and/or patient. The consultations carried out at the request of the oncologist and/or the patient will be counted The first part of the pharmaceutical consultation focuses on a complete clinical medication review including Establishment of the patient profile: medical history, drug allergies and intolerance, comorbidities, age, understanding capacities, organizational capacity
61999470|NCT03821558|ACTIVE_COMPARATOR|Continuous training group|Patients to be randomized to the 'continuous training group' will have exercise training sessions 3 times per week for a period of 12 weeks. During training, they will undergo moderate continuous exercise training at 75% of peak exercise performance.
62775066|NCT02937766|EXPERIMENTAL|Treatment A|Subcutaneous (SQ) injection using an autoinjector weekly over 4 weeks (4 injections)
61999471|NCT01863472|ACTIVE_COMPARATOR|HeartLight(TM) Laser Balloon|Safety and efficacy of pulmonary vein isolation using the HeartLight(TM) Laser Balloon (endoscopically guided ablation)
61999472|NCT01863472|ACTIVE_COMPARATOR|irrigated radiofrequency current ablation|Safety and efficacy of pulmonary vein isolation using the irrigated radiofrequency current ablation
62775067|NCT02937766|ACTIVE_COMPARATOR|Treatment B|Intramuscular injection (IM) using syringe and needle weekly over 4 weeks (4 injections)
62775068|NCT03596450|EXPERIMENTAL|Semaglutide|Participants will receive semaglutide subcutaneously (s.c.) in addition to metformin monotherapy as treatment intensification in the course of routine clinical practice. Participants will be followed for 2 years, regardless of changes in antidiabetic treatment over the course of the study.
62775069|NCT03596450|ACTIVE_COMPARATOR|Standard of care|Participants will receive standard of care in addition to metformin monotherapy as treatment intensification in the course of routine clinical practice. Participants will be followed for 2 years, regardless of changes in antidiabetic treatment over the course of the study.
62775070|NCT01507480|EXPERIMENTAL|Bevacizumab|This study is to be carried out sequentially (dose escalation) on 5 groups of 8 patients. Each group is made up of 6 verum and 2 placebos.
62775071|NCT03134781|EXPERIMENTAL|Control|Participated only in measurements at baseline, at 20 weeks and at 40 weeks.
62775072|NCT03134781|EXPERIMENTAL|Training|Participated in a supervised 40-week DoIT workout exercise training program and in measurements at baseline, at 20 weeks and at 40 weeks.
62775073|NCT03134781|EXPERIMENTAL|Training-Detraining|Participated in a supervised 20-week DoIT workout exercise training program and then entered a 20-week detraining period. They also participated in measurements at baseline, at 20 weeks and at 40 weeks.
62775074|NCT04519853|EXPERIMENTAL|Low Glycemic Load Diet|Feeding study with dietary composition (approximately) 50% fat, 30% carbohydrate, 20% protein.
62775075|NCT05889078|EXPERIMENTAL|Nature condition|Participants will walk in a nature setting 3x per week for a period of 4 weeks.
62775076|NCT05889078|EXPERIMENTAL|Urban condition|Participants will walk in an urban setting 3x per week for a period of 4 weeks.
62775077|NCT03003507|ACTIVE_COMPARATOR|Diet 1|Low-carbohydrate Enteral Formula With Fructose
62775078|NCT03003507|ACTIVE_COMPARATOR|Diet 2|Low-carbohydrate Enteral Formula Without Fructose
61999473|NCT04640948|EXPERIMENTAL|High flow nasal therapy (HFNT)|Characterized by an elevated arterial CO2 (PaCO2) level of \> 6kPa due to ventilatory failure. The ventilatory failure relates to the imbalance between the respiratory demand and the capacity of the respiratory system to match the demand.
61999474|NCT04640948|ACTIVE_COMPARATOR|Low flow oxygen (LFO)|Characterized by an elevated arterial CO2 (PaCO2) level of \> 6kPa due to ventilatory failure. The ventilatory failure relates to the imbalance between the respiratory demand and the capacity of the respiratory system to match the demand.
62393568|NCT03081858|EXPERIMENTAL|TSD-001 Administration Part 1, Cohort 2|"Part 1, Cohort 1: For the next 3 subjects enrolled, the initial dose will be 90 mg in SWFI. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If DLT does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (180, 270, 360, 450, and 540 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged \[greater than 14 days\] grade 2 toxicity) is observed.~If no DLT is observed in the first 6 subjects (cohorts 1 and 2) after titration up to 540 mg, then the maximum deliverable dose (MDD) will be defined and dose recommended for part 2 of the study."
62393569|NCT03081858|EXPERIMENTAL|TSD-001 Administration Part 2|"In part 2, the dose will be selected as the MTD/MDD, established in part 1 and provided weekly via the intravesical route.~During part 2, up to 10 additional subjects will receive intravesical instillations of TSD-001 via urethral catheterization of the urinary bladder at the MTD/MDD established in part 1 at weekly intervals for 6 consecutive weeks. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure)."
62775079|NCT00951405|EXPERIMENTAL|A|
61977772|NCT06486090|EXPERIMENTAL|#Utviklingsklar|The intervention consists of 1) an e-learning course, 2) a workshop to create plans and practices for injury-prevention, 3) a mid-season meeting
61999475|NCT05983718|ACTIVE_COMPARATOR|FREE HAND (GUIDE-PIN-assisted)|
61999476|NCT05983718|EXPERIMENTAL|FULL GUIDED|
61999477|NCT03395314|PLACEBO_COMPARATOR|midazolam|Midazolam IV; 0.04mg/kg over 40 minutes
61999478|NCT03395314|ACTIVE_COMPARATOR|low dose ketamine|ketamine IV; 0.5 mg/kg over 40 minutes
61999479|NCT03467425|EXPERIMENTAL|TRELEGY ELLIPTA (FF/UMEC/VI: 100 mcg/62.5 mcg/25 mcg)|Eligible subjects will receive a blended combination of FF in the first strip (100 mcg per blister) and UMEC/VI in second strip (62.5 mcg UMEC per blister and 25 mcg VI per blister), a single inhalation once daily in the morning in the same TRELEGY ELLIPTA Dry Powder Inhaler (DPI) via inhalation route for a period of 24 weeks. Study treatment may be augmented with other prescribed COPD medications such as including rescue medications, which will be prescribed and obtained according to usual practice.
62775080|NCT00951405|EXPERIMENTAL|B|
62775081|NCT00951405|EXPERIMENTAL|C|
62775082|NCT02666105|EXPERIMENTAL|Exemestane Therapy|
62775083|NCT04684992|EXPERIMENTAL|GEBT Telehealth Administration Usability|Establish the usability of a telehealth platform for the administration of GEBT
62775084|NCT01306383|ACTIVE_COMPARATOR|SODIS Bottles given|Caregivers in the intervention group were given two 2-litre plastic bottles. Bottle was filled with available water and placed in direct sunlight for a minimum of 6 hours. Water was consumed the next day while second bottle was being consumed.
62775085|NCT01306383|ACTIVE_COMPARATOR|Usual practices|Caregivers in this group were asked to maintain their usual practices regarding drinking water so that disease rates could be compared with the SODIS arm
62775086|NCT03217214||EP-PT|"Existing Procedure EP- Passive Thermography PT (40 patients)~Passive Thermography (PT): 2 thermoscans of the following parts:~1. Both carotid artery on left and right of the neck.~2. Both superficial temporal artery on the left and right of forehead.~3. Left forearm. No relaxation time will be given between the two tests. Each thermoscanning of region will take 60 seconds. The complete procedure will take 10-15 minutes of time."
62775087|NCT03217214||EP-ATLIC/ATPC|"Existing Procedure EP- Active Thermography ATLIC/ATPC (60 patients)~Active Thermography (AT): Temperature mapping over both carotid arteries will be done with the application of maximum cooling for 45-60 seconds in pulsed or lock-in manner. Pulsed mode is continuous, lock-in cooling will be intermittent. Maximum cooling time is 45-60 seconds, using a cooling pad/ cold air blower. Continuous thermoscanning will be done from the instance of application of cooling to reaching of a fixed temperature during rewarming. Procedure will be done 2 times per subject on both carotid arteries. Relaxation time between procedures is 10 minutes. A warming pad/ hot air blower will be used after the test to bring the skin temperature to normal. The complete procedure will take 60 min."
62775088|NCT03968263|ACTIVE_COMPARATOR|Hycon device(Routine protocol)|The hycon device in this group will be activeted into half turn every 3 days in accordance with the manufacturer's instructions.
62775089|NCT03968263|ACTIVE_COMPARATOR|Hycon device(Modified protocol)|The activation period of the hycon device in this group will be modified. The first day will be clockwise half a turn, the second day will be half-turn clockwise and the third day will be turned half a turn counterclockwise.
62775090|NCT03968263|ACTIVE_COMPARATOR|Hycon device(Routine protocol) and Vibration|The hycon device in this group will be activeted into half turn every 3 days in accordance with the manufacturer's instructions. In addition, patients in this group twice a day for 10 minutes with acceledent device vibration will be applied.
62775091|NCT03968263|ACTIVE_COMPARATOR|Hycon device(Modified protocol) and Vibration|The activation period of the hycon device in this group will be modified. The first day will be clockwise half a turn, the second day will be half-turn clockwise and the third day will be turned half a turn counterclockwise. In addition, patients in this group twice a day for 10 minutes with acceledent device vibration will be applied.
62775092|NCT05500326|EXPERIMENTAL|Intervention|"ITCHY Study:~All participants will receive one dose of oral 3mg Ivermectin tablet.~ITCHY2 study:~Participants will receive one age-specific dose of oral ivermectin tablet.~Age specific ivermectin dose:~* 0.75mg of ivermectin will be given to participants aged 3 to 7 months~* 1.5mg of ivermectin will be given to participants aged 8 to 12 months~* 3mg of ivermectin will be given to participants aged 13 to 24 months"
62775093|NCT06540989|EXPERIMENTAL|Immediate treatment|Participants will receive speech treatment immediately after their second pre-treatment assessment.
62775094|NCT06540989|ACTIVE_COMPARATOR|Deferred treatment|Participants will receive speech treatment one month after their second pre-treatment assessment. This arm receives the same speech treatment as Arm 1.
62775095|NCT02554981|EXPERIMENTAL|RESTASIS®|1 drop of RESTASIS® ophthalmic emulsion instilled in each eye twice a day for 6 months.
61999480|NCT03467425|ACTIVE_COMPARATOR|Non-ELLIPTA MITT|Eligible subjects will receive the ICS/LAMA/LABA products twice daily and dosing regimens as prescribed by their physician for a period of 24 weeks. Study treatment may be augmented with other prescribed COPD medications such as including rescue medications, which will be prescribed and obtained according to usual practice.
62568892|NCT01294241|OTHER|Non-adhesive wound dressing|Mepilex® soft silicone faced polyurethane foam dressing was used as non-active comparator. The eligible wound (half) was covered with Mepilex® as control on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
62775096|NCT03762447|EXPERIMENTAL|INCB086550|
62775097|NCT00562562|OTHER|MOT|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
62775098|NCT01174394|EXPERIMENTAL|DCEAS|"Body electroacupuncture plus dense cranial electroacupuncture stimulation (DCEAS)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
62775099|NCT01174394|PLACEBO_COMPARATOR|n-CEA|"Body electroacupuncture plus non-invasive cranial electroacupuncture (n-CEA)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
62775100|NCT03320330|EXPERIMENTAL|Treatment (pepinemab)|Patients receive pepinemab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity.
62775101|NCT01403116|EXPERIMENTAL|Oral testosterone undecanoate (TU)|"Treatment Period 1: 100 mg capsules, BID, with food~Treatment Period 2: One of the following dosages:~* 100 mg BID~* 150 mg BID~* 100 mg BID~* 100 mg and 150 mg BID~* 150 mg capsules BID~Safety Follow-up Phase:~Initial dose: \~84 doses Maintenance dose-Titrated dose: \~96 doses Safety follow-up at maintenance dose: \~540 doses"
61999481|NCT00327704|ACTIVE_COMPARATOR|Albumin|
61999482|NCT00327704|PLACEBO_COMPARATOR|Saline|
61999483|NCT04503057||COVID-19 positive|COVID-19-positive patients with pulmonary infection, ALI or ARDS
61999484|NCT04503057||COVID-19 negative|COVID-19-negative patients with pulmonary infection, ALI or ARDS
61999485|NCT01565330|EXPERIMENTAL|111 MBq (3 mCi) AD Group|Subjects with AD who received 111MBq (3 mCi) of florbetapir F 18; MBq=megabecquerel
61999486|NCT01565330|EXPERIMENTAL|111 MBq (3 mCi) Control Group|Healthy controls who received 111MBq (3 mCi) of florbetapir F 18
62791643|NCT05936983||Healthy group|Participants will be asked to fill out a structured questionnaire containing their sociodemographic characteristics. Then, Anthropometric Measurements, Eurofit test battery, Rapid Depressive Symptom Inventory-Self-Report Form and International physical activity questionnaire will be applied respectively.
61999487|NCT01565330|EXPERIMENTAL|370 MBq (10 mCi) AD Group|Subjects with AD who received 370MBq (10 mCi) of florbetapir F 18
62184955|NCT01983553||CYD Dengue Vaccine Group|Participants who received 3 injections of 0.5 milliliter (mL) CYD dengue vaccine, 1 injection each at 0, 6, and 12 months, subcutaneously in study CYD23, were followed up for safety in this study for 4 years after the 3rd vaccination at Month 12 in CYD23.
62775102|NCT01403116|ACTIVE_COMPARATOR|topical testosterone gel|"Treatment Period 1: 5 g of 1% transdermal T-gel applied QD~Treatment Period 2:~* 2.5 g of 1% transdermal T-gel applied QD~* 5 g of 1% transdermal T-gel applied QD~* 7.5 g of 1% transdermal T-gel applied QD~* 10 g of 1% transdermal T-gel applied QD~Safety Follow-up Phase:~Initial dose: \~42 doses Maintenance dose-Titrated dose: \~48 doses Safety follow-up at maintenance dose: \~270 doses"
62775103|NCT01567995|EXPERIMENTAL|Clobetasone Butyrate 0.05% Cream|Clobetasone Butyrate 0.05% Cream
61999488|NCT01565330|EXPERIMENTAL|370 MBq (10 mCi) Control Group|Healthy controls who received 370MBq (10 mCi) of florbetapir F 18.
61999489|NCT01588912|EXPERIMENTAL|Telbivudine-Tenofovir roadmap|
61999490|NCT01588912|ACTIVE_COMPARATOR|Entecavir|
61999491|NCT03320681|ACTIVE_COMPARATOR|Active Stimulation|Acupuncture needles will be inserted into the auricular zones and electrical stimulation will be given for 20 minutes.
61999492|NCT03320681|OTHER|Dry Needling|Acupuncture needles will be inserted into the auricular zones for 20 minutes. However, no electrical stimulation will be given
62775104|NCT01567995|OTHER|Vehicle (base cream)|Vehicle (base cream)
62775105|NCT03968848|EXPERIMENTAL|Subjects with Severe Hepatic Impairment|Subjects with severe hepatic impairment (score of 10 to 15 on the Child-Pugh scale) will be administrated a 50-mg single oral dose of acalabrutinib.
61999493|NCT04369248||Control group|30 healthy women with BMI \< 30 between 18 and 35 years old
61999494|NCT04369248||Non-obese PCOS|2003 Rotterdam ESHRE/ASRM PCOS Consensus Criteria were used to diagnose PCOS that fulfilled at least two of the followings: chronic oligo-anovulation, clinic or biochemical hyperandrogenism and presence of polycyctic ovary by ultrasound (Rotterdam). Oligo-anovulation is defined as periods lasting more than 35 days and/or amenorrhea. Clinic or biochemical hyperandrogenism is defined as the presence of acnes and/ or Ferriman-Galleway modified score \>8 and/ or hyperandrogenemia defining the testosterone level \> 0.6 ng/ml (2 nmol/l) and/or dehydroepiandrosterone level \> 3 ng/ml (10.5 nmol/l). Polycyctic ovaries are defined as the presence of more than 12 follicules 2-9 mm in diameters or ovarian volume \>10 cm3 under transvaginal or abdominal ultrasound. non-obese group are the women BMI \< 30 between age of 18 and 35.
61999495|NCT04369248||Obese PCOS|Obese group are the women with BMI \> 30 between age of 18 and 35.
61999496|NCT05140577||18-30 years old|Subjects in this group is aged between 18 ans 30 years old
61999497|NCT05140577||31-65 years old|Subjects in this group is aged between 31 ans 65 years old
61999498|NCT05140577||65+ years old|Subjects in this group is aged over 65 years old
61999499|NCT06225089|NO_INTERVENTION|control group|All patients will receive routine monitoring ( ECG monitoring, SpO2, noninvasive blood pressure, and EtCO2) and routine anesthesia management. 20 gauge to patients IV Cannulation will be provided and isotonic fluid will be started according to the fluid calculation. General anesthesia induction 1mg midazolam IV, 2 mg/kg propofol IV, 1.5 mcg /kg fentanyl IV, 0.6 mg/kg rocuronium It will be done by giving IV. Patients will be intubated and the minimum amount of anesthesia required for maintenance alveolar Sevoflurane + 50% oxygen + 50% air will be given so that the concentration (MAC) value is 1 and 0.05 mcg/kg/min. remifentanil infusion will begin. The patients will then be released to the surgical team. After the surgical procedure is completed, all patients are given IV paracetamol 1 g 3x1, IV tenoxicam 20 mg 2x1, and IV dexamethasone 8mg will be administered 1x1. All patients will be administered IV 1mg/kg tramadol as rescue analgesic when NRS is 3 or above
62184956|NCT01983553||Control Group|Participants who received either 0.5 mL Rabies vaccine (Verorab®) or placebo control, subcutaneously as a first injection on Day 0, placebo for second and third injections at 6 and 12 months, respectively in the study CYD23, were followed up for safety in this study for 4 years after the 3rd vaccination at Month 12 in CYD23.
62184957|NCT06209203|EXPERIMENTAL|lowe-dose ZKY001 eye drops|The drug was given once immediately after surgery on D0, and 1 drop was given 4 times a day from D0 to D6
62775106|NCT03968848|EXPERIMENTAL|Matched-Control Subjects|Subjects with normal hepatic function will be administrated a 50-mg single oral dose of acalabrutinib.
62775107|NCT04254120|ACTIVE_COMPARATOR|Cognitive-behavioral therapy (CBT)|
62775108|NCT04254120|EXPERIMENTAL|Integrated motivational interviewing and CBT|
62775109|NCT02794545|EXPERIMENTAL|Recent infection patient|The patient who infected with HIV-1 and screened out by P24 ELISA, and they would receives early cART course.
62775110|NCT03007095|EXPERIMENTAL|preterm children|
62775111|NCT03007095|ACTIVE_COMPARATOR|term children|
61977773|NCT06486090|NO_INTERVENTION|Control|Practice as usual, which may include other injury-preventive coaching practices
62568893|NCT04387565||Preeclampsia|The diagnosis of LOPE, as will be defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will be established based on the presence of proteinuria and a blood pressure level of ≥140/90 mmHg that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure ≥ 160/110 mm Hg, it will be accepted as mild; and in case these values exceeded this level, it will be accepted as severe.
62184958|NCT06209203|EXPERIMENTAL|Medium-dose ZKY001 eye drops|The drug was given once immediately after surgery on D0, and 1 drop was given 4 times a day from D0 to D6
61999500|NCT06225089|ACTIVE_COMPARATOR|pericapsuler nerve block group|all patients are given IV paracetamol 1 g 3x1, iv tenoxicam 20 mg 2x1, and IV dexmethasone 8mg will be administered 1x1. Patients in Group P will also receive a pericapsuler nerve block. All patients will be administered IV 1mg/kg tramadol as rescue analgesic when NRS is 3 or above. 4mg IV to all patients with nausea and vomiting Ondansetron will be administered. Once patients are extubated, they will be transferred to the postanesthetic care unit (PACU) for observation.
61999501|NCT03811756|ACTIVE_COMPARATOR|Test group|Participants will receive investigational product - Test syrup containing CoQ10 and collagen (daily dose 10 mL: fish collagen (Peptan®): 4000 mg, water soluble CoQ10 (Q10Vital®): 50 mg, vitamin C: 80 mg, vitamin A: 920 μg, biotin: 150 μg).
61999502|NCT03811756|PLACEBO_COMPARATOR|Placebo group|Placebo group participants will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
62184959|NCT06209203|PLACEBO_COMPARATOR|placebo|The drug was given once immediately after surgery on D0, and 1 drop was given 4 times a day from D0 to D6
62184960|NCT00376012|ACTIVE_COMPARATOR|1|2EHRZ3/4RH3
62184961|NCT00376012|EXPERIMENTAL|2|2EHRZ3/7RH3
62184962|NCT01491542|EXPERIMENTAL|rhBMP-2 / ACS|
62184963|NCT01491542|ACTIVE_COMPARATOR|Autogenous bone|
62184964|NCT02902653|EXPERIMENTAL|Oral misoprostol|"Administration of oral misoprostol according to a 3x1 diagram, that is,3 oral doses (1 per hour) and then 1 hour without treatment"
62184965|NCT02902653|ACTIVE_COMPARATOR|Vaginal misoprostol|vaginal misoprostol, 25 microgs every 4 hours
62184966|NCT02902653|ACTIVE_COMPARATOR|Vaginal dinoprostone|vaginal dinoprostone, 10 mg during 24 hours (maximum)
62184967|NCT06133686|OTHER|Group A|Oral Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC) followed by choice of TDF-FTC or CAB-LA
62184968|NCT06133686|OTHER|Group B|Long-acting injectable cabotegravir (CAB-LA) followed by choice of TDF-FTC or CAB-LA
61999503|NCT02256891|EXPERIMENTAL|Double Row|Double Row
61999504|NCT02256891|EXPERIMENTAL|Double Row with PRFM|Double Row with PRFM
61999505|NCT02365636|EXPERIMENTAL|TV-45070 4%|TV-45070 ointment in a 4% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
61999506|NCT02365636|EXPERIMENTAL|TV-45070 8%|TV-45070 ointment in a 8% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
61999507|NCT02365636|PLACEBO_COMPARATOR|Placebo|Placebo ointment applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
62568894|NCT04387565||control pregnant group|These participants with normal healthy pregnancies at the third trimester (before birth)
62775112|NCT05327361|ACTIVE_COMPARATOR|Control Group|Participant will receive sunscreen in the morning and at the beginning of the afternoon for 3 months.
62775113|NCT05327361|EXPERIMENTAL|Liftactiv B3|Participants will undergo a wash out phase of two weeks where they regularly apply a moisturizer (Hydreane Legere) in the morning and a sunscreen in the morning and at the beginning of the afternoon. On the 3rd week, participants will apply Liftactiv B3 serum daily in the morning before sunscreen and in the evening (two applications daily) on half face for 3 months.
62775114|NCT02728297|EXPERIMENTAL|Staged ETS|Video-assisted endoscopic sympathicotomy from level of T3 to level of T12 on one side
62775115|NCT02792023|OTHER|Colonoscopy followed by upper endoscopy|In case of a positive immunochemical fecal occult blood test result, colonoscopy will be the first examination
62775116|NCT02792023|OTHER|Upper endoscopy followed by colonoscopy|In case of a negative immunochemical fecal occult blood test result, upper endoscopy will be the first examination
62184969|NCT05692609||Implant overdenture group|In the control session, participants' acoustic sound quality, implant and prosthesis success will be measured.
62568895|NCT04387565||control non-pregnant group|A volunteer group of healthy women who visited the gynaecology clinic for routine examinations and women who were admitted for pre-pregnancy tests were invited randomly to this research as a control group.
61999508|NCT03595410||Recurrence laryngeal cancer|
61999509|NCT03595410||No recurrence laryngeal cancer|
62568896|NCT06397690|EXPERIMENTAL|My Choice for HIV Prevention (MyChoice)|The MyChoice intervention consists of PrEP shared decision-making counseling delivered by a trained counselor. It begins with a review of HIV risk in pregnancy/breastfeeding including discussion of population-specific risk factors which may apply to the participant. Next, the counselor presents HIV prevention options including CAB-LA, daily oral PrEP, and internal and external condoms (discussing attributes and potential advantages and disadvantages of each method). This is followed by a values clarification exercise to identify which features of the competing options matter most to the participant (product attributes and personal and interpersonal implications of each method). The counselor reviews information about these valued features for each offered method. This information and checks to understand and address any unmet participant decision support needs serve as the basis for structured deliberation to collaboratively identify participant preferred method(s).
61999510|NCT00992810|EXPERIMENTAL|Lateral-to-Medial Approach|Needle approach to the brachial plexus nerves will be made using a lateral-to-medial direction.
62184970|NCT05692609||All-on-4 group|In the control session, participants' acoustic sound quality, implant and prosthesis success will be measured.
61999511|NCT00992810|EXPERIMENTAL|Medial-to-Lateral Approach|Needle approach to the brachial plexus nerves will be made using a lateral-to-medial direction.
61999512|NCT04222738|EXPERIMENTAL|Non-randomized single-arm of GINOFF1|"Non-randomized single-arm clinical trial with a before and after design. The study population consisted on all type 2 diabetes mellitus (T2DM) patients with a target population of T2DM patients with HbA1c between 42 to 64mmol/mol (6-8%) with no change in anti-diabetic treatment during the last three months, previous the study.~The intervention consisted on the administration of Zingiber officinale Roscoe extracts, at a daily dose of 2g/day (equivalent overall daily dose of extract in simple powdered form) for a period of 6weeks. The extracts were given as capsules, either one capsule three times per day (1 capsule x 3 / day) and after meals. Each capsule contains 399mg of pure Zingiber officinale Roscoe extracts."
61999513|NCT06189456|EXPERIMENTAL|Group A|Patients with diagnosis of moderate to severe dry eye syndrome will start a 60 days treatment period with BLUgel A free (2 drops per eye, 3 times a day, bilaterally)
61999514|NCT06189456|EXPERIMENTAL|Group B|Patients with diagnosis of mild dry eye syndrome will start a 60 days treatment period with BLUyal A free (2 drops per eye, 3 times a day, bilaterally).
62184971|NCT01930214||None/mild calcification|Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis.
62184972|NCT01930214||Moderate Calcification|Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion.
62184973|NCT01930214||Severe calcification|Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion.
62184974|NCT02933307|NO_INTERVENTION|Control group|Patients with regular measurements by nurses only (Modified Early Warning Score (MEWS))
62184975|NCT02933307|EXPERIMENTAL|HealthPatch (Intervention)|Patients with HealthPatch and regular MEWS measurements
62393570|NCT04505007|NO_INTERVENTION|Usual clinical care|In this arm, patients with devices and heart failure will undergo usual clinical care. This consists of follow-up as deemed necessary by their primary care providers.
62568897|NCT06397690|ACTIVE_COMPARATOR|Standard of care (control arm)|Participants randomized to the control arm will receive PrEP counseling as based on the current standard of care (SOC). The SOC counseling will be delivered by a trained study staff member. The SOC counselor PrEP counseling according to national guidelines. Control arm participants will receive comprehensive education on both the advantages and limitations of each PrEP method, including guidance on potential side effects. The SOC counselor will assess the woman's eligibility, willingness, and readiness to start using PrEP.
62184976|NCT02933307|EXPERIMENTAL|ViSi Mobile (Intervention)|Patients with ViSi Mobile and regular MEWS measurements
62184977|NCT01124838|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injection at Baseline followed by every other week (eow) dosing starting at Week 1 for up to 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 10 to 35 mg/day at study entry followed by a protocol-defined mandatory taper until Week 19.
62568898|NCT05715411|PLACEBO_COMPARATOR|Control|
61999515|NCT05713123|EXPERIMENTAL|Person suffering from thyroid cancer and treated by iodine 131 (1100 MBq or 3700 MBq)|The study will be offered to patients suffering from thyroid cancer and treated by iodine 131 (1100 MBq or 3700 MBq). When they come in nuclear medicine to have the iodine scan in Anger's camera, if they signed the consent, they will the SPECT/CT whole body in VERITON-CT camera
62393571|NCT04505007|EXPERIMENTAL|Specialized clinic|"In this arm, patients with devices and heart failure will be enrolled in a specialized clinic with the following aims:~1. Referral to a heart failure nurse practitioner to undergo optimization of medical therapy.~2. Optimization of device programming with reduction of ventricular pacing where possible, rate responsiveness when indicated.~3. For those patients with CRT - ECG optimization using a previously tested protocol will be performed. This will consist of attempts to achieve the shortest QRS duration with the following guidelines:~   1. Two BV fusion patterns in leads V1 and V2: QRS normalization or a new or an increased R wave.~  2. QRS difference ≤-25 ms. Remodelling probability increases as QRS difference takes on larger negative values (QRS difference = BV paced QRS - LBBB QRS duration, in ms)."
61999516|NCT06228430|EXPERIMENTAL|Acyclovir 800 mg (Test Drug)|Generic Acyclovir 800 mg Tablet
61999517|NCT06228430|ACTIVE_COMPARATOR|ZoviraxTM 800 mg Tablet (Reference Drug)|ZoviraxTM 800 mg Tablet
62184978|NCT01124838|EXPERIMENTAL|Adalimumab|Participants received adalimumab 80 mg subcutaneous loading dose at Baseline followed by 40 mg doses eow starting at Week 1 for a maximum of 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper until Week 19.
62184979|NCT01538225|EXPERIMENTAL|first sativex, second placebo|2 weeks first titration period (as per approved SmPC), a 2-week first treatment period (Sativex), a 2-week washout, a cross-over followed by another 2 weeks titration period (as per SmPC), followed by a second 2-week period treatment (placebo)
62393572|NCT01593566|ACTIVE_COMPARATOR|0.25% bupivacaine|femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine
62393573|NCT01593566|ACTIVE_COMPARATOR|0.5% bupivacaine|femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine
61999518|NCT02510794|EXPERIMENTAL|Port Delivery System with Ranibizumab 10mg/mL|Participants had the Implant (prefilled with approximately 20 μL of 10-mg/mL ,approximately 0.2 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 10-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
62215302|NCT05352243|ACTIVE_COMPARATOR|Expressive Disclosure|Participants will be instructed to write about their deepest thoughts and feelings surrounding their bereavement experience.
61999519|NCT02510794|EXPERIMENTAL|Port Delivery System with Ranibizumab 40mg/mL|Participants had the Implant (prefilled with approximately 20 μL of 40-mg/mL, approximately 0.8 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 40-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
62184980|NCT01538225|EXPERIMENTAL|first placebo, second sativex|2 weeks first titration period (as per approved SmPC), a 2-week first treatment period (placebo), a 2-week washout, a cross-over followed by another 2 weeks titration period (as per SmPC), followed by a second 2-week period treatment (Sativex)
62184981|NCT01865500|ACTIVE_COMPARATOR|Metil prednisolone & Budesonide 4mg|
62184982|NCT01865500|ACTIVE_COMPARATOR|Metil prednisolone & Budesonide 8 mg|
62184983|NCT01865500|ACTIVE_COMPARATOR|Budesonide 4 mg & Budesonide 8 mg|
62184984|NCT02353871|EXPERIMENTAL|BTX-A-HAC NG|Clostridium Botulinum Toxin Type A (BTX-A-HAC NG) 50 Unit (U) solution, single dose (intramuscular injection). The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region. A total of 50 U was injected.
62184985|NCT02353871|PLACEBO_COMPARATOR|Placebo|Single dose (intramuscular injection). The total placebo volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region.
62184986|NCT05940831|EXPERIMENTAL|Intervention|Scheduled SMS-audio messages from the final messaging prototype (SM), messages, plus social supporter engagement through SMS (SS)
62184987|NCT05940831|ACTIVE_COMPARATOR|Control|Routine care/ information giving
62184988|NCT05479461|EXPERIMENTAL|Mobile Health Technology|
62184989|NCT05479461|ACTIVE_COMPARATOR|Usual Care|
62184990|NCT01727206|EXPERIMENTAL|Tocilizumab|Tocilizumab 8 mg/kg intravenously every month for six months
62184991|NCT01540162||Group I|Patients of group I are exposed to the probiotic Mutaflor: 1 ml once a day during first week of life, and three times per week during the second and third week of life.
61999520|NCT02510794|EXPERIMENTAL|Port Delivery System with Ranibizumab 100mg/mL|Participants had the Implant (prefilled with approximately 20 μL of 100-mg/mL, approximately 2 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 100-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
62184992|NCT01540162||Group II|Patients of group II remain unexposed to the probiotic Mutaflor.
62184993|NCT03298529|EXPERIMENTAL|Traditional egg pasta|"Traditional egg pasta. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta made with 8 eggs/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
62184994|NCT03298529|EXPERIMENTAL|Pasta with only eight egg whites/kg flour|"Pasta with only eight egg whites/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with only eight egg whites/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
62568899|NCT05715411|EXPERIMENTAL|Light therapy|
62184995|NCT03298529|EXPERIMENTAL|Pasta with four eggs/kg flour|"Pasta with four eggs/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with four eggs/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
62184996|NCT03298529|EXPERIMENTAL|Hyperproteic pasta (with added gluten and albumin)|"Hyperproteic pasta (with added gluten and albumin). 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with added gluten and albumin. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
62791644|NCT04289792|EXPERIMENTAL|SBRT with concurrent chemotherapy|SBRT with nab-Paclitaxel plus Gemcitabine (nab-P+Gem) chemotherapy
62791645|NCT01405612|EXPERIMENTAL|Midazolam|Those subjects to receive Treatment A will receive a single dose of midazolam on Day 1 and will be discharged from the study unit on Day 2, at least 30 hours after midazolam dosing.
62791646|NCT01405612|EXPERIMENTAL|Ulimorelin|Those subjects to receive Treatment B will receive once daily ulimorelin on Days 1 to 5. Midazolam will be administered on Day 5 with the last dose of ulimorelin and subjects will be discharged from the study unit on Day 6, at least 30 hours after midazolam dosing.
62791647|NCT06725160|EXPERIMENTAL|Parent Coaching|Parents will receive 3 sessions based on PCIT-ED aimed at increasing child positive affect.
62791648|NCT06725160|ACTIVE_COMPARATOR|Active Control|Parents will receive 3 sessions based on traditional PCIT providing more general parenting supporting, including basic psychoeducation and child directed interaction skills.
62791649|NCT06671106|EXPERIMENTAL|Gingivitis - test intervention|Gingivitis patients assigned to test intervention will use: manual toothbrush (meridol) and dental floss (meridol) associated with amine and zinc lactate - containing toothpaste (meridol Gum Protection) and amine and zinc lactate - containing mouthrinse (meridol Gum Protection)
62791650|NCT06671106|ACTIVE_COMPARATOR|Gingivitis - control intervention|Gingivitis patients assigned to control intervention will use: manual toothbrush (meridol) and dental floss (meridol) associated with amine and zinc lactate - containing toothpaste (meridol Gum Protection)
62791651|NCT06671106|OTHER|Periodontal health - no treatment|Periodontally healthy subjects will be compared for baseline assessments with gingivitis patients of the other two arms. However, periodontally subjects will conclude their participation in the study within the baseline visit after receiving devices and instructions related to the control intervention.
62791652|NCT05026216|EXPERIMENTAL|Single-arm study|Using CCH-ases on bilateral buttocks and thigh injections. No placebo being used.
62184997|NCT03298529|EXPERIMENTAL|Pasta with only four egg whites/kg flour|"Pasta with only four egg whites/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with only four egg whites/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
62393574|NCT05471401|EXPERIMENTAL|Occlusion balloon catheter|-Each participant will have an embolectomy balloon that is FDA approved for peripheral and neurovasculature temporary occlusion placed by nose or mouth. Anatomical position of balloon will be verified by on-board MR or CT imaging in to assess feasibility of using a duodenal balloon in this population. Participants who are imaged on the MR treatment machine will also be imaged with 4 or 8 frame per second sagittal imaging to assess real-time stomach and balloon respiratory motion. Participants imaged on CT based imaging (i.e. Ethos/Halcyon ring gantry system) will have CBCTs acquired at timed intervals (approximately 5-10 minutes between scans). After imaging, the balloon will be deflated and removed at that time.
62393575|NCT05352958||Patients with Amyotrophic Lateral Sclerosis|"ALS~* certain or probable according to the revised Escorial criteria~* no indication for non-invasive ventilation"
62568900|NCT04830969|EXPERIMENTAL|A: Diabetic + SRP + SPT|The first group, A, includes diabetics with periodontal disease; they will receive standard therapy, scaling \& root planing plus supportive periodontal therapy (SPT) chlorhexidine gluconate (Paroex®) mouthrinse + Soft-Picks.
62568901|NCT04830969|EXPERIMENTAL|B: Non-Diabetic + SRP + SPT|The second group, B, includes non-diabetics with periodontal disease; they will receive standard therapy, scaling \& root planing plus supportive periodontal therapy (SPT) chlorhexidine gluconate (Paroex®) mouthrinse + Soft-Picks.
62568902|NCT04830969|ACTIVE_COMPARATOR|C: Diabetic + SRP|The third group, C, includes diabetics with periodontal disease; they will receive standard therapy, scaling and root planing (SRP).
62568903|NCT04830969|ACTIVE_COMPARATOR|D: Non-Diabetic + SRP|The second group, D, includes non-diabetics with periodontal disease; they will receive standard therapy, scaling and root planing (SRP).
62568904|NCT02340429|EXPERIMENTAL|video otoscopy|children under 18y admitted to the pediatric emergency room for any reason, will undergo video otoscopy
62568905|NCT02340429|NO_INTERVENTION|standard otoscopy|children under 18y admitted to the pediatric emergency room for any reason, undergoing routine otoscopy
62568906|NCT01847586|EXPERIMENTAL|Alzheimer's disease-rPAS|The intervention procedure will done in this group is r-Paired Associative Stimulation. This involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC
62184998|NCT02854618|EXPERIMENTAL|Everolimus treatment|
62184999|NCT02321267|OTHER|Macular disease with adequate treatments|Macular diseases can be treated with most appropriate treatment, including pegaptanib, ranibizumab, afibercept, visudyne, or vitrectomy.
62185000|NCT03507153|ACTIVE_COMPARATOR|Bre-fllex group|Maxillary class III modification I edentulous patients that will recieve Bre-flex partial denture
61999521|NCT02510794|ACTIVE_COMPARATOR|Intravitreal Injection with Ranibizumab 0.5mg|Participants received ranibizumab 0.5 mg monthly ITV injections of 10 mg/mL formulation at Day 1 and every month thereafter.
62185001|NCT03507153|EXPERIMENTAL|PEEK group|Maxillary class III modification I edentulous patients that will recieve PEEK partial denture
62185002|NCT01924637|EXPERIMENTAL|FIASP|Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal.
62185003|NCT01924637|ACTIVE_COMPARATOR|NovoRapid®|Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal.
62185004|NCT05010785|EXPERIMENTAL|alveolar ridge splitting with GBR and i-PRF|alveolar ridge splitting in combination with the use of GBR with i-PRF (sticky bone) with immediate implant placement
62568907|NCT01847586|PLACEBO_COMPARATOR|Alzheimer's disease-rPAS-C|The intervention procedure being done with this group is PAS-C. This is a control Paired Associative Stimulation paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
62568908|NCT01847586|OTHER|Control|Controls will have a one time Paired Associative Stimulation-Control (PAS-C) paradigm intervention in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
62568909|NCT00583765||A|Critically ill patients with acute renal failure requiring continuous renal replacement therapy
62568910|NCT03922308|PLACEBO_COMPARATOR|Standard of Care (SoC) + Placebo|Participants received SoC daily PEX followed by placebo immediately and 12 +/- 1 hours after completion of PEX until remission was achieved (up to approximately 6 months).
62775117|NCT03464149||Study Arm|"One armed study, blood from each patient is analysed by the following assays:~Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)"
62775118|NCT06526910|ACTIVE_COMPARATOR|Phase 1 Standard of Care|A four-week period of standard of care dysphagia treatment consisting of physical swallowing-related exercises. According to guidelines for single case design, this standard of care treatment will serve as a baseline/control period for comparison to the subsequent experimental treatment period. Participants will complete either 6, 7, or 8 baseline measurement visits across these 4 weeks (multiple baseline design).
62775119|NCT06526910|NO_INTERVENTION|Phase 2 Wash-out period #1|A three-week wash-out period. All participants will attend 6 measurement sessions across the 3-week period but will not complete any swallowing exercises.
62775120|NCT06526910|EXPERIMENTAL|"Phase 3 Experimental"|A four-week exercise period. Five participants will be assigned to complete a second period of standard of care swallowing exercises while the other five will be assigned to the experimental treatment which includes standard of care plus motor imagery practice. According to single case design, participants will complete either 6, 7, or 8 measurement visits across these 4 weeks.
62775121|NCT06526910|NO_INTERVENTION|Phase 4 Wash-out period #2|A final three-week wash-out period. All participants will attend 6 measurement sessions across the 3-week period but will not complete either the standard of care or the experimental swallowing exercises.
62775122|NCT06463054|EXPERIMENTAL|Dialectical Behavior Therapy Skills Group Training|The investigators will employ Dialectical Behavior Therapy Skills Training in order to experimentally manipulate maternal emotion dysregulation, our targeted mechanism.
62775123|NCT06463054|EXPERIMENTAL|Safety Planning Intervention|Safety Planning Intervention (SPI) or SPI only for 6 months, such that all mothers with history of suicidal behavior + ER difficulties will receive SPI.
62775124|NCT03792568|EXPERIMENTAL|ALK mutation|
62775125|NCT06342596|EXPERIMENTAL|[14C]-LY3473329 (Part 1)|Single dose of \[¹⁴C\]-LY3473329 administered orally
61999522|NCT06305533|OTHER|Control|Root surface debridement only
61999523|NCT06305533|ACTIVE_COMPARATOR|Test group 1 (Biolase group)|Root surface debridement and laser disinfection, the diode Laser (Bolas) will be used to disinfect the inner layer of the pockets and thus reducing the microbial load.
62185005|NCT05010785|ACTIVE_COMPARATOR|alveolar ridge splitting with GBR|alveolar ridge splitting in combination with the use of GBR without i-PRF (sticky bone) with immediate implant placement
62185006|NCT04211311|EXPERIMENTAL|FES-legcycling with voluntary arm-work|FES-legcycling combined with arm ski-ergometer or arm-cycling
62185007|NCT00336336|EXPERIMENTAL|1|N-3PUFA
62185008|NCT00336336|PLACEBO_COMPARATOR|2|
62185009|NCT00336336|EXPERIMENTAL|3|Rosuvastatin
62185010|NCT00336336|PLACEBO_COMPARATOR|4|
62185011|NCT00331708|EXPERIMENTAL|Artesunate plus sulphadoxine-pyrimethamine|
62185012|NCT05603897|EXPERIMENTAL|Mann Assessment of Swallowing Ability (MASA) Group|Participants in this group will receive the MASA dysphagia screening once upon admission to inpatient rehabilitation for approximately 20 minutes.
62185013|NCT05603897|OTHER|Non-standardized clinical swallow evaluation Group|Participants in this group will receive standard of care treatment (dysphagia screening once upon admission to inpatient rehabilitation using a non-standardized clinical swallow evaluation for approximately 15 minutes).
62185014|NCT03774875|EXPERIMENTAL|Apremilast 30 mg|Participants will take apremilast 30 mg tablets orally twice a day for up to 52 weeks.
62185015|NCT03774875|PLACEBO_COMPARATOR|Placebo / Apremilast 30 mg|Participants will take placebo tablets orally twice a day for 16 weeks. After week 16, participants will be switched to receive apremilast 30 mg twice daily until Week 52.
61999524|NCT06305533|ACTIVE_COMPARATOR|Test group 2 (Quicklase group)|Root surface debridement and photodynamic therapy using a Indocyanine green photosensitizer activated with diode laser (Quicklase)
62775126|NCT06342596|EXPERIMENTAL|LY3473329 + [14C]-LY3473329 (Part 2)|Single dose of LY3473329 administered orally followed by a single dose of \[¹⁴C\]-LY3473329 administered intravenously (IV)
61999525|NCT03440671|EXPERIMENTAL|Hutox Inj|Hutox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
62185016|NCT01427738|EXPERIMENTAL|Arm A: Topical GV solution|Topical GV 0.00165% solution (5 mL swish and gargle for 1 minute and expectorate \[spit\] 2 times per day \[BID\]) for 14 days
62775127|NCT02733653|EXPERIMENTAL|Jetstream Atherectomy System|Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention
61999526|NCT03440671|ACTIVE_COMPARATOR|Botox Inj|Botox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
62775128|NCT01753401|EXPERIMENTAL|Period 2: Placebo/Acthar|Participants receive Placebo in Part 1, but after completion of Week 8 in the double-blind phase, patients who received Placebo may choose to participate in the optional open-label phase where they will receive an Acthar maintenance regimen for 44 weeks. The initial Acthar regimen will be assigned based on the study medication regimen the patient received at the completion of the double-blind phase (Visit 6, Week 8). Acthar regimen during Part 2 may be adjusted based on the Investigator's judgment with the goal of achieving a stable Acthar regimen no later than Week 28. Once the stable Acthar regimen is achieved, the Investigator should consider tapering the steroid regimen to a low daily dose or completely discontinue.
62775129|NCT01753401|EXPERIMENTAL|Period 2: Acthar/Acthar|After completion of Week 8 in the double-blind phase, patients who received Acthar may choose to participate in the optional open-label phase where they will receive an Acthar maintenance regimen for 44 weeks. The initial Acthar regimen will be assigned based on the study medication regimen the patient received at the completion of the double-blind phase (Visit 6, Week 8). Acthar regimen may be adjusted based on the Investigator's judgment with the goal of achieving a stable Acthar regimen no later than Week 28. Once the stable Acthar regimen is achieved, the Investigator should consider tapering the steroid regimen to a low daily dose or completely discontinue.
61999527|NCT01642238|EXPERIMENTAL|Ticagrelor + ASA + Bivalirudin|Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
61999528|NCT01642238|ACTIVE_COMPARATOR|Clopidogrel + ASA + Bivalirudin|Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
61999529|NCT04578847|EXPERIMENTAL|The TKI dose reduction|Imatinib, nilotinib, dasatinib or bosutinib; the two stage of TKI dose reduction phase for 12 months (6 months and 6 months, respectively).
62185017|NCT01427738|ACTIVE_COMPARATOR|Arm B: Nystatin oral suspension|Nystatin oral suspension (5 mL of 100,000 units/mL swish for 1 minute and swallow 4 times per day \[QID\]) for 14 days
62185018|NCT05774171||Cancer patients with SARS-CoV-2 vaccination|Cancer patients with SARS-CoV-2 vaccination
62775130|NCT01753401|PLACEBO_COMPARATOR|Period 1: Placebo|Participants receive matching placebo (in 0.5 mL daily or in 1 mL every other day) for 4 weeks. In Weeks 5-8, they will taper the study medication. Participants will continue on their stable steroid regimen during this phase of the study. After completion of Week 8 in the double-blind phase, they may choose to participate in the optional open-label phase. Participants will continue on their stable steroid regimen during this phase of the study.
62185019|NCT05774171||Cancer patients without SARS-CoV-2 vaccination|Cancer patients without SARS-CoV-2 vaccination
62568911|NCT03922308|EXPERIMENTAL|SoC + SHP655 + Placebo|Participants received SoC daily PEX and SHP655 40 +/- 4 international units per kilogram (IU/kg), IV injection, QD, immediately after PEX and placebo 12 +/- 1 hours after completion of PEX until remission was achieved (up to approximately 6 months).
61999530|NCT03734120||men|men undergoing routine semen analysis for infertility
61999531|NCT03377946|EXPERIMENTAL|probiotics on type 2 diabetes|take probiotics
61999532|NCT03377946|EXPERIMENTAL|probiotics on pre-diabetes|take probiotics
61999533|NCT03377946|PLACEBO_COMPARATOR|placebo on type 2 diabetes|take placebo
61999534|NCT03377946|PLACEBO_COMPARATOR|placebo on pre-diabetes|take placebo
61999535|NCT03751215|EXPERIMENTAL|Monofocal IOL|Patients will be implanted with two different monofocal lenses (Clareon and AcrySof) during cataract surgery
61999536|NCT02646696||Children with Autism Spectrum Disorder|Boys between the age of 4 to 11 years old with Autism Spectrum disorder will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
61999537|NCT02646696||Typically Developing Children|typically developing boys between the age of 4 to 11 years will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
62185020|NCT05474898|EXPERIMENTAL|Group (A)|
62185021|NCT05474898|EXPERIMENTAL|Group (B)|
62185022|NCT05474898|OTHER|Group (c)|
62185023|NCT02682004||Women with postpartum depression|
62185024|NCT02682004||Women without postpartum depression|
62185025|NCT00932295|ACTIVE_COMPARATOR|Own brand cigarette|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
62185026|NCT00932295|SHAM_COMPARATOR|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
61999538|NCT00807534|ACTIVE_COMPARATOR|ipratropium bromide|acute bronchodilation: ipratropium bromide
62775131|NCT01753401|EXPERIMENTAL|Period 1: Acthar|Participants receive Acthar (40 units in 0.5 mL daily or 80 units in 1 mL every other day) for 4 weeks. In Weeks 5-8, they will taper the study medication. Participants will continue on their stable steroid regimen during this phase of the study. After completion of Week 8 in the double-blind phase, they may choose to participate in the optional open-label phase. Participants will continue on their stable steroid regimen during this phase of the study.
62775132|NCT03876665||Focus Group|"Active Duty Air Force, Army and Navy women diagnosed with PCOS.~Up to three focus groups per service branch will be conducted. Considering attrition for those who may volunteer and not show up for the FG session, the investigators will recruit up to 20 participants per site, with the goal of including a maximum of six participants per FG to maximize individual participation."
62775133|NCT05367128|EXPERIMENTAL|Posture-focus group|Participants will be instructed to pay most attention to practice the posture task during training
62775134|NCT05367128|EXPERIMENTAL|Supraposture-focus group|Participants will be instructed to pay most attention to practice the cognitive task during training
62775135|NCT05367128|ACTIVE_COMPARATOR|Control group|Participants will not be receive any instruction to prioritize either task
62185027|NCT00932295|EXPERIMENTAL|Electronic cigarette Version One C7|"10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)"
62775136|NCT03731078||Motor Functional Neurological Disorder|The cohort will consist of patients with clinically-established motor functional neurological disorder, which includes individuals with functional movement disorders and functional limb weakness. Individuals with functional movement disorders and/or functional limb weakness who also have psychogenic nonepileptic seizures will be included. Patients will receive CBT informed PT intervention. The physical therapy intervention will be usual care in FND and based on consensus recommendations, clinical trials and good practices.
62775137|NCT02305238|EXPERIMENTAL|2 Weeks adjustment|Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals with the criteria of Treat and Extend regimen. In the case the study eye of a participant met the criteria, the length of treatment interval was to be extended or shortened by 2 weeks from the last interval, respectively. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
62775138|NCT02305238|EXPERIMENTAL|4 Weeks adjustment|Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals. In the case the study eye of a participant met the criteria of the shortening, the length of the treatment interval was to be shortened by 2 weeks. But when the last treatment interval for a participant was extended by 4 weeks from the second last interval, the treatment interval was shortened by 4 weeks. In the case the study eye of a participant met the criteria of the extension, the length of the treatment interval was to be extended by 4 weeks. But when a participant had a history of receiving treatment with interval shortened by 4 weeks during this study, the length of the extension was 2 weeks. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
62775139|NCT04232436||Planned vaginal delivery|Planned vaginal delivery
62775140|NCT04232436||Planned cesarean delivery|Planned cesarean delivery
62775141|NCT03555682|PLACEBO_COMPARATOR|Placebo|Placebo
62775142|NCT03555682|EXPERIMENTAL|2-HOBA Low Dose|2-Hydroxybenzylamine acetate: 500mg dose
62775143|NCT03555682|EXPERIMENTAL|2-HOBA High Dose|2-Hydroxybenzylamine acetate: 750mg dose
62775144|NCT04672421|EXPERIMENTAL|Medicurtain®|Treat Medicurtain® 5ml prefilled syringe after laparoscopic surgery
62775145|NCT04672421|SHAM_COMPARATOR|Placebo|laparoscopic surgery
62775146|NCT03514433|NO_INTERVENTION|Control- Usual Care|This study will be utilizing electronic health record data to identify patients that match the TRIP eligibility criteria and received patient navigation prior to study rollout. These patients will receive standard patient navigation at their care site and will act as controls in comparison to the TRIP experimental group.
62775147|NCT03514433|EXPERIMENTAL|TRIP Patient Navigation Intervention|This study will be enhancing current patient navigation at the participating 5 hospitals with the 3 components of the TRIP intervention (a shared patient registry, a social determinants of health platform, and additional training and support for Patient Navigators). All patients that are identified as TRIP eligible will receive these intervention benefits and will be categorized into the experimental arm of the study.
62775148|NCT00366327|EXPERIMENTAL|A|
62775149|NCT06190080|OTHER|Management of eosinophilic esophagitis|Follow-up visits are always organized in the same way. A consultation with a gastropediatrician will take place, with assessment of symptoms (PEESS score) and quality of life (PedsQL module for eosinophilic esophagitis and PedsQL 4.0 Generic Core Scales). Then, if treatment needs to be introduced or changed, a digestive endoscopy with biopsies will be carried out at 3 months to determine whether the patient is in remission or not. Depending on the results, the patient may be advised to adapt or maintain the current treatment.
62775150|NCT00771056|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine 400 mg po daily for up to one year.
62775151|NCT02379468|EXPERIMENTAL|Pedyphar|Ointment
62775152|NCT02379468|ACTIVE_COMPARATOR|Panthenol|Ointment
62775153|NCT01042652|ACTIVE_COMPARATOR|Nevirapine|
62775154|NCT01042652|EXPERIMENTAL|Raltegravir|
61999539|NCT00807534|PLACEBO_COMPARATOR|placebo|placebo nebulization
62185028|NCT00932295|EXPERIMENTAL|Electronic cigarette version 2: NJ|"10 puffs from a so-called electronic cigarette named NJOY (16 mg cartridge; 30 second inter puff interval)"
62185029|NCT03790904|ACTIVE_COMPARATOR|Co. mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
62185030|NCT03790904|PLACEBO_COMPARATOR|Kin mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
62775155|NCT02989285||HIV+ cognitively impaired (HAND)|Participants will be assessed based on their performance on the neuropsychological test battery at study entry. HAND status will be diagnosed per FRASCATI research criteria and this will determine which study cohort they are allocated to. Participants will continue to receive their standard of care treatment during the study period.
61999540|NCT01242657|NO_INTERVENTION|Brief Advice|Standard of care arm with no intervention; includes standard communication regarding youth tobacco cessation such as a brief discussion and printed materials
61999541|NCT01242657|ACTIVE_COMPARATOR|Not On Tobacco (N-O-T) Program|Teens randomized to this arm participated in the N-O-T program, a proven teen cessation program.
61999542|NCT01242657|EXPERIMENTAL|Quit & Fit|Teens randomized to this arm participated in the Not On Tobacco (N-O-T) program with an added physical activity module.
61999543|NCT02281136|EXPERIMENTAL|ALA|20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment
62185031|NCT03790904|PLACEBO_COMPARATOR|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
62185032|NCT03227978|EXPERIMENTAL|PCL mesh group|Intervention: The participants will be received thoracoscopic bullectomy and abrasion of pleura, then PCL mesh will be applied over the lung.
62185033|NCT00397020|EXPERIMENTAL|1 Divalproex ER|Divalproex ER
62568912|NCT03922308|EXPERIMENTAL|SoC + SHP655|Participants received SoC daily PEX and SHP655 40 +/- 4 IU/kg, IV injection, BID, immediately after PEX and 12 +/- 1 hours after completion of PEX until remission was achieved (up to approximately 6 months).
62775156|NCT02989285||HIV+ cognitively normal (no-HAND)|Participants will be assessed based on their performance on the neuropsychological test battery at study entry. HAND status will be diagnosed per FRASCATI research criteria and this will determine which study cohort they are allocated to. Participants will continue to receive their standard of care treatment during the study period.
62775157|NCT05240521|OTHER|ARM A: GA-AT0119 / Placebo|Cross-over Study
61999544|NCT01067768|EXPERIMENTAL|Daily review|In the intervention group a nurse reviewed daily, by using a checklist designed for this study, the indications and pertinence of the catheter. If it was not indicated she asked the doctor to order the removal of the catheter, but the doctor would make the final decision.
62775158|NCT05240521|OTHER|ARM B: Placebo / GA-AT0119|Cross-over Study
61999545|NCT01067768|NO_INTERVENTION|Routine care|In the control group, the attending team would remove the catheter as routine, without any suggestion by the research protocol.
62775159|NCT03090672|EXPERIMENTAL|tSVF + PRP Arm1|Stromal Vascular Fraction tSVF + Platelet Rich Plasma (PRP) concentrate
62775160|NCT03090672|EXPERIMENTAL|tSVF + PRP + cSVF Enrichment Arm 2|tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) concentration + (cSVF)
62775161|NCT03090672|EXPERIMENTAL|Normal Saline IV + cSVF Arm 3|Cellular Stromal Vascular Fraction (cSVF); Normal Saline IV introduction
62775162|NCT06203587|EXPERIMENTAL|patients with colorectal cancer|Subjects were recruited from the Department of Gastroenterology, Huashan Hospital, Fudan University, Shanghai, China.
62568913|NCT00734994|EXPERIMENTAL|Hyperthermia system, Mitomycin C|Pilot study single arm study to test the safety, tolerability and clinical benefit of regional hyperthermia and mitomycin-C intravesical chemotherapy to treat non-invasive Transitional Cell carcinoma (TCC) of the bladder that has recurred after standard resection and adjuvant therapy.
62568914|NCT03426618||Pediatric participants with Hepatitis B Virus (HBV)|All participants who received at least 1 dose of Baraclude.
61999546|NCT03098069||KMC Scale up in a district|This is an implementation research project on scaling up KMC in selected government and private health facilities in an entire district, aiming to cover newborns weighing less than 2000gms at birth.
62568915|NCT05017675|EXPERIMENTAL|High fructose diet|Participants will receive dietary products high in fructose for 4 weeks.
62185034|NCT00397020|ACTIVE_COMPARATOR|2 Quetiapine Fumarate|quetiapine fumarate
62185035|NCT03647202|EXPERIMENTAL|Sequence ABC|Participants receive milademetan in a fasted condition (A), then with a high-calorie, high-fat breakfast (B), then with a standard breakfast (C) - with a washout period between treatments.
62185036|NCT03647202|EXPERIMENTAL|Sequence ACB|Participants receive milademetan in a fasted condition (A), then with a standard breakfast (C), then with a high-calorie, high-fat breakfast (B) - with a washout period between treatments.
62185037|NCT03647202|EXPERIMENTAL|Sequence BAC|Participants receive milademetan with a high-calorie, high-fat breakfast (B), then in a fasted condition (A), then with a standard breakfast (C) - with a washout period between treatments.
62185038|NCT03647202|EXPERIMENTAL|Sequence BCA|Participants receive milademetan with a high-calorie, high-fat breakfast (B), then with a standard breakfast (C), then in a fasted condition (A) - with a washout period between treatments.
62568916|NCT05017675|EXPERIMENTAL|High saturated fat diet|Participants will receive dietary products high in saturated fat for 4 weeks.
62568917|NCT06541457|EXPERIMENTAL|Treatment for intravenously: dose 1|
62185039|NCT03647202|EXPERIMENTAL|Sequence CAB|Participants receive milademetan with a standard breakfast (C), then in a fasted condition (A), then with a high-calorie, high-fat breakfast (B) - with a washout period between treatments.
62185040|NCT03647202|EXPERIMENTAL|Sequence CBA|Participants receive milademetan with a standard breakfast (C), then with a high-calorie, high-fat breakfast (B), then in a fasted condition (A) - with a washout period between treatments.
62185041|NCT04070729|PLACEBO_COMPARATOR|Negative control|Placebo gel
62568918|NCT06541457|EXPERIMENTAL|Treatment for intravenously: dose 2|
62775163|NCT01781780|ACTIVE_COMPARATOR|General Nutrition Recommendations|Participants will be provided with a free USDA nutrition pamphlet describing general good nutrition habits. They will also receive an instruction handout to emphasize some of the points in the dietary guidelines in the handout. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the suggestions as best they can into their daily life.
62775164|NCT01781780|EXPERIMENTAL|Breakfast Recommendation|Participants randomized to the breakfast group will be instructed to consume breakfast before 10:00 a.m. every day, and will be asked to not eat again until after 11:00 a.m. Participants will be counseled on what a healthy breakfast is using an instruction handout. No specific restrictions will be given on types of foods that can be consumed for the breakfast meal. They will be instructed to keep track of their breakfast consumption (yes/no) using a calendar diary that will be provided to them. Participants will also be provided with a free USDA nutrition pamphlet describing general good nutrition habits. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the recommendations into their daily life as much as they can.
62568919|NCT06541457|EXPERIMENTAL|Treatment for intravenously: dose 3|
62775165|NCT01781780|EXPERIMENTAL|No Breakfast Recommendation|Participants randomized to the no breakfast group will receive a detailed handout with instructions to not consume any calories before 11:00 a.m. every day. Only water or 0 calorie beverages may be consumed from the time of waking until 11:00 a.m. They will be instructed to keep track of their breakfast consumption (yes/no) using a calendar diary that will be provided to them. Participants will also provided with a free USDA nutrition pamphlet describing general good nutrition habits. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the recommendations into their daily life as much as they can.
62775166|NCT05753163|EXPERIMENTAL|treatment|
62775167|NCT04005079|EXPERIMENTAL|Treatment Group|2% pilocarpine and standard of care post op drops ( Prednisolone acetate and Ofloxacin)
62775168|NCT04005079|ACTIVE_COMPARATOR|Control Group|Standard of care post op drops-Prednisolone acetate and Ofloxacin, without pilocarpine
62775169|NCT06329024|EXPERIMENTAL|rehabilitation treatment+ Myofascial Release group|Study lasts 21 days for each patient. All patients are given rehabilitation treatment.The experimental group was given the Myofascial Release Therapy, five days a week, once a day, for 30-60 minutes each time.
62775170|NCT06329024|ACTIVE_COMPARATOR|rehabilitation treatment group|Study lasts 21 days for each patient. All patients are given rehabilitation treatment, five days a week, once a day, for 30-60 minutes each time.
62775171|NCT01919736|ACTIVE_COMPARATOR|Moderate gait retraining|a moderate 7 degree toe-in modification
62775172|NCT01919736|ACTIVE_COMPARATOR|Mild gait retraining|A 2 degree toe-in gait retraining
62775173|NCT03344627|ACTIVE_COMPARATOR|Meropenem standard dose|Meropenem 1 g every 8 hours
62775174|NCT03344627|ACTIVE_COMPARATOR|Meropenem high dose|Meropenem 2 g every 8 hours
62791653|NCT02128724|EXPERIMENTAL|BKM120 plus radiotherapy|Three cohorts of patients will be treated with escalating doses of oral buparlisib. The doses will be 50mg, 80mg and 100mg, once daily. Patients will be treated with buparlisib for a total of fourteen days. One week after commencing buparlisib, patients will start palliative radiotherapy treatment. Radiotherapy treatment will be delivered as 20Gy in 5 fractions over a one week period. There will be an expansion cohort at the MTD. Patients in an optional fourth cohort will take buparlisib for 4 weeks at the MTD.
62568920|NCT06541457|EXPERIMENTAL|Treatment for intravenously: dose 4|
62568921|NCT06541457|EXPERIMENTAL|Treatment for intravenously: dose 5 (optional)|
62568922|NCT06541457|EXPERIMENTAL|Treatment for intravenously: dose 6 (optional)|
62568923|NCT00902772|PLACEBO_COMPARATOR|A|Placebo
62568924|NCT00902772|ACTIVE_COMPARATOR|B|Lorazepam
62568925|NCT00902772|ACTIVE_COMPARATOR|C|Lorazepam
62791654|NCT06080685|EXPERIMENTAL|Intervention Group|Who receives intervention. Character strengths intervention will be administered in 5 sessions.
62185042|NCT04070729|EXPERIMENTAL|Test group 1|Hyaluronic acid gel
62185043|NCT04070729|EXPERIMENTAL|Test group 2|injectable prf
62185044|NCT02609152|EXPERIMENTAL|Continuous perfusion of esmolol|Intervention: Drug: Continuous perfusion of esmolol
62185045|NCT02609152|PLACEBO_COMPARATOR|Continuous perfusion of saline|Intervention: Continuous perfusion of saline
62185046|NCT01684111|EXPERIMENTAL|BIBF 1120, Vinorelbine|"To determine the 'Maximum Tolerated Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle.~Under certain conditions the dose level will be escalated to 200mg bid in a second cohort."
62568926|NCT00902772|ACTIVE_COMPARATOR|D|Lorazepam
62568927|NCT00902772|EXPERIMENTAL|E|AZD7325
62568928|NCT00902772|EXPERIMENTAL|F|AZD7325
62568929|NCT00902772|EXPERIMENTAL|G|AZD7325
62568930|NCT00637312|EXPERIMENTAL|Advent™ Cervical Disc|Cervical artificial disc replacement: Advent™ Cervical Disc
62568931|NCT00637312|ACTIVE_COMPARATOR|Standard care - Control|Anterior cervical discectomy and fusion (ACDF) with Hallmark™ Anterior Cervical Plate System
62568932|NCT02431676|ACTIVE_COMPARATOR|Self-Directed|In this group, the study staff will meet with you once at the beginning of the study to give you written information about weight management.
61999547|NCT01622946|ACTIVE_COMPARATOR|Placebo|The patients who receive placebo form the control group. The results can be compared with the results of the patients who did receive TXA
62185047|NCT01276613|EXPERIMENTAL|Intraoperative Gemcitabine|Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min. Drug infusion started 100 minutes prior to complete gross tumor removal in order to have drug administration complete at tumor removal.
62393576|NCT04027127|ACTIVE_COMPARATOR|ACS GRUP|"Demographic characteristics, history, vital signs, laboratory findings, coronary angiography (CAG) and echocardiography (ECO) findings of the patients were recorded. Netrin-1 levels were studied with blood collected at the hospital and 6-8 hours after CAG. CAG results were evaluated by TIMI flow. The patients were divided into two groups with and without TIMI 3 flow and Netrin-1 levels were compared.~GRACE (Global Registry of Acute Coronary Events) and TIMI (Thrombolysis in Myocardial Ischemia) clinical risk assessments were performed and Netrin-1 values were compared."
62775175|NCT05351775|EXPERIMENTAL|Interventional AF detection arm|The patients will be monitored during index hospitalization according normal practice and additionally with a bed sensor, smartphone app, and patch-holter ECG. In addition, patients will have PDL monitoring device during hospitalization. During the index hospitalization, patients will download the CardioSignal app to their own smartphone or if patient does not have a smartphone one can be provided to the patient by the study group. Patients are asked to do the first recordings at hospital to test the device and then preferably twice daily for 1 minute period of time during the 3-month study period. When discharged home, the study subject will have the bed sensor for home-based use up to 3 months. If the average pulse rate in the bed sensor recordings have increased with 20% or the device has recorded rhythm irregularity lasting over 5 minutes (could be longer to reduce false alarms), a 12-lead ECG will be taken, and in the case of a normal ECG, a 7-day Holter monitoring is performed.
62775176|NCT05351775|NO_INTERVENTION|Standard of care treatment arm|Patient will be followed as in routine clinical practice.
61999548|NCT01622946|PLACEBO_COMPARATOR|Tranexamic acid|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
62393577|NCT04027127|ACTIVE_COMPARATOR|plasebo grup|It consisted of those without any disease and netri-1 values at admission were compared with the uptake patient group.
62568933|NCT02431676|EXPERIMENTAL|Coach Directed Behavioral Weight Loss|The Remote Lifestyle Coaching intervention is based on the Call Center Directed intervention to help you loss weight
62568934|NCT02431676|EXPERIMENTAL|Metformin|This group will be given the study drug called Metformin. Metformin comes in tablet form that you take with meals
62775177|NCT06156501|EXPERIMENTAL|ACL Reconstruction|Patients undergoing ACL reconstruction
62775178|NCT05283590||All patients|The IVC will be measured by the automated mode and manual measures will be recorded. All patients will have PPv by LiDCO
62775179|NCT03624127|EXPERIMENTAL|BMS-986165|
61999549|NCT01458327|EXPERIMENTAL|MDMA-assisted therapy|One experimental session of MDMA-assisted therapy
61999550|NCT04044417|PLACEBO_COMPARATOR|open flap debridement only|surgical treatment of periodontal defects
61999551|NCT04044417|ACTIVE_COMPARATOR|curcumin and simvastatin|open flap debridement followed by application of curcumin-simvastatin paste (2% curcumin and 1.2% simvastatin).
62775180|NCT03624127|PLACEBO_COMPARATOR|Placebo|
62775181|NCT03624127|ACTIVE_COMPARATOR|Apremilast|
62775182|NCT00261703|EXPERIMENTAL|1|(Docetaxel + Cisplatin + 5-FU) + Cisplatin + Radiotherapy
62775183|NCT00261703|EXPERIMENTAL|2|(Cisplatin + 5-FU) + Cisplatin + Radiotherapy
62775184|NCT00261703|EXPERIMENTAL|3|Cisplatin + Radiotherapy
62775185|NCT04759469|EXPERIMENTAL|High-intensity interval training (HIIT)|A high-intensity interval training program for 3 days/week (day after day) for 12 weeks on atreadmill (Biodex RTM500, Biodex Inc., New York), with a gradual increase in the program intensity.
62775186|NCT04759469|ACTIVE_COMPARATOR|Moderate intensity interval training (MIIT)|A moderate intensity interval training program for 3 days/week (alternate days) on a treadmill (Biodex RTM500, Biodex Inc., New York), with a gradual increase in the program.
62775187|NCT01426776|OTHER|heart valve replacement|a normal surgery that rheumatic valvular heart disease patients received.
61999552|NCT04044417|ACTIVE_COMPARATOR|EDTA, curcumin and simvastatin|open flap debridement followed by 24% EDTA root surface etching and application of curcumin-simvastatin paste (2% curcumin and 1.2% simvastatin).
62775188|NCT01935414|EXPERIMENTAL|geko™|geko™ use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge
61999553|NCT00633191|EXPERIMENTAL|Anti-pseudomonas IgY gargle|Intervention: Gargles with anti-pseudomonas IgY every night
61999554|NCT06178172|EXPERIMENTAL|Early discharge with remote home monitoring.|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. At home, patients receive guidance for the management of pain, nutrition and pancreatitis-related complaints by a daily phone call from a nurse from the Virtual Monitoring Centre (VMC). The pancreatitis-related complaints, intake of fluids and food, pain and the use of analgesics are assessed using short questionnaires in a smartphone app. Core temperature is monitored using an ear thermometer and a wearable sensor measures heart rate, respiratory rate, posture and movement every 5 minutes. Remote home monitoring will continue for at least 4 days.
61999555|NCT04114253||Liver transplant patients|Adult patients undergoing deceased donor liver transplantation.
61999556|NCT02272413|EXPERIMENTAL|BI 695502|
61999557|NCT02272413|ACTIVE_COMPARATOR|Avastin|
62215303|NCT05352243|EXPERIMENTAL|Expressive Helping|Participants will be instructed to write about their deepest thoughts and feeling surrounding their bereavement experience in their first two essays and to provide advice and support for someone who recently experienced a loss in their final essay.
62393578|NCT01272349|EXPERIMENTAL|Low oxygen|
62393579|NCT01272349|SHAM_COMPARATOR|Room Air|
62393580|NCT03684902|EXPERIMENTAL|xpolration|women who underwent emergency midline laprotomy
62393581|NCT00643006|EXPERIMENTAL|A. High intensive exercise|High intensive exercise
62393582|NCT00643006|ACTIVE_COMPARATOR|B. Low-intensive exercise|Low-to-moderate intensive supervised walks
62393583|NCT01370499|EXPERIMENTAL|LY2216684 + SSRI|"LY2216684: 12 milligrams (mg) or 18 mg, administered orally, once daily for 52 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI).~During the open-label phase, all participants started at the 12 mg dose and could have the dose increased to 18 mg after the first week of treatment. During the first 12 weeks, participants were allowed (at scheduled or unscheduled visits) to decrease their dose to 12 mg based on response. After a decrease in dose to 12 mg, participants could have had an increase back up to 18 mg at any scheduled visit based on response and tolerability. After 12 weeks of treatment, participants maintained a stable dose.~Open-label treatment was followed by a 1-week abrupt discontinuation phase. Participants who either completed study visits through Week 52 or discontinued early from the study for any reason returned 1 week later for follow-up visit. Participants did not receive LY2216684 but continued their SSRI treatment at a stable dose."
62393584|NCT05829434|EXPERIMENTAL|Magrolimab + intensive chemotherapy (7+3)|"Patients will receive magrolimab in combination with 7+3"
62393585|NCT05829434|EXPERIMENTAL|Magrolimab + intensive chemotherapy (CPX-351)|Patients will receive magrolimab in combination with CPX-351
62393586|NCT05714176|EXPERIMENTAL|Liposomal iron|30 pediatric patients who will receive oral liposomal iron (Novoferr) 30 mg/day for 12 weeks.
62393587|NCT05714176|EXPERIMENTAL|Iron supported Lactoferrin|30 pediatric patients who will receive oral iron supported Lactoferrin iron (Provan) 100 mg/day for 12 weeks.
62393588|NCT05714176|EXPERIMENTAL|Iv iron dextran|30 pediatric patients who will receive IV iron dextran 50 mg/3 times weekly for 12 weeks.
62393589|NCT00623753|EXPERIMENTAL|A|
62393590|NCT05901506|EXPERIMENTAL|Motivational Interview|Participants will receive the nurse-led, motivational interview educational intervention in this group.
62568935|NCT01987089|EXPERIMENTAL|CBT-I|Eight Session CBT-I: Cognitive Behavioral therapy is conducted in 8 individual sessions with the study clinician. Session 1 serves as an orientation. No active treatment is delivered at this time. Sessions 2 \& 3 are used to deliver the three main components of the intervention which are Sleep Restriction (SRT), Stimulus Control, and Sleep Hygiene. All but two of the remaining sessions are dedicated to the titration of total sleep time and to ensuring patient adherence. One session (session 5) entails the delivery of a specific form of cognitive therapy. The final session (session 8) is used to engage in a relapse-prevention didactic, i.e., to review first, how insomnia becomes chronic and second, the strategies that are likely to abort an extended episode of insomnia.
62775189|NCT01935414|ACTIVE_COMPARATOR|TEDS stockings|TEDS use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge
62775190|NCT02564484||Neuropathy|Adult survivors who developed persistent treatment-related neuropathy.
62775191|NCT02564484||Control|Adult survivors who did not develop persistent treatment-related neuropathy.
62791655|NCT06080685|ACTIVE_COMPARATOR|Waitlist Control Group|Who would receive the intervention after the study completion.
62185048|NCT01276613|EXPERIMENTAL|Intraoperative Gemcitabine + Losartan|"Losartan 50 mg by mouth daily for one week and 50 to 100 mg of Losartan by mouth daily for at least 1 week and at most 3 weeks prior to surgical resection.~Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min. Drug infusion started 100 minutes prior to complete gross tumor removal in order to have drug administration complete at tumor removal."
62393591|NCT05263973|EXPERIMENTAL|Music group|The infants in the music group (Acem Aşiran Maqam music prepared by TÜMATA group) will be applied music for a about total of 12 minutes, starting 3 minutes before the ROP examination and continuing during the ROP examination, 3 minutes after ROP examination.
62393592|NCT05263973|NO_INTERVENTION|No intervention|The infants in the control group will not be subjected to any intervention other than their clinical routines, only observation will be made.
62393593|NCT04116905|EXPERIMENTAL|Intensive Lifestyle Intervention|Participants in the intensive lifestyle intervention arm are offered individual and group sessions designed to help achieve and maintain a 15% weight loss.
62393594|NCT04116905|ACTIVE_COMPARATOR|Conventional Treatment|The conventional treatment arm provides group sessions on metabolic syndrome management and social support, aimed at a 5% weight loss.
62393595|NCT03081494|EXPERIMENTAL|spartalizumab (PDR001) + regorafenib|Subjects with metastatic MSS CRC received a combination of spartalizumab and regorafenib.
62393596|NCT06384872|EXPERIMENTAL|Hard-Hard cushioned running shoes|Running shoes with cushioned properties (linear equivalent stiffness) as follow: about 60 and 80 N/mm at the rear and forepart of the shoe, respectively.
62393597|NCT06384872|EXPERIMENTAL|Soft-Hard cushioned running shoes|Running shoes with cushioned properties (linear equivalent stiffness) as follow: about 40 and 80 N/mm at the rear and forepart of the shoe, respectively.
62393598|NCT06384872|EXPERIMENTAL|Soft-Soft cushioned running shoes|Running shoes with cushioned properties (linear equivalent stiffness) as follow: about 40 and 50 N/mm at the rear and forepart of the shoe, respectively.
61999558|NCT03159728|EXPERIMENTAL|Educative intervention|"Who wish to participate in the program Caring for Caregivers will be the intervention group. The intervention or program Caring for Caregivers to develop was proposed by the Group of Chronic Care Patient and Family School of Nursing at the National University of Colombia. This program includes four sessions or meetings with the caretaker, induction and three modules, the first is geared to strengthen the knowledge; the second, to strengthen the value and the third, to strengthen patience."
61999559|NCT03159728|NO_INTERVENTION|Control group|"The control group will receive training about knowledge of chronic disease and care.~In addition, once it confirmed the effectiveness of the intervention participants in the control group will be contacted to contemplate the possibility of receiving the benefits of the intervention."
61999560|NCT02928328|EXPERIMENTAL|GABA oral solution|This study will test if oral administration of GABA containing solutions will reduce the pain and sensitivity induced by application of capsaicin to the tongue of healthy human subjects.
62775192|NCT04547582|EXPERIMENTAL|Spinal cord stimulation|"Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.~Participants in this study receive spinal cord stimulation will be trans-tibial amputees that are at least six month post--amputation. Subjects will have varying levels of phantom limb sensation and pain, but should have no other significant neurological disorders."
62775193|NCT01789216|PLACEBO_COMPARATOR|Placebo|"Standard pain management + perioperative intravenous placebo \& oral placebo.~Control group will receive an oral dose of placebo up to two hours prior to surgery and twice daily for up to 48 hours following any surgery, in addition to an intravenous dose of placebo up to two hours prior to surgery and every 6 hours for up to 48 hours following surgery. All study medications will be in addition to standard of care pain medication.~\*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall."
62775194|NCT01789216|ACTIVE_COMPARATOR|NSAID|"Standard pain management + perioperative intravenous ketorolac \& oral placebo.~The NSAID group will receive 30 mg of intravenous (IV) ketorolac (Ketorolac 30 mg/ml dose vial, NDC 00409-3795-01; manufacturer: Hospira) administered up to two hours prior to the procedure and every 6 hours for up to 48 hours following the procedure. In addition, as part of the perioperative protocol, patients will receive an oral dose of placebo up to two hours prior to the procedure and every 12 hours for up to 48 hours following the procedure.~\*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall."
62775195|NCT01789216|ACTIVE_COMPARATOR|Gabapentinoid|"Standard pain management + perioperative intravenous placebo \& oral pregabalin.~The Pregabalin group will receive an oral bolus dose of 300 mg of pregabalin up to two hours prior to the procedure and a 75 mg dose every 12 hours for up to 48 hours following the procedure. In addition, as part of the perioperative protocol, patients will receive an IV dose of placebo up to two hours prior to the procedure and every 6 hours for up to 48 hours following the procedure.~\*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall."
61999561|NCT02928328|EXPERIMENTAL|Intramuscular GABA|This study will test the hypothesis that intramuscular injection of GABA alone will not be painful, but will reduce muscle pain sensitivity in healthy human subjects.
61999562|NCT02928328|EXPERIMENTAL|Pain modulation|This study will test the hypothesis that intramuscular injection of GABA with glutamate will decrease the intensity of glutamate-evoked muscle pain in healthy human subjects.
61999563|NCT04464681|EXPERIMENTAL|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
61999564|NCT04464681|PLACEBO_COMPARATOR|Placebo|Placebo: M201-A Placebo Route of administration: continuous intravenous injection
62393599|NCT04162873|EXPERIMENTAL|Celecoxib Arm|Patients receive celecoxib PO or via feeding tube BID starting 1 to 7 days prior to surgery and continues until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.
61999565|NCT03580603|EXPERIMENTAL|Antibiotic visualization tool|Provider will answer microbiological sensitivity questions using a new antibiotic visualization tool.
61999566|NCT03580603|NO_INTERVENTION|Standard practice|Provider will answer microbiological sensitivity questions using standard medical record tools.
61999567|NCT05005858|EXPERIMENTAL|Autograft|"The filler used in ridge splitting is autologous bone block harvested from mandible~* Interventions:~* Procedure: ridge splitting~* Procedure: bone core biopsy~* Device: dental implant placement~* Measurement: clinical measurement with Williams probe~* Micro-CT analysis~* Histomorphometric measurements"
61999568|NCT03142880|ACTIVE_COMPARATOR|commonly hyperbaric ropivacaine group|This group will receive spinal anesthesia with commonly hyperbaric ropivacaine solution,which was made by adding 50% glucose to the plain ropivacaine commercially availablethe to make it's density is close to commonly hyperbaric bupivacaine.
61999569|NCT03142880|EXPERIMENTAL|marginally hyperbaric ropivacaine group|This group will receive spinal anesthesia with marginally hyperbaric ropivacaine,which was made by adding 5% glucose to the plain ropivacaine commercially availablethe to make it's density is slightly denser than cerebrospinal fluid but much less denser than commonly hyperbaric bupivacaine/ropivacaine.
62185049|NCT01903083|EXPERIMENTAL|Immunochemoradiotherapy|Immunotherapy with oral tadalafil daily; three doses of chemotherapy with IV Gemcitabine in 21-day cycles for up to 4 cycles; three fractions of external beam radiation to the pancreas and and regional lymph nodes; pancreaticoduodenectomy (surgical resection) for eligible patients.
62775196|NCT04405245|EXPERIMENTAL|AKB-9778 4% QD + Latanoprost|• AKB-9778 4% daily (AM) and placebo for ophthalmic solution daily (PM) plus latanoprost daily (PM) for 28 days
62775197|NCT04405245|EXPERIMENTAL|AKB-9778 4% BID + Latanoprost|• AKB-9778 4% twice daily (AM \& PM) plus latanoprost daily (PM) for 28 days
62775198|NCT04405245|PLACEBO_COMPARATOR|Placebo Twice Daily + Latanoprost|• Placebo for AKB-9778 4% ophthalmic solution twice daily (AM \& PM) plus latanoprost daily (PM) for 28 days
62775199|NCT04046731|EXPERIMENTAL|Study Group|Study team is developing a new diagnostic skin testing procedure for patients who receive NMBAs during surgery in order to determine Negative Predictive Values and Non-Irritant Concentrations.
62775200|NCT04371692||High-risk|staff working in a unit specifically for patients infected or suspected of being infected with SARS-Cov2
62775201|NCT04371692||Medium- risk|staff working in a unit that can accommodate patients infected or suspected of being infected with SARS-Cov2, i.e., all care services that do not fall into the high-risk group.
62775202|NCT04371692||Low-risk|off-patient staff
61999570|NCT02547129|ACTIVE_COMPARATOR|Static Antibiotic Spacer|Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the Static Antibiotic Spacer Surgical Implant being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
61999571|NCT02547129|ACTIVE_COMPARATOR|Articulating Antibiotic Spacer|Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the Articulating Antibiotic Spacer Surgical Implant being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
61999572|NCT04365699|EXPERIMENTAL|Interventional Patients: AT-001|AT-001 1500 mg (3 capsules) were administered by mouth twice daily for up to 14 days
62215304|NCT05352243|SHAM_COMPARATOR|Fact-Writing|Participants will be instructed to write objectively about different time frames (e.g., routine for getting up in the morning, routine for going to sleep at night).
62215305|NCT05564780|EXPERIMENTAL|Treatment|"Antihypertensive drugs will be provided to the participants in the arm, including RASI and/or a single pill combination based on RASI.~If the blood pressure of a participant elevates to above 140/90 mmHg, antihypertensive therapy will be provided."
62775203|NCT00902174|EXPERIMENTAL|imatinib mesylate|Imatinib mesylate (QTI571) 200 mg once daily for two weeks, increased to 400 mg once daily if well tolerated. If 400 mg dose was not well tolerated, a down titration to 200 mg once daily was permitted.
62775204|NCT00902174|PLACEBO_COMPARATOR|Placebo|Placebo to imatinib mesylate taken once daily. Participants receiving placebo were allowed to receive already approved PAH treatments.
61999573|NCT04365699|NO_INTERVENTION|Control Match Group 1|Matched control from a contemporaneous de-identified registry of hospitalized patients with clinical COVID-19 diagnosis at the same institution was selected. The first matching approach selected all subjects with diabetes mellitus and hypertension, and available data to match participants who received AT-001 for gender, age group (in bins of 5 years), weight, and C-reactive protein (CRP) value at the time of hospital admission.
62775205|NCT03461081|EXPERIMENTAL|Group I|Period I: administration of telmisartan/Amlodipine for 10 days then administration of telmisartan/amlodipine and atorvastatin for 4 days Period II: atorvastatin for 4 days
61999574|NCT04365699|NO_INTERVENTION|Control Match Group 2|Matched control from a contemporaneous de-identified registry of hospitalized patients with clinical COVID-19 diagnosis at the same institution was selected. The second matching approach selected all subjects in the registry with diabetes mellitus and available data to match participants who received AT-001 for gender, age group (in bings of 5 years), and weight (+/- 0.5 kgs).
62185050|NCT05051423||Patients diagnosed with primary gastric tumors referred to our department for EUS local staging.|"Patients will be included or excluded according to the following criteria used throughout the study:~* Inclusion criteria: Patients diagnosed with primary gastric tumors referred for local staging by EUS (n=40); Age 18 to 90 years old, men or women; Signed informed consent for EUS with contrast-enhancement and tissue sampling~* Exclusion criteria: Prior treatment with chemo-radiotherapy; Failure to provide informed consent; severe coagulopathy.~Data collected for each participant will include: Personal data (name, surname, age, sex); results from previous investigations (blood count, liver and renal function tests, tumoral markers, gastroscopy, computed tomography), EUS variables (including CEH-EUS), histological and immunohistochemical findings, TNM and pTNM status (if possible), molecular analysis findings."
62185051|NCT01357109|EXPERIMENTAL|Bosentan|
62393600|NCT04162873|PLACEBO_COMPARATOR|Placebo Arm|Patients receive placebo PO or via feeding tube BID starting 1 to 7 days prior to surgery and continues until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.
62393601|NCT05945173|EXPERIMENTAL|Experimental group 1|35 non-carious cervical lesions (NCCL) will receive composite resin restorations in the selective enamel etching strategy.
62568936|NCT01987089|PLACEBO_COMPARATOR|QDT|"This form of placebo therapy has been commonly used in prior studies investigating behavioral interventions for insomnia. The therapist presents the QDT as a means to eliminate conditioned arousal, occurring after nocturnal arousal using 8 sessions on a weekly basis. The therapist initially helps the subject to develop a chronological 12-item hierarchy of commonly practiced activities on awakening at night, like opening eyes and clock watching. As a next step, the subject develops 6 imaginable scenes of himself/herself engaged in neutral activities like reading a newspaper. The therapist then helps the subject pair the neutral scenes with the items from the 12-item hierarchy, which is then practiced by the subject 2 hours before bedtime."
62568937|NCT04299568|EXPERIMENTAL|Anti gravity treadmill training|Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization followed by Lower Body Positive Pressure (LBPP) treadmill training for 15 minutes.
62775206|NCT03461081|EXPERIMENTAL|Group II|Period I: administration of atorvastatin for 4 days Period II: administration of telmisartan/amlodipine for 10 days then administration of telmisartan/amlodipine and atorvastatin for 4 days
62775207|NCT03368235|EXPERIMENTAL|AZD9567|oral suspension of 40 mg AZD9567 once daily (OD) for two weeks
62775208|NCT03368235|ACTIVE_COMPARATOR|Prednisolone|oral OD treatment of 20 mg prednisolone administered as capsules
62775209|NCT01309269||Cohort|
62775210|NCT00480870|EXPERIMENTAL|A|Donepezil treated Alzheimer patients
62775211|NCT00480870|PLACEBO_COMPARATOR|B|Placebo treated Alzheimer patients
62775212|NCT01026220|EXPERIMENTAL|Regimen I (consolidation therapy)|Patients receive 2 more courses of ABVE-PC comprising doxorubicin hydrochloride IV over 1-120 minutes and cyclophosphamide IV over 30-60 minutes on days 1 and 2; bleomycin sulfate IV over at least 10 minutes or subcutaneously (SC) and vincristine sulfate IV on days 1 and 8; etoposide IV over 1-2 hours on days 1-3; oral prednisone twice daily on days 1-7; and filgrastim SC or IV daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression.
61999575|NCT06237153|EXPERIMENTAL|Triamcinolone acetonide extended release suspension injection|Active drug treatment
61999576|NCT06237153|PLACEBO_COMPARATOR|Saline Placebo Injection|Placebo comparator
61999577|NCT01577758|EXPERIMENTAL|MLN0264|MLN0264 starting dose 0.3 mg/kg escalated until Maximum Tolerated Dose (MTD) was determined, 30-minute infusion, on Day 1 of each 21-Day treatment cycle.
61999578|NCT05693610|EXPERIMENTAL|Portable OSP|Outcomes will be assessed with the portable version of the OSP.
61999579|NCT05693610|EXPERIMENTAL|Cloud-based OSP|Outcomes will be assessed with the cloud-based version of the OSP.
61999580|NCT01618357|EXPERIMENTAL|Intervention|All subjects will receive pre-operative Neo-Adjuvant Chemotherapy (NAC) but only those with an incomplete response to NAC will be treated with the PARPi experimental portion of the trial explained below. Those with a complete response will be treated per standard of care.
61999581|NCT03984422||Raynaud phenomenon|Use of smartphone application
62185052|NCT01357109|PLACEBO_COMPARATOR|Placebo|
62185053|NCT03993561|EXPERIMENTAL|TSSP Group|A one-hour treatment summary and survivorship care plan (TSSP) intervention specifically tailored to the needs of head and neck cancer patients based on the best available evidence and consultation with patients and a multidisciplinary team of head and neck cancer specialists will be provided
62215306|NCT05564780|NO_INTERVENTION|Control|If the blood pressure of a participant elevates to above 140/90 mmHg, antihypertensive therapy will be provided.
62215307|NCT04601870|EXPERIMENTAL|No Financial Incentive|N=180 participants randomized to not be offered monetary incentive to participate in an intervention to quit smoking.
62393602|NCT05945173|EXPERIMENTAL|Experimental group 2|35 non-carious cervical lesions (NCCL) will receive composite resin restorations in the selective enamel etching strategy.
61999582|NCT03915249||Allogeneic-HSCT candidates|Physical activity, pulmonary functions (FEV1, FVC, FEV1/FVC, FEF25-75%, PEF), exercise capacity, respiratory (maximal inspiratory and expiratory pressures (MIP, MEP)) and peripheral muscle strength were evaluated in allogeneic-HSCT candidates.
62393603|NCT05945173|ACTIVE_COMPARATOR|Control group 1|35 non-carious cervical lesions (NCCL) will receive composite resin restorations in the selective enamel etching strategy.
62393604|NCT05945173|ACTIVE_COMPARATOR|Control group 2|35 non-carious cervical lesions (NCCL) will receive composite resin restorations in the selective enamel etching strategy.
61999583|NCT00757835|ACTIVE_COMPARATOR|Travoprost/timolol therapy|treatment with travoprost/timolol fixed combination drops once in the evening for 3 months. 24-hour pressure monitoring.
62393605|NCT02411032|EXPERIMENTAL|Reminder control|Customers receive a mailing on a random day, which does not coincide with any of the predictable fresh start events.
62775213|NCT01026220|EXPERIMENTAL|Regimen II (consolidation therapy)|Patients receive ifosfamide IV continuously on days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, and filgrastim SC or IV beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression. Patients then receive 2 more courses of ABVE-PC in the absence of unacceptable toxicity or disease progression.
62393606|NCT02411032|EXPERIMENTAL|Birthday framed|Customers receive a mailing on the most recent Wednesday before the customers' birthday, and the mailing frames the customers' birthday by emphasizing a fresh start associated with the customers' birthday.
62393607|NCT02411032|EXPERIMENTAL|New Year's framed|Customers receive a mailing on 1/21/15, and the mailing frames the customers' birthday by emphasizing a fresh start associated with the customers' birthday.
62393608|NCT02411032|EXPERIMENTAL|Birthday un-framed|Customers receive a mailing on the most recent Wednesday before the customers' birthday, but the mailing does not frame the customers' birthday.
62393609|NCT02411032|EXPERIMENTAL|New Year's un-framed|Customers receive a mailing on 1/21/15, but the mailing does not frame New Year's.
62568938|NCT04299568|ACTIVE_COMPARATOR|Control|Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization only
62568939|NCT06198231|EXPERIMENTAL|Pilates exercises|The experimental group will receive the same program of exercises given to the control group, 45 minutes of Pilates exercises (such as back twists, single leg circles, standing splits, alternate toe touches, ball leg lifts).The Pilates exercises will be aimed at improving lower-limb strength, flexibility, and coordination, and they will be performed on a mat, using a medical ball. The focus will be on maintaining core contraction, spinal and pelvic alignment, and respiration rhythm. Ten repetitions of Pilates exercises will be performed, with a 2-minute rest period between repetitions.
62568940|NCT06198231|ACTIVE_COMPARATOR|Flexibility ,strength and endurance excercises|Control group will perform flexibility exercises for the hip (flexors and adductors), knee (flexors and extensors), and calf muscle, with a hold of 15 sec ,5 repetitions. Strengthening exercises for core muscles (curl-ups, prone extension),hip extensors (in prone position), hamstrings, quadriceps (knee extension in high sitting).Walking in all directions, standing on rough and soft surfaces, stepping down and up, walking,standing on one limb with both eyes closed and open. Each session will start with a 5-minute warm-up and 5-minute cool-down, session duration 45 minutes,3 times a week.
62568941|NCT03418688|ACTIVE_COMPARATOR|COR388|Increasing doses of COR388 will be administered for 10 days in cohorts 1-3 and for 28 days in cohort 4.
62568942|NCT03418688|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules will be administered for 10 days in cohorts 1-3 and for 28 days in cohort 4.
62568943|NCT00764660|EXPERIMENTAL|SCH 900435|Participants received SCH 900435 12 mg (as three SCH 900435 4 mg tablets) by mouth twice daily for 12 weeks.
62568944|NCT00764660|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo tablets by mouth twice daily for 12 weeks.
62775214|NCT01026220|EXPERIMENTAL|Induction: all patient|All patients receive ABVE-PC induction therapy then they are assigned to Group 2 (RER), Group 3 (SER) or taken off study if they develop progressive disease.
62215308|NCT04601870|EXPERIMENTAL|Financial Incentive (100 dollars)|N=180 randomized participants will be offered a 100 dollar incentive to participate in an intervention to quit smoking.
62215309|NCT04601870|EXPERIMENTAL|Financial Incentive (50 dollars)|N=180 randomized participants will be offered a 50 dollar incentive to participant in an intervention to quit smoking.
62393610|NCT04504682|EXPERIMENTAL|Ambulation|Participants in this arm will be encouraged to ambulate with epidural in place.
62393611|NCT00086060|EXPERIMENTAL|1 - Relaxation Training|Participants will receive relaxation training and standard care for FM
62393612|NCT00086060|EXPERIMENTAL|2 Exercise Regimen|Participants will receive an exercise regimen and standard care for FM
62393613|NCT00086060|ACTIVE_COMPARATOR|3 Standard Care|Participants will receive standard of care for FM
62393614|NCT00086060|NO_INTERVENTION|4 Health Controls|Health participants will act as a control
62393615|NCT03339440|EXPERIMENTAL|Intervention Group|Patients in this group will be receiving the Hearts and Parks intervention.
62393616|NCT03339440|NO_INTERVENTION|Control Group|Patients in this group will continue receiving standard of care.
62393617|NCT04902547|EXPERIMENTAL|Multidisciplinary Tapering Program Only|Patients in this arm will take part in the clinical multidisciplinary opioid tapering program (MTP).
62393618|NCT04902547|EXPERIMENTAL|Patient Education Workshop & Multidisciplinary Tapering Program|As above, though patients in this group will also take part in an opioid education workshop
62393619|NCT02103400|EXPERIMENTAL|Experimental group|Patients hospitalized for community-acquired pneumonia
62393620|NCT02103400|ACTIVE_COMPARATOR|Control group|Patients hospitalized for community-acquired pneumonia
62393621|NCT01408953|EXPERIMENTAL|bevacizumab for all patients|This is a single arm trial. All patients receive treatment with bevacizumab.
62393622|NCT06329245||high-risk group|Subjects in the case group have one or more older siblings with ASD.
62393623|NCT06329245||low-risk group|Subjects in the controlled group do not have older siblings with ASD.
62393624|NCT00451776|EXPERIMENTAL|1|patients who received etomidate
62568945|NCT05587322|EXPERIMENTAL|BLI5100 Low Dose|During the Treatment Period, patients will take BLI5100 low dose once daily, orally, for 8 weeks. During the Extension Period, patients will continue to take BLI5100 low dose once daily, orally, for 20 weeks.
62185054|NCT05127018|ACTIVE_COMPARATOR|the average-dose method|With the average-dose method, the dose was individualized according to the severity of anterior gingival exposure pretreatment. For mild gingival smile (3-5 mm), a single-site injection of 2 U botulinum toxin type A \[total, 4 U\] at both the right and left levator labii superioris alaeque nasi muscles) was administered. For moderate (5-7 mm) and severe (≥7 mm) gingival smile, 3 U and 5 U of botulinum toxin type A, respectively, were injected per side (total, 6 U and 10U, respectively). The injection points were located at bilateral levator labii superioris alaeque nasi muscles and at the Yonsei point26, with half doses administered at each point.
62185055|NCT05127018|EXPERIMENTAL|the higher-dose method|With this method, patients were administered botulinum toxin type A after 8 months when the effect of the previous injection had vanished. The injection dose (U) per side was set as the absolute value of the preoperative anterior gingival exposure (mm). For example, if the preoperative anterior gingival exposure was 5mm, then the patient would be injected with 5 U of botulinum toxin per side (total, 10U). The injection points were located at bilateral levator labii superioris alaeque nasi muscles and at the Yonsei point26, with half doses administered at each point.
62393625|NCT00451776|ACTIVE_COMPARATOR|2|patients who received propofol
62393626|NCT03029572|ACTIVE_COMPARATOR|Standard diet|Standard healthy diet after RYGB surgery
62393627|NCT03029572|EXPERIMENTAL|Micro-nutriments' supplementation|Healthy diet and probiotics, minerals, aminoacids, omega-3 acids vitamin and mineral supplementation after RYGB surgery
62393628|NCT02211287|EXPERIMENTAL|Intervention|The intervention will include five key elements: a Project Nurse - ACP facilitator; family education on comfort care at the end of life for individuals with dementia using the 'Comfort Care at the end of life for persons with dementia' booklet; a family meeting with follow-up telephone call; documentation of ACP decisions, and orientation and education directed towards General Practitioners (GPs) and nursing home staff about the intervention.
62393629|NCT02211287|NO_INTERVENTION|Usual care|Care will continue as usual for the nursing home residents
62393630|NCT04246359|EXPERIMENTAL|RP induction and maintenance|"1. Induction phase:~1. Rituximab: 375mg / m2, ivd, d1;~2. Pegylated interferon α-2b: 135 μg (500,000 U), H, d1, 8 Repeated every 21 days, Maximum 6 cycles 2. Maintenance phase:~1) Rituximab: 375mg / m2, ivd, d1; 2) Pegylated interferon α-2b: 135 μg (500,000 U), H, d1,30 Repeated every 2 months, Maximum 12 cycles"
62393631|NCT03485976|EXPERIMENTAL|Ixekizumab treatment arm|Ixekizumab 160 mg subcutaneous injection at week 0, followed by 80 mg subcutaneous injections at week 2, 4, 6, 8, 10, 12, 16, and 20
62393632|NCT03319602|ACTIVE_COMPARATOR|Oxygenation only with nasal canula|intervention: classical oxygenation with nasal canula (High flow)
62393633|NCT03319602|EXPERIMENTAL|Oxygenation with double trunk masknasal canula|oxygenationwith DTM above nasal canula
62393634|NCT04920331|EXPERIMENTAL|Erenumab|Subjects with episodes of status migrainosus will receive a single dose of IV erenumab
62568946|NCT05587322|EXPERIMENTAL|BLI5100 High Dose|During the Treatment Period, patients will take BLI5100 high dose once daily, orally, for 8 weeks. During the Extension Period, patients will continue to take BLI5100 high dose once daily, orally, for 20 weeks.
62568947|NCT05587322|PLACEBO_COMPARATOR|Placebo|During the Treatment Period, patients will take placebo once daily, orally, for 8 weeks. In the Extension Phase, patients who received placebo in the Treatment Phase will be re-randomized to receive either BLI5100 low dose or BLI5100 high dose to take once daily, orally, for 20 weeks.
62393635|NCT03788109|OTHER|device: combined solid state HRiM|combined solid state high resolution esophageal impedance and manometry (HRiM)
62393636|NCT02030067|EXPERIMENTAL|RX-3117|All subjects will receive RX-3117.
62393637|NCT05813769|ACTIVE_COMPARATOR|Dairy protein 1|
62393638|NCT05813769|ACTIVE_COMPARATOR|Dairy protein 2|
62393639|NCT05813769|EXPERIMENTAL|Plant protein 1|
62568948|NCT02894372|EXPERIMENTAL|Subjects with oral spray 1|Research subjects, who got oral spray 1. Spray was used 3 times a day 3 sprays a time for seven days. Spray 1 was Faringomoss or simple oily oral spray (unknown because of double blind method).
62393640|NCT05813769|EXPERIMENTAL|Plant protein 2|
62393641|NCT05813769|EXPERIMENTAL|Plant protein 2 + added AA|
62393642|NCT05813769|EXPERIMENTAL|Plant protein 2 + Dairy protein 2|
62393643|NCT05283161|PLACEBO_COMPARATOR|Placebo|10 participants will receive placebo (vehicle). The placebo will match the study drug in odor, taste, color and appearance. The administration will occur daily, once a day, during the night period, before going to bed and 30 minutes after the meal, during the next 120 days.
62393644|NCT05283161|EXPERIMENTAL|cannabidiol and tetrahydrocannabinol 1:1 (0.1 mg/ml)|10 participants will receive CBD and THC in the same concentration (1:1) (0.1 mg/ml). The administration will occur daily, once a day, during the night period, before going to bed and 30 minutes after the meal, during the next 120 days.
62393645|NCT05283161|EXPERIMENTAL|cannabidiol and tetrahydrocannabinol 1:1 (1.0 mg/ml)|10 participants will receive CBD and THC in the same concentration (1:1) (1.0 mg/ml). The administration will occur daily, once a day, during the night period, before going to bed and 30 minutes after the meal, during the next 120 days.
62393646|NCT05283161|EXPERIMENTAL|cannabidiol and tetrahydrocannabinol 1:1 (10.0 mg/ml)|10 participants will receive CBD and THC in the same concentration (1:1) (10.0 mg/ml). The administration will occur daily, once a day, during the night period, before going to bed and 30 minutes after the meal, during the next 120 days.
62393647|NCT03759002||Patients|Children with end stage renal disease
62393648|NCT03759002||Controls|Healthy sex- and age adjusted children
62393649|NCT00646737|EXPERIMENTAL|1|Mycophenolate sodium
62568949|NCT02894372|EXPERIMENTAL|Subjects with oral spray 2|Research subjects, who got oral spray 2. Spray was used 3 times a day 3 sprays a time for seven days. Spray 2 was Faringomoss or simple oily oral spray (unknown because of double blind method).
62568950|NCT00766012|EXPERIMENTAL|1|4 dose panels receiving a specified volume of AZD2066 oral solution once daily for 11 days
62568951|NCT00766012|PLACEBO_COMPARATOR|2|Included in each dose panel
62775215|NCT02858557|EXPERIMENTAL|Group A|Patients will be allocated to 7 days of Mediterranean diet and then will cross over to 7 days of specific carbohydrate diet
62775216|NCT02858557|EXPERIMENTAL|Group B|Patients will be allocated to 7 days of specific carbohydrate diet and then will cross over to 7 days of Mediterranean diet
62775217|NCT02157077|EXPERIMENTAL|Aflibercept|Patients will receive 2 mg of aflibercept by intravitreal injection every 4 weeks until week 8, followed by every 6 weeks to week 26
62775218|NCT03842072|NO_INTERVENTION|No post-operative bracing|patients in this arm will not be prescribed a cervical collar following anterior cervical discectomy and fusion surgery
62775219|NCT03842072|ACTIVE_COMPARATOR|Post-operative bracing|Patients in this arm will be prescribed a cervical collar following anterior cervical discectomy and fusion surgery.
62393650|NCT02701374|EXPERIMENTAL|1:TRK-700|high dose
62775220|NCT03665584|ACTIVE_COMPARATOR|FxCO2 Laser|FxCO2 laser treatment will be performed by scanning across the entire affected anogenital region. The FxCO2 treatment will be performed at baseline and then repeated at 4 week intervals for a total of 5 treatments. The laser parameters change with each treatment: power (18, 20, 22, 24, 26W), dwell time (800, 900, 1000, 1000, 1000us) and spacing (1200, 1100, 1000, 1000, 1000um) in respective order.
62393651|NCT02701374|EXPERIMENTAL|2:TRK-700|low dose
62775221|NCT03665584|SHAM_COMPARATOR|Sham Laser|Sham laser treatment will be performed by scanning across the entire affected anogenital region. The sham treatment will be performed using 4W (power), 400us (dwell time), and 1500um (spacing). The laser has no effect on the vulvar tissue using these parameters.
62775222|NCT02940483|EXPERIMENTAL|5-Azacytidine Infusion|12 infusions (once a week) into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle.
62775223|NCT02744651|ACTIVE_COMPARATOR|EUS-FNA|All patients with a confirmed suspicion of a submucosal tumor in the upper GI tract will be included in this study. A senior endoscopist will perform multiple passes of EUS-FNA until she/he has collected enough material for the pathologist to establish a possible diagnosis.
62775224|NCT02744651|ACTIVE_COMPARATOR|EUS-Endodrill biopsy|All patients who are included in the study will also be examined by a senior endoscopist performing multiple EUS guided passes with the Endodrill biopsy. The harvested tissue from the tumor will be examined by a pathologist in order to establish a diagnosis.
62775225|NCT06526000||Relapsing Multiple Sclerosis Cohort|Patients with relapsing forms of multiple sclerosis who had newly initiated anti-CD20 treatment after March 2017.
62185056|NCT04105062|EXPERIMENTAL|Phase I: LS301 Dose Level 1 (0.05 mg/kg)|"* The patient will undergo intravenous injection of LS301 4-24 hours prior to surgery.~* The operating surgeon will conduct surgery as usual without using a device to visualize LS301 fluorescence. To prevent bias in data acquisition, a second surgeon will wear the CVG at the completion of the surgery to examine the excised tissue at the surgical margins and the surgical resection bed.~* The operating surgeon will remain blinded to the fluorescence images throughout the operation. The examining surgeon will wear the CVG and image all six anatomical aspects (superior, inferior, anterior, posterior, medial and lateral) of the surgical specimen as well as the surgical cavity for LS301 fluorescence."
62185057|NCT04105062|EXPERIMENTAL|Phase I: LS301 Dose Level 2 (0.075 mg/kg)|"* The patient will undergo intravenous injection of LS301 4-24 hours prior to surgery.~* The operating surgeon will conduct surgery as usual without using a device to visualize LS301 fluorescence. To prevent bias in data acquisition, a second surgeon will wear the CVG at the completion of the surgery to examine the excised tissue at the surgical margins and the surgical resection bed.~* The operating surgeon will remain blinded to the fluorescence images throughout the operation. The examining surgeon will wear the CVG and image all six anatomical aspects (superior, inferior, anterior, posterior, medial and lateral) of the surgical specimen as well as the surgical cavity for LS301 fluorescence."
62215310|NCT02774967|ACTIVE_COMPARATOR|extended flap technique|"root coverage comparing two techniques The aim of this study was to compare and show the benefits of the extended flap technique compared to Tunnel technique both techniques using the acellular dermal matrix for root coverage.~Other Names:~acellular dermal matrix extended flap technique"
62775226|NCT05338879||Cohort 1|Participants with r/r FL grade 1-3a who were treated with at least 2 prior systemic therapies in the real-world setting.
62393652|NCT02701374|PLACEBO_COMPARATOR|3:Placebo|Placebo
62393653|NCT05707819||Sintilimab+Chemoradiotherapy|Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.
62393654|NCT01953419|EXPERIMENTAL|Treatment group|received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity
62393655|NCT03391427|EXPERIMENTAL|Lidocaine|This group will receive lidocaine infusion perioperatively
62393656|NCT03391427|EXPERIMENTAL|Ketamine|This group will receive ketamine infusion perioperatively
62393657|NCT03391427|EXPERIMENTAL|Lidocaine+ketamine|This group will receive a combination of lidocaine and ketamine infusion, perioperatively
62393658|NCT03391427|PLACEBO_COMPARATOR|placebo|This group will receive saline infusion as placebo perioperatively
62393659|NCT06231186|EXPERIMENTAL|iHD-SRT|isotoxic high dose SRT
62393660|NCT05325502|PLACEBO_COMPARATOR|Placebo|7 days placebo intake.
62393661|NCT05325502|ACTIVE_COMPARATOR|Acute caffeine|6 days placebo followed by 1 day caffeine intake.
62393662|NCT05325502|EXPERIMENTAL|Daily caffeine|7 days caffeine intake
62393663|NCT04881266||Post Critical Illness due to COVID-19|
62775227|NCT05188703|EXPERIMENTAL|Intervention arm|Intervention consists of standard of care eye exam and enrollment in a patient navigation program.
62775228|NCT05856565||Retrospective|Photograph
62775229|NCT05856565||Prospective|
62775230|NCT00915551|EXPERIMENTAL|PEP005 (Ingenol Mebutate) gel|
62775231|NCT00915551|PLACEBO_COMPARATOR|Vehicle gel|
62775232|NCT01983774|PLACEBO_COMPARATOR|Placebo|A matching placebo (sugar pill) to esomeprazole 40mg twice daily
62775233|NCT01983774|ACTIVE_COMPARATOR|Esomeprazole|Esomeprazole 40mg twice daily
62775234|NCT04181177||Informed group|This group will receive the Cosmetic product RV4429A balm and targeted educational action between V1 and V2 or between V2 and V3 according to the randomization
61999584|NCT00757835|ACTIVE_COMPARATOR|Latanoprost/timolol therapy|Treatment with latanoprost/timolol fixed combination for 3 months. 24-hour pressure monitoring.
61999585|NCT05827497|EXPERIMENTAL|Group A|baricitinib 2 mg once daily
61999586|NCT05827497|ACTIVE_COMPARATOR|Group B|methotrexate on 25 mg weekly
62775235|NCT04181177||Control group|"The control group, in the first period between V1 and V2, is a group not informed about his skin condition, not receiving any emollient product and not receiving targeted educational action. It's representative of the real life called best supportive care/Supportive care: the doctor prescribes what it seems to be the best for his patient according to his opinion in view of his condition, at a given moment.~A high variability exists within this group. In order to answer the investigator's hypothesis and demonstrate the effectiveness of the RV4429A balm, the parallel group design is chosen for the first follow-up period and then a second follow-up period is chosen for the initial control group to replace the inter-individual variability by intra-individual variability."
62775236|NCT02953886|EXPERIMENTAL|Silver Diamine Fluoride (SDF)|Application of Silver Diamine Fluoride (SDF) to root or cervical carious lesions (cavities). Collection of plaque pre- and one month post-SDF application.
62775237|NCT05233345|EXPERIMENTAL|Experimental group: web based occupational therapy program|"Web-based occupational therapy classes were carried out as 5 sessions per week, each session lasting 1 hour, for 3 weeks. In total, 15 sessions were performed during the study period.~Group activities were performed through the Zoom application by means of a video camera. Included painting and cake making together, sports activities to be performed simultaneously with the movements shown by the researcher, memory games, and games that can be played with the group, such as the categories game. Sports activities were performed in the last 15 minutes of group activities, 5 days a week, in order to increase the physical activity level of children whose physical activities decreased during the lockdown period at home.~Also, all study participants continued taking classes from the EBA program as part of their routine education plan while taking occupational therapy program. EBA program is online classes given by government on local television."
62393664|NCT04881266||Caregivers of Post critically ill COVID-19 patients|
62393665|NCT04576702|EXPERIMENTAL|Investigational aIIV4c group|aIIV4c will be administered as a single dose intramuscularly on Day 1
62393666|NCT04576702|ACTIVE_COMPARATOR|licensed IIV4c group|IIV4c will be administered as a single dose intramuscularly on Day 1
62393667|NCT04576702|ACTIVE_COMPARATOR|licensed aIIV4 group|aIIV4 will be administered as a single dose intramuscularly on Day 1
62775238|NCT05233345|NO_INTERVENTION|Control Group|There are no interventions except EBA which all study participants are already taking classes from as part of their routine education plan. EBA program is online classes given by government on local television. This program is out of our study.
62775239|NCT01078168|ACTIVE_COMPARATOR|Acitretin|oral, 30 mg per day, day 1-28
62775240|NCT01078168|PLACEBO_COMPARATOR|Placebo|oral, day 1-28
62775241|NCT01341028|ACTIVE_COMPARATOR|Roux-en-Y gastric bypass (LRYGBP)|Twelve subjects underwent laparoscopic Roux-en-Y gastric bypass
62775242|NCT01341028|EXPERIMENTAL|LRYGBP plus gastric fundus resection|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass plus gastric fundus resection
62775243|NCT05281055||EVT group|Patients who received endovascular thrombectomy for acute ischemic stroke with large vessel occlusion.
61999587|NCT02431208|EXPERIMENTAL|Cohort A: ATZ (Run-In)|Cohort A will involve a safety run-in to evaluate atezolizumab administered as a single agent in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort has been completed.
62775244|NCT00695552|EXPERIMENTAL|1|Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
62775245|NCT00695552|PLACEBO_COMPARATOR|2|Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises.
62775246|NCT01116973|OTHER|CICC comparison with PICC|All patients will be having CVP reading taken from the CICC
61999588|NCT02431208|EXPERIMENTAL|Cohort B1: ATZ + LEN (Dose Escalation)|Cohort B1 will involve a dose escalation to evaluate atezolizumab administered in combination with ascending-dose lenalidomide in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort has been completed.
61999589|NCT02431208|EXPERIMENTAL|Cohort C: ATZ + LEN (Post-ASCT):|Cohort C will evaluate atezolizumab administered in combination with lenalidomide in participants with MM who have measureable disease after ASCT. NOTE: This cohort is closed to enrollment.
61999590|NCT02431208|EXPERIMENTAL|Cohort D1: ATZ + DAR (Run-in)|Cohort D1 will involve a safety run-in to evaluate atezolizumab administered in combination with daratumumab in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment.
62393668|NCT04576702|ACTIVE_COMPARATOR|licensed RIV4 group|RIV4 will be administered as a single dose intramuscularly on Day 1
62393669|NCT03196401|EXPERIMENTAL|Durvalumab Plus Radiation Therapy|Durvalumab (1500mg administered intravenously every 28 days), concurrently with definitive radiation therapy to the solitary bone plasmacytoma to start within 14 days of the first dose of durvalumab.
61999591|NCT02431208|EXPERIMENTAL|Cohort D2: ATZ + DAR (Expansion)|Cohort D2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab in participants with relapsed or refractory MM who have received 2 but no more than 3 lines of prior treatment that must have included a PI and IMiD and are refractory to the last line of treatment.
61999592|NCT02431208|EXPERIMENTAL|Cohort D3: ATZ + DAR (Progressed)|Cohort D3 will involve an expansion to evaluate atezolizumab in combination with daratumumab in participants with relapsed or refractory MM who have received 2 or more lines of prior treatment and have progressed with an anti-cluster of differentiation (CD) 38 monoclonal antibody, either alone or in combination, and are refractory to both a proteasome inhibitor (PI) and immunomodulatory drug (IMiD).
62393670|NCT06151821|EXPERIMENTAL|Group MTG|The intervention arm received Guided Meditation sessions
62393671|NCT06151821|NO_INTERVENTION|Group STG|The control arm received standard care without any Guided meditation sessions
62393672|NCT00920166|EXPERIMENTAL|Modilac Pétunia 1|Formula with reduced total protein concentration, enriched in alpha-lactalbumin and containing a symbiotic
62393673|NCT00920166|ACTIVE_COMPARATOR|Modilac 1|Regular milk
62393674|NCT01220024|EXPERIMENTAL|2, 5x5cm bupivacaine collagen sponges|collagen sponges
62393675|NCT01220024|PLACEBO_COMPARATOR|2, Placebo collagen sponges|Placebo collagen sponges
62568952|NCT01965756|EXPERIMENTAL|Metformin, Then Placebo|Participants first received metformin for 8 weeks, according to the following dosing schedule: 500 mg by mouth daily for 1 week, then daily dose (in divided doses) increased by 500 mg per week until a maximum of 2000 mg/d (1000mg twice daily) was reached. After 8 weeks, subjects were switched to matching placebo for an additional 8 weeks.
62393676|NCT04229342|ACTIVE_COMPARATOR|Conventional|"In the conventional group, standard posterior myotomy will be performed and the sling or the oblique fibers will not be spared beyond the gastroesophageal junction."
62393677|NCT04229342|EXPERIMENTAL|Oblique or sling fiber sparing group|In the oblique or sling fiber group, only the circular muscle fibers will be severed selectively and the sling fibers will be spared
62393678|NCT05984225|EXPERIMENTAL|Physiotherapy students|Physiotherapy students of the 2nd course of the Grade of Physiotherapy of the University of Valencia.
62393679|NCT03236701|NO_INTERVENTION|Control|usual diet
62393680|NCT03236701|EXPERIMENTAL|Intervention|egg white instead of meat or fish in two meals twice a week for three months
62393681|NCT04678804|EXPERIMENTAL|Matrix Graft Group|patients treated with Porcine Derived Volume Stable Matrix
62393682|NCT04678804|OTHER|Autogenous ctg group|patients treated with autologous tissue
62393683|NCT04745052||Patients with acute ischemic stroke|The first is to verify the application effect of intravenous thrombolytic hemorrhage prediction models (HAT, SIT-sICH, THRIVE) in the population of acute ischemic stroke in Guangdong Province, and verify the clinical application effects of existing prediction models. Secondly, analyze the predictive value of clinical indicators, optimize HAT, SIT-sICH, and THRIVE scores, construct an improved HT prediction model, and optimize and improve the existing prediction model. The third is to apply the improved HT prediction model to the clinic, collect clinical data prospectively, evaluate the prediction effect of the model, and evaluate the clinical application effect of the improved prediction model.
62393684|NCT05507840|EXPERIMENTAL|Intervention|Near or infra red light provided by the Valeda machine will be applied in the intervention eye
62393685|NCT05507840|SHAM_COMPARATOR|Control|Light with very low intensity provided by the same Valeda machine will be applied in the control eye
62393686|NCT03445494|EXPERIMENTAL|Brace|After surgery the patient must wear the brace for 6 weeks, for the first 3 weeks during day and night and for the following 3 weeks only at night
62393687|NCT03445494|EXPERIMENTAL|Normal sling|After surgery the patient must wear the normal sling for two weeks
62393688|NCT03854552|EXPERIMENTAL|BI 764198|Single rising oral doses
62393689|NCT03854552|PLACEBO_COMPARATOR|Placebo|Single rising oral doses
62393690|NCT05461846|EXPERIMENTAL|Group (A)|The integrated neuromuscular inhibition technique (INIT) is a manual deactivation trigger points technique and includes the application of ischemic pressure and stretch, the muscle energy technique and the Strain-counterstrain technique.
62393691|NCT05461846|NO_INTERVENTION|Group (B)|control group
62393692|NCT05303051|EXPERIMENTAL|Study Population|The investigators will conduct an electronic medical record (EMR) query of individuals in the University of California, San Francisco (UCSF) primary care clinics without a prior diagnosis of DM and who are undergoing, or who have recently undergone, a lab measured HBA1c before or after 1 month of enrollment. sample size estimation for testing the estimated AUROC in the validation sample vs. the null value of AUC 0.7. The investigators will target an enrollment of 5006 subjects in order to obtain a pre-specified AUROC 95% confidence interval width of 0.07 (i.e. AUROC = 0.76 \[95%CI 0.725, 0.795\]). The investigators assume that \~4% of the cohort will have undiagnosed diabetes based on national prevalence estimates.
62393693|NCT05303051|EXPERIMENTAL|Alternative Sample Group|The investigators also aim to perform a sensitivity analysis to estimate the DNN performance in a target general population without a diabetes diagnosis. The investigators will recruit patients from the UCSF EHR system without a history of diabetes, no prior HBA1c measured, and no history of known diabetic risk factors. The investigators will target an enrollment of 1000 subjects in order to obtain a pre-specified AUROC 95% confidence interval width of 0.18 (i.e. AUROC = 0.76 \[95%CI 0.67, 0.85\]). The investigators assume that \~3% of the cohort will have undiagnosed diabetes based on national prevalence estimates.
62393694|NCT05185908||Group 1|The patients undergoing laparoscopic transperitoneal nephrectomy.
62393695|NCT06308796|EXPERIMENTAL|CaP + Fluoride|Irradiated head and neck cancer patients receiving topical CaP mousse to be applied at home (once a day for the first 3 months, then once a day for one week per month as maintenance), besides topical fluoride (F) in form of professional varnishes (every 6 months) and home products (once a day oral rinse with F mouthwash; three times a day toothpaste with brushing).
62393696|NCT06308796|NO_INTERVENTION|Only fluoride|Irradiated head and neck cancer patients receiving only topical fluoride (F) in form of professional varnishes (every 6 months) and home products (once a day oral rinse with F mouthwash; three times a day toothpaste with brushing). Topical fluoride is included in the standard of care, according to national and international guidelines.
62393697|NCT03440398|ACTIVE_COMPARATOR|Open NSM|Conventional Nipple Sparing Mastectomy
62775247|NCT01116973|OTHER|PICC group|The transition to the PICC, a 5.0-French, 18-gauge double lumen PICC (BARD, Power PICC Solo Catheter with Tip Location Stylet; Salt Lake City, UT) will be inserted
62791656|NCT04633928|EXPERIMENTAL|N-TEC|N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membranes for about 2 weeks to allow cells to produce extracellular matrix containing cartilage specific proteins. The tissue engineered graft is then implanted in the nasal septum in an interposition graft with a temporoparietal fascia flap.
62393698|NCT03440398|EXPERIMENTAL|Robotic NSM|Robotic Nipple-Sparing Mastectomy
62393699|NCT00565721|EXPERIMENTAL|Fluciclatide Injection - (AH111585 (F18))|Using of the drug product named, AH111585 (F18) Injection. It's generic chemical name is Fluciclatide.
62393700|NCT04559048||FK506-treated group|In FK506-treated group, the patients who underwent liver transplant are treated with FK506 immunosuppressive therapy.
62393701|NCT04559048||control group without FK506 treatment|In control group, the patients who underwent liver transplant are treated without FK506.
62775248|NCT01142427||Ancillary-Correlative (classification)|Patients undergo blood sample collection and bone marrow biopsies at baseline and during and after induction therapy for immunophenotyping for ALL confirmation and classification, DNA ploidy, genomic variation, and cytogenetic (BCR-ABL, trisomies 4+10, and molecular testing for translocations) analysis by flow cytometry and FISH. Immunophenotype results obtained on this study are used to determine patient's assignment to specific clinical-trial treatments. Some samples (leukemic and germline) may be banked for current and/or future analyses.
62775249|NCT00911339|ACTIVE_COMPARATOR|Atorvastatin 10 mg|
61999593|NCT02431208|EXPERIMENTAL|Cohort E1: ATZ + DAR + LEN (Dose Escalation)|Cohort E1 will involve a dose escalation to evaluate atezolizumab administered in combination with daratumumab and ascending-dose lenalidomide in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort is closed to enrollment.
62393702|NCT04658511|EXPERIMENTAL|Participants|Patients diagnosed with cubital tunnel syndrome who are being scheduled for a primary endoscopic cubital tunnel release by the principle investigator will be recruited
62393703|NCT04889989|OTHER|Microwave Ablation of Lung Tumor|Adult patients with non-small cell lung cancer (NSCLC) or oligometastatic lung tumors who plan to receive percutaneous microwave ablation.
62393704|NCT05006404|EXPERIMENTAL|Autus Valve Arm|Pulmonary Valve Replacement Surgery with the Autus Valve
62393705|NCT04984668|EXPERIMENTAL|GT90001+KN046|"GT90001, 100 mg/10 mL/vial. GT90001 will be administered via intravenous infusion (IV) for around 60 minutes, once every 2 weeks (Q2W) in each 14-day cycle.~KN046, 40 mg/1.6 mL/vial, 300 mg/12 mL/vial KN046 will be administered via intravenous infusion (IV) for at least 120 minutes (up to 4h for the first 6 cycles), once every 2 weeks (Q2W) in each 14-day cycle, after 60 minutes post the GT90001 taken."
62393706|NCT04350749|EXPERIMENTAL|Test group (PRF group)|PRF membrane is added to the bone block to evaluate if any effect on bone healing, soft healing, post-operativ pain
62393707|NCT04350749|ACTIVE_COMPARATOR|Control group (Standard operation)|A standard bone augmentation procedure, which is weel-described is performed to compare the outcome of the test group
62393708|NCT05359094|PLACEBO_COMPARATOR|Placebo|Placebo
62393709|NCT05359094|ACTIVE_COMPARATOR|Probiotics|Probiotics
62393710|NCT01858675|EXPERIMENTAL|Biomarkers, total blood volume|
62393711|NCT01836900|ACTIVE_COMPARATOR|Standard Therapy|Endoscopic therapy with Standard Clip + injection of epinephrine solution or thermal therapy + injection of epinephrin-solution
62393712|NCT01836900|EXPERIMENTAL|OTSC (Over The Scope Clip)|Endoscopic therapy with Application of OTSC Clip and Injection of epinephrin-solution
62393713|NCT00517166||A|Individuals on whom tourniquet was used.
62393714|NCT03923062|EXPERIMENTAL|G I A (right side): will be treated by chemical peeling|right sideof patient's face will be treated by chemical peeling( Trichloroacetic acid 20% concentration).
62393715|NCT03923062|EXPERIMENTAL|G I B(left side):will be treated by cryopeeling|left side of the patient's face will be treated by cryopeeling using Liquid Nitrogen.
62393716|NCT03923062|EXPERIMENTAL|G II A (right side): will be treated by chemical peeling|right sideof patient's face will be treated by chemical peeling( Trichloroacetic acid 20% concentration).
62393717|NCT03923062|EXPERIMENTAL|G II B (left side):will be treated by tranexemic acid|left side of patient's face will be treated by tranexemic acid(cyclokapron)
62393718|NCT02492321|ACTIVE_COMPARATOR|EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day
62393719|NCT02492321|PLACEBO_COMPARATOR|Vehicle|Placebo Comparator: One of two study arms: placebo topical administered 3 times per day
62775250|NCT00911339|ACTIVE_COMPARATOR|Atorvastatin 80 mg|
62393720|NCT04275024|EXPERIMENTAL|Experimental group|"AD-MSCs: adipose-derived multipotent mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg of body weight at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks.~The basic treatment is oral PSORI-CM01 Granule plus calcipotriol ointment (Dovonex;LEO Laboratories Ltd, Ireland) for topical use twice daily for 12 weeks."
62393721|NCT06347523|EXPERIMENTAL|experimental group|The experimental group will receive an enhanced preoperative rehabilitation program incorporating Virtual Reality (VR) technology
62791657|NCT04579159|OTHER|only control group|To investigate the specificity of the wearable and to gather more information on ECG abnormalities in the population studied, a randomly selected group of participants without wearable-detected AA within 8 weeks of screening (same number as screen-positives and verified by Telecare) will also be invited to obtain a 14day Tele ECG (patch).
62393722|NCT06347523|ACTIVE_COMPARATOR|control group|The control group will receive standard nursing care.
62393723|NCT05472168|OTHER|Obese|Age 18-55 years Obesity (BMI ≥30 kg/m2) Written informed consent Normosmia (defined by sniffing Sticks test)
62393724|NCT05472168|OTHER|Lean|Age 18-55 years Lean (BMI 18-25 kg/m2) Written informed consent Normosmia (defined by sniffing Sticks test)
62393725|NCT01826305|ACTIVE_COMPARATOR|Formal Rehabilitation Therapy|Patients randomized to the formal rehabilitation therapy cohort will receive a prescription for therapy for twelve weeks following their primary knee replacement.
62393726|NCT01826305|EXPERIMENTAL|Independent Exercise Cohort|Patients randomized to the independent exercise cohort will receive online access to a twelve-week protocol of exercises to perform at home to strengthen and improve function of the replaced knee.
62393727|NCT00285857|EXPERIMENTAL|Lovastatin 80 mg/day|Lovastatin 80 mg/day as 40 mg orally twice daily, for 6 months.
62393728|NCT05910606|EXPERIMENTAL|Exercise Intervention|Digitally delivered strength, balance and postural control exercises
62393729|NCT00804323|EXPERIMENTAL|Group 1|Patients with open-angle glaucoma
62568953|NCT01965756|EXPERIMENTAL|Placebo, Then Metformin|Participants first received placebo for 8 weeks. After 8 weeks, subjects were switched to metformin, according to the following dosing schedule: 500 mg by mouth daily for 1 week, then daily dose (in divided doses) increased by 500 mg per week until a maximum of 2000 mg/d (1000mg twice daily) was reached.
62775251|NCT03543943|EXPERIMENTAL|Individualized treatment|The ruptured achilles tendon is examined by ultrasonography. If the overlap of the tendon ends is less than 25 % or the tendon is elongated 7 % or more the patient receives conventional open operative treatment. The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below the knee cast after surgery. The ankle is held at maximal plantar flexion. Weight bearing is not allowed. After 3 weeks the cast is removed and the injured leg is transferred to a functional brace with 3 heel wedges. The patient will follow standard functional rehabilitation and the follow-up evaluations.
62775252|NCT03543943|ACTIVE_COMPARATOR|Control group 1|For the patients allocated to non-operative treatment the injured leg is placed in a circulated below the knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle. The patient will follow standard functional rehabilitation and the follow-up evaluations.
62775253|NCT03543943|ACTIVE_COMPARATOR|Control group 2|The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below the knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle. The patient will follow standard functional rehabilitation and the follow-up evaluations.
62775254|NCT00653081|ACTIVE_COMPARATOR|A|Supervised Exercises performed at ulleval Hospital for patients with shoulder pain. Dosage: 45 minutes each time, max 2-3 times a week in max 12 weeks
62775255|NCT00653081|ACTIVE_COMPARATOR|B|Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
62775256|NCT00651365|EXPERIMENTAL|001|
61999594|NCT02431208|EXPERIMENTAL|Cohort E2: ATZ + DAR + LEN (Expansion)|Cohort E2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab and the maximum tolerated dose (MTD) of lenalidomide determined in Cohort E1 in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort is closed to enrollment.
61999595|NCT02431208|EXPERIMENTAL|Cohort F1: ATZ + DAR + POM (Dose Escalation)|Cohort F1 will involve a dose escalation to evaluate atezolizumab administered in combination with daratumumab and ascending-dose pomalidomide in participants with relapsed or refractory MM who have received 4 or more lines of prior treatment and are refractory to the last line of treatment. NOTE: This cohort has been completed.
61999596|NCT02431208|ACTIVE_COMPARATOR|Cohort F2: ATZ + DAR + POM (Expansion)|Cohort F2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab and the MTD of pomalidomide determined in Cohort F1 in participants with relapsed or refractory MM who have received 4 or more lines of prior treatment and are refractory to the last line of treatment. NOTE: This cohort is randomized.
61999597|NCT02431208|ACTIVE_COMPARATOR|Cohort F3: DAR + POM + Dexamethasone|Cohort F3 is an expansion control arm for cohort F2. Participants will receive daratumumab in combination with pomalidomide at the MTD and dexamethasone. NOTE: This cohort is randomized.
61999598|NCT02619695|EXPERIMENTAL|Ketoprofen|Interventional arm: ketoprofen gel 2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
61999599|NCT02619695|PLACEBO_COMPARATOR|Placebo|Placebo arm: placebo gel form of ketoprofen
61999600|NCT04751591|EXPERIMENTAL|Endoscopic resection|The endoscopist will perform endoscopic resection for patients enrolled in this group.
62393730|NCT04752111|EXPERIMENTAL|Group E (esmolol infusion)|10 minutes before induction of anesthesia the patients will receive a loading dose of injection esmolol 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery After induction of anesthesia and before starting the surgery, patients will receive bilateral in-plane ultrasound guided transversus abdominis plane block with 40 ml of bupivacaine 0. 25% after induction of anesthesia 20 ml in each side .
62393731|NCT04752111|PLACEBO_COMPARATOR|Group T (TAP block)|10 minutes before induction of anesthesia the patients will receive a loading dose of injection 30 ml isotonic saline in the iv line, followed by an IV infusion of saline at a rate of 0.05 mg/kg/min till the completion of surgery After induction of anesthesia and before starting the surgery, patients will receive bilateral in-plane ultrasound guided transversus abdominis plane block with 40 ml of bupivacaine 0. 25% after induction of anesthesia 20 ml in each side.
62393732|NCT00719511|EXPERIMENTAL|1|Patch allergen dose 1
62393733|NCT00719511|EXPERIMENTAL|2|Patch allergen dose 2
62584765|NCT04637581|NO_INTERVENTION|treatment-as-usual|"The treatment-as-usual group will receive a packet of local services and referral contacts and treatment as usual as directed by any healthcare providers working with the family. The project team will contact treatment-as-usual families on a monthly basis to confirm any services the family may be receiving, provide reminders of scheduled assessment dates, and give small incentives ($10 gift card) when families report changes in contact information to reduce risk for loss to follow-up."
61999601|NCT04751591|OTHER|Laparoscopic partial gastrectomy|The endoscopist will perform laparoscopic partial gastrectomy for patients enrolled in this group.
62185058|NCT04105062|EXPERIMENTAL|Phase I: LS301 Dose Level 3 (0.1 mg/kg)|"* The patient will undergo intravenous injection of LS301 4-24 hours prior to surgery.~* The operating surgeon will conduct surgery as usual without using a device to visualize LS301 fluorescence. To prevent bias in data acquisition, a second surgeon will wear the CVG at the completion of the surgery to examine the excised tissue at the surgical margins and the surgical resection bed.~* The operating surgeon will remain blinded to the fluorescence images throughout the operation. The examining surgeon will wear the CVG and image all six anatomical aspects (superior, inferior, anterior, posterior, medial and lateral) of the surgical specimen as well as the surgical cavity for LS301 fluorescence."
62393734|NCT00719511|EXPERIMENTAL|3|Patch allergen dose 3
62775257|NCT05718960|PLACEBO_COMPARATOR|Reassurance-alone|
62775258|NCT05718960|ACTIVE_COMPARATOR|Traditional Dietary Advice|
61999602|NCT06103006|EXPERIMENTAL|Telerehabilitation Group|Participants in this group will receive telerehabilitation exercises.
62775259|NCT04708860|EXPERIMENTAL|Prolonged Nightly Fasting Plus Exercise|"Participants will be grouped into two cohorts determined by whether they receive palbociclib or alpelisib as part of their breast cancer treatment and then receive a 12 week prolonged nightly fasting plus exercise program consisting of:~* Prolonged overnight fasting: Not consume any calorie-containing food/drinks after 8pm, waiting a minimum of 13 hours after their last meal of the day before eating the next day, target goal of fasting at least 6 days a week, daily record of first and last meals~* Exercise Program: Coach provided at-home, personalized exercise regimen with target goal of 120 minutes of moderate-intensity aerobic activity each week as well as two 30-45-minute virtual strength training classes per week, receive fitbit for exercise and heart rate monitoring, weekly telephone-based support sessions with coach."
62393735|NCT00719511|EXPERIMENTAL|4|Placebo
62393736|NCT02985996|NO_INTERVENTION|Phase I/Pre-Drug|Ten participants will be asked to complete study phase 1. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
62393737|NCT02985996|EXPERIMENTAL|Phase II/Genvoya|Participants will receive one dose Genvoya. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
62393738|NCT02985996|EXPERIMENTAL|Phase II/Truvada|Participants will receive one dose of Truvada. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
62775260|NCT03180307|SHAM_COMPARATOR|no fluorescent imaging|Patient injected with OTL38, but does not undergo fluorescent imaging
62775261|NCT03180307|EXPERIMENTAL|near infrared imaging arm|Patient injected with OTL38 and undergoes near infrared imaging
62775262|NCT01702506|EXPERIMENTAL|Fasted|Dacomitinib administered under fasted conditions
62775263|NCT01702506|EXPERIMENTAL|Fed|Dacomitinib administered under fed conditions
61977774|NCT05361993|EXPERIMENTAL|Biofeedback therapy|three times a week, every other day interval, 30 minutes each time, each subject received 20 biofeedback training (using the Infiniti3000A biofeedback system Patients in the theta group decreased the theta amplitude at Cz. Patients in the theta group received positive feedback when their theta activity was below the feedback threshold.
61999603|NCT02241499|EXPERIMENTAL|Radiotherapy and chemotherapy (oxaliplatin and fluorouracil).|Radiotherapy (5 x 4 Gy) will be given. After completion of radiotherapy, 4 cycles of chemotherapy will be administered, cycle length 14 days. Each patient will receive oxaliplatin as infusion at a dose of 85 mg/m2, followed by a bolus injection of fluorouracil at a dose of 400 mg/m2, and a long time infusion (44 hours) of fluorouracil at a dose of 2 400 mg/m2.
61999604|NCT02489175|EXPERIMENTAL|Stomaplasty KoringTM group|The KoringTM is a stomaplasty ring made of propylene, flexible and non-absorbable. It is fixed to the anterior sheath of the abdominal wall in order to prevent PSH.
61999605|NCT02489175|NO_INTERVENTION|No preventive measure|In these patients, the stoma creation will be traditional, with no mesh implanted
61999606|NCT02315638||Dosed subjects|There is no intervention. This is a observational study monitoring subjects that were dosed with TT-034 in the Tacere B2801001 study,
62185059|NCT04105062|EXPERIMENTAL|Phase II: LS301 Dose determined in Phase I|"* The patient will undergo intravenous injection of LS301 4-24 hours prior to surgery.~* The operating surgeon will conduct surgery as usual without using a device to visualize LS301 fluorescence. To prevent bias in data acquisition, a second surgeon will wear the CVG at the completion of the surgery to examine the excised tissue at the surgical margins and the surgical resection bed.~* The operating surgeon will remain blinded to the fluorescence images throughout the operation. The examining surgeon will wear the CVG and image all six anatomical aspects (superior, inferior, anterior, posterior, medial and lateral) of the surgical specimen as well as the surgical cavity for LS301 fluorescence."
62393739|NCT02985996|EXPERIMENTAL|Phase III/Genvoya|Participants will receive Genvoya once daily for ten days. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
62393740|NCT02985996|EXPERIMENTAL|Phase III/Truvada|Participants will receive Truvada once daily for ten days. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
62393741|NCT04832243|EXPERIMENTAL|Experimental: V1: List No. 1|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. The first version of the questionnaire includes 6 sets of 3 true-false statements that are innocuous and contextually applicable (e.g., weather, cultural norms) such that there is a low likelihood that the participant will answer untruthfully. The statements on food and water insecurity that are included in the experimental version are omitted."
62393742|NCT04832243|EXPERIMENTAL|Experimental: V2: List No. 2|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. The second version of the questionnaire includes 6 sets of 4 true-false statements that are innocuous and contextually applicable (e.g., weather, cultural norms) such that there is a low likelihood that the participant will answer untruthfully for 3 of the true-false statements. One statement in each set relates to food and water insecurity and is designed to determine the extent to which social desirability bias may influence responses to food and water insecurity questions."
62393743|NCT04346017|EXPERIMENTAL|Ventilation support|The experimental group will include Covid-19 infected patients with non-invasive or invasive ventilation support (BCRSS score ≥3).
62393744|NCT04346017|OTHER|Control group|The control group will include Covid-19 infected patients who don't have respiratory problems justifying a transfer to intensive care.
62775264|NCT01702506|EXPERIMENTAL|Antacid|Dacomitinib administered under antacid treatment
62775265|NCT03330470|EXPERIMENTAL|exercise and carnosine supplementation|exercise: participants will be subjected to 3 months supervised exercise intervention carnosine supplementation: participants will be instructed to take carnosine 2 times daily
61999607|NCT01069055|PLACEBO_COMPARATOR|Placebo Control|Group I (Placebo Control) 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.
61999608|NCT01069055|ACTIVE_COMPARATOR|Lornoxicam|Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
61999609|NCT01069055|ACTIVE_COMPARATOR|Paracetamol|Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
61999610|NCT06496126|EXPERIMENTAL|Cerasmart 270 (GC Coop, Tokyo, Japonya)|Composition: Bis-MEPP, UDMA, dimethacrylate, silica (20 nm), barium glass (300 nm) 71 wt% Tooth measurement and digital design are done using a camera. The design is sent to a milling device for restoration fabrication. Tooth surface is roughened with 37% orthophosphoric acid for 10 seconds, air dried, and Adhesive Primer is applied. Inner surface of the endocrown restoration is sandblasted with aluminum oxide powder, cleaned with alcohol, and coated with Adhesive Primer. CEM ONE self-adhesive resin cement is applied to the tooth surface, and the restoration is cemented.Final polymerization process lasts 10 seconds per surface to ensure bonding.Rough edges of the restoration are polished with diamond burs and discs. Excess material is removed, and occlusion and tooth areas are checked.Any cement residues in the mouth are carefully cleaned.
61999611|NCT06496126|EXPERIMENTAL|EverX Flow (GC Coop, Tokyo, Japonya)|Resin: semi-IPN matrix composed of Bis-GMA, TEGDMA and PMMA. Fillers: E-glass fiber, barium borosilicate (57 vol%) After cavity preparation, 37% phosphoric acid gel will be applied to the enamel for 30 seconds, washed with water and dried slightly. G-Premio Bond adhesive agent (GC, Tokyo, Japan) is applied to the enamel and dentin surfaces with a disposable applicator for 20 seconds and waited for 10 seconds according to the manufacturer's recommendations. Then, air is squeezed with light air pressure for 5 seconds and polymerised with LED light at 1200 mW/cm2 for 10 seconds. The restoration walls are formed with composite G-ænial™ A'CHORD (GC, Tokyo, Japan). EverX Flow composite (GC, Tokyo, Japan) is applied to the cavities in 4 mm layers and polymerised with light for 10 seconds. G-ænial™ A'CHORD (GC, Tokyo, Japan) composite is applied on the top layer. It is shaped with finishing cutters and polished with polishing rubbers.
62775266|NCT03330470|EXPERIMENTAL|exercise and supplementation with placebo|exercise: participants will be subjected to 3 months supervised exercise intervention supplementation with placebo: participants will be instructed to take placebo 2 times daily
62775267|NCT03330470|EXPERIMENTAL|stretching controls and carnosine supplementation|stretching controls: participants will be subjected to 3 months supervised stretching program carnosine supplementation: participants will be instructed to take carnosine 2 times daily
62775268|NCT03330470|EXPERIMENTAL|stretching controls and supplementation with placebo|stretching controls: participants will be subjected to 3 months supervised stretching program supplementation with placebo: participants will be instructed to take placebo 2 times daily
62775269|NCT05817032|EXPERIMENTAL|Telerehabilitation group|Baseline measurement will be done in the rehabilitation center. Prescription for rehabilitation will be determined based on the result of baseline measurement. Participants will receive rehabilitation intervention that include telerehabilitation (video conference regular meeting, text message reminder, and mobile app). Participants will attend a regular check up at the center once a month. After 12 weeks post intervention measurement will be taken.
62775270|NCT05817032|ACTIVE_COMPARATOR|Control group|Baseline measurement will be done in the rehabilitation center. Prescription for rehabilitation will be determined based on the result of baseline measurement. Participants will be given instruction how to do proper exercise training at home. Participants will attend a regular check up at the center once a month. After 12 weeks post intervention measurement will be taken.
62775271|NCT04472312||Cirrhotic patients undergoing a liver transplantation|The investigators aim to conduct a prospective observational, non-interventional study including all cirrhotic patients undergoing a liver transplantation with a planned use of vasopressin during the surgery.
62775272|NCT01431963|EXPERIMENTAL|Lamotrigine|No comparison.
62775273|NCT01108198|ACTIVE_COMPARATOR|mometasone furoate cream|The study patient consecutive patients who were referred to outpatient clinic of Pediatric surgery for surgical treatment of non-retractable foreskin. The study patients were randomized to have either mometasone cream or placebo
62775274|NCT01108198|PLACEBO_COMPARATOR|moisturizer|
62775275|NCT01735370|EXPERIMENTAL|Etodolac Tablets USP 500mg|Etodolac Tablets USP 500 mg of Ipca Laboratories Limited, India
62775276|NCT01735370|ACTIVE_COMPARATOR|Etodolac Tablets USP 500 mg|Etodolac Tablets USP 500 mg of Taro Pharmaceutical Industries Ltd., USA
62775277|NCT04631965||Cohort in Finland|253 young patients who attend clinics in Finland with no hospital-wide transition support service available
62775278|NCT04631965||Cohort in Australia|250 young patients who attend clinics in Victoria, Australia and who have received support from a hospital-wide transition support service
62775279|NCT00988364|ACTIVE_COMPARATOR|Ezetimibe|Randomly chosen participants will receive ezetimibe 10mg daily for 3 months.
62775280|NCT00988364|ACTIVE_COMPARATOR|Simvastatin|Randomly chosen participants will receive Simvastatin 20mg daily for 3 months.
62775281|NCT00988364|ACTIVE_COMPARATOR|Vytorin|Randomly chosen participants will receive Vytorin 20/10mg daily for 3 months.
62775282|NCT00988364|PLACEBO_COMPARATOR|Placebo|Randomly chosen participants will receive Placebo tab 1 daily for 3 months.
61999612|NCT04712604|EXPERIMENTAL|MSOS Group|The participants in this group will receive the MSOS Intervention for 4 consecutive weeks.
62393745|NCT03350763|EXPERIMENTAL|Plastic biliary stent|A plastic (ie Tannenbaum 10 Fr) biliary stent is used to achieve biliary decompression
62584766|NCT02582450||Patients with haemophilia|Sample of patients with haemophilia over 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
62584767|NCT04559438|EXPERIMENTAL|Rotary Neoniti GPS|Glide path preparation using Rotary Neoniti GPS file (Neolix, châtres-la-Forêt, France).
62775283|NCT04194814|OTHER|crisaborole and topical Corticosteroid|"crisaborole (2%) ointment on the other forearm, twice daily application for 4 weeks (randomised site allocation)~betamethasone valerate (0.1%) cream on one forearm, twice daily application for 4 weeks (randomised site allocation)"
62775284|NCT01970059|EXPERIMENTAL|Extended-Release Carvedilol Sulfate|18-72mg/d,po
62775285|NCT01970059|ACTIVE_COMPARATOR|Sustained-release Metoprolol Succinate|47.5-190mg/d,po
62775286|NCT03125460||Initial Enrollment|Initial enrollment of patients with history of bladder cancer
62775287|NCT03125460||Longitudinal Cohort|Longitudinal Cohort - patients considered anticipatory positive at the time of enrollment and one random disease negative patient per anticipatory positive patient
62775288|NCT01179165||Type 2 diabetes age 40-75|Only one diagnostic/observational group
62775289|NCT01675362|PLACEBO_COMPARATOR|Control group|They will receive placebo
62775290|NCT01675362|ACTIVE_COMPARATOR|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
61999613|NCT02484495|EXPERIMENTAL|Program evaluation in intervention areas|"A quasi-experimental matched-control cluster design will be used in which outcomes are compared in intervention and non-intervention areas. The program evaluation will have three points of data collection to assess effect of the program on the nutritional status of children 6-29 months. Sixty intervention clusters have been purposively selected whereas the data will be collected from randomly selected subjects. The following interventions will be provided:~* Processed complementary food rations will be distributed to all children 6-23 months of age, from a grain bank based on bartering of raw materials.~* Monthly 15 sachets of MNP will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification."
62185060|NCT00665132|EXPERIMENTAL|StimRouter (SR) for CTS|Percutaneous implantation of StimRouter System
62185061|NCT02836041||Pediatrics cancer patients|Eligible patients will be approached for enrollment after their first night in the hospital (i.e.: not on day of admission). Patient/parent will be asked to complete a brief questionnaire describing the child's general sleep habits prior to admission. The parent and/or child will then be asked to complete a questionnaire describing sleep while in the hospital; this in-hospital sleep questionnaire will be obtained for 3 consecutive nights after enrollment, or until discharge, whichever is soonest. A subgroup of patients (between the ages of 5 and 18) will be invited to participate in an additional aspect of the study, where they wear an actigraph (a small device that looks like a watch) for up to 72 hours. This device reliably measures sleep by monitoring the child's motion. This will be used to relate sleep perception to more objective measures of sleep as provided by actigraphy.
62185062|NCT04287140|EXPERIMENTAL|Saline|1000 ml of 0.9% normal saline bolus over one hour.
62393746|NCT03350763|EXPERIMENTAL|Self-expandable metallic biliary stent|A self-expandable metallic biliary stent is used to achieve biliary decompression
62393747|NCT02120274|NO_INTERVENTION|Control|Pegylated Interferon-Alfa plus ribavirin for 48 weeks
62393748|NCT02120274|EXPERIMENTAL|Vitamins|Pegylated Interferon-Alfa plus ribavirin for 48 weeks together oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level. Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
62568954|NCT01836731|EXPERIMENTAL|Classic Intervention|"The standard classic approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones."
62584768|NCT04559438|ACTIVE_COMPARATOR|Stainless steel K-files|Glide path preparation using manual stainless steel K-files #10, #15 (Dentsply Maillefer, Ballaigues, Switzerland).
62584769|NCT01415817|NO_INTERVENTION|Baseline Data collection|
62775291|NCT01675362|ACTIVE_COMPARATOR|Calcium channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
62775292|NCT01675362|ACTIVE_COMPARATOR|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
62775293|NCT01086176||Patient-control|
62393749|NCT00957827|EXPERIMENTAL|keflex|keflex 500mg twice a day for five days
62393750|NCT00957827|PLACEBO_COMPARATOR|placebo|placebo 500mg twice a day for five days
62393751|NCT05566366|OTHER|population who lost a loved one during the COVID19 health crisis|"Analyze the grieving process of people who have lost a close first degree relative, understand the impact of death conditions on this process and model a theory of mourning in the context of the actual epidemic health crisis."
62775294|NCT02660892|EXPERIMENTAL|Protein Intake|Threonine intake - Dietary supplement
62775295|NCT04794881|EXPERIMENTAL|24 hours|Newborn infants in this group will undergo repeat lumbar puncture at 24 hours after a traumatic lumbar puncture
62185063|NCT04287140|NO_INTERVENTION|No Saline|10 ml of 0.9% normal saline over one hour.
62185064|NCT00870532|EXPERIMENTAL|1|60 mg/week of vinorelbine + sorafenib
62185065|NCT00870532|EXPERIMENTAL|2|90 mg/week of vinorelbine + sorafenib
62185066|NCT00870532|EXPERIMENTAL|3|120 mg/week of vinorelbine + sorafenib
62393752|NCT04606862|EXPERIMENTAL|Investigational Arm|The patients enrolled into the investigational arm at each participating hospital will be monitored with the Morley Medical Sepsis (MMS) Software Device for the prediction and early identification of sepsis.
61977775|NCT05361993|ACTIVE_COMPARATOR|Drug therapy|Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
62185067|NCT02475876|OTHER|clindamycin|Each subject will be assigned to study drug (clindamycin or TMP-SMX) at the discretion of the treating clinician. The dose and dosing interval of study drug are dictated by this protocol (see interventions).
62185068|NCT02475876|OTHER|trimethoprim-sulfamethoxazole|Each subject will be assigned to study drug (clindamycin or TMP-SMX) at the discretion of the treating clinician. The dose and dosing interval of study drug are dictated by this protocol (see interventions).
62185069|NCT00900783|EXPERIMENTAL|2|FV-100, 400 mg once daily AND valacyclovir placebo, three times a day, for seven days
62185070|NCT00900783|ACTIVE_COMPARATOR|3|Valacyclovir, 1 gram, three times a day AND FV-100 placebo, once daily, for seven days
62393753|NCT04606862|NO_INTERVENTION|Control Arm|The patients enrolled into the control group of each participating hospital will not be monitored with the Morley Medical Sepsis (MMS) Software Device for the prediction and early identification of sepsis. These patients will be monitored according to each institution's standard sepsis screening practices.
62393754|NCT06724146|EXPERIMENTAL|Lax Tissue and Muscles|
62584770|NCT01415817|EXPERIMENTAL|Randomization and Training Arm|
62185071|NCT00900783|EXPERIMENTAL|1|FV-100, 200 mg once daily AND valacyclovir placebo, three times a day, for seven days
62584771|NCT01490073|ACTIVE_COMPARATOR|Active nitroglycerin ointment|
62584772|NCT01490073|PLACEBO_COMPARATOR|Placebo ointment|
62185072|NCT04571697||Participants Initiating Therapy with Methotrexate or Anti-TNF|Data will be collected for participants initiating therapy with either methotrexate or an anti-tumor necrosis factor (TNF) from united states (US) claims databases: optum de-identified clinformatics data mart database and IBM marketscan medicare supplemental database (MDCR). Data collection period: 01-Jan-2000 through 31-Jul2019.
62185073|NCT03585283|EXPERIMENTAL|Myofascial Group|Myofascial release will be applied by physiotherapist two times a week for four weeks which is a manual therapy technique includes stretching and compression of soft tissues according to fascial chains.Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
62185074|NCT03585283|SHAM_COMPARATOR|Sham Group|Sham application will be applied two times a week for four weeks. Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
62393755|NCT04022265|ACTIVE_COMPARATOR|Control Site -Drill site|The control sites (Drills) will be prepared with a lanceolate drill (FS 230, Sweden / Martina), with a maximum diameter of 2.3 mm,
62393756|NCT04022265|EXPERIMENTAL|Test site -sonic site|test sites will be prepared with conical diamond inserts of increasing diameter (SFS99.000.014 to SFS99.000.024, Komet-Brasseler-GmbH, Germany) mounted on a sonic-air surgical instrument
62393757|NCT02895074|EXPERIMENTAL|femtosecond laser-assisted cataract surgery group|
62393758|NCT02895074|EXPERIMENTAL|conventional phacoemulsification surgery group|
62393759|NCT02109965|ACTIVE_COMPARATOR|Control|Use midazolam or propofol for sedation
62393760|NCT02109965|EXPERIMENTAL|Dexmedetomidine|Use dexmedetomidine for sedation
62393761|NCT02815670|EXPERIMENTAL|Idarucizumab|
62393762|NCT00039377|EXPERIMENTAL|Treatment (imatinib mesylate, chemotherapy, PBSCT)|See Detailed Description.
62393763|NCT02625610|EXPERIMENTAL|Chemotherapy + Best Supportive Care (BSC)|In Maintenance Phase, participants continued the same regimen of oxaliplatin-fluoropyrimidine doublet chemotherapy (oxaliplatin + 5FU/LV or oxaliplatin + capecitabine) as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation. Participants who were not deemed eligible to receive chemotherapy at the dose and schedule specified above received BSC alone once every 3 weeks. BSC was defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and was based on Investigator's discretion.
62393764|NCT02625610|EXPERIMENTAL|Avelumab|In Maintenance phase, participants received avelumab as a 1-hour intravenous (IV) infusion at 10 milligrams per kilogram (mg/kg) once every 2-week treatment cycle until progressive disease or unacceptable toxicity or discontinuation.
62393765|NCT04531891|EXPERIMENTAL|All-out, high-intensity, intermittent exercise protocol|
62393766|NCT04531891|EXPERIMENTAL|5 min, high-intensity, intermittent exercise protocol|
62393767|NCT04780087||Weight lifting women|Experienced resistance exercise trained and pregnant women
62393768|NCT04780087||Reference women|Physically active pregnant women (not experienced with free weight lifting)
62393769|NCT02756195||Neonates receiving first-time non-cardiac surgery|No intervention will be administered. This is a prospective observational patient safety study focusing on the safety of care delivered to neonates in perioperative care settings. Neonates who receive NICU care both pre- and post-operatively will be eligible for this study.
62393770|NCT04052711|EXPERIMENTAL|FMX-101|
62393771|NCT04583410|EXPERIMENTAL|Nicotine patch|
62393772|NCT04583410|PLACEBO_COMPARATOR|Placebo patch|
62393773|NCT05937646|EXPERIMENTAL|EHR (Control), then AWARE|In this hour-long task, participants in this arm will first review and complete tasks using the institutional EHR. Then after an approximate 5 minute rest, participants will then review and complete tasks using AWARE.
62393774|NCT05937646|EXPERIMENTAL|AWARE Intervention, then EHR (Control)|In this hour-long task, participants in this arm will first review and complete tasks using the AWARE intervention. Then after an approximate 5 minute rest, participants will then review and complete tasks using the institutional EHR.
62393775|NCT04825639||Sepsis|"Patients admitted to PICU who are selected from registry based on primary diagnoses with codes for the following search codes were selected:~Sepsis is defined as per the International Consensus Conference pediatric sepsis definition (2005) \[citation 1\].~In silico analysis will be carried out in the sepsis cohort comparing admissions with Acute Kidney Injury (AKI) and those without AKI to identify factors associated with AKI.~In those selected admissions to PICU, information on Renal Function, Chloride levels, clinical outcome and medication use as well as fluid resuscitation will be collected from hospital online resources such as discharge summaries, results portal and the PICANet database. In addition the Paediatric Index of Mortality 3 severity of illness scores will be reported for all admissions.~Sepsis will be defined based on the International Pediatric Consensus Conference definition of sepsis (2005)"
62393776|NCT04825639||Diabetic Ketoacidosis (DKA)|"This group is defined based on the British Society of Paediatric Endocrinology and Diabetes.case definition for Diabetic Ketoacidosis \[citation 2\].~The data collected will be similar to the sepsis cohort. In silico analysis will be carried comparing those with AKI and without AKI in the DKA cohort."
62393777|NCT03516201||obese patients after bariatric surgery|obese adults (≥ 18 years) who underwent bariatric surgery
62393778|NCT03516201||obese adultes without bariatric surgery|obese adults (≥ 18 years) who did not underwent bariatric surgery at the time of the examination
62775296|NCT04794881|ACTIVE_COMPARATOR|48 hours|Newborn infants in this group will undergo repeat lumbar puncture at 48 hours after a traumatic lumbar puncture
62185075|NCT05988034|EXPERIMENTAL|Cohort 1: Avacopan|Participants will be randomized to receive multiple doses of avacopan orally twice daily (BID): 30 mg for 7 days and 100 mg for 7 days, for a total of 14 dosing days, and placebo for moxifloxacin on Days 1 and 15.
62185076|NCT05988034|ACTIVE_COMPARATOR|Cohort 2A: Moxifloxacin/Placebo|Participants will be randomized to receive moxifloxacin 400 mg orally on Day 1, placebo for avacopan BID on Days 1 to 14, and placebo for moxifloxacin on Day 15.
62185077|NCT05988034|ACTIVE_COMPARATOR|Cohort 2B: Placebo/Moxifloxacin|Participants will be randomized to receive placebo for moxifloxacin orally on Day 1, placebo for avacopan BID on Days 1 to 14, and moxifloxacin 400 mg orally on Day 15.
62185078|NCT05698329|EXPERIMENTAL|AIV007 low dose|Periocular injection, low dose
62185079|NCT05698329|EXPERIMENTAL|AIV007 intermediate dose 1|Periocular injection, intermediate dose 1
61999614|NCT02484495|NO_INTERVENTION|Non intervention areas|A quasi-experimental matched-control cluster design will be used in which outcomes will be compared in intervention and non-intervention clusters. The program evaluation will have three points of data collection to assess effect of the program on the nutritional status of children 6-29 months. Matching sixty non-intervention clusters have been purposively selected out of the predetermined non- intervention districts whereas study subjects will be randomly selected from the identified clusters on a population based sampling method both groups. These non-intervention areas do not get processed complementary food rations and do not receive MNPs.
61999615|NCT03588637||Study population|Patient who receive at least one dose of daptomycin
61999616|NCT03298828|EXPERIMENTAL|CD19 CAR|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19 CAR T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19 CAR T-cells.
62393779|NCT01199952|NO_INTERVENTION|Control|The control group will not receive a counseling phone call one month after enrollment.
62393780|NCT01199952|EXPERIMENTAL|Intervention|Intervention arm receives a counseling phone call 3 to 4 weeks after enrollment. The call is from a health educator intended to assist with contraception.
62393781|NCT00505765|EXPERIMENTAL|AL-108, 30 mg/day|AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
62393782|NCT00505765|EXPERIMENTAL|AL-108, 5 mg/day|AL-108, 5 mg/day- one spray in each nostril once per day
62393783|NCT00505765|PLACEBO_COMPARATOR|Placebo, 3 sprays BID|Placebo- 3 sprays in each nostril, twice per day
62393784|NCT00505765|PLACEBO_COMPARATOR|Placebo, 1 Spray Daily|Placebo- one spray in each nostril, once per day
62393785|NCT01310491|NO_INTERVENTION|Usual Care|
62393786|NCT05584917|EXPERIMENTAL|surgery patient|phone call after surgery to answer the tegner activity scale
62393787|NCT01700660||VIO|Patients operated under VIO.
62393788|NCT01700660||Control|Patients operated without VIO.
61977776|NCT01590238|EXPERIMENTAL|Treatment with PRFM|Subjects treated monthly 3 times with intradermal injections of PRFM into bald/balding scalp. Post-treatment hair density index measured and compared to hair density index measured prior to treatment for each subject.
62393789|NCT04681872|EXPERIMENTAL|Marshall Plan arm|Patients will undergo (1) the destruction of Marshall bundles by ethanol infusion followed by ablation of the distal coronary sinus bundles, the ridge and the saddle; (2) the standard pulmonary veins sleeves isolation; (3) and finally the ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
62393790|NCT04681872|ACTIVE_COMPARATOR|Pulmonary vein isolation arm|
62393791|NCT04839627||serum progesterone measurement|
62775297|NCT01311440|EXPERIMENTAL|Modified Atkins diet treatment|12 weeks of Modified Atkins diet treatment, recording seizures
62775298|NCT01311440|NO_INTERVENTION|No intervention|12 weeks seizure record
62775299|NCT05060965|EXPERIMENTAL|Cessation intervention|"All participants will receive nicotine replacement therapy and a referral to both Maryland Quitline and Johns Hopkins Tobacco Treatment Clinic for continued cessation care.~Nicotine replacement therapy: Nicoderm patches, gum, lozenges~* Low nicotine dependence: Lozenge (2 mg) or Gum (2 mg) or Patch (7 mg)~* Moderate nicotine dependence: Patch (14 mg) and Lozenge (2 mg) or Gum (2 mg)~* High nicotine dependence: Patch (21 mg) and Lozenge (4 mg) or Gum (4 mg)~Regardless of the level of nicotine addiction and subsequent dose of nicotine replacement therapy (NRT), participants of this trials are described as recipients of NRT products."
61999617|NCT03298828|EXPERIMENTAL|CD19 CAR and PD-1 knock out|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19 CAR and PD-1 knock out engineered T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19 CAR and PD-1 knock out engineered T-cells.
61999618|NCT05363735||Ultrasound Elastography|Patients will be examined by ultrasound elastography.
62393792|NCT02512120|EXPERIMENTAL|volume controlled ventilation|Randomized 23 patients will be applied VCV during RALP.
62393793|NCT02512120|ACTIVE_COMPARATOR|autoflow-volume controlled ventilation|Randomized 23 patients will be applied autoflow-VCV during RALP.
62393794|NCT03633461|ACTIVE_COMPARATOR|OC-02 (simpinicline) spray spray, 11.1 mg/ml|OC-02 (simpinicline) nasal spray, 11.1 mg/ml
62393795|NCT03633461|PLACEBO_COMPARATOR|Placebo|Placebo (vehicle) nasal spray
62393796|NCT02267460|ACTIVE_COMPARATOR|AA4500 with investigator modeling and vacuum therapy|AA4500 with investigator modeling and home use of the ErecAid® Esteem® Manual Vacuum Therapy System.
62393797|NCT02267460|ACTIVE_COMPARATOR|AA4500 without investigator modeling/with vacuum therapy|AA4500 without investigator modeling but with home use of the ErecAid® Esteem® Manual Vacuum Therapy System.
62393798|NCT02012257|EXPERIMENTAL|Anterior Site|AMSA nerve block injection
62393799|NCT02012257|EXPERIMENTAL|Common Site|AMSA nerve block injection
62393800|NCT02012257|EXPERIMENTAL|Posterior Site|AMSA nerve block injection
62393801|NCT01845129|EXPERIMENTAL|anodal tDCS|atDCS will be administered for 20 minutes with 1 milliampere (1 mA) to the left primary hand motor cortex
62393802|NCT01845129|SHAM_COMPARATOR|sham tDCS|sham tDCS will be administered to the left primary hand motor cortex
62393803|NCT05635695|ACTIVE_COMPARATOR|Free Museum visit|Free museum visit during 45 to 75 minutes
62393804|NCT05635695|EXPERIMENTAL|Cultural pathways App|Cultural pathways App during 45 to 75 minutes
62775300|NCT03164330|NO_INTERVENTION|Control|The control group takes a baseline survey, and thereafter has minimal interaction with the project, until a follow-up biometric screening is conducted during the one-year follow-up.
61999619|NCT06311383||First-line Ribociclib + endocrine therapy|Ribociclib + letrozole, or Ribociclib + anastrozole, or Ribociclib + exemestane, or Ribociclib + fulvestrant
61999620|NCT06311383||First-line endocrine therapy|As of physicians choice
61999621|NCT06311383||First-line chemotherapy|As of physicians choice
62393805|NCT01711073|EXPERIMENTAL|Mobilization with G-CSF plus Mozobil|Patients will receive G-CSF (Filgrastim) plus Mozobil (Plerixafor)
62393806|NCT01363232|EXPERIMENTAL|BKM120 + MEK162|
62393807|NCT03374982|EXPERIMENTAL|DentalVibe turned On then turned Off|DentalVibe will be turned on during local anesthetic injection at the first appointment. DentalVibe will be turned off during local anesthetic injection at the second appointment.
62393808|NCT03374982|EXPERIMENTAL|DentalVibe turned Off and then turned On|DentalVibe will be turned off during local anesthetic injection at the first appointment. DentalVibe will be turned on during local anesthetic injection at the second appointment.
62393809|NCT02534324||High SBP+antihypertensive meds|Patients with pre-discharge systolic blood pressure at discharge \< 180 mmHg
62393810|NCT02534324||Severely high SBP+antihypertensive meds|Patients with pre-discharge systolic blood pressure at discharge \>= 180 mmHg
62393811|NCT03708926|EXPERIMENTAL|abaloparatide|abaloparatide 80 mcg subcutaneously once daily for 90 days
62393812|NCT03708926|PLACEBO_COMPARATOR|placebo|placebo formulated similarly but without active abaloparatide injected subcutaneously once daily for 90 days
62393813|NCT06459635||Patients with episodic migraine|Patients with episodic migraine who present between 4 and 10 migraine attacks per month. These patients must have a diagnosis of migraine by a headache neurologist and according to the criteria proposed by ICHD-3. In addition, they must present at least 1 year of evolution of the migraine, as well as a normal neurological examination and have given their informed consent.
62393814|NCT06459635||Control patients|People who have never had a headache episode with migraine characteristics. These may present, at most, one episode per month of headache with non-migraine characteristics in the last 3 months. In turn, they should not have a family history of migraine (1st and 2nd degree).
62393815|NCT01639807|ACTIVE_COMPARATOR|latanoprost 2-8˚ C|latanoprost(0.005%)stored at 2-8˚ C
62393816|NCT01639807|EXPERIMENTAL|SLT|Selective laser Trabeculoplasty
62393817|NCT01661075||mTBI|These individuals will have had an mTBI during their respective collegiate athletic season.
62393818|NCT01661075||healthy controls|Recruitment of healthy controls who have not suffered an mTBI for balancing testing.
62393819|NCT05921942|NO_INTERVENTION|Group A|Patients will receive standard therapy FOLFOX/XELOX PROTOCOL
62393820|NCT05921942|ACTIVE_COMPARATOR|Group B|Patients will receive metformin (500 mg twice daily or 1000 mg once daily) in addition to standard therapy FOLFOX/XELOX PROTOCOL
62393821|NCT06152991|EXPERIMENTAL|Test Group|Oral administration of 2 capsules of Godex® three times a day (tid) for 96 weeks
62393822|NCT06152991|PLACEBO_COMPARATOR|Control Group|Oral administration of 2 placebo capsules three times a day (tid) for 96 weeks
62393823|NCT04138758||Patients initiating Tiotropium+Olodaterol therapy|
62393824|NCT04138758||Patients initiating Long-acting beta agonist/inhaled corticosteroid therapy|
61977777|NCT04018950|EXPERIMENTAL|ETX2514 and 14C-ETX2514|Participants will receive a single intravenous infusion of 1 gram non-labeled ETX2514 and 1 microCurie (µCi) of 14C-ETX2514 in normal saline, administered as a 3-hour infusion.
62393825|NCT00201682|EXPERIMENTAL|Arm I|Etanercept 25 mg administered sub-cutaneously twice weekly (Monday and Thursday) weeks 1-5 of therapy (total of 10 doses). The third dose of etanercept will be administered 1 hour prior to receiving rituximab. Rituximab: Patients will receive 375 mg/M2 of rituximab three times weekly for four weeks (a total of 12 doses of rituximab).
62393826|NCT06212960|EXPERIMENTAL|DWP712|Patients were intramuscularly injected (IM) with a total of 20U of DWP712 in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line.
62393827|NCT06212960|ACTIVE_COMPARATOR|Botox®|Patients were intramuscularly injected (IM) with a total of 20U of BOTOX® in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line.
62393828|NCT00450814|EXPERIMENTAL|Stage 1 (MV-NIS alone)|Patients receive MV-NIS IV over 1 hour on day 1. (Closed to accrual on 12/17/2009 and reopened 10/13/2011)
62393829|NCT00450814|EXPERIMENTAL|Stage 2 (MV-NIS and cyclophosphamide)|Patients receive cyclophosphamide IV over 30 minutes and then MV-NIS IV over 1 hour 2 days later. (Temporarily closed to accrual on 10/13/11)
62393830|NCT03189680|EXPERIMENTAL|Exercise therapy|Parkinson's disease group that receive 3 weeks of intensive exercise therapy in a rehabilitation center.
62393831|NCT03189680|NO_INTERVENTION|Control|Parkinson's disease control group that will not receive exercise treatment.
62393832|NCT03189680|NO_INTERVENTION|Healthy|A healthy group whose results will be compared with Parkinson's disease groups.
62393833|NCT06063382|EXPERIMENTAL|Standard time|40 minutes provided to complete the exam.
62393834|NCT06063382|EXPERIMENTAL|25% extra time|50 minutes provided to complete the exam.
62393835|NCT06063382|EXPERIMENTAL|50% extra time|60 minutes provided to complete the exam.
62393836|NCT04657809|EXPERIMENTAL|Insulin fast dissolving film|Formulated bioadhesive fast dissolving film contains 100IU of insulin
62393837|NCT04657809|PLACEBO_COMPARATOR|Plain fast dissolving film|Formulated bioadhesive fast dissolving film contains no drug
62393838|NCT01773850||Patients|Patients with a breast lesion undergoing surgical biopsy. All patients will undergo stationary Carbon Nanotube x-ray digital breast tomosynthesis imaging in addition to routine conventional digital mammography.
62393839|NCT05881590|EXPERIMENTAL|Hybrid pulmonary rehabilitation|
62393840|NCT01396811|EXPERIMENTAL|Active|Product 33525
61977778|NCT00815581|OTHER|photorefraction|
61999622|NCT05827627|OTHER|Pelvic simulator group (PSG)|The trainer positioned the foetus in the pelvic simulator in frank breech presentation. Descent of the baby in the pelvic simulator was administered by a person independent of the study and the training.
62185080|NCT05698329|EXPERIMENTAL|AIV007 intermediate dose 2|Periocular injection, intermediate dose 2
62393841|NCT01396811|PLACEBO_COMPARATOR|Placebo|Product 33525 Placebo
62393842|NCT01749696||Patients with pelvic organ prolapse|Patients, who were operated on because of pelvic organ prolapse.
62393843|NCT01749696||Patients without pelvic organ prolapse|Patients, who had hysterectomy due to other reasons than pelvic organ prolapse.
62393844|NCT04987684|OTHER|Standard of Care|
62393845|NCT00606463|EXPERIMENTAL|(Gen2 Cardiac Ablation System)|Ablation of isthmus-dependent atrial flutter
62393846|NCT04957706||Acute injury|injury ≤ 2 months
62185081|NCT05698329|EXPERIMENTAL|AIV007 intermediate dose 3|Periocular injection, intermediate dose 3
62185082|NCT05698329|EXPERIMENTAL|AIV007 intermediate dose 4|Periocular injection, intermediate dose 4
62185083|NCT05698329|EXPERIMENTAL|AIV007 High dose|Periocular injection, high dose
61977779|NCT02308852|ACTIVE_COMPARATOR|real tDCS|"Patients will receive non-invasive and painless brain stimulation over the brain areas involved in cognitive aptitudes.~tDCS will be applied during 20 minutes while patients will perform motor bimanual tasks"
61999623|NCT05827627|EXPERIMENTAL|Computer-based simulator group (CBSG)|The trainer positioned the foetus in the computer-based full-body childbirth simulator in frank breech presentation. The pregnancy simulator streamed audio to increase reality and the patient monitor displayed vital signs of the pregnant simulator and foetal heart rate.
62185084|NCT00963443|EXPERIMENTAL|Arm 1|
62568955|NCT01836731|EXPERIMENTAL|Minimum Intervention|"The lite trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers."
62568956|NCT01836731|NO_INTERVENTION|Control|"The control group is not enrolled in the CBEHPP.~Because of the government's commitment for the national roll out to the CBEHPP, the control population will receive the intervention as soon as possible following the conclusion of the trial phase. Nevertheless, we will continue to evaluate the sustained impact of the intervention for two additional years by monitoring various behavioural outcomes and indicators and their impact on exposure outcomes (drinking water, hand hygiene, consumption, schooling and labour market participation etc.). We will use data from the RCT phase and clinical records to estimate the effect of any sustained impact on health. Long term impacts can be inferred by using data from the trial as well as data on long term behavioural outcomes."
62775301|NCT03164330|EXPERIMENTAL|A25|"Group A25 is offered no compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - No compensation, Wellness Activities - low compensation"
62775302|NCT03164330|EXPERIMENTAL|A75|"Group A75 is offered no compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - No compensation, Wellness Activities - high compensation"
62775303|NCT03164330|EXPERIMENTAL|B25|"Group B25 is offered moderate compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - moderate compensation, Wellness Activities - high compensation"
61999624|NCT01886248|EXPERIMENTAL|Antithrombin-III Human 500IU|"Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU~Units required (IU)/kg = 50 + \[(desired-baseline AT-III level) x weight (kg) / 1.4\]"
61999625|NCT00952341|EXPERIMENTAL|Aprepitant (MK-0869)|
61999626|NCT00952341|PLACEBO_COMPARATOR|Standard Therapy|
61999627|NCT03566628|EXPERIMENTAL|Warmed Saline|Patients allocated to this arm will receive a warmed (39ºC) solution of up to 500mL of isotonic saline. This solution will be administered directly to the cerebral vasculature as part of the angiography.
61999628|NCT03566628|ACTIVE_COMPARATOR|Room-Temperature Saline|Patients allocated to this arm will receive isotonic saline at room temperature. This solution will be administered directly to the cerebral vasculature as part of the angiography.
61999629|NCT01890772|ACTIVE_COMPARATOR|VitD+telaprevir+peginterferon+ribavirin|Participants randomized to the treatment group will receive 5,000IU/day of vitamin D3 during the lead-in phase. When the serum 25(OH)D level is ≥35ng/ml the participant will begin telaprevir + vitamin D3 (15,000IU/week) + peginterferon alfa-2a (180ug/week) + weight based ribavirin treatment.
61999630|NCT01890772|ACTIVE_COMPARATOR|Telaprevir + Peginterferon + Ribavirin|Participants randomized to the control group immediately begin treatment with telaprevir + 180ug of peginterferon alfa-2a (Pegasys) per week and either weight based ribavirin.
61999631|NCT06486571|EXPERIMENTAL|All participants|
62185085|NCT00963443|ACTIVE_COMPARATOR|Arm 2|
62393847|NCT04957706||Chronic injury|injury \> 2 months
62393848|NCT01255449|EXPERIMENTAL|albuterol|Twenty-six consecutive patients undergoing allogeneic HSCT for hematological malignancies were studied. All patients were in stable clinical conditions at the time of study. All patients received a myeloablative conditioning regimen either including or not including total body irradiation. Spirometry, lung volumes, FOT and lung CT scan were obtained before the start of conditioning treatment and, approximately, two months after HSCT. On each study day, all the above measurements were taken before and 30 min after inhaling four consecutive albuterol doses, of 100 mcg each, through a valved-holding chamber. DLco was measured only after bronchodilator inhalation.
62393849|NCT03397472|EXPERIMENTAL|treatment group|use the sleep pillow with the magnetic field modulation treatment
62568957|NCT02143505|EXPERIMENTAL|Ca plus vit D|elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements for 3 years
62185086|NCT00963443|ACTIVE_COMPARATOR|Arm 3|
62185087|NCT00963443|PLACEBO_COMPARATOR|Arm 4|
62185088|NCT01827098|EXPERIMENTAL|Delayed induction|The root canal is disinfected and calcium hydroxide is placed in the canal. Blood clot is induced in the canal 4 weeks later. Endodontic Regeneration is performed.
62185089|NCT01827098|EXPERIMENTAL|Immediate Induction|Blood clot is induced after disinfection of the canal during the same visit. Endodontic regeneration is performed.
62185090|NCT06254755|EXPERIMENTAL|suction aspiration group|suction aspiration group is based on a large bore catheter for thrombus removal under negative pressure of pump or manual syringe.
62185091|NCT06254755|ACTIVE_COMPARATOR|combination group|combination group is based on a stent retrieval with a large bore catheter for thrombus removal under negative pressure of pump or manual syringe.
62185092|NCT00356993|EXPERIMENTAL|NRT + Behavioural Support|Nicotine Replacement Therapy plus Behavioural Intervention
62393850|NCT03397472|PLACEBO_COMPARATOR|placebo group|use the sleep pillow without magnetic field modulation treatment
61999632|NCT00301405|ACTIVE_COMPARATOR|Thalidomide|Open Label drug
61999633|NCT04269759||Pregnancy women|
62185093|NCT03122847||Patients|30 patients with Graves' ophthalmopathy in which treatment with intravenous methylprednisolone is indicated
62393851|NCT03937882|EXPERIMENTAL|RGN-259|RGN-259: It is a preservative-free, sterile eye drop solution containing Thymosin beta 4
62568958|NCT02143505|PLACEBO_COMPARATOR|placebo|identical-appearing placebo supplements for 3 years
62568959|NCT01104805|EXPERIMENTAL|Therapeutic Education System (TES)|Participants randomized to this arm will replace approximately 2 hours of Standard Treatment with the Therapeutic Education System (TES) (comprised of a web-based version of the Community Reinforcement Approach and contingency management).
62568960|NCT01104805|OTHER|Treatment-as-Usual (TAU)|Participants randomized to TAU will receive standard treatment offered and prescribed, as usual, in the outpatient substance abuse treatment program.
62568961|NCT00595920|EXPERIMENTAL|Tovaxin, open-label|Tovaxin; 30-45 million autologous myelin reactive T cells
62568962|NCT04086953|EXPERIMENTAL|Chronic Respiratory Disease Group|"Each patient receive the same intervention : 4 visits with different exercise tests.~Visit 1: Inclusion Visit, Functional Assessment and TTLM Speed Determination (6-minute walk test x2, cardiopulmonary exercise testing on ergocycle, questionnaires and accelerometer)~Visit 2 : Functional Evaluation and Shuttle Tests (ISWT, ESWT, Speed tests on 4m, Quadriceps muscle strength)~Visit 3 : Feasibility of the WTLT (WTLT x2 or 3)~Visit 4 : Reproducibility of the WTLT (WTLT x2) Specific measures for COPD subjects : Respiratory Functional Assessment and Dyspnea questionnaire"
62568963|NCT04086953|EXPERIMENTAL|Cardiovascular diseases Group|"Each patient receive the same intervention : 4 visits with different tests.~Visit 1: Inclusion Visit, Functional Assessment and TTLM Speed Determination (6-minute walk test x2, cardiopulmonary exercise testing on ergocycle,, questionnaires and accelerometer)~Visit 2 : Functional Evaluation and Shuttle Tests (ISWT, ESWT, Speed tests on 4m, Quadriceps muscle strength)~Visit 3 : Feasibility of the WTLT (WTLT x2 or 3)~Visit 4 : Reproducibility of the WTLT (WTLT x2)"
62775304|NCT03164330|EXPERIMENTAL|B75|"Group B75 is offered moderate compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - moderate compensation, Wellness Activities - high compensation"
61999634|NCT05981638|OTHER|Group WM (Water+mobilization)|All patients were randomized according to a table created on a computer using the closed-envelope method.Patients in the WM group (water+mobilization) were given water and mobilized
61999635|NCT05981638|OTHER|Group WR(water+rest)|All patients were randomized according to a table created on a computer using the closed-envelope method. Patients in the WR group (water+rest) were given water and stay in rest
62393852|NCT03937882|PLACEBO_COMPARATOR|Placebo|It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
62185094|NCT02927652||Questionnaires for new patients|New patients seen at Duke Clinic for Head and Neck Surgery \& Communication Sciences or Duke Raleigh Otolaryngology will be administered questionnaires (BSI-18, CG-CAHPS, and patient control scale).
62185095|NCT01184898|EXPERIMENTAL|Sirolimus and MEC|Sirolimus and MEC (Mitoxantrone, Etoposide, and Cytarabine)
62185096|NCT01515722|EXPERIMENTAL|Health education intervention (HEI)|
62393853|NCT03383406|EXPERIMENTAL|I Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM)|
62393854|NCT03166774||patient consulting in oncology ervice|Program of support of the sexual health in oncology by questionnaire
62393855|NCT04533204|EXPERIMENTAL|Mnemonic strategy training|Training using mnemonic strategies
62185097|NCT01515722|NO_INTERVENTION|No intervention|
62185098|NCT04833244|ACTIVE_COMPARATOR|Interventional|Patients are taught to draw their shoulders away from their heads and necks, activating the subscapularis and pectoralis muscles. When asked immediately afterwards to abduct and flex their shoulders, these muscles perform the action that generally engages the injured supraspinatus muscle, causing significant pain. However, when these muscles are substituted for the injured supraspinatus, abduction and flexion subsequently occur painlessly.
62393856|NCT04533204|ACTIVE_COMPARATOR|Spaced retrieval training|Training using spaced retrieval
62393857|NCT05204576|NO_INTERVENTION|Standard care treatment as usual (TAU)|Individuals will receive buprenorphine or methadone in addition to regular individual or group sessions as offered by the clinic
62393858|NCT05204576|EXPERIMENTAL|CBT4CBT-Copes|Individuals will receive standard agonist treatment plus access to the CBT4CBT-COPES website plus daily texts with a link to a survey.
62393859|NCT02959034||BMI > 95%|No Intervention
62393860|NCT02959034||Healthy Weight Siblings|Control
62393861|NCT02959034||Healthy Weight Unrelated|Control
62393862|NCT02479022|EXPERIMENTAL|Level 1-7 escalating doses|
62775305|NCT03164330|EXPERIMENTAL|C25|"Group C25 is offered high compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - high compensation, Wellness Activities - high compensation"
61999636|NCT05981638|OTHER|Group AR(apple juice+rest)|All patients were randomized according to a table created on a computer using the closed-envelope method. Patients in the AR group (apple juice+rest) were given apple juice and stay in rest
62393863|NCT02895477|EXPERIMENTAL|Intervention group|Hearing aid
62393864|NCT02895477|EXPERIMENTAL|Test group|Hearing aid
62393865|NCT04535921||Prostatectomy|FCR7 questionnaire pre and postoperative
62393866|NCT04535921||Cystectomy|FCR7 questionnaire pre and postoperative, 6 months follow
62393867|NCT04535921||Nephrectomy|FCR7 questionnaire pre and postoperative
62393868|NCT04535921||Orchidectomy|FCR7 questionnaire pre and postoperative
62393869|NCT02070562||Community Group|Chinese lactating mothers from community maternal \& child healthcare centre
62393870|NCT02070562||VIP Group|Chinese lactating mothers from VIP clinics (maternal care center)
62393871|NCT03190252||Trimix|Exposure to ambient pressure of maximum 11 ATA breathing Trimix. Exposure to oxygen partial pressure of 130 kPa breathing Trimix.
62393872|NCT00422227|ACTIVE_COMPARATOR|1|Etanercept + Methotrexate
61999637|NCT05981638|OTHER|Group AM (apple juice+mobilization)|All patients were randomized according to a table created on a computer using the closed-envelope method. Patients in the AM group (apple juice+mobilization) were given water and mobilized
61999638|NCT04174313||VILI VORTEX and No VILI VORTEX|Measurement of pulmonary pressures and volumes in the same patient
61999639|NCT03904771|ACTIVE_COMPARATOR|Food for Mind -intervention group|Nutrition counselling + peer support
61999640|NCT03904771|ACTIVE_COMPARATOR|Befriending group -control group|Social activation + peer support
61999641|NCT04212585||children with upper gastrointestinal symptoms|
61999642|NCT04212585||children without upper gastrointestinal symptoms|
61999643|NCT01402362||Ethiopians participating in previous study, year 2000|
61999644|NCT05277311|EXPERIMENTAL|LongShengZhi capsule|Experimental group
61999645|NCT05277311|PLACEBO_COMPARATOR|LongShengZhi capsule placebo|Placebo group
62185099|NCT04833244|PLACEBO_COMPARATOR|Control|Patients are taught a sham maneuver that does little or nothing to alleviate the pain of abduction and flexion of the shoulders. Therefore their pain levels before and after learning the maneuver are likely to be similar.
62185100|NCT01683305||Subjects who have no mammographically detectable tumors|This group will be evaluated for marker presence in NAF. no drugs administered
62393873|NCT00422227|ACTIVE_COMPARATOR|2|DMARD therapy Methotrexate + Sulfasalazine/Hydroxychloroquine/Leflunomide
62393874|NCT04008173||Male|Non-interventional patient registry
61999646|NCT01686412|ACTIVE_COMPARATOR|Healthy patients|
61999647|NCT01686412|ACTIVE_COMPARATOR|Oncology patients|
61999648|NCT04238728|EXPERIMENTAL|Silverlon arm|Silverlon is a silver-nylon dressing approved for treatment of burns and wounds. In this study, the Silverlon dressing will be applied to the whole breast area receiving radiation therapy throughout the prescribed course of radiation therapy starting the first day of radiation therapy and until two weeks post-radiation. The Silverlon dressing will be held in place by a bra and worn daily except when bathing/showering, received radiation therapy, or swimming. Subject document when they remove the dressing and apply the dressing every day.
61999649|NCT01190254|EXPERIMENTAL|Asenapine 2.5 mg BID|Participants receive active asenapine 2.5 mg tablets sublingually BID for 8 weeks.
61999650|NCT01190254|EXPERIMENTAL|Asenapine 5.0 mg BID|Participants receive active asenapine 2.5 mg tablets sublingually BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive active asenapine 5.0 mg tablets sublingually BID for the remainder of the 8-week treatment period.
61999651|NCT01190254|PLACEBO_COMPARATOR|Placebo|Participants receive placebo asenapine tablets sublingually BID for 8 weeks.
61999652|NCT01801787|EXPERIMENTAL|verum tDCS|left-hemispheric tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3
61999653|NCT01801787|SHAM_COMPARATOR|sham tDCS|left-hemispheric sham tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3
61999654|NCT01918527|OTHER|A, Conventional treatment|Operation + 4 or 8 cycles of adjuvant chemotherapy, if indicated.
61999655|NCT01918527|OTHER|B, Neoadjuvant chemotherapy|3 cycles of neoadjuvant chemotherapy + operation. Adjuvant chemotherapy only if indicated.
61999656|NCT02210429|ACTIVE_COMPARATOR|IV Opioids|
61999657|NCT02210429|ACTIVE_COMPARATOR|Supraclavicular Single-Shot Block|
61999658|NCT02210429|ACTIVE_COMPARATOR|Supraclavicular Catheter|
61999659|NCT02210429|ACTIVE_COMPARATOR|Supraclavicular Angiocath|
61999660|NCT03483935|EXPERIMENTAL|Microwave energy treatment|The microwave treatment will be delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for this indication, will be used to deliver the microwave treatment. The microwave dose will be between 2 Watt and 4 Watt. The treatment will consist of 3, 2 to 3 second bursts delivered to the same lesion with 5-20 seconds between bursts.
61999661|NCT03483935|NO_INTERVENTION|Control|No treatment will be given.
61999662|NCT00906191|EXPERIMENTAL|1|Single oral dose
61999663|NCT04516265|ACTIVE_COMPARATOR|NGT Group|A personally designed treatment program will be applied in line with the principles of neurodevelopmental treatment.
61999664|NCT04516265|ACTIVE_COMPARATOR|Video-based training group|Trunk training will be done with games developed for the use of children with cerebral palsy.
61999665|NCT04516265|ACTIVE_COMPARATOR|Video-based training group with theratogs|Video-based trunk training (45 minutes) will apply with Theratogs to the group
62393875|NCT04008173||Female|Non-interventional patient registry
61999666|NCT01353378|EXPERIMENTAL|dexmedetomidine|intravenously injecting 0.125microgram/kg and 0.25microgram/kg within 10 minutes as soon as the operation begins respectively.
61999667|NCT05872009||Women with gestational diabetes|Any treatment. N=200.
61999668|NCT05872009||Control group|Gestational-age matched, euglycemic, normotensive pregnant women (n=150)
61999669|NCT01262014|EXPERIMENTAL|Experimental single arm|Single arm of pazopanib 800 mg (2x400mg) given as a single agent.
61999670|NCT05196919|EXPERIMENTAL|0.15mg XT-150|0.15mg XT-150 administered in 1.0 mL total delivered by two 0.5 mL injections on Day 0 and Day 90.
61999671|NCT05196919|EXPERIMENTAL|0.45mg XT-150|0.45mg XT-150 administered in 1.0 mL total delivered by two 0.5 mL injections on Day 0 and Day 90.
61999672|NCT05196919|PLACEBO_COMPARATOR|Placebo|Placebo administered in 1.0 mL total delivered by two 0.5 mL injections on Day 0 and Day 90.
61999673|NCT04050111|EXPERIMENTAL|SVF injection|"Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate stromal vascular fraction of cells (SVF). After SVF isolation autologous cells suspension will be injected intraarticularly into knee joint.~Interventions:~Procedure: Liposuction Other: SVF isolation Other: Intraarticular administration of autologous SVF"
62393876|NCT04008173||Kidney Disease|Non-interventional patient registry
61999674|NCT01106456|EXPERIMENTAL|All Nations Breath of Life (ANBL)|"All participants in the proposed study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT) then randomized into either the culturally-tailored All Nations Breath of Life program (ANBL) or Nontailored program (NT)."
61999675|NCT01106456|EXPERIMENTAL|Nontailored (NT)|"All participants in the proposed study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT) then randomized into either the culturally-tailored All Nations Breath of Life program (ANBL) or Nontailored program (NT)."
61999676|NCT02091791|EXPERIMENTAL|LT10|"Long duration (30 minutes) traction sessions of low force (10% of body weight) for 2 weeks (5 sessions/week)."
61999677|NCT02091791|EXPERIMENTAL|LT50|"Long duration (30 minutes) traction sessions of high force (50% of body weight) for 2 weeks (5 sessions/week)."
61999678|NCT01783951|EXPERIMENTAL|DC-CIK plus S-1 based chemotherapy|Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone. Meanwhile those patients will receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
62393877|NCT04008173||Diabetes|Non-interventional patient registry
62393878|NCT04008173||Elderly|Non-interventional patient registry
62393879|NCT03716128||Low turnover bone disease|PTH\<150 pg/ml
62393880|NCT03716128||High turnover bone disease|PTH\>300 pg/ml
61999679|NCT01783951|ACTIVE_COMPARATOR|S-1 based chemotherapy|Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone.Cycles were repeated every 21 days. Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
61999680|NCT03640065|EXPERIMENTAL|freeze-dried probiotic sachets|
62393881|NCT03716128||Normal renal function|Patients under examination for prostate cancer
62393882|NCT05141058|EXPERIMENTAL|Prevention of SARS-CoV-2 infection in immunocompromised adult patients|In this dose escalation trial, donor derive coronavirus-specific T cell (CST) (three doses, 1x107/m2, 2x107/m2, and 4x107/m2) will be tested for safety, with study arms for adult (≥18 years of age and \<80 years) HSCT recipients (Arm A)
62393883|NCT05141058|EXPERIMENTAL|Prevention of SARS-CoV-2 infection in immunocompromised pediatric patients|In this dose escalation trial, donor derive coronavirus-specific T cell (CST) (three doses, 1x107/m2, 2x107/m2, and 4x107/m2) will be tested for safety, with study arms for pediatric (≥12 years of age and \<18 years) HSCT recipients (Arm B).
62568964|NCT03570619|EXPERIMENTAL|Metastatic CRPC|Patients with metastatic castration resistant prostate cancer (mCRPC) will be enrolled in cohort A.
61999681|NCT03640065|ACTIVE_COMPARATOR|fermented dairy product (yogurt)|
61999682|NCT01072695|EXPERIMENTAL|Arm 1|
61999683|NCT01072695|EXPERIMENTAL|Arm 2|
61999684|NCT01072695|EXPERIMENTAL|Arm 3|
61999685|NCT02972528|ACTIVE_COMPARATOR|Platelet Lysate|Patients will receive 5ml peri-lesional injections of Platelet Lysate at weekly intervals, for 4 consecutive times (week 0,1,2,3).
62185101|NCT01683305||Subjects who have non-cancerous growths|This group will be evaluated to study whether marker(s) detected in NAF are also expressed in non-cancerous tumors. No drugs administered
62185102|NCT01683305||subjects who have cancerous growths|In this group, any markers detected in NAF could also be detected in tumor tissues. No drugs administered.
62185103|NCT06544252|EXPERIMENTAL|Low glycaemic index, Then high glycaemic index|The participants were randomised to receive pre-exercise low glycaemic index rice-based mixed meal followed by a cross-over with the high glycaemic index rice-based mixed meal after one week
61977780|NCT02308852|PLACEBO_COMPARATOR|Sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
61999686|NCT02972528|PLACEBO_COMPARATOR|Platelet Poor Plasma|Patients will receive 5ml peri-lesional injections of Platelet Poor Plasma at weekly intervals, for 4 consecutive times (week 0,1,2,3).
61999687|NCT00849966|EXPERIMENTAL|A|Celebrex suspension
62185104|NCT06544252|EXPERIMENTAL|High glycaemic index, Then low glycaemic index|The participants were randomised to receive pre-exercise high glycaemic index rice-based mixed meal followed by a cross-over with the low glycaemic index rice-based mixed meal after one week
62185105|NCT04198948|EXPERIMENTAL|Omeprazole, Then Placebo|Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive 20 mg of omeprazole alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive placebo under same conditions in a cross-over manner.
62185106|NCT04198948|EXPERIMENTAL|Placebo, Then Omeprazole|Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive placebo alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive omeprazole under same conditions in a cross-over manner.
61977781|NCT01537744|EXPERIMENTAL|oral 5-azacitidine + romidepsin|oral 5-azacitidine in combination with romidepsin
61999688|NCT00849966|PLACEBO_COMPARATOR|B|Placebo
61999689|NCT03080103||Patients submitted to appendectomy as first-line treatment|"Open or Laparoscopic Appendectomy The assignment of each patient to either the antibiotic-first management arm or the immediate surgery arm, will be non-randomized and decided independently by the Staff Specialist Surgeon on Call, upon careful assessment of AIR score, laboratory findings and imaging. The decision of the management pathway will not be influenced in any case by the participation of the patient in the study, and the assignment of the treatment will be decided by the consultant surgeon according to current good surgical practice and standard practice patterns in Italy."
62185107|NCT01114672|ACTIVE_COMPARATOR|Ergocalciferol|
62185108|NCT01114672|PLACEBO_COMPARATOR|oral placebo|
62185109|NCT00286962|EXPERIMENTAL|CIPII|Intraperitoneal insulin infusion by means of an implanted insulin pump
62185110|NCT00286962|ACTIVE_COMPARATOR|CSII/ MDI|Optimized subcutaneous insulin infusion by means of continuous subcutaneous insulin infusion (CSII) or by multiple daily injections (MDI)
62185111|NCT02992444|EXPERIMENTAL|Cohort 5|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin after 8 hours.~There is one visit:~Two adhesive strips (standard adhesive strip and Experimental adhesive strip)are applied on the peristomal skin and allowed to sit for 8hours before being removed."
62393884|NCT05105958|EXPERIMENTAL|Tideglusib|Patients receive 1000 mg Tideglusib once daily per os
61977782|NCT04208204|EXPERIMENTAL|Somatocognitive physiotherapy|Every participant will maximally receive 15 individual sessions of somatocognitive physiotherapy
61977783|NCT00849381|EXPERIMENTAL|Cervarix Compliance Issue Centre Group|Subjects from one centre where compliance issues were discovered, who received the Hepatitis A control vaccine in the primary study (NCT00122681) and the Cervarix vaccine in the current study
61999690|NCT03080103||Patients treated with antibiotic-first strategy|Antibiotic therapy.maging. Patients managed conservatively will receive one of the following parenteral antibiotic treatments: Piperacillin/Tazobactam (4.5 g) three intravenous administration per day; Ceftriaxone (2 g) once per day or Ciprofloxacin (500 mg) twice per day plus Metronidazole (500 mg) three times per day; Amoxicillin/Clavulanic acid (2 g) four times per day for a length depending on the clinical conditions; Ertapenem (1 g) one administration per day for three days. Patients were discharged with oral antibiotics (amoxicillin/clavulanic acid or ciprofloxacin) for at least four days.
61999691|NCT03479866|EXPERIMENTAL|Dietary intervention|2 week dietary intervention using standardized test meals
61999692|NCT05076643||University students|University students in Universiti Tunku Abdul Rahman Sungai Long Campus
62185112|NCT04400344||Survey Respondents|Respondents are members of the American Association of Diabetes Educators recruited via an introductory email sent out by the AADE on behalf of Podimetrics.
62185113|NCT00696553|ACTIVE_COMPARATOR|B1|Nutrition
62185114|NCT00696553|EXPERIMENTAL|B2|Nutrition plus Exercise
62393885|NCT05105958|PLACEBO_COMPARATOR|Placebo|Patients receive placebo matching Tideglusib 100 mg once daily per os
62393886|NCT05682638|EXPERIMENTAL|Vaccine group|Phase 3(Base the result of Phase 1 and Phase 2, intervent 100μg): initial vaccination stage- LVRNA009; crossover vaccination stage- placebo
61999693|NCT02423616|EXPERIMENTAL|Healthy individuals|Study population was consisted by healthy volunteers from hospital staff of physical therapy department, Intensive Care Unit, and cleaning service. All subjects were men and women aged between 20 and 65 years old, who never had major problems with the respiratory system or with the hand flexors.
62393887|NCT05682638|PLACEBO_COMPARATOR|Control group|Phase 3: initial vaccination stage- placebo; crossover vaccination stage- LVRNA009
62393888|NCT05713019|PLACEBO_COMPARATOR|Effect of saline|Saline will be inhaled from a nebuliser
62393889|NCT05713019|ACTIVE_COMPARATOR|Effect of ATP|ATP solution will be inhaled from a nebuliser
62393890|NCT00532441|EXPERIMENTAL|Erlotinib and Docetaxel: Biliary|"Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28~Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15"
62393891|NCT00532441|EXPERIMENTAL|Erlotinib and Docetaxel: Hepatocellular|"Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28~Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15"
62393892|NCT04018716|EXPERIMENTAL|MTA|mineral trioxide aggregate
62393893|NCT04018716|ACTIVE_COMPARATOR|Dycal|calcium hydroxide cement
62393894|NCT04067687|NO_INTERVENTION|Control|No palliative home visit intervention
62393895|NCT04067687|EXPERIMENTAL|Intervention|Palliative home visit intervention
62393896|NCT02283411|OTHER|Diabetes Mellitus, Type 1 and Type 2|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
62393897|NCT01682343|PLACEBO_COMPARATOR|Placebo|Breakfast consisting of milk-based porridge with a normal calcium content.
62393898|NCT01682343|EXPERIMENTAL|High-Calcium|As control, but with a high-calcium content.
62393899|NCT02979275||BRAIN+THENAR MUSCLE INVOS|Patients undergoing open heart surgery on cardiopulmonary bypass.
62393900|NCT02546102|EXPERIMENTAL|1|Arm 1 will receive ICT-107 in combination with the standard of care, temozolomide (TMZ). ICT-107 will be given once a week for 4 weeks in the induction phase. During the maintenance phase, ICT-107 will be given monthly for the 11 months after induction and once every 6 months thereafter until depletion of supply or confirmation of progressive disease (PD). Administration is intradermal in axilla.
62393901|NCT02546102|PLACEBO_COMPARATOR|2|Arm 2 will receive TMZ with a blinded control. Control will be given once a week for 4 weeks in the induction phase. During the maintenance phase, Control will be given monthly for the 11 months after induction and once every 6 months thereafter until depletion of supply or confirmation of progressive disease (PD). Administration is intradermal in axilla.
62393902|NCT04914650|EXPERIMENTAL|Telerehabilitation intervention|
62393903|NCT04677816|EXPERIMENTAL|Vitamin D Supplementation Group - Deficient Levels|Along with standard of care neoadjuvant chemotherapy treatments and procedures, participants will receive oral 50,000 international units of Vitamin D3 supplementation at the initiation of chemotherapy once a week.
62393904|NCT04677816|ACTIVE_COMPARATOR|Observational Arm - Vitamin D at Normal Levels|Standard of care neoadjuvant chemotherapy
62393905|NCT00887822|EXPERIMENTAL|Bevacizumab, Capecitabine and Cisplatin|Participants will receive bevacizumab 7.5 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every 3-week cycle in combination with capecitabine 1000 milligrams per square meter (mg/m\^2) orally twice daily (total daily dose 2000 mg/m\^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m\^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
62393906|NCT00887822|PLACEBO_COMPARATOR|Placebo, Capecitabine and Cisplatin|Participants will receive placebo matched to bevacizumab on Day 1 of every 3-week cycle in combination with capecitabine 1000 mg/m\^2 orally twice daily (total daily dose 2000 mg/m\^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m\^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
62393907|NCT02086240|EXPERIMENTAL|XBD173|XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity. In a previous study (approved by NRES Committee London-West London, REC ref No. 12/LO/0735), we administered an oral dose of XBD173 (up to 90mg) in 12 subjects. No adverse events due to XBD173 occurred and it was well tolerated.
62393908|NCT05642689|OTHER|1|Comparison of iron absorption from FAP to Ferrous sulfate in milk
62393909|NCT05642689|OTHER|2|Comparison of iron absorption from ferric pyrophosphate to Ferrous sulfate in milk
62393910|NCT06713577||Group 1 Crowns|35 crowns delivered with a universal resin cement (Calibra Universal + by Dentsply Sirona).
62393911|NCT06713577||Group 2 Onlays|35 onlays delivered with selective enamel etch, bonding agent, and universal resin cement (Prime \& Bond Active with Calibra Universal + by Dentsply Sirona).
62393912|NCT06713577||Group 3 Fixed Partial Dentures (FPD)|12 Fixed Partial Dentures (FPD) delivered with a universal resin cement (Calibra Universal + by Dentsply Sirona).
62393913|NCT05180071|EXPERIMENTAL|TEMA elbow arthroplasty|
62393914|NCT02067208|NO_INTERVENTION|Waitlist Control|A waitlist control condition, where the participant receives no insole for 3 months. During this 3 month period, the participant will continue to be monitored for outcome variables.
62393915|NCT02067208|EXPERIMENTAL|Experimental wedged insole|Either a medially wedged or laterally wedged footwear insole (whichever reduces knee joint mechanical loading more, as determined from subject-specific biomechanical tests), constructed using a 3D printer will be inserted into each participant's shoe. The participant will be asked to utilize this insole as much as possible throughout the day over the course of 3 months.
62393916|NCT06080789|EXPERIMENTAL|RABI-767 plus Standard-of-Care|Single-dose 125 mg RABI-767 plus standard-of-care
62568965|NCT03570619|EXPERIMENTAL|Solid Tumors (non-prostate)|Patients with all other metastatic subtypes will be enrolled in cohort B
61999694|NCT02507414|EXPERIMENTAL|Group 1|"Patients under going Whipple's procedure, gastric resection and liver resection (n=75).~Interventions:~Blood samples obtained pre-, intra-, and one day postoperatively (n=15).~Measurements of microcirculation using LSCI from procedure start and up to 60 min during surgery.~Head down tilt of 20 degrees at three time points."
61999695|NCT01285648|OTHER|Cpap|This group joined chest physiotherapy with CPAP via nasal masks for two hours.CPAP was continued from the immediate postoperative day until the second postoperative day, twice a day.
61999696|NCT01285648|OTHER|Chest Physiotherapy|Chest Physiotherapy consisted of bronchial hygiene techniques and pulmonary expansion, in addition to exercises, and received oxygen supplementation to maintain the pulse oxymetry saturations \> 90%.
62393917|NCT06080789|NO_INTERVENTION|Standard-of-Care Only|No Intervention, Standard-of-Care Only
62393918|NCT01912482|EXPERIMENTAL|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
62393919|NCT01912482|ACTIVE_COMPARATOR|Ventilatory Training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
62393920|NCT01912482|NO_INTERVENTION|Crontrol Group|This condition will last six weeks, this period will be held six lectures sixty minutes long and periodization weekly.
62393921|NCT06624475|EXPERIMENTAL|Cohort 1|Nivolumab 480 mg IV and Relatlimab 160 mg IV. Every 4 weeks, up to 4 cycles
62393922|NCT06624475|EXPERIMENTAL|Cohort 2|Nivolumab 480 mg IV. Every 4 weeks, up to 4 cycles
62393923|NCT04374604||Paturients with preeclampisia|The participants will be pregnant women with late-onset pre-eclampsia
62393924|NCT02399345|EXPERIMENTAL|Ombitasvir/Paritaprevir/r, Dasabuvir, and SOF plus RBV|Ombitasvir/paritaprevir/ritonavir (ombitasvir/paritaprevir/r) (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) and sofosbuvir (SOF) (400 mg once daily), plus weight-based ribavirin (RBV) (dosed 1,000 or 1,200 mg daily divided twice a day) for 6 weeks.
62393925|NCT04706026|EXPERIMENTAL|Open Inguinal Repair- Local anesthesia|This arm will receive local anesthesia for their open inguinal hernia repair.
62393926|NCT04706026|ACTIVE_COMPARATOR|Inguinal Hernia Repair- General Anesthesia|This arm will receive general anesthesia for their open inguinal hernia repair.
62393927|NCT02834351|ACTIVE_COMPARATOR|Peripheral artery diseased group|pad Patients referred for femoro popliteal bypass Muscle biopsy during surgery
62393928|NCT02834351|SHAM_COMPARATOR|Cardiac group|Patients referred for saphenous withdrawal for coronary bypass Muscle biopsy during surgery
62393929|NCT00323934|EXPERIMENTAL|1|MGCD0103 Oral 2 times weekly
62393930|NCT06722781|ACTIVE_COMPARATOR|Standard Unified Protocol (UP)|Standard sequence of UP modules, 1, 2, 3, 4, 5 6, 7, 8.
62393931|NCT06722781|ACTIVE_COMPARATOR|UP Sequence 1|Sequence of modules, 1, 2, 5, 7, 4, 3, 6, 8.
62393932|NCT06722781|ACTIVE_COMPARATOR|UP Sequence 2|Sequence of modules, 1, 2, 6, 3, 5, 7, 8.
62775306|NCT03164330|EXPERIMENTAL|C75|"Group C75 is offered high compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - high compensation Wellness Activities - high compensation"
62393933|NCT06722781|ACTIVE_COMPARATOR|UP Sequence 3|Sequence of modules, 1, 2,4, 6, 7, 5, 3, 8.
62393934|NCT06722781|ACTIVE_COMPARATOR|UP Sequence 4|Sequence of modules, 1, 2, 7, 5, 3, 4, 6, 8.
62775307|NCT05974813|EXPERIMENTAL|L-Citrulline|Participants will receive 6 g (3 g every 12 h) of L-citrulline (Now, L-citrulline Pure Powder) for six-days.
62775308|NCT05974813|PLACEBO_COMPARATOR|Placebo|Participants will receive 6 g (3 g every 12 h) of maltodextrin (Now, Maltodextrin) for six-days.
62775309|NCT03010020|EXPERIMENTAL|STI-Positive: PCC|MSM diagnosed with rectal GC and/or CT infection counseled for HIV prevention using Personalized Cognitive Counseling (PCC) and treated with appropriate antibiotic therapy
61999697|NCT04966338|EXPERIMENTAL|Ocrelizumab (CinnaGen, Iran)|Ocrelizumab (CinnaGen, Iran) 600 mg (given as dual infusions of ocrelizumab 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as single infusions of 600 mg on Day 1 for each 24-week treatment cycle, thereafter) every 24 weeks.
62775310|NCT03010020|PLACEBO_COMPARATOR|STI-Positive: Traditional Counseling|MSM diagnosed with rectal GC and/or CT infection counseled for HIV prevention using traditional risk reduction counseling and treated with appropriate antibiotic therapy
62775311|NCT03010020|NO_INTERVENTION|STI-Negative|MSM without rectal GC and/or CT infection
62775312|NCT00486382|EXPERIMENTAL|Low dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
61999698|NCT04966338|ACTIVE_COMPARATOR|Ocrelizumab (Roche, Switzerland)|Ocrelizumab (Roche, Switzerland) 600 mg (given as dual infusions of ocrelizumab 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as single infusions of 600 mg on Day 1 for each 24-week treatment cycle, thereafter) every 24 weeks.
61999699|NCT03132051|EXPERIMENTAL|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
62393935|NCT01474291||Tocilizumab|Tocilizumab administered as monotherapy or in combination with other standard of care therapy according to prescribing information and normal clinical practice.
62393936|NCT02651740|EXPERIMENTAL|Combining therapy|taking rifaximin for 3 days and then receiving fecal microbiota transplantation with donor stool through enteral nutrition tube
62393937|NCT05524376||sepsis group|
62775313|NCT00486382|EXPERIMENTAL|Medium dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
62393938|NCT05524376||control group|
62393939|NCT05965947|EXPERIMENTAL|Medical Nutrition Therapy|The intervention group will be scheduled for three one-on-one sessions with a Registered Dietitian, where they will receive nutrition education and counseling. Sessions with the Registered Dietitian will include a review of the client's nutrition assessment data, development of problem list with the client, nutrition diagnosis, assessment of motivation to change, a discussion of barriers and facilitators, an intervention plan, goal setting, and monitoring and evaluation. Because individuals with brain injury may not do their own grocery shopping and meal preparation, caregivers will be encouraged to attend sessions. Checklists will be used to ensure treatment fidelity across participants and nutrition sessions. Sessions will be conducted by telehealth and will be recorded for fidelity checks and ongoing research team training. Sessions will be scheduled approximately 2 weeks apart.
62393940|NCT05965947|NO_INTERVENTION|Nutrition Handout Packet|The control group will receive a packet of nutrition education handouts from the MyPlate program found at USDA.gov. The handouts are publicly available and represent nutrition information that could be readily accessed by individuals who want to change their dietary habits, but do not have access to services from a Registered Dietitian.
62568966|NCT03570619|EXPERIMENTAL|Metastatic CRPC with Monotherapy|Patients with metastatic castration resistant prostate cancer (mCRPC) will be enrolled in cohort C once enrollment to cohort A has been completed.
62775314|NCT00486382|EXPERIMENTAL|High dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
62775315|NCT03925051|EXPERIMENTAL|CMAB807|60mg by subcutaneous injection once on the first day.
62775316|NCT03925051|ACTIVE_COMPARATOR|Prolia®|60mg by subcutaneous injection once on the first day.
62393941|NCT02875262|EXPERIMENTAL|Treatment|Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day. duration 3 days
62775317|NCT02746185|ACTIVE_COMPARATOR|Low-molecular-weight heparin|dalteparin, 200 IU/kg subcutaneously once daily for one month followed by 150 IU/kg subcutaneously once daily for 2 months
61977784|NCT00849381|EXPERIMENTAL|Cervarix All Centres Group|Subjects from all study centres who received the Hepatitis A control vaccine in the primary study (NCT00122681) and the Cervarix vaccine in the current study.
62185115|NCT04547621|EXPERIMENTAL|HSRT+IMRT+Temozolomide|"* Intensity-modulated radiotherapy 20Gy/10fx, 5 days a week for 2 weeks.~* Hypofractionated stereotactic radiotherapy 30Gy/5fx, 5 days a week for 1 week.~* Temozolomide once daily (75mg/m2/d) orally administered concurrently with radiotherapy."
62185116|NCT00468130|EXPERIMENTAL|Aripiprazole|Subjects in the experimental group will receive Aripiprazole
62185117|NCT00468130|PLACEBO_COMPARATOR|Placebo|Subjects in the control group will receive sugar pill
62185118|NCT05722405|OTHER|Ixazomib|Ixazomib as the single drug for maintenance. This group as control arm
62185119|NCT05722405|EXPERIMENTAL|Ixazomib plus low-dose lenalidomide|Ixazomib combined with low-dose lenalidomide(10mg) for maintenance
62185120|NCT05148702|ACTIVE_COMPARATOR|Standard care|Clinician decided antibiotic treatment duration
62185121|NCT05148702|EXPERIMENTAL|Fixed-extended-duration antibiotics|28 day antibiotic treatment duration
62185122|NCT01159483|EXPERIMENTAL|Cohort A|"Period 1: Participants received 0.01 milligrams (mg) of PF-04958242 or matching placebo, once, orally.~Period 2: Participants received 0.03 mg of PF-04958242 or matching placebo, once, orally.~Period 3: Participants received 0.1 mg of PF-04958242 or matching placebo, once, orally."
62185123|NCT01159483|EXPERIMENTAL|Cohort B|"Period 1: Participants received 0.3 mg of PF-04958242 or matching placebo, once, orally (fasted).~Period 2: Participants received 0.6 mg of PF-04958242 or matching placebo, once, orally.~Period 3: Participants received 1.0 mg of PF-04958242 or matching placebo, once, orally (fed)."
62185124|NCT02832284|EXPERIMENTAL|iNod System|Multi-center, Prospective, Single-arm Feasibility Study with Salvage.
62185125|NCT06480435|EXPERIMENTAL|Chest Physical Therapy|Chest Percussion is a conventional method to clear airway and mobilize the thick mucus from the chest wall. Percussion can be applied by both manually and mechanically, but the mechanical percussion is more useful. Percussion should be given in comfortable and gravity assisted position. Therapist Position the hands in cupped shape and the patient in the supine position. Percussions are performed rhythmically striking patient's chest, the sound produced should be hollow. Percussion duration should be 5 minutes on each lobe. The rate of percussion must be 100-480/ minutes. Percussion will be applied for 20 minutes per session, 3 sessions per week for the periods of 4 weeks
62185126|NCT06480435|ACTIVE_COMPARATOR|Lungs squeezing technique|The hand position will be so that hands should be placed on the posterolateral side of the hemi thorax while the second hand will be at anterior chest extending from the lower ribs to above clavicle. In squeezing phase, in full expiration position, 3-4 chest wall compressions are applied to increase the expiratory flow rate to remove air trapped in lungs and mobilize secretions. This phase lasts only for 4-6 seconds. Chest wall compressions should be gentle and in comfortable position In release phase of lung squeezing technique at the end of expiration the compressed thoracic segment is quickly released. It increases the Trans pulmonary pressure and it opens the obstructed airways by plugging the mucus from small airways. creates the negative traction force on small airways which mobilize the thick and sticky mucus. The duration of each session will be of 20 minutes, 3 sessions per week for the periods of 4 weeks.
62185127|NCT06544447|EXPERIMENTAL|taVNS group|
62568967|NCT03920839|EXPERIMENTAL|INCMGA00012 + gemcitabine/cisplatin|
62568968|NCT03920839|EXPERIMENTAL|INCMGA00012 + pemetrexed/cisplatin|
62568969|NCT03920839|EXPERIMENTAL|INCMGA00012 + pemetrexed/carboplatin|
62185128|NCT06544447|SHAM_COMPARATOR|Control Group|
62393942|NCT02875262|PLACEBO_COMPARATOR|placebo|NaCl 0.9% in similar dosis to treatment arm
62393943|NCT03048981|EXPERIMENTAL|Fish oil intake|Healthy volunteers given maximum dose of fish oil for 10 days.
62393944|NCT06018766|EXPERIMENTAL|LAM-001|
62393945|NCT06018766|PLACEBO_COMPARATOR|Placebo|
62393946|NCT02531009||Healthy|Approximately 10 healthy adults will be enrolled into this study
62393947|NCT02531009||SSc|Participants with dcSSc and lcSSc
62568970|NCT03920839|EXPERIMENTAL|INCMGA00012 + paclitaxel/carboplatin|
62568971|NCT02936297|PLACEBO_COMPARATOR|Lactose free placebo|Lactose free placebo pill
62568972|NCT02936297|ACTIVE_COMPARATOR|Low dose Gluten (0.5g)|Low dose gluten pill
61977785|NCT02316041|EXPERIMENTAL|Small incision lenticule extraction|Small incision lenticule extraction (SMILE) is a form of corneal laser refractive surgery performed using a femtosecond laser
61977786|NCT04974112||General Surgery|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
62393948|NCT01666301|ACTIVE_COMPARATOR|C.E.R.A.|C.E.R.A. every 4 and then every 2 weeks
62393949|NCT01666301|ACTIVE_COMPARATOR|Darbepoetin|Darbepoetin alfa every 4 and then every 2 weeks
62568973|NCT02936297|ACTIVE_COMPARATOR|High Dose Gluten (2.0g)|High dose gluten pill
62568974|NCT00511745||001|
62568975|NCT05389137|OTHER|Trial group 1 (No previous influenza vaccination)|Subjects with no previous influenza vaccination
62568976|NCT05389137|OTHER|Trial group 2 (previous vaccinated with one dose of influenza vaccine)|Subjects previously vaccinated with one dose of influenza vaccine
62568977|NCT05389137|OTHER|Trial group 2 (previous vaccinated with two doses of influenza vaccine)|Subjects previously vaccinated with two dose of influenza vaccine
62568978|NCT01303172|ACTIVE_COMPARATOR|Gemcitabine chemotherapy|Patients in the control arm will receive normal standard of care - up to 12 cycles of Gemcitabine. Dosing of Gemcitabine is as per the normal prescribing information for pancreatic cancer.
62775318|NCT02746185|EXPERIMENTAL|Rivaroxaban|rivaroxaban, orally, 15 mg twice daily for 3 weeks followed by 20 mg once daily for 9 weeks
62775319|NCT03035682|ACTIVE_COMPARATOR|Traditional Group|The control group will receive traditional PT services as deemed clinically appropriate via examination to include traditional home exercise prescription.
62775320|NCT03035682|EXPERIMENTAL|Augmented Media Group|The Augmented Media group will receive traditional PT services as deemed clinically appropriate via examination and include home exercise prescription via a mobile health application.
62775321|NCT06216249|EXPERIMENTAL|Arm I (177Lu-PSMA-617)|"Patients receive 177Lu-PSMA-617 IV once every 6 weeks on study. Beginning with the third cycle, treatments may be postponed beyond the 6 weeks interval based on defined response criteria (treatment holiday period). Treatment repeats every 6 weeks for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients receive 68Ga-PSMA-11 IV and undergo PSMA PET/CT throughout the trial. Patients also undergo SPECT/CT, PET/CT, or CT on the trial."
61999700|NCT00974714|EXPERIMENTAL|1|Oral L-arginine 2 g twice a day, for 14 weeks
62185129|NCT03305887|EXPERIMENTAL|Barbed suture group|"The deep layer and the intermediate layer will be repaired and closed by using one STRATAFIX™ Symmetric Knotless Tissue suture respectively. STRATAFIX Spiral sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation."
62185130|NCT03305887|ACTIVE_COMPARATOR|Conventional suture group|VICRYL® Plus sutures will be used to close the deep and the intermediate layers with interrupted suturing manner. STRATAFIX Spiral sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation.
62185131|NCT01692145|EXPERIMENTAL|KCT-0809 ophtalmic solution|
62185132|NCT01692145|PLACEBO_COMPARATOR|Placebo|
62185133|NCT06002646|ACTIVE_COMPARATOR|first group (Group A)|using a 1:5 dilution of Buckley's FC (SSA, Produits Dentaires, Switzerland). A sterile cotton pellet will be moistened with a 1:5 concentration formocresol and it will be placed on the pulp stumps for 5 minutes for achieving hemostasis before being covered with MTA. If hemostasis will not be achieved after 5 minutes, it will presume that the pulp tissue in the canal was infected, and the tooth will be removed from the research
62185134|NCT06002646|EXPERIMENTAL|second group (Group B)|using 3% NaOCl(Tahno-dent, Greece) A sterile cotton pellet will be moistened with a 3% NaOCl and it will be placed on the pulp chamber for 5 minutes for achieving hemostasis before being covered with MTA
62185135|NCT06002646|EXPERIMENTAL|third group (Group C)|In this group hemostasis will be achieved by exposure to diode laser (Biolase, epic X) of 940 nm. The laser energy will be introduced into the canal orifice through a 300 µm optical fiber at 2 W, in a contact mode with continuous mode CW(According to the user manual('EpicX_CAN_UM.pdf', no date) for 1 second at each orifice for three times to achieve complete hemostasis. During laser application patients, operator and assistant will use protective eye shields according to the safety measures of the device user manual.
62584773|NCT05184283||Prospective Cohort|Chart review will be performed for patients who consent to inclusion in the study. Information from routine care will be reviewed and body composition assessment will be done by routine MRI with an additional 6-8 minute scan using AMRA® Profiler 4 Muscle Assessment Score (MAsS) by performing volumetric quantification of fat and water images acquired with 2-point Dixon magnetic resonance imaging (MRI).
62775322|NCT06216249|ACTIVE_COMPARATOR|Arm II (177Lu-PSMA-617)|Patients receive 177Lu-PSMA-617 IV once every 6 weeks on study. Treatment repeats every 6 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients receive 68Ga-PSMA-11 IV and undergo PSMA PET/CT throughout the trial. Patients also undergo SPECT/CT, PET/CT, or CT on the trial.
62775323|NCT00783081|EXPERIMENTAL|low dose K-134|
62775324|NCT00783081|EXPERIMENTAL|mid dose K-134|
61999701|NCT00974714|PLACEBO_COMPARATOR|2|oral placebo twice a day for 14 weeks
61999702|NCT04019041|EXPERIMENTAL|bermekimab ew|2 800 mg bermekimab loading dose subcutaneous injections, followed by weekly 400 mg bermekimab injections
61999703|NCT04019041|EXPERIMENTAL|bermekimab eow|2 800 mg loading dose subcutaneous injections, followed by alternating weekly 400 mg bermekimab injections with matching placebo injections
61999704|NCT04019041|PLACEBO_COMPARATOR|placebo ew|2 800 mg placebo loading dose subcutaneous injections, followed by weekly placebo subcutaneous injections
62185136|NCT06002646|EXPERIMENTAL|fourth group (Group D)|Irradiation of the floor of the pulp chamber with Er,Cr:YSGG laser 2790 nm (Waterlase MD, Biolase) at a Power of 1.5 w, Frequency of 50 Hz, mode S (soft tissue mode) , 20%air and no water with a gold handpiece and Tip type MZ6, for 10 sec.(According to the manufacturer manual iPlus™ software copyright ©2016 BIOLASE, Inc.)('WaterLase-iPlus-UM.pdf', no date). In which a fixed char layer should be formed over the pulpal tissue of the canals orifices. During laser application patients, operator and assistant will use protective eye shields according to the safety measures of the device user manual.
62185137|NCT06397547|EXPERIMENTAL|Flipped learning|"The experimental group will receive digital materials (such as explanatory and demonstration videos, Edpuzzle, etc.) prior to the topic. The links to these materials will be sent to the students, who can access them via their mobile phones and watch the explanatory and demonstration videos as many times as they wish.~Subsequently, the topic Thorax and Heart Examination will be presented to the students. They will summarize the information learned from the videos and engage in question-answer sessions and discussions using prepared digital resources to address any points they do not understand. To reinforce the practices in the experimental group, online word clouds and quizzes will be sent. All activities will be conducted at an appropriate time for the students."
62775325|NCT00783081|EXPERIMENTAL|high dose K-134|
62775326|NCT00783081|ACTIVE_COMPARATOR|Comparator|
62775327|NCT00783081|PLACEBO_COMPARATOR|Placebo|
62775328|NCT02161419|ACTIVE_COMPARATOR|BAY1000394|Roniciclib 5 mg bid 3 days on / 4 days off in combination with chemotherapy (carboplatin/etoposide or cisplatin/etoposide) during 6 cycles (21 days each) followed by monotherapy
62775329|NCT02161419|PLACEBO_COMPARATOR|Placebo|Matching placebo 3 days on / 4 days off in combination with chemotherapy (carboplatin/etoposide or cisplatin/etoposide) during 6 cycles (21 days each) followed by monotherapy
62775330|NCT03409250|OTHER|1-Arm study|prospective, 1-arm, monocenter, investigator initiated study Intravitreal injection with Lucentis (Ranibizumab)
61999705|NCT00913094||ICG|Group will have results blinded during observational phase of study. Results will be revealed at time of testing during the validation phase of the study.
61999706|NCT02189057|EXPERIMENTAL|GeneSight guided treatment|GeneSight guided group will have their research psychiatrist make treatment recommendations based on AssureRx GeneSight genotyping results.
62775331|NCT05934864||Gene mutation profile of PTCL|84-gene penal was targeted sequenced in 1000 PTCL patients to investigate their mutation profile and molecular subtypes.
62775332|NCT00875862|ACTIVE_COMPARATOR|1. 0.2% Ropivicaine perinueral infusion|Patients will receive normal standard of care post-manipulation (single-injection brachial plexus nerve block, oral analgesics, and cold therapy). They will then be randomized to 0.2% Ropivicaine attached to the perineural catheter and an infusion will be initiated. The outcome measures will be assessed by study staff on the phone and at regular visits to the surgeon's office.
62775333|NCT00875862|PLACEBO_COMPARATOR|2. Normal Saline perineural infusion|Patients will receive normal standard of care post-manipulation (single-injection brachial plexus nerve block, oral analgesics, and cold therapy). They will then be randomized to normal saline attached to the perineural catheter and an infusion will be initiated. The outcome measures will be assessed by study staff on the phone and at regular visits to the surgeon's office.
62775334|NCT02088567|EXPERIMENTAL|dHACM|Total knee arthroplasty, per the usual practice of the physician with application of dHACM between the underlying fascia and the overlying skin layers to reduce scar formation
62775335|NCT02088567|OTHER|Control|Total knee arthroplasty, per the usual practice of the physician without application of dHACM.
62775336|NCT03191253|EXPERIMENTAL|Intervention|The intervention consists of comprehensive, medically-appropriate food support (meals and groceries), individual nutritional counseling, and group-based nutritional education.
61999707|NCT02189057|ACTIVE_COMPARATOR|Treatment as usual group|Treatment as usual group will have treatment recommendations based on clinical judgment
61999708|NCT05010928|EXPERIMENTAL|Tea mouthwash group|
61999709|NCT05010928|NO_INTERVENTION|Control group|
62393950|NCT01439932|EXPERIMENTAL|ankle mobilization for pain release|"stretching exercise for the plantar fascia and triceps surae muscles three times a day throughout the study period.~During each visit the exercise performance will be checked by the therapist. In addition, participants from both groups will get ultra sound therapy in frequency of 1 MHz, power of 1.5 watts per centimeter-squared, pulses of 50% for 5 minutes.~The study group will receive the same treatment and a number of manual techniques that include antero-posterior (AP) mobilization for talocrural joint in two variations (weight baring and non-weight baring) to improve the range of dorsi flexion, subtalar joint mobilization to improve range of eversion and mid-tarsal mobilization to improve pronation / supination of the forefoot. Each technique will be carried out for 1 to 1.5 minutes for a total of 5 minutes of manual treatment.~All patients will receive information and guidance to practice at home."
62393951|NCT01579240|EXPERIMENTAL|program visits|visits to intervention program
62393952|NCT05707702|EXPERIMENTAL|Probiotic lozenges|Participants in this arm will be be instructed to take a lozenge daily for 6 weeks. They will also receive oral dysplasia standard of care.
62393953|NCT05707702|ACTIVE_COMPARATOR|Standard of care for oral dysplasia|Participants in this arm will receive oral dysplasia standard of care.
62393954|NCT03039959||Pulmonary hypertension cohort|Consecutive adult Pulmonology inpatients with suspected or pre-diagnosed pulmonary hypertension undergoing invasive right heart catheterization.
62393955|NCT03039959||Heart failure cohort|Consecutive adult Cardiology inpatients with a new or pre-existing diagnosis of heart failure who are referred to the consultant nephrologist with a history of diuretic-resistant fluid overload and impaired renal function.
62393956|NCT03164629|EXPERIMENTAL|3D Angiogram + Emboguide|Participants will receive cone-beam CT 3D Emboguide: cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
62775337|NCT03191253|NO_INTERVENTION|Control|The control group will continue to receive their regular Project Open Hand services (standard of care) which includes 1-2 food services/day.
62775338|NCT00559988|EXPERIMENTAL|Home Monitoring Guided OAC|Home Monitoring is fully enabled and continuous remote surveillance data is available to investigators. Patients will be treated according to a predefined anticoagulation plan, which uses the total duration of AF/AFL combined with patients' CHADS2 score to determine the start, stop, and restart of OAC.
62393957|NCT03164629|ACTIVE_COMPARATOR|No 3D Angiogram + Emboguide|Embolization will be guided by a standard of care CT.
62775339|NCT00559988|ACTIVE_COMPARATOR|Physician-Directed OAC|"In Control (Group 2), Home Monitoring is active for Safety Net alerts, but the remote AF/AFL data is not revealed to the patient or treating physician. These patients receive physician-directed OAC consistent with current standards of care.~Safety Net data include:~* ERI/EOS~* Special Implant Status~* Implant in Backup Mode (ROM)~* VT/ VF Detection Inactive~* Emergency Pacing~* 250 Ω \> RV Pacing Impedance \> 1500 Ω~* Symptomatic VT/VF therapies including both ATP and shock~* VT/VF storm~* HM transmission failure \>3 days"
62775340|NCT02251210|EXPERIMENTAL|BIIL 284 BS low dose|
62775341|NCT02251210|EXPERIMENTAL|BIIL 284 BS medium dose|
62775342|NCT02251210|EXPERIMENTAL|BIIL 284 BS high dose|
62775343|NCT02251210|PLACEBO_COMPARATOR|Placebo|
62775344|NCT03106467|EXPERIMENTAL|Single-port laparoscopic appendectomy|Single-port laparoscopic appendectomy is performed through single-port which is installed in umbilicus.
62775345|NCT03106467|ACTIVE_COMPARATOR|Three-port laparoscopic appendectomy|Three-port laparoscopic appendectomy is performed using conventional three-port technique which needs two additional ports outside umbilicus in addition to trans-umbilical port
62775346|NCT02350738|EXPERIMENTAL|MCET_Mock group|Period I: MCET for 8 weeks (3 sessions/ week); Washout for 4 weeks and cross-over; Period II: mock therapy for 8 weeks (3 sessions/week)
62393958|NCT02713633|OTHER|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
62775347|NCT02350738|EXPERIMENTAL|Mock_MCET group|Period I: mock therapy for 8 weeks (3 sessions/week); Washout for 4 weeks cross-over; Period II: MCET for 8 weeks (3 sessions/ week);
62775348|NCT05036291|EXPERIMENTAL|NB004|"Part1: Dose escalation phase of study drug NB004 monotherapy:~Part 2: Dose Escalation Phase for the NB004 in combination with Sotorasib:~Part 3: COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:"
62775349|NCT01798030||Vitamin D|Specimen analysis
62775350|NCT01028170|EXPERIMENTAL|Furosemide with Hypertonic Saline|Furosemide with 150 mL of 2.4% NaCl
62775351|NCT01028170|ACTIVE_COMPARATOR|Pulse Furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
61999710|NCT02460770|EXPERIMENTAL|autologous mesenchymal stem cells|After bone-marrow aspiration by an authorized person, Mesenchymal Stem Cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of Mesenchymal Stem Cells during Left Ventricular Assist Device surgery
62775352|NCT00934674|EXPERIMENTAL|1|Commercial Tablet manufactured by Excella
62775353|NCT00934674|EXPERIMENTAL|2|Clinical Tablet manufactured by Wyeth Montreal
62775354|NCT06453317|ACTIVE_COMPARATOR|Infliximab|Infliximab 5 mg/kg i.v at Weeks 0, 2, 6 and then every 8 weeks for 52 weeks.
62775355|NCT06453317|ACTIVE_COMPARATOR|Ustekinumab|Ustekinumab: first dose i.v. at Week 0 (Patients with body weight ≤55 kg - 260 mg, patients with body weight \>55-≤85 kg 390 mg, patients with body weight \>85 kg - 520 mg) then 90 mg s.c. every 8/12 weeks for 52 weeks.
62775356|NCT06453317|EXPERIMENTAL|Infliximab + Ustekinumab|"Infliximab 5 mg/kg i.v. at Week 0, 2, 6.~+ Ustekinumab: first dose i.v. at Week 0 (Patients with body weight ≤55 kg - 260 mg, patients with body weight \>55-≤85 kg 390 mg, patients with body weight \>85 kg - 520 mg) then 90 mg s.c. every 8/12 weeks for 52 weeks"
62775357|NCT00551291|EXPERIMENTAL|Mycophenolate Mofetil + Prednisone + Erythropoietin Beta|Mycophenolate mofetil (MMF) 1 gm twice daily orally and prednisone 10 mg/day orally until the end of the study. Recombinant human erythropoietin beta 30,000 IU/week, subcutaneously for 6 weeks was added in case of no significant response at Week 12.
62775358|NCT01310478|EXPERIMENTAL|Endostar combined with mFOLFOX6|
62791658|NCT00721240|EXPERIMENTAL|single-arm|This investigation is a single-center, two-phase, single-arm study. In order to detect a potential placebo effect, the treatment phase will be preceded by a single-blinded two-week placebo run-in phase, followed by a 12 week open-label treatment phase.
62775359|NCT05065450|EXPERIMENTAL|Brain Stimulation|Neurosurgical epilepsy patients that undergo placement of medial temporal electrode for seizure localizations will be recruited. All participants will view a series of images of emotionally-neutral objects on a computer screen. After each item presentation, they will randomly undergo either active-BLAES or sham-stimulation. Over subsequent days, free recall and recognition memory for these items, relative to new distractor items will be tested. Memory for items presented with and without stimulation will be compared. Brain activity recorded in the medial temporal lobe during item presentations will be used to predict subsequent memory. Such good and bad memory states (biomarkers) will be used to perform closed-loop stimulation when bad memory states are detected in order to enhance subsequent memory.
61999711|NCT04152122||Intermittent exotropia group|Intermittent exotropia group
62185138|NCT06397547|NO_INTERVENTION|Control group|"Students who meet the inclusion criteria for the study will be administered the Introductory Characteristics Form, the Thoracic and Cardiac Examination Information Evaluation Form, and the Self-directed Learning Skills Scale (SRLSS) (pretest).~Control group, the topic will be delivered using only traditional teaching methods. No additional resources will be provided to the students for preparation.~The topic will be presented using a PowerPoint presentation, and question-answer sessions, demonstrations, and discussions will be conducted.~After the presentation, and again 4 weeks later, the Thorax and Heart Examination Knowledge Assessment Form and the Self-directed Learning Skills Scale (SRLSS) will be administered to the both groups for evaluation (posttest)."
62185139|NCT00532246|EXPERIMENTAL|A|raloxifene
62393959|NCT02713633|OTHER|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
62393960|NCT00627913|ACTIVE_COMPARATOR|1|Healon 5
62393961|NCT00627913|EXPERIMENTAL|2|Retrobulbar Anesthetic Injection
62775360|NCT01691976|NO_INTERVENTION|Controls|Age-matched male patients with benign prostatic hyperplasia, otherwise healthy, as controls
62775361|NCT01691976|ACTIVE_COMPARATOR|LHRHa|Prostate cancer patients receiving androgen deprivation therapy by luteinising hormone releasing-hormone agonists (LHRHa)
62775362|NCT01691976|EXPERIMENTAL|Oestrogen|Prostate cancer patients recruited from the Prostate Adenocarcinoma TransCutaneous Hormones (PATCH) Trial, randomised to receive ADT via transdermal oestrogen patches.
62775363|NCT03006887|EXPERIMENTAL|lenvatinib 20 mg plus pembrolizumab 200 mg|Participants with selected tumors will receive oral lenvatinib at a starting dose of 20 milligrams (mg) once daily in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.
62775364|NCT02215005|EXPERIMENTAL|Telmisartan + Ramipril|5 days qd
62775365|NCT02215005|ACTIVE_COMPARATOR|Telmisartan|5 days qd
62775366|NCT02215005|ACTIVE_COMPARATOR|Ramipril|5 days qd
62775367|NCT00932165||Exemestane|Patients taking Exemestane Tablets.
61999712|NCT04152122||Normal group|Normal group
62185140|NCT00532246|PLACEBO_COMPARATOR|B|placebo
62393962|NCT01778673||Distal radius fractures Sundsvall Hospital|
62393963|NCT01778673||Distal radius fractures Östersund Hospital.|
62393964|NCT05776511|OTHER|suggestive demyelinating disease|White matter lesions suggestive demyelinating diseases
62393965|NCT05776511|OTHER|no suggestive demyelinating diseases|White matter lesions not suggestive demyelinating diseases
62393966|NCT05776511|OTHER|Controls|patients controls
62393967|NCT05144516|EXPERIMENTAL|Patient Caregiver Dyad|Participants who are 65 years or older with cancer and mild cognitive impairment with their caregiver.
62393968|NCT06097364|EXPERIMENTAL|Odronextamab + Chemotherapy|Part 1 of the study includes ordonextamab dose escalation for participants with previously untreated FL and relapsed/refractory FL (Part 1A only) followed by a randomized exploration of 2 regimens of odronextamab (Odro) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) with the objective of dose optimization (Part 1B) in previously untreated patients with FL.
62393969|NCT06097364|ACTIVE_COMPARATOR|Rituximab + Chemotherapy|In Part 2 only, participants will be randomized 1:1:1 to receive rituximab (R) with chemotherapy (CHOP), followed by rituximab monotherapy maintenance.
62775368|NCT05041348||liver cirrhosis patients with muscle mass loss|The diagnosis of cirrhosis was made based on the combination of clinical and laboratory features or by liver histopathology. Skeletal muscle mass index (SMI), which was the ratio of lean tissue area to body height. Muscle mass loss was defined as an SMI less than 46.96 cm²/m² for males and less than 32.46 cm²/m² for females
62775369|NCT05041348||liver cirrhosis patients with normal muscle mass|Skeletal muscle mass index (SMI) was not decreased in this group.
62775370|NCT05041348||healthy group|People in healthy control group were excluded metabolic diseases (including diabetes, thyroid disorder, and so on) and other chronic diseases, according to their ultrasound and laboratory assessment.
62775371|NCT00592332|EXPERIMENTAL|2|Hyperinsulinemic glucose clamp with Xanax given orally at beginning of each 2 hour clamp on day 1.
62185141|NCT03801187|SHAM_COMPARATOR|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
62185142|NCT03801187|EXPERIMENTAL|Er:YAG laser|Er: Yag laser treatment will be provided on the implant surface.
62185143|NCT03801187|ACTIVE_COMPARATOR|Air Powder|An Air-Powder treatment will be provided on the implant surface
62185144|NCT01240252|EXPERIMENTAL|Type 2 Diabetes Mellitus Subjects|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours.
62185145|NCT01240252|EXPERIMENTAL|Overweight or Obese Subjects with Normal Glucose Tolerance|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours.
62185146|NCT01240252|PLACEBO_COMPARATOR|Non-Obese Control Subjects|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours.
62185147|NCT00579709|EXPERIMENTAL|1|Thymus Tissue for Transplantation
62185148|NCT04134884|EXPERIMENTAL|ASTX727 + Talazoparib|
62185149|NCT04022577|EXPERIMENTAL|experimental group|The experimental group will participate in a eight session course of Adherence Therapy
62185150|NCT04022577|PLACEBO_COMPARATOR|control group|The control group received routine care
62185151|NCT02202109|ACTIVE_COMPARATOR|CHWs facilitated Self-Sampling|CHW and Self-sampling for Cervical Cancer. Home visit, self-sampler, collection of test
62185152|NCT02202109|ACTIVE_COMPARATOR|Mailed Self-Sampler|Mailed Self Sampler. Self sampler is mailed to participant; follow up by phone
62185153|NCT01537445||Patients with pancreastransplantation|All patients undergoing pancreas transplantation.
62185154|NCT02609802|EXPERIMENTAL|Sevoflurane|Anesthesia was maintained with sevoflurane.
62775372|NCT00592332|EXPERIMENTAL|1|Hyperinsulinemic glucose clamp in group with no drug.
62775373|NCT03100110|EXPERIMENTAL|NeuroCognitive Communicator|
62775374|NCT06267664||Patients with migraine treated with triptans, Lasmiditan or Gepants|Patients that fulfill the criteria for migraine, according to the International Classification of Headache Disorders, 3rd version treated with triptans, Lasmiditan or Gepants as acute therapies according to their responsible physician criteria under routine clinical practice criteria
62775375|NCT03254550|NO_INTERVENTION|Control phase|This is the provision of PrEP without the use of the PrEP Promotion Package. PrEP promotion in the control phase consists of each clinic displaying posters that advertise PrEP, pamphlets, and palm cards that patients can take home from the clinic.
61977787|NCT04974112||Thoracic Surgery|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
62185155|NCT02609802|EXPERIMENTAL|Desflurane|Anesthesia was maintained with desflurane.
62185156|NCT02476747|EXPERIMENTAL|Cold snare polypectomy|CSP will be performed by closing the snare loop after positioning the open snare at the point of lesion.
62185157|NCT02476747|ACTIVE_COMPARATOR|Endoscopic mucosal resection|EMR will be performed in the way of drawing the lesion into the loop of the snare and resecting followed by saline injection to the its margin.
62185158|NCT02360813|EXPERIMENTAL|Cognitive Remediation Therapy|Principle driven cognitive remediation therapy, cognitive rehabilitation, cognitive training, cognitive enhancement.
62185159|NCT02360813|ACTIVE_COMPARATOR|Treatment as Usual|Usual care.
62185160|NCT02880683|EXPERIMENTAL|Single arm, transvenous cardiac autonomic nerve stimulation|
62185161|NCT04128800|EXPERIMENTAL|Apatinib and S-1 group|
62185162|NCT05714423|ACTIVE_COMPARATOR|Mini-PCNL Group|In this group kidney stones will be treated with Mini-PCNL Surgery
62185163|NCT05714423|ACTIVE_COMPARATOR|RIRS Group|In this group kidney stones will be treated with Retrograde Intrarenal Surgery.
62185164|NCT06547047|EXPERIMENTAL|Experimental Group: SAQ Training|Participants in the experimental group will undergo Speed, Agility, and Quickness (SAQ) training three times per week, with each session lasting 60 minutes, for a duration of 12 weeks. The training intensity will range from 70% to 100% of the participants' maximum effort. This program is designed to enhance physical fitness, cognitive abilities, and soccer-specific skills.
62393970|NCT06097364|EXPERIMENTAL|Odronextamab + Chemotherapy + Maintenance|In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy \[CHOP, or cyclophosphamide, vincristine, and prednisone (CVP)\], followed by odronextamab monotherapy maintenance.
62393971|NCT06097364|EXPERIMENTAL|Odronextamab + Chemotherapy + No maintenance|In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy (CHOP, or CVP) without maintenance.
62393972|NCT03999931||schizophrenia with positive symptoms|schizophrenia with positive symptoms
62185165|NCT06547047|ACTIVE_COMPARATOR|Control Group: Regular Training|Participants in the control group will engage in their regular training routine, which does not include the specific SAQ training regimen. The training intensity for the control group will also range from 70% to 100% of the participants' maximum effort. This routine will last for 12 weeks, with training sessions occurring three times per week for 60 minutes each session.
62185166|NCT05037253|ACTIVE_COMPARATOR|high dose|Vitamin D therapy will initiate at a dosage of 50,000 IU on the first and second week, followed by a switch to a daily intake of 5,000 IU for 3 months.
62185167|NCT05037253|ACTIVE_COMPARATOR|Low dose:|Vitamin D therapy will prescribe for 3 months at a dosage of 2,000 IU/day.
62185168|NCT06283498|EXPERIMENTAL|Device Treatment|20 female patients with overactive bladder symptoms, aged 21 to 80 years old, inclusive from two sites.
62185169|NCT03893006|EXPERIMENTAL|UnAssisted (UA)|This term refers to driving a vehicle manually without any vehicle automation technology. It will serve as a baseline concerning behaviors, representations and neural results associated with unassisted automobile driving.
62185170|NCT03893006|EXPERIMENTAL|Assisted (A)|This term refers to driving with warning technology which upon activation sounds an a warning when the vehicle is too close to the edge of the road (off-road warning , Navarro, Mars, \& Hoc, 2007; Suzuki \& Jansson, 2003) or too close to the vehicle in front of it (anti-collision warning; Lee, McGehee, Brown, \& Reyes, 2002).
62185171|NCT03893006|EXPERIMENTAL|Shared Control (SC)|This term refers to shared tactical control between the driver and the automated assistive technology, both working simultaneously on the physical trajectory of the vehicle, laterally (Griffiths \& Gillespie, 2005; Mulder, Abbink, \& Boer, 2012) as well as longitudinal (Adell, Várhelyi, \& Hjälmdahl, 2008).
62185172|NCT03893006|EXPERIMENTAL|Partly Autonomous (PA)|"This term refers to a situation where the lateral and longitudinal control of the driving are delegated to the automated assistive technology. It consists of a level of automatisation that today is possible to put into application and which often is referred to by the name Highly Automated Driving (Navarro, 2018). In this case, the driver is no longer the one who physically ensures the lateral and longitudinal control of the vehicle, but instead supervises the actions of the automated assistive technology."
62393973|NCT03999931||schizophrenia with negative symptoms|schizophrenia with negative symptoms
62393974|NCT03999931||bipolar disorder|bipolar disorder
62393975|NCT03999931||depression|depression
62185173|NCT03893006|EXPERIMENTAL|Fully Autonomous (FA)|This term refers to a completely automated driving experience. The on-board technologies take over all the driving tasks for any driving situation.
62393976|NCT03999931||panic disorder|panic disorder
61999713|NCT00025883|EXPERIMENTAL|Metreleptin|subcutaneous metreleptin injections in one to two daily doses ranging from 0.06 to 0.24 mg/kg per day.
61999714|NCT04576533|EXPERIMENTAL|walk out from operating room|patients will return to the ward after surgery by walking
62185174|NCT03893006|EXPERIMENTAL|Any Automation (AA)|This term refers to a situation where the drivers can choose the automation device of their choice among the five types presented above and can change it whenever they think it is good to do so.
62185175|NCT05744102|OTHER|Adult patients having MRI planned at Paul Brousse Hospital|Evaluate new MRI sequences on a population of patients undergoing MRI as part of their usual care
62185176|NCT02828150|EXPERIMENTAL|Parenteral nutrition|Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements
62393977|NCT03999931||obsessive-compulsive disorder|obsessive-compulsive disorder
62393978|NCT03999931||control|
62393979|NCT00661310|EXPERIMENTAL|I|Intervention by team consisting of Doctor, pharmacist and nurse
62393980|NCT00661310|NO_INTERVENTION|C|
62393981|NCT01365897|PLACEBO_COMPARATOR|Placebo|Control Group
62393982|NCT01365897|EXPERIMENTAL|Modafinil 200mg|Modafinil 200mg taken orally.
62393983|NCT04550741|EXPERIMENTAL|Telerehabilitation|Experimental group of 100 patients using the M-Réhab BPCO telerehabilitation solution. The solution will be provided during the fourth and final week of RR's stay during which patients will be trained to use all of the solution's features. Patients will carry out the entire post-rehabilitation using the remote rehabilitation solution and will benefit from medical assessments by teleconsultation at 1, 3, 6 and 12 months as well as assessments at 3, 6 and 12 months by filling. electronic auto-questionnaires followed by a telephone quality control if necessary. A final evaluation at 12 months, by videoconference, will be carried out at the patient's home.
62393984|NCT04550741|NO_INTERVENTION|Standard chronic care|following usual standard chronic care. Patients will receive during the last week of stay in the center, the usual advice to continue physical activity and nutritional advice at home. The evaluations at 3, 6 and 12 months will be done by electronic filling of auto-questionnaires followed by a telephone quality control if necessary. A final evaluation at 12 months, by videoconference, will be carried out at the patient's home.
62185177|NCT03324113|EXPERIMENTAL|SAR408701 Monotherapy|SAR408701 Dose escalation administered as a single agent intravenously, on Day 1 and once every two weeks, to patients with malignant solid tumors
62185178|NCT01542398|EXPERIMENTAL|Family-Focused Psychosocial Intervention|Intervention Group
62185179|NCT01542398|NO_INTERVENTION|Waiting List Control|
62185180|NCT02107742|EXPERIMENTAL|Injection speed|each participant receives 3 injections with the same amount of lidocaine subcutaneously on the abdomen, given over 15, 30 and 45 seconds
62185181|NCT03170843|EXPERIMENTAL|O-Trac|The experimental group will use the plastic ring wound retractor for wound protection during the surgery.
62393985|NCT06290934|EXPERIMENTAL|Part A, Part B, Part C: GS-1427 Dose A|"Participants will receive GS-1427 Dose A Day 1 through Week 12 (Part A).~Participants who complete the 12-week Part A treatment period will be eligible to continue and remain on the same dose of GS-1427 through Week 52 (Part B).~Participants who complete Part B of the study will continue onto Part C: Blinded treatment extension for an additional 24 weeks (through Week 76)."
62393986|NCT06290934|EXPERIMENTAL|Part A, Part B, Part C: GS-1427 Dose B|"Participants will receive GS-1427 Dose B Day 1 through Week 12 (Part A).~Participants who complete the 12-week Part A treatment period will be eligible to continue and remain on the same dose of GS-1427 through Week 52 (Part B).~Participants who complete Part B of the study will continue onto Part C: Blinded treatment extension for an additional 24 weeks (through Week 76)."
62775376|NCT03254550|EXPERIMENTAL|Intervention phase|This is the provision of PrEP as in the control phase plus the addition of five PrEP promotion components, which constitute the PrEP Promotion Package (PPP). These five additions are: 1) a PrEP promotion video to be played in the waiting room, 2) T-shirts advertising PrEP to be worn by healthcare workers, iii) a flipchart to support healthcare workers' PrEP counseling, iv) an informational booklet for clients to take home, and v) self-risk assessment forms to be displayed in the waiting room.
62775377|NCT05505409|EXPERIMENTAL|pirfenidone group|CTD-ILD patients treated with pirfenidone、glucocorticoid and immunosuppressant.
62775378|NCT05505409|ACTIVE_COMPARATOR|No-pirfenidone group|CTD-ILD patients treated with glucocorticoid and immunosuppressant,without pirfebidone
62775379|NCT02412332|NO_INTERVENTION|Group 1 - Control|The patients will be followed during the course of 12 months and evaluated regarding disease progression. No interventions will be performed other than conventional (in-course) treatment.
62775380|NCT02412332|EXPERIMENTAL|Group 2 - BMMC|Patients will be submitted to bone marrow harvesting. Bone marrow mononuclear cells (BMMC) will be obtained by Ficoll separation and returned to patients by systemic infusion (1x10\^8 BMMC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
62775381|NCT02412332|EXPERIMENTAL|Group 3 - ASC|Patients will be submitted to liposuction. The obtained fat tissue will be cultivated by 21 days and adipose-derived stem cell (ASC) will be returned to patients by systemic infusion (1x10\^8 ASC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
62775382|NCT02412332|EXPERIMENTAL|Group 4 - BMMC + ASC|Patients will be submitted to liposuction and the obtained fat tissue will be cultivated by 21 days and adipose-derived stem cell (ASC) obtained. Patients will be submitted to bone marrow harvesting and bone marrow mononuclear cells (BMMC) will be obtained by Ficoll separation. BMMC and ASC will be returned to patients by systemic infusion (5x10\^7 ASC + 5x10\^7 BMMC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
62775383|NCT06256653|EXPERIMENTAL|Freeze-dried Blueberries|Participants will be provided with an 8-week supply of study product (freeze-dried blueberry) to be consumed daily.
62775384|NCT06256653|PLACEBO_COMPARATOR|Maltodextrin, Glucose, Fructose and Sucrose Placebo|Participants will be provided with an 8-week supply of placebo product (maltodextrin, glucose 31%, fructose 30%, sucrose 0%; produced as a purple powder, with blueberry aromatics generated from natural (non-anthocyanin) and artificial colour and flavourings) to be consumed daily.
62775385|NCT03330184|EXPERIMENTAL|Berberine Hydrochloride group|2/day, 16 weeks
62775386|NCT03330184|EXPERIMENTAL|Bifidobacterium group|2/day, 16 weeks
62775387|NCT03330184|EXPERIMENTAL|Berberine Hydrochloride and Bifidobacterium group|2/day, 16 weeks
62775388|NCT03330184|PLACEBO_COMPARATOR|placebo|bifidobacterium mimetic capsules berberine mimetic tablets,2/day, 16 weeks
62775389|NCT03312205|EXPERIMENTAL|Autologous CAR-T cells|Patients will be be treated with autologous CAR-T cells
62775390|NCT03289117|EXPERIMENTAL|Novel gel installation device procedure|"Catheter change with novel device.~Each subject will undergo catheter change with novel gel instillation device procedure"
61999715|NCT04576533|NO_INTERVENTION|leave operating room by transporting bed|patients will return to the ward after surgery by lying on the transporting bed
61999716|NCT01464515|ACTIVE_COMPARATOR|Real TMS|this group will receive high frequency deep TMS treatment of 10HZ
61999717|NCT01464515|SHAM_COMPARATOR|SHAM TMS|this group will receive SHAM treatment of deep TMS
61999718|NCT01247090|ACTIVE_COMPARATOR|Group 1: Vasopressin - Very Low Dose|0.15 mU per kg per minute
61999719|NCT01247090|ACTIVE_COMPARATOR|Group 2: Vasopressin - Low Dose|0.30 mU per kg per minute
61999720|NCT01247090|PLACEBO_COMPARATOR|Group 3: Placebo|No Dose
61999721|NCT04333810||Active IBD patients|Patients with active IBD, based on colonoscopic evaluation and biopsy results.
61999722|NCT04333810||IBD patients in remission|IBD patients in remission, with no recently colonoscopic evidence of disease, and only on maintenance therapy.
61999723|NCT00423306|EXPERIMENTAL|Single Arm|
61999724|NCT00542152|ACTIVE_COMPARATOR|CICLO|"Cyclosporine will be administered by continuous intravenous infusion at the initial dose regimen of 2mg/kg per day.~After 24 hours of treatment, cyclosporine trough level will be measured and the dose adapted in order to obtain a cyclosporinaemia level between 150 and 250 ng/ml. Cyclosporinaemia will be reassessed every 48 hours for the duration of the continuous intravenous treatment."
61999725|NCT00542152|ACTIVE_COMPARATOR|INFLIXIMAB|"INFLIXIMAB (REMICADE) Infliximab in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution, and slowly infused at the dose of 5mg/kg in 2 hours.~In patients with clinical response at D7 (Lichtiger Index score \< 10 for 2 consecutive days), two additional infliximab infusions will be administered at the dose of 5mg/kg at D14 and D42."
61999726|NCT06109428|EXPERIMENTAL|Treatment Group 1 Cohort 2|HTX-011 + MMA regimen
61999727|NCT06109428|ACTIVE_COMPARATOR|Treatment Group 2 Cohort 2|Bupivacaine HCl + MMA regimen
62185182|NCT03170843|NO_INTERVENTION|Surgical pad|The control group will use a conventional surgical pad for wound protection during the surgery.
62185183|NCT02325830|EXPERIMENTAL|Treatment Group|Implantation of the Carillon Mitral Contour System
62185184|NCT02325830|NO_INTERVENTION|Control Group|Optimized stable medical therapy
62185185|NCT00107978|EXPERIMENTAL|Telavancin|
62185186|NCT00107978|ACTIVE_COMPARATOR|Vancomycin|
62185187|NCT01395498||fiberoptic bronchoscopy|patients undergoing fiberoptic bronchoscopy who are not immunocompromized and in whom an opportunistic infection is not suspected.
62185188|NCT03399838|EXPERIMENTAL|Dexmedetomidine|Application of single dose of 4mcg/kg dexmedetomidine intranasally for pediatric procedural sedation at the emergency department
62185189|NCT03399838|ACTIVE_COMPARATOR|Midazolam|0.5mg po/pr midazolam for pediatric sedation at the emergency department
62185190|NCT05455372|NO_INTERVENTION|oral H. pylori negative and gastric H. pylori negative group|These people are tested negative for C13-urea breath test (C13-UBT) and negative for H. pylori Saliva Test Cassette (HPS).
62185191|NCT05455372|NO_INTERVENTION|oral H. pylori positive and gastric H. pylori negative group|These people are tested negative for C13-urea breath test (C13-UBT) and positive for H. pylori Saliva Test Cassette (HPS).
62185192|NCT05455372|EXPERIMENTAL|oral H. pylori negative and gastric H. pylori positive group|These patients are tested positive for C13-urea breath test (C13-UBT) and negative for H. pylori Saliva Test Cassette (HPS),they are given PPI quadruple therapy for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT will be performed to confirm the results of gastric H. pylori eradication.At the same time, Patients with successful eradication will be instructed to conduct 13C-UBT examination after 1year to confirm whether the recurrence of gastric H. pylori.
62185193|NCT05455372|EXPERIMENTAL|oral H. pylori positive and gastric H. pylori positive group|These patients are tested positive for C13-urea breath test (C13-UBT) and positive for H. pylori Saliva Test Cassette (HPS),they are given PPI quadruple therapy for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT will be performed to confirm the results of gastric H. pylori eradication, and the oral H. pylori infection will be re-detected by HPS.At the same time, Patients with successful eradication will be instructed to conduct 13C-UBT examination after 1year to confirm whether the recurrence of gastric H. pylori.
62185194|NCT02776098||Cystic Fibrosis without Cystic Fibrosis-related Diabetes|Subjects with a confirmed diagnosis of Cystic Fibrosis (CF) without Cystic Fibrosis-related diabetes will be followed annually for 2 years for a total of four study visits over 2 years (screening, baseline, 12 and 24 month visits).
62185195|NCT02776098||Newly Diagnosed Cystic Fibrosis-Related Diabetes|Subjects with a confirmed diagnosis of Cystic Fibrosis (CF) and new diagnosis of Cystic Fibrosis-Related Diabetes (CFRD) will be followed for a total of 3 study visits over 6 months (screening, baseline and 6 months).
62185196|NCT02776098||Healthy Controls|Age, sex, ethnicity and body mass index matched (at time of enrollment to CF without CFRD subjects) healthy controls will be followed annually for 2 years for a total of four study visits (screening, baseline, 12 and 24 month visits).
62185197|NCT00280683|ACTIVE_COMPARATOR|Arginine|Enrolled subjects will take L-arginine orally, at 0.1 g/kg/day. Subjects will take three to four 1 g capsules (based on weight) of L-arginine twice daily for three months. L-arginine capsules were obtained from Jarrow Pharmaceuticals.
62185198|NCT00280683|PLACEBO_COMPARATOR|Placebo|Enrolled subjects took three to four placebo capsules that matched color and size of the intervention twice daily for three months. Matching placebo capsules were obtained from Jarrow Pharmaceuticals.
62393987|NCT06290934|EXPERIMENTAL|Part A, Part B, Part C: GS-1427 Dose C|"Participants will receive GS-1427 Dose C Day 1 through Week 12 (Part A).~Participants who complete the 12-week Part A treatment period will be eligible to continue and remain on the same dose of GS-1427 through Week 52 (Part B).~Participants who complete Part B of the study will continue onto Part C: blinded treatment extension for an additional 24 weeks (through Week 76)."
62393988|NCT06290934|EXPERIMENTAL|Part A, Placebo; Part B, Part C: GS-1427|"Participants will receive Placebo to match GS-1427 Day 1 through Week 12 (Part A). Part A placebo participants will be eligible to undergo re-randomization in a double-blind manner after endoscopy assessment at Week 12 to receive one of the GS-1427 dose A, B, or C treatments.~Participants will be eligible to continue and remain on the new dose through Week 52 (Part B). Participants who complete Part B of the study will continue onto Part C: blinded treatment extension for an additional 24 weeks (through Week 76)."
62393989|NCT00703729|EXPERIMENTAL|Cold Compression (CC)|The Game Ready device provides both active, continuous cold and intermittent, pneumatic compression to the post-op shoulder. The first group will use the Game Ready™ Device (CC) for one week following surgery and will use standard ice bags wrapped to the shoulder (IW) for the remainder of the study period.
61999728|NCT05115383|ACTIVE_COMPARATOR|Sedentary Group|Individuals who are physically active for less than 75 minutes of moderate to vigorous physical activity a week will be placed in the sedentary group.
61999729|NCT05115383|ACTIVE_COMPARATOR|Active Group|Individuals who are physically active for greater than 150 minutes of moderate to vigorous physical activity will be placed in the active group.
61999730|NCT04975464||Control|eGFR ≥ 60 ± 5 ml/min/1.73m2 at the first baseline visit in BRINK 1.0. Non-CKD population.
61999731|NCT04975464||Mild CKD|eGFR 45 - \<60
61999732|NCT04975464||CKD|eGFR \< 45
62185199|NCT03211728|EXPERIMENTAL|experimental group|
62185200|NCT03211728|PLACEBO_COMPARATOR|placebo group|
62775391|NCT03289117|ACTIVE_COMPARATOR|Standard procedure|"Catheter change with standard procedure.~Each subject will undergo catheter change with standard procedure"
61999733|NCT04975464||Dialysis/Transplant|active dialysis for dialysis participants or kidney transplant for transplant participants
61999734|NCT01972672|EXPERIMENTAL|Icaritin|Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
62185201|NCT05028036|EXPERIMENTAL|Personalized lifestyle intervention|The intervention consists of a personalized lifestyle treatment program to address specific lifestyle issues.
62775392|NCT00861328|EXPERIMENTAL|A|Treatment of escalating doses of ON 01910.Na in combination with irinotecan
62775393|NCT00861328|EXPERIMENTAL|B|Treatment of escalating doses of ON 01910.Na in combination with oxaliplatin
61999735|NCT05938361||Single group|Cohort of patients with difficult-to-treat psoariasis locations on the nail, scalp, genital and/or palmoplantar area.
61999736|NCT01659112|EXPERIMENTAL|Stabilization Group|A core stabilization plus traditional upper extremity rehabilitation approach was performed.
61999737|NCT01659112|ACTIVE_COMPARATOR|Control Group|A traditional upper extremity rehabilitation-only approach was performed.
61999738|NCT00122343|EXPERIMENTAL|1|AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
61999739|NCT05687240|ACTIVE_COMPARATOR|Qigong/Tai Chi Intervention|Meditative movement practice based on qigong and tai chi, delivered via video link
61999740|NCT05687240|EXPERIMENTAL|Qigong/Tai Chi (QTC) + Heart Rate Variability (HRVB) Intervention|Meditative movement practice based on qigong and tai chi, delivered via video link with the addition of a brief practice with a the feedback on heart rate variability from an Inner Balance app.
61999741|NCT00749775||Eplerenone|Subjects who are treated with Eplerenone tablet for hypertension disease
61999742|NCT03225612|EXPERIMENTAL|Open Label|Non-randomized, open label clinical study that intends to treat up to 60 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.
61999743|NCT04561076|EXPERIMENTAL|Sequence 1|Random allocation to HLX70 3 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
61999744|NCT04561076|EXPERIMENTAL|Sequence 2|Random allocation to HLX70 10 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
62185202|NCT00494026|EXPERIMENTAL|Pemetrexed + Carboplatin|
62185203|NCT03532399||Pediatric Cardiac Catheterization|
62393990|NCT00703729|ACTIVE_COMPARATOR|Ice Wrap (IW)|The ice bag (IW)is secured to the shoulder using an elastic wrap. The second group will use standard ice bags wrapped to the shoulder (IW) for one week following surgery and will use the Game Ready™ Device (CC) for the remainder of the study period
62185204|NCT03532399||Pediatric Cardiac Surgery|
62185205|NCT03532399||Pediatric Extracorporeal Life Support (ECLS)|
61999745|NCT04561076|EXPERIMENTAL|Sequence 3|Random allocation to HLX70 30 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
61999746|NCT02439112|ACTIVE_COMPARATOR|Exercise|Supervised exercise combined with home based exercise and physical activity
61999747|NCT02439112|NO_INTERVENTION|Control|Usual care consisting of advice regarding exercise, physical activity, person lifting and moving.
61999748|NCT01411306||Med/Surg ICU Inpatients, Intubated ≥ 48 hours|
61999749|NCT05897879|OTHER|Children between 0 and 15 years with suspected pertussis|
61999750|NCT04364529|EXPERIMENTAL|Intervention (pit crew model group)|13 groups being taught the pit crew model
61999751|NCT04364529|NO_INTERVENTION|control (traditional ALS education)|13 groups being taught along traditional ALS education
61999752|NCT02888899|EXPERIMENTAL|Standard treatment|
61999753|NCT02888899|EXPERIMENTAL|PTNS in addition to standard treatment|
61999754|NCT03730948|EXPERIMENTAL|All subjects|All subjects will receive the vaccine and be followed per the schedule of procedures.
61999755|NCT01619033|EXPERIMENTAL|impaired renal function subjects|impaired renal function subjects
61999756|NCT01619033|OTHER|Healthy volunteers|matched with impaired renal function subjects on ethnic group, sex, age (+/- 5 years), and BMI (+/- 20%)
61999757|NCT05905588|EXPERIMENTAL|Hydrogen-rich water|Patients receive hydrogen-rich water.
61999758|NCT05905588|PLACEBO_COMPARATOR|Placebo|Patients receive placebo.
62185206|NCT01539408|ACTIVE_COMPARATOR|Misoprostol|400 mcg of sublingual misoprostol in one dose
62185207|NCT01539408|ACTIVE_COMPARATOR|Manual vacuum aspiration (MVA)|Standard surgical treatment (MVA)
62393991|NCT05487027|NO_INTERVENTION|Control|This arm will have no intervention or instructions from researchers. Participants in this arm will perform their work planning as normal.
62393992|NCT05487027|EXPERIMENTAL|Intervention|Introduce a deliberate variation between workers in how much they care for physically strenuous users. Some workers may receive more strenuous work compared to before, some less.
62393993|NCT03516461|EXPERIMENTAL|Fecal Microbiota Transplantation (FMT)|Patients receive a course of FMT during hospitalization
62393994|NCT03516461|NO_INTERVENTION|Basic treatment|Patient receives basic therapy for RE during hospitalization
62775394|NCT03992092|EXPERIMENTAL|C-Mac VS|Intubation using the C-MAC Video Stylet
62775395|NCT03992092|ACTIVE_COMPARATOR|FB|Intubation using the Flexible Bronchoscope
62775396|NCT02461745|ACTIVE_COMPARATOR|Genotype 1a|Study participants with chronic Hepatitis C Genotype 1A receiving VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) and RBV (ribavirin tablets) for 12 weeks.
62775397|NCT02461745|ACTIVE_COMPARATOR|Genotype 1b|Study participants with chronic Hepatitis C Genotype 1B receiving VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) for 12 weeks.
62775398|NCT01841255|SHAM_COMPARATOR|Tidal breathing using the facemask|Control
62775399|NCT01841255|EXPERIMENTAL|Tidal volume breathing with the UMOXTM, device, no instruction|First experimental measure
62775400|NCT01841255|EXPERIMENTAL|Tidal volume breathing with the UMOXTM device, instructions|Second experimental measure
62775401|NCT01841255|EXPERIMENTAL|Tidal volume breathing with the UMOXTM, device, nose clip|Third experimental measure
62775402|NCT02700594|ACTIVE_COMPARATOR|Hip mobilization|Prone posterior-to-anterior Grade IV hip joint mobilization: The subject will be placed in prone on a treatment table. The intervening physical therapist will place the heel of his hand on the greater trochanter of the femur on the involved side provide rhythmic anterior-directed force. The subject will receive 3 bouts of 30 seconds of continuous mobilizations with 10 seconds rest in between bouts. For the prone posterior-to-anterior Grade IV hip joint mobilization, the intervening therapist will perform all 3 bouts in the same position.
62775403|NCT02700594|ACTIVE_COMPARATOR|Spine mobilization|Prone unilateral posterior-to-anterior Grade IV lumbar spinal joint mobilization: The subject will be placed in prone on the treatment table. The intervening physical therapist will place his thumbs on the transverse process, on the affected side, of the L3, L4 or L5 vertebrae and provide a rhythmic anterior-directed force. Prone unilateral posterior-to-anterior Grade IV lumbar spinal joint mobilization, the intervening therapist will perform 1 bout on each of L3, L4 and L5 for a total of 3 bouts
62775404|NCT04566692|EXPERIMENTAL|IGSC 20%: Treatment-experienced Cohort|Participants first received 16 weekly doses of IGSC 20% using a subcutaneous (SC) infusion pump from Week 0 to Week 15. Participants entering study on intravenous immune globulin (IVIG), IGSC 20% was dosed at 1.37 times the equivalent weekly dose and participants entering on subcutaneous immunoglobulin (SCIG) received the same milligram/kilogram (mg/kg) equivalent weekly dose as given prior to study entry, without using a dose adjustment factor (DAF). Participants then received 9 biweekly doses of IGSC 20 % (i.e, IGSC 20% every 2 weeks) using an SC infusion pump, with the first IGSC 20% dose administered at Week 16 and the final dose given at Week 32.
62185208|NCT04947462|EXPERIMENTAL|Chronically Implanted Neural and Muscular Interface|6 eligible participants will be chronically implanted with neural and muscular interfaces to characterize proprioceptive sensations using Functional Electrical Stimulation (FES).
62185209|NCT00934700|EXPERIMENTAL|Combination of hypothermia and xenon|Combination of hypothermia and inhaled xenon
62185210|NCT00934700|NO_INTERVENTION|Hypothermia and standard intensive care|Hypothermia and standard intensive care
62185211|NCT00197106|ACTIVE_COMPARATOR|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg
62393995|NCT02083406|EXPERIMENTAL|Treatment A: OZ439 Prototype 1|800mg OZ439 prototype formulation 1 and 960mg PQP single doses
61999759|NCT06068569|EXPERIMENTAL|Healthy patients|Drug: GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile); A total of 50 people will be randomized and receive the study drug (vaccine). Two intramuscular injections of the investigational medicinal product (IMP) will be performed. 1st injection - component I, 2nd injection - component II.
61999760|NCT01308190|ACTIVE_COMPARATOR|Chemoradiotherapy+TEM|Preoperative chemotherapy: capecitabine 825 mg/m2 every 12 hours orally, plus Radiotherapy (50.4 Gy). After 6-8 weeks, transanal endoscopic microsurgery (TEM)is done
61999761|NCT01308190|OTHER|Total Mesorectal Excision|Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer
62185212|NCT00197106|OTHER|fluticasone propionate 2 x 100 mcg|fluticasone propionate 2 x 100 mcg
62185213|NCT01979263|ACTIVE_COMPARATOR|Attention Bias Modification|Attention Bias Modification computer task
62185214|NCT01979263|PLACEBO_COMPARATOR|Placebo Computer Task|Placebo computer task
62185215|NCT00889967|EXPERIMENTAL|1|Ciprofloxacin for Inhalation 100 mg/day by inhalation
62185216|NCT00889967|EXPERIMENTAL|2|Ciprofloxacin for inhalation 150 mg/day by inhalation
62185217|NCT00889967|PLACEBO_COMPARATOR|Placebo|Placebo by inhalation
62584774|NCT03972657|EXPERIMENTAL|mCRPC - dose escalation cohort|"Participants will receive REGN5678 monotherapy for presumptive recommended phase 2 dose(s) (presumptive RP2D) identification~Note: Dose escalation on monotherapy lead-in of REGN5678 followed by combination therapy of REGN5678 with full dose cemiplimab is no longer actively enrolling new participants. The prophylactic use of sarilumab is no longer in use."
62185218|NCT00890890|EXPERIMENTAL|Avagacestat (50 mg)|
61999762|NCT01221974|EXPERIMENTAL|Essure,Hydrosalpinx, Infertility|
61999763|NCT00151814|EXPERIMENTAL|Olmesartan|Children less than 6 years old received 0.3 mg/kg. Children 6 years old or older received 40 mg, if they weighed 35 kg or more; 20 mg if they weighed less than 35 kg.
62185219|NCT00890890|PLACEBO_COMPARATOR|Placebo|
62185220|NCT01615172|ACTIVE_COMPARATOR|Aortic cannulation|routine placement of aortic cannula
62185221|NCT01615172|ACTIVE_COMPARATOR|axilaris cannulation|new type of cannulation
62185222|NCT00264563||Behavioral|The intervention is basically by letting the care givers to be aware that there is active recording of iatrogenesis
62185223|NCT06224010||Non-COVID|"* This group includes patients diagnosed with Acute Respiratory Distress Syndrome (ARDS) caused by etiologies other than COVID-19.~* ARDS was defined following Berlin criteria (2012)"
62185224|NCT06224010||COVID-Moderate|"* Moderate COVID indicates a less severe level of hypoxemia compared to the Severe COVID group (according to Berlin criteria).~* The moderate COVID group is further characterized by a diagnosis of moderate Acute Respiratory Distress Syndrome (ARDS), based on a P/F ratio (partial pressure of oxygen/fraction of inspired oxygen) at ICU admission.~* The diagnosis of COVID-19 in these patients was confirmed using the Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) technique.~* RT-PCR involves collecting a sample from the lower respiratory tract and detecting the presence of SARS-CoV-2 viral RNA."
62393996|NCT02083406|EXPERIMENTAL|Treatment B: OZ439 Prototype 2|800mg OZ439 prototype formulation 2 and 960mg PQP single doses
62393997|NCT02083406|EXPERIMENTAL|Treatment C: OZ439 Prototype 3|800mg OZ439 prototype formulation 3 and 960mg PQP single doses
62393998|NCT01348464||lifestyle, wound satisfaction|single site access three site access for appendectomy
62393999|NCT03707249|EXPERIMENTAL|Iron|Received a blinded single 15 mg/kg dose of iv ferric carboxymaltose (Ferinject) up to a maximum off 1g total dose 2 weeks prior to ascent to very high-altitude.
62394000|NCT03707249|SHAM_COMPARATOR|Saline control|Received a blinded single dose of iv normal saline 2 weeks prior to ascent to very high-altitude.
62584775|NCT03972657|EXPERIMENTAL|mCRPC - dose expansion cohort|Participants will receive the REGN5678 presumptive RP2D(s)
62568979|NCT01303172|EXPERIMENTAL|IMM-101 in addition to gemcitabine|"Patients in the experimental arm will receive IMM-101 in addition to the current standard of care, namely chemotherapy (Gemcitabine). The treatment regimen with IMM-101 will be every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.~For patients in the active group, chemotherapy (Gemcitabine) will begin at least 14 days after first dose of IMM-101.~Chemotherapy plus IMM-101 will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks).~Patients who complete the Main Study and who provide informed consent are eligible to participate in a long term treatment Sub-Study (IMM-101-002A)"
62568980|NCT06353464|EXPERIMENTAL|Preloads|Delivery of two different preloads to all participants, each preload tested on a separate day/participant, prior to consumption of pizza
62568981|NCT05931380|EXPERIMENTAL|Orforglipron Dose 1|Participants will receive orforglipron orally.
62568982|NCT05931380|EXPERIMENTAL|Orforglipron Dose 2|Participants will receive orforglipron orally.
61999764|NCT03521258|EXPERIMENTAL|Human Amnion/Chorion Membrane + skin graft|Dehydrated Human Amnion/Chorion Membrane (dHACM) will be placed on wound at the initial debridement to promote granulation tissue at the wound bed. Approximately 5-7 days following debridement, wound will be assessed for suitability of split thickness skin grafting. If an adequate granulation tissue is present, skin grafting will be performed and assessed for take in 5 days.
62185225|NCT06224010||COVID-Severe|"* The severe COVID group has a diagnosis of Acute Respiratory Distress Syndrome (ARDS)~* The severity of COVID-19 in this group is determined by a P/F ratio at ICU admission, indicating a higher level of hypoxemia and a more critical clinical condition.~* The diagnosis of COVID-19 in these patients was confirmed using the Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) technique.~* RT-PCR involves collecting a sample from the lower respiratory tract and detecting the presence of SARS-CoV-2 viral RNA."
62185226|NCT03493568|EXPERIMENTAL|Genvoya 150Mg-150Mg-200Mg-10Mg Table|switch to the treatment Genvoya 150Mg-150Mg-200Mg-10Mg Table (1 pill every 24 hour)
62568983|NCT05931380|EXPERIMENTAL|Orforglipron Dose 3|Participants will receive orforglipron orally.
62568984|NCT05931380|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62568985|NCT03377231|EXPERIMENTAL|Prevention|
62568986|NCT03377231|EXPERIMENTAL|Treatment|
62568987|NCT01663961|EXPERIMENTAL|YM178 OCAS + digoxin|
62775405|NCT04566692|EXPERIMENTAL|IGSC 20%: Treatment-naïve Cohort|Treatment-naïve participants received a loading dose of 150 mg/kg/day of IGSC 20% for 5 consecutive days (Week 0, Days 1 to 5) followed by weekly maintenance infusions of 150 mg/kg IGSC 20% starting Week 1 (Day 8) through Week 32. IGSC 20% infusion was administered using an SC infusion pump.
62185227|NCT03493568|ACTIVE_COMPARATOR|Dolutegravir 50 mg plus one RTI (at label dose)|Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)
62568988|NCT03103152|EXPERIMENTAL|High dose Aspirin & Vitamin D|Aspirin high dose (300mgs) daily \& Vitamin D 4,000 IU (0.1mg) per day
62568989|NCT03103152|EXPERIMENTAL|High dose Aspirin, Vitamin D placebo|high dose aspirin (300mgs) daily and Vitamin D placebo (Miglyol®812 Oil)
62185228|NCT04038697|EXPERIMENTAL|Ischemic Conditioning + Treadmill Training|Study participants with prior history of stroke will receive both ischemic conditioning and treadmill training.
62185229|NCT04038697|PLACEBO_COMPARATOR|Ischemic Conditioning Sham + Treadmill Training|Study participants with prior history of stroke will receive both ischemic conditioning sham and treadmill training.
62185230|NCT04038697|ACTIVE_COMPARATOR|Ischemic Conditioning Only|Study participants with prior history of stroke will receive only ischemic conditioning.
62185231|NCT04038697|ACTIVE_COMPARATOR|Healthy Control - Ischemic Conditioning + Treadmill Training|Healthy control participants will receive both ischemic conditioning and treadmill training.
62185232|NCT05936918|EXPERIMENTAL|TT group|Bilateral Neiguan acupuncture points (PC6), Hegu acupuncture points (LI4), Zusanli (ST36) were selected, and percutaneous acupuncture points were electrically stimulated with electronic acupuncture equipment 30min before anesthesia, and then bilateral abdominal transverse plane blockade was performed
62185233|NCT05936918|ACTIVE_COMPARATOR|TE group|Bilateral Neiguan acupuncture points (PC6), Hegu acupuncture points (LI4), Zusanli (ST36) were selected, and percutaneous acupuncture points were electrically stimulated with electronic acupuncture equipment 30min before anesthesia
62568990|NCT03103152|EXPERIMENTAL|Low dose Aspirin , Vitamin D|Low dose aspirin (100mgs) daily \& Vitamin D 4,000 IU (0.1mg) per day
62568991|NCT03103152|PLACEBO_COMPARATOR|Low dose Aspirin, Vitamin D placebo|Low dose aspirin (100mgs) daily and Vitamin D placebo (Miglyol®812 Oil)
62568992|NCT03103152|EXPERIMENTAL|Aspirin Placebo, Vitamin D|Aspirin placebo and Vitamin D active ingredient - Vigantol® Oil
62568993|NCT03103152|EXPERIMENTAL|Aspirin placebo, Vitamin D placebo|Aspirin placebo and Vitamin D placebo - Miglyol®812 Oil
62568994|NCT04786678|EXPERIMENTAL|All participants|All participants will have a baseline before all participants undergo intervention. The purpose is to pilot the intervention to establish possible effects, as well as to determine if there are any usability or other issues.
62568995|NCT06418022|OTHER|Fluid challenge (control)|"This study is evaluating the potential of Trendelenburg positioning (TP) in determining fluid responsiveness by using the change in velocity time integral (VTI), and echocardiographic parameter that can be used as a surrogate for stroke volume and cardiac output.~There are essentially two arms, whereby the patients is being compared to themselves.~The control arm is the patient receiving a fluid challenge (FC; IV fluid bolus of 500cc crystalloids- either 0.9% Normal Saline or Lactated Ringer's solution) that the clinician would have given regardless of the study; the change of VTI is collected after administration of IV fluids with comparison to the baseline supine position.~The intervention arm is the same patient undergoing TP from the baseline supine position to determine the change in VTI after subjecting to TP."
62568996|NCT04319263|EXPERIMENTAL|intermediate and high risk non muscle invasive bladder cancer|
62568997|NCT06577324|EXPERIMENTAL|Intervention|Live group music therapy
62568998|NCT06577324|NO_INTERVENTION|Non-intervention|Standard health care
62568999|NCT06199700|EXPERIMENTAL|Esketamine treatment|Esketamine, diluted with 20ml Saline at a dose of 0.25mg/kg, intravenously for 40 minutes, once a week; 5 weeks in total.
62569000|NCT02110082|EXPERIMENTAL|Cohort 1: Urelumab + Cetuximab|Urelumab every 3 weeks with Cetuximab weekly through Intravenous infusion
61999765|NCT03521258|ACTIVE_COMPARATOR|Flap Reconstruction (Standard of Care)|A negative pressure wound dressing (NPWD) will be applied at the time of debridement until the wound is clean and adequate for flap reconstruction. Flap-based reconstruction is performed. Following flap reconstruction,patient will have 5 days of bed rest to allow proper healing and coverage of the wounds. If flaps are successful, patients starts a limb dangle protocol which gradually increases the dependent position and allows the flap to acclimate to new physiologic demands. Following dangle protocol patient will require inpatient physical and occupational therapy prior to discharge.
61999766|NCT02296814|ACTIVE_COMPARATOR|Sinusitis Hevert SL Tablet|two weeks treatment
62569001|NCT02110082|EXPERIMENTAL|Cohort 2: Urelumab + Cetuximab|Urelumab every 3 weeks with Cetuximab weekly through Intravenous infusion
62775406|NCT04752332|EXPERIMENTAL|Abemaciclib Plus (+) Endocrine Therapy (ET)|Abemaciclib administered orally and standard adjuvant ET (physician's choice) administered according to package label.
61999767|NCT02296814|PLACEBO_COMPARATOR|Placebo for Sinusitis Hevert SL Tablet|two weeks treatment
61999768|NCT03634553|EXPERIMENTAL|Intervention|Training with e-health product The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
61999769|NCT03634553|ACTIVE_COMPARATOR|Control|usual care, i.e. participates in regular training regime at the physiotherapy department
62775407|NCT04752332|ACTIVE_COMPARATOR|Placebo + ET|Placebo administered orally and standard adjuvant ET (physician's choice) administered according to package label.
62775408|NCT04383275|EXPERIMENTAL|IRIS-A|
61999770|NCT06423235|PLACEBO_COMPARATOR|placebo regular dose group|
62185234|NCT05936918|ACTIVE_COMPARATOR|TA group|Bilateral transverse abdominal plane block is performed prior to anesthesia
62394001|NCT00923481|EXPERIMENTAL|Multi-kinase inhibitor Fostamatinib Disodium (R935788)|200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
62569002|NCT03359616|EXPERIMENTAL|transanal total mesorectal excision|Transanally, the rectum is mobilized through the mesorectal plane according to the TME principles, assisted by the transanal surgical platform (Transanally curable surgical resection).
62569003|NCT03359616|ACTIVE_COMPARATOR|laparoscopic total mesorectal excision|By standard laparoscopic techniques, the rectal cancer will be resected by the conventional laparoscopic TME (LaTME).
62569004|NCT06352788|EXPERIMENTAL|NoCDO, A, B, C|Participants will first be evaluated without a CDO (NoCDO), then in CDO configuration A, CDO configuration B, and finally CDO configuration C.
62569005|NCT06352788|EXPERIMENTAL|NoCDO, A, C, B|Participants will first be evaluated without a CDO (NoCDO), then in CDO configuration A, CDO configuration C, and finally CDO configuration B.
61999771|NCT06423235|PLACEBO_COMPARATOR|placebo 2x regular dose group|
61999772|NCT06423235|ACTIVE_COMPARATOR|regular dose group of Prunella oral liquid group|
61999773|NCT06423235|ACTIVE_COMPARATOR|2x regular dose group of Prunella oral liquid group|
61999774|NCT04412330|EXPERIMENTAL|ICU followup + physical therapy|Patients surviving ICU admission for Covid-19 will receive ICU follow-up care in an ICU Recovery Clinic plus 8 weeks of physical therapy interventions. ICU Recovery Clinic is standard of care for patients surviving medical ICU admission at University of Kentucky with potential to attend in person or complete through telemedicine up to 5 appointments in the first year after hospital discharge. Physical therapy interventions completed at an outpatient pulmonary rehabilitation center or through telemedicine is not currently standard of care for patients in the short-term recovery phase (1-6 months after hospital discharge) after critical illness.
62569006|NCT06352788|EXPERIMENTAL|NoCDO, B, A, C|Participants will first be evaluated without a CDO (NoCDO), then in CDO configuration B, CDO configuration A, and finally CDO configuration C.
62394002|NCT01619176|EXPERIMENTAL|Acupuncture|Acupuncture plus conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)
62394003|NCT01619176|ACTIVE_COMPARATOR|Control|Conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)
62394004|NCT02647931|EXPERIMENTAL|Voice Therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia patients.
62394005|NCT06383988|ACTIVE_COMPARATOR|Group 1 (Standard care followed by generic resource list)|Caregivers receive standard care and are then given a generic resource list at week 24.
62569007|NCT06352788|EXPERIMENTAL|NoCDO, B, C, A|Participants will first be evaluated without a CDO (NoCDO), then in CDO configuration B, CDO configuration C, and finally CDO configuration A.
62569008|NCT06352788|EXPERIMENTAL|NoCDO, C, A, B|Participants will first be evaluated without a CDO (NoCDO), then in CDO configuration C, CDO configuration A, and finally CDO configuration B.
62569009|NCT06352788|EXPERIMENTAL|NoCDO, C, B, A|Participants will first be evaluated without a CDO (NoCDO), then in CDO configuration C, CDO configuration B, and finally CDO configuration A.
62775409|NCT04383275|EXPERIMENTAL|IRIS-B|
62775410|NCT01865383|EXPERIMENTAL|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
62775411|NCT01865383|NO_INTERVENTION|Control|Control: Participants will receive delayed HIV prevention training at the conclusion of the intervention involving participants in the other condition.
62775412|NCT05476029||Sepsis complicated with ARDS group|Blood samples and alveolar lavage fluid were collected within 24h after admission to ICU. After blood samples were collected, they were placed in static stratification at 4°C and centrifuged at 3000×g for 10 min. Serum samples and alveolar lavage fluid samples were transferred to a cleaning tube and stored in a refrigerator at -80°C for exosome sorting, identification, differential miRNAs, and analysis of serum oxidation and inflammatory indicators.
62775413|NCT05476029||control group|Blood samples and alveolar lavage fluid were collected. After blood samples were collected, they were placed in static stratification at 4°C and centrifuged at 3000×g for 10 min. Serum samples and alveolar lavage fluid samples were transferred to a cleaning tube and stored in a refrigerator at -80°C for exosome sorting, identification, differential miRNAs, and analysis of serum oxidation and inflammatory indicators.
61999775|NCT06210087|EXPERIMENTAL|Spontaneous pushing|The researcher provided training on the spontaneous pushing technique to the pregnant women selected for the experimental group in the first stage of labor and showed how to do it. During the second stage of labor, the women were encouraged and supported in this direction.
61999776|NCT06210087|NO_INTERVENTION|Valsalva-type pushing|Routine procedures of the delivery room were performed on the pregnant women in the control group, and the researcher carried out no intervention.
61999777|NCT05232604|EXPERIMENTAL|Aerobic exercise group (AE)|The session training will be divided into a warm-up, main exercise period, and cool-down, with a total duration of 60 minutes (guided by a PT). The training will be performed on a cycle ergometer, three times per week for 12 weeks. The duration of the main AE will be between 30-45 minutes and the intensity will be based on the maximal heart rate (HRmax), heart rate reserve (HRR), and the Borg Rating of Perceived Exertion Scale (Borg Scale), which will be monitored. The intensity of the AE program will be progressively increased according to each patient's response and tolerance but will be standardized as much as possible: 1) first two weeks, low to moderate intensity (60% HRmax or 9-11 on the Borg scale); 2) 2-6 weeks, moderate-intensity (55-70% HRmax or 12-14 on the Borg scale), and 3) last 6 weeks, high intensity interval training (HIT) (75-90% HRmax or 15-17 on the Borg scale; 4 min\*4 times HIT followed by 3 min of 70%HRmax in between) will be targeted per literature endorsements.
62569010|NCT06119893|ACTIVE_COMPARATOR|Control Group|Patient received an indication periodontal flap surgery. In this randomized controlled split mouth study, the patient underwents periodontal flap surgery in their mandibular. Following local anesthesia (2% lidocaine and 1:100,000 epinephrine), sulcular incisions were made. Vertical incision was not used in any operation. The mucoperiosteal flap was elevated until the buccal and lingual bone defects were adequately exposed. Defects were thoroughly debrided firstly by using periodontal curettes, and then cleaned by piezoelectric ultrasonic scaler to ensure all granulation tissues were thoroughly removed. Buccal and lingual flaps were closed primarily. In the control group, 2 mL 0.9% isotonic sodium chloride (saline) with 27-gauge single-type disposable syringes was applied to the buccal surface of flap after the operation
62569011|NCT06119893|ACTIVE_COMPARATOR|Test Group|Patient received an indication periodontal flap surgery. In this randomized controlled split mouth study, the patient underwents periodontal flap surgery in their mandibular. Following local anesthesia (2% lidocaine and 1:100,000 epinephrine), sulcular incisions were made. Vertical incision was not used in any operation. The mucoperiosteal flap was elevated until the buccal and lingual bone defects were adequately exposed. Defects were thoroughly debrided firstly by using periodontal curettes, and then cleaned by piezoelectric ultrasonic scaler to ensure all granulation tissues were thoroughly removed. Buccal and lingual flaps were closed primarily. In the test group, 8 mg (2 mL) submucosal dexamethasone with 27-gauge single-type disposable syringes was applied to the buccal surface of flap after the operation
61999778|NCT05232604|ACTIVE_COMPARATOR|Neck motor control exercise group|The treatment will consist of a 12-week progressive exercise program targeted to the neck flexor and extensor muscles supervised by a physical therapist (PT). This exercise protocol has been successfully tested in subjects with NP. Low load craniocervical exercises (nodding) will be performed at early stages (first 6 weeks) guided by visual feedback from a pressure unit. Higher-load neck exercises will be performed at later stages (last 6 weeks). During the first month, subjects will receive 30-45 min of MCTF three times per week, in the second month twice per week, and in the third month once per week. This duration of treatment is commonly used in clinical settings and has proven to be sufficient to improve muscle function, clinical, and brain outcomes.
61999779|NCT01228630|EXPERIMENTAL|Cloratadd-D|Loratadine 5 mg + 120 mg of sulfate pseudoephedrina and coated tablet of placebo (identical to comparator drug). The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
61999780|NCT01228630|ACTIVE_COMPARATOR|Allegra-D|Loratadine 5 mg + 120 mg of sulfate pseudoephedrina and coated tablet of placebo (identical to test drug). The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
61999781|NCT04262336|ACTIVE_COMPARATOR|DB-020 for Injection, 12%/placebo|dosage
61999782|NCT04262336|ACTIVE_COMPARATOR|DB-020 for Injection, 25%/placebo|dosage
62569012|NCT02431286|EXPERIMENTAL|Aprepitant|patient will receive aprepitant 80 mg per os one hour before surgery; palonosetron and dexamethasone will be intravenously administered during surgery
62185235|NCT05936918|NO_INTERVENTION|C group|Percutaneous electrical stimulation of acupoints and transverse abdominis plane block are not permitted before anesthesia
62569013|NCT02431286|PLACEBO_COMPARATOR|placebo|patient will receive placebo per os one hour before surgery; palonosetron and dexamethasone will be intravenously administered during surgery
62569014|NCT04518241|EXPERIMENTAL|Condition 1|Core, fixed compensation, TMQQ, MI sessions
61999783|NCT00003196|EXPERIMENTAL|Treatment (irradiation, transplant, immunosuppression, DLI)|"CYTOREDUCTION: If necessary, patients with advanced malignancies undergo cytoreductive chemotherapy to reduce tumor size at discretion of primary physician and study investigators.~CONDITIONING REGIMEN: Patients undergo low-dose total-body irradiation followed by allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV BID on days -1 to 0 and then PO BID on days 1-35 with taper to day 56. Patients also receive mycophenolate mofetil PO BID on days 0-27.~POST-TRANSPLANT DLI: Patients with mixed chimerism on day 56 and no evidence of GVHD undergo DLI over 30 minutes on day 65 and may receive up to 3 additional infusions in the absence of GVHD and disease progression or persistence. Patients who have not achieved mixed chimerism at day 56 undergo DLI if complete response is not obtained after a 2 month monitoring period."
62569015|NCT04518241|EXPERIMENTAL|Condition 2|Core, lottery prize, TMQQ, MI sessions
62185236|NCT03598881|EXPERIMENTAL|Treatment|Toothpaste containing 0.32%NaF and no sodium lauryl sulphate (SLS)
62185237|NCT03598881|ACTIVE_COMPARATOR|Comparator|Toothpaste containing 0.8% sodium monofluorophosphate (SMFP) and sodium lauryl sulphate (SLS)
62185238|NCT00704171|EXPERIMENTAL|PleuraSeal|PleuraSeal Lung Sealant System
62185239|NCT00704171|ACTIVE_COMPARATOR|Standard of Care|Standard tissue closure techniques (control) - sutures or staples only
62185240|NCT05034536|EXPERIMENTAL|Anti-PD-1 therapy + Infliximab|"Participants will be randomly assigned to receive physician's choice of anti-PD-1 therapy (pembrolizumab or nivolumab+relatlimab) and infliximab.~* Pembrolizumab will be administered every 3 weeks for up to 2 years~* Nivolumab+relatlimab will be administered every 4 weeks for up to 2 years~* Infliximab will be administered on weeks 0, 2, and 6 (+/- 3 days) for a total of 3 doses"
61999784|NCT01399593|EXPERIMENTAL|Eculizumab|Patients were to receive eculizumab 1200 mg prior to allograft transplantation (Day 0, starting approximately one hour prior to kidney allograft reperfusion), eculizumab 900 mg (Days 1, 7, 14, 21, and 28), and eculizumab 1200 mg (Weeks 5, 7 and 9). All doses of eculizumab were administered intravenously: the median infusion time was 39 minutes.
61999785|NCT01399593|NO_INTERVENTION|Standard of Care|Patients received standard of care (SOC) prophylactic therapy for acute AMR according to the SOC choice at each participating investigative site, which could have included any combination of plasmapheresis (PP) and intravenous immunoglobulin (IVIg). Patients randomized to SOC who were diagnosed with AMR could have received eculizumab for the treatment of AMR after initially receiving PP and/or IVIg.
62185241|NCT05034536|EXPERIMENTAL|Anti-PD-1 therapy + Placebo|"Participants will be randomly assigned to receive physician's choice of anti-PD-1 therapy (pembrolizumab or nivolumab+relatlimab) and placebo.~* Pembrolizumab will be administered every 3 weeks for up to 2 years~* Nivolumab+relatlimab will be administered every 4 weeks for up to 2 years~* Placebo. will be administered on weeks 0, 2, and 6 (+/- 3 days) for a total of 3 doses"
62185242|NCT05272709|EXPERIMENTAL|Cohort 1M (Monotherapy escalation cohort)|This cohort will recruit patients with solid tumours.
62775414|NCT02271945|EXPERIMENTAL|MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
62569016|NCT04518241|EXPERIMENTAL|Condition 3|Core, fixed compensation, MI sessions
62775415|NCT02271945|EXPERIMENTAL|MEDI-551 12 mg/kg and MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
62775416|NCT04518033|EXPERIMENTAL|Face covering use|Participants will be provided various commercially available face coverings
61977788|NCT04974112||orthopedics|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
61999786|NCT03857087||Diagnostic 68Ga PSMA PET/MRI|Patients receive gallium Ga 68-labeled PSMA-11 IV over 1-2 minutes. After about 60 minutes, patients undergo PET/MRI for approximately over 50-60 minutes. Patients may undergo an optional repeat gallium Ga 68-labeled PSMA-11 PET between 8 and 12 weeks after completion of the first PET/MRI.
61999787|NCT01277939|EXPERIMENTAL|Therapeutic Education System (TES)|Experimental (E) condition, the Therapeutic Education System (TES) delivered via effective informational technologies and multimedia learning tools.
61999788|NCT01277939|ACTIVE_COMPARATOR|Standard Care|The Control (C) condition, Standard Care, consisting of psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
62185243|NCT05272709|EXPERIMENTAL|Cohort 2M: mCRPC (Monotherapy expansion cohort)|This cohort will recruit patients with mCRPC only.
62185244|NCT05272709|EXPERIMENTAL|Cohort 2M: MSI/MMR defective tumours (Monotherapy expansion cohort)|This cohort will recruit patients with MSI/MMR defective tumours only.
62185245|NCT05272709|EXPERIMENTAL|Cohort 2M: TNBC (Monotherapy expansion cohort)|This cohort will recruit patients with TNBC only.
62569017|NCT04518241|EXPERIMENTAL|Condition 4|Core, lottery prize, MI sessions
62569018|NCT04518241|EXPERIMENTAL|Condition 5|Core, fixed compensation, TMQQ
62775417|NCT01879046|EXPERIMENTAL|Surgical intervention|Blood, bone marrow and Hoffa's fat pad samplings during surgical intervention
62775418|NCT05749692||The COVID-19 infected group|Functional dyspepsia patients infected with COVID-19
62775419|NCT02690441|EXPERIMENTAL|CBT augmented with physical exercise|Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of physical exercise pre-treatment, and 10 weeks of physical exercise alongside CBT. Both treatment and physical exercise is administered individually.
61999789|NCT03001921||Hemodialysis patients|End stage renal disease patients receiving hemodialysis treatment
62185246|NCT05272709|EXPERIMENTAL|Cohort 1A (TT-702 + Darolutamide combination escalation cohort)|This cohort will recruit patients with mCRPC only.
62185247|NCT05272709|EXPERIMENTAL|Cohort 2A (TT-702 + Darolutamide combination expansion cohort)|This cohort will recruit patients with mCRPC only.
62394006|NCT06383988|ACTIVE_COMPARATOR|Group 2 (Generic resource list)|Caregiver receive a generic resource list at the start of the study.
62394007|NCT06383988|EXPERIMENTAL|Group 3 (CONNECT, personalized list, and navigation)|Caregivers receive access to the CONNECT tool, watch an educational video on self care and receive a personalized list of resources based on caregiver preferences. Caregivers also receive access to and complete at least 2 calls, at baseline and at week 4, with a caregiver navigator to review the resource list and address any additional needs.
62394008|NCT00872131||Generalized social anxiety disorder participants|Participants with generalized social anxiety disorder will undergo MRI scanning and sertraline treatment.
62394009|NCT00872131||Healthy control participants|Healthy control participants will undergo MRI scanning.
62394010|NCT04526262|EXPERIMENTAL|BBB disruption|All participant in this arm will undergo 2 sessions of transcranial magnetic resonance guided focused ultrasound blood brain barrier disruption every 3 months.
62394011|NCT01979250|NO_INTERVENTION|Normal corneas|Normal corneas from patients that undergo cataract surgery.
62394012|NCT01979250|OTHER|DSAEK surgery|Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK).
62394013|NCT05664412|ACTIVE_COMPARATOR|Active group|Participants will receive 20 sessions of In-phase online theta tACS paired with working memory training.
61999790|NCT03143270|EXPERIMENTAL|Cohort 1, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Two weeks after deb-TACE, participants will begin nivolumab every two weeks for up to one year. If no participants experience a dose limiting toxicity (DLT), or 1 of 6 participants experiences a DLT, a new group of participants will be enrolled into Cohort 2.
62215311|NCT02774967|EXPERIMENTAL|tunnel technique|"root coverage comparing two techniques The aim of this study was to compare and show the benefits of the extended flap technique compared to Tunnel technique both techniques using the acellular dermal matrix for root coverage.~Other Names:~acellular dermal matrix extended flap technique"
62394014|NCT05664412|SHAM_COMPARATOR|Control group|Participants will receive 20 sessions of sham tACS paired with working memory training. After unblinding (by someone from our lab but external to the study), they will receive 20 sessions of in-phase offline theta tACS.
62394015|NCT06096766||Diminished Ovarian Reserve Group|women with DOR
62394016|NCT06096766||Premature Ovarian Insufficiency Group (POI)|women with premature ovarian insufficiency
62394017|NCT06096766||Control Group|women with normal menstruation and levels of sex hormones
62394018|NCT05879016|EXPERIMENTAL|Group 1|Functional Correction Technique
62394019|NCT05879016|EXPERIMENTAL|Group 2|Fascia Correction Technique
62394020|NCT05879016|EXPERIMENTAL|Group 3|Star Taping Technique
62394021|NCT05879016|SHAM_COMPARATOR|Group 4|I taping technique without tension
62394022|NCT02720627|EXPERIMENTAL|CB-03-01 cream, 1%|Topical CB-03-01 (cortexolone 17α-propionate) cream containing 1% active drug applied to the face and trunk twice daily for 14 days
62394023|NCT06634381||Survivors|Cancer survivors with any type of cancer seen at the Department of Supportive Oncology (DSO) at the Charlotte campus or the Winston-Salem campus of AHWFBCCC who have completed curative treatment for more than 6 months.
62394024|NCT06634381||Clinicians|Any providers working with post-treatment oncology survivors at the DSO at the Charlotte campus or at the Winston Salem campus of AHWFBCCC
62394025|NCT04964882|EXPERIMENTAL|C-E Mask ventilation under PIP 10 cmH2O|Two-handed C-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 10 cmH2O.
62394026|NCT04964882|EXPERIMENTAL|C-E Mask ventilation under PIP 15 cmH2O|Two-handed C-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 15 cmH2O.
62394027|NCT04964882|EXPERIMENTAL|C-E Mask ventilation under PIP 20 cmH2O|Two-handed C-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 20 cmH2O.
62394028|NCT04964882|EXPERIMENTAL|V-E Mask ventilation under PIP 10 cmH2O|Two-handed V-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 10 cmH2O.
62394029|NCT04964882|EXPERIMENTAL|V-E Mask ventilation under PIP 15 cmH2O|Two-handed V-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 15 cmH2O.
62394030|NCT04964882|EXPERIMENTAL|V-E Mask ventilation under PIP 20 cmH2O|Two-handed V-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 20 cmH2O.
62394031|NCT04786782||Three-dimensional reconstruction group|Portal hypertension is controlled with upper endoscopic screening and vPPG was detected by the noninvasive PPG-detecting software
62394032|NCT04786782||Natural follow-up group|Portal hypertension is controlled with the most updated guideline for clinical practice, namely, cirrhotic patients with either liver stiffness measurement \>15kPa or PLT\<150\*10\^9 should be screened with upper GI endoscopy and treated according to endoscopic results
62394033|NCT01978717|EXPERIMENTAL|general anesthesia & epidural anesthesia|26 patients received general anesthesia combined with epidural anesthesia for surgery, and patient-controlled epidural analgesia for 2 days after surgery
62394034|NCT01978717|EXPERIMENTAL|general anesthesia|27 patients received general anesthesia for surgery, and patient-controlled intravenous analgesia for 2 days after surgery
62394035|NCT01349816|EXPERIMENTAL|PT003 (Dose 1)|PT003 MDI Dose 1
62394036|NCT01349816|EXPERIMENTAL|PT003 (Dose 2)|PT003 MDI Dose 2
62394037|NCT01349816|EXPERIMENTAL|PT003 (Dose 3)|PT003 MDI Dose 3
62394038|NCT01349816|EXPERIMENTAL|PT003 (Dose 4)|PT003 MDI Dose 4
62394039|NCT01349816|EXPERIMENTAL|PT001|PT001 MDI
62394040|NCT01349816|EXPERIMENTAL|PT005|PT005 MDI
62394041|NCT02815007|EXPERIMENTAL|Chidamide with EGFR-TKI|"Chidamide: Per Os, 30mg (5mg\*6), twice a week, time interval between 2 medications should be ≥3 days, medicine taken 30 minutes after breakfast.~EGFR-TKI:~Taken according to the instruction book"
62569019|NCT04518241|EXPERIMENTAL|Condition 6|Core, lottery prize, TMQQ
61999791|NCT03143270|EXPERIMENTAL|Cohort 2, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Participants will receive nivolumab every two weeks for up to one year, starting 4 weeks prior to deb-TACE (week -4). Participants in this cohort will not receive nivolumab on the day of deb-TACE. If no participants experience a DLT in the initial group of 3 participants or if 1 of 6 participants experiences a DLT, a new group of participants will be enrolled into Cohort 3.
61999792|NCT03143270|EXPERIMENTAL|Cohort 3, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Nivolumab will be dosed every two weeks starting 4 weeks prior to deb-TACE (Week 4) and continue every 2 weeks for up to one year. If no participants experience a DLT in the initial group of 3 participants, an additional 3 participants will be added to confirm safety. If less than or equal to 1 of 6 participants experiences a DLT, this will be considered the optimal schedule.
61999793|NCT03050905|EXPERIMENTAL|Treatment|The study will include 1 group. Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (VEKIRAX) and Dasabuvir (EXVIERA).
61999794|NCT01120210|EXPERIMENTAL|Part 1 (Main Study)|3 consecutive 1-hour infusions of JNJ-39588146 5, 15, or 30 ng/kg/min or matching placebo
61999795|NCT01120210|EXPERIMENTAL|Part 2 (Extended Infusion Sub-Study)|1 18-hr infusion of JNJ-39588146 of the highest tolerated dose from Part 1 of the study or matching placebo
61999796|NCT00885833|EXPERIMENTAL|Fludarabine|
61999797|NCT05718635|EXPERIMENTAL|patients candidate for lateral arm flap|
61999798|NCT01327352|EXPERIMENTAL|Oshadi D|"2 dose levels of Oshadi D in 2 food regimen will be administered as following:~* Subjects will receive placebo on the morning of day 1 during fast. Late breakfast will be provided 4 hours following placebo administration.~* On day 8 a single dose of 180mg Oshadi D will be administrated during fast. Late breakfast will be provided 4 hours following drug administration~* On day 16 subjects will be administered with 360mg of Oshadi D during fast. Late breakfast will be provided 4 hours following drug administration.~* On day 24, 180mg of Oshadi D will be administrated immediately after breakfast.~* On day 32, subject will be administered with 360mg of Oshadi immediately after breakfast."
61999799|NCT05675553|EXPERIMENTAL|robot-assisted rehabilitation intelligent treatment|Both groups will receive treatment as usual(TAU) provided by the clinical team, including medication, exercise, and psychotherapy. Robot-assisted intelligent rehabilitation treatment will be delivered to participants in the testing group through an addiction prevention and relapse intervention intelligent system.
62215312|NCT02647775|OTHER|multi-port VATS|Multi-port VATS is an operative method
62215313|NCT02647775|OTHER|single-port VATS|Single-port VATS is an operative method
62394042|NCT01973205|PLACEBO_COMPARATOR|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
62394043|NCT01973205|EXPERIMENTAL|Acetaminophen 250 mg and aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and aspirin 250 mg
62394044|NCT05600101|EXPERIMENTAL|care.coach Pilot|"The research study procedures include screening for eligibility, a brief call with a research assistant after tablet is given to subject, and a survey after a subject has completed the study.~* 3 consecutive cohorts of 6 RIC HCT patients each.~* care.coach is a human-in the-loop conversational agent (avatar) used to interact and converse with patients through natural dialogue and text-to-speech software that is powered by a team of trained human staff, called health advocates. A subject uses the avatar for up to 3 weeks."
62569020|NCT04518241|EXPERIMENTAL|Condition 7|Core, fixed compensation
62569021|NCT04518241|EXPERIMENTAL|Condition 8|Core, lottery prize
62569022|NCT05496270||TME|patients only underwent TME
62569023|NCT05496270||nCRT+TME|patients underwent TME following neoadjuvant treatment
61999800|NCT05675553|OTHER|treatment as usual|Participants in the treatment-as-usual group were offered standard treatment at the mental health hospitals, which consisted of group and/or individual therapy, as determined by the clinical team.
61999801|NCT05479578|EXPERIMENTAL|Treatment (cyclophosphamide, dexamethasone)|Patients receive cyclophosphamide PO QD and dexamethasone PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61999802|NCT05761275|ACTIVE_COMPARATOR|Conventional Abdominal Laparoscopy|Use of conventional transabdominal laparoscopy as the surgical approach to perform the indicated procedure in the included patient with benign adnexal pathology (elective cystectomy/oophorectomy elective salpingectomy or tubal sterilization).
61999803|NCT05761275|EXPERIMENTAL|vNOTES|Use of vNOTES (Transvaginal Natural Orifice Transluminal Endoscopic Surgery) as the surgical approach to perform the indicated procedure in the included patient with benign adnexal pathology (elective cystectomy/oophorectomy elective salpingectomy or tubal sterilization).
62394045|NCT03726320|EXPERIMENTAL|Intervention Group|A decision aid along with decision coaching on PSA screening from a Community Health Worker (CHW). The intervention will be administered directly prior to the participant's appointment with their provider.
62185248|NCT01663558|ACTIVE_COMPARATOR|imiquimod|"i. Each subject will use an imiquimod anal suppository three times weekly (overnight on Monday, Wednesday, Friday) for 12 weeks.~ii. Each subject will be asked to abstain from receptive anal sex during therapy period (12 weeks).~iii. If local imiquimod adverse effects are severe, a 7-day period off of treatment will be permitted.~iv. During 12 week therapy period, each subject will be evaluated 2, 4, 8, and 12 weeks after starting therapy. At each visit, subject will complete a therapy questionnaire and undergo anal Pap, HRA with biopsies as indicated, and anal HPV testing.~v. After therapy completed (12 weeks), subject will enter 12 month observation period."
62185249|NCT01663558|ACTIVE_COMPARATOR|ablative|"i. Subject will be referred to colorectal surgeon, will complete a therapy questionnaire, and will be treated in accordance with treatment algorithm which is already in use.~ii. Subject will be asked to abstain from receptive anal sex for 12 weeks after ablative therapy.~iii. After therapy, subject will enter 12 month observation period."
62185250|NCT01663558|NO_INTERVENTION|Observation|"i. Given lack of accepted guidelines and outcome data on dysplasia management, the study PI will thoroughly discuss risks and benefits of observation/monitoring and treatment of dysplasia.~ii. If treatment is chosen, subject will be randomized to 1) ablative group, or 2) imiquimod group and begin therapy. Observation subjects will continue observation visits (observation questionnaire, anal Pap, HRA with biopsies as indicated, and anal HPV testing) every 3 months for 12 months (4 additional study visits)."
62185251|NCT04657601||Treatment Group|Patients undergo polypectomy facilitated by the study device.
62185252|NCT01582906||Control Group|Participants randomised to the control group would receive usual rehabilitation care via the existing referral pathways.
62394046|NCT03726320|ACTIVE_COMPARATOR|Control Group|A decision aid along with CHW interaction on dietary and lifestyle modification to serve as an attention control. The intervention will be administered directly prior to the participant's appointment with their provider.
62394047|NCT04322552|EXPERIMENTAL|Treament|In phase A, subjects receiving a single 0.25 mg of digoxin orally and wash-out for 5 days, then apatinib once daily will be conducted on D5 through D16 ； In addition, a single dose of 0.25 mg digoxin (in combination with apatinib) will be orally administered in fasting conditions on D12；
62394048|NCT00496574|ACTIVE_COMPARATOR|1|
62775420|NCT02690441|ACTIVE_COMPARATOR|CBT and placebo control|Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of placebo control (15 minutes telephone follow-up call each week) pre-treatment, and 10 weeks of attention placebo alongside CBT. Both treatment and placebo control is administered individually.
62775421|NCT02342262|EXPERIMENTAL|Probiotics|EcologicBarrier, 5x10E9 cfu/day
62775422|NCT02342262|PLACEBO_COMPARATOR|Placebo|carrier material of Ecologic Barrier, not containing bacterial strains
62775423|NCT03922087||Control Group|The pregnancy women without any diseases.
62775424|NCT03922087||Disease Group|The pregnancy women with cardio-metabolic and endocrinic disorders such as gestational diabetes, obesity, hypertension, thyroid diseases, anemia and other cardio-metabolic diseases.
62775425|NCT00825721|ACTIVE_COMPARATOR|1.3% (low dose)|
62775426|NCT00825721|ACTIVE_COMPARATOR|2% (medium dose)|
62775427|NCT00825721|ACTIVE_COMPARATOR|2.6% (high dose)|
62775428|NCT00825721|PLACEBO_COMPARATOR|Placebo|
61999804|NCT03073096|OTHER|Intervention arm|LVA at time of nodal dissection
61999805|NCT01365780|ACTIVE_COMPARATOR|With HBOT|Patients, who receive hyperbaric Oxygen Therapy after their surgical treatment
61999806|NCT01365780|NO_INTERVENTION|Without HBOT|"Patients who receive the same surgical treatment of their radius fracture than the patients of the group with HBOT, but no hyperbaric oxygen therapy (comparison group)"
61999807|NCT03672695|EXPERIMENTAL|Initial Schedule - S64315 low dose and venetoclax high dose administered in combination|
61999808|NCT03672695|EXPERIMENTAL|Initial Schedule - S64315 medium dose and venetoclax low dose administered in combination|
61999809|NCT03672695|EXPERIMENTAL|Initial Schedule - S64315 medium dose and venetoclax medium dose administered in combination|
62394049|NCT00496574|NO_INTERVENTION|2|no intevention
62394050|NCT05404321||Patient with early stage triple negative breast cancer|
62775429|NCT05261009|EXPERIMENTAL|Peri-capsular Nerve Group (PENG)|Those subjects assigned to the PENG treatment arm will receive a PENG block using 20mL of 0.2% ropivacaine with 1:400,000 epinephrine dosed in 5mL increments with negative aspiration beforehand and between each aliquot.
62775430|NCT05261009|ACTIVE_COMPARATOR|Lumbar Plexus Block (LPB)|Those subjects assigned to the LPB treatment arm will receive a stimulation-based LPB dosed with 20cc of 0.2% ropivacaine with 1:400,000 dilution epinephrine dosed in 5mL increments with negative aspiration beforehand and between each aliquot.
62775431|NCT05157581||Sezary Syndrome|15 subjects with Sezary Syndrome will comprise the single arm of this study
62775432|NCT01133119|ACTIVE_COMPARATOR|Treatment Group 1|
62775433|NCT01133119|EXPERIMENTAL|Treatment Group 2|
62775434|NCT02248402|EXPERIMENTAL|Vax-DC/MM|
62775435|NCT04516772|OTHER|Visian TICL|STAAR Visian Toric implantable collamer lens (TICL) for the correction or reduction of myopia with astigmatism.
62775436|NCT04928118||Impella protected Percutaneous coronary intervention (PCI)|Patients undergoing Impella protected PCI as deemed necessary by interventional cardiologist - VCU Medical Center case based standard of care
62775437|NCT04042727|EXPERIMENTAL|Dexmedetomidine plus Standard of Care|Dexmedetomidine hydrochloride infusion will be prepared by the investigational pharmacy and administered intravenously at a rate of 1mcg/kg/hr for a duration of 8 hrs to patients in rapid Afib in addition to the usual standard of care as deemed necessary by patient's ICU team.
62775438|NCT04042727|PLACEBO_COMPARATOR|Placebo plus Standard of Care|Normal Saline solution will be prepared by investigational pharmacy and administered intravenously at a rate of 1mcg/kg/hr for a duration of 8 hrs to patients in rapid Afib in addition to the usual standard of care as deemed necessary by patient's ICU team.
62775439|NCT04314076|ACTIVE_COMPARATOR|Gait Training (GT) with Rhythmic Auditory Stimulation (RAS)|Participants in this arm will complete 16 supervised gait training sessions consisting of continuous overground walking on a track for 30 minutes,with RAS
62775440|NCT04314076|OTHER|Gait training (GT) without Rhythmic Auditory Stimulation (RAS)|Participants in this arm will complete 16 supervised gait training sessions consisting of continuous overground walking on a track for 30 minutes without RAS
62394051|NCT00354120|EXPERIMENTAL|1|Alentuzumab
62775441|NCT02408523|EXPERIMENTAL|Lacosamide|"Lacosamide 50 mg tablets: starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400 mg/day for adult subjects and pediatric subjects \>= 50 kg.~Lacosamide oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects \< 30 kg.)~Lasosamide oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30 kg to \< 50 kg.)"
62775442|NCT02408523|PLACEBO_COMPARATOR|Placebo|"Placebo 50 mg tablets: starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400mg/day for adult subjects and pediatric subjects \>= 50kg.~Placebo oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects \< 30kg.)~Placebo oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30kg to \< 50kg.)"
62775443|NCT05515939||InPen|Patients who will begin using the InPen device as per standard of care
62775444|NCT02214043||Group 2|
62775445|NCT02214043||group 1|
62775446|NCT00820222|EXPERIMENTAL|Lapatinib plus capecitabine|Lapatinib 1250 mg once daily and capecitabine 2000mg/m2/day, days 1-14, every 21 days
62775447|NCT00820222|ACTIVE_COMPARATOR|Trastuzumab plus capecitabine|trastuzumab loading dose of 8mg/kg followed by 6mg/kg q3weekly infusions, and capecitabine 2500mg/m2/day, days 1-14, every 21 days
62394052|NCT00354120|ACTIVE_COMPARATOR|2|Globulina antilinfocitaria
62569024|NCT03451253|EXPERIMENTAL|amino acid mixture beverage|amino acid based hydration beverage. It will be given 8 oz, twice daily for the first 4 weeks of randomized blinded intervention. It will be given in same dose during 4 week open label intervention.
62569025|NCT03451253|ACTIVE_COMPARATOR|glucose based sports drink|glucose based hydration beverage. It will be given 8oz, twice daily for the first 4 weeks of randomized blinded intervention.
62569026|NCT02861807|EXPERIMENTAL|Active stimulation with mindfulness|Brain stimulation with mindfulness-based relapse prevention. Treatment sessions will be 2 hours for 8 sessions, with the first 30 minutes consisting of transcranial direct current stimulation (tDCS) with the current set to 2.0 milliamps (mA) and guided meditation practice.
61999810|NCT03672695|EXPERIMENTAL|Initial Schedule - S64315 medium dose and venetoclax high dose administered in combination|
62185253|NCT01582906||Intervention Group|Participants randomised to the intervention group will be offered two rehabilitation appointments at three month intervals. They will complete the screening tool, the Distress (Concerns) Thermometer before the first appointment; this will be reviewed after three months. Appointments will make use of communication skills recognised to promote motivation via self-efficacy. Self efficacy is a person's belief in their ability to achieve a goal. Their sense of mastery will influence their behaviour, their perception of stress and the effort they put into achieving that goal.
62775448|NCT06191107|EXPERIMENTAL|PEEK-RPDs|Participants with removable partial dentures made of PEEK
62775449|NCT02175914|EXPERIMENTAL|Erythromycin|Oral treatment with Erythromycin 500mg twice daily.
62775450|NCT04088110|EXPERIMENTAL|Pyrotinib and trastuzumab plus aromatase inhibito|Participants will receive pyrotinib in combination with trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
62775451|NCT05141604|EXPERIMENTAL|Field expansion view|Various configurations of field expansion views will be additionally displayed on HMD
62775452|NCT03969017|EXPERIMENTAL|NAs+Peg IFN Group|NAs+Peg IFN Group will receive the treatment of NAs (patients previously treated with telbivudine will be changed to entecavir) plus pegylated interferon (Peg IFN)α-2b.
62775453|NCT03969017|OTHER|NAs Group|NAs Group will be treated with NAs as before enrollment.
62775454|NCT00556413|EXPERIMENTAL|ERBIRINOX|5FU + Irinotecan + Oxaliplatine + Cetuximab
62775455|NCT06203418|EXPERIMENTAL|Intervention|Multi-Family Therapy
62775456|NCT02421679|EXPERIMENTAL|TNX-102 SL|TNX-102 SL taken daily at bedtime for 12 weeks
62775457|NCT03891368|EXPERIMENTAL|Virtual Learning Collaborative|The virtual learning collaborative (VLC) is an 18-month intensive training, skill building, and structured implementation process focused on reinforcing fidelity to the InSHAPE model.
62185254|NCT04618380||Bilateral trifocal implantation|Bilateral implantation of trifocal diffractive intraocular lenses (Panoptix, Alcon) targeting emmetropia
62775458|NCT03891368|ACTIVE_COMPARATOR|Technical Assistance|"The technical assistance (TA) condition includes four scheduled conference calls between an InSHAPE expert TA coach and the agency's InSHAPE team, with the option for sites to request additional calls as needed through 18-months post-randomization."
62775459|NCT02045693|EXPERIMENTAL|Part 1: Methadone + DCV 3DAA FDC + BMS-791325|"Methadone 40-120 mg tablet or solution orally once on Day 1~Methadone 40-120 mg tablet or solution orally once daily + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3 direct-acting antiviral (3DAA) fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12"
61999811|NCT03672695|EXPERIMENTAL|Initial Schedule - S64315 high dose and venetoclax medium dose administered in combination|
61999812|NCT03672695|EXPERIMENTAL|Alternative Schedule - Venetoclax medium dose administered with no S64315|
61999813|NCT03672695|EXPERIMENTAL|Alternative Schedule - S64315 medium dose and venetoclax medium dose administered in combination|
61999814|NCT03672695|EXPERIMENTAL|Alternative Schedule - S64315 high dose and venetoclax low dose administered in combination|
61999815|NCT04091646|ACTIVE_COMPARATOR|Roflumilast Foam 0.3%|Participants apply roflumilast foam 0.3% once daily (QD) to all areas of seborrheic dermatitis once daily for 8 weeks.
61999816|NCT04091646|PLACEBO_COMPARATOR|Vehicle Foam|Participants apply inactive vehicle foam matched to roflumilast foam QD for 8 weeks.
61999817|NCT03810066|EXPERIMENTAL|Osimertinib|
61999818|NCT04466475|EXPERIMENTAL|Treatment (211At-OKT10-B10, melphalan, PBSC transplantation)|Patients receive 211At-OKT10-B10 IV continuously on day -10 to day - 4 (approximately day -7) and melphalan via infusion on day -2. Patients then undergo HCT on day 0.
61999819|NCT04780425|EXPERIMENTAL|DESMOND|receive usual care plus a structured diabetes self-management education program delivered once over 6hours
61999820|NCT04780425|ACTIVE_COMPARATOR|USUAL CARE|Receive usual care as per standard treatment guidelines of ghana unstructured education during clinic visits for routine care
62185255|NCT04618380||Myopic monovision|The dominant eye defocus is targeted to -0.50 diopters while the recessive one to -1.25 diopters with bilateral implantation of monofocal intraocular lenses (SN60WF, Alcon)
62569027|NCT02861807|SHAM_COMPARATOR|Sham brain stimulation with mindfulness|Brain stimulation with mindfulness-based relapse prevention. Treatment sessions will be 2 hours for 8 sessions, with the first 30 minutes consisting of transcranial direct current stimulation (tDCS) with the current set to ramp up to 2.0 milliamps (mA) and then ramp down to 0.0 mA and guided meditation practice.
62775460|NCT02045693|ACTIVE_COMPARATOR|Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325|"Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once on Day 1~Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3DAA fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12"
61977789|NCT04974112||Gastroenterology|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
61999821|NCT02069522|ACTIVE_COMPARATOR|Standard Milk-based Formula Containing Carotenoid|milk-based ready to feed infant formula
61999822|NCT02069522|EXPERIMENTAL|Investigational Milk-based Formula Containing Carotenoid|investigational milk-based ready to feed infant formula
61999823|NCT04169867||Healthy Volunteers|This cohort will consist of 1000 healthy volunteers from Poland.
61999824|NCT04169867||Melanoma|This cohort will consist of 160 patients with melanoma.
61999825|NCT04001569|EXPERIMENTAL|AZD8186 in combination with paclitaxel|
62775461|NCT02882100|EXPERIMENTAL|aTIV|NH facilities randomized to receive adjuvanted trivalent influenza vaccine (aTIV, FLUAD) for the residents
62775462|NCT02882100|ACTIVE_COMPARATOR|TIV|NH facilities randomized to receive standard trivalent influenza vaccine (TIV, Fluvirin) for the residents
61999826|NCT03570866||Early stage endometrial cancer|Women with diagnosis of intermediate and high-risk early stage endometrial cancer.
61999827|NCT02487394||COPD Smoker Subjects|Smokers Active smoking will be defined as daily use of cigarettes, pipes, cigarillos or cigars at time of entry into the study and through duration of study.
61999828|NCT02487394||Asthma Non-Smoker Subjects|Non-Smokers Subjects with no active smoking. No active smoking defined as never smoking or having stopped smoking for 5 years or greater.
61999829|NCT05076266||Women Who Decline TMIST|Women who decline TMIST will be asked to fill out a survey with questions about demographics, income and employment, attitudes and experiences about COVID-19, and emotional well-being.
61999830|NCT03026465|EXPERIMENTAL|Coroflex ISAR stent|PCI with a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR stent) with very thin struts (50 µm). During the PCI, an OCT assessment (baseline and post-implantation) will be performed.
61999831|NCT03026465|ACTIVE_COMPARATOR|Biomatrix stent|PCI with a biodegradable-polymer biolimus-eluting stent (Biomatrix stent) with 120 µm struts. During the PCI, an OCT assessment (baseline and post-implantation) will be performed.
61999832|NCT04347304|EXPERIMENTAL|cocoa polyphenols|21 grams of dark chocolate (289 mg polyphenols)
61999833|NCT04347304|PLACEBO_COMPARATOR|polyphenols free|21 grams of white chocolate (0 mg polyphenols)
61999834|NCT06329102||Access (Open, laparoscopic, robotic)|Outcomes will be analysed for the different groups
61999835|NCT06329102||Extend of lymphadenectomy described by VAS score|The extend of lymphadenectomy achieved will be described by a visual analogue scale (VAS) after the operation
62185256|NCT04618380||Hybrid monovision|Hybrid monovision combines a monofocal intraocular (SN60WF, Alcon) in the dominant eye and a trifocal diffractive intraocular lens (Panoptix, Alcon) in the recessive one
61999836|NCT06329102||Quality of the specimen|The quality of the specimen will be documented postoperatively by a graded classification system
61999837|NCT03111420|EXPERIMENTAL|Clopidogrel|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
61999838|NCT03111420|EXPERIMENTAL|Prasugrel|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
61999839|NCT03111420|EXPERIMENTAL|Ticagrelor|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
61999840|NCT04854915|ACTIVE_COMPARATOR|Liverpool Overweight and Obesity Programme (LOOP) only|Patients will continue to follow the LOOP@ Alder Hey programme.
61999841|NCT04854915|EXPERIMENTAL|LOOP + mHealth technology assisted exercise counselling|Patients will continue to work with the LOOP MDT. However, exercise and physical activity advise will be taken over by an exercise specialist. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 5 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
61999842|NCT04966676|EXPERIMENTAL|Non-Small cell Lung Cancer|"Nivolumab, intravenously (given by vein), once every 3 weeks Ipilimumab, intravenously (given by vein), once every 6 weeks~Participants will have blood samples taken for cell free deoxyribonucleic acid (cfDNA) testing.~If there is an increasing or stable tumor cfDNA, platinum-doublet chemotherapy will be given."
61999843|NCT04623333|EXPERIMENTAL|TQB2450 injection|TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
61999844|NCT04019691|ACTIVE_COMPARATOR|Mix-and-Match group|Cataract surgery and implantation of a Tecnis ZKB00 multifocal IOL with +2.75 D add power (Abbott Medical Optic Inc., Santa Ana, CA) in the dominant eye, and a Tecnis ZLB00 multifocal IOL with +3.25 D add power (Abbott Medical Optics Inc.) in the non-dominant eye.
61999845|NCT04019691|ACTIVE_COMPARATOR|EDOF group|Cataract surgery and implantation of Tecnis Symfony ZXR00 trifocal IOLs (Abbot Medical Optics Inc.) in both eyes.
61999846|NCT04019691|ACTIVE_COMPARATOR|Trifocal group|Cataract surgery and implantation of FineVision PodFT IOLs (PhysIOL SA) in both eyes.
62569028|NCT01472042||Sports induced concussion|Exposure to sports induced concussion
62569029|NCT01472042||Routine Athletic Exertion|Exposure to routine athletic exertion (non-concussion control)
62569030|NCT01472042||Other Non-Penetrating Trauma to the Head|Exposure to other non-penetrating trauma to the head that is witnessed or self-reported
62775463|NCT04680949|PLACEBO_COMPARATOR|Placebo|Patients receiving standard-of-care (SOC) and placebo. Placebo is injected subcutaneously once daily for 10 days
62775464|NCT04680949|EXPERIMENTAL|Anakinra|Patients receiving SOC and anakinra. Anakinra is injected subcutaneously as 100 mg once daily for 10 days
61999847|NCT01344369|EXPERIMENTAL|Investigational Test Product|Norethindrone/Ethinyl Estradiol 0.4 mg/0.035 mg Chewable Tablets (Teva)
61999848|NCT01344369|ACTIVE_COMPARATOR|Reference Listed Drug|FEMCON® Fe 0.4 mg/0.035 mg Chewable tablets (Warner Chilcott)
61999849|NCT04155515|OTHER|Non-cirrhotic, HCV genotype 1 infected subjects|Subjects will be treated with TG-2349 400mg combined with DAG181 200mg and Ribaverin 1000mg/1200mg for 12 weeks.
61999850|NCT04155515|OTHER|Cirrhotic, HCV genotype 1 infected subjects|Subjects will be treated with TG-2349 400mg combined with DAG181 200mg and Ribaverin 1000mg/1200mg for 12 weeks.
61999851|NCT03941210||HIV+/TB+|"Frozen samples and data from participants recruited in the ANRS 12095 CAMELIA clinical trial and the ANRS 12153 CAPRI NK study will be used for this study arm~All plasma samples were collected before any treatment during IRIS diagnosis and at W8 post TB treatment initiation"
61999852|NCT03941210||HIV+/TB-|"Participants included in this study arm will be HIV+ and TB-~One time collection of 5 ml of blood will be drawn in EDTA tube for each patient before starting cART and sent to the laboratory for protocol analysis"
61999853|NCT03941210||HIV-/TB+|"Participants included in this study arm will be HIV- and TB+~Collection of 5 ml of blood drawing in EDTA tube will be requested for each patient before starting TB drug treatment and after week 2 and 8 of treatment"
62185257|NCT04618380||Premium monovision|Participants received a bifocal hybrid (refractive at the centre, diffractive at the periphery) intraocular lens (Restor +2.50 diopters, Alcon) in the dominant eye and a trifocal diffractive intraocular lens (Panoptix, Alcon) in the recessive one, targeting emmetropia in both eyes.
62185258|NCT03567135||Experimental 1|concurrent chemoradiotherapy（Temozolomide+apatinib） maintenance therapy（Temozolomide）
62569031|NCT01659983|EXPERIMENTAL|Primary wound closure|A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
62775465|NCT04325230|EXPERIMENTAL|Arterial Spin Labeling sequence|ASL sequence added to the usual care brain MRI
62775466|NCT03807284|EXPERIMENTAL|A group psycho-social course|The intervention group received a group psycho-social course, a 2 hour, weekly, eleven week intervention delivered by a health professional working in stroke and usual care.
62775467|NCT03807284|NO_INTERVENTION|Control Group|Participants in the usual care control group will continue to receive all other services routinely available to them as is usual practice.
62775468|NCT04691856|PLACEBO_COMPARATOR|placebo|250 ml saline will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml/h, lockout period: 7 min.
62775469|NCT04691856|ACTIVE_COMPARATOR|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml/h, lockout period: 7 min.
62775470|NCT04691856|ACTIVE_COMPARATOR|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml/h, lockout period: 7 min.
62775471|NCT03529279|EXPERIMENTAL|Experimental Group|The patients in the Experimental Group are allocated to receive CNG staging and CNG chemotherapy strategy and CNG radiation strategy
62775472|NCT03529279|ACTIVE_COMPARATOR|Controlled Group|The patients in the Controlled Group are allocated to receive the eighth edition of UICC/AJCC staging and NCCN chemotherapy strategy and NCCN radiation strategy
62775473|NCT00367276|EXPERIMENTAL|Arm 1|
62775474|NCT04514211||Propofol|General anesthesia using propofol infusion
62775475|NCT04514211||Sevoflurane|General anesthesia using sevoflurane
62775476|NCT02924740|ACTIVE_COMPARATOR|control|pelvic floor muscle training
62775477|NCT02924740|EXPERIMENTAL|intervention|vaginal tampon training.
62775478|NCT02968628||Cases: Infants of Diabetic Mothers|"Cases: Neonates born at or over 35 weeks gestation whose mother's were recommended to receive medication for diabetes during pregnancy. This includes pre-gestational and gestational diabetics.~Interventions:~1. Video Electroencephalogram (EEG)~2. Point-of Care Blood Sugar Testing~3. Medical Record Data Extraction~4. Maternal Questionnaire"
62775479|NCT02968628||Controls|"Controls: Neonates born at or over 35 weeks gestation whose mother's had normal glycemic control testing during pregnancy.~Interventions:~1. Video Electroencephalogram (EEG)~2. Point-of Care Blood Sugar Testing~3. Medical Record Data Extraction~4. Maternal Questionnaire"
62775480|NCT04306653|EXPERIMENTAL|ACTH|patients with acute gout treated with ACTH
62394053|NCT04061668|OTHER|single needle path PECS I and II block group(|The probe is placed inferior to the clavicle . A probe and needle is introduced with in-plane technique . The US is placed below outer third of the clavicle showing pectoralis major and minor muscles then moved infero-laterally to locate fourth rib where pectoralis major and pectoralis minor muscles is visualised . The US probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles will be identified at 4th rib at the level of thoraco-acromial artery then the needle is inserted from caudal to cranial using an inclined manner, 15mL of bupivacaine 0.25% is put between pectoralis minor muscle and serratus muscle (PECS II) then it is withdrawn to inject 15 ml of bupivacaine in thel plane between pectoralis muscles . The block will be performed with needle introduced in-plane with the ultrasound probe, and the local anesthetic injection will be visualized .
62569032|NCT01659983|ACTIVE_COMPARATOR|Delayed primary wound closure|A wound will be left open with saline-soaked gauze packing after the operative procedure and will be sutured around day 3 to 7 after operation
62775481|NCT04306653|ACTIVE_COMPARATOR|Betamethasone|patients with acute gout treated with betamethasone
62775482|NCT04463667|EXPERIMENTAL|The effects of exercise intervention on fatty liver|The effects of exercise intervention on fatty liver and the improvement of the above-mentioned various metabolic indicators, including improvement of sleep patterns and changes of intestinal microflora.
62775483|NCT06171646|EXPERIMENTAL|Experimental, Breathing Group|Breathing exercises were applied to the participants.
62775484|NCT06171646|NO_INTERVENTION|No Intervention: Standard care|Participants received standard care.
62775485|NCT04878913||C21|Participants treated with C21 in the VP-C21-006 trial
62775486|NCT04878913||Placebo|Participants treated with placebo in the VP-C21-006 trial
62775487|NCT05061498|OTHER|Additional Pacing maneuvers|In all study participants additional pacing maneuvers (cycle lenght and output) are performed
62791659|NCT01999400|EXPERIMENTAL|Arm 1: Pentasa then Delzicol then Apriso then Lialda|"1. Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~2. Washout period of 10 days.~3. Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~4. Washout period of 10 days.~5. Apriso 375 mg capsule x 3 with 240 mL water, single dose.~6. Washout period of 10 days.~7. Lialda 1200 mg tablet x 1 with 240 mL water, single dose."
61999854|NCT03941210||HIV-/TB-|"Participants included in this study arm will be HIV- and TB-~Clinical examination to rule out overt evidence of TB and, whenever needed, routine TB testing as per national guidelines (sputum smear ± chest X-ray) in case of symptoms/clinical manifestations suggestive of TB."
62394054|NCT04061668|SHAM_COMPARATOR|double needle path PECS I and II block group|The probe will be placed below outer third of the clavicle showing pectoralis major and minor muscles and the thoraco- acromial artery then moved inferolaterally to locate fourth rib where pectoralis major and pectoralis minor muscles are visualised, then the needle is inserted in plane with probe and 15mL of bupivacaine are put into between pectoralis muscles. In the second puncture , the US probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles are identified , the needle will be inserted in plane with the probe from caudal to cranial , 15mL of bupivacaine will be put into the potential space between pectoralis minor muscle and serratus muscle (PECS II).
62775488|NCT04094675|EXPERIMENTAL|Treatment arm|"There will be a clinic visit and colonoscopy at study entrance with standard of care sampling and assessment of polyps, including resection of concerning polyps. The investigators will also collect data on well-being via the SF-36 health survey (a validated questionnaire to help monitor this aspect given anecdotal patient-level reports of improvement while on therapy).~Study subjects will then begin sirolimus 2 mg by mouth daily for 1 year.~Laboratories will be checked at 4 days after initiation, at 2 weeks after initiation, then every 4 weeks for 3 months, then every 3 months to complete the year of therapy~Participants will have a clinic visit at 3, 6 and 9 months and include well-being assessment with the SF-36 health survey.~Participants will have a clinic visit with well-being assessment and perform colonoscopy at study closure at 12 months. The investigators will perform standard of care sampling and assessment of polyps, including resection of concerning polyps."
61999855|NCT02367599|ACTIVE_COMPARATOR|Vitamin D Supplement + PrEP|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks in addition to their PrEP provided through the main study.
61999856|NCT02367599|NO_INTERVENTION|PrEP Only|Subjects not enrolled into this sub-study will continue receiving PrEP through the main study. Subjects taking unsupplemented PrEP may still be used as matched controls to sub-study subjects.
61999857|NCT01813318|PLACEBO_COMPARATOR|Placebo/sugar pill|Placebo will be dosed similar to acamprosate, in terms of dosage form, frequency and duration.
61999858|NCT01813318|ACTIVE_COMPARATOR|Acamprosate|"Acamprosate: The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.~Other Name: Campral"
61999859|NCT01725568||Implantable cardiac monitor diagnostics|Patients has standard indication for implantable cardiac monitor diagnostic.
61999860|NCT00628290|EXPERIMENTAL|1|
61999861|NCT00628290|ACTIVE_COMPARATOR|2|
61999862|NCT05638646|OTHER|Intervention group|Practice standard for clinical diagnosis and treatment of chronic obstructive pulmonary disease
61999863|NCT05638646|OTHER|control group|Maintain current treatment
61999864|NCT04752501|EXPERIMENTAL|Psychologically Informed Video Series|"This 3 part educational video series will teach participants how the body processes nociception and experiences pain, and pain does not mean tissues are being damaged. Additionally we will use the framework called the Common Sense Model of Self-Regulation which advocates for education to address five cognitive dimensions: (1) identity (the effort to evaluate symptoms and label the illness); (2) cause (the subjectively formulated belief of what is causing the symptoms); (3) time-line (the patient's perception of how long the problem will last); (4) consequences (the patient's predictions of how the illness will affect them in different areas of their life); and (5) controllability (the patient's belief regarding their outcome and personal ability to change it); Simple methods of cognitive restructuring; and how to respond to activity-related pain."
61999865|NCT04752501|ACTIVE_COMPARATOR|Biomedical Education Video Series|Participants in the control (biomedical education) group will watch a series videos on the iPad equal in length to the psychologically informed video series. The control video will discuss basic anatomy of the knee and provide no psychosocial education or positive reinforcement about their condition, basic strengthening exercises and proper lower extremity mechanics
61999866|NCT04865796|EXPERIMENTAL|Group 1|Patients will use products based on lactoferrin.
61999867|NCT04865796|EXPERIMENTAL|Probiotics|Patients will use products based on probiotics for home oral care.
61999868|NCT04865796|ACTIVE_COMPARATOR|Standard therapy|Patients will use standard toothpastes for home oral care.
62569033|NCT02311127|EXPERIMENTAL|SecurAcath|Subcutaneous securement
61999869|NCT01202825|EXPERIMENTAL|001|
61999870|NCT01202825|PLACEBO_COMPARATOR|008|
62569034|NCT02311127|ACTIVE_COMPARATOR|StatLock|Adhesive securement
61999871|NCT01202825|PLACEBO_COMPARATOR|002|
62394055|NCT01042431||Ward population|Patients hospitalized in the Orthopedics B Ward in the Hillel Yaffe Medical Center that choose to participate in the study
62394056|NCT01401179|ACTIVE_COMPARATOR|cefazolin|
62394057|NCT01401179|ACTIVE_COMPARATOR|cefazolin plus erythromycin|cefazolin, erythromycin
62394058|NCT01401179|ACTIVE_COMPARATOR|cefazolin plus clarithromycin|
62775489|NCT00837759|OTHER|T1D group|This study was terminated prior to full subject accrual because of changes to study personnel. The original study design was changed from a double-blind, placebo-controlled study to an open-label pilot study in order to collect safety data on enrolled subjects prior to study termination.
62775490|NCT03728179|EXPERIMENTAL|Cohort 1|0,5 Gy of RT + Cyclophosphamide + Nivolumab + Ipilimumab + Aspirin
62775491|NCT03728179|EXPERIMENTAL|Cohort 2|1 Gy of RT + Cyclophosphamide + Nivolumab + Ipilimumab + Aspirin
61999872|NCT01202825|EXPERIMENTAL|009|
61999873|NCT01202825|EXPERIMENTAL|003|
61999874|NCT01202825|PLACEBO_COMPARATOR|004|
62394059|NCT04391660|ACTIVE_COMPARATOR|0.5% sodium hypochlorite solution|
62775492|NCT03728179|EXPERIMENTAL|Cohort 3a|1 Gy of RT + Cyclophosphamide + Nivolumab + Celecoxib
61999875|NCT01202825|EXPERIMENTAL|005|
62775493|NCT03728179|EXPERIMENTAL|Cohort 4a|2 Gy of RT + Cyclophosphamide + Nivolumab + Celecoxib
61999876|NCT01202825|EXPERIMENTAL|010|
61999877|NCT01202825|PLACEBO_COMPARATOR|006|
61999878|NCT01202825|EXPERIMENTAL|007|
61999879|NCT04067284|ACTIVE_COMPARATOR|Education|Nutrition education on dietary diversity.
61999880|NCT04067284|EXPERIMENTAL|Yogurt|A combination of similar education plus daily supplementation of homemade yogurt
61999881|NCT04067284|ACTIVE_COMPARATOR|Control|Control group.
61999882|NCT06143475|EXPERIMENTAL|FPS group|"In the FPS group, in addition to same physical therapy ran in the control group, the patient received FPS from the apparatus Vibramoov (Techno Concept, France) on their upper limbs. The patients received in total 12 Vibramoov sessions of 30 minutes, 5 times a week."
61999883|NCT06143475|ACTIVE_COMPARATOR|Conventional therapy group|In the conventional therapy group patients received sessions of traditional physical therapy: individual therapy sessions including exercises to strengthen muscles, stretching, reflex exercises for large, medium and small muscle groups of the upper limbs (ontogeny-oriented kinesiotherapy (OOKT), PNF - proprioceptive neuro-muscle facilitation, training and practice of functional rational self-service tasks). 12 sessions in total were realized 5 times a week and lasted 40 minutes each.
61999884|NCT02889354|EXPERIMENTAL|Cognitive-behavioral therapy|
61999885|NCT03680274|EXPERIMENTAL|Vitamin C|Vitamin C: 50 mg/kg every 6 hours for 96 hours.
62394060|NCT04391660|ACTIVE_COMPARATOR|0.5% sodium hypochlorite solution and 70% ethanol|
62394061|NCT02452138||Low EAA|Endotoxin Activity Assay \[EAA\] level \< 0.40 EAA units
62394062|NCT02452138||Intermediate EAA|Endotoxin Activity Assay \[EAA\] level between 0.40-0.59 EAA units
62394063|NCT02452138||High EAA|Endotoxin Activity Assay \[EAA\] level \>= 0.60 EAA units
62394064|NCT02647021|ACTIVE_COMPARATOR|Therapeutic Exercise|"Therapeutic Exercise Program (standard care) will include:~1. Neck range of motion and strengthening, and posture retraining.~2. Shoulder specific progressive resistance exercise program that focuses on spinal accessory nerve dysfunction and rehabilitation of trapezius muscle function."
62569035|NCT02146014|EXPERIMENTAL|Transcranial Direct Current Stimulation|These subjects will receive real transcranial direct current stimulation.
62569036|NCT02146014|PLACEBO_COMPARATOR|Sham tDCS|These subjects will receive sham transcranial direct current stimulation (placebo)
62569037|NCT06441604|EXPERIMENTAL|16mg Extended-Release Buprenorphine|The first 10 participants will receive XR-BUP 16mg in single-blind fashion.
62569038|NCT06441604|EXPERIMENTAL|24mg Buprenorphine|After first 10 participants have been completed, the next 10 participants will receive 24mg in a single-blind fashion.
62569039|NCT06441604|EXPERIMENTAL|32mg Buprenorphine|After the 20 participants have been completed, the next 10 participants will receive 32mg in a single-blind fashion.
62775494|NCT03728179|EXPERIMENTAL|Phase I b|Recommended Phase Ib RT dose (RP1bD) + Nivolumab + Ipilimumab or Cyclophosphamide + Celecoxib
61999886|NCT03680274|PLACEBO_COMPARATOR|Control|Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
61999887|NCT02127502||Critically ill patients sepsis suspected|
61999888|NCT06113952||Patients treated with weekly growth hormone|Approximately 200 children with a diagnosis of pGHD who are treatment naïve or currently receiving once weekly Ngenla will be enrolled.
61999889|NCT06113952||Patients treated with daily growth hormone|Approximately 200 children with a diagnosis of pGHD who are treatment naive or currently receiving daily GH injections will be enrolled
61999890|NCT04596150|EXPERIMENTAL|ARM A - CX-2009 Monotherapy, HR-positive/HER2-negative|CX-2009 Monotherapy in advanced, metastatic Hormone Receptor (HR)-positive / Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer
61999891|NCT04596150|EXPERIMENTAL|ARM B - CX-2009 Monotherapy, TNBC|CX-2009 Monotherapy in advanced, metastatic Triple-Negative Breast Cancer (TNBC)
62394065|NCT02647021|EXPERIMENTAL|Therapeutic + Lower Body Exercise|"The Therapeutic Exercise Program (standard care) will include:~1. Neck range of motion and strengthening, and posture retraining.~2. Shoulder specific progressive resistance exercise program that focuses on spinal accessory nerve dysfunction and rehabilitation of trapezius muscle function.~The Resistance Exercise component will target 6-8 muscle groups of the lower extremities and core including gluteal, quadriceps, hamstrings, abdominals, and gastrocnemius muscles. A progressive introduction of exercises will occur over the first 3 weeks.~1. a personalized program of lower extremity resistance exercises~2. core strengthening exercises"
61999892|NCT04596150|EXPERIMENTAL|ARM C - CX-2009 Combination therapy, TNBC|CX-2009 and CX-072 Combination therapy in advanced, metastatic TNBC
61999893|NCT02815228|EXPERIMENTAL|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
61999894|NCT02029534|ACTIVE_COMPARATOR|Atorvastatin 20 mg|atorvastatin 20 mg daily 2 to 7 days prior to surgery and up to 7 post surgery
62394066|NCT06001164|ACTIVE_COMPARATOR|Double-bundle|
62394067|NCT06001164|ACTIVE_COMPARATOR|Single-bundle|
62394068|NCT05861882||handball player|"* To be a licensed handball athlete~* Not having undergone a surgical operation involving the musculoskeletal system in the last six months~* Not having any obstacle to perform the tests to be performed within the study~* Volunteering to participate in the study"
61999895|NCT02029534|EXPERIMENTAL|Atorvastatin 80 mg|atorvastatin 80 mg daily 2 to 7 days prior to surgery and up to7 days post surgery
61999896|NCT03800719|EXPERIMENTAL|Intervention Group|AWARD advice, health warning leaflet, active referral to smoking cessation (SC) services, regular messages through Instant Messaging (IM), psychosocial support and referral to SC services through IM
62394069|NCT05861882||sedantary young people|-being a volunteer
62394070|NCT02944604|EXPERIMENTAL|PEG-rhG-CSF|Patients with breast cancer who were treated with intensive chemotherapy received PEG-rhG-CSF.
62394071|NCT02010099|EXPERIMENTAL|PP110 Gel|PP110 Gel
62394072|NCT02010099|EXPERIMENTAL|PP110 medicated wipes|PP110 Medicated wipes
62394073|NCT02010099|ACTIVE_COMPARATOR|Preparation-H cream|Preparation-H cream
62394074|NCT02053415|EXPERIMENTAL|Krill oil low dose|3 capsules krill oil per day, for 28 days
62394075|NCT02053415|EXPERIMENTAL|Krill oil high dose|9 capsules krill oil per day, for 28 days
61999897|NCT03800719|ACTIVE_COMPARATOR|Control Group|AWARD advice, health warning leaflet, active referral to smoking cessation (SC) services, SMS message on general health
61999898|NCT01331031||Adolescents|Adolescents between 10 and 20 years of age and enrolled in a municipal school system.
61999899|NCT04204018|EXPERIMENTAL|Experimental|Experimental-arm providers will complete four simulated patient cases (CPVs) with two additions described in the next column:
61999900|NCT04204018|NO_INTERVENTION|Control|These providers will complete four simulated patient cases (CPVs) only.
62185259|NCT03567135||control|concurrent chemoradiotherapy（Temozolomide） maintenance therapy（Temozolomide）
62394076|NCT01855919|EXPERIMENTAL|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for first 3 days and 20 mg for last 4 days of week.
61999901|NCT04287907|EXPERIMENTAL|Monitor|Qualitative End Tidal Co2 detector will be attached to the face mask used to provide mask ventilation to the preterm baby before connected to the T piece resuscitator. Respiratory function monitor sensor will be placed within circuit to measure parameters e.g. PIP, PEEP, FiO2, tidal volume.
62394077|NCT01855919|PLACEBO_COMPARATOR|Placebo|Placebo administered orally once every day for 15 weeks.
62569040|NCT02897102|ACTIVE_COMPARATOR|Control group|The individuals in the control group chose to participate in different group activities: ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants). The activities were offered once per week in 2 hours classes for 35 weeks and were held between April and November of 2013.
62569041|NCT02897102|EXPERIMENTAL|Training group|was offered in one weekly class for 2 hours for 35 weeks between April and November of 2013. The first 50 minutes were spent performing exercises with the abacus, with increasing difficulty. One or two of the following activities followed the abacus training: playing games, neurobic and group dynamics.
62569042|NCT03197389|OTHER|Cohort A1|Cohort A1 will include patients with a triple negative breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
62569043|NCT03197389|OTHER|Cohort A2|Cohort A2 will include patients with ER/PR negative and Her2 positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
62569044|NCT03197389|OTHER|Cohort B1|Cohort B1 will include patients with a triple negative breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
62569045|NCT03197389|OTHER|Cohort B2|Cohort B2 will include patients with a ER/PR negative and Her2 positive breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
62775495|NCT03728179|EXPERIMENTAL|Cohort 3b|1 Gy of RT + Ipilimumab + Nivolumab + Celecoxib
62775496|NCT03728179|EXPERIMENTAL|Cohort 4b|2 Gy of RT + Ipilimumab + Nivolumab + Celecoxib
62775497|NCT02762331|EXPERIMENTAL|Vitamin C|Intravenous ascorbic acid 50 mg/kg in 50 mL normal saline every six hours for 48 hours.
62394078|NCT00135694|EXPERIMENTAL|Immunosuppression Withdrawal|Subjects may randomize to this group at 12 to 24 months after transplantation. This is followed by tapered withdrawal of calcineurin inhibitor-based immunosuppression therapy over the course of 1 year.
62394079|NCT00135694|ACTIVE_COMPARATOR|Immunosuppression Maintenance|Liver transplant, followed by maintenance doses of continuous calcineurin inhibitor-based immunosuppression therapy.
62185260|NCT03567135||Experimental 2|concurrent chemoradiotherapy（Temozolomide+apatinib） maintenance therapy（Temozolomide+apatinib）
62394080|NCT04422301|EXPERIMENTAL|High intensity eccentric training|"High intensity eccentric training high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.~eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction."
62775498|NCT02762331|PLACEBO_COMPARATOR|Normal saline|Intravenous normal saline 50 mL every six hours for 48 hours
61977790|NCT04974112||Respiratory|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
61977791|NCT04974112||Neurology|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
62775499|NCT03905902|EXPERIMENTAL|DCVAC/OvCa with standard of care|"Induction period: DCVAC/OvCa with carboplatin and gemcitabine, or carboplatin and paclitaxel, or carboplatin and pegylated liposomal doxorubicin, with or without bevacizumab~Maintenance period: DCVAC/OvCa with bevacizumab, best supportive care or a PARPi"
62775500|NCT03905902|PLACEBO_COMPARATOR|Placebo with standard of care|"Induction period: DCVAC Placebo with carboplatin and gemcitabine, or carboplatin and paclitaxel, or carboplatin and doxorubicin, with or without bevacizumab~Maintenance Period:DCVAC placebo with bevacizumab, best supportive care or a PARPi carboplatin and gemcitabine or carboplatin and paclitaxel with or without bevacizumab, best supportive care or a PARPi"
62569046|NCT03197389|OTHER|Cohort A3|Cohort A3 will include patients with ER positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
62569047|NCT03197389|OTHER|Cohort B3|Cohort B3 will include patients with a ER positive breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
62185261|NCT00687947|EXPERIMENTAL|1|MA-patients
61999902|NCT04287907|NO_INTERVENTION|Control|face mask used to provide mask ventilation to the preterm baby will be connected directly to the T piece resuscitator. Respiratory function monitor sensor will be placed within circuit to measure parameters e.g. PIP, PEEP, FiO2, tidal volume.
62569048|NCT04603872|EXPERIMENTAL|Administration of CD19/BCMA Targeted CAR T-cells and dasatinib|Dose levels of CAR-T cells are based on clinical trials of similar foreign products. Meanwhile, dasatinib would be combined as the following regimens: 1) Dasatinib preconditioning CAR-T cells during the manufacturing; 2) Dasatinib for the intervention of cytokine release storm after CAR-T cell infusion; 3) Dasatinib for the intervention of neurotoxicities after CAR-T cell infusion; 4) Dasatinib for the phase of CAR-T cell decreasing.
61999903|NCT04700696|EXPERIMENTAL|EPIC Participants|EPIC participants are 1) matched with trained peer recovery supporters with lived experience related to child welfare and substance EPIC participants are also incentivized to participate in 2) family treatment drug court (FTDC), with medications for opioid use disorders (MOUD); and 3) home-based parenting supports based on the Nurturing Parenting Program.
61999904|NCT04700696|ACTIVE_COMPARATOR|Ohio Sobriety Treatment And Reducing Trauma (START) participants|Adapted from the evidence-based national START model (Sobriety Treatment and Recovery Teams) this intervention matches child welfare parents in need of addiction services to caseworker and family peer mentor (FPM) dyads for intensive case management services.
61999905|NCT04700696|NO_INTERVENTION|Treatment as usual (TAU)|Treatment as usual includes home visits by the assigned caseworker, referrals to SUD assessment/treatment, family group decision making, and (non-incentivized) referral to FTDC.
61999906|NCT06355869||Ambulatory children with spastic CP|Ambulant children with cerebral palsy between 6 and 17 years old with a consistent gait pattern. They have prescribed ankle-foot orthoses by the medical team as part of the standard care.
61999907|NCT06355869||TD children|Our TD-database of the Clinical Motion Analysis Laboratory (CMAL) of UZ Leuven was used for the calculation of the gait indices.
62569049|NCT04603872|EXPERIMENTAL|Administration of CD19/BCMA Targeted CAR T-cells|Dose levels of CAR-T cells are based on clinical trials of similar foreign products.
62569050|NCT03137160|EXPERIMENTAL|Ixekizumab (Taltz)|We have received funding for only a small pilot study to prove a benefit from Interleukin-17 inhibition in Pyoderma Gangrenosum . Therefore, there is only one treatment arm. The primary outcome will be a comparison of week 12 to baseline regarding a two-point improvement in the Investigator Global Assessment.
62569051|NCT04055701|OTHER|dichorionic diamniotic twin pregnancy|rutin examination: the assesment of fetal thymus volume at all cases.
62584776|NCT03972657|EXPERIMENTAL|ccRCC - dose escalation cohort|"Participants will receive REGN5678 monotherapy for presumptive RP2D identification~Note: Dose escalation on monotherapy lead-in of REGN5678 followed by combination therapy of REGN5678 with full dose cemiplimab is no longer actively enrolling new participants. The prophylactic use of sarilumab is no longer in use."
62584777|NCT03972657|EXPERIMENTAL|ccRCC - dose expansion cohort|Participants will receive the REGN5678 presumptive RP2D(s)
62584778|NCT06684522|EXPERIMENTAL|Upadacitinib Treatment|Participants on upadacitinib 15mg daily
62584779|NCT06239194|EXPERIMENTAL|Phase 1a - MDX2001 Dose Escalation|Patients with metastatic solid tumors will receive MDX2001 as intravenous (IV) infusion.
61999908|NCT06416865|EXPERIMENTAL|AJU-C52L, AJU-C52|"Treatment Period 1: AJU-C52L+C52R1L placebo~Treatment Period 2: AJU-C52+C52R1M placebo"
61999909|NCT06416865|EXPERIMENTAL|C52R1L, C52R1M|"Treatment Period 1: C52R1L+AJU-C52L placebo~Treatment Period 2: C52R1M+AJU-C52 placebo"
61999910|NCT02322554||wounds treated with CTPs|All cellular and tissue based products currently reimbursed in the hospital based outpatient department, administered at intervals as determined in the course of clinical practice
61999911|NCT03612037|PLACEBO_COMPARATOR|Control Phase|cellulose (600 mg)
61999912|NCT03612037|EXPERIMENTAL|Experimental Phase|alpha lipoic acid (600 mg)
62185262|NCT00687947|EXPERIMENTAL|2|FHM-patients
62584780|NCT06239194|EXPERIMENTAL|Phase 1b - Dose Expansion - Dose A|Patients with a single tumor indication receive MDX2001 as intravenous (IV) infusion.
61999913|NCT05328492|EXPERIMENTAL|iVAPS-AE|Patients with ALS and respiratory insufficiency randomised to this arm will be treated with home NIV using the Intelligent Volume-Assured Pressure Support with automatic EPAP (iVAPS-AE) mode.
61999914|NCT05328492|ACTIVE_COMPARATOR|ST-mode|Patients with ALS and respiratory insufficiency randomised to this arm will be treated with home NIV using the spontaneous timed (ST) home NIV mode.
61999915|NCT01965808|EXPERIMENTAL|LY2157299 (Fasted)|Single dose of 150 mg LY2157299 administered orally in fasted state in one of two study periods.
61999916|NCT01965808|EXPERIMENTAL|LY2157299 (Fed)|Single dose of 150 mg LY2157299 administered orally in fed state in one of two study periods.
61999917|NCT00952094|ACTIVE_COMPARATOR|KRN1493 50mg group|KRN1493 50mg single oral administration
61999918|NCT00952094|ACTIVE_COMPARATOR|KRN1493 75mg group|KRN1493 75mg single oral administration
61999919|NCT00952094|ACTIVE_COMPARATOR|KRN1493 100mg group|KRN1493 100mg single oral administration
61999920|NCT04013620|EXPERIMENTAL|transient belatacept|
62185263|NCT00687947|ACTIVE_COMPARATOR|3|Healthy controls
62569052|NCT05280938|EXPERIMENTAL|MAAP Intervention|The MAAP intervention is an 8-week adapted mindfulness intervention based upon Kabat-Zinn's MBSR. The intervention includes spirituality, self-empowerment, interdependence, and story-telling which are salient to AAW. Session topics include Tasting Your Life, Seeing and Believing, The Scent of Roses, When Life Hurts, Hearing Your Own Cries, Embracing Inner Peace, Holding on, Welcoming Stillness. Each session will include an introduction, opening mindfulness practice, class responses to the previous week, review guidelines for class, guided individual reflection, group go-around/discussion, yoga, abdominal breathing, body scan, conclusion, and home practice. Face to face sessions 1, 4, 8 will be in a quiet room to allow group sitting or free floor space. Sessions 2, 3, 5, 6, are virtual on the zoom app. Participants receive practice links and a program workbook. Program attendance, type/amount of practice (weekly logs), and changes in mindfulness will be included in data analysis.
62569053|NCT05280938|ACTIVE_COMPARATOR|Educational Program|"The Education Program (attention control group) will be an 8-week educational program matched in duration and frequency to the MAAP intervention. Session topics are:1) Perineum and Incision Care, 2) Safe Sexual Practices, 3) Understanding Infant Feeding Methods, 4) How to Communicate Effectively with your Child's Health Care Providers, 5) Healthy Eating, 6) Infant Changing and Baths, 7) Infant Safety at Home, and 8) Utilizing Support from Family and the Community.~Sessions will be given in groups by the same expert clinicians/educators for all cohorts. Subject receipt of the attention control will be monitored by attendance. Control group instructor will not include content on stress reduction or methods (yoga, meditation, etc.) taught in the MAAPI intervention. Classes will be given in the same setting as the MAAPI intervention, at the same time but on a different evening, to avoid crossover of effects."
62569054|NCT04050852|EXPERIMENTAL|SMA patients receiving nusinersen treatments|
61999921|NCT00532896||bariatric surgery|patients with morbid obesity undergoing a bariatric surgery
61999922|NCT00532896||No bariatric surgery|patients with morbid obesity on a waiting list for a bariatric surgery but who will have their surgery in more than one year.
61999923|NCT02752009|EXPERIMENTAL|Axillary Lymph Node Sampling Clip|"* Axillary Lymph Node Biopsy~  -- Axillary lymph node sampling with clip placement into the sampled lymph node. After the tissue sampling of any suspicious nodes, a marker clip will be placed to allow for intra-operative identification of the biopsied nodes.~* Neoadjuvant therapy at the discretion of the treating Medical Oncologist. Once Neoadjuvant therapy is completed, surgery in the form of either Lumpectomy or Mastectomy is performed.~  * Wire-localization of the clipped node on the day of surgery.~ * Lymphatic mapping performed with either radiocolloid and/or blue dye.~ * Sentinel lymph node biopsy will be performed on the day of surgery.~    --- If the clipped node which contains the wire is not part of this sentinel lymph node specimen, then it will be removed separately and be sent to Pathology as a separate specimen.~ * Axillary lymph node dissection as is the standard of care."
61999924|NCT00245765|PLACEBO_COMPARATOR|Placebo|Subcutaneous injections of Placebo every 2 weeks
61999925|NCT00245765|EXPERIMENTAL|Certolizumab Pegol 200 mg|Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter
61999926|NCT00245765|EXPERIMENTAL|Certolizumab Pegol 400 mg|Subcutaneous injections of 400 mg every 2 weeks
61999927|NCT04413929||Ergoferon|Oral administration in the therapeutic dosage specified in the instructions for medical use.
62185264|NCT01482429|EXPERIMENTAL|Protocol-directed|Discontinuation of ventilation was based in multidisciplinary protocol.
62185265|NCT01482429|NO_INTERVENTION|Usual care|Discontinuation of ventilation was left entirely to the discretion of the physicians.
62185266|NCT03732781|EXPERIMENTAL|Radspherin|
62185267|NCT00277368||001|
62185268|NCT05395026|EXPERIMENTAL|Investigational Stimulation Parameters|
62185269|NCT04374383|EXPERIMENTAL|main treatment group|LASER assisted SRP followed by antimicrobial photodynamic therapy with a novel photosensitizer dye Phthalocyanine
62185270|NCT04374383|PLACEBO_COMPARATOR|control group|LASER assisted SRP
61999928|NCT05753059|PLACEBO_COMPARATOR|Placebo/ Placebo|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
61999929|NCT05753059|ACTIVE_COMPARATOR|Placebo/ Amiloride|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
61999930|NCT05753059|ACTIVE_COMPARATOR|Placebo/ Bendroflumethiazide|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
61999931|NCT05753059|ACTIVE_COMPARATOR|Bendroflumethiazide/ Amiloride|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
61999932|NCT05203471|NO_INTERVENTION|Historical controls|Patients with diabetic foot ulcers cared for by a primary care provider participating in the study prior to launching the integrated care intervention.
62569055|NCT04752956|ACTIVE_COMPARATOR|Grup1|Nasal steroid spray only (NS) (Each dose contains 27.5 micrograms of fluticasone furoate; administered single dose per day as 1 puff through both nostrils)
62569056|NCT04752956|ACTIVE_COMPARATOR|Grup 2|NS + administered ambient temperature normal saline (NSS) through both nostrils by means of nasal douche device twice a day 15 minutes before NS. (NSS; 0,09% NaCl, pH:4-5)
62569057|NCT04752956|ACTIVE_COMPARATOR|Grup 3|NS + administered ambient temperature hyaluronic acid (HA) through both nostrils by means of nasal douche device twice a day 15 minutes before NS. (Nasorinse plus pediatric® Ingredients: water, sodium chlorine, sodium bicarbonate, and HA; pH balanced)
61977792|NCT03698747||mTBI Study Group with McDESPOT sequence|Study group (30 subjects) of football players diagnosed with mTBI (scan at diagnosis, 3-month follow-up scan, genetic screening, concussion assessment at both interaction)
61999933|NCT05203471|ACTIVE_COMPARATOR|Integrated care|Patients with diabetic foot ulcers cared for by a primary care provider participating in the study after launching the integrated care intervention. Only patients who provide informed consent and enroll in the study will be treated with our integrated care model. All other patients with a participating primary care provider will be treated using a standard care model and will not be considered study participants.
61999934|NCT05943912||Single Vision Spectacle Lens|Participants who chose to correct myopia with single vision spectacle lenses.
61999935|NCT05943912||Defocus Incorporated Multiple Segments (DIMS) Spectacle Lens|Participants who chose to correct myopia with DIMS spectacle lenses.
61999936|NCT06156254|EXPERIMENTAL|Community Health Worker (CHW) Intervention to Enhance Vaccination Behavior|Patients randomized to the CHW intervention will receive up to 3 psychoeducational sessions in English or Spanish targeting the specific reason(s) why a patient is not up to date with their COVID-19 vaccine. CHWs will use motivational interviewing techniques to promote vaccination behaviors.
61999937|NCT06156254|NO_INTERVENTION|Usual Care|Patients will receive the care that they would usually receive independent of the study but won't have access to the intervention.
62569058|NCT02773901|EXPERIMENTAL|HS-1000 recording|ICP monitoring will be done with the HS-1000 to compare to CSF measurement from lumbar puncture (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals last 10 minutes.
62569059|NCT02209350|ACTIVE_COMPARATOR|Group 1|Operations technique on the abdominal aorta. Aorta-femoral bypass. Medication: after surgery all patients are prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
62569060|NCT02209350|ACTIVE_COMPARATOR|Group 2|Standard endovascular treatment (stenting) in patients with the iliac segment occlusive disease. Medication: after stenting all patients are prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
62569061|NCT04163120|EXPERIMENTAL|Intervention|In this single arm study subjects follow a low calorie mediterranean ketogenci diet
62569062|NCT03989128||Observational (survey)|Participants complete a survey over 5-10 minutes
62569063|NCT03204994|EXPERIMENTAL|Tumour injection of ICG|Indocyanine green injection into tumour before or during surgery.
62569064|NCT06578819|EXPERIMENTAL|experimental group (moderate dementia)|The experimental group will receive doll therapy four days a week.
62569065|NCT06578819|NO_INTERVENTION|control group (moderate dementia)|No intervention will be applied to the control group.
62569066|NCT06578819|EXPERIMENTAL|experimental group (severe dementia)|Doll therapy will be applied to the experimental group 4 days a week.
61999938|NCT03806582|ACTIVE_COMPARATOR|intervention|intervention with norepinephrine to reach a MAP of 85 mmHg for a maximum duration of 1 hour, observation of the effect on right ventricular function
61999939|NCT03806582|NO_INTERVENTION|control|control group; treatment according to current standards, observation of the effect on right ventricular function
61999940|NCT05736679|EXPERIMENTAL|In2Care EaveTube|EaveTube installation with deltamethrin treated netting; in addition to standard of care (standard pyrethroid-only bednets)
61999941|NCT05736679|NO_INTERVENTION|Control|Standard of care (standard pyrethroid-only bednets)
61999942|NCT05595915|EXPERIMENTAL|Experimental Group|All subjects recruited in this study will be in the experimental group receiving the oral supplement, COMP-4, twice daily for 14 days.
62185271|NCT03448705|EXPERIMENTAL|Group 1 - Study drug 1 (i.e. 4Fluart ID 1 µg/0.1 ml QIV)|Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 1 µg haemagglutinin per virus strain in 0.1 ml as a single dose.
62185272|NCT03448705|EXPERIMENTAL|Group 2 - Study drug 2 (i.e. 4Fluart ID 2 µg/0.1 ml QIV)|Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 2 µg haemagglutinin per virus strain in 0.1 ml as a single dose.
62185273|NCT03448705|ACTIVE_COMPARATOR|Group 3 - Comparator drug (i.e. 3Fluart IM 6 µg/0.5 ml TIV)|Vaccination of 12 subjects will be performed with the intramuscular trivalent influenza vaccine containing 6 µg haemagglutinin per virus strain in 0.5 ml as a single dose.
62394081|NCT04422301|EXPERIMENTAL|High intensity eccentric training with blood flow restriction|High intensity eccentric training with blood flow restriction high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction
62394082|NCT04422301|EXPERIMENTAL|Low intensity eccentric training|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
62394083|NCT04422301|EXPERIMENTAL|Low intensity eccentric training with blood flow restriction|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure)will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
62394084|NCT02852239|EXPERIMENTAL|Group 1 - Normal renal function|Subjects with normal renal function defined as GFR ≥ 90 mL/min at baseline and matching to the renal impaired subject based on gender, race, age, and weight.
62394085|NCT02852239|EXPERIMENTAL|Group 2 - Severe renal function|Subjects with severe renal impairment defined as GFR of 15-29 mL/min at baseline.
62394086|NCT02852239|EXPERIMENTAL|Group 3 - End stage renal disease (ESRD)|Subjects with end stage renal disease (ESRD), defined as GFR of \<15 mL/min at baseline.
62394087|NCT01396434||Prevenar 13 patients|
62569067|NCT06578819|NO_INTERVENTION|control group (severe dementia)|No intervention will be applied to the control group.
62584781|NCT06239194|EXPERIMENTAL|Phase 1b - Dose Expansion - Dose B|Patients with a single tumor indication will receive MDX2001 as intravenous (IV) infusion.
61999943|NCT03581110||16-slice CT scanner|1426 patients that have received a noncontrast-enhanced chest CT on our 16-slice clinical routine CT scanner in inspiration only.
61999944|NCT03581110||2nd generation dual-source CT|320 patients that have received a noncontrast-enhanced chest CT on our second generation dual-source CT scanner in inspiration only.
61999945|NCT03581110||3rd generation dual-source CT|211 patients that have received a noncontrast-enhanced chest CT on our third generation dual-source CT scanner in inspiration and expiration.
61999946|NCT02353091|NO_INTERVENTION|APD Control Group|Comprised 13 children diagnosed with APD and acts as a control without using any form of intervention.
61977793|NCT03698747||Control Group|Control group (30 subjects) of age match non-contact sport players (scan, genetic testing, concussion assessment)
61999947|NCT02353091|EXPERIMENTAL|APD Intervention Group|Comprised 13 children diagnosed with APD and received the Remote Microphone Hearing AId intervention at the start of the study, after baseline testing, and used for 6 months.
62185274|NCT06007105|EXPERIMENTAL|SUCCEED Community-Based Intervention|The SUCCEED community-based intervention (offering a combination of peer support, case management and livelihoods activities) will be delivered to 10 participants with lived experience of psychosis at each of the 4 pilot sites.
62185275|NCT04387045|EXPERIMENTAL|Guilty feelings|Write for 20 minutes about a situation that in the participant's past life has caused feelings of guilt.
62185276|NCT04387045|PLACEBO_COMPARATOR|Neutral feelings|Write for 20 minutes about a situation that in the participant's past life has caused neutral feelings.
62185277|NCT04288206|PLACEBO_COMPARATOR|Placebo control|Patient will receive 'study drug' which is comprised of 300 mL of normal saline without any medication/antibiotic, which will be delivered by intravenous means at the time of surgery.
61999948|NCT05147896|ACTIVE_COMPARATOR|Interventional Arm|Beside metformin and sulphonyl urea treatment, the active, interventional arm, will be receiving Semaglutide Oral Tablets as per protocol, 3 mg for the first month, 7 mg in the second month and 14 mg form the third month onwards.
61999949|NCT05147896|NO_INTERVENTION|Comparative Arm|This group will not be receiving the additional therapy besides metformin and sulphonyl urea treatment. After 6 months a revaluation of glycemic control will be performed, if needed, rescue therapy with basal insulin will be implemented.
61999950|NCT02378766|EXPERIMENTAL|Website A|Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé.
61999951|NCT02378766|OTHER|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites.
61999952|NCT03010787|EXPERIMENTAL|Part 1|Single ascending dose of oral V565
61999953|NCT03010787|EXPERIMENTAL|Part 2 - V565|Single dose level of oral V565 TID for 14 days
62185278|NCT04288206|ACTIVE_COMPARATOR|Cefazolin prophylaxis|Patient will receive 'study drug' which is comprised of weight-based dose of cefazolin mixed in 300 mL of normal saline, which will be delivered by intravenous means at the time of surgery.
62775501|NCT06264258|EXPERIMENTAL|DVx-T1D+Standard Care|Participants will continue receiving the clinic's standard of care. Anthropometrics, clinical and laboratory data will be collected at three time points, baseline, 6 weeks and 3 months. Participants will be asked to maintain food, glucose, and activity logs. In addition, participants in this arm will be provided a tablet that has the gaming applications already loaded and receive training on the application. Exposure time will be tracked by the application.
61999954|NCT03010787|PLACEBO_COMPARATOR|Part 1 and 2 - placebo|Oral placebo single dose (Part 1) or TID for 14 days (Part 2)
62215314|NCT02961543|EXPERIMENTAL|Group 1.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isokinetic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
62775502|NCT06264258|NO_INTERVENTION|Standard Care|Participants will receive the clinic's standard of care. Anthropometrics, clinical and laboratory data will be collected at three time points, baseline, 6 weeks and 3 months. Participants will be asked to maintain food, glucose, and activity logs.
61977794|NCT00770796|PLACEBO_COMPARATOR|Placebo|placebo
61999955|NCT03010787|EXPERIMENTAL|Part 3|Single dose of V565 in patient volunteers
61999956|NCT03010787|EXPERIMENTAL|Part 4|Single ascending dose of V565 in patients with Crohn's Disease
61999957|NCT00159588|ACTIVE_COMPARATOR|Prophylaxis from the start|Use of preventive drugs from the start without abrupt withdrawal
61999958|NCT00159588|OTHER|Abrupt withdrawal|Device: Abrupt withdrawal. Standard out-patients detoxication program including telephone call after 2 weeks and rescue medicine up to 2 days/week
61999959|NCT00159588|OTHER|Controls|Active control: No instruction for abrupt withdrawal or prophylactic treatment. The controls finished the study period after 5 months observation, and were then offered the optimal type of treatment
62394088|NCT00132665|ACTIVE_COMPARATOR|1|Procedure/Surgery: A: Radiotherapy alone
62394089|NCT00132665|EXPERIMENTAL|2|Drug: B: CBDCA and Radiotherapy
62775503|NCT02687698|EXPERIMENTAL|Ketogenic diet|Patients will be suggested to follow a ketogenic diet for 8 weeks.
62775504|NCT02687698|NO_INTERVENTION|Control|Usual diet.
62775505|NCT02915913|EXPERIMENTAL|High Intensity Interval|One session for 30-60 minutes of high intensity aerobic exercise
62775506|NCT02915913|EXPERIMENTAL|Resistance training|One session for 30-60 minutes of resistance exercise
62775507|NCT02915913|EXPERIMENTAL|Plus: High Intensity Interval + Resistance Training|One session for 30-60 minutes of high intensity aerobic exercise and resistance exercise
62775508|NCT02915913|PLACEBO_COMPARATOR|Non-exercise|Non-exercise
62775509|NCT05683002|EXPERIMENTAL|Aronia|Aronia Melanocarpa supplementation
62775510|NCT05683002|PLACEBO_COMPARATOR|Control|Cellulose supplementation
62775511|NCT01254825|EXPERIMENTAL|Adductor-Canal-Block, Ropivacain|Adductor-Canal-Block, 30 mL Ropivacain 7,5 mg/mL. Single dose. Ultrasound-guided application. 36 patients
62775512|NCT01254825|PLACEBO_COMPARATOR|Adductor-Canal-Block (ACB) - Saline|Adductor-Canal-Block, Placebo (30 mL Saline). Ultrasound-guided application. 36 patients.
62775513|NCT01074983||Written standard of care|
62775514|NCT01074983||Usual practice pattern|
62775515|NCT03903887|EXPERIMENTAL|PD1-TIL combined with chemotherapy|Participants would receive anti-PD1 antibody-activated TILs after the final cycle of adjuvant chemotherapy.
62791660|NCT01999400|EXPERIMENTAL|Arm 2: Pentasa then Delzicol then Lialda then Apriso|"1. Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~2. Washout period of 10 days.~3. Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~4. Washout period of 10 days.~5. Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~6. Washout period of 10 days.~7. Apriso 375 mg capsule x 3 with 240 mL water, single dose."
61999960|NCT05395962|ACTIVE_COMPARATOR|BLM|
61999961|NCT05395962|EXPERIMENTAL|BLM+CBP|
61999962|NCT01391065|OTHER|1|The study arm will undergo baseline multifunctional PET and MRI scans, before brachytherapy and at follow up
61999963|NCT05703529|EXPERIMENTAL|Positive Psychotherapy group|
61999964|NCT05703529|OTHER|Control group|Usual Care means treating as usual, including a regular home visit.
61999965|NCT03553628|ACTIVE_COMPARATOR|Chlorhexidine Once Daily|Chlorhexidine HCL 0.12% mouthwash to be used once daily for one week each month for six months
61999966|NCT03553628|ACTIVE_COMPARATOR|Chlorhexidine Twice Daily|Chlorhexidine HCL 0.12% mouthwash to be used twice daily for one week each month for six months
61999967|NCT03553628|EXPERIMENTAL|Propolis Once Daily|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash to be used once daily for one week each month for six months
61999968|NCT03553628|EXPERIMENTAL|Propolis Twice Daily|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash to be used twice daily for one week each month for six months
62185279|NCT03201900|EXPERIMENTAL|E2007|The Treatment Phase consists of the 4 milligrams (mg) Treatment Phase (the Titration Period \[6 weeks\] and the Maintenance Period \[26 weeks\]) and the 8 mg Treatment Phase (the Titration Period \[4 weeks\] and the Maintenance Period \[26 weeks\]) if participants require a higher dose. In the 4 mg Titration Period (6 weeks), participants will initiate 2 mg perampanel once daily (QD) for 2 weeks and then will be up-titrated to 4 mg QD and will continue this dose for 4 weeks. If participants have no safety issues at the end of the Titration Period, they will start the 4 mg Maintenance Period for 26 weeks. Participants will only need the higher dose if they are having seizures. In the 8 mg Titration Period (4 weeks), participants will be administered 6 mg perampanel QD for 2 weeks and then will be up-titrated to 8 mg QD and will continue this dose for 2 weeks. If participants have no safety issues at the end of the Titration Period, they will start the 8 mg Maintenance Period for 26 weeks.
62394090|NCT06401382|EXPERIMENTAL|Modified aligner appliance with NiTi springs|The patients in this group will be treated using a Modified aligner appliance with NiTi springs.
62394091|NCT06401382|ACTIVE_COMPARATOR|Conventional fixed appliances|The patients in this group will be treated using conventional fixed appliances.
62569068|NCT01155856|EXPERIMENTAL|telemedicine|Within 24 hours after admission for exacerbation of COPD, patients in the intervention group are sent home for further treatment (telemedicine based) instead of the conventional treatment at the hospital. Patients in the intervention group will receive the same treatment as the control group and have daily contact with the physician/nurse at the hospital through a videoconference system.
62775516|NCT05113992|EXPERIMENTAL|Intervention group massaged with frankincense and myrrh oil|In the intervention group, 4% massage oil (3 ml jojoba fixed oil, 2% Frankincense and 2% Myrrh essential oil mixture) was applied on the skin on the forearm. Individuals who did not develop any reaction after thirty minutes and who met other inclusion criteria were included in the study. At the beginning of the study, the patient information form, VAS for back pain severity, and GCQ for comfort evaluation were applied by face-to-face interview method before the intervention. Then, in accordance with the massage application protocol, a back massage was applied for a total of 15 minutes, using 4% massage oil. Then EPS was applied to the individuals. VAS and GCQ were applied again at the 4th hour, which is the ambulation hour.
62775517|NCT05113992|SHAM_COMPARATOR|. Placebo group massaged with jojoba oil,|In the placebo massage group, jojoba fixed oil was applied to the skin on the forearm. Individuals who did not develop any reaction after 30 minutes and who met other inclusion criteria were included in the study. At the beginning of the study, a patient information form, VAS for back pain severity, and GCQ for comfort evaluation were applied by face-to-face interview method before the intervention. Then, in accordance with the massage application protocol, a back massage was applied for a total of 15 minutes, using jojoba fixed oil. Then EPS was applied to the individuals. VAS and GCQ were applied again at the 4th hour, which is the ambulation hour.
61999969|NCT00430092|EXPERIMENTAL|Difluprednate 0.05% BID|Difluprednate 0.05% 1 drop BID for 14 days
61999970|NCT00430092|EXPERIMENTAL|Difluprednate 0.05% QID|Difluprednate 0.05% 1 drop QID for 14 days
61999971|NCT00430092|PLACEBO_COMPARATOR|Placebo|Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.
61999972|NCT03663595|EXPERIMENTAL|PFPS: Model 1 (Hip and Knee)|Females symptomatic for PFPS. This group will be submitted to the rehabilitation program with exercises focusing in proximal (hip) and local (knee) factors.
61999973|NCT03663595|EXPERIMENTAL|PFPS: Model 2 (knee, foot and ankle)|Females symptomatic for PFPS This group will be submitted to the rehabilitation program with exercises focusing in distal (foot and ankle) and local (knee) factors.
61999974|NCT03663595|NO_INTERVENTION|Healthy group|Healthy females not submitted to intervention
61999975|NCT02459392|OTHER|Epiduroscopy mechanical lysis - failed back surgery syndrome|Epiduroscopy only mechanical lysis
61999976|NCT02459392|EXPERIMENTAL|Epiduroscopy combination - failed back surgery syndrome|Epiduroscopy together mechanical lysis of epidural adhesions together with epidural drug administration Hyaluronic acid 150 IU and Depo-Medrol 80mg
61999977|NCT02459392|OTHER|Epiduroscopy mechanical lysis - chronic low back pain without previous spine surgery|Epiduroscopy only mechanical lysis
61999978|NCT02459392|EXPERIMENTAL|Epiduroscopy combination - chronic low back pain without previous spine surgery|Epiduroscopy together mechanical lysis of epidural adhesions together with epidural drug administration Hyaluronic acid 150 IU and Depo-Medrol 80mg
61999979|NCT01579942||Patients with Major Depressive Disorder|Patients who have Major Depressive Disorder and are taking a Selective Serotonin Re-uptake Inhibitor (SSRI) as part of another study at our clinic.
61999980|NCT01579942||Healthy Controls|Patient with no history of significant mental health problems.
61999981|NCT06363487|EXPERIMENTAL|Semaglutide|Semaglutide pre-filled pen, 0.5mg in 1.5mL, subcutaneous injection
61999982|NCT06363487|PLACEBO_COMPARATOR|Placebo|Saline solution 0.9% NaCl, solution for injection 1.5mL, subcutaneous injection syringe
61999983|NCT05321394|ACTIVE_COMPARATOR|Sotrovimab|Sotrovimab 500 mg administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour
61999984|NCT05321394|EXPERIMENTAL|Tixagevimab Cilgavimab|300 mg of tixagevimab and 300 mg of cilgavimab administered as two separate consecutive intramuscular injections
61999985|NCT05321394|EXPERIMENTAL|Nirmatrelvir Ritonavir|300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together twice daily for 5 days
61999986|NCT04999111|EXPERIMENTAL|Cohort 1: Group 1: Ad26.COV2.S (Dose Level 1)|Participants who have previously received primary vaccination with Ad26.COV2.S will receive single intramuscular (IM) injection of Ad26.COV2.S booster vaccination at dose level 1 on Day 1.
61999987|NCT04999111|EXPERIMENTAL|Cohort 1: Group 2: Ad26.COV2.S (Dose Level 2)|Participants who have previously received primary vaccination with Ad26.COV2.S will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 2 on Day 1.
61999988|NCT04999111|EXPERIMENTAL|Cohort 1: Group 3: Ad26.COV2.S (Dose Level 3)|Participants who have previously received primary vaccination with Ad26.COV2.S will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 3 on Day 1.
61999989|NCT04999111|EXPERIMENTAL|Cohort 2: Group 4: Ad26.COV2.S (Dose Level 1)|Participants who have previously received primary vaccination with BNT162b2 will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 1 on Day 1.
61999990|NCT04999111|EXPERIMENTAL|Cohort 2: Group 5: Ad26.COV2.S (Dose Level 2)|Participants who have previously received primary vaccination with BNT162b2 will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 2 on Day 1.
61999991|NCT04999111|EXPERIMENTAL|Cohort 2: Group 6: Ad26.COV2.S (Dose Level 3)|Participants who have previously received primary vaccination with BNT162b2 will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 3 on Day 1.
61999992|NCT00701129|EXPERIMENTAL|Alglucosidase Alfa|Alglucosidase alfa (Myozyme®) 20 milligrams per kilogram (mg/kg) intravenous (IV) infusion every other week (qow) (or optionally 20 mg/kg IV infusion every week \[qw\]) beginning from Day 0 to a minimum of 18 months or if the patient was less than (\<) 6 months of age at the time of enrollment, until the patient was 2 years of age, along with methotrexate 0.4 mg/kg subcutaneously for 3 consecutive days qow beginning from Day 0 to Week 6 (9 doses) and rituximab 375 milligrams per square meter (mg/m\^2) (or 12.5 mg/kg for patients with body surface area less than or equal to 0.5 m\^2) IV infusion qw beginning from Day -1 to Week 4 (4 doses) as per local prescribing information. An additional 4-week cycle of rituximab (up to 4 additional doses) and 6-week cycle of methotrexate (up to 9 additional doses) may have been administered within the first 6 months of the study as per local prescribing information.
61999993|NCT03554291|EXPERIMENTAL|Famotidine|"20mg of oral famotidine (pill) daily~Other names: Pepcid"
61999994|NCT03554291|PLACEBO_COMPARATOR|Placebo|Daily oral placebo (pill)
61999995|NCT01911507|EXPERIMENTAL|Treatment ( INCB028, erlotinib)|Patients receive INC280 PO BID and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61999996|NCT05850650|ACTIVE_COMPARATOR|Controlled|The extraction socket will not receive a collagen sponge
61999997|NCT05850650|EXPERIMENTAL|Collagen|The extraction socket will receive a collagen sponge
61999998|NCT03189030|EXPERIMENTAL|Treatment arm|pLADD treatment cycle is once every 3 weeks; starting dose 1×10\^8 colony-forming units (CFU) administered IV over 1 hour, and if tolerated increasing to 1×10\^9 CFU
61999999|NCT06216392|EXPERIMENTAL|Experimental: GR1802|GR1802 injection 300mg every two weeks for 52-week treatment.
62000000|NCT06216392|PLACEBO_COMPARATOR|Placebo|Placebo every two weeks for 16-week treatment. Crossover to GR1802 injection for another 36 weeks
62000001|NCT00699010|ACTIVE_COMPARATOR|Acurox 5/30mg taken first|oxycodone HCl/Niacin 5/30mg tablets; 8 tablets per dose
62000002|NCT00699010|ACTIVE_COMPARATOR|Oxycodone 5mg taken first|oxycodone HCl 5mg tablets; 8 tablets per dose
62569069|NCT01155856|NO_INTERVENTION|control|The control group will receive usual care and treatment at the hospital until discharge(typically between 5-7 days).
62569070|NCT02841995|EXPERIMENTAL|Cohort 1: Belumosudil 200 mg QD|Participants received belumosudil 200 mg orally QD in each 28-day treatment cycle until disease progression, unacceptable toxicity, or death whichever occurred first (maximum duration: 64.2 months).
62569071|NCT02841995|EXPERIMENTAL|Cohort 2: Belumosudil 200 mg BID|Participants received belumosudil 200 mg orally BID in each 28-day treatment cycle until disease progression, unacceptable toxicity, or death whichever occurred first (maximum duration: 45.9 months).
62000003|NCT01037946|NO_INTERVENTION|Standard Care Arm|Families living with HIV, offered intervention at the end of study (24 months after recruitment)
62000004|NCT01037946|EXPERIMENTAL|Intervention|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
62000005|NCT04703452||Covid-19 infected patients|In this study male and female patients who were previously infected with covid-19 will be included. Patients will only be eligible if they had a positive covid-19 test at least 6 months before inclusion in the study.
62000006|NCT05874180|EXPERIMENTAL|Sequence A|Period 1: Linagliptin and Metformin / Period 2: DW6013
62569072|NCT02841995|EXPERIMENTAL|Cohort 3: Belumosudil 400 mg QD|Participants received belumosudil 400 mg orally QD in each 28-day treatment cycle until disease progression, unacceptable toxicity, or death whichever occurred first (maximum duration: 49.2 months).
62569073|NCT02119403|EXPERIMENTAL|Hand Held NitrousTM|There are no other interventions to this device
62569074|NCT03779230|EXPERIMENTAL|L19TNF|Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
62000007|NCT05874180|EXPERIMENTAL|Sequence B|Period 1: DW6013 / Period 2: Linagliptin and Metformin
62000008|NCT03993938|EXPERIMENTAL|Patients for TMVR|Patients with severe mitral regurgitation scheduled for TMVR procedure at Henry Ford Hospital - main campus.
62000009|NCT03755141|EXPERIMENTAL|Herzuma|Herzuma + TPC
62569075|NCT04973150|EXPERIMENTAL|the children were given gauze covering training in one eye or both eyes|According to the operation method, the children were given gauze covering training in one eye or both eyes.
62569076|NCT04973150|NO_INTERVENTION|Using regular tablet computer to play cartoon animation video|
62569077|NCT02588794|ACTIVE_COMPARATOR|intervention|Standart CVVHD plus CytoSorb 300 ml device (3804606CE01)
62775518|NCT05113992|NO_INTERVENTION|Control group|At the beginning of the study, a patient information form, VAS for back pain severity, and GCQ for comfort evaluation were applied by face-to-face interview method before the intervention. No intervention was applied to individuals in the control group. In order to ensure standardization between the groups, after 15 minutes of verbal communication, they were taken to the EPS process. After the procedure, VAS and GCQ were applied again at the 4th hour, which is the ambulation hour.
62775519|NCT01081743|EXPERIMENTAL|Social worker|
62000010|NCT00957203|EXPERIMENTAL|Istradefylline|
62569078|NCT02588794|NO_INTERVENTION|control|Standart CVVHD
62569079|NCT02099890|EXPERIMENTAL|Anti-inflammatory Supplementation|Omega-3 pill (500 EPA / 250 DHA) taken orally 3 times daily, Vegetation Protein Powder (45g) taken orally once daily, InflanNox capsule (400mg curcumin) taken 3 times daily, Anti-oxidant Network capsule (615mg) taken twice daily, Chlorella tablet (1000mg) taken 6 times daily
62569080|NCT03134144|EXPERIMENTAL|First without exoskeleton then with exoskeleton|"Subject will perform the conditions as described under model description first without the exoskeleton and then with the exoskeleton."
62775520|NCT01081743|NO_INTERVENTION|Control|Control group is followed-up as usually (usual care)
62775521|NCT01531751|EXPERIMENTAL|High Cut-off Hemodialysis|
62775522|NCT00967096|EXPERIMENTAL|1|The primary clinical endpoint to be assessed in this study will be the proportion of Rifaximin doses successfully administered. Because of mucositis, compliance with oral agents, even those that are well tolerated in other settings, may be limited in the early post-transplant period. Thus, it will be important to demonstrate the feasibility of administering Rifaximin to BMT patients before embarking on larger scale studies. Secondary outcomes will include AGVHD, event-free survival, overall survival, non-relapse mortality, neutrophil and platelet engraftment.
62775523|NCT06507683|EXPERIMENTAL|Radiotherapy combined with ripretinib group|Radiotherapy (50-70Gy/25-30f)+ ripretinib(150mg QD)
62775524|NCT01736618||S-ICD System Implant Attempt|All participants undergo an S-ICD System Implant attempt.
62000011|NCT04685876|ACTIVE_COMPARATOR|liposomal bupivacaine|40 ml of plain bupivacaine 0.25% will be mixed with 20 ml liposomal bupivacaine and 20 ml of saline. 20 ml of the mix will be injected at each location of the 4-quadrant TAP block.
62569081|NCT03134144|EXPERIMENTAL|First with exoskeleton then without exoskeleton|"Subject will perform the conditions as described under model description first with the exoskeleton and then without the exoskeleton."
62569082|NCT05201872||laparoscopic surgery|Different surgical methods for rectal cancer resection
62775525|NCT02861599|EXPERIMENTAL|proprioceptive therapy|
62775526|NCT02861599|PLACEBO_COMPARATOR|speech therapy|
62775527|NCT01202058|EXPERIMENTAL|NEVO™ SES|"Design Protocol Am3.0 - safety follow-up:~The study population consists of 103 subjects with atherosclerotic coronary artery disease treated with the NEVO™ SES. Candidates for the initial NEVO II Study must have met ALL inclusion criteria and NO exclusion criteria.~Design Original Protocol~Subjects randomized to treatment with the NEVO™ Sirolimus-eluting Coronary Stent System."
62000012|NCT04685876|ACTIVE_COMPARATOR|plain bupivacaine|50 ml of plain bupivacaine 0.5% will be combined with 30 ml of normal saline making a total of 80 ml. 20 ml will be injected at each location of the 4-quadrant TAP block.
62000013|NCT04685876|PLACEBO_COMPARATOR|Normal Saline|patients will receive total of 80 ml of normal saline, injected 20 ml in each of the four-quadrant sites.
62000014|NCT03216850||Patients in ICU requiring parenteral nutrition|
62000015|NCT00866632|EXPERIMENTAL|Group Cognitive Behavioural Therapy|
62000016|NCT00866632|EXPERIMENTAL|Telephone Cognitive Behavioural Therapy|
62569083|NCT05201872||Transanal endoscopic surgery|Different surgical methods for rectal cancer resection
62569084|NCT04052217|OTHER|Control Ring|"Normal intercourse with very thin (less than 0.5cm) ring randomised to either 3, 4 or 5 episodes of intercourse (Phase A)"
62775528|NCT01202058|ACTIVE_COMPARATOR|XIENCE V®/XIENCE PRIME™/PROMUS®|Subjects randomized to treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System
62000017|NCT00866632|NO_INTERVENTION|Group Education|
62000018|NCT00866632|NO_INTERVENTION|Telephone Education|
62000019|NCT05754177|EXPERIMENTAL|Probiotic|Arm receiving investigation product (probiotic)
62000020|NCT05754177|PLACEBO_COMPARATOR|Placebo|Arm receiving placebo
62775529|NCT06357052||NAFLD patients without liver cirrhosis (NLCs, n = 28)|
62000021|NCT00322010|EXPERIMENTAL|Early PT OT|Early PT/OT Therapy assessments to begin on the first day that consent is obtained. Therapy is delivered by a team consisting of a physical and occupational therapist and coordinated with daily sedative interruption.
62000022|NCT00322010|NO_INTERVENTION|Standard Care|PT/OT delivered as ordered by the primary ICU team
62394092|NCT02283801|EXPERIMENTAL|Group A|"Group A~* Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;~* Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days~* Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 50 mg for two consecutive days~* Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 150 mg for seventeen consecutive days"
62569085|NCT04052217|EXPERIMENTAL|"1 RIng"|"Intercourse wearing a 1 ring. Randomised to either 3, 4, or 5 episodes of intercourse (Phase B)"
62569086|NCT04052217|EXPERIMENTAL|"1.5 Ring"|"Intercourse wearing a 1.5 ring randomised to either 3, 4, or 5 episodes of intercourse (Phase C)"
62569087|NCT04052217|EXPERIMENTAL|"2 Ring"|"Intercourse with a 2 ring randomised to either 3, 4, or 5 episodes of intercourse (Phase D)"
62569088|NCT06526741||Alport syndrome patients|Patients with a confirmed diagnosis of Alport syndrome by a certified genetic counselor, treating physician, or nephrologist.
62569089|NCT02259374|ACTIVE_COMPARATOR|TAP BLOCK 0.2% ROPIVACAINE|"Patients randomised into this group will receive bilateral TAP block (single shot) with 0.2% ropivacaine after hysterectomy.~Intervention: TAP block Dose: 20 ml 0.2% ropivacaine"
62775530|NCT06357052||NAFLD patients with liver cirrhosis (LCs, n = 14)|
62775531|NCT06357052||healthy individuals (HIs, n = 12)|
62775532|NCT06002568|PLACEBO_COMPARATOR|Control|In the control group, a silent state (a wave file made without sound) is applied via the sound generator and a headset, at the starting of general anesthesia induction. The sound generator volume is set to 60 dB. The sound generator and the headset is assigned after the randomization, and is blinded to the patient and the investigator. This sound is applied during the operation, and at the time of the final skin suture, the sound generator and the headset will be removed from the patient.
62775533|NCT06002568|EXPERIMENTAL|Binaural Beat|In the experimental group, the binaural beat which is produced by the beat of 1Hz difference is applied via the sound generator and a headset, at the starting of general anesthesia induction. The sound generator volume is set to 60 dB. The sound generator and the headset is assigned after the randomization, and is blinded to the patient and the investigator. This sound is applied during the operation, and at the time of the final skin suture, the sound generator and the headset will be removed from the patient.
62775534|NCT02039856|EXPERIMENTAL|EBQI-Supported WH-PACT Implementation|Evidence-based Quality Improvement (EBQI) is a structured research-clinical partnership approach to facilitating implementation of new care models, including multilevel stakeholder engagement, quality improvement (QI) education/training, technical support, formative feedback, external practice facilitation, and national policy guidance.
62775535|NCT02039856|ACTIVE_COMPARATOR|Routine WH-PACT Implementation|National policy guidance
62000023|NCT03887039||ADHD group|clinical examination
62000024|NCT03887039||normal group|clinical examination
62000025|NCT03857633||Pre Dialysis (CKD Stage 4/5)|Patients recruited from low clearance clinic with advanced CKD (stage 4/5). Patients will undergo Cardiac MRI 1 - With Gadolinium Contrast at the time of recruitment and Cardiac MRI 2 - With Gadolinium Contrast at time of commencement on renal replacement therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
62569090|NCT02259374|ACTIVE_COMPARATOR|TAP BLOCK 0.4% ROPIVACAINE|"Patients randomised into this group will receive bilateral TAP block (single shot) with 0.4% ropivacaine after hysterectomy.~Intervention: TAP block Dose: 20 ml 0.4% ropivacaine"
62000026|NCT03857633||Haemodialysis Dialysis (CDK Stage 5d)|Patients started on Haemodialysis will have Cardiac MRI 3 - With Gadolinium Contrast after 6 months of therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
62185280|NCT03757078||Patients with acute hemorrhoids|Patients with acute hemorrhoids of 1-2 stage were prescribed Fluocortolone + Lidocaine by a physician. No drug will be provided to Patient by the Investigator, only prescription order, based on International Nonproprietary name (Fluocortolone + Lidocaine)
62185281|NCT04069533|EXPERIMENTAL|RP-L102|RP-L102 is CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene
62185282|NCT01648036|EXPERIMENTAL|Unfractionated Heparin|
62185283|NCT01648036|ACTIVE_COMPARATOR|Dalteparin|Standard of care
62185284|NCT05174598|EXPERIMENTAL|Calcipotriol/AKVANO, 50 μg/g cutaneous solution|Spray formulation applied topically, twice daily, for the duration of 8 weeks.
62185285|NCT05174598|ACTIVE_COMPARATOR|Calcipotriol Ointment 50 micrograms/g, Sandoz|Ointment applied topically, twice daily, for the duration of 8 weeks.
62185286|NCT05174598|PLACEBO_COMPARATOR|Placebo|Spray formulation applied topically, twice daily, for the duration of 8 weeks.
62185287|NCT02803593|ACTIVE_COMPARATOR|Control|Asian American breast cancer survivors who do not use the TICAA, but use the information on breast cancer by the American Cancer Society (ACS). Participants are asked to use the online ACS resources for 3 months.
62569091|NCT05859919|EXPERIMENTAL|"The main group receiving the drug Rutan 0.1 and"|"The main group will receive the drug Rutan 0.1"
62775536|NCT01940081||Group A: Nonischemic cardiomyopathy - not admitted for surgery|"Patients with nonischemic cardiomyopathy with:~* documented ventricular arrhythmia or~* suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or~* high risk for ventricular arrhythmia (LVEF ≤ 35%) or~* intermediate risk for ventricular arrhythmia (LVEF ≤ 50% and late enhancement on contrast-enhanced MRI)~who are not admitted for cardiac surgery"
62775537|NCT01940081||Group B: Nonischemic cardiomyopathy -admitted for surgery|"Patients with nonischemic cardiomyopathy with:~* documented ventricular arrhythmia or~* suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or~* high risk for ventricular arrhythmia (LVEF ≤ 35%)~who are admitted for cardiac surgery (e.g., mitral valve annuloplasty or CorCap)"
62775538|NCT01940081||Group C: Controls|"Patients without nonischemic cardiomyopathy (controls) who are admitted for:~* Coronary artery bypass graft surgery and who do not have prior myocardial infarction~* Aortic valve replacement"
62775539|NCT05551052||Next-Gen CRC Screening Test|Adults 45 years of age and older who are at average risk of developing colorectal cancer and eligible for a screening colonoscopy
62775540|NCT05847413|EXPERIMENTAL|Targeting Beta cell Dysfunction with Verapamil in Longstanding T1D|Participants will receive verapamil for 12 weeks
62775541|NCT02204488|ACTIVE_COMPARATOR|Total Joint Arthroplasty|Total Joint Arthroplasty
62775542|NCT02204488|ACTIVE_COMPARATOR|Trapeziectomy|Trapeziectomy
62775543|NCT02757612|ACTIVE_COMPARATOR|Interventional|"Device Laser diode parameters: spot size of 0.04 mm2, average power (output) of 40 mW and 0.4 J per irradiation point, energy density of 10 J cm2, irradiation time of 10 seconds per point~1 session per week during 4 session"
62775544|NCT02757612|SHAM_COMPARATOR|Comparator|"laser probe inactive for similar duration as for the laser diode group; only a beep sound was produced by the laser machine~1 session per week during 4 session"
62775545|NCT03652675|EXPERIMENTAL|Intervention: (Clinician's Guide + HealthCall for HIV/HCV)|
62775546|NCT03652675|NO_INTERVENTION|Educational control condition|Participant will spend 20 minutes at the clinic, observed by the counselor, reviewing an educational pamphlet on drinking, HIV, and HCV.
62000027|NCT03857633||Peritoneal Dialysis (CDK Stage 5d)|Patients started on Peritoneal Dialysis will have Cardiac MRI 3 - Without Gadolinium Contrast after 6 months of therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
62185288|NCT02803593|EXPERIMENTAL|TICAA Intervention|Asian American breast cancer survivors who use the TICAA intervention and the information by the ACS. The intervention is a technology-based information and coaching/support program to enhance survivorship experience of Asian American breast cancer survivors. Participants are asked to use the TICAA program for 3 months.
62185289|NCT04040049|EXPERIMENTAL|FLT190|FLT190 is a recombinant adeno- associated viral (AAV) vector. Administered by a single intravenous infusion.
62185290|NCT03094962|OTHER|Motion capture, MR scan, CT scan|All volunteers will go through the same data collection process
62775547|NCT02434965|EXPERIMENTAL|Autologous Cord Blood and HPDSC|Autologous cord blood and placental blood will be collected after birth of child and administered in divided aliquots during the first week of life.
62775548|NCT05132777|EXPERIMENTAL|JMT101 in combination with Osimertinib|
62775549|NCT02356679|EXPERIMENTAL|Eupasidin-s tab.|three times per day, 1 tab for each time, PO, during 2weeks
62775550|NCT02356679|ACTIVE_COMPARATOR|Stillen tab.|three times per day, 1 tab for each time, PO, during 2weeks
62775551|NCT04708002|OTHER|First EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
62775552|NCT04708002|OTHER|Early intermediate EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
62775553|NCT04708002|OTHER|Late intermediate EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
62185291|NCT02757313|EXPERIMENTAL|Regular Users|People who use marijuana regularly will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the study visits.
62185292|NCT02757313|EXPERIMENTAL|Occasional Users|People who use marijuana occasionally will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the study visits.
62569092|NCT05859919|OTHER|The control group not receiving Rutan 0.1|The control group will not be given the study drug Rutan 0.1
62185293|NCT03937713|EXPERIMENTAL|BBTI plus eszopiclone|participants randomized to the combination therapy will receive eszopiclone 2 mg orally at bedtime or placebo starting with the BBTI sessions for a period of 2 weeks in combination with 4 sessions of BBTI over 4 weeks.
62185294|NCT03937713|ACTIVE_COMPARATOR|BBTI|participants randomized to BBTI will receive 4 sessions of BBTI over 4 weeks.
62569093|NCT06360198||Group 1|The only group of this cross-sectional observational study consists of individuals over the age of 18. There were no orthopedic and neurological chronic diseases included. Individuals with severe visual and hearing problems and individuals who had undergone surgery within the last 6 months were excluded.
62569094|NCT02522884|EXPERIMENTAL|Tack Implant|Implantation of a Tack using the Intact Vascular Tack Endovascular System for the repair of post angioplasty dissections.
62569095|NCT04595045|EXPERIMENTAL|patients with spastic lower limb paresis|patients with spastic lower limb paresis secondary to Multiple Sclerosis
62185295|NCT00639977|SHAM_COMPARATOR|2|20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
62569096|NCT03930355||Transfused|Patients who received blood transfusion in the perioperative period
62185296|NCT00639977|ACTIVE_COMPARATOR|1|20-minute session of acupuncture with needles inserted in specific points (Tong Zi Liao, Yang Bai and Jing Ming)
62185297|NCT00639977|NO_INTERVENTION|3|
62569097|NCT03930355||Non transfused|Patients who did not receive blood transfusion in the perioperative period
62569098|NCT02555228|EXPERIMENTAL|Simethicone premedication|Liquid simethicone (1ml volume) in 5mls of water
62569099|NCT02555228|PLACEBO_COMPARATOR|Placebo|Just 5 mls of water
62569100|NCT05272293|EXPERIMENTAL|expanded haploidentical NK cell immunotherapy|After a cycle of chemotherapy a patient receive three intravenous infusions of expanded haploidentical NK cells.
62569101|NCT02133560|OTHER|Medication Administration + Education|Subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip during months 1-3 and completing the medication administration log during months 1-6. During months 1-6 subjects will meet with study staff and receive educational materials on a monthly basis. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
62569102|NCT01492907|ACTIVE_COMPARATOR|Healthy Control Participants|age/sex matched normal controls - the subject will swallow a capsule with a dietary relevant dose of MeIQx
62000028|NCT02682316|ACTIVE_COMPARATOR|usual standard dry gauze used for wound management|Patients who are randomized to the standard dry gauze arm will have the standard dry gauze placed at time of wound closure. Their dressing will be removed on post-operative day 2 as per routine departmental practice.
62569103|NCT01492907|ACTIVE_COMPARATOR|Pancreatic Cancer Patients|Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
62569104|NCT02479451|EXPERIMENTAL|Nasal theophylline|20 μg intranasal theophylline (theophylline methylpropyl paraben in a 0.4-mL saline solution) once daily (in the morning) into each naris for a total of 6 weeks
62569105|NCT06575803|EXPERIMENTAL|crowns constructed from repressed ceramics|clinical performance of single restorations fabricated for the patients from pressed and repressed ceramics
62569106|NCT02174601||colonoscopy group|
62569107|NCT03340012|EXPERIMENTAL|GTR + radiation-sterilize allogenic bone graft (TEST)|The surgical procedure will be performed in line with minimally invasive surgical technique by Cortellini and Tonetti (2007). The intrabony defects will be debrided and the roots will be planned. The required quantity of radiation-sterilized allogenic bone graft will be delivered into intrabony defects. Subsequently, a trimmed collagen membrane will be placed over graft. The flaps will be sutured with non-absorbable modified internal mattress sutures.
62569108|NCT03340012|ACTIVE_COMPARATOR|GTR + xenogenic graft (CONTROL)|The surgical procedure will be performed in line with minimally invasive surgical technique by Cortellini and Tonetti (2007). The intrabony defects will be debrided and the roots will be planned. The required quantity of xenogenic graft will be delivered into intrabony defects. Subsequently, a trimmed collagen membrane will be placed over graft. The flaps will be sutured with non-absorbable modified internal mattress sutures.
62569109|NCT02015611|PLACEBO_COMPARATOR|Placebo|Matched bottle/pill placebo
62569110|NCT02015611|EXPERIMENTAL|Vitamin D|2,000 IU Vitamin D3 per day
62569111|NCT02027454|EXPERIMENTAL|Sequence 1|Participants in this arm will receive treatment A in period 1, treatment B in period 2 and treatment C in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
62569112|NCT02027454|EXPERIMENTAL|Sequence 2|Participants in this arm will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
62569113|NCT02027454|EXPERIMENTAL|Sequence 3|Participants in this arm will receive treatment B in period 1, treatment A in period 2 and treatment C in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
62569114|NCT02027454|EXPERIMENTAL|Sequence 4|Participants in this arm will receive treatment B in period 1, treatment C in period 2 and treatment A in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
62569115|NCT02027454|EXPERIMENTAL|Sequence 5|Participants in this arm will receive treatment C in period 1, treatment A in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
62569116|NCT02027454|EXPERIMENTAL|Sequence 6|Participants in this arm will receive treatment C in period 1, treatment B in period 2 and treatment A in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
62185298|NCT01582373|EXPERIMENTAL|Cognitive-behavioral couple therapy|The goals of CBCT are to enable participants to: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of their sexual functioning, reduce their sexual distress and increase their sexual satisfaction; (5) consolidate skills.
62569117|NCT00921609||Acromegaly patients|All patients will undergo oral glucose tolerance test at postoperative day 1, 6 weeks, 3 months, and 1 year
62569118|NCT05794893|EXPERIMENTAL|Good Behavior Game|28 classes receiving Good Behavior Game intervention
62569119|NCT05794893|NO_INTERVENTION|Service-as-usual|16 classes receiving usual classroom teaching
62569120|NCT03468491|EXPERIMENTAL|Combined training group|Biomechanical taping will first being applied to the participants of the combined training group. They will be asked to perform following exercises in this session afterwards. As the treatment session goes on, a set of foot intrinsic muscle strengthening exercise and lower extremity neuromuscular exercise will be provided.
62569121|NCT03468491|ACTIVE_COMPARATOR|Proximal training group|For participants of the proximal training group, only a set of lower extremity neuromuscular exercise will be provided. This set of exercises is designed to be the same as for participants of combined training group.
62569122|NCT01317888|EXPERIMENTAL|Treated with MAB-425|All patients receive the same treatment of MAb-425 +Iodine 125 in a total of three injections.
62569123|NCT04021030|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT)|
62775554|NCT04708002|OTHER|Last EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
62775555|NCT02463864|EXPERIMENTAL|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercise sessions
62775556|NCT02463864|SHAM_COMPARATOR|Sham exercise|Twice daily, individual, stretching and relaxation exercise sessions
62000029|NCT02682316|EXPERIMENTAL|Prevena Negative Pressure Wound Therapy System (NPWT)|Patients who are randomized to the Prevena Therapy System arm will have the Prevena Incision Management System device placed at time of wound closure. The device will be removed on day of discharge from the hospital or post-operative day 7, whichever comes first.
62000030|NCT00637195|EXPERIMENTAL|Cervarix™ & Engerix™ Group|Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™) (Months 0, 1 \& 6) and 4 doses of Hepatitis B (Engerix™) vaccine (Months 0, 1, 2 \& 12).
62569124|NCT03722563|ACTIVE_COMPARATOR|TLHS|total laparoscopic hysterectomy with sacrocolpopexy will be performed
62775557|NCT05487183|EXPERIMENTAL|Healthy Volunteers|QST devices and computer tasks are used to measure OA, OH, pain intensity, and other outcomes
62775558|NCT03649009|PLACEBO_COMPARATOR|Normal Saline|"Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days for placebo group after recruitment and randomization done.~If patients develop rashes or redness after normal saline administration, IV hydrocortisone (corticosteroid) 200mg stat dose will be given."
62775559|NCT03649009|ACTIVE_COMPARATOR|IV Thiamine|"IV Thiamine 200mg diluted in 50mls normal saline infused over 1 hour 3 times per day for total 3 days for Thiamine group after recruitment and randomization done.~If patients develop nausea after thiamine administration, IV metoclopramide (antiemetic)10mg stat dose will be given. If patients develop redness and rashes after Normal Saline infusion, IV hydrocortisone (corticosteroid) 200mg stat dose will be given."
62000031|NCT00637195|ACTIVE_COMPARATOR|Engerix™ Group|Subjects received 4 doses of Hepatitis B (HBV) vaccine (Months 0, 1, 2 \& 12).
62000032|NCT03071796|EXPERIMENTAL|multivitamin supplement|liquid multivitamin supplement for 12 weeks
62000033|NCT03071796|PLACEBO_COMPARATOR|placebo|liquids with similar appearance and taste like multivitamin supplement for 12 weeks
62000034|NCT03854916|EXPERIMENTAL|Caminemos Juntas App|Participants use the Caminemos app.
62000035|NCT03854916|ACTIVE_COMPARATOR|World Walking App|Participants use the World of Walking App.
62569125|NCT03722563|EXPERIMENTAL|TLHLS|total laparoscopic hysterectomy with lateral suspension will be performed
61977795|NCT00770796|ACTIVE_COMPARATOR|Atorvastatin|80 mg die of Atorvastatin given at least two days before elective angiography or angioplasty and continued for two days after.
61977796|NCT01028339|ACTIVE_COMPARATOR|Mannitol|
61977797|NCT01028339|EXPERIMENTAL|Hypertonic saline|
61977798|NCT05701774|EXPERIMENTAL|DCCR|75 - 525 mg DCCR
62000036|NCT04103528|OTHER|morning group(from 8:00 to 12:00)|
62000037|NCT04103528|OTHER|afternoon group(from 14:00 to 18:00)|
62000038|NCT02909556|EXPERIMENTAL|ACURATE neo AS|
62000039|NCT03435549|NO_INTERVENTION|Arm 1: Control Arm (Usual care)|If Patient is randomized to Arm 1, no contact will occur, patient will receive standard and routine clinical care
62000040|NCT03435549|EXPERIMENTAL|Arm 2a: Remote monitoring|If Patient is randomized to Arm 2a they will remote monitoring for 6 weeks post-surgery
62000041|NCT03435549|EXPERIMENTAL|Arm 2b: Remote monitoring plus goal setting and social support|If Patient is randomized to Arm 2b, they will receive a remote monitoring plus social support and nudge messaging for 6 weeks post-surgery
62569126|NCT06090825||Pancreatic cancer patients|
62569127|NCT03187418|EXPERIMENTAL|Micropulse trans-scleral CPC|A treatment session of micropulse trans-scleral cyclophotocoagulation in the affected eye, using the MicroPulse® P3 Glaucoma Device (MP3) powered by the CYCLO G6™ Glaucoma Laser System (Iridex, Mountain View, CA, USA).
62000042|NCT01807052||Observational|Tissue samples are analyzed for tumor factor expression levels by immunohistochemistry.
62000043|NCT04059848|EXPERIMENTAL|tDCS combined with NMES|In addition to conventional rehabilitation, all subjects received an additional tDCS combined with NMES protocol with a total of 15 sessions for 3 weeks (5 times per week, 30 minutes daily).
62000044|NCT04059848|ACTIVE_COMPARATOR|tDCS combined with sham NMES|In addition to conventional rehabilitation, all subjects received an additional tDCS combined with sham NMES protocol with a total of 15 sessions for 3 weeks (5 times per week, 30 minutes daily).
62000045|NCT04059848|SHAM_COMPARATOR|sham tDCS combined with sham NMES|In addition to conventional rehabilitation, all subjects received an additional sham tDCS combined with sham NMES protocol with a total of 15 sessions for 3 weeks (5 times per week, 30 minutes daily).
62000046|NCT00733720|ACTIVE_COMPARATOR|1|Each subject will receive all 3 doses of suboxone and placebo
62000047|NCT05154448|EXPERIMENTAL|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound|Non-Invasive Thermal Ablation of the Medial Branch Nerves using the Neurolyser XR High Intensity Focused Ultrasound device
62000048|NCT05154448|SHAM_COMPARATOR|Sham treatment|"The procedure would be done in an identical manner to the NeurolyserXR treatment without any person in the procedure room knowing that this is a sham procedure.~The only difference is that the acoustic energy would not be output from the system during a sham procedure."
62000049|NCT02171481|EXPERIMENTAL|Dabigatran etexilate polymorph II|
62000050|NCT02171481|ACTIVE_COMPARATOR|Dabigatran etexilate polymorph I|
62000051|NCT03569670|EXPERIMENTAL|Posterior Stabilized|A posterior stabilized, all-polyethylene tibial component will be used during surgery.
62775560|NCT06502938|EXPERIMENTAL|Pan-vascular interventional robotic system group|Pan-vascular interventional robotic system assisted PCI
62000052|NCT03569670|ACTIVE_COMPARATOR|Cruciate Retaining|A cruciate retaining, all-polyethylene tibial component will be used during surgery.
62000053|NCT05137795|EXPERIMENTAL|Severe COVID-19 ZYESAMI™|Patients with Severe COVID-19 to be treated with inhaled ZYESAMI™ (aviptadil) by mesh nebulizer 100μg 3x daily
62775561|NCT06502938|EXPERIMENTAL|Artificial control group|Traditional artificial percutaneous coronary intervention
62775562|NCT00479479|EXPERIMENTAL|Cobalamin|An intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
62775563|NCT00479479|NO_INTERVENTION|No intervention|No intervention
62775564|NCT00187070|OTHER|1|
62000054|NCT05137795|EXPERIMENTAL|Severe COVID-19 Placebo|Patients with Severe COVID-19 to be treated with inhaled placebo 3x daily
62775565|NCT01807377|EXPERIMENTAL|PF-05175157, Midazolam|Day 0: Midazolam 2 mg administered alone Days 1-14: 200 mg PF-05175157 administered BID Day 11: Midazolam and PF-05175157
62000055|NCT02166983|EXPERIMENTAL|Arm IA (Lumosity, relaxation, compensatory strategies)|Participants complete Lumosity cognitive exercises. Lumosity cognitive exercises are online video game-based activities that are designed to practice various cognitive skills including processing speed, attention, memory and executive function. Participants complete cognitive exercises at least 20 minutes a day, 5 days a week for 6 weeks. Participants also complete relaxation exercises (guided imagery, progressive muscle relaxation, and/or autogenics) at least 10 minutes a day for 6 weeks and compensatory strategies (the use of external devices such as a notebook, day planner, or smartphone for cuing, reminding, and organizing; the use of memory strategies such as repetition, paraphrasing, and active listening; and the use of executive strategies such as self-talk for planning and attention orientation) as much as possible.
62185299|NCT03051893|EXPERIMENTAL|Part A1|Three formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
62569128|NCT01462760|OTHER|First assessment: inclinometer|First assessment: inclinometer Second assessment: actigraph and inclinometer
62775566|NCT01807377|EXPERIMENTAL|Placebo, Midazolam|Day 0: Midazolam 2 mg administered alone Days 1-14: Placebo administered BID Day 11: Midazolam and Placebo
62775567|NCT05626127||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the validation cohort.
62775568|NCT04546594||Orthopedic surgery|
62775569|NCT04546594||Thoracic surgery|
62775570|NCT04546594||Gynecological surgery|
62775571|NCT06037408|EXPERIMENTAL|20mM sodium pyruvate nasal spray treatment|
62775572|NCT06037408|PLACEBO_COMPARATOR|Saline placebo control|
62775573|NCT02901132||Cancer group 1|Colorectal cancer patients, under 18 years old, no inflammatory disease, weight loss greater 10% habitual body weight, sarcopenic.
62775574|NCT02901132||Control group|No cancer patients, under 18 years old, no inflammatory disease, no weight loss, no sarcopenic.
62775575|NCT03281083|EXPERIMENTAL|Levothyroxine (LT4)|Levothyroxine sodium (LT4) dose titrated at TSH 0.34 - 1.70mIU/L during maximum 12 weeks, followed by a maintenance phase of 16 weeks using the dose necessary for titration.
62000056|NCT02166983|EXPERIMENTAL|Arm IB (Active Journaling, relaxation, compensatory strategy)|Participants complete Active Journal cognitive exercises. Active Journaling requires participants to keep a written diary or journal where she discusses what her thoughts and feelings about various events with a focus on describing the meaning of the activities and experiences, particularly new things that were learned. Active Journaling is a method of practicing various cognitive skills including communication, organization, memory and executive function. Participants complete cognitive exercises at least 20 minutes a day, 5 days a week for 6 weeks. Participants also complete relaxation exercises and compensatory strategies as in Arm IA.
62000057|NCT02166983|EXPERIMENTAL|Arm II (Lumosity only)|Participants complete Lumosity exercises as in Arm IA.
62775576|NCT03251950|EXPERIMENTAL|Intervention group|15 week healthy eating and gardening curriculum to be implemented in Osage Nation Early Childhood Programs; 15 week healthy eating parenting curriculum to be implemented online to parents of enrolled children
62000058|NCT02383667||Patients with Electrocardiograms|"Any patient within the hospital either for procedure or for admission will be screened. Patients will be simultaneously be hooked up to two ambulatory Holter monitors for the period of time to be not less than one hour.~One holter will use standard electrodes in a standard electrode distribution. The second holter will use dry electrodes in a derived; data will be collected for 1-6 hours. After the data is collected the Holters will be removed and the data will be downloaded into the reading software to be scanned."
62185300|NCT03051893|EXPERIMENTAL|Part A2|Three additional formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
62185301|NCT03051893|EXPERIMENTAL|Part B|The best formulation of Chronocort was then selected from Parts A1 \& A2. This was then administered in four separate treatment periods, in dosages of 5mg, 10mg, 20mg and 30mg. Each treatment was administered in a randomised, crossover manner.
62185302|NCT01491906|EXPERIMENTAL|Text-Messaging|The group that receives the behavioral counseling and text messaging lifestyle intervention
62185303|NCT01491906|NO_INTERVENTION|Usual Care|This group will receive usual care
62569129|NCT01462760|OTHER|first: Inclinometer and actigraph|first: Inclinometer and actigraph second: inclinometer
62569130|NCT05598424|EXPERIMENTAL|Oral Glucocorticoids group|"Intervention Period I: nasal spray, Budesonide Nasal Spray, 64ug per Nostril, bid, for 4-week duration.~Intervention Period II: oral glucocorticoids methylprednisolone 24mg qd, and nasal spray, Budesonide Nasal Spray 64ug per Nostril, bid, for 2-week duration."
62569131|NCT04812223|ACTIVE_COMPARATOR|Delayed Clamping|In this group, the umbilical cord will be clamped 60 seconds after the baby is born.
62775577|NCT03251950|OTHER|Control group|Wait list control -- to receive intervention after serving as wait list group
62775578|NCT05278832|EXPERIMENTAL|QLS31905|QLS31905 injection
62185304|NCT04515056|EXPERIMENTAL|Papain dosage|In the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm). The two areas will be located 4 cm apart. Three areas will be exposed to 10, 50 or 100 µg of papain, while the last area will be used as control (exposed to a vehicle).
62215315|NCT02961543|ACTIVE_COMPARATOR|Group 2.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isotonic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
62775579|NCT02986815|EXPERIMENTAL|[11C]Acetate Brain Imaging|\[11C\]Acetate will be administered The patient will have one intravenous line placed prior to \[11C\]Acetate administration. The patient will receive the low-dose CT portion of a PET/CT scan, after which \[11C\]Acetate will be administered intravenously over approximately 1 min at a dose of 0.3 mCi/kg (maximum 30 mCi) and followed by a saline flush. The injection and imaging procedure will be terminated in any patient who exhibits anaphylaxis, significant dyspnea or chest pain. The administering physician will stay with the patient for at least 15 min after injection and will remain in the Clinical PET Facility through the duration of the imaging procedure.
62775580|NCT05606055|EXPERIMENTAL|SDT|-75 patients of immediate treatment, will be those patients without immuno-virological data that accept to start the treatment the same day of the first consultation with the hospital specialist (arm 1 or SDT).
62775581|NCT05606055|ACTIVE_COMPARATOR|Conventional|- 75 patients of conventional treatment, will be those who in their first consultation with the hospital specialist already have previous immuno-virological data or reject the start of immediate treatment (arm 2 or conventional).
62569132|NCT04812223|ACTIVE_COMPARATOR|Early Clamping|In this group, the umbilical cord will be clamped 15 seconds after the baby is born.
62569133|NCT04812223|ACTIVE_COMPARATOR|Milking Clamping|In this group in which the umbilical cord will be milked, the cord will be milked 5 times with 2 seconds milking, then letting 2 seconds for spontaneous blood flow.
62569134|NCT03353714|PLACEBO_COMPARATOR|Pudendal block with saline|Pudendal block with normal saline
62569135|NCT03353714|ACTIVE_COMPARATOR|Pudendal block with bupivacaine|Pudendal block with bupivacaine
62569136|NCT01203163||PDT with porfimer sodium|
62569137|NCT05906381|PLACEBO_COMPARATOR|Control group|Subjects will take a capsule of containing microcrystalline cellulose per day for 35 days.
62569138|NCT05906381|EXPERIMENTAL|Treatment group|Subjects will take a capsule of containing Streptococcus thermophilus per day for 35 days.
61977799|NCT03356951||Lateral approach group|TAR through lateral approach and subtalar fusion
61977800|NCT03356951||Anterior approach group|TAR through anterior approach and subtalar fusion
62000059|NCT01989351||VAS<4|
62569139|NCT05697172|EXPERIMENTAL|Active Low Intensity Focused Ultrasound (LIFU)|An 80-second train of 20-millisecond bursts of ultrasound (0.5 MHz), repeated every 200 milliseconds (400 bursts). Acoustic simulations will be performed with the k-Wave Matlab Toolbox to individually confirm the estimated total energy delivered during sonication and verify tissue temperature increases are \<1°C, decreasing actual Power/Channel values if necessary. We estimate a 75% tissue attenuation of energy when the ultrasound wave reaches its target, therefore we will set the free-field Intensity Spatial-Peak Pulse-Average (ISPPA) at 9.04 Watt /cm2 or 518 kPascal (to achieve 2.26 Watt/cm2 derated ISPPA).
62569140|NCT05697172|SHAM_COMPARATOR|Sham LIFU|Identical parameters of sonication and positioning procedures as those in the Active LIFU arm will be employed, but a Sorbothane(R) film will be interposed between the transducer and the subject's scalp.
62775582|NCT01900288|EXPERIMENTAL|HPN Group Clinic Appointments (Group 1)|"A mobile device (iPad mini) is loaned to Group 1 subjects providing a connection to HPN Internet information for the 6 to 12 months of the study. Two scheduled times during the study period, visual connections to geographically distant professionals and peers over the iPad mini (HPN Group Clinic Appointment) will be held for approximately 1 ½ to 2 hours each time (called Healthy Living Connections).~On the iPad mini screen during the HPN Group Clinic Appointments, subjects will be able to see professionals and peers all at the same time and they will be able to see them in their home. This group will also receive electronic prompts about healthy activities."
62775583|NCT01900288|PLACEBO_COMPARATOR|Mobile Device Access (Group 2)|"A mobile device (iPad mini) is loaned to Group 2 subjects providing a connection to Internet information for the 6 to12 months of the study. At the end of the study period, Group 2 subjects will have 1 scheduled time during the study to connect to professionals and peers over the iPad mini for approximately 1 ½ to 2 hours (called Healthy Living Connections) before the study concludes.~On the iPad mini screen during the placebo control group clinics, subjects will be able to see professionals and peers all at the same time and they will be able to see them in their home. This group will also receive one electronic prompt about healthy activities as a comparison control to the intervention group."
62000060|NCT01989351||VAS>4|
62000061|NCT05421208|EXPERIMENTAL|Compare inflammatory markers (IL-6) in post- COVID 19 POTS patients with Controls|"Biochemical endpoints: Measurement of Inflammatory markers (especially IL-6) in both Post- COVID-19 POTS patients and compare it with controls.~Controls are the participants who recovered from COVID 19 infection with no sequelae"
62000062|NCT05421208|EXPERIMENTAL|Effect of OI symptoms & inflmmation after Restoring PNS functions in post-COVID POTS patients.|Effects of restoring PNS function in post-COVID-19 POTS patients with chronic transcutaneous vagus nerve stimulation (tVNS) on inflammation, orthostatic tachycardia and OI symptoms.The subjects with POTS will be randomized, where TENS 7000 device will be placed to active and sham location.Autonomic symptoms assessment questionnaire (COMPASS-31),32 quality of life EQ-5D and neuropsychological tests
62000063|NCT06375005|EXPERIMENTAL|Mycophenolate Mofetil + Telitacicept|All patients who enroll in this trial will receive mycophenolate mofetil (MMF), which is a drug commonly given to patients with systemic sclerosis in clinical practice. Participants will be treated with MMF 0.5g twice a day for 48 weeks. Telitacicept will be subcutaneously injected at a dose of 160mg per week, lasting for 48 weeks.
62000064|NCT06375005|ACTIVE_COMPARATOR|Mycophenolate Mofetil|Participants will be treated with MMF 0.5g twice a day for 48 weeks.
62775584|NCT04672850|PLACEBO_COMPARATOR|Placebo|Rice flour
62000065|NCT01446731|EXPERIMENTAL|Arm A|DC vaccine (mRNA transfected dendritic cell) + Docetaxel
62185305|NCT04515056|EXPERIMENTAL|Papain SPT|Each forearm of the subject will be divided into two squared areas (4x4 cm). The provocations of three areas will be performed with 100 µg of papain by SPT lancets. To assess the potential importance of repeated pricks, papain will be applied by 1, 5 or 25 SPT pricks thought the skin. The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.
62185306|NCT05032846|EXPERIMENTAL|Ultrasound Guided Laparoscopic Ovarian Cystectomy|During surgical resection of the ovarian cyst, a clinician with experience of ultrasound and laparoscopy will perform an ultrasound scan during surgery to resect cyst tissue only and preserve healthy ovarian tissue.
62185307|NCT05032846|ACTIVE_COMPARATOR|Laparoscopic Ovarian Cystectomy|A laparoscopic ovarian cystectomy will be performed without ultrasound guidance. This is currently standard clinical practice.
62185308|NCT04431752||Healthy Volunteer|10 healthy volunteers to undergo radiographic examinations of the knee joint.
62569141|NCT04997252|EXPERIMENTAL|high-risk and oligometastatic prostate cance|Neoadjuvant therapy with apalutamide in combination with luteinizing hormone-releasing hormone analogues
62775585|NCT04672850|ACTIVE_COMPARATOR|Probiotic|Probiotic bacteria, yeast, zinc and rice brand
62775586|NCT05897697||Pregnant / postpartum women|Adult women during pregnancy or the early postpartum period (within 7 days of delivery)
62775587|NCT06547073|EXPERIMENTAL|Frozen shoulder group|Patient group
62775588|NCT06547073|ACTIVE_COMPARATOR|Healthy group|Healthy subjects without shoulder pain
62000066|NCT01446731|ACTIVE_COMPARATOR|Arm B|Docetaxel alone
62000067|NCT00152217|EXPERIMENTAL|1|TS-1 (S-1)
62000068|NCT00152217|OTHER|2|Surgery alone
62000069|NCT00219674|ACTIVE_COMPARATOR|2|Group II
62000070|NCT00219674|ACTIVE_COMPARATOR|3|
62000071|NCT00219674|ACTIVE_COMPARATOR|4|
62000072|NCT00219674|ACTIVE_COMPARATOR|1|Group I
62000073|NCT03422341|EXPERIMENTAL|GenePOC testing|"The swab will be used for the testing on the revogene using the GenePOC Strep A, C/G assay.~Intervention will be the Comparison between GenePOC CR and Reference Method."
62000074|NCT03422341|ACTIVE_COMPARATOR|Reference Method|"The swab will be used to detect the presence or absence of Strep A, C/G using standard microbiology method.~Intervention will be the Comparison between GenePOC CR and Reference Method."
62000075|NCT02617316|OTHER|barefoot first|Ten runners carried on barefoot test first and then in-shoes.
62000076|NCT02617316|OTHER|in shoes first|Ten runners carried on in-shoes test first and then barefoot.
62000077|NCT00096044|EXPERIMENTAL|Oral Lenalidomide|Patients receive oral lenalidomide (CC-5013) once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity
62000078|NCT03735862||Observations Group|Patients who have undergone a hiatal hernia repair with MIROMESH.
62569142|NCT04823273|EXPERIMENTAL|General improvement|"Using the expertise of the study personnel, electronic-health record system architects working for UCHealth, and incorporating feedback from the users who participated in the user-centered design sessions we made changes to the blood transfusion order-set as well as the prepare and transfuse orders. The intention of the changes to the interface are to be more intuitive for ordering clinicians."
62185309|NCT04431752||Kellgren-Laurence grading I Osteoarthritis Knee|10 patients in Kellgren-Laurence grading I to undergo radiographic examinations of the knee joint.
62569143|NCT04823273|EXPERIMENTAL|In-line help text|In addition to general improvement changes, subjects exposed to the in-line help text arm receive text detailing evidence-based transfusion recommendations that appear if the most recent hemoglobin level is above 7.0 g/dL. This text appears within the transfusion order but is non-interruptive as it does not require users to acknowledge the text nor does is require any additional keystrokes or clicks.
62569144|NCT04823273|EXPERIMENTAL|Interruptive alert|In addition to general improvement changes, subjects exposed to the interruptive alert arm receive text detailing evidence-based transfusion recommendations that appear if the most recent hemoglobin level is above 7.0 g/dL. In contrast to the in-line help text arm, this arm includes an interruptive alert that appears when the user selects the transfusion order. This alert offers users the option to remove the order which results in no-blood product ordered. Alternatively, users may continue to order blood and are asked to select the reason for proceeding with the intended order.
62775589|NCT05894811||control|obese people with normal glucose tolerance
62185310|NCT04431752||Kellgren-Laurence grading II Osteoarthritis Knee|10 patients in Kellgren-Laurence grading II to undergo radiographic examinations of the knee joint.
62185311|NCT04431752||Kellgren-Laurence grading III Osteoarthritis Knee|10 patients in Kellgren-Laurence grading III to undergo radiographic examinations of the knee joint.
62185312|NCT04431752||Kellgren-Laurence grading IV Osteoarthritis Knee|10 patients in Kellgren-Laurence grading IV to undergo radiographic examinations of the knee joint.
62185313|NCT02066610|EXPERIMENTAL|PN selenium and formula sodium selenate|Parenteral nutrition (PN) with selenium and sodium selenate supplementation of infant formula
62185314|NCT02066610|EXPERIMENTAL|PN selenium and formula sodium selenite|Parenteral nutrition (PN) with selenium and sodium selenite supplementation of infant formula
62185315|NCT02066610|EXPERIMENTAL|PN without selenium and formula sodium selenate|Parenteral nutrition (PN) without selenium and sodium selenate supplementation of infant formula
62185316|NCT02066610|EXPERIMENTAL|PN without selenium and formula sodium selenite|Parenteral nutrition (PN) without selenium and sodium selenite supplementation of infant formula
62185317|NCT04587583|ACTIVE_COMPARATOR|WeCareAdvisor|immediate use of the WeCareAdvisor tool for a 1 month period
62185318|NCT04587583|ACTIVE_COMPARATOR|WeCareAdvisor after 1 month|after a wait period of 1 month, use of the WeCareAdvisor tool for a 1 month period
62185319|NCT00639769|EXPERIMENTAL|Therapeutic Intervention|
62569145|NCT00246194||Patients with schizophrenia|Long-acting injectable of risperidone given as per the prescription from the prescribing physician (Observational study).
62569146|NCT03691454|EXPERIMENTAL|DOS|Docetaxel+Oxaliplatin+S-1
62185320|NCT04574232|OTHER|athletic subjects|athletic subjects who may need intra-articular knee infiltration
62185321|NCT05553223|EXPERIMENTAL|Microdoses of Activity|5-min bouts of walking will break up 3 hours of sitting at minutes 30, 90 and 150.
62185322|NCT05553223|NO_INTERVENTION|Control|Prolonged sitting (3 hours)
62569147|NCT03691454|ACTIVE_COMPARATOR|SOX|Oxaliplatin+S-1
62569148|NCT01075269||Conventional open thyroidectomy group|All patients were told about the operative techniques involved in conventional open and robotic thyroidectomy, and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
62775590|NCT05894811||IGT|obese people with injured glucose tolerance
61977801|NCT02677987|EXPERIMENTAL|Intervention light|30 minutes of intervention systematic light exposure daily for 4 weeks.
62185323|NCT02240797||Anorexia Nervosa - Recovered (AN-REC)|Anorexia Nervosa - Recovered (AN-REC)
62185324|NCT02240797||Healthy Control (HC)|Healthy Control (HC)
62185325|NCT01076309||Tamsulosin|Patients taking tamsulosin
62775591|NCT05894811||T2D|obese people with type 2 diabetes
62775592|NCT01756222||Bicuspid Aortic Valve Disease Patients|Patients with the diagnosis of BAV disease.
62775593|NCT03537313|NO_INTERVENTION|Control-douching group|No preoperative vagina douching
62775594|NCT03537313|NO_INTERVENTION|Control-painting group|No intra-operative vagina painting
62775595|NCT03537313|EXPERIMENTAL|Vaginal douching group|Preoperative vaginal douches with povidone-iodine solution
62185326|NCT01076309||Non-tamsulosin|Patients not taking tamsulosin.
62185327|NCT03104283|EXPERIMENTAL|Apatinib Group|take apatinib orally (500mg/d or 250mg/d, once a day, continuously )
62185328|NCT05245591|EXPERIMENTAL|Pentosan Polysulfate Sodium|U101 is available as a capsule containing 100 milligrams (mg) of pentosan polysulfate sodium. Subjects will be administered U101 at a dose of 300 milligrams (mg) three times daily (tid) for the initial 8 weeks and then 200 milligrams (mg) twice daily (bid) for another 8 weeks during the study.
62185329|NCT05245591|PLACEBO_COMPARATOR|Placebo Control|Placebo to match U101 is available as a capsule in 100 milligrams (mg). Subjects will be administered placebo at a dose of 300 milligrams (mg) three times daily (tid) for the initial 8 weeks and then 200 milligrams (mg) twice daily (bid) for another 8 weeks during the study.
62185330|NCT00945399|EXPERIMENTAL|Autologous Chondrocytes Implantation|
62185331|NCT00945399|ACTIVE_COMPARATOR|Microfracture|
62185332|NCT06282640|EXPERIMENTAL|Vitamin D in Carpal Tunnel Syndrome|
62584782|NCT06239194|EXPERIMENTAL|Phase 2a - Cohort Expansion|Patients with a single tumor indication will receive MDX2001 as intravenous (IV) infusion at the recommended Phase 2 dose.
62775596|NCT03537313|EXPERIMENTAL|Vaginal painting group|Intra-operative vaginal painting with povidone-iodine solution
62775597|NCT00938522|EXPERIMENTAL|Cilostazol loading|
62775598|NCT00938522|PLACEBO_COMPARATOR|Placebo|
62775599|NCT04699461|EXPERIMENTAL|Loncastuximab Tesirine|Participants will be administered loncastuximab tesirine as an intravenous (IV) infusion on Day 1 of each cycle, where 1 cycle is 3 weeks. Loncastuximab tesirine will be administered at a dose of 150 μg/kg for 2 cycles, then at a dose of 75 μg/kg for subsequent cycles.
62775600|NCT04699461|ACTIVE_COMPARATOR|Idelalisib|Participants will be administered 150 mg idelalisib, orally, twice a day throughout each cycle, where 1 cycle is 4 weeks.
62775601|NCT01681524|EXPERIMENTAL|Flurpiridaz F18|Open-label study of a single injection of flurpiridaz F18 for PET MPI compared to SPECT MPI in patients with suspected or known coronary artery disease referred for coronary cathertization
62775602|NCT04538313|EXPERIMENTAL|High dose group|10\^10 TIL
62775603|NCT04538313|EXPERIMENTAL|Low dose group|10\^9 TIL
62775604|NCT04538313|EXPERIMENTAL|Extension set|The number of TIL is decided by dose escalation experiment.
62775605|NCT02461082|OTHER|EMST and sham-TMS|Active expiratory muscle strength training in combination with sham transcranial magnetic stimulation
62775606|NCT02461082|OTHER|sham-EMST and TMS|Sham expiratory muscle strength training in combination with active transcranial magnetic stimulation
62775607|NCT02461082|OTHER|EMST and TMS|Active expiratory muscle strength training in combination with active transcranial magnetic stimulation
62775608|NCT02461082|OTHER|sham-EMST and sham-TMS|Sham expiratory muscle strength training in combination with sham transcranial magnetic stimulation
62775609|NCT00303888|EXPERIMENTAL|Arm I|Patients receive docetaxel IV over 1 hour on days 1, 8, and 15 and oral placebo three times daily on days 1-21.
62775610|NCT00303888|EXPERIMENTAL|Arm II|Patients receive oral phenoxodiol three times daily on days 1-21 and docetaxel IV over 1 hour on days 1, 8, and 15.
62775611|NCT01306656|EXPERIMENTAL|Group 1|10,000 IU Vitamin D3 plus a multivitamin with 400 IU vitamin D
62185333|NCT03512197|EXPERIMENTAL|Midostaurin + chemotherapy|Participants received Midostaurin in Induction 50mg twice daily on Day 8 until 48 hrs before start of next cycle. During Induction 2 and consolidation 50mg twice daily on Day 4 until 48 hrs before start of next cycle. During post-consolidation 50mg twice daily for 28 consecutive days of each 28-day treatment cycle up to 12 cycles. For participants who could not tolerate the protocol-specified dosing schedule, dose interruptions and/or reductions were either recommended or mandated allowing participants to continue the study treatment. Chemotherapy consisted of daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation.
62775612|NCT01306656|PLACEBO_COMPARATOR|Group 2|Placebo plus a multivitamin with 400 IU vitamin D
62775613|NCT03189901|NO_INTERVENTION|Regular Management|Patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level who treated by regular strategy in guideline.
62775614|NCT03189901|EXPERIMENTAL|Regular management+Levosimendan|Patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level who treated by regular strategy in guideline and levosimendan.
62775615|NCT02055300|EXPERIMENTAL|LY03005 - 20|LY03005 Dose Strength 20mg
62185334|NCT03512197|PLACEBO_COMPARATOR|Placebo + chemotherapy|Participants received matching placebo to midostaurin with same dose, plus chemotherapy. Chemotherapy consisted of daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation
62185335|NCT02995382|EXPERIMENTAL|Anterior Intramuscular Transposition|This is the only arm in our study, patients with cubital tunnel syndrome will undergo anterior intramuscular transposition, one of many surgical techniques utilized on patients with Cubital Tunnel Syndrome to alleviate symptoms.
62215316|NCT01240187|EXPERIMENTAL|Experimental 1|
62775616|NCT02055300|EXPERIMENTAL|LY03005 - 40|LY03005 Dose Strength 40mg
62775617|NCT02055300|EXPERIMENTAL|LY03005- 80|LY03005 Dose Strength 80mg
61977802|NCT02677987|ACTIVE_COMPARATOR|Comparison light|30 minutes of comparison systematic light exposure daily for 4 weeks.
61977803|NCT04092101|EXPERIMENTAL|RC 1 only|Research Cigarettes #1
61977804|NCT04092101|EXPERIMENTAL|RC 2 only|Research Cigarettes #2
62775618|NCT02055300|EXPERIMENTAL|LY03005 - 120|LY03005 Dose Strength 120mg
62775619|NCT02055300|EXPERIMENTAL|LY03005 - 160|LY03005 Dose Strength 160 mg
62775620|NCT02055300|EXPERIMENTAL|LY03005 - 200|LY03005 Dose Strength 200mg
62775621|NCT02055300|EXPERIMENTAL|LY03005 - 120 - Fed|LY03005 120mg under Fed Conditions
62775622|NCT02055300|ACTIVE_COMPARATOR|Pristiq|Pristiq - 50mg
62775623|NCT02055300|PLACEBO_COMPARATOR|Placebo|Placebo
62775624|NCT04353700|ACTIVE_COMPARATOR|Yoga group|A certified yoga instructor led the supervised yoga session. An exercise physiologist taught how to record your Rating of Perceived Exertion to monitor their exercise intensity during the in-home yoga intervention. During the in-home yoga intervention, participants performed 30 to 50 minutes of yoga postures three to five times a week for 12 weeks.
62775625|NCT04353700|NO_INTERVENTION|Control group|If participants were in a CON group, they did not receive the yoga intervention. Instead, they were encouraged to maintain a normal daily lifestyle monitored by the BPAQ at one-month intervals during the 12-week intervention.
62775626|NCT05390658||Survival|
62775627|NCT05390658||Death|
62775628|NCT01075503|EXPERIMENTAL|retrograde infraclavicular|Patients were received retrograde infraclavicular brachial plexus block.
62775629|NCT01075503|ACTIVE_COMPARATOR|interscalene|Patients were received interscalene brachial plexus block.
62775630|NCT01075503|ACTIVE_COMPARATOR|supraclavicular|Patients were received supraclavicular brachial plexus block.
62775631|NCT03172156||Stage I NSCLC patients after surgery with ctDNA detection|Stage I NSCLC patients;ctDNA detection
62791661|NCT01999400|EXPERIMENTAL|Arm 3: Apriso then Delzicol then Pentasa then Lialda|"1. Apriso 375 mg capsule x 3 with 240 mL water, single dose.~2. Washout period of 10 days.~3. Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~4. Washout period of 10 days.~5. Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~6. Washout period of 10 days.~7. Lialda 1200 mg tablet x 1 with 240 mL water, single dose."
62569149|NCT01075269||Robotic thyroidectomy group|All patients were told about the operative techniques involved in conventional open and robotic thyroidectomy, and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
62569150|NCT05637853||HFrEF patients (diagnosed within 3 months or hospitalized for worsening of HFrEF)|"Standardized sequencing of all for main HFrEF drugs: Betablockers, RAASi, SGLT2i, MRA.~All patients will be started on an SGLT2i (Empagliflozin or Dapagliflozin) and a betablocker (Metoprolol, Bisoprolol or Carvedilol) right after study inclusion. In the second week, RAASi will be introduced with either angiotensin converting enzyme inhibitor (ACEi)(Ramipril or Enalapril) or angiotensin receptor neprilisyn inhibitor (ARNI)(Sacubitril/Valsartan). If the patient is intolerant to either of these, an angiotensin receptor blocker (ARB)(Candesartan, Losartan, Valsartan) will be introduced. During the following weeks, both BB and ACEi/ARNI/ARB will be up titrated every second week according to the sequencing algoritm. MRA (Spironolactone, Eplerenone) will be introduced and up titrated in week 3 and 7 respectively. If the patient is already on either BB or ACEi/ARNI/ARB/MRA they will continue with the previous prescription and dose until the titration scheme indicates uptitration."
62775632|NCT02508324|OTHER|Cord Blood Unit|"The CBU unit must supply a minimum of 0.5 x 10\^7/kg and a maximum of 2.5 x 10\^7/kg nucleated cell dose pre-cryopreservation. The unit must match at a minimum of 4 of 6 at HLA-A, -B antigens, -DRB1 alleles with the recipient. Mismatches (0-2) can be at any loci. Although molecular level typing will be available for the patient and the CBU unit, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1. The CBU donor will have also undergone HLA typing of the mother, thus allowing determination of the CBU-IPA and NIMA.~CBU grafts in this study will be investigational units that meet all criteria for clinical use. Better matching units will be preferred over less matching units as long as the CBU dose exceeds 0.5 x 10\^7 nucleated blood cells/kg."
62569151|NCT00954941|EXPERIMENTAL|Group 1: Ondansetron|Ondansetron 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.
62569152|NCT00954941|ACTIVE_COMPARATOR|Group 2: Ondansetron + Aprepitant|Ondansetron 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy. Aprepitant 125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
62569153|NCT01511978|ACTIVE_COMPARATOR|Continuous 3,4-DAP|Subjects continued taking their usual individualized regimen of 3,4-DAP base, 30 to 100 mg daily divided into at least 3 doses.
62569154|NCT01511978|PLACEBO_COMPARATOR|Taper 3,4-DAP to Placebo|Subjects were tapered over 3 days from their usual individualized regimen of 3,4-DAP base (30 to 100 mg daily divided into at least 3 doses) to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
62569155|NCT02863094|ACTIVE_COMPARATOR|Real Stimulation|The continuous theta burst stimulation (cTBS) protocol lasted 40 s and consisted of burst of 3 pulses delivered at 50 Hz, with bursts being repeated every 200 ms (at 5 Hz) for a total of 600 pulses. In the cTBS session, this 40s protocol was repeated for three times (1800 pulses in total) separated by two 15 min breaks (controlled by a stopwatch). MRI dataset should be acquired before the first cTBS session and after the last cTBS session.
62569156|NCT02863094|SHAM_COMPARATOR|Placebo Stimulation|The procedure of this protocol was performed by a placebo coil. Each session lasted 40 s and consisted of burst of 3 pulses delivered at 50 Hz, with bursts being repeated every 200 ms (at 5 Hz) for a total of 600 pulses. No actual magnetic stimulation was applied on the head of the volunteers. MRI dataset should be acquired before the first sham TBS session and after the last sham TBS session.
62569157|NCT04394234||Treatment Group|Participants data who are new users of rivaroxaban, apixaban and dabigatran with prior Non-valvular atrial fibrillation/Venous thromboembolism/Total hip replacement (NVAF/VTE/THR) or Total knee replacement (TKR) in a nationally representative population of insured participants in the United States (US) will be compared pairwise.
62775633|NCT02508324|OTHER|Haploidentical|"Haploidentical healthy related donor (i.e. parent, child, sibling, possibly third degree or farther removed relative like cousin, aunt, nephew etc.).~Collected using standard methods and approximately 3 x10\^6 CD34 cells/kg will be infused within 72 hours after completion of treatment."
62775634|NCT05019768|ACTIVE_COMPARATOR|sCXL|Standard protocol of Dresden Riboflavin-VEPTGS solution applied every 2 mins during UV UVA fluence of 3mW/cm2 UVA Irradiation time 30 minutes
62775635|NCT05019768|EXPERIMENTAL|aCFXL|"Accelerated custom fast CXL protocol. The protocol has been developed on a published mathematical model that takes into consideration objective variables such as the equation governing the UVA-induced riboflavin con-sumption rate and the corneal thickness at its thinnest point.~Riboflavin-VEPTGS solution: Epithelial lavage before UV UVA fluence of 1.8 ±0.9 mW/cm2 UVA Irradiation time 10 ± 1.5 minutes"
62775636|NCT03657095|EXPERIMENTAL|Esuberaprost|Participants who received esuberaprost during the BPS-314d-MR-PAH-302 double-blind study will receive 2 tablets of 15 μg esuberaprost sodium tablets for oral administration QID for up to 7 months (which will include the 4 weeks of blinded transition).
62775637|NCT03657095|PLACEBO_COMPARATOR|Placebo/Esuberaprost|Participants who received placebo during the BPS-314d-MR-PAH-302 double-blind study will receive 1 esuberaprost tablet and 1 placebo tablet QID during the first 2 weeks of the blinded transition and then receive 2 esuberaprost tablets QID for the rest of the study, for up to 7 months (which will include the other 2 weeks of the total 4-week blinded transition).
62775638|NCT04628234||Patients with an onco-hematologic solid tumor in palliative care|
62775639|NCT03424122|EXPERIMENTAL|Treatment A|Parsaclisib + Rituximab
62185336|NCT01936324|EXPERIMENTAL|Phase 1|Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 7 days in healthy volunteers
62775640|NCT03424122|EXPERIMENTAL|Treatment B|Parsaclisib + Bendamustine + Rituximab
62215317|NCT01240187|EXPERIMENTAL|Experimental 2|
62569158|NCT04394234||Comparator Group|Participants data who are new users of warfarin, apixaban, and dabigatran with prior NVAF/VTE/THR or TKR in a nationally representative population of insured participants in the US will be compared pairwise.
62569159|NCT01545531||Iohexol GFR|
62569160|NCT06578754||Healthy volunteers|About 10 blood samples to be taken from this group
62569161|NCT06578754||Dialysis patients without a background of hyperoxaluria|About 10 blood samples to be taken from this group
62569162|NCT06578754||Hyperoxaluria patients receiving drug treatment or after a liver transplant|About 5 blood samples from this group
62569163|NCT06578754||Patients advanced kidney failure not on dialysis|About 5 blood samples from this group
62775641|NCT03424122|EXPERIMENTAL|Treatment C|Parsaclisib + Ibrutinib
62185337|NCT01936324|EXPERIMENTAL|Phase 2a|Olumacostat Glasaretil Gel, 7.5%, or Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
62185338|NCT01278706|NO_INTERVENTION|no treatment|
62569164|NCT03747380|EXPERIMENTAL|inspiratory muscle program|Inspiratory muscle training preoperative with standard of care
62569165|NCT03747380|OTHER|no inspiratory muscle program|standard of care: postoperative spirometry with enhanced recovery program in thoracic surgery
62569166|NCT06142487|EXPERIMENTAL|Silk Pillowcase|100% Mulberry Silk Pillowcase used every night
62569167|NCT06142487|ACTIVE_COMPARATOR|Cotton Pillowcase|100% Cotton Pillowcase used every night
62569168|NCT01198769|EXPERIMENTAL|Rotarix Group|subjects received 2 oral doses of Rotarix™ vaccine at 2 and 4 months of age.
62569169|NCT05228223|ACTIVE_COMPARATOR|Group S|Patients reversed with Sugammadex 2mg/kg after TOF count is 1-2.
62569170|NCT05228223|ACTIVE_COMPARATOR|Group SN1|Patients reversed with Sugammadex 1mg/kg + Neostigmin 0.02 mg/kg after TOF count is 1-2.
62775642|NCT03337464|EXPERIMENTAL|Parkinson's disease|Subjects with Parkinson's disease
62775643|NCT03337464|ACTIVE_COMPARATOR|Control|Subjects without Parkinson's disease
61977805|NCT04092101|EXPERIMENTAL|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1
62185339|NCT01278706|EXPERIMENTAL|one biopsy, proliferative phase|
62185340|NCT01278706|EXPERIMENTAL|one biopsy, secretory phase|
62569171|NCT05228223|ACTIVE_COMPARATOR|Grup SN2|Patients reversed with sugammadex 1.5 mg/kg + Neostigmin 0.02 mg/kg after TOF count is 1-2.
62569172|NCT03063788|EXPERIMENTAL|HIV uninfected|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 2 HIV uninfected individuals
62569173|NCT03063788|EXPERIMENTAL|HIV infected viremic|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 4 HIV infected individuals with viremia who are not receiving antiretroviral therapy
62569174|NCT03063788|EXPERIMENTAL|HIV infected aviremic|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 4 HIV infected individuals with undetectable HIV viral load who are receiving antiretroviral therapy
62569175|NCT02737488|EXPERIMENTAL|TST|
62569176|NCT02737488|ACTIVE_COMPARATOR|TAU Group|
62569177|NCT03995537||Patients with severe liver disease waiting liver transplant|Only patients with the most frequent LT indications will be eligible: complicated cirrhosis of hepatocellular carcinoma (HCC), acute or chronic decompensation of cirrhosis, with or without multi-visceral failure and fulminant hepatitis.
62569178|NCT02363218|EXPERIMENTAL|CyberKnife|Hepatocellular Carcinoma Patients Treated With CyberKnife
62569179|NCT03911063|EXPERIMENTAL|Cognitive behavioral therapy (CBT)|
62569180|NCT03911063|ACTIVE_COMPARATOR|Placebo Talking Sessions|
62569181|NCT04295083|EXPERIMENTAL|Experimental group|The experimental group will be six 1,5 h weekly of clay based group study and interviewed face-to-face twice by the researchers.
62775644|NCT01533662|EXPERIMENTAL|phenylephrine|patients more than 60 years receiving 100micrograms of phenylephrine infusion (2 groups 60-75 years and more than 75 years)
62775645|NCT01533662|PLACEBO_COMPARATOR|placebo|patients more than 60 years receiving saline infusion (2 groups 60-75 years and more than 75)
62775646|NCT03050320|EXPERIMENTAL|Exercise|The participants in this arm will be asked to attend 3 group classes per week for 12 weeks taught by a certified exercise instructor. Five class times will be offered per week. These classes included a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
62775647|NCT03050320|OTHER|No Exercise|The participants in this arm will be asked to refrain from changing their physical activity over the 12 weeks and maintain any strategies typically used to manage knee and/or hip pain. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the no exercise group will be offered the same exercise program following completion of the study. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
62775648|NCT00711789|ACTIVE_COMPARATOR|Angiotensin II|
62775649|NCT00711789|PLACEBO_COMPARATOR|Placebo|
62775650|NCT00733941|EXPERIMENTAL|High frequency training|24 interval exercises performed 8 times per week
62775651|NCT00733941|EXPERIMENTAL|Normal frequency training|24 interval exercises performed 3 times per week
62775652|NCT05345028|ACTIVE_COMPARATOR|Boswellia Phytosome|
62775653|NCT05345028|PLACEBO_COMPARATOR|Placebo|
62775654|NCT05784519|EXPERIMENTAL|experimental group|The MSCs eye drops was administered to enrolled patients with 5×10\^5 /50μl in each eye, twice a day for 2 weeks.
62775655|NCT00079677|EXPERIMENTAL|1|Armodafinil 150 mg/day
62775656|NCT00079677|PLACEBO_COMPARATOR|2|Placebo
62775657|NCT06028360|ACTIVE_COMPARATOR|Progressive Muscle Relaxation|Progressive muscle relaxation will be applied for 15-20 minutes for 3 consecutive days for 1 week.
62000079|NCT00004918|EXPERIMENTAL|Arm I (dose level 1 PR1 leukemia peptide vaccine)|Patients receive dose level 1 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
62185341|NCT01278706|EXPERIMENTAL|two biopsies|
62185342|NCT06413264|EXPERIMENTAL|USG-guided Veress needle insertion|Ultrasonography-guided Veress needle will be inserted, and a real-time pneumoperitoneum will be created as the first step of a laparoscopic bariatric surgical procedure. The bariatric procedures include laparoscopic sleeve gastrectomy and gastric bypass procedures. The ultrasound's high-frequency (10-13Hz) linear probe will be used peri-operatively to identify the planes of the abdominal wall. Once the Veress needle is successfully inserted into the peritoneal cavity in real-time visualisation and pneumoperitoneum created, thereafter the bariatric procedures will be continued as routinely done.
62185343|NCT06413264|ACTIVE_COMPARATOR|Blind Veress needle insertion|The Veress needle is inserted blindly, as regularly done in any other laparoscopic surgery, and the successful pneumoperitoneum is confirmed by aspiration of the needle, saline drop test and percussion on the abdomen.
62185344|NCT02820064|OTHER|only one arm|Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
62185345|NCT00006010|EXPERIMENTAL|docetaxel + gemcitabine|"Patients receive docetaxel IV over 15-60 minutes and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks. Patients achieving complete response after 2 courses of therapy receive 2 additional courses of therapy. Patients with stable disease or partial response continue therapy until disease progression.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
62185346|NCT05085561|ACTIVE_COMPARATOR|REC-994 200 mg|REC-994 200 mg po once daily (QD) (1 200 mg REC-994 tablet, 1 matching placebo tablet)
62185347|NCT05085561|ACTIVE_COMPARATOR|REC-994 400 mg|REC-994 400 mg po QD (2 200 mg REC-994 tablets)
62775658|NCT06028360|EXPERIMENTAL|Virtual Reality|Virtual reality session will be given for 8 mins for 3 consecutive days for 1 week.
62775659|NCT04557046|OTHER|Group A: Sample Collection|Nasal Swab and Saliva Sample Collection
62775660|NCT04557046|OTHER|Group B: Sample Collection|Nasal swab, Capillary Blood (from fingerstick) and Saliva Collection
62775661|NCT04557046|OTHER|Group C: Sample Collection|Nasal Swab, Throat Swab and Saliva Sample Collection
62569182|NCT04295083|NO_INTERVENTION|Control group|The control group will interviewed face-to-face twice
62569183|NCT01654185|EXPERIMENTAL|AI plus Dimethyldiguanide|AI 1 tablet qd plus Dimethyldiguanide 0.5 bid
62569184|NCT01654185|ACTIVE_COMPARATOR|Aromatase Inhibitor|AI monotherapy
62775662|NCT04557046|OTHER|Group D: Sample Collection|Nasopharyngeal Swab and Saliva Sample Collection
62775663|NCT04557046|OTHER|Group E: Sample Collection|Nasal swab
62775664|NCT01767623|ACTIVE_COMPARATOR|Cohort 1: Participants with Normal Liver Function|Participants with normal liver function (according to National Cancer Institute \[NCI\] liver dysfunction criteria) will receive vemurafenib 960 mg BID from Day 1 until the morning dose on Day 20 and then from Day 27 onward until disease progression, safety-related treatment termination, withdrawal of consent, death, or a decision by the Sponsor to terminate the study, whichever occurs first.
62569185|NCT03055780||CT-FFR. CTA. FFR|59 patients with suspected CAD that have been scheduled for an interventional FFR study
62775665|NCT01767623|EXPERIMENTAL|Cohort 2: Participants with Severe Liver Dysfunction|Participants with severe liver dysfunction (according to NCI liver dysfunction criteria) will receive vemurafenib 720 mg BID from Day 1 until the morning dose on Day 20 and then from Day 27 onward until disease progression, safety-related treatment termination, withdrawal of consent, death, or a decision by the Sponsor to terminate the study, whichever occurs first.
62775666|NCT00922805|ACTIVE_COMPARATOR|fiber-enriched formula then fiber-free formula|Subjects first receive a fiber-enriched formula for one week but then will be crossed over and receive a fiber-free formula
62775667|NCT00922805|ACTIVE_COMPARATOR|fiber-free formula then fiber-enriched formula|Subjects receive first formula only then will be crossed over and receive a fiber-enriched formula
62775668|NCT00679874||I|Consecutive patients with first-time diagnosis of metastatic breast cancer undergoing chemotherapy with anthracyclines and/or trastuzumab.
62775669|NCT03628274|EXPERIMENTAL|Magnetic Resonance Imaging (RMI) 7 Tesla|
61977806|NCT04092101|EXPERIMENTAL|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2
62000080|NCT00004918|EXPERIMENTAL|Arm II (dose level 2 PR1 leukemia peptide vaccine)|Patients receive dose level 2 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
62584783|NCT01042119||Botox|patients who received intravesical injections of botulinum neurotoxin type A
62185348|NCT05085561|PLACEBO_COMPARATOR|Placebo|Matching Placebo po QD (2 matching placebo tablets)
62185349|NCT01074697|ACTIVE_COMPARATOR|Fosaprepitant dimeglumine|
62775670|NCT05082727|EXPERIMENTAL|KOVIR (TD0068)|Standard dose, 5 capsules/time x 3 times/day x 14 days
62775671|NCT05082727|PLACEBO_COMPARATOR|Placebo|Placebo, 5 capsules/time x 3 times/day x 14 days
62185350|NCT01074697|PLACEBO_COMPARATOR|Saline water|
62000081|NCT00004918|EXPERIMENTAL|Arm III (dose level 3 PR1 leukemia peptide vaccine)|Patients receive dose level 3 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
62000082|NCT00737516|EXPERIMENTAL|single arm|HPC, Cord Blood
62000083|NCT03385239|PLACEBO_COMPARATOR|Pooled Placebo|Participants in each cohort (A, B, C and D) were randomized to receive placebo at a dose-matched volume of study drug (ISIS 678354).
62394093|NCT02283801|EXPERIMENTAL|Group B|"Group B~* Pre-treatment: 50 mg once daily dose of lamotrige (LMT) administered for two consecutive days;~* Treatment: 150 mg once daily dose of lamotrige (LMT) administered for six consecutive days;~* Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1600 mg and lamotrigine 150 mg for two consecutive days~* Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 150 mg for seventeen consecutive days"
62394094|NCT01378624|EXPERIMENTAL|Bronchoscopy|
62394095|NCT06606171|EXPERIMENTAL|Chair Sitting Experimental Arm|Participants in this arm will undergo a 30-minute session of chair sitting in a non-swivel chair. Activities during this session include engaging in typical desk activities to simulate a natural office environment.
62000084|NCT03385239|EXPERIMENTAL|Cohort A: ISIS 678354: 10 mg Q4W|Cohort A participants received 10 milligrams (mg) ISIS 678354, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
62000085|NCT03385239|EXPERIMENTAL|Cohort C: ISIS 678354: 15 mg Q2W|Cohort C participants received 15 mg ISIS 678354, SC injection, once every 2 weeks (Q2W) for up to 51 weeks and a maximum of 26 doses.
62000086|NCT03385239|EXPERIMENTAL|Cohort D: ISIS 678354: 10 mg QW|Cohort D participants received 10 mg ISIS 678354, SC injection, once weekly (QW) for up to 52 weeks and a maximum of 52 doses.
62569186|NCT03966300|EXPERIMENTAL|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/fear/fainting mitigation interventions from CARD during vaccination)
62569187|NCT03966300|NO_INTERVENTION|Control (standard/usual care)|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting)
62584784|NCT05882305|EXPERIMENTAL|KSD-101|Biological: Dendritic Cell Vaccine( (Autologous monocyte-derived DCs pulsed withEBV-associated antigen) Patients will receive approximately （2.5-10）x10\^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
62000087|NCT03385239|PLACEBO_COMPARATOR|Cohort B: ISIS 678354: 50 mg Q4W|Cohort B participants received 50 mg ISIS 678354, SC injection, once Q4W for up to 49 weeks and a maximum of 13 doses.
62000088|NCT04086264|EXPERIMENTAL|Regimen A (Closed to Enrollment)|IMGN632, administered intravenously on Day 7 of a 28 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with azacitidine, administered subcutaneously or intravenously daily at 75 mg/m2 on Days 1 to 7 of a 28 day cycle. Cycle 1 azacitidine dose in subsequent cohorts may be reduced.
62394096|NCT06606171|EXPERIMENTAL|Floor Sitting Experimental Arm|Participants in this arm will undergo a 30-minute session of floor sitting on a cushioned mat. They will engage in the same desk activities as the chair sitting arm to maintain consistency across conditions.
62000089|NCT04086264|EXPERIMENTAL|Regimen B (Closed to Enrollment)|IMGN632, administered intravenously on Day 7 of a 21 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with venetoclax, administered orally daily at 100 mg on Day 1, 200mg on Day 2, and 400 mg on the day 3 up to Day 21 of a 21 day cycle. Alternate schedules with reduced venetoclax administration may be explored.
62000090|NCT04086264|EXPERIMENTAL|Regimen C - Frontline & Relapsed / Refractory (Closed to Enrollment)|IMGN632, administered intravenously on Day 7 of a 28 day cycle at 0.015 mg/kg or 0.045 mg/kg, in combination with azacitidine, administered subcutaneously or intravenously daily at 35-75 mg/m2 given for Days 1 to 7 of a 28 day cycle and venetoclax, administered orally daily at 100 mg on Day 1, 200mg on Day 2, and 400 mg on Day 3 up to Day 28 of a 28 day cycle. Alternate schedules with reduced venetoclax administration or reduced azacitidine dose or administration may be explored.
62000091|NCT04086264|EXPERIMENTAL|Regimen D (Closed to Enrollment)|IMGN632, administered intravenously on Day 1 of a 21 day cycle at 0.045 mg/kg, as a monotherapy for Fit and Unfit MRD+ patients.
62000092|NCT06221696|EXPERIMENTAL|Active Fiber Supplement Group|
62185351|NCT03954769||Inpatients|Patients admitted to Stanford Hospital and Clinics medical and surgical units
62185352|NCT03587337||Prophylaxis|
62185353|NCT03587337||Antibiotic tp|
62394097|NCT06606171|EXPERIMENTAL|Extended Floor Sitting Intervention|Participants in this arm will engage in daily floor sitting as part of their usual activities at home to assess the long-term effects of floor sitting on well-being and health.
62394098|NCT06205875|EXPERIMENTAL|Intervention group|Patients in the intervention group will receive a mixture of high-dose local anesthetic and epinephrine administered via a serratus anterior plane block.
62394099|NCT06205875|ACTIVE_COMPARATOR|Control group|Patients in the control group will receive a serratus anterior plane block with a low dose local anesthetic (based upon our primary trial).
62394100|NCT00277862|ACTIVE_COMPARATOR|1|"1. Pegylated IFN- alpha 2b~2. Ribavirin for 24 weeks (patients with RVR)"
62394101|NCT00277862|ACTIVE_COMPARATOR|2|"1. Pegylated IFN- alpha 2b~2. Ribavirin for 36 weeks (patients with complete EVR)"
62000093|NCT06221696|PLACEBO_COMPARATOR|Placebo Group|
62000094|NCT00945022|EXPERIMENTAL|Lipsus|
62185354|NCT02139462|EXPERIMENTAL|Standard training|Therapists will receive standard training in FBT.
62185355|NCT02139462|EXPERIMENTAL|Novel training|Therapists will receive a novel, more efficient training in FBT
62569188|NCT03097757|ACTIVE_COMPARATOR|Fracture reduction without ultrasound|Fracture reduction as per standard of care involves closed fracture reduction without real-time imaging, or with c-arm or portable x-ray. Closed reduction of a fractured bone. Closed reduction is a procedure to set (reduce) a broken bone without surgery. This allows the bone to grow back together. It works best when it is done as soon as possible after the bone breaks.
62394102|NCT00277862|ACTIVE_COMPARATOR|3|"1. Pegylated IFN- alpha 2b~2. Ribavirin for 48 weeks (patients with partial EVR)"
62569189|NCT03097757|EXPERIMENTAL|Fracture reduction with ultrasound|Ultrasound guided Fracture reduction involves closed fracture reduction with the use of real-time ultrasound imaging, prior to, during and after the reduction procedure. C-arm or portable x-ray may also be used as an adjunct.
62569190|NCT03916237|NO_INTERVENTION|CONTROL|Control group
62569191|NCT03916237|EXPERIMENTAL|GROUP A no referral|Screener does not document need for home visit or medical legal partnership referral.
62569192|NCT03916237|EXPERIMENTAL|GROUP B1 home assessment only|Screener documents need for home assessment. Home assessment does not document need for home remediation. Screener does not document need for medical legal partnership.
62569193|NCT03916237|EXPERIMENTAL|GROUP B2 home assessment only|Screener documents need for home assessment. Home assessment does not document need for home remediation. Screener documents need for medical legal partnership.
62569194|NCT03916237|EXPERIMENTAL|GROUP C1 home assessment and remediation|Screener documents need for home assessment. Home assessment documents need for home remediation. Screener does not document need for medical legal partnership.
62569195|NCT03916237|EXPERIMENTAL|GROUP C2 home assessment and remediation|Screener documents need for home assessment. Home assessment documents need for home remediation. Screener documents need for medical legal partnership.
62569196|NCT03916237|EXPERIMENTAL|D medical legal partnership only|Screener does not document need for home assessment. Screener does not document need for medical legal partnership.
62569197|NCT02019472|EXPERIMENTAL|Group 1 (adalimumab 40 mg)|Adalimumab 40 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. At Week 16, subjects who have \< 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive adalimumab 40 mg every week through Week 52.
62569198|NCT02019472|EXPERIMENTAL|Group 2 (sirukumab 100 mg)|Sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. Subjects may meet the early escape criteria at Week 16 (\< 20% improvement from baseline in both swollen and tender joint counts) but no sirukumab dose adjustments will made for these subjects. However, these subjects will receive placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
62000095|NCT03517527|NO_INTERVENTION|Control|
62000096|NCT03517527|EXPERIMENTAL|Intervention|
62394103|NCT00277862|ACTIVE_COMPARATOR|4|"1. Pegylated IFN- alpha 2b~2. Ribavirin for 48 weeks (control)"
62394104|NCT02850666|EXPERIMENTAL|Interdisciplinary Process drama|Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
62000097|NCT01984138|EXPERIMENTAL|Estring|ESTRING
62394105|NCT02516605|EXPERIMENTAL|LJN452|
62394106|NCT02516605|PLACEBO_COMPARATOR|Placebo|
62394107|NCT02286206|EXPERIMENTAL|Clozapine bid|"Participants have been taking clozapine once daily and have reached steady-state prior to the start of this study.~Intervention: Days 1-14"
62569199|NCT02019472|EXPERIMENTAL|Group 3 (sirukumab 50 mg)|Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks through Week 50. At Week 16, subjects who have \< 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive sirukumab 100 mg every 2 weeks through Week 52 and placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
62584785|NCT06476912|EXPERIMENTAL|active VNS|active vagus nerve stimulation
62000098|NCT01984138|ACTIVE_COMPARATOR|REPLENS|Replens
62185356|NCT00884416|EXPERIMENTAL|Sorafenib dose titration|
62394108|NCT00712608|ACTIVE_COMPARATOR|1|Marketed cow's milk-based formula
62584786|NCT06476912|SHAM_COMPARATOR|sham VNS|sham vagus nerve stimulation
62584787|NCT04623034|EXPERIMENTAL|400 mg MSI-195 - SAD|400 mg MSI-195 (within Stage 1, single ascending dose)
62584788|NCT04623034|EXPERIMENTAL|800 mg MSI-195 - SAD|800 mg MSI-195 (within Stage 1, single ascending dose)
62584789|NCT04623034|EXPERIMENTAL|1600 mg MSI-195 -SAD|1600 mg MSI-195 (within Stage 1, single ascending dose)
62000099|NCT01856816|EXPERIMENTAL|Meal Pattern Treatment A|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group A.
62000100|NCT01856816|EXPERIMENTAL|Meal Pattern Treatment B|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group B.
62185357|NCT01144962|SHAM_COMPARATOR|Control group|Patients in the control group will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.
62394109|NCT00712608|EXPERIMENTAL|2|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
62185358|NCT01144962|ACTIVE_COMPARATOR|Cohort 1|10x10\^6 MSC
62185359|NCT01144962|ACTIVE_COMPARATOR|Cohort 2|30x10\^6 MSC
62185360|NCT01144962|ACTIVE_COMPARATOR|Cohort 3|90x10\^6 MSC
62185361|NCT05184777|EXPERIMENTAL|Patients undergoing ovarian stimulation for IVF/ICSI|90 patients undergoing ovarian stimulation for IVF/ICSI; Low, average and high responders will be included in equal proportions, in order to cover the widest range of hormonal values (30 blood and saliva samples per ovarian stimulation point will be taken for determination of progesterone and oestradiol).
62584790|NCT04623034|EXPERIMENTAL|800 mg MSI-195 - fasted|800 mg MSI-195 fed (within Stage 2, cross-over comparison)
62775672|NCT06583915|EXPERIMENTAL|Transcutaneous electrical nerve stimulation|Low voltage electrical pulses that are applied to the central nervous system
62394110|NCT00712608|EXPERIMENTAL|3|Cow's milk based formula with prebiotic, different level of fatty acids and fat and a different calcium source
62000101|NCT01856816|OTHER|Treatment Group C|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group C.
62000102|NCT03616158||Pre-RA|"Subjects with interstitial lung disease (ILD) or airways disease, no rheumatoid arthritis (RA), and positive antibodies will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~1. Medical History and Physical Exams~2. Quality of Life Questionnaires~3. Collection of blood~4. Radiology~5. Lung Function Test~6. 6 Minute Walk Test~7. Bronchoscopy (Clinically indicated)~8. Sputum (Optional)~9. Musculoskeletal ultrasound (Optional)"
62185362|NCT05184777|EXPERIMENTAL|Patients for embryo transfer (ET) undergoing hormonal replacement therapy|30 patients for embryo transfer (ET) undergoing hormonal replacement therapy. These patients will only have a progesterone determination in their blood and saliva samples on the day of ET.
62185363|NCT03297398|PLACEBO_COMPARATOR|Other|Placebo Group
62394111|NCT03425240|EXPERIMENTAL|Nerve Stimulation|Acute placement of electrodes and electrostimulation of the pelvic plexus nerves during open radical prostatectomy.
62394112|NCT05119283|EXPERIMENTAL|Phtalox|Patients will undergo scaling and coronal-radicular smoothing and rinses with PHTALOX mouthwashes.
62185364|NCT03297398|EXPERIMENTAL|Drug Group 1|15mg, OPK-88004
62185365|NCT03297398|EXPERIMENTAL|Drug Group 2|25,mg OPK-88004
62185366|NCT04157218|ACTIVE_COMPARATOR|Treatment with HIFU and immediately after insertion of threads|
62185367|NCT04157218|ACTIVE_COMPARATOR|Treatment with HIFU and 6 months later insertion of theads|
62185368|NCT04157218|ACTIVE_COMPARATOR|Treatment with lifting threads alone|
62185369|NCT04380883|EXPERIMENTAL|InnoSEAL+TRB|InnoSEAL is a hemostatic patch which will be applied along with TRB to control bleeding from access site
62185370|NCT04380883|ACTIVE_COMPARATOR|TRB alone|
62185371|NCT02813083||Rheumatoid Arthritis|Rheumatoid arthritis patients
62185372|NCT00619268|EXPERIMENTAL|A|
62394113|NCT00318032|OTHER|Intensive Treatment|Frequent specialised diabetes clinician contact. DESMOND self-management programme
62394114|NCT03724318|ACTIVE_COMPARATOR|Closure|Patients randomized to the active Group will undergo closure of the left atrium appendage during Heart surgery by means of commercial clips
62394115|NCT03724318|NO_INTERVENTION|Control|The left atrium appendage will remain open in patients randomized to the control group
62775673|NCT06583915|ACTIVE_COMPARATOR|Dry Needling|insertion of a solid filiform needle into a trigger point without the administration of any substance
62775674|NCT04476914||Family Member|Family members of ICU patients admitted with respiratory failure from COVID-19
62775675|NCT05408026|EXPERIMENTAL|Combination of Pomalidomide, Bortezomib, Low-Dose Dexamethasone, and Daratumumab|Combination of Pomalidomide, Bortezomib, Low-Dose Dexamethasone, and Daratumumab
62775676|NCT04512924|ACTIVE_COMPARATOR|Group 1|
62185373|NCT00619268|ACTIVE_COMPARATOR|B|
62775677|NCT04512924|EXPERIMENTAL|Group 2|
62775678|NCT04839120|ACTIVE_COMPARATOR|MDPK67b|
62775679|NCT04839120|PLACEBO_COMPARATOR|Placebo|
62775680|NCT06075966|EXPERIMENTAL|Non-fusion group|Patients who have undergone the INTRA-Spine dynamic stabilization system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.
62775681|NCT06075966|ACTIVE_COMPARATOR|Fusion group|Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University.
62775682|NCT04004013|ACTIVE_COMPARATOR|Lifenol|50 participants who meet the eligibility criteria will be randomised under active arm and will receive Lifenol product during 12 months
62775683|NCT04004013|PLACEBO_COMPARATOR|Placebo|50 participants who meet the eligibility criteria will be randomised under Placebo arm and will receive placebo product during 12 months
62394116|NCT05066516|EXPERIMENTAL|Period 1: Individual components (ICs), period 2: FCDP|Period 1: Individual components (ICs), period 2: FCDP
62775684|NCT00370838|EXPERIMENTAL|Levetiracetam|"Levetiracetam (Keppra) is used in one phase of this cross-over study.~The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase."
62775685|NCT00370838|ACTIVE_COMPARATOR|Clonidine|"Clonidine is used in one phase of this cross-over study.~The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase."
62775686|NCT03610776|EXPERIMENTAL|Portion control plate|Portion control plate first (50% of subjects experiment with this plate first)
62775687|NCT03610776|ACTIVE_COMPARATOR|Conventional plate|Conventional plate first (50% of subjects experiment with this plate first)
62775688|NCT03090555|EXPERIMENTAL|Translational Manipulation|"Participants received an interscalene block on the affected side. Then, a physical therapist performed thrust manipulations on the affected shoulder until full passive physiologic motion was restored. These participants returned to the clinic approximately 3 days later for the first of 6 manual therapy (MT) sessions.~The first clinic treatment session included instruction in a home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program."
62775689|NCT03090555|ACTIVE_COMPARATOR|Comparison Group|Participants in the comparison group did not undergo a session of translational manipulation. In order to equalize the number of intervention sessions, members of this group underwent 7 in-clinic sessions of manual therapy (MT). The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and MT by a physical therapist that included all indicated grades of non-thrust manipulation. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
62775690|NCT03262467|ACTIVE_COMPARATOR|Aneurysmorrhaphy with external porous prosthesis (Provena©)|
62775691|NCT03262467|PLACEBO_COMPARATOR|Aneurysmorrhaphy without external porous prosthesis|
62775692|NCT02768753|EXPERIMENTAL|The Axillary Bilateral-breast Approach (ABBA) group|All patients were told about the operative techniques involved in robotic thyroidectomy via the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA), and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
62775693|NCT02768753|EXPERIMENTAL|The bilateral Axillo-breast Approach (BABA) group|All patients were told about the operative techniques involved in robotic thyroidectomy via the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA), and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
62185374|NCT00619268|ACTIVE_COMPARATOR|C|
62185375|NCT01165606|EXPERIMENTAL|Physiotherpy|
62185376|NCT02281500|EXPERIMENTAL|Single|Human Plasma-Derived Fibrinogen Concentrate Grifols (FIB Grifols)
62185377|NCT02163707|OTHER|Psilocybin Dose 1|0.3 mg/kg (approximately 20mg/70kg)
62394117|NCT05066516|EXPERIMENTAL|Period 1: FCDP, period 2: ICs|Period 1: FCDP, period 2: ICs
62394118|NCT04932564|EXPERIMENTAL|Leflunomide Arm|Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children. This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD.
62394119|NCT00262457|OTHER|Arm 1|
62185378|NCT02163707|OTHER|Psilocybin Dose 2|0.45 mg/kg (approximately 30 mg/70 kg)
62185379|NCT02163707|OTHER|Psilocybin Dose 3|0.6 mg/kg (approximately 40 mg/70 kg)
62584791|NCT04623034|EXPERIMENTAL|1600 mg SAM-e Complete TM - fasted|1600 mg SAM-e Complete (within Stage 2, cross-over comparison)
62584792|NCT04623034|EXPERIMENTAL|800 mg MSI-195 - fed|800 mg MSI-195- fed (within Stage 2, fed arm)
62584793|NCT00166543|EXPERIMENTAL|TAS-108 40 mg|
62775694|NCT03869307|EXPERIMENTAL|Shoulder strengthening exercises|Progressive heavy shoulder strengthening exercises three times weekly and advice on load and pain management. Exercise sessions are supervised twice a week corresponding to 32 supervised exercise sessions during the 16 weeks.
62394120|NCT01708473|ACTIVE_COMPARATOR|Advil with Ultherapy|Subjects randomized to this study arm will receive Advil prior to an Ulthera System Treatment.
62775695|NCT03869307|ACTIVE_COMPARATOR|Shoulder stability exercises|Recommendations of shoulder stability exercises which are to be performed unsupervised (e.g. at home) three times weekly and advice on load and pain management. Three supervised sessions are offered during the 16 weeks, and exercises are primarily performed unsupervised at home.
62775696|NCT02350504|EXPERIMENTAL|Full interactive instruction|Full interactive instruction- which will include an instructional booklet, a movie and a simulator's practice
62775697|NCT02350504|PLACEBO_COMPARATOR|Partial instruction|Partial instruction which included the booklet only.
62775698|NCT03966885|EXPERIMENTAL|Brief Intervention (BI)|30 minute alcohol brief intervention delivered by lay provider during HIV clinic visit.
62394121|NCT01708473|ACTIVE_COMPARATOR|Lortab with Ultherapy|Subjects randomized to this study arm will receive Lortab prior to an Ulthera System Treatment.
62394122|NCT00561795|EXPERIMENTAL|Arm A|Oral Pazopanib 800 mg once a day+ carboplatin area under the concentration-time curve (AUC) 5 intravenous (IV) over 1 hour every 3 weeks + paclitaxel 175 mg/m\^2 IV over three hours day one q 3 weeks for six cycles
62394123|NCT00561795|EXPERIMENTAL|Arm B|Oral Pazopanib 800 mg once a day+ carboplatin AUC 6 IV over 1 hour every 3 weeks + paclitaxel 175 mg/m\^2 IV over three hours day one q 3 weeks for six cycles
62394124|NCT04406259|OTHER|Verapamil|administration of verapamil to treat cluster headache
62394125|NCT00283153|EXPERIMENTAL|FAR|Facial affect recognition training (with computer assistance)
62394126|NCT00283153|EXPERIMENTAL|SEI|Stories of Emotional Inference
62584794|NCT00166543|EXPERIMENTAL|TAS-108 80 mg|
62584795|NCT00166543|EXPERIMENTAL|TAS-108 120 mg|
62775699|NCT03966885|EXPERIMENTAL|Brief Intervention + CETA|30 minute alcohol brief intervention delivered by lay provider during clinic visit followed by 6-12 weekly sessions of CETA.
62775700|NCT04675996|EXPERIMENTAL|Phase 1/1b|"Phase 1: dose escalation phase with a 'hybrid' 3+3 design in all-comers cancer patients. Approximately 30 patients will be included.~Phase 1b: dose expansion phase in selected tumor types at the recommended phase 2 dose. Approximately 50 patients will be included."
62185380|NCT01709396|EXPERIMENTAL|18 cGY ED-TBI|18 cGY ED-TBI followed by an allogenic done marrow transplant
62185381|NCT00445575|EXPERIMENTAL|1|treatment duration: 1 year
62185382|NCT00445575|PLACEBO_COMPARATOR|2|treatment duration: 1 year
62185383|NCT00445575|EXPERIMENTAL|3|duration treatment: 3 years
62185384|NCT00445575|PLACEBO_COMPARATOR|4|treatment duration: 3 years
62215318|NCT04318847|EXPERIMENTAL|Ondransetron|Administration of ondansetron
62215319|NCT04318847|NO_INTERVENTION|Habitual Clinical Practice|Habitual Clinical Practice
62215320|NCT04546490|EXPERIMENTAL|Pressure release|It will be applied with the patient in a supine position. The therapist will clamp his first and second fingers over the Myofascial Trigger Point located on the upper trapezium, it will be marked previously. The pressure will increase as the therapist perceives a reduction in the resistance offered by the soft tissue under his finger within a period of 90 seconds.
62215321|NCT04546490|EXPERIMENTAL|Ischemic pressure|Patient in supine position, the therapist performs pressure with first and second finger in PGM marked previously, this is performed until the patient tolerance, when the patient refers a decrease in pain or have a correct adaptation to the perceived pain increase the pressure to a new painful barrier. Repeat the process for 90 seconds.
62215322|NCT04546490|NO_INTERVENTION|Control Group|Patient in supine position on the stretcher, the therapist performs a clamp with the first and second finger on the upper trapezius muscle without making any pressure on it during 90 seconds
62215323|NCT05331092|EXPERIMENTAL|Cryotherapy|20 minutes of cryotherapy on the dominant ankle with ice bags
62215324|NCT05331092|NO_INTERVENTION|Control|20 minutes of rest
62215325|NCT03130153|EXPERIMENTAL|hypertensives on Aspirin mouthwash|
62215326|NCT03130153|ACTIVE_COMPARATOR|non-hypertensives on Aspirin mouthwash|
62215327|NCT03130153|ACTIVE_COMPARATOR|hypertensives on Saline mouthwash|
62215328|NCT06013527|EXPERIMENTAL|Physical Therapy Intervention|The intervention group will receive a structured exercise program which will run for 2 months and a follow-up will be done after 3 months.
62215329|NCT06013527|NO_INTERVENTION|Control Group|This group will continue with their routine life and will receive standard care given by the hospital.
62215330|NCT01910181|EXPERIMENTAL|Vemurafenib: Pharmacokinetic Cohort|Participants will receive vemurafenib orally as 960 mg twice daily on Days 1 to 21 (morning dose only on Day 21), with a drug holiday from Days 22 to 27, and from Day 28 until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation.
62215331|NCT01910181|EXPERIMENTAL|Vemurafenib: Expansion Cohort|Participants will receive vemurafenib orally as 960 mg twice daily from Day 1 until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation.
62215332|NCT04501211|OTHER|Patch arm|Transdermal Granisetron patch to be given for application for 24 weeks with 2 weeks on and one week off pattern for a total of 24 weeks
62215333|NCT03914729|ACTIVE_COMPARATOR|Primary Closure|After pilonidal sinus is excised, subcutaneous fat and skin are closed in midline with a running suture
62215334|NCT03914729|ACTIVE_COMPARATOR|Gluteus Maximus Plasty Flap|After pilonidal sinus is excised, gluteus maximus fascia flaps will be mobilised, approximated in the midline and fixed with a running suture. Subcutaneous fat and skin are closed in midline with a running suture.
62215335|NCT04650243|EXPERIMENTAL|ursodeoxycholic acid 250mg bid|Patients will receive a reduced dosage of ursodeoxycholic acid 250mg orally twice a day.
62215336|NCT04650243|EXPERIMENTAL|ursodeoxycholic acid 250mg qd|Patients will receive a reduced dosage of ursodeoxycholic acid 250mg orally once a day.
62775701|NCT01431391|EXPERIMENTAL|Arm 1: Sipuleucel-T followed by ADT|Arm 1: Subjects received one infusion of sipuleucel-T every two weeks for a total of three infusions. Two weeks after the third sipuleucel-T infusion, subjects started ADT with 45 mg leuprolide acetate depot injection (Eligard® 45 mg). An additional leuprolide acetate injection was administered at 6 months after the first injection for a total of 2 injections and 12 months of ADT.
62775702|NCT01431391|EXPERIMENTAL|Arm 2: ADT followed by sipuleucel-T|Arm 2: Subjects started ADT with 45 mg leuprolide acetate depot injection (Eligard® 45 mg) 12 weeks before infusion 1 of sipuleucel-T. An additional leuprolide acetate injection was administered at 6 months after the first injection for a total of 2 injections and 12 months of ADT. Twelve weeks after the initial leuprolide 45 mg depot injection, subjects began one infusion of sipuleucel-T every two weeks for a total of three infusions.
62775703|NCT03389178||stress group (SG)|"We will identify prospective subjects according with the inclusion criteria of the study, consistent on singleton pregnant women between 18 to 45 years of age in their third trimester (at least 28 weeks gestation). Upon acceptance participants will enter to Phase I-IV.~Women and participants will be categorized as stressed or controls after scoring the Cohen Perceived Stress Scale-10 (PSS-10). The PSS-10 has been validated in German speaking populations and will be a quick tool for screening stress among prospective subjects. For the purposes of the current study, a participant with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. Recruitment will continue until reaching the aimed cohort of n=75 subjects/group."
62775704|NCT03389178||control group (CG)|"For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score \< 19 will be entered into Phase II as control.~Recruitment will continue until reaching the aimed cohort of n=75 subjects/group."
62775705|NCT05196685||Group Vertigo|Patients who have Carotid Doppler Ultrasonography and Vertigo screening test scores of 1 and above will be sent to ENT
62775706|NCT05196685||Group control|Patients who have Carotid Doppler Ultrasonography and Vertigo screening test score below 1
62569200|NCT01383707|EXPERIMENTAL|Bevacizumab + mFOLFOX-6|Participants will receive combination therapy of bevacizumab 5 mg/kg IV dose and mFOLFOX-6 (Levofolinic acid, 5-FU and oxaliplatin) on Day 1 of every 2 weeks' cycle for 5 cycles (Cycle 1-5), followed by 1 cycle (Cycle 6) of mFOLFOX6 alone (preoperative treatment phase). After 3 weeks of preoperative treatment phase, participants satisfying the surgical criteria for hepatic resectability will undergo a liver metastasectomy. Thereafter participants will receive combination therapy of mFOLFOX-6 + bevacizumab for another 6 cycles (Cycle 7-12); (post-operative treatment phase) followed by bevacizumab alone for 52 weeks (26 cycles) (maintenance therapy).
62775707|NCT06007053|EXPERIMENTAL|ReACT Intervention|At the end of the baseline visit, half of the participants will be randomized to receive Retraining and Control Therapy (ReACT)
62775708|NCT06007053|ACTIVE_COMPARATOR|Supportive Therapy|At the end of the baseline visit, half of the participants will be randomized to receive supportive therapy
62775709|NCT06007053|NO_INTERVENTION|Healthy Control|Healthy controls are ages 12-18 with no significant comorbid medical or mental health conditions. Healthy controls and their parent come for 1 baseline laboratory visit and a follow up visit 13 weeks after the baseline visit. These visits will be identical to baseline and follow-up visits of children with PNES.
62775710|NCT02526225|ACTIVE_COMPARATOR|ginkgo diterpene lactone meglumine injection|ginkgo diterpene lactone meglumine injection
62775711|NCT02526225|PLACEBO_COMPARATOR|Ginkgo diterpene lactone meglumine injection simulation|Ginkgo diterpene lactone meglumine injection simulation
62775712|NCT01685021|EXPERIMENTAL|MOR00208 (formerly Xmab5574)|intravenous Infusion of MOR00208, Fc-optimized Anti-CD19 Antibody
62775713|NCT01415492|NO_INTERVENTION|Usual Care|At recruitment this group only received five pamphlets from the study. Four of these pamphlets were from the American Cancer Society, and one from Quitworks (a smoking cessation program).
62775714|NCT01415492|ACTIVE_COMPARATOR|HD2|The intervention study information was delivered via print materials or access to a HD2 Web Site. Patients chose modality. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention.
62569201|NCT03413982||BC Patients|Patients with bladder cancer. This registry involves no intervention. Blood, urine, and tissue samples will be collected to be used for research.
62569202|NCT03511105|EXPERIMENTAL|Subjects receiving GSK2798745|Eligible subjects will receive two tablets of 2.4 milligrams GSK2798745 on the morning of Day 1. Subjects will then undergo segmental challenge at 2 hours after first dose wherein LPS will be instilled into the right middle segment and saline control into the lingula segment of the contralateral side. The second dose of a single tablet of 2.4 milligrams of GSK2798745 will be administered 10 hours after LPS and saline challenge.
62569203|NCT03511105|PLACEBO_COMPARATOR|Subjects receiving matching Placebo|Eligible subjects will receive two tablets of placebo on the morning of Day 1. Subjects will then undergo segmental challenge at 2 hours after first dose wherein LPS will be instilled into the right middle segment and saline control into the lingula segment of the contralateral side. The second dose placebo will be administered 10 hours after LPS and saline challenge.
62569204|NCT00304096|EXPERIMENTAL|Stratum 1: Receiving Hormone Therapy|Patients treated with 9 peptide vaccine who received hormone therapy
62569205|NCT00304096|EXPERIMENTAL|Stratum 2: Not receiving hormone therapy|Patients receiving 9 peptide vaccine who did not receive hormone therapy
62775715|NCT01415492|ACTIVE_COMPARATOR|HD2+|The intervention study information was delivered via print materials or access to a HD2 Web Site. Patients chose modality. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention.
62775716|NCT05673525|EXPERIMENTAL|Treatment Group|
62791662|NCT01999400|EXPERIMENTAL|Arm 4: Apriso then Delzicol then Lialda then Pentasa|"1. Apriso 375 mg capsule x 3 with 240 mL water, single dose.~2. Washout period of 10 days.~3. Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~4. Washout period of 10 days.~5. Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~6. Washout period of 10 days.~7. Pentasa 500 mg capsule x 2 with 240 mL water, single dose."
62185385|NCT00796627|SHAM_COMPARATOR|Healthy volunteers|"Healthy volunteers with no burn wounds Volunteers donate blood that will be studied in comparison to patients who have sustained burns. The circulating bone marrow stem cells will be counted and compared to the levels in burn patients. Six 12 ml tubes will be taken for the study. You will not be compensated. But you will be helping to advance science if you join the study."
62000103|NCT03616158||RA without LD|"Subjects with rheumatoid arthritis (RA), and no interstitial lung disease (ILD) or airways disease, will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~1. Medical History and Physical Exams~2. Quality of Life Questionnaires~3. Collection of blood~4. Radiology~5. Lung Function Test~6. 6 Minute Walk Test~7. Bronchoscopy (Clinically indicated)~8. Sputum (Optional)~9. Musculoskeletal ultrasound (Optional)"
62215337|NCT04650243|ACTIVE_COMPARATOR|ursodeoxycholic acid standard dosage|Patients will receive standard dosage of ursodeoxycholic acid 250mg orally three times a day.
62215338|NCT04873401|EXPERIMENTAL|Chain Referral|"In the chain-referral intervention, a discrete number of seeds will be recruited from the community partners, trained and incentivized to recruit and refer members of their social networks to receive COVID-19 testing; these recruits are then trained to do the same."
62394127|NCT03553121|ACTIVE_COMPARATOR|Walk preoperativelying|Patients will be operated gynecologic cancers and have American Society of Anesthesia score 1 or 2. Subjects will walk during one hour with average speed 3 km/hour 12 hour before surgery.
62569206|NCT02590744|EXPERIMENTAL|eye patch|cover the sick eye with eye patch for 3 hours preoperatively.
62569207|NCT02590744|PLACEBO_COMPARATOR|non-eye patch|do not cover the sick eye before surgery.
62775717|NCT04833595|EXPERIMENTAL|Mindfulness Arm|"A recommendation on healthy food intake will be sent to participants. At the end of each week, participants will be required 1) to submit THREE photos of the meals that they are most satisfied with in terms of healthiness and 2) using the photos to answer a questionnaire about their diet. The photos and completed questionnaire must be submitted to the research investigator each week for a total of 8 weeks. After 8 weeks, participants will be required to get tested for your fasting total cholesterol and blood glucose level in the appointed pharmacy for the second time. It is estimated to require 15-30 minutes of their time weekly.~The questionnaire used for experimental group contains reflective questions as part of the mindfulness intervention."
62569208|NCT05287035|ACTIVE_COMPARATOR|Steroid injection|Dexamethasone will be injected 1 dose intraoperatively, 3 doses post-operatively every 8hrs
61977807|NCT04284618||assessment of radiographic angles on standardized films|On Standing standardized radiographs of the foot the most common angles for describing a hallux valgus interphalangeus deformity are measured. The measured angles are the following: The hallux interphalangeal angle (HIA), the proximal to distal phalangeal articular angle (PDPAA), the proximal phalangeal articular angle (PPAA) or distal articular set angle (DASA), and the distal phalangeal articular angle (DPAA).
62215339|NCT04873401|EXPERIMENTAL|Credible Messenger|In the credible messenger intervention, peers identified as popular and socially influential individuals within their respective communities with lived experience are trained to engage within formal and informal social networks to promote behavior change.
62569209|NCT05287035|PLACEBO_COMPARATOR|Saline solution|Saline will be injected 1 dose intraoperatively, 3 doses post-operatively every 8hrs
62569210|NCT00218023|EXPERIMENTAL|Modafinil plus MI, CM, and CBT|"The modafinil dose began at 200 mg (day 1) and increased to the fixed dose of 200 mg twice daily (day 2) during the 12 weeks of Phase II.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
62775718|NCT04833595|ACTIVE_COMPARATOR|Non-mindfulness Arm|Everything is similar to the experimental arm. However, the questionnaire used for control group does not contain reflective questions to serve as control group.
62775719|NCT03344172|EXPERIMENTAL|PGHA|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine and Avelumab
62775720|NCT03344172|EXPERIMENTAL|PGH|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine
62185386|NCT00796627|ACTIVE_COMPARATOR|Burn volunteer|To recruit burn wound patients with defined clinical criteria for study. A second-degree burn of at least 10 cm2 to up to 95% BSA; age = 14-75 years; BP \> 100 mm Hg systolic; heart rate \< 100 beats/minute; urine output \> 30 ml/hour; area of burn \< 20% of BSA; body temperature = 98.5-101 degrees Fahrenheit; serum albumin \> 3 mg/ml; and informed consent. We will also obtain a history regarding the presence or absence of risk factors that may affect CAC numbers: hypertension \> 1 year; smoking \> 2 pack-years or within the last year; diabetes mellitus; and family history of premature coronary artery disease (men \< 55 and women \< 65 years of age).Six 12 ml tubes will be taken at 5 time points
62394128|NCT03553121|ACTIVE_COMPARATOR|not walking preoperatively|Patients will be operated gynecologic cancers and have American Society of Anesthesia score 1 or 2. Subjects will not walk preoperatively.
62394129|NCT04489511|EXPERIMENTAL|Dose 1|STG-001 given orally at Dose 1 once a day for 28 days
62394130|NCT04489511|EXPERIMENTAL|Dose 2|STG-001 given orally at Dose 2 once a day for 28 days
62394131|NCT05949827||Active Comparator: LSA-1|Light Scheduling Algorithm-1 (LSA-1): High circadian effective irradiances + Blue Enriched Light episodes
62394132|NCT05949827||Active Comparator: LSA-2|Light Scheduling Algorithm-2 (LSA-2): High circadian effective irradiances without Blue Enriched Light episodes.
62394133|NCT05949827||Active Comparator: LSA-3|Light Scheduling Algorithm-3 (LSA-3): Irradiance levels comparable to conventional hospital lighting (control group).
62394134|NCT04141098|EXPERIMENTAL|Total Nucleus Replacement|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
62394135|NCT03359811|EXPERIMENTAL|Standard-of-Care Thoracic Epidural Analgesia (TEA)|An epidural catheter placed before induction of anesthesia by an anesthesiologist. A bolus or infusion of the local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
62394136|NCT03359811|ACTIVE_COMPARATOR|4Q-TAP Blocks|Participants have an ultrasound guided 4Q-TAP block. A maximum of 80 cc of a solution consisting of 30 mg of bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) and 65 mg of liposomal bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
62394137|NCT06547502|EXPERIMENTAL|Normal renal function|GFR between 90-130 ml/min
62394138|NCT06547502|EXPERIMENTAL|Mildly decreased renal function|GFR between 60-90 ml/min
62394139|NCT06547502|EXPERIMENTAL|moderately decreased renal function|GFR between 30-60 ml/min
62394140|NCT02221258|EXPERIMENTAL|FURESTEM-RA Inj.+DMARDs|FURESTEM-RA Inj. 1. 2.5x10\^7 stem cells+DMARDs after registration FURESTEM-RA Inj. 2. 5.0x10\^7 stem cells+DMARDs after registration FURESTEM-RA Inj. 3. 1.0x10\^8 stem cells+DMARDs after registration
62394141|NCT01233076|OTHER|Nelfilcon A / Narafilcon B|Nelfilcon A worn first, with narafilcon B worn second. Each product worn bilaterally in a daily wear, daily disposable basis for one week.
62394142|NCT01233076|OTHER|Narafilcon B / Nelfilcon A|Narafilcon B worn first, with nelfilcon A worn second. Each product worn bilaterally in a daily wear, daily disposable basis for one week.
62394143|NCT02436993|EXPERIMENTAL|Carboplatin+Paclitaxel+Bevacizumab (HER2-)|Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Bevacizumab every other week, 5 doses
62394144|NCT02436993|EXPERIMENTAL|Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)|Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Trastuzumab weekly 12 doses Pertuzumab every 3 weeks, 4 doses
62394145|NCT03053180||Paritaprevir/Ritonavir + Ombitasvir + Dasabuvir|"Participants with chronic hepatitis C (CHC) genotype 1b (GT1b) and compensated liver cirrhosis received paritaprevir/ritonavir (r), ombitasvir and dasabuvir (3DAA ABBVIE REGIMEN) for 12 weeks.~The prescription of a treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer a patient the opportunity to participate in this study."
62394146|NCT03611907|ACTIVE_COMPARATOR|SL1(Cook® Single Lumen)|Oocyte retrieval with only aspiration system
62394147|NCT03611907|ACTIVE_COMPARATOR|DL1 (Cook® EchoTip® Double Lumen)|Oocyte retrieval with aspiration and flushing system
62394148|NCT06475365|NO_INTERVENTION|Control|This arm will receive no intervention. The patients in this arm will only be asked to complete the questionnaires related to the study. They will only receive the care as prescribed by their physician and care teams.
62394149|NCT06475365|EXPERIMENTAL|Salt Water Gargle|"After their surgery, this arm will receive treatment. Patients will be asked to gargle with a warm sodium chloride (salt water) solution. Patients will gargle with 15mL (15cc) of a premade solution of salt water one time (q.d.) on postoperative day 0 (POD 0), and three times a day (t.i.d.) for the next seven (7) days following their surgery (POD 1 - POD 7). Patients will also be asked to complete a series of study-related questionnaires at specified time points."
62394150|NCT03990168|EXPERIMENTAL|Experimental|Participants will receive one anodal tDCS at 1 mA intensity over the left superior temporal gyrus (T3 in 10-20 international system) and the cathode tDCS over the right orbitofrontal area (Fp2 in 10-20 international system). tDCS will be delivered for 20 minutes during fluency intervention for six consecutive days.
62394151|NCT03990168|SHAM_COMPARATOR|Sham Comparator|Participants will receive sham tDCS while the one anode electrode will be positioned over the left superior temporal gyrus and the cathode will be placed over the right orbitofrontal similar to the active mode. The sham stimulation will break down after 30 seconds at the beginning of 20 minutes of fluency intervention for six consecutive days.
62394152|NCT00015912|EXPERIMENTAL|Treatment (interferon-alpha, thalidomide)|Patients receive interferon alfa subcutaneously every 12 hours and oral thalidomide daily in the absence of disease progression or unacceptable toxicity.
62185387|NCT06198699|EXPERIMENTAL|Jing Si Herbal Tea Group|Frequency: Two times of herbal tea (one in the morning; one in the afternoon) per day Duration: Consumption for three months Dosage: One pack (14g) with 600 ml water for each time of herbal tea consumption
62185388|NCT06198699|PLACEBO_COMPARATOR|Barley Tea Group|Frequency: Two times of barley tea (one in the morning; one in the afternoon) per day Duration: Consumption for three months Dosage: 600 ml each time of barley tea consumption
62569211|NCT00218023|EXPERIMENTAL|Levodopa/Carbidopa plus MI, CM, and CBT|"Levodopa-carbidopa, in the sustained-release formulation (Sinemet CR), began at a dose of levodopa/carbidopa 400/100 mg (day 1) and increased to the fixed dose of 400/100 mg twice daily (day 2) during the 12 weeks of Phase II.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
61977808|NCT04284618||assessment of radiographic angles on off axis view films|On off axis view radiographs of the foot the most common angles for describing a hallux valgus interphalangeus deformity are measured. The measured angles are the following: The hallux interphalangeal angle (HIA), the proximal to distal phalangeal articular angle (PDPAA), the proximal phalangeal articular angle (PPAA) or distal articular set angle (DASA), and the distal phalangeal articular angle (DPAA).
61977809|NCT03935191||Group|Device: Dexcom CGM System
61977810|NCT01654094|EXPERIMENTAL|P6 Low Adherent Dressing|All participants will serve as their own control. All participants will receive both the P6 Low Adherent Dressings and the Standard of Care (SOC).
62000104|NCT03616158||RA-LD|"Subjects with rheumatoid arthritis (RA) and interstitial lung disease (ILD) or airways disease, will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~1. Medical History and Physical Exams~2. Quality of Life Questionnaires~3. Collection of blood~4. Radiology~5. Lung Function Test~6. 6 Minute Walk Test~7. Bronchoscopy (Clinically indicated)~8. Sputum (Optional)~9. Musculoskeletal ultrasound (Optional)"
62000105|NCT03616158||LD Controls|"Subjects with interstitial lung disease (ILD) or airways disease, no rheumatoid arthritis (RA), and negative antibodies will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~1. Medical History and Physical Exams~2. Quality of Life Questionnaires~3. Collection of blood~4. Radiology~5. Lung Function Test~6. 6 Minute Walk Test~7. Bronchoscopy (Clinically indicated)~8. Sputum (Optional)~9. Musculoskeletal ultrasound (Optional)"
62000106|NCT05449028|EXPERIMENTAL|H. pylori eradication scheme A|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days
62000107|NCT05449028|EXPERIMENTAL|H. pylori eradication scheme B|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h, for 14 days
62000108|NCT05449028|EXPERIMENTAL|H. pylori eradication scheme C|Esomeprazole 40mg bid + bismuth subsalicylate 420mg 6/6h + metronidazole 375mg 6/6h + tetracycline 375mg 6/6h, for 10 days
62000109|NCT05449028|EXPERIMENTAL|H. pylori eradication scheme D|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
62000110|NCT05449028|EXPERIMENTAL|H. pylori eradication scheme E|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
62000111|NCT03738371||Team of health professionals|Team of health professionals involved in thrombectomy (including specialized nurses in anesthesiology, anesthesiologists, neuroradiologist and technicians specialized in electro-radiology) will participate to in situ simulation.
62185389|NCT03089736|EXPERIMENTAL|TAU + Education and self care|Treatment as usual (TAU; i.e. pharmacological treatments and advices) + structured education + instructions on self care
62185390|NCT03089736|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU; i.e. pharmacological treatments and advices)
62185391|NCT04016272|EXPERIMENTAL|Active tDCS|
62185392|NCT04016272|PLACEBO_COMPARATOR|Sham tDCS|
62185393|NCT04633954|EXPERIMENTAL|Brimonidine Group|Patients in this arm receive an extra drop of brimonidine in addition to routine eye drops prior to femtosecond laser assisted cataract surgery (FLACS)
62185394|NCT04633954|NO_INTERVENTION|Control Group|Patients in this arm only receive routine eye drops prior to femtosecond laser assisted cataract surgery (FLACS)
62185395|NCT01536197||Gastric Bypass|morbidly obese subjects undergoing gastric bypass surgery
62185396|NCT01536197||Gastric banding|morbidly obese subjects undergoing laparoscopic gastric banding surgery
62185397|NCT01536197||Sleeve gastrectomy|morbidly obese subjects undergoing sleeve gastrectomy surgery
62185398|NCT04115267||Combined modality|Patients receiving radiotherapy and a molecular agent for the treatment of cancer
62185399|NCT02861196|EXPERIMENTAL|Therapy Arm|Patients who have response to neoadjuvant chemotherapy will be separated into two groups (GI cT0-1 and G2 ≥cT2). G1receive concurrent radiochemotherapy, and G2 receive partial resection of the bladder+lymphadenectomy+adjuvant radiotherapy.Patients who have no response to neoadjuvant chemotherapy or disagree to receive the sequential treatment will receive the radical resection of bladder.
62185400|NCT05815823|EXPERIMENTAL|conventional therapy|20 sessions of conventional therapy was applied for 5 days a week for 4 weeks, 1 hour a day
62185401|NCT05815823|EXPERIMENTAL|robot-assisted therapy|20 sessions of upper extremity robot-assisted therapy was applied for 4 weeks, 5 days a week, 30 minutes a day.
62185402|NCT05029011||Patients of the Sleep Disorders Laboratory|Monitoring vital signs
62185403|NCT04378374|EXPERIMENTAL|Baked food made of lentil flour|Food prepared with 100% lentil flour
62185404|NCT04378374|EXPERIMENTAL|Baked food made of lentil flour and wheat flour|Food prepared with a mixture of lentil flour and wheat flour
62394153|NCT05782738|ACTIVE_COMPARATOR|Reverse TAP|
62185405|NCT04378374|EXPERIMENTAL|Baked food made of wheat flour|Food prepared with 100% wheat flour
62185406|NCT04378374|EXPERIMENTAL|Water|Potable water (energy and carbohydrate-free control)
62185407|NCT01507077|PLACEBO_COMPARATOR|ZGN-440 sterile diluent|
62185408|NCT01507077|EXPERIMENTAL|ZGN-440|
62185409|NCT01687946||Pulmonary fibrosis in aged individuals|"Group A and B:~Patients with UIP (histologically and/or radiologically proven) providing informed consent. According to functional and radiological assessment, the disease may be either limited (Group A) or advanced (Group B). The patients are usually older than 55 years."
62185410|NCT01687946||Pulmonary fibrosis and inflammation|"Groups C and D:~Patients with HP (histologically and radiologically proven) providing informed consent. According to functional and radiological assessment, the disease will be either acute or chronic. The patients will be significantly younger (mean \> 10 years) than in groups A and B."
62185411|NCT01687946||Regular wound healing in lung|Patients receiving lung biopsy or bronchoscopy for reasons other that the study and volunteers providing informed consent. The group will consist of young (18-40 years) and old individuals (older than 55 years).
62185412|NCT03533777|ACTIVE_COMPARATOR|Antegrade Intravenous Catheter|A 20 gauge 30 millimeter peripheral intravenous catheter will be placed in an upper extremity vein in standard antegrade fashion (with the tip pointed towards the direction of blood flow). Blood draws from this IV catheter will be attempted twice throughout the study. An infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
62185413|NCT03533777|EXPERIMENTAL|Retrograde Intravenous Catheter|A 20 gauge 30 millimeter peripheral intravenous catheter will be placed in an upper extremity vein in a retrograde fashion (with the tip pointed away from the direction of blood flow). Blood draws from this IV catheter will be attempted twice throughout the study. An infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
62185414|NCT01013740|EXPERIMENTAL|Lapatinib + Vinorelbine|Lapatinib + Vinorelbine
62394154|NCT05782738|ACTIVE_COMPARATOR|External Minicrush|
62394155|NCT06029439|EXPERIMENTAL|NMRA-335140 80 milligrams (mg) once daily (QD)|Participants will receive a NMRA-335140 tablet at a dose of 80 mg once daily (QD) during a 52-week treatment period.
62394156|NCT05694364|EXPERIMENTAL|Phase 1 Dose Escalation (Group A)|"Participants from group A (hematologic malignancies) will undergo leukapheresis followed by lymphodepletion and infusion of PRGN-3007. Lymphodepletion will include 3 days of treatment with fludarabine (30 mg/m\^2) and cyclophosphamide (500 mg/m\^2) prior to study day 0.~Participants will then receive PRGN-3007 in 3 dose levels beginning at Dose Level 1, using a standard 3+3 escalation design to determine Maximum Tolerated Dose (MTD). The target maximum doses infused at each dose level is:~Dose Level 1: 1x10\^6 cells/kg Dose Level 2: 3x10\^6 cells/kg Dose Level 3: 1x10\^7 cells/kg"
62394157|NCT05694364|EXPERIMENTAL|Phase 1 Dose Escalation (Group B)|"Participants from group B (solid tumors) will undergo leukapheresis followed by lymphodepletion and infusion of PRGN-3007. Lymphodepletion will include 2 days of cyclophosphamide (500 mg/m\^2) prior to study day 0.~Participants will then receive PRGN-3007 in 3 dose levels beginning at Dose Level 1, using a standard 3+3 escalation design to determine Maximum Tolerated Dose (MTD). The target maximum doses infused at each dose level is:~Dose Level 1: 1x10\^6 cells/kg Dose Level 2: 3x10\^6 cells/kg Dose Level 3: 1x10\^7 cells/kg"
62394158|NCT05694364|EXPERIMENTAL|Phase 1b Dose Expansion (Group A)|Participants from group A (hematologic malignancies) will undergo leukapheresis followed by lymphodepletion and infusion of PRGN-3007. Lymphodepletion will include 3 days of treatment with fludarabine (30 mg/m\^2) and cyclophosphamide (500 mg/m\^2) prior to study day 0. Participants will then receive PRGN-3007 at the dose level determined to be the Maximum Tolerated Dose (MTD) in the dose escalation portion of the study.
62394159|NCT05694364|EXPERIMENTAL|Phase 1b Dose Expansion (Group B)|Participants from group B (solid tumors) will undergo leukapheresis followed by lymphodepletion and infusion of PRGN-3007. Lymphodepletion will include 2 days of cyclophosphamide (500 mg/m\^2) prior to study day 0.Participants will then receive PRGN-3007 at the dose level determined to be the Maximum Tolerated Dose (MTD) in the dose escalation portion of the study.
62394160|NCT03817658|EXPERIMENTAL|SHR-1210|SHR-1210
62394161|NCT03817658|PLACEBO_COMPARATOR|placebo|placebo
62394162|NCT01277757|EXPERIMENTAL|Treatment (Akt inhibitor MK-2206)|Akt Inhibitor MK-2206 mg orally once a week on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62584796|NCT05078866|EXPERIMENTAL|Part I (GAd20-209-FSPs, MVA-209-FSPs)|Patients receive GAd20-209-FSPs IM on day 1 and MVA-209-FSPs IM at week 8. Patients undergo endoscopy with biopsy during screening and follow up as well as blood sample collection on the trial.
61977811|NCT01654094|ACTIVE_COMPARATOR|Standard of Care (SOC)|All participants will serve as their own control. All participants will receive both the P6 Low Adherent Dressings and the Standard of Care (SOC).
62185415|NCT01013740|ACTIVE_COMPARATOR|Lapatinib + Capecitabine|Lapatinib + Capecitabine
62185416|NCT05530330||Infants with concern regarding late onset sepsis|Infants who are being investigated for late onset sepsis will be included. These infants may ultimately be classified in a number of ways, including culture positive late onset sepsis, culture negative late onset sepsis, necrotising enterocolitis or non infectious etiologies suspected (i.e prematurity)
62185417|NCT02121327|ACTIVE_COMPARATOR|usual care|usual care group receive regular outpatient treatment
62185418|NCT02121327|EXPERIMENTAL|disease management|desease management program include self management education by nurse on 6months.
62185419|NCT00867737|EXPERIMENTAL|Advair 115/21 MDI|Advair HFA 115/21 MDI Intervention = initiate intervention after screening
62185420|NCT00867737|ACTIVE_COMPARATOR|2 = Symbicort 160/4.5|Symbicort initiated after screening
62185421|NCT05445167|EXPERIMENTAL|KLH-2109|
62185422|NCT05445167|PLACEBO_COMPARATOR|Placebo|
62215340|NCT01572376|EXPERIMENTAL|Bone marrow stem cells|Bone marrow was obtained by posterosuperior iliac crest aspiration under topical anesthesia. Mononuclear cells were isolated by Ficoll density gradient and will be resuspended in heparinized isotonic saline for infusion into the wound.
62215341|NCT06228794||Newly diagnosed multiple myeloma cohort|Participants who meet the multiple myeloma diagnostic criteria of IMWG are eligible.
62569212|NCT00218023|EXPERIMENTAL|Naltrexone HCl plus MI, CM, and CBT|"Naltrexone hydrochloride (HCl) doses began at 25 mg (day 1) and increased to the fixed dose of 25 mg twice daily (day 2) during the 12 weeks of Phase II.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
62569213|NCT00218023|PLACEBO_COMPARATOR|Placebo plus MI, CM, and CBT|"Placebo capsules were identical in appearance to active drug capsules, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
62569214|NCT02074358|EXPERIMENTAL|Treatment A: Apixaban + Placebo (Saline solution)|Apixaban 10 mg Tablet orally \[Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)\] followed 3hr later by Saline solution (placebo) 0 IU/kg infusion for 30 min Intravenously
62569215|NCT02074358|EXPERIMENTAL|Treatment B: Apixaban + Cofact (4-Factor PCC)|Apixaban 10 mg Tablet orally \[Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)\] followed 3hr later by a Cofact (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously
62569216|NCT02074358|EXPERIMENTAL|Treatment C: Apixaban + Beriplex P/N (4-Factor PCC)|Apixaban 10 mg Tablet orally \[Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)\] followed 3hr later by a Beriplex P/N (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously
62569217|NCT01251419|EXPERIMENTAL|Testimonial and Union Arm|The testimonial and union arm will receive the same letter as the testimonial treatment arm but with the addition of the union affiliation of the employee giving the testimonial.
62569218|NCT01251419|EXPERIMENTAL|Control|The control arm will receive a letter signed by our partner company's Chief Medical Officer, explaining the health and monetary benefits of switching from brand name prescription medication to generic prescription medication.
62569219|NCT01251419|EXPERIMENTAL|Testimonial Treatment Arm|The testimonial treatment arm will receive the exact same letter as the control arm, but the letter will feature an employee's testimonial along with the first name, last initial, city and state of the employee giving the testimonial.
62569220|NCT01547260|EXPERIMENTAL|Lenalidomide|Phase I; Lenalidomide capsules will be taken orally each day on days 1-21 of each 28-day cycle. 3 subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day. Gemcitabine, 1000 mg/m2 in 0.9% sodium chloride will be administered iv over 30 minutes, at days 1, 8, 15 of each 28-day cycle. Phase II: Every other consecutive included subject in phase II part will be treated with either single lenalidomide (days 1-21 of 28) or single gemcitabine (days 1, 8, 15 of 28) during Cycle 1. The first included patient in phase II part will start with single lenalidomide. From treatment cycle number 2 and beyond, all subjects in the phase II part of the study will be treated with lenalidomide in combination with gemcitabine.
62569221|NCT01547260|EXPERIMENTAL|gemcitabine|Gemcitabine, 1000 mg/m2 in 0.9% sodium chloride will be administered iv over 30 minutes, at days 1, 8, 15 of each 28-day cycle in both phase I and II. Phase I:Lenalidomide capsules will be taken orally each day on days 1-21 of each 28-day cycle. 3 subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day. Phase II: Every other consecutive included subject in phase II part will be treated with either single lenalidomide (days 1-21 of 28) or single gemcitabine (days 1, 8, 15 of 28) during Cycle 1. The first included patient in phase II part will start with single lenalidomide. From treatment cycle number 2 and beyond, all subjects in the phase II part of the study will be treated with lenalidomide in combination with gemcitabine.
62569222|NCT06426732||Natural pregnancy group|
62569223|NCT06426732||Assisted Reproductive Technology Group|
62569224|NCT03010384|ACTIVE_COMPARATOR|Intervention|Consultation with a physician specialized in social medicine. The consultation lasted about one hour. Together with the patient a return-to-work (RTW) schedule was made to ascertain the need for contact to the workplace (to adjust work functions), municipality, general practitioner or short-term supportive consultations with a psychologist. If relevant, patients were offered up till 5 sessions with a psychologist.
62569225|NCT03010384|NO_INTERVENTION|Control|Standard treatment from the Department of Rheumatology
61977812|NCT04954781|EXPERIMENTAL|TACE in combination with Tislelizumab|
62185423|NCT03837236|EXPERIMENTAL|Study group|Evaluation parameters will be performed to the patients. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.
62185424|NCT01962311|EXPERIMENTAL|All patients|lumbar puncture
62185425|NCT02182232|EXPERIMENTAL|BIBF 1120 with paclitaxel and carboplatin|
62569226|NCT01256450|EXPERIMENTAL|BEMA Buprenorphine|buprenorphine buccal soluble film
62569227|NCT01256450|PLACEBO_COMPARATOR|BEMA Placebo|placebo buccal soluble film
62569228|NCT01918488|EXPERIMENTAL|Nephropathy|Diabetics with diabetic nephropathy receiving first a standardized salt diet (200 mmol NaCl/day) for 4 days and then amiloride tablet 20 mg two times daily (morning and afternoon) for 2 days.
62569229|NCT01918488|EXPERIMENTAL|Control|Diabetics without nephropathy receiving a standardized salt diet (200 mmol NaCl/day) for 4 days, then amiloride tablet 20 mg two times daily (morning and afternoon) for 2 days.
62569230|NCT05807295|EXPERIMENTAL|Intervention|caregivers receiving a relaxation program
62185426|NCT02182232|EXPERIMENTAL|BIBF 1120 monotherapy|
62185427|NCT00984438|EXPERIMENTAL|BCNU wafter followed by chemotherapy|Surgical Implantable BCNU wafer followed by Chemotherapy with Irinotecan and Bevacizumab for up to one year
61977813|NCT05442320|ACTIVE_COMPARATOR|500 ppm|Toothpaste with 500 ppm fluoride (Biodent, Ilirija d.d)
62185428|NCT02819219|PLACEBO_COMPARATOR|Placebo|Participants will receive a flavored water placebo supplement. Part of the supplemental intervention. This, and all groups, simultaneously took part in the exercise intervention.
62185429|NCT02819219|EXPERIMENTAL|ElevATP|Participants will receive the flavored water placebo with an additional 150mg of ElevATP (blend of ancient peat and apple extracts). Part of the supplemental intervention.This, and all groups, simultaneously took part in the exercise intervention.
62569231|NCT05807295|NO_INTERVENTION|Control group|the group that did not receive any training
62569232|NCT03285828|OTHER|First group|Students received three four-hour sessions of a basic motivationnal interviewing training over a one week period. The students interviewed for 15 minutes a caregiver playing the role of a patient, six weeks before and three weeks after the training.
62569233|NCT03285828|OTHER|Second group|Students received three four-hour sessions of a basic motivationnal interviewing training over a one week period. The students interviewed for 15 minutes a caregiver playing the role of a patient, six weeks before and three weeks after the training.
62569234|NCT03839004|EXPERIMENTAL|Intervention group|200 woman with single spontaneous pregnancies who recieve, as well as traditional obstetrical care, yoga classes, myndfulness classes, coaching, nutrition counselling and osteopathic treatment
62569235|NCT03839004|NO_INTERVENTION|Controls|200 woman with single spontaneous pregnancies recieving traditional obstetrical care
62569236|NCT04346797|EXPERIMENTAL|Eculizumab|Eculizumab
62569237|NCT04346797|NO_INTERVENTION|Standard of Care|Best standard of care
62569238|NCT04380831|EXPERIMENTAL|Treatment (TBI using IMRT, cyclophosphamide, HSCT)|Patients undergo TBI using IMRT BID on days -5 and -4 in the absence of disease progression or disease progression. Patients then receive cyclophosphamide on days -3 and -2 and undergo HSCT on day 0 in the absence of disease progression or unacceptable toxicity.
62569239|NCT03993054|ACTIVE_COMPARATOR|Standard CBSM|Participants will receive standard web-based cognitive behavioral stress management (CBSM) over 4 weeks.
62775721|NCT02169856|OTHER|control group|"control group was not given any EFTs (emotional freedom techniques) therapy for postoperative nausea and vomiting.~Following medications were given to both groups. details are in respective interventions.~Tab. Midazolam 7.5 mg Inj. Midazolam IV 0.7 mg/kg inj. propofol (2.5 mg/kg) inj. atracuium (0.5 mg/kg). sevoflurane (2.5 vol %) oxygen in air mixture (0.50 ratio) Inj. Cefuroxime 1.5 gm. IV Inj. Ketorolac 30mg IV Inj. Zantac 50 mg IV inj. Metoclopramide 10mg IV"
62775722|NCT02169856|EXPERIMENTAL|EFTs study group|"EFTs (emotional freedom techniques) was applied to the patietns. one session of 5 to 10 min at 6 hours postoperatively.~Following medications were given to both groups. details are in respective interventions.~Tab. Midazolam 7.5 mg Inj. Midazolam IV 0.7 mg/kg inj. propofol (2.5 mg/kg) inj. atracuium (0.5 mg/kg). sevoflurane (2.5 vol %) oxygen in air mixture (0.50 ratio) Inj. Cefuroxime 1.5 gm. IV Inj. Ketorolac 30mg IV Inj. Zantac 50 mg IV inj. Metoclopramide 10mg IV"
62185430|NCT02819219|EXPERIMENTAL|ElevATP w/Caffeine|Participants will receive the flavored water placebo with an additional 150mg of ElevATP (blend of ancient peat and apple extracts), a 180 mg blend of caffeine (caffeine anhydrous, pterostilbene-bound caffeine), and 38mg B vitamins. Part of the supplemental intervention.This, and all groups, simultaneously took part in the exercise intervention.
62569240|NCT03993054|EXPERIMENTAL|Culturally-tailored CBSM|Participants will receive web-based CBSM that is culturally-tailored for Latino men specifically over 4 weeks.
62569241|NCT02066480||women between 50 and 80 years hospitalized in CHD Vendée|
62185431|NCT05054465|EXPERIMENTAL|Pre-transplant consolidation and post-transplant maintnance with navitoclax and venetoclax.|Patients will be treated with VEN 400 mg QD and NAV 50mg QD according to the RP2D presented by Pullarkat et al. (doi: 10.1158/2159-8290.CD-20-1465) for two 28 day cycles. Following 2 cycles re-staging marrow including MRD assessment and imaging will be followed by alloSCT according to local protocol.Within 90 days from alloSCT patients will be started on VEN and NAV maintenance. For post-alloSCT maintenance a dose escalation scheme based on the BOIN design will be applied with a maximal dose of VEN 400 mg QD and NAV 50mg QD according to the RP2D presented by Pullarkat et al.
62185432|NCT01183715|EXPERIMENTAL|Cohort 1|Subjects in Cohort 1 will receive 2 single doses of PF-05161704 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-05161704 will be administered in Period 4 in the fasted state.
62569242|NCT04387435|EXPERIMENTAL|Intervention Arm|Single arm
62569243|NCT01171027|EXPERIMENTAL|NOTES(R) Cholecystectomy|Natural Orifice Translumenal Endoscopic Surgery techniques
62569244|NCT01171027|ACTIVE_COMPARATOR|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
62569245|NCT04405492|EXPERIMENTAL|Population 1 : Patients|Hospitalized patients, positive or suspected of SARS-CoV-2 infection
62569246|NCT04405492|EXPERIMENTAL|Population 2 : Hospital caregivers exposed to SARS-CoV-2|Longitudinal study of a hospital caregiver cohort
62569247|NCT04405492|EXPERIMENTAL|Population 3 : Lay users|Suitability of rapid test in view of its intended purpose for self-testing
62775723|NCT04476199|EXPERIMENTAL|Treatment with VEN-DEC|Venetoclax will be given with a 3-day ramp up beginning with 100 mg dose on Day 1, with 200mg on Day 2, to reach the final dose of 400 mg on Day 3 of Cycle 1. Venetoclax will be continued at 400 mg daily. Tumor lysis prophylaxis will be administered from day -4, cycle 1 (oral uric acid reducing agent and hydration with at least 1.5 L/day).Decitabine will be administered at the dose of 20 mg/sqm intravenously from day 1 to day 5 every 28 days (VEN-DEC) for 2 cycles.
62569248|NCT00510211||olanzapine coated tablet|
62569249|NCT00510211||olanzapine orodispersable tablet|
62569250|NCT04671420|EXPERIMENTAL|HLX01|
62569251|NCT04671420|ACTIVE_COMPARATOR|EU-sourced rituximab (Mabthera®)|
62569252|NCT03981250|NO_INTERVENTION|Control Group|The control group will be asked to keep their lifestyle behaviour and not increase their physical activity levels during the study period.
62569253|NCT03981250|EXPERIMENTAL|Exercise Group|The exercise group will engage in a home-based resistance exercise intervention for 12 weeks. They will perform 6 exercises, one each day for one minute, for 6 days a week.
62569254|NCT05877118|ACTIVE_COMPARATOR|Standard education|Written instructions and information communicated to the patient through MyChart. The following four key points are covered: (1) When someone overdoses on opiates, their breathing will get very slow and may stop (2) Naloxone is a safe life-saving medication that can reverse an opioid overdose (3) You give someone naloxone by injecting it through the nostril, (4) If a first dose of naloxone does not work after about 3 minutes, give a second dose.
62185433|NCT01183715|EXPERIMENTAL|Cohort 2|Subjects in Cohort 2 will receive 2 single doses of PF-05161704 and 1 placebo dose in random order in Periods 1-3
62185434|NCT01811498|EXPERIMENTAL|SIACI of Bevacizumab|Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab
62185435|NCT00715689|EXPERIMENTAL|A|
62185436|NCT00715689|EXPERIMENTAL|B|
62185437|NCT00715689|EXPERIMENTAL|C|
62185438|NCT00715689|EXPERIMENTAL|D|
62791663|NCT01999400|EXPERIMENTAL|Arm 5: Lialda then Delzicol then Pentasa then Apriso|"1. Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~2. Washout period of 10 days.~3. Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~4. Washout period of 10 days.~5. Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~6. Washout period of 10 days.~7. Apriso 375 mg capsule x 3 with 240 mL water, single dose."
62791664|NCT01999400|EXPERIMENTAL|Arm 6: Lialda then Delzicol then Apriso then Pentasa|"1. Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~2. Washout period of 10 days.~3. Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~4. Washout period of 10 days.~5. Apriso 375 mg capsule x 3 with 240 mL water, single dose.~6. Washout period of 10 days.~7. Pentasa 500 mg capsule x 2 with 240 mL water, single dose."
62185439|NCT03981497||Small Renal Tumors|Subjects with small renal tumors (SRT) ad described by current ESMO (European Society for Medical Oncology) guidelines who are candidates for MWA
62185440|NCT03981497||Primary and Secondary Liver cancer|Primary liver tumors: subjects who are candidates for MWA with nodules ≤ 3 cm Liver metastases: subjects who are candidates for MWA with nodules less than ≤ 3 cm
62185441|NCT03526978|EXPERIMENTAL|Experimental Group|"The investigational vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd.~Intervention: investigational sIPV"
62185442|NCT03526978|ACTIVE_COMPARATOR|Control Group|The control vaccine was manufactured by Sanofi Pasteur Company. Intervention: control IPV
62185443|NCT05650541|EXPERIMENTAL|Study Group|The study group will use the CPM device daily for 6 months (beginning at visit 1 and ending at visit 2). The ADI triaging team will monitor the CPM device data and call the patient as indicated by the data. The ADI care team will then forward the device data and patient symptomology collected to the patient's care team where that team will device if intervention is necessary. The patient's care team will also have access to view device data at any time using the CPM website.
62185444|NCT05650541|NO_INTERVENTION|Control Group|The control group will not receive a device and will continue their normal standard of care.
62394163|NCT05778734|OTHER|Treatment group|"For the R00 phase: CM-PST treatment group will receive CM-PST intervention, which will consist of 8 sessions total, delivered remotely via Zoom videoconferences in individual sessions over 12 weeks. The first 4 sessions will be delivered weekly, and the remaining 4 sessions every other week. CM-PST will teach participants problem-solving skills using a structured 5-step method. In addition, participants will receive incentives for alcohol abstinence and submission of urine samples twice/wk.~K99 phase participants will also receive CM-PST intervention."
62394164|NCT05778734|OTHER|Control group|For the R00 phase: Participants in CM-only control will receive incentives for alcohol abstinence and submission of urine samples twice/wk. Participant incentives will start at a $10 gift card, with a $5 increase each subsequent measurement point on which alcohol is not detected or reported, to a maximum of $25, but no gift card on days when alcohol use is detected or reported, and the gift card reinforcer value will be re-set to $10.
62394165|NCT00602043|EXPERIMENTAL|Diagnostic (FES)|Patients undergo \[\^18F\] FES PET scan. Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to \[\^18F\] FES PET scan.
62394166|NCT05303428|EXPERIMENTAL|LIFU, fMRI Cognitive|fMRI resting and cognitive tasks performed after LIFU application to known brain region of interest or active sham region (within participant all conditions tested).
62394167|NCT02160262|EXPERIMENTAL|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed
62394168|NCT02260804|EXPERIMENTAL|CT-P10|CT-P10, intervention 375mg/m2, intravenous, 4 cycles in induction period and additional 12 cycles in maintenance period
62394169|NCT02260804|ACTIVE_COMPARATOR|Rituxan|Rituxan, 375mg/m2 intravenous, 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
62394170|NCT04323345|EXPERIMENTAL|Natural Honey Group|"Natural Honey~1gm/kg/day divided into 2 to 3 doses for 14 days in addition to standard care"
62394171|NCT04323345|ACTIVE_COMPARATOR|Standard Care|Current standard care including supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.
62394172|NCT04540627|PLACEBO_COMPARATOR|Placebo|Sodium Chloride 0.9% Solution (Normal Saline)
62394173|NCT04540627|ACTIVE_COMPARATOR|Palivizumab (Synagis™)|Sterile vial 50mg/0.5mL
61977814|NCT05442320|EXPERIMENTAL|1000 ppm|Toothpaste with 1000 ppm fluoride (Biodent, Ilirija d.d)
61977815|NCT06137716|EXPERIMENTAL|Participant Group/Arm|Participants will rehabilitation with a robotic hand exoskeleton.
62185445|NCT05840562|EXPERIMENTAL|Experimental Arm|"The capsaicin 179 mg patch should be applied to the most painful extremities.~Application:~* Capsaicin patches must be applied to intact, dry and non-irritated skin and allowed to remain in place for 30 minutes for the feet and maximum 60 minutes for hands depending on immediate tolerance.~* If all the areas to be treated cannot be treated in once, a second session will be organised between 3 and 7 days later. Further sessions can be held within 15 days of the 1st session (up to 4 sessions in total). All sessions will be considered as one application.~* 1 application may require several treatment sessions.~* The patch, which may be cut to shape, was used within 2 h of opening the foil pouch.~After the first treatment session, treatment may be repeated every 2 months (at weeks 9, 17, 25) as warranted by the persistence or return of pain."
62185446|NCT05840562|ACTIVE_COMPARATOR|Control Arm|"Duloxetine should be initiated at an initial dose of 30 mg orally for 1 week followed by a maintenance dose of 60 mg per day, given either once a day or 30 mg orally 2 times a day.~After W6, in case of insufficient response to the 60 mg dose, the dosage may be increased to the maximum dose of 120 mg."
62394174|NCT00967473|EXPERIMENTAL|Toric Intraocular Lens|ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Models SN60T9/SN60T8
62394175|NCT01853319|EXPERIMENTAL|Regorafenib|Regorafenib, 40 mg tablets
62394176|NCT03252223|ACTIVE_COMPARATOR|Women with normal menses|
62394177|NCT03252223|ACTIVE_COMPARATOR|Women with Polycystic Ovary Syndrome|
62394178|NCT04362527|EXPERIMENTAL|Milrinone|The patients randomized to this arm will have Milrinone (Laboratoires STRAGEN, France)
62185447|NCT04550559|ACTIVE_COMPARATOR|Group 1|The patients in group 1 were instructed to masturbate at least 3-4 times a week
62000112|NCT01957475|EXPERIMENTAL|First Coloplast Test product Z; then Coloplast Test product Y|The subjects first test Coloplast Test product Z and after cross-over Coloplast Test product Y
62000113|NCT01957475|EXPERIMENTAL|First Coloplast Test product Y, Then Coloplast Test product Z|The subjects first test test product Y and after cross-over test product Z
62000114|NCT03793907|ACTIVE_COMPARATOR|Cohort 2 (walking program)|Patients receive a Fitbit to track their physical activity, and complete an unsupervised walking program daily at home, increasing physical activity stepwise weekly, for 6 months.
62185448|NCT04550559|OTHER|Group 2|The patients in group 2 were prescribed oral tamsulosin 0.4 mg once daily
62185449|NCT04550559|NO_INTERVENTION|Group 3|The patients in group 3 acted as controls and received only standard medical therapy
61977816|NCT03387839||Medial-Pivot Knee Prosthesis|
61977817|NCT03387839||Posterior-Stabilized Knee Prosthesis|
62185450|NCT03379558||Cohort 1 : alirocumab exposed|Pregnant women diagnosed with primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and exposed to alirocumab during the current pregnancy.
61977818|NCT03387839||Cruciate-Stubstituting Knee Prosthesis|
61977819|NCT00955591|OTHER|swab test|
62000115|NCT03793907|EXPERIMENTAL|Cohort 1 (strength training)|Patients receive a Fitbit to track their physical activity, and complete an in-person personalized and supervised full-body strength training program over 1 hour BID up to 52 sessions for 6 months.
62185451|NCT03379558||Cohort 2 : disease matched comparison|Pregnant women diagnosed of primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and unexposed to alirocumab during the current pregnancy.
62185452|NCT03379558||Cohort 3 : non disease comparison|Healthy pregnant women who do not have a known diagnosis of primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and have no known exposure to a known human teratogen.
62000116|NCT04436523|EXPERIMENTAL|Blood flow restriction|The blood flow restriction arm will include the use of the pneumatic tourniquet applied to the operative lower extremity throughout post-operative rehabilitation sessions. The tourniquet pressure will be titrated to 80% of the measured extremity arterial limb occlusion pressure with the participant lying supine.
62775724|NCT03590249|EXPERIMENTAL|Osteopathic Manipulative Treatment (OMT)|Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
62000117|NCT04436523|SHAM_COMPARATOR|Standard rehabilitation|The standard rehabilitation arm will undergo the same rehabilitation protocol as the experimental arm. A tourniquet will still be applied, but will only be inflated to 20 mmHg, a pressure that will not occlude blood flow.
62000118|NCT04380311|EXPERIMENTAL|Precision Tacrolimus|Participants in this arm of the study will have their tacrolimus dose determined using a precision medicine decision support software tool. The participant's transplant physician will consider the recommended dose from the decision support tool in combination with the physician's expertise and experience to determine the proper tacrolimus dose for the participant.
62000119|NCT02333916|EXPERIMENTAL|Overfeeding + exercise pre/post training|"overfeeding + exercise pre-training: day1 energy balance; day2 and day3: energy intake equals 1.25 times day 2 and day 3 energy expenditure respectively, no exercise; day4: 3 cycling bouts to expend 0.25 times day3 energy expenditure + energy intake equals 1.25 times day4 energy expenditure - before training period.~fitness training: 10-week training period (3 times per week at a gym, 30-45 minutes cardio training and 15-30 minutes strength training).~overfeeding + exercise post-training: day1 energy balance; day2 and day3: energy intake equals 1.25 times day 2 and day 3 energy expenditure respectively, no exercise; day4: 3 cycling bouts to expend 0.25 times day3 energy expenditure + energy intake equals 1.25 times day4 energy expenditure - after training period."
62000120|NCT03663283|EXPERIMENTAL|Liposomal Bupivacaine|Administered utilizing ultrasound guidance by an anesthesiologist. Study patients will receive 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.
62000121|NCT03663283|ACTIVE_COMPARATOR|Plain Bupivacaine|Peripheral nerve blocks will be performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride will be utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block will be utilized. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.
62000122|NCT04855643|EXPERIMENTAL|Treatment|
62394179|NCT04362527|PLACEBO_COMPARATOR|Placebo|The patients randomized to this arm will have Saline solution
62394180|NCT00206752|EXPERIMENTAL|unilateral radiation therapy|definitive external beam radiation in the ipsilateral neck.
62775725|NCT03590249|NO_INTERVENTION|No Intervention|Participants in the No Intervention arm will undergo the planned assessments, but not receive any intervention.
62775726|NCT05419037||off-spring of above|Off-spring of the women who took metreleptin during her pregnancy.
62775727|NCT05419037||Women with past pregnancy on metreleptin|Women who took metreleptin during pregnancy.
62775728|NCT04943432|EXPERIMENTAL|People who inject drugs|People who inject drugs recruited from a needle exchange program who will participate in a psychosocial intervention
62775729|NCT05899101||1 - Opioid Only|Illicit and/or sustained prescription opioids only (no cannabis use)
62775730|NCT05899101||2 - OAT Only|Opioid agonist therapy (OAT) only (no cannabis use)
62775731|NCT05899101||3 - Opioid and Cannabis|Illicit and/or sustained prescription opioids with concurrent cannabis use
62775732|NCT05899101||4 - OAT and Cannabis|Opioid agonist therapy (OAT) with concurrent cannabis use
62775733|NCT05899101||5 - Nicotine Only|Nicotine users without opioid exposure
62775734|NCT05899101||6 - Cannabis Only|Cannabis-users without opioid exposure
62775735|NCT05899101||7 - Unexposed|Non-substance exposed healthy pregnancies
62775736|NCT05954767|OTHER|Efficacy|Single intravenous injection of IS-001 and ureter visualization and delineation will be compared in white light standard of care and near-infrared (NIR) imaging mode.
62775737|NCT01424527||Chronic Obstructive Pulmonary Disease|Males and females 40 years of age or older with a diagnosis of COPD
62775738|NCT02935413|ACTIVE_COMPARATOR|tDCS|group receiving complete treatment of transcranial direct current stimulation
62775739|NCT02935413|ACTIVE_COMPARATOR|Standard rehabilitation|Standard rehabilitation procedures
62775740|NCT05230849|ACTIVE_COMPARATOR|control group|conventional physiotherapy treatment
62775741|NCT05230849|EXPERIMENTAL|dry needling treatment|group that includes a dry needling treatment on the tibialis anterior and posterior muscles.
62775742|NCT03045341|EXPERIMENTAL|BWL + NB medication|Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
62775743|NCT03045341|EXPERIMENTAL|BWL + Placebo|Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and placebo. Placebo will be inactive and taken daily in pill form.
62775744|NCT03045341|EXPERIMENTAL|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
62775745|NCT03045341|PLACEBO_COMPARATOR|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
62775746|NCT01089790|EXPERIMENTAL|1|
62775747|NCT01089790|ACTIVE_COMPARATOR|2|
62775748|NCT04067661|EXPERIMENTAL|Intervention|Participants and their partners will complete four couples counseling sessions focused on developing and enhancing relationship skills to decrease HIV risk behaviors.
62000123|NCT04855643|SHAM_COMPARATOR|Control Group|
62000124|NCT04361526|NO_INTERVENTION|Control|standard intensive care alone
62775749|NCT04067661|ACTIVE_COMPARATOR|Control|Participants and their partners will receive information and referrals on HIV risk and prevention strategies.
62000125|NCT04361526|EXPERIMENTAL|Cytokine Adsorption|cytokine adsorption plus standard intensive care
62000126|NCT05952648|EXPERIMENTAL|Film-array Pneumonia Panel Plus group|Patients with suspected HAP or VAP in which lower tract respiratory samples are analyzed with new multiplex PCR assay (Film-array Pneumonia Panel Plus)
62000127|NCT05952648|ACTIVE_COMPARATOR|Standard culture group (control group)|Patients with suspected HAP or VAP in which lower tract respiratory samples are analyzed with standard culture
62185453|NCT00752245|EXPERIMENTAL|1|Dialysis during 4 hours
62185454|NCT00752245|ACTIVE_COMPARATOR|2|Dialysis during 6 hours
62185455|NCT00752245|ACTIVE_COMPARATOR|3|Dialysis during 8 hours
62394181|NCT03854669|EXPERIMENTAL|Assessing pain reporting accuracy|Subjects will undergo pre-operative evaluation of their pain reporting accuracy ability in order to assess its relation to post-operative acute pain and analgesic consumption
62394182|NCT03306589|EXPERIMENTAL|Subjects receiving LPS: Part I and Part II|Eligible subjects will be randomized to receive LPS in a dose-escalation manner ranging from 0.5 nanogram (ng)/kg to 4 ng/kg. Subjects will be hydrated prior to administration of LPS with normal saline at a rate of 250 mL/hour for 4 hours prior to dosing and 8 hours after dosing.
62000128|NCT05548608||Group I (Healthy control)|Group I consists of patient relatives and patients who applied to the outpatient clinic for another ailment.
62000129|NCT05548608||Group II (chronic low back pain due to LSS )|Group II consisted of patients diagnosed with LSS and confirmed by MRI findings.
62000130|NCT05548608||Group III (undergoing surgery due to LSS )|Participants who had surgery for LSS at least 3 months ago were included in Group III.
62000131|NCT06493630|EXPERIMENTAL|Experimental group|Hypnobreastfeeding Education
62000132|NCT06493630|NO_INTERVENTION|Control group|Control
62000133|NCT06223646|EXPERIMENTAL|Phase 1: Low dose group|Infusion of KQ-2003 CAR T-cells by single dose of 1.0×10\^6 CAR-T cells/kg
62000134|NCT06223646|EXPERIMENTAL|Phase 1: Medium dose group|Infusion of KQ-2003 CAR T-cells by single dose of 2.0×10\^6 CAR-T cells/kg
62000135|NCT06223646|EXPERIMENTAL|Phase 1: High dose group|Infusion of KQ-2003 CAR T-cells by single dose of 3.0×10\^6 CAR-T cells/kg
62000136|NCT06223646|EXPERIMENTAL|Phase 2a: RP2D|After all subjects in the Phase 1 dose-escalation study completed DLT observation, RP2D was determined based on the analysis results for the phase 2a expansion study.
62000137|NCT05069922|ACTIVE_COMPARATOR|Fresh Frozen Plasma|At 6-8 hours, Initiate FFP infusion
62185456|NCT02411617|ACTIVE_COMPARATOR|Single drain in modified radical mastectomy|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
62185457|NCT02411617|ACTIVE_COMPARATOR|Double drain in modified radical mastectomy|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
62000138|NCT05069922|ACTIVE_COMPARATOR|Albumin|At 7 hours, Initiate 5% Albumin infusion
62185458|NCT02142634|EXPERIMENTAL|A|Budesonide granules 9 mg
62185459|NCT02142634|PLACEBO_COMPARATOR|B|Placebo granules
62394183|NCT03306589|EXPERIMENTAL|Subjects receiving GM-CSF: Part I and Part II|Eligible subjects will be randomized to receive GM-CSF in a dose-escalation manner ranging from 5 to 15 microgram (µg)/kg.
62185460|NCT04721899||Vitamin D- recurrent implantation failure (RIF)|All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.
62394184|NCT03796858|EXPERIMENTAL|Group 1: Guselkumab|Participants will receive guselkumab 100 milligram (mg) Subcutaneous (SC) injection at Weeks 0, 4, 12, 20, 28, 36, and 44 and placebo SC at Week 24 to maintain the blind. At Week 16, Participants who meet the early escape criteria will receive placebo at Week 16 and guselkumab at Week 20, then guselkumab every 8 weeks (q8w).
62584797|NCT05078866|EXPERIMENTAL|Part II Arm A (GAd20-209-FSPs, MVA-209-FSPs)|Patients receive GAd20-209-FSPs IM at week 52 and MVA-209-FSPs IM at week 60. Patients undergo endoscopy with biopsy as well as blood sample collection on the trial.
62775750|NCT02085330|EXPERIMENTAL|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
62775751|NCT02085330|NO_INTERVENTION|Standard follow up|
62775752|NCT05018858|EXPERIMENTAL|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
62775753|NCT02758327|EXPERIMENTAL|TheraTears Lubrication Drop|TheraTears Lubricating Eye Drops to be instilled 1 drop in both eyes 4 times per day over a period of 8 weeks.
62775754|NCT03135977|EXPERIMENTAL|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
62569255|NCT05877118|EXPERIMENTAL|Enhanced Overdose Education (EOE)|A one-page education pamphlet handed to participants and their identified support individual and a 4-minute video clip that will be viewed in the hospital and emailed or texted to both. EOE is purposefully brief and intended to increase uptake by participants and their support network who may not be motivated or willing to engage in face-to-face or extensive education. The pamphlet and video both emphasize the Why and How. That is, the significance of naloxone in decreasing the likelihood of death following an overdose while providing simple instructions on how to use the nasal kit. They also emphasize an important point missing in standard education: to tell others in the support network where it is and how to use it.
62569256|NCT03680378|EXPERIMENTAL|Cefepime 2 gram + AAI101 1 gram|cefepime 2 grams in combination with AAI101 1 gram intravenous infusion
62569257|NCT06111014|EXPERIMENTAL|Open Label|Latozinemab (AL001) administered by IV infusion over 60 minutes, q4w
62569258|NCT01610882|OTHER|Panda first|Panda evaluation of post-operative pain first, followed by manual method of pain assessment.
62569259|NCT01610882|OTHER|Manual first|Manual evaluation of post-operative pain first followed by Panda pain assessment.
62569260|NCT01216241|ACTIVE_COMPARATOR|Daptomycin|Daptomycin intravenous 8mg/kg once per day 5-10 days.
62569261|NCT01216241|PLACEBO_COMPARATOR|Saline Placebo|Saline solution
61977820|NCT01366560|EXPERIMENTAL|GSK962040|The subjects will be administered GSK962040 125 mg tablet as a single dose on Day 1 of study treatment visit. After 2 hours, the subjects will be administered wireless motility capsule. The subjects will be observed for expulsion of WMC in stool. Each subject will attend the clinical unit for two study treatment visits which will be separated by at least one week.
62000139|NCT03053895|EXPERIMENTAL|CSDH Bedside twist drill technique|For patients randomized to bedside drainage of Chronic Subdural Hematoma, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic.
62000140|NCT03053895|ACTIVE_COMPARATOR|CSDH Operating Room Burr-hole technique|For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
62000141|NCT04727658|EXPERIMENTAL|Radiosurgical thalamotomy on GammaKnife|
62000142|NCT03277261|EXPERIMENTAL|Ublituximab + Oral Placebo|Participants were administered ublituximab 150 milligrams (mg), intravenous (IV) infusion over 4 hours (h) on Day 1 followed by 450 mg over 1 h on Days 15, 168, 336 and 504 (Week 72) along with the oral placebo once daily (QD) from Day 1 up to the last day of Week 95.
62000143|NCT03277261|ACTIVE_COMPARATOR|Teriflunomide + IV Placebo|Participants were administered teriflunomide 14 mg tablet, orally, QD from Day 1 up to the last day of Week 95 along with the placebo IV infusion on Days 1, 15, 168, 336 and 504 (Week 72).
62000144|NCT03938142||patients with chronic pain|
62000145|NCT02501603|EXPERIMENTAL|afatinib plus paclitaxel|afatinib plus paclitaxel
62000146|NCT01600586|EXPERIMENTAL|Pacifier-Activated-Lullaby system (PAL)|Pacifier-Activated-Lullaby system (PAL) group.
62000147|NCT01600586|NO_INTERVENTION|No PAL group|No PAL. Standard of care procedures.
62000148|NCT01489046|EXPERIMENTAL|Arm 1: BMS-986001 (100 mg) + Placebo + Efavirenz + Lamivudine|
62000149|NCT01489046|EXPERIMENTAL|Arm 2: BMS-986001 (200 mg) + Placebo + Efavirenz + Lamivudine|
62000150|NCT01489046|EXPERIMENTAL|Arm 3: BMS-986001 (400 mg) + Efavirenz + Lamivudine|
62000151|NCT01489046|EXPERIMENTAL|Arm 4: Tenofovir (300 mg) + Efavirenz + Lamivudine|
62000152|NCT05156580||Obese hypertensive group|Patients who were diagnosed with obesity (body mass index (BMI)≥28kg/m2) and hypertension (systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥ 140/90 mmHg).
62000153|NCT05156580||Overweight hypertensive group|Overweight patients (24 kg/m2≤BMI≤28 kg/m2) diagnosed with hypertension (SBP/DBP≥140/90 mmHg).
62000154|NCT05156580||Lean hypertensive group|Lean patients (BMI ≤ 24 kg/m2) diagnosed with hypertension (SBP/DBP ≥ 140/90 mmHg).
62000155|NCT05428475|EXPERIMENTAL|[18F]FDG-PET Scan|Participants with unclear symptoms of cognitive impairment who will undergo the \[18F\]FDG-PET scan (185 MBq of \[18F\]FDG administered once during study).
62000156|NCT05933681|EXPERIMENTAL|Determination of DLPFC neurophysiology biomarkers of DBS associated cognitive impairment|Neurophysiology recordings will be performed from dorsolateral prefrontal cortex (DLPFC) during deep brain stimulation surgery, with and without STN or GPI stimulation, at rest and during a working memory task.
62185461|NCT04721899||Vitamin D- recurrent pregnancy loss (RPL)|All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.
62569262|NCT01158235|EXPERIMENTAL|LTX-109 (Lytixar)|Ascending dose study. Start enrollment to group 1: 1% LTX-109/placebo, then group 2: 2%LTX-109/placebo and finally group 3: 5%LTX-109/placebo dosed in each nostril TID for 3 consecutive days.
62569263|NCT05556954||Infected DFU cohort|25 participants that have an infected DFU will be enrolled.
62569264|NCT05556954||Non-infected DFU cohort|75 non-infected participants with DFU will be enrolled.
62569265|NCT04615403|EXPERIMENTAL|Implantation and Exchange|Subjects will undergo implantation and exchange of a Travoprost Intraocular Implant through a small temporal clear corneal incision.
62584798|NCT05078866|EXPERIMENTAL|Part II Arm B (MVA-209-FSPs)|Patients receive MVA-209-FSPs IM at week 52. Patients undergo endoscopy with biopsy as well as blood sample collection on the trial.
62000157|NCT05933681|EXPERIMENTAL|Neurophysiology biomarkers of DBS mediated cognitive impairment following chronic stimulation|Neurophysiology recordings will be performed from subthalamic nucleus (STN) or globus pallidus internus (GPI) with stimulation on and off, at rest and during a working memory task, in patients who have previously been implanted with DBS and have implantable pulse generators capable of recording local field potentials.
62394185|NCT03796858|EXPERIMENTAL|Group 2: Placebo followed by Guselkumab|Participants will receive placebo SC injection at Weeks 0, 4, 12, and 20, and will crossover to receive guselkumab 100 mg SC injection at Weeks 24, 28, 36, and 44. At Week 16, Participants who meet the early escape criteria will receive guselkumab at Weeks 16 and 20, then guselkumab q8w.
62569266|NCT05967013|EXPERIMENTAL|4-period cross-over|"After a screening period of a maximum of 21 days, eligible subjects will be randomized in a 1:1:1:1 allocation ratio to one of the 4 treatment sequences (settings):~* Sequence 1: A\&B in Period 1 / C\&D in Period 2~* Sequence 2: D\&A in Period 1 / B\&C in Period 2~* Sequence 3: C\&D in Period 1 / A\&B in Period 2~* Sequence 4: B\&C in Period 1 / D\&A in Period 2~Setting definitions:~* Setting B = volume 0.64mL of physiological serum with ZENEO® injector, setting GAMMA - Bare skin.~* Setting A = volume 0.64mL of physiological serum with ZENEO® injector, setting GAMMA - Through Clothing.~* Setting D = volume 0.64mL of physiological serum with ZENEO® injector, setting GAMMA low - Bare skin.~* Setting C = volume 0.64mL of physiological serum with ZENEO® injector, setting GAMMA low - Through Clothing."
62569267|NCT02064998|EXPERIMENTAL|Promillekoll|Smartphone app monitoring alcohol use with feedback on eBAC level.
62569268|NCT02064998|EXPERIMENTAL|PartyPlanner|Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
62569269|NCT02064998|NO_INTERVENTION|Control Study 1|Waitlist control group that is given access to the Promillekoll and PartyPlanner apps after a 12-week wait.
62775755|NCT04862026||Telemonitoring group|The telemonitoring group will be connected to electronic medical systems, through which medical workers will remotely assess clinical and emotional status, adherence to drug therapy, and carry out nutritional adjustments.
62775756|NCT04862026||Control group|Patients with standard administration.
62775757|NCT04467125|EXPERIMENTAL|EMLA|Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.
62775758|NCT04467125|ACTIVE_COMPARATOR|Subcutaneous Lidocaine|Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected at the removal site and then undergo Nexplanon removal.
62775759|NCT02197949||Breast cancer patients with infiltrated axillary l|
62775760|NCT02759848||with history of TB|
62775761|NCT02759848||without history of TB|
62775762|NCT04194125|EXPERIMENTAL|177Lu-DOTATOC combined with CAPTEM|"* The therapy will include 4 courses (14 days per one) with 8-week intervals;~* 177Lu-DOTATOC in doses from 5,55GBq up to 7,4 GBq will be administered i.v. up to four times at 10th day;~* Concomitant amino acids will be given with each administration;~* Capecitabine will be administrated for 14 days (twice a day) followed by Temozolomide at 10-14th days in each therapy sessions."
62775763|NCT05382897|EXPERIMENTAL|Fasting-Mimicking Diet|Participants will be followed for 3 weeks for baseline assessment and then consume a plant-based fasting-mimicking diet for 5 days once a month for 3 months.
62775764|NCT05382897|EXPERIMENTAL|Caloric-Sufficient Diet|Participants will be followed for 3 weeks for baseline assessment and then consume a plant-based caloric-sufficient diet for 5 days once a month for 3 months.
62775765|NCT04868149|EXPERIMENTAL|Laparoscopic ALPPS|Laparoscopic ALPPS procedure
62775766|NCT04868149|ACTIVE_COMPARATOR|Open ALPPS|Open ALPPS procedure
62775767|NCT05486585|EXPERIMENTAL|Children and Adolescents|30 children aged 8-12 years old and their parents, 30 adolescents aged 13-17 years old and their parents
62775768|NCT05416307|EXPERIMENTAL|ELA026|"Cohort 1: Single dose escalation up to 3.0 mg/kg IV or SC~Cohorts 2-4: dose, route, and frequency of administration (IV or SC) to be determined"
62775769|NCT04677127|EXPERIMENTAL|Intervention|The intervention group was given training based on the health belief model with groups of 10-12-13 people every week for 6 weeks in the Family Health Center, followed by telephone counseling in the following 6 weeks and follow-up for 12 weeks.
62775770|NCT04677127|NO_INTERVENTION|Control|Patients in the control group were assessed at the first interview and the last interview, received routine health care, and no intervention was performed during the research.
62775771|NCT04832763|EXPERIMENTAL|Physical function testing, questionnaire|Patients on active treatment complete questionnaires and undergo collection of blood samples and physical function assessments at baseline, and at 3 and 6 months. Survivors in surveillance complete questionnaires and undergo collection of blood sample and physical function assessment at baseline.
62775772|NCT02772900|ACTIVE_COMPARATOR|Beetroot gel (dietary nitrate)|Beetroot-based nutritional gel containing approximately 10.0 mmol of nitrate per dose
62394186|NCT03953651||Patients|Patients admitted in the emergency department presenting a myocardial oxygenation imbalance and are therefore at risk for Myocardial Infarction (MI) type 2.
62394187|NCT06471361|EXPERIMENTAL|Zilucoplan-auto-injector (ZLP-AI)|Study participants will self-administer zilucoplan (ZLP) based on their body weight using auto-injector (AI).
62569270|NCT02064998|EXPERIMENTAL|Crossover group 1: TeleCoach - Control|Six-week access to the TeleCoach app, with exercises and vignettes for reducing or abstaining from alcohol consumption, followed by a 6-week period with no access to the app.
62394188|NCT01873274|ACTIVE_COMPARATOR|basic yogurt enriched with MK-7|one study group will receive daily two basic dairy products enriched with MK-7 (50 μg)
62775773|NCT02772900|ACTIVE_COMPARATOR|Placebo gel (nitrate-depleted)|Nutritional gel nitrate-depleted
62775774|NCT05001139|EXPERIMENTAL|Relizema ecofoam|Reizema ecofoam for 42 days, 2 times per day
62775775|NCT00967759|EXPERIMENTAL|Decongex Plus|
62775776|NCT00967759|ACTIVE_COMPARATOR|Bronpheniramine isolated|
62775777|NCT00967759|ACTIVE_COMPARATOR|Fenilefrine isolated|
62775778|NCT04499859|EXPERIMENTAL|ezetimibe 10 mg plus rosuvastatin 5 mg|Rosuzet 5/10 mg , once a day for 24 months
62775779|NCT04499859|ACTIVE_COMPARATOR|rosuvastatin 20 mg only|Any brand drugs of rosuvastatin 20mg, once a day for 24 months
62775780|NCT02385435|ACTIVE_COMPARATOR|Bupivacaine|single shot caudal plain bupivacaine at a dose of 2mg/kg is used as a reference control drug.
62775781|NCT02385435|ACTIVE_COMPARATOR|dexmedetomidine 1μg.kg-1|Single shot Caudal dexmedetomidine 1μg.kg-1 used as the second arm intervention
62775782|NCT02385435|ACTIVE_COMPARATOR|dexmedetomidine 2μg.kg-1|Single shot Caudal dexmedetomidine 2 μg.kg-1 used as the second arm intervention
62569271|NCT02064998|EXPERIMENTAL|Crossover group 2: Control - TeleCoach|Initially a 6 week no-app control period, followed by 6-week access to the TeleCoach app, offering exercises and vignettes for reducing or abstaining from alcohol consumption.
62775783|NCT04439318|EXPERIMENTAL|Treatment (trametinib)|Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62394189|NCT01873274|ACTIVE_COMPARATOR|MK-7 containing capsule|one study group will receive daily a softgel capsule consisting of 50 μg MK-7
62569272|NCT06504979|EXPERIMENTAL|ICURA follow-up|
62569273|NCT06504979|NO_INTERVENTION|Standard Group|
62775784|NCT03189966|EXPERIMENTAL|Group T|Patients in transversalis fascia plane block group(Group T) will receive ultrasound-guided transversalis fascia plane block using0.3% ropivacaine(0.8 ml/kg) after general anesthesia
62000158|NCT04698356|EXPERIMENTAL|Validation of auditory-cognitive training paradigm|In order to provide maximal speech-in-noise training benefit for older, normal-hearing adults, a validation of our new training materials is required. The investigators will evaluate the translated and adjusted sentences (based on the Nottingham UK PLUS training paradigm), the adaptive procedure, and the short-term memory component, in young, normal-hearing adults (18-30 years). Based on the results of this pilot study, the investigators can further optimize the sentences and procedures to be used during the training paradigm for older adults.
62000159|NCT01041625|EXPERIMENTAL|Apremilast|Apremilast 20 mg PO administered BID over 12 weeks
62000160|NCT06407089|EXPERIMENTAL|Spinertial Group (SG)|"Endurance training program of deep cervical flexors and deep cervical extensors with Spinertial device for treatment.~Endurance training program of deep cervical flexors and deep cervical flexors with Spinertial device for treatment."
62000161|NCT06407089|NO_INTERVENTION|Control Group (CG)|The subject continues activities of daily living without intervention.
62000162|NCT03615950||Intervention Group|30 Children with eosinophilic esophagitis who are started on swallowed corticosteroids by their clinical provider.
62000163|NCT03615950||Control Group|30 children, 5-12 years of age, not taking swallowed corticosteroids. Age and sex matched 1:1 with intervention group.
62394190|NCT01873274|ACTIVE_COMPARATOR|nutrient enriched yogurt with MK-7|one study group will receive daily two nutrient-enriched dairy products containing extra nutrients and omega-3 FA (fish-oil)
62569274|NCT00256412|PLACEBO_COMPARATOR|1|
62569275|NCT00256412|ACTIVE_COMPARATOR|2|Low Dose
62569276|NCT00256412|ACTIVE_COMPARATOR|3|High Dose
62569277|NCT03096314|ACTIVE_COMPARATOR|High dose vitamin D formulation|A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
62569278|NCT03096314|PLACEBO_COMPARATOR|Placebo|A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
62775785|NCT03189966|EXPERIMENTAL|Group Q|Patients in quadratus lumborum block group（Group Q） will receive ultrasound-guided quadratus lumborum block using0.3%ropivacaine(0.8 ml/kg).after general anesthesia.
62000164|NCT02388984|EXPERIMENTAL|Compound danshen dripping pills|Compound danshen dripping pills,20pills,tid. Duration: 24 weeks.
62000165|NCT02388984|PLACEBO_COMPARATOR|Placebo|Placebo,20pills,tid. Duration: 24 weeks.
62000166|NCT06263335|EXPERIMENTAL|Interventional Group (Receiving Mindfulness Based Intervention)|after the young adults have been randomized into interventional and control groups based on high levels of psychological distress, SI and NSSI, n=30 participants from this group would receive the mindfulness based intervention.
62000167|NCT06263335|NO_INTERVENTION|Control Group (No Intervention)|A wait list control group of n=30 randomized participants from the initial cohort would be in this group and receive no intervention, until the trial is completed.
62185462|NCT04721899||Vitamin D- infertility|All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.
62185463|NCT05998330|NO_INTERVENTION|Usual Hepatology Care|Usual hepatology care
62394191|NCT04301271|EXPERIMENTAL|Simvastatin|Simvastatin and Escitalopram
62394192|NCT04301271|PLACEBO_COMPARATOR|Placebo|Placebo and Escitalopram
62394193|NCT06331429|NO_INTERVENTION|Control Group|Patients who receive the treatment program, will previously constitute their own control group (waiting list control group).
62569279|NCT06319989|OTHER|Biplane Ultrasound|The intervention group will receive caudal epidural block under the guidance of biplane ultrasound.
62000168|NCT04763499|EXPERIMENTAL|Freeze dried strawberry powder|"39g of freeze dried strawberry powder, which represents three daily servings of strawberries.~The powder will be mixed in one cup of water."
62185464|NCT05998330|EXPERIMENTAL|Usual Hepatology Care with Early Palliative Care|Usual hepatology care with early palliative care
62185465|NCT04224454||Primary Sjögren's syndrome|111 consecutive patients with primary Sjögren's syndrome (European-American 2002 criteria)
62185466|NCT00003477|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62185467|NCT01388062|EXPERIMENTAL|virus detection|
62775786|NCT03189966|NO_INTERVENTION|Group C|Patients in the third group as control (Group C)receive no nerve block.Patients will be extubated based on clinical criteria.
62775787|NCT05492916|EXPERIMENTAL|INCLUDE|Participants will receive one Diabetes Prevention Program (DPP) video per week for 24 weeks. Additionally, community health workers (CHWs) will help participants to join the community-supported agriculture (CSA) program and assess and address other social determinants of health (SDOH) barriers.
62775788|NCT05492916|NO_INTERVENTION|CONTROL|Participants will receive the standard of usual care.
62775789|NCT05629507|EXPERIMENTAL|Virtual Reality|In the virtual reality arm, patients will use a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and High Definition audio stereo.
62185468|NCT02859064|EXPERIMENTAL|Lanreotide/Y-90 microspheres|"Lanreotide: 120 mg by subcutaneous injection (SQ) on Day 1 of every cycle (every 28 days) in combination with SIR-Spheres therapy.~Y-90 (Yttrium-90) microspheres \[SIR-Spheres therapy\]: dose and treatment day to be determined by treating radiation oncologist."
62185469|NCT02462343|OTHER|2 minute walk test|
62185470|NCT02462343|OTHER|6 minute walk test|
62185471|NCT03014908||NMR-T1DM|type 1 diabetic children and adolescents
62185472|NCT03014908||NMR-C|non-diabetic children and adolescents
62185473|NCT00135577|EXPERIMENTAL|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally once in the morning and once in the evening.
62185474|NCT00135577|EXPERIMENTAL|Alvimopan 1 mg Once Daily (QD)|"Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg in the morning and received placebo in the evening.~Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan in the morning and placebo in the evening for 3 days, then 1 mg of alvimopan in the morning and placebo in the evening for the remaining 3 weeks."
62185475|NCT00135577|EXPERIMENTAL|Alvimopan 1 mg Twice Daily (BID)|"Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg once in the morning and once in the evening.~Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan once in the morning and once in the evening for 3 days, then 1 mg of alvimopan once in the morning and once in the evening."
62000169|NCT04763499|PLACEBO_COMPARATOR|control powder|39 g of a powder that matches the sugar and caloric content of the experimental powder. The powder will be mixed in one cup of water.
62000170|NCT06008613|EXPERIMENTAL|Intervention|Electromagnetic guidance and tracking as an adjunct to and confirmed by fluoroscopic imaging to be used with Cook Zenith Flex AAA Endovascular Graft.
62185476|NCT00135577|PLACEBO_COMPARATOR|Placebo|Placebo was administered orally once in the morning and once in evening.
62185477|NCT00723385|PLACEBO_COMPARATOR|Placebo|Placebo administration for 12 weeks with repeated 25-OH D determinations over 12 weeks, dietary, sunshine questionnaire recording
62185478|NCT00723385|EXPERIMENTAL|Vitamin D|Vitamin D (1000 or 2000 IU/day)
62185479|NCT05473936|NO_INTERVENTION|Control Arm - Standard Treatment (Group 1)|"The standard care for the control arm will be: the LACDHS Vaccine Hesitancy Outreach Group calling patients once every month to remind patients of the need to be vaccinated and tested if needed. During the duration of the six weeks, the study participants will be exposed to the call from the LACDHS Vaccine Hesitancy Outreach Group.~Participants will receive two phone calls six-weeks apart, where they will complete a pre-survey in the first phone call, and 2 surveys (post-survey and CDE survey) in the second phone call. The survey will measure their trust in medical institutions, rate their self-efficacy, and intention, knowledge, and perceptions on COVID-19 testing and vaccination."
62569280|NCT06319989|OTHER|Single plane Ultrasound|The procedures for patients in the control group will be guided by conventional single-plane ultrasound.
62775790|NCT05629507|NO_INTERVENTION|Narrative Medicine|In narrative medicine arm, patients will express their subjective experience regarding to the chemotherapy through writing. The experience will be written in free form by the patient and will cover both the cognitive, emotional and perceptual aspects. A nurse will always be available to guide the patient in the activity of expressing cognitive, emotional and perceptual contents.
62775791|NCT05629507|NO_INTERVENTION|Standard Care|In control arm, patients will be free to choose different activities during the infusion of chemotherapy, such as conversation with nurses, doctors, trainees, reading, writing, watching television, listening to music or videos on their smartphone.
62775792|NCT05229250||Healthy subjects|Subjects without FLIA
62775793|NCT05229250||Patient subjects|Subjects with FLIA
62775794|NCT05501795||WaveLight® FS200 femtosecond laser|Flap creation with the WaveLight® FS200 femtosecond laser
62185480|NCT05473936|EXPERIMENTAL|Intervention Arm - CHW-led curriculum (Group 2)|Participants assigned to the intervention group will complete the same activities as Group 1 and be asked to participate in the virtual intervention, consisting of six-weekly group classes via Zoom, and six-weekly personalized teleconsultations (via phone call or Zoom) at a suitable time for both participants and CHWs. Study participants will receive 6 linguistically and ethnically concordant weekly two-hour group classes and personalized teleconsultations led by CHWs. The total time commitment for Group 2 will be a maximum of 20 hours (6 two-hour group classes, + 6 one hour personal session, + 2 half hour phone calls), over the next 6 weeks.
62185481|NCT06294197|EXPERIMENTAL|Pelvic Floor Exercises|In the intervention types, women are given training on pelvic floor exercises, that they can perform in the form of home exercises for 12 weeks. Before starting pelvic floor exercises therapy, a physiotherapist who specializes in pelvic floor compatibility will provide information about the location of the pelvic floor muscles through anatomical models and their effect on healthy, vaginal and sexual function. The effects of pelvic floor exercises on this system will be explained on an individual basis, and normal palpation is required to demonstrate their correct execution of contraction of the pelvic floor muscles. Participants will be taught how to contract and contract different muscles, such as the abdominal muscles, hip muscles, and gluteal muscles, or how to avoid pelvic tilt during contraction, and how to perform both rapid and sustained contractions.
62185482|NCT06294197|NO_INTERVENTION|Control|No intervention will be made in the control unit.
62185483|NCT05849324|EXPERIMENTAL|Straight needle|25 gauge straight chiba needle
62185484|NCT05849324|ACTIVE_COMPARATOR|Bent needle|25 gauge bent chiba needle
62185485|NCT02187289|ACTIVE_COMPARATOR|Standard care|Weeks 1-12, Standard Care only (Compression Sleeve, daytime wear)
62185486|NCT02187289|EXPERIMENTAL|Standard Care plus Night-time Compression Bandages|Weeks 1 - 12, Daytime compression sleeve plus night-time compression by self-administered or assisted multi-layered Compression Bandages.
62185487|NCT02187289|EXPERIMENTAL|Standard Care Plus Night-time Compression System Garment|Weeks 1 - 12, Standard care (day-time sleeve) plus night-time use of a custom-made Night-time Compression System Garment
62185488|NCT04657562||De novo renal/liver transplant recipients|The group of 40 consecutive adult (age \> 18 years) male and female recipients of deceased kidney or liver transplant from the Regional Qualification Center (Warsaw, Poland).
62775795|NCT05380167|EXPERIMENTAL|BRJ Nitrate|This arm consumed daily for 12 weeks a 70 mL bottle of beetroot juice containing 380 mg of nitrate.
62394194|NCT06331429|EXPERIMENTAL|Experimental group|Adolescents who receive the treatment program, will previously constitute their own control group (waiting list control group). Thus, diagnostic measures will be obtained in all of them in an initial evaluation (T1), and after 6 weeks of this assessment the treatment program will be started. In the first contact session at 6 weeks after T1 all adolescents will be re-assessed (T2) and after this the treatment program will be started (within an estimated time of 15 days maximum from this second pre-treatment evaluation, the estimated duration of treatment being 6 weeks). After the completion of the serious game, a new asssesment pass will be performed (T3) in order to assess the post-treatment change. Thus, the estimated time between T2 and T3 will be equivalent to that between T1 and T2, being 6 weeks.
62775796|NCT05380167|PLACEBO_COMPARATOR|BRJ Placebo|This arm consumed daily for 12 weeks a 70 mL bottle of beetroot juice containing 0 mg of nitrate.
62185489|NCT04657562||Random renal transplant recipients|The group of 300 random adult (age \> 18 years) male and female recipients of deceased kidney attending the local outpatient clinic.
62185490|NCT04657562||Renal transplant recipients experiencing graft rejection|The group of 40 consecutive adult (age \> 18 years) male and female recipients of deceased kidney experiencing acute rejection of the renal allograft.
62185491|NCT03041298||All included patients|All included patients underwent MR mammography with Dotarem
62185492|NCT05256810|EXPERIMENTAL|Part A: ALN-XDH|A single dose of ALN-XDH administered by subcutaneous (SC) injection.
62775797|NCT01012323|EXPERIMENTAL|NewGam|Participants received NewGam 200-800 mg/kg intravenously every 3 weeks (17 infusions) or 4 weeks (13 infusions) for 1 year.
62185493|NCT05256810|PLACEBO_COMPARATOR|Part A: Placebo|A single dose of placebo administered by SC injection.
62185494|NCT05256810|EXPERIMENTAL|Part B: ALN-XDH Single Dose|A single dose of ALN-XDH administered by SC injection.
62185495|NCT05256810|EXPERIMENTAL|Part B: ALN-XDH Multiple Dose|Multiple doses of ALN-XDH administered by SC injection.
62185496|NCT05256810|PLACEBO_COMPARATOR|Part B: Placebo|Multiple doses of placebo administered by SC injection.
62775798|NCT05372549|OTHER|Oncology preservation|
62185497|NCT05256810|EXPERIMENTAL|Part C: ALN-XDH|A single dose of ALN-XDH administered by SC injection.
62775799|NCT05372549|OTHER|Social (elective) preservation|
62185498|NCT05256810|PLACEBO_COMPARATOR|Part C: Placebo|A single dose of placebo administered by SC injection.
62185499|NCT02628483|EXPERIMENTAL|Ultimate Omega|5 capsules of Ultimate Omega fish oil daily in the morning with food
62185500|NCT02628483|ACTIVE_COMPARATOR|Meg-3|5 capsules of Meg-3 fish oil daily in the morning with food
62185501|NCT03539029||Control group|age and sex matched healthy control persons
62775800|NCT04474314|EXPERIMENTAL|Higher dose IMR-687|Oral administration of once daily IMR-687
62775801|NCT04474314|EXPERIMENTAL|Lower Dose IMR-687|Oral administration of once daily IMR-687
62775802|NCT04474314|PLACEBO_COMPARATOR|Placebo|Oral administration of once daily Placebo
62775803|NCT03951558|EXPERIMENTAL|Diet for calciuria prevention|placebo capsules and a strict eating plan will be given. The placebo will look similar to that of hydrochlorothiazide and will be prepared in the Nephrology Research Laboratory by Biol. Ana María Hernández Sánchez and Quim Lourdes Ortiz.
62775804|NCT03951558|PLACEBO_COMPARATOR|hydrochlorothiazide for calciuria prevention|recommendations for water intake and decrease in salt intake will be given.
62775805|NCT05848362|OTHER|SINGLE GROUP|This is a quasi-experimental study with a single group and simultaneous (matched) sample will conduct with the purpose of to determine whether glucose values are different for a bedside glucose meter compared to the main clinical laboratory and whether the blood sampling site has a significant effect on glucose values.
62791665|NCT03505203|EXPERIMENTAL|Sleep Soothe|An intervention in which parents are given information on how to respond to their baby's cues related to sleeping and fussiness.
62185502|NCT03539029||Surgery|patients with ankle fracture treated surgically
62775806|NCT06439303||Patients with moderate or severe tobacco use disorder.|"Patients hospitalized at the IRE anti-smoking center, National Cancer Institute Regina Elena, suffering from moderate or severe tobacco use disorder, who are prescribed pharmacological therapy with Cytisine 1.5 mg."
62185503|NCT03539029||Conservative treatment|patients with ankle fracture treated conservatively
62185504|NCT05318235||Children|Children between 6 weeks and 4 years of age who have a older sibling or attend day care
62185505|NCT02869048||ALS patients|Patients diagnosed with ALS will be included in this group. Blood and spinal fluid samples will be stored in biobank and later analyzed. A subset of this group (20 ALS patients) will give blood and spinal fluid every 6 months during progression of the disease. A subset of 10 will donate a muscle biopsy.
62185506|NCT02869048||Control group with patients with other neurological disease|Patients referred to hospital with symptoms of acute or chronic headache.
62185507|NCT02869048||Neurologically healthy control group|Patients having orthopaedic surgery performed in spinal anaesthesia.
62185508|NCT03194945|ACTIVE_COMPARATOR|Linagliptin plus metformin|CSII followed by Linagliptin 5 mg Qd + Metformin 0.5 g bid for 48 weeks
62185509|NCT03194945|ACTIVE_COMPARATOR|Linagliptin|CSII followed by Linagliptin 5mg Qd for 48 weeks
62185510|NCT03194945|ACTIVE_COMPARATOR|Metformin|CSII followed by Metformin 0.5 bid for 48 weeks
62185511|NCT03194945|ACTIVE_COMPARATOR|Lifestyle alone|No OHA is given after CSII
62394195|NCT06423521|EXPERIMENTAL|SOC-RPM|SOC-RPM arm, would follow the Standard of Care (SOC) for the first six months and then receive the Remote Patient Monitoring (RPM).
62394196|NCT06423521|EXPERIMENTAL|RPM-SOC|RPM-SOC arm: would receive the intervention (RPM) for the first six months and then follow the SOC for the remaining six months.
62775807|NCT05348486|EXPERIMENTAL|Dose escalation|Dose escalated radiotherapy protocol: 75,9 - 79,2 Gy in 33 fractions GTV hypoxic or any hypoxic LN \> 2cm - PTV (0mm): dose 75,9 - 79,2 Gy/33 (Contours must be subtracted and reduce by 3mm in case of close relation to the skin, bones or large blood vessels) GTV primary - CTV - PTV (5+5mm): for dose 70 Gy/33 LN low risk (for elective irradiation) - CTV - PTV (3mm-5mm): for dose 54 Gy/33
62394197|NCT03749031|PLACEBO_COMPARATOR|Orange juice only|16 oz. orange juice per day for 4 weeks
62394198|NCT03749031|EXPERIMENTAL|orange juice + orange Pomace|16 oz. orange juice + orange Pomace per day for 4 weeks
62394199|NCT03749031|PLACEBO_COMPARATOR|Apple juice only|16 oz. apple juice per day for 4 weeks
62394200|NCT03749031|EXPERIMENTAL|Apple Juice + Apple Pomace|16 oz. apple juice + apple Pomace per day for 4 weeks
62185512|NCT02141971||Non-demented; Ages 30-40|Four non-demented Down syndrome patients between the ages of 30-40 years old
62185513|NCT02141971||Non-demented; Ages 40-50|Four non-demented Down syndrome patients between the ages of 40-50 years old
62185514|NCT02141971||Demented; Ages 50-60|Four demented Down syndrome patients between the ages of 50-60 years old
62185515|NCT04639986|EXPERIMENTAL|Sacituzumab Govitecan-hziy|Participants will receive Sacituzumab Govitecan-hziy 10 mg/kg on Days 1 and 8 of a 21-day cycle.
62185516|NCT04639986|ACTIVE_COMPARATOR|Treatment of Physician's Choice (TPC)|"Participants will receive recommended doses and schedules as per package insert depending on region.~* Eribulin (1.4 mg/m\^2 of eribulin mesylate or 1.23 mg/m\^2 of eribulin on Days 1 and 8 of a 21-day cycle)~* Capecitabine (1000 to 1250 mg/m\^2 twice daily on Days 1 to 14 of a 21-day cycle)~* Gemcitabine (800 to 1200 mg/m\^2 on Days 1, 8, and 15 of a 28-day cycle)~* Vinorelbine (25 mg/m\^2 on Day 1 weekly)"
62185517|NCT00461643|ACTIVE_COMPARATOR|Strategy A|clomiphene followed by clomiphene plus metformin followed by gonadotropins
62185518|NCT00461643|ACTIVE_COMPARATOR|Strategy B|metformin followed by metformin plus clomiphene followed by gonadotropins
62185519|NCT00461643|ACTIVE_COMPARATOR|Strategy C|metformin plus clomiphene followed by gonadotropins
62185520|NCT04458220||difficult airway|C-L≥Ⅲ grade
62185521|NCT04458220||none difficult airway|C-L\<Ⅲgrade
62185522|NCT03569605|ACTIVE_COMPARATOR|Self-help|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group.
62185523|NCT03569605|EXPERIMENTAL|Intervention|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group, behavioral lessons, adaptive physical activity goals, tailored feedback summaries, and text messages.
62185524|NCT01018732|EXPERIMENTAL|I: MenACWY-CRM vaccine|Subjects had been given one dose of Meningococcal ACWY (MenACWY) vaccine conjugated to CRM197 (cross-reactive material-mutant of diptheria toxin) 5 years ago. All subjects were given one dose of the Men ACWY in the present study.
62185525|NCT01018732|EXPERIMENTAL|II: Licensed Polysaccharide Meningococcal vaccine|Subjects had been given one dose of a licensed MenACWY polysaccharide meningococcal vaccine (Menomune) 5 years ago. All subjects were given one dose of Men ACWY vaccine in the present study.
62394201|NCT00863564|ACTIVE_COMPARATOR|Whey Isolate|
62394202|NCT00863564|ACTIVE_COMPARATOR|Caseine|
62394203|NCT00863564|ACTIVE_COMPARATOR|Cod|
62394204|NCT00863564|ACTIVE_COMPARATOR|Gluten|
62775808|NCT05348486|NO_INTERVENTION|Standard fractionation|Standard fractionation regimen: 70 Gy/54 Gy in 33 fractions GTV primary - CTV - PTV (5+5mm): for dose 70 Gy/33 GTV LN bulky (\> 3cm) - PTV (5mm): for dose 70 Gy/33 LN low risk (for elective irradiation) - CTV - PTV (3mm-5mm): for dose 54 Gy/33
62775809|NCT02453555|ACTIVE_COMPARATOR|Linagliptin|patient to receive 5 mg linagliptin once daily
62775810|NCT02453555|EXPERIMENTAL|Empagliflozin + linagliptin low dose|patient to receive one tablet once daily
62584799|NCT04590911|EXPERIMENTAL|CEP intervention|Cognitive Enrichment Program (CEP) : tailored for individuals who sustain a TBI in later adulthood. The CEP is a 12-week multimodal intervention structured into three modules designed to simultaneously address cognitive problems resulting from TBI, as well as age-related cognitive issues in the following domains: self-awareness, attention and memory, and executive functions.
62775811|NCT02453555|EXPERIMENTAL|Empagliflozin + linagliptin high dose|patient to receive one tablet once daily
62775812|NCT02453555|PLACEBO_COMPARATOR|Linagliptin placebo|
62775813|NCT02453555|PLACEBO_COMPARATOR|Empagliflozin + linagliptin high dose placebo|
62185526|NCT01018732|EXPERIMENTAL|III: Meningococcal Naive|Subjects were age matched with groups 1 and 2 (age inclusive: 16 years to 23 years) and enrolled at visit 1 and given one dose of Men ACWY vaccine during the present study.
62185527|NCT04325009|EXPERIMENTAL|RTRT|"R: Lipitor 80mg Tab T: Dong-A Atorvastatin 80mg Tab"
62775814|NCT02453555|PLACEBO_COMPARATOR|Empagliflozin + linagliptin low dose placebo|
62775815|NCT06207734|ACTIVE_COMPARATOR|Control arm CDK4/6 continuation|"* Continuation of CDK4/6 inhibitor treatment~* Continuation of endocrine treatment"
62000171|NCT02547662|EXPERIMENTAL|Treatment (ixazomib citrate, pomalidomide, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62000172|NCT01209910|EXPERIMENTAL|free water|The subjects in this arm will be able to drink water followings study rules.
62000173|NCT01209910|NO_INTERVENTION|Control|These subjects will be observed during the study.
62000174|NCT05940935||Group 1|Patients who have used Zonisamide or Topiramate
62000175|NCT05940935||Group 2|Patients who have used Lacosamide
62000176|NCT05940935||Group 3|Patients who have used Carbamazepine
62185528|NCT04325009|EXPERIMENTAL|TRTR|"R: Lipitor 80mg Tab T: Dong-A Atorvastatin 80mg Tab"
62185529|NCT06486727|EXPERIMENTAL|675-nm laser (RedTouch)|Paramete: Moveo, power 5 W, Energy/DOT 500 mJ/DOT then Standard, power 4 W, spacing 2000 μm, 1 pass per side for 4 times with 4-week interval
62000177|NCT05940935||Group 4|Patients who have used levetiracetam
62000178|NCT03671902|OTHER|Lower Body Negative/Positive Pressure|
62000179|NCT04900077|EXPERIMENTAL|treatment group|treated by Carriere® Motion™ Appliance
62000180|NCT04900077|NO_INTERVENTION|control group|no treatment
62000181|NCT00934544|EXPERIMENTAL|Ruxolitinib|5 mg tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule
62185530|NCT01382498|PLACEBO_COMPARATOR|Placebo|Placebo tablets will be administered to the patients in Placebo arms daily for three months.
62185531|NCT01382498|EXPERIMENTAL|Calcium dobesilate|Calcium dobesilate as 500 mg tablets will be administered once to the patients daily.
62185532|NCT05428111|ACTIVE_COMPARATOR|control|healthy control individuals
62185533|NCT05428111|ACTIVE_COMPARATOR|case|Newly diagnosed and under treatment cases of acute lymphoblastic leukemic
62185534|NCT00469456|ACTIVE_COMPARATOR|1|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
62394205|NCT05645731||Lung cancer patient|Lung cancer patients or lung cancer survivors willing to refer close contacts for lung cancer screening
62394206|NCT05645731||Referred participants|Participants referred to the study by close contacts living with lung cancer.
62394207|NCT01655368|EXPERIMENTAL|Interventional: STEM modules|8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module (for schizophrenia or depression)
62394208|NCT01655368|OTHER|Interventional Control|11 sessions + 1 booster session of psychoeducation for schizophrenia or depression)
62394209|NCT02982122|EXPERIMENTAL|CPPopt intervention group|Patients are managed according to Brain Trauma Foundation guidelines, except for CPP where the CPPopt is targeted.
62394210|NCT02982122|ACTIVE_COMPARATOR|CPP control group|"Patients are managed according to Brain Trauma Foundation guidelines with CPP between 60 and 70 mmHg.~CPPopt information is recorded but hidden for the treating clinicians."
62394211|NCT04357834||Smartwatch group|
62394212|NCT06242886|EXPERIMENTAL|Oxytocin massage|The mother was positioned on a chair with her breasts bare and free, placing her arms on the table at her height and her head on her arms. The researcher who applied the massage applied the massage up and down to either side of the spine between the mother's scapula bones with her thumbs in front and pressing her fists tightly and making small circular movements with her thumbs for three minutes. The mothers received four oxytocin massages over the course of 24 hours.
62394213|NCT06242886|EXPERIMENTAL|Breast massage|The mother's upper clothes were removed by the researcher. With the palms of the hand the breast grasped from the bottom and top. The hands were advanced by pressing slowly from the base of the nipple towards the nipple. With the palms, the breast was grasped from the bottom and top and gently pressed. Using fingertips, the breast was scanned by massaging from the base of the nipple to the nipple in circular movements. The mothers received breast massage four times over the course of 24 hours.
62394214|NCT06242886|NO_INTERVENTION|Control|No intervention
62394215|NCT02434640|EXPERIMENTAL|BAY1128688 [Dose1]|BAY1128688 dose level 1
62394216|NCT02434640|EXPERIMENTAL|BAY1128688 [Dose2]|BAY1128688 dose level 2
62394217|NCT02434640|EXPERIMENTAL|BAY1128688 [Dose3]|BAY1128688 dose level 3
62394218|NCT02434640|EXPERIMENTAL|BAY1128688 [Dose4]|BAY1128688 dose level 4
62394219|NCT02434640|PLACEBO_COMPARATOR|Placebo|Placebo to match arm 1,2, 3 and 4
62394220|NCT02347540||Women with a history of preeclampsia (cases)|"Cases: women with a history of preeclampsia. Measurements will be performed in a postpartum interval from 0.5 years until 30 years after the first complicated pregnancy.~This group will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure."
62394221|NCT02347540||Women with a history of uncomplicated pregnancy (controls)|Controls include women with a history of uncomplicated pregnancies. The controlgroup will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure.
62394222|NCT02000674|ACTIVE_COMPARATOR|Administration of Succinylcholine|Intubation after IV administration of Succinylcholine 1mg/kg
62775816|NCT06207734|EXPERIMENTAL|Experimental arm CDK4/6 inhibitor discontinuation|"* Discontinuation of CDK4/6 inhibitor treatment~* Continuation of endocrine treatment"
62775817|NCT04114110||Admitted inpatients|no intervention
62775818|NCT04114110||Staff with RTLS badges|no intervention
62185535|NCT00469456|PLACEBO_COMPARATOR|2|Placebo oral administration twice daily for 12 weeks
62185536|NCT02872311|ACTIVE_COMPARATOR|High Dose Influenza Vaccine|This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
62185537|NCT02872311|ACTIVE_COMPARATOR|Adjuvanted Influenza Vaccine|This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
62185538|NCT02872311|ACTIVE_COMPARATOR|Standard Dose Influenza Vaccine+HD|This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study.
62185539|NCT02872311|ACTIVE_COMPARATOR|Standard Dose Influenza Vaccine +Adj|This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
62185540|NCT02872311|ACTIVE_COMPARATOR|Standard Dose Influenza Vaccine+Recomb|This group will be administered a standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
62185541|NCT05761912||Ultrasound fusion targeted biopsy|Prostate ultrasound had abnormal echo and radiomics analysis showed high scores
62185542|NCT05761912||mpMRI cognitive fusion targeted biopsy|PI-RADS score ≥ 3
62394223|NCT02000674|EXPERIMENTAL|Administration of Rocuronium|Intubation after IV administration of Rocuronium 1.2 mg/kg
62775819|NCT04015674|EXPERIMENTAL|Exercise group|Patients will remain in supine position for 5 minutes to measure their vascular caliber of the AVF by echography. After, will be instructed to perform 30 minutes on stationary bicycle (Model Monark). The AVF vascular caliber will be measured during aerobic exercise. Because it is a cross-over trial, participants will perform the other arm after 7 days.
62394224|NCT06305767|EXPERIMENTAL|Adjuvant Cohort: Pembrolizumab + V940|Adjuvant Cohort participants receive adjuvant treatment with up to 9 cycles of pembrolizumab plus up to a total of 9 doses of V940. V940 doses may begin as soon as Day 22 of Cycle 1. The total duration of treatment is up to approximately 13 months.
62394225|NCT06305767|ACTIVE_COMPARATOR|Adjuvant Cohort: Pembrolizumab + Placebo|Adjuvant Cohort participants receive adjuvant treatment with up to 9 cycles of pembrolizumab plus up to a total of 9 doses of placebo. Placebo doses may begin as soon as Day 22 of Cycle 1. The total duration of treatment is up to approximately 13 months.
62394226|NCT06305767|EXPERIMENTAL|Perioperative Cohort: Pembrolizumab + V940 + EV and Surgery|Participants will receive neoadjuvant treatment with up to 4 cycles of pembrolizumab plus EV and 1 to 4 doses of V940, followed by radical cystectomy \[RC\] plus pelvic lymph node dissection \[PLND\], and then adjuvant treatment with up to 13 cycles of pembrolizumab plus up to 5 cycles of EV and 5 to 8 doses of V940 (for a total of 9 neoadjuvant plus adjuvant V940 doses), or until any of the protocol-specified criteria for discontinuation of study intervention are met. The total duration of treatment is up to approximately 16 months.
62394227|NCT00542321|EXPERIMENTAL|Kinetic Therapy Bed|Kinetic Therapy Bed: Continuous automated turning to 45 degrees with head of the bed elevated 30 degrees or more for up to 7 continuous days
62394228|NCT00542321|ACTIVE_COMPARATOR|Manual Turn|Manual Turn: lateral rotation every 2 hours from back to left to back to right to back, with \>/= 45 degree lateral rotation angle and 30 degree head of bed elevation
62394229|NCT05222516|EXPERIMENTAL|OM-85|Daily administration of OM-85 (Broncho-Vaxom) 3.5 mg capsules
62394230|NCT05222516|PLACEBO_COMPARATOR|Placebo|Daily administration of Placebo capsules
62185543|NCT04488861||IVF-conceived|Those who have conceived by IVF (for whatever indication); target 80 participants of which it is anticipated 20 would have conceived by frozen embryo transfer IVF.
62185544|NCT04488861||Spontaneously conceived|Those who have conceived spontaneously (within 12 months and without use of hormonal or other contraception); target 20 participants
62394231|NCT02984631|OTHER|Preventing pulm HTN during exercise 2nd|Standard of care invasive cardiopulmonary exercise test (CPET) followed by CPET with pre-load control.
62185545|NCT04488861||Ovulation induction-conceived|Those who have conceived by ovulation induction (after more than 12 months); target 20 participants.
62185546|NCT00478647|EXPERIMENTAL|GA-GCB (velaglucerase alfa)|15-60 U/kg, every other week via intravenous infusion
62394232|NCT02984631|OTHER|Preventing pulm HTN during exercise 1st|Pre-load control of invasive cardiopulmonary exercise test (CPET) followed by standard CPET.
62775820|NCT04015674|ACTIVE_COMPARATOR|Control group|The patients will perform 30 minutes of rest in a chair and the measurements will be performed in the same moments established by the exercise group. Because it is a cross-over trial, participants will perform the other arm after 7 days.
62775821|NCT01765725|NO_INTERVENTION|Control group|The control group will be offered to take part in the patient education group as soon as they have completed the last outcome evaluations
62775822|NCT01765725|EXPERIMENTAL|Patient education program|Patient education program
62775823|NCT03404856|OTHER|Treatment with ORL-1G - D-galactose|
62791666|NCT03505203|ACTIVE_COMPARATOR|Sleep Safe|An intervention in which parents are given information on a safe sleep environment, as well as other strategies to keep baby safe
62791667|NCT04274621||Patients, family members of patient, medical staff|
62185547|NCT05731505|EXPERIMENTAL|THE EFFECT OF A SUPPORTIVE APPROACH STRUCTURED ACCORDING TO KOLCABA'S COMFORT THEORY|The study group consisted of parents who were given a supportive approach structured according to Kolcaba's Comfort Theory by the researcher.
62394233|NCT05548270|EXPERIMENTAL|DPI-386|Each 0.12 gram of the gel contains0.2 mg of scopolamine HBr
62569281|NCT05031611|EXPERIMENTAL|Intuitive Eating Treatment|"The intervention was a novel 10-week program aimed at promoting IE through pre-recorded videos, reading material, and bi-weekly discussion sessions. The intervention introduced the following modules sequentially: Unconditional Permission to Eat, Reliance to Hunger and Fullness Cues, Body-Food Choice Congruence, Gentle Nutrition, and Joyful Movement.~Every other week, a new module was introduced. Participants were taught the concept of this module through video and reading, then prompted to practice it over the week. On opposite weeks, the module last introduced was discussed in greater detail through video, and participants were given the opportunity to discuss amongst one another and have all questions answered by the researchers."
62584800|NCT04590911|NO_INTERVENTION|Usual care|Usual care : interventions within a holistic interdisciplinary rehabilitation program focused on resuming daily activities and social roles, if needed, as determined by treating physician; does not include any form of cognitive rehabilitation.
62185548|NCT05731505|EXPERIMENTAL|KOLCABA COMFORT THEORY APPLİED TO PARENTS OF CHİLDREN WİTH CEREBRAL PALSY|During the training given by the researcher, the children continued their routine education in the rehabilitation center. Although the education to be done is for the child and their parents, the education was given directly to the parents, since the mental perception levels of the children may not be sufficient and mostly children with CP live dependent on their parents. The parent who will be involved in the research is the primary caregiver who is most interested in the child.
62185549|NCT00510146|EXPERIMENTAL|Olanzapine|During double-blind treatment, participants receive olanzapine at a dose of 5 milligram (mg) which is increased to 10 mg per day no later than 3-7 days after randomization (Baseline). Subsequent dose increases above 10 mg (up to a maximum of 20 mg per day) are permitted in 5 mg per day increments, based upon tolerability and symptoms. Dosing may be decreased by any number of decrements, however dosing below 5 mg requires study discontinuation.
62394234|NCT05548270|PLACEBO_COMPARATOR|Placebo|Placebo Nasal Gel (0.12 g)
62394235|NCT04797676||EUS-FNB group|Each patient participated in the EUS-FNB group and the surgery group. The procedure of EUS-FNB with wet suction technique is as follow: before the needle was inserted into the biopsy channel, the stylet was removed, and the needle was flushed with saline solution until the fluid dripped out of the needle tip. The air column was replaced with the fluid. A 10-mL syringe was prefilled with 2 mL of saline solution, and the valve was closed. The syringe was loaded to the 5-mL position (i.e. a 3-mL vacuum) and then attached to the proximal port and used for biopsy after inserting into the biopsy channel and puncturing the lesion. Each patient was performed 1-2 passes to obtain specimens for subsequent experiments.
62394236|NCT04797676||surgery group|Each patient participated in the EUS-FNB group and the surgery group. The patient underwent EUS-FNB with wet suction technique first, followed by surgery (palliative surgery without excising tumor is not included) for pancreatic cancer. According to the size of the specimen, 0.5cm3-1cm3 tumor specimen was used for subsequent experiments.
62394237|NCT06238882|EXPERIMENTAL|Intervention|Patients will be given patches of nitroglycerin during treatment with radiation therapy (30 Gy in 10 fractions, i.e. 10 days of treatment).
62185550|NCT00510146|PLACEBO_COMPARATOR|Placebo|Matching placebo administered once daily, by mouth during double-blind treatment.
62185551|NCT00510146|EXPERIMENTAL|Olanzapine (open-label treatment period)|During open-label treatment, participants randomized to placebo in double-blind period will receive olanzapine 5 mg starting at Week 6. Participants randomized to olanzapine must be at a 5 mg olanzapine dose at Week 7. Those on higher doses will be reduced between Week 6 and Week 7 (10 mg reduced to 5 mg; 15 mg reduced to 10 mg and then to 5 mg at Week 7; 20 mg reduced to 15 mg and then 10 mg to dosing at 5 mg at Week 7). Dose increases beyond Week 7 are permitted and at the investigator's discretion.
62185552|NCT02635178|EXPERIMENTAL|Active|Cognitive Anxiety Sensitivity Treatment (CAST) is a computerized treatment designed to model the educational and behavioral techniques used in anxiety treatments. The psychoeducational component focuses on the nature of stress and its effects on the mind and body. CAST was designed to dispel myths concerning the immediate dangers of stress on cognitive processes. Individuals are taught that psychological arousal from stress is not dangerous and that they may have developed a conditioned fear to these sensations, as indicated by their elevated levels of AS cognitive concerns. In addition to psychoeducation, interoceptive exposure exercises will be introduced to correct the conditioned fear response. The program will demonstrate exercises that elicit sensations consistent with AS cognitive concerns.
62185553|NCT02635178|PLACEBO_COMPARATOR|Control|The Physical Health Education Training (PHET) control condition was designed to control for the effects of general education provided in the CAST condition. Participants will be presented with information regarding the importance and benefits of maintaining a healthy lifestyle. The program will discuss diet, alcohol and water consumption, exercise, sexual health, and sleep. PHET will instruct the participant how to monitor their daily health habits in order to achieve a healthy lifestyle. PHET will take approximately 45 minutes to complete. Based on the findings of Schmidt and colleagues (in press), this intervention does not appear to exert a strong effect on AS.
62185554|NCT04692376|EXPERIMENTAL|MSCs group|MSCs group refers to treatment with mesenchymal stem cells (1×10\^6 cells/kg, intravenously) weekly for 8 doses. Besides, glucocorticoids and cyclosporine (CsA) will be used for treatment concurrently.
62185555|NCT04692376|ACTIVE_COMPARATOR|Control group|Glucocorticoids and CsA will be used for treatment.
62185556|NCT02382523|EXPERIMENTAL|Acthar injection 2 times per week|Acthar 80 unit injection 2 times a week
62185557|NCT02382523|EXPERIMENTAL|Acthar injection 3 times per week|Acthar 80 unit injection 3 times a week
62185558|NCT06307067||Pre-intervention group|patients being treated according to the old method (no dipstick as diagnostic test)
62185559|NCT06307067||Post-intervention group|patients being treated according to the new method (dipstick as diagnostic test)
62185560|NCT03182296|EXPERIMENTAL|Gestational diabetes|Women with a history of gestational diabetes
62185561|NCT03182296|ACTIVE_COMPARATOR|Control|Women without a history of gestational diabetes
62185562|NCT05758987|EXPERIMENTAL|Blended Trauma focused Cognitive Behavioral Therapy (B-Tf-CBT)|B-Tf-CBT shares key features with Internet-based CBT (I-CBT) in that it is based on a digital support accessible to the patient. This digital support equips blended treatment with the same proposed advantages as I-CBT in terms of improving treatment accessibility, adherence, and reducing therapist-time. In addition, incorporating 6 biweekly face-to-face sessions to facilitate and augment delivery of more demanding components of TF-CBT such as memory exposure.
62185563|NCT05758987|ACTIVE_COMPARATOR|Prolonged exposure|Gold standard Tf-CBT Prolonged exposure will constitute the control condition. Prolonged exposure will be delivered by trained therapists under supervision adhering to the evidence based manual delivered face-to-face over 9-15 weeks.
62185564|NCT03559829|EXPERIMENTAL|Single Arm - Intervention arm|RAPAEL Smart Glove Arm The participant will be issued a Smart Glove and a tablet preloaded with the game software. The available games provide various kinds of motion tasks such as ADL-related tasks presented in an entertaining manner. The learning schedule algorithm automatically adjusts to the optimal level of difficulty to balance challenge and motivation. The participant will be expected to use the Smart Glove at home for 60 min per day for at least 5 days per week.
62569282|NCT05031611|NO_INTERVENTION|Waitlist Control|Waitlist control group participants completed a series of questionnaires at the beginning and end of a 10-week interval, to compare changes in those who completed the intervention versus those who did not. This group was subsequently invited to participate in the intervention after their time on the wait-list.
62569283|NCT02989870|EXPERIMENTAL|SBRT, Sorafenib and Bavituximab|This will be a 3+3 design with 3 dose cohorts. Following the dose escalation phase, an additional 6 patients will be enrolled as part of the dose expansion cohort.
62185565|NCT00344032|EXPERIMENTAL|Cervarix|Subjects who received 3 doses of HPV-16/18 VLP/AS04 Vaccine (Cervarix TM) (at 0, 1, 6 months).
62185566|NCT00344032|PLACEBO_COMPARATOR|Placebo|Subjects who received 3 doses of Placebo (at 0, 1, 6 months).
62185567|NCT02676609|ACTIVE_COMPARATOR|Use of smart phone application (device glucal)|"Before each meal patient will enter in the application food intakes. Automated carbohydrate and meal insulin dose computing according to individual meal insulin/carbohydrate ratio.~During the first month, then during the second month they'll use as usual their traintement and meal without the apllication"
62569284|NCT03964675|EXPERIMENTAL|Respiratory rate measurement|Simultaneous measurement of respiratory rate using SenseGuard and Capnography
62394238|NCT06238882|NO_INTERVENTION|Control|Patients will be given a conventional treatment with radiation therapy (30 Gy in 10 fractions, i.e. 10 days of treatment).
62569285|NCT00591565|EXPERIMENTAL|1|acamprosate tablets
62569286|NCT02564653|OTHER|Technical Assistance, training,clinical reminders|provider adherence to tobacco use treatment guidelines
62569287|NCT02564653|OTHER|TTC + help of community health workers|We will assess this secondary aim by comparing smoking cessation outcomes among smokers who receive brief provider counseling alone only vs. smokers who receive provider counseling + community health worker counseling. The purpose of this assessment is to specifically analyze the impact of the community health worker counseling component of the intervention using a quasiexperimental design that leverages the larger RCT.
62569288|NCT01870011|EXPERIMENTAL|Desflurane balanced anesthesia group|
62569289|NCT01870011|ACTIVE_COMPARATOR|Propofol total intravenous anesthesia group|
62584801|NCT04349059|ACTIVE_COMPARATOR|Plant-based arm|The plant-based arm consists of 3 visits to the clinical research center, following a plant-based diet and using the Rigiscan™ device to measure the frequency, rigidity, and duration of nocturnal erections.
62185568|NCT02676609|ACTIVE_COMPARATOR|Use of smart phone application (second month)|"During the first month they'll use as usual their traintement and meal without the apllication ,then during the second month they'll use the apllicatioin.~Before each meal patient will enter in the application food intakes. Automated carbohydrate and meal insulin dose computing according to individual meal insulin/carbohydrate ratio."
62569290|NCT05150483||Patients with de novo acute hypoxemic respiratory failure|We will consider for inclusion patients presenting in the emergency department with de novo acute hypoxemic respiratory failure (AHRF). De novo AHRF is defined as the requirement of oxygen flow rate of 5 liters per minute or more to maintain SpO2 of 90% or more in a patient who does not receive long term oxygen therapy.
62185569|NCT02875002|EXPERIMENTAL|All subjects|Subjects have relapsed and refractory aggressive B- and T-cell lymphomas and will receive both Belinostat and Volasertib.
62185570|NCT02760485|EXPERIMENTAL|itacitinib + ibrutinib|
62185571|NCT06148402|EXPERIMENTAL|Fruquintinib plus camrelizumab and capecitabine|fruquintinib 5 mg once daily, 2 weeks on/1 week off, plus camrelizumab 200 mg Q3W and capecitabine 750mg/square meter twice, 2 weeks on/1 week off, q3w
62185572|NCT02471482|EXPERIMENTAL|Music First group|"Mozart music lullaby for 30 minutes with recording of cerebral oxygenation (by using Near infrared spectroscopy) and vital signs (respiratory rate, heart rate, oxygen saturations and frequency of apneic episodes continuously) followed by 10 minutes of washout period and then period of no music for next 30 minutes (with same variables recorded as outlined for music session).~This cycle is repeated every 6 hours for 24 hours. In addition, the behavioral response of baby is observed during the study period by video recording which will be in 'Mute' video mode and then reviewed by our developmental staff"
62185573|NCT02471482|EXPERIMENTAL|No Music First group|"No music in first 30 minutes of study followed by 10 minutes of washout period and then 30 minutes of Mozart music lullaby while recording same variables. This cycle was repeated every 6 hours for 24 hours."
62185574|NCT03852108|EXPERIMENTAL|Group comfort care|Socio-aesthetic care
62185575|NCT03852108|NO_INTERVENTION|Group control|Conventional care
62185576|NCT01518088|EXPERIMENTAL|Low dose dietary fiber|
62185577|NCT01518088|EXPERIMENTAL|High dose dietary fiber|
62185578|NCT01518088|PLACEBO_COMPARATOR|No added fiber|
62569291|NCT02547220|EXPERIMENTAL|Cinryze®|Participants will receive 5000 Units of CINRYZE (50 millilitre \[mL\] of CINRYZE/ 50 mL of normal saline) on Day 1 and 2500 Units of CINRYZE (25 mL of CINRYZE/ 75 mL of normal saline) on Day 3, 5, 7, 9, 11, and 13 respectively.
62569292|NCT02547220|PLACEBO_COMPARATOR|Placebo|Participants will receive 7 doses of matched placebo over 13 days of treatment.
62569293|NCT04150978|ACTIVE_COMPARATOR|5% Dextrose|the parenteral formulation as prescribed by the intensive care specialist
62569294|NCT04150978|EXPERIMENTAL|High Protein Polymeric Formula|"Procedure :~1. The daily calorie and protein prescriptions were calculated from standard recommendations (calories 25-30 kcal/kg/d, proteins 1.2-2 g/kg/d)~2. Administered as boluses via a nasogastric tube. A total of 5 aliquots were administered at 4-hourly intervals in a daily feeding period of 24 hours, with the participant positioned 30° head-up."
62000182|NCT00934544|ACTIVE_COMPARATOR|Best Available Therapy (BAT)|"Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.~Patients randomized to BAT were eligible to cross over to receive open-label ruxolitinib after a qualifying progression event, if they met the safety criteria. After the primary analysis in January 2011, patients randomized to receive BAT were allowed to cross over to receive ruxolitinib and move to the extension phase of the study without a qualifying progression event."
62000183|NCT01179971|EXPERIMENTAL|Fish oil|3g/d
62000184|NCT01179971|EXPERIMENTAL|Gamma-linolenic Acid|3g/d gamma-linolenic acid
62000185|NCT01179971|EXPERIMENTAL|Fish oil plus GLA|1.5 g/d DHA + EPA plus 1.5g/d gamma-linolenic acid
62000186|NCT01179971|SHAM_COMPARATOR|Olive oil|3 g/d olive oil
62000187|NCT00658281||OBI KV System + CBCT Scanning|Breast cancer patient radiation treatment set up using OBI KV system and CBCT scanning or CT-on-rail system to verify standard EPID for positioning.
62000188|NCT03000582|EXPERIMENTAL|Creatine monohydrate|5 gm creatine monohydrate, 1.5 gm dextrose
62000189|NCT03000582|ACTIVE_COMPARATOR|Creatine nitrate-1|1 gm creatine monohydrate, 0.5 gm nitrate, 5 gm dextrose
62000190|NCT03000582|ACTIVE_COMPARATOR|Creatine nitrate-2|2 gm creatine monohydrate, 1 gm nitrate, 3.5 gm dextrose
62000191|NCT03000582|PLACEBO_COMPARATOR|Placebo|6.5 gm dextrose
62000192|NCT06197789|EXPERIMENTAL|TPX-105|Autologous human dermal fibroblasts
62000193|NCT06197789|SHAM_COMPARATOR|Placebo|Suspension media
62000194|NCT05750303||Subacute ischemic stroke|blood sample collection to determine VEGF, IGF-1 and MMP-9 level in plasma and expression of genes VEGF, IGF-1, MMP-9 in whole blood samples
62000195|NCT05750303||No ischemic stroke and no other neurological disease control group|blood sample collection to determine VEGF, IGF-1 and MMP-9 level in plasma and expression of genes VEGF, IGF-1, MMP-9 in whole blood samples
62000196|NCT03897790||Patients under vasoconstrictor|Patients older than 65 years old and hypertensive, requiring vasoconstrictor (phenylephrine or Neosynephrine) during general anesthesia.
62000197|NCT02736656|EXPERIMENTAL|Open-Label Treatment|"Cohort 'A' Subjects 6-11 yrs of age will be treated with 100 to 400 mg SPN-812 (100 mg capsule).~Subjects 12-17 yrs of age will be treated with 100 to 600 mg SPN-812 (100, 200 mg capsule).~Subjects are given a choice to extend their participation in the study every 6 months for up to 72 months.~Cohort 'B' Subjects 4-5 yrs of age will be treated with 100 mg SPN-812 (100 mg capsule). Subjects may participate for up to 24 months."
62394239|NCT04983849|ACTIVE_COMPARATOR|hydrogel metronidazole 25%|metronidazole hydrogel in adjunct to non surgical periodontal therapy
62394240|NCT04983849|ACTIVE_COMPARATOR|scaling and root planing|the only use of scaling and root planing
62394241|NCT05500911|ACTIVE_COMPARATOR|NINA- MultiNeO NH|After the sinus lift procedure (performed with OSSIX® BONE on all study subjects) treatment group will be treated with a bioactive surfaced implant (NINA MultiNeO NH)
62569295|NCT04150978|EXPERIMENTAL|Oligomeric Formula|Similar to the High Protein Polymeric Formula Procedure
62584802|NCT04349059|ACTIVE_COMPARATOR|Animal-based arm|The animal-based arm consists of 3 visits to the clinical research center, following an animal- based diet and using the Rigiscan™ device to measure the frequency, rigidity, and duration of nocturnal erections.
62185579|NCT06538298|EXPERIMENTAL|Multimodal Exercise Program with Gamification|"The exercise program will be for 6 weeks, 3 days per week for 60 minutes per session and will consist of strengthening, balance, aerobic, flexibility, and use a computerized game to challenge thinking and reactions skills. The exercise program will also consist of non-contact boxing to improve strength, balance, and aerobic endurance.~Each exercise session will be conducted by a licensed physical therapist. The format will consist of a 10-15-minute warm-up followed by 30 minutes of moderate to vigorous circuit training using boxing drills and a computerized game called SMARTfit. SMARTfit consists of a standing computer board that allows participants to touch, punch or kick it while playing a game. At the end of the 30 minutes, participants will complete a 10-15-minute cool-down consisting of core strengthening, posture training, and hip strengthening and stretching exercises. Participants will also be instructed to maintain their normal activities outside of the study intervention."
62185580|NCT06538298|NO_INTERVENTION|Wait List Control|Participants randomly assigned to the wait list control group, will perform baseline testing and be instructed not to change their exercise habits. After 6 weeks participants will complete post-testing (described below) and be offered to be enrolled in the 6-week exercise group as described above. If participants decide to participate in the exercise group and still meet the inclusion and exclusion criteria, they will perform baseline testing, 6 weeks of exercise followed by another post-testing.
62185581|NCT02394665|EXPERIMENTAL|Group 1: SIB + IMRT|"* Simultaneous Integrated Boost (SIB) plus Fractionated Intensity Modulated Radiation therapy (IMRT), with concurrent Temozolomide therapy for 6 weeks;~* 3D MRSI during week 3, end of RT and other protocol-defined time points during adjuvant Temozolomide therapy;~* Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire administered at protocol-defined time points;~* Adjuvant Temozolomide Therapy for up to 12 cycles."
62185582|NCT02394665|EXPERIMENTAL|Group 2: SRS Boost + IMRT|"For patients with High-Risk Tumor Volumes (HTV) \<= 4cm; or multiple HTVs \<= 3 cm:~* Stereotactic Radiosurgery Boost (SRS Boost) followed one week later by Fractionated Intensity Modulated Radiation therapy (IMRT), and concurrent Temozolomide therapy for 6 weeks;~* 3D MRSI during week 3, end of RT and other protocol-defined time points during adjuvant Temozolomide therapy;~* Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire administered at protocol-defined time points;~* Adjuvant Temozolomide Therapy for up to 12 cycles."
62185583|NCT05147298|EXPERIMENTAL|Environmental group intervention (E only)|Changing the environment surrounding the PHDs making it more amenable to walking and advocating for changes to the built environment
62185584|NCT05147298|EXPERIMENTAL|Individual-level eHealth phone program intervention (I only)|An automated telephone-based physical activity program.
62185585|NCT05147298|EXPERIMENTAL|Combined group (E and I interventions)|Changing the environment surrounding the PHDs making it more amenable to walking and advocating for changes to the built environment and an automated telephone-based physical activity program.
62185586|NCT05147298|NO_INTERVENTION|Control group (no interventions)|No interventions for residents to increase activity levels.
62185587|NCT04654962||patients receiving preoperative analgesic management with anesthetic block|This cohort includes all patients that received preoperative anesthetic block for hip fracture surgery as main analgesic management during the study period.
62000198|NCT03211169|EXPERIMENTAL|Pediatric Biopsy Forceps directed biopsies|Biopsies of the stricture will be taken with Pediatric Biopsy Forceps after bile duct brushings have been obtained.
62185588|NCT04654962||patients receiving conventional preoperative analgesic management|This cohort includes all patients that received conventional preoperative analgesic management (oral, intravenous or intramuscular medication) for hip fracture surgery as main analgesic management during the study period.
62185589|NCT06385106|EXPERIMENTAL|Repetitive transcranial magnetic stimulation|participants will receive10 sessions of high frequency rTMS treatment applied to the dorsolateral prefrontal cortex over a 5 days real rTMS
62185590|NCT06385106|SHAM_COMPARATOR|Sham repetitive transcranial magnetic stimulation|participants will receive10 sessions of high frequency rTMS treatment applied to the dorsolateral prefrontal cortex over a 5 days sham rTMS
62394242|NCT05500911|ACTIVE_COMPARATOR|MultiNeO CS|After the sinus lift procedure (performed with OSSIX® BONE on all study subjects) control group will be treated with a traditional implant surface (MultiNeO CS)
62775824|NCT03626545|EXPERIMENTAL|Safety run-in part: Canakinumab+docetaxel|Participants were treated with full doses of docetaxel 75mg/m\^2 intravenous and canakinumab 200 mg subcutaneous on Day 1 of each 21-Day cycle (dose level 1). Subjects were assessed for at least 2 complete cycles of treatment (21 days per cycle; a total of 42 days) for safety evaluation (DLT) to define RP3R. De-escalation to canakinumab 200 mg subcutaneous every 6 weeks + docetaxel 75 mg/m\^2, every 3 weeks could also be considered.
62775825|NCT03626545|EXPERIMENTAL|Randomized part: Canakinumab + docetaxel|Participants were treated with canakinumab subcutaneous at RP3R and docetaxel at 75 mg/m\^2 every 3 weeks
62775826|NCT03626545|PLACEBO_COMPARATOR|Randomized part: Placebo + docetaxel|Participants were treated with placebo subcutaneous at RP3R and docetaxel at 75 mg/m\^2 every 3 weeks
62775827|NCT06004570|EXPERIMENTAL|Complex product|18 volunteers
62775828|NCT06004570|ACTIVE_COMPARATOR|Polyphenol-rich extracts|18 volunteers
62775829|NCT06004570|PLACEBO_COMPARATOR|Placebo|18 volunteers
62000199|NCT03211169|ACTIVE_COMPARATOR|Cholangioscopy-directed biopsies|Biopsies of the stricture will be taken under cholangioscopic guidance after bile duct brushings have been obtained.
62775830|NCT04199143|EXPERIMENTAL|healthy voluntary controls|A single Non-blinded One-hour administration of 50% Nitrous oxyde (N2O) 50%oxygen (O2) Gas Mixture
62000200|NCT01170728||Virtue® Male Sling|Device: Coloplast Virtue® Male Sling
62000201|NCT04672005|EXPERIMENTAL|Treatment Regimen: mFOLFIRINOX + mGnabP|"All study participants will receive the following treatment:~mFOLFIRINOX (28-day cycle)~Day 1 and Day 15:~Oxaliplatin 85 mg/m2 2-hour intravenous infusion followed by leucovorin 400 mg/m2 2-hour infusions with the addition of irinotecan 150 mg/m2 as a 90 minute infusion. 5-FU 2400 mg/m2 continuous intravenous infusion over 46 hours will follow irinotecan.~Day 3 and Day 17:~Pegylated-Granulocyte Colony Stimulating Facotr (peg-GCSF) 6 mg subcutaneous injection following disconnection of 5-FU infusion, first cycle and then per investigator discretion.~Biweekly mGnabP (28-day cycle)~Day 1 and Day 15:~Nab-paclitaxel 125 mg/m2 infused over 30 minutes, immediately followed by Gemcitabine 1200 mg/m2 intravenously infused at the rate of 10mg/m2/min (over 120 minutes).~Patients will receive one month of each regimen, alternately monthly until progression of disease."
62569296|NCT02053766|ACTIVE_COMPARATOR|Sevoflurane|In the Operating Room (OR) after applying routine monitors, anesthesia will be induced with a mask using Sevoflurane up to 8%. Sevoflurane will be used for maintenance for the rest of the procedure with dosage between 1.5% and 4%. Vitals will be monitored. Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Sevoflurane will be turned off at the end of procedure.
62569297|NCT02053766|ACTIVE_COMPARATOR|Dexmedetomidine (Precedex®)|These subjects will receive Dexmedetomidine intravenously. In the OR routine monitors will be placed. Vitals will be monitored. A loading dose of Precedex 1mcg/ kg will be given over 10 minutes. Infusion will be started using Precedex 1mcg/ kg/ hr and can be increased or decreased as needed. Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Precedex infusion will be stopped at the end of the procedure.
62000202|NCT01248026|EXPERIMENTAL|Buttermilk|
62000203|NCT01248026|PLACEBO_COMPARATOR|Placebo|
62000204|NCT03001570|EXPERIMENTAL|Arm 1|"Radiotherapy treatment associated with concurrent Cetuximab administration.~Patients candidate to curative concurrent Cetuximab and Radiotherapy are eligible for this study. After expressing written informed consent, patients will perform CT simulation. Then an IMRT-SIB (Simultaneous Integrated Boost) treatment plan will be elaborated and deliver the following Cetuximab pharmacokinetic:~Length: 6 weeks; 1 fraction daily (From Monday to Friday) 30 Total Fractions (5 per week, 6 weeks of treatment). Cetuximab will be administered weekly from a week before starting radiotherapy until the end of treatment for 7 subsequent administration accordingly to the standard schedule (1 before and 6 during radiotherapy)."
62000205|NCT05934292|EXPERIMENTAL|Panel A: Moderate Renal Impairment (RI)|Period 1 Day 1: Participants receive enlicitide decanoate 20 mg tablet single dose orally (Period 1 = 15 days)
62000206|NCT05934292|EXPERIMENTAL|Panel B: Severe RI|Period 1 Day 1: Participants receive enlicitide decanoate 20 mg tablet single dose orally (Period 1 = 15 days)
62394243|NCT06265389|EXPERIMENTAL|50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form|50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form at a dose of 20 mg/kg/day, as an adjunct therapy to the usual pneumonia treatment for 5 days
62394244|NCT06265389|NO_INTERVENTION|50 children with community-acquired pneumonia with the standard pneumonia treatment.|50 children with community-acquired pneumonia with the standard pneumonia treatment as a control group
62394245|NCT03741075|ACTIVE_COMPARATOR|BUAL plus placebo|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures plus 200 ml saline topical application to placental bed
62394246|NCT03741075|EXPERIMENTAL|BUAL plus topical tranexamic acid|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures plus topical application of 20ml saline contains 2 gm tranexamic acid
62394247|NCT03114150|EXPERIMENTAL|Cardiorespiratory fitness training|Cardiorespiratory fitness training will be a 24-week supervised cycling program designed to improve cardiorespiratory fitness, with supervision directly from the research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes moderate intensity cycling and 30 minutes light intensity cycling, and 5 minute cool-down per session, for 3 sessions/week. In each additional week, 6 minutes of moderate intensity cycling per session will be added, until the total time for moderate intensity is 50 minutes per session by the start of week 5 (with additional 5 minute warm-up and 5 minute cool-down).
62394248|NCT03114150|ACTIVE_COMPARATOR|Functional fitness training|Functional fitness training will be a 24-week supervised exercise program designed to focus on functional flexibility and mobility, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes of light intensity cycling and 20 minutes of dynamic stretching to increase range of motion and functional fitness, for 3 sessions/week. In each additional week, additional stretches will be added to maintain variety and improve flexibility of all major muscle groups.
62394249|NCT04030364|OTHER|Self-referral to group exercise classes|"Structured, multi-component, supervised group exercise classes are the health related intervention proposed for this study. The group classes will occur at a local CrossFit gym facility.~For the purposes of this project, all eligible Rosemount Clinic patients with type 2 diabetes mellitus will receive an email or letter mail invitation to self-refer to a structured, facility-based, supervised aerobic and resistance exercise program. Interested patients will be invited to attend a 1-hour information session at the exercise facility at the time of implementation start up where they will complete an initial baseline survey. This session will also serve as an initial meet and greet for participants to meet exercise trainers prior to starting exercise classes and to receive a tour of the facility."
62394250|NCT02406586|EXPERIMENTAL|Salsalate|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one salsalate 750 mg tablet twice daily for two weeks. If the subject has no side effects, the dose will be increased to two salsalate 750 mg tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
62569298|NCT02053766|ACTIVE_COMPARATOR|Propofol|These subjects will receive propofol for anesthesia maintenance. In the OR routine monitors will be placed. Vitals will be monitored. A loading dose of Propofol 2mg/ kg will be given over 2 minutes. Infusion will be started using Propofol 50 mcg/ kg/min and can be increased or decreased as needed (range 50-300mcg/kg/min). Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Propofol infusion will be stopped at the end of the procedure.
62569299|NCT00952965||blood pressure monitor|wrist circumference: 14cm-25cm
62000207|NCT05934292|EXPERIMENTAL|Panel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD)|Period 1 Day 1: Participants receive enlicitide decanoate 20 mg tablet single dose orally (Period 1 = 15 days). Period 2 Day 1: Participants receive enlicitide decanoate 20 mg tablet single dose orally (Period 2 = 15 days). A washout period of 14 days will separate Period 1 and Period 2.
62569300|NCT00952965||stethoscopy|wrist circumference: 14cm-25cm
62569301|NCT05003804|EXPERIMENTAL|STMC-103H Part A1|Once daily dosing with one capsule of STMC-103H mixed with milk, formula, or a milk product for 28 days
62394251|NCT02406586|EXPERIMENTAL|Carvedilol|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one carvedilol 3.125 mg tablet twice daily for two weeks. If the subject has no side effects, the dose will be increased to two carvedilol 3.125 mg tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
62394252|NCT02406586|PLACEBO_COMPARATOR|Placebo|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one placebo tablet twice daily for two weeks. The dose will be increased to two placebo tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
62394253|NCT03382951||Healthy children|Each study is an observational study with no group assignments and no control/placebo.
62394254|NCT02387827|EXPERIMENTAL|Diet+ short -term physical activity (DST)|
62394255|NCT02387827|EXPERIMENTAL|Diet+ long -term physical activity (DLT)|
62394256|NCT06341452|OTHER|Na zero-diffusive treatment|Patients will be treated for 12 weeks sodium zero-diffusive prescription thrice weekly Hemodialysis or Hemodiafiltration sessions resulting in 36 sessions per patient.
62394257|NCT06341452|OTHER|standard treatment without Na-control|Patients will be treated for 12 weeks either with standard dialysate prescription thrice weekly Hemodialysis or Hemodiafiltration sessions resulting in 36 sessions per patient.
62394258|NCT01213121|EXPERIMENTAL|bipolar depression|unmedicated patients with bipolar depression receiving quetiapine treatment
62394259|NCT01213121|NO_INTERVENTION|Control|healthy controls matched for age, gender, and body mass index
62394260|NCT03618576|EXPERIMENTAL|Balance exercise group|During the 2-week postoperative intervention period, patients will participate in the hospital's exercise program beginning 5-7 days after HFS. All participants will follow the computer-based balance specific exercise (BSE) program.
62394261|NCT04011514||Baseline period|Usual care. Stroke patients admitted to the ED during the 3-month baseline inclusion period.
62394262|NCT04011514||Intervention period|Intervention: 2 month implementation period of specialized stroke nurses allocated to ED for nurse specific treatment of stroke patients specific observations and care
62394263|NCT06563102|EXPERIMENTAL|Group 1 - Participants randomized to receive albuterol/budesonide|Participants will be randomized based on Visit 1 FeNO levels (\< 50 ppb / ≥ 50 ppb) and geographic region. Participants who are randomized to receive albuterol/budesonide for as-needed rescue therapy will be compared to participants randomized to receive albuterol for as-needed rescue therapy.
62394264|NCT06563102|ACTIVE_COMPARATOR|Group 2 - Participants randomized to receive albuterol|Participants will be randomized based on Visit 1 FeNO levels (\< 50 ppb / ≥ 50 ppb) and geographic region. Participants who are randomized to receive albuterol/budesonide for as-needed rescue therapy will be compared to participants randomized to receive albuterol for as-needed rescue therapy.
62394265|NCT00672464|ACTIVE_COMPARATOR|Olanzapine only|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine
62569302|NCT05003804|PLACEBO_COMPARATOR|Placebo Part A1|Once daily dosing with one capsule of placebo mixed with milk, formula, or a milk product for 28 days
62569303|NCT05003804|EXPERIMENTAL|STMC-102H Part A2|Once daily dosing with one capsule of STMC-103H mixed with milk, formula, or a milk product for 28 days
62569304|NCT05003804|PLACEBO_COMPARATOR|Placebo Part A2|Once daily dosing with one capsule of placebo mixed with milk, formula or a milk product for 28 days
62394266|NCT00672464|EXPERIMENTAL|Added Metformin|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Metformin
62569305|NCT05003804|EXPERIMENTAL|STMC-103H Part B|Once daily dosing with one capsule of STMC-103H mixed with breastmilk, formula or a milk product for 336 days
62569306|NCT05003804|PLACEBO_COMPARATOR|Placebo Part B|Once daily dosing with one capsule of placebo mixed with breastmilk, formula or a milk product for 336 days
62569307|NCT06256601|EXPERIMENTAL|Theracal (calcium silicate)|"TheraCal LC is a light-cured resin-modified calcium silicate pulp protectant/liner designed to perform as a barrier and to protect the dental pulpal complex. It contains; resin bis-phenyl glycidyl methacrylate (BisGMA) \& polyethylene glycol dimethacrylate (PEGD), modified calcium silicated with CaO, calcium silicate particles (type III Portland cement), Sr glass, fumed silica, barium sulphate, barium zirconate.~After caries removal, TheraCal is applied directly to the cavity floor in incremental layers. The layer is not to exceed 1 mm in depth. Each layer polymerized for 20 seconds."
62394267|NCT00672464|EXPERIMENTAL|Added Simvastatin|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Simvastatin
62000208|NCT05934292|EXPERIMENTAL|Panel D: Healthy|Period 1 Day 1: Participants receive enlicitide decanoate 20 mg tablet single dose orally (Period 1 = 15 days)
62000209|NCT04583813|ACTIVE_COMPARATOR|Empagliflozin|Empagliflozin 10 mg oral tablet, once daily, for 24 months
62000210|NCT04583813|PLACEBO_COMPARATOR|Placebo|Empagliflozin matching placebo oral tablet, once daily for 24 months
62000211|NCT02023151|OTHER|Omalizumab|Active
62000212|NCT06173206|ACTIVE_COMPARATOR|Sulfadoxine-pyrimethamine (SP)|Groups in the SP group will receive a 7-day course of placebo artesunate (at day -7, -6, -5, -4, -3, -2, and -1), followed by a single course of SP plus placebo AQ for 3 days.
62000213|NCT06173206|ACTIVE_COMPARATOR|Sulfadoxine-pyrimethamine plus amodiaquine (SPAQ)|Groups in the SPAQ group will receive a 7-day course of placebo artesunate (at day -7, -6, -5, -4, -3, -2, and -1), followed a single course of placebo SP placebo plus AQ for 3 days.
62185591|NCT04715685|EXPERIMENTAL|40 minute session, home practice e-health, phone call|This intervention arm consists of mind body skill introduction session that is 40 minutes in duration. The daily home practice component for headache management will utilize a migraine specific interactive web portal, Migraine e-health portal. This arm will also receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
62185592|NCT04715685|EXPERIMENTAL|40 minute session, home practice e-health, no phone call|This intervention arm consists of mind body skill introduction session that is 40 minutes in duration. The daily home practice component for headache management will utilize a migraine specific interactive web portal, Migraine e-health portal. This arm will not receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
62775831|NCT04199143|EXPERIMENTAL|Depressive Patients|A single Non-blinded One-hour administration of 50% Nitrous oxyde (N2O) 50%oxygen (O2) Gas Mixture
62394268|NCT00672464|EXPERIMENTAL|Added Metf. + Simv.|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Metformin and Simvastatin
62394269|NCT00672464|NO_INTERVENTION|Matched Controls|Matched Control Subjects by age, race, and gender
62394270|NCT01780441||Tuberous Sclerosis Complex (TSC)|Tuberous Sclerosis Complex
62394271|NCT02879968||Head and Neck squamous cell carcinoma|"A single measurement of serum squamous cell carcinoma antigen level is performed in the eligible Head and Neck squamous cell carcinoma patients.~The study tool measuring serum squamous cell carcinoma antigen level is ARCHITECT SCC (Abbott).~The gross tumor volume in the cross sectional imaging obtained within 2 weeks of each patient is calculated with the typical ellipsoid formula."
62394272|NCT05018390|EXPERIMENTAL|OMT|Osteopathic manipulative treatment : participants will receive low-amplitude tissue mobilizations on peripheral, vertebral, cranial and/or visceral articular systems.
62000214|NCT06173206|ACTIVE_COMPARATOR|Artesunate monotherapy (AS)|Groups in the AS group will receive a 7-day course of active artesunate (at day -7, -6, -5, -4, -3, -2, and -1), followed a single course of placebo SP plus placebo AQ for 3 days.
62000215|NCT01112384|EXPERIMENTAL|SB939|
62000216|NCT03445416|EXPERIMENTAL|Intervention: POL arm|POL intervention. Enrolled POLs will be randomized at their intake visit; those randomized to the intervention arm will attend the popular opinion leader training (developed in Aim 1) and will be asked to diffuse the intervention messages to their network recruits.
62000217|NCT03445416|ACTIVE_COMPARATOR|Comparison group|POLs who are randomized to the comparison arm will receive an abbreviated version of the POL training that includes general health messaging, but does not incorporate medical mistrust, stigma or specific vaccination messaging.
62394273|NCT05018390|SHAM_COMPARATOR|Sham|Participants will be applied gestures that look like actual osteopathic manipulations but are not therapeutic.
62394274|NCT05018390|NO_INTERVENTION|Test-retest|Participants will undergo the two eye movement measurements, but will not receive any (actual or sham) treatment. 30 minutes will elapse between the two measurements.
62394275|NCT02467504|ACTIVE_COMPARATOR|Experimental|hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
62394276|NCT02467504|PLACEBO_COMPARATOR|Placebo Comparator|hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
62775832|NCT04687371|EXPERIMENTAL|Grup I|Proprioceptive vestibular rehabilitation exercises, Cawthorne Cooksey Exercises and Gaze Stabilization exercises,
62775833|NCT04687371|EXPERIMENTAL|Grup II|Cawthorne Cooksey Exercises and Gaze Stabilization exercises
62000218|NCT02273843|EXPERIMENTAL|High-dose vitamin D|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU
62000219|NCT02273843|ACTIVE_COMPARATOR|Conventional-dose vitamin D|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
62000220|NCT04033003|EXPERIMENTAL|Group ANC|Intervention groups consist of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman.
62394277|NCT06055868||Qualitative Focus Group|Participants will be asked to a series of questions to help place them in a focus group with other individuals of shared identity and will also complete a short quantitative survey either emailed to the participant or the outreach worker/study coordinator will administer the survey by phone. Participants will then participate in one 1.5-2 hour, facilitated, focus group discussions (FGD).
62394278|NCT00848302|EXPERIMENTAL|L-arginine|Assess the effects of regional L-arginine supplementation in patients with chronic lower extremity occlusive disease undergoing angiography
62775834|NCT04687371|OTHER|Grup III|No intervention will be made, patients will be asked to continue their daily life
62775835|NCT03754829|EXPERIMENTAL|HSKA - Web Group|The first experimental group will receive direct access to the web version of HSKA.
62775836|NCT03754829|EXPERIMENTAL|HSKA - Mobile Group|The second experimental group will receive direct access to the mobile app of HSKA as well as automated supportive text messages based on PST.
62775837|NCT03754829|NO_INTERVENTION|Control Group|The control group consists of a wait-list and for ethical reasons, participants in this group will gain access to the intervention (either web or mobile application) four months after the baseline.
62775838|NCT00613093|ACTIVE_COMPARATOR|Patients with glioblastoma multiforme|
62775839|NCT00613093|ACTIVE_COMPARATOR|Patients with Anaplastic Glioma|
62775840|NCT05435118|NO_INTERVENTION|EMONO (usual care administered to all the children undergoing painful procedures)|Use of the Equimolar Mixture of Oxide Nitrous and Oxygen (EMONO) with facial mask. In the hospital EMONO is administered to all the children for procedure pain control.
62775841|NCT05435118|EXPERIMENTAL|EMONO + audiovisuals tool|Use of the Equimolar Mixture of Oxide Nitrous and Oxygen (EMONO) with facial mask and vision of audiovisual toll with smartphone or tablet. The intervention is represented by the audiovisual tool.
62000221|NCT04033003|NO_INTERVENTION|Stand ANC|Individual standard antenatal care delivered at health facilities in Ghana
62000222|NCT02550327|EXPERIMENTAL|All Patients|"All patients will receive Nab-paclitaxel, Gemcitabine, Cisplatin, and Anakinra given on Day 1 and 8 of a 21 day cycle (two weeks on with one week rest). Anakinra will be self-administered subcutaneously corresponding with chemotherapy.~The patient will complete a total of 6 cycles of chemotherapy."
62185593|NCT04715685|EXPERIMENTAL|40 minute session, home practice handout, phone call|This intervention arm consists of mind body skill introduction session that is 40 minutes in duration. The daily home practice component for headache management will utilize a handout with explanations of mind body skills and a home practice plan. This arm will also receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
62775842|NCT02872272|EXPERIMENTAL|Treatment with Amikacin|Dressing impregnated by administration of amikacin
62775843|NCT02386501|EXPERIMENTAL|ADXS31-164|Dose/Potency 5 x 108 CFU; 1 x 109 CFU; 5 x 109 CFU; 1 x 1010 CFU
62775844|NCT04311931|EXPERIMENTAL|Experimental Creative Dance group|The experimental group intervention will attend the creative dance program. The program integrates 3 sessions / week of 60 minutes on alternated days.
62775845|NCT04311931|NO_INTERVENTION|Control group|"The control group will maintain the usually daily activities, not attending any exercise program.~After study end, the control group will have the opportunity to participate on an exercise program."
62775846|NCT06188299|NO_INTERVENTION|Liberal Group Therapy|Liberal Fluid Therapy was administered to this group. Fluid restrictions were not used.
62775847|NCT06188299|OTHER|Targeted Fluid Therapy|Targeted (restrictive) Fluid therapy was administered to this group. Fluids were given according to targeted blood pressure levels and aimed to avoid from fluid overload.
62775848|NCT03504748|ACTIVE_COMPARATOR|deep rTMS-active doble coil|patients undergoing of deep rTMS real with doble coil
62775849|NCT03504748|SHAM_COMPARATOR|deep rTMS-sham|patients undergoing to placebo deep rTMS
62775850|NCT05840536|EXPERIMENTAL|Combination Diuretic Therapy|Patients will receive lasix infusion starting at 5mg/hr along with a bolus dose of chlorothiazide 250mg at the initiation of the protocol. The lasix infusion can be titrated to 10mg after 12hrs based on volume of diuresis. This arm will also receive 250mg bolus doses of chlorothiazide every 12hrs for the duration of the study.
62775851|NCT05840536|ACTIVE_COMPARATOR|Monotherapy Diuretic|Patients will receive furosemide infusion at 5mg/hr along with an initial bolus dose of furosemide equal to twice their home oral dose. The furosemide infusion can be increased to 10mg/hr after 12hrs based on urine output. This arm will receive bolus doses of furosemide every 12hrs equal to twice their home oral dose until completion of the protocol.
62185594|NCT04715685|EXPERIMENTAL|40 minute session, home practice handout, no phone call|This intervention arm consists of mind body skill introduction session that is 40 minutes in duration. The daily home practice component for headache management will utilize a handout with explanations of mind body skills and a home practice plan. This arm will not receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
62775852|NCT05077007|ACTIVE_COMPARATOR|Percutaneous nephrolithotomy|patients suffering of pelvic renal stones underwent Percutaneous nephrolithotomy
62394279|NCT04651153|EXPERIMENTAL|UCB7853|Part 1: Single intravenous infusion of UCB7853 Part 2: Multiple intravenous infusions of UCB7853 at pre-specified time-points
62394280|NCT04651153|PLACEBO_COMPARATOR|Placebo|Part 1: Single intravenous infusion of Placebo Part 2: Multiple intravenous infusions of Placebo at pre-specified time-points
62775853|NCT05077007|ACTIVE_COMPARATOR|Extracorporeal Shock Wave Lithotripsy|patients suffering of pelvic renal stones underwent Extracorporeal Shock Wave Lithotripsy
62394281|NCT05014945|EXPERIMENTAL|Atelocollagen group|After obtaining informed consent for the study, epidural nerve block was performed. The patient is asked to return to the outpatient clinic of the pain center after 2 weeks. At this time, when the NRS of back pain does not improve by more than 50% compared to before the epidural nerve block and the cross-sectional area of the multifidus muscle using ultrasound is 5 cm2 or less, final enrollment is decided. The evaluation of the cross-sectional area and thickness of the multifidus muscle using ultrasound is performed with the patient prone, and the cross-sectional area of the multifidus muscle is measured at the same position as the level of the lesion on MRI.
62394282|NCT01873027|EXPERIMENTAL|OFDI-guided PCI|"* OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12 months after PCI."
62394283|NCT01873027|ACTIVE_COMPARATOR|IVUS-guided PCI|"* IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12 months after PCI."
62775854|NCT05077007|NO_INTERVENTION|control group|Healthy volunteers with negative history of renal stones or renal impairment to measure the level of urinary markers in their urine samples
62775855|NCT02803996|ACTIVE_COMPARATOR|Part A- Single Dose- 400 mg Aramchol|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
62775856|NCT02803996|ACTIVE_COMPARATOR|Part A- Single Dose- 600 mg Aramchol|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
62775857|NCT02803996|PLACEBO_COMPARATOR|Part A-Single Dose-Placebo|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
62000223|NCT04167774|EXPERIMENTAL|Camrelizumab +nb-Paclitaxel|Participants receive Camrelizumab 200mg(3mg/kg for underweight patients) iv and nb-Paclitaxel 260mg/m2 iv every 3 weeks until disease progression or unacceptable toxicity
62584803|NCT02610335|ACTIVE_COMPARATOR|Control group (C)|Kyphosis reeducation + patient education + auto-reeducation at home
62775858|NCT02803996|ACTIVE_COMPARATOR|Part B-Multiple Dose-400 mg Aramchol|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
62775859|NCT02803996|ACTIVE_COMPARATOR|Part B-Multiple Dose-600 mg Aramchol|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
62569308|NCT06256601|ACTIVE_COMPARATOR|Dycal (calcium hydroxide)|"Dycal,Calcium Hydroxide Liner is a two-component, rigid-setting, self-curing material designed for use in direct and indirect pulp capping and as a protective liner under dental adhesives, varnishes, filling materials, cements, and other base materials. It will not inhibit the polymerization of acrylic and composite restorations. Dycal, a two-paste system made of a base paste (1,3-butylene glycol disalicylate, zinc oxide, calcium phosphate, calcium tungstate, iron oxide pigments) and a catalyst paste (calcium hydroxide, N-ethyl-o/p-toluene sulphonamide, zinc oxide, titanium oxide, zinc stearate, iron oxide pigments) is prepared following the manufacturer's instructions by mixing equal amounts of catalyst paste and base paste.~After caries removal, Dycal is applied directly to the cavity floor, material thickness should be approximately 0.8mm-1mm. The mixed material will set in approximately 2-3 minutes."
62569309|NCT02025725|EXPERIMENTAL|10 mg Metoclopramide Nasal Spray|Metoclopramide Nasal Spray 10 mg, 30 minutes before meals and at bedtime (QID) for 4 weeks
62569310|NCT02025725|PLACEBO_COMPARATOR|Placebo Nasal Spray|Placebo Nasal Spray 30 minutes before meals and at bedtime (QID) for 4 weeks
62000224|NCT00378703|ACTIVE_COMPARATOR|Arm A (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15.
62000225|NCT00378703|EXPERIMENTAL|Arm B (bevacizumab and temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and bevacizumab as in Arm A.
62569311|NCT06133517|EXPERIMENTAL|Single Arm|Patients who are eligible to participate in the study will receive 3 cycles of sacituzumab govitecan, zimberelimab and domvanalimab every 3 weeks prior to cystectomy, unless there are signs of unacceptable toxicity, progressive disease, or the patient requests withdrawal from the study. Patients who do not achieve a pCR or that achieving a pCR still have positive ctDNA will also complete an adjuvant phase of the study consisting of 12 additional cycles of zimberelimab and domvanalimab after cystectomy.
62000226|NCT00378703|EXPERIMENTAL|Arm C (bevacizumab and sorafenib tosylate)|Patients receive bevacizumab as in Arm A and sorafenib tosylate PO BID on days 1-5, 8-12, 15-19, and 22-26.
62000227|NCT00378703|EXPERIMENTAL|Arm D (sorafenib tosylate and temsirolimus)|Patients receive sorafenib tosylate PO BID on days 1-28 and temsirolimus as in Arm B.
62000228|NCT05411796|EXPERIMENTAL|Tampax menstrual cup (regular flow), then Other menstrual cup (size 1)|
62185595|NCT04715685|EXPERIMENTAL|20 minute session, home practice e-health, phone call|This intervention arm consists of mind body skill introduction session that is 20 minutes in duration. The daily home practice component for headache management will utilize a migraine specific interactive web portal, Migraine e-health portal. This arm will also receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
62185596|NCT04715685|EXPERIMENTAL|20 minute session, home practice e-health, no phone call|This intervention arm consists of mind body skill introduction session that is 20 minutes in duration. The daily home practice component for headache management will utilize a migraine specific interactive web portal, Migraine e-health portal. This arm will not receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
62185597|NCT04715685|EXPERIMENTAL|20 minute session, home practice handout, phone call|This intervention arm consists of mind body skill introduction session that is 20 minutes in duration. The daily home practice component for headache management will utilize a handout with explanations of mind body skills and a home practice plan. This arm will also receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
62394284|NCT04677738|PLACEBO_COMPARATOR|Placebo|Placebo delivered in capsule format. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of placebo in the morning before breakfast for 12 weeks.
62394285|NCT04677738|EXPERIMENTAL|B. breve|Capsule containing B breve. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of B. breve B-3 in the morning before breakfast for 12 weeks.
62394286|NCT00545974|EXPERIMENTAL|1|Memantine 10mg BID
62394287|NCT00545974|PLACEBO_COMPARATOR|2|Placebo condition
62394288|NCT03378531|EXPERIMENTAL|AEB1102|Each patient may receive AEB1102 administered IV for up to approximately 4 years.
62569312|NCT05641805||Duchenne Muscular Dystrophy|
62584804|NCT02610335|OTHER|Test group (M)|Spinal mobility reeducation + patient education + auto-reeducation at home.
62584805|NCT03554395|EXPERIMENTAL|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
61977821|NCT01366560|PLACEBO_COMPARATOR|Placebo|The subjects will be administered placebo tablet as a single dose on Day 1 of study treatment visit. After 2 hours, the subjects will be administered wireless motility capsule. The subjects will be observed for expulsion of WMC in stool. Each subject will attend the clinical unit for two study treatment visits which will be separated by at least one week.
61977822|NCT02480543|ACTIVE_COMPARATOR|PO Misoprostol|Cervical preparation with per-os (PO) Misoprostol 400 mcg 2-4 hours prior to curettage
62000229|NCT05411796|EXPERIMENTAL|Other menstrual cup (size 1), then Tampax menstrual cup (regular flow)|
62000230|NCT05797506|EXPERIMENTAL|Sulforaphane (Avmacol Extra Strength)|Four tablets of Sulforaphane (Avmacol Extra Strength) per day. The tablets will be provided by Nutramax.
62000231|NCT05797506|PLACEBO_COMPARATOR|Placebo|Nutramax will provide the matched placebo tablets.
62000232|NCT02787252|EXPERIMENTAL|HF DRG|HF DRG Implants
62000233|NCT02005978||Acromegaly1|Acromegalic patients treated with radiation therapy
62000234|NCT02005978||Healthy controls|Health controls matched for age, gender and BMI to the patients
62000235|NCT02005978||Acromegaly 2|Acromegalic patients treated with pituitary surgery
62000236|NCT06021067|EXPERIMENTAL|Death mesenchymal stem cell therapy plus standard treatment for radiation pneumonia|Subjects (n=3) received a standard treatment regimen combined with a pre-specified starting dose of dead mesenchymal stem cells (2.0×10\^7 for 60kg patient), infusion every 3 days, continuous infusion 4 times, treatment duration is 4\~6 weeks. . If dose-limiting toxicity (DLT) does not occur within 30 days of the first administration, the dose is escalated by three times.
62000237|NCT05828277|EXPERIMENTAL|Repotrectinib (TPX-0005)|"Oral repotrectinib (TPX-0005):~Cohort 1: Patients with moderate hepatic impairment Cohort 2: Patients with severe hepatic impairment Cohort 3: Patients with normal hepatic function"
62000238|NCT05098639|ACTIVE_COMPARATOR|BASICS|Participants in the active control will receive a modified single session BASICS. BASICS is a well-documented and empirically supported prevention/intervention program for college student drinkers. BASICS targets heavy drinking students that have experienced or are at an increased risk for a variety of alcohol-related problems linked to college student life. The program is designed to help students make better alcohol-use decisions based on a broader understanding of the risks associated with problem drinking. It enhances motivation to change and promotes the development of skills to moderate drinking. The overall style of the program uses motivational interviewing and emphasizes empathy and non-judgmental interaction. The aims of BASICS are to (1) reduce alcohol consumption and consequences, (2) promote healthier and more responsible choices, and (3) provide information and coping skills.
62000239|NCT05098639|EXPERIMENTAL|Deviance Regulation Theory|DRT participants receive an initial intervention session that is consistent with their current (pre-intervention) PBS frequency norm beliefs. For the initial intervention session, participants discuss their perception of the use of alcohol and use of protective behavioral strategies among campus peers. They are given feedback on the injunctive norms of alcohol use and PBS use by their peers which is tailored to each individuals normative perceptions. Following the initial intervention session, participants will carry a mobile device that allows for individuals to report current drinking environments. They then receive DRT consistent feedback based on the norms reported in their current drinking environment.
62000240|NCT05098639|EXPERIMENTAL|Deviance Regulation Theory+BASICS|DRT participants receive an initial intervention session that is consistent with their current (pre-intervention) PBS frequency norm beliefs but also follows the framework of BASICS. For the initial intervention session, participants discuss their perception of the use of alcohol and use of protective behavioral strategies among campus peers. They are given feedback on both descriptive and injunctive norms of alcohol use and PBS use by their peers which is tailored to each individuals normative perceptions. Following the initial intervention session, participants will carry a mobile device that allows for individuals to report current drinking environments. They then receive DRT consistent feedback based on the norms reported in their current drinking environment.
62000241|NCT00518908|EXPERIMENTAL|Sevoflurane|Sevoflurane for pharmacological postconditioning
62000242|NCT00518908|EXPERIMENTAL|Propofol|Anesthesia maintenance with propofol instead of Sevoflurane postconditioning
62000243|NCT04984655|OTHER|30-minute Virtual Reality (VR) Experience delivered through Oculus Quest 2 VR headset|
62000244|NCT01289808|EXPERIMENTAL|glucose 25%|"180 healthy babies born term in the Baruch Padeh Medical Center, Poriya.~There will be three study groups:~Study Group: 60 newborn infants who will receive 1cc 25% Glucose, 2-3 minutes prior red-reflex examination.~Base line (control) Group 1: 60 newborn infants who will receive 1cc Water for Injection (WFI), 2-3 minutes prior red-reflex examination.~Base line (control ) Group 2: 60 newborn infants who will not receive neither glucose nor Water for Injection (WFI), 2-3 minutes prior red-reflex examination"
62775860|NCT02803996|PLACEBO_COMPARATOR|Part B-Multiple Dose-Placebo|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
62000245|NCT02696551|EXPERIMENTAL|Interventional hospital|Interventional hospital, which will receive 3-month medical education
62000246|NCT02696551|NO_INTERVENTION|Non-interventional hospital|Non-interventional hospital, which will not receive 3-month medical education.
62000247|NCT04222179|OTHER|Naso-enteric tube placement|The participants needed nutrition from naso-enteric tube feeding are enrolled into this study. Double-blind was not needed here.
62000248|NCT03494036|EXPERIMENTAL|Synbiotic|Synbiotic capsule containing 3x1.000.000.000 Colony Forming Units probiotics (Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, dan Bifidobacterium bifidum R0071 20%) and fructooligosaccharide 80 mg. The dosage is once daily and it is given for 60 days
62000249|NCT03494036|PLACEBO_COMPARATOR|Placebo|Placebo capsule containing saccharum lactis. The dosage is once daily and it is given for 60 days
61977823|NCT02480543|ACTIVE_COMPARATOR|PV Misoprostol|Cervical preparation with per-vagina (PV) Misoprostol 400 mcg 2-4 hours prior to curettage
61977824|NCT02480543|ACTIVE_COMPARATOR|Buccal Misoprostol|Cervical preparation with buccal Misoprostol 400 mcg 2-4 hours prior to curettage
62000250|NCT06224530|EXPERIMENTAL|Levetiracetam, then Placebo|Participants will receive two levetiracetam 250mg capsules on the first scanning visit. On the second scanning visit they will receive two 37.5mg capsules of ascorbic acid.
62000251|NCT06224530|EXPERIMENTAL|Placebo, then Levetiracetam|Participants will receive two 37.5mg capsules of ascorbic acid on the first scanning visit. On the second scanning visit they will receive two levetiracetam 250mg capsules.
62000252|NCT00748644|EXPERIMENTAL|1|Experimental drug = rituximab for maintenance
62000253|NCT00748644|ACTIVE_COMPARATOR|2|Comparator drug = azathioprine for maintenance
62000254|NCT00000252|SHAM_COMPARATOR|0% N2O|Subjects will inhale 0% N2O
62000255|NCT00000252|ACTIVE_COMPARATOR|10% N2O|Subjects will inhale 10% N2O
62000256|NCT00000252|ACTIVE_COMPARATOR|20% N2O|Subjects will inhale 20% N2O
62000257|NCT00000252|ACTIVE_COMPARATOR|30% N2O|Subjects will inhale 30% N2O
62185598|NCT04715685|EXPERIMENTAL|20 minute session, home practice handout, no phone call|This intervention arm consists of mind body skill introduction session that is 20 minutes in duration. The daily home practice component for headache management will utilize a handout with explanations of mind body skills and a home practice plan. This arm will not receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
62185599|NCT05700604||Cystic Fibrosis|10-18 year-old children with Cystic Fibrosis
62185600|NCT05700604||Healthy Controls|age and sex matched healthy controls
62185601|NCT03360110|ACTIVE_COMPARATOR|Test lens|Subjects randomized to wear pair of test lens either first or second
62185602|NCT03360110|ACTIVE_COMPARATOR|stenfilcon A lens (control)|Subjects randomized to wear pair of control lens either first or second
62775861|NCT00490620|PLACEBO_COMPARATOR|1|blinded placebo control
62775862|NCT00490620|ACTIVE_COMPARATOR|2|Antiretroviral therapy
62775863|NCT03927404|EXPERIMENTAL|Adaptive Vacuum test Prosthesis|The experimental socket system uses an active vacuum pump to push air out of the socket. The level of vacuum is controlled by hardware that automatically detects the socket fit based on in-socket motion and adjusts vacuum as needed to eliminate this motion.
62000258|NCT00000252|ACTIVE_COMPARATOR|40% N2O|Subjects will inhale 40% N2O
62000259|NCT02267629|EXPERIMENTAL|Experimental:Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13) infusion followed by assessments daily for a week, and weekly for a week.
62000260|NCT05012605||SLEEPR cohort|Individuals within first 3 months following stroke who did not have obstructive sleep apnea within the first 15 days following stroke
62000261|NCT03945812|ACTIVE_COMPARATOR|Granulocyte Colony Stimulating Factor Arm|"Women in this group will receive G-CSF with conventional hormonal therapy:~Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer will be performed."
62000262|NCT03945812|ACTIVE_COMPARATOR|Platelet Rich Plasma Arm|"Women in this group will receive PRP with conventional hormonal therapy:~Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer will be performed."
62000263|NCT03945812|PLACEBO_COMPARATOR|Saline|"Women in this group will receive saline with conventional hormonal therapy:~Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer will be performed."
62000264|NCT05094297|EXPERIMENTAL|Investigate the effects of an exercise intervention on U.S. Veterans.|A total of 25 U.S. Veterans (≥ 18 years of age), who suffer from pain, fatigue, low energy levels or are unable to physically do things they were once able to do, will be enrolled.
62000265|NCT06247033|ACTIVE_COMPARATOR|Active TNS - Chronic stroke patients with urgency symptoms, followed with PFTE, BT, TNS|Study group was followed with tibial nerve stimulation for 6 weeks, 2 sessions in a week, for 30 minutes. Stimulation was performed with TENS device, with settings of 10 Hz frequency, 200 msn wavelenght, continuous symetrical biphasic current. Amptlitude was increased just below the motor range that cause flexion in toes. All patiens were followed for PFTE and BT according to standard schedule.
62000266|NCT06247033|SHAM_COMPARATOR|Sham TNS - Chronic stroke patients with urgency symptoms, followed with PFTE, BT, Sham TNS|Control group was followed with sham tibial nerve stimulation, which were performed by after starting electric current with TENS device, current were decreased and completely shut down. Sham stimulation was also applied for 6 weeks, 2 times in a week, 30 minutes. All patients were followed for PFTE and BT according to given standard schedule.
62000267|NCT05028504|EXPERIMENTAL|Penpulimab+Anlotinib|Penpulimab 200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules 12mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
62000268|NCT00963339||Dry AMD|subjects diagnosed as intermediate AMD in at least one eye
62000269|NCT00424905|EXPERIMENTAL|1|Enterogermina® vials containing 2×109 spores of polyantibiotic resistant Bacillus clausii (test drug)
62000270|NCT00424905|NO_INTERVENTION|2|No treatment (reference group)
62000271|NCT03044197|EXPERIMENTAL|MRI/ultrasound transperineal prostate biopsy|In arm A, all patients with positive mpMRI evidence of lesions suspicious for PCa, i.e. PI RADS ≥ 3 will be submitted to transperineal mpMRI-targeted prostate biopsy (arm A MRI+). The gland and the regions of interest will be contoured, and the prostate contour will be fused in real time with the TRUS image. Biopsies will be performed via a transperineal approach in the operating room. The patient will be placed in dorsal lithotomy position. mpMRI-targeted biopsies will be performed on regions of interest, and three to six cores will be obtained for biopsy from each lesion and is standard of care according to START criteria for targeted biopsy. In cases of negative mpMRI results i.e. PI RADS\<3, arm A patients will undergo TRUS-guided transrectal 12-core prostate biopsy (arm A MRI-) as described in arm B.
62000272|NCT03044197|ACTIVE_COMPARATOR|transrectal ultrasound-guided prostate biopsy|TRUS-guided transrectal prostate biopsy will be performed using a disposable 18-gauge biopsy gun with a specimen size of 18-22 mm (Bard Medical, Covington, GA, USA). The 12 cores will be obtained from 12 separate anatomical regions of the prostate which is standard practice in performing TRUS-guided transrectal prostate biopsy: left medial apex, left lateral apex, left medial midgland, left lateral midgland, left medial base, left lateral base, right medial apex, right lateral apex, right medial midgland, right lateral midgland, right medial base and right lateral base.
62000273|NCT00844792|EXPERIMENTAL|1|This group of men will be on active treatment (antioxidants)for 6-8 weeks prior to their radical prostatectomy.
62000274|NCT00844792|PLACEBO_COMPARATOR|2|This group of men will be on placebo for 6-8 weeks prior to their radical prostatectomy.
62000275|NCT03261583||Thoracic Surgery|Observational study. It is only a matter of collecting clinical data.
62000276|NCT00963690|EXPERIMENTAL|CloSys HD with standard compression|CloSys Arm
62000277|NCT00963690|ACTIVE_COMPARATOR|Standard compression alone|Manual compression arm
62000278|NCT00123188|EXPERIMENTAL|Ultrasound and Biopsy|Transvaginal Ultrasound and Endometrial Biopsy
62000279|NCT02944318|EXPERIMENTAL|"The Movement Program"|The intervention program was structured according three main components: (1) training and activities in general curriculum and Physical Education classes; (2) active facilities in the school environment; (3) health education in school community.
62000280|NCT02944318|NO_INTERVENTION|No intervention|"Schools in the control group will maintain a regular academic year with conventional activities. Thus schools have two weekly Physical Education classes which are organized by according to the perspective of their teachers. Besides that, the Program Saúde na Escola is also performed."
62000281|NCT00715793|EXPERIMENTAL|Single Arm|
62000282|NCT02619890||Patients with glioma requiring treatment|Patients with glioma requiring treatment, who undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and perfusion (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent
62000283|NCT02881294|ACTIVE_COMPARATOR|Food Effect|SUVN-G3031 tablets single dose
62000284|NCT02881294|ACTIVE_COMPARATOR|Gender Effect|SUVN-G3031 tablets single dose
62185603|NCT02125071||Hepabig|Those who receiving I.V. Hepabig injection used for prevention of hepatitis B relapse after liver transplantation
62185604|NCT01182064||Non infarct|
62000285|NCT02881294|ACTIVE_COMPARATOR|Age Effect|SUVN-G3031 tablets single dose
62185605|NCT01182064||Posttraumatic acute myocardial infarct without coronary injury|
62185606|NCT01182064||Posttraumatic acute myocardial infarct with coronary injury|
62185607|NCT03708705||Relapse|Relapse of tumor within two years after liver transplantation
62185608|NCT03708705||Non-relapse|Non-relapse of tumor within two years after liver transplantation
62775864|NCT02516228|EXPERIMENTAL|GTEN 100|All patients will receive treatment according to the protocol with the GTEN 100 device, pulsed only.
62775865|NCT01821482|EXPERIMENTAL|A|After complete resection or TACE, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK) (every 4 weeks)
62775866|NCT01821482|NO_INTERVENTION|B|After complete resection or TACE, Patient only regularly follow up
62000286|NCT02271308|NO_INTERVENTION|Control group|Residents in control group will receive regular activity in nursing homes.
62000287|NCT02271308|EXPERIMENTAL|Experimental group|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
62394289|NCT04486586|EXPERIMENTAL|Active tDCS plus Speech-Language Therapy first|Active tDCS will be applied at the beginning of 45 minutes speech-language therapy session and then participant will be switched to sham tDCS after a washout period.
62775867|NCT06128746|EXPERIMENTAL|Interventional rTMS group|The intervention group will receive 1 Hz active rTMS during treatment, lasting for 20 minutes, follow up by 30 minutes of intensive limb training.
62775868|NCT06128746|SHAM_COMPARATOR|Sham rTMS group|The sham group will not receive any Hz of rTMS during treatment, also lasting for 20 minutes with 30 minutes of intensive limb training afterwards.
62775869|NCT01009866|EXPERIMENTAL|MR1-1|All subjects are enrolled onto this arm. All subjects will receive MR1-1.
62775870|NCT00888485|EXPERIMENTAL|Behavioral intervention|Group exposed to behavioral intervention program
62775871|NCT00888485|ACTIVE_COMPARATOR|Standard treatment|
62775872|NCT05523375|EXPERIMENTAL|Intensive Lifestyle Intervention|"The intervention arm receives a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Obesity Guidelines, delivered remotely using eHealth technology, by trained health coaches embedded in the Digital Medicine Group in the Ochsner Health System. The intervention includes remote sessions with the health coach using evidence-based components such as the use of portion control and various behavioral strategies .Patients in the Intervention arm attend weekly sessions in the first six months, followed by monthly sessions for the remaining 18 months."
62000288|NCT01385124|EXPERIMENTAL|Oral Cannabidiol|Oral Cannabidiol 10 mg twice daily will be given from conditioning starting day and until day +30 after allogeneic transplantation. Dose can be doubled every 7 days if no significant side effects documented.
62000289|NCT04949269|EXPERIMENTAL|Part A|
62000290|NCT04949269|EXPERIMENTAL|Part B|
62775873|NCT05523375|NO_INTERVENTION|Usual Care|Patients in the usual care arm will receive their normal, usual care from their primary care team.
62775874|NCT01230138|EXPERIMENTAL|FP187 - TID|FP187 250mg TID (total daily dose of 750mg)
62775875|NCT01230138|EXPERIMENTAL|FP187- BID|FP187 375mg BID (total daily dose of 750mg)of 750mg administered as 375mg BID
62000291|NCT04949269|EXPERIMENTAL|Part C|
62000292|NCT04949269|EXPERIMENTAL|Part D|
62000293|NCT04936958||patients having had an osteomyelitis since 2017|
62000294|NCT03848546|EXPERIMENTAL|PDA|Intervention group: receives the personalized dietary advice
62000295|NCT03848546|ACTIVE_COMPARATOR|Control|Receives the general advice (two flyers containing information about fiber intake)
62000296|NCT03135197||Migalastat|Migalastat administered according to SmPC
62000297|NCT04765007|EXPERIMENTAL|Mindfulness group|This arm will be treated with a mindfulness-based stress reduction therapy.
62000298|NCT04765007|OTHER|Control group|This arm will be treated with a minimal intervention.
62000299|NCT04101266|ACTIVE_COMPARATOR|Interscalene nerve block|preoperative interscalene nerve block to be applied with ultrasound guidance.
62000300|NCT04101266|ACTIVE_COMPARATOR|suprascapular and infraclavicular nerve block|preoperative suprascapular and infraclavicular nerve block to be with ultrasound guidance
62000301|NCT03469921||15-17 years old|15-17 years old
62000302|NCT03469921||18-25 years old|18-25 years old
62000303|NCT03469921||26-30 years old|26-30 years old
62394290|NCT04486586|SHAM_COMPARATOR|Sham plus Speech-Language Therapy first|Sham will be applied at the beginning of 45 minutes speech-language therapy session and then participant will be switched to an active tDCS after a washout period.
62394291|NCT03846466|EXPERIMENTAL|Part1 Dose 1A|Single administration
62394292|NCT03846466|PLACEBO_COMPARATOR|Part1 Dose 1P|Single administration
62775876|NCT01230138|EXPERIMENTAL|FP187-LD-BID|FP187 250mg BID (total daily dose of 500mg)
62775877|NCT01230138|PLACEBO_COMPARATOR|Placebo|Placebo treatment
62775878|NCT01230138|EXPERIMENTAL|Open, flexible dosing treatment arm|Open treatment using a flexible dosing schedule for 8 weeks with maximum dose of 750mg FP187 and with a total dosing of 20 weeks. All investigations following same schedule.
62775879|NCT03650790|ACTIVE_COMPARATOR|preeclamptic obese pregnancy|CTRP 9 level will be assessed by 40 obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.
62775880|NCT03650790|ACTIVE_COMPARATOR|preeclamptic non-obese pregnancy|CTRP 9 level will be assessed by 40 non-obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.
62775881|NCT03650790|ACTIVE_COMPARATOR|normal pregnancy|CTRP 9 level will be assessed by 40 normal gestational ELISA methods
62775882|NCT00975663|EXPERIMENTAL|1|Optimized TDM of tacrolimus and MMF dosing
62775883|NCT00975663|ACTIVE_COMPARATOR|2|Current tacrolimus and MMF dosing strategies
62775884|NCT02156336|PLACEBO_COMPARATOR|PLACEBO|"* 500 mg PLACEBO PO 2 times a day for 1 week (Week 1)~* 1000 mg PLACEBO PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)"
62569313|NCT05643469|EXPERIMENTAL|Intervention group|Each subject will receive a specially designed leaflet for smokers with cancer. subjects will receive brief interventions using the AWARD model and they will be allowed to select their own quit schedules (quit immediately, or quit progressively) with the ultimate goal of complete cessation. Subjects who opt to quit progressively will receive a smoking reduction leaflet. Over the next 6 months, the research nurse will help them to adhere to their schedules by sending WhatsApp/WeChat messages. subjects will receive four independent 1-minute videos (one video will be sent in weeks 1, 5, 9, and 13) via WhatsApp/WeChat.
62569314|NCT05643469|PLACEBO_COMPARATOR|Control group|Subjects will receive a brief intervention using the AWARD model. However, all subjects will be advised to quit immediately. Control group subjects will receive the same leaflet for smokers with cancer as intervention group subjects. Subjects will receive a placebo intervention that follows the same WhatsApp/WeChat schedule as the intervention group, but the messages will contain only general health advice, such as to perform more physical activity and eat more fruit and vegetables. The control group will not receive any videos.
62569315|NCT04492176|EXPERIMENTAL|CO2 fractional laser（ACUPULSE,Lumenis）|gradually withdrawn from inside to outside of vaginal. with CO2 fractional laser therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%，ACUPULSE,Lumenis) ,once a month for a total of 3 times .CO2 fractional laser stimulates fibroblasts to synthesize and secrete collagen fibers, elastic fibers, reticular fibers and organic matrix through dot exfoliation and thermal stimulation, thus thickening the vaginal wall and achieving long-term vaginal tightening effect. The heat effect of CO2 laser can stimulate vasodilation, increase blood flow, increase cell oxidation and nutrients, increase mitochondrial ATP release, activate cell function, enhance vaginal mucosal secretion, enhance secretion, normalize vaginal PH and bacterial flora, and then reduce the probability of gynecological infection.
62569316|NCT04492176|NO_INTERVENTION|before treatment|the patient did not receive laser treatment
62569317|NCT04439929|EXPERIMENTAL|Adalimumab-TUR01|
62569318|NCT04439929|ACTIVE_COMPARATOR|Adalimumab-EU|
62569319|NCT02746718|OTHER|Restrictive Respiratory Failure|A CPK dosage, muscular questionnaires and a Pompe Disease test are practiced on patient with Restrictive Respiratory Failure without etiology
62569320|NCT02553018|EXPERIMENTAL|Auto-injector of methotrexate|"The Auto-injector is a disposable, fixed, single dose, auto-injector to be used for Methotrexate (25mg/ml) therapy.~Dosage form: solution for injection Dosage: 0.3ml contains 7.5mg of Methotrexate, 0.4ml contains the 10.0mg of Methotrexate, 0.6ml contains 15.0 mg of Methotrexate, 0.8ml contains 20.0 mg of Methotrexate, 1.0ml contains 25.0 mg of Methotrexate.~Frequency: one injection per week Duration: until the end of the study"
62569321|NCT02553018|ACTIVE_COMPARATOR|Pre-filled syringe of methotrexate|"Pre-filled syringes contains a volume of 1 ml with attached injection needle. Dosage form: solution for injection. Dosage: 0.15 ml contains 7.5 mg of methotrexate, 20 ml contains 10 mg of methotrexate, 0.30 ml contains 15 mg of methotrexate, 0.40 ml contains 20 mg of methotrexate, 0.50 ml contains 25 mg of methotrexate disodium.~Frequency: one injection per week Duration: until the end of the study"
62569322|NCT00717301||Head Trauma|Patients presenting to any of the AHCC/ERNES Emergency Departments with head trauma.
62569323|NCT00717301||Control subjects|Patients presenting to the Univ of Rochester Medical Center/Strong Memorial Hospital Outpatient Laboratory for routine blood draw.
62569324|NCT01463189|EXPERIMENTAL|painACTION: Arthritis|
62569325|NCT01463189|NO_INTERVENTION|treatment as usual|
62569326|NCT02545959|ACTIVE_COMPARATOR|Control group|receive a single pulse of methylprednisolone IV (120mg)
62775885|NCT02156336|ACTIVE_COMPARATOR|RANOLAZINE|"* 500 mg RANOLAZINE PO 2 times a day for 1 week (Week 1)~* 1000 mg RANOLAZINE PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)"
62775886|NCT01349764||No vitamin D replacement|The control arm will not receive vitamin D replacement, but patients in both study arms will receive care consistent with best care practices for stone disease. All patients will be evaluated by the stone clinic clinical nutritionist and full nutritional evaluation will be performed. All patients will be advised to maintain adequate hydration (\>2L/day), no-added salt diet (Na 80-100mmol/day), low protein diet (1 g/kg/day). Patients with hyperoxaluria will be advised to follow low-oxalate diet. All patients will be advised to maintain moderate calcium intake; 800-1200mg/day.
62569327|NCT02545959|EXPERIMENTAL|Rituximab IT group|receive a single intrathecal infusion of rituximab (with IV methylprednisolone 120mg to avoid side effect)
62569328|NCT02545959|EXPERIMENTAL|Rituximab IT + IV group|receive Rituximab IT as previous and Rituximab IV (375mg/m2) the same day
62569329|NCT05333068|EXPERIMENTAL|MVD > 2 50% angiographic stenosis PCI revascularization strategy based FFR and OCT assessment|MVD \> 2 50% angiographic stenosis PCI revascularization strategy based FFR and OCT assessment
62569330|NCT05333068|SHAM_COMPARATOR|MVD > 2 50% angiographic stenosis PCI revascularization strategy based FFR assessment (and sham OCT)|MVD \> 2 50% angiographic stenosis PCI revascularization strategy based FFR assessment (and sham OCT)
62569331|NCT02173691|EXPERIMENTAL|Tiotropium|
62569332|NCT02173691|ACTIVE_COMPARATOR|Salmeterol|
62569333|NCT02173691|PLACEBO_COMPARATOR|Placebo|
62775887|NCT01349764||Vitamin D3 tabs|The active arm of randomization will receive vitamin D repletion in the form of oral vitamin D3 tablets 10 000 IU twice/ week for 8 consecutive weeks, followed by a maintenance dose of 1 000 IU daily for further 22 months.
62775888|NCT00242593|EXPERIMENTAL|A|oral rosiglitazone 4 mg twice daily for 18 months
62775889|NCT00242593|PLACEBO_COMPARATOR|B|placebo pill twice daily for 18 months
62775890|NCT06259890|OTHER|Patients with radiographic/non-radiographic Axial Spondylitis or psoriatic arthritis|Patients with radiographic/non-radiographic Axial Spondylitis or psoriatic arthritis managed in the rheumatology departments of the study centres.
62775891|NCT03579173||Nutrition and Infant PFT|To examine the relationship between nutritional status (weight-for-age (WFA) and weight-for-length (WFL)) at 6 months of age and lung function at 1-2 years of age in infants with CF.
62775892|NCT03579173||Nutrition and Lung Clearance Index|To examine the relationship between nutritional status (WFA and WFL) in infants with CF at 12 months of age and the lung clearance index (LCI) at 3-5 years of age.
62775893|NCT03579173||Passive Tidal Breathing and Infant PFT|To delineate the relationship between passive tidal breathing lung function testing in infants with CF at 4-8 weeks of age and subsequent lung function at 6-12 months of age.
62775894|NCT03822000||Elderly Patients with Femoral Fracture|Elderly patients with fall-induced femoral fracture. Patients were categorized into two groups: death (n = 42) and survival (n = 2,365).
62775895|NCT05713539|EXPERIMENTAL|Cooled metal placed on skin|Metal is placed onto the skin at a temperature of -2 degrees Celsius for 30 seconds. A thermal imaging camera will be used to identify how long it takes for the skin to return to its initial temperature.
62775896|NCT04706000||Study group|endometrial polyp
62775897|NCT04706000||Control group|normal endometrium
62394293|NCT03846466|EXPERIMENTAL|Part1 Dose 2A|Single administration
62394294|NCT03846466|PLACEBO_COMPARATOR|Part1 Dose 2P|Single administration
62394295|NCT03846466|EXPERIMENTAL|Part1 Dose 3A|Single administration
62394296|NCT03846466|PLACEBO_COMPARATOR|Part1 Dose 3P|Single administration
62394297|NCT03846466|EXPERIMENTAL|Part1 Dose 4A|Single administration
62775898|NCT01014039|ACTIVE_COMPARATOR|Flexible Sigmoidoscopy Screening arm|Intervention by flexible sigmoidoscopy screening
62775899|NCT01014039|NO_INTERVENTION|Control arm|No intervention (no screening)
62775900|NCT06000605|ACTIVE_COMPARATOR|Fed|Exercise and passive infusions of ketones and lactate in the fed state. Participants will be fed a small meal in the middle of the protocol, also.
62000304|NCT03469921||acute leukemia|acute leukemia
62775901|NCT06000605|EXPERIMENTAL|Fasted|Exercise and passive infusions of ketones and lactate in the fasted state. Participants will be required to fast for 72 hours prior to arriving to the lab for this testing arm.
62000305|NCT03469921||non-Hodgkin's lymphoma|non-Hodgkin's lymphoma
62394298|NCT03846466|PLACEBO_COMPARATOR|Part1 Dose 4P|Single administration
62000306|NCT03469921||Hodgkin lymphoma|Hodgkin lymphoma
62394299|NCT03846466|EXPERIMENTAL|Part1 Dose 5A|Single administration
62394300|NCT03846466|PLACEBO_COMPARATOR|Part1 Dose 5P|Single administration
62775902|NCT03610009|ACTIVE_COMPARATOR|2D ultrasound|Two-dimensional (2D) ultrasound is used to identify number and size of ovarian follicles, to select optimal day for triggering final oocyte maturation.
62000307|NCT03469921||pediatric therapeutic regimen administered|pediatric therapeutic regimen administered
62000308|NCT03469921||adult therapeutic regimen administered|adult therapeutic regimen administered
62000309|NCT03469921||patients included in clinical trials|patients included in clinical trials
62000310|NCT03469921||patients not included in clinical trials|patients not included in clinical trials
62185609|NCT02832349|EXPERIMENTAL|EA group (Educational Actions)|Epileptic patients participating to the educational actions program
62394301|NCT03846466|EXPERIMENTAL|Part1 Dose 6A|Single administration
62394302|NCT03846466|PLACEBO_COMPARATOR|Part1 Dose 6P|Single administration
62394303|NCT03846466|EXPERIMENTAL|Part1 Dose 7A|Single administration
62394304|NCT03846466|PLACEBO_COMPARATOR|Part1 Dose 7P|Single administration
62394305|NCT03846466|EXPERIMENTAL|Part2 Dose 1A|Multiple administration
62394306|NCT03846466|PLACEBO_COMPARATOR|Part2 Dose 1P|Multiple administration
62394307|NCT03846466|EXPERIMENTAL|Part2 Dose 2A|Multiple administration
62394308|NCT03846466|PLACEBO_COMPARATOR|Part2 Dose 2P|Multiple administration
62394309|NCT03794310|EXPERIMENTAL|NPF-08 （1-day treatment）|
62394310|NCT03794310|EXPERIMENTAL|NPF-08 （2-day split dose）|
62394311|NCT03794310|ACTIVE_COMPARATOR|Moviprep（1-day treatment）|
62394312|NCT02819882||Luminal A-like subtype|Patients that express Estrogen receptor (ER), express Progesterone Receptor (PgR)+ (≥ 20%), don't express HER2 and have Ki-67 'low' (\< 14%).
62394313|NCT02819882||Luminal B-like (HER2 negative) subtype:|Patients that express ER and are either PgR- or low (\< 20%) and/or Ki67 'high' (≥ 14%).
62394314|NCT02819882||Luminal B-like (HER2 positive) subtype:|Patients that express ER and HER2 irrespective of PgR or Ki67 status.
62394315|NCT02819882||HER2-enriched subtype|Patients that express HER2 and don't express ER or PgR.
62394316|NCT02819882||Triple Negative (TN) subtype|Patients who are negative for the expression of ER, PgR and HER2.
62394317|NCT02291952|EXPERIMENTAL|Experimental|During Forced Desynchrony sleep and wake will occur at different circadian phases, while meals are restricted to the biological day.
62394318|NCT02291952|OTHER|Control|During Forced Desynchrony sleep and wake, as well as meals, will occur at different circadian phases.
62394319|NCT04594122|NO_INTERVENTION|Control|No intervention in this group
62394320|NCT04594122|EXPERIMENTAL|Intervention|Hygiene package, training, branding, and certification
62775903|NCT03610009|ACTIVE_COMPARATOR|SonoAVC|SonoAVC is used to identify number and size of ovarian follicles, to select optimal day for triggering final oocyte maturation.
62775904|NCT05485324||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
62775905|NCT05485324||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
62775906|NCT02916251|EXPERIMENTAL|ZP4207(dasiglucagon)|Intervention: ZP4207(dasiglucagon) glucagon analogue (4 mg/mL) planned doses: 0.03, 0.08, 0.2 and 0.6 mg at euglycemic and hypoglycemic conditions.
62775907|NCT02916251|ACTIVE_COMPARATOR|Glucagon (Native glucagon)|Intervention: Glucagon (Native glucagon) 1 mg/mL as active comparator planned doses: 0.03, 0.08 and 0.2 mg at euglycemic conditions.
62775908|NCT02454062|EXPERIMENTAL|Dose Escalation TAS-114 (PART 1)|Each cycle will be 21 days: 14 days of treatment and 7 days recovery. TAS-114 and S-1 will be escalated according to a defined dosing table and specific DLT criteria.
62185610|NCT02832349|NO_INTERVENTION|Control group|Epileptic patients with standard follow-up
62185611|NCT02834936|EXPERIMENTAL|pyrotinib treatment|
62185612|NCT02394652|EXPERIMENTAL|Experimental: Metformin with Standard Chemoradiation|"Metformin: About 1 week prior to the start of chemoradiation, take 850 mg of metformin, orally, once a day for 3 days, followed by 850 mg twice a day and continued for the duration of external radiation.~Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation.~FAZA-PET scan at baseline and after about 1 week of metformin (just prior to the start of chemoradiation)"
62394321|NCT03861442||Subjects|Adult unilateral MED-EL Cochlear implant users (≥ 6 months), with post-lingual, severe to profound sensory-neural hearing loss.
62394322|NCT01539473|EXPERIMENTAL|TR-701 FA with Tyramine|TR-701 FA 200 oral with Tyramine
62569334|NCT01276756|ACTIVE_COMPARATOR|Standard of care|Group A: comprises 50 treatment-naive chronic hepatitis c patients who will receive the standard of care treatment: peginterferon Alfa 2a 160 ug once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight \< 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
62569335|NCT01276756|EXPERIMENTAL|Triple therapy|Group B: comprises 50 treatment-naive chronic HCV patients who will receive oral Nitazoxanide 500 mg twice daily for 4 weeks (lead-in phase) followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (160ug once weekly) and weight-based ribavirin 1000-1200 mg daily (based on body weight \< 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
62569336|NCT03778892|EXPERIMENTAL|Novel Intervention|Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services
62569337|NCT03778892|NO_INTERVENTION|Standard Intervention|Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services
62775909|NCT02454062|EXPERIMENTAL|Expansion phase TAS-114 (PART 2)|"The TAS-114 and S-1 MTD established in the Dose Escalation Phase will be administered BID for 14 days followed by a 7 day recovery period.~This regimen is repeated every 21 days thereafter. Approximately 40 to 60 evaluable patients will be enrolled in the Expansion Phase. PGx, PD and PK analysis will be performed based on specific criteria."
62775910|NCT05413148|ACTIVE_COMPARATOR|Wharton jelly-derived mesenchymal stem cell|Single subtenon injection of Wharton jelly-derived mesenchymal stem cells will be performed on a single eye after randomization
62775911|NCT05413148|ACTIVE_COMPARATOR|Mesenchymal stem cell exosome (Wharton jelly-derived)|Single subtenon injection of mesenchymal stem cell exosomes (Wharton jelly-derived)will be performed on a single eye after randomization.
62185613|NCT02394652|ACTIVE_COMPARATOR|Standard Chemoradiation|"Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation.~FAZA-PET scan at baseline and about 1 week later (just prior to the start of chemoradiation)."
62185614|NCT01377168|PLACEBO_COMPARATOR|Placebo pill|Daily oral placebo.
62185615|NCT01377168|ACTIVE_COMPARATOR|NTX|Daily oral naltrexone.
62185616|NCT02976168|NO_INTERVENTION|Horizontal|Subjects will be in horizontal supine Position for 21 hours
62185617|NCT02976168|EXPERIMENTAL|-12° head down tilt|Subjects will be in 12° head down supine Position for 21 hours
62185618|NCT06262425|EXPERIMENTAL|repetitive Transcranial Magnetic Stimulation over primary somatosensory cortex|Participants in the experimental group will receive 5 weekly sessions of repetitive Transcranial Magnetic Stimulation (rTMS) for two weeks. An excitatory stimulation over the primary somatosensory area corresponding to the dominant hand will be applied. For this purpose, the motor area will be localized and a coil will be placed 2 cm posterior to it. An isolated pulse will be applied to the motor area to ensure that the coil is not placed over the motor area using 110% of the motor resting threshold. After this, 22 trains of 10 Hz at an intensity of 90% of the motor resting threshold will be applied for 4 seconds, with a rest between series of 10 seconds (a total of 880 pulses). After the stimulation, participants will train with the Forced Response training program for a total of 500 correct repetitions and the Purdue Pegboard Test with 4 repetitions for right hand, left hand and both hands.
62394323|NCT01539473|PLACEBO_COMPARATOR|Placebo-controlled with Tyramine|Placebo-controlled with Tyramine
62394324|NCT04759001|EXPERIMENTAL|Donor FMT|Patients enrolled in this arm will receive donor FMT
62394325|NCT04759001|PLACEBO_COMPARATOR|Placebo FMT|Patients enrolled in this arm will receive placebo FMT (that will be made of water)
62394326|NCT01219179|EXPERIMENTAL|sterile water|Intervention group received sterile water if their sodium value was greater or equal to 150 mEq/liter
62394327|NCT05470530|ACTIVE_COMPARATOR|IT group|Participants were received normal saline 2 mL intravenously with intrathecal injection of heavy bupivacaine 0.5% 2 mL (10mg) plus 0.5 mL (2mg) dexamethasone diluted in 0.5 ml of 0.9% saline, overall 3 ml volume intrathecally. The dose of 2mg of dexamethasone was demonstrated by Amer (2018) to be the least effective intrathecal dose.
62394328|NCT05470530|ACTIVE_COMPARATOR|IV group|Participants were received dexamethasone 2 mL (8mg) intravenously with intrathecal injection of heavy bupivacaine 0.5% 2 mL plus 1 mL of 0.9% saline
62394329|NCT01016912|EXPERIMENTAL|Arm A (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
62569338|NCT00698672|ACTIVE_COMPARATOR|2|articulation Spectron EF CoCr/ Reflection All-Poly Eto-sterilized
62569339|NCT00698672|ACTIVE_COMPARATOR|3|articulation Spectron Ef CoCr/ Reflection All-Poly XLPE
62569340|NCT00698672|ACTIVE_COMPARATOR|4|articulation Spectron EF Oxinium/ Reflection All-Poly Eto-sterilized
62569341|NCT00698672|ACTIVE_COMPARATOR|5|articulation Spectron EF Oxinium/ Reflection XLPE
62569342|NCT00698672|ACTIVE_COMPARATOR|1|articulation Charnley/ Ogee
62569343|NCT01182051|EXPERIMENTAL|Cognitive behavioral therapy|Key treatment ingredients in CBT include psychoeducation, trigger identification, progressive muscle relaxation training, cognitive restructuring, problem solving, in vivo exposure, and relapse prevention (see Appendix I for an outline of the treatment manual).
62569344|NCT01182051|ACTIVE_COMPARATOR|Relaxation Training|RT will consist of progressive muscle relaxation training, diaphragmatic breathing, and thermal biofeedback.
62569345|NCT00629252|EXPERIMENTAL|1|Schizophrenic patients treated with sertindole
62185619|NCT06262425|ACTIVE_COMPARATOR|repetitive Transcranial Magnetic Stimulation over primary motor cortex|Participants in the active comparator group will receive 5 weekly sessions of repetitive Transcranial Magnetic Stimulation (rTMS) for two weeks. An excitatory stimulation over the primary motor cortex corresponding to the dominant hand will be applied. For this purpose, the motor area will be localized, and an isolated pulse will be applied to the motor area to ensure that the coil is placed over the motor area using 100% of the motor resting threshold. After this, 22 trains of 10 Hz at an intensity of 90% of the motor resting threshold will be applied for 4 seconds, with a rest between series of 10 seconds (a total of 880 pulses). After the stimulation, participants will train with the Forced Response training program for a total of 500 correct repetitions and the Purdue Pegboard Test with 4 repetitions for right hand, left hand and both hands.
62185620|NCT06262425|SHAM_COMPARATOR|Sham repetitive transcranial magnetic stimulation|Participants in the sham group will receive 5 weekly sessions of sham repetitive Transcranial Magnetic Stimulation (rTMS) for two weeks.To achieve the placebo, the localization of the area to be stimulated will be carried out but the coil will be placed in a vertical position so the current will not go through the skull and the patient will just feel the vibration, communicating to the participant that it is likely that during the stimulation process he/she will not feel anything. After the sham stimulation, participants will train with the Forced Response training program for a total of 500 correct repetitions and the Purdue Pegboard Test with 4 repetitions for right hand, left hand and both hands.
62185621|NCT04171245|EXPERIMENTAL|Experimental|One minute laughter prescription 3x a day Tracking sleep using equipment
62185622|NCT04171245|ACTIVE_COMPARATOR|Control|Tracking sleep using equipment
62185623|NCT04830683||ICU Covid-19 patients|Covid-19 patients admitted for refractory respiratory failure despite conventional oxygen therapy requiring Intensive Care Unit (ICU) admission and oxygenation through either High Flow Nasal Cannula (HFNC) therapy or endotracheal intubation with mechanical ventilation
62185624|NCT04830683||non-ICU Covid-19 patients|Covid-19 patients admitted at hospital requiring conventional oxygen or continuous positive airways pressure (cpap)
62185625|NCT04830683||matched control subjects|Healthy subjects matched for similar cardiovascular risk factors than ICU Covid-19 patients
62185626|NCT04830683||ICU septic shock patients|Septic shock patients corresponded to refractory hypotension in response to an infection, in non Covid-19 patients, requiring ICU hospitalisation for vasopressors to maintain mean arterial pressure (MAP) \> 65mm Hg despite adequate volume resuscitation according to the Surviving Sepsis Campaign
62185627|NCT05052710|EXPERIMENTAL|Treatment Arm|Subjects will receive midazolam on Day 1 and AZD4831 once daily from Days 2 to 10, and AZD4831 plus midazolam on Day 11.
62394330|NCT01016912|EXPERIMENTAL|Arm B (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
62394331|NCT01016912|PLACEBO_COMPARATOR|Arm C (Placebo, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
62394332|NCT01016912|EXPERIMENTAL|Arm D (BMS-790052, plus peginterferon alfa-2b, Ribavirin)|Non-Responder
62394333|NCT01016912|EXPERIMENTAL|Arm E (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Non-Responder
62394334|NCT04761835|ACTIVE_COMPARATOR|Dietary Peanut|Participants in this group will be asked to continue peanut in their diet for 1 year at a dose determined from the double blind placebo controlled food challenge at baseline. After the 1 year period, participants will be given another double blind placebo controlled food challenge which will be used to determine their current peanut threshold. The current peanut threshold will be used to determine which participants will go into clinical care and which will get sustained unresponsiveness food challenges to peanut.
62394335|NCT04761835|NO_INTERVENTION|Strict avoidance|Participants in this group will be asked to strictly avoid any peanut in their diet for 1 year. After the 1 year period, participants will be given another double blind placebo controlled food challenge which will be used to determine whether they will transition to daily dietary peanut or continue with clinical care.
62394336|NCT01274104|ACTIVE_COMPARATOR|Vitamin D|Subjects will take 5,000 IU-capsules of vitamin D3 three times a day (for a total of 15,000 IU) for 14 days
62185628|NCT01704443|EXPERIMENTAL|Immediate treatment|Women in the Immediate treatment arm will receive the Group Psychoeducational treatment in the next available group. There will be 8-9 womenper group and each session will be 2.25 hours in duration and there will be 4, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
62394337|NCT01274104|PLACEBO_COMPARATOR|Control|Subjects will take 3 capsules of placebo every day for 14 days
62394338|NCT02968095|EXPERIMENTAL|Text Message Craving Program|Text messages designed to help smokers to modify their thinking styles to be more adaptive, delivered 2-3 times per day.
62775912|NCT05413148|PLACEBO_COMPARATOR|Placebo|A single subtenon injection of saline will be performed on a single eye after randomization.
62775913|NCT03678168|OTHER|Control|Standard care (Throat pack) which will be used as a control.
62775914|NCT03678168|EXPERIMENTAL|Intervention|Pharyngeal tampons which will be used as a comparator against throat pack.
62791668|NCT02960464|ACTIVE_COMPARATOR|Active Arm|Active sessions will involve the placement of the anode over the scalp corresponding to the F3 (10-20 EEG system), and cathode over F4. Current intensity will be 2mA, and the stimulation will last for 20 minutes.
62185629|NCT01704443|EXPERIMENTAL|Waitlist Control- delayed treatment|Women in the Waitlist Control arm will receive no treatment for a period of approximately 8 weeks. After the waitlist period they will receive the same Group Psychoeducational treatment as the participants in the immediate treatment arm of the study.
62185630|NCT02165826|EXPERIMENTAL|Roflumilast 500 μg once daily|Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
62394339|NCT02968095|ACTIVE_COMPARATOR|Self-Help Manual Plus Control Texts|A print, self-help manual plus general motivational text messages delivered 2-3 times per day.
62394340|NCT05799976|NO_INTERVENTION|Usual Care|This is a group will serve as usual care and have no intervention during the study period
62394341|NCT05799976|EXPERIMENTAL|Text Message Group|This group of primary care practices will be randomized to have the text message intervention
62394342|NCT02116439||Violent events|People in this group were observed to manifest violence.
62394343|NCT02116439||Victims|People in this group are the victims of the other group.
62000311|NCT05371964|EXPERIMENTAL|Imetelstat + Ruxolitinib|"Part 1: Participants who have received ruxolitinib orally (PO) as part of standard of care (SOC) for at least 12 weeks prior to Screening will be enrolled. After enrollment, participants will initiate imetelstat therapy. Dose levels of imetelstat may include 4.7, 6, 7.5, 9.4mg, until a RP2D is established.~Part 2: Janus kinase (JAK) inhibitor naïve participants will receive initial treatment with ruxolitinib for at least 12 weeks, including 4 weeks at a stable dose, followed by imetelstat treatment at the RP2D in combination with ruxolitinib."
62185631|NCT02165826|EXPERIMENTAL|Roflumilast 500 μg every other day|Roflumilast 500 μg, tablets, orally, every other day, and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
62569346|NCT00629252|ACTIVE_COMPARATOR|2|Schizophrenic patients treated with risperidone
62569347|NCT00629252|NO_INTERVENTION|3|Healthy controls without any treatment.
62569348|NCT05040425|EXPERIMENTAL|Chinese herbal medicine treatment|
62569349|NCT05040425|NO_INTERVENTION|Non-Chinese herbal medicine treatment|
62569350|NCT04022057|ACTIVE_COMPARATOR|Pre-GA|10 mL of 1% ropivacaine injection before the start of surgery and 10 ml of 5% dextrose injection at the end of surgery through both the popliteal and the saphenous catheter
62569351|NCT04022057|SHAM_COMPARATOR|Post-GA|10 mL of 5% dextrose injection before the start of surgery and 10 ml of 1% ropivacaine injection at the end of surgery through both the popliteal and the saphenous catheter
62569352|NCT00418860|EXPERIMENTAL|A|
62775915|NCT05807685|NO_INTERVENTION|control group|"At the beginning of the study, Data collection tools such as Individual Identification Form, Expressed Guilt Scale and Burnout Scale Short Version will be applied to the control group.~No intervention will be made in the control group. In the post-test, the Expressed Guilt Scale and the Burnout Scale Short Version will be administered again."
62185632|NCT02165826|EXPERIMENTAL|Roflumilast 250 μg once daily|Roflumilast 250 μg, tablets, orally, once daily for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
62185633|NCT00708851|ACTIVE_COMPARATOR|NB-UVB Light Device (311-315 nm)|the subject will receive full body NB-UVB light therapy
62185634|NCT00708851|EXPERIMENTAL|LCD Solution with NB-UVB Phototherapy|on half of the body will receive LCD while the full body receives NB-UVB therapy
62185635|NCT03691545|EXPERIMENTAL|Intervention Group|(1) 12 weekly interactive sessions with a health coach to help them set goals and make changes toward becoming physically active and consuming the recommended number of fruits and vegetables.
62394344|NCT05587621|ACTIVE_COMPARATOR|Cloud-based software|cloud-based software system (CLIMEDO GmbH) will support patients in ESC/EAS LDL-C target attainment (\< 55mg/dl/1.4 mol/L)
62394345|NCT05587621|PLACEBO_COMPARATOR|Standard Care|Patients will be treated by general practitioners (GPs) after hospital discharge. The discharge letter will recommend ESC/EAS dyslipidemia LDL-cholesterol targets (\< 55mg/dl/1.4 mol/L)
62569353|NCT04947215||Cases group|It includes 100 neonates who are admitted in the neonatal intensive care unit in Assiut University children hospital suffering from RDS. The cases will be subdivided into subgroups according to1. Full term or preterm, 2. Type of pregnancy (normal or complicated), 3. Mode of delivery, and 4. LPCAT1 genetic polymorphism.
62791669|NCT02960464|SHAM_COMPARATOR|Sham Arm|Sham stimulation will follow the same procedure as the Active, however after 30 seconds of stimulation, the current is turned off, mimicking the initial sensation of the tDCS session but providing no clinical or physiological effect.
62791670|NCT03761901||Patients with EGFR mutation positive NSCLC|
62569354|NCT04947215||control group|include 60 neonates without RDS.
62569355|NCT03831009|ACTIVE_COMPARATOR|Weight-bearing stable/Gravity stable|Ankles that are considered stable using weight-bearing radiographs AND gravity stress test will be assigned to conservative treatment
62569356|NCT03831009|ACTIVE_COMPARATOR|Weight-bearing stable/Gravity unstable|Ankles that are considered stable using weight-bearing radiographs but unstable using gravity stress test will be assigned to conservative treatment
62569357|NCT03831009|ACTIVE_COMPARATOR|Weight-bearing unstable/Gravity unstable|Ankles that are considered unstable using weight-bearing radiographs AND gravity stress test will be assigned to open reduction internal fixation (ORIF)
62569358|NCT03831009|ACTIVE_COMPARATOR|Weight-bearing unstable/Gravity stable|Ankles that are considered unstable using weight-bearing radiographs but stable using gravity stress test will be assigned to open reduction internal fixation (ORIF)
62000312|NCT02025101||Slow Coronary Flow|Patients who were hospitalized with anginal pain and with laboratory markers or pathological ECG for ischemia.
62185636|NCT01067287|ACTIVE_COMPARATOR|Group 1|Monoclonal antibody CT-011 will be given 1-3 months following autologous transplant. 3 doses will be given at 6 week intervals.
62185637|NCT01067287|ACTIVE_COMPARATOR|Group 2|Vaccination with DC/myeloma fusion cells will be given 1-3 months following autologous transplant. Vaccination will be given at 6 weeks intervals. The monoclonal antibody CT-011 will be given 1 week following each vaccination. 3 doses of CT-011 will be given at 6 week intervals.
62569359|NCT04618523|EXPERIMENTAL|Artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days for children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
62569360|NCT04618523|EXPERIMENTAL|Artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to \<15 kg, two tablets twice daily for those weighing 15 to \<25 kg and three tablets twice daily for those weighing 25 to \< 35 kg, for three days."
62569361|NCT05091580|EXPERIMENTAL|Intervention: Interpersonal Counseling for Depression|New adult TB patients with depressive symptoms (PHQ-9 \> 10) will be offered 4-8 sessions of Interpersonal Counseling delivered by a trained lay counsellor.
62584806|NCT03554395|ACTIVE_COMPARATOR|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length\<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
62185638|NCT04896788|OTHER|Monitoring of the immune response|Immune response controlled with blood sample at 3, 6, 12, 18 and 24 months
62775916|NCT05807685|EXPERIMENTAL|experimental group|"Arm Title: Experimental Group: Individual Identification Form, Expressed Guilt Scale and Burnout Scale Short Version will be administered to the mothers of children studying at Sinop Atatürk Primary School in the 2022-2023 spring semester before the laughter therapy. At the end of the laughter therapy, the Expressed Guilt Scale and the Short Version of the Burnout Scale will be administered as a post-test.~The Individual Identification Form, Expressed Guilt Scale and Burnout Scale Short Version will be used for all mothers of the students studying in Atatürk Primary School in the 2022-2023 academic year. All women whose Burnout Scale Short Form is above the average will be included in the study. Since all women whose Burnout Scale Short Form is above the average, who volunteered to participate in the study and who met the inclusion criteria will be included in the study, no additional sample selection will be made."
62775917|NCT02032407|EXPERIMENTAL|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
62775918|NCT06371976||Patients undergoing cardiac surgery|The patients included will be adult patients scheduled for cardiac surgery with extracorporeal circulation.
62775919|NCT04322825|EXPERIMENTAL|intervention|24 weeks of TENS
62775920|NCT00752726|ACTIVE_COMPARATOR|Orlistat|Orlistat 60 milligram (mg) capsules to be consumed orally with each meal 3 times per day
62775921|NCT00752726|PLACEBO_COMPARATOR|Placebo|Placebo to match Orlistat 60 mg capsules to be consumed orally with each meal 3 times per day.
62775922|NCT04379778|EXPERIMENTAL|Aerobic exercise|Moderate to high intensity aerobic exercise for 24 weeks.
62000313|NCT03165708||anesthesiologist|The active comparators for this study will be expert anaesthesiologists (operator). The operators will be blinded to all visual and audible CompuFlo® real-time pressure feedbacks.Inter-rater agreement, or concordance, between an expert anaesthesiologist and the CompuFlo® Epidural Computer Controlled System for the epidural space verification will be assessed by blinded tagging of the operator's feeling of the ligamenta and epidural space on the screen of the Compuflo to be eventually compared with the pressure's variations
62000314|NCT06332521||birth of term babies|Study of crying in a group of newborns (birth of term babies)
62000315|NCT06332521||Premature babies|Study of crying in a group of newborns (Premature babies )
62000316|NCT05374499|EXPERIMENTAL|Liposomal bupivacaine|A double-blinded randomization process will be used to preoperatively assign patient's left or right side to receive either Exparel (Liposomal bupivacaine) (39.9 mg/3 mL) or standard bupivacaine (5 mg/mL). At the end of the mandibular third molar extraction surgical procedure and at least twenty minutes following the most recent administration of 2% lidocaine with 1:100,000 epinephrine (routine for this procedure), all patients will receive one side of their mandibular infiltrations with 3mL of 1.3% liposomal bupivacaine (Exparel).
62185639|NCT04843982|EXPERIMENTAL|esketamine plus propofol|"After inclusion, patients are sedated primarily with propofol (0-3 mg/kg/h) using a microinfusion pump and adjusted according to the depth of sedation (Richmond Agitation Sedation Scale (RASS): 0 to -2).~After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days."
62185640|NCT04843982|NO_INTERVENTION|propofol|After inclusion, patients are sedated primarily with propofol (0-3 mg/kg/h) using a microinfusion pump and adjusted according to the depth of sedation (Richmond Agitation Sedation Scale (RASS): 0 to -2).
62394346|NCT06699849|EXPERIMENTAL|Part A: CSL889 Regimen A1|Participants in this arm will receive CSL889 as per regimen A1.
62394347|NCT06699849|EXPERIMENTAL|Part A: CSL889 Regimen A2|Participants in this arm will receive CSL889 as per regimen A2.
62569362|NCT05091580|OTHER|Control: Enhanced Treatment as Usual|"New adult TB patients will be screened for depression and those with significant symptoms (PHQ-9 \> 15 and/or suicidal ideation) will be referred to the clinic nurse for evaluation and referral to specialized mental health care as needed. Routine screening for depression is not a standard practice for TB patients; therefore assessment and referral is considered enhanced treatment as usual. Individuals will be interviewed at baseline and treatment completion."
62569363|NCT01030289|ACTIVE_COMPARATOR|real tDCS First Visit|On the First Visit, A single 20-minute tDCS session will be conducted using 2.0mA current. Using the international 10-20 EEG system, the anode will be placed over F4, which corresponds to the right dorsolateral prefrontal cortex (DLPFC), and the cathode will be placed over F3, which corresponds to the left dorsolateral prefrontal cortex. Electrodes will be standard sponge electrodes soaked In a sterile solution of .9% sodium chloride insulated by a latex casing.
62569364|NCT01030289|SHAM_COMPARATOR|sham tDCS First Visit|On the First Visit, For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
62569365|NCT01030289|ACTIVE_COMPARATOR|real tDCS Second Visit|Participant returns for the second visit 48-72 hours after completing the first visit. A single 20-minute tDCS session will be conducted using 2.0mA current. Using the international 10-20 EEG system, the anode will be placed over F4, which corresponds to the right dorsolateral prefrontal cortex (DLPFC), and the cathode will be placed over F3, which corresponds to the left dorsolateral prefrontal cortex. Electrodes will be standard sponge electrodes soaked In a sterile solution of .9% sodium chloride insulated by a latex casing.
62569366|NCT01030289|SHAM_COMPARATOR|sham tDCS Second Visit|Participant returns for the second visit 48-72 hours after completing the first visit. For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
62569367|NCT00516022|EXPERIMENTAL|Investigator product|The patients randomized to this arm will receive the IP injections at home 3 times a week (the patients will inject the IP themselves).
62569368|NCT00516022|OTHER|Control|The patients randomized to this arm will continue to receive chemotherapy as usual without further treatment (unless prescribed by the Doctor).
62569369|NCT00793962|EXPERIMENTAL|hypofractionation radiotherapy|breast cancer women with mastectomy high-risk: T3-4 and/or 4 or more axillary nodes involvement postmastectomy hypofractionation radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
62569370|NCT00793962|ACTIVE_COMPARATOR|conventional fractionation radiotherapy|breast cancer women with mastectomy high-risk with T3-4 and/or 4 or more axillary nodes postmastectomy conventional fractionation radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
62569371|NCT06370676|ACTIVE_COMPARATOR|Correctly placed oesophageal probe at +20 degrees celsius ambient temperature|Oesophageal probe tip located in the lower third of the oesophagus, i.e. behind the left atrium, +20°C ambient temperature, outside terraXcube
62394348|NCT06699849|EXPERIMENTAL|Part A: CSL889 Regimen A3|Participants in this arm will receive CSL889 as per regimen A3.
62569372|NCT06370676|EXPERIMENTAL|Oesophageal probe tip too high at +20 degrees celsius ambient temperature|Oesophageal probe tip located too high the oesophagus, i.e. behind the trachea, 1-2 cm above the level of the tracheal bifurcation, +20°C ambient temperature, outside terraXcube
62569373|NCT06370676|ACTIVE_COMPARATOR|Correctly placed oesophageal probe at -20 degrees celsius ambient temperature|Oesophageal probe tip located in the lower third of the oesophagus, i.e. behind the left atrium, -20°C ambient temperature, inside terraXcube
62000317|NCT05374499|ACTIVE_COMPARATOR|0.5% bupivacaine with 1:200,000 epinephrine|A double-blinded randomization process will be used to preoperatively assign patient's left or right side to receive either Exparel (Liposomal bupivacaine) (39.9 mg/3 mL) or standard bupivacaine (5 mg/mL). At the end of the procedure and at least twenty minutes following the most recent administration of 2% lidocaine with 1:100,000 epinephrine (routine for this procedure), all patients will receive one side of their mandibular infiltrations with 3mL of diluted 0.5% bupivacaine with 1:200,000 epinephrine.
62000318|NCT06297356|EXPERIMENTAL|intervention|This group will use a stress ball during nebuliser therapy. This process will be repeated at least twice a day.It will be a single application since the patients' current dyspnea and anxiety levels will be evaluated.
62000319|NCT06297356|NO_INTERVENTION|Control|Patients in this group will receive nebuliser therapy at least twice a day. However, no intervention will be made in the meantime. Measurements will be taken before and after any nebulizer treatment.
62000320|NCT02011048||Giant ventral incisional hernia|Patient with a giant ventral incisional hernia (\> 10 cm fascial defect) scheduled to undergo endoscopic components separation.
62000321|NCT02011048||Control group|Patients scheduled to undergo surgery on other indications.
62000322|NCT04702087|EXPERIMENTAL|OLEP|Omega 3 (500 mg), leucine (2,5 g), probiotic Lactobacillus paracasei PS23
62000323|NCT04702087|PLACEBO_COMPARATOR|Placebo|isocaloric formula
62000324|NCT06179082|ACTIVE_COMPARATOR|Group A|received Botox then threads
62000325|NCT06179082|ACTIVE_COMPARATOR|Group B|received threads insertion only
62000326|NCT03072212||HIV infected with stroke|No intervention will be administered
62000327|NCT03072212||HIV uninfected with stroke|No intervention will be administered
62000328|NCT02126969|EXPERIMENTAL|Chemotherapy plus Radiation Therapy|Low dose fractionated radiation - 80cGy with chemotherapy
62000329|NCT02126969|ACTIVE_COMPARATOR|Chemotherapy without Radiation|Chemotherapy only
62000330|NCT03612167|EXPERIMENTAL|multi-modal cognitive intervention|a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.
62000331|NCT03612167|ACTIVE_COMPARATOR|nutritional group|A quasi-experimental design with nonequivalent control was adopted in a senior center. The intervention for control group was a 12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
62569374|NCT06370676|EXPERIMENTAL|Oesophageal probe tip too high at -20 degrees celsius ambient temperature|Oesophageal probe tip located too high the oesophagus, i.e. behind the trachea, 1-2 cm above the level of the tracheal bifurcation, -20°C ambient temperature, inside terraXcube
62569375|NCT01464593|EXPERIMENTAL|Thermodox|Thermodox 50 mg/m2 intravenous infusion over 30 minutes starting 15 minutes before thermal ablation.
62569376|NCT02716168|EXPERIMENTAL|Video consultation|Video consultation between cancer patient, general practitioner and oncologist at the start of chemotherapy treatment
62569377|NCT02716168|NO_INTERVENTION|usual care|Usual care. The patients General Practitioner will receive standard discharge summary and ambulant notes from the oncologist specialist
62569378|NCT04972552|ACTIVE_COMPARATOR|Watermelon Diet & Coenzyme Q10|800-1200 mg of coenzyme Q10 daily plus diet high in watermelon
62569379|NCT04972552|ACTIVE_COMPARATOR|Usual Diet & Coenzyme Q10|800-1200 mg of coenzyme Q10 daily plus no watermelon in diet
62000332|NCT00643370||1|single arm study
62000333|NCT05884697|EXPERIMENTAL|K-Talk Intervention: Storytelling and AI Chatbot|After completing the pre-test survey, participants from all intervention groups will receive the written information. Subsequently, they will be randomly assigned to one of the intervention groups. The K-Talk group will receive a series of weekly storytelling videos, and access to the chatbot via the web-based platform KakaoTalk for 3 months.
62000334|NCT05884697|EXPERIMENTAL|Storytelling Intervention|After completing the pre-test survey, participants from all intervention groups will receive the written information. Subsequently, they will be randomly assigned to one of the intervention groups. The storytelling intervention group will only be exposed to periodic release of stories via email for 3 months.
62000335|NCT05884697|EXPERIMENTAL|K-Bot (AI Chatbot Intervention) Intervention|After completing the pre-test survey, participants from all intervention groups will receive the written information. Subsequently, they will be randomly assigned to one of the intervention groups. The K-Bot group will only interact with the chatbot via the web-based platform or KakaoTalk for 3 months.
62000336|NCT05884697|ACTIVE_COMPARATOR|Written Information|This group will only be exposed to written, didactic HPV education materials after the pre-test.
62000337|NCT02140034|EXPERIMENTAL|Study Arm: Extensive Peritoneal Lavage|The peritoneal cavity of subject will be washed with 10 liters of warmed normal saline (1 liter per cycle for 10 cycles) . The abdomen will be closed as per standard
62000338|NCT02140034|NO_INTERVENTION|Control Arm: Standard Treatment|The peritoneal cavity of subjects will be washed with 2 liters or less of warmed normal saline. The abdomen will be closed as per standard.
62569380|NCT04972552|PLACEBO_COMPARATOR|Watermelon Diet & Placebo|Placebo pill plus diet high in watermelon
62000339|NCT03815162|EXPERIMENTAL|High Flavanol Cocoa extract|278mg total flavanols (38.3mg epicatechin) per opaque cellulose capsule 3 capsules consumed once per day (836 mg total flavanols; 115mg epicatechin) for 3 months
62000340|NCT03815162|PLACEBO_COMPARATOR|Alkalised cocoa|0mg total flavanols (0mg epicatechin) per opaque cellulose capsule 3 capsules consumed once per day (0mg total flavanols; 0mg epicatechin) for 3 months
62394349|NCT06699849|PLACEBO_COMPARATOR|Part A: Placebo|Participants in this arm will receive placebo matching to CSL889 regimen of Part A.
62569381|NCT04972552|PLACEBO_COMPARATOR|Usual Diet & Placebo|Placebo pill plus no watermelon in diet
62569382|NCT01850238|PLACEBO_COMPARATOR|Placebo (adjuvant in saline solution)|"Placebo patients will receive 1 dose of placebo per month over 3 months, for a total of 3 administrations.~Placebo consists of vaccine adjuvant in saline solution. Placebo is administered subcutaneously."
62569383|NCT01850238|EXPERIMENTAL|AADvac1|"AADvac1 patients will receive 1 dose of AADvac1 per month over 3 months, for a total of 3 administrations.~AADvac1 is a vaccine (single-use vials with solution ready for injection) AADvac1 is administered subcutaneously."
62000341|NCT01080313||Patients with head and neck cancer|
62000342|NCT03151356||Patients|Patients addressed for prostate biopsies because of clinical and/or biological suspicion of prostate cancer.
62000343|NCT06146166|EXPERIMENTAL|Oral herbal supplement|Oral supplement containing an herbal blend
62000344|NCT06146166|PLACEBO_COMPARATOR|Oral Placebo Supplement|Oral placebo supplement
62000345|NCT04648930||Xolair|S.C. Injection
62000346|NCT05656547||Encephalographic spectrogram group|The dexmedetomidine and propofol infusions were titrated to maintain robust alpha power in the encephalographic spectrogram
62394350|NCT06699849|EXPERIMENTAL|Part B: CSL889|Participants in this arm will receive CSL889, as per regimen selected after Part A.
62569384|NCT03192488|EXPERIMENTAL|Cetirizine/Hypoxia|Subjects orally ingested 10 mg of Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
62569385|NCT03192488|PLACEBO_COMPARATOR|Placebo/Normoxia|Subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normoxic (room-air) environment (20.9% oxygen).
62569386|NCT03192488|PLACEBO_COMPARATOR|Placebo/Hypoxia|Subjects orally ingested a 10 mg Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
62569387|NCT06578663|SHAM_COMPARATOR|conventional program|will receive conventional physical therapy, including transcutaneous electrical nerve stimulation (TENS) and an exercise therapy program (stretching exercises, both hip and knee strengthening, balance, and stability exercise)
62000347|NCT05656547||Encephalographic index group|The dexmedetomidine and propofol infusions were titrated to maintain the bispectral index score between 40 and 60.
62000348|NCT01158794||Study participants|Participants with sickle cell disease and transfusional iron-overload, and non-sickle cell disease (thalassemia major, cancer patients, etc.) and iron overload. Participants with iron overload, defined as too much iron in the body as a consequence of too many blood transfusions.
62000349|NCT02003625|PLACEBO_COMPARATOR|A. GCSF + Placebo|GCSF + Placebo Patients in this group will receive GCSF 10 ug/kg s.c. daily, beginning 4 days prior to the 1st apheresis \[days -4, -3, -2, -1\] and continued on daily GCSF for a total of 4 apheresis or until ≥ 5 x 10\^6 CD34+ cells/kg are collected. They will also receive oral placebo for 5 days on days -6 through -2. Patients will undergo apheresis for 300 minutes to achieve approximately 3 to 4 whole blood volumes processed. This is a standard institutional protocol for autologous HSPC collection at the MGH.
62000350|NCT02003625|EXPERIMENTAL|B. GCSF + meloxicam|"B. GCSF + meloxicam:~Patients in this group will be treated with meloxicam and GCSF in an approximate two-day staggered dose schedule as described in our preclinical studies. Meloxicam will be given orally at a dose of 15 mg/day for 5 days (days -6 through -2). GCSF at 10 ug/kg/day subcutaneously will be started on day -4 and continued daily for a total of 4 apheresis or until ≥ 5 x 10\^6 CD34+ cells/kg are collected."
62000351|NCT03578510|ACTIVE_COMPARATOR|SHD|Standard hemodialysis
62000352|NCT03578510|EXPERIMENTAL|HHD|Hemocontrol hemodialysis
62569388|NCT06578663|EXPERIMENTAL|dry needling and conventional program|will receive conventional physical therapy, plus electrical dry needling.
62569389|NCT06578663|EXPERIMENTAL|Glucosamine sulfate iontophoresis and conventional program|will receive conventional physical therapy, plus Glucosamine sulfate iontophoresis.
62185641|NCT03373851||Zalviso|Patient willing to participate to the study, and scheduled for major functional surgery (arthroplasty, valgisation osteotomy, DIEP flap surgery, total body lift procedures) will be consented to use the Zalviso device in postoperative period as a main analgesia method.
62000353|NCT00859170|EXPERIMENTAL|Accordion use|Use of an Accordion device during the lithotripsy.
62569390|NCT00204698|ACTIVE_COMPARATOR|1|All subjects will be given active drug.
62775923|NCT04379778|NO_INTERVENTION|Standard care|Habitual lifestyle including standard care.
62775924|NCT01205477|EXPERIMENTAL|Methylprednisolone|Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine
62000354|NCT00859170|NO_INTERVENTION|Control Group|Patients who will not have an Accordion device used during lithotripsy.
62185642|NCT01287819||APOE4 (+) and APE4 (-)|APOE4 (+) 10 people APOE4 (-) 20 people from 200 participants
62185643|NCT02080390||Transthoracic echocardiogram (ultrasound)|Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
62185644|NCT06198543||experimental group|proliferative diabetic retinopathy
62185645|NCT06198543||control group|patients with macular epiretinal membranes and macular holes without diabetes.
62185646|NCT02149706|EXPERIMENTAL|NeuroVax|NeuroVax
62394351|NCT06699849|PLACEBO_COMPARATOR|Part B: Placebo|Participants in this arm will receive placebo matching the selected CSL889 regimen after Part A.
62569391|NCT03387371|ACTIVE_COMPARATOR|Ultrasonics & Gracey Curettes|Scaling and root planning is done with ultrasonics and gracey curettes in 24 hours with two visits.
62569392|NCT03387371|EXPERIMENTAL|Ultrasonics & Gracey Curettes & Laser|Scaling and root planning is done with ultrasonics, gracey curettes and Er:YAG laser in 24 hours with two visits.
62569393|NCT03862313|EXPERIMENTAL|active-rtACS arm|Active rtACS on 10 consecutive working days, in addition to standard-of-care corticosteroid treatment.
62775925|NCT01205477|PLACEBO_COMPARATOR|Placebo|Infiltration of 1 mL of xylocaine
62775926|NCT00418977|EXPERIMENTAL|Family Based Therapy|Participants will receive family based therapy (FBT)
62775927|NCT00418977|ACTIVE_COMPARATOR|Individual Supportive Psychotherapy|Participants will receive individual supportive psychotherapy (ISP)
62775928|NCT05204433||normal control|healthy volunteers
62775929|NCT05204433||adenoma|pathologically reported colorectal adenoma
62775930|NCT05204433||colorectcal cancer|pathologically reported colon cancers
62775931|NCT05204433||High risk group|pathologically reported inflammatory bowel diseases
62000355|NCT00843869||Chronic Rhinosinusitis|Participants with chronic rhinosinusitis
62000356|NCT01243346|EXPERIMENTAL|Crenolanib (CP-868,596)|
62000357|NCT03159884|EXPERIMENTAL|3+Q12W|"The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, followed by every 12 weeks. If the subject meets the additional medication criteria in 12 weeks during treatment, additional injection can be given;"
62185647|NCT02149706|PLACEBO_COMPARATOR|IFA Incomplete Freund's Adjuvant|Incomplete Freund's Adjuvant IFA
62185648|NCT05370014|EXPERIMENTAL|iCINGS Fam Intervention|Integrating Community-based Intervention Under Nurse Guidance with Families (iCINGS FAM) is 14-week, nurse coordinated, Community Health Worker (CHW) supported telehealth intervention structure. After baseline assessment, dyads randomized to the intervention group (n= 125 dyads) will have two planning sessions (over 2 weeks) followed by eight topic-guided sessions delivered by a member of the RN-CHW team over 12 weeks (weekly the first 4 weeks, then bi-weekly), Follow up assessments will occur at month 4 and month 7.
62394352|NCT02653131|EXPERIMENTAL|DPP-4|The administration of the DPP-4 inhibitor in the form of a pill once per day
62394353|NCT02653131|NO_INTERVENTION|NO DPP|no therapy
62394354|NCT02094066|ACTIVE_COMPARATOR|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
62394355|NCT02094066|SHAM_COMPARATOR|serum physiologic|preoperative 100 cc serum physiologic
62569394|NCT03862313|SHAM_COMPARATOR|sham-rtACS arm|Sham rtACS on 10 consecutive working days, in addition to standard-of-care corticosteroid treatment.
62569395|NCT02156011||Instrumented knee implant|"4-6 subjects with an instrumented TKA, that has been implanted within the study Kniemessprothese: Belastungsmessung bei Patienten mittels einer instrumentierten Knie-Endoprothese (EA4/069/06) approved and conducted at the Charité- Universitätsmedizin in Berlin, Germany, will be involved in this project."
62569396|NCT00558467|OTHER|Pramipexole|
62569397|NCT00558467|PLACEBO_COMPARATOR|Placebo|
62775932|NCT02014779|EXPERIMENTAL|eChange web-based relapse prevention|A relapse intervention program consisting of 14 modules. Patients will have access to therapist support through an internal secure messaging system.
62775933|NCT02014779|ACTIVE_COMPARATOR|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be vary for different therapists, but all have an evidence-based approach to therapy
62775934|NCT03841760|EXPERIMENTAL|PSMA PET/CT|One (1) PSMA PET/CT scan with with either PSMA-11 or DCFPyL
62791671|NCT06112691||main group|diabetes mellitus
62791672|NCT06112691||control group|without diagnosis of diabetes mellitus without retinal diseases
62000358|NCT03159884|EXPERIMENTAL|3+TAE|"The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, then the researcher will determine the next follow-up visit time/treatment interval based on results of each follow-up assessment as per the treatment-extended dosing criteria. When the follow-up/treatment interval of the subject is extended to 12 weeks, additional safety follow-up visit can be arranged if any suspicious active lesion is deemed by the researcher; additional injection can be given if the result of safety follow-up assessment meets the extra dosing criteria."
62569398|NCT05215977|EXPERIMENTAL|MW031|MW031 injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial, according to the investigator's assessment.
62185649|NCT05370014|NO_INTERVENTION|Attention Control|After baseline assessment, dyads randomized to the attention control group (n= 125 dyads) will receive monthly (3 in total; 7-10 min each) scripted phone calls on focused on general health risks and health promotion. Monthly telephone calls will cover readily accessible evidence-based public health messaging from the Centers for Disease Control and Prevention (CDC) Your Health, NIH and other public health community facing websites related to COVID-19 mitigation such as risk reduction and prevention strategies including flu vaccines, asymptomatic spread, and contact tracing. Follow up assessments will occur at month 4 and month 7.
62185650|NCT05092698|ACTIVE_COMPARATOR|Vit_D_suppl|Patients will receive 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil orally or via feeding tube weekly followed by 5,000 IU of cholecalciferol (two drops) daily until discharge or death.
62569399|NCT05215977|PLACEBO_COMPARATOR|placebo|Placebo was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
62569400|NCT06509087||TAME responder|Transarterial microembolization (TAME) is performed on all included patients with chronic shoulder or knee joint pain. Responders are determined if pain score reduction is two points or more based on the Visual Analogue Scale (VAS) at 1-month follow-up after the TAME.
62775935|NCT05781321|EXPERIMENTAL|Arm A (short course RT)|Patients undergo short course RT for 5-10 fractions over 1-2 weeks on study. Patients also receive temozolomide PO on days 1-5 every 28 days during radiation therapy. Starting one month post-radiation, patients continue temozolomide on days 1-5 every 28 days for up to 5 adjuvant cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT with 18-F-DOPA administered IV prior to RT on study, and undergo MRI prior to RT and throughout the trial. Patients may optionally undergo blood sample collection during screening and on the trial.
62775936|NCT05781321|ACTIVE_COMPARATOR|Arm B (standard course RT)|Patients undergo standard course RT for 15-30 fractions over 3-6 weeks on study. Patients also receive temozolomide PO QD concurrently with radiation therapy and for up to 6 adjuvant cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT with 18-F-DOPA administered IV prior to RT on study, and undergo MRI prior to RT and throughout the trial. Patients may optionally undergo blood sample collection during screening and on the trial.
62775937|NCT04457492|EXPERIMENTAL|Acute Facial Nerve Injury with Intact Facial Nerve|"40 sessions of FES (in a 14 week period)~Assessments will be taken during the beginning, middle, and end of each study arm."
62185651|NCT05092698|PLACEBO_COMPARATOR|Vit_D_placebo|Patients will receive 45 ml of herbal oil orally or via feeding tube followed by 45 ml of herbal oil weekly followed by two drops of herbal oil daily until discharge or death.
62775938|NCT04457492|EXPERIMENTAL|Facial Nerve Grafting After Surgical Excision|"40 sessions of FES (in a 14 week period)~Assessments will be taken during the beginning, middle, and end of each study arm."
62000359|NCT00983554|NO_INTERVENTION|Placebo|
62000360|NCT00983554|EXPERIMENTAL|Anastrazole and Testosterone|
62185652|NCT06062199|NO_INTERVENTION|Control arm|Nurses will place a peripheral venous line on these patients without having been trained in the venous status score predictive of failure.
62185653|NCT06062199|EXPERIMENTAL|Experimental arm|Nurses will place a peripheral venous line on these patients after being trained in the venous status score predictive of failure.
62185654|NCT02341586|EXPERIMENTAL|Lucky Iron Fish|This group will receive a Lucky Iron Fish to use during cooking.
62185655|NCT02341586|ACTIVE_COMPARATOR|18 mg iron|This group will receive a daily oral iron supplement.
62185656|NCT02341586|OTHER|Control group|This group will receive nutrition education
62185657|NCT00428337|EXPERIMENTAL|1|Participants will receive one injection of DNA vaccine EP-1233 or placebo in each shoulder on Days 0 and 28 and one injection of MVA-mBN32 or placebo in each arm on Days 84 and 168
62775939|NCT04457492|NO_INTERVENTION|Standard of Care Group|"No FES~Assessments will be taken at the same intervals as the interventions group."
62775940|NCT05282420|ACTIVE_COMPARATOR|Ranibizumab group|Ranibizumab injection monthly for 3 successive months
62000361|NCT00983554|EXPERIMENTAL|Dutasteride and Testosterone|
62000362|NCT00983554|EXPERIMENTAL|Testosterone|
62569401|NCT06509087||TAME non-responder|Transarterial microembolization (TAME) is performed on all included patients with chronic shoulder or knee joint pain. Non-responders are determined if pain score reduction is less than two points or if pain score increases based on the Visual Analogue Scale (VAS) at 1-month follow-up after the TAME.
62569402|NCT01354002||Protocol Participants|All participants enrolled on protocols
62569403|NCT02962648|EXPERIMENTAL|Iron isomaltoside/ferric derisomaltose|Administered IV
62569404|NCT01822639|EXPERIMENTAL|Sequence 1|Subjects in this arm will receive Treatment A in period 1 and Treatment B in period 2. Treatment A is co-administration of 5mg amlodipine tablet and 20 mg enalapril maleate tablet. Treatment B (GSK2944404) is fixed dose combination tablet of 5 mg amlodipine and 20 mg enalapril.
62000363|NCT05374811||Multiple sclerosis.|Those diagnosed with Multiple Sclerosis according to the 2017 Revised McDonald criteria
62000364|NCT02404311|ACTIVE_COMPARATOR|Part A, Group 1: Vaccine|ALVAC-HIV at months 0 and 1, and ALVAC-HIV + bivalent subtype C gp120/MF59 at months 3, 6, and 12
62000365|NCT02404311|PLACEBO_COMPARATOR|Part A, Group 2: Placebo|Placebo for ALVAC-HIV at months 0 and 1, and placebo for ALVAC-HIV + placebo for bivalent subtype C gp120/MF59 at months 3, 6, and 12
62000366|NCT02404311|ACTIVE_COMPARATOR|Part B, Group 1a: Vaccine|Participants originally in Part A Group 1 (Vaccine) receive ALVAC-HIV + bivalent subtype C gp120/MF59 at month 30
62000367|NCT02404311|ACTIVE_COMPARATOR|Part B, Group 1b: Vaccine + Placebo|Participants originally in Part A Group 1 (Vaccine) receive placebo for ALVAC-HIV + bivalent subtype C gp120/MF59 at month 30
62000368|NCT02404311|PLACEBO_COMPARATOR|Part B, Group 2: Placebo|Participants originally in Part A Group 2 (Placebo) receive placebo for ALVAC-HIV + placebo for bivalent subtype C gp120/MF59 at month 30
62000369|NCT03019276|EXPERIMENTAL|TQ-B3101|TQ-B3101 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62569405|NCT01822639|EXPERIMENTAL|Sequence 2|Subjects in this arm will receive Treatment B in period 1 and Treatment A in period 2. Treatment A is co-administration of 5mg amlodipine tablet and 20 mg enalapril maleate tablet. Treatment B (GSK2944404) is fixed dose combination tablet of 5 mg amlodipine and 20 mg enalapril.
62775941|NCT05282420|ACTIVE_COMPARATOR|Aflibercept group|Aflibercept injection monthly for 3 successive months
62185658|NCT00428337|EXPERIMENTAL|2|Participants will receive one injection of DNA vaccine EP-1233 or placebo in each shoulder on Days 0, 28, 84, and 168
62775942|NCT03120377|ACTIVE_COMPARATOR|Platform group|Group submitted to the whole body vibration training program
62775943|NCT03120377|SHAM_COMPARATOR|Platform sham group|Group that will receive the whole body vibration simulation treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display on and a sound device coupled with vibration-generated noise recording, but without therapeutic purposes.
62775944|NCT05406609||General|Shoulder surgery under general anesthesia
62775945|NCT05406609||Regional|Shoulder surgery under regional anesthesia
62775946|NCT00973245|EXPERIMENTAL|Arm 1|
62775947|NCT00973245|EXPERIMENTAL|Arm 2|
62775948|NCT00973245|ACTIVE_COMPARATOR|Arm 4|
62775949|NCT00973245|EXPERIMENTAL|Arm 3|
62569406|NCT06091956|EXPERIMENTAL|Deucravacitinib Treatment for Lichen Planopilaris|Subjects diagnosed with Lichen Planopilaris (LP) will receive Deucravacitinib for 24 weeks.
62775950|NCT01229449|EXPERIMENTAL|Ibuprofen/acetaminophen (lower dose)|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet
62775951|NCT01229449|EXPERIMENTAL|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg
62775952|NCT01229449|ACTIVE_COMPARATOR|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®)
62775953|NCT01229449|ACTIVE_COMPARATOR|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra)
62775954|NCT01229449|PLACEBO_COMPARATOR|Placebo|Two placebo tablets
62775955|NCT04040621|EXPERIMENTAL|Ceftazidime-avibactam|This arm includes 4 cohorts
62775956|NCT01620528|EXPERIMENTAL|Elagolix 150 mg QD|Elagolix 150 mg once daily (QD) for the 6-month Treatment Period
62775957|NCT01620528|EXPERIMENTAL|Elagolix 200 mg BID|Elagolix 200 mg twice daily (BID) for the 6-month Treatment Period
62775958|NCT01620528|PLACEBO_COMPARATOR|Placebo|Placebo BID for the 6-month Treatment Period
62775959|NCT03474783|EXPERIMENTAL|multidisciplinary intervention|
62775960|NCT03291392||Atherosclerosis|"Patient with intracranial stenosis or extracranial stenosis equal to or more than 70% would be invited to join the study for blood taking.~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
62775961|NCT03291392||Family members|"The stroke patient who had family history of stroke, their parents and siblings would also be invited to join the study for blood taking or buccal swab/ saliva collection.~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
62775962|NCT03291392||Normal subjects|"Normal subjects without ischemic stroke or intracranial/extracranial stenosis would be invited to join the study for blood taking.~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
62775963|NCT04900285|OTHER|Dental Device Arm|Subjects in this single arm study serve as their own control by recording snoring on the SnoreLab device for five days and completing the Snore Outcomes survey. After five nights with now device, the lower dental device is used for five nights and snoring is recorded in the SnoreLab app. At the end of the five nights the subjects complete the Comfort and Difficulties Form and the bed partner completes the Snore Outcomes Survey. If the lower device was tolerated well, the process is repeated with the upper dental device used with the lower device.
62775964|NCT01093066|EXPERIMENTAL|surgical resection and chemotherapy|"Maximal and optimal TURB using a standardized procedure. The TURB will always try to be optically complete.~Neoadjuvant chemotherapy for 3 months with the intensified MVAC (6 cycles administered every 2 weeks): METHOREXATE: 30 mg/m2 D1 - VINBLASTINE: 3 mg/m2 D2 - ADRIAMYCINE 30 mg/m2 D2 - CISPLATINE 70 mg/m2 D2. + G-CSF: 5 µg/kg from D4 to D10 New maximal standardized TURB at the end of the chemotherapy. In case of a lesion localized at the bladder dome, and if a maximal TURB appears to be unsafe, a partial cystectomy without lymph node dissection will be performed."
62000370|NCT05399524|EXPERIMENTAL|Additional pre- and intra-operative imaging|Surgery to resect the GB using Diffusion Tensor Imaging (DTI) and intraoperative Ultrasound (iUS) (navigated iUS where available) in addition to standard care (i.e. neuronavigation based on preoperative MRI and intraoperative use of 5-aminolevulinic acid (5-ALA))
62775965|NCT02667470|EXPERIMENTAL|Solifenacin|
62775966|NCT01072253||eye amputated|lost an eye
62775967|NCT03301467|EXPERIMENTAL|Avacopan|Avacopan (formerly CCX168) 10 mg capsules x 3 administered twice daily during the blinded 26 week blinded treatment period
62775968|NCT03301467|PLACEBO_COMPARATOR|Avacopan Matching Placebo|Matching placebo capsules x 3 administered twice daily during the 26 week blinded treatment period period
62775969|NCT05749952|ACTIVE_COMPARATOR|Standard of Care - Non-Weight Bearing (Socket A)|A non-digital weight-bearing socket will be used to create the check socket (temporary socket), which will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
62775970|NCT05749952|EXPERIMENTAL|Symphonie Aqua System - Non-Digital (Socket B)|We will digitally capture (via computer) the shape of your limb, which will create a digital file (computer file) of what the internal shape of your socket should be. This file will then be used with a computer software program to optimize the fit of your prosthesis. This image will be used to create a check socket (temporary socket) to confirm a correct anatomical and comfortable socket. Then the check socket (temporary socket) will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
62775971|NCT05042973|ACTIVE_COMPARATOR|Active drug (Empagliflozin)|Empagliflozin 10 mg, 1 capsule per day
62775972|NCT05042973|PLACEBO_COMPARATOR|Inactive drug (placebo)|Placebo, 1 capsule per day
62569407|NCT03104140|EXPERIMENTAL|Ketamine group|This group of patients will receive: 1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
62569408|NCT03104140|ACTIVE_COMPARATOR|Thiopental group|2 mg/Kg thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
62569409|NCT03688867|EXPERIMENTAL|At-home prehabilitation regimen|"1. Grip strength: Squeeze a stress ball in your hand, holding it squeezed for 5 seconds. Perform this at least thirty times with each hand over the course of a day.~2. Lower body strength: Perform at least one hundred chair sit-stands in a day.~3. Endurance: Walking at least 7,500 steps in a day."
62569410|NCT04412967|ACTIVE_COMPARATOR|Standard Technique PVC placement|Standard PVC placement technique
62569411|NCT04412967|EXPERIMENTAL|DUST|Dynamic ultrasound-guided short-axis needle tip navigation (DUST)
62000371|NCT05399524|ACTIVE_COMPARATOR|Standard of Care|The comparator is standard care as per current NICE guidelines (i.e. neuronavigation based on preoperative MRI and intraoperative use of 5-ALA).
62569412|NCT04939987|ACTIVE_COMPARATOR|Opioid Control Cohort|"One treatment selected:~Tramadol (50mg) Hydrocodone-Acetaminophen (2.5mg/325mg) Oxycodone-Acetaminophen (2.5mg/325mg)"
62569413|NCT04939987|EXPERIMENTAL|Experimental Cohort|"Multimodal Approach:~Gabapentin (100mg TID) Ketorolac (15mg q6) Acetaminophen (1mg IV q6) Ketamine (1.5mg/kg) Ketorolac tromethamine (15mg or 30mg Q4)"
62000372|NCT04270500|ACTIVE_COMPARATOR|Prehabilitation program|The preoperative period (prehabilitation) represents a more appropriate time than the postoperative period to implement an intervention. Prehabilitation is a process of enhancing an individual's functional capacity before the scheduled surgery, aimed at improving the patient's tolerance to upcoming physiologic stress, by three principal elements: exercise training, nutritional intervention, and psychological support.
62000373|NCT04270500|NO_INTERVENTION|Standard of care (SOC)|Common to both groups as part of the enhanced recovery after surgery (ERAS) protocol as the standard of care in our institution.
62000374|NCT02553746|EXPERIMENTAL|Ultrasound|
62000375|NCT02553746|ACTIVE_COMPARATOR|Landmarks|
62000376|NCT03277846|EXPERIMENTAL|Accept ECT - TES|Accept ECT where subject is randomized to TES
62000377|NCT03277846|PLACEBO_COMPARATOR|Accept ECT - SHAM|Accept ECT where subject is randomized to a SHAM condition
62569414|NCT06576856||Perio-Healthy|Individuals included in this cohort, other than meet the eligibility criteria, should present no clinical sign of periodontal disease. We anticipate to find from a very small number to none participants at this cohort. No intervention are anticipated.
62569415|NCT06576856||Periodontitis Stage I|Individuals included in this cohort, other than meet the eligibility criteria, should present clinical sign of periodontal defined as Stage I according to the American Academy of Periodontology. We anticipate low to moderate number of participants in this cohort. No interventions are anticipated.
62569416|NCT06576856||Periodontitis Stage II|Individuals included in this cohort, other than meet the eligibility criteria, should present clinical sign of periodontal defined as Stage II according to the American Academy of Periodontology. We anticipate a moderate number of participants in this cohort. No interventions are anticipated.
62569417|NCT06576856||Periodontitis Stage III|Individuals included in this cohort, other than meet the eligibility criteria, should present clinical sign of periodontal defined as Stage III according to the American Academy of Periodontology. We anticipate moderate to high number of participants in this cohort. No interventions are anticipated.
62569418|NCT06576856||Periodontitis Stage IV|Individuals included in this cohort, other than meet the eligibility criteria, should present clinical sign of periodontal defined as Stage IV according to the American Academy of Periodontology. We anticipate low to moderate number of participants in this cohort. No interventions are anticipated.
62775973|NCT05117177|EXPERIMENTAL|Inupadenant sequential dose escalation (Part 1A)|Part 1A will evaluate the safety as well as to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of inupadenant in participants with advanced solid tumors.
62775974|NCT05117177|EXPERIMENTAL|Inupadenant randomized crossover (Part 1B)|The effect of food on the exposure to inupadenant will be investigated in participants with advanced solid tumors.
62775975|NCT05117177|EXPERIMENTAL|Inupadenant single treatment assignment (Part 1C)|Part 1C will investigate an additional formulation of inupadenant in participants with advanced solid tumors.
62775976|NCT04922905|OTHER|NEURO +|"Patients neuro + are those with a CASE score ≥ 2, Neuro + patients will benefit from additional evaluations using paraclinical examinations"
62775977|NCT04922905|OTHER|NEURO -|"Patients neuro - are those with a CASE score \< 2"
62000378|NCT03277846|EXPERIMENTAL|Reject ECT - TES|Reject ECT where subject is randomized to TES
62000379|NCT03277846|PLACEBO_COMPARATOR|Reject ECT - SHAM|Reject ECT where subject is randomized to SHAM
62000380|NCT01989013|OTHER|biweekly intervention|biweekly intervention
62185659|NCT00428337|EXPERIMENTAL|3|Participants will receive one injection of MVA-mBN32 or placebo in each arm on Days 0, 28, 84, and 168
62185660|NCT04684056||Riva-control group|Routine concentration of Rivaroxaban (Peak)
62185661|NCT04684056||Riva-High group|High concentration of Rivaroxaban (Peak)
62000381|NCT01578044|EXPERIMENTAL|Intervention|"1. Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.~2. Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescription.~3. Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban has not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication."
62000382|NCT01578044|PLACEBO_COMPARATOR|Control|Usual care
62000383|NCT02555995|EXPERIMENTAL|All study participants|Patient's eyes are OCT-scanned with standard device and investigational device.
62000384|NCT03732053|EXPERIMENTAL|GPR Intervention Research group|A total of 135 subjects with AD in the mild or moderate phase participated in the study from which 90 pertain to research group.The intervention implemented to the patients with AD was the Global Postural therapy which lasted about 30-40 min in repeated sessions of 2 meetings per week by making 48 sessions in total during a six month period.
62000385|NCT03732053|NO_INTERVENTION|Control Group|45 subjects of the study belongs to the control group which has not received the same treatment .
62000386|NCT01715818|EXPERIMENTAL|Aleglitazar|
62000387|NCT01715818|PLACEBO_COMPARATOR|Placebo|
62000388|NCT04565054|EXPERIMENTAL|Abemaciclib plus ET|Abemaciclib 150 mg, 2 x daily, resulting in 300 mg/day, oral, 24 months plus endocrine treatment of physician´s choice
62185662|NCT04684056||Riva-Low group|low concentration of Rivaroxaban (Peak)
62185663|NCT04684056||Dabi-control group|Routine concentration of Dabigatran(Peak)
62569419|NCT06216132|EXPERIMENTAL|BIOPIN-6 active implant|3 sequential cohorts receiving 4.8, 9.6, or 14.4 g BIOPIN 6 implanted into a subcutaneous pocket in the upper abdominal wall.
62569420|NCT06216132|PLACEBO_COMPARATOR|BIOPIN-6 placebo implant|The placebo will be an implant consisting of the poly-d-l Lactic Acid and polycaprolactone contained in BIOPIN 6 without naltrexone.
62569421|NCT03517176|EXPERIMENTAL|Part A (Dose Escalation)|Safety of ascending dose levels of CEND-1 in combination with gemcitabine and nab-paclitaxel will be evaluated. Patients will receive an IV bolus of CEND-1 on Day 1 of the 1-week run-in period. This is followed by one treatment cycle (28 days) with the CEND-1 / nab-paclitaxel (125mg/m\^2) / gemcitabine (1000mg/m\^2) combination given on Days 1, 8, 15.
62185664|NCT04684056||Dabi-High group|High concentration of Dabigatran(Peak)
62775978|NCT05574465|OTHER|Manometry Device|At 10 minutes prior to anticipated removal of the endotracheal tube, pass the routine manometry catheter per naris to 30 cms.
62185665|NCT04684056||Dabi-low group|low concentration of Dabigatran(Peak)
62185666|NCT04684056||Edo-control group|Routine concentration of Edoxaban(Peak)
62185667|NCT04684056||Edo-high group|High concentration of Edoxaban(Peak)
62394356|NCT05531565|EXPERIMENTAL|Part A (Phase 2): Litifilimab|Participants will receive litifilimab subcutaneously (SC) once every 4 weeks (Q4W) from Week 0 to Week 20, with an additional dose of litifilimab at Week 2 during the double-blind placebo-controlled (DBPC) treatment period. Following the DBPC treatment period, participants will receive litifilimab during the extended treatment period (ETP) from Week 24 to Week 48, with an additional dose of litifilimab-matching placebo at Week 26.
62775979|NCT05307809|EXPERIMENTAL|Psoriasis|
62185668|NCT04684056||Edo-low group|low concentration of Edoxaban(Peak)
62185669|NCT03416413|ACTIVE_COMPARATOR|Ambulatory Phlebectomy|Ambulatory phlebectomy of varicose vein tributaries
62000389|NCT04565054|NO_INTERVENTION|Standard-of-care ET|"Standard-of-care ET according to clinical guidelines.~Pre-/perimenopausal patients:~* Either aromatase inhibitor + GnRH agonist~* or Tamoxifen +/- GnRH-agonist (as per investigator´s decision) or~Postmenopausal patients:~* Either Aromatase inhibitor~* or Tamoxifen OR"
62000390|NCT06202742|EXPERIMENTAL|Cognitive behavioral therapy|Cognitive behavioral therapy for insomnia (CBTI) is non-medical treatment to improve insomnia. CBTI group will attend online meeting, 1 hour weekly for 8 weeks.
62000391|NCT06202742|ACTIVE_COMPARATOR|Health education|Health education group will attend online meeting, 1 hour weekly for 8 weeks.
62000392|NCT00648219|EXPERIMENTAL|1|Olmesartan Medoxomil Tablets 40 mg
62000393|NCT00648219|ACTIVE_COMPARATOR|2|Benicar® Tablets 40 mg
62394357|NCT05531565|PLACEBO_COMPARATOR|Part A (Phase 2): Placebo|Participants will receive litifilimab-matching placebo SC Q4W from Week 0 to Week 20, with an additional dose of litifilimab-matching placebo at Week 2 during the DBPC treatment period. Following the DBPC treatment period, participants will receive litifilimab during the ETP from Week 24 to Week 48, with an additional dose of litifilimab at Week 26.
62569422|NCT03517176|EXPERIMENTAL|Part B (Expansion)|Safety and early efficacy of CEND-1 in combination with nab-paclitaxel (125mg/m\^2) and gemcitabine (1000mg/m\^2) will be evaluated (dosing on Days 1, 8, 15 of the 28-day treatment cycle). Treatment cycles will be repeated every 4 weeks based on toxicity and response. Treatment may continue as long as there is perceived benefit or until disease progression.
62569423|NCT02151851|EXPERIMENTAL|Certolizumab Pegol + Methotrexate|"Subjects will receive loading doses of CZP 400 mg (200 mg / prefilled syringe \[PFS\], ie, 2 injections) at Baseline, and Weeks 2 and 4; then CZP 200 mg (1 injection) Q2W until Week 22.~All subjects will continue their treatment on Methotrexate (MTX), with or without folic acid, at the same dose and route of administration as at entry (unless there is a need to reduce the dose for reasons of toxicity, minimum dose permitted 10 mg per week)."
62394358|NCT05531565|EXPERIMENTAL|Part B (Phase 3): Litifilimab|Participants will receive litifilimab SC Q4W from Week 0 to Week 20, with an additional dose of litifilimab at Week 2 during the DBPC treatment period. Following the DBPC treatment period, participants will receive litifilimab during the ETP from Week 24 to Week 48, with an additional dose of litifilimab-matching placebo at Week 26.
62569424|NCT02151851|PLACEBO_COMPARATOR|Placebo + Methotrexate|"Subjects will receive Placebo (1mL / prefilled syringe \[PFS\], ie, 2 injections) at Baseline, and Weeks 2 and 4; then Placebo (1 injection) Q2W until Week 22.~All subjects will continue their treatment on Methotrexate (MTX), with or without folic acid, at the same dose and route of administration as at entry (unless there is a need to reduce the dose for reasons of toxicity, minimum dose permitted 10 mg per week)."
62775980|NCT05307809|EXPERIMENTAL|Psoriatic arthritis|
62000394|NCT02659215|EXPERIMENTAL|Hyalofast with BMAC|A hyaluronan-based scaffold (Hyalofast®) is utilized together with autologous bone marrow aspirate concentrate (BMAC) in a one-step arthroscopic/mini-arthrotomic procedure.
62000395|NCT02659215|ACTIVE_COMPARATOR|Microfracture|Microfracture is an arthroscopic surgical technique involving placement of microfracture penetrations within the cartilage defect to provide stem cells and growth factors from the bone marrow to aid cartilage repair.
62000396|NCT06269471||Trailers|Group of major trail runners who have already taken part in at least one trail running competition in their lives.
62000397|NCT05958212|EXPERIMENTAL|Intervention Group|Participants in the intervention group will receive a weekly gait training program at PolyU in addition to conventional treatment at Outpatient Patient Department (OPD) of The Hong Kong Buddhist Hospital twice per week for 4 consecutive weeks. Gait training program at PolyU is a supervised rehabilitation program performed on the dual-belt treadmill.
62000398|NCT05958212|ACTIVE_COMPARATOR|Control Group|Participants in control group will only receive conventional treatment at Outpatient Patient Department (OPD) of BH twice per week for 4 consecutive weeks.
62000399|NCT02371499|EXPERIMENTAL|1st Arm|Treatment with Lactobacillus casei DG (Enterolactis plus®)
62000400|NCT02371499|PLACEBO_COMPARATOR|2nd Arm|Treatment with equivalent product without bacteria (Enterolactis placebo)
62775981|NCT05307809|ACTIVE_COMPARATOR|Controls|
62775982|NCT06041633||Clinical|One hundred and thirty patients diagnosed with TMD constituted the study group (group I)
62775983|NCT06041633||Control|One hundred and thirty patients were excluded from having TMD based on the RDC/ TMD questionnaire, and these patients constituted the control group (group II).
62775984|NCT01500304|EXPERIMENTAL|Minimally invasive surgery|Minimally invasive inguinal lymph node dissection is a 10-step technique to provide novel inguinal lymph node staging and treatment.
62775985|NCT05675228||young adults|men and women aged 25 to 35
62775986|NCT05216471||Mild illness|individuals who have any of the various signs and symptoms of covid-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) but who do not have shortness of breath, dyspnea, or abnormal chest imaging findings .
62000401|NCT01352390|ACTIVE_COMPARATOR|Control Condition|A basic reminder mailing will prompt each subject to receive a health test as specified on the mailing
62185670|NCT03416413|ACTIVE_COMPARATOR|Foam Sclerotherapy|Injection of foam sclerosant into varicose vein tributaries
62775987|NCT05216471||Moderate illness|individuals who show evidence of lower respiratory tract disease during clinical assessment or imaging and who have an oxygen saturation (SpO2) ≥94% on room air .
62775988|NCT05216471||Severe illness|individuals who have spO2\<94% on room air, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2)\<300 mm hg, respiratory frequency\>30 breaths/min, or lung infiltrate \>50%.
62775989|NCT06020755|EXPERIMENTAL|Toripalimab Plus Actinomycin-D|Toripalimab 200mg intravenously(IV) every 2 weeks (Q2W) Actinomycin-D 1.25mg/m2，2mg max dos, intravenously(IV) every 2 weeks (Q2W)
62000402|NCT01352390|EXPERIMENTAL|Artwork Prompt Condition|A basic reminder mailing will prompt each subject to give their child a reminder postcard to color
62000403|NCT00002816|EXPERIMENTAL|EARLY # CNS RELAPSE with BM DONOR|Induction (Etoposide, Ifosfamide with Mesna Uroprotection,Ifosfamide, Dexamethasone, Vincristine sulfate, PEG, ITT (methotrexate, cytosine arabinoside and therapeutic hydrocortisone), and leucovorin calcium then Intensification (4 courses of 6 weeks, ITT, dexamethasone, vincristine, methotrexate, leucovorin, 6-Thioguanine, cytarabine (Ara-C), Etoposide, pegaspargase, Ifosfamide with Mesna) and Idarubicin and CXRT.
62000404|NCT00002816|EXPERIMENTAL|LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR|Induction (Etoposide, Ifosfamide with Mesna Uroprotection,Ifosfamide, Dexamethasone, Vincristine sulfate, pegaspargase, ITT (methotrexate, cytosine arabinoside and therapeutic hydrocortisone), and leucovorin calcium then Intensification (4 courses of 6 weeks, ITT, dexamethasone, vincristine, methotrexate, leucovorin, 6-Thioguanine, cytarabine (Ara-C), Etoposide, PEG, Ifosfamide with Mesna) and Idarubicin), and Maintenance (4 x 12 courses) of ITT, Vincristine, Methotrexate, T-thioguanine.
62000405|NCT03073278|OTHER|Group 1|This group of 12 patients will be given 36Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
62000406|NCT03073278|OTHER|Group 2|This group (12 patients) will be given 38Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
62000407|NCT03073278|OTHER|group 3|This group (12 patients) will be given 40Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
62000408|NCT01536496|ACTIVE_COMPARATOR|Control (INR, PTT, fibrinogen, D-dimer)|Patients randomized to the Control Group will receive blood component therapy guided by conventional coagulation tests per usual clinical practice. The control arm involves the use of conventional coagulation tests (aPTT, INR, fibrinogen level, D-dimer) to diagnose and describe post-injury coagulopathy and to guide blood product replacement. In the Control Group, blood will be drawn for conventional coagulation testing (aPTT, INR, platelet count, fibrinogen level, D-dimer) at Baseline (as defined above), then twice more during the first six hours at the discretion of the treating team, then again at 12 hours and at 24 hours post-injury. The current institutional massive transfusion protocol will be followed. Only the results pertinent to the group to which randomized will be released to the treating team, unless otherwise requested.
62000409|NCT01536496|ACTIVE_COMPARATOR|Test (r-TEG)|Patients randomized to the r-TEG guided haemostatic resuscitation group (Test Group) will receive blood component therapy per usual clinical practice. The test arm involves the use of rapid-TEG to diagnose and describe post-injury coagulopathy and to guide blood product replacement per institutional algorithm. In the Test Group, blood for r-TEG will be collected on admission, or upon entering the operating room, depending on the acuity of the injury (Baseline), and this will be followed by two additional r-TEG analyses during the first six hours at the discretion of the treating team (attending surgeon, anesthesiologist) and then two further r-TEG analyses at 12 hours and at 24 hours post-injury respectively. The current institutional massive transfusion protocol will be followed. Only the results pertinent to the group to which randomized will be released to the treating team, unless otherwise requested.
62000410|NCT04546958|ACTIVE_COMPARATOR|Nutritional counseling arm|Nutritional counseling, targeting daily protein intake 1.2 g/kg Dietitian will provide one-to-one dietary education, 30 minutes duration, on a monthly basis
62000411|NCT04546958|EXPERIMENTAL|Nutritional counseling plus whey protein supplements arm|Nutritional counseling plus whey protein supplements, targeting daily protein intake 1.5 g/kg In addition to receiving nutritional counseling, participants are instructed to take an additional whey protein supplement at the dose of \~0.3 g/kg protein intake.
62569425|NCT04798911||Observational - phase 1|"Determination of Informational Needs (Months 0- 9)~* Qualitative interviews with patients with SS~* Interview transcriptions and thematic analysis"
62000412|NCT01296516|PLACEBO_COMPARATOR|Control Group|A group matched for age and BMI will be selected to serve as control subjects in this study.
62394359|NCT05531565|PLACEBO_COMPARATOR|Part B (Phase 3): Placebo|Participants will receive litifilimab-matching placebo SC Q4W from Week 0 to Week 20, with an additional dose of litifilimab-matching placebo at Week 2 during the DBPC treatment period. Following the DBPC treatment period, participants will receive litifilimab during the ETP from Week 24 to Week 48, with an additional dose of litifilimab at Week 26.
62569426|NCT04798911||Observational - phase 2|"Phase 2 Development of the informational need instrument for SS \[SS-INQ\] (Months 9-32)~* Adaptation of TINQ-BC for use in patients with SS - generation of relevant questions using themes from Phase 1 qualitative study (removal of those solely related to breast cancer from TINQ-BC) by the expert group~* Pilot testing of SS-INQ for content and readability will be done via focus groups whilst structural validity will be explored using factor analysis~* Testing of SS-INQ for reliability - internal consistency reliability and test-retest reliability"
62394360|NCT04839900|ACTIVE_COMPARATOR|Proactive iCCM|Community health workers (CHWs) will conduct weekly visits of all households in their communities to detect children \< 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. Weekly household visits will be conducted year round. CHWs will be available for consultation throughout the week for sick visit consultations as per national iCCM policy (with malaria case management for all ages).
62394361|NCT04839900|NO_INTERVENTION|Standard Passive iCCM|Community health workers (CHWs) will provide case management per national iCCM policy to all who are brought for consultation, but will not conduct household visits to provide active case detection. CHWs will be available for consultation throughout the week for sick visit consultations as per national iCCM policy (with malaria case management for all ages).
62394362|NCT00390741|ACTIVE_COMPARATOR|1|Home-based exercise program
62394363|NCT00390741|NO_INTERVENTION|2|Usual care
62000413|NCT01296516|ACTIVE_COMPARATOR|Face-to-face group|Participants randomized to the face-to-face intervention will attend motivational meetings held once per week in Phase I and biweekly in Phase II. Behavioral sessions will be led by a trained interventionist and will take place at Pennington Biomedical Research Center.
62394364|NCT00629135|EXPERIMENTAL|1|For adult patients with intra-abdominal abscesses matching the criteria to be included will and enrolled in the study arm 1: Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily.
62394365|NCT00629135|ACTIVE_COMPARATOR|2|For adult patients with intra-abdominal abscesses matching the criteria to be included will and enrolled in the study arm 2: Piperacillin / Tazobactam 4,5 g administered intravenously three times daily
62000414|NCT01296516|ACTIVE_COMPARATOR|Telehealth Group|Participants randomized to the Telehealth intervention will receive behavioral counseling through Trestletree, phone system.
62569427|NCT00317187|EXPERIMENTAL|Hib-MenAC Lot 1 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 1 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
62000415|NCT02348528|EXPERIMENTAL|Lenalidomide and dexamethasone|"Cycle 1: 25 mg oral lenalidomide once daily on Days 1-21 every 28 Days and 40 mg oral dexamethasone on Days 8, 15, and 22. Cycle 2 and beyond: 25 oral lenalidomide once daily on Days 1-21 every 28 days and 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22.~The starting doses of Rd regimen will be the same last doses that the subjects received in Study CC-5013-MM-021, unless event(s) that require dose adjustments (dose modifications, reductions and interruptions) per protocol occurred prior to roll-over."
62000416|NCT04548674|PLACEBO_COMPARATOR|Positive Control Group|Whiteness HP 35%
62000417|NCT04548674|EXPERIMENTAL|Laser Group|Whiteness HP 35% + Laser
62569428|NCT00317187|EXPERIMENTAL|Hib-MenAC Lot 2 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 2 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
62775990|NCT01343732|NO_INTERVENTION|healthy volunteeres|this arm will undergo only EEG measurement
62000418|NCT04548674|EXPERIMENTAL|CPP Group|Whiteness HP 35% + CPP
62000419|NCT04548674|EXPERIMENTAL|Nano Group|Whiteness HP 35% + NANO
62000420|NCT04548674|NO_INTERVENTION|Negative Control|Without intervention
62000421|NCT04534842|EXPERIMENTAL|SYNB1618|Dose ramp of SYNB1618
62000422|NCT04534842|EXPERIMENTAL|SYNB1934|Dose ramp of SYNB1934
62000423|NCT03571087|EXPERIMENTAL|HL140 5/10|Treatment(W0\~W8), Extension(W9\~W20): : 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)
62000424|NCT03571087|EXPERIMENTAL|HL140 10/10|Treatment(W0\~W8), Extension(W9\~W20): : 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)
62000425|NCT03571087|EXPERIMENTAL|HL140 20/10|Treatment(W0\~W8), Extension(W9\~W20): : 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)
62394366|NCT01752244|EXPERIMENTAL|Alfacalcidol|Alfacalcidol
62394367|NCT01752244|PLACEBO_COMPARATOR|Placebo|Corn oil pearl Capsules 1 gram: were given to the intervention group once a day for 8 weeks
62000426|NCT03571087|EXPERIMENTAL|Rosuvastatin 5mg → HL140 5/10|"1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 5mg~2. Extension period(W9\~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)"
62000427|NCT03571087|EXPERIMENTAL|Rosuvastatin 10mg → HL140 10/10|"1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 10mg~2. Extension period(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)"
62000428|NCT03571087|EXPERIMENTAL|Rosuvastatin 20mg → HL140 20/10|"1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 20mg~2. Extension period(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)"
62000429|NCT01720069|ACTIVE_COMPARATOR|Dose 1 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
62000430|NCT01720069|ACTIVE_COMPARATOR|Dose 2 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
62000431|NCT01720069|ACTIVE_COMPARATOR|Dose 3 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
62000432|NCT02134457|EXPERIMENTAL|Ranibizumab 0.12 mg|"20 µl of the 6 mg/ml ranibizumab concentration will be applied intravitreally. After an initial response the same dose as in the first injection can be re-applied after at least four weeks post injection.~A maximum number of 3 regular re-injections can be applied."
62000433|NCT02134457|EXPERIMENTAL|Ranibizumab 0.20 mg|"20 µl of the 10 mg/ml ranibizumab concentration will be applied intravitreally. After an initial response the same dose as in the first injection can be re-applied after at least four weeks post injection.~A maximum number of 3 re-injections can be applied."
62000434|NCT03102918|ACTIVE_COMPARATOR|Cannabidiol|Epidiolex
62000435|NCT03102918|PLACEBO_COMPARATOR|Placebo|Placebo
62000436|NCT02299050|OTHER|Cycloset|"Drug - Cycloset Cycloset 2.4 -3.2 mg/day~Other Names:~Bromocriptine Mesylate Quick Release"
62000437|NCT06135662|ACTIVE_COMPARATOR|CAF + CTG|This arm involves patients treated with the Coronally Advanced Flap (CAF) technique, a recognized method for treating gingival recession. As an active comparator, this arm serves to compare the effectiveness and outcomes of CAF against the alternative surgical method used in the study.
62394368|NCT00804804|EXPERIMENTAL|Y1|young volunteers (20-30 years), morningness chronotype
62394369|NCT00804804|EXPERIMENTAL|Y2|young volunteers (20-30 years), eveningness chronotype
62394370|NCT00804804|EXPERIMENTAL|O1|Aged volunteers (65-75 years), morningness chronotype
62394371|NCT00804804|EXPERIMENTAL|O 2|aged volunteers (65-75 years), eveningness chronotype
62000438|NCT06135662|ACTIVE_COMPARATOR|Tunnel Technique + CTG|Patients in this arm receive the Tunnel Technique (TT) with Connective Tissue Grafts (CTG). Also an established method for gingival recession treatment, this arm acts as an active comparator to assess and compare the effectiveness of TT+CTG against the CAF technique.
62394372|NCT06420921|EXPERIMENTAL|Participants with cochlear implant|
62394373|NCT06420921|ACTIVE_COMPARATOR|Normal hearing participants|
62394374|NCT02927990||Study group|Percutaneous coronary interventions with additional imaging provided by the new software package
62394375|NCT02927990||Control group|Percutaneous coronary interventions without the new software package
62394376|NCT02616120|PLACEBO_COMPARATOR|Placebo|placebo identified to SQJZ herbal mixtures, 29.375g, 2 times per day.for 12 weeks.
62394377|NCT02616120|ACTIVE_COMPARATOR|SQJZ herbal mixtures|SQJZ herbal mixtures 29.375g, 2 times per day.for 12 weeks.
62775991|NCT01343732|ACTIVE_COMPARATOR|real - low frequency|this arm will receive DTMS treatment with low frequency
62791673|NCT04247737|EXPERIMENTAL|gluten free diet|six week gluten free diet
62000439|NCT02173197||OT arm|"Through the initial evaluation of the complex patients' needs, the OT will propose a targeted intervention to the needs emerged and decide which approach will use to achieve the goal (i.e. compensatory or restorative).~We will describe the characteristics of the population included and identify common needs and problems of the complex patients through the COPM.~The needs and problems identified will be grouped into macro-areas, and the OT will propose the appropriate treatment on the basis of the area identified, the patient's needs and the available resources regardless of the origin of the disease."
62000440|NCT01092247|PLACEBO_COMPARATOR|Standard diet: Nutritional support|
62000441|NCT01092247|EXPERIMENTAL|Nutritional intervention: Ketogenic diet.|
62000442|NCT03791658|OTHER|Asthmatics|"From the patients file the following information will be collected by the investigators:~* Age~* Sex~* FEV1 derived from the last spirometry (including spirometry performed on day of study visit).~* GINA step (Global Initiative for Asthma).~* Number of exacerbations in the year prior to the study.~* The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.~* Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of asthma.~* FENO (Fraction Exhaled Nitric Oxide) from the day of the study visit (if available).~Patients will fill out:~* The 12-question TAI-questionnaire (test for the adherence to inhalers)~* The Asthma Control Test (ACT)"
62000443|NCT03791658|OTHER|COPD-patients|"From the patients file the following information will be collected by the investigators:~* Age~* Sex~* Pack Years~* GOLD stage (Global Initiative for Chronic Obstructive Lung Disease)(post-bronchodilator FEV1)~* Number of exacerbations in the year prior to the study.~* The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.~* Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of COPD.~Patients will fill out:~* The 12-question TAI-questionnaire (test for the adherence to inhalers)~* The COPD Assessment Test (CAT)"
62000444|NCT02788734||INC Contact Registry|INC Contact Registry will complete the online questionnaires
62000445|NCT02813343|EXPERIMENTAL|Immediate Treatment Group|The Immediate Treatment group will receive access to the study intervention - BlueStar app, immediately after consenting for a total duration of 6 months.
62000446|NCT02813343|OTHER|Delayed Treatment Group|The Delayed Treatment group will receive access to the study intervention - BlueStar app, 3 months after consenting for a total duration of 3 months.
62000447|NCT01816464|EXPERIMENTAL|Trivalent Influenza Vaccine|"The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus;~* a B/Wisconsin/1/2010-like virus.~Dose: Single Dose 0.5 mL of TIV from pre-filled syringe."
62000448|NCT00820612|ACTIVE_COMPARATOR|1|Indomethacin suppository
62000449|NCT00820612|PLACEBO_COMPARATOR|2|Placebo suppository
62000450|NCT03816631|EXPERIMENTAL|Part A: Group 1: Severe hepatic function|Participants with severe hepatic function will receive single oral dose of pimodivir 600 milligram (mg) (2\*300 mg tablet) under fasted condition on Day 1.
62000451|NCT03816631|EXPERIMENTAL|Part A and B: Group 2: Normal hepatic function|Participants with normal hepatic function will receive single oral dose of pimodivir 600 mg (2\*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
62000452|NCT03816631|EXPERIMENTAL|Part B: Group 3: Moderate hepatic function|Participants with moderate hepatic function will receive single oral dose of pimodivir 600 mg (2\*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
62000453|NCT03816631|EXPERIMENTAL|Part B: Group 4: Mild hepatic function|Participants with mild hepatic function will receive single oral dose of Pimodivir 600 mg (2\*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
62000454|NCT02637843|ACTIVE_COMPARATOR|Slender arm|Uses the terumo slender sheath for radial angiography or angioplasty
62000455|NCT02637843|NO_INTERVENTION|Standard arm|Uses the terumo standard sheath (Routine) for radial angiography or angioplasty
62000456|NCT03789201|EXPERIMENTAL|Healthy Volunteers|thematic permission to use non-invasive techniques regarded as having minimal risk in healthy individuals, such as, MRI, EEG, EMG, low-frequency stimulation (= 1 Hz), electrical stimulation of the skin to mimic the somatosensory artifact of TMS, and behavioral tests
62000457|NCT05256238|EXPERIMENTAL|usual supportive care + comprehensive supervised exercise program (CSEP)|
62000458|NCT05256238|NO_INTERVENTION|usual supportive care|
62394378|NCT03567811|OTHER|Chronic Fatigue Syndrome|"Inclusion and exclusion criteria based on 1994 Center for Disease Control (Fukuda) criteria of persistent, disabling, moderate to severe fatigue that was relieved by rest, plus at least 4 of the 8 following ancillary features: cognitive dysfunction affecting short term memory or concentration, sore throat, sore lymph nodes, sore muscles, sore joints, headache, sleep disturbance, and exertional exhaustion (post-exertional malaise). Intervention: Procedure/Surgery: Submaximal bicycle exercise stress test on Days 1 and 2"
62000459|NCT04182035|EXPERIMENTAL|Patient-tailored treatment group|Objectives \& approach: The subjects in the PTT group will receive the individual tailored treatment program combining best evidence active and passive treatment strategies (manual therapy, individual exercises) in combination with education tailored to the individual situation of the patient and selected home exercises. 9 individual therapy sessions will be performed, in combination with 9 additional home exercise sessions.. NRS and NDI-scores will be monitored before every treatment. The therapist will register when the cut-off score of 30% NDI reduction is present in order to determine the evolution in pain/disability reduction. The importance of self-efficacy will be emphasized and tailored home-exercises will be monitored and adjusted every week.
62185671|NCT02854371|EXPERIMENTAL|CLD and LC|Patients with underlying chronic liver disease. Gadoxetic acid enhanced liver MRI and ICG R15 are performed in this group.
62185672|NCT00675792|EXPERIMENTAL|Sugammadex|4 mg/kg sugammadex
62569429|NCT00317187|EXPERIMENTAL|Hib-MenAC Lot 3 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 3 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
62569430|NCT00317187|ACTIVE_COMPARATOR|Hiberix Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB vaccine mixed extemporaneously with conjugate vaccine Hiberix at 2, 4 and 6 months of age as intramuscular injection in the anterolateral part of the thigh.
62775992|NCT01343732|ACTIVE_COMPARATOR|real - high frequency|this arm will receive DTMS treatment with high frequency
62775993|NCT01343732|SHAM_COMPARATOR|sham - low / high frequency|this arm will receive DTMS sham treatment with low or high frequency
62775994|NCT04940884|EXPERIMENTAL|Supervised exercise training|Pre- and Post- exercise training effects. Part of the participants were randomly assigned to underwent additional 24 sessions of supervised exercise training (SET) and the remaining participants follow the above instruction without additional supervised exercise training. After the 24 sessions of SET, they were then followed a 16-week of follow-up of their daily activities without additional exercise training.
62394379|NCT03567811|OTHER|Sedentary Control|Subjects who lived a sedentary lifestyle, did not meet Chronic Fatigue Syndrome criteria, and did not have any exclusionary chronic medical, psychiatric or other conditions were our Sedentary Control subjects. By design, this control group included controlled Type II diabetes and thyroid disease, chronic idiopathic fatigue, hypertension (other heart disease excluded) and other stable medical conditions. This variety of subjects were included to prevent ceiling (CFS) vs. floor (control) effects if the control group had totally pristine subjects with zero health issues. Intervention: Procedure/Surgery: Submaximal bicycle exercise stress test on Days 1 and 2
62775995|NCT04940884|ACTIVE_COMPARATOR|home exercise training|All included subjects were instructed to walk\>=8000 steps per day (stp/d), which was recorded by wrist-worm smart watches
62775996|NCT04228432|EXPERIMENTAL|Patients with breast cancer treated by adjuvant hormonotherapy|
62775997|NCT02942654|EXPERIMENTAL|LY900014|Test formulation. 15-U dose of LY900014 administered subcutaneously (SC) in one of two periods.
62000460|NCT04182035|ACTIVE_COMPARATOR|Non patient-tailored treatment group|Objectives \& approach: The NPTT will receive an individual (hands-off) treatment, which includes an active neck exercise program, non-tailored education and non-tailored home exercises, according to a previously published program with good results.53 The sessions will be performed once a week under supervision (9 therapy sessions, standard exercise program) and once a week by the patient at home (9 home exercise sessions, standard exercise program).
62394380|NCT01160029|EXPERIMENTAL|Nateglinide|Nateglinide Tablets 120 mg of Dr. Reddys Laboratories Limited
62394381|NCT01160029|ACTIVE_COMPARATOR|Starlix|Starlix Tablets 120 mg of Novartis
62394382|NCT02853097||Ancillary-Correlative (blood collection)|Patients undergo blood collection every 4-12 weeks during ADT, abiraterone, enzalutamide, or docetaxel treatment. Patients switched from ADT to either abiraterone or enzalutamide during the study will undergo phlebotomy every 6-12 weeks. Samples are analyzed for cfRNA, and cfDNA, AR-V7, and other AR-Vs via quantitative RT-PCR.
62569431|NCT01913548||Sickle Cell Disease (SCD)|Patients with sickle cell diseases, 16 years or older with 10-20 years of transfusion (defined as 0.2-0.6mg Fe/kg/day exposure with annual ferritin levels greater than 2500 in at least 60% of years of chronic transfusion); 0 to 9 years old at the initiation of chronic transfusions; no exchange transfusions in the previous 6 months; and iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC (liver iron content) of greater than 7 mg/g dry wt in the previous 6 months or ferritin level greater than 1500mg/dl.
62775998|NCT02942654|ACTIVE_COMPARATOR|Insulin Lispro|Reference formulation. 15-U dose of Insulin Lispro administered SC in one of two periods.
62775999|NCT01137253|EXPERIMENTAL|Trimethaphan|Response to intrabrachial vasodilators during autonomic withdrawal
62776000|NCT01137253|PLACEBO_COMPARATOR|Placebo|Response to intrabrachial vasodilators during saline intravenous (IV) infusion
62776001|NCT04029571|EXPERIMENTAL|TCM-FMD|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
62185673|NCT00675792|ACTIVE_COMPARATOR|Neostigmine|50 µg/kg neostigmine
62569432|NCT01913548||Thalassemia Major (TM)|Patients with β-thalassemia major and transfusion-dependent E-beta THAL. 16 years or older with 10-20 years of chronic transfusion (defined above), 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
62776002|NCT04029571|ACTIVE_COMPARATOR|FMD|"A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD."
62776003|NCT04029571|NO_INTERVENTION|Normal diet|Carrying out normal diet under the guidance of a dietitian, for 12 weeks.
62776004|NCT02427503||Asthma with NP and require surgery|Patients receiving standardized treatment for nasal polyposis, according to the POLINA guidelines and for persistent asthma who will undergo FESS-BP.
62776005|NCT02427503||Asthma with NP and NOT require surgery|Patients receiving standardized treatment for nasal polyposis, according to the POLINA guidelines and for persistent asthma who will NOT undergo FESS-BP.
62791674|NCT02088489|ACTIVE_COMPARATOR|Atrial flutter, irrigated catheter|Patients with isthmus dependent atrial flutter, undergone to catheter ablation with Thermocool® (Biosense Webster, Diamond Bar, CA) irrigated catheter
62185674|NCT01896453|ACTIVE_COMPARATOR|tDCS real + TENS real|"Real transcranial direct current stimulation associated with real transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes, 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
62394383|NCT06088017|EXPERIMENTAL|Sequence 1|"* Period 1: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition~* Period 2: CKD-391(2) - A single oral dose of 1 tablet under fasting condition~* Period 3: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition~* Period 4: CKD-391(2) - A single oral dose of 1 tablet under fasting condition"
62394384|NCT06088017|EXPERIMENTAL|Sequence 2|"* Period 1: CKD-391(2) - A single oral dose of 1 tablet under fasting condition~* Period 2: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition~* Period 3: CKD-391(2) - A single oral dose of 1 tablet under fasting condition~* Period 4: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition"
62776006|NCT03595488|EXPERIMENTAL|Treatment arm|"Single-blinded, Dupilumab or matching placebo will be administered to the patients at the study visits. At each study visit, a single dose of dupilumab or placebo will be dispensed to the patients to be administered at home.~300 mg/2 ml solution in a single-dose pre-filled syringe with needle shield given once every 2 weeks in a subcutaneous injection"
62776007|NCT05327764|ACTIVE_COMPARATOR|40:20|Walking for 40 minutes, resting for 20
62776008|NCT05327764|EXPERIMENTAL|20:10|Walking for 40 minutes, resting for 20
62776009|NCT03584243|EXPERIMENTAL|Patient with progressive keratoconus|"Patient with progressive keratoconus will be included after providing their consent.~The intervention administrated is a cross-linking with oxygen treatment"
62776010|NCT03149029|EXPERIMENTAL|BRAFV600 mutant|"* Pembrolizumab administered intravenously every three weeks~* Dabrafenib taken every twelve hours orally~* Trametinib taken every twelve hours orally"
62776011|NCT03149029|EXPERIMENTAL|BRAFV600 wild type|"* Pembrolizumab administered intravenously every three weeks~* Trametinib taken every twelve hours orally"
62776012|NCT04588181|EXPERIMENTAL|CBT 6 sessions|
62776013|NCT04588181|ACTIVE_COMPARATOR|CBT 12 sessions|
62776014|NCT00791596|EXPERIMENTAL|1|The first Arm received the intervention between baseline and the first follow-up, whereas the second Arm was the Control group
62394385|NCT00985114|EXPERIMENTAL|Device|EndoBarrier implanted for 6 months. Subject followed for 6 months after device was explanted.
62569433|NCT01913548||Diamond Blackfan Anemia (DBA)|Patients with DBA, 16 years or older with 10-20 years of transfusion, 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
62569434|NCT00462709|EXPERIMENTAL|Open-label C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 7 days.
62584807|NCT03554395|NO_INTERVENTION|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62584808|NCT06685458||Benign Nodule Group|Participants with benign solid pulmonary nodules.
62776015|NCT00791596|EXPERIMENTAL|2|The second Arm received the intervention between the third and the fourth follow-up, whereas the first Arm was the Control group
62776016|NCT03903939|EXPERIMENTAL|Iloprost|Patients randomized to active treatment (n = 110 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first
62776017|NCT03903939|PLACEBO_COMPARATOR|Placebo|Patients randomized to placebo treatment (n= 110 patients) will receive continuous infusion of isotonic saline (equal volume) for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
62776018|NCT05515289|EXPERIMENTAL|Treatment group: mild renal insufficiency|
62776019|NCT05515289|EXPERIMENTAL|Treatment group: moderate renal insufficiency|
62185675|NCT01896453|EXPERIMENTAL|tDCS real + TENS sham|"Real transcranial direct current stimulation associated with sham transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes (30 seconds ON), 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
62185676|NCT01896453|EXPERIMENTAL|tDCS sham + TENS real|"Sham transcranial direct current stimulation associated with real transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes, 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
62394386|NCT00985114|ACTIVE_COMPARATOR|Diet + Lifestyle counseling|Multidisciplinary lifestyle and nutritional counseling for 12 months
62394387|NCT05164068|EXPERIMENTAL|Information video|The experimental group likewise consisted of 60 individuals that received information about the biopsy procedure in video format
62776020|NCT05515289|EXPERIMENTAL|Treatment group: healthy subjects|
62776021|NCT05849519|EXPERIMENTAL|Intervention Group|Procedure:Coenzyme I for Injection,5mg，im，qd；Nacl，2ml，im，qd.
62776022|NCT05849519|OTHER|Control Group|Procedure: conventional treatment.
62394388|NCT05164068|NO_INTERVENTION|Information face-to -face|The control group consisted of 60 patients that received face-to-face verbal information in a homogeneous and reproducible manner
62776023|NCT01826734||Patients with dacryolits|The study population consisted of patients following a dacryolit extraction procedure. The extraction procedure was not a part of this study.
62000461|NCT04182035|NO_INTERVENTION|Control group|The subjects randomized to the control group will not receive any intervention, if necessary medication use is permitted and will be monitored using the iMTAQ. Patients will be asked not to seek other treatment options (if possible). If this is not possible, patients will be considered lost to follow-up.
62000462|NCT05262205|ACTIVE_COMPARATOR|sevoflurane group with BIS monitor for depth of anesthesia|child will be anesthetized with sevoflurane 2% and atracurium 0.25mg/kg and paracetamol 15mg/kg, then bispectral index will be recorded after intubation and every five minutes till end of surgery. Position of the globe will recorded every five minutes. Angle of deviation of the globe will be calculated via withdrawing horizontal line passing from the lateral and medial canthi, and another vertical one passing the medial canthus(90-0--90 degree). Bis should be 40-65 to ensure adequate depth of anesthesia. If more than 65 or less than 40, sevoflurane concentration will be adjusted till having the target range. pupillary dilation in surgical eye will be assessed after speculum insertion, 20 minutes after speculum insertion, and before speculum removal by pupil ruler((pupil gauge), whether it will be maintained or not (considered maintained if pupil size equal or more than 5mm).
62000463|NCT05262205|ACTIVE_COMPARATOR|propofol-midazolam group with BIS monitor for depth of anesthesia|Child will be anesthetized with midazolam 0.05 mg/kg IV bolus and propofol 1mg/kg IV bolus, paracetamol 15mg\\kg IV infusion, and atracurium 0.25mg/kg IV bolus ,then anesthesia will be maintained with propofol infusion according to Mcfarlan protocol, then BIS will be recorded after intubation and every five minutes till end of surgery. Position of the globe will recorded every five minutes till the end of surgery. Angle of deviation will be calculated in same way as group A. Bis should be 40-65. If more than 65 or less than 40, sevoflurane concentration will be adjusted till having the target range. pupillary dilation in surgical eye will be assessed after speculum insertion, 20 minutes after speculum insertion, and before speculum removal by pupil ruler((pupil gauge) and will be observed all over the surgery with the help of surgeon feedback whether it will be maintained or not (considered maintained if pupil size equal or more than 5mm).
62000464|NCT04196166||Cases|nested from on going retrospective cohort study. Participants who had change in their surgical plan after hospitalization.
62000465|NCT04196166||Controls|nested from on going retrospective cohort study. Participants who didn't have change in their surgical plan after hospitalization.
62000466|NCT04073316|EXPERIMENTAL|"Intervention group"|
62000467|NCT04073316|ACTIVE_COMPARATOR|"Control group"|
62000468|NCT04107480|EXPERIMENTAL|Intervention|Patients in the intervention groups will be referred to one of the participating neurosurgical centers, for surgical consultation. After this consultation, the patient may choose to continue with surgery or not.
62000469|NCT04107480|ACTIVE_COMPARATOR|Standard care|Patients in the standard care groups will receive treatment as usual as described by the US Endocrine Society.
62000470|NCT03192839|EXPERIMENTAL|Low dose PUFA|
62000471|NCT03192839|EXPERIMENTAL|High dose PUFA|
62000472|NCT03192839|PLACEBO_COMPARATOR|Placebo|
62000473|NCT04618718|EXPERIMENTAL|Intervention|ProtEmbo device will be used as distal protection device in subjects undergoing TAVR
62000474|NCT02321696|EXPERIMENTAL|Acupuncture and eccentric exercise|Treatment will be performed according to traditional Chinese methods (STRICTA: Standards for reporting interventions in controlled trials of acupunc-ture). Therapists will select points frequently recommended for the treatment of LE. As local point, LI11 and LI10 over the muscular origin of the lateral extensor group of the forearm will be used, and LU5 in the cubical region. LI4 and TE5 will be regional points for pain therapy in the upper limb, GB34 will be used as a distal point for treatment of tendinosis in general, and ST36 for treatment of pain. Needles will be inserted down to the musculature and obtaining De Qi sensation and will remain in situ for 20 min. All patients will receive four treatment sessions; this may be extended to eight depending on patient's pain report and the therapists' clinical evaluation. Maximum treatment period is 4 weeks. Patients will also be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward.
62584809|NCT06685458||Malignant Nodule Group|Participants with malignant solid pulmonary nodules.
62394389|NCT04976205|EXPERIMENTAL|TMI/TMLI|"The standard planning optimization for TMI/TMLI preview a two-free-breathing-CT scan without contrast will be performed for simulation at day -15(-10) to the BMT. The same day a WB-MRI will be acquired for lymph-nodes delineation. WB-MRI scans will be performed using a 1.5T MR scanner. The two CT will be co-registered to the WB-MRI.~CTV will be manually defined as the bones excluding mandible and hands (CTVBones), the spleen (CTVSpleen), and lymph nodes (CTVLN) using both MRI and CT images. The day -3 (4) to the BMT, further two-CT series will be acquired and co-registered to the first CTs for dose verification. Pre-treatment quality assurance (QA) will be performed the day before the treatment using the standard internal procedure.~The treatment will be performed the day before the BMT."
62584810|NCT05274854|EXPERIMENTAL|Preconsultation Intervention|Pre-consultation intervention includes 4 arms ((a) standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing)
62776024|NCT04803955|EXPERIMENTAL|16mg,KB|Group A:16mg,Q8h±3min,Day1-Day7
62776025|NCT04803955|PLACEBO_COMPARATOR|Placebos|Group B:Placebos,Q8h±3min,Day1-Day7
62776026|NCT01654809|EXPERIMENTAL|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
62776027|NCT01654809|ACTIVE_COMPARATOR|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
62776028|NCT01654809|ACTIVE_COMPARATOR|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
62776029|NCT00718770|EXPERIMENTAL|Bexarotene|Open label - all patients receive intervention
62776030|NCT03125694|ACTIVE_COMPARATOR|Sitagliptin|
62776031|NCT03125694|ACTIVE_COMPARATOR|Pioglitazone|
62000475|NCT02321696|EXPERIMENTAL|Physiotherapy and eccentric exercise|"Manual techniques as gliding mobilization of elbow, therapists are spezialised in manual therapy. At least four treatment sessions will be performed, but depending on the patient's perceived intensity of pain and the therapists' clinical evaluation, a maximum of eight treatment session can be given. All treatment session will be performed during a period of maximum 4 weeks.~In addition, patients will be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward."
62000476|NCT02321696|ACTIVE_COMPARATOR|Watchful waiting and eccentric exercise|Patients will be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward.
62185677|NCT01896453|SHAM_COMPARATOR|Sham tDCS + Sham TENS|"Sham transcranial direct current stimulation associated with sham transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes (30 seconds ON), 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
62185678|NCT06140394|ACTIVE_COMPARATOR|old age group|old age group above 60 years old
62776032|NCT05896813|EXPERIMENTAL|CMOP+Chi|Cyclophosphamide: 750 mg/m2, d1; Mitoxantrone Hydrochloride Liposome: 20 mg/m2, d1; Vincristine: 1.4 g/m2, d1 (maximum dose of 2 mg), or vindesine 3 mg/m2, d1; Prednisone: 60 mg/m2, d1-d5; Chidamide:20 mg, biw. The treatment is administered every 3 weeks as a cycle and lasts for a total of 6 cycles.
62776033|NCT02248636|EXPERIMENTAL|Real discontinuation|This group is tapered off their previous cholinesterase inhibitor medication.
62185679|NCT06140394|PLACEBO_COMPARATOR|young aged group|young age group below 40 years old
62394390|NCT06219304|EXPERIMENTAL|Multimodal functional training|Multimodal training to reduce fatigue and to improve balance and strength
62776034|NCT02248636|SHAM_COMPARATOR|Sham discontinuation|This group receives their previous cholinesterase inhibitor medication, but in in placebo form.
62776035|NCT05730972|EXPERIMENTAL|true TEAS|"A pair of conductive gel patch, connecting to the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, are respectively affixed to the ipsilateral Jiaji acupoint group (EX-B2) or the ipsilateral limb acupoint group(Hegu (LI4) - Waiguan (TE5), or Zusanli (ST36) - Sanyinjiao (SP6)), so as contralateral side.~A single TEAS treatment takes 30 min. TEAS specific parameters were dilatation wave 2Hz and stimulus current intensity in degrees as tolerated by the patient.~7 days was considered as 1 session. Self-controlled treatment refers to not setting an upper limit on the number of treatment times, but must have met at least 3 days or 5 times of TEAS treatment within each session.~A total of 4 sessions of treatment were administered."
62776036|NCT05730972|SHAM_COMPARATOR|sham TEAS|Each step of the sham TEAS operation is the same as the TEAS group. A total of 4 sessions of treatment were administered. 10 free TEAS treatments will be given after the trial.
62776037|NCT00439036|EXPERIMENTAL|Behavior Therapy: Acceptance and Commitment Therapy|"The Act-ODT intervention consists of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.~--------------------------------------------------------------------------------"
62791675|NCT02088489|EXPERIMENTAL|Atrial flutter, porous tip catheter|Patients with isthmus dependent atrial flutter, undergone to catheter ablation with Thermocool® SF(Biosense Webster, Diamond Bar, CA) irrigated catheter
62394391|NCT06219304|ACTIVE_COMPARATOR|Usual care|Rehabilitative intervention to improve balance and mobility
62394392|NCT02023476|EXPERIMENTAL|wide tourniquet|(Zimmer A.T.S.®3000 ) wide tourniquet MRI intervention
62394393|NCT02023476|ACTIVE_COMPARATOR|narrow tourniquet|HemaClear ™ tourniquet MRI intervention
62394394|NCT06316076|EXPERIMENTAL|CD19-CAR-DNT cells|8-24 patients are planned to be enrolled in the dose-escalation trial and 12-24 patients in the dose-expansion trial.
62394395|NCT02723461|ACTIVE_COMPARATOR|pulsatile oxytocin|Using a programmable syringe pump, the pulsatile regime, oxytocin (Syntocinon, stock solution: 10 iU/mL) will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). This regime stems from the observation that physiologic oxytocin may be released in a pulsatile fashion every 4-6 minutes (Dawood et al.,1979)
62394396|NCT02723461|ACTIVE_COMPARATOR|continuous oxytocin|Continuous group will be administrated oxytocin (Syntocinon, stock solution: 10 iU/mL) at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
62569435|NCT05509907|EXPERIMENTAL|healthy adolescents within 12-18 years old|Adolescents aged 12-18 years who continue secondary education, do not have any chronic diseases or disabilities and volunteer to participate in the study will be included. Within the scope of the project, participants' demographic data, health parameters, physical fitness, functional capacity, fatigue level, exercise behavior, system availability and satisfaction will be evaluated. All evaluations, training on the use of smart watches and mobile and web-based physical activity tracking applications will be carried out at the school where the adolescents receive education.
62569436|NCT05509907|EXPERIMENTAL|Adolescents aged 12-18 years with chronic rheumatic disease|Children with rheumatic disease who were diagnosed with chronic rheumatic disease, diagnosed at least 6 months ago, whose medical treatment was stable, and who volunteered to participate in the study will be included. Within the scope of the project, participants' demographic data, health parameters, physical fitness, functional capacity, fatigue level, exercise behavior, system availability and satisfaction will be evaluated. All assessments and training on smartwatches and mobile and web-based physical activity tracking applications will be held at Department of Pediatric Rheumatology, Istanbul Faculty of Medicine, Istanbul University.
62569437|NCT03811548|EXPERIMENTAL|Janagliflozin 25mg|Each patient will receive 25 mg of Janagliflozin once daily for 52 weeks (24 weeks core period followed by 28 Weeks Extension period)
62569438|NCT03811548|EXPERIMENTAL|Janagliflozin 50mg|Each patient will receive 50 mg of Janagliflozin once daily for 52 weeks (24 weeks core period followed by 28 Weeks Extension period)
62569439|NCT03811548|EXPERIMENTAL|Placebo/Janagliflozin|In the core period, each patient will receive placebo once daily for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin once daily until Week 52.
62569440|NCT01573832|EXPERIMENTAL|Diabetic Foot Ulcer Intervention|
62569441|NCT01573832|NO_INTERVENTION|Diabetic Foot Ulcer Usual Care|
62569442|NCT01573832|EXPERIMENTAL|Pionidal Sinus Ulcer Intervention|
62569443|NCT01573832|NO_INTERVENTION|Pionidal Sinus Ulcer Usual Care|
62569444|NCT06209723|EXPERIMENTAL|Vegetarian diet|Vegetarian diet during five weeks
62569445|NCT06209723|NO_INTERVENTION|No change diet|The 'habitual' diet during five weeks. There are no specific restrictions to their diet.
62394397|NCT03518996|EXPERIMENTAL|TMS/tACS|Subjects will receive 5 days of 3x daily rTMS (intermittent theta burst stimulation) or tACS (transcranial alternating current stimulation) targeted over the cerebellum.
62394398|NCT03518996|SHAM_COMPARATOR|Sham TMS/tACS|Subjects will receive 5 days of 3x daily sham stimulation of the cerebellum.
62569446|NCT06491537|EXPERIMENTAL|eTRE Intervention|A 10-hour eating/14-hour fasting time-restricted eating (eTRE) intervention with tapered remote behavioral support sessions delivered by a trained interventionist.
62569447|NCT06491537|ACTIVE_COMPARATOR|Control|Control condition in which participants are instructed to maintain their baseline eating window with tapered remote behavioral support check-ins delivered by a trained interventionist to encourage maintenance of the baseline eating window.
62394399|NCT03639493|EXPERIMENTAL|Sequence 1|"* Period 1: receive Exforge® tab 10/160mg, Crestor® tab 20mg~* Period 2: receive CJ-30060 10/160/20mg"
62394400|NCT03639493|EXPERIMENTAL|Sequence 2|"* Period 1: receive CJ-30060 10/160/20mg~* Period 2: receive Exforge® tab 10/160mg, Crestor® tab 20mg"
62394401|NCT01967927|EXPERIMENTAL|GRID 18F-MISO|
62394402|NCT06722885||Markerless tracking|"* Gross tumor volume for MLT (GTV_MLT): lesion delineated on stable exhale phase of the 4DCT.~* Planning target volume for MLT (PTV_MLT): GTV + 8 mm isotropic expansion"
62569448|NCT05219591|OTHER|Polysomnographic night|intermittent application of the EPR technology on CPAP device during step 2, on polysomnographic night of the study.
62776038|NCT00439036|ACTIVE_COMPARATOR|Drug Counseling|The Drug Counseling intervention consists of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
62776039|NCT02986113|EXPERIMENTAL|Men and Providers Preventing Suicide|Tailored interactive multimedia intervention, aimed at activating suicidal middle-aged men to disclose and discuss their suicide thoughts with and be receptive to treatment offers from a primary care provider during a linked office visit
62394403|NCT06722885||ITV approach|"* Gross tumor volume (GTV): lesion delineated on the ten phases of the 4DCT.~* Internal target volume (ITV): propagate all GTV on stable exhale phase of the 4DCT.~* Planning target volume for ITV (PTV_ITV): ITV + 5 mm isotropic expansion"
62394404|NCT06722885||Markerbased tracking|"* Gross tumor volume for tracking (GTV_Track): lesion delineated on stable exhale phase of the 4DCT.~* Planning target volume for tracking (PTV_Track): GTV + 5 mm isotropic expansion"
62394405|NCT01083121||Adalimumab|Participants who were prescribed with adalimumab per approved prescribing information of adalimumab in Korea.
62394406|NCT03535441||voluteer group|No treatment, only blood sample collection
62776040|NCT02986113|ACTIVE_COMPARATOR|Sleep hygiene video|A brief (3 minute) video regarding sleep hygiene, accompanied by introductory text summarizing research linking sleep problems with increased suicide risk.
62000477|NCT00482391|EXPERIMENTAL|AC, PACLITAXEL , TRASTUZUMAB & LAPATINIB|The regimen consists of AC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 4 with pegfilgrastim, followed by weekly paclitaxel (80 mg/m2) x 12 + trastuzumab (H) + lapatinib (L). Pegfilgrastim 6mg is given subcutaneously (SQ) on day # 2 of each AC. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion. Trastuzumab will be administered weekly starting with paclitaxel treatment # 1. Near the completion of all chemotherapy, patients may receive trastuzumab on a q 3-weekly schedule, starting as early as with paclitaxel cycle # 12. The total duration of trastuzumab from beginning to end is 52 weeks. Lapatinib will be given orally at 1000 mg daily, starting with trastuzumab for a total duration of 52 weeks. Hormonal therapy such as tamoxifen or an aromatase inhibitor will be given to patients with hormone receptor positive disease at the physician's discretion. Radiation therapy to the breast or chest is recommended to patients as appropriate.
62000478|NCT01302821|EXPERIMENTAL|Radiotherapy|AMT positron emission tomography with integrated computed tomography (PET/CT)scanning in metastatic breast cancer patients to identify tumors with increased AMT uptake due to up-regulated IDO expression.
62000479|NCT02915744|EXPERIMENTAL|NKTR-102|In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.
62394407|NCT03535441||hemorrhagic shock group|HS was defined as out-of-hospital systolic blood pressure (SBP) of 70 mmHg or less or SBP ranging 71 to 90 mmHg with a heart rate of 108 beats/min or more. Exclusion criteria were pregnancy, \<15 years old, more than 2,000 mL of intravenous fluids or blood before enrollment, hypothermia, drowning, asphyxia, burns, isolated penetrating head injury, time of call received by dispatch to study intervention longer than 4 h, known prisoners, and transfer from another hospital
62394408|NCT04599543|EXPERIMENTAL|Administration of IL3 CAR T-cells|
62394409|NCT03514160|ACTIVE_COMPARATOR|Group exercise|Group exercise training at a community site. Exercises included supervised upper and lower-body strength and balance exercises twice per week. Hand-made, weighted bars were used for resistance props and balance. The exercises included: chair squats; standing single leg hip abduction; hip extension; balance heal-to-toe walking; seated hip adduction and knee extension; wall push-ups; bent-over rows; shoulder press; elbow flexion and extension).
62394410|NCT03514160|NO_INTERVENTION|Attention-Control group|Attendance to community site usual activities offered to older adults. Participants in this group were offered the exercise routine after completing the 12-week study.
62394411|NCT02133612|EXPERIMENTAL|single arm paclitaxel and cisplatin|
62394412|NCT01503866|EXPERIMENTAL|20 mg bardoxolone methyl|
62394413|NCT02213965||Vasofix® Safety|Peripheral IV catheter Vasofix® Safety
62000480|NCT02915744|ACTIVE_COMPARATOR|Treatment of Physician's Choice (TPC)|In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.
62000481|NCT01088009|EXPERIMENTAL|early add-on|
62000482|NCT01088009|ACTIVE_COMPARATOR|SOC|Patients will receive oral lamivudine 100mg,daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
62000483|NCT01088009|OTHER|De-novo combination|patients in this arm will receive oral lamivudine 100mg and adefovir 10mg for 104 weeks
62394414|NCT02213965||Introcan Safety®|Peripheral IV catheter Introcan Safety® IV catheter
62394415|NCT06230107|EXPERIMENTAL|Participants diagnosed with Binge Eating Disorder|The intervention was divided into 8 individual weekly meetings, guided by Mindful eating session, nutritional educational dynamics, cooking workshop, food sensory analysis and applications of questionnaires
62569449|NCT05219591|OTHER|Outpatient CPAP use|Application of EPR technology during outpatient CPAP usage, on steps 3 and 4 of the study
62569450|NCT02525783|EXPERIMENTAL|Hemi Shoulder Arthroplasty|Hemi Shoulder Arthroplasty using the Aequalis Pyrocarbon Humeral Head
62776041|NCT01727414|OTHER|OROS-Methylphenidate and placebo for inattentive type pts|Children with ADHD-inattentive type. Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
62776042|NCT01727414|OTHER|OROS-Methylphenidate and placebo for combined type pts|Children with ADHD-combined type type. Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
62776043|NCT01508845|ACTIVE_COMPARATOR|High MUFA/PUFA, 1600 IU vitamin D3|Subjects will receive 3 meals (1 day) with a high MUFA/PUFA ratio (20g/5g), along with 800 IU of vitamin D3 and 800 IU of deuterated vitamin D3
62776044|NCT01508845|ACTIVE_COMPARATOR|High MUFA/PUFA, 50,800 IU vitamin D3|Subjects will receive 3 meals (1 day) with a high MUFA/PUFA ratio (20g/5g), along with 50,000 IU of vitamin D3 and 800 IU of deuterated vitamin D3
62000484|NCT03493334|EXPERIMENTAL|Visual feedback|Participants in this group will receive visual feedback of their neck when performing 10 repetitions of each of neck movements (flexion, extension, side-flexion and rotation).
62394416|NCT02680158|EXPERIMENTAL|Sequence 1-Intranasal: Extranasal: Sham|Oculeve device, intranasal (test) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by sham device, intranasal (control) application, for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
62569451|NCT05818501|EXPERIMENTAL|The dysphagia cups|The participants will use the one of the two models of dysphagia cups for 5 days during trial period.
62569452|NCT03786328|OTHER|Clinical cases of Mental Disorder|The group of individuals identified with a clinical mental disorder on the basis of the diagnostic interviews This group will be assigned to Standard Psychiatric Treatment
62569453|NCT03786328|OTHER|Subclinical cases of Mental Disorder|The group of individuals identified with a sub-clinical mental condition on the basis of the diagnostic interviews This group will be assigned to Preventive Psychological Treatment
62569454|NCT03123393|EXPERIMENTAL|Cohort A: TAK-659 100 mg|TAK-659 100 mg tablet, orally, once daily (QD), during each 28-days cycle (median exposure was 41 days).
62569455|NCT03123393|EXPERIMENTAL|Cohort B: TAK-659 Ramp-up Dosing|TAK-659 60-100 mg tablet, orally, QD, dose based on safety and tolerability during each 28-days cycle (median exposure was 28 days).
62569456|NCT04166942|EXPERIMENTAL|Normal Hepatic Function (Group 1--Control)|Matched healthy subjects with normal hepatic function
62569457|NCT04166942|EXPERIMENTAL|Mild Hepatic Impairment (Group 2)|Subjects with mild hepatic impairment based on Child-Pugh Class A score of 5 or 6
62569458|NCT04166942|EXPERIMENTAL|Moderate Hepatic Impairment (Group 3)|Subjects with moderate hepatic impairment based on Child-Pugh Class B score of 7 to 9
62569459|NCT04166942|EXPERIMENTAL|Severe Hepatic Impairment (Group 4)|Subjects with severe hepatic impairment based on Child-Pugh Class C score of 10 to 14
62569460|NCT05660161|EXPERIMENTAL|Nanofracture|"The planned study intervention consists of nanofracture surgical procedure for the treatment of cartilage lesions of the knee.~Nanofractures will be standardized 9 mm deep perforations in the subchondral bone.~Under arthroscopic view, the cartilage lesion is shaved to expose the margins of the lesion and remove damaged tissue. After a satisfactory lesion debridement is performed, a nanofracture device (Plasmaconcept NanoFx®) is placed through the arthroscopic portal. The awl is repeatedly penetrated through the bone until marrow elements are seen in the joint. The flow of arthroscopic fluid is interrupted to better observe the marrow elements emanating from the nanofracture holes. The distance between two consecutive perforations will be approximately 2-3 mm, and the number of perforations will depend on the cartilage lesion extension. All post-operative procedures, including the rehabilitation protocol, will be carried out according to the usual standard of care."
62569461|NCT05749744||Home-based cardiac telerehabilitation (interventional group)|Patients followed the cardiac rehabilitation program at home.
62569462|NCT05749744||Traditional centre-based cardiac rehabilitation (control group)|Patients participates in the cardiac rehabilitation program in hospital.
62569463|NCT01051791|EXPERIMENTAL|Everolimus 10 mg daily|"The study of the efficacy of everolimus will proceed in two stages after the method of Simon1. In the first stage 15 patients will be accrued and treated. If 9 or fewer patients show clinical benefit the study will be terminated. If 10 or more patients show clinical benefit the study will proceed to the second stage, accruing an additional 26 patients. If the second stage is complete and a total of 29 or more patients show clinical benefit among the 41 patients treated, the treatment CBR for will be considered high enough to warrant further study. Conversely, if the evaluation of everolimus concludes at the first stage, or if 28 or fewer patients experience a clinical benefit after completing the second stage, the therapy will not be considered for further study.~1"
62776045|NCT01508845|ACTIVE_COMPARATOR|Low MUFA/PUFA, 50,800 IU vitamin D3|Subjects will receive 3 meals (1 day) with a low MUFA/PUFA ratio (5g/20g), along with 50,000 IU of vitamin D3 and 800 IU of deuterated vitamin D3
62776046|NCT01508845|ACTIVE_COMPARATOR|Fat free meal, 50,800 IU vitamin D3|Subjects will receive 3 fat-free meals (1 day) and 50,000 IU vitamin D3 and 800 IU of deuterated vitamin D3
62776047|NCT03892135||Physicians|3 paediatricians and 3 rheumatologists
62776048|NCT03892135||Parents|Parents
62000485|NCT03493334|ACTIVE_COMPARATOR|No visual feedback|Participants in this group will perform 10 repetitions of each of neck movements (flexion, extension, side-flexion and rotation) without feedback.
62569464|NCT00598741|EXPERIMENTAL|1|
62569465|NCT06385574|EXPERIMENTAL|Virtual reality therapy group|Individuals in this group will be given hand exercises (wrist flexion, extension and deviations) for 45 minutes, 2 days a week for 8 weeks, using a leap motion control device and games selected in accordance with this device.
62569466|NCT06385574|EXPERIMENTAL|Conventional exercise group|Hand exercises (wrist flexion, extension and deviations)) will be applied to individuals in this group under the supervision of a specialist physiotherapist for 45 minutes, 2 days a week for 8 weeks.
62776049|NCT03892135||Children|Children
62776050|NCT00480389|EXPERIMENTAL|Sorafenib|"All patients on study will be accrued to this arm. Sorafenib (200 mg tablets x 2) will be administered orally twice a day for 12 weeks (full daily dose of 800 mg). Patient visits for safety will be conducted at least every 4 weeks. Sorafenib dose reductions for drug-related toxicity will be applied based on considerable prior clinical experience. Surgery will be performed at the completion of the 13th week, allowing for a one-week washout period. Sorafenib will be continued post operatively (around 6 weeks post surgery or when complete wound healing has occurred) until patient progresses or unacceptable toxicity occurs."
62776051|NCT03459365|EXPERIMENTAL|Euflexxa|Two sets of Euflexxa injection at 0 and 6 months. Each set consists of 3 injections 1 week apart.
62776052|NCT02591459|OTHER|Autism|Using the app to assist routine anticipation for autistic children in Android mobile devices
62776053|NCT01286571|EXPERIMENTAL|BI 135585 (T)|single dose per subject as tablet formulation after high fat, high caloric meal
62776054|NCT01286571|EXPERIMENTAL|BI 135585 (R)|single dose per subject as tablet formulation after an overnight fast
62776055|NCT04495725|PLACEBO_COMPARATOR|Voucher for a Discounted Placebo Product|Voucher for a Discounted Placebo Soft-Gel Capsule Product
62776056|NCT04495725|EXPERIMENTAL|Voucher for a Discounted High THC:Low CBD Product|Voucher for a Discounted 4.3mg THC/0.7mg CBD Soft-Gel Capsule Product
62776057|NCT04495725|EXPERIMENTAL|Voucher for a Discounted Equal THC:CBD Product|Voucher for a Discounted 2.5mg THC/2.5mg CBD Soft-Gel Capsule Product
62000486|NCT05379296|ACTIVE_COMPARATOR|Diabetes Prevention Program (DPP)|CDC-approved 12-month DPP virtual lifestyle program
62000487|NCT05379296|EXPERIMENTAL|Diabetes Prevention Program Plus (DPP+)|CDC-approved 12-month DPP virtual lifestyle program expanded to include a CDC-approved module on hypertension prevention and treatment
62185680|NCT01177995|EXPERIMENTAL|Social Network|Leaders of labor migrant social networks will be trained to disseminate HIV prevention messages to the members of their social networks. The training will sequentially target ways to increase network members' HIV-related knowledge and norms, attitudes, intentions, and confidence in how to avoid risk. Leaders will be encouraged to have these discussions with network members between and after training sessions.
62185681|NCT00678483|EXPERIMENTAL|1|10 mg
62185682|NCT00678483|EXPERIMENTAL|2|20 mg
62185683|NCT00965120|PLACEBO_COMPARATOR|1|Ischaemia 20 minutes. Blood pressure cuff will be inflated to 200mmHg around the upper arm for 20 minutes to induce ischaemia. Systemic infusion of placebo (saline).
62185684|NCT00965120|ACTIVE_COMPARATOR|2|Ischaemia 20 minutes. Blood pressure cuff will be inflated to 200mmHg around the upper arm for 20 minutes to induce ischaemia. Systemic infusion of bradykinin receptor antagonist (HOE-140).
62185685|NCT01079247|ACTIVE_COMPARATOR|Liberal|Maintain hemoglobin at 10-11 g/dL
62185686|NCT01079247|ACTIVE_COMPARATOR|Restrictive|Maintain hemoglobin at 7-8 g/dL
62185687|NCT02019641|EXPERIMENTAL|Aerobic Exercise Intervention (AET+)|Participant with interstitial lung disease performed aerobic exercise three times a week plus weekly education for 10 weeks
62185688|NCT02019641|ACTIVE_COMPARATOR|Control Group (CON)|Participant with interstitial lung disease performed weekly education for 10 weeks, then crossed over to perform aerobic exercise three times a week for 10 weeks
62185689|NCT03062085||High myopic cataract group|Cataract patients with high myopia.
62185690|NCT03062085||Age-related cataract group|Age-related cataract patients.
62000488|NCT03900299|OTHER|oncoplastic breast surgery|
62000489|NCT03822728|NO_INTERVENTION|Without 3D-DESS MRI|As for deep seated tumors in preoperative CT or US (or tumors in both superficial and deep parotid glands), the patients will undergo surgery without 3D-DESS MRI (currently routine practice).
62000490|NCT03822728|EXPERIMENTAL|With 3D-DESS MRI|As for deep seated tumors in preoperative CT or US (or tumors in both superficial and deep parotid glands), preoperative 3D-DESS MRI will be additionally performed to delineate the intra-parotid facial nerve.
62000491|NCT06399146|EXPERIMENTAL|Evaluation of bilirubin estimates in a population in Botswana|Compare smartphone estimates of total serum bilirubin in the blood to total serum bilirubin determined through a blood sample.
62000492|NCT03641352|EXPERIMENTAL|CKD-501 0.5mg|CKD-501 0.5mg
62000493|NCT03641352|PLACEBO_COMPARATOR|Placebo|Placebo
62000494|NCT03609541||Patient with stable COPD|Evaluation of serum amlyoid A, lipoxin A4, CRP and fibrinogen
62000495|NCT03609541||Patient with COPD exacerbation|Evaluation of serum amlyoid A, lipoxin A4, CRP and Fibrinogen at beginning and at the end of COPD exacerbation
62185691|NCT03062085||Ametropic cataract group|Cataract patients with ametropia.
62185692|NCT01980602|EXPERIMENTAL|Supervised Exercise Program|
62185693|NCT05803642|EXPERIMENTAL|Olanzapine|
62185694|NCT05803642|ACTIVE_COMPARATOR|Haloperidol|
62185695|NCT03277352|EXPERIMENTAL|INCAGN01876 + Pembrolizumab + Epacadostat|INCAGN01876 in combination with pembrolizumab and epacadostat
62185696|NCT00839332|EXPERIMENTAL|LY2603618 + Gemcitabine|"Participants participated in Phase 1 or 2.~LY2603618 (Phase 1): 70 to 250 milligrams/meter squared (mg/m\^2) LY2603618 as a 1-hour continuous intravenous (IV) infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until disease progression (DP). Participants received LY2603618 as part of the dose escalation cohort (dose of 70, 105, 150, 200, or 250 mg/m\^2) or the expansion cohort (flat dose of 200 mg or 230 mg).~LY2603618 (Phase 2): 230 mg LY2603618 as a 1-hour continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until DP.~Gemcitabine (Phase 1 and 2): 1000 mg/m\^2 gemcitabine as a 30-minute continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until DP. Participants received gemcitabine 24 hours prior to LY2603618 administration."
62185697|NCT00839332|ACTIVE_COMPARATOR|Gemcitabine|"Participants participated in Phase 2 only.~Gemcitabine (Phase 2): 1000 mg/m\^2 gemcitabine as a 30-minute continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until disease progression."
62185698|NCT01309477|EXPERIMENTAL|ADVAGRAF|All subjects in the study will take the Tacrolimus Sustained-release Capsules (ADVAGRAF) orally at the basis of low dose prednisone treatment
62185699|NCT03201237|EXPERIMENTAL|30 min AOT|
62185700|NCT03201237|PLACEBO_COMPARATOR|60 min AOT|
62185701|NCT00677768||Early ALS|
62185702|NCT00677768||Suspected ALS|
62185703|NCT00677768||Disease Mimics of ALS|
62185704|NCT00677768||Healthy Controls|
62185705|NCT02827032|EXPERIMENTAL|MobiusHD™|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
62185706|NCT02330276|EXPERIMENTAL|10 mg (+)-epicatechin|4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
62185707|NCT02330276|EXPERIMENTAL|30 mg (+)-epicatechin|4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
62185708|NCT02330276|EXPERIMENTAL|100 mg (+)-epicatechin|4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
62185709|NCT04188756|OTHER|Exercise|Group under exercise training for 15 weeks with High intenstiy interval training under medical control
62185710|NCT04188756|NO_INTERVENTION|Control|Group with standard care according to current guidelines
62569467|NCT06385574|NO_INTERVENTION|Control group|This group is waiting list. After the study, patients will do hand exercises with the leap motion controller device.
62394417|NCT02680158|EXPERIMENTAL|Sequence 2-Intranasal: Sham: Extranasal|Oculeve device, intranasal (test) application for approximately 3 minutes followed by sham device, intranasal (control) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
62569468|NCT03253653|EXPERIMENTAL|Waterpipe smoking|In a repeated measures design, 50 adult male and female exclusive WP smokers will smoke WP tobacco weekly over a 3-week study period with 3 WP smoking practices.
62569469|NCT03253653|NO_INTERVENTION|Control|A total of 25 adult make and female nonsmokers will be recruited as a control.
62569470|NCT02118116|NO_INTERVENTION|Wait-list Control|No training, wait-listed for ASIST at a later date
62569471|NCT02118116|EXPERIMENTAL|ASIST|Applied Suicide Intervention Skills Training is a 2-day, 14 hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The course, facilitated by 2 trained facilitators, allows for a maximum enrollment of 30 participants.
62394418|NCT02680158|EXPERIMENTAL|Sequence 3-Extranasal: Intranasal: Sham|Oculeve device, extranasal (control) application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes, followed by sham device (control), intranasal application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
62394419|NCT02680158|EXPERIMENTAL|Sequence 4-Extranasal: Sham: Intranasal|Oculeve device, extranasal (control) application for approximately 3 minutes followed by sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
62394420|NCT02680158|EXPERIMENTAL|Sequence 5-Sham: Intranasal: Extranasal|Sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by on Day 0. There was rest period of 60 minutes before proceeding to the next application.
62394421|NCT02680158|EXPERIMENTAL|Sequence 6-Sham: Extranasal: Intranasal|Sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes followed by on Day 0. There was rest period of 60 minutes before proceeding to the next application.
62394422|NCT00243477|ACTIVE_COMPARATOR|Treatment|Escitalopram given
62569472|NCT02118116|EXPERIMENTAL|ASIST uncontrolled arm|The ASIST workshop will be offered to participants who refuse to be part of the waitlist control arm. This is due to the reality in gathering data in these communities. Many times it is not possible for participants to be waitlisted, and therefore we would still want to gather data on those that refuse to participate in the RCT design and will collect uncontrolled data on these participants only.
62569473|NCT03195621|EXPERIMENTAL|Interventional therapy group|
62569474|NCT03195621|NO_INTERVENTION|Conservative treatment group|
62569475|NCT01924832|EXPERIMENTAL|BG00012 Part 1|BG00012 120 mg delivered to varying locations of the GI tract
62569476|NCT01924832|EXPERIMENTAL|BG00012 Part 2|BG00012 240 mg delivered to varying locations of the GI tract
62569477|NCT05709678|PLACEBO_COMPARATOR|Control|Group Education (General nutrition and sport nutrition)
62185711|NCT05359692|EXPERIMENTAL|Part 1: Cohort 1|INCAGN01876 every 2 weeks (Q2W) with retifanlimab every 4 weeks (Q4W).
62569478|NCT05709678|ACTIVE_COMPARATOR|Treatment|Group Education (General nutrition and sport nutrition with athlete testimonials on impacts of RED-S on health)
62569479|NCT06209528||School-aged children|No intervention
62569480|NCT03944668|EXPERIMENTAL|Intervention|Exercise intervention
62569481|NCT04735601|EXPERIMENTAL|Ahmed valve coated with PLGA is implanted in secondary glaucoma in Sturge Weber syndrome|Ahmed valve coated with PLGA is implanted in secondary glaucoma in Sturge Weber syndrome
62185712|NCT05359692|EXPERIMENTAL|Part 1: Cohort 2|INCAGN01876 Q2W with retifanlimab Q4W.
62185713|NCT05359692|EXPERIMENTAL|Part 2 (Expansion): Treatment Group A|INCAGN01876 and retifanlimab combination in participants who have been previously treated with anti-PD-(L)1 therapy.
62185714|NCT05359692|EXPERIMENTAL|Part 2 (Expansion): Treatment Group B|INCAGN01876 and retifanlimab combination in participants who are naive to anti-PD-(L)1 therapy.
62569482|NCT04735601|ACTIVE_COMPARATOR|Ahmed valve implanted in secondary glaucoma in Sturge Weber syndrome|Ahmed valve will be implanted alone with no PLGA
62569483|NCT02395250|EXPERIMENTAL|anti-GPC3 CAR T|
62569484|NCT05334693|EXPERIMENTAL|Expanded haploidentical NK cell immunotherapy|After a lymphodepleting chemotherapy a patient receive two intravenous infusions of expanded haploidentical NK cells.
62569485|NCT04515654|EXPERIMENTAL|Audience participants|Community members viewed the performance (intervention) and completed pre/post stigma questionnaire
62185715|NCT04055259|EXPERIMENTAL|mobile Health and Wellness Coaching|
62185716|NCT04055259|ACTIVE_COMPARATOR|Usual Care|
62394423|NCT00243477|PLACEBO_COMPARATOR|Placebo|Placebo given
62394424|NCT00575692||PulmoHypertension|Patients with suspected, latent or manifest pulmonary hypertension
62394425|NCT00575692||Controls|Controls without history of cardiac or pulmonary diseases
62394426|NCT06722144|EXPERIMENTAL|emotion status|Geriatric Depression Scale and Short Form Health Scale(GDS-15)
62394427|NCT06722144|EXPERIMENTAL|cognition status|Short Portable mental state questionnaire(SPMSQ)
62394428|NCT06722144|EXPERIMENTAL|feeling healthy|Brief Symptom Rating Scale(BSRS-5)
62394429|NCT06722144|EXPERIMENTAL|activities of daily living status|Barthel index scale
62569486|NCT05903404||Target Population|The target population includes individuals diagnosed with PCOS by a healthcare provider, self-diagnosed with PCOS, or who are exhibiting PCOS Symptoms and willing to sign the consent.
62569487|NCT05903404||Control Population|The control population includes people born biologically female who have not been diagnosed with PCOS and who also do not have symptoms of PCOS.
62569488|NCT05879536||TRON (Tramadol-Ondansetron)|Women who receive an infusion of tramadol-ondansetron from the end of the cesarean section and for the following 24 h. The infusion (TRON) is composed of 300 mg of tramadol and 12 mg of ondansetron dissolved in 250 ml of 0.9% saline, which is routinely programmed at 11 ml/h until the content is exhausted (approximately 23 hours).
62569489|NCT05879536||AL-EPI (Local anesthetics via epidural)|Women who maintain the epidural catheter as the main measure of analgesia for 24 h. The epidural catheter after caesarean section is programmed with a 0.2% ropivacaine PCA (Patient controlled analgesia) pump at 7 ml/h with 7 ml on-demand boluses, with block every 20 min.
62569490|NCT02506868|EXPERIMENTAL|BCD-066|Patients in this arm will receive weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
62569491|NCT02506868|ACTIVE_COMPARATOR|Aranesp|Patients in this arm will receive weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
62569492|NCT02594982|OTHER|intervention bundle|An intervention bundle consisting of optimized sedation, pain assessment and treatment, early mobilization and sleep.
62569493|NCT03088072|OTHER|Edoxaban Arm|All patients enrolled in the study will receive 6 weeks of edoxaban therapy, at which time a TEE will be performed. If the result is acceptable, edoxaban will be discontinued, and the patient will be treated with dual antiplatelet therapy (aspirin and clopidogrel) until 6 month follow-up. If device thrombus is present at 6 week TEE, patient will be transitioned to aspirin and adjusted-dose warfarin and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference. Subjects will have a 6 month follow-up visit prior to study completion. After study completion, patients may be treated with aspirin monotherapy according to the FDA instructions for use for the WATCHMAN device, or according to operator discretion.
62569494|NCT01837511||Cancer Group|Patients with pathologically proven stage I, II and III NSCLC.
62569495|NCT05522998|EXPERIMENTAL|Ciprofol Group|Experimental drug: Ciprofol; Dosage form: injection; Specification: 20ml: 50mg; Frequency and duration: intravenous infusion with micropump, anesthesia induction dose 0.4-0.5mg/kg, Administration for 30s (± 5S)
62776058|NCT04495725|EXPERIMENTAL|Voucher for a Discounted Low THC:High CBD Product|Voucher for a Discounted 0.2mg THC/4.8mg CBD Soft-Gel Capsule Product
62776059|NCT01867138|EXPERIMENTAL|Cefazolin group|Initial empirical treatment with cefazolin and amikacin
62776060|NCT01867138|ACTIVE_COMPARATOR|Vancomycin|Initial empirical treatment with vancomycin and amikacin
62776061|NCT06033872|ACTIVE_COMPARATOR|Intervention|Focused education, medication adjustment and telemonitoring
62000496|NCT02346240|EXPERIMENTAL|CZP 200 mg|"Certolizumab Pegol (CZP) subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~* Subjects with a PASI75 response at Week 16 will be re-randomized to receive either CZP 200 mg Q2W or CZP 400 mg every 4 weeks (Q4W; with Placebo administered on alternate dosing weeks to maintain the blind) or Placebo Q2W.~* Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
62394430|NCT04501380|EXPERIMENTAL|1st regimen|15 patients will receive AEMCOLO (Rifamycin SV MMX) 194 mg two tablets to take twice daily for 14 days (56 Tablets)
62394431|NCT04501380|EXPERIMENTAL|2nd regimen|15 patients will receive AEMCOLO (Rifamycin SV MMX) 194 mg tablets to take two tablets three times daily for 14 days (84 Tablets).
62394432|NCT04474717|OTHER|The natural history of COPD|Monitoring risk factors, chronic respiratory symptoms and respiratory function in the natural history of chronic obstructive pulmonary disease
62394433|NCT04474717|EXPERIMENTAL|Study of systemic inflammation and molecular mechanisms|Study of systemic inflammation and molecular mechanisms underlying the comorbid course of COPD and atherosclerosis
62394434|NCT04474717|OTHER|Exhaled breath condensate|A study of the clinical and biochemical COPD phenotype with systemic inflammation and comorbidity
62394435|NCT01554033||Huntington's disease patients|Huntington's disease patients and his(/her) family
62394436|NCT01554033||age-sex matched control|age-sex matched control about huntington patients
62394437|NCT03311295|EXPERIMENTAL|ARTO System|
62394438|NCT01738516|OTHER|epileptic patients|Electroencephalography
62394439|NCT01738516|OTHER|Healthy Volunteers|Electroencephalography and additional experimental tasks
62394440|NCT02771782|EXPERIMENTAL|BCG|Subjects are vaccinated with BCG vaccine (SSI) alone, 0,1ml intradermal
62394441|NCT02771782|EXPERIMENTAL|TDaP-IPV|Subjects are vaccinated with TDaP-IPV vaccine (Boostrix Polio) vaccine alone, 0,5ml intramuscular
62394442|NCT02771782|EXPERIMENTAL|BCG+TDaP-IPV|Subjects are vaccinated with BCG vaccine (SSI) (0.1ml intradermal) and TDaP-IPV vaccine Boostrix Polio (0.5ml intramuscular) simultaneously
62776062|NCT06033872|NO_INTERVENTION|Control|Standard care
62776063|NCT04891107|EXPERIMENTAL|Walking Program with a Music-based, Rhythm-modulating Wearable Sensor System|
62776064|NCT04448353||Development / training|Selected by stratified partitioning
62776065|NCT04448353||Sequestered / test|Selected by stratified partitioning
62776066|NCT01262664|EXPERIMENTAL|Prohibitin-TP01|Prohibitin-TP01 starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
62776067|NCT00013169|OTHER|Arm 1|
62000497|NCT02346240|EXPERIMENTAL|CZP 400 mg|"Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W) through Week 14.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~* Subjects with a PASI75 response at Week 16 will be re-randomized to CZP 200 mg Q2W or CZP 400 mg Q2W or Placebo Q2W.~* Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
62000498|NCT02346240|ACTIVE_COMPARATOR|Etanercept|"Etanercept (ETN) subcutaneous (sc) injection 50 mg twice weekly through Week 12.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~* Subjects with a PASI75 response at Week 16 will be re-randomized to either Certolizumab Pegol (loading dose of 400 mg at Weeks 16, 18, and 20 followed by 200 mg Q2W) or Placebo Q2W.~* Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
62000499|NCT02346240|PLACEBO_COMPARATOR|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~* Subjects with a PASI75 response at Week 16 continue to receive blinded Placebo.~* Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
62000500|NCT00572507|EXPERIMENTAL|MonoMax|MonoMax is used for abdominal wall closure
62000501|NCT00098111|ACTIVE_COMPARATOR|Azathioprine 0.5 mg/kg body weight|
62000502|NCT00098111|ACTIVE_COMPARATOR|Azathioprine 2.5 mg/kg body weight|
62000503|NCT00098111|ACTIVE_COMPARATOR|Azathioprine 3.5 mg/kg body weight|
62000504|NCT05448482|EXPERIMENTAL|Hybrid transobturator tape|"Anterior rectus fascia will be exposed and an approximately 8-10 cm × 1 cm strip of rectus fascia will be marked out. The sling will be harvested using sharp dissection. Thereafter, a Polyprolene monofilamentous mesh of 15 cm x 1 cm will be sutured to each edge of the rectus fascia sling that had been harvested.~Then, a 2-cm midline incision over the anterior vaginal wall at the level of mid-urethra. A combination of blunt and sharp dissection will be carried out to the obturator foramen bilaterally.~Next, a stab incision will be made at a point approximately 2.5 cm infero-lateral to the pubic tubercle bilaterally, corresponding to the level of clitoris. A trocar will be passed through each obturator foramen (outside-in) and the edge of the mesh will be retracted through the incision. Next, the retraction of both meshes will continue until the rectus fascia sling remain flushed with the urethra."
62000505|NCT05448482|ACTIVE_COMPARATOR|Conventional transobturator tape|The conventional mesh using mid urethral sling through the trans obturator route
62000506|NCT04978792|EXPERIMENTAL|Self-compassion Intervention|The intervention will include 14 self-compassion exercises completed over a 3-week period. The intervention will include methods of psychoeducation, meditation, and self-compassion exercises similar to Beshai et al.'s (2020) self-compassion-based intervention. The psychoeducation will focus on self-compassion, the meditations will be kindness and loving meditations and self-compassion breaks. The self-compassion exercises will be based on the writing exercises available on Neff's self-compassion website.
62185717|NCT06239259||Carpal tunnel syndrome patients|Carpal tunnel syndrome patients
62185718|NCT04191876|EXPERIMENTAL|Active|This study has only one arm. All patients enrolled will take part in the experimental arm.
62185719|NCT01470599|EXPERIMENTAL|5mg BID|
62185720|NCT01470599|EXPERIMENTAL|10mg BID|
62394443|NCT04170725|EXPERIMENTAL|Patients and Healthy volunteers|Patients and Healthy volunteers will undergo a 14-day training protocol. No study drugs will be administered. Patients and Healthy volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Participants will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
62776068|NCT00599508|ACTIVE_COMPARATOR|grape juice active intervention|Concord grape juice administered daily for 12 or 16 weeks
62776069|NCT00599508|PLACEBO_COMPARATOR|juice placebo|berry placebo juice administered daily for 12 or 16 weeks
62776070|NCT00599508|ACTIVE_COMPARATOR|blueberry juice active intervention|wild blueberry juice administered daily for 12 weeks
62776071|NCT00599508|ACTIVE_COMPARATOR|blueberry powder intervention|whole fruit blueberry powder administered daily for 16 weeks
62185721|NCT01965509|EXPERIMENTAL|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 12 weeks
62185722|NCT01965509|EXPERIMENTAL|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication continued for 12 weeks
62185723|NCT01965509|PLACEBO_COMPARATOR|Placebo|Placebo qw sc. and the medication continued for 12 weeks
62394444|NCT06346639|EXPERIMENTAL|16-day hot and cold acclimation|Healthy young subjects will participate in a 16-days hot and cold acclimation program. During cold procedure, the participant will be immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 5-min, and during hot procedure, the participant will be immersed in 45° water bath in semi recumbent position up to the level of the manubrium for 5-min.
62569496|NCT05522998|ACTIVE_COMPARATOR|Propofol Group|Experimental drug: Propofol; Dosage form: injection; Specification: 20ml: 200mg; Frequency and duration: intravenous infusion with micropump, anesthesia induction dose 2-2.5mg/kg, Administration for 30s (± 5S)
62569497|NCT02564601|EXPERIMENTAL|A1 Piano Training|16 weekly classes will be provided to the piano training group. Each piano class session will focus upon review of materials (15-20 min), and the remaining portion of the class will focus upon learning new skills and concepts. This course includes finger dexterity exercises, basic piano technique, and basic piano repertoire.
62394445|NCT00859495|EXPERIMENTAL|Multimodal lung sparing regimen|"Intrapleural chemotherapy plus systemic chemotherapy:~Thoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy."
62394446|NCT03705858|EXPERIMENTAL|Ac-lintuzumab|Subjects with AML will receive Ac-lintuzumab.
62394447|NCT04293211||Control|Upon completion of B-Con presentation, this group will be tested regarding tourniquet placement using the rubric. A tourniquet is regarded as appropriately placed if it is 2 inches above the wound, not located on a joint, appropriate tightness (meaning a finger cannot be placed under it and it is indenting the mannequin). This is as per prior studies. Feedback will be given at the end of this session.
62394448|NCT04293211||Simulation|This group will have to interact with a panicked actor/actress as well as the SIM MAN 3G who will have two wounds under his clothes. One that will be actively pumping a large amount of arterial blood that will require tourniquet placement and the other wound with trace venous bleeding that will require simple pressure with a clean cloth. Participants will be given feedback on items that they missed. The observer will fill out the rubric and give feedback to the group.
62569498|NCT02564601|EXPERIMENTAL|A2 Computer Cognitive Training|16 weekly classes will be provided to the computerized cognitive training group. Computerized cognitive training involves process-based computerized practice of adaptive perceptual exercises. Each computer cognitive training class session will focus upon practice of cognitive exercises that vary in difficulty ranging from basic auditory processing speed to application through memory and working memory exercises. Within each exercise, the stimuli (i.e., tones, speech sounds, words, sentences) become less discriminable and speed of presentation increases (making the exercises more difficult) as performance improves.
62569499|NCT02564601|NO_INTERVENTION|A 3 No Treatment Controls|No classes will be provided to our control group. This is a no-treatment control group.
62569500|NCT00683722|EXPERIMENTAL|Prochymal™|Participants received Prochymal™ a total of 400×10\^6 cells, intravenous (IV) infusions on Days 0, 30, 60, and 90.
62569501|NCT00683722|PLACEBO_COMPARATOR|Placebo|Participants received placebo-matching IV infusions on Days 0, 30, 60 and 90.
62584811|NCT05274854|EXPERIMENTAL|Consultation Intervention|Consultation intervention includes 2 arms (a) consultant-led outpatient clinic or b) a integrated care clinic depending on their response to the initial preconsultation intervention.
62776072|NCT00599508|PLACEBO_COMPARATOR|powder placebo|placebo powder administered daily for 16 weeks
62776073|NCT04622813|PLACEBO_COMPARATOR|Placebo group|Patients received sevoflurane-dexmedetomidine-based anesthesia with saline, ketoprofen and paracetamol for postoperative pain control,
62776074|NCT04622813|EXPERIMENTAL|Multimodal group|patients received sevoflurane-dexmedetomidine-based anesthesia with nefopam, ketoprofen, and paracetamol for postoperative pain control.
62185724|NCT04634370|EXPERIMENTAL|Intervention|"Each patient will receive on dose of intravenous natural killer cell in following levels:~Level 1 : 1x106 cells/kg body weight (patients 1 to 3) Level 2: 5x106 cells/kg body weight (patients 4 to 6) Level 3: 1x107 cells/kg body weight (patients 7 to 24)"
62185725|NCT06541639|EXPERIMENTAL|EVM 0.1mg|EVM16 0.1mg Q2W for 2 cycles, then EVM16 0.1mg Q3W combined with tislelizumab (anti-PD1 antibody) 200mg Q3W for 7 cycles.
62185726|NCT06541639|EXPERIMENTAL|EVM 0.3mg|EVM16 0.3mg Q2W for 2 cycles, then EVM 0.3mg Q3W combined with tislelizumab (anti-PD1 antibody) 200mg Q3W for 7 cycles.
62185727|NCT06541639|EXPERIMENTAL|EVM 1.0mg|EVM16 1.0mg Q2W for 2 cycles, then EVM 1.0mg Q3W combined with tislelizumab (anti-PD1 antibody) 200mg Q3W for 7 cycles.
62185728|NCT06541639|EXPERIMENTAL|EVM RP2D|EVM16 RP2D Q3W combined with tislelizumab (anti-PD1 antibody) 200mg Q3W for 9 cycles.
62776075|NCT02788058|EXPERIMENTAL|EGFR-TKI|Patients take EGFR-TKI alone till tumor progression
62776076|NCT02788058|ACTIVE_COMPARATOR|EGFR-TKI+hypofractionated radiotherapy|After 3 mos TKI, patients with limited metastatic take EGFR-TKI concurrent with hypofractionated radiotherapy till tumor progression.
62776077|NCT02951429|PLACEBO_COMPARATOR|Pirfenidone + Placebo|Participants will receive pirfenidone along with placebo matched to sildenafil, orally, three times a day (TID) for 52 weeks.
62776078|NCT02951429|EXPERIMENTAL|Pirfenidone + Sildenafil|Participants will receive pirfenidone along with sildenafil, orally, TID for 52 weeks.
62776079|NCT02368821||normal pregnancy|placental from normal pregnancy
62776080|NCT02368821||complacted pregnancy|placental from complicated pregnancy ( intrauterine growth restriction, preeclampsia , placenta accrete
62776081|NCT02423980|EXPERIMENTAL|Glucagon|1 mg G-Pen™ (glucagon injection) first, followed by 0.5 mg
62776082|NCT01345682|EXPERIMENTAL|Afatinib (BIBW 2992)|Once daily
62776083|NCT01345682|ACTIVE_COMPARATOR|Methotrexate|Weekly
62000507|NCT04978792|ACTIVE_COMPARATOR|Control Group|The active control will also include 14 exercises completed over a 3-week period. The 14 exercises will comprise of a psychoeducation video, writing exercises, video/audio-guided relaxation, and journal entries. The same psychoeducation video used in the intervention will be shown to participants, however, the other exercises will be altered to focus on factual information and not focused on self-compassion. The exercises will be matched to the self-compassion exercise so that similar exercises are completed in parallel time with the intervention.
62000508|NCT02840877|OTHER|DOT Adherence Monitoring|Daily adherence monitoring by study-employed directly observed therapy (DOT) worker on weekdays throughout the course of TB therapy
62000509|NCT05385939||Time period 1|Time period one included infants admitted to the current traditional, open bay NICU.
62000510|NCT05385939||Time period 2|Time period 2 included infants admitted to the private, single family room NICU.
62000511|NCT03343691||Screening Population|"Cohort 1:Screening Population - Women presenting for routine XRM and / or breast US.~Participants will be followed for one year and the outcome of those who undergo an annual XRM / breast ultrasound will be recorded."
62000512|NCT03343691||Breast Cancer Population|Cohort 2:Breast Cancer Population - Women who were diagnosed with malignant breast tumors, as determined by biopsy, and have not yet begun any treatment for the disease.
62000513|NCT01424553|OTHER|Cohort|All patients
62000514|NCT05954481|OTHER|HHT patients with hepatic involvement and high cardiac index|HHT patients with a dilated (diameter \> 6mm) or tortuous hepatic artery and an elevated cardiac index (\> 3.5 l/mn/m²)
62776084|NCT03429543|PLACEBO_COMPARATOR|Placebo - DINAMOᵀᴹ & DINAMOᵀᴹ Mono|Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily, until end of treatment.
62776085|NCT03429543|EXPERIMENTAL|Placebo - Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono|Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily, until end of treatment.
62000515|NCT05954481|OTHER|HHT patients with hepatic involvement and normal cardiac index|HHT patients with a dilated or tortuous hepatic artery and a normal cardiac index
62776086|NCT03429543|EXPERIMENTAL|Placebo - Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono|Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily. At week 26, patients were re-randomised to receive 10 milligram (mg) empagliflozin, taken once daily, until end of treatment.
62776087|NCT03429543|EXPERIMENTAL|Placebo - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono|Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily. At week 26, patients were re-randomised to receive 25 milligram (mg) empagliflozin, taken once daily, until end of treatment.
62791676|NCT01005095|EXPERIMENTAL|High dose vitamin D|800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
62791677|NCT01005095|ACTIVE_COMPARATOR|Low dose vitamin D|800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
62000516|NCT03019627|EXPERIMENTAL|rhNGF 20μg/mL|Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
62000517|NCT03019627|PLACEBO_COMPARATOR|Vehicle|vehicle eye drops six times daily
62000518|NCT02927457|EXPERIMENTAL|Group A1- Skin Sites A/C/D (A/P/A)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving GSK2646264 1% (A) for Area A- PV lesion, Placebo (P) for Area C- PV lesion and GSK2646264 1% for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
62000519|NCT02927457|EXPERIMENTAL|Group A2- Skin Sites A/C/D (A/P/P)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving GSK2646264 1% for Area A- PV lesion, Placebo for Area C- PV lesion and Placebo for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
62000520|NCT02927457|EXPERIMENTAL|Group A3- Skin Sites A/C/D (P/A/A)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving Placebo for Area A- PV lesion, GSK2646264 1% for Area C- PV lesion and GSK2646264 1% for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
62000521|NCT02927457|EXPERIMENTAL|Group A4- Skin Sites A/C/D (P/A/P)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving Placebo for Area A- PV lesion, GSK2646264 1% for Area C- PV lesion and Placebo for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
62394449|NCT02548442||Autism Spectrum Disorder|Subjects identified as having Autism Spectrum Disorder using behavioral based methods.
62394450|NCT02548442||Developmental Delay|Subjects identified as having a developmental delay that is not Autism Spectrum Disorder using behavioral methods.
62394451|NCT02548442||Typically Developing Children|Subjects identified as not having a developmental delay or autism spectrum disorder using behavioral methods as well as not having another serious medical or psychological condition.
62394452|NCT04805242|ACTIVE_COMPARATOR|Dextrose prolotherapy groups|In the first group, dextrose prolotherapy injection will be applied.
62394453|NCT04805242|SHAM_COMPARATOR|Saline groups|In the second group, physiological saline injection will be applied.
62394454|NCT06607549|EXPERIMENTAL|Treatment: All Patients|"This study has two main goals:~Goal 1: The study will investigate the safety and tolerability of loncastuximab tesirine and rituximab (lonca-R).~Goal 2: The study will determine the maximum tolerated dose of lonca-R."
62000522|NCT02927457|EXPERIMENTAL|Group B1- Skin Sites F/ G (A/P)|In group B, two chosen lesions will be labeled F and G based on size (F \>G). Subjects will be receiving GSK2646264 1% for lesion F and Placebo for lesion G once daily for 28 days according to randomisation. Skin area H- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
62394455|NCT01244646||1|Patients with Diabetes Mellitus Type 2
62394456|NCT02316652|NO_INTERVENTION|Healthy sites|Healthy sites with no inflammation; observational only
62394457|NCT02316652|PLACEBO_COMPARATOR|Scaling and root planing sites|Inflamed pocket receiving mechanical instrumentation
62394458|NCT02316652|ACTIVE_COMPARATOR|Scaling and root planing with solution|Inflamed pocket receiving mechanical instrumentation with sodium hypochlorite solution
62394459|NCT00884195|EXPERIMENTAL|1|Gratitude Journaling
62394460|NCT00884195|PLACEBO_COMPARATOR|2|Neutral Journaling
62394461|NCT04064099|EXPERIMENTAL|Rugby Players|Rugby player will be given custom-fitted mouthguards to be worn for 6-month
62394462|NCT04099693||General Anesthesia|"All the patients will be intubated and ventilated using cisatracurium (0.15 mg/kg) as a muscle relaxant and propofol (1.5-2mg/kg) for induction. The inhalational anesthetic, sevoflurane, will be used to maintain the depth of anesthesia using 50% mix of nitrous oxide and oxygen.~Fentanyl will be used in both groups at a rate of 1-2 microgram /kg to achieve an adequate level of analgesia in both groups."
62394463|NCT04099693||Anesthetist Administered sedation for ERCP|To ensure a steady level of AAS each patient in this group will be sedated using propofol. An induction bolus of propofol (0.5 - 1 mg/kg) will be administered followed by continuous infusion with variable doses depending on the patients' age, weight, and clinical condition. In addition, fentanyl 1.5 μg/kg will be used at the anesthetist discretion.
62394464|NCT05842590|EXPERIMENTAL|Direct Composite Veneer|This is a single-arm study. Direct composite veneer restoration will be performed to all patients.
62394465|NCT01720901|EXPERIMENTAL|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
62394466|NCT06420024|EXPERIMENTAL|Intervention|Participant will receive ACT intervention
62584812|NCT01031836|EXPERIMENTAL|MEDI-545 1.0 mg/kg|Cohort 1
62584813|NCT01031836|EXPERIMENTAL|MEDI-545 3.0 mg/kg|Cohort 2
62584814|NCT01031836|EXPERIMENTAL|MEDI-545 10.0 mg/kg|Cohort 3
62569502|NCT02887183|OTHER|LCZ696(sacubitril/valsartan)|"Subjects received sacubitril/valsartan (LCZ696) on Day 1. The initial dose was determined by the investigator and per the approved indication described in the United States prescribing information/package insert (USPI). The three doses available were: 24/26 mg (Dose Level 1), 49/51mg (Dose Level 2) and 97/103mg (Dose Level 3).~Titration of the dosage were performed per USPI at 2 to 4 week intervals as clinically tolerated until maximal tolerated or target dosage was achieved. Target dosage was sacubitril/valsartan 97/103 mg twice daily."
62185729|NCT04302129|EXPERIMENTAL|ultrasound guided erector spinae block and general anaesthesia|Ultrasound guided erector spine plane block is done after general anaesthesia and prone positioning
62185730|NCT04302129|ACTIVE_COMPARATOR|Multimodal analgesia with general anaesthesia|Multimodal analgesia given with general anaesthesia in form of ketorolac and paracetamol
62185731|NCT00912145|EXPERIMENTAL|1|Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)
62185732|NCT00912145|ACTIVE_COMPARATOR|2|Alprazolam Tablets, 2 mg, Xanax (The Upjohn Company)
62185733|NCT05780762|EXPERIMENTAL|IMPACT program - experimental group|patients followed for one or more stabilized chronic pathologies and benefiting from usual care with an Advanced Practice Nurse AND benefiting from the IMPACT program, which combines management at 3 levels: (1) co-definition of the health situation, (2) co-planning of care and co-actions, and (3) co-assessment with the patient and his or her care team, and incorporates evidence-based measurement tools.
62185734|NCT05780762|SHAM_COMPARATOR|Usal care : control group|patients followed for one or several stabilized chronic pathology(ies) and benefiting from a usual management with a Nurse in Advanced Practice.
62776088|NCT03429543|EXPERIMENTAL|Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono|Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of 5 milligram (mg) Linagliptin once daily, until end of treatment.
62185735|NCT01711398|EXPERIMENTAL|IPP204106N|
62185736|NCT03310398||Anxiety|elevated anxiety (as indicated by a GAD-7 score of 8 or higher)
62185737|NCT03310398||Depression|elevated anxiety (as indicated by a GAD-7 score of 8 or higher)
62185738|NCT02800447|EXPERIMENTAL|Treatment|baseline BEACOPP regimen
62185739|NCT02800447|ACTIVE_COMPARATOR|controlled group|ABVD regimen
62185740|NCT04366362|ACTIVE_COMPARATOR|Convetional reconstruction group|Patients will undergo ACL reconstruction based on conventional ACL surgery
62185741|NCT04366362|EXPERIMENTAL|Individualised reconstruction group|Patients will undergo ACL reconstruction based on their special anatomical and functional characteristics and with the use of a navigation system
62185742|NCT05575570|ACTIVE_COMPARATOR|Pre-emptive AAA sac embolization|
62185743|NCT05575570|SHAM_COMPARATOR|No pre-emtive AAA sac embolization|
62185744|NCT04419363|EXPERIMENTAL|The whole cohort|Children affected with X-linked hypophosphatemia of average age of 9.8 years were switch from conventional therapy to burosumab
62394467|NCT02658279|EXPERIMENTAL|Pembrolizumab (MK-3475)|Pembrolizumab 200 mg will be administered as an approximately 30 minute (-5/+10 mins) IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. Patients will be followed with DCE perfusion MRI done at baseline and every 9 weeks (+/- 7 days). Patients will be allowed to stay on treatment in spite of increase in tumor size, provided the patient has no, or manageable, new neurologic symptoms, and at the discretion of treating physician. In that situation, tumor resection should be encouraged for the distinction between tumor progression and immunologic reactions. Patients undergoing surgical resection will have tissue collected for collateral studies. All collected tissue will be stored in the Pathology Core Tissue bank at MSK.
62394468|NCT02988115|EXPERIMENTAL|bempedoic acid|bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
62394469|NCT02988115|PLACEBO_COMPARATOR|placebo|Matching placebo tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
62394470|NCT00981422||Glaucoma patients|POAG patients selected by an ophthalmologist from the Glaucoma Service, Ophthalmology Institute, University of Parma
62185745|NCT05281289|EXPERIMENTAL|Kinesio-tape application+stretchinge exercises|"the patient received AYstripof KT was applied to the testing leg 30% tension for 48h and was asked to assume comfortable supine position and the therapist applied 15 seconds of passive stretch to the calf muscle followed by 30 seconds of rest and this exercise was repeated 6 times per session for 2 days and ecieved instructions about dealing with calf cramps with self low sustained stretch of calf muscle."
62185746|NCT05281289|EXPERIMENTAL|self low sustained strestch|the patient recieved instructions about dealing with calf cramps with self low sustained stretch of calf muscle.
62394471|NCT00981422||Healthy|healthy subjects with negative history for (a) neurodegenerative diseases, (b) autoimmune diseases, (c) cancer, (d) viral infection, (e) diabetes, and (f) systemic inflammation
62569503|NCT00010335|EXPERIMENTAL|1|Participants will receive a stem cell transplant.
62776089|NCT03429543|EXPERIMENTAL|Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono|Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of 10 milligram (mg) Empagliflozin once daily, until Week 14. Responder patients were not re-randomised at week 14 and continued 10 mg empagliflozin, taken once daily, until end of treatment. Non responder patients were re-randomised at Week 14 to receive 10 mg empagliflozin, taken once daily, until end of treatment.
62185747|NCT06090175|EXPERIMENTAL|projector colleyscope group|Approximately 10 minutes for the child. Inhaler medication will be given with a mask that lasts. Before starting the procedure, the child will be introduced to the projector colleidoscope. Before the procedure, this device, which looks like a toy, will be projected onto the wall to divert attention. The projection will continue throughout the inhaler medication administration process. Vital signs (pulse, blood pressure, SPo2, respiration) before and after the application, Child Fear Scale will be evaluated by the researcher and the parent and recorded in the intervention follow-up form by the researcher.
62776090|NCT03429543|EXPERIMENTAL|Empagliflozin 10 mg - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono|Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of 10 milligram (mg) Empagliflozin once daily until Week 14. Non responder patients were re-randomised at Week 14 to receive 25 mg empagliflozin, taken once daily, until end of treatment.
62000523|NCT02927457|EXPERIMENTAL|Group B2- Skin Sites F/ G (P/A)|In group B, two chosen skin lesions will be labeled F and G based on size (F \>G). Subjects will be receiving Placebo for lesion F and GSK2646264 1% for lesion G once daily for 28 days according to randomisation. Skin area H- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
62000524|NCT00934206|EXPERIMENTAL|Training|One month of endurance training (running / walking at 60 % heart rate reserve for 45 min 4 times per week)
62000525|NCT05157594||All patients|A fasting blood sample will be taken on the day of the beginning and the day of the end of the radiotherapy and during the adjuvant chemotherapy (every 3 cycles). A follow-up will be performed for 9 months, with a blood sample taken every three months on the day of the follow-up MRI.
62569504|NCT04276246|EXPERIMENTAL|Experimental|All included participants receive each side 1 posterior implant in the edentulous areas bilaterally in Kennedy class I. Participants are provided with a conventional clasp retained removable partial denture (RPD) worn for 3 months. When implant osseointegration is ensured (3 months healing period), patients are assigned to retentive components (Group A, Test) which are connected to the implants to retain the RPD
62000526|NCT03960502|EXPERIMENTAL|AG881|On Day 1, after fasting for 10 hours participants, will receive an oral capsule of \[14C\]AG-881 followed 2 hours later by a single intravenous (IV) infusion of \[13C315N3\]AG-881.
62000527|NCT00854503|ACTIVE_COMPARATOR|Simvastatin|Simvastatin 20 mg/day
62000528|NCT00854503|ACTIVE_COMPARATOR|Rosuvastatin|Rosuvastatin 20 mg/day
62000529|NCT01040481||Malabsorptive distal gastric bypass|
62000530|NCT00542750|EXPERIMENTAL|N-Acetylcysteine|All participants will receive N-Acetylcysteine 1200 mg twice daily during four weeks of participation. Tolerability, marijuana use, and reactivity to marijuana cues will be investigated.
62000531|NCT05498558||Ovulation occurs on the healthy side|In tubal-presering patient who received treatment of tubal ectopic pregnancy,only when ovulation occurs on the healthy side of ovary,it may be considered to try to conceive; otherwise, contraception is recommended.
62394472|NCT02419443|PLACEBO_COMPARATOR|Placebo|Patients randomized to the placebo-group were administered placebo-pills orally one hour prior to surgery, then three times a day for a maximum of 6 total doses.
62584815|NCT01031836|EXPERIMENTAL|MEDI-545 100 mg|Cohort 4
62791678|NCT03914755|EXPERIMENTAL|Cohort 1|50 mg twice daily on Days 1-13 and once daily on Day 14
62000532|NCT05498558||Ovulation occurs on the either side|In tubal-presering patient who received treatment of tubal ectopic pregnancy,ovulation occurs on the either side of ovary,it may be considered to try to conceive.
62000533|NCT06099262||Tower Hamlets 1|Delivering the GenPMTO programme to one group of caregivers within the Tower Hamlets borough.
62000534|NCT06099262||Tower Hamlets 2|Delivering the GenPMTO programme to a second group of caregivers within the Tower Hamlets borough.
62000535|NCT06099262||Brent 1|Delivering the GenPMTO programme to one group of caregivers within the Brent borough.
62000536|NCT06099262||Brent 2|Delivering the GenPMTO programme to a second group of caregivers within the Brent borough.
62000537|NCT06099262||Barking & Dagenham 1|Delivering the GenPMTO programme to one group of caregivers within the Barking \& Dagenham borough.
62000538|NCT06099262||Barking & Dagenham 2|Delivering the GenPMTO programme to a second group of caregivers within the Barking \& Dagenham borough.
62000539|NCT02639481|ACTIVE_COMPARATOR|Control group standard physiotherapy|Patients will receive standard physiotherapy for 60 minutes, including the goal of verticalization and stimulation of the patient but without the use of the robotic Erigo®Pro device.
62000540|NCT02639481|ACTIVE_COMPARATOR|Erigo®Pro group without FES|Patients will receive 60 minutes of therapy with the robotic Erigo®Pro verticalization device but without functional electrical stimulation (FES) of the leg muscles.
62000541|NCT02639481|ACTIVE_COMPARATOR|Erigo®Pro group with FES|Patients will receive 60 minutes of therapy with the robotic Erigo®Pro verticalization device including functional electrical stimulation (FES) of the leg muscles.
62584816|NCT01031836|EXPERIMENTAL|MEDI-545 600 mg|Cohort 5
62584817|NCT01031836|EXPERIMENTAL|MEDI-545 1,200 mg|Cohort 6
62791679|NCT03914755|EXPERIMENTAL|Cohort 2|150 mg twice daily on Days 1-13 and once daily on Day 14
62791680|NCT03914755|EXPERIMENTAL|Cohort 3|300 mg twice daily on Days 1-13 and once daily on Day 14
62776091|NCT05387057|EXPERIMENTAL|Intervention Group - Exergame Training|Participants in the intervention group will perform a twelve-week training intervention in addition to their usual care (as provided by the (memory) clinics where the patients are recruited). The training intervention will be prescribed according to our newly developed exergame-based training concept (called 'Brain-IT' exergame-based training concept). Our complete 'Brain-IT' exergame-based training concept has recently been published including sufficient details about the exergame components as well as the exercise and training characteristics (i.e. including all predefined levels of task demands as well as the detailed progression rules) to allow full replication (i.e. consider supplementary file 3 of doi: 10.3389/fnagi.2021.734012). This training concept was planned and will be reported using the Consensus on Exercise Reporting Template (CERT; doi: 10.1136/bjsports-2016-096651).
62776092|NCT05387057|ACTIVE_COMPARATOR|Usual Care|The control group will proceed with usual care as provided by the (memory) clinics where the patients are recruited.
62776093|NCT05899582|EXPERIMENTAL|Surgery|The patients in the surgical group will be treated with direct extracranial to intracranial bypass surgery plus best medical treatment.
62776094|NCT05899582|ACTIVE_COMPARATOR|Medical treatment|The patients will receive medical treatment alone according to the AHA/ASA Stroke and Transient Ischemic Attack (TIA) Stroke Prevention Guidelines (2021 edition).
62776095|NCT01959243|EXPERIMENTAL|Brimonidine Tartrate|Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.
62776096|NCT01959243|PLACEBO_COMPARATOR|Brimonidine Tartrate Vehicle|Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.
62000542|NCT03945981|EXPERIMENTAL|Participants receiving Dolutegravir + Lamivudine FDC|Participants will receive DTG 50mg and 3TC 300 mg FDC tablet orally once daily (OD) with or without food
62000543|NCT04295603|EXPERIMENTAL|Toucher Massage intervention|The intervention for the Experimental Group (EG) includes a massage time of about 15 minutes on the foot area .
62776097|NCT01392612|OTHER|Erythropoietin|all subjects received epo iv.
62776098|NCT03441698|EXPERIMENTAL|Genuine acupuncture (A)|Genuine acupuncture (A) with neutral communication (A1) or positive communication (A2)
62776099|NCT03441698|PLACEBO_COMPARATOR|Sham Acupuncture (B)|Sham acupuncture (B) with neutral communication (B1) or positive communication (B2)
62776100|NCT03441698|ACTIVE_COMPARATOR|Rest (C)|Rest (C) with neutral communication (C1) or positive communication (C2)
62000544|NCT04295603|EXPERIMENTAL|Homedics Machine intervention|"The Control Group (CG) will benefit from an intervention of identical duration. The treatment consists of a foot massage with a Homedics HM MP RELEX 90 device, a heat-free shiatsu program, which lasts about 15 minutes."
62000545|NCT04168177|ACTIVE_COMPARATOR|control group|
62000546|NCT04168177|ACTIVE_COMPARATOR|ESP Group|
62000547|NCT04931901|EXPERIMENTAL|Stimpod NMX450X|
62000548|NCT04931901|ACTIVE_COMPARATOR|Datex-Ohmeda E-NMT|
62394473|NCT02419443|ACTIVE_COMPARATOR|Gabapentin|Patients randomized to the gabapentin-group were administered 300 mg orally one hour prior to surgery, then three times a day for a maximum of 6 total dose.
62776101|NCT01068080||Myocardial fatty acid metabolism, Insulin resistance|"Myocardial fatty acid metabolism was evaluated by myocardial fatty acid imaging using BMIPP SPECT.~Insulin resistance was evaluated by HOMA-IR."
62776102|NCT05136261|ACTIVE_COMPARATOR|Treatment|Ceradan Advanced Moisturising Skin Barrier cream - applied twice a day
62776103|NCT05136261|PLACEBO_COMPARATOR|Control|Aqueous Cream - applied twice a day
62776104|NCT01694108|EXPERIMENTAL|BCG-vaccine (SSI)|"Children born to mothers, who have accepted to participate, will be randomised to either intervention group or to the control group at birth. Block-randomisation stratified by hospital, gender and gestational age (≥37 weeks of gestation vs. \< 37 weeks of gestation) will be performed electronically just before vaccination by the overall study electronic case report system (e-crf).~Children randomised to the BCG vaccination group will receive an intradermal BCG vaccine (Statens Serum Institute CG vaccine in the standard dose 0.05 ml in the upper, lateral part of the arm of the child by a specially trained midwife or a study physician."
62000549|NCT01393743|EXPERIMENTAL|Perampanel|Participants received 6 tablets (initially 1 tablet of 2-mg perampanel plus 5 tablets of perampanel matched placebo) and up-titrated weekly in 2-mg increments to a target dose range of 8 mg per day maintaining the blind with administration of 6 tablets per day of either perampanel/placebo.
62000550|NCT01393743|PLACEBO_COMPARATOR|Placebo|Participants received 6 tablets of perampanel matched placebo, once a day.
62394474|NCT02449733|EXPERIMENTAL|HIV+ subjects|Men who test positive for HIV will receive a comprehensive package of HIV prevention services, including condom choices, condom-compatible lubricant choices, risk-reduction counseling, couples HIV counseling and testing, and linkage to care
62000551|NCT02126540|EXPERIMENTAL|Primary Cohort|Main cohort; treatment Arm with Pantheris Atherectomy System
62000552|NCT01762943|EXPERIMENTAL|Women with Postpartum Depression (PPD)|4 monthly (intramuscular) IM injections of leuprolide acetate (Lupron) 3.75 mg; micronized estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day; progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day. Participants will also receive placebo.
62584818|NCT04767997|EXPERIMENTAL|Experimental group|Participants in this group will be randomized to receive probiotic formulation for the following 12 weeks.
62584819|NCT04767997|PLACEBO_COMPARATOR|Control group|Participants in this group will be randomized to receive placebo for the following 12 weeks.
62394475|NCT02449733|EXPERIMENTAL|HIV- subjects|"Men who test negative for HIV will receive a comprehensive package of HIV prevention services, including condom choices, condom-compatible lubricant choices, enhanced HIV testing options, risk-reduction counseling, couples HIV counseling and testing, linkage to care, and screening for and offering of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP).~If men test positive for HIV during the study, they will be transitioned into the HIV+ subjects arm."
62394476|NCT02776631|EXPERIMENTAL|Pinloc|Plate and 3 interlocked pins. A new device for fixation of femoral neck fractures.
62394477|NCT02776631|ACTIVE_COMPARATOR|LIH (Hansson pins)|2 pins. An established method for fixation of femoral neck fractures.
62000553|NCT01762943|EXPERIMENTAL|Women without any psychiatric history (Control)|4 monthly (intramuscular) IM injections of leuprolide acetate (Lupron) 3.75 mg; micronized estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day; progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day. Participants will also receive placebo.
62000554|NCT01765127||Asenapine|Patients prescribed asenapine for any indication by a National Health Service (NHS) general practitioner (GP) in England.
62000555|NCT00742313|EXPERIMENTAL|Arm A|Arm A has FloSeal Matrix applied to EVH wound bed.
62000556|NCT00742313|NO_INTERVENTION|Arm B|Arm B does not have FloSeal Matrix applied to EVH wound bed.
62000557|NCT04487327|EXPERIMENTAL|Dry Needling within the Myofascial Trigger Point|Randomized to receive DN at the site of the MTrP
62000558|NCT04487327|ACTIVE_COMPARATOR|Dry Needling away from Myofascial Trigger Point Site|Randomized to receive DN 2 cm away from the site of the MTrP but within the same muscle
62000559|NCT02759068|EXPERIMENTAL|patients behavior|Behavior (motor reaction) to stimuli (sounds and odors)
62000560|NCT02759068|ACTIVE_COMPARATOR|healthy volunteers behavior|Behavior (motor reaction) to stimuli (sounds and odors)
62000561|NCT00655564|EXPERIMENTAL|Alefacept|Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.
62000562|NCT03085589||Amulet adaptation and validation|The Amulet development team will develop and configure applications assessing: steps/distance; strength; activity type; gait speed; and real-time, self-monitored activity feedback. Objective measures will be validated with the Amulet from 60 participants ensuring usability and feasibility. Each participant will be asked to come into the clinic for one afternoon for about 2-3 hours.
62000563|NCT03817619|ACTIVE_COMPARATOR|Treatment R (reference)|Single-dose ELB/GZR as a whole tablet in a fasted state.
62569505|NCT04276246|EXPERIMENTAL|Control|All included participants receive each side 1 posterior implant in the edentulous areas bilaterally in Kennedy class I. Participants are provided with a conventional clasp retained removable partial denture (RPD) worn for 3 months. When implant osseointegration is ensured (3 months healing period), patients are assigned to supportive components (Group B, Control), which are connected to the implants to support the RPD
62569506|NCT03340454|ACTIVE_COMPARATOR|Health systems-level intervention|using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies;
62569507|NCT03340454|ACTIVE_COMPARATOR|CHW-led patient navigation program|a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability
62569508|NCT06577753||Traditional Chinese Medicine cohort|ILD subjects who have continuously used traditional Chinese medicine for standardized treatment for 3 months or more within 1 year, or have accumulated treatment time for 6 months or more.
62569509|NCT06577753||Non Traditional Chinese Medicine cohort|Other ILD patients who do not meet the traditional Chinese medicine cohort.
62776105|NCT01694108|NO_INTERVENTION|No Intervention|Control children will be treated as usual, since no suitable placebo exists.
62776106|NCT02315482|EXPERIMENTAL|Group A|after induction of general anesthesia (i) a pneumoperitoneum is induced then (ii) patient is placed in steep trendelenburg position at 25 degrees head down
62000564|NCT03817619|EXPERIMENTAL|Treatment T (test)|Single-dose crushed ELB/GZR in a fasted state.
62000565|NCT01125215|PLACEBO_COMPARATOR|Placebo|Matched gel base of capsaicin nanoparticle
62000566|NCT01125215|EXPERIMENTAL|Capsaicin|0.075% capsaicin nanoparticle gel
62000567|NCT04076644|ACTIVE_COMPARATOR|TMS Treatment Arm|Subjects will receive either a 20min 10hz TMS treatment, or a 3min theta-burst TMS treatment at certain monthly intervals. The TMS treatment protocol they receive depends on what they received in their acute clinical treatment. Subjects in the arm will be tapered off antidepressant medication before TMS treatment begins. Subjects will be assessed monthly for depression using QIDS and PHQ9.
62394478|NCT01617343|NO_INTERVENTION|Usual care|Patients in this control group will receive usual care following stroke including standard physiotherapy and occupational therapy.
62394479|NCT01617343|EXPERIMENTAL|HEP-OKS|
62394480|NCT06158087|EXPERIMENTAL|Test group|Patients can be included in the study if they meet all of the inclusion and none of the exclusion criteria and have provided written informed consent, intent to use pEGASUS stent system assisted to treat intracranial aneurysm.
62776107|NCT02315482|EXPERIMENTAL|Group B|after induction of general anesthesia (i) the patient is placed in steep trendelenburg position at 25 degrees head down then (ii) a pneumoperitoneum is induced
62776108|NCT06544031|EXPERIMENTAL|Experimental Education-Pre and Post Test G1 and G2|"Arm Title: Experimental Pre-education Group 1-2 Arm Type: Experimental Description: Participants receive a pre-test, followed by the educational intervention, and then a post-test.~Intervention(s): Healthy Nutrition Education"
62776109|NCT06544031|NO_INTERVENTION|Control Group with only Pre and Post test G3 and G4|Arm Title: Control Group 1 Arm Type: No Intervention Description: Participants receive a pre-test and a post-test without any intervention.
62776110|NCT06544031|EXPERIMENTAL|Experimental Education- Post Test G5|"Arm Title: Experimental Group 2 Arm Type: Experimental Description: Participants receive the educational intervention followed by a post-test.~Intervention(s): Healthy Nutrition Education"
62000568|NCT04076644|NO_INTERVENTION|No TMS Arm|Subjects will be followed and assessed for depressive symptoms at monthly time intervals similar to the active treatment arm using QIDS and PHQ9. This group does not receive TMS treatment.
62569510|NCT06577012||Eyes with SMILE surgeries|Eyes with SMILE surgeries which were performed by three surgeons with different experiences.
62776111|NCT06544031|NO_INTERVENTION|Control Group with only Post test G6|Arm Title: Control Group 2 Arm Type: No Intervention Description: Participants receive only a post-test without any intervention.
62000569|NCT04019158|EXPERIMENTAL|Parkinson's Disease patients|Parkinson's Disease patients will walk in three conditions for +- 15 minutes per condition: walking over ground, walking on a treadmill, walking on a treadmill in virtual reality
62000570|NCT01883401|EXPERIMENTAL|High dose strawberry|50g freeze-dried strawberries/day
62000571|NCT01883401|EXPERIMENTAL|Low-dose strawberry|25g freeze-dried strawberries/day
62394481|NCT04183868|EXPERIMENTAL|Empagliflozin|"Eligible patients (meeting all inclusion criteria) will be randomized to receive empagliflozin in addition to existing metformin background therapy (daily dose of ≥1.500 mg, which has to remain unchanged throughout the study) for 26 weeks.~At the end of 26 weeks of treatment, subjects belonging to empagliflozin arm will be shifted to glimepiride treatment."
62569511|NCT05769387||Patients with no hormonal deficit|
62569512|NCT05769387||Patients with hormonal deficiencies|
62569513|NCT02480673|EXPERIMENTAL|Free diet plus Chia|This subjects will consume 1 cookie oatmeal with chia before breakfast and dinner for 90 days without changing their diet
62776112|NCT04927572|EXPERIMENTAL|FMX114|
62776113|NCT04927572|PLACEBO_COMPARATOR|Vehicle|
62776114|NCT06106763|EXPERIMENTAL|Mandala group|Mandala coloring page
62776115|NCT06106763|NO_INTERVENTION|Control group|Routine maintenance will be applied
62776116|NCT00875342|EXPERIMENTAL|D-cycloserine|100 mg on days of therapy session
62776117|NCT00875342|PLACEBO_COMPARATOR|Placebo|Sugar pill
62776118|NCT00759525|ACTIVE_COMPARATOR|1|Glycyrrhetic Acid
62776119|NCT00759525|PLACEBO_COMPARATOR|2|Placebo
62776120|NCT02924909|EXPERIMENTAL|induction carboplatin paclitaxel|carboplatin AUC=6 21 day cycle for 2 cycles paclitaxel 175 mg/m2 21 day cycle for 2 cycles radiotherapy 4500 cGy in 25 fractions carboplatin AUC=2 in a week regimen during radiotherapy paclitaxel 50 mg/m2 in a week regimen during radiotherapy Minimal Invasive Surgery
62776121|NCT04637399||Ulcerative Colitis|Participants diagnoses with Ulcerative Colitis.
62000572|NCT01883401|OTHER|Fiber/calorie control (high dose)|Dietary fiber (8g)
62000573|NCT01883401|OTHER|Fiber/calorie control (low dose)|Dietary fiber (4g)
62000574|NCT04415541|EXPERIMENTAL|Psychodynamic Psychotheray|Following Coordinated Specialty Care, we will offer weekly psychodynamic psychotherapy and medication management sessions which will be conducted solely by the PI, Keith Gallagher, in the initial pilot period. Consent will be obtained to record audio and video of the sessions
62000575|NCT04415541|ACTIVE_COMPARATOR|Treatment as Usual|Following Coordinated Specialty Care, patients will be referred to general mental health providers in the community, which would typically include less intensive and frequent psychotherapy by a social worker or psychologist as well as medication management by a psychiatrist who may not be a specialist in psychotic disorders.
62000576|NCT01752205|ACTIVE_COMPARATOR|Chemoradiotherapy|The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV ，dosing schedule: 45mg/m2/w.
62569514|NCT02480673|EXPERIMENTAL|Normocaloric diet plus chia|This subjects will consume 1 cookie oatmeal with chia before breakfast and dinner for 90 days along with a normocaloric diet
62569515|NCT02480673|ACTIVE_COMPARATOR|Normocaloric diet plus oatmeal|This subjects will consume 1 cookie oatmeal before breakfast and dinner for 90 days along with a normocaloric diet
62569516|NCT02480673|ACTIVE_COMPARATOR|Normocaloric diet|This subjects will only go under a normocaloric diet for 90 days
62569517|NCT04236492||Fresh osteochondral allografting|Transplantation of a fresh osteochondral allograft in the knee
62776122|NCT04637399||Crohn's Disease|Participants diagnosed with Crohn's Disease.
62776123|NCT01107223|EXPERIMENTAL|Training to antibiotic prescription|Physicians randomized in the education group attended a two days seminar focussed on evidence-based guidelines on antibiotic use in respiratory tract infections.
62776124|NCT01107223|PLACEBO_COMPARATOR|control|
62776125|NCT02578329|EXPERIMENTAL|Med Diet|Intensively advised Mediterranean diet
62776126|NCT02578329|ACTIVE_COMPARATOR|Low Fat diet|usual low-fat dietary advice
62776127|NCT01098526|EXPERIMENTAL|Cohort 1|Subjects will receive a single dose of GSK1349572 100 mg in Period 1 followed by a washout of at least 6 days. Subjects will then receive GSK1349572 50 mg once a day for 5 days in Period 2. Period 3 will begin immediately after Period 2. In Period 3 subjects will receive GSK1349572 50 mg once a day in the morning and Efavirenz 600 mg once a day at bedtime for 14 days. There will be a screening visit up to 30 days before Period 1 and a follow up visit 7-14 days after the end of Period 3.
62776128|NCT04349956||Patients from a randomized placebo-controlled study of UBX0101|Patients with moderate to severe, painful OA of the knee who participated in a randomized, placebo-controlled study of UBX0101.
62776129|NCT02567994|EXPERIMENTAL|Teneligliptin|20mg qd
62776130|NCT02567994|ACTIVE_COMPARATOR|Sitagliptin|100mg qd
62776131|NCT01976260|ACTIVE_COMPARATOR|Fractional Radiofrequency|Subjects will be randomly assigned to receive fractional radiofrequency treatment to either the right or left side of the face and the contralateral side will receive 1550-nm fractional photothermolysis. Subjects will receive treatments at baseline, week 4, and week 8 for a total of three treatments. Follow up visits will take place at week 16, two months following the last treatment visit.
62776132|NCT01976260|ACTIVE_COMPARATOR|1550-nm Fractional Photothermolysis|Subjects will be randomly assigned to receive fractional radiofrequency treatment to either the right or left side of the face and the contralateral side will receive 1550-nm fractional photothermolysis. Subjects will receive treatments at baseline, week 4, and week 8 for a total of three treatments. Follow up visits will take place at week 16, two months following the last treatment visit.
62000577|NCT01752205|EXPERIMENTAL|Erlotinib and chemoradiotherapy|The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV (45mg/m2/w) and erlotinib PO QD.
62000578|NCT05019222|EXPERIMENTAL|Arm 1) Sevoflurane group|Sevoflurane based inhalation anesthesia
62000579|NCT05019222|ACTIVE_COMPARATOR|Arm 2) Remimazolam group|Remimazolam based total intravenous anesthesia
62569518|NCT01603693|EXPERIMENTAL|Bio-Oss|In this arm,GBR will be performed with DBBM (Bio-Oss, Geistlich) in 25 patients.
62000580|NCT00400647|EXPERIMENTAL|EC MPS|Up to 1440mg taken in two doses
62000581|NCT00400647|ACTIVE_COMPARATOR|Mycophenolate mofetil|250 mg or 500 mg in two equal doses
62569519|NCT01603693|EXPERIMENTAL|Bio-Oss and BondBone|In this arm, GBR will be performed using a combination of DBBM (Bio-Oss, Geistlich) and bi-phasic calcium sulphate (BondBone, Augma) in 25 patients.
62569520|NCT03718637|ACTIVE_COMPARATOR|Control|Surgical treatment alone, consisting of tendon debridement and repair. Ultrasounds preoperatively and 6 months postoperatively.
62569521|NCT03718637|EXPERIMENTAL|Experimental|Identical surgical treatment plus Smith \& Nephew bio-inductive patch implant. Ultrasounds preoperatively and 6 months postoperatively.
62000582|NCT03973242|ACTIVE_COMPARATOR|DF-NBI|Initially, gastric mucosa is observed by conventional wight light endoscopy. Then, converting to dual-focus mode with narrow band imaging is done. Gastric mucosa is observed once again by DF-NBI mode.
62000583|NCT03973242|PLACEBO_COMPARATOR|WL|Conventional white light endoscopy use It is routine practice for the upper gastrointestinal endoscopy.
62000584|NCT02002494||volunteers in different positions|"The following will be compared in the same volunteer:~* Bilateral internal jugular venous flow in supine and prone position~* Bilateral internal jugular venous flow in supine and park bench position~* Bilateral internal jugular venous flow in prone and park bench"
62000585|NCT01470391|EXPERIMENTAL|Adductor-Canal-Blockade|
62000586|NCT01470391|ACTIVE_COMPARATOR|Femoral Nerve Block|
62000587|NCT05686512|EXPERIMENTAL|Step-by-Step treatment|Stepped care cognitive behavioral therapy
62000588|NCT05686512|EXPERIMENTAL|Cool Kids treatment|Cognitive behavioral therapy
62569522|NCT05974878|EXPERIMENTAL|Treatment Group|"Participants in this group are going to be in physiotherapy program, which is created specific to diabetic patients, contains;~* Exercises for stability, flexibility and strength,~* Exercises which improves wrist proprioception,~* Exercises for sensation recovery,~* Mirror therapy and motor imagination~* Physiotherapy program will be changed in every 3 weeks. Participant will be informed about their disease, about process of healing and will check by phone calls 2 times a week. They will be given recommendations about disease management. Home exercises will be given to this group and will be added new exercises every 3 weeks while physiotherapy program continues."
62776133|NCT04867460|EXPERIMENTAL|Ultrasound guided venous access|Vascular access of the axillary vein will be performed using an ultrasound system (Siemens Acuson Freestyle) with a wireless vascular ultrasound probe (L8-3 or L13-5). One or more vascular punctures will be performed, as needed.
62776134|NCT04867460|NO_INTERVENTION|Standard of care|Vascular access of the axillary or subclavian vein will be performed using anatomical landmarks, fluoroscopy and/or injection of X-ray contrast in the antecubital vein, at the choice of the implanter. One or more vascular punctures will be performed, as needed.
62776135|NCT03930407||Hayman group|Who had undergone cesarean section within the last 6 months and received a The Hayman uterine compression suture for uterine atony.
62776136|NCT03930407||Control|Who had undergone cesarean section within the last 6 months and did not experience neither any complication nor any additional intervention
62000589|NCT01391728|ACTIVE_COMPARATOR|Lifestyle counseling|
62000590|NCT01391728|NO_INTERVENTION|Control|
62000591|NCT04551846|EXPERIMENTAL|Oligomeric enteral feeding group|Oligomeric enteral nutrition will be administered according to the study protocol
62000592|NCT04551846|ACTIVE_COMPARATOR|Polymeric enteral feeding group|Polymeric enteral nutrition will be administered according to the study protocol
62000593|NCT04605757||Patients with acute respiratory failure due to SARS-COV-2|Patients admitted to hospital with acute respiratory failure due to SARS-COV-2 infection causing pneumonia
62000594|NCT05325463|EXPERIMENTAL|conventional|
62000595|NCT05325463|ACTIVE_COMPARATOR|ultrasound- guided|
62000596|NCT05256433|EXPERIMENTAL|IASTM|
62000597|NCT05256433|ACTIVE_COMPARATOR|Transverse friction massage|
62000598|NCT02965443|ACTIVE_COMPARATOR|Verum|Dapagliflozin 10 mg + Saxagliptin 5 mg, each once daily, for 24 weeks
62000599|NCT02965443|PLACEBO_COMPARATOR|Placebo|Placebo 1 10 mg + Placebo 2 5 mg, each once daily, for 24 weeks
62000600|NCT04425330|EXPERIMENTAL|physiotherapy exercises + PBM|"Physiotherapy exercises will be individualized and personalized for each child. It will take into account complaints and / or motor delay resulting from the injury. Circuit exercises will be performed involving muscle strengthening exercises, sensory stimulation and balance.~For irradiation, the subjects will be positioned comfortably in prone position on the examination table. Four points will be irradiated above the injury level. The level of the lesion will be located by palpation. Four points will be irradiated above the injury level. The level of the lesion will be located by palpation. The irradiation will be with LED with a wavelength of 850 nm, energy per point of 25 J, 50 seconds per point and power of 200 mW.~Treatment will be performed in 24 sessions 2 times a week"
62569523|NCT05974878|EXPERIMENTAL|Control Group|Control group will take conventional physiotherapy as in the literature. Diabetic individuals in routine takes aerobic exercise recommendation and resistive exercises. In our study control group will continue 12 sessions of resistive exercise program focused on upper extremity, also aerobic exercise recommendation.
62569524|NCT01767766|EXPERIMENTAL|TGR-1202|TGR-1202 Daily Oral Dose
62000601|NCT04425330|SHAM_COMPARATOR|physiotherapy exercises + SHAM PBM|"Physiotherapy exercises will be individualized and personalized for each child. It will take into account complaints and / or motor delay resulting from the injury. Circuit exercises will be performed involving muscle strengthening exercises, sensory stimulation and balance.~For irradiation, the subjects will be positioned comfortably in prone position on the examination table. Four points will be irradiated above the injury level. The level of the lesion will be located by palpation. The same LED device will be used in groups. However, in the placebo group (Sham), the device does not emit light.~Treatment will be performed in 24 sessions 2 times a week"
62569525|NCT05043974|EXPERIMENTAL|Dry immersion|5 days of dry-immersion.
62000602|NCT05508529|ACTIVE_COMPARATOR|Chaga Mushroom|Chaga mushroom extract (1 capsule daily) Active ingredients: 480mg chaga mushroom extract Inactive ingredients: none
62000603|NCT05508529|ACTIVE_COMPARATOR|Algae Extract|Algae Concentrate (2 tablets daily) Active ingredients: 8mg algae concentrate Inactive ingredients: none
62000604|NCT05508529|ACTIVE_COMPARATOR|Black Cumin Seed Oil|Black cumin seed oil (1 softgel daily) Active ingredients: 500mg black cumin seed oil Inactive ingredients: medium chain triglyceride (MCT) oil
62000605|NCT05508529|ACTIVE_COMPARATOR|Black Cumin Seed Oil + Astaxanthin|Black Cumin Seed Oil + Astaxanthin (3 softgels daily) Active ingredients: 500mg black cumin seed oil + 8mg astaxanthin oleoresin Inactive ingredients: medium chain triglyceride (MCT) oil
62000606|NCT05508529|ACTIVE_COMPARATOR|Black Cumin Seed Oil + Omega 3|Black Cumin Seed Oil + Omega 3 (3 softgels daily) Active ingredients: 500mg black cumin seed oil + 1200mg omega3 from 1500mg fish oil Inactive ingredients: none
62000607|NCT05508529|PLACEBO_COMPARATOR|Placebo|Placebo (1 capsule daily) Inactive ingredients: 500 mg Cornstarch/Maltodextrin
62000608|NCT02064452|EXPERIMENTAL|Triple P Online System|The Triple P Online System (TPOS) is an interactive, video-driven online parenting support website, delivered with 3 different levels of intensity, depending on severity of children's behavior problems. In this arm, pediatric clinics are randomized to receive training in child disruptive behavior disorders, Triple P principles and target parenting strategies, the Triple P Online System, effectively referring eligible families to TPOS, and supporting their use of the program. Referred parents in this condition receive access to TPOS immediately.
62000609|NCT02064452|PLACEBO_COMPARATOR|Enhanced Usual Community Care-Waitlist|In this arm, pediatric clinics are randomized to receive access for their parents and practitioners to a referral website designed to assist parents of children with disruptive behavior disorders in accessing appropriate community resources; on the website, community resources for treatment of child disruptive behavior disorders (mental health services, parenting services) are described and can be searched by location, cost, and acceptance of Medicare. Parents in this condition receive access to the Triple P Online System (TPOS) after completion of their 1-year follow-up assessment. Pediatricians receive free training in TPOS at the end of their waiting period.
62000610|NCT02016963|EXPERIMENTAL|Raxibacumab arm|A maximum of 25 subjects (to include 3 evaluable female subjects) will receive a second dose of raxibacumab equal to that of the previous dose \>= 4 months following the first dose.
62569526|NCT04981002|ACTIVE_COMPARATOR|Adult patients with orthopedic complaints - telemedicine self exam before face-to-face evaluation|First care will be performed via telemedicine with a clinical physician, guiding self-examination guided by telemedicine. After the remote consultation, a face-to-face evaluation will be performed with an orthopedist, according to institutional protocol.
62569527|NCT04981002|ACTIVE_COMPARATOR|Adult patients with orthopedic complaints - only face-to-face evaluation|Face-to-face care with an orthopedist, according to institutional protocol.
62584820|NCT04373395|EXPERIMENTAL|D-CLAG|Administration of D-CLAG regimen (Decitabine+Cladribine+Cytarabine+Granulocyte Colony Stimulating Factor)
62584821|NCT02149758|EXPERIMENTAL|Etoricoxib|Etoricoxib 60 mg once daily
62776137|NCT03249103|EXPERIMENTAL|All subjects|Up to 24 subjects will receive placebo, NYX-2925 20 mg QD, and NYX-2925 200 mg QD for sequential 2 week treatment periods, then go into Follow-up for 1 week.
62776138|NCT03522727|NO_INTERVENTION|Control|Participants will be asked to complete a questionnaire.
62776139|NCT03522727|EXPERIMENTAL|Intervention 1|"Single self-incentivising implementation intention~After completing a questionnaire, participants will be asked to form a self-incentivising implementation intention:~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself.~Please complete the following sentence with a reward of your own choosing.~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by...~\*\*Drop down menu\*\*~Learning a new skill..."
62776140|NCT03522727|EXPERIMENTAL|Intervention 2|"Multiple self-incentivising implementation intentions~After completing a questionnaire, participants will be asked to form self-incentivising implementation intentions:~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself. You can choose as many rewards as you like! Please complete the following sentence with a reward of your own choosing.~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by... and/or...~\*\*Drop down menu\*\*~Learning a new skill..."
62776141|NCT03522727|EXPERIMENTAL|Intervention 3|"Self-generated self-incentivising implementation intentions~After completing a questionnaire, participants will be asked to form a self-incentivising implementation intention:~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself.~Please complete the following sentence with a reward of your own choosing.~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by..."
62000611|NCT02994537||acute autoimmune hepatitis|Patients diagnosed autoimmune hepatitis(AIH) are divided into acute cohort or chronic cohort (acute-on-chronic and chronic were all included)by biochemical results, such as liver function and coagulation, then the investigators will compare the histological results, treatment effects and prognosis between the two groups. Further more, the investigators will study the pathogenesis of different forms of autoimmune hepatitis. Even more, the investigators want to explore drug induced AIH and viral hepatitis related AIH.
62185748|NCT06090175|EXPERIMENTAL|Matching card group|Approximately 10 minutes for the child. Inhaler medication will be given with a mask that lasts. The child will be allowed to play with the matching cards 2-3 minutes before starting the drug treatment and will then be encouraged to play throughout the procedure. Vital signs (pulse, blood pressure, SPo2, respiration) before and after the application, Child Fear Scale will be evaluated by the researcher and the parent and recorded in the intervention follow-up form by the researcher.
62185749|NCT06090175|NO_INTERVENTION|Control group|Approximately 10 minutes for the child. Inhaler medication will be given with a mask that lasts. Nothing will be shown to the child during the application. Vital signs (pulse, blood pressure, SPo2, respiration) before and after the application, the Child Fear Scale will be evaluated by the researcher and the parent and recorded by the researcher in the intervention follow-up form.
62185750|NCT03884712|EXPERIMENTAL|CalmiGo Recipients|This arm will receive a CalmiGo handheld device during their participation in the study. Participants will first complete validated surveys assessing their anxiety and panic attack symptoms. Investigators will then demonstrate how to use the CalmiGo handheld device. Participants will use the device with the investigator and then participants will use the device on their own for at least 2 times. After using CalmiGo, participants will complete validated surveys reassessing their anxiety and panic attack symptoms, asking about their past medical history, and inquiring about their experience using CalmiGo.
62185751|NCT05595811||Inuit|Inuit living in Greenland
62185752|NCT05595811||Danish|Danish patients living in Denmark
62185753|NCT01783509||LGMD|Patients with GENETICALLY CONFIRMED limb girdle muscular dystrophy
62185754|NCT00663273|EXPERIMENTAL|1|Lactic acid in small quantity during 21 days.
62185755|NCT02267564|EXPERIMENTAL|MPFLR without tibial tubercle transfer|Patients with patellar instability undergo MPFL reconstruction without tibial tubercle transfer.
62569528|NCT06080997||Spinal surgery|"No intervention will take place Recruiting autumn 2023 until autumn 2024. All patients at Zealand University Hospital, who meet the inclusion criteria, undergoing spinal surgery during 1 year, will be invited to participate in the quantitative part of the study.~We estimate that 300 patients will be eligible for the quantitative part. For the qualitative part, we will include 10 - 15 patients undergoing spinal surgery."
62569529|NCT01719367|EXPERIMENTAL|Atenolol|Patients will undergo a standardized, graded exercise protocol before and after receiving a dose of oral atenolol.
62569530|NCT01871844|EXPERIMENTAL|ITF2984 500 mcg/Placebo sc bid for 7 days|TF2984 500 mcg/Placebo sc bid for 7 days
62185756|NCT02267564|ACTIVE_COMPARATOR|MPFLR with tibial tubercle transfer|Patients with patellar instability undergo MPFL reconstruction with tibial tubercle transfer.
62185757|NCT01881152|EXPERIMENTAL|Intervention|Educational campaign
62569531|NCT01871844|EXPERIMENTAL|ITF2984 1000 mcg/Placebo sc bid for 7 days|ITF2984 1000 mcg/Placebo sc bid for 7 days
62569532|NCT01871844|EXPERIMENTAL|ITF2984 2000 mcg/Placebo sc bid for 7 days|ITF2984 2000 mcg/Placebo sc bid for 7 days
62569533|NCT01871844|ACTIVE_COMPARATOR|octreotide 50 mcg tid|octreotide 50 mcg tid
62569534|NCT00660257|EXPERIMENTAL|No.1: 1.25 ug|
62569535|NCT00660257|EXPERIMENTAL|No.2: 2.5 ug|
62569536|NCT00660257|EXPERIMENTAL|No.3: 5.0 ug|
62776142|NCT00504894|PLACEBO_COMPARATOR|Placebo|Placebo given in low dose to gauge subject's responses to visual stimuli.
62000612|NCT00499603|EXPERIMENTAL|Paclitaxel + FEC|Paclitaxel 80 mg/m\^2 intravenously (IV) on day 1(+/- 2 days) of each week, followed by four cycles of combination 5-Fluorouracil at 500 mg/m\^2, Epirubicin at 100 mg/m\^2 and Cyclophosphamide at 500 mg/m\^2 (FEC) on day 1 every 3 weeks (+/- 7 days).
62000613|NCT00499603|EXPERIMENTAL|Paclitaxel + RAD001 + FEC|Paclitaxel + RAD001 Followed by FEC (5-Fluorouracil + Epirubicin + Cyclophosphamide)
62185758|NCT01881152|OTHER|Control|Usual care
62185759|NCT02838576|EXPERIMENTAL|Conjugated Equine Estrogen|"Thirty-six healthy postmenopausal women aged between 45 and 55 years will receive 0,625 mg/day conjugated equine estrogen (CEE) for 12 weeks. These 1 active pill containing conjugated equine estrogen, 0,625 mg will be provided by a laboratory with no trademark identification.~The bottles will be numbered in code by a pharmaceutist not involved directly in study and they will donated to volunteers.~During the intervening period, use of conjugated equine estrogen, there will be blinding. After this phase, blinding will be interrupted in order to identify volunteers who used the active drug."
62569537|NCT00660257|EXPERIMENTAL|No. 4: 10 ug|
62569538|NCT00536939|EXPERIMENTAL|Enzastaurin + Bevacizumab + Paclitaxel|"Participants randomized to this arm (Arm A) will receive enzastaurin, paclitaxel and bevacizumab until disease progression.~Prior to randomization, a safety lead-in will be conducted in 6 participants who will be treated according to Arm A for 2 cycles (1 cycle = 28 days). Only after an acceptable safety analysis of the safety lead-in, will other participants be randomized to Phase 2 (either Arm A or Arm B). In Phase 2, participants from the safety lead-in will continue treatment according to Enzastaurin + Bevacizumab + Paclitaxel (Arm A)."
62569539|NCT00536939|PLACEBO_COMPARATOR|Bevacizumab + Paclitaxel + Placebo|Participants randomized to this arm (Arm B) will receive bevacizumab, paclitaxel and placebo until disease progression.
62569540|NCT06576011|EXPERIMENTAL|Gamified Social Norms Marketing Campaign|Participants randomized to this arm will receive a gamified social norms marketing campaign that is primarily delivered via advertisements on the social media platform Instagram.
62584822|NCT02149758|PLACEBO_COMPARATOR|matching placebo|matching placebo once daily
62569541|NCT06576011|EXPERIMENTAL|Social Norms Marketing Campaign|Participants randomized to this arm will receive a social norms marketing campaign that is primarily delivered via advertisements on the social media platform Instagram.
62185760|NCT02838576|PLACEBO_COMPARATOR|Placebo|"Thirty-six healthy postmenopausal women aged between 45 and 55 years will receive placebo pills, identical in size, shape and color to the active drug, via oral administration, for 12 weeks.~The bottles, without trademark identification, will be numbered in code by a pharmaceutist not involved directly in study and they will donated to volunteers.~During the intervening period, use of placebo, there will be blinding. After this phase, blinding will be interrupted in order to identify volunteers who used the active drug and placebo."
62185761|NCT00522717|EXPERIMENTAL|1|
62185762|NCT00522717|ACTIVE_COMPARATOR|2|
62185763|NCT06326879||Early Onset Colorectal Cancer (EOCRC)|Patients aged less or equal to 49 years old at the time of colorectal cancer diagnosis
62185764|NCT06326879||Late Onset Colorectal Cancer (LOCRC)|Patients aged more or equal to 50 years old at the time of colorectal cancer diagnosis
62569542|NCT06576011|NO_INTERVENTION|Assessment-Only Control|Participants do not receive anything besides the surveys.
62569543|NCT06308458|EXPERIMENTAL|Study Group (A)|Experimental (Breather Exerciser Trainer + conventional breathing exercises) Group 30 healthy elders will receive inspiratory muscle training by breather exerciser trainer (Gradual intensity from 2-3 rate of perceived exertion (RPE) up to reach 5-7 RPE, with gradual frequency; 1st week 8 sets of 5 repetitions '1 minute rest', 2nd week be 9 sets, and 3rd week reach 10 sets of 5 repetitions. then from 4-8 weeks 'end of study protocol' will be 10 sets of 6 repetitions with 1 minute rest between sets.), along with conventional breathing exercises (Diaphragmatic breathing, Pursed-up breathing, and Exercise connected with respiration), for 5 sessions per week for eight weeks.
62185765|NCT00827736|EXPERIMENTAL|Botox injection|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline. In addition, a placebo ointment has to be applied to the anoderm six times a day
62185766|NCT00827736|ACTIVE_COMPARATOR|ISDN ointment|application of ISDN 1% ointment 6 times a day. injection of placebo into internal anal sphincter
62185767|NCT01867970|EXPERIMENTAL|Tool + Self-management Support Program|"The system consists of three elements: a 3D accelerometer worn on the hip together with; an application (app) on a smartphone; a server and a website. The patient receives three types of feedback on the mobile phone concerning the amount of activity, the amount of activity in relation to an activity goal, and the response of a nurse based on the measured activity. Practice nurses will use a consultation approach to coach patients in their self-management regarding physical activity based on a five A's cycle counselling technique (assess-advise-agree-assist-arrange). Motivational interviewing, risk assessment, and goal setting are specific aspects of this approach.The patient comes to the practice four times: in the first week, after 2 weeks, after 8-12 weeks and after 16-24 weeks."
62185768|NCT01867970|EXPERIMENTAL|Self- management Support Program|"Practice nurses will use a consultation approach to coach patients in their self-management regarding physical activity based on a five A's cycle counselling technique (assess-advise-agree-assist-arrange). Motivational interviewing, risk assessment, and goal setting are specific aspects of this approach.The patient comes to the practice four times: in the first week, after 2 weeks, after 8-12 weeks and after 16-24 weeks."
62394482|NCT04183868|ACTIVE_COMPARATOR|Glimepiride|"Eligible patients will be randomized to receive glimepiride (starting dose: 2 mg daily) treatment arm, can undergo to up-titration of glimepiride to a maximum of 6 mg/day, if they experience fasting plasma glucose (FPG) levels \> 112 mg/dl (6,2 mmol/l) at scheduled visit at 6th week or at any later scheduled visit.~Whereas, glimepiride-treated patients experiencing recurrent hypoglycemic episodes should down-titrate glimepiride to a dose, considered as appropriate by Investigator.~Hypoglycemic events are defined as symptoms suggestive of low blood glucose confirmed by self monitored blood glucose (SMBG) \< 56 mg/dl (3,1 mmol/l).~Severe hypoglycemia is defined as any hypoglycemic episode requiring the assistance of another party for recovery.~At the end of 26 weeks of treatment, subjects belonging to glimepiride arm will be shifted to treatment with empagliflozin for 26 weeks."
62394483|NCT03853915|EXPERIMENTAL|FDG PET Scan|\[F-18\] - FDG PET Scan and blood sample to measure HPV DNA
62394484|NCT01811004|EXPERIMENTAL|Botox®|Botox®
62569544|NCT06308458|OTHER|Control Group (B)|"Control (conventional breathing exercises) Group:~30 health elders will receive conventional breathing exercises (Diaphragmatic breathing; Pursed-up breathing, Exercise connected with respiration for 5 times a week for a total 8 weeks"
62569545|NCT05063279|EXPERIMENTAL|Resistance training group|Participants in two age groups will receive moderate (three sets of per exercise per session) and low-volume (one set of resistance per session) training allocated to either right or left upper- and lower extremities. A total of 24 sessions will be performed over 10-12 weeks.
62000614|NCT05130411|EXPERIMENTAL|DLM - Test product|The dietary supplement is designed to be taken in servings of two gummies per day.
62394485|NCT01811004|EXPERIMENTAL|miraDry®|miraDry®
62394486|NCT01811004|EXPERIMENTAL|Nd: YAG laser|Nd: YAG laser 1440nm
62394487|NCT01407068|EXPERIMENTAL|AA4500|AA4500 collagenase clostridium histolyticum
62394488|NCT01870765|ACTIVE_COMPARATOR|non-invasive ventilation|Performance of bronchoscopy during non-invasive ventilation.
62394489|NCT01870765|EXPERIMENTAL|high-flow oxygen|Performance of bronchoscopy during high-flow oxygen therapy.
62569546|NCT05063279|NO_INTERVENTION|Negative control group|A negative control group is included in the study which will not receive any resistance training.
62569547|NCT04730596|PLACEBO_COMPARATOR|Group I (Control group)|- The patients in this group will receive normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study.
62569548|NCT04730596|EXPERIMENTAL|Group II (Ketamine group)|- The patients in this group will receive ketamine at a dose of 0.3 mg/kg dissolved in normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study.
62776143|NCT00504894|ACTIVE_COMPARATOR|Propofol|Propofol given at 0.90 μgml-1 to gauge subject's responses to visual stimuli.
62000615|NCT04720365|EXPERIMENTAL|play-based rehabilitation|"Patients randomized in the play-based rehabilitation group will perform 2 to 3 gambling rehabilitation sessions at home using the Kinect® system linked to the Curapy.com platform for 12 months."
62000616|NCT04720365|NO_INTERVENTION|routine care|"Patients randomized in the usual care group will have their usual rehabilitation care provided by their physiotherapist."
62000617|NCT00876473||1|Acute Respiratory Failure patients
62000618|NCT03771833|OTHER|Main MARIA scan visit|For Arm 1, participants will be identified in clinic as having a suitable symptomatic breast and approached about the study. They will have the study design explained to them and will be informed that they are under no obligation to participate. Arm 1 participants will receive study information that they will be sent home with and informed that they will be approached via a telephone call in 2-3 days (or the closest working day to that date) to enquire if they would like to schedule an appointment for the study visit. If so, this will be scheduled to occur around 7 days from the date of the phone call.
62000619|NCT03771833|OTHER|Same-day MARIA scan visit|"For Arm 2, participants will be identified in clinic as having a suitable symptomatic breast and approached about the study. They will have the study design explained to them and will be informed that they are under no obligation to participate. Arm 2 participants will receive study information and as much time as possible to consider their involvement with the study (at least 1 hour). If the patient agrees to participate, they will be scheduled to have their MARIA scans at a time that suits their commitments that day.~This arm also includes the 2b group, who can optionally consent to a dielectric constant reading of their routinely-aspirated cyst fluid before this is disposed of as per usual site process."
62000620|NCT02281851||Supplemented|The group consists of well-trained cyclists who habitually consume vitamin/antioxidant supplements for a period longer than 6 months
62000621|NCT02281851||Non-supplemented|The group consists of well-trained cyclists who do not consume vitamin/antioxidant supplements
62000622|NCT06123546|NO_INTERVENTION|Usual discharge preparation|Discharge teaching according to the usual discharge preparation process in participating units
62000623|NCT06123546|EXPERIMENTAL|Teaching with a patient-oriented discharge summary|Discharge teaching with a patient-oriented discharge summary, using the teach-back technique and inclusion of caregivers
62000624|NCT05501106|NO_INTERVENTION|Comparison Arm|All hospitals will receive general interventions (comparison program), including: recommendation for implementing quality improvement programs to reduce vaginal delivery complications; trainings on obstetric quality management and clinical skills on the prediction and treatment of vaginal delivery complications (3 times a year); monitoring postpartum hemorrhage after vaginal delivery and reporting data to the NCHQMO by monitoring platform every month.
62000625|NCT05501106|EXPERIMENTAL|Experimental Arm|The hospitals in the experimental group will receive general interventions and additionally implement integrated improvement strategies which include postpartum hemorrhage risk screening, hierarchical management and preparedness, postpartum hemorrhage rescue recording, and review of postpartum hemorrhage cases (detailed in the Intervention Description).
62000626|NCT04020302|EXPERIMENTAL|Shopping group|Participants will receive an 8-week intervention which will include weekly sessions that are delivered in an alternating group-individual format. Sessions will provide participants the opportunity to practice and apply self-monitoring techniques across a variety of shopping tasks and settings to promote generalization and transfer of learning (Phase B).
62000627|NCT02457325|EXPERIMENTAL|Surgery With 2% Articaine first, then Surgery With 4%Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
62000628|NCT02457325|EXPERIMENTAL|Surgery With 4%Articaine first, then Surgery With 2% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
62000629|NCT05361681|EXPERIMENTAL|interventional arm|Participants were charging full electric cars, using high power charging systems
62000630|NCT00003694|EXPERIMENTAL|Treatment (omacetaxine mepesuccinate, cytarabine)|Patients receive cytarabine and homoharringtonine concurrently by continuous intravenous infusion for 7 days. Courses repeat every 28 days. Patients receive a minimum of 9 courses of therapy in the absence of disease progression and unacceptable toxicity. Patients who are major cytogenetic responders at 9 months may continue therapy or switch to interferon. Minor cytogenetic responders are switched to interferon, and nonresponders are removed from therapy and given the option to switch to interferon.
62569549|NCT04730596|EXPERIMENTAL|Group III (Dexmedetomidine group)|- The patients in this group will receive Dexmedetomidine in a dose of 0.5 ug/kg dissolved in normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study.
62569550|NCT04726696|NO_INTERVENTION|Control group|None intervention to be administered, they continue their normal routine.
62776144|NCT00504894|ACTIVE_COMPARATOR|Thiopental|Thiopental given at 3.0 μgml-1 to gauge subject's responses to visual stimuli.
62776145|NCT05934331|EXPERIMENTAL|LM-302 in combination with Toripalimab|LM-302 (recombinant humanized anti-CLDN18.2 monoclonal antibody, MMAE conjugate), Toripalimab(recombinant humanized anti-PD1 monoclonal antibody)
62776146|NCT05314959|EXPERIMENTAL|Physician Awareness|The physician will have access to the pre-visit Control Preference Scale survey results for women assigned to this group
62776147|NCT05314959|ACTIVE_COMPARATOR|Usual Care|The physician will not have access to the pre-visit Control Preference Scale survey results for women assigned to this group
62776148|NCT02929212|OTHER|Solid Meal Study Group A|Patients Pre and Post-GBP who are randomly assigned to receive solid meals on study days given as one, 600 kcal, meal.
62185769|NCT01867970|NO_INTERVENTION|Care as usual|Patients attend the practice regularly: at least once a year for a consultation with the GP. In addition, COPD patients have consultations (15-30 minutes) with the practice nurse once or twice a year. Most patients with diabetes type 2 see the GP ones per year and the practice nurse three times per year for a health check.Normally, physical activity is not high on the agenda during consultations with the practice nurse. Barriers for paying attention are the competition with other topics that should also be covered during consultations, co-morbidity and limitations of patients, and the assumption of most practice nurses that nowadays the patient decides on the topics of the consultation. All interviewees agreed that many patients do not perceive physical activity as an important issue.
62394490|NCT02348710|EXPERIMENTAL|exercise outcome expectation workbook|Intervention arm participants will receive: 1) the ACS exercise and diet guidelines; and 2) an exercise outcome expectation workbook. The workbook contains self-directed activities to increase OE importance, certainty, and accessibility. The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many positive exercise outcomes breast cancer survivors may experience. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes.
62394491|NCT02348710|ACTIVE_COMPARATOR|diet workbook|Attention control participants will receive via mail 1) the ACS exercise and diet guidelines; and 2) a diet workbook. The diet workbook contains the same activities as the exercise outcome expectation workbook but is focused on diet instead of exercise.
62394492|NCT02433704|ACTIVE_COMPARATOR|Intraosseous Administration|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
62394493|NCT02433704|NO_INTERVENTION|Systemic Intravenous Administration|Historical controls will be used and will have received systemic dosing of cefazolin within one hour of the incision.
62394494|NCT03695471|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 cycles or until complete response in the absence of disease progression or unacceptable toxicity.
62394495|NCT04318015|EXPERIMENTAL|High-risk Treatment|Hydroxychloroquine 200mg per day for 60 days.
62394496|NCT04318015|PLACEBO_COMPARATOR|High-risk Placebo|Placebo tablet per day for 60 days.
62394497|NCT04318015|EXPERIMENTAL|Low-risk Treatment|Hydroxychloroquine 200mg per day for 60 days
62394498|NCT04318015|PLACEBO_COMPARATOR|Low-risk Placebo|Placebo tablet per day for 60 days.
62394499|NCT03616782|EXPERIMENTAL|Ixazomib|Ixazomib 3mg on day a, 8, 15 q 4 weeks for 24 months or until to progression
62000631|NCT06037746|EXPERIMENTAL|Graston Group|Miyofascial release was performed by graston tool on the entire plantar fascia.
62000632|NCT06037746|EXPERIMENTAL|Percussive Massage Group|Miyofascial release was performed by theragun tool on the entire plantar fascia.
62000633|NCT06037746|NO_INTERVENTION|Control Group|No application has been made.
62000634|NCT06265402|ACTIVE_COMPARATOR|Retrolaminar block in abdominal plastic surgery|In first group induction done with general anaesthia then Patient will receive bilateral us guided rertrolaminar block then bubivacane ,25%with dexa methasone 4mg as addiditive injected on the lamina at dose 20ml injected each side
62000635|NCT06265402|ACTIVE_COMPARATOR|Tab block as post operative analgesia in abdominal plastic surgery|In secound group after general anaesthia induction bilateral us guided tap block with ,25%bupivacaine with dexamethasone 4mg as addiditve injected on the lamina at doses 20ml in each side
62000636|NCT01971346|OTHER|Etanercept|100 mg Etanercept injections per week for 3 months.
62000637|NCT05283252|EXPERIMENTAL|Guided Endodontic Micro-Surgery|Use of the 3-D printed guide in endodontic micro-surgery
62000638|NCT05283252|PLACEBO_COMPARATOR|Conventional Endodontic Micro-Surgery|Free-hand endodontic micro-surgery
62000639|NCT04135638|OTHER|Cover Group (CG)|"All patients will undergo a 25G standard 3-port PPV with posterior vitreous detachment induction (if not already present), ILM staining with 0,25 g/l of brilliant blue-G and creation of a 360°ILM flap around the MH rim.~Phakic patients will undergo combined phacoemulsification with IOL implant in-the-bag.~In the Cover Group the ILM flap will be folded as a single layer to bridge tissue dehiscence during air-fluid exchange. All eyes will recive a mixture of 20% sulfur hexafluoride tamponade and will be instructed to position face down for 4 hours a day during the first 3 days post-operative"
62185770|NCT04243122|ACTIVE_COMPARATOR|Aspirin and cytoreductive therapy (if applicable)|Patients who are randomized to this group will take a low-dose aspirin 81mg pill once per day (standard-of-care) for at least 6 months along with cytoreductive therapy, if applicable. Patients will then be treated and followed up as per standard of care at the discretion of his or her treating physician after the completion of the study.
62394500|NCT04257656|EXPERIMENTAL|Remdesivir group|active remdesivir
62776149|NCT02929212|OTHER|Liquid Meal Study Group A|Patients Pre and Post-GBP who are randomly assigned to receive liquid meals on meal study days, given as one, 600 kcal, meal
62776150|NCT02929212|OTHER|Solid Meal Study Group B|Patients Pre and Post-GBP who are randomly assigned to receive solid meals on study days given as three, 200 kcal, meals.
62776151|NCT02929212|OTHER|Liquid Meal Study Group B|Patients Pre and Post-GBP who are randomly assigned to receive liquid meals on meal study days, given as three, 200 kcal, meals.
62776152|NCT02134678|EXPERIMENTAL|self-system therapy|self-system therapy for depression
62776153|NCT02134678|ACTIVE_COMPARATOR|cognitive therapy|cognitive therapy for depression
62776154|NCT03902119|EXPERIMENTAL|INIBY tool|Patients will undergo a single treatment session consisting of applying a suboccipital muscle inhibition technique using the so-called INYBI tool. The treatment session will last approximately 5 minutes
62185771|NCT04243122|EXPERIMENTAL|Apixaban and cytoreductive therapy (if applicable)|Patients who are randomized to this group will receive apixaban 2.5mg twice daily for at least 6 months along with standard intervention, cytoreductive therapy, if applicable. Patients will then be treated and followed up as per standard of care at the discretion of their treating physician after the completion of the study.
62185772|NCT03534011|EXPERIMENTAL|REBOA|Resuscitative Balloon Occlusion of the Aorta after advanced cardiac life support if return of spontaneous circulation is not achieved
62185773|NCT05669976|EXPERIMENTAL|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention integrates a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to mental health and social support resources (e.g., SGM-specific support groups within the community).
62185774|NCT05669976|ACTIVE_COMPARATOR|Safety Planning Intervention|The Safety Planning Intervention (SPI) is a single-session, empirically supported, suicide prevention intervention. The patient navigator will deliver the SPI.
62185775|NCT05316909|EXPERIMENTAL|Baby doll with remote controlled jaw|In this arm, standardized patients will use the Newborn Oral Assessment and Latch Simulator (NORALSim) to demonstrate and teach newborn positioning and attachment in the simulation.
62185776|NCT05316909|ACTIVE_COMPARATOR|Standard care/doll|In this arm, standardized patients will use a cloth doll/standard treatment to demonstrate and teach newborn positioning and attachment in the breastfeeding skills workshop.
62185777|NCT05160571||Subjects with Ion Endoluminal sampling of pulmonary nodule|Subjects in which a pulmonary lesion biopsy was attempted or performed with the Ion Endoluminal System
62394501|NCT04257656|PLACEBO_COMPARATOR|Control group|Placebos matched remdesivir
62394502|NCT00773994|OTHER|Normal velopharyngeal mechanism|All participants in this study are normal healthy adults, who have agreed to undergo to a videofluoroscopic Televex. These participants are acceptable control subjects because they are not diagnosed with VPI and/or submucous cleft palate (SMCP) and the velopharyageal mechanism functions the same in adults as it does in children. This procedure will take approximately 3 minutes to 5 minutes.
62394503|NCT03388450|ACTIVE_COMPARATOR|Omega 3|Patients received enteral nutrition supplemented with 1000 mg omega-3.
62394504|NCT03388450|PLACEBO_COMPARATOR|Placebo|Patients received enteral nutrition supplemented without 1000 mg omega-3.
62569551|NCT04726696|EXPERIMENTAL|Intervention group|ROLE-AP is a multifaceted program offered over a month period to participating primary care nurses and includes three interactive workshops. Each workshop will be 4 hours long.
62776155|NCT03902119|ACTIVE_COMPARATOR|Manual suboccipital inhibition|Patients will receive a single treatment session consisting of the use of the manual suboccipital muscles inhibition technique.The treatment session will last approximately 5 minutes
62776156|NCT03337009|EXPERIMENTAL|Naloxone Navigator|"Targeted, web-based animated video (Naloxone Navigator \[NN\]):~This arm is a web-based intervention targeted to patients receiving chronic opioid therapy identified in the electronic health record. Participants in this arm have access to naloxone under standing orders from the pharmacy or with a prescription from their providers."
62185778|NCT06011278|EXPERIMENTAL|Community-supported videos|"Community-supported videos will be sent to the children in the experimental group once a week for a month. At the end of four weeks, the Chıld Attıtude Toward Illness Scale and the Memorial Symptom Assessment Scale will be administered to the children again."
62185779|NCT06011278|NO_INTERVENTION|Standard care|"Children in the control group will receive the standard care of the pediatric oncology clinic.At the end of four weeks, the Chıld Attıtude Toward Illness Scale and the Memorial Symptom Assessment Scale will be administered to the children again."
62185780|NCT02803671|EXPERIMENTAL|patent ductus arteriosus|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
62000640|NCT04135638|OTHER|Fill Group (FG)|"All patients will undergo a 25G standard 3-port PPV with posterior vitreous detachment induction (if not already present), ILM staining with 0,25 g/l of brilliant blue-G and creation of a 360°ILM flap around the MH rim.~Phakic patients will undergo combined phacoemulsification with IOL implant in-the-bag.~In the Fill Group, multiple layers of ILM will be deliberately folded within the loss of tissue before air-fluid exchange. All eyes will receive a mixture of 20% sulfur hexafluoride tamponade and will be instructed to position face down for 4 hours a day during the first 3 days post-operative"
62000641|NCT05052424||Children with MIS-C|"* Children (age \<18 years) hospitalized in the Children´s University Hospital of Cologne diagnosed with MIS-C (WHO criteria)~* Assessment of clinical data~* Blood samples are taken before therapy and on days 1,2,5,7 und 9.~* RNA and protein expression of cytokines and immune cell-related markers will be determined via multiplex ELISA, FACS, quantitative PCR, RNAseq, and Western blot."
62000642|NCT02285231|EXPERIMENTAL|TEST|Arginyl-fructose Supplementation
62000643|NCT02285231|EXPERIMENTAL|Placebo|Placebo Supplementation
62000644|NCT02733510||subclinical rejection group|patients whose protocol biopsy outcome is subclinical rejection and treat with steroid pulse therapy (methylprednisolone)
62000645|NCT02733510||No rejection group|patients whose protocol biopsy outcome is normal
62000646|NCT05605262|EXPERIMENTAL|Intervention|Manukamed - 100% sterile manuka honey
62776157|NCT03337009|NO_INTERVENTION|Usual Care|Participants in the usual care arm will receive usual care from their health plan, pharmacy and clinicians. As part of usual care, participants can access naloxone through physician prescription or standing orders.
62000647|NCT05605262|NO_INTERVENTION|Control|No intervention was given. Participants receive standard wound care of the tympanic membrane which includes 0.3% Ofloxacin otic ear drops which were used twice a day for 5 days.
62569552|NCT04161469|OTHER|Group 1|Patients diagnosed with anal fistula treated by laser closure of the tract
62776158|NCT05016843|EXPERIMENTAL|CBT, 8 weeks and access to forum.|
62776159|NCT05016843|EXPERIMENTAL|CBT, 16 weeks and access to forum.|
62000648|NCT05146856||Control|Residents in control group have a usual day with clinical activity before night shift
62000649|NCT05146856||Intervention|Residents in intervention group have a day off clinic before night shift (i.e day off or day with university activity)
62000650|NCT02561130|EXPERIMENTAL|Intervention|Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise
62000651|NCT02561130|NO_INTERVENTION|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
62000652|NCT01753453|ACTIVE_COMPARATOR|G-CSF alone|Patients will receive G-CSF for 5 consecutive days
62000653|NCT01753453|EXPERIMENTAL|G-CSF plus plerixafor|Patients will receive G-CSF for 4 consecutive days, then receive plerixafor before the 5th dose of G-CSF
62000654|NCT01691027|EXPERIMENTAL|Visuo-motor training for low vision|All participants undergo training on scotoma awareness, Line and Circle Tracing and Video games
62569553|NCT04161469|OTHER|Group 2|Patients diagnosed with anal fistula treated by laser closure of the tract with an additional surgical technique as the closure of the internal orifice with a purse-string suture using 2-0 polyglactin
62569554|NCT00386360|PLACEBO_COMPARATOR|Placebo|Placebo dose
62776160|NCT05016843|EXPERIMENTAL|CBT, 8 weeks and no access to forum.|
62776161|NCT05016843|EXPERIMENTAL|CBT, 16 weeks and no access to forum.|
62776162|NCT05016843|EXPERIMENTAL|Psychodynamic therapy, 8 weeks and access to forum.|
62776163|NCT05016843|EXPERIMENTAL|Psychodynamic therapy, 16 weeks and access to forum.|
62776164|NCT05016843|EXPERIMENTAL|Psychodynamic therapy, 8 weeks and no access to forum.|
62776165|NCT05016843|EXPERIMENTAL|Psychodynamic therapy, 16 weeks and no access to forum.|
62776166|NCT05016843|EXPERIMENTAL|Waitlist, 8 weeks and access to forum.|
62776167|NCT05016843|EXPERIMENTAL|Waitlist, 16 weeks and access to forum.|
62000655|NCT05091307|EXPERIMENTAL|Group 1: Ad26.COV2.S + Quadrivalent (Q) Standard-dose (SD) Influenza Vaccine and Placebo|Participants aged greater than or equal to (\>=) 18 years will receive a single intramuscular (IM) injection of Ad26.COV2.S and a seasonal Q SD influenza vaccine on Day 1 and placebo on Day 29.
62000656|NCT05091307|PLACEBO_COMPARATOR|Group 2: Placebo + Q SD Influenza Vaccine and Ad26.COV2.S|Participants aged \>=18 years will receive a single IM injection of placebo and a seasonal Q SD influenza vaccine on Day 1 followed by Ad26.COV2.S on Day 29.
62000657|NCT05091307|EXPERIMENTAL|Group 3: Ad26.COV2.S + Q High-dose (HD) Influenza Vaccine and Placebo|Participants aged \>=65 years will receive a single IM injection of Ad26.COV2.S and a seasonal Q HD influenza vaccine on Day 1 followed by placebo on Day 29.
62776168|NCT05016843|EXPERIMENTAL|Waitlist, 8 weeks and no access to forum.|
62776169|NCT05016843|EXPERIMENTAL|Waitlist, 16 weeks and no access to forum.|
62776170|NCT05834348||Advanced/metastatic non-small cell lung cancer patients|
62776171|NCT02161926|EXPERIMENTAL|obese men from 60 to 70 years old|Dietary restrictions in obese men (30\<Body Mass Index\<40 kg/m2)
62776172|NCT02161926|ACTIVE_COMPARATOR|obese men from 30 to 40 years old|Dietary restrictions in obese men (30\<Body Mass Index\<40 kg/m2)
62000658|NCT05091307|PLACEBO_COMPARATOR|Group 4: Placebo + Q HD Influenza Vaccine and Ad26.COV2.S|Participants aged \>=65 years will receive a single IM injection of placebo and a seasonal Q HD influenza vaccine on Day 1 followed by Ad26.COV2.S on Day 29.
62000659|NCT04586803|EXPERIMENTAL|A|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
62000660|NCT04586803|EXPERIMENTAL|B|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
62000661|NCT04586803|EXPERIMENTAL|C|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
62000662|NCT04586803|EXPERIMENTAL|D|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
62000663|NCT04586803|EXPERIMENTAL|E|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
62000664|NCT04586803|EXPERIMENTAL|F|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
62000665|NCT01542515||Osteoarthritis of the carpometacarpal joint of the thumb|The group of patients enrolled in this study all have the diagnosis of carpometacarpal arthritis of the thumb. The patients did not respond favorably to non-operative management including oral anti-inflammatory medications, corticosteroid injections, and thumb splinting. Operative management was therefore recommended using the technique of meniscal allograft arthroplasty.
62185781|NCT02803671|EXPERIMENTAL|without patent ductus arteriosus|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
62185782|NCT02803671|EXPERIMENTAL|patent ductus arteriosus + cardiac or respiratory therapy|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
62185783|NCT04466410|EXPERIMENTAL|0.015 milligram (mg) XT-150|0.015 mg of XT-150. Cohort 1 of the study
62000666|NCT04025528||Hypercapnic|Obese patients with daytime hypercapnia
62185784|NCT04466410|EXPERIMENTAL|0.15 mg XT-150|0.15 mg of XT-150. Cohort 2 of the study
62185785|NCT04466410|EXPERIMENTAL|0.45 mg XT-150|0.45 mg of XT-150. Cohort 3 of the study
62569555|NCT00386360|EXPERIMENTAL|Risedronate|35 mg risedronate, orally, once weekly
62569556|NCT04267198|ACTIVE_COMPARATOR|Massed Intention Treatment (massed-INT)|Participants will receive 30 hours of Intention Treatment (INT) over 3 weeks.
62000667|NCT04025528||Eucapnic|Obese patients with normal daytime carbon dioxide levels
62185786|NCT04466410|PLACEBO_COMPARATOR|Placebo|PBS for injection.
62185787|NCT03593330|EXPERIMENTAL|Transitional Care Programme|The primary intervention of the Transitional Care Programme (TCP) will be additional patient education, framing of expectations for the hospital course and length of stay, coordinated team preparation for discharge, a dedicated discharge appointment, and a follow up phone call.
62185788|NCT03593330|NO_INTERVENTION|Standard of Care|Patients are admitted without a pre-determined discharge date. They do not receive a dedicated discharge appointment, and will not receive a follow up phone call 48 hours after discharge.
62185789|NCT03952507|EXPERIMENTAL|Group 1: JNJ-64417184|Participants will receive JNJ-64417184 600 milligram (mg) oral tablet under fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg oral tablet in fed conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg as oral suspension in fasted condition on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62569557|NCT04267198|ACTIVE_COMPARATOR|Distributed Intention Treatment (distributed-INT)|Participants will receive 30 hours of Intention Treatment (INT) over 12 weeks.
62000668|NCT03651791|EXPERIMENTAL|USPIO labeled MSC injection|USPIO labeled MSC injection
62569558|NCT04962919||Public institution|Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017
62569559|NCT04962919||Private institution|Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017
62569560|NCT01002989||All eligible patients|"Subjects assessed for hypertension, were subjected to the measurement of ankle brachial index (ABI) by two methods:~1. Doppler~2. WatchBP Office oscillometric The order for performing the two methods was randomized."
62000669|NCT00990483|EXPERIMENTAL|3D investigational imaging|patients returning with an area of interest will undergo investigational 3D imaging in 2 modes of imaging to the breast of interest and compare to the subjects standard of care imaging
62000670|NCT06290401|ACTIVE_COMPARATOR|Active Treatment|SCThrive is a virtual, 8-week, virtual group-based, behavioral self-management intervention that includes daily use of a companion mobile app.
62569561|NCT03426592|ACTIVE_COMPARATOR|Vitamin D3, 10000 Intl Units Oral Capsule|Vitamin D3, 10000 Intl Units Oral Capsule, daily for 6 months
62569562|NCT03426592|PLACEBO_COMPARATOR|Placebo oral capsule|Oleic acid capsule by mouth, daily for 6 months
62569563|NCT01056783|EXPERIMENTAL|OC000459|OC000459 100mg twice daily
62776173|NCT03299283||Respiratory/Pharyngitis|Subject presents with signs/symptoms of respiratory infection including but not limited to fever, cough, sore throat (pharyngitis), runny nose, myalgia, headache, chills, or fatigue
62776174|NCT03299283||Gastrointestinal|Subject presents with suspected gastroenteritis (e.g. diarrhea, vomiting, nausea, etc.) with duration of symptoms less than or equal to 7 days
62776175|NCT05453045|EXPERIMENTAL|Albendazole|400 mg po single dose
62776176|NCT03009968|NO_INTERVENTION|Traditional backfill assisted voiding trial|Backfill the bladder with up to 300 ml as tolerated of normal saline or sterile water through an indwelling Foley catheter. The catheter is removed and the patient is given 15 minutes to void and the voided volume is measured. A post void residual (PVR) is measured after voiding (or attempt to void) using either an in and out catheter or a bladder scanner. The participant is considered to have passed the void trial if they have a PVR of less than 100 mL or less than half the voided volume if voided volume is greater than 200 mL.
62394505|NCT06383715|EXPERIMENTAL|Cognitive Behavioural Workshop|The experimental group will attend 4 weekly group sessions of 90 minutes each. The intervention will be delivered by a Ph.D. clinical psychologist with over 15 years of clinical experience.
62569564|NCT01056783|PLACEBO_COMPARATOR|Placebo|
62569565|NCT02175511|EXPERIMENTAL|Cloud-based home BP monitoring|170 were assigned to the experimental group
62776177|NCT03009968|EXPERIMENTAL|Post-void residual free voiding trial|The post-void residual free voiding trial (intervention): Backfill the bladder with up to 300 ml as tolerated of normal saline or sterile water through an indwelling Foley catheter. The catheter is removed and the patient is given 15 minutes to void and the voided volume is measured. The participant is considered to have passed the void trial if they void more than 1/2 the instilled volume. A PVR will not be performed.
62569566|NCT02175511|NO_INTERVENTION|Traditional Care|212 patients were assigned to the traditional care group (paper-based data)
62185790|NCT03952507|EXPERIMENTAL|Group 2: JNJ-64417184|Participants will receive JNJ-64417184 600 mg oral tablet under fed conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62185791|NCT03952507|EXPERIMENTAL|Group 3: JNJ-64417184|Participants will receive JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62185792|NCT03952507|EXPERIMENTAL|Group 4: JNJ-64417184|Participants will receive JNJ-64417184 600 mg tablet under fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62185793|NCT03952507|EXPERIMENTAL|Group 5: JNJ-64417184|Participants will receive JNJ-64417184 600 mg tablet under fed conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62185794|NCT03952507|EXPERIMENTAL|Group 6: JNJ-64417184|Participants will receive JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62185795|NCT00600847|ACTIVE_COMPARATOR|1|desloratadine 20 mg
62185796|NCT00600847|ACTIVE_COMPARATOR|2|desloratadine 5 mg
62185797|NCT00600847|PLACEBO_COMPARATOR|3|
62394506|NCT02486458|NO_INTERVENTION|Negative control|No treatment will be applied
62776178|NCT02512211||Patients adults|Sample of patients with haemophilia over 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
62776179|NCT02512211||Children with haemophilia|Sign hemophilia patients under 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
62185798|NCT01380288|ACTIVE_COMPARATOR|without white matter change|
62394507|NCT02486458|EXPERIMENTAL|Varnish 4 h|Fluoride varnish will be applied on teeth and removed after 4 hours
62185799|NCT01380288|ACTIVE_COMPARATOR|with white matter change group|
62185800|NCT04373837|EXPERIMENTAL|Group 1: Without pre - With post|"Patients will perform two weeks treatment (10 sessions in total). First week: 5 days/week for 1 week, a daily session of pointing with neutral goggles inducing no-adaptation (NA) + Virtual Reality (VR) task (5 sessions).~Second week: 5 days/week for 1 week, a daily session of pointing with prismatic goggles inducing prismatic adaptation (PA) + VR task (5 sessions)."
62185801|NCT04373837|EXPERIMENTAL|Group 2: With pre - Without post|"Patients will perform two weeks treatment (10 sessions in total). First week: 5 days/week for 1 week, a daily session of pointing with prismatic goggles inducing prismatic (PA) + Virtual Reality (VR) task (5 sessions).~Second week: 5 days/week for 1 week, a daily session of pointing with neutral goggles inducing no-adaptation (NA) + VR task (5 sessions)."
62185802|NCT02422225|EXPERIMENTAL|Eldith DC-STIMULATOR group|"Intervention:~20-minutes of transcranial Direct Current Stimulation (tDCS) application 5 days a week for 2 weeks (30 applications for each 3 groups: total 90 applications)"
62185803|NCT02422225|SHAM_COMPARATOR|sham-Eldith DC-STIMULATOR group|Intervention: 20-minutes of sham-tDCS application 5 days a week for 2 weeks (total 30 applications)
62185804|NCT03516097|EXPERIMENTAL|Experimental Group A|Structured school based intervention + mobile app usage
62185805|NCT03516097|EXPERIMENTAL|Experimental Group B|mobile app usage
62185806|NCT03516097|ACTIVE_COMPARATOR|Control Group|Structured school based intervention
62185807|NCT02830048|EXPERIMENTAL|Glibenclamide dose titration|Increasing doses of glibenclamide oral suspension from 0.3mg/day to 6mg/day.
62185808|NCT05254717|EXPERIMENTAL|Interventional arm|Following baseline study, the interventional arm assigned to receive counselling intervention on complementary food flour soaking
62394508|NCT02486458|EXPERIMENTAL|Varnish 24 h|Fluoride varnish will be applied on teeth and removed after 24 hours
62394509|NCT02486458|EXPERIMENTAL|Fluoride Gel|Fluoride gell will be applied on teeth and removed after 4 minutes
62394510|NCT04435093||MFM completion|
62394511|NCT06453915|EXPERIMENTAL|Imaging|Participants will undergo positron emission tomography scans. One scan will be performed after administration of 18F-FDG while the other will be perfomred after administration of 18F-DPA-714.
62185809|NCT05254717|NO_INTERVENTION|control arm|The control group will be monitored for presence of any other intervention that might have a potential to mask the effect of the current intervention.
62394512|NCT04766411|EXPERIMENTAL|Unresisted sprint training|Participants will perform an acute training bout of unresisted sprints.
62394513|NCT04766411|EXPERIMENTAL|Resisted sprint training with load equal to 10% of body weight|Participants will perform an acute training bout of resisted sprints with load equal to 10% of body weight.
62394514|NCT04766411|EXPERIMENTAL|Resisted sprint training with load equal to 20% of body weight|Participants will perform an acute training bout of resisted sprints with load equal to 20% of body weight.
62394515|NCT04766411|EXPERIMENTAL|Control trial|Participants will perform no training protocol. They will only perform all the measurements.
62394516|NCT03153085|EXPERIMENTAL|TBI-1401(HF10) + Ipilimumab|1x10\^7 TCID50/mL TBI-1401(HF10) administered to a single or multiple eligible tumors in a total volume up to 5.0 mL (injection volume will be adjusted based on the size of tumor mass) by intratumoral injection and 3 mg/kg ipilimumab administered by intravenous infusions.
62776180|NCT02512211||Parents of children with haemophilia|Sample of parents of children with hemophilia under 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
62776181|NCT01939366|EXPERIMENTAL|Cebranopadol 300 µg|
62776182|NCT01939366|EXPERIMENTAL|Cebranopadol 600 µg|
62776183|NCT01939366|ACTIVE_COMPARATOR|Pregabalin|
62776184|NCT01939366|PLACEBO_COMPARATOR|Matching Placebo|
62776185|NCT01939366|EXPERIMENTAL|Cebranopadol 100 µg|
62776186|NCT03420404|EXPERIMENTAL|Collaborative care with TCM physicians|TCM physician involved collaborative care model (TCMCMC): The intervention arm will involve the TCM physician in the management of patients with AxSpA in addition to the usual rheumatological care.
62776187|NCT03420404|NO_INTERVENTION|Usual care only|The attending rheumatologist will prescribe a variety of treatment inclusive of medications such as non-steroidal anti-inflammatory drugs and physiotherapy.
62776188|NCT02064790||Group G - receiving gabapentin|Receiving gabapentin as standard of care. No intervention
62776189|NCT02064790||Group P - receiving pregabalin|Receiving pregabalin as standard of care No intervention
62776190|NCT02064790||Group Z - no neuropathic agent|Receiving only conservative treatment No drug treatment No intervention
62394517|NCT01928186|EXPERIMENTAL|Diagnostic (FLT PET)|Patients undergo FLT PET at baseline and 1-6 weeks after the start of treatment.
62394518|NCT04097106||Lean BMI (19-25)|
62776191|NCT06027021||Treatment group|Patients received radioembolization with hepatocellular cancer or colorectal cancer liver metastases
62776192|NCT06158113|EXPERIMENTAL|Baricitinib|Participants will be asked to take 4mg of baricitinib by mouth daily for up to 24 weeks.
62776193|NCT04563013|SHAM_COMPARATOR|Sham taVNS|The participants under conventional radiotherapy were applied with sham taVNS at the left tragus with the power off for 30min. The intervention would last until to the end of conventional radiotherapy.
62776194|NCT04563013|ACTIVE_COMPARATOR|taVNS|"For taVNS group, the electrodes were attached to the tragus of left ear after skin preparation with an alcohol pad. The stimulation current was a single-phase rectangular pulse with the following stimulation parameters: duty circle: 60 s on periods and 10 s off periods; frequency: 30 Hz; pulse width: 200 μs; pulse amplitude of 0.5 mA to 1.5 mA; stimulation time:30 min."
62776195|NCT02424045|OTHER|BCD chemotherapy|"All patients are scheduled to receive 2 cycles of three-weekly Bendamustine, carboplatin and dexamethasone combination chemotherapy(BCD Chemotherapy).~D1,D2 Bendamustine 80mg/m2 IV over 30-60min D1 Carboplatin AUC 5.0 IV D1-4 Dexamethasone 40mg #2 PO or IV"
62394519|NCT04097106||Obese BMI (30-35)|
62394520|NCT02101866|EXPERIMENTAL|Vapendavir 300 mg tablet|Vapendavir 300 mg tablet single dose with up to 7 day washout period followed by two vapendavir 132 mg capsules single dose
62394521|NCT02101866|EXPERIMENTAL|Two Vapendavir 132 mg capsules|Two Vapendavir 132 mg capsules single dose with up to 7 day washout period followed by Vapendavir 300 mg tablet single dose
62394522|NCT01869920|EXPERIMENTAL|intervention group|Intervention group receive a training education on breastfeeding. Education training is provided by an expert group from General Direction of Primary Care
62394523|NCT01869920|OTHER|Controll group|Usual care
62394524|NCT00348348|ACTIVE_COMPARATOR|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5%
62394525|NCT00348348|EXPERIMENTAL|Besifloxacin Suspension|Besifloxacin hydrochloride ophthalmic suspension 0.6%
62394526|NCT02227420|EXPERIMENTAL|Anakinra|Anakinra 100mg s.c. x 5
62569567|NCT03485963|EXPERIMENTAL|Fixed dose HIV-1 specific T-cells (HST-NEETs)|Patients will be screened for eligibility in Step 1 and undergo a blood draw of 100-120mL to allow production of autologous HST-NEETS. patients will receive a fixed dose of 2x10e7/m2. For the first 3 recipients, the infusions will occur 4 weeks apart. If no adverse reactions occur that are attributable to the HST-NEETs, the recipients thereafter will receive the two infusions separated by 2 weeks.
62569568|NCT02492204||Survivors|
62569569|NCT02492204||Non survivors|
62776196|NCT01181258|EXPERIMENTAL|Patients Receiving NK Cell Infusion|Non-Myeloablative Conditioning Using Rituximab, Fludarabine, Cyclophosphamide and Methylprednisolone followed by Interleukin 2-activated Allogeneic Natural Killer Cells infusion for Patients with Refractory NHL and CLL
62776197|NCT04028466|EXPERIMENTAL|Vonoprazan|Patients will be randomized to receiving vonoprazan, which will be taken 30 minutes before the first meal of the day for 14 days
62776198|NCT04028466|ACTIVE_COMPARATOR|Omeprazole|Patients will be randomized to receiving omeprazole, which will be taken 30 minutes before the first meal of the day for 14 days
62776199|NCT01124955|ACTIVE_COMPARATOR|Intervention Group|Patients receive 5 sessions of real acupuncture. The technique of acupuncture used in this study is Yamamoto New Scalp Acupuncture called YNSA.
62776200|NCT01124955|PLACEBO_COMPARATOR|Non-penetrating acupuncture|The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
62776201|NCT02136147||Children with ADHD medication|Identified responders and non-responders in children/adolescents starting medication for treatment of ADHD in public child and adolescent psychiatric services in Stockholm, on Gotland, and in Västerbotten.
62776202|NCT02136147||Lisdexamphetamine medication|Identified responders and non-responders in children/adolescents starting medication with lisdexamphetamine in public child and adolescent psychiatric services in Stockholm and on Gotland.
62776203|NCT02136147||Atomoxetine medication|Identified responders and non-responders in children/adolescents starting medication with atomoxetine in public child and adolescent psychiatric services in Stockholm and on Gotland.
62776204|NCT02136147||Methylphenidate medication|Identified responders and non-responders in children/adolescents starting medication with methylphenidate in public child and adolescent psychiatric services in Stockholm and on Gotland.
62776205|NCT02136147||Guanfacine medication|Identified responders and non-responders in children/adolescents starting medication with guanfacine in public child and adolescent psychiatric services in Stockholm and on Gotland.
62776206|NCT06249906|ACTIVE_COMPARATOR|Commercial bone implant product Group|Bone repair products in the market such as artificial bones and allogeneic bones.
62776207|NCT06249906|EXPERIMENTAL|Mirco-structured Bioceramic Group|β-Tricalcium phosphate (β-TCP) is a material with excellent biocompatibility and osteoinduction and bone guidance properties, which can provide mechanical strength equal to or better than that of human cancellous bone.
62569570|NCT04063553|OTHER|Intervention arm|Subjects in the intervention group will receive standard physiotherapy care and an additional volunteers session once a day for at least 3 times during their stay in the hospital. The volunteer will set up the TKR exercise video for the subjects, then supervise or guide the subjects with the exercises.
62569571|NCT04063553|OTHER|Control arm|The control group subjects will receive only standard physiotherapy care and they will be instructed to perform 1 set of exercises daily following a brochure given
62569572|NCT03859479|EXPERIMENTAL|Cold snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the snare will be opened and encircled the polyp without air aspiration. Then, the snare will be captured the polyp with at least 1-2 mm of surrounding normal tissue. The polyp will be guillotined and would not be lifted or tented until complete closure is achieved. After resection, the mucosal defect the marginal mucosa was carefully observed, with used of magnification and image enhancement. If residual polyp tissue was recognised, additional removal using the cold snare technique or biopsy forceps will be performed. If a submucosal injection prior to snaring was necessary it will be permitted. After polypectomy all patients will be observed for 3-4 days in-hospital
62569573|NCT03859479|ACTIVE_COMPARATOR|Hot snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the polyp with minimal normal tissue will be captured by the snare. The ensnared polyp should be tented away from the colonic wall and removed by one the types of electric currents. After resection, the mucosal defect will be washed thoroughly and the marginal mucosa was carefully observed, with used of magnification and image enhancement, such as near focus imaging or narrow band imaging. If a submucosal injection prior to snaring was necessary it would be permitted. If residual polyp tissue was recognised, additional removal using coagulation or biopsy forceps will be performed. After polypectomy all patients will be observed for 3-4 days in-hospital
62569574|NCT02443714|EXPERIMENTAL|Needle-free jet injection|Jet injectors deliver insulin at a high velocity (typically.100 m/s) across the skin in the subcutaneous tissue and may dispense the insulin over a larger area than insulin injected with a syringe.
62569575|NCT02443714|EXPERIMENTAL|Conventional pen|Conventional insulin administration with insulin pens.
62569576|NCT02898597|EXPERIMENTAL|Video|Video-call delivered cognitive behavioral therapy
62776208|NCT01893918||COPD patients|COPD patients, males and females, older than 65 years, with smoking history \> 20 pack/years
62185810|NCT02530398|EXPERIMENTAL|cinobufacini group|48 patients(half males and half females) will be in the group.Central venous catheters will be preserved for drainage of ascites, after the drainage of most of ascites, we will slowly inject a dilute concentration of cinobufacini injection with escalated dosage through the catheters. Then we will evaluate the observation indexes, including adverse events, vital signs, electrocardiogram, blood routine, urine routine, hepatic and renal function, etc.
62569577|NCT02898597|ACTIVE_COMPARATOR|Voice|Voice-call delivered cognitive behavioral therapy
62776209|NCT02277119|EXPERIMENTAL|Normal Eyes|Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
62776210|NCT02277119|EXPERIMENTAL|Glaucomatous Eyes|Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
62776211|NCT02277119|EXPERIMENTAL|Eyes with Retinal Diseases|Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
62185811|NCT05601128|EXPERIMENTAL|HIV + severe renal impairment|CAB LA + RPV LA administered to HIV virologically suppressed participants with CKD stage 4/5 (CrCl \< 30 mL/min) with (n = 6) or without (n = 6) hemodialysis receiving CABENUVA monthly for 6 months followed by every 2 months for 6 months.
62776212|NCT00958932|EXPERIMENTAL|Speech recognition (TEAM intervention)|Parents randomized to the intervention received speech recognition phone calls if their child's medication refill was overdue.
62776213|NCT00958932|NO_INTERVENTION|Control|Usual care
62776214|NCT04506801|PLACEBO_COMPARATOR|Placebo|liquid oral formulation 9 drops once a day
62776215|NCT04506801|EXPERIMENTAL|Probiotic|The probiotic contained Lactobacillus acidophilus LA3; 1 · 1011 CFU / g, Bifidobacterium animalis subsp. Lactis BLC1; 1.5 · 1011 CFU / g and Lactobacillus casei BGP93 2 · 1011cfu / g in the form of a liquid oral formulation
62185812|NCT02124499||All patients|Patients undergoing elective surgery with anesthesia
62185813|NCT01828866|ACTIVE_COMPARATOR|Community Reinforcement Approach|Treatment as usual, provided in out-patient setting
62185814|NCT01828866|EXPERIMENTAL|Community Reinforcement Approach + EMDR|Treatment as usual + additional sessions of EMDR
62569578|NCT03313557|EXPERIMENTAL|Wee-1 kinase inhibitor AZD1775|To assess the safety of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in patients who have previously completed 1 of the AZD1775 clinical pharmacology studies and not have met any requirements to permanently discontinue treatment with AZD1775.
62569579|NCT02029066|EXPERIMENTAL|SR-T100 gel|dosage form: topical gel dosage: 2g of 2.3% SR-T100 frequency: once duration: 24 hours
62776216|NCT00166231||Chest pain patients|
62776217|NCT00166231||Murmur group|
62776218|NCT05102253|EXPERIMENTAL|TEAS+DCEAS group|Subjects assigned to TEAS+DCEAS group will receive TEAS+DCEAS in addition to routine care.
62776219|NCT05102253|OTHER|Wait-list control: Routine care group|Subjects assigned to this group will continue their current routine care as usual.
62000671|NCT06290401|PLACEBO_COMPARATOR|Control Condition|Participants randomized to SCHealthED will receive usual care plus 7 text messages consisting of SCD educational facts to ensure the care is uniform across sites.
62569580|NCT00954031||case|hospitalized patients, adult or child, including the diagnosis of APA was made, after consulting their physician.
62776220|NCT01105598|EXPERIMENTAL|Cohort 1|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
62185815|NCT01973062|EXPERIMENTAL|rituximab and yttrium Y 90 ibritumomab tiuxetan|Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.
62185816|NCT06485739|EXPERIMENTAL|Irinotecan liposome combined administration group|The combination of irinotecan liposomes and cisplatin or carboplatin regimen is recommended for treatment, with a recommended dose of 70mg/m2 for irinotecan liposomes. For UGT1A1 \* 28 homozygous patients, the initial dose of irinotecan liposomes is adjusted to 50mg/m2. If the patient tolerates during the first treatment cycle, the dose can be adjusted to 70mg/m2 for subsequent treatment cycles; Every 4 weeks is a treatment cycle, with 6 cycles of treatment. If the researcher determines that the patient can continue to benefit from 6 cycles of treatment, the treatment will continue until 8 cycles;
62185817|NCT04988399|EXPERIMENTAL|Reiki Recipients|The Practitioner enters a gassho (two hands coming together at the heart) meditative state with the Distance Symbol. Reiji-ho - moving the joined hands until the thumbs touch the space between the brows. Going into a relaxed state by using a breathing technique. Say the person's name three times. Proceed with byosen (method using the sensitivity in the hands to treat those areas in need of Reiki) scanning technique. Chiryo (standard session visualizing all hand positions) for 5 minutes each: Jawbone-Back of the head-Throat-Lungs-Area of participant's concern-Stomach-Intestines-Kidneys-Spinal cord. At the end of the session, visualize towards the participant's feet to help integrate the healing. Visualize brushing the Biomagnetic field around the participant's body from head to feet. Inform the participant that the session has been completed. Include time to rest quietly for a few minutes. Encourage participant to sip water (if they prefer) and ask them about their experience.
62185818|NCT02590471|ACTIVE_COMPARATOR|Stenting of the femoral artery.|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent of all the extension is mounted.
62185819|NCT02590471|EXPERIMENTAL|Stenting of the femoral artery and fasciotomy.|Under local anesthesia standard endovascular exposure is made and lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent of all the extension is mounted. The exposure is carried out to the distal part of superficial femoral artery when it lives Hunter's canal and the first portion of popliteal artery. Intermuscular vastoadductoria sept is dissected and the following arteries are ligated and dissected: а. superior medialis genus, а. superior lateralis genus.
62185820|NCT01169636|EXPERIMENTAL|Panobinostat MTD + ICE|Phase 1: Escalating Panobinostat dose with routine ICE Chemotherapy
62185821|NCT01169636|EXPERIMENTAL|ICE Chemotherapy|Phase 2: Routine ICE Chemotherapy (Ifosfamide, Carboplatin, + Etoposide)
62185822|NCT01169636|EXPERIMENTAL|Panobinostat + ICE|Phase 2: Panobinostat with ICE Chemotherapy
62185823|NCT04865055|ACTIVE_COMPARATOR|cyclic merocyanine|cyclic merocyanine long-UVA absorber
62185824|NCT04865055|PLACEBO_COMPARATOR|placebo|
62185825|NCT01718431|EXPERIMENTAL|indigestible carbohydrates|test meal: indigestible carbohydrates
62185826|NCT01718431|EXPERIMENTAL|reference|reference meal: no indigestible carbohydrates
62776221|NCT01105598|EXPERIMENTAL|Cohort 2|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
62776222|NCT01105598|EXPERIMENTAL|Cohort 3|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
62185827|NCT01876615|EXPERIMENTAL|YH4808 or Diclofenac or YH4808+Diclofenac(arm 1)|"6 arm, 3 Sequence design~* YH4808 or Diclofenac or YH4808+Diclofenac~* 3 week wash out period is between each period."
62185828|NCT01876615|EXPERIMENTAL|YH4808 or Diclofenac or YH4808+Diclofenac (arm 2)|"6 arm, 3 Sequence design~* YH4808 or Diclofenac or YH4808+Diclofenac~* 3 week wash out period is between each period."
62185829|NCT01876615|EXPERIMENTAL|YH4808 or Diclofenac or YH4808+Diclofenac (arm 3)|"6 arm, 3 Sequence design~* YH4808 or Diclofenac or YH4808+Diclofenac~* 3 week wash out period is between each period."
62185830|NCT01876615|EXPERIMENTAL|YH4808 or Diclofenac or YH4808+Diclofenac (arm 4)|"6 arm, 3 Sequence design~* YH4808 or Diclofenac or YH4808+Diclofenac~* 3 week wash out period is between each period."
62185831|NCT01876615|EXPERIMENTAL|YH4808 or Diclofenac or YH4808+Diclofenac (arm5)|"6 arm, 3 Sequence design~* YH4808 or Diclofenac or YH4808+Diclofenac~* 3 week wash out period is between each period."
62185832|NCT01876615|EXPERIMENTAL|YH4808 or Diclofenac or YH4808+Diclofenac (arm6)|"6 arm, 3 Sequence design~* YH4808 or Diclofenac or YH4808+Diclofenac~* 3 week wash out period is between each period."
62185833|NCT00578578|ACTIVE_COMPARATOR|1|"Active Arm:~1000 mg Lemon flavored Capsules. Three capsules every morning."
62185834|NCT00578578|PLACEBO_COMPARATOR|2|"Placebo Arm:~Cornstarch Capsules provided by Clinical Encapsulation services. Three capsules every morning."
62185835|NCT04393792|ACTIVE_COMPARATOR|Povidone-Iodine|0.23% sinus rinse and mouthwash three times daily (tds) for days 1-3 of study
62185836|NCT04393792|PLACEBO_COMPARATOR|Normal Saline|sinus rinse and mouthwash three times daily (tds) for days 1-3 of study
62185837|NCT03292523||Hyperventilation syndrome|
62776223|NCT01105598|EXPERIMENTAL|Cohort 4|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
62776224|NCT01105598|EXPERIMENTAL|Cohort 5|Free-living subjects (18 active/6 placebo) with mild dyslipidemia
62776225|NCT02954666|EXPERIMENTAL|Patients with neurally mediated syncope|Tailored radio-frequency ablation of the ARGP (CardNM).
62776226|NCT02954666|EXPERIMENTAL|Patients with sick sinus syndrome|Tailored radio-frequency ablation of the ARGP (CardNM).
62776227|NCT01174173|EXPERIMENTAL|Ranolazine|1000 mg PO BID
62776228|NCT06229054|EXPERIMENTAL|group Dexmedetomidine|: Patients in this group will receive regional anesthesia and obturator nerve block bilaterally (10 ml 2% preservative-free lignocaine along with 5 ml 0.5% preservative-free bupivacaine) and dexmedetomidine 100 mcg/mL (2µg/kg).
62776229|NCT06229054|OTHER|group Bupivacaine|:Patients in this group will receive regional anesthesia and bilateral obturator nerve block only (10 ml 2% preservative-free lignocaine along with 5 ml 0.5% preservative-free bupivacaine).
62776230|NCT03539991|EXPERIMENTAL|Supportive care (online course, virtual meeting)|Participants complete an online course focusing on different aspects of tobacco prevention and cessation over 1 hour each per week for 4 weeks. They also engage in 6 virtual meetings over 1 hour about tobacco use once per month.
62776231|NCT01183754||patients receiving drug-eluting stents|
62776232|NCT01587235|EXPERIMENTAL|Vytorin|
62776233|NCT01587235|ACTIVE_COMPARATOR|Other Statin|
62776234|NCT02033239|EXPERIMENTAL|FIAsp|Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
62776235|NCT02033239|ACTIVE_COMPARATOR|NovoRapid®|Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
62776236|NCT02238834|EXPERIMENTAL|SAD Cohorts 1-8 Experimental Arm|
62776237|NCT02238834|PLACEBO_COMPARATOR|SAD Cohorts 1-8 Placebo Arm|
62776238|NCT02238834|EXPERIMENTAL|MAD Cohorts 1 through 4 Experimental Arm|Note: The planned MAD portion of the study was not conducted. Evaluation of FP-025 MAD is being conducted under a separate protocol (Study No. FP02C-17-001).
62776239|NCT02238834|PLACEBO_COMPARATOR|MAD Cohorts 1 through 4 Placebo Arm|Note: The planned MAD portion of the study was not conducted. Evaluation of FP-025 MAD is being conducted under a separate protocol (Study No. FP02C-17-001).
62776240|NCT02068417|ACTIVE_COMPARATOR|Shock wave treatment|Shock waves are applied extracorporeally with 0.1 millijoule per square millimeter (mJ/mm2)
62776241|NCT02068417|PLACEBO_COMPARATOR|Placebo Shock wave treatment|Shock waves are prohibited to enter the body by placebo stand-off.
62776242|NCT06303245|EXPERIMENTAL|ABDOMINAL BINDERS|
62776243|NCT06303245|ACTIVE_COMPARATOR|TENS|
62776244|NCT03147989||Group 1, 0.10 mmol/kg|For patients having received MULTIHANCE at a standard dose of 0.10 mmol/kg for their clinically indicated MRI examination.
62776245|NCT03147989||Group 2, 0.05 mmol/kg|For patients having received MULTIHANCE at a dose of 0.05 mmol/kg for their clinically indicated MRI examination.
62776246|NCT01577472|ACTIVE_COMPARATOR|High Dose Clomiphencitrat|450 IU Merional® plus 100mg Serophene®
62776247|NCT01577472|ACTIVE_COMPARATOR|Low Dose Clomiphencitrat|150 IU Merional® plus 100mg Serophene®
62394527|NCT03253380|EXPERIMENTAL|early rehabilitation program on mechanical ventilated COPD pat|compare the effect of early rehabilitation program on mechanical ventilated COPD patient in RICU to those using current standard care as regarding (morbidity and thirty day mortality ,diaphragm function and weaning outcomes, disease exacerbation , Duration spent on machin , Length of ICU stay.
62394528|NCT04067804|NO_INTERVENTION|Usual Care|Standard school disciplinary practices.
62776248|NCT01577472|PLACEBO_COMPARATOR|High Dose Placebo|450 IU Merional® plus Placebo
62776249|NCT01577472|PLACEBO_COMPARATOR|Low Dose Placebo|150 IU Merional® plus Placebo
62776250|NCT03525132|EXPERIMENTAL|Healthy subjects|120 healthy subjects in the first session and 30 in the second Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
62776251|NCT03525132|EXPERIMENTAL|Glaucoma|60 subjects with glaucoma Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
62776252|NCT03525132|EXPERIMENTAL|Retinal vein occlusion|80 subjects with retinal vein occlusion including 40 with peripheric occlusion and 40 with central occlusion Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
62776253|NCT05679063|EXPERIMENTAL|Therapeutic Exercise and Pain Neurophysiology Education|"Therapeutic exercise is the systematic and planned execution of posture movements and physical activities to correct or prevent alterations, improve or enhance physical functioning, and prevent risk factors for solid and optimized overall health status.~Pain Neurophysiology Education:~Education in pain neurophysiology consists in describing to the patient the neurobiology and neurophysiology of his nervous system pain to improve the processing of it and decrease the threatening meaning of pain."
62776254|NCT05679063|SHAM_COMPARATOR|Sham Comparator|Talks about healthy habits
62776255|NCT03926988|OTHER|Intervention|NeVa Stent Retriever
62776256|NCT04320368||Alzheimer's disease cohort|"1. Aged 40-100 years old (≥ 40 years old, ≤ 100 years old).~2. Diagnosed with AD according to Alzheimer disease diagnostic criteria following NINCDS-ADRDA 1984 or NIA-AA 2011 guideline.~3. Had adequate hearing, vision and comprehension and verbal expression to complete the cognitive assessments.~4. Had at least 3 years of education.~5. Signed informed consent."
62776257|NCT04320368||Post-stroke cognitive observation cohort|"1. Aged 40-100-years old (≥ 40 years old, ≤ 100 years old).~2. Cerebral infarction is diagnosed according to World Health Organization diagnostic criteria and was the first symptomatic onset.~3. The time from onset to enrollment was less than 7 days.~4. Had adequate hearing, vision and comprehension and verbal expression to complete the cognitive assessments.~5. Had at least 3 years of education.~6. Signed informed consent."
62776258|NCT04320368||A cohort of people with normal cognitive function|"1. Aged 40-100 years old (≥ 40 years old, ≤ 100 years old).~2. The patients are cognitively normal and able to live and work independently~3. Had adequate hearing, vision and comprehension and verbal expression to complete the cognitive assessments.~4. Had at least 3 years of education.~5. Signed informed consent."
62776259|NCT04678791|EXPERIMENTAL|Nimotuzumab+ chemoradiotherapy|Patients receive nimotuzumab combined with cisplatin and undergo external-beam radiation and brachytherapy.
62776260|NCT04678791|ACTIVE_COMPARATOR|Chemoradiotherapy|Patients receive cisplatin and undergo external-beam radiation and brachytherapy
62776261|NCT02343718|EXPERIMENTAL|Vinblastine and Temsirolimus|"Vinblastine starting dose:~Weight \>12 kg 4mg/m\^2 Weight ≤ 12 kg 0.13mg/kg IV push for 1 minute Days 1, 8, 15, 22, 29 and 36. Cycle length is 6 weeks up to 6 cycles.~Temsirolimus starting dose:~Weight \>12 kg 15mg/m\^2 Weight ≤ 12 kg 0.5 mg/kg IV for 1 hour on days 1, 8, 15, 22, 29 and 36. Cycle length is 6 weeks up to 6 cycles."
62776262|NCT01816724||Men with nocturia|Men older than 60 years old suffering from nocturia (one or more voidings overnight) without exclusion criteria
62776263|NCT01816724||Women with nocturia|Women older than 60 years old suffering from nocturia (one or more voidings overnight) without exclusion criteria
62776264|NCT00644111|PLACEBO_COMPARATOR|1|Control group receiving saline placebo through an epidural catheter
62776265|NCT00644111|ACTIVE_COMPARATOR|2|Experimental group receiving active medication through the epidural catheter
62185838|NCT01379456|EXPERIMENTAL|physiotherapy|exercises
62185839|NCT01379456|NO_INTERVENTION|conventional treatment|care as usual
62185840|NCT03765398|EXPERIMENTAL|VR Cognitive-motor-balance training|Virtual reality based cognitive-motor balance (VR-CogMoBal) training will be delivered using the commercially available Wii-Fit Nintendo in conjunction with cognitive training. All participants will undergo 12 sessions of training in a tapering manner for four weeks with 90 minutes of training per session, i.e., 5 sessions for the first week, 3 sessions for the second week, and 2 sessions for the third and fourth week. Each session will be divided into 3 sub-sessions, where each sub-session will consist of playing 4 games in conjunction with cognitive task. All the games will be performed using a Wii-Fit balance board in front of a TV screen.
62185841|NCT00523068|ACTIVE_COMPARATOR|1|Tension Free Vaginal Tape
62185842|NCT00523068|ACTIVE_COMPARATOR|2|Tolterodine tartrate 4mg
62185843|NCT04886817|NO_INTERVENTION|Control|The control group participants in this study will not receive any intervention as is the current standard of clinical care for excess sugary drink consumption. They will receive monthly check-in reminders from research staff to promote engagement and retention and will participate in data collection visits at baseline, 3 and 6 months.
62185844|NCT04886817|EXPERIMENTAL|Intervention|"Intervention group participants will receive a 6-month behavioral intervention with the following components:~1. A water promotion toolkit that includes water bottles, water flavor infusers, stickers to decorate bottles, and a children's book about water consumption, as well as instructions for other intervention components (how to view video, download app, and prepare for calls)~2. A 5-minute educational video that introduces parents to healthy drink choices for the family.~3. Ready, Set Gulp! A smartphone application for families that will help all family members track their beverage intake, find out how much water and sugar they are consuming, set goals, compete for points, answer quiz questions and create new recipes for flavor infused water.~4. A series of 14 interactive voice response phone calls to parents over 6 months that educate parents on topics relevant to improving family drink choices."
62185845|NCT03893110|EXPERIMENTAL|Instrumentation with Carbon/PEEK pedicle screw system|Posterior instrumentation using a Carbon/PEEK pedicle screw system two levels above and below the affected segment(s). The medical device is a commercial product, bears a conformity marking and is used in accordance with the instructions.
62185846|NCT03893110|ACTIVE_COMPARATOR|Instrumentation with titanium pedicle screw system|Posterior instrumentation using a titanium pedicle screw system two levels above and below the affected segment(s). The medical device is a commercial product, bears a conformity marking and is used in accordance with the instructions.
62185847|NCT00450398|EXPERIMENTAL|1|YSPSL (rPSGL-Ig)
62185848|NCT00450398|PLACEBO_COMPARATOR|2|
62185849|NCT02514226|PLACEBO_COMPARATOR|G1-control group|"Arm description: G1 - control group - (n = 30) dental hygiene orientation (DHO) + supragingival treatment + simulation of using photodynamic therapy (PDT).~In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes and ultrasound. Supragingival treatment will be performed above the gingival margin. The simulation of using photodynamic therapy (PDT) will be performed with laser turned off. No antibiotics and oral antiseptics will be prescribed."
62185850|NCT02514226|ACTIVE_COMPARATOR|G2- positive control group|"Arm description: G2 - positive control group (gold standard) - (n = 30) - DHO + periodontal treatment + simulation of using PDT.~All participants will receive periodontal treatment - scaling and root planning (SRP) by an experienced specialist with universal curetes and ultrasound in a full mouth manner. The simulation of using photodynamic therapy (PDT) will be performed with laser turned off. No antibiotics and oral antiseptics will be prescribed"
62185851|NCT02514226|ACTIVE_COMPARATOR|G3 -experimental active comparator group|"Arm description: G3 - experimental group - (n = 30) DHO +SRP + PDT with methylene blue~In G3, periodontal treatment and photodynamic therapy (PDT) will be performed. The scaling and root planing will be performed identical as G2. The PDT will be administered in periodontal pockets \> 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the photosensitizer"
62185852|NCT02812875|EXPERIMENTAL|CA-170|Taken orally in a once or twice daily schedule.
62185853|NCT04276298|ACTIVE_COMPARATOR|Metronidazole|Group A receiving 10% metronidazole cream
62185854|NCT04276298|ACTIVE_COMPARATOR|Metronidazole + Diltiazem|Metronidazole 10% + Diltiazem 2%
62185855|NCT04276298|ACTIVE_COMPARATOR|Metronidazole + Lignocaine|Metronidazole 10% + Lignocaine 4%
62185856|NCT04276298|ACTIVE_COMPARATOR|Metronidazole + Diltiazem + Lignocaine|Metronidazole 10% + Diltiazem 2% + Lignocaine 4%
62000672|NCT06158802||Chronic condition|Girls and young women between the ages of 11 and 20 suffering from chronic condition
62000673|NCT06158802||Control|Girls and young women between the ages of 11 and 20 in good health
62000674|NCT03405142|EXPERIMENTAL|T1 or T2 stage and node-negative|T1 or T2 stage primary tumor and node-negative (ie, cN0)
62000675|NCT03405142|EXPERIMENTAL|Any T stage and node-positive|Any T stage tumor and node-positive (ie, cN+)
62000676|NCT00838201|EXPERIMENTAL|Arm 1|
62185857|NCT03842436|EXPERIMENTAL|Digital Pills|Digital Pills containing Truvada ingested once daily as PrEP
62185858|NCT05040945|ACTIVE_COMPARATOR|Traditional corticotomy|Adult patients will be treated by en-masse retraction associated with traditional corticotomy
62185859|NCT05040945|EXPERIMENTAL|Flapless corticotomy|Adult patients will be treated by en-masse retraction associated with flapless corticotomy
62000677|NCT04657536|EXPERIMENTAL|TRF group|the group who treated with temperature controlled radiofrequency
62000678|NCT04657536|ACTIVE_COMPARATOR|Estriol group|the group who treated with promestriene vaginal soft capsules
62000679|NCT02014675||SD01 ICD lead|
62000680|NCT05305599|EXPERIMENTAL|ZED1227 (low dose) 10 mg|
62000681|NCT05305599|EXPERIMENTAL|ZED1227 (middle dose) 25 mg|
62000682|NCT05305599|EXPERIMENTAL|ZED1227 (high dose) 50 mg|
62000683|NCT05305599|PLACEBO_COMPARATOR|Placebo|
62000684|NCT02100007|EXPERIMENTAL|ME-344|ME-344 IV, 10 mg/kg on Days 1, 8, 15 and 22 of each 28 day cycle Topotecan IV, 4 mg/m2 on Days 1, 8 and 15 of each 28 day cycle
62000685|NCT01282593|OTHER|CD9 expression level|Impact of CD9 expression level on motility assays
62185860|NCT06542406|OTHER|Endotracheal intubation|Patients admitted to the emergency department between 01/05/2021 and 30/05/2022, who were older than 18 years of age and who underwent ETE outside the hospital or within the first hour of arrival to the emergency department were included in the study.
62569581|NCT00954031||The control group|"Two patients witnesses will be matched to each case:~Chronological criterion: consultation for a sore throat 10 days (± 3 days) before the date of hospitalization of cases, between 13 and J-J-7.~Age criteria: year of birth ± 5 years Geographical criteria: living in the same department, failing in an adjacent Department Social criteria: beneficiary or otherwise of the CMU, to avoid a selection bias leading social most frequently at the onset of the APA"
62000686|NCT02273648||Orsiro|"Subjects requiring coronary revascularization with Drug Eluting Stents (DES) as well as Subjects presenting with~1. Diabetes (all types) at least 300 subjects should be included and analyzed in this segment~2. Small vessels (≤2.75 mm) approx. 150 subjects~3. Chronic total occlusion (CTO) approx. 50 subjects~4. Acute Myocardial Infarction (incl. STEMI and NSTEMI) approx. 100 subjects~5. Multivessels approx. 250 subjects~6. In stent restenosis approx. 100 subjects~7. Different type of DAPT interruption : \<3 months, between 3 and 6 months, after 6 months approx. 300 subjects subjects who stopped \<3 months"
62185861|NCT04961632|EXPERIMENTAL|Dose-determination|
62185862|NCT04961632|EXPERIMENTAL|Dose-confirmation|
62185863|NCT01078922|EXPERIMENTAL|Ofatumumab|The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
62185864|NCT05792761|EXPERIMENTAL|treatment-naïve children with hepatitis B|
62185865|NCT05792761|EXPERIMENTAL|previously treated children with hepatitis B|
62185866|NCT05792761|EXPERIMENTAL|chronic HBV carrying children with normal ALT|
62185867|NCT02028286|EXPERIMENTAL|CLS001|CLS001
62185868|NCT03853252|OTHER|Skin biopsy|
62185869|NCT03498105||Emergency Department (ED)|"450-500 participants who will;~1. self present to the Emergency Department (ED) will chest pain~2. be brought in by ambulance to ED with acute chest pain~3. be referred from Primary care or Urgent care centre with cardiac sounding chest pain"
62185870|NCT03498105||Community Cardiology Service (CCS)|This study group will consist of between 80-100 participants who self present to the Community Cardiology Service (CCS) in Milton Keynes primary care surgery
62185871|NCT03498105||Participants with stable angina|This study group will consist of 450-500 participants with stable angina who have been referred for Stress Echocardiography.
62185872|NCT03498105||Elective Coronary Angioplasty|This study group will consist of between 50-100 participants who will have been referred for elective coronary angioplasty
62185873|NCT03498105||Cardio-toxic Chemotherapy|Consecutive patients being initiated on any of the following medication deemed as cardio toxic and requiring cardiac function will be approached to be recruited into the study.
62185874|NCT03498105||Invasive Coronary Angiography|The dynamics and performance characteristics of the CEB during acute coronary occlusion in patients undergoing invasive coronary angiography.
62185875|NCT06128213|EXPERIMENTAL|NRX101 Treatment arem|oral NRX-101 (a fixed dose combination of 487.5 mg D-cycloserine (DCS) and 16.5 mg lurasidone HCl (lurasidone)
62185876|NCT04641117|EXPERIMENTAL|Exercise|Six months of power training
62394529|NCT04067804|EXPERIMENTAL|Dynamic Adaptation Process|Using the Dynamic Adaptation Process, specialist coordinators will convene and lead Implementation Resource Teams (IRTs). With the assistance of expert trainers and coaches, the coordinator-led IRTs will then engage in an iterative process of assessment and planning to build school capacity and implement restorative practices to reduce adverse student outcomes related to discipline.
62394530|NCT04225026|EXPERIMENTAL|GC4419 (avasopasem manganese)|
62776266|NCT00660985|EXPERIMENTAL|Differin® Gel, 0.3%|Gel, 0.3%, 2g, once daily for 30 days
62185877|NCT02023190||Nutritional assessment|Nutritional assessment will be performed by bioelectrical impedance vector analysis
62185878|NCT02485314||Participation|Parents will complete the PEM-CY (Participation and Environment Measure for Children and Youth).
62185879|NCT02529943||Surgery Group|Consecutive patients from a two surgeon practice
62185880|NCT00904709|EXPERIMENTAL|Tranexamic acid, Menorrhagia, Bleeding|Tranexamic acid with titrated doses. All women with menorrhagia will take .
62776267|NCT00660985|ACTIVE_COMPARATOR|Differin® Gel, 0.1%|Gel, 0.1%, 2g, once daily for 30 days
62185881|NCT01095133|EXPERIMENTAL|Amiloride|
62185882|NCT01095133|PLACEBO_COMPARATOR|Placebo|
62185883|NCT01642147|EXPERIMENTAL|Patients undergoing craniotomy|"Patients undergoing craniotomy who are scheduled for selective supratentorial tumor removal surgery will be randomly chosen and recruited.~Transcranial Doppler (TCD) measures,jugular venous bulb catheterization, radial artery catheterization, and tumor removal surgery under general anesthesia will be performed."
62394531|NCT02899884||Cohort 1|Participants with cancer pain that is adequately controlled with opioids were observed for a period of 1 month in this observational study.
62394532|NCT04749316|EXPERIMENTAL|AcuTENS|Patients treated with TENS over Acupuncture points for faecal incontinence
62394533|NCT04749316|SHAM_COMPARATOR|Sham|Sham treatment arm with no electrical stimulations over acupuncture points
62394534|NCT04630067|EXPERIMENTAL|AZD3427: Cohort 1a|Participants will receive single SC dose A of AZD3427 on Day 1.
62394535|NCT04630067|EXPERIMENTAL|AZD3427: Cohort 2a|Participants will receive single SC dose B of AZD3427 on Day 1.
62185884|NCT01642147|ACTIVE_COMPARATOR|Patients undergoing abdominal surgery|Randomly chosen patients undergoing selective abdominal surgery. Transcranial Doppler (TCD) measures,radial artery catheterization, and major abdominal surgery under general anesthesia will be performed.
62185885|NCT03434028|OTHER|Restrictive Fluids|The general approach will be to use vasopressors to treat hypotension as opposed to intravenous fluids. Maintenance fluids should not be used.
62185886|NCT03434028|OTHER|Liberal Fluids|The general approach is to use fluid boluses to treat hypotension.
62185887|NCT01898715|EXPERIMENTAL|ATR-101|ATR-101 will be administered as capsules or tablets by mouth once or twice per day to ascending dose cohorts
62000687|NCT03454555|ACTIVE_COMPARATOR|Shared Decision Making (SDM)|SDM participants will receive guideline-concordant pharmacotherapy based on clinical guidelines for opioid therapy for chronic noncancer pain plus the SDM intervention during their opioid management visits.
62185888|NCT05156515|EXPERIMENTAL|Imaging cohort|All enrolled participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-THP-APN09 PET/CT scans.
62185889|NCT04105075||Patients with COPD and obesity|Patients consented to have a blood sample taken
62185890|NCT04105075||Normal body weight patients with COPD|Patients consented to have a blood sample taken
62185891|NCT04220268||Participants|All the patients with proved malignant ground glass nodule will be enrolled.
62185892|NCT05604807|EXPERIMENTAL|Dementia course with virtual reality|Dementia course with virtual reality consists of dementia virtual reality activity, intergenerational learning, world café teaching method and community practice
62185893|NCT05604807|ACTIVE_COMPARATOR|Dementia course with no virtual reality|Dementia course with no virtual reality consists of intergenerational learning, world café teaching method and community practice with no dementia virtual reality activity.
62185894|NCT04219280|ACTIVE_COMPARATOR|Quillivant XR|Once-daily, long-lasting MPH solution with the following dosing schedules: 7.5mg/15mg/22.5mg/30mg for children 20-25kg 10mg/20mg/30mg/40mg for children 26-30kg 10mg/22mg/34mg/46mg for children \> 30 mg
62394536|NCT04630067|EXPERIMENTAL|AZD3427: Cohort 3a|Participants will receive single SC dose C of AZD3427 on Day 1.
62394537|NCT04630067|EXPERIMENTAL|AZD3427: Cohort 4a|Participants will receive single SC dose D of AZD3427 on Day 1.
62394538|NCT04630067|EXPERIMENTAL|AZD3427: Cohort 5a|Participants will receive single IV dose E of AZD3427 on Day 1.
62394539|NCT04630067|EXPERIMENTAL|AZD3427: Cohort 6a|Participants of Japanese descent will receive single SC dose anticipated equal to the highest dose of AZD3427 in the global cohorts on Day 1.
62776268|NCT03196531|EXPERIMENTAL|Cohort 1: Sequence 1 (ABAB)|Participants will receive 10 milligram (mg) loratadine (1\*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1\*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
62000688|NCT03454555|ACTIVE_COMPARATOR|Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT-CP)|MI+CBT-CP participants will receive the guideline-concordant pharmacotherapy based on clinical guidelines for opioid therapy for chronic noncancer pain plus the MI+CBT-CP intervention.
62000689|NCT05819034|ACTIVE_COMPARATOR|Control Group|Adolescents in the control group will receive a scoliosis-specific exercise program which will be prescribed to control the progression of the scoliotic curve
62000690|NCT05819034|EXPERIMENTAL|Experimental Group|Adolescents in the experimental group will receive a scoliosis-specific exercise program which will be prescribed to control the progression of the scoliotic curve in addition to wearing the soft orthoses with external strapping.
62000691|NCT06125821||questionnaire|Arabic Version Of Henry Ford Hospital Headache Disability Inventory Questionnaire : Cross Cultural Adaptation, Validity, And Reliabilit
62185895|NCT04219280|PLACEBO_COMPARATOR|Placebo|Liquid-based suspension to match the color and banana-flavor of Quillivant XR.
62185896|NCT04216485|EXPERIMENTAL|Lifestyle intervention|Intervention group: Intensive lifestyle intervention will be initiated from the first trimester (8-12wks) to delivery, with follow up every 2-4 weeks. Participants in the intervention group will be provided with an individualized dietary protocol with not less than 1500 calories per day in the first trimester and not less than 1800 calories per day after 13 weeks of gestation. Guidance on regular exercise is reinforced at the first and each follow up visit.
62185897|NCT04216485|ACTIVE_COMPARATOR|Standard Care|Standard care group: Participants will receive a 1.5-hour group session in which standard prenatal intervention on diet, nutrition and physical activity and recommendation for gestational weight gain are reviewed by a registered dietitian. Thereafter, participants will receive their regularly scheduled follow up visits without additional lifestyle guidance.
62185898|NCT04745845|EXPERIMENTAL|Noradrenalin|treatment with 2 different NA concentrations in 2 different states of fluid responsiveness
62185899|NCT03413215|NO_INTERVENTION|Standard Care|Patients randomized to the standard care group will receive usual care, which consists of clinic visits 4 monthly for review of BP, HbA1c and other investigations, and titration of medications;counseling with the diabetes nurse educator (DNE), and provision of educational materials on diabetes.
62394540|NCT04630067|EXPERIMENTAL|AZD3427: Cohort 7a|Participants will receive single SC dose F of AZD3427 on Day 1
62394541|NCT04630067|PLACEBO_COMPARATOR|Part A: Placebo|Participants will receive single SC or IV dose of placebo matched to AZD3427 on Day 1.
62394542|NCT04630067|EXPERIMENTAL|AZD3427: Cohort 1b|Participants with HFrEF will receive SC dose A of AZD3427 on Days 1, 8, 15, 22, and 29.
62185900|NCT03413215|EXPERIMENTAL|Intensive|Patient randomized to the intensive group will receive additional counselling and education by the DNE, medical social worker (MSW) on self-care and coping strategies for diabetes, and see the renal pharmacist for more intensive titration of antihypertensive medication between doctor visits. They will also be loaned blood pressure monitors and glucometers with test strips to perform self-monitoring at home in between outpatient visits. Smartphone and online technologies will be utilized to improve remote monitoring, education and self-care.
62185901|NCT04296045|ACTIVE_COMPARATOR|Glucose|Glucose
62185902|NCT04296045|EXPERIMENTAL|MCE|
62394543|NCT04630067|EXPERIMENTAL|AZD3427: Cohort 2b|Participants with HF with EF ≥ 41% will receive SC dose A of AZD3427 on Days 1, 8, 15, 22, and 29.
62394544|NCT04630067|EXPERIMENTAL|AZD3427: Cohort 3b|Participants with HFrEF will receive SC dose B of AZD3427 on Days 1, 8, 15, 22, and 29.
62394545|NCT04630067|EXPERIMENTAL|AZD3427: Cohort 4b|Participants with HF with EF ≥ 41% will receive SC dose B of AZD3427 on Days 1, 8, 15, 22, and 29.
62394546|NCT04630067|EXPERIMENTAL|AZD3427: Cohort 5b|Participants with HFrEF will receive SC dose C of AZD3427 on Days 1, 8, 15, 22, and 29.
62394547|NCT04630067|EXPERIMENTAL|AZD3427: Cohort 6b|Participants with HF with EF ≥ 41% will receive SC dose C of AZD3427 on Days 1, 8, 15, 22, and 29.
62394548|NCT04630067|PLACEBO_COMPARATOR|Part B: Placebo|Participants with HFrEF or HF with EF ≥ 41% will receive SC dose of placebo matched to AZD3427 on Days 1, 8, 15, 22, and 29.
62394549|NCT02716402|OTHER|Cyanotic congenital heart disease|Patients who previously have been examined with cerebral MRI and V/Q SPECT/CT will be re-examined with cerebral MRI and V/Q SPECT/CT
62394550|NCT01798433|EXPERIMENTAL|One stent technique alone|One stent technique alone for non-true LM bifurcation
62776269|NCT03196531|EXPERIMENTAL|Cohort 1: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
62394551|NCT01798433|EXPERIMENTAL|One stent technique + Elective FKB|One stent technique + Elective FKB for non-true LM bifurcation
62394552|NCT01798433|EXPERIMENTAL|Provisional approach|Provisional approach for true LM bifurcation
62394553|NCT01798433|EXPERIMENTAL|Elective 2-stent|Elective 2-stent for true LM bifurcation
62394554|NCT05103202||10 weeks or less|Patients receiving botulinum toxin injections at a frequency of 10 weeks or less
62394555|NCT05103202||12 weeks or more|Patients receiving botulinum toxin injections at a frequency of 12 weeks or more
62394556|NCT01379911|ACTIVE_COMPARATOR|Yogurt with added inulin|Yogurt with 6g of added inulin
62000692|NCT03164499|ACTIVE_COMPARATOR|Control group|Individual counselling on lifestyles.
62000693|NCT03164499|EXPERIMENTAL|Intervention group|Individual counselling on lifestyles and additional group counselling on lifestyles.
62185903|NCT04296045|EXPERIMENTAL|MCE + Glucose|
62185904|NCT05455086|EXPERIMENTAL|Arm I (pronated e-liquid, unprotonated e-liquid|"VISIT 2: Patients receive 1 puff of tobacco flavored or unflavored protonated e-liquid and undergo 0-15 min head and 5 min chest PET?CT and then 0-15 min chest and 5 min head PET/CT. About 2 hours post initial PET/CT, patients receive a second puff of tobacco flavored or unflavored protonated e-liquid and undergo 0-15 min chest and 5 min head PET/CT and then 0-15 min head and 5 min chest PET/CT.~VISIT 3: Patients receive 1 puff of tobacco flavored or unflavored unprotonated e-liquid and undergo 0-15 min head and 5 min chest PET/CT and then 0-15 min chest and 5 min head PET/CT. About 2 hours post initial PET/CT, patients receive a second puff of tobacco flavored or unflavored protonated e-liquid and undergo 0-15 min chest and 5 min head PET/CT and then 0-15 min head and 5 min chest"
62394557|NCT01379911|PLACEBO_COMPARATOR|Regular yogurt|Regular yogurt without added inulin
62394558|NCT05163964||Control Group|Prediabetes patients aged 18-65 years old, who plan to continue healthcare services at a community clinic in Malacca, no literacy barries
62394559|NCT05604859|ACTIVE_COMPARATOR|non-intervening group|conventional treatment，including symptomatic and supportive treatment, antiviral treatment etc.
62394560|NCT05604859|EXPERIMENTAL|intervention group|"Part A group: Patients received methylprednisolone 1-2mg/kg/d（or other glucocorticoid equivalent to methylprednisolone 1-2mg/kg/d) + IVIG 0.2g-0.4g/kg/d for a total of 3-5 days. If the disease progressed after treatment, the patients were given the dose of rescue therapy (methylprednisolone \> 2mg/kg/d or other glucocorticoid equivalent to methylprednisolone \> 2mg/kg/d + IVIG 0.4g/kg/d) for another 3-5 days.~Part B group: Patients received tocilizumab 4mg/kg once.~Part C group: Patients received low molecular weight heparin 100U/kg, qd or q12h IH for 4-7 days.~All patients received conventional treatment. All patients were followed up from the end of treatment to day 28 after completion of treatment."
62776270|NCT03196531|EXPERIMENTAL|Cohort 2: Sequence 1 (ABAB)|Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
62776271|NCT03196531|EXPERIMENTAL|Cohort 2: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
62185905|NCT05455086|ACTIVE_COMPARATOR|Arm II (unprotonated e-liquid, protonated e-liquid|"VISIT 2: Patients receive 1 puff of tobacco flavored or unflavored unprotonated e-liquid and undergo 0-15 min head and 5 min chest PET/CT and then 0-15 min chest and 5 min head PET/CT. About 2 hours post initial PET/CT, patients receive a second puff of tobacco flavored or unflavored unprotonated e-liquid and undergo 0-15 min chest and 5 min head PET/CT and then 0-15 min head and 5 min chest.~VISIT 3: Patients receive 1 puff of tobacco flavored or unflavored protonated e-liquid and undergo 0-15 min head and 5 min chest PET/CT and then 0-15 min chest and 5 min head PET/CT. About 2 hours post initial PET/CT, patients receive a second puff of tobacco flavored or unflavored protonated e-liquid and undergo 0-15 min chest and 5 min head PET/CT and then 0-15 min head and 5 min chest PET/CT."
62185906|NCT05710289||Primary series of mRNA-1273|Manufactured by ModernaTX
62185907|NCT05710289||Primary series of ChAdOx1 nCOV-19|Manufactured by Astrazeneca or Serum Institute of India Pvt., Ltd
62185908|NCT05710289||A single dose vaccination of Ad26.COV2.S|Manufactured by Janssen Pharmaceuticals/Johnson \& Johnson
62185909|NCT05710289||Primary series of BNT162b2|Manufactured by Pfizer
62185910|NCT05710289||Primary series of BBIBP-CorV|Manufactured by Sinopharm
62185911|NCT05710289||Primary series of CoronaVac|Manufactured by Sinovac
62394561|NCT00002715|EXPERIMENTAL|Combination Chemotherapy (Stanford V)|A combination chemotherapy regimen consisting of mechlorethamine, doxorubicin hydrochloride, vinblastine, vincristine, bleomycin, etoposide and prednisone, administered on a compressed schedule
62394562|NCT01007227|OTHER|Lifestyle instruction|
62394563|NCT05327868|EXPERIMENTAL|Obese|BMI in Obesity range
62394564|NCT05327868|EXPERIMENTAL|Normal weight (lean)|Normal body weight
62394565|NCT01256424|EXPERIMENTAL|HAL 5% with illumination|HAL PDT 5%
62394566|NCT01256424|EXPERIMENTAL|HAL 1% with illumination|HAL PDT 1%
62394567|NCT01256424|EXPERIMENTAL|HAL 0.2% with illumination|HAL PDT 0.2%
62776272|NCT03322670||Signs of CAP and a positive chest X-Ray|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and a chest X-Ray not compatible with CAP
62394568|NCT01256424|PLACEBO_COMPARATOR|Placebo ointment without illumination|Placebo without illumination
62394569|NCT04617379|EXPERIMENTAL|Active Treatment Group|15 minutes daily stretch for 1 year
62394570|NCT04617379|NO_INTERVENTION|Control Group|No stretches
62394571|NCT04490421|EXPERIMENTAL|Experimental|Experimental:Camrelizumab combined with Apatinib, Etoposide and Cisplatin
62394572|NCT00779506|EXPERIMENTAL|Quetiapine Fumarate XR|Seroquel XR 400-800mg
62394573|NCT01385839|EXPERIMENTAL|alopecia areata|pts will have one area (or ½ of a large area) treated by hair transplant and another (or the other ½) treated by simple irritation with a large gauge sterile hypodermic needle
62394574|NCT02497274|EXPERIMENTAL|Roux Y gastric bypass|candidates for bariatric surgery by Roux Y gastric bypass with taste assessment and epithelium gustatory smear and biopsy
62394575|NCT02497274|EXPERIMENTAL|Sleeve gastrectomy|candidates for bariatric surgery by sleeve gastrectomy with taste assessment and epithelium gustatory smear and biopsy
62776273|NCT03322670||Patients directly hospitalized|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and who are directly hospitalized before complementary examinations
62776274|NCT03322670||Control patients|Healthy Patients (age-matched with a radiologically confirmed CAP patient)
62185912|NCT06168253|EXPERIMENTAL|Experimental: Safety Behavior Fading|This treatment lasts a total of 28 days. Participants will be asked to identify common safety behaviors related to social anxiety. For the next 14 days, participants will receive instructions to fade out these behaviors. After 14 days, participants will be asked to re-select their target safety behaviors and continue to reduce them over the next two weeks.
62394576|NCT03301246|EXPERIMENTAL|Artimes Pro Low Profile Dilatation Catheter|Subjects who require initial pre-dilatation using the study device, and then undergo definitive therapy using additional PTCA catheters and stents, according to standard of care will be enrolled in this study.
62791681|NCT00971139|EXPERIMENTAL|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
62185913|NCT06168253|ACTIVE_COMPARATOR|Unhealthy Behavior Fading|This treatment lasts a total of 28 days. Participants will be asked to identify common unhealthy behaviors related to social anxiety. For the next 14 days, participants will receive instructions to fade out these behaviors. After 14 days, participants will be asked to re-select their target unhealthy behaviors and continue to reduce them over the next two weeks.
62185914|NCT04674254|ACTIVE_COMPARATOR|Anti-vascular endothelial growth factor agent|Intravitreal injections of 1.25 mg/0.05 ml of Bevacizumab every 4 weeks through 12- week visit then pro re nata to complete 12 months according to Protocol S.
62394577|NCT01014442|EXPERIMENTAL|Mycophenolate Mofetil; Cystic Fibrosis|Participants with cystic fibrosis will receive mycophenolate mofetil 1.5 g, orally (PO), BID from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.
62394578|NCT01014442|EXPERIMENTAL|Mycophenolate Mofetil; Other|Participants with COPD, emphysema, idiopathic pulmonary fibrosis, or A1AD will receive mycophenolate mofetil 1.5 g, PO, BID, from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.
62394579|NCT04670523|OTHER|Test group|Test group: The patients of the study group are getting their chest tube removed according to the investigators' current airleak protocol (Flow \<20 mL/ min on digital suction device) but already in the operating room immediately following wound closure (Postoperative day 0 (POD0)). If airleak is persisting than chest tube removal will be performed according to the traditional protocol not earlier than on postoperative day 1 (POD 1).
62394580|NCT04670523|OTHER|Control group|In the control group, the chest tube gets removed according to the investigators' traditional standard protocol not earlier than on postoperative day 1 (POD1).
62394581|NCT02118909|EXPERIMENTAL|Part 1 (Pracinostat + Itraconazole)|Single-dose pracinostat and itraconazole dosing every day for 8 days
62000694|NCT02151708|ACTIVE_COMPARATOR|motilitone 90mg|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
62000695|NCT02151708|ACTIVE_COMPARATOR|motilitone 180mg|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
62000696|NCT02151708|PLACEBO_COMPARATOR|placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
62000697|NCT03577431|EXPERIMENTAL|arTreg-CSB|"arTreg CSB: alloantigen-reactive T regulatory cells costimulatory blockade per protocol.~The investigational product is donor alloantigen-specific T regulatory cells (arTreg-CSB). Supportive regimen for receipt of arTregs-CSB includes everolimus, leukapheresis, cyclophosphamide, and mesna.~Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10\^6 total cells. arTreg-CSB will be administered as a single peripheral intravenous (IV) infusion over approximately 15 to 30 minutes.~Note: Participants who receive at least the minimum Treg product (arTreg-CSB) dose of 1 to \< 2.5 x 10\^6 cells will be included in intent-to-treat analysis."
62000698|NCT04630093|EXPERIMENTAL|Panel-based pharmacogenetic genotyping|All patients will receive clinical preemptive pharmacogenetic testing. Genotype results and consult notes will returned in the EHR pre-emptively. Data on implementation success metrics and PROs via patient report and TSQM measures will be collected. In addition, data on effectiveness outcomes and socioeconomic measures will be collected via the EHR and patient report, respectively.
62000699|NCT00265616|ACTIVE_COMPARATOR|1|propofol, 2mg/kg as bolus, then titrated up to EEG burst-suppression as a continuous infusion; no maximum doses defined
62000700|NCT00265616|ACTIVE_COMPARATOR|2|thiopental/pentobarbital, 2mg/kg as bolus, then titrated up to EEG burst-suppression as a continuous infusion; no maximum doses defined
62000701|NCT02269891|EXPERIMENTAL|Nu Femme|Two capsules (500mg total) taken once daily in the morning after breakfast for 24 weeks
62000702|NCT02269891|PLACEBO_COMPARATOR|Placebo|Two capsules taken once daily in the morning after breakfast for 24 weeks
62000703|NCT03196752|EXPERIMENTAL|Only arm|Patient's cricoid membrane is identified using both laryngeal handshake method and simple palpation
62000704|NCT03271879|ACTIVE_COMPARATOR|Empagliflozin at a dose of 10 mg/day|Patients will be treated with 10mg Empagliflozin once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
62000705|NCT03271879|PLACEBO_COMPARATOR|Placebo|Patients will be treated with Placebo once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
62000706|NCT05886569|EXPERIMENTAL|Interventional group|This arm includes all study participants.
62000707|NCT01974193|EXPERIMENTAL|Floseal|application of floseal to one side of pelvis after pelvic lymphadenectomy
62000708|NCT01974193|NO_INTERVENTION|Control|counter-site of pelvis; no intervention after pelvic lymphadenectomy
62000709|NCT03688321|ACTIVE_COMPARATOR|Probiotic capsule GR-1 and RC-14|The intervention for study group is taking 2 capsules containing probiotic strains GR-1 and RC-14 before sleep for 18 weeks after being confirmed as GBS positive on 28th week gestation
62000710|NCT03688321|PLACEBO_COMPARATOR|Placebo capsule|The intervention for placebo group is taking 2 capsules not containing probiotic strains GR-1 and RC-14 before sleep for 18 weeks after being confirmed as GBS positive on 28th week gestation
62000711|NCT04586179|ACTIVE_COMPARATOR|Aerobic (treadmill) Exercise|Participants will wear a heart rate monitor and complete the Buffalo Concussion Treadmill Test
62000712|NCT04586179|EXPERIMENTAL|Dynamic Exercise|Participants will wear a heart rate monitor and complete a dynamic exertion assessment that incorporates directional changes that incrementally increases in exercise intensity
62000713|NCT01849588|EXPERIMENTAL|Treatment Arm|Sorafenib taken orally twice per day
62791682|NCT00971139|NO_INTERVENTION|Control group|Patients receiving usual care
61977825|NCT05127447|EXPERIMENTAL|ES group|External neuromuscular electrical stimulation was applied to the patients in supine position. It was applied for 30 minutes 3 days a week for 8 weeks. This stimulation consists of a total of eight external electrodes, including 2 sheaths wrapped around the thigh area and 4 electrodes for each leg. Electrodes were placed on the anterior and posterior proximal thighs, buttocks, and outside of the hips. The treatment protocol was applied with symmetrical biphasic current at a frequency of 50 Hertz (Hz), with stimulation and rest periods of 5 seconds of contraction and 5 seconds of rest.
62000714|NCT05018715||coronary heart disease|A total of 300 patients with CHD WHO were hospitalized in the First Affiliated Hospital of Xinjiang Medical University from August 2021 to February 2022 were selected, all of whom met the DIAGNOSTIC criteria of CHD formulated by the World Health Organization (WHO) and excluded diseases such as highly severe valvular disease and congenital heart disease
62000715|NCT05018715||Healthy person|.A total of 300 healthy subjects from the First Affiliated Hospital of Xinjiang Medical University during the same period were selected as controls.
62000716|NCT00354172|EXPERIMENTAL|Treated Patients|All patients receiving treatment with chemotherapy and radiation, along with natural killer cells, aldesleukin and umbilical cord blood transplant.
62000717|NCT01812928|NO_INTERVENTION|Gel only|This group will be given only intraurethral gel during flexible cystoscopy.
62000718|NCT01812928|EXPERIMENTAL|Diclofenac and Gel|This group will also receive intraurethral gel during cystoscopy but additionally diclofenac suppository will be given per rectally one hour before procedure as preemptive analgesia.
62000719|NCT01457599||Marking Liver|
62000720|NCT04670991|OTHER|EXATRAC imaging|For each radiotherapy session, patient will first have an Exatrac imaging and then a CBCT imaging. Patient's repositionning will be performed accoding to CBCT data
62000721|NCT00205712|PLACEBO_COMPARATOR|Ketamine plue saline|Ketamine without dexmedetomidine
62000722|NCT00205712|EXPERIMENTAL|Ketamine plus dexmedetomidine|Ketamine infusion plus dexmedetomidine
62000723|NCT01524562||Rakai Community Cohort|HIV Patients
62000724|NCT01524562||Rakai HIV Care Program|HIV Patients
62000725|NCT01573780|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive gemcitabine hydrochloride IV over 30 minutes and smac mimetic TL32711 IV over 30 minutes once weekly for 2 weeks. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62000726|NCT01440348|EXPERIMENTAL|Achilles allograft|
62569582|NCT06577246|ACTIVE_COMPARATOR|Conventional Method (CM)|Individuals in this group receive instructions on oral care after initial periodontal treatment from the physician (SG) who is familiar with the patient groups. The physician verbally explains the development of periodontal disease, its causes, symptoms, and the potential consequences of irregular oral care, using a brochure to reinforce these points.
62569583|NCT06577246|ACTIVE_COMPARATOR|Three-Dimensional Animation (3DA)|"The video used in the study was created by DentalMaster (MD Stimulation Ltd) by combining their own footage (http://www.mdsimulation.com/). This video is divided into three parts, summarized below:~* i. Overview of the causes and symptoms of periodontal disease (section 1)~* ii. Treatment of periodontal disease and daily oral care practices for individuals (section 2)~* iii.Consequences of periodontal disease (such as gingival recession and tooth loss) that individuals may face if periodontal diseases are not treated and if they do not perform regular oral care (section 3). In this group, patients watch the video together with the physician (SG), who is familiar with the randomized patient groups."
62185915|NCT04674254|ACTIVE_COMPARATOR|Targeted retinal photocoagulation|Targeted retinal photocoagulation guided by fundus fluorescein angiography will be administered after topical anesthesia, directed to areas of nonperfused peripheral retina plus a 1-disc area margin using the Mainster lens. Subsequent treatments if needed will be delivered at 3 monthly intervals for a minimum follow-up of 12 months. The extent of the laser applied will be determined based on areas of nonperfusion identified by fundus fluorescein angiography.
62185916|NCT04674254|ACTIVE_COMPARATOR|Standard pan-retinal photocoagulation|"Standard pan-retinal photocoagulation will be performed at baseline and then every 3 months thereafter if needed, for a minimum follow-up period of 12 months.~PRP will be performed at two consecutive sessions with adherence to the guidelines of the Early Treatment Diabetic Retinopathy Study Group. Following topical anesthesia, 1000 to 1200 laser spots will be applied to the retina at each session with a 532 nm frequency doubled Nd-YAG laser (VISULAS, Carl Zeiss, Germany) using a spot size of 300-500 μm. PRP will be applied in all 4 retina quadrants.~The Mainster lens will be used. Retreatment will be done according to the Diabetic Retinopathy Clinical Research network protocol S classification for patients with stable, worsening, or with failure of regression of neovascularization."
62185917|NCT01710800|PLACEBO_COMPARATOR|Placebo arm|Patients will be randomized to receive either PPI or placebo and then undergo a 24 hour pH study with impedance to measure the number of reflux episodes
62569584|NCT06577246|EXPERIMENTAL|Periodontal Disease Prediction (PDP)|The patients in the test group viewed sections 1 and 2 videos in the same manner as the 3DA group. However, unlike the 3DA group, they did not view section 3. Instead, they were shown estimates of their current condition and potential future periodontal tissue loss (gingival recession) for 1-5 years, 5-10 years, and 10-20 years (1). These projections were presented to the patients in three dimensions with PDP visualisation.
62569585|NCT02214329|EXPERIMENTAL|Sensor-based exercise training|The intervention group receives sensor-based balance training with real-time joint feedback through an interactive interface on LC monitor screen.
62569586|NCT02214329|ACTIVE_COMPARATOR|In-home balance training|The control group performs similar exercise as intervention group at home without use of sensor or any joint feedback from sensor data.
62569587|NCT04299815|ACTIVE_COMPARATOR|Oral lactate|Sodium D/L lactate solution, 25g/L in 300mL water
62569588|NCT04299815|PLACEBO_COMPARATOR|Iso-lactic intravenous lactate infusion|iv sodium D/L lactate to elevate \[lactate\] to the same levels as measured on day 1 + oral sodium chloride, 300 mL
62000727|NCT03732911|EXPERIMENTAL|Intervention|Intervention arm
62185918|NCT01710800|ACTIVE_COMPARATOR|Esomeprazole|Patients were randomly assigned to receive 40 mg esomeprazole twice daily prior to undergoing a 24 hour pH study with impedance to measure the number of reflux episodes
62185919|NCT04920747||S group|platin-5FU + trastuzumab
62185920|NCT04920747||T group|taxanes + platin-5FU + trastuzumab
62394582|NCT02118909|EXPERIMENTAL|Part 2 (Pracinostat + Ciprofloxacin)|Single dose pracinostat and ciprofloxacin 2 times a day for 7 days
62569589|NCT01051596|EXPERIMENTAL|ABT-888 and temozolomide|Temozolomide Days 1-5 and ABT-888 Days 1-7 of each 28-day cycle
62569590|NCT04494503|EXPERIMENTAL|APG-2575 single agent in Relapse/Refractory CLL/SLL|APG-2575 orally once daily at 400mg, 600mg, 800mg dose levels respectively, every 28 days as a cycle.
62569591|NCT04494503|EXPERIMENTAL|APG-2575+Rituximab in Relapse/Refractory CLL/SLL|"Stage 1:APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg. Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1. Every 28 days as a cycle.~Stage 2: APG-2575 MTD/RP2D combined with rituximab. Every 28 days as a cycle."
62569592|NCT04494503|EXPERIMENTAL|APG-2575+ibrutinib in Relapse/Refractory CLL/SLL|"Stage 1: APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg.Ibrutinib 420mg orally once daily during C1D8-28 and following cycles. Every 28 days as a cycle.~Stage 2: APG-2575 MTD/RP2D combined with ibrutinib. Every 28 days as a cycle."
62776275|NCT03322670||Patients with partial participation|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and who can not or do not want to perform all the complementary examinations of the study
62776276|NCT03322670||Signs of CAP and a negative Chest X-Ray|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and a chest X-Ray not compatible with CAP
62776277|NCT03613363|EXPERIMENTAL|Helix Ventilator|The Helix ventilator is a non-FDA cleared ventilator device. The Helix ventilator has similar modalities to the Trilogy ventilator, which has FDA clearance. The Helix device has improved algorithms, controls, and features to enhance the therapy delivery. Additionally, Helix has an updated hardware platform which has been adequately tested to ensure that the device specifications are met. No pre-clinical or developmental clinical work was required because of Trilogy being the established predicate.
62000728|NCT03490370|EXPERIMENTAL|Electronic Muscle Stimulation Activity|Electro-muscular stimulation using NeuroTrac MyoPlus 2/4. All participants taking part will be allocated to the Electronic Muscle Stimulation Activity (EMS) intervention from baseline for the duration of 12 weeks. There will be 6 EMS sessions of 35mins/per session each week.
62000729|NCT01483196|EXPERIMENTAL|Diagnostic (TCD)|Patients undergo TCD examination including bilateral evaluation of standard intracranial arterial segments including the M1 and M2 segments of the MCA, the ACA and PCA, via the transtemporal acoustic windows, the ICA siphon via transorbital approach, and the vertebral and basilar arteries (proximal, mid, and distal) via the suboccipital approach. Patients also undergo MRI. All tests occur between 21 days after completion of surgery and up to 30 days prior to adjuvant chemotherapy and between 20-60 days after completion of adjuvant chemotherapy.
62394583|NCT04631835|EXPERIMENTAL|HS-10352|There are five escalating dose cohorts
62394584|NCT02506101|EXPERIMENTAL|narrow-band ultraviolet B phototherapy|We will use the 3 Series PC \& SP Phototherapy Cabinet for treatment of vitiligo.
62394585|NCT02506101|NO_INTERVENTION|no intervention|untreated
62394586|NCT01784081||palliative care with iPC3|Palliative care with decision aids will be administered at each palliative care visit.
62394587|NCT05119751|ACTIVE_COMPARATOR|Birch allergy|"randomised (1:1) to receive vestibular or sublingual birch pollen~once daily tree 12 SQ-Bet AIT tablet"
62394588|NCT05119751|ACTIVE_COMPARATOR|Grass allergy|"randomised (1:1) to receive vestibular or sublingual grass pollen~grass 2800 BAU AIT tablet"
62394589|NCT05119751|ACTIVE_COMPARATOR|ragweed allergy|randomised (1:1) to receive vestibular or sublingual ragweed pollen ragweed 12 Amb a 1-U AIT Tablet
62394590|NCT05119751|ACTIVE_COMPARATOR|House dust mite allergy|"randomised (1:1) to receive vestibular or sublingual HDM~HDM 12 SQ-HDM"
62394591|NCT05574920|EXPERIMENTAL|Al18F-NOTA-FAPI-04 PET/CT|Inject Al18F-NOTA-FAPI-04 and then perform PET/CT scan.
62394592|NCT06452485||Postoperative re-irradiation with hyperthermia|Postoperative re-irradiation with hyperthermia in patients with locoregional recurrent breast cancer
62394593|NCT06452485||Postoperative re-irradiation without hyperthermia|Postoperative re-irradiation without hyperthermia in patients with locoregional recurrent breast cancer
62394594|NCT03287960|EXPERIMENTAL|Setmelanotide|Participants received titrated doses of setmelanotide once daily, by SC injection during titration period for 2 - 12 weeks. Thereafter, participants continued setmelanotide at their specific therapeutic dose for an additional 10 weeks during the open label treatment period. Participants who achieved at least a 5 kg weight loss (or at least 5% weight loss if baseline body weight was \<100 kg) at the end of the open label treatment period, continued into the 8-week double-blind withdrawal period and received 4 weeks setmelanotide and 4 weeks placebo. Following the withdrawal period, participants entered open label treatment period and received setmelanotide to complete approximately 52 weeks (\~1 year) of treatment at a therapeutic dose.
62394595|NCT05451758|EXPERIMENTAL|Natural outdoor environment|The park is a well-managed green space containing trees, shrubs, flower beds, lawns and a lake, and includes facilities such as benches, wooden bridges, a bandstand and monuments. The experiment was carried out in a location defined by planted areas containing shrubs and small trees, with some distant views.
62000730|NCT00360334|EXPERIMENTAL|1|
62000731|NCT00360334|ACTIVE_COMPARATOR|2|
62394596|NCT05451758|EXPERIMENTAL|Built outdoor environment|A courtyard on the university campus was chosen as a built outdoor environment. The courtyard was surrounded by concrete and brick built settings, with no visible vegetation.
62394597|NCT05451758|EXPERIMENTAL|Indoor environment|The indoor setting was a seminar room: a white painted room without windows in the basement of a university building. It contained chairs, a neutral coloured picture and no vegetation.
62394598|NCT01641731|ACTIVE_COMPARATOR|Cow's milk|
62394599|NCT01641731|NO_INTERVENTION|Control group|
62394600|NCT03207516|ACTIVE_COMPARATOR|Sourdough --> Brewer's Yeast|"Sourdough --\> Brewer's Yeast~1. administration of two 100 g croissants prepared with sourdough after an overnight fast.~2. Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points.~3. washout period: 7 days~4. administration of two 100 g croissants prepared with brewer's yeast after an overnight fast.~5. Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points."
62569593|NCT00245466|EXPERIMENTAL|Degarelix 80/80 + 40|In the main study (FE200486 CS02; NCT00819247) loading doses of degarelix 80 mg were given on Days 0 and 3. Maintenance doses of 40 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
62776278|NCT03207802||Cohort 3|This cohort is living at home with a chronic condition.
62776279|NCT00002921|EXPERIMENTAL|Suramin|
62776280|NCT02668913|EXPERIMENTAL|Diagnostic Analysis|This arm will be subject to Caris Molecular profiling.
62776281|NCT03052023|EXPERIMENTAL|group A (dual approach lap hernioplasty)|dual approach laparoscopic inguinal hernioplasty by combination of TAPP (group B) and pneumo-dissection preperitoneal instead of sharp dissection
62776282|NCT03052023|ACTIVE_COMPARATOR|group B (TAPP)|trans-abdominal preperitoneal hernioplasty (TAPP) after induction of pneumoperitoneum through peritoneal approach peritoneal incision and preperitoneal dissection then mesh fixation done
62776283|NCT03052023|ACTIVE_COMPARATOR|group C (Lichtenstein hernioplasty)|open inguinal hernioplasty (lichtenstein) repair through inguinal incision and dissection of the sac anteriorly , excision of the sac and then mesh fixation in the posterior wall of inguinal canal
62000732|NCT04013191|EXPERIMENTAL|Adult study participants|Participants will receive assigned single and multiple doses of padsevonil.
62185921|NCT02975791|ACTIVE_COMPARATOR|palpation|"Marking the cricothyroid membrane after ultrasound~The intervention is to mark the cricothyroid membrane in order to know exactly where it is in case that it should be needed fur emergency cricothyrotomy. The doctors mark the cricothyroid membrane with a pen after using palpation for identification."
62000733|NCT04013191|EXPERIMENTAL|Elderly study participants|Participants will receive assigned single and multiple doses of padsevonil.
62000734|NCT01587495|EXPERIMENTAL|Ertapenem|Women diagnosed with postpartum endometritis
62000735|NCT04216082|EXPERIMENTAL|Anlotinib|Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
62185922|NCT02975791|ACTIVE_COMPARATOR|ultrasound|"Marking of the cricothyroid membrane after Palpation~intervention is to mark the cricothyroid membrane in order to know exactly where it is in case that it should be needed fur emergency cricothyrotomy doctors mark the cricothyroid membrane with a pen after using ultrasonography for the identification"
62185923|NCT00746356|EXPERIMENTAL|Promote RF CRT-D|Patients with CRT-D device will have the autocapture features of the device tested.
62185924|NCT00746356|EXPERIMENTAL|Current RF ICD|Patients with ICD device will have the autocapture features of the device tested.
62185925|NCT04570696||Adult haemophilia patients|Adult (≥ 18 years old) haemophilia patients, only men
62185926|NCT05050526|EXPERIMENTAL|Exercise program|Participants in the experimental group will take part in a 12-week exercise program.
62185927|NCT05050526|NO_INTERVENTION|Control|Participants in the control group will not receive any intervention.
62185928|NCT06189989|EXPERIMENTAL|Intervention Group|In addition to the clinical routine care, the newborn temporary tachypnea care package that we created was applied to the babies in the intervention group. Physiological parameters and blood gas results were recorded.
62185929|NCT06189989|NO_INTERVENTION|Control group|Only clinical routine care practices were applied to the babies in the control group. Physiological parameters and blood gas results were recorded.
62185930|NCT05444036|EXPERIMENTAL|Ketamin-bupivacaine Group|in this method,30 patients which received 0.5 mg/kg of preservative free ketamine (i.e. 0.05ml/kg of 10mg/ml ketamine diluted up to 1ml in normal saline) plus1ml/kg of 0.25 % bupivacaine caudally, after induction of general anaesthesia
62394601|NCT03207516|ACTIVE_COMPARATOR|Brewer's Yeast --> Sourdough|"Brewer's Yeast --\> Sourdough~1. administration of two 100 g croissants prepared with brewer's yeast after an overnight fast.~2. Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points.~3. washout period: 7 days~4. administration of two 100 g croissants prepared with sourdough after an overnight fast.~5. Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points."
62394602|NCT01508221|EXPERIMENTAL|Trental + Vitamin E|Trental 400 mg TID and Vitamin E 400IU BID starting the first day after the last radiosurgery treatment
62394603|NCT05206201|EXPERIMENTAL|ZY19489 Capsule|Experimental study drug
62394604|NCT05206201|PLACEBO_COMPARATOR|Placebo|Matching placebo
62185931|NCT05444036|EXPERIMENTAL|bupivacaine-saline Group|30 patients received 1ml/kg of 0.25 % bupivacaine plus 1ml of normal saline caudally of just after induction of general anaesthesia, just after induction of general anaesthesia
62394605|NCT03944096|EXPERIMENTAL|FMT+MTX|"FMT One FMT is performed at baseline by gastroscopic guidance. The same FMT is repeated 4 weeks later. The transplant consists of 50 g mixed feces obtained from 3-5 non-related healthy donors. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 150 mL and its temperature will be 37 degrees celsius when infused into ileus of the recipient.~Drug: Methotrexate (MTX) Weekly methotrexate"
62394606|NCT03944096|PLACEBO_COMPARATOR|autologous FMT+MTX|"autologous FMT (the feces used in FMT is from participant themselves) One identical FMT is performed at baseline using gastroscopic guidance and is repeated 4 weeks later. The corresponding participant's feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 150 mL and its temperature will be 37 degrees celsius when infused into ileus of the participant himself or herself.~Drug: Methotrexate (MTX) Weekly methotrexate"
62394607|NCT05406882|EXPERIMENTAL|combination therapy group|From the first day of chemoradiotherapy, live combined Bifidobacterium and Lactobacillus tablets(2000mg each time, 3 times/day) combined with compound glutamine enteric-coated capsules (3 capsules each time, 3 times/day) until 1 month after the end of chemoradiotherapy.
62776284|NCT03148015||ADH/LCIS|Atypical Ductal Hyperplasia or Lobular carcinoma in situ with DCIS
62776285|NCT03148015||DCIS|Pure Ductal Carcinoma in Situ
62000736|NCT02886052|EXPERIMENTAL|ICBT for insomnia|Therapist guided Internet-CBT for insomnia
62000737|NCT02886052|ACTIVE_COMPARATOR|Active control|Written information on sleep, insomnia, and sleep hygiene
62185932|NCT00913068|EXPERIMENTAL|TAP arm|in the experimental arm, the procedure will consist of the staff urologist injecting local anesthetic into the anterior abdominal wall bilaterally from the inside of the abdomen at the end of their surgery
62185933|NCT00913068|ACTIVE_COMPARATOR|standard post operative pain control|Our current post operative analgesic strategy involves a multi-modal approach, using local injectable anesthetic around the incision and systemic medications (i.e. non-steroidal anti-inflammatories, acetaminophen and break-through doses of opiates). Some of the more common adverse reactions are reparatory depression, sedation, confusion, delirium, nausea, pruritis, constipation, hypotension and bradycardia. Often it is these resulting side effects that extend the length of in hospital rehabilitation, and decrease a patient's overall satisfaction.
62185934|NCT05476510|ACTIVE_COMPARATOR|Group M-TAPA = M-TAPA Block Group|Under aseptic conditions, a high-frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with total of 60 ml (30 ml for each side) of %0,25 bupivacaine.
62185935|NCT05476510|ACTIVE_COMPARATOR|Group OSTAP = OSTAP Block Group|In the supine position, the transducer is placed in the subcostal region in an oblique plane, and a 15-20 cm needle is first inserted between the rectus abdominis and the transversus abdominis muscle and advanced towards the iliac crest in the interfascial plane. The block location will be confirmed with 5 ml of saline. After the block location is confirmed, a total of 30 ml + 30 ml of 0.25% bupivacaine (total of 60 ml for both sides) will be injected bilaterally.
62185936|NCT03253068|EXPERIMENTAL|Pembrolizumab plus amurubicin|Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
62185937|NCT05243615|EXPERIMENTAL|Stroke internet delivered cognitive behavioural therapy|A 10-week internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a stroke. In addition to the online program, a Guide with experience delivering ICBT will provide support by email or phone call once a week. The Guide will spend approximately 15 minutes per week/per client.
62185938|NCT05243615|ACTIVE_COMPARATOR|Stroke Rehabilitation Education|A 10-week stroke-specific rehabilitation education program for stroke patients in usual care at specialized stroke rehabilitation units. The lessons will include information on spinal cord injury rehabilitation: 1)stroke basics, 2)mental health after stroke, 3)pain after stroke, 4)understanding rehabilitation 5)summary of lessons through an online platform. A Guide will check in with participants once a week to answer any content-related questions. The Guide will spend approximately 15 minutes per week/per client.
62394608|NCT05406882|NO_INTERVENTION|control group|After the start of chemoradiotherapy, the control group don't take the experimental drug orally . When patients have radiation proctitis of grade ≥2, they would be crossed over to the combined treatment group：live combined Bifidobacterium and Lactobacillus tablets(2000mg each time, 3 times/day) combined with compound glutamine enteric-coated capsules (3 capsules each time, 3 times/day) until 1 month after the end of chemoradiotherapy.
62394609|NCT00940719|EXPERIMENTAL|Vitamin D3|Patients receive 1dd 500ug vitamin D3 for 3 months
62394610|NCT01657994|EXPERIMENTAL|therapy plus fes|robotic gait training plus functional electrical stimulation
62776286|NCT03148015||Invasive|invasive ductal carcinoma with DCIS
62185939|NCT03896074|EXPERIMENTAL|Atezolizumab|Patients allocated to Arm A will be treated with atezolizumab administered intravenously at 1200 mg every 3 weeks given until disease progression, toxicity or patient refusal
62394611|NCT01040000|EXPERIMENTAL|NPC-1C/NEO-102|
62394612|NCT06539715|EXPERIMENTAL|TEMPO|Visual field assessment with the TEMPO
62394613|NCT06539715|ACTIVE_COMPARATOR|Humphrey Field Analyzer|Visual field assessment with the Humphrey Field Analyzer
62394614|NCT06539715|ACTIVE_COMPARATOR|VisuALL|Visual field assessment with the VisuALL
62394615|NCT05090813|EXPERIMENTAL|TECNIS Eyhance IOL|Model ICB00
62394616|NCT01308385||Patients with pectus excavatum|
62776287|NCT06455748|EXPERIMENTAL|Daratumumab/daratumumab and hyaluronidase-fihj in combination with pomalidomide, dexamethasone (DPd)|"Observed patients meeting the screening criteria were treated with Daratumumab/daratumumab and hyaluronidase-fihj + pomalidomide + dexamethasone regimen as appropriate.~Combined regimen of the above until disease progression or up to 2 years."
62394617|NCT01858701|OTHER|AO for Astig / Biofinity Toric|Lotrafilcon B toric contact lenses worn in Period 1, followed by comfilcon A toric contact lenses in Period 2, as randomized. Each product will be worn bilaterally on a daily wear basis for 30 days, removed nightly. A minimum 1-day washout of no contact lens wear will precede each wear period.
62394618|NCT01858701|OTHER|Biofinity Toric / AO for Astig|Comfilcon A toric contact lenses worn in Period 1, followed by lotrafilcon B toric contact lenses in Period 2, as randomized. Each product will be worn bilaterally on a daily wear basis for 30 days, removed nightly. A minimum 1-day washout of no contact lens wear will precede each wear period.
62394619|NCT01773460|EXPERIMENTAL|Everolimus|Everolimus is given beyond progress
62394620|NCT01773460|PLACEBO_COMPARATOR|Everolimus-placebo|Everolimus-placebo is given beyond progress
62394621|NCT04087733|EXPERIMENTAL|GROUP / TREATED EYE|OZODROP® (ozonized oil 0.5% in liposomes) ophthalmic solution, 2 drops 4 times a day. OZODROP® will be instilled in the eye that will have to undergo cataract surgery.
62776288|NCT03380767|EXPERIMENTAL|POC group|In this group, patients will be treated according to the information gathered by TEG or ROTEM assays.
62776289|NCT03380767|EXPERIMENTAL|Conventional group|In this group, patients will be treated according to the information gathered by conventional laboratory assays (platelet count, fibrinogen level, PT or INR and d dimer for fibrinolysis)
62776290|NCT04412447|EXPERIMENTAL|Subjects|"Phase V1: 1 month of home-based FES-training using isometric contractions of quadriceps and hamstring muscles (3 times a week).~Phase V2: 2 months of home-based FES-training on an ergo-cycle with arm support (3 times a week)~Phase V3: 1 month of home-based FES-training on an ergo-cycle with arm support (1-2 times a week) and FES-cycling training overground on a tricycle (1-2 times a week) in the clinical setting.~Optional (only for selected pilot):~Phase V4: 2-4 months of home-based FES-training on an ergo-cycle with arm support (1-2 times a week) and FES-cycling training overground on a tricycle (1-2 times a week) in the clinical setting. This phase is focussing on optimizing the performance of the pilot and improving the mechanical efficiency of the tricycle.~Phase V5: Participation on Cybathlon 2020"
62185940|NCT03896074|EXPERIMENTAL|Atezolizumab plus bevacizumab|Patients in the Arm B will receive atezolizumab administered intravenously at 1200 mg every 3 weeks plus bevacizumab intravenously at 15 mg/kg every 3 weeks given until disease progression, toxicity or patient refusal
62185941|NCT04298099|ACTIVE_COMPARATOR|Ropivacaine 0.2% at 0.3ml/kg|Ropivacaine 0.2% at 0.3ml/kg
62185942|NCT04298099|ACTIVE_COMPARATOR|Ropivacaine 0.5% at 0.3ml/kg|Ropivacaine 0.5% at 0.3ml/kg
62185943|NCT04797598|ACTIVE_COMPARATOR|Virtual Reality group|In this group patients will be treated with virtual reality . This group will receive therapy session for 1 hour, two times in a week and for 12 weeks, total session will be 24. The virtual reality group will receive 30 minutes virtual reality training and 30 minutes conventional treatment.
62185944|NCT04797598|ACTIVE_COMPARATOR|Cyclic training group|In this group patients will be treated with cyclic training . This group will receive therapy session for 1 hour, two times in a week and for 12 weeks, total session will be 24. The cyclic training group will receive 30 minutes cyclic training and 30 minutes conventional treatment
62185945|NCT03110263|EXPERIMENTAL|Multicomponent internet-based self-help|Multicomponent internet-based self-help
62185946|NCT03110263|EXPERIMENTAL|Internet-based sleep restriction|Internet-based sleep restriction
62185947|NCT03110263|NO_INTERVENTION|Waiting control group|Access to internet-based intervention after 8-weeks
62394622|NCT04087733|NO_INTERVENTION|GROUP / CONTROL EYE|Saline solution 2 drops 4 times a day. As a check it will be used the contralateral eye that will not have to undergo cataract surgery.
62776291|NCT00973492||patients with functional insulinotherapy|There is only one group in this study. The participants will attend a functional insulinotherapy class.
62000738|NCT04408846|OTHER|Minimally invasive lumbar fusion|
62394623|NCT06270160|EXPERIMENTAL|Arm 1: HIVST Alone|Participants will be provided with HIVST instructions and education from peer navigators, who will also emphasize the importance of receiving a confirmatory test irrespective of HIV positive result. Peer navigators will demonstrate how to use an HIVST kit, including how to 1) open the kit, 2) collect the oral fluid samples, and 3) read the results. In addition to HIVST education, participants will be offered optional pre-test counselling and SMS contact information to connect with their peer navigator. If participants do not want post-test counselling, the PN will follow up within two weeks. If the participants report testing positive, then they will be immediately scheduled for confirmatory testing and enrolled in the support programs at MARPI for young people living with HIV.
62569594|NCT00245466|EXPERIMENTAL|Degarelix 40/40 + 40|In the main study (FE200486 CS02; NCT00819247) loading doses of degarelix 40 mg were given on Days 0 and 3. Maintenance doses of 40 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
62791683|NCT04195217|ACTIVE_COMPARATOR|With art therapy|Art therapy as supportive care in 6 consecutive sessions of cancer treatments with or without additional supportive care
62000739|NCT04408846|OTHER|Open posterior lumbar fusion|
62185948|NCT04585100|EXPERIMENTAL|Bioequivalent test of FM101 oral solution and FM101 tablet|
62185949|NCT04585100|EXPERIMENTAL|Phase 2a|
62185950|NCT05047978|ACTIVE_COMPARATOR|A routine cow's milk-based infant formula|A routine cow's milk-based infant formula
62185951|NCT05047978|EXPERIMENTAL|A partially hydrolyzed cow's milk protein (PHP) infant formula|A partially hydrolyzed cow's milk protein (PHP) infant formula
62185952|NCT01398462|EXPERIMENTAL|CWP232291|
62185953|NCT00535938||Naïve to Botox® treatment|Initiating treatment with BOTOX® upon entry to the project.
62185954|NCT00535938||Non-naïve to Botox® treatment|Receiving ongoing treatment with BOTOX® upon entry to the project.
62185955|NCT02745639|EXPERIMENTAL|VMAT-SIB + XELOX|"A VMAT-SIB technique was used. Radiation dose prescribed to PTV2 was 45 Gy (1.8 Gy/fraction), five sessions weekly in 25 daily fractions. A simultaneous boost was delivered on PTV1 with a total dose of 57.5 Gy (2.3 Gy/fraction). Dose-volume histograms (DVHs) were calculated for the PTV1, PTV2 and Organs at risks.~The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment."
62185956|NCT05400252|EXPERIMENTAL|Omnis Salutis|Omnis Salutis is a Veteran-targeted, Whole Health program for mental health care settings and teaches Veterans the skills to identify and communicate their Whole Health goals to providers and social supports
62185957|NCT05400252|ACTIVE_COMPARATOR|Health and Wellness|Health \& Wellness is an educational wellness intervention
62000740|NCT04385784|EXPERIMENTAL|Sedentary Intervention Group (SIG)|Group of sedentary older adults who perform the intervention and a home-based exercise program.
62000741|NCT04385784|EXPERIMENTAL|Active Intervention Group (AIG)|Group of active older adults who perform the intervention and a home-based exercise program.
62000742|NCT04385784|ACTIVE_COMPARATOR|Control Group (CG)|Group of sedentary older adults who perform a home-based exercise program.
62185958|NCT05568368||Index cases|
62776292|NCT01340599|EXPERIMENTAL|Arm I (Polyphenon E)|Patients receive defined green tea catechin extract PO once daily QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.
62776293|NCT01340599|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.
62776294|NCT00084149|EXPERIMENTAL|Cyclosporin|Cyclosporin arm (Arm A) will receive one tablet of Abacavir sulfate, Lamivudine, and Zidovudine (ABC/3TC/AZT) twice daily, 3 capsules or 2 tablets of lopinavir/ritonavir (LPV/r) twice daily, and liquid cyclosporin A (CsA) (dose determined by weight) twice daily. At Week 5, Arm A patients will stop CsA but continue both ABC/3TC/AZT and LPV/r.
62776295|NCT00084149|EXPERIMENTAL|No Cyclosporin|The No Cyclosporin arm (Arm B) will receive one tablet of Abacavir sulfate, Lamivudine, and Zidovudine (ABC/3TC/AZT) twice daily and 3 capsules or 2 tablets of lopinavir/ritonavir (LPV/r) twice daily for all 48 weeks
62776296|NCT01274520|EXPERIMENTAL|Experimental: Hypothermic Machine Perfusion Group|The Medtronic Portable Bypass System (PBS®) with Model 550 Bioconsole and the BioCal® blood temperature control module will be used for machine perfusion of liver grafts. These products are commercially available and used in clinical practice for cardiopulmonary bypass and extracorporeal membrane oxygenation. The Medtronic system utilizes an atraumatic centrifugal pump that can deliver the flow rates approximating portal venous flow in human livers, and it has modules for online membrane oxygenation, and electronic flow measurement.
62776297|NCT01274520|NO_INTERVENTION|Matched control group|The proposed study is a matched cohort design. Subjects will be matched with 24 historical control patients who received similar cold stored ECD grafts. Subjects will be matched on known covariates including donor age, donation after cardiac death, steatosis, both warm and cold ischemia times, recipient age, MELD score and disease etiology. Additional analyses will be performed on historical control blood and/or tissue samples previously collected and stored in the study's sample repository.
62776298|NCT00383162|OTHER|Combination Product - Placebo|Combination product (sumatriptan and naproxen sodium) \[Attack 1\] followed by placebo \[Attack 2\]
62776299|NCT00383162|OTHER|Placebo - Combination Product|Placebo \[Attack 1\] followed by Combination Product (sumatriptan and naproxen sodium) \[Attack 2\]
62776300|NCT05717023|EXPERIMENTAL|Online guided self-help intervention for sexual distress following sexual assault|The intervention only has one arm. All participants will be provided 4 sessions of guided self-help intervention to be completed once weekly.
62776301|NCT06083818|PLACEBO_COMPARATOR|Placebo|Participants in this group will undergo a conventional physical preparation programme.
62776302|NCT06083818|EXPERIMENTAL|ACL injury prevention protocol|Participants in this group will undergo a specific 12-week prevention protocol.
62185959|NCT05091476|EXPERIMENTAL|Eyes treated with the OPTiC System|Eyes that OPTiC System treatment has been completed
62394624|NCT06270160|EXPERIMENTAL|Arm 2: HIVST + mHealth|Participants in this arm will be enrolled into the HIVST intervention (as described above) as well as mHealth. The mHealth intervention is a 5-week program that includes a: 1) weekly SMS check-in moderated by the peer navigator; 2) weekly themed informational SMS and accompanying questions to enhance engagement; 3) WhatsApp group multi-media sharing with peer navigators. The peer navigator and coordinator will review group discussions weekly to incentivize engagement; 4) participatory comic books. The investigators are collaborating with the WelTel non-profit agency for a supportive SMS intervention. Weekly 2-way supportive messages will automatically be sent on the same weekday with WelTel software to Arm 2+3 participants, who should respond within 48 hours.
62569595|NCT00245466|EXPERIMENTAL|Degarelix 80 + 20|In the main study (FE200486 CS02; NCT00819247) one loading dose of degarelix 80 mg was given on Days 0. Maintenance doses of 20 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
62584823|NCT05590416||adalimumab group|The initial dose of glucocorticoid is 1 mg/kg/day, and gradually stops within 90-180 days. Adalimumab is administered subcutaneously at an initial loading dose of 80 mg, followed by a 40 mg dose every other week (q2w) starting from the second week. Therapy will be continued 6 months after the disappearance of active ocular inflammation. Then, injection will extend for 3 days until withdrawal after 40 days apart.
62584824|NCT05590416||traditional therapy group|Acute VKH patients treatment with only glucocorticosteroid or glucocorticosteroid combined with immunosuppressive agents.
62776303|NCT01417364|ACTIVE_COMPARATOR|Testosterone weekly injections continuously|Testosterone enanthate 100 mg Intramuscular (IM) weekly injections throughout the study
62776304|NCT01417364|EXPERIMENTAL|Cyclic testosterone administration|Testosterone injections 100 mg. IM weekly for one month alternating with placebo injections weekly for one month throughout the study
62584825|NCT05131464|EXPERIMENTAL|CM310|
62584826|NCT06664905|ACTIVE_COMPARATOR|Placebo|control, with no exercise
62185960|NCT05091476|NO_INTERVENTION|Fellow Eye|Contralateral comparator
62185961|NCT03666195|ACTIVE_COMPARATOR|Group A|complete dentures will be fabricated using poly methyl methacrylate resin denture base material modified with 5%wt titanium dioxide nanoparticles.
62185962|NCT03666195|NO_INTERVENTION|Group B|complete dentures will be fabricated with poly methyl methacrylate resin denture base material.
62185963|NCT01486381|EXPERIMENTAL|BIAsp 30|
62776305|NCT01417364|PLACEBO_COMPARATOR|Placebo injections|Placebo injections weekly throughout the study.
62776306|NCT03867942|ACTIVE_COMPARATOR|monolayer group|monolayer of Gemigliptin/Rosuvastatin
62776307|NCT03867942|EXPERIMENTAL|bilayer group|bilayer of Gemigliptin/Rosuvastatin
62776308|NCT00552604|EXPERIMENTAL|1|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
62776309|NCT00552604|PLACEBO_COMPARATOR|2|matching placebo capsules, twice daily
62776310|NCT02707796|EXPERIMENTAL|Hemicolectomy|Oxygen reserve index and partial oxygen pressure will be noted for patients undergoing hemicolectomy
62776311|NCT03032549|EXPERIMENTAL|RTD|2.1 g. beta alanine, 1.3 g arginine nitrate, 200 mg caffeine, 65 mg niacin, 325 mcg folic acid, 45 mcg vitamin B12
62776312|NCT03032549|PLACEBO_COMPARATOR|Placebo|dextrose and non-caloric flavoring
62776313|NCT00730678||All Participants|All participants enrolled on this study will have blood drawn for genetic testing.
62776314|NCT01154751|OTHER|Device SUPERA Stent|SUPERA Interwoven Self-Expanding Nitinol Stent System
62569596|NCT05990322|EXPERIMENTAL|Project EMPOWER|"Project EMPOWER is a web-based, self-administered SSI for parents that takes about 30 minutes to complete. The program includes 5 elements, based on current best-practices in SSI design (Schleider, Dobias, Sung, \& Mullarkey, 2020) and existing interventions targeting accommodation (Lebowitz \& Omer, 2014): (1) an introduction to the program's rationale; (2) psychoeducation around child anxiety and avoidance, along with how parental accommodation can inadvertently maintain child anxiety; (3) information on how parents can better identify children's patterns of avoidance and encourage brave behavior instead; (4) facilitating parents' creation of an action plan for promoting brave behavior and reduce avoidance in their own child; (5) a vignette exercise in which parents read about another family's difficulty managing their child's anxiety; parents identify the elements of the anxiety cycle and provide possible solutions to these parents based on what they learned."
62569597|NCT05990322|PLACEBO_COMPARATOR|Online Resources and Referrals|Online Resources and Referrals (ORR) is an information sheet containing materials about the nature of child anxiety and a list of national resources related anxiety treatment. ORR does not include any psychoeducational components regarding parental accommodation.
62569598|NCT00599118||atrial fibrillation|Atrial fibrillation
62776315|NCT00996060|EXPERIMENTAL|Hydralazine and Valproic Acid|Starting dose of Hydralazine is 25 mg orally daily, days 1-28. (See Intervention for Dose Escalation Schema) Valproic acid 250 mg orally three times per day for days -14 through -8, then 500 mg orally three times per day daily for days -7 through 28, with the dose titrated to keep the serum level between 0.4 and 0.7 mM.
62776316|NCT00756782|EXPERIMENTAL|A|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days
62776317|NCT00756782|PLACEBO_COMPARATOR|B|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
62000743|NCT02239250|EXPERIMENTAL|Water filter and cookstove|All household that appear on Government approved lists as belonging to ubudehe 1 \& 2 categories in the 72 sectors randomised as intervention sectors will be eligible to receive one free water filtering device and one free cookstove. All households will be given instructions of how to use the intervention.
62394625|NCT06270160|EXPERIMENTAL|Arm 3: HIVST + mHealth + Creating Futures Livelihoods program|In addition to HIVST and mHealth access, participants in Arm 3 will also be in enrolled in an 8-week Creating Futures program. This manualized program was developed with youth in South Africa and adapted for the Kenyan context (manual is appended). Topics within the Creating Futures program include: 1) introduction and situating self; 2) sustainable and social resources; 3) peer group meeting; 4) education and learning; 5) getting and keeping jobs; 6) income generating activities; 7) saving and coping with shocks; 8) reflection and looking ahead. This intervention aims to help participants think about, and plan for, their futures to assist them in making a living in the long term. Each workshop is facilitated by pairs of peer navigators and runs from 2-4 hours.
62394626|NCT00423137|PLACEBO_COMPARATOR|Placebo - low dose|Twice daily (b.i.d.)
62394627|NCT00423137|PLACEBO_COMPARATOR|Placebo - high dose|Twice daily (b.i.d.)
62569599|NCT00599118||Control|Control subjects with no atrial fibrillation
62569600|NCT04880395|EXPERIMENTAL|Experimental : Dolutegravir plus Lamivudine|DOVATO: Dolutegravir 50mg/lamivudine 300 mg, FDC, 1 coformulated tablet QD
62569601|NCT04880395|ACTIVE_COMPARATOR|active comparator : TDF/XTC plus Dolutegravir (XTC stands for lamivudine OR emtricitabine)|"Unit Dose:~* TDF/FTC 300/200 mg, 1 coformulated tablet QD (FDC) plus Dolutegravir 50 mg, 1 tablet QD OR~* TDF/3TC 300/300 mg, 1 coformulated tablet QD (FDC) plus Dolutegravir 50 mg, 1 tablet QD"
62569602|NCT02679417|ACTIVE_COMPARATOR|aerobic exercise|Each participant reach a minimum of 50 minutes of some form of aerobic exercise including running on a treadmill 5 to 7 days per week for 12 weeks under the supervision of fitness center trainers.
62569603|NCT02679417|ACTIVE_COMPARATOR|resistant exercise|Each participant reach a minimum of 50 minutes of some form of strength training involving repetitions of a resistance training exercise for each major muscle group at an intensity for at least 60% of a one-repetition max, 5 to 7 days per week for 12 weeks under the supervision of fitness center trainers.
62569604|NCT01609296|EXPERIMENTAL|IN.PACT Admiral DEB|"The subjects in this trial will be treated with the IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon (hereinafter referred as IN.PACT Admiral™ DEB)manufactured by Medtronic. The IN.PACT Admiral™ is a CE (Conformité Europeénne, European Confirmity) marked medical device utilized within its intended use in the IN.PACT Global trial."
62569605|NCT06574932|EXPERIMENTAL|Intervention group|The experimental group will be engaged in multi-strategy approaches including screen time and sanity challenges, weekly screen-free days, screen time reduction goals, screen time tracking, structured daily routines, parental involvement, and monitoring, family media plans, alternative engagements, and promotion of offline social interactions.
62569606|NCT06574932|NO_INTERVENTION|Control|The control group will be given no intervention.
62569607|NCT03872206|EXPERIMENTAL|Fixed IV|HPN536 administered once weekly via IV infusion in doses ranging from 6 to 560 ng/kg
62569608|NCT03872206|EXPERIMENTAL|1 Prime Step IV 600-1200 ng/kg Target|Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (200/600 ng/kg, 200/1200 ng/kg, and 500/900 ng/kg)
62584827|NCT06664905|EXPERIMENTAL|4 sets|4 sets of 10RM of knee extensions
62584828|NCT06664905|EXPERIMENTAL|8 sets|8 sets of 10RM of knee extensions
62584829|NCT06664905|EXPERIMENTAL|12 sets|12 sets of 10RM of knee extensions
62776318|NCT00624754|EXPERIMENTAL|1|Patients with OAD will receive Symbicort® at the dose of two puffs morning and evening, each delivering 400/12 µg of budesonide/formoterol. Symbicort® will be administered by inhalation using the Turbuhaler (TH) system
62776319|NCT00624754|PLACEBO_COMPARATOR|2|Patients with OAD will receive lactose as a placebo, administered by inhalation using the Turbuhaler (TH) system
62776320|NCT04454944|NO_INTERVENTION|Control|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. Participants in the control arm will receive no other intervention.
62000744|NCT02239250|NO_INTERVENTION|Control|All household that appear on Government approved lists as belonging to ubudehe 1 \& 2 categories in the 24 sectors randomised as control sectors will continue with their traditional cooking methods and drinking practices.
62000745|NCT05355844|SHAM_COMPARATOR|Patients without Benzoyl peroxide|
62000746|NCT05355844|EXPERIMENTAL|Patients with Benzoyl peroxide|
62000747|NCT04970758||study group|Athletes /strength exercise
62000748|NCT04970758||control group|
62000749|NCT05114304||Pulmonary Langerhans cell histiocytosis (PLCH)|Adults with pulmonary Langerhans cell histiocytosis
62000750|NCT01603875|ACTIVE_COMPARATOR|PrEP and Simulated PEP with PVRV by intramuscular route|
62000751|NCT01603875|EXPERIMENTAL|PrEP and Simulated PEP with new CPRV by intramuscular route|
62000752|NCT01603875|EXPERIMENTAL|PrEP and Simulated PEP with new CPRV by intradermal route|
62000753|NCT02456324|EXPERIMENTAL|Treatment Group|Patients Treated with PICS-AF device
62000754|NCT02456324|OTHER|Historical Controls|Patients Treated with Commercially Available Fistula Plug Devices at Same Sites
62000755|NCT02930850|EXPERIMENTAL|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter sensor for measurement of hemoglobin.
62185964|NCT05799469|EXPERIMENTAL|treatment arm|Participants receive envafolimab 150 mg subcutaneously (SC) on Day 1 of each week cycle (QW) for 8 cycles followed by envafolimab 300 mg SC on Day 1 of each 3-week cycle (Q3W) until disease progression, intolerable toxicity, investigator determines that the participant cannot continue to benefit, withdraws informed consent, or envafolimab treatment over 2 years. During the QW dosing period of envafolimab, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m\^2 IV once per week (QW) for 5 or 6 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 45 Gray Units (Gy)with the total duration of radiation treatment not to exceed 56 days.
62185965|NCT05092568||covid pregnancy|Pregnant patients with positive polymerase chain reaction assay COVID-19 test results, who were followed up and treated in the pandemic service of Başakşehir Çam and Sakura City Hospital.
62185966|NCT02099136|EXPERIMENTAL|Group I (placebo)|Patients receive placebo PO BID for 14 days.
62394628|NCT00423137|EXPERIMENTAL|BIBW2948 - low dose|Twice daily (b.i.d.)
62185967|NCT02099136|EXPERIMENTAL|Group II (low-dose celecoxib)|Patients receive low-dose celecoxib PO BID for 14 days.
62394629|NCT00423137|EXPERIMENTAL|BIBW2948 - high dose|Twice daily (b.i.d.)
62185968|NCT02099136|EXPERIMENTAL|Group III (higher dose celecoxib BID)|Patients receive higher dose celecoxib PO BID for 14 days.
62185969|NCT02099136|EXPERIMENTAL|Group IV (higher dose celecoxib QD)|Patients receive same dose of celecoxib PO as Group III QD for 14 days.
62394630|NCT04340102|EXPERIMENTAL|BecomeAnEx|Participants will have three individual meetings with a research staff person while they are in the hospital. At these meetings participants will answer questions about their smoking and interest in quitting, learn about BecomeAnEx, and register with the BecomeAnEx program so that they can use it when you leave the hospital. Participants will be given two weeks of nicotine replacement therapy when they leave the hospital. Participants will be asked to use BecomeAnEx as much as they want when they leave the hospital program.
62569609|NCT03872206|EXPERIMENTAL|2 Prime Step IV 900-14000 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (200/600/900 ng/kg and 200/600/1200 ng/kg; 500/900/1200 ng/kg, 500/900/1800 ng/kg, 500/900/3600 ng/kg, 500/900/7200 ng/kg, and 500/900/14400 ng/kg)
62394631|NCT05578820|EXPERIMENTAL|Dose escalation phase|"Stimotimagene copolymerplasmid will be administered intratumoral once in a dose of 20 mkg of DNA per 1 cm3 of tumor (for cohort 1) and 40 mkg of DNA per 1 cm3 of tumor (for cohort 2).~Ganciclovir (Cimeven®) will be administrated intravenous twice a day at 12-hour intervals for 15 days."
62394632|NCT05578820|EXPERIMENTAL|Two times administration of Stimotimagene copolymerplasmid|"Stimotimagene copolymerplasmid will be administered intratumorally twice with 5-day interval in the optimal dose selected at previous stage of the trial.~Ganciclovir (Cimeven®) will be administrated intravenous twice a day at 12-hour intervals for 15 days."
62394633|NCT05578820|EXPERIMENTAL|Tree times administration of Stimotimagene copolymerplasmid|"Stimotimagene copolymerplasmid will be administered intratumorally three times with 5-day interval in the optimal dose selected at first stage of the trial.~Ganciclovir (Cimeven®) will be administrated intravenous twice a day at 12-hour intervals for 15 days."
62000756|NCT02812667|EXPERIMENTAL|Nivolumab + Plinabulin|Nivolumab 240mg IV, day 1 and 15 until disease progression Plinabulin 3.5mg/m2, 20mg/m2, 30 mg/m2 or 40mg/m2 IV, day 1,8 and 15 until disease progression
62000757|NCT01926795|ACTIVE_COMPARATOR|Short Leg Cast|Patient will be placed in a short leg cast for approximately 3 weeks or until radiographic union
62000758|NCT01926795|EXPERIMENTAL|No immobilization|No cast or splint will be applied to the injured extremity
62000759|NCT01926795|OTHER|Observational|Patient will be treated based on the parents comfort. This arm will consist of individuals in which the parent/guardian did not agree to randomization, but did consent for observational follow-up regardless of treatment.
62000760|NCT00720941|ACTIVE_COMPARATOR|Sunitinib|Control arm
62000761|NCT00720941|EXPERIMENTAL|Pazopanib|Experimental arm
62000762|NCT01653522|EXPERIMENTAL|Triptan|
62185970|NCT02099136|EXPERIMENTAL|Group V (high-dose celecoxib)|Patients receive high-dose celecoxib PO QD for 14 days.
62185971|NCT03021278|EXPERIMENTAL|Saline Injection|In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl).
62185972|NCT03021278|EXPERIMENTAL|Sham Injection|In the sham injection group, a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience.
62185973|NCT03021278|NO_INTERVENTION|Control Group|The control group will not receive any kind of pain or pinprick sensation.
62569610|NCT05463757||Oral hedgehog inhibitor|Oral hedgehog inhibitors vismodegib (Erivedge) or sonidegib (Odomzo)
62000763|NCT01653522|EXPERIMENTAL|Doxycycline|
62000764|NCT01653522|EXPERIMENTAL|Triptan + Doxycycline|
62000765|NCT01653522|NO_INTERVENTION|Control|
62000766|NCT01760083|ACTIVE_COMPARATOR|Biolimus-eluting stent implantation|PCI of CTO using a Biomatrix drug-eluting stent system + optimal medical therapy.
62569611|NCT03986307|EXPERIMENTAL|Omega-3|Elderly supplemented with omega-3.
62185974|NCT04952701|ACTIVE_COMPARATOR|Control Lens|All subjects will wear control lenses for two weeks and then will wear Test lenses for two weeks.
62569612|NCT03986307|PLACEBO_COMPARATOR|Placebo|Elderly supplemented with corn oil.
62185975|NCT04952701|EXPERIMENTAL|Test Lens|After wearing control lenses for two weeks, all subjects will wear test lenses for two weeks.
62185976|NCT04118283|EXPERIMENTAL|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) will be conducted in accordance with the Cognitive Behavioral Therapy for Chronic Pain: Therapist Manual and the VA Evidence-Based Practice (EBP) roll-out training. CBT-CP consists of a 12-session protocol, including an initial assessment session (BL assessment; Session 1), 10 content-specific sessions (pain education, goal-setting, cognitive and behavioral skill building; Sessions 2-11), and a booster session scheduled approximately one month after the final CBT-CP session (Session 12). Participants randomized to the CBT-CP condition (n = 30) will complete one 60-minute individual session per week. Each CBT-CP session will be led by a trained study interventionist using a manualized curriculum, following a basic structure including review of previous session material, introduction of new information or skills, and discussion of how to implement learned material into a home action plan.
62185977|NCT04118283|ACTIVE_COMPARATOR|Health and Wellness|Health \& Wellness was developed by VISN 5 MIRECC investigators and consists of psychoeducation on topics related to physical and emotional wellbeing. Its structure is similar to CBT-CP (10 weekly individual 60-minute sessions, no booster session). Each Health \& Wellness session will be led by a trained interventionist using a manualized curriculum that includes review of previous session material, introduction of new information, and discussion of a range of health-related topics (physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating) that do not include pain. Typical sessions include discussion of the impact of the topic on overall health and well-being, identifying benefits and challenges to improving or maintaining health in that area, and strategies to address challenges in that area.
62185978|NCT01411098|EXPERIMENTAL|Treatment (radiation therapy and chemotherapy)|Patients undergo 3D-CRT or IMRT 5 days a week for 8 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 28, and 36 and etoposide IV over 60 minutes on days 1-5, and 28-32.
62185979|NCT04354246|EXPERIMENTAL|COM902 monotherapy dose escalation.|Monotherapy dose escalation. COM902 monotherapy administered IV every 3 weeks in sequential dose escalation. Up to 7 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended dose for expansion (RDFE) is identified.
62185980|NCT04354246|EXPERIMENTAL|Dual combination (COM902 + COM701) for evaluation of safety/tolerability (both at RDFE).|COM902 will be combined with COM701 for evaluation of safety and tolerability. All study drugs will be administered IV every 3 weeks.
62185981|NCT04354246|EXPERIMENTAL|COM902 monotherapy cohort expansion at RDFE.|COM902 monotherapy at the RDFE - in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.
62185982|NCT04354246|EXPERIMENTAL|COM902 + COM701 combination cohort expansion both at RDFE.|COM902 + COM701 (both at the RDFE) evaluated in subjects with select tumor types who have exhausted standard of care treatment: HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.
62569613|NCT01538277|EXPERIMENTAL|Contact Force arm|the real-time contact force will be known to the operator
62569614|NCT01538277|ACTIVE_COMPARATOR|Standard|Standard ablation arm
62569615|NCT02796222||Hemophilia A patients on rFVIIIFc|Patients with hemophilia A who switch from on-demand or prophylactic treatment with rFVIII to rFVIIIFc
62569616|NCT02796222||Hemophilia A patients on rFVIII|Patients with hemophilia A who remain on on-demand or prophylactic treatment with rFVIII
62776321|NCT04454944|EXPERIMENTAL|No subsidy, distance variation|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. This intervention arm will receive an assigned depot where they have to make liquefied petroleum gas (LPG) purchases.
62776322|NCT04454944|EXPERIMENTAL|Subsidy, no distance variation|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. This intervention arm receives a price subsidy on liquefied petroleum gas (LPG) purchases.
62776323|NCT04454944|EXPERIMENTAL|Subsidy, distance variation|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. This intervention arm receives a price subsidy on liquefied petroleum gas) (LPG) purchases an assigned depot where they have to make liquefied petroleum gas (LPG) purchases.
62776324|NCT05600582|EXPERIMENTAL|10e7 PFU dose 3 injections|10e7 PFU CodaLytic administered intratumorally once every 4 weeks (3 doses total)
62185983|NCT04354246|EXPERIMENTAL|MSS-CRC Triplet combination (COM902 + COM701 + Pembrolizumab).|Triplet combination of COM902 + COM701 + Pembrolizumab evaluated in subjects with MSS-CRC. All study drugs will be administered IV every 3 weeks.
62776325|NCT05600582|EXPERIMENTAL|10e7 PFU dose 5 injections|10e7 PFU CodaLytic administered intratumorally once every 2 weeks (5 doses total)
62185984|NCT04354246|EXPERIMENTAL|Platinum resistant ovarian cancer Triplet combination (COM902 + COM701 + Pembrolizumab).|Triplet combination of COM902 + COM701 + Pembrolizumab evaluated in subjects with PROC. All study drugs will be administered IV every 3 weeks.
62394634|NCT04123743|EXPERIMENTAL|Experimental Group|The experimental group will be given topical cream containing Trigonella foenum-graceum extract, Wardah brand facial wash, and Parasol sunscreen SPF 33.
62394635|NCT04123743|PLACEBO_COMPARATOR|Control Group|The control / placebo group will be given placebo topical cream, Wardah brand facial wash, and Parasol sunscreen SPF 33
62776326|NCT05600582|EXPERIMENTAL|10e8 PFU dose 3 injections|10e7 PFU CodaLytic administered intratumorally once every 4 weeks (3 doses total)
62776327|NCT05600582|EXPERIMENTAL|10e8 PFU dose 5 injections|10e8 PFU CodaLytic administered intratumorally once every 2 weeks (5 doses total)
62394636|NCT01061073|EXPERIMENTAL|Omexel|
62394637|NCT01061073|ACTIVE_COMPARATOR|spasfon|
62394638|NCT04465903||Dysphagia patients|The first group consists of 85 dysphagia patients who have at least six months of dysphagia complaints. The participants will given the Turkish version of Sydney Swallow questionnaire (SSQ-T), consisted of 17 questions, eating assessment tool-10 and two scales evaluated with FEES. After the two weeks, 30 participants will given the SSQ-T for sampling.
62394639|NCT04465903||Healthy adults|The second group consists of 85 healty participants will given the SSQ-T consists of 17 questions, eating assessment tool-10.
62394640|NCT00953849|EXPERIMENTAL|Arm 1: Celecoxib|Celecoxib treatment prior to surgery
62569617|NCT02796222||Hemophilia B patients on rFIXFc|Patients with hemophilia B who switch from on-demand or prophylactic treatment with rFIX to rFIXFc
62569618|NCT02796222||Hemophilia A patients on rFIX|Patients with hemophilia B who remain on on-demand or prophylactic treatment with rFIX
62569619|NCT02198664|EXPERIMENTAL|ARC001 placebo group|Subjects who received placebo in study ARC001.
62569620|NCT02198664|EXPERIMENTAL|ARC001 AR101 group|Subjects who received AR101 and tolerated up to 300 mg peanut protein (443 mg cumulative) in the DBPCFC at the end of study ARC001.
62569621|NCT04696822|EXPERIMENTAL|Adults with seasonal allergic rhinitis|Single administration of 1.6mg or 3.2 mg Epinephrine powder nasal spray, with or without allergenic challenge, and single IM 0.3 mg Epinephrine without allergenic challenge.
62569622|NCT00975182|EXPERIMENTAL|A|
62569623|NCT01464333||Humira|Participants who were prescribed Humira per approved prescribing information of Humira in Japan.
62569624|NCT04544241|EXPERIMENTAL|Clergy Wives and Widows|We will provide cancer survivorship and caregiving leadership education and activities for African American Clergy Wives and Widows by creating an educational partnership program aimed towards church-based health education on cancer survivorship and caregiving
62569625|NCT01608802|ACTIVE_COMPARATOR|Standard care|Standard care will be provided to the control group, i.e. existing HIV outpatient multiprofessional care, ART monitoring and adherence support.
62569626|NCT01608802|EXPERIMENTAL|Palliative care|Palliative care delivered by an existing nurse who has been provided with palliative care training, palliative care patient management planning records, and clinical supervision
62776328|NCT01520025|EXPERIMENTAL|18F-FDG PET imaging|Positron Emission Tomography nuclear stress scan following either pharmacologic or treadmill stress test with radiopharmaceutical injection at peak stress or within 1 hour following peak stress.
62776329|NCT05014568|EXPERIMENTAL|tapinarof cream|tapinarof cream, 1%, applied topically once daily
62776330|NCT05014568|PLACEBO_COMPARATOR|vehicle cream|vehicle cream, applied topically once daily
62776331|NCT01896245|ACTIVE_COMPARATOR|sevoflurane 1,0|sevoflurane 1,0: sevoflurane is administered with a concentration of 1,0 MAC
62776332|NCT01896245|ACTIVE_COMPARATOR|sevoflurane 1,2|sevoflurane 1,2: sevoflurane is administered with a concentration of 1,2 MAC
62185985|NCT02150395|EXPERIMENTAL|music therapy|pt received a protocolized music therapy intervention that included altered state induction, music driven guided visualiztion, and psychoeducation on relaxation techniques to be used during simulation for radiation therapy. Prescribed pre-recorded music program provided to be used during simulation.
62185986|NCT02150395|NO_INTERVENTION|control|no intervention
62569627|NCT04610801|NO_INTERVENTION|No treatment|No treatment given
62569628|NCT04610801|EXPERIMENTAL|Treatment|Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray, 2 puffs per nosetrils, every 6 hours
62185987|NCT05111743||Brolucizumab|Participants received brolucizumab injection during the index period
62185988|NCT01280604|EXPERIMENTAL|Intervention 'Fenofibrate 54mg'|Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.
62185989|NCT01280604|NO_INTERVENTION|Control 'Fenofibrate 160mg'|Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).
62185990|NCT02500745||Transesophageal echocardiography|Patients referred for transesophageal echocardiography for a clinical indication
62185991|NCT01189422|EXPERIMENTAL|Segment 1: 3 Arms|
62185992|NCT01189422|EXPERIMENTAL|Segment 2: 4 Arms|
62569629|NCT04610801|PLACEBO_COMPARATOR|Placebo|Saline nasal spray, 2 puffs per nosetrils, every 6 hours
62569630|NCT04835610||PVI values|PVI values measured at the finger and forehead areas in pediatric patients
62569631|NCT04835610||no control group|no control group
62569632|NCT00932048|NO_INTERVENTION|Control|
62569633|NCT00932048|EXPERIMENTAL|Atorvastatin|
62569634|NCT02982681|EXPERIMENTAL|Platelet rich Fibrin|The intrabony defects were treated with Full thickness mucoperiosteal flap was raised and thorough open flap debridement done under local anesthesia In the test site the graft was then carefully compacted from the base of the defect coronally. PRF membrane was placed in the test site secured with vicryl sutures.
62569635|NCT02982681|ACTIVE_COMPARATOR|Bioactive glass|The intrabony defects were treated with Full thickness mucoperiosteal flap was raised and thorough open flap debridement done under local anesthesia and The control site were packed with the graft alone
62776333|NCT01896245|ACTIVE_COMPARATOR|sevoflurane 1,4|sevoflurane 1,4: sevoflurane is administered with a concentration of 1,4 MAC
62776334|NCT05460156|EXPERIMENTAL|NM Bridges|Receive NM Bridges supportive care from trained personnel
62776335|NCT01882868|EXPERIMENTAL|Aflibercept + FOLFIRI|Aflibercept 4 mg/kg intravenous (IV) infusion (1-2 hours) on Day 1 of Cycle 1 and every 2 weeks (q2w) thereafter, in combination with FOLFIRI regimen on Days 1-3 of Cycle 1 and q2w thereafter until disease progression (DP), unacceptable toxicity or participant's refusal. FOLFIRI regimen: IV infusions of levofolinate 200 mg/m\^2 (2 hours) and irinotecan 180 mg/m\^2 (90 minutes) simultaneously, followed by 5-FU 400 mg/m\^2 IV bolus injection followed by continuous IV infusion of 5-FU (46 hours) at 2400 mg/m\^2.
62776336|NCT01653236|EXPERIMENTAL|Experimental Arm B|48 weeks of peginterferon alfa-2b and ribavirin Plus Boceprevir 800 mg
62776337|NCT01653236|ACTIVE_COMPARATOR|Control Arm|48 weeks of peginterferon alfa-2b and ribavirin
62776338|NCT02929940||PiZZ|Observational
62776339|NCT02929940||PiMZ|Observational
62776340|NCT02929940||Other AATD variants|Observational
62776341|NCT02929940||PiMM (Control)|Observational
62776342|NCT06221891||case group|This group contains the patients with chronic kidney disease.
62776343|NCT06221891||control group|This group contains the healthy adults.
62185993|NCT04950062|EXPERIMENTAL|High intensity interval training|Group A included 30 subjects who will participate in high intensity interval training on a treadmill for 12 weeks, 3 times/week.
62185994|NCT04950062|ACTIVE_COMPARATOR|Intermittent fasting|Group B that included 30 subjects will participate in intermittent fasting for 12 weeks, 3 times/week.
62185995|NCT03928392|EXPERIMENTAL|SCUBA Dive with OT|Two SCUBA dives in conjunction with occupational therapy intervention. The occupational therapy intervention will take place on the beach or on the boat before/after the SCUBA dive. The intervention will consist of learning 3 different breathing techniques. Participants will also be educated about mindfulness principals. Additionally, participants will complete journaling activities between dives.
62185996|NCT03928392|ACTIVE_COMPARATOR|SCUBA Dive without OT|The group will engage in two SCUBA dives.
62185997|NCT04431245||Stop antiviral|HBeAg-negative non-cirrhotic CHB patients on long-term NA ≥3 years will be identified. Only those who have undetectable serum HBV DNA by the conventional assay (Cobas Taqman, Roche Diagnostics, Branchburg, NJ) which has a lower limit of detection (LLOD) of 10 IU/mL will be recruited. CHB patients were treated with potent oral NA (i.e. tenofovir or entecavir). All recruited patients will have written informed consent for participation of study. Patients with HCC, cirrhosis, history of liver transplantation, or on immunosuppressants, will be excluded.
62185998|NCT00635401|EXPERIMENTAL|0.5 mg BID|
62185999|NCT04145388|OTHER|Comparator 1|Participants will have their cancer risk assessed via usual care. Usual Care is defined as provider capture of family history during a clinical encounter and its entry into the electronic health record (EHR). Participants will take the a patient reported outcomes (PRO) survey once to assess participants experience, perspectives and thoughts on cancer, cancer risk, and cancer risk assessments.
62186000|NCT04145388|EXPERIMENTAL|Comparator 2|Participants will have their cancer risk assessed using a short, standardized web-based questionnaire that will populate validated cancer risk models (such as Breast Cancer Risk Assessment Tool/Gail model 2, PREMM and/or MMRpro) which will take 5-10 minutes to complete. Following the cancer risk assessment, participants will be asked to take a PRO survey. PRO surveys will also be administered at the time of the cancer risk assessment and then 6 and 12 months following.
62186001|NCT04145388|EXPERIMENTAL|Comparator 3|Participants will have their cancer risk assessed using a more detailed, full version of the family history survey than the one comparator 2 participants take. This version is a full pedigree assessment, which entails family health history for all 1st, 2nd, and 3rd-degree relatives. Time needed for completion is 15-25 minutes, depending on family size and cancer risk. Participants will also be asked to take the PRO survey following the full cancer risk assessment and also at 6 and 12 months.
62776344|NCT03005808|NO_INTERVENTION|control group|All patients had the same protocol of anesthesia and analgesia. The control group didn´t received block.
62776345|NCT03005808|EXPERIMENTAL|TAP 0.25 group|The TAP 0.25 group received TAP block with ropivacaine 0.25% 0.4ml/kg. All patients had the same protocol of anesthesia and analgesia.
62186002|NCT03470545|EXPERIMENTAL|mavacamten (MYK-461)|
62186003|NCT03470545|PLACEBO_COMPARATOR|Placebo|
62186004|NCT01806935|EXPERIMENTAL|DC086|cream
62569636|NCT06575361|EXPERIMENTAL|Patients with the indication of prostate biopsy|The trained AI algorithms were embedded into proprietary structured reporting software. Before prostate biopsy, the MR images of patients were uploaded to the AI software. The prostate gland and suspicious lesions were annotated and highlighted by AI software. Urogenital radiologists who were blinded to MRI-AI reports independently reviewed the MR images, annotated the suspicious lesions. Then the urologists read both the MRI-AI reports and urogenital radiologist's reports, and conducted 3-5 core targeted biopsy (TB) at each suspicious lesion found by MRI-AI and urogenital radiologists, followed by 12 core systematic biopsy (SB).
62569637|NCT06234839|EXPERIMENTAL|Probiotic group|The experimental group received conventional mechanical periodontal therapy and oral anti-plaque hygiene training, plus the administration of two daily tablets, containing both L. reuteri strains, for 30 days.
62776346|NCT03005808|EXPERIMENTAL|TAP 0.5 group|The TAP 0.5 group received TAP block with ropivacaine 0.5% 0.4ml/kg. All patients had the same protocol of anesthesia and analgesia.
62776347|NCT03467672||Infected patients|
62776348|NCT03467672||Control group|
62776349|NCT01571856|ACTIVE_COMPARATOR|zinc sulfate|zinc sulphate solution.
62186005|NCT01806935|PLACEBO_COMPARATOR|placebo|
62394641|NCT00953849|EXPERIMENTAL|Arm 2: Calcitriol|Treatment with Calcitriol prior to surgery
62776350|NCT01571856|PLACEBO_COMPARATOR|cornstarch solution|cornstarch powder diluted in distilled water
62776351|NCT04512508|OTHER|Group 1, HIV negative patients.|Only HIV negative patients
62776352|NCT04512508|OTHER|Group 2, HIV positive patients|Only HIV positive patients
62186006|NCT02336256|EXPERIMENTAL|TEP SILS|Procedures of hernia repair. Patients operated due to inguinal hernia using modified single incision laparoscopic surgery (SILS) methods.
62186007|NCT02336256|ACTIVE_COMPARATOR|Typical TEP|Procedures of hernia repair. Patients operated due to inguinal hernia using typical totally extra peritoneal.
62186008|NCT00732992|EXPERIMENTAL|CDD|
62186009|NCT00732992|EXPERIMENTAL|2/1|
62186010|NCT05227664|EXPERIMENTAL|cohort1(AK117 +AK112 +Nab-Paclitaxel/ Paclitaxel)|Subjects receive AK117 and AK112 Plus Nab-Paclitaxel/ Paclitaxel until disease progression or unacceptable toxicity.
62394642|NCT00953849|EXPERIMENTAL|Arm 3: Celecoxib plus Calcitriol|Treatment with Celecoxib plus Calcitriol prior to surgery.
62394643|NCT00953849|NO_INTERVENTION|Arm 4: No Treatment|no treatment prior to surgery
62394644|NCT01684930|EXPERIMENTAL|BR Juice (Beet-It Stamina Shot) and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 \& 2) and at the end of the trial (between Visits 3 \& 4). It also allows for comparisons of the combination of beetroot juice and chronic training effects (between Visits 2 \& 3) to when the subject has not consumed the beverage (Visits 1 \& 4). All subjects will consume Beet-It Stamina Shot 3 hours prior to all beverage tolerance visits, Testing Visits 2 \& 3 and for all supervised exercise training visits during the 12 week intervention.
62000767|NCT01760083|NO_INTERVENTION|Medical therapy|Optimal medical therapy. Subsequent PCI only if symptoms of angina persist despite optimal medical therapy. At least 2 anti-anginal agents or the maximum tolerated anti-anginal therapy should be used before crossover. Medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate.
62394645|NCT01684930|PLACEBO_COMPARATOR|BR Juice Placebo and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot; Placebo) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 \& 2) and at the end of the trial (between Visits 3 \& 4). It also allows for comparisons of the combination of placebo beverage and chronic training effects (between Visits 2 \& 3) to when the subject has not consumed the beverage (Visits 1 \& 4). All subjects will consume Beet-It Stamina Shot (Placebo) 3 hours prior to all beverage tolerance visits, Testing Visits 2 \& 3 and for all supervised exercise training visits during the 12 week intervention.
62394646|NCT01781858||pulmonary embolism|Consecutive outpatients and inpatients with first episode of acute pulmonary embolism
62394647|NCT00772031|ACTIVE_COMPARATOR|1|Participants will receive propranolol and topiramate.
62394648|NCT00772031|PLACEBO_COMPARATOR|2|Participants will receive a placebo and topiramate.
62394649|NCT04372121|EXPERIMENTAL|Linzagolix 75 mg|
62394650|NCT04372121|EXPERIMENTAL|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
62394651|NCT06051461|ACTIVE_COMPARATOR|Metabolic Syndrome patients|
62394652|NCT06051461|EXPERIMENTAL|Healthy patients|
62394653|NCT02304484|EXPERIMENTAL|Evolocumab|Participants received 420 mg evolocumab once a month for up to 2 years.
62394654|NCT06392009|EXPERIMENTAL|TSC|Liquid suspension of radiprodil, at concentrations 0.25 mg/mL or 2.50 mg/mL for 1% and 10% formulation respectively. It will be administered twice a day (bid) either orally or via gastric or nasogastric tube.
62394655|NCT06392009|EXPERIMENTAL|FCD Type II|Liquid suspension of radiprodil, at concentrations 0.25 mg/mL or 2.50 mg/mL for 1% and 10% formulation respectively. It will be administered twice a day (bid) either orally or via gastric or nasogastric tube.
62394656|NCT01647204|NO_INTERVENTION|usual mealtime care|patients admitted to the control ward receiving no intervention but usual mealtime help from ward staff
62569638|NCT06234839|NO_INTERVENTION|No probiotic group|The control group also received conventional mechanical periodontal therapy and oral anti-plaque hygiene training; however, this group did not receive the administration of the probiotic tablets.
62000768|NCT05697042|EXPERIMENTAL|MY-Skills Mobile|8-week intervention merging yoga and self-management offered via secure remote tools including Zoom (video-conferencing software), Canvas (education software), and Qualtrics (survey software) that can be accessed via a computer or tablet. Each participant will have an initial yoga therapy individual session prior to start of group yoga. Group yoga is offered synchronously via Zoom two times per week for 60 minutes (120 minutes per week). The self-management content is delivered primarily through asynchronous tools that include educational videos, facilitated discussion boards, and interactive activities for goal setting, monitoring goals, and problem-solving practice. Self-management content is reiterated during the bi-weekly synchronous sessions, discussed as a group, and mantras are carried through both practices.
62000769|NCT04573036|EXPERIMENTAL|HRS4800 tablets cohort 1|Part 1 - HRS4800 Single Ascending Dose
62000770|NCT04573036|EXPERIMENTAL|HRS4800 tablets cohort 2|Part 1 - HRS4800 Single Ascending Dose
62000771|NCT04573036|EXPERIMENTAL|HRS4800 tablets cohort 3|Part 1 - HRS4800 Single Ascending Dose
62000772|NCT04573036|EXPERIMENTAL|HRS4800 tablets cohort 4|Part 1 - HRS4800 Single Ascending Dose
62394657|NCT01647204|EXPERIMENTAL|mealtime assistance|Additional lunchtime help from trained volunteer mealtime assistants to supplement help from the ward staff
62569639|NCT02871154|EXPERIMENTAL|Delay|Delaying oocyte pick up beyond 39 hours post hCG
62569640|NCT05413213|EXPERIMENTAL|Experimental Group|Ambulatory rehabilitation program based on mobilization and muscular solicitation
62000773|NCT04573036|EXPERIMENTAL|HRS4800 tablets cohort 5|Part 2 - HRS4800 Food Effect
62000774|NCT04573036|PLACEBO_COMPARATOR|Placebo tablets|
62186011|NCT05227664|EXPERIMENTAL|cohort2(AK117 +Nab-Paclitaxel/ Paclitaxel)|Subjects receive AK117 Plus Nab-Paclitaxel/ Paclitaxel until disease progression or unacceptable toxicity.
62394658|NCT00825929||1|Treated with one of the antiretroviral agents under study, PK parameters during pregnancy will be compared with PK parameters after pregnancy (within the same woman)
62394659|NCT00438815|EXPERIMENTAL|Open-label C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously. If there was no response to treatment 60 minutes after the first dose, a second 1,000 U dose could be administered.
62394660|NCT05720923||MFS_f|Patients with Marfan syndrome with fatigue
62394661|NCT05720923||MFS_nf|Patients with Marfan syndrome without fatigue
62394662|NCT05720923||EDS_f|Patients with Ehlers Danlos syndrome with fatigue
62394663|NCT05720923||EDS_nf|Patients with Ehlers Danlos syndrome without fatigue
62394664|NCT05720923||Volunteers|Healthy adult volunteers without fatigue
62186012|NCT05227664|EXPERIMENTAL|cohort3(AK112 +Nab-Paclitaxel/ Paclitaxel)|Subjects receive AK112 Plus Nab-Paclitaxel/ Paclitaxel until disease progression or unacceptable toxicity.
62394665|NCT04827420|EXPERIMENTAL|MiQuit Care|Intervention arm: Advise to quit + automatic linkage to quitline + patient navigation
62394666|NCT04827420|ACTIVE_COMPARATOR|Enhanced Standard of Care|Active Comparator: Advise to quit + written self-help materials
62394667|NCT03427931|EXPERIMENTAL|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data by wearing the device at home a minimum of 28 days but may continue for up to 3 months.
62394668|NCT02296541|EXPERIMENTAL|Group 1: DNA Nat-B env and MVA-CMDR|Participants will receive a single injection of DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
62394669|NCT02296541|PLACEBO_COMPARATOR|Group 1: Placebo vaccines for DNA Nat-B env and MVA-CMDR|Participants will receive a single injection of placebo for DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
62394670|NCT02296541|EXPERIMENTAL|Group 2: DNA CON-S env and MVA-CMDR|Participants will receive a single injection of DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
62394671|NCT02296541|PLACEBO_COMPARATOR|Group 2: Placebo vaccines for DNA CON-S env and MVA-CMDR|Participants will receive a single injection of placebo for DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
62394672|NCT02296541|EXPERIMENTAL|Group 3: DNA Mosaic env and MVA-CMDR|Participants will receive a single injection of DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
62394673|NCT02296541|PLACEBO_COMPARATOR|Group 3: Placebo vaccines for DNA Mosaic env and MVA-CMDR|Participants will receive a single injection of placebo for DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
62394674|NCT05441722|EXPERIMENTAL|Exercise|"Participants will be invited to perform a bout of supervised moderate-intensity aerobic exercise. Patients receiving chemotherapy with sequential anthracycline-docetaxel will be offered the exercise before each docetaxel-containing infusion, whilst patients receiving weekly paclitaxel will perform the exercise every three weeks during treatment. Each session will comprise of moderate-intensity aerobic exercise on a cycle ergometer. Participants will perform a 5 to 10-minute warm-up.~Participants will then complete a 30-minute bout at 13-14 RPE whilst. This corresponds to a qualitative description of somewhat hard and equates to approximately 60% age-predicted heart rate reserve. Heart rate will be monitored continuously with a Polar heart rate monitor and RPE will be collected every 5-minutes. The resistance on the bike will be reduced if heart rate reserve is \> 65% or RPE is \> 14 on the 6-20 Borg scale. Each session will finish with a 5 min cool-down at low-intensity (≤ 11 RPE)."
62394675|NCT05441722|NO_INTERVENTION|Control|"Participants allocated to this group will not receive a specific exercise intervention, but will be given a leaflet that provides general physical activity recommendations for cancer patients.~Recommendations will be based on published guidelines from the American College of Sports Medicine and American Cancer Society."
62394676|NCT04537312|EXPERIMENTAL|Supportive care (RNSM, surveys)|RNMS Surveys
62394677|NCT05707663||JoHD|Children adolescents and young adults ages 6-30 who have been clinically diagnosed with Juvenile-onset Huntington's Disease
62394678|NCT03865550|PLACEBO_COMPARATOR|Placebo|
62394679|NCT03865550|ACTIVE_COMPARATOR|Ketamine|
62394680|NCT04682158|ACTIVE_COMPARATOR|Chemoradiation Therapy - Group I|Patients receiving beta-blockers undergo radiation therapy in the form of IMRT or 3D CRT over 23-28 fractions for 5 days per week (Monday-Friday) for 5 weeks, and receive paclitaxel IV QW and carboplatin IV QW for 5 weeks in the absence of disease progression or unacceptable toxicity.
62186013|NCT04246853|ACTIVE_COMPARATOR|Active tDCS of the resting state motor network|The active comparator is the Active tDCS group. The active tDCS will target the resting-state motor network and will apply a distributed direct current during the whole session. (The TIME during the direct current is applied is the only difference with Sham tDCS) Each tDCS session lasts 20 minutes and applies a total current of 4mA.
62394681|NCT04682158|ACTIVE_COMPARATOR|Chemoradiation Therapy - Group II|Patients undergo CRT as in Group I in the absence of disease progression or unacceptable toxicity.
62394682|NCT04682158|EXPERIMENTAL|Chemoradiation Therapy plus Propanolol|Patients undergo radiation therapy as in Group I. Patients receive propranolol PO BID for 4-6 weeks while receiving CRT in the absence of disease progression or unacceptable toxicity.
62394683|NCT01125852|ACTIVE_COMPARATOR|Intervention group|Patients in this group are treated with usual therapeutic endoscopy including endoscopic combination therapy and 72 hours intravenous proton pump inhibitor. Within 24 hours from the therapeutic endoscopy they receive supplementary angiographic embolization.
62394684|NCT01125852|ACTIVE_COMPARATOR|Control group|Patients in this arm receive standard treatment including therapeutic endoscopy with endoscopic combination therapy followed by 72 hours intravenous proton pump inhibitor.
62394685|NCT03222245||Exposed group|This group consists of participants identified as needing to start injectable therapy within 1 month from the recruitment date (50% insulin and 50% GLP-1 analogues)
62394686|NCT03222245||Non-exposed group|This group consists of participants treated with oral anti- hyperglycaemic agents (OAHAs) and their combinations
62394687|NCT03354065|ACTIVE_COMPARATOR|Early oral feeding|TIME OF FEEDING. 48 hours after pancreatitis general management is started ( liquid diet)
62394688|NCT03354065|EXPERIMENTAL|Immediate oral feeding|TIME OF FEEDING: 8 hours of after pancreatitis general management is started (enteral formula)
62394689|NCT03538496|ACTIVE_COMPARATOR|ultrasound guided erector spinae plane block|ultrasound guided erector spinae plane block with 20 ml %0.25 bupivacaine
62776353|NCT03976999|EXPERIMENTAL|Biological collection|"For all the patients include in the studie :~* Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)~* Tissue samples (tumor tissue and healthy tissue) collected during the surgery~In parallel to this biological collection, standardized clinical data will be entered into a database"
62394690|NCT03538496|ACTIVE_COMPARATOR|ultrasound guided paravertebral block|ultrasound guided paravertebral block with 20 ml %0.25 bupivacaine
62569641|NCT05413213|ACTIVE_COMPARATOR|Control Group|Ambulatory rehabilitation program using ultrasound physiotherapy
62000775|NCT00632697|ACTIVE_COMPARATOR|1|
62186014|NCT04246853|SHAM_COMPARATOR|Sham tDCS of the resting state motor network|This study has a parallel design and 2 groups: Active tDCS and Sham tDCS. Sham tDCS applies a standard sham protocol consisting of ramping up and down during 30 seconds at the beginning and at the end of each tDCS session. Each tDCS session lasts 20 minutes and applies a total current of 4mA.
62186015|NCT06342479|EXPERIMENTAL|Discharge training given|In addition to the standard clinical monitoring applied in the clinic in a quiet and calm environment in the patient's room, outside of the doctor's visit, meal time, visiting and treatment hours and approximately two hours after the painkiller application, approximately 30 minutes (related to the subjects included in the developed booklet, nutrition, Discharge training (such as surgical recovery, movement, excretion, self-care skills, pain, exercise) will be given to patients. The patient will be asked to demonstrate the trainings (movements, exercises, etc.) that are explained to the patient by doing them at least three times. At the end of the training, a booklet prepared in accordance with the surgery the patient underwent will be given to the patient.
62186016|NCT06342479|NO_INTERVENTION|No discharge training provided|Patients included in the control group will receive routine discharge training and clinical follow-up at the Orthopedics Clinic. During standard clinical follow-up, service nurses provide verbal information to patients hospitalized in the Orthopedic Clinic about wound care, signs of infection at the wound site, medication use and post-discharge control times before discharge, but no written training materials are used.
62186017|NCT02482610|ACTIVE_COMPARATOR|Glucose|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
62186018|NCT02482610|EXPERIMENTAL|Glucose with Whole Fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
62394691|NCT03099096|EXPERIMENTAL|Mepolizumab SC 100 mg/milliliter (mL) in autoinjector|Three doses of mepolizumab liquid drug product in autoinjector will be self-administered by the subject/caregiver at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
62394692|NCT01741558|EXPERIMENTAL|Methotrexate|Established treatment associated with methotrexate
62394693|NCT01741558|PLACEBO_COMPARATOR|Placebo (Riboflavin)|Established treatment associated with placebo (riboflavin sodium fosfate 0.1%). We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
62394694|NCT05409742|ACTIVE_COMPARATOR|Modified Hall technique|
62394695|NCT05409742|EXPERIMENTAL|Hall Technique|
62394696|NCT01697631|EXPERIMENTAL|BIAsp|
62394697|NCT01697631|EXPERIMENTAL|Insulin aspart|
62394698|NCT04130633|PLACEBO_COMPARATOR|Placebo|Placebo (5mL distilled water)
62394699|NCT04130633|EXPERIMENTAL|Vaporized high THC alone|25mg of vaporized pure THC
62776354|NCT04079881|EXPERIMENTAL|A (Pre-prandial insulin administration) : B (post-prandial insulin administration)|"VISIT 1: Pre-prandial insulin: will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min prior the meal.~Then VISIT 2: Post-prandial insulin: will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min post the meal."
62776355|NCT04079881|EXPERIMENTAL|B (post-prandial insulin administration) : A (Pre-prandial insulin administration) :b|"VISIT 1: Post-prandial insulin: will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min post the meal.~Then VISIT 2: Pre-prandial insulin: will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min prior the meal."
62186019|NCT02482610|EXPERIMENTAL|Glucose with Non-fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
62000776|NCT00632697|PLACEBO_COMPARATOR|2|
62394700|NCT04130633|EXPERIMENTAL|Vaporized low alpha-pinene|0.5mg of vaporized alpha-pinene
62394701|NCT04130633|EXPERIMENTAL|Vaporized high alpha-pinene|5mg of vaporized alpha-pinene
62394702|NCT04130633|EXPERIMENTAL|Vaporized high THC and low alpha-pinene|0.5mg of vaporized alpha-pinene with 25mg vaporized THC
62394703|NCT04130633|EXPERIMENTAL|Vaporized high THC and high alpha-pinene|5mg of vaporized alpha-pinene with 25mg vaporized THC
62394704|NCT04130633|EXPERIMENTAL|Vaporized low THC alone|10mg of vaporized pure THC
62394705|NCT04130633|EXPERIMENTAL|Vaporized low THC and low alpha-pinene|0.5mg of vaporized alpha-pinene with 10mg vaporized THC
62394706|NCT04130633|EXPERIMENTAL|Vaporized low THC and high alpha-pinene|5mg of vaporized alpha-pinene with 10mg vaporized THC
62394707|NCT06388538||Patients with WSES stage 2b acute diverticulitis|Patients with WSES stage 2b acute diverticulitis on the left or sigmoid colon acutely presenting to the emergency departments of the participating centers
62394708|NCT06062394|NO_INTERVENTION|Usual Care|This group will not receive the intervention and will continue with usual care.
62000777|NCT02649881||isolated heart from heart transplantation|
62394709|NCT06062394|EXPERIMENTAL|Penn Med Healthy Heart Program|The Intervention group will receive the blood pressure monitor and move through the 4 HDPP modules of the intervention.
62394710|NCT01101321|EXPERIMENTAL|Reformulated OXY 80 mg (Totowa)|Reformulated OXY 80 mg (Totowa) x 1 dose
62394711|NCT01101321|ACTIVE_COMPARATOR|Reformulated OXY 80 mg (Wilson)|Reformulated OXY 80 mg (Wilson) x 1 dose
62000778|NCT04495114|NO_INTERVENTION|Control Arm|Modern fasting guidelines without the carbohydrate load preoperatively.
62394712|NCT01430559|OTHER|Meloxicam|
62394713|NCT01430559|PLACEBO_COMPARATOR|Placebo|2 Placebo capsules once a day for 12 weeks
62394714|NCT00561912|EXPERIMENTAL|Decitabine + Interferon Alfa-2b|Decitabine 15 mg/m\^2 intravenous (IV) daily over one hour for 5 days + Interferon Alfa-2b 0.5 million Units Subcutaneously Twice Daily Continuously, as of Cycle 3, Day 1.
62394715|NCT02999295|EXPERIMENTAL|Phase 1|Ramucirumab: 8 mg/kg, every two week Nivolumab: 3.0 mg/kg or 1.0 mg/kg (optional), every two weeks
62394716|NCT02999295|EXPERIMENTAL|Phase 2|Ramucirumab: 8 mg/kg, every two week Nivolumab: recommended dose established in the phase 1, every two weeks
62394717|NCT06006481||1.group|patient area in the children's area
62394718|NCT06006481||2.group|patient area in the field of orthopedics and athletes
62000779|NCT04495114|EXPERIMENTAL|Intervention Arm|40g carbohydrate load preoperatively.
62394719|NCT06006481||3.group|patient area in neurology and intensive care
62394720|NCT06006481||4.group|general group receiving patients in many fields
62394721|NCT06006481||5.group|physiotherapists working in public health
62394722|NCT05643794|EXPERIMENTAL|Treatment sequence 1|Study participants on Treatment sequence 1 will receive rozanolixizumab and Placebo during the dosing period at pre-specified timepoints.
62394723|NCT05643794|EXPERIMENTAL|Treatment sequence 2|Study participants on Treatment sequence 2 will receive rozanolixizumab and Placebo during the dosing period at pre-specified timepoints.
62186020|NCT02801864|EXPERIMENTAL|Combined real tDCS + IST|Participants will receive tDCS via a Starstim device at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. The stimulation will be ramped up for 45 seconds and ramped down for 15 seconds. For the experimental group, the stimulation will be ramped up for 45 seconds and stay there for 20 min. The participants will receive three weeks of tDCS and continue receiving only intensive speech therapy for five weeks for three hours a day.
62186021|NCT02801864|SHAM_COMPARATOR|Combined sham tDCS + IST|Participants will receive tDCS via a Starstim device at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. For the sham group, the stimulation will be ramped up for 45 seconds and ramped down for 15 seconds. The stimulation will be ramped up for 45 seconds and then ramp down after the initial 45 seconds. The participants will receive three weeks of tDCS and continue receiving only intensive speech therapy for five weeks for three hours a day.
62186022|NCT04603833|EXPERIMENTAL|SHR3680+Docetaxel|
62000780|NCT01218516|ACTIVE_COMPARATOR|Farletuzumab plus Chemotherapy|During Combination Therapy, farletuzumab will be given with a protocol-approved platinum doublet (either carboplatin/paclitaxel, carboplatin/pemetrexed, or cisplatin/pemetrexed) for at least 4, but not more than 6, cycles. Participants who experience clinical benefit from the Combination Therapy will enter the Monotherapy Phase and receive farletuzumab as monotherapy until disease progression.
62186023|NCT04603833|ACTIVE_COMPARATOR|SHR3680|
62000781|NCT01218516|PLACEBO_COMPARATOR|Placebo plus Chemotherapy|During Combination Therapy, placebo will be given with a protocol-approved platinum doublet (either carboplatin/paclitaxel, carboplatin/pemetrexed, or cisplatin/pemetrexed) for at least 4, but not more than 6 cycles. Participants who experience clinical benefit from the Combination Therapy will enter the Monotherapy Phase and receive placebo as monotherapy until disease progression.
62000782|NCT01139281|ACTIVE_COMPARATOR|Study Group|The Study Group(SG) received Ginkgo biloba extract(GBE761)(240mg/day)plus cisplatin(CDDP)
62000783|NCT01139281|PLACEBO_COMPARATOR|Control Group(CG)|The Control Group received Placebo plus CDDP
62000784|NCT00645333|EXPERIMENTAL|MK-0752, Docetaxel, Pegfilgrastim|MK-0752, Docetaxel, Pegfilgrastim in combination with escalating doses of MK-0752
62000785|NCT03676361|EXPERIMENTAL|Desmopressin|All ten subjects will be evaluated pre and post nephrectomy at 6 months.
62000786|NCT03826758|OTHER|E-DYNAMIC CDS|E-DYNAMIC clinical decision support (CDS) retrieves near-real time patient data from the electronic health record to help primary care providers identify patients with stage 3-5 CKD, present ASCVD risk, statin use and clinical recommendations for ASCVD risk reduction at point of care. E-DYNAMIC directs referrals to nurses for CKD education and to dietitians for MNT. Providers are also nudged to prescribe statin medications and address hypertension management.
62000787|NCT03826758|NO_INTERVENTION|Standard care|No change in their clinical practice.
62000788|NCT03597516|EXPERIMENTAL|RP-G28|galacto-oligosaccharide, spray-dried powder for reconstitution for oral administration, 7.5 grams 2 times per day
62186024|NCT04603833|ACTIVE_COMPARATOR|Docetaxel|
62186025|NCT01303315|OTHER|GLP-1 receptor agonist therapy|Group A: Subjects on GLP-1 receptor agonist therapy only. After run in of 12 weeks on GLP-1 receptor agonist therapy, Patients with HbA1c \< 7.5 are moved to Group A, continue GLP-1 receptor agonist therapy, and then start the Evaluation Period These patients will not be implanted with the TANTALUS system.
62186026|NCT01303315|EXPERIMENTAL|GLP-1 receptor agonist and TANTALUS|Group B: subjects on GLP-1 receptor agonist therapy and TANTALUS therapy After run in of 12 weeks on GLP-1 receptor agonist therapy, Patients with HbA1c \> 7.5 are moved to Group B, continue GLP-1 receptor agonist therapy, implanted with TANTALUS within 4 weeks, and then start the Evaluation Period
62186027|NCT01303315|ACTIVE_COMPARATOR|Subjects on TANTALUS therapy only|Group C: subjects on TANTALUS therapy only After run in of 12 weeks on GLP-1 receptor agonist therapy, patients intolerant to low dosage of GLP-1 receptor agonist therapy will be implanted with the TANTALUS system
62186028|NCT02397343|OTHER|Session 1|HBO given the first day of study period and sensory test battery performed. 4 weeks later no intervention is given but the sensory test battery performed.
62186029|NCT02397343|OTHER|Session 2|No intervention first day of study period and sensory test battery performed. 4 weeks later HBO intervention is given and the sensory test battery performed.
62394724|NCT05643794|PLACEBO_COMPARATOR|Treatment sequence 3|Study participants on Treatment sequence 3 will receive Placebo during the dosing period at pre-specified timepoints.
62776356|NCT04690244|EXPERIMENTAL|Tai Chi Chuan group|"Fifteen healthy elderly subjects participated in 10 weeks of Tai Chi Chuan practice. Inclusion criteria were:~* aged 60 years and older;~* sedentary behavior for at least 6 months;~* no previous experience of Tai Chi Chuan practice;~* good physical health determined by Physical Activity Readiness Questionnaire as - confirmed by medical history;~* no cognitive impairments determined by baseline Mini-Mental State Examination score of ≥ 45.~All participants were asked to not perform any sports activities while the research was ongoing."
62000789|NCT03597516|PLACEBO_COMPARATOR|Placebos|maltodextrin, powder for reconstitution for oral administration, 7.5 grams 2 times per day
62000790|NCT05426837|PLACEBO_COMPARATOR|Health Education Training|Health Education Training (HET) control condition covers standard healthy lifestyle behaviors as well as broad coping strategies to address stress. HET is a fully computerized 1-hour control condition focused on increasing healthy behaviors and decreasing unhealthy behaviors. Content includes healthy eating, hydration, sleep and rest, exercise, stress management as well as other healthy lifestyle tips. The HET protocol has been used in prior studies as a control condition for CSI to account for intervention modality and time (e.g. Schmidt et al., 2014). HET is perceived positively, with high rates of acceptability. Importantly, HET is inert with respect to the proposed mechanism of action (PB/TB) (Schmidt et al., 2014; Schmidt et al., 2007; Short et al., 2015). Also, home practice will be prescribed to match the procedures used in CSI and practice forms are provided wherein participants will self-monitor some of the behaviors addressed in HET.
61977826|NCT05127447|SHAM_COMPARATOR|Sham group|In the Sham group, for 45 minutes, 2 days a week, a vacuum electrode was connected from combined vacuum electrotherapy device over the pelvis and thigh, and only vacuum was applied while the patient was in the supine position, and no current was given from the applied device.
62186030|NCT00578162||1|Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory.
62186031|NCT00950196|EXPERIMENTAL|amantadine (PKMERZ)|
62186032|NCT04805450|ACTIVE_COMPARATOR|ES before SEMS placement|ERCP with ES before biliary fully covered SEMS placement.
62569642|NCT06041360||study group Study group(Group1)|"Thirty participants of the group will meet the following criteria Inclusion criteria:~1. Age ranges from 12 to 50 years old.~2. Disproportionate speech recognition score (SRS) with the hearing threshold level.~3. The auditory brainstem response (ABR) test with no waveform or, disturbed waves or, detectable wave V at high intense stimulus.~4. The otoacoustic emission (OAE) and/or cochlear microphonic (CM) potential may be present.~Exclusion criteria:~While the participants who have these criteria will be excluded from the study:~1. Consistent SRS and ABR response with hearing threshold level.~2. Abnormal finding in brain imaging.~3. Patients with history of diabetes and/or other causes of peripheral neuropathy."
62776357|NCT04690244|NO_INTERVENTION|Control group|In the control group, fifteen subjects also had to meet the same criteria and did not perform any exercises or make changes in their daily living life.
62186033|NCT04805450|ACTIVE_COMPARATOR|no ES before SEMS placement|ERCP without ES before biliary fully covered SEMS placement.
62186034|NCT01037062|EXPERIMENTAL|Entecavir|
62776358|NCT01150968|EXPERIMENTAL|Internal Medicine Residents|All UCSf Internal Medicine residents for 2009-2010
62186035|NCT04902599|ACTIVE_COMPARATOR|Vaser ulstrasound-assisted dissection technique|Patient's arm that undergoes treatment using Renuvion/j-Plasma for subdermal skin tightening and contouring with the Vaser ultrasound-assisted dissection technique.
62569643|NCT06041360||Control group (Group 2)|"Thirty participants have the following criteria:~1. Age and sex matched with the study group.~2. Patients with sensorineural hearing loss with degree of hearing matched with study group"
62569644|NCT02935127|EXPERIMENTAL|Absorbable Group|In this group of patients absorbable sutures will be used for vascular anastomoses.
62776359|NCT01073917|OTHER|Spontaneous Breathing|Patients will be breathing spontaneously during anesthesia
62776360|NCT01073917|OTHER|Pressure controlled ventilation|Patients in the PPV group will be ventilated by pressure control (tidal volume 8-10 ml/kg, frequency 10-14, I:E 1:1, no PEEP, target CO2 4.5 kPa).
62776361|NCT01073917|OTHER|Pressure Support Ventilation|The patients in the PSV group will breathing spontaneously on the ventilator with assistance by inspiratory support pressure. The support pressure will be adjusted to achieve a tidal volume of 8-10 ml/kg.
62776362|NCT03173768|NO_INTERVENTION|pre-intervention period|The charts of patients who were prescribed intravenous antibiotics at hospital discharge were reviewed. Appropriateness of intravenous antibiotics was assessed by ID specialists.
62186036|NCT04902599|ACTIVE_COMPARATOR|Blunt dissection technique|Patient's arm that undergoes treatment using Renuvion/j-Plasma for subdermal skin tightening and contouring with blunt dissection technique.
62186037|NCT02294097|NO_INTERVENTION|Non-biopsy|Population in this arm will be adjusted immunosuppressive drug only from the result of tough level.
62186038|NCT02294097|EXPERIMENTAL|Protocol biopsy|Population in this arm will be adjusted immunosuppressive drug upon both pathological findings and the result of tough level.
62186039|NCT02686073||Group A|Underweight participants whose body mass index is less than 18.5 kg/m2
62569645|NCT02935127|EXPERIMENTAL|Non-Absorbable Group|In this group of patients non-absorbable sutures will be used for vascular anastomoses.
62569646|NCT05642897|EXPERIMENTAL|Mind|The Mind programme is an ACT, mindfulness and compassion intervention for women with breast cancer. It will include 8 weekly group sessions, with the duration of 120 minutes each, and will be delivered at the Radiotherapy Service of the CHUC or through an online platform. All participants will continue on receiving the recommended medical treatment for their clinical diagnosis.
62776363|NCT03173768|EXPERIMENTAL|post-intervention period|The intervention is the charts of patients who were prescribed intravenous antibiotics at hospital discharge by the primary team were prospectively reviewed and intervened by ID team (ID specialist approval)
62776364|NCT06061029|EXPERIMENTAL|Yoga- and Mindfulness-Based Psychoeducation Program Group|
62186040|NCT02686073||Group B|Control group, in which the participants belong to the normal body mass index range , from 18.5 to 29.9 kg/m2
62776365|NCT06061029|NO_INTERVENTION|Waitlist Control Group|
62776366|NCT01304589|EXPERIMENTAL|Milnacipran|This was an 18-week, open-label, flexible-dose exploratory trial where eligible patients were treated with 200 mg/day of milnacipran (or the maximum tolerated dose) for a total of 12 weeks. The study design involved 3 phases: screening and baseline assessment, dose escalation and stable-dose phase. All women received 12 weeks of stable dose treatment after a 6-week dose-escalation period for a total of 18 weeks of drug exposure.
62776367|NCT03536026|EXPERIMENTAL|Bronchoscopic evaluation and biopsy|-Bronchoscopy will be performed by pulmonary and/or critical care fellows who have performed fewer than 10 bronchoscopies (inexperienced bronchoscopists) under direct supervision by an attending Interventional Pulmonologist. The inexperienced bronchoscopist will attempt to navigate to the targeted peripheral pulmonary lesion without virtual bronchoscopic navigation, using only standard axial CT images as a reference. The attending physician will directly observe, but will provide no guidance during this period, which will last no longer than 10 minutes. If the lesion is located and confirmed with radial probe endobronchial ultrasound prior to 10 minutes, biopsies will be performed as per routine clinical practice. If the 10 minute time period elapses prior to localization of the peripheral pulmonary lesion, virtual bronchoscopic navigation will be used.
62776368|NCT03775564|EXPERIMENTAL|REMEDRUGBY|TAU + RemedRugby Program
62776369|NCT03775564|ACTIVE_COMPARATOR|TAU + TOUCH RUGBY|TAU + Touch Rugby Program
62186041|NCT02686073||Group C|Obese participants whose body mass index is more than or equal to 30 kg/m2.
62186042|NCT02820545||Sociological interview|Patients will take a sociological interview with a sociologist during their hospital stay
62776370|NCT03240159|ACTIVE_COMPARATOR|Deg-24mg|"Single dose of Degarelix 24mg, on day 24th of previous luteal face cycle. On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
62186043|NCT02820545||Self-administrated questionnaire|Patients will take a self-administrated questionnaire at the end of their hospital stay and one week after they left hospital
62394725|NCT06304493|EXPERIMENTAL|"Alarm ON Cohort"|"The ON cohort will receive the standard-of-care instructions for IS and information about the auditory and visual reminders. The ON cohort patients will receive audible and visual signals from the InSee monitor attached to their incentive spirometer every 20 minutes and upon successfully reaching certain achievements."
62394726|NCT06304493|PLACEBO_COMPARATOR|"Alarm OFF Cohort"|"The OFF cohort will receive only the standard-of-care instructions for IS. The OFF patients will receive no signals from the InSee monitor attached to their incentive spirometer."
62394727|NCT03902158|EXPERIMENTAL|Glasses|
62569647|NCT05642897|ACTIVE_COMPARATOR|Support group|A support group intervention, with 8 weekly 90-120-minute sessions, will be delivered to the active control group at the Radiotherapy Service of the CHUC or through an online platform. All participants will continue on receiving the recommended medical treatment for their clinical diagnosis.
62569648|NCT04001725|ACTIVE_COMPARATOR|A (Dexamethasone)|Patients subjected at a minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route (control arm). The total dose can either administered once a day or through a refracted schedule
62776371|NCT03240159|ACTIVE_COMPARATOR|Deg-16mg|"Single dose of Degarelix 16mg, on day 24th of previous luteal face cycle. On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
62776372|NCT03240159|ACTIVE_COMPARATOR|Deg-12mg|"Single dose of Degarelix 12mg, on day 24th of previous luteal face cycle.On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
62776373|NCT05729984|EXPERIMENTAL|Paula|The patients will perform Paula exercises after cesarean delivery.
62776374|NCT05729984|ACTIVE_COMPARATOR|Gum chewing|The patients will chew gum after the cesarean delivery.
62776375|NCT00898391||Ancillary-Correlative|Circulating DNA is extracted from serum. PCR amplification of MYCN is performed and analyzed by agarose gel electrophoresis. Real-time quantitative PCR is also performed.
62186044|NCT02486419||Summer|
62186045|NCT02486419||Winter|
62186046|NCT05605288|EXPERIMENTAL|Distal transradial artery access|Vascular access after cannulation of distal transradial artery through anatomical snuffbox for coronary angiography and interventions
62186047|NCT05605288|ACTIVE_COMPARATOR|Conventional transradial artery access|Vascular access after puncturing on the conventional transradial artery for performing coronary angiography and interventions
62186048|NCT05258955|ACTIVE_COMPARATOR|Chlorhexidine|these are the group which received chlorhexidine based preparation for plaque reduction
62569649|NCT04001725|EXPERIMENTAL|B (Dexamethasone and Metformin)|"Patients subjected at a minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route.The total dose can either administered once a day or through a refracted schedule.~The same patients subjected at a metformin. Metformin initial dosage will be 850 mg per day, and will be escalated based on patient tolerability up to a maximum of 2550 mg daily (experimental arm)."
62569650|NCT04189978||2001-2002 study participants|Children who participated in the study conducted in 2001-2002, their parents and the siblings who were exposed to the same environment at this period.
62569651|NCT01098773||patients requiring ventilation|
62569652|NCT01098773||patients who weaned permanently|
61977827|NCT04464915|EXPERIMENTAL|Isopropyl alcohol swab every 10 minutes|One deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 10 minutes for a total of one hour.
62186049|NCT05258955|EXPERIMENTAL|Natural honey|these group will received the honey base mouthwash and the its effect on plaque reduction will be observed in follow up visits
62186050|NCT03021551|EXPERIMENTAL|Rainbow sensor|
62186051|NCT01748305|EXPERIMENTAL|Moderate-to-vigorous intensity exercise|Moderate-to-vigorous intensity exercise three times per day for three weeks
62186052|NCT01646528||Consecutive patients for CLE examination|
62186053|NCT05337488||Subject with solitary drinking behaviour|A convenience sample of 40 solitary drinkers aged between 10 and 24 will be invited to undergo complete a questionnaire and an individual semi-structured interviews.
62186054|NCT03226301|EXPERIMENTAL|Ibrutinib until progression/relapse|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRDpositive patients (PB and BM) will continue on Ibrutinib maintenance (non-randomized group) until progression/relapse"
62394728|NCT03902158|NO_INTERVENTION|Distraction techniques|No glasses will be used
62394729|NCT03108560|EXPERIMENTAL|Sublobar group|Patients receive sublobar resection, including wedge resection and segmentectomy.
62394730|NCT03108560|ACTIVE_COMPARATOR|Lobectomy group|Patients receive lobectomy.
62394731|NCT02535858|EXPERIMENTAL|Heart and respiratory rate and video|To determine the limits between normal and emotional anxious, thirty volunteers male's adults (GL) with age range between 20 and 50 years were recruited. None of them had any pathology associated with anxiety or psychiatric disorders, and none was drugs user or taking medication.
62000791|NCT05426837|ACTIVE_COMPARATOR|Combatting Social Isolation|"Combating Social Isolation (CSI). CSI and a similar version of this intervention called Building Stronger Allies, has gone through a rigorous treatment development phase, pilot RCT, and larger RCTs (Schmidt et al., 2014; Schmidt et al., 2017; Schmidt et al., 2007; Norr et al., 2017; Short et al., 2015; Short et al., 2017a; Schmidt et al., submitted for publication). CSI is a transdiagnostic cognitive behavioral therapy (CBT)-based protocol designed to address elevated perceived burdensomeness (PB) and thwarted belongingness (TB). The CSI intervention was designed in consultation with clinicians experienced in treating individuals dealing with issues related to PB/TB. CSI is a fully computerized, 1-hour intervention. The latest version of CSI uses Vyond software for video animation and audio narration throughout, as well as interactive features (e.g., brief quizzes to promote comprehension). Procedures draw heavily on standard CBT techniques."
62000792|NCT01971658|ACTIVE_COMPARATOR|VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD)|"Arm A:~1. Induction therapy 4 cycles of VTD (21 days) Thalidomide® 100 mg/day Per Os Day1 to Day21 Velcade® 1.3 mg/m²/day Subcutaneous Day1, 4, 8 and 11 Dexamethasone 40 mg/day Per Os Day 1 to 4 and Day 9 to 12~2. Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and one week after the last dose of Thalidomide, stem cells have to be harvested"
62000793|NCT01971658|ACTIVE_COMPARATOR|VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD)|"For arm B:~1. Induction therapy : 4 cycles of VCD (21 days)~   * Cyclophosphamide 500 mg/m²/day, Per Os Day 1, 8, 15~  * Velcade® and Dexamethasone identical treatment to Arm A~2. Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and two weeks after the last dose of Cyclophosphamide, stem cells have to be harvested"
62000794|NCT01633697|EXPERIMENTAL|Education-Pranayama|Subjects will receive education about COPD with special attention to breathing techniques
62000795|NCT01633697|SHAM_COMPARATOR|Education-Control|Subjects will receive education alone about COPD.
62000796|NCT05090020||Hypernatremia|Hypernatremia (plasma sodium value above 145 mmol/L) due to HS use in the treatment of hydatid cyst.
62000797|NCT05832645|EXPERIMENTAL|A novel mindfulness approach|
62000798|NCT05832645|OTHER|Breathing meditation|
62000799|NCT03611569|EXPERIMENTAL|Lu AF82422|"Part A:~Cohort A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4,A5,A6: 36 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects per cohort (aiming for an equal number of men and women)~Part B:~Cohort B1, B2, B3: 24 patients with Parkinson's disease"
62000800|NCT03611569|PLACEBO_COMPARATOR|Placebo|"Part A:~Cohort A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4,A5,A6: 36 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects per cohort (aiming for an equal number of men and women)~Part B:~Cohort B1, B2, B3: 24 patients with Parkinson's disease"
62000801|NCT00365326|EXPERIMENTAL|Treatment with autologous bone marrow (BM)-derived CD133+ stem cell therapy|The Phase I single arm clinical study, was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia.
62000802|NCT05330650|ACTIVE_COMPARATOR|Triclosan coated suture|
62394732|NCT02535858|EXPERIMENTAL|Heart and respiratory rate and VE|A second group has fifty adult volunteers (DG) ongoing outpatient chemical dependency clinic \[treatment average's population: 5 months and 14 days\]. The patients were abstained from drugs use for at least two months, and they were selected to test the VE. None of the DG's participants had any pathology associated with anxiety or psychiatric disorders, and none was taking medications. The DG volunteers were narcotic users of two or more illicit drugs, such as alcohol, marijuana, tobacco, cocaine and crack cocaine. Addiction for alcohol and tobacco were 72% and 56% respectively. The group's percentage for using psychoactive drugs were, 70% for cocaine and crack cocaine and 32% for marijuana.
62394733|NCT01710709|EXPERIMENTAL|Experimental|Aripiprazole, Intramuscular (IM) Depot
62000803|NCT05330650|ACTIVE_COMPARATOR|Non coated suture|
62000804|NCT02135575|EXPERIMENTAL|Premenopausal women|The Premenopausal women are randomized to exercise by spinning (cycle)
62000805|NCT02135575|EXPERIMENTAL|Postmenopausal women|The Postmenopausal women are randomized to exercise by spinning (cycle)
62186055|NCT03226301|EXPERIMENTAL|Arm A|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRD negative patients (PB and BM) will be randomized to Arm A or Arm B. Arm A: Ibrutinib until progression/relapse (Continuous ibrutinib treatment until toxicity or progression)"
62394734|NCT03601611|EXPERIMENTAL|Experimental|Tocilizumab 8 mg/kg is to be given as an IV infusion over 60 minutes every 4 weeks (Q4W).
62394735|NCT03582254|EXPERIMENTAL|[18F]-FDG PET/MR|\[18F\]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital
62394736|NCT02594150|NO_INTERVENTION|usual care|Each FIT kit will include a tube in which to deposit the stool sample, directions on how to collect and mail the sample, a letter about colorectal cancer screening, a Labcorp requisition form, and a pre-paid return envelope.
62776376|NCT00488904|EXPERIMENTAL|a|
62776377|NCT00488904|PLACEBO_COMPARATOR|b|
62776378|NCT02467842|EXPERIMENTAL|NBP607-QIV|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria on Day 0
62776379|NCT02467842|ACTIVE_COMPARATOR|NBP607-Y|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata on Day 0
62776380|NCT02467842|ACTIVE_COMPARATOR|NBP607-V|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria on Day 0
62776381|NCT04426136||1. WLE group|patients in this group receiving WLE merely
62776382|NCT04426136||2. other method group|patients in this group receiving any other surgical procedures except WLE
62791684|NCT04195217|NO_INTERVENTION|Without art therapy|6 consecutive sessions of cancer treatments without art therapy with other supportive care added.
62000806|NCT04619706|EXPERIMENTAL|Arm A: FSD201 600 mg|Participants will receive 600 milligrams (mg) FSD201 tablet twice daily (BID) orally along with the placebo matched to 600 mg FSD201 tablet from Day 1 to Day 14.
62569653|NCT02569801|ACTIVE_COMPARATOR|Fulvestrant|Participants will receive 500 milligrams (mg) of fulvestrant as two intramuscular injections (250 mg each) on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.
62569654|NCT02569801|EXPERIMENTAL|GDC-0810|Participants will receive three 200 mg tablets (total dose = 600 mg) of GDC-0810 orally once daily until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.
62000807|NCT04619706|EXPERIMENTAL|Arm B: FSD201 1200 mg|Participants will receive 1200 mg (2x600 mg) tablets FSD201 BID orally from Day 1 to Day 14.
62000808|NCT04619706|PLACEBO_COMPARATOR|Arm C: Placebo|Participants will receive placebo matched to 600 mg FSD201 tablets (2xplacebo tablets) from Day 1 to Day 14.
62569655|NCT00762437|EXPERIMENTAL|1|
62776383|NCT05850923|EXPERIMENTAL|a speech competition experimental group|The speech competition training was arranged twice a day, each lasting 15 minutes. The training included word search in sequence, word search out of order and word sorting. Patients need to follow the instructions in time for training. The reaction time, accuracy rate and the number of auditory hallucinations during the task were recorded.
62000809|NCT06391463||infants admitted in the neonatal unit of croix rousse hospital|Infant born between January 1, 2018 and September 27, 2020, admitted in the neonatology department of the Croix Rousse hospital who had at least one coproculture during their stay
62000810|NCT04173143|EXPERIMENTAL|Group 1|This group will receive Cranio cervical flexion training with pressure biofeedback protocol.
62000811|NCT04173143|ACTIVE_COMPARATOR|Group 2|This group will receive Cranio cervical flexion training without pressure biofeedback protocol
62186056|NCT03226301|EXPERIMENTAL|Arm B|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRD negative patients (PB and BM) will be randomized to Arm A or Arm B. Arm B: Observation until event.~Patients randomized to Arm B will get reinitiation of therapy during the observation period in case of:~* progression according to IWCLL criteria or~* MRD≥10-3 (PB) and at least one month later MRD ≥10-2 (PB).~Treatment reinitiation will consist of ibrutinib and venetoclax (with ramp up of venetoclax from cycle 1) for 12 cycles"
62394737|NCT02594150|EXPERIMENTAL|unconditional fixed incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will also receive a financial incentive in the form of a gift card and a note explaining that this gift card is a token of our appreciation for completing the kit.
62569656|NCT02923011|ACTIVE_COMPARATOR|MRgFUS|Magnetic resonance-guided focused ultrasound ablation
62569657|NCT02923011|ACTIVE_COMPARATOR|CTgRFA|Computed tomography-guided radiofrequency ablation
62734585|NCT02266147|EXPERIMENTAL|SD-101 in combination with low-dose radiation|"PART 1~* Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1~* COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29~* COHORT 2: 2 mg/mL at Days 1, 8, 15, 22, and 29~* COHORT 3: 4 mg/mL at Days 1, 8, 15, 22, and 29~* COHORT 4: 8 mg/mL at Days 1, 8, 15, 22, and 29~PART 2~Cycle 1: Required~* Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1~* COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29~* COHORT 2: 8 mg/mL at Days 1, 8, 15, 22, and 29~Cycle 2: Optional~* Radiation: 2 fractions of 2 Gy over 2 days at Days 180 and 181~* COHORT 1: 1 mg/mL at Days 181, 188, 195, 202, and 209~* COHORT 2: 8 mg/mL at Days 181, 188, 195, 202, and 209"
62776384|NCT05850923|ACTIVE_COMPARATOR|Control group|The patient will listen to the soothing music twice a day, each lasting 15 minutes.
62791685|NCT04327024|EXPERIMENTAL|Verinurad 12 + allopurinol|"Dose \[mg\] verinurad/allopurinol:~Step 1 - titration_3/100 Step 2 - titration_7.5/200 Step 3 - target dose 12/300"
62791686|NCT04327024|EXPERIMENTAL|Allopurinol alone|"Dose \[mg\] verinurad/allopurinol:~Step 1 - titration_0/100 Step 2 - titration_0/200 Step 3 - target dose 0/300"
62000812|NCT02480556|EXPERIMENTAL|Group A|manual seperation of the placenta
62000813|NCT02480556|ACTIVE_COMPARATOR|Group B|Conservative separation of placenta
62000814|NCT01838005|NO_INTERVENTION|Standard of Care|"Routine implementation of the national PMTCT guidelines which are an adaptation of the WHO's Option A"
62000815|NCT01838005|EXPERIMENTAL|Conditional Cash Transfer|Financial incentive to attend regular clinic visits and receive PMTCT care
62000816|NCT00003075|EXPERIMENTAL|Fenretinide|
62000817|NCT00003075|PLACEBO_COMPARATOR|Placebo|
62000818|NCT04338464|EXPERIMENTAL|Treatment Group|
62000819|NCT06502288|EXPERIMENTAL|Intervention Group-A: Administration of a specific antibiotic regimen post-extraction.|Patients will be prescribed 625 mg of amoxicillin with combined clavulanic acid tablets three times a day after meals for 7 days following extraction and also a non-steroidal anti-inflammatory drug, 400 mg ibuprofen, and an H2 receptor blocker, 20 mg omeprazole, twice daily before meals.
62000820|NCT06502288|NO_INTERVENTION|Control Group-B: Administration of no antibiotic.|No post-operative antibiotics will be administered, patients will be prescribed a non-steroidal anti-inflammatory drug, 400 mg ibuprofen, and an H2 receptor blocker, 20 mg omeprazole, twice daily before meals.
62000821|NCT00557791|ACTIVE_COMPARATOR|A|Lucentis® (0.5 mg) every 4 weeks.
62000822|NCT00557791|EXPERIMENTAL|B|Bevasiranib (1.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 \& 6.
62000823|NCT00557791|EXPERIMENTAL|C|Bevasiranib (2.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 \& 6.
62569658|NCT04039568|ACTIVE_COMPARATOR|Active Control Group|"Ten to fifteen participants in the HEP arm will participate in the program for 4 consecutive days (2hrs/day) in the 1st week, followed by 75 min/week reinforcement sessions for 11 weeks.~The Health-Enhancement Program (HEP) was designed and used as a manualized active control in meditation-based intervention trials. HEP controls for several non-specific factors found in a meditation groups, including: group support and morale, behavioural activation, reduction of stigma, facilitator attention, treatment duration, and time spent on at-home practice. HEP is tailored to be structurally equivalent to SSM with similar-sized groups, meeting schedule, total contact hours, amount of home practice and encouragement to keep practice logs."
62569659|NCT04039568|EXPERIMENTAL|Intervention Group|"Ten to fifteen participants in the SSM arm will be trained for 4 consecutive days (2hrs/day) in the 1st week, followed by 75 min/week reinforcement sessions for 11 weeks.~This standardized, manualized therapy will be delivered by certified meditation instructors. On day 1, participants will learn the nature of meditation, and then undergo personal guided meditation. Training on days 2-4 includes understanding the nature of the mind and the thoughts arising from it, guided meditations by the instructor, and a discussion of meditation processes. Weekly 75 min reinforcement sessions will include 20 minutes of guided meditation practice, and then focus on participants' experiences with meditation during the week, additional observations, and a review of relevant knowledge to support their home practice. Participants will also be encouraged to practice twice daily at home for 20 minutes per session."
62000824|NCT00557791|EXPERIMENTAL|D|Bevasiranib (2.5 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 \& 6.
62000825|NCT04248569|EXPERIMENTAL|DNAJB1-PRKACA peptide vaccine, Nivolumab, and Ipilimumab|
62186057|NCT05578508|EXPERIMENTAL|Treatment Arm|Submucosal endoscopic injection of 60 million allogeneic bone marrow derived mesenchymal stem cells (MSCs) into ileal pouch at baseline and possibly again after 3 months if not completely healed.
62569660|NCT02176655|ACTIVE_COMPARATOR|VVD-101|One sumatriptan succinate 12.5 mg combined with acetylsalicylic acid 325 mg (VVD-101) capsule taken after the onset of a delayed alcohol induced headache.
62569661|NCT02176655|PLACEBO_COMPARATOR|Placebo|One placebo capsule to match taken after the onset of a delayed alcohol induced headache.
62186058|NCT03993457|OTHER|CRP<1, CRP consistent antidepressant selection|Participants with CRP\<1 will be prescribed escitalopram
62186059|NCT03993457|OTHER|CRP> or equal to 1, CRP consistent antidepressant selection|Participants with CRP\> or equal to 1 will be prescribed bupropion XL
62569662|NCT06409481||Adverse Events with Antineoplastic agents|Cases reported in VigiBase, FAERS and other pharmacovigilance databases of patients treated by antineoplastic agents, with a chronology compatible with the drug toxicity.
62734586|NCT04173286||short term antibiotics|\< 7 days
62000826|NCT03325166|EXPERIMENTAL|Treatment (pembrolizumab, ferumoxytol MRI)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (or up to 32 cycles) in the absence of disease progression or unacceptable toxicity. Patients also receive ferumoxytol IV and undergo MRI at baseline, 12 weeks after radiation, at suspected radiographic progression, and 6 weeks after suspected radiographic progression.
62000827|NCT04061603|EXPERIMENTAL|iCLAS Ablation|Ablation of the left and right atrium with the Adagio Medical iCLAS System
62734587|NCT04173286||long terms antibiotics|\> 7 days
62791687|NCT04327024|PLACEBO_COMPARATOR|Placebo|Placebo \[mg\] in 3 steps 0/0
62000828|NCT05291364|ACTIVE_COMPARATOR|Group 1|injection of ethanol and lidocaine with dexmedetomidine
62000829|NCT05291364|ACTIVE_COMPARATOR|Group 2|injection of ethanol and lidocaine Without dexmedetomidine
62000830|NCT05069012|ACTIVE_COMPARATOR|50 micrograms|Patients in this arm will receive 50 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery
62186060|NCT03993457|OTHER|CRP<1, CRP inconsistent antidepressant selection|Participants with CRP\< 1 will be prescribed bupropion XL
62186061|NCT03993457|OTHER|CRP> or equal to 1, CRP inconsistent antidepressant selection|Participants with CRP\> or equal to 1 will be prescribed escitalopram
62186062|NCT01073319|PLACEBO_COMPARATOR|Placebo|Matching oral placebo capsule as control.
62569663|NCT02892773|OTHER|Incentive Spirometry Group|"* Participant will be asked to take 10 deep breaths through the mouthpiece of an incentive spirometer, followed by a 60 second pause.~* This cycle will be repeated two more times.~* A Respiratory Therapist will coach participants three times per day.~* Each duration of Incentive Spirometry will last about 15 minutes."
62569664|NCT02892773|ACTIVE_COMPARATOR|EzPAP® Positive Airway Pressure Group|"* Participant will be coached by a Respiratory Therapist to breathe through the mouthpiece of an EzPAP® device for 10 breaths, followed by a 60 second pause.~* This cycle will be repeated two more times.~* The Respiratory Therapist will coach participants three times per day.~* Each duration of EzPAP® therapy will last about 15 minutes."
62569665|NCT01020630|EXPERIMENTAL|Sunitinib|25 mg (2 capsules of 12.5 mg) for oral administration
62776385|NCT06583421|EXPERIMENTAL|4-week MVPA intervention group|The 4-week MVPA intervention engaged in supervised aerobic exercise, resistance training and interesting sport for 60 minutes, 3 days/week (Monday, Wednesday and Friday). As shown in Table S1, participants completed four sessions including preparation module (15 min), training module (30 min), and relaxation module (15 min). Another aerobic module (15 min) was added in each Friday. Children in intervention group were also encouraged to take exercise for 10 minutes together with their parents at home two hours later after dinner including ten minutes' walking (at least 1000 meters) or at least 200 times rope skipping.
62186063|NCT01073319|ACTIVE_COMPARATOR|Rivastigmine 3 mg|
62186064|NCT01073319|ACTIVE_COMPARATOR|Rivastigmine 6 mg|
62186065|NCT04234945|EXPERIMENTAL|study|Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7.
62186066|NCT04234945|PLACEBO_COMPARATOR|control|Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7
62186067|NCT01610960|ACTIVE_COMPARATOR|HELMET|The HELMET and HELMET NEXT modes will be tested by each patient.
62186068|NCT01610960|SHAM_COMPARATOR|Facemask|The facemask will be used by each patient.
62186069|NCT06039722|EXPERIMENTAL|experimental group|Each subject underwent pulse ablation catheter ablation
62186070|NCT02814045||Alzheimer with OSA|Alzheimer with OSA after PSG
62186071|NCT02814045||Alzheimer without OSA|Alzheimer without OSA after PSG
62186072|NCT02674269|EXPERIMENTAL|300 IU of BotuGelTM (60ml)|One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
62186073|NCT02674269|EXPERIMENTAL|400 IU of BotuGelTM (60ml)|One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
62569666|NCT01020630|PLACEBO_COMPARATOR|Placebo|2 capsules for oral administration
62776386|NCT06583421|NO_INTERVENTION|Control group|No physical activity interventions were conducted in the control group. In order to safeguard the rights of the control groups, the same physical activity intervention was given to the control group at the end of the research.
62776387|NCT03110575|EXPERIMENTAL|TNX-102 SL|2 x TNX-102 SL, 2.8 mg tablets taken daily at bedtime for 12 weeks
62776388|NCT05327504|EXPERIMENTAL|Written Exposure Therapy|Written Exposure Therapy (WET) plus Treatment As Usual (TAU). WET is a 5 session, evidence-based trauma-focused written narrative exposure treatment. At each session, patients are instructed to write about the same trauma event and therapists provide feedback about adherence and offer suggestions. The first session includes psychoeducation about PTSD and a treatment rationale prior to general trauma narrative writing instructions, and specific instructions for completing the first writing session, before completing the first writing (30 minutes) session. Participants are instructed to write about the same trauma event at each following session, with an emphasis on delving into their deepest emotions and thoughts, in as much detail as possible, about the event. All writing sessions begin with specific instructions from the therapist followed by 30 minutes of writing by the participant.
62000831|NCT05069012|ACTIVE_COMPARATOR|150 micrograms|Patients in this arm will receive 150 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery
62569667|NCT02227498|EXPERIMENTAL|Effect of Argus II on Functional Vision|All subjects enrolled in the study will be implanted with the Argus II Retinal Prosthesis. To evaluate safety and effectiveness of Argus II on visual function.
62569668|NCT05697354|EXPERIMENTAL|Tablet group|The Tablet group will carry out the exercises using the Khymeia VRRS Home Tablet.
62000832|NCT05069012|ACTIVE_COMPARATOR|250 micrograms|Patients in this arm will receive 250 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery
62000833|NCT04689087|EXPERIMENTAL|Second line conventional treatment|
62000834|NCT01319149||No treatment|Patient records would be extracted from the electronic health record system of Southwest Regional Wound Care Center and placed in a separate bin.
62000835|NCT00381420|EXPERIMENTAL|1|sirolimus-coated Bx Velocity stent
62000836|NCT00381420|ACTIVE_COMPARATOR|2|uncoated Bx Velocity stent
62000837|NCT02453295|EXPERIMENTAL|Intervention Group|The IG will meet weekly for 2 hours for 8 weeks. All workshops will be recorded and transcribed, then analyzed qualitatively. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will take place over the phone. The questionnaires will be administered 3 days prior to workshop 1 (T0), between workshop 4 and 5 (T1), and 3 days following the completion of the intervention (T2). The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2.
62776389|NCT05327504|ACTIVE_COMPARATOR|Neutral Topic Writing|Treatment As Usual (TAU) augmented by a neutral topic writing condition. The neutral topic writing condition involves writing about an assigned topic during each of the five writing sessions. As opposed to writing about trauma, the specific focus of this condition is on writing for 30 minutes about topics related to their life without writing about emotions or opinions. Rather, they are asked to write about specific objects or events in detail, as accurately as possible, and with as much description as possible. All writing sessions begin with specific instructions from the therapist followed by 30 minutes of writing by the participant.
62776390|NCT05709639|EXPERIMENTAL|Responder|Increased carbohydrate intake (top 50%) vs moderate to regression in carbohydrate intake (lower 50%)
61977828|NCT04464915|EXPERIMENTAL|Isopropyl alcohol swab every 20 minutes|One deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 20 minutes for a total of one hour.
62000838|NCT02453295|NO_INTERVENTION|Comparison Group|The CG will receive LE treatment as usual, without the hope intervention. They will be administered the same questionnaires (by phone) as the IG at the same timepoints. Potential participants (n=46) will be screened based MIQ. The individuals scoring in the top \~30% (n=16) will be excluded from the study. The remaining 30 individuals scoring the lowest level of hope will be admitted into the study.
62000839|NCT05599035|ACTIVE_COMPARATOR|1st group received active rTMS,|Active rTMS was applied using a figure-of-8 coil (7-cm diameter loop) positioned over the parietal area for ten sessions (10 trains, with frequency of stimulation 20-Hz, each lasting for 10 seconds with an inter-train interval of 30 seconds. The intensity of stimulation was set at 80% of the RMT for the first dorsal interosseous (FDI) of the contralateral hand with a total 2000 pulses for each hemisphere). Each patient received five sessions /week for two consecutive weeks with ten total sessions over the parietal area. The parietal region was determined according to the 10-20 system for electroencephalographic electrode positioning at P3 and P4, respectively.
62186074|NCT02674269|PLACEBO_COMPARATOR|TC-3 Gel|One intravesical instillation of 60 ml TC-3 gel
62569669|NCT05697354|EXPERIMENTAL|App group|The App group will perform the exercises on their smartphone using the Khymeia Medico Amico App.
62776391|NCT06152549||MACE First Group|This group (N=250) will be presented with the Maltreatment and Abuse Chronology of Exposure (MACE) scale toward the beginning of the session and the Math/Verbal Test toward the end.
62186075|NCT01805986||MS patient|
62186076|NCT00302523|ACTIVE_COMPARATOR|FK506|
62734588|NCT05444907||DBS-induced Mania Cohort|Patients diagnosed with Parkinson's Disease (PD) who were submitted to deep brain stimulation (DBS) surgery irrespective of its target and who developed a manic episode or mixed affective state diagnosed after surgery and associated to DBS modulation, i.e., after switching on the device or changing modulation parameters.
61977829|NCT04464915|NO_INTERVENTION|No treatment arm|No intervention administered.
62569670|NCT03142009|EXPERIMENTAL|Program group|Tribal Research Team members recruit participants by sending letters home with the fourth and fifth grade children. This letter provides an overview of the FL/CP and invite interested parents and children to learn more. TRT and UNM team members follow-up with interested parents individually. If families are committed to being a part of FL/CP, a meeting is set to conduct the informed consent process and complete pretest. Families in the program group then attend FL/CP sessions which covers the intergenerational culturally adapted curriculum. Program families also participate in various aspects of the program including completing a Community Action Project.
62776392|NCT06152549||Standardized Test Questions First Group|This group (N=250) will be presented with the standardized test questions (Math/Verbal) toward the beginning of the session and the Maltreatment and Abuse Chronology of Exposure (MACE) scale toward the end.
62776393|NCT01877577|ACTIVE_COMPARATOR|2000 I/U Vitamin D3|2000 I/U Vitamin D3 Daily
62776394|NCT01877577|ACTIVE_COMPARATOR|4000 I/U Vitamin D3|4000 I/U Vitamin D3 Daily
62186077|NCT01128114|EXPERIMENTAL|Quetiapine XR|Quetiapine fumarate (Seroquel XR)
62186078|NCT00480155|ACTIVE_COMPARATOR|1|FluMist
62394738|NCT02594150|EXPERIMENTAL|conditional fixed incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will receive a note stating that they will receive a financial incentive in the form of a gift card if they return their completed FIT within two months of receiving the FIT kit.
62569671|NCT03142009|NO_INTERVENTION|Comparison group|Upon receiving the letter families that selected not to participate or who decline to participate will be invited to take part in the research study as comparison participants. Comparison participants do not attend the FL/CP sessions and only complete the pre, post and 1 year post tests.
62569672|NCT05113550||Young group|patients \< 70 years of age
62776395|NCT04591236|EXPERIMENTAL|Gait training with brain stimulation|Treadmill gait training and transcranial direct current stimulation (tDCS) on the leg motor areas
62000840|NCT05599035|SHAM_COMPARATOR|2nd group was the sham group|rTMS was applied using the same parameters, but with the coil edge was applied perpendicular to the scalp in the sagittal plane jut to reproduce the noise of the stimulation
62186079|NCT00480155|PLACEBO_COMPARATOR|2|Placebo
62186080|NCT04522206|EXPERIMENTAL|Patients undergoing elective spine surgery|
62214630|NCT05303558||Participants With High-risk Localized Prostate Cancer|Adult participants from Japan, South Korea, and Taiwan with high-risk localized prostate cancer (HR LPC) who received radical prostatectomy (RP) and perioperative (neoadjuvant and/ or adjuvant) hormonal therapy will be observed from the date of confirmed HR LPC diagnosis until death, lost to follow-up (last known visit), or end of study period, whichever comes first. This study will utilize data from electronic medical records (EMR) in South Korea and Taiwan, and data from chart reviews in Japan. Data will be analyzed retrospectively from 1 January 2015 to 30 June 2017, with a follow-up till 30 June 2022.
62394739|NCT02594150|EXPERIMENTAL|conditional lottery incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will receive a note stating that they will be entered in a 1/10 chance lottery to receive a financial incentive in the form of a gift card if they return their completed FIT within two months of receiving the FIT kit.
62394740|NCT05748860||Adult patients commencing on VA-ECMO|The study population is adult patients on VA-ECMO for cardiogenic shock or cardiac arrest that are or will be enrolled in the national ECMO registry (EXCEL).
62569673|NCT05113550||Elderly|Patients ≥ 70 years of age)
62569674|NCT02942797||NRS 2002 score ≥ 3|
62569675|NCT02942797||NRS 2002 score < 3|
62569676|NCT05370950|EXPERIMENTAL|Treatment group A|
62569677|NCT05370950|EXPERIMENTAL|Treatment group B|
62569678|NCT05370950|EXPERIMENTAL|Treatment group C|
62776396|NCT04591236|ACTIVE_COMPARATOR|Gait training with sham brain stimulation|Treadmill gait training and anodal sham transcranial direct current stimulation (tDCS) on the leg motor areas
62776397|NCT01501123|EXPERIMENTAL|Haloperidol|IM Haloperidol
62776398|NCT01501123|ACTIVE_COMPARATOR|IM Midazolam|
62776399|NCT04485884|EXPERIMENTAL|Group A|IN-C005 dose A
62776400|NCT04485884|EXPERIMENTAL|Group B|IN-C005 dose B
62776401|NCT04485884|EXPERIMENTAL|Group C|IN-C005 dose C
62776402|NCT04485884|EXPERIMENTAL|Group D|IN-C005 dose D
62776403|NCT04485884|EXPERIMENTAL|Group E|IN-C005 dose E
62776404|NCT04485884|EXPERIMENTAL|Group F|IN-C005 dose F
62776405|NCT01092663|ACTIVE_COMPARATOR|Colesevelam HCl: 3 tablets, 2x/day|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
62776406|NCT01092663|ACTIVE_COMPARATOR|Colesevelam plus Sitagliptin|"Colesevelam: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.~Sitagliptin: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks."
62776407|NCT05606341|EXPERIMENTAL|CpG 1018 0.1 mg/kg|"3 injections at Day 1, Week 4, and Week 8.~Treatment administered as morning injection of dose 0.1mg/kg, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions."
62186081|NCT03641456|EXPERIMENTAL|VRD for Followed by VR|The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22; oral lenalidomide 25mg on days 1 to 21; and oral dexamethasone 40mg on days 1, 8, 15 and 12 of a 28-day cycle.Patients are allowed to proceed to stem-cell transplantation after four cycles of VRD at the discretion of the treating physician.Two months after hematologic recovery, nonprogressive patients are to receive consolidation therapy comprising two cycles of VRD.Patients who do not proceed to stem-cell transplantation receive more two induction cycles after obtaining maximum response but no less than six cycles totally. Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib 1.3mg/m2 on days 1 and 15 and lenalidomide on days 1 to 21 at the dose level of 10mg.
62569679|NCT04394780|NO_INTERVENTION|Peritoneal dialysis at 37 C|Patients underwent peritoneal dialysis with the standard temperature.
62000841|NCT01451346|PLACEBO_COMPARATOR|Placebo|Placebo sachets contained 5 grams of Maltodextrin only.
62000842|NCT01451346|EXPERIMENTAL|B Infantis 35624|Each 5gram freeze-dried powder contained ≥1\*1010 Colony forming units (CFU) of B. infantis 35624/sachet.
62776408|NCT05606341|EXPERIMENTAL|CpG 1018 0.25 mg/kg|"3 injections at Day 1, Week 4, and Week 8.~Treatment administered as morning injection of dose 0.25 mg/kg, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions."
62776409|NCT05606341|EXPERIMENTAL|CpG 1018 0.5 mg/kg|"3 injections at Day 1, Week 4, and Week 8.~Treatment administered as morning injection of dose 0.5 mg/kg, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions."
62776410|NCT05606341|PLACEBO_COMPARATOR|Placebo|3 injections of sterile saline at Day 1, Week 4, and Week 8, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions.
62000843|NCT01032135|ACTIVE_COMPARATOR|1-MI-IOP Engaged|Randomized to treatment as usual, and they attend regularly but dropped out of treatment after randomization.
62000844|NCT01032135|EXPERIMENTAL|2-MI-IOP Non-Engaged|Randomized to treatment as usual, and do not attend.
62000845|NCT01032135|ACTIVE_COMPARATOR|3-MI-PC Engaged|Randomized to treatment choice, but remain attending treatment as usual then dropped out of treatment after randomization.
62000846|NCT01032135|EXPERIMENTAL|4-MI-PC Non-engaged|Randomized to treatment choice, and do not attend treatment as usual, so the choice option is used.
62000847|NCT00613028|EXPERIMENTAL|Temo + Avastin|Patients treated with bevacizumab + temozolomide
62000848|NCT00613028|EXPERIMENTAL|VP-16 + Avastin|Patients treated with bevacizumab and VP-16 (etoposide)
62000849|NCT05071092|EXPERIMENTAL|Intervention group|The intervention will consist of personalized guidance from a dietician focussing on improving adherence to the Dutch dietary guidelines.
62000850|NCT05071092|NO_INTERVENTION|Usual care group|The usual care group will not receive any special guidance regarding healthy nutrition, but will have access to their care team as usual.
62000851|NCT05891938|EXPERIMENTAL|Single arm|Single group treatment
62000852|NCT01398891|EXPERIMENTAL|Positive Psychology Exercises|
62000853|NCT00004412|OTHER|Standard local care dressing|Each subject provided his/her own dressing e.g,standard local care includes cleaning, saline irrigation, dressing changes only for 8 weeks twice a week.
62000854|NCT00004412|EXPERIMENTAL|Arginine Butyrate|Arginine Butyrate IV plus Standard local care dressing for a total of 12 weeks. Low dose 500 mg/kg or, increased dose 750 mg/kg. First week AB given 5 days in a row, over 6 to 12hours.
62776411|NCT02773654||Healthy Volunteers|Asymptomatic subjects: subjects without complaints or history of shoulder pain or obvious movement abnormalities.
62000855|NCT00004412|OTHER|Crossover|Patients are randomly assigned (following a table of random numbers prepared by a blinded statistician) between two arms of the study. Arm I is Standard local care dressing only, and Arm II is standard local care plus Arginine Butyrate (AB), the Investigational New Drug. Ulcers observed \& traced weekly. Ulcer area calculated by computerized planimetry. After 12 weeks of therapy, if the ulcer size decreased by at least 25%, the AB may be continued for another 8 weeks (twice), or until the ulcer closes, plus an additional 2 weeks. The patients randomized to the Control Arm (standard local care) were given the option of crossing over to Arm II If, ulcers did not close after 8 weeks of standard local care.
62000856|NCT05060393|EXPERIMENTAL|Intervention group|Daily use of mindfulness-based mobile application for 30 days.
62000857|NCT05060393|NO_INTERVENTION|Control group|Treatment as usual
62000858|NCT00111228|EXPERIMENTAL|Continuous use of the Guardian RT|Continuous use of the Guardian RT group
62000859|NCT00111228|EXPERIMENTAL|Bi-weekly use of the Guardian RT (once every 2 weeks)|Bi-weekly use of the Guardian RT (once every 2 weeks) group
62000860|NCT00111228|ACTIVE_COMPARATOR|Control group. SMBG monitoring|Control group. SMBG monitoring group
62000861|NCT02271633|ACTIVE_COMPARATOR|Sodium nitrate|Dietary supplement: 800 mg of nitrate in sodium nitrate added with water to get a 140 mL solution (BASF, Ludwigshafen, Germany)
62000862|NCT02271633|ACTIVE_COMPARATOR|Beetroot juice|Dietary supplement: 800 mg of nitrate in concentrated beetroot juice (Beet-IT)
62000863|NCT02271633|ACTIVE_COMPARATOR|Spinach|Dietary supplement: 800 mg of nitrate in a spinach based beverage
62000864|NCT02271633|ACTIVE_COMPARATOR|Rocket salad|Dietary supplement: 800 mg of nitrate in a rocket salad based beverage
62000865|NCT04888975|EXPERIMENTAL|Patients with Breast-cancer related lymphedema (BCRL) after lymphatic surgery|Patients with Breast-cancer related lymphedema (BCRL) after lymphatic surgery
62000866|NCT05322187|EXPERIMENTAL|PLEN(PD-1/PD-L1 inhibitor and LENvatinib)|Treatment of PD-1/PD-L1 Inhibitor and LENvatinib would be employed in PLEN
62776412|NCT02773654||Symptomatic Volunteers|Symptomatic subjects: subjects with shoulder pain who have active range of motion beyond 120° of elevation.
62776413|NCT03481140||Control|donor site DIEP flap breast reconstruction procedure with standard wound closure with drains
62569680|NCT04394780|ACTIVE_COMPARATOR|Peritoneal dialysis at 32 C|Patients started on continuous ambulatory peritoneal dialysis using a peritoneal dialysate cooled to between 32-33 degrees centigrade, at a pre-determined and precisely controlled temperature for the 4 hour duration treatment.
62776414|NCT03481140||TissuGlu Surgical Adhesive|donor site DIEP flap breast reconstruction procedure with standard wound closure with TissuGlu Surgical Adhesive and no drains
62776415|NCT04401878|EXPERIMENTAL|the treatment group (A)|Patients who have PDPH are manged by SPGB, they are assessed by NRS before the block, at 30 mins, 2h, 4h, 6h, 12h, and 24hours after block. The patients are also examined by TCD before and after the block.
62000867|NCT03879889|EXPERIMENTAL|Intervention|Intervention arm will include face-to-face counseling on smoking reduction and adherence to nicotine replacement therapy (NRT) with motivational interviews, provision of free NRT, referral to quit smoking hotline, monthly phone follow-up and two follow-up visits.
62000868|NCT03879889|NO_INTERVENTION|Control|Smoking parents will be given standard advice on smoking cessation. They will be given an information leaflet showing standard information on the currently available smoking cessation service as well as a smoking cessation hotline.
62000869|NCT00350766|EXPERIMENTAL|Treated Group|Intracoronary injection in the infarcted-related artery of 100 million bone marrow mononuclear cells resuspended in a 10 ml solution of saline with autologous serum.
62000870|NCT00350766|PLACEBO_COMPARATOR|Control Group|Intracoronary injection in the infarcted-related artery of placebo solution consisting of a saline containing autologous blood serum.
62000871|NCT01371656|EXPERIMENTAL|Arm I (levofloxacin)|Patients receive levofloxacin PO or IV over 60-90 minutes once or twice daily beginning on day 3 during 2 consecutive courses of chemotherapy or beginning on day -2 during HSCT and continuing until blood counts recover.
62569681|NCT06358547|EXPERIMENTAL|PGT-A|PGT-A and freeze-all (by vitrification) of day 5 and/or day 6 and/or day 7 blastocyst(s) and subsequent transfer of euploid or mosaic (≤80%) blastocysts in FET cycles. Luteal phase supplementation (LPS) will be administered according to the participating clinics standard practice.
62734589|NCT05444907||DBS Control Cohort|Patients diagnosed with PD who were submitted to DBS surgery irrespective of its target and who did not develop DBS-induced mania.
62776416|NCT04401878|EXPERIMENTAL|control group (B)|The control group (B) of 60 patients with no PDPH were examined by TCD
62776417|NCT05382611||Patients Controls|Control group
62776418|NCT05382611||Patients with aneurysma|Patients with aneurysma
62776419|NCT01331291|EXPERIMENTAL|Arm A|Patients who are surgical candidates. Participants are given oral bosutinib, 400mg daily, for 7-9 days prior to resection. After at least 10 days elapsed post-operatively, bosutinib dosing was resumed.
62000872|NCT01371656|NO_INTERVENTION|Arm II (standard of care)|Patients receive established standard of care and receive chemotherapy or HSCT as patients in Arm I.
62000873|NCT01539226|PLACEBO_COMPARATOR|Placebo Vaginal Ring|Vaginal Ring containing 0.0 mg Dapivirine
62000874|NCT01539226|EXPERIMENTAL|Dapivirine Vaginal Ring|Vaginal Ring containing 25mg of Dapivirine
62776420|NCT01331291|EXPERIMENTAL|Arm B|Patients that are not surgical candidates. Participants are given oral bosutinib, 400 mg daily in 28 day cycles until disease progression, intolerability or withdrawal of consent.
61977830|NCT03222596|EXPERIMENTAL|Multiple Sclerosis Exercise|Ambulatory and non-ambulatory MS individuals that will exercise-group (MSE). Intervention is exercise training.
61977831|NCT03222596|NO_INTERVENTION|Multiple Sclerosis Control (no-Exercise)|Ambulatory and non-ambulatory MS individuals that will not exercise-group (MSC).
62000875|NCT02045771|OTHER|Support Group (Control Group)|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
62000876|NCT02045771|EXPERIMENTAL|Behavioral Activation|Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
62000877|NCT03376178|EXPERIMENTAL|six-hole group|lidocaine and ropivacaine injection through catheters
62000878|NCT03376178|ACTIVE_COMPARATOR|end-hole group|lidocaine and ropivacaine injection through catheters
62000879|NCT01485458|EXPERIMENTAL|Early surgery|
62776421|NCT06195189|EXPERIMENTAL|Sunvozertinib combined with chemotherapy (Pemetrexed +platinum)|Sunvozertinib 200mg Quaquedie (QD) combined with chemotherapy (Pemetrexed +platinum)
62776422|NCT00982202|EXPERIMENTAL|PGZ|
62776423|NCT00982202|PLACEBO_COMPARATOR|Placebo|
62776424|NCT05047848|EXPERIMENTAL|chidamide + fulvestrant|
62776425|NCT01026740|EXPERIMENTAL|001|Ceftobiprole 500 mg, single infusion over 2 hours
62776426|NCT01761695||CML CP|Diagnosed as CML with chronic phase
62776427|NCT01761695||CML AP|Diagnosed as CML with accelerated phase
62776428|NCT01761695||CML BC|Diagnosed as CML with blast crisis
62776429|NCT01761695||CML other|Diagnosed as CML, which is not included in any of other category
62776430|NCT02326233|EXPERIMENTAL|Pen of SB5|Pen of SB5, single-dose of 40 mg via subcutaneous injection (study drug)
62776431|NCT02326233|ACTIVE_COMPARATOR|PFS of SB5|PFS of SB5, single-dose of 40 mg via subcutaneous injection (reference drug)
62776432|NCT01599741|EXPERIMENTAL|ClarityIQ|Low-dose DSA (83% reducation compared to normal dose) with novel X-ray imaging technology.
62776433|NCT01599741|ACTIVE_COMPARATOR|AlluraXper|Normal dose DSA with conventional X-ray imaging technology.
62776434|NCT01973504|EXPERIMENTAL|MP4OX 500-mL|500-mL dose of MP4OX
62000880|NCT01485458|ACTIVE_COMPARATOR|Delayed surgery|
62000881|NCT01411878|EXPERIMENTAL|Reducing the Risk|Students will be randomly assigned to participate in Reducing the Risk training
61977832|NCT04918264||Uracil concentration <16 ng/mL|Patients were included in this arm if they have digestive cancer and an uracil dosage \<16 ng/mL performed between February 2018 to January 2020, and if they received at least one cycle of fluoropyrimidine-based chemotherapy in one of the four oncology departments (Hopital Edouard Heriot \[Lyon\], Centre Hospitalier de Lyon Sud \[Lyon\], Hopital de la Croix Rousse \[Lyon\].
62000882|NCT01411878|EXPERIMENTAL|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, \& Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov).
62000883|NCT01120431|ACTIVE_COMPARATOR|Oral rehydration therapy|
62000884|NCT01120431|EXPERIMENTAL|hylenex-facilitated SC hydration|
62000885|NCT00820742||Phase IV Post Marketing Surveillance Study|Open-label, observational study
62186082|NCT01505322||Thoracic surgery|Lung cancer patients
62186083|NCT01699464|EXPERIMENTAL|AR-12286 Ophthalmic Solution 0.7%|AR-12286 Ophthalmic Solution 0.7%, both eyes
62776435|NCT01973504|EXPERIMENTAL|MP4OX 750-mL|750-mL dose of MP4OX
62776436|NCT01973504|SHAM_COMPARATOR|Control|Standard crystalloid Keep Vein Open (KVO) infusion
62186084|NCT01699464|EXPERIMENTAL|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5% both eyes
62186085|NCT01699464|ACTIVE_COMPARATOR|Timolol maleate ophthalmic solution 0.5%|Timolol maleate ophthalmic solution 0.5% both eyes
62186086|NCT05098691||Group 1 (Early onset Preeclampsia )|43 cases The groups were matched for gestational age and gravidity.
62776437|NCT01571232|ACTIVE_COMPARATOR|Ozurdex|Patients in this group receive Ozurdex at initial visit and at month 4
62776438|NCT01571232|ACTIVE_COMPARATOR|Avastin|Patients in this group receive Avastin Q1 month for 5 months.
62776439|NCT06496334||Head CT scan|Adult Caucasian patients undergoing head CT scanning.
62776440|NCT04408911||Midazolam|Critically ill intensive care unit patients receiving midazolam
62186087|NCT05098691||Group 2 ( Healthy pregnant woman) control group|41 cases The groups were matched for gestational age and gravidity
62214631|NCT00557947|EXPERIMENTAL|I|Dermabond Protape-Incision segments are randomized \& patient is own control
62776441|NCT04408911||Lormetazepam|Critically ill intensive care unit patients receiving lormetazepam
62776442|NCT05943782|EXPERIMENTAL|additive manufacturing of onlays|additive CAD/CAM manufacturing of dental restorations by 3D printing
62776443|NCT05943782|ACTIVE_COMPARATOR|subtractive manufacturing of onlays|subtractive CAD/CAM manufacturing of dental restorations by milling
62776444|NCT00908466|EXPERIMENTAL|Intravitreal Injection|Will receive intravitreal injections of sirolimus 352 µg in study eye on Days 0, 60, and 120.
62776445|NCT00908466|EXPERIMENTAL|Subconjunctival Injection|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
62776446|NCT06351722||Non-smoking periodontitis (NSP)|participants who reported never smoking, with clinical attachment loss ≥3 mm in \>30% of sites, with probing depth ≥5 mm in at least six teeth, and with radiographic bone loss extending to or beyond the middle third of the root in the coronal third will be included.
62776447|NCT06351722||smoking periodontitis (SP)|participants who reported smoking \>10 cigarettes per day for \>5 years with clinical attachment loss ≥3 mm in \>30% of sites, with probing depth ≥5 mm in at least six teeth, and with radiographic bone loss extending to or beyond the middle third of the root in the coronal third will be included.
62186088|NCT04381923|ACTIVE_COMPARATOR|Helmet Continuous Positive Airway Pressure (CPAP)|When a patient has an Sp02 \< 92% on ≥ 6 LPM NC, helmet CPAP will be applied unless a specific contraindication is present.
62186089|NCT04381923|ACTIVE_COMPARATOR|High Flow Nasal Oxygen (HFNO)|When a patient has an Sp02 \< 92% on ≥ 6 LPM NC , HFNO (≥ 40 LPM) will be applied unless a specific contraindication is present
62186090|NCT04402983|EXPERIMENTAL|Telerehabilitation Group|Physiotherapy will be carried out by conducting online conference method. Program content; Respiratory exercise (chest breathing, diaphragmatic breathing, basal expansion exercises), Breath control training, Active breathing techniques cycle Light aerobic exercise Posture exercises Self walking
62776448|NCT06351722||non-smoking periodontal health (HC)|participants who reported never smoking and periodontal healthy.
62776449|NCT06351722||smoking periodontal health (HCS)|participants who reported smoking \>10 cigarettes per day and periodontal healthy.
62776450|NCT05262283||2019-2020 season|Injuries in the first 26 games of 2019-2020
62776451|NCT05262283||2020-2021 season|Injuries in the first 26 games of 2020-2021 in the new post-COVID season
62776452|NCT01377870|PLACEBO_COMPARATOR|cell free media|15 patients with relapsing remitting multiple sclerosis who receive cell free media
62186091|NCT04402983|NO_INTERVENTION|Control group|Information and exercise brochure will be provided
62776453|NCT01377870|EXPERIMENTAL|mesenchymal stem cell reciepiants|Patients with relapsing remitting multiple sclerosis who underwent intravenous injection of mesenchymal stem cells
62776454|NCT00588094|EXPERIMENTAL|Treatment|R-ICEesc will be administered with the intent of administering 2 cycles, each 21 days apart admixed with 4 doses of rituximab. G-CSF will be administered at 960 ug or 10 ug/kg if patient is \> 100 kg after cycles one and two for PBPC collection for the first 10 patients enrolled. G-CSF will be administered in standard dosing for cycle one and then at 960 ug or 10 ug/kg (if patient is \> 100 kg) after cycle two for PBPC collection for the remaining 22 patients. All responding patients who make at least 2 x 106 CD34+ cells/kg will receive high dose therapy and ASCT on other protocols.
62186092|NCT05294718|ACTIVE_COMPARATOR|Internal shunt|glenn with internal shunt (veno-atrial shunt) where the surgeon established a shunt between distal SVC and the right atrium, Establishing a veno-atrial shunt.
62186093|NCT05294718|ACTIVE_COMPARATOR|External shunt|Glenn with external shunt where the anesthesiologist connected the internal Jagular venous cannula which represent the SVC with the main lumen of the femoral cannula which represent the IVC through long venous extension
62186094|NCT02411708|EXPERIMENTAL|SANGUINATE|320 mg/kg
62186095|NCT02411708|PLACEBO_COMPARATOR|Placebo|Normal saline IV infusion
62186096|NCT04964895|OTHER|patients with cystectomy|
62186097|NCT03787420|ACTIVE_COMPARATOR|traditional communication system|
62186098|NCT03787420|EXPERIMENTAL|intelligent communication system|
62776455|NCT04117698|EXPERIMENTAL|Antitubercular treatment and local corticosteroid therapy|"Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:~* RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months~* associated with a treatment similar to the control group."
62776456|NCT04117698|NO_INTERVENTION|Local Corticosteroid Therapy Only|"Treatment of Ocular Inflammation by Local Corticosteroid Therapy Only comprising:~* Dexamethasone (DEXAFREE® eye drops) at an attack dose for one week (4 to 6 drops / d maximum and if severe inflammation 1 drop / hour) then decrease and stop over 3 weeks, with relay by fluorometholone (Flucon®) for 2 months maximum. The modalities of the decrease of the local steroids are left to the ophthalmologists own judgment. Maximum total duration of 3 months.~* Mydriatic (tropicamide) 1gx3 / d if necessary.~* Neosynephrine 5% if posterior synechiae.~* Atropine (Alcon 0.3%) if pain."
62776457|NCT03068208|EXPERIMENTAL|MB-PDT|
62776458|NCT03068208|NO_INTERVENTION|Control|
62776459|NCT02504307|EXPERIMENTAL|Inspiron|Sirolimus Eluting Stent Inspiron
62776460|NCT02504307|ACTIVE_COMPARATOR|Cronus|Bare Metal Stent
62186099|NCT04597190|ACTIVE_COMPARATOR|SSRI Then Augmentation by WET|Prescribers will prescribe one of three SSRIs (sertraline, fluoxetine or paroxetine). Patients who do not respond to treatment by four months will have their treatment augmented by Written Exposure Therapy (WET) delivered by an integrated behavioral health consultant.
62214632|NCT00557947|ACTIVE_COMPARATOR|II|Intradermal Suture - Incision segments are randomized \& patient is own control. Investigator selected suture on the basis of standard local practice.
62776461|NCT02161107|EXPERIMENTAL|Grass-SPIRE 1|Grass-SPIRE regimen 1 given 2 weeks apart
62776462|NCT02161107|EXPERIMENTAL|Grass-SPIRE 2|Grass-SPIRE regimen 2 given 2 weeks apart
62776463|NCT02161107|PLACEBO_COMPARATOR|Placebo|Placebo given 2 weeks apart
62394741|NCT03089229|EXPERIMENTAL|HAT01H cream|HAT01H medicated cream will come in a blinded tube. This topical medicated cream will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
62776464|NCT04716920|EXPERIMENTAL|Supportive Care (Tai Chi, Fitbit, Tai4Chijoint group)|Patients attend Tai Chi exercise classes over 1 hour BIW and wear a Fitbit device for up to 12 weeks. Patients are encouraged to complete self-practice over 30 minutes and record practice times daily in a diary log form. Patients also join a Facebook private TaiChi4joint group where they receive instructional videos matching the progress of weekly classes for at-home practices and peer support in Tai Chi engagement.
62776465|NCT00934908|PLACEBO_COMPARATOR|1|"Non-active sugar pill"
62776466|NCT00934908|ACTIVE_COMPARATOR|2|Green Tea Capsules
62776467|NCT04345094|EXPERIMENTAL|Comparator|Emulsion containing 1% Hexylresourcinol
62186100|NCT04597190|ACTIVE_COMPARATOR|SSRI Then Switch to SNRI|Prescribers will prescribe one of three SSRIs (sertraline, fluoxetine or paroxetine). Patients who do not respond to treatment by four months will have their treatment switched to the SNRI (serotonin-norepinephrine reuptake Inhibitor) venlafaxine.
62394742|NCT03089229|PLACEBO_COMPARATOR|Vehicle cream|Vehicle cream will come in a blinded tube. This topical medicated vehicle will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
62569682|NCT06358547|NO_INTERVENTION|Control|Non-PGT-A and fresh blastocyst transfer. In the non-PGT-A group, fresh day 5 single blastocyst transfer and/or FET of day 6 and/or day 7 blastocysts is used. LPS will be administered according to the participating clinics standard practice. All surplus day 5, day 6, or day 7 blastocysts will be vitrified. If there is a risk of OHSS, elective freeze-all will be performed. None of the blastocysts will be PGT-A tested.
62776468|NCT04345094|ACTIVE_COMPARATOR|Intervention|Emulsion containing 2% Hydroquinone
62776469|NCT05697796||patients had pelvic organ prolapse who undergone Sacrospinal ligament fixation|
62776470|NCT05697796||patients had pelvic organ prolapse who undergone Extraperitoneal high sacral ligament suspension|
62776471|NCT03086902|EXPERIMENTAL|Cryo Ablation|PVCs will be mapped and ablated with a Cryo Ablation catheter
62776472|NCT03086902|ACTIVE_COMPARATOR|Radiofrequency Ablation|In this arm PVCs will be mapped and ablated with a Radiofrequency Ablation catheter
62776473|NCT03033199|ACTIVE_COMPARATOR|Probiotic Agent Combining HD-DXM|"probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.~Dexamethasone 40mg per day, 4 consecutive day"
62776474|NCT03033199|ACTIVE_COMPARATOR|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days
62776475|NCT00472966|OTHER|1|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
62776476|NCT01420822||Subjects prescribed ALLERMIST|Subjects with allergic rhinitis prescribed ALLERMIST during study period
62776477|NCT01181674|EXPERIMENTAL|Group 1 (short)|
62394743|NCT03795233|EXPERIMENTAL|Fecal microbiota transplantation|Fecal microbiota transplant G3 capsules will be administered after standard of care with oral vancomycin therapy in participants with primary Clostridium difficile infection.
62394744|NCT03795233|ACTIVE_COMPARATOR|Oral vancomycin alone (Control)|Oral vancomycin therapy will be administered as per standard of care in participants with primary clostridium difficile infection.
62394745|NCT05898633|EXPERIMENTAL|Recombinant fragment of human surfactant protein D (rfhSP-D) administration|"This is a single arm trial with administration of rfhSP-D.~All participants will be administered rfhSP-D via an endotracheal tube in 1-3 doses in the first 24-48hrs after birth whilst the infant is still intubated and ventilated.~A dose escalation design from 1mg/kg to 4mg/kg will be used. Infants are enrolled in cohorts of three, with the first cohort receiving the lowest dose 1mg/kg.~Participants are followed up until they are discharged from hospital."
62569683|NCT04948502|EXPERIMENTAL|SaExten vena cava filter|Manufacturer: ShenZhen KYD BioTech Co., Ltd., China. SaExten vena cava filter system is a retrievable filter system consisting of two parts: the vena cava filter and the delivering system. The vena cava filter is a mesh filtering device that prevents the formation of pulmonary embolism by filtering the thrombus. The SaExten vena cava filter can be inserted through jugular or femoral veins, and can be retrieved through jugular vein within 90 days or indwelled in vena cava permanently.
62776478|NCT01181674|EXPERIMENTAL|Group 2 (long)|
62776479|NCT01181674|OTHER|Standard care|
62791688|NCT01939847|EXPERIMENTAL|Molecular prolfiling in tissue|Participant's tumor will be analyzed by Foundation Medicine on their FoundationOne platform - a targeted whole exome sequencing of 182 cancer related genes (3,230 exons) as well as 37 introns from 14 genes commonly rearranged or altered in cancer via next-generation sequencing technology to provide a molecular profile for a possible treatment suggestion
62000886|NCT02915029|EXPERIMENTAL|Education and Lifestyle Coaching|"Education and life style coaching includes:~education about diabetes and kidney disease Coaching /counseling about lifestyle, nutrition and medication adherence"
62000887|NCT02915029|NO_INTERVENTION|Usual care (UC) control arm|once randomize to the Usual Care control group, the participants are left alone and are suggested to contact their providers for health care. The group gets labs and other survey done at 6 and 12 months of the intervention.
62569684|NCT04948502|ACTIVE_COMPARATOR|Denali inferior vena cava filter|Manufacturer: C. R. BARD, Inc., USA
62569685|NCT00774163|EXPERIMENTAL|1|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
62000888|NCT03397290|EXPERIMENTAL|Ultrasound Imaging|A Single Ultrasound Imaging to diagnose of pneumothorax post transthoracic lung biopsy.
62000889|NCT04275128||Conventional Genicular Ablation|This group is scheduled to receive conventional genicular ablation to treat their chronic knee pain.
62000890|NCT04275128||Cooled radiofrequency Ablation|This group is scheduled to receive cooled radiofrequency ablation to treat their chronic knee pain.
62000891|NCT02567071|EXPERIMENTAL|Intervention Group|75 children born by planned C-section will be exposed to the perineal microbiota of their mothers through perineal impregnated swab.
62394746|NCT06112314|EXPERIMENTAL|Arm A: Brenetafusp Low Dose + Nivolumab|Participants receive brenetafusp Low Dose once weekly (QW) for the first 13 weeks, then every 2 weeks (Q2W) through Week 51, and then every 4 weeks (Q4W). Nivolumab is given Q4W.
62394747|NCT06112314|EXPERIMENTAL|Arm B: Brenetafusp High Dose + Nivolumab|Participants receive brenetafusp High Dose once weekly (QW) for the first 13 weeks, then every 2 weeks (Q2W) through Week 51, and then every 4 weeks (Q4W). Nivolumab is given Q4W.
62394748|NCT06112314|ACTIVE_COMPARATOR|Arm C: Nivolumab OR Nivolumab + Relatlimab|Participants receive nivolumab 480 mg monotherapy, or nivolumab 480 mg + relatlimab 160 mg, Q4W.
62394749|NCT02615158|EXPERIMENTAL|Maternal Physical Activity and Nutrition|A maternal intervention focusing on healthy diet and physical activity patterns for mothers.
62569686|NCT00774163|PLACEBO_COMPARATOR|2|Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
62569687|NCT04699474|EXPERIMENTAL|Early in-bed leg cycling|
62569688|NCT01808599|EXPERIMENTAL|Chlorambucil, Rituximab i.v., Rituximab s.c.|"Chlorambucil 6 mg/m2 daily p.o for 42 consecutive days (weeks 1-6) in combination with intravenous Rituximab 375mg/m2 on days 1, 8, 15 and 22 (day 1 of weeks 1, 2, 3 and 4).~Starting from d56, (month 3) patients will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days (d1-14) every 28 days for 4 cycles in combination with subcutaneous Rituximab 1400mg on day 1 of each 28-day cycle. Therefore subcutaneous Rituximab 1400mg every two months for 2 years (in total 12 injections)."
62569689|NCT05419219|ACTIVE_COMPARATOR|The Multi-domain Tai Chi Digital Therapy Group|participants will be provided via a tablet or smart phone the traditional Tai Chi exercise with background music and respiratory control exercise with 18 BPM metronome, and 40 Hz sound stimulation for 4-week therapeutic session.
62569690|NCT05419219|PLACEBO_COMPARATOR|The regular Tai Chi Exercise Group|participants will be provided by the same way to deliver traditional Tai Chi exercise with plain music background, but without respiratory control exercise or 40 Hz sound stimulation. All participants will receive any other routine care or treatment as usual (TAU).
62569691|NCT00289419|ACTIVE_COMPARATOR|A|
62000892|NCT02567071|PLACEBO_COMPARATOR|Placebo Group|75 children born by planned C-section will be exposed to clean swab.
62000893|NCT02567071|NO_INTERVENTION|Control Group|75 children born vaginally.
62000894|NCT01004367|EXPERIMENTAL|1|Environmental- and individual based components carried out in the school.
62000895|NCT01004367|NO_INTERVENTION|2|No intervention
62000896|NCT01197469|PLACEBO_COMPARATOR|Placebo|Placebo
62000897|NCT01197469|ACTIVE_COMPARATOR|Tadalafil|
62000898|NCT02051049||Inborn errors of liver metabolism|
62569692|NCT00289419|EXPERIMENTAL|B|
62569693|NCT03415932|EXPERIMENTAL|Health education|Assessment of healt care Contacts Before and after intervention
62000899|NCT00694980|EXPERIMENTAL|1|
62000900|NCT02567396|EXPERIMENTAL|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62000901|NCT03431116||Low implanted placenta group|
62000902|NCT01061138||Screening Patients|Female patients scheduled for routine annual screening mammograms
62000903|NCT01061138||Biopsy Patients|Female patients scheduled for routine breast biopsy procedures
62000904|NCT01823874|EXPERIMENTAL|ID virtual reality distraction|virtual reality distraction
62394750|NCT02615158|EXPERIMENTAL|Parenting|A toddler parenting intervention focusing on parenting, limit setting, and development strategies.
62394751|NCT02615158|EXPERIMENTAL|Child Safety|Attention control group. The parents received intervention to promote safety among toddlers.
62394752|NCT01503229|EXPERIMENTAL|Treatment (abiraterone acetate and prednisone)|Patients receive abiraterone acetate orally once daily and prednisone orally twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62186101|NCT04597190|ACTIVE_COMPARATOR|WET Then Switch to SSRI|Integrated behavioral health consultants will deliver WET. Patients who do not respond to treatment by four months will be switched to one of three SSRIs (sertraline, fluoxetine or paroxetine).
62394753|NCT05434741|EXPERIMENTAL|CBT Group|This 12-week intervention program leverages evidence-based traditional and contemporary CBT strategies, with the goal of improving the psychological and physical functioning of older people with HIV by providing education and support to learn strategies to: a.) better manage stressors associated with HIV and aging (e.g., treatment access and engagement, and multi-morbidity), and b.) increase health-promoting behaviors (e.g., physical activity).
62186102|NCT00632385|EXPERIMENTAL|A|
62569694|NCT00818766|ACTIVE_COMPARATOR|Antibiotic|Participants received intravenous (IV) cefazolin or vancomycin (for participants allergic to cephalosporin) immediately following surgery for 48 hours or until all chest tubes were removed, whichever occurred first.
62186103|NCT02316262|EXPERIMENTAL|TR|All subjects enrolled in this study will undergo pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). Gentle traction will be applied to the nerve while excising the neuroma (traction neurectomy) allowing the nerve to retract more proximally.Targeted muscle reinnervation involves transfer of residual nerves to otherwise redundant target muscles. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle.
62186104|NCT01654068|EXPERIMENTAL|Radiation Therapy to Local Spine Metastasis|Conformal High Dose Intensity Modulated Radiation Therapy to a single asymptomatic local spine metastasis.
62186105|NCT03465943|ACTIVE_COMPARATOR|Ringer|This group will receive 1 L of Ringer's solution as a preload
62186106|NCT03465943|ACTIVE_COMPARATOR|Voluven|This group will receive 500 ml of 6% hydroxyethyl starch ( Voluven ) and 500 ml Ringer's solution as a preload
62394754|NCT05434741|EXPERIMENTAL|Information-only Group|"Participants in the control group will receive a one-time trifold brochure titled HIV: 50 Years or Older."
62569695|NCT00818766|PLACEBO_COMPARATOR|Placebo|Participants received IV placebo-matching antibiotics immediately following surgery for 48 hours or until all chest tubes were removed, whichever occurred first.
62186107|NCT01686490|OTHER|D.|The focus is evaluation of LifeSkills Video/Workbook for patients about to receive an AICD. Patients who now have received their AICD were given a video/workbook pre-implantation as an intervention to reduce their concerns/distress. After implantation, they will be asked what was and was not helpful about the materials they received.
62186108|NCT03707847|EXPERIMENTAL|Crizotinib + etoposide capsule+Auto-HSCT|"Crizotinib and etoposide capsule followed by autologous hematopoietic stem cell transplantation.~Crizotinib: 250mg, bis in die （BID）, PO.~Etoposide capsule:50mg, quaque die （QD）, PO, d1-10，21days for one cycle.~Patients will receive the treatment of crizotinib and etoposide capsule, and those who have achieved CR（complete response）or VGPR（very good partial response）will undergo the Auto-HSCT."
62186109|NCT02725567|EXPERIMENTAL|Part A: 3 to <24 months|Participants weighing 5 to less than (\<) 7 kilogram (kg) received 25 milligram (mg) IVA, 7 to \<14 kg received 50 mg IVA, and those weighing 14 to \<25 kg received 75 mg IVA administered every 12 hours (q12h) on Days 1 through 3 and 1 morning dose on Day 4.
62186110|NCT02725567|EXPERIMENTAL|Part B + A/B:1 to < 24 months|Participants 4 to \<6 months of age and weighing greater than or equal to (≥) 5 kg received 25 mg IVA q12h. At 6 months of age and older, participants weighing 5 to \<7 kg received 25 mg IVA, 7 to \<14 kg received 50 mg IVA, and those weighing 14 to \<25 kg received 75 mg IVA q12h for 24 weeks on Part B. For Part A/B, participants 1 to \<4 months weighing 3 kg to \<5 kg received an initial low dose of 5.7 mg q12h IVA and those weighing ≥5 kg received 11.4 mg q12h IVA for the first 15 days of IVA treatment. Doses were maintained or adjusted upward at Day 15 and based on weight and/or age once they reached 4 months of age.
62186111|NCT05006222|ACTIVE_COMPARATOR|ERT group|The participants are enrolled in this group whose get enzyme replacement therapy
62394755|NCT05030220||Phase 1|51 subjects with serum levels of testosterone, free testosterone, and sex hormone binding globulin as well as the SpCuV from the cultures obtained in clinic, immediately pre-operative skin cultures, and incised wound cultures.
62569696|NCT04548193|EXPERIMENTAL|Arm A (Experimental arm)|6-month Cruciferae intervention
62569697|NCT04548193|ACTIVE_COMPARATOR|Arm B (Control arm)|6-month fruit and vegetable intervention based on NCI guidelines for cancer survivors
62569698|NCT04031846|EXPERIMENTAL|V114|Full-term infants received a 0.5 mL intramuscular injection of V114 at approximately 2, 4, and 11-15 months of age (Study Day 1, Month 2, and Month 9-13). Preterm infants received a 0.5 mL intramuscular injection of V114 at approximately 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13). All infants also received intramuscular injection of 0.5 mL Infanrix™ hexa at approximately 2, 3, 4, and 11-15 months of age and 1.5 mL oral dose of Rotarix™ at 2 and 4 months of age.
62776480|NCT05702086|EXPERIMENTAL|"Play now intervention group"|"The sequence of SPARX play differed for the youth depending on whether they were in Group A (play now intervention group) or Group B (play later waitlist group). Both groups completed the pre-intervention surveys at Time 1, the beginning of the study. Group A youth then began to play SPARX for seven weeks while Group B waited. During their wait time of seven weeks, Group B youth were not required to participate in any SPARX activities or meet with the community facilitator during their wait period, and they were provided with no additional SPARX-related information. After seven weeks (Time 2), Group A youth completed post-intervention surveys, while Group B youth began their engagement with SPARX by first completing an additional set of pre-intervention surveys, immediately followed by seven weeks of SPARX play. Once Group B youth completed their SPARX gameplay (Time 3), they completed post-intervention surveys."
62000905|NCT01823874|EXPERIMENTAL|HMD virtual reality distraction|virtual reality distraction
62186112|NCT05006222|NO_INTERVENTION|non-ERT group|The participants are enrolled in this group whose not get enzyme replacement therapy
62394756|NCT05030220||Phase 2|Subjects enrolled to help determine if preoperative serum testosterone levels are associated with risk for shoulder PJI in patients undergoing primary shoulder arthroplasty and if preoperative serum testosterone levels are predictive of bacterial load of deep tissue cultures taken at the time of revision shoulder arthroplasty in patients undergoing primary shoulder arthroplasty.
62394757|NCT02360358|EXPERIMENTAL|autologous cultured skin|autologous cultured skin patches (Tiscover) is applied on wound in 2-step procedure with 1 week interval. Dosage: number of patches depends on wound size. Application week 0 is removed after one week (week1). Week 1: wound is completely covered with new Tiscover patches.
62394758|NCT02360358|ACTIVE_COMPARATOR|acellular donor dermis|"acellular donor dermis (AS210) is applied on wound in 2-step procedure with 1 week interval. Dosage: number of patches depends on wound size.~Application week 0 is removed after one week (week1). Week 1: wound is completely covered with new AS210 patches."
62776481|NCT05702086|ACTIVE_COMPARATOR|"Play later waitlist group"|"The sequence of SPARX play differed for the youth depending on whether they were in Group A (play now intervention group) or Group B (play later waitlist group). Both groups completed the pre-intervention surveys at Time 1, the beginning of the study. Group A youth then began to play SPARX for seven weeks while Group B waited. During their wait time of seven weeks, Group B youth were not required to participate in any SPARX activities or meet with the community facilitator during their wait period, and they were provided with no additional SPARX-related information. After seven weeks (Time 2), Group A youth completed post-intervention surveys, while Group B youth began their engagement with SPARX by first completing an additional set of pre-intervention surveys, immediately followed by seven weeks of SPARX play. Once Group B youth completed their SPARX gameplay (Time 3), they completed post-intervention surveys."
62776482|NCT05293678|EXPERIMENTAL|Lower IV Dose|Randomized 3:1
62000906|NCT03247439|EXPERIMENTAL|Cartiva|Synthetic Cartilage Implant
62776483|NCT05293678|EXPERIMENTAL|Mid IV Dose 1|Randomized 3:1
62776484|NCT05293678|EXPERIMENTAL|Mid IV Dose 2|Randomized 3:1
62776485|NCT05293678|EXPERIMENTAL|Higher IV Dose|Randomized 3:1
62776486|NCT05293678|EXPERIMENTAL|Lower SC Dose|Randomized 3:1
62776487|NCT05293678|EXPERIMENTAL|Mid SC Dose|Randomized 3:1
62776488|NCT05293678|EXPERIMENTAL|Higher SC Dose|Randomized 3:1
62000907|NCT03151759||No radiotherapy|Surgery only
62000908|NCT03151759||25 Gray radiotherapy|Surgery after short term radiotherapy
62000909|NCT03151759||50 Gray radiotherapy|Surgery after long term radiotherapy
62186113|NCT05972304|EXPERIMENTAL|Intervention Group|Patients undergoing endoscopic procedures receiving oxygen supplementation through nasal positive airway pressure system ( 10 litters/minute).
62776489|NCT01816802||In-vitro fertilization using Eeva|Patients undergoing in-vitro fertilization treatment who provide informed consent and use Eeva in their treatment cycle.
62776490|NCT03256253|EXPERIMENTAL|pregabalin|pregabalin up to daily dose of 600 mg
62000910|NCT04185168|ACTIVE_COMPARATOR|isoflavone|100 mg soy isoflavone (as 2 tablets)
62186114|NCT05972304|NO_INTERVENTION|Control Group|Patients undergoing endoscopic procedures receiving conventional oxygen supplementation through nasal cannula (6 litters/minute).
62000911|NCT04185168|PLACEBO_COMPARATOR|control|2 tablets of placebo
62000912|NCT02829749|EXPERIMENTAL|NeoChord DS1000 Artificial Chordae Delivery System|Subjects randomized to the experimental group will undergo the NeoChord implantation
62000913|NCT02829749|OTHER|Control|traditional mitral valve repair performed under cardiac arrest
62000914|NCT06290856||Advanced gastrointestinal malignancy|Pancreatic cancer, Colorectal cancer, Cholangiocarcinoma
62000915|NCT06130722|EXPERIMENTAL|A Single Arm|
62000916|NCT05749081|EXPERIMENTAL|Lacidophilin tablets group|2400mg lacidophilin tablets three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
62000917|NCT05749081|PLACEBO_COMPARATOR|Placebo group|2400mg placebo three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
62186115|NCT03578588|EXPERIMENTAL|Banapenem B1 group|Dose in the 1st period 250mg; Dose in the 2nd period 500mg; Dose in the 3rd period 1000mg
62394759|NCT05221840|EXPERIMENTAL|Arm A: Durvalumab and Oleclumab|Durvalumab on Day 1 of each 28-day cycle + Oleclumab on Days 1 and 15 of cycles 1 and 2, then on Day 1 of each subsequent 28-day cycle for up to 12 months
62776491|NCT03194360||delirium group|
62776492|NCT03194360||nondelirium group|
62776493|NCT02093338|EXPERIMENTAL|fermentum 3x|Lactobacillus fermentum CECT5716 at 3x10e9 cfu/day
62776494|NCT02093338|EXPERIMENTAL|fermentum 6x|Lactobacillus fermentum CECT5716 at 6x10e9cfu/day
62776495|NCT02093338|EXPERIMENTAL|fermentum 9x|Lactobacillus fermentum CECT5716 at 9x10e9cfu/day
62776496|NCT02093338|PLACEBO_COMPARATOR|maltodextrin|maltodextrin
62776497|NCT00450073|ACTIVE_COMPARATOR|Vitamin D3|Vitamin D3=cholecalciferol 50,000 IU weekly
62776498|NCT00450073|ACTIVE_COMPARATOR|vitamin D2|The intervention is an oral tablet of vitamin D2 (ergocaliferol 50,000 IU weekly) for 12 weeks.
62776499|NCT00450073|ACTIVE_COMPARATOR|Sunlamp|The intervention is the use of a Sunlamp (Sperti) to the skin 5 times a week for 12 weeks
62000918|NCT02686346|EXPERIMENTAL|BV-ICE|"Phase I:~4 cycles of treatment, every 21 days: Brentuximab Vedotin (BV) + Etoposide- Carboplatine - Ifosfamide (ICE) = BV-ICE for cycles 1 to 3 and BV alone at cycle 4;~Phase II:~4 cycles of treatment, every 21 days: BV-ICE for cycles 1 to 3, BV alone at cycle 4"
62000919|NCT01156285||AAU|patient with acute attack of anterior uveitis
62000920|NCT03940365|EXPERIMENTAL|Study Group|As detailed above, a single group will be used for the study to compare the output of the study device with the output of the standard device in each patient.
62000921|NCT04074317|EXPERIMENTAL|PRAM9 to Regular Insulin to Regular Insulin+pramlintide|Xeris pramlintide + insulin co-formulation (PRAM9) to Regular Insulin (Humulin®) to Regular Insulin+pramlintide (Symlin® pen) as separate SC injections
62776500|NCT04806802|EXPERIMENTAL|APIOC Sphere or Astigmatism|Single Vision Spherical or Toric Contact Lens
62569699|NCT04031846|ACTIVE_COMPARATOR|Prevenar 13™|Full-term infants received a 0.5 mL intramuscular injection of Prevenar 13™ at approximately 2, 4, and 11-15 months of age (Study Day 1, Month 2, and Month 9-13). Preterm infants received a 0.5 mL intramuscular injection of Prevenar 13™ at approximately 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13). All infants also received intramuscular injection of 0.5 mL Infanrix™ hexa at approximately 2, 3, 4, and 11-15 months of age and 1.5 mL oral dose of Rotarix™ at 2 and 4 months of age.
62776501|NCT01075737||Subjects with Multiple Sclerosis|Subjects with diagnosed MS according to the revised Mc Donald criteria 2005; aged \>21 years.
62394760|NCT05221840|EXPERIMENTAL|Arm B: Durvalumab and Monalizumab|Durvalumab + Monalizumab on Day 1 of each 28-day cycle for up to 12 months. Placebo infusion will be administered on Day 15 of cycles 1 and 2 only
62776502|NCT01075737||Caregivers|Caregivers (aged \>21 years) for MS subjects.
62776503|NCT00541853|ACTIVE_COMPARATOR|A|ADPKD patients with blood pressure above 130/85 are enrolled. The patients whose blood pressure is controlled under 130/85 by Candesartan alone are classified into group A.
62776504|NCT00541853|EXPERIMENTAL|B|The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group B, blood pressure is controlled by Candesartan plus Cilnidipine. If blood pressure is not lowered by Candesartan plus Cilnidipine alone, another antihypertensive agents except CCB and ACEI are allowable.
62776505|NCT00541853|ACTIVE_COMPARATOR|C|The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group C, blood pressure is controlled by Candesartan plus non-CCB agents such as beta- or alpha- adrenergic blockers or another ARB. Any CCB and ACEI are not allowable.
62569700|NCT03051100|EXPERIMENTAL|Triplet Therapy|Bempedoic acid 180 mg, ezetimibe 10 mg, and atorvastatin 20 mg taken orally, daily.
62569701|NCT03051100|PLACEBO_COMPARATOR|placebo|Matching placebos taken orally, daily.
62569702|NCT02110212|ACTIVE_COMPARATOR|U/S Surgery and CCC|Ultrasound (U/S) cataract surgery and continuous curvilinear capsulorhexis (CCC).
62569703|NCT02110212|EXPERIMENTAL|FS Laser Surgery|For femtosecond laser-assisted cataract surgery (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the femtosecond laser device.
62569704|NCT05094271|ACTIVE_COMPARATOR|Supplemental Oxygen during PSG|Subjects will be instrumented with a nasal cannula to receive 2L/min supplemental oxygen. The oxygen will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats \>90% based on oximetry readings.
62569705|NCT05094271|PLACEBO_COMPARATOR|Room Air during PSG|Subjects will be instrumented with a nasal cannula to receive 2L/min of pressurized room air. The room air will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats \>90% based on oximetry readings.
62186116|NCT03578588|EXPERIMENTAL|Banapenem B2group|Dose in the 1st period 500mg; Dose in the 2nd period 1000mg; Dose in the 3rd period 250mg
62186117|NCT03578588|EXPERIMENTAL|Banapenem B3group|Dose in the 1st period 1000mg; Dose in the 2nd period 250mg; Dose in the 3rd period 500mg
62186118|NCT03578588|EXPERIMENTAL|Banapenem C1group|250mg Once daily for 7 consecutive days
62186119|NCT03578588|EXPERIMENTAL|Banapenem C2group|500mg Once daily for 7 consecutive days
62186120|NCT05632380|EXPERIMENTAL|ASCT and C-CAR088|Patients will undergo ASCT followed by C-CAR088 single dose infusion.
62186121|NCT03020069|EXPERIMENTAL|Glucose Meter|Continuing Glucose Monitoring Device
62186122|NCT03020069|ACTIVE_COMPARATOR|No Glucose Meter|Average Blood glucose measure
62569706|NCT05094271|EXPERIMENTAL|Supplemental Oxygen for 3 Months|Over a 12-week period, participants randomized to receive supplemental Oxygen for treatment of OSA will be contacted weekly to be asked about their adherence. Participants' adherence will also be monitored remotely through cloud-based monitoring.
62569707|NCT05094271|EXPERIMENTAL|PAP Therapy for 3 Months|Over a 12-week period, participants randomized to receive supplemental PAP therapy for treatment of OSA will be contacted weekly to be asked about their adherence. Participants' adherence will also be monitored remotely through cloud-based monitoring.
62569708|NCT00857987|EXPERIMENTAL|1|Guaifenesin, doxylamine succinate and hydrochloride etafedrine syrup
62569709|NCT00857987|PLACEBO_COMPARATOR|2|Vehicle
62569710|NCT06530550|EXPERIMENTAL|PI3K inhibitor|Linperlisib 80mg QD orally, or Duvelisib 25mg BID orally
62776506|NCT02349750|ACTIVE_COMPARATOR|endometrial scratch injury|Patients received 100 mg of oral clomiphene citrate for five days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of hMG and when more than two dominant follicles reached a diameter of 17 mm 5,000 IU of hCG was injected intramuscularly. Group S had ESI using No.8 neonatal feeding tube and after 24 to 36 hours, IUI was performed.
62776507|NCT02349750|NO_INTERVENTION|Non endometrial scratch injury|Patients received 100 mg of oral clomiphene citrate for five days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of hMG and when more than two dominant follicles reached a diameter of 17 mm 5,000 IU of hCG was injected intramuscularly. Group C received IUI without ESI and after 24 to 36 hours, IUI was performed.
62776508|NCT02795091|OTHER|Manual clean|clean the rag and floor towel manually
62394761|NCT05221840|ACTIVE_COMPARATOR|Arm C: Durvalumab and Placebo|Durvalumab on Day 1 of each 28-day cycle + Placebo on Days 1 and 15 of cycles 1 and 2, then on Day 1 of each subsequent 28-day cycle for up to 12 months
62394762|NCT04835142|EXPERIMENTAL|Double blind control period|"experiment arm： All eligible subjects will receive A140 in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks.~control arm: All eligible subjects will receive Erbitux in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks."
62776509|NCT02795091|OTHER|machine clean|clean the rag and floor towel by machine
62776510|NCT04424927|EXPERIMENTAL|PRV-015 Low Dose|PRV-015 Low Dose, sterile solution for subcutaneous administration
62776511|NCT04424927|EXPERIMENTAL|PRV-015 Medium Dose|PRV-015 Medium Dose, sterile solution for subcutaneous administration
62776512|NCT04424927|EXPERIMENTAL|PRV-015 High Dose|PRV-015 High Dose, sterile solution for subcutaneous administration
62776513|NCT04424927|PLACEBO_COMPARATOR|Placebo|Placebo, sterile solution for subcutaneous administration
62776514|NCT00304863|NO_INTERVENTION|Arm 1|This are will not receive Lactobacillus
62776515|NCT00304863|EXPERIMENTAL|Arm 2|This arm will receive lactobacillus
62776516|NCT05686642|EXPERIMENTAL|LT3001 Drug:high dose|
62776517|NCT05686642|PLACEBO_COMPARATOR|Placebo|
62776518|NCT05686642|EXPERIMENTAL|LT3001 Drug:low dose|
62776519|NCT06220019||TCM Group|"The study will include adult patients discharged after hospitalization for pneumonia, with no restrictions on TCM syndromes. Patients diagnosed with pneumonia via laboratory or imaging tests at admission and treated in the hospital will be eligible if enrolled within seven days of discharge. Follow-ups will occur every three months over one year, documenting treatment methods (TCM or Western medicine), hospitalizations, respiratory infections, mortality, and quality of life.~Subgroup analyses will be conducted based on age, type of pneumonia (community- or hospital-acquired), specific TCM treatments (e.g., Chinese patent medicines or external therapies), and treatment duration."
62776520|NCT06220019||Non-TCM Group|All patients who do not meet the defined criteria for the TCM group will be classified into the non-TCM group.
62776521|NCT03057080|OTHER|PTA procedure|Percutaneous transluminal angioplasty (PTA) in patients with ischemic leg ulcer
62776522|NCT02800265|EXPERIMENTAL|Avmacol during week 2 for 3 days|"Buccal cells line the inner cheek, and will be collected from the inner right cheek with a cytobrush (a q-tip like swab) by a trained investigator.~During the second week the participant will take 8 Avmacol tablets every evening for 3 evenings (Day 2, 3, 4), and record the time of each dose in the provided diary. Research blood collection: on days 1 and 5. Overnight urine collection."
62776523|NCT04409093|EXPERIMENTAL|Nail bed repair with eponychial sent|
62776524|NCT04409093|ACTIVE_COMPARATOR|Nail bed repair without eponychial stent|
62776525|NCT03341455|OTHER|Intervention preschools|"Capacity building to support families affected by IPV \& substance misuse will be provided to the intervention preschools.~Specifically, capacity building, training and support will be provided to~* selected mothers on the provision of safe, confidential and relevant community-based referral and support services for women affected by IPV.~* selected fathers on the provision of safe, confidential and relevant community-based referral and support to men seeking support for substance misuse problems.~* intervention preschool teachers on provision of IPV and substance misuse prevention educational messages and referral pathways to services for these issues."
62394763|NCT04835142|EXPERIMENTAL|Open single period|All eligible subjects will receive A140 in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks.
62776526|NCT03341455|NO_INTERVENTION|Control preschool|No intervention or training will not be provided to the control group in order to assess the impact of the intervention between the control and intervention arms of the study.
62776527|NCT01635803|ACTIVE_COMPARATOR|Ranibizumab|Monthly injections with ranibizumab during 6 months
62776528|NCT01635803|ACTIVE_COMPARATOR|Bevacizumab|Monthly injections with bevacizumab during 6 months
62776529|NCT06508229|EXPERIMENTAL|Immuno-chemotherapy for locally advanced ESCC|Adebrelimab + albumin paclitaxel + nedaplatin
62776530|NCT02825212|EXPERIMENTAL|Participant with Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia|"Participants treated with either Harvoni or Epclusa~* Harvoni 90mg/400 mg FDC once daily. Subjects will take 1 tablet daily with or without food.~* Epclusa 400mg/100mg 400mg/100mg FDC once daily"
62734590|NCT01911650|EXPERIMENTAL|Autologous Platlet Rich Plasma|This subject arm will receive one injection of autologous platelet rich plasma for the treatment of Achilles tendinopathy. In addition, they will be asked to undergo a palpatory exam of the Achilles tendon; complete Quality of Life Questionnaires at three different time points; and complete a 30 minute ultrasound imaging exam of the Achilles tendon.
62394764|NCT04591782|EXPERIMENTAL|PomJuice (PJ)|8 oz of PJ
62394765|NCT04591782|ACTIVE_COMPARATOR|Sugar Water|8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved into it
62776531|NCT02562807|ACTIVE_COMPARATOR|Treatment A|TAS-303 18mg single-dose and then Placebo single-dose.
62776532|NCT02562807|PLACEBO_COMPARATOR|Treatment B|Placebo single-dose and then TAS-303 18mg single-dose.
62776533|NCT02562807|ACTIVE_COMPARATOR|Treatment C|TAS-303 9mg single-dose and then Placebo single-dose.
62394766|NCT04591782|OTHER|Water|8 oz of water
62394767|NCT02911311|EXPERIMENTAL|IVC group|intravitreal injection of conbercept (IVC) group：all study eyes randomised to receive conbercept will receive an intravitreal injection of conbercept 2 mg/ 0.05 mL at baseline and at 1 and 2 moths. Further treatment since months 3 is determined by the degree of regression of neovascularization (NV) of disc and elsewhere on clinical examination
62394768|NCT02911311|ACTIVE_COMPARATOR|PRP group|panretinal photocoagulation (PRP) group:all study eyes randomised to receive PRP will receive an fill-in PRP in 1-2 two weekly sessions as per routine clinical practice with emphasis on targeting retinal nonperfusion areas
62776534|NCT02562807|PLACEBO_COMPARATOR|Treatment D|TAS-303 Placebo single-dose and then TAS-303 9mg single-dose.
62776535|NCT03706300|EXPERIMENTAL|Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets|Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets 1200/120 mg of Dr. Reddy's Laboratories Limited
62776536|NCT03706300|ACTIVE_COMPARATOR|Mucinex D|Mucinex D extended-release bi-layer tablets 1200/120 mg of Reckitt Benckiser Inc., USA
62776537|NCT00737633|EXPERIMENTAL|16-Week population|Placebo subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)
62776538|NCT00737633|EXPERIMENTAL|72-Week population|Active treatment subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)
62776539|NCT05652153|OTHER|Longitudinal Assessments|Participants in both groups (Dep/SI and Dep/SB) will undergo identical assessments at baseline, 6 months, and 12 months. Assessments will include clinical interviews and rating scales, questionnaires (including a self-report scale of negative urgency), and single-/paired-pulse transcranial magnetic stimulation (sp/ppTMS) measurement of cortical inhibition.
62776540|NCT05648565|EXPERIMENTAL|Radiofrequency ablation (RFA)|
62569711|NCT00684411|EXPERIMENTAL|Imatinib mesylate|The initial starting dose of imatinib mesylate was 400 mg by mouth once daily but intra-patient dose escalation for patients who did not achieve complete response (CR) was built in upon restaging at weeks 8 and 16. At week 8, patients with partial response (PR) or stable disease (SD) were dose escalated to 600 mg. At week 16, if these patients continued in PR or SD, dose escalated to 800 mg and for patients on 400 mg dose escalated to 600 mg. Patients who experienced disease progression could be dose escalated per MD discretion. Patients were treated as long as receiving clinical benefit and no unacceptable toxicity.
62569712|NCT04737629|EXPERIMENTAL|Expectancy and Water Condition|
62000922|NCT04074317|EXPERIMENTAL|Regular Insulin to Regular Insulin+pramlintide to PRAM9|Regular Insulin (Humulin®) to Regular Insulin+pamlintide (Symlin® pen) as separate SC injections to PRAM9
62569713|NCT04737629|EXPERIMENTAL|No Expectancy and Water Condition|
62776541|NCT02193412|EXPERIMENTAL|patients|"1. noxious stimulus~2. change in operating table slope: head-down tilt position~3. change in operating table slope: head-up tilt position"
62776542|NCT02816229|EXPERIMENTAL|Insertion of endobronchial valve|Patients in this group will have one or more EBV inserted into the relevant lung regions to manage the haemoptysis via flexible bronchoscopy.
62776543|NCT02816229|NO_INTERVENTION|Best care|Patients will receive best medical care.
62000923|NCT04074317|EXPERIMENTAL|Regular Insulin+pramlintide to PRAM9 to Regular Insulin|Regular Insulin (Humulin®)+pramlintide (Symlin® pen) as separate SC injections to Xeris pramlintide + insulin co-formulation (PRAM9) to Regular Insulin
62776544|NCT04456374||Under-12 (U12) players|
62000924|NCT04074317|EXPERIMENTAL|PRAM9 to Regular Insulin+pramlintide to Regular Insulin|Xeris pramlintide + insulin co-formulation (PRAM9) to Regular Insulin (Humulin®)+pramlintide (Symlin® pen) as separate SC injections to Regular Insulin
62394769|NCT01824368|EXPERIMENTAL|People with liver transplantation|People with liver transplantation over 2 years following treatment with immunosuppression including cyclosporine or tacrolimus.
62776545|NCT04456374||Under-14 (U14) players|
62569714|NCT04737629|EXPERIMENTAL|No Water Condition|
62776546|NCT04456374||Under-16 (U16) players|
62776547|NCT04456374||Under-18 (U18) players|
62776548|NCT04708509|EXPERIMENTAL|Intervention Arm|Wave form data from participants' spontaneous breathing trials (SBT) will be analyzed using Extubation Advisor (EA) to generate an EA report that provides clinical decision support regarding extubation.
62000925|NCT04074317|EXPERIMENTAL|Regular Insulin to PRAM9 to Regular Insulin+pramlintide|Regular Insulin (Humulin®) to Xeris pramlintide + insulin co-formulation (PRAM9) to Regular Insulin+pramlintide (Symlin® pen) as separate SC injections to Regular Insulin
62569715|NCT03508219|EXPERIMENTAL|BiOSS LIM C|The treatment strategy consists of contemporary PCI of the left-main bifurcation, using the BiOSS LIM C stent system, following diagnostic angiography demonstrating significant distal unprotected left main disease and local Heart Team discussion applying the anatomic SYNTAX Score.
62569716|NCT03478566|EXPERIMENTAL|Transcutaneous CO2 monitoring|
62000926|NCT04074317|EXPERIMENTAL|Regular Insulin+pramlintide to Regular Insulin to PRAM9|Regular Insulin (Humulin®)+pramlintide (Symlin® pen) as separate SC injections to Xeris pramlintide + insulin co-formulation (PRAM9) to Regular Insulin to Xeris pramlintide + insulin co-formulation (PRAM9)
62569717|NCT05663073|EXPERIMENTAL|Irbesartan/Amlodipine Fixed dose combination|participants will receive one tablet of Irbesartan/Amlodipine FDC in a crossover design
62569718|NCT05663073|EXPERIMENTAL|Co-administration of Irbesartan and Amlodipine|participants will receive one table each of Irbesartan and Amlodipine in a crossover design
62000927|NCT04385602|PLACEBO_COMPARATOR|CON group|placebo
62000928|NCT04385602|ACTIVE_COMPARATOR|DT group|Intratracheal dexmedetomidine
62000929|NCT04089540|EXPERIMENTAL|Study group: New intubation method|In the new intubation method the respirator is connected to the tube prior to insertion into the mouth (oral intubation) or into the nose (nasopharyngeal intubation). Therefore an oxygen flow is already administered via the tube during the intubation process.
62569719|NCT04860973|EXPERIMENTAL|Weighted blankets|Provided with weighted blanket suitable for participant's weight
62569720|NCT04860973|NO_INTERVENTION|Standard linen|Use of standard hospital linen
62569721|NCT05110417|EXPERIMENTAL|Pyridostigmine (Mestinon)|Pyridostigmine (Mestinon) will be assigned to patients in this arm.
62569722|NCT01707966|EXPERIMENTAL|Orteronel and best supportive care|Arm A: 300mg Orteronel twice daily and best supportive care until occurrence of an event.
62569723|NCT01707966|PLACEBO_COMPARATOR|Placebo and best supportive care|Arm B: Placebo twice daily and best supportive care until occurrence of an event.
62569724|NCT06045676||Drug Resistant Epilepsy|Seizures Not Respond to two lines of Anti epileptic Medications
62776549|NCT04836247|EXPERIMENTAL|Disclosure Intervention Arm|Participants will be guided through a workbook and accompanying worksheet designed to help them: (1) decide whether or not they want to share information about their substance use with others, and (2) build skills for disclosing (e.g., planning what to say). Importantly, the intervention is not designed to encourage participants to disclose or not disclose, but rather to help participants decide whether they want to disclose based on their own goals and values.
62776550|NCT04836247|ACTIVE_COMPARATOR|Control Arm|Participants will be able to choose from several guided meditations to promote mindfulness.
62569725|NCT06045676||Drug Responsive Epilepsy|Seizures Respond to one or two lines of Anti epileptic Medications
62569726|NCT06045676||Febrile Seizures|type of seizure occurring due to fever over 38 °C without a history of convulsion
62569727|NCT06045676||Breath Holding Spells|children's behaviors look like epileptic seizures due to crying up to a minute followed by losing consciousness
62569728|NCT06045676||Control|Healthy Children free from any convulsion
62776551|NCT05049187||Group 1 COVISHIELD|Participants will receive one dose of COVID-19 vaccine (Covishield) at baseline and one second dose after 28 days (Window period of +3 days) intra muscularly.
62776552|NCT05049187||Group 2 COVAXIN|Participants will receive one dose of COVID-19 vaccine (Covaxin) at baseline and one second dose after 28 days (Window period of +3 days) intra muscularly.
62776553|NCT01854424||ARDS|Ventilated patients with ARDS criteria (Berlin criteria) will be recruited in 3 ICU (2 from Bichat Hospital and 1 from Tenon Hospital, Paris) during the first 48 hours of their evolution. The patients will considered in 2 groups during analysis by taking into account their vital status at day-28 of inclusion.
62186123|NCT03666806|EXPERIMENTAL|Influenza vaccine|Influenza vaccine: An inactivated influenza vaccine (split virion) shall be used during the study. The product information is attached as an appendix to the proposal. Brief description of the type of influenza vaccine to be used for the study, mechanism of action, dose justification, efficacy, safety and its use in the population.
62186124|NCT03666806|PLACEBO_COMPARATOR|Normal saline|Placebo: Placebo will be normal saline which shall be prepared by the pharmacist for injection by the immunization nurse in a similar syringe as the investigational product.
62186125|NCT02629198||normal weight|Healthy men and women ages 25-40 and 55-75. BMI 18.5 to 25.0
62186126|NCT02629198||overweight|Healthy men and women ages 25-40 and 55-75. BMI 25.0 to 30.0
62186127|NCT02629198||obese|Healthy men and women ages 25-40 and 55-75. BMI over 30
62186128|NCT01184534||Questionnaires + Video|
62186129|NCT01184534||Questionnaires|
62186130|NCT04745936|EXPERIMENTAL|C-curve group (group C)|In group C, stylet curvature is made similar to the natural curvature of endotracheal tube.
62776554|NCT03544307|EXPERIMENTAL|Taekwondo Training|Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks.
62186131|NCT04745936|ACTIVE_COMPARATOR|Hockey stick curve group (group H)|In group H, stylet curvature is made similar to hockey stick shape.
62569729|NCT04934813|EXPERIMENTAL|Alveolar ridge preservation with particulated allograft covered with collagen sponge.|Alveolar ridge preservation after tooth extraction. Freeze-dried bone allograft (FDBA) was applied in the socket immediatelly after tooth extraction and it was covered with collagen sponge (CS).
62000930|NCT04089540|OTHER|Control group: Conventional intubation|In the control group the respirator is connected to the tube and ventilation is started after the insertion of the tube into the trachea. Therefore there is no oxygen flow administered during the intubation process.
62000931|NCT01069289|EXPERIMENTAL|1|Symbicort Turbuhaler 160/4.5 microgram, 2 inhalations twice daily
62186132|NCT02454049|ACTIVE_COMPARATOR|beetroot juice|beetroot juice containing 6mmol nitrate, ingested 3hours before the exercise test
62186133|NCT02454049|ACTIVE_COMPARATOR|sodium nitrate|6mmol sodium nitrate dissolved in plain water, ingested 3hours before the exercise test
62186134|NCT02454049|PLACEBO_COMPARATOR|water|85ml of plain water, ingested 3 hours before the exercise test
62186135|NCT02572635|EXPERIMENTAL|Cohort 1|50 µg of PnuBioVax
62186136|NCT02572635|EXPERIMENTAL|Cohort 2|200 µg of PnuBioVax
62186137|NCT02572635|EXPERIMENTAL|Cohort 3|500 µg of PnuBioVax
62186138|NCT02572635|PLACEBO_COMPARATOR|Placebo|Placebo
62186139|NCT05283356|ACTIVE_COMPARATOR|Acetylsalicylic acid 100mg/day|Aspirin 100 mg/day after TAVI
62186140|NCT05283356|EXPERIMENTAL|Ticagrelor 60mg twice per day|Ticagrelor 60 mg twice per day after TAVI
62214633|NCT05832697|ACTIVE_COMPARATOR|Treatment A|P1: DWJ1439(ursodeoxycholic acid) 100mg, P2: DWC202108(usrodeoxycholic acid) 250mg, P3: DWJ1464(ursodeoxycholic acid) 100mg
62776555|NCT03544307|NO_INTERVENTION|Control|Sedentary control asked not to exercise
62776556|NCT04680819||Compared with given anatolian propolis group and do not use anatolian propolis group|According to the spectrophotometic analysis report of this anatolian group, there should be a minimum phenolic 106.0 mg gae per ml and 73.1 mg ke flavonoid content in each ml and a total content of 253.9 mg te / ml.
62776557|NCT00094107|EXPERIMENTAL|Axitinib [AG-013736]|
62776558|NCT05265897|NO_INTERVENTION|Usual Care|Brief form letter with lung cancer screening results
62776559|NCT05265897|EXPERIMENTAL|CAQ|"Usual care, plus Commonly Asked Questions after Lung Cancer Screening informational document (CAQ)"
62776560|NCT01868334|EXPERIMENTAL|Intervention with the Toolkit|"Pillar 1: Convenient Vaccination Services Pillar 2: Patient notification Pillar 3: Enhanced Office Systems Pillar 4: Motivation~13 clinical practices (intervention sites) will receive the Toolkit in Year 1 to increase their adult influenza, PPSV, Tdap/Td vaccination rates. In Year 2, those who choose to continue will maintain use of the Toolkit and online resources available but will receive no active intervention from study staff."
62776561|NCT01868334|NO_INTERVENTION|12 clinical practices (control sites)|12 diverse clinical practices will receive no additional assistance in Year 1 to increase their adult influenza, PPSV, Tdap/Td vaccination rates, they will follow guidelines for usual care. In Year 2 however they will become intervention sites and receive the 4 Pillars Toolkit for use in increasing vaccination rates
62776562|NCT02554526||Combination therapy|Effects of aPCC reaction in the presence of FVIII
62776563|NCT01099436|EXPERIMENTAL|TAC + Zoledronic acid|six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC) and zoledronic acid (Zometa)
62776564|NCT01099436|ACTIVE_COMPARATOR|TAC|six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC)
62569730|NCT04934813|EXPERIMENTAL|Alveolar ridge preservation with particulated allograft covered with autogenous soft tissue punch|Alveolar ridge preservation after tooth extraction. Freeze-dried bone allograft (FDBA) was applied in the socket immediatelly after tooth extraction and it was covered with free gingival graft (FGG).
62569731|NCT04934813|EXPERIMENTAL|Alveolar ridge preservation with particulated xenograft covered with autogenous soft tissue punch|Alveolar ridge preservation after tooth extraction. Demineralized bovine bone mineral xenograft (DBBM) was applied in the socket immediatelly after tooth extraction and it was covered with free gingival graft (FGG).
62569732|NCT04934813|EXPERIMENTAL|Alveolar ridge preservation without bone grafting covered with socket sealing mean|Alveolar ridge preservation after tooth extraction. No bone graft was applied and the socket was covered with free gingival graft (FGG).
62569733|NCT04816617|EXPERIMENTAL|Aerobic Exercise|The whole exercise lasts for 12 months, consisted of 6-month supervised exercise and 6-month maintenance period. It is moderate -intensity exercise (60-80% Maximum heart rate), each time last for 30 mins (plus 10-minutes for warm-up and cool-down), 3-4 times a week, for the first six months, which will be supervised in person by physical educators and/or physical professionals. In the maintenance period, participants are asked to exercise at the same intensity and frequency, but will not be supervised in person by physical educators/professionals. They will receive reminder on a weekly basis and their physical activities be recorded by accelerometer. Types of exercise will be chosen according to individual school's facility and feasibility, including jogging, fast walking, badminton, running, football etc.
62776565|NCT05207683||patients with pulmonary hypertension|patients who are more than 18 years old , diagnosed with pulmonary hypertension by echocardiography
62394770|NCT04585191|EXPERIMENTAL|Pre-Visit Conversation Aid|"Patients in the intervention arm will receive a newly developed, 1-page conversation aid/communication tool entitled Talking to Your Doctor about Diabetes: Are My Current Medicines Still Right for Me? prior to a scheduled appointment with their PCP. This document will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps."
62569734|NCT04816617|PLACEBO_COMPARATOR|Psycho-education|It consists of 6 sections of psycho-education, with topics covering mood regulations and mental well-being. Approximately 1 section in every two months.
62000932|NCT01069289|ACTIVE_COMPARATOR|2|Oxis Turbuhaler 4.5 microgram, 2 inhalations twice daily
62569735|NCT00618592|EXPERIMENTAL|CHO|
62569736|NCT00618592|NO_INTERVENTION|FAST|
62569737|NCT03604133||Patients receiving ICD devices|
62569738|NCT02576080|ACTIVE_COMPARATOR|Standard Group|The Standard Group will receive adjuvant imatinib at a dose of 400 mg per day for a period of 3 years. Patients will be assessed for metastases every three months for three years with thoraco-abdominal and pelvic CT scan.
62569739|NCT02576080|OTHER|Experimental Group|The Experimental Group will receive the same thoraco-abdominal and pelvic CT scan. Surveillance
62569740|NCT05884736||DCC Donors|Standard criteria DCC donors will be undergoing the A-NRP perfusion process to recondition organs prior to procurement. Multimodal neuromonitors will be placed on the donor prior to withdrawal of life support and readings will be recorded during the withdrawal process and for the duration of the A-NRP perfusion process. The neuromonitoring team will be looking for evidence of brain blood flow or activity.
62569741|NCT05186805|EXPERIMENTAL|tapinarof cream|Tapinarof (DMVT-505) cream, 1% applied topically once daily
62569742|NCT04988932|EXPERIMENTAL|Administration of iNO in SAH patients with severe vasospasm|iNO is started at a dose of 1 parts per million (ppm) and increased stepwise to 2 ppm, 5 ppm, 12 ppm, 25 ppm, until a maximum dose of 40 ppm is reached.
62569743|NCT05302531|EXPERIMENTAL|Amoxicillin|Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.
62569744|NCT05302531|EXPERIMENTAL|Ofloxacin|Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.
62776566|NCT03076723|SHAM_COMPARATOR|Fixed opening pressure|The shunt opening pressure is changed to the same setting as at surgery.
62000933|NCT00448422|EXPERIMENTAL|1|Tablet
62000934|NCT00448422|PLACEBO_COMPARATOR|2|Tablet
62000935|NCT00419562|EXPERIMENTAL|Oral Insulin|7.5 mg oral insulin capsules given before breakfast on a daily basis.
62000936|NCT00419562|PLACEBO_COMPARATOR|Placebo|Placebo capsule designed to match appearance of treatment capsule
62000937|NCT00846924|ACTIVE_COMPARATOR|repeat 24-hour Holter monitor|
62000938|NCT00846924|EXPERIMENTAL|30-day ambulatory cardiac event monitor|
62000939|NCT01013233|EXPERIMENTAL|training|Patients in this group start the cognitive training over 6 weeks directly after randomization.
62186141|NCT01017263|ACTIVE_COMPARATOR|Open label Vyvanse|Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
62394771|NCT04585191|ACTIVE_COMPARATOR|General Health Education Handout|"Patients in the attention control arm will receive an existing 1-page health education handout entitled Embracing Life as You Age which provides some general advice geared towards older patients such as remaining physically active, limiting sun exposure, and eating well."
62394772|NCT06524856|EXPERIMENTAL|Lung Function in Young and Older Adults|Lung functions will be assess for two groups: young and older adults. The age range of 19 to 35 is categorized as young adulthood. This age range was selected because the lungs mature around 19-25 years old. The age range above 65 is designated as late adulthood, where lung function gradually declines.
62776567|NCT03076723|EXPERIMENTAL|Individual shunt opening pressure|The shunt opening pressure is adjusted (up one step, down one step or unchanged) according to an individual analysis of the pulsatility curve (as assessed after shunt surgery).
62776568|NCT00025246|EXPERIMENTAL|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate daily beginning within 84 days of surgical resection. Treatment continues for 1 year in the absence of disease recurrence or unacceptable toxicity.
62776569|NCT04253587|EXPERIMENTAL|LabyrinthVR Trackers|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive spatial wayfinding challenge. Game movement via participant ambulation wearing leg-position trackers.
62776570|NCT04253587|EXPERIMENTAL|LabyrinthVR Scoot|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive spatial wayfinding challenge. Game movement via teleporting technique.
62776571|NCT04253587|PLACEBO_COMPARATOR|Placebo Controls|Multi-session cognitive intervention with handheld tablet or wireless virtual reality headset presentation of commercially available, narrative computer games.
62776572|NCT04253587|ACTIVE_COMPARATOR|Coherence|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive rhythm training game.
62776573|NCT04253587|EXPERIMENTAL|Labyrinth Tablet|Multi-session cognitive intervention with tablet computer, displaying 2.5D version of Labyrinth game in an adaptive spatial wayfinding challenge. Game movement via on-screen control buttons.
62776574|NCT04253587|EXPERIMENTAL|Labyrinth VR wireless|Multi-session cognitive intervention with head-mounted display virtual reality computer game using wireless, narrower filed technology to presents an adaptive spatial wayfinding challenge. Game movement via teleporting technique.
62776575|NCT03951116|EXPERIMENTAL|Dose escalation cohort of FCN-437c|"The dose-escalation cohort:~* Participants will receive FCN-437c monotherapy once daily (QD) for 21 days followed by a 7 day rest period (28-day cycle).~* FCN-437c will be administered orally.~* Participants with histologically or cytologically confirmed advanced unresectable/metastatic solid tumor will participate in this cohort."
62776576|NCT04896593|EXPERIMENTAL|Intervention|Smartphone app teaching suicide prevention skills.
62776577|NCT02579681|EXPERIMENTAL|BG00012|BG00012 administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter.
62776578|NCT05504005|EXPERIMENTAL|Clinical Validation of mμSORS for Noninvasive Blood Glucose Detection|Enrolled subjects will perform oral glucose tolerance test. A measurement session of blood glucose consists of plasma sample and a measurement by mμSORS will be conducted synchronously.
62776579|NCT03872791|EXPERIMENTAL|KN046|Subjects will receive KN046 at a dose of 3 mg/kg or 5 mg/kg via intravenous infusion on Days 1 and 15 of every 28-day cycle until disease progression, unacceptable toxicity or completion of 2 years of treatment
62000940|NCT01013233|PLACEBO_COMPARATOR|control|In this control group begin the training in a cross-over design 7 weeks after randomization.
62000941|NCT03171350|EXPERIMENTAL|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test
62000942|NCT02386943|EXPERIMENTAL|Sitagliptin|Subjects are assigned to take one pill of sitagliptin(100mg po once) at 7am on experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
62000943|NCT02386943|EXPERIMENTAL|Saxagliptin|Subjects are assigned to take one pill of saxagliptin(5mg po once) at 7am on experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
62000944|NCT02386943|EXPERIMENTAL|Blank control|Subjects take no medication for blank control at experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
62000945|NCT00810953|EXPERIMENTAL|single arm|Use of pentamidine in locally advanced or metastatic pancreatic cancer
62000946|NCT01367769||Thrombosis|"Patients with acute, idiopathic or provoked, unilateral proximal DVT (involving the popliteal vein or further proximal veins) and SVT of the lower-extremity detected with duplex ultrasound.~Age and sex matched controls (volunteers)"
62776580|NCT03872791|EXPERIMENTAL|KN046 plus nab-paclitaxel|Subjects will receive KN046 at a dose of 3 mg/kg or 5 mg/kg via intravenous infusion on Days 1 and 15 of every 28-day cycle until disease progression, unacceptable toxicity or completion of 2 years of treatment Subjects will receive nab-paclitaxel at a dose of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity
62776581|NCT04693351|EXPERIMENTAL|Troriluzole|Troriluzole- 2 100mg capsules once daily for the first two weeks. Troriluzole- 2 140mg capsules once daily from week two through week ten.
62776582|NCT04693351|PLACEBO_COMPARATOR|Placebo|Placebo- 2 100mg capsules once daily for the first two weeks. Placebo- 2 140mg capsules once daily from week two through week ten.
62776583|NCT02913495|EXPERIMENTAL|Vaginal Progesterone|200mg micronized progesterone vaginally, to be taken daily starting at 16 0/7 - 23 6/7 weeks, and continued daily until 36 6/7 weeks' gestation or delivery
62000947|NCT02158416||Hematology-oncology|hematology-oncology outpatients requiring platelet transfusion
62186142|NCT00673127|EXPERIMENTAL|KHAD|Ketoconazole, Hydrocortisone and Dutasteride Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Dutasteride: 0.5 mg once a day
62776584|NCT02913495|ACTIVE_COMPARATOR|Intramuscular Progesterone|250mg intramuscular progesterone to be administered weekly starting at 16 0/7 - 23 6/7 weeks, and continued weekly until 36 6/7 weeks' or delivery.
62000948|NCT02694315||Induction of labor|200 women all are primigravida between 37-42 weeks gestation to whom induction of labor will be carried out in the casualty of Ain Shams University Maternity Hospital. All participants will have an assessment of the cervix by both Bishop score system and transvaginal measurement of cervical length.
62000949|NCT04349722|ACTIVE_COMPARATOR|Hyoscine|Participants receive intravenous bolus of 1ml (20 mg) Hyoscine
62000950|NCT04349722|PLACEBO_COMPARATOR|Placebo|Participants receive intravenous bolus of 1ml normal saline
62000951|NCT00945503|EXPERIMENTAL|GSK1018921|All subjects will received a dose of GSK1018921 and will peforme three PET scans using the ligand \[11C\]GSK931145, but in order to obtain adequate sampling of the exposure-time-occupancy curves, a range of doses will be evaluated, and the timing of the post-dose scans will differ between subjects.
62000952|NCT02693574|ACTIVE_COMPARATOR|Clarithromycin|Clarithromycin 500 mg Tablets and Esomeprazole 20 mg Capsule And Amoxicillin 1000 mg,Tablets by mouth every 12 hours for 14 days
62776585|NCT02975726|EXPERIMENTAL|Peritoneal Dialysis Catheter Insertion|Catheters will be inserted at the bedside in a special procedure room.Argyle PD catheter kits will be used:2 cuffed curled catheters at 57cm or 62cm lengths. At time of PD catheter insertion,most patients will be drained of 5-10L of ascites or more to decrease the chance of catheter leaks.The volume removed will be at sole discretion of physician doing the procedure.Patients will be administered 25% Human Serum Albumin injection: 100cc after the 5-10L drainage,and 200cc if 10-15L is removed.Patients will undergo an initial drain and training with a specialized nurse.Patients in this arm will be instructed to drain a maximum of 2L per day after the initial drain.Monthly bloodwork will be performed.
62000953|NCT02693574|EXPERIMENTAL|Levofloxacin|Levofloxacin 500 mg coated tablets and Esomeprazole 20 mg Capsule and Amoxicillin 1000 mg Tablets by mouth every 12 hours for 14 days
62000954|NCT01538693|ACTIVE_COMPARATOR|escitalopram oxalate|Exercise testing with escitalopram oxalate dose
62000955|NCT01538693|ACTIVE_COMPARATOR|cyproheptadine|exercise testing with cyproheptadine dose
62000956|NCT01538693|PLACEBO_COMPARATOR|placebo|exercise testing with placebo dose
62000957|NCT00774033|EXPERIMENTAL|1|Treatment of acute burn in adults and children by epidermal cell spray
62000958|NCT00774033|ACTIVE_COMPARATOR|2|Treatment of acute burn in adults and children by classic skin grafts
62000959|NCT06277804|EXPERIMENTAL|Dose-escalation phase|"LTC004 combined with fludarabine, cyclophosphamide, 3+3design； LTC004 was given on day 1 and cyclophosphamide (250 mg/m2) combined with fludarabine (25 mg/m2) on days 3 and 4 of each cycle.Q3W."
62000960|NCT06277804|EXPERIMENTAL|Dose-expansion phase|Further evaluation of the safety and efficacy of this dosing regimen in patients with sarcoma who have failed standard treatment according to the RP2D identified in Dose-escalation phase.
62000961|NCT02150174|EXPERIMENTAL|Patients with schizophrenia|
62000962|NCT02150174|ACTIVE_COMPARATOR|Healthy subjects|
62394773|NCT04374331|EXPERIMENTAL|Video-Assisted Training Group|The patients in the VAT group watch a training video in the patient rooms before RCR in addition to the routine treatment and care in the unit.
62000963|NCT01194206|EXPERIMENTAL|Arm I|Patients undergo 3 fractions of stereotactic body radiation therapy in 3 fractions delivered within 14 days in the absence of disease progression or unacceptable toxicity.
62569745|NCT05302531|EXPERIMENTAL|Levofloxacin|Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.
62000964|NCT01308307|EXPERIMENTAL|one arm|
62000965|NCT04277091|NO_INTERVENTION|Control|No exercise
62000966|NCT04277091|EXPERIMENTAL|High-intensity interval exercise|10 x 60 s intervals at 80% peak power output (interspersed with 60 s recovery intervals at 10% peak power output)
62000967|NCT04277091|EXPERIMENTAL|Moderate-intensity continous exercise|50% peak power output (duration determined to elicit same energy expenditure as high-intensity interval exercise condition)
62000968|NCT05437289|EXPERIMENTAL|300 mg AZD7442 IM|Administration of a single dose of 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) sequentially by intramuscular (IM) injection.
62000969|NCT05437289|PLACEBO_COMPARATOR|300mg placebo IM|Administration of placebo with dose match to AZD7442 in the same cohort sequentially by intramuscular (IM) injection.
62000970|NCT05437289|EXPERIMENTAL|600 mg AZD7442 IM|Administration of a single dose of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) sequentially by intramuscular (IM) injection.
62000971|NCT05437289|PLACEBO_COMPARATOR|600mg placebo IM|Administration of placebo with dose match to AZD7442 in the same cohort sequentially by intramuscular (IM) injection.
62000972|NCT05437289|EXPERIMENTAL|300 mg AZD7442 IV|co-administration of a single dose of 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) by intravenous (IV) infusion.
62394774|NCT04374331|NO_INTERVENTION|control group|The control group received the routine treatment and care in the unit. The routine treatment and care of the unit includes verbal briefing by physicians and nurses about the surgical procedure before RCR, cold application and analgesic application for pain control after RCR, using arm sling, verbal discharge training (e.g., drug use, exercises, follow-up time, etc.) and discharge on the first post-operative day in the absence of complications. In addition, patients are invited to weekly controls to explain how to do the exercises and, if necessary, they are referred to physiotherapy.
62394775|NCT00187655|OTHER|Cefotaxime|Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
62394776|NCT06090227|EXPERIMENTAL|Metformin + Standard of Care|Administration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.
62000973|NCT05437289|PLACEBO_COMPARATOR|300mg placebo IV|co-administration of a single dose of placebo in equivalent volume by intravenous (IV) infusion.
62000974|NCT05437289|EXPERIMENTAL|600 mg AZD7442 IV|co-administration of a single dose of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by intravenous (IV) infusion.
62000975|NCT05437289|PLACEBO_COMPARATOR|600mg placebo IV|co-administration of a single dose of placebo in equivalent volume by intravenous (IV) infusion.
62000976|NCT00573716||1|15 subjects who are taking aripiprazole monotherapy
62000977|NCT00573716||2|15 subjects who are taking Risperidone therapy
62000978|NCT00573716||3|30 healthy volunteers with an ethnicity, sex, and pubertal stage match of subjects taking aripiprazole monotherapy and Risperidone therapy
62000979|NCT03042234|EXPERIMENTAL|Group Insulin-resistant|Insulin-resistant obese adolescents
62000980|NCT03042234|EXPERIMENTAL|Group Insulin-sensitive|Insulin-sensitive obese adolescents
62000981|NCT01565291|EXPERIMENTAL|Subjects With AD|Probable AD, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with mild/moderate dementia (Mini-Mental State Examination (MMSE) from 10 to 24)
62394777|NCT06090227|PLACEBO_COMPARATOR|Placebo + Standard of Care|Administration of daily placebo tablets with standard of care for 6 months.
62394778|NCT06681051||OSTENIL® TENDON|2 injections of sodium hayluronate 2 % (40 milligrams (mg) / 2.0 millilitres (ml)) in weekly interval.
62394779|NCT02974764||Chemotherapy Group|This cohort includes patients who will receive chemotherapy at any stage or their treatment.
62394780|NCT02974764||Radiation therapy Group|This cohort includes patients who will receive radiation therapy at any stage or their treatment.
62394781|NCT02974764||Surgical resection of the primary tumor|This cohort includes patients who will undergo resection of the primary tumor.
62394782|NCT06373640|OTHER|EVD first|Vancomycin to be administered first through an EVD
62394783|NCT06373640|OTHER|Lumbar drain first|Vancomycin to be administered first through a lumbar drain
62394784|NCT02217020|EXPERIMENTAL|FOLFOXIRI|patients received FOLFOXIRI alone for 4 cycles before surgery.
62394785|NCT04799821|EXPERIMENTAL|Intervention|Daily walnut consumption
62394786|NCT04799821|OTHER|Control|No walnut consumption
62000982|NCT01565291|EXPERIMENTAL|Healthy Elderly Subjects|Cognitively normal with MMSE of 29 or higher; age 50 years or older
62569746|NCT05302531|EXPERIMENTAL|Sulfamethoxazole trimethoprim|Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.
62569747|NCT03693638|ACTIVE_COMPARATOR|Single dose (SD)|2,5 ml total anesthetic drug dose (Bupivacaine-fentanyl) were given with 0.2 ml/second rate, and subjects were asked to remain sitted for 90 seconds
62569748|NCT03693638|ACTIVE_COMPARATOR|Fractionated dose (FD)|1,5 ml of total anesthetic drug dose (Bupivacaine-fentanyl) followed by 1 ml remaining dose after 90 s interval were given
62000983|NCT04709575|EXPERIMENTAL|REGN5713-5714-5715|REGN5713-5714-5715 administered subcutaneously
62000984|NCT04709575|PLACEBO_COMPARATOR|Placebo Only|Placebo matching REGN5713-5714-5715 administered subcutaneously
62000985|NCT00473720|EXPERIMENTAL|satraplatin abraxane|Satraplatin and abraxane will be given in escalating cohorts on a 3 + 3 design from satraplatin 40mg/m2 and abraxane 80mg/m2
62000986|NCT04507932|EXPERIMENTAL|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
62394787|NCT00635362|EXPERIMENTAL|postplacental insertion after cesarean|"Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta~Device of intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)"
62569749|NCT06382701|ACTIVE_COMPARATOR|Intervention|This is the group in which 0.5-1 ml of clove oil is applied as a spray to the arterio-venous fistula area, depending on the length of the fistula, ten minutes before needle cannulation in all hemodialysis sessions for four weeks in individuals receiving standard hemodialysis treatment.
62569750|NCT06382701|PLACEBO_COMPARATOR|Placebo|This is the group in which 0.5-1 ml of aromatic clove, which does not contain active ingredients and is dissolved in pure water, is applied as a spray to the arterio-venous fistula area, depending on the length of the fistula, ten minutes before needle cannulation in all hemodialysis sessions for four weeks in individuals receiving standard hemodialysis treatment.
62569751|NCT06119620|OTHER|ABAB|all participants will go through sham (control) and active (experimental) stimulation. So either sham - active - sham - active or active - sham - active - sham
62569752|NCT01961219|ACTIVE_COMPARATOR|Adhesive Capsulitis with MUA|"Subjects with idiopathic adhesive capsulitis in the frozen or thawing phase who have failed pain management and failed improvement in range of motion after at least 3 months of supervised, regimented conservative treatment; or who after less than 3 months of conservative treatment demand a quicker return to function. Treatment closed manipulation under anesthesia."
62569753|NCT01961219|ACTIVE_COMPARATOR|Adhesive Capsulitis with Arthroscopy|"Subjects with idiopathic adhesive capsulitis in the frozen or thawing phase who have failed pain management and failed improvement in range of motion after at least 3 months of supervised, regimented conservative treatment; or who after less than 3 months of conservative treatment demand a quicker return to function. Treatment Arthroscopic Capsular Release"
62569754|NCT06300203|EXPERIMENTAL|Interleukin-4 receptor responders|Interleukin-4 receptor was injected subcutaneously.
62569755|NCT06300203|PLACEBO_COMPARATOR|Placebo|Placebo was injected subcutaneously.
62569756|NCT04370873|EXPERIMENTAL|Part 1: MK-5475|Participants receive MK-5475 360 μg once daily (QD) via inhalation from Days 1-7. Following review of pharmacokinetic (PK) and safety data, a second 7 days of dosing may be initiated. A dose of up to 360 μg up to twice a day may be administered based on PK data in these participants.
62569757|NCT04370873|PLACEBO_COMPARATOR|Part 1: Placebo|Participants receive placebo QD via inhalation from Days 1-7.
62569758|NCT04370873|EXPERIMENTAL|Part 2: MK-5475|Participants receive MK-5475 32 µg, 100 µg, 195 µg or 380 μg QD via inhalation from Days 1-28.
62569759|NCT04370873|PLACEBO_COMPARATOR|Part 2: Placebo|Participants receive placebo QD via inhalation from Days 1-28.
62569760|NCT04129489|EXPERIMENTAL|Sintetic Cannabidiol|Synthetic Cannabidiol, dissolved in pharmaceutical grade olive oil at a concentration of 5% will be administered orally twice a day
62000987|NCT04036656|EXPERIMENTAL|Cohort 1:SYHA136 0.5 mg or Placebo matching SYHA136 0.5 mg|Participants will receive a single oral dose of SYHA136 0.5 mg or Placebo matching SYHA136 0.5 mg under fasted conditions.
62000988|NCT04036656|EXPERIMENTAL|Cohort 2:SYHA136 1 mg or Placebo matching SYHA136 1 mg|Participants will receive a single oral dose of SYHA136 1 mg or Placebo matching SYHA136 1 mg under fasted conditions.
62000989|NCT04036656|EXPERIMENTAL|Cohort 3:SYHA136 2.5 mg or Placebo matching SYHA136 2.5 mg|Participants will receive a single oral dose of SYHA136 2.5 mg or Placebo matching SYHA136 2.5 mg under fasted conditions.
62000990|NCT04036656|EXPERIMENTAL|Cohort 4:SYHA136 5 mg or Placebo matching SYHA136 5 mg|Participants will receive a single oral dose of SYHA136 5 mg or Placebo matching SYHA136 5 mg under fasted conditions.
62569761|NCT04043494|OTHER|SR I/II: R1 into protocol Ia-Pred|"1. cytoreductive prephase with prednisone~2. standard induction phase (protocol Ia-prednisone)~3. consolidation phase (protocol Ib)~4. non-HR extra-compartment phase (protocol M)~5. maintenance therapy"
62569762|NCT04043494|EXPERIMENTAL|SR I/II: R1 into protocol Ia-Dexa|"1. cytoreductive prephase with prednisone~2. experimental induction phase (protocol Ia-dexamethasone)~3. consolidation phase (protocol Ib)~4. non-HR extra-compartment Phase (protocol M)~5. maintenance therapy"
62569763|NCT04043494|OTHER|SR: R1 into protocol Ia-Pred|"1. cytoreductive prephase with prednisone~2. standard induction phase (protocol Ia-prednisone)~3. consolidation phase (protocol Ib)~4. non-HR extra-compartment phase (protocol M)~5. reintensification phase (protocol II)~6. maintenance therapy"
62569764|NCT04043494|EXPERIMENTAL|SR: R1 into protocol Ia-Dexa|"1. cytoreductive prephase with prednisone~2. experimental induction phase (protocol Ia-dexamethasone)~3. consolidation phase (protocol Ib)~4. non-HR extra-compartment phase (protocol M)~5. reintensification phase (protocol II)~6. maintenance therapy"
62569765|NCT04043494|OTHER|"HR: R1 into Pred and R2 into non-HR extra-compartment phase"|"1. cytoreductive prephase with prednisone~2. standard induction phase (protocol Ia-prednisone)~3. consolidation phase (protocol Ib)~4. non-HR extra-compartment phase (protocol M)~5. reintensification phase (protocol II)~6. maintenance therapy"
62569766|NCT04043494|EXPERIMENTAL|"HR: R1 into Dexa and R2 into non-HR extra-compartment phase"|"1. cytoreductive prephase with prednisone~2. experimental induction phase (protocol Ia-dexamethasone)~3. consolidation phase (protocol Ib)~4. non-HR extra-compartment phase (protocol M)~5. reintensification phase (protocol II)~6. maintenance therapy"
62776586|NCT02975726|ACTIVE_COMPARATOR|Large Volume Paracentesis|Patients in this arm of the study will continue their usual practice of LVP as required. They will continue to undergo their LVP procedures through their regular means.Monthly bloodwork will be performed.
62000991|NCT04036656|EXPERIMENTAL|Cohort 5:SYHA136 10 mg or Placebo matching SYHA136 10 mg|Participants will receive a single oral dose of SYHA136 10 mg or Placebo matching SYHA136 10 mg under fasted conditions.
62000992|NCT04036656|EXPERIMENTAL|Cohort 6:SYHA136 20 mg or Placebo matching SYHA136 20 mg|Participants will receive a single oral dose of SYHA136 20 mg or Placebo matching SYHA136 20 mg under fasted conditions.
62000993|NCT04036656|EXPERIMENTAL|Cohort 7:SYHA136 35 mg or Placebo matching SYHA136 35 mg|Participants will receive a single oral dose of SYHA136 35 mg or Placebo matching SYHA136 35 mg under fasted conditions.
62000994|NCT04036656|EXPERIMENTAL|Cohort 1:SYHA136 50 mg or Placebo matching SYHA136 50 mg|Participants will receive a single oral dose of SYHA136 50 mg or Placebo matching SYHA136 50 mg under fasted conditions.
62569767|NCT04043494|EXPERIMENTAL|"HR: R1 into Pred and R2 into HR extra-compartment phase"|"1. cytoreductive prephase with prednisone~2. standard induction phase (protocol Ia-prednisone)~3. consolidation phase (protocol Ib\*)~4. HR extra-compartment phase (intensified protocol M)~5. reintensification phase (protocol II)~6. maintenance therapy"
62569768|NCT04043494|EXPERIMENTAL|"HR: R1 into Dexa and R2 into HR extra-compartment phase"|"1. cytoreductive prephase with prednisone~2. experimental induction phase (protocol Ia-dexamethasone)~3. consolidation phase (protocol Ib\*)~4. HR extra-compartment phase (intensified protocol M)~5. reintensification phase (protocol II)~6. maintenance therapy"
62569769|NCT02037178||The study population|"See inclusion/exclusion criteria.~Intervention: First ultrasound reading~Intervention: Second ultrasound interpretation"
62776587|NCT02836431|EXPERIMENTAL|DEX 1 mcg/kg Intranasal|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
62000995|NCT01529359|PLACEBO_COMPARATOR|Placebo|Probiotics Excipients
62000996|NCT01529359|EXPERIMENTAL|Lactibiane Tolerance|Probiotics combination
62000997|NCT00218543|EXPERIMENTAL|Atomoxetine|Atomoxetine
62000998|NCT05558228||Patients achieving return of spontaneous circulation|All patients in cardiac arrest with an arterial line in place in the emergency department will be a potential subject. The FloPatch FP120 device will be placed on patients and the carotid artery peak systolic velocity associated with a systolic blood pressure ≥60 mmHg on a femoral arterial line during a pulse check will be determined.
62214634|NCT05832697|ACTIVE_COMPARATOR|Treatment B|P1: DWC202108(usrodeoxycholic acid) 250mg, P2: DWJ1439(ursodeoxycholic acid) 100mg, P3: DWC202109(ursodeoxycholic acid) 250mg
62394788|NCT00635362|ACTIVE_COMPARATOR|delayed insertion group|"Insertion of the LNG-IUS 4-8 weeks after cesarean delivery~Device of intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)"
62394789|NCT02357394|EXPERIMENTAL|Device: Arabin Pessary|Participants randomized to this group will receive the pessary.
62394790|NCT02357394|NO_INTERVENTION|Standard of Care|Patients randomized to the control group will receive standard of care for their condition. This includes surveillance of cervical length, vaginal progesterone, and emergency cerclage.
62394791|NCT05249504|EXPERIMENTAL|1. Intervention group|"AMICOPE multicomponent intervention:~* Physical activity (VIVIFRAIL program): 10 hours.~* Nutrition: 6,5 hours.~* Psychology: 6,5 hours.~* Personal autonomy: 4,5 hours~* Learn about community resources: 2, 5 hours"
62394792|NCT05249504|ACTIVE_COMPARATOR|2. Control group|Control group participants will receive usual advice on healthy lifestyle habits and a follow-up phone call from healthcare professionals.
62394793|NCT03108352|EXPERIMENTAL|Conbercept ophthalmic injection|Conbercept ophthalmic injection
62394794|NCT03108352|SHAM_COMPARATOR|Sham Comparator|sham / Conbercept ophthalmic injection
62394795|NCT05459987|EXPERIMENTAL|Intervention|"Behavioral: Lifestyle changes Nutritional advice to progressively integrate a moderate-carbohydrate Mediterranean diet with intermittent fasting 16:8 (5 times/week for 12 weeks).~Personalized exercise prescription and training (3 times per week)~Personalized education and motivational interviewing"
62394796|NCT00928863||Haemorrhagia post partum|Women with a high risk for haemorrhagia post partum.
62394797|NCT01609049||Participants with Chronic Hepatitis C|Naive and previously treated participants who received peginterferon alfa-2a in combination with ribavirin as per local labeling requirements.
62394798|NCT01499498|EXPERIMENTAL|Sildenafil and Boceprevir|Healthy volunteers
62394799|NCT03616652|EXPERIMENTAL|Non-deceptive placebo group (additional information)|Participants receive a placebo pill and are told that it is placebo. They receive additional information about the power of placebo effects via a film sequence before they take the placebo.
62214635|NCT05832697|ACTIVE_COMPARATOR|Treatment C|P1: DWJ1464(ursodeoxycholic acid) 100mg, P2: DWC202109(ursodeoxycholic acid) 250mg, P3: DWJ1439(ursodeoxycholic acid) 100mg
62214636|NCT05832697|ACTIVE_COMPARATOR|Treatment D|P1: DWC202109(ursodeoxycholic acid) 250mg, P2: DWJ1464(ursodeoxycholic acid) 100mg, P3: DWC202108(usrodeoxycholic acid) 250mg
62214637|NCT03882541|NO_INTERVENTION|Control group|headphones without music, without sedation
62214638|NCT03882541|ACTIVE_COMPARATOR|sedative group|headphones without music, with sedation
62214639|NCT03882541|EXPERIMENTAL|experimental group|headphones with music, without sedation
62214640|NCT02136082|EXPERIMENTAL|Asha Support + Training|Asha Support + Training: 1) Group discussions delivered over a six month period that cover four main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; and d) Healthy Eating for Self and Family; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen.
62214641|NCT02136082|EXPERIMENTAL|Asha Support + Food|Asha Support + Food 1) Group discussions delivered over a six month period that cover three main categories a) Staying Healthy; b) Caregiving; and c) Staying Upbeat; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen; 4) Food supplementation of high protein food such as urad dal or tur dal.
62214642|NCT02136082|EXPERIMENTAL|Asha Support + Training + Food|Asha Support + Training + Food: 1) Group discussions delivered over a six month period that cover four main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; and d) Healthy Eating for Self and Family; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen; 4) Food supplementation of high protein food such as urad dal or tur dal.
62000999|NCT05558228||Patients not achieving return of spontaneous circulation|All patients in cardiac arrest with an arterial line in place in the emergency department will be a potential subject. The FloPatch FP120 device will be placed on patients and the carotid artery peak systolic velocity associated with a systolic blood pressure ≥60 mmHg on a femoral arterial line during a pulse check will be determined.
62776588|NCT02836431|EXPERIMENTAL|DEX 2 mcg/kg Intranasal|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
62776589|NCT02836431|EXPERIMENTAL|DEX 1 mcg/kg Intravenous|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
62001000|NCT00654381|ACTIVE_COMPARATOR|voglibose 0.2 mg three times a day (TID)|patient to receive a tablet containing 0.2 mg voglibose TID plus 2 placebo tablets matching BI 1356
62394800|NCT03616652|PLACEBO_COMPARATOR|Non-deceptive placebo group (no additional information)|Participants receive a placebo pill and are told that it is placebo. They do not receive additional information about placebo effects. Instead, they watch a neutral film sequence about sleep.
62776590|NCT04794023|EXPERIMENTAL|Intervention_Corneal Ablation|
62776591|NCT05831605|NO_INTERVENTION|Control group|Venipuncture without near-infrared light
62776592|NCT05831605|EXPERIMENTAL|Experimental group|Venipuncture with near-infrared light
62776593|NCT06086483|ACTIVE_COMPARATOR|iPACK block+ABC block|Patients received a preoperative ultrasound-guided iPACK block with 20 mL of 0.25% ropivacaine and an Adductor Canal block with 20mL 0.25% ropivacaine.
62001001|NCT00654381|EXPERIMENTAL|BI 1356 low dose|patient to receive a tablet containing BI 1356 and matching placebo plus 3 placebo tablets matching voglibose
62001002|NCT00654381|EXPERIMENTAL|BI 1356 high dose|patient to receive 2 tablets containing BI 1356 plus 3 placebo tablets matching voglibose
62001003|NCT00654381|PLACEBO_COMPARATOR|placebo|patient to receive 2 placebo tablets matching BI 1356 plus 3 placebo tablets matching voglibose
62001004|NCT05118841|EXPERIMENTAL|ZX-4081 Dose Level 1|Starting dose (SD) of ZX-4081 administered orally twice daily (BID) in a 28-day cycle
62001005|NCT05118841|EXPERIMENTAL|ZX-4081 Dose Level 2|2-times the SD of ZX-4081 administered orally BID in a 28-day cycle
62001006|NCT05118841|EXPERIMENTAL|ZX-4081 Dose Level 3|4-times the SD of ZX-4081 administered orally BID in a 28-day cycle
62001007|NCT05118841|EXPERIMENTAL|ZX-4081 Dose Level 4|6-times the SD of ZX-4081 administered orally BID in a 28-day cycle
62001008|NCT05118841|EXPERIMENTAL|ZX-4081 Dose Level 5|8-times the SD of ZX-4081 administered orally BID in a 28-day cycle
62394801|NCT02539160|ACTIVE_COMPARATOR|CKD - Ticagrelor 90|Patients with chronic kidney disease will receive ticagrelor 90mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 60mg twice/daily for 7-10 days.
62394802|NCT02539160|EXPERIMENTAL|CKD - Ticagrelor 60|Patients with chronic kidney disease will receive ticagrelor 60mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 90mg twice/daily for 7-10 days.
62394803|NCT02539160|ACTIVE_COMPARATOR|Non-CKD - Ticagrelor 90|Patients without chronic kidney disease will receive ticagrelor 90mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 60mg twice/daily for 7-10 days.
62776594|NCT06086483|ACTIVE_COMPARATOR|Sham blocks|Patients received a preoperative ultrasound-guided iPACK block with 20 mL of 0.9% normal saline and an Adductor Canal block with 20mL 0.9% normal saline.
62776595|NCT05754593|EXPERIMENTAL|MS patients|Diagnosis of multiple sclerosis based on McDonald Criteria 2017
62776596|NCT05754593|ACTIVE_COMPARATOR|Controls|Healthy controls
62776597|NCT05417191|ACTIVE_COMPARATOR|Conventional fish|This arm will consume 2 portions of gilthead seabream fed with conventional diet. Each portion weighed on average 380 g (raw, quantity of edible fillet approximately 170 g). Participants were instructed to consume fish twice weekly, one portion at a time.
62776598|NCT05417191|EXPERIMENTAL|Enriched fish|This arm will consume 2 portions of gilthead seabream fed with olive pomace enriched diet. Each portion weighed on average 380 g (raw, quantity of edible fillet approximately 170 g). Participants were instructed to consume fish twice weekly, one portion at a time.
62776599|NCT02092311|EXPERIMENTAL|Combined Microscopic Varicocelectomy|Patients in this arm were operated with Combined Mini-incision Microscopic approach
62569770|NCT06578052|OTHER|Irinotecan liposome Capecitabine|"Irinotecan liposome: intravenous infusion, day 1, every 2 weeks (Q2W). Capecitabine: oral, twice daily (bid), days 1 to 7, take for one week and then have a one-week interval.~Each 2-week period is considered a treatment cycle, with an expected treatment of 6 cycles. Subsequent maintenance treatment will be determined by the investigator's protocol until disease progression or intolerable toxicity occurs."
62569771|NCT05944744|EXPERIMENTAL|Intervention|The patient is given Cobamamide 2 x 3000 mg for 28 days.
62001009|NCT05118841|EXPERIMENTAL|ZX-4081 Dose Level 6|10-times the SD of ZX-4081 administered orally BID in a 28-day cycle
62001010|NCT05118841|EXPERIMENTAL|ZX-4081 Expansion Dose Level|Recommended Phase 2 Dose (RP2D) (to be determined) of ZX-4081 administered orally BID in a 28-day cycle
62001011|NCT02254707|EXPERIMENTAL|BILB 1941 ZW|Escalating Doses
62001012|NCT02254707|PLACEBO_COMPARATOR|Placebo|
62001013|NCT00829322|EXPERIMENTAL|Treatment group|
62001014|NCT00829322|PLACEBO_COMPARATOR|Control group|
62776600|NCT02092311|ACTIVE_COMPARATOR|Inguinal and Subinguinal Varicocelectomy|Patients in this arm have the same including criteria as Experimental arm but they were operated with conventional and currently popular approach of Microscopic Inguinal and Sub inguinal varicocelectomy suggested by Goldstien and associates
62001015|NCT04933591|ACTIVE_COMPARATOR|study group|Individuals aged 18-50 with varicose veins and CEAP C2-C4, Ep, As, Pr. Clinical and ultrasound examinations will be used to confirm varicose veins disease. It is planned to take blood samples from a varicose vein before and after administration of Venarus® (100 mg hesperidin + 900 mg diosmin) for 2 months
62001016|NCT04933591|NO_INTERVENTION|control group|Individuals aged 18-50 with varicose veins and CEAP C2-C4, Ep, As, Pr vein. Clinical and ultrasound examinations will be used to confirm varicose veins disease. It is planned to take blood samples from a varicose vein at inclusion and 2 months later/
62001017|NCT01442363|EXPERIMENTAL|BLI-1300 (low dose)|Investigational Product (10%) Ointment
62001018|NCT01442363|EXPERIMENTAL|BLI-1300 (high dose)|Investigational Product (20%) Ointment
62001019|NCT01442363|PLACEBO_COMPARATOR|placebo|Placebo Ointment
62001020|NCT05863741||control study|patients will be operated with conventional instrumentation
62001021|NCT05863741||NextAR study|patients will be operated using the NextAR guidance system
62001022|NCT00640510|EXPERIMENTAL|IM olanzapine 10mg|Patients will receive at least one injection of Intramuscular (IM) olanzapine 10mg. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
62001023|NCT00640510|PLACEBO_COMPARATOR|IM placebo|Patients will receive at least one injection of Intramuscular placebo. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
62001024|NCT04087291|ACTIVE_COMPARATOR|Phase 1: Low Dose (1-5 visits)|Veterans with cLBP who will be randomly allocated to undergo a course of a low dose (1-5 visits) of multimodal, evidence-based chiropractic care for 10 weeks (Phase 1).
62001025|NCT04087291|ACTIVE_COMPARATOR|Phase 1: Higher Dose (8-12 visits)|Veterans with cLBP who will be randomly allocated to undergo a course of a higher dose (8-12 visits) of multimodal, evidence-based chiropractic care for 10 weeks (Phase 1).
62001026|NCT04087291|ACTIVE_COMPARATOR|Phase 2: CCPM|After Phase 1, Veterans with cLBP who will be randomly allocated again to receive chiropractic chronic pain management (CCPM) consisting of scheduled monthly chiropractic care for 10 months.
62001027|NCT04087291|NO_INTERVENTION|Phase 2: No CCPM|After Phase 1, Veterans with cLBP who will be randomly allocated again to receive no CCPM in which they will receive no chiropractic care for 10 months.
62001028|NCT01401933|EXPERIMENTAL|Linifanib|
62394804|NCT02539160|EXPERIMENTAL|Non-CKD - Ticagrelor 60|Patients without chronic kidney disease will receive ticagrelor 60mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 90mg twice/daily for 7-10 days.
62569772|NCT05944744|PLACEBO_COMPARATOR|Control|The patient is given placebo 2 x 1 capsule for 28 days.
62569773|NCT06205914|EXPERIMENTAL|patient group|patients more than 16 years old with patella frature
62569774|NCT05958199|EXPERIMENTAL|NPX267 Treatment|
62569775|NCT01454323|EXPERIMENTAL|Intervention|Dose of bone marrow mononuclear cells: 5-7 x 108 total cells
62569776|NCT01075165|EXPERIMENTAL|Silicone Spray|Apply spray silicone
62569777|NCT01075165|PLACEBO_COMPARATOR|Saline Spray|Apply Saline Spray
62776601|NCT02163421|EXPERIMENTAL|Vedolizumab SC 54 mg|Vedolizumab SC, once on Day 1.
62776602|NCT02163421|EXPERIMENTAL|Vedolizumab SC 108 mg|Vedolizumab SC, once on Day 1.
62776603|NCT02163421|EXPERIMENTAL|Vedolizumab SC 160 mg|Vedolizumab SC, once on Day 1.
62776604|NCT02163421|ACTIVE_COMPARATOR|Vedolizumab IV 300 mg|Vedolizumab IV, once on Day 1.
62776605|NCT06228898||patients with type 2 diabetes with improved HbA1c|Participants with type 2 diabetes with a reduction in HbA1c ranging from 5% to 11.6% in three months time (n=56)
62776606|NCT06228898||patients with type 2 diabetes with a better HbA1c|Group 2 comprised individuals with type 2 diabetes who exhibited a decline in HbA1c levels ranging from 2.8% to 4.9% in three months time (n=56).
62001029|NCT03287388|EXPERIMENTAL|No Rocuronium|Phase 1: no neuromuscular blockade
62776607|NCT06228898||patients with type 2 diabetes with little or no HbA1c change|Group 3 comprised 58 participants who exhibited a decrease in HbA1c levels ranging from 2.7% to 0%, in addition to an increase ranging from 0.1% to 3.4%.
62776608|NCT05021575||2020|Data on outpatient care, hospitalisation and cardiovascular mortality were collected for the year 2020.
62394805|NCT02806804|EXPERIMENTAL|one dose test vaccine|One dose of quadrivalent influenza virus vaccine will be randomly given in aged 3-60 years old.
62394806|NCT02806804|EXPERIMENTAL|one dose commercially available trivalent influenza vaccine|One dose of trivalent influenza virus vaccine will be randomly given in aged 3-60 years old.
62394807|NCT02806804|EXPERIMENTAL|One dose quadrivalent influenza virus vaccine|One dose of quadrivalent influenza virus vaccine (trivalent influenza virus vaccine added to a new influenza B component) will be randomly given in aged 3-60 years old.
62394808|NCT06003582|EXPERIMENTAL|Infant Parent Support|Families engage with the new therapeutic intervention, Infant Parent Support.
62394809|NCT06003582|NO_INTERVENTION|Services As Usual|Families randomised to Services As Usual, engage with already existing services.
62394810|NCT01766466|EXPERIMENTAL|Cangrelor IV + Ticagrelor 180mg at 0.5 hr|On Day 1: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours. Ticagrelor (180 mg) was administered at 0.5 h after the initiation of cangrelor infusion.
62394811|NCT01766466|EXPERIMENTAL|Cangrelor IV + Ticagrelor 90mg (7 doses)|"On Day 1: Following completion of cangrelor and ticagrelor dosing, patients were discharged and instructed to take 90 mg ticagrelor every 12 hours for 7 doses (12, 24, 36, 48, 60, 72, and 84 h).~On Day 5: 12 h post last ticagrelor dose (90 mg), patients received another open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours."
62394812|NCT01766466|EXPERIMENTAL|Cangrelor IV + Ticagrelor 180mg at 1.5 hr|On Day 1: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours. Ticagrelor (180 mg) was administered at 1.5 h after the initiation of cangrelor infusion.
62394813|NCT01766466|EXPERIMENTAL|Cangrelor IV + Ticagrelor 90mg (6 doses)|"On Day 1: Following completion of cangrelor and ticagrelor dosing, patients were discharged and instructed to take 90 mg ticagrelor every 12 hours for 6 doses (12, 24, 36, 48, 60, and 72 h).~On Day 5: 24 h post last ticagrelor dose (90 mg), patients received another open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours."
62394814|NCT02828852|EXPERIMENTAL|Pregnancy|Blood sample
62776609|NCT05021575||2019|Data on outpatient care, hospitalisation and cardiovascular mortality were collected for the year 2019.
62776610|NCT06392269||Tasso+|Comparison of capillary blood collected with a Tasso+ lancet vs. venous blood obtained via venipuncture
62776611|NCT04859374|OTHER|Treatment as usual (TAU)|Any pharmacological therapy used for managing chronic pain or chronic migraine
62776612|NCT04859374|OTHER|TAU plus behavioral approach|Any pharmacological therapy used for managing chronic pain or chronic migraine added with behavioral approach (mindfulness) delivered on line and smart phone for 6 weekly sessions
62776613|NCT03950310|EXPERIMENTAL|ELCA|On the antegrade delivery of the laser catheter after wiring, we used safe laser techniques and injected saline before and during the laser procedure at a 0.5 mm/sec catheter advancement rate. Whether to perform a retrograde laser method depended on each operator. After ablation by ELCA, patients undergo balloon dilation via standard techniques, and as appropriate, receive drug-eluting stent deployment.
62776614|NCT03950310|NO_INTERVENTION|non ELCA|In non ELCA group, the conventional PCI procedure, including thrombus aspiration, POBA, and stent implantation was performed. The indication for aspiration was at the discretion of the physician based on angiographic, intravascular ultrasound, or optical coherence tomography/Optical Frequency-Domain Imaging.
62776615|NCT02905487||GDM|Mother-child pairs from mothers with GDM diagnosis (ADA, 2012)
62776616|NCT02905487||No GDM|Mother-child pairs from mothers without GDM diagnosis (ADA, 2012)
62776617|NCT03612908||Normothyroid pregnant women|Healthy pregnant women with the TSH serum values within the recommended ranged per trimester of pregnancy.
62776618|NCT03612908||Patients with a thyroid disease|Patients with a thyroid disease named hypothyroidism or hyperthyroidism.
62776619|NCT02272166|ACTIVE_COMPARATOR|propofol|Hypnotic used in this arm is exclusively intra-venous propofol.
62776620|NCT02272166|ACTIVE_COMPARATOR|sevoflurane|Hypnotic used in this arm is exclusively inhaled sevoflurane.
62001030|NCT03287388|EXPERIMENTAL|Rocuronium (moderate NMB)|Phase 2: moderate neuromuscular blockade (TOF 1-3)
62001031|NCT03287388|EXPERIMENTAL|Rocuronium (deep NMB)|Phase 3: deep neuromuscular blockade (PTC 0-1)
62001032|NCT00616850|ACTIVE_COMPARATOR|Group A|Group A subjects will receive a continuous femoral block catheter and a Patient Controlled Analgesia (PCA).
62001033|NCT00616850|EXPERIMENTAL|Group B|Group B subjects will receive a low dose lidocaine (1.33 mg/kg/hr) infusion and a Patient Controlled Analgesia.
62776621|NCT06486415|EXPERIMENTAL|ectopic pregnancy patients|the group diagnosed as ectopic pregnancy after serial testing of Beta Human Chorionic Gonadotropin (BHCG) levels
62776622|NCT06486415|ACTIVE_COMPARATOR|Normal pregnancy|The group diagnosed with normal pregnancy after serial measurements of serum BHCG levels.
62776623|NCT03530501|PLACEBO_COMPARATOR|Placebo|Very low calorie ketogenic diet followed by low calorie diet
62001034|NCT00616850|PLACEBO_COMPARATOR|Group C|Group C subjects will receive placebo (preservative free normal saline) infusion and a Patient Controlled Analgesia.
62569778|NCT06390150|EXPERIMENTAL|Stimulation On|Spinal cord stimulators will be optimized to each participant and then programmed to deliver high frequency stimulation below detectable threshold for 6 weeks.
62569779|NCT06390150|PLACEBO_COMPARATOR|Stimulation Off|Spinal cord stimulators will be optimized to each participant as in the experimental arm, and then programmed to deliver no stimulation for 6 weeks.
62569780|NCT05107609|EXPERIMENTAL|Self-Compassion Intervention|Participants will be guided through an acute, 30-minute self-compassion intervention consisting of psychoeducation, guided loving-kindness meditation, compassionate imagery and a compassionate writing activity.
62569781|NCT05107609|NO_INTERVENTION|Resting Control Intervention|Participants will be asked to sit quietly and independently for 30 minutes. They can read neutral magazines provided or their own reading/writing material, but will be asked not to use outside electronic devices or communicate with anyone external.
62569782|NCT05487001|EXPERIMENTAL|dexamethasone group|a iliopsoas plane block before surgery
62569783|NCT05487001|SHAM_COMPARATOR|sham group|sham block before surgery
62569784|NCT01174381|EXPERIMENTAL|Lifestyle modification|Lifestyle modification for behavior change related to NCD prevention
62569785|NCT04736498|NO_INTERVENTION|Control arm|Control group will follow the standard procedure in our centre and will not undergo USG assessment before spinal anaesthesia. The spinal anaesthesia procedure will be standardized. Under strict aseptic precautions spinal anesthesia will be performed at L3-L4 inter-space using a 25 Gauge Quincke spinal needle (B. Braun Medical SA, Melsungen, Germany) in sitting position. 3 ml of hyperbaric bupivacaine 0.5% (15 mg) will be injected with the needle orifice oriented cranially. After injection, patients will be immediately positioned supine. Meanwhile, the non-invasive blood pressure will be measured and recorded every 3 minute for 30 min and then every 5 min throughout surgery and anesthesia.
62569786|NCT04736498|EXPERIMENTAL|USG arm|In the IVC USG group, USG assessment and volume optimisation using collapsibility index will be done prior to spinal anaesthesia. all patients will be lying supine, for at least 5 min before IVC examination. Ultrasound measurements will be performed using a Sonosite M-Turbo (Sonosite Inc., USA) machine and phased array 5-1 Megahertz transducer (Sonosite Inc.) set to abdominal mode by an M-mode modality through the subcostal view. All IVC measurements will be performed by principal investigator before spinal anaesthesia. Principal investigator should have performed more than 25 scans before the commencement of the study.
62569787|NCT02213172|EXPERIMENTAL|Bifidobacterium longum R0175|10 x 10\^9 CFU per capsule, 1 capsule daily for 8 weeks
62569788|NCT02213172|EXPERIMENTAL|Lactobacillus paracasei HA-196|10 x 10\^9 CFU per capsule, 1 capsule daily for 8 weeks
62569789|NCT02213172|PLACEBO_COMPARATOR|Placebo|1 capsule daily for 8 weeks
62569790|NCT01996241|EXPERIMENTAL|Intervention Village Clusters|Receive multi-level, structural and norms-based intervention
62569791|NCT01996241|NO_INTERVENTION|Control Village Clusters|No multi-level, structural and norms-based intervention
62569792|NCT06071910|OTHER|Aortic balloon occulsion|Delivery of ER-REBOA catheter to achieve aortic occlusion during resuscitation for out of hospital cardiac arrest, refractory to conventional advanced life support
62186143|NCT03871621|ACTIVE_COMPARATOR|Dapagliflozin add-on group|T2D subjects aged 20-80 years, presenting with HbA1C 7.1-9.0%, preserved kidney function (defined as estimated glomerular filtration rate (eGFR) \> 60 mL/min/1.73 m2), preserved LV function (defined as EF ≥ 50% by echocardiographic screening in the initial 2-week run-in period), and those treated with oral anti-diabetic drugs (except SGLT2i) and/or insulin therapy at least 3 months prior to the study were randomised to Dapagliflozin (10 mg/qd) add-on group.
62001035|NCT04974970|EXPERIMENTAL|Peanut allergenic extract|injected peanut extract.
62569793|NCT05628935||Group G|Patients Undergoing Forearm Surgery under general anesthesia
62569794|NCT05628935||Group P|Patients Undergoing Forearm Surgery under peripheral nerve block
62569795|NCT05745818||colchicine group|
62569796|NCT05745818||control group|
62569797|NCT06576297|ACTIVE_COMPARATOR|Standard of Care|Participants in the usual care group will be telephoned at 4 and 8 weeks, and AE/SAE will be reviewed.
62569798|NCT06576297|EXPERIMENTAL|IMT Group: Inspiratory Muscle Training (IMT)|IMT exercise sessions addition to standard of care.
62569799|NCT01100086|EXPERIMENTAL|Reformulated OXY 10 mg|Reformulated OXY 10 mg x 1 dose
62569800|NCT01100086|ACTIVE_COMPARATOR|Original OxyContin® (OXY)10 mg|Original OxyContin® (OXY)10 mg x 1 dose
62569801|NCT01479465|EXPERIMENTAL|FOLFIRI + SIM 700 mg (Part A)|Participants will receive SIM 700 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
62569802|NCT01479465|EXPERIMENTAL|FOLFIRI + SIM 200 mg (Part B)|Participants will receive SIM 200 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
62001036|NCT03090256|EXPERIMENTAL|PanOptix IOL|AcrySof® IQ PanOptix™ IOL, bilateral implantation
62001037|NCT01176292|OTHER|Rotating Platform High-Flex Cruciate Substituting TKA|
62001038|NCT01176292|OTHER|Rotating Platform Cruciate Substituting TKA|
62394815|NCT02828852|EXPERIMENTAL|No pregnancy|Blood sample
62394816|NCT03965416|EXPERIMENTAL|Doctor with white coat|Doctor during consultation is wearing a white coat
62394817|NCT03965416|EXPERIMENTAL|Doctor without white coat|Doctor during consultation is not wearing a white coat
62569803|NCT01479465|EXPERIMENTAL|FOLFIRI + SIM 700 mg (Part B)|Participants will receive SIM 700 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
62569804|NCT01479465|EXPERIMENTAL|FOLFIRI + Placebo (Part B)|Participants will receive placebo to match SIM via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
62001039|NCT02743572|NO_INTERVENTION|control group|preterm infants of this group with iron-free PN for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
62001040|NCT02743572|EXPERIMENTAL|iron sucrose-1|preterm infants of this group with iron supplementation of 100μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
62776624|NCT03530501|EXPERIMENTAL|Synbiotic1+synbiotic2|Very low calorie ketogenic diet supplemented with synbiotic 1 followed by low calorie diet supplemented with synbiotic2
62776625|NCT03530501|EXPERIMENTAL|placebo +synbiotic2|Very low calorie ketogenic diet supplemented with placebo followed by low calorie diet supplemented with synbiotic2
62776626|NCT01353911|EXPERIMENTAL|Grazoprevir 100 mg|TN non-cirrhotic (NC) participants receive Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
62394818|NCT06019208||GENOMED4ALL - SCD patients|Non transplanted SCD patients aged over 1 year.
62394819|NCT00329433|ACTIVE_COMPARATOR|Heparin|Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
62569805|NCT05918120|EXPERIMENTAL|Home Sleep Apnea Test|Patients will undergo assessment for obstructive sleep apnea using a home sleep apnea test.
62569806|NCT05918120|ACTIVE_COMPARATOR|In-laboratory Polysomnography|Patients receive standard of care for diagnosing obstructive sleep apnea, which is in-laboratory polysomnography.
62569807|NCT02865967|EXPERIMENTAL|Block1_Intervention|Usual care + a-GPS
62776627|NCT01353911|EXPERIMENTAL|Grazoprevir 200 mg|TN NC participants receive Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
62776628|NCT01353911|EXPERIMENTAL|Grazoprevir 400 mg|TN NC participants receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
62569808|NCT02865967|OTHER|Block1_Control|Usual Care
62569809|NCT02865967|EXPERIMENTAL|Block2_Intervention|Usual care + a-GPS
62569810|NCT02865967|OTHER|Block2_Control|Usual care
62569811|NCT02865967|EXPERIMENTAL|Block3_Intervention|Usual care + a-GPS
62001041|NCT02743572|EXPERIMENTAL|iron sucrose-2|preterm infants of this group with iron supplementation of 200μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
62001042|NCT02743572|EXPERIMENTAL|iron sucrose-3|preterm infants of this group with iron supplementation of 300μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
62001043|NCT02743572|EXPERIMENTAL|iron sucrose-4|preterm infants of this group with iron supplementation of 400μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
62569812|NCT02865967|OTHER|Block3_Control|Usual care
62584830|NCT00695292|EXPERIMENTAL|Intervention|"Patients in the study will receive the following for the duration of the study: irinotecan 60 mg/m2 intravenously on Days 1, 8, and 15 and carboplatin AUC=4 on Day 1. The study will consist of 28-day cycles, to a maximum of 6 cycles of therapy with irinotecan and carboplatin. After treatment with irinotecan and carboplatin, sunitinib will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During sunitinib maintenance therapy, patients will receive sunitinib at 25 mg orally daily. Sunitinib maintenance therapy will continue until progressive disease or irreversible toxicity occurs.~Re-staging will be performed every 2 cycles (every 8 weeks) during the study."
62776629|NCT01353911|EXPERIMENTAL|Grazoprevir 800 mg|TN NC participants receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
62569813|NCT05345392|ACTIVE_COMPARATOR|Mindfulness-Based Intervention (MBI)|The MBI is based on mindfulness-based stress reduction and mindfulness-based cognitive therapy, borrowing publicly available materials from the Mindfulness in Schools Program and Acceptance and Commitment Therapy. The MBI consists of 8 weekly groups, 45-60 minutes in length, and include 3-8 youth. Group content will consist of brief, age-appropriate mindfulness practices, videos, and discussions to engage participants. Parents will be involved at the beginning of each session and will receive a handout detailing session content. Each week will focus on a different aspect of mindfulness: introduction to mindfulness, attention, being with internal experiences, the stories minds tell, watching thought traffic, waking up to now, flow, and wrap-up/mindfulness in daily life. A home practice given each week will be discussed at the next group. Groups will be taught by two trained instructors with an ongoing mindfulness practice, who have training and experience teaching mindfulness to youth.
62001044|NCT02484703|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo by mouth (PO) twice daily (BID) for up to 26 weeks.
62001045|NCT02484703|EXPERIMENTAL|RO5186582 120 mg BID|Participants will receive RO5186582 at a dosage of 120 milligrams (mg) PO BID for up to 26 weeks.
62776630|NCT01353911|ACTIVE_COMPARATOR|Boceprevir 800 mg|TN NC participants start a 4 week lead-in with Peg-IFN + RBV, then receive Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.
62776631|NCT01353911|EXPERIMENTAL|Grazoprevir 400 mg/100 mg|As the result of an interim analysis, TN NC participants assigned to the 400 mg grazoprevir group were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV and will remain in the study.
62776632|NCT01353911|EXPERIMENTAL|Grazoprevir 800 mg/100 mg|As the result of an interim analysis, TN NC participants assigned to the 800 mg grazoprevir group were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV and will remain in the study.
62776633|NCT01353911|EXPERIMENTAL|OL Grazoprevir 100 mg|TN cirrhotic participants receive open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
62776634|NCT04100941|EXPERIMENTAL|standard suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the standard suction technique with 10ml negative pressure
62776635|NCT04100941|EXPERIMENTAL|slow pull|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the slow pull technique
62776636|NCT04100941|EXPERIMENTAL|wet suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the wet suction technique
62776637|NCT06531317||NP Subjects|Subjects suffering from NP pain after an SCI. Will receive a tDCS treatment.
62776638|NCT06502847||Case ABO1|Newborns who receive treatment due to the ABO Incompability will be included in this group.
62776639|NCT06502847||Case ABO2|Newborns who have the ABO Incompability, but do not require treatment will be included in this group.
62776640|NCT06502847||Control|Healthy newborns without any disease or health condition will be included in this group
62776641|NCT02727491|EXPERIMENTAL|dextromethorphan|1 mg/kg of dextromethorphan syrup orally 30 min preoperatively and then again 8 hours post-tonsillectomy
62776642|NCT02727491|PLACEBO_COMPARATOR|Placebo|30 min preoperatively and then again 8 hours postoperatively, received inactive placebo syrup identical in volume, appearance and taste as the experimental group
62776643|NCT05234203|EXPERIMENTAL|HTB Rejuvenate|4 capsules of study interventional supplement delivered as 2 capsules two times a day for 90 days.
62776644|NCT02175368|EXPERIMENTAL|Adhese One F Upgrade|Adhese One F Upgrade (AOFU) is administered after phosphoric acid etching (etch-and-rinse protocol).
62776645|NCT02501525|ACTIVE_COMPARATOR|UAS (+)|RIRS with ureteral access sheath: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
62776646|NCT02501525|EXPERIMENTAL|UAS (-)|RIRS without ureteral access sheath: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
62776647|NCT01065831|EXPERIMENTAL|Lifestyle counseling|This MINT-TLC group will be asked to attend 12 weekly counseling meetings focused on weight loss (if overweight), limiting sodium, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained Lay Health Advisors. Participants will attend weekly group classes targeted at lifestyle changes for the first 12 weeks (intensive phase); followed by three individual MINT sessions conducted monthly for the following three months (maintenance phase). The MINT-TLC sessions aim to help participants make useful therapeutic lifestyle changes (TLC) and develop skills to maintain these changes long-term.
62776648|NCT01065831|PLACEBO_COMPARATOR|Health Education Control Condition|Participants randomized to this control condition will receive traditional, group health education classes for 12 weeks delivered by experts on various health topics unrelated to hypertension such as cancer, health insurance, and depression.
62776649|NCT05364320||Men aged 50-64|
62776650|NCT05364320||Men aged 65 and over|
62776651|NCT05364320||Women aged 50-64|
62001046|NCT02484703|EXPERIMENTAL|RO5186582 40 mg BID|Participants will receive RO5186582 at a dosage of 40 mg PO BID for up to 26 weeks.
62001047|NCT02484703|EXPERIMENTAL|RO5186582 60 mg BID|Participants will receive RO5186582 at a dosage of 60 mg PO BID for up to 26 weeks.
62001048|NCT05782595|EXPERIMENTAL|Aquatic therapy|Aquatic exercise program: Each woman in group (A) will receive aquatic exercises for 40 minutes.
62001049|NCT06319326||Preterm infants|Preterm infants (≤33 weeks gestational age) of any birth weight receiving full bolus enteral feeding, aged 1-4 weeks.
62001050|NCT06319326||Term infants|Term infants of any birth weight aged 1-4 weeks.
62001051|NCT04433468|ACTIVE_COMPARATOR|RIPC|
62001052|NCT04433468|NO_INTERVENTION|Control|
62001053|NCT04411342||patients with type 2 diabetes|patients with type 2 diabetes and have normal range of albumine in urine and decline in renal functions
62001054|NCT06424080|OTHER|laparoscopic partial nephrectomy|cases of renal cell carcinoma , localized tumors , candidate for laparoscopic partial nephrectomy
62776652|NCT05364320||Women aged 65 and over|
62776653|NCT04919096|EXPERIMENTAL|SCB-420|Subjects randomized to SCB-420 will receive SCB-420 2mg (0.05 mL) via intravitreal injection in the study eye every 4 weeks for the first 3 months.
62584831|NCT01681680|OTHER|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
62584832|NCT01316211|ACTIVE_COMPARATOR|coflex™|Implantation of coflex™ device in assigned patients
62776654|NCT04919096|ACTIVE_COMPARATOR|Aflibercept|Subjects randomized into Aflibercept (Eylea) group will receive Aflibercept (Eylea) 2 mg (0.05 mL) via intravitreal injection in the study eye every 4 weeks for the first 3 months.
62001055|NCT06424080|OTHER|robotic partial nephrectomy|cases of renal cell carcinoma , localized tumors , candidate for robotic partial nephrectomy
62001056|NCT06375057||patients undergoing laparoscopic cholecystectomy|
62001057|NCT03407326|EXPERIMENTAL|Alternative|Participants will receive approximately 190 kcal/kg/day of alternative RUTF till recovery or up to 12 weeks of treatment.
62776655|NCT01362387|NO_INTERVENTION|Group 1|Women assigned to Group 1 will receive the standard post-abortion follow-up currently used at bpas and will be undertaken as usual by staff at the treating clinic
62776656|NCT01362387|EXPERIMENTAL|Group 2|Follow-up after medical abortion using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test.
62001058|NCT03407326|ACTIVE_COMPARATOR|Standard|Participants will receive approximately 190 kcal/kg/day of standard RUTF till recovery or up to 12 weeks of treatment.
62001059|NCT01521611|EXPERIMENTAL|Targeted radiotherapy|Patients receive therapy with an yttrium-90 labelled anti-CD66 following favourable dosimetry with the same antibody radiolabelled with indium-111.
62001060|NCT05882682||Consumers of cereal products|Caregivers with children under 5 years of age who are consumer of cereal products in the Eldoret area.
62394820|NCT00329433|EXPERIMENTAL|Desirudin (Iprivask™)|Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
62584833|NCT01316211|ACTIVE_COMPARATOR|Surgical decompression|Surgical decompression in patients with spinal stenosis without stabilization by an additional implant.
62584834|NCT05732779|EXPERIMENTAL|eMocha intervention|Adolescent patients randomized to the use of asynchronous mobile video directly observed therapy (DOT) intervention (eMocha DOT app)
62584835|NCT05732779|NO_INTERVENTION|Standard of care|Adolescent patients who continue enhanced goal-setting standard of care
62001061|NCT06207058||Influenza Positive|Subjects testing positive will receive baloxavir marboxil as a single oral dose as soon as possible and within 48-hours of influenza symptom onset. Dosing will be delivered based on the package insert
62001062|NCT06207058||Influenza Negative|Subjects testing negative for influenza will have no drug administered
62776657|NCT03161574|EXPERIMENTAL|FOLFOXIRI|patients with CRM positive who received FOLFOXIRI alone for 6 cycles before surgery
62776658|NCT05832749||Study Product: Ophtesis Bio 3%|Subjects to receive Ophtesis Bio 3% in one eye
62001063|NCT01690390|ACTIVE_COMPARATOR|Icotinib of Routine Dose|Oral Drug icotinib 125 mg three times per day
62001064|NCT01690390|EXPERIMENTAL|Icotinib of High Dose|Oral Drug icotinib 250 mg three times per day
62584836|NCT00522106|EXPERIMENTAL|A|Behavioral graded activity
62776659|NCT05832749||Control Product: Healon Endocoat 3%|Subjects to receive Healon Endocoat 3% in one eye
62776660|NCT06010134|EXPERIMENTAL|Control Group|Group 1 the control group received selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand pronator, wrist extensors, knee extensors and ankle dorsiflexors, coordination and balancing exercises.
62776661|NCT06010134|EXPERIMENTAL|Study group|Group 2 the study group received the same physical therapy program 15 min. plus Whole Body Vibration for 15 min.
62001065|NCT03193606|EXPERIMENTAL|nano silver fluoride solution|carious dentin to be treated with partial caries excavation with application of nano silver fluoride solution prior to glass ionomer restoration.
62001066|NCT03193606|NO_INTERVENTION|no nano silver fluoride|carious dentin to be treated with partial caries excavation without application of nano silver fluoride solution restored directly with glass ionomer.
62394821|NCT02247102|EXPERIMENTAL|Isomaltulose|Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)
62394822|NCT02247102|ACTIVE_COMPARATOR|Sucrose|Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)
62001067|NCT01456325|EXPERIMENTAL|Onartuzumab+Erlotinib|Participants will receive onartuzumab 15 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally once daily (QD) from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
62186144|NCT03871621|ACTIVE_COMPARATOR|Standard of care (SOC) group|T2D subjects aged 20-80 years, presenting with HbA1C 7.1-9.0%, preserved kidney function (defined as estimated glomerular filtration rate (eGFR) \> 60 mL/min/1.73 m2), preserved LV function (defined as EF ≥ 50% by echocardiographic screening in the initial 2-week run-in period), and those treated with oral anti-diabetic drugs (except SGLT2i) and/or insulin therapy at least 3 months prior to the study were randomised to SOC treatment group.
62569814|NCT05345392|ACTIVE_COMPARATOR|Health and Wellness Intervention (HWI)|The control intervention, Health and Wellness Intervention (HWI), is a manualized intervention that's inspired by the Health Enhancement Program that has been adapted for youth 11-14 years old, using brief, engaging, and age-appropriate activities to address topics related to physical and mental health. HWI consists of 8 weekly groups, 45-60 minutes in length, and include 3-8 youth. Parents will be involved at the beginning of each session and will receive a handout detailing session content. HWI will include the following modules: stress management, social support, strengths and values, sleep health, nutrition, and exercise. As with the MBI, a home practice given each week will be discussed at the next group. Groups will be taught by two trained instructors without extensive mindfulness practice or training. The intervention will be matched on time and social interaction, but the HWI will not contain any mindfulness or cognitive behavioral therapy (CBT) components.
62569815|NCT01871623|EXPERIMENTAL|Segmental Le Fort I Osteotomy|For some cases that bone filling over cleft site is not good enough for tooth movement, it is possible that we put them into this group which means by using Segmental Le Fort I Osteotomy to approximate two dental alveolar segments.
62569816|NCT01871623|ACTIVE_COMPARATOR|One-piece Le Fort I Osteotomy|For patients having ideal bone graft result over cleft site, traditional One-piece Le Fort I Osteotomy will be performed.
62569817|NCT04071912||ACL|All sports patients who had a muscle evaluation at 3-4 months and 6-8 months after ACL ligamentoplasty since January 2016
62186145|NCT04820647|EXPERIMENTAL|Kessler Foundation STRength IDentification and Expression (KF-STRIDE)|
62001068|NCT01456325|PLACEBO_COMPARATOR|Placebo+Erlotinib|Participants will receive onartuzumab matching placebo on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally QD from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
62001069|NCT01469468|EXPERIMENTAL|Single arm, fixed sequence dosing|
62001070|NCT03077165|EXPERIMENTAL|Group A|S42909 dose 100 mg p.o., 50 mg bid
62186146|NCT04820647|NO_INTERVENTION|Services as Usual|
62394823|NCT05031156|ACTIVE_COMPARATOR|non-splinting of OT Bridge system|Leaving the dental implants abutments solitary followed by denture pick up
62569818|NCT06455553|OTHER|Intervention (additional blood sample)|
62584837|NCT00522106|ACTIVE_COMPARATOR|B|Exercise therapy
62776662|NCT00375167|EXPERIMENTAL|Recovery Workbook Intervention|12-week Recovery Intervention: The intervention is a 12-week group-based intervention. The intervention is informed by the Recovery Workbook- a validated intervention for people with serious mental illness. The intervention includes 2 hour sessions for 12 weeks that focus on the following areas: Introduction to the intervention; Recovery; Knowledge and Control; Managing life stress; Enhancing personal meaning; Building personal support; and Setting personal goals. The total time period of the intervention is 24 hours. Participants in this arm also receive treatment as usual.
62776663|NCT00375167|NO_INTERVENTION|Treatment as usual|The participants in the control arm will continue to receive treatment as usual. TAU is Assertive Community Treatment. Assertive Community Treatments are structured to meet set fidelity standards that are evidence-based. This arm did not receive any intervention.
62776664|NCT03973762|EXPERIMENTAL|DR Grading with CAD|DR Grading with CAD
62776665|NCT03973762|OTHER|DR Grading by expert panel|DR Grading by expert panel
62776666|NCT03870425|PLACEBO_COMPARATOR|MINCED-SKEWED|Minced meat administered with a skewed protein distribution pattern
62776667|NCT03870425|EXPERIMENTAL|MINCED-EVEN|Minced meat administered with an even protein distribution pattern
62776668|NCT03111953|ACTIVE_COMPARATOR|RYGB|Subjects received Roux-en-Y Gastric Bypass surgery.
62776669|NCT03111953|EXPERIMENTAL|BPD|Subjects received Biliopancreatic Diversion Surgery
62776670|NCT01020084||Control|Subjects with normal salivary flow rate
62776671|NCT01020084||Hyposalivation|Subjects presenting low salivary flow rate as a side effect of systemic isotretinoin therapy.
62776672|NCT03422536|EXPERIMENTAL|Arm I (ficlatuzumab)|Patients receive ficlatuzumab IV over 30-60 minutes every 2 weeks in the absence of disease progression or unaccepted toxicity. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62001071|NCT03077165|EXPERIMENTAL|Group B|S42909 dose 200 mg p.o., 100 mg bid
62001072|NCT03077165|EXPERIMENTAL|Group C|S42909 dose 400 mg p.o., 200 mg bid
62001073|NCT03077165|EXPERIMENTAL|Group D|S42909 dose 800 mg p.o., 400 mg bid
62186147|NCT01232400|EXPERIMENTAL|esmolol|Esmolol will be used preferentially to control hypertension.
62186148|NCT01232400|NO_INTERVENTION|Standard care|Standard care for SAH includes other hypertensives such as nicardipine.
62186149|NCT00745771|ACTIVE_COMPARATOR|1|200 mg Ketoprofen
62186150|NCT00745771|ACTIVE_COMPARATOR|2|100 mg Ketoprofen
62186151|NCT05611853|EXPERIMENTAL|3.5mg/kg|Will be administered by intravenous infusion every 3 weeks on D1
62186152|NCT05611853|EXPERIMENTAL|4.2mg/kg|Will be administered by intravenous infusion every 3 weeks on D1
62186153|NCT05611853|EXPERIMENTAL|5.0mg/kg|Will be administered by intravenous infusion every 3 weeks on D1
62186154|NCT00682227|EXPERIMENTAL|1|
62394824|NCT05031156|EXPERIMENTAL|splinting of OT Bridge|Splinting of implants abutments using titanium wire then followed by denture pick up
62001074|NCT03077165|EXPERIMENTAL|Group E|S42909 dose 1200 mg p.o., 600 mg bid
62001075|NCT03077165|PLACEBO_COMPARATOR|Group F|Placebo p.o. bid
62001076|NCT02306356|EXPERIMENTAL|Interventional|Behavioral: Internet-delivered Cognitive Behavior Therapy
62001077|NCT04525612|EXPERIMENTAL|68Ga-BNU-PSMA|Each subject receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT imaging within the specificed time.
62001078|NCT00207142|ACTIVE_COMPARATOR|Switch|ATV 400 mg + 2 NRTIs (TBD), ATV once daily, NRTIs (TBD)
62001079|NCT00207142|ACTIVE_COMPARATOR|Continuation|ATV 300 mg + RTV 100 mg + 2 NRTIs (TBD), ATV and RTV once daily, NRTIs (TBD)
62001080|NCT00207142|OTHER|Rescue|ATV 300 mg + RTV 100 mg + 2 NRTIs (TBD), ATV and RTV once daily, NRTIs (TBD)
62001081|NCT01067352|EXPERIMENTAL|Group A (A1)|Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive Saizen at the daily dose of 0.035 milligram (mg)/kilogram (kg) (Group A1) or no treatment (Group A2) for two years.
62394825|NCT06252545|OTHER|Interview Group|Subjects with pancreatic carcinoma who joined the interview group.
62394826|NCT06252545|OTHER|User Testing Group|Subjects with pancreatic carcinoma who joined the user testing group
62394827|NCT01546909|EXPERIMENTAL|TETRAVAC-ACELLULAIRE|
62776673|NCT03422536|EXPERIMENTAL|Arm II (ficlatuzumab, cetuximab)|Patients receive cetuximab IV over 60 -120 minutes and ficlatuzumab IV over 30-60 minutes every 2 weeks in the absence of disease progression or unaccepted toxicity. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62001082|NCT01067352|NO_INTERVENTION|Group A (A2)|Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive no treatment (Group A2) for two years.
62001083|NCT01067352|NO_INTERVENTION|Group B|Participants were allocated to Group B being third percentile (thus showing a spontaneous catch-up growth).
62001084|NCT01988870|EXPERIMENTAL|Intra-operative Radiation Therapy (IORT)|Following breast conserving surgery, a CT-based plan will be prepared to deliver highly conformal IORT and the treatment will be administered.
62001085|NCT02963493|EXPERIMENTAL|melphalan flufenamide (melflufen) + dexamethasone|Melphalan flufenamide (melflufen) 40 mg Day 1 and dexamethasone 40 mg (20 mg for patients 75 years or older) on Days 1, 8, 15 and 22 of each 28-day cycle.
62001086|NCT00515827|EXPERIMENTAL|Raltegravir then Placebo (Arm A)|400 mg raltegravir (MK-0518) administered twice daily in addition to optimized background regimen (OBR) from entry to Week 12; halt raltegravir at Week 12 and add placebo twice daily for 12 weeks
62001087|NCT00515827|EXPERIMENTAL|Placebo then Raltegravir (Arm B)|Placebo administered twice daily in addition to OBR from entry until Week 12; halt placebo at Week 12 and add 400 mg raltegravir tablet twice daily for 12 weeks
62394828|NCT03639038||Blood Assay Phase - 1|TB Positive / HIV Positive: 65 participants
62776674|NCT06136611|EXPERIMENTAL|Optune|Patients will apply TTFields (a treatment device referred to as Optune) before surgery and continue using this once the stitches are removed (approximately one to two weeks after surgery). Patients will wear the Optune application for 2 to 3 weeks before their standard-of-care (SoC) surgery and 3 to 4 weeks after the surgery (while awaiting their postoperative radiotherapy). Treatment with TTFields will be delivered through 4 transducer arrays with 9 insulated electrodes each placed on the shaved scalp and connected to a portable device set to generate 200-kHz electric fields within the brain.
62001088|NCT06116422|ACTIVE_COMPARATOR|Cash Benefit Group|Provides financial support weekly, in the form of an unrestricted cash benefit. The investigators will partner with Held to provide the card to participants, load the card with $50/week for the 12 months of enrollment, and view the purchases at the vendor level using an existing dashboard Held maintains. Participants will also receive a monthly nutrition guidance brochure tailored to the infant's developmental stage.
62001089|NCT06116422|ACTIVE_COMPARATOR|Grocery Benefit Group|Provides financial support weekly in the form of a grocery benefit. The investigators will enroll participants in the Food Lion MVP program, linking the account to a Duke email address. The study team will work with the participants to order $50 worth of groceries from Food Lion, for the participants to pick up from the store. Groceries will be ordered weekly for the 12 months of enrollment and coordinators will have access to view items purchased at Food Lion by each participant.
62394829|NCT03639038||Blood Assay Phase - 2|TB positive / HIV Negative: 65 participants
62394830|NCT03639038||Blood Assay Phase - 3|TB positive and negative Paediatric: 30 participants
62776675|NCT06136611|NO_INTERVENTION|Non-Experimental Arm|Patients will follow the routine care pathway for glioblastoma and timings of the following will be determined by the clinical team.
62776676|NCT03564002||obese subjects|
62776677|NCT03564002||lean subjects|
62776678|NCT00093821|EXPERIMENTAL|Treatment (tanespimycin)|"Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11 (for patients with solid tumors) OR days 1, 4, 8, 11, 15, and 18 (for patients with leukemia). Courses for all patients repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tanespimycin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 15 patients are treated at the MTD."
62394831|NCT03639038||Blood Assay Phase - 4|TB Negative/HIV positive: 50 participants
62394832|NCT03639038||Blood Assay Phase - 5|Healthy controls: 30 participants
62394833|NCT03639038||Sputum Collection Phase - 1|TB Positive: Xpert Rif sensitive: 100 participants
62394834|NCT03639038||Sputum Collection Phase - 2|TB Positive: Xpert Rif resistant: 20
62394835|NCT03639038||Sputum Collection Phase - 3|TB Negative: Other chest: unknown number
62394836|NCT03639038||Sputum Collection Phase - 4|TB Negative: Smear negative/Xpert negative: 20
62394837|NCT06182839|ACTIVE_COMPARATOR|Canagliflozin (Invokana) 300 mg tablet|
62394838|NCT06182839|PLACEBO_COMPARATOR|Placebo tablet|
62394839|NCT06122961||Atherosclerotic cardiovascular disease (ASCVD) with chronic kidney disease (CKD)|electronic case report form (eGFR) below 60 ml/min/1.73m\^2
62394840|NCT06122961||ASCVD without CKD|eGFR greater than or equal to 60 ml/min/1.73m\^2
62394841|NCT06122961||HF with preserved ejection fraction (HFpEF) or HF with mildly reduced ejection fraction (HFmrEF)|
62584838|NCT06068218|OTHER|Patient Group|
62001090|NCT06292715|EXPERIMENTAL|microwave ablation of the spleen combined with splenic artery occlusion|The ablation puncture needle is percutaneously punctured into the spleen under ultrasound guidance, and the ablation method of one needle and multi-point method and needle insertion and pulling is mostly used
62001091|NCT00647621|EXPERIMENTAL|1|Extended Phenytoin Sodium Capsules 100 mg
62186155|NCT03654768|ACTIVE_COMPARATOR|Arm I (bosutinib, dasatinib, nilotinib, imatinib)|Patients receive bosutinib PO daily or dasatinib PO daily or nilotinib PO BID or imatinib PO daily on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62186156|NCT03654768|EXPERIMENTAL|Arm II (ruxolitinib phosphate, dasatinib, nilotinib, imatinib)|Patients receive ruxolitinib phosphate PO BID on days 1-90, and bosutinib PO daily or dasatinib PO daily or nilotinib PO BID or imatinib PO daily on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62186157|NCT04293952|EXPERIMENTAL|BRACE group|BRACE include combination of exercises including, Balance, Resistance, Aerobic, Cognition Exercises.
62186158|NCT04293952|ACTIVE_COMPARATOR|BRE group|this group include Balance Resistance Exercises Stretching Range Of Motion exercises Ankle flexion Ankle extension Knee flexion Knee extension Hip flexion Hip extension Hip adduction Hip abduction
62186159|NCT03965780|EXPERIMENTAL|Training group|Participants in the training group will receive a 13-week training program delivered via videoconference. The program includes 13 modules delivered via videoconference over the course of the 3-month program in weekly 60- to 90-minute sessions. Participants will receive a training manual, be shown filmed vignettes, and will have access to a chatroom and an online resource centre.
62186160|NCT03965780|NO_INTERVENTION|Wait-list control group|Participants in the wait-list control group will not receive the training program and will have no access to the resources indicated above.
62186161|NCT05056727|EXPERIMENTAL|Sodium Zirconium Cyclosilicate (SZC)|SZC 5 g every other day to 15 g once daily + Lisinopril/Valsartan
62186162|NCT05056727|PLACEBO_COMPARATOR|Placebo|Placebo + Lisinopril/Valsartan
62394842|NCT06122961||Heart failure (HF) with reduced ejection fraction (HFrEF)|
62001092|NCT00647621|ACTIVE_COMPARATOR|2|Dilantin® Kapseals® 100 mg
62001093|NCT04737538|EXPERIMENTAL|Experimental Dentifrice|Participants assigned to this arm will apply full ribbon of toothpaste (containing sodium bicarbonate, sodium hyaluronate and sodium fluoride) to cover the head of toothbrush provided and will brush their teeth for one timed minute twice a day (morning and evening).
62186163|NCT01186731|EXPERIMENTAL|Liposome Entrapped Docetaxel (LE-DT)|
62186164|NCT03029819|ACTIVE_COMPARATOR|Mindfulness-based Addiction Treatment (MBAT)|Nicotine patch; self-help guide; MBAT
62186165|NCT03029819|EXPERIMENTAL|iQuit Mindfully|Nicotine patch; self-help guide; MBAT; text messaging
62186166|NCT06469567|EXPERIMENTAL|Intervention Arm|"The target group received enhanced intervention in the form of culturally appropriate pamphlets/flipchart and doctor counselling."
62186167|NCT06469567|PLACEBO_COMPARATOR|Control Arm|The control group will receive the usual standard of care without the enhanced intervention.
62186168|NCT02421536|EXPERIMENTAL|Vibrent Smartphone Application|"We propose to pilot the application of the mobile application VibrentTM (research procedure) during a course of head and neck radiotherapy for eligible study subjects. Study subjects will be prospective consented and enrolled and will have baseline out of clinic assessment with the Vibrent smartphone application (research procedure)."
62186169|NCT01918371||Patients with RVO|Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.
62186170|NCT01918371||Patients with DME|Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.
62186171|NCT03980197|EXPERIMENTAL|Intervention|Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.
62186172|NCT03980197|ACTIVE_COMPARATOR|Control|No active surveillance test and preemptive isolation performed. Only standard precaution is needed, and if clinical isolates reveals MDRO, start contact precaution.
62186173|NCT01426113|EXPERIMENTAL|bimatoprost ophthalmic solution formulation A and vehicle|1 drop bimatoprost vehicle in the affected eye(s) in the morning and 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning and 1 drop bimatoprost vehicle in the affected eye(s) in the evening for 6 additional weeks.
62186174|NCT01426113|ACTIVE_COMPARATOR|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
62186175|NCT00321685|EXPERIMENTAL|Treatment (bevacizumab and chemoradiotherapy)|See Detailed Description
62001094|NCT04737538|ACTIVE_COMPARATOR|Positive control|Participants assigned to this arm will apply full ribbon of toothpaste (dentifrice containing 67% w/w sodium bicarbonate and 0.221% w/w sodium fluoride) to cover the head of toothbrush provided and will brush their teeth for one timed minute twice a day (morning and evening).
62001095|NCT04737538|ACTIVE_COMPARATOR|Negative control|Participants assigned to this arm will apply full ribbon of toothpaste (dentifrice containing 1100ppm fluoride as sodium fluoride \[Crest Cavity Protection\]) to cover the head of toothbrush provided and will brush their teeth for one timed minute twice a day (morning and evening).
62186176|NCT01547598|ACTIVE_COMPARATOR|LUMIGAN® RC|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
62394843|NCT03242291|ACTIVE_COMPARATOR|conventional resin-based flowable composite|
62394844|NCT03242291|OTHER|Hydroxyapatite Nanofiber reinforced flowable composite|
62394845|NCT06603571|EXPERIMENTAL|LY3841136 Dose 1|Participants will receive LY3841136 subcutaneously (SC)
62584839|NCT06068218|OTHER|Volunteer group|
62776679|NCT00610389|EXPERIMENTAL|1|
62776680|NCT01303198|ACTIVE_COMPARATOR|CPAP|Use of CPAP as treatment for sleep apnea
62569819|NCT03150719|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to TEZ/IVA fixed-dose combination tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 56 days.
62569820|NCT03150719|EXPERIMENTAL|TEZ/IVA|Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed-dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 56 days.
62001096|NCT03872180|EXPERIMENTAL|Venetoclax, bendamustine, obinutuzumab|Patients receive venetoclax PO on days 1-28 of course 1 and days 1-10 of subsequent courses, bendamustine IV on days 1 and 2, and obinutuzumab IV on days 1, 8, and 15 of course 1 and day 1 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unaccepted toxicity.
62001097|NCT02099214|EXPERIMENTAL|Patients with HFE hereditary haemochromatosis|"The patients (40) will undergo a medical examination in order to analyse their medical history, cardiovascular parameters and check inclusion and non-inclusion criterions.~Then will be performed :~* An electrocardiogram~* Blood tests : iron and cardiac markers (serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP), beta-hCG if needed, serum bank~* A 3Tesla cardiac MRI repeated twice (in order to respect the reproducibility criterion)~* A 3Tesla abdominal MRI~* An echocardiography at rest."
62001098|NCT02099214|EXPERIMENTAL|Healthy volunteers|"The healthy volunteers (10 men and 10 women) will undergo :~* A urinary pregnancy test (if applicable)~* A 3Tesla cardiac MRI repeated twice (in order to respect the reproducibility criterion)~* An echocardiography at rest."
62569821|NCT03540316|ACTIVE_COMPARATOR|Two short implants and 2 minutes LLLT|Patients receiving 2 short dental implants assisted mandibular over-denture and Low level laser therapy (LLLT) for 2 minutes .
62776681|NCT01303198|ACTIVE_COMPARATOR|APAP|Use of APAP as treatment for sleep apnea
62001099|NCT02586012|EXPERIMENTAL|TBW, LBM, IBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on TBW (Total Body Weight); Week 2, the dose will be based on LBM (Lean Body Mass); and Week 3, the dose will be based on IBW (Ideal Body Weight).
62776682|NCT04797871|EXPERIMENTAL|Exercise|Resistance training
62186177|NCT01547598|ACTIVE_COMPARATOR|DuoTrav®|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
62186178|NCT01135082|OTHER|1|Receive valent pneumococcal conjugated vaccine in HIV - infected children
62186179|NCT01135082|OTHER|2|Receive valent pneumococcal conjugated vaccine in HIV negative children
62186180|NCT01985646|EXPERIMENTAL|surgery treatment|one stage pull through left-colectomy
62394846|NCT06603571|EXPERIMENTAL|LY3841136 Dose 2|Participants will receive LY3841136 SC
62569822|NCT03540316|ACTIVE_COMPARATOR|Two short implants and 4 minutes LLLT|Patients receiving 2 short dental implants assisted mandibular over-denture and LLLT for 2 minutes .
62569823|NCT03540316|ACTIVE_COMPARATOR|Four short implants and 2 minutes LLLT|Patients receiving 4 short dental implants assisted mandibular over-denture and LLLT for 2 minutes .
62186181|NCT01985646|EXPERIMENTAL|conservative treatment|anal dilation, colonic lavage, oral probiotic
62186182|NCT00941642|ACTIVE_COMPARATOR|Lovaza|Single blind, active treatment arm Lovaza, is the only fish oil supplement approved by the FDA. The Lovaza treatment group will take 4g of Lovaza daily for a minimum of 48 weeks.
62394847|NCT06603571|EXPERIMENTAL|LY3841136 Dose 3|Participants will receive LY3841136 SC
62394848|NCT06603571|EXPERIMENTAL|LY3841136 Dose 1 + Tirzepatide Dose 1|Participants will receive LY3841136 SC and Tirzepatide SC
62394849|NCT06603571|EXPERIMENTAL|LY3841136 Dose 2 + Tirzepatide Dose 1|Participants will receive LY3841136 SC and Tirzepatide SC
62394850|NCT06603571|EXPERIMENTAL|LY3841136 Dose 2 + Tirzepatide Dose 2|Participants will receive LY3841136 SC and Tirzepatide SC
62776683|NCT04797871|ACTIVE_COMPARATOR|Standard care|Non-supervised ACSM exercise guidelines
62569824|NCT03540316|ACTIVE_COMPARATOR|Four short implants and 4 minutes LLLT|Patients receiving 4 short dental implants assisted mandibular over-denture and LLLT for 4 minutes .
62776684|NCT04241263|OTHER|Comparative assessment of data quality|Quantitative comparison between the current wired system and the new wireless system
62776685|NCT04241263|OTHER|Usability|Qualitative assessment of the new wireless system
62776686|NCT03117179|OTHER|Patient with an interview|
62569825|NCT06024174|EXPERIMENTAL|Part 1: DDI Cohort|
62569826|NCT06024174|EXPERIMENTAL|Part 1: Dose Escalation|
62569827|NCT06024174|EXPERIMENTAL|Part 2: Dose Expansion|
62569828|NCT06222138|EXPERIMENTAL|Patients with newly diagnosed glioblastoma|
62584840|NCT06682247||chidamide + PD-1/PD-L1 inhibitors +Bevacizumab or tyrosine kinase inhibitors|
62776687|NCT03117179|OTHER|Patient without an interview|
62776688|NCT06342973|EXPERIMENTAL|Xenograft and allograft|The group will consist of patients receiving horizontal ridge augmentation using a combination of Demineralized Freeze Dried Bone Allograft (DFDBA) layered with xenograft particulate bone using a resorbable collagen membrane. The DFDBA will be used internally in contact with the native bone and xenograft will be layered buccal to it.
62776689|NCT04841772|ACTIVE_COMPARATOR|Vegan Protein|
62776690|NCT04841772|PLACEBO_COMPARATOR|Placebo|
62776691|NCT01920737|EXPERIMENTAL|Leukemia Patients|"The treatment plan has 6 treatment cycles. The cycle names are listed in the following order:~Induction Phase I - Induction Phase II - Intensification I - Re-induction I - Intensification II - Re-induction II Each cycle is given over a period of 4-6 weeks and the interval between them can range between 1-3 weeks. Based the patients medical condition, the doctor may decide to change the timing of the drugs, the interval between the drugs in a cycle, or the interval between the cycles. After receiving all cycles you will continue with a 36 months treatment part that is called Maintenance."
62776692|NCT00439374|ACTIVE_COMPARATOR|17 alpha-hydroxyprogesterone caproate|250 mg of 17 alpha-hydroxyprogesterone caproate given by weekly injection until 37 weeks gestation or delivery
62776693|NCT00439374|PLACEBO_COMPARATOR|Placebo|Placebo oil given by weekly injection until 37 weeks gestation or delivery.
62776694|NCT04022655||ANCA-associated Vasculitis|Patients with ANCA-associated vasculitis admitted to the ICU
62186183|NCT00941642|PLACEBO_COMPARATOR|Placebo|Single blind, Placebo arm study drug will contain 994.0 mg of corn oil and 6mg of alpha tocopherol as an excipient in a soft gelatin capsule shell. Subjects will take 4g daily for a minimum of 48 weeks.
62186184|NCT06153030||Patient with right colonic diverticulitis|
62186185|NCT01527162|EXPERIMENTAL|SAFO worn|Child wears their prescribed SAFO for 14 days
62791689|NCT01939847|NO_INTERVENTION|Molecular prolfiling in blood|Participant's blood sample will be analyzed by Foundation Medicine on their FoundationOne platform - a targeted whole exome sequencing of 182 cancer related genes (3,230 exons) as well as 37 introns from 14 genes commonly rearranged or altered in cancer via next-generation sequencing technology; however, this is just being done to see if it is possible to generate similar results in blood samples. We do not yet know if blood sample results may be used for treatment decision (this will be tested in a future study) and results will not be given to participants; therefore, no treatment suggestion will be given.
62001100|NCT02586012|EXPERIMENTAL|LBM, IBW, TBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on LBM (Lean Body Mass); Week 2, the dose will be based on IBW (Ideal Body Weight); and Week 3, the dose will be based on TBW (Total Body Weight).
62001101|NCT02586012|EXPERIMENTAL|IBW, TBW, LBM|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on IBW (Ideal Body Weight); Week 2, the dose will be based on TBW (Total Body Weight); and Week 3, the dose will be based on LBM (Lean Body Mass).
62001102|NCT02586012|EXPERIMENTAL|TBW, IBW, LBM|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on TBW (Total Body Weight); Week 2, the dose will be based on IBW (Ideal Body Weight); and Week 3, the dose will be based on LBM (Lean Body Mass).
62001103|NCT02586012|EXPERIMENTAL|LBM, TBW, IBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on LBM (Lean Body Mass); Week 2, the dose will be based on TBW (Total Body Weight); and Week 3, the dose will be based on IBW (Ideal Body Weight).
62001104|NCT02586012|EXPERIMENTAL|IBW, LBM, TBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on, IBW (Ideal Body Weight); Week 2, the dose will be based on LBM (Lean Body Mass); and Week 3, the dose will be based on TBW (Total Body Weight).
62001105|NCT06077188|EXPERIMENTAL|intervention group|
62001106|NCT06077188|NO_INTERVENTION|Control group|
62001107|NCT03423732|ACTIVE_COMPARATOR|Active Group|Patients randomized to the active treatment group will receive CardioCell consist 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin); 15 000 000 via common femoral artery injection and 15 000 000 via intramuscular injections above the knee (ATK, 6 injection sites) and below the knee (BTK, 6 injection sites).
62001108|NCT03423732|PLACEBO_COMPARATOR|Control Group|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) injections in the same manner.
62001109|NCT03521453||Before|Conventionnel written information
62001110|NCT03521453||After, with PEPPER|Written information + presence of a robot (PEPPER) in the waiting room, who will give informations.
62001111|NCT03689764|EXPERIMENTAL|Group A|Group A underwent interactive video game-based exercise for the initial 6 weeks, with no treatment in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
62394851|NCT06603571|EXPERIMENTAL|LY3841136 Dose 3 + Tirzepatide Dose 3|Participants will receive LY3841136 SC and Tirzepatide SC
62394852|NCT06603571|ACTIVE_COMPARATOR|Tirzepatide Dose 3|Participants will receive Tirzepatide SC
62394853|NCT06603571|EXPERIMENTAL|LY3841136 Dose 2 + Tirzepatide Dose 3|Participants will receive LY3841136 SC and Tirzepatide SC
62394854|NCT06603571|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo administered SC.
62394855|NCT01287260|EXPERIMENTAL|Arm1|
62001112|NCT03689764|EXPERIMENTAL|Group B|Group B had no intervention in the first 6 weeks and then received interactive video game-based exercise in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
62001113|NCT02722928|NO_INTERVENTION|Conventional 1:1 oxygen/air gas mixture|80 patients will receive ventilation during the surgery with a 1:1 oxygen / air gas mixture
62001114|NCT02722928|EXPERIMENTAL|Pure oxygen ventilation|Patients will receive controlled ventilation with a conventional 1:1 oxygen / air gas mixture (60% oxygen concentration) during the approach and tumor removal phases. Once tumor resection is completed and hemostasis started, this group of patients will be switched to ventilation with 100% (pure) oxygen concentration
62394856|NCT01287260|ACTIVE_COMPARATOR|Arm 2|
62394857|NCT06384599|EXPERIMENTAL|VT Cryoablation Arm|all subjects will receive a cryoablation procedure with the VT System and be followed up for 6-month
62569829|NCT04803344|EXPERIMENTAL|Experimental Group|After the childbirth, writing group participants has been asked to write for 3 consecutive days, 20 minutes each days, all the deepest emotions and feelings related to the pregnancy.
62001115|NCT01624428|ACTIVE_COMPARATOR|varenicline|
62001116|NCT01624428|PLACEBO_COMPARATOR|Placebo|
62186186|NCT01527162|NO_INTERVENTION|SAFO not worn|Child does not wear the prescribed SAFO for 14 days
62186187|NCT05293197|EXPERIMENTAL|SonoCloud®|SonoCloud® : dose escalation 6 cycles of sonication
62186188|NCT00348868|EXPERIMENTAL|1|enhanced behavioral motivation counseling
62186189|NCT00348868|ACTIVE_COMPARATOR|2|
62186190|NCT04467346|EXPERIMENTAL|Ped-TMZ|Single oral administration on D1 or D2 according to randomization at the dose of 200 mg/m2. Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition.
62394858|NCT02187718|OTHER|SNPGA|Sentinel Node Procedure under General Anaesthesia
62394859|NCT02187718|OTHER|SNPLA|Sentinel Node Procedure under Local Anaesthesia
62394860|NCT05365204|EXPERIMENTAL|Voluven diluted indocyanine green|This arm participants uses Voluven diluted ICG for sentinel lymph node mapping.
62394861|NCT05365204|ACTIVE_COMPARATOR|Distilled-water diluted indocyanine green|This arm participants uses Distilled-water diluted ICG for sentinel lymph node mapping.
62569830|NCT04803344|ACTIVE_COMPARATOR|Control Group|
62001117|NCT04939285|EXPERIMENTAL|PEEP=5cmH2O|In PSV mode,PS = 8 cmH2O,PEEP= 5 cmH2O, and FiO2 level was consistent with that before SBT
62569831|NCT03682848|EXPERIMENTAL|Participants receiving DTG + 3TC FDC|Eligible participants will receive FDC of DTG + 3TC 50/300 milligrams, tablets, given orally once daily.
62569832|NCT00640120||1|Asthmatic subjects
62569833|NCT00640120||2|Healthy subjects
62569834|NCT04134533||Oral Feeding Group|Children with cerebral palsy who fed orally according to the Functional Oral Intake Scale
62776695|NCT01812512|OTHER|TIPS for HF Intervention HT Training-Charleston-Pre/Post|Group 1 (Charleston): In the proposed intervention, called Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF) , the observations from the previous RRP are used along with best practices from other studies of patient-centered communication in the VA , telephone coaching for chronic disease , problem-solving and counseling skills for telehealth nurse care managers , difficulties identified by patients working with the Health Buddy for telemonitoring , participation in provider-patient communication , essentials of patient education in heart failure process and content, and teach to goal theory to improve HF self-management for patients with low health literacy . Rather than an experimental trial, this implementation quasi-experimental pilot study examines pre- and post-training nurse practices and Veteran outcomes before and after communication skills training. The same intervention will then be delivered to Group 2 HT nurse care coordinators.
62776696|NCT01812512|OTHER|TIPS for HF Intervention HT Training-Columbia-Pre/Post|Group 2 (Columbia VAMC): To test the TIPS for HF educational intervention sufficiently in a sample not previously exposed to the information, the HT program at Dorn VA Medical Center in Columbia, South Carolina has volunteered to participate as a second study site. There are six nurse care coordinators who will be recruited; the larger number supports recruitment of a comparable number with 25 Veterans with HF to be recruited in the second site for a total of 50 Veterans. Both groups will use a purposeful sampling plan, beginning with an IRB-approved flyer for recruitment. The demographic make-up of the Charleston VAMC group is comparable Columbia HT group in age, race, and NYHA HF class. Also, consistent with an implementation quasi-experimental pilot study, the second site will examine pre-training and post-training nurse care coordinator communication practices and Veteran outcomes before and after communication skills training.
62776697|NCT02404428|ACTIVE_COMPARATOR|standard broccoli soup|one portion (300 g each) per week of a soup containing standard broccoli
62001118|NCT04939285|EXPERIMENTAL|PEEP=0cmH2O|In PSV mode,PS = 8 cmH2O,PEEP=0 cmH2O, and FiO2 level was consistent with that before SBT
62569835|NCT04134533||Non-Oral Feeding Group|Children with cerebral palsy who fed non-orally according to the Functional Oral Intake Scale.
62569836|NCT03242850|NO_INTERVENTION|Regular care group|This group will receive regular care including standard guidance on shared reading. Participants in this arm will not view the video at the time of enrollment nor will they receive the text messages throughout the 6 months of the randomized controlled trial.
62569837|NCT03242850|EXPERIMENTAL|Intervention group|
62569838|NCT00774501|EXPERIMENTAL|treatment of metastatic liver disease|The intervention is the use of image guidance with general anesthesia and suspended ventilation during treatment delivery. This will allow precise localization and delivery of dose to the tumor.
62569839|NCT01149980|EXPERIMENTAL|Citalopram|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's
62001119|NCT04615559|EXPERIMENTAL|contrast enhanced ultrasound|CEUS will be performed at one month post-op, six months post-op and at one year.
62569840|NCT01149980|ACTIVE_COMPARATOR|Celexa|Celexa 40 mg Tablets of Forest Labs
62001120|NCT05439356|EXPERIMENTAL|Colchicine Group|Patients in this arm will receive colchicine for 90 days in addition to standard medical care
62001121|NCT05439356|PLACEBO_COMPARATOR|Placebo Colchicine Group|Patients in this arm will receive placebo colchicine for 90 days in addition to standard medical care
62569841|NCT02593097|EXPERIMENTAL|Metformin first, then matching placebo|Subjects will be randomized into the Metformin group, treated for 12 weeks with a 4 week washout period in between treatments, then treated with matching placebo for 12 weeks.
62569842|NCT02593097|EXPERIMENTAL|Matching placebo first, then Metformin|Subjects will be randomized into the matching placebo group, treated for 12 weeks with a 4 week washout period in between treatments, then treated with Metformin for 12 weeks.
62776698|NCT02404428|EXPERIMENTAL|beneforte extra broccoli soup|one portion (300 g each) per week of a soup containing glucoraphanin-enriched broccoli named for the study 'Beneforte extra'
62776699|NCT00850083||Children in the ED|
62776700|NCT05420649|NO_INTERVENTION|Intubated general anesthesia LMS|Patients received LMS with intubated general anesthesia
62776701|NCT05420649|EXPERIMENTAL|Non-intubated LMS with apnea|Patients received non-intubated LMS with administration of muscle relaxant and optiflow(HFNO) device.
62569843|NCT05300581|OTHER|Observational Arm|Patients with a history of injection opioid use will receive home OPAT while also receiving substance use disorder care including medications for opioid use disorder and multidisciplinary health coach and case management support.
62569844|NCT04545671||Patients already implanted with study lens|No intervention as patients are already implanted.
62569845|NCT00917852|EXPERIMENTAL|GORE Conformable TAG® Thoracic Endoprosthesis|
62776702|NCT05420649|EXPERIMENTAL|Non-intubated LMS with spontaneous breathing|Patients received non-intubated LMS optiflow(HFNO) device and maintained spontaneous breathing.
62001122|NCT01150214||DE-MRI|All patients will undergo Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI)to quantify the degree of atrial structural remodeling or fibrosis pre-ablation and DE-MRI will be obtained at 3, 6, and 12 months follow-up to detect and quantify ablation-related scar formation.
62186191|NCT04467346|ACTIVE_COMPARATOR|Temodal capsule|Single oral administration on D1 or D2 according to randomization at the dose of 200 mg/m2. The administration will take place around 8:00 a.m. followed with 240 mL of tap water, in sitting position and under fasting condition
62186192|NCT00311246|EXPERIMENTAL|An open-label|Patients received adalimumab 40 mg weekly for 45 weeks, with a final follow-up at Week 52
62569846|NCT05131841|ACTIVE_COMPARATOR|One-week group|Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer
62569847|NCT05131841|EXPERIMENTAL|Three-week group|Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer
62001123|NCT01256710||Trifecta™ Valve Group|Subjects implanted with the Trifecta™ aortic bioprosthesis.
62569848|NCT03906617|EXPERIMENTAL|Bupivacaine/epinephrine + dexamethasone|
62569849|NCT03906617|ACTIVE_COMPARATOR|Liposomal bupivacaine|
62569850|NCT03098277|EXPERIMENTAL|Observational (physical activity, accelerometer, PROs)|Patients perform 2 physical activities in an exam room that are recorded using a Microsoft Kinect 2 stationary movement tracking device on days 1 and 21. The first activity is rising from a chair, walking 10 feet, and returning to the chair. The second activity is moving from the chair to the step-up examination table. Patients also wear a movement tracking wristband, Microsoft Band 2, around their wrist, complete a smartphone application based PRO questionnaire, and weigh themselves daily for 60 days.
62569851|NCT06182111||No morphine|Participants who have undergone surgery before anesthesia protocol was changed. These participants have not received morphine during surgery.
62569852|NCT06182111||Morphine|Participants who have undergone surgery after anesthesia protocol was changed. These participants have received morphine during surgery.
62776703|NCT00005834|EXPERIMENTAL|chemo with thalidomide|chemo with thalidomide
62776704|NCT00005834|ACTIVE_COMPARATOR|chemo without thalidomide|chemo without thalidomide
62776705|NCT03931694||All patients with chronic pain follow in pain clinic|
62776706|NCT05399290|ACTIVE_COMPARATOR|100 mg standard dose doxycycline BID|Oral, 12 weeks
62776707|NCT05399290|EXPERIMENTAL|20 mg sub-antimicrobial dose doxycycline BID|Oral, 12 weeks
62776708|NCT02807688|EXPERIMENTAL|Intervention|"Health Promotion Intervention package including elements of psychoeducation on healthy lifestyles and practical sessions of physical activity, with the use of motivational techniques."
62776709|NCT02807688|NO_INTERVENTION|Control|Control subjects receive treatment as usual at the Community Mental Health Services of the Department of Mental Health.
62776710|NCT03080636|EXPERIMENTAL|Men|11 men randomly underwent three experimental sessions in early morning prior to their work routine.
62776711|NCT03080636|EXPERIMENTAL|Women|9 women randomly underwent three experimental sessions in early morning prior to their work routine.
62394862|NCT04678089||Health group|The healthy control group mainly collected patients with other chronic diseases or blood tumors who did not meet the exclusion criteria and were not diagnosed with multiple myeloma. Also，we need some healthy volunteers. Healthy volunteers refer to people without serious physical disease, immune disease and family history of mental illness.There is no distinction between age, gender and nationality.
62569853|NCT06261489|EXPERIMENTAL|Tetrahydrocannabinol (THC) 25 mg|THC oil will be administered orally once a day for 15 weeks.
62776712|NCT01517386||paravertebral anesthesia|patients scheduled for elective unilateral thoracic surgery under paravertebral block and general anesthesia
62776713|NCT03753139||Atrial fibrillation|Patients with atrial fibrillation as recorded by Holter
62776714|NCT03753139||Sinus rhythm|Patients with sinus rhythm as recorded by Holter
62776715|NCT05095857|ACTIVE_COMPARATOR|S-ketamine|S-ketamine is given as a continuous infusion started at a dose of 2.0 mg/kg/hour. The infusion rate will be re-evaluated after 24 hours, where (1) the infusion will be stopped if 24 hours ensue without SDs, (2) maintained at 2.0 mg/kg/hour if the 24-hour incidence of SDs decreases below the rate of the previous 24 hours but SD is not totally abolished, or (3) increased to 3.0 mg/kg/hour if the incidence of SD is at or above the rate of the previous 24 hours. If the infusion rate has been increased to 3.0 mg/kg/hour, the rate will be returned to 2.0 mg/kg/hour if 24 consecutive hours of ECoG show no SD.
62776716|NCT05095857|PLACEBO_COMPARATOR|Isotonic saline|Isotonic saline is given as placebo. It will be given as a continuous infusion started at a dose corresponding to a dose of S-ketamine of 2.0 mg/kg/hour, and follow the criteria for increasing/decreasing infusion rates as S-ketamine. The infusion rate is read from a table listing different infusion rates (ml/hour) based on participant weight and if the treatment tier corresponds to a S-ketamine dose of 2 or 3 mg/kg/hour.
62776717|NCT05944627|EXPERIMENTAL|FURESTEM-OA Kit Inj.|"Subjects are slowly administered FURESTEM-OA Kit Inj. once into the knee joint cavity contained in a disposable sterile syringe mixed with Solution 1 and Solution 2 depending on the dose group assigned at the baseline (Visit 2).~The subjects are assigned sequentially to the following 3 dose groups in Phase 1 clinical trial, and in Phase 2a clinical trial, the subjects are randomized to 1-2 dose groups below MTD determined in Phase 1."
62394863|NCT04678089||Multiple Myeloma group|In the exposure group, all patients with multiple myeloma met the inclusion and did not meet exclusion criteria, including planning for autologous stem cell transplantation or not. There is no distinction between age, gender and nationality.
62776718|NCT05944627|PLACEBO_COMPARATOR|Placebo|Product name: Placebo of FURESTEM-OA Kit Inj. (placebo administration in Phase 2a clinical trial)
62394864|NCT03418727|EXPERIMENTAL|Study Drug Arm #1|Combination Therapy: brimonidine (0.2%) administered as eye drops, followed by corticosteroid eye drops, two times a day (BID) for 12 weeks
62569854|NCT06261489|EXPERIMENTAL|Cannabidiol (CBD) 50 mg|CBD oil will be administered orally once a day for 15 weeks.
62569855|NCT02084810|ACTIVE_COMPARATOR|NovoSeven®|
62569856|NCT02084810|EXPERIMENTAL|Eptacog alfa A 6 mg|
62569857|NCT06099522|EXPERIMENTAL|Internet-based cognitive behavioral therapy (iCBT)|"An 8-module internet-delivered cognitive behavioral therapy program. Participants receiving treatment will simultaneously use Spelpaus - a self-exclusion gambling service."
62776719|NCT04071678||A: Model A|Mode A was silent mode, back-to-back with endoscopic physicians to simultaneously display endoscopic images and record video, but did not interfere with the operation of endoscopic physicians.After the operation, the AI model automatically generates an endoscopy report, which is compared with the official report given by the endoscopy doctor in the endoscopy system. If the difference is large, video verification shall be played back immediately or endoscopic examination shall be performed again before the patient wakes up
62001124|NCT04347486|EXPERIMENTAL|Sugammadex 2mg|Administer 2mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
62001125|NCT04347486|EXPERIMENTAL|Sugammadex 4mg|Administer 4mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
62001126|NCT04347486|EXPERIMENTAL|Sugammadex 8mg|Administer 8mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
62001127|NCT04347486|ACTIVE_COMPARATOR|Conventional reversal|Administer conventional neuromuscular reversal agent (0.02mg/kg of atropine and 0.03mg/kg of neostigmine) on reappearance of T2 by Train-of-Four stimulation
62001128|NCT03314467||Cases DR|diabetic patients with diabetic retinopathy (DR)
62186193|NCT02250768|EXPERIMENTAL|GM-CSF|Injected oocytes were cultured in GM-CSF supplemented media until day of transfer
62569858|NCT06099522|NO_INTERVENTION|"Spelpaus (gambling self-exclusion)"|"Spelpaus only - a self-exclusion gambling service."
62569859|NCT00319579||Observation|Living Kidney Donors with controls who have not donated a kidney and meet certain criteria at the time of the donor's donation (i.e. no hypertension, no kidney disease, etc.).
62394865|NCT03418727|EXPERIMENTAL|Study Drug Arm #2|Monotherapy: brimonidine (0.2%) administered as eye drops followed by placebo, two times a day (BID) for 12 weeks
62569860|NCT01464424|OTHER|TRAVATAN, then LUMIGAN|Travoprost 0.004% ophthalmic solution (TRAVATAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by bimatoprost 0.01% ophthalmic solution (LUMIGAN), same dose, same duration, as randomized, for a total duration of 12 weeks
62569861|NCT01464424|OTHER|LUMIGAN, then TRAVATAN|Bimatoprost 0.01% ophthalmic solution (LUMIGAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by travoprost 0.004% ophthalmic solution (TRAVATAN), same dose, same duration, as randomized, for a total duration of 12 weeks
62569862|NCT00031629|EXPERIMENTAL|Treatment (gemcitabine, docetaxel, G-CSF, pegfilgrastim)|Patients receive gemcitabine IV over 90 minutes on days 1 and 8, docetaxel IV over 1 hour on day 8, and G-CSF SC on days 9-15 or pegfilgrastim SC on day 9 only. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62569863|NCT05137782|EXPERIMENTAL|Arm 1|Patients and care partners receive specialty primary care and participate in pre- and post- functional MRI scans to measure the effects of the specialty palliative care intervention.
62569864|NCT01286610|OTHER|vibration therapy and electrical muscle stimulation|
62569865|NCT02518048|ACTIVE_COMPARATOR|LEO 90100 Aerosol foam|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g (LEO 90100 Aerosol foam)
62569866|NCT02518048|ACTIVE_COMPARATOR|Betesil® 2.25 mg|Betamethasone (as valerate). Each 7.5 cm x 10 cm medicated plaster contains: 2.250 mg of betamethasone valerate (corresponding to 1.845 mg of betamethasone).(Betesil® )
62001129|NCT03314467||Cases other|diabetic patiens with other/multiple ocular disorder(s)
62569867|NCT00611923|PLACEBO_COMPARATOR|B|Participants will take placebo flutamide
62569868|NCT00611923|EXPERIMENTAL|A|Participants will take flutamide
62776720|NCT04071678||B: Model B|Mode B is a delayed reminder mode. If the lesion is found during the operation, it is required to be moved to the middle of the visual field within 5 seconds. If the lesion has been detected by the AI model (the lesion has been circled in the picture), but the doctor does not move the lesion to the middle of the visual field within 5 seconds, the AI system will give an alarm prompt
62776721|NCT04071678||C: Model C|Mode C is a real-time reminder mode, which is an alarm prompt when the focus is captured in the visual field.
62001130|NCT03314467||Control|diabetic patients without ocular abnormalities
62394866|NCT03418727|PLACEBO_COMPARATOR|Control Arm|Placebo: sodium carboxymethylcellulose (0.25%) administered as eye drops followed by a second application, two time a day (BID) for 12 weeks
62569869|NCT04791722|ACTIVE_COMPARATOR|Wave 1|Properties in Wave 1 (n=4) will implement a smoke-free policy on January 1, 2020.
62569870|NCT04791722|EXPERIMENTAL|Wave 2|Properties in Wave 2 (n=4) will implement a smoke-free policy on May 1, 2020.
62569871|NCT04791722|EXPERIMENTAL|Wave 3|Properties in Wave 3 (n=4) will implement a smoke-free policy on October 1, 2020.
62584841|NCT04623216|EXPERIMENTAL|Sabatolimab 400mg|Safety cohort 1: Participants in this arm will receive sabatolimab 400mg intravenously every 4 weeks.
62776722|NCT02823379|EXPERIMENTAL|Physical Activity|A culturally relevant physical activity promotion program delivered using a Smartphone application.
62776723|NCT02823379|ACTIVE_COMPARATOR|Wellness Contact Control|A wellness contract control condition delivered using a Smartphone application.
62776724|NCT00995995||All patients|
62776725|NCT04645589||Myfortic|Oral administration
62584842|NCT04623216|EXPERIMENTAL|Sabatolimab 800mg|Safety cohort 2: Participants in this arm will receive sabatolimab 800mg intravenously every 4 weeks.
62394867|NCT01777022|NO_INTERVENTION|Current treatment|Current education and management protocols will be followed
62776726|NCT04771676|EXPERIMENTAL|Oncorine (H101)|H101 diluted in 5ml 0.9% sodium chloride solution will be intraperitoneally injected through the drainage catheter. Each patient will receive a dose of 1.5×10\^12 vp by i.p. administration on day 1 and 3.
62776727|NCT05874622|EXPERIMENTAL|VC005 Tablets Low Dose groups|
62776728|NCT05874622|EXPERIMENTAL|VC005 Tablets Medium Dose groups|
62776729|NCT05874622|EXPERIMENTAL|VC005 Tablets High Dose groups|
62776730|NCT05874622|EXPERIMENTAL|VC005 Tablets Placebo Low Dose groups|
62001131|NCT04249128|EXPERIMENTAL|Veg Collagen & Keratin Free (Hair Skin Nails)|Participants will receive a free 3 month supply of Collagen \& Keratin for Hair, Skin \& Nail Health
62001132|NCT04249128|EXPERIMENTAL|Veg Collagen Extended with Powder Free (Hair Skin Nails)|Participants will receive a free 3- month supply of Collagen \& Keratin for Hair, Skin \& Nail Health extended with a pro-berry powder
62001133|NCT04249128|EXPERIMENTAL|Veg Collagen & Keratin $$$ (Hair Skin Nails)|Participants will receive a paid 3-month supply of Collagen \& Keratin for Hair, Skin \& Nail Health
62001134|NCT04249128|EXPERIMENTAL|Veg Collagen Extended with Powder $$$ (Hair Skin Nails)|Participants will receive a paid 3-month supply of Collagen \& Keratin extended with pro-berry powder for Hair, Skin \& Nail Health
62776731|NCT05874622|EXPERIMENTAL|VC005 Tablets Placebo Medium Dose groups|
62776732|NCT05874622|EXPERIMENTAL|VC005 Tablets Placebo High Dose groups|
62569872|NCT05352464|EXPERIMENTAL|cervical traction with EMG biofeedback|"Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position.~Ask the patient to assume sitting position on a comfortable chair. Place surface electrodes of EMG biofeedback at the level of C5-6 Para spinal muscles to pick up the activity of the muscles and convert it to vis-ual and auditory impulses produced from the device. Tell the patient to try to relax the tension of the neck muscles as much as he can by lowering the visual and auditory impulses from the device"
62569873|NCT05352464|ACTIVE_COMPARATOR|cervical traction and conventional physical therapy|Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position.
62569874|NCT04110626||Expériences Animées Programme|The Expériences Animées programme involves supervised short movies and talks with secondary school and high school pupils about the use of psychoactive substances.
62569875|NCT03550755|EXPERIMENTAL|V3-Cervix|Biological: V3-Cervix V3-Cervix is a tableted immunotherapeutic derived from hydrolyzed, heat-inactivated, pooled blood and tumor tissue from women with cervical cancer
62569876|NCT03999151|ACTIVE_COMPARATOR|Arm A: Reference Group|Arm A will receive print educational materials about the benefits of exercise and diet for men with prostate cancer, with recommendations geared at men living with prostate cancer, mailed around the date of surgery. They also receive a 10-week text messaging program focused on recovery after radical prostatectomy surgery.
62569877|NCT03999151|EXPERIMENTAL|Arm B (Arm A + Exercise)|Arm B receives the following: Arm A material plus access to an online portal with additional educational materials to help improve exercise habits and various tools, such as the ability to track exercise; additional educational print materials on exercise; additional text messages over 2 years that supports healthy exercise habits; and a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with an exercise coach over 2 years.
62776733|NCT03599479|EXPERIMENTAL|Virtual reality group|"* After experiencing the VR machine in the transfer bed for 5 minutes, the subject moves to the operating room.~* After the subject moves to the surgical bed, he/she takes the appropriate position for the fluoroscopic pain intervention, and wears the virtual reality device (headset, headphone, smartphone).~* After the subject starts the VR program, the practitioner starts the fluoroscopic pain intervention.~* Lidocaine skin infiltration and description of the practitioner during the intervention are performed with the intervention when necessary."
62776734|NCT03599479|NO_INTERVENTION|Conventional group|The fluoroscopic pain intervention is performed using only local anesthetics and description of the practitioner during the intervention as in the conventional cases.
62776735|NCT01371045||Acromegaly|Patients carrying the diagnosis of acromegaly who are on long-acting somatostatin for at least 3 months prior to study enrollment.
62776736|NCT01371045||Carcinoid Syndrome|Patients carrying a diagnosis of carcinoid syndrome who are taking long-acting somatostatin for at least 3 months prior to study enrollment.
62776737|NCT01371045||Healthy Controls|
62776738|NCT00595816|EXPERIMENTAL|1|Active treatment: physical training and counselling
62776739|NCT04397419|EXPERIMENTAL|Intervention group|This group is administered a total of 750 ml Red Bull® Energy Drink at defined time-intervals.
62776740|NCT04397419|PLACEBO_COMPARATOR|Placebo group|This group is administered a total of 750 ml still water at defined time-intervals.
62776741|NCT05417308|ACTIVE_COMPARATOR|Arm I (topical minoxidil)|Patients apply minoxidil foam topically to affected areas of the scalp QD for up to 12 months in the absence of disease progression or unacceptable toxicity.
62776742|NCT05417308|EXPERIMENTAL|Arm II (orally minoxidil)|Patients receive minoxidil PO QD for up to 12 months in the absence of disease progression or unacceptable toxicity.
62776743|NCT03286283|EXPERIMENTAL|J-Plasma|Each study subject will receive one procedure with J-Plasma at enrollment.
62791690|NCT00377208|ACTIVE_COMPARATOR|Intervention Condition|Receives web-based feedback specific to their blood-pressure and other health-related conditions.
62791691|NCT00377208|NO_INTERVENTION|Control Condition|The control group receives preventative feedback, general to the population.
62584843|NCT04623216|EXPERIMENTAL|Sabatolimab + Azacitidine|Expansion cohort 3: Participants in this arm will receive sabatolimab at the recommended dose for expansion in combination with azacitidine.
62584844|NCT04623216|EXPERIMENTAL|Sabatolimab|Expansion cohort 4: Participants in this arm will receive sabatolimab at the recommended dose for expansion.
62791692|NCT02581215|EXPERIMENTAL|Arm A: Experimental Arm|"mFOLFIRINOX will be administered every 2 weeks, and consist of:~* Oxaliplatin 85 mg/m2 over 2-4 hours~* Irinotecan 165 mg/m2 over 90 minutes~* 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.~* Arm A will receive ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks."
62186194|NCT04721964|EXPERIMENTAL|Intervention|All 24 participants will daily consume 6 mg iron/kg body weight for 13 weeks to correct their anaemia and increase their iron stores.
62569878|NCT03999151|EXPERIMENTAL|Arm C (Arm A + Diet)|Arm C receives the following: Arm A material plus access to an online portal with additional educational materials to help improve diet habits and various tools, such as the ability to track diet; additional educational print materials on diet; additional text messages over 2 years that supports healthy diet habits; and a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with a diet coach over 2 years.
62569879|NCT03999151|EXPERIMENTAL|Arm D (Arm A + Exercise + Diet)|Arm D receives the following: Arm A material plus access to an online portal with additional educational materials to help improve exercise and diet habits and various tools, such as the ability to track exercise and diet; additional educational print materials on exercise and diet; additional text messages over 2 years that supports healthy exercise and diet habits; a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with an exercise coach over 2 years; and a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with a diet coach over 2 years.
62569880|NCT00746889|ACTIVE_COMPARATOR|Corticosteroid Injection|40 mg of intraarticular triamcinolone acetonide
62569881|NCT00746889|PLACEBO_COMPARATOR|Placebo Injection|Intraarticular injection of 0.9% saline
62569882|NCT05567653|EXPERIMENTAL|Probiotic treatment group|ca. 30 participants
62569883|NCT05567653|PLACEBO_COMPARATOR|Placebo group|ca. 30 participants
62569884|NCT05484999|EXPERIMENTAL|Dual interventions|Receive both interventions: MamaMeals and MamaMatters Interventions
62569885|NCT05484999|ACTIVE_COMPARATOR|Meals intervention only|MamaMeals
62569886|NCT05484999|SHAM_COMPARATOR|Control|Wait-list control (received MamaMeals between 16-20 weeks postpartum) (after primary data collection time point)
62569887|NCT01504464|EXPERIMENTAL|mesenchymal stem cell|Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection.
62569888|NCT01504464|EXPERIMENTAL|placebo|The patients who are in control group and underwent placebo injection.
62569889|NCT00757042|EXPERIMENTAL|Tezepelumab|Participants will receive a single dose of tezepelumab administered subcutaneously or intravenously. The starting dose will be 2.1 mg tezepelumab.
62569890|NCT00757042|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo administered subcutaneously or intravenously.
62569891|NCT04457232|EXPERIMENTAL|Basic Science (68Ga-FAPi-46 PET/CT)|Patients receive 68Ga-FAPi-46 IV and undergo PET/CT imaging over 20-50 minutes.
62569892|NCT04084418|EXPERIMENTAL|Control diet followed by VLCHF diet|"* Phase 1 (1 to 3 weeks): Insulin dose optimization with usual diet~* Phase 2 (6 weeks): Control diet (50% of energy from carbohydrates)~* Phase 3 (4 weeks): Washout period~* Phase 4 (6 weeks): VLCHF diet (10% of energy from carbohydrates)"
62569893|NCT04084418|EXPERIMENTAL|VLCHF diet followed by Control diet|"* Phase 1 (1 to 3 weeks): Insulin dose optimization with usual diet~* Phase 2 (6 weeks): VLCHF diet (10% of energy from carbohydrates)~* Phase 3 (4 weeks): Washout period~* Phase 4 (6 weeks): Control diet (50% of energy from carbohydrates)"
62394868|NCT01777022|OTHER|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
62394869|NCT02449005|EXPERIMENTAL|Group A|Group A (BM-MSCs/fibrin glue/collagen fleece) will receive regenerative treatment using autologous bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue
62394870|NCT02449005|EXPERIMENTAL|Group B|in Group B (Fibrin glue/collagen fleece), a collagen fleece enriched with autologous fibrin glue devoid of stem cells will fill the osseous defect
62394871|NCT02449005|ACTIVE_COMPARATOR|Group C|Group C will receive open flap debridement retaining the soft tissue wall of the pocket
62569894|NCT03773029|ACTIVE_COMPARATOR|isoflavone|100 mg soy isoflavone (as 2 capsules)
62569895|NCT03773029|PLACEBO_COMPARATOR|control|2 capsules of placebo
62569896|NCT06182202|NO_INTERVENTION|Individuals Without Amputation|No Intervention Tested in identical tasks for comparison to Individuals with Amputation
62394872|NCT04032002|OTHER|Patients hereditary bradykinetic angioedema|
62394873|NCT04032002|OTHER|healthy volunteers|
62569897|NCT06182202|EXPERIMENTAL|Individuals With Amputation|Tasks with a passive prosthesis Tasks with a powered active prosthesis
62569898|NCT05820633|EXPERIMENTAL|ultra hypo fractionation radiation therapy (UHF)|5 radiation treatments (5 Gy per fraction) to the prostate, seminal vesicle and pelvic nodes given every other day over 2 weeks for a total of 25 Gy.
62569899|NCT05820633|ACTIVE_COMPARATOR|standard of care fractionation (SOC)|20-25 radiation treatments (range: 1,8 to 2,15 Gy per fraction) to the prostate, seminal vesicle and pelvic nodes given in 20-25 working day treatments over 4-5 weeks for a total of 43 Gy to 46 Gy.
62569900|NCT00251238|EXPERIMENTAL|Ginkgo biloba extract EGb 761|Receiving daily Ginkgo biloba extract EGb 761
62569901|NCT00251238|PLACEBO_COMPARATOR|Placebo|Receiving daily placebo
62569902|NCT01640119|PLACEBO_COMPARATOR|no intervention|
62569903|NCT01640119|EXPERIMENTAL|Bicarbonate|
62569904|NCT01295827|EXPERIMENTAL|Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)|During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2.
62394874|NCT00783055|EXPERIMENTAL|Treatment|12 weeks of individually tailored intervention programmes based on participants individual wishes for daily activities e.g.ADL, mobility, social, mental or creative that they want to improve, conserve - and/or to revive.
62776744|NCT05490004|ACTIVE_COMPARATOR|Facilitator-Led VEGA|"Facilitator-led VEGA uses a group-based approach where participants complete the Violence, Evidence, Guidance, Action Project (VEGA) content as a virtual or face-to-face workshop (i.e., facilitator-led VEGA). In this study, all workshops will be virtual to prevent social gathering during COVID-19.~If a participant is randomized to this arm, the active control arm, they will be informed that they need to attend a facilitator-led VEGA session via virtual workshop format. The AC intervention will be facilitated via Zoom technology, by two trained facilitators with between 10 to 20 participants in each workshop (keeping the recommended 10:1 participant-to-facilitator ratio) and will last approximately 3 hours. The workshop approach is delivered by trained facilitators and is standardized via the use of a flexibly structured facilitator's guide. Facilitator-led VEGA will deliver material didactically with synchronous lecturing, use case-based role play, and include group-based polling."
62776745|NCT05490004|EXPERIMENTAL|Self-Directed VEGA|"Self-directed VEGA uses an approach where participants complete the Violence, Evidence, Guidance, Action Project (VEGA) content online as a self-directed educational activity, at their own pace in a series of modules. Individuals will register to access the VEGA Education Resources site. Participants have the option of completing the self-directed VEGA arm in either English or French as the VEGA Educational Resources site offers the content in French and English.~If a participant is randomized to the experimental arm, they will be asked to complete the self-directed VEGA at their convenience, within one week of when they are informed they have been asked to complete the self-directed VEGA program. It will take approximately 3 hours for participants to complete all modules.~Participants will read didactic material, complete case-based animated simulations, and complete individual multiple-choice questions with response feedback."
62776746|NCT01041287|ACTIVE_COMPARATOR|Nebivolol/ Metoprolol|"Subjects were randomized to nebivolol for 3 months. They crossed over to take 3 months of metoprolol succinate. The initial 5 mg daily dose of nebivolol was titrated to 10 mg daily after 2 weeks if their BP remained \>125/80, and subsequently titrated to 20 mg daily after another 2 weeks if the BP remained \>125/80. Similarly, the initial 50 mg daily dose of metoprolol succinate was titrated to 100 mg daily after 2 weeks if BP remained \>125/80, and further increased to 200 mg after 2 weeks if BP remained \>125/80."
62186195|NCT00248534|EXPERIMENTAL|IV Rituximab|"IV Rituximab 750mg/m2 single infusion every week for up to 4 weeks.~Induction: Rituximab (750mg/m2) Day 1, 8, 15 and 22 and Temozolomide \[TMZ\] (150mg/m2) days 1-7 and 15-21, followed by six cycles of consolidation TMZ 150-200mg/m2 x5/28days, followed by maintenance with methylprednisolone (1g IV every 28days) until progression"
62186196|NCT01503164|ACTIVE_COMPARATOR|Positive pressure therapy (PAP)|Positive airway pressure(PAP) therapy is the standard of care for patients with obstructive sleep apnea. During sleep, a mask is worn over the nose and connected to the PAP machine.
62394875|NCT01827462|EXPERIMENTAL|18-30 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.~Beginning with 2014-2015 season, Quadrivalent, inactivated influenza vaccine (IIV4) was given."
62186197|NCT01503164|SHAM_COMPARATOR|Lifestyle counseling|
62186198|NCT02761863||CD74 - VEGF arm|
62186199|NCT02171130|EXPERIMENTAL|Nasal glucagon|3 mg nasal glucagon powder delivered using a nasal powder dosing device.
62186200|NCT03498586|EXPERIMENTAL|Half-normal saline|
62186201|NCT03498586|ACTIVE_COMPARATOR|Normal saline|
62186202|NCT03984877||Amyloidosis|TAVI patients with diagnosis of amyloidosis
62186203|NCT03984877||Non-Amyloidosis|TAVI patients without diagnosis of amyloidosis
62186204|NCT02418962|EXPERIMENTAL|Group 1 (pilot group)|Group 1 will be comprised of 3 volunteers who will be vaccinated first before the rest for demonstration of safety. The safety volunteers will receive 2 escalating doses of PfSPZ vaccine at a two week interval, 1.35x10\^5 and 2.7x10\^5 PfSPZ.
62186205|NCT02418962|EXPERIMENTAL|Group 2|The second group of 14 - 20 volunteers will receive three vaccinations of 2.7x10\^5 PfSPZ Vaccine that will be given at 0, 8 and 16 weeks
62186206|NCT02418962|PLACEBO_COMPARATOR|Group 3|The third group of 7 - 10 volunteers will act as control group for group 2 and will receive three injections of normal saline at 0, 8 and 16 weeks respectively.
62186207|NCT06546358|ACTIVE_COMPARATOR|Trazadone|Participants will be started on trazodone 12.5 mg or quetiapine 6.25 mg in identical opaque gelatin capsules at bedtime. The doses will be increased to a maximum of 50 mg for trazodone and 25 mg for quetiapine.
62186208|NCT06546358|ACTIVE_COMPARATOR|Quetiapine|Participants will be started on trazodone 12.5 mg or quetiapine 6.25 mg in identical opaque gelatin capsules at bedtime. The doses will be increased to a maximum of 50 mg for trazodone and 25 mg for quetiapine.
62186209|NCT03962322|EXPERIMENTAL|Weaning TDI|A tissue doppler evaluation, using a sector transducer, will be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration in the modality of ventilation which precedes the trial, during the SBT and after extubation.
62394876|NCT01827462|EXPERIMENTAL|60-80 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.~Beginning with 2014-2015 season, High-Dose trivalent, inactivated influenza vaccine (TIV High-Dose) was given."
62569905|NCT01295827|EXPERIMENTAL|Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)|During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.
62569906|NCT01295827|EXPERIMENTAL|Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)|During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.
62569907|NCT01295827|EXPERIMENTAL|Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.
62569908|NCT01295827|EXPERIMENTAL|Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.
62569909|NCT01295827|EXPERIMENTAL|Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.
62569910|NCT01295827|EXPERIMENTAL|MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)|Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
62569911|NCT01295827|EXPERIMENTAL|MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
62569912|NCT01295827|EXPERIMENTAL|MEL: Pembrolizumab 10 mg/kg Q2W (Part B)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
62186210|NCT01376297|EXPERIMENTAL|Netupitant and Palonosetron plus dexamethasone|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
62186211|NCT01376297|ACTIVE_COMPARATOR|Aprepitant and Palonosetron plus dexamethasone|Oral aprepitant hard capsule 125 mg (on Day 1) + 80 mg daily (for the following two days) and oral palonosetron soft capsule 0.50 mg (on Day 1) given with oral dexamethasone at each scheduled chemotherapy cycle.
62569913|NCT01295827|EXPERIMENTAL|NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)|Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
62776747|NCT01041287|ACTIVE_COMPARATOR|Metoprolol/Nebivolol|"Subjects were randomized to metoprolol succinate for 3 months. They crossed over to take 3 months of nebivolol. The initial 5 mg daily dose of nebivolol was titrated to 10 mg daily after 2 weeks if their BP remained \>125/80, and subsequently titrated to 20 mg daily after another 2 weeks if the BP remained \>125/80. Similarly, the initial 50 mg daily dose of metoprolol succinate was titrated to 100 mg daily after 2 weeks if BP remained \>125/80, and further increased to 200 mg after 2 weeks if BP remained \>125/80."
62776748|NCT02726022||Chronic Hepatitis C Participants|Participants with chronic hepatitis C, who were under treatment with peg-interferon alfa-2a and ribavirin for four weeks, will be observed up to 24 weeks after end of treatment (EOT) (up to 72 weeks). Peg-interferon alfa-2a and ribavirin will be administered as per treating physician discretion and according to summary of product characteristics.
62776749|NCT00806143|ACTIVE_COMPARATOR|1|patients will undergo sequential bilateral rTMS treatment
62186212|NCT05501782||Questionnaire|
62186213|NCT00673556|EXPERIMENTAL|Course A1|
62394877|NCT01827462|EXPERIMENTAL|80-100 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.~Beginning with 2014-2015 season, High-Dose trivalent, inactivated influenza vaccine (TIV High-Dose) was given."
62776750|NCT00806143|ACTIVE_COMPARATOR|2|patients will undergo unilateral low frequency right sided DLPFC rTMS
62394878|NCT01770080|ACTIVE_COMPARATOR|Euminz®|Acute treatment (3 to 5 time topical use of Euminz® = 10%ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
62186214|NCT00673556|PLACEBO_COMPARATOR|Course A2|
62394879|NCT01770080|PLACEBO_COMPARATOR|Placebo|Acute treatment (3 to 5 time topical use of Placebo= 0,5% ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
62394880|NCT02109731|EXPERIMENTAL|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
62776751|NCT03899051|EXPERIMENTAL|Test group|Papilla reconstruction would be done with platelet rich fibrin
62776752|NCT03899051|ACTIVE_COMPARATOR|Control group|Papilla reconstruction would be done with subepithelial connective tissue graft
62776753|NCT05722223|EXPERIMENTAL|Training group|Pancreatic patients will participate in the trimodal prehabilitation: nutrition, psychological and exercise support.
62001135|NCT04249128|EXPERIMENTAL|Ceramides and Astaxanthin Free (Skin)|Participants will receive a free 3-month supply of ceramides and Astaxanthin for Hair, Skin \& Nail Health
62569914|NCT01295827|EXPERIMENTAL|NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
62001136|NCT04249128|EXPERIMENTAL|Ceramides and Astaxanthin Extended with Powder Free (Skin)|Participants will receive a free 3-month supply of Ceramides and Astaxanthin for Hair, Skin \& Nail Health
62001137|NCT04249128|EXPERIMENTAL|Ceramides and Astaxanthin $$$ (Skin)|Participants will receive a paid 3-month supply of Ceramides and Astaxanthin extended with pro-berry powder for Hair, Skin \& Nail Health
62569915|NCT01295827|EXPERIMENTAL|NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
62569916|NCT01295827|EXPERIMENTAL|NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 2 mg/kg Q3W. No participants were enrolled in this arm.
62776754|NCT03865784|EXPERIMENTAL|Experimental|Each session will be held in a group and will last 35 minutes, taking place 2 sessions a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session and after drying the sweat of the area to be treated. After the training, the Core and Kinesiotape exercises with tension and stretching will be performed
62001138|NCT04249128|EXPERIMENTAL|Ceramides and Astaxanthin Extended with Powder $$$ (Skin)|Participants will receive a paid 3-month supply of Ceramides and Astaxanthin extended with pro-berry powder for Hair, Skin \& Nail Health
62776755|NCT03865784|ACTIVE_COMPARATOR|Control|Each session will be held in a group and will last 35 minutes, taking place 2 sessions a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session and after drying the sweat of the area to be treated. After the training, the Core and Kinesiotape exercises technique will be performed without tension or stretching
62776756|NCT01735942|EXPERIMENTAL|Ingenol Mebutate|Ingenol Mebutate applied to one side of face with skin lesions
62394881|NCT03237910|EXPERIMENTAL|AMSA-CPR|The professional rescuer decides to deliver the defibrillation attempt based on the AMSA value displayed in the defibrillator
62776757|NCT01735942|ACTIVE_COMPARATOR|Cryotherapy|Cryotherapy applied to other side of face with skin lesions
62776758|NCT00877396|EXPERIMENTAL|Influenza|Inactivated Influenza vaccination
62776759|NCT00877396|PLACEBO_COMPARATOR|Control|Hepatitis A vaccine
62776760|NCT06583785|EXPERIMENTAL|Black rice|"Black rice (210g/meal). Acute study: the volunteers will be asked to eat black rice meal and measured outcomes at 2 hours after consumption.~Short-term study: the volunteers will be asked to consume black rice meals for 7 consecutive days."
62001139|NCT05908279||PD|Patients with Parkinson's disease
62776761|NCT06583785|PLACEBO_COMPARATOR|Brown rice|"Brown rice (210g/meal). Acute study: the volunteers will be asked to eat brown rice meal and measured outcomes at 2 hours after consumption.~Short-term study: the volunteers will be asked to consume brown rice meals for 7 consecutive days."
62001140|NCT05908279||Control|Healthy volunteers
62001141|NCT02900820|EXPERIMENTAL|Novel intervention group|Discontinuing antibiotic therapy.
62394882|NCT03237910|ACTIVE_COMPARATOR|Standard-CPR|The defibrillation is delivered based on the 2015 European Resuscitation Council CPR guidelines
62394883|NCT00355251|EXPERIMENTAL|A|4 semanas manteniendo el tratamiento antirretroviral e iniciar atorvastatina 40 mg/día. A la semana 4 interrupción HAART y aumentar a 80 mg/día de atorvastatina hasta la semana 32 de seguimiento
62394884|NCT00355251|NO_INTERVENTION|B|4 semanas manteniendo el tratamiento antirretroviral. A la semana 4 interrupción HAART hasta la semana 32 de seguimiento
62001142|NCT02900820|EXPERIMENTAL|Usual intervention group|Usual strategy of continuing antibiotic treatment.
62001143|NCT01122667|EXPERIMENTAL|Part 1 - Panel A|Subjects with severe renal impairment
62001144|NCT01122667|EXPERIMENTAL|Part 1 - Panel B|Healthy matched control subjects
62001145|NCT01122667|EXPERIMENTAL|Part 2 - Panel C|Subjects with moderate renal impairment
62001146|NCT01122667|EXPERIMENTAL|Part 2 - Panel D|Healthy matched control subjects
62001147|NCT01122667|EXPERIMENTAL|Part 2 - Panel E|Subjects with mild renal impairment
62001148|NCT01122667|EXPERIMENTAL|Part 2 - Panel F|Healthy matched control subjects
62569917|NCT01295827|EXPERIMENTAL|NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 5 mg/kg Q3W. No participants were enrolled in this arm.
62569918|NCT01295827|EXPERIMENTAL|NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 10 mg/kg Q3W. No participants were enrolled in this arm.
62569919|NCT04153760|ACTIVE_COMPARATOR|Aspirin|Aspirin 81 mg daily for six weeks post-randomization (postpartum)
62569920|NCT04153760|PLACEBO_COMPARATOR|Placebo|Placebo daily for six weeks post-randomization (postpartum)
62569921|NCT01447550||Bosentan|Bosentan
62569922|NCT00780130||Group 1|male \& female college students ages 20 to 50, asymptomatic normals
62569923|NCT03260829|ACTIVE_COMPARATOR|vitamin C injection|orthodontic traction with vitamin C injection
62569924|NCT03260829|PLACEBO_COMPARATOR|orthodontic traction|orthodontic traction without vitamin C injection
62776762|NCT02242383||Essential hypertension|
62776763|NCT04576897|EXPERIMENTAL|Velacur by Sonic Incytes|Patients with compensated advanced chronic liver disease (cACLD) who have not undergone liver transplantation will be scanned with Velacur.
62001149|NCT03425617|EXPERIMENTAL|Tiotropium + Olodaterol first|tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose in Visit 3 followed by PLACEBO via Respimat® single dose in Visit 4
62186215|NCT00673556|EXPERIMENTAL|Course B|Open label extension
62394885|NCT03258710|EXPERIMENTAL|All subjects treated with Tenofovir Disoproxil Fumarate|Subjects with on-going ETV treatment will be switched to Tenofovir Disoproxil Fumarate treatment. Subjects will start TDF on the day ETV is discontinued, without having overlapping treatment periods. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
62569925|NCT05189652|EXPERIMENTAL|Myofascial Release and Exercise Group|Foam roller massage will be applied to the thoracolumbar posterior chain for participants in the myofascial release and exercise group. At the same time, balance training, squat exercises, reach forward with sitting and hamstring stretching exercises will be applied to this group for a period of four weeks. Before starting the exercise training programs, a 5 minute warm-up will be done. The first evaluation of the participants will be made before starting the 4-week program. Final assessments will be made within 2-3 days after the 4-week training ends. Evaluations will include flexibility measurements, muscular endurance measurements, balance evaluations.
62569926|NCT05189652|EXPERIMENTAL|Exercise Group|For the participants in the exercise group, the exercise program (balance training, squat exercises, reach forward with sitting and hamstring stretching exercises) will be applied 3 days a week for 4 weeks without any intervention to the thoracolumbar fascia. Before starting the exercise training programs, a 5 minute warm-up will be done. The first evaluation of the participants will be made before starting the 4-week program. Final assessments will be made within 2-3 days after the 4-week training ends. Evaluations will include flexibility measurements, muscular endurance measurements, balance evaluations.
62569927|NCT05189652|NO_INTERVENTION|Control Group|Any myofascial release or exercise program will not be applied to the participants in the control group. The first evaluation of the participants will be made before other groups starting the 4-week program. Final assessments will be made within 2-3 days after the other groups 4-week training ends. Evaluations will include flexibility measurements, muscular endurance measurements, balance evaluations.
62569928|NCT05890274|EXPERIMENTAL|AF and EKG Interpretation Project ECHO|All recruited participants participate in the AF and EKG Interpretation Project ECHO educational intervention.
62569929|NCT06405113|EXPERIMENTAL|Experimental Arm|Fecal Microbiota Transplantation(FMT)+SOX+Sintilimab
62569930|NCT06405113|PLACEBO_COMPARATOR|Placebo Comparator Arm|Placebo+SOX+Sintilimab
62569931|NCT06478966|EXPERIMENTAL|PechaKucha Method|Stoma care training was delivered using the PechaKucha method for the intervention group
62569932|NCT06478966|NO_INTERVENTION|Control|Stoma care training was delivered using a classic lecture presentation for the control group.
62569933|NCT00959114|EXPERIMENTAL|ALV003|ALV003 is an orally administered mixture of two recombinant proteases (cysteine endoprotease B-isoform 2 and prolyl endopeptidase) engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues common in gluten.
62569934|NCT00959114|PLACEBO_COMPARATOR|Placebo comparator|Excipients for ALV003 absent the experimental compounds
62569935|NCT02877004|ACTIVE_COMPARATOR|Laser for 4 weeks|3 Low-Level Laser Therapy Treatments Weekly
62001150|NCT03425617|EXPERIMENTAL|PLACEBO FIRST|Placebo via Respimat® single dose in Visit 3 followed bytiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose in Visit 4
62001151|NCT02262481|ACTIVE_COMPARATOR|Dydrogesterone|tocolytic + corticosteroids + Dydrogesterone 10 mg/tablet prepare in capsule, 1 cap oral every 12 hours, starting form enrollment until gestational age 37 weeks
62186216|NCT00927524|ACTIVE_COMPARATOR|Apidra (insulin glulisine)|Administration of Apidra at three meals during a 24 hour period.
62394886|NCT05581810|EXPERIMENTAL|Cognitive Behavioural Therapy (CBT)|11 weekly sessions of cognitive behavioural therapy (CBT) delivered over videoconference
62394887|NCT05581810|ACTIVE_COMPARATOR|Cognitive Rehabilitation|11 weekly sessions of traditional cognitive rehabilitation delivered over videoconference
62001152|NCT02262481|PLACEBO_COMPARATOR|Placebo|tocolytic + corticosteroids + Placebo prepare in capsule, 1 cap oral every 12 hours, starting form enrollment until gestational age 37 weeks
62186217|NCT00927524|ACTIVE_COMPARATOR|70/30 insulin|Administration of 73/30 insulin at three meals during a 24 hour period.
62186218|NCT01640171|OTHER|Top Anesthesia 1 Eye SC Lidocaine 1 Eye|"One eye:~Proparacaine Hydrochloride 0.5% Drop Tetravisc 0.5% Gel Acuvail Intra-vitreal Anti-VEGF Drug~Fellow Eye:~Proparacaine Hydrochloride 0.5% Drop Tetravisc 0.5% Gel Xylocaine 2% Injectable Anesthetic Acuvail Intra-vitreal Anti-VEGF Drug"
62394888|NCT04085120|EXPERIMENTAL|Ropivacaine/dexamethasone group|3ml of 0.75% ropivacaine and 1ml of 4mg/l dexamethasone will be injected.
62394889|NCT04085120|EXPERIMENTAL|10% lignocaine injection group|4 ml of 10% lignocaine
62394890|NCT03466216|EXPERIMENTAL|AlphaMedix|There is only a single treatment arm.
62569936|NCT02877004|ACTIVE_COMPARATOR|Laser for 6 weeks|2 Low-Level Laser Therapy Treatments Weekly
62569937|NCT02877004|ACTIVE_COMPARATOR|Laser for 12 weeks|1 Low-Level Laser Therapy Treatment Weekly
62569938|NCT02737254|EXPERIMENTAL|Oxytocin and Secure CBM training|
62569939|NCT02737254|ACTIVE_COMPARATOR|Placebo and Secure CBM training|
62569940|NCT02737254|ACTIVE_COMPARATOR|Oxytocin and Neutral CBM training|
62569941|NCT02737254|PLACEBO_COMPARATOR|Placebo and Neutral CBM training|
62569942|NCT04141241|EXPERIMENTAL|Low Dose PH100: 800mg/day|"* PH100 (Ecklonia cava Phlorotannin) 200mg/tablet~* PH100 2 tablets (400mg) and Placebo 2 tablets BID during 12wks"
62569943|NCT04141241|EXPERIMENTAL|High Dose PH100: 1600mg/day|- PH100 4 tablets (800mg) BID during 12wks
62569944|NCT04141241|PLACEBO_COMPARATOR|Placebo|"* Placebo 200mg/tablet~* Placebo 4 tablets BID during 12wks"
62569945|NCT04689620|EXPERIMENTAL|HELIUM NEON LASER plus regular ulcer care|laser scanning the wound with 9.6 jole/cm2 then regular dressing
62569946|NCT04689620|EXPERIMENTAL|GALLIUM ARSENIDE plus regular ulcer care|laser scanning the wound with 9.6 jole/cm2 then regular dressing
62569947|NCT04689620|ACTIVE_COMPARATOR|regular ulcer care|dressing for the ulcer
62569948|NCT01762644|EXPERIMENTAL|Arm 1|Immune Tolerance and Proton Pump Inhibitor
62569949|NCT01762644|ACTIVE_COMPARATOR|Arm 2|Proton Pump Inhibitor
62569950|NCT04853082|ACTIVE_COMPARATOR|Limonene capsules(marketed product in China)|Limonene capsules(marketed product in China) donate by pharmaceutical company
62001153|NCT02313610|EXPERIMENTAL|Qinbudan|the patient will receive 2HRZES/6HRE follow guidelines of the implementation of China tuberculosis control program （2HRZES/6HRE means： Intensive phase: isoniazid（H）, rifampicin（R）, pyrazinamide（Z）, ethambutol（E）, streptomycin（S）, once, for two months（2）；Consolidation: isoniazid（H）, rifampicin（R）, ethambutol（E）, once, for six months（6）.） Intervention: Qinbudan table, table, 4, thrice a day, 8 months
62001154|NCT02313610|PLACEBO_COMPARATOR|Control Qinbudan Placebo|the patient will receive 2HRZES/6HRE follow guidelines of the implementation of China tuberculosis control program（2HRZES/6HRE means： Intensive phase: isoniazid（H）, rifampicin（R）, pyrazinamide（Z）, ethambutol（E）, streptomycin（S）, once, for two months（2）；Consolidation: isoniazid（H）, rifampicin（R）, ethambutol（E）, once, for six months（6）.） Intervention: Qinbudan Placebo, table, 4, thrice a day, 8 months
62001155|NCT02567461|EXPERIMENTAL|DAPT plus high-dose edoxaban|High-dose edoxaban will be represented by edoxaban 60mg od, which will be reduced to 30mg od in patients with ClCr ≤50mL/min.
62001156|NCT02567461|EXPERIMENTAL|DAPT plus low-dose edoxaban|Low-dose edoxaban will be defined as edoxaban 30mg od, which will be reduced to 15mg od in patients with ClCr ≤50mL/min.
62001157|NCT02567461|ACTIVE_COMPARATOR|DAPT|Aspirin 81 mg od plus clopidogrel 75 mg od
62001158|NCT03548584|EXPERIMENTAL|Brexpiprazole 2 mg|Participants followed a titration schedule, to gradually increase their dose from 0.5 milligrams per day (mg/day) in the starting to 2 mg/day from Day 15. Participants continued to receive brexpiprazole 2 milligrams (mg), once daily until Week 12.
62569951|NCT04853082|PLACEBO_COMPARATOR|Limonene capsules(Placebo)|Same smell, color and shape as limonene capsules(marketed product in China), without limonene in capsules
62569952|NCT02671799|EXPERIMENTAL|VenTouch System Implant|The VenTouch System is indicated for patients who have moderately severe or severe functional mitral regurgitation (grade 3 or 4 MR).
62569953|NCT02019264|EXPERIMENTAL|Lorcaserin hydrochloride (HCL)10 mg|APD356 10 mg twice daily
62569954|NCT02019264|PLACEBO_COMPARATOR|Placebo|Placebo twice daily
62001159|NCT03548584|EXPERIMENTAL|Brexpiprazole 3 mg|Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 3 mg/day from Day 29. Participants continued to receive brexpiprazole 3 mg, once daily until Week 12.
62001160|NCT03548584|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo, once daily for 12 weeks.
62394891|NCT01475539|EXPERIMENTAL|Group A (Sequential 1): IPV-OPV-OPV|Participants will receive 1 dose of Sanofi Pasteur's injectable Inactivated Poliovirus Vaccine (IPV) followed by 2 doses of a commercially available Oral Poliovirus Vaccine (OPV)
62001161|NCT04132557||Cohort 1 (Target): Methylphenidate Monotherapy|Participants will be analyzed for Attention Deficit Hyperactive Disorder (ADHD) who are new users of methylphenidate monotherapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
62001162|NCT04132557||Cohort 2 (Comparator [C]): Lisdexamfetamine Monotherapy|Participants will be analyzed for ADHD who are new users of lisdexamfetamine monotherapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
62001163|NCT04132557||Cohort 3 (C): Atomoxetine Monotherapy|Participants will be analyzed for ADHD who are new users of atomoxetine monotherapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
62001164|NCT04132557||Cohort 4 (C):Amphetamine/Dextroamphetamine Combo Therapy|Participants will be analyzed for ADHD who are new users of amphetamine/dextroamphetamine combo therapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
62001165|NCT03643562|EXPERIMENTAL|Adrabetadex|Participants will receive prescribed adrabetadex by intra-thecal (IT) injection every 2 weeks.
62001166|NCT05336903|EXPERIMENTAL|APP-led model of care for chronic pain management|The APP-led model of care involves integrating an APP as the first point of contact within an interprofessional chronic pain clinic setting. This is in contrast to the usual physician- or nurse practitioner-led model of care.
62394892|NCT01475539|EXPERIMENTAL|Group B (Sequential 2): IPV-IPV-OPV|Participants will receive 2 doses of Sanofi Pasteur's injectable Inactivated Poliovirus Vaccine (IPV) followed by 1 dose of a commercially available Oral Poliovirus Vaccine (OPV)
62394893|NCT01475539|EXPERIMENTAL|Group C (Reference): OPV-OPV-OPV|Participants will receive 3 doses of a commercially available Oral Poliovirus Vaccine (OPV)
62394894|NCT00511602|EXPERIMENTAL|Technosphere Insulin Inhalation Powder|
62001167|NCT00565279|EXPERIMENTAL|ASF1057|
62001168|NCT00565279|PLACEBO_COMPARATOR|ASF1057 placebo|
62001169|NCT00565279|PLACEBO_COMPARATOR|ASF1057 Vehicle|
62394895|NCT00511602|PLACEBO_COMPARATOR|Technosphere Inhalation Powder|
62394896|NCT04893382|EXPERIMENTAL|PlasmaLyte|Seven (7) severely burned patients will be infused with PlasmaLyte (following randomization) during the resuscitation period following admission to the ICU. 50mL of blood will be withdrawn before the first infusion and for the following days (Day 1-2-5 and 10) in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.
62569955|NCT01632293|EXPERIMENTAL|exercise|Individuals with multiple sclerosis and age and gender matched healthy controls will participate in a supervised exercise program for 12 weeks.
62569956|NCT01659827|SHAM_COMPARATOR|Control|Initial injections of Marcaine and Saline (one each)
62569957|NCT01659827|EXPERIMENTAL|0.5cc AmnioFix Injectable|Initial injections of Marcaine and 0.5cc AmnioFix (one each)
62569958|NCT01659827|EXPERIMENTAL|1.25cc AmnioFix Injectable|Initial injections of Marcaine and 1.25cc AmnioFix (one each)
62569959|NCT05500885|EXPERIMENTAL|Active PEMF therapy for chronic ankle instability|Participants will be randomized into 1:1 allocation, blocked randomization with 20 participants in the PEMF group and 20 participants in the sham group. Each allocation will be assigned with a unique RFID (generated during block randomization by the PEMF supplier service) recognizable by the PEMF machine.
62569960|NCT05500885|SHAM_COMPARATOR|Sham PEMF therapy for chronic ankle instability|Control group will receive sham treatment on top of a standard rehabilitation (muscle strengthening and balance training).
62001170|NCT06137456|EXPERIMENTAL|Study group|Participants were involved in exoskeletal robotic therapy three days a week and conventional therapy five days a week for a maximum of eight weeks.
62001171|NCT06137456|ACTIVE_COMPARATOR|Control group|Participants were involved in conventional therapy five days a week for a maximum of eight weeks.
62001172|NCT02807181|ACTIVE_COMPARATOR|Chemotherapy (Cisplatin-Gemcitabine)|Cisplatin 25mg/m2 in 1000ml 0.9% saline given over 1 hour followed by 500 ml 0.9% saline over 30 minutes, followed by Gemcitabine 1000 mg/m2 in 250-500 ml 0.9% saline over 30 minutes by intravenous infusions on days 1, and 8 of a 21-day cycle.
62569961|NCT02293512|EXPERIMENTAL|Coping Effectiveness Training|Coping Effectiveness Training (CET) is provided in a 3-session intervention to facilitate coping strategies among individuals with tinnitus. The CET psychoeducational intervention teaches coping skills to increase understanding of stress and coping with tinnitus, and to help individuals better know how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.
62569962|NCT02293512|ACTIVE_COMPARATOR|Cognitive-behavioral therapy|Cognitive-behavioral therapy (CBT) is provided in a 3-session psychoeducational intervention to reduce negative affectivity triggered by tinnitus. CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.
62569963|NCT02293512|ACTIVE_COMPARATOR|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is provided in a 3-session psychoeducational intervention to decrease resistance to tinnitus and increase committed action based on values, despite having tinnitus.
62569964|NCT02293512|NO_INTERVENTION|Wait-list control group|Wait-list control group involves no intervention. This is a 'usual care' group.
62001173|NCT02807181|EXPERIMENTAL|Radiation: SIRT + chemotherapy (Cisplatin-Gemcitabine)|A single treatment of hepatic arterial injection of SIR-Spheres Y-90 resin microspheres (SIRT) followed 14-16 days later by systemic chemotherapy (ABC-02 CIS-GEM protocol) with an intention to treat with 8 cycles of cisplatin + gemcitabine, or until progression, toxicity or patient choice. Treatment may be continued beyond 8 cycles in the absence of significant disease progression, at the treating clinicians' discretion.
62394897|NCT04893382|EXPERIMENTAL|Ringer's Lactate|Seven (7) severely burned patients will be infused with Ringer's Lactate (following randomization) during the resuscitation period following admission to the ICU. 50mL of blood will be withdrawn before the first infusion and for the following days (Day 1-2-5 and 10) in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.
62001174|NCT02934230|EXPERIMENTAL|Prehabilitation Group|The intervention will be a home-based total-body exercise training program (prehabilitation) based on a protocol with proven efficacy in improving the function of non-frail surgical patients in less than 4 weeks of preoperative utilization.Prehabilitation will consist of 3 components: 1) strength training; 2) aerobic exercise and 3) flexibility. Prehabilitation will be prescribed as 1-hour sessions performed a minimum of 3 times per week. Intervention group patients will also be provided with nutritional advice. In addition to paper-based materials outlining the prehabilitation program, weekly prehabilitation teaching sessions will be held at our Cancer Centre for patients randomized to the intervention group, and activity logs and weekly phone calls will be used to measure compliance and to answer questions. During the final week of the program, patients will also participate in a brief qualitative interview over the phone to explore their experience with the program.
62394898|NCT01938443|EXPERIMENTAL|Part 1|Part 1 will determine the MTD and RP2D based on the safety and tolerability of GSK2256098 administered with trametinib. Subject will be administered starting dose of 1.0 mg OD trametinib combined with 500 mg BID GSK2256098. Dose escalation will continue until the MTD is established.
62394899|NCT01938443|EXPERIMENTAL|Part 2|Based on determination of combination dose regimen in Part 1, dose expansion cohorts for Part 2 will be opened.
62394900|NCT05931614|EXPERIMENTAL|Unlimited fluid intake|Patients have no restrictions of fluid intake
62569965|NCT01691560|EXPERIMENTAL|5% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate with sodium monofluorophosphate containing 1500 parts per million fluoride (ppmF).
62394901|NCT05931614|NO_INTERVENTION|Restricted fluid intake|Patients have restrictions in fluid intake of 1500 ml/day
62569966|NCT01691560|ACTIVE_COMPARATOR|0% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
62569967|NCT01691560|ACTIVE_COMPARATOR|Sodium monofluorophosphate|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
62569968|NCT01691560|ACTIVE_COMPARATOR|Sodium fluoride|Dentifrice containing 1100 ppmF as sodium fluoride
62569969|NCT02884050|EXPERIMENTAL|Topiramate|single, 100mg oral dose of topiramate
62569970|NCT02884050|PLACEBO_COMPARATOR|Placebo|matched inactive placebo
62569971|NCT06366451|EXPERIMENTAL|Rilvegostomig, Volrustomig, Sabestomig, Pembrolizumab|HNSCC patients presenting with a surface accessible lesion who are scheduled for tumor and/or regional node dissection as part of their standard treatment will be injected one to three days prior to surgery using the CIVO device. The planned injection scheme includes: vehicle control and microdoses of rilvegostomig, volrustomig, sabestomig, and pembrolizumab alone.
62186219|NCT02561806|ACTIVE_COMPARATOR|Ustekinumab|45 mg ustekinumab given as SC injection for participants ≤100 kilograms (kg) and 90 mg SC injection for participants \>100 kg at Week 0, 4, 16, 28, and 40. Placebo for ixekizumab injections will be used for blinding.
62776764|NCT06012110|EXPERIMENTAL|Transcutaneous electrical stimulation to reduce spasticity in PLS|Primary lateral sclerosis (PLS) is a progressive upper motor neuron neurodegenerative disorder. A hallmark of PLS is a presentation with lower extremity stiffness and spasticity as well as bulbar involvement. The investigators will be performing a preliminary study designed to assess transcutaneous electrical stimulation (tES), a non-pharmacological and non-invasive modality used in spinal cord injury and multiple sclerosis patients, as a treatment for reducing spasticity in the lower extremities and increasing mobility in patients with PLS.
62776765|NCT01136109||Bedside ultrasound only|Bedside ultrasound to determine the dimensions of the inferior vena cava
62776766|NCT01136109||Ultrasound with ventilator changes|Bedside ultrasound to determine the dimensions of the inferior vena cava pre and post ventilator changes.
62776767|NCT06503380||Group|1000 patients we are planning to observe will be included in one group.
62776768|NCT04169074|EXPERIMENTAL|Treatment with abemaciclib|Treatment will consist of a single neoadjuvant cycle of 10-21 days (+7 days if needed due to surgical delay). Abemaciclib will be administered from days 1-21. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery. Abemaciclib 200 mg PO twice daily on Days 1-21 (+7 days).
62776769|NCT01010152|EXPERIMENTAL|Codeine Sulfate|30 mg tablet
62776770|NCT01010152|ACTIVE_COMPARATOR|Tylenol #3|30 mg tablet
62776771|NCT03117413|OTHER|Asymmetric hearing loss|Asymmetric hearing loss treated with a cochlear implant will undergo positron emission tomography scan.
62776772|NCT03117413|OTHER|Normal hearing subjects|Normal hearing subjects will undergo positron emission tomography scan.
62186220|NCT02561806|EXPERIMENTAL|Ixekizumab|160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline followed by 80 mg ixekizumab given as a single SC injection once every 2 weeks from week 2 through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 52.Placebo for ustekinumab injections will be used for blinding.
62394902|NCT01100931|EXPERIMENTAL|YM155 in Solid Tumors|"Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m\^2, dose level 2:5 mg/m\^2 , dose level 3:6 mg/m\^2, dose level 4:8 mg/m\^2, dose level 5:10 mg/m\^2 (MTD), dose level 6:12 mg/m\^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).~Phase II: 10 mg/m\^2 (MTD)intravenous infusion over 72 hours every 21 days."
62186221|NCT03927183|OTHER|Person-centred practice|Person-centred care
62394903|NCT01639599|PLACEBO_COMPARATOR|dexamethasone|dexamethasone 5mg iv during anesthesia induction
62776773|NCT05320393|EXPERIMENTAL|Study Drug|40U of PrabotulinumtoxinA-xvfs
62776774|NCT05320393|ACTIVE_COMPARATOR|OnabotulinumtoxinA|20U of OnabotulinumtoxinA
62776775|NCT05320393|ACTIVE_COMPARATOR|PrabotulinumtoxinA-xvfs|20U of PrabotulinumtoxinA-xvfs
62776776|NCT06165263|NO_INTERVENTION|Control Group|"The researcher will present 2 hours of basic earthquake education to control group.~The control group will not receive any other intervention. Control group will consist of 80 students."
62776777|NCT06165263|EXPERIMENTAL|Mobile earthquake education|"The researcher will present 2 hours of basic earthquake education to experimental group.~The students in the experimental group will use mobile earthquake education for 4 weeks.~İnterventional group will consist of 80 students."
62791693|NCT02581215|PLACEBO_COMPARATOR|Arm B: Placebo Arm|"mFOLFIRINOX will be administered every 2 weeks, and consist of:~* Oxaliplatin 85 mg/m2 over 2-4 hours~* Irinotecan 165 mg/m2 over 90 minutes~* 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.~* Arm B will receive a placebo infusion every 2 weeks. Due to the double-blinded nature of this study, the volume of placebo will be calculated as if it were ramucirumab"
62791694|NCT03081026||Ages less than 12|Those having ACL Reconstruction surgery during the desired dates at age 12 or less.
62791695|NCT03081026||Ages 12-13|Those having ACL Reconstruction surgery during the desired dates at ages 12 and 13.
62791696|NCT03081026||Ages 14 - 16|Those having ACL Reconstruction surgery during the desired dates at ages 14 - 16.
62776778|NCT03865485|EXPERIMENTAL|Length: long; Engagement booster: high; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)~1. Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~2. Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),~3. Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
62584845|NCT04623216|EXPERIMENTAL|Sabatolimab (adolescent cohort)|Adolescent safety cohort (cohort 5): ≥12 to \< 18 year old adolescent participants in this arm will receive sabatolimab at the recommended dose for expansion.
62001175|NCT02934230|NO_INTERVENTION|Control Group|Patients randomized to the control group will be provided standard perioperative care as per our institutional standards. They will receive the World Health Organization (WHO) Global Recommendations for Physical Activity for Health for people 60 years and above pamphlet, as well as Canada's Food Guide. In-hospital perioperative care, and postoperative care, will be at the discretion of each patient's surgeon and anesthesiologist.
62001176|NCT02989207|ACTIVE_COMPARATOR|Trabeculectomy with Mitomycin-C|The current standard surgical treatment for glaucoma remains trabeculectomy.
62001177|NCT02989207|ACTIVE_COMPARATOR|Baerveldt tube surgery with Mitomycin C|It consists of a tube, draining aqueous humour to a plate
62001178|NCT02989207|ACTIVE_COMPARATOR|Baerveldt tube surgery without Mitomycin C|It consists of a tube, draining aqueous humour to a plate
62001179|NCT01458899|EXPERIMENTAL|A - first fed then fasted treatment|TC-5214
62001180|NCT01458899|EXPERIMENTAL|B - first fasted then fed treatment|TC-5214
62001181|NCT04117126|EXPERIMENTAL|urinary incontinence|Recruitment, 3-day voiding record, initiate a individualized prompted voiding schedule based on the client's toileting needs until discharge, 1, 3 and 6 month follow-up post-discharge.
62186222|NCT05501756|EXPERIMENTAL|Alemtuzumab|"Patients will be given 10 mg/m2 alemtuzumab divided over days -14, -13, and -12. The first dose should be limited to no more than 3 mg per the manufacturer's recommendation. If the calculated daily dose is greater than 3 mg, the first dose (day -14) should be limited to 3 mg and the remainder of the dosing should be divided over days -13 and -12.~Alemtuzumab will be drawn into a sterile syringe and given to patients subcutaneously."
62186223|NCT02625285||G6PD Deficient Volunteers|"* Subjects with age ≥ 18 years~* Male and female~* Previously tested G6PD deficient at SMRU clinic"
62186224|NCT02625285||G6PD Intermediate or Heterozygous Volunteers|"* Subjects with age ≥ 18 years~* Female~* Previously tested G6PD intermediate or heterozygous for G6PD variants at SMRU clinic"
62186225|NCT02625285||G6PD-Normal Volunteers|"* Subjects with age ≥ 18 years~* Male and female~* Previously tested G6PD normal at SMRU clinic"
62001182|NCT03234738|ACTIVE_COMPARATOR|Cohort A|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.5 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
62001183|NCT03234738|ACTIVE_COMPARATOR|Cohort B|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 1.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
62001184|NCT03234738|ACTIVE_COMPARATOR|Cohort C|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
62001185|NCT03234738|ACTIVE_COMPARATOR|Cohort D|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.5 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
62001186|NCT03234738|ACTIVE_COMPARATOR|Cohort E|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 3.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
62001187|NCT05466227|EXPERIMENTAL|Implementing Modified Valsalva|Implementing Modified Valsalva
62186226|NCT02484664|EXPERIMENTAL|celecoxib|Celecoxib 200mg PO QD for 6 months
62394904|NCT01639599|ACTIVE_COMPARATOR|dexamethasone, haloperiol 1mg|dexamethasone 5mg iv during anesthesia induction \& haloperidol 1mg iv 30 min before end of anesthesia
62001188|NCT01096784|ACTIVE_COMPARATOR|rhIGF-I/rhIGFBP-3|Continuous IV Infusion
62001189|NCT01096784|NO_INTERVENTION|Control|The comparator group will receive no treatment with rhIGF-1/rhIGFBP-3
62186227|NCT00736125|ACTIVE_COMPARATOR|1|
62186228|NCT00736125|ACTIVE_COMPARATOR|2|
62186229|NCT03061604|EXPERIMENTAL|Hemospray|"All subjects will be treated by medical treatment in the terms of combination of vasoactive medication, blood transfusion and Ceftriaxone PLUS Hemospray treatment within 2 hours of admission.~The medical treatment will be continued till 12 hours after admission and then second endoscopy will be performed (12-24 hours after admission)."
62584846|NCT04102176|ACTIVE_COMPARATOR|Continue nucleos(t)ide analogue|patients will be given open label tenofovir alafenamide
62584847|NCT04102176|EXPERIMENTAL|Stopping nucleos(t)ide analogue|patients will stop nucleos(t)ide therapy (such as entecavir, tenofovir, lamivudine or adefovir)
62186230|NCT03061604|ACTIVE_COMPARATOR|Non Hemospray|"All subjects will be treated by medical treatment in the terms of combination of Octreotide, blood transfusion and Ceftriaxone.~The medical treatment will be continued till 12 hours after admission and then second endoscopy will be performed (12-24 hours after admission)."
62394905|NCT01639599|ACTIVE_COMPARATOR|dexamethasone + haloperidol 2mg|dexamethasone 5mg iv during anesthesia induction \& haloperidol 2mg iv 30 min before end of anesthesia
62394906|NCT00526214|NO_INTERVENTION|1|In the control group, patients will not take the drug. We do not use placebo drugs.
62394907|NCT00526214|EXPERIMENTAL|2|In the intervention group, patients will take celecoxib.
62394908|NCT04019028|EXPERIMENTAL|Navigated low frequency rTMS|"Application of 1Hz low frequency repetitive transcranial magnetic stimulation to the primary motor area of the dominant hemisphere using a navigation system.~Using the BrainSight instrument, a navigation system, the TMS coil position can be fixed on the point precise target area based on the subject's MRI image."
62394909|NCT04019028|EXPERIMENTAL|only low frequency rTMS(not using Navigation System)|"Application of low frequency repetitive transcranial magnetic stimulation to the primary motor area of the dominant hemisphere not using a navigation system.~TMS coil is fixed on the target area based on MEP hotspot."
62394910|NCT04019028|SHAM_COMPARATOR|Navigated Sham rTMS|"Application of repetitive transcranial magnetic stimulation with sham mode(no stimulation) to the primary motor area of the dominant hemisphere using a navigation system.~Using the BrainSight instrument, a navigation system, the TMS coil position can be fixed on the point precise target area based on the subject's MRI image.~Sham stimulation is stimulated by the same frequency, intensity and time as the actual stimulus in such a way that the 8-shaped coil is placed at a 90 degree angle to the scalp in the same manner as rTMS and sounds are heard but the magnetic stimulus is not transmitted to the cerebrum"
62394911|NCT05499546|EXPERIMENTAL|Intervention arm|All patients within the study are included in the intervention arm: polyp detected within these patients will be measured according to the study protocol using four different methods.
62394912|NCT06674733|ACTIVE_COMPARATOR|Botox group|Group 1 will consist of patients with bruxism complaints who are indicated for botox treatment and will receive BTX-A.
62394913|NCT06674733|ACTIVE_COMPARATOR|aromatherapy group|Group 2 will consist of patients with bruxism complaints and will receive Origanum Majorana (marjoram oil)
62394914|NCT04013906|EXPERIMENTAL|Rotational atherectomy|Patients will undergo rotational atherectomy
62394915|NCT04013906|EXPERIMENTAL|Intravascular lithotripsy|Patients will undergo intravascular lithotripsy
62394916|NCT03029793||Biomarkers and Imaging analysis|This study will prospectively collect the tissue and blood samples of locally advanced esophageal cancer patients, perform CRT resistance biomarkers testing and functional imaging analysis including SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI before treatment, 2-3 weeks after the initiation of CRT, and 4 weeks post-nCRT. The investigators will use advanced statistical tools to establish the model and further validate the model in another group of patients. The investigators will also establish a model for survival prediction.
62394917|NCT04994860|EXPERIMENTAL|BIA 5-1058|Treatment Period 1: Subjects were admitted to the clinical unit on Day 1. Subjects received a single oral dose of BIA 5 1058 400 mg (4 x 100 mg tablets) on Day 1 after an overnight fast of at least 8 hours and remained fasted for at least 4 hours post-dose. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay.
62001190|NCT04294004|EXPERIMENTAL|KUR-113, Stage 1|During stage 1, subjects randomized to this arm will receive TGplPTH1-34 in fibrin (0.4mg/ml) that will be applied within and around a polyetheretherketone (PEEK) intervertebral cage. The maximum dose that will be applied is 4 mg of TGplPTH1-34 in 10mL KUR-113 Bone Graft.
62394918|NCT04994860|ACTIVE_COMPARATOR|Sildenafil|Treatment Period 2: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple three times a day (t.i.d.) oral doses of sildenafil (Revatio® 1 x 20 mg film coated tablet) approximately 2 hours before or after each meal (breakfast, lunch and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single morning dose of sildenafil (Revatio® 1 x 20 mg film coated tablet) and remained fasted for at least 2 hours post-dose. Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
62394919|NCT04994860|EXPERIMENTAL|BIA 5-1058 and Sildenafil|Treatment Period 3: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple t.i.d. oral doses of sildenafil (Revatio® 1 x 20 mg film coated tablet) approximately 2 hours before or after each meal (breakfast, lunch and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single concomitant dose of BIA 5-1058 400 mg (4 x 100 mg tablets) and sildenafil (Revatio® 1 x 20 mg film coated tablet) and remained fasted for at least 4 hours post-dose. Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
62394920|NCT05799482||Retrospective cross-sectional arm|One-to-one semi-structured interviews will be conducted with patients who have received care in the UHS COVID follow-up clinics in no more than 12 months prior to study enrolment. Interviews will be conducted at one time point
62584848|NCT04826965|ACTIVE_COMPARATOR|Wound vac application|Wound vac application for open upper/lower extremity open wound
62186231|NCT00702598|EXPERIMENTAL|1|Telephone-based Cognitive Behaviour Therapy
62791697|NCT03683017|EXPERIMENTAL|I-OP2.0|Patients receive Invisalign orthodontic treatment, with 3.5 day Aligner changes, by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.0 device.
62001191|NCT04294004|ACTIVE_COMPARATOR|Autologous Bone Graft|During stage 1 of the study, subjects randomized to this arm will receive local autologous bone graft. In the event of insufficient local autograft, Iliac crest bone graft may be used to supplement.
62186232|NCT00702598|PLACEBO_COMPARATOR|2|Telephone reminder calls
62776779|NCT03865485|EXPERIMENTAL|Length: long; Engagement booster: high; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)~1. Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~2. Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),~3. Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
62776780|NCT03865485|EXPERIMENTAL|Length: long; Engagement booster: low; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)~1. Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~2. Engagement booster - low: No Engagement Boosters~3. Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
62791698|NCT03683017|EXPERIMENTAL|I-OP2.1|Patients receive Invisalign orthodontic treatment, with 3.5 day Aligner changes, by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.1 device.
62001192|NCT04294004|EXPERIMENTAL|KUR-113, Stage 2|During stage 2, subjects will receive TGplPTH1-34 in fibrin that will be applied within and around a PEEK intervertebral cage at a concentration of 0.7mg/ml. The concentration received was selected by the DSMB based on the results of stage 1. The maximum dose that will be applied is 7 mg of TGplPTH1-34 in 10mL KUR-113 Bone Graft.
62001193|NCT03460587|EXPERIMENTAL|Home-based Telerehabilitation|Home-based Telerehabilitation
62001194|NCT00838266|EXPERIMENTAL|1|Antiplaque mouthrinse containing active component (Grape Seed Extract + nicométhanol fluorhydrate)
62394921|NCT05799482||Prospective, longitudinal arm|One-to-one semi-structured interviews will be conducted with patients with confirmed prior COVID-19 infection who are scheduled to receive care in the UHS COVID follow-up clinics. Interviews will be conducted before attending the first clinic appointment (baseline) and after discharge from the clinic (at 12 weeks).
62394922|NCT00617994|EXPERIMENTAL|Group A|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a small percent BSA.
62001195|NCT00838266|PLACEBO_COMPARATOR|2|Antiplaque mouthrinse containing non-active component
62394923|NCT00617994|EXPERIMENTAL|Group B|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 1.
62394924|NCT00617994|EXPERIMENTAL|Group C|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 2.
62394925|NCT04518826||FFR|In FFR group, FFR at maximum hyperemia will be measured after pretreatment of DES-ISR lesion by balloons(non-compliant balloon, cutting balloon or scoring balloon). If FFR \<0.9, the operator will dilate the DES-ISR lesion again before another FFR is measured. If FFR\>=0.9, DEB will be used and final FFR will be measured at the end of the procedure.
62394926|NCT04518826||CAG|In angiography group, the operator will treat the DES-ISR lesion with balloons(non-compliant balloon, cutting balloon or scoring balloon), and then DEB without FFR guidance.
62001196|NCT02403908|EXPERIMENTAL|PADN groups (radiofrequency denervation)|An 8-F long sheath will be inserted through the femoral vein and advanced to the main PA (MPA). The nMARQ Circular or Crescent (Biosense Webster) catheter will be advanced along this long sheath. After gently withdrawing the sheath and pushing the PADN catheter, the tip will be released from the sheath. Then, the tip of the catheter will be positioned first at the ostium of the left PA (Level 1 of ablation, \<2 mm distal to orifice. After ablation at this level, the catheter tip will be positioned at the ostium of right PA (Level 2 of ablation, \<2mm proximal to the bifurcation level). Finally, denervation of main pulmonary artery will be done by pulling the denervation catheter back into Level 3 of ablation (\<2 mm proximal to both ostia of right and left PA-s) into main pulmonary artery.
62001197|NCT02403908|NO_INTERVENTION|SHAM group|non-treated patients (controls)
62001198|NCT05709171|EXPERIMENTAL|Experimental|Each patient will undergo one standard of care 18FDG PET/CT and one 64Cu-DOTATATE PET/CT within 4 weeks.
62001199|NCT03029624|EXPERIMENTAL|Treatment Arm|Treatment Arm receives implanted eCoin device and therapy is turned ON.
62001200|NCT00685152|EXPERIMENTAL|Active rTMS|Repetitive Transcranial Magnetic Stimulation
62001201|NCT00685152|SHAM_COMPARATOR|2|Device: Sham (placebo)
62394927|NCT03682471||Deoxycholic Acid Injection, 5 mg/mL|Non-treatment observational follow-up study: Participants were previously treated with deoxycholic acid injection, 5 mg/mL in studies ATX-101-10-16 or ATX-101-10-17.
62584849|NCT04826965|ACTIVE_COMPARATOR|Wound vac application including irrigation|Wound vac application WITH irrigation for upper/lower extremity open wound
62001202|NCT02888327|OTHER|Oseltamivir and AL-794|Oseltamivir alone and with AL-794 over fourteen days.
62776781|NCT03865485|EXPERIMENTAL|Length: long; Engagement booster: low; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)~1. Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~2. Engagement booster - low: No Engagement Boosters;~3. Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
62791699|NCT03683017|EXPERIMENTAL|F-OP2.0|Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.0 device.
62001203|NCT02888327|OTHER|Digoxin, Midazolam, and AL-794|Single doses of Digoxin and Midazolam with and without AL-794 over seventeen days.
62001204|NCT02888327|OTHER|Pitavastatin and AL-794|Single doses of Pitavastatin with and without AL-794 over seventeen days.
62001205|NCT02888327|OTHER|JNJ-63623872 and AL-794|JNJ-63623872 alone and with AL-794 over fourteen days.
62394928|NCT03682471||Deoxycholic Acid Injection, 10 mg/mL|Non-treatment observational follow-up study: Participants were previously treated with deoxycholic acid injection, 10 mg/mL in studies ATX-101-10-16 or ATX-101-10-17.
62394929|NCT03682471||Placebo|Non-treatment observational follow-up study: Participants were previously treated with placebo in studies ATX-101-10-16 or ATX-101-10-17.
62394930|NCT01398176|EXPERIMENTAL|3 ounces of mushrooms|3 ounces of mushrooms consumed daily for 4 weeks
62394931|NCT01398176|EXPERIMENTAL|6 ounces of mushrooms|6 ounces of mushrooms consumed daily for 4 weeks
62394932|NCT01034345|EXPERIMENTAL|Sirolimus|Patients randomized to this arm will discontinue maintenance immunosuppression based on calcineurin inhibitors and start treatment with sirolimus.
62394933|NCT01034345|ACTIVE_COMPARATOR|Calcineurin inhibitor|Patients randomized to this arm will keep the same maintenance immunosuppression based on calcineurin inhibitors.
62394934|NCT00555711||Modulated Imaging|Modulated Imaging
62394935|NCT06276712|EXPERIMENTAL|Ks dental implant|Implant placement in edentulous jaws for a prosthetic implant rehabilitation with implant-retained overdenture (mucosally supported), on two implants using KS implant with 3.5 mm of diameter
62001206|NCT06481956|EXPERIMENTAL|T-DM1 combined with Ribociclib|"Enrolled patients will receive (repeat every 21 days) :~● T-DM1 3.6 mg/kg d1;● Ribociclib 400 mg qd, d8-d21;~\* ER-positive patients will receive endocrine therapy at the same time: aromatase inhibitors or fulvestrant , and ovarian suppression or ovariectomy in premenopausal women."
62394936|NCT06276712|ACTIVE_COMPARATOR|TS dental implant|Implant placement in edentulous jaws for a prosthetic implant rehabilitation with implant-retained overdenture (mucosally supported), on two implants using TS implant with 3.5 mm of diameter
62394937|NCT01190839|EXPERIMENTAL|Infliximab|Infliximab Type=equal unit=mg number=5 form=intravenous infusion route=intravenous use once every 8 weeks
62394938|NCT01190839|PLACEBO_COMPARATOR|Placebo|Placebo Type=equal unit=mg number=5 form=intravenous infusion route=intravenous use once every 8 weeks
62394939|NCT01687985|EXPERIMENTAL|BLI801 laxative - low dose|BLI801 laxative - oral solution
62394940|NCT01687985|EXPERIMENTAL|BLI801 laxative - high dose|BLI801 laxative - oral solution
62394941|NCT02136927|EXPERIMENTAL|SPARC1210|Intravenous administration of SPARC1210
62394942|NCT02136927|ACTIVE_COMPARATOR|Reference1210|Intravenous administration of Reference1210
62394943|NCT03576807|EXPERIMENTAL|CD20 CAR-T cells|Experimental: CD20 CAR-T cells
62791700|NCT02931552|EXPERIMENTAL|Nuevo Amancer-II Stress Management Program|Nuevo Amanecer-II (NA-II) is a 10-week peer-delivered cognitive-behavioral stress management program. Participants receive the stress management program as soon as possible after randomization.
62791701|NCT02931552|NO_INTERVENTION|Wait-list Control Group|Waits six months and at the end of the six months is offered the option of receiving the NA-II program.
61977833|NCT04918264||Uracil concentration ≥16 ng/mL|Patients were included in this arm if they have digestive cancer and an uracil dosage \<16 ng/mL performed between February 2018 to January 2020, and if they received at least one cycle of fluoropyrimidine-based chemotherapy in one of the four oncology departments (Hopital Edouard Heriot \[Lyon\], Centre Hospitalier de Lyon Sud \[Lyon\], Hopital de la Croix Rousse \[Lyon\].
62001207|NCT01057043|NO_INTERVENTION|Waiting list|In case of acute pain patients may take paracetamol as rescue medication, maximum dosage 2 gram per day.
62001208|NCT01057043|EXPERIMENTAL|Cupping|In case of acute pain patients may take paracetamol as rescue medication, maximum dosage 2 gram per day.
62394944|NCT03031327|EXPERIMENTAL|Lubricin 20µg/ml|"Lubricin 20µg/ml eye drops solution~Test investigational device was instilled t.i.d. (three times a day) approximately every 6 h, from day 1 to day 15±2.~All the patients instilled their assigned IMD into both eyes, unless only one eye met the eligibility criteria. If just one eye met the eligibility criteria, that was identified as the Study/Primary eye. If both eyes met the eligibility criteria, the worst one (highest VAS average score) was chosen as Study/Primary eye. In the event that the mean VAS score was equal in both eyes, right eye was to be chosen as Study/Primary eye.~The investigator instilled the morning study dose on Day 1 then the patients self-instilled the drops at home/site, as applicable.~After the end of the treatment period, all the subjects could use any ocular topical treatment allowed, including other artificial tears/lubricants as prescribed by the treating physician, from day 15±2 to day 21±2."
62584850|NCT06275620|EXPERIMENTAL|Group 1 (High Dose, Standard Corticosteroid)|"Following a pars plana vitrectomy, the previously untreated eye of participants (n=up to 12) will receive a central subretinal injection at the high dose in the study eye at the Baseline visit; no treatment will be administered in the previously treated fellow eye.~The corticosteroid taper for all treated participants in Groups 1 and 2 (high and low doses with standard corticosteroid regimen) will be a standard taper over the course of several weeks."
62186233|NCT02944396|EXPERIMENTAL|Veliparib and nivolumab with platinum doublet chemotherapy|Veliparib and nivolumab in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed)
62776782|NCT03865485|EXPERIMENTAL|Length: short; Engagement booster: high; Fidelity booster:high|"Behavioral: Parenting for Lifelong Health (PLH)~1. Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~2. Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),~3. Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
62001209|NCT02735070|EXPERIMENTAL|Corisitina D|The patient will use the medication 4 times a day - orally The tablets of Coristina® d contain 400 mg acetylsalicylic acid, dexchlorpheniramine 1 mg, 10 mg phenylephrine, and 30 mg of caffeine. Coristina® d is indicated as an analgesic, antipyretic, antiallergic, and nasal congestion for the treatment of the symptoms of influenza and common cold.
62001210|NCT02735070|ACTIVE_COMPARATOR|Resfenol|The patient will use the medication 4x / day - orally Resfenol® drug acts against the symptoms of colds and flu, such as nasal congestion, runny nose, fever, headache, muscle pain and other symptoms. The capsules containing 400mg of paracetamol, 4 mg chlorpheniramine and 4mg phenylephrine.
62001211|NCT01782781|PLACEBO_COMPARATOR|Group P|"Group P (Placebo) receives a local infiltration of saline in the operating field and ketorolac iv.~In Group P the injectant consists of saline, total volume 156 mL. This is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. Ketorolac 30 mg (1 mL) is also injected iv."
62186234|NCT02944396|EXPERIMENTAL|Veliparib with platinum doublet chemotherapy|Veliparib in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed)
62186235|NCT02394522|PLACEBO_COMPARATOR|Placebo|Spatial Repellent product without active ingredient (SHIELD)
62186236|NCT02394522|ACTIVE_COMPARATOR|Intervention|Spatial Repellent product with active ingredient (SHIELD)
62734591|NCT01911650|OTHER|Waitlist|Subjects in this arm will have already received standard of care interventions for Achilles tendinopathy with unsatisfactory outcomes. For this research they will be asked to undergo a palpatory exam of the Achilles tendon; complete Quality of Life Questionnaires at three different time points; and complete a 30 minute ultrasound imaging exam of the Achilles tendon.
62734592|NCT04760860|PLACEBO_COMPARATOR|Placebo Control Arm|Participants in this arm will receive placebo during the trial for 15 weeks, the placebo will follow the same schedule as the Terazosin group; the placebo capsules will have the same appearance as the Terazosin capsules.
62734593|NCT04760860|EXPERIMENTAL|Terazosin Arm|Participants in this arm will receive Terazosin during the trial for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
62734594|NCT04099355|EXPERIMENTAL|dronabinol|active group
62734595|NCT04099355|PLACEBO_COMPARATOR|control|control group
62734596|NCT02457689|PLACEBO_COMPARATOR|Group 1 (Transcutaneous and Placebo)|Group 1 (Transcutaneous and Placebo) Participants will receive 1.0ml intramuscular injections of the vaccine Sodium Chloride BP into the upper thigh. Participants will also have a further 0.2ml of Sodium Chloride BP delivered transcutaneously. An area of skin of approximately 4 x 4cm will be photographed and prepared first. During this preparation, the area is shaved to remove the hair, and then superglue is applied to remove the top layer of skin (like waxing). The vaccine is spread onto the skin surface. Once applied, the area is covered with a comfeel bandage, the investigator will ask volunteers to not engage in strenuous exercise, shower, or bathe for 24 hours afterwards.
62734597|NCT02457689|ACTIVE_COMPARATOR|Group 2 (Transcutaneous and Active)|Group 2 (Transcutaneous and Active) Participants will receive 1.0ml intramuscular injections of the GTU®-MultiHIV B Clade Vaccine (2 mg/ml) into the upper thigh. Participants will also have a further 0.2ml of the vaccine (2mg/ml) delivered transcutaneously. An area of skin of approximately 4 x 4cm will be photographed and prepared first. During this preparation, the area is shaved to remove the hair, and then superglue is applied to remove the top layer of skin (like waxing). The vaccine is spread onto the skin surface. Once applied, the area is covered with a comfeel bandage, the investigator will ask volunteers to not engage in strenuous exercise, shower, or bathe for 24 hours afterwards.
62776783|NCT03865485|EXPERIMENTAL|Length: short; Engagement booster: high; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)~1. Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~2. Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),~3. Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
62776784|NCT03865485|EXPERIMENTAL|Length: short; Engagement booster: low; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)~1. Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~2. Engagement booster - low: No Engagement Boosters~3. Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
62776785|NCT03865485|EXPERIMENTAL|Length: short; Engagement booster: low; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)~1. Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~2. Engagement booster - low: No Engagement Boosters~3. Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
62186237|NCT04690478|EXPERIMENTAL|Remote blood pressure management group|Remote blood pressure management group through remote blood pressure management the platform realizes functions such as automatic upload of patient measurement data, intelligent analysis, and early warning reminders
62394945|NCT03031327|EXPERIMENTAL|Lubricin 50µg/ml|"Lubricin 50µg/ml eye drops solution~Test investigational device was instilled t.i.d. (three times a day) approximately every 6 h, from day 1 to day 15±2.~All the patients instilled their assigned IMD into both eyes, unless only one eye met the eligibility criteria. If just one eye met the eligibility criteria, that was identified as the Study/Primary eye. If both eyes met the eligibility criteria, the worst one (highest VAS average score) was chosen as Study/Primary eye. In the event that the mean VAS score was equal in both eyes, right eye was to be chosen as Study/Primary eye.~The investigator instilled the morning study dose on Day 1 then the patients self-instilled the drops at home/site, as applicable.~After the end of the treatment period, all the subjects could use any ocular topical treatment allowed, including other artificial tears/lubricants as prescribed by the treating physician, from day 15±2 to day 21±2."
62394946|NCT03031327|ACTIVE_COMPARATOR|Sodium hyaluronate|"Vismed® 0.18% Sodium hyaluronate (HA) eye drops~Comparator was instilled t.i.d. (three times a day) approximately every 6 h, from day 1 to day 15±2.~All the patients instilled their assigned IMD into both eyes, unless only one eye met the eligibility criteria. If just one eye met the eligibility criteria, that was identified as the Study/Primary eye. If both eyes met the eligibility criteria, the worst one (highest VAS average score) was chosen as Study/Primary eye. In the event that the mean VAS score was equal in both eyes, right eye was to be chosen as Study/Primary eye.~The investigator instilled the morning study dose on Day 1 then the patients self-instilled the drops at home/site, as applicable.~After the end of the treatment period, all the subjects could use any ocular topical treatment allowed, including other artificial tears/lubricants as prescribed by the treating physician, from day 15±2 to day 21±2."
62394947|NCT04594213|PLACEBO_COMPARATOR|Main Period: Placebo (Group P)|Subjects will receive placebo injection in all three UFL (GFL, HFL and LCL) on Day 1 of main period.
62394948|NCT04594213|EXPERIMENTAL|Main Period: NT 201 (Group U)|Subjects will receive a total of 64 Units (U) of NT 201: 20 U of NT 201 injection both in the GFL area and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 of main period.
62394949|NCT04594213|EXPERIMENTAL|Main Period: NT 201 and Placebo (Group G and H)|Subjects will receive a total of 40 U of NT 201: 20 U of NT 201 injection both in the GFL and HFL area, and placebo injection in the LCL area on Day 1 of main period.
62394950|NCT04594213|EXPERIMENTAL|OLEX: NT 201 (Main Period: Group P)|Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.
62394951|NCT04594213|EXPERIMENTAL|OLEX: NT 201 (Main Period: Group U)|Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.
62394952|NCT04594213|EXPERIMENTAL|OLEX: NT 201 (Main Period: Group G and H)|Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.
62584851|NCT06275620|EXPERIMENTAL|Group 2 (Low Dose, Standard Corticosteroid)|"Following a pars plana vitrectomy, the previously untreated eye of participants (n=6) will receive a central subretinal injection at the low dose in the study eye at the Baseline visit; no treatment will be administered in the previously treated fellow eye.~The corticosteroid taper for all treated participants in Groups 1 and 2 (high and low doses with standard corticosteroid regimen) will be a standard taper over the course of several weeks."
62186238|NCT04690478|OTHER|Non-remote blood pressure management group|Non-remote blood pressure management group is distributed a set of ordinary household electronic sphygmomanometer, and the blood pressure is recorded by themselves at home following routine community office follow-up
62186239|NCT04690478|OTHER|Routine blood pressure management group|Routine blood pressure management group follows routine community office follow-up and uses office electronic sphygmomanometer to measure blood pressure
62186240|NCT01977027|OTHER|Stroke & age-matched Controls|"Alternate Hand Training or Affected Hand Training:~40 patients with stroke and 40 control subjects will participate over 7 visits. After completion of informed consent, subjects will undergo clinical assessments (Visit 1) which will involve testing for kinesthetic, visual, tactile and motor impairments and upper limb function. Visit 2, subjects will undergo no contrast MRI to identify lesion location. Healthy controls will not be imaged.~Visits 3-7 will involve psychophysical experiments to test adaptation with short-term Alternate Hand Training and Affected Hand Training. During 5 visits the subjects will grasp and lift an instrumented grip device of different weights, textures and shapes while data is being collected via surface electrodes from, upper arm and back muscles."
62186241|NCT01977027|OTHER|Phase 2 - Stroke ONLY|"Alternate Hand Training or Affected Hand Training:~Subjects will be randomized into two groups one receiving Alternate Hand Training and the other receiving Affected Hand Training. The groups will be matched by age, gender, handedness, side of lesion, extent of motor impairment and lesion location. They will complete 17 Study visits.~Visits 1 and 2 will involve clinical assessments and MRI. Visit 3. Pre-intervention assessments involving grasping and lifting objects of different weights, textures and shapes while fingertip forces, finger and arm movements. Muscle activity and performance is measured.~Visits 4-15. Subjects will participate in 12 training visits for 1 hour a day, twice a week for 6 weeks.~Visits 16-17. Recovery of hand function will be measured by repeating the pre-intervention clinical and grasping assessments (in 2 visits) immediately after 6-weeks of training, and another 6 weeks later."
62186242|NCT06060483|EXPERIMENTAL|CGM group|Wear CGM continuously and manage patients based on CGM. The treatment goals are TIR\>70%, TBR\<4%, TAR\<25%, and HbA1c\<7.0%. After the treatment reaches the standard, CGM is worn every six months.
62186243|NCT06060483|NO_INTERVENTION|HbA1c group|HbA1c testing is performed every three months, patient management is based on HbA1c, and the treatment target is HbA1c \<7.0%.
62186244|NCT04077697||ITBA group|ITBA group is : invasive tracheobronchitis aspergillosis form.
62186245|NCT04077697||IPA without tracheobronchial involvement|IPA group is : invasive pulmonary aspergillosis without tracheobronchial involvement
62186246|NCT01317823|ACTIVE_COMPARATOR|Bishop score|
62186247|NCT01317823|ACTIVE_COMPARATOR|transvaginal ultrasound|
62186248|NCT01700283|EXPERIMENTAL|exercise education and walking program|
62186249|NCT01700283|NO_INTERVENTION|maintain their daily activity|
62186250|NCT06428864||Cast|Patient with a Garchois brace produced after a plaster cast
62186251|NCT06428864||Scan|Patient with a Garchois brace produced after assessment of the thoracic volume with the 3D scan
62776786|NCT02670668|EXPERIMENTAL|Mutation analysis- NACwith PCR|consisting of 50 patients undergoing NACwith pathological compete response
62186252|NCT04933799|ACTIVE_COMPARATOR|PF-06650833 + Standard of Care treatment|Subjects randomized to the PF-06650833 arm of the study will receive 400 mg PF-06650833 (2 x 200 mg tablets) of the MR formulation orally QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). Subjects who cannot take tablets PO will receive PF-06650833 200 mg IR suspension formulation every 6 hours (NG tube or OG tube, or equivalent). Subjects for whom concomitant administration of a strong inhibitor of CYP3A4 (eg, ritonavir) will have the dose reduced to either 200 mg MR or IR QD. All dosing of study drug will be in addition to current hospital SOC treatment that must include treatment targeting SARS-CoV-2.
62186253|NCT04933799|PLACEBO_COMPARATOR|Placebo + Standard of Care treatment|Placebo will match the Active comparator in dosage form, dosage, frequency and duration.
62186254|NCT01589705||polycystic kidney ,no hypertension|The study evaluated the association of serum uric acid levels with endothelial dysfunction in early ADPKD patients with normal renal function
62186255|NCT02842983|EXPERIMENTAL|Esmolol|After, at least six hours of hemodynamic optimization, patients with a hyperdynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 10% reduction in heart rate. This infusion is maintained for 72 hours.
62186256|NCT02842983|NO_INTERVENTION|Control|Patients received conventional management of septic shock
62186257|NCT02619305|EXPERIMENTAL|Immediate treatment|Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
62186258|NCT02619305|NO_INTERVENTION|Delayed treatment|Participants will be social network ties of women receiving no intervention but who will be placed on a waitlist to receive the intervention after a 12-month delay.
62186259|NCT01472614|EXPERIMENTAL|DLBS3233|
62394953|NCT03219372|EXPERIMENTAL|Pravastatin Pill|Daily pravastatin (40mg)
62394954|NCT03219372|PLACEBO_COMPARATOR|Placebo Oral Tablet|Placebo
62776787|NCT02670668|EXPERIMENTAL|Mutation analysis-NAC with SD/PD.|consisting of 50 patients undergoing NAC with SD/PD
62776788|NCT01032031|ACTIVE_COMPARATOR|Green tea + vit C high dose|
62186260|NCT05124288||Acute Myeloid Leukemia relapsed patients|Adult patients (\< 18 years old), with Acute Myeloid Leukemia, who relapse after allogeneic transplantation from either family or unrelated donors, regardless of the cellular source of the transplant (bone marrow, mobilized peripheral stem cells or cord blood).
62394955|NCT03328962|NO_INTERVENTION|Control group|Newly diagnosed cancer patients at their first consultation for treatment at an oncological hospital Department, who report to be smoking, recruited from 15/09/17 to 15/3/18. Their smoking status will be observed over a period of six months.
62776789|NCT01032031|PLACEBO_COMPARATOR|Placebo|
62776790|NCT04528056|EXPERIMENTAL|Ambrisentan+Sulfasalazine|
62186261|NCT04394312|EXPERIMENTAL|Intervention|Participants will attended a 75 minute physical literacy workshop (Parent PLAYSHOP). A questionnaire will be completed at the beginning of the workshop and the end of the workshop to measure if there is a difference in parent's knowledge and confidence levels in regard to engaging in meaningful physical activity with their children.
62776791|NCT04528056|ACTIVE_COMPARATOR|Ambrisentan+Sulfasalazine's placebo|
62186262|NCT04394312|NO_INTERVENTION|Control|Participants will complete the 2 questionnaires online, one week or more apart. Once questionnaires are completed they will be invited to attended the 75 minute physical literacy workshop. The workshop content and delivery will be the same as the intervention group but will not include questionnaires.
62186263|NCT02409446|EXPERIMENTAL|Anthocyanin|34 patients will receive anthocyanin. We will analyze their blood samples both prior and after taking anthocyanin.
62186264|NCT02409446|NO_INTERVENTION|Controls|Healthy Controls, 20 persons. Will be giving blood samples at study start and study end.
62186265|NCT03981718|ACTIVE_COMPARATOR|Group: Standard|Breast cancer subjects with current injury to irradiated skin at the post-mastectomy site will receive fat grafting procedure per standard of care during their 2nd stage breast reconstruction.
62186266|NCT03981718|EXPERIMENTAL|Group: Experimental|Breast cancer subjects with current injury to irradiated skin at the post-mastectomy site will receive their fat grafting procedure until 6 months after their 2nd stage breast reconstruction.
62186267|NCT02874105|EXPERIMENTAL|experimental group|Dynamic Humeral Centering
62186268|NCT02874105|ACTIVE_COMPARATOR|control group|Conventional physiotherapy
62186269|NCT03712592|EXPERIMENTAL|160km|
62186270|NCT03712592|EXPERIMENTAL|40km|
62186271|NCT03712592|EXPERIMENTAL|100km|
62186272|NCT03712592|EXPERIMENTAL|4x40km|
62186273|NCT03055546|EXPERIMENTAL|Oxytocin|intranasal administration of oxytocin
62394956|NCT03328962|EXPERIMENTAL|Intervention group|Newly diagnosed cancer patients at their first consultation for treatment at an oncological hospital Department, who report to be smoking, recruited from 15/09/18 to 15/3/19. The intervention group will receive structured smoking cessation counselling based on MI and adapted for the cancer setting combined with provision of smoking cessation medication (nicotine replacement therapy) while in the control group there will be standard care which may vary from hospital to hospital. Their smoking status will be observed over a period of six months.
62394957|NCT03487120|NO_INTERVENTION|lumbar laminectomy|
62186274|NCT03055546|PLACEBO_COMPARATOR|Placebo|intranasal administration of placebo
62186275|NCT00995384|OTHER|CT scan|CT Scan for endocarditis patients. All patients receive intervention.
62186276|NCT04160806|ACTIVE_COMPARATOR|Active Group|Left anodal/right anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
62186277|NCT04160806|SHAM_COMPARATOR|Sham Group|Sham transcranial direct current stimulation over the dorsolateral prefrontal cortex
62186278|NCT05258409|ACTIVE_COMPARATOR|Media Advocacy (MA)|Participants assigned to this condition take place in a time and attention-matched active control where they discuss the role of media in promoting the body ideal.
62186279|NCT05258409|EXPERIMENTAL|Body Project: More than Muscles (MTM)|Participants assigned to this condition take part in a two-session intervention based on dissonance theory which encourages them to challenge the body ideal.
62186280|NCT01126320|EXPERIMENTAL|AnapnoGuard 100|Respiratory guard system during mechanical ventilation
62186281|NCT01126320|ACTIVE_COMPARATOR|Control|routine mechanical ventilator
62186282|NCT04363619|PLACEBO_COMPARATOR|Controls|
62186283|NCT04363619|EXPERIMENTAL|ICH|
62186284|NCT04363619|EXPERIMENTAL|aSAH|
62186285|NCT01192776|ACTIVE_COMPARATOR|33.5°C for 72 hours|Target Temp: 33.5°C Duration: 72 hrs
62186286|NCT01192776|EXPERIMENTAL|33.5°C for 120 hours|Target Temp: 33.5°C Duration: 120 hrs
62394958|NCT03487120|ACTIVE_COMPARATOR|lumbar laminectomy with denervation of the facet joint|
62394959|NCT06698133|NO_INTERVENTION|Control Arm|24 hour food recall 2x/week
62394960|NCT06698133|EXPERIMENTAL|Intervention Arm|24 Hour food recall 2x/week + Intervention Education group 3x/week
62394961|NCT02146911|EXPERIMENTAL|Bupropion|Bupropion hydrochloride SR, Sandoz Canada, Boucherville, Quebec. Dispense for 12 weeks. One tablet (150mg) once daily for first three days, then twice daily for the remainder of 12 weeks.
62776792|NCT04528056|EXPERIMENTAL|Ambrisentan's placebo+Sulfasalazine|
62776793|NCT04528056|PLACEBO_COMPARATOR|Ambrisentan's placebo+Sulfasalazine's placebo|
62776794|NCT02300181|PLACEBO_COMPARATOR|Placebo (flour)|5 placebo capsules for each test (4.88 kcal/5 cap)
62776795|NCT02300181|EXPERIMENTAL|Bacillus subtilis var natto DC-15|5 experimental capsules for each test (4.96 kcal/5 cap) Extract powder of the flour fermented with Bacillus subtilis var natto DC-15
62776796|NCT04797546|EXPERIMENTAL|Adductor Canal Block|With mild sedation, a continous bupivacaine 0.1% infusion catheter is placed in the adductor canal. Afterwards, patients are placed under General Anesthesia, and surgery starts. Preoperative, 2 hours and 24 hours stress biomarkers and analgesic quality will be measured.
62569972|NCT04476693|EXPERIMENTAL|Breakfast Consumption (BC)|"The consumption of a standardised breakfast followed by a standardised lunch 3-h after the last mouthful of breakfast meal. All the ingredients of the breakfast and lunch provided will be weighed, with the portion sizes calculated based on individual resting metabolic rate (RMR). The participants were instructed to consume the meals provided within 15 min. A minimum of seven days washout period will be provided to avoid carry-over effects between conditions.~The standardised lunch will consist of white bread without crust (Tesco), margarine 'Butter Me Up Spread' (Tesco), strawberry jam (Tesco), salted crisps (Walkers) and sparkling glucose drink (Lucozade Energy Original). This carbohydrate-rich high glycameic index lunch was designed to trigger quick and exaggerated glucose and insulin response."
62584852|NCT06275620|EXPERIMENTAL|Group 3 (High Dose, Modified Corticosteroid)|"Following a pars plana vitrectomy, the previously untreated eye of participants (n=approximately 3-6) will receive a central subretinal injection at the high dose in the study eye at the Baseline visit; no treatment will be administered in the previously treated fellow eye.~Participants in Group 3 (high dose, modified corticosteroid) will have a more rapid corticosteroid taper."
62584853|NCT06075446||Treatment|Those with an exposure.
62186287|NCT01192776|EXPERIMENTAL|32.0°C for 72 hours|Target Temp: 32.0°C Duration: 72 hrs
62186288|NCT01192776|EXPERIMENTAL|32.0°C for 120 hours|Target Temp: 32.0°C Duration:120 hrs
62186289|NCT04513977|NO_INTERVENTION|Usual care|For older adults with cancer with G8 score 14 or less. Randomized to usual oncology care.
62186290|NCT04513977|EXPERIMENTAL|Geriatric Oncology Supportive Clinic|For older adults with cancer with G8 score 14 or less. Randomized to attend Geriatric Oncology Supportive Clinic
62186291|NCT05811884|EXPERIMENTAL|House rehabilitation|"The subjects will be provided of the powered exoskeleton for home use. No specific indications will be provided, but using the technology as much as possible.~Every six months, the subjects will be asked to attend a single-day session by the clinical facility (follow-up session) consisting on the assessement of a series of qualitative and quantitative measurements."
62186292|NCT05811884|EXPERIMENTAL|Central rehabilitation|The subjects will be asked to attend to periodic rehabilitation sessions by the clinical facility. The rehabilitation session will consist in an intense 1-week activities session every three months. Every six months, the subjects will be asked to attend a single-day session by the clinical facility (follow-up session) consisting on the assessement of a series of qualitative and quantitative measurements.
62186293|NCT04555642||therapy group|lymphoma patients planned chemotherapy or immunotherapy scheme
62186294|NCT04555642||healthy control group|Inclusion criteria for the controls were no known diseases or syndromes, within the age range from 18 to 35 years.
62186295|NCT05269927|EXPERIMENTAL|TD (typically developing) infants|Typically developing infants, infants without familiar risk for ASD or LD.
62394962|NCT02146911|EXPERIMENTAL|Varenicline|Varenicline tartrate (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet or two 0.5mg tablets) twice daily for the remainder of 12 weeks.
62394963|NCT04480359|ACTIVE_COMPARATOR|Bawei Shenqi group|participants should administrate both Bawei Shenqi Pill and Meloxicam tablets
62186296|NCT05269927|EXPERIMENTAL|HR (high risk) for LD infants|Infants at high risk for language disorders
62186297|NCT05269927|EXPERIMENTAL|HR for ASD infants|Infants at high risk for autism spectrum disorder
62186298|NCT01050361|EXPERIMENTAL|Echo Guided HEmodyanmic Management (EGHEM)|EGHEM - Echo Guided HEmodyanmic Management - will receive their intraoperative maintenance fluid and possible drug therapy (furosemide) based on their hourly intraoperative Left Ventricular Diastolic Dysfunction (LVDD) grade.
62186299|NCT01050361|NO_INTERVENTION|Standard HEmodynamic Management (SHEM)|SHEM - Standard HEmodynamic Management - will NOT receive the study intervention, but will receive standard anesthesia and hemodynamic management based on current standards within the institution (control group).
62394964|NCT04480359|PLACEBO_COMPARATOR|placebo group|participants should administrate both Bawei Shenqi Pill placebo and Meloxicam tablets
62186300|NCT03371368|OTHER|Gastric Bypass Diabetic and Non-diabetic|Roux-en-Y gastric bypass surgery
62584854|NCT06075446||Control|Those without an exposure.
62186301|NCT03371368|OTHER|Sleeve Gastrectomy Diabetic and Non-diabetic|sleeve gastrectomy surgery
62186302|NCT03371368|ACTIVE_COMPARATOR|Very Low Calorie Diet Diabetic and Non-diabetic|very low calorie diet
62186303|NCT03371368|NO_INTERVENTION|Obese Control Group|Non-diabetic obese subjects
62186304|NCT03371368|NO_INTERVENTION|Lean Control Group|Non-diabetic lean subjects
62394965|NCT04606225|EXPERIMENTAL|Losartan group|Drug: Losartan
62394966|NCT04606225|PLACEBO_COMPARATOR|Placebo group|Drug: Placebo Oral Tablet
62394967|NCT06213831|EXPERIMENTAL|Maximal Use Ruxolitinib 1.5%|Participants will apply ruxolitinib 1.5% cream BID through Week 4 to all pruriginous lesions. At Week 4, participants who have completed 4 weeks of treatment with no safety concerns may enter the optional 4-week treatment extension period, during which all participants will apply ruxolitinib 1.5% cream BID to existing pruriginous lesions.
62394968|NCT00658918|ACTIVE_COMPARATOR|1|Ciclesonide 200µg
62584855|NCT04036435|EXPERIMENTAL|BMS-986165|
62001212|NCT01782781|ACTIVE_COMPARATOR|Group A|"Group A (Active) receives a local infiltration of ropivacaine, ketorolac and epinephrine in the operating field and saline iv.~Drug: ropivacaine, ketorelac and epinephrine~In Group A the injectant mixture consists of ropivacaine 300 mg mixed with 30 mg ketorolac and 0.5 mg epinephrine, total volume 156 mL. This mixture is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. One mL saline is also injected iv."
62001213|NCT06021392||Wide local excision of pilonidal sinus|
62001214|NCT06021392||Minimal excision of pilonidal sinus|
62001215|NCT02985294||Cross-sectional cohort|Multiple Excitability Measures of peripheral nerves on patients with chronic peripheral neuropathic pain
62186305|NCT00085566|EXPERIMENTAL|Everolimus (RAD-001) and Gefitinib|"•Phase I: Patients receive oral everolimus on day 1 and oral gefitinib once daily on days 8-21. Beginning on day 22, patients receive oral everolimus once weekly and oral gefitinib once daily. Treatment with the combination continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of everolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~•Phase II (prostate cancer patients only) (closed to accrual as of 10/19/2006): Patients receive oral everolimus (at the MTD determined in phase I) once weekly and oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity."
62001216|NCT02985294||Longitudinal cohort|Multiple Excitability Measures of peripheral nerves on painless patients before and after potential chronic neuropathic pain-inducing interventions (chemotherapy, surgery)
62186306|NCT04793750|EXPERIMENTAL|POC HIV VL Testing|Participants will receive the standard of care tests (DPP HIV-Syphilis Test System, OraQuick) plus the HIV POC VL test.
62186307|NCT04793750|ACTIVE_COMPARATOR|SOC HIV Testing|Participants will receive routine standard of care HIV testing.
62001217|NCT05697900|ACTIVE_COMPARATOR|Creatine monohydrate|5 g of creatine monohydrate per day for eight weeks
62001218|NCT05697900|EXPERIMENTAL|Creatine hydrochloride|5 g of creatine hydrochloride per day for eight weeks
62001219|NCT05697900|PLACEBO_COMPARATOR|Placebo|5 g of maltodextrin per day for eight weeks
62001220|NCT02773043|OTHER|non invasive imaging technique|
62001221|NCT00771433|EXPERIMENTAL|Group 1|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 6-11 of each course of chemotherapy as primary prophylaxis. Chemotherapy courses repeat every three weeks for 3-6 courses.
62001222|NCT00771433|EXPERIMENTAL|Group 2|Patients receive G-CSF SC once daily on days 6-11 of each course of chemotherapy as primary prophylaxis. Chemotherapy courses repeat every three weeks for 3-6 courses. Patients may also receive secondary prophylaxis with G-CSF if they experience an episode of neutropenia.
62001223|NCT02615951|OTHER|Nutrient transporters study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of nutrient transporters expression
62001224|NCT02615951|OTHER|Chemokine receptors study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of chemokine receptors expression
62001225|NCT02615951|OTHER|Genes study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of genes expression
62001226|NCT02615951|OTHER|Protein surface study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of protein surface expression
62001227|NCT02615951|OTHER|Protein surface & genes data validation|"Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure for validation of the data from protein surface study and genes study arms analysis."
62394969|NCT00658918|ACTIVE_COMPARATOR|2|Ciclesonide 100µg
62001228|NCT01321788||STUDY GROUP|will receive the study drug Innohep ® for 14 days
62001229|NCT01321788||CONTROL|The group that will receive placebo for 14 days
62001230|NCT05795894||patents|Questionnaires
62394970|NCT00658918|ACTIVE_COMPARATOR|3|Ciclesonide 25µg
62394971|NCT00658918|PLACEBO_COMPARATOR|4|Placebo
62394972|NCT02118272|OTHER|Physica KR|
62394973|NCT01633762|EXPERIMENTAL|meropenem, gentamicin, vancomycin|
62394974|NCT04131465|EXPERIMENTAL|Home HIV self-testing|Fieldworkers will visit potential participants in their homes and offer 3 oral HIV self-testing kits with a short introduction to HIV self-testing.
62394975|NCT04131465|EXPERIMENTAL|Home HIV rapid testing|Fieldworkers will visit potential participants in their homes and offer home-based HIV rapid testing and counselling.
62001231|NCT01664143|PLACEBO_COMPARATOR|Placebo|
62001232|NCT01664143|EXPERIMENTAL|RO5508887|
62001233|NCT03026712|EXPERIMENTAL|Real tDCS|
62001234|NCT03026712|SHAM_COMPARATOR|Sham tDCS|
62001235|NCT06484777|EXPERIMENTAL|SHR-9539 for injection|
62001236|NCT03065556|EXPERIMENTAL|188-0551 Solution|188-0551 Solution applied topically twice daily
62001237|NCT03065556|PLACEBO_COMPARATOR|Vehicle Solution|Vehicle Solution applied topically twice daily
62001238|NCT04256616||Bladder cancer patients|80 patients with carcinoma of the bladder; divided in 20 patients Ta (low grade), 20 patients Ta/T1 (high grade) and 20 patients T2. Only for liquid samples collection we will include 20 CIS (carcinoma in situ) patients
62569973|NCT04476693|EXPERIMENTAL|Breakfast omission (BO)|"Participant will consume water, the individual volume of which was calculated based on the liquid content of the breakfast. A standardised lunch will be consumed 3-h after the last mouthful of water. All the ingredients of the breakfast and lunch provided were weighed, with the portion sizes calculated based on individual resting metabolic rate (RMR). The participants were instructed to consume the meals provided within 15 min. A minimum of seven days washout period was provided to avoid carry-over effects between conditions.~The standardised lunch consists of white bread without crust (Tesco), margarine 'Butter Me Up Spread' (Tesco), strawberry jam (Tesco), salted crisps (Walkers) and sparkling glucose drink (Lucozade Energy Original). This carbohydrate-rich high glycameic index lunch was designed to trigger quick and exaggerated glucose and insulin response."
62569974|NCT02494258|EXPERIMENTAL|Oral Azacitidine (CC-486)|This study is an open-label, single-arm study and is divided into the screening period, treatment period and follow-up period. It is intended to evaluate the long-term safety of CC-486 and is to be taken at the same dose, schedule and frequency used from the last dose of CC-486 given in the parent study.
62569975|NCT01305382||Heart Transplant Cohort|This group consist of transplant subjects within 10 years of heart transplant
62569976|NCT01305382||Heart Failure Sub group|Consist of subjects with advanced heart failure (NYHA class III and IV)
62569977|NCT01305382||Healthy Volunteer|This groups consist of healthy individuals
62186308|NCT02910843|EXPERIMENTAL|Regorafenib & Capecitabine|"* Regorafenib dose level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.~* Regorafenib dose level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table.~* Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.~* External beam Radiotherapy~* Surgery"
62186309|NCT03995342|EXPERIMENTAL|exprimental: Inulin|Inulin 15 grams after dissolution by mouth， every morning for three months.
62569978|NCT04903158|EXPERIMENTAL|Test group|Test formulation of SHR3680
62001239|NCT04256616||Controls- Healthy subjects|30 age and sex-matched subjects not suffering from carcinoma of the bladder, already hospitalized in ICH; we expect to enroll 24 males and 6 females of which 10 of 40- 60 years old, 10 of 60-70 years old, 10 of \>70 years old.
62569979|NCT04903158|OTHER|Reference group|Reference formulation of SHR3680.
62001240|NCT00127140|EXPERIMENTAL|Vorinostat|Participants received (Cycle 1) once-daily vorinostat at assigned dose (100 or 200 mg) on Days 1 and 17 and twice-daily on Days 3-16. Thereafter, participants remaining on study received the same dose level therapy twice-daily for 14 consecutive days followed by 7 days of rest.
62569980|NCT05046080||Observational (medical record review)|Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.
62001241|NCT02563028|EXPERIMENTAL|SightSaver Visual Stimulator|A SightSaver Visual Stimulator mask will be applied during surgery. Baseline VEPs will be recorded prior to prone positioning. At the end of surgery, after supine positioning, the SightSaver Visual Stimulator mask will be removed and discarded.
62001242|NCT04405609|EXPERIMENTAL|ArmAssist group|"The post-stroke patients who participate in the study, are classified in differents stages (3 patients in each stage).~Group 1: subacute, between 2 - 6 months Group 2: chronic of short evolution, between 6 - 12 months Group 3: long-term chronic, more than 12 months.~The system is tested in a clinical (training) and patients' home setting. The ArmAssist system includes the ArmAsist 2.0 device (without motors), the tele rehabilitation platform based on serious games and Antari's HomeCare tele-care platform for the clinicians."
62001243|NCT01167062|PLACEBO_COMPARATOR|Placebo|
62001244|NCT01167062|EXPERIMENTAL|Tamsulosin Hydrochloride OCAS 0.4 mg|
62001245|NCT05976919||COPD|
62001246|NCT05976919||Asthma|
62001247|NCT05976919||Bronchiectasis|
62001248|NCT05976919||Cystic fibrosis|
62001249|NCT05976919||Primary ciliary dyskinesia|
62001250|NCT05880433||Before Eye drop instillation|For pupil dilatation, one drop of 2.5% phenylephrine hydrochloride and 0.5% tropicamide was instilled three times at 5 minute intervals, 1 hour before the exam. All infants were fed 1 hour before instillation of drops and infants were swaddled before the procedure.
62001251|NCT05880433||After Eye drop instillation|The same participiants investigated after eye drop instillation
62186310|NCT03995342|PLACEBO_COMPARATOR|Active comparator: maltodextrin|Placebo (maltodextrin) 15grams after dissolution by mouth， every morning for three months.
62186311|NCT02111408||Acute stroke|No interventions. Only tests for depression, sleepapnea and autonomic dysfunction.
62569981|NCT02581280||On ECMO|patients who are concomitantly receiving teicoplanin or levofloxacin or piperacillin/tazobactam or meropenem or vancomycin or remifentanil or cefepime or cefpirome or sufentanil or midazolam or clopidogrel or ticagrelor or prasugrel during ECMO
62569982|NCT02581280||Off ECMO|patients who are concomitantly receiving teicoplanin or levofloxacin or piperacillin/tazobactam or meropenem or vancomycin or remifentanil or cefepime or cefpirome or sufentanil or midazolam or clopidogrel or ticagrelor or prasugrel after removing ECMO
62569983|NCT03062930|ACTIVE_COMPARATOR|Track 1|Training of non-paretic arm for 3 weeks consisting of occupational therapy and kinematic tasks followed by sham condition (playing board games/computer games) for 3 weeks
62001252|NCT02696096|OTHER|All Participants|FMRI Suboxone
62186312|NCT01805206|EXPERIMENTAL|iFABP Monitored|Subjects monitored for urinary iFABP content during the first 4-12 days of life. Enteral feedings administered when iFABP levels are normal during the first four days of life or, if elevated during the first four days of life, have normalized for five days.
62186313|NCT01179412|EXPERIMENTAL|2% povidone-iodine|
62001253|NCT01428193|EXPERIMENTAL|Flutamide, estrace, progesterone|"For flutamide, subjects weighing \> 50 kg will receive 250 mg orally twice a day, and subjects weighing \< 50 kg will receive 125 mg orally twice a day for approximately 3 weeks.~Subjects will be given oral estrace, 0.5-1 mg once a day for 7 days following the first overnight study admission.~Subjects will be given oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days following the first overnight study admission."
62186314|NCT02220218|EXPERIMENTAL|Treatment Sequence ABDC|Treatment A (canagliflozin and metformin immediate release \[IR\] fixed dose combination \[FDC\] tablet 50 milligram \[mg\]/500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62186315|NCT02220218|EXPERIMENTAL|Treatment Sequence BCAD|Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62186316|NCT02220218|EXPERIMENTAL|Treatment Sequence CDBA|Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62186317|NCT02220218|EXPERIMENTAL|Treatment Sequence DACB|Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62186318|NCT02324777|EXPERIMENTAL|CanniMed™ DPF-I Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation (DPF) with a potency specification similar to CanniMed™ 22·1 product, of 21.9% w/w total THC and 0.8% w/w total CBD is vapourized and inhaled by study subjects.
62186319|NCT02324777|EXPERIMENTAL|CanniMed™ DPF-II Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification the same as the CanniMed™ 15·5 product, of 15.0% w/w total THC and 5.0% w/w total CBD is vapourized and inhaled by study subjects.
62776797|NCT04797546|ACTIVE_COMPARATOR|Patient Controlled Morphine Analgesia|Patients are placed under General Anesthesia, and after surgery, a Morphine patient controlled analgesia delivery system is installed. Preoperative, 2 hours and 24 hours stress biomarkers and analgesic quality will be measured.
62776798|NCT02072369|EXPERIMENTAL|VAEDA Glove|Voice And EMG-Driven Actuated glove used during hand occupational therapy training
62776799|NCT02072369|ACTIVE_COMPARATOR|No-glove|hand occupational therapy sessions without assistive device
62776800|NCT00895544|EXPERIMENTAL|1|Day 0: Single priming vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Vietnam strain) - Day 360: Randomization to booster vaccination with Dose B of whole virion, Vero cell-derived influenza vaccine (Indonesia strain)
62776801|NCT00895544|EXPERIMENTAL|2|Day 0: Single priming vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Vietnam strain) - Day 360: Randomization to booster vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Indonesia strain)
62776802|NCT00609739|EXPERIMENTAL|Cytarabine + Mitoxantrone|This is a phase I-II study designed to evaluate the efficacy of the administration of high dose cytosine arabinoside and mitoxantrone followed by HCT in patients with JMML who have residual disease or have relapsed after initial HCT.
62776803|NCT00784537|OTHER|Arm A|"Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)~The subsequent treatment will be as it follows:~* PET-2 positive patients will be high-dose salvage treatment;~* PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).~The following restaging procedures are planned as it follows:~* Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.~* Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).~PET-6 negative patients will be randomized to first arm:~No radiotherapy."
62776804|NCT00784537|OTHER|Arm B|"Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)~The subsequent treatment will be as it follows:~* PET-2 positive patients will be high-dose salvage treatment;~* PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).~The following restaging procedures are planned as it follows:~* Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.~* Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).~PET-6 negative patients will be randomized to second arm:~Adjuvant radiotherapy (30 Gy) on sites of initial bulky disease."
62776805|NCT00774683||Sub-study Group A|Six HIV-positive African American women from the main study, CID 0706
62776806|NCT03029507|EXPERIMENTAL|ACT enhanced ShipShape (ACT +SS)|"The ACT+SS intervention will be delivered in 8 1.5-hour weekly group sessions. The ACT~+SS protocol integrates ACT concepts and strategies within the existing standard SS protocol."
62776807|NCT03029507|ACTIVE_COMPARATOR|Standard ShipShape (SS)|Standard ShipShape (SS) The standard SS-only protocol will be delivered in 8 1.5-hour weekly group psychoeducation sessions.
62001254|NCT00743171||1|Good adherent patient: patient performed ≥ 80% of predicted HS within 24 months
62569984|NCT03062930|SHAM_COMPARATOR|Track 2|Sham condition (playing board games/computer games) for 3 weeks followed by training of the non-paretic arm for 3 weeks consisting of occupational therapy and kinematic tasks
62569985|NCT03919552|EXPERIMENTAL|Carboplatin|Patients receive carboplatin (AUC 4 on day 1) every three weeks
62569986|NCT03919552|ACTIVE_COMPARATOR|Cisplatin|Patients receive cisplatin (75mg/m2 on day 1) every three weeks
62776808|NCT00953940|EXPERIMENTAL|Isotonic saline|Isotonic saline
62776809|NCT00953940|NO_INTERVENTION|No treatment|Habitual therapy
62001255|NCT00743171||2|Moderate adherent patient: patient performed ≥ 50% of predicted HS within 24 months
62186320|NCT02324777|EXPERIMENTAL|CanniMed™ DPF-III Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification the same as CanniMed™ 9·9 product, of 9.0% w/w total THC and 9.5% w/w total CBD is vapourized and inhaled by study subjects.
62186321|NCT02324777|EXPERIMENTAL|CanniMed™ DPF-IV Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification similar to CanniMed™ 4·10 product, of 3.8% w/w total THC and 10.0% w/w total CBD is vapourized and inhaled by study subjects.
62186322|NCT02324777|EXPERIMENTAL|CanniMed™ DPF-V Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification similar to CanniMed™ 1·13 product profile of 0.6% w/w total THC and 13.0% w/w total CBD is vapourized and inhaled by study subjects.
62186323|NCT02324777|PLACEBO_COMPARATOR|CanniMed™ DPF-P Volcano® Vapourization|"Using the Volcano® Medic, a dose of 100 mg of ethanol extracted DPF-V, reducing the potency profile to \<0.3% w/w total THC and \<0.3% w/w total CBD (comparable to the threshold levels described for industrial hemp, as per the Canadian Industrial Hemp Regulations (SOR/98-156), is vapourized and inhaled by study subjects."
62186324|NCT04164862|ACTIVE_COMPARATOR|use ACCUVEIN AV400|Device to facilitate cannulation of the great saphenous vein at the ankle in infants
62394976|NCT04131465|EXPERIMENTAL|Home HIV self-testing and rapid testing|Fieldworkers will visit participants in their homes and offer 3 oral HIV self-testing kits with a short introduction to HIV self-testing as well as home-based HIV rapid testing and counselling.
62394977|NCT01267682|NO_INTERVENTION|Usual care|Participants receive standard clinical care
62394978|NCT01267682|EXPERIMENTAL|Treatment|Behavioral: cognitive stimulation
62394979|NCT03107741|NO_INTERVENTION|Passive Control|Subjects in this group will not receive any intervention.
62394980|NCT03107741|PLACEBO_COMPARATOR|Conventional Exercise|Subjects in this group will receive three 1-hour conventional exercise training sections per week for 12 weeks
62394981|NCT03107741|ACTIVE_COMPARATOR|Tai Chi|Subjects in this group will receive three 1-hour tai chi training sections per week for 12 weeks
62394982|NCT06192108|EXPERIMENTAL|Orforglipron Dose 1|Participants will receive orforglipron orally.
62394983|NCT06192108|EXPERIMENTAL|Orforglipron Dose 2|Participants will receive orforglipron orally.
62394984|NCT06192108|EXPERIMENTAL|Orforglipron Dose 3|Participants will receive orforglipron orally.
62394985|NCT06192108|ACTIVE_COMPARATOR|Dapagliflozin|Participants will receive dapagliflozin orally.
62394986|NCT04914182|EXPERIMENTAL|LASER|In the intervention group, the laser will be applied to the points of the edges of the lesion, with a distance of one centimeter between them. The laser will be applied in a punctual way, in points on the edges of the lesion site, with a distance of one centimeter between them. This application will take place three times: six hours after delivery, 24 and 48 hours after delivery.
62394987|NCT04914182|SHAM_COMPARATOR|CONTROL|In the control group, the sham laser will be applied the exact same way as the real laser, to the points of the edges of the lesion, with a distance of one centimeter between them. The sham laser will be applied in a punctual way, in points on the edges of the lesion site, with a distance of one centimeter between them. This application will take place three times: six hours after delivery, 24 and 48 hours after delivery.
62394988|NCT06629038||oral cancer patients|oral cancer patients with trismus, neck, or shoulder problems
62394989|NCT06629038||healthy adults|healthy adults without history of trismus, neck, or shoulder problems
62394990|NCT06602739|EXPERIMENTAL|REGN5713-5715|Participants will be randomized 1:1
62569987|NCT04389164|EXPERIMENTAL|Tissue engineering method|The thickness of scar tissue in the middle of the dermis is removed by a roller cutter with a thickness of about 0.01 -- 0.02mm. After cleaning, the dermis can be used for punching and mesh drawing in the dermal rolling machine.Autologous epidermal basal cell suspension was prepared according to the description of autologous epidermal basal cell extraction box.The size of the remaining skin should be the same as the wound surface. After washing with normal saline, the wet yarn should be wrapped for later use.The autogenous scar dermal scaffold was prepared and transplanted onto the wound surface. The autoepidermal basal cells prepared were sprayed or coated between the mesh and the dermal scaffold. Autologous skin slices were transplanted onto the wound surface and fixed with pressure bandaging.
62569988|NCT04389164|ACTIVE_COMPARATOR|Conventional therapy|Autologous skin was grafted onto the wound surface and fixed with pressure bandage
62776810|NCT02588209|EXPERIMENTAL|SMART Training|This group will receive the Strategic Memory Advanced Reasoning Training (SMART) program, twice a week for four weeks.
62776811|NCT02588209|ACTIVE_COMPARATOR|Health|This group will receive the Brain Health Workshop educational program, twice a week for four weeks.
62776812|NCT03782441|EXPERIMENTAL|RSP-19|Subjects will perform daily measurements on the IMD (Prototype 0.5) for 42 days.
62776813|NCT05387668|EXPERIMENTAL|Part A: Japanese cohort|Three ascending dose levels of either BGB-23339 or placebo.
62186325|NCT04164862|ACTIVE_COMPARATOR|ULTRASOUND GUIDED CANNULATION|Ultrasound cannulation of the great saphenous vein in infants
62186326|NCT04319146|OTHER|robot-assisted radical prostatectomy|patient with a prostate cancer will be operated with a robot-assisted method. They will be supported on an outpatient basis
62186327|NCT05142800||Target Therapy Drug-Stand Care|"Screening procedures confirm participation in the research study.~* Participants limb volume is measured prior to treatment start date.~* Participant is provided informational brochure about risk of lymphedema and Lymphedema Screening Program Card.~* Perometer and SOZO measurements will be incorporated as a part of the follow-up visits throughout the course of their trial and for at least 6 months beyond their last dose of trial medication"
62186328|NCT05142800||Target Therapy-Early or Metastatic Breast Cancer|"Screening procedures confirm participation in the research study.~* Participants limb volume is measured prior to treatment start date.~* Participant is provided informational brochure about risk of lymphedema and Lymphedema Screening Program Card.~* Perometer and SOZO measurements will be incorporated as a part of the follow-up visits throughout the course of their trial and for at least 6 months beyond their last dose of trial medication"
62186329|NCT02626442|EXPERIMENTAL|Group Exercise Class|6 month group balance/exercise class, three days a week - up to one hour. Exercise program includes walking around a track, bodyweight/balance exercises, and an obstacle course.
62186330|NCT02626442|NO_INTERVENTION|Testing|Subjects enrolled in other MERCE exercise and robotics interventions will receive balance/walking tests, MRI with famous name recognition task, and cognitive testing pre and post their intervention.
62186331|NCT01825005||group 1:surgery|treatment = surgery only
62186332|NCT01825005||group 2: radiotherapy|treatment = radiotherapy only
62186333|NCT01825005||group 3: RT and CT, and/or hyperthermia|treatment= radiotherapy combined with chemotherapy and/or hyperthermia
62186334|NCT01825005||group 4: stage IVb , any treatment|cervical cancer stage IV b, treatment = any systemic or radiation therapy and supportive care
62186335|NCT03354910|NO_INTERVENTION|Usual Care|All enrolled patients will receive Usual Care for transplant candidates at our two centers, which includes individual meetings with transplant providers, attendance at a patient group education session in the transplant center (focused on the specifics of the transplant experience), and a transplant education binder.
62186336|NCT03354910|ACTIVE_COMPARATOR|Usual Care (UC) + House Calls (HC)|Patients and their invited guests will be scheduled for one House Call. A house call is meeting done at a patient's home with transplant health educators facilitating a discussion on topics related to living kidney donation. Patients and guests also receive an information packet containing several brochures providing information about the living donation process, common concerns and misperceptions, and donation resources and information about our transplant center (e.g., copy of our quarterly newsletter, contact information). Patients in the group will also receive Usual Care, the regular education on living donation, provided as part of their routine transplant care.
62186337|NCT03354910|EXPERIMENTAL|UC + HC + Peer Mentorship|Patients in this condition will receive the Usual Care and the House Calls intervention as described previously. In addition, participants will receive access to a Peer Mentor trained by the National Kidney Foundation following their House Call.
62186338|NCT04040998|EXPERIMENTAL|CCT+TAU group|The participants in CCT+TAU group received compensatory cognitive training plus treatment as usual. The CCT intervention consisted of two 50-minute sessions each week for 10 weeks
62394991|NCT06602739|PLACEBO_COMPARATOR|Placebo|Participants will be randomized 1:1
62394992|NCT01679756|EXPERIMENTAL|Intracorporeal anastomosis|Laparoscopic right hemicolectomy for cancer. .For the IA group, colon, transverse mesocolon, ileum and terminal ileum mesentery will be resected intracorporeally through a 45 mm endoscopic linear stapler with vascular cartridge. Then, the linear stapler will inserted through two small enterotomies and a mechanical ileo-transverse, side-to-side isoperistaltic intracorporeal anastomosis performed using the vascular cartridge with six rows of closely placed staples. The enterotomies will be then closed using a double layered continuous intra corporeal manual suture with 3-0 Polyglactin 910. The mesenteric defects will be left open. The specimen will be placed in a protective plastic bag and then extracted through a Pfannestiel incision.
62776814|NCT05387668|EXPERIMENTAL|Part B: Caucasian cohort|One dose level of either BGB-23339 or placebo based on data collected in Part A.
62776815|NCT04268173|EXPERIMENTAL|Prevention Navigation|Participants enrolled in this arm will receive a 12-week community-based, client-centered, prevention intervention.
62186339|NCT04040998|NO_INTERVENTION|TAU group|The participants in TAU group received usual treatment at the same time as CCT+TAU group.
62776816|NCT04268173|NO_INTERVENTION|Usual Services|Participants enrolled in this arm will receive services as usual from Vivent Health and will not engage in the intervention.
62186340|NCT01211444|EXPERIMENTAL|HGNS System|
62186341|NCT02518347|EXPERIMENTAL|FDS-Strawberry|Freeze-dried strawberry powder (50g/d)
62776817|NCT03730415|EXPERIMENTAL|Viscoelastic (VE) guided transfusion|The intervention made in the VE guided transfusion group is that the VE results will be available to the treating physicians to guide transfusions based on VE results during their burn excision.
62776818|NCT03730415|NO_INTERVENTION|Standard practice transfusion|The standard practice transfusion group will receive the current standard transfusion practice during their burn excision, which is based solely on physician preference using standard lab values.
62776819|NCT01997671|EXPERIMENTAL|Information Support System|Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering.
62776820|NCT01997671|NO_INTERVENTION|Control group|Routine clinical practice
62776821|NCT03052816|EXPERIMENTAL|ICE T|"1. ICE PACKS applied to the perineum every hour for 20 minutes ATC until discharge.~2. 6 hours from the time of first dose of surgery patients will receive 30mg of IV toradol ATC until discharge.~3. Once out of the PACU will receive 1 gram of Tylenol every 6 hours for a total of 4 grams daily ATC until discharge~4. Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.~5. Patients will be discharged home with PO Tylenol and PO toradol PRN."
62776822|NCT03052816|ACTIVE_COMPARATOR|Standard|"1. Motrin 600mg PO Q4h PRN pain 1-3~2. Percocet 1 tab PO Q4-6 hours PRN 4-6 pain~3. Percocet 2 tabs PO Q 7-10 hours PRN 7-10 pain~4. Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.~5. Patients will be discharged home with Motrin and Percocet for pain PRN."
62776823|NCT06368934|EXPERIMENTAL|The intervention group|The intervention group was to receive frontal, temporal, parietal, and occipital sub-lobotomies that met anatomical criteria.
62776824|NCT06368934|OTHER|The control group|The control group was to receive imaging total resection (T1-enhanced borders) that met RANO criteria.
62776825|NCT05870683|EXPERIMENTAL|14-day Tegoprazan-Amoxicillin dual therapy|14-day Tegoprazan-Amoxicillin dual therapy, Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid, Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid
62776826|NCT05870683|ACTIVE_COMPARATOR|14-day Esomeprazole-Amoxicillin dual therapy|14-day Esomeprazole-Amoxicillin dual therapy, Esomeprazole（Astrazeneca Pharmaceutical Co., LTD.) 20mg qid, Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid
62776827|NCT02861482|EXPERIMENTAL|Bakri Ballon|All the enrolled patients who would undergo the laying of Bakri Balloon
62776828|NCT00225784|EXPERIMENTAL|Cetuximab, Gemcitabine, RT|weekly cetuximab, twice-weekly gemcitabine and intensity modulated radiotherapy
62776829|NCT00865319|EXPERIMENTAL|99 m Tc-EC-DG|99m Tc-Ec-DG injection followed by SPECT/CT imaging (range 20-30 mCi) 1mg EC-DG
62776830|NCT00865319|ACTIVE_COMPARATOR|18F-FDG|18 F FDG injection followed by PET/CT imaging
62001256|NCT00743171||3|Non-adherent patient: patient performed \< 50% of predicted HS within 24 months.
62186342|NCT02518347|PLACEBO_COMPARATOR|Placebo|Powder matched for carbohydrates and fiber in the strawberries
62186343|NCT04696783|EXPERIMENTAL|Drug Group|Esomeprazole Magnesium Enteric-coated Tablets and lifestyle adjustment
62186344|NCT04696783|PLACEBO_COMPARATOR|non-Drug Group|Only lifestyle adjustment
62186345|NCT03631303||ICD patients with ATP/shock|10 primary prevention 2-chamber ICD patients (LVEF \<35 percent) who received appropriate ICD therapy during follow-up.
62569989|NCT00791778|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)
62569990|NCT00791778|PLACEBO_COMPARATOR|Placebo|Participants received 2 matching placebo tablets per oral twice daily
62776831|NCT01771445|ACTIVE_COMPARATOR|IL-1Ra|
62776832|NCT01771445|PLACEBO_COMPARATOR|Placebo|
62776833|NCT00844558|EXPERIMENTAL|Gait Training|Gait Training Intervention Group Participants
62776834|NCT00844558|PLACEBO_COMPARATOR|Control|Gait Training Control Group Participants
62776835|NCT05318911|ACTIVE_COMPARATOR|Supplement Group|"10 participants will provide baseline blood samples after overnight fasting, on day 0 of the study. Following this they will initially consume 200 mL of novel yogurt drink per day for a period of 28 days.~Then, after a 2-week washout period in which the subjects do not take any yoghurt drink , Phase II of the clinical trial will commence. This is the crossover phase in which subjects who took YD will now be given a placebo drink, and vice versa, over 4 weeks. A total of 80 blood samples will be collected for analysis."
62776836|NCT05318911|PLACEBO_COMPARATOR|Placebo Group|"10 participants will provide baseline blood samples after overnight fasting, on day 0 of the study. Following this they will initially consume 200 mL of placebo drink per day for a period of 28 days.~Then, after a 2-week washout period in which the subjects do not take any placebo drink , Phase II of the clinical trial will commence. This is the crossover phase in which subjects who took YD will now be given a placebo drink, and vice versa, over 4 weeks. A total of 80 blood samples will be collected for analysis."
62776837|NCT00683839|EXPERIMENTAL|2|"Dental practitioners provide the following intervention:~5As plus nicotine replacement therapy The 5As consist of: Ask, Advise, Assess, Assist and Arrange."
62776838|NCT00683839|NO_INTERVENTION|1|Usual Care Control: Patients receive treatment as usual.
62569991|NCT03657420|EXPERIMENTAL|ABI-009 + Pomalidomide + Dexamethasone|"* Pomalidomide is given orally daily on days 1-21, 7 days off~* ABI-009 is given intravenously on days 1, 8, and 15~* Dexamethasone is given orally weekly on days 1, 8, 15, 22"
62569992|NCT05306691|EXPERIMENTAL|Bio-smart Light Cured Protective Shield with bioactive S-PRG filler technology (PRG Barrier Coat)|Surface reaction-type pre-released glass ionomer (S-PRG) fillers containing dental materials are now commercially available. It was shown that PRG filler is an active ingredient with the ability to release and recharge fluoride ions. In addition, S-PRG fillers release five other active ions, Sr2þ, SiO3 2, Naþ, BO3 3, and Al3þ. S-PRG filler has a modulation effect on acidic conditions, causing the surrounding environment to become weakly alkaline upon contact with water or acidic solutions. This effect was thought to be brought by Sr, B, Na, and F ions released from S-PRG filler. A fluoride-releasing coating material containing S-PRG filler (PRG BarrierCoat®, SHOFU, Japan) was manufactured as a coating material to suppress dentin hypersensitivity and prevent caries on smooth surface areas
62569993|NCT05306691|ACTIVE_COMPARATOR|5% NaF varnish (Proflourid Varnish VOCO America Inc.).|The gold standard remineralizing agent recommended by the guidelines
62001257|NCT01265446|EXPERIMENTAL|Lidocaine 8mg +CPC 2mg|one single dose
62186346|NCT03631303||ICD patients without ATP/Shock|10 primary prevention 2-chamber ICD patients (LVEF \<35 percent) who were free from appropriate ICD therapy during follow-up.
62186347|NCT03631303||Pacemaker-patients|10 2-chamber pacemaker-patients (LVEF \>50%).
62186348|NCT03750526|EXPERIMENTAL|rTMS and AR group|Ten participants in group A will undergo repetitive transcranial magnetic stimulation (real, 1 Hz, 15 minutes), follow by a session of augmented reality exercise (45 minutes), 3 days per week for 4 weeks.
62186349|NCT03750526|ACTIVE_COMPARATOR|Sham rTMS and AR group|Ten participants in group B will receive repetitive transcranial magnetic stimulation (sham,1 Hz, 15 minutes), follow by a session of augmented reality exercise (45 minutes), 3 days per week for 4 weeks.
62776839|NCT05557305|EXPERIMENTAL|Videogame therapy|The participants of the experimental group will only undergo video game therapy and will be called twice a week to perform supervised video game rehabilitation therapy, for a period of 45-50 minutes per session, for 10 weeks
62776840|NCT05557305|ACTIVE_COMPARATOR|Conventional therapy|The participants in the control group will undergo the conventional therapy prescribed by their treating physician, at the INP they are prescribed occupational therapy, which is usually focused on game activities with balls, dice, cubes, tying ropes, etc., twice a week for 10 weeks.
62186350|NCT03750526|ACTIVE_COMPARATOR|AR group|Ten participants in group C will undergo augmented reality exercise 60 minutes a day and 3 days per week for four weeks.
62186351|NCT03750526|ACTIVE_COMPARATOR|Conventional physiotherapy group|Ten participants allocated to the group D will receive conventional physiotherapy 60 minutes a day and 3 days per week for four weeks.
62186352|NCT05194670|EXPERIMENTAL|Acunex Vario AN6V|Patient will receive the enhanced depth of focus IOL during cataract surgery
62186353|NCT05194670|EXPERIMENTAL|Acunex AN6|Patient will receive the monofocal IOL during cataract surgery
62186354|NCT01587118|EXPERIMENTAL|antidepressant plus asenapine|adjunctive asenapine
62186355|NCT00479219|EXPERIMENTAL|A|
62186356|NCT00479219|PLACEBO_COMPARATOR|B|
62186357|NCT02989571|PLACEBO_COMPARATOR|Group 1 - Placebo Arm|Intravenous normal saline administered at 125ml/hr
62186358|NCT02989571|ACTIVE_COMPARATOR|Group 2 - Intervention Arm|Intravenous normal saline administered at 250ml/hr
62186359|NCT05088109||SI|adult patients with septic shock will be enrolled,At the time of admission (before the start of vasopressors), age of patients, source of sepsis, baseline systolic (SBP), diastolic (DBP), mean blood pressure (MAP), heart rate (HR), shock index (SI), adjusted shock index (ASI), modified shock index (MSI), diastolic shock index (DSI), baseline lactate, ABG, capillary refill time and body temperature will be recorded. Subsequent recordings will be at 0 (before starting vasopressors), 1, 2, 4, 8, and 12, 24, 48, 72 hours for all parameters except for lactate and ABG will be every 12 hours. SOFA scores, APACHE II, GCS, Charlson Comorbidity Index, will be recorded at admission; and mean total vasopressor dose, urine output will be recorded daily. Cause of death will be documented. All readings will continue for 72 after admission.
62186360|NCT00755456|ACTIVE_COMPARATOR|Glucose solution|
62001258|NCT01265446|ACTIVE_COMPARATOR|Lidocaine 1mg + CPC 2mg|one single dose
62001259|NCT06413199|EXPERIMENTAL|Hyper Training Group|2 training session per week for 2 months, 1 set of 10 unloaded repetitions in arms as a warm-up, 4 sets with a goal of 8-12 repetitions with 90 seconds of rest between sets and elbows had to be fully locked out to be counted as a repetition, 1.5 seconds for concentric and 1.5 seconds for eccentric portion.
62186361|NCT00755456|EXPERIMENTAL|Glucose and L-carnitine solution|
62569994|NCT01710579|OTHER|ARM 1 Healthy Volunteers|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
62569995|NCT01710579|OTHER|ARM 2: Patients with fecal incontinence|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
62776841|NCT04787562|EXPERIMENTAL|Cohort 1: normal renal function|Participants with an eGFR ≥ 90 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
62001260|NCT06413199|ACTIVE_COMPARATOR|1 Repetition Maximum Group|2 training session per week for 2 months, 1 set of 10 unloaded repetitions in arms as a warm-up, training protocol consisted of 5 attempts to lift as much weight as possible one time for that training visit with 90 seconds of rest between attempts. The load was progressively increased each attempt to try to reach or exceed their previous 1RM.
62001261|NCT00968591|EXPERIMENTAL|RAD001|
62001262|NCT00969553|EXPERIMENTAL|BI 6727|Schedule A
62001263|NCT02977234|EXPERIMENTAL|Iso-Amyl 2-Cyano Acrylate|Hysteroscopic Tubal Occlusion Using Iso-Amyl 2-Cyano Acrylate (Amcrylate) in Patients With Hydrosalpinx
62001264|NCT02129075|EXPERIMENTAL|Arm I (CDX-301, CDX-1401, poly-ICLC)|Patients receive recombinant Flt3 ligand (CDX-301) SC on days -7 to -1, 1-3, and 22-28 of cycle 1 and only on days 1-3 of cycle 2. Patients also receive CDX-1401 SC or ID on day 1 of each cycle and poly-ICLC SC on days 1-2 of each cycle. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
62001265|NCT02129075|ACTIVE_COMPARATOR|Arm II (CDX-1401, poly-ICLC)|Patients receive CDX-1401 and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
62569996|NCT01710579|OTHER|ARM 3 Patients with constipation|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
62569997|NCT03107039|EXPERIMENTAL|Exercise|This arm will use a resistance exercise curriculum.
62186362|NCT06547567|EXPERIMENTAL|Motivational Interviewing Group|In addition to receiving the same health education intervention as the control group, the children and adolescents in the intervention group will undergo a group-based motivational interviewing intervention. This will be conducted by a professional team that has been trained and is qualified in motivational interviewing. The intervention will embody the spirit of motivational interviewing and the stages of group motivation development, primarily including: introductory tasks, exploratory tasks, expansion tasks, and action planning tasks.
62186363|NCT06547567|NO_INTERVENTION|Health Education Intervention|Using various methods such as WeChat official accounts, video platforms, WeChat groups, and the distribution of health education pamphlets, we aim to disseminate scientific knowledge and practical skills related to healthy weight management and the prevention of overweight and obesity to children, adolescents, and their parents.
62186364|NCT01270698|EXPERIMENTAL|IMMU-130|
62776842|NCT04787562|EXPERIMENTAL|Cohort 2: Mild renal insufficiency|Participants with an eGFR 60 to \<90 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
62776843|NCT04787562|EXPERIMENTAL|Cohort 3: Moderate renal insufficiency|Participants with an eGFR 30 to \<60 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
62776844|NCT04787562|EXPERIMENTAL|Cohort 4: Severe renal insufficiency|Participants with an eGFR 15 to \<30 mL/min/1.73m2 receive a single dose of XNW4107 100mg IV co-administered with imipenem 200mg /cilastatin 200mg
62186365|NCT03763149|EXPERIMENTAL|IBI188|"Part 1: Accelerated Titration Phase 0.1 mg/kg IV; QW 0.3 mg/kg IV QW; 1 mg/kg IV QW~Part 2 : Dose Escalation Phase with initial fixed priming dose Priming dose of 1mg/kg on C1D1 followed by 3 mg/kg IV QW; 10 mg/kg IV QW; 20 mg/kg IV QW; 30 mg/kg IV QW."
62186366|NCT03421639|ACTIVE_COMPARATOR|GnRH analog alone|control group treated with GnRH analog alone
62186367|NCT03421639|EXPERIMENTAL|Aromatase inhibitor plus GnRH analog|experimental group treated with aromatase inhibitor plus GnRH analog
62186368|NCT06162481||Admitted during office hours|
62186369|NCT06162481||Admitted off hours|
62186370|NCT00554645|EXPERIMENTAL|1|Multi-disciplinary group intervention
62186371|NCT00554645|ACTIVE_COMPARATOR|2|traditional information
62776845|NCT04787562|EXPERIMENTAL|Cohort 5: End-stage renal disease (ESRD) receiving hemodialysis (HD) therapy|Participants with ESRD receiving HD therapy at least 3 times a week for at least 3 months prior to Screening visit receive a single dose of XNW4107 100mg IV co-administered with imipenem 200mg /cilastatin 200mg
62776846|NCT03187808|EXPERIMENTAL|Group A|Group A is a group of performing single thoracic manipulation at zygapophyseal joint of T6-T7.
62776847|NCT03187808|EXPERIMENTAL|Group B|Group B is a group of performing single thoracic manipulation combined with special massage technique (RT technique).
62776848|NCT00057408|EXPERIMENTAL|1|Treatment with olanzapine
62776849|NCT00057408|PLACEBO_COMPARATOR|2|Matching placebo treatment
62776850|NCT00454181|EXPERIMENTAL|IFN lozenges|500 IU Interferon-alpha lozenges for oral dissolution
62186372|NCT02450890|PLACEBO_COMPARATOR|Placebo First, then ORADUR®|Placebo once daily for 2 weeks in Period 1 and ORADUR®-Methylphenidate oral capsule at the optimal dose once daily for 2 weeks in period 2. (No washout period between two treatment periods)
62569998|NCT03107039|ACTIVE_COMPARATOR|Health Education|This arm will use health education curriculum.
62569999|NCT01588769|EXPERIMENTAL|One arm|3 doses of ALECSAT cell based immunotherapy planned for all enrolled patients
62570000|NCT06576999|EXPERIMENTAL|Sensor-based balance training|The sensor-based balance training is performed using an integrated system composed of five inertial measurement units (IMUs) and a force platform. The system analyze the data via a notebook and provide a real-time feedback for the patient in a 32 inch screen in form of exergaming.
62570001|NCT06576999|ACTIVE_COMPARATOR|Usual balance training|The usual balance training is performed using a series of conventional balance exercises administered by a formed physiotherapist that provided a verbal feedback about the quality of execution.
62001266|NCT04940845|EXPERIMENTAL|HS-20090-2|
62001267|NCT04940845|ACTIVE_COMPARATOR|Prolia®|
62186373|NCT02450890|EXPERIMENTAL|ORADUR® First, then Placebo|ORADUR®-Methylphenidate oral capsule at the optimal dose once daily for 2 weeks in Period 1 and Placebo once daily for 2 weeks in period 2. (No washout period between two treatment periods)
62186374|NCT02719314||Rh-GIOP(A)|Glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases
62186375|NCT02719314||Rh-GIOP(B)|Glucocorticoid-induced osteoporosis (GIOP) in the context of psoriasis
62186376|NCT02719314||Rh-GIOP(C)|Patients with or without chronic/inflammatory rheumatic diseases or psoriasis and/or without glucocorticoid treatment
62186377|NCT02230722|ACTIVE_COMPARATOR|Attention Control|The neutral 10-15 minute visit with the Care Manager will consist of a brief review of ATHENA-OT safety education and the patient's Pain Care Plan. The CM will answer patient questions, but will avoid using Motivational Interviewing communication. The Care Manager will review upcoming telephone check-in and assessment sessions.
62776851|NCT00454181|PLACEBO_COMPARATOR|placebo lozenges|200 mg lozenges containing anhydrous crystalline maltose
62776852|NCT00678834|ACTIVE_COMPARATOR|Arm 1|To surgery patients, Tocotrienol capsules. 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
62776853|NCT00678834|ACTIVE_COMPARATOR|Arm 2|To surgery patients, Tocopherol capsules. 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
62776854|NCT00678834|ACTIVE_COMPARATOR|Arm 3|Tocotrienol to healthy subjects - 200 mg to take orally two times a day (400 mg a day).
62776855|NCT03133923|EXPERIMENTAL|Attenuated Mumps vaccine (KMB-17), low|Biological/Vaccine: ≥3.0logCCID50/ml but \<3.5 logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[ ≥3.0logCCID50/ml but \<3.5 logCCID50/ml\] in 360 infants (8-24 months old) on 0 day
62001268|NCT03106207|OTHER|Upper gastric endoscopy (UGE)|Patients will be submitted to a UGE before the gastric bypass surgery without a ring and at two, six and 12 months after the surgical procedure .
62186378|NCT02230722|EXPERIMENTAL|Collaborative Care|Collaborative Care intervention in which one of two Care Managers delivering both interventions will assist primary care providers (PCPs) by using Motivational Interviewing to communicate computer-based ATHENA-OT (opioid therapy) decision support guidelines to veterans with chronic pain.
62186379|NCT01585545||patients with NSCLC|
62186380|NCT03025932||Patient cohort|Patients who underwent laparoscopic hernia repair of giant hiatal hernia with mesh and received anterior fundoplication
62186381|NCT02888236|EXPERIMENTAL|LEO 32731 tablet|LEO 32731 30 mg two times daily for 16 weeks
62186382|NCT02888236|PLACEBO_COMPARATOR|LEO 32731 Placebo tablet|LEO 32731 placebo two times daily for 16 weeks
62570002|NCT02421705|OTHER|Sample collection|Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
62570003|NCT04369144|EXPERIMENTAL|Intervention group|The dynamic scapular recognition exercise + rigid taping with 50%-75% tension.
62570004|NCT04369144|PLACEBO_COMPARATOR|Control|The dynamic scapular recognition exercise + placebo taping
62570005|NCT05214690|EXPERIMENTAL|Sequence A|cross-over
62186383|NCT00778921|EXPERIMENTAL|Amlodipine 10 mg|Amlodipine 10 mg
62186384|NCT00778921|EXPERIMENTAL|Aliskiren/Amlodipine 150/10 mg|Aliskiren/Amlodipine 150/10 mg
62186385|NCT00778921|EXPERIMENTAL|Aliskiren/Amlodipine 300/10 mg|Aliskiren/Amlodipine 300/10 mg
62186386|NCT01006499|PLACEBO_COMPARATOR|Placebo group|Receiving standard treatment plus placebo (5 mls/Kg of normal saline intravenously given over 4 hours).
62186387|NCT01006499|ACTIVE_COMPARATOR|Pentoxifylline group|Standard treatment plus 6 mg/Kg of Pentoxifylline intravenously (given over 4 hours) daily for three days.
62186388|NCT01006499|ACTIVE_COMPARATOR|Pentaglobin group|Standard treatment plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days
62186389|NCT01006499|ACTIVE_COMPARATOR|Pentoxifylline plus Pentaglobin group|Standard treatment plus 6 mg/Kg of Pentoxifylline plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days.
62186390|NCT02184299|EXPERIMENTAL|Nevirapine + Prednisone|"week 1-2: Nevirapine + Prednisone~week 3-24: Nevirapine alone"
62186391|NCT02184299|ACTIVE_COMPARATOR|Nevirapine|week 1-24: Nevirapine
62570006|NCT05214690|EXPERIMENTAL|Sequence B|cross-over
62570007|NCT05429801|EXPERIMENTAL|Ozone Therapy|Rectal ozone treatment along with medical treatment was administered to the patients in this group, in increasing doses for 5 sessions per week, 20 sessions in total for 4 weeks.
62776856|NCT03133923|EXPERIMENTAL|Attenuated Mumps vaccine (KMB-17), high|Biological/Vaccine: ≥4.5logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.5 logCCID50/ml\] in 360 infants (8-24 months old) on 0 day
62776857|NCT03133923|ACTIVE_COMPARATOR|Measles and Mumps Combined Vaccine，Live|manufacturer：Shanghai Institute of Biological Products Co., Ltd. (SIBP ) Measles and Mumps Combined Vaccine，Live in 360 infants in 360 infants (8-24 months old) on 0 day
62186392|NCT01672398|EXPERIMENTAL|Intervention Group|Telemonitoring plus self-management support
62186393|NCT01672398|NO_INTERVENTION|Usual Care Group|Usual Care
62186394|NCT05783999|EXPERIMENTAL|standard care + vibra plus|patients will undergo treatment with the vibra plus device on top of traditional rehabilitation
62570008|NCT05429801|ACTIVE_COMPARATOR|Control group|The patients in this group continued only their current medical treatment.
62570009|NCT01225198|PLACEBO_COMPARATOR|Placebo Group|Liquid placebo with identical packaging and flavoring to the real supplement.
62570010|NCT01225198|EXPERIMENTAL|Vitamin/Mineral Supplement Group|Multi-vitamin/mineral supplement designed for this study for children and adults with autism spectrum disorders.
62570011|NCT00505219|EXPERIMENTAL|Ixmyelocel-T|Core decompression \& treatment with Tissue Repair Cells (TRCs), demineralized bone matrix bound in autologous plasma
62570012|NCT00505219|ACTIVE_COMPARATOR|Standard of Care Only|Core decompression, demineralized bone matrix bound in autologous plasma, without any TRCs.
62186395|NCT05783999|NO_INTERVENTION|Standard care|patients undergo a traditional rehabilitation program
62186396|NCT04757077||GROUP 1|Patients 6-24 weeks after delivery with postpartum PGP (Patients with symptoms and signs of PGP, PGP confirmed with dedicated functional tests).
62186397|NCT04757077||GROUP 2|Patients 6-24 weeks after delivery, with no symptoms and signs of PGP.
62186398|NCT05696223||Early fetal growth restriction|Fetal growth restriction diagnosed before 32 SA
62186399|NCT05696223||Late fetal growth restriction|Fetal growth restriction diagnosed after 32 SA
62186400|NCT05809102|OTHER|Minimal incisions|Repair of Zone II using minimal incisions
62186401|NCT03437941|EXPERIMENTAL|Dose Determination Segment 1|Patients will be treated with enzalutamide monotherapy once daily for 28 days followed by combination treatment with CORT125281 at escalating dose levels and enzalutamide once daily in 28-day dosing cycles.
62394993|NCT01679756|ACTIVE_COMPARATOR|Extracorporeal anastomosis|"Laparoscopic right hemicolectomy for cancer. In the EA group, the bowel will be externalized by widening the incision of one of the trocars or by performing a mini-laparotomy at another location (subcostal, suprapubic) protected with a plastic sheet. The ileum and colon will be then resected through a 45 mm endoscopic linear stapler with vascular cartridge (staple height = 3.85 mm) and a side-to-side isoperistaltic mechanical anastomosis will be then performed using the same vascular cartridge. The enterotomies will be then closed using a double layered continuous manual suture using a 3-0 Polyglactin 910.~In both groups, a drain will not routinely inserted."
62394994|NCT02534428|EXPERIMENTAL|wool-first (wool-standard)|superfine merino wool clothing to be worn for 6 weeks followed by 6 weeks of standard clothing (cotton)
62776858|NCT00788710|EXPERIMENTAL|Etoricoxib 120 mg|etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.
62776859|NCT00788710|EXPERIMENTAL|Etoricoxib 90 mg|etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.
62001269|NCT00816101|EXPERIMENTAL|PROCELLERA™Antimicrobial Dressing|Dressing changes every 3 days, more frequently if needed
62001270|NCT00816101|ACTIVE_COMPARATOR|Mepilex® Border Lite|Dressing changes every 2-3 days, more frequently if needed
62001271|NCT00816101|ACTIVE_COMPARATOR|Band-Aid® Adhesive Bandage|Dressing changes every 2-3 days, more frequently if needed.
62001272|NCT01233375|EXPERIMENTAL|CO-1.01|
62001273|NCT03254134||Atrial Fibrillation|patients with atrial fibrillation
62001274|NCT03645629|ACTIVE_COMPARATOR|Food skin tests at 0 month|the skin test results of food extract at time 0 months after preparation
62001275|NCT03645629|ACTIVE_COMPARATOR|Food skin tests at 3 month|the skin test results of food extract at time 3 months after preparation
62001276|NCT03645629|ACTIVE_COMPARATOR|Food skin tests at 6 month|the skin test results of food extract at time 6 months after preparation
62001277|NCT01550419|EXPERIMENTAL|Atorvastatin(50 characters)|
62001278|NCT01550419|PLACEBO_COMPARATOR|Placebo(50 characters)|
62001279|NCT03078946|ACTIVE_COMPARATOR|Dexmedetomidine Group (N=30)|
62001280|NCT03078946|ACTIVE_COMPARATOR|Morphine with Midazolam (N=30)|
62186402|NCT03437941|EXPERIMENTAL|Dose Expansion - Abi-Resistant Cohort|Patients who have progressed during treatment with abiraterone and no other AR-blocking therapies will be treated with CORT125281 and enzalutamide.
62186403|NCT03437941|EXPERIMENTAL|Dose Expansion - Abi-Resistant Cohort Food Effect|Sub-Cohort (first 10 patients enrolled into Cohort A). Patients enrolled into this subcohort will receive a single dose of CORT125281 at Cycle 1 Day -7 and a single dose of CORT125281 at Cycle 1 Day 1 30 minutes after a standard breakfast to assess the effect of food on PK parameters. Patients will then begin CORT125281 in combination with enzalutamide on Cycle 1 Day 2 and continue in 28-day dosing cycles.
62186404|NCT03437941|EXPERIMENTAL|Dose Expansion - ARant-Resistant Cohort|Patients who progressed during treatment with enzalutamide or second-generation AR-blocking therapies will be treated with a daily dose of CORT125281 and enzalutamide.
62186405|NCT03437941|EXPERIMENTAL|Dose Determination Segment 2 (Double-Blind) - Arm A|Patients randomized to this cohort will receive enzalutamide and a titrated dose of CORT125281. Enzalutamide will be continued at the dose currently tolerated by the patient at screening.
62776860|NCT00788710|PLACEBO_COMPARATOR|Placebo|Placebo- 3 tablets once daily
62776861|NCT01476631|EXPERIMENTAL|Arm A: 30 minutes walking|First Step program with 30 minutes of walking and 10,000 steps per day for 3 months.
62394995|NCT02534428|ACTIVE_COMPARATOR|cotton-first (standard-wool)|standard (cotton) clothing to be work for 6 weeks followed by 6 weeks of superfine merino wool clothing
62776862|NCT01476631|EXPERIMENTAL|Arm B: 60 minutes walking|First Step program with 60 minutes of walking and 13,000 steps per day for 3 months.
62186406|NCT03437941|EXPERIMENTAL|Dose Determination Segment 2 (Double-Blind) - Arm B|Patients randomized to this cohort will receive enzalutamide, placebo, and CORT125281.
62186407|NCT02444728|ACTIVE_COMPARATOR|Group1:Hydroxychloroquine|Hydroxychloroquine: 100 mg tablets by mouth, 400mg everyday for 12 months Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months
62186408|NCT02444728|ACTIVE_COMPARATOR|Group 2:Cyclophosphamide|"Cyclophosphamide, Azathioprine \& Methylprednisolone Cyclophosphamide: 200mg powder intravenous infusion, 1000mg every month for 6 month.~Azathioprine: 100 mg tablets by mouth, everyday for 6 months. Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months"
62186409|NCT02743299|EXPERIMENTAL|CPR simulation|CPR simulation with and without ventilator
62186410|NCT03845075|EXPERIMENTAL|active arm|The active medication arm will be given co-administration of 0.5 mg tesofensine/50 mg metoprolol daily for 24 weeks.
62186411|NCT03845075|PLACEBO_COMPARATOR|placebo arm|The placebo arm will receive matching placebo tesofensine and placebo metoprolol.
62186412|NCT02033473|EXPERIMENTAL|Apelin|An apelin clamp in which an apelin infusion will be administered prior to reference clamp
62186413|NCT02033473|PLACEBO_COMPARATOR|Placebo|A clamp reference during which a placebo solution (saline solution) will be administered prior to apelin clamp
62186414|NCT03542162|EXPERIMENTAL|Healaflow group|The Healaflow group consists of patients with primary RRD, but exclude proliferative vitreoretinopathy grade C or more, dialysis, retinoschisis, eyes with secondary RRD, significant corneal or lens opacity precluding vitrectomy, giant retinal tears, a follow-up period of less than 3 months, and visual loss from causes other than RRD.
62394996|NCT06028191|OTHER|Kabat Technique along with baseline treatment|Kabat technique will be performed for 15 min along with baseline treatment will be given to Group A. They will have 45 min-1 hour session thrice a week in duration of six weeks.
62394997|NCT06028191|EXPERIMENTAL|Kabat Technique and LLLT along with baseline treatment|Kabat technique will be performed for 15 min and LLLT will be performed for 10 min to eight points of the effected side for 2 min at each point along with baseline treatment. They will have 45 min-1 hour session thrice a week in duration of six weeks
62394998|NCT04543526||Obese patients|Obese patients eligible for standard laparoscopic or robot-assisted laparoscopic RYGB surgery.
62394999|NCT04923776|EXPERIMENTAL|Experimental: Chemotherapy+SBRT|"Addition of SBRT, directed at liver metastases, to standard of care (SOC) treatment atezolizumab+chemotherapy in SCLC. All patients must undergo a mandatory biopsy of a liver lesion prior to chemotherapy initiation.~Cycle 1 of chemoimmunotherapy will be administered as per standard of care, with radiation planning to be done subsequently in anticipation of liver-directed SBRT."
62395000|NCT01430520|ACTIVE_COMPARATOR|Escitalopram|
62395001|NCT01430520|PLACEBO_COMPARATOR|Placebo|
62395002|NCT04596046|ACTIVE_COMPARATOR|Group S (systemic-peroral steroid)|Medication of oral methylprednisolonewas administered to the patients following the adjustment based on the severity of the lesion and regarding the clinic. The prednisolone dose was 0.5 mg/kg/day in patients with painful, small (\<5.0 cm) unilateral lesions whereas in multiple, bilateral lesions with the diameter of ≥5 cm or for those who had significant cutaneous ulceration, the prednisolone dose was specified as 1 mg/kg/day
62395003|NCT04596046|EXPERIMENTAL|Group L (local-intralesional steroid)|Triamcinolone acetonidewas administered to the patients through injecting inside the lesion. The practice was based on the dose of TCA administered in acute and chronic inflammatory skin lesions. If the lesion is single-focused and small (\<5.0 cm), 20mg / mL TCA was injected and if the lesion is multifocal or large (\>5.0 cm) then 40mg / mL TCA was injected into the lesion with the guidance of ultrasonography
62776863|NCT06108830|PLACEBO_COMPARATOR|Group of patients undergoing gastroenteroscopies with normal saline|Patients undergoing gastroenteroscopies were given propofol 2-3mg/kg and 10ml 0.9% saline before the procedure began
62186415|NCT04718311|ACTIVE_COMPARATOR|Tacrolimus treatment|Apply a small amount (about 1 teaspoon) of medication to the lesions, twice a day after brushing the teeth, with a soft bristle toothbrush or with a finger (covered with a well-fitting glove).
62776864|NCT06108830|ACTIVE_COMPARATOR|Group of patients undergoing gastroenteroscopies with esketamine|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and esketamine 0.2mg/kg before the procedure began
62001281|NCT03221985|OTHER|Questionnaires|
62186416|NCT04718311|PLACEBO_COMPARATOR|Anti-inflammatory mouthwash|Anti-inflammatory mouthwash In patients of the anti-inflammatory group, the mouthwash was used pure and without dilution at a dosage of 20 ml 3 times a day, immediately after normal daily oral hygiene was prescribed. It contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins. Patients were instructed to rinse for at least 5 minutes over the entire oral mucosa, with particular emphasis on the regions where the lesions are located.
62186417|NCT03701633||Prior to breastfeeding - cross section|Measurements of the UtA doppler postpartum ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
62776865|NCT06108830|ACTIVE_COMPARATOR|Group of patients undergoing gastroenteroscopies with remimazolam|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
62776866|NCT06108830|ACTIVE_COMPARATOR|Group of patients undergoing gastroenteroscopies with remimazolam and esketamine|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg， esketamine 0.2mg/kg and remimazolam 0.15mg/kg before the procedure began
62776867|NCT01020253|ACTIVE_COMPARATOR|Alendronate medication|
62001282|NCT05425420|EXPERIMENTAL|Single arm, Open label Methadone IV|All participants will be treated with Methadone Hydrochloride IV (over 10 minutes) and monitored overnight.
62186418|NCT03701633||After breastfeeding - cross section|Measurements of the UtA doppler postpartum ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
62186419|NCT05377515||IC-8 IOL Group|Visual outcomes in patients previously contralaterally implanted with the IC-8 IOL will be evaluated.
62186420|NCT03970499|EXPERIMENTAL|glial cerebral tumor|patient with an indication of glial cerebral tumor surgery
62186421|NCT05186896||Residents of areas at high risk of environmental crisis|1000 adult males and females living in areas declared at high risk of environmental crisis in the areas of Caltanissetta (Italy) and Tunis (Tunisia).
62186422|NCT05822128||Seniors with suspected sleep disorders referred for assessment|Seniors with suspected sleep disorders referred for assessment
62001283|NCT04499768||control|the age-related cataract patients
62001284|NCT04499768||DR group|the cataract patients with mild/moderate NPDR
62001285|NCT05047991|EXPERIMENTAL|Cohort 1: Irinotecan Liposome Injection + 5-FU/LV + Oxaliplatin|The patients in cohort 1 will receive irinotecan liposome injection combined with 5-fluorouracil (5-FU), leucovorin(LV) and oxaliplatin intravenously on day 1 and day 15 of every 28-day cycle until disease progression or unacceptable toxicity, or termination of the study due to other reasons.
62001286|NCT05047991|ACTIVE_COMPARATOR|Cohort 2: Nab-paclitaxel + Gemcitabine|The patients in cohort 2 will receive nab-paclitaxel and gemcitabine intravenously on day 1、day 8 and day 15 of every 28-day cycle until disease progression or unacceptable toxicity, or termination of the study due to other reasons.
62001287|NCT04259190|EXPERIMENTAL|Values rationale|Interoceptive exposure exercises will be introduced as a way to help participants engage in more that they value.
62001288|NCT04259190|ACTIVE_COMPARATOR|Standard rationale|Interoceptive exposure exercises will be introduced as a way to help participants experience less discomfort.
62186423|NCT03943836|EXPERIMENTAL|Music Group|Patients listen to music
62186424|NCT03943836|NO_INTERVENTION|No Music group|Patients do not listen to music
62214643|NCT02136082|ACTIVE_COMPARATOR|Asha Support Only|Asha Support Only 1) Group discussions delivered over a six month period that cover three main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen.
62776868|NCT01020253|ACTIVE_COMPARATOR|Alfacalcidol medication|
62776869|NCT01020253|NO_INTERVENTION|Non-medication|
62776870|NCT01005927|PLACEBO_COMPARATOR|No Fructooligosaccharide|0 g fructooligosaccharide added to calcium-containing beverage
62776871|NCT01005927|ACTIVE_COMPARATOR|3 g Fructooligosaccharide|3 g fructooligosaccharide added to calcium-containing beverage
62776872|NCT01292915||1|
62776873|NCT01961648|ACTIVE_COMPARATOR|Dead space|Participant will sleep connected to a mask with added dead space half of the night
62776874|NCT01961648|SHAM_COMPARATOR|room air|Participant will sleep connected to a mask open to rrom air, half of the night
62776875|NCT03673020|EXPERIMENTAL|ASV® AGEN2017|ASV® AGEN2017 + QS-21 Stimulon® Adjuvant Vaccine
62776876|NCT05987436||Group 1|Group 1 exercised for six weeks, involving once per day, five sessions per week under the supervision of a medical doctor, and a nurse in the aerobic exercise laboratory. The aerobic exercise training program lasted six weeks, and patients lived in the hospital for the whole period. Aerobic exercise training was performed on cycle ergometers (Ergoline, ergoselect II 100/200/Reha, Germany) equipped with a computed ergometer and developed to monitor electrocardiography (ECG), heart rhythm, and BP. Each session consisted of a 5-minute warm-up, followed by 50 minutes of aerobic exercise with an intensity of 50% to 70% of heart rate reserve, calculated by Karvonen formula, and ended with a 5-min cool-down period.
62776877|NCT05987436||Group 2|The subjects assigned to the control group (Group 2) were advised to maintain dietary habits and physical activity levels and the aerobic exercise program was provided to them after completing the study.
62776878|NCT00708695||Treatment 2: Transportation, Child Screening/Referral|The 514 families received: 1) free transportation for prenatal care; and 2) child developmental screening and referral services.
62776879|NCT00708695||Treatment 4: Nurse Home Visiting through Age 2|The 228 families: 1) free transportation for prenatal care; 2) nurse home-visiting during pregnancy and through child's second birthday; and 3) child developmental screening and referral.
62001289|NCT05630352|EXPERIMENTAL|Dose level 1|Injection in the muscle at 0-, 8-, and 16-weeks.
62001290|NCT05630352|EXPERIMENTAL|Dose level 2|Injection in the muscle at 0-, 8-, and 16-weeks
62001291|NCT05630352|EXPERIMENTAL|Dose level 3|Infection in the muscle at 0-, 8- and 16- weeks
62186425|NCT06408363|EXPERIMENTAL|Maneuver group|"Patients in the experimental group will receive detailed training and guidance on pressure equalization techniques and barotrauma prevention measures before undergoing treatment in a hyperbaric chamber. The specific maneuvers to be implemented are outlined below:~Toynbee Maneuver: This maneuver involves swallowing with both the mouth and nose closed, thereby reducing the pressure in the nasopharynx and tympanic cavity.~Unilateral Passive Valsalva Maneuver: This technique involves occluding one external nasal valve while performing a Valsalva maneuver on the opposite side.~These maneuvers will be performed continuously during the compression phase of the hyperbaric chamber, every 30 minutes after reaching the desired pressurization level, and continuously during the decompression phase."
62186426|NCT06408363|NO_INTERVENTION|Standard treatment|Patients will receive the standard instructions for the hyperbaric chamber without specific guidance on performing equalization maneuvers.
62186427|NCT05648396||Revascularization|Patients undergoing angiogram in which FFRangio is used to assess the physiologic significance of at least one coronary lesion, and based on this assessment are referred for coronary revascularization (PCI/CABG).
62186428|NCT05648396||Deferral|Patients undergoing angiogram in which FFRangio is used to assess the physiologic significance of at least one coronary lesion, and based on this assessment are assigned to conservative management (optimal guidelines directed medical treatment).
62186429|NCT01028612|EXPERIMENTAL|thermal ablation with external beam radiation|
62186430|NCT04950036||Normal control group-Grade 0|Arthroscopic examination of the hip was normal, and the labrum was intact without injury or tear.
62186431|NCT04950036||Ligament injury -Grade 1|Arthroscopic examination of the hip showed labrum degeneration or injury, but no local or complete tear.
62001292|NCT05630352|EXPERIMENTAL|Dose level 4|Injection in the muscle at 0-, 8- and 16- weeks
62186432|NCT04950036||Ligament tear-Grade 2|Arthroscopy of the hip revealed partial or complete loss of labrum.
62186433|NCT00723125|EXPERIMENTAL|Cohort 1|"Avastin 10 mg/kg IV over 90 minutes day -14~Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10~Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2\* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles~Definitive surgery~Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks"
62186434|NCT00723125|EXPERIMENTAL|Cohort 2|"Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7~Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7~Definitive surgery~Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2\* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks"
62186435|NCT01939561|ACTIVE_COMPARATOR|Lamotrigine|Participants are taken oral tablets Lamotrigine once daily. The dosis is escalating every other weeks, from 25 mg - 50 mg - 150 mg- 300mg during the period of 8 weeks.
62186436|NCT01939561|PLACEBO_COMPARATOR|Placebo|Participants are taken oral tablets placebo once daily. The dosis is escalating every other weeks, from 25 mg - 50 mg - 150 mg- 300 mg during the period of 8 weeks.
62186437|NCT05331976||Symptomatic subjects|"* Subjects must present with 1 or more signs or symptoms of COVID-19 infection\*.~* Subjects must have experienced symptom onset within the previous 5 days.~* Subject or Subject's legally authorized representative (LAR) is willing and able to provide informed consent. Adult subjects unable to consent will provide assent in addition to LAR's consent.~* Subject is ≥ 2 years of age. Subjects 2 ≥ x ≤ 17 will provide assent in addition to parent/legal guardian's consent."
62186438|NCT05331976||Asymptomatic Subjects|"* Subject must have been exposed to known SARS-CoV-2 positive or suspected SARS-CoV-2 symptomatic individuals within the previous 5 days.~* Subject or Subject's legally authorized representative (LAR) is willing and able to provide informed consent. Adult subjects unable to consent will provide assent in addition to LAR's consent.~* Subject is ≥ 2 years of age. Subjects 2 ≥ x ≤ 17 will provide assent in addition to parent/legal guardian's consent."
62186439|NCT00968305||Children with asthma|African American children with clinically diagnosed stable asthma
62186440|NCT03732976|EXPERIMENTAL|Modified ramped position group|In this group, induction of anesthesia will be performed in the modified ramped position.
62186441|NCT03732976|ACTIVE_COMPARATOR|Ramped position group|In this group, induction of anesthesia will be performed in the ordinary ramped position.
62186442|NCT03282981|EXPERIMENTAL|Timolol|Timoptic-XE plus standard of care (SOC)
62186443|NCT03282981|PLACEBO_COMPARATOR|SOC plus non biologically active gel|SOC plus non biologically active gel (hydrogel as placebo medication)
62186444|NCT04089072|EXPERIMENTAL|Control group|Patients in the control group will have phenylephrine infusion starting at 50 mcg/min and titrated to maintain a MAP \>65 mmHg as a third line vasopressor. Maximum dose of Phenylephrine is 300 mcg/min.
62214644|NCT03236675||EML4-ALK|ALK positive patients
62214645|NCT03236675||T790M EGFR|T790M positive patients
62214646|NCT01879722|EXPERIMENTAL|TAK-063 3 mg|TAK-063 3 mg, tablets, orally, once daily for 7 days.
62570013|NCT06050629||forme fruste keratoconus|1) no other eye abnormalities except myopia and astigmatism; 2) transparent cornea; 3) no positive signs of keratoconus on slit lamp examination or morphology examination (excluding the appearance of keratoconus as described above, and simultaneously satisfying A0B0C0D0, Index of Surface variance (ISV) \< 30, and Keratoconus Index (KI) \< 1.07); and 4) Belin/Ambrósio enhanced ectasia total derivation value(BAD-D)≤1.6
62570014|NCT06050629||Clinical keratoconus|46.5 D ≤ Mean K \<52 D; 55≤ ISV\<200; and 1.10 ≤ KI \<1.50
62776880|NCT05602077|EXPERIMENTAL|POCUS and Control Intervention|"POCUS: Point of care ultrasound~Control-Intervention: X-ray examination and Cone Beam Computed Tomography (CBCT)"
62001293|NCT05714488|EXPERIMENTAL|Blue Halo Coil Catheter for Urinary Retention|The indication for use of the Blue Halo Coil Catheter is to facilitate bladder drainage in adult male patients with urinary retention due to benign prostatic hyperplasia. The device is inserted for temporary use up to 28 days.
62001294|NCT00358527|EXPERIMENTAL|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray 200 mcg, once daily.
62001295|NCT00358527|PLACEBO_COMPARATOR|Matching placebo nasal spray|
62186445|NCT04089072|EXPERIMENTAL|Intervention group|Patients enrolled in the intervention group will receive 2 mg/kg IBW (Ideal Body Weight) bolus, given over 15 mins, of ProvayBlue® followed by a concomitant infusion at 2 mg/kg/hr (IBW) mixed in D5W, which will continue for 24 hours. ProvayBlue® ( Methylene Blue) will be used as the third-line vasopressor.
62570015|NCT06050629||severe keratoconus|Mean K ≥ 52D; ISV≥ 200; and KI≥ 1.50
62001296|NCT06278675|EXPERIMENTAL|Experimental group|Experimental group: Sterile stainless steel needle electroacupuncture treatment was applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days.
62001297|NCT06278675|NO_INTERVENTION|Control group|Control group: Placebo needles were applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days.
62570016|NCT06050629||normal eye|one eye of healthy participants before refractive surgery were randomly selected. Comprehensive ophthalmic examinations were performed before surgery, which confirmed that the cornea was clear and normal in shape. For this group, there was no family history of keratoconus, no other diseases except ametropia, and no corneal dilatation one year after surgery.
62776881|NCT03527524|EXPERIMENTAL|exercise with ball|The participant in core stabilization exercise with ball group performed 12 training sessions of the core stabilization exercises, 3 days/week for 4 weeks. Each exercise took 15 times/set and each participant did it repeatedly for 3 sets and rested 1 minute between sets. The total time of core stabilization exercise was 20 minutes and assessment time was 10 minutes.
62776882|NCT03527524|OTHER|exercise without ball|The participant in core stabilization exercise without ball group performed 12 training sessions of the core stabilization exercises, 3 days/week for 4 weeks. Each exercise took 15 times/set and each participant did it repeatedly for 3 sets and rested 1 minute between sets. The total time of core stabilization exercise was 20 minutes and assessment time was 10 minutes.
62776883|NCT05201950|EXPERIMENTAL|Virtual simulation|- Virtual simulation group: Participants will log in to the virtual simulation software from home and play 2 cases (1 case of sepsis, 1 case of trauma). Learners are instructed to play each case as many times as they like within 70 minutes, to reach the highest score possible in that time. This process is proctored, with participants sharing their screen over video conferencing with study team members (JCL or LZY) to ensure adherence to time limit and cases played.
62001298|NCT06288516|EXPERIMENTAL|Benralizumab Arm A|Benralizumab (30mg) administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks.
62001299|NCT06288516|NO_INTERVENTION|No intervention Arm B|No intervention. Standard of care as treatment.
62001300|NCT05660694|EXPERIMENTAL|Group 1: Triamcinolone|Injection steroid Triamcinolone 400mg with lidocaine 1:1 was given twice a week for 4 weeks in bi-lateral buccal mucosa in multiple sites
62001301|NCT05660694|EXPERIMENTAL|Group 2: Pentoxifylline with Vitamin E|Pentoxifylline 40mg twice a day along with vitamin E supplement one tablet per day for 4 weeks
62001302|NCT03702478||No intervention, cross-sectional study|Questionnaire, cross-sectional study
62570017|NCT00461630|EXPERIMENTAL|ER niacin/laropiprant|1 g ER niacin plus 20 mg laropiprant per tablet. 2 tablets orally per day. With either 40 mg simvastatin tablet or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily
62570018|NCT00461630|ACTIVE_COMPARATOR|Placebo|Placebo (for ER niacin/laropiprant) 2 tablets orally per day. With either 40 mg simvastatin tablet orally per day or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily
62001303|NCT03746821|OTHER|Biotin|Volunteers to take biotin suppliment
62001304|NCT04916327|EXPERIMENTAL|Antioxidant then Placebo|Subjects will ingest an antioxidant cocktail prior to their second visit and a placebo prior to third second visit
62001305|NCT04916327|EXPERIMENTAL|Placebo then Antioxidant|Subjects will ingest a placebo prior to their second visit and an antioxidant cocktail prior to their third visit.
62001306|NCT03765736||Screening (genetic testing)|Patients submit blood samples for genetic testing.
62001307|NCT06122207|ACTIVE_COMPARATOR|Probiotic|"Women will take two daily doses containing approximately 2\*10E9 Colony Forming Unit (CFU) of Ligilactobacillus salivarius PS11610 (Fertibiome®). Men will take one daily dose containing approximately 1\*10E9 CFU of Ligilactobacillus salivarius PS11610 (Fertibiome®).~In case of pregnancy during intervention, only women will continue taking 1 daily dose for the first 12 weeks of gestation."
62001308|NCT06122207|PLACEBO_COMPARATOR|Placebo|"Women will take two daily doses of Placebo supplement. Men will take one daily dose of Placebo supplement.~In case of pregnancy during intervention, only women will continue taking 1 daily dose for the first 12 weeks of gestation."
62001309|NCT03270917|OTHER|Open|Open liver surgery
62001310|NCT03270917|OTHER|Laparoscopy|Laparoscopic liver surgery
62186446|NCT04289259||Biopsy sample|Tumor mutational burden (TMB) will be assessed on a sample of the biopsy done during standard care of patients.
62186447|NCT04289259||Surgical sample|TMB will be assessed on a sample of the tumor surgical specimen resected during standard care of patients.
62214647|NCT01879722|EXPERIMENTAL|TAK-063 10 mg|TAK-063 10 mg, tablets, orally, once daily for 7 days.
62186448|NCT04289259||Biopsy sample + surgical sample|TMB will be assessed both on a sample of the biopsy and a sample of the tumor surgical specimen resected during standard care of patients.
62570019|NCT06379997|ACTIVE_COMPARATOR|Oral supplemention|Assumption of 1 vial/day starting from the day after enrollment for 56 days. This supplement contains Collagen, Hyaluronic Acid, Vitamin C, and Manganese.
62001311|NCT05706363|ACTIVE_COMPARATOR|MPFL reconstruction with gracillis graft|MPFL reconstructrion with gracillis graft and screw fixation in femur
62186449|NCT03764995|EXPERIMENTAL|Abdominal Massage|
62186450|NCT03764995|PLACEBO_COMPARATOR|Placebo Ultrasound|
62186451|NCT05172986|EXPERIMENTAL|RAAC (Program Arm)|Patient under RAAC Program
62776884|NCT05201950|ACTIVE_COMPARATOR|Team based in situ simulation|- Team based in situ simulation group: Faculty observing and debriefing learners at the mock code will be variable and consist of a wide range of NUH emergency department faculty outside of this study, due to logistical constraints in having the same faculty being present consistently in the entire year. The in situ simulation will cover 1 case of sepsis, and 1 case of trauma, with case content matched to the cases in the virtual simulation group, and time matched at 70 minutes.
62776885|NCT03570320|NO_INTERVENTION|Control group|The first treatment group will be our control arm. On discharge following their surgery, these patients will receive a single prescription for 225 Morphine Milligram Equivalents (MMEs). This corresponds to #30 pills of 5mg oxycodone/acetaminophen, #45 pills of 5mg hydrocodone/acetaminophen, or #30 pills of 7.5mg Morphine.
62186452|NCT05172986|NO_INTERVENTION|Standard Arm|Standard patient procedure
62186453|NCT01674920|EXPERIMENTAL|Choices|"The 3-month twelve-session intervention, Choices, included topics on nutrition, physical activity, and resiliency. Parents, boys and girls met separately. The sessions were developed for delivery by a family physician, two family medicine residents, and a nutritionist, who received training in positive psychology and resilience skills. All children were measured on the same dates, but children were randomly assigned to two cohorts, beginning 6 months apart, to facilitate statistical analysis by having one group experience normal growth on study prior to intervention."
62186454|NCT01440010||IORT with 50 kV x-rays, 20 Gy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
62776886|NCT03570320|EXPERIMENTAL|Interventional Arm|Patients who are randomized into the second group will also receive prescriptions for 225 MME's on discharge following their surgery, however their medications will be broken up equally into 3 separate scripts, each for 75 MME's. This corresponds to 3 scripts for #10 pills of 5mg oxycodone/acetaminophen, 3 scripts for #15 pills of 5mg hydrocodone/acetaminophen, or 3 scripts for #10 pills of 7.5mg Morphine. Each script will be post-dated to ensure that patients wait the appropriate amount of time between filling their scripts, and that they cannot fill multiple scripts on the same day or at the same time.
62776887|NCT01276223|EXPERIMENTAL|Durezol|Difluprednate 0.05% ophthalmic emulsion, 1 drop to the study eye 2 times a day for 4 weeks, followed by 1 drop to the study eye once daily for 1 week to allow for tapering of the steroid exposure.
62186455|NCT02298049|OTHER|Scanning|"Repeated measures:~Satiation scan + Pre-meal scan~All participants undertook both scans"
62186456|NCT02081937|EXPERIMENTAL|Anti-CD19 CAR T cells|Patients receive anti-CD19-CAR retroviral vector-transduced autologous or donor-derived T cells on d1-5 in the absence of disease progression or unacceptable toxicity.
62186457|NCT02400814|EXPERIMENTAL|Arm I (concurrent cohort)|Patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of course 1, patients also undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions.
62186458|NCT02400814|EXPERIMENTAL|Arm II (induction cohort)|Patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of course 3, patients also undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions.
62570020|NCT06379997|ACTIVE_COMPARATOR|Intra-articolar infiltration|Intra-articular injections of a viscous solution of sodium salt hyaluronic acid (500-730 kDa) in pre-filled 20 mg/2 ml syringes, 1/week for 3 weeks.
62570021|NCT00504712|EXPERIMENTAL|Active|Testosterone 200 mg intramuscular every 2 weeks
62570022|NCT00504712|PLACEBO_COMPARATOR|Placebo|Saline
62570023|NCT04504448|EXPERIMENTAL|HNC664 capsules|HNC664 capsules,single ascending doses Single dose
62570024|NCT04504448|PLACEBO_COMPARATOR|HNC664 placebos|HNC664 placebos,single ascending doses Single dose
62570025|NCT04504448|EXPERIMENTAL|HNC664 capsules FED|HNC664 capsules,food effect,Single dose
62570026|NCT02734966|EXPERIMENTAL|arm 1|lower dose： Magnesium Isoglycyrrhizinate injection 100mg OD for 4 weeks
62570027|NCT02734966|EXPERIMENTAL|arm 2|higher dose：Magnesium Isoglycyrrhizinate injection 200mg OD for 4 weeks.
62570028|NCT02734966|ACTIVE_COMPARATOR|Tiopronin Injection|Tiopronin Injection 200mg OD for 4 weeks
62570029|NCT05002790|EXPERIMENTAL|Data collection|All 20 anticipated subjects to be scanned under MRI, with data collected and analysed together
62570030|NCT06525831|EXPERIMENTAL|Patient with kidney cancer surgery|"the patients will have an additionnal MRI elastography and Ultrasound exams for the research. The exams will be performed between the inclusion of the patient and the day before the surgery.~Both exams are non-invasive, without radiation"
62570031|NCT03199560|ACTIVE_COMPARATOR|Tilmanocept|Tc 99m tilmanocept
62570032|NCT03199560|ACTIVE_COMPARATOR|Sulfur Colloid|Tc 99m filtered sulfur colloid
62570033|NCT05856331|EXPERIMENTAL|INBRX-101 Q3W|IV every 3-weeks (Q3W) and placebo (normal saline)
62570034|NCT05856331|EXPERIMENTAL|INBRX-101 Q4W|IV every 4-weeks (Q4W) and placebo (normal saline)
62186459|NCT02400814|EXPERIMENTAL|Arm III (sequential cohort)|Patients undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions beginning on day 1 of course 1. After completion of SAR (beginning on day 1 of course 2), patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62186460|NCT05765747|EXPERIMENTAL|Yunnan Baiyao|The Yunnan Baiyao group will be given 4 times a day, 2 capsules each time after morning, afternoon and evening meals and before going to bed. One capsule of Baoxianzi will be provided for the first time to be taken at the same time with Yunnan Baiyao Capsule, which will be given continuously for 2 weeks.
62570035|NCT05856331|ACTIVE_COMPARATOR|Zemaira (A1PI)|60 mg/kg IV once weekly (QW) and placebo (normal saline)
62186461|NCT05765747|ACTIVE_COMPARATOR|celecoxib|The celecoxib group will be given 1 capsule twice a day after breakfast and dinner for 2 weeks.
62186462|NCT03913169|OTHER|Students in Interprofessional Education Curriculum|The interprofessional intervention for the students to be employed in this study will include five modalities in a scaffolded structure progressing from low- to high-fidelity experiences over a two-year period: (1) classroom didactic sessions; (2) simulation laboratory sessions; (3) standardized patient sessions; (4) community-based clinical case conferences; and, (5) community-based interprofessional rotations.
62214648|NCT01879722|EXPERIMENTAL|TAK-063 20 mg|TAK-063 20 mg, tablets, orally, once daily for 7 days.
62214649|NCT01879722|EXPERIMENTAL|TAK-063 30 mg|TAK-063 30 mg, tablets, orally, once daily for 7 days.
62214650|NCT01879722|EXPERIMENTAL|TAK-063 100 mg|TAK-063 100 mg, tablets, orally, once daily for 7 days.
62214651|NCT01879722|PLACEBO_COMPARATOR|Placebo|Placebo matching TAK-063, tablets, orally, once daily for 7 days.
62570036|NCT05998187|EXPERIMENTAL|intra-rectal botulinum toxin injections|Patients with fecal incontinence who have failed conservative treatments and are candidates for intra-rectal botulinum toxin injections.
62570037|NCT06577129|EXPERIMENTAL|Ladder training|Participants 21 out of 42 received ladder training.
62570038|NCT06577129|ACTIVE_COMPARATOR|Plyometric training|21 participants out of 42 received ladder training.
62570039|NCT01567774|ACTIVE_COMPARATOR|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
62570040|NCT01567774|ACTIVE_COMPARATOR|Rosuvastatin|Patients will receive randomly rosuvastatin (10 mg per day) for 30 days
62570041|NCT06219356|EXPERIMENTAL|Dose Escalation of GLB-002 in Participants with R/R NHL-Phase 1a|Part 1a (Dose Escalation) of the study will enroll R/R NHL participants and will evaluate the safety, tolerability, PK, PD and preliminary efficacy of GLB-002 administered orally, and determine the maximum tolerated dose (MTD) and/or recommended expansion doses (RED) in R/R NHL patients who are eligible for dose limiting toxicity (DLT) evaluation.
62570042|NCT06219356|EXPERIMENTAL|Dose Expansion of GLB-002 in Participants with R/R FL (Grade 1, 2, 3a)-Phase 1b Cohort 1|Part 1b (Dose Expansion) Cohort 1 will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R Follicular Lymphoma (Grade 1、2、3a).
62570043|NCT06219356|EXPERIMENTAL|Dose Expansion of GLB-002 in Participants with R/R DLBCL and FL (Grade 3b)-Phase 1b Cohort 2|Confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R Diffuse Large B-cell Lymphoma and R/R Follicular Lymphoma (Grade 3b).
62776888|NCT01276223|PLACEBO_COMPARATOR|Vehicle|Difluprednate vehicle, 1 drop to the study eye 2 times a day for 4 weeks, followed by 1 drop to the study eye once daily for 1 week.
62214652|NCT02342470|PLACEBO_COMPARATOR|Placebo|Placebo Comparator / Bid
62214653|NCT02342470|EXPERIMENTAL|PMK-S005 1|Total 50mg, by mouth, bid
62214654|NCT02342470|EXPERIMENTAL|PMK-S005 2|Total 100mg, by mouth, bid
62570044|NCT06219356|EXPERIMENTAL|Dose Expansion of GLB-002 in Participants with other R/R NHL-Phase 1b Cohort 3|Part 1b (Dose Expansion) Cohort 3 will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for other R/R NHL, including, but not limited to Mantle-cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL) /Chronic Lymphocytic Leukemia (CLL) and Peripheral T-cell Lymphoma (PTCL).
62570045|NCT02685176|EXPERIMENTAL|No Heat|No active heating will be provided post cooling
62570046|NCT02685176|EXPERIMENTAL|Head|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, Vancouver) will be applied to the head following cooling
62570047|NCT02685176|EXPERIMENTAL|Torso|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, Vancouver) will be applied to the torso following cooling
62570048|NCT00806897||A|
62776889|NCT05900973|EXPERIMENTAL|NUBEQA® (darolutamide) administered to participants|Oral use of Darolutamide as an Inducer of Increased Expression of Prostate-specific membrane antigen (PSMA) in patients with Localized prostate cancer
62186463|NCT03913169|OTHER|Patients Experience with Interprofessional Care|For patients and their families, those who receive care from an Interprofessional team will receive the usual health care they normally receive at the participating clinics. In many cases patients already receive this care, but are unaware of it. Most of what occurs in Interprofessional practice happens outside of the patient encounter. For patients the process is generally invisible, but its affects are felt in terms of better communications with the patient. In this study, patients will be informed as usual about the presence of students as learners and will have the opportunity to decline student involvement in their care. The only difference for the patients and their families will be a request to fill out a survey form on paper indicating their perception of the experience in terms of quality of care and its potential impact on their access to care.
62186464|NCT03913169|OTHER|Clinician (Preceptor) Interprofessional Education Curriculum|Clinicians will experience many of the same learning experiences as the students, but will differ in the level of education and its focus. Clinicians and faculty will be taught the concepts of Interprofessional education, the same as the students, but they will also be taught how to educate students using Interprofessional practices.
62186465|NCT03913169|OTHER|Faculty in Interprofessional Education Curriculum|Doctor of Osteopathic Medicine and Physician Assistant Faculty will be taught the concepts of Interprofessional education, the same as the students, but they will also be taught how to educate students using Interprofessional practices.
62186466|NCT03336099|EXPERIMENTAL|Spa Treatment|Bicarbonate and sulfurated water cares in Vals-les-Bains thermal cure center, massage, cataplasm.
62186467|NCT03288077|EXPERIMENTAL|Triptophan beverage|Proprietary blend of nutritional interventions aimed at increasing sleepiness
62186468|NCT01517607||Mesalazine|
62186469|NCT02802358||Hip fracture|Patients with a hip fracture due to an accidental fall
62186470|NCT02802358||Wrist fracture|Patients with a wrist fracture due to an accidental fall
62186471|NCT02594046|EXPERIMENTAL|stem cell group|stem cell group who apply 1.2 g of allogeneic human adipose derived stem cell component extract on their scalp for 16 weeks
62186472|NCT02594046|PLACEBO_COMPARATOR|placebo group|placebo group who apply a placebo on their scalp for 16 weeks
62186473|NCT05604196||STUDY GROUP|Study group included 79 people (48 women and 31 men), with BMI = 30.0-39.9 kg / m2) and excessive total body fat percent (TBF%) content (\>30% TBF women and \>25% TBF men).
62186474|NCT05604196||CONTROL GROUP|Control group included 41 people (31 women and 10 men), with BMI = 18.5-24.9 kg / m2) and normal total body fat percent (TBF%) content (20-30% TBF women and 15-20% TBF men).
62186475|NCT04454788|EXPERIMENTAL|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
62186476|NCT04454788|ACTIVE_COMPARATOR|Intravenous tissue plasminogen activator (tPA)|Patients will receive standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
62186477|NCT01642095||Basic science (FAK expression)|Archived tumor tissue samples are analyzed for FAK expression by IHC. IHC staining is compared in normal renal tissue, Wilms tumor (routine and anaplastic), malignant rhabdoid tumor of the kidney, clear cell sarcoma of the kidney, and mesoblastic nephroma.
62776890|NCT05792527|NO_INTERVENTION|control group|this group will include 23 patients which will receive the traditional therapy of RA for 3 months.
62776891|NCT05792527|ACTIVE_COMPARATOR|L-carnitine group|this group will include 23 patients which will receive 500mg L-carnitine two times daily after meal plus the traditional therapy of RA for 3 months.
62776892|NCT03532139|EXPERIMENTAL|Enoxaparin|-Enoxaparin is administered subcutaneous daily
62186478|NCT00381797|EXPERIMENTAL|Arm I|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and irinotecan hydrochloride IV over 90 minutes on day 16 or 17 for course 1. Patients receive bevacizumab and irinotecan hydrochloride on days 1 and 15 for all subsequent courses. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo MRIs of the brain, magnetic resonance perfusion/diffusion, and fludeoxyglucose F 18 positron emission tomography at baseline and periodically during treatment."
62186479|NCT01542554|EXPERIMENTAL|Low glycaemic index diet|
62186480|NCT01542554|ACTIVE_COMPARATOR|Usual diabetic diet|
62186481|NCT05512078|EXPERIMENTAL|intervention|patient specific surgical positioning guide
62186482|NCT05512078|ACTIVE_COMPARATOR|control|onlay bone graft
62186483|NCT04077385|EXPERIMENTAL|Retrieval Extinction (R-E) Training Group|"On the two retrieval-extinction (R-E)/extinction training days, participants randomized to the R-E training group will observe 5-min of high calorie pictorial food cues during retrieval which will purportedly retrieve cue-reward associative memories. This will be followed by 60-min of extinction training to high calorie food cues. The R-E training group will only differ from the extinction control group in regards to the 5-min exposure to high calorie food cues prior to the 60-min of extinction training to high calorie food cues."
62214655|NCT02342470|EXPERIMENTAL|PMK-S005 3|Total 150mg, by mouth, bid
62214656|NCT01551459|ACTIVE_COMPARATOR|Arm 1: Dacarbazine|Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
62214657|NCT01551459|EXPERIMENTAL|Arm 2: Sunitinib|Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity.
62776893|NCT03532139|EXPERIMENTAL|Enoxaparin + Rosuvastatin|"* Enoxaparin is administered subcutaneous daily.~* Rosuvastatin is administered daily orally starting on day 15"
62776894|NCT03532139|EXPERIMENTAL|Thromboprophylaxis|-Thromboprophylaxis is administered per clinician discretion
62776895|NCT05013788|EXPERIMENTAL|Treatment|
62776896|NCT05013788|ACTIVE_COMPARATOR|Control Group|
62791702|NCT06140966|EXPERIMENTAL|Study Treatment|"Pretrial induction chemotherapy (if required): bortezomib, cyclophosphamid, dexamethasone (VCD).~Induction Chemotherapy: Daratumumab, Carfilzomib,Lenalidomide, Dexamethasone, CisPlatin, epirubicin, Cyclophosphamide and Etoposide (Dara-KRd-PACE).~Autologous Stem Cell Transplant (ASCT) : Melphalan, ASCT.~Consolidation: Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone (Dara-KRd).~Maintenance: Daratumumab, Carfilzomib, and Dexamethasone (Dara-Kd)."
62570049|NCT03227289||Stayed in NRDS|The neonates with NRDS are stayed in NRDS
62570050|NCT03227289||Converted to ARDS|The neonates with NRDS are converted to ARDS
62001312|NCT05706363|EXPERIMENTAL|MPFL reconstruction with quadriceps graft|MPFL reconstructrion with quadriceps graft and suture anchor fixation in femur
62001313|NCT03189394|EXPERIMENTAL|PRIDE|The in-person experimental condition, PRIDE, consists of in-person intervention activities that are scheduled over two Saturdays, back to back, approximately 3 hours each (6 hours total). This intervention consists of relationship-focused activities for couples to take part in together, focusing on relationship communication, dynamics, and sexual agreements.
62570051|NCT02810366|ACTIVE_COMPARATOR|Physician Coded Verbal Autopsy|"Of the approximately 12,500 VAs collected, 50% in each district will be randomly collected using the electronic Verbal Autopsy (eVA) instrument.~In addition to general information about the deceased (e.g. name, sex, age, etc.), this VA instrument contains a short checklist questionnaire to capture from the respondent the signs and symptoms noted during the final illness, followed by a free-text narrative.~Cause of death for these VAs will be assigned by trained physicians using the MDS physician coding system; this includes dual, independent coding of VA records, disagreements resolved by reconciliation, and remaining cases by adjudication by a third physician. The assignment of cause of deaths will be in line with the international classification of disease version 10 (ICD-10)."
62570052|NCT02810366|EXPERIMENTAL|Computer Coded Verbal Autopsy|"Of the approximately 12,500 VAs collected, 50% in each district will be randomly collected using the Extended Symptom List (ESL) VA instrument.~In addition to general information about the deceased (e.g. name, sex, age, etc.), this VA instrument contains a long checklist questionnaire to capture from the respondent the signs and symptoms noted during the final illness. This VA instrument does not contain a free-text narrative.~The cause of death for these VAs will be independently assigned by five leading computer-coding VA algorithms. The assignment of cause of deaths will be in line with 17 broad cause of death categories."
62001314|NCT03189394|EXPERIMENTAL|ePRIDE|ePRIDE is an online adaptation of the experimental condition, PRIDE, and consists of online intervention activities that are scheduled to be completed over two weeks, lasting approximately 6 hours total. This intervention consists of relationship-focused activities for couples to take part in together, focusing on relationship communication, dynamics, and sexual agreements, and is designed for couples to take together sitting side by side.
62001315|NCT03189394|ACTIVE_COMPARATOR|Men's Health|Men's Health is the active comparator group. Participants in this group go through in-person intervention days, scheduled on Saturdays back to back, but differ from the PRIDE arm because this intervention does not focus on relationship dynamics. Instead, these two Saturday intervention days focus on general men's health, including heart health, cancer, and STDs.
62001316|NCT02805335|NO_INTERVENTION|Control group|Group with the sutureless device actually used
62001317|NCT02805335|EXPERIMENTAL|Innovative group|Group with the new device ( KTFIX PLUS)
62001318|NCT02500069|PLACEBO_COMPARATOR|Placebo|Tap water infusion in all three locations (duodenum, jejunum and ileum)
62001319|NCT02500069|EXPERIMENTAL|Duodenum|Infusion of casein in duodenum
62570053|NCT04022538|EXPERIMENTAL|Sandwich osteotomy with simultaneous implant placement|This group will undergo Sandwich osteotomy procedure and segment will be fixed using the dental implants placed simultaneously during the same surgical procedure. The remaining gap will be filled using xenograft.
62001320|NCT02500069|EXPERIMENTAL|Jejunum|Infusion of casein in jejunum
62214658|NCT02299180|NO_INTERVENTION|Control arm|The control arm patients will not take part in ACP discussions and documentation, but will continue to receive usual care.
62570054|NCT04022538|ACTIVE_COMPARATOR|Sandwich osteotomy using micro-plates fixation|This group will undergo Sandwich osteotomy procedure and segment will be fixed using micro-plates and screws, and the gap will be filled using xenograft.
62570055|NCT05013320|ACTIVE_COMPARATOR|Dexmedetomidine only|dexmedetomidine is administered during the surgery
62001321|NCT02500069|EXPERIMENTAL|Ileum|Infusion of casein in ileum
62001322|NCT06243133|EXPERIMENTAL|Dual antiplatelet therapy for 30 days|Clopidogrel 300mg on the first day, then 75mg/ day for 30 consecutive days; Aspirin 100mg/ day for 90 days
62001323|NCT06243133|ACTIVE_COMPARATOR|Dual antiplatelet therapy for 90 days|Clopidogrel 300mg on the first day, then 75mg/day for 90 consecutive days; Aspirin 100mg/day for 90 days
62001324|NCT03732066|EXPERIMENTAL|Intervention Group|The intervention group will receive usual text messages, personalized reminders and interactive responses.
62001325|NCT03732066|OTHER|Control Group|The control group will receive usual text messages only.
62001326|NCT04569045|EXPERIMENTAL|HA + Lidocaine|Sodium Hyaluronate with Lidocaine Hydrochloride
62001327|NCT04569045|ACTIVE_COMPARATOR|HA|Sodium Hyaluronate
62001328|NCT02164552||Vitamin D3 pills|Vitamin D3 (cholecalciferol) supplementation (50,000 IU/week for 8 weeks) followed by 1000 IU/day for 16 weeks
62776897|NCT05500430|EXPERIMENTAL|surface pretreatment sandblasting|"Air abrasion sandblasting aluminum oxide particles (Al2O3) Aqua Care single (London, UK) will be done for the defective area then repairing with bioactive injectable composite, Beautiful Flow Plus X F00 (Shofu, Japan).~The surface treatment for aged composite will be applied according to manufacturer instructions.~Repairing with bioactive injectable composite, Beautiful Flow Plus X F00(Shofu, Japan) The material will be applied according to manufacturer instructions. After shade selection incremental insertion in layers not exceeding 2 mm and light curing for 10 sec using 3M Eliper curing unite (Elipar Deepcure-S, 3M)."
62776898|NCT05500430|ACTIVE_COMPARATOR|Repairing with conventional nanohybrid composite|The nanohybrid resin composite will be applied to the the cavity using the conventional incremental technique according to manufacturer instructions.
62776899|NCT05393024||Belantamab Mafoditin|MMRR patients included in Named Patient Program and Expanded Access Program
62395004|NCT04469140||Cohort 1 'IMPACT Cohort'|Subjects with intermediate AMD in both eyes, and at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR subjects with AMD (early or intermediate) diagnosed in one eye and exudative AMD diagnosed in the fellow eye will undergo SS-OCT imaging every 3 months for 2 years
62395005|NCT04469140||Cohort 2 'SWAGGER Cohort'|Subjects with GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye will undergo SS-OCT imaging every 3 months for 2 years
62570056|NCT05013320|EXPERIMENTAL|Combined dexmedetomidine and glycopyrrolate|glycopyrrolate and dexmedetomidine are administered during the surgery
62570057|NCT04767945||Adults with liver cirrhosis admitted to hospital liver unit|Consenting adults admitted with liver cirrhosis; recorded/uploaded are demographic, clinical, laboratory and imaging data
62570058|NCT01467713|PLACEBO_COMPARATOR|Placebo|Ramelteon SL placebo-matching, tablets, sublingual (SL) \[dissolved under the tongue\], once daily, every night at bedtime for up to 9 months.
62570059|NCT01467713|EXPERIMENTAL|Ramelteon SL 0.1 mg|Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
62570060|NCT01467713|EXPERIMENTAL|Ramelteon SL 0.4 mg|Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
62570061|NCT01467713|EXPERIMENTAL|Ramelteon SL 0.8 mg|Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
62570062|NCT05713890|EXPERIMENTAL|VR-AOT|Home-based Action Observation Treatment with virtual-reality for upper limb rehabilitation
62570063|NCT05713890|ACTIVE_COMPARATOR|VR-LO|Home-based landscape observation with virtual-reality for upper limb rehabilitation
62570064|NCT01965366|ACTIVE_COMPARATOR|Dexamethasone + VRE|0.5 mg DEX + virtual reality exposure therapy
62570065|NCT01965366|PLACEBO_COMPARATOR|Placebo + VRE|Placebo + virtual reality exposure therapy
62570066|NCT00703586|EXPERIMENTAL|1|"ARM A:~Intensification with maraviroc for 24 weeks at one of the following doses:~* 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor~* 600 mg orally BID when coadministered with efavirenz or nevirapine"
62570067|NCT00703586|ACTIVE_COMPARATOR|2|"ARM B~Intensification with an additional NRTI for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:~* Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc~* Addition of an alternate FDA approved NRTI \[such as zidovudine (AZT) or didanosine (ddi)\] at standard oral dosing to a tenofovir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc."
62570068|NCT04653181|EXPERIMENTAL|Iron arm|Half of patients get i.v. iron preoperatively
62570069|NCT04653181|NO_INTERVENTION|non-iron arm|Half of patients are treated without i.v. iron substitution
62570070|NCT06183307|EXPERIMENTAL|Nattokinase group|Participants will receive 1 capsule per day, providing the active nattokinase daily, at a dosage of 100mg, standardized at 2,000 Fibrinolytic Units.
62570071|NCT06183307|PLACEBO_COMPARATOR|Placebo Group|The placebo group will receive the same amount of 100mg placebo, at the same time, containing corn starch.
62001329|NCT02164552||Placebo pill|Placebo pills will be given 1 per week for 8 weeks followed by 1 per day for 16 weeks
62001330|NCT06210529|EXPERIMENTAL|Group A (treatmen once)|
62001331|NCT06210529|EXPERIMENTAL|Group B (treatmen twice)|
62001332|NCT01209897|ACTIVE_COMPARATOR|Stage of Change|Participant received booklet based on stage of change.
62395006|NCT04469140||Cohort 3|Subjects with GA enrolled in another trial
62395007|NCT04468555|EXPERIMENTAL|Global postural reeducation|Patients completed 3 sessions of global postural reeducation for 3 weeks.
62570072|NCT05340088||Patients who underwent RIRC for 2-4 weeks after DJ stent placement for passive dilatation|Patients who underwent RIRC for 2-4 weeks after DJ stent placement for passive dilatation
62001333|NCT01209897|EXPERIMENTAL|Common Sense Model|Participant received booklet based on common sense model.
62001334|NCT01209897|ACTIVE_COMPARATOR|Action Model|Participant received booklet based on the action stage of change.
62776900|NCT01671631||Acute Coronary Syndrome|Patients with Acute Coronary Syndrome and multivessel coronary artery disease undergoing functional evaluation of non-culprit lesions.
62791703|NCT05516719||SNCA (Alpha-synuclein gene)|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
62186484|NCT04077385|ACTIVE_COMPARATOR|Extinction Control Group|"On the two retrieval-extinction (R-E)/extinction training days, participants randomized to the extinction control group will observe 5-min of non-food-related cues (e.g., pictures of office supplies, tools) during retrieval, which will purportedly avoid retrieval of the food cue-reward associative memories that are targeted in the R-E training group. The 5-min of exposure to non-food-related cues will be followed by the same 60-min of extinction training to high calorie food cues that the R-E training group receives."
62186485|NCT02952859||historic control group|Work-up and follow-up of the historic control will be performed through similar means by contacting primary care physicians and/or medical oncologists, if information cannot be received, the patient will be directly contacted. In case the patient cannot be reached and no other information can be received on patients outcome, the death registry will be contacted.
62186486|NCT02952859||comparator group|All patients with potentially and borderline resectable pancreatic cancer are potentially candidates for IRE and will be considered for this treatment. Patient will be recruited/referred through daily clinical practice from the Inselspital Bern. Final inclusion into the study will be performed by the responsible investigators at the Inselspital Bern. Patients will be included according to the inclusion/exclusion criteria mentioned.
62186487|NCT02274779|EXPERIMENTAL|Hight dose IMRT, ELIGARD|"* PTV1 PTV5 to 66 Gy in 30 fractions of 2.2 Gy~* PTV Pelvis: 54 Gy in 30 fractions of 1.8 Gy~* PTV Loge 60 Gy in 30 fractions of 2 Gy 6 Gy A complement of 3 in two additional fractions Gy may be delivered across the lodge PTV.~* PTV Relapse Lodge: In addition to treating the PTV Lodge, additional radiation of 6 Gy in 3 fractions of 2 Gy may be made to bring the total dose of 72 Gy in 36 fractions of 2 Gy."
62186488|NCT03163043|EXPERIMENTAL|Active, Male and Female Children|Participants will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
62570073|NCT05340088||Patients who underwent RIRC for 4-6 weeks after DJ stent placement for passive dilatation|Patients who underwent RIRC for 4-6 weeks after DJ stent placement for passive dilatation
62570074|NCT01314339|EXPERIMENTAL|Desloratadine Tablets, 5 mg|Desloratadine Tablets, 5 mg of Dr. Reddy's Laboratories
62570075|NCT01314339|ACTIVE_COMPARATOR|Clarinex|Clarinex® 5 mg Tablets of Schering-Plough
62570076|NCT03786848|EXPERIMENTAL|MiniPDX Group|Patients medication plan based on MiniPDX drug sensitivity test.
62570077|NCT01627574|EXPERIMENTAL|Motivational Intervention|There are two, 45-60 minute sessions of tailored Motivational Interviewing (MI). The first session occurs at the enrollment of the study, the second at 3 month follow-up.
62001335|NCT02338752|ACTIVE_COMPARATOR|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line
62570078|NCT01627574|ACTIVE_COMPARATOR|Didactic Educational Intervention|There are two, 45-60 minute sessions of didactic educational intervention related to promoting awareness for sexual health involving contraception and STI prevention. The first session occurs at the enrollment of the study, the second at 3 month follow-up.
62570079|NCT02646540|EXPERIMENTAL|Tolvaptan 30 mg and IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive 30 mg of tolvaptan concomitantly with their standard dose of diuretics.
62570080|NCT02646540|ACTIVE_COMPARATOR|Metolazone 5mg and IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive 5mg metolazone concomitantly with their standard dose of diuretics.
62570081|NCT02646540|ACTIVE_COMPARATOR|IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive two and a half (2.5) times their standard dose of diuretics.
62570082|NCT04900818|EXPERIMENTAL|TJ033721|"Dose Escalation: TJ033721 will be administered at up to 8 dose levels (0.1, 0.3, 1, 3, 5, 8, 12 and 15 mg/kg) bi weekly (Q2W) and 1 dose level (18 mg/kg) every 3 weeks (Q3W)~During dose expansion, TJ033721 will be administered Q2W, starting at the RP2D or MTD in dose escalation."
62186489|NCT04470843|ACTIVE_COMPARATOR|Acetazolamide|Group 1 (acetazolamide): Patients undergoing RALP with the peri-operative use of one-time 250 mg dose of acetazolamide
62186490|NCT04470843|PLACEBO_COMPARATOR|Placebo|Group 2 (placebo): Patients undergoing RALP with the peri-operative use of 10 mL normal saline as placebo.
62186491|NCT02162017|EXPERIMENTAL|The lying flat intervention|Patients in lying flat intervention to be nursed lying flat (0°) immediately after diagnosis of acute stroke is made and to remain in this position for 24 hours
62186492|NCT02162017|ACTIVE_COMPARATOR|The sitting-up intervention|Patients in the sitting up intervention to be nursed with their head elevated (≥30°) by raising the head of the bed (or with extra pillows or wedge) immediately after the diagnosis of acute stroke is made, and to remain in this position for the next 24 hours
62570083|NCT04900818|EXPERIMENTAL|TJ033721 in combination with nivolumab and chemotherapy|TJ033721 will be administered in combination with nivolumab and chemotherapy
62001336|NCT02338752|ACTIVE_COMPARATOR|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line and simultaneous injection of mix vaccine (MV).
62186493|NCT05639998|EXPERIMENTAL|Group 1(COVAXIN® + COVAXIN®)|"Group 1 (COVAXIN® + COVAXIN®):~In this group, 152 participants will be recruited who will receive COVAXIN® on day 0 and on day 28 via the intramuscular route"
62186494|NCT05639998|EXPERIMENTAL|Group 2(COVAXIN® + BBV154)|"Group 2 (COVAXIN® + BBV154):~In this group, 152 participants will be recruited who will receive COVAXIN® (Intramuscular) on day 0 and BBV154 (Intranasal) day 28.~\*Post 56 days of vaccination, participants with seroconversion rate less than 3 folds will receive another dose of COVAXIN® via intramuscular route"
62570084|NCT06440239|EXPERIMENTAL|Investigational Product|PMS-101
62570085|NCT06440239|OTHER|Control|Standard of care or treatment
62570086|NCT05440045|EXPERIMENTAL|6MW3211|6MW3211 injection, 30mg/kg
62570087|NCT02163096||History of Wheezing, Benign Joint Hypermobility Syndrome|
62570088|NCT02163096||Asthma, Benign Joint Hypermobility Syndrome|
62570089|NCT06012396|EXPERIMENTAL|Exercise group|
62570090|NCT06012396|NO_INTERVENTION|Daily life group|
62570091|NCT02151305|EXPERIMENTAL|Total intravenous anesthesia group|This group received propofol and remifentanil for the maintenance of general anesthesia.
62570092|NCT02151305|EXPERIMENTAL|Inhalation anesthesia group|This group received sevoflurane for the maintenance of general anesthesia.
62570093|NCT03955705|EXPERIMENTAL|Nefopam|Nefopam: 20 mg (infuse at least 15 minutes) every 4-6 hours, max 120 mg/day
62186495|NCT05639998|EXPERIMENTAL|Group 3(BBV154 + COVAXIN®)|"Group 3 (BBV154 + COVAXIN®):~In this group, 152 participants will be recruited who will receive BBV154 (Intranasal) on day 0 and COVAXIN® (Intramuscular) on day 28.~\*Post 56 days of vaccination, participants with sero-conversion rate less than 3 folds will receive another dose of COVAXIN® via intramuscular route"
62186496|NCT05639998|EXPERIMENTAL|Group 4(BBV154 + BBV154)|"Group 4 (BBV154 + BBV154):~In this group, 152 participants will be recruited who will receive BBV154 on day 0 and on day 28 via the intranasal route."
62186497|NCT01719588||Prolonged release tapentadol|Patients will be taking prolonged release tapentadol hydrochloride as per the product insert approved in Philippines.
62570094|NCT03955705|PLACEBO_COMPARATOR|Normal saline solution|Normal saline or 0.9% Sodium Chloride (NaCl) or NSS
62186498|NCT01339624|ACTIVE_COMPARATOR|NASAL FENTANYL,|
62186499|NCT01339624|ACTIVE_COMPARATOR|KETOROLAC + MORPHINE|
62186500|NCT03772600|EXPERIMENTAL|Dexcom G6|Use a Dexcom G6 CGM for 36 months
62186501|NCT03772600|NO_INTERVENTION|FreeStyle Libre|"Keep using their FreeStyle Libre for 6 months. Before the 6 month time point is reached, patients will wear a blinded Dexcom G6 for 28 days, together with their FreeStyle Libre.~Cross-over to Dexcom G6 for 30 months."
62186502|NCT03088098|ACTIVE_COMPARATOR|Treatment|Patient receiving LAAO
62186503|NCT03088098|NO_INTERVENTION|Control|Patient undergoing medical therapy for stroke prevention
62186504|NCT00832000|EXPERIMENTAL|1|Participants will receive mexiletine for 4 weeks, then no intervention for 1 week, and finally placebo for 4 weeks.
62186505|NCT00832000|EXPERIMENTAL|2|Participants will receive placebo for 4 weeks, then no intervention for 1 week, and finally mexiletine for 4 weeks.
62186506|NCT05200325|NO_INTERVENTION|Control Group|The control group does not receive educational materials about the TissueCypher diagnostic test and will treat their simulated patients with the current standard of care tools.
62186507|NCT05200325|EXPERIMENTAL|Intervention Group 1|Intervention group 1 receives educational materials about the TissueCypher diagnostic test. These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report. This intervention group is then forced to use the test results in treating their simulated patients.
62186508|NCT05200325|EXPERIMENTAL|Intervention Group 2|Intervention group 2 receives educational materials about the TissueCypher diagnostic test. These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report. This intervention group then gets to decide whether or not they want to use the TissueCypher test results for their simulated patients.
62186509|NCT05194475|EXPERIMENTAL|Thermogenic Ready-to-drink Beverage|Arm in which a thermogenic ready-to-drink beverage is ingested.
62020997|NCT03574454|OTHER|Phase 3 - Disease Burden Paired Data Set|Machine Learning (ML): Approximately 200 paired WB-MRI scans from 100 patients (scanned at baseline with active disease and then post treatment) will be used to develop a machine learning tool to quantify the burden of disease. The machine learning algorithm will then be tested on a further additional set of 60 patients who previously had two WB-MRI scans comprising paired baseline (with active disease) and post treatment scans. The agreement of radiology readers to evaluate the burden of disease will be measured against the reference standard (expert panel) with and without machine learning support.
62186510|NCT05194475|PLACEBO_COMPARATOR|Placebo Ready-to-drink Beverage|Arm in which a placebo ready-to-drink beverage is ingested.
62186511|NCT04488042|EXPERIMENTAL|Stapler-less|after the LSG stapler line removal by electrothermal bipolar-activated device (LigaSure Atlas™, Valleylab, Boulder, CO, USA), a stapler-less hand-sewn reconstruction was adopted. A single extra-mucosal running barbed suture (3/0 V-Loc™ suture; Covidien, Mansfield, MA, USA), incorporating sero- and submucosal gastric layers, closed the gastric tube.
62186512|NCT04488042|ACTIVE_COMPARATOR|Conventional Stapler|no reinforcement was performed, the stomach was re-sleeved along a 40F bougie with Echelon Flex Endopath 60-mm linear stapler (Ethicon Endo-Surgery, Cincinnati, OH, USA) to reproduce standard volume of remnant LSG stomach and/or eliminating zig-zag shape of suture-line.
62186513|NCT05969405||Laparoscopy|Laparoscopic staging group
62186514|NCT05969405||Robotic|Robotic staing group
62186515|NCT05969405||Laparotomic|Laparotomic group
62186516|NCT02579824|EXPERIMENTAL|DS-3032b|"Dose Escalation Phase: DS-3032b administered once daily by mouth on Days 1 - 21 of a 28 day cycle. Starting dose level 90 mg/day.~Dose Expansion Phase: Starting dose level maximum tolerated dose from Dose Escalation Phase."
62186517|NCT00521859|EXPERIMENTAL|Cloretazine + Fludarabine|
62186518|NCT04843410|EXPERIMENTAL|Experimental: Exercise group|"In this prospective study, patients who applied to Zonguldak Atatürk State Hospital Oncology Outpatient Clinic received at least three cures of taxane and platinum-based treatment (monotherapy or combined) and developed grade 2 and higher peripheral neuropathy (lung cancer, breast cancer) as a result of motor and sensory neuropathy evaluation. , gynecological cancers, colorectal cancers), patients with stable vital signs who can tolerate the exercise, patients without bone metastases, patients older than 18 years of age, and patients who agree to participate in the study.~The experimental group will be taught an exercise program to apply regularly twice a day. The researcher will give the patient the barbed ball and barbed roller required for the exercise. In addition, visual training material will be given for the exercise program so that the patient can repeat the training whenever he wants to ensure the permanence of the patient education."
62186519|NCT04843410|SHAM_COMPARATOR|The routine care: Control Group|In this prospective study, patients who applied to Zonguldak Atatürk State Hospital Oncology Outpatient Clinic received at least 3 cures of taxane and platinum-based treatment (monotherapy or combined) and developed grade 2 and higher peripheral neuropathy (lung cancer, breast cancer) as a result of motor and sensory neuropathy evaluation. , gynecological cancers, colorectal cancers), patients with stable vital signs, patients without bone metastases, patients older than 18 years of age, and patients who agree to participate in the study. The routine care of the clinic will be applied to the control group.
62186520|NCT06226662|EXPERIMENTAL|NM8074|6 subjects will receive a biweekly dose of 20 mg/kg of NM8074 plus SOC (cyclophosphamide/azathioprine or rituximab plus corticosteroids)
62186521|NCT06226662|PLACEBO_COMPARATOR|Placebo|6 subjects will receive a biweekly dose of placebo plus SOC (cyclophosphamide/azathioprine or rituximab plus corticosteroids)
62186522|NCT00983905|ACTIVE_COMPARATOR|Theophylline alone|baseline theophylline kinetics
62570095|NCT06438614|EXPERIMENTAL|Arm 1|"Treatment involves 2 cycles of HITS: hu3F8, irinotecan, temozolomide, and GM-CSF. Irinotecan and temozolomide are given for 5 days, and hu3F8 and GM-CSF on specific days.~Following this, 5 cycles of Naxitamab + GM-CSF are administered. Patients without a response receive NICE: hu3F8, GM-CSF, carboplatin, ifosfamide, and etoposide for 4 cycles.~Patients with a complete response (CR) move to Naxitamab consolidation (5 cycles). This involves GM-CSF before and after, and hu3F8 on days 1, 3, and 5.~Those with less than CR undergo 2 more NICE cycles, evaluated after the 4th. Lack of response leads to removal from the study."
62570096|NCT00961350|EXPERIMENTAL|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
62570097|NCT00961350|ACTIVE_COMPARATOR|EC Aspirin|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
62570098|NCT05511324|OTHER|Baseline Assessment|"Participants will be asked to complete a baseline assessment of questionnaires that will ask:~* Demographic information (such as your age, sex, and race)~* Psychological and physical health"
62001337|NCT04199429|EXPERIMENTAL|Experimental|"Each nurse applied the RBC model through the treatment Take 5 minutes (T5M), to parents allocated to the experimental group. This consisted in devoting some time (from 5 to 10 minutes) to improving the relationship with the parent. This treatment can be considered as the practical development of the core principles of the RBC model by the study team.~During the T5M the nurse applied the strategies of empathic communication and active listening, learned during the education and training phase. The treatment lasted from 5 to 10 minutes and was delivered once per day during the admission of the patient.~The T5M time was considered as additional or supplementary, but not substitutive, of the standard nursing time dedicated daily to patients and parents."
62001338|NCT04199429|ACTIVE_COMPARATOR|Control|Standard nursing time dedicated daily to patients and parents.
62001339|NCT04347265|EXPERIMENTAL|NMP in level 1|Participants in this group received NMP of the sciatic nerve in the gluteus region
62776901|NCT05301309|EXPERIMENTAL|Breastfeeding Consultation|"The intervention group would receive integrative early breastfeeding support and intervention programs, including breastfeeding for prematurity brochure, group education class, weekly interview, one-by-one breastfeeding consultation and online peer group support."
62001340|NCT04347265|EXPERIMENTAL|NMP in level 2|Participants in this group received NMP of the sciatic nerve in the middle of the thigh
62001341|NCT04347265|EXPERIMENTAL|NMP in level 3|Participants in this group received NMP of the sciatic nerve before popliteus region
62186523|NCT00983905|EXPERIMENTAL|Theophylline with steady-state Colchicine|theophylline pharmacokinetics upon administration with colchicine at steady-state
62001342|NCT03424538|EXPERIMENTAL|MSt|The MSt group that received 5 weeks of intensive therapy.
62001343|NCT03424538|NO_INTERVENTION|MSc|The MS controll group that did not receive treatment.
62001344|NCT03424538|EXPERIMENTAL|MStp|The MStp Group performs a traditional physiotherapy for 5 weeks.
62186524|NCT04367077|EXPERIMENTAL|MultiStem|
62186525|NCT04367077|PLACEBO_COMPARATOR|Placebo|
62395008|NCT04468555|NO_INTERVENTION|Control group|Patients allocated to the control group did not receive any treatment.
62570099|NCT05511324|OTHER|Caregiver Intervention Sessions|Caregiver will take part in 4 caregiver intervention sessions. The first 2 sessions will take place in the Simulation Center at the hospital when you are scheduled for treatment or a follow-up appointment. The remaining 2 sessions will be done remotely using a videoconference platform (such as Zoom) and will focus on discussing your caregiver's role and experiences and suggesting coping and self-care strategies.
62776902|NCT05301309|ACTIVE_COMPARATOR|routine care|"The control group only receive breastfeeding for prematurity brochure and routine care."
62776903|NCT02999633|EXPERIMENTAL|Isatuximab|Participants received intravenous administration of isatuximab at a dose of 20 milligrams/kilogram (mg/kg) at Day 1, 8, 15 and 22 of each Cycle (up to 2 treatment cycles, each cycle 28 days).
62776904|NCT01683578|ACTIVE_COMPARATOR|Variable Ventilation|Variable tidal volumes with mean at 8 mL/kg of predicted body weight
62776905|NCT01683578|NO_INTERVENTION|Non-variable Ventilation|Conventional mechanical ventilation with tidal volume 8 mL/kg of predicted body weight
62776906|NCT00700505|EXPERIMENTAL|Heating Garment|FlowPants(R) Garment with Heating
62395009|NCT04692324||Basic science (biospecimen collection)|Patients undergo collection of CSF samples via lumbar puncture at least 2 times. Patients may undergo additional collection of additional CSF samples if they choose.
62395010|NCT06267859|NO_INTERVENTION|First stage|"Study of children from the group of frequently ill children, and with congenital diseases, collection of anamnesis, their examination, clinical and laboratory examination. Purpose: to identify the most frequently encountered group of diseases among children."
62395011|NCT06267859|NO_INTERVENTION|Second stage|Study the effectiveness of treatment according to approved treatment standards
62395012|NCT06267859|NO_INTERVENTION|third stage|Based on the research results, develop your treatment tactics. It is approved by the Ethics Committee for working with patients.
62395013|NCT06267859|EXPERIMENTAL|fourth stage|Use your treatment tactics among a group of patients. Study the effectiveness of the proposed therapy and rehabilitation methods.
62395014|NCT06267859|NO_INTERVENTION|fifth stage|Based on the research data, clinical recommendations for doctors will be developed.
62395015|NCT01365026|EXPERIMENTAL|PVS intervention|
62395016|NCT01365026|NO_INTERVENTION|Control group|
62395017|NCT02025127|EXPERIMENTAL|Trophic feeding|Mechanically ventilated patients with septic shock \> 18 years old randomized to this group will receive more than 50 but less than 600 kilocalories of enteral nutrition per day while on vasopressors. This will be started within 24 hours of intensive care unit admission.
62395018|NCT02025127|NO_INTERVENTION|No Enteral Nutrition|Mechanically ventilated patients with septic shock randomized to this group will receive no enteral nutrition while on vasopressor support.
62395019|NCT06217627|EXPERIMENTAL|Umbilical cord (UC)- mesenchymal stem cells (MSCs) secretome|19 participants received UC-MSCs secretome injections in the neck and different areas of the face including the forehead, cheeks, under eyes, chin, and nasolabial folds.
62395020|NCT06217627|EXPERIMENTAL|UC-explants secretome|30 participants received UC-explants secretome in the left and right hands
62395021|NCT05795127||Reoperated|Primary arthrodesis operations later requiring reoperation.
62395022|NCT05795127||Control|Primary arthrodesis operations with no further operations. Size of the control group is four fold.
62395023|NCT04534868|OTHER|Patient Acceptance and satisfaction for teledermoscopy|"The aim of the first part of the study is to evaluate patients' skin monitoring habits, their knowledge of skin cancer, and their preconceptions about new telemedicine tools such as teledermoscopy. This is a written quantitative questionnaire with answers to tick.~An explanatory folder will be given to patients and they will be asked to read it beforehand in order to allow a good understanding of the terms used and the goal of the project. This part will include 70 to 100 patients.~The second part of the study is a qualitative study and the aim of it is to evaluate the satisfaction, acceptance and future expectations of those who have benefited from teledermoscopy. Individual and anonymous interviews, lasting 15 to 20 minutes, intended for patients who have benefit of teledermoscopy at the office. An explanatory folder will also be given to the patients concerned in order to explain to them the procedure of the interview. This part will include 8 to 10 patients."
62395024|NCT04246918|PLACEBO_COMPARATOR|Standard Treatment Group|The patients would receive customized diet charts providing 30-35Kcal/ideal body wt/day and 1.5 gm protein/ideal body wt/day) describing the food items along with the quantity and approximate household measurements. Diet would be so planned for each patient keeping in mind the individual food habits and choices. This group would not receive any supplement other than the prescribed diet. Whey protein will be included in this group.
62395025|NCT04246918|ACTIVE_COMPARATOR|Intervention Arm|The patients would receive customized diet charts providing 30-35Kcal/ideal body wt/day and 1.5 gm protein/ideal body wt/day) describing the food items along with the quantity and approximate household measurements. Diet would be so planned for each patient keeping in mind the individual food habits and choices. In addition to the normal diet this group would receive 16gm of branched chain amino acid (BCAA) supplement (Commercial oral BCAA granules) daily in 4 divided doses, keeping the protein levels within the same range of 1.5 gm/Kg/day.
62776907|NCT03033264|EXPERIMENTAL|BMI>30+Dinoprostone|Women with a BMI\>30 at term that will be induced for obstetrical indications with 10 mg of a Dinoprostone vaginal insert.
62776908|NCT03033264|EXPERIMENTAL|BMI<30+Dinoprostone|Women with a BMI\<30 at term that will be induced for obstetrical indications with 10 mg of a Dinoprostone vaginal insert.
62776909|NCT03033264|EXPERIMENTAL|BMI>30+Cervical ripening balloon|Women with a BMI\>30 at term that will be induced for obstetrical indications with a double lumen cervical ripening balloon.
62776910|NCT03033264|EXPERIMENTAL|BMI<30+Cervical ripening balloon|Women with a BMI\<30 at term that will be induced for obstetrical indications with a double lumen cervical ripening balloon.
62776911|NCT01195493|EXPERIMENTAL|test mouthrinse|
62776912|NCT01195493|ACTIVE_COMPARATOR|control group|
62776913|NCT03888209|EXPERIMENTAL|Anodal tDCS|Patients will receive 20min anodal tDCS
62776914|NCT03888209|SHAM_COMPARATOR|Sham tDCS|Patients will receive 20 minutes of Sham anodal tDCS
62776915|NCT00671606|EXPERIMENTAL|Intraoperative Lymphatic Mapping|Intraoperative sentinel lymph node identification (lymphatic mapping)
62776916|NCT01686282|PLACEBO_COMPARATOR|Placebo|8 weeks of freeze-dried blueberry powder taken in two doses of 22g each per day.
62186526|NCT02378298|ACTIVE_COMPARATOR|Non-responder RTX+MTX|"Patients with moderate-severe TAO with an inflammatory CAS of ≥ 4 that do not respond to iv GC (deltaCAS \<2 compared to baseline after 4 weeks of iv GC ) or do relapse (deltaCAS ≥2 and total CAS ≥4) after steroid treatment compared to previous CAS measurement at 12 weeks. Rituximab (1000 mg iv with 2 weeks in between) is combined with methotrexate (15-20 mg once a week) to minimize the risk of antibody developement. MTX is always combined with RTX and is never given as a monotherapy in this study.~rituximab and methotrexate"
62186527|NCT02378298|ACTIVE_COMPARATOR|Relapse RTX+MTX|Patients that respond to iv GC (Methylprednisolone iv) but relapse after 6 weeks will be randomised to either RTX+MTX or per oral GC (po GC+MTX) rituximab and methotrexate
62186528|NCT02378298|ACTIVE_COMPARATOR|Relapse po GC+MTX|"Patients that respond to iv GC but relapse after 6 weeks will be randomised to either RTX+MTX or per oral GC (po GC+MTX) This is the conventional therapy arm.~methotrexate and methylprednisolone"
62186529|NCT02378298|NO_INTERVENTION|Responders without relapse|Patients that respond to iv GC and have no relapse at 18 weeks of study.
62186530|NCT02378298|ACTIVE_COMPARATOR|Methylprednisolone iv|All patients in the study have a 4 weeks period of 500 mg methylprednisolone iv/week. Depending of the response patients are classified as non- responders (and are given RTX and MTX) or responders. The responders continue with intravenous infusion of Methylprednisolone 500 mg /week in 2 weeks and thereafter 250 mg iv/week in 6 weeks.
62186531|NCT04533009|ACTIVE_COMPARATOR|tramadol/acetaminophen|Tramadol-paracetamol two tablets 37,5mg/325mg twice daily up to five days for patients undergoing spinal surgery
62186532|NCT04533009|PLACEBO_COMPARATOR|placebo|Placebo two tablets twice daily up to five days for patients undergoing spinal surgery
62395026|NCT06531798|EXPERIMENTAL|Single arm|It will be a single-arm interventional phase 4 clinical study where participants will receive treatment with Breztri aerosphereTM containing budesonide 160 mcg/ glycopyrronium 7.2 mcg/ formoterol fumarate dehydrate 5 mcg (Breztri aerosphereTM pMDI) two actuations twice daily through oral inhalation for 24 weeks.
62186533|NCT03259399||wild genotype|Detection of genotype will be carried out through next generation sequencing, distinguish wild genotype of enalapril
62186534|NCT03259399||mutant genotype|Detection of genotype will be carried out through next generation sequencing, distinguish mutant genotype of enalapril
62186535|NCT04407598||Glenfield Complex COPD Clinic Cohort|Patients previously seen in the complex COPD clinic at the Glenfield Hospital.
62186536|NCT01006616|EXPERIMENTAL|Navarixin 10 mg|Participants receive navarixin 10 mg, as one navarixin 10 mg capsule and two placebo capsules, administered orally once daily (QD) for up to 2 years
62186537|NCT01006616|EXPERIMENTAL|Navarixin 30 mg|Participants receive navarixin 30 mg, as one navarixin 30 mg capsule and two placebo capsules, administered orally QD for up to 2 years
62186538|NCT01006616|EXPERIMENTAL|Navarixin 50 mg|Participants receive navarixin 50 mg, as two navarixin 10 mg capsules and one navarixin 30 mg capsule, administered orally QD for up to 2 years
62001345|NCT05360836|EXPERIMENTAL|Conservative|Conservative Treatment Program
62001346|NCT05360836|EXPERIMENTAL|Motor Imagery|Conservative Treatment + Motor Imagery Program
62001347|NCT02784301|EXPERIMENTAL|Belly breathing with biofeedback app|
62001348|NCT02784301|NO_INTERVENTION|Standard of Care|
62186539|NCT01006616|PLACEBO_COMPARATOR|Placebo|Participants receive placebo to navarixin, as three placebo capsules, administered orally QD for up to 2 years
62776917|NCT01686282|EXPERIMENTAL|Blueberry|8 weeks of freeze-dried blueberry powder taken in two doses of 22g each per day.
62776918|NCT06543342|EXPERIMENTAL|Bystander Brief Motivational Intervention|Two 2-hour in person sessions focusing on identifying alcohol risks among peers, determining optimal bystander strategies to use, and identifying personal barriers to intervening.
62776919|NCT06543342|NO_INTERVENTION|Assessment Control|Comparison group selected using the same criteria but receive no intervention.
62776920|NCT06245538|EXPERIMENTAL|Seated rest|Participants will be resting while seated on a comfortable chair for 20 minutes
62776921|NCT06245538|EXPERIMENTAL|Exercise at moderate intensity|Participants will perform a 20-min leg cycling exercise on a cycle ergometer at moderate intensity (60% of VO2max)
62776922|NCT06245538|EXPERIMENTAL|Exercise at vigorous intensity|Participants will perform a 20-min leg cycling exercise on a cycle ergometer at vigorous intensity (80% of VO2max)
62776923|NCT02837042|EXPERIMENTAL|Pembrolizumab 200 mg|Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks.
62791704|NCT05516719||Idiopathic Parkinson's Disease|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
62186540|NCT05531890|EXPERIMENTAL|Group 1 GTX-102 medium dose fast or slow in Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered fast or slow over two periods
62186541|NCT05531890|EXPERIMENTAL|Group 2a GTX-102 high dose fast in Period 1 and Period 2|"GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered fast over two periods~Note: Note under US IND"
62186542|NCT05531890|ACTIVE_COMPARATOR|Group 2b Oral comparator in Period 1 and Period 2|"0.1 mg/kg betamethasone solution oral drops solution over two periods~Note: Not under US IND"
62570100|NCT03727919|EXPERIMENTAL|Early Experimental Group|N = 20 Intervention = 1-hour sessions of exoskeleton-assisted gait training, using the Ekso GT (Ekso Bionics, CA, USA) in addition to standard care Frequency = 4 times per week for 4 weeks, provided within the first 6 weeks post-stroke
62570101|NCT03727919|EXPERIMENTAL|Delayed Experimental Group|N = 20 Intervention = 1-hour sessions of exoskeleton-assisted gait training, using the Ekso GT (Ekso Bionics, CA, USA) in addition to standard care Frequency = 4 times per week for 4 weeks, provided between week 8 and week 12 post-stroke
62570102|NCT04989946|ACTIVE_COMPARATOR|Arm 1: Degarelix|- Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57
62186543|NCT05531890|EXPERIMENTAL|Group 3 GTX-102 high dose fast or low dose fast in Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) or GTX-102 Betamethasone oral spray low dose (0.025 mg/kg) administered fast over two periods
62186544|NCT05531890|EXPERIMENTAL|Group 4a GTX-102 high dose fast in Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered fast over two periods
62186545|NCT05531890|ACTIVE_COMPARATOR|Group 4b betamethasone intramuscular in Period 1 and Period 2|0.1 mg/kg betamethasone solution as intramuscular injection administered over two periods
62186546|NCT03636373|EXPERIMENTAL|Etanercept|Subjects will be administered etanercept 50 mg subcutaneously and a placebo intramuscularly
62186547|NCT03636373|ACTIVE_COMPARATOR|Triamcinolone acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly and a placebo subcutaneously
62186548|NCT04721782||otherwise healthy, smoking, singleton pregnant women between 24- 36 weeks|Fetal liver circulation will be evaluated with doppler ultrasound, The degree of maternal smoking will be assessed by measuring urine cotinine and exhaled carbon monokside levels
62186549|NCT04721782||otherwise healthy, non-smoking, singleton pregnant women between 24- 36 weeks|Fetal liver circulation will be evaluated with doppler ultrasound, The degree of maternal smoking will be assessed by measuring urine cotinine and exhaled carbon monokside levels
62186550|NCT01329471||Umbilical cord blood|
62186551|NCT04826276|EXPERIMENTAL|All Subjects|"for the abstinence intervention, 12+ hours after smoking will be assessed before assessments following smoking as normal~For the satiated intervention, smoking as normal will be assessed first before assessments following 12+ hours of abstinence from smoking"
62570103|NCT04989946|EXPERIMENTAL|Arm 2: Degarelix and pTVG-AR|"* Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57~* pTVG-AR (100 µg) administered intradermally (i.d.) at days 1, 8, 15, 22, 29, 43, 57 and 71"
62570104|NCT04989946|EXPERIMENTAL|Arm 3: Degarelix and pTVG-AR and Nivolumab|"* Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57~* pTVG-AR (100 µg) administered intradermally (i.d.) at days 1, 8, 15, 22, 29, 43, 57 and 71~* Nivolumab 240 mg IV administered at days 29, 43, 57 and 71"
62186552|NCT01966198|EXPERIMENTAL|all patients|tilt
62186553|NCT02449083||Arm 1|Patients with indication for MRI and coronary angiography
62186554|NCT02449083||Arm 2|Patients with atrioseptal or ventriculoseptal Shunt with indication to coronary angiography
62570105|NCT04989946|EXPERIMENTAL|Arm 4: Degarelix and pTVG-AR and Cemiplimab|"* Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57~* pTVG-AR (100 µg) administered intradermally (i.d.) at days 1, 8, 15, 22, 29, 43, 57 and 71~* Cemiplimab 350 mg IV administered at days 1, 22, 43 and 64"
62186555|NCT02449083||Arm 3|Patients with chronic obstructive pulmonary disease with indication to coronary angiography
62186556|NCT05421767|ACTIVE_COMPARATOR|Low RNS-induced SBP change group|25 patients with the RNS-induced systolic BP change \<20mmHg immediately after RDN
62186557|NCT05421767|PLACEBO_COMPARATOR|High RNS-induced SBP change group|8 patients with the RNS-induced systolic BP change \>20mmHg immediately after RDN
62570106|NCT04989946|EXPERIMENTAL|Arm 5: Degarelix and pTVG-AR and Cemiplimab and Fianlimab|"* Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57~* pTVG-AR (100 µg) administered intradermally (i.d.) at days 1, 8, 15, 22, 29, 43, 57 and 71~* Cemiplimab 350 mg IV administered at days 1, 22, 43 and 64~* Fianlimab 1600 mg IV administered at days 1, 22, 43 and 64"
62186558|NCT05421767|EXPERIMENTAL|intensive RDN group|17 patients with the initial RNS-induced systolic BP change \>20mmHg immediately after RDN, received intensive RDN therapy and let the second RNS-induced systolic BP change \< 20mmHg
62186559|NCT00801411|EXPERIMENTAL|Arm I|Patients receive cyclophosphamide IV and docetaxel IV over 1 hour on day 1.
62186560|NCT00801411|ACTIVE_COMPARATOR|Arm II|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1.
62186561|NCT00538356|EXPERIMENTAL|Home Monitoring|ICD or CRT-D with Home Monitoring feature activated Home Monitoring data will be analyzed regularly and patients will be contacted and scheduled for additional follow-up after predefined events
62186562|NCT00538356|ACTIVE_COMPARATOR|Control|ICD or CRT-D with Home Monitoring feature deactivated Patients will be treated as per standard of care in each participating clinic
62186563|NCT01955759|EXPERIMENTAL|beta blocker and amiodarone|The inteventin will be that patients will receive beta blocker Bisoprolol in adjusted dose + Amiodarone per os starting 7 days before coronary by-pass surgery, 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge
62186564|NCT01955759|EXPERIMENTAL|beta blocker and statin|The intervention will be that patients will receive beta blocker (Bisoprolol tab in adjusted dose)+ Rosuvastatin 20 mg. x 1 starting 7 days before coronary by-pass surgry untill discharge.
62186565|NCT01955759|PLACEBO_COMPARATOR|beta blocker|Patients will receive beta blocker (Bisoprolol tab in adjusted dose).
62570107|NCT05390333|OTHER|Self-Care Sampler for Family Care Partners|The 6-week Self-Care Sampler for Family Caregivers program was created to provide a variety of evidence-based self-care practices that improve the mental and physical health of caregivers by relieving stress. Sessions will take place once a week for 90 minutes, each starting with a centering exercise and focusing on a new form of self-care. The first 30 minutes will be used for a support group and the last 60 minutes will be for a self-care practice. Self-care practices that will be offered throughout the 6 weeks include mindfulness, mindful drawing, exercise, and health prevention and promotion.
62570108|NCT02996825|EXPERIMENTAL|Treatment (IMGN853, gemcitabine hydrochloride)|Patients receive mirvetuximab soravtansine IV on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Cycles repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
62570109|NCT04242472|EXPERIMENTAL|SMS group|Nutrition-related SMS messages in addition to standard of care TB treatment with directly observed therapy
62570110|NCT04242472|NO_INTERVENTION|Control group|Standard care of TB treatment with directly observed therapy alone
62570111|NCT05860192|EXPERIMENTAL|Virtual Reality|Each patient undergoes to a virtual reality session of mindfullness. This lasts about 30 minutes.
62570112|NCT02523183||Subjects with medically refractory epilepsy|Pediatric epilepsy patients who are followed at Children's Hospital Colorado with medically refractory epilepsy, and whom the family has decided to treat with medical cannabis.
62570113|NCT06574776||A single cohort|It is a study with a single cohort.
62570114|NCT06022315|EXPERIMENTAL|restricted high carbohydrate low fat diet with exercise training program|exercise training combined with the consumption of caloric restricted high CHO-low FAT diet. The interventions will last for four weeks.
62570115|NCT06022315|EXPERIMENTAL|restricted High fat low carbohydrate diet with exercise training program|exercise training with consumption of caloric restricted low CHO-high FAT diet. The interventions will last for four weeks.
62776924|NCT05040360|EXPERIMENTAL|Arm I (capecitabine, temozolomide)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO once QD on days 10-14. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62776925|NCT05040360|NO_INTERVENTION|Arm II (surveillance)|Patients undergo surveillance with no active treatment.
62186566|NCT04827589|EXPERIMENTAL|Tirabrutinib|Participant will receive tirabrutinib twice daily in addition to their standard-of-care therapy for up to 8 weeks.
62186567|NCT04827589|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo twice daily in addition to their standard-of-care therapy for up to 8 weeks.
62186568|NCT04827589|EXPERIMENTAL|Tirabrutinib, Open Label Extension|At Week 8, participants who have not discontinued the study drug will receive tirabrutinib twice daily in addition to their standard-of-care therapy for up to 16 weeks.
62186569|NCT03693209|EXPERIMENTAL|General trigger|"VHS with one general trigger: If I am getting angry... and 10 strategies (e.g. Then I will take deep breaths). Participants are instructed to link trigger with strategies."
62186570|NCT03693209|EXPERIMENTAL|Specific triggers|"VHS with a list of 10 specific situations that can act as anger triggers (e.g. If I am getting angry when people act like they know it all) and 10 strategies. Participants are instructed to link triggers with strategies."
62186571|NCT03693209|NO_INTERVENTION|Control|List of 10 specific situations that can act as anger triggers and 10 strategies. Participants are instructed to select most encountered triggers and most useful strategies.
62186572|NCT00992719|ACTIVE_COMPARATOR|Group 3: Non-pregnant Women: 15 mcg H1N1 Vaccine|100 non-pregnant women to receive 15 mcg inactivated H1N1 vaccine.
62186573|NCT00992719|EXPERIMENTAL|Group 2: Pregnant Women: 30 mcg H1N1 Vaccine|100 pregnant women to receive 30 mcg inactivated H1N1 vaccine.
62186574|NCT00992719|EXPERIMENTAL|Group 1: Pregnant Women: 15 mcg H1N1 Vaccine|100 pregnant women to receive 15 mcg inactivated H1N1 vaccine.
62186575|NCT06145425|EXPERIMENTAL|Single arm|Participants will be asked to utilize the app.
62570116|NCT01314872|PLACEBO_COMPARATOR|Part 1: placebo|Participants received two placebo matching vibegron tablets and one placebo matching tolterodine extended release (ER) capsule, taken orally each morning, for 8 weeks.
62570117|NCT01314872|EXPERIMENTAL|Part 1: vibegron 3 mg|Participants received one vibegron 3 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
62776926|NCT06358144|EXPERIMENTAL|Flavor Imagery|Four edible product packages (gummies, chocolate, mints, cookies) with package imagery in a flavor theme.
62776927|NCT06358144|EXPERIMENTAL|Animal Imagery|Four edible product packages (gummies, chocolate, mints, cookies) with package imagery in an animal theme.
62776928|NCT06358144|EXPERIMENTAL|Nature Imagery|Four edible product packages (gummies, chocolate, mints, cookies) with package imagery in a nature theme.
62776929|NCT06358144|EXPERIMENTAL|Medical Imagery|Four edible product packages (gummies, chocolate, mints, cookies) with package imagery in a medical theme.
62776930|NCT06358144|EXPERIMENTAL|No Imagery (Control)|Four edible product packages (gummies, chocolate, mints, cookies) without any added packaging imagery.
62776931|NCT00852241|EXPERIMENTAL|Restalyne and Perlane|One syringe of Perlane® (1.0cc) and one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
62001349|NCT02784301|ACTIVE_COMPARATOR|Belly breathing without biofeedback app|
62001350|NCT02784301|ACTIVE_COMPARATOR|Belly breathing + visual distraction|
62186576|NCT04312542||SRP with minocycline HCl microspheres|Participants in this cohort received the intervention of minocycline HCl microspheres, 1 mg in the interventional phase of the trial.
62186577|NCT04312542||SRP without minocycline HCl microspheres|Participants in this cohort did not have minocycline HCl microspheres, 1 mg administered during the interventional phase of the trial.
62186578|NCT00646464||2|Children 6-12 years old diagnosed as not suffering from ADHD
62186579|NCT00646464||1|children 6-12 diagnosed as ADHD
62186580|NCT01551810|EXPERIMENTAL|Influenza Virus Vaccine|Influenza Virus Vaccine（no Preservative ) 0.5ml intramuscular injections
62186581|NCT01551810|EXPERIMENTAL|Influenza Virus Vaccine(Preservative)|Influenza Virus Vaccine（add Preservative ) 0.5ml intramuscular injections
62570118|NCT01314872|EXPERIMENTAL|Part 1: vibegron 15 mg|Participants received one vibegron 15 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
62570119|NCT01314872|EXPERIMENTAL|Part 1: vibegron 50 mg|Participants received one vibegron 50 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
62570120|NCT01314872|EXPERIMENTAL|Part 1: vibegron 100 mg|Participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
62776932|NCT05367323||Group A|22 women who underwent cesarean delivery using spinal anesthesia
62776933|NCT05367323||Group B|22 women who were in the control group (they never experience pregnancy, or anaesthesia)
62776934|NCT06234787||ICU Patients|Patients admitted to the Intensive Care Unit (ICU) at HLA Moncloa Hospital
62001351|NCT04908254|EXPERIMENTAL|Dayspring Active Wearable Compression Device|The Dayspring Active Wearable Compression Device is an FDA cleared calibrated active gradient pressure full-arm compression garment that is segmental and programmable and applies controlled sequential pressure from the distal to proximal-end of the limb in a cyclic manner.
62570121|NCT01314872|ACTIVE_COMPARATOR|Part 1: tolterodine ER 4 mg|Participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 8 weeks.
62570122|NCT01314872|EXPERIMENTAL|Part 1: vibegron 50 mg + tolterodine ER 4 mg/vibegron 50 mg|Participants received one vibegron 50 mg tablet and one placebo matching vibegron tablet, taken orally each morning, for 8 weeks. They also received one tolterodine ER 4 mg capsule for the first 4 weeks and one placebo matching tolterodine ER capsule for the second 4 weeks, both taken orally each morning.
62570123|NCT01314872|PLACEBO_COMPARATOR|Part 2: placebo|Participants received two placebo matching vibegron tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 4 weeks.
62186582|NCT03801681||myocarditis|patients with clinically suspected myocarditis
62570124|NCT01314872|EXPERIMENTAL|Part 2: vibegron 100 mg|Participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 4 weeks.
62570125|NCT01314872|ACTIVE_COMPARATOR|Part 2: tolterodine ER 4 mg|Participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 4 weeks.
62570126|NCT01314872|EXPERIMENTAL|Part 2: vibegron 100 mg + tolterodine ER 4 mg|Participants received two vibegron 50 mg tablets and one tolterodine ER 4 mg capsule, taken orally each morning, for 4 weeks.
62584856|NCT03821714|EXPERIMENTAL|Glucocorticoid combination therapy Group|Hydrocortisone 200mg continuous intravenous infusion(24h) combined with vitamin C1.5g intravenous infusion every 6 hours and vitamin B1 200mg intravenous infusion every 12 hours.
62584857|NCT03821714|ACTIVE_COMPARATOR|Glucocorticoid Group|Hydrocortisone 200mg continuous intravenous infusion(24h)
62584858|NCT06214936|OTHER|Oocytes allocated to the benchtop incubator|Half of the mature oocytes and subsequent embryos will be cultured in the benchtop incubator
62776935|NCT00517569|EXPERIMENTAL|1|GX-12 combined with HAART
62776936|NCT05522595|EXPERIMENTAL|Standard of care arm|The patient is his own comparator. During the intervention, the eyes movements measurements will be performed using the standard of care and the medical device S360.
62776937|NCT02524418|OTHER|Cholangiopancreatoscopy|A standard of care Endoscopic Retrograde Cholangiopancreatoscopy (ERCP) will be performed using the Spyglass DS. The clinical outcomes will be collected and analyzed.
62776938|NCT01232348||Symbicort|Those with an exposure
62186583|NCT01838486|EXPERIMENTAL|Bladder Thermal Distention (BTD)|Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using the PelvixTT system
62186584|NCT02670122||Patients with non resectable HCC|DEB-TACE with doxorubicin eluting 100 µ microspheres
62570127|NCT01314872|EXPERIMENTAL|Extension Study: vibegron 50 mg|Participants in Base Study/Part 1 who received vibegron 50 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received vibegron 3 mg received vibegron 50 mg in the Extension Study. Also, participants in Base Study/Part 1 who received vibegron 50 mg + tolterodine ER for 4 weeks, followed by vibegron 50 mg alone for 4 weeks, remained on vibegron 50 mg in the Extension Study. In the extension, participants received one vibegron 50 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 52 weeks.
62570128|NCT01314872|EXPERIMENTAL|Extension Study: vibegron 100 mg|Participants in Base Study/Part 1 or Part 2 who received vibegron 100 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received vibegron 15 mg received vibegron 100 mg in the Extension Study. In the extension, participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 52 weeks.
62570129|NCT01314872|EXPERIMENTAL|Extension Study: tolterodine ER 4 mg|Participants in Base Study/Part 1 or Part 2 who received tolterodine ER 4 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received placebo also received tolterodine ER 4 mg in the Extension Study. In the extension, participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 52 weeks.
62570130|NCT01314872|EXPERIMENTAL|Extension Study: vibegron 100 mg + tolterodine ER 4 mg|Participants in Base Study/Part 1 who received vibegron 100 mg + tolterodine ER 4 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 2 who received placebo were assigned to the vibegron 100 mg + tolterodine ER 4 mg arm in the Extension Study. In the extension, participants received two vibegron 50 mg tablets and one tolterodine ER 4 mg capsule, taken orally each morning, for 52 weeks.
62570131|NCT00630825|EXPERIMENTAL|1.0/2.0 milligram (mg) LY2189265|LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks
62570132|NCT00630825|EXPERIMENTAL|1.0/1.0 milligram (mg) LY2189265|LY2189265: 1.0 mg, subcutaneous (SC) injection, once weekly (QW) for 16 weeks
62570133|NCT00630825|EXPERIMENTAL|0.5/1.0 milligram (mg) LY2189265|LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks
62776939|NCT04266756|EXPERIMENTAL|Cohort 1: Selexipag Matrix Tablets|Participants will receive oral doses of selexipag matrix tablets based on release profiles (IR=immediate release, F=fast release, M=medium release and S=slow release) in treatment sequence 1 (IR+F+M+S), treatment sequence 2 (F+S+IR+M), treatment sequence 3 (M+ IR+ S+F) and treatment sequence 4 (S+M+F+IR) in periods 1, 2, 3, and 4, respectively under fasted condition. A washout period of at least 7 days will be maintained between each treatment period.
62001352|NCT04908254|ACTIVE_COMPARATOR|Advanced Pneumatic Compression Device|A commercially available advanced pneumatic compression device that is FDA-cleared for the same indication for use as the Dayspring Wearable Compression Device.
62186585|NCT01976221||Prioritization|Team-based multifaceted interactive training
62186586|NCT01547117|EXPERIMENTAL|High Sodium Level|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The high sodium diet will provide 300 milliequivalents (mEq) sodium/day.
62186587|NCT01547117|EXPERIMENTAL|Low Sodium Dietary Level|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The low sodium diet will provide 10 mEq sodium/day.
62001353|NCT03981224||plasma EBV DNA detectable|the NPC patient received curative treatment and post-treatment plasma EBV DNA was detectable.
62186588|NCT00559377|EXPERIMENTAL|Diagnostic FMISO AND FDG PET|Patients receive \^18F FMISO IV over 1 minute followed by PET scanning. Patients undergo a second \^18F FMISO PET scan 4-8 weeks later. Patients who have not had a prior \^18F FDG PET scan as part of their routine clinical management undergo \^18F FDG PET scanning at baseline.
62001354|NCT03981224||plasma EBV DNA undetectable|the NPC patient received curative treatment and post-treatment plasma EBV DNA was undetectable.
62001355|NCT03535220||Observational/ Interventional|Hematologic Disease
62001356|NCT00964392|EXPERIMENTAL|More-Experienced Physicians (MEP)|Physicians who perform greater than or equal to 50 atrial fibrillation ablation procedures per year.
62001357|NCT00964392|EXPERIMENTAL|Less-Experienced Physicians (LEP)|Physicians who perform less than 50 atrial fibrillation ablation procedures per year.
62001358|NCT03066765|EXPERIMENTAL|LTR Treatment|An implant device (Linguaflex Tongue Retractor) will be placed in the tongue and assessed for safety and efficacy
62186589|NCT04640818||CLAD-GROUP|Patients with cladribine therapy
62186590|NCT04640818||CD20-GROUP|Patients with anti CD20 therapy (ocrelizumab or rituximab)
62186591|NCT02754336|ACTIVE_COMPARATOR|Cogmed Robomemo, working memory training|Robomemo working memory training, 25 sessions with 8 verbal and non-verbal tasks per session.
62186592|NCT02754336|ACTIVE_COMPARATOR|Othmer, neurofeedback|Othmer method neurofeedback, 25 sessions a 30 minutes.
62186593|NCT04410809|PLACEBO_COMPARATOR|Placebo|The same composition as the active medication but without the active substance TA-46
62186594|NCT04410809|EXPERIMENTAL|TA-46|Decoy protein of the fibroblast growth factor receptor 3
62186595|NCT05569863||Hypospadias group|Patients with hypospadias diagnosis
62186596|NCT05569863||Control group|Patients without hypospadias
62570134|NCT00630825|PLACEBO_COMPARATOR|Placebo|Placebo: subcutaneous (SC) injection, once weekly (QW) for 16 weeks
62570135|NCT00661128||1|European American people who have experienced SCA.
62570136|NCT00661128||2|European American people who have not experienced SCA.
62570137|NCT00661128||3|African American people who have experienced SCA.
62570138|NCT00661128||4|African American people who have not experienced SCA.
62570139|NCT03777267|EXPERIMENTAL|Experimental: Active CR|For this single arm, open label, exploratory trial this will be the intervention arm using active CR.
62570140|NCT02368223|EXPERIMENTAL|YouGrabber training|Home-based YouGrabber training
62570141|NCT00726856||Patients|patients with dyslipidemia
62570142|NCT04090060|EXPERIMENTAL|Practice Self-/Companion Exams|300 individuals and 50 couples will be randomized to practice arm.
62186597|NCT06241729||Patients with diffuse large-cell B lymphoma|Patients with diffuse large-cell B lymphoma in a single-centre cohort at Grand Hôpital de Charleroi
62001359|NCT03781076|EXPERIMENTAL|Sleep Intervention|1-hour brief behavioral intervention to improve sleep consolidation and nocturnal sleep duration.
62186598|NCT01178307||Part 1|Patient interview and developmental questionnaires
62186599|NCT01178307||Part 2|Content Expert Panel (doctors, nurses) + Patients and Caregivers Questionnaire Development
62395027|NCT00241891|OTHER|Healthy Lifestyle (Active Intervention)|Parents and children in this program which will participate in a series of consultations and activities focused on multiple healthy interventions including healthy eating, drinking, and physical activity. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on healthy eating, drinking, and physical activity. In addition, your child will receive information on developing healthy interpersonal and social skills.
62395028|NCT00241891|OTHER|Healthy Drinks (Active Intervention)|Parents and children in this program will participate in a series of consultations and activities focused on a single intervention, the effects of beverage choices on diet, general health and teeth health. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on beverages and health. In addition, your child will receive information on healthy nutrition, physical activity, and interpersonal and social skills.
62570143|NCT04090060|OTHER|Control Arm|300 individuals and 50 couples will neither be encouraged nor discouraged to practice self-/companion exam.
62570144|NCT05930054|OTHER|tooth-bone-borne (TBB) group|The TBB appliance was composed of a central expansion jackscrew (Dentarum), 4 tubes, 2 bands on the upper first molars to facilitate placement of the appliance, and 1.5-mm diameter stainless steel arms extending to the premolar teeth. Soldered stainless steel tubes (internal diameter: 2.0 mm; external diameter: 3.0 mm; length: 2.0 mm) served as guides for miniscrew placement. The size of the screws (PSM) was chosen as 1.8 mm in diameter and 11 mm in length, considering the 2 mm height of the tubes, 1 to 2 mm gap between the appliance and the palate surface, 1 to 2 mm gingiva thickness, and 5 to 6 mm length required for the bicortical placement of the screw in the bone.
62186600|NCT01178307||Part 3|Patient MDASI-GIST Questionnaire
62001360|NCT03781076|NO_INTERVENTION|Control|"In this care as usual arm, no specific behavioral sleep intervention is provided."
62001361|NCT05136729|EXPERIMENTAL|Face-to-face Self-Natural Posture Exercise training|Off-line training
62001362|NCT05136729|ACTIVE_COMPARATOR|Online Self-Natural Posture Exercise training|"Virtual training~This group as a wait-list control group will receive online SNPE intervention after serving as an untreated comparison group."
62570145|NCT05930054|OTHER|bone-borne (BB) group|The BB appliance was composed of a central expansion jackscrew, 4 tubes as described in TBB group, and less acrylic used around it to adjust its position. In order to carry it to the mouth after preparation on the cast model, essix was used, which also included the patient's teeth
62001363|NCT01176552|EXPERIMENTAL|Study group: GM-CSF, IFN, IL-2|
62186601|NCT00751634|EXPERIMENTAL|A|Application of the Gaymar Rapr-Round device per approved use
62186602|NCT03946098|EXPERIMENTAL|iCBT for Gambling Disorder|Treatment will consist of a 1+10 module internet delivered CBT program targeting problem gambling, newly developed. A bottom-up procedure was used to develop the treatment protocol, inspired by Clark's (2004) method for developing novel CBT treatments. We developed a clinical model delineating what factors contribute to the persistence of problem gambling behavior, and aligned these with targeted treatment interventions; based on behavioral upon research on the learning and maintenance processes of gambling behavior (Ramnerö et al, in press), theoretical models of gambling and comorbidity (Blaszczynski \& Nower, 2002); as well as qualitative interviews with treatment seeking gamblers with or without comorbidity.
62186603|NCT05421156||Subtotal Laparoscopic Hysterectomy|Women who underwent subtotal laparoscopic hysterectomy
62186604|NCT05421156||Total Laparoscopic Hysterectomy|Women who underwent total laparoscopic hysterectomy
62570146|NCT00866281|EXPERIMENTAL|30 mg/m^2 bid|Participants received bodyweight and body surface area (BSA) stratified dose of midostaurin 30 mg/m\^2 twice daily (bid) through oral route. The total daily dose in 30 mg/m\^2 bid cohort was 60 mg/m\^2.
62570147|NCT00866281|EXPERIMENTAL|60 mg/m^2 bid|Participants received bodyweight and BSA stratified dose of midostaurin 60 mg/m\^2 bid through oral route. The total daily dose in 60 mg/m\^2 bid cohort was 120 mg/m\^2.
62570148|NCT01396135|EXPERIMENTAL|Single dosing|Single doses of CP-601,927 (1, 2 or 3 mg) or placebo
62570149|NCT01396135|EXPERIMENTAL|Multiple dosing|Multiple doses of CP-601,927 (2 mg BID, 4mg/day) or placebo
62570150|NCT06475911||Perioperative Hyponatremia|Perioperative Hyponatremia \<135 mEq/L
62570151|NCT06475911||No Perioperative Hyponatremia|No Perioperative Hyponatremia, i.e s.sodium \>135 mEq/L
62570152|NCT06314438|EXPERIMENTAL|Family Care Project workbook|Caregivers will be administered the Family Care Project workbook.
62570153|NCT05975619|EXPERIMENTAL|HyperSight Imaging arm|Subjects are imaged with the new HyperSight CBCT imaging system.
62584859|NCT06214936|OTHER|Oocytes allocated to the box incubator|Half of the mature oocytes and subsequent embryos will be cultured in the box incubator
62776940|NCT04266756|EXPERIMENTAL|Cohort 2: Selexipag Encapsulated Pellets|Participants will receive oral doses of selexipag encapsulated) pellets based on release profiles (IR=immediate release, F=fast release, M=medium release and S=slow release) in treatment sequence 1 (IR+F+M+S), treatment sequence 2 (F+S+IR+M), treatment sequence 3 (M+ IR+ S+F) and treatment sequence 4 (S+M+F+IR) in periods 1, 2, 3, and 4, respectively under fasted condition. A washout period of at least 7 days will be maintained between each treatment period.
62776941|NCT01204762|EXPERIMENTAL|Part A Arm 1: pegIFN (180 μg)|
62186605|NCT00144846|OTHER|Arm 1|
62186606|NCT05035797|ACTIVE_COMPARATOR|CaRe-ECMO group|Patients in the CaRe-ECMO group will be treated with usual care, ECMO therapy, and cardiopulmonary rehabilitation program.
62186607|NCT05035797|PLACEBO_COMPARATOR|Control group|Usual care and ECMO therapy
62395029|NCT00241891|OTHER|Social and Leadership Skills (Control Intervention)|Parents and children in this program will participate in a series of consultations that are designed to help your child learn strategies to make and keep friends, to express feelings appropriately, and to successfully decrease conflicts that often occur at school among children. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on these friendship making strategies. In addition, your child will receive information on healthy nutrition and physical activity. There is o intervention with regards to healthy weight.
62395030|NCT00514059|OTHER|1|
62395031|NCT06086613|EXPERIMENTAL|AGA2115|"In Part A, up to 6 single ascending dose cohorts.~In Part B, up to 3 multiple ascending dose cohorts."
62395032|NCT06086613|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo.
62395033|NCT00586027||NT-proBNP|150 consecutive patients undergoing cardiac surgery with an intraoperative measured cardiac output \<2L/min/m².
62395034|NCT02832986||Patients in frailty consultation|Patients consulting in frailty consultation, at this occasion they will complete a medical questionary for the collection of study data
62395035|NCT05997134|EXPERIMENTAL|Group A|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h) at post anesthetic care unit(PACU) over 6 hours for 3days
62395036|NCT05997134|EXPERIMENTAL|Group B|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 5 days .
62395037|NCT05997134|EXPERIMENTAL|Group C|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 7 days
62395038|NCT00807768|ACTIVE_COMPARATOR|Arm I (pelvic radiation therapy)|Patients undergo conventional or intensity-modulated pelvic radiation therapy once daily, 5 days a week, for 5-6 weeks (total of 25-28 fractions) in the absence of disease progression or unacceptable toxicity. Patients with stage II disease or stage I disease with a confirmed diagnosis of clear cell and/or papillary serous histology may also undergo 1 or 2 intravaginal (i.e., vaginal cuff) brachytherapy boost treatments.
62395039|NCT00807768|EXPERIMENTAL|Arm II (brachytherapy, paclitaxel, carboplatin)|Patients undergo vaginal cuff brachytherapy comprising 3-5 high-dose rate brachytherapy treatments over approximately 2 weeks or 1 or 2 low-dose rate brachytherapy treatments over 1-2 days. Beginning within 3 weeks after initiating brachytherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Chemotherapy repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62395040|NCT04366869|ACTIVE_COMPARATOR|control|traditional approach of removing denture at night
62395041|NCT04366869|EXPERIMENTAL|intervention 1|occlusal splint
62776942|NCT01204762|ACTIVE_COMPARATOR|Part A Arm 2: pegIFNα-2a|
62186608|NCT01114763||Metabolic syndrome|40 men with metabolic syndrome
62395042|NCT04366869|EXPERIMENTAL|intervention 2|Botox
62395043|NCT04856072|EXPERIMENTAL|Treatment|All patients will be implanted with a deep brain stimulation system and will receive personalized fornix stimulation; parameters will be selected based on the dose finding cognitive tests.
62395044|NCT04695535||Chemotherapy with Anlotinib|Patients received chemotherapy with Anlotinib.
62570154|NCT06010017|EXPERIMENTAL|STEPP|"Participants will be randomized in 1:1 fashion, stratified by transplant type (autologous vs. allogeneic), and will complete study procedures as follows:~* Baseline self-reported assessment (in-person or remotely).~* Virtual, STEPP intervention sessions 1x weekly for five weeks with peer mentor.~* HSCT and hospitalization per standard of care.~* Day +30 (+/- 10 days) and Day +60 (+/- 10 days) self-reported assessments.~* Optional exit interview with study staff (40 participants)."
62186609|NCT01114763||Control|40 physically active men
62186610|NCT03121209|ACTIVE_COMPARATOR|Revascularization Arm (CEA or CAS)|These patients will have been randomized (via the parent trial, CREST-2) to receive intensive medical management as well as either Carotid Endarterectomy (CEA--if they are in the parent study Surgical trial) or Carotid Artery Stenting (CAS--if they are in the parent study Stenting trial).
62186611|NCT03121209|ACTIVE_COMPARATOR|Intensive Medical Management (IMM) Arm|These patients will have been randomized (via the parent trial, CREST-2) to receive medical management only, which includes aspirin. high dose cholesterol lowering agent to a target LDL\<70, intensive blood pressure management to target \<130/80, smoking cessation, and diabetic control.
62186612|NCT00528671|ACTIVE_COMPARATOR|A|Low dose oral anticoagulation, INR self-management once a week
62395045|NCT02531282|EXPERIMENTAL|Health promotion in patient education|The self-management patient education has been developed at the Healthy Life Centre in Trondheim municipality based on cognitive behavioural theory and psychomotor physiotherapy. The intervention is developed in a health promotion framework focusing on salutogenesis aiming to improve the participants ability to activate their own resources for health behaviour changes .
62395046|NCT02531282|ACTIVE_COMPARATOR|Physical activity in groups|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. .
62395047|NCT04495400||Percutaneous Screw Fixation|Patients who have had a Percutaneous Screw fixation procedure.
62395048|NCT04495400||Open Fixation|Patients who have had an Open Fixation procedure.
62776943|NCT01204762|EXPERIMENTAL|Part B: pegIFN lambda + Entecavir|
62776944|NCT01915979|EXPERIMENTAL|Plasma rich in growth factors (PRGF)|This group will receive a total of three intraarticular injections of 6-8 ml. One injection every two weeks.
62570155|NCT06010017|NO_INTERVENTION|Usual Care|"Participants will be randomized in 1:1 fashion, stratified by transplant type (autologous vs. allogeneic), and will complete study procedures as follows:~* Baseline self-reported assessment.~* HSCT and hospitalization per standard of care.~* Day +30 (+/- 10 days) and Day +60 (+/- 10 days) self-reported assessments."
62570156|NCT04620837|EXPERIMENTAL|Treatment Arm|Tislelizumab：200mg Q3W IV Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated.
62570157|NCT02362360|EXPERIMENTAL|Coloplast Test Product then Comparator|The subject first tests the Coloplast Test Product and then tests the Comparator
62570158|NCT02362360|EXPERIMENTAL|Comparator then Coloplast Test Product|The subject first tests the Comparator and then tests the Coloplast Test Product.
62570159|NCT03498430|EXPERIMENTAL|Copanlisib (Aliqopa, BAY80-6946)|Planned at least 12 patients who meet the entry criteria will receive 60 mg copanlisib as single agent, with dosing on Days 1, 8 and 15 of each 28-day treatment cycle
62570160|NCT01087125||Pregnant RA patients with abatacept exposure during pregnancy|
62570161|NCT00618644|EXPERIMENTAL|1|Ranibizumab injection
62570162|NCT04553939|EXPERIMENTAL|Toripalimab in Combination With Gemcitabine Therapy|
62570163|NCT02386319|ACTIVE_COMPARATOR|Melatonin|"Melatonin 10 mg, gelatin capsules. Pharmacokinetic study: 10 mg x 2. In the morning before surgery and in the evening after surgery.~Anxiolytic and analgesic study: 10 mg x 4. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery."
62776945|NCT01915979|ACTIVE_COMPARATOR|Celestone cronodose (bethametasone)|This group will receive a total of three intraarticular injections of 2ml. One injection every two weeks.
62186613|NCT00528671|ACTIVE_COMPARATOR|B|very low dose oral anticoagulation, INR self-management once a week
62186614|NCT00528671|EXPERIMENTAL|C|very low dose oral anticoagulation, INR self-management twice a week
62186615|NCT03371745|ACTIVE_COMPARATOR|PGS-FET|The PGS-FET arm involves deferred transfer of embryos following cryopreservation at the blastocyst stage following pre-implantation genetic screening. This arm will culture embryos to day 5/6/7 (blastocyst stage). The embryos will be cryopreserved following trophectoderm biopsy. A subsequent frozen embryo transfer cycle will be performed during which 1 euploid (chromosomally normal) embryo will be thawed and transferred.
62186616|NCT03371745|ACTIVE_COMPARATOR|FET|"The Freeze only arm involves the deferred transfer of embryos following cryopreservation. In this arm embryos will be cryopreserved. A subsequent frozen embryo transfer cycle will be performed during which one or more embryos will be thawed and transfered based on local clinical site, age-specific embryo number transfer guidelines."
62186617|NCT03371745|ACTIVE_COMPARATOR|Fresh|The Fresh arm will have an immediate embryo(s) transfer based on local clinical site, age-specific embryo number transfer guidelines within the stimulation cycle.
62186618|NCT03419676|NO_INTERVENTION|Control|No reinforcement.
62186619|NCT03419676|EXPERIMENTAL|Hemopatch|Reinforcement with Hemopatch.
62395049|NCT05804539|EXPERIMENTAL|Manual therapy|Each lesson has a duration of 40 minutes, including the first five minutes of warm-up, 30 minutes of manual therapy and the last five minutes of cool-down.
62395050|NCT05804539|EXPERIMENTAL|Tai Chi|Each lesson has a duration of 40 minutes, including the first five minutes of warm-up, 30 minutes of Tai Chi and the last five minutes of cool-down.
62395051|NCT05804539|EXPERIMENTAL|Tai Chi and Manual therapy|Each lesson has a duration of 40 minutes, including the first five minutes of warm-up, 15-min Tai Chi exercise and 15-min manual therapy, with the order of intervention being Tai Chi exercise first and then manual therapy, and the last five minutes of cool-down.
62570164|NCT02386319|PLACEBO_COMPARATOR|Placebo|Gelatin capsules. Anxiolytic and analgesic study. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.
62570165|NCT02957253|EXPERIMENTAL|Intervention (CI)|Compensated intervention (CI). Nurse-led clinic one time per year. Focus on Life style and risk factors.
62570166|NCT02957253|NO_INTERVENTION|Control (CC)|Compensated Control (CC)
62570167|NCT02957253|EXPERIMENTAL|Intervention (DI)|Decompensated intervention (DI). Nurse-led clinic two times every month to every third month. Focus on Lifestyle, risk factors, nutrition, selfcare and psychosocial needs
62570168|NCT02957253|NO_INTERVENTION|Control (DC)|Decompensated Control (DC)
62570169|NCT01498796|EXPERIMENTAL|Ketorolac|
62570170|NCT01498796|PLACEBO_COMPARATOR|Placebo|
62570171|NCT06274190|NO_INTERVENTION|Pre-Delphi patient focus group|"During this focus group, we aim to achieve various goals:~* To gain insight into the bowel symptoms and the consequences patients experienced after treating rectal cancer~* To understand the expectations of the patients regarding an electronic bowel diary~* To determine whether the questions/items derived from the literature study for the bowel diary are clear and understandable for the patients~* To explore other relevant questions/items that should be added to the bowel diary~We will include 8-12 patients in this focus group."
62584860|NCT03945747||Control group|Individuals continue current treatment regimen with either standard insulin pump therapy or multiple daily insulin injections for the duration of the study.
62776946|NCT05496556|OTHER|All patients included in the study|Patient with stage IV non-small cell bronchopulmonary carcinoma receiving first-line treatment and received LFQP questionnaire
62584861|NCT03945747||Hybrid closed-loop artificial pancreas system group|Individuals transition from either standard insulin pump therapy or multiple daily injections to a hybrid closed-loop system at the beginning of the study after initial labs and imaging studies are completed.
62584862|NCT03945747||Predictive low glucose suspend system group|Individuals transition from either standard insulin pump therapy or multiple daily injections to a predictive low glucose suspend system at the beginning of the study after initial labs and imaging studies are completed.
62776947|NCT01263145|EXPERIMENTAL|Treatment (Akt inhibitor MK2206 and paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and Akt inhibitor MK2206 PO QD on days 2, 9, and 16. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62776948|NCT00908037|EXPERIMENTAL|eltrombopag plus standard of care|eltrombopag
62776949|NCT00908037|PLACEBO_COMPARATOR|placebo plus standard of care|placebo
62186620|NCT03330964|EXPERIMENTAL|electroacupuncture group|The experimental group adopted chemotherapy combined with electro-acupuncture stimulated related acupoints for 3 days running.
62186621|NCT03330964|NO_INTERVENTION|control group|The control group received chemotherapy only(same as the experimental group),but no electroacupuncture treatment.
62001364|NCT00610493|EXPERIMENTAL|Bevacizumab + Temsirolimus|Bevacizumab 5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle. Temsirolimus 5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle. First tumor biopsy during screening visit and Second at the end of Cycle 1. DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1.
62186622|NCT01010087|ACTIVE_COMPARATOR|Standard Oseltamivir dose 75 mg bid|Standard dosing
62570172|NCT06274190|NO_INTERVENTION|Delphi survey|"In this Delphi survey, a multidisciplinary group of experts and patients will score each item of the long list on a 1-9-point Likert scale from 'Not relevant' (1) to 'Essential' (9) for inclusion in the bowel diary. Finally, a patient consultation meeting and a consensus meeting will be held for the participants who completed the Delphi survey.~We will recruit 10-18 Delphi panelists per area of expertise. These panelists are experts with international expert recognition in treating bowel symptoms in the following health care categories (abdominal surgeons, digestive/radiation oncologists, specialized pelvic floor muscle physiotherapists, nursing specialists). In addition, we will include one group comprising 10-18 patients in the Delphi survey, ensuring a comprehensive and holistic perspective on treating bowel symptoms across various healthcare categories."
62570173|NCT06274190|NO_INTERVENTION|Post-Delphi patient focus group|"During this focus group, our objective is to ensure that both the questions and answers are meaningful.~We will include 8-12 patients in this focus group."
62570174|NCT06274190|EXPERIMENTAL|Usability of e-diary|"The participants will be asked to use the newly developed electronic bowel diary for 7 consecutive days.~To evaluate the usability of the e-diary, a group of 10 patients will participate in the assessment using the System Usability Scale (SUS).~Furthermore we will have conversations with these patients regarding the use of the application: complexity, need for additional support, coherence of the application, user-friendliness, and the need for prior knowledge."
62570175|NCT06274190|EXPERIMENTAL|Psychometric properties of e-diary|To evaluate the validity of the e-diary, encompassing test-retest reliability, construct validity and responsiveness, participants will be instructed to use the e-diary for two separate 7-day periods.
62570176|NCT06295965||Observational|Patients undergo blood sample collection and complete surveys on study. Patients' medical records are also reviewed.
62186623|NCT01010087|EXPERIMENTAL|High Dose Oseltamivir arm 225mg bid|High dose arm of the study
62186624|NCT05252728||Healthy control|
62186625|NCT05252728||Childhood-onset type 1 diabetes|
62395052|NCT02488564|EXPERIMENTAL|Liposomal doxorubicin +Docetaxel+Trastuzumab+Metformin|"Day 1: Liposome-encapsulated doxorubicin, 50 mg/m2 IV 1 hour infusion; Day 2 and 9: Docetaxel, 30 mg/m2 IV 1 hour infusion; Day 2, 9 and 16: Trastuzumab 4 mg/kg for the first infusion loading dose, then 2 mg/kg/week for subsequent injections.~Day -13 to 0: Metformin is administered as single agent. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10 Metformin 1000 mg will be administered twice a day continuously until end of the study treatment."
62570177|NCT00700219||1|Women presenting in preterm labor with intact amniotic membranes
62570178|NCT01354652|EXPERIMENTAL|entecavir|"Oral 0.5mg/day until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18.~Participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
62570179|NCT01354652|ACTIVE_COMPARATOR|lamivudine|"Oral 100mg/day lamivudine until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18.~Participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
62570180|NCT01354652|NO_INTERVENTION|no NRTI group|hepatitis C virus associated LC patients for the calculation of lactic acidosis incidence
62791705|NCT05516719||Healthy Control|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD patholog
62395053|NCT03210909|EXPERIMENTAL|BMS-986231 Intravenous Infusion|A single continuous intravenous infusion of BMS-986231
62395054|NCT01856920|EXPERIMENTAL|A|GI-6207 for 1 year
62395055|NCT01856920|EXPERIMENTAL|B|6 months of surveillance followed by GI-6207 for 1 year
62001365|NCT06030414|EXPERIMENTAL|Sentinel Cohort|
62186626|NCT05252728||Adult-onset type 1 diabetes|
62186627|NCT05252728||Type 2 diabetes|
62186628|NCT04286763||Hilar stricture|Bile duct Stricture (corresponding to E3, E4 and E5 from of Strasberg. -According to the classification proposed by Strasberg of operative bile duct injuries).
62570181|NCT01912092|EXPERIMENTAL|Askina Calgitrol Paste|
62584863|NCT01957436|ACTIVE_COMPARATOR|Arm A|androgen deprivation therapy + docetaxel
62791706|NCT04853719|EXPERIMENTAL|Vascular dose|Rivaroxaban 2.5 mg BID and aspirin 100 mg OD for 6 months
62186629|NCT04286763||Low level Stricture|Bile duct Stricture (corresponding to E1 and E2 from Strasberg. -According to the classification proposed by Strasberg of operative bile duct injuries).
62186630|NCT04099485|NO_INTERVENTION|Current State|Clinicians of patients randomized to this arm will have access to the Atrial Fibrillation Decision-Support Tool (AFDST) embedded in our EHR (as they do now), but will not receive BPAs alerting them to patients who might benefit significantly from a change in anticoagulation treatment.
62186631|NCT04099485|EXPERIMENTAL|AFDST with BPA|Clinicians of patients randomized to this arm will receive BPAs when they are in the medical record of an AF patient who might gain significantly from a change in anticoagulation treatment. In addition, clinicians will have the ability to refer patients to a pharmacist-staffed AF Thromboprophylaxis Shared Decision-Making Service based in our Anticoagulation Clinic.
62186632|NCT03888222|PLACEBO_COMPARATOR|Placebo|"Thirty (30) participants will be recruited and randomized into 2 groups (arms) (1:1) .Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) capsule orally once daily for 3 months (90 days)."
62570182|NCT05455203|EXPERIMENTAL|ADAPT-ITT guided implementation and adaptation|ADAPT-ITT is an implementation science framework that guides the adaptation of evidence-based interventions (EBI) for specific settings or populations. ADAPT-ITT will be used to adapt the target interventions in partnership with a Family and Community Advisory Board, consisting of parents, caregivers, and leaders of family-based organizations in New Jersey.
62570183|NCT01916096||Delica 28g Depth 3 vs Delica 30g Depth 3|30 subjects with diabetes
62570184|NCT01916096||Delica 28g Depth 5 vs Delica 30g Depth 5|30 subjects with diabetes
62570185|NCT01916096||Delica 28g Depth 7 vs Delica 30g Depth 7|30 subjects with diabetes
62570186|NCT01916096||Delica 28g Depth 3 vs Delica 33g Depth 3|30 subjects with diabetes
62570187|NCT01916096||Delica 28g Depth 5 vs Delica 33g Depth 5|30 subjects with diabetes
62570188|NCT01916096||Delica 28g Depth 7 vs Delica 33g Depth 7|30 subjects with diabetes
62570189|NCT03911726|OTHER|Healthy subjects|30 healthy subjects will undergo a single PET/MR-measurement.
62570190|NCT03911726|EXPERIMENTAL|First-episode, drug-naive patients with schizophrenia|20 first-episode, drug-naive patients with schizophrenia will undergo a single PET/MR-measurement.
62570191|NCT03911726|EXPERIMENTAL|Pretreated chronically ill patients with schizophrenia|90 pretreated chronically ill patients with schizophrenia will undergo a single PET/MR-measurement.
62570192|NCT04629911|EXPERIMENTAL|HFNO arm|Patients will receive HFNO therapy during laryngomicrosurgery.
62570193|NCT02946554|OTHER|Low dose cohort|"Two dose regimens of HepaStem will be given, which differ in the amount of cells per infusion.~The low dose regimen will be given to the first cohort (first 6 patients included in the study)."
62570194|NCT02946554|OTHER|High dose cohort|The high dose regimen will be given to the second cohort after evaluation of the safety of the 1st cohort (stepwise approach)
62186633|NCT03888222|ACTIVE_COMPARATOR|100 mg of Bosutinib|Thirty (30) participants will be recruited and randomized into 2 groups (arms) (1:1) .Fifteen (15) patients in group 2 will receive the 100 mg of Bosutinib one (1) capsule orally once daily for 3 months (90 days).
62186634|NCT03672487|ACTIVE_COMPARATOR|60/300mg|"The investigators will use a preparation of benznidazole (BZN) that is commercially available in Argentina: Abarax® 100mg and 50mg tablets from ELEA laboratories (Buenos Aires, Argentina). The investigators will purchase the drug at full cost.~Interventions: The standard 60d course will be 300 mg per day, which is similar to the dose used in the second phase of the BENEFIT trial. The drug will be administered orally in two doses per day: the standard course will be one 100mg and one 50mg tablet in the morning and in the evening for 60 days."
62395056|NCT00852800|ACTIVE_COMPARATOR|Standard regimen|Albumin in standard regimen (1.5 g/Kg IV on day 1 and 1 g/kg IV on day 3)with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3
62570195|NCT05705739|EXPERIMENTAL|Retrolaminar plane block|
62570196|NCT05705739|EXPERIMENTAL|ESPB|
62570197|NCT01907490|EXPERIMENTAL|1|Ha44 Gel 0.74%, topical solution, maximum feasible amount applied for 10 minutes
62570198|NCT00607620|EXPERIMENTAL|Intervention|Providers receive training in alcohol screening and brief interventions from study staff in compliance with American College of Surgeons' Alcohol Screening and Brief Intervention Mandate
62570199|NCT00607620|NO_INTERVENTION|Usual Care|Usual care for alcohol use problems after American College of Surgeons' Alcohol Screening and Brief Intervention Mandate
62570200|NCT03863535|EXPERIMENTAL|Intravitreal conbercept+Panretinal coagulation|
62570201|NCT03863535|ACTIVE_COMPARATOR|Panretinal coagulation|
62570202|NCT01347723||Supportive care (pain therapy)|Patients undergo scrambler therapy for 30 minutes daily for up to 10 consecutive days. Treatment continues in the absence of unacceptable toxicity.
62570203|NCT01877642|OTHER|Open Label (lorazepam 1 mg + Inhaled loxapine 10 mg)|Inhaled Staccato loxapine 10 mg + IM lorazepam 1 mg to confirm tolerability of combined treatment
62570204|NCT01877642|OTHER|Treatment Sequence ABC|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
62570205|NCT01877642|OTHER|Treatment Sequence ACB|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
62570206|NCT01877642|OTHER|Treatment Sequence BCA|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
62570207|NCT01877642|OTHER|Treatment Sequence BAC|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
62001366|NCT06030414|EXPERIMENTAL|Main Cohort Group 1|
62001367|NCT06030414|EXPERIMENTAL|Main Cohort Group 2|
62001368|NCT06030414|EXPERIMENTAL|Main Cohort Group 3|
62186635|NCT03672487|EXPERIMENTAL|30/150mg|"The investigators will use a preparation of benznidazole (BZN) that is commercially available in Argentina: Abarax® 100mg and 50mg tablets from ELEA laboratories (Buenos Aires, Argentina). ELEA laboratories will prepare the placebo oral tablets, which will be identical to the drug tablets in aspect and taste. The investigators will purchase the drug and placebo at full cost.~Interventions: The BZN short course low dose scheme will be 150 mg per day for 30 days. The drug will be administered orally in two doses per day: the short course treatment will start with the active drug and then placebo oral tablet; one 100 mg tablet and one placebo tablet in the morning and one 50 mg tablet and one placebo tablet in the evening for the first 30 days. The last 30 days will be two placebo tablets in the morning and the evening."
62186636|NCT02650466|EXPERIMENTAL|Nanopulse treatment|The study will be a single center, open label, non-randomized clinical trial that will provide efficacy data for the treatment of common warts by the Nanopulse system in terms of efficacy and cosmetic outcome with 1 - 4 application (treatment) sessions. All subjects will receive a minimum number of applications per discrete skin wart lesion. Up to 4 warts per subject will be treated with the Nanopulse device. The wart will be debulked to the point of pinpoint bleeding prior to the initial application. The subject will return after 1 week for an evaluation visit and at 4 weeks for a second treatment and 2 additional monthly treatments if warranted. If the subject is declared clinically clear at any of the application visits, they will be placed into follow up. The minimum number of treatments per wart is one and the maximum is 4. They will return at the 12 week point post last visit for final assessment and evaluation.
62186637|NCT01096576|EXPERIMENTAL|A|
62186638|NCT01096576|PLACEBO_COMPARATOR|B|
62186639|NCT03182998|EXPERIMENTAL|Arm A (Knowing Your Options)|"Arm A (Knowing your Options) Patients receive Knowing your Options decision aid before their consultation visit."
62186640|NCT03182998|EXPERIMENTAL|Arm B (Prostate Choice)|"Patients receive Prostate Choice decision aid during their consultation visit."
62186641|NCT03182998|ACTIVE_COMPARATOR|Arm C (Usual Care)|Patients undergo usual care.
62186642|NCT05876169|OTHER|Prospective longitudinal study design|Patients that will undergo orthognatic surgery will be given opportunity to participate in jaw and neck motor function analysis.
62395057|NCT00852800|EXPERIMENTAL|Dose reduced regimen|Albumin in dose reduced regimen (1 g/kg IV on day 1 and 0.5 g/kg IV on day 3) with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3
62395058|NCT04542252|EXPERIMENTAL|Group 1|SyB V-1901 alone, Simultaneous administration of SyB V-1901 and cyclosporine, Coadministration of cyclosporine at 2 hours after the completion of SyB V-1901 infusion
62570208|NCT01877642|OTHER|Treatment Sequence CAB|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
62570209|NCT01877642|OTHER|Treatment Sequence CBA|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
62791707|NCT04853719|ACTIVE_COMPARATOR|Aspirin|Aspirin 100 mg OD for 6 months
62186643|NCT03159351|EXPERIMENTAL|active rTMS treatment|received active rTMS treatment 20 times for 20 days
62186644|NCT03159351|SHAM_COMPARATOR|sham rTMS treatment|received sham rTMS treatment 20 times for 20 days
62186645|NCT02670499|EXPERIMENTAL|GAP-FLEX|Study Device will be used up to 6 times per day for up to 6 minutes to aid in the recovery and improve the degree of flexion from TKR
62395059|NCT04542252|EXPERIMENTAL|Group 2|Simultaneous administration of SyB V-1901 and cyclosporine, SyB V-1901 alone, Coadministration of cyclosporine at 2 hours after the completion of SyB V-1901 infusion
62395060|NCT06080529|EXPERIMENTAL|30-SEC|Participants will execute each exercise for 30 seconds
62395061|NCT06080529|EXPERIMENTAL|45-SEC|Participants will execute each exercise for 45 seconds
62395062|NCT00267202|PLACEBO_COMPARATOR|Placebo|The dose of placebo was determined according to the omalizumab US product label using a dosing table nomogram that ensures patients receive at least 0.016 mg/kg/IgE (IU/ml) per 4 weeks. The study drug was administered by subcutaneous injection every 2 or 4 weeks according to the dosing table nomogram.
62570210|NCT05302596|EXPERIMENTAL|Semaglutide|Semaglutide, added to standard of care, starting dose of 0.25mg titrated up to 1mg dose. for a total of 16 weeks.
62570211|NCT05302596|NO_INTERVENTION|standard of care only|Standard of Care (SOC) weight loss intervention alone (personalized lifestyle and exercise)
62570212|NCT04218656|EXPERIMENTAL|Group A|111 patients with intermittent claudication
62570213|NCT04218656|EXPERIMENTAL|Group B|48 patients with critical limb ischemia with pain at rest and/or foot ulcers
62395063|NCT00267202|EXPERIMENTAL|Omalizumab|The dose of omalizumab was determined according to the omalizumab US product label using a dosing table nomogram that ensures patients receive at least 0.016 mg/kg/IgE (IU/ml) per 4 weeks. The study drug was administered by subcutaneous injection every 2 or 4 weeks according to the dosing table nomogram.
62570214|NCT04062929||Intervention|The investigators included 32 patients who participated to a monocentric 4-day program for secondary prevention in cardiovascular disease, between January 2017 and October 2018. Participation to the program was on a voluntary basis and individuals were referred by their own physician, cardiac rehabilitation center or spontaneously. Eligibility criteria included age 18 years and older, stable coronary artery disease with appropriate medical certificate of fitness and no current medical conditions affecting sports participation. Patients unable to give written constent, with impaired cognitive functions, chronic motor deficiency or severe medical disorder (other than heart disease) significantly affecting functional abilities and individuals with insufficient information about medical history of documented coronary disease were excluded.
62570215|NCT02503124|EXPERIMENTAL|Chronobiological intervention|Single night's wake therapy followed by bright light therapy for a week as add-on treatment to treatment as usual.
62395064|NCT06268288|ACTIVE_COMPARATOR|Standard Postural Orthostatic Tachycardia Syndrome management/ STEPS|The General Pediatric and Adolescent Medicine providers at Mayo Clinic utilize a specific management program for their patients with Postural Orthostatic Tachycardia Syndrome utilizing the acronym STEPS. S is for liberal intake of salt, T is for drinking 90-100 ounces/day of fluid, E is for slowly and gradually improve continuous aerobic exercise duration to a goal of 50 minute most days of the week, P is for possible utilization of 1 of two prescription medications (metoprolol or midodrine), and S is for setting priorities and goals such as encouraging good sleep hygiene, attendance at school, social interactions, and counseling.
62395065|NCT06268288|EXPERIMENTAL|STEPS + GammaCore Intervention (noninvasive vagal nerve stimulation)|Utilization of STEPS management goals plus the addition of non invasive vagal nerve stimulators for two 2 minutes of intervention performed three times a day.
62570216|NCT02503124|ACTIVE_COMPARATOR|Control|Treatment as usual including a private educational meeting in sleep hygiene.
62570217|NCT01567917||Group A|"Patients who gave a permission to this study and underwent doppler US (Doppler US cohort~- Expected subject no.: 400 patients"
62570218|NCT01567917||Group B|"Patient who gave a permission to this study, but who did not receive doppler US (Although this group of patients did not undergo doppler US, these patients will be included as group B \[simple observation cohort without doppler US examination\])~- Expected subject no.: 200 patients"
62570219|NCT02278445|EXPERIMENTAL|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
62570220|NCT05710653|EXPERIMENTAL|HTNex|The participants will adhere to 12 weeks of exercise training, three times a week.
62570221|NCT05710653|NO_INTERVENTION|HTNcg|These participants will maintain their normal lifestyle without intervention.
62570222|NCT05710653|EXPERIMENTAL|ELEex|The participants will adhere to 12 weeks of exercise training, three times a week.
62570223|NCT05710653|NO_INTERVENTION|ELEcg|These participants will maintain their normal lifestyle without intervention.
62186646|NCT02670499|ACTIVE_COMPARATOR|CPM|Control Device will be used up to 2 hours per day for up to 3 times per day to aid in the recovery and improve the degree of flexion from TKR and be compared to the Study Device
62395066|NCT03398759|EXPERIMENTAL|Butorphanol|Butorphanol 20ug/kg , anesthesia induction，Intravenous injection
62395067|NCT03398759|PLACEBO_COMPARATOR|Placebo|Normal saline 5ml ， anesthesia induction，Intravenous injection
62395068|NCT04065412|ACTIVE_COMPARATOR|Conventional laryngeal handshake technique|The conventional laryngeal handshake technique is performed to localize the cricothyroid membrane
62395069|NCT04065412|EXPERIMENTAL|Modified laryngeal handshake technique|The modified laryngeal handshake is performed to localize the cricothyroid membrane
62395070|NCT02224261|EXPERIMENTAL|Physical Therapy|"Physical therapy protocol includes manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active and action-assisted arm exercises stretching cords and patient education."
62395071|NCT02224261|ACTIVE_COMPARATOR|Control|Control protocol includes standard progressive active and action-assisted arm exercises \& patient education.
62395072|NCT06361381|EXPERIMENTAL|Active TaVNS|Active TaVNS: frequency of 25 Hz, pulse duration of 200 µs, at a strong but comfortable intensity.
62395073|NCT06361381|PLACEBO_COMPARATOR|Placebo TaVNS|Placebo TaVNS: the intensity will be increased to a sensory level and then decreased to 0 mA
62570224|NCT05710653|EXPERIMENTAL|NTex (Control Group-exercise)|The participants will adhere to 12 weeks of exercise training, three times a week.
62570225|NCT05710653|NO_INTERVENTION|NTcg (Control Group-no exercise)|These participants will maintain their normal lifestyle without intervention.
62570226|NCT04122742||Patients with RSTS|
62570227|NCT02606916|EXPERIMENTAL|SMART & S-1/DDP|Patients in experimental group receive daily simultaneous modulated accelerated radiotherapy combined with DDP and S-1.
62570228|NCT00212550||TB diagnosis|
62570229|NCT04311333|EXPERIMENTAL|All patients|"All patients undergo endostomal three-dimensional ultrasonography, computerized tomography, clinical examination and laparotomy/laparoscopy.~At all the respective examinations, the presence of a parastomal hernia as well as hernia location and size is evaluated."
62186647|NCT02164006|EXPERIMENTAL|TGR-1202 + brentuximab vedotin|TGR-1202 oral daily dose in combination with a fixed IV infusion of brentuximab vedotin
62186648|NCT04615598|EXPERIMENTAL|Action observation group|
62186649|NCT04615598|PLACEBO_COMPARATOR|Placebo group|
62395074|NCT02701933|OTHER|Ketamine-Saline|Each participant receives both ketamine and placebo (saline) in randomised order in a repeated-measures design. In this arm, ketamine is administered on the first assessment and placebo (saline) is administered on the second assessment.
62186650|NCT04718233|EXPERIMENTAL|sildenafil citrate|Sildenafil citrate at a dose of 25mg will be administered orally in patients with recurrent pregnancy loss and the blood flow indices will be measured initially and after 3 hours.
62186651|NCT04718233|PLACEBO_COMPARATOR|placebo|placebo will be administered orally in patients with recurrent pregnancy loss and the blood flow indices will be measured initially and after 3 hours.
62395075|NCT02701933|OTHER|Saline-Ketamine|Each participant receives both ketamine and placebo (saline) in randomised order in a repeated-measures design. In this arm, placebo (saline) is administered on the first assessment and ketamine is administered on the second assessment.
62395076|NCT04605120|EXPERIMENTAL|Allogeinic Bone Paste|Supercritical CO2 viral-inactivated allogeinic bone paste derived from human living donor femoral heads
62395077|NCT04075903|EXPERIMENTAL|Intervention|"Storytelling A health literacy-appropriate and culturally-adapted intervention delivered on a tablet computer containing storytelling to improve patient gout knowledge and approaches to prevent flares, destigmatize gout, and enhance readiness to adopt available long-term treatments for gout including medications, diet, and exercise, or ii) usual gout care (control state)."
62395078|NCT04075903|NO_INTERVENTION|Control|Usual Care
62395079|NCT02074657|EXPERIMENTAL|Activated natural killer cells|
62395080|NCT06677086|EXPERIMENTAL|Treatment with BTL-899|Four (4) BTL-899 treatments will be applied to the impaired musculoskeletal area, either on the upper or lower extremity.
62395081|NCT00003524|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62395082|NCT02628574|EXPERIMENTAL|TRX518 monotherapy (Parts A and B)|Subjects receive an assigned dose of TRX518 administered intravenously one time per week or one time per cycle on a 21-day cycle
62395083|NCT02628574|EXPERIMENTAL|TRX518 with gemcitabine (Part C)|Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with gemcitabine (dosed two times per cycle) on a 21-day cycle
62395084|NCT02628574|EXPERIMENTAL|TRX518 with pembrolizumab (Part D|Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with pembrolizumab (dosed one time per cycle) on a 21-day cycle
62395085|NCT02628574|EXPERIMENTAL|TRX518 with nivolumab (Part E)|Subjects receive an assigned dose of TRX518 (dosed two times per cycle) intravenously administered in combination with nivolumab (dosed two times per cycle) on a 28-day cycle
62395086|NCT01617265|EXPERIMENTAL|Prevention of oversedation group|In this arm sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated intravenous (IV) hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
62395087|NCT01617265|ACTIVE_COMPARATOR|Conventional sedation group|In this arm, sedation will be administered according to the usual practices in each participating center.
62395088|NCT04697719|EXPERIMENTAL|Aspirin 81mg, Then Aspirin 325mg|After a 3 week placebo run-in period, participants first receive Aspirin 81mg capsule daily for 3 weeks. After a placebo washout period of 3 weeks, they then receive Aspirin 325mg capsule daily for another 3 weeks.
62395089|NCT04697719|EXPERIMENTAL|Aspirin 325mg, Then Aspirin 81mg|After a 3 week placebo run-in period, participants first receive Aspirin 325mg capsule daily for 3 weeks. After a placebo washout period of 3 weeks, they then receive Aspirin 81mg capsule daily for another 3 weeks.
62395090|NCT05218148|EXPERIMENTAL|Group A|Group A: SOX regimen (oxaliplatin + Seggio) ) + sintilimab + trastuzumab; 3 cycles of treatment, followed by D2 radical resection, and 5 cycles of adjuvant chemotherapy with the original regimen after surgery
62395091|NCT05218148|ACTIVE_COMPARATOR|Group B|Group B: SOX regimen, 3 cycles of treatment, followed by D2 radical resection, and 5 cycles of adjuvant chemotherapy with the original regimen after surgery
62395092|NCT04362514|EXPERIMENTAL|IG|Intervention Group
62395093|NCT04362514|ACTIVE_COMPARATOR|aCG|Control Group
62395094|NCT01304576|EXPERIMENTAL|patient with right parietal lesions|
62395095|NCT01304576|ACTIVE_COMPARATOR|patient with left parietal lesions|
62395096|NCT05129566|EXPERIMENTAL|IOL Clareon AutonoMe|The first group of patients (39 eyes) who received the monofocal IOL Clareon AutonoMe after the phacoemulsification of cataract.
62395097|NCT05129566|ACTIVE_COMPARATOR|IOL Hoya iSert 251|the second group of patients (39 eyes) who received the monofocal IOL Hoya iSert 251 after the phacoemulsification of cataract
62395098|NCT00579605|EXPERIMENTAL|1 Motivational Interviewing|1 intervention group 1 attention intervention group Behavioral: Motivational Interviewing Client-centered strategy that may decrease ambivalence in behavior performance
62395099|NCT01074320||Breast cancer patients on AIs|Breast cancer patients beginning Aromatase Inhibitor therapy
62395100|NCT05106101|EXPERIMENTAL|L-glutamine|Participants received L-glutamine oral powder 15 grams twice daily for 48 weeks
62395101|NCT05647174|ACTIVE_COMPARATOR|MGPOCUS-assisted bronchoscope-guided intubation|
62395102|NCT05647174|EXPERIMENTAL|Bronchoscope-guided Intubation|
62395103|NCT04500925||UPSCALED|
62395104|NCT04500925||NOT UPSCALED|
62570230|NCT01749826|EXPERIMENTAL|Chronic Opioid Exposure|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
62395105|NCT05925530|EXPERIMENTAL|Durvalumab|Durvalumab will be administered to the participants via intravenous infusion (IV)
62395106|NCT03975881|EXPERIMENTAL|Open Label|Patients aged 15 to 35 who made a suicide attempt and went through the emergency departments of the participating hospitals (Nantes, Angers, Rennes and Poitiers).
62395107|NCT01974310|ACTIVE_COMPARATOR|Face-down positioning|Patients advised face-down positioning after surgery for macular hole.
62570231|NCT01749826|EXPERIMENTAL|Acute Opioid Exposure|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
62584864|NCT01957436|EXPERIMENTAL|Arm B|androgen deprivation therapy + docetaxel + abiraterone acetate + prednisone
62584865|NCT01957436|EXPERIMENTAL|Arm C|Arm A + radiotherapy
62584866|NCT01957436|EXPERIMENTAL|Arm D|Arm B + radiotherapy
62776950|NCT04766554|ACTIVE_COMPARATOR|Cerebral Oxymetry Monitoring|"The following procedures should be performed sequentially in the event of cerebral desaturation after 30 seconds:~1. The positioning of the head, the presence of facial plethora, and bad position of catheters should be corrected;~2. In case of arterial hypotension, the causal factors should be assessed and treated;~3. In the presence of arterial hypoxemia, the causal factors should be assessed and treated to maintain a PaO2 \> 150 mmHg;~4. In the presence of hypercapnia, adjust the ventilation parameters avoiding hyperventilation;~5. In the presence of anemia, the causal factors should be assessed, and the decision to undergo transfusion should also take into consideration the presence of tissue hypoperfusion;~6. In cases of SvO2 below 70% and signs of hemodynamic instability, optimize fluid replacement and ventricular global contractility;~7. Assess the increase of brain consumption of O2, avoiding the superficial level of anesthesia, hyperthermia, and tremors."
62001369|NCT01384084|EXPERIMENTAL|POP repair plus mini-sling|Patients affected by urogenital prolapse and urinary incontinence, who are candidates for pelvic organ prolapsed repair using sacropexy, will receive sacropexy plus anti-incontinence procedure (mini-sling).
62776951|NCT04766554|NO_INTERVENTION|Control Group|Patients will be treated according to the attending anesthesiologist, without the monitoring of cerebral oximetry, but to maintain a heart rate between 70 - 100 bpm, lactate levels \<3 mmol/L and urine output\> 0.5mL/Kg/h. In case of arterial hypotension the causal factors should be assessed and treated; in case of SvO2 below 70% and signs of hemodynamic instability, optimize volume replacement and global ventricular contractility through inotropic agents (epinephrine, dobutamine or milrinone); in the presence of anemia (Hb \<6 to 7g/dL during CPB or Hb \<8g/dL in the pre-CPB or post-CPB period), the causal factors should be assessed and the decision to transfuse should also take into account the presence of hypoperfusion tissue (increased lactate, low SvO2, acidosis); in episodes of bradycardia with hemodynamic instability, atropine may be used.
62001370|NCT01384084|ACTIVE_COMPARATOR|pelvic organ prolapse repair|Patients affected by urogenital prolapsed and urinary incontinence, who are candidates for pelvic organ prolapsed repair using sacropexy, will receive sacropexy alone.
62001371|NCT06293846|EXPERIMENTAL|What I Learned at Home|What I Learned at Home is a self-efficacy behavioral intervention that will help provide the framework of implementation for the BeFIT program in the future. The BeFIT program will be a component of the WILAH framework.
62001372|NCT02674412|EXPERIMENTAL|Buspirone then Placebo|Buspirone 10 mg PO TID for two weeks, followed by a washout period for two weeks and placebo for two weeks
62001373|NCT02674412|EXPERIMENTAL|Placebo then Buspirone|Placebo Tablet TID for two weeks, followed by a washout period for two weeks and Buspirone 10mg TID for two weeks.
62001374|NCT04928326||Patients with heart failure undergoing right heart catheterization|Subjects with a diagnosis of NYHA class II-IV heart failure who meet the inclusion and exclusion criteria will be eligible for participation in this study.
62001375|NCT00839293|EXPERIMENTAL|A|ABT -335 capsules 135mg
62001376|NCT00839293|EXPERIMENTAL|B|ABT-335 capsules 45mg
62001377|NCT05289596|EXPERIMENTAL|Evidence-based digital therapy to treat insomnia|Participants will be assigned an evidence-based digital therapy to treat insomnia (Sleep Healthy Using the Internet (SHUT-i)
62776952|NCT05638243||High-risk residents|
62776953|NCT06216548|ACTIVE_COMPARATOR|Delayed Enhanced Primary Care (E-PRIME) Group|Children will receive usual care before receiving E-PRIME intervention.
62001378|NCT01942629||Lung adenocarcinoma|"This group will include 100 patients with lung adenocarcinoma, the clinical outcomes will be retrospectively assessed.~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
62001379|NCT01942629||Breast adenocarcinoma|"This group will include 100 patients with breast adenocarcinoma, the clinical outcomes will be retrospectively assessed.~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
62001380|NCT01942629||Pancreatic ductal adenocarcinoma|"This group will include 100 patients with pancreatic ductal adenocarcinoma, the clinical outcomes will be retrospectively assessed.~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
62001381|NCT02021682||Amyloid positive (Amyloidosis)|Amyloidosis defined by positive Positive emission tomography (PET)/Pittsburg Compound B (PIB) score, or low CSF Aβ42 concentration.
62001382|NCT02021682||Amyloid negative (Control)|Amyloid negative defined by negative Positive emission tomography (PET)/Pittsburg Compound B (PIB) score or high/normal CSF Aβ42 concentration .
62001383|NCT01163994|ACTIVE_COMPARATOR|MEM-ceftriaxone|
62001384|NCT01163994|ACTIVE_COMPARATOR|MEM-doxycycline|
62001385|NCT01163994|NO_INTERVENTION|controls|
62001386|NCT01163994|ACTIVE_COMPARATOR|EM-doxycycline|
62186652|NCT00565838||2|G1 - Autologous Fascial Sling G2 - TVT
62001387|NCT03101904|EXPERIMENTAL|Nitrate then Placebo|"Participants will consume a daily a beetroot shot for six days. Each shot will consist of: 1x70ml concentrated NO-3 shot of rich Beetroot juice (\~7mmol nitrate; Beet It, James White Drinks Ltd, Ipswich, UK).~Following a minimum of ten days wash out, participants will then consume a daily Nitrate-depleted beetroot shot for six days. Each shot will consist of 1x70ml nitrate-depleted beetroot Placebo shot (\~0.003mmol of nitrate; Beet It, James White Drinks Ltd, Ipswich, UK)."
62186653|NCT01045863|EXPERIMENTAL|PART A: Ascending Cohorts|Single ascending dose cross-over. (0.05, 0.15, 0.5, 1.5, 5, 15 mg)
62186654|NCT01045863|EXPERIMENTAL|PART B: Food effect|Food effect on PF-03382792 PK
62186655|NCT01045863|EXPERIMENTAL|PART C: CSF Cohort|Optional CSF Cohort
62186656|NCT01850498||Partial seizures|Partial seizures with secondary generalization which results in visible clonic or tonic-clonic motor behavior
62001388|NCT03101904|PLACEBO_COMPARATOR|Placebo then Nitrate|"Participants will consume a daily Nitrate-depleted beetroot shot for six days. Each shot will consist of 1x70ml nitrate-depleted beetroot Placebo shot (\~0.003mmol of nitrate; Beet It, James White Drinks Ltd, Ipswich, UK).~Following a minimum of ten days wash out, participants will then consume a daily beetroot shot for six days. Each shot will consist of: 1x70ml concentrated NO-3 shot of rich Beetroot juice (\~7mmol nitrate; Beet It, James White Drinks Ltd, Ipswich, UK)."
62395108|NCT01974310|EXPERIMENTAL|Non-face-down positioning|Patients advised non-face-down positioning after surgery for macular hole.
62570232|NCT06569199|EXPERIMENTAL|Functional Bracing|Premade fabricated braces in three sizes (small, medium and large) that have been designed for the pediatric age group between 0-5 years old will be stocked at the Alberta Children's Hospital. Participants who are randomized to the functional bracing group will be administered the functional brace within the emergency department under light procedural sedation. Brace will be used for up to 8 weeks administration until adequate callous formation confirmed with X-ray imaging.
62570233|NCT06569199|ACTIVE_COMPARATOR|Hip Spica Cast|Participants who are randomized to the spica casting group will undergo casting in the operating room and be given general anesthesia to apply the hip spica cast. Cast will be used for up to 8 weeks administration until adequate callous formation confirmed with X-ray imaging.
62570234|NCT02295826|EXPERIMENTAL|Dabigatran therapy|150 mg BID for 30 days (dose modification - reduced to 110mg BID in patients \>80 years of age and/or an eGFR of 30-50 ml/min)
62570235|NCT02295826|ACTIVE_COMPARATOR|Acetylsalicylic Acid thereapy|325 mg loading dose then 81 mg/day for 30 days
62570236|NCT03048747|EXPERIMENTAL|Tolvaptan|Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
62570237|NCT06152562||Individualized ASA therapy group using platelet inhibition monitoring|The first VerifyNow ARU measurement will be done minimum 2 hours and at latest 24 hours after the first four doses of ASA. If the ARU is ≤ 549, the current daily ASA dose will be continued and the patient will be discharged with this dose. If the ARU is ≥ 550, the dose will be increased by 50 mg and the test is repeated after two doses. We will increase the dose step by step until the ARU decreased below 550 or a maximum ASA dose of 300 mg per day is reached. If there is no sufficient drug effect at the maximum dose assessed by VerifyNow, the patient will be count as non-responder and a change to a P2Y12-inhibitor (e.g. Clopidogrel 75 mg) is indicated. A resistance against Clopidogrel will not be examined. The other tests will be held at the first follow-up visit and six months after implantation.
62570238|NCT06152562||Standard ASA therapy|Initiation of standard dose ASA therapy as per center guidelines with HeartMate 3: 100mg/day; HVAD: 200mg/day
62570239|NCT05043207|EXPERIMENTAL|uAud|Patients which hearing aid is fitted based on the audiometry obtained with user-operated automated audiometry.
62570240|NCT05043207|ACTIVE_COMPARATOR|control|Patients which hearing aid is fitted based on the audiometry obtained with traditional audiometry.
62570241|NCT05874128|EXPERIMENTAL|Medical Device (Software)|ONLY FOR CLINICAL TRIALS
62570242|NCT01307865|EXPERIMENTAL|Sculptra Aesthetic|Patients receiving Sculptra Aesthetic
62570243|NCT02599285||Fixation|Patients with a trimalleolar AO Weber C fracture with open reduction and fixation of the posterior malleolar fragment.
62570244|NCT02599285||No Fixation|Patients with a trimalleolar AO Weber C fracture without open reduction and fixation of the posterior malleolar fragment.
62395109|NCT05296239|EXPERIMENTAL|SimpleC Wellness Platform with Social Robot Interaction|
62395110|NCT03846895|EXPERIMENTAL|Laser Group|"Microablative Fractional CO2 laser therapy at monthly intervals.~The laser parameters that will be used are the following:~1. Power: 40 watts,~2. Dwell time:1000μs,~3. Spacing 1000 μm,~4. Depth: SmartStak parameter 3~5. D-pulse mode."
62395111|NCT03846895|PLACEBO_COMPARATOR|Placebo Group|"Placebo CO2 laser therapies at monthly intervals.~The laser parameters that will be used are the following:~1. Power: 0.5 watts,~2. Dwell time:1000μs,~3. Spacing 1000 μm,~4. Depth: SmartStak parameter 1,~5. Smart-pulse mode."
62395112|NCT03947333|EXPERIMENTAL|Intervention|Patients have access to an existing patient web portal (My Health at Vanderbilt) embedded with the My Diabetes Care.
62570245|NCT03208335|EXPERIMENTAL|rh-endostatin combination|Continuous intravenous pumping (CIP) recombinant human endostatin(rh-endostatin) 30mg/d, from 5 days before radiotherapy,for 7days,21 per cycle.Standard radiotherapy for HCC is conducted concurrently.Those patients will receive 3-5 cycles rh-endostatin after the radiotherapy is finished,4-6 cycles in all.
62570246|NCT06278935|EXPERIMENTAL|Lifestyle-based intervention by an occupational therapist|Participants with diabetic foot ulcers will be offered lifestyle-based treatment sessions over telemedicine for up to 8 weeks with a licensed occupational therapist.
62570247|NCT01806051|EXPERIMENTAL|PKU Participants (Arm 1)|"* Subjects will be administered Kuvan once daily.~* They will undergo several blood draws, including a 24-Hour Blood Assessment (at Study Visit #2 before the commencement of Kuvan), plasma Phe/Tyr draws (at Study Visits #3, 4, and 5), and another 24-Hour Blood Assessment (at Study Visit #6)."
62570248|NCT01806051|NO_INTERVENTION|Control Group (Arm 2)|"* Subjects allocated into this group will be healthy, non-PKU individuals that may be a relative (ex: sibling) of a PKU participant, but they don't have to be a blood relation.~* These subjects will undergo a 24-Hour Blood Assessment (at Study Visit #2)."
62395113|NCT03947333|NO_INTERVENTION|Control|Patients will have access to an existing patient web portal (My Health at Vanderbilt) NOT embedded with the My Diabetes Care (i.e., usual care).
62395114|NCT04672694|ACTIVE_COMPARATOR|VNB (vagus nerve block)|Vagus nerve block
62395115|NCT04672694|PLACEBO_COMPARATOR|Control|No vagus nerve block
62001389|NCT04568252|EXPERIMENTAL|Intervention|Millimetric wave emission bracelet.
62001390|NCT04568252|SHAM_COMPARATOR|Control|Placebo bracelet.
62001391|NCT00748956|EXPERIMENTAL|Low dose NPY|Low dose, Receive 50 nmol dose of NPY
62395116|NCT01500291||Anesthesiologist|
62395117|NCT01500291||Nurse anesthetist|
62395118|NCT04945291|EXPERIMENTAL|research built JA Method mobile application + Counting method using the hands|The participant will watch a video that explains a new counting method using the hands and use the research built mobile application to log and track the calories
62001392|NCT00748956|EXPERIMENTAL|High dose NPY|High Dose, Receive 100 nmol dose of NPY
62001393|NCT00748956|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62001394|NCT06452524||ROP-Tx Group|less than 37 weeks were divided into three groups: 29 children born prematurely who were treated with laser photocoagulation
62001395|NCT06452524||ROP-non-Tx Group|26 children who developed ROP and did not need treatment
62001396|NCT06452524||Premature Group|25 children who did not develop ROP
62001397|NCT06452524||Control Group|27 healthy children with a history of full-term born
62001398|NCT01826162|EXPERIMENTAL|sigmoidoscopy|2 actetate concentrations and 1 placebo are administered in randomized order after clipping a catheter in the proximal colon (sigmoidoscopy)
62001399|NCT01826162|EXPERIMENTAL|colonoscopy|2 actetate concentrations and 1 placebo are administered in randomized order after clipping a catheter in the distal colon (colonoscopy)
62001400|NCT05483491|EXPERIMENTAL|KK-LC-1 TCR-T cells|Subjects will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin.
62001401|NCT01488643||OBESITY PATIENTS|PATIENTS WITH BMI \>35
62001402|NCT01488643||CONTROL TEAM BMI <35|
62570249|NCT03464188|NO_INTERVENTION|Usual Care|Usual care family caregiver participants will be informed of the UAB Comprehensive Cancer Center Patient and Family Resources webpage.
62570250|NCT03464188|EXPERIMENTAL|Project Cornerstone|The intervention is lay navigator-led with regular supervision by a specialist palliative care clinician. Regular caregiver distress thermometer screening and problem support and self-care coaching. Caregivers receive a Project Cornerstone Family Supporting Family (FSF) Binder that organizes intervention materials and contains educational information pertaining to the 6 base coaching sessions.
62570251|NCT03964857|OTHER|Refined olive oil (ROO)|Control
62570252|NCT03964857|EXPERIMENTAL|Blended Oil 1|BO1, propriety blend of cooking oil containing rice bran, flaxseed and sesame oil blended at proportions different from 'Blended Oil 2
62001403|NCT02577237|EXPERIMENTAL|Intervention Group: Caregiver education|The intervention includes caregivers who will receive an education and support program throughout radiation treatment in addition to usual care by their doctors and nurses.
62001404|NCT02577237|ACTIVE_COMPARATOR|Control Group: educational booklet|The control group will receive an educational booklet about caregiving in addition to usual care by their doctors and nurses
62001405|NCT03086174|EXPERIMENTAL|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg Q2w PLUS axitinib 5 mg orally Q2w until disease progresses or unacceptable tolerability occurs
62001406|NCT02084771|EXPERIMENTAL|Oral Salt and Water|"Oral Salt and Water Loading:~Participants randomized to this arm of the trial will receive 0.1 g/kg of salt (NaCl) and 12 mL/kg of water. Patients weighing more than 110 kg will receive the same amount as per a 110 kg patient. One third of the oral salt and water will be given before the CT and 2/3 post-CT as in the intravenous saline arm. Specifically, 0.03 g/kg of NaCl and 4 mL/kg of water in the one hour before CT and 0.07 g/kg of NaCl and 8 mL/kg of water taken over 2 hours post-CT. The ingestion of the oral salt and water will be directly observed by the study nurse to ensure adherence to the protocol."
62001407|NCT02084771|ACTIVE_COMPARATOR|Intravenous Saline|Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg give in the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
62001408|NCT05487729||Young adults|Young adults without neurological and serious structural condition.
62001409|NCT02139566|EXPERIMENTAL|Hi-tech video consent|This group will be shown a professionally animated video that presents the major components of the informed consent document. Intervention is Video Consent (high-tech) PDF informed consent document.
62001410|NCT02139566|EXPERIMENTAL|Low-tech video consent|"Participants in this arm will be provided with informed consent information through viewing a talking head video produced by a non-professional presenter, with widely available and inexpensive video equipment. Intervention is video consent (low-tech), PDF informed consent document."
62001411|NCT02139566|EXPERIMENTAL|FAQ consent|"Participants in this arm will be provided with informed consent content through an interactive frequently asked questions format, in which the participant will click on a question and be shown text that provides an answer to that question. Major informed consent topics will have one or more question and answer pairs. Intervention is FAQ format consent, PDF informed consent document"
62001412|NCT02139566|ACTIVE_COMPARATOR|Standard consent process|Participants in this arm will be provided with informed consent content by being shown a standard informed consent document in a scrolling window within the browser window, PDF informed consent document
62570253|NCT03964857|EXPERIMENTAL|Blended Oil 2|BO2, propriety blend of cooking oil containing rice bran, flaxseed and sesame oil blended at proportions different from 'Blended Oil 1
62570254|NCT02387671|EXPERIMENTAL|mHealth Platform|The primary interventions employed in the study are wifi enabled tracking devices, text message communications and behavioral counseling.
62001413|NCT03340129|ACTIVE_COMPARATOR|Nivolumab + ipilimumab|"Nivolumab 1mg/kg and ipilimumab 3mg/kg Q3W x 4 doses, then nivolumab 480 mg every 4 weeks.~Any form of salvage therapy (surgery or radiotherapy) may be administered to either cohort for the treatment of intracranial disease progression."
62020998|NCT05688813|EXPERIMENTAL|Caudal block group|An echogenic block needle (22 Gauge 50 mm) was then advanced into the sacral canal through the sacrococcygeal membrane while a longitudinal position was used, continuing with the in-plane technique. After ensuring that there is no blood or cerebrospinal fluid with aspiration, 0.5 ml/kg 0.25% bupivacaine was administered while observing caudal epidural space dilation or turbulent flow with Doppler.
62570255|NCT02473939|EXPERIMENTAL|VR942 Dose 1|VR942 Dose 1
62570256|NCT02473939|EXPERIMENTAL|VR942 Dose 2|VR942 Dose 2
62570257|NCT02473939|EXPERIMENTAL|VR942 Dose 3|VR942 Dose 3
62570258|NCT02473939|EXPERIMENTAL|VR942 Dose 4|VR942 Dose 4
62570259|NCT02473939|EXPERIMENTAL|VR942 Dose 5|VR942 Dose 5
62570260|NCT05915663|EXPERIMENTAL|Nasogastric|nasogastric tube in period 1 and orogastric tube in period 2
62570261|NCT05915663|EXPERIMENTAL|Orogastric|orogastric tube in period 1 and nasogastric tube in period 2
62001414|NCT03340129|ACTIVE_COMPARATOR|Nivolumab + ipilimumab,concurrent SRS|"Nivolumab 1mg/kg and ipilimumab 3mg/kg Q3W x 4 doses, then nivolumab 480 mg every 4 weeks.~Stereotactic radiotherapy 16 to 22 Gy in 1 fraction or 24 to 30 Gy, hypofractionated for larger lesions. Stereotactic radiotherapy to commence within 7 days of of the baseline / planning MRI brain. Hypofractionated stereotactic radiotherapy should be completed within 14 day of the first fraction.~Any form of salvage therapy (surgery or radiotherapy) may be administered to either cohort for the treatment of intracranial disease progression."
62001415|NCT03869593||Patients presenting E. coli and S. aureus bacteremia|Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia
62001416|NCT01077960|EXPERIMENTAL|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment \[Serono Study 24380\] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
62001417|NCT01239368|EXPERIMENTAL|Cohort B - Relapsed Multiple Myeloma|Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) .Rapamycin (Rapa) for Relapsed Multiple Myeloma
62001418|NCT01239368|EXPERIMENTAL|Cohort A - Prevention of Relapse|Th1/Tc1.Rapa Prevention of Relapse
62001419|NCT01768611||Withou Diabetic Nephropathy|Patients who have persistent normoalbuminuria (\<30 mg/g creatinine or \<20 μg/min).
62395119|NCT04945291|ACTIVE_COMPARATOR|FitnessPal mobile application (or Arabic alternative) + Counting method using the hands|the participants will watch a video that explains a new counting method using the hands and they will be asked to use a commercial mobile app to log and track the calories
62395120|NCT04945291|ACTIVE_COMPARATOR|Fitness Pal Mobile Application (or Arabi alternative)|The participants will watch a generic video about the mobile app and they will be asked to use a commercial mobile app to log and track the calories
62395121|NCT06724003|EXPERIMENTAL|Computer-based simulation of virtual reality .|Interactive virtual reality simulation group will practice oral care in the unconscious patient with interactive virtual reality simulation after the oral care practice in the unconscious patient is demonstrated on a low reality patient manikin. After the application, a briefing will be given to the participants and the application will be discussed in detail. Participants will perform oral care in the unconscious patient on a low-reality patient manikin 15 days after the simulation application.
62001420|NCT01768611||Incipient Nephropathy|Patients who have persistent microalbuminuria (30-300 mg/g creatinine or 20-200 μg/min).
62395122|NCT06724003|NO_INTERVENTION|Low-reality patient model group|Participants will be demonstrated the unconscious patient oral care practice with a low-reality patient manikin by the researcher nurse faculty member. Participants will perform the application on the low-reality patient manikin. After the application, participants will be briefed and talked about the application. Oral care of the unconscious patient will be practiced on a low-reality patient manikin 15 days after the application.
62395123|NCT06230822|EXPERIMENTAL|VUM02 Injection (hUCT-MSCs)+Conventional treatment|3 predefined dose groups: 5x10\^7 cells/person/time, 1x10\^8 cells/person/time and 2x10\^8 cells/person/time, administered intravenously on D0, D3 and D6 for a total of 3 doses.
62395124|NCT05453552|EXPERIMENTAL|G-CSF+DAC+BF|For patients with high-risk MDS undergoing allo- HSCT, Granulocyte Colony-Stimulating Factor (G-CSF)+Decitabine+BF conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -6 to -3, Fludarabine (FLU) 30mg/m2/ day on days -7 to -3.
62186657|NCT01850498||Generalized seizures|Primarily generalized seizures (in patients with either primary \[idiopathic\] or secondary \[symptomatic\] generalized epilepsy), which may involve the following depending on the motor manifestation observed: myoclonic seizures, clonic seizures, tonic-clonic seizures, or atonic seizures.
62186658|NCT05833659||The prepectoral breast reconstruction|The patients received prepectoral breast reconstruction after single-port insufflation endoscopic nipple-sparing mastectomy
62395125|NCT05453552|ACTIVE_COMPARATOR|G-CSF+DAC+BUCY|For patients with high-risk MDS undergoing allo- HSCT, Granulocyte Colony -Stimulating Factor (G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -7 to -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3, -2.
62395126|NCT03776435||CT-exposed group|
62395127|NCT03776435||CT-unexposed group|
62395128|NCT02358720|EXPERIMENTAL|A: single fraction IMRT with 1 x 24 Gy|single fraction IMRT with 1 x 24 Gy on bone metastasis
62395129|NCT02358720|ACTIVE_COMPARATOR|B: fractionated RT with 10 x 3 Gy|fractionated RT with 10 x 3 Gy on bone metastasis
62395130|NCT00591305|EXPERIMENTAL|PDL+DIM pill|once-time 585 nm pulsed dye laser (PDL) treatment on the lesions, immediately followed by 3-month oral taking diindolylmethane (DIM, at 1.2-1.75mg/kg/day), in 15 subjects
62395131|NCT00591305|PLACEBO_COMPARATOR|PDL+placebo pill|once-time PDL treatment on the lesions, then followed by 3-month oral taking DIM placebo, in other 15 subjects
62395132|NCT04676022|EXPERIMENTAL|Spinal Cord Stimulation|To receive Spinal Cord Stimulation programming
62570262|NCT01394731|EXPERIMENTAL|Paracetamol 1|
62001421|NCT01768611||Overt Diabetic Nephropathy|Patients who have persistent macroalbuminuria (\>300 mg/g creatinine or \>200 µg/min), proteinuria (\>500 mg/24 h) or renal replacement therapy.
62395133|NCT04676022|OTHER|Conventional Medical Management|To receive conventional medical management
62395134|NCT01670331|ACTIVE_COMPARATOR|Psychological preparation|Patients undergo 3 seminar sessions with the bariatric psychologist prior to their surgery. These will aim to prepare them for the lifestyle changes that will occur / they will have to make after surgery
62570263|NCT01394731|EXPERIMENTAL|Paraceatmol 2|
62570264|NCT01394731|ACTIVE_COMPARATOR|Meperidine|
62570265|NCT01950468|EXPERIMENTAL|NAV5001|
62570266|NCT01950468|ACTIVE_COMPARATOR|DaTscan|
62570267|NCT01764360|OTHER|KS structured clinical care training|Eight primary care sites in Zimbabwe will be randomized at different timepoints to receive structured training for diagnosis and treatment of Kaposi sarcoma (KS)
62001422|NCT00989833|ACTIVE_COMPARATOR|A|budesonide 400yg + terbutaline 0.4 mg as-needed
62001423|NCT00989833|ACTIVE_COMPARATOR|B|placebo + terbutaline 0.4 mg as-needed
62001424|NCT00989833|ACTIVE_COMPARATOR|C|placebo + budesonide/formoterol 160/4.5 yg as-needed
62001425|NCT03978975|ACTIVE_COMPARATOR|normal weight women|20 women with a body mass index ranging between 18,5 and 24,9 kg.m2
62001426|NCT03978975|EXPERIMENTAL|overweight women|20 women with a body mass index ranging between 25 and 29,9 kg.m2
62001427|NCT03878134|EXPERIMENTAL|Patients undergoing conventional and Photon Counting CT scan on the investigational scanner|18 and older patients who undergo the conventional CT scan and the photon counting CT (PCCT) scan. Patient's images on the conventional scanner provide internal control to compare to the PCCT images.
62001428|NCT06108817|EXPERIMENTAL|Information material|The intervention involved distributing an educational waiting room poster and flyers informing patients regarding the appropriate indications for prescription of an ARM for dyspepsia, which also referred to an online decision aid.
62001429|NCT06108817|ACTIVE_COMPARATOR|No information material|No intervention
62001430|NCT05138939|PLACEBO_COMPARATOR|Control|Participants in this group are randomized to receive Isocaloric beverage (a beverage that has similar caloric content to the red wines) as the first intervention.
62001431|NCT05138939|EXPERIMENTAL|Red wine A|Participants in this group are randomized to receive red wine A as the first intervention (can be the younger or older vintage).
62001432|NCT05138939|EXPERIMENTAL|Red wine B|Participants in this group are randomized to receive red wine B as the first intervention (can be the younger or older vintage)
62186659|NCT05833659||The subpectoral breast reconstruction|The patients received subpectoral breast reconstruction after single-port insufflation endoscopic nipple-sparing mastectomy
62395135|NCT01670331|NO_INTERVENTION|Surgery as usual|Patients will proceed to surgery as usual. They will complete psychological assessment forms at their follow up clinic sessions.
62395136|NCT02831595||Patients undergoing unilateral TKA|
62186660|NCT06110065||Cohort 1|
62395137|NCT03434665|OTHER|Recruited patients|Transradial celiac artery angiography
62395138|NCT02103894|EXPERIMENTAL|[18F]T807 ([18F]MNI-777)|At the \[18F\]MNI-777 PET imaging visit, subjects will be injected with no more than 10 mCi (370 MBq) of \[18F\]MNI-777).
62570268|NCT03852472|PLACEBO_COMPARATOR|Group A|Placebo twice daily (BID) for Period 1 of the study
62570269|NCT03852472|EXPERIMENTAL|Group B|Avacopan 10 mg twice daily (BID) for Period 1+2 of the study
62570270|NCT03852472|EXPERIMENTAL|Group C|Avacopan 30 mg twice daily (BID) for Period 1+2 of the study
62001433|NCT04233281|EXPERIMENTAL|Kori-tofu added to a carbohydrate rich meal|Kori tofu as part of a carbohydrate rich meal
62001434|NCT04233281|ACTIVE_COMPARATOR|Whey protein added to a carbohydrate rich meal|Whey protein as part of a carbohydrate rich meal
62186661|NCT03253432||Strata 0-0.05|Lowest probability of having familial hypercholesterolemia
62001435|NCT02089061|EXPERIMENTAL|Cohort 1: Rosuvastatin + BMS-919373|"Rosuvastatin 10 mg tablet orally once for Day 1 and 5~BMS-919373: 100 mg dose on Day 4 and 30 mg dose once daily on Days 5, 6 and 7 of Microcrystalline suspension"
62001436|NCT02089061|EXPERIMENTAL|Cohort 2: Atorvastatin + BMS-919373|"Atorvastatin 40 mg tablet once for Days 1 and 5~BMS-919373: 100 mg dose on Day 4 and 30 mg dose once daily on Days 5, 6 and 7 of Microcrystalline suspension"
62001437|NCT01494610|EXPERIMENTAL|SERETIDE Rotacaps|Fluticasone propionate (250 micrograms \[ug\])/Salmeterol (50 ug) combination delivered in a capsule-based inhaler
62001438|NCT01494610|ACTIVE_COMPARATOR|SERETIDE Diskus|Fluticasone propionate (250 ug)/Salmeterol (50 ug) combination delivered in a multi-dose dry powder inhaler
62001439|NCT01494610|PLACEBO_COMPARATOR|Placebo Rotacaps|Placebo delivered in a capsule-based inhaler
62001440|NCT01494610|PLACEBO_COMPARATOR|Placebo Diskus|Placebo delivered in a multi-dose dry powder inhaler
62001441|NCT01416168|NO_INTERVENTION|Control Arm|Usual post-surgical care
62001442|NCT01416168|EXPERIMENTAL|Intervention arm|In addition to usual post-surgical care, the patients will receive a 4 week geriatric nurse practitioner-centered intervention, based on the McCorkle model.
62001443|NCT03658083||Thoracotomy|Individuals referred for a lung resection via thoracotomy with a primary or secondary diagnosis of lung cancer. Those with a tumor \>7cm will be excluded.
62186662|NCT03253432||Strata 0.06-0.15|Second lowest probability of having familial hypercholesterolemia
62186663|NCT03253432||Strata 0.16-0.19|Moderate probability of having familial hypercholesterolemia
62186664|NCT03253432||Strata 0.20-0.34|Second highest probability of having familial hypercholesterolemia
62395139|NCT03986658|EXPERIMENTAL|Adolescents|Device: First Dawn rTMS System used in 18 patients divided into groups of 3. Each group will receive a different and gradually increasing frequency of treatment sessions/day (1-10) over a decreasing number of days (10-1). The total number of pulses for all levels will be 30,000. The use of each level will be dependent on tolerability and safety of the previous lower level, i.e., if one level is not tolerated well by a group, progression to the next level will not occur.
62395140|NCT02833779|ACTIVE_COMPARATOR|Group Therapy Exercises|Patients will be taught exercises in groups of six persons, on a daily basis for twelve sessions.
62395141|NCT02833779|ACTIVE_COMPARATOR|Individual Manual Therapy Exercises|Patients will be taught the same exercises as in a Group 1, individually, and will receive manual therapy consisting of muscular and joint re-centering
62395142|NCT02590211|OTHER|non-poker players|(control group)
62395143|NCT02590211|OTHER|expert unproblematic poker players|(comparator)
62395144|NCT02590211|OTHER|pathological poker players|(comparator)
62395145|NCT02618681||AMI with earlobe crease|To observe the prognosis for AMI with earlobe crease
62001444|NCT03658083||Robotic-assisted thoracic surgery|Individuals referred for a lung resection via robotic-assisted thoracic surgery with a primary or secondary diagnosis of lung cancer. Those with a tumor \>7cm will be excluded.
62570271|NCT03852472|EXPERIMENTAL|Placebo to Avacopan 10 mg|Treatment period 2, subjects randomized to placebo during period 1 were rerandomized 1:1 to receive 10 mg or 30 mg avacopan BID in period 2.
62570272|NCT03852472|EXPERIMENTAL|Placebo to Avacopan 30 mg|Treatment period 2, subjects randomized to placebo during period 1 were rerandomized 1:1 to receive 10 mg or 30 mg avacopan BID in period 2.
62776954|NCT06216548|EXPERIMENTAL|Early Enhanced Primary Care (E-PRIME) Group|Subjects of this arm will receive E-PRIME intervention at the start of enrollment.
62776955|NCT03866564||Multi-Afflicted|Participants with multiple self reported afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
62776956|NCT03866564||Un-Afflicted|Participants who report no afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
62001445|NCT01556542|ACTIVE_COMPARATOR|standard PTA|nitinol stent implantation
62001446|NCT01556542|EXPERIMENTAL|DEB|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
62776957|NCT03866564||Single Afflicted|Participants with one self reported afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
62776958|NCT06415773|EXPERIMENTAL|HTD1801|Administered orally twice daily (BID)
62776959|NCT06415773|ACTIVE_COMPARATOR|Dapagliflozin|Administered orally once daily (QD)
62776960|NCT03222947||Taybi-Linder index cases|Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
62776961|NCT03222947||Blood relatives of Taybi-Linder index cases|Blood relatives of Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
62776962|NCT01936415|EXPERIMENTAL|Regenerex|One of the two prosthesis investegated
62776963|NCT01936415|ACTIVE_COMPARATOR|Vanguard|
62001447|NCT04943965||Patient undergoing a cardiac surgery|Patients undergoing cardiac surgeries listed in inclusion criteria will be in this group.
62001448|NCT04943965||Clinicians|Clinicians defined as physicians (e.g. attendings, fellows, residents) or advanced practice providers (e.g. nurse practitioners and physician assistants) will be in this group.
62001449|NCT05300165|OTHER|Normal population|20 participants representing a normal population will include a daily beer in their meals, changing the kind of beer every 2 weeks from alcohol-free lager beer, lager beer, or dark beer.
62001450|NCT01400867|EXPERIMENTAL|Ceftaroline fosamil|
62001451|NCT01400867|ACTIVE_COMPARATOR|Comparators|Vancomycin +/- Aztreonam Cefazolin +/- Aztreonam
62001452|NCT04259112|EXPERIMENTAL|high pressure + deep block|Intra-abdominal pressure will be set to 12-15 mmHg during the surgery. Deep neuromuscular block will be induced by rocuronium bolus 1 mg/kg, maintained by a continuous infusion of rocuronium (0.6mg/kg/h), and titrated towards post-tetanic count (PTC) 1-2.
62186665|NCT03253432||Strata greater than or equal to 35|Highest probability of having familial hypercholesterolemia
62395146|NCT02618681||AMI without earlobe crease|To observe the prognosis for AMI without earlobe crease
62395147|NCT00133276|ACTIVE_COMPARATOR|1|
62395148|NCT00133276|PLACEBO_COMPARATOR|2|
62395149|NCT01970020|EXPERIMENTAL|JNJ-38518168|
62570273|NCT02909712|ACTIVE_COMPARATOR|sulfadoxine-pyrimethamine (SP)|"* Group 1 (50 CareStart™ RDT-positive women)~* Group 2 (50 CareStart™ RDT-negative women)~These 100 women will have an ECG exam, provide blood for microscopy and molecular analysis, and receive SP on day 0. On days 7, 14, 21, and 28 women will provide blood for microscopy and molecular analysis."
62570274|NCT02909712|EXPERIMENTAL|dihydroartemisinin-piperaquine (DHA-PQP)|"* Group 3 (50 CareStart™ RDT-positive women)~* Group 4 (50 CareStart™ RDT-negative women)~These 100 women will have an ECG exam, provide blood for microscopy, molecular, and PK analysis, and receive DHA-PQP day 0. On day 1, women will receive dose 2. On day 2, women will have an ECG exam, begin Holter monitoring, provide blood for PK analysis, and receive dose 3. Blood for PK analysis will be drawn at 4, 5, and 6 hours following dose 3. An ECG exam will be conducted during this period and, again, on day 7. On days 7, 14, 21, and 28, women will provide blood for microscopy and molecular analysis."
62570275|NCT06574646|EXPERIMENTAL|LAL+|
62776964|NCT02973516|EXPERIMENTAL|P03277 triphasic imaging|P03277 will be administered in order to acquire triphasic liver imaging
62776965|NCT06525233||Treatment|humans that diagnosed as coronary artery disease, joined two aerobic exercise groups. One of this group includes interval exercise and the other one includes continuous exercise.
62776966|NCT02328027|EXPERIMENTAL|99mTc-rhAnnexin V-128, i.v.|Patients will receive 2 administrations of the 99mTc-rhAnnexin V-128 medical imaging agent: one at Day 1 and the other at Day 42.
62776967|NCT01392209|EXPERIMENTAL|Bevacizumab & Stereotactic Radiotherapy|This will be a multicenter (MSKCC and UCSF) phase I dose escalation study to determine the maximum tolerated dose (MTD) of hypofractionated stereotactic radiotherapy when administered in combination with a fixed dose of bevacizumab.
62776968|NCT00875290|NO_INTERVENTION|Control|Observational arm
62776969|NCT00875290|EXPERIMENTAL|Real-time glucose sensor|Subjects wear real-time glucose sensor
62395150|NCT01084096|ACTIVE_COMPARATOR|Intervention|Eligible women at high risk for preterm birth will be identified and four 6 mg doses of dexamethasone will be administered before delivery.
62776970|NCT05698953|EXPERIMENTAL|Reiki Group|Reiki is applied to the Reiki group for 20-30 minutes for three consecutive days.
62001453|NCT04259112|EXPERIMENTAL|high pressure + moderate block|Intra-abdominal pressure will be set to 12-15 mmHg during the surgery. Moderate neuromuscular block will be induced by rocuronium bolus 0.6 mg/kg, maintained by a continuous infusion of rocuronium (0.3mg/kg/h), and titrated towards train-of-four (TOF) twitch 1-2.
62001454|NCT04259112|EXPERIMENTAL|low pressure + deep block|Intra-abdominal pressure will be set to 7-10 mmHg during the surgery. Deep neuromuscular block will be induced by rocuronium bolus 1 mg/kg, maintained by a continuous infusion of rocuronium (0.6mg/kg/h), and titrated towards PTC 1-2.
62001455|NCT04259112|EXPERIMENTAL|low pressure + moderate block|Intra-abdominal pressure will be set to 7-10 mmHg. Moderate neuromuscular block will be induced by rocuronium bolus 0.6 mg/kg, maintained by a continuous infusion of rocuronium (0.3mg/kg/h), and titrated towards TOF twitch 1-2.
62001456|NCT01551342||Cystoscopic surveillance, TURT or Cystectomy|The following subjects will be enrolled: Subjects previously diagnosed with bladder cancer undergoing routine cystoscopic surveillance, TURT or Cystectomy.
62001457|NCT01497210|EXPERIMENTAL|EASH|
62001458|NCT06408467|EXPERIMENTAL|The effect and monitoring of maintenance therapy for peri-implantitis|
62001459|NCT00882791||Historical Arm|266 cases of BCC treated with Mohs surgery approximately 2-5 years ago will be assessed for recurrence.
62395151|NCT01084096|NO_INTERVENTION|Control|Control arm will not receive a specific intervention for comparison.
62395152|NCT05962658||Fibromyalgia|Our sample consisted of 11 women with fibromyalgia enrolled according to the criteria of the American College of Rheumatology (ACR). Participants were underwent to clinical and electrophysiological assessments using the McGill Pain Questionnaire, the Hospital Anxiety and Depression Scale, and qEEG in frontal (F3, F4, Fz, F7, F8) and central (C3, C4,Cz) areas. qEEG data was collected with patients in resting eyes-closed: the relative spectral power of the frequency bands delta, theta, alpha and beta was evaluated.
62776971|NCT05698953|PLACEBO_COMPARATOR|Placebo Group|Placebo group is applied to the sham Reiki group for 20-30 minutes for three consecutive days Placebo Reiki group is applied to the sham Reiki by an independent nurse during the same application period.
62776972|NCT05698953|NO_INTERVENTION|Control Group|No intervention is made in the control group. Standard care was used
62776973|NCT03292276|EXPERIMENTAL|Amadeo training|All participants will receive 40 sessions of treatment (45-minute) for 8 consecutive weeks (5 days/week). The robotic exercises will be carried in passive modality (15 minutes), passive/plus (15 minutes), assisted modality (15 minutes).
62776974|NCT03292276|ACTIVE_COMPARATOR|occupational therapy|All participants will receive 40 sessions of treatment (45-minute) for 8 consecutive weeks (5 days/week). The control group will receive the same amount of training by physiotherapist skilled in occupational tharapy.
62776975|NCT02086422|ACTIVE_COMPARATOR|ivabradine|Exercise with ivabradine
62776976|NCT02086422|PLACEBO_COMPARATOR|Placebo|Exercise with placebo
62776977|NCT05375214|OTHER|Treatment Arm|Open label study, all participants will receive novel iTBS
62776978|NCT01659099|EXPERIMENTAL|GA101|GA101 - Chemotherapy (ACVBP or CHOP)
62776979|NCT01659099|ACTIVE_COMPARATOR|Rituximab|Rituximab - Chemotherapy (ACVBP or CHOP)
62001460|NCT00882791||Prospective Arm|300 cases of BCC will be followed annually for 3 years after Mohs surgery to assess for recurrence.
62001461|NCT03548766|EXPERIMENTAL|Healthy Subjects|Six healthy subjects will receive an ABT (Autologous Blood Transfusion)
62001462|NCT03548766|EXPERIMENTAL|Anemic Patients|Six patients with anemia will receive a HBT (Homologous Blood Transfusion)
62001463|NCT04198727|EXPERIMENTAL|DPD activity|
62001464|NCT04979585|EXPERIMENTAL|Experimental|Patients with untreated advanced mucosal melanoma
62776980|NCT03326622|EXPERIMENTAL|moderate exercise + standard care|This group performed a moderate exercise protocol with training zone determined by Cardiopulmonary Exercise testing added to standard care program based on American Academy of Neurology guidelines.
62776981|NCT03326622|ACTIVE_COMPARATOR|Standard care|This group performed a standard care program based on American Academy of Neurology guidelines, without exercise intensity control.
62776982|NCT05892640|EXPERIMENTAL|Low-Salt Diet|Low-salt diet (LS diet) according to DASH eating plan, with sodium intake of 1500 mg (3.75 g of salt), within the period of 14 days
62001465|NCT04603729|ACTIVE_COMPARATOR|group 1 dexamethasone|participants will receive dexamethasone 8mg/day Intravenous for 5 days
62001466|NCT04603729|ACTIVE_COMPARATOR|group 2 methylprednisolone|participants will receive methylprednisolone 1mg/kg/day intravenous for 5 days
62186666|NCT00002796|EXPERIMENTAL|Treatment (fluorouracil, phenylbutyrate, indomethacin, IFN-G|"Phase I: Patients receive 5-FU IV over 24 hours on day 1; phenylbutyrate IV over 120 hours and oral indomethacin daily on days 2-6; and interferon gamma subcutaneously on days 2, 4, and 6. Courses repeat weekly in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which less than 2 of 6 patients experience dose-limiting toxicity (DLT).~Phase II: Patients receive 5-FU, phenylbutyrate, indomethacin, and interferon gamma as in phase I at the MTD."
62186667|NCT03953456|EXPERIMENTAL|elafibranor 120mg followed by placebo|Participants will first receive elafibranor 120mg for 6 weeks. After a washout period of 4-6 weeks, they will then receive placebo for 6 weeks
62395153|NCT05962658||Healthy individuals|A control group was enrolled and data was collected from healthy subjects to confirm different patterns of cortical electrical activity in people with fibromyalgia. For that, self-declared healthy and pain-free individuals, matched by gender and age with the women with fibromyalgia included in the sample were recruited through advertising in digital media.
62395154|NCT02224495|PLACEBO_COMPARATOR|Control|Standard of care
62395155|NCT02224495|EXPERIMENTAL|Structured exercise training|8-week outpatient exercise-training program, encompassing 3 sessions per week, including endurance and resistance training
62570276|NCT06574646|ACTIVE_COMPARATOR|Clareon Vivity Toric IOLs|
62570277|NCT04915313|EXPERIMENTAL|Intervention group|Subjects in the intervention group will recieve remote ischemic conditioning (RIC) treatment twice a day for 4 weeks.
62570278|NCT04915313|SHAM_COMPARATOR|Sham control group|Subject in the sham control group will recieve sham remote ischemic conditioning (Sham-RIC) treatment twice a day for 4 weeks..
62570279|NCT02680808|EXPERIMENTAL|midazolam with F901318|Pharmacokinetic profile of midazolam 2 mg orally when given after dosing with F901318 to steady state.
62186668|NCT03953456|PLACEBO_COMPARATOR|placebo followed by elafibranor 120mg|Participants will first receive placebo for 6 weeks. After a washout period of 4-6 weeks, they will then receive elafibranor 120mg for 6 weeks
62395156|NCT05903976|EXPERIMENTAL|CLOPIDOGREL 75 mg qd|50 patients treated with clopidogrel 75mg
62395157|NCT05903976|EXPERIMENTAL|PRASUGREL 5mg qd|50 patients treated with prasugrel 5mg
62570280|NCT06174103|EXPERIMENTAL|BiVACOR TAH|The BiVACOR TAH System will be implanted as a bridge to transplant (BTT) for adults with severe irreversible biventricular heart failure or univentricular heart failure in which LVAD support is not recommended, and who are eligible for cardiac transplantation.
62001467|NCT02262351|EXPERIMENTAL|Screening|"Subjects will undergo three screening methods for atrial fibrillation:~30 Second Pulse Check Watch BP Home A HeartCheck Hand-held ECG device"
62001468|NCT06007014|EXPERIMENTAL|Intervention group|Metformin and insulin glargine combined with sitaglitat sodium tablets 48mg/ day group;
62001469|NCT06007014|PLACEBO_COMPARATOR|Placebo group|Metformin and insulin glargine combined with placebo group
62570281|NCT05655364|EXPERIMENTAL|Experimental|
62186669|NCT05270369|EXPERIMENTAL|digital cognitive behavioural therapy for insomnia (CBTI)|The digital CBTI group will receive 6-session on their smartphone application
62186670|NCT05270369|EXPERIMENTAL|group cognitive behavioural therapy for insomnia (CBTI)|The group CBTI will receive 6-session CBTI in group
62186671|NCT05270369|NO_INTERVENTION|waitlist|The waitlist group will receive treatment sessions after about 10 weeks' time
62186672|NCT02482532|EXPERIMENTAL|tvs-CTL Vaccine|Infusion of activated T-cells generated from a patient's own peripheral blood mononuclear cells.
62186673|NCT00817245|ACTIVE_COMPARATOR|1|Oral Amoxicillin Capsule Metronidazole Tablet Omeprazole Capsule
62186674|NCT00817245|NO_INTERVENTION|2|No medical treatment
62186675|NCT00133055|EXPERIMENTAL|Treatment booklet and telephone coaching|
62570282|NCT05655364|NO_INTERVENTION|No intervention|
62570283|NCT06577844|EXPERIMENTAL|experimental|
62570284|NCT06577844|NO_INTERVENTION|control|
62570285|NCT06578000|ACTIVE_COMPARATOR|group 1 ( Iontophoresis therapy (MgO4 will be applied to the active positive electrode))|Iontophoresis therapy (MgO4 will be applied to the active positive electrode and the treatment will be repeated twice a week for four weeks) + conventional therapy (Splint + Stretch + strength).
62570286|NCT06578000|SHAM_COMPARATOR|Control Group (2): conventional physical therapy treatment|conventional therapy (Splint + Stretch + strength) twice a week for six weeks
62570287|NCT02549404|EXPERIMENTAL|KHK7580|
62776983|NCT02113358|EXPERIMENTAL|Normovolemic group (keeping SVV<10% in supine; <15% in prone)|"1. The anesthesiologist will infuse Voluven (Fresenius Kabi, Bad Homburg, Germany) 250 ml if stroke volume variation is over 10% during the surgery to keep the normovolemia.~2. If total Voluven use is over 1500ml and then the anesthesiologist will infuse Saline 250 ml instead.~3. The maintenance of basal fluid, criteria to use inotropes (If cardiac index is below 2.5 l/min/m2 ) are the same standards in the both groups."
62776984|NCT02113358|ACTIVE_COMPARATOR|Restricitve group (keeping SVV < 18% in supine; <23% in prone)|"1. The anesthesiologist will infuse Voluven (Fresenius Kabi, Bad Homburg, Germany) 250 ml if stroke volume variation is over 18% during the surgery to keep the normovolemia.~2. If total Voluven use is over 1500ml and then the anesthesiologist will infuse Saline 250 ml instead.~3. The maintenance of basal fluid, criteria to use inotropes (If cardiac index is below 2.5 l/min/m2 ) are the same standards in the both groups."
62395158|NCT05903976|EXPERIMENTAL|TICAGRELOR 60mg bid|50 patients treated with ticagrelor 60mg bid
62570288|NCT02772926|PLACEBO_COMPARATOR|Placebo|450 g per pill, 2 pills per day to get 900 mg per day
62186676|NCT00133055|OTHER|Usual Care|
62186677|NCT03716388|EXPERIMENTAL|FMT Vs Placebo|Fecal microbiota transplantation (fresh sample, colonoscopic administration at weeks 0,2,6,10,14) plus placebo granules (4g/day)
62395159|NCT05903976|ACTIVE_COMPARATOR|Continue Potent P2Y12i Full-Dose|50 patients in the full-dose potent P2Y12 inhibitor (prasugrel 10 mg or ticagrelor 90 mg bid according to prior prescription)
62395160|NCT06193057|ACTIVE_COMPARATOR|Traditional|In the STANDARD group, patients will undergo a primary TAR by implanting a prosthetic model of a standard design, that is the same for all using the usual surgical technique and instrumentation (based on the use of external leg guidance)
62570289|NCT02772926|ACTIVE_COMPARATOR|Benfotiamine|Benfotiamine (S-Benzoylthiamine O-monophosphate) 450 mg per pill, 2 pills per day to get 900 mg per day
62570290|NCT01446861||Cystic fibrosis patients|Consecutive cystic fibrosis patients attending regular Controls at the CF clinic in Bergen
62001470|NCT04027218|ACTIVE_COMPARATOR|Current clinical practice-Dry heat|"The standardized and approved Clinical and Laboratory Standards Institute (CLSI) GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (dry heat) or 1 period (dry heat) and 2 period (current clinical practice)."
62001471|NCT04027218|ACTIVE_COMPARATOR|Current clinical practice- Hihg pressure|"The standardized and approved CLSI GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (high pressure) or 1 period (high pressure) and 2 period (current clinical practice)."
62001472|NCT04027218|ACTIVE_COMPARATOR|Current clinical practice-Combination|"The standardized and approved CLSI GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (combination of dry heat and high pressure) or 1 period (combination of dry heat and high pressure) and 2 period (current clinical practice)."
62186678|NCT03716388|ACTIVE_COMPARATOR|FMT Vs Mesalamine|Fecal microbiota transplantation (fresh sample, colonoscopic administration at weeks 0,2,6,10,14) plus mesalamine granules (4g/day)
62395161|NCT06193057|EXPERIMENTAL|Custom|In the PERSONALIZED group, patients will undergo a primary TAR by implanting a prosthetic model with a design specifically based on each patient's actual ankle morphology and using PSI surgical technique and instrumentation.
62395162|NCT03276858|EXPERIMENTAL|CRN00808 Oral Solution|CRN00808 oral solution, single-dose
62395163|NCT03276858|EXPERIMENTAL|CRN00808 Oral Capsule|CRN00808 oral capsule, single-dose and multiple-doses
62395164|NCT03276858|PLACEBO_COMPARATOR|Placebo Oral Solution|Placebo oral solution, single-dose
62395165|NCT03276858|PLACEBO_COMPARATOR|Placebo Oral Capsule|Placebo oral capsule, single-dose and multiple doses
62776985|NCT01656070|EXPERIMENTAL|Vitamin D|"oral cholecalciferol 1000000 UI (vitamin D3).~At 0, 3, 6 and 9 months, the vitamin D group received orally 100000 IU of cholecalciferol suspended in 2 mL of olive oil in sealed plastic syringes labeled with the unique identification numbers."
62776986|NCT01656070|PLACEBO_COMPARATOR|placebo|"placebo~At 0, 3, 6 and 9 months, the placebo group received 2 mL of olive oil, in sealed plastic syringes labeled with the unique identification numbers."
62776987|NCT03675984|EXPERIMENTAL|asymmetrical stabilization exercise group|'asymmetrical stabilization exercise' patient learn asymmetrical stabilization exercise according to the asymmetrical paraspinal muscles weakness and curve type
62776988|NCT03222024||Severe ischaemic stroke|patients with severe stroke on admission
62776989|NCT03222024||Malignant ischaemic stroke|patients without severe stroke on admission but developing it in hospital
62776990|NCT03222024||Mild to moderate ischaemic stroke|patients without severe stroke from onset to discharge
62776991|NCT04338737|ACTIVE_COMPARATOR|fluid and soft food|It consists of 100 patients that will be allocated for early post-operative oral feeding receiving water and clear fluid approximately 2 hours after surgery, followed by soft food and regular diet 4 hours later irrespective to intestinal sounds, flatus or stool.
62776992|NCT04338737|ACTIVE_COMPARATOR|fluid only|It consists of 100 patients that will be allocated for early Postoperative oral feeding receiving water and clear fluid approximately 2 hours after surgery till the return of intestinal sounds, then soft food and regular diet later on.
62776993|NCT04338737|ACTIVE_COMPARATOR|Npo|It consists of 100 patients that will receive no oral feeding till passage of flatus instead 2 to 3 Litres of intravenous fluid will be used for feeding. Water and fluid will be then offered, followed by soft foods and then a regular diet.
62776994|NCT01553643|EXPERIMENTAL|Chinese Herb Huang-Chi-Wu-Wu-Tang|
62776995|NCT01553643|PLACEBO_COMPARATOR|Placebo|
62776996|NCT05551507|EXPERIMENTAL|IN10018 in combination with PLD|IN10018 in combination with PLD in platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneum cancer with the subtype limited to high-grade serous carcinoma subjects.
62776997|NCT05137977||SIR|All adult intensive care patients. Data from the The Swedish intensive care registry
62776998|NCT04166539||Metallosis Patients|Patients who are being seen by surgeons for metal-related issues in the blood, pain, or revision surgery.
62776999|NCT04166539||Control Group|Patients who have had total hip or knee arthroplasty no less than 5-10 years ago, who have no symptoms.
62777000|NCT05750550|EXPERIMENTAL|Instrument Assisted Soft Tissue Mobilization Group|With the IASTM device, application will be made over the skin to the triceps surae muscle and plantar fascia for 15 minutes. The application will be made in the prone position. Massage oil will be used to reduce tissue friction before the application.
62186679|NCT03716388|ACTIVE_COMPARATOR|Placebo Infusion Vs Mesalamine|Placebo infusion (colonoscopic administration at weeks 0,2,6,10,14) plus mesalamine granules (4g/day)
62570291|NCT01446861||Healthy controls|Age and gender matchet healthy Controls recruited by Board notice and advertising.
62186680|NCT00766402|EXPERIMENTAL|Tramadol/Acetaminophen|Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
62186681|NCT00766402|ACTIVE_COMPARATOR|Diclofenac|Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
62395166|NCT03276858|OTHER|Midazolam Oral Solution|Midazolam oral solution, two single-doses as part of the drug-drug interaction arm of the study
62570292|NCT01512004|ACTIVE_COMPARATOR|Propiverine Hydrochloride Extended-Release Capsule|30 mg/capsule; oral; once per day
62186682|NCT02536495|EXPERIMENTAL|Treatment (docetaxel, selinexor)|Patients receive docetaxel IV on day 1 and selinexor PO BID on days 1, 3, 7, 9, 13, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62570293|NCT01512004|PLACEBO_COMPARATOR|Tolterodine Extended-release Tablet|4mg/tablet; oral; once per day
62777001|NCT01656668|EXPERIMENTAL|BC1036|BC1036 300 mg capsule capsule by mouth, twice daily, for 14 days.
62186683|NCT01356563|EXPERIMENTAL|clinical pharmacist intervention|
62186684|NCT01356563|NO_INTERVENTION|usual care|Patients randomized to usual care group will receive routine review of medication by outpatient department pharmacists and nurse.
62395167|NCT04001790|EXPERIMENTAL|Project Search + ASD Supports|Project SEARCH is an intensive 9-month job training program where youth with developmental disabilities in their last year of high school are embedded in a large community business such as a hospital, government complex, or banking center where they rotate through three 10-12 week internships within the business learning marketable skills, social communication, and adaptive behavior in the business setting. In order to meet the unique needs of youth with ASD, Wehman, et al. (2014) enhanced the Project SEARCH model by adding autism supports to the original model. Those added supports were: 1) on-site, intensive, systematic instruction using the principles of applied behavior analysis, 2) on-site support and consultation from a behavior/autism specialist, and 3) intensive staff training in ASD and the Project SEARCH Model.
62395168|NCT04001790|NO_INTERVENTION|Business as Usual|Business as Usual means these youth remain in their high school programs as determined on their individualized education plans
62584867|NCT03462394||Current Script Version|This arm will receive the version of the call script currently used as part of regular care at NYU Langone Health.
62584868|NCT03462394||Script Iterations|This arm will receive an iterated version of the script that might contain changes in wording or structure that are different from the current version of the script.
62777002|NCT01656668|PLACEBO_COMPARATOR|Sugar Pill|Sugar placebo capsule by mouth, twice daily, for 14 days.
62777003|NCT02854254|EXPERIMENTAL|PICC|peripherally inserted central catheter
62777004|NCT02854254|OTHER|Control|peripherally venous access
62777005|NCT05691010|EXPERIMENTAL|Participants with Endometrial Cancer|Participants have stage III endometrial cancer
62777006|NCT03335280||Positive for PTEN deletion|Confirmed by immunohistochemistry of tissue biopsy
62777007|NCT03335280||Negative for PTEN deletion|Confirmed by immunohistochemistry of tissue biopsy
62777008|NCT03511456||FLLDH-PELD|Extraforaminal LDH patients received PELD operation
62777009|NCT01243827|EXPERIMENTAL|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP \<140/90 mmHg.
62777010|NCT01243827|EXPERIMENTAL|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP \<140/90 mmHg.
62777011|NCT00809653|EXPERIMENTAL|Visit 1|2 hour walk in city centre location in Beijing China
62777012|NCT00809653|EXPERIMENTAL|Visit 2|2 hour walk in city centre location in Beijing China
62777013|NCT03485170|OTHER|PET|Hemophilia patients receive PET evaluation
62777014|NCT02643537||Luxation erecta|All patients with Inferior shoulder dislocation in fixed abduction, also known as luxatio erecta humeri (LEH)
62777015|NCT06527534|EXPERIMENTAL|Filgotinib|Filgotinib 200 mg qd
62777016|NCT06527534|ACTIVE_COMPARATOR|Adalimumab|Adalimumab 40 mg q2wk
62777017|NCT04758923|ACTIVE_COMPARATOR|Two-Stage|Two-stage approach The treatment process commenced with an intial treatment phase. This will be udertaken Under General anaesthesia and entailed ERCP and endoscopic sphincterectomy
62791708|NCT04381169|EXPERIMENTAL|Aggressive fluid resuscitation|"Lactated Ringer Solution 20 ml/kg bolus (administered over 2 hours) followed by an infusion of 3 ml/kg/h.~At 12(±4) hours:~A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped~Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours~Fluid resuscitation is maintained at least 48h, and then it can be stopped in case of tolerating oral feeding for at least 8 hours"
62186685|NCT03828188|EXPERIMENTAL|group A|"Red Ginseng Concentrated Powder in 12 weeks → rest in 4 weeks → Placebo 12 weeks.~* Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)~* Placebo: Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)"
62186686|NCT03828188|EXPERIMENTAL|group B|"Placebo 12 weeks→ rest in 4 weeks → Red Ginseng Concentrated Powder in 12 weeks.~* Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)~* Placebo: Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)"
62186687|NCT02188394|EXPERIMENTAL|Anesthetic blockades with bupivacaine|Patients will receive a bilateral greater occipital nerve blockade with bupivacaine 0,5%
62777018|NCT04758923|ACTIVE_COMPARATOR|Single stage|Single stage approach Under General anaesthesia a5 trocar method will be used to access the abdominal cavity. Aconventional approach to laparoscopic cholecystectomy will be first udertaken with dissection of calot's triangle. The cystic duct will be pulled laterally to facilitate exposure of the anterior wall of the CBD, and the CBD will be opened longitudinally for a distance of approximately 1 to 1.5 cm using laparoscopic scissors. A5 mm flexible choledoscope will be used to identify the cbd stone which will be removed by flushing with sterile saline, passing a stone basket or electrohydroulic lithotripsy as neccesary to clear the CBD. A T-tube will be inserted into the CBD via the choledochotomy which will be closed by interrupted resorbable sutures before completing the cholecystectomy.
62584869|NCT01961154|OTHER|Medication reduction|All participants undergo similar type of asthma medical reduction. Thus, there is only one arm.
62584870|NCT02419014|NO_INTERVENTION|Usual Care|Participants in this group will continue receiving their previously prescribed therapy during the 8 week data collection period.
62777019|NCT04189029||HFpEF patients|Heart failure patients (NYHA II-IV) with left ventricular ejection fraction ≥ 50%, 1000 patients anticipated among which up to 300 with extensive phenotyping
62777020|NCT04189029||HFrEF patients|Heart failure patients (NYHA II-IV) with left ventricular ejection fraction ≤ 40%, 1000 patients anticipated among which up to 100 with extensive phenotyping (age- and gender-matched on participating HFpEF patients)
62001473|NCT05845788||Erector Spina Plan Block Group (Group E)|Patients who underwent erector spina plane block before initiation of surgery after induction of anesthesia
62001474|NCT05845788||Posterior Quadratus Lumborum Block Group ( Group Q)|Patients who underwent posterior quadratus lumborum block block before initiation of surgery after induction of anesthesia
62001475|NCT01791361||Round 1|50 oncologists participate in Round 1. At least 3 medical records will be reviewed per oncologist
62186688|NCT02188394|PLACEBO_COMPARATOR|Isotonic saline injection|Patients will receive a bilateral occipital injection with isotonic saline
62186689|NCT01057251|EXPERIMENTAL|1|
62186690|NCT01057251|PLACEBO_COMPARATOR|2|
62186691|NCT02719756|EXPERIMENTAL|Metformin & Dapagliflozin|Metformin stable dose tablets and Dapagliflozin 10 mg tablets by mouths, once daily in morning for 3 months
62186692|NCT02719756|ACTIVE_COMPARATOR|Metformin up-titration|Metformin tablets up-titration by mouths, for 3 months
62186693|NCT05889845|EXPERIMENTAL|Candin treatment|Candida albicans Skin Test Antigen for Cellular Hypersensitivity will be administered as a 0.5 mL injection at the region of the interdigitated base of the treatment wart (epidermal/dermal junction) every 2 weeks for up to 10 injections
62186694|NCT05889845|PLACEBO_COMPARATOR|Placebo|Matching placebo (sterile saline) will be administered as a 0.5 mL injection at the region of the interdigitated base of the treatment wart (epidermal/dermal junction) every 2 weeks for up to 10 injections
62186695|NCT04692545||A|patients receiving immunonutrition supply
62186696|NCT04692545||B|patients receiving standard dietary advice
62186697|NCT03643757|ACTIVE_COMPARATOR|Thoracic Epidural Analgesia|Population to whom thoracic epidural analgesia with bupivacaine as a component of multimodal analgesia was administered.
62395169|NCT02140996|EXPERIMENTAL|Ad-sig-hMUC-1/ecdCD40L vector vaccine|Experimental: Ad-sig-hMUC-1/ecdCD40L vector vaccine This trial has six cohorts with 3 subjects planned for each cohort. Subjects in the 1st cohort will receive 1 dose of vaccine injection at the lowest planned dose of the vector, 1 x 10\^9 VP. If none of the patients in the 1st cohort experience Dose limiting toxicity (DLT), a 2nd cohort will receive 1 dose of 1x10\^10 VP. If none of the patients in the 2nd cohort experience DLT, the dose escalation will continue with the 3rd cohort receiving 1 doses of 5 x 10\^10 VP per injection. The patients in the 4th cohort will receive 1 injection of 1x10\^11 if no DLT occurs in the preceding cohort. Additional patients will be added to cohort 5 or 6 if DLTs are encountered in the first 3 patients tested in each of these cohorts.
62570294|NCT06272539|ACTIVE_COMPARATOR|Spinal Cord Stimulation|Spinal cord stimulation (SCS) involves an implantable pulse generator with the potential for enhanced therapeutic success through stimulation algorithms and parameters (28). Spinal cord stimulation (SCS) targeting distal areas, such as the dorsal root ganglion, may offer greater anatomical specificity in therapy. Subthreshold stimulation, utilizing high-frequency or burst energy delivery, has the potential to eliminate noxious and off-target paresthesiae. Recent studies have demonstrated that subthreshold stimulation at high frequencies and/or utilizing different stimulation paradigms can provide equal or even superior pain relief compared to standard SCS (29). The procedure entails the placement of two octapolar electrodes inserted through the epidural space, positioned beneath the dorsal area posterior to the spinal cord's posterior horn.
62777021|NCT04189029||Subjects apparently without heart failure|Subjects without history or signs of heart failure, up to 100 subjects anticipated with extensive phenotyping (age- and gender-matched on participating HFpEF patients)
62001476|NCT01791361||Round 2|50 oncologists will participate in Round 2. At least 3 medical records will be reviewed per oncologist. Round 2 will occur approximately 12 months after Round 1
62001477|NCT01791361||Round 3|50 oncologists will participate in Round 3. At least 3 medical records will be reviewed per oncologist. Round 3 will occur approximately 24 months after Round 1
62001478|NCT03254901||health care workers|health care workers in Assiut health directorate, Abutig central hospital, El-Quseya central hospital and Sahil selim central hospital in Assiut governorate .All of them will be screened for hepatitis C infection and interviewed about mode of transmission of infection
62001479|NCT05425290|EXPERIMENTAL|Intervention Arm|
62001480|NCT01782651||HER2+ metastatic breast cancer patients treated with lapatinib|HER2+ metastatic breast cancer patients treated with lapatinib plus capecitabine
62186698|NCT03643757|ACTIVE_COMPARATOR|Intravenous analgesia|Population to whom combined intravenous analgesia was administered.
62186699|NCT03745586|EXPERIMENTAL|All study participants|
62395170|NCT05846412|EXPERIMENTAL|Rhythm Control by Catheter Ablation:|Patients randomized to rhythm control with CA will undergo CA of AF.
62777022|NCT03720002|EXPERIMENTAL|Active treatment|Will receive HF2 add-on
62777023|NCT03720002|PLACEBO_COMPARATOR|Placebo|Will receive placebo
62777024|NCT03180970|EXPERIMENTAL|group 1|This group patients were given dosages of 1.2% Lugol's solution for chromoendoscopy.
62777025|NCT03180970|EXPERIMENTAL|group 2|This group patients were given dosages of 1.0% Lugol's solution for chromoendoscopy.
62777026|NCT03180970|EXPERIMENTAL|group 3|This group patients were given dosages of 0.8% Lugol's solution for chromoendoscopy.
62001481|NCT06492811|EXPERIMENTAL|GAT@F nanoenzyme hydrogel complex|The glucose oxidase (GOx) and catalase (CAT) cascade systems have been included in the therapeutic system of diabetic wounds,with GOx primarily consumes glucose to create H2O2, while CAT further catalyzes H2O2 to provide sufficient oxygen.Natural enzymes have excellent cascade catalytic efficiency as well as biocompatibility. Hydrogels have high water content and cargo loading efficiency, as well as superior biocompatibility, making them popular in wound healing applications.
62020999|NCT05688813|EXPERIMENTAL|Sacral erector spinae block|Following antiseptic preparation of block site linear ultrasound probe was placed longitudinally to midline just above the sacrum. After the median sacral crests and erector spinae were identified, a 22G, 50 mm block needle was advanced from the cranial to the caudal direction until it touched the top of the 4th median sacral crest with the in-plane technique. After hydrodissection was achieved with 1 ml of saline, 0.5 ml/kg of 0.25% bupivacaine was administered after negative aspiration.
62777027|NCT03180970|EXPERIMENTAL|group 4|This group patients were given dosages of 0.6% Lugol's solution for chromoendoscopy.
62777028|NCT03180970|EXPERIMENTAL|group 5|This group patients were given dosages of 0.4% Lugol's solution for chromoendoscopy.
62777029|NCT05954429|EXPERIMENTAL|Serplulimab+Fruquintinib|Participants will receive serplulimab 300 mg every 3 weeks (Q3W) concurrently with fruquintinib regimen: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks. Treatment repeats every 3 weeks until disease progression or intolerable toxicity.
62570295|NCT06272539|EXPERIMENTAL|Spinal Cord Stimulation+Exercise|The experimental group will perform a Lumbo-pelvic core stability training program combined with motor control exercises through specific therapeutic exercises of the lumbopelvic centre combined with neurostimulation treatment. The exercise will be adapted according to the phases based on the results already published, the following intervention plan has been designed. Additionally, in each of the phases, the exercises were designed, limiting the degree of flexion/extension and lumbar traction of the exercises. Two weekly sessions will be scheduled during 8 weeks with a total of 24 sessions, each one of 60 minutes of duration. A certified physiotherapist in exercised with at least 10 years of clinical practice has applied treatment.
62570296|NCT04874870|ACTIVE_COMPARATOR|No Splint Group|This group will receive Xiaflex injection only
62001482|NCT06492811|ACTIVE_COMPARATOR|Medical chitosan bio-gel dressing|"The medical device database of the National Medical Products Administration (NMPA) was searched and the Medical chitosan bio-gel dressing (6S YinYu)(20182640080) was selected.~The positive control product used in this trial is based on the following points:~1. The properties of the test products are similar, and both the test products and the control products are hydrogel dosage forms;~2. In terms of the duration of therapeutic effect, both the experimental product and the control product could achieve the maintenance of therapeutic effect;~3. The control product is widely used by clinicians at this stage, and its clinical efficacy is relatively confirmed, with good clinical effect and safety, and it is one of the treatment products recognized by the industry for wound repair."
62001483|NCT06492811|PLACEBO_COMPARATOR|Blank hydrogel dressing|Hydrogel dressings can maintain a moist environment at the wound site, which promotes cell migration and tissue regeneration, thus accelerating the healing process. Hydrogels have excellent absorption capabilities, helping to manage wound exudate and reduce the risk of infection by forming a physical barrier against bacteria and contaminants. Moreover, hydrogels are biocompatible and unlikely to cause allergic reactions or rejection. Their softness and flexibility enable them to conform to irregular wound surfaces, providing effective coverage and protection.
62001484|NCT06323642|EXPERIMENTAL|A|probiotic mixture will be given daily to patients probiotic mixture containing: Lactobacillus rhamnosus GG
62186700|NCT06266598|OTHER|obesity|"Children with obesity were recommended to have a diet appropriate for their age and gender and exercise at least 3 days a week for at least 60 minutes each time.~All obese children under the age of 14 were started on metformin treatment at 1000 mg (500 mgx2) per day, and children over this age were started on metformin treatment at the adult dose of 2000 mg (1000 mgx2) per day."
62570297|NCT04874870|ACTIVE_COMPARATOR|Splint Group|This group will receive Xiaflex injection and hand-based custom orthosis to maintain finger extension
62777030|NCT03746041|EXPERIMENTAL|abaloparatide and bevacizumab treatment|In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days. In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
62777031|NCT01640262||localized prostate cancer|Danish men with localized prostate cancer
62777032|NCT04473664|EXPERIMENTAL|Participants with Moderate Hepatic Impairment|Participants with moderate hepatic impairment as defined by NCI-ODWG criteria who received a single, oral dose of quizartinib 30 mg on Day 1.
62777033|NCT04473664|EXPERIMENTAL|Control Participants with Normal Hepatic Function|Healthy participants with normal hepatic function matched as a group by sex, age (±10 years), and weight (±20%) who received a single, oral dose of quizartinib 30 mg on Day 1.
62777034|NCT02335424|EXPERIMENTAL|Pembrolizumab|Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 2 years. Eligible participants who stopped the initial course of pembrolizumab due to complete response (CR) or completed initial course of pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator's discretion for up to an additional year.
62570298|NCT02550782|ACTIVE_COMPARATOR|perineural bupivacaine|"patient-controlled infraclavicular perineural bupivacaine~(1% bupivacaine (marcaine), 5 ml bolus dose, infusion rate of 5 ml / h, lockout time 1 hour)"
62186701|NCT00808145|EXPERIMENTAL|Gemcitabine/Cisiplatin/Sorafenib|All eligible patients will receive intravenous gemcitabine/cisplatin + daily oral sorafenib until disease progression occurs
62186702|NCT02420041|ACTIVE_COMPARATOR|Fluoroscopic Guidance|Patients referred to the Naval Medical Center-San Diego Pain Medicine Clinic. Need a history and physical showing objective findings of sacroiliac joint (SIJ) dysfunction. If the patient meets inclusion / exclusion criteria, they will be presented with the study. After accepting and being consented, they will then be scheduled. The day of the appointment they will be randomised to Group A or B. In Group A : Fluoroscopy will be used to Guide Needle Placement to inject Steroid into joint. Then complete the multidimensional pain inventory (MPI) and rate their pain on the NRS from 0-11. After procedure, they will rate their pain from 0-10 in the recovery area and then be discharged to home. They will complete an MPI, Patient Global Impression of Change (PGIC), numerical rating scale (NRS), and adverse events questionnaire 1-2 weeks post-procedure and 3 months post-procedure.
62186703|NCT02420041|EXPERIMENTAL|Ultrasound Guidance|Patients referred to the Naval Medical Center-San Diego Pain Medicine Clinic. Need a history and physical showing objective findings of SIJ dysfunction. If the patient meets inclusion / exclusion criteria, they will be presented with the study. After accepting and being consented, they will then be scheduled. The day of the appointment they will be randomised to Group A or B. In Group B Ultrasound will be used to Guide Needle Placement to inject steroid into joint. Then complete the MPI and rate their pain on the NRS from 0-11. After procedure, they will rate their pain from 0-10 in the recovery area and then be discharged to home. They will complete an MPI, Patient Global Impression of Change (PIGC), NRS, and adverse events questionnaire 1-2 weeks post-procedure and 3 months post-procedure.
62186704|NCT03932578|ACTIVE_COMPARATOR|Atropine group|Patients will receive IV study solution which is 2 ml saline 0.9% as a placebo + intrathecal study solution which is a premised solution of 2.5 ml of 0.5% hyperbaric bupivacaine, 25 μg fentanyl and 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
62186705|NCT03932578|ACTIVE_COMPARATOR|Metoclopramide group|Patients in will receive IV study solution which is metoclopramide 10 mg in 2 ml + intrathecal study solution which is a premised solution of 2.5 ml of 0.5% hyperbaric bupivacaine, 25 μg fentanyl and 100 μg of preservative-free saline 0.9% as a placebo
62186706|NCT01299142|EXPERIMENTAL|FGI-101-1A6|Intervention: Drug-FGI-101-1A6
62186707|NCT01299142|PLACEBO_COMPARATOR|Placebo|Intervention: Drug-Placebo
62186708|NCT06545578|EXPERIMENTAL|Group (A):|Group A received motor control exercises with low level laser therapy
62186709|NCT06545578|EXPERIMENTAL|Group (B):|Group B received motor control exercises with transcutaneous electrical nerve stimulation
62186710|NCT02491710|EXPERIMENTAL|Low-cost box trainer|Trainees in this arm will perform their basic laparoscopic skills training on a low-cost tablet-based box trainer.
62186711|NCT02491710|ACTIVE_COMPARATOR|Standard box trainer|Trainees in this arm will perform their basic laparoscopic skills training on a standard box trainer
62570299|NCT02550782|EXPERIMENTAL|perineural dexmedetomidine|"patient-controlled infraclavicular perineural dexmedetomidine~(1% bupivacaine + 200 mic / 100cc dexmedetomidine, 5 ml bolus dose, infusion rate of 5 ml / h, lockout time 1 hour)"
62001485|NCT06323642|PLACEBO_COMPARATOR|B|placebo mixture will be given to patients with pneumonia
62395171|NCT05846412|ACTIVE_COMPARATOR|M-TEER (Control):|Patients randomized to the M-TEER group will undergo M-TEER with the MitraClip or PASCAL device to reduce FMR severity.
62001486|NCT06054048|ACTIVE_COMPARATOR|Telemedicine|Those patients who received specialized outpatient palliative care plus telemedicine.
62570300|NCT06536361|EXPERIMENTAL|Virtual Reality-Based Learning Tool Group|At the beginning of the study, all participants will receive theoretical training. One week later, they will review the topic through thorax and lung physical examination videos. Two weeks after theoretical training, participants will undergo skills training in the simulation laboratory. At the semester's end, participants taking the final exam will be grouped based on gender and course success scores. Two weeks before the intervention, pre-reading materials and demonstration videos will be distributed. Knowledge and skill levels will be assessed seven days prior to the intervention. The experimental group will receive training using a VR-based learning tool. Final assessments will occur seven days post-intervention. Feedback on the VR tool from the experimental group will be collected using a student opinion form after the final skills assessment.
62001487|NCT06054048|NO_INTERVENTION|No telemedicine (Standard of Care)|Those patients who received standard specialized outpatient palliative care only.
62021000|NCT06216626|EXPERIMENTAL|Prebiotic fibre|The treatment group will consume 10g per day of a diverse prebiotic fibre supplement. Supplements are powdered and unflavoured, and given to the participants in 300g packets lasting for 30 days. A 10g scoop is included in each packet and participants are advised to consume one level scoop at any time of the day. Participants are provided with examples on how to consume the supplement (e.g., breakfast cereal, coffee, tea, water).
62777035|NCT04051502||Group 1|First group of 10 participants enrolled
62777036|NCT04051502||Group 2|Second group of 10 participants enrolled
62777037|NCT04051502||Group 3|Third group of 10 participants enrolled
62186712|NCT01473745|ACTIVE_COMPARATOR|modified alar base cinch suture|Before closure of the maxillary wound, an alar base cinch suture was performed with 3-O Nylon. The modified alar cinch suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
62186713|NCT01473745|PLACEBO_COMPARATOR|conventional alar base cinch suture|Before closure of the maxillary wound, an alar base cinch suture was performed with 3-O Nylon. The conventional alar base cinch suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
62186714|NCT05416411|NO_INTERVENTION|Usual Care|Patients who are candidates for thoracic resection surgeries will be advised to stay active and quit smoking.
62186715|NCT05416411|ACTIVE_COMPARATOR|Intervention group|Patients who are candidates for thoracic resection surgeries will be handed a flow resistive device that helps inspiratory muscle training (2\*30 repetitions a day for 7 days) and will be advised to walk 5000 steps a day.
62395172|NCT01617161|ACTIVE_COMPARATOR|PBT|Proton Beam Therapy
62395173|NCT01617161|ACTIVE_COMPARATOR|IMRT|Intensity Modulated Radiation Therapy
62395174|NCT04084860|EXPERIMENTAL|CI-581a + MET/MBRP|Administration of CI-581a during weeks 1 and 6 at 0.71 mg/kg in the context of a 12 wk outpatient treatment (behavioral treatment combination of MET/MBRP will be provided)
62570301|NCT06536361|ACTIVE_COMPARATOR|Traditional Small Group Training|At the beginning of the study, all participants will receive theoretical training. One week later, the topic will be reviewed through thorax and lung physical examination videos. Two weeks after the theoretical training, participants will undergo skills training in the simulation laboratory. At the end of the semester, participants will take a final exam and be assigned to research groups based on their gender and course success scores. Two weeks prior to the implementation, pre-reading materials and thorax and lung physical examination videos will be distributed. Knowledge and skill levels will be assessed seven days before the implementation. Students in the control group will receive training in small groups in the skills laboratory, using the thorax and lung physical examination skills control form. Following the training, all participants will practice on each other. Final knowledge and skills assessments will be conducted seven days after the intervention
62570302|NCT05014659|EXPERIMENTAL|Creatine monohydrate|Participants received 4 x 5g doses of creatine monohydrate (powdered form) for 5 days, followed by 1 x 5g doses of creatine monohydrate (powdered form) for 23 days.
62570303|NCT05014659|PLACEBO_COMPARATOR|Placebo|Participants received 4 x 5g doses of placebo (powdered Maltodextrin) for 5 days, followed by 1 x 5g doses of placebo (powdered Maltodextrin) for 23 days.
62570304|NCT05372835|EXPERIMENTAL|mouthwash|The 15 mL of commercially available La Chlogen mouthwash (Republic of China Patent No. M616466) was used for intervention to rinse in mouth for 5 minutes. The main ingredient in the mouthwash is low-concentration high-purity HOCl (100 ppm) solution.
62570305|NCT05372835|EXPERIMENTAL|mouthwash and periodontal flosser|The 15 ml of commercially available La Chlogen mouthwash (Republic of China Patent No. M616466) in conjunction with the La Chlogen periodontal flosser (Republic of China Patent No. M590033) were used for intervention in the mouth for 5 minutes. The main ingredient in the mouthwash is low-concentration high-purity HOCl (100 ppm) solution.
62021001|NCT06216626|ACTIVE_COMPARATOR|Control|Participants are provided with standard of care (dietary advice). Recommendations for diet and lifestyle advice are provided by a UK-registered GP, and follow the Heart UK's Healthy Eating Guidelines. These recommendations emphasise a Mediterranean diet, rich in fruit, vegetables, and healthy fats (omega-3 fatty acids), while reducing refined sugar, salt, processed foods, and alcohol intake. The Mediterranean diet is considered a gold-standard for participants with MetS and poor mental health.
62021002|NCT00902200|PLACEBO_COMPARATOR|Vehicle|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
62186716|NCT05082181|EXPERIMENTAL|Arm 1: UPLIFT (Using Practice and Learning to Increase Favorable Thoughts)|UPLIFT is a telephone-based depression self-management program for people with epilepsy.
62395175|NCT04084860|EXPERIMENTAL|CI-581a + Medication Management|Administration of CI-581a during weeks 1 and 6 at 0.71 mg/kg in the context of a 12 wk outpatient treatment ( no MET/MBRP sessions will be provided, only general check-ins and psychiatrist visits)
62395176|NCT04084860|ACTIVE_COMPARATOR|CI-581b + MET/MBRP|Administration of CI-581b during weeks 1 and 6 at 0.0125 mg/kg in the context of a 12 wk outpatient treatment (behavioral treatment combination of MET/MBRP will be provided)
62395177|NCT04084860|ACTIVE_COMPARATOR|CI-581b + Medication Management|Administration of CI-581b during weeks 1 and 6 at 0.0125 mg/kg in the context of a 12 wk outpatient treatment (no MET/MBRP sessions will be provided, only general check-ins and psychiatrist visits)
62395178|NCT05732324||IVUS PCI optimization group|"PCI will be optimized according to the IVUS. IVUS will be performed before PCI and will be used to select PCI strategy.~Operators will try to reach an optimal anatomical PCI result as assessed by IVUS aiming for the following criteria:~1. good stent apposition;~2. good stent expansion (minimal stent area (MSA) \>90% of distal reference lumen area and/or MSA ≥5.5mm2);~3. plaque burden 5mm proximal and distal to the stent \<50%);~4. no stent edge dissection.~After stent optimization an IVUS run will be performed. The IVUS run will be considered as final when further anatomical optimization will not be thought to be possible."
62395179|NCT05732324||Historical FFR PCI optimization group|The goal will be to achieve the optimal functional result, defined as an FFR post PCI ≥ 0.95. Further stented segment post-dilatation will be mandatory if FFR post PCI \< 0.95. In case of a clear evidence of significant atheroma proximal or distal to the stented segment, the operators will be encouraged to optimize the functional result further by implanting additional stents.
62570306|NCT05372835|PLACEBO_COMPARATOR|control|The pure water without HOCl chemical was applied in this intervention to rinse in mouth for 5 minutes.
62570307|NCT03809663|PLACEBO_COMPARATOR|Part A: Placebo|"Matching placebo administered via SC injection Q2W for a maximum of 52 weeks.~Participants defined as non-responders (those who do not achieve at least 50% improvement in EASI at Week 16 compared to baseline) will switch to receive tezepelumab 420 mg SC injection Q2W for the remainder of the study beginning with the Week 18 dose."
62570308|NCT03809663|EXPERIMENTAL|Part A: Tezepelumab 210 mg|"Tezepelumab 210 mg administered via SC injection once every 4 weeks (Q4W) from Week 4 for a maximum of 52 weeks.~All participants randomized to tezepelumab will receive 420 mg SC injection as their first dose. Participants will then receive a placebo at Week 2 to maintain blinding.~Participants defined as non-responders (those who do not achieve at least 50% improvement in EASI at Week 16 compared to baseline) will switch to receive tezepelumab 420 mg SC injection Q2W for the remainder of the study beginning with the Week 18 dose."
62021003|NCT00902200|EXPERIMENTAL|AR-12286 0.05%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
62021004|NCT00902200|EXPERIMENTAL|AR-12286 0.1%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
62186717|NCT05082181|ACTIVE_COMPARATOR|Arm 2: BOOST (Bringing Out Our Strength Together)|BOOST is a telephone-based support program for people with epilepsy.
62395180|NCT02778477|EXPERIMENTAL|Part A_Cohort 1_Active|Multiple ascending dose of PF-06423264
62186718|NCT02418715|EXPERIMENTAL|Water Aerobics Training|The training period was composed by a 12-week macrocycle with two sessions per week. The macrocycle was divided into three four-week mesocycles that were, in turn, divided into four one-week microcycles composed by two training sessions. Each training session took 45 min. Nine different water-aerobics exercises were used during the training period. These exercises were performed alternating the right and left limbs. Exercise intensities were controlled using the Borg Scale. Interval training was used alternating intensities ranged between 9 (easy) and 15 (hard). During the first mesocycle, participants performed sets of 3min at intensity 13 interspersed by 2min at intensity 9; during the second mesocycle, sets of 3min at intensity 15 followed by 2min at intensity 9 were performed; finally, sessions of the third mesocycle were composed by sets of 3min at intensity 15 followed by 2min at intensity 11.
62186719|NCT02418715|NO_INTERVENTION|Control|No training, no intervention.
62186720|NCT02787811|ACTIVE_COMPARATOR|Pregnant|women with positive serum beta HCG done 14 days after Intrauterine insemenation
62570309|NCT03809663|EXPERIMENTAL|Part A: Tezepelumab 280 mg|"Tezepelumab 280 mg administered via SC injection Q2W from Week 2 for a maximum of 52 weeks.~All participants randomized to tezepelumab will receive 420 mg SC injection as their first dose. Participants will then receive their randomized dose of 280 mg Q2W from Week 2.~Participants defined as non-responders (those who did not achieve at least 50% improvement in EASI at Week 16 compared to baseline) will switch to receive tezepelumab 420 mg SC injection Q2W for the remainder of the study beginning with the Week 18 dose."
62570310|NCT03809663|EXPERIMENTAL|Part A: Tezepelumab 420 mg|Tezepelumab 420 mg administered via SC injection Q2W for a maximum of 52 weeks.
62570311|NCT03809663|EXPERIMENTAL|Part B: Placebo and Topical Corticosteroids Regimen|Matching placebo administered via SC injection Q2W with topical corticosteroids (TCS) for a maximum of 52 weeks.
62570312|NCT03809663|EXPERIMENTAL|Part B: Tezepelumab 420 mg and Topical Corticosteroids Regimen|Tezepelumab 420 mg administered via SC injection Q2W with TCS for a maximum of 52 weeks.
62570313|NCT04509336|EXPERIMENTAL|orphenadrine group|orphenadrine
62570314|NCT04509336|ACTIVE_COMPARATOR|Baclofen group|Baclofen
62021005|NCT00902200|EXPERIMENTAL|AR-12286 0.25%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
62021006|NCT05027217||Standard ICU Arm (Main study)|We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU prior to the COVID-19 surge in the country, who are invasively mechanically ventilated for more than 12 hours. We will include medical, surgical, trauma and neurological/neurosurgical patients who are COVID-19 negative.
62186721|NCT02787811|ACTIVE_COMPARATOR|Nonpregnant|women with negative serum beta HCG done 14 days after Intrauterine insemenation
62186722|NCT04965753|EXPERIMENTAL|FHD-609|Up to approximately 104 patients will be enrolled in dose escalation and expansion.
62186723|NCT03569475|EXPERIMENTAL|Levomilnacipran ER 40-80 mg/day|Levomilnacipran extended release (ER) capsules, orally, 10 milligram per day (mg/day) on Days 1 to 3, 20 mg/day on Days 4 to 7, and 40 mg/day from Week 2 through Week 8 of the Double-blind Treatment Period followed by levomilnacipran ER 40 mg/day on Days 1 and 2, and then 20 mg/day from Day 3 through Day 7 in the Down-taper Period. Based on therapeutic response and tolerability, an additional dose increase to 80 mg/day was permitted at Week 3 of the Double-blind Treatment Period.
62186724|NCT03569475|ACTIVE_COMPARATOR|Fluoxetine 20 mg/day|Fluoxetine capsule, orally, 10 mg/day at Week 1, and 20 mg/day from Week 2 through Week 8 of the Double-blind Treatment Period followed by fluoxetine 10 mg/day from Day 1 through Day 7 of the Down-taper Period.
62186725|NCT03569475|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules once daily through 8 weeks in the Double-blind Treatment Period and Days 1 through 7 in the Down-taper Period.
62186726|NCT04212754||Procedure: Emergency surgery for traumatic brain injury|
62570315|NCT00602459|ACTIVE_COMPARATOR|Arm A (rituximab, fludarabine phosphate)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: Patients receive rituximab IV over 1-4 hours on days 1 (50 mg/m\^2), 3 (325 mg/m\^2), and 5 (375 mg/m\^2) of course 1 and on day 1 (375 mg/m\^2) of all subsequent courses. Patients also receive fludarabine phosphate 25 mg/m\^2/day IV over 30 minutes or PO on days 1-5.
62570316|NCT00602459|EXPERIMENTAL|Arm B (rituximab, fludarabine phosphate, lenalidomide)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: rituximab IV over 1-4 hours on days 1 (50 mg/m\^2), 3 (325 mg/m\^2), and 5 (375 mg/m\^2) of course 1 and on day 1 (375 mg/m\^2) of all subsequent courses. Patients also receive fludarabine phosphate 25 mg/m\^2/day IV over 30 minutes or PO on days 1-5. Participants without progression receive consolidation therapy lenalidomide 5mg/day cycle 1, 10 mg/day cycles 2-6 PO QD on days 1-21 of 28 day cycle.
62570317|NCT00602459|EXPERIMENTAL|Arm C (rituximab, fludarabine phosphate, cyclophosphamide)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: rituximab IV over 4 hours on days 1 (50mg/m\^2) and 3 (325 mg/m\^2) of course 1 and on day 1 (500 mg/m\^2) of all subsequent courses. Patients then receive fludarabine phosphate (age \< 70: 25 mg/m\^2/day; age \>= 70: 20 mg/m\^2/day) IV piggyback over 30 minutes or PO (32 mg/m\^2/day) followed by cyclophosphamide (age \< 70: 250 mg/m\^2/day; age \>= 70: 150 mg/m\^2/day) IV piggyback over 30 minutes on days 1-3.
62570318|NCT00602459|EXPERIMENTAL|Arm D (rituximab, fludarabine, cyclophosphamide, lenalidomide)|Patients receive the first course of induction therapy as in Arm A or B before being re-assigned to Arm D. Beginning in course 2, patients receive rituximab IV (500 mg/m\^2) on day 1 and fludarabine phosphate (age \< 70: 25 mg/m\^2/day; age \>= 70: 20 mg/m\^2/day) IV piggyback over 30 minutes or PO (32 mg/m\^2/day) and cyclophosphamide IV (age \< 70: 250 mg/m\^2/day; age \>= 70: 150 mg/m\^2/day) piggyback over 30 minutes on days 1-3. Participants without progression receive consolidation therapy: lenalidomide 5mg/day cycle 1, 10 mg/day cycles 2-6PO QD on days 1-21 of 28 day cycle.
62395181|NCT02778477|PLACEBO_COMPARATOR|Part A_Cohort 1_Placebo|Multiple dose of placebo
62570319|NCT06368466|EXPERIMENTAL|iStatis Performance|capillary (fingerstick) blood, EDTA venous whole blood, serum and plasma samples will be tested on iStatis HBsAg Test
62570320|NCT06368466|NO_INTERVENTION|Reference Test to evaluate iStatis Performance|Either serum or plasma samples will undergo reference lab testing using DiaSorin Liaison XL Murex HBsAg Quant Assay and DiaSorin Murex HBsAg Confirmatory assay
62001488|NCT06306443|EXPERIMENTAL|extended-release buprenorphine (XR-B)|Participants will receive sublingual (sl; taken under the tongue) buprenorphine/naloxone doses of 2 mg for two days followed by 4mg for 2 days. The speed of induction will be based on their response to sl buprenorphine/naloxone. If they tolerate sl buprenorphine, on day 4 they will be administered an 8 mg dose of BRIXADI on day 5 (if they do not tolerate sl buprenorphine/naloxone we will extend sl dosing). During week two of dosing, they will receive 16 mg dose of BRIXADI will be given, based on the participant's response to the previous dose. During week three of dosing, they will receive a 24 mg dose of BRIXADI. During week four they will be administered a monthly dose of 64mg, 96mg, or 128mg. In all cases, the dose selected will be based on their response to the previous weeks' dose. We will endeavor to get you on the 96 mg or 128 mg monthly dose as there is a lack of opioid blockade data for the 64 mg monthly dose.
62001489|NCT06306443|ACTIVE_COMPARATOR|sublingual buprenorphine (SL-B)|Participants will receive sublingual (sl; taken under the tongue) buprenorphine/naloxone doses of 2 mg for two days followed by 4mg for 2 days. The speed of induction will be based on their response to sl buprenorphine/naloxone.
62001490|NCT00949624|EXPERIMENTAL|Cohort 1|60 mg BID/ 75 mg/m2
62001491|NCT00949624|EXPERIMENTAL|Cohort 2|100 mg BID/75 mg/m2
62777038|NCT04051502||Group 4|Fourth group of 10 participants enrolled
62777039|NCT04217213|EXPERIMENTAL|ropivacaine combined with mecobalamine|Intercostal nerve block with 0.5% ropivacaine combined with mecobalamine (0.5mg).
62777040|NCT04217213|ACTIVE_COMPARATOR|ropivacaine|Intercostal nerve block with 0.5% ropivacaine alone.
62001492|NCT00949624|EXPERIMENTAL|Cohort 3|100 mg BID/100 mg/m2
62001493|NCT00949624|EXPERIMENTAL|Cohort 4b|CP-868,596 + AG-013736 + TXT 75
62001494|NCT03077503|EXPERIMENTAL|Dexmedetomidine (Group A)|In induction period, group A received dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline 10 minute through a syringe pump. Three minutes before application of skull pins, group A received infusion of 2 ml of 0.9% normal saline.
62186727|NCT04502290|EXPERIMENTAL|Combined non-invasive brain and Functional Electrical Stimulation|In this arm of the study participants will receive repeated non-invasive brain stimulation synchronously paired with FES
62186728|NCT05917860|EXPERIMENTAL|3-month neoadjuvant Degarelix followed by whole-gland MRI-guided transurethral ultrasound ablation|After three months of neoadjuvant ADT with Degarelix, the subject will undergo whole-prostate gland MRI-guided transurethral ultrasound ablation (TULSA) (TULSA-PRO, Profound Medical Inc., Toronto, Canada) treatment.
62001495|NCT03077503|ACTIVE_COMPARATOR|Fentanyl (group B)|In induction period, group B received 20ml of 0.9% normal saline.Three minutes before application of skull pins, group B received infusion of fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline
62001496|NCT00980551|EXPERIMENTAL|Topotecan/Vincristine with subtenon Carboplatin|
62186729|NCT05691972|EXPERIMENTAL|Treatment|
62186730|NCT05691972|NO_INTERVENTION|Control|
62001497|NCT02673775|PLACEBO_COMPARATOR|Clean Air|Subjects will be exposed to clean air for 3 hours.
62001498|NCT02673775|EXPERIMENTAL|Ozone|Subjects will be exposed to 0.2 ppm ozone for 3 hours.
62001499|NCT03707769|EXPERIMENTAL|Fistula treatment|Treatment of fistula with TIPS microspheres
62001500|NCT02738684||lung cancer|A small sample exploratory study to predict gefitinib' s efficacy for late stage lung adenocarcinoma patients by plasma free nucleic acids EGFR gene mutation test
62001501|NCT04218058|ACTIVE_COMPARATOR|study (ultrasound guided closed reduction of zygomatic arch))|reduction of zygomatic arch guided by ultrasound
62001502|NCT04218058|ACTIVE_COMPARATOR|control (open reduction of zygomatic arch)|open reduction of zygomatic arch through coronal incision
62001503|NCT04070300|EXPERIMENTAL|Interval training group|Aerobic interval training during 12 weeks 3 times a week.
62001504|NCT04070300|NO_INTERVENTION|Control group|No lifestyle recommendations. Usual daily life.
62001505|NCT01339975||Group A. Surgically treated patients|Patients having a radical or partial nephrectomy.
62001506|NCT01339975||Group B. Patients treated with targeted therapies|Patients treated by RCC-directed targeted therapy
62001507|NCT05097131||All Participants|Participants who have been prescribed with aducanumab-avwa in the post-marketing setting according to standard care of practice will be enrolled.
62001508|NCT02462577|ACTIVE_COMPARATOR|local instillation of morphine 5 mg|5 ml plain bupivacaine 0.5% and 5 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
62001509|NCT02462577|ACTIVE_COMPARATOR|local instillation of morphine 10 mg|5 ml plain bupivacaine 0.5% and 10 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
62001510|NCT02462577|ACTIVE_COMPARATOR|local instillation of morphine 15 mg|5 ml plain bupivacaine 0.5% and 15 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
62001511|NCT02462577|PLACEBO_COMPARATOR|local instillation of local anesthetics|5 ml plain bupivacaine 0.5% .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
62001512|NCT02969928|ACTIVE_COMPARATOR|Amoxicillin and Metronidazole|In this group (n = 23), patients will take Amoxicillin 500 mg tid for 7 days and Metronidazole 400 mg tid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
62001513|NCT02969928|EXPERIMENTAL|Clarithromycin|In this group (n = 23), patients will take Clarithromycin 500 mg bid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
62001514|NCT02410720|ACTIVE_COMPARATOR|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
62001515|NCT02410720|EXPERIMENTAL|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
62001516|NCT01109082||Adolescents with idiopathic scoliosis|Adolescents with idiopathic scoliosis
62001517|NCT01133691||healthy children aged 6 - 12 years|
62570321|NCT05636696|EXPERIMENTAL|couple eMBCT|The couple eMBCT has nine sessions, takes 15-20 weeks, can be followed from home and will be supervised remotely by a trained therapist. Consistent with the original (patient-only) eMBCT, the couple eMBCT aims to change the patient's behavioral and cognitive reactions to fatigue and other cancer-related stressors. Couple eMBCT includes information for partners each session, the possibility for partners to perform exercises and one session specifically dedicated to the couple's mutual relationship and mindful communication about CCRF. Couples can determine themselves to which degree the partner is involved in the therapy.
62570322|NCT03495531|NO_INTERVENTION|Standard of Care|Standard of Care
62570323|NCT03495531|EXPERIMENTAL|VR Use|Obstetrics patients who use virtual reality
62001518|NCT03219060|EXPERIMENTAL|Intervention group|MI based four individual sessions
62001519|NCT03219060|ACTIVE_COMPARATOR|Control group|Brief advice following 5As
62001520|NCT04528446||BoneGN participants|Participants who have already been recruited into the CureGN study, or meet its criteria.
62570324|NCT04367545|EXPERIMENTAL|Patient with COVID-19 infection suspicion|Patient with COVID-19 infection suspicion are tested using standard diagnosis method
62001521|NCT03458130|ACTIVE_COMPARATOR|AG10 Low Dose|AG10 400mg tablets twice daily for 28 days
62186731|NCT06242704|EXPERIMENTAL|Working Memory Training|The intervention is a computer-based training aimed at improving working memory in order to decrease delay discounting. Active training sessions include: Sequenced Recall of Digits - Auditory, Sequenced Reverse Recall of Digits - Auditory, Sequenced Recall of Digits - Visual, Sequenced Reverse Recall of Digits - Visual, Sequenced Recall of Words - Auditory, Sequenced Recall of Words - Visual, Sequenced Reverse Recall of Words - Auditory, Sequenced Reverse Recall of Words - Visual. Participants will complete at least 10 sessions with each session taking approximately 30 minutes to complete.
62395182|NCT02778477|EXPERIMENTAL|Part A_Cohort 2_Active|Multiple ascending dose of PF-06423264
62570325|NCT01003860||0.5% Ropivicaine (150 mg)|
62570326|NCT01003860||0.75% Ropivicaine (225 mg)|
62570327|NCT06150066||Smokers with peri-implantitis|24 patients with smokers with peri-implantitis were included in this group.
62001522|NCT03458130|ACTIVE_COMPARATOR|AG10 High Dose|AG10 800mg tablets twice daily for 28 days
62001523|NCT03458130|PLACEBO_COMPARATOR|Placebo|Placebo tablets twice daily for 28 days
62001524|NCT02941679|EXPERIMENTAL|HCP1202|Test
62395183|NCT02778477|PLACEBO_COMPARATOR|Part A_Cohort 2_Placebo|Multiple dose of placebo
62570328|NCT06150066||Non-smoker individuals with peri-implantitis|24 patients with non-smokers with peri-implantitis were included in this group.
62570329|NCT06150066||Smokers with healthy peri-implant tissues|24 patients with smokers with healthy peri-implant tissues were included in this group.
62570330|NCT06150066||Non-smoker individuals with healthy peri-implant tissues|24 patients with non-smokers with healthy peri-implant tissues were included in this group.
62001525|NCT02941679|ACTIVE_COMPARATOR|HGP1011|Control
62001526|NCT02941679|ACTIVE_COMPARATOR|HCP0910|Control
62001527|NCT04230148|EXPERIMENTAL|Egaten|All subjects will receive Egaten as two 10 mg/kg doses given 12 hours apart.
62001528|NCT03470337|EXPERIMENTAL|Phlogenzym|Treatment with German licensed drug Phlogenzym (6 tablets/day)
62001529|NCT03470337|PLACEBO_COMPARATOR|Placebo|Placebo equates Phlogenzym but without active ingredients
62001530|NCT01899599|EXPERIMENTAL|PankoMab-GEX|1700mg, i.v., q3w
62001531|NCT01899599|PLACEBO_COMPARATOR|Placebo|matching placebo
62001532|NCT01530126|ACTIVE_COMPARATOR|B-TCP +buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed in sodium acetate buffer only.
62001533|NCT01530126|EXPERIMENTAL|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 0.3 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.
62777041|NCT06236490||Study Particpants - Speedskating Athletes|All the study participants were members of the Polish National Development Team or Polish National Elite Team in either long-track or short-track speedskating. Inclusion criteria were as follows: a valid medical certificate for competitive speedskating, a minimum of six years of training, and no prior exposure to respiratory or respiratory muscle training. Exclusion criteria were as follows: any chronic medical conditions, recent acute medical conditions within the last 4 weeks, COVID-19 infection within the last 6 months, recent stay in an altitude over 1500 meters above sea level within the last 4 weeks, and the use of any ongoing medications.
62791709|NCT04381169|EXPERIMENTAL|Moderate fluid resuscitation|"At recruitment:~A) Hypovolemia: Lactated Ringer Solution 10 ml/kg bolus (administered over 2 hours) followed by an infusion of 1.5 ml/kg/h.~B) No hypovolemia: infusion of lactated Ringer Solution of 1.5 ml/kg/h (no bolus).~At 12(±4) hours:~A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped~Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours~Fluid resuscitation can be stopped before the first 48h in case of tolerating oral feeding for at least 8 hours"
62001534|NCT01530126|EXPERIMENTAL|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 1.0 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.
62001535|NCT01787084||Inoperable Patients Alternative Access|Non-femoral delivery (or alternative access) in patients iwht severe symptomatic native aortic valve stenosis who have been determined by a cardiac surgeon to be inoperable for open aortic valve replacement and in whom existing co-morbidities would not preclude the expected benefit from correction of the aortic stenosis
62395184|NCT02778477|EXPERIMENTAL|Part A_Cohort 3_Active|Multiple ascending dose of PF-06423264
62001536|NCT05856838|EXPERIMENTAL|NovaSure ablation|
62186732|NCT06242704|ACTIVE_COMPARATOR|Working Memory|The comparison control condition is a multi-session control computer training condition that is designed to not engage working memory during computer-based engagement sessions: Sequenced Recall of Digits - Auditory, Sequenced Reverse Recall of Digits - Auditory, Sequenced Recall of Digits - Visual, Sequenced Reverse Recall of Digits - Visual, Sequenced Recall of Words - Auditory, Sequenced Recall of Words - Visual, Sequenced Reverse Recall of Words - Auditory, Sequenced Reverse Recall of Words - Visual. Participants will complete at least 10 sessions with each session taking approximately 30 minutes to complete.
62791710|NCT01659229||PFC CR 150 total knee implant|Study group implant: PFC CR 150 Control group implant: PFC CR standard
62791711|NCT01659229||PFC CR Standard|study group implant: PFC CR 150 control group implant: PFC CR Standard
62186733|NCT05810805||Control group|
62791712|NCT00878748|EXPERIMENTAL|A|Effexor XR
62001537|NCT02377089|SHAM_COMPARATOR|Sham|The stimulators are the same device for the active and sham treatment conditions.
62186734|NCT05810805||Imflammtory bowel disease group|
62186735|NCT05810805||Irritable bowel syndrome group|
62395185|NCT02778477|PLACEBO_COMPARATOR|Part A_Cohort 3_Placebo|Multiple dose of placebo
62001538|NCT02377089|ACTIVE_COMPARATOR|Active|The stimulators are the same device for the active and sham treatment conditions.
62001539|NCT02131480|EXPERIMENTAL|Soft tissue|
62001540|NCT02131480|EXPERIMENTAL|Uterus|
62001541|NCT03941535|EXPERIMENTAL|Decreasing Daily Dose of Vitamin K|"This group of patients will receive a decreasing dose of Vitamin K IV:~Days 1-2 = 10mg/day (standard of care) Days 3-4 = 5mg/day Days 5-90 (or date of discharge, death, etc) = 2mg/day"
62001542|NCT03941535|ACTIVE_COMPARATOR|Standard of Care Dose of Vitamin K|This group of patients will be reviewed retrospectively and would have received Vitamin K IV at 10mg/day during their entire hospital course
62001543|NCT03357458|EXPERIMENTAL|Family Integrated Care|Study participants receive FICare, a dynamic psycho-educational intervention, while their infant(s) was/were admitted to a Level II NICU.
62186736|NCT05810805||Colorectal neoplasms group|
62186737|NCT05810805||Helicobacter pylori infection group|
62186738|NCT05810805||functional dyspepia group|
62186739|NCT02718547|EXPERIMENTAL|Participants receiving Combigan drops in order to reduce IOP|All of the Participants in this study will be instructed to instill combigan eye drops twice daily in one eye (randomly chosen)
62395186|NCT02778477|EXPERIMENTAL|Part A_Cohort 4_Active|Multiple ascending dose of PF-06423264
62395187|NCT02778477|PLACEBO_COMPARATOR|Part A_Cohort 4_Placebo|Multiple dose of placebo
62395188|NCT02778477|EXPERIMENTAL|Part A_Cohort 5_Active|Multiple ascending dose of PF-06423264
62395189|NCT02778477|PLACEBO_COMPARATOR|Part A_Cohort 5_Placebo|Multiple dose of placebo
62001544|NCT03357458|NO_INTERVENTION|FICare Control Group|Study participants received standard care while their infant(s) was/were admitted to a Level II NICU.
62001545|NCT01743261|ACTIVE_COMPARATOR|usual care|In this arm patients were managed according to the organization of the management model which took on the care of the patient. The organization of these models is characterized by one or two professional figures (physiatrists, neurologist), with hierarchical relationships, in spaces limited to a specific pathology; access is determined by clinical stability; the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas; the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty.
62001546|NCT01743261|EXPERIMENTAL|Graded intensive rehabilitation|"Instruments of governance are the diagnostic-therapeutic rehabilitation. pathways (DTRP), the Quality system and product standards.~Medical care process with result-oriented autonomy. Technology support of vital signs. Multidisciplinary intervention"
62395190|NCT02778477|EXPERIMENTAL|Part A_Cohort 6_Active|Multiple ascending dose of PF-06423264
62777042|NCT01839136|EXPERIMENTAL|Intrauterine transfer of gametes|After the oocyte retrieval, the oocytes will be selected depending on the morphology of the granular cells. The transfer will be conducted in up to 2 hours after the oocytes collection, when the semen and up to 3 oocytes will be transferred. Surplus oocytes will be cryopreserved for future use. We will use a Sydney catheter (Cook Medical Inc., Bloomington, IN, USA) coupled to a 1 mL syringe to perform the transfer. The catheter will be loaded with oocytes and semen prepared in the following sequence: 10 µL of the prepared semen, a small space of air, 20 µL of the medium containing the oocytes, another small space of air and more 10 µL of prepared semen. The catheter will be placed through the endocervical canal up to the endometrial cavity guided by transabdominal ultrasound, where the liquid will be released. We will try to place the point of the catheter 1.0-1.5cm before touching the fundus of the endometrial cavity and release the liquid slowly, in approximately 30 seconds.
62777043|NCT01839136|ACTIVE_COMPARATOR|intrauterine transfer of embryos|The oocytes will be denuded and those considered to be mature will be selected for fertilization up to the number of seven. In vitro fertilization will be performed and up to two embryos will be transferred 2-3 days after the oocyte retrieval. The other embryos will be cryopreserved for future use. We will use Sidney catheter (Cook Medical Inc.) coupled to a 1 mL syringe to perform the transfer. The catheter will be loaded with embryos in the following sequence: 10 µL of culture medium, a small space of air, 20 µL of the medium containing embryos, another small space of air, and more 10 µL of culture medium. The catheter will be placed through the endocervical canal up to the endometrial cavity, guided by transabdominal ultrasound, where the liquid will be released. We will try to place the point of the catheter 1.0-1.5cm before touching the fundus of the endometrial cavity and release the liquid slowly, in approximately 30 seconds.
62777044|NCT02002520||case group|patients undergo third molar surgery
62777045|NCT02002520||control group|subjects do not require surgery
62777046|NCT00435084|EXPERIMENTAL|Single-arm mono therapy|APO866 will be administered by civ infusion at 0.126 mg/m2/hr for 4 consecutive days (96 hours). This constitutes 1 cycle.
62777047|NCT04577482||Participants treated with Glecaprevir/Pibrentasvir|Participants will receive glecaprevir/pibrentasvir (GLE/PIB) as prescribed by physician in accordance with local clinical practice.
62001547|NCT01870622|ACTIVE_COMPARATOR|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
62001548|NCT01870622|EXPERIMENTAL|Flow waves|Flow waves will be used to confirm correct tube placement
62001549|NCT01140425|EXPERIMENTAL|PF-00232798 supratherapeutic dose|PF-00232798 supratherapeutic dose
62001550|NCT01140425|EXPERIMENTAL|PF-00232798 therapeutic dose|PF-00232798 therapeutic dose
62001551|NCT01140425|PLACEBO_COMPARATOR|Placebo for PF-00232798|Placebo for PF-00232798
62001552|NCT01140425|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin
62001553|NCT01194024||Intubated within 24hrs of admission|All patients that are admitted to a participating burn center and intubated within 24 hours
62001554|NCT02244203|EXPERIMENTAL|Single rising doses of BI 60732|
62001555|NCT02244203|PLACEBO_COMPARATOR|Placebo|
62001556|NCT03791866|EXPERIMENTAL|30% target total enteral nutrition|
62001557|NCT03791866|EXPERIMENTAL|60% target total enteral nutrition|
62395191|NCT02778477|PLACEBO_COMPARATOR|Part A_Cohort 6_Placebo|Multiple dose of placebo
62395192|NCT02778477|EXPERIMENTAL|Part A_Cohort 7_Active|Multiple ascending dose of PF-06423264
62395193|NCT02778477|PLACEBO_COMPARATOR|Part A_Cohort 7_Placebo|Multiple ascending dose of placebo
62395194|NCT02778477|EXPERIMENTAL|Part B_Cohort 1_Active|Multiple doses of PF-06423264
62395195|NCT02778477|PLACEBO_COMPARATOR|Part B_Cohort 1_Placebo|Multiple doses of placebo
62395196|NCT02778477|EXPERIMENTAL|Part B_Cohort 2_Active|Multiple doses of PF-06423264
62395197|NCT02778477|PLACEBO_COMPARATOR|Part B_Cohort 2_Placebo|Multiple doses of placebo
62001558|NCT03791866|ACTIVE_COMPARATOR|100% target total enteral nutrition|
62001559|NCT03291613|EXPERIMENTAL|Pinpoint App|Tablet application.
62001560|NCT02859649|EXPERIMENTAL|healthy volunteers|
62395198|NCT05548582|OTHER|Post-operative opioid prescription|"Ibuprofen 600mg every 6 hours x 48 hours then as needed (total 30 tablets). If allergy or contraindication to ibuprofen, then will receive Meloxicam 15mg daily x 48 hours then as needed~Acetaminophen 500mg every 6 hours x 48 hours then as needed (total 30 tablets)~Oxycodone 5mg every 4 hours as needed (total 12 tablets)"
62570331|NCT00390871|ACTIVE_COMPARATOR|Fentanyl/Propofol sedation first|Patient given fentanyl only first, then sedated with fentanyl/propofol as needed to have Richmond Agitation Sedation Scale (RASS) Score 0 to -1. After washout with fentanyl only, patient sedated with fentanyl/dexmedetomidine to have RASS Score 0 to -1.
62570332|NCT00390871|ACTIVE_COMPARATOR|Fentanyl/Dexmedetomidine sedation first|Patient given fentanyl only first, then sedated with fentanyl/dexmedetomidine as needed to have RASS Score 0 to -1. After washout with fentanyl only, patient sedated with fentanyl/propofol to have RASS Score 0 to -1.
62570333|NCT05750212||Cases|Cases are adult female patients with a diagnosis of pelvic floor disorder.
62001561|NCT03284216|OTHER|Normal glycemia + exercise|Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered, but an exercise bout will be completed.
62001562|NCT03284216|EXPERIMENTAL|Steady-state hyperglycemia + exercise|Participants will be studied during experimental steady-state hyperglycemia-induced via a variable-rate intravenous glucose infusion, and an exercise bout will be completed.
62001563|NCT03284216|EXPERIMENTAL|Fluctuating hyperglycemia + exercise|Participants will be studied during experimental fluctuating hyperglycemia-induced via repeated intravenous glucose injections, and an exercise bout will be completed.
62001564|NCT03284216|NO_INTERVENTION|Normal glycemia, no exercise|Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered and no exercise will be completed.
62001565|NCT05041790|EXPERIMENTAL|Choline Alfoscerate|
62001566|NCT05041790|PLACEBO_COMPARATOR|Placebo|
62001567|NCT06114264|SHAM_COMPARATOR|Control Group|This group will not receive any treatment during the intervention period.
62395199|NCT05548582|ACTIVE_COMPARATOR|No Opioid prescription|"Ibuprofen 600mg every 6 hours x 48 hours then as needed (total 30 tablets). If allergy or contraindication to ibuprofen, will receive Meloxicam 15mg daily x 48 hours then as needed~Acetaminophen 500mg every 6 hours x 48 hours then as needed (total 30 tablets)"
62570334|NCT05750212||Controls|Controls are adult female patients sampled from an outpatient primary care center
62570335|NCT04712162|OTHER|D: maintain anesthesia with desflurane|D: maintain anesthesia with Suprane® (Desflurane) at 6%. Volatile concentration was titrated according to end-tidal MAC to maintain 0.7-1.3 MAC using end-tidal monitor of Dräger Primus anesthesia machine.
62570336|NCT04712162|OTHER|S: maintain anesthesia with sevoflurane.|S: maintain anesthesia with Sevorane® (Sevoflurane) at 2%. Volatile concentration was titrated according to end-tidal MAC to maintain 0.7-1.3 MAC using end-tidal monitor of Dräger Primus anesthesia machine.
62570337|NCT04226547|EXPERIMENTAL|Device Group|Randomized to Amplatzer Amulet LAA occluder
62777048|NCT00545103|EXPERIMENTAL|SPD476 (1.2 g)|
62777049|NCT00545103|EXPERIMENTAL|SPD476 (2.4 g)|
62777050|NCT00545103|EXPERIMENTAL|SPD476 (4.8 g)|
62777051|NCT00545103|PLACEBO_COMPARATOR|Placebo|
62021007|NCT05027217||COVID19 ICU arm (COVID-19 sub-study)|We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU who are invasively mechanically ventilated for more than 12 hours. We will include data from patients admitted with a confirmed diagnosis of acute respiratory failure due to COVID-19 infection.
62186740|NCT06426095|EXPERIMENTAL|instructional video|Participants in Group A received access to a specially prepared pre-recorded instructional video detailing the step-by-step process of porcelain-fused-to-metal tooth preparation for molars
62570338|NCT04226547|ACTIVE_COMPARATOR|Control Group|Randomized to NOAC
62570339|NCT05971784|EXPERIMENTAL|Telerehabilitation group|In addition to the exercise program consisting of balance and walking activities, the group will receive task-oriented upper extremity training via telerehabilitation accompanied by a physiotherapist.
62777052|NCT01574885|EXPERIMENTAL|Aerosal|This arm include all patients treated with Aerosal®
62777053|NCT01574885|PLACEBO_COMPARATOR|Placebo|This arm include all patients treated with placebo
62777054|NCT04161170|NO_INTERVENTION|Control A|no intervention conventional diabetes treatment and clinic visit every 3 months
62777055|NCT04161170|ACTIVE_COMPARATOR|Intervention B|apply digital integrated healthcare platform clinic visit every 3 months
62777056|NCT04161170|EXPERIMENTAL|Intervention C|apply digital integrated healthcare platform, CGMS, and medical team monitoring, and education clinic visit every 3 months
62777057|NCT02146027|EXPERIMENTAL|Fermented Milk Drink Yakult 40|"Lactobacillus casei Shirota, contained in the Fermented Milk Drink Yakult 40~Once daily Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10\^8 CFU/g). Intervention will be used for 12 weeks."
62777058|NCT02146027|PLACEBO_COMPARATOR|Placebo|"The placebo would be an analogous product without Live Lactic Bacteria (Lactobacillus casei Shirota) presented in the same bottle and similar flavor.~Both, Yakult 40 and placebo should be stored refrigerated between 1° and 10°C and"
62777059|NCT06092775||RA group|DEXA scan X_rays lumber, dorsal spine
62777060|NCT06092775||AS group|DEXA scan X_rays lumber, dorsal spine
62777061|NCT06092775||Control group|DEXA scan X_rays lumber, dorsal spine
62777062|NCT02619032|ACTIVE_COMPARATOR|Remifentanil|Drug: Remifentanil (Ultiva). Intraoperative intravenous infusion of remifentanil 0.5-1 μg/kg/min for up to 1 h.
62777063|NCT02619032|ACTIVE_COMPARATOR|Fentanyl|Drug: Fentanyl (FNT). Intraoperative administration of fentanyl given as one single bolus dose of 50 μg at the time of induction of anesthesia.
62777064|NCT00861471|EXPERIMENTAL|Docetaxel +Gleevec|
62791713|NCT00878748|OTHER|B|Effexor XR discontinue
62001568|NCT06114264|EXPERIMENTAL|Multimodal + Resistance Program|Multimodal program including exercise program 2 days / week (45 minutes per session) during a period of 8 weeks + Behaviour change program daily /24 hours via a wrist-worn activity prompting device during a period of 8 weeks + Education program 2 days / week (1.5 hour per session, except the final session lasting 2 hours) during a period of 3 weeks + Mindfulness intervention 1 day / week (2.5 hour per session) during a period of 8 weeks, and will continue with an extended exercise program (functional resistance training) additionally 3 days / week (50 minutes per session) during 8 weeks.
62186741|NCT06426095|EXPERIMENTAL|live demonstrations|live demonstrations of the same procedure conducted by the same experienced Prosthodontist to ensure consistency in teaching quality and technique.
62186742|NCT06426095|EXPERIMENTAL|hybrid|both video and live demonstrations will be given
62186743|NCT03722498|EXPERIMENTAL|HAIC of FOLFOX|Hepatic arterial infusion chemotherapy with oxaliplatin, leucovorin, and 5-fluorouracil
62186744|NCT03722498|ACTIVE_COMPARATOR|Sorafenib|Sorafenib 400 mg orally twice a day
62186745|NCT05425407|PLACEBO_COMPARATOR|Placebo|Only whey protein will be provided
62570340|NCT05971784|EXPERIMENTAL|Control group|The group that will receive a home exercise program consisting of only balance and walking activities
62001569|NCT01786629|EXPERIMENTAL|SUPREP Bowel Prep Kit|SUPREP Bowel Prep Kit
62570341|NCT06089564|ACTIVE_COMPARATOR|Skit video|The video was shown to children lasting for 5 minutes. It was about oral habits, good and bad food. Video was also showed brushing technique.
62777065|NCT00498355|EXPERIMENTAL|Ranibizumab|0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
62777066|NCT05138887|PLACEBO_COMPARATOR|placebo group|The placebo group was administered a vitamin tablet (Centrum) orally, once a day
62777067|NCT05138887|EXPERIMENTAL|experimental group 1|The experimental group 1 was administered BH4 orally, with a dose of 2mg/kg.d (If the drug dose is within the range of 51-150mg, the drug dose will be 100mg), once per day
62777068|NCT05138887|EXPERIMENTAL|experimental group 2|The experimental group 2 was administered BH4 orally, with a dose of 5 mg/kg.d (If the drug dose is within the range of 151-250mg, the drug dose will be 200mg, two times a day; If the drug dose is within the range of 251-350mg, the drug dose will be 300mg, three times a day)
62777069|NCT01452919|EXPERIMENTAL|LY2140023/LY2140023|"Open label phase: 40 milligram (mg) LY2140023 administered orally; given twice daily for up to 4 weeks. At the discretion of the investigator, dose may be adjusted one time to 80 mg. 80 mg dose may be adjusted back to 40 mg one time. Current dose level at randomization will remain constant through the double blind phase.~Double blind phase: 40 mg or 80 mg LY2140023 administered orally; given twice daily for up to 3 weeks."
62777070|NCT01452919|PLACEBO_COMPARATOR|LY2140023/Placebo|"Open label phase: 40 mg LY2140023 administered orally; given twice daily for up to 4 weeks. At the discretion of the investigator, dose may be adjusted one time to 80 mg. 80 mg dose may be adjusted back to 40 mg one time.~Double blind phase: placebo administered orally; given twice daily for up to 3 weeks."
62777071|NCT00020878|EXPERIMENTAL|Study|See intervention description.
62777072|NCT00828750|EXPERIMENTAL|Treatment|Eltrombopag oral tablets once daily
62001570|NCT01786629|ACTIVE_COMPARATOR|FDA approved bowel preparation|FDA approved bowel preparation containing electrolytes
62186746|NCT05425407|EXPERIMENTAL|Collagen|A mix of whey protein and collagen peptides will be provided
62186747|NCT01805245|EXPERIMENTAL|Mindfulness Based Stress Reduction|
62777073|NCT06085313|EXPERIMENTAL|CAI: Web App-based, individualized coaching and support program for cancer pain|Web App-based information and coaching/support program for cancer pain management with the individual optimization functionality
62777074|NCT06085313|ACTIVE_COMPARATOR|CAPA: Web App-based information and coaching/support program for cancer pain|Web App-based information and coaching/support program for cancer pain management
62791714|NCT02134925|EXPERIMENTAL|Arm I (MUC1 peptide-poly-ILCLC adjuvant vaccine)|Participants receive MUC1 peptide-poly-ICLC adjuvant vaccine SC in weeks 0, 2 and 10 and a booster injection in week 53.
62186748|NCT01805245|ACTIVE_COMPARATOR|Health Education Control|
62791715|NCT02134925|PLACEBO_COMPARATOR|Arm II (saline)|Participants receive saline SC in weeks 0, 2, and 10 and a booster injection in week 53.
62186749|NCT06202911|ACTIVE_COMPARATOR|intervention group|preterm neonates with feeding intolerance, pre-Nec., receive the drug
62186750|NCT06202911|PLACEBO_COMPARATOR|control group|preterm neonates
62186751|NCT00719043|EXPERIMENTAL|A/Indonesia primed-A/turkey Influenza (H5N1)-F1-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 1 at Day 0 followed by one booster dose of A/turkey H5N1 vaccine formulation 1 at Day 182 and one dose of placebo (phosphate buffered saline, PBS) at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and Placebo vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, A/turkey H5N1 vaccine was administered intramuscularly in the deltoid region of the dominant arm.
62186752|NCT00719043|EXPERIMENTAL|A/Indonesia primed-A/turkey Influenza (H5N1)-F2-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 2 at Day 0 followed by one booster dose of A/turkey H5N1 vaccine formulation 2 at Day 182 and one dose of placebo (phosphate buffered saline, PBS) at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and Placebo vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, A/turkey H5N1 vaccine was administered intramuscularly in the deltoid region of the dominant arm.
62570342|NCT06089564|ACTIVE_COMPARATOR|Pictorial|The pictures related to brushing technique and oral health advices such as good and bad habits was provided in the form of laminated cards. The children has taken those cards along with them.
62570343|NCT06089564|NO_INTERVENTION|Signed Language|The oral health education related to oral habits, good and bad food was delivered via sign language with the help of children sign language teacher.
62395200|NCT03061162|EXPERIMENTAL|Study Arm|Gastric cancer patients with peritoneal metastasis undergo pulsed low dose rate 3-dimensional conformal radiation therapy, QD, 5 days a week for 25 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
62570344|NCT02596204|ACTIVE_COMPARATOR|Data Upload|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. FitBit, pump and sensor (if applicable) data will be uploaded at least weekly. Subjects will continue to receive usual diabetes care. Phone calls and emails to the diabetes clinic will be initiated by the family.
62777075|NCT04110080|EXPERIMENTAL|Enhanced recovery after surgery|Preoperatively, patients will be counseled on optimization of physical and nutritional status. They will receive carbohydrate loading drinks prior to surgery. Intraoperatively, standard ASA monitors will be utilized, and patients will receive general anesthesia. Goal directed fluid management will be enforced with bolus options based on hemodynamics. Transabdominal plane and rectus sheath block will be performed in the operating room by the regional anesthesia team. Post-operatively pain management will include multimodal analgesic medications. Regular diet will be allowed and encouraged on post-operative day 0 (POD). Lines and drains will be minimized to encourage early mobilization and bowel function. Patients will be counseled on expectations of discharge criteria POD0.
62395201|NCT03881072|OTHER|Ultrasounicelastography|Ultrasounicelastography:non-invasive, convenient and comprehensive evaluation method.
62001571|NCT04281381||Desmoid Fibromatosis|Participants will have a clinical diagnosis of desmoid fibromatosis, either new or newly recurrent
62001572|NCT03096665||Blood test group|All patients receive the three types of blood test (venous blood test, skin puncture blood (capillary blood) test and arterial blood gas analysis
62001573|NCT02142166|EXPERIMENTAL|SAB analysis|"Patients with acute aneurysmal SAH, confirmed by CT or MRI, or lumbar puncture~Daily (21 days) analysis of Biomarker in serum, in liquor and in micro-dialysate"
62001574|NCT02142166|EXPERIMENTAL|Control|"Patients who undergo a lumbar puncture for myelography as part of the investigation of a cervical or lumbar foraminal stenosis without cranial or myeläre pathology -or- Patients who receive perioperative prophylactic lumbar drainage without cranial or myeläre pathology~Single analysis of Biomarker in serum and liquor"
62001575|NCT04253717|EXPERIMENTAL|Motor control exercise program|Participants will be physically trained during pregnancy and will receive the standard care including basic information on what to do when suffering from lumbopelvic pain.
62001576|NCT04253717|NO_INTERVENTION|Control|Participants will receive the standard care including basic information on what to do when suffering from lumbopelvic pain.
62395202|NCT01054443|PLACEBO_COMPARATOR|Placebo|Participants received placebo tablets orally once a day for 42 days.
62395203|NCT01054443|EXPERIMENTAL|Lusutrombopag 0.5 mg|Participants received 0.5 mg lusutrombopag orally once a day for 42 days.
62001577|NCT00436748|EXPERIMENTAL|Darbepoetin Alfa QW|Participants received darbepoetin alfa once a week (QW) for 24 weeks. The initial dose was 0.45 μg/kg; thereafter, active doses were administered to achieve and then maintain hemoglobin levels within a target range of 10.0 to 12.0 g/dL. Participants not on dialysis or who were receiving peritoneal dialysis were administered darbepoetin alfa subcutaneously; participants receiving hemodialysis were administered darbepoetin alfa intravenously.
62001578|NCT00436748|EXPERIMENTAL|Darbepoetin Alfa Q2W|Participants received darbepoetin alfa every 2 weeks (Q2W) and a placebo every other 2 weeks to maintain the blind for 24 weeks. The initial dose was 0.75 μg/kg; thereafter, active doses were administered to achieve and then maintain hemoglobin levels within a target range of 10.0 to 12.0 g/dL. Participants not on dialysis or who were receiving peritoneal dialysis were administered darbepoetin alfa subcutaneously; participants receiving hemodialysis were administered darbepoetin alfa intravenously.
62001579|NCT03331068||Patients with prostate cancer|online questionnaire of MAX-PC
62021008|NCT05027217||Non-COVID19 ICU arm (COVID-19 sub-study)|We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU who are invasively mechanically ventilated for more than 12 hours. We will include data from medical, surgical, trauma and neurological/neurosurgical patients who are not admitted for COVID-19.
62395204|NCT01054443|EXPERIMENTAL|Lusutrombopag 0.75 mg|Participants received 0.75 mg lusutrombopag orally once a day for 42 days.
62395205|NCT01054443|EXPERIMENTAL|Lusutrombopag 1.0 mg|Participants received 1.0 mg lusutrombopag orally once a day for 42 days.
62395206|NCT03102541||Cardiac Surgery|214 adult patients with estimated GFR ≥60 ml/min/1.73 m2 (CKD-Epidemiology Collaboration equation) undergoing elective cardiac surgery (coronary artery bypass, valve replacements, combined or other surgery, with cardiopulmonary bypass) between November 2014 and October 2015 at the San Bortolo Hospital, Vicenza, Italy
62395207|NCT05502809|EXPERIMENTAL|Deep-frozen platelets|-80°C stored fresh, leukocyte depleted (leukodepleted) platelet concentrates.
62395208|NCT05502809|ACTIVE_COMPARATOR|Room-temperature stored platelets|+22°C stored platelets
62395209|NCT01572129|EXPERIMENTAL|Reload|600 mg of clopidogrel loading dose 6-8 h before coronary angiogram, in addition to the chronic daily dose of 75 mg
62395210|NCT01572129|PLACEBO_COMPARATOR|Placebo|Placebo arm in addition to the chronic daily dose of 75 mg
62395211|NCT04370808||Mild to severe disease|Mild to severe disease (admission to isolation room)
62395212|NCT04370808||Critical patients|Critical patients (admission to ICU)
62395213|NCT02681692|ACTIVE_COMPARATOR|MEI colonoscopy Group|Patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system
62395214|NCT02681692|NO_INTERVENTION|Standard colonoscopy Group|Patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) without the assistance of magnetic scope navigation system
62395215|NCT02681692|ACTIVE_COMPARATOR|MEI colon model Group|"Colonoscopist would be randomized to perform colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part.~All force variation data would be recorded by a image storage device."
62395216|NCT02681692|NO_INTERVENTION|Standard colon model Group|Colonoscopist would be randomized to perform conventional colonoscopy on a colon model without an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
62395217|NCT02528149||patients with renal aneurysm|Patient with one or more renal artery aneurysm (RAA) operated and with tissue; adjacent part and aneurysm; cryopreserved. Blood sample performed at day 1.
62001580|NCT01276314|EXPERIMENTAL|anti- TNF-a treatment|"1. Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF~2. Fill out the case report form~3. Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis~4. Etanercept administration:~The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks"
62570345|NCT02596204|EXPERIMENTAL|Weekly Review|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. FitBit, pump and sensor (if applicable) data will be uploaded at least weekly. For subjects in the weekly review group, research staff (diabetes educator, nurse practitioner and/or physician) will review uploaded blood glucose, pump, and available sensor, activity and sleep data on a weekly basis. If glucose patterns are identified which suggest a change to diabetes management (ie insulin dose changes), the family will be contacted by text, email or telephone to review glucose patterns and to review staff recommendations.
62777076|NCT04110080|ACTIVE_COMPARATOR|Standard of care|Patients will receive traditional care for donor nephrectomy. Patients will be instructed to fast for 24 hours preoperative. On day of surgery, standard monitors will be used, and intraoperative management per anesthesiologists discretion including pain management. Post-operative, patients will receive pain medications, including opioids, as needed. Intravenous fluids will be continued until patients tolerate liquids per os. Bowel regimen will be ordered as needed. Patients will be discharged once meeting pre-set criteria.
62777077|NCT06505486||HAIC+SYS+LEN+PD-1i|
62777078|NCT02891382|EXPERIMENTAL|Individual incentives - Arm 1|This arm receives diabetes education + goal setting + individual rewards
62001581|NCT01276314|ACTIVE_COMPARATOR|control group|"1. Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF~2. Fill out the case report form~3. Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis~4. Drug administration:~The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose."
62186753|NCT00719043|EXPERIMENTAL|A/Indonesia primed-A/turkey Influenza (H5N1)-F3-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 3 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 3 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
62395218|NCT01685099||Group with tuberculous pleurisy|
62395219|NCT01685099||Group with non-tuberculous pleurisy|
62395220|NCT06369766||Healthy Controls|Healthy control subjects without neurological diseases
62395221|NCT06369766||Patients with Multiple Sclerosis|
62777079|NCT02891382|EXPERIMENTAL|Mixed incentives (Altruism) - Arm 2|This arm receives diabetes education + goal setting + companion support + individual rewards
62777080|NCT02891382|EXPERIMENTAL|Mixed Incentives (Cooperation) - Arm 3|This arm receives diabetes education + goal setting + companion support + shared rewards
62777081|NCT06564896|ACTIVE_COMPARATOR|CPAP Airsense 10|Participants in CPAP Airsense 10
62777082|NCT06564896|ACTIVE_COMPARATOR|CPAP AIr-Mini|Participants in CPAP AIr-Mini
62777083|NCT04519580||Patients with suspected polymyalgia rheumatica|The study investigates patients with suspected polymyalgia rheumatica (PMR). For Patients where the PMR diagnosis is dismissed, the study terminates after the first visit. Patients diagnosed with PMR will be treated with prednisolone with taper corresponding to usual care. At baseline all patients will have medical history taken, physical examination, blood drawn, Synacthen® test, PET/CT, and ultrasound performed. Physical examination, PET/CT, and ultrasound are repeated after 8 weeks of prednisolone treatment while the patients iare on 10 mg prednisolone as well as after prednisolone taper two weeks later, where Synachten® test is also performed. After 10 weeks prednisolone is restarted at 10 mg and the patient is followed by their general practitioner or at the department of rheumatology, where prednisolone is tapered according to usual care. Patients are invited to a follow up visit after one year.
62777084|NCT01887847|EXPERIMENTAL|sublingual nicotine tablet|investigational 2 mg sublingual nicotine tablet
62777085|NCT01887847|ACTIVE_COMPARATOR|COMMIT nicotine lozenge|COMMIT 2 mg nicotine lozenge
62777086|NCT05713435|ACTIVE_COMPARATOR|Mona Lisa Touch CO2 laser|"1. Power: 30 W.~2. Dwell time: 1000 μs.~3. Spacing: 1000 μm.~4. Depth: SmartStack parameter from 1 to 3 depending on the treatment status.~5. D-pulse mode.~6. At the introitus the power will be reduced to 24 W"
62777087|NCT05713435|ACTIVE_COMPARATOR|Fotona Smooth erbium:YAG laser|"1. Phase I (vaginal) Renovalase™ mode with (a) fluence of 5,5J/cm2, (b) SMOOTHTM mode frequency 1.6 Hz, and (c) spot size 7 mm.~2. Phase II (vestibulum and introitus) Renovalase™ mode with (a) fluence 10 J/cm2, (b) SMOOTHTM mode frequency 1.6Hz, and (c) spot size 7 mm."
62791716|NCT05044858|EXPERIMENTAL|Midpoint transverse process block group|Patients will receive midpoint transverse process block after induction of general anesthesia and before surgical incision
62001582|NCT00326612|ACTIVE_COMPARATOR|Intranasal Midazolam 0.2mg/kg|GIve once for seizure longer than 5 minutes
62001583|NCT00326612|ACTIVE_COMPARATOR|Rectal Diazepam 0.3-0.5 mg/kg|Given once for seizure longer than 5 minutes
62001584|NCT00696956|PLACEBO_COMPARATOR|A|Normal balloon for balloon angioplasty (Submarine, Ampherion Deep by Invatec)
62001585|NCT00696956|ACTIVE_COMPARATOR|2|Paclitaxel coated balloon (same balloon like in the control group, but coated with 3 µg/mm2 Paclitaxel)
62001586|NCT01885390|EXPERIMENTAL|Experimental: Group A|ROX Coupler + continuing standard antihypertensive medications
62777088|NCT05713435|SHAM_COMPARATOR|sham treatment|"1. The blocking device is inserted over the laser outlet before attaching the application speculum. With this device the laser beam is blocked entirely.~2. Phase I (vaginal) Renovalase™ mode with (a) fluence of 5,5J/cm2, (b) SMOOTHTM mode frequency 1.6 Hz, and (c) spot size 7 mm.~3. Phase II (vestibulum and introitus) Renovalase™ mode with (a) fluence 1,5 J/cm2, (b) SMOOTHTM mode frequency 1.6Hz, and (c) spot size 7 mm."
62001587|NCT01103934|ACTIVE_COMPARATOR|Fluticasone Propionate plus Vitamin D3|Subjects will be treated with fluticasone propionate and Vitamin D once daily for 2 weeks during allergy season
62001588|NCT01103934|PLACEBO_COMPARATOR|Fluticasone Propionate plus Placebo|Subjects will be treated with fluticasone propionate and placebo for Vitamin D once daily for 2 weeks during allergy season
62395222|NCT06369766||Patients with other neuroinflammatory diseases of the CNS|
62395223|NCT03025295|EXPERIMENTAL|Dexmedetomidine group|Induction dose of dexmedetomidine is 1ug/kg with 10min, maintain dose is 0.4ug/kg/h until 30 min before surgery completion.
62395224|NCT03025295|PLACEBO_COMPARATOR|Saline group|Control group given equal volume of saline with the dexmedetomidine group.
62777089|NCT00666965|PLACEBO_COMPARATOR|1|inactive placebo
62001589|NCT02355132||Insurance Intervention Arm|Oregon OCHIN patients that put their names on the reservation list for the Oregon Experiment and were randomly chosen to apply for insurance coverage via the Oregon Experiment
62001590|NCT02355132||Control|Oregon OCHIN patients that put their names on the reservation list for the Oregon Experiment and were not chosen to apply for insurance coverage via the Oregon Experiment
62001591|NCT05713032|ACTIVE_COMPARATOR|standard voltage group|The Standard voltage group will be given a onetime pulsed radiofrequency (PRF) therapy. All subjects in this group will be given radiofrequency therapy on the dorsal root ganglion using the same tools and procedures by the same operator. Pulsed RF mode of RF generator will be used with following parameters --Temperature 42°C -- Frequency 2 Hertz - Pulse Width 20msec-Amplitude output voltage 45 Volt for Duration of 480sec done in 2 cycles.
62395225|NCT05602818|EXPERIMENTAL|Soticlestat 300 mg|Participants will receive a single oral dose of soticlestat 300 milligrams (mg).
62777090|NCT00666965|EXPERIMENTAL|2|2.25 mg first week: 2.25 mg 1 sheet plus placebo 1 sheet 2nd to 6th week :2.25mg 1 sheet plus placebo 2 sheets
62777091|NCT00666965|EXPERIMENTAL|3|4.5 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 2 sheets pus placebo 1 sheet
62777092|NCT00666965|EXPERIMENTAL|4|6.75 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 3sheets
62186754|NCT00719043|EXPERIMENTAL|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F1-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) vaccine formulation 1 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 1 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
62186755|NCT00719043|EXPERIMENTAL|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F4-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 4 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 4 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
62186756|NCT00719043|EXPERIMENTAL|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F2-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 2 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 2 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
62001592|NCT05713032|ACTIVE_COMPARATOR|high voltage group|The High voltage group will be given a onetime pulsed radiofrequency (PRF) therapy. All subjects in this group will be given radiofrequency therapy on the dorsal root ganglion using the same tools and procedures by the same operator. Pulsed RF mode of RF generator will be used with following parameters --Temperature 42°C -- Frequency 2 Hertz - Pulse Width 20msec-Amplitude output voltage will be gradually increased to reach the highest voltage for each patient (55-75 Volt) for Duration of 480sec done in 2 cycles.
62186757|NCT00719043|PLACEBO_COMPARATOR|Naïve Placebo-A/turkey Influenza (H5N1)-F3-Group|Healthy subjects aged 18 years of age or older at the time of vaccination received one dose of placebo (phosphate buffered saline, PBS) at Day 0 followed by two doses of A/turkey H5N1 vaccine formulation 3, one dose administered at Day 182 and the other at Day 549. Placebo vaccine and one dose of A/turkey H5N1 vaccine (Day 549) was administered intramuscularly in the deltoid region of the non-dominant arm while the other dose of A/turkey H5N1 vaccine (Day 182) was administered intramuscularly in the deltoid region of the dominant arm.
62186758|NCT00573651|OTHER|JIA except SJIA with active systemic symptoms|Females age 9-26 with JIA of all types that have had arthritis and do not have active systemic symptoms. All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some Blood Draws for serum titers taken to measure antibody.
62186759|NCT02363998|OTHER|Open Label Lofexidine|During this open-label study, subjects will be given the option to receive lofexidine tablets for 7 days and up to 14 days if requested.
62186760|NCT03245177|EXPERIMENTAL|Pembrolizumab plus radiotherapy|Pembrolizumab is given by intravenous infusion over 30 minutes at a maximum dose of 200mg. The first dose of pembrolizumab is administered 14 days prior to the initiation of radiotherapy and every 3 weeks thereafter. Radiotherapy is given as a standard dose (60-66 Gy in 2 Gy/fraction) over 40-45 days (daily on Mon-Fri) Following completion of radiotherapy, participants will continue to receive pembrolizumab every 3 weeks for up to 12 months of maintenance treatment.
62395226|NCT05602818|EXPERIMENTAL|Soticlestat 600 mg|Participants will receive a single oral dose of soticlestat 600 mg.
62395227|NCT05602818|EXPERIMENTAL|Soticlestat 900 mg|Participants will receive a single oral dose of soticlestat 900 mg.
62395228|NCT05602818|ACTIVE_COMPARATOR|Alprazolam 2 mg|Participants will receive a single oral dose of over encapsulated alprazolam 2 mg.
62395229|NCT05602818|PLACEBO_COMPARATOR|Placebo|Participants will receive a single oral dose of matching placebo.
62395230|NCT01734070|EXPERIMENTAL|Cherry consumption|Volunteers will supplement their diets with 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories. We will prefer that the subjects split the cherries into three equal portions and consume one with each meal; however, this will not be mandatory.
62395231|NCT05033821|EXPERIMENTAL|Intervention|Participants who receive the FOY+ImPACT intervention
62395232|NCT05033821|NO_INTERVENTION|Control|Participants who receive standard library programing, but not the FOY+ImPACT intervention.
62395233|NCT06440876|EXPERIMENTAL|Music and Imagery|MI sessions will be delivered by board-certified music therapists with specialized training in MI and the study treatment protocol. The 8-session protocol has two stages. Stage 1 (sessions 1-4) is focused on learning to use music and imagery for self-regulation. Once the Veteran has demonstrated skill in using music for self-regulation, Stage 2 (sessions 5-8) shifts to identify and deepen their inner resources and how they can use those resources for self-care.
62395234|NCT01288820|EXPERIMENTAL|DHP+PQ|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
62395235|NCT01288820|ACTIVE_COMPARATOR|AS-AQ +PQ|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
62395236|NCT01489449|PLACEBO_COMPARATOR|Stent|Stent Implantation (DES or BMS), no further treatment
62395237|NCT01489449|ACTIVE_COMPARATOR|DCB|"DEBonly strategy: treatment with drug coated balloon, additional spot-stenting in case of severe dissection"
62570346|NCT00171210|EXPERIMENTAL|Deferasirox|All participants received Deferasirox (ICL670) orally once a day. Dosage based on body weight.
62001593|NCT02203864|EXPERIMENTAL|BIBW2 with IL-2 secreting cell line|
62001594|NCT02203864|EXPERIMENTAL|BIBW2 without IL-2 secreting cell line|
62001595|NCT01703793|PLACEBO_COMPARATOR|Vehicle|Vehicle (placebo) treatment, twice a week for four weeks.
62777093|NCT03589755|ACTIVE_COMPARATOR|mindful meditation|Behavioral intervention, providing meditation
62777094|NCT03589755|NO_INTERVENTION|Waiting list|Patient on a waiting list
62001596|NCT01703793|EXPERIMENTAL|Test Product 10156|Product 10156 treatment, twice a week for four weeks.
62001597|NCT01703793|EXPERIMENTAL|Test Product 49778|Product 49778 treatment, twice a week for four weeks.
62001598|NCT01254799|PLACEBO_COMPARATOR|Placebo|Women in this arm will receive identical Placebo capsules twice daily for 5 days
62001599|NCT01254799|ACTIVE_COMPARATOR|Doxycycline|Women in this arm will receive 100 mg doxycycline capsules twice daily for 5 days
62001600|NCT05830630|EXPERIMENTAL|Bupivacaine methylene blue group|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml methylene blue 1% (10 mg) plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of methylene blue plus bupivacaine 0.25% (1 ml of methylene blue added to each 49 ml of bupivacaine 0.25%) will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
62001601|NCT05830630|ACTIVE_COMPARATOR|Bupivacaine saline group|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml normal saline plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of bupivacaine 0.25% will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
62001602|NCT04307485|ACTIVE_COMPARATOR|standard dose ticargrelor based DAPT therapy|treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group
62001603|NCT04307485|EXPERIMENTAL|low dose ticargrelor based DAPT|treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT treatment
62186761|NCT05142579|EXPERIMENTAL|ENDOTRACHEAL TUBE HOLDER|Endotracheal tube holder was used for endotracheal tube detection of patients in this group.
62186762|NCT05142579|ACTIVE_COMPARATOR|BANDAGE|The bandage was used for endotracheal tube detection of patients in this group.
62186763|NCT01979289|EXPERIMENTAL|Computer Treatment: Active|Computerized Cognitive Remediation: Targeted to underlying cerebral networks associated with remission.
62395238|NCT04553497|ACTIVE_COMPARATOR|Rehabilitation and interferential current therapy|Flipping a coin was used for simple randomization (tails - interferential current). In this arm, interferential current therapy was applied to the patients in addition to the rehabilitation program.
62395239|NCT04553497|SHAM_COMPARATOR|Rehabilitation and sham therapy|Flipping a coin was used for simple randomization (heads - sham). In this arm, sham therapy was applied to the patients in addition to the rehabilitation program.
62570347|NCT02478424|EXPERIMENTAL|Cannabidiol arm|Patients undergoing an allogeneic hematopoietic cell transplantation will be given standard GVHD prophylaxis comprising cyclosporine and a short course of methotrexate plus CBD 150 mg BID starting 7 days before transplantation until day 100.
62777095|NCT00620113|PLACEBO_COMPARATOR|Placebo|After an observation period of \~5 weeks, participants receive dose-matched placebo to odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 International Units (IU) vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium \<1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
62570348|NCT04798053|EXPERIMENTAL|Patient affected by a chronic inflammatory rheumatism|patient affected by a chronic inflammatory rheumatism (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Systemic lupus, Still disease, scleroderma...),
62570349|NCT04798053|ACTIVE_COMPARATOR|Controls|patient affected by a non-inflammatory or degenerative musculo-skeletal disease during the containment period
62570350|NCT02623062|ACTIVE_COMPARATOR|Compound Sodium Alginate Oral Suspension sachets|Each patient will be instructed to take Compound Sodium Alginate Oral Suspension sachet or matching placebo as a 2x10ml sachets four times daily regimen. Prior to dosing, all patients will be instructed by the Investigator on how they will take the medication. Patients will be instructed to start taking their medication the day after their randomisation visit (Day 1) for seven days (20ml taken four times a day: 30 minutes after breakfast, 30 minutes after lunch, 30 minutes after dinner and immediately before lying down for bed. Shake well before use).
62777096|NCT00620113|EXPERIMENTAL|Odanacatib 10 mg|After an observation period of \~5 weeks, participants receive 10 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium \<1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
62777097|NCT00620113|EXPERIMENTAL|Odanacatib 25 mg|After an observation period of \~5 weeks, participants receive 25 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium \<1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
62777098|NCT00620113|PLACEBO_COMPARATOR|Odanacatib 50 mg|After an observation period of \~5 weeks, participants receive 50 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium \<1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
62001604|NCT02148328|EXPERIMENTAL|Trivalent virosomal influenza vaccine|Trivalent virosomal influenza vaccine will be administered intramuscularly (injection of a substance into a muscle) on Day 1 in healthy participants.
62001605|NCT02148328|ACTIVE_COMPARATOR|Commercial vaccine 1|Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
62001606|NCT02148328|EXPERIMENTAL|Quadrivalent virosomal influenza vaccine|Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
62001607|NCT02148328|ACTIVE_COMPARATOR|Commercial vaccine 2|Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
62001608|NCT03855735|EXPERIMENTAL|TeamBaby Online Training Intervention Group Phase 2 (IG1)|Those who give birth and relatives who have been arbitrarily assigned to the intervention group receive an interactive online training on different communication models and competencies (Phase 2).
62021009|NCT03579836|EXPERIMENTAL|Phase I-1 (#4 Cohort)|BEY1107 monotherapy, 4 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)
62001609|NCT03855735|NO_INTERVENTION|No Intervention|Those who give birth and relatives who have been arbitrarily assigned to the control group do not receive any training on different communication models competencies and will not gain access to the digital app prior to giving birth.
62001610|NCT03855735|EXPERIMENTAL|TeamBaby App Training Intervention Group Phase 3 (IG2)|Those who give birth and relatives who have been arbitrarily assigned to the intervention group will gain access to the digital app and receive a communication training via the app (Phase 3).
62186764|NCT01979289|ACTIVE_COMPARATOR|Computer Treatment: Control|Computerized Cognitive Remediation: Non-targeted
62186765|NCT01441583|ACTIVE_COMPARATOR|Pacemaker - RYTHMIQ Off at Pre-discharge, On at 1-Month|For the RYTHMIQ endpoint only, subjects implanted with a pacemaker will be randomized. Those randomized to RYTHMIQ Off at Pre-Discharge will have RYTHMIQ programmed Off until their 1-month follow up, when they will be crossed over to RYTHMIQ On until their 3-month follow up.
62186766|NCT01441583|ACTIVE_COMPARATOR|Pacemaker - RYTHMIQ On at Pre-Discharge, Off at 1-Month|For the RYTHMIQ endpoint only, subjects implanted with a pacemaker will be randomized. Those randomized to RYTHMIQ On at Pre-Discharge will have RYTHMIQ programmed On until their 1-month follow up, when they will be crossed over to RYTHMIQ Off until their 3-month follow up.
62777099|NCT04411745||Parturition|Healthy women who are carrying a healthy singleton pregnancy, but have not yet gone to labor at 40 weeks of gestation or who are at term and admitted to hospital for any sign of labor.
62186767|NCT01441583|EXPERIMENTAL|CRT-P|CRT-P devices were not involved in RYTHMIQ endpoint evaluation, only RAAT.
62395240|NCT01411917|EXPERIMENTAL|TAP block group|Patients in this group will have a preoperative, ultrasound guided injection of 30ml of 0.375% bupivacaine into the muscle plane between the transversus abdominis muscle and internal oblique muscles.
62395241|NCT01411917|PLACEBO_COMPARATOR|Placebo|Patients in this group will have an ultrasound guided subcutaneous injection of 30 ml of sterile preservative free saline.
62001611|NCT01153581|EXPERIMENTAL|Ganirelix acetate|Subjects were given 250 μg in 0.5ml normal saline for 16 days. (Organon, Roseland, NJ, USA)
62777100|NCT01211340|NO_INTERVENTION|Usual Care|Usual hospice care- there is no intervention in this arm
62777101|NCT01211340|EXPERIMENTAL|ACTIVE|Behavioral intervention using web conferencing
62777102|NCT04792827||analgosedation group|analgosedation concept
62186768|NCT01182103||Major depressive patients|
62777103|NCT04792827||historical group|standard historical concept
62777104|NCT00615641||1|3 year old children
62777105|NCT00615641||2|4 year old children
62777106|NCT00615641||3|5 year old children
62777107|NCT04443166|EXPERIMENTAL|Group A|At the beginning of the study (T0), group A will receive one course of PRP+HA program and group B will receive one HA course (a single HA injection (Hyajoint) weekly for 3 weeks). The PRP+HA program includes 3 HA injections and a single PRP injection (Arthrex double syringe system).
62777108|NCT04443166|ACTIVE_COMPARATOR|Group B|In the 6th month, alternately, group B will receive one PRP+HA program and group A will receive one HA course.
62001612|NCT01153581|EXPERIMENTAL|17β-Oestradiol, E2|The same women added 17β-Oestradiol, E2; 0.2 mg day-1 patch (Vivelle; CIBA Pharmaceuticals, Summit, NJ) for days 4-16.
62186769|NCT01182103||Healthy subjects|
62186770|NCT00568698|EXPERIMENTAL|Hydroxyurea|
62186771|NCT00568698|PLACEBO_COMPARATOR|Placebo|
62186772|NCT03166046|ACTIVE_COMPARATOR|Study Group|Subjects will use the active pulsed shortwave therapy device (ActiPatch) as a prophylactic treatment for episodic migraine
62001613|NCT01153581|EXPERIMENTAL|Progesterone|The same women added progesterone (P4, 200 mg day-1 Prometrium, oral, Solvay Pharmaceuticals, Marietta, GA, USA) on days 13-16.
62021010|NCT03579836|EXPERIMENTAL|Phase I-2 (#3 Cohort)|BEY1107 in combination with Gemcitabine, 3 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)
62186773|NCT03166046|PLACEBO_COMPARATOR|Control Group|Subjects will use the placebo pulsed shortwave therapy device (Placebo ActiPatch) as a prophylactic treatment for episodic migraine
62186774|NCT04476836|EXPERIMENTAL|AAT group|Animal-assisted therapy will be provided one 1-hour session per week for 48 weeks.
62186775|NCT04476836|NO_INTERVENTION|control group|routine care
62395242|NCT01428570|EXPERIMENTAL|Pentax-AWS|Patients in this group will be intubated using Pentax-AWS
62395243|NCT01428570|ACTIVE_COMPARATOR|laryngoscopy|Patients in this group will be intubated using Macintosh laryngoscope.
62395244|NCT01393925|EXPERIMENTAL|parecoxib, normal saline|
62395245|NCT06663384|EXPERIMENTAL|ARVIS arm|TKA using ARVIS software
62395246|NCT06663384|PLACEBO_COMPARATOR|conventional TKA|Conventional Total Knee Arthroplasty
62777109|NCT01571453|EXPERIMENTAL|Vortioxetine (Lu AA21004)|
62777110|NCT01571453|ACTIVE_COMPARATOR|Venlafaxine extended release|
62777111|NCT04224506||Myasthenia Gravis|Patients who have been diagnosed with Myasthenia Gravis.
62777112|NCT02678455|EXPERIMENTAL|TV005 vaccine|Participants will receive one dose of TV005 vaccine at study entry (Day 0).
62777113|NCT02678455|PLACEBO_COMPARATOR|Placebo|Participants will receive one dose of placebo at study entry (Day 0).
62777114|NCT00808548||Lifestyle counseling|
62777115|NCT04161001|EXPERIMENTAL|Amlodpine, Olmesartan, Rosuvastatin, Ezetimibe|co-administration of Olmesartan, Amlodipine and Rosuvastatin, Ezetimibe
62777116|NCT04161001|PLACEBO_COMPARATOR|Olmesartan, Rosuvastatin, Ezetimibe|co-administration of Olmesartan and Rosuvastatin, Ezetimibe
62777117|NCT04161001|PLACEBO_COMPARATOR|Amlodpine, Olmesartan|co-administration of Olmesartan, Amlodipine
62777118|NCT05401318||Primary resectable colon and rectal cancer|Patients with primary resectable, localized colon and rectal cancer eligible for blood and tissue sampling for organoid development.
62777119|NCT01772576|EXPERIMENTAL|Reliance 4-Front|Single arm, all patients will be implanted with the Reliance 4-Front lead
62777120|NCT02217917|EXPERIMENTAL|Cohort 1|Single ascending dose in 3 period cross-over design (with optional 4th period)
62777121|NCT02217917|EXPERIMENTAL|Cohort 2|Multiple ascending dose
62777122|NCT02217917|EXPERIMENTAL|Cohort 3|Multiple ascending dose
62777123|NCT00395850|PLACEBO_COMPARATOR|1|microcrystalline cellulose
62570351|NCT02623062|PLACEBO_COMPARATOR|Matching placebo sachets|Each patient will be instructed to take Compound Sodium Alginate Oral Suspension sachet or matching placebo as a 2x10ml sachets four times daily regimen. Prior to dosing, all patients will be instructed by the Investigator on how they will take the medication. Patients will be instructed to start taking their medication the day after their randomisation visit (Day 1) for seven days (20ml taken four times a day: 30 minutes after breakfast, 30 minutes after lunch, 30 minutes after dinner and immediately before lying down for bed. Shake well before use).
62186776|NCT03954223|EXPERIMENTAL|LSC + blinded CGM|Group 1) Low sugar and carbohydrate diet (LSC, \<90 gm carbohydrate (CHO)/day, \<25 gm added sugar/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback)
62570352|NCT04659954|EXPERIMENTAL|Application O'DIDE|The subjects will use the application O'DIDE during 8 weeks
62570353|NCT05916417|ACTIVE_COMPARATOR|TMS-fNIRS over the dl-PFC (Active)|TMS-fNIRS dl-PFC data will be acquired with participants being randomized to active or sham stimulation of the dl-PFC, with the randomizing of the order of four different TMS-fNIRS protocols.
62570354|NCT05916417|SHAM_COMPARATOR|TMS-fNIRS over the dl-PFC (Sham)|TMS-fNIRS dl-PFC data will be acquired with participants being randomized to active or sham stimulation of the dl-PFC, with the randomizing of the order of four different TMS-fNIRS protocols.
62570355|NCT02626026|EXPERIMENTAL|Cohort 1, Part A: Tirabrutinib 20 mg QD|Tirabrutinib 20 mg capsules orally once daily (QD) in the morning for 1 week.
62570356|NCT02626026|PLACEBO_COMPARATOR|Cohort 1, Part A: Placebo|Placebo to match tirabrutinib capsules orally QD in the morning for 1 week.
62570357|NCT02626026|EXPERIMENTAL|Cohort 2, Part A: Tirabrutinib 10 mg BID|Tirabrutinib 10 mg capsules orally twice daily (BID) (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
62186777|NCT03954223|EXPERIMENTAL|LSC+TLE + blinded CGM|Group 2) LSC+Time limited eating (TLE) (16-hour fast/8-hour feed for 3 days per week) + blinded CGM
62395247|NCT05468619|EXPERIMENTAL|Cohort 1|A cohort of neonates who are at risk of acquiring neonatal herpes simplex virus disease will receive 10 mg/kg of valacyclovir will be administered orally two times daily for 5 days. N=8
62395248|NCT05468619|EXPERIMENTAL|Cohort 2|If the safety profile and the drug exposure concentrations in Cohort 1 are acceptable, eight new subjects will be enrolled in Cohort 2. If the mean of observed acyclovir exposures of subjects in Cohort 1 are below 24,000 ngxhr/mL, AND if no Grade 3 or Grade 4 AEs or SAEs are detected in any of the study subjects, then the 8 subjects enrolled in Cohort 2 will receive oral valacyclovir at a dose of 20 mg/kg administered two times daily for 5 days. Alternatively, if the mean of observed acyclovir exposures of subjects in Cohort 1 are above 48,000 ngxhr/mL AND if no Grade 3 or Grade 4 AEs or SAEs are detected in any of the study subjects, then the 8 subjects enrolled in Cohort 2 will receive oral valacyclovir at a dose that has been linearly adjusted downward to target 36,000 ngxh/mL area-under-the-concentration-time curve from 0 to 12 hours (AUC12).
62570358|NCT02626026|PLACEBO_COMPARATOR|Cohort 2, Part A: Placebo|Placebo to match tirabrutinib capsules orally BID (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
62570359|NCT02626026|EXPERIMENTAL|Part B: Tirabrutinib 20 mg QD|Tirabrutinib 20 mg capsules orally QD for 4 weeks.
62570360|NCT02626026|PLACEBO_COMPARATOR|Part B: Placebo|Placebo to match tirabrutinib capsules orally QD for 4 weeks.
62186778|NCT03954223|EXPERIMENTAL|LSC+TLE+ real time feedback via CGM|Group 3) LSC+TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy).
62186779|NCT02804451|EXPERIMENTAL|Intubation without chest compression|normal airway, without chest compression during intubation.
62395249|NCT06534580||Phase I|"People living with advanced cancer and experiencing pain.~Participants will complete two interviews. In each interview, they will use a Virtual Reality headset and discuss with the researcher the potential benefits, any changes they would make to the experiences, and how they might use it in practice."
62570361|NCT02892669||patients admitted to the intensive care department|
62570362|NCT00466245|EXPERIMENTAL|A|Previously vaccinated for smallpox, 1x10-8 dose
62570363|NCT00466245|EXPERIMENTAL|B|Smallpox vaccine naive, 1x10-8 dose
62570364|NCT00466245|EXPERIMENTAL|C|Previous smallpox vaccination, 1x10-7 dose
62570365|NCT00466245|EXPERIMENTAL|D|Smallpox vaccine naive, 1x10-7 dose
62570366|NCT00466245|EXPERIMENTAL|E|Previous smallpox vaccination, 1x10-6 dose
62186780|NCT02804451|EXPERIMENTAL|Intubation with uninterrupted chest compression|normal airway, with continuous chest compressions
62021011|NCT03579836|EXPERIMENTAL|Phase II (#1 Cohort)|BEY1107 in combination with Gemcitabine, 6 Cycles / 24 weeks (administered on a 3-week-on and 1-week-off)
62186781|NCT01407276|EXPERIMENTAL|Part 1: Mild Renal Impairment (Panel A)|
62186782|NCT01407276|EXPERIMENTAL|Part 1: Control to Match Panel A (Panel B)|
62186783|NCT01407276|EXPERIMENTAL|Part 1: Moderate Renal Impairment (Panel C)|
62186784|NCT01407276|EXPERIMENTAL|Part 1: Control to Match Panel C (Panel D)|
62570367|NCT00466245|EXPERIMENTAL|F|Smallpox vaccine naive, 1x10-6 dose
62570368|NCT00466245|EXPERIMENTAL|G|Previous smallpox vaccination, placebo dose
62570369|NCT00466245|EXPERIMENTAL|H|Smallpox vaccine naive, placebo dose
62570370|NCT03349060|EXPERIMENTAL|PF-04965842 100 mg|
62570371|NCT03349060|EXPERIMENTAL|PF-04965842 200 mg|
62570372|NCT03349060|PLACEBO_COMPARATOR|Placebo|
62777124|NCT00395850|EXPERIMENTAL|2|disulfiram at 250 mg/day
62777125|NCT00395850|EXPERIMENTAL|3|Disulfiram at 375 mg/day
62777126|NCT00395850|EXPERIMENTAL|4|Disulfiram at 500 mg/day
62777127|NCT03310385|EXPERIMENTAL|High-dose GHX02 group(1,920mg/day)|4 tablets of the GHX02, three times daily for 7 days
62777128|NCT03310385|EXPERIMENTAL|Standard-dose GHX02 group(960mg/day)|2 tablets of the GHX02 and 2 tablets of the placebo, three times daily for 7 days
62777129|NCT03310385|PLACEBO_COMPARATOR|Placebo control|4 tablets of the placebo, three times daily for 7 days
62777130|NCT04918355||Provider Group 1: no alert|Control group to enable tracking of temporal changes in prescribing. Providers will not see any alert.
62777131|NCT04918355||Provider Group 2: Mandated alert|Control group where providers will see a generic pop-up alert within the Electronic Health Record (EHR) whenever they initiate an opioid or benzodiazepine prescription without recording use of the PDMP. Patient risk factors are not assessed or presented in the alert. Providers in ambulatory clinics will not be assigned to this group. Alerts do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders.
62777132|NCT04918355||Provider Group 3: PDMP alert|"Providers will see a pop-up alert within the EHR when they initiate an opioid or benzodiazepine prescription without recording use of the PDMP and patients have one or more positive risk factors based on past/current prescriptions received. Patient risk factors are assessed and presented in the alert. Risk factors included are numbers of active or recent opioid and benzodiazepine prescriptions, overlapping prescriptions, co-prescribing of benzodiazepines and opioids, and use of long-acting opioids in opioid naïve patients.~Alerts are seen only once regardless of the number of positive risk factors and do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders."
62777133|NCT04918355||Provider Group 4: PDMP + EHR alert|"Providers will see a pop-up alert within the EHR when they initiate an opioid or benzodiazepine prescription without recording use of the PDMP and patients have one or more positive risk factors based on both prescriptions and other factors recorded in the patient's Electronic Health Record. Patient risk factors are assessed and presented in the alert. Risk factors included the risks described as in Group 3, along with a history of accidental opioid overdose, diagnosis of Opioid Use Disorder, multiple recent acute care incidents with opioid use, or high risk psychiatric diagnoses.~Alerts are seen only once regardless of the number of positive risk factors and do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders."
62777134|NCT00661947||Public|General public. Those who are not currently taking any medication besides birth control pills.
62395250|NCT06534580||Phase II|"Participants: Staff working at participating sites, technology specialists, Patient and Public Involvement (PPI) representative.~There will be a workshop at each participating site. Participants will work together to manualise the intervention so that it is ready for a feasibility trial and process evaluation.~They will discuss the following:~* Indications of use for virtual reality as a pain therapy~* Frequency of use: recommended number of sessions, duration.~* Barriers or facilitators that might impact the use of virtual reality.~* Pain and other patient-reported outcomes identified.~* What possible longer-term goals of using virtual reality as a pain therapy could include.~* Guidance for specific settings, including safety considerations.~* Operator instructions: patient or operator delivered.~* Infection control management."
62395251|NCT06534580||Phase III|"Participants: People living with advanced cancer and experiencing pain.~During this phase, we will implement the recommendations from the manual from phase II. A headset will be available for use on an as needed basis at each study location. Participants will be asked to provide feedback each time they use the headset. Specific for data on pain, the Brief Pain Inventory (BPI) will be completed. This looks at pain severity as well as how much pain impacts their daily life. Whilst the availability of only one headset per site will limit the frequency of use, particularly for those who are outpatients, this is reflective of current availability of virtual reality headsets in each location. This data will generate recommendations for future research and clinical practice, including the consideration of the economic impact."
62395252|NCT03492242||Adverse drug reaction induced by immune checkpoint inhibitors|Case reported in the World Health Organization (WHO) and the Base Nationale de PharmacoVigilance of patient treated by ICI, with a chronology compatible with the drug toxicity
62395253|NCT00712634|EXPERIMENTAL|CMV-seropositive participants|Participants are randomized to receive 1 of 4 escalating doses of CMVpp65-A\*0201 peptide vaccine containing either helper T-lymphocyte (HTL) PADRE peptide or HTL tetanus toxoid peptide. Within each vaccine dose group, two participants are randomized to receive a placebo. Participants receive the vaccine or a placebo subcutaneously (SC) on days 0 and 28 in the absence of unacceptable toxicity.
62395254|NCT00712634|EXPERIMENTAL|CMV-seronegative participants|Participants are randomized to receive 1 of 4 established doses (established in CMV-seropositive participants) of CMVpp65-A\*0201 peptide vaccine containing either HTL PADRE peptide or HTL tetanus toxoid peptide. Participants receive the vaccine on days 0, 28, and 56 in the absence of unacceptable toxicity. Participants with a partial or low-level immune response receive one additional booster vaccine on day 90.
62395255|NCT05999773||SGLT-2i Group|Patients diagnosed with Child-Turcotte-Pugh A6-B9 class Hepatic Cirrhosis (moderately impaired liver function) and type 2 Diabetes Mellitus assigned to start SGLT-2 inhibitors intake, according diabetology indications, in addition to standard medical therapy for 6 months.
62395256|NCT05999773||Standard Therapy Group|Patients diagnosed with Child-Turcotte-Pugh A6-B9 class Hepatic Cirrhosis (moderately impaired liver function) and type 2 Diabetes Mellitus assigned to continue standard medical therapy, according diabetology indications, for 6 months.
62186785|NCT01407276|EXPERIMENTAL|Part 1: Severe Renal Impairment (Panel E)|
62186786|NCT01407276|EXPERIMENTAL|Part 1: Control to Match Panel E (Panel F)|
62186787|NCT01407276|EXPERIMENTAL|Part 2: End-stage Renal Disease needing hemodialysis (Panel G)|
62777135|NCT05842681|ACTIVE_COMPARATOR|Conventional therapy group|Patients will receive conventional treatment for acute exacerbation of IPF, including pulse corticosteroid therapy and supportive treatment, and oxygen therapy.
62777136|NCT05842681|ACTIVE_COMPARATOR|Add-on Azithromycin|Patients will receive conventional therapy and Add-on Azithromycin 500 mg single daily dose for five days
62777137|NCT05583019||Healthy Control|Those who do not have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Clear (0) or Almost Clear (1) on the Investigator's Static Global Assessment (ISGA) at intake.
62777138|NCT05583019||Mild Atopic Dermatitis (AD)|Those who have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Mild (2) on the Investigator's Static Global Assessment (ISGA) at intake.
62777139|NCT05583019||Moderate Atopic Dermatitis (AD)|Those who have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Moderate (3) on the Investigator's Static Global Assessment (ISGA) at intake.
62777140|NCT05583019||Severe Atopic Dermatitis (AD)|Those who have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Severe (4) on the Investigator's Static Global Assessment (ISGA) at intake.
62777141|NCT06199362||Swedish National Cohort|Children born in Sweden during the years 1987-2010, to be followed for diagnoses of neurodevelopmental disorders.
62777142|NCT06199362||Stockholm Regional Obstetrix Cohort|Children born in Region Stockholm during the years 2007-2010, to be followed for diagnoses of neurodevelopmental disorders.
62186788|NCT01407276|EXPERIMENTAL|Part 2: Control to Match Panel G (Panel H)|
62186789|NCT02701998|EXPERIMENTAL|mHealth-Enhance Physical Activity Intervention|Tech-PAI participants will be given 3 goals: 1) to increase their average baseline daily walking exercise by 30 minutes at week 12; 2) to increase their average baseline daily steps by 4,000 at week 12; and 3) to get up and walk for at least 2 minutes after every 60 minutes of sitting. Participants will receive instruction on how to gradually and safely increase their bout-related walking exercise and steps over the 12 week period. In addition to goal setting, Tech-PAI participants will receive a commercially available activity tracker and accompanying that provides real-time monitoring of steps, activity minutes, and issues a text-based prompt after 60 minutes of sitting to get up and move. Also, participants will receive a weekly e-mail feedback message from research staff on goal progress and will be asked to view weekly Internet-based video lessons that will provide behavioral strategies to increase MPA and steps and decrease SB during the first 6 weeks of the intervention period.
62186790|NCT02701998|ACTIVE_COMPARATOR|Physical Activity Intervention|PAI participants will be given the same goals as Tech-PAI intervention participants and receive a pedometer and related print materials to assist them in recording and increasing daily steps and bout-related MPA (but no activity tracker, access to video-based skills training lessons, or weekly feedback).
62395257|NCT04440137|NO_INTERVENTION|Control Group|Mother of children will receive a brochure with a standard of care info (with only essential information regarding the harmful effect of bottle feeding) and kid toothbrush and toothpaste (1000ppm of fluoride).
62395258|NCT04440137|EXPERIMENTAL|Intervention group|Mother of the children will be provided with intervention brochure (which include detailed information regarding the harmful effect of bottle feeding), kid toothbrush and toothpaste (1000ppm of fluoride) and a sippy cup.
62186791|NCT00912223|EXPERIMENTAL|Hematopoietic Stem Cell Transplant|Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
62777143|NCT03891758|EXPERIMENTAL|BK1310|
62777144|NCT03891758|ACTIVE_COMPARATOR|ActHIB® and Tetrabik|
62395259|NCT03414372|EXPERIMENTAL|Tough Talks Online|Participants will use Tough Talks Online
62777145|NCT02653547|EXPERIMENTAL|standard multisite four weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation; complete treatment of four weeks
62777146|NCT02653547|EXPERIMENTAL|high-frequency multisite four weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and high-frequency temporoparietal (bilateral) stimulation; complete treatment of four weeks
62777147|NCT02653547|EXPERIMENTAL|standard multisite two weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation; discontinuation after two weeks
62777148|NCT02653547|EXPERIMENTAL|high-frequency multisite two weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and high-frequency temporoparietal (bilateral) stimulation; discontinuation after two weeks
62777149|NCT03355677|ACTIVE_COMPARATOR|Case finding clinics|The visit will be a minimum 90 minutes long at the participants own GP surgery. This will include a respiratory assessment including spirometry will performed by a RT Respiratory Nurse Specialist (RNS) and where possible a Practice Nurse or Nurse Practitioner will attend. The visit will consist of objective measurements, investigations and questionnaires
62777150|NCT03355677|PLACEBO_COMPARATOR|Case finding Usual care|In the control arm of the study, practices will continue with usual care according to national guidance for case finding for COPD (NICE, 2010). Matched practices will have their eligible population identified through electronic searches based on data routinely recorded in primary care run in the HHRa. Case finding yield will be measured as the percentage of patients from the eligible population identified with a respiratory diagnosis in the 12 months from study beginning to study end.
62777151|NCT03355677|ACTIVE_COMPARATOR|At Risk Case clinics|The complex case clinic will be a minimum 120 minute appointment at the participants own GP surgery. The intervention will include an initial assessment by a RT Respiratory Nurse Specialist (RNS) and followed by a joint assessment by a respiratory physician (RP) working alongside a practice clinician (GP and/or Practice Nurse/Nurse Practitioner). The visit will consist of objective measurements, investigations and questionnaires as outlined in section 3 below. A personalised disease management and action plan will be agreed jointly between the RT, practice clinician and participant. The practice clinician will undertake the necessary tasks required for the agreed management plan. The clinical responsibility for the participant will remain with the GP practice.
62186792|NCT04354168|EXPERIMENTAL|Nthabi mHealth Application|About 20 women from each of the ten district hospitals will be recruited. Each district hospital will have a separate administrative page on the Nthabi server where women will be enrolled with a unique username and password. Upon enrollment, the women will be asked to engage with Nthabi for two months to discuss the relevant content areas they are interested in learning more about.
62186793|NCT04433325||Patients transferred|Patients transferred from Paris's Intensive Care Units
62186794|NCT04433325||Patients not transferred|Patients admitted in Intensive Care Units with no transfer from Paris
62395260|NCT03414372|EXPERIMENTAL|Tough Talks Clinic|Participants will use receive Tough Talks in a clinic
62395261|NCT03414372|PLACEBO_COMPARATOR|Standard of Care|Participants will receive the standard of care (SOC).
62395262|NCT00387829|ACTIVE_COMPARATOR|1|Use of DuraGen Plus Adhesion Barrier Matrix as an adhesion barrier in the spine
62395263|NCT00387829|NO_INTERVENTION|2|Control arm is surgery alone (no adhesion barrier)
62395264|NCT00991458|EXPERIMENTAL|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
62395265|NCT00991458|EXPERIMENTAL|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
62395266|NCT00991458|PLACEBO_COMPARATOR|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
62395267|NCT02198040|EXPERIMENTAL|Manual Therapy group|The treatment of this group consisted of two sessions per week, one hour each. We used joint traction, passive muscles stretching and Proprioceptive Neuromuscular Facilitation
62395268|NCT02198040|EXPERIMENTAL|Educational group|The treatment had education and home daily exercises for the improvement of the range of motion, biceps strength, perimeter of arm and the perception of pain in patients with haemophilia and arthropathy of the elbow.
62395269|NCT02198040|NO_INTERVENTION|Control group|The control group did not receive any intervention. The patients in this group were assessed by the same reviewers (blinded to the study conditions) and under the same conditions, that patients in the experimental groups.
62186795|NCT03067363|EXPERIMENTAL|Part 1, MOR107 Dose level 1|MOR107, single subcutaneous injection
62186796|NCT03067363|EXPERIMENTAL|Part 1, MOR107 Dose level 2|MOR107, single subcutaneous injection
62186797|NCT03067363|EXPERIMENTAL|Part 1, MOR107 Dose level 3|MOR107, single subcutaneous injection
62395270|NCT00405756|EXPERIMENTAL|MPR+R|Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
62395271|NCT00405756|EXPERIMENTAL|MPR+p|Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
62186798|NCT03067363|EXPERIMENTAL|Part 1, MOR107 Dose level 4|MOR107, single subcutaneous injection
62777152|NCT03355677|PLACEBO_COMPARATOR|At Risk Usual Care|In the control arm of the study, practices will continue with usual care according to national guidance for the management of COPD and asthma . A cohort of patients matched for practice and for age, sex, disease condition and, where possible, disease control will be identified. This cohort will be monitored against markers of sub-optimal disease (medication usage, exacerbations, unscheduled visits to the practice, attendance or admission to hospital).
62001614|NCT01537783|EXPERIMENTAL|Intervention group|In this arm, patients are treated with chlorhexidine scrubs once a day for 5 days and mupirocin nasal ointment inserted to both nostrils twice a day for 5 days. Both treatments are begun 7 days after enrollment, or when the abscess has healed fully if it has not healed by day 7.
62001615|NCT01537783|NO_INTERVENTION|Standard of Care|In this arm, patients receive routine care of their abscess, which may or may not include either topical or oral antibiotics, at the discretion of the treating clinician.
62001616|NCT04145570|EXPERIMENTAL|Erlotinib HCl 150 mg|Crossover
62001617|NCT04145570|ACTIVE_COMPARATOR|Tarceva® 150 mg|Crossover
62001618|NCT05338190|EXPERIMENTAL|ARM A|Belimumab 200 mg subcutaneous weekly (i.e., every 7 days ±1 day) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
62001619|NCT05338190|PLACEBO_COMPARATOR|ARM B|Placebo subcutaneous weekly (i.e., every 7 days ±1 day starting from day 0) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
62001620|NCT00733343|ACTIVE_COMPARATOR|Treatment Group|treatment with Adaptive Servoventilation (Europe: AutoSet CS (USA: VPAP (Variable Positive Airway Pressure) Adapt SV)) + standard medical therapy according to applicable guidelines (ESC, ACC/AHA)
62186799|NCT03067363|EXPERIMENTAL|Part 1, MOR107 Dose level 5|MOR107, single subcutaneous injection
62001621|NCT00733343|NO_INTERVENTION|Control Group|standard medical therapy according to applicable guidelines (ESC, ACC/AHA)
62001622|NCT04063033|EXPERIMENTAL|IV Iron treatment|Patients will be administered IV Iron for 3-5 days. 125 mg per day.
62186800|NCT03067363|EXPERIMENTAL|Part 1, MOR107 Dose level 6|MOR107, single subcutaneous injection
62395272|NCT00405756|OTHER|MPp+p|Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
62395273|NCT05584007|PLACEBO_COMPARATOR|Intervention|Flucloxacillin 500mg four times a day (QDS) for 5 days (unblinded NHS prescription) followed by blinded placebo QDS for 2 days (5 days of antibiotic)
62395274|NCT05584007|ACTIVE_COMPARATOR|Control|Flucloxacillin 500mg QDS for 5 days (unblinded NHS prescription) followed by flucloxacillin 500mg QDS (blinded) for 2 days (7 days of antibiotic)
62395275|NCT05267964|ACTIVE_COMPARATOR|Epping resection arthroplasty|During the Epping resection-suspension arthroplasty the trapeziectomy is performed, the flexor carpi radialis tendon is divided into two parts and one of these is stripped and cut proximally. To prevent shortening of the first ray with following loss of strength, this tendon strip is pulled through a drill hole in the base of the 1st metacarpal from ulnar palmar to radial dorsal. The rest of the tendon strip is sutured to a roll replacing the os trapezium.
62395276|NCT05267964|ACTIVE_COMPARATOR|CMC I prosthesis group|During implantation of the prosthesis the CMC joint is opened and 3 mm of the metacarpal base as well as osteophytes are resected. Following the release of the trapezium the first metacarpal and the trapezium are prepared for the prosthesis by broaching and drilling. After the test-implants have shown satisfying joint tension and anatomic conditions, the HA coated stem and cup are pressfit inserted in the appropriate size followed by the modular head.
62777153|NCT04368793||Discharged COVID-19 patient cohort|All enrolled participants will be given 8 weeks (online 2 weeks + offline 6 weeks) pulmonary rehabilitation intervention, and will be followed up for at least one year, to assess their adherence and efficacy of the rehabilitation program.
62777154|NCT00871962||1|COPD patients on necessity of long-term oxygen therapy
62001623|NCT04063033|NO_INTERVENTION|No IV Iron treatment|Patients will receive standard treatment for heart failure without IV Iron.
62001624|NCT02940691|EXPERIMENTAL|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.
62001625|NCT00783042|ACTIVE_COMPARATOR|1|
62001626|NCT00783042|PLACEBO_COMPARATOR|2|
62001627|NCT00847275|PLACEBO_COMPARATOR|1|"Exclusive nephrology follow-up arm"
62001628|NCT00847275|EXPERIMENTAL|2|"Geriatric follow-up arm"
62001629|NCT06121271|EXPERIMENTAL|Bronchial and Thymic Neuroendocrine Tumour|
62186801|NCT03067363|PLACEBO_COMPARATOR|Part 1, Placebo|Placebo, single subcutaneous injection
62186802|NCT03067363|EXPERIMENTAL|Part 2: MOR107 low dose|MOR107 low dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
62186803|NCT03067363|EXPERIMENTAL|Part 2: MOR107 medium dose|MOR107 medium dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
62001630|NCT06121271|EXPERIMENTAL|Paraganglioma/ Phaeochromocytoma|
62001631|NCT06121271|EXPERIMENTAL|Medullary Thyroid Carcinoma|
62001632|NCT06121271|EXPERIMENTAL|Those Requiring Repeat Peptide Receptor Radionuclide Therapy|
62001633|NCT00213148|ACTIVE_COMPARATOR|Clomiphene Citrate 50 Milligram (mg)|
62001634|NCT00213148|ACTIVE_COMPARATOR|Clomiphene Citrate 100 mg|
62001635|NCT00213148|EXPERIMENTAL|Anastrozole 1 mg|
62001636|NCT00213148|EXPERIMENTAL|Anastrozole 5 mg|
62186804|NCT03067363|EXPERIMENTAL|Part 2: MOR107 high dose|MOR107 high dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
62186805|NCT03067363|PLACEBO_COMPARATOR|Part 2: Placebo|Placebo single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
62186806|NCT05505370|EXPERIMENTAL|Study Arm Study device|Patients who meet all eligibility criteria were included and had a clinically indicated colonoscopy procedure performed using the study device. Immediately thereafter, patients had a colonoscopy procedure using standard colonoscope (Olympus CF 180) by a second endoscopist.
62186807|NCT05505370|ACTIVE_COMPARATOR|Study Arm - Predicate Device|Patients who meet all eligibility criteria were included and had a clinically indicated colonoscopy procedure performed using the study device. Immediately thereafter, patients had a colonoscopy procedure using standard colonoscope (Olympus CF 180) by a second endoscopist.
62186808|NCT04962698|EXPERIMENTAL|Healthy participants|All participants will receive seven types of interventions in random order. The types of interventions are the same across subjects.
62186809|NCT04962698|EXPERIMENTAL|Post-Stroke participants|All participants will receive three types of interventions in random order. The types of interventions are the same across subjects.
62186810|NCT01601613|EXPERIMENTAL|rFVIIa|
62186811|NCT01601613|PLACEBO_COMPARATOR|placebo|
62186812|NCT01682746|EXPERIMENTAL|Treatment|Photofrin (porfimer sodium) photodynamic therapy.
62186813|NCT01477736|ACTIVE_COMPARATOR|Botulinum toxin A|
62186814|NCT01477736|ACTIVE_COMPARATOR|oxybutynin|
62001637|NCT00213148|EXPERIMENTAL|Anastrozole 10 mg|
62186815|NCT01840449||Neuroendocrine Tumours|The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
62186816|NCT01840449||Acromegaly|The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
62186817|NCT02893098|EXPERIMENTAL|Humia inj.|Participants with symptomatic Primary Osteoarthritis of Knee received a single injection of 3ml Humia inj.
62186818|NCT02893098|ACTIVE_COMPARATOR|High Hyal Plus inj.|Participants (Control Group) with symptomatic Primary Osteoarthritis of Knee received single injection of 2ml High Hyal Plus inj. given weekly for 3 weeks
62186819|NCT04967183|EXPERIMENTAL|Group I|Annual FIT surveillance
62186820|NCT04967183|ACTIVE_COMPARATOR|Group II|Endoscopic surveillance
62186821|NCT03155217||patients over 75 years|Patients with MM treated with single or combination therapy over 75 years of age.
62186822|NCT03155217||patients between 65 and 75 years|Patients aged 65-75 years with MM treated with single or dual therapy
62186823|NCT03155217||patients less than 65 years|patients less than 65 years with MM treated with single or dual therapy
62186824|NCT05163210|EXPERIMENTAL|AO+VR|Participants of the experimental group will undergo a treatment based on observation of actions followed by their immediate reproduction in VR (AO+VR treatment).
62001638|NCT04061694|EXPERIMENTAL|Digital Immediate loading|Single dental implant installed with the assistance of fully guided-surgery, submitted to immediate loading with restorations fabricated with the help of intraoral scanning and 3D printing
62001639|NCT04061694|OTHER|Immediate loading|Historic cohort subjected to immediate loading
62001640|NCT01388829|EXPERIMENTAL|formulation comparison|formulation comparison
62001641|NCT03181542|EXPERIMENTAL|Infrared vein illumination|Infrared illumination of veins, using the FDA approved AccuVein device, will be used to assist in vein location when inserting an intravenous access line
62001642|NCT03181542|NO_INTERVENTION|Standard Technique|Standard vein location techniques will be used when inserting an intravenous access line
62001643|NCT02643524|ACTIVE_COMPARATOR|Nutrition and Exercise Counseling|CAM boot prescribed as standard of care Nutritional counseling provided Upper body exercise counseling provided Blood drawn for Albumin level at enrollment and final visit Height and weight measured at enrollment and final visit Patients in this arm compared with patients in control arm
62186825|NCT05163210|PLACEBO_COMPARATOR|CO+VR|Participants randomly assigned to the control group will receive an equal number of rehabilitation sessions, as the experimental group. Differently from the latter, patients of the control group will be required to observe videos depicting naturalistic scenes, without motor contents, for 1.5 min. Then, they will receive a motor training in the VR environment, performing the same type of exercises included in the above-described experimental treatment, prompted by the verbal instructions of an expert therapist.
62186826|NCT04266847|EXPERIMENTAL|unilateral mild cataract patients|The patients who underwent monocular IOL implantation before and then present mild cataract in the fellow eye.
62186827|NCT04885647|EXPERIMENTAL|Arm1|Low dose once every 2 weeks group
62186828|NCT04885647|EXPERIMENTAL|Arm2|Low dose once every 4 weeks group
62186829|NCT04885647|EXPERIMENTAL|Arm3|High dose once every 2 weeks group
62186830|NCT04885647|EXPERIMENTAL|Arm4|High dose once every 4 weeks group
62186831|NCT03856047|EXPERIMENTAL|NNC0174-0833, 4.5 mg|Patients will receive 4.5 mg of NNC0174-0833 once a week as injections for 26 weeks.
62186832|NCT03856047|EXPERIMENTAL|NNC0174-0833, 2.4 mg|Patients will receive 2.4 mg of NNC0174-0833 once a week as injections for 26 weeks.
62186833|NCT03856047|EXPERIMENTAL|NNC0174-0833, 1.2 mg|Patients will receive 1.2 mg of NNC0174-0833 once a week as injections for 26 weeks.
62186834|NCT03856047|EXPERIMENTAL|NNC0174-0833, 0.6 mg|Patients will receive 0.6 mg of NNC0174-0833 once a week as injections for 26 weeks.
62186835|NCT03856047|EXPERIMENTAL|NNC0174-0833 0.3 mg|Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.
62186836|NCT03856047|PLACEBO_COMPARATOR|Placebo 2.4 mg (NNC0174-0833)|Patients will receive 2.4 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
62186837|NCT03856047|PLACEBO_COMPARATOR|Placebo 4.5 mg (NNC0174-0833)|Patients will receive 4.5 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
62395277|NCT05426694|EXPERIMENTAL|Group A|The interventional group received stretching and strengthening exercises along with scapular clock exercises. For the first two weeks, only scapular clock exercises were performed by the patient actively. After 2 weeks, the subjects performed scapular clock exercises by using the thera-band.
62186838|NCT03856047|PLACEBO_COMPARATOR|Placebo 1.2 mg (NNC0174-0833)|Patients will receive 1.2 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
62186839|NCT03856047|PLACEBO_COMPARATOR|Placebo 0.6 mg (NNC0174-0833)|Patients will receive 0.6 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
62186840|NCT03856047|PLACEBO_COMPARATOR|Placebo 0.3 mg (NNC0174-0833)|Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.
62186841|NCT03856047|ACTIVE_COMPARATOR|Liraglutide 3.0 mg|Patients will receive 3.0 mg of liraglutide once daily as injections for 26 weeks.
62186842|NCT03856047|PLACEBO_COMPARATOR|Placebo 3.0 mg (Liraglutide)|Patients will receive placebo 3.0 mg(liraglutide) once daily as injections for 26 weeks.
62186843|NCT05910892|ACTIVE_COMPARATOR|Aromatherapy before treatment|Subject receives aromatherapy before IMS treatment or trigger point injection
62186844|NCT05910892|PLACEBO_COMPARATOR|Placebo before treatment|Subject receives placebo before IMS treatment or trigger point injection
62186845|NCT03989921||normo responders|that have an AMH dosage greater than or equal to 1.2 ng/mL
62186846|NCT03989921||poor responders|with a dosage of less than 1.2 ng/mL
62186847|NCT05651425||surgeon-independent group|the coiling diameter is predicted by experienced surgeon alone.
62186848|NCT05651425||surgeon-software-assistant group|the coiling diameter is predicted by experienced surgeon with software assistant.
62186849|NCT00038298|EXPERIMENTAL|50 mg|50 mg 3 times weekly
62186850|NCT00038298|EXPERIMENTAL|400 mg|400 mg 3 times weekly
62186851|NCT00038298|EXPERIMENTAL|200 mg|200 mg 3 times weekly
62186852|NCT00038298|PLACEBO_COMPARATOR|Placebo|Placebo comparator associated with each active arm. (3:1 active vs placebo)
62186853|NCT06547385|EXPERIMENTAL|ONO-4578+ONO-4538+XELOX plus bevacizumab|
62186854|NCT06547385|EXPERIMENTAL|ONO-4578+ONO-4538+FOLFOX plus bevacizumab|
62186855|NCT02599922|EXPERIMENTAL|Group 1: 2.0 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 2.0 x 10\^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
62186856|NCT02599922|EXPERIMENTAL|Group 2: 4.0 x 10^10 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 4.0 x 10\^10 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
62186857|NCT02599922|EXPERIMENTAL|Group 3: 1.2 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 1.2 x 10\^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
62186858|NCT02599922|EXPERIMENTAL|Group 4: 3.6 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 3.6 x 10\^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
62186859|NCT02599922|EXPERIMENTAL|Group 4a: 3.6 x 10^11 vg/mL of AGTC-401|Subjects 6 to 17 y/o treated with 3.6 x 10\^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
62186860|NCT02599922|EXPERIMENTAL|Group 5: 1.1 x 10^12 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 1.1 x 10\^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
62186861|NCT02599922|EXPERIMENTAL|Group 5a: 1.1 x 10^12 vg/mL of AGTC-401|Subjects 4 to 8 y/o treated with 1.1 x 10\^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
62186862|NCT02599922|EXPERIMENTAL|Group 6: 3.2 x 10^12 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 3.2 x 10\^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
62186863|NCT02599922|EXPERIMENTAL|Group 7: MTD of AGTC-401|Subjects 4 to 8 y/o treated with a maximum tolerated dose of rAAV2tYF-PR1/7-hCNGB3 study drug determined by Groups 1-6.
62186864|NCT06418230||MEDULLARY SPONGE KIDNEY|medullary sponge kidney attending medical consultation
62570373|NCT05067608|ACTIVE_COMPARATOR|Control arm|"Subjects in the control arm will receive normal pooled platelets for all of their transfusion within a single thrombocytopenic period. If subjects participate in the study for more than one thrombocytopenic period, they will automatically be enrolled in the opposing arm for their second thrombocytopenic period."
62777155|NCT02339792|OTHER|Intervention|e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
62186865|NCT03371277|EXPERIMENTAL|Arm1|patients with Parkinson's disease treated with deep brain stimulation.
62186866|NCT03371277|EXPERIMENTAL|Arm2|patients with Parkinson's disease treated without deep brain stimulation.
62186867|NCT03268109||people living with HIV|subjects infected with HIV and with cognitive complaints
62186868|NCT03268109||control subjects|subjects not infected with HIV and with cognitive complaints
62186869|NCT02457442|ACTIVE_COMPARATOR|PR1|(Arm closed in May 2022) Propofol-Remifentanil: Prop high, Remi low. Changing Remi (up-and-down)
62395278|NCT05426694|ACTIVE_COMPARATOR|Group B|The active control group received stretching and strengthening exercises only. The stretching and strengthening exercises include corner stretch, wall-washes and pectoralis minor muscle stretch.
62777156|NCT02339792|OTHER|Control|e-learning program of medical education, focused on teaching only geriatric pharmacological notions (GPNs)
62777157|NCT01321593||hemoglobin determination|emergency unit patients
62777158|NCT02692378|ACTIVE_COMPARATOR|Treatment|"Standard haemodialysis treatment thrice weekly (using a standard dialysate containing bicarbonate at a concentration of 35mmols/L) with the addition of oral sodium bicarbonate 500mg capsules for 12 weeks (weeks 5-16 of the study).~The dosage will be titrated to individual blood levels. Starting dose will be 1g twice daily and if predialysis bicarbonate levels remain \<22mmols/L the dose will be increased by 0.5g twice daily each week. The maximum dose would be 3g twice daily.~The oral sodium bicarbonate may be withheld on dialysis days, when bicarbonate will be supplemented through the dialysate. This will be assessed on a case by case basis."
62777159|NCT02692378|NO_INTERVENTION|Control|Standard haemodialysis treatment thrice weekly using a standard dialysate containing bicarbonate at a concentration of 35mmols/L.
62570374|NCT05067608|EXPERIMENTAL|Treatment arm|"Subjects in the treatment arm will receive thawed cryopreserved pooled platelets for all of their transfusions (except for unplanned or urgent platelet transfusions outside stipulated periods when thawed cryopreserved platelets are unavailable) within a single thrombocytopenic period. If subjects participate in the study for more than one thrombocytopenic period, they will automatically be enrolled in the opposing arm for their second thrombocytopenic period."
62777160|NCT01402648|PLACEBO_COMPARATOR|Dietary supplement|900 mg Maltodextrins
62777161|NCT01402648|ACTIVE_COMPARATOR|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside) + 750 mg non starch, insoluble and indigestible fiber (6% in lignin).
62777162|NCT01608841|NO_INTERVENTION|Gemcitabine|
62777163|NCT01608841|EXPERIMENTAL|Gemcitabine plus erlotinib|
62777164|NCT01623739|ACTIVE_COMPARATOR|Type 1 implant placement|Placement of a dental implant: Implant is placed immediately following tooth extraction in one surgical procedure
62777165|NCT01623739|ACTIVE_COMPARATOR|Type 2 implant placement|Placement of a dental implant: Once the tooth is extracted. The site is left to heal for 4 to 8 weeks before a dental implant is placed during a second surgical procedure.
62186870|NCT02457442|ACTIVE_COMPARATOR|PR2|(Arm closed in May 2022) Propofol-Remifentanil: Prop low, Remi high. Changing Prop (up-and-down)
62186871|NCT02457442|ACTIVE_COMPARATOR|SR1|(Arm closed in May 2022) Sevoflurane-Remifentanil: Sevo high, Remi low. Changing Remi (up-and-down)
62186872|NCT02457442|ACTIVE_COMPARATOR|SR2|(Arm closed in May 2022) Sevoflurane-Remifentanil: Sevo low, Remi high. Changing Sevo (up-and-down)
62186873|NCT02457442|ACTIVE_COMPARATOR|SPR1|(Arm closed in October 2023) Sevoflurane-Propofol-Remifentanil: Sevo plus Remi intermediate, Remi intermediate; changing Propofol.
62186874|NCT02457442|ACTIVE_COMPARATOR|SPR2|(Arm closed in October 2023) Sevoflurane-Propofol-Remifentanil: Sevo plus Remi intermediate, Remi intermediate; changing Sevoflurane.
62186875|NCT04698915|EXPERIMENTAL|Arm A Active GC4711|
62186876|NCT04698915|PLACEBO_COMPARATOR|Arm B Placebo|
62186877|NCT00826228|EXPERIMENTAL|PTH/Weight-Bearing|
62186878|NCT04886960|EXPERIMENTAL|Amniotic Fluid Injection|Amniotic Fluid Injection, 3ml, one time dose.
62186879|NCT04886960|ACTIVE_COMPARATOR|Standard of Care Steroid Injection|Corticosteroids, 3ml, one time dose.
62186880|NCT04956562||Vaccinated with sinovac|Vaccinated COVID-19 patients over 65 years consisted the study group
62186881|NCT04956562||Unvaccinated|Unvaccinated patients over 65 years composed the control group
62186882|NCT01818609|EXPERIMENTAL|Step Reduction|"Step reduction:~* Take less than 1500 steps/d~* No disease"
62186883|NCT01452737|EXPERIMENTAL|2L Golytely/15mg bisacodyl|Subjects will be asked to take 2L Golytely + 15mg bisacodyl for bowel prep the day before colonoscopy.
62186884|NCT01452737|ACTIVE_COMPARATOR|Standard bowel prep|Subject will receive standard bowel prep (4L Golytely) prior to colonoscopy.
62777166|NCT01734759|EXPERIMENTAL|Taste Test|
62777167|NCT00258934|EXPERIMENTAL|1|
62777168|NCT00258934|ACTIVE_COMPARATOR|2|
62777169|NCT05997706|EXPERIMENTAL|Infertile patients|Infertile patients going to surgery for fertility preservation or infertility treatment at University Clinic Saint-Luc Brussels
62777170|NCT00317382|NO_INTERVENTION|No Ultrasound|Standard LP without ultrasound use
62777171|NCT00317382|EXPERIMENTAL|Ultrasound Use|Ultrasound used to assess spine and best location for lumbar puncture.
62777172|NCT04190277|EXPERIMENTAL|36-week Closed-Loop|2-week baseline period in open-loop condition, then 12-week period in closed-loop condition followed by a 24-week extension period in closed-loop condition
62777173|NCT04190277|ACTIVE_COMPARATOR|12-week open-loop and 24-week closed-loop|2-week baseline period in open-loop condition, then 12-week period in open-loop condition followed by a 24-week extension period in closed-loop condition
62777174|NCT02259894|EXPERIMENTAL|BIRT 2584|single rising doses
62186885|NCT03911362|ACTIVE_COMPARATOR|Lumbopelvic Stabilisation Exercises|Starting with co-contraction of the transversus abdominis (TA) muscle and other muscles together with diaphragm breathing, and continuing the exercises with upper and lower extremity movements together with TA and multifidus contraction
62395279|NCT05906043|NO_INTERVENTION|Cross Sectional Study to define the extent and severity of fatigue|All patients attending the IBD service that meet inclusion criteria will be given the opportunity to participate in this study. Information will be collected at baseline including demographic data, IBD history and symptoms, co-morbidities and disease activity. Patients will have baseline blood tests taken to assess for causes of fatigue as well as faecal calprotectin to assess for evidence of inflammation. Patients without fatigue will at this point exit the study and will not require any further follow up.
62395280|NCT05906043|NO_INTERVENTION|Treatment for active disease and its effect on fatigue.|A longitudinal study of contemporary treatment for active disease and its effect on fatigue. Patients with active disease and fatigue will be followed prospectively while undergoing treatment for active IBD with the IBD team. If their fatigue resolves, they will exit the study at this point. If their fatigue persists, they will be further assessed as detailed below.
62001644|NCT02643524|ACTIVE_COMPARATOR|Control|CAM boot prescribed as standard of care No nutritional or exercise counseling provided Blood drawn for Albumin level at enrollment and final visit Height and weight measured at enrollment and final visit
62001645|NCT06036069|EXPERIMENTAL|Conventional physical therapy group|It consisted of 20 children received conventional physical therapy
62001646|NCT06036069|EXPERIMENTAL|Core stability exercises group|It consisted of 20 children received conventional physical therapy and core stability exercises
62186886|NCT03911362|ACTIVE_COMPARATOR|Pelvic Floor Exercises|The pelvic flor exercise will be in the form of contraction-release for rapidly contracting muscle fibres and for slowly contracting muscle fibres,slow contraction by counting to ten hold for a count of ten, then gradually relax by counting to ten.
62001647|NCT06036069|EXPERIMENTAL|Whole body vibration|It consisted of 20 children received conventional physical therapy and whole body vibration exercises
62001648|NCT04524312|ACTIVE_COMPARATOR|NexGen|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet NexGen prosthesis
62186887|NCT01743976|EXPERIMENTAL|Donepezil|donepezil 5 mg every day
62186888|NCT01743976|PLACEBO_COMPARATOR|Placebo|Placebo (sugar pill) every day
62395281|NCT05906043|NO_INTERVENTION|The effect of treating anaemia on fatigue in IBD|A longitudinal study assessing anaemia and the effect of treatment on fatigue in those subjects with inactive IBD.Patients with anaemia and fatigue will be followed prospectively while undergoing treatment for anaemia with the IBD team. The study outcomes will be assessed at recruitment and when their anaemia has resolved (this may occur in parallel with the disease activity arm). If their fatigue resolves, they will exit the study at this point. If their fatigue persists, they will be further assessed as detailed below.
62570375|NCT05977660||With chronic ankle instability (CAI)|Participations with CAI diagnosed by a medical doctor
62570376|NCT05977660||control (without CAI)|Participations without CAI who didn't have any ankle injury 2 years before the study recruitment
62777175|NCT02259894|PLACEBO_COMPARATOR|Placebo|
62777176|NCT02286557|EXPERIMENTAL|Arm I|Arm 1 will undergo four weeks of treatment with MP extended-release (20 mg/day in the morning). Following the four weeks of treatment, all assessments performed at baseline will be repeated. To minimize practice effects, alternate versions of the neuropsychological tests will be used wherever available. A 7-day washout period will follow in which no medication will be administered. Following the washout period, Arm 1 will undergo four weeks of placebo. This will be followed by a final assessment consisting of measures of fatigue, cognitive functioning, and physical disability.
62777177|NCT02286557|EXPERIMENTAL|Arm II|Arm 2 will undergo four weeks of placebo (in the morning). Following the four weeks of placebo, all assessments performed at baseline will be repeated. To minimize practice effects, alternate versions of the neuropsychological tests will be used wherever available. A 7-day washout period will follow in which no medication will be administered. Following the washout period, Arm 2 will undergo four weeks of treatment with MP extended-release (20mg/day). This will be followed by a final assessment consisting of measures of fatigue, sleep quality, cognitive functioning, and physical disability.
62186889|NCT03441945|NO_INTERVENTION|control|"The patients swallowed the capsule with water in the lying position.After finishing the stomach examination, the operation of the capsule is adjusted to small bowel mode without magnetic control. Capsule entered the duodenum under physiological peristalsis. The position of the capsule was established using a real-time viewer. If the capsule failed to enter the duodenum after one hour, domperidone (10 mg) was orally administered."
62001649|NCT04524312|ACTIVE_COMPARATOR|K-Mod|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Bioimplanti K-MOD prosthesis
62186890|NCT03441945|EXPERIMENTAL|magnetic steering|"After finishing the stomach examination as the control protocol, the capsule was lifted with the magnetic control, then rotating the capsule until the camera end oriented toward the pylorus . Next, the endoscopist could drag the capsule close to the pylorus with the guidance magnet robot, waiting for the open of pylorus. Once the pylorus opened, the capsule could enter the duodenum with gastric peristalsis. After reaching the duodenal bulb, capsule was held to the maximum position of Z, then the capsule would scan the duodenal bulb automatically with the mode 360° automatic scanning."
62001650|NCT04347395|NO_INTERVENTION|Group 1: Control Group|Current best practice for prevention of HAP
62186891|NCT03875781|EXPERIMENTAL|A: Modified Folfirinox|"Experimental : preoperative chemotherapy:~Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively."
62186892|NCT03875781|ACTIVE_COMPARATOR|B: Modified Folfirinox followed by Radiochemotherapy|Active comparator: preoperative chemotherapy : Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively FOLLOWED BY Preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor
62186893|NCT02470923|OTHER|Group 1|Usual care including medical advice to quit and confrontation with abnormal spirometry results if relevant.
62186894|NCT02470923|OTHER|Group 2|Intensive counseling (15 minutes) by a smoking cessation counselor including confrontation with abnormal spirometry results if relevant, and follow up for at least 5 weeks after discharge (will be done weekly by phone for five consecutive weeks).
62186895|NCT02470923|OTHER|Group 3|Intensive counseling (15 minutes) by a smoking cessation counselor including confrontation with abnormal spirometry results if relevant, offering and providing nicotine replacement therapy (NRT) and follow up (will be done weekly by phone for five consecutive weeks).
62186896|NCT05109936|EXPERIMENTAL|Experimental arm|Immediate prescription (at randomization) of ADENURIC 80 mg / day (febuxostat), urate-lowering treatment, for a period of 2 x 6 weeks.
62186897|NCT05109936|NO_INTERVENTION|Standard care arm|Prescription deferred to 6 weeks (42 days +/- 3 days) of ADENURIC 80 mg / day (febuxostat): hypouricemic treatment, for a period of 6 weeks.
62186898|NCT01542346|EXPERIMENTAL|wound closure with subcutaneous adaption|
62186899|NCT03003598|ACTIVE_COMPARATOR|Videolaryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
62395282|NCT05906043|OTHER|Assessing exercise therapies in IBD subjects with fatigue|A longitudinal study assessing of dietary and exercise therapies for IBD subjects with fatigue using a single case study (SCS) design. They will have their physical activity levels assessed at recruitment and as needed after active disease/anaemia/nutritional deficiencies have been adequately treated. Those with fatigue despite optimisation will be offered a physical activity intervention. Each participant will be assessed initially and subsequently assigned a physical activity intervention with a physical therapist.
62395283|NCT05906043|OTHER|Acceptance and commitment therapy (ACT) in IBD subjects with fatigue|A longitudinal study of acceptance and commitment therapy (ACT) in IBD subjects with psychological disability and fatigue using a single case study (SCS) design. All patients will undergo psychological assessment as detailed above at recruitment and as needed after active disease/anaemia/nutritional deficiencies have been adequately treated. Those with fatigue and psychological disability will be referred to the IBD psychology service or recruited to a psychological intervention. Participants will receive an online intervention with a psychologist from the School of Psychology in University College Dublin to address psychological disability and associated fatigue.
62395284|NCT05906043|OTHER|ACT for IBD subjects with sleep disturbance and fatigue|A longitudinal study of ACT for IBD subjects with sleep disturbance using a single case study (SCS) design. Patients will have their sleep quality assessed at recruitment and as needed after active disease/anaemia/nutritional deficiencies have been adequately treated. Those with sleep disturbance will undergo sleep studies at home both at the start and end of the intervention. This device will be a non-invasive, widely available sleep device worn on the wrist or the patient's index finger for one to three consecutive nights. They will be referred to the sleep medicine unit in SVUH if sleep apnea or another diagnosis that requires medical intervention is identified. Otherwise they will undergo an online intervention with a psychologist from the School of Psychology in University College Dublin to address their sleep quality.
62395285|NCT05906043|OTHER|A longitudinal study of probiotics for IBD subjects with fatigue|Participants will have their stool analysed to assess the diversity of their microbiome. They will receive a twelve-week course of a probiotic which will be taken once daily. They will then have their stool re-assessed at the completion of the intervention.
62395286|NCT03145376||patients before and after TAVI/MitraClip|geriatric assessment of patients before and after TAVI/Mitraclip
62395287|NCT02985541|EXPERIMENTAL|Levonorgestrel IUS (Mirena, BAY86-5028)|Mirena during extended use (Years 6 to 8).
62395288|NCT00528294|EXPERIMENTAL|1|GRID-radiotherapy followed by biological imaging guided IMRT
62395289|NCT06393504||QUVIVIQ-exposed group|Pregnant women with insomnia exposed to QUVIVIQ during pregnancy or within 5 half-lives prior to date of conception.
62001651|NCT04347395|EXPERIMENTAL|Group 2: Intervention|Respiratory Bundle Intervention
62001652|NCT01586468|PLACEBO_COMPARATOR|NaCl Solution|
62001653|NCT01586468|EXPERIMENTAL|WF10 0.5 ml/kg BW|
62186900|NCT03003598|ACTIVE_COMPARATOR|Direct laryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
62186901|NCT01893853|OTHER|Water|Electrolyte- and mineral-free water with exercise intervention
62186902|NCT01893853|PLACEBO_COMPARATOR|Placebo|Calorie- and electrolyte-free, sweetened flavored water with exercise intervention
62186903|NCT01893853|EXPERIMENTAL|Carbohydrate-electrolyte beverage|Commercially-available flavored beverage carbohydrate-electrolyte beverage with Exercise Intervention
62186904|NCT05317559|EXPERIMENTAL|room light|The room light condition (n=10) included one night of sleep in dim light (\< 3 lux) followed by one night of sleep with overhead room lighting (100 lux).
62777178|NCT02035319||capillary malformation treated by laser|capillary malformation treated by laser
62777179|NCT02180958||Cerebral Arteriovenous Malformations|Adult patients requiring endovascular treatment of Cerebral Arteriovenous Malformations.
62777180|NCT06497296|PLACEBO_COMPARATOR|1-minute group|6 puff of lidocaine was delivered 1 minute before the initiation of EGD insertion
62777181|NCT06497296|ACTIVE_COMPARATOR|3-minute group|6 puff of lidocaine was delivered 3 minutes before the initiation of EGD insertion
62777182|NCT01780753|EXPERIMENTAL|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
62001654|NCT03548012|EXPERIMENTAL|The Carer Support Needs Assessment Tool (CSNAT) intervention|('Standard' basic palliative care +) The Carer Support Needs Assessment Tool (CSNAT) intervention.
62001655|NCT03548012|NO_INTERVENTION|Control|('Standard' basic palliative care). No intervention offered.
62001656|NCT03765294|EXPERIMENTAL|Treatment A: ACT-541468|50 mg once daily from Day 1 to Day 5 of Period A
62001657|NCT03765294|PLACEBO_COMPARATOR|Treatment B: Placebo|Matching placebo once daily from Day 1 to Day 5 of Period B
62186905|NCT05317559|NO_INTERVENTION|dim light|The dim light condition (n=10) included two consecutive nights of sleep in dim light.
62186906|NCT02658175|EXPERIMENTAL|Treatment-naïve Group|Treatment naïve group included combined group of ISIS 304801-CS7 (CS7-New) study participant and participant on placebo in index studies (ISIS 304801-CS6 \[NCT02211209\] and ISIS 304801-CS16 \[NCT02300233\]), were to receive 300 mg of volanesorsen as single SC once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following Week 52 visit, participants had option of participating in expanded access program or continuing treatment with 300 mg of volanesorsen as single SC once-weekly for up to additional 52 weeks (Weeks 53-104) and in France participants, up to additional 104 weeks for total of 156 weeks (Weeks 105 to Week 156) until expanded access program was approved and available in their country. Participants who were not participating in expanded access program were to enter 13-week post-treatment (PT) evaluation period and in France, participants not continuing treatment were to enter 26-week PT follow-up period.
62395290|NCT06393504||Active comparator group|Pregnant women with insomnia exposed to non-orexin receptor antagonist insomnia medications during pregnancy or within 5 half-lives of the respective insomnia medication prior to date of conception.
62395291|NCT06393504||Unexposed comparator group|Pregnant women with insomnia unexposed to insomnia medications during pregnancy and within 5 half-lives of any insomnia medication taken prior to date of conception.
62395292|NCT00953173||LapBand|Patients who have already consented to receive the LAP-BAND AP® Adjustable Gastric Banding System
62395293|NCT00951587|EXPERIMENTAL|1|Patients that are indicated for colonoscopy or who are suspected or known to suffer from colonic diseases.
62395294|NCT03642249|EXPERIMENTAL|experimental group|"1. face-to-face delirium care session (30 minutes in duration);~2. online learning delirium care activities (20 minutes in duration); and~3. delirium care OSCE and reflective activity (30 minutes in duration)."
62395295|NCT03642249|ACTIVE_COMPARATOR|control group|"1. face-to-face delirium care session (30 minutes in duration);~2. online learning delirium care activities (20 minutes in duration)"
62395296|NCT01139645|EXPERIMENTAL|Proton Pump Inhibitors|patients were started on Proton Pump inhibitors for 3 months (the whole duration of the study)
62395297|NCT01139645|NO_INTERVENTION|No Proton Pump Inhibitors|patients are not taking any Proton Pump Inhibitor, and they are matched by age to patients in the experimental group.
62395298|NCT02442284|EXPERIMENTAL|3-DAA ± RBV for 12 or 24 weeks|3-DAA (ombitasvir/paritaprevir/ritonavir \[25 mg/150 mg/100 mg once daily\] and dasabuvir \[250 mg twice daily\]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on genotype and presence of cirrhosis.
62395299|NCT06065371|EXPERIMENTAL|Sacituzumab govitecan and capecitabine|The trial has three dose levels. Dose level -1 has capecitabine at 500mg/m2 twice daily taken orally for two weeks on and one week off, plus sacituzumab govitecan at 7.5mg/kg given intravenously on Days 1 and 8. Each cycle is 21 days. Dose level 0 has capecitabine at 500mg/m2 and sacituzumab govitecan at 10mg/kg. Dose level 1 has capecitabine at 825mg/m2 and sacituzumab govitecan at 10mg/kg.
62395300|NCT00816244|EXPERIMENTAL|Atorvastatin|
62395301|NCT01132040|EXPERIMENTAL|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories
62777183|NCT02060643||Cross-sectional hemi-neck RT|
62791717|NCT05044858|SHAM_COMPARATOR|Sham group|Patients will receive general anesthesia and the same intervention steps will be performed i.e., the block under investigation but instead of local anesthetic a placebo (2ml normal saline) will be injected (sham block)
62791718|NCT00659932|EXPERIMENTAL|1|
62791719|NCT00659932|ACTIVE_COMPARATOR|2|
62791720|NCT06126341||Participant Cohort 1|Relapse/refractory multiple myeloma/RRMM patients less than 70 years of age.
62791721|NCT06126341||Participant Cohort 2|Relapse/refractory multiple myeloma/RRMM patients 70 years of age or greater
62791722|NCT06126341||Physician Group 1: Primary Myeloma Therapy|Physicians in this group refer for cellular therapy but do not perform the infusions.
62570377|NCT02245399|EXPERIMENTAL|A canola oil enriched mediterranean diet|Participants will be advised to consume, a low-carbohydrate diet (26-32% of calories), high in vegetable protein (28-32%) and fat (41-45%) with canola as the major component (10%). Carbohydrate sources will feature viscous fiber-containing foods (including psyllium cereal, oats and barley) and low-starch vegetables (emphasizing okra and eggplant) for the relatively limited amount of carbohydrate.
62570378|NCT02245399|ACTIVE_COMPARATOR|A high wheat fiber diet|Participant will be advised to consume a high carbohydrate diet (58% carbohydrate, 16% protein and 25% fat) emphasizing whole wheat/whole grain cereals and increased high fiber alternatives, with fruits and vegetables.
62395302|NCT01132040|ACTIVE_COMPARATOR|Mysoline|Mysoline Tablets of Yamanouchi Pharma Technologies Inc,
62395303|NCT06555172|EXPERIMENTAL|Action In Mindfulness (AIM)+|Participants randomized to the intervention arm will receive the AIM+ mindfulness meditation app.
62395304|NCT06555172|ACTIVE_COMPARATOR|Resource+|Participants randomized to the active control arm will receive the Resource+ informational resource app.
62395305|NCT01471197|EXPERIMENTAL|Arm 1: Ipilimumab|
62570379|NCT06577311|EXPERIMENTAL|Photodynamic Therapy (using Red light dose)|20 participants will be enrolled to this arm
62570380|NCT02551562|PLACEBO_COMPARATOR|Group A: Basic Skin Care|Subjects will use a basic skin care regime following a full facial rejuvenation with hyaluronic acid soft-tissue filler and botulinum neurotoxin.
62001658|NCT06571188|ACTIVE_COMPARATOR|TEB GROUP|In group TEB, The epidural catheter will be inserted preoperatively at the T5-T7 vertebral level; the exact level will be at the discretion of the attending anaesthesiologist. A loading dose of bupivacaine 0.25% (max 10 ml) will be administered, followed by an intraoperative infusion of bupivacaine 0.125 % with Fentanyl 1 μg/ml.\].
62001659|NCT06571188|ACTIVE_COMPARATOR|ESPB group|In group ESPB, The ESP block will be performed as described by Forero et al. A Tuohy needle will be inserted with an in-plane technique in a caudal to cephalad direction until bony contact with the transverse process is obtained. Hydro dissection with normal saline will be performed to identify and open up the correct plane for injection. A loading dose of Bupivacaine will be injected followed by the insertion of an 18-g catheter 5 cm beyond the needle tip. No further local anaesthetic will be administered intra-operatively. Following the end of surgery, a continuous infusion of 5 ml/h of Bupivacaine 0.125%, supplemented by a 10-ml bolus injection every 3 h, will be administered through the ESPB catheter
62001660|NCT03140202|EXPERIMENTAL|Guide then blind|This group use the CPRmeter visual feedback during cardiopulmonary resuscitation (screen visible) first, then have no access to the CPRmeter visual feedback during cardiopulmonary resuscitation (screen mask).
62001661|NCT03140202|EXPERIMENTAL|Blind then guide|This group have no access to the CPRmeter visual feedback during cardiopulmonary resuscitation (screen mask) first then use the CPRmeter visual feedback during cardiopulmonary resuscitation (screen visible).
62001662|NCT04765488|EXPERIMENTAL|Study group|"A group of patients in relation to whom the Wash In / WashOut procedure will be applied. In this group we stop the supply of sevoflurane to the first signs of awakening and record the level of sevoflurane , then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and stop the supply of sevoflurane to the first signs of awakening again, then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and finally ( the third time) stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness."
62001663|NCT04765488|NO_INTERVENTION|Control group|A group of patients in relation to whom will be applied the traditional method of recovery from anesthesia. In this group during the period of awakening we stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness.
62395306|NCT01471197|ACTIVE_COMPARATOR|Arm 2: Pemetrexed|
62395307|NCT06175845|ACTIVE_COMPARATOR|Arm A: ablation arm|Systemic chemotherapy and bile duct stenting with intraductal RFA of malignant bile duct obstructions employing a CE-certified ablation catheter prior to stent placement.
62395308|NCT06175845|NO_INTERVENTION|Arm B: control arm|Systemic chemotherapy and bile duct stenting without RFA.
62395309|NCT05677373|EXPERIMENTAL|Treatment (PLX2853, trametinib)|Patients receive PLX2853 PO in combination with trametinib PO throughout the study. Patients also undergo collection of blood at screening and on study. Patients also undergo CT or MRI with contrast and collection of blood at screening and on study.
62570381|NCT02551562|EXPERIMENTAL|Group B: NuDerm® System|Subjects will use the Nu-Derm® system following a full facial rejuvenation with hyaluronic acid soft-tissue filler and botulinum neurotoxin.
62395310|NCT04234841||Surgical Aortic Valve Replacement (SAVR)|This cohort includes patients who will be undergoing surgical aortic valve replacement
62395311|NCT04234841||Transcatheter Aortic Valve Implantation (TAVI)|This cohort includes patients who will be undergoing Transcatheter Aortic Valve Implantation
62395312|NCT00761891|EXPERIMENTAL|Chewable aspirin|81 mg daily for 2 weeks
62570382|NCT01237574||Patients|Patients with chronic alcoholic and/or metabolic liver disease
62791723|NCT06126341||Physician Group 2: CAR Enabled|These physicians can order and infuse CAR T cells but not stem cells.
62791724|NCT06126341||Physician Group 3: HCT and CAR Enabled|These physicians can order and infuse stem cells and CAR T cells
62791725|NCT04926948|EXPERIMENTAL|Treatment (SBRT, immunotherapy)|Patients undergo 3-5 daily fractions of SBRT in the absence of disease progression or unacceptable toxicity. Patients also receive immunotherapy at the discretion of the treating medical oncologist.
62791726|NCT02698514|EXPERIMENTAL|Sevoflurane|Anesthesia was maintained with sevoflurane.
62395313|NCT03205605|OTHER|baseline patch|patch
62395314|NCT03205605|OTHER|baseline gel|gel
62395315|NCT03205605|OTHER|patch with heat|patch
62395316|NCT03205605|OTHER|gel with occlusion|gel
62395317|NCT01977664||oocyte maturation failure|no intervention
62395318|NCT00755976|EXPERIMENTAL|Epirubicin hydrochloride (75mg/m2 i.v.) Sulindac: 600mg|
62570383|NCT05501821|EXPERIMENTAL|Part A, dose escalation monotherapy|KBA1412 monotherapy, given intravenously, Q3W, multiple dose levels
62570384|NCT05501821|EXPERIMENTAL|Part B, expansion monotherapy|KBA1412 monotherapy, given intravenously, Q3W, at fixed dose as defined in dose-escalation phase (Part A)
62791727|NCT02698514|EXPERIMENTAL|Desflurane|Anesthesia was maintained with desflurane.
62186907|NCT02658175|EXPERIMENTAL|CS6-Volanesorsen|Participants with FCS rolling over from the ISIS 304801-CS6 (NCT02211209) index study after receiving volanesorsen, were to receive 300 mg of volanesorsen as a single SC injection once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following the Week 52 visit, participants had the option of participating in an expanded access program or continuing treatment with 300 mg of volanesorsen as a single SC injection once-weekly for up to an additional 52 weeks (Weeks 53-104) and in France participants, up to an additional 104 weeks for total of 156 weeks of treatment (Weeks 105 to Week 156) of this study until an expanded access program was approved and available in their country. Participants who were not participating in an expanded access program were to enter a 13-week post-treatment evaluation period and in France, participants not continuing treatment were to enter a 26-week post-treatment follow-up period.
62570385|NCT05501821|EXPERIMENTAL|Part C, expansion combination therapy|KBA1412 in combination with pembrolizumab, given intravenously, Q3W, KBA1412 at fixed dose as defined in dose-escalation phase (Part A), Pembrolizumab at fixed dose
62570386|NCT01467102||Patients|\> 18 years of age
62570387|NCT02328313|EXPERIMENTAL|Intervention Cohort|Breast cancer patients 65 and older undergoing chemotherapy and participating in a home-based physical activity intervention.
62570388|NCT02289248|EXPERIMENTAL|Ketamine/CBT Group|Subjects will undergo 2 week course of 4 intravenous infusions of ketamine (given twice weekly for two weeks) in combination with twice weekly cognitive behavioral therapy for a total of 8 weeks.
62570389|NCT01867125|EXPERIMENTAL|Lebrikizumab (125 mg)|Participants will receive SC injection of lebrikizumab (125 milligrams \[mg\]) every 4 weeks for 104 weeks.
62570390|NCT01867125|EXPERIMENTAL|Lebrikizumab (37.5 mg)|Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.
62570391|NCT01867125|PLACEBO_COMPARATOR|Placebo|Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.
62570392|NCT03649932|EXPERIMENTAL|L-citrulline 100 mg/kg/day|50 mg/kg given two times a day (100 mg/kg/day) for total 7 days.
62570393|NCT03649932|EXPERIMENTAL|L-citrulline 200 mg/kg/day|100 mg/kg given two times a day (200 mg/kg/day) for total 7 days
62570394|NCT03649932|EXPERIMENTAL|L-citrulline 300 mg/kg/day|150 mg/kg given two times a day (300 mg/kg/day) for total 7 days.
62791728|NCT03079895|NO_INTERVENTION|Control Arm|After enrollment in the study, the subject will continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being.
62001664|NCT05092659|OTHER|patient interviews|Patient enrolled in a bariatric surgical pathway scheduled for visceral surgery.
62001665|NCT04593030||Warfarin|Reference group
62001666|NCT04593030||Apixaban|Exposure group
62570395|NCT05486182|EXPERIMENTAL|Prospective population|
62001667|NCT03607916|EXPERIMENTAL|Cohort 1 : HB Prilocaine 2%,(60mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
62570396|NCT00628212|EXPERIMENTAL|Teneligliptin 10 mg|Teneligliptin 10 mg, orally, once daily
62570397|NCT00628212|EXPERIMENTAL|Teneligliptin 20 mg|Teneligliptin 20 mg, orally, once daily
62570398|NCT00628212|EXPERIMENTAL|Teneligliptin 40 mg|Teneligliptin 40 mg, orally, once daily
62570399|NCT00628212|PLACEBO_COMPARATOR|Placebo|Teneligliptin placebo-matching tablets, orally, once daily
62791729|NCT03079895|EXPERIMENTAL|Intervention Arm|"After enrollment in the study, the subject will be granted 8 weeks of access to Thrive, an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy. During the first 4 weeks, they will receive 4 coaching emails and/or phone calls encouraging their participation in the study, and answering any program-related questions. The subject will also continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being."
62570400|NCT04670549|OTHER|Pre and post implementation phases|"Pre-implementation phase: during the pre-implementation period persons with hip or knee osteoarthritis will receive usual care as it is currently delivered by physiotherapists and general practitioners.~Post-implementation phase: during the post-implementation phase patients with hip and knee OA will receive OA care more in line with the treatment recommendations."
62001668|NCT03607916|EXPERIMENTAL|Cohort 2 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
62186908|NCT02658175|EXPERIMENTAL|CS16-Volanesorsen|Participants with FCS rolling over from the ISIS 304801-CS16 (NCT02300233) index study after receiving volanesorsen, were to receive 300 mg of volanesorsen as a single SC injection once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following the Week 52 visit, participants had the option of participating in an expanded access program or continuing treatment with 300 mg of volanesorsen as a single SC injection once-weekly for up to an additional 52 weeks (Weeks 53-104) and in France participants, up to an additional 104 weeks for total of 156 weeks of treatment (Weeks 105 to Week 156) of this study until an expanded access program was approved and available in their country. Participants who were not participating in an expanded access program were to enter a 13-week post-treatment evaluation period and in France, participants not continuing treatment were to enter a 26-week post-treatment follow-up period.
62186909|NCT02274077|ACTIVE_COMPARATOR|EXPAREL|Bilateral, one time injections using 30ml of EXPAREL ((bupivacaine liposome injectable suspension) 1.3% ( 13.3mg/ml)) into the transverse abdominal plane at the time of abdominal component separation. A total of 60cc used with a Bupivacaine concentration of 0.44%.
62186910|NCT02274077|PLACEBO_COMPARATOR|Normal Saline|Bilateral, one time injections of 30ml normal saline into the transverse abdominal plane at the time of abdominal component separation.
62186911|NCT03462043|ACTIVE_COMPARATOR|Sequence A|
62186912|NCT03462043|ACTIVE_COMPARATOR|Sequence B|
62186913|NCT03462043|ACTIVE_COMPARATOR|Sequence C|
62395319|NCT03957629|ACTIVE_COMPARATOR|TDF group|93 patients would receive treatment of oral medication of tenofovir disoproxil fumarate (TDF) 300mg once per day from baseline to 48 weeks. Then they would receive oral medication of TDF 300 mg once per day from 49 to 96 weeks.
62395320|NCT03957629|ACTIVE_COMPARATOR|Combination group|93 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg once per week and meanwhile oral medication of tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 48 weeks. Then they would receive oral medication of TDF 300 mg once per day from 49 to 96 weeks.
62395321|NCT01079260|ACTIVE_COMPARATOR|Standard ONS|
62395322|NCT01079260|EXPERIMENTAL|High Energy, Low volume ONS|High energy, low volume ONS
62395323|NCT03206333||Breast cancer patients treated with radiotherapy|
62395324|NCT03219996||non-survivor group|
62395325|NCT03219996||survivor group|
62395326|NCT06394414|EXPERIMENTAL|Part 1: Dose escalation|YL201 in Combination with Serplulimab with or without Platinum-based Chemotherapy
62395327|NCT06394414|EXPERIMENTAL|Part2: Cohort Expansion|YL201 in Combination with Serplulimab with or without Platinum-based Chemotherapy
62395328|NCT02247167|EXPERIMENTAL|adenotonsillectomy (AT)|Children with SDB studied before and after before adenotonsillectomy.
62395329|NCT03551158|OTHER|Atrial fibrillation patients|Patients with atrial fibrillation who underwent cryoballoon ablation
62570401|NCT03136237|EXPERIMENTAL|Cohort 1|Day 1: Digoxin 0.25 mg oral dose Day 11-18: BCX7353 350 mg oral dose Day 19: Digoxin 0.25 mg oral dose and BCX7353 350 mg oral dose Day 20-21: BCX7353 350 mg oral dose
62186914|NCT03462043|ACTIVE_COMPARATOR|Sequence D|
62186915|NCT00301561|EXPERIMENTAL|1|Simplify treatment follow-up
62186916|NCT00301561|ACTIVE_COMPARATOR|2|Standard treatment follow-up
62186917|NCT01458925|OTHER|P1 capsule and screening Cscopy|"Male and female patients older than 40 and younger than 75 years old who volunteer for the experiment and qualify with the inclusion / Exclusion criteria.~The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study"
62186918|NCT00616330|EXPERIMENTAL|1|clindamycin phosphate/butoconazole nitrate
62186919|NCT00616330|ACTIVE_COMPARATOR|2|clindamycin phosphate
62186920|NCT00616330|ACTIVE_COMPARATOR|3|butoconazole nitrate
62186921|NCT06270589|EXPERIMENTAL|A Single Bout Of Mindful High-Intensity Interval Training (Mindful HIIT)|
62186922|NCT06270589|ACTIVE_COMPARATOR|A Single Bout Of High-Intensity Interval Training (HIIT)|
62186923|NCT06270589|ACTIVE_COMPARATOR|A Single Bout Of Mindfulness|
62186924|NCT06270589|OTHER|A Single Bout Of Sitting Rest|
62395330|NCT03986905|EXPERIMENTAL|Scopolamine Nasal Gel|DPI-386 Nasal Gel + placebo patch
62395331|NCT03986905|PLACEBO_COMPARATOR|Placebo|placebo nasal gel + placebo patch
62395332|NCT03986905|ACTIVE_COMPARATOR|TDS Patch|placebo nasal gel + TDS patch
62395333|NCT01177241||CLBP|
62395334|NCT01177241||CLBP OU|
62395335|NCT01009320||Pacemaker with magnets|Patients with pacemakers who will be tested for magnetic interference with a magnetic drape.
62395336|NCT01098019|EXPERIMENTAL|Xeomin|Each bottle of Xeomin will be reconstituted with 2 mL of NaCl 0.9 which will give a final concentration of 5 U of botulinum toxin A per 0.1 mL. The area affected will be injected with 0.1 mL at each 1-2 square cm for a maximum total dose of 200 units (4mL).
62395337|NCT01098019|PLACEBO_COMPARATOR|Placebo|Patients will receive 0.9% mL NaCl alone. The area affected will be injected with 0.1 mL at each 1-2 square cm for a maximum volume of 4 mL.
62395338|NCT06722729|EXPERIMENTAL|KDT-3594|KDT-3594 capsules will be orally administered at escalating doses ranging from 0.25 to 2 mg per day for 17 weeks.
62395339|NCT06722729|PLACEBO_COMPARATOR|Placebo|Placebo capsules will be orally administered at escalating doses ranging from 0.25 to 2 mg per day for 17 weeks.
62570402|NCT03136237|EXPERIMENTAL|Cohort 2|Day 1: Rosuvastatin 10 mg oral dose Day 7-14: BCX7353 350 mg oral dose Day 15: Rosuvastatin 10 mg oral dose and BCX7353 350 mg oral dose Day 16: BCX7353 350 mg oral dose
62791730|NCT02655549|EXPERIMENTAL|Cohort 1 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
62570403|NCT03136237|EXPERIMENTAL|Cohort 3|Day 1: BCX7353 350 mg oral dose Day 14: single oral dose of Cyclosporine 600 mg and BCX7353 350 mg
62570404|NCT03857529|EXPERIMENTAL|conventional tDCS concurrent with CCFES|tDCS anode placed over the lesioned hemisphere and cathode placed over the non-lesioned hemisphere
62570405|NCT03857529|EXPERIMENTAL|unconventional tDCS concurrent with CCFES|tDCS cathode placed over the lesioned hemisphere and anode placed over the non-lesioned hemisphere
62570406|NCT03857529|EXPERIMENTAL|conventional tDCS preceding CCFES|tDCS anode placed over the lesioned hemisphere and cathode placed over the non-lesioned hemisphere
62570407|NCT03857529|EXPERIMENTAL|unconventional tDCS preceding CCFES|tDCS cathode placed over the lesioned hemisphere and anode placed over the non-lesioned hemisphere
62570408|NCT03857529|SHAM_COMPARATOR|sham tDCS with CCFES|sham tDCS preceding and concurrent with CCFES
62570409|NCT02806908|PLACEBO_COMPARATOR|Placebo|Once daily dosing
62186925|NCT06079268|EXPERIMENTAL|0 ml/kg of water|The child does not drink water, and then the gastric ultrasound is performed 3 minutes later blindly to the ingested volume.
62186926|NCT06079268|EXPERIMENTAL|0.6 ml/kg of water|The child drinks 0.6 ml/kg water, and then the gastric ultrasound is performed 3 minutes later blindly to the ingested volume.
62186927|NCT06079268|EXPERIMENTAL|1 ml/kg of water|The child drinks 1 ml/kg water, and then the gastric ultrasound is performed 3 minutes later blindly to the ingested volume.
62186928|NCT06079268|EXPERIMENTAL|1.25 ml/kg of water|The child drinks 1.25 ml/kg water, and then the gastric ultrasound is performed 3 minutes later blindly to the ingested volume
62186929|NCT06079268|EXPERIMENTAL|1.5 ml/kg of water|The child drinks 1.5 ml/kg water, and then the gastric ultrasound is performed 3 minutes later blindly to the ingested volume.
62186930|NCT06079268|EXPERIMENTAL|2 ml/kg of water|The child drinks 2 ml/kg water, and then the gastric ultrasound is performed 3 minutes later blindly to the ingested volume.
62186931|NCT03225976|EXPERIMENTAL|Infrared LED group (G-I)|The Light-Emitting Diode Device with wavelength of 904nm will be applied throughout the quadriceps femoralis extension bilaterally.
62791731|NCT02655549|EXPERIMENTAL|Cohort 2 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
62186932|NCT03225976|EXPERIMENTAL|Red LED group (G-V)|The Light-Emitting Diode Device with a wavelength of 620nm will be applied throughout the quadriceps femoralis extension bilaterally.
62186933|NCT03225976|SHAM_COMPARATOR|Sham Group (G-S)|The Sham Light-Emitting Diode Device will be positioned throughout the quadriceps femoral muscle extension, however, there will be no light emission.
62186934|NCT03225976|EXPERIMENTAL|Infrared plus Red LED group (G-IV)|The Light-Emitting Diode Device with a wavelength of 620nm plus 904nm will be applied throughout the quadriceps femoralis extension bilaterally.
62186935|NCT05184270|EXPERIMENTAL|Sleep Measurements|LFP recording from STN using externalized wires or implanted neurostimulator, while simultaneously recording clinical surface EEG and applying AS during deep sleep.
62186936|NCT05700448|EXPERIMENTAL|Sugemalimab+PGemOx|Participants receive sugemalimab 1200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS PGemOx regimen Q3W (pegaspargase 2000-2500 IU/m\^2 via intramuscular injection on Day 1, gemcitabine 1000 mg/m\^2 via IV infusion on Days 1 \& 8 and oxaliplatin 130 mg/m\^2 via IV infusion on Day 1.
62186937|NCT05700448|PLACEBO_COMPARATOR|Placebo+PGemOx|Participants receive placebo via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS PGemOx regimen Q3W (pegaspargase 2000-2500 IU/m\^2 via intramuscular injection on Day 1, gemcitabine 1000 mg/m\^2 via IV infusion on Days 1 \& 8 and oxaliplatin 130 mg/m\^2 via IV infusion on Day 1.
62395340|NCT02460185|NO_INTERVENTION|Control|Without maternal physical exercise practice
62186938|NCT00966979|OTHER|Triathlon PKR|All subjects enrolled will receive the Triathlon PKR device.
62186939|NCT05080205|EXPERIMENTAL|Morbidly obese subjects|Bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy)
62186940|NCT05080205|NO_INTERVENTION|Control subjects|Non-obese controls are only studied at baseline
62186941|NCT00224029|EXPERIMENTAL|Oxybutynin transdermal system|Oxybutynin transdermal system 3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day dosing
62395341|NCT02460185|ACTIVE_COMPARATOR|Study Group|Behavioral: 30 minutes of walking, 3 times a week at 4 Km/h. Induction of labor was performed at 41 weeks.
62570410|NCT02806908|ACTIVE_COMPARATOR|JZP-110|150 mg/day for first 3 days and 300 mg/day for next 4 days
62570411|NCT05586347|EXPERIMENTAL|group N|Nicardipine was infused after initiation of CPB
62570412|NCT05586347|PLACEBO_COMPARATOR|group C|Give the same volume of normal saline
62570413|NCT04076293|EXPERIMENTAL|HM15912|
62570414|NCT04076293|PLACEBO_COMPARATOR|Placebo|
62570415|NCT00703157|ACTIVE_COMPARATOR|1|Arm 1: Catheter Ablation
62570416|NCT00703157|ACTIVE_COMPARATOR|2|Arm 2: Surgical Ablation.
62570417|NCT01339260|EXPERIMENTAL|Netupitant and Palonosetron+dexamethasone-cycle 1|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle
62570418|NCT01339260|ACTIVE_COMPARATOR|Palonosetron+dexamethasone-cycle 1|Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle
62570419|NCT01339260|EXPERIMENTAL|Netupitant and Palonosetron+dexamethasone-multicycle extension|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle
62570420|NCT01339260|ACTIVE_COMPARATOR|Palonosetron+dexamethasone-multicycle extension|Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle
62570421|NCT04666987||Xultophy®|Participants are patients with Type 2 Diabetes (T2D) treated with Xultophy® (IDegLira) in a real-world setting in Italy
62570422|NCT00090025|EXPERIMENTAL|becatecarin|becatecarin
62570423|NCT00090025|ACTIVE_COMPARATOR|5-FU Plus Leucovorin (LV)|5-Fluorouracil (5-FU) Plus Leucovorin (LV)
62570424|NCT04439474|EXPERIMENTAL|Patients with vitamin D deficiency|This group receives 50,000 units of vitamin D3 daily for up to 8 days until the serum level of vitamin D reaches above 30 ng/ml.
62570425|NCT04439474|ACTIVE_COMPARATOR|Patients without vitamin D deficiency|Participants in this group receive only their usual treatments
62791732|NCT02655549|EXPERIMENTAL|Cohort 3 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
62570426|NCT00758290|ACTIVE_COMPARATOR|A|
62570427|NCT00758290|EXPERIMENTAL|B|
62570428|NCT00879905|EXPERIMENTAL|once weekly dosing schedule|
62777184|NCT02677857|ACTIVE_COMPARATOR|Lifestyle|Participants will be educated on the relationship between MVPA and improved health outcomes, including weight management, and cancer survivorship. The goal will be to increase MVPA to \> 40 min/day 5 times/wk As participants will be overweight/obese, inactive, and coming into the program with different levels of baseline fitness and time since last cancer treatment, participants will shape their MVPA to meet the targeted goals. Initially, participants will be encouraged to complete MVPA \> 10 min/day 5 times/wk, and then progressively increase MVPA by 5 min/day every week until reaching the intervention goal (week 7 of the 12 week intervention). Participants will be encouraged to do brisk walking and be allowed to accumulate time spent being physically active by engaging in multiple short bouts (i.e., \> 10 min in length). Any MVPA in bouts of \> 10 min in length will be counted towards the MVPA goal. Participants will self-monitor their MVPA using the Polar® Loop tracking system.
62791733|NCT05011513|EXPERIMENTAL|PF-07321332/ritonavir|Orally administered PF-07321332+ritonavir
62001669|NCT03607916|EXPERIMENTAL|Cohort 3 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
62186942|NCT01733589|EXPERIMENTAL|Recombinant Human Endostatin|All patients received recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7. During week 2 through 8, patients received etoposide 50mg/m2 days 1-5 and cisplatin 50mg/m2 on day 1,8, every 4 weeks for two cycles with concurrent thoracic radiation at 60\~66Gy in 30\~33 fractions for 6\~7 weeks.
62186943|NCT04709978||Pneumonia|Participants will be over the age of 60 and diagnosed with pneumonia in the UW Emergency Department or treated for pneumonia in the past 6 months.
62186944|NCT03547245|ACTIVE_COMPARATOR|HIV-uninfected, healthy adults|
62186945|NCT03547245|PLACEBO_COMPARATOR|HIV-uninfected, healthy adults - placebo|
62791734|NCT05011513|PLACEBO_COMPARATOR|Placebo|Orally administered Placebo
62186946|NCT03581669||THA + cerclage acetabulum|
62186947|NCT03634722|EXPERIMENTAL|The intervention group|the transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
62186948|NCT03634722|NO_INTERVENTION|The observational group|routine nursing
62186949|NCT00020761|EXPERIMENTAL|Gastro Esophogeal cohort|"Patients with adenocarcinoma of the esophagus, gastroesophageal (GE) junction and gastric cardia (GE cohort)~The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
62186950|NCT00020761|EXPERIMENTAL|Distal Stomach cohort|"Patients with adenocarcinoma of the rest of the stomach (Distal Stomach cohort)~The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
62186951|NCT04752033|EXPERIMENTAL|Morphine|Subjected to sequential up and down dose titration using biased coin method in parallel with the hydromorphone arm
62570429|NCT00879905|EXPERIMENTAL|twice weekly dosing schedule|
62186952|NCT04752033|EXPERIMENTAL|Hydromorphone|Subjected to sequential up and down dose titration using biased coin method in parallel with the morphine arm
62570430|NCT03390751||Aged patients|Data collection of patients admitted to the orthopedic department of the University Hospital of Toulouse for surgical management of a fracture of the upper end of the femur in emergency or for the installation of a hip or knee prosthesis.
62570431|NCT05468112|EXPERIMENTAL|Sky Meditation and Mindfulness Intervention|In person meditation classes will be 3 hours long on each of three consecutive days, and participants must be willing to attend all three sessions. An additional 7 online sessions will be delivered to participants in successive days after the initial in-person intervention. Participants will be asked to engage in daily 10 to 25 minute home resilience practice sessions performed five days per week. To support participants stabilization of the practices, optional daily guided practice will be offered online at a determined convenient time for all participants to allow full participation. The breathing techniques will be taught by certified instructors.
62570432|NCT03396653|ACTIVE_COMPARATOR|Peer-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month patient-delivered behavioral weight maintenance intervention. Specifically, group sessions will be delivered by a mentor (i.e., successful weight loser) and weekly coaching will be delivered by a peer (other member of their weight maintenance group).
62570433|NCT03396653|ACTIVE_COMPARATOR|Professionally-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month reduced intensity behavioral weight maintenance intervention, delivered by a professional. The intervention will consist of 24 group sessions.
62570434|NCT05284331|OTHER|follow-up visit at 6 months and 1 year after inclusion.|addition of a follow-up visit at 6 months and 1 year after inclusion. No treatment will be given specifically for this study. Other visits are part of the normal and usual rhythm of follow-up and evaluation of treatment in these patients
62186953|NCT01459146|EXPERIMENTAL|AL plus ABZ; Arm 1|Artemether-Lumefantrine combination 20mg/120mg 12 hourly for 3 days oral, plus albendazole 400mg stat oral
62186954|NCT01459146|ACTIVE_COMPARATOR|AL plus PZQ plus ABZ; Arm 2|artemether-lumefantrine combination 120mg/20mg 12 hourly for 3 days; plus praziquantel 40mg/kg stat; plus albendazole 400mg stat oral
62186955|NCT01459146|ACTIVE_COMPARATOR|ABZ plus PZQ; Arm 3|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
62186956|NCT01159522|EXPERIMENTAL|SCB01A|This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
62186957|NCT06302595|EXPERIMENTAL|MRI-guided prostate biopsy|Participants who receive biopsy under MRI-guidance and a needle holder frame.
62186958|NCT05739539|ACTIVE_COMPARATOR|pars plana vitrectomy with ILM peeling|Diabetic patients who fulfill the inclusion critera and will undergo pars plana vitrectomy and ILM peeling
62186959|NCT05739539|ACTIVE_COMPARATOR|pars plana vitrectomy without ILM peeling|Diabetic patients who fulfill the inclusion critera and will undergo pars plana vitrectomy without ILM peeling
62186960|NCT02585297||Control- semen|Semen of fertile men
62186961|NCT02585297||Control- vaginal discharge|Vaginal discharge of partners of fertile men
62186962|NCT02585297||Case-semen|Semen of infertile men
62186963|NCT02585297||Case- vaginal discharge|Vaginal discharge of partners of infertile men
62186964|NCT01200498|EXPERIMENTAL|SB939|SB939 starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
62186965|NCT04456712|EXPERIMENTAL|ciprofloxacin for diabetic patients|50 diabetic patients received intravenous ciprofloxacin 400mg/12 hours.
62186966|NCT04456712|EXPERIMENTAL|levofloxacin for diabetic patients|50 diabetic patients received intravenous levofloxacin 750mg/24 hours.
62186967|NCT04456712|EXPERIMENTAL|ciprofloxacin for non-diabetic patients|50 non-diabetic patients received intravenous ciprofloxacin 400mg/12 hours.
62186968|NCT04456712|EXPERIMENTAL|levofloxacin for non-diabetic patients|50 non-diabetic patients received intravenous levofloxacin 750mg/24 hours.
62186969|NCT05383638|OTHER|Health promotion|Health education and popularization of science
62186970|NCT06177899||Split-box group|"Before augmentation, according to the 3D topography of the alveolar ridge of the patients, the split-box technique was applied if there was more than 3 mm bone thickness at the top of the crest and the bone thickness did not increase towards the lower border.~All surgical procedures were performed under local anesthesia. A mid-crestal incision was made along the ridge crest and two vertical incisions were made at the termination of the crestal incision. All osteotomies were made using with piezoelectric surgery. Horizontal and vertical osteotomies were performed 1.5 mm away from adjacent teeth. Lower border osteotomy of the vestibular cortical bone was performed. A chisel osteoma was used to separate completely and mobilize the segmented bone. This separated, corticocancellous block was stabilized on the distance to the native alveolar crest with micro screws. The space between the block and the alveolar crest was filled with allograft. The flaps were closed using 3-0,4-0 vicryl."
62186971|NCT06177899||Reverse split-box group|"Before augmentation, according to the 3D topography of the alveolar ridge of the patients, the reverse split-box technique was applied if there was more than 3 mm bone thickness at the top of the crest and the bone thickness increase towards the lower border.~This technique differs from the split-box technique as follows: If the bone thickness of the alveolar crest is thick enough to be split, in addition to the bone thickness increases toward the lower border at the alveolar bone, it involves reversing the separated corticocancellous bone block before fixation."
62186972|NCT06177899||Sliding split-box group|"Before augmentation, according to the 3D topography of the alveolar ridge of the patients, the sliding split-box technique was applied if there was less than 3 mm bone thickness at the top of the crest and the bone thickness increase towards the lower border.~This technique differs from the split-box technique as follows: If the bone thickness of the alveolar crest is not thick enough to split at the alveolar crest (\<3 mm), but the bone thickness increases toward the lower border of the alveolar bone, horizontal osteotomy is performed at the level where the bone thickness reaches at least 3 mm. Separated corticocancellous bone block is slid toward the coronal of alveolar crest and fixed in line with the native alveolar bone."
62186973|NCT02639806||Prospective - General Anesthetic|The prospective treatment group will have an anesthetic induction according to the anesthetic provider's preference that will include propofol and fentanyl as IV induction agents and rocuronium as a muscle paralytic. Maintenance of anesthesia for the treatment group will include sevoflurane with a target end tidal concentration of 1-1.5%, rocuronium as a paralytic as needed, opioids and any other standard medication deemed necessary by the provider.
62186974|NCT02639806||Retrospective - Local Anesthetic with Sedation|The retrospective group will have received local anesthetic from the surgeon using lidocaine injected subcutaneously and received sedation using fentanyl and midazolam as needed to achieve the desired level of sedation.
62186975|NCT03655665|EXPERIMENTAL|Treatment Ear|Participants will serve their own control. Participants will receive 3 drops of ofloxacin otic solution intra- and post-operatively 3 times per day for 3 days in ONE ear. Ear sidedness will be randomized by participant.
62186976|NCT03655665|NO_INTERVENTION|No Intervention|Participants will serve their own control. Participants will receive no intervention in the ear contralateral to the treated ear. Ear sidedness will be randomized by participant.
62570435|NCT01164189|OTHER|Temozolomide|Administered orally on day 1-5, 150-200 mg/m(2), repeated every 4 weeks, up to 12 cycles
62777185|NCT02677857|ACTIVE_COMPARATOR|Lifestyle + SB|Participants will receive everything that is described in Lifestyle. Additionally, they will be educated on the relationship between SB and weight management, and cancer survivorship risk. The goal will be to reduce sedentary time by \> 2 hrs/day or \> 14 hrs/wk. Participants will shape towards the goal. Baseline measures will be used as the starting point from where to calculate the 2 hrs/day reduction, providing participants with a total SB goal per day. For example, if baseline measures indicate that a participant has a mean daily SB amount of 9.75 hrs, the participant's SB goal will be 7.75 hrs/day. To achieve that goal, participants will reduce SB by 20 minutes a day, starting week 2, with a decrease of an additional 20 minutes/day occurring weekly until the SB goal is achieved (week 7 of the 12 week intervention. Participants will self-monitor their SB using the Polar® Loop tracking system.
62001670|NCT03607916|EXPERIMENTAL|Cohort 4 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
62001671|NCT03607916|EXPERIMENTAL|Cohort 5 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
62001672|NCT03607916|EXPERIMENTAL|Cohort 6 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
62001673|NCT03607916|EXPERIMENTAL|Cohort 7 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
62001674|NCT03607916|EXPERIMENTAL|Cohort 8 : HB Prilocaïne 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
62001675|NCT03607916|EXPERIMENTAL|Cohort 9 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
62001676|NCT03607916|EXPERIMENTAL|Cohort 10 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
62001677|NCT03466502|NO_INTERVENTION|No oral vancomycin|
62001678|NCT03466502|EXPERIMENTAL|Oral vancomycin 125 mg twice daily|
62001679|NCT03466502|EXPERIMENTAL|Oral vancomycin 125 mg daily|
62001680|NCT04403321|PLACEBO_COMPARATOR|Eltrombopag|Eltrombopag and the placebo would be applied. Eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day, or the best response was achieved.
62186977|NCT03990142|EXPERIMENTAL|Group 1: patients without intradialytic hypotension|The investigators will measure the cutaneous conductance to chlorine by SUDOSCAN® in all dialysis patients without intradialytic hypotension and to seek a link between the results of this examination and the occurrence of discomfort during hemodialysis sessions.
62001681|NCT04403321|EXPERIMENTAL|Eltrombopag + Tacrolimus|Eltrombopag and tacrolimus would be applied. Eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day, or the best response was achieved. Tacrolimus will be given at 1mg bid with the target trough concentration of 4-10 ng/mL throughout the study.
62186978|NCT03990142|EXPERIMENTAL|Group 2: patients with intradialytic hypotension|The investigators will measure the cutaneous conductance to chlorine by SUDOSCAN® in all dialysis patients with intradialytic hypotension and to seek a link between the results of this examination and the occurrence of discomfort during hemodialysis sessions.
62395342|NCT06510894||Ketogenic Diet with sotagliflozin|40 volunteers will take a SGLT1/2i, sotagliflozin (400 mg QD), for 7 days prior to the PET scan visit and will undergo FDG PET/CT after 1-3 day of dietary modification (ketogenic diet for at least 3-9 meals) and overnight fasting prior to FDG injection.
62395343|NCT01533974|EXPERIMENTAL|ACT|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
62186979|NCT03632083|ACTIVE_COMPARATOR|Hy-Care Contact Lens Solution|Each subject will wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Hy-Care contact lens solution.
62395344|NCT01533974|ACTIVE_COMPARATOR|CBT|
62395345|NCT02713490|ACTIVE_COMPARATOR|EXPAREL|Single dose of EXPAREL 266 mg in 20 mL admixed with bupivacaine HCl 0.5% in 20 mL and expanded in volume with 80 mL normal saline (total volume of 120 mL).
62395346|NCT02713490|ACTIVE_COMPARATOR|Bupivacaine|Bupivacaine HCl 0.5% in 20 mL expanded in volume with 100 mL normal saline (total volume of 120 mL).
62395347|NCT04795570||Cases. Patients who develop urethral stricture|Patients who develop urethral stricture within 6 months after TUR P/B
62395348|NCT04795570||Controls. Patients who DO NOT develop urethral stricture|Patients who DO NOT develop urethral stricture within 6 months after TUR P/B
62395349|NCT06724848||Cohort A|Healthy controls from asthma translational study: at least 50 healthy participants aged 30 or older.
62570436|NCT01164189|EXPERIMENTAL|Temozolomide + Bevacizumab|"TMZ: Administered orally on day 1-5, 150-200 mg/m(2), repeated every 4 weeks, up to 12 cycles~Beva: 10 mg/kg bw IV in 90 minutes on day 1 and 14, 4 week cycles."
62570437|NCT03622684|EXPERIMENTAL|Muscle relaxation according to Jacobson|. Does the use of the method of progressive relaxation according to Jacobson will be beneficial to reduce pain and improve the functioning of the stomatognathic system being evaluated in clinical trials?
62395350|NCT06724848||Cohort B|"early COPD, normal lung function with symptoms approximately 200 smokers or ex-smokers, early COPD participants at 30 to 45 years of age (inclusive) with normal lung function defined as FEV1/FVC ratio \> 70% (lower limit of normal) and FEV1 \> 80% of predicted normal with symptoms defined as presence of chronic cough and/or chronic sputum and/or breathlessness equivalent to mMRC Grade 1 or higher, with any of the risk factors below:~* History suggestive of COPD exacerbation;~* Evidence of emphysema on CT scan;~* Evidence of small airways disease on CT scan or oscillometry."
62570438|NCT03803007|EXPERIMENTAL|Intravenous glenzocimab (ACT017) 1000 mg|Intravenous glenzocimab (ACT017) 1000 mg to be added to a tissue plasminogen activator +/- mechanical thrombectomy
62570439|NCT03803007|PLACEBO_COMPARATOR|Intravenous Placebo|Intravenous Placebo to be added to a tissue plasminogen activator +/- mechanical thrombectomy
62570440|NCT03392246|EXPERIMENTAL|Osimertinib + Selumetinib|"* Selumetinib are to be administered orally intermittently (4 days on, 3 days off)~* Osimertinib are to be administered orally on a daily basis"
62570441|NCT01761604|OTHER|Nasal ganglion block for TN|Sphenopalatine ganglion block using the Tx360™ device
62570442|NCT05051189|ACTIVE_COMPARATOR|Patients with sleep apnea having oxygen Saturation >85%|Children with OSA having procedures requiring endotracheal intubation and an who will receive opioids for evaluation of respiratory changes
62395351|NCT06724848||Cohort C1|Approximately 100 physician diagnosed COPD participants with mild airflow limitation defined as post-bronchodilation FEV1/FVC \< 70% and FEV1 ≥ 80% of predicted. Participants at 30 to 50 years of age (inclusive)
62395352|NCT06724848||Cohort C2|Approximately 100 physician diagnosed COPD participants with mild airflow limitation defined as post-bronchodilation FEV1/FVC \< 70% and FEV1 ≥ 80% of predicted. Defined as participants elder than 50 years of age (exclusive)
62395353|NCT06724848||Corhort D|Moderate to very severe COPD Approximately 450 COPD participants (males and females aged 50 years or older) with moderate to very severe airflow limitation defined as post-bronchodilation FEV1/FVC \< 70% and FEV1 ≥ 25% and \<80% of predicted, and presence of respiratory symptoms quivalent to CAT ≥ 10 or mMRC ≥ 2.
62395354|NCT01882101|EXPERIMENTAL|Posterior tibial nerve stimulation|
62395355|NCT01882101|EXPERIMENTAL|Biofeedback|
62395356|NCT00850213||Endeavor Resolute Stent|Patients implanted with the Medtronic Endeavor Resolute stent
62570443|NCT05051189|ACTIVE_COMPARATOR|Patients with sleep apnea having oxygen Saturation <85%|Children without OSA having procedures requiring endotracheal intubation and an who will receive opioids for evaluation of respiratory changes
62570444|NCT06302556||Lung re-transplant cohort|This cohort includes consecutive participants who underwent lung re-transplantation for chronic lung allograft dysfunction from 2010 to 2020; the immune checkpoints analyses will be conducted on stored specimens from lungs explanted during re-transplantation.
62570445|NCT06302556||Previous lung transplant cohort|This cohort includes participants who received first bilateral lung transplantation from 2017 to 2020. The immune checkpoints analyses will be conducted on stored specimens from postoperative transbronchial biopsy performed for clinical suspicious of rejection.
62570446|NCT06302556||Prospective lung transplant cohort|This cohort includes participants who will have their first bilateral lung transplant from April 2024 to April 2025. Immunopathological characterization of bronchoalveolar leukocytes and analysis of immuno checkpoints will be performed on leftover material of bronchoalveolar lavage and transbronchial lung biopsy samples performed for clinical suspicious of rejection.
62570447|NCT01581437|OTHER|64 pole basket catheter|all patients participating undergo mapping using the 64 pole basket catheter to assess for Atypical areas of drivers that may cause atrial fibrillation
62570448|NCT01532518|EXPERIMENTAL|Cohort 3|Nepadutant low dose (0.1mg/kg) for 7 days followed by Nepadutant high dose (1mg/kg) for additional 7 days
62570449|NCT01532518|EXPERIMENTAL|Cohort 2|Nepadutant medium dose (0.5mg/kg) for 7 days followed by Nepadutant high dose (1mg/kg) for additional 7 days
62570450|NCT01532518|EXPERIMENTAL|Cohort 1|Nepadutant low dose (0.1mg/kg) for 7 days followed by Nepadutant medium dose (0.5mg/kg) for additional 7 days
62570451|NCT05107908|EXPERIMENTAL|Active Implicit Priming|Participants will complete active implicit priming, in which food images are implicitly primed (i.e., below conscious awareness) with images of positive or negative affect. This will be completed on a weekly basis for 12 weeks, for approximately 10 minutes each time.
62570452|NCT05107908|PLACEBO_COMPARATOR|Control Implicit Priming|Participants will complete control implicit priming, which matches the active intervention, but with neutral stimuli as primes. This will be completed on a weekly basis for 12 weeks, for approximately 10 minutes each time.
62570453|NCT05107908|ACTIVE_COMPARATOR|Food Exposure Task|Participants will complete a Food Exposure Task, in which they will be asked to smell, feel, lick, and imagine eating food items, but without actually eating them. This will be completed on a weekly basis for 12 weeks, for approximately 10-30 minutes each time.
62570454|NCT04876326|ACTIVE_COMPARATOR|Autologous Adipose MSC Group|This group will receive the implantation of autologous mesenchymal stem cell origin of adipose tissue with a dose of 2 x 50 million cells given with a distance of 1 month
62570455|NCT04876326|ACTIVE_COMPARATOR|Allogeneic Umbilical Cord MSC Group|This group will receive intrathecal implantation of allogeneic mesenchymal stem cells from the umbilical cord with a dose of 2 x 50 million cells given a distance of 1 month.
62570456|NCT04876326|ACTIVE_COMPARATOR|Allogeneic Umbilical Cord MSC and Adipose Secretome Group|This group will receive intrathecal implantation of allogeneic mesenchymal stem cells from the umbilical cord as much as 2 x 50 million followed by 2 x 10cc mesenchymal stem cell secretions from adipose tissue intravenously given at a distance of 1 month.
62570457|NCT01886209|EXPERIMENTAL|Cohort 1|Prednisone 10 mg tablet on Day 1 and 7; VX-509 200 mg tablets on Days 2 thru 7
62570458|NCT01886209|EXPERIMENTAL|Cohort 2|Methylprednisolone 8 mg tablet on Day 1 and 7; VX-509 200 mg tablets on Days 2 thru 7
62395357|NCT05797467|EXPERIMENTAL|Combining targeted therapy group|Adjuvant chemotherapy with targeted therapy
62186980|NCT03632083|ACTIVE_COMPARATOR|Lite Contact Lens Solution|Each subject will wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Lite contact lens solution.
62186981|NCT01190722|EXPERIMENTAL|etoricoxib|active study drug, coxib
62186982|NCT01190722|ACTIVE_COMPARATOR|diclofenac|active traditional NSAID control
62186983|NCT04055610|EXPERIMENTAL|H-MEX|10 participants with paraplegia will participate in explorative gait training using H-MEX powered exoskeleton.
62186984|NCT02024659|EXPERIMENTAL|budesonide|
62395358|NCT05797467|SHAM_COMPARATOR|Single adjuvant chemotherapy group|Adjuvant chemotherapy alone
62395359|NCT02204722|EXPERIMENTAL|Group B|the group who has more than 10% of the BCR-ABL(IS) level for three months will receive 600mg/day of Imatinib after three months.
62395360|NCT02204722|EXPERIMENTAL|Group A|the group who has more than 10% of the BCR-ABL(IS) level for three months will maintain the dose, 400mg/day of Imatinib, after three months.
62395361|NCT06125847|EXPERIMENTAL|NGGT006|4 doses of NGGT006 will be administered according to the principle of dose escalation
62395362|NCT04910360||ICU patients with severe COVID-19 pneumonia|Without using any intervention, this group has been included in the study to research certain genetic dispositions determining the severity of the COVID-19 pneumonia
62570459|NCT04838522||All Study Participants|Participants with chronic idiopathic constipation who are treated with prucalopride oral tablets which was initiated prior to enrollment, and are breastfeeding their infant at the time of enrollment and sample collection will be observed prospectively.
62570460|NCT06142500|EXPERIMENTAL|Patients with testicular cancer|Patient with testicular cancer
62570461|NCT06142500|ACTIVE_COMPARATOR|First-degree family members of patients with testicular cancer|First-degree family members of patients with testicular cancer
62570462|NCT00167583|ACTIVE_COMPARATOR|A Cyclosporin A|Cyclosporin A
62570463|NCT00167583|ACTIVE_COMPARATOR|B Interferon alpha|Interferon-alpha2a
62001682|NCT05030142|EXPERIMENTAL|Mechanical thrombectomy|Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
62001683|NCT05030142|ACTIVE_COMPARATOR|Active Comparator|Best medical treatment alone (usual care)
62001684|NCT00839839|EXPERIMENTAL|Oocyte Vitrification|
62001685|NCT02997033||Total study cohort|
62001686|NCT00394030|EXPERIMENTAL|Group A|In Group A healthy subjects will be randomized to receive 16 milligram (mg) of GSK716155 to abdomen.
62001687|NCT00394030|EXPERIMENTAL|Group B|In Group B healthy subjects will be randomized to receive 64 mg of GSK716155 to abdomen.
62001688|NCT00394030|EXPERIMENTAL|Group C|In Group C Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to abdomen.
62001689|NCT00394030|EXPERIMENTAL|Group D|In Group D Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to arm.
62001690|NCT00394030|EXPERIMENTAL|Group E|In Group E Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to leg.
62186985|NCT02024659|PLACEBO_COMPARATOR|placebo|
62186986|NCT00979693|EXPERIMENTAL|Full Dose|Participant will receive 25 mg psilocybin during two day-long sessions of psychotherapy in combination with psilocybin, with each session scheduled seven to 14 days apart.
62186987|NCT00979693|ACTIVE_COMPARATOR|Active Placebo|The participant will receive 4 mg psilocybin during two day-long sessions of psychotherapy in combination with psilocybin, with sessions scheduled seven to 14 days apart.
62186988|NCT03013140|EXPERIMENTAL|Goal-directed preloading|"Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until change in SV (ΔSV) \<5%"
62186989|NCT03013140|ACTIVE_COMPARATOR|Preloading|"Fluid therapy: Within 30 mins before spinal anaesthesia, infuse 1000ml Ringer's injection with a pressurizer within 15 minutes."
62186990|NCT04088929|EXPERIMENTAL|CBD for Treatment of Diabetic Neuropathic Pain|Patients are instructed to take 3 total tablets a day, under the tongue, six hours apart for three weeks. Patients are to enter their pain scale score into the smartphone app as instructed during the initial site visit. Patients are to enter into the notes section of the app any additional information such as side effects (positive or negative), medication changes.
62395363|NCT04910360||Random population|This group has been included as a control group to compare the genetic predisposition of ICU patients with severe COVID-19 pneumonia with the normal population.
62395364|NCT00045565|EXPERIMENTAL|Group A|Patients receive arsenic trioxide IV over 2 hours once weekly for 6 weeks. Patients in both groups also undergo radiotherapy once daily 5 days a week for 6 weeks.
62777186|NCT02677857|NO_INTERVENTION|Newsletter|Participants in this condition will receive standard care and every month they will receive a newsletter that provides information and tips about healthy eating and activity behaviors. This newsletter will include information on myPlate,28 activity guidelines,29 reading food labels, healthy recipes, and seasonal activity suggestions.
62001691|NCT00394030|EXPERIMENTAL|Group F|In Group F Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to abdomen.
62001692|NCT00394030|EXPERIMENTAL|Group G|In Group G Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to arm.
62001693|NCT00394030|EXPERIMENTAL|Group H|In Group H Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to leg.
62186991|NCT06317038|OTHER|Digital Device uses for 8 hours per day|Observational responses from patients using digital devices for 8 hours per day will be given a monthly Total 30 Contact lens.
62186992|NCT05760911|EXPERIMENTAL|Outdoor activities motivating group|Wear a smartwatch and receive Mini Program reminders and encouragement for outdoor activities. The required outdoor time is at least 2 hours from Monday to Friday and more than 2 hours on weekends.
62186993|NCT05760911|NO_INTERVENTION|Outdoor activities monitoring group|Outdoor activities are monitored with smartwatches.
62186994|NCT01537185|EXPERIMENTAL|Cohort 1 SPWCV+Alum 100 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
62186995|NCT01537185|EXPERIMENTAL|Cohort 2 SPWCV+Alum 300 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
62186996|NCT01537185|EXPERIMENTAL|Cohort 3 SPWCV+Alum 600 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
62186997|NCT01537185|PLACEBO_COMPARATOR|Normal Saline Injection|"placebo group within each cohort receive 3 injections of normal saline 28 days apart~normal saline injection: 3 cohorts of normal saline injection"
62186998|NCT04418661|EXPERIMENTAL|SAR442720 + Pembrolizumab|"Part 1:~SAR442720 (also known as RMC-4630) will be administered orally twice a week (BIW) followed by pembrolizumab which is given intravenously (IV) once every 3 weeks (Q3W). The dose of SAR442720 will be escalated or de-escalated depending on the emerging safety data of the combination."
62186999|NCT04418661|EXPERIMENTAL|SAR442720 + Pembrolizumab: Non-small cell lung cancer with Tumor proportion score > 50%|"Part 2:~SAR442720 dose will be administered orally in combination with Pembrolizumab which is given by IV infusion once every 3 weeks (Q3W) or once every 6 weeks (Q6W)"
62187000|NCT04418661|EXPERIMENTAL|SAR442720 + Pembrolizumab: Non-small cell lung cancer with Tumor proportion score 1-49%|"Part 2:~SAR442720 dose will be administered orally in combination with Pembrolizumab which is given by IV infusion once every 3 weeks (Q3W) or once every 6 weeks (Q6W)"
62187001|NCT04418661|EXPERIMENTAL|SAR444270 + adagrasib: Dose Escalation|Part 3A; SAR442720 and adagrasib will be administered orally on a continuous basis.
62187002|NCT04418661|EXPERIMENTAL|SAR444270 + adagrasib: Dose Expansion|"Part 3B:~Once SAR442720 dose is confirmed in Part 3A SAR442720 and adagrasib will be administered orally on a continuous basis."
62187003|NCT04418661|EXPERIMENTAL|SAR442720 + Pembrolizumab continuous|"Part 4:~SAR442720 will be administered orally in combination with Pembrolizumab which is given by IV infusion once every 3 weeks (Q3W) or once every 6 weeks (Q6W)"
62187004|NCT04531306|ACTIVE_COMPARATOR|Pre-tape|
62187005|NCT04531306|EXPERIMENTAL|With tape 1|
62187006|NCT04531306|EXPERIMENTAL|With tape 2|
62187007|NCT04531306|EXPERIMENTAL|Post-tape|
62187008|NCT00996502|EXPERIMENTAL|Combination regimen|"Bevacizumab, Erlotinib, Docetaxel, Prednisone (dose escalation)~Phase I:~* Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid~* Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid~* Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid"
62570464|NCT06224647|EXPERIMENTAL|Access to the intervention|"Participants assigned to the intervention group will have full access to the mobile app intervention, namely ROOM app, for the whole duration of the 12-week trial.~As part of the app's onboarding process, participants will receive tips on optimal app usage and can decide to take part in a 21-day challenge where they are encouraged to assess their emotional states on a daily basis and complete one exercise per day. During the onboarding process, participants are encouraged to explore different emotional regulation exercises offered in the app and to save the ones they find most beneficial in their virtual Room, curating a personalized well-being toolkit. While daily notifications prompt regular app engagement, no additional efforts are made to further promote its use."
62570465|NCT06224647|NO_INTERVENTION|Waitlist control condition|Participants allocated to the control group will be put on a waitlist and granted access to the mobile intervention after the trial concludes. They will then receive the same intervention with the identical onboarding process as the intervention group.
62001694|NCT01966926|EXPERIMENTAL|Daily Weight Tracking|weighing frequency instructions and tips
62187009|NCT01089309|EXPERIMENTAL|Aldosteron blokade, Arterial stiffness, Glucose homeostasis|
62187010|NCT06102226||coronary artery disease group / non- coronary artery disease group|Recruited patients were categorized into a coronary artery disease group and a non-coronary artery disease group on the basis of coronary angiography findings, and the presence of CAD was defined as the presence of a coronary artery lesion with a stenosis
62187011|NCT02173145|ACTIVE_COMPARATOR|Azithromycin first, Placebo second|Medication with Azithromycin 500mg/d 3x/week p.o. o.d. for 12 weeks or placebo.
62187012|NCT02173145|ACTIVE_COMPARATOR|Placebo first, Azithromycin second|Medication with Azithromycin 500mg/d 3x/week p.o. o.d. for 12 weeks or placebo. Placebo will be capsulated similar to verum and given 3 times a week.
62187013|NCT01764308|EXPERIMENTAL|O3FA|Omega 3 Fatty Acid 1200mg twice a day for 24 weeks
62570466|NCT01611935|ACTIVE_COMPARATOR|Vasopressin|Vasopressin will be given as an initial bolus (4 Units) followed by an infusion titrated between 0 units/min to 0.04 units per min to maintain a mean arterial blood pressure greater than or equal to 65 mmHg
62001695|NCT01966926|EXPERIMENTAL|Weekly Weight Tracking|weighing frequency instructions and tips
62001696|NCT04138407|EXPERIMENTAL|Intervention|
62001697|NCT04138407|OTHER|Control|Usual rehabilitation exercise
62001698|NCT01595360|PLACEBO_COMPARATOR|Placebo|Placebo
62001699|NCT01595360|EXPERIMENTAL|TT-173|TT-173
62570467|NCT01611935|PLACEBO_COMPARATOR|Normal Saline|An initial bolus of normal saline will be given (10 cc) and an infusion of 0.1 ml per minute will be started and titrated down in as the mean arterial blood pressure reaches 65 mmHg or more.
62187014|NCT01764308|PLACEBO_COMPARATOR|Placebo|4 tablets twice a day for 24 weeks
62187015|NCT03156205|EXPERIMENTAL|Interactive Music Therapy|
62187016|NCT03156205|OTHER|passive music listening|
62187017|NCT03156205|OTHER|passive earphone-use|
62001700|NCT05483946|EXPERIMENTAL|CPM#1|Compartment compressibility ratio measurement using the CPM#1 device
62395365|NCT00045565|EXPERIMENTAL|Group B|Patients receive arsenic trioxide at a lower dose IV over 2 hours twice weekly for 6 weeks. Patients in both groups also undergo radiotherapy once daily 5 days a week for 6 weeks.
62395366|NCT06713746||ICU patients|muscle weakness
62187018|NCT06401837|EXPERIMENTAL|Acupressure application ( AA ) group|Patients in the AA group will have the circadian based acupressure application twice a day, 5 days per week for 2 weeks. Acupressure application will be performed in the morning after one hour of breakfast and in the evening 1-2 hour before bedtime by a nurse well-trained with Chinese medicine nursing during the first week.
62187019|NCT06401837|NO_INTERVENTION|Routine care control (RC) group|Patients in the RC group will get routine care as usual for rehabilitation. The ambient light at night will keep as dark or dim (\<30 lux) as well. The same education program for circadian-based life style as the AA group will be provided to patients and caregivers too.
62187020|NCT05596747|EXPERIMENTAL|LY3209590|LY3209590 administered subcutaneously (SC).
62187021|NCT05596747|ACTIVE_COMPARATOR|Insulin glargine|Insulin glargine administered SC.
62187022|NCT01488955|EXPERIMENTAL|Ibuprofen|Ibuprofen 400 mg oral once daily from day 0 for 3 days, placebo granulate oral day 0
62187023|NCT01488955|EXPERIMENTAL|Fosfomycin-Trometamol|Fosfomycin-Trometamol (Monuril) 3 g granulate oral at day 0, placebo to Ibuprofen once a day from day 0 for 3 days
62187024|NCT04780984|PLACEBO_COMPARATOR|Placebo|Placebo, 2mL
62187025|NCT04780984|EXPERIMENTAL|Group 1 Tiotropium Bromide Inhalation Solution|"Treatment Dose (µg) Volume (mL) Concentration (µg/mL)~8 µg, 2.0 mL, 4 µg/mL"
62187026|NCT04780984|EXPERIMENTAL|Group 2 Tiotropium Bromide Inhalation Solution|"Treatment Dose (µg) Volume (mL) Concentration (µg/mL)~16 µg, 2.0 mL, 8 µg/mL"
62187027|NCT04780984|EXPERIMENTAL|Group 3 Tiotropium Bromide Inhalation Solution|"Treatment Dose (µg) Volume (mL) Concentration (µg/mL)~24 µg, 2.0 mL, 12 µg/mL"
62187028|NCT04780984|ACTIVE_COMPARATOR|Spiriva Respimat|5 ug, 2 actuations, 2.5 µg/actuation
62187029|NCT03781245|EXPERIMENTAL|Early|Intervention is administered for cycle 1 and 2 with researchers and following this the company continues intervention independently.
62570468|NCT04939272|EXPERIMENTAL|Treatment (copanlisib hydrochloride, venetoclax)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15, and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Copanlisib will be given at 30mg, 45mg, or 60 mg depending on the assigned dose level. Venetoclax will have a weekly dose ramp up from 20mg, 50mg, 100mg, 200mg, and then 400mg thereafter.
62570469|NCT06298448||eGPA|Eosinophilic granulomatosis with polyangiitis patients before and after treatment with mepolizumab will be compared
62001701|NCT00993785|EXPERIMENTAL|OTW Catheter System|
62001702|NCT01726010|EXPERIMENTAL|22-G Procore Needle|
62187030|NCT03781245|ACTIVE_COMPARATOR|Lagged|Intervention is not administered for cycle 1; researchers administer intervention in cycle 2 and following this the company continues intervention independently.
62187031|NCT04334278|EXPERIMENTAL|GetHealthy-OA|The GetHealthy-OA is an 6-week group mind body program with efficacy in improving depression, physical function and aiding in weight loss, that has been adapted for the unique needs of patients with knee osteoarthritis, depression and obesity. The GetHealthy-OA will be delivered by secure telehealth.
62187032|NCT04334278|ACTIVE_COMPARATOR|Health Enhancement Program|The Health Enhancement Program is a chronic pain-specific program adapted for the specific needs of patients with knee osteoarthritis. It is an 6-week group mind body program that will be delivered via secure telehealth. To control for in between session practice, participants will receive an mp3 recording and informational handout to complete after each session.
62001703|NCT04514601||Pre-Intervention Group|The verbal and written handover of these patients was observed. This included 146 general orthopaedic admissions patients and 43 trauma patients. All patient data was anonymised.
62187033|NCT00830687|OTHER|Targon FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
62570470|NCT06298448||GPA|Comparator group not treated with mepolizumab
62570471|NCT06298448||Asthma|Asthma patients before and after treatment with mepolizumab
62570472|NCT06298448||CRSwNP|Chronic rhinosinusitis patients before and after treatment with mepolizumab
62570473|NCT06298448||Healthy|Healthy comparator group
62570474|NCT00408642|EXPERIMENTAL|1|enhanced adherence support for patients initiating antiretroviral therapy
62570475|NCT00408642|ACTIVE_COMPARATOR|2|standard adherence support
62570476|NCT05028790|EXPERIMENTAL|Single vision soft contact lens first, then multifocal soft contact lens|Participants wore the single vision soft contact lens first, then a multifocal soft contact lens
62791735|NCT01407666|EXPERIMENTAL|Bilateral paravertebral blocks|Bilateral continuous paravertebral blocks for open liver resection
62791736|NCT01407666|NO_INTERVENTION|epidural block|received thoracic epidural block for open liver resection
62187034|NCT02957695|PLACEBO_COMPARATOR|Control group|Control Intervention: Placebo-Neurofeedback, 20 sessions
62187035|NCT02957695|ACTIVE_COMPARATOR|Intervention group|Experimental Intervention: Active-Neurofeedback, 20 sessions
62187036|NCT02614690|ACTIVE_COMPARATOR|No split Cast of forearm fractures|"Patient will have a No split cast long arm cast applied after a closed reduction of forearm fractures. The cast will not be split. 20 patients will be randomized to this arm."
62187037|NCT02614690|ACTIVE_COMPARATOR|Univalve Split Cast of forearm fractures|"Patients will have a Univalve Split Cast long arm cast applied after undergoing closed reduction of of forearm fractures. This is a cast that is split on only one side of the cast. 20 patients will be randomized to this arm"
62187038|NCT02614690|ACTIVE_COMPARATOR|Bivalve Split Cast of forearm fractures|"Patients will have a Bivalve Split Cast long arm cast applied after they have undergone a closed reduction of of forearm fractures. This is a cast that will be split on both sides of the cast. 20 patients will be randomized to the bivalve split arm cast."
62187039|NCT02493465|EXPERIMENTAL|LVH everolimus|Progression of left ventricular hypertrophy in recipients of kidney transplant after conversion of immunossupression from azathioprine to everolimus.
62187040|NCT04728139|ACTIVE_COMPARATOR|patients with colorecta cancer|
62187041|NCT04728139|NO_INTERVENTION|healthy individuals|
62187042|NCT01193998|ACTIVE_COMPARATOR|Clinician exposed to Model result|
62187043|NCT01193998|EXPERIMENTAL|Clinician blinded to Model result|
62187044|NCT04303442||Patients undergoing TEP|Patients diagnosed with unilateral or bilateral primary and/or recurrence inguinal hernia undergoing Total Extraperitoneal laparoscopic hernia repair.
62187045|NCT03931993|PLACEBO_COMPARATOR|Treatment Group 1|Six 1.0mL placebo injections (2% w/v L-tyrosine)
62187046|NCT03931993|EXPERIMENTAL|Treatment Group 2|Six 1.0mL injections of Grass MATA MPL 900, 2700, 8000, 8000, 8000, and 8000 SU
62187047|NCT05549167|EXPERIMENTAL|intervention/treatment|
62395367|NCT04864964|OTHER|combined conventional and pulsed radiofrequency of trigeminal nerve nucleus|"The technique of the CCPRF is described as follows;~1. the classic Hartle technique is used to reach the Gasserian ganglion~2. Sensory stimulation with the RF equipment is conducted and parathesia of the affected branch is achieved at 0.1-0.2 V (50 Hz), keeping in mind that the mandibular part of the Gasserian ganglion is ventrolateral and the ophthalmic rootlets are postrolateral. Motor pre-stimulation (2 Hz) is achieved with masseter contraction at 0.1-0.3 V .~3. After sensory and motor stimulation, RF therapy is conducted by use of the RF generator , in the sequence:~   * Conventional RF 1st lesion at 60 °C for 60 s then 2nd lesion at 65°C for 60 seconds then 3rd lesion at 70°C for 60 seconds~  * Finally, PRF is applied for 360 second repeated at 45 V, with a pulse width of 10 ms and a pulse frequency of 4 Hz. The cut-off needle tip temperature is set at 42 °C.~4. Before withdrawal of needle 1 cc xylocaine 1% + 0.5 cc dexamethasone 4mg to be given ."
62395368|NCT02186548|ACTIVE_COMPARATOR|Closed surgical technique|After randomization, the PDC:s randomized to this arm, are to undergo closed surgical exposure, which is an intervention to correct the position of PDC:s.
62570477|NCT05028790|EXPERIMENTAL|Multifocal soft contact lens first, then single vision soft contact lens|Participants wore the multifocal soft contact lens first, then the single vision soft contact lens
62187048|NCT04156399|EXPERIMENTAL|Acupuncture|All subjects will receive active acupuncture.
62395369|NCT02186548|ACTIVE_COMPARATOR|Open surgical technique|After randomization, the PDC:s randomized to this arm, are to undergo open surgical exposure, which is an intervention to correct the position of PDC:s.
62395370|NCT04741880|EXPERIMENTAL|Group L (Lidocaine)|Lidocaine bolus 1.5 mg.kg-1 intravenous before the onset of lidocaine infusion Lidocaine 2mg.kg-1.h-1
62395371|NCT04741880|PLACEBO_COMPARATOR|Group S (saline solution)|Lidocaine bolus 0.75 mg.kg-1 intravenous before the onset of saline infusion Saline solution infusion
62570478|NCT06416774|EXPERIMENTAL|Ia: Low-dose group|The injection dose of 68Ga-HX01 for low-dose group is 0.05 mCi/kg.
62570479|NCT06416774|EXPERIMENTAL|Ia: High-dose group.|The injection dose of 68Ga-HX01 for the high-dose group is 0.1 mCi/kg.
62570480|NCT06416774|EXPERIMENTAL|Ib: Patients with malignancy.|The injection dose for phase Ib patients was 0.07 mCi/ kg.
62570481|NCT03554733|EXPERIMENTAL|Treatment|Re-Inventing Yourself after SCI protocol - 6-week educational sessions
62570482|NCT03554733|NO_INTERVENTION|Control|No intervention during course of study; participants offered the option of receiving the study intervention after completion of study.
62777187|NCT06233097|EXPERIMENTAL|Sequence 1-Esomeprazole magnesium dihydrate test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Esomeprazole magnesium dihydrate 40 mg tablets test product, treatment 2= Esomeprazole magnesium dihydrate 40 mg tablets reference product.
62187049|NCT03449862|EXPERIMENTAL|LEGAL-COST|Clinicians were first presented malpractice case law summary information (which suggests clinician not likely to be sued for not ordering CT scan) then patient out-of-pocket cost information for brain CT image (which provides them insight into what the patient is likely to pay for the test)
62187050|NCT03449862|ACTIVE_COMPARATOR|COST-LEGAL|Clinicians were first presented with patient out-of-pocket cost information for brain CT image (which provides them insight into what the patient is likely to pay for the test) then malpractice case law summary information (which suggests clinician not likely to be sued for not ordering CT scan)
62187051|NCT04241809||A: Notified TB with sputum laboratory confirmation|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.~Repeat bioaerosol sampling will be conducted at 14 days."
62187052|NCT04241809||B: Notified TB without sputum laboratory confirmation|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.~Repeat bioaerosol sampling will be conducted at 14 days."
62187053|NCT04241809||C: Not Notified for TB|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.~Repeat bioaerosol sampling will be conducted at 14 days."
62187054|NCT06276400|EXPERIMENTAL|Duration difference estimation|Participants will view emotional sequences composed of four emotional images. They will be asked to indicate whether the total duration of positive or negative emotional events was longer, by responding with a button press to a contextual cue defining the relevant action (Left vs Right button). The amount of temporal evidence in favor of one valence in a 12-s sequence is varied orthogonally with respect to the (predominant) emotional valence by varying individual picture presentation times. Participants will undergo one fMRI session and 3 TMS+fMRI sessions (2 of the TMS sessions target prefrontal (PFC) sites, and 1 targets a non-PFC control site).
62187055|NCT00692458|EXPERIMENTAL|1|odanacatib
62187056|NCT00692458|PLACEBO_COMPARATOR|2|placebo
62187057|NCT03887169|EXPERIMENTAL|Methionine|
62395372|NCT03622294|EXPERIMENTAL|Right Breast Mammogram Measurements and Survey|"A right breast screening mammogram will be performed with Bella Blankets protective coverlets on the imaging receptor plate, then removed from the equipment.~The screening mammogram continues with a left breast and second right breast screening mammogram on a bare imaging receptor plate.~Clinical image quality measurements for the right breast mammograms will automatically be captured by VolparaEnterprise for a comparative analysis.~A patient satisfaction survey will be completed by each participant and the results will be analyzed."
62001704|NCT04514601||Post-Intervention Group|The verbal and written handover of these patients was observed after the introduction of the intervention. This included 81 general orthopaedic admissions patients and 47 trauma patients. All patient data was anonymised.
62001705|NCT05326139|ACTIVE_COMPARATOR|Tranexamic acid|Group TA (n=25): TA ( Tranexamic acid, 250mg/2.5 ml inj ) soaked pledgets were placed under the skin flap to cover the osteotomy line
62001706|NCT05326139|PLACEBO_COMPARATOR|Isotonic saline|Group Co (n=25): Isotonic saline ( NaCl, 0.9 %) soaked pledgets were placed under the skin flap to cover the osteotomy line
62395373|NCT04066205|EXPERIMENTAL|SLEEPSMART PROGRAM|"Arm: Placebo Comparator (Usual care)-This treatment arm will receive usual JIA care, including annual Rheumatology clinic visits, medications, routine clinical and laboratory tests, physical therapy, follow-up appointments, and no sleep intervention.~Arm: Experimental -Each child and parent will create a login, choose treatment goals, and interact with fields in the Web site. The modules will focus on improving sleep hygiene, relaxation, or increasing sleep duration. The intervention will last 6 to 8 weeks."
62395374|NCT05245227|ACTIVE_COMPARATOR|Intravenous Oxytocin only|Patients will receive standard postpartum Oxytocin IV per protocol
62570483|NCT03822585|OTHER|Close Relatives Of β-thalassemia|Laboratory diagnostic tests as (CBC, Iron Study, Serum Ferritin, HPLC, Genetic study) will be done to Brothers, Sisters \& Cousins of β-thalassemia Children With Microcytic Hypochromic Anemia Attending Assiut University Child Hospital
62570484|NCT04380935|EXPERIMENTAL|convalescent plasma and standard of care|
62777188|NCT06233097|EXPERIMENTAL|Sequence 2-Esomeprazole magnesium dihydrate reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Esomeprazole magnesium dihydrate 40 mg tablets test product, treatment 2= Esomeprazole magnesium dihydrate 40 mg tablets reference product.
62777189|NCT01555125|EXPERIMENTAL|secukinumab 150 mg|Drug
62777190|NCT01555125|EXPERIMENTAL|secukinumab 300 mg|Drug
62777191|NCT01555125|PLACEBO_COMPARATOR|placebo|
62777192|NCT04809259|EXPERIMENTAL|Continuous infusion of meropenem|The meropenem solution will be administered continuously using elastomeric pumps which will be changed every 24 hours and which will be inserted in an isothermal pouch to ensure that the antibiotic solution is maintained at a temperature between 10° and 15°
62777193|NCT06398717|ACTIVE_COMPARATOR|group C: will receive unilateral adductor canal block alone|
62777194|NCT06398717|ACTIVE_COMPARATOR|group H:will receive unilateral peri-hamstring injection combined to adductor canal block|
62777195|NCT06398717|ACTIVE_COMPARATOR|group O: will receive unilateral anterior obturator nerve block combined to adductor canal block|
62777196|NCT00230542|EXPERIMENTAL|Carboplatin / Pemetrexed|Single Arm Study Carboplatin AUC 5 Pemetrexed 500 mg/m2
62777197|NCT04969692|NO_INTERVENTION|non-warming group|non-warming of local skin (puncture site)
62777198|NCT04969692|ACTIVE_COMPARATOR|warming group|warming to increase local skin (puncture site) temperature
62777199|NCT03666221|EXPERIMENTAL|Nimotuzumab plus IMRT|Patients with recurrent nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent intensity modulated radiation therapy(IMRT) , folowing weekly nimotuzumab (200 mg/week) for totally 8 weeks concurrent with IMRT.
62777200|NCT00599638|ACTIVE_COMPARATOR|1|
62777201|NCT00599638|EXPERIMENTAL|2|
62777202|NCT00599638|PLACEBO_COMPARATOR|3|
62777203|NCT04684953|ACTIVE_COMPARATOR|Thyroid autotransplantation|Implantation of 5-10 gm thyroid gland after mincing it in saline in quadriceps femoris muscle.
62777204|NCT04684953|OTHER|control group|the patients in this group won't undergo thyroid autotransplantation. instead, hormonal replacement therapy shall be prescribed for them.
62777205|NCT03468894|NO_INTERVENTION|Control|The control group will continue to work as usual at their regular workstations.
62777206|NCT03468894|EXPERIMENTAL|Intervention|A shared treadmill workstation will be installed in participating offices, or in a nearby location in case there is no space to fit the workstation in the office, enrolled to this group. Within the intervention group there will be a maximum allocation of two participants per treadmill desk. The participants in the intervention group will be asked to interrupt their sitting with 20 minutes of self-selected light-intensity walking at a speed of 1-4 km/h each hour for a minimum of 6 hours per shift to accumulate a total of 2 hours of light-intensity activity per work day.
62777207|NCT04203420||patients with PA|patients who finally been diagnosed with primary aldosteronism
62777208|NCT04203420||patients without PA|patients who finally been diagnosed without primary aldosteronism
62777209|NCT03157037|EXPERIMENTAL|Imlifidase|Imlifidase 0.25 mg/kg body weight intravenous infusion
62777210|NCT06515262|EXPERIMENTAL|Anti-BCMA CAR-T|BCMA-GPRC5D CAR-T is a novel CAR cell therapy for the treatment of relapsed/refractory multiple myeloma.
62777211|NCT02678299|EXPERIMENTAL|Treatment|
62777212|NCT03879304|EXPERIMENTAL|Multimodal physiotherapy program with RV|The RV intervention group receives a tele multimodal physiotherapy program with tradicional exercises of physiotherapy like stretching, aerobic, training through videos and gamification with VR glasses.
62570485|NCT04380935|ACTIVE_COMPARATOR|standard of care|
62570486|NCT04272944|EXPERIMENTAL|10 mg/kg Q2W|10 mg/kg IV every 2 weeks
62570487|NCT04272944|EXPERIMENTAL|20 mg/kg Q3W|20 mg/kg IV every 3weeks
62570488|NCT01760031||Subjects with impaired renal function|Subjects with baseline impaired renal function undergoing cardiac catheterization with contrast-medium exposure
62570489|NCT05505669||Adults with type 1 diabetes|Adults with type 1 diabetes
62570490|NCT05505669||Adult healthy volunteers|Adult healthy volunteers
62570491|NCT05505669||Children with type 1 diabetes|Children with type 1 diabetes
62570492|NCT05505669||Adults with type 2 diabetes|Adults with type 2 diabetes
62570493|NCT05505669||Adults with high blood sugar|Adults with high blood sugar
62570494|NCT05505669||Those at risk of developing type 1 diabetes|Those at risk of developing type 1 diabetes
62570495|NCT04276961|EXPERIMENTAL|Acupuncture plus usual care|Acupuncture will be given on the basis of usual care. A total of 12 sessions of acupuncture will be given over a period of 4 weeks.
62570496|NCT04276961|SHAM_COMPARATOR|Sham acupuncture plus usual care|Sham acupuncture refers to acupuncture at sham points. Sham acupuncture will be given on the basis of usual care. A total of 12 sessions of sham acupuncture will be given over a period of 4 weeks.
62777213|NCT03879304|ACTIVE_COMPARATOR|Traditional physiotherapy program|Traditional intervention group receives assistance of a program of physiotherapy traditional without virtual reality glasses.
62001707|NCT01368575|ACTIVE_COMPARATOR|subgroup B1|subgroup B1 will receive CABG combined with MV repair with annuloplasty rigid ring
62001708|NCT01368575|ACTIVE_COMPARATOR|subgroup B2|B2 - CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus
62187058|NCT00872001|ACTIVE_COMPARATOR|Acadesine|Acadesine intravenous (IV) infusion, plus cardioplegia solution with acadesine, and priming solution with acadesine in the heart lung machine during cardiopulmonary bypass (CPB)
62187059|NCT00872001|PLACEBO_COMPARATOR|Placebo|Normal saline, IV infusion, plus cardioplegia solution with added normal saline, and priming solution with added normal saline in the heart lung machine during CPB
62187060|NCT03176901|EXPERIMENTAL|Mindfulness-Based Stress Reduction|8 week manualized, standardized mindfulness-based stress reduction program taught by a certified Mindfulness-Based Stress Reduction instructor
62187061|NCT03176901|ACTIVE_COMPARATOR|Health Enhancement Program|8 week manualized, standardized health enhancement program, taught by a certified health education specialist
62777214|NCT03715946|EXPERIMENTAL|Radiotherapy (RT) + Nivolumab Injection|RT of 45 or 50 Gy in 25 daily fractions, 6 fractions per week. Nivolumab will be administered at 240 mg every 2 weeks during radiotherapy, and at 480 mg every 4 weeks for 6 doses after radiotherapy.
62001709|NCT01368575|ACTIVE_COMPARATOR|subgroup A2|CABG combined with MV repair with remodeling annuloplasty rigid ring
62001710|NCT01368575|ACTIVE_COMPARATOR|subgroup A1|only CABG
62001711|NCT01368575|ACTIVE_COMPARATOR|subgroup B3|patients in subgroup B3 will be performed CABG and MV replacement with preservation of subvalvular apparatus
62001712|NCT01127503|EXPERIMENTAL|Metyrosine|
62001713|NCT01127503|PLACEBO_COMPARATOR|Placebo|
62187062|NCT06485648|PLACEBO_COMPARATOR|Control|
62187063|NCT06485648|EXPERIMENTAL|Treatment|
62001714|NCT04521491|EXPERIMENTAL|FOLFOX4|Patients who will receive FOLFOX4 chemotherapy after liver resection
62001715|NCT04521491|NO_INTERVENTION|placebo|No adjuvant therapy after liver resection
62001716|NCT01944059|ACTIVE_COMPARATOR|Theramine|"2 capsules before breakfast and dinner (BID) for 16 weeks.~Migraine preventative medications will be permitted, but no changes in dosage will be allowed during the four month study. Migraine abortive meds will be permitted and will be administered per their standard routine."
62187064|NCT00960609||caval confluence HV involvement|Patients carriers of primary or metastatic tumour with direct contact or invasion of one HV at the caval confluence.
62187065|NCT02414347||Experimental F 18 T807|Participants will undergo a PET scan using the flortaucipir imaging tracer
62187066|NCT04370535|PLACEBO_COMPARATOR|Control group + cellulose (Group A)|healthy subjects (control group) receive placebo (cellulose) as powder
62570497|NCT05382819|EXPERIMENTAL|Part 1A Single Ascending Dose (SAD) - Active|Increasing dose of FRTX-02 Capsules will be administered to healthy volunteers.
62570498|NCT05382819|PLACEBO_COMPARATOR|Part 1A Single Ascending Dose (SAD) - Placebo|Matching placebo will be administered to healthy volunteers.
62570499|NCT05382819|EXPERIMENTAL|Part 1B Multiple Ascending Dose (MAD) - Active|Increasing dose of FRTX-02 Capsules will be administered to healthy volunteers.
62570500|NCT05382819|PLACEBO_COMPARATOR|Part 1B Multiple Ascending Dose (MAD) - Placebo|Matching placebo will be administered to healthy volunteers.
62570501|NCT05382819|EXPERIMENTAL|Part 2 Subjects with Moderate to Severe Atopic Dermatitis (AD) - Active|FRTX-02 Capsules will be administered daily for 28 days to subjects with atopic dermatitis.
62570502|NCT05382819|PLACEBO_COMPARATOR|Part 2 Subjects with Moderate to Severe Atopic Dermatitis (AD) - Placebo|Matching placebo will be administered daily for 28 days to healthy volunteers.
62570503|NCT02367118|EXPERIMENTAL|Prednisone|Intervention: prednisone 5 mg tablets taken orally, in decreasing doses. Beginning with 6 tablets (30 mg) daily for 7 days, then 3 tablets (15 mg) daily for 7 days, then 1 tablet (5 mg) daily for 7 days. Total days of treatment: 21 days.
62777215|NCT01587365|EXPERIMENTAL|Panel 1: BMS-962476 SC (0.01 mg/Kg) or Placebo|BMS-962476 0.01 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
62570504|NCT02367118|PLACEBO_COMPARATOR|Placebo|Intervention: placebo tablets taken orally (similar to prednisone), in decreasing doses. Beginning with 6 tablets daily for 7 days, then 3 tablets daily for 7 days, then 1 tablet daily for 7 days. Total days of treatment: 21 days.
62570505|NCT05307640|EXPERIMENTAL|CG-Well|CG-Well is a web \& phone based psychosocial intervention that teaches caregivers how to obtain information, education \& support
62001717|NCT01944059|PLACEBO_COMPARATOR|placebo (l-alanine)|"2 capsules before breakfast and dinner (BID) for 16 weeks.~Migraine preventative medications will be permitted, but no changes in dosage will be allowed during the four month study. Migraine abortive meds will be permitted and will be administered per their standard routine."
62187067|NCT04370535|ACTIVE_COMPARATOR|Control group + PMA-zeolite(Group B)|healthy subjects (control group) receive PMA-zeolite as powder
62187068|NCT04370535|PLACEBO_COMPARATOR|UCD-group + Cellulose (Group C)|subjects with uncontrolled Crohn disease (UCD group) receive placebo (cellulose) as powder
62187069|NCT04370535|ACTIVE_COMPARATOR|UCD-group + PMA-zeolite (Group D)|subjects with uncontrolled Crohn disease receive PMA-zeolite as powder
62187070|NCT03040830|EXPERIMENTAL|Egg retrieval arm|67 ICSI cases are started daily 100 mg IM prontogest on the day of egg retrieval until the day of pregnancy test.
62395375|NCT05245227|EXPERIMENTAL|Misoprostol plus intravenous Oxytocin|Patients will receive standard postpartum Oxytocin IV per protocol and also be given Misoprostol 400 mcg sublingual
62395376|NCT04795674|EXPERIMENTAL|ADHD EWM|Participants will receive EWM training sessions.
62395377|NCT04795674|PLACEBO_COMPARATOR|ADHD Placebo|Participants will receive placebo training sessions.
62395378|NCT03935074||group 1|Patients who received intra-arterial chemotherapy as a first line treatment
62395379|NCT03935074||group 2|Patients who received intra-arterial chemotherapy as a salvage treatment after systemic chemotherapy
62395380|NCT01973920|EXPERIMENTAL|Oshadi Icp|Oshadi Icp oral insulin,
62395381|NCT05431816|EXPERIMENTAL|dietary fiber intervention|Participants take a certain amount of dietary fiber per day.
62395382|NCT05431816|PLACEBO_COMPARATOR|Placebo|Participants take a certain amount of placebo (Maltodextrin) per day.
62395383|NCT06113731|EXPERIMENTAL|Test vaccine dose 1, 2 dose|
62395384|NCT06113731|EXPERIMENTAL|Test vaccine dose 2, 2 dose|
62395385|NCT06113731|ACTIVE_COMPARATOR|Active Comparator, 2 dose|
62001718|NCT00811564|ACTIVE_COMPARATOR|1|Fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution
62395386|NCT06113731|EXPERIMENTAL|Test vaccine dose 1, 1 dose|
62570506|NCT05307640|PLACEBO_COMPARATOR|Information Support and Referral|Attention control group that receives phone calls and modules from the Brain Injury Association of America.
62570507|NCT04008719|OTHER|Patients|Assessments are made by a psychiatrist
62001719|NCT00811564|ACTIVE_COMPARATOR|2|Latanoprost 0.005% ophthalmic solution
62001720|NCT04126928|OTHER|Participant|Each participant will go through (i) screening using DMFT and PUFA, (ii) orthopantomography assessment using PAI, and (iii) comprehensive clinical examination to derive pulpal and periapical diagnoses
62187071|NCT03040830|ACTIVE_COMPARATOR|Embryo transfer arm|66 ICSI cases are started daily 100 mg IM prontogest on the day of embryo transfer until the day of pregnancy test.
62187072|NCT00894998|EXPERIMENTAL|1|Heparin sodium 5.000 UI - Cristália
62777216|NCT01587365|EXPERIMENTAL|Panel 2: BMS-962476 SC (0.03 mg/Kg) or Placebo|BMS-962476 0.03 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
62187073|NCT00894998|ACTIVE_COMPARATOR|2|Heparin Sodium 5.000 USP - APP
62187074|NCT03613636||CAP cohort|"* Children of age 3 to 16 years;~* In- and outpatients;~* Clinically diagnosed community-acquired pneumonia (CAP)."
62187075|NCT03613636||Healthy control cohort|"* Healthy asymptomatic children of age 3 to 16 years;~* undergoing an elective surgical procedure."
62187076|NCT03613636||Family control cohort|- Family members of index CAP patients.
62187077|NCT02772718|EXPERIMENTAL|Part 1 - single dose|Cohorts A, B, and C
62187078|NCT02772718|EXPERIMENTAL|Part 2 - multiple doses|Cohort 1
62395387|NCT06113731|EXPERIMENTAL|Test vaccine dose 2, 1 dose|
62395388|NCT06113731|ACTIVE_COMPARATOR|Active Comparator,1 dose|
62395389|NCT01494753|ACTIVE_COMPARATOR|Prostaglandin|One drop.
62395390|NCT01494753|EXPERIMENTAL|T2345|One drop
62395391|NCT00958282|ACTIVE_COMPARATOR|lisdexamfetamine/Behavior Therapy|lisdexamfetamine 70mg/day plus Behavior Therapy
62395392|NCT00958282|PLACEBO_COMPARATOR|placebo|Placebo Comparator once per day
62395393|NCT05761301|EXPERIMENTAL|Part A: ALN-KHK|Participants will be administered a single dose of ALN-KHK.
62395394|NCT05761301|PLACEBO_COMPARATOR|Part A: Placebo|Participants will be administered a single dose of placebo.
62395395|NCT05761301|EXPERIMENTAL|Part B: ALN-KHK|Participants will be administered a multiple doses of ALN-KHK.
62395396|NCT05761301|PLACEBO_COMPARATOR|Part B: Placebo|Participants will be administered a multiple doses of placebo.
62395397|NCT01444638|EXPERIMENTAL|Ultrasound|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
62395398|NCT01444638|NO_INTERVENTION|Control|Control group. (Standard practice) Trainees will NOT receive pre-procedure U/S guided examination.
62777217|NCT01587365|EXPERIMENTAL|Panel 3: BMS-962476 SC (0.1 mg/Kg) or Placebo|BMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
62570508|NCT04663633|EXPERIMENTAL|Core stability training|"The EG performed an 8-week core stability training, consisting in 30 min of core stability and plyometric exercises 3 days per week, 24 sessions in total.~The CST sessions were conducted in a gym suitable for RG practise and the safety of the participants will be maintained. The equipment necessary for the training was provided to the participants.~The coaches are RG professionals with national coach level in RG and volunteered to lead the specific CST designed by a RG national coach and an expert core stability physiotherapist.~Before each session EG and CG performed a 15 min warm up. The load of the session was calculated by the RPE (rate of perceived exertion). And was modulated in order to maintain 7-8 intensity."
62001721|NCT05435378|EXPERIMENTAL|vitamin B3|Vitamin B-3 capsule consists of Manufacturer: DSM Nutritional products Ltd generic name: nicotine amide Constituent components: 100mg of nicotine amide Route of administration: orally dosing schedule:1capsule/day/ before meal duration: for 30 days
62001722|NCT05435378|EXPERIMENTAL|Vitamin B-9|Vitamin B-9 capsule Manufacturer: Hebei Jiheng pharmaceutical Co. Ltd generic name: folic acid. Constituent components: 5 mg of folic acid. Route of administration: orally dosing schedule: 1capsule/day/before meal duration: for 30 days
62001723|NCT05435378|PLACEBO_COMPARATOR|Placebo capsule|Placebo capsule Manufacturer: Shivangan Foods \& Pharma Products Pvt. Ltd Constituent components: inactive fillers Route of administration: orally dosing schedule: 1capsule/day/before meal duration: for 30 days
62001724|NCT00330551|EXPERIMENTAL|Long-acting injectible risperidone|Participants who are randomly assigned to this arm will be administered the long-acting injectible form of risperidone (Risperdal Consta) every two weeks, plus group skills training and case management, for 12 months.
62187079|NCT04915131|OTHER|Bloomlife MFM-Pro|
62187080|NCT05635175|ACTIVE_COMPARATOR|physiotherapist-supervised pelvic floor muscle training|physiotherapist-supervised pelvic floor muscle (PFM) training (PFMT) and self training PFMT
62187081|NCT05635175|EXPERIMENTAL|hip abductors self training program|physiotherapist-supervised pelvic floor muscle (PFM) training (PFMT) and self training hip abductors self training program
62187082|NCT05397366|EXPERIMENTAL|Task Specific Training|Using Task Specific Training
62395399|NCT04215159|EXPERIMENTAL|Samfenet and Treatment of physician's choice|"* Samfenet : 1st cycle 8 mg/kg by IV infusion over 90 mins, from 2nd cycle 6mg/kg by IV infusion over 30 mins. every 3weeks.~* Treatment of physician's choice (Gemcitabine or Irinotecan)~  1. Gemcitabine : 1000 mg/m2 by IV infusion over 30 minutes on Day 1, Day 8. every 3weeks.~ 2. Irinotecan : 100 mg/m2 by IV infusion over 90 minutes on Day 1, Day 8. every 3weeks."
62395400|NCT06048601|EXPERIMENTAL|two diagnostic approaches to the diagnosis of AL-CA in patients with a monoclonal protein|traditional invasive approach vs. non-invasive approach using the visual assessment of 18F-florbetaben PET/TC
62395401|NCT03736122|EXPERIMENTAL|BSG-001|Inhalation route, daily
62395402|NCT05931094|EXPERIMENTAL|AR group|Augmented Reality based games
62395403|NCT05931094|ACTIVE_COMPARATOR|Traditional therapy group|Traditional therapy
62395404|NCT06566157|EXPERIMENTAL|Prebiotic|WellBiome® prebiotic complex Inulin 67%, Xylooligosaccharides (XOS) 27%, Magnesium Chloride (MgCl2) 9.8 %
62570509|NCT04663633|NO_INTERVENTION|Traditional RG training|The CG performed the traditional training while the EG carried out the CST. The training load was calculated to be 7-8 RPE in order that both groups (EG and CG) undergo an equivalent intensity and training load.
62001725|NCT00330551|ACTIVE_COMPARATOR|Oral risperidone|Participants who are randomly assigned to this arm will be treated with the oral version of risperidone (Risperdal) daily, plus group skills training and case management, for 12 months.
62001726|NCT04462705|ACTIVE_COMPARATOR|Usual physiotherapeutic intervention|"the usual physiotherapeutic intervention (respiratory and walking exercices). Each patients will be treated following the ERAS Guideline.~- At D + 1 post-surgical:~1. - First lift with verticalization.~2. - A session with the Cliniflo® in a seated position.~3. - Walk at least 100 m with the help of the physiotherapist.~At- D+2 and D+3 post-surgical Same session as on D+1 with progressive increase in the walking perimeter. Add up and down stairs on D+ 3"
62187083|NCT05397366|EXPERIMENTAL|Neurodevelopmental Training|Using Neurodevelopmental Training
62187084|NCT02272361|OTHER|laparoscopic sacrocolpopexy|laparoscopic sacrocolpopexy
62187085|NCT02272361|OTHER|vaginal mesh surgery|vaginal mesh surgery
62187086|NCT01181609|EXPERIMENTAL|1|
62187087|NCT03202485|ACTIVE_COMPARATOR|Toric Implantable Collamer Lens|Subjects in this group will implant Toric Implantable Collamer Lens for high myopic astigmatism
62570510|NCT02369965|EXPERIMENTAL|albuvirtide, lopinavir-ritonavir|albuvirtide once a week and lopinavir-ritonavir twice daily for 48 weeks
62570511|NCT02369965|ACTIVE_COMPARATOR|lopinavir-ritonavir,tenofovir,lamivudine|lopinavir-ritonavir twice daily, tenofovir once daily and lamivudine once daily for 48 weeks
62570512|NCT06068101||Patients with papillary thyroid cancer (PTC) and EH (essential hypertension)|Primary Aldosteronism was investigated in all patients with PTC and EH (n= 137), regardless of hypertension severity, under active surveillance at a cancer institute from 2019 to 2022.
62777218|NCT01587365|EXPERIMENTAL|Panel 4: BMS-962476 SC (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
62187088|NCT03202485|EXPERIMENTAL|ICL+ Astigmatic keratotomy|Subjects in this group will implant Implantable Collamer Lens and combined with astigmatic keratotomy for high myopic astigmatism
62187089|NCT00890539|EXPERIMENTAL|Quadrupling|methacholine challenge using quadrupling concentrations
62187090|NCT00890539|ACTIVE_COMPARATOR|doubling|doubling concentrations of methacholine
62187091|NCT02264782|EXPERIMENTAL|Group I (PreView)|Patients complete PreView, the Video Doctor plus Provider Alert, over 45 minutes on an iPad in the waiting room before a doctor visit.
62395405|NCT06566157|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin (Corn origin)
62395406|NCT00848380||1|Patients with hypertension and hyperlipidemia and other CV risk factors
62395407|NCT03720639|ACTIVE_COMPARATOR|Abbott, Inc Confirm Rx™|Every other consenting subject will receive the Abbott Inc. Confirm Rx™ device.
62395408|NCT03720639|ACTIVE_COMPARATOR|Medtronic, Inc Reveal LINQTM|Every other consenting subject will receive the Medtronic, Inc. Reveal LINQTM.
62395409|NCT03455556|EXPERIMENTAL|Treatment (anetumab ravtansine, atezolizumab)|Participants receive anetumab ravtansine IV over 60 minutes and atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62777219|NCT01587365|EXPERIMENTAL|Panel 5: BMS-962476 IV (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day
62777220|NCT01587365|EXPERIMENTAL|Panel 6: BMS-962476 IV (1.0 mg/Kg) or Placebo|BMS-962476 1.0 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day
62001727|NCT04462705|EXPERIMENTAL|abdominal massage and usual physiotherapeutic intervention|"the usual physiotherapeutic intervention (respiratory and walking exercices). Each patients will be treated following the ERAS Guideline.~- At D + 1post-surgical:~1. - First lift with verticalization.~2. - A session with the Cliniflo® in a seated position.~3. - Walk at least 100 m with the help of the physiotherapist.~At- D + 2 and D + 3 post-surgical Same session as on D + 1 with progressive increase in the walking perimeter. Add up and down stairs on D+ 3~In this experimental arm, a abdominal massage will be performed in addition to the usual physiotherapeutic intervention (respiratory and walking exercices).~The sessions take place on D+1, D+2 and D+3 post-surgical The first session is performed at least 20 hours after surgery (incision begins) Never within an hour of a meal. The session is timed."
62187092|NCT02264782|ACTIVE_COMPARATOR|Group II (educational video)|Patients watch a video about healthy lifestyles including information about exercise and healthy eating over 45 minutes on an iPad in the waiting room before a doctor visit.
62187093|NCT03096756|OTHER|Part 1: Single Ascending Dose Escalation GC4702|Serially increase dose escalation of orally formulated GC4702 or placebo (6:2 ratio), preceded by single dose of active comparator, GC4419 IV.
62777221|NCT01587365|EXPERIMENTAL|Panel 7: Statin + BMS-962476 SC (0.1 mg/Kg) or Placebo|BMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
62570513|NCT06068101||Patients with EH (essential hypertension) previously investigated for PA (primary aldosteronism)|The control group included 137 (1:1) age,sex and body mass index (BMI) matched individuals from a retrospective cohort of EH previously investigated for PA from 2011 to 2022.
62777222|NCT01587365|EXPERIMENTAL|Panel 8: Statin + BMS-962476 SC (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
62777223|NCT03757377|ACTIVE_COMPARATOR|BackBeat Moderato System (PHC ON)|Eligible patients randomized after optimization phase to PHC ON (PHC algorithm active) for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
62777224|NCT03757377|PLACEBO_COMPARATOR|BackBeat Moderato System (PHC OFF)|Eligible patients randomized after optimization phase to pacemaker only (PHC OFF or PHC algorithm not active) for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
62570514|NCT04900259||COVID-19 Bladder Cancer|Patients diagnosed with primary bladder cancer in the COVID-19 period
62570515|NCT04900259||PreCOVID-19 Bladder Cancer|Patients diagnosed with primary bladder cancer in the preCOVID-19 period
62570516|NCT06557642|EXPERIMENTAL|ENTONOX (50% nitrous oxide:50% oxygen)|ENTONOX to be administered for 30 minutes.
62570517|NCT06557642|PLACEBO_COMPARATOR|Medical Air|Medical Air to be administered for 30 minutes.
62570518|NCT06526481|EXPERIMENTAL|Double nasoseptal flap|"Nasoseptal double flap group:~-On one side full sized nasoseptal flap will be elevated and a smaller sized nasoseptal flap will be elevated on the other side."
62570519|NCT06526481|EXPERIMENTAL|Rescue nasoseptal flap|"Nasoseptal rescue flap group:~- A horizontal incision will be performed in the nasal septum in a posterior to anterior direction starting from the sphenoid ostium to a point opposite anterior end of the middle turbinate ( approximately up to one half of septum)."
62570520|NCT03010800|EXPERIMENTAL|With Yoni.Fit|Subjects will perform the Abbreviated Pad Test with the Yoni.Fit first, then without the Yoni.Fit.
62570521|NCT03010800|EXPERIMENTAL|Without Yoni.Fit|Subjects will perform the Abbreviated Pad Test without the Yoni.Fit first, then with the Yoni.Fit.
62187094|NCT03096756|EXPERIMENTAL|Part 2: Food Effect Study|Following Part 1 dose find, single dose level of GC4702 administered under fasting for and fed condition.
62395410|NCT02816853|EXPERIMENTAL|Sequence 1|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
62395411|NCT02816853|EXPERIMENTAL|Sequence 2|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
62395412|NCT02816853|EXPERIMENTAL|Sequence 3|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
62395413|NCT02816853|EXPERIMENTAL|Sequence 4|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
62395414|NCT01786707|EXPERIMENTAL|Autologous SC and HOT|Autologous stem cells and hyperbaric oxygen therapy
62395415|NCT01786707|ACTIVE_COMPARATOR|Control group|Patients in a control group will continue with standard medical treatment (Insulin and Metformin)
62570522|NCT05676606|EXPERIMENTAL|monitoring group|a group of chemotherapy-naive patients with first time diagnosed various kinds of tumors, planned for the first cycle polychemotherapy treatment.
62570523|NCT04216836|EXPERIMENTAL|High magnesium diet (SUP condition)|Participants followed a low magnesium diet \<260mg/day and consumed 500 mg/day of magnesium oxide. This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.
62570524|NCT04216836|EXPERIMENTAL|Low magnesium diet (CON condition)|Participants followed a low magnesium diet \<260mg/day and consumed 500 mg/day of placebo (cornflour). This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.
62570525|NCT03337113|EXPERIMENTAL|WMT + rTMS|WMT + rTMS is the Working Memory Training + repetitive Transcranial Magnetic Stimulation arm. Both conditions are active.
62570526|NCT03337113|ACTIVE_COMPARATOR|Sham WMT + rTMS|Sham WMT + rTMS is the sham Working Memory Training + repetitive Transcranial Magnetic Stimulation arm. This condition isolates the effects of rTMS. WMT is inactive.
62187095|NCT02377323|OTHER|Treatment with Rebif|Patients treated with Rebif only, for at least two years, and for up to 18 years
62187096|NCT02377323|OTHER|Never treated|Patients never treated with a disease-modifying drug (DMD)
62187097|NCT04509674|EXPERIMENTAL|Empagliflozin|
62187098|NCT04509674|PLACEBO_COMPARATOR|Placebo|
62187099|NCT03287778|ACTIVE_COMPARATOR|Pyridoxine|Pyridoxine will be administered in dosages of 200 mg with a maximum dose of 400 mg.
62187100|NCT03287778|PLACEBO_COMPARATOR|Placebo|Matching placebos will be administered for each active drug.
62570527|NCT03337113|ACTIVE_COMPARATOR|WMT + sham rTMS|WMT + sham rTMS is the Working Memory Training + sham repetitive Transcranial Magnetic Stimulation arm. This condition isolates the effects of WMT. rTMS is inactive.
62570528|NCT03337113|SHAM_COMPARATOR|Sham WMT + sham rTMS|sham WMT + sham rTMS is the sham Working Memory Training + sham repetitive Transcranial Magnetic Stimulation arm. Both are inactive in this arm.
62570529|NCT05951829|OTHER|Cerebral Palsy|
62570530|NCT04520542|EXPERIMENTAL|acupressure|The application was performed on the determined acupressure points by considering the direction of the meridian in a certain order. It was performed with the administration order of Spleen 6th point (SP 6) and Large Intestine 4th point (Li 4). In total, the administration was performed with 4 acupressure points including 2 points in the upper/lower extremity along with the parallel points in each intervention. Each acupressure point was massaged for 30 seconds to provide circulation before the pressure. After the massage, consecutive pressures were applied for 90 seconds. In each intervention, a total of 8-minute sessions were applied to 4 points as 2 minutes for each point. Consecutive pressures were applied on a frequency that did not disturb the women, did not cause pain, and had a soothing effect. Until the end of the intervention it was continued 2 times a week, 16 times in total in 8 weeks.
62570531|NCT04520542|NO_INTERVENTION|Control Group|no intervation
62570532|NCT06465173||'High self-compassion' group|Participants' total mean score on the Self-compassion Scale - Short Form (Raes et al., 2011) will be used as the independent variable. A median split (+/-1 standard error of the median) on the Self-compassion Scale - Short Form will be used to retrospectively allocate participants to groups, with participants scoring ≥ + 1 standard error of the median on the Self-compassion Scale - Short Form allocated to a 'High self-compassion' group.
62570533|NCT06465173||'Low self-compassion' group|Participants' total mean score on the Self-compassion Scale - Short Form (Raes et al., 2011) will be used as the independent variable. A median split (+/-1 standard error of the median) on the Self-compassion Scale - Short Form will be used to retrospectively allocate participants to groups, with participants scoring ≤ - 1 standard error of the median on the Self-compassion Scale - Short Form allocated to a 'Low self-compassion' group.
62570534|NCT01501539|NO_INTERVENTION|Standard postop gastrostomy tube care|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions and the gastrostomy tube will be covered with dermabond, steristrips, and/or tegaderm dressings, according to surgeon preference. Standard postop gastrostomy tube care. Insertion site cleaned with soap and water. No dressing added.
62570535|NCT01501539|EXPERIMENTAL|Standard hydrocolloid dressing|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions will be covered with dermabond, steristrips, and/or tegaderm dressings, according to the surgeons preference. The gastrostomy tube will have a thin layer of hydrocolloid dressing (HD) placed around the gastrostomy tube. The HD will be changed once every other day fo the first 30 days after gastrostomy tube placement. After 30 days, care will revert to standard care.
62570536|NCT01501539|EXPERIMENTAL|Silver hydrocolloid dressing|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions will be covered with dermabond, steristrips, and/or tegaderm dressings, according to surgeon preference. The gastrostomy tube will have a thin layer of silver hydrocolloid dressing (HD) placed around the gastrostomy tube. The silver HD will be changed once every other day for the first 30 days after gastrostomy tube placement. After 30 days, care will revert to standard care.
62570537|NCT03500731|EXPERIMENTAL|Lung and Bone Marrow Transplantation|"All patients will undergo a cadaveric, partially HLA-matched lung transplantation followed by a CD3+/CD19+ depleted BMT from the same donor. In this study, the investigators will use a ≥1/6 HLA-matched T cell depleted bone marrow transplantation from a cadaveric organ donor with an identical ABO blood type as the recipient. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.~Subjects will undergo lung transplantation utilizing standard induction regimens selected by the CO-PIs based on the subject's underlying comorbidities and allosensitization. Rituximab may be initiated prior to the lung transplantation with tacrolimus as the ongoing maintenance immunosuppression.~Subjects will undergo BMT utilizing CD3+/CD19+-depleted bone marrow with bone marrow conditioning beginning no less than 8 weeks after lung transplantation. Bone marrow will be recovered alongside solid organs and will be processed and cryopreserved."
62570538|NCT02825628|EXPERIMENTAL|Osteodex 3.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
62570539|NCT02825628|EXPERIMENTAL|Osteodex 6.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
62570540|NCT02825628|EXPERIMENTAL|Osteodex 9.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
62570541|NCT05831501|EXPERIMENTAL|TAP block group|At the end of the cesarean section, a TAP block will be given by Injecting of 20ml 0.25% Bupivacaine on both sides of the midline using ultrasound-guided subcostal approach
62570542|NCT05831501|NO_INTERVENTION|Placebo group|At the end of the cesarean section, 20 ml of saline will be injected on both sides of the midline
62570543|NCT03142139||Danish Birth Cohorts 1997-2012|"RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib~RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib among children who received a timely first dose of DTaP-IPV-Hib~RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated on development of Atopic Dermatitis."
62187101|NCT02452099|OTHER|5% DMSO|
62187102|NCT02452099|OTHER|7.5% DMSO|
62187103|NCT02452099|OTHER|10% DMSO|
62187104|NCT06402214|EXPERIMENTAL|Case group|patients affected by adductor laryngeal dystonia
62187105|NCT06402214|ACTIVE_COMPARATOR|Control group|healthy patients
62187106|NCT05238649|EXPERIMENTAL|V-01 10 μg|10 μg(0.5ml)/vial, one dose administrated by intramuscular injection
62187107|NCT05238649|EXPERIMENTAL|V-01 25 μg|25 μg(0.5ml)/vial, one dose administrated by intramuscular injection
62187108|NCT05238649|ACTIVE_COMPARATOR|Inactivated vaccine|0.5ml/vial, containing 100U inactivated COVID-19 virus antigen. One dose administrated by intramuscular injection
62187109|NCT03108976|SHAM_COMPARATOR|Control group|Children with a typical development.
62187110|NCT03108976|ACTIVE_COMPARATOR|Case group|Children with Autism Spectrum Disorders.
62570544|NCT06311916|EXPERIMENTAL|Neoadjuvant therapy group|Patients in the neoadjuvant therapy group received neoadjuvant therapy before undergoing liver resection.
62570545|NCT06311916|ACTIVE_COMPARATOR|Direct surgical resection group|Patients in the control group undergoing liver resection directly.
62570546|NCT04120259|ACTIVE_COMPARATOR|Group 1|Intervention: Metformin Tablet oral 750 mg OD
62570547|NCT04120259|EXPERIMENTAL|Group 2|Intervention: Metformin 750 mg oral plus 2 tablespoons of apple cider vinegar OD
62570548|NCT05344157|EXPERIMENTAL|XSTEM-OA|Single intra-articular injection of XSTEM-OA
62570549|NCT04486937|EXPERIMENTAL|SC10914|400mg TID，oral admination on an fasting state
62570550|NCT05274243|EXPERIMENTAL|2-HOBA|2-HOBA acetate (2-Hydroxybenzlamine acetate) 750mg (provided as three 250mg capsules) three times per day for 4 weeks
62570551|NCT05274243|PLACEBO_COMPARATOR|Placebo|Matching placebo (provided as three capsules) three times per day for 4 weeks
62570552|NCT01942577|NO_INTERVENTION|No treatment|
62570553|NCT01942577|ACTIVE_COMPARATOR|NoSting|
62570554|NCT04600765|ACTIVE_COMPARATOR|Diet Before|Typical diet contaminated with Bisphenol A. Patient assigned to this arm will consume a typical American diet as defined by USDA.
62570555|NCT04600765|ACTIVE_COMPARATOR|Diet After|Bisphenol A reduced. Patient assigned to this arm will consume a diet analogous to atypical American diet as defined by USDA, but with known Bisphenol A sources reduced or eliminated.
62570556|NCT02040103|EXPERIMENTAL|Intermittent Pneumatic Compression(IPC)|The intervention group will be receiving Intermittent Pneumatic Compression(IPC)
62570557|NCT02040103|NO_INTERVENTION|No Intermittent Pneumatic Compression|patients will not receive Intermittent Pneumatic Compression
62570558|NCT00969930||healthy controls|
62570559|NCT00969930||BD type I patients|
62570560|NCT02464592|ACTIVE_COMPARATOR|Biopsy with Cryoprobes|Transbronchial lung biopsy with a cryoprobe.
62395416|NCT06050733||Solid cancer patients with disease progression|8 patients with a diagnosis of solid cancer undergoing standard of care treatment, with a PD-1 or PD-L1 inhibitor, with disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines.
62570561|NCT02464592|ACTIVE_COMPARATOR|Biopsy with Conventional Forceps|Transbronchial lung biopsy with conventional forceps.
62570562|NCT02673931|EXPERIMENTAL|GLP-1|"700 patients will be randomized to GLP-1, that will be administered as follows:~248.5 mL of isotonic sodium chloride added 1.5 mL of 20% human albumin added 25 microg Byetta (Lilly, Exenatide).~The study drug infusion is initiated immediately before open heart surgery and ended after 6 hours and 15 minutes. A set dose of 17.4 microg will be given."
62570563|NCT02673931|PLACEBO_COMPARATOR|Placebo|"20% Human Albumin is given as placebo. 700 patients will be randomized to placebo, that will be administered as follows:~248.5 mL of isotonic sodium chloride added 1.5 mL of 20% human albumin.~The placebo infusion is initiated immediately before open heart surgery and ended after 6 hours and 15 minutes at the same rate as the study drug."
62570564|NCT02673931|EXPERIMENTAL|Restrictive Oxygenation|"The intervention is FiO2 of 50%, given as 'Conoxia (AGA, oxygen)'. 700 patients will be randomized to a FiO2 of 50% as long as the arterial O2 saturation (Sa02) remains above 91% during cardiopulmonary bypass, when weaning from and the following hour after weaning from cardiopulmonary bypass. The oxygenation strategy is discontinued and the patient is treated at the discretion of the attending physician after~1. a maximum of 1 hours of intervention or~2. the patient is slid from the operating table to a hospital bed for transfer to the intensive care unit, whichever comes first."
62395417|NCT06050733||Solid cancer patients with stable or experience shrinkage in tumor size|8 patients with a diagnosis of solid cancer undergoing standard of care treatment, with a PD-1 or PD-L1 inhibitor, with tumor size stable or shrinkage, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines.
62777225|NCT02346513||A: Ceramic on Metal THA|"Subgroup A1: Consist of ceramic on metal THAs with short term follow-up (less than 2years)~Subgroup A2: Consist of ceramic on metal THAs with midterm follow-up (more than 2years)~Subgroup A3: Consist of bilateral ceramic on metal THAs"
62777226|NCT02346513||B: Non-Ceramic on Metal THA|Patients have THA with non COM bearing
62777227|NCT02346513||C: Healthy subjects|Patients without any implant or systemic disease, to served as controls
62187111|NCT03349411||Acute Ischemic Stroke Sample|45 acute patients with first ever ischemic stroke on the right side of the brain will be recruited at NYC Health + Hospitals/Bellevue . They will undergo testing with the Confusion Assessment Method (CAM), Behavioral Inattention Test (BIT), Montreal Cognitive Assessment (MOCA) and Geriatric Depression Scale (GDS)
62395418|NCT06639711|EXPERIMENTAL|Application of Taurine-containing Eye Drops|
62395419|NCT05222841|EXPERIMENTAL|Spermotrend|
62395420|NCT02138929|EXPERIMENTAL|Everolimus + LDE 225|"Dose Escalation: Everolimus at a dose of 10 mg by mouth daily with dose escalation of LDE 225 from 200 mg - 800mg by mouth daily. Study cycle is 28 days.~Dose Expansion: Everolimus at a dose of 10 mg by mouth daily. LDE 225 at MTD from Dose Escalation. Study cycle is 28 days."
62395421|NCT01955005|EXPERIMENTAL|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
62395422|NCT01955005|ACTIVE_COMPARATOR|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
62395423|NCT02688452|ACTIVE_COMPARATOR|Group 1|Young Healthy Adults
62395424|NCT02688452|ACTIVE_COMPARATOR|Group 2|Young Healthy Adults
62395425|NCT05642884|EXPERIMENTAL|Teleprehab|The participants selected for the teleprehab arm will undergo a supervised 8-week multi-modal exercise program in a telehealth format (using doxy.me, a free telehealth platform) delivered by licensed physical or occupational therapists who have undergone cancer specific rehabilitation training within Select Medical's ReVital® cancer rehabilitation program. Participants will attend teleprehab sessions 2 times per week for a total of 16 sessions.
62777228|NCT03219411|ACTIVE_COMPARATOR|Cinnamon|Cinnamon burmannii administered orally as 500-mg capsules three times daily over 12 weeks
62777229|NCT03219411|PLACEBO_COMPARATOR|Placebo|Placebo administered orally as capsules three times daily over 12 weeks
62777230|NCT00738218|OTHER|MDCT|Single Arm study. All patients underwent MDCT.
62001728|NCT03364088|ACTIVE_COMPARATOR|Spinal anesthesia with tourniquet|"This group will be operated under spinal anesthesia (15 mg of bupivacaine) and in continuous light propofol sedation. Surgical tourniquet (with the pressure of 250 mmHg or \> 100 mmHg higher than systolic blood pressure) is used during the operation.~Local infiltration analgesia (LIA) will be administered during the operation. Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the removal of the tourniquet.~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
62001729|NCT03364088|ACTIVE_COMPARATOR|Spinal anesthesia without tourniquet|"This group will be operated under spinal anesthesia (15 mg of bupivacaine) and in continuous light propofol sedation. Surgical tourniquet is not used during the operation.~Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the surgical incision. Local infiltration analgesia (LIA) will be administered during the operation.~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
62001730|NCT03364088|ACTIVE_COMPARATOR|General anesthesia with tourniquet|"This group will be operated under general anesthesia (propofol and remifentanil are used with target-controlled infusion (TCI) mode) and surgical tourniquet (with the pressure of 250 mmHg or \> 100 mmHg higher than systolic blood pressure) is used during the operation.~Local infiltration analgesia (LIA) will be administered during the operation. Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the removal of tourniquet. Intravenous bolus of oxycodone 0.1 mg/kg (ideal body weight) is given when the closure of surgical wound begins.~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
62001731|NCT03364088|ACTIVE_COMPARATOR|General anesthesia without tourniquet|"This group will be operated under general anesthesia (propofol and remifentanil are used with target-controlled infusion (TCI) mode) without the use of surgical tourniquet.~Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the surgical incision. Local infiltration analgesia (LIA) will be administered during the operation. Intravenous bolus of oxycodone 0.1 mg/kg (ideal body weight) is given when the closure of surgical wound begins.~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
62001732|NCT03288597||A: advanced and metastatic neuroendocrine tumors|Advanced and metastatic neuroendocrine tumors receive syestematic treatment
62001733|NCT03288597||A: advanced and metastatic neuroendocrine carcinomas|Advanced and metastatic neuroendocrine carcinomas receive syestematic treatment
62001734|NCT01247766||Patients with rheumatoid arthritis (RA) who receive abatacept|
62001735|NCT01247766||Patients with RA who receive BDM drugs|biologic disease-modifying (BDM)
62001736|NCT01247766||Patients with RA who receive non-biologic DMARDs|disease-modifying anti-rheumatic drugs (DMARDs)
62001737|NCT04625738|EXPERIMENTAL|MSC Arm|"Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.~day 0: 1.10\^6 MSC/kg day 3: 0.5. 10\^6 MSC/kg day 5: 0.5 . 10\^6 MSC/kg"
62001738|NCT04625738|PLACEBO_COMPARATOR|Placebo Arm|Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day).
62001739|NCT03270046|PLACEBO_COMPARATOR|No enema group|"Consecutive participants will be randomly assigned to take a preparation regimen of 3 liter of PEG 8-16 hr. before colonoscopy without water enema.~Before the procedure, investigators record baseline parameters. Colonoscopies underwent by experienced endoscopists and by GI fellows. During the colonoscopy, the investigators recorded video, cecal intubation and withdraw time, amount and position of polyps, rate of complete examination and complication. The video was sent to other 2 endoscopists who did not known which participant was enema to evaluate the quality of bowel cleansing by using Ottawa bowel preparation scale and Likert scale for evaluation of side effect, complication during PEG ingestion, enema and colonoscopy, and participant satisfactory."
62395426|NCT05642884|OTHER|Attention Control|The participants randomized to the attention control arm will not undergo an exercise regimen, but will be contacted by the study staff on the phone once a week..
62395427|NCT03153436|ACTIVE_COMPARATOR|Normal S.A group|Infertile men with normal semen analysis. each sample is divided into 2 identical aliquots: one aliquot (Myo aliquot) is supplied with myoinositol, The other aliquot is left as it is (control aliquot).
62395428|NCT03153436|ACTIVE_COMPARATOR|Abnormal S.A group|Infertile men with abnormal semen analysis. each sample is divided into 2 identical aliquots: one aliquot (Myo aliquot) is supplied with myoinositol, The other aliquot is left as it is (control aliquot).
62395429|NCT04177940|ACTIVE_COMPARATOR|Denosumab (DMAB) to Alendronate (ALN)|Switch from Denosumab 60 mg administered subcutaneously (SC) to weekly oral alendronate (70 mg; started 6 months after last denosumab dose)
62395430|NCT04177940|ACTIVE_COMPARATOR|"DMAB to Early Zoledronic Acid (ZA)"|"Switch from Denosumab 60 mg administered subcutaneously (SC) to one early zoledronic acid infusion (5 mg; 6 months after last denosumab dose)"
62395431|NCT04177940|ACTIVE_COMPARATOR|"DMAB to Late ZA"|"Switch from Denosumab 60 mg administered subcutaneously (SC) to one late zoledronic acid infusion (5 mg; 9 months after last denosumab dose)"
62395432|NCT04499521|EXPERIMENTAL|Arm A: BrachyGel in fractions 3 and 5|BrachyGel VHPS in fractions 3 and 5 and standard packing in fractions 2 and 4
62395433|NCT04499521|EXPERIMENTAL|Arm B: BrachyGel in fractions 2 and 4|BrachyGel VHPS in fractions 2 and 4 and standard packing in fractions 3 and 5
62395434|NCT02201966||Female gymnasts with low back pain|Subset of competitive female gymnasts who report significant low back pain that affects their ability to perform gymnastics.
62395435|NCT02201966||Female gymnasts without low back pain|Subset of competitive female gymnasts who deny significant low back pain that affects their ability to perform gymnastics.
62395436|NCT05311631|EXPERIMENTAL|Intervention|Improved breastfeeding support provided by health visitors supporting families after discharge from maternity ward at hospital. The intervention is implemented into the existing national health visitor program that is offered free of charge to all. The program is accepted by more than 95% of families.
62395437|NCT05311631|NO_INTERVENTION|Control|Health visitors in the control municipalities will give breastfeeding support according to standard care.
62777231|NCT03091764||NMIBC Patient High Risk|"Any of the following:~* T1 tumours~* CIS (carcinoma in situ)~* Multiple and recurring and large (\>3cm) Ta, G1, G2 tumours (all these conditions must be presented)~(Patients requiring intravesical Bacillus Calmette-Guérin (BCG) (immunotherapy), which starts with 6 week induction treatment and continues with maintenance for 1 to 3 years)"
62187112|NCT03349411||Subacute Ischemic Stroke Sample|30 patients with first ever ischemic stroke on the right side of the brain who are within 3 months of their stroke will be recruited at Kessler Institute for Rehabilitation. They will undergo testing with the Confusion Assessment Method (CAM), Behavioral Inattention Test (BIT), Florida Mental Status Examination (FMSE); Kessler Foundation Neglect Assessment Process (KF-NAP); and Geriatric Depression Scale (GDS). These participants will also complete a research Magnetic Resonance Imaging (MRI) scan.
62187113|NCT01463228|EXPERIMENTAL|Treatment Sequence AB|
62570565|NCT02673931|ACTIVE_COMPARATOR|Liberal Oxygenation|"The intervention is a FiO2 of 100%, given as 'Conoxia (AGA, oxygen)'. 700 patients will be randomized to a FiO2 of 100% during cardiopulmonary bypass, when weaning from and the following hour after weaning from cardiopulmonary bypass. The oxygenation strategy is discontinued and the patient is treated at the discretion of the attending physician after~1. a maximum of 1 hours of intervention or~2. the patient is slid from the operating table to a hospital bed for transfer to the intensive care unit, whichever comes first."
62187114|NCT01463228|EXPERIMENTAL|Treatment Sequence BA|
62187115|NCT02790775|ACTIVE_COMPARATOR|Injection Anti-VEGF in quadrant 1|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 1
62187116|NCT02790775|ACTIVE_COMPARATOR|Injection Anti-VEGF in quadrant 2|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 2
62187117|NCT02790775|ACTIVE_COMPARATOR|InjectionAnti-VEGF in quadrant 3|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 3
62187118|NCT02790775|ACTIVE_COMPARATOR|InjectionAnti-VEGF in quadrant 4|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 4
62187119|NCT01560195|EXPERIMENTAL|Pegylated rhG-CSF: 100µg/kg|Staged III or IV NSCLC patients receiving chemotherapy and Pegylated rhG-CSF 100µg/kg
62570566|NCT03825939|EXPERIMENTAL|Intravenous Tranexamic Acid|"* 1g TXA administered intravenous piggyback at start of surgery OR~* 1g TXA administered intravenous piggyback at start and at time of closure of surgery"
62570567|NCT03825939|PLACEBO_COMPARATOR|Intravenous Placebo|- IV 0.9% sterile saline
62570568|NCT03825939|ACTIVE_COMPARATOR|Intravenous Tranexamic Acid followed by Intravenous Placebo|"* 1g TXA administered intravenous piggyback at start of surgery OR~* 1g TXA administered intravenous piggyback at start and at time of closure of surgery~* IV 0.9% sterile saline"
62187120|NCT01560195|EXPERIMENTAL|Pegylated rhG-CSF: 6mg|Staged III or IV NSCLC patients receiving chemotherapy and pegylated rhG-CSF 6mg
62187121|NCT01560195|PLACEBO_COMPARATOR|Placebo|Staged III or IV NSCLC patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF in cycle 2 to 4
62395438|NCT04301557|EXPERIMENTAL|PD1 Antibody and Chemoradiotherapy for dMMR/MSI-H LACRC|Induction regimen: Capeox+PD1 antibody for 1 cycle, Concurrent chemoradiotherapy regimen: Capeox+PD1 antibody for 2 cycles and concurrent , Interval regimen: Capeox+PD1 antibody for 1 cycle, TME surgery or watch and wait for cCR patients Adjuvant regimen: Capeox+PD1 antibody for 2 cycles, Capecitabine+PD1 antibody for 2 cycles
62570569|NCT06345859|EXPERIMENTAL|Osc+|Osc+ condition. In the Osc+ condition, participants will see an on-going record of their heart rate over time. They will be instructed to engage in paced breathing and to try to maximize their oscillation score. The paced breathing will be adapted to a rate that allows them to maximize their high amplitude heart rate oscillations.
62187122|NCT01501409|EXPERIMENTAL|Group I|
62187123|NCT01501409|ACTIVE_COMPARATOR|Group II|
62187124|NCT01501409|ACTIVE_COMPARATOR|Group III|
62187125|NCT04178811||Benign Prostatic Hyperplasia patients with predominant voiding lower urinary tract symptoms|Outcomes of Holmium Laser Enucleation of Prostate in Management of Benign Prostatic Hyperplasia patients with predominant voiding lower urinary tract symptoms
62187126|NCT04178811||Benign Prostatic Hyperplasia patients with predominant storage lower urinary tract symptoms|Outcomes of Holmium Laser Enucleation of Prostate in Management of Benign Prostatic Hyperplasia patients with predominant storage lower urinary tract symptoms
62187127|NCT03941899|OTHER|QLB II|Quadratus Lomborum Blocck II type will be performed before robot-assisted laparoscopic radical prostatectomy
62187128|NCT03001622|OTHER|IFX-1|
62777232|NCT03091764||NMIBC Patient Intermediate Risk|"All cases between High and Low Risk~(Patients requiring intravesical therapy which lasts between 6 weeks to 3 years)"
62187129|NCT02591862|OTHER|Coversin (Nomacopan)|"This is an open label, non-comparator study.~Patient will be given a single ablating dose of 0.57mg/kg per subject followed by daily repeat maintenance doses. The initial repeat dose will be 25% of the ablating dose. If this is insufficient to maintain complement inhibition at ≤10% of baseline (pre-treatment) level after 5 days of treatment the daily dose will be increased by doubling until that level of inhibition is achieved. In the event of 100% inhibition being achieved the dose may be titrated downwards at the PI's discretion until a satisfactory clinical result is obtained. If at any point in treatment complement inhibition falls to less than 50% of baseline a further ablating dose of 0.57mg/kg should be given. Coversin lyophilised powder in each vial was diluted with 0.6 mL water for injection prior to use."
62187130|NCT02735590|EXPERIMENTAL|Open-label 3HP|Participants in the Treatment Arm will receive high dose INH (15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg) with Pyridoxine supplementation (25mg), and Rifapentine based on body weight (\>32kg - 50kg: 750 mg; \>50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months. Dispensing of IP and Directly Observed Treatment (DOT) field visits in Treatment Arm participants will be performed by staff members not involved in TB symptom screening or investigation. Participants receiving 3HP who develop symptoms of hepatotoxicity will be evaluated by an Investigator.
62001740|NCT03270046|ACTIVE_COMPARATOR|Water enema group|"Consecutive participants will be randomly assigned to take a preparation regimen of 3 liter of PEG 8-16 hr. before colonoscopy and enema with sterile water until stool was clear or patient felt discomfort but not exceed 3 liter, before colonoscopy.~Before the procedure, investigators record baseline parameters. Colonoscopies underwent by experienced endoscopists and by GI fellows. During the colonoscopy, the investigators recorded video, cecal intubation and withdraw time, amount and position of polyps, rate of complete examination and complication.The video was sent to other 2 endoscopists who did not known which participant was enema to evaluate the quality of bowel cleansing by using Ottawa bowel preparation scale and Likert scale."
62001741|NCT05720325|ACTIVE_COMPARATOR|Adaptive Phenotypes randomized to study drug|This group will be comprised of the Adaptive-A and Adaptive-B subgroup and will consist of the adaptive phenotype participants identified during the initial HDM ACC challenge, administered the study drug.
62187131|NCT02735590|NO_INTERVENTION|Baseline Screening; Active Surveillance|Adult volunteers living in TB hyperendemic communities of South Africa will be consented and screened. Individuals with HIV infection and conditions likely to affect the performance of the COR assay, or the safety and/or efficacy of the 3HP investigational regimen, will not be enrolled. Active surveillance for TB disease (Observation Arm), including regular symptom screening and symptom-targeted TB investigation (all participants) will be conducted on this Arm.
62395439|NCT05173532|EXPERIMENTAL|Balance Training|Static and dynamic balance and gait stability training exercises are performed with supervision by a physical therapist or physical therapist assistant for 30 minutes, 3 times per week, for 8 weeks.
62395440|NCT05173532|ACTIVE_COMPARATOR|Breathing and Stretching Exercises|Patients perform static stretches for all major muscle groups while performing diaphragmatic breathing with supervision by a physical therapist or physical therapist assistant for 30 minutes, 3 times per week, for 8 weeks.
62395441|NCT04693481|EXPERIMENTAL|experimental group: 5 seconds for each photo|receive the intervention, which is viewing each nature photo for 5 seconds
62395442|NCT04693481|EXPERIMENTAL|experimental group: 15 seconds for each photo|receive the intervention, which is viewing each nature photo for 15 seconds
62395443|NCT04693481|EXPERIMENTAL|experimental group: 30 seconds for each photo|receive the intervention, which is viewing each nature photo for 30 seconds
62395444|NCT04693481|NO_INTERVENTION|control group|not receive the intervention, which is viewing each nature photo for 0 seconds.
62395445|NCT02225626|EXPERIMENTAL|BI 1060469 fed|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administr
62395446|NCT02225626|EXPERIMENTAL|BI 1060469 fasted|tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
62777233|NCT03091764||NMIBC Patient Low Risk|"Primary, solitary, Ta, LG/G1, \<3cm, no CIS~(Patients receiving frequent cystoscopies, possible tumour resections and single instillations of postoperative chemotherapy)"
62791737|NCT05455528||renal insufficiency group|"1. Surgical population currently on dialysis~2. Surgical population with estimated GFR \< 60 ml/min per 1.73 square meter within 90days before the index surgery. The estimated GFR"
62187132|NCT01740154|EXPERIMENTAL|Supportive care (sunitinib malate, neuromuscular testing)|Patients receive sunitinib malate PO daily for 4 weeks. Patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28.
62187133|NCT05820113|EXPERIMENTAL|Deep learning based reconstruction of T2-TSE sequence|Participants undergo multiparametric MRI of the prostate with inclusion of standard cartesian T2-TSE and non-cartesian T2-weighted sequences, as well as a newly developed deep learning enhanced T2-TSE sequence. All patients in this study undergo the same imaging protocol.
62187134|NCT05410119|EXPERIMENTAL|Resilience group|
62395447|NCT03391258|EXPERIMENTAL|Bone Regeneration with GLAM technique|At the beginning of each surgery, a venipuncture will be performed, to obtain the L-PRF membranes. Also, two white topped tubes will be centrifuged for 3 minutes to obtain PRP. After implant placement, achieving a primary stability of at least 45 Ncm, the stiff bone-block (L-PRF membranes and PRP combined with bovine xenograft) will be used in the buccal plate of the pre-maxilla, to enhance bone volume in the esthetic area.
62395448|NCT02862366||Primary Myelofibrosis (PMF)|Blood sampling during routine visit
62395449|NCT02862366||Essential thrombocytosis (ET)|Blood sampling during routine visit
62395450|NCT02862366||Polycythemia vera (PV)|Blood sampling during routine visit
62395451|NCT03912506||Patient admitted in the ICU for leptospirosis|Patient admitted in the ICU for leptospirosis None intervention was performed according to retrospective design
62395452|NCT01789333|EXPERIMENTAL|9 mw/cm2 at 10 minutes group|30 patients will be treated with UVA light source at 9 mw/cm2 at 10 minutes. Drug: Riboflavin Dose:1 drop every 2 to 3 minutes for 15 to 20 minutes
62395453|NCT00792467|EXPERIMENTAL|ITF2357|"Patients received the following therapy cycle~* ITF2357, 50 mg every 6 hours, per os, days 1 - 3;~* Mechlorethamine, 6 mg/sqm, intravenously , day 4. Therapy was administered every 21 days as long as there was no evidence of progressive disease or unacceptable toxicity, but in any case for a maximum of 12 cycles.~The mean number of complete treatment cycles received by patients was 5.25, with a minimum of 1 cycle and a maximum of 12 cycles."
62395454|NCT02042742|EXPERIMENTAL|Antioxidant supplement|Treatment consist of consuming 65g of punicalagin and 3,3g of hydroxytyrosol (plus 331,7g of maltodextrin) three times daily, during 8 weeks.
62570570|NCT06345859|ACTIVE_COMPARATOR|Osc-|Osc- condition. In the Osc- condition, participants will also see an on-going record of their heart rate over time, and will be instructed to engage in paced breathing. However, they will be asked to try to keep their heart rate steady and avoid oscillations and will get points on an 'alertness' score that inverts the Osc+ 'oscillation' score.
62001742|NCT05720325|EXPERIMENTAL|Maladaptive Phenotypes randomized to study drug|This group will be comprised of the Maladaptive-A and Maladaptive-B subgroup and will consist of the maladaptive phenotype participants identified during the initial HDM ACC challenge administered the study drug.
62001743|NCT05720325|PLACEBO_COMPARATOR|Adaptive Phenotype randomized to placebo|This group will be comprised of the Adaptive-A and Adaptive-B subgroup and will consist of the adaptive phenotype participants identified during the initial HDM ACC challenge, administered the placebo.
62570571|NCT06574451|EXPERIMENTAL|VR-assisted postoperative analgesia group|"Patients will receive postoperative analgesic adjunctive therapy software to assist in pain control, with one postoperative analgesic adjunctive therapy software intervention at 24 hours and 48 hours after surgery, and pain evaluation within 30 minutes.~All participants will receive intravenous analgesics pumped with mechanical pumps (analgesic pumps: Flurbiprofen cilexil Injection 5ml: 50mg/stick\*4 sticks, combined with Dezocine Injection 1ml: 5mg/stick\*6 sticks, add Ondansetron Hydrochloride Injection: 2ml: 4mg/stick\*2 sticks; or add Tolisetron Mesylate Injection: 2ml: 6 mg/stick\*4 sticks, diluted to 100mL with 0.9% sodium chloride injection).In case of an outbreak of pain (when analgesic pump is ineffective and the pain is unbearable), analgesic medication regimen: flurbiprofen cilofen injection 5 ml: 50 mg/piece, intravenous injection."
62777234|NCT02258087|ACTIVE_COMPARATOR|LDRPBT|Patients with low and selected intermediate risk prostate cancer are treated with Prostate LDR brachytherapy as monotherapy. 145 Gy is prescribed to the prostate. I-125 radioactive sources are used. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time dose optimization is applied.
62777235|NCT02258087|EXPERIMENTAL|HDRPBT|Patients with low and selected intermediate risk prostate cancer are treated with prostate HDR brachytherapy as monotherapy. The prescribed dose is 1x19 Gy to the whole prostate. Ir-192 radioactive source is used. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time dose optimization is applied.
62001744|NCT05720325|PLACEBO_COMPARATOR|Maladaptive Phenotype randomized to placebo|This group will be comprised of the Maladaptive-A and Maladaptive-B subgroup and will consist of the maladaptive phenotype participants identified during the initial HDM ACC challenge administered the placebo.
62001745|NCT00846118|ACTIVE_COMPARATOR|Pitavastatin|Pitavastatin in addition to optimal standard care
62001746|NCT00846118|NO_INTERVENTION|optimal standard care|
62001747|NCT02008500|PLACEBO_COMPARATOR|Placebo Mouthwash Group|Group 1 (placebo mouthwash group) contained 51 individuals
62001748|NCT02008500|ACTIVE_COMPARATOR|Herbal Mouthwash Group|Group 2 ( Herbal mouthwash) contained 52 individual
62001749|NCT02008500|SHAM_COMPARATOR|Non Herbal Mouthwash Group|Group 3 (Non Herbal mouthwash) contained 50 individuals
62001750|NCT01882270||Mild Pericoronitis|Those with mild signs/symptoms of pericoronitis affecting at least one lower 3rd molar with adjacent 2nd molar will be monitored for 12 months following study entry or 3 months for those electing to have 3rd molar extraction.
62001751|NCT01686646|ACTIVE_COMPARATOR|highest dose Paracetamol + caffeine|highest dose of Paracetamol and caffeine
62001752|NCT01686646|ACTIVE_COMPARATOR|low-dose Paracetamol + caffeine|lowest dose of Paracetamol and caffeine
62001753|NCT01686646|ACTIVE_COMPARATOR|high dose paracetamol|highest dose paracetamol
62001754|NCT01686646|ACTIVE_COMPARATOR|low dose paracetamol|lowest dose paracetamol
62001755|NCT02457533|NO_INTERVENTION|Control|Only SF-36 and CAT
62001756|NCT02457533|ACTIVE_COMPARATOR|Active|Lifestyle behavioral. Health plan, telephone support
62001757|NCT04874506|EXPERIMENTAL|Cohort 1|"Cohort 1 will receive standard of care concomitantly with1000 mg/day of MBM-02.~Patients will receive standard of care treatment for newly diagnosed Glioblastoma multiforme consisting of four sequential periods:~1. 1 week run-in with MBM-02 prior to radiotherapy;~2. 6 weeks of radiotherapy and concomitant temozolomide;~3. 4 weeks of rest post-radiotherapy and concomitant temozolomide; and~4. Adjuvant temozolomide treatment post 4-week rest period. Patients will be administered daily MBM-02 during all four sequential periods."
62187135|NCT05410119|ACTIVE_COMPARATOR|Controlled group|
62584871|NCT02419014|ACTIVE_COMPARATOR|Active CES Device|The Alpha-Stim® device is a Class II FDA-approved device for the delivery of cranial electrotherapy using microcurrents that are delivered via two electrodes worn on the earlobes. Active CES devices will be pre-programmed by the manufacturer to deliver a bipolar, asymmetric rectangular waveform at a current of 100 µa, a level that is generally undetectable by the wearer of the device. At these settings, the manufacturer recommends a treatment duration of 60 minutes. Participants will not be able to alter the settings in any way.
62001758|NCT04874506|EXPERIMENTAL|Cohort 2|"Cohort 2 will receive standard of care concomitantly with1200 mg/day of MBM-02.~Patients will receive standard of care treatment for newly diagnosed Glioblastoma multiforme consisting of four sequential periods:~1. 1 week run-in with MBM-02 prior to radiotherapy;~2. 6 weeks of radiotherapy and concomitant temozolomide;~3. 4 weeks of rest post-radiotherapy and concomitant temozolomide; and~4. Adjuvant temozolomide treatment post 4-week rest period. Patients will be administered daily MBM-02 during all four sequential periods."
62001759|NCT04874506|EXPERIMENTAL|Cohort 3|"Cohort 2 will receive standard of care concomitantly with1400 mg/day of MBM-02.~Patients will receive standard of care treatment for newly diagnosed Glioblastoma multiforme consisting of four sequential periods:~1. 1 week run-in with MBM-02 prior to radiotherapy;~2. 6 weeks of radiotherapy and concomitant temozolomide;~3. 4 weeks of rest post-radiotherapy and concomitant temozolomide; and~4. Adjuvant temozolomide treatment post 4-week rest period. Patients will be administered daily MBM-02 during all four sequential periods."
62001760|NCT04874506|EXPERIMENTAL|Cohort 4|"Cohort 2 will receive standard of care concomitantly with1400 mg/day of MBM-02.~Patients will receive standard of care treatment for newly diagnosed Glioblastoma multiforme consisting of four sequential periods:~1. 1 week run-in with MBM-02 prior to radiotherapy;~2. 6 weeks of radiotherapy and concomitant temozolomide;~3. 4 weeks of rest post-radiotherapy and concomitant temozolomide; and~4. Adjuvant temozolomide treatment post 4-week rest period. Patients will be administered daily MBM-02 during all four sequential periods."
62001761|NCT01227512|EXPERIMENTAL|Tolvaptan 15-60mg|Oral tablet without fluid restriction. After the initial dose, daily dose may be titrated based on response.
62777236|NCT02678923|EXPERIMENTAL|MDCO-216|20 mg/kg of MDCO-216 administered intravenously (IV) as a 360 milliliter (mL) infusion over 2 hours on Days 1, 8, 15, 22, and 29
62777237|NCT02678923|PLACEBO_COMPARATOR|Placebo|360 mL of placebo (0.9% sodium chloride \[NaCl\] solution) infusion, IV, over 2 hours on Days 1, 8, 15, 22, and 29
62777238|NCT02178696|EXPERIMENTAL|Known Placebo First|"This arm gets a placebo that they know is a placebo (called inactive), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called active medication (which is also actually a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa or alternative as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated."
62791738|NCT05455528||Non-renal insufficiency group|Defined as the study subjects with eGFR \> 90 60 ml/min per 1.73 square meter within 90 days before the index surgery
62791739|NCT04057521|EXPERIMENTAL|CHECK Program|Participants were offered enrollment into CHECK care coordination services.
62791740|NCT04057521|ACTIVE_COMPARATOR|Comparison Group|Participants were not offered enrollment into CHECK.
62001762|NCT01227512|ACTIVE_COMPARATOR|Fluid Restriction|Placebo tablet with prescribed fluid restriction. After the initial dose, level of fluid restriction may titrated based response.
62777239|NCT02178696|EXPERIMENTAL|"Active (blinded) Placebo first group"|"This arm gets a placebo that they don't know is a placebo (called Active), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called inactive medication (which participants know is a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated."
62395455|NCT02042742|PLACEBO_COMPARATOR|Control supplement|Treatment consist of consuming 400g of maltodextrin three times daily, during 8 weeks.
62395456|NCT02463097|EXPERIMENTAL|Study Arm|All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm
62001763|NCT03592121|EXPERIMENTAL|AB-101|Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
62187136|NCT04751240|EXPERIMENTAL|SIT and Resistance|Participants will complete 10 weeks of a SIT and resistance training paradigm.
62395457|NCT05417581|EXPERIMENTAL|All patients|a sample of adipose tissue will be collected during the scheduled surgery
62777240|NCT05115916|NO_INTERVENTION|Standard of Care|This group will receive standard FIT mailer protocol (includes mailed FIT kit plus standardized messaging via EHR portal)
62001764|NCT03592121|PLACEBO_COMPARATOR|Placebo|Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
62187137|NCT01510353|EXPERIMENTAL|Use of a radiation monitoring device|Use of a radiation monitoring device that provides real-time auditory feedback on radiation exposure during cardiac catheterization
62187138|NCT01510353|NO_INTERVENTION|No use of radiation monitoring device|No use of a radiation monitoring device that provides real-time auditory feedback on radiation exposure during cardiac catheterization
62777241|NCT05115916|EXPERIMENTAL|MyChart Message|This group will receive a message via EHR portal informing them about the incoming FIT Kit
62187139|NCT04159662||Individuals with Schizophrenia or Schzioaffective Disorders|Clinical group
62187140|NCT04159662||Individuals with Major Depressive Disorder|Clinical group
62791741|NCT05285540|EXPERIMENTAL|Single Dose: DT-216|DT-216 will be administered once
62001765|NCT02677792|EXPERIMENTAL|Behavioral Family Intervention (BFI)|
62001766|NCT01536639||BIAsp 30 users|
62001767|NCT04125316||Asthma|Asthma patients
62001768|NCT03296228||Hong Kong|"Radiation: Flexibility Radiographs (supine, supine side-bend, FB)~supine side-bending and fulcrum bending films"
62187141|NCT04159662||Healthy Individuals|Control group
62187142|NCT05893914|OTHER|4 week baseline|Randomization to the first tier will include 4 weeks (28 days) of baseline measures (phase A), followed by 5 weeks of treatment and symptom monitoring (phase B)
62395458|NCT05909046|ACTIVE_COMPARATOR|Immediate inpatient postpartum OGTT|The intervention includes immediate inpatient postpartum 2-hour oral glucose tolerance test (OGTT) prior to delivery discharge
62395459|NCT05909046|OTHER|Standard of care|Standard of care is 4-12 week outpatient postpartum OGTT
62395460|NCT02958098||Myocardial infarction|Individuals with myocardial infarction before age 50 years.
62395461|NCT02958098||Stroke|Individuals with stroke before age 50 years
62395462|NCT02958098||Aortic dissection|Individuals with aortic dissection before age 50 years
62395463|NCT02958098||Systolic heart failure|Individuals with systolic heart failure/dilated cardiomyopathy before age 50 years.
62395464|NCT02958098||Atrial fibrillation|Individuals with atrial fibrillation before age 50 years
62395465|NCT02080988||Silent aspirators|Stroke patients with dysphagia with severe aspiration
62395466|NCT02080988||Non aspirating, no dysphagia group|Stroke patients with no dysphagia and no evidence of aspiration
62395467|NCT01240629|EXPERIMENTAL|Arm I|Patients receive doxorubicin-GnRH agonist conjugate AEZS-108 intravenously (IV) over 2 hours once every 21 days (21 days = 1 cycle). Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62395468|NCT01364506|EXPERIMENTAL|Water exercise|
62395469|NCT01364506|NO_INTERVENTION|Control|
62001769|NCT03296228||Turkey|"Radiation: Flexibility Radiographs (supine, supine side-bend, FB)~Radiation: Flexibility Radiographs (awake traction)~Radiation: Flexibility Radiographs (STUGA)~supine side-bending, fulcrum bending films, awake traction and supine traction under GA"
62001770|NCT01027793|ACTIVE_COMPARATOR|Tretinoin|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
62001771|NCT01027793|ACTIVE_COMPARATOR|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center.
62001772|NCT01482520||Renal cell carcinoma|
62001773|NCT01482520||Hepatocellular carcinoma patients|
62001774|NCT04860310||21 years old group|
62187143|NCT05893914|OTHER|5 week baseline|Randomization to the second tier will include 5 weeks (35 days) of baseline measures (phase A), followed by 5 weeks of treatment and symptom monitoring (phase B)
62187144|NCT05893914|OTHER|6 week baseline|Randomization to the third tier will include 6 weeks (42 days) of baseline measures, followed by 5 weeks of treatment and symptom monitoring (phase B)
62187145|NCT05893914|OTHER|7 week baseline|Randomization to the fourth tier will include 7 weeks (49 days) of baseline measure, followed by 5 weeks of treatment and symptom monitoring
62187146|NCT02201901|EXPERIMENTAL|SOF/VEL 12 weeks|Participants will receive SOF/VEL FDC for 12 weeks.
62187147|NCT02201901|EXPERIMENTAL|SOF/VEL+RBV 12 weeks|Participants will receive SOF/VEL FDC plus RBV for 12 weeks.
62187148|NCT02201901|EXPERIMENTAL|SOF/VEL 24 weeks|Participants will receive SOF/VEL FDC for 24 weeks.
62187149|NCT00550446|ACTIVE_COMPARATOR|1|
62395470|NCT05525533|EXPERIMENTAL|No feedback|AGYW customer feedback will be collected but not shared with shopkeepers
62187150|NCT00550446|EXPERIMENTAL|2|
62187151|NCT00550446|EXPERIMENTAL|3|
62187152|NCT00550446|EXPERIMENTAL|4|
62187153|NCT00550446|EXPERIMENTAL|5|
62187154|NCT00550446|EXPERIMENTAL|6|
62187155|NCT00550446|PLACEBO_COMPARATOR|7|
62395471|NCT05525533|EXPERIMENTAL|Private feedback|Biweekly summarized reports of AGYW customer feedback will be given directly to shopkeepers
62584872|NCT02419014|PLACEBO_COMPARATOR|Sham CES Device|The inactive (sham) devices look identical to the active device but are inactivated by the manufacturer so as not to deliver any electrical current.
62001775|NCT04860310||28 years old group|
62001776|NCT04860310||35 years old group|
62001777|NCT04860310||42 years old group|
62001778|NCT04860310||49 years old group|
62001779|NCT03309280||Patient at risk for OSA scheduled for Cardiac surgery|Patients with a positive STOP-Bang and DES-OSA score (that means patients at risk for OSA)
62001780|NCT03309280||Patient not at risk for OSA scheduled for Cardiac surgery|Patients with a negative STOP-Bang and DES-OSA score (that means patients not at risk for OSA)
62001781|NCT06440070|EXPERIMENTAL|Loop Carpal Tunnel Release group|
62187156|NCT02987998|EXPERIMENTAL|Resectable Patients|Chemoradiation (Cisplatin + Etoposide + Pembrolizumab with concurrent radiation). Patients will be assessed for surgery followed by consolidation therapy
62187157|NCT04467398||Tuohy needle group|The participants who undergo the trigeminal nerve block using 22 guage Tuohy needle.
62187158|NCT04467398||Quincke needle group|The participants who undergo the trigeminal nerve block using 22 guage Quincke needle.
62187159|NCT04183010|NO_INTERVENTION|Control|At the end of this initial week of monitoring, participants will be randomized to a control group or an intervention group. Both groups will be followed for three months, with outcome measurements collected monthly. Both arms will continue to receive their seven day physical activity assessment using the phone's core motion sensors and HealthKit/ Google Health step count. Both groups will also be prompted to complete monthly fitness tests: the 6-minute walk test, a 12 minute run test, and the Tecumseh step test.
62187160|NCT04183010|EXPERIMENTAL|Physical activity coaching|"In addition to the tasks performed and feedback received by the Control arm (see above), the intervention arm will also undergo daily coaching with the goal of increasing their daily step count. Members of this arm will receive daily app notifications indicating that they have activities to complete. They will be provided with 5 exercise options:~* Low intensity activity options (i.e. walking in the part, bicycling to the store, etc.).~* Moderate to vigorous endurance activity, performed on their own (running, bicycling, rowing, swimming, etc)~* An on demand group session video~* No exercise today~* Alternate physical activity -- the participants will have the option to record alternate physical activity that they performed~Participants will be asked to indicate if they completed the exercise with three options:~* Yes~* No~* Request for a different exercise to be shown"
62187161|NCT00549978|OTHER|1|Two compartments with cross-over and parallel
62187162|NCT00549978|OTHER|2|Two compartments with cross-over and parallel
62777242|NCT02343198|EXPERIMENTAL|Stimulation|Custom-built research muscle stimulator. Muscle stimulator is set to provide a comfortable stimulation when applied to the soleus muscle using two 5x5cm electrodes.
62777243|NCT02343198|PLACEBO_COMPARATOR|Placebo-control|Custom-built research muscle stimulator. Muscle stimulator is set to provide sensory stimulation but will not cause an active muscle contraction. Stimulation is also delivered to the soleus muscle through two 5x5cm electrodes.
62187163|NCT06538467|EXPERIMENTAL|Inertial|Hip extension exercise performed under inertial loading conditions using the EPTE Inertial Concept (Ionclinics SL, L'Alcudia, Spain) during six weeks with two sessions per week. The EPTE Inertial Concept is an inertial device that combines a series of output pulleys and telescopic arms, capable of implementing 6 disks of different weights and radii.
62187164|NCT06538467|EXPERIMENTAL|Gravitational|Hip extension exercise performed under gravitational loading conditions using free-weight equipment during six weeks with two sessions per week.
62570572|NCT06574451|NO_INTERVENTION|Non-VR-assisted analgesia group|"The control group will not experience postoperative analgesic adjuvant therapy software and will only record the pain level within 30 minutes at 24 hours and 48 hours after surgery.~All participants will receive intravenous analgesics pumped with mechanical pumps (analgesic pumps: Flurbiprofen cilexil Injection 5ml: 50mg/stick\*4 sticks, combined with Dezocine Injection 1ml: 5mg/stick\*6 sticks, add Ondansetron Hydrochloride Injection: 2ml: 4mg/stick\*2 sticks; or add Tolisetron Mesylate Injection: 2ml: 6 mg/stick\*4 sticks, diluted to 100mL with 0.9% sodium chloride injection).In case of an outbreak of pain (when analgesic pump is ineffective and the pain is unbearable), analgesic medication regimen: flurbiprofen cilofen injection 5 ml: 50 mg/piece, intravenous injection."
62777244|NCT01828411||Cardiopulmonary bypass group|Patients requiring normothermic (or mild hypothermic) cardiopulmonary bypass.
62777245|NCT01828411||Hypothermic Cardiopulmonary Bypass Group|Patients requiring (deep) hypothermic cardiopulmonary bypass.
62187165|NCT06538467|NO_INTERVENTION|Control|Participans was advised to continue their regular levels of physical activity but not to perform any lower body resistance training
62187166|NCT05496309||Group|The group is a cohort of 4 persons.
62187167|NCT00543153||Patients diagnosed with cancer|
62187168|NCT03132662|ACTIVE_COMPARATOR|Very Low Calorie Diet|The first group will continue according to the standard bariatric preoperative protocol and will be assigned a VLCLD of 900 cal/day (Optifast ® 4 servings/day each containing: 225 cal + 0.35 g linolenic acid) for 2-3 weeks prior to surgery according to the surgeon's preferences.
62187169|NCT03132662|EXPERIMENTAL|Omega-3|The second group will be assigned to 3 gr. daily oral intake of Ω-3 PUFAs ((Oceano3 ® 1000 mg Krill Oil tabs (150 mg EPA + 90 mg DHA) 3 times a day) for 4 weeks with only regular dietary suggestions before surgery.
62570573|NCT00664768|EXPERIMENTAL|New Neocate|new Neocate
62777246|NCT01008904|EXPERIMENTAL|Supportive care (magnesium oxide)|Patients receive magnesium oxide by mouth daily or twice daily for 4 weeks.
62777247|NCT05120141|EXPERIMENTAL|Prototype 1 Mouth Rinse|Participants will brush their teeth using soft bristled Toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 milliliters (mL) of the Prototype 1 Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
62777248|NCT05120141|EXPERIMENTAL|Prototype 2 Mouth Rinse|Participants will brush their teeth using soft bristled Toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Prototype 2 Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
62777249|NCT05120141|EXPERIMENTAL|Prototype 3 Mouth Rinse|Participants will brush their teeth using soft bristled Toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Prototype 3 Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
62791742|NCT05285540|EXPERIMENTAL|Single Dose: DT-216 matching placebo|Placebo will be administered once
62187170|NCT03132662|NO_INTERVENTION|No-treatment|The third group will not receive treatment for liver size reduction prior to surgery.
62187171|NCT01130311|EXPERIMENTAL|Cholecalciferol (Vitamin D)|Intramuscular injection of VITAMIN D, 600,000 UNITS WILL BE GIVEN TO THE TEST SUBJECTS AT WEEK 0 and at week 4 OF the TRIAL
62187172|NCT01130311|PLACEBO_COMPARATOR|SALINE, INTRAMUSCULAR INJECTION|NORMAL SALINE INJECTION WILL BE GIVEN TO THE CONTROL SUBJECTS at week 0 and week 4 of the trial
62001782|NCT04197570|ACTIVE_COMPARATOR|Opioid-based anesthetic|"Premedication~-midazolam 2mg IV x 1 as need for anxiety, at the discretion of the anesthesiologist~Induction~* Fentanyl 2-4 mcg/kg IV bolus~* Propofol 1-3 mg/kg IV~* Paralytic and vasoactive medications at the discretion of the anesthesiologist~Maintenance~* Fentanyl 1-2 mcg/kg IV bolus immediately prior to sternotomy \& aortic cannulation~* Fentanyl 1-2mcg/kg IV bolus immediately following removal of bypass cannula~* Dexmedetomidine 0.4 mcg/kg/hr IV infusion~* Isoflurane titrated at the discretion of the anesthesiologist~* Vasoactive medications at the discretion of the anesthesiologist for hemodynamic management~During chest closure:~* start Propofol 25-75mcg/kg/min IV infusion~* continue dexmedetomidine 0.4mcg/kg/hr IV infusion~* titrate off isoflurane~* Acetaminophen 1000mg IV"
62187173|NCT04796675|EXPERIMENTAL|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (300 mg/kg) on day -5, -4, and -3, followed by one infusion of CAR-NK-CD19 cells on day 0. The study will be divided into three groups: Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, and Non Hodgkin's Lymphoma. Doses of 0.01×10\^7, 0.1×10\^7, 1.0×10\^7 CAR+ T cells (with an allowance of ±20%) will be tested in each group in the 3+3 dose-escalation study. Each dose group has 3 patients. If no dose-limited toxicity (DLT) emerges in the group, then the subsequent higher dose will be used in the next group. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. The maximum dose could be extended.
62187174|NCT02489409|EXPERIMENTAL|Experimental group|Gemcitabine (Gem): 1.0 m/m2, iv 0.5h, d1, 8; Navelbine (NVB): 40 mg/d, iv, d1, 8; Platinum (DDP): 30 mg/m2, iv 3h, d1-3; Xeloda Tablets: 2 000 mg/m2, po, d1-14; EndostarTM Injection: 210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h).
62187175|NCT02489409|ACTIVE_COMPARATOR|Control group|Gemcitabine (Gem): 1.0 m/m2, iv 0.5h, d1, 8; Navelbine (NVB): 40 mg/d, iv, d1, 8; Platinum (DDP): 30 mg/m2, iv 3h, d1-3; Xeloda Tablets: 2 000 mg/m2, po, d1-14.
62187176|NCT03815383|EXPERIMENTAL|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
62570574|NCT00664768|ACTIVE_COMPARATOR|Neocate Infant|Neocate Infant formula
62187177|NCT02031536|EXPERIMENTAL|Arm A (everolimus)|Patients receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62570575|NCT05147415|PLACEBO_COMPARATOR|Placebo|Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated Tesomet dose from the double-blind period
62777250|NCT05120141|ACTIVE_COMPARATOR|Listerine Cool Mint Mouth Rinse (Positive Control)|Participants will brush their teeth using soft bristled Toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Listerine Cool Mint Mouth rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
62570576|NCT05147415|EXPERIMENTAL|Tesomet Low Dose|Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period
62570577|NCT05147415|EXPERIMENTAL|Tesomet Medium Dose|Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period
62570578|NCT05147415|EXPERIMENTAL|Tesomet High Dose|Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period
62570579|NCT03561714||CMC-TI|Cardiometabolic Care Team Intervention
62570580|NCT03561714||Non-Intervention Comparator site|Non intervention comparator site with usual care
62570581|NCT03548961|EXPERIMENTAL|Neoadjuvant chemotherapy|
62570582|NCT04455087||before intervention|1000 patients befor sensitization
62777251|NCT05120141|ACTIVE_COMPARATOR|Hydroalcohol Mouth Rinse (Negative Control)|Participants will brush their teeth using soft bristled Toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Hydroalcohol Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
62777252|NCT00225095|ACTIVE_COMPARATOR|Chondrogen - dose 1|Chondrogen - 50 million cells
62777253|NCT00225095|ACTIVE_COMPARATOR|Chondrogen - dose 2|Chondrogen - 150 million cells
62777254|NCT00225095|OTHER|Vehicle Control|Vehicle Control
62187178|NCT02031536|PLACEBO_COMPARATOR|Arm B (placebo)|Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62187179|NCT00908349|OTHER|Oxcarbazepine XR|Open Label Study
62187180|NCT04477356|ACTIVE_COMPARATOR|Swim-up technique (SU)|The SU method's principle is that the normal and highly motile sperm will move against the gravity and separate from the dead or abnormal sperms to swim up to the upper media culture layer.
62584873|NCT06314646||Transanal Transection and Single-Stapled anastomosis (TTSS)|Patients will undergo rectal cancer surgery through low rectal resection with Transanal Transection and Single-Stapled anastomosis (TTSS)
62777255|NCT01504204|EXPERIMENTAL|Medication with sample and demonstration|Subjects will receive a sample tube of the Adapalene + benzoyl peroxide samples with demonstration of how to use it at the first visit.
62777256|NCT01504204|ACTIVE_COMPARATOR|Medication without samples|Subjects will receive the Adapalene + benzoyl peroxide from standard tube without a sample or demonstration of proper use of the medication.
62777257|NCT05018026|NO_INTERVENTION|Arm 1 (Control Arm)|A default NUSMart that mirrors a conventional web-grocery store in Singapore where some healthier products are displayed with Singapore's Healthier Choice Symbol (HCS) logos (Control).
62777258|NCT05018026|EXPERIMENTAL|Arm 2 (Nutri-Grade Arm)|Similar to Arm 1 except that beverages will be displayed with a color-coded and graded Nutri-Grade label.
62187181|NCT04477356|ACTIVE_COMPARATOR|Density gradient centrifugation technique (DG)|The DG method is based on the density in which mature and normal sperms are capable of passing through filtration layer to be isolated from dead or abnormal sperms in semen.
62187182|NCT00265720|PLACEBO_COMPARATOR|Control|Written materials only
62187183|NCT00265720|EXPERIMENTAL|Reduced out-of-pocket expense|Reimbursed up to $500 out-of-pocket expense for colorectal cancer screening
62777259|NCT03846557||Treatment|Transcatheter Aortic Valve Implantation (TAVI)
62187184|NCT00265720|EXPERIMENTAL|One-on-one education|Individual education with a health educator on CRC screening
62187185|NCT00265720|EXPERIMENTAL|Group Education|Education on CRC screening in a small group with a health educator
62187186|NCT04287283||HBOT|Patients with chronic brain injury or cognitive complaints that have been treated with Hyperbaric oxygen therapy and underwent computerized cognitive tests before and after the treatment
62777260|NCT00705887|NO_INTERVENTION|Control|Brochure from the American Academy of Dermatology on protecting your skin from UV rays.
62777261|NCT00705887|EXPERIMENTAL|Intervention|Participation in a brief motivational enhancement session. These participants also received the same American Academy of Dermatology brochure on protecting your skin from UV rays.
62777262|NCT01281319||Asymptomatic normal pregnant women|
62777263|NCT01281319||Women with high risk pregnancy|Women at risk for preterm birth or recurrent abortions that are being followed at the high risk pregnancy unit (outpatients clinic, high risk day care center)
62777264|NCT01281319||Women admitted with preterm labor|Women that are admitted to the gynecology department due to pregnancy complications: preterm labor with intact membranes (PTL) or with preterm PROM.
62777265|NCT04518683|EXPERIMENTAL|Groupe 1 - Study group|"The home program (outside of the sessions with the physiotherapist) will be done with a mobile application equipped with a vaginal probe. The exercises should be done 3x/week for 10 minutes (time corresponding to 1 programe). The correct use of the prob will have been checked during the sessions with the physiotherapist. This training will work on the strength, relaxation and endurance of the pelvic floor.~The program includes 3 levels of difficulty. Once the user has successfully completed one level, she can move on to the next."
62777266|NCT04518683|ACTIVE_COMPARATOR|Groupe 2 - Control group|"The home program (outside of the sessions with the physiotherapist) will be done without a mobile application. The exercises will have been explained during the sessions with the physiotherapist by oral instructions. The exercises will be done 3x/week for 10 minutes. The correct realization of the exercises will have been verified during the sessions with the physiotherapist.~This training will work on pelvic floor strength, relaxation and endurance. The program includes 3 levels of difficulty"
62777267|NCT05747534|EXPERIMENTAL|Larazotide Acetate (AT1001)|Subjects will receive 250 or 500 µg of Larazotide Acetate orally four times a day (QID) for 21 days. Subjects \<25.0 kg will receive 250 µg dose of Larazotide Acetate (AT1001), and subjects ≥25.0 kg will receive 500 µg dose of Larazotide Acetate (AT1001).
62777268|NCT05747534|PLACEBO_COMPARATOR|Placebo|Subjects will receive 250 or 500 µg of placebo orally four times a day (QID) for 21 days. Subjects \<25.0 kg will receive 250 µg dose of placebo and subjects ≥25.0 kg will receive 500 µg dose of placebo.
62187187|NCT02304081|ACTIVE_COMPARATOR|Saxagliptin|Metformin and Dapagliflozin background therapy
62187188|NCT02304081|PLACEBO_COMPARATOR|Placebo|Metformin and Dapagliflozin background therapy
62187189|NCT04346810||Recovery room caregivers|Caregivers working at a recovery room shifted into an intensive care unit for the management of patients suffering from coronavirus infection and needing a resuscitation
62777269|NCT02640495||Study subjects|Patients admitted with malaria, caused by Plasmodium falciparum, treated with parenteral artesunate.
62777270|NCT01257607|EXPERIMENTAL|1% MIM-D3 Ophthalmic Solution|
62777271|NCT01257607|EXPERIMENTAL|5% MIM-D3 Ophthalmic Solution|
62777272|NCT01257607|PLACEBO_COMPARATOR|Placebo Ophthalmic Solution|
62777273|NCT06141759|EXPERIMENTAL|Intervention group|Schroth Best Practice Exercises and Cheneau braces. There were 18 sessions, each lasting 90 minutes, a total of 6 weeks for the exercise training.
62777274|NCT06141759|NO_INTERVENTION|Control Group|For six weeks, no application was made.
62001783|NCT04197570|EXPERIMENTAL|Opioid-free anesthetic|"Premedication~-midazolam 2mg IVx1 as needed for anxiety, at the discretion of the anesthesiologist~Induction~* Dexmedetomidine 1mcg/kg IV~* Propofol 1-3mg/kg IV~* Paralytic and vasoactive medications at the discretion of the anesthesiologist~Maintenance~* Dexmedetomidine 0.8-1.0 mcg/kg/hr IV infusion~* Isoflurane titrated at the discretion of the anesthesiologist~* May add propofol infusion if clinically indicated~* Vasoactive medications at the discretion of the anesthesiologist for hemodynamic management~During chest closure:~* start Propofol 25-75mcg/kg/min IV infusion~* continue dexmedetomidine 0.4 - 1.0 mcg/kg/hr IV infusion~* titrate off isoflurane~* Acetaminophen 1000mg IV"
62187190|NCT04346810||Intensive care unit caregivers|Caregivers working at a conventional intensive care unit for the management of patients suffering from coronavirus infection and needing a resuscitation
62777275|NCT02037217|EXPERIMENTAL|ExAblate Treatment|
62777276|NCT00997360|EXPERIMENTAL|1|PKI-179
62777277|NCT01636349|EXPERIMENTAL|Recreational soccer training|12 men participate in recreational soccer training for 6 months
62777278|NCT01636349|NO_INTERVENTION|Control group|10 subjects serve as a control group with no change in lifestyle in the study period
62777279|NCT04058886|EXPERIMENTAL|Telephone-delivered Mindfulness|Participating caregivers and care partners will receive mindfulness training in 8 weekly telephone sessions plus one retreat. Respite care for the care recipient is provided for the retreat.
62777280|NCT02553408|OTHER|Neo meter|This is a single arm purely qualitative (interview only) study with no comparator. All participants will use the FreeStyle Precision Neo-Meter for at least 3 months for self-monitoring of their blood glucose.
62001784|NCT03156010|OTHER|TBI Group|Subjects with history of TBI will undergo testing with all three devices.
62001785|NCT03156010|OTHER|Control Group|Subjects with no history of TBI will undergo testing with all three devices.
62001786|NCT01281748|EXPERIMENTAL|methylprednisolone|
62001787|NCT01281748|PLACEBO_COMPARATOR|normal saline solution|
62001788|NCT00403273|EXPERIMENTAL|A|Single Intra-articular Injection of 100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
62187191|NCT03664206||Patients|"MRS, conventional TMS and treshold tracking TMS~The participants will be told not to consume coffee or alcohol or do exhausting exercise 12, 24 and 48 hours, respectively, prior to the examinations"
62187192|NCT03664206||Healthy subjects|"MRS, conventional TMS and treshold tracking TMS~The participants will be told not to consume coffee or alcohol or do exhausting exercise 12, 24 and 48 hours, respectively, prior to the examinations"
62187193|NCT03214536|EXPERIMENTAL|erector spinae block|bilateral erector spine block with 20 ml 0,375% ropivacaine
62187194|NCT00301483|EXPERIMENTAL|1|HBOC-201 followed by standard therapy
62187195|NCT00301483|ACTIVE_COMPARATOR|2|Standard Therapy
62187196|NCT01657799|EXPERIMENTAL|Veliparib 200 mg BID + WBRT|Participants received veliparib 200 mg twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
62777281|NCT01177566|ACTIVE_COMPARATOR|pimecrolimus (Elidel)|pimecrolimus twice daily to a chosen target lesion on one side of body
62777282|NCT01177566|ACTIVE_COMPARATOR|topical medical device cream (Eletone)|topical medical device cream three times daily to a chosen target lesion on one side of the body
62777283|NCT03750643|EXPERIMENTAL|LY3454738 - Part A|Escalating doses of LY3454738 administered intravenously (IV) or subcutaneously (SC) to healthy participants
62777284|NCT03750643|PLACEBO_COMPARATOR|Placebo - Part A|Placebo administered IV to healthy participants
62777285|NCT03750643|EXPERIMENTAL|LY3454738 - Part B|LY3454738 administered IV to healthy participants
62777286|NCT03750643|PLACEBO_COMPARATOR|Placebo - Part B|Placebo administered IV to healthy participants
62777287|NCT03750643|EXPERIMENTAL|LY3454738 - Part C|LY3454738 administered IV to participants with atopic dermatitis (AD)
62777288|NCT03750643|PLACEBO_COMPARATOR|Placebo - Part C|Placebo administered IV to participants with AD
62777289|NCT00682318|EXPERIMENTAL|Fish oil|Omega-3 polyunsaturated fatty acids (n-3 PUFA)
62777290|NCT00682318|ACTIVE_COMPARATOR|Safflower Oil|Omega-6 polyunsaturated fatty acids (n-6 PUFA)
62187197|NCT01657799|EXPERIMENTAL|Veliparib 50 mg BID + WBRT|Participants received veliparib 50 mg twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
62777291|NCT05094141|NO_INTERVENTION|Non-VR (Virtual reality)|The patient is not assigned to play the VR game. mYPAS scoring for port access is done.
62777292|NCT05094141|EXPERIMENTAL|VR (Virtual Reality)|The patient is assigned to play the VR game for 15 minutes prior to actual port access procedure start. mYPAS scoring while playing VR device for Port access
62570583|NCT02764762|EXPERIMENTAL|Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)|In Triple Combination Therapy Phase, vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2, 6, 14 and 22, with adalimumab 160 mg subcutaneously (SC), once at Week 0, then 80 mg once at Week 2, then 40 mg once at Week 4 and every 2 weeks thereafter until Week 26 along with oral methotrexate 15 mg tablets orally once weekly from Weeks 0 up to Week 34. In Monotherapy Phase, vedolizumab 300 mg IV infusion once at Weeks 30, 38, 46, 54, 62, 70, 78, 86, 94 and 102.
62777293|NCT02738424||3T patients : Calculate the ADC scores|In this group all the patients perform a 3 Tesla RMI. With these data, three methods will be used to calculate the ADC score : Siemens, PACS (picture archiving and communication system) Carestream, Osirix. The ADC scores obtained with these three post-processing softwares will be compared.
62777294|NCT02738424||1.5T patients : Calculate the ADC scores|In this group all the patients perform a 1,5 Tesla RMI. With these data, three methods will be used to calculate the ADC score : Siemens, PACS Carestream, Osirix. The ADC scores obtained with these three post-processing softwares will be compared.
62777295|NCT04928560||disease free survival|disease free survival
62777296|NCT04928560||non-disease free survival|non-disease free survival
62777297|NCT02828332|OTHER|Patient with autism disorder|Interview with a psychologist who do Vineland II (VABS -II) and evaluate Quality of life and comorbidities
62001789|NCT00403273|PLACEBO_COMPARATOR|B|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
62187198|NCT01657799|PLACEBO_COMPARATOR|Placebo BID + WBRT|Participants received placebo twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
62187199|NCT00329563|EXPERIMENTAL|Cold fluid|
62570584|NCT04033354|EXPERIMENTAL|A|HLX10 + chemotherapy (carboplatin nab paclitaxel)
62570585|NCT04033354|PLACEBO_COMPARATOR|B|Placebo + chemotherapy (carboplatin nab paclitaxel), After 1st PD, the subject will be unblinded by the investigator and be continued with HLX10 monotherapy
62001790|NCT06464042||Premature Coronary Artery Disease|Patients between 18 and 40 years old diagnosed with coronary artery disease, including: ST-elevation myocardial infarction (STEMI), non-ST-elevation acute coronary syndrome (NSTE-ACS), unstable angina, stable angina, MINOCA or silent angina
62777298|NCT01371305|EXPERIMENTAL|BG00011|Participants will receive 8 consecutive weekly doses of BG00011
62777299|NCT01371305|PLACEBO_COMPARATOR|Placebo|Participants will receive 8 consecutive weekly doses of placebo.
62187200|NCT00329563|NO_INTERVENTION|control, standard of care|
62395472|NCT05525533|EXPERIMENTAL|Public feedback|Shopkeepers will get biweekly summarized reports of AGYW customer feedback, gold stars reflecting the level of AGYW customer feedback (e.g., 1-5 star rating) will be placed in the shop in a visible location, and shopkeepers will be invited to an awards ceremony every 6 months to recognize shopkeepers who receive high levels of positive AGYW customer feedback
62777300|NCT00952900|EXPERIMENTAL|Early Biobehavioral Intervention|This intervention involves the use of non-invasive treatment modalities such as relaxation/biofeedback, stress management, and cognitive coping skills. It is based upon previous clinical research studies demonstrating the efficacy of this intervention in allowing acute TMD patients to better cope with stress and lifestyle issues that produce the TMD pain/discomfort.
62777301|NCT00952900|ACTIVE_COMPARATOR|Attention Control Group|This intervention involves the presentation of helpful information to patients that explains etiology and potential treatment modalities used to modify/reduce TMD pain/discomfort.
62777302|NCT00952900|NO_INTERVENTION|No Active Treatment Comparison Group|Unlike the other two treatment groups, that involve high-risk acute TMD patients, this group includes low-risk acute TMD patients. Past studies have shown that these low risk patients do not need any early intervention in order to prevent chronicity.
62777303|NCT06262243|EXPERIMENTAL|experimental group|The group that will receive routine care and electric blankets after cesarean section.
62777304|NCT06262243|NO_INTERVENTION|control group|The group that will receive routine care after cesarean section.
62777305|NCT03194438|EXPERIMENTAL|UZIT arm|Multi-modal components integrative therapy intervention program, Urban Zen Integrative Therapy.
62570586|NCT03721796||Arm 1 Physician/APP|Surgical, medical, and radiation oncologists and/or Advanced Practice Provider (APP)
62570587|NCT03721796||Arm 2 Patients|For each participating oncologist, we will may enroll up to three adult cancer patients presenting for consultation, since certain disease sites have a higher incidence in the HIV population.
62777306|NCT04147806|ACTIVE_COMPARATOR|IGRT 45 Gy in 5 fractions of 9 Gy|Hypofractionated IGRT at a prescription dose of 45 Gy in 5 fractions of 9 Gy delivered in five consecutive days
62187201|NCT05815706|EXPERIMENTAL|Experimental|The experimental group participants were breastfed for ten minutes (five minutes for each breast) every day from the day they started oral feeding until they switched to exclusive breastfeeding. The nurse placed the warmed breast milk or formula in SNS. She then fixed it to the mother's nipples. Each experimental group participant sucked on the two breasts for 15 minutes. Breastfeeding (ten minutes), resting and SNS preparation (five minutes), and SNS feeding (15 minutes) were limited to a total of 30 minutes in light of earlier research.
62777307|NCT04147806|EXPERIMENTAL|IGRT 24 Gy single dose|single fraction IGRT at a prescription dose of 24 Gy
62777308|NCT03012867|ACTIVE_COMPARATOR|fat-based|Patients receive a fat-based enteral nutrition formula, which is routinely used as standard care in our ICU
62777309|NCT03012867|ACTIVE_COMPARATOR|glucose-based|Patients receive a glucose-based enteral nutrition formula, which is routinely used as standard care in our ICU
62777310|NCT05328752|EXPERIMENTAL|XXB750 Cohort 1|XXB750, single dose
62777311|NCT05328752|PLACEBO_COMPARATOR|Placebo Cohort 1|Placebo, single dose
62777312|NCT05328752|EXPERIMENTAL|XXB750 Cohort 2|XXB750, multiple doses
62777313|NCT05328752|PLACEBO_COMPARATOR|Placebo Cohort 2|Placebo, multiple doses
62777314|NCT03983863||IRB|Our target study population consists of all members/staff of NIH IRBs and IRB panels that fall under the NIH Intramural Federal Wide Assurance (FWA).
62187202|NCT05815706|NO_INTERVENTION|Control|Preterm infants were fed according to the clinical feeding protocol. They were not SNS-fed.
62021012|NCT05360524|ACTIVE_COMPARATOR|Laminectomy alone in patients with traumatic cervical spinal cord injury without instability|laminectomy only with expected less operative time, blood loss and restriction of neck motion (compared to laminectomy with fusion). Instrumented fusions also entail the risks of screw misplacement, pseudoarthrosis, distal junction kyphosis, and adjacent segment pathology.
62570588|NCT03721874|ACTIVE_COMPARATOR|Dapagliflozin 10 mg|"Patients will receive dapagliflozin 10 mg in tablet for a maximum of 14 days based on randomization sequence in Period 1.~Patients that received 10 mg dapagliflozin in the first treatment period will receive matching placebo in the second treatment period for a maximum of 14 days."
62570589|NCT03721874|PLACEBO_COMPARATOR|Placebo matching to dapagliflozin 10 mg|"Patients will receive matching placebo in tablet for a maximum of 14 days based on randomization sequence.~Patients who received placebo in the first treatment will receive 10 mg dapagliflozin in the second treatment period, for a maximum of 14 days"
62570590|NCT05111912|EXPERIMENTAL|Cohort A|Participants will follow a fixed up-titration scheme. For XW003 groups, the dose will be up-titrated to 1.2, 1.8, or 2.4 mg once weekly starting with 0.2 mg in dose increments of 0.2, 0.4, 0.6, or 0.8 mg. In order to mitigate the dose-related side effects, liraglutide is up-titrated over 4 weeks to the maintenance dose, 3.0 mg once daily.
62584874|NCT06314646||Double-stapled Total Mesorectal Excision (TME)|Patients will undergo rectal cancer surgery through low rectal resection with double-stapled anastomosis Total Mesorectal Excision (TME)
62777315|NCT02540993|EXPERIMENTAL|Finerenone (BAY94-8862)|Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy
62777316|NCT02540993|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo once daily in addition to standard of care therapy
62777317|NCT00922714|EXPERIMENTAL|Glutamine|Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
62777318|NCT00922714|PLACEBO_COMPARATOR|Control|saline
62777319|NCT06536556||TAX Group|Woman with early breast cancer receiving a first cycle of TAX
62777320|NCT06536556||TAX+TRASTU Group|Woman with early breast cancer receiving a first cycle of TAX+TRASTU
62777321|NCT06536556||TAX+CARBO Group|oman with early breast cancer receiving a first cycle of TAX+CARBO
62777322|NCT00890682|EXPERIMENTAL|Sky0402|Injection of Study Drug
62777323|NCT00890682|PLACEBO_COMPARATOR|Placebo|Injection of study drug
62777324|NCT02641067|EXPERIMENTAL|Severe Renal Impairment|Participants with severe renal impairment receive a single oral dose of 100 mg doravirine
62777325|NCT02641067|EXPERIMENTAL|Healthy Matched Control|Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine
62777326|NCT04420403|EXPERIMENTAL|Manual therapy plus cervical stabilization exercise group|The patients diagnosed with chronic neck pain (CNP) with 18-55 years of age followed by routine controls and who were volunteered will be included in the study.
62570591|NCT05111912|EXPERIMENTAL|Cohort B|Participants will follow a fixed up-titration scheme. For XW003 groups, the dose will be up-titrated to 1.2, 1.8, or 2.4 mg once weekly starting with 0.2 mg in dose increments of 0.2, 0.4, 0.6, or 0.8 mg. In order to mitigate the dose-related side effects, liraglutide is up-titrated over 4 weeks to the maintenance dose, 3.0 mg once daily.
62777327|NCT04420403|ACTIVE_COMPARATOR|Only manual therapy group|The patients diagnosed with CNP with 18-55 years of age followed by routine controls and who were volunteered will be included in the study.
62777328|NCT00695864|PLACEBO_COMPARATOR|Placebo - sugar pill|Placebo - sugar pill
62777329|NCT00695864|EXPERIMENTAL|Ondansetron|Ondansetron
62777330|NCT05945303|EXPERIMENTAL|Responder group|About 20 Adult patients Planned for elective CABG surgery
62777331|NCT05945303|EXPERIMENTAL|Not Responder group|About 20 Adult patients Planned for elective CABG surgery
62777332|NCT02408263||Total Hip Replacement (THR) and Total Knee Replacement (TKR)|25 patients receiving a THR and 25 patients receiving aTKR. The investigators are using Skin Conductance Algesimeter (SCA) to measure pain by analyzing changes in skin conductance.
62001791|NCT06464042||Non Coronary Artery Disease|"Patient without coronary artery disease~For each case, 3 controls matched by age (±1 year), sex, postal code, and/or primary care center will be included. To avoid the selection of controls that could be associated with an overestimation of exposure to cardiovascular risk factors, the controls will be recruited from the preoperative unit and selected from subjects who have undergone minor clinical procedures (vasectomy, hernia repair, phimosis, prominent ear correction, tubal ligation, euthyroid thyroid nodule, plastic surgery, lipomas, vocal cord cysts, among others), or from the trauma service, selecting those attending for fractures or sprains. This approach ensures a complete medical history along with analytical values in their electronic medical records"
62777333|NCT06035848|EXPERIMENTAL|Intervention group|Components of metabolic derangement measurement every 3rd day, it was considered positive when 3 or more points were present. These patients underwent paracentesis and if it was positive (faecal aspiration, serous fluid with Gram + staining, or serohematic fluid) the decision for surgery was made.
62777334|NCT06035848|ACTIVE_COMPARATOR|Control group|Determination of surgery in a conventional manner according to Bell's criteria (absolute indication: pneumoperitoneum), with radiographic surveillance every 6 hours.
62777335|NCT03981068|EXPERIMENTAL|Re-Irradiation with protons|60 Gy in 50 fraktions, 10 weekly with protons
62570592|NCT05111912|EXPERIMENTAL|Cohort C|Participants will follow a fixed up-titration scheme. For XW003 groups, the dose will be up-titrated to 1.2, 1.8, or 2.4 mg once weekly starting with 0.2 mg in dose increments of 0.2, 0.4, 0.6, or 0.8 mg. In order to mitigate the dose-related side effects, liraglutide is up-titrated over 4 weeks to the maintenance dose, 3.0 mg once daily.
62001792|NCT03825289|EXPERIMENTAL|Treatment (trametinib, hydroxychloroquine)|Patients receive trametinib PO QD on days 1-28 and hydroxychloroquine PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62584875|NCT06408610|EXPERIMENTAL|moderate intensity continuous training|"Patients will receive moderate intensity continuous training The program will be in form of Frequency Moderate continues training will be scheduled 3 times per week for 12 weeks Intensity 65-75% of target heart rate.~Duration 40 minutes per session."
62777336|NCT03637517|EXPERIMENTAL|DSM265-TPGS 34% SDD, 400 mg fasted|Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
62777337|NCT03637517|ACTIVE_COMPARATOR|DSM265-TPGS 34% SDD, 400 mg fed|Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
62777338|NCT03637517|ACTIVE_COMPARATOR|DSM265 25% SDD, 400 mg fasted|Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
62187203|NCT03061058|EXPERIMENTAL|Individualized Group|"mRNA levels of BRCA1, topoisomerase I (TOPO1), and thymidylate synthase (TS) were assessed in tumor tissue. Chemotherapeutic agents were selected based on the mRNA levels.~Patients with high level BRCA1 will receive intraperitoneal docetaxel (15mg/m\^2, d1, d15, q4w), intravenous docetaxel (30mg/m\^2, d1, d15, q4w), and oral S-1 (40mg/m\^2, d1-14, q4w).~Patients with low level BRCA1 will receive intraperitoneal cisplatin (25mg/m\^2, d1, d15, q4w), intravenous oxaliplatin (75mg/m\^2, d1, d15, q4w), and oral S-1 (40mg/m\^2, d1-14, q4w).~Patients with middle level BRCA1 and high level TOPO1 will receive intraperitoneal irinotecan (45mg/m\^2, d1, d15, q4w), intravenous docetaxel (90mg/m\^2, d1, d15, q4w), and oral S-1 (40mg/m\^2, d1-14, q4w).~Patients with middle level BRCA1, low or middle level TOPO1, and low level TS will receive intraperitoneal pemetrexed (150mg/m\^2, d1, q3w), and intravenous pemetrexed (350mg/m\^2, d1, q3w)."
62570593|NCT05111912|ACTIVE_COMPARATOR|Cohort D|Dose titration Saxenda (from 0.6 mg to 3.0 mg liraglutide once daily), should take place during the first 4 weeks after randomisation as described: Dose Escalation Schedule of Reference Product (Saxenda). All participants assigned to the open-labeled control group should aim to reach the final target dose of 3.0 mg liraglutide once daily.
62570594|NCT00802230|ACTIVE_COMPARATOR|1|Carvedilol IR
62777339|NCT06379282|EXPERIMENTAL|HIT Group|"Exercise Only~* 3 sessions per week~* Aerobic + Resistance Exercises"
62777340|NCT06379282|EXPERIMENTAL|EXE+ Group|"Exercise + Nutritional Guidance~* 3 sessions per week~* Aerobic + Resistance Exercises~* Dietary assessment at baseline and during with guidance on eating a healthy diet provided"
62777341|NCT06379282|NO_INTERVENTION|Control Group|Control group will receive no exercise or nutritional guidance
62777342|NCT04183608|ACTIVE_COMPARATOR|Group Standard of care|In standard of care, patient only visits every 3 months the doctor so the optimization of treatment can be done only at this frequency.
62777343|NCT04183608|ACTIVE_COMPARATOR|Groupe T2T with telemonitoring and patient education|Treatment with e-Monitoring, home fecal calprotectin testing and therapy education.
62777344|NCT03154749|EXPERIMENTAL|DCb|Docetaxel (75 mg/m2 administered intravenously every 3 weeks) and carboplatin (area under the concentration-time curve \[AUC\] 6, intravenously every 3 weeks) for six cycles
62777345|NCT03154749|ACTIVE_COMPARATOR|EC-D|Epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2), both administered intravenously every 3 weeks for four cycles, followed by docetaxel (100 mg/m2) administered intravenously every 3 weeks for four cycles
62777346|NCT02218944|EXPERIMENTAL|Response Inhibition Training: A|In the experimental condition, 20% of responses are no-go, with the majority of no-go responses paired with smoking images.
62777347|NCT02218944|ACTIVE_COMPARATOR|Response Inhibition Training: B|In the active comparator condition, 20% of responses are no-go trials, with no-go responses spread evenly across the various images.
62777348|NCT02218944|PLACEBO_COMPARATOR|Benign|A benign condition has also been added to control for the possibility that response inhibition training, regardless of target, increases behavioral control and hence decreases relapse likelihood. The benign condition has 50% no-go trials, with no-go responses spread evenly across images.
62777349|NCT00133224|EXPERIMENTAL|1|
62777350|NCT00133224|OTHER|2|
62777351|NCT01141491|EXPERIMENTAL|Arm A|Vaccine plus OPT-821
62777352|NCT01141491|ACTIVE_COMPARATOR|Arm B - OPT-821 immunologic adjuvant|Patients will be given 10 injections of OPT-821 alone as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
62777353|NCT02387489|ACTIVE_COMPARATOR|NBI|Nurse-delivered Brief Intervention
62001793|NCT04510935|EXPERIMENTAL|general anesthesia|Patients in this group will have RF ablation for treatment of HCC under general anesthesia.
62570595|NCT00802230|ACTIVE_COMPARATOR|2|Metoprolol Succinate
62570596|NCT05565833|EXPERIMENTAL|SHUTi OASIS|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) for Older Adult Sufferers of Insomnia and Sleeplessness (OASIS) online intervention optimized for older adults. CBTi will be delivered online and metered out over time with each new core becoming available one week after the completion of the previous core. The intervention period is 9 weeks. They will spend 1-2 hours during the intervention period completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention targeting issues specific to older adults. As users progress through the intervention, they will receive automated, tailored instructions on how to improve their sleep.
62777354|NCT02387489|EXPERIMENTAL|CBI|Computerized Brief Intervention
62001794|NCT04510935|ACTIVE_COMPARATOR|local anesthesia|In this group, patients will receive radiofrequency ablation under local anesthesia.
62001795|NCT01079871|EXPERIMENTAL|FID 114657 (ORB Preserved Ocular Emulsion)|ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
62777355|NCT01555489|EXPERIMENTAL|Ascorbic Acid, Gemcitabine & Erlotinib|Ascorbic Acid (50-100g, 3x weekly) Standard Chemotherapy of Gemcitabine and Erlotinib for Pancreatic Cancer
62777356|NCT06068465|EXPERIMENTAL|Pimavanserin tartrate|Pimavanserin, 34 mg, capsule,once daily by mouth for 6 weeks Interventions
62777357|NCT06068465|PLACEBO_COMPARATOR|Placebo|Placebo, capsule, once daily by mouth for 6 weeks
62777358|NCT04379076|EXPERIMENTAL|CYT107|Intra-muscular administration of CYT107 twice a week for a total of 5 administrations
62777359|NCT04379076|PLACEBO_COMPARATOR|Saline|Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations
62777360|NCT02462993|EXPERIMENTAL|Aloe vera group|Group recieving scaling and root planing and aloe vera gel local drug delivery
62777361|NCT02462993|NO_INTERVENTION|SRP group|Group recieving only scaling and root planing
62001796|NCT02852265|EXPERIMENTAL|COC users or new starts|Subjects will have a etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users. Women starting a COC or recently started a COC within the past month will be considered new starts.
62001797|NCT04397536||Cohort|Patients diagnosed with MDR-TB
62777362|NCT05819944||Pathway 1- Diagnostic case control study undertaken in a secondary care population|evaluates whether the technology can distinguish between people with asthma and healthy volunteers, and other respiratory conditions in a well characterised secondary care population;
62777363|NCT05819944||Pathway 2- Prospective diagnostic study undertaken in a primary care population|assesses whether the technology can accurately diagnose asthma (either independently or alongside current diagnostic tests) in a primary care population of patients where there is a clinical suspicion of asthma;
62777364|NCT05819944||Pathway 3- A phenotypic characterisation study undertaken in participants with confirmed asthma|explores the ability of the technology to identify clinically important phenotypic characteristics which are difficult to measure in primary care and/or significantly impact on patient management and treatment;
62001798|NCT02718638|OTHER|physical exercises group|Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months (36 sessions). The patients remained seated while performing the exercises that were performed in both lower limbs. Ankle-cuffs and elastic bands (Theraband®, Akron-OH, USA) were used for performed the exercises. The physical exercises consisted of four different exercises and they were administered by a physical therapist following the adapted protocol.
62001799|NCT03076424||1|Obese patients (BMI greater than or equal to 30 kg/m2) with Type 2 Diabetes Mellitus.
62001800|NCT03076424||2|Obese patients (BMI greater than or equal to 30 kg/m2) without Type 2 Diabetes Mellitus.
62001801|NCT03076424||3|Normal weight lean controls without Type 2 Diabetes Mellitus.
62001802|NCT03309683|EXPERIMENTAL|Clip group|Olympus Quick Clip Pro - Single Use Repositionable Clips will be used for Prophylactic clipping after EMR
62001803|NCT03309683|NO_INTERVENTION|Control group|Standard treatment after EMR (as described in the detailed study description above)
62001804|NCT05737472|ACTIVE_COMPARATOR|Standard RUTF|The standard RUTF dose is according to weight as per the WHO 2013 guideline, thus 150-220Kcal/kg/day. A child will receive a weekly ration for 8 consecutive weeks from enrolment.
62001805|NCT05737472|EXPERIMENTAL|High-protein RUTF|The high-protein RUTF dose is according to weight as per the WHO 2013 guideline, thus 150-220Kcal/kg/day. A child will receive a weekly ration for 8 consecutive weeks from enrolment.
62001806|NCT01072201|EXPERIMENTAL|Total toothpaste|Triclosan/copolymer/fluoride toothpaste
62001807|NCT01072201|PLACEBO_COMPARATOR|Ultrabrite toothpaste|Fluoride Toothpaste
62001808|NCT05393375||Group 1 Amyoplasia|Patients with diagnosis of Amyoplasia
62001809|NCT05393375||Group 2 Distal Arthrogryposis|Patients with diagnosis of Distal Arthrogryposis
62777365|NCT02280447|EXPERIMENTAL|1/3 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/3 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL suspension for injection for intramuscular use"
62001810|NCT05393375||Group 3 Other|Patients with diagnosis of other form of AMC
62001811|NCT04002414|ACTIVE_COMPARATOR|Usually Active- Decrease|Participants who usually meet or exceed recommended levels of physical activity who will be asked to minimize activity during stimulation.
62001812|NCT04002414|EXPERIMENTAL|Usually Active- Maintenance|Participants who usually meet or exceed recommended levels of physical activity who will be asked to maintain usual level of activity during stimulation.
62001813|NCT04002414|EXPERIMENTAL|Usually Insufficiently Inactive- Increase|Participants who are usually inactive who will be asked to try to increase activity to the recommended level during stimulation.
62001814|NCT04002414|ACTIVE_COMPARATOR|Usually Insufficiently Inactive- Maintenance|Participants who are usually inactive who will be asked to maintain inactivity during stimulation.
62001815|NCT02611258|EXPERIMENTAL|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
62001816|NCT01481116|EXPERIMENTAL|TAK-875 25 mg QD|
62001817|NCT01481116|EXPERIMENTAL|TAK-875 50 mg QD|
62001818|NCT01481116|ACTIVE_COMPARATOR|Glimepiride 1-2 mg QD|
62777366|NCT02280447|EXPERIMENTAL|1/5 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/5 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL suspension for injection for intramuscular use"
62395473|NCT06302829|EXPERIMENTAL|Intramuscular Electrical stimulation|Myofascial trigger point would be targeted by direct intramuscular electrical stimulation by using direct electrode placement method, where anode pole and the cathode pole of the stimulator connected to the needles of the MTrPs of the shoulder girdle muscles using the alligator clip connector in which both electrodes are on the muscle belly in which anode pole at proximal end and cathode pole at the distal end along the musculotendinous junction. The special programmed comfy stim (a double channeled multipurpose electrical stimulator) was used to deliver electrical impulses with following parameters; pulse duration 80µs, frequency 100HZ, and time duration for 10 min
62777367|NCT02280447|EXPERIMENTAL|1/10 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/10 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL suspension for injection for intramuscular use"
62001819|NCT04570293|EXPERIMENTAL|The LMP group|The LMP group will receive lidocaine patches (active patches) measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w).
62001820|NCT04570293|PLACEBO_COMPARATOR|The control group|The control group will receive vehicle patches that are identical to the active patch, except for the absence of lidocaine, without any optical differences.
62001821|NCT04352140|EXPERIMENTAL|Dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand, ToFscan placed on non-dominant hand
62001822|NCT04352140|EXPERIMENTAL|Non-dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the non-dominant hand, ToFscan placed on dominant hand
62001823|NCT02398552|ACTIVE_COMPARATOR|Sunitinib 50mg/day schedule 4/2|Sunitinib 50mg/day 4 weeks on/2 weeks off per 6 weeks till disease progression or intolerable toxicity.
62001824|NCT02398552|EXPERIMENTAL|Sunitinib 50mg/day schedule 2/1|Sunitinib 50mg/day 2 weeks on/1 week off per 6 weeks till disease progression or intolerable toxicity.
62001825|NCT01397695|EXPERIMENTAL|bevacizumab|
62777368|NCT02280447|ACTIVE_COMPARATOR|IPV SSI|"Non-adjuvated full dose IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL solution for injection for intramuscular use"
62777369|NCT03309930|EXPERIMENTAL|Comprehension Acquired Brain Injury|All participants will be exposed to 3 conditions: (a) written text, (b) auditory output (synthetic speech), and combined conditions for study 1. For study 2 participants will be repeatedly exposed to synthetic speech output to determine the influence on comprehension. Participants are not required to participate in both studies.
62001826|NCT04607226|EXPERIMENTAL|Active tVNS - 2 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 2 Hz stimulation frequency
62001827|NCT04607226|EXPERIMENTAL|Active tVNS - 8 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 8 Hz stimulation frequency
62001828|NCT04607226|EXPERIMENTAL|Active tVNS - 30 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 30 Hz stimulation frequency
62001829|NCT04607226|EXPERIMENTAL|Active tVNS - 100 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 100 Hz stimulation frequency
62001830|NCT04607226|SHAM_COMPARATOR|Sham tVNS|Sham transcutaneous vagus nerve stimulation on the left auricle
62001831|NCT04147442|EXPERIMENTAL|Music program fine-tuned and standard|The fine-tuned program and the standard program will be compared within the same instrument as a hearing aid can have up to 4 different listening programs in it.
62021013|NCT05360524|ACTIVE_COMPARATOR|Laminectomy and fusion in patients with traumatic cervical spinal cord injury without instability|Multi-level laminectomy compromises the posterior tension band and increases the mobility of the neck, resulting in post laminectomy kyphosis and potential dynamic injury to the spinal cord . In contrast, spinal instrumentation and fusion helps to eliminate movement at the treated levels and reduce spinal cord tension with less incidence of kyphosis.
62777370|NCT00269633|PLACEBO_COMPARATOR|Red Light Box 657 nm|Red Light Box 657 nm
62777371|NCT00269633|ACTIVE_COMPARATOR|Blue Light Box 467 nm|Blue Light Box 467 nm
62001832|NCT04566328|ACTIVE_COMPARATOR|Arm A (daratumumab, lenalidomide, dexamethasone)|INDUCTION: All patients receive standard induction therapy comprising the following: daratumumab subcutaneously (SC) on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide orally (PO) daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.
62395474|NCT06302829|ACTIVE_COMPARATOR|Dry Needling|DN for the MTrPs will be performed over the identified trigger points locations at a suitable angle. The needles of suitable length and thickness (30-mm), depending on the depth of the MTrPs location inserted into the shoulder girdle muscles to deactivate the active MTrPs. Subsequently, the inserted needles moved to-and-fro direction to elicit the local twitch responses, which further reaffirms the ideal placement of needle into the MTrPs. After the twitch response obtained, the dry needles were kept within the muscles approximately for 10 minutes. Dry needling was performed subscapularis, latissimus dorsi, supraspinatus, deltoid, teres minor.
62570597|NCT05565833|PLACEBO_COMPARATOR|Patient Education Website|Participants will be assigned to a relevant patient education website. It will include information about insomnia symptoms, diagnosis, prognosis, and information about CBT strategies for the older adult. Unlike SHUTi, the content will not be tailored and will be presented all at once.
62395475|NCT06715891|EXPERIMENTAL|Raphamin|"Per os without food. The tablet should be kept in mouth until completely dissolved.~On day 1 of treatment, 8 tablets should be taken using the following regimen: 1 tablet every 30 minutes for the first 2 hours (5 tablets in total for 2 hours), then 1 more tablet 3 times at equal intervals during the same day. On day 2 and onwards, 1 tablet should be taken 3 times a day. The duration of treatment is 5 days."
62777372|NCT04135014|PLACEBO_COMPARATOR|Midazolam|Patients were assigned to receive oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
62777373|NCT04135014|EXPERIMENTAL|Dexmedetomidine|Patients were assigned to receive intranasal dexmedetomidine 2ug/kg approximately 30-40 minutes before surgery using a computer-generated random number table.
62777374|NCT04135014|EXPERIMENTAL|Midazolam and Dexmedetomidine|Patients were assigned to receive intranasal dexmedetomidine 1ug.kg-1 and oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
62777375|NCT06583551|ACTIVE_COMPARATOR|Group 1|A single session of Botox (Botulinum toxin A) injection was performed. 50 IU was administered bilaterally by intramuscular injection: 30 IU within the masseter muscles and 20 IU within the anterior temporalis muscles.
62395476|NCT06715891|PLACEBO_COMPARATOR|Placebo|Placebo using the Raphamin dosage regimen.
62570598|NCT04050163|EXPERIMENTAL|Low Dose|Cells dosage, 0.5x10\^7 cells/kg body weight
62570599|NCT04050163|EXPERIMENTAL|Intermediate Dose (aka Effective or High)|Cells dosage, 1.6x10\^7 cells/kg body weight
62570600|NCT04050163|EXPERIMENTAL|Toxic Dose|Cells dosage, 5.0 x10\^7 cells/kg body weight
62570601|NCT02364830|ACTIVE_COMPARATOR|Anise-oil EC|Intervention Group: Anise-oil EC Capsule,One Cap(187mg)/day for 4 weeks. Patients will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
62791743|NCT02451514|EXPERIMENTAL|MenABCWY+OMV Group|Subjects who received 2 doses of MenABCWY+OMV vaccine in the parent study V102_02 (NCT01210885) and received no subsequent meningococcal vaccines, received a booster dose of MenABCWY+OMV vaccine in the current study at Day 1.
62001833|NCT04566328|EXPERIMENTAL|Arm B (bortezomib, daratumumab, lenalidomide, dexamethasone)|"CONSOLIDATION: Patients receive bortezomib SC on days 1, 8, and 15, daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21 and daratumumab SC on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62001834|NCT04566328|ACTIVE_COMPARATOR|Arm C (daratumumab, lenalidomide, dexamethasone)|"CONSOLIDATION: Patients receive daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21, and daratumumab SC on day 1. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity."
62001835|NCT04435327||Oxygen therapy|Patients who were hospitalised due to COVID-19 pneumonia and received only oxygen support therapy.
62777376|NCT06583551|ACTIVE_COMPARATOR|Group 2|Dry needling was performed using sterile plastic cylindrical guide needles (25 mm length, 0.25 mm diameter) The needles were inserted 5 mm deep into hypertonic and irritable nodules (trigger points, TrPs) within the masseter and temporalis muscles. Each needle was rotated twice clockwise and then removed after remaining in the TrPs for a total of 20 minutes. The treatment was administered in three sessions, each one week apart.
62777377|NCT06583551|ACTIVE_COMPARATOR|Group 3|Pharmacological treatment was administered by prescribing Miyorel, a combination of methocarbamol (380 mg) and paracetamol (300 mg). The prescribed dosage was two tablets, taken three times daily, for a period of three weeks.
62001836|NCT04435327||Non invasive ventilation (NIV/CPAP)|Patients who were hospitalised due to COVID-19 pneumonia and received non invasive ventilation (NIV/CPAP) as maximum support therapy
62001837|NCT04435327||Invasive ventilation|Patients who were hospitalised due to COVID-19 pneumonia and received invasive mechanical ventilation (IMV)
62777378|NCT06583551|ACTIVE_COMPARATOR|Group 4|Manual therapy was administered, consisting of bilateral facial massage and stretching maneuvers targeting the masseter and temporalis muscles. This treatment was performed for 20 minutes daily over a period of three weeks.
62187204|NCT03061058|ACTIVE_COMPARATOR|Control Group|"mRNA levels of BRCA1, TOPO1, and TS were assessed in tumor tissue for every enrolled patients.~Patients in control group will receive intravenous docetaxel (45mg/m\^2, d1, d15, q4w), and oral S-1 (40mg/m\^2, d1-14, q4w)."
62395477|NCT05338827|EXPERIMENTAL|Polyvinyl Chloride Tube group|The PVC tube used is a stiff tube with an anterior curvature of approximately 130°, which retains the additional curvature imposed by its passage through the ventilation conduit of the ILMA. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
62001838|NCT03265626|EXPERIMENTAL|Comprehensive (Intervention 1)|A total of 586 study particpnats will be invloved on this comprehensive (main) experiment group.This arm will receive a comprehensive intervention package that include advocacy to local governors, community mobilization, awareness creation, training of community representatives and engagement partners. community mobilization through engaging husband as change agent to avert domestic violence in collaboration with community Health Extension Workers. The intervention will target married or cohabited women, partner, and community representatives (religious leaders, and elders). The intervention will be focused on physical, psychological and sexual violence, decision making, negotiation, communication on household matters, gender equality and equity norms, and their relationship with women's health. In addition, massive public information dissemination will be done in the intervention community.
62001839|NCT03265626|ACTIVE_COMPARATOR|Intervention 2|A total of 586 study particpnats will be invloved on this active comprator group. The intervention package such as advocacy to local governors, community mobilization, awareness creation and training of community representatives will be carried out for 12 months period.The main diffrence from the arm-1,here is no husband involvment in the interevntion targets. This intervention will be targeted married and cohabited women and community representatives (religious leaders, health care provider, police, politicians and associations). This group of participant will be selected from one urban and one rural Kebele in Banja District. Same tool and approach will be used to track the intervention progress.
62021014|NCT00761501|EXPERIMENTAL|1|
62021015|NCT00761501|ACTIVE_COMPARATOR|2|
62021016|NCT00761501|ACTIVE_COMPARATOR|3|
62187205|NCT01416935|ACTIVE_COMPARATOR|No Amiodarone|Patient will be randomized not to receive to Amiodarone post Cox-Maze procedure unless indicated.
62570602|NCT02364830|PLACEBO_COMPARATOR|Placebo|Placebo Group: One Placebo Capsule/Day for 4 Weeks. Patients Will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
62570603|NCT02364830|ACTIVE_COMPARATOR|Colpermin®|Colpermin® Group: One Colpermin® Capsule/Day for 4 Weeks. Patients Will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
62021017|NCT01748994|PLACEBO_COMPARATOR|Placebo|Administration of placebo to upper- and lower-body obese women
62777379|NCT03442660|OTHER|Data collection|An electronic data capture (EDC) system will be used to collect data in electronic format. Data will be collected at the enrolment visit, at the follow-up visit (8 weeks +/-2 weeks) and 1 to 4 days after the follow-up visit.
62001840|NCT03265626|OTHER|Control/Comparator|"A total of 586 study partipants will be assigned to the control group that will receive the existing standard services from both urban and rural kebeles of the Guagussa Shikudad district. As comparator purpose, baseline and endline evaluation data will be taken.~-No intervention package but standard service will be maintained"
62001841|NCT06009952|EXPERIMENTAL|Group A|•Group A will receive cryolipolysis with vegan diet,
62001842|NCT06009952|EXPERIMENTAL|Group B|Group B will receive cavitation with vegan diet
62570604|NCT05709574|EXPERIMENTAL|Tadalafil + chemotherapy|Subjects will receive Tadalafil monotherapy for 2 weeks followed by Tadalafil in combination with neoadjuvant FLOT chemotherapy for 8 weeks in the window between their cancer diagnosis and surgical intervention.
62570605|NCT05951803|OTHER|Brief Behavioral Intervention in Insomnia through Tele-Consultation (BBII-TC)|Brief therapy organized into four sessions, lasting 60 minutes each, where behavioral therapy techniques are taught (stimulus control, sleep restriction, progressive muscle relaxation, sleep hygiene). The teleconsultation modality is given through the ZOOM platform synchronously.
62777380|NCT06389110|ACTIVE_COMPARATOR|Alleance®|"Alleance®. Atropine sulfate 0.01%. Ophthalmic solution.~* Dosage: 1 drop QD \[1\] (once a day), at night, for 12 months.~* Route of administration: Ophthalmic"
62777381|NCT06389110|PLACEBO_COMPARATOR|Placebo|"* Placebo. Ophthalmic solution.~* Dosage: 1 drop QD \[1\] (once a day), at night, for 12 months.~* Route of administration: Ophthalmic"
62777382|NCT02337634|PLACEBO_COMPARATOR|Placebo|Matched dosage of milk thistle daily.
62777383|NCT02337634|ACTIVE_COMPARATOR|Milk Thistle|Capsule form, 150mg BID to 300mg BID
62777384|NCT06377709|EXPERIMENTAL|ProACTive™ intervention|ProACTive™ intervention. Participants will choose how many, and which, modules to complete.
62777385|NCT05769049|EXPERIMENTAL|REC610|Lyophilized gE antigen: white cake or powder. clear to opalescent, colorless liquid after reconstitution with water for injection BFA01 adjuvant suspension: opalescent white liquid After reconstitution: opalescent white liquid. Each dose (0.5 mL) contains 50 μg of Quillaja Saponin (QS-21), 50 μg of MPL, 1 mg of dioleoyl phosphatidylcholine, and 0.25 mg of cholesterol
62777386|NCT05769049|ACTIVE_COMPARATOR|Shingrix|Lyophilized gE antigen: white cake or powder. clear to opalescent, colorless liquid after reconstitution with water for injection AS01B adjuvant suspension: opalescent, colorless to pale brownish liquid suspension After reconstitution: opalescent, colorless to pale brownish liquid. Each dose (0.5 mL) contains 50 μg of QS-21, 50 μg of MPL, 1 mg of dioleoyl phosphatidylcholine, and 0.25 mg of cholesterol
62777387|NCT00342953||Cohort|Women receiving implants and other plastic surgery.
62001843|NCT06009952|EXPERIMENTAL|Group C|Group C will receive vegan diet only.
62001844|NCT05703061|NO_INTERVENTION|Normal Sleep Condition Group|This group will not partake in the intervention, they will sleep the normal amount that they do on a regular basis. Participants will wear a hip physical activity monitor and a wrist actigraph to measure sleep.
62570606|NCT05090436|EXPERIMENTAL|Schroth Exercise|The Schroth Method is a nonsurgical option for scoliosis treatment. It uses exercises customized for each patient to return the curved spine to a more natural position. The goal of Schroth exercises is to de-rotate, elongate and stabilize the spine in a three-dimensional plane. it will be applied 3 session per week for 3 months.
62570607|NCT05090436|EXPERIMENTAL|Functional Electrical Stimulation|30 minutes of Functional Electrical Stimulation (FES) three times a week for 3 months. Two electrodes were attached on the lateral parts of the convex side of the body, and two others on the erector spinae muscles. FES (CU-FS1; Novastim, Korea) was set at a frequency of 35 Hz, with a 250-μs pulse width. Electrical stimulation lasted for 6 seconds, followed by a 6-second rest.
62570608|NCT04287257|ACTIVE_COMPARATOR|Standard treatment + Active FHP|The PEMF device - FHP (supplied by commercial support) will be placed under the cast in the ER after diagnosing the fracture and will be applied for 24 hours a day continuously for 30-40 days.
62584876|NCT06408610|EXPERIMENTAL|high intensity interval training|Patients will receive high intensity interval training. The program will be in form of Frequency: High intensity interval training will be scheduled 3 times per week for 12 week Intensity 90% of target heart rate including 10 bouts of 1 minute interspersed with 10 bouts of 1 minute of active recovery 50% of target heart rate. Duration the session will last 30 minutes includes warming up and cooling down periods.
62001845|NCT05703061|EXPERIMENTAL|10-hour Time in Bed Group|This group will partake in the intervention of increasing time in bed to 10 hours per night. Participants will wear a hip physical activity monitor and a wrist actigraph to measure sleep.
62001846|NCT04999631|EXPERIMENTAL|Squaric Acid Dibutyl Ester (SADBE)|Following sensitization, subjects will apply 0.2% SADBE in ethanol to a predetermined area of their nevus 3 times per week for 12 weeks, with adjustment of frequency depending on response.
62001847|NCT04999631|PLACEBO_COMPARATOR|Control|Subject will apply an ethanol solution to a specified area of the nevus.
62021018|NCT01748994|ACTIVE_COMPARATOR|Drug|Administration of pioglitazone to upper- and lower-body obese women
62021019|NCT00755586|EXPERIMENTAL|A|
62021020|NCT00755586|EXPERIMENTAL|B|
62021021|NCT00755586|NO_INTERVENTION|C|
62021022|NCT00744536|EXPERIMENTAL|Lenalidomide and Melphalan|Lenalidomide + Melphalan both given metronomically
62777388|NCT02919514|ACTIVE_COMPARATOR|Physical training on hard surface|Subject will participate in exercise training on a firm surface for 50 min/session, 3 days/week for 6 weeks in total.
62777389|NCT02919514|EXPERIMENTAL|Physical training on sand surface|Subject will participate in exercise training on a sand surface for 50 min/session, 3 days/week for 6 weeks in total.
62777390|NCT02919514|EXPERIMENTAL|Physical training on soft surface|Subject will participate in exercise training on a soft surface for 50 min/session, 3 days/week for 6 weeks in total.
62777391|NCT02048488|EXPERIMENTAL|Experimental Drug TSR-011|Experimental Drug TSR-011
62001848|NCT05957133|ACTIVE_COMPARATOR|Multicomponent exercise group without action observation (MTG)|"The main part of the multicomponent exercise program integrates different exercise modalities: Aerobic, mobility, strength, balance and coordination exercises, playful activities or games are also included with some activities aimed at working on cognitive functions to reinforce the overall effects of the program, such as games with colors, numbers, letters, right-left laterality, memory, etc.~The progression of the different models is as follows:~E. Aerobic: Start with continuous work, then intervallic, and decrease rest times in intervallic work.~E. Strength: Increase sets, repetitions and decrease rest time. Balance: start with static and evolve with blindfolds, perturbations, dynamic balance, etc.~Coordination, and cognitive games will also become more complicated, with more complicated and faster decision making."
62187206|NCT01416935|NO_INTERVENTION|Amiodarone|Patients randomized to receive Amiodarone post Cox-Maze procedure which is our current standard of care.
62187207|NCT03471377||standard scheduling process|Scheduling office assigns start time and room for case and places case on schedule. At this point a default case duration is evaluated by the scheduling office, to see if the value is considered excessively short or excessively long.
62187208|NCT03471377||assigned a planned case duration value from predictive model|Predictive model calculates new duration for case at 3AM the day before surgery, and the predictions are made available on a SecureShare-site.
62187209|NCT02772562|EXPERIMENTAL|PROSTVAC-V/F|
62187210|NCT02580175|ACTIVE_COMPARATOR|Blinded evacuation|Ring evacuation was performed in the conventional way without use of ultrasound followed by sharp gentle curettage until complete evacuation
62187211|NCT02580175|ACTIVE_COMPARATOR|Evacuation under ultrasound guidance|Ring evacuation was performed under ultrasound guidance followed by sharp gentle curettage until complete evacuation. The surgery was considered complete when the endometrial cavity appeared as a regular echogenic line.
62187212|NCT03817723||Specialist surgeon|Radiation exposure of intraoperative cholangiography during cholecystectomy. C-arm cholangiography is performed routinely. KAP (Kerma area product) is the product of air Kerma in the center of the imaging area multiplied with size of the imaging area. For simplicity we have unified varying units received from different c-arms and will only use Gray multiplied by square centimeters (Gycm2 ). KAP values were measured using inbuilt ionization chambers in c-arms. For this study we collected the KAP values from exposure and pulsed fluoroscopy. We also recorded the fluoroscopy time (s).
62187213|NCT03817723||Resident surgeon|Radiation exposure of intraoperative cholangiography during cholecystectomy.C-arm cholangiography is performed routinely. KAP (Kerma area product) is the product of air Kerma in the center of the imaging area multiplied with size of the imaging area. For simplicity we have unified varying units received from different c-arms and will only use Gray multiplied by square centimeters (Gycm2 ). KAP values were measured using inbuilt ionization chambers in c-arms. For this study we collected the KAP values from exposure and pulsed fluoroscopy. We also recorded the fluoroscopy time (s).
62777392|NCT03320590||Couple|Couple with female aged under 37 years
62777393|NCT03683745||Maryland|Maryland is a county in southeast Liberia. Survey clusters based on catchment populations served by community health volunteers (CHVs) around 24 district health facilities (primary sampling unit). Clusters will constitute \~600 people (\~100 households) with population-weighted cluster selection applied. In total, 80 clusters will be required. CHVs would conduct house-to-house visits to develop a full census and listing of all possible cases using broad case definitions. Full details of all potential cases will then be passed to an expert verification team based at the closest health facility. Suspected cases will arrive at the health facility over a 10-day verification period to receive a diagnosis using clinical examination and/or laboratory confirmation.
62777394|NCT05379101||Transthyretin (ATTR) cardiac amyloidosis|Subjects diagnosed with ATTR cardiac amyloidosis will have CMR, TTE, and 6-minute walk
62777395|NCT05379101||Light chain amyloidosis (AL) with cardiac involvement|Subjects diagnosed with AL with cardiac involvement will have CMR, TTE, and 6-minute walk
62777396|NCT05379101||Light chain amyloidosis (AL) without cardiac involvement|Subjects diagnosed with AL without cardiac involvement will have CMR, TTE, and 6-minute walk
62777397|NCT05379101||Healthy Control|Subjects without history of cardiovascular diseases will have CMR, TTE, and 6-minute walk
62777398|NCT04507971|EXPERIMENTAL|MET-3 2.5 g daily for 4 weeks|MET-3 is composed of twenty-two strains of bacteria and was designed to treat metabolic syndrome. The strains that were selected are based on strains that are known butyrate producers, associated with healthy subjects and improved gut barrier function. MET-3 is provided in capsule form and 5 capsules will be swallowed by each subject once daily for 4 weeks.
62777399|NCT04507971|EXPERIMENTAL|MET-5 2.5 g daily for 4 weeks|MET-5 is a new product composed of twenty-six strains of bacteria isolated from the stool of a different healthy donor than MET-3. Although it is expected to work in a similar fashion to MET-3, it contains some strains that are unique in comparison to the original MET-3 formulation and have been associated with leanness in the scientific literature. MET-5 is provided in capsule form and 5 capsules will be swallowed by each subject once daily for 4 weeks.
62187214|NCT05302297||Treatment Group (Cemiplimab)|Patients treated with cemiplimab in monotherapy through the Cohort Temporary Authorization for Use (cATU) or patients included in the Nominative Temporary Authorization for Use( nATU) that evolved into the cATU and meeting the inclusion/exclusion criteria of the study.
62584877|NCT06408610|EXPERIMENTAL|low fermentable short chain carbohydrates diet|Patients will be instructed to follow low fermentable short chain carbohydrates diet (low FODMAP) intervention for 12 weeks limiting daily fermented carbohydrate and dairy products and increase intake of protein, whole grains, fruits and vegetables
62584878|NCT00628238|ACTIVE_COMPARATOR|A|Subjects younger than 65 years old.
62001849|NCT05957133|EXPERIMENTAL|Multicomponent exercise group associated to action observation (AOG)|"It is the same intervention as the other group with the addition of the observation of actions thanks to the fact that the physiotherapist carries out the exercises with them at all times.~The main part of the multicomponent exercise program integrates different exercise modalities: Aerobic, mobility, strength, balance and coordination exercises, playful activities or games are also included with some activities aimed at working on cognitive functions to reinforce the overall effects of the program, such as games with colors, numbers, letters, right-left laterality, memory, etc.~The progression of the exercises will be the same as in the other group."
62001850|NCT00003217|EXPERIMENTAL|Treatment|See detailed description.
62001851|NCT00706966|EXPERIMENTAL|Dutasteride|Dutasteride was administered at a dose of 3.5 mg as an oral soft gelatin capsule once daily for 6 months
62001852|NCT03139916|EXPERIMENTAL|Bavituximab + Standard of Care Radiation + Temozolomide|"Cycle 1 consists of 6 weeks (42 days) of chemoradiation. Radiation therapy is administered per standard of care. Bavituxumab 3 mg/kg IV administration starts during the 1st week of chemoradiation and continues weekly. Temozolomide 75/m2 is administered orally once daily.~Cycle 2 is 4 weeks (28 days) long and Bavituxumab 3 mg/kg IV administration occurs weekly.~Cycle 3 and beyond are each 4 weeks (28 days) long. Bavituxumab 3 mg/kg IV administration occurs weekly for a cumulative total of 18 weeks; treatment may continue beyond 18 weeks at the discretion of the treating physician if the participant is deriving clinical benefit. Temozolomide 150-200 mg/m2 is administered orally once daily on days 1-5 in cycles 3 and 4."
62001853|NCT05974904||Non-MAFLD group|controlled attenuation parameter\<274 dB/m
62001854|NCT05974904||MAFLD group|controlled attenuation parameter ≥ 274 dB/m
62001855|NCT05974904||Non-fibrosis group|liver stiffness measurement \< 8.2 kPa
62001856|NCT05974904||Fibrosis group|liver stiffness measurement ≥ 8.2 kPa
62001857|NCT04466163|EXPERIMENTAL|Schema Therapy and the Healthy Adult|For this study the ST-HA protocol outlined by Broersen \& Claassen (2019) will be followed, consisting of ten one-and-a-half hour individual sessions across ten weeks with daily homework assignments (30-60 minutes). The ST-HA protocol is based on three pillars, aimed at improving self-compassion, well-being and positive affect. First psycho-education about compassionate affect regulation is given and patients learn to recognize the importance of self-caring behavior in stimulating the soothing- affect system to buffer against stress. The second pillar of the ST-HA protocol concerns the development of personal values and committed action as well as getting insight in values of important others. The third pillar concerns developing self-compassion
62001858|NCT04466163|NO_INTERVENTION|Baseline|Outcome variables will be measured repeatedly in a pre-treatment baseline condition (2-5 weeks). Patients are randomly assigned to a pre-treatment/baseline phase. In the present study a restricted randomisation is chosen (Heyvaert \& Onghena, 2014a). A minimum length of the phases is decided a priori in order to prevent for the assignment of too few measurements per phase and to ensure that the full treatment protocol can be offered
62001859|NCT05279521|EXPERIMENTAL|Experimental group|Mandatory exercise the lung rehabilitation exercise is divided into three parts: upper and lower limb muscle strength, endurance training and breathing training skills. It lasts for eight weeks of exercise training, and the exercise frequency is: three times a week.
62001860|NCT05279521|NO_INTERVENTION|Control group|Voluntary exercise the lung rehabilitation exercise is divided into three parts: upper and lower limb muscle strength, endurance training and breathing training skills. It lasts for eight weeks of exercise training, and the exercise frequency is: three times a week.
62187215|NCT05302297||Control Group|Patients treated with other systemic treatments meeting the inclusion/exclusion criteria of the study who initiated at least one systemic treatment for advanced CSCC before start date of the cemiplimab nATU
62187216|NCT05480462|EXPERIMENTAL|Clodivac|
62187217|NCT05480462|ACTIVE_COMPARATOR|Td-Impfstoff Merieux|
62187218|NCT03038269|SHAM_COMPARATOR|Sham tDCS|Participant will receive a placebo-type stimulation followed by upper extremity robotic training.
62570609|NCT04287257|SHAM_COMPARATOR|Standard treatment + Sham FHP|Half of the PEMF devices will be not activated at random before the application to the patients. Two types of activators will be provided by the company: active and sham. Sham activated devices will give outward signs of normal function but will not generate a signal. The investigators will be unaware of the device's functionality. The patients will not be able to determine whether the device is working or not. At study completion, device serial numbers will be used to determine which patients received a working device. The company supplying the PEMF-devices will have no knowledge of patient outcome.
62570610|NCT03268226|EXPERIMENTAL|CHF5993|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI
62570611|NCT00780884|EXPERIMENTAL|acupuncture needles|Acupuncture needles named acuzone needles. The acuzone needles are sterile and single use, manufactured by DONG BANG MEDICAL CO.,LTD.
62570612|NCT05459246|EXPERIMENTAL|Virtual reality glasses|"Beginning 1 minute before the start of the procedure, the patients will be watched (30-45 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30-45 minutes)."
62570613|NCT05459246|NO_INTERVENTION|Control group|Routine maintenance will be applied
62001861|NCT04817826|EXPERIMENTAL|Cohort 1|"Pre-operative treatment with tremelimumab 300 mg single administration (day 1) and durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).~Patients in Cohort 1 will undergo standard gastrectomy with D2 lymphadenectomy and then they will be followed by an active follow-up every 12 weeks for two years and then a standard follow-up every six months until the end of the fifth year from surgery."
62570614|NCT03445741|ACTIVE_COMPARATOR|Supervised treadmill group (%70 VO2 max)|Supervised treadmill group (%70 VO2 max) (group 1): The participants were instructed walking exercise at their target heart rate, (% 70 of maximum oxygen consumption) on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
62570615|NCT03445741|EXPERIMENTAL|Supervised treadmill group (%50 VO2 max)|Supervised treadmill group (%50 VO2 max) (group 2): The participants were instructed walking exercise at their target heart rate, (% 50 of maximum oxygen consumption) on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
62187219|NCT03038269|ACTIVE_COMPARATOR|Active tDCS|Participant will receive active transcranial direct current stimulation followed by upper extremity robotic training.
62187220|NCT00598871|PLACEBO_COMPARATOR|2|There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of eyedrops to the affected eye, identical to the active drug but with no thymosin beta 4 (0.00% thymosin beta 4, w/w), 2 drops 4 times a day (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
62187221|NCT00598871|ACTIVE_COMPARATOR|1|There are 2 groups: active drug and placebo. The patients in the active comparator arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times a day (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
62187222|NCT01854736|ACTIVE_COMPARATOR|GRAZAX|Tablet 75.000SQ-T once daily
62187223|NCT01854736|PLACEBO_COMPARATOR|Placebo|Tablet with no active grass component
62187224|NCT01423708|NO_INTERVENTION|Control|Standard immunosuppression protocol with Tacrolimus, maintaining trough levels between 6 and 12 ng/ml in the first month, in association with steroids (20 mg/day with subsequent weaning within 3 months after transplantation).
62187225|NCT01423708|EXPERIMENTAL|Everolimus|Administration of Everolimus in association with Tacrolimus and steroids.
62187226|NCT03840356||Postoperative|The study will evaluate orthopedic postoperative patients during the hospitalization.
62187227|NCT04752800|EXPERIMENTAL|active tDCS|"Participants will receive 10 ETCC sessions, for 20 minutes, on alternate days (3 times a week). The electrodes will be positioned on the primary motor cortex (position C3 or C4 according to the international electroencephalogram system - EEG 10/20), with the anode positioned on the affected hemisphere and the cathode on the supraorbital region in the hemisphere contralateral to the injury. The electrodes will be wrapped with sponges of 5 x 7 cm and moistened with saline (NaCl 0.9%).~The current intensity will be 2mA."
62187228|NCT04752800|SHAM_COMPARATOR|Sham tDCS|The protocol for placebo stimulation will be identical, but the device will stop emitting current 30 seconds after the start of stimulation.
62570616|NCT03445741|EXPERIMENTAL|ECE PEDO pedometer group (%50 VO2 max)|ECE PEDO pedometer group (%50 VO2 max) (group 3): The participants were instructed walking with ECE PEDO which the number of steps taken in a minute corresponding to target HR at % 50 of maximum oxygen consumption were provided.
62584879|NCT00628238|ACTIVE_COMPARATOR|B|Subjects aged 65 years and older
62187229|NCT03421405|EXPERIMENTAL|Intervention Arm|All participants will be asked to attend 4 separate experimental sessions over the course of approximately 4 weeks (i.e. one session/week). During each session, participants will listen to three different auditory stimulus sequences including sounds and words while EEG activity is recorded using the NeuroCatch Platform™ device.
62187230|NCT05928663|EXPERIMENTAL|double surgical gloves|
62187231|NCT05928663|OTHER|single surgical gloves|
62187232|NCT04770870|OTHER|Treatment Arm|All subjects who meet eligibility, consented, and enrolled into the study will receive treatment.
62187233|NCT00569010|EXPERIMENTAL|Low-Dose Ara-C + AZA-Level 0|"Group 1 = Low-Dose Ara-C + Azacitidine-Level 0~Low-Dose Ara-C: 100 mg/m\^2 Daily continuous intravenous infusion (CIV) for 7 days Azacitidine (AZA): 37.5 mg/m\^2 intravenous (IV) Over 20-30 minutes Daily for 7 Days"
62777400|NCT03565835|EXPERIMENTAL|Abiraterone and Prednisone without a GnRH Analogue|Abiraterone (1000 mg daily) with Prednisone (5 mg) with Discontinuation of GnRH Analogue Injection
62187234|NCT00569010|EXPERIMENTAL|Low-Dose Ara-C + AZA-Level 1|"Group 2 = Low-Dose Ara-C + Azacitidine-Level 1~Low-Dose Ara-C: 100 mg/m\^2 Daily continuous intravenous infusion (CIV) for 7 days AZA: Level 1 = 75.0 mg/m\^2 IV Over 20-30 minutes Daily for 7 days"
62395478|NCT05338827|EXPERIMENTAL|Wire-Reinforced Tube group|In contrast to the PVC tube, the WR tube is flexible with a slightly anterior curvature. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
62395479|NCT04450927||1|Data collection and treatment according to guidelines of standard of medical evaluation and care. No investigational treatments or procedures will be administered on this protocol.
62187235|NCT00569010|EXPERIMENTAL|High-Dose Ara-C + AZA-Level 0|Group 3 = High-Dose Ara-C + Azacitidine-Level 0 High-dose Ara-C: 1 g/m\^2 Daily CIV for 4 days (age\<65years) or 3 days (age\>=65years) AZA: 37.5 mg/m\^2 IV Over 20-30 minutes Daily for 7 Days
62395480|NCT00405925|ACTIVE_COMPARATOR|combivir/kaletra|All patients started with combivir/Kaletra and were randomized if they reached undetectable viral load (2 times) within 24 weeks into continuation of the same regimen or Trizivir (2 arms)
62395481|NCT00405925|EXPERIMENTAL|Trizivir|patients who reach undetectable HIV-RNA within 24 weeks are randomized to switch to trizivir or continuation of combivir/kaletra
62395482|NCT00672490|EXPERIMENTAL|1|Quetiapine Fumarate - tablets
62395483|NCT00672490|EXPERIMENTAL|2|Quetiapine Fumarate - tablets and Lithium
62395484|NCT06368596|OTHER|Study arm|Patients in reproductive age, who will undergo elective surgery for endometriosis.
62395485|NCT06368596|OTHER|Control arm|Women in reproductive age, without endometriosis, as control group for secondary objective 1 and 2.
62777401|NCT02215304|ACTIVE_COMPARATOR|Bifidobacterium longum R0033|Bifidobacterium longum ssp infantis R0033, 3\*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
62777402|NCT02215304|ACTIVE_COMPARATOR|Lactobacillus helveticus R0052|Lactobacillus helveticus R0052, 3\*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
62187236|NCT00569010|EXPERIMENTAL|High-Dose Ara-C + AZA-Level 1|"Group 4 = High-Dose Ara-C + Azacitidine-Level 1~High-dose Ara-C: 1 g/m\^2 Daily CIV for 4 days (age\<65years) or 3 days (age\>=65 years) AZA:Level 1 = 75.0 mg/m\^2 IV Over 20-30 minutes Daily for 7 days"
62187237|NCT04054414|ACTIVE_COMPARATOR|Normal Saline|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
62395486|NCT03980665|EXPERIMENTAL|Arsenic trioxide combined with cART|Receiving intravenous arsenic trioxide, 0.16mg/kg/day, no more than 10 mg per-day , two to four weeks, combined with continuous cART after attaining plasma HIV-1 suppression (plasma HIV RNA \<50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
62395487|NCT03980665|NO_INTERVENTION|Without arsenic trioxide therapy|Only receiving cART without arsenic Trioxide after attaining plasma HIV-1 suppression (plasma HIV RNA \<50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
62395488|NCT06332677|EXPERIMENTAL|the main genes and expression by comparing the transcriptomic lipidomic profile|"To identify the main genes and pathways differentially expressed and the main factors associ- ated with SUV420H1/H2 expression by comparing the transcriptomic and lipidomic profile of indi- viduals with low hepatic SUV420H1/H2 mRNA expression levels (lowest expression quartile) to that from individuals with high expression levels (top quartile).~In order to evaluate the role of SUV420H1/H2 in the regulation of gene expression in NAFLD pa- tients, we will exploit already available transcriptomic and lipidomic data by analyzing the gene ex- pression databases deriving from ongoing studies conducted at the Fondazione and by the PI of the Catanzaro collaborating centre. Data have been generated from liver and visceral adipose biopsy of obese individuals at high risk of developing NASH (SERENA Study at Fondazione, and MAFALDA Study, coordinated by prof Stefano Romeo, PI of the Università Magna Graecia Catanzaro)."
62395489|NCT01737463|ACTIVE_COMPARATOR|Group A|"Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope (JF-240, TJF-240, JF-260, TJF-260; Olympus Optical Co, Ltd, Tokyo, Japan).~A pancreatic duct stent was inserted immediately after the excision."
62570617|NCT06159842|EXPERIMENTAL|Photodynamic Therapy (Blue light dose 10 J/cm2 at 10 mW/cm2)|30 participants will be enrolled to this arm
62570618|NCT02962492|ACTIVE_COMPARATOR|Dapagliflozin Arm:|dapagliflozin 10mg (oral tablet) and exenatide (5µg acutely)/Exenatide extended release (long term) placebo (subcutaneous injection)
62570619|NCT02962492|ACTIVE_COMPARATOR|Exenatide extended release Arm:|subcutaneous injection of Exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin placebo
62570620|NCT02962492|PLACEBO_COMPARATOR|Placebo Arm:|dapagliflozin placebo (oral tablet) and exenatide (5µg acutely)/Exenatide extended release (long term) placebo (subcutaneous injection)
62570621|NCT02962492|ACTIVE_COMPARATOR|Exenatide extended release & dapagliflozin Arm:|Exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin 10mg
62570622|NCT02678169||Penumbra Aspiration System|Penumbra Aspiration System with the ADAPT technique
62570623|NCT04613921||Group 1|patients listed for liver transplantation with ACLF-2 or 3 at the time of listing or developing ACLF 2-3 while on the waiting list (n=2,000)
62570624|NCT04613921||Group 2|patients listed for liver transplantation with decompensated cirrhosis without ACLF-2 or 3 and poor liver function (MELD \> 20) at the time of listing (n=500)
62570625|NCT04613921||Group 3|patients having ACLF-2 or 3, are assessed for inclusion in the waiting list, but are finally not listed for liver transplantation (n=500)
62001862|NCT04817826|EXPERIMENTAL|Cohort 2|"Pre-operative treatment with tremelimumab 300 mg single administration (day 1) and durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).~In Cohort 2, patients with no evidence of complete clinical response will undergo standard gastrectomy with D2 lymphadenectomy and then they will be followed up. Patients with complete clinical response will undergo a non-operative management (NOM) with an active follow-up phase every 12 weeks for two years, followed by standard follow-up every six months until the end of the fifth year. At any time during follow-up, in case of clinical suspicion or confirmation of residual gastric cancer, patients will undergo standard surgery according to the clinical practice at their Centre."
62001863|NCT00649064|EXPERIMENTAL|Ziprasidone|
62001864|NCT03061539|EXPERIMENTAL|Nivolumab & Ipilimumab - Cohort 1|Patients will receive Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every three weeks for a maximum of 4 doses followed by a 6 week gap after last combination dose. The patients will then receive 480 mg flat dose of nivolumab every 4 weeks for up to one year, or until progression, unacceptable toxicity or withdrawal of consent.
62001865|NCT03061539|EXPERIMENTAL|Nivolumab & Ipilimumab - Cohort 2|Patients will receive Nivolumab 3 mg/kg + ipilimumab 1 mg/kg every three weeks for a maximum of 4 doses followed by a 3 week gap after last combination dose. The patients will then receive 480 mg flat dose of nivolumab every 4 weeks for up to one year, or until progression, unacceptable toxicity or withdrawal of consent.
62187238|NCT04054414|EXPERIMENTAL|PMZ-1620|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
62187239|NCT02542410|ACTIVE_COMPARATOR|Control|Norethindrone acetate 5 mg po daily x 6 months
62187240|NCT02542410|EXPERIMENTAL|Experimental|cabergoline 0.5 mg PO twice weekly x 6 months
62570626|NCT01137149|ACTIVE_COMPARATOR|Treatment as Usual- Psychotherapy|The TAU condition will be implemented consistent with usual and customary clinical practices within the Child Psychiatry Clinic at Seattle Children's Hospital (SCH. Within the SCH system, TAU for a depressed adolescent will typically consist of an individual therapy approach with adjunct family sessions and pharmacotherapy as deemed necessary by the primary therapist. The therapeutic approach typically used is cognitive behavioral but is administered in an eclectic, non-manualized fashion. Therapists for the TAU arm of the study will be care providers currently working within the SCH system. For this phase of the study, we will draw on clinicians whose level of experience is comparable to that of the Behavioral Activation therapists.
62570627|NCT01137149|EXPERIMENTAL|Behavioral Acitivation Therapy|Behavioral activation is a 12 week psychotherapeutic intervention utilizing a semi-structured format. Initial sessions focus on specific areas (Assessment and orientation, Activation, Problem Solving, Goal Setting, Overcoming Barriers, Avoidance) interspersed as needed by sessions that focus on individual issues and applications. In these sessions the therapists maintains the session structure, but can use techniques presented in earlier sessions based on their functional analysis of the particular case. Parents participate in at least two of the ATA sessions but more active parental participation can be included as needed.
62570628|NCT06170476|EXPERIMENTAL|HSK21542-60μg|
62570629|NCT06170476|EXPERIMENTAL|HSK21542-120μg|
62570630|NCT06170476|EXPERIMENTAL|HSK21542-180μg|
62570631|NCT06170476|PLACEBO_COMPARATOR|Placebo|
62001866|NCT02613533|EXPERIMENTAL|Narrow Angle Glaucoma Study Group|Subjects will be given 10ml/kg of water over 15 min prior to surgery and Intra-ocular pressure measurement (IOP) is checked every 15 min before and after surgical procedure.
62187241|NCT00943722|EXPERIMENTAL|9- to 15-Year-Old Females (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
62570632|NCT02954601|ACTIVE_COMPARATOR|Placebo|Placebo (fish oil)
62777403|NCT02215304|ACTIVE_COMPARATOR|Bifidobacterium bifidum R0071|Bifidobacterium bifidum R0071, 3\*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
62570633|NCT02954601|ACTIVE_COMPARATOR|Dose1|Dose 1 ORMD-0801 (qd)
62777404|NCT02215304|PLACEBO_COMPARATOR|Placebo|potato starch 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
62777405|NCT03076294|EXPERIMENTAL|MT after rTMS group|High frequency TMS will be applied with an eight-shaped coil angled at zero degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1). Twenty four stimulus trains will be provided at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 1200 pulses for approximately 12 minutes, with 90% of resting motor threshold (RMT). After TMS, patients will be submitted to 45 minutes of manual therapy protocol.
62187242|NCT00943722|EXPERIMENTAL|9- to 15-Year-Old Females (Lot 2)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 2.
62187243|NCT00943722|EXPERIMENTAL|9- to 15-Year-Old Females (Lot 3)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 3.
62187244|NCT00943722|EXPERIMENTAL|9- to 15-Year-Old Males (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
62777406|NCT03076294|EXPERIMENTAL|rTMS after MT group|Patients will be submitted to 45 minutes of manual therapy protocol. After that, high frequency TMS will be applied with an eight-shaped coil angled at zero degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1). Twenty four stimulus trains will be provided at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 1200 pulses for approximately 12 minutes, with 90% of resting motor threshold (RMT).
62777407|NCT03076294|SHAM_COMPARATOR|Control group|In this group, the order of interventions will be randomized. Therefore, the volunteer can start with manual therapy or sham TMS. In manual therapy, patients will be submitted to 45 minutes of a protocol. In addition, with regard to sham TMS, the same parameters will be used, however, it will be performed using two coils, one connected to the magnetic stimulator, away from the patient's scalp and another uncoupled from the stimulator and positioned in the same way as in real stimulation.
62777408|NCT00296153|ACTIVE_COMPARATOR|1|Omacor 1000mg x 4 / day
62777409|NCT00296153|PLACEBO_COMPARATOR|2|
62001867|NCT05833503|EXPERIMENTAL|Integrative Couple Treatment for Addiction (ICT-A)|"Inspired by the Alcohol Behavior Couple Therapy from Epstein \& McCrady, the ICT-A will be offered over 12 to 16 sessions of 90 minutes. Typically, approximately the first half of each session is dedicated to GD/SUD problems,in a predominantly cognitive behavioral model. In the second part of each session, the clinician will help the couple to improve their communication,to reduce the reinforcements (non-voluntary) of the behaviors of GD/SUD and to increase marital pleasure situations incompatible with the use of GD/SUD.Particular attention will also be paid to feelings of betrayal and interpersonal attacks to restore trust. Plus,they will received a sefl-care guide."
62187245|NCT00943722|EXPERIMENTAL|16- to 26-Year-Old Females (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
62570634|NCT02954601|ACTIVE_COMPARATOR|Dose2|Dose 2 ORMD-0801 (bid)
62570635|NCT02954601|ACTIVE_COMPARATOR|Dose 3|Dose 3 ORMD-0801 (tid)
62187246|NCT01812798|ACTIVE_COMPARATOR|Peanut|"Double Blind Placebo Controlled Food Challenge 5 gram peanut challenge~17 doses of peanut will be administered. Dose will be increased every 20-30 minutes. All doses listed are in g of peanut flour.~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000"
62187247|NCT01812798|PLACEBO_COMPARATOR|Placebo|Double Blind Placebo Controlled Food Challenge (No peanut - placebo only)
62777410|NCT05215730|ACTIVE_COMPARATOR|Copper oxide dressings (COD)|"MedCu wound dressings with copper oxide (COD) (Copper Arm)."
62777411|NCT05215730|ACTIVE_COMPARATOR|"Vacuum-assisted closure (VAC) treatment (VAC Arm)"|"Negative Pressure Wound Therapy (NPWT) known also as Vacuum-assisted closure (VAC) treatment (VAC Arm)."
62187248|NCT02371772|OTHER|Self-management anticoagulation treatment|Trained to monitor INR and dose warfarin
62187249|NCT02371772|NO_INTERVENTION|Conventional anticoagulation treatment|Before enrolment
62395490|NCT01737463|ACTIVE_COMPARATOR|Group B|"Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope (JF-240, TJF-240, JF-260, TJF-260; Olympus Optical Co, Ltd, Tokyo, Japan).~A pancreatic duct stent was not inserted immediately after the excision."
62187250|NCT01972997|EXPERIMENTAL|SENSIMED Triggerfish|There is only 1 arm in the study. SENSIMED Trigerfish lens sensors with different base curves are placed on subjects in random and double-blinded manner in sequential sessions.
62395491|NCT01334281||Blood: Undergoing Desensitization|Transplant subjects give blood at specified time points. Sensitization to HLA antigens is a barrier to transplant. Several U.S. institutions have protocols for desensitization where patients are treated with IV immunoglobulins (IVIg) and plasmapheresis (PP) to reduce circulating HLA-directed antibody levels. Labs provide doctors information on circulating donor-specific antibody (DSA) levels. These results are the main indicator whether to proceed with transplant. However, no information is given on the fate of the B cells that produce the DSA.
62395492|NCT01334281||Blood: NOT Undergoing Desensitization|Transplant subjects give blood at specified time points. Sensitization to HLA antigens is a barrier to transplant. Several U.S. institutions have protocols for desensitization where patients are treated with IV immunoglobulins (IVIg) and plasmapheresis (PP) to reduce circulating HLA-directed antibody levels. Labs provide doctors information on circulating donor-specific antibody (DSA) levels. These results are the main indicator whether to proceed with transplant. However, no information is given on the fate of the B cells that produce the DSA.
62395493|NCT05944731|EXPERIMENTAL|Arm 1|Arm 1 is those participants randomized to use of CGM in a continuous fashion; CGM use for the duration of 9 months.
62777412|NCT00835341||p16-methylated|patients with mild or moderate oral epithelial dysplasia containing methylated p16 CpG island.
62777413|NCT00835341||p16-unmethylated|patients with mild or moderate oral epithelial dysplasia NOT containing methylated p16 CpG island.
62777414|NCT01106235|EXPERIMENTAL|Treatment (immunostimulant, autologous lymphocytes, and chemo)|Patients receive cyclophosphamide IV on days -3 and -2 followed by an infusion of IL-21 modulated, MART-1 specific CD8+ cytotoxic T lymphocytes over 30-60 minutes on day 0. Beginning within 24 hours of T cell infusion, patients receive low-dose aldesleukin SC BID for 14 days in the absence of disease progression or unacceptable toxicity.
62777415|NCT03450265|EXPERIMENTAL|Hemopatch|Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.
62777416|NCT03450265|ACTIVE_COMPARATOR|TachoSil|Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.
62187251|NCT02058836|EXPERIMENTAL|Botox Injection|The participant will be given an injection of Botox along the spermatic cord under ultrasound guidance. Before drug administration, a nerve block using bupivacaine will be completed to numb the area for treatment. This will be a 10 mL injection done one time at the initial patient visit.
62187252|NCT02058836|PLACEBO_COMPARATOR|Saline Injection|The patient will receive an inactive injection of normal saline along the spermatic cord under ultrasound guidance. This will be a 10 ml injection done once at the initial visit. Before the injection of saline, a spermatic cord block using bupivacaine will be completed to numb the area for treatment.
62187253|NCT00458146|EXPERIMENTAL|1|MM-093
62187254|NCT00458146|PLACEBO_COMPARATOR|2|Placebo
62187255|NCT01447576|EXPERIMENTAL|OPC-34712 + ADT|Experimental: OPC-34712, Oral Tablets, 0.25 - 3 mg; Antidepressant drug treatment
62187256|NCT03660397|EXPERIMENTAL|Intervention|Selective endovascular chemical ablation of adrenal gland after adrenal angiography.
62395494|NCT05944731|EXPERIMENTAL|Arm 2|Arm 2 is those participants randomized to intermittent use of CGM; CGM use for 4 time points consisting of 2 weeks of CGM use each, for the duration of 9 months.
62570636|NCT01209520|EXPERIMENTAL|Adjuvant Chemotherapy + Vidaza|
62777417|NCT04725487|EXPERIMENTAL|Standard integration program with social and health promoting intervention|Participants follow the standard integration program offered by Naestved Municipality and participate in various social and health promoting activities in addition
62001868|NCT05833503|ACTIVE_COMPARATOR|Individual treatment as usually offered|"The usual treatment control group will receive individual treatment as already offered by the specialized centres in addiction.~For the person with GD/SUD, this treatment consists of 12 to 16 individual cognitive-behavioral sessions of 60 minutes. In general, the intervention aims to secure financial assets, awareness of erroneous thoughts and improvement of alternative skills to gambling in order to meet the normal demands of psychic and relational life. People undergoing this intervention will receive a self-care guide.~As for the partners randomized in this intervention, they will receive the services that are usually offered to members of the entourage of a person with GD/SUD. In groups or individually, these services are generally aimed at improving the partner's well-being and relationship with their spouse, which includes information about GD/SUD and the recovery process."
62001869|NCT03070353|EXPERIMENTAL|Dextran 40|Dextran 40 infusion
62001870|NCT05296694||Coronary Care Patients|All patients admitted to coronary care unit with cardiovascular diseases.
62187257|NCT03660397|ACTIVE_COMPARATOR|Control|No intervention, but treated with standard antihypertensive drugs
62187258|NCT06171022|EXPERIMENTAL|Cherry seed pillow|4 Weeks, 5 days a week, 20 minutes, in addition to the physiotherapy application of the routine, a heated cherry seed pillow will be applied.
62187259|NCT06171022|ACTIVE_COMPARATOR|Control|4 Weeks, 5 days a week, 20 minutes, in addition to the physiotherapy application of the routine, a hot-pack will be applied.
62395495|NCT05944731|NO_INTERVENTION|Arm 3|Arm 3 is those participants randomized to standard of care; regular use of self-monitoring of blood glucose (SMBG) for the duration of 9 months.
62777418|NCT04725487|ACTIVE_COMPARATOR|Standard integration program|Participants follow the standard integration program offered by Naestved Municipality
62777419|NCT02682797||1|At all study visits a complete ophthalmic examination, visual acuity and refractive error, Spectralis OCT, Cirrus OCT, Topcon OCT, PS-OCT, Optomap Fundus photography will be performed.
62777420|NCT05908201|EXPERIMENTAL|early time-restricted eating|The Early Time Restricted Eating (eTRE) group will be asked to consume calorie containing food or drinks only between 9am to 5pm, daily. At other times they are to avoid consuming any calorie containing food or drinks.
62777421|NCT05908201|NO_INTERVENTION|Control|The Control group will follow their usual eating routine.
62777422|NCT04913740|NO_INTERVENTION|Control group|health care workers who did not use any preventive measures on the basis of tertiary protection
62777423|NCT04913740|EXPERIMENTAL|Experimental group|"On the basis of three-level protection, skin correlation prevention is carried out:~1. pay attention to the protection of exposed skin, so that it is local dry.~2. Do a good job of facial moisturizing work before workuse moisturizing ointment, more durable and non-irritating cream or emulsion, such as vitamin E cream, petroleum jelly, to do a good job of moisturizing work.~3. Use appropriate dressing to avoid direct contact between the mask and the skin, and select the appropriate type of protective device; Reduce friction by applying foam patches, hydrocolloidal dressings, and empleters to the hair area. However, it should be noted that it must be confirmed that airtightness is good and that the protective effect is still the primary purpose of the medical staff.~4. After work, avoid using irritantsto clean the face, and massage local skin with skin moisturizer; (5) If severe skin damage occurs, treat it as prescribed by the doctor"
62791744|NCT02451514|EXPERIMENTAL|MenACWY Group|Subjects who received MenACWY vaccine in the parent study V102_02 (NCT01210885) and received no subsequent meningococcal vaccines, received 2 doses of MenABCWY+OMV vaccine, one month apart (Day 1 and Day 31), in the current study.
62001871|NCT04037202|EXPERIMENTAL|Study Group|"The first session of the foot massage was performed after mothers were taken to the postpartum service and after the effect of the first analgesia had elapsed (4-6 hours after birth).~The researcher prepared the mother for foot massage (foot care, proper position, etc.) and gave a total of 20-minute massage of foot massage, 10 minutes for each foot. VAS was repeated immediately after the first session (in the 20th minute) and after 30 minutes (in the 50th minute). The second session was performed on the second day, 20-24 hours after the first session (before the discharge). The VAS was analyzed before the second (last) session (0th minute), and the VAS was repeated immediately after the application (20th minute) and 30 minutes (50th minute), and the PCS was administered for the last time. Administered analgesics were recorded in the DFC and the administration made with package leaflet was supported."
62001872|NCT04037202|NO_INTERVENTION|Control Group|Routine procedures were applied and VAS was repeated at the same time periodical as the study group mothers (0th, 20th and 50th minute) and after 20-24 hours (before discharge), at the same time intervals (0th, 20th and 50th minute) pain status was measured by using VAS and PCS was administered for the last time and analgesics administered were recorded on the DFC.
62187260|NCT05276778||People with type 2 diabetes|People diagnosed with type 2 diabetes age 18-70
62187261|NCT04087564|EXPERIMENTAL|music intervention|Healthy volunteers, and patients diagnosed with HIV or fibromyalgia will complete 4 rounds of QST testing; baseline + 3 music conditions to determine effect of music on pain sensitivity.
62395496|NCT05449431|EXPERIMENTAL|TLC1_TM6|Patient doing 1-minute chair lift test (TLC1) before 6-minute Walk Test (TM6).
62395497|NCT05449431|EXPERIMENTAL|TM6_TLC1|Patient performing 6-minute Walk Test (TM6) before 1-minute chair lift test (TLC1)
62187262|NCT03235362|EXPERIMENTAL|1|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 3."
62187263|NCT03235362|EXPERIMENTAL|2|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 3."
62187264|NCT03235362|EXPERIMENTAL|3|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1706 QD for 6 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 3."
62001873|NCT00958776|EXPERIMENTAL|Peramivir+SOC|"* Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.~* Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care."
62001874|NCT00958776|PLACEBO_COMPARATOR|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
62001875|NCT00996762|EXPERIMENTAL|Part 1-3|2-period crossover, Period 1 (D1-7) will receive either the commercial formulation or the alternative formulation. Period 2 (D1-7) will receive the formulation not received in Period 1. There will be 3 parts with 3 different alternative formulations. Subjects will only participate in one part.
62001876|NCT00861211|EXPERIMENTAL|Active treatment arm|
62001877|NCT00861211|PLACEBO_COMPARATOR|Placebo|
62001878|NCT02915549|EXPERIMENTAL|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
62187265|NCT03235362|EXPERIMENTAL|4|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1706 QD for 6 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 3.~There will be a washout of at least 10 days between the last dose in one period and the first dose in the subsequent period."
62395498|NCT00435266|EXPERIMENTAL|1|Remote ischemic preconditioning
62570637|NCT04821180||patients treated by angle stable plate PHILOS|
62570638|NCT04821180||patients treated by reverse total shoulder arthroplasty SMR|
62570639|NCT04227197|EXPERIMENTAL|Intervention Group|The participants randomized to the intervention group completed the DSC2U questionnaire, and received online access to a personalized Caregiver Checklist and PCP plan. Caregivers were encouraged to share and discuss the PCP plan at their next wellness visit with the PCPs.
62001879|NCT02915549|ACTIVE_COMPARATOR|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
62001880|NCT02485912|ACTIVE_COMPARATOR|Group 1|ChAd3-EBO Z (2.5 - 3.7 x 10\^10 vp) and MVA-EBO Z (1.0 x 10\^8 pfu) 7 days later. Both vaccinations are administered in the same arm.
62001881|NCT02485912|ACTIVE_COMPARATOR|Group 2|ChAd3-EBO Z (2.5 - 3.7 x 10\^10 vp) and MVA-EBO Z (1.0 x 10\^8 pfu) 7 days later. The MVA-EBO Z is administered in the opposite arm to the ChAd3-EBO Z.
62187266|NCT03235362|EXPERIMENTAL|5|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 3."
62395499|NCT00435266|NO_INTERVENTION|2|
62395500|NCT00638248|ACTIVE_COMPARATOR|1|Desmoteplase 90µg/kg BW
62395501|NCT00638248|ACTIVE_COMPARATOR|2|Desmoteplase 125 µg/kg BW
62395502|NCT00638248|PLACEBO_COMPARATOR|3|Placebo
62395503|NCT00993382|EXPERIMENTAL|Celivarone 50 mg|Celivarone, 50 mg once daily up to 10-15 days before the common study end date
62001882|NCT01559311|ACTIVE_COMPARATOR|CRT-P OFF|"Patients randomized into the Echo-guided Group were implanted with a CRT-P device (St. Jude Medical), which was programmed to DDDR pacing mode (CRT-P OFF) at implant. For each Echo-guided Group patient, presence of RVA pacing induced ventricular dyssynchrony was assessed within 24-hour of implant using the standardized criteria of Doppler echocardiography. The Echocardiography Core Laboratory (Echo Core Lab) then analyzed each image and the treatment allocation of the Echo-guided Group was done within 72-hour post implant based on the Echo Core Lab outcomes:~• Patients with the absence of RVA pacing induced ventricular dyssynchrony were allocated to the DDDR standard therapy with CRT-P remained OFF"
62187267|NCT03235362|EXPERIMENTAL|6|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 3."
62777424|NCT04597840|EXPERIMENTAL|biosynthetic mesh group|Patient will undergo incisional hernia repair with biosynthetic mesh reinforcement. Based on the discretion of the surgeon, two types of biosynthetic mesh from different brand can be used: the Phasix mesh from BARD or the BioA mesh from GORE. These two biosynthetic meshes are resorbable, which means they are gradually absorbed by the body.
62001883|NCT01559311|EXPERIMENTAL|CRT-P ON|"Patients randomized into the Echo-guided Group were implanted with a CRT-P device (St. Jude Medical), which was programmed to DDDR pacing mode (CRT-P OFF) at implant. For each Echo-guided Group patient, presence of RVA pacing induced ventricular dyssynchrony was assessed within 24-hour of implant using the standardized criteria of Doppler echocardiography. The Echocardiography Core Laboratory (Echo Core Lab) then analyzed each image and the treatment allocation of the Echo-guided Group was done within 72-hour post implant based on the Echo Core Lab outcomes:~• Patients with the presence of RVA pacing induced ventricular dyssynchrony were allocated to the CRT-P standard therapy with CRT-P turned ON"
62187268|NCT04648826|EXPERIMENTAL|1/ Phase I Dose Escalation|Azacytidine (aerosolized) at escalating doses (given on 3 consecutive days in the first week of every 3-week cycle) with a flat dose of Bintrafusp alfa 2400 mg (given on day 13 \[+/- 3 days\] of every 3-week cycle starting with Cycle 2)
62187269|NCT04648826|EXPERIMENTAL|2/ Phase II Dose Expansion|Azacytidine (aerosolized) at the RP2D established in Phase I (given on 3 consecutive days in the first week of every 3-week cycle) with a flat dose of Bintrafusp alfa 2400 mg (given on day 13 \[+/- 3 days\] of every 3-week cycle)
62187270|NCT02744170|EXPERIMENTAL|COPD patients with delivery order 1, 2, 3|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
62187271|NCT02744170|EXPERIMENTAL|COPD patients with delivery order 2,3, 1|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
62187272|NCT02744170|EXPERIMENTAL|COPD patients with delivery order 3, 2, 1|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
62187273|NCT02744170|EXPERIMENTAL|COPD patients with delivery order 1, 3, 2|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
62395504|NCT00993382|EXPERIMENTAL|Celivarone 100 mg|Celivarone, 100 mg once daily up to 10-15 days before the common study end date
62777425|NCT04597840|OTHER|standard of repair group|Patient will undergo incisional hernia repair according to the standard of repair, which is simple suture or mesh reinforcement (using synthetic or biological meshes).
62777426|NCT05354193||vasoplegic syndrome|Patients undergoing on-pump coronary artery bypass graft who develops vasoplegic syndrome 24 - 48 hours after surgery.
62187274|NCT02744170|EXPERIMENTAL|COPD patients with delivery order 2, 1, 3|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
62187275|NCT02744170|EXPERIMENTAL|COPD patients with delivery order 3, 1, 2|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
62187276|NCT05090267|EXPERIMENTAL|Dietary Supplement (e.g., vitamins, minerals)|Visbiome probiotic supplement
62570640|NCT04227197|NO_INTERVENTION|Control Group|The participants randomized to the control group, received usual care for 7 months, after their scheduled PCP appointment. They did not receive DSC2U during these 7 months, but did receive the online, personalized health assessment tool (DSC2U) at the end of the 7 months, after the primary and secondary outcomes were measured.
62570641|NCT01829100|EXPERIMENTAL|Group Behavioral Activation Therapy|Group Behavioral Activation Therapy (GBAT)
62570642|NCT01829100|NO_INTERVENTION|waitlist|15-week waitlist
62001884|NCT01559311|ACTIVE_COMPARATOR|DDDR|Patients randomized into the Control Group were implanted with a DDDR device (St. Jude Medical) standard therapy.
62001885|NCT01637688||Amino acid formula|Comparison of growth between subjects who are fed with a newly innovated amino acid formula (NAAF) and who are fed with either Neocate or nutramigen AA.
62187277|NCT05090267|ACTIVE_COMPARATOR|Device (including sham)|Transcutaneous Vagal Nerve Stimulation (tVNS)
62777427|NCT05354193||control|Patients undergoing on-pump coronary artery bypass graft who does not develop vasoplegic syndrome.
62001886|NCT01302392|ACTIVE_COMPARATOR|Best Supportive Care|
62001887|NCT01302392|EXPERIMENTAL|Carfilzomib|
62001888|NCT03706235||No recurrence|Subjects at least 30 days from end of primary treatment for colorectal cancer in a clinically indicated surveillance program (e.g. ASCO, NCCN) provide a blood sample before the next clinically indicated surveillance scan/imaging. Imaging documents no recurrence.
62001889|NCT03706235||Recurrence|Subjects at least 30 days from end of primary treatment for colorectal cancer in a clinically indicated surveillance program (e.g. ASCO, NCCN) provide a blood sample before the next clinically indicated surveillance scan/imaging or imaging has confirmed recurrence. Imaging documents recurrence.
62187278|NCT03137706||Ancillary-correlative (tissue stiffness analysis)|Patients undergo fresh tumor tissue collection at the time of surgery. The fresh tumor tissue samples are analyzed for tissue stiffness measurements using optical polarimeter device and cell viability using automated cell counter.
62187279|NCT03082898|EXPERIMENTAL|AIS A or B using Indego Exoskeleton|Patients with American Spinal Injury Association Injury Scale (AIS) A or B (non- ambulatory) will receive regular dosing of exoskeleton walking.
62187280|NCT03082898|EXPERIMENTAL|AIS C or D using Indego Exoskeleton|Patients with American Spinal Injury Association Injury Scale (AIS) C or D (Poorly ambulatory) will receive regular dosing of exoskeleton walking.
62187281|NCT04563598||ILI/ Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention (ILI), consented to administrative data linkages, and were successfully linked to Social Security Administration databases.
62187282|NCT04563598||DSE/Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education (DSE) control arm, consented to administrative data linkages, and were successfully linked to Social Security Administration databases.
62395505|NCT00993382|EXPERIMENTAL|Celivarone 300 mg|Celivarone, 300 mg once daily up to 10-15 days before the common study end date
62570643|NCT02550379|PLACEBO_COMPARATOR|Placebo|The placebo protocol consists of 3 phases, baseline, training, and test. The baseline phase consists of 45 trials which calculates the balance point at which the participant rates a face as 'happy' rather than 'disgusted' over a continuum of 15 faces ranging from happy through ambiguous to disgust. 3 training blocks are then administered with 30 trials per block. Behavioural feedback is given during training (correct/incorrect) based on the participant's balance point at baseline. A test phase is then administered which is identical to the baseline phase to reassess the participant's balance point. The task takes approximately 15 minutes to complete all 3 phases.
62777428|NCT06019377|EXPERIMENTAL|Intervention|The Intervention group receives the SYNC intervention in addition to typical child welfare services (i.e., services as usual). The SYNC intervention includes 10 weekly remote (videoconference) 90-minute sessions delivered by a facilitator and a near-peer young adult aged 20-26, both with lived experience in child welfare.
62777429|NCT06019377|NO_INTERVENTION|Services-as-usual|The Services-as-usual (SAU) group receives typical child welfare services, which include ILP, or federally funded transition planning (e.g., identifying and supporting youth education and employment goals) and life skills (e.g., budgeting, renting an apartment, insurance) services typically delivered through a mix of classes, group activities, and/or individual skill-building with a paraprofessional service provider.
62001890|NCT00594828|EXPERIMENTAL|1|6 months of supervised patient self testing using an expert system
62001891|NCT00594828|ACTIVE_COMPARATOR|2|6 months of routine medical care by the anticoagulation management service
62001892|NCT04787939|EXPERIMENTAL|Early Feeding Arm|Early Feeding Group
62187283|NCT03939481||Observational (non-study chemo, questionnaire, assessments)|Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52.
62395506|NCT00993382|ACTIVE_COMPARATOR|Amiodarone|Amiodarone, 600 mg once daily for 10 days (loading dose) then 200 mg once daily up to 10-15 days before the common study end date
62570644|NCT02550379|EXPERIMENTAL|Intervention|The ER training protocol consists of 3 phases, baseline, training, and test. The baseline phase consists of 45 trials which calculates the balance point at which the participant rates a face as 'happy' rather than 'disgusted' over a continuum of 15 faces ranging from happy through ambiguous to disgust. 3 training blocks are then administered with 30 trials per block. Behavioural feedback is given during training (correct/incorrect) based on the participant's balance point however this balance point is adjusted by 2 points on the 15 face continuum to train the participant to rate more faces as 'happy'. A test phase, identical to the baseline phase, is then administered to reassess the participant's balance point. The task takes approximately 15 minutes to complete all 3 phases.
62570645|NCT00470717|OTHER|Phone calling|Weekly telephone call. There are not two arms to the study. The primary intervention is phone calling weekly to assess ability to complete phone call and obtain feeding data.
62777430|NCT03450733||Previously Implanted (Group 1)|Subjects previously implanted with components of the Wright Medical Technology (WMT) Metal-on-Metal (MoM) Total Hip Arthroplasty (THA) System
62187284|NCT00974181|ACTIVE_COMPARATOR|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Conor Medsystems COSTAR™ stent loaded with the antiproliferative compound paclitaxel (10 µg), pre-mounted on a rapid exchange, percutaneous transluminal coronary angioplasty balloon catheter.
62395507|NCT00993382|PLACEBO_COMPARATOR|Placebo|Matching placebo once daily up to 10-15 days before the common study end date
62570646|NCT04402762|EXPERIMENTAL|TR treatment sequence|Period 1-Test Treatment: Ovine enoxaparin sodium 60 mg SC injection, manufactured by Metiska Farma. Period 2-Reference Treatment: Porcine enoxaparin sodium 60 mg SC injection (Lovenox), manufactured by Sanofi, France.
62777431|NCT03450733||Control (Group 2)|Control, non-implanted subjects
62777432|NCT03913494|EXPERIMENTAL|4 Week Snoozeal Use|Participants will take the device home and be required to use it for 20 minutes morning and night every day for at least 4 weeks. The SnooZeal records usage time to allow assessment of compliance.
62777433|NCT05368168|EXPERIMENTAL|Group 1: Posterior tibial nerve stimulation (PTNS)|Patients operated on at the Hospital Álvaro Cunqueiro for rectal neoplasia with anastomosis below 10 cm and who, after randomization, WILL BE treated with posterior tibial nerve stimulation.
62777434|NCT05368168|NO_INTERVENTION|Group 2: Standard of care|Patients operated on at the Hospital Álvaro Cunqueiro for rectal neoplasia with anastomosis below 10 cm and who, after randomization,WILL NOT BE treated with posterior tibial nerve stimulation.
62395508|NCT05638009|NO_INTERVENTION|Control|regular salt (99% sodium chloride)
62395509|NCT05638009|EXPERIMENTAL|Salt substitute 1|Salt substitute 1 is a potassium-enriched salt substitute composed of 66% potassium chloride and 33% sodium chloride
62395510|NCT05638009|EXPERIMENTAL|Salt substitute 2|Salt substitute 2 is a potassium-enriched salt substitute composed of 33% potassium chloride and 66% sodium chloride
62395511|NCT00766870|EXPERIMENTAL|1|
62395512|NCT00766870|EXPERIMENTAL|2|
62395513|NCT00766870|EXPERIMENTAL|3|
62395514|NCT00766870|OTHER|4|
62395515|NCT00766870|PLACEBO_COMPARATOR|5|
62570647|NCT04402762|ACTIVE_COMPARATOR|RT treatment sequence|Period 2-Reference Treatment: Porcine enoxaparin sodium 60 mg SC injection (Lovenox), manufactured by Sanofi, France. Period 1-Test Treatment: Ovine enoxaparin sodium 60 mg SC injection, manufactured by Metiska Farma.
62570648|NCT04553822|EXPERIMENTAL|Assisted autogenous drainage group (DAA)|The technique consists of positioning the patient in a supine position with the head slightly elevated on the supporting plane and then placing both hands around the rib cage and applying bimanual expiratory compression on both hemithoraxes.
62777435|NCT00968877|ACTIVE_COMPARATOR|Cholecalciferol|
62001893|NCT06075680|NO_INTERVENTION|Healthy|Periodontally healthy patients received no intervention.
62001894|NCT06075680|ACTIVE_COMPARATOR|Gingivitis|Gingivitis group received Non-Surgical Periodontal Treatment. They received Scaling and Root Planning procedure with ultrasonic scalers and hand curettes. The entire non-surgical periodontal treatment of gingivitis groups was completed in a total of 2 sessions in a week.
62001895|NCT06075680|ACTIVE_COMPARATOR|Stage III Grade C Periodontitis|Stage III Grade C group received Non-Surgical Periodontal Treatment. They received Scaling and Root Planning procedure with ultrasonic scalers and hand curettes. The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
62001896|NCT04623580||Inguinal or femoral hernia repair|All consecutive inguinal or femoral hernia repair (primary or mesh)
62001897|NCT01778166|ACTIVE_COMPARATOR|Standard early enteral nutrition|There would be 100 patients in this group
62570649|NCT04553822|EXPERIMENTAL|Group prolonged slow expiration (ELPr)|This technique is applied to the baby by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume.
62570650|NCT04553822|ACTIVE_COMPARATOR|Control group (CG)|Nebulization with 4 ml Muconeb® 3% hypertonic serum, for 8 minutes in a Philips® vibrating mesh nebulizer.
62001898|NCT01778166|EXPERIMENTAL|Immuno-enhanced early enteral nutrition|There would 100 patients in this group
62001899|NCT03717038|EXPERIMENTAL|Arm A (Sym004)|Sym004 will be administered as a loading dose of 9 mg/kg on Cycle 1 Day 1, followed by weekly doses of 6 mg/kg beginning Cycle 1 Day 8.
62001900|NCT03717038|ACTIVE_COMPARATOR|Arm B (TAS-102)|TAS-102 is commercially available and will be administered as per local prescribing instructions.
62001901|NCT03200782|PLACEBO_COMPARATOR|Placebo-Placebo|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
62001902|NCT03200782|ACTIVE_COMPARATOR|Investigational Drug A Empagliflozin|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an 10mg of empagliflozin 2 hours before the test meal will be administered by an independent nurse to the blinded patient
62001903|NCT03200782|ACTIVE_COMPARATOR|Investigational Drug B Anakinra|subcutaneous injection of 100mg anakinra 3 hours before the test meal and an oral placebo (winthrop tablet)before the test meal will be administered by an Independent nurse to the blinded patient
62001904|NCT06404203|EXPERIMENTAL|Royal Jelly 500 mg|30 volunteer
62001905|NCT06404203|EXPERIMENTAL|Royal Jelly 1000 mg|30 volunteer
62001906|NCT06404203|EXPERIMENTAL|Royal Jelly 1500 mg|30 volunteer
62001907|NCT06404203|PLACEBO_COMPARATOR|Placebo|30 volunteer
62570651|NCT01073605|ACTIVE_COMPARATOR|Genotonorm A|Continuous 0.7 IU/kg/week or 0.03 mg/kg/day
62570652|NCT01073605|ACTIVE_COMPARATOR|Genotonorm B|Continuous, 1.4 IU/kg/week or 0.06 mg/kg/day
62570653|NCT01073605|ACTIVE_COMPARATOR|Genotonorm C|Intermittent, 1.4 IU/kg/week or 0.06 mg/kg/day
62570654|NCT00643474|EXPERIMENTAL|A|
62570655|NCT00643474|EXPERIMENTAL|B|
62570656|NCT06292845|EXPERIMENTAL|Topical application of a fluorescent imaging agent|In this arm the investigators use the freshly resected human solid tumor specimens to assess the performance of topically applied fluorescent imaging agents for the detection of tumor tissue and close / tumor-positive resection margins ex vivo.
62570657|NCT02594293|NO_INTERVENTION|Controlled Group|Discontinue the NA treatment and follow up for 96 weeks
62001908|NCT04723433|EXPERIMENTAL|"Conservative O2 Supplementation"|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) between 90 and 94%.
62570658|NCT02594293|EXPERIMENTAL|Pegasys 48 weeks|Discontinue the NA treatment ,PegIFN alfa-2a 180 μg by week for 48 weeks and follow up for 48 weeks
62570659|NCT01323387|OTHER|Treatment|Interbody fusions with Anterior Plating
62187285|NCT00974181|ACTIVE_COMPARATOR|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Conor Medsystems COSTAR™ stent loaded with the antiproliferative compound paclitaxel (30 µg), pre-mounted on a rapid exchange, percutaneous transluminal coronary angioplasty balloon catheter.
62570660|NCT03793205|EXPERIMENTAL|Long-acting G-CSF group|Patients in long-acting G-CSF group accept long-acting with or without short-acting G-CSF.
62570661|NCT03793205|EXPERIMENTAL|Short-acting G-CSF group|Patients in long-acting G-CSF group only accept short-acting G-CSF.
62570662|NCT05486195|EXPERIMENTAL|SDI-118 Dose 1|
62777436|NCT00968877|PLACEBO_COMPARATOR|Placebo|
62001909|NCT04723433|ACTIVE_COMPARATOR|"Liberal O2 Supplementation"|Oxygen administration will titrated to an SpO2 \> 96%.
62187286|NCT04306146|EXPERIMENTAL|CAD-9303|Capsules of CAD-9303 will be administered as a single or multiple dose(s). The initial dose will be 3 mg up to 1000 mg total daily dose.
62187287|NCT04306146|PLACEBO_COMPARATOR|Placebo|Matching placebo will be provided in capsules and administered as a single or multiple dose(s).
62187288|NCT05785065|EXPERIMENTAL|Mycophenolate mofetil|2 to 4 capsules of mycophenolate mofetil twice daily.
62570663|NCT05486195|EXPERIMENTAL|SDI-118 Dose 2|
62570664|NCT05486195|EXPERIMENTAL|SDI-118 Dose 3|
62570665|NCT05486195|EXPERIMENTAL|SDI-118 Dose 4|
62570666|NCT05486195|EXPERIMENTAL|SDI-118 Dose 5|
62777437|NCT05458323|EXPERIMENTAL|Free near and distance glasses|All participants randomised to the intervention group will be provided with free near and/or distance spectacles based on the results of refraction. Glasses will be provided at the time of enrolment into the study. The participants will be asked to choose from an assortment of 20 frames. Participants will be asked to report to the study team member in case of any issue with spectacles or if spectacles are lost or broken. Replacement glasses will be provided in case of broken or lost spectacles whenever required. Participants will undergo annual eye exams and refraction, and change of glasses will be prescribed as needed.
62187289|NCT05785065|PLACEBO_COMPARATOR|Placebo|2 to 4 capsules of placebo twice daily.
62395516|NCT01995396|ACTIVE_COMPARATOR|APE with intersphincteric dissection|Abdominoperineal excision with intersphincteric dissection and a stoma is performed in patients with rectal cancer and fecal incontinence and/or severe co-morbidity
62001910|NCT06019416|EXPERIMENTAL|Intervention group|As the intervention group, the participants should participate in three weekly scheduled mindfulness-positive psychological intervention sessions using virtual reality for 15 - 20 minutes per session.
62395517|NCT01995396|ACTIVE_COMPARATOR|Hartmann´s procedure|Hartmann´s operation and stoma is performed in patients with rectal cancer and fecal incontinence and/or severe co-morbidity
62570667|NCT05486195|EXPERIMENTAL|SDI-118 Dose 6|
62570668|NCT05486195|PLACEBO_COMPARATOR|SDI-118 Placebo|
62570669|NCT00092118|EXPERIMENTAL|1|Montelukast
62570670|NCT00092118|PLACEBO_COMPARATOR|2|Placebo
62570671|NCT05914662|EXPERIMENTAL|Zanubrutinib, bendamustine, rituximab combination therapy Group|Patients were treated with ZBR regimen for 6 cycles, followed by zanubrutinib monotherapy for an additional 6 months.
62570672|NCT04138537|OTHER|Acromegaly group|CCCRC test and OB volume results
62570673|NCT04138537|OTHER|Control Group|CCCRC test and OB volume results
62570674|NCT02927236|EXPERIMENTAL|Cocaine - Active (EFS)|designed to implement the iTBS administration parameters established from P1 with a larger sample of treatment seeking CD participants. Though the schedule may change slightly based on the outcome of the pilot, a schedule of 3 daily iTBS sessions with a 20 minute interval between administrations is planned and used throughout the design.
62777438|NCT05458323|NO_INTERVENTION|Control-No treatment|All participants randomised to the control group will receive a prescription for spectacles and given free near and/or distance glasses as needed at study close out.
62777439|NCT00730548|EXPERIMENTAL|1|Remote Arm (OptiVol plus Connexus Telemetry plus CareLink plus Intervention Algorithm), Clinical Management Alerts ON
62777440|NCT00730548|NO_INTERVENTION|2|No Care Alerts available, standard treatment of the patient
62395518|NCT04298229|ACTIVE_COMPARATOR|Protocolized diuretic therapy|"The patients with diabetes will receive standard of care point of care blood glucose monitoring 4 times daily (before meals and at bedtime) and sliding scale insulin.~The initial loop diuretic regimen after enrollment:~Loop diuretic naïve: If the patient does not take a scheduled loop diuretic as an outpatient, the initial IV loop diuretic dose will be 40mg of furosemide equivalents every 12 hours.~Chronic, oral loop diuretic therapy: If the patient takes a scheduled loop diuretic regimen as an outpatient prior to hospital admission, the initial IV loop diuretic daily dose will be 2 times the total daily home regimen dose. Diuretic therapy will be titrated to goal urine output using a standardized diuretic protocol."
62395519|NCT04298229|EXPERIMENTAL|Protocolized diuretic therapy plus SGLT2 inhibitor therapy|"The patients with diabetes will receive standard of care point of care blood glucose monitoring 4 times daily (before meals and at bedtime) and sliding scale insulin.~The initial loop diuretic regimen after enrollment:~Loop diuretic naïve: If the patient does not take a scheduled loop diuretic as an outpatient, the initial IV loop diuretic dose will be 40mg of furosemide equivalents every 12 hours.~Chronic, oral loop diuretic therapy: If the patient takes a scheduled loop diuretic regimen as an outpatient prior to hospital admission, the initial IV loop diuretic daily dose will be 2 times the total daily home regimen dose. Diuretic therapy will be titrated to goal urine output using a standardized diuretic protocol.~The patient will receive SGLT2 inhibitor therapy with dapagliflozin 10 mg orally once daily until 5 days or hospital discharge."
62395520|NCT04916808||Ductal Carcinoma In Situ (DCIS)|Patients must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast without evidence of invasive cancer (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable).
62570675|NCT02927236|SHAM_COMPARATOR|Cocaine - Sham (EFS)|To test the efficacy of the iTBS.
62570676|NCT02927236|OTHER|Healthy Control-Main (EFS)|Population comparison of acute experimental iTBS.
62570677|NCT02927236|EXPERIMENTAL|Pilot|P1 is designed to establish safety and tolerability criteria for administering iTBS to treatment seeking cocaine users, initially as in-patient followed by an out-patient cohort
62777441|NCT02607111|EXPERIMENTAL|open label|Dalteparin injected as a bolus into the arterial port of the hemodialysis machine every dialysis session for four weeks
62777442|NCT01091441||Patients with heart failure|Patients hospitalized for acute heart failure
62777443|NCT03679026||CVRF|individuals with cardio-vascular risk factors and diseases
62777444|NCT03679026||WCVRF|individuals without cardio-vascular risk factors and diseases
62777445|NCT02849015|EXPERIMENTAL|Cryosurgery and NK immunotherapy|In this group, the patients will receive liver cryosurgery first to destroy big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62777446|NCT02849015|ACTIVE_COMPARATOR|Cryosurgery|In this group, the patients will receive liver cryosurgery to destroy big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62777447|NCT02927938|OTHER|Evaluable Cohort - Transplant Arm|"Other - Standard of Care Consolidation (HCT)~Enrolled subjects that will contribute to the population of subjects who are evaluable for the primary and secondary objectives. This will not include any subjects who end up in either observational cohort. To be included in the evaluable cohort, the subject must meet the following requirements:~1. Complete remission (CR1) from standard cytarabine or HMA-based induction therapy per standard clinical criteria (Cheson Criteria)~2. Have confirmed presence of CD34+CD38-ALDHint population by flow cytometry at the diagnostic LSC assay (LSC0)~3. Cytarabine-based induction subjects: Are candidates for (as determined by the investigator) and receive consolidation therapy (cytarabine-based chemotherapy or HCT); HMA-based induction subjects: Are candidates for (as determined by the investigator) and receive HCT"
62777448|NCT02927938|OTHER|Evaluable Cohort - Consolidation Chemo Arm|"Other - Standard of Care Consolidation (cytarabine-based chemo)~Enrolled subjects that will contribute to the population of subjects who are evaluable for the primary and secondary objectives. This will not include any subjects who end up in either observational cohort. To be included in the evaluable cohort, the subject must meet the following requirements:~1. Complete remission (CR1) from standard cytarabine or HMA-based induction therapy per standard clinical criteria (Cheson Criteria)~2. Have confirmed presence of CD34+CD38-ALDHint population by flow cytometry at the diagnostic LSC assay (LSC0)~3. Cytarabine-based induction subjects: Are candidates for (as determined by the investigator) and receive consolidation therapy (cytarabine-based chemotherapy or HCT)"
62791745|NCT02451514|EXPERIMENTAL|Naive Group|Subjects similar in age to subjects in the MenABCWY+OMV and MenACWY groups, who had not previously received any meningococcal vaccine and who received 2 doses of MenABCWY+OMV vaccine, 1 month apart (Day 1 and Day 31), in the current study.
62001911|NCT06019416|NO_INTERVENTION|Waitlist group|As the waitlist group, no treatment was given to the participants, while the intervention group participated in the mindfulness-positive psychological intervention for three weeks. After the three-week waiting period, the participants were contacted and asked to complete the post-measurements. After completion, the participants started with the three-week mindfulness-positive psychological intervention using virtual reality for 15 - 20 minutes. No further data was obtained from these participants after the completion of the program.
62001912|NCT04886011|PLACEBO_COMPARATOR|placebo gel|Methylcellulose gel was applied to the ulcer till complete healing
62001913|NCT04886011|EXPERIMENTAL|camel whey protein gel|camel whey protein dissolved in methycellulose gel was applied to the ulcer till complete healing
62001914|NCT05404269||Group AGC|The FLOW-i anesthesia machine (Maquet, Solna, Sweden) can be equipped with automated gas control (AGC), an automated low flow tool with target control of the inspired oxygen concentration (FIO2) and end-expired concentration (FA) of a potent inhaled anesthetic. İnitially before induction, we set the minimal fresh gas flow to 0.5 L min-1 and target end-expired agent concentration for 1 MAC (minimal alveolar concentration). Shortly after intubation of the patient, we switched to AGC mode.
62001915|NCT05404269||Group Minimal Flow|İn this group; following intubation, we set the fresh gas flow to 4 L min-1 and than we readjusted fresh gas flow manually to 0.5 L min-1 after sevoflurane concentration reaching to 1 MAC.
62001916|NCT05404269||Group Medium Flow|İn this group; following intubation, we set the fresh gas flow to 4 L min-1 and than we readjusted fresh gas flow manually to 2 L min-1 after sevoflurane concentration reaching to 1 MAC.
62001917|NCT01790464|PLACEBO_COMPARATOR|NS gauze|Standard airway anesthesia with 20 ml of aerosolized 2% lidocaine and peritonsillar instillation of gauze soaked in normal saline (Control Group)
62187290|NCT06544564|EXPERIMENTAL|Group 1- Membrane-Wrap Lite™ plus SOC|"Membrane-Wrap Lite™ plus SOC~Membrane- Wrap Lite™: is a human tissue allograft derived from amniotic membrane that provide structural tissue for use as a wound and protectant covering. It is a single-layer human tissue allograft, containing solely the amnion layer of Amniotic Membrane \[Human Cellular and Tissue Based Product (HCT/P)\] for transplantation regulated by the US Food and Drug Administration under 21 CFR Part 1271. Group will receive the assigned biologic plus Compression treatment per Wound Healing Society guidelines Compression for treatment of Venous Ulcers SOC treatment"
62187291|NCT06544564|EXPERIMENTAL|Group 2- CT-Shield™ plus SOC|"CT-Shield™ plus SOC- CT Shield™: is a human tissue allograft derived from the amniotic membrane that provides protection, coverage and shielding for connective tissue. It is a triple-layered human tissue allograft, containing amnion-chorion-amnion layers \[Human Cellular and Tissue Based Product (HCT/P)\] for transplantation regulated by the US Food and Drug Administration under 21 CFR Part 1271. Group will receive the assigned biologic plus Compression treatment per Wound Healing Society guidelines Compression for treatment of Venous Ulcers SOC treatment"
62187292|NCT06544564|EXPERIMENTAL|Group 3: Membrane Wrap™ plus SOC|"Group 3: Membrane Wrap™ plus SOC- Membrane Wrap™: is a human tissue allograft derived from the amniotic membrane that provides structural tissue for use as a wound and protectant covering. It is a human tissue allograft \[Human Cellular and Tissue Based Product (HCT/P)\] for transplantation regulated by the US Food and Drug Administration under 21 CFR Part 1271.Group will receive the assigned biologic plus Compression treatment per Wound Healing Society guidelines Compression for treatment of Venous Ulcers SOC treatment"
62001918|NCT01790464|ACTIVE_COMPARATOR|Lidocaine gauze|20 ml of aerosolized 2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
62570678|NCT00321698|EXPERIMENTAL|Phase I Dose 1-4|"Group 1=radiation only; Group 2=Docetaxel IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=Docetaxel IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=Docetaxel IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
61977834|NCT03752359|EXPERIMENTAL|whey protein group|Participants received a dose of 35 grams of whey protein after resistance training (RT). Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
62001919|NCT01563068|EXPERIMENTAL|Calcipotriene Foam|Calcipotriene foam 0.005% administered under maximal-use conditions to adolescent patients with plaque psoriasis
62001920|NCT04449367||Randomized and Single-Arm Trials|a sham comparator (no intervention)
62001921|NCT02761811|EXPERIMENTAL|Renal Sympathetic Denervation|Percutaneous renal denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator.
62001922|NCT02761811|SHAM_COMPARATOR|Masked Procedure|Percutaneous renal artery angiography
62001923|NCT00413725|EXPERIMENTAL|1|Three doses of MRKAd5 HIV-1 gag/pol/nef vaccine
62001924|NCT00413725|PLACEBO_COMPARATOR|2|Placebo
62001925|NCT00993096|EXPERIMENTAL|IDegAsp low|
62001926|NCT00993096|EXPERIMENTAL|IDegAsp middle|
62001927|NCT00993096|EXPERIMENTAL|IDegAsp high|
62001928|NCT00993096|EXPERIMENTAL|BIAsp 30 low|
62187293|NCT06544564|EXPERIMENTAL|Group 4: Membrane Wrap - Hydro™ plus SOC|"Group 4: Membrane Wrap - Hydro™ plus SOC- Membrane Wrap Hydro™: is a human tissue allograft derived from the amniotic membrane that provides structural tissue for use as a wound and protectant covering. It is a saline-hydrated human tissue allograft \[Human Cellular and Tissue Based Product (HCT/P)\] for transplantation regulated by the US Food and Drug Administration under 21 CFR Part 1271. Group will receive the assigned biologic plus Compression treatment per Wound Healing Society guidelines, Compression for treatment of Venous Ulcers SOC treatment"
62187294|NCT06544564|OTHER|Group 5: SOC only|"Group 5: Standard of Care only- Subjects randomized to Group 5 (SOC, or Active Control treatment) will not receive Biologic, but will receive SOC alone. SOC) is defined as: Compression treatment per Wound Healing Society guidelines, Compression for treatment of Venous Ulcers \[10\].~SOC, or Active Control treatment, is defined as: 1) debridement of non-viable, necrotic tissue, 2) application of a primary, wound contact dressing that maintains moisture balance, 3) application of a Class 3 high compression system, and 4) wrapping with a covering, tertiary dressing. A Class 3 (most supportive) high-compression system is required. High compression bandages provide and maintain high levels of compression pressures in the range 25-35 mm Hg at the ankle. High strength compression can be applied successfully using many methods including multilayered elastic compression, inelastic compression, Unna's boot, compression stockings, and other."
62187295|NCT01449786|EXPERIMENTAL|treatment with rMal d 1|these apple and birch pollen allergic patients are treated with daily sublingual application of 25µg recombinant Major apple allergen, Mal d 1 during 4 months
62187296|NCT01449786|ACTIVE_COMPARATOR|treatment with rBet v 1|These apple and birch pollen allergic patients are treated with daily sublingual application of 25µg recombinant Major birch pollen allergen,Bet v 1 during 4 months
62187297|NCT01449786|PLACEBO_COMPARATOR|treatment with placebo drops|These apple and birch pollen allergic patients are treated daily with placebo applied sublingually during 4 months
62187298|NCT04073797|EXPERIMENTAL|Stable CVD - treatment|Stable CVD with LDL ≥2.6 despite maximally tolerated statins ± other lipid lowering therapies, randomised to add on therapy with inclisiran + placebo tablet
62187299|NCT04073797|ACTIVE_COMPARATOR|Stable CVD - placebo control|Stable CVD with LDL ≥2.6 despite maximally tolerated statins ± other lipid lowering therapies, randomised to placebo injection + colchicine tablet
62777449|NCT02927938|NO_INTERVENTION|Observational Cohort 1|Enrolled subjects who do not achieve a CR to induction therapy, regardless of diagnostic phenotype. Following completion of induction therapy and remission bone marrow aspirate, if a subject is determined to not have achieved a complete remission to induction therapy, he or she would be included in observational cohort 1.
62187300|NCT04073797|PLACEBO_COMPARATOR|HeFH - treatment|Stable CVD with LDL ≥2.6 despite maximally tolerated statins ± other lipid lowering therapies, randomised to placebo injection + placebo tablet
62187301|NCT02549417|EXPERIMENTAL|KHK7580|
62777450|NCT02927938|NO_INTERVENTION|Observational Cohort 2|"Enrolled subjects who achieve a CR to induction therapy but meet one or more of the following criteria:~* Lack the immunophenotype of interest,~* Cytarabine based induction subjects: Are not candidates for \[as determined by the investigator (e.g. unfit or refusal)\] and do not receive consolidation therapy (cytarabine-based chemotherapy or HCT)~* HMA-based induction subjects: Are not candidates for \[as determined by the investigator (e.g. unfit, lack of donor, refusal)\] and do not receive HCT~Final investigator determination of fit-ness can occur at any time until the start of consolidation therapy.~HMA-based induction subjects will not receive consolidation cytarabine-based chemotherapy as part of the evaluable cohort if they do not receive HCT."
62777451|NCT03729245|EXPERIMENTAL|Combination of bempegaldesleukin + nivolumab|Patients in Arm A will receive bempegaldesleukin in combination with nivolumab.
62777452|NCT03729245|ACTIVE_COMPARATOR|sunitinib or cabozantinib|Patients in Arm B will receive the Investigator's choice of either one of two treatment options.
62777453|NCT05733078|PLACEBO_COMPARATOR|Control / Crossover|"The patients in control group will have a oral rehydration effervescent tablet to take with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks.~Crossover: After first 12 weeks, the control group will then be provided vitamin C (intervention) effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks to see if there is any difference on biochemical testing or clinical scores."
62777454|NCT05733078|EXPERIMENTAL|Intervention|The patient in test group will be provided vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The patients who wish to continue at the end of 12 weeks will be provided another 12 weeks supply of vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for with thyroid function tests and clinical score assessed at the end of week 24.
62777455|NCT00164515|NO_INTERVENTION|Arm 1: Physical activity awareness|The awareness group received a physician-recommendation to exercise an informational brochure, and pedometer.
62001929|NCT00993096|EXPERIMENTAL|BIAsp 30 middle|
62187302|NCT01473992|ACTIVE_COMPARATOR|Prosthetic knee 1 (Otto Bock C-Leg)|This arm included unilateral transfemoral amputees who were assessed while using their preferred knee at study start(C-Leg). The Otto Bock C-Leg is a microprocessor knee using 2 sensors (1 for kinetics and 1 for kinematics).
62777456|NCT00164515|EXPERIMENTAL|Arm 2: Lower Support|The lower support group received arm 1 plus monthly newsletter, weekly personalized exercise support via telephone.
62777457|NCT00164515|EXPERIMENTAL|Arm 3: Higher support|The higher support group received arm 1 plus arm 2 plus a face-to-face monthly exercise support group.
62777458|NCT01720238||Group 1|Entecavir Therapy
62187303|NCT01473992|ACTIVE_COMPARATOR|Prosthetic knee 2 (Otto Bock Genium)|This arm included unilateral transfemoral amputees who were assessed while using the experimental/study knee, the Genium. The Otto Bock Genium is a microprocessor knee using multiple sensors that hypothetically increase mobility functions (e.g. walking backwards, intuitive stance)
62187304|NCT01473992|NO_INTERVENTION|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
62187305|NCT02573545|EXPERIMENTAL|Test group: with IFE|Patients treated with IFE software
62584880|NCT06581523|EXPERIMENTAL|Individual with Parkinson's Disease|The intervention is the Sudarshan Kriya Yoga or SKY Breath and Meditation Practice. This will be taught over a 10-12 hour period, 2.25 hours for 4 early mornings. The participants will practice 6 days a week (a 35-45 minute practice)for a total of 8 weeks.
62777459|NCT01720238||Group 2|Lamivudine plus Adefovir Dipivoxil Therapy
62777460|NCT00567411|ACTIVE_COMPARATOR|I|Eyes receiving Apraclonidine 0.5% (Iopidine) prior to SLT
62001930|NCT00993096|EXPERIMENTAL|BIAsp 30 high|
62187306|NCT02573545|ACTIVE_COMPARATOR|Test group: without IFE|Patients treated with Numaris 4 software
62187307|NCT01772823|EXPERIMENTAL|3MV Behavioral Intervention Group|3MV Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
62187308|NCT01772823|EXPERIMENTAL|PCC Behavioral Intervention Group|PCC Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
62187309|NCT02699736||Cohort I|Enrolled from August 1994. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count \< 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
62777461|NCT00567411|ACTIVE_COMPARATOR|A|Eyes receiving Brimonidine 0.1% (Alphagan) prior to SLT
62777462|NCT02832024|ACTIVE_COMPARATOR|Intervention: Stents|Stents group
62777463|NCT02832024|ACTIVE_COMPARATOR|Intervention: Atherectomy|Direct Atherectomy group
62777464|NCT02832024|ACTIVE_COMPARATOR|Intervention: Balloon|Balloon group
62777465|NCT03689855|EXPERIMENTAL|Ramucirumab + Atezolizumab|"* Ramucirumab will be given intravenously over the course of an hour on an outpatient basis on Day 1 of each 21-day cycle at a dose of 10 mg/kg.~* Atezolizumab will be given intravenously on an outpatient basis on Day 1 of each 21-day cycle at a dose of 1200 mg."
62777466|NCT01700712|ACTIVE_COMPARATOR|L. reuteri (DSM 17938 and ATCC PTA 5289; 1x108 CFU|2 tablets a day for 2 weeks
62777467|NCT01700712|PLACEBO_COMPARATOR|Sugar pill|2 tablets a day for 2 weeks
62777468|NCT05597332|OTHER|Intervention|Insertion of care bundle in the electronic medical record of patients who develop AKI.
62777469|NCT06421922|ACTIVE_COMPARATOR|Group 1-regular constipation diet|Group 1 received a regular constipation diet (n=21)
62777470|NCT06421922|ACTIVE_COMPARATOR|Group 2-soluble fiber|group 2 received a constipation diet rich in soluble fiber (n=17)
62001931|NCT06336369||Cases|"Cases: (Gilbert-Syndrom):~* Total bilirubin in the blood \> 1.2 mg/dL (17.1 μM)~* Unconjugated (indirect bilirubin) \> 1 mg/dL"
62001932|NCT06336369||Controls|"Controls (non-Gilbert-Syndrom):~* Total bilirubin in the blood ≤ 1.2 mg/dL (17.1 μM)~* Unconjugated (indirect bilirubin) ≤ 1 mg/dL"
62777471|NCT06421922|ACTIVE_COMPARATOR|Group 3-probiotic yogurt|group 3 received a constipation diet with added probiotic yogurt (n=22).
62777472|NCT06014099|EXPERIMENTAL|Midline catheter|The test group2 used MC for blood collection.
62001933|NCT05857124|EXPERIMENTAL|Active treatment devices|Vielight Neuro RX Gamma active device
62001934|NCT05857124|SHAM_COMPARATOR|Sham devices|Vielight Neuro RX Gamma sham device
62001935|NCT02627859|EXPERIMENTAL|Durolane SJ|Durolane SJ intra-articular injection; device
62001936|NCT06439979|EXPERIMENTAL|RAYS Intervention|The RAYS arm is the intervention being tested, which will include skin cancer prevention education and providing participants with sun-safety supplies.
62001937|NCT06439979|NO_INTERVENTION|Control|The Control arm of the study will not receive any skin cancer prevention information or sun-safety materials but will only receive general injury prevention information.
62777473|NCT06014099|EXPERIMENTAL|Long peripheral venous catheters|In the test 1 group, blood was collected using LPC.
62777474|NCT06014099|OTHER|short peripheral venous catheters|In the control group,blood was collected using SPC.
62777475|NCT05169060|EXPERIMENTAL|Fish oil capsules|Subjects will be randomized for the treatment of fish oil capsules. Subjects will take daily supplements of two or four fish oil capsules per day, 2 and 4 g respectively. Treatment will continue for 16 weeks. Fish oil capsules are enriched in omega-3 polyunsaturated fatty acids.
62777476|NCT05169060|EXPERIMENTAL|Fish oil and Salsalate|Salsalate is a non-steroid anti-inflammatory drug. Subjects taking 2 or 4g of fish oil capsules will be randomized to take in addition 1.5 or 3.0 g of salsalate per day. The combined treatment of fish oil and salsalate will continue for 8 weeks.
62777477|NCT03275038|NO_INTERVENTION|Control group|Maintain the original life style
62777478|NCT03275038|EXPERIMENTAL|Tai-Chi exercise group|Receive three one-hour Tai Chi exercise sessions weekly for 24 weeks, supervised for the first 12 weeks and unsupervised for the next 12 weeks
62777479|NCT03275038|EXPERIMENTAL|Aerobic exercise group|Receive three one-hour aerobic exercise sessions weekly for 24 weeks, supervised for the first 12 weeks and unsupervised for the next 12 weeks
62777480|NCT04086992|NO_INTERVENTION|Control Group|This group will continue to receive standard care for ACTH monitoring and follow-up with includes blood pressure by the patient's PCP while on therapy, a one week nursing follow-up phone call, and a two-week EEG and Neurology appointment.
62001938|NCT06466174|ACTIVE_COMPARATOR|Placebo 1 to Probiotic A|Sequence A1 (n=25): Placebo 1 administered daily for 42 days, followed by 21 days washout, then 1 x 10\^9 colony forming units (CFU) of Probiotic A administered daily for 42 days
62001939|NCT06466174|ACTIVE_COMPARATOR|Placebo 2 to Probiotic B|Sequence B1 (n=25): Placebo 2 administered daily for 42 days, followed by 21 days washout and 42 days Probiotic formula: containing 1 x 10\^9 CFU of Probiotic B administered daily
62001940|NCT06466174|ACTIVE_COMPARATOR|Probiotic A to Placebo 1|Sequence A2 (n=25): 1 x 10\^9 CFU of Probiotic A administered daily for 42 days, followed by 21 days washout, then Placebo 1 administered daily for 42 days
62570679|NCT00321698|EXPERIMENTAL|Phase II MTD Dose|"Phase II with no phase I dose-limiting toxicities=Docetaxel IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
62570680|NCT06578481|EXPERIMENTAL|SLPS Group|Scapular and lumbopelvic stabilization group
62570681|NCT06578481|ACTIVE_COMPARATOR|CS group|Cervical stabilization group
62777481|NCT04086992|EXPERIMENTAL|Intervention Group|This group will be provided remote monitoring technology where they will be able to monitor blood pressure at home. In addition, they will receive a nurse-led telemedicine visit at one week and three weeks of therapy. Like the control group, they will still receive a two-week EEG and Neurology appointment.
62777482|NCT01496755|PLACEBO_COMPARATOR|Placebo|
62777483|NCT01496755|EXPERIMENTAL|RG7667|
62777484|NCT06530771||Malignant thyroid nodules|
62777485|NCT06530771||Benign thyroid nodules|
62777486|NCT05469139||Portable MRI group|Patients on ECMO who undergo portable MRI to assess brain injury within 24-48 hours of ECMO initiation
62777487|NCT01439373|EXPERIMENTAL|GSK2336805|Study Part 1
62777488|NCT01439373|PLACEBO_COMPARATOR|Placebo|Study Part 1
62777489|NCT01439373|EXPERIMENTAL|GSK2336805 + pegylated interferon alfa-2a + ribavrin|Study Part 2
62777490|NCT01439373|ACTIVE_COMPARATOR|Placebo + pegylated interferon alfa-2a + ribavirin|Study Part 2
62001941|NCT06466174|ACTIVE_COMPARATOR|Probiotic B to Placebo 2|Sequence B2 (n=25): 1 x 10\^9 CFU of Probiotic B administered daily for 42 days, followed by 21 days washout and 42 days Placebo 2 administered daily for 42 days
62001942|NCT04383821|EXPERIMENTAL|Double-Trunk Mask|The oxygen delivery system is the DTM
62187310|NCT02699736||Cohort II|Enrolled from January 1996. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count \< 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
62187311|NCT02699736||Cohort III|Enrolled from February 1997. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count \< 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
62187312|NCT02699736||Cohort IV|Enrolled from March 1999. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). The eligibility criteria of a cluster of differentiation 4 (CD4) count \< 500 cells/µL within the last 5 months before inclusion has been removed for patients joining the study in 1999 and beyond, since the intention of the study is to include most patients eligible for antiretroviral therapy. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
62187313|NCT02699736||Cohort V|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
62395521|NCT04457310|EXPERIMENTAL|CVL-562 (PF-06412562) 1 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
62395522|NCT04457310|EXPERIMENTAL|CVL-562 (PF-06412562) 4 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
62777491|NCT05964543|EXPERIMENTAL|Phase Ib: Dose escalation Q-1802+XELOX,|"According to 3+3 design, a dose of Q-1802 with two dose groups from low to high and one cycle fixed-dose XELOX will be given in DLT observation period. After DLT observation period, Q-1802+XELOX will be given by investigator,s decision until the subject meets study treatment discontinuation criteria."
62777492|NCT05964543|PLACEBO_COMPARATOR|Phase II: Q-1802 + XELOX Vs XELOX ;|Phase II:Participants will be randomized to group A and B. Group A:receive a dose of Q-1802 at Cycle 1 Day 1 followed by a same dose in subsequent cycles every 2 weeks. Additionally, participants will receive XELOX (capecitabine/oxaliplatin) treatment until investigator confirmed disease progression or a total of 8 treatments (each cycle is defined as approximately 21 days). Oxaliplatin is administered on day 1 of each cycle, whereas capecitabine is taken twice daily on days 1 through 14. After a maximum of 8 treatments of Oxaplatin, subjects may continue to receive Q-1802 a every 2 weeks each cycle and capecitabine every 3 weeks at the investigator's discretion until the subject meets study treatment discontinuation criteria. Group B:Participants will receive XELOX (capecitabine/oxaliplatin) treatment alone until a total of 8 treatments (each cycle is defined as approximately 21 days). subjects may continue to receive capecitabine every 3 weeks at the investigator's discretion.
62777493|NCT05628909|EXPERIMENTAL|Silicone oil group|Patients randomized into this group were received pars plana vitrectomy surgery with silicone oil tamponade and without internal limiting membrane peeling. And silicone oil tamponade was removed at least 12 months after the primary surgery with completely resolved of foveoschisis.
62570682|NCT05741801||health care professionals|Hospital healthcare professionals who use, or help implement, deteriorating patient/sepsis alerts in NHS trusts.
62777494|NCT05628909|ACTIVE_COMPARATOR|Gas group 1|Patients randomized into this group were received pars plana vitrectomy surgery with fovea-sparing internal limiting membrane peeling and gas tamponade.
62001943|NCT04383821|ACTIVE_COMPARATOR|Non-Rebreather Mask|The oxygen delivery system is the NRM
62001944|NCT06131515|EXPERIMENTAL|Group A (experimental group)|This group includes 34female patients who will receive extra corporeal shock wave therapy one session per week for 4 weeks in addition to physical therapy exercises (including carpal bone mobilization, nerve glide skin care and manual lymph drainage 2 sessions per week for 4 weeks.
62187314|NCT02699736||Cohort VI|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
62187315|NCT02699736||Cohort VII|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
62187316|NCT02699736||Cohort VIII|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
62187317|NCT02699736||Cohort IX|Enrolled from December 2011. Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
62395523|NCT04457310|EXPERIMENTAL|CVL-562 (PF-06412562) 15 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
62395524|NCT04457310|EXPERIMENTAL|CVL-562 (PF-06412562) 25 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
62777495|NCT05628909|ACTIVE_COMPARATOR|Gas group 2|Patients randomized into this group were received pars plana vitrectomy surgery with gas tamponade and without internal limiting membrane peeling.
62777496|NCT01701934|EXPERIMENTAL|Roflumilast|Roflumilast 500 mcg, once daily for 6 months
62777497|NCT01701934|PLACEBO_COMPARATOR|Placebo pill|Placebo pill, once daily for 6 months
62777498|NCT05755984|EXPERIMENTAL|Arm 1: 3D printed model|a 3-D printed model of your breast will be created and discussed with participants during your surgical consultation.
62777499|NCT05755984|NO_INTERVENTION|Arm 2: No 3D printed model|Participants will have a standard-of-care surgical consultation using traditional breast imaging.
62777500|NCT00448305|EXPERIMENTAL|1|EndoTAG-1 + Paclitaxel
62777501|NCT00448305|EXPERIMENTAL|2|EndoTAG-1
62777502|NCT00448305|ACTIVE_COMPARATOR|3|Paclitaxel
62777503|NCT04863651||Securely Attached Parturients|Parturients who have a secure attachment style according to the Revised Adult Attachment Scale (Collins, 1996)
62777504|NCT04863651||Insecurely Attached Parturients|Parturients who have an insecure attachment style according to the Revised Adult Attachment Scale (Collins, 1996)
62777505|NCT01803022||Low Molecular Weight Heparin|
62777506|NCT01894438|NO_INTERVENTION|Control Group|This arm will receive written general advice for a healthy lifestyle.
62791746|NCT04778826|ACTIVE_COMPARATOR|Lung Lobectomy with standard ipsilateral lymphadenectomy|Lung lobectomy with ipsilateral lymphadenectomy
62001945|NCT06131515|EXPERIMENTAL|Group B (control group)|This group includes 34female patients who will receive shame extra corporeal shock wave therapy one session per week for 4 weeks in addition to physical therapy exercises (including carpal bone mobilization, nerve glide exercises, skin care and manual lymph drainage 2 sessions per week for 4 weeks.
62187318|NCT02699736||Cohort X|All patients should be consecutive patients (except those already enrolled in EuroSIDA), or patients who had a scheduled visit (i.e. those who made an appointment \>2 weeks prior to their visit) in the outpatient clinic regardless of cluster of differentiation 4 (CD4) cell count and ART status). Enroll patients of 16 years or older and positive for antibodies against hepatitis C virus (regardless of HCV-RNA status, fibrosis stage and prior treatment against hepatitis C). For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
62187319|NCT02699736||Cohort XI|"HIV-1 positive persons ≥18 years of age, not already enrolled in EuroSIDA, are eligible for inclusion. Participants should be enrolled consecutively in one of the following two groups:~1. Participants who have started integrase inhibitor (INSTI) based antiretroviral therapy (ART) after 1/1/2012 and have a CD4 cell count and HIV-RNA available in the 12 months prior to starting INSTI or within 3 months after starting INSTI~2. If participants have not started INSTI, they should be included providing they have a CD4/HIV-RNA in the 12 months prior to baseline or within 3 months after baseline.~For all patients enrolled and under follow up, laboratory, therapeutic, clinical and demographic data, date on pregnancy and data on hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually."
62395525|NCT04457310|PLACEBO_COMPARATOR|Placebo|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
62777507|NCT01894438|EXPERIMENTAL|Mediterranean Diet Group|Mediterranean Diet Group participants will attend a comprehensive program,focusing on Mediterranean diet, comprising of seven 60-min group counseling sessions, conducted every two weeks for the first 2 months and every month for the following 4 months, until the 6-month evaluation.
62187320|NCT03729713|EXPERIMENTAL|Intervention|Computerized Cognitive Rehabilitation
62777508|NCT01894438|EXPERIMENTAL|Mediterranean Lifestyle Group|Mediterranean Lifestyle Group participants will attend a comprehensive program,focusing on Mediterranean lifestyle, comprising of seven 60-min group counseling sessions, conducted every two weeks for the first 2 months and every month for the following 4 months, until the 6-month evaluation.
62777509|NCT02195167|EXPERIMENTAL|Dasotraline|"Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg. The language should precede the text that is currently there"
62187321|NCT03729713|SHAM_COMPARATOR|Placebo|Video game
62187322|NCT02196805|EXPERIMENTAL|1|
62187323|NCT02196805|EXPERIMENTAL|2|
62187324|NCT01434680|EXPERIMENTAL|MenC-CRM LIQ (Liquid Formulation)|Subjects received 1 injection of MenC-CRM vaccine,liquid formulation.
62187325|NCT01434680|EXPERIMENTAL|MenC-CRM ROS (Rosia)|Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy
62187326|NCT01434680|ACTIVE_COMPARATOR|MenC-CRM EMV (Emeryville)|Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA
62187327|NCT03238807|EXPERIMENTAL|Intervention Group|Group that will receive intrauterine injection of human Chorionic Gonadotropin before ET
62187328|NCT03238807|NO_INTERVENTION|Control Group|Control Group
62187329|NCT01061190|ACTIVE_COMPARATOR|Propranolol|
62777510|NCT05347303|EXPERIMENTAL|Experimental group|The experimental group (EG) after taking initial measurements and signing their informed consent will be subjected to an 8-week intervention plan with 2 sessions per week where they will receive 1 MTOH and 1 Foam roller on discontinuous days. MTOH consists of first evaluating the structures that have restrictions, whether soft tissues or joints, to later be treated with a specific manual technique. For this, evaluation methods based on Kaltenborn are used when it comes to joints and Pilat when focusing on soft tissues. Interventions will not exceed 20 minutes per subject. For the foam roller, subjects will perform slides on the instrument using their body weight on the following muscles: quadriceps, hamstrings, gastrocnemius, and tensor fascia lata, for 60 seconds with 3 repetitions for each. Each repetition will have a rest period of 30 seconds, this will be done on both lower limbs.
62001946|NCT03086785|EXPERIMENTAL|apatinib|apatinib 500mg qd po or combined Capecitabine 1000mg/m2 bid d1-d14 q3w
62001947|NCT02696356|EXPERIMENTAL|Cohort 1|0.1mg GRN-1201
62187330|NCT01061190|PLACEBO_COMPARATOR|Placebo|
62187331|NCT05140681|EXPERIMENTAL|apical group|FibReORS with apically flap positioning 2 mm below the bone crest (apical group)
62187332|NCT05140681|ACTIVE_COMPARATOR|Crestal group|FibReORS with apically flap positioning at the level of bone crest (crestal group).
62187333|NCT02077725||Interdisciplinary polypharmacy clinic|Patients will be seen in the interdisciplinary polypharmacy clinic for a complete comprehensive medication review
62187334|NCT03780010|EXPERIMENTAL|TRC105 + B + P + C|TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
62777511|NCT05347303|ACTIVE_COMPARATOR|Control group|After taking measurements, they will perform 2 foam roller sessions per week following the same indications expressed in the experimental group.
62777512|NCT01940627|EXPERIMENTAL|Ubiquinol|Firemen consuming 200 mg ubiquinol/day during two weeks
62777513|NCT01940627|PLACEBO_COMPARATOR|Control|Firemen consuming placebo capsules during two weeks
62777514|NCT00881465|EXPERIMENTAL|Cognitive-behavioral therapy|Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks. The first session will be held face-to-face to foster rapport. Sessions 1-4 will be held twice weekly; thereafter sessions will be held weekly. Sessions 1-3 are devoted to psychoeducation, treatment discussion, and hierarchy development. Sessions 4-10 involve CBT exercises specific to each youth.
62777515|NCT00881465|PLACEBO_COMPARATOR|Waitlist|Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
62001948|NCT02696356|ACTIVE_COMPARATOR|Cohort 2|1.0mg GRN-1201
62001949|NCT02696356|EXPERIMENTAL|Cohort 3|3.0mg GRN-1201
62001950|NCT02066012||group DIOS|group DIOS composed of subjects with dysmetabolic hepatosiderosis
62001951|NCT02066012||group M|group M composed of subjects with metabolic syndrom without iron overload
62001952|NCT02066012||group T|group T composed of lean subjects
62001953|NCT03884621|EXPERIMENTAL|EHP Group|The Enhanced post-discharge home-based care program (EHP) offers one coaching session upon hospital discharge and 12-week home follow-up (including 6 home visits, 6 telephone calls and 24-hour hotline) post hospital discharge to participants by an especially trained nurse case manager with the support of a clinical team. The five intervention protocols integrate with an individualized home-based rehabilitation training and self-care plan.
62001954|NCT03884621|NO_INTERVENTION|Control Group|Usual discharge care and post-discharge care provided to all stroke patients discharged home.
62187335|NCT03448536|EXPERIMENTAL|Naproxen Sodium : Acetaminophen|Subjects received one single oral dose of 440 mg naproxen sodium in treatment period 1, followed by one single oral dose of 1000 mg acetaminophen in treatment period 2
62187336|NCT03448536|EXPERIMENTAL|Acetaminophen : Naproxen Sodium|Subjects received one single oral dose of 1000 mg acetaminophen in treatment period 1, followed by one single oral dose of 440 mg naproxen sodium in treatment period 2
62187337|NCT00803777|EXPERIMENTAL|Intended Users of the Monitoring System|Subjects with type 1 diabetes and healthcare professionals (HCP) used a new blood glucose monitoring system (BGMS) with subject capillary blood. Any subject under age 18 was accompanied by a parent or guardian, who assisted subject if applicable.
62187338|NCT04231162|EXPERIMENTAL|probiotic powder, Bifidobacterium lactis|
62187339|NCT04231162|PLACEBO_COMPARATOR|Placebo|
62187340|NCT02361398|EXPERIMENTAL|EIT group|the Individualized PEEP titration by EIT was administered to the patients in the EIT group.
62001955|NCT04838314|NO_INTERVENTION|Standard of cares|Peri operative analgesia by opioids
62001956|NCT04838314|EXPERIMENTAL|regional analgesia|Peri operative analgesia by continuous bilateral ESP catheters
62001957|NCT00886210|ACTIVE_COMPARATOR|1LC with drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
62001958|NCT00886210|ACTIVE_COMPARATOR|2LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. no drain at the end of operation.
62187341|NCT02361398|NO_INTERVENTION|control group|If patients are assigned to the control group, the Individualized PEEP Setting was by PEEP-FiO2 table based on ARDS-net protocol.
62187342|NCT01517087||1|neurologically normal, healthy adults, age 35 or older.
62187343|NCT00987883||Malnutrition cohort|The patients with undernutrition
62187344|NCT00987883||Well nourished cohort|Patient that well nourished and without undernutrition
62187345|NCT04678908|EXPERIMENTAL|HB0025|HB0025 IV every 2 weeks (q2w)
62187346|NCT05401383||Group A|fasting from solids (6 hours before) and clear fluids (2 hours before the exam)
62187347|NCT05401383||Group B|Lumevis intake (50 ml), 30 minutes before the exam plus fasting as group A
62187348|NCT06183983|OTHER|Extended MRI group|In this group, patients with a glioblastoma undergo an extended MRI-scan prior to radiotherapy.
62187349|NCT04256369||Primary Cohort|Starting premixed Olimel N9E and follow for electrolyte irregularities.
62187350|NCT02788071|EXPERIMENTAL|FMT capsules|FMT capsules
62187351|NCT02788071|PLACEBO_COMPARATOR|FMT placebo|Placebo capsules
62187352|NCT06120647||Sarcopenic obesity|Age: 70-80 years Men, ALM/W \< 25.7 %, body fat % \> 35 Women, ALM/W \< 19.7 %, body fat % \> 40
62187353|NCT06120647||Non-sarcopenic obese|Age: 70-80 years Men, ALM/W \> 25.7 %, body fat % \> 35 Women, ALM/W \> 19.7 %, body fat % \> 40
62187354|NCT06120647||Non-sarcopenic lean|Age: 70-80 years Men, ALM \> 7.0 kg/m2, body fat % \< 25 Women, ALM \> 5.5 kg/m2, body fat % \< 32
62187355|NCT06120647||Young lean|Age: 18-40 years Men, ALM \> 7.0 kg/m2, body fat % \< 25 Women, ALM \> 5.5 kg/m2, body fat % \< 32
62187356|NCT01313169|EXPERIMENTAL|EMR reminder|EMR reminder
62187357|NCT01313169|EXPERIMENTAL|EMR reminder + Panel management|EMR reminder + Panel manager
62187358|NCT01313169|NO_INTERVENTION|Control|Control
62187359|NCT00565071|OTHER|Field microscopy|Field microscopy is the main method of malaria diagnosis
62001959|NCT01940120|EXPERIMENTAL|High Risk Registry Arm|Includes patients with a predicted procedural mortality of 12% or higher. The high risk registry arm of the study is powered to show superiority of safety of treatment with the MitraClip compared to mitral valve surgery. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip implant.
62001960|NCT03712475|EXPERIMENTAL|Phudialin Hard Capsules|Phudialin Hard Capsules Dosing Regimen: Single dosing
62001961|NCT03712475|ACTIVE_COMPARATOR|Lyrica Hard Capsule|Lyrica Hard Capsule Dosing Regimen: Single dosing
62001962|NCT00833924|OTHER|1|Treatment with Endovascular Graft
62001963|NCT02790346|EXPERIMENTAL|arthrodesis talonavicular|arthrodesis talonavicular in addition to tendon gestures
62001964|NCT02790346|ACTIVE_COMPARATOR|tendon gestures|tendon gestures only
62001965|NCT05811624|EXPERIMENTAL|Experimental Intervention|Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.
62001966|NCT05811624|ACTIVE_COMPARATOR|Control Intervention|Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.
62001967|NCT05430828||Group 1|Subjects with hyperlipidaemia under PCSK9 inhibitors treatment (Repatha/Praulent).
62001968|NCT00617682|ACTIVE_COMPARATOR|Group 1|Group 1 (experimental)
62001969|NCT00617682|PLACEBO_COMPARATOR|Group 2|Group 2 (placebo comparator)
62187360|NCT00565071|OTHER|Paracheck Pf® device|Paracheck Pf® device (Rapid Diagnostic Test) is the main method for malaria diagnosis
62187361|NCT00565071|NO_INTERVENTION|Presumptive diagnostic method|
62187362|NCT02247843|EXPERIMENTAL|βAS3-FB vector transduced peripheral blood CD34+ cells|This is a single arm study without randomization. All subjects will receive the intervention of BetaAS3 lentiviral vector-modified autologous peripheral blood stem cell transplant.
62187363|NCT01993849|ACTIVE_COMPARATOR|N-Acetylcysteine (NAC)|Oral N-acetylcysteine 1200 mg twice daily dosing for 8 weeks
62187364|NCT01993849|PLACEBO_COMPARATOR|Placebo|Oral placebo (matched in appearance to active treatment) twice daily dosing for 8 weeks
62187365|NCT03993275||Patients with Stroke|30 Patients suffering a stroke will be included in the study. After clinical measurements of balance, gait, trunk control and cognition, patients will train 2-3 times a week for on average 4 weeks with the MindMotion GO system. Afterwards, clinical measures will be repeated.
62187366|NCT03993275||Patients with Multiple Sclerosis|50 Patients suffering multiple sclerosis will be included in the study. After clinical measurements of balance, gait, trunk control and cognition, patients will train 2-3 times a week for on average 3 weeks with the MindMotion GO system. Afterwards, clinical measures will be repeated.
62187367|NCT01390142|EXPERIMENTAL|Control|
62187368|NCT01390142|ACTIVE_COMPARATOR|RIPer|Remote ischemic preconditioning
62187369|NCT01390142|ACTIVE_COMPARATOR|RIPer + IPost|Remote ischemic preconditioning and Local ischemic postconditioning
62570683|NCT05741801||ex-patients/survivors and family members/carers|Ex-patients recruited from NHS trusts and other charities, who have previously had sepsis or family members of patients who have had sepsis.
62570684|NCT01657721|NO_INTERVENTION|Wait-list Control|"Participants randomized to this group will not undergo The Cogmed Working Memory Training Program during the 5 week period, but will receive weekly phone calls from a member of the research team to review progress and advice on general time management, organization, and mnemonic strategies.~After a 5-week period, participants in this arm will have access to the working memory training."
62395526|NCT00142207|ACTIVE_COMPARATOR|1|Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine
62001970|NCT00789282|ACTIVE_COMPARATOR|Usual Care Group|The 'usual care' study arm (control) will reflect current patterns of care for patients with thpe 2 diabetes in the Capital Health region
62395527|NCT00142207|ACTIVE_COMPARATOR|2|Device: Insecticide-treated mosquito bed net
62395528|NCT00142207|ACTIVE_COMPARATOR|3|"Combination of Drug + Device:~Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine Device: Insecticide-treated mosquito bed net"
62395529|NCT05425082|ACTIVE_COMPARATOR|Motor relearning program|"Emphasis of MRP is on practice of specific activities, the training of cognitive control over muscles \& movement. Components of activities \& conscious elimination of unnecessary muscle activity.• Based on 3 factors -~1. Elimination of unnecessary muscle activity~2. Feedback~3. Practice"
62395530|NCT05425082|EXPERIMENTAL|Neurodevelopmental therapy|"The abnormal patterns must be stopped not by modifying the sensory input, but by giving back to the patient the • The hemiplegic side should be incorporated into all treatment activities to reestablish symmetry and increased functional use~* Treatment should produce a change in the quality of movement and functional performance of the involved side~* Increase active use of the involved side~* Provide practice to improve motor performance that led to motor learning lost or undeveloped control over his output in developmental sequence"
62395531|NCT01621763|EXPERIMENTAL|Clopidogrel|Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited
62395532|NCT01621763|ACTIVE_COMPARATOR|Plavix|Clopidogrel Tablet 300 mg
62570685|NCT01657721|EXPERIMENTAL|15 Minute Training|Participants will receive a low intensity version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 15 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
62570686|NCT01657721|EXPERIMENTAL|30 Minute Training|Participants will receive the standard-length version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 30 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
62570687|NCT00577746||surgery|Those subjects who went to surgery for treatment for their lung cancer.
62570688|NCT00577746||no surgery|The subjects who did not go to surgery for treatment of their lung cancer.
62395533|NCT05604976|EXPERIMENTAL|SC-PCI|Primary PCI is initiated with a universal guiding catheter (Ikari left). The guiding catheter is used to contrast the left and right coronary arteries and PCI is started directly. This method does not require a catheter exchange. It is Single Catheter PCI (SC-PCI) method.
62570689|NCT00683618|EXPERIMENTAL|1|Rosuvastatin 5mg qd
62570690|NCT00683618|EXPERIMENTAL|2|Rosuvastatin 10mg qd
62001971|NCT00789282|EXPERIMENTAL|Enhanced Care Group|In the enhanced care group(intervention arm) the participants will receive a multifactorial intervention with three main components that include: optimized medical management, 2) support for development of enhanced patient self management skills, and 3) organized proactive follow-up by chronic disease management teams to support improvement in care.
62001972|NCT01448018|ACTIVE_COMPARATOR|ranibizumab|patients in this arm receive 3 monthly injection of ranibizumab
62001973|NCT01448018|ACTIVE_COMPARATOR|Hemodilution|hemodilution using erythrocytapheresis is performed as early as possible after inclusion, in order to lessen hematocrit level (target hematocrit of 35%)
62001974|NCT01448018|ACTIVE_COMPARATOR|ranibizumab and hemodilution|patients receive both treatments
62570691|NCT00683618|ACTIVE_COMPARATOR|3|Atorvastatin 10mg qd
62570692|NCT04968080||Full Analysis Set|Participants will have their temperature collected by infrared thermal camera (IRT), oral, forehead, and ear thermometers.
62777516|NCT04858282|EXPERIMENTAL|shared decision-making group (SDMG)|Receiving mobile application( BC-SDM)
62187370|NCT00565266|EXPERIMENTAL|"Tio + 1xICS || LABA + 1xICS || 2xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~* tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~* salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~* beclomethasone dipropionate 160 mcg twice daily (2xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
62187371|NCT00565266|EXPERIMENTAL|"TIO + 1xICS || 2xICS || LABA + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~* tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~* beclomethasone dipropionate 160 mcg twice daily (2xICS)~* salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
62187372|NCT00565266|EXPERIMENTAL|"LABA + 1xICS || Tio + 1xICS || 2xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~* salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~* tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~* beclomethasone dipropionate 160 mcg twice daily (2xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
62395534|NCT05604976|ACTIVE_COMPARATOR|Conventional|Primary PCI is initiated with a diagnostic catheter. The catheter is used to contrast one of the coronary arteries. Then, the catheter is replaced with a contralateral side diagnostic catheter. Then, the catheter is replaced with a guiding catheter and PCI is started.
62395535|NCT04883905||Patients with AHP|Patients with a diagnosis of AHP will be eligible for the study and will be managed and treated per routine clinical practice.
62395536|NCT06723223|EXPERIMENTAL|Eligible patients|
62570693|NCT00425750|EXPERIMENTAL|Treatment|"Docetaxel (40 mg/m2) IV Infusion over 30 minutes every 3 weeks (Day 1 and 8 of 21 day cycle)except the first dose is held on Day 1 of Cycle 1.~Bortezomib (1.6mg/m2) IV 3-5 second push every 3 weeks (Day 1 and 8 of 21 day cycle).Bortezomib is given as a single agent only on Day 1 of Cycle 1."
62001975|NCT03775668|EXPERIMENTAL|1 µCi of 14C-AAI101 + 500 mg AAI101|14C-AAI101 + 500 mg AAI101 iv infusion
62001976|NCT04683185|EXPERIMENTAL|Cohort 2: E6742 200 mg or Placebo|Participants will receive E6742 200 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.
62001977|NCT04683185|EXPERIMENTAL|Cohort 3: E6742 400 mg or Placebo|Participants will receive E6742 400 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.
62001978|NCT04683185|EXPERIMENTAL|Cohort 1: E6742 100 milligram (mg) or Placebo|Participants will receive E6742 100 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.
62001979|NCT02489747|EXPERIMENTAL|WBE group|wheat bran extract
62001980|NCT02489747|PLACEBO_COMPARATOR|Placebo group|placebo
62001981|NCT00569686|ACTIVE_COMPARATOR|1|treatment with lovaza
62001982|NCT00569686|PLACEBO_COMPARATOR|2|
62001983|NCT00915798||Smokers with ADHD|Smokers with ADHD participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
62001984|NCT00915798||Nonsmokers with ADHD|Nonsmokers with ADHD participated in one condition.
62001985|NCT00915798||Control smokers|Control smokers participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
62001986|NCT00915798||Control nonsmokers|Control nonsmokers participated in one condition.
62001987|NCT00534690|OTHER|1|
62001988|NCT00534690|OTHER|2|
62001989|NCT06424886|EXPERIMENTAL|Video Instructed Training Group|Before the study is conducted, the expert video that will be used for the VI group instructions will be created. The expert video will be created with an athlete with a LESS score of less than 4 and an FPPA of less than 100 who performs a DVJ task in accordance with the instructions. A video recording will be taken of the person designated as an expert performing the DVJ task. The video recording will be used only for the VI group instructions.
62001990|NCT06424886|EXPERIMENTAL|Verbal Combined Focus Instructed Training Group|"It was emphasized that the participants should jump from the 30 cm high box and immediately after landing, jump as high and forward as possible and maintain the final landing stance for 5 seconds. Participants were asked to perform 5 drop vertical jumps and the jumps performed were evaluated. After pretest evaluations were recorded, verbal training group participants performed two training blocks, receiving instructions specific to their group. Participants were given a combined verbal instruction such as Focus on how hard you push yourself off the ground after the jump and how quickly you straighten your knees during this push, in which internal and external focus directions were given simultaneously. After receiving the instructions, the participants performed 2 drop vertical jumps, 10 times each."
62001991|NCT06424886|EXPERIMENTAL|Control Group|Participants will be explained how to do the DVJ task in the same way as other groups. Then, after the participants' measurements will be taken, they will start the training blocks without any instructions. Participants will not receive any feedback during training blocks.
62001992|NCT05811611|EXPERIMENTAL|WeChat Mini Program plus tailored online promotion videos|"1. Having access to a WeChat Mini Program providing HIV and STI prevention information during the project period~2. The WeChat Mini Program proactively asks questions assessing sexual risk behaviors at Month 0 and Month 1, and invite participants two watch online health promotion videos tailored to their sexual risk behaviors status."
62570694|NCT00753285|EXPERIMENTAL|Renal Denervation|
62187373|NCT00565266|EXPERIMENTAL|"LABA + 1xICS || 2xICS || Tio + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~* salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~* beclomethasone dipropionate 160 mcg twice daily (2xICS)~* tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
62187374|NCT00565266|EXPERIMENTAL|"2xICS || Tio + 1xICS| || LABA + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~* beclomethasone dipropionate 160 mcg twice daily (2xICS)~* tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~* salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
62187375|NCT00565266|EXPERIMENTAL|"2xICS || LABA + 1xICS || Tio + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~* beclomethasone dipropionate 160 mcg twice daily (2xICS)~* salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~* tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
62187376|NCT00902902||1|
62187377|NCT00902902||2|
62187378|NCT02198976||Barrett's Oesophagus|Patients with Barrett's Oesophagus with either high grade dysplasia (HGD) or intramucosal cancer (IMC)
62187379|NCT00336817|ACTIVE_COMPARATOR|Myfortic Group|Subjects in the Myfortic arm will receive Myfortic 360mg or 720 mg BID for 90 days
62187380|NCT00336817|ACTIVE_COMPARATOR|CellCept Group|Subjects in the CellCept arm will receive CellCept 500mg or 1000mg BID for 90 days
62395537|NCT05986292|EXPERIMENTAL|LY3016859 Osteoarthritis ISA|Participants are randomized to receive either active LY3016859 or matching placebo
62395538|NCT05986292|EXPERIMENTAL|LY3016859 Diabetic Neuropathic Pain ISA|Participants are randomized to receive either active LY3016859 or matching placebo
62570695|NCT04390490|NO_INTERVENTION|control|Automatic chemiluminescence analyzer will be used for dectecting the concentration of cardiac troponin I as control group.
62777517|NCT04858282|NO_INTERVENTION|usual care group (UCG)|Receiving material health education
62777518|NCT02725866||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
62777519|NCT06197763|EXPERIMENTAL|Fontan participants|Participants will be randomized to be treated with either colesevelam (625 mg tablets - 3 tables twice per day) or placebo (3 tablets twice per day) for 6 weeks, interspersed by 8 week of washout time.
62777520|NCT06197763|SHAM_COMPARATOR|Healthy control participants|These healthy control participants will be comparators to the randomized Fontan participants. Healthy controls will only undergo the baseline visit and will not receive the investigational drug or placebo.
62777521|NCT06175013|EXPERIMENTAL|Group 1 : Sérum Mycose des ongles PURIFIANT|Participant will apply Sérum PURIFIANT on the affected toenail, twice daily during the 112 days of the study.
62777522|NCT06175013|EXPERIMENTAL|Group 2 : Sérum Mycose des onglesPURIANT associated with Sérum Mycose des ongles BOOSTER|"Participant will apply Sérum PURIFIANT on the affected toenail, twice daily during the 112 days of the study.~They will also apply Sérum BOOSTER, twice weekly before the Sérum PURIFIANT."
62001993|NCT05811611|ACTIVE_COMPARATOR|WeChat Mini Program Only|Having access to a WeChat Mini Program providing HIV and STI prevention information during the project period
62001994|NCT04488328|EXPERIMENTAL|Magnetic Therapy Group|patients received the routine medical treatment (Bisphosphonates, Calcium, and Vitamin D) in addition to pulsed magnetic therapy on the pelvic region for 12 weeks
62001995|NCT04488328|EXPERIMENTAL|Exercise group|patients received the routine medical treatment in addition to moderate-intensity aerobic exercise for 12 weeks
62187381|NCT00184379|EXPERIMENTAL|1 S+E|Relatives of patients with schizophrenia, who receive education
62187382|NCT00184379|NO_INTERVENTION|2 S-E|Relatives of patients with schizophrenia, who do not receive education
62187383|NCT00184379|EXPERIMENTAL|3 B+E|Relatives of patients with bipolar disorder, who receive education
62187384|NCT00184379|NO_INTERVENTION|4 B-E|Relatives of patients with bipolar disorder, who do not receive education
62187385|NCT00666198||SILDENAFIL|Patients taking SILDENAFIL.
62395539|NCT05986292|EXPERIMENTAL|LY3016859 Chronic Back Pain ISA|Participants are randomized to receive either active LY3016859 or matching placebo
62395540|NCT05986292|EXPERIMENTAL|LY3556050 Osteoarthritis ISA|Participants are randomized to receive either active LY3556050 or matching placebo
62395541|NCT05986292|EXPERIMENTAL|LY3556050 Diabetic Neuropathic Pain ISA|Participants are randomized to receive either active LY3556050 or matching placebo
62570696|NCT04390490|EXPERIMENTAL|Photoelectrochemical immunosensor|Photoelectrochemical immunosensor will be used for dectecting the concentration of cardiac troponin I as test group.
62001996|NCT04488328|EXPERIMENTAL|Combined Magnetic Therapy and Exercise Therapy group|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks
62570697|NCT04729829|ACTIVE_COMPARATOR|FAD + SBC|Community will be exposed to increased availability of fish from a fish aggregating device and will receive information and messaging as part of a social and behaviour change communication about consuming fish.
62570698|NCT04729829|ACTIVE_COMPARATOR|FAD only|Community will be exposed to increased availability of fish from a fish aggregating device only
62570699|NCT04729829|ACTIVE_COMPARATOR|SBC only|Community will receive information and messaging as part of a social and behaviour change communication about consuming fish.
62570700|NCT04729829|NO_INTERVENTION|Control|Control (No FAD or SBC)
62570701|NCT05252572|EXPERIMENTAL|Treatment of CLL1-positive Hematological Malignancies|Administration of CLL1 CAR T-cells A dose levels of 2-8\*10E6/kg are administrated for each subject.
62570702|NCT04399616|EXPERIMENTAL|Experimental|"The intervention consists of the availability in the patient's medical history of the visual risk map. The patients in the intervention group will have a risk map in their medical history similar to the one presented in image (annex 2), and any care provider will have immediate access to this map which we think will help them to prioritize the implementation of the relevant practices. safe (in relation to the areas that appear in red).~Areas of risk:~Other independent variables will be the areas of risk:~* Identification of the patient~* Functional autonomy and quality of life~* Caregiver~* Safe management and use of medicines~* Risk of falls~* Risk of injuries and pressure ulcers~* Symptom control~* Risk of infection associated with health care~* Patient and family values and beliefs~* Social risk~* Unplanned hospital admissions / proactive monitoring~* Continuity of care 7X24 h~* Transfers (between care levels)~* Safety culture~* Nursing work environment"
62570703|NCT04399616|NO_INTERVENTION|No intervention|The patients in the control group will have in their medical records the usual records of the comprehensive geriatric assessment.
62570704|NCT05730075||Phase 1 HBCC providers|This group will include up to 9 Spanish-speaking HBCC providers, who will receive the Spanish version of the provider questionnaire.
62777523|NCT03134690|EXPERIMENTAL|delayed start antagonist|60 women with poor ovarian responses undergo ovarian stimulation with delayed start antagonist.
62187386|NCT02276638||18-28 years old Non-pathologic|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
62395542|NCT05986292|EXPERIMENTAL|LY3556050 Chronic Back Pain ISA|Participants are randomized to receive either active LY3556050 or matching placebo
62395543|NCT05986292|EXPERIMENTAL|LY3526318 Osteoarthritis ISA|Participants are randomized to receive either active LY3526318 or matching placebo
62395544|NCT05986292|EXPERIMENTAL|LY3526318 Diabetic Neuropathic Pain ISA|Participants are randomized to receive either active LY3526318 or matching placebo
62395545|NCT05986292|EXPERIMENTAL|LY3526318 Chronic Back Pain ISA|Participants are randomized to receive either active LY3526318 or matching placebo
62777524|NCT03134690|EXPERIMENTAL|conventional antagonist|60 women with diagnose of poor ovarian response will have undergone ovarian stimulation with conventional antagonist protocol.
62395546|NCT05986292|EXPERIMENTAL|LY3857210 Osteoarthritis ISA|Participants are randomized to receive either active LY3857210 or matching placebo
62395547|NCT05986292|EXPERIMENTAL|LY3857210 Diabetic Neuropathic Pain ISA|Participants are randomized to receive either active LY3857210 or matching placebo
62395548|NCT05986292|EXPERIMENTAL|LY3857210 Chronic Back Pain ISA|Participants are randomized to receive either active LY3857210 or matching placebo
62570705|NCT05730075||Phase 1 families|This group will include up to 9 Spanish speaking families and up to 9 English speaking families who will each receive the family questionnaire and who will participate in cognitive interviews.
62570706|NCT05730075||2 HBCC providers|This group will include 150 purposively selected providers from diverse backgrounds who will each complete the provider questionnaire and will also be asked to recruit one or more families to complete the family questionnaire.
62570707|NCT05730075||Phase 2 families|This group will include up to 150 purposively selected families who will each receive the family questionnaire.
62570708|NCT00961571|EXPERIMENTAL|sunitinib and cepecitabine|Administration of sunitinib and capecitabine
62570709|NCT01010529|EXPERIMENTAL|occupational therapy|
62570710|NCT01010529|NO_INTERVENTION|No occupational therapy|Patients and their caregivers in the control group will have no occupational therapy intervention until their last measurement has taken place (3 months).
62570711|NCT00301119||lung cancer screening cohort|observational only. no intervention. current, former and never smokers over age 50 without history of cancer, except for non melanoma skin cancer, no previous treatment with chemotherapy.
62570712|NCT00301119||r/o lung cancer|observational only. no intervention. patients with CT findings suspicious for lung cancer who are undergoing bronchoscopy and/or surgery.
62570713|NCT03225105|EXPERIMENTAL|M3541 50 mg + RT|Participants received 50 milligrams (mg) M3541 orally once per fraction day (FD) in combination with palliative radiotherapy (RT) administered in fraction of 30 Gray (Gy) given in 10 fractions of 3 Gy/FD on FD 1 to FD 10, for 2 consecutive calendar weeks (ie, Monday through Friday, with the intervening Saturday and Sunday as M3541 / RT holidays).
62777525|NCT01854281||Patent foramen ovale dive A group|Divers with a previously diagnosed patent foramen ovale observed after Dive A.
62777526|NCT01854281||Closure dive A group|Divers with a patent foramen ovale previously closed by a catheter-based procedure observed after Dive A.
62187387|NCT02276638||29-80 years old Non-pathologic|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
62187388|NCT02276638||29-80 years old pathological|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
62395549|NCT03569241|OTHER|MDT + ADT|Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + 6 months androgen deprivation therapy
62395550|NCT03569241|EXPERIMENTAL|MDT + WPRT + ADT|Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + whole pelvic radiotherapy + 6 months androgen deprivation therapy
62395551|NCT01461187|EXPERIMENTAL|exercise in pregnancy|37 pregnant women who performed supervised aerobic physical exercises twice a week
62395552|NCT01461187|NO_INTERVENTION|Control group|29 pregnant women who had not performed any kind of physical activity during pregnancy
62395553|NCT01705665||Aspirated Coronary Thrombi During AMI|
62395554|NCT05704933|EXPERIMENTAL|Pre-Surgery Nivolumab + Ipilimumab|Patients will be given one dose of Nivolumab (1mg/kg IV) and Ipilimumab (3mg/kg IV) prior to standard of care surgery for tumor resection.
62777527|NCT01854281||patent foramen ovale dive B group|Divers with a previously diagnosed patent foramen ovale observed after Dive B.
62777528|NCT01854281||closure dive B group|Divers with a patent foramen ovale previously closed by a catheter-based procedure observed after Dive B.
62777529|NCT03083678|EXPERIMENTAL|Afatinib|Afatinib active treatment.
62777530|NCT05188131|EXPERIMENTAL|Intravenous Infusion of Diclofenac Sodium|Intravenous Infusion of Diclofenac Sodium in healthy subjects.
62777531|NCT05188131|PLACEBO_COMPARATOR|Intravenous Infusion of Placebo|Intravenous Infusion of Placebo (isotonic saline) in healthy subjects.
62777532|NCT03244826|EXPERIMENTAL|Shared Care|"* For the first 90 days, patients alternate between local oncologist and DFCI for weekly visits.~* From 90 to 180 days, patients alternate between local and DFCI every 2-3 weeks.~* Shared Care include the following~  * Formal Care Coordination Plan~ * Patient Engagement and Education~ * Local Oncologist Engagement and Education~ * Patient/Local Oncologist/Transplant Oncologist Web Portal"
62777533|NCT03244826|OTHER|Usual Care|"* Patients receive all follow-up care at DFCI only, which is currently the Standard Care.~* Majority of routine visits in first 180 days will be at DFCI."
62395555|NCT05704933|EXPERIMENTAL|Pre-Surgery Nivolumab + Relatlimab(Opdualag)|Patients will be given one dose of Opdualag (Nivolumab 480 mg IV + Relatlimab160 mg IV), prior to standard of care surgery for tumor resection.
62001997|NCT01828034|EXPERIMENTAL|Gemcitabine, Cisplatin and MEK162|Phase I component of the study, a classic 3+3 cohort dose escalation scheme will be used to identify the MTD of MEK162 when administered with gemcitabine at dose 800 mg/m2 and cisplatin given at dose 20 mg/m2 week 2 \& 3 of a 3 week cycle. The final cohort will receive gemcitabine 1000mg/m2 and cisplatin 20mg/m2 week 2 and 3 of a 3 week cycle in combination with MEK162 at the MTD as determined above. In the phase II part of the study, patients will receive MEK162 at the MTD dose plus gemcitabine and cisplatin at the dose level determined acceptable in the phase I portion. In the phase II part of the study, patients will receive MEK162 at 45mg BID plus gemcitabine (800 mg/m2) and cisplatin (20 mg/m2) as determined by the phase I portion.
62001998|NCT03800498|EXPERIMENTAL|Intervention|For twelve weeks, only intervention group were given DASH education
62395556|NCT03023124|EXPERIMENTAL|Trabectedin|trabectedin: 1.5 mg/m² - 1.3 mg/m² given in 24-hour continuous infusion every 21 days for 6 cycles
62395557|NCT03023124|EXPERIMENTAL|Adriamycin and Dacarbazine|Adriamycin: 75 mg/m2/day, bolus, day 1 every 21 days for 6 cycles Dacarbazine: 400 mg/m2/day, days 1, 2 every 21 days for 6 cycles
62395558|NCT05171686|EXPERIMENTAL|Diuretic augmentation|The participant's blood pressure medication regimen will be altered to initiate a thiazide-type or loop diuretic in those not already prescribed a diuretic, or to increase the dose if one is already prescribed.
62395559|NCT06395441|EXPERIMENTAL|Group I (Western ginseng)|Patients receive Western ginseng PO BID on days 1-56. Treatment continues in the absence of disease progression or unacceptable toxicity.
62395560|NCT06395441|PLACEBO_COMPARATOR|Group II (placebo)|Patients receive placebo PO BID on days 1-56. Treatment continues in the absence of disease progression or unacceptable toxicity.
62395561|NCT00784225|EXPERIMENTAL|Vitamin E + selenium placebo|vitamin E and selenium placebo daily for 7-12 years
62395562|NCT00784225|EXPERIMENTAL|Selenium + vitamin E placebo|selenium and vitamin E placebo daily for 7-12 years
62395563|NCT00784225|EXPERIMENTAL|Vitamin E + selenium|vitamin E and selenium placebo daily for 7-12 years
62395564|NCT00784225|PLACEBO_COMPARATOR|Vitamin E placebo + selenium placebo|vitamin E placebo and selenium placebo daily for 7-12 years
62395565|NCT06521632|EXPERIMENTAL|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulators. Electrical stimulation is given for 2 hours
62395566|NCT06521632|NO_INTERVENTION|Control|Electrodes are placed at acupoints but no electrical stimulation is given
62395567|NCT00121251|EXPERIMENTAL|Sorafenib + Gemcitabine + Capecitabine|Patients receive sorafenib\* PO BID on days 1-21, gemcitabine IV over 30 minutes on days 1 and 8, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for at least 3 courses in the absence of unacceptable toxicity or disease progression.
62395568|NCT06580548|EXPERIMENTAL|CHW-supported telerehabilitation|
62395569|NCT06580548|ACTIVE_COMPARATOR|Usual care|
62395570|NCT06165341|EXPERIMENTAL|Fazirsiran 200 mg|Participants will receive fazirsiran 200 milligrams (mg), injection, subcutaneously on Day 1, at Week 4 and then every 12 weeks (Q12W) for up to Week 100.
62395571|NCT06165341|PLACEBO_COMPARATOR|Placebo|Participants will receive fazirsiran matching placebo injection, subcutaneously on Day 1, at Week 4 and Q12W for up to Week 100.
62395572|NCT06036407|EXPERIMENTAL|Participants|Participants make an appointment at a hearing aid shop in Switzerland. They get the results right after the hearing test and may take it to their respective physician if wanted.
62395573|NCT05766631|ACTIVE_COMPARATOR|Methadone Treatment-as-Usual|Participants randomized to the Methadone Treatment-as-Usual (TAU) Condition will receive treatment-as-usual at the community methadone clinics, which will include daily medication, individual and group addiction counseling, and outpatient or intensive outpatient behavioral health services, depending on the clinic and the needs of the patient. After randomization into the TAU arm, participants will complete the program's psychosocial and medical intake, methadone dose induction and adjustment, and provide urine tests and receive medication take-homes per the program's policies and methadone treatment regulations.
62570714|NCT03225105|EXPERIMENTAL|M3541 100 mg + RT|Participants received 100 mg M3541 orally once per FD in combination with palliative RT administered in fraction of 30 Gray (Gy) given in 10 fractions of 3 Gy/FD on FD 1 to FD 10 for 2 consecutive calendar weeks (ie, Monday through Friday, with the intervening Saturday and Sunday as M3541 / RT holidays).
62570715|NCT03225105|EXPERIMENTAL|M3541 200 mg + RT|Participants received 200 mg M3541 orally once per FD in combination with palliative RT administered in fraction of 30 Gray (Gy) given in 10 fractions of 3 Gy/FD on FD 1 to FD 10 for 2 consecutive calendar weeks (ie, Monday through Friday, with the intervening Saturday and Sunday as M3541 / RT holidays).
62777534|NCT03244826|OTHER|Non-Randomized|Patients receive all follow-up care at DFCI only (Standard Care).
62777535|NCT06143033|EXPERIMENTAL|DIME Beauty Luminosity Eye Serum|Participants will use the serum twice daily after their morning and evening skincare routine (i.e., after cleansing, and applying facial serums and moisturizers), but before the application of sunscreen.
62777536|NCT02053961|ACTIVE_COMPARATOR|1Hz dTMS Real|This group will receive dTMS real treatment of 1Hz
62570716|NCT03225105|EXPERIMENTAL|M3541 300 mg + RT|Participants received 300 mg M3541 orally once per FD in combination with palliative RT administered in fraction of 30 Gray (Gy) given in 10 fractions of 3 Gy/FD on FD 1 to FD 10 for 2 consecutive calendar weeks (ie, Monday through Friday, with the intervening Saturday and Sunday as M3541 / RT holidays).
62001999|NCT03800498|NO_INTERVENTION|Controlled|Controlled group not received DASH education
62777537|NCT02053961|SHAM_COMPARATOR|1HZ dTMS SHAM|This group will receive 1HZ dTMS SHAM treatment
62777538|NCT02706587|EXPERIMENTAL|Neuromuscular electrical stimulation|NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
62777539|NCT02706587|SHAM_COMPARATOR|Sham Control|No electrostimulation
62777540|NCT02790424|EXPERIMENTAL|Patients|Imaging devices
62777541|NCT05544149|EXPERIMENTAL|TRT|Patients with es-SCLC after first line treatment with immune checkpoint inhibitors will be treated with thoracic radiotherapy.
62777542|NCT03342625|EXPERIMENTAL|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound for the treatment of breast tumors, guided by MRI
62777543|NCT01769820|ACTIVE_COMPARATOR|Dexamethasone|Study 1, and study2(2 arms); Dexamethasone 1.5mg daily Study 3 (adaptive -7 arms): Dexamethasone of 0.4, 0.8, 1.0, 1.2, 1.5, and 1.8 mg total dose per day
62777544|NCT01769820|PLACEBO_COMPARATOR|Placebo|Placebo
62777545|NCT02126839|PLACEBO_COMPARATOR|Placebo MDPI QID|Placebo multidose dry powder inhaler (MDPI) administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 3 weeks.
62777546|NCT02126839|EXPERIMENTAL|Albuterol MDPI 180 mcg QID|Albuterol multidose dry powder inhaler (MDPI) 90 mcg/inhalation administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for a total daily dose of 720 mcgs for 3 weeks.
62002000|NCT03304899|EXPERIMENTAL|Case group|"Severe isolated Traumatic Brain injury patients with serum fibrinogen level under 200 mg/dl that receive Fibrinogen concentrate after common emergency resuscitation. Instruction:~1. Airway control \& breathing.~2. Circulation (Serum therapy, Epinephrine,Packed cell, FFP and ...).~3. Fibrinogen Concentrate(IV injection): Each vial contains 1gr fibrinogen concentrate. Fibrinogen concentrate will be given until serum fibrinogen level riches to 200 mg/dl.~Dose (mg/kg body weight) = (\[Target level (mg/dL) - measured level (mg/dL)\])/(1.7 (mg/dL per mg/kg body weight))"
62002001|NCT03304899|ACTIVE_COMPARATOR|Control group|"Severe isolated Traumatic Brain injury patients with serum fibrinogen level under 200 mg/dl that receive common emergency resuscitation. Instruction:~1. Airway control \& breathing.~2. Circulation (Serum therapy, Epinephrine,Packed cell, FFP and ...)."
62584881|NCT06581523|EXPERIMENTAL|Care Partner of Individual with Parkinson's Disease|The intervention is the Sudarshan Kriya Yoga or SKY Breath and Meditation Practice. This will be taught over a 10-12 hour period, 2.25 hours for 4 early mornings. The participants will practice 6 days a week (a 35-45 minute practice)for a total of 8 weeks.
62777547|NCT02936284|EXPERIMENTAL|Music Enhancement|37 weekly Music Together classes for one year, then 12 monthly Music Together classes the following year.
62777548|NCT02936284|ACTIVE_COMPARATOR|Play Date|37 weekly group Play Date sessions for one year, then 12 monthly group Play Date sessions the following year.
62777549|NCT02243891|ACTIVE_COMPARATOR|Control|Atrial fibrillation ablation only
62777550|NCT02243891|EXPERIMENTAL|ROX Coupler|Atrial fibrillation ablation with concurrent ROX Coupler insertion
62777551|NCT01978444|EXPERIMENTAL|laparoscopic D2 lymphadenectomy plus CME|Laparoscopic D2 lymphadenectomy plus CME will be performed for the treatment of patients assigned to this group.
62777552|NCT01978444|ACTIVE_COMPARATOR|laparoscopic D2 lymphadenectomy|Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
62777553|NCT05122429|EXPERIMENTAL|myCompass Only|Self-guided e-health treatment
62777554|NCT05122429|EXPERIMENTAL|myCompass + Delayed Text Therapy Support|Self-guided e-health treatment with delayed (44min) text support from a therapist.
62777555|NCT05122429|EXPERIMENTAL|myCompass + Delayed Video Therapy Support|Self-guided e-health treatment with delayed (44min) video support from a therapist.
62002002|NCT01410734|EXPERIMENTAL|ICG|Patient will received IV injection of ICG intra-operatively. Surgeon will view bile ducts under fluorescence imaging mode to see if ICG helps to identify biliary ducts.
62002003|NCT03060772|EXPERIMENTAL|Alcohol use disorder - Pioglitazone Treatment|Participants with alcohol use disorder randomized to this group will receive pioglitazone. Study procedures include a bronchoscopy at baseline and an additional bronchoscopy after taking the study medication for 2 to 4 weeks.
62002004|NCT03060772|NO_INTERVENTION|Alcohol use disorder - No Pioglitazone|Participants with alcohol use disorder randomized to this group will receive their usual care but will not receive pioglitazone. Study procedures include a bronchoscopy at baseline and an additional bronchoscopy 2 to 4 weeks later.
62187389|NCT02727257|EXPERIMENTAL|MIRT|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The first session comprise cardiovascular warm-up activities, relaxation, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. All the exercises are aerobic. The third is a session of occupational therapy to improve autonomy in day living activities. The last session includes one hour of speech therapy.
62187390|NCT02727257|NO_INTERVENTION|healthy controls|we assessed the attentive Reaction Times in healthy controls, that don't receive rehabilitative treatment
62187391|NCT00501956|EXPERIMENTAL|Intradialytic parenteral nutrition|Individually compounded intradialytic parenteral nutrition (IDPN) including glucose, amino acids, lipids, L-Carnitine, trace elements and water-soluable vitamins 3x / week over 16 weeks + 12 weeks postinterventional observation.
62187392|NCT00501956|NO_INTERVENTION|Control Group|Observation over 28 weeks (16 + 12 weeks).
62187393|NCT06078098||AIH patients|AIH population in Italy aged at least 1 year
62777556|NCT04544683|OTHER|Cervical Pain for 6 months or less and scheduled for TFESI|Participants who meet inclusion and exclusion criteria will be enrolled into the study after consenting to and before receiving a first cervical TFESI. The baseline examination and all baseline questionnaires will be completed within 2 weeks before the first cervical TFESI. Participants will be given a daily pain diary chart to record NRS and percentage improvement during the 1st month post-injection. Participants will be contacted in the 1st week post-injection with a standardized questionnaire about their symptoms and a reminder about the 4 week (+/- 1 week) post-injection follow up. Routine scheduled follow-up by clinic visit or telephone call will occur at 4 weeks (+/- 1 week), 8 weeks (+/- 2 weeks), 3 months (+/- 2 weeks), 6 months (+/- 1 month), and 12 months (+/- 1 month), at which times all follow-up measures will be obtained.
62777557|NCT01818063|EXPERIMENTAL|Arm 1 (paclitaxel, carboplatin)|Patients receive paclitaxel IV and carboplatin IV on day 1 (course 1 only) or day 2 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62777558|NCT01818063|EXPERIMENTAL|Arm 2 (veliparib, paclitaxel, carboplatin)|Patients receive veliparib PO BID on days 1-5. Patients also receive paclitaxel IV and carboplatin IV on day 3 (course 1 only) or day 4 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62187394|NCT02619526|EXPERIMENTAL|Nebivolol|Nebivolol 10mg, once a day
62187395|NCT02619526|ACTIVE_COMPARATOR|Carvedilol|Carvedilol 25mg, twice a day
62570717|NCT04251481|EXPERIMENTAL|Optimization of Techniques|To optimize the diffusion MRI methods for assessment of cell viability, metabolism and perfusion in head and neck cancer. There will be 24 subjects enrolled for 2 year duration. Treatment-naïve patients with cervical metastatic lymph nodes (diameter \> 10 mm) of HNSCC will be recruited to have one research PET/MR scan (including dMRI) and one dMRI-only scan within three days prior to treatment. These data will be used to optimize the dMRI method and assess the repeatability.
62002005|NCT03060772|NO_INTERVENTION|Healthy controls without alcohol use disorder|Healthy individuals who do not have alcohol use disorder will be enrolled will serve as a control group. Healthy controls will be a matched to participants receiving the treatment based on age, gender, and smoking status. This group will have a single bronchoscopy.
62002006|NCT01620580|ACTIVE_COMPARATOR|Self Management Strategies|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3."
62002007|NCT01620580|ACTIVE_COMPARATOR|Dietary Information|Control arm
62002008|NCT01392950|ACTIVE_COMPARATOR|Air Optix Aqua|Compare safety and efficacy using OptiFree Replenish solution
62002009|NCT01392950|ACTIVE_COMPARATOR|Clariti|Compare safety and efficacy of the lens using OptiFree Replenish solution
62187396|NCT01099579|EXPERIMENTAL|Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg|Patients weighing 5 to \<10 kg received atazanavir (ATV), 150-mg powder dosed in 50-mg packets, and ritonavir (RTV) oral solution, 80 mg. Stage 1: Initial dose was determined by patient's weight on the day of first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage. All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from the powder to the capsule formulation of ATV. Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
62002010|NCT05103124|EXPERIMENTAL|Hydral|The participants will be asked to rinse their mouth five times a day with the experimental product. After one month, the administration will be stopped and the patients will be asked to fulfill the questionnaires mentioned in the methods section (XQ, QLQ-C30, QLQ HN35)
62002011|NCT05103124|PLACEBO_COMPARATOR|Placebo|The participants will be asked to rinse their mouth five times a day with the placebo comparator. After one month, the administration will be stopped and the patients will be asked to fulfill the questionnaires mentioned in the methods section (XQ, QLQ-C30, QLQ HN35)
62187397|NCT01099579|EXPERIMENTAL|Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg|Patients weighing 10 to \<15 kg received ATV powder, 200 mg, dosed in 50-mg sachet packets and RTV oral solution, 80 mg. Stage 1: Initial dose was determined by the patient's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from the powder to the capsule formulation of ATV. Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
62187398|NCT01099579|EXPERIMENTAL|Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg|Patients weighing 15 to \<25 kg received 250 mg of ATV powder dosed in 50-mg sachet packets, with 80 mg of RTV solution. Stage 1: Initial dose was determined by the patient's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from powder to the capsule formulation of ATV. Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
62187399|NCT04353206|EXPERIMENTAL|Intubated COVID-19 patients in the ICU|Mechanically ventilated intubated patients with respiratory failure due to COVID-19
62777559|NCT02152774|EXPERIMENTAL|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.
62002012|NCT00120432|ACTIVE_COMPARATOR|A|single dose vs three doses of 1%tropicamide and 10%phenylephrine
62187400|NCT02780505|ACTIVE_COMPARATOR|vitamin c|vitamin C supplement orally up to 250 mg per day for 6 weeks was prescribed. Plasma levels of vitamin C and other clinical parameters including hemoglobin, ferritin, TIBC, iron and CRP were measured at the beginning and end of the study.
62187401|NCT02780505|PLACEBO_COMPARATOR|placebo|ُPlacebo prescribed to Group B. Plasma levels of vitamin C and other clinical parameters including hemoglobin, ferritin, TIBC, iron and CRP were measured at the beginning and end of the study
62187402|NCT05074199|ACTIVE_COMPARATOR|W-plasty|"The cosmetic appearance of scars closed in a in a zig-zag  fashion (W-plasty)."
62187403|NCT05074199|ACTIVE_COMPARATOR|Linear closure|"The cosmetic appearance of scars closed in a standard straight line fashion (linear closure)."
62187404|NCT01983462|EXPERIMENTAL|Clonidine|Oral 0.2 mg/day (0.1 mg bid)for 4 weeks
62187405|NCT01983462|ACTIVE_COMPARATOR|Hydrochlorothiazide|Oral, 12.5 mg/day qd, 4 weeks
62187406|NCT01983462|PLACEBO_COMPARATOR|Placebo|Placebo
62584882|NCT04418128|NO_INTERVENTION|Conventional therapy|The conventional therapy comprised, as necessary, Lopinavir/ritonavir, Hydroxychlorquine, supplemental oxygen, Non-invasive and invasive ventilation, antibiotic agents, renal-replacement therapy (e.g.: CRRT, HD), extracorporeal membrane oxygenation (ECMO).
62002013|NCT00638703|EXPERIMENTAL|I|Size 2 enteric coated capsule containg lyophilized Oxalobacter formigenes
62002014|NCT00638703|PLACEBO_COMPARATOR|II|Size 2 enteric coated capsule containg placebo
62002015|NCT01610128||chronic urticaria patients|all patients suffering from chronic types of urticaria (chronic spontaneous urticaria as well as chronic inducible forms such as cold contact urticaria)
62002016|NCT02332551|EXPERIMENTAL|NanoKnife IRE System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
62002017|NCT02332551|NO_INTERVENTION|Control|
62187407|NCT01101061|EXPERIMENTAL|Romosozumab|Japanese women in cohorts 1, 2, and 4 will receive a single dose of 1, 3, or 5 mg/kg romosozumab. Non-Japanese women in cohort 3 will receive a single dose of 3 mg/kg romosozumab.
62002018|NCT04834934||COVID-19 first wave patients|1700 patients retrospectively enrolled in 15 Italian hospitals from 16/2/2020 to 29/4/2020.
62187408|NCT01101061|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo.
62187409|NCT04086238|OTHER|Formulation A Fasted|EPI01 Formulation A (moderate release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.
62002019|NCT04834934||COVID-19 second wave patients|300 patients prospectively enrolled in IRCCS San Raffaele Hospital from 19/10/2020 to 31/12/2020.
62187410|NCT04086238|EXPERIMENTAL|Formulation A Fed|EPI01 Formulation A (moderate release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.
62187411|NCT04086238|OTHER|Formulation B Fasted|EPI01 Formulation B (slow reelase): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.
62187412|NCT04086238|EXPERIMENTAL|Formulation B Fed|EPI01 Formulation B (slow release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.
62187413|NCT04086238|OTHER|Formulation C Fasted|EPI01 Formulation C (retarded release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.
62187414|NCT04086238|EXPERIMENTAL|Formulation C Fed|EPI01 Formulation C (retarded release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.
62187415|NCT05347862|OTHER|Control group|Usual standard advice to practice physical activity as an important measure to promote health benefits.
62187416|NCT05347862|EXPERIMENTAL|Physical Activity Promotion|The intervention will consist of telephone calls and text messages to promote the practice of 150 minutes/week of physical activity in the daily life of participants.
62002020|NCT05525182|EXPERIMENTAL|Phase II|ES16001: 480 mg/day ES16001: 720 mg/day ES16001: 960 mg/day Placebo
62002021|NCT05525182|EXPERIMENTAL|Phase III|ES16001 Placebo
62187417|NCT06194812|OTHER|İNTERVENTİON|The surveys in the study will be applied to the patients in this group and initial and final measurements will be taken.
62187418|NCT01263054|EXPERIMENTAL|TransDiscal System|Kimberly-Clark TransDiscal System in addition to standard medical management
62187419|NCT01263054|OTHER|Medical Management|Standard medical management
62187420|NCT05271318|EXPERIMENTAL|Phase 1 part - TILT-123 and pembrolizumab|"Patients will receive multiple administrations of TILT-123 and pembrolizumab.~Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level."
62187421|NCT05271318|EXPERIMENTAL|Phase 1b part - TILT-123 and pembrolizumab and pegylated liposomal doxorubicin|"Patients will receive multiple administrations of TILT-123 and pembrolizumab and pegylated liposomal doxorubicin.~TILT-123 will be administered at the maximum tolerated dose or maximum feasible dose."
62187422|NCT04758052|EXPERIMENTAL|simultaneous tracheostomy with gastrostomy (TSG)|This arm include the patients assigned to placement of gastrostomy immediately after tracheostomy.
62002022|NCT00607763|EXPERIMENTAL|1. Micafungin|
62002023|NCT05828017|EXPERIMENTAL|Participants with Hearing Loss|Individuals with hearing loss that meet the candidacy to wear hearing aids. All interventions are associated with the fitting of binaural hearing aids with various coupling methods. All participants will be assessed under all interventions.
62187423|NCT04758052|NO_INTERVENTION|non-simultaneous or delayed approach tracheostomy and gastrostomy (TDG)|"This arm include the patients who proceed with usual care placement of tracheostomy and gastrostomy as per Neurocritical care Unit service standard."
62187424|NCT00441922|EXPERIMENTAL|1|D
62187425|NCT00441922|EXPERIMENTAL|2|V
62791747|NCT04778826|ACTIVE_COMPARATOR|Lung Lobectomy with VAMLA|Lung lobectomy combined with video-assisted mediastinal lymphadenectomy through the neck (VAMLA). The approach is similar to transcervical mediastinoscopy and allows for a radical bloc dissection of all mediastinal lymph node stations. Besides the benefit of bilateral lung ventilation during this phase of the operation a bilateral mediastinal lymphadenectomy offers improved surgical radicality.
62187426|NCT03497715|EXPERIMENTAL|Experimental 1|Treatment order: Ibuprofen liquid capsules, Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen (Wockhardt)
62187427|NCT03497715|EXPERIMENTAL|Experimental 2|Treatment order: Ibuprofen lysine, Ibuprofen (Wockhardt), Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen liquid capsules
62187428|NCT03497715|EXPERIMENTAL|Experimental 3|Treatment order: Ibuprofen liquid capsules, Ibuprofen (Nurofen)1, Ibuprofen sodium, Ibuprofen (Wockhardt), Ibuprofen lysine
62187429|NCT03497715|EXPERIMENTAL|Experimental 4|Treatment order: Ibuprofen (Wockhardt), Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen liquid capsules, Ibuprofen sodium
62187430|NCT03635086|EXPERIMENTAL|Group A: Two MV-CHIK lyophilized low dose|Participants received two vaccinations with MV-CHIK lyophilized formulation, low dose, on day 0 and day 28.
62187431|NCT03635086|EXPERIMENTAL|Group B: Two MV-CHIK liquid frozen low dose|Participants received two vaccinations with MV-CHIK liquid frozen low dose formulation on day 0 and day 28.
62187432|NCT03635086|EXPERIMENTAL|Group C: Two MV-CHIK liquid low dose stabilizing and protecting solution (SPS®)|Participants received two vaccinations with MV-CHIK liquid low dose SPS® formulation on day 0 and day 28.
62187433|NCT03635086|EXPERIMENTAL|Group D: Two MV-CHIK liquid frozen high dose|Participants received two vaccinations with MV-CHIK liquid frozen high dose formulation on day 0 and day 28.
62187434|NCT03635086|EXPERIMENTAL|Group E: One MV-CHIK liquid frozen high dose/placebo|Participants received one vaccination with MV-CHIK liquid frozen high dose formulation on day 0 and placebo on day 28.
62002024|NCT06008964|ACTIVE_COMPARATOR|Ylang Ylang oil Group|GROUP 1
62002025|NCT06008964|NO_INTERVENTION|Control Group|No intervention
62002026|NCT06008964|ACTIVE_COMPARATOR|Lavender oil|GROUP 2
62002027|NCT02923518||Inclusion group|Inclusion group: Those with a positive score in a questionnaire including symptoms and family history and/or high risk-score in the NORRISK-score system.
62187435|NCT02386878|EXPERIMENTAL|Interpersonal Psychotherapy for Groups (IPTG)|The intervention consists of 16 weekly 60 to 90 minute psychotherapy sessions, implemented once a week by a trained lay facilitator.
62187436|NCT02386878|EXPERIMENTAL|Vhutshilo 2|The intervention consists of 13 group sessions, implemented once a week by a trained lay facilitator.
62187437|NCT02386878|EXPERIMENTAL|IPTG and Vhutshilo|Participants receive the IPTG intervention first, followed by Vhutshilo 2.
62002028|NCT02923518||Control group|Those without a positive score on the two scores listed above.
62002029|NCT06381869|OTHER|Young volunteers|Volunteers under 30 years old
62002030|NCT06381869|OTHER|Elderly volunteers|Volunteers over 65 years old.
62002031|NCT03972839||D-Dimers patients|population recruited in Brest for a period of 1 year: patients for whom a dose of VIDAS D-dimers is prescribed (approximately 3700 patients)
62002032|NCT00670228|ACTIVE_COMPARATOR|Intensive Insulin Therapy (IIT)|In IIT arm, subjects received intravenous (IV) insulin glulisine and subcutaneous (sc) insulin glargine to maintain a Blood Glucose (BG) concentration between 90-130 mg/dL.
62002033|NCT00670228|ACTIVE_COMPARATOR|Standard Glycemic Care (SGC)|"In SGC arm subjects assigned to standard of care received subcutaneous regular insulin per sliding scale."
62002034|NCT01541826|PLACEBO_COMPARATOR|Color-matched rice powder pill|Color-matched rice powder pill
62002035|NCT01541826|ACTIVE_COMPARATOR|Chokeberry extract capsule|Chokeberry extract capsule
62002036|NCT01541826|EXPERIMENTAL|Chokeberry extract capsule (acute)|Chokeberry extract capsule pharmacokinetics
62187438|NCT02386878|NO_INTERVENTION|No Intervention|No intervention
62187439|NCT02370901|EXPERIMENTAL|Helmet|Patients will be referred to a cranial orthotist who will create a custom cranial orthotic device. They will undergo adjustments monthly. At these appointments anthropometric measurements will be done by the cranial orthotist. The orthotist will be blinded and will not be informed of which patient is involved in the study.
62187440|NCT02370901|EXPERIMENTAL|home therapies|Patients will be referred to a physical therapist. They will be offered education, neck stretching exercises, and repositioning techniques, and reassurance.
62187441|NCT00739076|EXPERIMENTAL|1|Virtual Reality Hypnosis
62187442|NCT00739076|EXPERIMENTAL|2|Virtual Reality Distraction
62187443|NCT00739076|EXPERIMENTAL|3|Standard treatment.
62187444|NCT00130845|EXPERIMENTAL|Octreotide Acetate in Microspheres|
62187445|NCT00130845|PLACEBO_COMPARATOR|Placebo|
62187446|NCT05840900|EXPERIMENTAL|App-based mindfulness training|App-based daily mindfulness training Standard prenatal and pregnancy care
62187447|NCT05840900|NO_INTERVENTION|Usual Care|Standard prenatal and pregnancy care
62187448|NCT05217355|EXPERIMENTAL|MBA-P01|Experimental group, Dose: 20U
62187449|NCT05217355|PLACEBO_COMPARATOR|Placebo|Placebo gorup, Normal saline
62187450|NCT04191408|EXPERIMENTAL|Mechanically ventilated patients after surgery|After ICU admission the patient's hemodynamics (MAP, HR, CO, PPV) will be measured in supine position. It will be remeasured after PEEP has been increased from +5 to +15 cmH20. Then the baseline measurement will be repeated. Then passive leg raise will be performed and all the parameters will be remeasured.
62187451|NCT02977299|EXPERIMENTAL|Aripiprazole Augmentation|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics at their current dose throughout the 8-week trial and initiate adjunctive aripiprazole. The starting dose will be 5mg daily. The dose may be reduced to as low as 2mg for tolerability issues (this will be the lowest dose permitted for continuation in the trial). The dose may be adjusted in 2 or 5mg increments. The minimum time per increment will be 7 days. The maximum dose will be set at 15mg daily. For patients who are not on potent cytochrome 2D6 inhibitors (such as paroxetine, fluoxetine, duloxetine) or on potent cytochrome 3A4 inhibitors (such as fluvoxamine and nefazodone) and who are able to tolerate 15mg daily, the maximum dose can be raised to 20mg daily for efficacy.
62187452|NCT02977299|EXPERIMENTAL|rTMS Augmentation|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics at their current dose throughout the 8-week trial. We will use clinical TMS stimulators with focal figure-of-eight coils. We will start by measuring the patient´s motor threshold (MT), which is a measure of cortical excitability used to standardize the intensity of stimulation across subjects.
62187453|NCT02977299|EXPERIMENTAL|Switching To Venlafaxine XR|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics throughout the 8-week trial, except for their antidepressant(s). They will be instructed to discontinue all antidepressants and initiate venlafaxine that day, as direct switch to serotonergic antidepressants is well tolerated and avoids loss of precious therapeutic time (Montgomery et al., 2014), including to switching to venlafaxine in STAR\*D (Rush et al., 2006b). For patients who do not prefer a direct switch, or when clinically indicated otherwise in the opinion of the site investigator, a gradual tapering during the screening period will be permitted as long as a direct switch to venlafaxine is made on the baseline visit from the final antidepressant dose. The starting dose of venlafaxine will be 75mg daily. The dose may be reduced to as low as 37.5mg for tolerability issues (this will be the lowest dose permitted for continuation in the trial).
62187454|NCT01106365|EXPERIMENTAL|prefrontal cortex (PFC)|rTMS with the H-coil to the prefrontal cortex (PFC)
62187455|NCT01106365|ACTIVE_COMPARATOR|motor cortex|rTMS with the H-coil to the motor cortex
62187456|NCT01106365|SHAM_COMPARATOR|sham treatment|sham treatment
62187457|NCT01408810|EXPERIMENTAL|Infliximab|Infliximab 5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter. The treatment should follow infliximab's Summary of Product Characteristics.
62395574|NCT05766631|EXPERIMENTAL|DynamiCare Plus Methadone Treatment-as-Usual|DynamiCare Plus Methadone Treatment-as-Usual (DCM+TAU) participants will receive the same services as TAU participants, plus access to the DynamiCare Health smartphone app for 48 weeks. After randomization, the research assistant (RA) will download the DynamiCare Health app onto their smart phone (or provide them with a smartphone with the app already installed). Participants will get oral fluid testing kits and a Next Step debit card. Participants will be trained in use of the app and oral fluid test kits and will practice until they can produce two valid tests in a row without aid of the research staff. Participants will earn $40 for successful completion of the orientation and training. DCM+TAU participants will then use the app to complete remote random drug screenings, prove attendance to appointments and medication pickups, interact with modules designed to improve substance use reductions, and other treatment-related activities.
62002037|NCT02171598|EXPERIMENTAL|Fixed sequence 1|multiple-dose, fixed-sequence with 2 periods of 4 days separated by a washout period of at least 14 days. A single dose of 300 mg clopidogrel will be given on top of 75 mg or 150 mg dabigatran in steady state.
62002038|NCT02171598|EXPERIMENTAL|Crossover|clopidogrel + dabigatran / clopidogrel / dabigatran in randomized order
62777560|NCT02152774|EXPERIMENTAL|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.
62002039|NCT02171598|EXPERIMENTAL|Fixed sequence 2|intra-individual comparison with the fixed sequence of a single dose of 600mg clopidogrel alone and the combination of dabigatran 150 mg in steady state plus single dose of 600 mg clopidogrel
62187458|NCT01756144|ACTIVE_COMPARATOR|Autologous bone grafting|autologous bone of the iliac crest
62002040|NCT02450214|SHAM_COMPARATOR|Control group (C)|50 mL syringe with saline, plus 1 flask of 100 mL saline (Saline)
62187459|NCT01756144|EXPERIMENTAL|rhBMP-2|Inductos, recombinant human bone morphogenetic protein
62187460|NCT00463398||Patients operated at the LUFc|All patients operated at the Leuven University Fertility Centre (LUFc) between september 2006 and August 2008.
62187461|NCT05221138|EXPERIMENTAL|VV116 after High-fat meal intake|a single oral after High-fat meal intake
62187462|NCT05221138|EXPERIMENTAL|VV116 after Fasting+Standard diet|a single oral after Fasting
62002041|NCT02450214|EXPERIMENTAL|Ketamine group (K)|50 mL syringe with ketamine (50mg / 50ml), plus 1 flask of 100 mL saline (Ketamine)
62002042|NCT02450214|EXPERIMENTAL|Magnesium + ketamine group (MGK)|50mL syringe with ketamine (50mg / 50ml), plus a flask of 100ml of saline with 5 g of magnesium sulfate (Ketamine + magnesium)
62002043|NCT05037565|EXPERIMENTAL|Treatment group|One group receive PHGG following study protocol (treatment group).
62002044|NCT05037565|NO_INTERVENTION|Control group|This group will not receive PHGG
62002045|NCT00998634|EXPERIMENTAL|LITHIUM CARBONATE 150 and/or 300 mg|
62002046|NCT00998634|PLACEBO_COMPARATOR|PLACEBO|
62002047|NCT04399161|EXPERIMENTAL|Child Participants|Residential school children aged 5-12 yrs at high risk for caries. A total of 36 children will be recruited for the study and randomly divided into 3 groups with 12 participants per group.The subjects will be asked to rinse their mouth once daily (at night) for 2 minutes, using 15 ml of mouth rinse provided to them. The intervention will be carried out for a period of 14 days.
62002048|NCT04399161|EXPERIMENTAL|Elderly Participants|Elderly citizens (above 60 yrs) at high risk for caries. A total of 36 elderly will be chosen based on eligibility criteria and randomly divided into 3 groups with 12 participants per group. The subjects will be asked to rinse their mouth once daily (at night) for 2 minutes, using 15 ml of mouth rinse provided to them. The intervention will be carried out for a period of 14 days.
62002049|NCT01299831|EXPERIMENTAL|72 hour fast|
62002050|NCT01299831|EXPERIMENTAL|12 hours fast|
62187463|NCT05221138|EXPERIMENTAL|VV116 after Standard meal intake|a single oral after Standard meal intake
62187464|NCT05367505|EXPERIMENTAL|iFuse-3D|Titanium fusion implant in combination with trans-iliac screws
62187465|NCT04197479|EXPERIMENTAL|Open label: resmetirom|100 mg daily
62187466|NCT04197479|PLACEBO_COMPARATOR|Double blinded: matching placebo|Placebo daily
62002051|NCT01299831|EXPERIMENTAL|12 hour fast, growth hormone bolus|
62002052|NCT01299831|EXPERIMENTAL|72 hour fast, inhibition of lipolysis|
62187467|NCT04197479|EXPERIMENTAL|Double blinded: resmetirom 80 mg|80 mg daily
62187468|NCT04197479|EXPERIMENTAL|Double blinded: resmetirom 100 mg|100 mg daily
62187469|NCT01927107|ACTIVE_COMPARATOR|Probiotic mixture|Probiotic mixture including Lactobacillus acidophilus (4.3x108CFU/per sachet), Lactobacillus rhamnosus (4.3x108CFU/ per sachet), Bifidobacterium bifidum (4.3x108CFU/ per sachet), Bifidobacterium longum (4.3x108CFU/ per sachet), Enterococcus faecium (8.2x108CFU/ per sachet, per oral daily for 30 days in addition to standard approach
62187470|NCT01927107|ACTIVE_COMPARATOR|Control|Standard diet therapy
62187471|NCT01547624|EXPERIMENTAL|Neck Specific exercises|3 months of neck specific exercises for 30 patients.
62187472|NCT01547624|NO_INTERVENTION|Waiting list|Thirty patients on the waiting list for 3 month before they have their intervention
62187473|NCT01547624|NO_INTERVENTION|Healthy controls|Forty healthy controls. Comparisons between forty included WAD patients and 40 healthy controls matched for age and gender will be investigated at baseline.
62187474|NCT00226915|ACTIVE_COMPARATOR|1|Drug: Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
62187475|NCT00226915|EXPERIMENTAL|2|Drug: Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
62187476|NCT02126462|EXPERIMENTAL|30 µg Na-GST-1 + 30 µg Na-APR-1 (M74)|30 µg Na-GST-1/Alhydrogel plus 5 µg GLA-AF co-administered with 30 µg Na-APR-1 (M74)/Alhydrogel plus 5 µg GLA-AF
62187477|NCT02126462|ACTIVE_COMPARATOR|Hepatitis B vaccine|Hepatitis B vaccine co-administered with saline
62187478|NCT02126462|EXPERIMENTAL|100 µg Na-GST-1 plus 100 µg Na-APR-1 (M74)|100 µg Na-GST-1/Alhydrogel plus 5 µg GLA-AF co-administered with 100 µg Na-APR-1 (M74)/Alhydrogel plus 5 µg GLA-AF
62395575|NCT06131931|EXPERIMENTAL|Connecting Latinxs en Pareja (CLP)|CLP is a four-session intervention grounded in social cognitive theory and a relationship oriented ecological framework.
62187479|NCT01555398|EXPERIMENTAL|Fasting conditions|Investigational product administrated under fasting condition.
62395576|NCT06131931|ACTIVE_COMPARATOR|Wellness Promotion (WP)|WP focuses on nutrition, fitness, healthcare, and stress management and emphasizes adherence to medical regimens and medication management.
62395577|NCT03564860||HBP device data collection group|Device electrograms and 12-lead ECG will be collected from patients over the age of 18 years who have been previously implanted with a permanent His Bundle pacing lead and an Abbott pacemaker, defibrillator, or cardiac resynchronization therapy device during a standard-of-care device follow-up visit.
62570718|NCT04251481|EXPERIMENTAL|: Longitudinal Monitoring|To assess the feasibility of using diffusion MRI metrics at early stages of treatment for prediction of treatment response in head and neck cancer patients undergoing standard-of-care chemoradiation therapy. There will be 36 subjects enrolled for 3 year duration. The study will do bi-weekly measurement to monitor tumor response longitudinally. This study will be restricted to treatment-naïve patients who present pathologically confirmed HNSCC with metastatic lymph nodes and who are scheduled to receive standard care of radiation therapy with concurrent chemotherapy. The patients enrolled in this arm of the study will have 4 dMRI scans. The imaging data for each patient will be the proposed dMRI measures at the baseline and their changes at each follow-up time period. DCE-MRI will be included in the baseline scan for tumor delination as in standard-of-care cancer imaging and to compare with the proposed dMRI method.
62777561|NCT03916484|EXPERIMENTAL|AQ HIV Medication Adherence app-delivered intervention|AQ: At minimum, intended app usage (dose) is for participant to complete a set of activities (record medication taking, complete a challenge, complete a forum post) one time per day (frequency) for 6 months (duration). The participant may or may not stay solely on AQ throughout the study.
62777562|NCT03916484|EXPERIMENTAL|AQ HIV Medication Adherence app-delivered intervention + NSC|AQ+NSC: At minimum, intended app usage (dose) is for participant to complete a set of activities (record medication taking, complete a challenge, complete a forum post) one time per day (frequency) for 6 months (duration). NSC sessions are scheduled approximately every other week (frequency) and last approximately 30 minutes per session (dose). The participant may or may not stay on AQ+NSC throughout the study.
62777563|NCT03916484|EXPERIMENTAL|AQ followed by AQ+NSC|At 3 months, those who were initially randomized to AQ who meet protocol defined definition for intervention non-responsiveness, are reassigned to AQ+NSC to complete months 4 - 6 of the trial.
62777564|NCT03916484|EXPERIMENTAL|AQ+NSC followed by AQ|At 3 months, those who were initially randomized to AQ+NSC who meet protocol defined definition for intervention responsiveness, may get re-randomized to AQ alone to complete months 4 - 6 of the trial.
62777565|NCT05266391||group 1|patients who received US-guided subacromial corticosteroid injections
62777566|NCT05266391||group 2|patients who underwent blind subacromial corticosteroid injections
62777567|NCT05367843|EXPERIMENTAL|A-Cohorts: Pre-vaccinated|Participants aged 18-55 years who have been pre-vaccinated against COVID-19 with at least two doses of a SARS-CoV-2 mRNA vaccine will be assigned to five groups that receive increasing doses of PRIME-2-CoV_Beta (two doses, 28 days apart).
62777568|NCT05367843|EXPERIMENTAL|A-Cohorts: SARS-CoV-2 Vaccine-naïve|Participants aged 18-55 years who are SARS-CoV-2 vaccine-naïve will receive one preferred dose level of PRIME-2-CoV_Beta that has been identified as optimal in pre-vaccinated A-Cohorts (two doses, 28 days apart).
62777569|NCT05367843|EXPERIMENTAL|B-Cohorts: Pre-vaccinated elderly|Elderly participants aged 65-85 years who have been previously vaccinated against COVID-19 with at least two doses of a SARS-CoV-2 mRNA vaccine will be assigned to three groups to receive previously identified doses of PRIME-2-CoV_Beta (two doses, 28 days apart).
62777570|NCT05050656|ACTIVE_COMPARATOR|Group D (duloxetine group)|Two hours before surgery, participants received oral duloxetine 60 mg tablets in the ward then transferred to OR to receive spinal anesthesia before surgery.
62395578|NCT05255159|EXPERIMENTAL|18F-DOPA PET/CT scan|4 MBq/kg (minimum 100 MBq, maximum 600 MBq) 18F-DOPA injected intravenously with 40 mg furosemide and subsequent whole body PET/CT scan
62570719|NCT01735916|ACTIVE_COMPARATOR|CRT-P ON|CRT-P Implant CRT-P ON
62570720|NCT01735916|PLACEBO_COMPARATOR|CRT-P OFF|CRT-P Implant CRT-P OFF
62570721|NCT02262520|EXPERIMENTAL|Treatment A: Digoxin|Digoxin tablet by mouth on specified days
62777571|NCT05050656|PLACEBO_COMPARATOR|Group C (control group)|Two hours before surgery, participants received oral placebo tablets in the ward then transferred to OR to receive spinal anesthesia before surgery.
62777572|NCT01140061|EXPERIMENTAL|Panel A - MK-0873 5.1 mg|In Part I, healthy participants received skin patches containing nothing (plain patch), placebo, and various potencies of MK-0873 cream (0.05%, 0.5%, or 2%; yielding a dose of 5.1 mg of MK- 0873) once daily for 21 days.
62777573|NCT01140061|PLACEBO_COMPARATOR|Panel A - Placebo|In Part I, healthy participants received skin patches containing nothing (plain patch) or placebo once daily for 10 days.
62777574|NCT01140061|EXPERIMENTAL|Panel B - MK-0873 25 mg|In Part II, healthy participants received skin application of 0.5% MK-0873 cream (yielding a dose of 25 mg of MK- 0873) twice daily for 10 days.
62777575|NCT01140061|PLACEBO_COMPARATOR|Panel B - Placebo|In Part II, healthy participants received skin application of placebo cream twice daily for 10 days.
62777576|NCT01140061|EXPERIMENTAL|Panel C - MK-0873 100 mg|In Part II, healthy participants received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) once daily for 10 days.
62777577|NCT01140061|PLACEBO_COMPARATOR|Panel C - Placebo|In Part II, healthy participants received skin application of placebo cream once daily for 10 days.
62187480|NCT01555398|ACTIVE_COMPARATOR|Fed conditions|Investigational product administrated 30min after starting a high-fat breakfast.
62187481|NCT04083924|EXPERIMENTAL|Basic cardiac ultrasound training|Single group education intervention study. No control group. Pre-post educational outcomes only.
62187482|NCT02311088|EXPERIMENTAL|Caffeine|Caffeine capsules. 200 mg twice daily orally for 7-10 days.
62777578|NCT01140061|EXPERIMENTAL|Panel D - MK-0873 200 mg|In Part II, healthy participants received skin application of 2% MK-0873 (yielding a dose of 100 mg of MK-0873) twice daily for 10 days.
62187483|NCT02311088|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules twice daily orally for 7-10 days.
62187484|NCT04797117|OTHER|blood sample|The blood samples for the study for each patient will be collected in the form of additional tubes.
62187485|NCT04952363|EXPERIMENTAL|HFCWO+WBVT|Subjects received HFCWO+WBVT intervention twice a week for a period of 8 weeks
62187486|NCT04952363|ACTIVE_COMPARATOR|HFCWO only|Subjects received HFCWO intervention twice a week for a period of 8 weeks
62187487|NCT00835185|EXPERIMENTAL|IMC-11F8 (necitumumab) /mFOLFOX-6 regimen|Participants will receive IMC-11F8 (necitumumab) once every 2 weeks in combination with the mFOLFOX-6 regimen (oxaliplatin/5-FU/FA)
62187488|NCT02912754|EXPERIMENTAL|Ibrutinib plus Ruxolitinib|Patients taking ibrutinib for relapsed CLL will add ruxolitinib twice per day at the dose identified in a preliminary phase I trial for 7 cycles (3 weeks on/2 weeks off).
62395579|NCT05451693||Outreach-ER|Outreach-ER is a psychosocial intervention designed by dementia experts in the field of care partner interventions. The care plan will be personalized to the needs of the care partner/PLWD.
62395580|NCT05568420||Colorectal Cancer Cohort|"* Stool collection prior to starting treatment (i.e. chemotherapy, chemoradiotherapy, etc.)~* Blood sample to be collected either prior to starting treatment (i.e. chemotherapy, chemoradiotherapy, etc.) or during surveillance.~* Prospective tissue collection will be utilized from clinically indicated diagnostic colonoscopies/biopsies/resections s, including surveillance colonoscopies. Non-diagnostically indicated tissue collections will not be performed. Some EOCRC patients will have already undergone prior surgical resection, with tissue (including normal colonic mucosae distant from the malignant tumor). The pathology FFPE blocks may be used as a source of normal colon tissue for genomic analysis."
62187489|NCT02912754|NO_INTERVENTION|Ibrutinib alone|Patients will continue to take Ibrutinib for the equivalent period of time.
62395581|NCT05568420||Healthy Control Cohort|"Tissue collection of normal colon mucosa will be utilized from clinically indicated colonoscopies or from tissue obtained from a prior colonoscopy, non-diagnostically indicated tissue collections will not be performed. Colonoscopies for indications of IBD, anemia, and/or genetic predisposition will be excluded.~* Stool samples will be collected at time of colonoscopy. Samples to be collected either within 3-14 days before or at least 14 days after colonoscopy, to avoid changes in microbiome caused by colonoscopy prep.~* Blood samples will be collected at time of colonoscopy.~* Risk factor questionnaire will be completed at time of colonoscopy. Will also try to collect stool from healthy control patients; however, if accrual is low after 3-6 months, remainder of cohort will be filled with specimen data from the Human Microbiome Project Data Portal."
62395582|NCT03672565|ACTIVE_COMPARATOR|Hospital setting|ERPs may be conducted in various settings on hospital grounds (e.g., cafeteria, hallways) but will not be conducted off property.
62395583|NCT03672565|ACTIVE_COMPARATOR|Community setting|Community ERP sessions will be conducted locations deemed most relevant to the child's symptom presentation such as in the home or at other community locations (e.g., church, downtown).
62395584|NCT03247140|EXPERIMENTAL|Group I (JLP-1401)|JLP-1401(Telmisartan 80 mg, amlodipine 10 mg, rosuvastatin 20 mg)
62395585|NCT03247140|EXPERIMENTAL|Group II(Telmisartan/Amlodipine, Rosuvastatin)|Twinsta(Telmisartan 40 mg, amlodipine 5 mg) 2 tab and Crestor(rosuvastatin 20 mg)
62395586|NCT02092155||Indwelling tunneled pleural catheter|
62395587|NCT00368212|EXPERIMENTAL|1|"Participants will receive psychoeducational counseling (termed health care counseling)"
62395588|NCT00368212|ACTIVE_COMPARATOR|2|Participants will receive relaxation response training
62395589|NCT03302260|NO_INTERVENTION|Control|Participants in the control arm will receive standard postpartum clinical care through the participants' usual healthcare providers. No intervention will be administered. Participants in both arms will receive educational material about the risk of CVD, and CVD prevention for women with HDP from the Preeclampsia Foundation.
62395590|NCT03302260|EXPERIMENTAL|CardioPrevent® Program|In addition to standard care, participants randomized to the intervention arm will also receive the CardioPrevent® Program. This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context. Participants in both arms will receive educational material about the risk of CVD, and CVD prevention for women with HDP from the Preeclampsia Foundation.
62570722|NCT02262520|EXPERIMENTAL|Treatment B: Apixaban and Digoxin|Apixaban and Digoxin tablets by mouth on specified days
62777579|NCT01140061|PLACEBO_COMPARATOR|Panel D - Placebo|In Part II, healthy participants received skin application of placebo cream twice daily for 10 days.
62777580|NCT01140061|EXPERIMENTAL|Panel E and Extension - MK-0873 200 mg|In Part III, participants with mild psoriasis received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) twice daily for up to 28 days.
62187490|NCT05549947|EXPERIMENTAL|Treatment group A：SHR-1819|
62187491|NCT05549947|EXPERIMENTAL|Treatment group B：SHR-1819|
62187492|NCT05549947|EXPERIMENTAL|Treatment group C：SHR-1819|
62187493|NCT05549947|PLACEBO_COMPARATOR|Treatment group D：placebo|
62187494|NCT06015906|SHAM_COMPARATOR|socket|Tooth extraction socket filled only clot.
62187495|NCT06015906|ACTIVE_COMPARATOR|Socket associated with exposed absorbable membrane|Socket filled with clot and covered with the Plenum® Guide membrane exposed in the intraoral region.
62187496|NCT06015906|ACTIVE_COMPARATOR|Socket associated with covered absorbable membrane|Socket filled with clot and covered with the Plenum® Guide membrane and covered by mucosa (gingival tissue) in the intraoral region.
62187497|NCT06015906|EXPERIMENTAL|Socket filled with synthetic bone graft and covered absorbable membrane|Socket filled with synthetic bone graft and the Plenum® Guide membrane covered by gingival tissue in the intraoral region.
62187498|NCT06015906|EXPERIMENTAL|Socket filled with synthetic bone graft and exposed absorbable membrane|Socket filled with synthetic bone graft and Plenum® Guide membrane, where this membrane will be exposed in the intraoral region.
62187499|NCT04839055|EXPERIMENTAL|Experimental: Coenzyme A 200U|Coenzyme A 200U per day
62002053|NCT04124172|ACTIVE_COMPARATOR|Real rTMS|"rTMS (Magstim Super Rapid, Magstim Company, Whitland, Wales, UK) with eight-shaped coil (1 Hz, 1500 stimuli) in M1of the contralateral hemisphere to the lesion (healthy side). M1 is defined like the hot spot to elucidated a motor evoked potential in the Abductor Pollicis Brevis (APB) muscle of the contralateral hand. Intervention will be performed before one hour rehabilitation session of the upper limb according to our clinical protocol, completing 15 sessions."
62187500|NCT04839055|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Abiraterone without coenzyme A
62395591|NCT03879811|EXPERIMENTAL|MMR-Proficient Colorectal Cancer|"The first 3 subjects will receive oral TMZ at 150mg/m2 day 1 to 5 during cycle~1, followed by nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1 (i.e. Cycle 2 day 1). Nivolumab will continue for up for 2 years maximum. If confirmed that TMB increased in at least 2 of 3 subjects following 1 cycle of TMZ, then subsequent patients will continue to receive TMZ during cycle 1 only, and the original three participants will not be replaced. If it is determined that TMB did not increase following 1 cycle of TMZ, then subsequent patients will receive TMZ up to cycle 3, those first 3 patients will discontinue further Nivolumab and be replaced and an additional 6 patients will initially be enrolled. If confirmed that TMB increased in at least 1 of 6 subjects following 3 cycles of TMZ, then 12 more patients will be allowed to enroll for a total of 18 in stage I."
62570723|NCT01482637||CAS|There are no separate groups. All subjects are being asked to complete the CAS measure.
62187501|NCT01287728|EXPERIMENTAL|treatment BY METROMIDAZOLE|
62187502|NCT05750589|EXPERIMENTAL|IRX-101|Subjects randomized to IRX-101 will receive the investigational product, IRX-101.
62187503|NCT05750589|ACTIVE_COMPARATOR|5% Povidone-iodine|Subjects randomized to this arm will receive the standard of care, Providone-iodine, at a concentration of 5%.
62187504|NCT01540604|EXPERIMENTAL|CRD007 10 mg tablet|
62187505|NCT02531867|EXPERIMENTAL|Asfotase Alfa|Patients will receive asfotase alfa by subcutaneous injection. Asfotase alfa will be administered at either 2 mg/kg 3 times per week or 1 mg/kg 6 times per week depending on investigator's discretion.
62187506|NCT01921907|EXPERIMENTAL|Active|topical treatment
62187507|NCT01921907|PLACEBO_COMPARATOR|Placebo|topical treatment
62570724|NCT04892329|EXPERIMENTAL|EUS AI navigation system augmentation|The endoscopists in the experimental group will be assisted by EndoAngel, which can assist in identifying important anatomical structures adjacent to the pancreas in real time. The system is an non-invasive AI system .
62187508|NCT03232710|EXPERIMENTAL|pilot study group|
62187509|NCT03232710|EXPERIMENTAL|group 1 (under fasting condition)|
62187510|NCT03232710|EXPERIMENTAL|group 2 (under fasting condition)|
62187511|NCT03232710|EXPERIMENTAL|group 3 (under fed condition)|
62187512|NCT03232710|EXPERIMENTAL|group 4 (under fed condition)|
62187513|NCT01275768|EXPERIMENTAL|Experimental arm|Insertion and activation of the endo-biliary RF catheter at the site of the stricture before insertion of a Self-expandable Metal Stent (SEMS)
62187514|NCT01275768|PLACEBO_COMPARATOR|Control arm|Insertion and sham activation of the endo-biliary RF catheter at the site of the stricture before insertion of a SEMS
62777581|NCT01140061|PLACEBO_COMPARATOR|Panel E and Extension - Placebo|In Part III, participants with mild psoriasis received skin application of placebo cream twice daily for up to 28 days.
62187515|NCT02131727|EXPERIMENTAL|Hand Hygiene Improvement Intervention|Hand Hygiene Improvement Intervention: Participants receive a 4 minute training video about actions to take to reduce risk of respiratory and GI infections that includes hand hygiene practices, along with educational posters and hand hygiene supplies.
62187516|NCT02131727|PLACEBO_COMPARATOR|Ask Me 3|Participants in the control group received a 4 minute training video about the Ask Me 3 program for clearer communication with health care providers, a brochure, and a key chain containing principles for clear communication with health care providers.
62777582|NCT06334068|EXPERIMENTAL|Short-term glycemic control group|Patients will be admitted to the hospital for 2-3 days before surgery. During this pilot study, patients will be admitted to the intermediate care unit to monitor and control preoperative blood glucose. We aim to maintain moderate glucose control (140-180 mg/dl) using the basal-bolus insulin protocol, plus correctional doses as needed.
62777583|NCT06334068|ACTIVE_COMPARATOR|Standard-of-care group|Patients will be admitted the day before surgery with the usual patient treatment.
62777584|NCT01066962|ACTIVE_COMPARATOR|darunavir/r + tenofovir/emtricitabine|
62187517|NCT04266444|ACTIVE_COMPARATOR|Level 4|10Cubes game in virtual reality using very small bouncing blocks
62187518|NCT04266444|ACTIVE_COMPARATOR|Level 3|10Cubes game in virtual reality using very small non-bouncing blocks
62187519|NCT04266444|ACTIVE_COMPARATOR|Level 2|10Cubes game in virtual reality using large bouncing blocks
62187520|NCT04266444|ACTIVE_COMPARATOR|Level 1|10Cubes game in virtual reality using large non-bouncing blocks
62187521|NCT03616795|EXPERIMENTAL|LY3154207 and [14C]-LY3154207|A single dose of LY3154207 and \[14C\]-LY3154207administered orally.
62395592|NCT03053531|EXPERIMENTAL|HERO-ED RCT|Subjects will be instructed on use of the HAD. The model that we will use is the PockeTalker Mini-Cog. This is a small (9.0cm X 5.5cm X 2.0cm) battery-powered electronic box that can be worn around the neck which connects via wires to both earphones and headphones (we will supply both earpieces, and let the patient choose). The RA, trained on use of the HAD by an experienced research audiologist, will instruct the patient in use of the HAD, and test the device to ensure proper functioning. The patient will also receive an instruction sheet (Appendix 3). Subjects will be encouraged to use the HAD during any encounters with ED staff.
62395593|NCT03050723|OTHER|Princess® FILLER|
62395594|NCT05372991|ACTIVE_COMPARATOR|0.025% atropine sulphate|The comparator formulation of 0.025% atropine sulfate monohydrate in normal saline will be prepared by diluting commercial 1% atropine sulphate solution with physiologic saline.
62777585|NCT01066962|EXPERIMENTAL|darunavir/r + raltegravir|
62187522|NCT04157036|EXPERIMENTAL|800mg Ibuprofen|Subject will take 800mg of Ibuprofen 45 minutes prior to anesthetic delivery.
62395595|NCT05372991|PLACEBO_COMPARATOR|vehicle|CBT-009 vehicle formulation is a proprietary sterile ophthalmic solution that does not contain CBT-009 drug substance.
62187523|NCT04157036|EXPERIMENTAL|40mg Methylprednisolone|Subject will take 40mg of Methylprednisolone 45 minutes prior to anesthetic delivery.
62570725|NCT04892329|NO_INTERVENTION|without EUS AI navigation system augmentation|The endoscopists in the contrpl group performs the examination routinely without special prompts.
62777586|NCT01846650|EXPERIMENTAL|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
62777587|NCT01846650|ACTIVE_COMPARATOR|XELODA|Single oral XELODA 2000mg qd
62777588|NCT04890015|EXPERIMENTAL|Intraoperative transanal decompression tube placement|Intraoperatively under direct vision in the lower rectum, the balloon of the catheter will be inflated with 5-10cc of distilled water and it will be secured with a dressing / tape to the buttock connected to a collection bag.
62187524|NCT03672942|EXPERIMENTAL|Communication Skills|Male and female participants will listen to a description of John Gottman's Gentle Start-up communication skills training exercise and practice the technique in the lab for approximately 8 minutes.
62187525|NCT03672942|EXPERIMENTAL|Mindfulness|Male and female participants will listen to a script about Acceptance/Willingness of unwanted emotions written by Amie Zarling and practice this technique in the lab for approximately 8 minutes.
62187526|NCT03672942|PLACEBO_COMPARATOR|Placebo|Male and female participants will listen to music in lieu for 8 minutes.
62187527|NCT03362541|EXPERIMENTAL|MS INFoRm group|Participants in the MS INFoRm group will be given a login and password that will take them to the MS INFoRm webpage. Access will be granted for 3-months, starting on the date of the first login. Participants can access the website at any time, at their own volition over the 3-months.
62187528|NCT03362541|ACTIVE_COMPARATOR|Usual care control group|Participants in the usual care group will be given a login and password that will take them to a usual care webpage. Access will be granted for 3-months, starting on the date of the first login. Participants can access the website at any time, at their own volition over the 3-months.
62187529|NCT01741389|PLACEBO_COMPARATOR|Sleep only|Placebo given at night to tetraplegic individuals before going to sleep,
62187530|NCT01741389|ACTIVE_COMPARATOR|Melatonin|Melatonin given at night to tetraplegic individuals before going to sleep.
62570726|NCT04244552|EXPERIMENTAL|ATRC-101 Q3W|
62777589|NCT04890015|NO_INTERVENTION|Non intraoperative transanal decompression tube placement|The usual postoperative care approved by the unit will be followed.
62570727|NCT04244552|EXPERIMENTAL|ATRC-101 Q2W|
62570728|NCT04244552|EXPERIMENTAL|ATRC-101 Q3W + Pembrolizumab|Pembrolizumab 200mg IV Q3W or 400mg IV Q6W
62002054|NCT04124172|SHAM_COMPARATOR|Sham rTMS|"Sham rTMS (Magstim Super Rapid, Magstim Company, Whitland, Wales, UK) with eight-shaped coil (1 Hz, 1500 stimuli) in M1of the contralateral hemisphere to the lesion (healthy side). Investigators will make the simulation disconnecting the coil but keeping its position during the same time as the real one. Intervention will be performed before one hour rehabilitation session of the upper limb according to our clinical protocol, completing 15 sessions."
62002055|NCT06340035|EXPERIMENTAL|Percutaneous Peripheral Nerve Stimulation|Nerves are localized at an ultrasound-guided level and with respect to the vascular-nervous package two acupuncture needles are inserted, one for each nerve. The stimulation is the same as the TENS group: 10 stimulations x 10 times x 10 seconds, evoking the maximum contraction without pain.
62002056|NCT06340035|ACTIVE_COMPARATOR|Transcutaneous electrical nerve stimulation|Two surface electrodes are inserted at the level of the superior gluteal and inferior gluteal nerve tract. A protocol of 10 stimulations x 10 seconds of stimulations x 10 times is performed with a 10 second rest between each repetition. A maximum contraction evoked without pain is sought.
62002057|NCT03759912||PVI using Ultra-High-Resolution Mapping|The paroxysmal atrial fibrillation patients who received pulmonary vein antral catheter ablation for electrical isolation of pulmonary veins using ultra-high-resolution mapping system (Rhythmia High Density mapping system).
62002058|NCT03636750|EXPERIMENTAL|HB002.1T 2mg/kg|Participants received a 2mg/kg dose of HB002.1T via intravenous injection.
62395596|NCT05372991|EXPERIMENTAL|CBT-009, Low Dose|CBT-009 low dose formulation is a proprietary sterile ophthalmic solution that contain low dose of CBT-009 drug substance.
62002059|NCT03636750|EXPERIMENTAL|HB002.1T 4mg/kg|Participants received a 4mg/kg dose of HB002.1T via intravenous injection.
62002060|NCT03636750|EXPERIMENTAL|HB002.1T 8mg/kg|Participants received a 8mg/kg dose of HB002.1T via intravenous injection.
62002061|NCT03636750|EXPERIMENTAL|HB002.1T 12mg/kg|Participants received a 12mg/kg dose of HB002.1T via intravenous injection.
62002062|NCT03636750|EXPERIMENTAL|HB002.1T 16mg/kg|Participants received a 16mg/kg dose of HB002.1T via intravenous injection.
62002063|NCT03636750|EXPERIMENTAL|HB002.1T 20mg/kg|Participants received a 20mg/kg dose of HB002.1T via intravenous injection.
62002064|NCT04107571||Cohort|
62002065|NCT05286190|ACTIVE_COMPARATOR|Transversus Abdominis Plane Block|US-guided Transversus Abdominis Plane Block was applied with 0.5 ml/kg of %25 Bupivacaine at each side before the surgical incision
62002066|NCT05286190|ACTIVE_COMPARATOR|Caudal Epidural Block|US-guided Caudal Block was applied with 0.7ml/kg of %25 Bupivacaine before the surgical incision
62395597|NCT05372991|EXPERIMENTAL|CBT-009, Mid Dose|CBT-009 mid dose formulation is a proprietary sterile ophthalmic solution that contain mid dose of CBT-009 drug substance.
62002067|NCT04776967|ACTIVE_COMPARATOR|Compression Profile 4|Compression Profile/Schedule 4 = 10 minute linear, Total Time Interval of Compression to treatment depth = 10 minutes, Rate (slope) of compression = Linear rate of compression = 4.5 fsw/min to arrival at treatment depth 45 fsw
62002068|NCT04776967|ACTIVE_COMPARATOR|Compression Profile 3|Compression Profile/Schedule 3 = 10 minute non-linear, Total Time Interval of Compression to treatment depth = 10 minutes Rate (slope) of compression = Non-Linear rate of compression = 3 fsw/min to a depth of 17 fsw, then 5 fsw/min up to a depth of 38.5 fsw, then 6.5 fsw/min to arrival at the treatment depth of 45 fsw
62002069|NCT04776967|ACTIVE_COMPARATOR|Compression Profile 2|Compression Profile/Schedule 2 = 15 minute linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Linear rate of compression = 4.5 fsw/min to arrival at the treatment depth 45 fsw
62002070|NCT04776967|ACTIVE_COMPARATOR|Compression Profile 1|Compression Profile/Schedule 1 = 15 minute non-linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Non-Linear rate of compression = 2 fsw/min to a depth of 13 fsw, then 3 fsw/min up to a depth of 35 fsw, then 5 fsw/min to arrival at the treatment depth of 45 fsw
62002071|NCT03973346|EXPERIMENTAL|Intervention group|Encounters at primary care clinics with the risk screening tool
62395598|NCT05372991|EXPERIMENTAL|CBT-009, High Dose|CBT-009 high dose formulation is a proprietary sterile ophthalmic solution that contain high dose of CBT-009 drug substance.
62395599|NCT06219733|EXPERIMENTAL|Vactosertib and imatinib combination|Vactosertib 200 mg PO BID 5 days on / 2 days off in combination with imatinib 400 mg PO QD daily
62395600|NCT06219733|ACTIVE_COMPARATOR|Imatinib alone|Imatinib 400 mg PO QD daily
62395601|NCT06724705|PLACEBO_COMPARATOR|Placebo|Participants consume sucrose and wear the Smart Underwear device
62002072|NCT03973346|NO_INTERVENTION|Comparison group|Propensity score matched comparison encounters
62002073|NCT03434756|EXPERIMENTAL|Propioceptive Training|
62002074|NCT02075320|EXPERIMENTAL|Stationary Digital Chest Tomosynthesis|All patients will be included in the experimental group.
62002075|NCT02665871|EXPERIMENTAL|one dose of Influenza Vaccine in aged 18 years and older|One dose of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in aged 18 years and older
62002076|NCT02665871|EXPERIMENTAL|One dose of Influenza Vaccine in aged 3-17 year|One dose of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in aged 3-17 years
62002077|NCT02665871|PLACEBO_COMPARATOR|placebo in aged 18 years and older|placebo in 10 subjects aged 18 years and older on day 0
62002078|NCT02665871|PLACEBO_COMPARATOR|placebo in aged 3-17 years|placebo in 10 subjects aged 3-17 years on day 0
62002079|NCT04767009|EXPERIMENTAL|SBRT for oligo-residual NSCLC|
62002080|NCT00858871|ACTIVE_COMPARATOR|Brivanib|
62002081|NCT00858871|ACTIVE_COMPARATOR|Sorafenib|
62791748|NCT03653143|EXPERIMENTAL|Treatment Group|Assessment #1 Baseline Visit \>\> 3 month JASPER intervention (weekly) \>\> Assessment #2 Research Visit \>\> 3 month treatment as usual \>\> Assessment #3 Research Visit
62002082|NCT01485861|EXPERIMENTAL|Phase Ib: Ipatasertib 400 mg + abiraterone|Participants will receive ipatasertib 400 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg twice daily (bid) continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
62002083|NCT01485861|EXPERIMENTAL|Phase Ib: Apitolisib 30 mg + abiraterone|Participants will receive apitolisib 30 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg twice daily (bid) continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
62002084|NCT01485861|EXPERIMENTAL|Phase II: Ipatasertib 400 mg + abiraterone|Participants will receive Ipatasertib 400 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
62395602|NCT06724705|EXPERIMENTAL|Experimental|Participants consume lactose and wear the Smart Underwear device
62002085|NCT01485861|EXPERIMENTAL|Phase II: Ipatasertib 200 mg + abiraterone|Participants will receive Ipatasertib 200 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
62002086|NCT01485861|PLACEBO_COMPARATOR|Phase II: Placebo + abiraterone|Participants will receive placebo (for Ipatasertib) once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
62187531|NCT03188653|ACTIVE_COMPARATOR|CeraVe® Eczema Soothing Body Wash|One of the 7 forearm locations will be selected to receive CeraVe® Eczema Soothing Body Wash one time only.
62187532|NCT03188653|ACTIVE_COMPARATOR|Cetaphil® RestoraDerm® Eczema Calming Body Wash|One of the 7 forearm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash one time only.
62187533|NCT03188653|ACTIVE_COMPARATOR|Dove® Sensitive Skin Body Wash|One of the 7 forearm locations will be selected to receive Dove® Sensitive Skin Body Wash one time only.
62187534|NCT03188653|ACTIVE_COMPARATOR|Eucerin® Skin Calming Body Wash|One of the 7 forearm locations will be selected to receive Eucerin® Skin Calming Body Wash one time only.
62395603|NCT05485961|EXPERIMENTAL|CSL300 (low dose)(Phase 2b)|Intravenous (IV) administration
62395604|NCT05485961|EXPERIMENTAL|CSL300 (medium dose)(Phase 2b)|IV administration
62395605|NCT05485961|EXPERIMENTAL|CSL300 (high dose)(Phase 2b)|IV administration
62395606|NCT05485961|PLACEBO_COMPARATOR|Placebo (Phase 2b)|IV administration
62395607|NCT05485961|EXPERIMENTAL|CSL300 (Phase 3)|IV administration
62395608|NCT05485961|PLACEBO_COMPARATOR|Placebo (Phase 3)|IV administration
62395609|NCT06722742|ACTIVE_COMPARATOR|Group K|Group K receive Inj: ketamine
62395610|NCT06722742|ACTIVE_COMPARATOR|Group T|Group T receive Inj: Tramadol
62395611|NCT02557308||Remsima™|Patients who have received only Remsima were included in this analysis group
62395612|NCT02557308||Switch to Remsima I|Patients who switched from Remicade to Remsima were included in this analysis group.
62395613|NCT02557308||Switch to Remsima II|Patients who switched to Remsima from biologic treatment other than Remicade were included in this analysis group
62791749|NCT03653143|EXPERIMENTAL|Control/Wait-list Group|Assessment #1 Baseline Visit \>\> 3 month treatment as usual \>\> Assessment #2 Research Visit \>\> 3 month JASPER intervention \>\> Assessment #3 Research Visit
62395614|NCT02557308||Remicade|Patients who switched from Remsima to Remicade were included in this analysis group.
62395615|NCT02557308||Switch to Remicade I|Patients who switched from Remsima to Remicade were included in this analysis group.
62395616|NCT02557308||Switch to Remicade II|Patients who switched to Remicade from biologic treatment other than Remsima were included in this analysis group.
62395617|NCT02557308||Other anti-TNF drugs|"Following patients were included in other anti-TNF group.~* Patients who have received only anti-TNF other than Remsima or Remicade~* Patients who switched from biologic treatment other than anti-TNF before study enrollment to anti-TNF other than Remsima or Remicade"
62395618|NCT02557308||Switch to Other Anti-TNF|Patients who switched from Remsima or Remicade to other anti-TNF other than Remicade were included in this analysis group
62791750|NCT03374033|NO_INTERVENTION|NUTR (Nutrition) 0_STIMUL(Stimulation) 0|Standard Nutrition and no Physical Stimulation
62791751|NCT03374033|EXPERIMENTAL|NUTR 0_STIMUL +|Standard Nutrition and Physical Stimulation
62791752|NCT03374033|EXPERIMENTAL|NUTR +_STIMUL 0|Enhanced Nutrition, and no Physical Stimulation
62791753|NCT03374033|EXPERIMENTAL|NUTR +_STIMUL +|Enhanced Nutrition and Physical Stimulation
62791754|NCT00432406|ACTIVE_COMPARATOR|1|infliximab
62791755|NCT00432406|ACTIVE_COMPARATOR|2|etanercept
62791756|NCT01035489|ACTIVE_COMPARATOR|CRT; RV apical lead placement|Right ventricular apical lead placement in CRT
62791757|NCT01035489|ACTIVE_COMPARATOR|CRT; RV high posterior septum|High posterior septal lead placement in CRT
62791758|NCT02001935|OTHER|theophylline|
62791759|NCT05851820||diabetic patients with COVID-19|patients hospitalized for COVID-19 and were diabetic
62791760|NCT05851820||Non-diabetic patients with COVID-19|patients hospitalized for COVID-19 and were not diabetic
62791761|NCT06263816|EXPERIMENTAL|Carvédilol|
62791762|NCT06263816|PLACEBO_COMPARATOR|Placebo|
62570729|NCT04244552|EXPERIMENTAL|ATRC-101 Q2W + Pegylated liposomal doxorubicin (PLD)|PLD 40mg/m\^2 IV Run-in period of 28 days, and then 40mg/m\^2 IV Q4W
62777590|NCT05932368||patients undergoing open heart surgery|"Patients who underwent open heart surgery at Istanbul University, Istanbul Medical Faculty, Department of Cardiovascular Surgery between 2018 and 2022, and whose data required for the study are complete in their discharge file.~The inclusion criteria of the files were: the patient was between the ages of 25-70, had undergone open heart surgery, was included in a phase 1 cardiac rehabilitation program, and had a preoperative ejection fraction of over 40%. Files of patients who do not meet the inclusion criteria and do not give the necessary permission to use their data will not be included in the study."
62187535|NCT03188653|ACTIVE_COMPARATOR|Aveeno® Skin Relief Body Wash|One of the 7 forearm locations will be selected to receive Aveeno® Skin Relief Body Wash one time only.
62570730|NCT02660567|EXPERIMENTAL|Amr Maneuver|Active management of third stage plus Amr's maneuver
62570731|NCT02660567|NO_INTERVENTION|Active management alone|Active management of third stage alone
62187536|NCT03188653|ACTIVE_COMPARATOR|MooGoo® Milk Wash|One of the 7 forearm locations will be selected to receive MooGoo® Milk Wash one time only.
62187537|NCT03188653|ACTIVE_COMPARATOR|Free & Clear Liquid Cleanser|One of the 7 forearm locations will be selected to receive Free \& Clear Liquid Cleanser
62570732|NCT06354036|EXPERIMENTAL|ThTV（the Transhiatal Tunnel Valvuloplasty technique group）|Patients who meet the inclusion criteria will undergo ThTV anastomosis after proximal gastrectomy
62570733|NCT01703572|EXPERIMENTAL|OMP-52M51|
62570734|NCT05891093|EXPERIMENTAL|Fluzoparib+Endocrine Therapy|Fluzoparib 50mg bid orally for 1 year, combined with physician's choice of endocrine therapy as clinically indicated (eg, aromatase inhibitor, tamoxifen, toremifene endocrine therapy for 5 to 10 years; CDK4/6 inhibitor therapy for 2 years; ovarian function suppression with LHRH agonist).
62570735|NCT05891093|ACTIVE_COMPARATOR|Endocrine Therapy|Physician's choice of endocrine therapy as clinically indicated (eg, aromatase inhibitor, tamoxifen, toremifene endocrine therapy for 5 to 10 years; CDK4/6 inhibitor therapy for 2 years; ovarian function suppression with LHRH agonist).
62187538|NCT04510610|EXPERIMENTAL|Camrelizumab plus decitabine|Decitabine 10 mg/day, days 1-5; Camrelizumab 200 mg, day 8, every 3 weeks.
62395619|NCT04969653||Cases|All adults with an episode of active atopic dermatitis at any point between 1st Jan 2010 to 1st Jan 2015 will be included for analysis.
62395620|NCT04969653||Controls|Adults without atopic dermatitis or other skin conditions matched to cases by age, gender, and duration of practice registration.
62570736|NCT00957801|ACTIVE_COMPARATOR|Testosterone injection|Testosterone enanthate given as a single 100 mg Intramuscular (IM) injection
62002087|NCT01485861|EXPERIMENTAL|Safety Cohort: Ipataseritib 400 mg + Abiraterone + Prednisone|Participants will receive ipatasertib 400 mg orally once daily and/or prednisone/prednisolone 5 mg orally once daily or bid and/or abiraterone 1000 mg orally once daily according to the following schedule: ipatasertib in the morning during Cycle 1, Days 1-7; ipatasertib in the morning plus prednisone/prednisolone once at night during Cycle 1, Day 8; ipatasertib in the morning plus prednisone/prednisolone bid (morning and night) during Cycle 1, Days 9-11; ipatasertib in the morning plus prednisone/prednisolone bid (morning and night) and abiraterone in the morning during Cycle 1, Days 12-18; ipatasertib in the evening plus prednisone/prednisolone bid (morning and night) and abiraterone at the same time as ipatasertib during Cycle 1, Days 19-25; Cycle 2 and beyond ipatasertib once daily in the morning or evening, abiraterone at the same time as ipatasertib, and prednisone/prednisolone bid.
62002088|NCT04131101|EXPERIMENTAL|Community Organizing|All tenants in three TCHC buildings will be invited to participate in a survey on their building conditions at baseline, 6 months and 12 months. Once baseline data collection is complete, there will be a community organizing campaign involving tenants to advocate for improved building conditions.
62570737|NCT00957801|ACTIVE_COMPARATOR|Testosterone gel|Testosterone topical gel (Androgel 1%) 10 mg administered daily for seven days
62002089|NCT03018392|EXPERIMENTAL|Tritanium|TLIF with Tritanium® PL cage and pedicle screw fixation
62002090|NCT04512911|ACTIVE_COMPARATOR|Patients who didn't fail AAD|This group of patients will be randomized to 3 subgroups: 1) Endocardial ablation; 2) Endocardial - Epicardial ablation; 3) Antiarrhythmic medications
62395621|NCT05024721|EXPERIMENTAL|HIP2101|Taking HIP2101+HPP2102 once daily for 2 weeks.
62570738|NCT00957801|ACTIVE_COMPARATOR|Testosterone injection and Medrol 6 day dose pack|Testosterone enanthate given as a single 100mg Intramuscular (IM) injection. Medrol 6 day dose pack was administered as directed with daily doses decreasing by 4mg per day with an additional 4mg given on day 7. Day one dose: 24mg, day two dose: 20mg, day three dose: 16mg, day four dose: 12mg, day five dose: 8mg, day six dose: 4 mg, day seven dose: 4mg.
62570739|NCT00957801|ACTIVE_COMPARATOR|Medrol 6 day dose pack|Medrol 6 day dose pack was administered as directed with daily doses decreasing by 4mg per day with an additional 4mg given on day 7. Day one dose: 24mg, day two dose: 20mg, day three dose: 16mg, day four dose: 12mg, day five dose: 8mg, day six dose: 4 mg, day seven dose: 4mg.
62791763|NCT03672292|EXPERIMENTAL|SCY-078 plus Voriconazole|"Either IV voriconazole (loading dose of 6 mg/kg BID on Day 1 followed by maintenance dose of 4 mg/kg BID from Day 2 onwards) OR oral voriconazole (loading dose of 400 mg BID on Day 1 followed by maintenance dose of 200 mg BID from Day 2 onwards).~PLUS Oral SCY-078 tablets (loading dose of 500 mg BID on Days 1 and 2 followed by maintenance dose of 500 mg QD from Day 3 onwards). Treatment duration = minimum 6 weeks/Max 13 weeks"
62395622|NCT05024721|ACTIVE_COMPARATOR|RLD2101|Taking RLD21012101+HPP2101 once daily for 2 weeks.
62002091|NCT04512911|ACTIVE_COMPARATOR|Patients who failed AAD|This group of patients will be randomized to 2 subgroups: 1) Endocardial ablation; 2) Endocardial - Epicardial ablation
62002092|NCT00862407||1|Non-pulsatile Group (conventional)
62002093|NCT00862407||2|Pulsatile group (Alternate)
62002094|NCT01641562||TAXANES|patients with early breast cancer, scheduled to receive taxanes, with doses according to the stage of the disease
62002095|NCT04688164|EXPERIMENTAL|REL-1017|A 75 mg REL-1017 loading dose (three 25 mg REL-1017 tablets) will be administered on Day-1 of the 28-day treatment period. From Day-2 to Day-28, participants will take 25 mg REL-1017 in addition to their ongoing antidepressant.
62002096|NCT04688164|PLACEBO_COMPARATOR|Placebo|Three tablets of matching placebo will be administered on Day-1 of the 28-day treatment period. From Day-2 to Day-28, participants will take 1 placebo tablet in addition to their ongoing antidepressant.
62002097|NCT02159547|ACTIVE_COMPARATOR|Dexketoprofen|50 mg intravenous dexketoprofen in 50 ml normal saline in 5 minutes infusion.
62002098|NCT02159547|PLACEBO_COMPARATOR|normal slaline|50 ml normal saline
62002099|NCT03627728|EXPERIMENTAL|regorafenib|Regorafenib 160 mg, 4 tablets once daily on days 1-21, every 4 weeks, until intolerance or progression disease
62002100|NCT03627728|PLACEBO_COMPARATOR|placebo|Placebo 4 tablets once daily on day 1-21, every 4 weeks, until intolerance or progression disease
62777591|NCT03907462|EXPERIMENTAL|Treatment One|Participants assigned to the SMART 2.0 with technology and personal health coaching treatment group (i.e., treatment one) will receive the following: 1) consumer-level wearable and scale with a corresponding app, 2) daily text messages related to physical activity, diet, sleep and weight loss/maintenance, 3) access to SMART 2.0 social media pages and content through an online group with 6 to 12 participants total, and 4) technology-mediated, real-time individual health coaching. Participants will receive 1 to 2 text messages on a daily basis; be asked to use their wearable on a daily basis and self-weigh using the scale at least once per week; be asked to interact with their online group via social media as frequently as possible; and speak with their health coach at a predetermined session schedule.
62777592|NCT03907462|EXPERIMENTAL|Treatment Two|Participants assigned to the SMART 2.0 technology alone treatment group (i.e., treatment two) will receive the following: 1) consumer-level wearable and scale with a corresponding app, 2) daily text messages related to physical activity, diet, sleep and weight loss/maintenance, and 3) access to SMART 2.0 social media pages and content through an online group with 6 to 12 participants total. Participants will receive 1 to 2 text messages on a daily basis; be asked to use their wearable on a daily basis and self-weigh using the scale at least once per week; and be asked to interact with their online group via social media as frequently as possible.
62777593|NCT03907462|NO_INTERVENTION|Control|Participants assigned to the control group will receive a consumer-level wearable and scale with a corresponding app to use at their discretion.
62777594|NCT03778385|EXPERIMENTAL|Isometric Exercise|Submaximal isometric resistance exercise of the arm.
62777595|NCT03778385|EXPERIMENTAL|Dynamic Exercise|Submaximal dynamic resistance exercise of the arm.
62777596|NCT06228690|EXPERIMENTAL|Gold Fish exercises|Gold Fish exercises for the flexibility of TMJ that will target the Jaw muscles.
62777597|NCT06228690|EXPERIMENTAL|Cervico-thoracic postural correction training.|Cervico-thoracic postural correction training for upper thoracic and neck muscles.
62777598|NCT06228690|ACTIVE_COMPARATOR|Conventional PT treatment|Conventional PT including Hot Pack for 10mins, Active-Passive neck Stretching Exercise + jaw Isometric Exercises.
62777599|NCT05740865||patients who developed deep surgical site infection after thoracolumbar surgery|this group included patients who developed deep surgical site infection after open posterior instrumented thoracolumbar surgery
62777600|NCT05740865||patients who did not develop deep surgical site infection after thoracolumbar surgery|this group included patients who did not develop deep surgical site infection after open posterior instrumented thoracolumbar surgery
62777601|NCT05994079|EXPERIMENTAL|high intensity focused ultrasound group|This group includes 43 patients who have abdominal skin laxity post sleeve gastrectomy and who will receive high intensity focused ultrasound. patients will receive one session; time of session is 40 minutes.
62777602|NCT05994079|ACTIVE_COMPARATOR|medical topical firming creams group|This group includes 43 patients who have abdominal skin laxity post sleeve gastrectomy and who will receive medical topical firming creams.
62002101|NCT06021236|EXPERIMENTAL|mindfulness-based intervention and routine care|mindfulness-based intervention including: breathing awareness, body scanning, mindful yoga, mindful eating, and loving-kindness meditation. From the time when the patients signed up to be the first to receive the cardiac device surgery schedule, the experimental group that met the including criteria, in addition to following the routine care of the hospital, was involved in teaching the above mindfulness skills, and Osaka continued to follow the regular care.
62002102|NCT06021236|OTHER|The control group received the CIED procedure routine care|From the time when the patients signed up to be the first to receive the cardiac device surgery schedule, the control group that met the including criteria take routine care of the hospital.
62002103|NCT03072173|EXPERIMENTAL|PSG with Xylometazoline then placebo|"Patients are administered nasal CPAP with humidifier prior to PSG~Patients in this arm receive Xylometazoline on night 2 of PSG and placebo on night 3 of PSG."
62570740|NCT05154669|ACTIVE_COMPARATOR|Standard Smoking Cessation Coaching|Participants will receive 5 counseling sessions over approximately 8 weeks as per standard smoking cessation programs. Participants will receive 8 weeks of nicotine replacement therapy (patches, gum, and/or lozenges).
62570741|NCT05154669|EXPERIMENTAL|Integrated Financial-Smoking Cessation Coaching|The integrated intervention will provide 5 counseling sessions over approximately 8 weeks that integrates financial coaching into the smoking cessation program. Participants will receive 8 weeks of nicotine replacement therapy (patches, gum, and/or lozenges).
62187539|NCT02782611|EXPERIMENTAL|Treatment|ENHANCE (Enduring Happiness and Continued Self-Enhancement) is a 12-week program that includes an introductory session, 10 weekly sessions focusing on different happiness principles, and a final session focusing on integrating aspects of the program and continuing to practice these principles moving forward. Through completing this program, participants will gain an education on a wide-range of happiness principles and an arsenal of strategies for developing happiness boosting habits and skills.
62570742|NCT01069042|ACTIVE_COMPARATOR|preserved LVEF under ACEi treatment|preserved LVEF under ACEi treatment
62570743|NCT01069042|EXPERIMENTAL|Poor LVEF group|Poor LVEF under ACEi treatment
62002104|NCT03072173|EXPERIMENTAL|PSG with placebo then Xylometazoline|"Patients are administered nasal CPAP with humidifier prior to PSG~Patients in this arm receive placebo on night 2 of PSG and Xylometazoline on night 3 of PSG."
62187540|NCT02782611|NO_INTERVENTION|Waiting Group Control|The waiting group control will complete the same assessments as the experimental group but without receiving the intervention.
62187541|NCT02432170|EXPERIMENTAL|Foot/Ankles imaged with tomosynthesis|"Intervention: Digital Tomosynthesis of Foot and Ankle~The intervention, digital tomosynthesis of the foot and ankle, will be done on eligible participants. The resulting images will be compared to radiography and weight-bearing CT images from the same participants."
62187542|NCT04311645|OTHER|1st group|Oral activated charcoal in a dose of 30 gm/day
62187543|NCT04311645|OTHER|2nd group|Dry seeds in a dose of 1 gm/ day
62187544|NCT04311645|NO_INTERVENTION|3rd group|control group
62187545|NCT01158989||Critically ill|Critically ill subjects were intubated, mechanically ventilated and sedated
62395623|NCT06303791|EXPERIMENTAL|Digital Psychosocial Intervention group|The intervention group will be made up of five successive groups of 8 to 10 families that will receive 12 weekly 90-minute sessions in a synchronous virtual mode by zoom platform The integrity of the sessions will be guaranteed by a digital manual that clearly outlined all the procedures to be used in the intervention. Additionally, sessions will be audiotaped and reviewed by a team member through a checklist to ensure groups receive equivalent set of information.
62395624|NCT06303791|NO_INTERVENTION|Control group|The control group of parents will be made up of another five successive groups of 8 to 10 families who will receive 12 sessions weekly 90 minutes. In these sessions these families will be encouraged to discuss their thoughts and share their experiences in a non-directive environment. The therapist will not be allowed to provide specific psychotherapy, psychoeducation or psychosocial techniques, nor any additional comments or information, but rather to guide the groups and allow everyone to express and give their personal point of view. The use of an active control group will ensure that the observed benefits are primarily due to the digitally supported psychosocial program only.
62395625|NCT06722651|EXPERIMENTAL|Renal Denervation|Renal angiogram and Renal Denervation procedure
62395626|NCT06722651|SHAM_COMPARATOR|Sham Control group|Renal angiogram followed by Sham procedure
62395627|NCT06722651|NO_INTERVENTION|Open-label Control group|The patient will not undergo either the renal angiogram or the RDN procedure.
62570744|NCT05321043|OTHER|Vitamin B2 labeled group|A liquid of vitamin B2 and hand sanitizer (0.12mg/mL) is marked on the patients' hands outside the endoscopy center.
62570745|NCT06571721|EXPERIMENTAL|Almond Oil|Almond Oil. 1-2 Drops of randomized topical product will be applied on entire face nightly. Duration: 16 weeks
62570746|NCT06571721|EXPERIMENTAL|Almond oil augmented with 0.5% Vitamin E|Almond oil augmented with 0.5% Vitamin E. 1-2 Drops of randomized topical product will be applied on entire face nightly. Duration: 16 weeks
62002105|NCT02832674|EXPERIMENTAL|Single Treatment|All enrolled subjects will receive a Percutaneous Radiofrequency Single Treatment'
62002106|NCT03282552|ACTIVE_COMPARATOR|Study Group 1|"The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 1, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment.~The first Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=60L/min."
62002107|NCT03282552|ACTIVE_COMPARATOR|Study Group 2|"The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 2, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment.~The second Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=40L/min."
62187546|NCT01158989||Ambulatory Group|Subjects were scheduled for an outpatient procedure but were otherwise healthy
62187547|NCT03948464|EXPERIMENTAL|Slow release oral morphine (SROM)|Daily witnessed ingestion of SROM (24-hour formulation) for 24 weeks as per provincial and national guidelines for opioid use disorder.
62777603|NCT06583564|EXPERIMENTAL|ICG group|Approximately 0.3 ml of ICG dissolved in 2.5 mg/ml of sterile water was injected submucosally by the endoscopic doctors through colonoscopy at two points around the tumor.All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose using ICG lymphangiography procedure
62777604|NCT06583564|NO_INTERVENTION|Non-ICG group|All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose.
62777605|NCT05032339||Remnant/ Leftover specimens|Specimens that meet inclusion/exclusions criteria and are leftover from routine flow cytometry testing for plasma cell disorders
62187548|NCT03948464|ACTIVE_COMPARATOR|Methadone|Daily witnessed ingestion of methadone for 24 weeks as per provincial and national guidelines for opioid use disorder.
62187549|NCT02250534|EXPERIMENTAL|0.8 mg nicotine|0.8 mg nicotine very low nicotine content cigarettes
62187550|NCT02250534|EXPERIMENTAL|0.12 mg nicotine|0.12 mg nicotine very low nicotine content cigarettes
62187551|NCT02250534|EXPERIMENTAL|0.03 mg nicotine|0.03 mg nicotine very low nicotine content cigarettes
62187552|NCT01168336|EXPERIMENTAL|betahistine|Betahistine 24 mg tablets
62187553|NCT01168336|EXPERIMENTAL|betahistine XR|betahistine 32 mg tablets
62187554|NCT01168336|PLACEBO_COMPARATOR|placebo|
62187555|NCT00609401|EXPERIMENTAL|1|Sorafenib 400 bid + IL-2 3 MU per 5 day/week for 2 weeks every 4
62187556|NCT00609401|EXPERIMENTAL|2|Sorafenib 400 mg bid
62187557|NCT03876106|EXPERIMENTAL|LUT014 dose level 1|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
62187558|NCT03876106|EXPERIMENTAL|LUT014 dose level 2|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
62187559|NCT03876106|EXPERIMENTAL|LUT014 dose level 3|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
62187560|NCT04669379|EXPERIMENTAL|Intervention group (IG/EXPECT)|
62187561|NCT04669379|NO_INTERVENTION|Standard of Care (SOC)|
62187562|NCT01869140|SHAM_COMPARATOR|sham spinal manual therapy|activator set to zero
62187563|NCT01869140|EXPERIMENTAL|percussive spinal manual therapy|activator set to the maximum force
62187564|NCT01869140|EXPERIMENTAL|Firm thoracic spinal manual therapy|Firm thoracic manipulation
62187565|NCT03967912|EXPERIMENTAL|MOVE UP for Caregivers|12-week lifestyle intervention focusing on diet and activity
62777606|NCT04872517|EXPERIMENTAL|34 head and neck cancer patients, expected to proceed chemotherapy or radiotherapy in hospital.|Total 34 anticipants will recruit in this research. Age was limited between 20years old to 75 years old. All of anticipants agree to join this trail and be followed through treatment , and without underlying disease that threaten life.
62777607|NCT00084487|EXPERIMENTAL|Treatment (becatecarin)|Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62187566|NCT04185298|ACTIVE_COMPARATOR|Group 1 (No treatment)|Group 1: Participants will have continuous activity monitoring (via Fitbit)
62187567|NCT04185298|EXPERIMENTAL|Group 2 (Experimental)|Group 2: Participants will receive the mSIM treatment and have their activity monitored continuously (via Fitbit)
62187568|NCT03633864|EXPERIMENTAL|FMT treatment|FMT treatment arm: Accept fecal microbiota transplantation without changing the ongoing treatment strategy.
62187569|NCT01606319|EXPERIMENTAL|acetaminophen|acetaminophen given as needed for pain or fever
62187570|NCT01606319|EXPERIMENTAL|ibuprofen|ibuprofen given as needed for pain or fever
62187571|NCT06311747|EXPERIMENTAL|Oculo-motor exercise|Additional oculo-motor exercises will be administered to participants' warm-up before forehand and backhand stroke evaluation. As oculo-motor exercises, 3 different exercises will be applied: stepping exercise with eye movements and head rotation (The eyes are fixed on the thumb and the head rotates right and left and walks 10 steps forward and 10 steps back.), accommodation (First eyes fixed on the near target, then fixed on a target approximately 20-30 m away.) and pen tracking with 5 different movements (Horizontal, vertical, diagonal, circular, infinite eight).
62187572|NCT02469883|EXPERIMENTAL|Sinotecean|
62187573|NCT05046106|PLACEBO_COMPARATOR|Placebo|500-mg placebo capsule, 4 capsules twice a day for 24 weeks.
62187574|NCT05046106|ACTIVE_COMPARATOR|MLC1501 Low-dose|MLC1501 low-dose 500-mg capsule, 4 capsules twice a day for 24 weeks.
62187575|NCT05046106|ACTIVE_COMPARATOR|MLC1501 High-dose|MLC1501 high-dose 500-mg capsule, 4 capsules twice a day for 24 weeks.
62187576|NCT01410864||DuraSeal Arm|Prospective enrollment of subjects who have received DuraSeal Exact Spinal Sealant System for treatment of an intentional or incidental dural tear during spine surgery.
62187577|NCT01410864||Control Arm|Subjects who have undergone a spinal procedure where techniques other than DuraSeal were administered for the treatment of either an intentional or incidental opening of the dura may be enrolled either prospectively or retrospectively (via medical record screening)
62187578|NCT03796000||colonoscopy: obese and smoker|"* 10 small tissue samples of the Colon transversum~* 3 EDTA blood samples and 1 Serum blood sample~* in some cases 1 single stool sample"
62187579|NCT03796000||colonoscopy: obese and non-smoker|"* 10 small tissue samples of the Colon transversum~* 3 EDTA blood samples and 1 Serum blood sample~* in some cases 1 single stool sample"
62777608|NCT04341688|EXPERIMENTAL|Povidone-Iodine 0.2% (BETADINE®)|0.2% Povidone-Iodine (BETADINE®) 10 ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
62777609|NCT04341688|EXPERIMENTAL|Hydrogen peroxide 1% (ActiveOxy)|ActiveOxy (1% Hydrogen peroxide) 10 ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
62777610|NCT04341688|ACTIVE_COMPARATOR|Neem extract (Azadirachta indicia)|Neem extract (Azadirachta indicia) gargle will be prepared by chemistry laboratory. patients will do 10ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
62777611|NCT04341688|ACTIVE_COMPARATOR|Hypertonic saline (2%NaCl)|10 ml gargle and nasal lavage using Hypertonic saline for 20-30 seconds, thrice daily for 6 days.
62187580|NCT03796000||colonoscopy: lean and smoker|"* 10 small tissue samples of the Colon transversum~* 3 EDTA blood samples and 1 Serum blood sample~* in some cases 1 single stool sample"
62777612|NCT04341688|PLACEBO_COMPARATOR|Positive controls|10 ml gargle and nasal lavage using distilled water for 20-30 seconds, thrice daily for 6 days.
62777613|NCT01950312|EXPERIMENTAL|gevokizumab|Solution for subcutaneous injection
62777614|NCT02795325|EXPERIMENTAL|PH Patients|
62777615|NCT02795325|EXPERIMENTAL|Healthy Volunteers|
62777616|NCT03851432|EXPERIMENTAL|Janagliflozin 25 mg plus metformin|Each patient will receive 25 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)
62777617|NCT03851432|EXPERIMENTAL|Janagliflozin 50 mg plus metformin|Each patient will receive 50 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)
62777618|NCT03851432|PLACEBO_COMPARATOR|Placebo/Janagliflozin plus metformin|In the core period, each patient will receive placebo plus metformin for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin plus metformin until Week 52.
62187581|NCT03796000||colonoscopy: lean and non-smoker|"* 10 small tissue samples of the Colon transversum~* 3 EDTA blood samples and 1 Serum blood sample~* in some cases 1 single stool sample"
62187582|NCT03796000||gastroscopy: obese and non-smoker undergoing bariatric surgery|"* 6 small tissue samples of the gastric corpus and 6 of the Duodenum~* 3 EDTA blood samples and 1 Serum blood sample~* in some cases 1 single stool sample~* 1cm long piece of the jejunum, which is usually disposed during bariatric surgery."
62187583|NCT03796000||gastroscopy: lean and non-smoker|"* 6 small tissue samples of the gastric corpus and 6 of the Duodenum~* 3 EDTA blood samples and 1 Serum blood sample~* in some cases 1 single stool sample"
62187584|NCT00687245|EXPERIMENTAL|1|esomeprazole magnesium 5 mg, weight 8 kg to \< 20kg
62777619|NCT03852095||minor trauma|Child from 1 to 18 years old suffering an isolated minor trauma presenting at the hospital emergency services.
62777620|NCT01406990||Aspirin 81 mg|Women with CAD taking 81 mg aspirin.
62187585|NCT00687245|EXPERIMENTAL|2|esomeprazole magnesium 10 mg, weight 8 kg to \< 20kg
62187586|NCT00687245|EXPERIMENTAL|3|esomeprazole magnesium 10 mg, weight \> 20 kg
62777621|NCT03895255|ACTIVE_COMPARATOR|IMA high ligation with routine SFM|Inferior mesenteric artery is ligated close to its origin. Splenic flexure is always mobilized.
62777622|NCT03895255|EXPERIMENTAL|IMA skeletonization and low ligation with selective SFM|Inferior mesenteric artery is ligated below the origin of left colic artery. Splenic flexure is mobilized only if needed.
62777623|NCT03505515||Lung Cancer Patricipants in China|Participants with advanced/metastatic lung cancer (advanced NSCLC (IIIB/IV) and extensive disease SCLC) in China
62187587|NCT00687245|EXPERIMENTAL|4|esomeprazole magnesium 20 mg, weight \> 20 kg
62187588|NCT03234712|EXPERIMENTAL|ABBV-321|ABBV-321 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
62187589|NCT04245345|OTHER|Single-arm|Subjects implanted with the Medtronic Micra AV device
62777624|NCT05011526|EXPERIMENTAL|MVC-COV1901|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
62777625|NCT05011526|EXPERIMENTAL|AZD1222|ChAdOx1 nCoV-19 vaccine
62777626|NCT05755568||MLD Participants|Data from medical records of participants diagnosed with late infantile or juvenile MLD at any time from 1 January 2000 to 31 December 2022 will be observed retrospectively.
62777627|NCT04683120|EXPERIMENTAL|Single Arm Study|This is a single arm study, which will involve all patients qualifying for Breast Conservation Therapy as a part of their breast cancer management excluding patients undergoing neoadjuvant therapy for inoperable disease.
62777628|NCT00400569|EXPERIMENTAL|Sunitinib Malate (SU011248) Treatment|Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks
62777629|NCT01548196|OTHER|standard percutaneous nephrostomy|Standard PCN
62777630|NCT01548196|OTHER|double-J ureteral stent,|double-J ureteral stent,
62777631|NCT01548196|OTHER|open-ended ureteral catheter|open-ended ureteral catheter
62777632|NCT01548196|NO_INTERVENTION|no nephrostomy or ureteral stent/catheter.|no nephrostomy or ureteral stent/catheter.
62777633|NCT00804934||0|
62777634|NCT01494597|EXPERIMENTAL|Isavuconazole and cyclosporine|Isavuconazole three times per day (TID) for two days followed by once a day (QD) for 6 days. Cyclosporine single doses on Days 1 and 15.
62777635|NCT02770300|NO_INTERVENTION|Conventional therapy|"The control group of patients will perform a conventional therapy without the use of the exoskeleton. The conventional therapy will consist in a traditional treatment of occupational therapy or physiotherapy without the use of the robotic device. The therapist will provide a specific conventional treatment comparable with the robotic treatment in terms of session time and therapeutic goals (i.e., 45 minutes per session, about 100, 150, 200 and 250 movements respectively for the first, second, third and fourth week). The level of difficulty of the exercises will be increased by the physiotherapist according to the degree of impairment of the patients.~The muscle and cerebral activity during the execution of the conventional therapy could be acquired."
62002108|NCT03282552|NO_INTERVENTION|Control group|"In the third group (control group) all patients will receive oxygen treatment according to the standard practice of our cardiac ICU department, i.e., Venturi mask with FiO2=60% and flow of 15L/min.~In this group all patients will receive the usual standard of care, with no other interventions included"
62002109|NCT04026919|EXPERIMENTAL|to analyze the effectiveness of Ok en Casa Zaindoo|The multicomponent online programme is composed of the components explained in the detailed study description:
62187590|NCT04865692|EXPERIMENTAL|Interventional group|The interventional group received resisted knee extension 20% of 1RM with blood flow restriction along with routine physical therapy.
62187591|NCT04865692|OTHER|Control Group|The Control group received routine physical therapy alone including knee isometrics and resisted knee extension
62187592|NCT03446638|EXPERIMENTAL|Computational Biology-Informed Treatment|Patients randomized to this arm will receive an FDA-approved drug or combination of drugs predicted to have a therapeutic effect based on their individual MDS disease genetic profile by a computational biology simulation software program. The specific drug or combination of drugs that a patient on this arm will receive will be decided jointly by a molecular oncology board comprised of physicians, pharmacists, and nurse coordinators and the treating physician. Patients will receive a minimum of 2 months and a maximum of 4 months of treatment with the selected drug or combination of drugs.
62187593|NCT03446638|ACTIVE_COMPARATOR|Standard of Care Treatment|Patients randomized to this arm will receive either one of three standard of care treatment regimens of the treating physician's choice (low-dose cytarabine, 7 + 3 induction, or FLAG induction) or supportive care alone. Patients will receive a minimum of 2 months and a maximum of 4 months of the selected treatment regimen or of supportive care alone.
62570747|NCT06571721|EXPERIMENTAL|0.025% Tretinoin oil augmented with castor oil|0.025% Tretinoin oil augmented with castor oil. 1-2 Drops of randomized topical product will be applied on entire face nightly. Duration: 16 weeks
62570748|NCT05015634|ACTIVE_COMPARATOR|Active Arm|Patients will be discharged from the hospital with the telemedicine package. If the patient develops possible cardiac symptoms and seeks medical attention, the data provided by the telemedicine package will be acted upon, as appropriate, by the trial cardiology team. With remote follow up over the phone at 3, 6 and 9 months.
62570749|NCT05015634|PLACEBO_COMPARATOR|Control Arm|Standard routine clinical care will be carried out, with remote follow up over the phone at 3, 6 and 9 months.
62002110|NCT02699944|EXPERIMENTAL|CRT sub-optimal responder|Subjects who have had CRT for at least 6 months and who have not responded as well as they could, in their cardiologists opinion. Subjects' ejection fraction are still \<50% despite CRT. A ECG Vest Optimization protocol will be utilized as one aspect to determine the best CRT programming for each individual subject.
62002111|NCT00931307|EXPERIMENTAL|Lotrafilcon A|
62002112|NCT05848310||Good prognosis + Poor prognosis|"Good prognosis: the serum total bilirubin level was less than 20 umol/l three months after surgery, and no liver transplantation or death occurred within a year after surgery.~Poor prognosis: the serum total bilirubin level was higher than 20 umol/l three months after surgery, and no liver transplantation or death occurred within a year after surgery."
62002113|NCT01922024||Prospective Fresh Clinical Specimens|Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against composite (comparator) which is based on routine clinical microbiology and a second PCR test
62187594|NCT02897089|NO_INTERVENTION|acid-etch|Acid etch+fissure sealant
62187595|NCT02897089|OTHER|All Bond universal adhesive|Acid etch+ All Bond universal adhesive agent+fissure sealant
62570750|NCT03980145|ACTIVE_COMPARATOR|Conventional Physical Therapy|Conventional physical therapy (CPT): CPT sessions will involve a 3-5 minute warm-up, stretching, progressive strength training exercises, and gait and balance training.40-43 Additional strategies for home exercises, energy conservation, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided.
62187596|NCT02897089|OTHER|All Bond universal|All Bond universal adhesive agent+fissure sealant
62187597|NCT02897089|OTHER|Scotchbond universal adhesive|Acid etch+ Scotchbond universal adhesive agent+fissure sealant
62570751|NCT03980145|EXPERIMENTAL|End-Effector Robotic Training|G-EO training: Using the G-EO System, participants will be secured with the appropriate sized harness and attached to an overhead body-weight support system, with feet secured to pressure sensitive footplates. Each session will begin with a 3-5 minute warm-up in the continuous passive mode (cadence \~40-45 steps/minute). The participant will then be transitioned into the adaptive training phase for practicing repetitive floor walking and stair climbing for up to 30 minutes. During this phase, the force produced by the robot is modulated to support the effort of the patient in producing a typical walking pattern.
62570752|NCT03386591|EXPERIMENTAL|Mucosal Atomization (1 administration)|One Intranasal administration of 2 mL naloxone using a mucosal atomization device and syringe (1 mL/nostril)
62570753|NCT03386591|EXPERIMENTAL|Mucosal Atomization (2 administrations)|Two Intranasal administrations of 2 mL naloxone using mucosal atomization device and syringe (1 mL/nostril) 2 minutes apart
62187598|NCT02897089|OTHER|Scotchbond universal|Scotchbond universal adhesive agent+fissure sealant
62187599|NCT02897089|OTHER|Clearfil universal adhesive|Acid etch+ Clearfil universal adhesive agent+fissure sealant
62187600|NCT02897089|OTHER|Clearfil universal|Clearfil universal adhesive agent+fissure sealant
62187601|NCT02897089|OTHER|Total-etch Dental Adhesive|Acid etch+ Single Bond adhesive agent+fissure sealant
62002114|NCT01922024||Retrospective Frozen Clinical Specimens|Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against routine clinical microbiology
62570754|NCT03386591|EXPERIMENTAL|Narcan 2mg|One Intranasal administration of 2 mg naloxone using Narcan nasal spray
62570755|NCT03386591|EXPERIMENTAL|Narcan 4mg|One Intranasal administration of 4 mg naloxone using Narcan nasal spray
62187602|NCT05475847|EXPERIMENTAL|C-TIL052A treatment group|C-TIL052A autologous infiltrating lymphocytes injection followed by injection of Interleukin 2 (IL-2)
62395628|NCT05463731|EXPERIMENTAL|Remternetug (IV)|"Participants will receive remternetug intravenously (IV)~Participants will receive remternetug IV during the treatment period, then switch to placebo IV in the extension period."
62395629|NCT05463731|EXPERIMENTAL|Remternetug (SC)|"Participants will receive one of two dosing regimens of remternetug subcutaneously (SC)~Participants will receive remternetug SC during the treatment period, then switch to placebo SC in the extension period."
62570756|NCT03386591|EXPERIMENTAL|Intramuscular auto injector|One Intramuscular administration of 2 mg naloxone using Evzio auto-injector
62570757|NCT06539403||Patients Diagnosed with Mild Cognitive Impairment|Two-three hour (including breaks) behavioural testing session: taking part in memory tasks and completing questionnaires
62570758|NCT06539403||Participants attending Memory Clinics who do not have diagnosis of Mild Cognitive Impairment|Two-three hour (including breaks) behavioural testing session: taking part in memory tasks and completing questionnaires
62570759|NCT06539403||Healthy Control Participants|Two-three hour (including breaks) behavioural testing session: taking part in memory tasks and completing questionnaires
62187603|NCT06392893|EXPERIMENTAL|Intervention|"Consumption of an additive and allergen-free cooked ham or cooked turkey breast.~Quantity: 100 grams.~Consumption time: 6 days a week during 5 weeks."
62187604|NCT06392893|PLACEBO_COMPARATOR|Control|"Consumption of a commercial cooked ham or cooked turkey breast.~Quantity: 100 grams.~Consumption time: 6 days a week during 5 weeks."
62395630|NCT05463731|PLACEBO_COMPARATOR|Placebo|"Participants will receive placebo matching remternetug IV or SC.~Participants will receive placebo IV during the treatment period, then switch to remternetug IV in the extension period.~Participants will receive placebo SC during the treatment period, then switch to LY3372993 SC in the extension period."
62002115|NCT01585480|EXPERIMENTAL|weight gain prevention intervention|
62002116|NCT01585480|NO_INTERVENTION|No treatment comparison group|
62002117|NCT00261716|EXPERIMENTAL|IPS and VOMI|Individual Placement and Support (IPS), a form of evidence-based supported employment with 4 sessions of manualized vocationally-oriented motivational interviewing (VOMI) prior to each course of job searching
62002118|NCT00261716|ACTIVE_COMPARATOR|IPS and IE|Individual placement and support (IPS), a form of evidence-based supported employment with 4 sessions of education about schizophrenia/schizoaffective disorder (IE), as appropriate, prior to each course of job searching
62002119|NCT02096458|EXPERIMENTAL|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg delayed-release orally disintegrating tablets at Assessment 1 Day 1, Assessment 2 Day 1, and Assessment 3 Day 1.
62002120|NCT01604343|EXPERIMENTAL|Placebo then Sirukumab 50 mg or Sirukumab 100 mg|
62002121|NCT01604343|EXPERIMENTAL|Sirukumab 100 mg|
62002122|NCT01604343|EXPERIMENTAL|Sirukumab 50 mg + Placebo|
62002123|NCT03533062|ACTIVE_COMPARATOR|trigonal sparing botox injection|Using a 7 gauge needle injection were allocated uniformly and evenly throughout the designed area excluding trigone in other arm Dilution of BOTOX vial (100 u) in 10 ml normal saline (10 u/ml) and injected in 20 sites (0.5ml /site).•then after 6 months postoperative anticholinergics administration .
62570760|NCT04566614||Biliary Tract Cohort|Patients with suspected biliary tract cancer will be offered ctDNA to support a diagnosis in patients with suspected early stage, locally advanced and advanced disease. This includes patients with tumours that are technically challenging to access with invasive biopsy or due to limitations in endoscopic ultrasound due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. Patients with suspected cancer will have ctDNA result (positive or negative) discussed at MDT in conjunction with PREVAIL-imaging risk stratification pathway to risk stratify in terms of cancer risk (low, intermediate and high risk), serum tumour markers and patient presentation which will dictate the appropriate treatment. Those with metastatic disease will have their treatment decision based on ctDNA result, radiology and patient characteristics after discussion between the treating clinician and patient
62002124|NCT03533062|ACTIVE_COMPARATOR|trigonal involved|Using a 7 gauge needle injection were allocated uniformly and evenly throughout the designed area including the trigone .Dilution of BOTOX vial (100 u) in 10 ml normal saline (10 u/ml) and injected in 20 sites (0.5ml /site).then after 6 months postoperative anticholinergics administration .
62002125|NCT05914727|OTHER|ASMD patients|ASMD patients
62002126|NCT05914727|OTHER|Healthy controls|Healthy controls
62002127|NCT00075829|ACTIVE_COMPARATOR|Auto transplants plus Therapy|One autologous transplant along with a second autologous transplant will be preformed followed by one year of Dexamethasone and Thalidomide maintenance therapy.
62002128|NCT00075829|ACTIVE_COMPARATOR|Auto transplants|One autologous transplant along with a second autologous transplant will be preformed followed by one year of observation.
62002129|NCT00075829|ACTIVE_COMPARATOR|Auto and Allo transplants|One autologous transplant and one non-myeloablative allogeneic transplant will be preformed and followed by one year of observation.
62002130|NCT04428866||Participants with post-bariatric hypoglycemia|Individuals with history of Roux-en-Y gastric bypass surgery, who have a history of hypoglycemia will be recruited from the Joslin Hypoglycemia Clinic.
62002131|NCT04428866||Asymptomatic participants with Roux-en-Y gastric bypass (RYGB)|Individuals with history of RYGB, without a history of or symptoms of hypoglycemia will be recruited from local postoperative surgical clinics and from the community.
62002132|NCT04428866||Control group|Individuals without a history of bariatric surgery will be recruited by local advertisement.
62002133|NCT00581282||1|Cocaine abstinent group
62570761|NCT04566614||Bladder Cancer Cohort|Patients with suspected bladder cancer (localised and metastatic) will be offered ctDNA to support their diagnosis, in cases where cystoscopy and biopsy are difficult to obtain due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. A positive ctDNA result will be supportive of a diagnosis of bladder cancer, their treatment may be prioritised and decided based on this result in conjunction with radiological findings, patient presentation and after discussion between the treating physician and patient
62395631|NCT05463731|EXPERIMENTAL|Open-Label Addenda Remternetug (IV)|Participants will receive one of six dosing regimens of remternetug IV during the open-label addenda.
62002134|NCT00581282||2|Normal healthy control group
62002135|NCT01060267|ACTIVE_COMPARATOR|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
62002136|NCT01060267|NO_INTERVENTION|Placebo Group endoscopic therapy|Endoscopic therapy of variceal bleeding.
62002137|NCT04306510|OTHER|Group 1|TEGSEDI
62187605|NCT05574751|ACTIVE_COMPARATOR|Titanium tacker group (n=30)|Group A
62187606|NCT05574751|ACTIVE_COMPARATOR|Polypropylene group (n=30)|Group B
62395632|NCT05463731|EXPERIMENTAL|Open-Label Addenda Remternetug (SC)|Participants will receive one of nine dosing regimens of remternetug SC during the open-label addenda.
62777636|NCT02770300|EXPERIMENTAL|Traditional robotic rehabilitation with ALEx RS|The rehabilitative task will be constituted of 3D reaching movements covering a sphere of fourteen centimeter of radius in front of the patient. The initial rehabilitative task will be the same for all the patients belonging to this group and the workspace will be extended accordingly to the therapist evaluation during the following training sessions. In order not to bias the comparisons of the effects of the different rehabilitative treatments, the therapist assisting this group during the rehabilitation will be the same for all the subjects belonging to this group and he/she will not take part in the rehabilitative treatment of the other groups. Initially, the patients will execute reaching movements in different directions in the horizontal plane. If the therapist will evaluate that the movements have been sufficiently recovered, reaching movements in the other planes will be proposed.
62187607|NCT02461862||Intra Uternine Device|Women who came to the medical service, to insert an intra uterine Device (IUD) of Cu or a Levonorgestrel Intra Uterine System( Lng- IUS) after have been attended in the Family Planning Service of Federal University of São Paulo . All patient have had the pain evaluated by Application of the Visual Analog Scale of Pain (VAS), and also their vital signs ( Evaluation of blood pressure,Evaluation of radial pulse) evaluated pre and five minutes after the IUD/ IUS insertion.
62395633|NCT02675933|NO_INTERVENTION|Standard of Care|"The control arm participants will receive only a satisfaction survey once disposition is determined by the physician provider. The satisfaction survey will be collected by the research associated and kept in a protected location, along with all other study materials.~All patients will receive standard of care, which at this institution is the help of Child Life Specialists, when they are available and requested by the physician. Physicians will be instructed to request Child Life Specialists with the same discretion as with all patients."
62777637|NCT02770300|EXPERIMENTAL|Automatic personalized robotic rehabilitation with ALEx RS|
62777638|NCT05553184|ACTIVE_COMPARATOR|Acute Cold Exposure|3h-acute cold exposure.
62777639|NCT05553184|EXPERIMENTAL|Formoterol with nicotinic acid|"Formoterol fumarate or Oxeze® Turbuhaler®: 48 µg (4 inhalations of 12 µg).~Nicotinic acid or Niacin: repeated doses of 150 MG every 30 minutes, for 3 hours."
62777640|NCT05553184|EXPERIMENTAL|Formoterol without nicotinic acid|Formoterol fumarate or Oxeze® Turbuhaler®: 48 µg (4 inhalations of 12 µg).
62777641|NCT02044861|EXPERIMENTAL|ACT-PFK-158|dose escalation
62777642|NCT05532605|ACTIVE_COMPARATOR|Cardiac rehab phase I protocols|will be treated with cardiac rehab phase I protocols
62777643|NCT05532605|EXPERIMENTAL|Cardiac rehab phase I protocols + Mindfullness base therapy|will be treated with cardiac rehab phase I protocols along with Mindfullness base therapy
62777644|NCT05490927|EXPERIMENTAL|Smoking Deprivation|16 hours of smoking abstinence prior to experimental visit.
62777645|NCT05490927|EXPERIMENTAL|Smoking as Usual|Smoking as usual prior to experimental visit.
62777646|NCT00783458|ACTIVE_COMPARATOR|Nasonex Followed by Flonase|
62777647|NCT00783458|ACTIVE_COMPARATOR|Flonase Followed by Nasonex|
62777648|NCT04241302|ACTIVE_COMPARATOR|Free Field Voice test|The examiner will inform the patient to repeat a sequence of Spondee words or a combination of numbers and letters whispered by the examiner initially. The examiner will be standing at the same distances as in the FFCT examination (starting with 2 feet). If the patient fails to hear the whispered voice at 2 feet, the examiner increases the loudness of voice to conversational tone at the same distance. The test is repeated thrice each time with a different set of Spondee words to avoid the patients recognizing the same sequence. If the patient is unable to respond, the examiner moves closer to 6 inches and whispers to the patient, and if no further response, then, conversational voice is used. The patient's free-field threshold is the voice and distance level at which more than 50% correct is obtained.
62002138|NCT06132022|EXPERIMENTAL|Intervention group|The intervention group will be asked to practice the mandala twice a week, for 30 minutes, for a month. At the end of one month, the scales will be applied again.
62570762|NCT04566614||Pancreatic Cancer Cohort|Patients with suspected pancreatic cancer will be offered ctDNA to support a diagnosis in patients with suspected early stage, locally advanced and advanced disease. This includes patients with tumours that are technically challenging to access with invasive biopsy or due to limitations in endoscopic ultrasound due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. Patients with suspected cancer will have ctDNA result (positive or negative) discussed at MDT in conjunction with PREVAIL-imaging risk stratification pathway to risk stratify in terms of cancer risk (low, intermediate and high risk), serum tumour markers and patient presentation which will dictate the appropriate treatment. Those with metastatic disease will have their treatment decision based on ctDNA result, radiology and patient characteristics after discussion between the treating clinician and patient
62777649|NCT04241302|EXPERIMENTAL|Free Field Click Test|The app is designed by our team by a broadband (500-3000 Hz) click sound of 30-40 dB for soft sound/whisper and 60-70dB for loud sound/conversation voice. This app is designed by the Flutter-Dart programming tool and the speaker is produced via hand-held devices of Apple and Android brands. The tone is produced 3 times, with 2 out of 3 answers are considered as the patient's hearing threshold. The examiner stands at the distance of 2 feet away behind the seated patient and a soft sound from the FFCT is tested. The patient is then asked to respond yes or to nod if able to hear the sound. When the patient is unable to answer or no response is received upon thrice testing, the examiner then moves closer to 6 inches to the patient and again the soft sound is tested thrice. Loud sound is then tested if the patient is unable to respond, starting from 2 feet distance for three times. And then, the loud sound is tested at 6 inches of distance if no further response is obtained.
62002139|NCT06132022|PLACEBO_COMPARATOR|Control group|Caregivers in the control group will not take any action, and at the end of one month, after the scales have been applied, they will be offered mandala applications.
62002140|NCT06032624|ACTIVE_COMPARATOR|Ketamine group (group K)|Ketamine group (group K):40 ml 0.5%bupivacaine and 0.5 mg\\kg ketamine.
62002141|NCT06032624|ACTIVE_COMPARATOR|Dexmedetomidine group (group D)|Dexmedetomidine group (group D) 40 ml 0.5% bupivacaine and 50µg\\kg dexmedetomidine.
62187608|NCT01137747|EXPERIMENTAL|Dose Level 0 (starting dose)|"Carfilzomib - 20 mg/m2 days 1 and 2, 27 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 36 mg/m2 for all subsequent doses. If DLT occurs while receiving 36 mg/m2, the dose may be reduced to 27 mg/m2.~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
62002142|NCT04146480|EXPERIMENTAL|Cardiac amyloidosis patients|
62002143|NCT01528241|EXPERIMENTAL|ABP688|Elderly MDD patients and demography matched healthy volunteer
62002144|NCT00143611|EXPERIMENTAL|Resatorvid 1.2 mg/kg/day|
62187609|NCT01137747|EXPERIMENTAL|Dose Level +1|"Carfilzomib - 20 mg/m2 days 1 and 2, 36 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 45 mg/m2 for all subsequent doses. If DLT occurs while receiving 45 mg/m2, the dose may be reduced to 36 mg/m2.~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
62187610|NCT01137747|EXPERIMENTAL|Dose Level +2|"Carfilzomib - 20 mg/m2 days 1 and 2, 45 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 56 mg/m2 for all subsequent doses. If DLT occurs while receiving 56 mg/m2, the dose may be reduced to 45 mg/m2.~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
62002145|NCT00143611|EXPERIMENTAL|Resatorvid 2.4 mg/kg/day|
62002146|NCT00143611|PLACEBO_COMPARATOR|Placebo|
62002147|NCT01876264|EXPERIMENTAL|Extended resection|Patients undergoing an extended resection are subjected to a traditional ileocolic resection with a 2cm macroscopically normal proximal margin. A further 8cm of ileum is then resected from the proximal margin prior to formation of the ileocolic anastomosis
62187611|NCT01522703|EXPERIMENTAL|Broccoli Sprouts|Broccoli Sprout sandwich/wrap will be eaten daily for 3 consecutive days
62002148|NCT01876264|ACTIVE_COMPARATOR|Conventional resection|Patients undergoing a traditional ileocolic resection for Crohn's disease with a 2cm proximal macroscopically disease-free margin
62002149|NCT02385812|EXPERIMENTAL|High lung cancer risk|Individuals with lung cancer risk \>= 1.5% over 6 years
62002150|NCT02385812|EXPERIMENTAL|Low lung cancer risk|Individuals with lung cancer risk \<1.5% over 6 years
62002151|NCT02847793|ACTIVE_COMPARATOR|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial
62002152|NCT02847793|PLACEBO_COMPARATOR|Placebo intervention|Using a matching procedure (i.e., yoked control group), participants are required to maintain their gaze in a given picture (e.g., a happy face), for the same average time that their counterparts in the Gaze training group (i.e. Experimental group)
62002153|NCT00660062|EXPERIMENTAL|Escitalopram 10 mg daily|Escitalopram 10 mg daily
62002154|NCT00660062|EXPERIMENTAL|Escitalopram 20 mg daily|Escitalopram 20 mg daily
62002155|NCT00660062|EXPERIMENTAL|escitalopram 30 mg daily|escitalopram 30 mg daily
62002156|NCT00660062|ACTIVE_COMPARATOR|Nortriptylin 100 mg daily|Nortriptylin 100 mg daily
62002157|NCT05886166|EXPERIMENTAL|robot assisted training|Rebless® (H-ROBOTICS, KOREA) is a knee or ankle robot for range of motion (ROM) and strength training that can operate in passive or active mode in knee or ankle flexion and extension. The patients underwent 30 min of robot training using Rebless® with 30 min conventional therapy, 5 days a week for 8 weeks.
62777650|NCT05963971|EXPERIMENTAL|PEDALL|The intervention group (PEDALL) will receive twenty-six contact hours of virtually-delivered nutrition education. Participants and/or caregivers will meet with their nutrition educator once weekly for one hour for six months.
62777651|NCT05963971|ACTIVE_COMPARATOR|Standard of Care (SOC)|Subjects randomized to SOC will receive printed educational materials at study entry and will continue to receive nutritional education/care per their institution's standards of care.
62777652|NCT05180149||Psychedelics-only Group|"A group of participants who reported using in their past psychedelic substances only (both classical and non-classical psychedelics are included). Specifically, in the current study this group included reports on the following substances:~Psilocybin (magic mushrooms, truffles) LSD (acid) Mescaline (peyote, san pedro) Dimethyltryptamine (DMT) Ayahuasca 5-MeO-DMT 3-MMC Ibogaine Salvia Phenethylamines (2C family)"
62777653|NCT05180149||Stimulants-only Group|"A group of participants who reported using in their past drugs identified as stimulating compounds only (both recreational and prescribed usages are included). Stimulating compounds are considered, in the context of the current study, substances that increase the overall activity of the central nervous system. Specifically, in the current study this group included reports on the following substances:~Cocaine Crack Amphetamines Methamphetamines Prescription stimulants (e.g., Adderall, Ritalin, Concerta)"
62777654|NCT05180149||Depressants-only Group|"A group of participants who reported using in their past drugs identified as depressing compounds only (both recreational and prescribed usages are included). Depressing compounds are considered, in the context of the current study, substances that decrease the overall activity of the central nervous system. Specifically, in the current study this group included reports on the following substances:~Benzodiazepines Opiates (recreational use of heroin, opium, hydrocodone, oxycodone, oxymorphone, codeine, fentanyl) Prescription opioids"
62777655|NCT05180149||Cannabinoids Group|"A group of participants who reported using in their past cannabinoids compounds only (both recreational and prescribed usages are included). Specifically, in the current study this group included reports on the following substances:~THC (cannabis, marijuana) CBD Medical Cannabis (both THC and CBD)"
62791764|NCT03672292|PLACEBO_COMPARATOR|Voriconazole mono-therapy|"Either IV voriconazole (loading dose of 6 mg/kg BID on Day 1 followed by maintenance dose of 4 mg/kg BID from Day 2 onwards) OR oral voriconazole (loading dose of 400 mg BID on Day 1 followed by maintenance dose of 200 mg BID from Day 2 onwards).~PLUS Oral Placebo Tablets matching SCY-078 tablets (loading dose of 2 tablets given BID on Days 1 and 2 followed by maintenance dose of 2 tablets given QD from Day 3 onwards).~Treatment duration = minimum 6 weeks/Max 13 weeks"
62791765|NCT02451995|EXPERIMENTAL|Ripple Mapping guided AT ablation|Ripple Mapping (Imperial College) software (Biosense Webster) will be used to diagnose the mechanism of AT and guide ablation
62002158|NCT02699294|EXPERIMENTAL|Contract-relax PNF stretch|A contract-relax PNF stretching techniques of the pectoralis minor muscle including latent trigger points will be applied by Group 1 after a single intervention of manual pressure release will be performed according to the techniques describe by Simons et al. (1999).
62187612|NCT01522703|PLACEBO_COMPARATOR|Alfalfa Sprouts|Alfalfa Sprouts will be eaten daily in a sandwich form for 3 consecutive days
62187613|NCT03534583|ACTIVE_COMPARATOR|Health Enhancement Program (HEP)|The Health-Enhancement Program (HEP) is structurally equivalent to a SKY intervention, with similar-sized groups, meeting for 3 consecutive days for 1.5-3 hours. There will then be a a gap of 4 days where participants will practice what they have learned, followed by 3 consecutive days of 1.5-3 hours of instruction. Starting the following week participants will attend once weekly follow up sessions (60-90 min/wk) for 3 weeks and then bimonthly sessions for the next 8 weeks. Participants will be asked to complete 25 min/day of course homework. Participants will learn about health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation. In HEP, which has been manualized, participants get the support of a group and facilitator, and talk through and try to implement positive health-enhancing life changes, HEP will be delivered by a trained social worker (or equivalent).
62570763|NCT04566614||Gastrointestinal Stromal Tumour Cohort|Those with suspected Gastrointestinal Stromal Tumour Cohort (GIST) are eligible for this study. KIT and PDGFR mutation detected using ctDNA in conjunction with radiological features will be supportive of a diagnosis of GIST. This may allow for the use of directed targeted therapy, or prioritise surgical resection in some cases. Patients with histological diagnosis will not be eligible for this study. However, patients with inadequate tissue for KIT/PDGFR analysis will be eligible for PREVAIL-ctDNA to confirm the diagnosis of GIST and help guide treatment decisions
62570764|NCT04566614||Lung Cancer Cohort|The use of ctDNA in the diagnosis and adaptive management of patients with lung cancer is well established, however not funded by NHS. As aerosol-generating bronchoscopy procedures have reduced due to the COVID-19 pandemic, patients with suspected lung cancer may be offered ctDNA to support the diagnosis. A positive ctDNA result in conjunction with radiological findings will assist in prioritising those suitable for upfront surgical resection, radiotherapy or systemic anti-cancer treatment. It may provide sufficient genotypic information to guide standard of care targeted therapies (usually two tests are required - biopsy and then next generation sequencing of extracted DNA), including in patients without sufficient tissue for EGFR and ALK testing which can be detected using ctDNA. The use of ctDNA to guide treatment decisions in this cohort will not require signed consent as it is considered a standard approach (not yet NHS funded)
62570765|NCT04566614||Colorectal Cancer Cohort|Patients with suspected colorectal cancer will often be referred following either suspicion on imaging or faecal immunochemical testing (FIT). FIT testing results will be used to prioritise patients for screening colonoscopy, in conjunction with the PREVAIL-imaging risk stratification pathway
62570766|NCT04566614||Part 2 Cohort|Patients with suspected advanced pancreatic or biliary tract cancer who have ctDNA via the ACCESS implementation pathway. The results must be deemed consistent with or diagnostic of pancreatic/biliary tract cancer by the molecular tumour board, discussed at central MDT and the patient cannot have a histological diagnosis.
62570767|NCT00703651|EXPERIMENTAL|1|
62570768|NCT00703651|EXPERIMENTAL|2|
62570769|NCT00703651|ACTIVE_COMPARATOR|3|
62777656|NCT05180149||Psychedelic and Non-psychedelic Substances Group|"A group of participants who reported using in their past drugs identified as psychedelics and stimulants and/or depressants (both recreational and prescribed usages are included). In this group participants will be included who reported using at least one non-psychedelic drug additionally to a psychedelic one. Specifically, the following options were provided:~1. Psychedelic compounds:~   Psilocybin (magic mushrooms, truffles) LSD (acid) Mescaline (peyote, san pedro) Dimethyltryptamine (DMT) Ayahuasca 5-MeO-DMT 3-MMC Ibogaine Salvia Phenethylamines (2C family)~2. Non-psychedelic compounds:~THC (cannabis, marijuana) Medical Cannabis (both THC and CBD) CBD MDMA (ecstasy) Ketamine Cocaine Crack Amphetamines Methamphetamines Prescription stimulants (e.g., Adderall, Ritalin, Concerta) Benzodiazepines Opiates (e.g., heroin, opium, hydrocodone, oxycodone, oxymorphone, codeine, fentanyl) Prescription opioids"
62777657|NCT05180149||Substance-naive Group|"A group of participants who reported no past experience with any of the substances listed in the current study nor reported using other substances (excluding alcohol and nicotine). Participants will be assigned to this group if and only if they choose the None of the above option from the Substance Use Survey (item 1)."
62777658|NCT05994833|NO_INTERVENTION|paper-based standard care exercise program|
62395634|NCT02675933|ACTIVE_COMPARATOR|Questionnaire|"Participants who are randomized to the questionnaire arm will receive a patient-centered questionnaire at the beginning of their visit. This single page document will ask questions about their child including, but not limited to, diagnoses, suggestions for distraction, sensory issues that may affect their visit, and method to best administer medications. The research associate will ask them to fill it out to the best of their ability and will collect the questionnaire prior to a physician provider seeing the patient. At least one physician provider must review the questionnaire prior to seeing the patient.~Once disposition is determined, the satisfaction survey will be distributed by the research associate along with an envelope for the parent to seal their survey within."
62570770|NCT02242682|NO_INTERVENTION|Control|This group of subjects will not be exposed to a video during their time in the ED waiting room
62570771|NCT02242682|EXPERIMENTAL|Child passenger safety video|This group of subjects will be exposed to a video during their time in the ED waiting room
62777659|NCT05994833|EXPERIMENTAL|VPT|
62395635|NCT06355934||ATTR cardiomyopathy|Patients with Transthyretin Amyloidosis Cardiomyopathy
62791766|NCT02451995|ACTIVE_COMPARATOR|Local activation Time Mapping AT Ablation|Standard activation mapping will be used to guide ablation.
62395636|NCT06355934||ATTR polyneuropathy|Patients with Transthyretin Amyloidosis Neuropathy
62777660|NCT01836328|ACTIVE_COMPARATOR|Parenteral /oral methadone ratio 1:2|"Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase.~Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient.~Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization.~INTERVENTION: Patients randomized to this arm will receive the double of OPTIMISED DOSE of parenteral METHADONE, orally every 24h in 3 administrations during the following 3 days."
62002159|NCT02699294|EXPERIMENTAL|Z-stretch|The Z- stretch of the pectoralis minor muscle including latent trigger points will be applied by Group 2 after a single intervention of manual pressure release will be performed according to the techniques describe by Simons et al. (1999).
62395637|NCT06355934||ATTR unknown|Patients with ATTR unknown genotype
62777661|NCT01836328|EXPERIMENTAL|Parenteral /oral methadone ratio 1:1.2|"Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase.~Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient.~Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization.~INTERVENTION: Patients randomized to this arm will receive the following Oral Methadone dose: 20% increase of optimised parenteral methadone dose every 24h in 3 administrations during the following 3 days."
62777662|NCT01242852|EXPERIMENTAL|Additional diagnostic tests|Participants in the experimental arm will undergo standard hysteroscopy with treatment-on-the spot of predefined intrauterine abnormalities. In two of the participating clinics, also a 'Saline Infusion Sonography' (SIS) will be performed, 1 week before the hysteroscopy. After the additional diagnostic test(s), standard IVF/ICSI treatment will be initiated.
62777663|NCT01242852|NO_INTERVENTION|Routine fertility workup|Patients allocated to the conventional strategy will be scheduled for IVF and undergo standard treatment, without SIS or hysteroscopy.
62777664|NCT03931798|EXPERIMENTAL|Treatment|Healthy participants were administered the Visual Scanning Test
62395638|NCT06355934||ATTR with mixed phenotype|Patients with ATTR mixed phenotype
62777665|NCT02540265|EXPERIMENTAL|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
62777666|NCT02540265|EXPERIMENTAL|N1539 60mg|N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.
62777667|NCT02540265|PLACEBO_COMPARATOR|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
62777668|NCT05623358|EXPERIMENTAL|Pharmacist-led HFrEF medication optimization|
62777669|NCT05623358|OTHER|Usual care|Both the intervention group and comparator group will receive usual care by the multidisciplinary HF clinic, including standard-of-care clinical pharmacy services.
62777670|NCT05199961|EXPERIMENTAL|Single Arm Cohort Receiving Digital Health Coaching|A single cohort of up to 100 individuals receiving chimeric antigen receptor T cell therapy will be enrolled in the study, all of whom will be enrolled in a 6-month digital health coaching program. Individuals will be enrolled at The Ohio State University Comprehensive Cancer Center.
62777671|NCT01014468|ACTIVE_COMPARATOR|Ranibizumab|Intravitreal injection of Ranibizumab (3 monthly injection followed by monthly injections as long as required)
62777672|NCT01014468|ACTIVE_COMPARATOR|Bevacizumab|Intravitreal injection of Bevacizumab (3 monthly injection followed by monthly injections as long as required)
62777673|NCT00732108|EXPERIMENTAL|topiramate|topiramate 50mg orally for 2 weeks, then 100mg orally for 6 weeks
62777674|NCT00732108|PLACEBO_COMPARATOR|2|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
62002160|NCT02699294|EXPERIMENTAL|Manual pressure release|The single intervention of manual pressure release will be only applied to Group 3 according to the techniques describe by Simons et al. (1999).
62002161|NCT02699294|NO_INTERVENTION|Control|This is a control group.
62395639|NCT06355934||ATTR wild type|Patients with Transthyretin Amyloidosis wild type
62395640|NCT06355934||ATTR hereditary|Patients with Transthyretin Hereditary
62777675|NCT05237947|EXPERIMENTAL|Arm I (Gardasil 9)|Patients receive one dose of Gardasil 9 IM.
62777676|NCT05237947|EXPERIMENTAL|Arm II (Cervarix)|Patients receive one dose of Cervarix IM.
62777677|NCT05237947|ACTIVE_COMPARATOR|Arm III (Adacel)|Patients receive one dose of Adacel IM.
62777678|NCT03230682||major depressive disorder|
62777679|NCT06104098|OTHER|One dose daily for 7 consequtive days (dose acc to IFU)|Open user study with Vernivia once daily for 7 consequtive days. Dosage according to IFU/Instructions For Use.
62777680|NCT04823624|EXPERIMENTAL|MG MBG453|Participants will be given MBG453 On Day 1 of each cycle 28 days (4 weeks) study cycle
62187614|NCT03534583|EXPERIMENTAL|Sudarshan Kriya Yoga (SKY)|The SKY PTSD program is a mind-body resilience building program developed for persons with PTSD. Through SKY breathing, interactive discussions, journaling, yoga and guided meditations, the workshop builds a framework for resilience and empowerment, and develops self-awareness, connectedness and community, and a positive outlook. SKY training will take place in group-format (6-8 participants). During the first week participants will attend three 2.5-3 hour sessions on three consecutive days. There will then be a gap of 4 days where participants can apply the tools provided, followed by three more consecutive days of 1.5-3 hours of instruction. This will be followed by once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions (every 2 weeks) for the next 8 weeks. In addition, participants will be asked to practice SKY at home daily (25 min/day) throughout the duration of the study period (up to 26 weeks) and log practice frequency.
62395641|NCT04115904|EXPERIMENTAL|Post-endodontic Pain after a RCT|Ibuprofen for Post operative pain. Take 400 mg takena week after. Incidence of flare ups after a single vsmultiple visits root canal treatments.
62002162|NCT00379470|ACTIVE_COMPARATOR|Best Standard of Care|Patients randomized to the BSC group will be treated with one chemotherapy according to the BSC practiced at each center.
62777681|NCT05104970|ACTIVE_COMPARATOR|SunnyD STAT softgel capsule|Cholecalciferol 200000 IU
62777682|NCT05104970|PLACEBO_COMPARATOR|Placebo SunnyD STAT softgel capsule|Olive oil only
62777683|NCT05104970|ACTIVE_COMPARATOR|SunnyD insta ampoule|Vitamin D3 200000 IU
62777684|NCT05104970|PLACEBO_COMPARATOR|Placebo SunnyD insta ampoule|Olive oil only
62777685|NCT03932630|EXPERIMENTAL|Study intervention|
62777686|NCT03932630|ACTIVE_COMPARATOR|Control intervention|
62777687|NCT02514148|OTHER|NO Intervention Control group|No therapeutic intervention are being giving to the group of patients, they only will have their Neurologist previously prescribed pharmacological treatment.
62777688|NCT02514148|EXPERIMENTAL|Therapeutic exercise( TE)|The intervention giving to the patients consist on a therapeutic exercise protocol based on neck and low intensity general exercises.
62777689|NCT02514148|EXPERIMENTAL|Therapeutic patient education ( TPE)|The intervention giving to the patients consist on a therapeutic patient education based on pain neurophysiology protocol.
62777690|NCT02514148|EXPERIMENTAL|TE + TPE|The intervention giving to the patients consist on the combination of the therapeutic exercise protocol and the therapeutic patient education protocol.
62777691|NCT02514148|EXPERIMENTAL|TE + TPE + Manual therapy|The intervention giving to the patients consist on the combination of the therapeutic exercise protocol and the therapeutic patient education protocol plus a manual therapy techniques protocol.
62777692|NCT02134730|NO_INTERVENTION|Wait list|Schools in waitlist condition will be offered the intervention after the 12-months follow up. Waitlist means that the schools work as usual with issues of mental health.
62777693|NCT02134730|EXPERIMENTAL|FRIENDS for life|The intervention is delivered for 10 consecutive weeks, 60 minutes per session.
62777694|NCT05551611|ACTIVE_COMPARATOR|Playgroup|The participants were informed about the research and the mean score was calculated by applying the Vaginal Breech Delivery Management Knowledge Test to the participants before the vaginal delivery management training of the breech-presented fetus was given within the scope of the Risky Delivery and Postpartum Period Course. After playing the mobile game, Vaginal Breech Birth Management Post-Knowledge Test and General Satisfaction Level Test were applied to the participants again. In addition, the Mobile Game Evaluation Form was applied to the participants in the game group and their opinions on the mobile educational game were determined. Test-retest reliability was calculated by applying the Vaginal Breech Delivery Management Knowledge Retention Test 14 days later.
62777695|NCT05551611|ACTIVE_COMPARATOR|Control group|The participants were informed about the research and the mean score was calculated by applying the Vaginal Breech Delivery Management Knowledge Test to the participants before the vaginal delivery management training of the breech-presented fetus was given within the scope of the Risky Delivery and Postpartum Period Course. On the same date as the playgroup, but at a different time and in a class, the researcher gave a theoretical lesson through the presentation prepared in the powerpoint program about the birth management of a breech-presented fetus in the classroom as in the traditional education method. After the lesson, the Vaginal Breech Birth Management Post-Knowledge Test and the General Satisfaction Level Test were administered to the participants again. Test-retest reliability was calculated by applying the Vaginal Breech Delivery Management Knowledge Retention Test 14 days later.
62777696|NCT00741403|EXPERIMENTAL|A|IV Infusion of CPI-613 on Days 1,4,8,11,15,18 of 28 day cycle in patients with advanced malignancies
62777697|NCT05989854|EXPERIMENTAL|Exercise|Exercise arm
62777698|NCT04911972||Functional muscle transfer group|Patients who have undergone functional muscle transfer to restore function after tumour surgery or injury, in which the tumour surgery or injury has resulted in functional loss.
62777699|NCT04911972||Non-functional muscle transfer group|Patients who have not undergone functional muscle transfer to restore function after tumour surgery or injury, in which the tumour surgery or injury has resulted in functional loss.
62777700|NCT01573156|EXPERIMENTAL|VTP treatment to small renal mass|
62777701|NCT06545695|EXPERIMENTAL|Erlotinib Treatment Arm|
62777702|NCT04351724|EXPERIMENTAL|(Hydroxy)Chloroquine (STOPPED)|"Due to limited availability of the experimental substances, this arm will include both chloroquine and hydroxychloroquine treatment. However, both substances are similar chemically and also with regards to the mechanism of action comparable.~Dosage: Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available"
62777703|NCT04351724|EXPERIMENTAL|Lopinavir/Ritonavir|Dosage: 200mg/50mg 4-0-4 on day 1 and 3-0-3 thereafter
62777704|NCT04351724|OTHER|Standard of Care|"patients will be treated with standard of care, which precludes treatment with lopinavir/ritonavir or (hydroxy-)chloroquine"
62395642|NCT04115904|EXPERIMENTAL|Acute pain|Acetaminophen 325 mg for Acute pain. Taken secondday after. Incidence of Post operative pain after rootcanal treatment in one vs two visits
62002163|NCT00379470|EXPERIMENTAL|NovoTTF-100A|
62570772|NCT03325816|EXPERIMENTAL|Phase II - Arm 1|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.~The Phase II dose of 177Lu-DOTA0-Tyr3-Octreotate will be the maximum tolerated dose as determined in the Phase I portion."
62570773|NCT03325816|EXPERIMENTAL|Phase I - Dose Level -1|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.~177Lu-DOTA0-Tyr3-Octreotate dose will be 3.7 GBq (100 mCi) every 8 weeks for 4 doses."
62777705|NCT04351724|EXPERIMENTAL|Rivaroxaban|5mg 1-0-1
62187615|NCT03338647|ACTIVE_COMPARATOR|TACE|Transarterial chemoembolization with drug eluted beads or doxorubicin/lipiodol
62187616|NCT03338647|EXPERIMENTAL|SBRT|Stereotactic radiation therapy with risk adapted dose prescription
62570774|NCT03325816|EXPERIMENTAL|Phase I - Dose Level 0|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.~177Lu-DOTA0-Tyr3-Octreotate dose will be 7.4 GBq (200 mCi) every 8 weeks for 4 doses."
62570775|NCT03325816|NO_INTERVENTION|Phase II - Arm 2|Patients randomized to this arm will be followed (observation). Cross-over to Phase II Arm 1 at the time of disease progression will be allowed
62777706|NCT04351724|ACTIVE_COMPARATOR|Thromboprophylaxis|according to local standard
62002164|NCT02836171|EXPERIMENTAL|Treatment|subjects receiving a single 250 mg oral dose of apatinib mesylate tablets and wash-out for 3 days,then Itraconazole capsules 100 mg/day orally for 6 days with a single 250 mg oral dose of apatinib mesylate tablets co-administered on day 4 . apatinib mesylate tablets was administered in the morning after an overnight fast of at least 10 h
62187617|NCT00699985||1|Behcet's Disease patients that their diagnosis was based on the new International Criteria for Behcet's Disease (ICBD).
62187618|NCT00699985||2|Non-Behcet's Disease patients were patients mimicking BD.
62395643|NCT05261126|EXPERIMENTAL|Enclitide Chloride 6 mg|Participants will receive 6 mg of enlicitide chloride orally QD for 8 weeks
62570776|NCT00925951|EXPERIMENTAL|Wet Cupping|
62570777|NCT00925951|NO_INTERVENTION|Waiting Control|They can't use any other specific treatment except exercises and behavior modification (we'll offer a brochure which includes exercise method and directions about behavior modifications).
62570778|NCT04589377|EXPERIMENTAL|Mindfulness Training|Participants receive 20 minutes of mindfulness training per day for five continuous days (Monday through Friday). Training is delivered remotely to participants' computers and smartphones.
62570779|NCT04589377|NO_INTERVENTION|No-Training|Participants do not receive training. On Monday and Friday, they listen to a 20 minute audiobook to match for time.
62777707|NCT04351724|EXPERIMENTAL|RAS Blockade|Renin-Angiotensin-System-Blockade (RAS) by candesartan intake starting with 4mg once daily and titrated to normotension patients \> 120/80 mmHG are eligible
62777708|NCT04351724|ACTIVE_COMPARATOR|non-RAS-Blockade|non-RAS blocking antihypertensive agents titrated to normotension Those with normal blood pressure may only be controlled without further treatment
62777709|NCT04351724|EXPERIMENTAL|Asunercept 25mg|25mg 1x per week, maximum of four doses only patients with oxygen requirement
62187619|NCT02344017|EXPERIMENTAL|ODM-204 Phase I dose escalation|Dose escalation
62187620|NCT02344017|EXPERIMENTAL|ODM-204 Phase II dose expansion|
62187621|NCT03049345|EXPERIMENTAL|Sentinel Node Sampling Arm|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Patients will then under regular gastric cancer resection with D2 lymphadenectomy as per routine in our institution.
62187622|NCT01945398|EXPERIMENTAL|Inspiratory Muscle Training (IMT)|Patients from the inspiratory muscle training group will utilize a linear pressoric resistance equipment with an inspiratory charge of 30% of maximum inspiratory pressure (adjusted weekly), during 7 days of the week, session duration of 30 minutes, during 8 weeks.
62395644|NCT05261126|EXPERIMENTAL|Enclitide Chloride 12 mg|Participants will receive 12 mg of enlicitide chloride orally QD for 8 weeks
62395645|NCT05261126|EXPERIMENTAL|Enclitide Chloride 18 mg|Participants will receive 18 mg of enlicitide chloride orally QD for 8 weeks
62570780|NCT04409223|EXPERIMENTAL|Famitinib|
62570781|NCT04409223|ACTIVE_COMPARATOR|Sunitinib|
62395646|NCT05261126|EXPERIMENTAL|Enclitide Chloride 30 mg|Participants will receive 30 mg of enlicitide chloride orally QD for 8 weeks
62570782|NCT01622218|EXPERIMENTAL|Medical Clown|Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers.
62570783|NCT01622218|NO_INTERVENTION|Control|Assessment of child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect on the total consumption of analgesics and on the post- surgery inflammatory markers.
62570784|NCT01367886|OTHER|Fesoterodine|Females with overactive bladder symptoms will be given Fesoterodine 4 mg. daily for six weeks.
62570785|NCT00730535|EXPERIMENTAL|Tolterodine 1|
62570786|NCT00730535|EXPERIMENTAL|Toterodine 3|
62570787|NCT00730535|EXPERIMENTAL|Tolterodine 6|
62570788|NCT06576609|EXPERIMENTAL|INJEX|Needle less device
62777710|NCT04351724|EXPERIMENTAL|Asunercept 100mg|100mg 1x per week, maximum of four doses only patients with oxygen requirement
62777711|NCT04351724|EXPERIMENTAL|Asunercept 400mg|400mg 1x per week, maximum of four doses only patients with oxygen requirement
62777712|NCT04351724|OTHER|Best Standard of Care - Control Group for Asunercept|only patients with oxygen requirement
62777713|NCT04351724|EXPERIMENTAL|Remdesivir|200mg loading dose on day 1, 100mg for a total treatment duration of 5-10 days
62777714|NCT04351724|EXPERIMENTAL|Pentaglobin|Patients treated at the intensive care unit only, continuous infusion of 7ml/kg/day over 12h for 5 days
62777715|NCT04351724|OTHER|best standard of care|Patients treated at the intensive care unit only
62777716|NCT05949489||Knee Osteoarthritis|Patients with physician-diagnosed knee osteoarthritis
62777717|NCT05862090|EXPERIMENTAL|Arm 1 (First RLD2301, then RLD2301+RLD2007)|Period1 : RLD2301 Period2 : RLD2301 + RLD2007
62777718|NCT05862090|EXPERIMENTAL|Arm 2 (First RLD2007, then RLD2301+RLD2007)|Period1 : RLD2007 Period2 : RLD2301 + RLD2007
62777719|NCT01369732|PLACEBO_COMPARATOR|Saline group|We administrate the saline single bolus (5ml, intravenously) 30 min before the commencement of ischemia.
62002165|NCT05580224|EXPERIMENTAL|Patients with hepatocellular carcinoma (equal or less than 3 cm)|Under the guidance of multimodality-ultrasound (US) fusion image, one of the three electrodes was placed across the portal vein branch near the tumor, and the other two electrodes were placed around the tumor through the previously planned approach path. After placement of electrodes, the temperature is maintained at 90-100 degrees Celsius for about 6-30 minutes depending on the size of the tumor, using the combined energy transfer mode that sequentially adds the bipolar mode and/or the monopolar mode.
62002166|NCT04223076|EXPERIMENTAL|Chlorhexidine 0.2% mouthwash control|Chlorhexidine 0.2%, Corsodyl Intervention rinsing 60 sec twice daily
62002167|NCT04223076|EXPERIMENTAL|Chlorhexidine 0.2% mouthwash with an Anti Discoloring System|Chlorhexidine 0.2%, Curasept Intervention rinsing 60 sec twice daily
62002168|NCT06042790||Covid-19 ICU patients|Patients with confirmed Covid-19 admitted to ICU care
62002169|NCT06042790||non-Covid-19 patients|Non Coivd-19 patients admitted to ICU before 2020
62187623|NCT01945398|PLACEBO_COMPARATOR|Sham IMT|Patients in the placebo group will be submitted to inspiratory muscle training with the same equipment as the intervention group, however without a resistance generating spring.
62777720|NCT01369732|EXPERIMENTAL|erythropoietin group|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
62777721|NCT03974373|EXPERIMENTAL|BFP removal|this will be the group evaluated in this study, individuals who performed the BFP removal procedure.
62777722|NCT03645512|EXPERIMENTAL|Intervention|The intervention group will attend in the 1-day Corporate Athlete Resilience (CAR) Training Program in Lake Nona.
62777723|NCT03645512|NO_INTERVENTION|Control|The control group will attend the 1-day CAR Training Program in Lake Nona after a 3-month wait list period, which will be three months after the intervention group attends the intervention.
62777724|NCT00148941|EXPERIMENTAL|SB213503 lot 1 + M-M-R Group|"Subjects aged 4 to 6 years received a dose of lot 1 of SB213503 vaccine and a dose of M-M-R II vaccine.~SB213503 was administered by deep intramuscular injection in the left deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid."
62777725|NCT00148941|EXPERIMENTAL|SB213503 lot 2 + M-M-R Group|"Subjects aged 4 to 6 years received a dose of lot 2 of SB213503 vaccine and a dose of M-M-R II vaccine.~SB213503 was administered by deep intramuscular injection in the left deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid."
62777726|NCT00148941|EXPERIMENTAL|SB213503 lot 3 + M-M-R Group|"Subjects aged 4 to 6 years received a dose of lot 3 of SB213503 vaccine and a dose of M-M-R II vaccine.~SB213503 was administered by deep intramuscular injection in the left deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid."
62187624|NCT01477580|EXPERIMENTAL|Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|
62187625|NCT01477580|EXPERIMENTAL|Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
62187626|NCT01477580|EXPERIMENTAL|Medium-dose Non-adjuvanted V180|
62395647|NCT05261126|PLACEBO_COMPARATOR|Placebo|Participants will receive enlicitide chloride-matching placebo orally QD for 8 weeks
62570789|NCT06576609|ACTIVE_COMPARATOR|Needle syringe|traditional dental needle
62777727|NCT00148941|ACTIVE_COMPARATOR|Infanrix + IPOL + M-M-R Group|Subjects aged 4 to 6 years received a dose of Infanrix and a dose of IPOL vaccines separately and a dose of M-M-R II vaccine. Infanrix was administered by deep intramuscular injection in the upper left deltoid. IPOL was administered subcutaneously in the lower right deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid.
62777728|NCT05900492||previous 1 cesarean section|patient who had her first Cesarean section
62187627|NCT01477580|EXPERIMENTAL|Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|
62187628|NCT01477580|EXPERIMENTAL|Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
62187629|NCT01477580|EXPERIMENTAL|Medium-Dose V180 with Alhydrogel™ adjuvant|
62777729|NCT05900492||previous 2 cesarean sections|patient who had her second Cesarean sections
62187630|NCT01477580|EXPERIMENTAL|High-dose Non-adjuvanted V180|
62187631|NCT01477580|EXPERIMENTAL|High-dose V180 with low-dose ISCOMATRIX™ adjuvant|
62187632|NCT01477580|EXPERIMENTAL|High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
62187633|NCT01477580|EXPERIMENTAL|Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|
62187634|NCT01477580|EXPERIMENTAL|Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|
62187635|NCT01477580|EXPERIMENTAL|High-dose V180 with high-dose ISCOMATRIX™ adjuvant|
62777730|NCT05900492||previous 3 or more cesarean sections|patient who had 3 or more Cesarean sections
62777731|NCT04855019|ACTIVE_COMPARATOR|periarticular injection group (PI)|the group to be given a periarticular injection by an orthopedist
62777732|NCT04855019|ACTIVE_COMPARATOR|Combined suprascapular-axillary nerve block group (CSAB)|the group in which an anesthesiologist will perform combined suprascapular axillar border block under ultrasound guidance
62777733|NCT04291768|EXPERIMENTAL|Intervention group|Shortened antibiotic treatment of 5 days
62187636|NCT01477580|PLACEBO_COMPARATOR|Placebo|
62187637|NCT02447718|ACTIVE_COMPARATOR|Experimental|Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.
62187638|NCT02447718|NO_INTERVENTION|Healthy Control|Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.
62187639|NCT02914899|ACTIVE_COMPARATOR|Pilot RCT Control Group|Eligible NYC Chinese livery drivers will receive written materials only
62777734|NCT04291768|ACTIVE_COMPARATOR|Control group|Standard antibiotic treatment of minimum 7 days at the discretion of treating physician
62777735|NCT00376896|EXPERIMENTAL|GW876008 20mcg|GW876008 20mcg
62187640|NCT02914899|EXPERIMENTAL|Pilot RCT CHW Intervention Group|Eligible NYC Chinese livery drivers will receive written materials and navigation for shared decision making (SDM) and lung cancer screening (LCS).
62777736|NCT00376896|EXPERIMENTAL|GW876008 200mcg|GW876008 200mcg
62777737|NCT00376896|PLACEBO_COMPARATOR|Placebo|Placebo
62777738|NCT02177474|EXPERIMENTAL|Telephone based peer support|The telephone based peer support was delivered by 11 women with chd aged 54 to 73 years, living all over Germany. Participants could call according to their needs during scheduled times on workdays.
62187641|NCT02914899|EXPERIMENTAL|Focus Group|The investigators conducted a series of 4-6 focus groups with Chinese livery drivers who (currently, or in the past) smoke.
62187642|NCT02914899|EXPERIMENTAL|In-Depth Interview Group|12-15 in-depth interviews with livery base management and staff, and with 12-15 primary care physicians (PCPs), clinic directors, hospital CFOs, heads of financial services and counseling, and heads of radiology facilities serving the Chinese community.
62187643|NCT02914899|EXPERIMENTAL|Pre-pilot Group|Approximately 10 Chinese livery drivers who smoke or who quit smoking with the past 15 years and have a 30 pack-year history of smoking
62187644|NCT05143112|EXPERIMENTAL|Treatment group|Allogeneic CD19 CR-T cell infusion
62187645|NCT04715022|PLACEBO_COMPARATOR|Placebo infusion|Saline will be administered over 2 hours
62395648|NCT06323356|EXPERIMENTAL|TAK-279 for Generalized Pustular Psoriasis|Participants with generalized pustular psoriasis will receive TAK-279 from Day 1 up to Week 52.
62395649|NCT06323356|EXPERIMENTAL|TAK-279 for Erythrodermic Psoriasis|Participants with erythrodermic psoriasis will receive TAK-279 from Day 1 up to Week 52.
62777739|NCT02177474|OTHER|Waitlist Group|Waitlist condition with delayed telephone based peer support starting at 5 months
62777740|NCT03539575|OTHER|Synthetic Psychoactive Cannabinoid Users|Synthetic Psychoactive Cannabinoid dependent subjects who are frequent spice/K2 users will receive the radiotracer \[11-C\]OMAR.
62777741|NCT05339230|EXPERIMENTAL|Active|Salovum egg powder high in antisecretory factor, 4 g/sachet. Four sachets, ie 16 g q 8 h for 6 days starting 6 days before 1st cycle of chemotherapy. SPC-flakes flat dose of 75 g/d divided in 2 - 4 doses started in parallel with Salovum to be continued during the first 8 weeks of chemotherapy.
62395650|NCT03029052|NO_INTERVENTION|Control group|Medical and pharmaceutical management (at admission, during hospitalization and at discharge) will follow standard healthcare procedures of the department.
62395651|NCT03029052|EXPERIMENTAL|Reconciliation group|Standard healthcare procedures and pharmacist's involvement
62395652|NCT06724783|ACTIVE_COMPARATOR|Standard resorbable collagen membrane|GBR with implant placement
62395653|NCT06724783|EXPERIMENTAL|Compressed, stronger resorbable collagen membrane|GBR with implant placement
62395654|NCT01443468||1|Patients within a family with a known TP53 mutation who are positive for that mutation.
62395655|NCT01443468||2|Patients within a family with a known TP53 mutation who are negative for that mutation.
62777742|NCT05339230|PLACEBO_COMPARATOR|Control|Salovum placebo powder without antisecretory factor, 4 g/sachet. Four sachets, ie 16 g q 8 h for 6 days starting 6 days before 1st cycle of chemotherapy. SPC placebo flakes flat dose of 75 g/d divided in 2 - 4 doses started in parallel with Salovum placebo to be continued during the first 8 weeks of chemotherapy.
62777743|NCT01990859|EXPERIMENTAL|Arm A: Ipilimumab|Ipilimumab Intravenous Injection 3 mg/kg for every 3 weeks upto 4 doses
62570790|NCT03960008|OTHER|Stereotactic Body Radiation Therapy (SBRT)|Radiation Therapy
62570791|NCT03960008|OTHER|Trans-Arterial Chemoembolization (TACE)|Procedure/Surgery - Chemoembolization Drug: Doxorubin
62570792|NCT04679766|EXPERIMENTAL|Patients with non-restorable tooth in maxillary bi-cuspid region with labial/buccal plate dehiscence|
62570793|NCT00596232||Asthma|People who have been diagnosed with Asthma
62570794|NCT00596232||Cystic Fibrosis|People who have been diagnosed with Cystic Fibrosis
62570795|NCT00596232||Healthy|People who are non-asthmatic, non smokers with less than 10 pack years and who do not have cystic fibrosis
62570796|NCT00952835||asthma and rhinitis control|
62777744|NCT03667690|EXPERIMENTAL|Group 1: Rezafungin for Injection|"Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 2 to 4 doses.~Daily intravenous placebo infusions, when not administered Rezafungin and a daily placebo for oral step-down therapy (first eligibility on Day 4 or later as advised by a site's national/regional/local guidelines) administered every day."
62187646|NCT04715022|ACTIVE_COMPARATOR|Ascorbic acid infusion|"Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the University of Kansas (KU) Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min."
62187647|NCT02460562|ACTIVE_COMPARATOR|PMMA resin|A denture base will be made with PMMA resin as a standard material.
62187648|NCT02460562|EXPERIMENTAL|PMMA resin & S-PRG filler|A denture base will be made from PMMA resin \& S-PRG filler for subject to wear.
62187649|NCT05208346|EXPERIMENTAL|Canola oil high-fat|Participants randomized to receive a mixed meal with 50 g canola oil
62395656|NCT01443468||3|Unaffected family members.
62395657|NCT01443468||4|Patients who meet clinical LFS criteria but haven't had TP53 testing.
62395658|NCT01443468||5|Patients within a family with an negative/unknown TP53 mutation.
62395659|NCT06112366|EXPERIMENTAL|The study group used tissue adhesive for wound closure after extraction of impacted wisdom teeth|In this study of 30 patients, 21 females and 9 males, 60 fully impacted lower wisdom teeth were extracted bilaterally and in the same position. One of the bilaretal teeth of the patients was randomly selected and tissue adhesive (Periacryl 90) was applied for wound closure as an experimental group.
62570797|NCT01679782||COPD nocturnal desaturator|COPD patients who spend 30% of the nigth with a SaO2 \< 90%.
62570798|NCT01679782||COPD no nocturnal desaturator|COPD patients who spend less than 30% of the night with a SaO2 \< 90%
62570799|NCT01679782||control group|healthy sedentary subjects
62570800|NCT02158585|PLACEBO_COMPARATOR|Placebo|The placebo will match the lamotrigine dosage, frequency and duration.
62570801|NCT02158585|ACTIVE_COMPARATOR|Lamotrigine|Lamotrigine will be taken orally for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses are 25mg twice a day, 50mg twice a day, and 100 mg twice a day during titration; 150mg twice a day for the 12-week study period; 150mg once a day for Week 1 of the taper; and 75mg once a day for Week 2 of the taper. Patients who withdraw at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
62570802|NCT03992963|ACTIVE_COMPARATOR|Hearing Aid without frequency lowering enabled|
62570803|NCT03992963|EXPERIMENTAL|Hearing Aid with frequency lowering enabled|
62570804|NCT06336928||Observational|Patients undergo blood sample collection and have their medical records reviewed on study.
62187650|NCT05208346|EXPERIMENTAL|Coconut oil high-fat|Participants randomized to receive a mixed meal with 50 g coconut oil
62187651|NCT05208346|EXPERIMENTAL|Canola oil low-fat|Participants randomized to receive a mixed meal with 25 g canola oil
62187652|NCT05208346|EXPERIMENTAL|Coconut oil low-fat|Participants randomized to receive a mixed meal with 25 g coconut oil
62187653|NCT02968823|ACTIVE_COMPARATOR|Licorice|Licorice gargle
62187654|NCT02968823|PLACEBO_COMPARATOR|Sugar water|Sugar gargle
62187655|NCT00377988||001|Transdermal Contraceptive System In each 4-week period exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
62187656|NCT00377988||002|Norgestimate-containing oral contraceptives with EE NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days then no pill or a drug-free pill 7 days.
62187657|NCT05975632|EXPERIMENTAL|Potassium measurement|Calibration Phase : 1 visit (duration 1 day) for subjects not on dialysis and hemodialysis patients Comparaison Phase : 1 visit (diration 1 day) for hemodialysis patients Comparaison Phase : 2 visits (diration 1 day) for subjects not on dialysis
62570805|NCT03710967|EXPERIMENTAL|Bilateral TMS|
62570806|NCT03710967|ACTIVE_COMPARATOR|Unilateral TMS|
62570807|NCT03403140|EXPERIMENTAL|Single arm|"Enerceptan®. Injectable Solution in prefilled syringes~Source: GEMABIOTECH S. A. Formulation per unit:~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week"
62570808|NCT02529657|PLACEBO_COMPARATOR|Placebo|23 patients were induced to think they will be getting the same treatment, although the LLLT is not operating.
62570809|NCT02529657|EXPERIMENTAL|Low level Laser Therapy|25 patients were submitted to spine surgery and have received low level laser therapy during surgery, 24 hours after surgery and 48 hours after surgery.
62570810|NCT04289025|ACTIVE_COMPARATOR|Exercise|Personalised exercise programme is provided to the exercise group.
62570811|NCT04289025|NO_INTERVENTION|No Intervention|This group of patients will receive no intervention.
62187658|NCT00985270|ACTIVE_COMPARATOR|Rifampicin|
62570812|NCT01739231|EXPERIMENTAL|ACE527 alone|In Part A of the study, subjects were split into two cohorts whereby enrollment of the second cohort depended on the safety profile of the first cohort. In Part A, subjects received three oral doses of ACE527 at 0, 1, and 2 months. For Part B of the study, eligible subjects who expressed interest of the study were administered H10407 challenge strain 5-7 months after the three-dose vaccination series.
62777745|NCT03667690|ACTIVE_COMPARATOR|Group 2: Caspofungin|"Subjects in caspofungin arm will receive a total treatment of ≥14 days beginning with a single caspofungin 70 mg IV loading dose on Day 1 followed by 50 mg IV once daily up to 28 days. After ≥3 days of caspofungin treatment(or the minimum duration of IV therapy advised by the site's national/regional/local guidelines, whichever is greater), subjects may be switched to oral fluconazole if specific parameters are met.~If the subject qualifies, then oral step-down therapy of fluconazole (6 mg/kg to the nearest 200 mg) is administered. After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind."
62777746|NCT00387036|OTHER|1|Arm 1: drug, crossing over to Pbo comparator
62777747|NCT00387036|OTHER|2|Arm 2: Pbo comparator, crossing over to drug
62777748|NCT05595772|ACTIVE_COMPARATOR|group A (Concentrated Growth Factor) CGF|ten patients indicated for immediate implant in the maxillary anterior region (class II socket)
62777749|NCT05595772|ACTIVE_COMPARATOR|group B (Plasma Rich in Growth Factor) PRGF|Ten patients who indicated immediate implant in the maxillary anterior region (class I or class II socket),
62187659|NCT00985270|PLACEBO_COMPARATOR|Placebo|
62187660|NCT00907764|EXPERIMENTAL|Regadenoson alone|
62395660|NCT06112366|PLACEBO_COMPARATOR|Control group used silk sutures after extraction of impacted wisdom teeth|Bilateral impacted wisdom teeth of the patients were randomly selected. After the tooth in the experimental group was extracted, the other impacted wisdom tooth was selected as the control group and silk sutures were used for wound closure.
62395661|NCT06377670||Wassel IV Thumb Duplication Cases|This group consists of pediatric patients who have undergone surgical correction for Wassel IV thumb duplication. All participants have had a minimum of one year post-operative follow-up. This cohort will be assessed for functional and aesthetic outcomes using the Japanese Society for Surgery of the Hand (JSSH) scoring method. This includes evaluating thumb mobility, functionality, global aesthetics, and other quality of life aspects for each patient using their contralateral healthy thumb as a control. Data will be collected on preoperative metacarpophalangeal angle, type of skin flap used, surgical reconstruction technique, immobilization method, postoperative complications, and patient satisfaction with surgery and daily pain levels.
62395662|NCT00001367||family members|Family Members who are 2 years old or older of people with a neurological disorder
62395663|NCT00001367||healthy volunteers|healthy volunteers age 18 and older
62395664|NCT00001367||patients|subjects with neurological disorders who are 2 years old or older
62395665|NCT04153526||Surgical Cohort|Surgical Cohort: Patients offered surgery, with or without adjuvant chemotherapy.
62777750|NCT03665116|EXPERIMENTAL|Arginine|L-arginine 1.5 g capsule by mouth, once daily for 6 months
62777751|NCT03665116|NO_INTERVENTION|No Intervention|no supplement for 6 months
62187661|NCT00907764|EXPERIMENTAL|Regadenoson with exercise|
62187662|NCT00907764|EXPERIMENTAL|Regadenoson with contrast agent|
62187663|NCT00907764|EXPERIMENTAL|Regadenoson with contrast agent (perfusion)|
62187664|NCT04344665|EXPERIMENTAL|Virtual Care and Remote Automated Monitoring|
62187665|NCT04344665|NO_INTERVENTION|Standard Care|
62187666|NCT00692549|EXPERIMENTAL|Ultrasound|use of ultrasound
62187667|NCT00692549|NO_INTERVENTION|no ultrasound|no ultrasound
62187668|NCT00810342|EXPERIMENTAL|1- physical activity tailored|Tailored telephone counseling about how to become more physically active and goal setting. Email feedback on physical activity progress. Website listing resources new mothers can use to become more active.
62187669|NCT00810342|ACTIVE_COMPARATOR|2 - physical activity standard|Standard Website resources / information on physical activity
62187670|NCT03357198||cough peak flow measurement|All enrolled patients will undergo measurement of cough peak flow by two methods, i.e. using a handheld electronic spirometer, and using the ventilator flowmeter, in a randomized order.
62777752|NCT04038762|ACTIVE_COMPARATOR|Conventional nasal intubation|Passage of an endotracheal tube via the nare followed by video laryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
62777753|NCT04038762|EXPERIMENTAL|Nasotracheal Intubation with cuff inflation-deflation method|Nasotracheal intubation placed with video laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
62777754|NCT00386165|EXPERIMENTAL|Larazotide acetate|Larazotide acetate capsules: 12 mg QD x 3 days
62570813|NCT01739231|EXPERIMENTAL|ACE527 plus dmLT|In Part A of the study, subjects were split into two cohorts whereby enrollment of the second cohort depended on the safety profile of the first cohort. In Part A, subjects received three oral doses of ACE527 with mucosal adjuvant (dmLT) at 0, 1, and 2 months. For Part B of the study, eligible subjects who expressed interest of the study were administered H10407 challenge strain 5-7 months after the three-dose vaccination series.
62570814|NCT01739231|ACTIVE_COMPARATOR|Control: Part A and B|In Part A of the study, subjects were split into two cohorts whereby enrollment of the second cohort depended on the safety profile of the first cohort. In Part A, subjects received three oral doses of CeraVacx placebo at 0, 1, and 2 months. For Part B of the study, eligible subjects who expressed interest of the study were administered H10407 challenge strain 5-7 months after the three-dose vaccination series.
62570815|NCT01739231|ACTIVE_COMPARATOR|Control: Part B only|Eligible participants were screened and administered H10407 challenge strain concurrently with other arms in Part B of the study. Their results for Part B are combined with that of the Control Arm in Part A, which received three oral doses of CeraVacx placebo.
62570816|NCT01559077|ACTIVE_COMPARATOR|ALN-TTR02|
62777755|NCT00386165|PLACEBO_COMPARATOR|Placebo|Placebo capsules: QD x 3 days
62777756|NCT02228447|NO_INTERVENTION|No intervention group|The control group will not receive any intervention during the one year of this study. Only the baseline, 6-12 months assessments (anthropometrics, PA, dietary intake, social cognitive mediators and sedentary behaviors). To prevent compensatory rivalry and resentful demoralization, the control school will be provided with a condensed version of the following 12-month assessments. The condensed version of the program will include the professional learning workshops for intervention schools and the intervention materials (i.e., nutrition and PA handbooks and PA leadership handbook).
62002170|NCT04174729|EXPERIMENTAL|Hand strength|"The tests were performed in two sessions lasting 1 hour each. The volunteers used the devices: door handle, tap, door pull handle, switch and door key to quantify hand strength. The tests were performed in two sessions lasting 1 hour each. The volunteers used the devices: door handle, tap, door pull handle, switch and door key to quantify hand strength.~In the first session, the volunteers performed the movements 3 times in each device of daily living activities with the right limb, with a 1-minute rest interval between the 3 measurements. The entire procedure performed in the session was repeated again after 30 minutes to verify the reliability and reproducibility of the Intra-evaluator test. The Inter-rater test was repeated after 7 days by the second rater to analyze reliability between the rater."
62777757|NCT02228447|EXPERIMENTAL|Healthy habits, healthy girls group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
62187671|NCT02888223|EXPERIMENTAL|Group A|a single dose administration of SCT800 followed by Xyntha (50 IU.kg-1, based upon the manufacturer's labeled potency)
62570817|NCT01559077|PLACEBO_COMPARATOR|Sterile Normal Saline (0.9% NaCl)|
62570818|NCT05814263|EXPERIMENTAL|HIS/LBB pacing|"In this arm a right ventricular (RV) lead or implantable cardioverter defibrillator (ICD) lead is placed first and then implantation of a HIS-pacing lead is attempted. If it is not possible to find and pace HIS, to correct the LBBB or the threshold for correcting the LBBB is \> 2.5 V at 1 ms, implantation of a LBB-pacing lead is attempted instead. If that is not possible either, a left ventricular (LV) lead is implanted.~Intervention: Device: HIS/LBB pacing"
62570819|NCT05814263|ACTIVE_COMPARATOR|LV pacing|"In this arm an RV-lead or ICD-lead is placed first and then implantation of a LV-pacing lead is attempted. If this is not possible due to anatomical difficulties (no coronary sinus (CS) access, no available branches other than v cordis anterior or v cordis media) or electrical difficulties (no capture below 4 V at 1.0 msec or phrenic nerve stimulation \< 2x pacing threshold), implantation of a HIS-pacing lead is attempted instead. If that is not possible or the threshold for correcting the LBBB is \> 2.5 V at 1 ms, implantation of a LBB-pacing lead is attempted instead.~Intervention: Device: LV pacing"
62570820|NCT06575504||Neonates|High risk newborn infants admitted to NICU
62777758|NCT03147534|ACTIVE_COMPARATOR|Children Age 1 month to 2 years|"Collecting temperatures on patients using the ARC InstaTemp MD and a Welch Allyn rectal thermometer."
62570821|NCT04839302||Patients with possible nectrotizing fascitis|Patients with clinical suspicion of necrotizing fasciitis would receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) with immediate fluorescence imaging of the affected body part and simultaneous imaging of an unaffected region
62777759|NCT03147534|ACTIVE_COMPARATOR|Children > 2 to 5 years|"Collecting temperatures on patients using the ARC InstaTemp MD, the Welch Allyn rectal and Covidien tympanic thermometer."
62777760|NCT03147534|ACTIVE_COMPARATOR|Children > 5 to ≤ 10 years|"Collecting temperatures on patients using the ARC InstaTemp MD, the Welch Allyn oral and the Covidien tympanic thermometer."
62777761|NCT03574402|EXPERIMENTAL|Arm1: Avitinib Maleate|Patients with EGFR de novo T790m mutation receive Avitinib 300mg orally (PO) twice daily (BID) on day 1-28.
62777762|NCT03574402|EXPERIMENTAL|Arm2: Chidamide plus Afatinib|"Patients with EGFR sensitive mutation with BIM deletion polymorphism receive Afatinib plus Chidamide.~Chidamide will be administered 30mg orally twice weekly, 28 days as one cycle. Afatinib will be administered 40mg orally once a day, 28 days as one cycle."
62777763|NCT03574402|EXPERIMENTAL|Arm3: crizotinib|Patients with MET 14 exon mutation receive crizotinib 250mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62187672|NCT02888223|EXPERIMENTAL|Group B|a single dose administration of Xyntha followed by SCT800(50 IU.kg-1, based upon the manufacturer's labeled potency)
62187673|NCT06149845|EXPERIMENTAL|Pulpotomy|Participants diagnosed with symptomatic irreversible pulpitis in vital primary molars will receive the pulpotomy treatment intervention
62187674|NCT03848884|EXPERIMENTAL|Adherence monitoring and education|
62187675|NCT04423419|OTHER|A|will undergo Peri -articular nerve group block for hip joint under ultrasound guide as analgesia post operative after hip arthroscopy
62187676|NCT04423419|OTHER|B|will undergo ultrasound guided fascia iliaca block as postoperative analgesia after hip arthroscopy
62570822|NCT05865860||ophthalmologists with microsurgical training|Participants underwent training by digital and microscope, and we observed the changes of functions before and immediately after the training
62570823|NCT01419756||Single Arm|Imaging comparison study. No intervention.
62570824|NCT06331351|PLACEBO_COMPARATOR|control group|placebo: 2 times a day, 1 sachet each time.
62570825|NCT06331351|EXPERIMENTAL|Jing Si herbal tea liquid packets group|Jing Si herbal tea liquid packets: 2 times a day, 1 sachet each time.
62570826|NCT06348238|EXPERIMENTAL|Self-Affirmation|Participants review a list of values and are instructed to choose up to two that are important to them. The values listed are intentionally unrelated to the threat-inducing domain so that the exercise broadens participants' focus. Next, participants are asked to write a few sentences about why their chosen values are important to them and identify times in which these values have helped them navigate challenges.
62570827|NCT06348238|SHAM_COMPARATOR|Waitlist Control|"Participants in the waitlist control condition will also complete writing exercises but they will be abbreviated (this in the psychological literature is referred to as a low affirmation condition). At the end of the study, waitlist control participants will have access to the full exercise should they like to receive it."
62570828|NCT02862665|EXPERIMENTAL|IV iron|The patients will receive iron isomaltoside 1000 (Monofer®) as an i.v. infusion of 1000 mg (diluted with normal saline, 10 mg/ml) twice; 3 days before surgery and 3 days after surgery. They will receive iron isomaltoside 1000 (Monofer®) 1000 mg over 15 min.
62570829|NCT02862665|PLACEBO_COMPARATOR|Control|The patients will receive normal saline 100 ml as an i.v. infusion twice; 3 days before surgery and 3 days after surgery. They will receive normal saline 100 ml over 15 min.
62570830|NCT06322732||Newborn at or near term|Newborn at or near term (≥ 36 weeks of amenorrhea), considered to be alive at the onset of labor and presenting severe perinatal asphyxia
62777764|NCT03574402|EXPERIMENTAL|Arm4: X396|Patients with MET amplification receive X396 225mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62570831|NCT02838797|PLACEBO_COMPARATOR|Placebo|"For the single ascending dose study, subjects will receive a single dose of oral acetate buffer on a single day.~For the multiple ascending dose study, subjects will receive a single daily dose of oral acetate buffer each day for 14 days."
62570832|NCT02838797|EXPERIMENTAL|RQ-00000010|"For the single ascending dose study, subjects will receive a single dose of either:~2 micrograms, 50 micrograms or 200 micrograms of RQ-00000010 on a single day.~For the multiple ascending dose study, subjects will receive single daily doses of either 10 micrograms, 50 micrograms or 100 vs. 200 micrograms of RQ-00000010 each day for 14 days."
62570833|NCT05462938|ACTIVE_COMPARATOR|Propofol group|Continuous infusion of propofol
62187677|NCT04423419|OTHER|C|will receive ordinary IV analgesia during operation hip arthroscopy
62570834|NCT05462938|ACTIVE_COMPARATOR|Dexmedetomidine group|Continuous infusion of dexmedetomidine
62570835|NCT06178211|EXPERIMENTAL|adebrelimab and chemotherapy|
62570836|NCT05300815||Dry Needling Experts|"Experts will be defined as adult individuals with a high level of knowledge within the area of patient safety and adverse events related to dry needling which will be confirmed using the following eligibility criteria:~(1) Must have \>= 5 years of clinical practice performing dry needling and at least ONE of the following secondary criteria:~1. Certification in Dry Needling~2. Completion of a manual therapy fellowship that included dry needling training~3. \>= 1 total scholarly product (poster presentation, author of a peer-reviewed publication) involving the use of dry needling~Eligible participants will be identified through existing professional networks and social media/internet-based searching. They will be recruited worldwide and be aged 18 or above, able to read and write in English, and willing to provide signed informed consent."
62570837|NCT02701829|EXPERIMENTAL|Health Fairs (HF)|Drivers will undergo U\&C Health Fair follow-up either Regular or Urgent Follow-up: Timeline is determined by health status, with regular follow-up continuing for at least two weeks and urgent follow-up continuing for at least a month
62002171|NCT00749463|EXPERIMENTAL|Gum 2|Nicotine Gum 2 mg for subjects smoking less than 20 cigarettes per day; 2 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
62002172|NCT00749463|EXPERIMENTAL|Gum 4|Nicotine Gum 4 mg for subjects smoking 20 or more cigarettes per day; 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
62002173|NCT00749463|EXPERIMENTAL|Patch|Nicotine Patch; Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
62187678|NCT04944498|EXPERIMENTAL|Intervention Group|Patients who received surgery with modified tarsorrhaphy technique
62187679|NCT04944498|ACTIVE_COMPARATOR|Control group|Patients who received surgery with gold weight implant technique
62187680|NCT01993277|ACTIVE_COMPARATOR|Fischer Wallace Stimulator|30 20-minute sessions of the Fischer Wallace Stimulator administered twice-per-day within a 3-week time-frame;
62570838|NCT02701829|EXPERIMENTAL|HF + text messaging + home BP monitoring|Drivers will receive: U\&C HF follow-up, Mobile text messaging intervention w/ interactive 2- way messaging to encourage BP management for nine months A home BP monitoring equipment with instructions to self-monitor BP for nine months
62777765|NCT03574402|EXPERIMENTAL|Arm5: X396|Patients with ROS1 fusion receive X396 225mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
62187681|NCT01993277|ACTIVE_COMPARATOR|Nexalin Brain Stimulator|15 40-minute sessions of Nexalin Brain Stimulator adminsitered once-per-day within a 3-week time-frame
62187682|NCT01993277|ACTIVE_COMPARATOR|DAVID Delight Stimulator|15 40-minute sessions of the DAVID Delight administered once-per-day within a 3-week time-frame
62187683|NCT01993277|ACTIVE_COMPARATOR|Relaxation Therapy|15 40-minute relaxation therapy sessions once-per-day within a 3-week time-frame
62777766|NCT03574402|EXPERIMENTAL|Arm6: X396|Patients with Ntrk1/2/3 fusion receive X396 225mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
62777767|NCT03574402|EXPERIMENTAL|Arm7: Pyrotinib Maleate|Patients with HER2 mutation receive Pyrotinib Maleate 400mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
62002174|NCT04733157|EXPERIMENTAL|Study group/Group A|The study group will receive TXA 1g intravenously at the onset of skin incision.
62002175|NCT04733157|PLACEBO_COMPARATOR|Control group/Group B|There is an equivalent volume of normal saline for the control group.
62002176|NCT05364528||clinical pregnancies with direct catheter|Clinical pregnancies occurred after fresh and frozen blastocyst transfers using direct technique.
62002177|NCT05364528||clinical pregnancies with afterload catheter|Clinical pregnancies occurred after fresh and frozen blastocyst transfers using afterload technique.
62002178|NCT04310761||pregnancy population after one single blastocyst transfer|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from a period between 2014 and 2018.
62002179|NCT03410225|EXPERIMENTAL|CAMI-TPP|Young men, ages 15 to 24 years, will be receiving a modified CAMI aimed at Teen Pregnancy Prevention (CAMI-TPP).
62002180|NCT03410225|ACTIVE_COMPARATOR|CAMI-Fitness|Young men, ages 15 to 24 years, will be receiving CAMI aimed at healthy diet, physical activity and tobacco avoidance (CAMI-Fitness).
62002181|NCT06336772|EXPERIMENTAL|Restylane Shaype|"Restylane Shaype is approved and commercially available for use in Canada and is manufactured by Q-Med AB, part of the Galderma Group.~The participant will be treated at the Baseline visit and will be eligible for retreatment 2 weeks later if a touch up is deemed necessary by the Treating Investigator. Volumes used for each participant will be determined by the aesthetic judgement of the Treating Investigator."
62002182|NCT06336772|ACTIVE_COMPARATOR|Juvederm Volux|"Juvéderm Volux is approved and commercially available for use in Canada and is manufactured by Allergan Aesthetics, an Abbvie company.~The participant will be treated at the Baseline visit and will be eligible for retreatment 2 weeks later if a touch up is deemed necessary by the Treating Investigator. Volumes used for each participant will be determined by the aesthetic judgement of the Treating Investigator."
62002183|NCT03970473|ACTIVE_COMPARATOR|PRM 30 cm H2O|In this group, following the laparoscopic surgery and just before the extubation, patients will receive PRM with 30 cm H2O in the semi-fowler position.
62002184|NCT03970473|ACTIVE_COMPARATOR|PRM 15 cm H2O|In this group, following the laparoscopic surgery and just before the extubation, patients will receive PRM with 15 cm H2O in the semi-fowler position.
62002185|NCT06187103|EXPERIMENTAL|HyperSight Imaging arm|Subjects are imaged with the new HyperSight CBCT imaging system.
62777768|NCT03574402|EXPERIMENTAL|Arm8: AZD3759|EGFR sensitive mutation with brain/meningeal metastasis receive AZD3759 200mg PO BID on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
62777769|NCT03574402|EXPERIMENTAL|Arm9: Pirotinib|"Patients with EGFR20ins mutation positive receive Pirotinib.~This arm was divided into three groups:~Group 1, 60mg PO QD on days 1-28. 28 days as one cycle. Group 2, 40mg PO BID on days 1-28. 28 days as one cycle. Group 3, Dosage was determined according to the number of PR patients in Group 2."
62777770|NCT03574402|EXPERIMENTAL|Arm10: Nimotuzumab plus gemcitabine and carboplatin|"Lung squamous cell carcinoma with EGFR amplification. Nimotuzumab 400mg, iv gtt. on day 1,8,15. Gemcitabine 1250mg/m\^2, iv gtt. on day 1,8. Carboplatin AUC5, iv gtt. Q3W on day 1.~21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
62777771|NCT03574402|EXPERIMENTAL|Arm11: Nimotuzumab plus pemetrexed and cisplatin|"Lung adenocarcinoma with EGFR amplification. Nimotuzumab 400mg, iv gtt. on day 1,8,15. pemetrexed 500mg/m\^2, iv gtt. on day 1. Cisplatin 75mg/m\^2, iv gtt. Q3W on day 1.~21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
62002186|NCT02800148|EXPERIMENTAL|Azelaic acid foam|
62002187|NCT02800148|ACTIVE_COMPARATOR|Finacea Foam|
62002188|NCT02800148|PLACEBO_COMPARATOR|Placebo Foam|
62002189|NCT03352921|EXPERIMENTAL|clinical pilates exercises|The experimental group will receive clinical pilates exercise training in group form for 3 weeks a week for 8 weeks. The training will be done 40-50 minutes per one day. The exercise session will be started with a 10 minute warming program, 30 minutes with the core stabilization training and the clinical pilates exercises with the postural alignment exercises will be applied and the exercise session will be ended with the 10 minutes cooling period.
62002190|NCT03352921|ACTIVE_COMPARATOR|Home exercises program|For 8 weeks the member in comparison group will be ask to do the exercise program 3 days a week at home. This group will receive a program of stretching, strengthening, and posture exercises. All the exercises in the program will be illustrated on a descriptive form with images. In terms of the follow-up during 8-week duration, the individuals will be called frequently and in the interview by the end of the study.
62002191|NCT00287768|EXPERIMENTAL|1|Docetaxel + S-1
62002192|NCT00287768|ACTIVE_COMPARATOR|2|S-1
62002193|NCT05575648|OTHER|Duchenne Muscular Dystrophy|Children who have been diagnosed with Duchenne Muscular Dystrophy.
62002194|NCT05575648|ACTIVE_COMPARATOR|Healthy Subjects|Children who have a normal motor and cognitive development.
62002195|NCT06381349||Adult patients with gastroparesis|"1. Provision of signed and dated informed consent form understand the risks and benefits of the study~2. Aged ≥18 years old~3. Patients must be clinically selected for GPOEM at their respective study site.~4. Patients are undergoing their index GPOEM procedure"
62187684|NCT06456606||group a|30 moderate-to-severe C-ARDS patients who were treated with prone position in the first 48 hours of invasive mechanical ventilation support. It was evaluated with transesophageal echocardiography three times: before prone position (T0), the first hour of prone position (T1), and the first hour of returning to the supine position (T0 + 24 hours) (T2) after 23 hours prone position treatment.
62570839|NCT02701829|EXPERIMENTAL|HF +Tech + social network support (SNS).|"Drivers will receive:~U\&C HF follow-up, Mobile text messaging intervention w/ interactive 2- way messaging to encourage BP management for nine months and home BP monitoring equipment with instructions to self-monitor BP for nine months A social network support intervention in which selected family/peers encourage drivers to maintain healthy behaviors for nine months"
62570840|NCT05448274|PLACEBO_COMPARATOR|Placebo|The placebo will consist of solely glycerol-phosphate-buffered isotonic saline.
62570841|NCT05448274|EXPERIMENTAL|Ruminococcus torques|10\^11 live bacterial cells in glycerol-phosphate-buffered isotonic saline
62570842|NCT06314113||Low-grade Cervical Lesions (L-SIL)|Women affected by Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) Infection
62570843|NCT05590793|EXPERIMENTAL|Triptorelin pamoate 22.5 mg 6-month formulation|All enrolled participants will receive one intramuscular (i.m.) injection of containing 22.5 mg 6-month formulation triptorelin pamoate on Day 1.
62570844|NCT04873921|EXPERIMENTAL|Group 1: Sterile Kinesio tape application|Sterile Kinesio Taping application will be applied with Sterile Web Cut Kinesio Tape (Sterile Kinesio Tex Tape, Alberquerque, USA) without tension.
62570845|NCT04873921|NO_INTERVENTION|Group 2: Control group|Group 2 will not receive any taping
62570846|NCT04287660|EXPERIMENTAL|BiRd combined with BCMA CAR T-cells infusion|
62570847|NCT01114802|EXPERIMENTAL|Project Onward website + social network|This arm has the website which includes 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
62570848|NCT01114802|ACTIVE_COMPARATOR|Project Onward website|This arm has the website which includes 8 weeks of Internet-based cognitive behavioral therapy.
62570849|NCT04142736|EXPERIMENTAL|Prone position|Patients with acute hypoxemic respiratory failure from any cause
62570850|NCT04142736|NO_INTERVENTION|Supine position|Patients with acute hypoxemic respiratory failure from any cause
62570851|NCT00725153|OTHER|PureVision/Acuvue 2|PureVision contact lenses worn first, with Acuvue 2 contact lenses worn second. Both products worn for 10 hours each.
62570852|NCT00725153|OTHER|Acuvue 2/PureVision|Acuvue 2 contact lenses worn first, with PureVision contact lenses worn second. Both products worn for 10 hours each.
62570853|NCT03522012|EXPERIMENTAL|LusiNex|4 mg/kg, single-dose IV infusion (Mycenax tocilizumab)
62777772|NCT03574402|EXPERIMENTAL|Arm12: Pirotinib|"Patients with rare EGFR mutation receive Pirotinib.~This arm was divided into two groups:~Group 1, 40mg PO BID on days 1-28. 28 days as one cycle. Group 2, Dosage was determined according to the number of PR patients in Group 1."
62777773|NCT03574402|EXPERIMENTAL|Arm13: Avitinib|Patients with EGFR sensitive mutation receive Avitinib 300mg PO BID on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
62187685|NCT00895726|EXPERIMENTAL|APD209|
62187686|NCT02138097||Glitazones|
62187687|NCT02138097||Linagliptin|
62187688|NCT02138097||Meglitinides|
62187689|NCT02138097||Metformin|
62187690|NCT02138097||Non-insulin injectables|
62187691|NCT02138097||Saxagliptin|
62187692|NCT02138097||Sitagliptin|
62187693|NCT02138097||Sulfonylurea|
62187694|NCT04374786|EXPERIMENTAL|Intervention Group|"Will receive a 30-day are trial of the mobile meditation app Calm on study day 0"
62570854|NCT03522012|ACTIVE_COMPARATOR|RoActemra|4 mg/kg, single-dose IV infusion (RoActemra; tocilizumab marketed in EU )
62570855|NCT03522012|ACTIVE_COMPARATOR|Actemra|4 mg/kg, single-dose IV infusion (Actemra; tocilizumab marketed in US)
62570856|NCT05527171|EXPERIMENTAL|VR Mindfulness Meditation Group|Participants will complete 8-weeks of virtual reality mindfulness meditation and an advanced neuromuscular training program. Mindfulness meditation is the practice of sustaining attention on the body, breath, or sensations in any given moment and allows for the self-regulation of attention by decreasing rumination about past or future events. During the practice of mindfulness meditation, the individual is aware of all incoming thoughts and feelings, but rather than reacting to them, the individual accepts them. Virtual reality mindfulness meditation has been demonstrated to be superior in inducing mindfulness states when compared to traditional mindfulness meditation. Use of a virtual reality system to implement mindfulness meditation not only decreases the barrier of time to implement psychological interventions, but also improves the clinician's confidence in implementing the intervention as the virtual reality system guides the patient through the mindfulness meditation process.
62570857|NCT05527171|SHAM_COMPARATOR|VR Sham Group|Participants will complete 8-weeks of virtual reality sham and an advanced neuromuscular training program. Participants will be immersed in a virtual environment but will not receive the mindfulness meditation.
62570858|NCT01510301|OTHER|Self-report|
62570859|NCT01969773|EXPERIMENTAL|Botulinum toxin A|Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
62570860|NCT01969773|PLACEBO_COMPARATOR|Control arm-Normal saline instillation|Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
62570861|NCT04578457|ACTIVE_COMPARATOR|Hearing Aid without NR(0) enabled|Hearing Aid without Noise Reduction (NR 0) enabled serves as reference condition.
62570862|NCT04578457|EXPERIMENTAL|Hearing Aid with NR (1)|Hearing Aid with Noise Reduction I (NR) enabled.
62570863|NCT04578457|EXPERIMENTAL|Hearing Aid with NR(2)|Hearing Aid with Noise Reduction II (NR) enabled.
62002196|NCT03493490|EXPERIMENTAL|Neodolpasse|"In the Neodolpasse® arm patients receive two infusions over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.~Neodolpasse® Infusion Solution combines 75 mg (250 mL) of the NSAID diclofenac with 30 mg of the muscle-relaxant orphenadrine."
62002197|NCT03493490|ACTIVE_COMPARATOR|Diclofenac|"In the Diclofenac arm patients receive two infusions over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.~The Infusion solution contains 75 mg (250 mL) of the NSAID diclofenac."
62002198|NCT03493490|PLACEBO_COMPARATOR|Placebo|In the Placebo arm patients receive two physiologic saline infusion (250 mL) over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.
62570864|NCT04578457|EXPERIMENTAL|Hearing Aid with NR(3)|Hearing Aid with Noise Reduction III (NR) enabled.
62570865|NCT04468178|EXPERIMENTAL|Shoulder prosthesis system GLOBAL ICON from DePuy|The GLOBAL ICON stemless is a shaftless shoulder prosthesis system for anatomical reconstruction of the shoulder joint in cases of total or hemiarthroplasty in the shoulder. The base plate consists of titanium coated with hydroxyapatite, the head of cobalt-chrome.
62570866|NCT04468178|ACTIVE_COMPARATOR|SIMPLICITY shoulder prosthesis system from Wright Medical|The SIMPLICITY is a shaftless shoulder prosthesis system for anatomical reconstruction of the shoulder joint in cases of total or hemiarthroplasty in the shoulder. The base plate consists of titanium coated with hydroxyapatite, the head of cobalt-chrome.
62570867|NCT02802124|EXPERIMENTAL|carbon-ion radiotherapy for tumor away from GI|For tumor location which is away from gastrointestine (the distance is more than 1 cm). We use carbon-ion radiotherapy for the treatment of hepatocellular carcinoma. Four dose levels \[55 Gray equivalent (GyE)/10 fractions (Fx), 60GyE/10Fx, 65GyE/10Fx, 70GyE/10Fx\] are planned within the Phase I part.
62570868|NCT02802124|EXPERIMENTAL|carbon-ion radiotherapy for tumor adjacent to GI|"For tumor location which is adjacent to gastrointestine (less than 1 cm).We use carbon-ion radiotherapy for the treatment of hepatocellular carcinoma.~Three dose levels (carbon 60GyE/15Fx, carbon 67.5GyE/15Fx, carbon 75GyE/15Fx) are planned within the Phase I part."
62570869|NCT06371235|OTHER|pregnant women|"Pregnant woman over 18 years old~- Woman whose gestational age is less than 30 weeks"
62570870|NCT04009525|EXPERIMENTAL|MSD-HSCT|matched sibling donors hematopoietic stem cell transplantation
62570871|NCT04009525|EXPERIMENTAL|URD-HSCT|unrelated donor hematopoietic stem cell transplantation
62570872|NCT04009525|EXPERIMENTAL|haplo-HSCT|haplo-identical hematopoietic stem cell transplantation
62002199|NCT06060574||Menstrual Cycle 1-2nd days|The Blood samples will be drawn from the participants on 1st-2nd day of the menstrual cycle of each of these 36 participants. PRF will be obtained from the blood taken these days.
62002200|NCT06060574||Menstrual Cycle 8-10. days : proliferative phase (PP)|The Blood samples will be drawn from the participants on 8-10. days of the menstrual cycle of each of these 36 participants. PRF will be obtained from the blood taken these days.
62002201|NCT06060574||Menstrual Cycle 12-14. days: ovulation phase (OP)|The Blood samples will be drawn from the participants on 12-14. days of the menstrual cycle of each of these 36 participants. PRF will be obtained from the blood taken these days.
62002202|NCT06060574||premenstrual (PmD) 22-24. days|The Blood samples will be drawn from the participants on 22-24. days of the menstrual cycle of each of these 36 participants. PRF will be obtained from the blood taken these days.
62187695|NCT04967352||Developed Persistent Opioid Use after 3 months following surgery|
62187696|NCT04967352||Did not develop persistent opioid use after 3 months following surgery|
62187697|NCT03535805|EXPERIMENTAL|Mind My Mind (MMM)|Mind My Mind (MMM)
62187698|NCT03535805|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Treatment as Usual (TAU)
62187699|NCT01902186|EXPERIMENTAL|raltegravir|raltegravir and atazanavir and ritonavir
62570873|NCT06468059|EXPERIMENTAL|Layered Low Profile Foot (LPF) vs. Prescribed Ankle|In this arm, subjects will first test the LPF and then complete the tests with their prescribed ankle.
62570874|NCT06468059|EXPERIMENTAL|Prescribed Ankle vs. Layered Low Profile Foot (LPF)|In this arm, subjects will first complete the tests with their prescribed ankle and then test the LPF.
62187700|NCT01902186|ACTIVE_COMPARATOR|tenofovir/emtricitabine|tenofovir/emtricitabine and atazanavir and ritonavir
62187701|NCT02602483|EXPERIMENTAL|Triple combination|Powder for oral administration
62187702|NCT02602483|ACTIVE_COMPARATOR|Ibuprofen|Powder for oral administration
62187703|NCT02602483|ACTIVE_COMPARATOR|Magnesium + ascorbic acid|Powder for oral administration
62187704|NCT02602483|PLACEBO_COMPARATOR|Placebo|Powder for oral administration
62570875|NCT03092856|EXPERIMENTAL|Arm I (axitinib, anti-OX40 antibody PF-04518600)|Patients receive axitinib PO BID on days 1-14 and anti-OX40 antibody PF-04518600 IV over 60 minutes on day 1 beginning with course 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62570876|NCT03092856|ACTIVE_COMPARATOR|Arm II (axitinib, placebo)|Patients receive axitinib as in Arm I and placebo IV on day 1 beginning with course 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62570877|NCT02609815|EXPERIMENTAL|gemigliptin/metformin|zemimet-SR 50/1000 mg x 1 tablet
62570878|NCT02609815|ACTIVE_COMPARATOR|glimepiride/metformin|amaryl-Mex 1/500 mg x 2 tablets
62570879|NCT00205023|EXPERIMENTAL|A|
62777774|NCT03574402|EXPERIMENTAL|Arm14: Sintilimab|Patients with PD-L1(TPS)≥50% without EGFR mutation or ALK rearrangement. Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
62187705|NCT06107049|ACTIVE_COMPARATOR|Probiotic group|Participants in the probiotic group received 3g of BLa80 product per day.
62570880|NCT01686672|EXPERIMENTAL|Web Intervention|BeInCharge has two components: an electronic diet tracker and a 7 session intervention. The 7 treatment sessions are designed to be completed over a 7 to 10 week period. Each treatment module includes both a nutrition education and child behavior management component. Treatment sessions should be completed every 7 to 10 days, while the electronic diet tracker requires daily input.
62570881|NCT01686672|NO_INTERVENTION|Usual Care|Participants will receive usual care and be assessed at baseline and week 10 for study outcomes.
62570882|NCT05773105|EXPERIMENTAL|Cadonilimab+regorafenib|
62570883|NCT05587530|EXPERIMENTAL|Treatment engagement and retention intervention for suicidal clients|Participants will receive the manualized treatment engagement and retention protocol for suicidal outpatient clients (single-arm intervention pilot). The manualized treatment engagement and retention protocol will be based on client and staff stakeholder preferences, informed by data from qualitative participatory interviews and secondary data analysis of administrative databases (conducted in phase 1).
62570884|NCT00655408|ACTIVE_COMPARATOR|A|"For infants with ages between six and 24 months, iron supplementation is the main treatment for iron deficiency.This study was carried out using two intervention groups. All children received 12 weekly doses of 25 mg of elemental iron.~Group 1 administered in the government healthcare clinic. Group 2 administered children's home.~The study showed treatment compliance in both groups."
62570885|NCT06576778|ACTIVE_COMPARATOR|No Provisional Prosthesis (PEKKTON as Definitive Framework)|Implant-supported full arch maxillary prosthesis utilising 6 implants, for constructing PEKKTON framework without provisionalization.
62570886|NCT06576778|EXPERIMENTAL|Glass Fiber Reinforced Composite Framework for Provisionalization Then PEKKTON Framework|Implant-supported full arch maxillary prosthesis utilising 6 implants, then Glass fiber composite as a temporary framework followed by PEKKTON definitive framework.
62570887|NCT00119249|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62777775|NCT03574402|EXPERIMENTAL|Arm15: Sintilimab|"Patients with TMB≥10 mut/Mb，1%≦PD-L1\<50% without EGFR mutation or ALK rearrangement.~Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
62187706|NCT06107049|PLACEBO_COMPARATOR|Placebo group|Participants in the placebo group received 3g of maltodextrin per day.
62570888|NCT00872911|EXPERIMENTAL|Nutritional supplement|
62570889|NCT00872911|EXPERIMENTAL|Placebo + Exercise|
62570890|NCT00872911|EXPERIMENTAL|Nutritional Supplement + Exercise|
62570891|NCT00872911|NO_INTERVENTION|Placebo|
62570892|NCT01090778|OTHER|Norditropin SimpleXx sc bolus injection|Single sc bolus injection of 3 mg growth hormone without interval exercise
62570893|NCT01090778|OTHER|Norditropin SimpleXx single sc injection|Single sc bolus injection of 3 mg growth hormone with interval exercise
62570894|NCT01090778|OTHER|Norditropin SimpleXx contin. sc infusion|Continuous sc infusion of 3 mg growth hormone without interval exercise
62570895|NCT01090778|OTHER|Norditropin SimpleXx cont. sc infusion|Continuous sc infusion of 3 mg growth hormone with interval exercise
62777776|NCT03574402|EXPERIMENTAL|Arm16: Sintilimab|"Patients with KRAS and TP53 mutation, 1%≦PD-L1\<50%, TMB\<10 mut/Mb without EGFR mutation or ALK rearrangement.~Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
62002203|NCT01495481|EXPERIMENTAL|Adenosine and Dexmedetomidine|Patients will receive adenosine and then dexmedetomidine for the termination of SVT
62002204|NCT00020670|EXPERIMENTAL|CD40 Cell Vaccination|Patients will undergo tumor cell collection followed by vaccine preparation and then vaccination. Autologous acute lymphoblastic leukemia (ALL) cells are harvested, cultured with CD40 ligand, pulsed with keyhole limpet hemocyanin (KLH), and then irradiated to produce the vaccine. Patients receive either 1 x 10\^7 or 1 x 10\^8 CD40 cells/vaccination depending on the number of tumor cells obtained. Vaccinations are administered every two weeks as outpatient therapy. Evaluable patients receive the course of at least 4 vaccinations at weeks 0, 2, 4, 6. Patients may continue receiving vaccinations every 2 weeks if chemotherapy is not required for symptomatic disease.
62002205|NCT05598229|EXPERIMENTAL|Watch the Tik Tok|Encouraged to watch the Tik Tok.
62002206|NCT05598229|NO_INTERVENTION|Tik Tok is not allowed|Tik Tok is not allowed.
62002207|NCT00131235|PLACEBO_COMPARATOR|Control|Standard antenatal care as described in intervention
62002208|NCT00131235|EXPERIMENTAL|Monthly SP|Standard antenatal care + monthly intermittent presumptive treatment of malaria with sulfadoxine pyrimethamine, as described in intervention
62002209|NCT00131235|EXPERIMENTAL|AZI-SP|Standard antenatal care + monthly intermittent presumptive treatment of malaria with sulfadoxine pyrimethamine + two presumptive treatments of sexually transmitted infections and malaria with azithromycin, as described in intervention
62002210|NCT05702216|OTHER|Cardiac rehabilitation|
62002211|NCT05702216|OTHER|Cardiac Tele-rehabilitation|Tele cardiac rehabilitation in hybrid form
62002212|NCT02109328|EXPERIMENTAL|Alisertib + Paclitaxel|After the first single arm phase with Alisertib monotherapy (20 patients, primary endpoint: response-rate), 110 patients will be randomized 1:1 in the second part of the trial.
62002213|NCT02109328|PLACEBO_COMPARATOR|Paclitaxel + Placebo|Weekly paclitaxel + oral Placebo
62002214|NCT05130190|OTHER|RF Treatment|At the time of the subject's trans-abdominal or laparoscopic hysterectomy, the ProVu System will be used to apply RF treatment to one or two adenomas, focal areas of adenomyosis, or diffuse adenomyosis.
62002215|NCT03538340|ACTIVE_COMPARATOR|Control Arm|Control Arm: Surgery without intercostal Cryoanalgesia + Standard of Care (thoracic epidural)
62002216|NCT03538340|EXPERIMENTAL|Study Arm|Study Arm: Surgery with intercostal Cryoanalgesia + Standard of Care (thoracic epidural)
62002217|NCT03957434|EXPERIMENTAL|Physiotherapy|12-weekly physiotherapy treatment sessions.
62395666|NCT04153526||Non Surgical Cohort|Non-Surgical Cohort: Stage I/II/IIIB patients undergoing radical radiotherapy (with or without chemotherapy) or stereotactic ablative radiotherapy (SABR).
62395667|NCT00300976|EXPERIMENTAL|Intensive therapy|
62002218|NCT03957434|NO_INTERVENTION|Standard usual care|Participants will be asked to continue the usual care established during the regular follow-up with their medical doctor for 12 weeks.
62002219|NCT03198910||Pulmonary arterial hypertension|
62002220|NCT03198910||Chronic thromboembolic pulmonary hypertension|
62002221|NCT02719158|EXPERIMENTAL|6 mg OTO-201|6 mg OTO-201 (sustained-release suspension of ciprofloxacin), single 0.1 mL supra-tympanostomy tube (STT) administration to the affected ear(s)
62395668|NCT00300976|ACTIVE_COMPARATOR|Conventional therapy|
62395669|NCT06279169|EXPERIMENTAL|Heart sound group|"In the heart sound group, the heart sound with an average heart rate of 70 beats is transmitted to the loudspeaker via an Mp3 player. Two small 200 W loudspeakers (SONY®)/JBL brand loudspeakers are used, placed on either side of the newborn's head, 30 cm from the newborn's ears."
62002222|NCT02719158|EXPERIMENTAL|12 mg OTO-201|12 mg OTO-201 (sustained-release suspension of ciprofloxacin), single 0.2 mL supra-tympanostomy tube (STT) administration to the affected ear(s)
62570896|NCT03238664|EXPERIMENTAL|Arm A (laparoscopic HIFU, RARC)|Patients undergo pre-HIFU CEUS, standard of care biopsy of the bladder tumor, laparoscopic HIFU, and post-HIFU CEUS. Patients then undergo standard of care RARC.
62570897|NCT03238664|ACTIVE_COMPARATOR|Arm B (RARC)|Patients undergo standard of care RARC.
62570898|NCT01573182|EXPERIMENTAL|Donor|VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the intramuscular (IM) route 4 to 6 weeks prior to stem cell harvesting..
62570899|NCT05890924||Patients|First venous thromboembolic event associated with combined oral contraceptives intake
62570900|NCT05890924||Controls|regular follow-up of their combined oral contraception
62570901|NCT06577298|EXPERIMENTAL|Phase I, Toddler Group A, Experimental vaccine, High dose, IM|One dose of VLP-Polio on Day 0
62570902|NCT06577298|ACTIVE_COMPARATOR|Phase I, Toddler Group A, Control vaccine, IM|One dose of IPV control on Day 0
62570903|NCT06577298|EXPERIMENTAL|Phase I, Infant Group B, Experimental vaccine, Low-adjuvant dose, IM|4 dose of VLP-Polio on Day 0, Day 28, Day 56 and Month 12-18 of age
62570904|NCT06577298|ACTIVE_COMPARATOR|Phase I, Infant Group B, Control vaccine, IM|4 dose of IPV on Day 0, Day 28, Day 56 and Month 12-18 of age
62570905|NCT06577298|EXPERIMENTAL|Phase I, Infant Group C, Experimental vaccine, Medium dose, IM|4 dose of VLP-Polio on Day 0, Day 28, Day 56 and Month 12-18 of age
62570906|NCT06577298|ACTIVE_COMPARATOR|Phase I, Infant Group C, Control vaccine, IM|4 dose of IPV on Day 0, Day 28, Day 56 and Month 12-18 of age
62570907|NCT06577298|EXPERIMENTAL|Phase I, Infant Group D, Experimental vaccine, High dose, IM|4 dose of VLP-Polio on Day 0, Day 28, Day 56 and Month 12-18 of age
62570908|NCT06577298|ACTIVE_COMPARATOR|Phase I, Infant Group D, Control vaccine, IM|4 dose of IPV on Day 0, Day 28, Day 56 and Month 12-18 of age
62777777|NCT03574402|EXPERIMENTAL|Arm17: Sintilimab plus pemetrexed and cisplatin|"Patients with PD-L1\<1%, TMB\<10 mut/mb without EGFR mutation, ALK rearrangement, KRAS or TP53 mutation.~Sintilimab 200mg iv gtt. Q3W on day1. Pemetrexedb 500mg/m\^2 iv gtt. Q3W on day1. Cisplatin 75mg/m\^2 iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
62777778|NCT03574402|EXPERIMENTAL|Arm18: Sintilimab plus Gemcitabine and carboplatin|"Patients with PD-L1\<1%, TMB\<10 mut/mb without EGFR mutation, ALK rearrangement, KRAS or TP53 mutation.~Sintilimab 200mg iv gtt. Q3W on day1. Gemcitabine 1g/m\^2 iv gtt. on day1,8. Carboplatin AUC5 iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
62570909|NCT06577298|EXPERIMENTAL|Phase II, Infant Group E, Experimental vaccine, Low-adjuvant dose, IM|4 dose of VLP-Polio on Day 0, Day 28, Day 56 and Month 12-18 of age
62570910|NCT06577298|ACTIVE_COMPARATOR|Phase II, Infant Group E, Control vaccine, IM|4 dose of IPV vaccine on Day 0, Day 28, Day 56 and Month 12-18 of age
62570911|NCT06577298|EXPERIMENTAL|Phase II, Infant Group F, Experimental vaccine, Medium dose, IM|4 dose of VLP-Polio on Day 0, Day 28, Day 56 and Month 12-18 of age
62570912|NCT06577298|ACTIVE_COMPARATOR|Phase II, Infant Group F, Control vaccine, IM|4 dose of IPV on Day 0, Day 28, Day 56 and Month 12-18 of age
62570913|NCT06577298|EXPERIMENTAL|Phase II, Infant Group G, Experimental vaccine, High dose, IM|4 dose of VLP-Polio on Day 0, Day 28, Day 56 and Month 12-18 of age
62570914|NCT06577298|ACTIVE_COMPARATOR|Phase II, Infant Group G, Control vaccine, IM|4 dose of IPV on Day 0, Day 28, Day 56 and Month 12-18 of age
62570915|NCT04297748|EXPERIMENTAL|Cohort A|Patients (pts) will receive an initial trace (100 mg, IV) dose of zirconium-89 (1.8-2.5 mCi) labelled M7824 (89Zr-M7824) on day 1, sequential PET imaging over 1 week will be performed to determine the biodistribution 89Zr-M7824 into the tumour and normal tissues. All patients who remain on study after Day 14 will have a 1200 mg dose of M7824 q2w beginning on Cycle 1 Day 15. Pts will then receive a 2nd infusion of 100 mg of 89Zr-M7824 with cold M7824 making a total dose of 1200mg on Day 29. All patients will then receive a dose of cold 1200mg M7824 on Cycle 1 Day 43. Patients will continue to receive a therapeutic dose of 1200 mg q2w of M7824 until disease progression or unacceptable toxicity. Patients who do not achieve a CR after 3 doses of M7824 in Cycle 1, may then commence treatment with concurrent chemotherapy with carboplatin and pemetrexed at conventional doses.
62002223|NCT02719158|SHAM_COMPARATOR|Sham (empty syringe)|Sham (empty syringe), single 0.1 mL STT administration to the affected ear(s)
62002224|NCT05680766|EXPERIMENTAL|Intervention arm|IBS subjects fulfilling the eligibility criteria will follow a structured and personalised cardiovascular endurance training (CET).
62002225|NCT01720459|ACTIVE_COMPARATOR|Micronized trans-resveratrol|Micronized trans-resveratrol
62002226|NCT01720459|PLACEBO_COMPARATOR|Placebo|
62002227|NCT03287856|EXPERIMENTAL|Treatment|Transcatheter Aortic Valve Implantation (TAVI) in failing surgical bioprosthesis
62002228|NCT05065476||Study Group|"Participants signed up for the webinar will be learning and practicing the Isha Kriya practice (meditation for beginners) taught by the Isha Foundation."
62002229|NCT01007695|EXPERIMENTAL|All patients|All participants enrolled.
62002230|NCT01533246|EXPERIMENTAL|Treatment (linsitinib)|Patients receive linsitinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo serum and plasma sample collection at baseline, on day 1 of courses 2 and 4, and after completion of study treatment for correlative studies.
62002231|NCT02674178|ACTIVE_COMPARATOR|Age <35|\< 35 years old included 201 women who are further subdivided according o FSH/LH ratio into G1A (201 patients) with FSH/LH ratio \<2 and G1B (37 patients) with FSH/LH ratio ≥2.
62002232|NCT02674178|ACTIVE_COMPARATOR|Age ≥ 35|. Group 2 ≥ 35 years old included 34 women who are further subdivided according o FSH/LH ratio into G2A (25 patients) with FSH/LH ratio \<2 and G2B (9 patients) with FSH/LH ratio ≥2
62002233|NCT05039970|EXPERIMENTAL|Experimental Arm - WellQuest™ Users|Participants in National DPP groups randomized to the experimental arm will be instructed by lifestyle coaches to download the WellQuest™ game application and will receive instructions on how to use the game throughout the LCP.
62002234|NCT05039970|NO_INTERVENTION|Control Arm|Participants in National DPP groups randomized to the control arm will proceed with their routine National DPP participation.
62570916|NCT04297748|EXPERIMENTAL|Cohort B|Cohort A will determine whether or not high PD-L1 positive disease is required at study entry to Cohort B. All other assessments within cohort A will be undertaken.
62570917|NCT00777296|EXPERIMENTAL|Cohort 1 - 280 mg ARIKACE™|Subjects in this cohort will receive 280 mg of ARIKACE™
62570918|NCT00777296|PLACEBO_COMPARATOR|Cohort 1 - Placebo|Subjects in this arm of cohort 1 will receive matching placebo
62570919|NCT00777296|EXPERIMENTAL|Cohort 2 - 560 mg ARIKACE™|Subjects in this cohort will receive 560 mg of ARIKACE™
62570920|NCT00777296|PLACEBO_COMPARATOR|Cohort 2 - Placebo|Subjects in this arm of cohort 2 will receive matching placebo
62570921|NCT02091089|EXPERIMENTAL|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
62570922|NCT03099837||Pregnant mothers|
62570923|NCT03099837||infants|
62570924|NCT03099837||children|
62570925|NCT02818946|OTHER|MRI|Patients who have undergone mammography, breast sonography, and planning to have a contrast-enhanced breast MRI for evaluation of nipple discharge.
62570926|NCT02093780|EXPERIMENTAL|Alberta Anti-inflammatory Diet|Patients randomized into this group will receive a dietary menu plan that contains anti-inflammatory foods/nutrients that have been shown to be effective in the management of IBD in previous studies. The main aim of this diet will be to increase dietary intakes of prebiotics/probiotics, omega 3 fatty acids, fiber (soluble), antioxidants and decrease dietary intake of red and processed meat.
62570927|NCT02093780|ACTIVE_COMPARATOR|Canada's Food Guide Diet|"Patients that have been randomized into this group will receive simple dietary recommendations based on the Canada's Food Guide. The details of Canada's Food Guide can be available here:~http://www.hc-sc.gc.ca/fn-an/food-guide-aliment/index-eng.php"
62570928|NCT06512285||Adenotonsillectomy patients|Patients having undergone adenotonsillectomy at Texas Children's Hospital admitted for overnight observation based on our institutional protocol will be enrolled. A Wrist OX 3150 (Nonin Medical) will be placed in PACU with saturations recorded until the following morning after the surgery. The patient will undergo pulse oximetry monitoring separately based on the hospital protocol that will be used to guide care. Data from the Wrist Ox will not be avail to the treatment team and will only be analyzed for research purposes.
62570929|NCT03830697|EXPERIMENTAL|Menstruation situation TCM symptom score standard|
62002235|NCT00134381|ACTIVE_COMPARATOR|active drug|bilateral comparison of green tea constituent
62002236|NCT00134381|PLACEBO_COMPARATOR|placebo|bilateral comparison of placebo vehicle
62002237|NCT05117944|EXPERIMENTAL|Drama|Students in the intervention group will act as the patient and act out the case given to them. Nursing care to be provided by a professional nurse to the student who will play the role of the patient in line with the case content includes helping the patient (student) eat, perform personal hygiene (oral care, etc.), dress and move. The case content will not be shared with the students in advance, and the student will not need to make any preliminary preparations. However, ten minutes before the start of the practice, the situations that are expected to be portrayed as the patient specified in the case will be explained to the students. The skills laboratory will be used as three separate patient rooms (with two or three patients), in which students in the role of inpatient will receive care from a professional nurse. Each student will experience the patient role only once.
62002238|NCT05117944|NO_INTERVENTION|Control|Students in the control group will fill in the datasheet, Altruism Scale and Empathy Scale simultaneously with the intervention group, without any intervention, and then the Altruism Scale and Empathy Scale at the 1st and 3rd months.
62002239|NCT06388551|EXPERIMENTAL|LY03017|Ascending single oral doses of LY03017 in healthy adult subjects
62002240|NCT06388551|PLACEBO_COMPARATOR|Placebo|LY03017-Placebo
62002241|NCT01010282|ACTIVE_COMPARATOR|Glycerin and Polysorbate 80 based artificial tear|Glycerin and Polysorbate 80 based artificial tear
62002242|NCT01010282|EXPERIMENTAL|Artificial Tears Formulation 1|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear
62002243|NCT01010282|EXPERIMENTAL|Artificial Tears Formulation 2|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear
62002244|NCT01589432|EXPERIMENTAL|ABT-639|
62002245|NCT01589432|PLACEBO_COMPARATOR|Placebo|
62777779|NCT04407234|EXPERIMENTAL|Tirzepatide + Acetaminophen|Participants received 5mg tirzepatide on Day 1 and Day 8; 10 mg tirzepatide on Day 15, 22 and 29; 15 mg tirzepatide on Day 36 administered subcutaneously (SC) and 160 mg acetaminophen administered orally on Day -1, Day 2 and Day 37.
62002246|NCT01589432|ACTIVE_COMPARATOR|Lidocaine|
62002247|NCT04710251|ACTIVE_COMPARATOR|Colonoscopy with the speedometer|
62002248|NCT04710251|NO_INTERVENTION|Colonoscopy without the speedometer|
62187707|NCT00899145||Ancillary-Correlative (biomarker sampling and analysis)|Previously collected DNA samples and associated clinical information obtained from BRCA mutation-positive participants enrolled on GOG-0199 are studied. DNA samples are analyzed by mutation testing for variants (i.e., SNPs) in candidate genes of interest. Once genetic testing for a given set of variants has been completed, the coded laboratory data file is merged with selected demographic, clinical, and epidemiological data obtained from the GOG-0199 baseline questionnaire and submitted to the CIMBA Central Database to analyze and publish the data. The epidemiological and SNP data contributed to the central database are then distributed to the investigators responsible for analysis of a particular SNP or set of SNPs from a candidate gene or genetic pathway.
62570930|NCT03830697|PLACEBO_COMPARATOR|Sham intervention|
62777780|NCT00470418|OTHER|NIC5-15|Subjects with Alzheimer's Disease
62002249|NCT03217929|ACTIVE_COMPARATOR|Active-taVNS|
62002250|NCT03217929|SHAM_COMPARATOR|Sham-taVNS|
62777781|NCT00470418|PLACEBO_COMPARATOR|Placebo|Subjects with Alzheimer's Disease
62777782|NCT01810315|NO_INTERVENTION|Baseline|Premenopausal women will undergo baseline sampling in each the follicular and luteal phase. Postmenopausal women will undergo baseline sampling one time.
62777783|NCT01810315|EXPERIMENTAL|TFV 1% Gel|"Participants will vaginally insert 1 applicator of TFV gel followed by a 2nd applicator 2 hours later. Each applicator contains 4.4 gm of TFV 1% gel.~Premenopausal women will undergo sampling after TFV gel use in each the follicular and luteal phase. Postmenopausal women will undergo sampling after TFV gel use one time."
62002251|NCT02378844|ACTIVE_COMPARATOR|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
62570931|NCT05445466|ACTIVE_COMPARATOR|Active HD-tDCS|10 tDCS; Two, twenty-minute sessions of tDCS to the OFC for 5 days (10 total sessions).
62002252|NCT02378844|SHAM_COMPARATOR|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
62002253|NCT01973322|EXPERIMENTAL|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
62002254|NCT01973322|EXPERIMENTAL|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
62002255|NCT01973322|EXPERIMENTAL|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
62002256|NCT01973322|EXPERIMENTAL|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
62002257|NCT01020019|EXPERIMENTAL|Lofexidine and Dronabinol|Maintained at 1.8mg/day Lofex. and 60 mg/day of Dronabinol
62002258|NCT01020019|PLACEBO_COMPARATOR|Placebo|Lofex. matched placebo Dronabinol placebo
62002259|NCT00497536|ACTIVE_COMPARATOR|1|≈ bolus protocol.
62002260|NCT00497536|ACTIVE_COMPARATOR|2|≈ CSII protocol
62002261|NCT00497536|ACTIVE_COMPARATOR|3|≈ CIII protocol.
62002262|NCT01395940|EXPERIMENTAL|KLH-2109, lower dose|
62002263|NCT01395940|EXPERIMENTAL|KLH-2109, higher dose|
62002264|NCT00754182|EXPERIMENTAL|A|Patients underwent thyroidectomy, emithyroidectomy, parathyroidectomy sutured with synthetic glue
62002265|NCT00754182|ACTIVE_COMPARATOR|B|Patients underwent thyroidectomy, emithyroidectomy, parathyroidectomy sutured with subcuticular suture
62002266|NCT05796245||Infliximab (Genetical Recombination)[Infliximab Biosimilar 3]|
62002267|NCT05796245||Remicade|
62002268|NCT05192837|EXPERIMENTAL|Intervention group|The study intervention consists of a smoking cessation counselling meeting by a Tabacco Treatment Specialist (TSS) 4 weeks before surgery. The goal of this first intervention meeting is to implement an individual treatment plan for preoperative smoking cessation.
62002269|NCT05192837|NO_INTERVENTION|Control group|Patients randomised to the control arm will get advice only. Their preoperative course will be as if they were not participating in this study, meaning they will receive inconsistent perioperative smoking cessation advice from nurses, surgeons, or anaesthesiologists but no further study-specific smoking cessation intervention. Importantly, participants in the control group will not be discouraged from using perioperative smoking cessation aids and can still obtain help on one's own initiative.
62570932|NCT05445466|SHAM_COMPARATOR|Active Control (alpha, 10 Hz)|10 passive sham control; Two, twenty-minute sessions of passive sham control to the OFC for a 30 second ramped up and down at the beginning and end of the 20 min period for 5 days (10 total sessions).
62570933|NCT05445466|EXPERIMENTAL|Personalized Beta-Gamma tACS|10 tACS; Two, twenty-minute sessions of tACS to the OFC for 5 days (10 total sessions).
62002270|NCT00953329|EXPERIMENTAL|Alefacept 15 mg IM qweek|Alefacept will be given to subjects with plaque psoriasis who have failed treatment with Fnbrel.
62002271|NCT04902495|EXPERIMENTAL|Pulp Dressing MTA Angelus|pulp therapy
62002272|NCT04902495|EXPERIMENTAL|Pulp Dressing MTA Pro Root|pulp therapy
62002273|NCT04902495|EXPERIMENTAL|Pulp Dressing Biodentine|pulp therapy
62002274|NCT02648191|EXPERIMENTAL|Active stimulation|
62002275|NCT02648191|SHAM_COMPARATOR|Inactive stimulation|
62002276|NCT01310322|EXPERIMENTAL|1|AZD5423 iv
62002277|NCT01310322|EXPERIMENTAL|2|AZD5423 inhalation, Spira
62002278|NCT01310322|EXPERIMENTAL|3|AZD5423 inhalation I-neb
62777784|NCT01810315|EXPERIMENTAL|Estradiol Vaginal Cream|Post menopausal women only: Participants will insert 2 grams of estradiol cream into the vagina every night for 14 days and then one gram of estradiol cream into the vagina every other night
62002279|NCT01310322|EXPERIMENTAL|4|AZD5423 oral
62002280|NCT05133882|EXPERIMENTAL|Arm 1|Queue 1:Clifutinib Besylate:30mg qd d8-21;Daunorubicin 60 mg/m2 qd d1-3;Cytarabine 100 mg/m2 qd d1-7 Queue 1:Clifutinib Besylate:30mg qd d1-28 ;Azacitidine 75 mg/m2 qd d1-7
62570934|NCT06286137|ACTIVE_COMPARATOR|Control group|The control group will be seated for 20 minutes without doing anything else, and not listen to music.
62002281|NCT05133882|EXPERIMENTAL|Arm 2|Queue 1:Clifutinib Besylate:40mg qd d8-21;Daunorubicin 60 mg/m2 qd d1-3;Cytarabine 100 mg/m2 qd d1-7 Queue 1:Clifutinib Besylate:40mg qd d1-28 ;Azacitidine 75 mg/m2 qd d1-7
62002282|NCT05133882|EXPERIMENTAL|Arm 3|Queue 1:Clifutinib Besylate:60mg qd d8-21;Daunorubicin 60 mg/m2 qd d1-3;Cytarabine 100 mg/m2 qd d1-7 Queue 1:Clifutinib Besylate:60mg qd d1-28 ;Azacitidine 75 mg/m2 qd d1-7
62002283|NCT04187365|NO_INTERVENTION|GROUP 1 (NonSevere PUR and women without PUR)|Women in GROUP 1 will be prospectively observed to characterize their clinical outcomes.
62002284|NCT04187365|EXPERIMENTAL|GROUP 2 (Severe PUR)|Women in GROUP 2 will be a randomized to either 3 or 7 days of indwelling catheterization.
62002285|NCT02178475||Chemotherapy + Pegfilgrastim|Patients with non-Hodgkin's lymphoma or breast cancer being treated with a permitted standard-dose chemotherapy regimen with a high FN risk (\> 20%) and who had pegfilgrastim prophylaxis initiated in the first cycle of chemotherapy.
62002286|NCT06379490|ACTIVE_COMPARATOR|Ropivacaine 5 mg/ml|30 ml of ropivacaine 5 mg/ml (Injectable solution - perineural administration - only once)
62002287|NCT06379490|EXPERIMENTAL|Ropivacaine 2 mg/ml|30 ml of ropivacaine 2 mg/ml (Injectable solution - perineural administration - only once)
62002288|NCT06379490|EXPERIMENTAL|Lidocaine 10 mg/ml|30 ml of lidocaine 10 mg/ml with epinephrine 5 μg/ml (Injectable solution - perineural administration - only once)
62002289|NCT03660410||Yanomamis|Yanomami Indians, Anamnesis and oral clinical examination
62002290|NCT03660410||Macuxi|Macuxi Indians, Anamnesis and oral clinical examination
62002291|NCT03660410||Wapixana|Wapixana Indians, Anamnesis and oral clinical examination
62002292|NCT05441735|EXPERIMENTAL|experimental group|will have access to information on the Long-Term Care Plan 2.0 through the app-based digital care program, while the
62570935|NCT06286137|EXPERIMENTAL|1 minute music group|The 1 minute music group will be seated for 19 minutes without doing anything else, and listen to music for 1 minute.
62002293|NCT05441735|NO_INTERVENTION|control group|will only have access to information on the Long-Term Care Plan 2.0 through conventional paper-based media.
62002294|NCT03085329|EXPERIMENTAL|Seattle-PAP|bubble nasal cpap respiratory support with Seattle-PAP bubbler device, with all other aspects of care per usual care noninvasive respiratory support
62570936|NCT06286137|EXPERIMENTAL|5 minutes music group|The 5 minutes music group will be seated for 15 minutes without doing anything else, and listen to music for 5 minutes.
62570937|NCT06286137|EXPERIMENTAL|20 minutes music group|The 20 minutes music group will listen to music for 20 minutes.
62777785|NCT01810315|EXPERIMENTAL|TFV 1% gel and estradiol cream|Postmenopausal women only: Participants will vaginally insert 1 applicator of TFV gel followed by a 2nd applicator 2 hours later. Each applicator contains 4.4 gm of TFV 1% gel. In addition, participants will one gram of estradiol cream into the vagina every other night.
62570938|NCT02718833|EXPERIMENTAL|Elotuzumab, pomalidomide, bortezomib, dex|"Each cycle is 28 days.~Elotuzumab will be administered by intravenous infusion. For cycles 1-2, elotuzumab will ge given weekly. For cycles 3-8, elotuzumab will be given every other week. For cycles 9+, elotuzumab will be given on day 1.~Pomalidomide will be given orally on days 1-21.~Bortezomib will be given weekly subcutaneously on days 1, 8, 15.~Dexamethasone will be given as a combination orally and intravenously."
62570939|NCT05103982|EXPERIMENTAL|Coping with Infertility Program|"The program consists of brief weekly videos, each addressing a particular psychological technique to be implemented that week. Participants receive the videos by email from the researcher and watch them on their own. Each video also assigns a homework exercise for the participant to complete that week."
62570940|NCT02208193|EXPERIMENTAL|healthy controls group|Healthy volunteers
62570941|NCT02208193|EXPERIMENTAL|Alzheimer subjects group|"Group A Alzheimer group: patients with mild to severe stages of Alzheimer's disease: subgroup A1 Alzheimer group hospitalized at the Paul Spillmann Centre (Centre Paul Spillmann, CPS) (CHU de Nancy, France); subgroup A2 Alzheimer group monitored at the Resource and Research Memory Centre (Centre Mémoire de Ressources et de Recherche, CMRR) (CHU de Nancy, France)"
62777786|NCT00712803|EXPERIMENTAL|1|One subcutaneous vaccination (10\^3 dose of vaccine) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm.
62187708|NCT02562898|EXPERIMENTAL|Dose escalation for safety and toxicity|All patients in phase Ib dosing escalation with extended safety and toxicity cohorts will start treatment with daily dosing of ibrutinib concurrently with standard doses of gemcitabine and nab-paclitaxel. Ibrutinib (560 mg/day, 840 mg/day, or 420 and 280 mg/day if de-escalation is necessary) will be started on day 1. Approximately patients 15-30 will be enrolled in escalation and extended safety cohort.
62187709|NCT02562898|EXPERIMENTAL|Immune Response cohort|Subjects who are assigned to the Immune Response Cohort will have a biopsy before starting ibrutinib-only therapy. They will then receive ibrutinib for 7 days and have a second biopsy after completing the ibrutinib-only therapy, before starting the combination of chemotherapy with ibrutinib. Approximately 20 patients will be enrolled in this arm.
62187710|NCT01486368|EXPERIMENTAL|PF-03446962|
62187711|NCT01241006|ACTIVE_COMPARATOR|Dexamethasone|Single dose of Dexamethasone 12 mg PO and 4 days of placebo capsules
62570942|NCT05509790|EXPERIMENTAL|LY3484356 Dose Level 1|Administered orally.
62570943|NCT05509790|EXPERIMENTAL|LY3484356 Dose Level 2|Administered orally.
62570944|NCT05739422|EXPERIMENTAL|Intervention|Participants in the intervention group will participate in a once weekly, 6 week online, remotely supervised neuropilates programme. Exercises will be taught by a chartered Physiotherapist who is also a pilates instructor with experience with stroke rehabilitation. Exercises will be aligned to the Australian Physiotherapy and Pilates Institute's (r) core teaching with modifications based on participant need and aligned to neurorehabilitation principles
62777787|NCT00712803|EXPERIMENTAL|2|One subcutaneous vaccination (10\^5 dose of vaccine or placebo) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm OR one subcutaneous vaccination (10\^1 dose of vaccine or placebo) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm.
62777788|NCT00652080|EXPERIMENTAL|1|Active Cream 3%; AM \& PM
62777789|NCT05271448|EXPERIMENTAL|Continue ACEI or ARBs|Randomized to continue on prescribed ACE1 or ARBs
62777790|NCT05271448|ACTIVE_COMPARATOR|Hold ACEI or ARBs|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held \>= 24 hours pre-cardiac catheterization and restarted post-catheterization after creatinine measurement (48-72 hours post)
62777791|NCT02722265|EXPERIMENTAL|CS-3150|CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
62777792|NCT00330681|EXPERIMENTAL|1|MCI-186
62777793|NCT00330681|PLACEBO_COMPARATOR|2|Placebo of MCI-186
62777794|NCT00941122||MRSA/VRE patients|patients known to be colonized with MRSA/VRE
62187712|NCT01241006|ACTIVE_COMPARATOR|Prednisone|Prednisone 60mg PO capsules for 5 days
62187713|NCT05573100|EXPERIMENTAL|CU06-1004 100mg|CU06-1004 100 mg tablets. Dosed at 100 mg (1 capsule) QD within 30 minutes after meal on each evening
62187714|NCT05573100|EXPERIMENTAL|CU06-1004 200mg|CU06-1004 100 mg tablets. Dosed at 200 mg (2 capsules) QD within 30 minutes after meal on each evening
62187715|NCT05573100|EXPERIMENTAL|CU06-1004 300mg|CU06-1004 100 mg tablets. Dosed at 300 mg (3 capsules) QD within 30 minutes after meal on each evening
62187716|NCT02911194|EXPERIMENTAL|Treatment|a2 milk intervention period
62187717|NCT02911194|PLACEBO_COMPARATOR|Control|a1 containing milk (normal) intervention period
62187718|NCT04400968|EXPERIMENTAL|Auricular therapy group|The auricular therapy group received an intervention based on the bilateral application of 7 adhesive tapes with vaccaria seeds. The points were located with a retractable 250 gr. pressure palpator (Sedatelec®). An experienced health professional trained on acupuncture techniques applied the vaccaria seeds.
62187719|NCT04400968|SHAM_COMPARATOR|Auricular therapy Placebo group|The auricular therapy placebo group had adhesive tapes without seeds displaced from the treatment points.
62187720|NCT04400968|EXPERIMENTAL|Kinesio tape group|The kinesio tape group received an intervention that consisted on the standard application of three elastic bandages. An experienced kinesio tape certified physical therapist applied the taping.
62777795|NCT02661074||Fishermen|"Fisherman followed by the Service de Santé des Gens de Mer of Boulogne-sur-Mer, France (occupational exposure to fish).~A questionnaire will be completed."
62777796|NCT02661074||Fish processing factories|"Workers of fish processing factories who are followed by the Service de Santé au Travail (ASTIL) of Boulogne-sur-Mer, France (occupational exposure to fish).~A questionnaire will be completed."
62777797|NCT02661074||Control|"Workers who are followed by the Service de Santé au Travail (ASTIL) of Boulogne-sur-Mer, France, but do not work in fish processing factories.~A questionnaire will be completed."
62777798|NCT00915291|NO_INTERVENTION|Usual education|"Participants randomized into the no intervention arm were not exposed to the web-based educational modules"
62777799|NCT00915291|EXPERIMENTAL|Web-based educational modules|Participants randomized into the intervention arm were exposed to the web-based educational modules
62777800|NCT04491851|EXPERIMENTAL|LM3 group|In this arm, patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-DOTA-LM3 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
62002295|NCT03085329|EXPERIMENTAL|Conventional bubble nasal CPAP|qualified and enrolled infants randomized to this arm will receive noninvasive respiratory support by bubble nasal CPAP, using the Fisher \& Paykel bubbler, which is the standard of care at Nationwide Children's.
62002296|NCT04587193|EXPERIMENTAL|PD participants|Subjects will participate in a total of 10 walking sessions, twice per week for 5 weeks, while wearing a robotic-assist gait training device. There will also be 3 additional visits for assessments at: baseline (up to 1 prior to treatment), post (1 week after last treatment), and final (4-6 weeks after last treatment).
62002297|NCT02805530|EXPERIMENTAL|single arm|"Patients with synchronous metastases at Central Nervous System (CNS), evaluated in less than one week by the Multidisciplinary Committee at National Cancer Institute of Mexico to define the initial treatment. Patients with metastases at other sites than CNS will receive first line systemic treatment, in those EGFR-mutated with tyrosine kinase inhibitors (TKI) and in patients without a driver mutation with first line duplet of chemotherapy based on platin. The type of TKI or chemotherapy will be at discretion of the treating physician.~After 4 cycles of treatment, patients with stable disease or partial response will be evaluated by de Multidisciplinary Committee to establish the type of radical treatment to the primary and to the metastases, radiation therapy and chemoradiotherapy."
62002298|NCT00340262||FIT Participants|
62002299|NCT01045304|EXPERIMENTAL|Gencitabine + iniparib twice weekly|"Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles.~Iniparib, 5.6 mg/kg IV over 60 minutes on Days 1, 4, 8 and 11 of 3-week cycles"
62002300|NCT01045304|EXPERIMENTAL|Gencitabine + iniparib weekly|"Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles.~Iniparib, 11.2 mg/kg IV over 60 minutes on Days 1 and 8 of 3-week cycles"
62002301|NCT02850874|EXPERIMENTAL|HIPEC|Immediately following laparoscopy for diagnosis and staging of disease, closed neoadjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) will be performed using the anatomical site of the laparoscopic procedure in the same operative encounter. Perfusion will be initiated with 4-6 L of 1.5% dextrose at a 500 mL/min flow rate with manual agitation of the abdominal wall. Once the temperature in the abdomen becomes stable above 40°C, perfusate volume will be reduced to 1.5 L/m sq, and gemcitabine (GEMZAR®) will be instilled into the abdomen (1000 mg/m sq) for 90 min. Neoadjuvant chemotherapy with gemcitabine will be administered prior to open pancreaticoduodenectomy by the standard Whipple or pylorus-preserving approach. Adjuvant systemic chemotherapy with gemcitabine will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional protocol.
62002302|NCT02850874|OTHER|Historical Control|Case-matched historical controls will have received neoadjuvant chemotherapy with gemcitabine prior to open pancreaticoduodenectomy (PD) by the standard Whipple or pylorus-preserving approach. Adjuvant systemic chemotherapy (SCT) with gemcitabine will be administered for 6 mo (including period of neoadjuvant therapy) according to established institutional protocol.
62002303|NCT06317493||Hearing threshold without aids|Case group with hearing impairment (HI) (hearing threshold \>35 dB) without aids
62002304|NCT06317493||Hearing threshold with cochlear implant|Case group with hearing threshold corrected with cochlear implant (CI)
62002305|NCT06317493||Hearing threshold with aids|Case group with hearing threshold corrected with hearing aids
62002306|NCT06317493||Control group|Control group of normally hearing age-matched children
62002307|NCT03307668|EXPERIMENTAL|CaReS-1S|
62777801|NCT04491851|EXPERIMENTAL|NODAGA group|In this arm, patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-NODAGA-JR11 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
62777802|NCT05501743|EXPERIMENTAL|Study treatment group (T)|The treatment by intra-articular injection of autologous microfat and PRP will be performed during a half-day outpatient stay in the hand and limb repair surgery department at the Hôpital de la Timone. The total duration of the procedure is approximately 4 hours and includes 2 surgical times performed in the operating room and an intermediate waiting time for the patient in an outpatient room during the preparation of the experimental products.
62777803|NCT05501743|ACTIVE_COMPARATOR|Reference treatment group (R)|The surgical treatment by total denervation of the wrist will be performed during a one-day outpatient stay in the hand and limb surgery department at the Hôpital de la Timone. It will be performed under loco-regional anesthesia by axillary plexus block.
62777804|NCT06315738|OTHER|Cohort 1 - lower dose active + SOC treatment vs. SOC alone in higher weight range|Infants with birth weight ≥1000 g and ≤3000 g; 0.5 mL/kg of ST266, QD, + Standard of Care (SOC) treatment (n=6); SOC (n=3)
62002308|NCT03307668|ACTIVE_COMPARATOR|Microfracture|
62187721|NCT04400968|SHAM_COMPARATOR|kinesio tape Placebo group|The kinesio tape placebo group had the application of three elastic bandages that were shorter than the used in the kinesio tape group. In addition, the tape was adhered with no tension and not place in the treatment area.
62187722|NCT04400968|NO_INTERVENTION|Control group|The control group did not receive any treatment. The participants continued with their routine medical treatment. However, the controls completed all the questionnaires to collect the information regarding their symptoms in order to observe their progress with no intervention.
62187723|NCT01793077||Prostate Cancer patients|
62187724|NCT05611541|EXPERIMENTAL|İntervention group|"Progressive Muscle Relaxation Training Program; The training was carried out in a single session for 2 hours and a break of 10-15 minutes was given.~Pregnant women were instructed to perform PMR at least 1 hour after dinner 5 days a week."
62002309|NCT04042883|ACTIVE_COMPARATOR|ANH|500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
62187725|NCT05611541|ACTIVE_COMPARATOR|Control group|"The Progressive Muscle Relaxation Training Program and the Progressive Muscle Relaxation were not applied.~The pregnant women were asked to continue their normal daily activities for 8 weeks."
62187726|NCT01859611|EXPERIMENTAL|Radiofrequency|Radiofrequency (RF) treatment with the TriActive+ RF device on the peri-oral and/or peri-orbital areas of the face once a week for eight weeks.
62187727|NCT00698347||M2a-Magnum™ Hip System|Patients who received the M2a-Magnum™ Hip System
62187728|NCT03964051|EXPERIMENTAL|Omalizumab 300 mg for s.c.injection|Omalizumab 300 mg steril solution in prefilled syringes are administrated every 2. week for 12 weeks
62187729|NCT03339947||Travel medicine|All adult travellers who attended the consultation for travel medicine and international vaccination in Reims University Hospital.
62395670|NCT06279169|EXPERIMENTAL|White noise group|"In the white noise group, the mother of the baby is told that the white noise to be used in the study will be used for pain relief. For the white noise, the musician Osman Orhan's colic album, which was released by the production and often used in the literature. The song Bebeğiniz Ağlamasın Pt-3 from the album Kolik will be used (permission to use it in this work has been granted by ON Music Production). The volume is set to 45 db. The JBL loudspeaker is placed on the newborn's toe 5 minutes before the procedure, about 30 cm from the newborn's ear, and white noise is played 5 minutes before, during (at the 1st minute) and 5 minutes after the administration of the Hep B vaccine."
62187730|NCT05889962|EXPERIMENTAL|Pudendal block group|Receiving bilateral pudendal nerve block with 0.5% ropivacaine (10 ml each side)
62187731|NCT05889962|PLACEBO_COMPARATOR|Placebo group|Receiving bilateral pudendal nerve block with normal saline (10 ml each side)
62187732|NCT04356625|OTHER|MEPic|"* Ready for extubation (pass SBT)~* Measurement of maximum expiratory pressure during the induced cough (MEPic)"
62395671|NCT06279169|NO_INTERVENTION|Control|Newborns in the control group will not receive any intervention other than Hepatitis B vaccination.
62395672|NCT03287089|ACTIVE_COMPARATOR|Nitrofurantoin|Receives twice daily 100mg nitrofurantoin for 5 days following catheter removal
62570945|NCT05739422|ACTIVE_COMPARATOR|Control Group A|Participants in control group A will participate in a once weekly, 6 week, online, remotely supervised generalised exercise class. This class will be instructed by a chartered Physiotherapist and will consist of general strengthening and flexibility exercises for upper and lower limbs.
62777805|NCT06315738|OTHER|Cohort 2 - higher dose active + SOC treatment vs. SOC alone in higher weight range|Infants with birth weight ≥1000 g and ≤3000 g; 1.0 mL/kg of ST266, QD; + Standard of Care (SOC) treatment (n=6); SOC (n=3)
62777806|NCT06315738|OTHER|Cohort 3 - lower dose active + SOC treatment vs. SOC alone in lower weight range|Infants with birth weight ≥800 g and ≤999 g; 0.5 mL/kg of ST266, QD; + Standard of Care (SOC) treatment (n=6); SOC (n=3)
62002310|NCT04042883|NO_INTERVENTION|Control|No intervention
62002311|NCT02967367|EXPERIMENTAL|Jawbone/Withings sleep trackers, Bodymedia Sensewear|2 types of Consumer sleep trackers, including Jawbone and Withings, and one research actigraph (Bodymedia Sensewear) are added to classical polysomnography in order to assess their accuracy to measure sleep parameters in obstructive sleep apnea patients
62002312|NCT02420106|ACTIVE_COMPARATOR|OMM alone|Subjects who are not receiving botulinum treatment consenting to Osteopathic Manipulative Medicine intervention
62002313|NCT02420106|ACTIVE_COMPARATOR|OMM plus Botulinum|Subjects who are receiving botulinum treatment and will have osteopathic manipulative medicine intervention.
62002314|NCT01026870|ACTIVE_COMPARATOR|Mometasone furoate (MF) metered-dose inhaler 100 mcg BID|2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks
62002315|NCT01026870|PLACEBO_COMPARATOR|Placebo metered-dose inhaler BID|2 inhalations from a matching placebo inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
62002316|NCT04702373|EXPERIMENTAL|Passive range-of-motion|daily assisted exercise sessions lasting 15-20 minutes, conducted by trained physical therapists, for up to 21 days prior to hospital discharge, plus standard of care
62002317|NCT04702373|NO_INTERVENTION|Standard of care|standard of care at study site
62002318|NCT00570518||1|randomly stopped drivers of motorised vehicles and bicycles
62002319|NCT00570518||2|drivers of motorised vehicles and bicycles injured or killed in road traffic accidents
62002320|NCT02677090|PLACEBO_COMPARATOR|Placebo|Placebo
62570946|NCT05739422|ACTIVE_COMPARATOR|Control Group B|Participants in control group B will be given a tailored, individualised home exercise programme to practice unsupervised at home over a 6 week period. They will receive a follow up phone call to discuss any issues they might be having and a training diary to log their exercise.
62570947|NCT02591160|OTHER|HCTZ cessation|Patients will stop taking HCTZ for 3 months while submitting serial blood and 24 hour urine samples
62570948|NCT02641418|OTHER|Exercise|only 1 arm to trial
62002321|NCT02677090|ACTIVE_COMPARATOR|Dose 1 - Promitor®|Investigational product Dose 1
62002322|NCT02677090|ACTIVE_COMPARATOR|Dose 2 - Promitor®|Investigational product Dose 2
62002323|NCT02677090|ACTIVE_COMPARATOR|Dose 3 - Promitor®|Investigational product Dose 3
62002324|NCT02266056|EXPERIMENTAL|Deep neuromuscular relaxation|
62002325|NCT02266056|ACTIVE_COMPARATOR|Moderate neuromuscular relaxation|
62002326|NCT05188352|EXPERIMENTAL|Training group|Patients in the training group received supervised aerobic exercise training on the treadmill with the intensity of 60-75% of maximal VO2 for 40-50 minutes, 3 days a week for 8 weeks. Work-load was gradually increased during the eight-week period. In addition, conventional chest physiotherapy and was instructed to continue their daily physical activity program at home patients in this group.
62002327|NCT05188352|ACTIVE_COMPARATOR|Control group|Patients in the control group received no aerobic exercise training but were asked to continue their chest physiotherapy and daily physical activity program at home.
62002328|NCT03109678|EXPERIMENTAL|Aura-i / Rüsch|Blind tracheal intubation: Combination of laryngeal mask Ambu Aura-i™ with Rüsch Super Safety Silk™ tracheal tube
62002329|NCT03109678|EXPERIMENTAL|Aura-i / LMA ETT|Blind tracheal intubation: Combination of laryngeal mask Ambu Aura-i™ with LMA ETT™ tracheal tube
62002330|NCT03109678|EXPERIMENTAL|Fastrach / Rüsch|Blind tracheal intubation: Combination of laryngeal mask Fastrach™ with Rüsch Super Safety Silk™ tracheal tube
62002331|NCT03109678|EXPERIMENTAL|Fastrach / LMA ETT|Blind tracheal intubation: Combination of laryngeal mask Fastrach™ with LMA ETT™ tracheal tube
62002332|NCT03684447|EXPERIMENTAL|Propofol High Dose|high propofol injectable, individually dosed, three times per week
62002333|NCT03684447|EXPERIMENTAL|Propofol Low Dose|low propofol injectable, individually dosed, three times per week
62002334|NCT01193907|EXPERIMENTAL|NVGH Vi-CRM197 conjugate vaccine 12.5 mcg|1 dose of 0.5 mL containing 12.5 mcg of Vi-CRM
62002335|NCT01193907|EXPERIMENTAL|NVGH Vi-CRM197 conjugate vaccine 5 mcg|1 dose of 0.5 mL containing 5 mcg of Vi-CRM
62187733|NCT04738643|NO_INTERVENTION|Usual Care|TUT Service Only
62395673|NCT03287089|PLACEBO_COMPARATOR|Placebo|Receives twice daily matching placebo for 5 days following catheter removal
62570949|NCT02523976|EXPERIMENTAL|Arm A|Dasatinib 100 mg per day will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Dasatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy.Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients who keep BCR/ABL negative can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation chemotherapy.
62570950|NCT01626196||Colonoscopy patients|Patients undergoing with bowel cleansing procedures according to the clinics' usual routine
62570951|NCT04381728|EXPERIMENTAL|Womed Leaf|"At the end of the hysteroscopic myomectomy, Womed Leaf is delivered in the uterus thanks to a 5mm diameter, flexible inserter. Then an endovaginal ultrasound will be performed to assess the positioning of the uterine film.~Another ultrasound will be performed at 2 hours, prior to patient discharge in order to record images of the uterine film deployment.~A second look hysteroscopy will performed at 4-8 weeks to evaluate the presence of intrauterine adhesion."
62570952|NCT01757184|EXPERIMENTAL|Double-blind Sebelipase Alfa|Double-blind Period: IV infusions of sebelipase alfa at a dose of 1 mg/kg administered qow for 20 weeks.
62570953|NCT01757184|PLACEBO_COMPARATOR|Double-blind Placebo|Double-blind Period: IV infusions of matched placebo administered qow for 20 weeks.
62777807|NCT06315738|OTHER|Cohort 4 - higher dose active + SOC treatment vs. SOC alone in lower weight range|Infants with birth weight ≥800 g and ≤999 g; 1.0 mL/kg of ST266, QD; + Standard of Care (SOC) treatment (n=6); SOC (n=3)
62002336|NCT01193907|EXPERIMENTAL|NVGH Vi-CRM197 conjugate vaccine 1.25 mcg|1 dose of 0.5 mL containing 1.25 mcg of Vi-CRM
62002337|NCT01193907|ACTIVE_COMPARATOR|Typherix|1 dose of 0.5 mL containing 25 mcg of Vi-polysaccharide
62002338|NCT00957437|EXPERIMENTAL|Part A: 3 way crossover|AZD1305: ER test formulation 1 (w/wo food) and reference formulation
62002339|NCT00957437|EXPERIMENTAL|Part B1: single arm|AZD1305: ER test formulation 1
62002340|NCT00957437|EXPERIMENTAL|Part B2: 3 way crossover|AZD1305: ER test formulation 2 (w/wo food) and reference formulation
62002341|NCT01454934|EXPERIMENTAL|Arm A|
62002342|NCT01454934|ACTIVE_COMPARATOR|Arm B|
62002343|NCT05161676|EXPERIMENTAL|Ketone monoester (3-OHB)|
62002344|NCT05161676|EXPERIMENTAL|Placebo Treatment|
62002345|NCT01140763||Sysmex's 5-blade cutter.|
62002346|NCT00754247|EXPERIMENTAL|Regimen A|0.5% hydrocortisone, silicone, vitamin E lotion
62002347|NCT00754247|EXPERIMENTAL|Regimen B|Onion extract gel
62002348|NCT00754247|PLACEBO_COMPARATOR|Regimen C|Cetearyl alcohol lotion
62002349|NCT01252290|EXPERIMENTAL|Lovaza™|Lovaza™ (two 1 gram capsules twice daily) for six months
62002350|NCT04181346|EXPERIMENTAL|Pregabalin|Pregabalin 75mg, twice a day, from the night before chemotherapy to day 5
62002351|NCT04181346|EXPERIMENTAL|Placebo|Placebo, twice a day, from the night before chemotherapy to day 5
62002352|NCT05818371|OTHER|Pathologic and non-pathologic intracranial pressure|Sonographic determination of Optic nerve sheath. Parallel recording of ICP
62187734|NCT04738643|EXPERIMENTAL|Tobacco Use Treatment Service + Varenicline Management|TUTS + Varenicline Management
62395674|NCT06723691|EXPERIMENTAL|Treatment group|
62395675|NCT03047408|EXPERIMENTAL|patients with PD-RBD|"patients with PD-RBD having already underwent vPSG, clinical and neuropsychological in clinical setting or in the study RBHP 2013 DURIF  at least three years ago."
62395676|NCT03688191|EXPERIMENTAL|Study Group|participants who received sirolimus treatment
62002353|NCT04490993|EXPERIMENTAL|APL-1202 treatment|
62395677|NCT03844048|EXPERIMENTAL|Venetoclax|Venetoclax at the same dose administered to each subject during the previous study in which they were enrolled.
62395678|NCT04226053|EXPERIMENTAL|Intervention Group|The treatment group will consist of 160 mothers who were randomly selected to receive Room to Grow services, which include three years of social and practical support for the mother and baby through a combination of one-on-one sessions with an expert clinical social worker in-person every three months and provision of essential baby items and equipment.
62395679|NCT04226053|NO_INTERVENTION|Control Group|The control group will consist of 160 mothers who will not receive Room to Grow services.
62395680|NCT04524663|EXPERIMENTAL|Camostat mesilate|Patients will receive camostat mesilate for 10 days in addition to standard of care treatment.
62395681|NCT04524663|PLACEBO_COMPARATOR|Placebo|Study participants will receive placebo to match camostat mesilate for 10 days in addition to standard of care treatment.
62777808|NCT03665688|EXPERIMENTAL|Outpatient Dilapan-S|"After Dilapan-S® placement, subjects will be given the option to either return home or to stay in a hotel if transportation is an issue.~Subjects will also be instructed to return to L\&D unit 12 hours after insertion, or earlier if any excessive bleeding, rupture of membranes, pain or other concerns (contractions, decreased fetal movement) develop before the 12 hours"
62777809|NCT03665688|ACTIVE_COMPARATOR|Inpatient Dilapan-S|"After Dilapan-S® placement, subjects will be admitted to L\&D unit and standard clinical protocol will be initiated for cervical ripening and labor induction. During the period of 12 hours of cervical ripening subject is to remain nothing per os (NPO), nothing per vagina and undergo continuous fetal heart rate monitoring. No other interventions are to occur during this period of 12 hours, unless clinically indicated."
62777810|NCT02081599|EXPERIMENTAL|Teneli (Teneligliptin) /Teneli + insulin|Teneligliptin for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
62777811|NCT02081599|PLACEBO_COMPARATOR|Placebo/Teneli (Teneligliptin) + insulin|Placebo for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
62777812|NCT00082381|EXPERIMENTAL|Exenatide Arm|exenatide subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
62777813|NCT00082381|ACTIVE_COMPARATOR|Insulin Glargine Arm|subcutaneous injection, once daily; forced titration to target blood glucose level
62777814|NCT01257022|EXPERIMENTAL|Family Function Intervention|Familias Unidas Intervention Program
62777815|NCT01257022|NO_INTERVENTION|Treatment as Usual|Control
62002354|NCT04490993|PLACEBO_COMPARATOR|Placebo|
62002355|NCT03214003|EXPERIMENTAL|SIB group|Patients in this group will receive concurrent twice-daily radiotherapy by SIB technique (95%PGTV 54Gy, 95%PTV 45Gy,both in 30 twice-daily fractions over 3 weeks, 5 days per week) and chemotherapy (etoposide and cisplatin).
62002356|NCT03214003|ACTIVE_COMPARATOR|BID group|Patients in this group will receive concurrent twice-daily standard radiotherapy (95%PTV 45Gy in 30 twice-daily fractions over 3 weeks, 5 days per week, without SIB) and chemotherapy (etoposide and cisplatin).
62002357|NCT02639364|ACTIVE_COMPARATOR|conventional ventilation strategy|The conventional ventilation strategy use volume-controlled ventilation (VCV) or pressure-controlled ventilation (PCV) mode, combination with low tidal volume and adequate PEEP level.
62395682|NCT00223990|EXPERIMENTAL|FMP1/AS02A|FMP1/AS02A candidate malaria vaccine was administered IM in the left anterolateral thigh muscle at 0, 1, and 2 months
62395683|NCT00223990|ACTIVE_COMPARATOR|RabAvert (rabies vaccine)|RabAvert vaccine was administered IM in the left anterolateral thigh muscle at 0, 1, and 2 months
62395684|NCT05534412|EXPERIMENTAL|Practice-Based Intervention|The intervention will include physician education, electronic decision support, implementation of an electronic referral system, and patient education/co-management by an advance practice provider.
62395685|NCT05534412|NO_INTERVENTION|Control|"Offices in this group will not receive the four-pronged intervention. However, after the study trial, there will be a validation phase in which the initial control group will then receive the intervention. This cross-over deign will then allow all 60 offices to receive the intervention. Data from the cross-over intervention group will be analyzed as a separate cohort to confirm improvements in patient care and outcomes as measured in the intervention group under the study trial can be duplicated."
62395686|NCT03825848|EXPERIMENTAL|Left Portal Vein Branch|Shunt left portal vein branch during the trans jugular intrahepatic portal systemic shunt
62395687|NCT03825848|EXPERIMENTAL|Right Portal Vein Branch|Shunt right portal vein branch during the trans jugular intrahepatic portal systemic shunt
62777816|NCT05564806|EXPERIMENTAL|Intervention/treatment|All subject will receive YH004 intravenously as single agent every three weeks (Q3W), until intolerable toxicity, disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
62395688|NCT01588873|ACTIVE_COMPARATOR|Oral contraceptive pill|
62395689|NCT01588873|ACTIVE_COMPARATOR|Contraceptive ring|
62002358|NCT02639364|EXPERIMENTAL|BILEVEL-APRV protocol|According to our BILEVEL-APRV protocol, BILEVEL-APRV APRV mode with specific settings,combination with spontaneous breathing.
62002359|NCT01632891|EXPERIMENTAL|LPV/r-based ART|Participants were prescribed to LPV/r-based antiretroviral therapy (ART) for 15 days, which includes lopinavir/ritonavir plus emtricitabine/tenofovir disoproxil fumarate; followed by an nNRTI-based ART, which includes efavirenz, nevirapine, plus emtricitabine/tenofovir disoproxil fumarate, and Trimethoprim/sulfamethoxazole prophylaxis to take from day 16 through day 30.
62002360|NCT01632891|EXPERIMENTAL|nNRTI-based ART|Participants were prescribed to nNRTI-based ART for 15 days, which includes efavirenz, nevirapine, plus emtricitabine/tenofovir disoproxil fumarate, followed by an nNRTI-based ART and Trimethoprim/sulfamethoxazole prophylaxis to take from day 16 through day 30.
62395690|NCT01080794|ACTIVE_COMPARATOR|Double rTMS|High frequency rTMS stimulation of the bilateral primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC).
62395691|NCT01080794|ACTIVE_COMPARATOR|M1 Active rTMS + DLPFC Sham rTMS|High frequency stimulation of the primary motor cortex (M1) and sham stimulation of the dorsolateral prefrontal cortex (DLPFC).
62395692|NCT01080794|ACTIVE_COMPARATOR|DLPFC Active rTMS + M1 Sham rTMS|High frequency stimulation of the dorsolateral prefrontal cortex (DLPFC) and sham stimulation of the primary motor cortex (M1).
62395693|NCT01080794|SHAM_COMPARATOR|Double Sham rTMS|Sham rTMS stimulation of the bilateral primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC).
62395694|NCT03910218|EXPERIMENTAL|NCM4HIV|Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring,Pre exposure prophylaxis (PrEP) eligibility screening,PrEP/non occupational post exposure prophylaxis(nPEP)services (labs, medication), healthcare planning/coordination, Motivational Interviewing (MI) counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
62570954|NCT01757184|EXPERIMENTAL|Open-label Sebelipase Alfa/Sebelipase Alfa|Participants who were randomized to receive sebelipase alfa during the Double-blind Period and received sebelipase alfa in the Open-label Period. All participants received sebelipase alfa at a dose of 1 mg/kg qow, irrespective of treatment received in the Double-blind Period. Dose modifications were permitted during the Open-label Period.
62777817|NCT03665311|PLACEBO_COMPARATOR|Normal Saline|100 mL 0.9% Normal Saline at the initiation of SLED and another 100 mL 0.9% Normal Saline after 4 hours of treatment
62777818|NCT03665311|ACTIVE_COMPARATOR|25% Albumin fluid|100 mL 25% Albumin fluid at the initiation of SLED and another 100 mL 25% Albumin fluid after 4 hours of treatment
62002361|NCT01703637|EXPERIMENTAL|Sitagliptin|Drug: sitagliptin sitagliptin 100mg tablet by mouth , once daily for 12 weeks
62002362|NCT01703637|EXPERIMENTAL|Vildagliptin|Drug: vildagliptin saxagliptin 50mg tablet by mouth , twice daily for 12 weeks
62002363|NCT01703637|EXPERIMENTAL|Saxagliptin|Drug: saxagliptin saxagliptin 5mg tablet by mouth , once daily for 12 weeks
62395695|NCT03910218|PLACEBO_COMPARATOR|Usual care|Participants will receive the usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling,substance use treatment referrals,PrEP/nPEP referrals
62002364|NCT03989193|EXPERIMENTAL|Computer guided alveolar ridge splitting technique|Computer guided alveolar ridge splitting using piezo electric device and a 3D printed surgical guide. An L shaped splitting pattern with one crestal and one distal cut will be performed.
62002365|NCT04450251||Pregnant women, at least 24 weeks gestation|
62002366|NCT04296396|EXPERIMENTAL|Individualized Opioid Prescription|Individualized opioid prescription protocol and shared decision making
62395696|NCT06722703|EXPERIMENTAL|ESWL group|The surgical technique of shock wave lithotripsy
62395697|NCT06722703|EXPERIMENTAL|FURS group|Flexible ureteroscope lithotripsy
62395698|NCT06723119|ACTIVE_COMPARATOR|Resveratrol Supplementation|Once daily (immediately upon waking) supplementation with 500mg (2 capsules) VeriSperse® resveratrol (VRES) for 17 days
62777819|NCT01497782|EXPERIMENTAL|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
62777820|NCT01497782|NO_INTERVENTION|No instructor feedback|Control group who did not receive instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
62777821|NCT04741672|EXPERIMENTAL|Intervention group|Providing guidance and calling after discharge routine procedure.
62777822|NCT04741672|EXPERIMENTAL|Control group|Discharge routine procedure.
62002367|NCT04296396|OTHER|Fixed Opioid Prescription|Fixed opioid prescription of 20 tablets of oxycodone 5mg
62002368|NCT01626261||cardiac pacemaker|
62002369|NCT01183975||Patients treated with SAGB by solicited teams|Patients treated with SAGB by solicited teams. No selection criteria at cohort inclusion applied to the 500 (+50) first patients treated in order to ensure consecutive and exhaustive recruitment in the concerned centers over the inclusion period.
62777823|NCT00980759|EXPERIMENTAL|EFI(Extended-Field Irradiation)|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
62777824|NCT00980759|EXPERIMENTAL|Pelvic RT|Pelvic Irradiation with chemotherapy(cisplatin)
62777825|NCT04739878|EXPERIMENTAL|Ultrasound Airway|Ultrasound Airway for subglottic secretion
62777826|NCT00223704|EXPERIMENTAL|HOE 140|Bradykinin receptor antagonist
62002370|NCT05934435|EXPERIMENTAL|Empowered Relief treatment|Participants randomized to the ER group will complete a HIPAA compliant, password protected 2-hour Zoom ER class delivered by an ER-trained ASPMN nurse.
62777827|NCT00223704|ACTIVE_COMPARATOR|Aminocaproic Acid|Antifibrinolytic
62395699|NCT06723119|PLACEBO_COMPARATOR|Placebo|Once daily (immediately upon waking) supplementation with 500mg (2 capsules) Placebo (maltodextrin) for 17 days
62002371|NCT05934435|OTHER|Wait-list Control|Participants randomized to the Wait-list Control group will continue their usual pain care for 2 months and complete surveys to compare with the experimental treatment group. After serving as controls, they will be invited to attend the 2-hour Zoom ER class delivered by an ER-trained ASPMN nurse.
62002372|NCT04528810||Child injuries|pediatric patients under the age of 18 years newly diagnosed with injuries in the emergency department
62002373|NCT02353559|EXPERIMENTAL|EASE|Patients assigned to the intervention arm will receive 8 - 12 psychotherapy sessions lasting 30 - 60 minutes each, delivered by a trained therapist at our center. Patients will receive specialized symptom control from a nurse/physician team in our Palliative Care Service, when indicated by routine symptom screening.
62002374|NCT02353559|NO_INTERVENTION|Usual Care|Usual care
62002375|NCT01660711|EXPERIMENTAL|FOLFIRINOX chemotherapy|"5FU 2400 mg/m2 IV over 48 hours Irinotecan 180 mg/m2 IV day 1 Oxaliplatin 85 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1~Cycles administered every 14 days for 4 cycles before and 4 cycles after surgery."
62002376|NCT03376243|EXPERIMENTAL|Emollient (LIPIKAR BAUME AP+)|Daily application of Lipikar Baume AP+ emollient AND Structured parent education
62002377|NCT03376243|NO_INTERVENTION|Control|Only structured parent education
62002378|NCT02482350|EXPERIMENTAL|Reading Training|A 3-months study design. There will be three distinct phases: base-line testing, reading training, and follow-up testing. T1-T7 indicate the 7 time-points at which we assess the following: reading speeds (word-per-minute), visual field test, visual search test, and Activities of Daily Living rating scale (T1: Day 1, Initial assessments; T2: Day 30, Pre-training assessments; T3: Day 60, During Reading Training (RT) after 5-hours; T4: During RT after 10-hours; T5: During RT after 15-hours; T6: During RT after 20-hour; T7: Day 90, Post-training assessments). Arabic reading patients with left-sided HA will receive app-delivered reading training in a single subject control based design for 1 month.
62002379|NCT05832346|EXPERIMENTAL|Laughter yoga programme|The intervention group will receive a 4-week laughter yoga programme (8 sessions). This group also receives routine care provided by the special school as usual.
62002380|NCT05832346|NO_INTERVENTION|Routine care|The control group receives routine care provided by the special school as usual.
62002381|NCT03761251|EXPERIMENTAL|Pet Fish|Participants will be instructed to partner thrice daily and once weekly fish care activities with diabetes care activities for 3 months
62002382|NCT00848328|EXPERIMENTAL|Lenalidomide and Rituximab|Rituximab 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15. Lenalidomide 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
62002383|NCT04491162|ACTIVE_COMPARATOR|Conventional gait therapy|Conventional gait therapy.
62395700|NCT00383292|EXPERIMENTAL|Tasisulam|
62395701|NCT03159052|EXPERIMENTAL|SHR3824 Placebo|once daily, 24 weeks
62395702|NCT03159052|EXPERIMENTAL|SHR3824 5 mg|once daily, 52 weeks
62777828|NCT00223704|PLACEBO_COMPARATOR|Placebo|Placebo
62777829|NCT04792684||Arm A.|Subjects that have a suspected advanced adenoma or have been newly diagnosed with CRC still not resected and scheduled for surgery
62777830|NCT04792684||Arm B|Subjects at average-risk for CRC and scheduled for CRC screening colonoscopy
62777831|NCT06583772||Patient group|Post-stroke patients
62395703|NCT03159052|EXPERIMENTAL|SHR3824 10 mg|once daily, 52 weeks
62570955|NCT01757184|EXPERIMENTAL|Open-label Placebo/Sebelipase Alfa|Participants who were randomized to receive placebo during the Double-blind Period and received sebelipase alfa in the Open-label Period. All participants received sebelipase alfa at a dose of 1 mg/kg qow, irrespective of treatment received in the Double-blind Period. Dose modifications were permitted during the Open-label Period.
62777832|NCT02597140|EXPERIMENTAL|Lidocaine group|Patients will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
62570956|NCT05784233|EXPERIMENTAL|0% Relevance|0% chance of the salient item being the target during visual search task.
62570957|NCT05784233|EXPERIMENTAL|25% Relevance|25% chance of the salient item being the target during visual search task.
62570958|NCT05784233|EXPERIMENTAL|50% Relevance|50% chance of the salient item being the target during visual search task.
62002384|NCT04491162|EXPERIMENTAL|BWST training|Conventional gait therapy + Body weight support treadmill training
62395704|NCT03919877|OTHER|Optimizing Diet for Glycemic Control|"Phase 1: Metabolic testing will include 3 metabolic tests:~1. The Oral Glucose Tolerance Test. The participant will wear the CGM while undergoing the OGTT + will be asked to repeat the test at home twice.~2. The Insulin Sensitivity Test (Steady State Plasma Glucose). This test is designed to measure how well cells remove glucose from the blood in response to insulin.~3. The Isoglycemic Intravenous Glucose Infusion (IIGI). This test is designed to measure the incretin hormone effect.~Phase 2: Participants follow their own diet while using the CGM. Participants are provided with 5-10 standardized foods to test during this phase.~Phase 3: Participants are provided with additional standardized foods and counseled to continue their own diet during this phase.~Phase 4: Participants are counseled on reducing or limiting the foods that caused glucose spikes and they are also counseled on macronutrient composition of their diet based on lipid profile."
62570959|NCT05784233|EXPERIMENTAL|75% Relevance|75% chance of the salient item being the target during visual search task.
62570960|NCT05784233|EXPERIMENTAL|100% Relevance|100% chance of the salient item being the target during visual search task.
62570961|NCT05790395|EXPERIMENTAL|Intervention group|The participants will also be given a Practical Resource Hub for Healthy Life leaflet containing information on various applications. The participants will receive a brief telephone intervention using the Ask, Warn, Advise, Refer and Do-it-again (AWARD) model. For the advice step, the research assistant will ask about the priority the participants place on engagement in desirable health-related lifestyle practices identified in the completed behavioural risk factor survey. The participants will also be asked to choose the goal that they consider easiest to achieve, such as quitting or reducing smoking, consuming more vegetables or less fatty foods or sugary drinks, performing more exercise or reducing alcohol consumption. The participants will be encouraged to quit health-risk behaviours (or adopt a healthy lifestyle) sequentially, but they will also be able to choose to quit them simultaneously if they are confident in doing so.
62570962|NCT05790395|PLACEBO_COMPARATOR|Control group|The control group participants will also be given a Practical Resource Hub for Healthy Life leaflet containing information on various applications. However, the health ambassadors will simply advise the participants to modify their health-risk behaviours and/or adopt a healthy lifestyle practice. The participants will also receive follow-up for outcome assessments with the same schedule as those in the intervention group.
62570963|NCT02288403|EXPERIMENTAL|Aerobic interval training|"Interval exercise at an intensity between 90-95% of maximum heart rate (15x30 s), with recoveries at an equivalent speed to 50-55 % of maximal oxygen consumption at baseline (14x60 s).~24 training sessions, 3x weekly (on alternate days)."
62570964|NCT02288403|ACTIVE_COMPARATOR|Continuous training|"40 minutes of continuous exercise at an intensity between 65-75% of maximum heart rate.~24 training sessions, 3x weekly (on alternate days)."
62570965|NCT01144065||Patient with acute MI|Patients with acute MI ( elevated cardiac enzymes + chest pain or typical ECG changes)admitted to the cardiology department at Meir Medical Center
62570966|NCT01144065||Patient with prior cardiovascular disease and/or diabetes|These patients do not have acute coronary syndrome or stroke. Prior cardiovascular disease (CVD) is defined as a history of hospital admission due to acute coronary artery occlusion, percutaneous coronary interventions (PCI), coronary artery bypass grafting, any aortic or peripheral vascular disease that was either symptomatic or required intervention, ischemic or hemorrhagic stroke or transient ischemic attack.
62002385|NCT04038489|EXPERIMENTAL|Tamoxifen and Aspirin with AC-T Chemotherapy|AC-T chemotherapy includes 4 cycles of doxorubicin and cyclophosphamide given every 2 or 3 weeks followed by either 12 weekly cycles of lower dose paclitaxel or 4 cycles of higher dose paclitaxel every 2 or 3 weeks. During this time, all participants would receive daily aspirin and daily tamoxifen. After the AC-T chemotherapy, participants will undergo standard of care surgery to remove any remaining tumor.
62395705|NCT06079879|EXPERIMENTAL|Bomedemstat|Participants will begin treatment at a dose of 50 mg of bomedemstat daily. Dosage will be adjusted either up or down within specified time parameters for each participant to the dose that provides sufficient exposure to safely inhibit thrombopoiesis to decrease platelet counts to the target range. All participants will be treated daily for up to 52 weeks, and are eligible for an extended treatment phase up to 152 weeks.
62570967|NCT01144065||Patients without prior cardiovascular disease or diabetes|These patients do not have acute coronary syndrome or stroke Prior cardiovascular disease (CVD) or diabetes
62570968|NCT04580940||Subjects with complex pancreaticobiliary disease|All subjects will undergo the percutaneous transhepatic cholangiopancreatoscopy with the SpyGlass Discover System.
62570969|NCT02619630|EXPERIMENTAL|High-Risk (HR) patients|Nelarabine during consolidation and maintenance
62570970|NCT01050582|EXPERIMENTAL|Risperidone|Risperidone as per local prescribing practices
62570971|NCT01050582|EXPERIMENTAL|Other atypical antipsychotic drugs|Other atypical antipsychotic drugs as per local prescribing practices
62570972|NCT02619357|EXPERIMENTAL|Cohort 1|10 subjects diagnosed with COPD (GOLD stages 2 and 3). Subjects will wear multiple devices simultaneously (SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband and Garmin Vivofit 2 wristband) up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests.
62570973|NCT02619357|EXPERIMENTAL|Cohort 2|10 subjects diagnosed with asthma. Subjects will wear multiple devices simultaneously (SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband and Garmin Vivofit 2 wristband) up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests.
62002386|NCT01639040|EXPERIMENTAL|Placebo QW|Placebo (for Dupilumab) once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent topical corticosteroid (TCS) for up to 28 days
62002387|NCT01639040|EXPERIMENTAL|Dupilumab 300 mg QW|Dupilumab 300 mg once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent TCS for up to 28 days
62002388|NCT04265573||Children under-five|Uncomplicated malaria case in this group will be managed using Pyronaridine-Artesunate at health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
62002389|NCT04265573||Individuals five years of age and above|Uncomplicated malaria case in this group will be managed using Dihydoartemisinin-Piperaquine health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
62777833|NCT02597140|PLACEBO_COMPARATOR|Control group|Patients will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous normal saline infusion of 2 mg/kg/hr.
62395706|NCT06079879|ACTIVE_COMPARATOR|Best Available Therapy|Each participant will receive either anagrelide, busulfan, interferon alfa/pegylated interferon alfa, or ruxolitinib as determined by investigator. All participants will be treated per respective approved product labels for up to 52 weeks. Participants receiving BAT for 52 weeks who stop responding to BAT are eligible to switch to bomedemstat and receive this for up to 152 weeks at the investigators discretion.
62395707|NCT05896709|EXPERIMENTAL|MK-RS|Patients' embryos will be selected by MK-RS integrative analytical method.
62395708|NCT05896709|NO_INTERVENTION|Conventional|Patients' embryos will be selected by conventional method (i.e by embryologists).
62395709|NCT03459092|EXPERIMENTAL|Botox-based treatment regimen|First intervention is a Botulinum toxin type A injection. If further treatment is necessary, strabismus surgery can be performed.
62395710|NCT03459092|ACTIVE_COMPARATOR|Surgery-based treatment regimen|First intervention is strabismus surgery. If further treatment is necessary, strabismus surgery can be repeated.
62395711|NCT05852574|EXPERIMENTAL|CP101|Extended Induction: Participants will receive the short induction dose of CP101 comprising 10 capsules daily for 5 days. Participants in this arm will then receive an extended induction daily dose of five CP101 capsules through Week 8.
62395712|NCT05852574|PLACEBO_COMPARATOR|CP101 + Placebo|Short Induction: Participants will receive the short induction dose of CP101 comprising 10 capsules daily for 5 days. Participants in this arm will then receive 5 capsules of placebo through Week 8.
62395713|NCT05247801|EXPERIMENTAL|Experimental Group (Psychoeducational Intervention)|Two hundred and sixteen caregivers of multi-pathological and polypharmacy patients will receive psychoeducational intervention based on virtual reality and a dosing device for safer medication use at home. The intervention will be developed in a previous project phase using a mixed methodology (observational study and qualitative techniques). The intervention will be group-based and consist of motivational discussions and a review of audiovisual materials to promote self-efficacy and health literacy on the safe use of medication at home (most frequent errors, preventive strategies, etc.). Study period: 15 days intervention and follow-up 12 months.
62395714|NCT05247801|ACTIVE_COMPARATOR|Control Group (Dosing Device)|The 216 subjects assigned to the control group will use a medication dosing device and will receive information on how to use it for medication errors. Study period: 15 days intervention and follow-up 12 months.
62395715|NCT04086745|EXPERIMENTAL|Baricitinib Low Dose|Baricitinib administered orally.
62395716|NCT04086745|EXPERIMENTAL|Baricitinib High Dose|Baricitinib administered orally.
62395717|NCT04086745|ACTIVE_COMPARATOR|TNF Inhibitor|Adalimumab or etanercept administered subcutaneously (SC) per standard of care.
62395718|NCT06101381|EXPERIMENTAL|CD19-directed CAR-T cell|After lymphodepletion, a single intravenous infusion of an academic, locally produced, autologous CD19-directed CAR-T cells will be administered.
62395719|NCT03758612|ACTIVE_COMPARATOR|TBI-223 50 mg|Cohort 1, single dose of TBI-223 50 mg dosed under fasted conditions
62395720|NCT03758612|ACTIVE_COMPARATOR|TBI-223 100 mg|Cohort 2, single dose of TBI-223 100 mg dosed under fasted conditions
62395721|NCT03758612|ACTIVE_COMPARATOR|TBI-223 300 mg|"Cohort 3a, Period 1 - gave a single dose of TBI-223 300 mg oral suspension dosed under fasted conditions.~Cohort 3b, Period 2 - participants in cohort 3a were invited after a washout period to return for an additional single dose of TBI-223 300 mg enteric capsule dosed under fasted conditions"
62395722|NCT03758612|ACTIVE_COMPARATOR|TBI-223 600 mg|Cohort 4, single dose of TBI-223 600 mg dosed under fasted conditions
62395723|NCT03758612|ACTIVE_COMPARATOR|TBI-223 1200 mg|"Cohort 5, Period 1, single dose of TBI-223 1200 mg dosed under fasted conditions.~Cohort 5, Period 2, participants were invited to return after a washout period to continue in period 2 and receive a single dose of TBI-223 1200 mg dosed under fed conditions"
62570974|NCT06081842|ACTIVE_COMPARATOR|Arm 1. Routine care|Routine contraceptive counseling and routine method availability
62570975|NCT06081842|EXPERIMENTAL|Arm 2. Package of contraceptive counseling interventions|The implementation package will be co-designed by providers and clients during the formative and research design phases
62570976|NCT06081842|EXPERIMENTAL|Arm 3. Expanded methods|Routine care with the contraceptive counseling package combined with wider method availability as recommended by national policies.
62570977|NCT02840539|EXPERIMENTAL|Experimental|Bortezomib, Cytarabine, Dexamethasone, Pegteograstim
62570978|NCT04179838|EXPERIMENTAL|Sleep-Deprived first, then Non-Sleep Deprived|Participants will first be tested after 1 night with partial sleep deprivation (sleep-deprived, 4 h sleep). After a washout period of 4 weeks, they will be tested again after 1 night with normal sleep (non-sleep deprived, 8 h sleep).
62777834|NCT01898013|ACTIVE_COMPARATOR|Pregnenolone|"Pregnenolone fixed escalating up to 500mg/day will consist of the following schedule:~Visit 1 (week -1, screening visit) and pain symptom assessment (no study medication) Visit 2 (week 0) placebo lead-in (all participants) Visit 3 (week 1, baseline visit): 50mg PO, BID x 1 week, Visit 4 (week 2): 150mg PO, BID x 1 week, Visit 5 (week 3): 250mg PO, BID for two weeks. Visit 6 (week 5): No medication will be dispensed; study medication will be tapered by 100mg per day and then discontinued."
62777835|NCT01898013|PLACEBO_COMPARATOR|Placebo|"Placebo will be administered exactly the same as the active comparator (pregnenolone) and will consist of the following schedule:~Visit 1 (week -1, screening visit) and pain symptom assessment (no study medication) Visit 2 (week 0) placebo lead-in (all participants) Visit 3 (week 1, baseline visit): placebo PO, BID x 1 week, Visit 4 (week 2): placebo PO, BID x 1 week, Visit 5 (week 3): placebo PO, BID for two weeks. Visit 6 (week 5): No medication will be dispensed; study medication will be tapered in the exact manner as active study medication and then discontinued."
62395724|NCT03758612|ACTIVE_COMPARATOR|TBI-223 2000 mg|Cohort 6, single dose of TBI-223 2000 mg dosed under fasted conditions
62395725|NCT03758612|ACTIVE_COMPARATOR|TBI-223 2600 mg|Cohort 7, single dose of TBI-223 2600 mg dosed under fasted conditions
62395726|NCT03758612|PLACEBO_COMPARATOR|TBI-223 placebo|"Period 1 Single dose matching placebo for TBI-223 under fasted conditions for cohorts 1 to 7~Period 2 Placebo participants in cohort 5 were invited to return after a washout period and were administered a single dose matching placebo for TBI-223 1200mg under fed conditions"
62395727|NCT03758612|ACTIVE_COMPARATOR|TBI-223 3x600 mg SR-1 tablet|Cohort 8, arm 1 - Single dose TBI-223 of 1800 mg (3 x 600 mg) sustained release (SR) tablet formulation 1 under fed conditions
62570979|NCT04179838|EXPERIMENTAL|Non-Sleep Deprived first, then Sleep-deprived|Participants will first be tested after 1 night with normal sleep (non-sleep deprived, 8 h sleep). After a washout period of 4 weeks, they will be tested again after 1 night with partial sleep deprivation (sleep-deprived, 4 h sleep).
62570980|NCT01346696|EXPERIMENTAL|OsseoSpeed™ TX implants|OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.
62570981|NCT02929589|EXPERIMENTAL|Opioid naïve patients-Group A|"Group A: Subjects will be prescribed ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days, and 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days.~."
62570982|NCT02929589|EXPERIMENTAL|Non-Opioid naïve patients-Group C|Group C: Subjects will be prescribed ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days, in addition to their preferred opioid medication prescription.
62570983|NCT02929589|PLACEBO_COMPARATOR|Opioid naïve patients-Group B|Group B:Subjects will be prescribed 800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain and 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days.
62570984|NCT02929589|EXPERIMENTAL|Non-Opioid naïve patients-Group D|Group D: Subjects will be prescribed or advised to continue to take only their preferred current oral opioid prescription (codeine, hydrocodone, hydromorphone, morphine, methadone, oxymorphone, or transdermal fentanyl).
62570985|NCT06070142|ACTIVE_COMPARATOR|TEP group|In 30 patients; Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides. During the surgery, the mesh will not be fixed to the Cooper ligament. Patients whose pain scores (VAS score) are measured on the first postoperative day and who are suitable for discharge will be discharged after a pelvis x-ray is taken. One month after the surgery and 6 months later, patients will be called to the outpatient clinic and examined, their pain scores will be measured (VAS score) and pelvic radiographs will be taken. The movement of the clips marked on the patch will be compared with previous radiographs in cm.
62777836|NCT04520724|EXPERIMENTAL|Study group|"30 patients with NAFLD which consumes rolls with a higher fiber content twice daily (ca. 300 kcal; no less than 12 g of fiber) for 8 weeks.30 patients with NAFLD which consumes rolls with a higher fiber content twice daily (12 g of fiber/per roll) for 8 weeks.~Rolls should be eaten for 1st and 2nd breakfast. Before starting the study, patients will receive nutritional guidelines how compose a meal that the caloric content does not exceed 400 kcal per breakfast. At the beginning patients will be trained by licensed dietitians on the principles of diet in NAFLD. During 8 weeks of intervention, patients will have telephone access to consultations with a dietitian."
62002390|NCT04265573||Pregnant women|Uncomplicated malaria case in this group will be managed using Artemether-Lumefantrin health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
62002391|NCT03492697|EXPERIMENTAL|PF-06882961|
62002392|NCT03987958||Venetoclax|"Participants in this observational study will receive treatment with venetoclax for AML.~The decision to treat with venetoclax has been made independently from this observational study before participants are offered the opportunity to participate in this study."
62002393|NCT01228929|EXPERIMENTAL|Normal|Subjects with no clinical diagnosis or symptoms of dry eye.
62395728|NCT03758612|ACTIVE_COMPARATOR|TBI-223 3x600 mg SR-2 tablet|Cohort 8, arm 2 - Single dose TBI-223 of 1800 mg (3 x 600 mg) sustained release (SR) tablet formulation 2 under fed conditions
62395729|NCT03758612|ACTIVE_COMPARATOR|TBI-223 2x900 mg SR-3 tablet|Cohort 8, arm 3 - Single dose TBI-223 of 1800 mg (2 x 900 mg) sustained release (SR) tablet formulation 3 under fed conditions
62395730|NCT03758612|ACTIVE_COMPARATOR|TBI-223 2x1000 mg IR tablet|"Cohort 8, arm 4 - Single dose TBI-223 of 2000 mg (2 x 1000 mg) immediate release (IR) tablet under fasted conditions~Cohort 9 - Participants from cohort 8 arm 4 were invited to return and were administered a single dose TBI-223 of 2000 mg (2 x 1000 mg) immediate release (IR) tablet under fed conditions"
62570986|NCT06070142|EXPERIMENTAL|eTEP Group|In 30 patients; Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides. During the surgery, the mesh will not be fixed to the Cooper ligament. Patients whose pain scores (VAS score) are measured on the first postoperative day and who are suitable for discharge will be discharged after a pelvis x-ray is taken. One month after the surgery and 6 months later, patients will be called to the outpatient clinic and examined, their pain scores will be measured (VAS score) and pelvic radiographs will be taken. The movement of the clips marked on the patch will be compared with previous radiographs in cm.
62570987|NCT01643343||Typically Developing|Typically developing toddler volunteers between the ages of 8 months and 3 years
62002394|NCT01228929|EXPERIMENTAL|Aqueous Deficiency Dry Eye (ADDE)|Subjects with low tear volume measured by Schirmer's test less than 10 mm.
62395731|NCT03846310|EXPERIMENTAL|Dose Escalation Arm A|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer.
62395732|NCT03846310|EXPERIMENTAL|Dose Escalation Arm B|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen and pembrolizumab in participants with Non-Small Cell Lung Cancer.
62395733|NCT03846310|EXPERIMENTAL|Dose Expansion Arm 1|Zimberelimab will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
62570988|NCT01643343||Autism|Children between the ages of 8 months and 6 years with a diagnosis of an autism spectrum disorder
62570989|NCT05643742|EXPERIMENTAL|CTX112|Administered by IV infusion following lymphodepleting chemotherapy.
62570990|NCT04651855|EXPERIMENTAL|Treatment arm|It is planned that IMP administration will be performed three times for each enrolled patient. IMP administration could be performed only if the patients does not have any contraindications for lumbar puncture.
62395734|NCT03846310|EXPERIMENTAL|Dose Expansion Arm 2|The etrumadenant at RDE determined from the dose escalation phase will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen and zimberelimab in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
62570991|NCT04021238|EXPERIMENTAL|Perflutren Lipid Microsphere or Lumason|Patients with suspected kidney cancer and planned surgery will be imaged using contrast-enhanced ultrasound with either perflutren or Lumason.
62570992|NCT00913263|EXPERIMENTAL|2-Hydroxyflutamide|Single injection of 2-Hydroxyflutamide (2-8mL ready-made paste)in one prostate lobe
62777837|NCT04520724|PLACEBO_COMPARATOR|Placebo group|"30 patients with NAFLD which consumes rolls with a lower fiber content twice daily (ca. 300 kcal; no less than 6 g of fiber) for 8 weeks.30 patients with NAFLD which consumes rolls with a lower fiber content twice daily (6 g of fiber/per roll) for 8 weeks.~Rolls should be eaten for 1st and 2nd breakfast. Before starting the study, patients will receive nutritional guidelines how compose a meal that the caloric content does not exceed 400 kcal per breakfast. At the beginning patients will be trained by licensed dietitians on the principles of diet in NAFLD. During 8 weeks of intervention, patients will have telephone access to consultations with a dietitian."
62002395|NCT01228929|EXPERIMENTAL|Meibomian Gland Dysfunction (MGD)|Subjects having mild to moderate Meibomian Gland Dysfunction by slit lamp evaluation.
62002396|NCT04334642|EXPERIMENTAL|Athletes from the Paralympic Boccia Brazilian Team|The research will have as a convenience sample 11 Athletes from the Paralympic Boccia Brazilian Team, which will be compared with itself in the data analysis. This study includes the category called Other participants formed by staff, freshmen, technicians and other professionals who are present during the interventions.
62002397|NCT03083691|OTHER|Cohort 1, NSCLC|During Treatment Part A nivolumab 240 mg IV q2w as monotherapy is administered. At the time of disease progression a re-biopsy is performed before initiation of combination therapy (Treatment Part B). Within Treatment Part B, nivolumab is given in a dose of 3 mg/kg q2w together with ipilimumab 1 mg/kg IV q6w.
62002398|NCT03083691|OTHER|Cohort 2, SCLC|Within Treatment Part A, nivolumab 1 mg/kg q3w together with ipilimumab 3 mg/kg q3w for a total of four doses is administered. After the four combined doses have been administered, a re-biopsy is performed before initiation of Treatment Part B. In Treatment Part B, nivolumab 240 mg q2w monotherapy is administered until disease progression or unacceptable toxicity
62002399|NCT01753635|EXPERIMENTAL|Baska mask|In this arm the Baska mask will be used as the airway management device
62002400|NCT01753635|ACTIVE_COMPARATOR|single use laryngeal mask airway device (LMA)|in this arm a single use LMA device will be used for airway management.
62395735|NCT02316106|EXPERIMENTAL|Arm A (Long Intense)|
62395736|NCT02316106|EXPERIMENTAL|Arm B (Intermediate)|
62570993|NCT02332057|ACTIVE_COMPARATOR|Diclofenac plus lidocaine|Diclofenac(100 mg) is administered 1 hour before IUD insertion and lidocaine gel is placed on cervix three minutes before IUD insertion
62570994|NCT02332057|PLACEBO_COMPARATOR|Placebo|Placebo tablets is administered 1 hour before IUD insertion and placebo gel is placed on cervix three minutes before IUD insertion
62002401|NCT01020071|OTHER|laser treatment|laser peripheral iridotomy and laser peripheral iridoplasty
62002402|NCT00889343|EXPERIMENTAL|1|
62002403|NCT00889343|PLACEBO_COMPARATOR|2|
62002404|NCT01331070|EXPERIMENTAL|PATIENT|Patients, half with moderate (GOLD II) and half with severe (GOLD III) COPD
62002405|NCT01331070|OTHER|Accepts Healthy Volunteers|Control arm with the same intervention
62395737|NCT02316106|EXPERIMENTAL|Arm C (Short Intense)|
62570995|NCT06521697|EXPERIMENTAL|Group 1 (HL-D)|Fresh gas flow at 0.5 L/min with dexmedetomidine-ketamine-lidocaine mixture
62570996|NCT06521697|EXPERIMENTAL|Group 2 (HL-ND)|Fresh gas flow at 0.5 L/min with placebo normal saline
62570997|NCT06521697|EXPERIMENTAL|Group 3 (L-D)|Fresh gas flow at 1.0 L/min with dexmedetomidine-ketamine-lidocaine mixture
62570998|NCT06521697|NO_INTERVENTION|Group 4 (L-ND)|Fresh gas flow at 1.0 L/min with placebo normal saline
62570999|NCT02350491||RA group|Pregnant women suffering from Rheumatoid Arthritis.
62571000|NCT02350491||SLE group|Pregnant women suffering from Systemic Lupus Erythematosus.
62571001|NCT02350491||healthy group|Healthy pregnant woman.
62571002|NCT00427648|ACTIVE_COMPARATOR|1|xylocaine
62777838|NCT01247480||Breast cancer patients|
62187735|NCT04966559|PLACEBO_COMPARATOR|Placebo treatment|"Film-coated matched placebo-tablets consisting of:~Core:~Mannitol, USP/Ph. Eur./JP Croscarmellose Sodium, NF/Ph. Eur./JP Magnesium Stearate, NF/Ph. Eur./JP~Coating:~Opadry Yellow Purified Water, USP/EP"
62187736|NCT04966559|ACTIVE_COMPARATOR|Naldemedine treatment|"Film-coated matched active-tablets consisting of:~Core:~Naldemedine Tosylate (0,2 mg) Mannitol, USP/Ph. Eur./JP Croscarmellose Sodium, NF/Ph. Eur./JP Magnesium Stearate, NF/Ph. Eur./JP~Coating:~Opadry Yellow Purified Water, USP/EP"
62571003|NCT00427648|PLACEBO_COMPARATOR|2|normal saline
62571004|NCT01275365|NO_INTERVENTION|Placebo/Low Protein|Placebo injections weekly; 0.8 g/kg/day protein
62571005|NCT01275365|NO_INTERVENTION|Placebo/High Protein|Placebo injections weekly; 1.3 g/kg/day protein
62571006|NCT01275365|OTHER|Testosterone/Low Protein|Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
62571007|NCT01275365|OTHER|Testosterone/High Protein|Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
62571008|NCT01930032||All subjects|
62571009|NCT04976010||CKD G3-5|Patients with CKD and an estimated eGFR \< 60ml/min not yet on dialysis
62571010|NCT04976010||End stage kidney disease (ESKD) CKD G5 Hemodialysis|Patients on hemodialysis for at least 3 months
62571011|NCT04976010||Normal kidney function|Patients enrolled with normal kidney function and/or CKD G1 and an estimated eGFR \> 90ml/min
62571012|NCT06574672|EXPERIMENTAL|Prospective Hospice and Palliative Care Intervention|This arm comprises patients admitted to the specific medical intensive care unit in which the hospice and palliative care practitioner is currently active. This will include all patients admitted to a single medical intensive care unit during the anticipated first half of the intervention timeframe, followed by all patients admitted to both medical intensive care units during the second half of the intervention timeframe.
62571013|NCT06574672|ACTIVE_COMPARATOR|Prospective Standard of Care|This arm comprises patients admitted to the medical intensive care unit in which the hospice and palliative care practitioner is not currently active, but which may experience a group effect due to the study's ongoing enrollment and the practitioner's presence. This will include all patients admitted to a single medical intensive care unit during the anticipated first half of the intervention timeframe, prior to the practitioner becoming active in both intensive care units.
62571014|NCT06574672|PLACEBO_COMPARATOR|Historical Controls|This arm comprises historical patients admitted to the medical intensive care units in the year prior to study enrollment.
62571015|NCT01438905|NO_INTERVENTION|Control|Parameters will be identical to the lower intensity (Small amplitude oscillation mobilization; Grade IV) talocrural mobilization. No force, other than light hand contact will be applied by the therapist.
62777839|NCT03517566|PLACEBO_COMPARATOR|placebo|Placebo
62777840|NCT03517566|EXPERIMENTAL|ZPL389 3mg|ZPL389 3 mg oral powder
62777841|NCT03517566|EXPERIMENTAL|ZPL389 10 mg|ZPL389 10 mg oral powder
62777842|NCT03517566|EXPERIMENTAL|ZPL389 30mg|ZPL389 30 mg oral powder
62002406|NCT01959646|PLACEBO_COMPARATOR|Placebo|Placebo Group
62002407|NCT01959646|EXPERIMENTAL|Aged Garlic Extract Supplementation|Aged Garlic Extract Supplementation Group
62002408|NCT00763659|ACTIVE_COMPARATOR|1|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
62777843|NCT03517566|EXPERIMENTAL|ZPL389 50mg|ZPL389 50 mg oral powder
62777844|NCT04809350|ACTIVE_COMPARATOR|Adjustable Human Milk Fortification|Human milk fortification based on blood urea levels
62777845|NCT04809350|EXPERIMENTAL|Targeted Human Milk Fortification|Human milk fortification based on milk analysis
62777846|NCT04283591|EXPERIMENTAL|Experimental Intervention|Acupuncture Treatment Group: will get acupuncture treatment which will be applied to Baihui (DU20), Yintang (EX-HN3) points and bilateral Tai Chong (LR3), Hegu (LI4) points for 4 weeks, twice a week. They also will continue to receive the conventional rehabilitation programme.
62777847|NCT04283591|OTHER|No Intervention|Control Group: will be included in the conventional rehabilitation programme and no interventional procedures will be made.
62002409|NCT00763659|ACTIVE_COMPARATOR|2|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
62002410|NCT00763659|PLACEBO_COMPARATOR|3|Placebo
62002411|NCT00577083|EXPERIMENTAL|Initial cap-fitted|Initial cap-fitted colonoscopy for the first insertion
62002412|NCT00577083|ACTIVE_COMPARATOR|Initial regular|Initial regular no cap on the end of the colonoscope for the first insertion
62002413|NCT00006125|EXPERIMENTAL|Doxorubicin + topotecan|"Patients receive doxorubicin IV over 5-10 minutes on day 1 and topotecan IV over 30 minutes on days 3-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression.~Patients are followed every 6 months for 2 years and annually for the next 3 years."
62002414|NCT02993679|OTHER|double-bundle ACL reconstruction|surgical reconstruction of the anterior cruciate ligament
62002415|NCT02993679|OTHER|anterolateral ligament reconstruction|surgical reconstruction of the anterolateral ligament
62002416|NCT02493634|OTHER|pressure gradient measurement|Diagnostic procedure to measure pressure gradient in series of patients. Focus is on safety and absence of adverse events
62002417|NCT03731533|EXPERIMENTAL|WellStart|WellStart is a 12-week virtual intensive therapeutic lifestyle program utilizing web-based encounters with physicians, dietitians, health coaches and additional resources.
62002418|NCT03731533|NO_INTERVENTION|Usual Care|The control group will continue with usual care.
62002419|NCT01764607|EXPERIMENTAL|Sirolimus treatment|Patients will receive sirolimus 5 weeks prior to removal of squamous cell skin carcinoma. After the 5 weeks of treatment, nephrology will determine/manage each patient's immunosuppressant therapy.
62002420|NCT05593796|ACTIVE_COMPARATOR|treatment-as-usual (TAU)|
62002421|NCT05593796|ACTIVE_COMPARATOR|Clinician-delivered CBT with tratment as usual|
62002422|NCT03179826||Study population|Adults consulting with one of the participating general practitioners and requiring long term inhaled corticoids and monitoring.
62002423|NCT00376168|EXPERIMENTAL|prGCD 30 Units/kg|
62002424|NCT00376168|EXPERIMENTAL|prGCD 60 Units/kg|
62187737|NCT05086419|EXPERIMENTAL|Exercise group|The exercise group will in addition to treatment as usual, receive sub-symptom threshold aerobic exercise for approx. 30 minutes 3-5x / week for 12 weeks. Sub-symptom threshold aerobic exercise is based on the individual patient's symptom threshold and will be between 80-90% of the maximum heart rate achieved during testing/BCTT. To ensure proper exercise dosage and progression, participants will be retested every 3 weeks. An experienced doctor and / or physiotherapist will carry out the testing and guide the participants in the content and dosage (duration, intensity, and frequency) of the sub-symptom threshold aerobic exercise/intervention.
62187738|NCT05086419|NO_INTERVENTION|Treatment as usual group|"The treatment as usual group will receive assessment and treatment provided by a multidisciplinary outpatient rehabilitation team. Patients will undergo a medical examination and assessment of physical, cognitive and mental health and functioning, followed by individually adapted rehabilitation. The interdisciplinary team consists of a specialist in physical medicine and rehabilitation, neuropsychologist, occupational therapist, physiotherapist, and social worker. The main focus is on stabilizing the level of function in everyday life and gradual return to work and education.~Participants receive general advice on physical activity based on recommendations from the Norwegian Directorate of Health, but not specific guidance in sub-symptom threshold aerobic exercise and help with exercise dosage (frequency, duration and intensity)."
62187739|NCT06228820|EXPERIMENTAL|Aspirin Arm|Healthy patients will then undergo at least a 2-week course of 81mg of Bayer Aspirin per oral daily, followed by platelet function testing. The patients will then undergo a washout period of 2 weeks, followed by another 2-week course of 81mg Vazalore Aspirin per oral daily, followed by a second round of platelet function testing.
62187740|NCT02132871||1|
62187741|NCT05267795|EXPERIMENTAL|Operationalization|The experiment used a 2x2 within-subjects design in which participants either listened to music or underwent a silent control period and either performed an active foot tapping task, or a passive control task with no movement resulting in four experimental trial types: (a) Music Active (music with tapping); (b) Music Passive (music without tapping); (c) Silence Active (silence with tapping); and (d) Silence Passive (silence without tapping). The allocation of the music excerpts to the task (active, passive) was random, and the order of the four experimental trial types was counterbalanced.
62187742|NCT00813098|EXPERIMENTAL|High dose|A high dose of LX1031; daily oral intake for 28 days
62571016|NCT01438905|EXPERIMENTAL|Lower intensity mobilization|The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
62002425|NCT01018459|EXPERIMENTAL|Group D: 10^11 vp/mL or placebo|10 subjects will receive 10\^11 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
62187743|NCT00813098|EXPERIMENTAL|Low Dose|A low dose of LX1031; daily oral intake for 28 days
62187744|NCT00813098|PLACEBO_COMPARATOR|Placebo|Matching placebo dosing with daily oral intake
62187745|NCT03754790|EXPERIMENTAL|Fitusiran|Participants will be administered fitusiran as a subcutaneous injection once monthly or every other month for up to 48 months post initiation of modified IMP dose/frequency or until fitusiran becomes commercially available, whichever comes first.
62187746|NCT04419805|EXPERIMENTAL|Single Palatal TAD|Single Palatal TAD for orthodontic molar intrusion
62187747|NCT04419805|EXPERIMENTAL|Two buccal TADs|Two buccal TADs for orthodontic molar intrusion
62187748|NCT03969576|EXPERIMENTAL|DEB-TACE|172 subjects in this study group will be receive the treatment of drug-eluting bead TACE
62187749|NCT03969576|ACTIVE_COMPARATOR|cTACE|172 subjects in this study group will be receive the treatment of conventional TACE
62571017|NCT01438905|EXPERIMENTAL|Higher intensity mobilization|The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
62002426|NCT01018459|EXPERIMENTAL|Group A: 10^9 vp/mL or placebo|10 subjects will receive 10\^9 viral particles (vp)/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
62002427|NCT01018459|EXPERIMENTAL|Group B: 10^10 vp/mL or placebo|10 subjects will receive 10\^10 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
62002428|NCT01018459|EXPERIMENTAL|Group C: 5 x 10^10 vp/mL or placebo|10 subjects will receive 5 x 10\^10 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
62002429|NCT03808402||High dose surfactant|Infants who receive a first dose of surfactant between 170 and 200 mg/kg
62187750|NCT02077205|EXPERIMENTAL|Manualised Cognitive Behavioral Therapy|Manualised Cognitive Behavioral Therapy in a Routine Care Setting
62571018|NCT04824430||SLH 3M|Second look hysteroscopy (SLH) performed 3 months post-ablation
62187751|NCT04517383|EXPERIMENTAL|POS group|Patients in the POS group will undergo ET under general anesthesia. After the surgery is done, patients will keep being intubated and mechanically ventilated for 6hrs, during which period the patients will be sedated with sedatives to maintain a BIS value of 50\~70 and Ramsay sedation score of 5 \~ 6. The SBP will be controlled between 120 \~ 180mmHg with vasoactive drugs. After 6hs, the patients will be recovered and extubated.
62187752|NCT04517383|ACTIVE_COMPARATOR|Con group|Patients in the Con group will undergo ET under general anesthesia and will be routinely recovered and extubated immediately after the surgery is done. The SBP will be controlled between 120 \~ 180mmHg with vasoactive drugs for at least 7hrs after the surgery.
62571019|NCT04824430||SLH 6M|Second look hysteroscopy (SLH) performed 6 months post-ablation
62777848|NCT01426477||Veritas Collagen Matrix|Observational study of subjects who undergo open ventral hernia repair using Veritas Collagen Matrix in an underlay technique.
62187753|NCT03860090|ACTIVE_COMPARATOR|AXILLARY VEIN ACCESS|This group of subjects will receive the implant of device via fluoroscopy-guided axillary puncture technique.
62777849|NCT05930236|EXPERIMENTAL|ultrasound guided infiltration verified by fluoroscopy|The 22G needle is introduced along a caudal-cranial axis to infiltrate at each level a volume of 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol (Methylprednisolone) 40mg with 1mL of Omnipaque (contrast product). At each level, contrast medium will be injected at the same time as the linisol-depomedrol mixture so that once the BBM under ultrasound is completed, an X-ray check is performed.
62571020|NCT04824430||SLH 12M|Second look hysteroscopy (SLH) performed 12 months post-ablation
62777850|NCT00609661||1|Patients presenting to the Ohio State University Emergency Department or directly admitted to the Ohio State University Burn Unit following thermal burn.
62571021|NCT05547139|NO_INTERVENTION|Usual care group|Infants randomized to this group will receive the present standard of care for weaning respiratory support. This means the attending provider will decide when each infant is ready to be changed from CPAP to nasal cannula and the nasal cannula will be weaned according to an existing unit protocol.
62571022|NCT05547139|ACTIVE_COMPARATOR|Protocol care group|Infants randomized to this group will remain on CPAP until they are at least 32 weeks corrected gestational age or 1250g. At that point, if they meet a set of criteria, they will be transitioned to either 2L nasal cannula if they require supplemental oxygen or room air.
62571023|NCT04849468|ACTIVE_COMPARATOR|Diclofenac (D) group|Diclofenac (D) group which will receive 75 mg (3ml) intramuscular Diclofenac in a 5ml syringe in the holding area 30 minutes before spinal block
62571024|NCT04849468|ACTIVE_COMPARATOR|Saline (S) group|Saline (S) group which will receive 3ml intramuscular saline in a similar 5ml syringe in the holding area 30 minutes before spinal block
62777851|NCT00609661||2|Healthy volunteers
62002430|NCT03808402||Low dose surfactant|Infants who receive a first dose of surfactant between 100 and 130 mg/kg
62571025|NCT02351414||Primary Total Knee Arthroplasty|Single study group previously implanted with the EVOLUTION® TKA System with cruciate sacrificing (CS) inserts
62777852|NCT03815565|EXPERIMENTAL|levobupivacaine 0.125%|continuous femoral block with levobupivacaine 0.125%. Use of PCA pump with the following parameters: 5 ml/h; bolus 5 ml; lockout 30 minutes
62777853|NCT03815565|ACTIVE_COMPARATOR|ropivacaine 0.2%|continuous femoral block with ropivacaine 0.2%. Use of PCA pump with the following parameters: 5 ml/h; bolus 5 ml; lockout 30 minutes
62777854|NCT05443711||obesity|Patients with obesity attended in the High-Risk Obesity clinic of the Complejo ASistencial Universitario de León, 50-60 years-old
62777855|NCT05443711||control|control group of healthy people of the same age group without obesity or cardiovascular risk factors that will be selected among volunteers from the CAULE staff. and University of Leon
62777856|NCT00218972|ACTIVE_COMPARATOR|AIT: aerobic interval training|High intensity interval training on treadmill at \> 90% of maximal HR for four bouts of four minutes with warm up, active pauses and cool down, three times per week for 12 weeks.
62187754|NCT03860090|ACTIVE_COMPARATOR|CEPHALIC VEIN ACCESS|This group of subjects will receive the implant of device via optimized cephalic vein cutdown technique.
62187755|NCT02230462|EXPERIMENTAL|Viewing of cancer excision defect|Patients in this arm of the study will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.
62187756|NCT02230462|NO_INTERVENTION|No viewing of cancer excision defect|Patients in this arm of the study will not be invited to view their cancer excision defect prior to its reconstruction.
62187757|NCT06475794||Patients with osteoporosis group|Osteoporosis patients will be evaluated in terms of pain, foot posture, Q angle and lower limbs muscle strength.
62187758|NCT06475794||Patients with osteoarthritis group|Osteoarthritis patients will be evaluated in terms of pain, foot posture, Q angle and lower limbs muscle strength.
62187759|NCT05379153|EXPERIMENTAL|Arm I (vaginal fractional CO2 laser therapy)|Patients undergo vaginal fractional CO2 laser therapy over 20-30 minutes every 6 weeks for 3 treatments in the absence of disease progression or unacceptable toxicity.
62187760|NCT05379153|SHAM_COMPARATOR|Arm II (placebo)|Patients undergo placebo procedure over 20-30 minutes every 6 weeks for 3 treatments in the absence of disease progression or unacceptable toxicity.
62395738|NCT02133716|EXPERIMENTAL|expressed breast milk|"A single dose of expressed breast milk was administered through a sterile syringe in the mouth 2 minutes before venopuncture to neonates, accompanied at all times provided the technique allows it to non-nutritive sucking and containment.~The doses administered: 0.1ml in infants less than 27 weeks , 0.25 ml for infants 27-31 weeks , 0.5 ml for infants 32-37 weeks."
62187761|NCT01465945|OTHER|Rectal Defect Sutured|The subject will have his/her defect sutured after the rectal tumors have been removed.
62187762|NCT01465945|OTHER|Rectal Defect Unsutured|The defect will be left open and let naturally close after the rectal tumor has been removed by TEM.
62395739|NCT02133716|ACTIVE_COMPARATOR|sucrose 24% oral|"A single dose of sucrose was administered through a sterile syringe in the mouth 2 minutes before venopuncture to neonates, accompanied at all times provided the technique allows it to non-nutritive sucking and containment.~The doses administered: 0.1ml in infants less than 27 weeks , 0.25 ml for infants 27-31 weeks , 0.5 ml for infants 32-37 weeks."
62395740|NCT01379339|EXPERIMENTAL|Cabazitaxel 10mg/m2|"* Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
62395741|NCT01379339|EXPERIMENTAL|Cabazitaxel 12.5mg/m2|"* Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
62395742|NCT01379339|EXPERIMENTAL|Cabazitaxel 15mg/m2|"* Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
62187763|NCT02734186|EXPERIMENTAL|Sh|Mono infected with Schistosoma haematobium
62395743|NCT01379339|EXPERIMENTAL|Cabazitaxel 17.5mg/m2|"* Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
62571026|NCT00813384|EXPERIMENTAL|Dose Escalation|The dose escalation part of the study is aimed at determining the maximum tolerated dose (MTD), if feasible, and evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 208.
62187764|NCT02734186|EXPERIMENTAL|ShMp|Coinfected with Schistosoma haematobium andMansonella perstans
62187765|NCT01519778|EXPERIMENTAL|TR-701 FA|
62187766|NCT02541045|PLACEBO_COMPARATOR|Group 1: Placebo|Placebo
62187767|NCT02541045|EXPERIMENTAL|Group 2: Metadoxine|therapy with metadoxine
62002431|NCT02090452|EXPERIMENTAL|Transmission of vital signs, ecg, chat|Data from patients transported in ambulances with equipment which enables real time transmission of vital signs, ecg and chat from ambulances to the emergency department.
62002432|NCT02090452|NO_INTERVENTION|No transmission of data|Patient transported with conventional ambulances without the possibility to transmit real time patient related data.
62002433|NCT05900479|EXPERIMENTAL|PTSD Service Dog|
62002434|NCT05900479|NO_INTERVENTION|Usual Care|
62002435|NCT02822508|EXPERIMENTAL|BLI801 Laxative (high dose)|BLI801 Laxative (high dose)
62002436|NCT02822508|EXPERIMENTAL|BLI801 Laxative (mid dose)|BLI801 Laxative (mid dose)
62002437|NCT02822508|EXPERIMENTAL|BLI801 Laxative (low dose)|BLI801 Laxative (low dose)
62002438|NCT02822508|PLACEBO_COMPARATOR|BLI801 Placebo|BLI801 Placebo
62395744|NCT01379339|EXPERIMENTAL|Cabazitaxel 20mg/m2|"* Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
62571027|NCT00813384|EXPERIMENTAL|Dose Expansion|The dose expansion will consist of up to 30 subjects and the dose level of AMG 208 will be dependent upon emerging safety and PK data from the dose escalation part of the study.
62777857|NCT00218972|ACTIVE_COMPARATOR|MIT, moderate intensity training|Moderate intensity treadmill continuous exercise at 70% of maximum heart rate for 47 minutes (in order to ensure isocaloric training amount), three times per week for 12 weeks.
62777858|NCT00218972|ACTIVE_COMPARATOR|Recommendation of regular exercise|No training intervention, general advice as prescribed in guidelines.
62002439|NCT01394926|EXPERIMENTAL|Arm Number 1|
62002440|NCT04482296|NO_INTERVENTION|SSRI with placebo|50 patients who will receive placebo with SSRIs for 8 weeks
62002441|NCT04482296|ACTIVE_COMPARATOR|SSRI with zinc sulfate|50 patients who will receive SSRIs with zinc sulfate for 8 weeks
62002442|NCT02567513|NO_INTERVENTION|Usual Care control group|Eligible, consented residents continue to receive usual care from nursing home staff and are independently monitored by trained research staff.
62002443|NCT02567513|EXPERIMENTAL|Supplement Intervention|Residents are offered a variety of supplement types and flavors consistent with prescribed orders twice per day (morning and afternoon), five days per week, for 24 consecutive weeks by trained research personnel. Research staff also provide the appropriate level and amount of assistance to encourage consumption.
62002444|NCT02567513|EXPERIMENTAL|Snack Intervention|Residents are offered a variety of snack options (foods and fluids, including supplement) consistent with prescribed orders twice per day (morning and afternoon), five days per week, for 24 consecutive weeks by trained research personnel. Research staff also provide the appropriate level and amount of assistance to encourage consumption.
62187768|NCT06021587||Levosimendan|Major patients in heart failure with impaired LVEF (\< 40%) who have undergone left heart surgery (coronary artery bypass grafting and/or mitral and/or aortic valve replacement) under extracorporeal circulation between 01/01/2018 and 28/02/2022 at different French Hospital, and who have received Levosimendan preoperatively
62395745|NCT04152200|EXPERIMENTAL|Lumasiran|All patients will receive open-label lumasiran.
62395746|NCT03072927||MILD|All Medicare patients treated with MILD as reported via CPT® Code 0275T (or successor code(s)).
62002445|NCT03394872||Drainage group|Patients under mechanical ventilator support due to acute respiratory failure who had significant pleural effusion and drainage plan according to the intensive Care Unit (ICU) protocols decided by primary physician
62571028|NCT03503669|ACTIVE_COMPARATOR|Memory Training|Group memory training will be administered for amnestic mild cognitive impairment (MCI)
62571029|NCT03503669|EXPERIMENTAL|Kundalini yoga and meditation|Participants will engage in weekly yoga classes and daily 12 minute meditation
62571030|NCT04340947|OTHER|Menthol very low nicotine cigarette|Participants will smoke menthol flavored very low nicotine cigarettes in their home environment for 7 days. At the end of 7-days, they will also smoke one menthol flavored very low nicotine cigarette in the laboratory.
62777859|NCT00945932|EXPERIMENTAL|28 day repeat dose|
62002446|NCT00775281||1|
62777860|NCT05220332|EXPERIMENTAL|Heart to Heart|
62002447|NCT00775281||2|
62002448|NCT00775281||3|
62002449|NCT05789836|EXPERIMENTAL|Study Group|This research was planned as a single group pretest-posttest quasi-experimental.
62002450|NCT01369875|EXPERIMENTAL|Standard Young TIL|"Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0~Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)~Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)~Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6"
62002451|NCT01369875|EXPERIMENTAL|ECCE Young TIL|"Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0~Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)~Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)~Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6"
62777861|NCT05220332|ACTIVE_COMPARATOR|Money Smart|
62777862|NCT03459456||OCD subjects|"Subjects meeting inclusion/exclusion criteria with OCD will be exposed to the following:~* Provocation OC task (Provoc)~* Trier Social Stress Test (TSST)~* Exposure provocation task"
62002452|NCT04359368||patients with hypersensitivity reactions to NDIPs|Patients with previous hypersensitivity reaction grades I-IV to intravenous ferric carboxymaltose (Ferinject) or to iron sucrose (Venofer)
62002453|NCT01693328||PecFent®|
62002454|NCT02240888|ACTIVE_COMPARATOR|vaccinated patients|patients with different inflammatory rheumatic disease immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
62002455|NCT02240888|ACTIVE_COMPARATOR|vaccinated controls|healthy controls immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
62002456|NCT02240888|ACTIVE_COMPARATOR|seasonal influenza vaccine|patients with different inflammatory rheumatic diseases immunized with 0,5 mg seasonal influenza vaccine i.m.
62002457|NCT02240888|ACTIVE_COMPARATOR|non-vaccinated controls|healthy controls immunized with 0,5 mg seasonal influenza vaccine i.m.
62002458|NCT01470846|EXPERIMENTAL|APD|patient with epidural analgesia
62002459|NCT01470846|ACTIVE_COMPARATOR|PCA|Patient with morphine analgesia
62002460|NCT00614016|EXPERIMENTAL|single|8 subjects total (6 active and 2 placebo)
62002461|NCT05867147|EXPERIMENTAL|Group 1|Participants will receive VNZ-matching placebo, moxifloxacin-matching placebo and VNZ at different time points.
62002462|NCT05867147|ACTIVE_COMPARATOR|Group 2A|Participants will receive VNZ-matching placebo, moxifloxacin, and moxifloxacin-matching placebo at different time points.
62002463|NCT05867147|ACTIVE_COMPARATOR|Group 2B|Participants will receive VNZ-matching placebo, moxifloxacin-matching placebo and moxifloxacin at different time points.
62002464|NCT01746758|EXPERIMENTAL|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
62002465|NCT01746758|NO_INTERVENTION|Comparison arm|No intervention will be implemented in intervention arm. Data on reproductive health conditions and treatments and data on referrals from drug stores in this arm will be obtained directly from ministry of health registers filled and filed at the dispensary and health centres, plus a tailor-made form which is filled by the dispensary and health centre clinicians whenever they receive a patient in the eligible categories.
62002466|NCT01140477|EXPERIMENTAL|Crystalens toric IOL|Toric Accommodating Lens Crystalens toric silicone multi-piece accommodating IOL (Models AT-50T/AT-52T)
62002467|NCT01140477|ACTIVE_COMPARATOR|Crystalens IOL|Accommodating Lens Crystalens silicone multi-piece accommodating IOL (Models AT-50SE/AT-52SE)
62395747|NCT03072927||Interspinous Process Decompression|All Medicare patients treated with interspinous process decompression (CPT Code 22869 or 22870, or successor code(s)) for the treatment of LSS with NC.
62002468|NCT00743912|EXPERIMENTAL|1|open-label rifaximin 550 mg TID
62002469|NCT01641367|EXPERIMENTAL|Cohort A|"Under Protocol version 1.0:~No resistance to NRTIs, PIs, or NNRTI~• Continue current second-line regimen; NRTIs could be modified~Changed under LOA#2 to:~No LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure~• Continue second-line regimen which may include LPV/RTV; NRTIs could be modified~Changed under LOA#3 to:~No LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure~• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued."
62395748|NCT03962166||Cohort|consecutive adult patients undergoing first-time elective open-heart surgery
62395749|NCT04027582|ACTIVE_COMPARATOR|Low Fidelity Simulator - Wooden block|This simulator consists of a simple series of wooden panels with holes. The resident learns how to manipulate the fiberoptic bronchoscope through the holes.
62002470|NCT01641367|EXPERIMENTAL|Sub-cohort B1|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening~• Best available NRTIs, RAL, \& DRV/RTV~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)~• Best available NRTIs, RAL, \& DRV/RTV"
62395750|NCT04027582|ACTIVE_COMPARATOR|High fidelity Simulator - ORSIM|The ORSIM® bronchoscopy is a virtual reality simulator (Airway Simulation Limited, Auckland, New Zealand). It consists of hardware and software components that interact to create a high-fidelity virtual reality simulation. A replica fiberoptic scope is advanced by the resident through a desktop sensor, which is connected to a laptop computer. The laptop software program provides a virtual airway in which the user must navigate the probe.
62187769|NCT06021587||Control - No Levosimendan|Major patients in heart failure with impaired LVEF (\< 40%) who have undergone left heart surgery (coronary artery bypass grafting and/or mitral and/or aortic valve replacement) under extracorporeal circulation between 01/01/2018 and 28/02/2022 at different French Hospital and who have not received Levosimendan preoperatively
62187770|NCT05328310|ACTIVE_COMPARATOR|Telmisartan|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, telmisartan is given as the primary antihypertensive agent.
62187771|NCT05328310|EXPERIMENTAL|Nebivolol|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, nebivolol is given as the primary antihypertensive agent.
62187772|NCT00207402|ACTIVE_COMPARATOR|rosiglitazone|Treatment with rosiglitazone 4 mg twice a day for 3 months prior to and during the course of 48 weeks of treatment with interferon alfacon-1 15mcg/0.5ml SQ daily and weight-based ribavirin.
62571031|NCT04340947|OTHER|Non-menthol very low nicotine cigarette|Participants will smoke non-menthol flavored very low nicotine cigarettes in their home environment for 7 days. At the end of 7-days, they will also smoke one non-menthol flavored very low nicotine cigarette in the laboratory.
62777863|NCT03459456||Control subjects|"Subjects meeting inclusion/exclusion criteria without OCD (age and gender matched with OCD subjects) will be exposed to the following:~* Provocation OC task (Provoc)~* Trier Social Stress Test (TSST)~* Exposure provocation task"
62777864|NCT01320592|EXPERIMENTAL|PD0332991 and Paclitaxel|PD0332991 in combination with weekly paclitaxel at a fixed dose of 80 mg/m2
62777865|NCT06284733|EXPERIMENTAL|Group A (WBV group)(30 HZ,4 mm ,eyes open)|This group includes 36 patients with unilateral trans-femoral traumatic amputation; they will receive WBV and conservative care.
62777866|NCT06284733|EXPERIMENTAL|Group B (visual feedback-deprived and WBV (VFD WBV) (30 HZ,4 mm ,eyes close)|This group includes 36 patients with unilateral trans-femoral traumatic amputation; they will receive visual feedback-deprived plus WBV (VFDWBV) and conservative care.
62777867|NCT06284733|SHAM_COMPARATOR|Group C(control group (0 Hz, eyes open)|This group includes 36 patients with unilateral trans-femoral traumatic amputation; they will receive conservative care.
62002471|NCT01641367|EXPERIMENTAL|Sub-cohort B2|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening~• ETR, RAL, and DRV/RTV~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)~• ETR, RAL, and DRV/RTV"
62002472|NCT01641367|EXPERIMENTAL|Sub-cohort B3|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening~• RAL, DRV/RTV, and FTC/TDF or TDF+3TC~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)~• RAL, DRV/RTV, and FTC/TDF or TDF+3TC"
62002473|NCT01641367|EXPERIMENTAL|Cohort C|"Under Protocol version 1.0:~Resistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV)~• Best available NRTIs, RAL, and DRV/RTV~Changed under LOA#2:~Resistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure~• Best available NRTIs, RAL, and DRV/RTV"
62002474|NCT01641367|EXPERIMENTAL|Cohort D|"Under Protocol version 1.0:~Multiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:~• Best available regimen, including study-provided and any locally available drugs~Changed under LOA#2:~Not eligible for Cohort A, B, or C:~• Best available regimen, including study-provided and any locally available drugs~Updated under protocol v2.0:~• Best available ART regimen, including study-provided and any locally available non-experimental drugs"
62002475|NCT06270550|EXPERIMENTAL|Dynamic movement intervention based group.|
62002476|NCT06270550|EXPERIMENTAL|Selective physical therapy program based group.|
62002477|NCT03391973|EXPERIMENTAL|Arm 1 - Pembrolizumab|Arm 1 - Pembrolizumab injection dosed at 200 mg given Q3 weeks by IV infusion on Day 1 of each 3 week cycle.
62777868|NCT05325385||OHCA attended by ambulance service|All adults attended by ambulance service where time of collapse and initial rhythm is known.
62777869|NCT03317119|EXPERIMENTAL|Treatment (TAS-102, trametinib)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12 and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62571032|NCT03946319|EXPERIMENTAL|Personalized, Transdiagnostic Assessments|One or more times per day, participants in the Experimental Arm will be presented with a variable-length assessment based on the personalization algorithm. The assessment will include a dynamic number of questions based on personalized relevancy, engagement level, and assessment completion metrics. Questions are scored immediately upon submission, regardless of how many questions are answered. As questions are scored, the personalization algorithm takes the previous responses and response times into consideration when determining what and when to ask additional questions.
62777870|NCT05371548|EXPERIMENTAL|Intervention (SAM app)|"Patients will receive training in and access to the SAM app at discharge. SAM uses prescribed and dispensed medication data to display a continuously updated drug list and provides patients and caregivers with tools to address barriers to adherence.~Drug information: Provides patient-friendly drug monographs. Interaction checker: Generates drug-drug interactions between the patient's medications and other OTC drugs.~Adherence alerts: Uses decision algorithms to alert users to adherence problems with the new regimen.~Side effect checker: Displays possible side effects for each medication and frequency of occurrence.~PIMs alerts: Alerts patients to potentially inappropriate medications in their list.~Pharmacist connect: Connects users with pharmacists through a secured messaging service.~Social connect: Allows users to share medication experiences. Caregiver connect: Allows patients to enroll caregivers who can use the app. Weekly medication schedule \& pill reminders"
62187773|NCT00207402|NO_INTERVENTION|No Avandia|Monitoring period without rosiglitazone for 3 months prior to 48 weeks of interferon alfacon-1 15mcg/0.5ml SQ daily and weight-based ribavirin
62002478|NCT03222375||Autism|Individuals with autism will have either Image converter (iSQUED™) for Hysteresis of Spiral Autowaves, Sound converter (sSQUED™) for Drift of Spiral Autowaves or Electromagnetic converter (eSQUED™) for Annihilation Autowave reverberator.
62002479|NCT01178892|PLACEBO_COMPARATOR|Placebo|
62002480|NCT01178892|EXPERIMENTAL|Omega-3|
62002481|NCT01178892|EXPERIMENTAL|Yoga|
62002482|NCT01178892|EXPERIMENTAL|Exercise|
62002483|NCT01178892|OTHER|Usual Activity 1|Usual Activity 1 and Usual Activity 2 arms will be compared to the Yoga and Exercise arms.
62002484|NCT01178892|OTHER|Usual Activity 2|Usual Activity 1 and Usual Activity 2 arms will be compared to the Yoga and Exercise arms.
62187774|NCT05439473|PLACEBO_COMPARATOR|Placebo|
62187775|NCT05439473|ACTIVE_COMPARATOR|Treatment|
62187776|NCT05462782|EXPERIMENTAL|Active TMS|Older healthy participants will be scanned with MRI and undergo memory task synchronized PAS with an active TMS in each visit with different stimulation localization and ISIs.
62777871|NCT05371548|NO_INTERVENTION|Control (usual care)|Patients will receive usual care at discharge. On study units, medication reconciliation is conducted for all patients. Patients have their community medication list obtained via fax from their community pharmacy. The list is validated by the unit pharmacist who then reconciles it with admission orders, and recommends changes as needed to the attending physician. At discharge, the community drug list is reconciled with medications administered in hospital and the discharge prescription is generated by the attending physician or resident, classifying each medication as new medication, dose modification, discontinued therapy, or continued community medication. The discharge prescription is provided to the patient. Patients fill their discharge prescription at their community pharmacy. If there are questions about changes to the community drug list, the pharmacist will ask the patient, and if not clear will contact the discharging physician.
62002485|NCT06031259|EXPERIMENTAL|Idursulfase-IT|Participants will receive idursulfase-IT once monthly and weekly IV infusions of elaprase at the dose used in previous studies (HGT-HIT-045/SHP609-302) via IDDD until benefit is no longer derived from the treatment, or treatment is no longer tolerable, or up to approximately 10.4 years.
62002486|NCT02361528|EXPERIMENTAL|Leukine|Sargramostim: Leukine (Genzyme USA), 125µg/m2 , once per day during 5 days, by subcutaneous route
62002487|NCT02361528|PLACEBO_COMPARATOR|placebo|placebo, once per day during 5 days by subcutaneous route
62002488|NCT02897596|EXPERIMENTAL|Genotype 1b|Grazoprevir 100 mg/d during 8 weeks. Elbasvir 50 mg/d during 8 weeks.
62002489|NCT02897596|EXPERIMENTAL|Genotype 1a and 4|Grazoprevir 100 mg/d during 12 weeks. Elbasvir 50 mg/d during 12 weeks.
62777872|NCT01726985||Patients hospitalized with CHF|Patients hospitalized with CHF Parameter Based Clinical Disposition
62777873|NCT01219062|PLACEBO_COMPARATOR|control|The patient will be performed spinal anesthesia alone, with postoperative PCA
62777874|NCT01219062|ACTIVE_COMPARATOR|Morphine|The patient will received intrathecal Morphine for 0.1 mg. in Isobaric bupivacaine in spinal anesthesia and postoperative PCA
62777875|NCT01219062|ACTIVE_COMPARATOR|bupivacaine|the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
62187777|NCT05462782|SHAM_COMPARATOR|Sham TMS|Older healthy participants will be scanned with MRI and undergo memory task synchronized PAS with a sham TMS coil in each visit with different ISIs application.
62777876|NCT01626417|NO_INTERVENTION|Patient Population|Chronic post-stroke subjects with varied impairment level, who have completed routine rehabilitative physical therapy.
62777877|NCT00606983|NO_INTERVENTION|1|
62777878|NCT00606983|EXPERIMENTAL|2|oral administration of Tamsulosin
62777879|NCT03837132||Advanced pancreatic cancers|Newly diagnosed patients with advanced pancreatic cancer
62777880|NCT02578173||AVERT PLUS|The AVERT PLUS will be used on the first 10 patients enrolled in the study. The AVERT PLUS is a contrast monitoring system which is used to precisely measure the volume of contrast delivered to the patient.
62777881|NCT02578173||Non device group|The second group of 10 patients will undergo the scheduled angiography using the standard method of measuring contrast dye delivery.
62777882|NCT02950675||Normal Adult|Control:Normal Adult
62777883|NCT02950675||Burn Patient|The burn patient will be identified according to the diagnoses (ICD-9-CM code: 940-949).
62777884|NCT04545463|ACTIVE_COMPARATOR|Insoluble Fibre|Cookies with insoluble fibre (wheat bran)
62002490|NCT05583188|EXPERIMENTAL|Aliya PEF ablation|Pulsed electric field treatment using the Aliya System
62002491|NCT04545515|EXPERIMENTAL|ELX/TEZ/IVA|Participants 6 to less than \<12 year of age and weighing \<30 kilogram (kg) at Day 1 received ELX 100 milligram (mg)/TEZ 50 mg /IVA 75 mg as fixed dose combination (FDC) tablets in the morning and IVA as mono tablet in the evening and those weighing more than or equal to (≥) 30 kg at Day 1 received ELX 200 mg/TEZ 100 mg /IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 96 weeks. Doses were adjusted upward with subsequent changes in weight. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 96 weeks.
62002492|NCT02667938|EXPERIMENTAL|Treatment 1|HCP1303 capsule 5/0.2mg + HCP1303 capsule 5/0.4mg placebo+ HGP1201 placebo
62002493|NCT02667938|EXPERIMENTAL|Treatment 2|HCP1303 capsule 5/0.2mg placebo+ HCP1303 capsule 5/0.4mg + HGP1201 placebo
62002494|NCT02667938|ACTIVE_COMPARATOR|Active Comparator|HCP1303 capsule 5/0.2mg placebo+ HCP1303 capsule 5/0.4mg placebo+ HGP1201
62002495|NCT03242681|EXPERIMENTAL|Endoscopy Assisted Probing|Endoscopy Assisted Probing
62002496|NCT03242681|ACTIVE_COMPARATOR|Simple Probing|Simple Probing
62002497|NCT02254538|EXPERIMENTAL|BILR 355 BS|escalating doses
62002498|NCT02254538|PLACEBO_COMPARATOR|Placebo|
62002499|NCT00895180|EXPERIMENTAL|Group 1|Patients receive ramucirumab IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62002500|NCT00895180|EXPERIMENTAL|Group 2|Patients receive olaratumab IV over 60-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62002501|NCT02634138|EXPERIMENTAL|Intervention|Revitive IX Neuromuscular Electrical Stimulation Device
62187778|NCT03922607|EXPERIMENTAL|Substudy 2: Group 2|Participants with chronic plaque psoriasis will be administered with ABBV-157 dose D or matching placebo on Day 1 through Day 28
62777885|NCT04545463|ACTIVE_COMPARATOR|Soluble Fibre|Cookies with soluble fibre (Psyllium plantago)
62777886|NCT04545463|EXPERIMENTAL|FIBRACEP|Cookies with FIBRACEP
62777887|NCT02708485|NO_INTERVENTION|Control group|No intervention
62777888|NCT02708485|EXPERIMENTAL|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
62777889|NCT03437824|EXPERIMENTAL|Cyanocobalamin|Vitamin B12, 1,000 mg, Once
62777890|NCT03437824|PLACEBO_COMPARATOR|Placebo|Normal Saline Solution (0.9% Sodium Chloride), Once
62777891|NCT04878952|NO_INTERVENTION|Arm I: Usual Care|Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy.
62777892|NCT04878952|EXPERIMENTAL|Arm II: Usual Care + Continuous physical activity monitoring via a wearable device|Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy along with continuous physical activity monitoring via a wearable device.
62777893|NCT02950376||Group1：amphetamine abusers|
62777894|NCT02950376||Group2: health control|
62777895|NCT02950376||Group3: norm of assessment system|
62777896|NCT05359601|EXPERIMENTAL|24-hour|Every 24-hour infusion set replacement
62777897|NCT05359601|PLACEBO_COMPARATOR|96-hour|Every 96-hour infusion set replacement
62571033|NCT03946319|ACTIVE_COMPARATOR|Monotopic Assessments|Once daily, participants in the Control Arm will be presented with the standard of care mental health surveillance assessments identified as relevant upon intake. The assessments will be scored in totality or not at all and have a fixed, predefined number of questions. No personalization of assessment will take place.
62571034|NCT03105180||0% dilution|Blood specimen which was diluted with 0% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
62187779|NCT03922607|EXPERIMENTAL|Substudy 2: Group 1|Participants with chronic plaque psoriasis will be administered with ABBV-157 dose C or matching placebo on Day 1 through Day 28
62571035|NCT03105180||10% dilution|Blood specimen which was diluted with 10% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
62002502|NCT04029467|ACTIVE_COMPARATOR|Precedex|participants will receive an ESP block with 20 ml Ropivacaine 0.375% in the induction room 20 minutes before their operation
62002503|NCT04029467|EXPERIMENTAL|Dexmedetomidine|participants will receive an ESP block with 20 ml Ropivacaine 0.375% + 0.5mcg/kg dexmedetomidine in the induction room 20 minutes before their operation
62002504|NCT05122949|EXPERIMENTAL|Adults with neurological disorders|
62002505|NCT02133729|EXPERIMENTAL|Gestational diabete|
62571036|NCT03105180||20% dilution|Blood specimen which was diluted with 20% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
62571037|NCT03105180||40% dilution|Blood specimen which was diluted with 40% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
62571038|NCT06384404||Osteosarcoma|Patients with newly diagnosed osteosarcoma
62777898|NCT03221361|ACTIVE_COMPARATOR|Thermoplastic resin group|Thermoplastic complete denture placement is done
62777899|NCT03221361|PLACEBO_COMPARATOR|conventional acrylic resin group|conventional acrylic resin complete denture placement is done
62777900|NCT02643342|NO_INTERVENTION|Single-vision glasses|Subjects wearing single-vision glasses CR-39 of refractive index 1.56.
62777901|NCT02643342|SHAM_COMPARATOR|Orthokeratology with normal compression factor|Subjects wearing orthokeratology lenses of normal compression factor about 0.50-0.75D.
62777902|NCT02643342|ACTIVE_COMPARATOR|Orthokeratology with increased compression factor|Subjects wearing orthokeratology lenses of increased compression factor about 1.50-1.75D.
62002506|NCT01445392|EXPERIMENTAL|1|Multi-cycle cohort
62187780|NCT03922607|EXPERIMENTAL|Substudy 1: Group 3|Participants, who are healthy volunteers, will be administered with ABBV-157 dose C or matching placebo on Day 1 through Day 14
62002507|NCT01445392|EXPERIMENTAL|2|Single cycle cohort
62002508|NCT03863210|EXPERIMENTAL|Participants who received informations about lifestyle change|
62187781|NCT03922607|EXPERIMENTAL|Substudy 1: Group 2|Participants, who are healthy volunteers, will be administered with ABBV-157 dose B or matching placebo on Day 1 through Day 14
62571039|NCT01866462|EXPERIMENTAL|Metformin, NM504|metformin 500mg b.i.d. with NM504 b.i.d. for 1 week followed by metformin 500mg t.i.d. with NM504 b.i.d. for 1 week.
62571040|NCT01866462|PLACEBO_COMPARATOR|Metformin, Placebo|metformin 500mg b.i.d. with Placebo b.i.d. for 1 week followed by metformin 500mg t.i.d. with Placebo b.i.d. for 1 week.
62777903|NCT03228212|EXPERIMENTAL|TEST/CONTROL/CONTROL|Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old. Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis. Subjects will be randomly assigned to one of the two lens wear sequences, (TEST/CONTROL/CONTROL)
62777904|NCT03228212|EXPERIMENTAL|CONTROL/TEST/TEST|Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old. Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis. Subjects will be randomly assigned to one of the two lens wear sequences, (CONTROL/TEST/TEST)
62777905|NCT01008085|EXPERIMENTAL|Self-expanding stent|Stentys stent
62777906|NCT01008085|ACTIVE_COMPARATOR|Balloon-expandable stent|VISION/Driver
62777907|NCT05238805|OTHER|Observational heart and kidney metabolism|Participants will have a PET scan with 11C-Acetate followed by a TEP Scan with 11C-Acetoacetate all in the same day.
62777908|NCT04629846|EXPERIMENTAL|Trastuzumab Plus（+） QL1209 + Docetaxel|Prior to surgery: trastuzumab, QL1209, and docetaxel for 4 cycles (1 cycle = 21 days) Drug: Docetaxel Drug: QL1209 Drug: Trastuzumab Procedure: Surgery
62571041|NCT02448394|EXPERIMENTAL|Intervention|At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. Strong preference will be given to matching CSWs and clients from the same kebele (village or neighborhood of residence). CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
62571042|NCT02448394|NO_INTERVENTION|Standard of Care|At control sites, patients will receive standard of care facility-based medical care and counseling, consistent with general standards of care offered to HIV patients throughout the country as determined by the Ethiopian Ministry of Health.
62777909|NCT04629846|ACTIVE_COMPARATOR|Trastuzumab Plus（+） Pertuzumab + Docetaxel|Prior to surgery: trastuzumab,pertuzumab , and docetaxel for 4 cycles (1 cycle = 21 days) Drug: Docetaxel Drug: Pertuzumab Drug: Trastuzumab Procedure: Surgery
62777910|NCT04084847|ACTIVE_COMPARATOR|Barberry|Daily consumption of barberry in powder form.
62777911|NCT04084847|PLACEBO_COMPARATOR|placebo|Daily consumption of placebo powder.
62777912|NCT02562859|EXPERIMENTAL|GLPG1837 as oral suspension fasted|Single dose of 500 mg GLPG1837 as oral suspension after an overnight fast
62777913|NCT02562859|EXPERIMENTAL|GLPG1837 as oral tablet fasted|Single dose of 500 mg GLPG1837 as oral tablet after an overnight fast
62777914|NCT02562859|EXPERIMENTAL|GLPG1837 as oral tablet fed|Single dose of 500 mg GLPG1837 as oral tablet after a high-fat high-calorie breakfast
62777915|NCT01071759||pregnancy|
62187782|NCT03922607|EXPERIMENTAL|Substudy 1: Group 1|Participants, who are healthy volunteers, will be administered with ABBV-157 dose A or matching placebo on Day 1 through Day 14
62187783|NCT01863628|PLACEBO_COMPARATOR|psychoeducation|including delivering knowledge on symptoms, discussion of suffering mental difficulties, and general coping techniques
62571043|NCT00263705|EXPERIMENTAL|capecitabine|capecitabine 2000 mg/m² daily
62571044|NCT00687544|EXPERIMENTAL|PEG-IFN + RBV|PEG-IFN + RBV therapy in previously untreated chronic HCV subjects coinfected with HIV
62571045|NCT03455088|EXPERIMENTAL|DBT group|DBT group has 55 patients, maybe will be divided them into 6 groups. Every group has 8-10 patients. Every group receive 12 times DBT group therapy and 1 times a week for 120 minutes each time.
62571046|NCT03455088|ACTIVE_COMPARATOR|Drug therapy group|Drug therapy group has 55 patients, and the investigator may use fluoxetine as treatment drug.
62187784|NCT01863628|EXPERIMENTAL|aerobic exercise|The aerobic exercise would include cycling, jogging, table tennis,and playing badminton for 40 mins at least 3 times per week for 3 months. In each exercise, participants are supposed to exercise to the extent of getting sweaty
62187785|NCT02548676||Glaucoma Patients|Patients with primary open angle glaucoma
62571047|NCT03455088|EXPERIMENTAL|DBT and drug therapy group|DBT and drug therapy group has 55 patients, maybe the investigator can divide them into 7 groups. Every group has 8-10 patients. Every group receive 12 times DBT group therapy and 1 times a week for 120 minutes each time. At the same time, the investigator use fluoxetine as treatment drug.
62571048|NCT02596555|EXPERIMENTAL|Dabigatran treatment|Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
62187786|NCT02548676||Healthy controls|age- and sex matched controls
62571049|NCT01441765|ACTIVE_COMPARATOR|CT-011|CT-011 3 mg/kg for 4 cycles of 6 weeks
62571050|NCT01441765|ACTIVE_COMPARATOR|CT-011 with DC/RCC fusion vaccine|CT-011 with DC/RCC fusion vaccine for subjects undergoing nephrectomy, resection of tumor tissue, or aspiration of malignant effusion
62777916|NCT02551029|EXPERIMENTAL|Duodenal capsaicin infusion|Through a naso-duodenal tube, a capsaicin solution will be infused into the duodenum.
62777917|NCT02551029|PLACEBO_COMPARATOR|Placebo (saline)|Through a naso-duodenal tube, a saline solution will be infused into the duodenum.
62777918|NCT03354624|EXPERIMENTAL|Nerve growth factor group|Three injections of sterile solutions of recombinant human nerve growth factor (NGF) will be performed in the right extensor carpi radialis muscle to induce muscle hyperalgesia.
62777919|NCT03354624|EXPERIMENTAL|Nerve growth factor group + delayed onset muscle soreness|Injections of nerve growth factor and eccentric exercise of the extensor carpi radialis muscle will be performed to induce muscle hyperalgesia.
62777920|NCT00642317||Asian Youth and Tobacco Control|Smoking Questionnaire for self-identified Chinese or Vietnamese participants.
62777921|NCT05946005|EXPERIMENTAL|Honey|Honey is referred to in the Qur'an as a wound healing agent (QS: 16:68 - 69) and has antimicrobial, antioxidant and anti-inflammatory effects. Honey, as an anti-inflammatory, has components of hydrogen peroxide, flavonoids, and phenolic acids that play a role in stimulating angiogenesis (8). Honey also has a high osmolality which provides moisture to the wound, thereby reducing edema and hyperemia and functioning as an antibacterial, so it is expected to reduce the use of antibiotics. Research reported in 2012 stated that honey had the same effect on wound healing and perineal wound pain in postpartum mothers with routine use two times a day for five days (P \< 0.05) (9).
62777922|NCT05946005|EXPERIMENTAL|Lidocaine|Lidocaine is used to reduce sensation in the tissues in certain areas. Lidocaine can be injected or applied topically, depending on the need. These topical anesthetics are popular due to their low cost and minimal side effects. The effect of lidocaine on wound healing is still controversial. A study showed the role of lidocaine in wound healing by significantly reducing wound tensile strength on day eight and increasing collagen maturation (7)
62777923|NCT05946005|EXPERIMENTAL|povidone - iodine|Povidone iodine is an antibacterial and anti-inflammatory agent that accelerates wound healing neovascularization. Several studies have used betadine in postpartum mothers with perineal rupture to provide faster wound healing. A study shows that povidone-iodine cream has a better absorption effect on the skin than betadine solution (10).
62777924|NCT05946005|OTHER|control groups|the control group were not given any intervention
62777925|NCT05688488|EXPERIMENTAL|Curcumin|
62395751|NCT01559584|EXPERIMENTAL|Phototherapeutic|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
62571051|NCT01523782|EXPERIMENTAL|GRASPA 50 IU/kg|Each patient will receive GRASPA 50 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase.
62571052|NCT01523782|EXPERIMENTAL|GRASPA 100 IU/kg|Each patient will receive GRASPA 100 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
62395752|NCT01559584|ACTIVE_COMPARATOR|Conventional therapy|One monthly injections of intralesional potent corticosteroids
62395753|NCT04701931||Subjects presenting with Normal Eyes|Subjects with no known ocular diseases will be imaged on the Maestro2 OCT, Zeiss Cirrus HD-OCT 5000, and TRC-50DX
62395754|NCT04701931||Subjects with retinal pathology present in the eye|Subjects with no known ocular diseases will be imaged on the Maestro2 OCT, Zeiss Cirrus HD-OCT 5000, and TRC-50DX
62395755|NCT04096924|EXPERIMENTAL|Treatment Group|Experimental group is allocated to use novel interventional guidewire for the echocardiography guided percutaneous interventions for ASD.
62395756|NCT04096924|ACTIVE_COMPARATOR|Control Group|Control Group is allocated to use Cook lunderquist guidewire for the echocardiography guided percutaneous interventions for ASD.
62395757|NCT05057494|EXPERIMENTAL|Arm A: Acalabrutinib plus Venetoclax (AV)|Participants will receive acalabrutinib and venetoclax orally.
62395758|NCT05057494|EXPERIMENTAL|Arm B: Venetoclax plus Obinutuzumab (VO)|Participants will receive Venetoclax orally and Obinutuzumab via IV infusion.
62002509|NCT05714579|EXPERIMENTAL|severe aortic stenosis with complete right bundle branch block|patients with aortic stenosis undergoing a Transcatheter Aortic Valve Implantation procedure
62002510|NCT02720575|ACTIVE_COMPARATOR|A|50,000 IU of crystalline D2 in 5 capsules.. Vitamin D2 in its natural state consumed orally via capsule
62002511|NCT02720575|ACTIVE_COMPARATOR|B|50,000 IU of crystalline D3 in 5 capsules.. Vitamin D3 in its natural state consumed orally via capsule
62395759|NCT02545465||BAY63-2521|Patients who have been switched from a Pulmonary Hypertension treatment to Adempas
62571053|NCT01523782|EXPERIMENTAL|GRASPA 150 IU/kg|Each patient will receive GRASPA 150 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
62571054|NCT05424848||patient group|"Inclusion Criteria~1. Having Parkinson's~2. 50-75 years old~Exclusion criteria~1. Limited cooperation~2. The patient has moderate to severe dementia or mental retardation, which may cause limitations in examination, testing and treatment~3. The patient's refusal to participate in the study~4. Application of total joint prosthesis for the knee area~5. Secondary osteoarthritis"
62571055|NCT05424848||Control group|Healthy control group
62777926|NCT05688488|ACTIVE_COMPARATOR|Mitomycin|
62777927|NCT00428870|EXPERIMENTAL|Arthroscopic acromioplasty|Arthroscopic acromioplasty
62002512|NCT02720575|ACTIVE_COMPARATOR|C|50,000 IU of vitamin D2 from vitamin D2 yeast in 5 capsules. Vitamin D generated in yeast. Acts as a comparator to the yeast in bread.
62002513|NCT02720575|ACTIVE_COMPARATOR|D|50,000 IU of vitamin D2 from yeast cell walls in 5 capsules. Yeast cell walls rich in Vitamin D. Acts as a comparator to the yeast in bread.
62002514|NCT02720575|EXPERIMENTAL|E|50,000 IU of vitamin D2 from 2 slices of bread made from bread. Bread raised with yeast rich in vitamin D. Main experimental arm.
62395760|NCT05169229|EXPERIMENTAL|Treatment arm|Combination of vancomycin and tobramycin mixed with allograft and locally administered during revision surgery after total hip arthroplasty.
62395761|NCT05169229|PLACEBO_COMPARATOR|Placebo|Saline locally added to allograft and locally administered during revision surgery after total hip arthroplasty.
62395762|NCT01024816|EXPERIMENTAL|Restorative yoga intervention|
62002515|NCT02720575|EXPERIMENTAL|F|50,000 IU of vitamin D2 from 2 slices of bread. Bread raised with yeast and yeast cell walls rich in vitamin D.
62002516|NCT00519649|EXPERIMENTAL|Group Engerix|Subjects received a single challenge dose of Engerix™ (hepatitis-B \[HBV\] vaccine)
62395763|NCT01024816|ACTIVE_COMPARATOR|Stretching group|
62395764|NCT01337921|EXPERIMENTAL|Multi-strain Synbiotic|Multi-strain probiotic with prebiotics
62395765|NCT01337921|ACTIVE_COMPARATOR|Multi-strain Probiotic|Multi-strain Probiotic without prebiotics.
62777928|NCT00428870|PLACEBO_COMPARATOR|Sham surgery|Shoulder arthroscopy without active treatment and subacromial arthroscopy without bursectomy, decompression or other active interventions
62777929|NCT00428870|ACTIVE_COMPARATOR|Conservative treatment|Standardized exercise rehabilitation (supervised by physiotherapist)
62777930|NCT03051919||no reinforcement|Group I: 25 patients; no reinforcement (NoR) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
62777931|NCT03051919||fibrin glue|Group II: 26 patients; fibrin glue (FG) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
62777932|NCT03051919||suture reinforcement|Group III: 44 patients; suture reinforcement with 2-0 polypropylene suture (S) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
62777933|NCT03051919||biological buttressing materaia|Group IV: 14 patients; biological buttressing material Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
62002517|NCT02529410|EXPERIMENTAL|Triventricular pacing|2 Left ventricular leads and one right ventricular lead
62002518|NCT02529410|ACTIVE_COMPARATOR|Biventricular leads|1 left ventricular lead and one right ventricular lead
62002519|NCT05899504|EXPERIMENTAL|(Interventional) Patients undergoing Esophageal stenting with over the scope clip (OTSC) stent fix|Marking clips will be placed with endoscopy at the upper end of the stricture. In mild stricture cases that allowed the passage of the endoscope, marking clips will also placed in the lower end. A stent that of at least 4 cm longer than the stricture will be used to allow at least a 2-cm extension above and below the proximal and distal tumor margins. The stent positioned over a guidewire and deployed under fluoroscopy guidance and, in some cases, also under endoscopy guidance. Subsequently, the OTSC system will be loaded onto the scope and part of the upper rim of the stent will be suctioned into the transparent cap before releasing the OTSC, grasping both the SEMS and esophageal wall. Investigator will avoid deploying the OTSC in areas of pulsations to prevent potential grasping of the vasculature structure. Only a single OTSC will be placed per participants.
62002520|NCT05899504|NO_INTERVENTION|(Non- Interventional) Participants undergoing Esophageal stenting without OTSC stent fix|This will be the standard procedure of esophageal stent placement under fluro imaging/screening
62002521|NCT00974571|EXPERIMENTAL|1|montelukast
62002522|NCT00974571|ACTIVE_COMPARATOR|2|cetirizine
62002523|NCT00974571|PLACEBO_COMPARATOR|3|placebo
62002524|NCT00006184|EXPERIMENTAL|Recipient - Chemotherapy Group|Induction chemotherapy with fludarabine, etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone, and granulocyte colony stimulating factor (GCSF) followed by transplant preparative regimen chemotherapy with fludarabine, cyclophosphamide, mesna, cyclosporine, and methotrexate, followed by stem cell infusion and immunization.
62002525|NCT00006184|OTHER|Donor - Vaccine Generation Group|3 subcutaneous injections of myeloma protein within 10 weeks before stem cell collection. The first (week 0) second (week 2), and third injection (week 6) with Id-KLH (Anti-idiotype-keyhole limpet hemocyanin) (0.5 mg subcutaneous day 1) and Granulocyte macrophage-colony stimulating factor (GM-CSF) (250 mcg/m\^2 subcutaneous on days 1-4). Stem cell collection is 4 weeks after the third vaccination.
62002526|NCT00395239|EXPERIMENTAL|1|
62002527|NCT05433220|EXPERIMENTAL|Alert when provider is entering orders|
62002528|NCT05433220|NO_INTERVENTION|No alert, usual care|
62395766|NCT06724484||Fragility fracture receiving surgery|In this group, patients who sustain a fragility fracture and receive surgical intervention will be recruited.
62395767|NCT06724484||Control|In this group, patients who sustain fragility fracture and receive conservative (non-surgical) management will be recruited.
62395768|NCT06196463|ACTIVE_COMPARATOR|(AG+ESP) Group|In AG+ ESP Group , the ESP block and the General anesthesia will be performed together in the same patient
62395769|NCT06196463|SHAM_COMPARATOR|AG Group|In AG Group the ESP block wont' be performed, but only a shamed block, realized through 4 skin puncture
62571056|NCT03059043|EXPERIMENTAL|viscoelastic-free system|Eyes in this group will use viscoelastic-free implantation system during the surgery
62002529|NCT00355238|EXPERIMENTAL|1|no comparator to brivanib
62002530|NCT01420302|EXPERIMENTAL|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
62002531|NCT01420302|ACTIVE_COMPARATOR|Nurse-directed|Nurse-directed blood glucose control (80-110 mg/dL)
62002532|NCT04772534|EXPERIMENTAL|3-dose in 9 to 15 year old boys|9 to 15 year old boys will receive a 3-dose regimen of 9-valent human papillomavirus (9vHPV) vaccine (Day 1, Month 2 and Month 6).
62002533|NCT04772534|EXPERIMENTAL|2-dose in 9 to 14 year old boys|9 to 14 year old boys receive a 2-dose regimen of 9vHPV vaccine (Day 1 and Month 6).
62002534|NCT04772534|EXPERIMENTAL|2-dose in 9 to 14 year old girls|9 to 14 year old girls receive a 2-dose regimen of 9vHPV vaccine (Day 1 and Month 6).
62002535|NCT00976534|EXPERIMENTAL|1|
62002536|NCT00976534|PLACEBO_COMPARATOR|2|
62002537|NCT05425901|EXPERIMENTAL|IBD|active or quiescent
62002538|NCT05425901|ACTIVE_COMPARATOR|control|polyp screening
62002539|NCT00750854|EXPERIMENTAL|NEM Treatment 1|NEM Formulation X (#0802), 500 mg, once daily, orally
62002540|NCT00750854|EXPERIMENTAL|NEM Treatment 2|NEM Formulation Y (#0505), 500 mg, once daily, orally
62002541|NCT03343769||Patient|
62002542|NCT03343769||Control|
62395770|NCT00496691|EXPERIMENTAL|1|Parent-child
62777934|NCT02780414||Study Cohort|A group of at least 1,541 pregnant women with NO Pre-E diagnosis
62187787|NCT04248907|EXPERIMENTAL|Socket A|To eliminate variables while casting the student investigators will be using a system very similar to that of Ossur's ICEX, developed in Reykjavik, Iceland. The ICEX system uses an air bladder system that allows a socket to be constructed directly onto the residuum; resulting in even pressure distribution during the time of casting. The ICEX system will ensure that the student investigators are obtaining consistent socket pressures and that the team will be precisely testing the distraction values on the multiple sockets obtained in this experiment. During this experiment, the researchers will be using a modified air bladder system.
62187788|NCT04248907|ACTIVE_COMPARATOR|Socket B|To eliminate variables while casting the student investigators will be using a system very similar to that of Ossur's ICEX, developed in Reykjavik, Iceland. The ICEX system uses an air bladder system that allows a socket to be constructed directly onto the residuum; resulting in even pressure distribution during the time of casting. The ICEX system will ensure that the student investigators are obtaining consistent socket pressures and that the team will be precisely testing the distraction values on the multiple sockets obtained in this experiment. During this experiment, the researchers will be using a modified air bladder system.
62187789|NCT04248907|ACTIVE_COMPARATOR|Socket C|To eliminate variables while casting the student investigators will be using a system very similar to that of Ossur's ICEX, developed in Reykjavik, Iceland. The ICEX system uses an air bladder system that allows a socket to be constructed directly onto the residuum; resulting in even pressure distribution during the time of casting. The ICEX system will ensure that the student investigators are obtaining consistent socket pressures and that the team will be precisely testing the distraction values on the multiple sockets obtained in this experiment. During this experiment, the researchers will be using a modified air bladder system.
62187790|NCT04974723||Patients Treated with Abaloparatide|Patients who filled ≥ 1 prescription for ABL (TYMLOS) as their index medication during the identification period.
62187791|NCT04974723||Patients Treated with Teriparatide|Patients who filled ≥ 1 prescription for TPTD (Forteo) as their index medication during the identification period.
62187792|NCT02166476|EXPERIMENTAL|Meropenem-Vaborbactam|Meropenem-vaborbactam (meropenem 2 grams \[g\] plus vaborbactam 2 g), infused in 250 milliliters (mL) normal saline, administered intravenously (IV) over 3 hours, every 8 hours (q8h), with 100 mL saline administered over 30 minutes q8h. Levofloxacin tablets administered orally as a 500-milligram (mg) dose every 24 hours (q24h) after a minimum of 15 doses of IV meropenem-vaborbactam plus saline, if clinically indicated. Total treatment was 10 days, unless a participant had baseline bacteremia where up to 14 days of therapy could be administered IV.
62187793|NCT02166476|ACTIVE_COMPARATOR|Piperacillin-Tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g), infused in 100 mL normal saline, administered IV over 30 minutes, q8h, with 250 mL saline administered over 30 minutes q8h. Levofloxacin tablets administered orally as a 500-mg dose q24h after a minimum of 15 doses of IV piperacillin-tazobactam plus saline, if clinically indicated. Total treatment was 10 days, unless a participant had baseline bacteremia where up to 14 days of therapy could be administered IV.
62187794|NCT05115708|ACTIVE_COMPARATOR|Kahook dual blade ab-interno Trabeculotomy|The Kahook dual blade® (KDB) assisted ab-interno trabeculotomy
62395771|NCT00496691|ACTIVE_COMPARATOR|2|Adolescent only intervention focusing on condom use skills and assertiveness training around sexual discussions
62395772|NCT00496691|PLACEBO_COMPARATOR|3|Health promotion intervention including general health promotion topics such as smoking, diet, exercise, etc.
62395773|NCT04067310|EXPERIMENTAL|Group Experimental|Participants who will use the spray skin protector
62571057|NCT03059043|ACTIVE_COMPARATOR|viscoelastic-assisted system|Eyes in this group will utilize the standard viscoelastic-assisted Implantation system during the surgery
62777935|NCT02780414||Positive Pre-E Control|A group of at least 250 pregnant women diagnosed with Pre-E
62395774|NCT04067310|ACTIVE_COMPARATOR|Group control|Participants who will use moisturizer Dnativ Revita Derm.
62395775|NCT03914703||EZ Pass Suture Passer|Patients who have surgery using the EZ Pass Suture Passer Instrument either in rotator cuff or soft tissue repair
62395776|NCT03914703||Precision Flexible Reamer|Patients who have surgery using the Precision Flexible Reamer Instrument in ACL repair
62395777|NCT00250731|EXPERIMENTAL|1|Telephone support and behavior change for couples
62395778|NCT00250731|ACTIVE_COMPARATOR|2|Telephone support and behavior change for individuals
62395779|NCT00250731|PLACEBO_COMPARATOR|3|Limited diabetes self-management education
62395780|NCT06037863|ACTIVE_COMPARATOR|Arm I (bladder filling, CT, radiation)|Patients perform SOC bladder filling and then undergo CT and radiation therapy in 2-39 fractions at the discretion of the treating clinician on study.
62395781|NCT06037863|EXPERIMENTAL|Arm II (bladder emptying, CT, radiation)|Patients perform bladder emptying and then undergo CT and radiation therapy in 2-39 fractions at the discretion of the treating clinician on study.
62395782|NCT01760317|ACTIVE_COMPARATOR|Midline|Midline Lumbar Epidural Steroid Injection
62571058|NCT05822076||L - paravertebral block left|30 woman above 18 years of age qualified for elective breast surgery on the left side of the body
62777936|NCT06418451|ACTIVE_COMPARATOR|sacrospinous ligament fixation (SLFF)|
62777937|NCT06418451|EXPERIMENTAL|modified ischial spinous fascia fixation (modified ISFF)|
62777938|NCT02146625|EXPERIMENTAL|Dose level 1 of CJ-40002|"* Single dose~* 8 volunteers will be administered dose level 1 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
62777939|NCT02146625|EXPERIMENTAL|Dose level 2 of CJ-40002|"* Single dose~* 8 volunteers will be administered dose level 2 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
62777940|NCT02146625|EXPERIMENTAL|Dose level 3 of CJ-40002|"* Single dose~* 8 volunteers will be administered dose level 3 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
62571059|NCT05822076||P - paravertebral block right|30 woman above 18 years of age qualified for elective breast surgery on the right side of the body
62187795|NCT05115708|ACTIVE_COMPARATOR|ab externo viscotrabeculotomy|In brief, a fornix-based conjunctival incision is followed by fashioning and dissection of a triangular scleral flap. Radial incisions at the limbus followed to identify Schlemm's canal. viscotrabeculotomy, is performed by injection of high-viscosity sodium hyaluronate (Healon GV, Pfizer, NY) into Schlemm's canal prior to completion of the procedure with the metal trabeculotome. while a Nylon 10/0 suture in inserted into schlemm's canal in visco-circumferential-suture trabeculotomy group.
62187796|NCT01386723||Discontinuation of eltrombopag|ITP subjects who have discontinued the use of eltrombopag
62187797|NCT02938897|EXPERIMENTAL|Telenutrition Intervention|Participants receive diet-related educational materials and self-monitoring tools PLUS registered dietitian nutritionist support.
62187798|NCT02938897|ACTIVE_COMPARATOR|Enhanced Usual Care Control|Participants receive diet-related educational materials and self-monitoring tools.
62187799|NCT00546247|EXPERIMENTAL|1|
62187800|NCT02864823|EXPERIMENTAL|Perichondrium|Perichondrium Autografts
62187801|NCT03834623|EXPERIMENTAL|CC-122 Plus Nivolumab|Participants will take CC-122 orally at 2mg daily for 5 consecutive days every 7 days, with intravenous nivolumab (240mg) in days 1 and 15 within a 28-day cycle.
62187802|NCT03527498|EXPERIMENTAL|intervention group|Baby treadmill + physical rehabilitation training
62187803|NCT03527498|ACTIVE_COMPARATOR|positive control group|Physical rehabilitation training only
62187804|NCT05054569|EXPERIMENTAL|10-week eHealth intervention|Weekly video conference groups led by a trained facilitator
62187805|NCT00507156|EXPERIMENTAL|Mek postcon|Re-opening of the infarcted coronary artery by several balloon inflations separated by reperfusion of the vessel.
62395783|NCT01760317|ACTIVE_COMPARATOR|Parasagittal|Parasagittal Lumbar Epidural Steroid Injection
62395784|NCT03088306|ACTIVE_COMPARATOR|Standard analgesia use|A strategy to manage pain in the peri-operative period that is in common clinical use.
62571060|NCT04201574|PLACEBO_COMPARATOR|Vehicle|Vehicle Ophthalmic Solution
62002543|NCT02716233|ACTIVE_COMPARATOR|Arm 1|pegaspargase 2500 IU/m2 x 1: infusion of a conventional dose of pegaspargase during induction therapy: 2500 IU/m2x1
62002544|NCT02716233|EXPERIMENTAL|Arm 2|pegaspargase 1250 IU/m2 x 2: fractionation of the 2500 IU/m2 pegaspargase dose in two infusions of 1250 IU/m2 each
62187806|NCT00507156|ACTIVE_COMPARATOR|Standard treatment|Standard treatment (primary PCI)
62187807|NCT00232219|NO_INTERVENTION|Control|No fish oil exposure
62187808|NCT00232219|EXPERIMENTAL|Fish oil|Patients given 6g/day of fish oil containing 1.8g/d of EPA+DHA in a 1.5:1 ratio.
62187809|NCT04949854|ACTIVE_COMPARATOR|Control Arm B.Braun 6.35 cm 20 Gauge catheter|Device 6.35 cm 20 Gauge B. Braun catheter without guidewire
62187810|NCT04949854|EXPERIMENTAL|Experimental Arm B.D. Accucath 5.71 cm 20 Gauge catheter|Device BD 5.71 cm Accucath IV catheter with guidewire
62395785|NCT03088306|ACTIVE_COMPARATOR|Multi-modal pain management|A strategy to manage pain in the peri-operative period that is in common clinical use that is designed to reduce the need for post-operative opioid medication.
62395786|NCT03251716|EXPERIMENTAL|berberine adjunctive group|Only one treatment group in this study, without a preset control group,subjects who meet the criteria will entere the berberine adjunctive group
62571061|NCT04201574|EXPERIMENTAL|ALY688 0.1%|ALY688 0.1% Ophthalmic Solution
62571062|NCT04201574|EXPERIMENTAL|ALY688 0.4%|ALY688 0.4%Ophthalmic Solution
62571063|NCT03454308|EXPERIMENTAL|SMASH|Automated reminder functions activated on pill monitoring device, motivational text messages, at home BP monitoring
62571064|NCT03454308|OTHER|Enhanced SC|No reminder functions on the pill monitoring device, attention control text messages
62571065|NCT02195869|EXPERIMENTAL|Phase 1b: Dose Level 1|Subjects receive daily dose of 420 mg of Ibrutinib capsules
62187811|NCT01383447|EXPERIMENTAL|Treatment (entinostat and imatinib mesylate)|Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62187812|NCT00949793|EXPERIMENTAL|All patients|
62187813|NCT03739372|EXPERIMENTAL|Newly diagnosed HGG (Stratum A)|Children and young adults with newly diagnosed HGG receive an individualized treatment plan. Each treatment is different and depends on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
62187814|NCT03739372|EXPERIMENTAL|Diffuse midline HGG (Stratum B)|Children and young adults with diffuse midline high grade gliomas receive an individualized treatment plan. Each treatment is different and depends on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
62187815|NCT00420784|EXPERIMENTAL|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 24 weeks.
62571066|NCT02195869|EXPERIMENTAL|Phase 1b: Dose Level 2|Subjects receive daily dose of 280 mg of Ibrutinib capsules
62571067|NCT02195869|EXPERIMENTAL|Phase 1b: Dose Level 3|Subjects receive daily dose of 140 mg of Ibrutinib capsules
62571068|NCT02195869|EXPERIMENTAL|Phase 2|Subjects receive daily dose of recommended phase 2 dose
62571069|NCT05693064|EXPERIMENTAL|Wait-list followed by chiropractic|
62571070|NCT02307942|EXPERIMENTAL|SURGERY|Patient will be operated for a gastric banding disposal
62571071|NCT02307942|NO_INTERVENTION|STANDARD|Standard of care for obesity
62187816|NCT00420784|EXPERIMENTAL|Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week|Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 48 weeks.
62571072|NCT04793711|EXPERIMENTAL|EpiCeram|Open-Label, 3 (three) times per day, topical, to hands and face, for 28 days.
62571073|NCT05969041|EXPERIMENTAL|A (MT-302)|Participants will receive MT-302 through intravenous infusion.
62187817|NCT00420784|EXPERIMENTAL|Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week|Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.
62187818|NCT00420784|PLACEBO_COMPARATOR|PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 48 weeks.
62395787|NCT03806166|EXPERIMENTAL|Shorter Systemic Antibiotics|Participants will receive local antibiotic therapy at the time of surgery, followed by one week or less of systemic antibiotic therapy, for bone and joint infection.
62395788|NCT03806166|ACTIVE_COMPARATOR|Long Systemic Antibiotics|Participants will receive local antibiotic therapy at the time of surgery, followed by four weeks or more of systemic antibiotic therapy (standard treatment recommended by international guidelines), for bone and joint infection.
62395789|NCT02852876|EXPERIMENTAL|Part 1: ASP2151 Single Ascending Dose Group A (Fasting)|Participants will receive single dose of ASP2151 assigned to Group A on day 1
62395790|NCT02852876|EXPERIMENTAL|Part 1: ASP2151 Single Ascending Dose Group B (Fasting)|Participants will receive single dose of ASP2151 assigned to Group B on day 1
62571074|NCT00521820|EXPERIMENTAL|Pioglitazone QD|
62187819|NCT04155034|ACTIVE_COMPARATOR|Arm I (PCI, MRI)|Patients undergo conventional or hippocampal avoidance PCI over 20 minutes 5 days per week for 2 weeks. Patients also undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
62571075|NCT00521820|ACTIVE_COMPARATOR|Glyburide QD|
62571076|NCT00586820|EXPERIMENTAL|BQ-123|BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
62187820|NCT04155034|EXPERIMENTAL|Arm II (MRI)|Patients undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
62187821|NCT01729715|EXPERIMENTAL|Internet|Internet site that offers parents tips on promoting sleep in infants and toddlers
62187822|NCT01729715|EXPERIMENTAL|DVD|DVD that offers parents tips on promoting sleep in infants and toddlers
62187823|NCT01729715|NO_INTERVENTION|No treatment|
62395791|NCT02852876|EXPERIMENTAL|Part 1: ASP2151 Single Ascending Dose Group C (Fasting)|Participants will receive single dose of ASP2151 assigned to Group C on day 1
62395792|NCT02852876|EXPERIMENTAL|Part 1: ASP2151 Single Ascending Dose Group D (Fasting)|Participants will receive single dose of ASP2151 assigned to Group D on day 1
62571077|NCT00586820|PLACEBO_COMPARATOR|Placebo|Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
62187824|NCT02119702||Infected Cohort|Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment.
62187825|NCT02119702||Uninfected Cohort|Perinatally HIV-exposed but uninfected participant at or beyond their 18th birthday at enrollment. May have horizontally-acquired HIV infection.
62187826|NCT00717548|EXPERIMENTAL|A|
62571078|NCT02752113|ACTIVE_COMPARATOR|Empagliflozin and Linagliptin|After the 4 weeks run-in phase (stable metformin medication), patients will be consecutively randomized (1:1) to empagliflozin 10 mg and linagliptin 5 mg orally once daily. After 14 days empagliflozin will be up-titrated to 25 mg (once daily), if fasting blood glucose is ≥ 100 mg /dl and no hypoglycemic symptoms are recognized.
62571079|NCT02752113|ACTIVE_COMPARATOR|Metformin and Insulin sc|Metformin p.o. and insulin sc After the 4 weeks run-in phase (stable metformin medication), patients will maintain on their metformin dosage (850 or 1000 mg orally twice daily) and insulin glargine (Lantus™) once daily subcutaneous will be added. Initially 2 - 4 U Lantus™ daily (depending on body weight) will be given, and adjusted every third day (telephone counseling) by adding 2 U if fasting blood glucose is not ≤ 125 mg/dl (16). After a stable dosage (i.e. no change of dosage for 1 week) has been reached, adjustments regarding an increment of Lantus™ will be based on confirmed fasting blood glucose of ≥ 126 mg/dl (on at least two consecutive day).
62571080|NCT06480539|PLACEBO_COMPARATOR|Placebo|The comparator is a placebo, namely pure saline (NaCl 0.9%), which will be administered following the same regimen as the intervention.
62777941|NCT02146625|EXPERIMENTAL|Dose level 4 of CJ-40002|"* Single dose~* 8 volunteers will be administered dose level 4 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
62777942|NCT02146625|EXPERIMENTAL|Dose level 5 of CJ-40002|"* Single dose~* 8 volunteers will be administered dose level 5 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
62571081|NCT06480539|ACTIVE_COMPARATOR|Dexmedetomidine|Nocturnal administration of dexmedetomidine (0.2-1.0 mcg/kg/h) during the first night after surgery. Dexmedetomidine infusion, not preceded by a bolus administration, will be started at 0.4 mcg/kg/h in the intervention group at 8 p.m. the day of surgery. Dexmedetomidine infusion will be titrated every 30 minutes with 0.1 mcg/kg/h steps until a RASS of -1 to -3 (drowsy, light to moderate sedation) is reached. The infusion will be discontinued at 6 a.m. the next morning.
62395793|NCT02852876|EXPERIMENTAL|Part 1: ASP2151 Single Ascending Dose Group E (Fasting)|Participants will receive single dose of ASP2151 assigned to Group E on day 1
62571082|NCT03291080|EXPERIMENTAL|Liquid|Oral liquid formulation of 13-Cis Retinoic Acid - test product.
62002545|NCT04522037||interventional group|patients hospitalized at the hospices civils of Lyon with a level of care 3 or 4 receiving morphinic treatment for COVID-19 disease dyspnea.
62002546|NCT04522037||control group|patients hospitalized at the hospices civils of Lyon with a level of care 3 or 4 not receiving morphinic treatment for COVID-19 disease dyspnea.
62002547|NCT06371222|ACTIVE_COMPARATOR|controlled group|controlled group
62002548|NCT06371222|EXPERIMENTAL|intervention group|intervention group
62002549|NCT00670800|NO_INTERVENTION|Normal Controls|Control subjects will have 5 visits (screening, oral glucose tolerance test (OGTT), neuropsychological testing, functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) as they will receive no treatment and will not have repeat studies. The baseline values obtained from the control subjects will be compared to the baseline values acquired from the PCOS affected subjects.
62002550|NCT00670800|EXPERIMENTAL|PCOS Affected Women-Metformin Treatment|Subjects with Polycystic Ovary Syndrome (PCOS) will be scheduled for 9 visits total: following the screening visit they will go through OGTT, neuro-psychological testing, fMRI and PET scan before and after 4 months of metformin use: 500mg tablets once daily with breakfast for 1 week, then increased to one tablet twice daily with breakfast \& lunch for 1 week, then increased to one tablet three times daily with breakfast, lunch \& dinner.
62002551|NCT02375672|EXPERIMENTAL|Pembrolizumab (MK-3475) + mFOLFOX6|"Following the safety run-in cohort:~mFOLFOX6 Treatment D1 and D15 (every 2 weeks); Pembrolizumab (MK-3475) IV over 30 minutes (every 3 weeks)"
62002552|NCT05871073|EXPERIMENTAL|Ropivacaine 0.75% Injectable Solution|Wound Infiltration for Postoperative Analgesia After Spinal Surgery
62002553|NCT05871073|EXPERIMENTAL|Dexamethasone 8mg|Wound Infiltration for Postoperative Analgesia After Spinal Surgery
62395794|NCT02852876|EXPERIMENTAL|Part 1: ASP2151 Single Ascending Dose Group F (Fasting)|Participants will receive single dose of ASP2151 assigned to Group F on day 1
62002554|NCT04808479|EXPERIMENTAL|UC imFREE Smartphone application intervention|The imFREE condition is a 32-week tailored, interactive text messaging intervention targeting buprenorphine treatment retention and adherence as well as opioid use and associated health consequences. Following a face-to-face CBT session with a clinician, participants receive CBT skills training via daily text messaging, with content themes around relapse prevention, adherence behaviors, and personalized plans to overcome risk factors for treatment discontinuation.
62002555|NCT04808479|ACTIVE_COMPARATOR|Health Education and pamphlet|The mHealth condition will provide participants with a manualized health psychoeducation session of equivalent duration to the face-to-face CBT session delivered to imFREE participants. Content focuses on various dimensions of health and well-being. Subsequent to this session participants will receive an informational pamphlet regarding BUP and the importance of adherence. the mHealth component of the intervention comprises text reminders for scheduled MM appointments.
62002556|NCT05470439|EXPERIMENTAL|MI-CARE Intervention|Pharmacist-community health worker team providing coordinated care tailored to high-risk patients with hypertension. MI-CARE intervention participants will meet with the pharmacist-CHW team for medication optimization and tailored case management. Pill counts will be completed to assess adherence and BP will be measured at each visit to guide antihypertensive medication optimization and provide feedback to participants about their adherence and BP control. Intervention visits will be followed by a booster one month later.
62395795|NCT02852876|PLACEBO_COMPARATOR|Part 1: Placebo Single Ascending Dose (Fasting)|Participants will receive single dose of matching placebo on day 1
62395796|NCT02852876|EXPERIMENTAL|Part 2: ASP2151 (Fasting)|Participants will receive a single dose of ASP2151 under fasted conditions on day 1 in the first treatment period (period 1). Following a wash-out period of at least five days, the treatment will be repeated in the reverse orientation (period 2)
62395797|NCT02852876|EXPERIMENTAL|Part 2: ASP2151 (Fed)|Participants will receive a single dose of ASP2151 under fed conditions on day 1 in the first treatment period (period 1). Following a wash-out period of at least five days, the treatment will be repeated in the reverse orientation (period 2)
62395798|NCT02852876|EXPERIMENTAL|Part 1: ASP2151 Single Ascending Dose Group G (Fasting)|Participants will receive single dose of ASP2151 assigned to Group G on day 1
62395799|NCT02852876|EXPERIMENTAL|Part 1: ASP2151 Single Ascending Dose Group H (Fasting)|Participants will receive single dose of ASP2151 assigned to Group H on day 1
62395800|NCT03929549|EXPERIMENTAL|RCMP titration|Remotely Controlled Mandibular Positioner
62571083|NCT03291080|EXPERIMENTAL|Capsule|Isotretinoin capsules (13-CRA extracted per standard of care)- reference product.
62571084|NCT05990712|EXPERIMENTAL|Omega-3|Participants in this arm will take oral omega-3 supplement for 4 weeks pre-operatively and 4 weeks post-operatively. They will also receive the Zocular intervention in clinic and the lid wipe and Thealoz eyedrops at home.
62395801|NCT03852446|EXPERIMENTAL|Part 1: Single Ascending Dose|
62395802|NCT03852446|EXPERIMENTAL|Part 2: Bioavailability and Food Effect|"1. Single dose of Indoximod HCL (F2) formulation under fasting conditions~2. Single dose of Indoximod HCL (F2) formulation under fed conditions~3. Single dose of Indoximod base formulation under fasting conditions"
62777943|NCT05989958|EXPERIMENTAL|HepaCure|Patients will receive Hepacure treatment on top of DPMAS
62571085|NCT05990712|ACTIVE_COMPARATOR|No Omega-3|Participants in this arm will not take oral omega-3 supplement. They will only receive the Zocular intervention in clinic and the lid wipe and Thealoz eyedrops at home.
62571086|NCT04137081|EXPERIMENTAL|App-based mindfulness training|The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
62571087|NCT04090671|ACTIVE_COMPARATOR|COPD Exacerbation|the questionnaire MDP will be administered at the day of hospital admission and at the day of discharge.
62571088|NCT04090671|ACTIVE_COMPARATOR|CHF|the questionnaire MDP will be administered at the day of hospital admission and at the day of discharge.
62571089|NCT04090671|ACTIVE_COMPARATOR|COPD|In stable state of COPD, the questionnaire MDP will be administered once during a routine control visit at the hospital or the medical practice.
62571090|NCT04090671|ACTIVE_COMPARATOR|OSA|The questionnaire MDP will be administered once during the first visit in the sleep laboratory.
62395803|NCT05725785|OTHER|FOCUS participants|FOCUS is a smartphone application system designed to improve illness self-management and facilitate recovery in individuals with serious mental illness. It delivers both system initiated (i.e. pre-programmed) and patient initiated (i.e. on demand) real-time assessment to individuals in their own environment.
62571091|NCT05904873|EXPERIMENTAL|The group who removed their hands from ice packs before 240 seconds|In our study, a cold pressor test was applied to the participants in order to measure the pain tolerance according to the time duration they could keep their hands on the ice pack before the operation. Participants were prepared for an ice test in another area other than the operation area. Participants were asked to place their hands on standardized ice packs and keep them on the ice pack for 240 seconds. It was also said that if they could not tolerate pain, they could remove their hands from the ice before 240 seconds. The participants were asked to express the pain as a number between 0 (no pain) and 10 (unbearable pain) according to the visual analog scale when they removed their hands from the ice pack. Participants were divided into two groups according to the time duration of ice test as less than 240 seconds and equal to seconds.
62571092|NCT05904873|EXPERIMENTAL|The group that can keep their hands on ice packs for 240 seconds|In our study, a cold pressor test was applied to the participants in order to measure the pain tolerance according to the time duration they could keep their hands on the ice pack before the operation. Participants were prepared for an ice test in another area other than the operation area. Participants were asked to place their hands on standardized ice packs and keep them on the ice pack for 240 seconds. It was also said that if they could not tolerate pain, they could remove their hands from the ice before 240 seconds. The participants were asked to express the pain as a number between 0 (no pain) and 10 (unbearable pain) according to the visual analog scale when they removed their hands from the ice pack. Participants were divided into two groups according to the time duration of ice test as less than 240 seconds and equal to 240 seconds.
62571093|NCT03261778|EXPERIMENTAL|Acromion 2.0 Brace|
62571094|NCT03261778|ACTIVE_COMPARATOR|Mitella Sling|
62571095|NCT01636193||Rota Group|Subjects will receive Rotarix® as per routine practice.
62395804|NCT01040507||primary laparoscopic gastric bypass|
62777944|NCT00171847|EXPERIMENTAL|A - HER-2 +ve patients with Femara alone|
62777945|NCT00171847|EXPERIMENTAL|B - HER-2 +ve patients with Femara + Herceptin|
62002557|NCT05470439|NO_INTERVENTION|Waitlist Control|Participants enrolled in this arm will receive usual medical care
62002558|NCT01403090|EXPERIMENTAL|Angel Catheter|
62002559|NCT01748786|EXPERIMENTAL|Mindfulness Emotion Regulation|12 on-line modules targeting social and emotional regulation through mindfulness training
62002560|NCT01748786|PLACEBO_COMPARATOR|Placebo|12 on-line modules providing information regarding health behaviors
62395805|NCT04762810|EXPERIMENTAL|Cyclophosphamide and Glucocorticoids|Through the selective depletion of proliferating lymphocytes, cyclophosphamide has an inhibitory effect on both humoral and cellular immunity. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
62777946|NCT00171847|EXPERIMENTAL|C - HER-2 -ve patients with Femara alone|
62777947|NCT04033783|EXPERIMENTAL|6MWT - assessor walks behind the patient|In this experimental condition, the assessor walks behind the patient to continuously measure oxygen saturation during the test (recommended procedure)
62777948|NCT04033783|ACTIVE_COMPARATOR|6MWT - assessor does not walk behind the patient|In this experimental condition, the assessor does not walk behind the patient. The patient carries the pulse oximeter to continuously measure oxygen saturation during the test.
62395806|NCT04762810|ACTIVE_COMPARATOR|Glucocorticoids monotherapy|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
62002561|NCT05850156||Adult sickle cell patients|In the context of routine care, 3 blood collection will be performed on adult sickle cell patients for the analysis of hemoglobin fractions. For each blood collection, an additional volume of blood will be taken for the research purposes.
62002562|NCT05850156||pediatric sickle cell patients|In the context of routine care, 3 blood collection will be performed on pediatric sickle cell patients for the analysis of hemoglobin fractions. For each blood collection, an additional volume of blood will be taken for the research purposes.
62002563|NCT05850156||Adult sickle cell carriers (heterozygous patients)|In the context of neonatal screening for sickle cell disease, the parents will be called altogether with their children in order to check if they are sickle cell carriers or not. Only 1 blood collection will be performed for this group.
62002564|NCT05850156||Control patients|In the context of neonatal screening for sickle cell disease, the parents will be called altogether with their children in order to check if they are sickle cell carriers or not. Only 1 blood collection will be performed for this group.
62002565|NCT04683991|EXPERIMENTAL|treatment group 1|At the same time of implant implantation, autologous tissue is transplanted into the recipient area by using Subepithelial connective tissue graft.
62002566|NCT04683991|EXPERIMENTAL|treatment group 2|During the second stage operation, autologous tissue is transplanted into the recipient area by using Subepithelial connective tissue graft.
62002567|NCT05973591||achieved HR ≥ 70 bpm without ivabradine|\*\*Achieved HR : heart rate (HR) at 12 month follow up after the initiation of GDMT\*\*
62002568|NCT05973591||achieved HR < 70 bpm without ivabradine|\*\*Achieved HR : heart rate (HR) at 12 month follow up after the initiation of GDMT\*\*
62002569|NCT05973591||achieved HR ≥ 70 bpm with ivabradine|\*\*Achieved HR : heart rate (HR) at 12 month follow up after the initiation of GDMT\*\*
62002570|NCT05973591||achieved HR < 70 bpm with ivabradine|\*\*Achieved HR : heart rate (HR) at 12 month follow up after the initiation of GDMT\*\*
62002571|NCT04976491||CD-C-Food group|During the first 3 months，participants received EEN；In the second 3months , CD-C-Food group received received CD-C-food .
62002572|NCT04976491||EEN group|During the period, participants received EEN for 6 months.
62002573|NCT04126512||Bedside ligation|Infants admitted to St. Orsola-Malpighi Hospital (SOM) NICU had their PDA ligated at bedside, with a timing of surgery dependent on the time schedule of the surgeons and anaesthesiologists.
62395807|NCT01444599||low FFR group (<0.8)|the patient with FFR values less than 0.8
62395808|NCT01444599||high FFR group (>0.8)|the patient with FFR values greater than 0.8
62395809|NCT04099329|EXPERIMENTAL|Pre-game Safety Huddles|Pre-game safety huddles will occur before each game and athletes and coaches will be surveyed.
62777949|NCT02396368|EXPERIMENTAL|Radium 223 and Tasquinimod|"During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day.~Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks)."
62777950|NCT04266236|ACTIVE_COMPARATOR|L3 LPB technique (P group)|ultrasound-guided shamrock approach L3 lumbar plexus block with single-needle technique
62777951|NCT04266236|ACTIVE_COMPARATOR|T12 combined with L3 and L4 LPB technique (TP group)|ultrasound-guided posterior approach thoracic 12 combined with L3 and L4 lumbar plexus block with mulitple-needle technique
62777952|NCT04266236|EXPERIMENTAL|L3 LPB combined with QLB (LPQLB-SNT, PQ group)|ultrasound-guided shamrock approach L3 lumbar plexus block combined with quadratus lumborum block with single-needle technique
62777953|NCT05082415||Brolucizumab|Participants received brolucizumab injection during the index period
62777954|NCT02469519|EXPERIMENTAL|Betamethasone - ACTIVE|Booster Course of Antenatal Steroids consists of Betamethasone \[12 mg intramuscular injection, 24 hours apart X 2 doses\] or if unavailable may give Dexamethasone \[6 mg intramuscularly 12 hours apart x 4 doses\]
62187827|NCT03085199|OTHER|Laparoscopic reinforcement suture|After cutting of duodenal stump of about 2 cm length using linear stapler, laparoscopic reinforcement suture commenced from upper to lower part on staple-line of duodenal stump. Continuous suture with invagination was performed using a barbed suture. In case of patient with short duodenal stump because of chronic ulcer or ectopic pancreas at duodenal bulb, 2 or 3 interrupted sutures without invagination of duodenal stump was conducted using barbed sutures.
62777955|NCT02469519|PLACEBO_COMPARATOR|normal saline - PLACEBO|Normal saline of equivalent volume given intramuscularly at the equivalent dosing regimes listed in experimental arm.
62002574|NCT04126512||Referred to specialist paediatric cardiac surgery centre|Due to the unavailability of local cardiac surgery, infants admitted to the Cambridge University Hospital (CUH) NICU were referred to specialist paediatric cardiac surgical centres, where PDA ligation was performed. In these cases, the surgical timing depended on both bed availability at the referral centre and the availability of the neonatal transfer team.
62002575|NCT04774159|ACTIVE_COMPARATOR|Colchicine|Colchicine 0.5mg daily for the duration of the trial
62002576|NCT04774159|PLACEBO_COMPARATOR|Colchicine-Placebo|Colchicine-Placebo daily
62187828|NCT00799955|PLACEBO_COMPARATOR|1|Subjects will receive 100 micrograms of spinal morphine, at the time of spinal needle insertion (standard care at BCW). At the end of the case, one of two investigators, using ultrasound, will visualize the transversus abdominis plane. A capped needle will be pushed against the skin to mimic the pressure sensation of the TAP block. The needle will not break the skin and nothing will be injected in this control group. The procedure will then be repeated on the other side. A dressing will be applied on each side to blind the subject and researcher to which group she is in.
62395810|NCT04099329|NO_INTERVENTION|Control|No intervention will be delivered by athletes and coaches will be surveyed.
62395811|NCT01062230|EXPERIMENTAL|All patients|All participants enrolled.
62395812|NCT06605131|EXPERIMENTAL|GP combined with Toripalimab + CCRT|"1. Induction Chemotherapy (GP Regimen combined with Toripalimab)~   * GP Regimen: Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles~  * Toripalimab: For patients weighing ≥ 40 kg: 240 mg on Day 1; For patients weighing \< 40 kg: 3 mg/kg; every 3 weeks for 3 cycles~2. Concurrent Chemoradiotherapy (CCRT):~Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles"
62395813|NCT06605131|ACTIVE_COMPARATOR|GP regimen + CCRT|"1. Induction Chemotherapy (GP Regimen):~   Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3, every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT):~Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy, every 3 weeks for 3 cycles."
62395814|NCT04556149||Case|Inpatients with confirmed COVID-19 with pulmonary symptoms
62395815|NCT04556149||Matched Control|Inpatients without COVID-19 with non-pulmonary diagnoses or symptoms
62395816|NCT03007732|EXPERIMENTAL|Cohort 1: Prostate Only Sites (ADT, SBRT, Pembrolizumab)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.~Pembrolizumab: Given IV every 21 days for up to 13 doses~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
62395817|NCT03007732|EXPERIMENTAL|Cohort 1: Prostate Only Sites (ADT, SBRT, Pembrolizumab, SD-101)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.~TLR9 agonist SD-101: Injected into the dominant prostatic tumor lesion at time of fiducial marker placement (1-5weeks prior to Cycle 1 Day 1) and 1-3 weeks after Cycle 1 Day 1~Pembrolizumab: Given IV every 21 days for up to 13 doses~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
62395818|NCT03007732|EXPERIMENTAL|Cohort 2: Prostate and Oligometastatic sites (ADT, SBRT, Pembrolizumab)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.~Pembrolizumab: Given IV every 21 days for up to 13 doses~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland and oligometastatic sites via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
62777956|NCT01079936|EXPERIMENTAL|Lenalidomide + High-Dose Melphalan|Lenalidomide beginning dose level 25 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.
62777957|NCT02161757|EXPERIMENTAL|Tralokinumab Dose Regimen 1|Tralokinumab subcutaneous injection
62777958|NCT02161757|PLACEBO_COMPARATOR|Placebo Dose Regimen 1|Placebo subcutaneous injection
62777959|NCT02161757|EXPERIMENTAL|Tralokinumab Dose Regimen 2|Tralokinumab subcutaneous injection
62777960|NCT02161757|PLACEBO_COMPARATOR|Placebo Dose Regimen 2|Placebo subcutaneous injection
62777961|NCT03696901||use of Xydalba, >18 years|Male and female patients, ≥18 years of age at the time of receipt of Xydalba. Patients who received at least one Xydalba administration in Germany
62777962|NCT04029298|EXPERIMENTAL|HBDC Intervention Group|Immediate enrollment in the 16-week, HBDC education-based intervention, followed by a 12-month observation period
62777963|NCT04029298|OTHER|Control/Usual Care/Delayed Intervention Group|16-week, HBDC education-based intervention will be delayed by 12 months. Following the delayed intervention, this group will be observed for an additional 12-month period
62777964|NCT01174212|EXPERIMENTAL|Experimental|Patients receiving antibiotics approximately 1 hour prior to incision are considered to be in the experimental group of this study.
62777965|NCT01174212|OTHER|Control|Control group is to receive no antibiotics until the intraoperative cultures have been obtained.
62777966|NCT03994198|EXPERIMENTAL|Alpha-lactalbumin|Participants will consume 60 g of alphalactalbumin (fraction of whey protein) for 3 training days.
62777967|NCT03994198|ACTIVE_COMPARATOR|Collagen peptides|Participants will consume 60 g of collagen peptides for 3 training days.
62002577|NCT00169650||1|Registry and database of subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction
62002578|NCT04568239||M184V + group and M184 - group|
62002579|NCT06482931||LMWH|Patients receiving LMWH thromboprophylaxis.
62002580|NCT06482931||Aspirin|Patients receiving aspirin thromboprophylaxis.
62395819|NCT03007732|EXPERIMENTAL|Cohort 2: Prostate and Oligometastatic sites (ADT, SBRT, Pembrolizumab, SD-101)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.~TLR9 agonist SD-101: Injected into the dominant prostatic tumor lesion at time of fiducial marker placement (1-5weeks prior to Cycle 1 Day 1) and 1-3 weeks after Cycle 1 Day 1~Pembrolizumab: Given IV every 21 days for up to 13 doses~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland and oligometastatic sites via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
62395820|NCT05743712|EXPERIMENTAL|SMART-Wrap|SMART-Wrap is a prototype measurement and feedback software system tailored to Wraparound service model (WSM) for emotional disorders to provide measurement-based care in care coordination for youth behavioral health.
62395821|NCT06372444||Patients with sepsis and AKI|
62395822|NCT06372444||Healthy controls|
62395823|NCT03086252|EXPERIMENTAL|Supportive care (patient-driven RBCT)|Patients undergo red blood cell transfusions (RBCT) based on their perception and/or the presence of anemia symptoms for up to 6 months.
62395824|NCT06643936|EXPERIMENTAL|Diabetes Team-Based Group|A multidisciplinary team composed of a pharmacist, social worker, community health worker, and dietician will provide glucose monitoring, medication titration, diet education and reinforcement, and referrals for social needs. The pharmacist will remind patients to get A1C readings at 3 months and 6 months. The team will interact with the patients predominantly via tele-health remotely for 6 months.
62395825|NCT06643936|ACTIVE_COMPARATOR|Diabetes Self-Guided Group|A registered nurse will ensure patients have glucose monitors and supplies on enrollment and will call to remind patients to obtain A1C readings at 3 months and 6 months. Patients will continue with standard clinical care for type 2 diabetes in addition to receiving timed, mailed educational materials on type 2 diabetes monitoring and diabetes diet and lifestyle recommendations for 6 months.
62395826|NCT00770731|EXPERIMENTAL|Torisel + Hycamtin + Velcade|"Torisel starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle.~Hycamtin starting Dose 0.8 mg/m\^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle.~Velcade starting Dose 0.3 mg/m\^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle."
62395827|NCT00770731|EXPERIMENTAL|Expansion Group|"Torisel + Hycamtin + Velcade Expansion Group~Addition of 10 participants at highest tolerated dose level"
62395828|NCT04941261|EXPERIMENTAL|18-59 years old group A|
62395829|NCT04941261|EXPERIMENTAL|18-59 years old group B|
62395830|NCT04941261|PLACEBO_COMPARATOR|18-59 years old group C|
62395831|NCT04941261|EXPERIMENTAL|6-17 years old group A|
62395832|NCT04941261|EXPERIMENTAL|6-17 years old group B|
62395833|NCT04941261|PLACEBO_COMPARATOR|6-17 years old group C|
62395834|NCT04941261|EXPERIMENTAL|3-5 years old group A|
62395835|NCT04941261|EXPERIMENTAL|3-5 years old group B|
62395836|NCT04941261|PLACEBO_COMPARATOR|3-5 years old group C|
62395837|NCT04941261|EXPERIMENTAL|6-35 months old group A|
62395838|NCT04941261|EXPERIMENTAL|6-35 months old group B|
62395839|NCT04941261|PLACEBO_COMPARATOR|6-35 months old group C|
62395840|NCT04941261|EXPERIMENTAL|6-35 months old group D|
62395841|NCT04941261|EXPERIMENTAL|6-35 months old group E|
62395842|NCT04941261|PLACEBO_COMPARATOR|6-35 months old group F|
62395843|NCT04968223||Patient Group|Patients with Schizophrenia
62395844|NCT04968223||Control Group|Healthy subjects without family history of psychotic illness
62395845|NCT04271904|SHAM_COMPARATOR|Placebo Diet|Participants on the placebo diet will be given a meal plan and recipes by the study dietitian. The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). There are many counter-intuitive restrictions in the anti-inflammatory diet that we will be using (banned foods include white beans, soy, eggplant, oats, raspberries, strawberries, prunes, walnuts, cashews, soy milk. Allowed foods include maple syrup, honey, lean beef, lamb, brown rice, feta cheese, butter). Therefore, even fairly astute and educated participants may have trouble discerning which diet they are consuming (anti-inflammatory or placebo).
62395846|NCT04271904|NO_INTERVENTION|Non-dieting Control|Those in the non-dieting control condition will not be asked to alter their diet in any way.
62395847|NCT02107716|EXPERIMENTAL|Bicarbonate|Each participant will receive two lidocaine injections on the abdomen with different pH
62395848|NCT06724211|ACTIVE_COMPARATOR|Control Group|Routine clinical care for kidney transplant patients
62395849|NCT06724211|EXPERIMENTAL|Surgical bundle|The surgical bundle will consist of: the use of plasmalyte for fluid management, maintaining mean arterial pressure \> 75 mmHg, identify and treat blood glucose \> 9 mmol/L, and a restrictive criteria for red blood cell transfusions (i.e. hemoglobin (Hb) \< 70 g/L).
62395850|NCT06723145|EXPERIMENTAL|Aspirin Continuation|perioperative aspirin continuation
62395851|NCT06723145|ACTIVE_COMPARATOR|Interruption of Antiplatelet Therapy|Interruption of aspirin 5-7 days before surgery
62571096|NCT05739838|EXPERIMENTAL|Periodontally compromised patients subjected to low level laser therapy|periodontally compromised patients with pocket depth of more than 5 mm before receiving nonsurgical periodontal treatment treatment or/and pocket depth of less than 4 mm with periodontal status identified as stable for at least 3 month after nonsurgical periodontal treatment subjected to low-level laser of 940 nm will be applied at day one after start of treatment , weekly during the first month, then monthly.
62571097|NCT05739838|NO_INTERVENTION|Periodontally compromised patients|periodontally compromised patients with pocket depth of more than 5 mm before receiving nonsurgical periodontal treatment treatment or/and pocket depth of less than 4 mm with periodontal status identified as stable for at least 3 month after nonsurgical periodontal treatment.
62571098|NCT00588133|EXPERIMENTAL|1|New drug dosing schedule
62571099|NCT00588133|ACTIVE_COMPARATOR|2|Standard drug dosing schedule
62571100|NCT06577831|EXPERIMENTAL|patient|Patients requiring dynamic MRI for the diagnosis of pelvic static disorders
62571101|NCT06577831|ACTIVE_COMPARATOR|control|Healthy volunteers for a dynamic MRI
62571102|NCT05574218|EXPERIMENTAL|Glycine - Test|Polishing treatment with glycine powder air-polishing after ultrasonic plaque debridement.
62571103|NCT05574218|ACTIVE_COMPARATOR|Rubber cup - Control|Polishing treatment with a rubber cup and polishing paste after ultrasonic debridement
62002581|NCT03852316|EXPERIMENTAL|Click Device|Each subject (females 14 years of age and older) will perform a self-collection vaginal swab for the Click device and be randomized to a particular order for three vaginal swab collections (performed by Health Care Providers (HCP) as defined by state/local regulatory authorities) for comparator methods. N=1750
62395852|NCT05626751|EXPERIMENTAL|HZN-825|HZN-825 will be administered by mouth (PO) twice daily (BID) for 52 weeks
62395853|NCT02731924||Ultrasound for Appendicitis|Emergency department patients undergoing point-of-care ultrasound to evaluate for suspected appendicitis
62395854|NCT04259749|ACTIVE_COMPARATOR|Status Quo|The StoreLab power wall will display all tobacco products.
62395855|NCT04259749|EXPERIMENTAL|Flavors Banned|The StoreLab will display tobacco products without characterizing flavors, but will allow mint and menthol products to be displayed.
62395856|NCT04259749|EXPERIMENTAL|Flavors and Menthol Banned|The StoreLab will display only tobacco products without characterizing flavors; mint and menthol will not be displayed.
62395857|NCT06012071|ACTIVE_COMPARATOR|Tissue-level|Two-piece zirconia implants with tissue-level platform will be supplied to the single gap premolar regions in maxillae.
62395858|NCT06012071|EXPERIMENTAL|Bone-level|Two-piece zirconia implants with bone-level platforms will be supplied to the single gap premolar regions in maxillae.
62395859|NCT04442932||Interventions|Per test, a minimum of 40 atopic subjects for a given allergy and a total of at least 100 non-atopic subjects. To ensure that sufficient subjects with valid results are enrolled, the atopic enrollment goal per allergy is approximately 50 subjects. For each allergen, approximately 20% of the samples must be in the range of 0.70 to 3.5 IUA/mL and the remainder must cover a measuring range that is representative of the target population. Results from a single positive subject can be used in the analyses of more than one allergen if the subject is sensitized for more than one allergen.
62395860|NCT05867875|EXPERIMENTAL|Experimental group (ORI)|ORI and SpO2 monitoring values during preoxygenation of patients will be provided to investigator to determine anaesthesia induction initiation. Anesthesic induction is provided after 30 secondes at ORI \> 0.6 and at least 2 min 30 of preoxygenation (so globaly 3 minutes of preoxygenation)
62395861|NCT05867875|OTHER|Standard of care (SoC) group|Only SpO2 values during preoxygenation of patients will be provided to investigator to determine anaesthesia induction initiation. Anesthesic induction is provided at least 3 min of preoxygenation
62571104|NCT06059261|EXPERIMENTAL|Envafolimab and recombinant human endostatin combined with chemoradiotherapy|Intervention Description: Induction envafolimab combined with recombinant endostatin and gemcitabine and cisplatin therapy for three cycles (every 3 weeks) followed by definitive radiotherapy with concurrent cisplatin chemotherapy. After 4 weeks of the completion of radiotherapy, adjuvant envafolimab therapy will begin every 3 weeks for 8 cycles or continue until progression or unacceptable toxicity.
62571105|NCT03911128||Participants with newly diagnosed ALL|
62571106|NCT06578676|EXPERIMENTAL|Empagliflozin 25mg|"* Period 1: Empagliflozin (QD, 5d)~* wash-out: 7d~* Period 2: Ezetimibe/Rosuvastatin (QD, 2d) and Empagliflozin and Ezetimibe/Rosuvastatin (QD, 5d)"
62395862|NCT06562192|EXPERIMENTAL|Arm 1|Patients will receive \[68Ga\]Ga-NNS309, and if eligible, \[177Lu\]Lu-NNS309
62395863|NCT04639895|EXPERIMENTAL|Virtual Reality|Standard treatment protocol and 12 sessions (30 minutes each) of personalized cognitive activities in a virtual city environment (Reh@City).
62571107|NCT06578676|EXPERIMENTAL|Rosuvastatin/Ezetimibe 10/10mg|"* Period 1: Ezetimibe/Rosuvastatin (QD, 7d)~* wash-out: 14d~* Period 2: Ezetimibe/Rosuvastatin (QD, 2d) and Empagliflozin and Ezetimibe/Rosuvastatin (QD, 5d)"
62395864|NCT04639895|EXPERIMENTAL|Paper and Pencil|Standard treatment protocol and 12 sessions (30 minutes each) of personalized paper-and-pencil cognitive activities,using the Task Generator tool.
62395865|NCT04639895|ACTIVE_COMPARATOR|Control Group|The standard treatment protocol.
62571108|NCT06163430|EXPERIMENTAL|Part 1- Dose Level 1 of TERN-701|Dose Level 1 of TERN-701 dosed once daily.
62571109|NCT06163430|EXPERIMENTAL|Part 1- Dose Level 2 of TERN-701|Dose Level 2 of TERN-701 dosed once daily.
62571110|NCT06163430|EXPERIMENTAL|Part 1- Dose Level 3 of TERN-701|Dose Level 3 of TERN-701 dosed once daily.
62571111|NCT06163430|EXPERIMENTAL|Part 1- Dose Level 4 of TERN-701|Dose Level 4 of TERN-701 dosed once daily.
62571112|NCT06163430|EXPERIMENTAL|Part 2 - Dose 1|Dose 1 will be selected from Part 1 based on the totality of safety, PK, PD and efficacy data from Part 1 will be selected. TERN-701 is planned to be administered once daily.
62571113|NCT06163430|EXPERIMENTAL|Part 2 - Dose 2|Dose 2 will be selected from Part 1 based on the totality of safety, PK, PD and efficacy data from Part 1 will be selected. TERN-701 is planned to be administered once daily.
62571114|NCT04535869|NO_INTERVENTION|A)standard therapy group|No intervention COVID- 19 patients who received a standard therapy group according to the ministry of health protocol
62571115|NCT04535869|ACTIVE_COMPARATOR|B)Standard Therapy group plus Ant-HCV drugs|Intervention COVID- 19 patients who received a standard therapy group according to the ministry of health protocol plus sofosbuvir 400 mg and Daclatasvir 200mg
62395866|NCT00738231|ACTIVE_COMPARATOR|I|"Group I's training material consisted of a brochure with the information we wanted the public to know about heart disease. The brochure had such titles as Cardiovascular Diseases, let us protect our hearts, the importance of cholesterol in preventing heart diseases, watch out for blood pressure, quit smoking for your health, weight watching, nutrition, food to avoid in cardiovascular disease, an easy method: exercise and exercise control, and an appropriate body weight vs. height chart for adults"
62395867|NCT00738231|ACTIVE_COMPARATOR|II|The Group II training material document was a letter in the form of a prescription in which the individual was addressed by name, the risk factors established at the first stage were explained, and the suggested measures for protection from such risk factors were indicated.
62002582|NCT04157062|EXPERIMENTAL|Study Group|Participants will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will receive excitatory rTMS with a stimulation frequency of 10 Hz or higher.
62571116|NCT04303806|EXPERIMENTAL|Group 1|40 preeclamptic parturient receive 20 mg rosuvastatin orally once daily.
62002583|NCT01879696|EXPERIMENTAL|Treatment|Treatment are subjects will have catheter vacuum active for the removal of fluid from the muscle compartment.
62395868|NCT04441619|ACTIVE_COMPARATOR|Repeated exposure|Participants will complete four exercise sessions designed to induce delayed onset muscle soreness in the biceps
62571117|NCT04303806|EXPERIMENTAL|Group 2|40 preeclamptic parturient receive 40 mg rosuvastatin orally once daily.
62571118|NCT04495972|ACTIVE_COMPARATOR|Experimental arm: Intestinimonas|Intestinimonas in capsules
62571119|NCT04495972|PLACEBO_COMPARATOR|Placebo arm: Placebo|Placebo in capsules
62002584|NCT01879696|NO_INTERVENTION|Control|Treatment are subjects will have catheter vacuum in-active for the removal of fluid from the muscle compartment.
62002585|NCT02314715||Knee Osteoarthritis|Participants with diagnosed knee osteoarthritis
62002586|NCT02314715||Controls|Participants without knee osteoarthritis
62571120|NCT03917446||Euvolaemic|Patients with stroke volume variation less than 8%
62571121|NCT03917446||Hypovolaemic|Patients with stroke volume variation greater than 13%
62002587|NCT05431062|ACTIVE_COMPARATOR|Thoracic paravertebral block|USG guided TPVB will be performed with 0.5 mL/kg %0.25 Buvicaine in the paravertebral space.
62002588|NCT05431062|ACTIVE_COMPARATOR|Erector spinae plane block|USG guided ESPB will be performed with 0.5 mL/kg %0.25 Buvicaine into the facial plane between erector spine muscle and transverse process
62571122|NCT01107522|EXPERIMENTAL|Arm A|Single Agent CTO
62571123|NCT01107522|EXPERIMENTAL|Arm B|Combination CTO and Temodar®
62571124|NCT01107522|EXPERIMENTAL|Arm C|Combination CTO, Temodar®, Radiation therapy
62571125|NCT04597177|ACTIVE_COMPARATOR|ST-IMRT|standard parotid sparing IMRT
62187829|NCT00799955|ACTIVE_COMPARATOR|2|No additional spinal medications will be given. At the end of the case, one of the two investigators, under sterile conditions, and using ultrasound, will visualize the tip of a blunt regional anaesthesia needle entering the transversus abdominis plane. After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected, under vision, into the transversus abdominis plane, on each side. The subjects will still have spinal anesthesia of the abdomen and therefore will not feel needle insertion as sharp although most will have a sensation of pressure. A dressing will be applied over the needle's entry points.
62777968|NCT01321957|ACTIVE_COMPARATOR|FOLFOX+Bevacizumab|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
62777969|NCT01321957|EXPERIMENTAL|FOLFOX+Bevacizumab+Irinotecan|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
62002589|NCT05431062|ACTIVE_COMPARATOR|Serratus anterior plane block|USG guided ESPB will be performed with 0.5 mL/kg %0.25 Buvicaine into the facial plane between serratus anterior muscle and external intercostal muscles
62187830|NCT01399762||mechanical recanalization|Patients with acute stroke being treated with endovascular devices for mechanical recanalization (no restriction to specific endovascular devices)
62187831|NCT01755546|EXPERIMENTAL|EN3409|Buprenorphine HCI Buccal File at doses ranging from 300-900 mcg twice daily
62395869|NCT04441619|ACTIVE_COMPARATOR|Single exposure|Participants will complete one exercise session designed to induce delayed onset muscle soreness
62395870|NCT04441619|NO_INTERVENTION|Natural history|Participants will complete all sensory testing and imaging but not perform any exercise sessions.
62777970|NCT02736981|ACTIVE_COMPARATOR|Behavioral Weight Loss (BWL)|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment.
62791767|NCT02581735||Patients with haemophilia|"Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.~At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale ."
62395871|NCT05892003|EXPERIMENTAL|Control-High Fibre Weight Loss-High Fibre Non-Nutritive Sweetener Weight Loss: CTRL-HF WL-HF-NNS WL|"* Phase 1 CTRL: Control diet with moderate fibre consumption for 14days.~* Phase 2 HF WL: High Fibre Weight Loss meal consumption for 14days.~* Phase 3 HF-NNS WL: High Fibre and Non-Nutritive Sweetener Weight Loss meal consumption for 14days."
62395872|NCT03922191||Pediatric population|Infants diagnosed with cardiac post-surgery mediastinitis within the HUDERF Hospital within the last 20 years.
62571126|NCT04597177|EXPERIMENTAL|SW-IMRT|swallowing sparing IMRT
62002590|NCT03131063||Septic patient under ECMO treatment|Every adult patient admitted to ICU, under ECMO treatment, with known or suspected sepsis and receiving antibiotic therapy, was eligible for inclusion. The concentration of the studied antibiotics was determined by a combination of liquid chromatography and mass spectrometry from blood samples. For intermittent administration of antibiotic, two successive samples were performed both at 50% (Cmax) and 100% (Cmin) of the dosing interval.
62002591|NCT01987427|EXPERIMENTAL|A|lorcaserin + phentermine placebo
62002592|NCT01987427|EXPERIMENTAL|B|lorcaserin + phentermine-HCl + phentermine placebo
62002593|NCT01987427|EXPERIMENTAL|C|lorcaserin + phentermine-HCl
62002594|NCT02033733||Adequate cooling time|"Patients that reached target temperature within 4 hours of initiation of the hypothermia protocol will be in the adequate cooling time group."
62777971|NCT02736981|ACTIVE_COMPARATOR|BWL + Autonomous Motivation|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
62777972|NCT02736981|ACTIVE_COMPARATOR|BWL + Extrinsic Motivation|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
62187832|NCT03638921|EXPERIMENTAL|MEOPA|Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
62571127|NCT02464423|NO_INTERVENTION|Control|"Usual care: WE-ACTx For Hope and CHUK offer a host of services for HIV+ young people, and these will represent the usual care condition for the study. Both clinics provide adolescent-friendly environments with multidisciplinary teams that offer weekly or monthly support groups, peer education, medical services, mental health screenings, sports activities, HIV and health education sessions, and outreach to parents and guardians. The services youth in the usual care condition receive will be carefully tracked."
62187833|NCT00311415|EXPERIMENTAL|Group 1: 2+4 Months (2-doses)|
62187834|NCT00311415|EXPERIMENTAL|Group 2: 2 Months (1-dose)|
62571128|NCT02464423|ACTIVE_COMPARATOR|Treatment|Culturally-adapted, trauma-informed cognitive behavioral therapy (TI-CBT) intervention: The components of the TI-CBT include a) psychosocial health education b) relaxation training c) cognitive restructuring d) adherence barriers e) caregiver psycho-education. The TI-CBTe will be administered in groups of 8-10 weekly for 2 hours for 3 Sundays each month over 2 months. Two IYL will co-lead each intervention, and two IYL will rate fidelity.
62571129|NCT00951743|EXPERIMENTAL|Adaptavir Treatment|MDAPTA (Adaptavir) will be administered intranasally at 0.01 mg twice per day. Individuals with plasma viral load (PCR Roche Amplicor Ultrasensitive assay) less than 200 copies/mL, sustained for the previous 90 days, with CD4\>350 cells/mm3 will be eligible to participate.
62777973|NCT02336542|EXPERIMENTAL|TB subjects|96 TB subjects are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.
62791768|NCT02906397|EXPERIMENTAL|Experimental: Galunisertib/SBRT|Galunisertib (LY2157299) 150mg by mouth twice a day on days 1-14 of 28 day cycles SBRT 18Gy, delivered in one fraction between Cycle 1 D15 and D28
62187835|NCT00311415|EXPERIMENTAL|Group 3: 6 Months (1-dose)|
62187836|NCT00311415|ACTIVE_COMPARATOR|Group 4: 12-16 Months (1 dose in the second year of life)|
62002595|NCT02033733||Inadequate cooling time|"Patients that did not reach target temperature within 4 hours of initiation of the hypothermia protocol will be in the inadequate cooling time group."
62002596|NCT04197635|ACTIVE_COMPARATOR|Dapagliflozin 10 mg|After providing informed consent, patients will be randomly assigned to receive dapagliflozin 10 mg per day.
62571130|NCT00951743|PLACEBO_COMPARATOR|Placebo|Placebo will be administered intranasally at 0.01 mg twice per day. Individuals with plasma viral load (PCR Roche Amplicor Ultrasensitive assay) less than 200 copies/mL, sustained for the previous 90 days, with CD4\>350 cells/mm3 will be eligible to participate.
62571131|NCT03196115||Observation|Patients with Hyaline fibromatosis syndrome or high-grade suspicion for Hyaline fibromatosis syndrome
62571132|NCT03267082|EXPERIMENTAL|Evaluation the role of Laparoscopic management of perforated a|
62571133|NCT02677571|EXPERIMENTAL|PVB|51 patients receiving US guided homolateral paravertebral thoracic block with 30ml of 0.25% levobupivacaine, before general anesthesia (TCI-TIVA).
62571134|NCT02677571|EXPERIMENTAL|PECS|51 patients receiving US guided pectorals nerve block with 30ml of 0.25% levobupivacaine, before general anesthesia (TCI-TIVA).
62571135|NCT01706939|EXPERIMENTAL|Reduced Dose Radiation|Patients randomized to receive a reduced (5600 cGy) dose radiotherapy with weekly Carboplatin
62571136|NCT01706939|ACTIVE_COMPARATOR|Standard Dose Radiation|Patients randomized to receive a standard (7000 cGy) dose radiotherapy with carboplatin
62002597|NCT04197635|PLACEBO_COMPARATOR|Placebo identical to dapagliflozin 10 mg|After providing informed consent, patients will be randomly assigned to receive placebo (one tablet a day orally).
62187837|NCT05768399||Asthma group|Children with asthma diagnosed by a respiratory physician
62187838|NCT05768399||Control group|Children without respiratory disease or inflammatory diseases
62187839|NCT06054919|EXPERIMENTAL|50,000 IU|Vitamin D3 50,000 IU weekly a standard prenatal multivitamin (fumarate Fe 90 mg; folic acid 0.4 mg; vitamin B6 3 mg; vitamin B12 5 mcg; sulphate cupric 0.35 mg, sulphate cobalt 0.15 mg, sulphate mangan 5 mcg, vitamin C 60 mg, vitamin E 5 mg, and phosphate calcium 60 mg)
62187840|NCT06054919|ACTIVE_COMPARATOR|5,000 IU|Vitamin D3 5,000 IU daily a standard prenatal multivitamin (fumarate Fe 90 mg; folic acid 0.4 mg; vitamin B6 3 mg; vitamin B12 5 mcg; sulphate cupric 0.35 mg, sulphate cobalt 0.15 mg, sulphate mangan 5 mcg, vitamin C 60 mg, vitamin E 5 mg, and phosphate calcium 60 mg)
62187841|NCT02656849|EXPERIMENTAL|BAY 1000394|"After the screening procedures confirm eligibility to participate in the research study:~* Each treatment cycle lasts 4 weeks.~* Participants will take the study drug orally at predetermined times and dosage per cycle."
62187842|NCT00476112|EXPERIMENTAL|1|Atrial flutter duration of 3 hours to \<45 days
62395873|NCT03922191||Adult population|Adults diagnosed with cardiac post-surgery mediastinitis within the CHU Brugmann Hospital within the last 20 years.
62395874|NCT04300556|EXPERIMENTAL|Dose Escalation Part: Farletuzumab ecteribulin|Participants with selected tumor type will receive farletuzumab ecteribulin (MORAb-202) as an intravenous infusion, once every 3 weeks in a 21 days cycle.
62777974|NCT02336542|ACTIVE_COMPARATOR|non-TB subjects with lung disease|96 non-TB subjects with lung disease are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.
62395875|NCT04300556|EXPERIMENTAL|Dose Confirmation Part: Farletuzumab ecteribulin|Participants with EC and OC will receive farletuzumab ecteribulin (MORAb-202) as an intravenous infusion, once every 3 weeks in a 21 days cycle.
62395876|NCT04300556|EXPERIMENTAL|Dose Optimization Part A, Cohort 1: Farletuzumab ecteribulin + Oral Corticosteroids|Participants with EC and OC will receive farletuzumab ecteribulin (MORAb-202) as an intravenous infusion, once on Day 1 and oral corticosteroids on Days 8, 9 and 10 of every 21-day cycle.
62395877|NCT04300556|EXPERIMENTAL|Dose Optimization Part A, Cohort 2: Farletuzumab ecteribulin|Participants with EC and OC will receive farletuzumab ecteribulin (MORAb-202) as an intravenous infusion, once on Days 1, 8 and 15 of every 21-day cycle.
62777975|NCT05243303|EXPERIMENTAL|Active taVNS|These patients will self-administer transcutaneous auricular vagus nerve stimulation (taVNS).
62777976|NCT05243303|SHAM_COMPARATOR|Sham taVNS|These patients will self-administer a sham procedure mimicking the active taVNS procedure.
62002598|NCT05705908|NO_INTERVENTION|Control Group - No foot bath|"* 24 hours after surgery - did not give foot bath to patients~* Pain was evaluated with VAS scale. Post-operative 24th hour, 28th hour, 32nd hour, 36th hour, 40th hour, 44th hour, 48th hour, 52nd hour, 56th hour, 58th hour, 62nd Hour, 64th Hour., 68th Hour, 72nd Hour~* Sleep Questionnaire was administered at 08:00-09:00 in the morning when the patient woke up; 24th hour, 48 th hour, 72 th hour."
62187843|NCT02431455|ACTIVE_COMPARATOR|Incentive Spirometry|Incentive spirometry 10 times per hour while awake
62187844|NCT02431455|EXPERIMENTAL|No Incentive Spirometry|No incentive spirometer provided
62187845|NCT01310699|EXPERIMENTAL|High Definition NBI Colonoscopy|Use of high definition narrow band imaging colonoscopy during examination for polyp detection. The same intervention is used on both arms: the Olympus Colonoscope CFHQ190AL, a technically improved colonoscope with close focus high definition narrow band imaging.
62187846|NCT01310699|PLACEBO_COMPARATOR|High Definition White Light Colonoscopy|Use of high definition white light colonoscopy during examination for polyp detection. The same intervention is used on both arms: the Olympus Colonoscope CFHQ190AL, a technically improved colonoscope with close focus high definition narrow band imaging.
62187847|NCT05812586|EXPERIMENTAL|Group 1: SCB-2019/Clover|Cohort A: complete primary immunization, no previous booster dose: SCB-2019/Clover
62187848|NCT05812586|EXPERIMENTAL|Group 2: AstraZeneca/Fiocruz|Cohort A: complete primary immunization, no previous booster dose: AstraZeneca/Fiocruz
62395878|NCT04300556|EXPERIMENTAL|Dose Optimization Part A, Cohort 3: Farletuzumab ecteribulin|Participants with EC and OC will receive farletuzumab ecteribulin (MORAb-202) as an intravenous infusion, once on Days 1 and 8 of every 21-day cycle.
62395879|NCT04300556|EXPERIMENTAL|Dose Optimization Part B, Cohort 1: Farletuzumab ecteribulin|Participants with EC will receive farletuzumab ecteribulin (MORAb-202) as an intravenous infusion, at a dosing regimen identified during Part A.
62395880|NCT04300556|EXPERIMENTAL|Dose Optimization Part B, Cohort 2: Farletuzumab ecteribulin|Participants with EC will receive farletuzumab ecteribulin (MORAb-202) as an intravenous infusion, at a dosing regimen identified during Part A.
62777977|NCT03921177|EXPERIMENTAL|Multiple micronutrient supplement|Daily micronutrient supplement
62777978|NCT03921177|PLACEBO_COMPARATOR|Placebo|Daily identifcal placebo tablet
62777979|NCT00527319|NO_INTERVENTION|Group A, control group|Supportive care only
62187849|NCT05812586|EXPERIMENTAL|Group 3: Pfizer/Wyeth|Cohort A: complete primary immunization, no previous booster dose: Pfizer/Wyeth
62187850|NCT05812586|EXPERIMENTAL|Group 4: SCB-2019/Clover|Cohort B: primary immunization plus one previous booster dose:SCB-2019/Clover
62187851|NCT05812586|EXPERIMENTAL|Group 5: AstraZeneca/Fiocruz|Cohort B: primary immunization plus one previous booster dose: AstraZeneca/Fiocruz
62187852|NCT05812586|EXPERIMENTAL|Group 6: Pfizer/Wyeth|Cohort B: primary immunization plus one previous booster dose: Pfizer/Wyeth
62187853|NCT05812586|EXPERIMENTAL|Group 7: SCB-2019/Clover|Cohort C: primary immunization plus two previous booster doses: SCB-2019/Clover
62187854|NCT05812586|EXPERIMENTAL|Group 8: AstraZeneca/Fiocruz|Cohort C: primary immunization plus two previous booster doses: AstraZeneca/Fiocruz
62187855|NCT05812586|EXPERIMENTAL|Group 9: Pfizer/Wyeth|Cohort C: primary immunization plus two previous booster doses: Pfizer/Wyeth
62395881|NCT01678287|EXPERIMENTAL|Arm 1 Non elderly receiving ASP1941|healthy subjects age 18 to 45 years receiving ASP1941
62395882|NCT01678287|EXPERIMENTAL|Arm 2 Non elderly receiving placebo|healthy subjects age 18 to 45 years receiving placebo
62777980|NCT00527319|ACTIVE_COMPARATOR|Group B, Low Dose VT-122|VT-122 (dose of etodolac: 400 mg/day) + supportive care
62777981|NCT00527319|ACTIVE_COMPARATOR|Group C, High Dose VT-122|VT-122 (dose of etodolac: 800 mg/day) + supportive care
62395883|NCT01678287|EXPERIMENTAL|Arm 3 Elderly receiving ASP1941|healthy subjects age ≥ 65 years receiving ASP1941
62395884|NCT01678287|EXPERIMENTAL|Arm 4 Elderly receiving placebo|healthy subjects age ≥ 65 years receiving placebo
62187856|NCT02750644||High-risk|Patients with atherosclerotic carotid disease with (1) severe comorbidity (class III/IV congestive heart failure, class III/IV angina, coronary disease involving ≥ 2 major vessels, left ventricular ejection fraction ≤ 30%, myocardial infarction, severe pulmonary disease, severe renal failure) and (2) Technical/challenging anatomical criteria (previous neck surgery, cervical irradiation, contralateral carotid occlusion, post-endarterectomy restenosis, inaccessible lesions or tracheotomy).
62187857|NCT02750644||Standard-risk|Patients with atherosclerotic carotid disease without (1) severe comorbidity (class III/IV congestive heart failure, class III/IV angina, coronary disease involving ≥ 2 major vessels, left ventricular ejection fraction ≤ 30%, myocardial infarction, severe pulmonary disease, severe renal failure) and (2) Technical/challenging anatomical criteria (previous neck surgery, cervical irradiation, contralateral carotid occlusion, post-endarterectomy restenosis, inaccessible lesions or tracheotomy).
62395885|NCT05237570|NO_INTERVENTION|Control group|After the molar extraction, no intervention will be performed.
62395886|NCT05237570|EXPERIMENTAL|Interradicular septum window group|After the extraction of the molar, the maxillary sinus membrane will be elevated through a micro-window, previously done in the interradicular septum.
62395887|NCT06001021|EXPERIMENTAL|Psychopharmacological Intervention|This group will receive psychopharmacological intervention with perinatal safe light doses of antidepressants (see Langan et al., 2016; Schoretsanitis et al., 2021) and/or anxiolytic medications (see Nishimura et al, 2021; Saito et al, 2022) by a gynecologist. Selective Serotonin Reuptake Inhibitor (Escitalopram, 5-10 mg in pregnancy and Sertraline, 12.5-25 mg in postpartum) and/or Benzodiazepine (Alprazolam, 0.25-0.5 mg) will be prescribed in tablet form per day.
62571137|NCT06040515||Symptomatic patients after acute diverticulitis|"Patients aged ≥18 with persistent symptoms at least three months after a radiologic and/or endoscopic documented acute diverticulitis or after six months of surgery for complicated acute diverticulitis.~Therapy with Escherichia coli Nissle 1917 (EcN®) will be prescribed for a global duration of six months with the following assumption schedule: 2 capsules b.i.d. during 4 weeks, followed by 1 capsule o.i.d during 20 days each month for 5 months."
62571138|NCT06040515||Diverticulosis|Patients with asymptomatic diverticulosis. No therapy will be administered. Microbiota assessment will be performed.
62571139|NCT06040515||Asymptomatic patients after acute uncomplicated diverticulitis|Asymptomatic patients assessed three months after an episode of acute uncomplicated diverticulitis. No therapy will be administered. Microbiota assessment will be performed.
62777982|NCT02262962|NO_INTERVENTION|Usual Well-Child Care|No change in Well-Child Visits.
62777983|NCT02262962|EXPERIMENTAL|Redesigned Well-Child Care|The Redesigned Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and text messaging services (HealthyTxt).
62395888|NCT06001021|EXPERIMENTAL|Cognitive Behavioral Couple Therapy (CBCT) Intervention|This group will receive CBCT intervention from a trained psychologist in CBT. There are two conditions of CBCT, i) with Zikr, and ii) without Zikr.
62395889|NCT06001021|EXPERIMENTAL|Combined Intervention|This group will receive Medicine (prescribed by a consultant gynecologist) and CBCT intervention (with or without Zikr) from a trained psychologist in CBT.
62395890|NCT06001021|PLACEBO_COMPARATOR|Control (Placebo and No Intervention)|This group will receive a placebo from a gynecologist or no intervention from a trained psychologist.
62395891|NCT06001021|NO_INTERVENTION|Other|This group will receive no intervention from a trained psychologist.
62395892|NCT06580756||group intervention|Group with a brief training
62395893|NCT06580756||group control|Group without a brief training
62395894|NCT01197846|EXPERIMENTAL|Quetiapine|Quetiapine 300 mg or 600 mg
62777984|NCT02448290|EXPERIMENTAL|docetaxel+selumetinib|Selumetinib 75 mg will be administered orally twice a day with continuous dosing schedule Docetaxel 60 mg/m2 will be administered via intravenous access every 3 weeks.
62777985|NCT02658773|ACTIVE_COMPARATOR|lidocaine-Prilocaine cream|lidocaine-Prilocaine anesthetic cream placed into their cervix prior to having the IUD inserted
62187858|NCT05018897|EXPERIMENTAL|To Share or Not to Share|"Manualized, peer-led, strategic disclosure program to guide participants in disclosing suicidality, held in group format, consisting of six sessions, each one hour in duration, once per week.~Pre-survey, post-survey, and 3-month follow-up survey"
62395895|NCT01197846|PLACEBO_COMPARATOR|Placebo|
62395896|NCT00230711|EXPERIMENTAL|Exercise Counseling|
62395897|NCT00230711|PLACEBO_COMPARATOR|Contact Control|
62395898|NCT03242811|EXPERIMENTAL|Examination by MRI|MRI scan of knee, ankle and wrist
62395899|NCT06410755|EXPERIMENTAL|Insole wearing group receiving monitoring and feedback|The experimental group wears the insole gait analyzer and is asked to wear the insole gait analyzer as much and as long as possible during outdoor activities. Researchers provide feedback to subjects once a week based on the collected measurement data. After 6 weeks, usability and satisfaction evaluation of the insole type gait analysis system will be conducted.
62395900|NCT06410755|NO_INTERVENTION|Control group|The control group is trained in the same exercise program as the experimental group, but not receives the insole gait analyzers and not receives any exercise feedback.
62395901|NCT01157819|ACTIVE_COMPARATOR|Ciloxan Ear Drops|Ciloxan (Alcon, Inc.) Sterile Ophthalmic and Ear Drops
62395902|NCT01157819|EXPERIMENTAL|Foam Otic Cipro|Patients randomized to this study arm will receive the experimental product
62395903|NCT03159715|EXPERIMENTAL|Internet-based Global Protocol|Intervention group that carries out the Internet-based Global Protocol and receives therapist support.
62395904|NCT03159715|EXPERIMENTAL|Internet-based Behavioral Activation Protocol|Intervention group that carries out the Internet-based Behavioral Activation Protocol and receives therapist support.
62395905|NCT03159715|EXPERIMENTAL|IInternet-based Positive Psychology Protocol|Intervention group that carries out the Internet-based Positive Psychology Protocol and receives therapist support.
62395906|NCT02598362|OTHER|intravenous|Participants who are treated with ciprofloxacin intravenously, at discretion of the treating physician.
62395907|NCT02598362|OTHER|oral|Participants who are treated with ciprofloxacin via the oral route, at discretion of the treating physician.
62395908|NCT06724952|ACTIVE_COMPARATOR|MTX S.C or IM _ Silymarin tab|IM or S.C MTX plus Silymarin 140 mg Tab once daily
62395909|NCT06724952|PLACEBO_COMPARATOR|MTX S.C or IM _ Placebo tablet|IM or S.C MTX plus Placebo Tablet once daily
62395910|NCT03781310|EXPERIMENTAL|Dose reduction|Reduce the Tocilizumab dose at the baseline visit (week 0) and maintain that dose until 20 weeks of follow-up. The reduced dose is dependent of the tocilizumab serum concentration, measured at the screening visit, and is calculated according to the pre-defined dose-reduction algorithm.
62395911|NCT03781310|ACTIVE_COMPARATOR|Maintain dose|Maintain the original dose at baseline visit (week 0) until 20 weeks of follow-up.
62395912|NCT06471595|EXPERIMENTAL|Intervention Group - PLP + SDoH|Participants randomized to the Intervention Group will be engaged in a 3-month randomized controlled trial and receive the PLP+SDoH curriculum from a trained Community Health Worker (CHW). Each week during the 3 months, participants will meet for approximately 1-1.5 hours and be taught a PLP Lesson or engage in an SDoH activity. Participants will also be asked to undergo an assessment collection point at baseline recruitment and 3-month completion time.
62395913|NCT06471595|NO_INTERVENTION|Waitlist Control Group|Participants randomized to the Waitlist Control Group will receive nothing from the research group while the Intervention Group is underway. Participants will be asked to undergo an assessment collection point at baseline recruitment and 3-month completion time. After the Control Group's 3-month follow-up assessment, they will be offered the PLP+SDoH curriculum.
62395914|NCT00666640||1|50 subjects who have suffered a hip fracture
62395915|NCT00666640||2|50 age matched controls
62395916|NCT05300126|EXPERIMENTAL|Usual care|No hypnosis session are proposed
62395917|NCT04230746|PLACEBO_COMPARATOR|Placebo|Participants will be recruited and enrolled. Participants will be surveyed regarding environmental, health, and behavioral practices. (Instrument 1) . Then a clean catch urine specimen will be collected. Participants will be provided with placebo to be taken twice daily. This will be considered day 0. Participants will then be instructed to take the study drug twice daily and return on Day 2, Day 5, Day 10, Day 30, and Day 180 for additional clean-catch urine specimen.
62395918|NCT04230746|EXPERIMENTAL|Bactrim|Participants will be recruited and enrolled. Participants will be surveyed regarding environmental, health, and behavioral practices. (Instrument 1) . Then a clean catch urine specimen will be collected. Participants will be provided with Bactrim 800/120 to take twice daily. This will be considered day 0. Participants will then be instructed to take the study drug twice daily and return on Day 2, Day 5, Day 10, Day 30, and Day 180 for additional clean-catch urine specimen.
62571140|NCT06040515||Asymptomatic patients after acute complicated diverticulitis|Asymptomatic patients assessed six months after an episode of acute complicated diverticulitis submitted to surgery with resection and without stoma . No therapy will be administered. Microbiota assessment will be performed.
62187859|NCT05018897|ACTIVE_COMPARATOR|Peer Support|"Peer-led support group, held in group format, consisting of six sessions, each one hour in duration, once per week.~Pre-survey, post-survey, and 3-month follow-up survey"
62187860|NCT04238533|ACTIVE_COMPARATOR|eADAPT|This arm includes transradial amputees who will be assessed while using the eADAPT trainer.
62187861|NCT04238533|ACTIVE_COMPARATOR|Conventional program|This arm includes transradial amputees who will be assessed while using the conventional training program.
62187862|NCT01266161|EXPERIMENTAL|Ibuprofen 600 mg extended release|
62571141|NCT01805518|ACTIVE_COMPARATOR|Scelectium Tortuosum|S Tortuosum
62571142|NCT01805518|PLACEBO_COMPARATOR|Sugar pill/placebo|Sugar pill/placebo
62571143|NCT03742661|EXPERIMENTAL|Treatment Group|SPEAC System
62571144|NCT03742661|NO_INTERVENTION|Standard of Care|Standard of Care
62187863|NCT01266161|PLACEBO_COMPARATOR|Placebo|
62571145|NCT00873743||1|60 women after elective cesarian section
62571146|NCT00873743||2|60 women after elective cesarian section
62571147|NCT00027066|ACTIVE_COMPARATOR|Active Warfarin and Aspirin Placebo|One 2 mg scored tablet daily of Warfarin and one 325 mg tablet daily of aspirin placebo.
62571148|NCT00027066|ACTIVE_COMPARATOR|Active Aspirin and Warfarin Placebo|One 325 mg tablet daily of aspirin and one 2 mg scored tablet daily of Warfarin placebo.
62571149|NCT02391012|EXPERIMENTAL|Fecal microbial l transplantation|patients with active colitis who will undergo treatment by fecal microbial transplantation
62571150|NCT01605240|ACTIVE_COMPARATOR|Acetaminophen and Codeine|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
62571151|NCT01605240|ACTIVE_COMPARATOR|Acetaminophen and Ibuprofen|Following reduction of their fracture, these patients will receive acetaminophen (15mg/ml) and ibuprofen (10mg/ml) at regular dosing intervals.
62571152|NCT04927780|EXPERIMENTAL|Arm 1: Perioperative mFOLFIRINOX|Patients in the intervention arm (arm 1) start with neoadjuvant mFOLFIRINOX (consisting of oxaliplatin 85 mg/m², irinotecan 150 mg/m², leucovorin 400 mg/m², all at day 1, and fluorouracil continuous IV infusion 2.4 g/m² over 46 hours). Cycles are repeated every 14 days. After eight cycles, surgical resection is performed in the absence of unresectable or metastatic disease. After resection, four cycles of adjuvant mFOLFIRINOX are scheduled.
62187864|NCT04457258|EXPERIMENTAL|Diagnostic (68Ga-FAPI-46 PET/CT)|Patients receive 68Ga-FAPi-46 intravenously (IV), and then undergo PET/computed tomography (CT) over 20-90 minutes. On another day, patients receive 18F-FDG and then undergo PET/computed tomography (CT) according to standard of care procedures (if applicable).
62187865|NCT00954005|EXPERIMENTAL|Rituximab, Gemcitabine and Oxaliplatin|Drug: Rituximab on day 0 or 1 of each 28-day cycle Drug: Gemcitabine on day 1 and 15 of each 28-day cycle Drug: Oxaliplatin on day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²) of each 28-day cycle
62571153|NCT04927780|ACTIVE_COMPARATOR|Arm 2: Adjuvant mFOLFIRINOX|Patients in the comparator arm (arm 2) start with surgery. After resection, 12 cycles of adjuvant mFOLFIRINOX (consisting of oxaliplatin 85 mg/m², irinotecan 150 mg/m², leucovorin 400 mg/m², all at day 1, and fluorouracil continuous IV infusion 2.4 g/m² over 46 hours) are scheduled.
62777986|NCT02658773|PLACEBO_COMPARATOR|placebo cream|an inert placebo cream placed into their cervix
62187866|NCT05204186||Group A|Patient with (Group A) any Grade 3 (and over) Clavien-Dindo grading complication rate (30dC and 90dC)
62777987|NCT04246632|EXPERIMENTAL|Open label|Single arm study, all subjects receive device
62777988|NCT06303232|EXPERIMENTAL|MANUAL LYMPHATIC DRAINAGE|
62777989|NCT06303232|ACTIVE_COMPARATOR|THERAPEUTIC ULTRASOUND|
62777990|NCT01862653|EXPERIMENTAL|Auricular Acupuncture|An insomnia auricular acupuncture protocol will be administered for 30 minutes, three times per week, for three weeks in the intervention group.
62395919|NCT05628389|OTHER|Ask-Advice-Assist (AAA)|All patients will be screened for tobacco use, and offer brief cessation advice and counseling.
62395920|NCT05628389|EXPERIMENTAL|Ask-Advise-Connect (AAC)|Patients in will be connected to phone counseling and will receive six sessions of telephone counseling.
62395921|NCT05628389|EXPERIMENTAL|Ask-Advise-Connect (AAC) + Nicotine Replacement Therapy (NRT)|In addition to AAC, patients will be offered NRT.
62395922|NCT03759795|EXPERIMENTAL|Intervention Group|Acceptance and Commitment Training (ACTr)
62395923|NCT03759795|NO_INTERVENTION|Wait-list control|No intervention during trial. Participants in this group will be offered the training once the study is complete.
62395924|NCT01130220||Brain Tumor Patient|"A one-time focus group will be held in a quiet room for approximately 30-60 minutes until a saturation of themes has been identified."
62395925|NCT01130220||Health Care Provider|"A one-time focus group will be held in a quiet room for approximately 30-60 minutes until a saturation of themes has been identified."
62002599|NCT05705908|EXPERIMENTAL|Experimental Group- Hot Foot Bath 1|"* Post operative 24th hour - 48 th hour - 72 nd hour - gave patients hot foot bath~* Patient was seated in an upright position.~* FM 4020 Grundig brand footbath device was used for the Hot Foot Bath.~* It was filled with 40 degrees water, 20 cm (4 lt. of water)~* Soaked in hot water up to the ankles~* The foot bath was continued for 20 minutes with the feet in the device.~* After 20 minutes, the patient's feet were dried with a towel.~* After the foot bath pain was evaluated with VAS scale. Post-operative 24th hour, 28th hour, 32nd hour, 36th hour, 40th hour, 44th hour, 48th hour, 52nd hour, 56th hour, 58th hour, 62nd Hour, 64th Hour., 68th Hour, 72nd Hour~* Sleep Questionnaire was administered at 08:00-09:00 in the morning when the patient woke up; 24th hour, 48 th hour, 72 th hour."
62395926|NCT04084652|EXPERIMENTAL|Mycoprotein|Mycoprotein in its full food matrix
62395927|NCT04084652|EXPERIMENTAL|Protein Isolated from Mycoprotein|Protein from mycoprotein isolated from the food matrix
62395928|NCT04905160|EXPERIMENTAL|Subjects Hospitalized with a Primary Diagnosis of ADHF or Acute MI|Phase 1 subjects 18 years or above hospitalized with a primary diagnosis of ADHF or acute MI. Patients will measure their vitals Weight, Sitting BP, Fluid Status, Heart Rate, Respiration Rate each morning for 30 days after discharge. The monitoring of this data of each patient daily will be done by dedicated H2O care team and hospitalist. The hospitalist will coordinate with the patient, the home health team, SNFs and the cardiologists as needed to correct/treat any major abnormalities picked up by the remote monitoring system in order to prevent readmissions. Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
62395929|NCT04905160|EXPERIMENTAL|Subjects Testing Positive Covid-19 Antigen Test|Phase 2 subjects 50 years or older with positive Covid-19 antigen test and one other risk factor as mentioned in the comorbid section of workflow will be enrolled in this arm of the study. Subjects will be randomized within 48 hours of Covid-19 antigen positive status. Patients will measure their vitals Weight, Sitting BP, Fluid Status, Heart Rate, Respiration Rate each morning for 30 days after discharge. The monitoring of this data of each patient daily will be done by dedicated H2O care team and hospitalist. The hospitalist will coordinate with the patient, the home health team, SNFs and the cardiologists as needed to correct/treat any major abnormalities picked up by the remote monitoring system in order to prevent readmissions. Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
62395930|NCT04085354|PLACEBO_COMPARATOR|Placebo|Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
62777991|NCT01862653|NO_INTERVENTION|Control|The control group is a wait-list control group and will be offered the auricular acupuncture intervention after the study is complete. No intervention will be performed on control group.
62777992|NCT05360745|EXPERIMENTAL|Experimental arm|ARACOMPLEX® (food supplement). 2 tablets per day, during 6 months.
62777993|NCT05360745|PLACEBO_COMPARATOR|Control arm|Placebo. 2 tablets per day, during 6 months.
62187867|NCT05204186||Group B|Patient without (Group B) any Grade 3 (and over) Clavien-Dindo grading complication rate (30dC and 90dC)
62395931|NCT04085354|ACTIVE_COMPARATOR|Dapoxetine|Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.
62395932|NCT04085354|ACTIVE_COMPARATOR|Dapoxetine and folic acid.|Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
62395933|NCT04085354|ACTIVE_COMPARATOR|Dapoxetine and vitamin B12|Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
62395934|NCT02711163|EXPERIMENTAL|Extensively hydrolyzed formula|Feeding extensively hydrolyzed formula
62187868|NCT00952848|EXPERIMENTAL|MC5-A Scramble instrument|Treatment of chronic neuropathic pain with the MC5-A device
62395935|NCT02711163|PLACEBO_COMPARATOR|Amino acid formula|Feeding amino acid formula
62395936|NCT01659411||Adult CHD Patients|observational
62395937|NCT02012504||Western medicine|venlafaxine or escitalopram
62395938|NCT02012504||Chinese medcine|Shuganjieyu capsule
62395939|NCT04522986|EXPERIMENTAL|Mesenchymal stem cell|4 times dose of Mesenchymal stem cell
62395940|NCT06724640|EXPERIMENTAL|VH4011499 Active Group|
62777994|NCT06165094||Diagnosed with supraclavicular LNM|There was no intervention(s) in any group
62777995|NCT06165094||Diagnosed with paraesophageal LNM|There was no intervention(s) in any group
62777996|NCT02255201|ACTIVE_COMPARATOR|Beverage A|Single dose, Pre-Workout Master Performance Blend Dose 1
62777997|NCT02255201|ACTIVE_COMPARATOR|Beverage B|Single dose, Pre-Workout Master Performance Blend Dose 2
62777998|NCT02255201|ACTIVE_COMPARATOR|Beverage C|Single dose, Pre-Workout Performance Energy Blend
62777999|NCT02255201|ACTIVE_COMPARATOR|Beverage D|Single dose, Pre-Workout Energy Blend
62778000|NCT02255201|PLACEBO_COMPARATOR|Beverage E|Single dose, Pre-Workout Placebo
62571154|NCT00777270|EXPERIMENTAL|1 continuous|continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
62571155|NCT00777270|EXPERIMENTAL|2 interrupted|interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
62778001|NCT01207349||close follow-up by nurse|close follow-up by nurse : patients were visited each tree months
62187869|NCT02984254|EXPERIMENTAL|functional patellofemoral neoprene brace|26 Patients will use a a functional patellofemoral neoprene brace and answer WOMAC, Lequesne questionnaires, perform Timed-up-and-go (TUG), five-times-sit-to-stand-test (FTSST) and the six-minute walk test.
62571156|NCT04570670|EXPERIMENTAL|Test (BLS-11)|A single oral dose administration of BLS-11 190 mg (2 × 95 mg monomethyl fumarate delayed-release capsules) at Hour 0 on Day 1
62187870|NCT02984254|EXPERIMENTAL|neoprene sleeve brace.|26 Patients will use a neoprene sleeve brace and answer WOMAC, Lequesne questionnaires, perform Timed-up-and-go (TUG), five-times-sit-to-stand-test (FTSST) and the six-minute walk test.
62571157|NCT04570670|ACTIVE_COMPARATOR|Reference (Tecfidera)|A single oral dose administration of Tecfidera 240 mg (1 × 240 mg dimethyl fumarate delayed-release capsule) at Hour 0 on Day 1
62571158|NCT02510664|EXPERIMENTAL|Intervention|There is no control/comparator group for this pilot study - all participants receive the intervention
62778002|NCT01207349||standard follow up|stantdard follow up at one year
62002600|NCT05705908|EXPERIMENTAL|Experimental Group- Hot Foot Bath 2|"* Post operative 24th hour - 48 th hour - 72 nd hour - gave patients hot foot bath with Lavender Essential Oil~* Patient was seated in an upright position.~* FM 4020 Grundig brand footbath device was used for the Hot Foot Bath.~* It was filled with 40 degrees water, 20 cm (4 lt. of water)~* Soaked in hot water up to the ankles~* The foot bath with Lavender Essential Oil was continued for 20 minutes with the feet in the device.~* After 20 minutes, the patient's feet were dried with a towel.~* After the foot bath with Lavender Essential Oil pain was evaluated with VAS scale. Post-operative 24th hour, 28th hour, 32nd hour, 36th hour, 40th hour, 44th hour, 48th hour, 52nd hour, 56th hour, 58th hour, 62nd Hour, 64th Hour., 68th Hour, 72nd Hour~* Sleep Questionnaire was administered at 08:00-09:00 in the morning when the patient woke up; 24th hour, 48 th hour, 72 th hour."
62002601|NCT04909086|ACTIVE_COMPARATOR|Standard Physical Therapy|Control group for the study.
62187871|NCT05241132|EXPERIMENTAL|BMCUP treated with Tislelizumab and chemotherapy|"Patients with bone metastases from cancer of unknown primary (BMCUP) diagnosed according to the criteria defined in the 2015 European Society of Medical Oncology (ESMO) clinical Practice Guidelines and with bone metastases confirmed by imaging and histology that cannot be completely resected~1. Cisplatin: 100mg/m2, injected intravenously every 3 weeks, 8 cycles (period 21 days)~2. Paclitaxel (albumin-bound) : paclitaxel, 175mg/m2, given intravenously every 3 weeks for 8 cycles (period 21 days).~3. Tislelizumab: 200mg, given intravenously every 3 weeks until disease progression or unacceptable toxicity or death or subject withdrawal of informed consent."
62187872|NCT01682798|ACTIVE_COMPARATOR|"Yili Chang Qing Pro-ABB yoghurt (Formula 1)"|"100g of Yili Chang Qing Pro-ABB yoghurt (Formula 1) will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
62395941|NCT06724640|PLACEBO_COMPARATOR|VH4011499 Placebo Group|
62571159|NCT02881515|EXPERIMENTAL|Blood Pressure Reactivity|Blood Pressure Responses to a cold pressor test and acute exercise will be assessed. This will be performed while subjects are on a low sodium diet (1000 mg/daily), medium sodium diet (2300 mg/daily), and high sodium diet (7000 mg/daily).
62571160|NCT02881515|EXPERIMENTAL|Blood Pressure Variability|Twenty four hour blood pressure variability will be assessed. This will be performed while subjects are on a low sodium diet (1000 mg/daily), medium sodium diet (2300 mg/daily), and high sodium diet (7000 mg/daily).
62571161|NCT06303401|EXPERIMENTAL|SI joint thrust Manipulation|The patient was supine and the therapist stood contralateral to the side which was to be manipulated. The patient was passively moved into side bending toward the side to be manipulated. The therapist passively rotated the patient, and then delivered a quick thrust to the Anterior Superior Iliac Spine (ASIS) in a posterior and inferior direction
62571162|NCT06303401|ACTIVE_COMPARATOR|Pelvic Stabilization Exercises|Heating pad for 10- 15 mints Pelvic stabilization exercises. Bridging (3 sets x 10 reps with 10 secs hold), Pelvic Tilt exercise (3 sets x 10 reps with 10 secs hold), Bird-Dog Exercise (3 sets x 10 reps with 10 secs hold), clamshell Exercise (3 sets x 10 reps with 10 secs hold).
62571163|NCT04412109|ACTIVE_COMPARATOR|injection of low volume of saline|low volume (5 cc) saline injection during thoracic epidural catheterization
62778003|NCT03123328|EXPERIMENTAL|Test Subjects|Each test subject will receive a Radical-7 Pulse CO-Oximeter and sensor that will remain on the subject for the first 24 hours following ED admission or discharge from the ICU/IMU.
62778004|NCT01224080|EXPERIMENTAL|Adiana Device|All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
62778005|NCT01201226|NO_INTERVENTION|Patients|Perimenopausal women, who will undergo oelvic organ surgery, and will allow harvest of about half an oary for the study purpose
62778006|NCT02207959|EXPERIMENTAL|Surveillance Endoscopy|White light examination, vital-dye enhanced fluorescence examination (VFI), High Resolution Microendoscope (HRME)
62778007|NCT02215824|EXPERIMENTAL|BIWH 3|in escalating doses
62778008|NCT02215824|PLACEBO_COMPARATOR|Placebo|
62778009|NCT06328309|EXPERIMENTAL|Rehabilitation treatment+Myofascial Release Therapy|Study lasts 21 days for each patient. All patients are given rehabilitation treatment.The experimental group was given the Myofascial Release Therapy, five days a week, once a day, for 30-60 minutes each time.
62778010|NCT06328309|ACTIVE_COMPARATOR|Rehabilitation treatment|Study lasts 21 days for each patient. All patients are given rehabilitation treatment, five days a week, once a day, for 30-60 minutes each time.
62778011|NCT05407155|EXPERIMENTAL|Experimental arm|Patients received bevacizumab plus nab-paclitaxel and platinum as second-line therapy.
62791769|NCT05484115|ACTIVE_COMPARATOR|Standard endovascular aneurysm repair (EVAR) using the Endurant II/IIs stent graft system|
62791770|NCT05484115|ACTIVE_COMPARATOR|Endosuture aneurysm repair (ESAR) with the Endurant II/IIs in conjunction with Endoanchors|
62791771|NCT01800591|NO_INTERVENTION|Control Arm|No other financial incentive other than for enrollment, 6-month weigh in, and completion.
62002602|NCT04909086|EXPERIMENTAL|Open Kinetic Chain|Standard care in addition to open kinetic chain exercises for the knee joint muscles.
62571164|NCT04412109|ACTIVE_COMPARATOR|injection of intermediate volume of saline|intermediate volume (10 cc) saline injection during thoracic epidural catheterization
62571165|NCT04412109|ACTIVE_COMPARATOR|injection of high volume of saline|high volume (20 cc) saline injection during thoracic epidural catheterization
62778012|NCT05504551|ACTIVE_COMPARATOR|group B|Superficial cervical plexus block (SCP) block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize superficial cervical plexus (SCP) posterior to the midpoint of sterno cleido mastoid (SCM) muscle. Once SCP is identified, a combination of 5 ml bupivacaine (0.5%) and 5 ml lidocaine (2%) is injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel Echogenic Needle.
62571166|NCT01117922|EXPERIMENTAL|Intervention|After consent, subjects will be assigned to either a usual care group (no intervention) or an intervention group (targeted interconceptional interventions).
62187873|NCT01682798|PLACEBO_COMPARATOR|Placebo yoghurt|100g of placebo yoghurt (normal yoghurt) will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
62778013|NCT05504551|PLACEBO_COMPARATOR|group S|SCP block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize SCP posterior to the midpoint of SCM muscle. Once SCP is identified, 10 ml of normal saline is injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel Echogenic Needle.
62778014|NCT00696969|ACTIVE_COMPARATOR|1|
62778015|NCT00696969|EXPERIMENTAL|2|
62778016|NCT00696969|EXPERIMENTAL|3|
62778017|NCT00696969|EXPERIMENTAL|4|
62778018|NCT00095173|ACTIVE_COMPARATOR|Abatacept|Double Blind Period
62778019|NCT00095173|PLACEBO_COMPARATOR|Placebo|Double Blind Period
62778020|NCT00095173|EXPERIMENTAL|Abatacept - Open Label|
62778021|NCT00803322||1|communities where tuberculosis patients followed the conventional health facility based tuberculosis case finding and treatment
62187874|NCT01682798|ACTIVE_COMPARATOR|"Yili Chang Qing Pro-ABB yoghurt (Formula 2)"|"100g of Yili Chang Qing Pro-ABB yoghurt (Formula 2) will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
62187875|NCT04398368|EXPERIMENTAL|Prevention (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride intravesically for at least 1 hour at the time of RNU.
62187876|NCT04472845|EXPERIMENTAL|1 week|Radiotherapy dose to chest wall, axilla level III and supraclavicular fossa will be of 26Gy in 5 fractions over 1 week in the study arm. BCS patients will receive a sequential boost of 8Gy/2#/2days or simultaneous integrated boost(SIB) to a total dose of 34Gy.Supraclavicular fossa(SCF) and axilla level III will be treated in patients with T3-4 disease with lymphovascular invasion, grade 3 or N2 disease and T3-4 disease treated with neoadjuvant chemotherapy after adequate axillary dissection. Level I and II axilla will only be irradiated in patients with inadequate axillary dissection(\<10 lymph nodes). Internal mammary node (IMNs) radiation will be done in T3-4 central and inner quadrant lesions and patients with N2 disease. IMNs will be irradiated with a separate single field. The first five intercostal spaces will be included in the IMN target volume.
62187877|NCT04472845|ACTIVE_COMPARATOR|2 week|Radiotherapy dose to chest wall, axilla level III and supraclavicular fossa will be 34Gy in 10 fractions over 2 weeks in the control arm. BCS patients will receive a sequential boost of 8Gy/2#/2days or simultaneous integrated boost(SIB) to a total dose of 42 Gy.
62187878|NCT05492968|EXPERIMENTAL|Epinephrine Group|Patients in the epinephrine group will receive a continuous infusion containing epinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
62187879|NCT05492968|ACTIVE_COMPARATOR|Norepinephrine Group|Patients in the norepinephrine group will receive a continuous infusion containing norepinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
62187880|NCT05492968|ACTIVE_COMPARATOR|Phenylephrine Group|Patients in the phenylephrine group will receive a continuous infusion containing phenylephrine with a concentration of 0.2mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
62187881|NCT03988998|EXPERIMENTAL|Radiofrequency ablation with radiotherapy|Patients in this arm will receive liver radiotherapy around the primary tumor margin within one month after radiofrequency ablation for hepatocellular carcinoma.
62187882|NCT03988998|ACTIVE_COMPARATOR|Radiofrequency ablation alone|Patients in this arm will only receive radiofrequency ablation for hepatocellular carcinoma.
62571167|NCT01117922|OTHER|Usual Care Group|This group will receive usual care.
62778022|NCT00803322||2|community where suspects of pulmonary tuberculosis were identified by community health workers and received treatment in the community
62187883|NCT04731974|PLACEBO_COMPARATOR|Placebo|Liquid Placebo
62187884|NCT04731974|ACTIVE_COMPARATOR|Melatonin|Liquid Melatonin
62778023|NCT06432166|PLACEBO_COMPARATOR|Placebo|Placebo treatment TID for 16 weeks.
62778024|NCT06432166|ACTIVE_COMPARATOR|250 mg 2-HOBA acetate|250 mg of 2-hydroxybenzylamine (2-HOBA) acetate TID for 16 weeks.
62778025|NCT06432166|ACTIVE_COMPARATOR|500 mg 2-HOBA acetate|500 mg of 2-hydroxybenzylamine (2-HOBA) acetate TID for 16 weeks.
62778026|NCT06432166|ACTIVE_COMPARATOR|750 mg 2-HOBA acetate|750 mg of 2-hydroxybenzylamine (2-HOBA) acetate TID for 16 weeks.
62778027|NCT05687513|EXPERIMENTAL|treatment group|
62778028|NCT05687513|PLACEBO_COMPARATOR|control group|
62778029|NCT02301624|EXPERIMENTAL|Eculizumab/Eculizumab|"Blind Induction Phase: Participants who had received blinded treatment with eculizumab in Study ECU-MG-301 were administered eculizumab (4 vials/1200 milligrams \[mg\]) on Day 1 and Week 2 and placebo (4 vials/0 mg) at Weeks 1 and 3.~Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study.~Eculizumab 1200 mg was administered for up to 4 years in this extension study."
62778030|NCT02301624|EXPERIMENTAL|Placebo/Eculizumab|"Blind Induction Phase: Participants who had received blinded treatment with placebo in Study ECU-MG-301 were administered eculizumab/placebo (3 vials/900 mg, plus 1 vial/0 mg, respectively) on Day 1 and Weeks 1 through 3.~Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study.~Eculizumab 1200 mg was administered for up to 4 years in this extension study."
62002603|NCT04909086|EXPERIMENTAL|Closed Kinetic Chain|Standard care in addition to closed kinetic chain exercises for the knee joint muscles.
62002604|NCT04186442|EXPERIMENTAL|Botulinum toxin type A (Botulax®)|
62002605|NCT04186442|ACTIVE_COMPARATOR|Botulinum toxin type A (Botox®)|
62002606|NCT02170610|EXPERIMENTAL|BIBR 1048 MS capsule|
62571168|NCT02425592||Men on Active Surveillance|This study will include men between age 30-80 with Gleason 6 prostate cancer, prostate specific antigen (PSA) \<20, clinical stage \<cT3, and a life expectancy of at least ten years. To be eligible, men must have undergone an MRI-USG fusion prostate biopsy for an elevated PSA or abnormal prostate examination that demonstrates Gleason 6 prostate cancer. If a man is already on active surveillance, the MRI-USG fusion biopsy may be negative or confirm Gleason 6 prostate cancer. Eligible men will be approached at their post fusion-biopsy visit to discuss the biopsy results and offered enrollment in the trial.
62571169|NCT00979316|EXPERIMENTAL|BMS-708163 (800 mg)|
62002607|NCT02170610|EXPERIMENTAL|BIBR 1048 capsule with pantoprazole|
62002608|NCT02170610|EXPERIMENTAL|BIBR 1048 capsule with food|
62002609|NCT05576116|EXPERIMENTAL|Group 1: Staggered Approach|The first 10 participants enrolled will undergo Sleeve Gastrectomy a minimum of 3 months prior to Pancreas Transplant.
62395942|NCT02950831|EXPERIMENTAL|Activity and sleep quality recording|Patients will receive a wrist worn accelerometer and accelerometry will be used to monitor physical activity and sleep quality during standard BurstDR Spinal Cord Stimulation clinical treatment
62571170|NCT00979316|EXPERIMENTAL|BMS-708163 (200 mg)|
62571171|NCT00979316|PLACEBO_COMPARATOR|Placebo|
62571172|NCT00979316|ACTIVE_COMPARATOR|Moxifloxacin|
62571173|NCT05432765|ACTIVE_COMPARATOR|Physician Dosing|Subjects will continue per SOC, where the management of their immunosuppression regimen will be determined by their physician per center practices, including dd-cfDNA data.
62778031|NCT04770792|EXPERIMENTAL|Experimental group|2% chlorhexidine gluconate with mineral trioxide aggregate.
62778032|NCT04770792|ACTIVE_COMPARATOR|Control group|Mineral trioxide aggregate.
62002610|NCT05576116|EXPERIMENTAL|Group 2: Combined Approach|Eligible participants will undergo SG and pancreas transplantation simultaneously
62002611|NCT04264286|ACTIVE_COMPARATOR|Esmolol group|Patients will receive intravenous esmolol after the end of the surgical procedure.
62002612|NCT04264286|PLACEBO_COMPARATOR|Placebo group|Patients will receive intravenous saline after the end of the surgical procedure.
62002613|NCT02412969|ACTIVE_COMPARATOR|Lumbar Epidural|Control group will have standard of care Lumbar Epidural
62002614|NCT02412969|EXPERIMENTAL|Dural Puncture Epidural|Will receive Dural Puncture Epidural
62002615|NCT00758511|ACTIVE_COMPARATOR|1|Orally administrated 25%sucrose before,during and after heel stick across 5 heel sticks during the first 14 days of postnatal life
62002616|NCT00758511|ACTIVE_COMPARATOR|2|facilitated tucking before, during and after heel stick across 5 heel stick during the first 14 days of postnatal life
62002617|NCT00758511|ACTIVE_COMPARATOR|3|orally administrated 25% sucrose AND facilitated tucking before, during and after heel stick across 5 heel sticks during the first 14 days of postnatal life
62002618|NCT04355962|EXPERIMENTAL|Sevoflurane Sedation|Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS
62778033|NCT02022436|ACTIVE_COMPARATOR|contrast ultrasound for patients with AAA|Contrast ultrasound
62778034|NCT02022436|ACTIVE_COMPARATOR|contrast ultrasound for patients without arterial disease|contrast enhanced ultrasound
62002619|NCT04355962|ACTIVE_COMPARATOR|Intravenous|No use of sevoflurane, but current intravenous sedation at discretion of the ICU physician in charge, e.g. with propofol, fentanyl, midazolam and dexmedetomidine
62002620|NCT01414569|ACTIVE_COMPARATOR|8 mg dexamethasone|
62002621|NCT01414569|PLACEBO_COMPARATOR|Placebo, saline|
62002622|NCT01414569|EXPERIMENTAL|40 mg dexamethasone|
62187885|NCT04792398|EXPERIMENTAL|Sleep Bruxism Subjects|"Ultrasound guided BTX-A injection: 25 units (divided in two injections) in each masseter muscle.~One-time intervention. Effect observation by measuring various biosignals (EMG, EOG, EEG), bite force, chewing efficiency, psychometric assessments."
62187886|NCT01906983||Doppler ultrasound.|Doppler ultrasound will be performed to All patients 18 and up, admitted to Rambam Medical Center with diagnosis of blunt splenic trauma and agree to participate the study.
62187887|NCT03099408|ACTIVE_COMPARATOR|Metronidazole Oral|Metronidazole Oral
62187888|NCT03099408|ACTIVE_COMPARATOR|"Metronidazole and Lactobacillus"|"Metronidazole and Lactobacillus"
62571174|NCT05432765|EXPERIMENTAL|PPM Dosing|Subjects will have dd-cfDNA data analyzed by PPM. Data, such as drug levels and regimens, will be used to fit a 2nd order polynomial for each patient to build patient-specific dose-response profiles with covariates that include the administered drugs tacrolimus, steroids, and MMF/MPA. PPM will be used to derive an optimal combination of tacrolimus, MMF/MPA, and prednisone to achieve minimal renal allograft injury, while staying within the therapeutic range of the medications. All else being equal, the most efficacious combination with the lowest dose of tacrolimus will be utilized.
62571175|NCT04105166|EXPERIMENTAL|RP-L301|RP-L301 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene
62002623|NCT01545921|EXPERIMENTAL|Arm A|"Patients will complete QoL questionnaires in the following order :~MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month until death"
62002624|NCT01545921|EXPERIMENTAL|Arm B|"Patients will complete QoL questionnaires in the following order :~QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month until death"
62002625|NCT01545921|EXPERIMENTAL|Arm C|"Patients will complete QoL questionnaires in the following order :~MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month and spontaneous QoL completion, until death"
62002626|NCT01545921|EXPERIMENTAL|Arm D|"Patients will complete QoL questionnaires in the following order :~QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month and spontaneous QoL completion, until death."
62187889|NCT03008109|EXPERIMENTAL|EGFR-TK inhibitor plus RH-endostatin|EGFR-TKI icotinib:125mg Tid RH-endostatin:15mg/m2 ,d1-7
62187890|NCT01359839|EXPERIMENTAL|Relaxation Response Mind Body Intervention|The Relaxation Response (RR) Mind Body Intervention Arm receives the Behavioral: Relaxation Response and Cognitive Behavioral Therapy Intervention which is a RR based Mind Body Group consisting of 1½ hour group classes held weekly for 8 weeks, in a conference room at the health center.
62187891|NCT04221789|EXPERIMENTAL|intervention: TB treatment assistant|Patients receiving instructions to use phone application
62187892|NCT04221789|NO_INTERVENTION|Control|Patients receiving instructions for usual care self administered treatment
62571176|NCT05940181|EXPERIMENTAL|XH001+ sintilimab|XH001: 2 dose level Sintilimab: 200mg iv, 21 day per cycle
62778035|NCT05409937|EXPERIMENTAL|Improved Hot Weather Combat Uniform|Wearing the Improved Hot Weather Combat Uniform; Asked to perform 60 min of standing with minimal movement, 60 min weighted (38.5lb) treadmill walking at 2.0mph, up to 4% grade, 60 min weight (38.5lb) treadmill walking at 2.5mph, up to 4% grade.
62002627|NCT03246867|EXPERIMENTAL|Isolytic stretching group|The participants in this group will receive isolytic stretching in modified cross body position.
62002628|NCT03246867|EXPERIMENTAL|Static stretching group|The participants in this group will receive static stretching in modified cross body position.
62002629|NCT03246867|ACTIVE_COMPARATOR|Control group|The participants in this group will receive no stretching. They will only be evaluated.
62778036|NCT05409937|EXPERIMENTAL|Army Combat Uniform|Wearing the Army Combat Uniform; Asked to perform 60 min of standing with minimal movement, 60 min weighted (38.5lb) treadmill walking at 2.0mph, up to 4% grade, 60 min weight (38.5lb) treadmill walking at 2.5mph, up to 4% grade.
62002630|NCT01038271|ACTIVE_COMPARATOR|Standard Palliative Care Group|
62002631|NCT01038271|ACTIVE_COMPARATOR|Integrated Palliative Care Group|
62002632|NCT01574872|EXPERIMENTAL|Aerosal|This arm include all patients treated with Aerosal®
62002633|NCT01574872|PLACEBO_COMPARATOR|Placebo|This arm include all patients treated with placebo
62002634|NCT01897675|ACTIVE_COMPARATOR|Incision and Drainage with Packing|Abscess is cared for in the standard fashion, using an incision and drainage with packing (wick) placement. Packing to be changed every 2-3 days, at the discretion of the treating clinician, until abscess is considered resolved
62002635|NCT01897675|EXPERIMENTAL|Loop Drainage|Abscess is cared for using a minimally invasive abscess drainage with loop placement technique. Two (or more) stab incisions are made in the abscess, the cavity is probed and pus is drained, and a vessel loop is inserted and tied off. The patient manipulates the loop 3 times per day, and removes the loop when all redness is gone and no more pus is present
62002636|NCT01405638|EXPERIMENTAL|Motivational Interviewing|The use of a one-on-one motivational interviewing counseling intervention, 4 visits over 5 months, focusing on changes to behavior related to blood pressure control.
62187893|NCT05675319|EXPERIMENTAL|Arm A (allo SCT)|Allogeneic stem cell transplantation
62571177|NCT04894825|EXPERIMENTAL|Dose Escalation Cohort|"Monotherapy: Five dose levels of M108 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.~Combined with chemotherapy: Three dose levels of M108 will be tested by a conventional 3 + 3 study design.~The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (21 days)."
62571178|NCT04894825|EXPERIMENTAL|Dose Expansion Cohort|Once the effective dose has been determined, 1\~2 expansion cohorts will be opened to evaluate the efficacy and safety of the selected dose.
62571179|NCT06491173|EXPERIMENTAL|InfraScanner 2500™|All patients entered into the trial will undergo at least one cranial scanning using the InfraScanner 2500™ upon arrival to the casualty unit at MRRH following CT. Patients will be scanned using the InfraScanner 2500™ following each subsequent CT as allowed by patient or representative. Patients will know the results of the CT but not the InfraScanner 2500™. The standard for comparison will be determined as follows. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative. In cases where the results of the CT are negative for hematoma and the results of the InfraScanner 2500™ are positive consideration of further follow-up will be given on a case-by-case basis.
62571180|NCT06576154|EXPERIMENTAL|Prophylaxis antibiotics Group|Patients with Antibiotic Prophylaxis post-open Repair of Primary Elective Groin Hernias in High-Risk Patients.
62571181|NCT06576154|NO_INTERVENTION|Non-antibiotics Group|Patients without Antibiotic Prophylaxis post-open Repair of Primary Elective Groin Hernias in High-Risk Patients.
62571182|NCT05827718|ACTIVE_COMPARATOR|RCT #1, Arm #1: Contact Method, Text Only|Potential participants in the parent trial will be randomized to receive a message via text message. This message will invite them to participate in the parent trial.
62571183|NCT05827718|ACTIVE_COMPARATOR|RCT #1, Arm #2: Contact Method, Email Only|Potential participants in the parent trial will be randomized to receive a message via email. This message will invite them to participate in the parent trial.
62571184|NCT05827718|ACTIVE_COMPARATOR|RCT #1, Arm #3: Contact Method, Email+Text|Potential participants in the parent trial will be randomized to receive a message via email and text message. This message will invite them to participate in the parent trial.
62002637|NCT01405638|EXPERIMENTAL|Patient Navigation|The use of a patient navigation intervention to guide participants through the process of getting screened for colorectal cancer.
62571185|NCT05827718|ACTIVE_COMPARATOR|RCT #2, Arm #1: Source of Contact, Personal Physician|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The sender of the message will be the person's personal physician.
62002638|NCT01405638|EXPERIMENTAL|PLUS|This group receives both the motivational interviewing intervention and the patient navigation intervention.
62002639|NCT01962558|EXPERIMENTAL|VNS Treatment|Vagus nerve stimulation and tones are used 2.5 hours per day for a 6-week period.
62778037|NCT05409937|EXPERIMENTAL|Army Combat Uniform + Silk Weights|Wearing the Army Combat Uniform + a base layer of silk weights; Asked to perform 60 min of standing with minimal movement, 60 min weighted (38.5lb) treadmill walking at 2.0mph, up to 4% grade, 60 min weight (38.5lb) treadmill walking at 2.5mph, up to 4% grade.
62778038|NCT05409937|EXPERIMENTAL|Army Combat Uniform- XR|Wearing the Army Combat Uniform; Asked to perform 60 min weighted (38.5lb) treadmill walking at 2.0mph, up to 4% grade, followed by 60 min of standing with minimal movement
62778039|NCT05254873||AD-TAR|AD subjects who took part to Facial Emotion Recognition rehabilitation (TAR) during EYE-TAR(MA) study
62002640|NCT01962558|SHAM_COMPARATOR|VNS Control|Vagus nerve stimulation and tones are given daily over a 2.5 hour period, but not in the same way as the experimental group, and in such a way that it is believed to be ineffective but still provide both VNS and tones so that blinding is maintained.
62002641|NCT03081585||Healthy Controls|Normal weight, healthy female participants
62002642|NCT03056131|EXPERIMENTAL|Diacutaneous Fibrolysis Treatment|
62778040|NCT05254873||AD-Cognitive Stim|AD subjects who took part to cognitive stimulation session (12 sessions during 4 weeks) during EYE-TAR(MA) study
62002643|NCT03056131|NO_INTERVENTION|Control Group|
62002644|NCT03827486|ACTIVE_COMPARATOR|Standard of care|
62187894|NCT05675319|ACTIVE_COMPARATOR|Arm B (conventional therapy)|"Currently approved triple regimens for first relapse:~* carfilzomib/lenalidomide/dexamethasone (KRD) or~* elotuzumab/lenalidomide/dexamethasone (ERD) or~* daratumumab/bortezomib/dexamethasone DVD) or~* daratumumab/lenalidomide/dexamethasone (DRD) or~* ixazomib/lenalidomide/dexamethasone (IRD) or~* pomalidomide/bortezomib/dexamethasone (PVD) or~* carfilzomib/daratumumab/dexamethasone (KDD) or~* daratumumab/pomalidomide/dexamethasone (DPD) or~* isatuximab/carfilzomib/dexamethasone (Isa-KD) or~* selinexor/bortezomib/dexamethasone (SVD)~Alternatively, autologous stem cell transplantation may also be performed, if sufficient stem cells are still cryopreserved."
62187895|NCT00907192||Opioids|Personal Interview and Questionnaire of Advanced cancer patients, taking narcotic pain drugs (opioids).
62187896|NCT02881047|EXPERIMENTAL|rAblative Fractional Laser for Sclerotic GVHD-Associated Joint|"Range of motion limitations and joint contractures due to sclerotic GVHD across a specific joint / limb"
62002645|NCT03827486|EXPERIMENTAL|Domicilary exercise program|
62002646|NCT03814954|ACTIVE_COMPARATOR|Salbutamol|Patients will receive salbutamol (2 units/kg) with 3 ml normal saline by nebulizer.
62187897|NCT01783158||Diagnostic group|A total of 132 patients with HNSCC were enrolled in this study. The patients underwent esophagoscopy and chromoendoscopy. The most frequent primary tumors were oropharyngeal (49/132), tumors of the oral cavity (36/132) and larynx (35/132). The majority of subjects (107/132 patients, 81.1%) had advanced HNSCC carcinomas (stages III and IV). Multiple LVLs were discovered in 24 subjects (18.2%), and no LVLs in 108 (81.8%) subjects. Fifty-five LVL biopsy specimens were obtained and assessed. Squamous cell carcinomas were detected in two patients, peptic esophagitis in 11 patients, gastric heterotopic mucosa in two patients, hyperplasia in two patients, and low- and high-grade dysplasia in three patients.
62187898|NCT04813497|OTHER|Participants who refuse the SARS-CoV-2 vaccine|Participant who does not wish to be vaccinated against the SARS-CoV-2 virus and who wishes to perform the serological test during the vaccination campaign and the second 12-14 weeks after the first serological test.
62571186|NCT05827718|ACTIVE_COMPARATOR|RCT #2, Arm #2: Source of Contact, Research Team|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The sender of the message will be the research team.
62778041|NCT00259207|ACTIVE_COMPARATOR|classic surgery|classic surgery
62778042|NCT00259207|EXPERIMENTAL|medical surgery hybride|medical surgery hybride
62778043|NCT06410456|EXPERIMENTAL|Schroth group|Effect of Schroth treatment on sensory and motor control
62002647|NCT03814954|EXPERIMENTAL|Epinephrine|Patients will receive epinephrine (0.5 mg/dose) with 3 ml normal saline by nebulizer.
62002648|NCT03268616|EXPERIMENTAL|Healthy Subjects|increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive.
62002649|NCT03268616|EXPERIMENTAL|Sever COPD Patients|increase the pressure support ventilation step by step, in order to decrease neural respiratory drive.
62002650|NCT05857709||Cystic fibrosis|No intervention - only assessments.
62002651|NCT05857709||Healthy Control|No intervention - only assessments.
62002652|NCT02496780|PLACEBO_COMPARATOR|placebo|once or 3x daily injectable placebo (insulin diluent)
62778044|NCT04359979|EXPERIMENTAL|tamsulosin treatment|patients will receive 0.4mg/day of Tamsulosin tablet for 3 months
62778045|NCT01183468|EXPERIMENTAL|Part 1a(Aralast NP)-Subjects Aged 16-35 Yrs|Subjects aged 16-35 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by intravenous (IV) infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
62791772|NCT01800591|EXPERIMENTAL|Delayed gratification|In addition to the standard enrollment, 6-month, and completion incentives, if the subject loses 5% of their initial weight by the end of the study, they will receive an annual discount (distributed across bi-weekly pay periods) for 12 months beginning after the 12-month study ends. Their premium will return to normal price after this 12-month discount ends.
62571187|NCT05827718|ACTIVE_COMPARATOR|RCT #3, Arm #1: Framing Method, Appeal to Altruism|"Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will appeal to the person's altruism, for example: Research studies like this one often do not include enough Black individuals. If Black people are not included in research like this, then doctors have less information about how cardiovascular disease might affect them and how new treatments could be used to improve their health. Your participation in this research can help doctors better understand how to treat members of your community in the future."
62571188|NCT05827718|NO_INTERVENTION|RCT #3, Arm #2: Framing Method, No Appeal to Altruism|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will include no appeal to altruism.
62571189|NCT05827718|ACTIVE_COMPARATOR|RCT #4, Arm #1: Framing Method, Social Proof|"Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will include language about social proof, i.e. information about participation of individuals similar to the person being contacted. For example, the message will include language such as: Clinical research studies and the development of effective new medications would not have been possible without the participation of thousands of people like you."
62571190|NCT05827718|ACTIVE_COMPARATOR|RCT #4, Arm #2: Framing Method, Perceived Scarcity|"Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will include language emphasizing constraints on enrollment/limited number of available spots for participating, i.e. perceived scarcity, For example, the message will include language such as: There are a limited number of slots available in this study, and enrollment is only possible in the next 4 weeks."
62571191|NCT05827718|NO_INTERVENTION|RCT #4, Arm #3: Framing Method, No Social Proof, No Perceived Scarcity|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will include no language about social proof or perceived scarcity.
62002653|NCT02496780|EXPERIMENTAL|basal insulin levemir|once daily basal insulin therapy with insulin levemir
62002654|NCT02496780|EXPERIMENTAL|rapid-acting insulin Novolog|pre-meal rapid-acting insulin 3x/day with insulin novolog
62002655|NCT04395716|EXPERIMENTAL|Treatment Group|This group will be treated with nebullized ResCure™ while hospitalized every 4 to 6 hours, depending on disease severity and ventilator status.
62571192|NCT05827718|NO_INTERVENTION|RCT #5, Arm #1: Framing Method, Opt-In|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. Instructions on how to enroll in the parent trial will be the same as all previous arms.
62571193|NCT05827718|ACTIVE_COMPARATOR|RCT #5, Arm #2: Framing Method, Opt-Out|"Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. Instead of receiving on how to enroll in the parent trial, thy will be told they have been conditionally enrolled in the parent trial, contingent on them providing some additional information, unless they choose to opt out."
62571194|NCT05827718|ACTIVE_COMPARATOR|RCT #6, Arm #1: Incentive Structure, Gain-framed, Guarantee|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will state that, if the person decides to participate, they will be receive a guaranteed participation incentive (e.g. $50).
62571195|NCT05827718|ACTIVE_COMPARATOR|RCT #6, Arm #2: Incentive Structure, Gain-framed, Lottery|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will state that, if the person decides to participate, they will receive a guaranteed participation incentive (e.g. $25) and also be enrolled in a lottery (e.g. 1 in 40 chance) to receive a larger participation incentive (e.g. $1,000).
62571196|NCT05827718|ACTIVE_COMPARATOR|RCT #6, Arm #3: Incentive Structure, Loss-framed, Guarantee|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will state that, if the person decides to participate, their participant incentive (e.g. $50) will be placed in a virtual account that they will be able to access once they have enrolled into the parent trial.
62002656|NCT01417403|EXPERIMENTAL|Treatment (radiosensitization therapy)|Beginning 3 days before the initiation of radiotherapy, patients receive hydroxychloroquine PO QD or BID. Treatment continues until completion of radiotherapy.
62002657|NCT06394388|EXPERIMENTAL|All participants|
62187899|NCT04813497|OTHER|Participants who received the first dose of SARS-CoV-2 vaccine before the first serological test|Participant who has received his first dose of vaccine and who performs his serological test when he receives the second dose of vaccine against the SARS-CoV-2 virus to determine his immunity. The second serological test will be done 12 to 14 weeks after the second dose of the SARS-CoV-2 vaccine to determine its immunity.
62002658|NCT02995252||Group 1: Hepatitis C infection|Participants with chronic hepatitis C infection; includes both hepatitis C mono infected and hepatitis C-HIV coinfected. Participants will attend study visits for research blood draws (once a year with optional additional visits), and a one-time optional knowledge questionnaire. No drugs will be given to this group.
62187900|NCT04813497|OTHER|Participants who start with the serological test before SARS-CoV-2 vaccine|Participant who performed the serological test before the first dose of vaccine and 12 to 14 weeks after the second dose of vaccine against the SARS-CoV-2 virus to determine his immunity.
62187901|NCT04813497|OTHER|Participants who received the third dose of SARS-CoV-2 vaccine|Participant who performs his serological test when he receives the third dose of vaccine against the SARS-CoV-2 virus to determine his immunity.
62778046|NCT01183468|EXPERIMENTAL|Part 1a (Aralast NP)-Subjects 8-15 Yrs|Subjects aged 8-15 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
62395943|NCT06722989|EXPERIMENTAL|mobile-guided exercise group|"Exercises for pregnant women in the SG will fall into moderate physical activity. They will be previously assessed by a perinatologist with a license to guide exercise during pregnancy. Each exercise will last 30 minutes, including initial warm-up exercises and final stretching exercises.~The recommended moderate activity for pregnant women is at least 150 minutes per week, achieved on at least three days. For pregnant women aged 29 years or less, this means within the limits of a heart rate of 125 to 146 beats/min. For pregnant women aged 30 years or more, it is within the limits of a heart rate of between 121 and 141 beats per minute. According to the Borg scale of perceived exertion from six to 20, moderate exercise is rated between 13 and 14, corresponding to the specified heart rate thresholds. The pregnant woman will rate her exercise on the Borg perceived exertion scale from six to 20. The recommended number of steps per day will be at least 6,000."
62395944|NCT06722989|ACTIVE_COMPARATOR|Unguided physical activity|In this arm, pregnant women will be physically active at their discretion.
62571197|NCT05827718|ACTIVE_COMPARATOR|RCT #6, Arm #4: Incentive Structure, Loss-framed, Lottery|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will state that, if the person decides to participate, their participant incentive (e.g. $50) will be placed in a virtual account that they will be able to access once they have enrolled into the parent trial.
62778047|NCT01183468|EXPERIMENTAL|Part 1b (Aralast NP)--Subjects Aged 18-35 Yrs|Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.
62778048|NCT01183468|EXPERIMENTAL|Part 1b (Aralast NP)-Subjects 8-17 Yrs|Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.
62778049|NCT03369002|EXPERIMENTAL|Normal|"Child-Pugh Score: N/A~Subjects will receive a single 10 mg oral dose of seladelpar"
62187902|NCT04813497|OTHER|Participant who received the third dose of SARS-CoV-2 vaccine and|Participant who performs a serological test between 12 and 14 weeks after the third dose of SARS-CoV-2 vaccine to determine immunity. And who has agreed to undergo serological testing prior to the third dose of the vaccine.
62187903|NCT04647305|EXPERIMENTAL|Closed face shield + Surgical face mask|Each participant will wear 21 surgical face masks corresponding to the follow-up days in the randomized clinical trial, as well as one closed face shield. Additionally, each participant will receive an educational intervention (video).
62187904|NCT04647305|ACTIVE_COMPARATOR|Surgical face mask|Each participant will wear 21 surgical face masks corresponding to the follow-up days in the randomized clinical trial. Additionally, each participant will receive an educational intervention (video).
62187905|NCT05256212||firefighters|firefighters in active service
62571198|NCT00941486|EXPERIMENTAL|FST-100 Ophthalmic Suspension|FST-100 (PVP-I 0.4% and dexamethasone 0.1%)
62571199|NCT00941486|PLACEBO_COMPARATOR|Vehicle|
62571200|NCT05864703|EXPERIMENTAL|Adjustment|Individuals with a subluxation who receive a true chiropractic adjustment
62395945|NCT04861766|EXPERIMENTAL|Treatment group Stylage L ®|"Each subject will receive STYLAGE® L in both NLFs.~STYLAGE® L will be injected in the NLFs by the Treating Investigator with optional touch-up injections on Month 1."
62778050|NCT03369002|EXPERIMENTAL|Mild Impairment|"Child-Pugh Score: A (5 to 6 points)~Subjects will receive a single 10 mg oral dose of seladelpar"
62778051|NCT03369002|EXPERIMENTAL|Moderate Impairment|"Child-Pugh Score: B (7 to 9 points)~Subjects will receive a single 10 mg oral dose of seladelpar"
62778052|NCT03369002|EXPERIMENTAL|Severe Impairment|"Child-Pugh Score: C (10 to 15 points)~Subjects will receive a single 10 mg oral dose of seladelpar"
62778053|NCT01487824||Preterm-born Young Adults|
62778054|NCT01487824||Term-born Young Adults|
62778055|NCT02689167|ACTIVE_COMPARATOR|Arm A 4/6|"Sunitinib 37.5 mg/day; regimen 4/6 (Marketing Authorisation Indication) 4 weeks on  alternating with 2 weeks off "
62778056|NCT02689167|EXPERIMENTAL|Arm B 2/3|"Sunitinib 50 mg/day; regimen 2/3 (experimental arm) 2 weeks on  alternating with 1 week off "
62778057|NCT04706156||Vaccinated Healthcare Workers (CZ)|Czech healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
62778058|NCT04706156||Vaccinated Healthcare Workers (DE)|German healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
62778059|NCT04706156||Vaccinated Healthcare Workers (SK)|Slovak healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
62002659|NCT02995252||Group 2: Hepatitis B infection|"Participants with chronic hepatitis B: includes patients with hepatitis B with and without hepatitis C and/or HIV. Participants will attend study visits for research blood draws (once a year with optional additional visits), and a one-time optional knowledge questionnaire. Participants who are already taking hepatitis B treatment are eligible.~Hepatitis B treatment sub-study: In this treatment sub-study, participants with hepatitis B monoinfection will receive tenofovir alafenamide (TAF) pill once a day for 2 years with study visits every 3 months. Liver transient elastography will be reviewed or obtained. In addition, approximately 40 participants will be invited to undergo optional liver biopsies at the start, end of year 1 and end of year 2 of the sub-study."
62002660|NCT03490266|ACTIVE_COMPARATOR|Laparoscopic Repair|The abdomen will be entered and insufflated utilizing a 5 mm optical port. Only 5 mm ports will be utilized laterally to take down all anterior abdominal wall adhesions. A mid-density polypropylene mesh with a one-sided adhesion barrier that provides at least 5 cm of overlap in all directions will be inserted through a 11 or 12 mm port placed through the defect. Excision of hernia sac and preperitoneal fat and defect closure will be performed per current practice. The mesh will be secured in four points with 0-PDS sutures and/or tacked with a double crown of tacks per our current practice.
62395946|NCT04861766|ACTIVE_COMPARATOR|Control group Active Comparator|"Each subject will receive the Active Comparator in both NLFs.~Active Comparator will be injected in the NLFs by the Treating Investigator with optional touch-up injections on Month 1."
62571201|NCT05864703|SHAM_COMPARATOR|Sham|Individuals with a subluxation who receive a light touch-only sham
62778060|NCT04706156||Vaccinated Healthcare Workers (TR)|Turkish healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
62778061|NCT02196480|NO_INTERVENTION|Methotrexate|JIA patients on stable dose of methotrexate vaccinated with PPV23
62778062|NCT02196480|EXPERIMENTAL|anti-TNF|JIA patients refractory to methotrexate immediately before the association of anti-TNF vaccinated with PPV23
62778063|NCT02186145|EXPERIMENTAL|Association of metronidazole; nystatin and dexamethasone|Intravaginal cream containing metronidazole (500 mg), nystatin ( 100.000 UI) and dexamethasone (0,32 mg) once a day. Period: 10 days.
62778064|NCT02186145|ACTIVE_COMPARATOR|Flagyl|Vaginal cream of metronidazole 500 mg, nystatin 100.000 UI - once a day. Period: 10 days
62778065|NCT04165629||Aspirin responders|On impedance aggregometry- Multiplate analyzer, if ASPI \< 600 or ASPI/TRAP \< 0.5
62778066|NCT04165629||Aspirin non-responders|On impedance aggregometry- Multiplate analyzer, if ASPI \> 600 or ASPI/TRAP \> 0.5
62778067|NCT04165629||Clopidogrel responders|On impedance aggregometry- Multiplate analyzer, if ADP \< 500 or ADP/TRAP \< 0.5
62778068|NCT04165629||Clopidogrel non-responders|On impedance aggregometry- Multiplate analyzer, if ADP \> 500 or ADP/TRAP \> 0.5
62778069|NCT05993962|PLACEBO_COMPARATOR|Control group|Participants received one daily serving (provided in one cup of 150grams) of unfortified yoghurt for 8 weeks
62778070|NCT05993962|EXPERIMENTAL|Fortified group|Participants received one daily serving (provided in one cup of 150grams) of yoghurt fortified with vitamin B12 for 8 weeks
62778071|NCT04071418||I-125 Seeds Implantation|All the enrolled patients were treated with CT-guided radioactive I-125 seeds implantation assisted by 3D printing template. Prescription dose 140-160gy.
62778072|NCT03633812||Beta blocker group|ESLD recipients who had beta blocker during more than 1 month before the liver transplantation
62778073|NCT03633812||Non-Beta blocker group|ESLD recipients who had not taken beta blocker more than 3 month before the liver transplantation
62395947|NCT05993481|ACTIVE_COMPARATOR|5 min. BP|"Clinicians will carry out randomized treatments in coordination with research staff.~The treatments will be: 1) Ephedrine treatment to maintain intraoperative MAP ≥60 mmHg, delayed resumption of chronic antihypertensive medications as monitoring with 5 min. Blood pressure management. The staff anesthesiologist will administer an ephedrine sulfate injection. An initial dose of 5 to 10 mg given as an intravenous bolus is advised for the treatment of clinically significant hypotension during anesthesia to provide an increase in blood pressure in case of MAP\< 60 mmHg. However, the dose of each will be titrated as necessary to reach the target mean arterial pressures."
62395948|NCT05993481|ACTIVE_COMPARATOR|2.5 min. BP|"Clinicians will carry out randomized treatments in coordination with research staff.~The treatments will be: 2) Ephedrine treatment to maintain intraoperative MAP ≥60 mmHg, delayed resumption of chronic antihypertensive medications as monitoring with 2.5 min. Blood pressure management.~The staff anesthesiologist will administer an ephedrine sulfate injection. An initial dose of 5 to 10 mg given as an intravenous bolus is advised for the treatment of clinically significant hypotension during anesthesia to provide an increase in blood pressure in case of MAP\< 60 mmHg. However, the dose of each will be titrated as necessary to reach the target mean arterial pressures."
62778074|NCT00345618|EXPERIMENTAL|Idrabiotaparinux|"Idrabiotaparinux sodium, 3.0 mg, once-weekly for 3 or 6 months depending on the stratum, after enoxaparin, 1.0 mg/kg, every 12 hours for at least 5 days.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or over-dosage)."
62778075|NCT00345618|ACTIVE_COMPARATOR|Warfarin|"Warfarin, INR-adjusted dose, started 24 hours after the start of enoxaparin, 1.0 mg/kg, every 12 hours for at least 5 days, and continued for 3 or 6 months depending on the stratum.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or over-dosage)."
62778076|NCT03688620|OTHER|Vaccinated_AlphaRix Tetra Group|Volunteered male and female subjects, 18 years of age and above, who received in Belgium one dose of GlaxoSmithKline's (GSK's) quadrivalent seasonal influenza vaccine (AlphaRix Tetra) between 01 October and 31 December 2018.
62778077|NCT03688620|OTHER|Vaccinated_Influsplit Tetra Group|Volunteered subjects male and female subjects, 18 years of age and above, who received in Germany one dose of GSK's quadrivalent seasonal influenza vaccine (Influsplit Tetra) between 01 October and 31 December 2018.
62395949|NCT00648765|EXPERIMENTAL|1|Anagrelide Hydrochloride Capsules 1 mg
62395950|NCT00648765|ACTIVE_COMPARATOR|2|Agrylin® Capsules 1 mg
62395951|NCT06598943|EXPERIMENTAL|Eltrekibart + Placebo|Participants will receive eltrekibart with placebo, eltrekibart or mirikizumab.
62395952|NCT06598943|EXPERIMENTAL|Mirikizumab + Placebo|Participants will receive mirikizumab and placebo or mirikizumab.
62395953|NCT06598943|EXPERIMENTAL|Eltrekibart + Mirikizumab|Participants will receive eltrekibart and mirikizumab in combination or separately as monotherapy.
62571202|NCT01315938|OTHER|Active treatment|Abatacept will be administered intravenously at a dose based on body weight at the screening visit (baseline): participants weighing \<60 kg received 500 mg, 60-100 kg received 750 mg and those \>100 kg received 1000 mg.
62395954|NCT06598943|EXPERIMENTAL|Placebo|Participants will receive placebo or mirikizumab.
62395955|NCT03858621|EXPERIMENTAL|fentanyl NOL guided|A bolus of 2 mcg/kg IV Fentanyl will be given at the induction of the anesthesia. A bolus of 0,5 - 1 mcg/kg IV Fentanyl will be given at the time of incision and during surgery following a predeterminate NOL index + heart rate + mean arterial blood pressure variations.
62395956|NCT03858621|NO_INTERVENTION|fentanyl standard analgesia|A bolus of 2 mcg/kg IV Fentanyl will be given at the induction of the anesthesia. A bolus of 0,5 - 1 mcg/kg IV Fentanyl will be given at the time of incision and during surgery following the heart rate and mean arterial blood pressure variations.
62395957|NCT03264560|ACTIVE_COMPARATOR|Synchronous Telepsychiatry (STP) group|
62395958|NCT03264560|EXPERIMENTAL|Asynchronous Telepsychiatry (ATP) group|
62571203|NCT01315938|OTHER|Delayed-onset treatment|Abatacept will be administered intravenously at a dose based on body weight at 3 months: participants weighing \<60 kg received 500 mg, 60-100 kg received 750 mg and those \>100 kg received 1000 mg.
62571204|NCT00916084|EXPERIMENTAL|Group A|
62778078|NCT03688620|OTHER|Vaccinated_Fluarix Tetra Group|Volunteered male and female subjects, between 6 months and 65 years of age, who received in Spain one or two dose(s) of GSK's quadrivalent seasonal influenza vaccine (Fluarix Tetra) between 01 October and 31 December 2018.
62778079|NCT04328272|EXPERIMENTAL|Hydroxychloroquine|tablet hydroxychloroquine (HCQ). Day-1 (initial) 1st dose, 3 tablets (200 mg per tablet), 2nd dose after 6 hours, 3 tablets (200 mg per tablet) per oral. From day 2 to 7 (maintenance dose), 2 tablets twice a day.
62187906|NCT03667937|EXPERIMENTAL|CUTIMED|"After an initial culture to determine the bacterial load by smear, we will proceed to the cure of the ulcer by washing the area with physiological saline solution and to mechanical debridement, if necessary, to apply the CUTIMED dressing. It will be covered with a secondary gauze dressing and a double compression bandage with a normal crepe bandage.~If the wound exudate decreases, or the removal of the dressing is difficult, it will be changed to CUTIMED gel; in case of abundant exudate, the use of alginate without silver will be allowed for the treatment, because it is neutral with the bacterial load, placed on the CUTIMED dressing.~Primary and secondary end-points will be measured at baseline and at 4, 8 and 12 weeks, except quality of life (only baseline and at 12 weeks)."
62187907|NCT03667937|ACTIVE_COMPARATOR|AQUACEL silver|"After an initial culture to determine the bacterial load by smear, we will proceed to the cure of the ulcer by washing the area with physiological saline solution and to mechanical debridement, if necessary, to apply Aquacel-Ag. It will be covered with a secondary gauze dressing and a double compression bandage with a normal crepe bandage.~Primary and secondary end-points will be measured at baseline and at 4, 8 and 12 weeks, except quality of life (only baseline and at 12 weeks)."
62187908|NCT00590226|EXPERIMENTAL|detremir + aspart insulin|Detemir insulin once daily + aspart insulin before meals three times a day at an initial total dose of 0.5 units/kg/day, subcutaneously
62187909|NCT00590226|ACTIVE_COMPARATOR|NPH + regular insulin|NPH insulin once a day + regular insulin before breakfast and dinner at an initial total dose of 0.5 units/kg/day, subcutaneously
62778080|NCT04328272|ACTIVE_COMPARATOR|Azithromycin|Tablet azithromycin (AZC) 500 mg orally as a single dose on day 1, followed by 250 mg orally once a day on days 2 to 7.
62778081|NCT04328272|PLACEBO_COMPARATOR|Suger Tablets|Placebo (sugar tablet) twice daily for 7 days
62187910|NCT00915577|EXPERIMENTAL|1st Injection|Manual injection with pre-filled syringe.
62187911|NCT00915577|EXPERIMENTAL|Single-use autoinjector|Single-use autoinjector with Avonex pre-filled syringe
62395959|NCT04445454|EXPERIMENTAL|MSC therapy for severe COVID-19 infection|After signed informed consent, patients will receive 3 infusions of (1.5)-3.0 x106/kg BM-MSC (from the same donor) at 3-4 days interval, in addition to the standard of care for COVID-19 disease.
62395960|NCT05205642|EXPERIMENTAL|Patients recovering from COVID-19|Pediatric and adult patients recovering from COVID-19 with or without complaints.
62395961|NCT03809962||Ostenil® Plus|1-3 injections of sodium hyaluronate 2% (40 milligrams (mg) / 2,0 millilitres (ml)) in weekly interval.
62395962|NCT06070298||Abnormal Echocardiography Diagnosis|Participants with abnormal echocardiography diagnosis within three years.
62395963|NCT06070298||Normal Echocardiography Diagnosis|Participants with normal echocardiography diagnosis within three years.
62187912|NCT00025506|EXPERIMENTAL|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62187913|NCT02626247|ACTIVE_COMPARATOR|Vitamin A + Long chain PUFA|The test product is a food supplement containing Vitamin A + Long chain Poly Unsaturated Fatty Acids (PUFA). It is presented as a hard shell capsule containing lipophylic nutrients.
62187914|NCT02626247|PLACEBO_COMPARATOR|Placebo|The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
62395964|NCT05620849|EXPERIMENTAL|Intervention only|This group will complete 4 weeks of the brief online program along with 5 weeks of check-in surveys.
62395965|NCT05620849|NO_INTERVENTION|Assessment only|This group will complete 5 weeks of check-in surveys.
62395966|NCT05372419|EXPERIMENTAL|Lebrikizumab|Participants will receive Lebrikizumab subcutaneously (SC).
62395967|NCT06722625|NO_INTERVENTION|Control group|Standard care involving regular visits to a hypertension clinic. Patients in the control group will receive standard care. They will have appointments according to the guidelines of the Polish Society of Hypertension -initially once a month and, after achieving control (i.e., blood pressure in office measurement \< 140/90 mmHg), once every 3 months.
62778082|NCT06023615|EXPERIMENTAL|Intervention Group|Usual Care + mHealth/Telehealth
62187915|NCT03051425|EXPERIMENTAL|Test group|Probiotic yogurt supplementation
62778083|NCT06023615|NO_INTERVENTION|Control Group|Usual Care + Attention Control
62778084|NCT03006692||Take arterial blood gas|Patients with impaired consciousness are randomised into having analysed a arterial blood gas.
62778085|NCT03006692||Do not take arterial blood gas|Patients with impaired consciousness are randomised into not having analysed a arterial blood gas.
62571205|NCT00916084|EXPERIMENTAL|Group B|
62571206|NCT04722705|EXPERIMENTAL|combined IPL/fractional Er:YAG laser treatment site|"At baseline, three lesions were randomized to IPL / fractional Er:YAG laser combination therapy site.~Topical anesthetic cream was applied to the scar 30 minutes before laser treatment. The same dermatologist performed all laser treatments including IPL and 2,940 nm Er:YAG fractional laser. The face was cooled after treatment with gauze soaked in ice water.~The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
62571207|NCT04722705|ACTIVE_COMPARATOR|fractional Er:YAG laser treatment alone site|"At baseline, three lesions were randomized to fractional Er:YAG laser combination therapy site.~Topical anesthetic cream was applied to the scar 30 minutes before laser treatment. The same dermatologist performed 2,940 nm Er:YAG fractional laser. The face was cooled after treatment with gauze soaked in ice water.~The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
62571208|NCT04722705|NO_INTERVENTION|untreated control site|At baseline, three lesions were randomized to untreated control site. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment. The evaluation of scar site was conducted 3 months later after last treatment.
62002661|NCT03490266|EXPERIMENTAL|Robotic Repair|Three lateral ports will be placed including a 12 port for the camera. Adhesions will be taken down from the anterior abdominal wall. Hernia sac and preperitoneal fat will be excised per current practice and defect will be closed using a running locking barbed suture. A mid-density polypropylene mesh with a one-sided adhesion barrier that provides at least 5 cm of overlap in all directions will be inserted through the 12 mm port. The mesh will be secured circumferentially with a running barbed suture.
62395968|NCT06722625|EXPERIMENTAL|Study group|In the intervention group, a care model using a system implementing an algorithm that supports therapeutic and diagnostic decisions made by the doctor in the care of patients with AH will be applied. The algorithm identifies patients who have or have not achieved therapeutic goals and suggests actions for specific patients, but the final therapeutic and diagnostic decisions are always made by the doctor. It is emphasized that the treating physician is not bound by the algorithm's recommendations.
62571209|NCT03704025|ACTIVE_COMPARATOR|Current guidelines rehabilitation|Exercise rehabilitation at home according to current guidelines. Training is guided and controlled by diary.
62187916|NCT03051425|PLACEBO_COMPARATOR|Placebo group|Placebo supplementation
62187917|NCT00884650|ACTIVE_COMPARATOR|Oral Analgesic Only|Group 1 will receive oral analgesic only
62187918|NCT00884650|ACTIVE_COMPARATOR|anesthetic continuous-infusion + oral analgesia|Group 2: anesthetic continuous-infusion device, e.g. intravenous analgesic per pump, with supplemental oral analgesia
62187919|NCT02353416|PLACEBO_COMPARATOR|INRAM guidelines' diet|Intervention in this arm consists in some general dietary advice about healthy dietary components, serving size and frequency of servings following the Italian official guidelines.
62187920|NCT02353416|ACTIVE_COMPARATOR|Low Glycemic Index Mediterranean Diet|Intervention in this arm consists in a Low Glycemic Index Mediterranean Diet with indication about type of foods than can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
62187921|NCT04427176||Nurses|"Nursing staff working 8 or 12 hours a day for 2 consecutive days in a COVID unit at the hospital of Saint Etienne will be included.~They will be wear ARFC mask."
62187922|NCT00495092|EXPERIMENTAL|1|This study arm will receive caffeine+placebo
62187923|NCT00495092|EXPERIMENTAL|2|this study arm will receive Caffeine+Biperiden
62395969|NCT06040437|EXPERIMENTAL|Be-Prox intervention|Training in the 6 Be-Prox module
62187924|NCT00495092|PLACEBO_COMPARATOR|3|this study arm will receive placebo+placebo
62187925|NCT04847310|EXPERIMENTAL|Group 1|
62187926|NCT04847310|EXPERIMENTAL|Group 2|
62187927|NCT04847310|ACTIVE_COMPARATOR|Group 3|
62187928|NCT01587443||Hemodialysis|
62395970|NCT06040437|NO_INTERVENTION|Control|Standard care
62395971|NCT06724367|EXPERIMENTAL|Transspinal direct current stimulation|This group will receive 10 sessions of transspinal direct current stimulation associated with gait training.
62395972|NCT06724367|SHAM_COMPARATOR|Transspinal direct current stimulation sham|This group will receive 10 sessions of sham transspinal direct current stimulation associated with gait training.
62395973|NCT02861248|EXPERIMENTAL|Laser treatment|Fractional micro-plasma radiofrequency treatment given to 95 patients with non-hypertrophic burn scar.
62395974|NCT03065010|OTHER|BCD-115 in dose escalation regimen|BCD-115 will be administered p.o. with intrapatient dose escalation in the population of patients with ER(+) HER2(-) advanced breast cancer in combination with a standard dose of endocrine therapy.
62395975|NCT05275855|EXPERIMENTAL|Part A: EDI048 or Placebo|Part A is a single ascending dose study
62395976|NCT05275855|EXPERIMENTAL|Part B: EDI048 or Placebo|Part B is a multiple ascending dose study
62395977|NCT05807464||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
62395978|NCT06722508|EXPERIMENTAL|behavioral intervention|The study involves a behavioral intervention (exercise and nutritional prehabilitation) designed to assess outcomes related to feasibility, acceptability, and safety in head and neck cancer patients. Outcomes are being measured following the intervention over a defined period (from diagnosis through 1-month post-surgery).
62395979|NCT06668584|EXPERIMENTAL|Olutasidenib Maintenance Therapy|Participants will be given screening tests to determine eligibility to study
62395980|NCT04663646|EXPERIMENTAL|Intervention Group|
62395981|NCT04663646|PLACEBO_COMPARATOR|Control Group|
62395982|NCT06533176|EXPERIMENTAL|Brain state-dependent TMS during strong states|
62395983|NCT06533176|ACTIVE_COMPARATOR|Brain state-dependent TMS during random states|
62395984|NCT06144749|EXPERIMENTAL|Ascending Multiple Dose|Drug: HBI-002 (oral liquid carbon monoxide drug product)
62187929|NCT01587443||Peritoneal dialysis|
62187930|NCT04519593|EXPERIMENTAL|Laparoscopic myomectomy with temporary blood supply occlusion|Laparoscopic myomectomy is performed with prior visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.
62187931|NCT04519593|ACTIVE_COMPARATOR|Conventional laparoscopic myomectomy|Laparoscopic myomectomy is performed without prior temporary blood supply occlusion.
62187932|NCT03391856|EXPERIMENTAL|intervention arm|NAC 400mg p.o tid from day 60 to day 90 post transplant
62187933|NCT03391856|OTHER|controlled arm|Supportive therapy including platelet infusion:prophylactic platelet transfusion was given when platelet count \<20000/ul
62187934|NCT02775838|EXPERIMENTAL|kidney transplantation|Intravenous injection of Indocyanine Green in patients receiving kidney transplantation
62187935|NCT01729468|EXPERIMENTAL|Aspirin|Aspirin 160 mg per day
62187936|NCT01729468|PLACEBO_COMPARATOR|Placebo|Placebo 160 mg per day
62187937|NCT00585078|EXPERIMENTAL|CAPOX|Participants self-administered capecitabine 1,000 mg/m2 orally twice daily (total daily dose 2,000 mg/m2), days 1-14 in 21-day cycles. Only 500 mg tablets were used, and doses were rounded to the nearest dose that could be administered with 500 mg tablets. Oxaliplatin 130 mg/m2 was administered intravenously on day 1 every 21 (±2) days. Treatment continued until tumor progression or toxicity requiring discontinuation of therapy.
62187938|NCT02386553|EXPERIMENTAL|Nusinersen|Nusinersen administered as an intrathecal injection
62187939|NCT00656201|ACTIVE_COMPARATOR|Crinone 8% Vaginal Gel|Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
62187940|NCT00656201|ACTIVE_COMPARATOR|Intramuscular Progesterone|"Progesterone-50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.~."
62187941|NCT05907642|EXPERIMENTAL|Prune|During the first 3 days of taking the prunes, 60 g (6 pieces of prune) were consumed per day, and if there were no symptoms corresponding to the safety endpoints for 3 days, the amount was increased to 100 g per day thereafter. Prunes were consumed twice, half each in the morning and afternoon, and the total intake period was 18 days.
62187942|NCT05907642|PLACEBO_COMPARATOR|No-prune|No intervention was provided to the control group, and all normal diets were allowed except for prunes during the study period, for 18 days.
62187943|NCT02830828||Patients|Patients fulfilling inclusion/exclusion criteria referred to the PI with suspected carpal tunnel syndrome.
62187944|NCT02830828||Controls|"Healthy volunteers fulfilling inclusion/exclusion criteria with no symptoms of carpal tunnel syndrome.~Mid-study, it was elected to also match patients to their own contralateral disease-free hand to act as a control."
62187945|NCT01806389||Buprenorphine|Buprenorphine maintained women at delivery of their infant
62187946|NCT00394589|EXPERIMENTAL|Increased Frequency|Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks
62187947|NCT00394589|EXPERIMENTAL|Increased Dose|3 mg/kg infliximab + 1 extra vial (100 mg) infliximab, every 8 weeks
62187948|NCT00394589|ACTIVE_COMPARATOR|Control|Continuation of infliximab 3 mg/kg every 8 weeks
62187949|NCT02595606|EXPERIMENTAL|treatment group|treatment with 0.3% Sodium Hyaluronate, by five times a day, one or two drop each time
62571210|NCT03704025|EXPERIMENTAL|Mobile device guided rehabilitation|Exercise rehabilitation at home according to current guidelines. Training is guided and controlled by virtual augmented reality glasses or by mobile device.
62571211|NCT04177095|EXPERIMENTAL|Belatacept treated patients|Renal transplant recipients treated with a combination of belatacept and any of the following: mycophenolate, sirolimus, everolimus and prednisone
62187950|NCT02595606|NO_INTERVENTION|control group|without treatment
62187951|NCT01102192||Myasthenia gravis with thymoma|Myasthenia gravis with thymoma
62571212|NCT06445712|EXPERIMENTAL|Pain Assessment|Children will submerge their hand in cold water and be asked to hold it in as long as possible. They will do this both alone and holding the hand of a parent (counterbalanced).
62571213|NCT00612274|EXPERIMENTAL|1|sirolimus, tacrolimus and short course methotrexate
62571214|NCT01602367|EXPERIMENTAL|Arm 1: BMS-823778 (2mg)|
62571215|NCT01602367|EXPERIMENTAL|Arm2: BMS-823778 (6mg)|
62571216|NCT01602367|EXPERIMENTAL|Arm 3: BMS-823778 (15mg)|
62187952|NCT01102192||Myasthenia gravis without thymoma|Myasthenia gravis without thymoma
62187953|NCT01102192||Thymoma without Myasthenia gravis|Thymoma without Myasthenia gravis
62187954|NCT01102192||cardiac, or thyroid surgery|cardiac, or thyroid surgery
62187955|NCT03082755|EXPERIMENTAL|Gabapentin Enacarbil (GEn)|1 to 2 GEn tablets (300 mg) will be administered by mouth (PO) once a day in the evening (about 5 pm) for 8 weeks then tapered for 1 week. The study drug will be adjusted up to a maximum dosage of 600 mg as tolerated.
62187956|NCT03082755|PLACEBO_COMPARATOR|Placebo|1 to 2 Placebo Oral Tablet(s) will be administered once a day in the evening (about 5 pm) for 8 weeks then tapered for 1 week. The placebo drug will be adjusted up to a maximum dosage of 2 tablets as tolerated.
62187957|NCT01605786|EXPERIMENTAL|PEBS Low dose|
62395985|NCT06624839|EXPERIMENTAL|HIV positive Transgender persons assigned male at birth (TG-AMAB)|One dose of human papillomavirus (HPV) vaccine, 9-valent (Gardasil9) will be administered on Day 0, Month 2, and Month 6
62571217|NCT01602367|EXPERIMENTAL|Arm4: Placebo|
62571218|NCT02175693||E2014|
62187958|NCT01605786|EXPERIMENTAL|PEBS High dose|
62395986|NCT06624839|ACTIVE_COMPARATOR|HIV Negative Assigned Male at Birth (AMAB)|One dose of human papillomavirus (HPV) vaccine, 9-valent (Gardasil9) will be administered on Day 0, Month 2, and Month 6
62395987|NCT06045468|EXPERIMENTAL|Study group|Patients in inpatient rehabilitation in study center.
62395988|NCT06045468|EXPERIMENTAL|Control group|Patients in inpatient rehabilitation facility of collaborating clinics.
62187959|NCT01605786|ACTIVE_COMPARATOR|Control|
62187960|NCT02270307|EXPERIMENTAL|MSC+CY|Cyclophosphamide 50 mg/kg/day at +3, +4 day once daily after BMT Mesenchymal stromal cells 1\*10\^6/kg at day of recovery
62395989|NCT06546709|EXPERIMENTAL|Cohort 1 - LASSARAB+ aPHAD-SE Vaccine at 700rU or Active Comparator (AC)|4:1 randomization to investigational vaccine or active comparator (n=5)
62571219|NCT01506401|ACTIVE_COMPARATOR|Conventional Ventilation|Low tidal volumes, relatively high PEEP.
62571220|NCT01506401|EXPERIMENTAL|High Frequency Oscillation|Open-lung strategy for high frequency oscillation.
62571221|NCT06461962|ACTIVE_COMPARATOR|Peer-supported Treatment as Usual|Participants will receive a peer-supported referral to a local primary care provider who will create a plan to treat the participants heart failure.
62571222|NCT06461962|EXPERIMENTAL|Peer-Supported Telehealth Cardiology|Participants will receive a virtual consultation with a cardiovascular specialist, referral for a locally performed echocardiogram (ECG), and transitional care management facilitated by a remote nurse care manager and the peer to treat the participants heart failure.
62571223|NCT05527275|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection Combined With Chidamide|
62778086|NCT04939792|PLACEBO_COMPARATOR|Placebo|"Initially, all of the study subjects will be provided placebo supplementation as a placebo run-in period for one month before randomization. The placebo run-in period is meant to stabilize subjects in the study and will prevent any effect due solely to inclusion in the study. Placebo and supplement capsules will be similar in appearance, taste, texture, and smell, and will be provided by the pharmacist, who will have the codes for which subjects are assigned to which supplement or placebo.~During testing, the placebo group will take two placebo capsules a day in the morning. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle"
62187961|NCT05726266|EXPERIMENTAL|Music Group|Patients randomized to this group will listen daily to a musical playlist for 30 - 60 minutes in a row through a mobile device. This will be performed in addition to the opioid treatment.
62187962|NCT05726266|PLACEBO_COMPARATOR|Audiobooks Group|Patients randomized to this group will listen to an audiobook daily for 30 - 60 minutes in a row through a mobile device. This will be performed in addition to the opioid treatment.
62571224|NCT00086684|EXPERIMENTAL|Pentosan polysulfate sodium 100 mg once a day|One 100 mg pentosan polysulfate sodium capsule in the morning and 1 matching placebo capsule in the afternoon and evening for 24 weeks
62187963|NCT04596605|EXPERIMENTAL|T2309|4 capsules daily for 12 weeks
62187964|NCT04596605|ACTIVE_COMPARATOR|Nutrof Total|2 capsules daily for 12 weeks
62187965|NCT02632812|EXPERIMENTAL|Rebamipide & Naproxen|Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg) for 7 days
62187966|NCT02632812|PLACEBO_COMPARATOR|Placebo & Naproxen|Sugar pill manufactured to mimic Rebamipide 100 mg effervescent granules (oral) Twice daily for 7 days
62187967|NCT03750253|OTHER|Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy to relieve pain after arthroscopy for osteochondral lesions of talus
62187968|NCT03626831|ACTIVE_COMPARATOR|Treatment|Baseline vascular function parameters will be obtained and the patient will be given an SC injection of the study drug by Evolocumab Prefilled Syringe (1x SC 420 mg evolocumab).
62187969|NCT03626831|PLACEBO_COMPARATOR|Placebo|Baseline vascular function parameters will be obtained and the patient will be given an SC injection of Placebos (1x SC Placebo).
62187970|NCT04003194|EXPERIMENTAL|Pinto beans|1/2 cup pinto beans eaten daily by free-living individuals for 12 consecutive weeks.
62187971|NCT04003194|ACTIVE_COMPARATOR|Green beans|1/2 cup green beans eaten daily by free-living individuals for 12 consecutive weeks.
62187972|NCT04213677|EXPERIMENTAL|Dapagliflozin|Dapagliflozin (Participants will receive dapagliflozin 10mg po qd).
62187973|NCT04213677|PLACEBO_COMPARATOR|Placebo|Placebo (Participants will receive placebo po qd)
62187974|NCT06421987||SURVIVOR|"A survivor of Hodgkin Lymphoma (HL) treated with chest radiation and bleomycin at St. Jude Children's Research Hospital.~and Control: Voluntarily taking part in this study because you are a relative, friend or employee of St. Jude Children's Research Hospital."
62778087|NCT04939792|EXPERIMENTAL|L-Cysteine|LC group will receive two capsules of LC daily. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle
62187975|NCT03362034|ACTIVE_COMPARATOR|single transfer tray|
62187976|NCT03362034|EXPERIMENTAL|double transfer trays|
62571225|NCT00086684|EXPERIMENTAL|Pentosan polysulfate sodium 100 mg three times a day|One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning afternoon and evening) for 24 weeks
62571226|NCT00086684|PLACEBO_COMPARATOR|Placebo|Placebo One placebo capsule 3 times a day (morning afternoon and evening) for 24 weeks
62571227|NCT03533153|EXPERIMENTAL|WJ-MSC cells implantation group|"MSC cells (allogeneic transplantation from WJ-MSC primary cells); the frequency: for one time within12h after emergency coronary artery revascularization; dose levels: 1X10\^8; method of administration: intravenous injection. Other kinds of treatment are in accordance with the treatment guidelines for MI patients, listed in the column Conventional drug therapy."
62778088|NCT04939792|EXPERIMENTAL|Vitamin D3|VD group will take two capsules and each capsule will contain 1000 IU VD daily. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle
62187977|NCT01847937||Diabetics Type I non-neuropathic|Diabetics with type 1 diabetes and without neuropathy
62187978|NCT01847937||Diabetics Type II non-neuropathic|Diabetics with type 2 diabetes without neuropathy
62187979|NCT01847937||Diabetics Type I neuropathic|Diabetics with type 1 diabetes and neuropathy
62187980|NCT01847937||Diabetics Type II neuropathic|Diabetics with type 2 diabetes and neuropathy
62187981|NCT01847937||Hereditary axonal neuropathic|
62187982|NCT01847937||Hereditary demyelinated neuropathic|This will mainly be patients with Chronic inflammatory demyelinating polyneuropathy (CIDP).
62187983|NCT00745498|EXPERIMENTAL|Preop IVB|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 1 to 14 days before vitrectomy
62187984|NCT00745498|EXPERIMENTAL|Intraop IVB|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
62187985|NCT00745498|NO_INTERVENTION|No IVB|Patients will not receive bevacizumab before nor during vitrectomy
62187986|NCT03065933|EXPERIMENTAL|clonidine as an antimanic agent|Subjects with Bipolar Disorder, Mania receive an extended-release form of clonidine on the second day of this 3-day study. Rating scales, record of sleep, and a questionnaire of adverse effects is recorded on each of the three days.
62571228|NCT03533153|PLACEBO_COMPARATOR|CTSTMD PBS without WJ-MSC group|"Saline only was injected in the control group. The frequency: for one time 2-12h after emergency coronary artery revascularization. Dose levels: the same dosage given to MSC group. Method of administration: intravenous injection. Other kinds of treatment are in accordance with the treatment guidelines for MI patients, listed in the column Conventional drug therapy."
62571229|NCT05609760|EXPERIMENTAL|Pictogram Group|"This intervention consists of using a pictogram system called SIMAP which was developed and validated in previous research.~Participants allocated to this arm will received a pictographic depiction of their medical indications generated by an automated system. Information will include a description of inhaler functions, inhaler technique and correct aerochamber use."
62571230|NCT05609760|SHAM_COMPARATOR|Usual Care Group|These patients will receive their medical indications in the usual way, as established by the health team of the participating clinics. In addition, these patients will receive a bronchial asthma information leaflet as part of the usual education when explaining the disease. No pictograms will be included in these leaflets.
62187987|NCT05784766|ACTIVE_COMPARATOR|Screen group|Patients randomized to screening will undergo a 30-second ECG using the Kardia Mobile device (AliveCor Inc, Cupertino, CA) paired with an iPad (Apple, Cupertino, CA). If the mobile ECG shows possible AF or unclassified, then patients will undergo a 12-lead standard ECG during the same visit, read by a cardiologist, to verify the correct diagnosis.
62778089|NCT04939792|EXPERIMENTAL|Vitamin D3 and L-Cysteine|VD+LC group will take daily two capsule containing 1000 IU+500 mg LC. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle
62187988|NCT05784766|ACTIVE_COMPARATOR|Usual Care|For patients in the usual care arm, medical record review will be done at end of study to assess for the newly diagnosed AF during the study period.
62187989|NCT00882076|EXPERIMENTAL|Treatment Cohort 1|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2 (3 doses); Clofarabine (Days 2-6) 20 mg/m2
62187990|NCT00882076|EXPERIMENTAL|Treatment Cohort 2|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 25 mg/m2
62187991|NCT00882076|EXPERIMENTAL|Treatment Cohort 3|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 30 mg/m2
62187992|NCT00882076|EXPERIMENTAL|Treatment Cohort 4|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-5) 8 mg/m2; Clofarabine (Days 2-6) 30 mg/m2
62187993|NCT00882076|EXPERIMENTAL|Treatment Cohort 0|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 10 mg/m2 (In the event of a DLT in Treatment Cohort 1)
62187994|NCT04484389|EXPERIMENTAL|Study Group|Individual exercises will be applied to individuals with Chronic disease.
62395990|NCT06546709|EXPERIMENTAL|Cohort 2 - LASSARAB+ aPHAD-SE Vaccine at 700rU or 1400rU or AC|11:4:3 randomization to investigational vaccine dose 700rU or 1400rU or active comparator (n=18)
62778090|NCT00336557||Regularly Scheduled NAb Testing Arm|Subjects will be scheduled for 5 study visits over the course of 12 months and any NAbs test results will be available to the investigator during the study.
62778091|NCT00336557||Usual Care Arm|Subjects will be scheduled for 2 study visits over the course of 12 months and any NAbs test results will be unknown by the investigator until the conclusion of the subject's study participation.
62778092|NCT06512740||Head Start children and families|Children (1,837) Parents (1,837) Teachers (631) Program directors (176) Center directors (344)
62778093|NCT06409364|EXPERIMENTAL|Study drug|Fludrocortisone Acetate 100ug Q6 hourly, given enterally for 14 days
62187995|NCT04484389|ACTIVE_COMPARATOR|Control Group|Group to be given an exercise brochure
62187996|NCT04592081|EXPERIMENTAL|DEXTENZA placed within the upper canaliculus|Dextenza placed within the upper canaliculus following bilateral cataract extraction surgery with posterior chamber intraocular lenses implantation.
62187997|NCT04592081|ACTIVE_COMPARATOR|DEXTENZA placed within the lower canaliculus|Dextenza placed within the lower canaliculus following bilateral cataract extraction surgery with posterior chamber intraocular lenses implantation.
62187998|NCT06024915|EXPERIMENTAL|Itraconazole drug-durg interaction (DDI)|Itraconazole capsule: 0.2g once daily on Days 2 to Day 5; TQ05105 tablets: single oral dose on Days 1 and Day 5.
62187999|NCT06024915|EXPERIMENTAL|Rifampicin DDI|Rifampicin Capsule: 0.6g once daily on Days 2 to Day 9; TQ05105 tablets: single oral dose on Days 1 and Day 9.
62395991|NCT06546709|EXPERIMENTAL|Cohort 3 - LASSARAB+ aPHAD-SE Vaccine at 1400rU Single or Double or AC or AC/Placebo|11:2:4:1 randomization to investigational vaccine single dose at 1400rU or investigational vaccine (2 doses) at 14rU or active comparator or active comparator and normal saline placebo
62395992|NCT06546709|EXPERIMENTAL|Cohort 4 - LASSARAB+ aPHAD-SE Vaccine at 1400rU (single) or AC/Placebo|11:3 randomization to investigational vaccine (2 doses) at 14rU or active comparator and normal saline placebo
62188000|NCT02762903|ACTIVE_COMPARATOR|Tenotomy|Subjects will receive shoulder prosthesis for subscapularis repair during TSA with tenotomy technique.
62188001|NCT02762903|ACTIVE_COMPARATOR|Osteotomy|Subjects will receive shoulder prosthesis for subscapularis repair during TSA with lesser tuberosity osteotomy technique.
62395993|NCT03104465|EXPERIMENTAL|Mindfulness training|6 90-minute sessions interactive, web-based mindfulness training complemented with mobile application
62395994|NCT01632007|EXPERIMENTAL|SYR-472 100 mg|
62395995|NCT01632007|ACTIVE_COMPARATOR|Alogliptin 25 mg|
62571231|NCT00778869|EXPERIMENTAL|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
62778094|NCT06409364|PLACEBO_COMPARATOR|Placebo|Matched placebo tablet Q6 hourly, given enterally for 14 days
62188002|NCT02239744|EXPERIMENTAL|True air purification|One group of subjects used an intervention of true air purifiers placed in the center of the room.
62395996|NCT01632007|PLACEBO_COMPARATOR|Placebo|
62778095|NCT02780544|EXPERIMENTAL|skin-to-skin contact + sucrose|the infants get 2 eye examinations within 1 week in randomized order, one in skin-to-skin position with a parent (intervention group) and one in the incubator (standard care). Sucrose (0.2 ml) lingual will be given for pain relief according to standard care two minutes before either eye examination.
62778096|NCT02780544|ACTIVE_COMPARATOR|incubator + sucrose|the infants get 2 eye examinations within 1 week in randomized order, one in the incubator (standard care) and one in skin-to-skin position with a parent (intervention group). Sucrose (0.2 ml) lingual will be given for pain relief according to standard care two minutes before either eye examination
62778097|NCT01123395|EXPERIMENTAL|Colcrys® (colchicine USP) 0.6 mg intact tablet|One Colcrys® (colchicine USP) 0.6 mg intact tablet taken by mouth
62778098|NCT01123395|EXPERIMENTAL|Colcrys® 0.6 mg tab in apple juice|One Colcrys® 0.6 mg tablet crushed and dissolved in apple juice
62188003|NCT02239744|SHAM_COMPARATOR|Sham air purification|This group of subjects used an intervention of sham air purifiers under the same conditions with true purifiers with the only difference being removal of the filter gauze in the sham purifiers.
62188004|NCT02526186|NO_INTERVENTION|Standard of Care|Standard of Care only
62188005|NCT02526186|EXPERIMENTAL|Battlefield Auricular Acupuncture|Standard of Care plus Battlefield Auricular Acupuncture
62188006|NCT00943046|EXPERIMENTAL|Siello pacemaker lead|Patients with Siello Pacemaker lead
62188007|NCT02138344||SCI subjects|Chronic and traumatic SCI subjects
62395997|NCT05391113|EXPERIMENTAL|Autism Spectrum Disorder|Characterized by two main diagnostic criteria: a socio-emotional deficit via a defect in communication and social reciprocity, and a behavioral deficit which manifests itself in repetitive behavioral patterns (stereotypes), restricted interests and/or activities.
62395998|NCT05391113|ACTIVE_COMPARATOR|Food Addictive Disorders|Characterized by regroup substance use disorders and behavioral addictions, are characterized in particular by the repeated occurrence of compulsive behavior and impaired social functioning
62395999|NCT05391113|PLACEBO_COMPARATOR|Healthy volonteers|Adult without neurological and psychiatric history, absence of progressive somatic pathologies or with vital risk.
62396000|NCT05464914|NO_INTERVENTION|Conventional upper immediate denture|Conventional upper immediate denture without any surgical lining
62002662|NCT05936255|EXPERIMENTAL|Give to Others Module|A brief, talk therapy protocol that targets negative interpersonal beliefs (i.e., perceived social disconnection, burdensomeness) using cognitive-behavioral strategies.
62002663|NCT01550874|NO_INTERVENTION|Control Group|Wear the pedometer provided by study everyday with weekly charging and syncing of data.
62002664|NCT01550874|EXPERIMENTAL|Experimental Group|Wear the pedometer provided by the study everyday and also participate in phone-based physical activity behavior-change counselling for 6 months and then check sustainability without further motivational support for another 6 months.
62002665|NCT05928650||Sprinters|Sprinters
62002666|NCT05928650||Long marathon runners|Long marathon runners
62002667|NCT05928650||Non-athletic Females|Non-athletic Females
62002668|NCT02994342|ACTIVE_COMPARATOR|Vaginal gel, Medical Device Class 2A|Every subject has been treated for 56 consecutive days, twice daily with a vaginal application
62002669|NCT02994342|NO_INTERVENTION|Lifestyle counseling|Every subject has been observed for 56 consecutive days
62002670|NCT01015248|EXPERIMENTAL|Rituximab and Bendamustine|
62002671|NCT02624284|SHAM_COMPARATOR|Sham dose|Participants in this arm will receive the sham transcranial direct current stimulation (tDCS) procedure. During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS.
62002672|NCT02624284|EXPERIMENTAL|1mA dose|Participants in this arm will receive the 1mA transcranial direct current stimulation (tDCS) procedure. A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).
62002673|NCT02624284|EXPERIMENTAL|2 mA dose|Participants in this arm will receive the 2 mA transcranial direct current stimulation (tDCS) procedure. A neuroConn DC-Stimulator Plus will apply a constant direct current (2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).
62188008|NCT02138344||Healthy control subjects|
62188009|NCT02138344||Subjects with peripheral nerve diseases|
62396001|NCT05464914|ACTIVE_COMPARATOR|Upper immediate denture lined by surgical dressing|Upper immediate denture lined by surgical dressing using CEO Pack dressing
62396002|NCT01106066|EXPERIMENTAL|S-1/oxaliplatin/RT|Radiotherapy + 4 dose levels of oxaliplatin/S-1
62396003|NCT01377142||Laparoscopic sacral hysteropexy|Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance
62396004|NCT01377142||Vaginal mesh hysteropexy|Vaginal Mesh Hysteropexy using the Uphold device which includes Sacrospinous Ligament Fixation
62396005|NCT00863265|EXPERIMENTAL|Crossover order ABC|The order of treatments is A (phytosterols + ezetimibe), B (double placebo), and C (active ezetimibe and phytosterol placebo).
62396006|NCT00863265|EXPERIMENTAL|Crossover order BCA|The order of treatments is B (double placebo), C (active ezetimibe and phytosterol placebo), and A (phytosterols + ezetimibe).
62396007|NCT00863265|EXPERIMENTAL|Crossover order BAC|The order of treatments is B (double placebo), A (phytosterols + ezetimibe), and C (active ezetimibe and phytosterol placebo)
62396008|NCT00863265|EXPERIMENTAL|Crossover order ACB|The order of treatments is A (phytosterols + ezetimibe), C (active ezetimibe and placebo phytosterols, and B (double placebo).
62396009|NCT00863265|EXPERIMENTAL|Crossover order CAB|The order of treatments is C (active ezetimibe and placebo phytosterols), A (phytosterols + ezetimibe), and B (double placebo).
62396010|NCT00863265|EXPERIMENTAL|Crossover order CBA|The order of treatments is C (active ezetimibe and placebo phytosterols), B (double placebo), and A (phytosterols and ezetimibe).
62396011|NCT04227678|OTHER|Control group- A0|"Control group: Healthy subjects with fasting glucose \< 5.6, 2-hour post 75g Oral Glucose Tolerance Test (OGTT) glucose \< 7.8 mmol/l and HbA1c \< 5.8%; fasting TG \< 1.5 mmol/l);~A0: without heparin administered"
62396012|NCT04227678|OTHER|LPLD group-A0|"LPLD group: LPL deficient subjects with history of fasting TG \> 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;~A0: without heparin administered"
62396013|NCT04227678|OTHER|Control group-A1|"Control group: Healthy subjects with fasting glucose \< 5.6, 2-hour post 75g OGTT glucose \< 7.8 mmol/l and HbA1c \< 5.8%; fasting TG \< 1.5 mmol/l);~A1: with an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours starting 15 minutes before ingestion of liquid meal."
62396014|NCT04227678|OTHER|LPLD group-A1|"LPLD group: LPL deficient subjects with history of fasting TG \> 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;~A1: with an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours starting 15 minutes before ingestion of liquid meal."
62188010|NCT02165410|EXPERIMENTAL|Eye tracking and RMI|
62571232|NCT02823665|EXPERIMENTAL|Exendin-(9-39)|To evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
62778099|NCT03969186|EXPERIMENTAL|Daily telehealth follow-up|The intervention arm will receive a simple telehealth intervention utilizing the Way to Health Platform engineered at the University of Pennsylvania. This platform will be used to send daily SMS messages to patients for 90 days following discharge and alert the research team to changes in patients' status. In addition, the patients in the intervention arm will receive a weekly phone call administered by members of the research team to assess their overall progress and well-being.
62188011|NCT03825536|EXPERIMENTAL|Oral methamphetamine, Then Placebo oral capsule|Participants will be randomized to oral methamphetamine first then placebo oral capsule using a random number generator. When oral methamphetamine is administered, an initial 10 mg of oral methamphetamine study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose two hours later. Then the participant will receive the placebo oral capsule for their second treatment phase starting at approximately Day 77. For the placebo treatment, one placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later.
62396015|NCT01150942|EXPERIMENTAL|vero cell-derived JE vaccine|vero cell-derived vaccine group
62396016|NCT01150942|ACTIVE_COMPARATOR|Mouse brain-derived JE vaccine|Mouse brain-derived JE vaccine group
62396017|NCT05609188|EXPERIMENTAL|Cash now|"Participants allocated to the cash now arm will receive a $500/month Guaranteed Income (GI) during the first twelve months of follow-up (Phase 1) and no GI in the second twelve months of follow-up (Phase 2)."
62396018|NCT05609188|OTHER|Cash in a year|"Participants allocated to the cash in a year arm will receive no Guaranteed Income (GI) during the first twelve months of follow-up (Phase 1) but will receive a $500/month GI in the second twelve months of follow-up (Phase 2)."
62396019|NCT04077112|ACTIVE_COMPARATOR|traditional PCIT|once a week parent training
62396020|NCT04077112|EXPERIMENTAL|intensive PCIT|every day for two weeks parent training
62396021|NCT06628622|EXPERIMENTAL|BI 1356225|
62396022|NCT06628622|PLACEBO_COMPARATOR|Placebo matching BI 1356225|
62396023|NCT04913584|EXPERIMENTAL|Immediate Intervention|Online Group CBT for PPD. Women in the treatment group will attend an online 9-week group Cognitive Behavioural Therapy intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton and designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. The CBT intervention will be delivered by eight lay-peers.
62571233|NCT02823665|EXPERIMENTAL|Atropine|to evaluate the effect of neural activation on insulin secretion and glucose metabolism
62571234|NCT05809960|EXPERIMENTAL|Investigation Group|"Education was given, which was prepared in line with the Roy Adaptation Theory and considering the literature, including the problems experienced in menopausal periods and the approaches used to cope with them. The progressive relaxation exercise was explained and taught to the women and the first application was provided with the instructions. Menopause and Life booklet prepared in line with Roy Adaptation Theory was given to support the education given and to remember the information afterwards."
62571235|NCT05809960|ACTIVE_COMPARATOR|Control Group|Routine nursing care was given to the control group. The clinical routine has not been exceeded.
62571236|NCT05508048|EXPERIMENTAL|Experimental Group|The existential approach and logotherapy-based psychosocial support program intervention
62571237|NCT05508048|NO_INTERVENTION|Control Group|
62571238|NCT01117038|EXPERIMENTAL|enalapril and avanafil|
62778100|NCT03969186|NO_INTERVENTION|Standard of care follow-up|Standard of care
62778101|NCT02874027||TBI Patients with depression|All the patients should be diagnosed by CCMD-3(evaluation of depression)
62002674|NCT04628962||Asthma-COPD Overlapped (aCOPD)|50 subjects affected by Asthma-COPD Overlapped comparable by age and sex with the other recruited subjects. The diagnosis of the mixed phenotypes will be established by the presence of a combination of the following factors: history of asthma and/or atopy, reversibility in the bronchodilator test, notable eosinophilia in respiratory and/or peripheral secretions, high IgE, positive prick test to pneumoallergens and high concentrations of exhaled NO
62002675|NCT04628962||Non-Exacerbator COPD (neCOPD)|50 subjects affected by Non-Exacerbator COPD comparable by age and sex with the other recruited subjects
62571239|NCT01117038|EXPERIMENTAL|amlodipine and avanafil|
62778102|NCT02874027||TBI Patients without depression|
62778103|NCT01879969|EXPERIMENTAL|asymmetric patients, classic procedure|random selected
62778104|NCT01879969|EXPERIMENTAL|asymmetric patients, computer assisted|random selected
62778105|NCT03313336|ACTIVE_COMPARATOR|Cohort 1|EMLA Test Patch.
62778106|NCT03313336|ACTIVE_COMPARATOR|Cohort 2|EMLA Reference Patch.
62002676|NCT04628962||frequent Excacerbator with Emphysema COPD (eeCOPD)|50 subjects affected by frequent exacerbation with emphysema COPD comparable by age and sex with the other recruited subjects
62002677|NCT04628962||frequent Excacerbator with chronic Bronchitis COPD (ebCOPD)|50 subjects affected by frequent excacerbation with chronic bronchitis COPD comparable by age and sex with the other recruited subjects
62002678|NCT04628962||Asthma patients (AST)|200 subjects affected by asthma comparable by age and sex with the other recruited subjects
62002679|NCT04628962||Healthy subjects (CTRL)|200 healthy subjects in a good health state comparable by age and sex with the other recruited subjects
62002680|NCT05255458|EXPERIMENTAL|AK102 regimen 1|
62778107|NCT03313336|PLACEBO_COMPARATOR|Cohort 3|Placebo patch.
62778108|NCT00687531|EXPERIMENTAL|Mometasone Furoate|Mometasone Furoate 400 mcg once daily in the evening through 12 weeks.
62778109|NCT05295355|EXPERIMENTAL|Tiotropium Bromide Combined With Odaterol|Tiotropium O Datlow inhalation spray 60 bottles per bottle, each containing 2.5 tiotropium ammonium g (equivalent to 3.124 g of thiotropium bromide) and 2.5 2.5 g (equivalent to 2.736 2.736 g of hydrochloric acid) by O Datlow. ® The inhaler was inhaled and administered twice a time, once a day, at the same time every day for 52 weeks
62778110|NCT05295355|EXPERIMENTAL|Tiotropium Bromide|Tiotropium Bromide Spray (Si Lihua ® Neng Beile ®）： 0.22624mg/ml (calculated by tiotropium), 60 strokes per bottle, containing 2.5 µ g of tiotropium bromide per stroke, through Neng Beile ® Inhaler inhalation administration, 2 presses per inhalation, once a day, administered at the same time every day for 52 weeks.
62778111|NCT01605721|EXPERIMENTAL|XIENCE PRIMETM everolimus-eluting coronary stent|
62778112|NCT04845178|EXPERIMENTAL|ABP-450 - Low Dose|ABP-450 Low Dose - intramuscular injections into specified muscles.
62002681|NCT05255458|PLACEBO_COMPARATOR|Placebo|
62002682|NCT02192944|ACTIVE_COMPARATOR|Chloroquine|Chloroquine base 600 mg single dose
62002683|NCT02192944|ACTIVE_COMPARATOR|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine 120/960 mg single dose
62002684|NCT01283048|EXPERIMENTAL|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
62002685|NCT02933138||Multifactorial Chylomicronemia|no intervention, phenotypic and genotypic study
62002686|NCT01280084||No labour analgesia/nitrous oxide|Women who use no analgesia during labour or who only used nitrous oxide.
62002687|NCT01280084||Systemic opioids|Women who receive only systemic opioids for analgesia during, either intravenously or intramuscularly
62002688|NCT01280084||Intermediate dose epidural fentanyl|Women who receive a total epidural fentanyl dose less than 150 micrograms
62571240|NCT03719781||Group1|patients undergoing pituitary tumor removal surgery will be tested with standardized minimental testing.
62571241|NCT05666037|EXPERIMENTAL|Intervention group|The intervention group will receive mobile health intervention.
62571242|NCT05666037|NO_INTERVENTION|Control group|The control arm will be received the existed current health delivery approach, not received mobile health sending message service.
62571243|NCT03293992|EXPERIMENTAL|0.01% RO7058584 or Matching Placebo|
62571244|NCT03293992|EXPERIMENTAL|0.1% RO7058584 or Matching Placebo|
62571245|NCT03293992|EXPERIMENTAL|1% RO7058584 or Matching Placebo|
62571246|NCT03293992|EXPERIMENTAL|RO7058584 and Latanoprost 0.005%|
62571247|NCT00771719|EXPERIMENTAL|Ceftobiprole|Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
62571248|NCT05631717|EXPERIMENTAL|MSCs group|In this group, patients will receive intravenous injection of human umbilical cord mesenchymal stem cells (2 × 10\^6 cells / kg body weight, suspended in 30ml saline)
62571249|NCT05631717|EXPERIMENTAL|IL-2 group|In this group, patients will receive subcutaneous injection of IL-2 (1×10\^6IU) every other day for 2 weeks (7 times), with an interval of 2 weeks.
62571250|NCT00485251|ACTIVE_COMPARATOR|1|hand assisted right hemicolectomy
62571251|NCT00485251|ACTIVE_COMPARATOR|2|laparoscopic right hemicolectomy
62571252|NCT04663997|EXPERIMENTAL|177 Lu-PSMA-617|
62571253|NCT04663997|ACTIVE_COMPARATOR|Docetaxel|
62571254|NCT05684991|EXPERIMENTAL|Treatment Group|One capsule of KSM-66 300 mg (contains Ashwagandha extract) two times a day, orally with water
62571255|NCT05684991|PLACEBO_COMPARATOR|Control Group|One capsule of Placebo two times a day, orally with water
62778113|NCT04845178|EXPERIMENTAL|ABP-450 - High Dose|ABP-450 High Dose - intramuscular injections into specified muscles.
62778114|NCT04845178|PLACEBO_COMPARATOR|Placebo|Placebo (0.9% saline, sterile, unpreserved, USP/Ph.Eur) intramuscular injections into specified muscles.
62396024|NCT04913584|EXPERIMENTAL|Wait-List Controls|Online Group CBT for PPD 9 weeks after enrollment. The women in this arm of the study will receive the same Cognitive Behavioural Therapy intervention as in the immediate intervention arm, however, they will begin the CBT group 9 weeks after enrolling in the study.
62571256|NCT02522364|ACTIVE_COMPARATOR|BioMonitor|Participants randomized for this arm will be implanted with a BioMonitor device an implantable loop recorder inserted under the skin in the region of the thorax. It continuously records heart rhythm for a period of up to 7 years. The device will be interrogated at 1 month intervals. All arrhythmic events and conductive disturbances will be noted. In addition will be followed as specified in the standard arm
62571257|NCT02522364|ACTIVE_COMPARATOR|Standard|Participants randomized for this arm will be followed by biannual office visits initialing clinical evaluation, review of clinical events, review and update of medical therapy. Participants will undergo ECG holter examination at 3 and 6 months after discharge
62778115|NCT03221309||Adults infected with HCV|"Phase 1 (first 100 enrolled participants) HCV-infected adults with on-going injection drug use use with opioids with 3 months of screening~Phase 2 (enrolled participants 101-200) HCV-infected adults with on-going opioid misuse of non-prescription opioids within twelve months of screening"
62396025|NCT03373916|EXPERIMENTAL|Peer Mentorship intervention|A Peer Specialist will be making weekly follow-up contact with study participants in the community or by telephone for 3 months following hospital discharge. The content of the peer mentorship interactions will be based on the manual developed by the study team and will address protective factors such as hope and belongingness.
62396026|NCT03373916|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|"The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts."
62396027|NCT04649606||Experimental|Eligible subjects will undergo repeated observations to evaluate the Meibomian gland appearance
62571258|NCT00930280||Hemorrhagic stroke cases|People who have had a hemorrhagic stroke, specifically an intracerebral hemorrhage, and live within a 100 mile radius of the University of Cincinnati.
62778116|NCT04354883|ACTIVE_COMPARATOR|Schmitz-Hinkelbein-Method|
62396028|NCT05959278|EXPERIMENTAL|Group 1 - Vestibular rehabilitation - initially supported by the app|First two and a half weeks - conventional vestibular rehabilitation supported by an app Second two and a half weeks - conventional vestibular rehabilitation without an app
62571259|NCT00930280||Healthy Control Subjects|Healthy volunteers who are randomly identified in the same 100 mile radius of the University of Cincinnati and have not had a hemorrhagic stroke.
62571260|NCT04304430||Dapagliflozin|Patients who initiated a new therapy with dapagliflozin
62571261|NCT04304430||DPP-4i|Patients who initiated a new therapy with a DPP-4i
62571262|NCT02262715|EXPERIMENTAL|Part 1|Participants will receive in random order Treatment A (VX-787, 600 mg tablet 2 times a day on Day 1 to 4, followed by VX 787, 600 mg tablet on Day 5); Treatment B (Oseltamivir, 75 mg capsule 2 times a day on Day 1 to 4, followed by oseltamivir 75 mg capsule in the morning on Day 5) or Treatment C (VX-787, 600 mg tablet, 2 times a day orally + oseltamivir, 75 mg capsule, 2 times a day on Day 1 to 4, followed by a single dose of VX-787, 600 mg + oseltamivir, 75 mg capsule on Day 5). Each participant will receive all three treatments (Treatment A, B and C) in a random sequence.
62571263|NCT02262715|EXPERIMENTAL|Part 2 VX-787|Participants will receive VX-787, 600 mg, tablet 2 times a day, orally on Day 1 to Day 9, followed by single dose of VX-787, 600 mg on Day 10.
62571264|NCT02262715|EXPERIMENTAL|Part 2 Placebo|Participants will receive placebo matching to VX-787, 2 times a day, orally on Day 1 to Day 9, followed by single dose of matching placebo on Day 10.
62571265|NCT02807038|EXPERIMENTAL|Lung function test|Pregnant women performed one spirometry at each trimester of pregnancy
62571266|NCT00005777|EXPERIMENTAL|Minimal ventilation with Dexamethasone|Minimal ventilator support strategy (permissive hypercapnia) and early stress dose dexamethasone therapy
62778117|NCT04354883|ACTIVE_COMPARATOR|Hinkelbein-Schmitz-Method|
62778118|NCT04118595|EXPERIMENTAL|Full Intervention (Video + Telecare + PCP communication)|Patients in this arm will watch an interactive pain management video; receive a pain assessment phone call and be given medication and behavioral pain management strategy recommendations; and an index visit and telecare summary will be shared with patient's primary care provider.
62778119|NCT04118595|EXPERIMENTAL|Video-only Intervention|Patients in this arm will watch an interactive pain management video.
62778120|NCT04118595|NO_INTERVENTION|Usual Care|Patients will receive the typical care provided by medical personnel for their acute pain.
62778121|NCT02113332|EXPERIMENTAL|Liraglutide|Liraglutide injected once per day for 24 weeks. Dose is 1,8 mg or highest tolerable dose.
62002689|NCT01280084||High dose epidural fentanyl|Women who receive a total epidural fentanyl dose more than 150 micrograms
62778122|NCT02113332|PLACEBO_COMPARATOR|Placebo|Placebo injected once per day for 24 weeks. Dose is 1,8 or highest tolerable dose.
62002690|NCT04949438|EXPERIMENTAL|Cohort 1: Participants with severe renal impairment|Participants with severe renal impairment will receive a single oral dose of AZD4831 on Day 1.
62571267|NCT00005777|EXPERIMENTAL|Minimal Ventilation without Dexamethasone|Minimal ventilator support strategy (permissive hypercapnia) and no dexamethasone therapy
62571268|NCT00005777|ACTIVE_COMPARATOR|Routine ventilation with Dexamethasone|
62571269|NCT00005777|ACTIVE_COMPARATOR|Routine ventilation without Dexamethasone|
62571270|NCT05421182|OTHER|Interview of the trusted person of evacuated patient|"The interview of the trusted person of evacuated patient will be done 8 months (+/-2 months) after the medical evacuation.~The interview will be carried out by a psychologist or by a doctor from the ICU"
62571271|NCT05421182|OTHER|Interview of the trusted person of the not evacuated patient|The interview of the trusted person of the not evacuated patient will be done 8 months (+/-2months) after the ICU admission The interview will be carried out by a psychologist or by a doctor from the ICU.
62571272|NCT04023032|EXPERIMENTAL|multicomponent cognitive intervention|
62778123|NCT05169411||angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) categories|The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none.
62778124|NCT05169411||Combined renin-angiotensin-aldosterone system (RAAS) blocker category|Secondary analyses will combine ACEi and ARB into a single RAAS blocker category.
62778125|NCT05169411||Urine protein dichotomous indicator|We will determine whether urine protein is evaluated at each encounter and create a dichotomous indicator.
62778126|NCT06448039|EXPERIMENTAL|FGF2 active arm|Active 0.1-0.2 ml of FGF2 will be placed on gelatin sponge in middle ear and on the lateral surface of the tympanic membrane and then covered with fibrin glue.
62778127|NCT06448039|PLACEBO_COMPARATOR|Saline control|0.1-0.2 ml of normal sterile saline will be placed on gelatin sponge in middle ear and on the lateral surface of the tympanic membrane and then covered with fibrin glue.
62778128|NCT01799551|ACTIVE_COMPARATOR|Ca CBT|Experimental arm will receive brief version of Culturally adapted CBT for depression. This is based on our previous work in which we adapted CBT for depression in Pakistan
62778129|NCT01799551|NO_INTERVENTION|Treatment As Usual|Patients in this arm will get only Treatment As Usual, which normally includes regular follow up and medicines.
62002691|NCT04949438|EXPERIMENTAL|Cohort 2 :Healthy participants|Healthy participants will receive a single oral dose of AZD4831 on Day 1.
62002692|NCT03672903|EXPERIMENTAL|Intervention|Subjects in this arm will carry heavy weight vests for three weeks.
62002693|NCT03672903|PLACEBO_COMPARATOR|Control|Subjects in this arm will carry light weight vests for three weeks.
62188012|NCT03825536|EXPERIMENTAL|Placebo oral capsule, Then Oral methamphetamine|Participants will be randomized to a placebo oral capsule first, then oral methamphetamine using a random number generator. For the placebo treatment, one placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later. Then the participant will receive the oral methamphetamine capsule for their second treatment phase starting at approximately Day 77. When oral methamphetamine is administered, an initial 10 mg of oral methamphetamine study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose two hours later.
62778130|NCT06169488|EXPERIMENTAL|Lumbar Interbody Fusion (LIF)|"Per center standard, the LIF procedure is done in one or two levels between the second lumbar vertebra and sacrum, as a transforaminal lumbar interbody fusion (TLIF) or anterior lumbar interbody fusion (ALIF). Stabilization with screws is mandatory. TLIF employs bilateral pedicle screws. ALIF uses either pedicle or intra-device screws.~At least one surgeon must be proficient in both procedure and implants. TLIF requires visual aids (microscope/magnifying glasses) for precise disc preparation. In the TLIF procedure, surgeons will maximize bone implantation into the disc space, anteriorly, posteriorly, or both.~If the disc space is too narrow for an interbody device, autologous bone grafting into the disc space (local, spongious, or both) with posterior pedicle screw fixation is accepted. Optional posterolateral autologous bone grafting is allowed, but no substitutes or osteoinductive proteins (e.g., BMP). Surgical drain is optional."
62778131|NCT06169488|ACTIVE_COMPARATOR|Multidisciplinary Rehabilitation|"Rehabilitation, guided by a team of experienced specialists in physical medicine and rehabilitation and physiotherapists trained in cognitive therapy, will direct the multidisciplinary treatment. Patients receive 2.5-5 hour sessions 2-4 days weekly over 3-5 weeks. Standardization is maintained through pre-study training for providers, including seminars, podcasts, videos, and lectures.~Individual screenings start the process, leading to focused discussions on thoughts, feelings, behaviour, and physical symptoms. A plan for the rehabilitation process with clearly defined individual goals will be worked out and revised every week. The three components described within the framework of cognitive functional therapy will be a template for the implementation of the functional and physical rehabilitation, involving pain understanding, exposure with control, and lifestyle changes like physical activity, sleep, diet, stress management, and social engagement."
62778132|NCT03401060|EXPERIMENTAL|Experimental medication 1|Denosumab 60 mg subcutaneously injection with prefilled syringe
62002694|NCT01513252|EXPERIMENTAL|1|Gröber and Buschke test
62002695|NCT03181828|EXPERIMENTAL|Acetohydroxamic Acid Oral Tablet then No Intervention|Participants receive a single oral dose of 60 mg/kg acetohydroxamic acid (rounded to the nearest 250 mg) in the fasted state on the morning of the study. After completion of the 4-h study, participants then enter a wash-out period of 3 days. Participants then completed an identical 4-h study in the fasted state without acetohydroxamic acid.
62002696|NCT03181828|EXPERIMENTAL|No Intervention then Acetohydroxamic Acid Oral Tablet|Participants completed a 4-h study in the fasted state without acetohydroxamic acid. 3 days later, participants then completed an identical 4-h study in the fasted state, after having received a single oral dose of 60 mg/kg acetohydroxamic acid (rounded to the nearest 250 mg).
62002697|NCT02388997|ACTIVE_COMPARATOR|Mild asthmatics treated with omalizumab|Subjects with mild asthma will be treated with omalizumab for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. Omalizumab will be given subcutaneously every 2 to 4 weeks according to the manufacturer's recommendations.
62002698|NCT02388997|PLACEBO_COMPARATOR|Mild asthmatics treated with placebo medication|Subjects with mild asthma will be treated with placebo medication for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. The placebo mediation will consist of the same diluent used for suspending the omalizumab without omalizumab added.
62188013|NCT03772093|ACTIVE_COMPARATOR|Patients with manual massage therapy|30 patients were randomly assigned to massage therapy. The procedures were performed for ten days, with weekend break. Manual massage of lumbar area was performed by certified massage therapist with the typical course of the procedure. The technique was consisted of stroking, kneading, grinding, patting and shaking. The procedure lasted twenty minutes.
62396029|NCT05959278|EXPERIMENTAL|Group 2 - Vestibular rehabilitation - initially without the support of the app|First two and a half weeks - conventional vestibular rehabilitation without an app Second two and a half weeks - conventional vestibular rehabilitation supported by an app
62002699|NCT01616186|EXPERIMENTAL|Everolimus/Sorafenib|Patients will be stratified by current smoking status (smoker: yes or no0, for each smoking stratum patients will be randomized in a 2:1 ratio
62002700|NCT01616186|ACTIVE_COMPARATOR|Sunitinib|"* Sunitinib is the concurrent control group~* Patients will be stratified by current smoking status (smoker: yes or no), for each smoking stratum patients will be randomized in a 2:1 ratio"
62002701|NCT01818804|ACTIVE_COMPARATOR|n-3PUFA|n-3 polyunsaturated fattyacids from fish oil
62778133|NCT03401060|PLACEBO_COMPARATOR|Experimental medication 2|NaCl 0.9%, 20ml phial, solution for injection
62002702|NCT01818804|PLACEBO_COMPARATOR|olive oil|Olive oil
62002703|NCT06431828|EXPERIMENTAL|Homemonitoring + APP|The patients receive the usual standard treatment with remote holter monitoring along with an app for the notification of adverse events.
62002704|NCT06431828|NO_INTERVENTION|Homemonitoring|The patients receive the usual standard treatment with remote holter monitoring
62002705|NCT04464642|EXPERIMENTAL|group A|"group A is a control arm who will get conventional drug (methotrexate). 25 mg subcutaneous weekly . at 3 months if DAS-28 not fall by at least 1.2, drug is to be changed and regarded as therapy failure. if at least 1.2 improvement of DAS-28 occur,then therapy is continued for 6 monyhs"
62002706|NCT04464642|EXPERIMENTAL|group B|"group B will get tofacitinib 10 mg weekly. if DAS-28 not improved at least 1.2 at 3 months, it is regarded as therapy failure. if improved at least 1.2, then therapy continued for 6 months"
62002707|NCT03524703|EXPERIMENTAL|Chewing Gum Group|Patients who receive anterior cervical fusion and have mild or moderate dysphagia postoperatively, will be randomized into two groups. Subjects assigned to the Chewing Gum Group are asked to chew gum four times a day for 5 days (15 minutes each time) after surgery in addition to standard cares. Standard cares include cleaning the wound every 2 days, wearing a collar, pain management, and education.
62002708|NCT03524703|NO_INTERVENTION|Control Group|Patients who receive anterior cervical fusion and have mild or moderate dysphagia postoperatively, will be randomized into two groups. Subjects assigned to the Control Group receive standard cares and are asked not to chew gum within 5 days after surgery. Standard cares include cleaning the wound every 2 days, wearing a collar, pain management, and education.
62002709|NCT00702130|EXPERIMENTAL|A|this arm will receive Pravastatin 40 mg per os daily
62188014|NCT03772093|ACTIVE_COMPARATOR|Patients with Trabert current therapy|30 patients were randomly assigned to Trabert current therapy. The Trabert current was administered by 143 frequency, time of 2 ms impulse, time of break 5 ms. The current was generated by Pulsotronic ST-6D device (ZAMED©). The electric pads were placed on the lumbar area, in the middle part of spine. The anode in the lower part, near to buttocks. The intensity of current was regulated between 15-25 mA. The time of procedure lasted fifteen minutes.
62188015|NCT05414383||CADx|Histopathology prediction by CADx device
62571273|NCT03929120|EXPERIMENTAL|Interstitial Lung Disease with Connective Tissue Disorder|Subjects with Interstitial Lung Disease (ILD) associated with Connective Tissue Disorder (CTD) will receive a new treatment called Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
62571274|NCT04806893|EXPERIMENTAL|LIB003 (lerodalcibep)|300 mg subcutaneously monthly (Q4W)
62571275|NCT04806893|PLACEBO_COMPARATOR|Placebo|matching placebo subcutaneously monthly (Q4W)
62002710|NCT00702130|NO_INTERVENTION|1|
62571276|NCT04459325|EXPERIMENTAL|Study drug and best available care|Best available care and Tigerase®/nebulised dornase alfa \[2.5 mg BID\] for 7 days
62778134|NCT00673283|EXPERIMENTAL|A|
62778135|NCT06260553|EXPERIMENTAL|tislelizumab plus metronomic oral vinorelbine|
62002711|NCT01072851|EXPERIMENTAL|Multimedia educational tool|Multimedia education tool - A culturally competent video explaining the importance of and the process of colorectal cancer screening
62002712|NCT01072851|EXPERIMENTAL|Print educational tool|Print media - A culturally competent printed brochure explaining the importance of and the process of colorectal cancer screening
62002713|NCT01072851|ACTIVE_COMPARATOR|No intervention|Usual and customary waiting room process - Usual and customary office waiting period with access to standard nationally generated colorectal cancer screening informational material in the waiting room and/or exam room.
62002714|NCT00753207|EXPERIMENTAL|Lapatinib and Epirubicin|Fixed dose of lapatinib in combination with escalating dose of epirubicin.
62188016|NCT05414383||Endoscopist|Real-time histopathology prediction by expert and non-expert endoscopists
62778136|NCT01183065|EXPERIMENTAL|pralatrexate and vitamin supplementation|This will be an open-label, single arm, Simon optimal two-stage design phase II study.
62778137|NCT04564677||Patients eligible for laparoscopic ventral mesh rectopexy|Female patients with primary rectal prolapse, rectocele and/or enterocele eligible for laparoscopic ventral mesh rectopexy (LVMR)
62778138|NCT05659472|EXPERIMENTAL|Intervention group = Combination mindfulness spiritual-based cognitive therapy plus hypnosis|Given to the intervention group with a frequency of once a week for eight weeks. Each session for 120 minutes or 2 hours with a set of MSBCT intervention packages resulting from modified mindfulness-based cognitive therapy with using the mindfulness concept of Kabat Zinn and the five-step model of mindfulness developed by Vidyamala Burch.
62778139|NCT05659472|EXPERIMENTAL|Control group = Mindfulness-based cognitive therapy|Given to the control group with a frequency of once a week for eight weeks. Each session is 90 minutes or 1.5 hours with a set of MBCT intervention packages developed by Teasdale, 2014
62571277|NCT04459325|OTHER|Control group (best available care)|Patients will receive the usual care in accordance with good practice.
62778140|NCT02911012||Study Group|The identified population will be assessed on VTE risk according to the risk score PADUA, CAPRINI, KHORANA, and IMPROVE for BLD risk.
62778141|NCT00965419|EXPERIMENTAL|Edivoxetine|All enrolled participants were administered starting dose of 0.1 milligram per kilogram per day (mg/kg/day), or participant specific known stable dose, rollover participants (LNBJ \[No NCT number\]) and (LNBF \[NCT00922636\]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
62778142|NCT02387554|EXPERIMENTAL|HGP0904+HGP0608+HGP1405|amlodipine + losartan + chlorthalidone
62002715|NCT05310266|ACTIVE_COMPARATOR|Group TAP|The investigators performed transversus abdominis plane block to that patient group for postoperative analgesia
62002716|NCT05310266|ACTIVE_COMPARATOR|Group QLB|The investigators performed quadratus lumborum block to that patient group for postoperative analgesia
62002717|NCT01613339|EXPERIMENTAL|Body awareness therapy|
62778143|NCT02387554|ACTIVE_COMPARATOR|HGP0904|amlodipine
62778144|NCT02387554|ACTIVE_COMPARATOR|HGP0608|losartan
62778145|NCT02387554|ACTIVE_COMPARATOR|HGP1405|chlorthalidone
62778146|NCT00642863|EXPERIMENTAL|Low birth iron|Infants with low birth iron who receive vitamins A and D + iron
62778147|NCT00642863|EXPERIMENTAL|Marginal birth iron 1|Infants with marginal birth iron randomized to receive vitamins A and D + iron
62778148|NCT00642863|ACTIVE_COMPARATOR|Marginal birth iron 2|Infants with marginal birth iron randomized to receive vitamins A and D without iron
62002718|NCT01613339|NO_INTERVENTION|Control|
62002719|NCT01469065|EXPERIMENTAL|PF-04991532|PF-04991532 experimental study medication
62002720|NCT01469065|PLACEBO_COMPARATOR|Placebo|PF-04991532 Matching Placebo
62002721|NCT02243150|EXPERIMENTAL|Cohort 1|6mg/m2 of G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion
62002722|NCT02243150|EXPERIMENTAL|Cohort 2|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 1; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
62188017|NCT03625453|EXPERIMENTAL|ABX-1431|Oral use of hard capsule (10 milligrams), maximum dose per day: 40 milligrams
62778149|NCT00642863|ACTIVE_COMPARATOR|Normal birth iron|Infants with normal birth iron who receive vitamins A and D without iron
62778150|NCT00642863|EXPERIMENTAL|Combined ID|Marginal-birth-iron vitamins only-treated infants who have IDA at 9 mo.
62002723|NCT02243150|EXPERIMENTAL|Cohort 3|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 2; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
62002724|NCT02243150|EXPERIMENTAL|Cohort 4|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 3; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
62002725|NCT02243150|EXPERIMENTAL|Cohort 5|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 4; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion. Subjects from this cohort may be selected to participate in the Whole Blood Ex-Vivo Stimulation group.
62002726|NCT02243150|EXPERIMENTAL|Cohort 6|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 5; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion. Subjects from this cohort may be selected to participate in the Whole Blood Ex-Vivo Stimulation group.
62188018|NCT03625453|PLACEBO_COMPARATOR|Placebo|Oral use of hard capsule
62188019|NCT03031210|EXPERIMENTAL|Twice a day regimen|Patients will received a prescription of amoxicillin (90mg/kg/day) divided in two doses daily.
62778151|NCT00642863|EXPERIMENTAL|Early postnatal IDA|Infants with IDA at 9 months whose cord blood was collected at birth but who were not assessed and assigned to vitamins with or without iron at 6 weeks
62778152|NCT00642863|EXPERIMENTAL|Late postnatal IDA|Infants with IDA at 18 months whose cord blood was collected at birth but who were not assessed and assigned to vitamins with or without iron at 6 weeks. These infants were also not anemic when screened at 9 months.
62778153|NCT04830488|EXPERIMENTAL|Body Image after Head and Neck Cancer Treatment|
62778154|NCT02229526|ACTIVE_COMPARATOR|Low dose fish oil|
62571278|NCT03418233|ACTIVE_COMPARATOR|Active Group|"Patients randomized to the active treatment group: Transcoronary or trans-bypass graft administration of CardioCell consist 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin) will be performed using a dedicated cell delivery catheter.~The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties."
62188020|NCT03031210|ACTIVE_COMPARATOR|Thrice a day regimen|Patients will received a prescription of amoxicillin (90mg/kg/day) divided in three doses daily.
62396030|NCT05618561||Nasopharyngeal specimen collection arm|Specimens collected in nasopharyngeal form from positive subjects with symptoms and negative subjects hospitalized and negative subjects with respiratory symptoms.
62571279|NCT03418233|PLACEBO_COMPARATOR|Control Group|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.
62571280|NCT02400918|EXPERIMENTAL|Workbook|They will be directed to use the 8-week plan included in The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming \& Kocovski, 2013), an ACT-based self-help book and to access mindfulness audio files located on the publisher's website (as described in the book).
62571281|NCT02400918|NO_INTERVENTION|Control|Waitlist control
62188021|NCT04759430|ACTIVE_COMPARATOR|Supervised Group|24 individuals will participate in the Supervised group. Patients in the supervised group will be treated individually by the researcher at the hospital. During the application, individuals will apply ten different stabilization exercises in company with a physiotherapist. Exercises will be applied under the supervision of a physiotherapist in the center where the work will be done for 20-30 minutes in each session, three days a week, for a total of 12 sessions for four weeks. The exercises program to be applied to the participants in the group is listed below: Supine position; Abdominal bracing, while continuing the abdominal bracing; heel slides, bridging, 90 degrees hip flexion. Quadruped position; Abdominal bracing while continuing the abdominal bracing; single arm lift, single leg lift, cross-arm leg raises activities. Standing position; Abdominal bracing.
62396031|NCT05618561||Combined nasal mid-turbinate and throat specimen collection arm|Specimens collected in combined nasal mid-turbinate form from positive subjects with symptoms and negative subjects hospitalized and negative subjects with respiratory symptoms.
62396032|NCT06724263|EXPERIMENTAL|B1962|advanced malignant neoplasm
62571282|NCT03900169||Stemi patient|Stemi patient who underwent Ppci
62571283|NCT01155180|EXPERIMENTAL|Leptin|We will start the leptin at a dose of 0.08mg/kg fat mass in men and 0.14mg/kg fat mass in women
62571284|NCT01155180|PLACEBO_COMPARATOR|Placebo|We will start the placebo at a dose of 0.08mg/kg fat mass in men and 0.14mg/kg fat mass in women
62571285|NCT06576258|EXPERIMENTAL|Intervention group (eplex implementation)|Positive blood culture samples from the intervention group are subjected to eplex multiplex PCR in addition to the SOC culture methods. cobas® eplex system with syndromic panels is a medical device designed for in vitro diagnostic use and is CE-IVD registered. The medical device is used in accordance with the terms of the CE mark.
62571286|NCT05234125|ACTIVE_COMPARATOR|Intervention arm|Sleep hygiene practices and cognitive-behavioral principles
62571287|NCT05234125|PLACEBO_COMPARATOR|Attention control|Training about pregnancy issues
62778155|NCT02229526|PLACEBO_COMPARATOR|Low dose olive oil|
62778156|NCT02229526|EXPERIMENTAL|High dose fish oil|
62778157|NCT02229526|PLACEBO_COMPARATOR|High dose olive oil|
62778158|NCT05071014|EXPERIMENTAL|pembrolizumab followed by cryoablation|The treatment will consist of 1 cycle of pembrolizumab (200mg/flat dose) intravenously followed by cryoablation of an ablation index lesion 1-7 days prior to the start of cycle 2. Pembrolizumab will be continued for up to 24 months, until disease progression, or intolerable toxicity. Treatment beyond progression at discretion of the treating physician and Study PI. There will be a research biopsy within 1 week of cycle 5 start and an optional biopsy at end of treatment and/or progression of disease.
62778159|NCT05899296|ACTIVE_COMPARATOR|Traditional syringe|Dental anesthesia delivered by a traditional syringe
62778160|NCT05899296|EXPERIMENTAL|NumBee|Dental anesthesia delivered by a novel needle-less syringe
62778161|NCT03299712|OTHER|ArteFill|This post-approval study will evaluate the continuing safety of ArteFill® as an injectable implant for correction of nasolabial folds over the course of five years post implantation, with a focus on determining the incidence of granuloma formation. Incidence of adverse events and subject satisfaction with respect to the subject's personal expectations will be assessed.
62778162|NCT05684185||IM, <15 years old|Group with Intramuscular (IM) rabies post-exposure prophylaxis
62778163|NCT05684185||IM, 15 years old and older|Group with Intramuscular (IM) rabies post-exposure prophylaxis
62778164|NCT05684185||ID, <15 years old|Group with Intradermal (ID) rabies post-exposure prophylaxis
62778165|NCT05684185||ID, 15 years old and older|Group with Intradermal (ID) rabies post-exposure prophylaxis
62778166|NCT06354387|EXPERIMENTAL|single arm|open label
62778167|NCT02943915|EXPERIMENTAL|Group 1: Ekso GT Rehabilitation Therapy|Participants in this group receive Ekso GT (gait training) PT therapy intervention 3 times per week for 12 weeks (36 sessions). Intervention: Ekso GT Rehabilitation therapy
62002727|NCT02243150|EXPERIMENTAL|Cohort 7 - Bone Marrow Cohort|All subjects in this cohort will receive active drug, G1T28-1. Dose of G1T28-1 will be determined based on the safety and PK data from previous cohorts. G1T28-1 will be administered in 50mL of 5% dextrose by IV infusion. Subjects in this cohort will be selected for the Ex-Vivo Stimulation group and will have a one time bone marrow aspirate at one of the following time points: pre dose, 12 or 24 hours post dose.
62396033|NCT03842228|EXPERIMENTAL|Treatment (copanlisib hydrochloride, olaparib, and durvalumab)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1 and 15 or days 1, 8, and 15 depending on dose level and olaparib PO BID on days 1-28 of each cycle. Beginning cycle 2, patients receive durvalumab IV over 1 hour on day 1 of each cycle. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples at baseline within 7 days of C1D1, days 8 and 15 of cycle 1 and day 15 of subsequent cycles, at time of restaging, and end of treatment/progression. Patients undergo x-ray, CT, and MRI at the end of cycle 2 and then every 8 weeks. Patients also undergo an ECHO during pre-study within 28 days of C1D1 and tumor biopsy at baseline within 7 days of C1D1 and day 15 of cycle 1 or 2, and may undergo an optional biopsy at end of treatment/progression.
62396034|NCT04047472|EXPERIMENTAL|Brolucizumab 6 mg|3 monthly intravitreal injections of brolucizumab 6 mg in the loading treatment period (q4w regimen) up to Week 8 followed by injections every 12 weeks (q12w regimen) or 8 weeks (q8w) up to Week 40 or Week 44, depending on disease activity status.
62396035|NCT04047472|ACTIVE_COMPARATOR|Aflibercept 2 mg|3 monthly intravitreal injections of aflibercept 2 mg in the loading treatment period (q4w regimen) up to Week 8 followed by injections every 8 weeks (q8w) up to Week 40.
62396036|NCT06333613|EXPERIMENTAL|Test Lens|Eligible subjects will be fitted bilaterally with the TEST lens for approximately 2 weeks of wear (two 1-week wear periods).
62396037|NCT04428723||Hypoglycemia, no upper gastrointestinal (GI) surgery|Males or females with hypoglycemia with neuroglycopenia, but no history of upper GI surgery, diabetes or prediabetes
62396038|NCT04428723||Hypoglycemia, with history of upper GI surgery|Males or females with hypoglycemia with neuroglycopenia, with history of upper GI surgery
62396039|NCT04428723||Controls, without hypoglycemia or upper GI surgery|Males or females with no history of upper gastrointestinal surgery, hypoglycemia, or diabetes.
62396040|NCT06328192|EXPERIMENTAL|Active Breathing Exercises|The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Active Breathing Exercises, with weekends off and training conducted only on weekdays. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors.
62396041|NCT03783884|ACTIVE_COMPARATOR|Treatment|Subject receives Lungpacer Catheter for transvenous phrenic nerve stimulation to deliver Diaphragm Pacing Therapy Sessions. DPT sessions are 6 sets of 10, delivered twice daily, for a total of 120 stimulation reps per day, plus standard of care for weaning from mechanical ventilation.
62396042|NCT03783884|NO_INTERVENTION|Control|Subject does not receive Lungpacer Catheter or DPT. Subject receives only Standard of care for weaning from mechanical ventilation.
62396043|NCT04737447|ACTIVE_COMPARATOR|Group A (Control Group)|20 participants treated with standardized urophysiotherapy twice a week, once for 45 Minutes and then for 15 Minutes. Urophysiotherapy is a well manifested and standardized therapy in the treatment für children's incontinence after the age of five years.
62188022|NCT04759430|EXPERIMENTAL|Telerehabilitation Group|24 individuals will participate in the Telerehabilitation group. Patients in the telerehabilitation group will attend the treatment from their homes. The exercises will be performed online with the patient by the researcher physiotherapist and supervised through the video conference or phone. The same stabilization exercises will be applied to the participants in the supervised group. Exercises will be applied for 20-30 minutes in each session, three days a week, for a total of 12 sessions for four weeks.
62188023|NCT04759430|NO_INTERVENTION|Control Group|
62188024|NCT01550432|EXPERIMENTAL|High-Dose Glutathione|2,260 mg/day
62188025|NCT01550432|EXPERIMENTAL|Low-Dose Glutathione|1,130 mg/day
62188026|NCT01550432|EXPERIMENTAL|High-Dose N-Acetylcysteine|1,200 mg/day
62188027|NCT01550432|EXPERIMENTAL|Low-Dose N-Acetylcysteine|600 mg/day
62188028|NCT01550432|PLACEBO_COMPARATOR|Placebo|Volume of liquid placebo product comparable to glutathione and 1 or 2 placebo pills/day.
62188029|NCT00480675|EXPERIMENTAL|1|Trochanteric bursa injections done into the bursa under fluoroscopic guidance
62188030|NCT00480675|ACTIVE_COMPARATOR|2|Trochanteric bursa injection done with sham fluoroscopy using only landmarks as guidance.
62188031|NCT03452813||ischemic stroke or intracerebral hemorrhage patients|patients discharged from hospital to home or discharged to rehab will be called at 30 day and 90 day to monitor their transition of care outcomes.
62188032|NCT02508597|OTHER|Physicians receiving smoking cessation training|On the training day, the investigators will explain at the beginning of the workshop the purpose of the training, and the details of the brief smoking cessation intervention to all physicians who attend the training workshop.
62396044|NCT04737447|ACTIVE_COMPARATOR|Group B (Study Group)|20 participants treated with standardized urophysiotherapy and Whole Body Vibration training (WBVT). These patients are treated with the standardized urophysiotherapy once a week and furthermore they train with WBVT twice a week for each time 15 minutes. Criteria for modifying the device utilization are based on participant's age and therapy progress. The utilized frequency of the device is individually adapted to the participant. Older patients (\> ten years old) are allowed to higher frequency standards than younger participants (\< 10 years old). The amplitude (0.5 mm - 2 mm) is alternated to the participant's age and height. If side effects occur (e.g. dizziness), frequency can be alternated. The intended frequency level is between 10 an 20 Hz.
62002728|NCT05814120|EXPERIMENTAL|Experimental arm|Geriatric-specific BLS training program
62002729|NCT05545670|PLACEBO_COMPARATOR|placebo|Group1: (Placebo, n=50) who will receive oral placebo tablet once daily FOR 6 MONTHS
62002730|NCT05545670|ACTIVE_COMPARATOR|allopurinol|Group 2:(Allopurinol n=50) who will receive oral allopurinol 300 mg daily for 6 months
62002731|NCT00864461||Case|Patients with clinical and cytogenetics diagnosis of Down syndrome, between 7 - 24 years old.
62002732|NCT00864461||Control|Siblings of the same gender of the case, between 7-24 years old.
62002733|NCT00409292|EXPERIMENTAL|RAD001|"RAD001 was administered continuously at a dose of 10 mg daily by mouth until disease progression, unacceptable toxicity, or withdrawal of consent.~Four weeks of study drug was considered to be one cycle of treatment."
62002734|NCT03584672||Patients with Multiple Sclerosis|Patients with Multiple Sclerosis (Expanded Disability Status Scale (EDSS) score \< 7)
62002735|NCT03584672||Healthy Controls|Healthy people
62396045|NCT04758624|EXPERIMENTAL|Deep Brain Stimulation(DBS)|
62396046|NCT05628012|EXPERIMENTAL|Circadian Based Time Restricted Eating|Personalized restricted eating protocol approximately \~4h before DLMO or sleep onset.
62396047|NCT05628012|NO_INTERVENTION|Control|Continue with normal dietary habits and behaviors.
62571288|NCT04932655|OTHER|Sequence A|This arm received Phase 2 tablet fasted (Period 1), Phase 3 tablet fasted (Period 2), Phase 3 tablet after a high-fat meal (Period 3), and Phase 3 tablet after a low-fat meal (Period 4).
62571289|NCT04932655|OTHER|Sequence B|This arm received Phase 3 tablet after a low-fat meal (Period 1), Phase 2 tablet fasted (Period 2), Phase 3 tablet fasted (Period 3), and Phase 3 tablet after a high-fat meal (Period 4).
62571290|NCT04932655|OTHER|Sequence C|This arm received Phase 3 tablet fasted (Period 1), Phase 3 tablet after a high-fat meal (Period 2), Phase 3 tablet after a low-fat meal (Period 3), and Phase 2 tablet fasted (Period 4).
62571291|NCT04932655|OTHER|Sequence D|This arm received Phase 3 tablet after a high-fat meal (Period 1), Phase 3 tablet after a low-fat meal (Period 2), Phase 2 tablet fasted (Period 3), and Phase 3 tablet fasted (Period 4).
62002736|NCT01739530|EXPERIMENTAL|Repaircell|allogenic differentiated adipocyte
62002737|NCT00649181|EXPERIMENTAL|1|Metolazone Tablets 5 mg
62002738|NCT00649181|ACTIVE_COMPARATOR|2|Zaroloxyn® Tablets 5 mg
62188033|NCT00628277|EXPERIMENTAL|1|Arm 1: high caloric expenditure exercise plus dietary counseling
62188034|NCT00628277|ACTIVE_COMPARATOR|2|Arm 2: low caloric expenditure exercise plus dietary counseling
62188035|NCT04423172|EXPERIMENTAL|Using the New Tissue Containment System group|using the new tissue containment system during Laparoscopic Hysterectomy. The divice is a soft specimen bag in which the uterus tissue is sealed and quickly morcellation and removed through vagina. The divice is named the new tissue containment system.
62188036|NCT04423172|NO_INTERVENTION|Open group|Without using any procteciton system during Laprascopic Hysterectomy.
62396048|NCT05544500|PLACEBO_COMPARATOR|Placebo|Sugar-free tablet
62396049|NCT05544500|ACTIVE_COMPARATOR|Basic sugar-free gum|Sugar-free chewing gum
62002739|NCT04382638|EXPERIMENTAL|RCO group|Patients in the experimental group will receive RCO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
62396050|NCT05544500|EXPERIMENTAL|Functional gum|Sugar-free chewing gum with functional ingredients
62778168|NCT02943915|ACTIVE_COMPARATOR|Group 2: Active controls - BWSTT Therapy|Participants in this group receive a matched number of sessions of standard gait training using body-weight supported treadmill training and overground training. Intervention: Body Weight Supported Treadmill Training
62778169|NCT02943915|NO_INTERVENTION|Group 3: Passive controls|Participants in this group continue with normal daily activities over 12 weeks.
62002740|NCT04382638|ACTIVE_COMPARATOR|TLSO group|Patients in the experimental group will receive TLSO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
62002741|NCT04724239|EXPERIMENTAL|The triplet group (sintilimab + chidamide + IBI305)|Every 3 weeks, patients received sintilimab 200 mg and IBI305(bevacizumab) 7.5 mg/kg on day one and chidamide 30 mg orally twice weekly.
62188037|NCT03238222|EXPERIMENTAL|MOSAIC Treatment|MOSAIC treatment plus Usual NHS Care. MOSAIC treatment comprises 2 x 60-minute individual face-to-face consultations (weeks 1 \& 2) and 2 x 20-minute follow-up telephone calls (weeks 6 \& 12) with a trained physiotherapist.
62188038|NCT03238222|NO_INTERVENTION|Usual Care Comparison|Usual NHS care for people with intermittent claudication typically consists of an initial assessment, drug therapy and simple advice to walk provided by a vascular specialist and delivered in the vascular outpatient clinic.
62188039|NCT05572853||Classification of oxygenation status stratification|Patients were classified into 3 groups with stratification of oxygenation status based on the relationship between blood oxygen saturation (SpO2) and fraction of inspired oxygen (FiO2) SpO2/FiO2, divided into three categories: normal (\> 315), mild to moderate (314 - 235) and severe (\< 234).
62188040|NCT00975676|EXPERIMENTAL|Triptorelin plus tamoxifen|Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.
62396051|NCT03249259|EXPERIMENTAL|Choline alfoscerate|choline alfoscerate 400mg (2 caps - 1 cap bid)
62396052|NCT03249259|PLACEBO_COMPARATOR|Control|Placebo (2 caps - 1 cap bid)
62778170|NCT01143584|EXPERIMENTAL|Rapid escalation|Weekly escalation of cabergoline dose in macroprolactinomas Start with 1 mg/week. increase by 1mg/wk every week till 4 weeks. after 4 weeks Cabergoline dose would be increased @1mg/wk every 4 weekly till normalization of prolactin and \>50% decrease in tumor volume from baseline.
62396053|NCT05005715|ACTIVE_COMPARATOR|Dexmedetomidine group|After the induction of anesthesia, the dexmedetomidine group received intravenous dexmedetomidine at a loading dose of 1µg/kg for 10 min, followed by a maintenance dose of 0.5µg/kg/h until the end of surgery.
62396054|NCT05005715|PLACEBO_COMPARATOR|Control group|After the induction of anesthesia, the control group received intravenous normal saline at the same loading volume for 10 min, followed by the same volume until the end of surgery.
62778171|NCT01143584|ACTIVE_COMPARATOR|Conventional escalation|"Conventional escalation of cabergoline~In the Conventional escalation group schedule of cabergoline dosing will be 0.5 mg once a week for 4 weeks. Cabergoline will be incrementally dose adjusted on the basis of individual Prolactin values till amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or till primary endpoint."
62778172|NCT03171818|EXPERIMENTAL|Darbepoetin|Darbepoetin alfa (Aranesp, Amgen)
62002742|NCT04724239|ACTIVE_COMPARATOR|The doublet group (sintilimab + chidamide)|Every 3 weeks, patients received sintilimab 200 mg on day one and chidamide 30 mg orally twice weekly.
62002743|NCT01670162|EXPERIMENTAL|3 loading doses, then every 2 months|All patients will receive 3 monthly intravitreal aflibercept injections followed by mandatory dosing every 3 months. If needed, patients can be treated monthly.
62188041|NCT00975676|EXPERIMENTAL|Triptorelin plus exemestane|Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years.
62188042|NCT03722511|ACTIVE_COMPARATOR|NET with carcinoid syndrome|Participants with NET and carcinoid syndrome will be instructed to drink two 8 oz. bottles of Amino Acid Based Medical Food/Drink (Enterade®) per day.
62396055|NCT04367324||Low level laser therapy|Applied the low-level laser irradiation
62778173|NCT03171818|PLACEBO_COMPARATOR|Placebo|Saline
62396056|NCT04367324||Control|No low-level laser application
62778174|NCT01918332|EXPERIMENTAL|Valsartan 160mg, Rosuvastatin 20mg|Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 8 weeks.
62778175|NCT01918332|ACTIVE_COMPARATOR|Valsartan 160mg, Rosuvastatin 20mg placebo|Intervention : Drug : Both Valsartan 160mg and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
62002744|NCT03306888|EXPERIMENTAL|Physical Activity Coaching Intervention|The intervention will entail one face-to-face coaching session (approximately 1 hour) to be held approximately 1 week following the baseline assessment, and three remote video sessions (via secure Webex connection via computer or smart phone, or phone call if internet/smart phone is not available to participant) lasting approximately 20 minutes.
62002745|NCT02412631|PLACEBO_COMPARATOR|Varenicline plus placebo|Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)
62002746|NCT02412631|EXPERIMENTAL|Varenicline plus lorcaserin|Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)
62188043|NCT03722511|ACTIVE_COMPARATOR|NET w/o cardinoid syndrome|Participants with NET w/o carcinoid syndrome will be instructed to drink two 8 oz. bottles of Amino Acid Based Medical Food/Drink (Enterade®) per day.
62778176|NCT01918332|ACTIVE_COMPARATOR|Valsartan 160mg placebo, Rosuvastatin 20mg|Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered daily by p.o. once a day for 8 weeks.
62778177|NCT01918332|PLACEBO_COMPARATOR|Placebo|Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
62778178|NCT03334812|EXPERIMENTAL|LNA043 20mg/ml|LNA043 20mg/ml single dose
62778179|NCT03334812|PLACEBO_COMPARATOR|Matching placebo to 20mg|Matching placebo to 20mg/3ml, single dose
62778180|NCT03334812|EXPERIMENTAL|LNA043 40mg/ml|LNA043 40mg/ml single dose
62778181|NCT03334812|PLACEBO_COMPARATOR|Matching placebo to 40mg|Matching placebo to 40mg/4ml, single dose
62778182|NCT02831933|EXPERIMENTAL|Experimental|"ADV/HSV-tk (5 x 1011 viral particles) in a 2-mL total volume will be injected intratumorally on day 0 of the study.~Valacyclovir will be orally administered at a dose of 2 g three times daily for 14 days. Valacyclovir treatment will be administered 24 hours after the gene vector injection from day 1 to day 15 of the study.~SBRT of 30 gray (Gy; 6 Gy X 5 fractions) will be administered over 2 weeks from day 2 to day 16 of the study.~Nivolumab (480 mg) will be administered intravenously over 30 minutes every 4 weeks starting on day 17 of the study and continuing until disease progression, unacceptable toxicity, or up to 12 months in patients without disease progression."
62778183|NCT01892891|EXPERIMENTAL|VBY-036|VBY-036 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg
62778184|NCT01892891|PLACEBO_COMPARATOR|Placebo comparator|Placebo
62778185|NCT00503321|EXPERIMENTAL|Arm B|S-1 plus PSK group
62778186|NCT00503321|ACTIVE_COMPARATOR|Arm A|S-1 alone
62778187|NCT01374178|EXPERIMENTAL|LY2963016|A single 0.5-unit per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously.
62002747|NCT01027169|EXPERIMENTAL|Arm 1|subjects with mild hepatic impairment
62002748|NCT01027169|EXPERIMENTAL|Arm 2|subjects with moderate hepatic impairment
62002749|NCT01027169|EXPERIMENTAL|Arm 3|matched subjects with normal hepatic function
62188044|NCT03016598|EXPERIMENTAL|Oxytocin|Patients in methadone maintenance treatment (MMT) programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with stimulant use disorders and receiving MMT for co-occurring opioid use disorder (OUD) to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
62188045|NCT03016598|PLACEBO_COMPARATOR|Placebo|Patients in MMT programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with stimulant use disorders and receiving MMT for co-occurring OUD to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
62188046|NCT00541905|EXPERIMENTAL|NT 201 (50-300 Units)|"NT 201 (Xeomin®, also know as IncobotulinumtoxinA or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
62396057|NCT04360538||COVID19 positive|ICU patients coronavirus positive
62778188|NCT01374178|ACTIVE_COMPARATOR|Lantus|A single 0.5-U/kg dose of Lantus will be administered subcutaneously.
62778189|NCT01272765|PLACEBO_COMPARATOR|Control Group|
62778190|NCT01272765|EXPERIMENTAL|Risperdal Group|Subjects who are on a stable dose of Ripserdal and taking 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
62778191|NCT01272765|EXPERIMENTAL|Seroquel Group|Subjects who are on a stable dose of Seroquel and taking 500 mg of IHBG-10 15 minutes before the three main meals of the day.
62778192|NCT01272765|EXPERIMENTAL|Zyprexa Group|Subjects who are on a stable dose of Zyprexa and taking 500 mg of IHBG-10 15 minutes prior to the three main meals of the day.
62778193|NCT02468349|EXPERIMENTAL|Telemedicine|The telehealth group will be remotely monitored and managed on medication adherence, dosage titration, and management of drug side effects, through a combination of feed-forward blood pressure monitoring, app-based education and medication reminders, and remote consultations.
62778194|NCT02468349|NO_INTERVENTION|Standard care|The standard care group will receive face-to-face consultations at one month, 6 months and 12 months.
62778195|NCT04213378|EXPERIMENTAL|Paclitaxel eluting PTCA balloon|Treatment of coronary in-stent restenosis with paclitaxel eluting PTCA balloon
62778196|NCT04213378|ACTIVE_COMPARATOR|SeQuent® Please paclitaxel eluting balloon|Treatment of coronary in-stent restenosis with SeQuent® Please paclitaxel eluting balloon
62002750|NCT04666090|EXPERIMENTAL|Carillizumab|"Preoperative neoadjuvant therapy for 2-3 cycles. Radical surgery is performed 4-6 weeks after the last dose. Postoperative radiotherapy is determined according to the clinical situation and pathological stage of the patient.~Carillizumab can be maintained for a maximum of 1 year. During the study, patients were be followed until disease progression, withdrawal of informed consent, loss of follow-up, or death."
62002751|NCT05844514||Control group - 470 patients|Symptomatic patients who are attending for a planned colonoscopy referred under the two-week wait pathway. Any patients who is found to have histology proven CRC on colonoscopy will be analysed as part of the CRC group.
62002752|NCT05844514||CRC group - 250 patients|Patients who are scheduled to undergo elective resection of histologically confirmed colorectal adenocarcinoma.
62002753|NCT01416883|EXPERIMENTAL|Active 1|8 subjects will receive ICI176,334-1
62778197|NCT00742755|EXPERIMENTAL|Prospective Intervention|Peer navigator intervention
62778198|NCT03125837||general anesthesia|Digital photographs of the face of each patient undergoing general anesthesia with endotracheal intubation
62778199|NCT02974842||Pre-Salpingo-Oophorectomy|Women with pelvic mass suspicious for malignancy or have BRCA1 or BRCA2 mutations that will undergo pre-salpingo-oophorectomy.
62778200|NCT04937283|EXPERIMENTAL|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed after a comprehensive evaluation. As with lobectomy, systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated in the same manner as with lobectomy. When lymph node metastasis is present or resection margin is not cancer-free, the surgical procedure must be converted to a lobectomy.
62778201|NCT04937283|ACTIVE_COMPARATOR|Lobectomy with systemic lymph node dissection|"lobectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively.~The distance from the dissection margin to the tumor edge must be evaluated intraoperatively. If the distance is either less than the maximum tumor diameter or ,20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery."
62002754|NCT01106300||Multi-organ failure|Sedated ventilated patients in multi-organ failure
62002755|NCT01106300||Single-organ failure|Sedated ventilated patients in single organ failure
62002756|NCT04722640|EXPERIMENTAL|RISAKIZUMAB|SKYRIZI
62002757|NCT00888303|ACTIVE_COMPARATOR|A (dexamethasone)|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
62002758|NCT00888303|PLACEBO_COMPARATOR|B (Control)|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
62002759|NCT02474199|EXPERIMENTAL|darTregs|Donor Alloantigen Reactive Tregs (darTregs). Participants will receive a target dose of 400X10\^6 darTregs (range 300-500 x10\^6) infused intravenously (IV) over an approximate 20-30 minute interval
62002760|NCT03858387||Meropenem|Critically ill patients who require meropenem therapy
62188047|NCT01233999|PLACEBO_COMPARATOR|Botox|single-drug dosage comparison cross-over study
62188048|NCT01789840|EXPERIMENTAL|Prostate artery embolization (PAE)|Prostate artery embolization using Embosphere Microspheres
62002761|NCT03858387||Imipenem|Critically ill patients who require imipenem therapy
62002762|NCT00678561|EXPERIMENTAL|2% CP-690,550 QD|
62002763|NCT00678561|EXPERIMENTAL|0.2% CP-690,550 QD|
62002764|NCT00678561|EXPERIMENTAL|0.02% CP-690,550 QD|
62002765|NCT00678561|EXPERIMENTAL|2% CP-690,550 BID|
62002766|NCT00678561|EXPERIMENTAL|0.2% CP-690,550 BID|
62002767|NCT00678561|EXPERIMENTAL|0.02% CP-690,550 BID|
62002768|NCT00678561|PLACEBO_COMPARATOR|Placebo Vehicle QD|
62002769|NCT00678561|PLACEBO_COMPARATOR|Placebo Vehicle BID|
62188049|NCT01789840|ACTIVE_COMPARATOR|Transurethral resection of the prostate (TURP)|Transurethral Resection of the Prostate (TURP)
62188050|NCT05889949||TACE+MKIs|
62188051|NCT05889949||TACE|
62188052|NCT03251612|OTHER|Treatment|1 drug or a combination of drugs considered standard anticancer treatment is given according to the result of the sensitivity analysis.
62188053|NCT02296892|EXPERIMENTAL|Remimazolam|"Double-blind Remimazolam arm: 5 mg iv for sedation induction, and 2.5 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
62396058|NCT04360538||non-COVID19|ICU patients without coronavirus
62396059|NCT02699918|EXPERIMENTAL|screening oxymetry|nocturnal oxymetry to screen for sleep apnea
62571292|NCT02215369|EXPERIMENTAL|VenaCure EVLT 400 µm fiber Procedure Kit|Only one limb can be treated and included in this study; however, multiple IPV's within the study limb may be treated. All IPV's treated will be followed according to the study schedule.
62002770|NCT01321801|ACTIVE_COMPARATOR|Pregabalin|Preoperative administration of pregabalin 600mg to patients undergo laparoscopic cholecystectomy.Patients receive oral Pregabalin 300 mg the night before the surgery, and another one dose of 300 mg 1 hour prior to surgery
62002771|NCT01321801|PLACEBO_COMPARATOR|Placebo|Preoperative administration of placebo to patients undergo laparoscopic cholecystectomy.Patients receive oral Placebo the night before the surgery, and another one dose 1 hour prior to surgery.
62571293|NCT01964222|EXPERIMENTAL|Decision Aid (DA)|The decision aid (DA) will be provided to patients randomized to the experimental/intervention group.
62778202|NCT03776461|EXPERIMENTAL|80-pin applicator|3 treatments with the 80-pin tip applicator at 0, 4, and 8 weeks.
62778203|NCT03776461|ACTIVE_COMPARATOR|160 pin applicator|3 treatments with the 160-pin tip applicator at 0, 4, and 8 weeks.
62778204|NCT04585607|EXPERIMENTAL|Expanded hemodialysis (HDx)|HDx therapies be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
62778205|NCT04585607|ACTIVE_COMPARATOR|Conventional hemodialysis|Conventional hemodialysis therapies be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
62778206|NCT03286816|EXPERIMENTAL|Lactate infusion|Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels
62778207|NCT03286816|PLACEBO_COMPARATOR|NaCl infusion|As a control condition, subjects will receive intravenous NaCl infusion
62778208|NCT05643534|EXPERIMENTAL|Tenpanor 50 mg BID|Patients will be randomized to receive 50 mg tenapanor twice daily
62188054|NCT02296892|PLACEBO_COMPARATOR|Placebo|"Double-blind placebo arm as inactive control~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
62188055|NCT02296892|ACTIVE_COMPARATOR|Midazolam|"Open-label Midazolam arm: 1.75 mg\* iv for sedation induction and 1.0 mg\* iv for sedation maintenance. \*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
62002772|NCT01329510|EXPERIMENTAL|methylphenidate|
62002773|NCT04419688|EXPERIMENTAL|STT-5058|
62002774|NCT04419688|PLACEBO_COMPARATOR|Placebo|
62188056|NCT03532269|EXPERIMENTAL|A: 3rd night with acoustic stimulation|Arm A: PSG (3 nights) with Nightly App - acoustic stimulation during the 3rd night.
62188057|NCT03532269|EXPERIMENTAL|B: 2nd night with acoustic stimulation|Arm B: PSG (3 nights) with Nightly App - acoustic stimulation during the 2nd night.
62396060|NCT06723561|EXPERIMENTAL|Low Dose Naltrexone|Daily dose of 4.5mg of naltrexone
62396061|NCT02543476||patients' group with tumor sample|SCCHN patients having available archived tumor sample(s).
62396062|NCT02551601||Healthy volunteers|to measure the subfoveal choroidal thickness in healthy volunteers
62396063|NCT06184100|EXPERIMENTAL|SMP Program with Standard Care|four 60-90 minute virtual educational sessions over 8 weeks with a group of 4-6 participants
62396064|NCT06184100|ACTIVE_COMPARATOR|Standard Care Only|Standard of care(no formal education program similar to SMP) and placed on 8-week waitlist for optional intervention.
62571294|NCT01964222|NO_INTERVENTION|Control|Participants randomized to the control group will receive usual care and will be shown Siteman Cancer Center website about clinical trials.
62571295|NCT04438837|NO_INTERVENTION|control group|no intervention
62002775|NCT02831270||Control Group|Patients undergoing cardiac surgery supposed not to get acute normovolemic hemodilution (ANH) before CPB
62188058|NCT05328024||Recurrent and/or metastatic head and neck carcinoma|Patients with indication of anti-PD1 immunotherapy according to recommendations
62188059|NCT01083199|EXPERIMENTAL|CONTINUUMTM|
62188060|NCT02023749|ACTIVE_COMPARATOR|Nut group|Subjects were supplemented with 30 g of mixed nuts including walnuts, peanuts, and pine nuts for 6 weeks
62188061|NCT02023749|NO_INTERVENTION|Control group|Control group maintained their usual diet without nut supplement
62188062|NCT05915533|OTHER|Before/after study|
62188063|NCT01907113|EXPERIMENTAL|BI 10773 / Group 2|Single Dose Administration (type 2 diabetes and mild renal impairment)
62396065|NCT01108588|EXPERIMENTAL|Sequence 1|Aspirin - Clopidogrel - Placebo
62396066|NCT01108588|EXPERIMENTAL|Sequence 2|Clopidogrel - Placebo - Aspirin
62396067|NCT01108588|EXPERIMENTAL|Sequence 3|Placebo - Aspirin - Clopidogrel
62571296|NCT04438837|ACTIVE_COMPARATOR|intervention group|participants will recieve hydroxychloroquine in a dosage regimen of 400mg BID in the first day followed by 200mg BID for overall 10 days.
62571297|NCT04668079|EXPERIMENTAL|Modified cross body stretch|modified cross body stretch
62571298|NCT04668079|EXPERIMENTAL|Modified sleeper stretch|modified sleeper stretch
62571299|NCT01247051|EXPERIMENTAL|Precoating|
62571300|NCT01247051|ACTIVE_COMPARATOR|Standard priming|
62571301|NCT03742518|EXPERIMENTAL|Topical SM04554 0.15% solution|Topical SM04554 0.15% solution, once daily for up to 48 weeks
62778209|NCT05643534|EXPERIMENTAL|Tenpanor 25 mg BID|Patients will be randomized to receive 25 mg tenapanor twice daily
62778210|NCT05643534|PLACEBO_COMPARATOR|Placebo Comparator|Patients will be randomized to receive matching placebo twice daily
62778211|NCT06199453|EXPERIMENTAL|Experimental|Treatment will consist of administration of 6 cycles of lutetium (177Lu) vipivotide-tetraxetan with an activity of 200 mCi (7.4 GBq) at intervals of 6 weeks.
62778212|NCT01232985|EXPERIMENTAL|RD047-26|Study Device
62778213|NCT06003088|EXPERIMENTAL|HSK7653(5mg) Sequence A(Formulation A + Formulation B)|Participants will receive a single oral dose of treatment 1: Formulation A followed by a washout period of at least 36 days from first dose of HSK7653(5mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(5mg) Formulation B.
62002776|NCT02831270||Active Comparator: Acute normovolemic hemodilution group|Patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB
62002777|NCT06196567|ACTIVE_COMPARATOR|active control group|will receive the standard prehabilitation a physio-based exercise program designed to increase quadriceps muscle strength for 2 sessions per week for 8 weeks. Sessions will be performed at the same time (i.e., in the morning). The main programme comprised 5 sets of 10 repetitions for each exercise, with 60 rest between sets.
62002778|NCT06196567|EXPERIMENTAL|Pulsed Electromagnetic Field (PEMF)|will receive the active PEMF treatment provided by a PEMF device (Quantum Tx, Singapore). Alternating leg will be exposed to PEMF for 10 minutes per session for 2 sessions per week for 8 weeks.
62002779|NCT06196567|EXPERIMENTAL|standard prehabilitation plus PEMF intervention|This group will have both the standard prehabilitation and PEMF intervention for 2 sessions a week for eight weeks.
62188064|NCT01907113|EXPERIMENTAL|BI 10773 / Group 3|Single Dose Administration (type 2 diabetes and moderate renal impairment)
62571302|NCT03742518|EXPERIMENTAL|Topical SM04554 0.25% solution|Topical SM04554 0.25% solution, once daily for up to 48 weeks
62002780|NCT03242499|EXPERIMENTAL|Active|Lovastatin 80mg per day for 48 weeks.
62002781|NCT03242499|PLACEBO_COMPARATOR|Placebo|Placebo 80mg per day for 48 weeks.
62002782|NCT02348242|EXPERIMENTAL|Aqueous gel|In the same patient : one eye receives regular administration of aqueous gel (experimental treatment 1) and the other eye receives regular administration of artificial tears (active comparator)
62396068|NCT01108588|EXPERIMENTAL|Sequence 4|Aspirin - Placebo - Clopidogrel
62002783|NCT02348242|EXPERIMENTAL|Eyelid occlusion dressing|In the same patient : one eye is closed with an eyelid closure dressing (experimental treatment 2) and the other eye receives regular administration of artificial tears (active comparator)
62188065|NCT01907113|EXPERIMENTAL|BI 10773 / Group 4|Single Dose Administration (severe renal impairment 8)
62188066|NCT01907113|EXPERIMENTAL|BI 10773 / Group 5|Single Dose Administration (kidney failure)
62188067|NCT01907113|EXPERIMENTAL|BI 10773 / Group 1|Single Dose Administration (type 2 diabetes and normal renal function)
62396069|NCT01108588|EXPERIMENTAL|Sequence 5|Clopidogrel - Aspirin - Placebo
62396070|NCT01108588|EXPERIMENTAL|Sequence 6|Placebo - Clopidogrel - Aspirin
62396071|NCT06071351|EXPERIMENTAL|Experimental intervention group|In addition to the informative brochure prepared by the researcher, a 6-session motivational interview-based training program will be given. The training program will include topics such as nutrition, physical activity, smoking and alcohol use.
62778214|NCT06003088|EXPERIMENTAL|HSK7653(5mg) Sequence B(Formulation B + Formulation A)|Participants will receive a single oral dose of treatment 1: Formulation B followed by a washout period of at least 36 days from first dose of HSK7653(5mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(5mg) Formulation A.
62778215|NCT06003088|EXPERIMENTAL|HSK7653(25mg) Sequence A(Formulation A + Formulation B)|Participants will receive a single oral dose of treatment 1: Formulation A followed by a washout period of at least 36 days from first dose of HSK7653(25mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(25mg) Formulation B.
62778216|NCT06003088|EXPERIMENTAL|HSK7653(25mg) Sequence B(Formulation B + Formulation A)|Participants will receive a single oral dose of treatment 1: Formulation B followed by a washout period of at least 36 days from first dose of HSK7653(25mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(25mg) Formulation A.
62778217|NCT05170178|EXPERIMENTAL|Women with parental experience caring for infants|Women parent of a child under 2 years old
62778218|NCT05170178|EXPERIMENTAL|Men with parental experience caring for infants|Men parent of a child under 2 years old
62778219|NCT05170178|EXPERIMENTAL|Women with professional experience in caring for infants|Women in daily contact with infants in professional circle (e.g., nannies, pediatricians, midwives, maternity nurses) without dependent children under 2 years old
62778220|NCT02702414|EXPERIMENTAL|Cohort 1: Hepatocellular Carcinoma (HCC)-Prior Systemic Therapy with Sorafenib|Participants with previously systemically treated HCC received a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stopped pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stopped after receiving 35 trial treatments were eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they met the criteria for re-treatment.
62002784|NCT04441567|NO_INTERVENTION|Phase 1|Participants in phase 1 will be observed and data about their recovery time will be collected from which recovery curves will be calculated for Phase 2
62002785|NCT04441567|EXPERIMENTAL|Phase 2|Participants in Phase 2 will have their clinic visits potentially revised based on the phase 1 recovery curves which may increase or decrease the number of clinic visits they receive based on the PROMs reported.
62571303|NCT03742518|PLACEBO_COMPARATOR|Vehicle|Topical vehicle solution, once daily for up to 48 weeks
62002786|NCT01768390|EXPERIMENTAL|5000 Test|Twice daily use of a toothpaste containing 5,000 ppm fluoride
62002787|NCT01768390|ACTIVE_COMPARATOR|1450 GCP|Twice daily use of a toothpaste containing 1,450 ppm fluoride
62571304|NCT03213002|EXPERIMENTAL|Capecitabine amd Temozolomide|Oral Capecitabine at 1500 mg/m2 divided into twice daily dosing, taken on days 1-14, and Temozolomide at 150 mg/m2 - 200 mg/m2 divided into twice daily dosing, taken on days 10-14; days 15-28 off.
62571305|NCT04399213|EXPERIMENTAL|Group A|From cubital fossae to wrist: 50 - 15 - 5 µg histamine dihydrochloride
62002788|NCT05036993|EXPERIMENTAL|Intervention|Coaching
62571306|NCT04399213|EXPERIMENTAL|Group B|From cubital fossae to wrist: 15 - 5 - 50 µg histamine dihydrochloride
62002789|NCT05036993|EXPERIMENTAL|Control|Control, Coaching later
62002790|NCT02215590|EXPERIMENTAL|Re-Step|"The system consists of a pair of special shoes which sole height and angles change in a specific given order, thereby facilitating motor learning and problem solving in real time.~This unpredictable change will introduce a situation of necessary adaptation to keep balance."
62571307|NCT04399213|EXPERIMENTAL|Group C|From cubital fossae to wrist: 5 - 50 - 15 µg histamine dihydrochloride
62571308|NCT03258918|EXPERIMENTAL|Low-Carbohydrate Diabetes Prevention Program|At least 20 individuals with prediabetes will participate in a year-long , group-based program.
62571309|NCT02138487|ACTIVE_COMPARATOR|Restricted postoperative activity|"Women in the restricted postoperative activity group must abstain from exercise and heavy lifting for 3 months postoperatively"
62002791|NCT06123884|EXPERIMENTAL|BAT1308|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W)
62778221|NCT02702414|EXPERIMENTAL|Cohort 2: HCC-Systemic Therapy Naïve|Participants with HCC who had not received treatment for systemic disease received a pembrolizumab 200 mg IV infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stopped pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stopped after receiving 35 trial treatments were eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they met the criteria for re-treatment.
62002792|NCT06123884|PLACEBO_COMPARATOR|BAT1308 monoclonal antibody|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W)
62002793|NCT00196781|EXPERIMENTAL|the Information + Decision Aid group|
62002794|NCT00196781|ACTIVE_COMPARATOR|Information Only group|
62002795|NCT03657472|EXPERIMENTAL|Sequence 1(RTR)|
62571310|NCT02138487|EXPERIMENTAL|Liberal postoperative activity|"Women in the liberal postoperative activity group will be allowed to resume their normal activities without restriction."
62571311|NCT06296771|EXPERIMENTAL|Dietary energy restriction and exercise group (D+E)|
62571312|NCT06296771|ACTIVE_COMPARATOR|Dietary energy restriction group (D)|
62571313|NCT03505684|EXPERIMENTAL|CTP group|1,000 mg of collagen tripeptide (CTP) was orally administered per day for 12 weeks.
62571314|NCT03505684|PLACEBO_COMPARATOR|Control group|1,000 mg of placebo (starch) was orally administered per day for 12 weeks
62571315|NCT03283787|ACTIVE_COMPARATOR|Group 1|MicroMatrix® and Cytal™ Wound Matrix 2-Layer
62778222|NCT03472144|EXPERIMENTAL|CRSwNP - Subgrp 1(Momentasone - Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only on right side and placebo on left side
62778223|NCT03472144|EXPERIMENTAL|CRSwNP-Subgrp 2(Levofloxacin - Right)|Patients undergoing balloon sinuplasty with receive a gel loaded with antibiotic (Levofloxacin) only on right side and placebo on left side
62002796|NCT03657472|EXPERIMENTAL|Sequence 2(RRT)|
62002797|NCT03657472|EXPERIMENTAL|Sequence 3(TRR)|
62002798|NCT06101264|EXPERIMENTAL|Virtual Reality Intervention|Participants will receive a post-operative virtual reality intervention following corrective surgery for idiopathic scoliosis.
62002799|NCT00688766|EXPERIMENTAL|IPI-504|retaspimycin hydrochloride (IPI-504) plus best supportive care
62002800|NCT00688766|PLACEBO_COMPARATOR|Placebo|Placebo plus best supportive care
62002801|NCT00610532|EXPERIMENTAL|A|intravenous phenytoin alone
62002802|NCT00610532|EXPERIMENTAL|B|intravenous phenytoin plus probenecid
62002803|NCT05960591|NO_INTERVENTION|Control|Participants will receive bore depth measurements with the manual depth gauge, which is the golden standard for bore depth measurements during plate osteosynthesis procedures.
62002804|NCT05960591|EXPERIMENTAL|Intervention|Participants will receive bore depth measurements with the ADEPTH sensor, which is a new sensor technology for bore depth measurements during plate osteosynthesis procedures.
62002805|NCT03946163|EXPERIMENTAL|first group|each patient will receive sixty capsules, each capsule contained 1gm of cinnamon bark powder and instructed to use it twice daily for one month
62002806|NCT03946163|PLACEBO_COMPARATOR|second group|each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
62002807|NCT01180712|ACTIVE_COMPARATOR|Blaeberry concentrated caspule|"30 obese male subjects (BMI \> 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given a total daily dose of 1.4 grams of mirtoselect (a concentrated blaeberry extract) a day formulated in hard gelatin capsules (0.47 gram per capsule) administered thrice a day for 21 days.~Mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/)"
62002808|NCT01180712|PLACEBO_COMPARATOR|Placebo capsules containing lactose|"30 obese male subjects (BMI \> 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given a placebo consisting of lactose formulated in hard gelatin capsules administered thrice a day for 21 days."
62571316|NCT03283787|ACTIVE_COMPARATOR|Group 2|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
62778224|NCT03472144|EXPERIMENTAL|CRSwNP-Subgrp 3(Steroid/Antibotic Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on right side and placebo on left side
62778225|NCT03472144|EXPERIMENTAL|CRSsNP - Subgrp 1 (Momentasone Right)|Patients undergoing ballon sinuplasty will receive a gel loaded with steroids (Momentasone) only on right side and placebo on left side
62571317|NCT03283787|ACTIVE_COMPARATOR|Group 3|Negative Pressure Wound Therapy
62002809|NCT00183716|EXPERIMENTAL|1|Participants will receive Trauma Recovery and Empowerment Model and usual care
62188068|NCT02875145||Keratoplasty with cataract surgery|Patients who underwent keratoplasty who also underwent a cataract surgery during follow up.
62571318|NCT03677284|EXPERIMENTAL|Intervention group|"Information brochure about daily time management, frequent problems, and suggested strategies to manage them.~Time assistive product. Time assistive products for time perception are products making the passage of time visible and understandable, to know for how long to perform an activity or how long to wait until the next activity starts e.g a time log.~Time assistive products for time orientation includes the use of schedules, calendars and other visual aids to promote orientation to the time of the day, week, or year.~Time assistive products for time management would compensate for deficits in time management and focus on self-scheduling skills."
62778226|NCT03472144|EXPERIMENTAL|CRSsNP - Subgrp 2 (Levofloxacin Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only on right side and placebo on left side
62778227|NCT03472144|EXPERIMENTAL|CRSsNP-Subgrp 3(Steroid/Antibiotic Right|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on right side and placebo on left side
62778228|NCT03472144|ACTIVE_COMPARATOR|CRSwNP - Subgrp 1 (Momentasone Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only on left side and placebo on right side
62778229|NCT03472144|ACTIVE_COMPARATOR|CRSwNP - Subgrp 2 (Levofloxacin Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only left side and placebo on right side
62778230|NCT03472144|ACTIVE_COMPARATOR|CRSwNP-Subgrp 3(Steroid/Antibiotic Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on left side and placebo on right side
62778231|NCT03472144|ACTIVE_COMPARATOR|CRSsNP - Subgrp 1 (Momentasone Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only left side and placebo on right side
62778232|NCT03472144|ACTIVE_COMPARATOR|CRSsNP - Subgrp 2 (Levofloxacin Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only left side and placebo on right side
62778233|NCT03472144|ACTIVE_COMPARATOR|CRSsNP-Subgrp 3(Steroid/Antibiotic Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on left side and placebo on right side
62778234|NCT04560153|EXPERIMENTAL|patient living with HIV|
62778235|NCT06547489|EXPERIMENTAL|GATE-251|GATE-251 (zelquistinel) will be administered as a single 10 mg oral tablet one time each week for 6 weeks.
62002810|NCT00183716|ACTIVE_COMPARATOR|2|Participants will receive usual care
62188069|NCT02875145||Keratoplasty without cataract surgery|Patients who underwent keratoplasty who never underwent cataract surgery.
62188070|NCT05760547||TIME-A|Group will complete periodic surveys
62188071|NCT00656032|ACTIVE_COMPARATOR|1|SOC medication for treatment of renal osteodystrophy
62778236|NCT06547489|PLACEBO_COMPARATOR|Placebo|Placebo tablet identical in appearance to the experimental treatment tablet, administered as as a single oral tablet one time each week for 6 weeks.
62778237|NCT03993041|EXPERIMENTAL|Cognitive-behavioral therapy (CBT)|Individuals in the CBT arm are expected to participate in a phone screen + baseline phase (one assessment) + 10-12 weeks of CBT intervention + post-intervention assessment + 6 week follow-up assessment.
62778238|NCT03993041|ACTIVE_COMPARATOR|Waitlist Control|Individuals in the Waitlist Control arm are expected to participate in a phone screen + baseline phase (two assessments, 12 weeks apart) + 10-12 weeks of CBT intervention + post-intervention assessment + 6 week follow-up assessment.
62778239|NCT04515108||Group 1 (Pregnants with COVID-19)|Study group included pregnant women with clinically confirmed COVID-19.
62002811|NCT03271736|EXPERIMENTAL|Freezer|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
62396072|NCT06071351|ACTIVE_COMPARATOR|Control Group|An informative brochure prepared by the researcher and traditional consultancy services will be provided.
62188072|NCT00656032|ACTIVE_COMPARATOR|2|alternate SOC medication for treatment of renal osteodystrophy
62396073|NCT05108818|EXPERIMENTAL|Influenza vaccination|Adults will receive a seasonal, inactivated, quadrivalent influenza vaccine administered intramuscularly at a dose of 15 ug of HA per component, as approved by the FDA.
62396074|NCT03547960|EXPERIMENTAL|Guar gum (intervention)|5 g of Guar gum fibre supplement with meals three times a day (total daily 15 g) for 12 weeks
62396075|NCT03547960|PLACEBO_COMPARATOR|Control/Cellulose|5 g of Cellulose fibre supplement with meals three times a day (total daily 15 g) for 12 weeks
62778240|NCT04515108||Group 2 (Pregnants without COVID-19)|Control group consisted of healthy pregnant women in the same number and same gestational week with the Study group.
62778241|NCT04541966||Nuchal translucency> = 99th percentile and <3.5mm|Nuchal translucency\> = 99th percentile and \<3.5mm
62188073|NCT05046925||24-hour PACU group|closely monitor in post-anesthetic unit (PACU) and the stay time is less than 24 hours, then patients can be discharged to floor
62188074|NCT05046925||24-hour ICU group|closely monitor in intensive care unit (ICU) and the stay time is less than 24 hours, even patients die within 24 hours in ICU
62188075|NCT02037776|PLACEBO_COMPARATOR|Rikkunshito Placebo|
62188076|NCT02037776|ACTIVE_COMPARATOR|Rikkunshito|
62396076|NCT01958411||18FDG-PET/CT|
62778242|NCT04541966||Nuchal translucency> = 3.5 mm|Nuchal translucency\> = 3.5 mm
62396077|NCT01000311|EXPERIMENTAL|MenACWY-CRM + Routine Vaccines|"Infants received 3 doses of MenACWY-CRM at 2, 4 and 6 months as a infant series vaccination and a toddler dose at 12 months of age.~Infants also received routine vaccines - 3 doses each of DTaP-IPV/Hib, HBV and PCV at 2, 4 and 6 months; and 1 dose each of PCV and MMR at 12 months."
62396078|NCT01000311|EXPERIMENTAL|Routine Vaccines|"Infants received routine vaccines - 3 doses each of DTaP-IPV/Hib, HBV and PCV at 2, 4 and 6 months; and 1 dose each of PCV and MMR at 12 months.~In addition subjects were offered a dose of MenACWY-CRM at 18 months as a benefit of participating in this study. However, blood was not drawn for immunogenicity analysis after this dose."
62396079|NCT06538610|EXPERIMENTAL|Holter monitor|Holter monitor for 48 hours
62571319|NCT03677284|ACTIVE_COMPARATOR|Control group|Information brochure about daily time management, frequent problems, and suggested strategies to manage them.
62571320|NCT01704495|EXPERIMENTAL|AZD5069 5 mg|AZD5069 oral capsules self-administered twice daily
62778243|NCT05418595||Group-1|PCOS patients intraovarian stromal conventional and SMI doppler findings
62778244|NCT03247959|EXPERIMENTAL|Group A|Group A: Videogame distraction during extraction procedure
62778245|NCT03247959|EXPERIMENTAL|Group B|Group B: Video distraction during extraction procedure
62778246|NCT03247959|ACTIVE_COMPARATOR|Group C|group C: Verbatim during extraction procedure
62778247|NCT03489928|EXPERIMENTAL|Oral Misoprostol|50ug po q4h orally, as needed
62778248|NCT03489928|EXPERIMENTAL|Low dose vaginal misoprostol|25-50ug q6h, vaginally, as needed
62778249|NCT03489928|EXPERIMENTAL|Usual vaginal dinoprostone|1-2mg q6h, vaginally as needed
62778250|NCT02929238|EXPERIMENTAL|Polypropylene Suture Right Side|Polypropylene suture will be placed over half the wound. There is an equal chance for the suture to be placed on the right or left through randomization. THe other half of the wound will not have the suture placed on it and will act as the control. The wound vac will be placed over entire wound.
62778251|NCT02929238|EXPERIMENTAL|Polypropylene Suture Left Side|Polypropylene suture will be placed over half the wound. There is an equal chance for the suture to be placed on the right or left through randomization. THe other half of the wound will not have the suture placed on it and will act as the control. The wound vac will be placed over entire wound.
62778252|NCT06469606|EXPERIMENTAL|Participant diagnosed with breast cancer|Participants diagnosed with breast cancer who will undergo a mastectomy operation
62778253|NCT06469606|EXPERIMENTAL|Participant not diagnosed with breast cancer|Participants who will undergo a mastectomy operation for a non-breast cancer related clinical indication
62002812|NCT03271736|EXPERIMENTAL|Non-freezer|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
62778254|NCT02652078|SHAM_COMPARATOR|Control|Sham treatment in identical format to treatment arm but without shockwave production
62778255|NCT02652078|EXPERIMENTAL|Shockwave|Active shockwave treatment to calf muscle bulk
62778256|NCT02114255|EXPERIMENTAL|BCG vaccination|BCG vaccination
62778257|NCT02114255|PLACEBO_COMPARATOR|NaCl 0.9%|administration of NaCl 0.9%.
62778258|NCT03943420||Experimental Group|Therapy A : Basic treatment + Qianyang Yuyin Granules
62002813|NCT01532765|ACTIVE_COMPARATOR|Epiretinal Membrane Surgery without ILM peel|
62571321|NCT01704495|EXPERIMENTAL|AZD5069 15 mg|AZD5069 oral capsules self-administered twice daily
62571322|NCT01704495|EXPERIMENTAL|AZD5069 45 mg|AZD5069 oral capsules self-administered twice daily
62778259|NCT03943420||Negative Control Group|Therapy B : Basic treatment
62778260|NCT03943420||Positive Control Group|Therapy C : Basic treatment + Donepezil
62778261|NCT01532869|PLACEBO_COMPARATOR|Placebo|
62778262|NCT01532869|EXPERIMENTAL|Tocilizumab|
62778263|NCT05693987||stage I-II ovarian cancer|54 patients with stage I-II ovarian cancer
62778264|NCT05693987||stage III-IV ovarian cancer|54 patients with stage III-IV ovarian cancer
62778265|NCT05693987||benign ovarian cancer|40 patients with benign ovarian cancer
62778266|NCT05693987||healthy people|100 healthy people
62002814|NCT01532765|ACTIVE_COMPARATOR|Epiretinal Membrane Surgery with ILM peel (ICG assisted)|
62002815|NCT01532765|ACTIVE_COMPARATOR|Combined CE & IOL and ERM surgery without ILM peel|
62002816|NCT01532765|ACTIVE_COMPARATOR|Combined CE & IOL and ERM surgery with ILM peel (ICG assisted)|
62571323|NCT01704495|PLACEBO_COMPARATOR|Placebo|Placebo oral capsules self-administered twice daily
62571324|NCT04957251|EXPERIMENTAL|Anterior approach|Patient's undergoing an anterior approach to the hip
62571325|NCT04957251|ACTIVE_COMPARATOR|Posterior Approach|Patient's undergoing an posterior approach to the hip
62571326|NCT05028582|ACTIVE_COMPARATOR|ARQ-154 Foam 0.3%|ARQ-154 Foam 0.3%
62571327|NCT05028582|PLACEBO_COMPARATOR|ARQ-154 Vehicle|ARQ-154 Vehicle
62778267|NCT04133272||Ehlers-Danlos Syndrome patients|The group comprises all patients affected by Ehlers-Danlos Syndrome, including prenatal and fetal diagnosis of Ehlers-Danlos Syndrome
62778268|NCT04883034|PLACEBO_COMPARATOR|pain management post total knee arthroplasty with analgetic oral|Patients in control group were given analgesic (etoricoxibe) on a daily basis, with the option to increase the dose if pain persisted, up to a maximum of 120 mg per day.
62778269|NCT04883034|ACTIVE_COMPARATOR|pain management post total knee arthroplasty with adductor canal block|On postoperative day 14 (POD 14), the ACB was performed for ACB group
62778270|NCT03405519|OTHER|Radiotherapy planning|Radiotherapy planning using both CT and MRI scans
62778271|NCT01870648|EXPERIMENTAL|Ondansetron|"4 mg oral disintegrating tablet of ondansetron~Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)"
62778272|NCT01870648|PLACEBO_COMPARATOR|Placebo (sugar pill)|
62778273|NCT06036316|EXPERIMENTAL|early psychotic symptoms|This group includes patients with ARMS and those with FEP. Although they are not in the same place in the continuum of psychosis, these patients benefit from the same language assessment and CAST, do not benefit from the TLC or the MINI, and the data from their neuropsychological and psychiatric assessment will be used , which is why we have chosen to bring them together in the same arm. They are between 16 and 35 years old and are cared for as part of their usual follow-up at the CPN (Nancy Psychotherapeutic Center). They must have received the diagnosis of ARMS and FEP according to the criteria of CAARMS and SPI-A.
62396080|NCT06722352|EXPERIMENTAL|Intervention -|Hospice nurses or social workers selected from LifePath and Suncoast Hospice organizations will train the AL interventionists on the PCEAL-DCP intervention. All hospice nurses and social workers who are facilitators will be licensed practical nurses, registered nurses or master's in social work. Prior to the intervention, the hospice facilitators will complete a four-hour workshop about the topics to cover and be trained on the protocol to follow for facilitation of the four-week PCEAL sessions so each cluster in the treatment group is trained in the same manner.
62396081|NCT06722352|NO_INTERVENTION|Control|Wait-listed group will receive the PCEAL-DCP curriculum after completion of the study.
62571328|NCT06571149|NO_INTERVENTION|Best Medical Treatment (standard of care)|Patients will receive Standard of care/Best medical treatment according to local applicable guidelines, including the current American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation/ European Society of Minimally Invasive Neurological Therapy (ESO/ESMINT) guidelines.
62778274|NCT06036316|EXPERIMENTAL|patients with schizophrenia|The schizophrenic patients group will benefit from language assessment, TLC and CAST. They are between 18 and 55 years old and are cared for as part of their usual follow-up at the CPN. They must have been diagnosed with schizophrenia according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) criteria.
62778275|NCT06036316|EXPERIMENTAL|healthy controls|The control group for this study will be made up of volunteers between the ages of 16 and 55, not suffering from any mental disorder detected on the MINI or from a developmental disorder of oral or written language. They will also benefit from an assessment of cannabis use using the CAST.
62396082|NCT05689554|EXPERIMENTAL|Intervention|Educational intervention
62571329|NCT06571149|EXPERIMENTAL|Intravenous Thrombolysis + Best medical treatment (standard of care)|Patients will receive intravenous administration of Tenecteplase or Alteplase.
62571330|NCT04394949|ACTIVE_COMPARATOR|Business as Usual Arm|Consumers will usual care
62778276|NCT02741206|ACTIVE_COMPARATOR|High Risk PTSD Group 1|Forty women who are eligible for the study will be randomized into either the Bellevue ROSE intervention (treatment group) or a psycho-education session and usual, standard of care (control group 1)
62778277|NCT02741206|ACTIVE_COMPARATOR|High Risk PTSD Group 2|Forty women who are eligible for the study will be randomized into either the Bellevue ROSE intervention (treatment group) or a psycho-education session and usual, standard of care (control group 1)
62778278|NCT02741206|EXPERIMENTAL|Low Risk PTSD Control|Twenty additional women, who are at lower risk and thus not eligible for randomization, will also receive one psycho-education session and usual care (control group 2).
62778279|NCT00761202|ACTIVE_COMPARATOR|1|Optive Eyedrops
62778280|NCT00761202|ACTIVE_COMPARATOR|2|Hylocomod Eyedrops
62188077|NCT05013515|EXPERIMENTAL|Salivary Gland Carcinomas|Patients with Salivary Gland Carcinomas were given Surufatinib .
62188078|NCT06334341|NO_INTERVENTION|No intervention|No intervention
62188079|NCT06334341|EXPERIMENTAL|Video|Patient PrEP Video only
62002817|NCT02300324|EXPERIMENTAL|Standard v Beneforte v Beneforte Extra|This is a randomized, double-blinded, three-phase crossover trial investigating the bioavailability of SF following consumption of three types of broccoli + stilton soup containing different concentrations of glucoraphanin. The three types of soup are standard broccoli and stilton soup, beneforte broccoli and stilton soup, and beneforte extra broccoli and stilton soup.
62002818|NCT04963179|EXPERIMENTAL|Womed Leaf|IUA prevention: The novel intrauterine barrier film (Womed Leaf) is inserted immediately after completion of the hysteroscopic adhesiolysis
62002819|NCT04963179|NO_INTERVENTION|Control|No IUA prevention - no placebo after adhesiolysis
62002820|NCT00638885||Group 1|
62002821|NCT05726578|EXPERIMENTAL|Lung recruitment|preterm infants with moderate to severe respiratory distress
62002822|NCT05551806|EXPERIMENTAL|CBT-I group|Participants in the CBT-I condition start the 6-week CBT-I immediately after randomization, complete the post-intervention assessment right after they finish the treatment, and complete the follow-up assessment 4 weeks after the post-intervention assessment. They will be invited to participate in an interview after completing the post-intervention assessment.
62002823|NCT05551806|NO_INTERVENTION|Waitlist control group|Participants in the waitlist control group will wait for 6 weeks without the CBT-I intervention and then complete the post-intervention assessment; while waiting for 4 more weeks and then completing the follow-up assessment. The waitlist control participants will start CBT-I (equivalent to that of the CBT-I group) immediately after completing the follow-up assessment.
62002824|NCT05408663|EXPERIMENTAL|Experimental- EXT608|Up to 6 sequential dose escalation cohorts will receive a single dose of EXT608 administered as a subcutaneous injection
62002825|NCT05408663|PLACEBO_COMPARATOR|Placebo comparator|Up to 6 participants will receive matching placebo administered as a subcutaneous injection
62002826|NCT05204381|EXPERIMENTAL|Theta Stimulation followed by Alpha Stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to frontal and parietal cortex during performance of a cognitive control task while electroencephalography (EEG) is recorded. In the fourth session, stimulation is delivered in near-zero phase lag theta-frequency, anti-synchrony theta-frequency, near-zero phase lag arrhythmic-in-synchrony stimulation, and arrhythmic-independent stimulation. In the fifth session, stimulation is delivered in near-zero phase lag alpha-frequency, anti-synchrony alpha-frequency, near-zero phase lag arrhythmic-in-synchrony stimulation, and arrhythmic-independent stimulation. The near-zero phase lag arrhythmic-in-synchrony stimulation and arrhythmic-independent stimulation is delivered in both the fourth and fifth session to serve as an active control. Each session is separated by at least one day as a washout period.
62002827|NCT05204381|EXPERIMENTAL|Alpha Stimulation followed by Theta Stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to frontal and parietal cortex during performance of a cognitive control task while electroencephalography (EEG) is recorded. In the fourth session, stimulation is delivered in near-zero phase lag alpha-frequency, anti-synchrony alpha-frequency, near-zero phase lag arrhythmic-in-synchrony stimulation, and arrhythmic-independent stimulation. In the fifth session, stimulation is delivered in near-zero phase lag theta-frequency, anti-synchrony theta-frequency, near-zero phase lag arrhythmic-in-synchrony stimulation, and arrhythmic-independent stimulation. The near-zero phase lag arrhythmic-in-synchrony stimulation and arrhythmic-independent stimulation is delivered in both the fourth and fifth session to serve as an active control. Each session is separated by at least one day as a washout period.
62002828|NCT04903132||Longhauler's Syndrome Cohort|Subject's with longhaulers
62002829|NCT04903132||Control Cohort|Control cohort will not have had a known case of COVID-19 or Longhauler's syndrome
62002830|NCT04903132||COVID Control Cohort|Subjects who have had COVID-19 but no known Longhauler's syndrome
62002831|NCT05572983|EXPERIMENTAL|Chidamide in Combination With CHOP|Patients with previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype will receive chidamide in combination with CHOP for 6 cycles (planned) (21 days per cycle). After 6 cycles of induction therapy, if complete remission (CR) was achieved, maintenance treatment with chidamide will be continued for two years.
62188080|NCT06334341|EXPERIMENTAL|Risk Assessment|Patient Risk Assessment only
62188081|NCT06334341|EXPERIMENTAL|Risk Assessment and Video|Patient Risk Assessment and Patient PrEP Video
62188082|NCT06334341|EXPERIMENTAL|Best Practice Alert|Best Practice Alert only
62188083|NCT06334341|EXPERIMENTAL|Best Practice Alert and Video|Best Practice Alert and Patient PrEP Video
62188084|NCT06334341|EXPERIMENTAL|Best Practice Alert and Risk Assessment|Best Practice Alert and Patient Risk Assessment
62188085|NCT06334341|EXPERIMENTAL|Best Practice Alert, Risk Assessment and Video|Best Practice Alert, Patient Risk Assessment, and Patient PrEP Video
62188086|NCT06334341|EXPERIMENTAL|Training|Provider Training
62188087|NCT06334341|EXPERIMENTAL|Training and Video|Provider Training and Patient PrEP Video
62188088|NCT06334341|EXPERIMENTAL|Training and Risk Assessment|Provider Training and Patient Risk Assessment
62188089|NCT06334341|EXPERIMENTAL|Training, Risk Assessment, and Video|Provider Training, Patient Risk Assessment, and Patient PrEP Video
62188090|NCT06334341|EXPERIMENTAL|Training and Best Practice Alert|Provider Training and Best Practice Alert
62188091|NCT06334341|EXPERIMENTAL|Training, Best Practice Alert, and Video|Provider Training, Best Practice Alert, and Patient PrEP Video
62188092|NCT06334341|EXPERIMENTAL|Training, Best Practice Alert, and Risk Assessment|Provider Training, Best Practice Alert, and Patient Risk Assessment
62188093|NCT06334341|EXPERIMENTAL|Training, Best Practice Alert, Risk Assessment, and Video|Provider Training, Best Practice Alert, Patient Risk Assessment, and Patient PrEP Video
62188094|NCT03040245||intervention group|The intervention group was instructed to complete the questionnaires at least 48 hours after the intervention that is, after reading the information booklet
62778281|NCT04839445|ACTIVE_COMPARATOR|General anesthesia + TAP block|Induction: remifentanil in total intravenous anesthesia (TIVA), Propofol 2 mg/kg/h and Rocuronium 0.6 mg/kg. Transversus abdominis plane (TAP) block: 20 minutes before surgery. Ropivacaine 0.37% 20ml + dexamethasone 2mg per side. Maintenance: TIVA with Propofol, the infusion rate will be adjusted according to the bispectral index system (BIS) values (30 \<BIS \<50). Patients will receive additional remifentanil by infusion at 0.02 mcg/kg/min per time if blood pressure and heart rate values exceed 20% pre-operative baseline values. Additional rocuronium 0.1 mg/kg based on clinical needs and train of four (TOF) monitoring. Analgesic starter bolus: 30 minutes before the end of the surgery, paracetamol 1 gr ev and ketorolac 30 mg ev. Postoperative pain: paracetamol 1 gr ev every 8 hours for 36 hours; ketorolac 30 mg ev if NRS \>4 / morphine 2 mg ev if NRS \>4 30 min after ketorolac administration. In case of nausea and vomiting ondansetron 4 mg ev.
62188095|NCT03040245||control group|The same items were included as in the initial folder, with an additional questionnaire enabling the intervention group to qualitatively assess the information booklet. If there was no response, reminders were sent by email, then by telephone, and lastly by post.
62571331|NCT04394949|EXPERIMENTAL|Experimental Arm|Center for Independent Living (CIL) consumers randomized to work with a group of CIL employees who received training in SOAR, Customized Employment, Supported Employments, and Benefits Planning (CWIC).
62571332|NCT00442897|EXPERIMENTAL|1|
62571333|NCT00442897|ACTIVE_COMPARATOR|2|
62778282|NCT04839445|ACTIVE_COMPARATOR|General anesthesia + ESP block|"Erector spinae plane (ESP) block: 20 minutes before surgery. T8 level bilaterally, ropivacaine 0.37% 20ml + dexamethasone 2mg per side.~Induction: Remifentanil in TIVA, Propofol 2 mg/kg/h and Rocuronium 0.6 mg/kg. Maintenance: TIVA with Propofol, the infusion rate will be adjusted according to the BIS values (30 \<BIS \<50). Patients will receive additional remifentanil by infusion at 0.02 mcg/kg/min per time if blood pressure and heart rate values exceed 20% pre-operative baseline values. Additional rocuronium 0.1 mg/kg based on clinical needs and TOF monitoring.~Analgesic starter bolus: 30 minutes before the end of the surgery, paracetamol 1 gr ev and ketorolac 30 mg ev.~Postoperative pain: paracetamol 1 gr ev every 8 hours for 36 hours; ketorolac 30 mg ev if NRS \>4 / morphine 2 mg ev if NRS \>4 30 min after ketorolac administration. In case of nausea and vomiting ondansetron 4 mg ev."
62188096|NCT01813305|ACTIVE_COMPARATOR|CSTC1|CSTC1 (vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof), topical, two times daily
62571334|NCT01372995|EXPERIMENTAL|Enteral vitamin D3 50,000 IU|An arm where subjects receive 50,000 IU of Vitamin D for 5 days.
62571335|NCT01372995|EXPERIMENTAL|Enteral Vitamin D3 100,000 IU|Arm where subjects receive 100,000 IU of Vitamin D for 5 days
62571336|NCT01372995|PLACEBO_COMPARATOR|Inactive Substance|Arm where patients receive inactive substance for 5 days.
62571337|NCT06254118|EXPERIMENTAL|group 2 polyunsaturated fatty acids|"intervention: systemic administration of 1000 mg polyunsaturated fatty acids. to be taken once daily with meals for 12 months~patients treated by scaling and root planing and oral systemic administration of Omega-3 fatty acids a soft gelatinous capsule containing 1000 mg polyunsaturated fatty acids (PUFAs)"
62571338|NCT06254118|SHAM_COMPARATOR|group 1 control|control group, patients treated by scaling and root planing and an oral soft gelatinous capsule containing olive oil to be taken once daily with meals for 12 months
61977835|NCT03752359|PLACEBO_COMPARATOR|placebo group|Participants received a dose of 35 grams of maltodextrin after resistance training (RT). Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
62188097|NCT01813305|PLACEBO_COMPARATOR|CSTC1 Matched vehicle|Matched vehicle, topical, two times daily
62188098|NCT00673608|EXPERIMENTAL|Deferasirox|
62571339|NCT03981380||MESA study participants|Current participants in the MESA study in New York City, 60 years or older, fluent in English or Spanish, able to participate in the brain imaging study
62396083|NCT05689554|NO_INTERVENTION|Usual Care|Usual care
62396084|NCT02131142|EXPERIMENTAL|BioFreedom|
62396085|NCT06656702|OTHER|Psilocybin|All subjects will be in the same, open label arm
62396086|NCT05769777|EXPERIMENTAL|Amlitelimab|Subcutaneous injection as per protocol
62396087|NCT00608426|NO_INTERVENTION|Usual Care|Group who can elect to receive reactive (usual) care for smoking cessation.
62396088|NCT00608426|EXPERIMENTAL|Proactive Care|Group who will be proactively offered smoking cessation care with their choice of smoking cessation services (telephone care or in-person care).
62571340|NCT04189315|EXPERIMENTAL|Group 1 Asfotase Alfa|Participants will be administered asfotase alfa per approved dose for 36 weeks.
62571341|NCT04189315|EXPERIMENTAL|Group 2 Asfotase Alfa|Participants will be administered asfotase alfa per approved dose for 12 weeks and then asfotase alfa at a lower dose for 24 weeks.
62188099|NCT02617979|EXPERIMENTAL|Arm 1: SAFECARE at Home|"* Patients randomized to the intervention arm will be assigned a username and password to access a SAFECARE at Home account via the internet. They will also be emailed a link to the site with their username and password.~* The investigators have worked directly with SAFECARE at Home to create customized lessons for patients undergoing pancreatectomy. These lessons are comprehensive and encompass preoperative preparation as well as postoperative recovery and care. This includes videos, printed material, web-based material, and modules that focus on the pre-treatment, treatment, and follow-up care of patients undergoing surgery for pancreatic cancer.~* All patients will receive standard pre- and post-operative instructions and care. This will include verbal education about the procedure by the surgeon as well as standard educational patient handouts, which are routinely provided preoperatively to pancreatectomy patients."
62188100|NCT02617979|NO_INTERVENTION|Arm 2: Standard of Care|-All patients will receive standard pre- and post-operative instructions and care. This will include verbal education about the procedure by the surgeon as well as standard educational patient handouts, which are routinely provided preoperatively to pancreatectomy patients.
62188101|NCT05417347|ACTIVE_COMPARATOR|Low-fat dairy products|Consumption of low-fat dairy products (4 servings/day with 2 servings/day coming from yogurt)
62188102|NCT05417347|ACTIVE_COMPARATOR|Full-fat dairy products|Consumption of high-fat dairy products (4 servings/day with 2 servings/day coming from yogurt)
62188103|NCT05417347|NO_INTERVENTION|Control|Will be recommended to choose low-fat dairy products and alternatives based on recommendations from the 2007 Canadian Food Guide (2 servings/day for adults and 3-4 servings/day for children)
62188104|NCT04157933|EXPERIMENTAL|A-1a|Part A, Arm 1 (active), Dose 1 (009-A1)
62188105|NCT04157933|EXPERIMENTAL|A-2a|Part A, Arm 2 (active), Dose 2 (009-A2)
62571342|NCT02576847|EXPERIMENTAL|Treatment|Omiganan gel applied once daily
62571343|NCT01139957||Ancillary-correlative|Patients complete the Health Update Questionnaire annually for up to 5 years. The questionnaire focuses specifically on cancer risk, incidence, and mortality. Patients also receive ongoing communication (e.g., periodic newsletters, copies of study-related publications, etc.) to keep them informed regarding study-related research results, new research findings, new research opportunities for which patients may be eligible, and evolving clinical recommendations regarding hereditary breast/ovarian cancer.
62778283|NCT06262217||Mobile MRI|Mobile MRI scan
62778284|NCT01667874|NO_INTERVENTION|No Collatamp sponge|Joint infection treated without the use of the Collatamp G sponge.
62778285|NCT01667874|EXPERIMENTAL|Collatamp G sponge|Use of Collatamp G Gentamicin impregnated sponge for the treatment of early total joint infections
62778286|NCT05113914|EXPERIMENTAL|Healthy, physically fit men|All participants underwent a single CPET test with pre- and post-exercise blood measurements.
62778287|NCT05540782||Survivors of Prostate Cancer|This is a cross-sectional study with a one-time data collection process and no subsequent follow-ups. If patients did not opt out of receiving study-specific text communications, they may also receive text messages with reminders about surveys and/or direct links to REDCap to complete the surveys. Text-based communications will be delivered using the secure, HIPAA-compliant Mosio texting platform developed for clinical research.
62778288|NCT03809819||Patients with MRKHS|Thirteen patients with MRKHS who underwent laparoscopic Vecchietti vaginoplasty
61977836|NCT04505774|OTHER|Therapeutic Dose Anticoagulation|"increased dose of heparin above standard of care.~1.0 - This arm was stopped in severe patients in December 2020 and results are published in PMID: 34351722 (NEJM, August, 2021) (see reference section for citation). This arm was stopped for moderate patients in January 2021."
61977837|NCT04505774|OTHER|Prophylactic Dose Anticoagulation|"Heparin standard of care~1.0 - this arm was stopped for all patients in January, 2021 and results are published in PMID: 34351721 (NEJM, August, 2021) (see reference section for citation)"
62188106|NCT04157933|EXPERIMENTAL|A-3a|Part A, Arm 3 (active), Dose 3 (009-A3)
62188107|NCT04157933|PLACEBO_COMPARATOR|A-0p|Part A, placebo comparator in all 3 arms, placebo dose (009-A0)
62188108|NCT04157933|EXPERIMENTAL|B-1 (009-B3 -> 009-B0)|Crossover (active to placebo)
62188109|NCT04157933|EXPERIMENTAL|B-1 (009-B0 -> 009-B3)|Crossover (placebo to active)
62188110|NCT04107597|EXPERIMENTAL|Core stabilization exercises|Patients with CLBP who practice core stabilization exercises
62188111|NCT04107597|EXPERIMENTAL|Core stabilization exercises and paced breathing training|Patients with CLBP who practice core stabilization exercises combined with paced breathing training
62778289|NCT03809819||Control group|A control group of 13 age-matched, childless, sexually active women
62778290|NCT02913716|EXPERIMENTAL|Defactinib treatment|Single dose of 400 mg \[14C\]-defactinib, oral suspension
62778291|NCT05257902|ACTIVE_COMPARATOR|Treatment group|Participants in the treatment group will take the choline alfoscerate as adjunctive therapy with their own antidepressants.
62778292|NCT05257902|PLACEBO_COMPARATOR|Control Group|Participants in the control group will take the placebo, which would not affect their medical condition, for the adjunctive therapy is the choice of agreement between clinician and participants. If there is the necessity of change in antidepressant or of adjustment of their dosage, investigator can stop the clinical trial and proceed to another treatment.
62778293|NCT04484207|EXPERIMENTAL|Video-based intervention|A brief video about coping with COVID-19 stress presented to the participants
62778294|NCT04484207|EXPERIMENTAL|vignette intervention|A brief vignette about coping with COVID-19 stress presented to the participants
62778295|NCT04484207|NO_INTERVENTION|Control|Only assessment, no intervention arrm
62778296|NCT02169765|ACTIVE_COMPARATOR|Hepatic resection|Indications for HR were the presence of appropriate residual liver volume determined by volumetric computed tomography and lack of hepatic encephalopathy.
62002832|NCT03231306|EXPERIMENTAL|Open label study of Binimetinib (MEK162)|"Subjects (≥ 18 years) (Stratum A) will receive a course of binimetinib by mouth twice a day (12 hours apart) of 45 mg/dose. Duration of each course is 4 weeks. After 8 courses, subjects will receive additional courses if MRI results showed at least 15% reduction in volume of the target tumor. Subjects can continue on therapy and will be evaluated at the end of 12 courses. Subjects who have ≥ 20% reduction in volume of the target tumor according to the MRI results can continue therapy up to an additional year (maximum of 24 total courses). Subjects who have not met the tumor reduction at the specified times will be removed from the study therapy. Subjects will be carefully monitored for toxicities associated with binimetinib.~Recruitment of subjects 1 - 17 years of age (Stratum B) is currently available. The pediatric maximum tolerated dose (MTD) of binimetinib the pediatric patients (Statum B) was established by a phase 1 study (NCT022)."
62002833|NCT06074107|EXPERIMENTAL|BEBT-908 for injection|BEBT-908 for injection, dosage form: injection, specification: 25mg, administration method: the initial dose was 22.5mg/m2, intravenous drip, 3 times a week, 21 days as a cycle, 6 cycles as the total treatment cycle.
62188112|NCT04107597|EXPERIMENTAL|Myofascial trigger point release|Patients with CLBP who receive myofascial trigger point release therapy
62188113|NCT04107597|EXPERIMENTAL|Myofascial trigger point release and paced breathing training|Patients with CLBP who receive myofascial trigger point release therapy combined with paced breathing training
61977838|NCT04505774|OTHER|Therapeutic Dose Anticoagulation + P2Y12 inhibitor|"increased dose of heparin above standard of care with an added P2Y12 inhibitor~This Arm enrolled moderate illness patients only. Enrollment of moderate illness patients in the trial was ended per DSMB on June 19, 2021 and results are published in PMID: PMID: 35040887 (JAMA, January, 2022) (see reference section for citation)"
61977839|NCT04505774|OTHER|Prophylactic Dose Anticoagulation + P2Y12 inhibitor|"Heparin standard of care with an added P2Y12 inhibitor~This Arm enrolled severe illness patients only. Enrollment of severe illness patients in the trial was ended per DSMB in June 2022."
62778297|NCT02169765|EXPERIMENTAL|Radiofrequency ablation|Radiofrequency ablation is performed in less than one week after clinical diagnosis.
62778298|NCT00913926||Group 1|
62188114|NCT00927901|EXPERIMENTAL|Indacaterol (ind) maleate-placebo-ind xinafoate-ind acetate|In treatment period 1, patients received indacaterol maleate 400 μg; in treatment period 2, patients received placebo to indacaterol; in treatment period 3, patients received indacaterol xinafoate 400 μg; and in treatment period 4, patients received indacaterol acetate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62188115|NCT00927901|EXPERIMENTAL|Indacaterol (ind) xinafoate-ind maleate-ind acetate-placebo|In treatment period 1, patients received indacaterol xinafoate 400 μg; in treatment period 2, patients received indacaterol maleate 400 μg; in treatment period 3, patients received indacaterol acetate 400 μg; and in treatment period 4, patients received placebo to indacaterol 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62571344|NCT05406479|EXPERIMENTAL|BE-PEP (Bedaquiline Post-Exposure Prophylaxis)|Eligible participants will receive one dose of Bedaquiline plus Rifampicin
62778299|NCT01705106|EXPERIMENTAL|Treatment (capecitabine, celecoxib)|Patients receive celecoxib PO BID for 7 days (course 0) and then on days 1-21 of course 1 and all subsequent courses. Patients also receive capecitabine PO BID on days 1-14 beginning in course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62778300|NCT04062825||VIH positive patients without lymphoma|200 VIH positive patients without lymphoma
62778301|NCT04062825||VIH positive patients with lymphoma|20 VIH positive patients with lymphoma
62778302|NCT04062825||healthy volunteers|20 healthy volunteers
62778303|NCT04369157||Elective surgery group|Patients undergoing hip/knee replacements or colorectal surgery will be recruited and tested on 3 occasions: pre-op, post-op and at follow-up. POCD status will be determined at post-op and follow up. Cognitive function, zinc status, POCD biomarkers and inflammatory markers will be measured on all 3 occasions.
62778304|NCT06024018|EXPERIMENTAL|first group|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months. Also they will undergo high intensity electromagnetic technique (40 minutes for every session) on abdomen of males which will be 3 sessions per week for 3 months
62778305|NCT06024018|ACTIVE_COMPARATOR|second group|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months.
62778306|NCT00395421|EXPERIMENTAL|A|NM283(200 mg QD)plus Peg-IFNα-2a (180 µg QW)
62778307|NCT03311347|EXPERIMENTAL|100%O2 breathing|Primary aim, item 1
62778308|NCT03311347|EXPERIMENTAL|Air breathing|Primary aim, item 1
62002834|NCT00298831|EXPERIMENTAL|Sugammadex|Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was administered. At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg MK-8616 was administered.
62002835|NCT00745914|EXPERIMENTAL|1|Pioglitazone drug 15mg daily for 3 months then 30mg for 9 months (Peroxisome Proliferator-Activated Receptor-gamma agonist)
62778309|NCT01985568|ACTIVE_COMPARATOR|Standard Behavioral Therapy (Standard BT)|Standard BT: This group will follow a traditional model of initiating exercise concurrently with a dietary intervention for weight loss within an 18 month behavioral weight loss program.
62778310|NCT01985568|EXPERIMENTAL|Sequential Behavioral Therapy (Sequential BT)|Sequential BT: This group will receive diet and exercise interventions delivered sequentially within an 18 month behavioral weight loss program.
62778311|NCT05899972|EXPERIMENTAL|Experimental: Experimental group|The protocol is initiated by the suboccipital inhibition technique, with an average duration of three minutes. Afterwards, the frontal lift and parietal lift techniques were performed, which lasted an average of five minutes, being two and a half minutes for each one. Finally, the IV ventricle technique was performed, with an average duration of three minutes.
62778312|NCT05899972|PLACEBO_COMPARATOR|Control group|For the control group the placebo technique will be applied for 6 minutes.
62188116|NCT00927901|EXPERIMENTAL|Indacaterol (ind) acetate-ind xinafoate-placebo-ind maleate|In treatment period 1, patients received indacaterol acetate 400 μg; in treatment period 2, patients received indacaterol xinafoate 400 μg; in treatment period 3, patients received placebo to indacaterol; and in treatment period 4, patients received indacaterol maleate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62396089|NCT05310227|EXPERIMENTAL|Treatment|Participants will receive a device and will be asked to treat headaches with it and report in the app the characteristics of the attacks at the beginning of the attack as well as at 2 hours after the treatment.
62396090|NCT03954418|EXPERIMENTAL|Intervention group|Participants will drink an artificially sweetened drink 2-4 hours before elective caesarean section.
62778313|NCT05111028|ACTIVE_COMPARATOR|Period 1|Each research subject will participate in two study periods that will crossover from one storage product to the other storage product (Cold Stored Platelets vs Room Temperature Platelets) based on the randomization assignment. In Period 1 subjects will undergo an apheresis platelet collection, aspirin dosing, transfusion of their autologous platelets, and followed by platelet response testing and safety assessments. This is repeated in Period 2 using the other storage product. CSP is the the experimental comparator and RTP is the active comparator.
62778314|NCT05111028|EXPERIMENTAL|Period 2|Each research subject will participate in two study periods that will crossover from one storage product to the other storage product (Cold Stored Platelets vs Room Temperature Platelets) based on the randomization assignment. In Period 1 subjects will undergo an apheresis platelet collection, aspirin dosing, transfusion of their autologous platelets, and followed by platelet response testing and safety assessments. This is repeated in Period 2 using the other storage product. CSP is the the experimental comparator and RTP is the active comparator.
62778315|NCT06365983|ACTIVE_COMPARATOR|Free Gingival Graft|
61977840|NCT04505774|OTHER|Standard of Care + Crizanlizumab|"Standard of care plus crizanlizumab infusion~This arm will enroll moderate and severe illness patients~This arm was ended for all patients per the DSMB in September 2022."
61977841|NCT04505774|OTHER|Standard of Care + SGLT2 inhibitor|"Standard of care plus SGLT2 inhibitor~This arm will enroll moderate and severe illness patients~This arm was ended in March 2023"
62396091|NCT03954418|NO_INTERVENTION|Control group|Participants in the control group will refrain from intake of artificial sweeteners.
62396092|NCT04190199||Type 2 diabetes mellitus (T2DM)|Subjects in this group are diagnosed with type 2 diabetes mellitus. They receive no intervention. Their nutritional status, metabolite profile, dietary pattern, and lifestyle practices will be assessed.
62396093|NCT04190199||Pre-diabetes (IFG or IGT)|Subjects in this group are diagnosed with pre-diabetes (impaired fasting glucose \[IFG\] or impaired glucose tolerance \[IGT\]). They receive no intervention. Their nutritional status, metabolite profile, dietary pattern, and lifestyle practices will be assessed.
62396094|NCT04190199||Non-type 2 diabetes mellitus (healthy)|Subjects in this group are not diagnosed with type 2 diabetes mellitus or pre-diabetes (healthy). They receive no intervention. Their nutritional status, metabolite profile, dietary pattern, and lifestyle practices will be assessed.
62396095|NCT01933269|EXPERIMENTAL|FACBC|
62396096|NCT06174428||Oral Squamous Cell Carcinoma (OSCC)|OSCC case cohort will consist of patients with Oral Squamous Cell Carcinoma (all stages, locations), recruited from either primary or secondary care.
62396097|NCT06174428||Oropharyngeal Squamous Cell Carcinoma (OPSCC)|OPSCC case cohort will consist of patients with Oral Squamous Cell Carcinoma (all stages, locations), recruited from either primary or secondary care.
62778316|NCT06365983|EXPERIMENTAL|Linear Incision|
62778317|NCT00595010|EXPERIMENTAL|Managing Child Behavior|Families with a high risk for or a history of child abuse and are enrolled in Comprehensive Home-Based Services and receive services as usual, which includes SafeCare, plus Managing Child Behavior module if they report significant behavior problems with their child between the ages of 2-12.
62778318|NCT01046214|EXPERIMENTAL|Budeprion XL™|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
62778319|NCT01046214|ACTIVE_COMPARATOR|Wellbutrin XL®|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
62778320|NCT06117124|ACTIVE_COMPARATOR|Quantitative ultrasound|Participants will undergo bone density measurement using two different modalities - quantitative ultrasound and digital x-ray radiogrammetry. Each method will be performed twice over a 12 month period, to assess changes in bone density over time.
62778321|NCT06117124|ACTIVE_COMPARATOR|Digital x-ray radiogrammetry.|Participants will undergo bone density measurement using two different modalities - quantitative ultrasound and digital x-ray radiogrammetry. Each method will be performed twice over a 12 month period, to assess changes in bone density over time.
62778322|NCT03394352|EXPERIMENTAL|Activity on Board|Blinded CGM data will be collected prior to the Experimental Admission to determine the insulin bolus that will be determined by the activity on board calculator. Subjects will wear a continuous glucose monitor during the study admission.
62778323|NCT03394352|PLACEBO_COMPARATOR|Usual Diabetes Care|Subjects will use their usual diabetes care, including basal rate, correction factor and carbohydrate-insulin ratio. Subjects will determine their own insulin usage during the Control Admission. Subjects will wear a continuous glucose monitor during the study admission.
62778324|NCT02340910|EXPERIMENTAL|Short duration|Short Duration WBV consists of 8 45-sec bouts of 50Hz WBV followed by a 1-minute seated rest
62778325|NCT02340910|EXPERIMENTAL|Long duration|Long Duration WBV consists of 16 bouts 45-sec of 50Hz WBV followed by a 1-minute seated rest
62778326|NCT04499222|EXPERIMENTAL|Portex|usage of PORTEX POLAR \[Smiths Medical International, Hythe, United Kingdom\] nasotracheal tube
62778327|NCT04499222|ACTIVE_COMPARATOR|Mallinckrodt|usage of Mallinckrodt TaperGuard \[Covidien, Ireland\] nasotracheal tube
62778328|NCT06582134|SHAM_COMPARATOR|Control|Three 10-minute audio recordings (1, 2, 3) in MPEG-1 Audio Layer 3 (MP3) format consisting of relaxing music that mimic BMBI in duration but do not contain instructions specific to mindfulness training.
62778329|NCT06582134|EXPERIMENTAL|Brief Mindfulness-Based Intervention|Three 10-minute audio recordings (A,B,C) for BMBI in MPEG-1 Audio Layer 3 (MP3) format that contain mindfulness training based on the breathing concept in a background of relaxing music.
62778330|NCT00830492|ACTIVE_COMPARATOR|2|In group A (n=100), the patients were stimulated conventional. They desensitized with buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (\<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg and ovarian stimulation would commence with 150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
62778331|NCT00830492|EXPERIMENTAL|clomiphen/gonadotropin/GnRH antagonist|Patients in group B ( n=100 ) were stimulated clomiphene citrate ( ) 100 mg from cycle day three through seven and continuous gonadotropin stimulation with of r_FSH 75 IU daily from cycle day 5. Ultrasound in two group was performed on 8 cycle day. In group B 0.25 mg GnRH antagonist (Ganirelix , Organon ,Netherland ) daily was started with dominant follicle ≥14mm and in this day 75 IU human menopoasl gonadotropin (HMG) (Menogon, ferring, pharmacenticals , Germany ) increased to the initial gonadotropin . LH assessment on the day of starting antagonist was performed and if LH was \>15 IU/L , cycle was cancelled. Human chorionic gonadotropin 10000 IU ((pregnyl, Organon, Oss, the Netherlands ) was given when 1 to 3 follicles reached 18 mm
62778332|NCT05663957||EVUSHELD arm|Individuals given EVUSHELD for prophylaxis
62778333|NCT05663957||Concurrent Control arm|Individuals eligible for Evusheld prophylaxis but did not receive EVUSHELD
62778334|NCT02362074||Adalimumab subjects|Subjects starting Adalimumab treatment at time of enrollment.
62778335|NCT02457949|NO_INTERVENTION|Treatment As Usual (TAU)|Receipt of social assistance on government cheque issue days for 6 income assistance cycles (approx 26 weeks).
62778336|NCT02457949|EXPERIMENTAL|Staggered Arm|Receipt of social assistance once monthly on a randomly assigned day that does not fall during the week of government cheque issue (Non-synchronized social assistance receipt), for 6 income assistance cycles (approx 26 weeks).
62778337|NCT02457949|EXPERIMENTAL|Staggered and Split Arm|Receipt of social assistance twice monthly on equally spaced randomly assigned days that do not fall during the week of government cheque issue (Non-synchronized social assistance receipt, cheque divided into two equal disbursements), for 6 income assistance cycles (approx 26 weeks).
61977842|NCT01085409||Tinnitus|Patients with tinnitus
62002836|NCT00745914|PLACEBO_COMPARATOR|2|placebo comparator drug 15mg daily for 3months, then 30mg for 9 months
62188117|NCT00927901|EXPERIMENTAL|Placebo-indacaterol (ind) acetate-ind maleate-ind xinafoate|In treatment period 1, patients received placebo to indacaterol; in treatment period 2, patients received indacaterol acetate 400 μg; in treatment period 3, patients received indacaterol maleate 400 μg; and in treatment period 4, patients received indacaterol xinafoate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62396098|NCT06174428||Cancer-free|Participants will be recruited following clinical adjudication with self-reported confirmation of no cancer and from primary and secondary care facilities.
62571345|NCT05406479|ACTIVE_COMPARATOR|SDR-PEP (Single-Dose Rifampicin Post-Exposure Prophylaxis)|Eligible participants will receive one dose of Rifampicin (WHO recommendation)
62396099|NCT04924608|EXPERIMENTAL|Arm A|Selumetinib
62396100|NCT04924608|PLACEBO_COMPARATOR|Arm B|Placebo
62396101|NCT05692726||Patients|Patients with non-hypervolemic hypotonic hyponatremia
62396102|NCT03284762||Treatment-naïve NVAF patients in Korea and Taiwan|Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions. NVAF: Non-valvular atrial fibrillation
62396103|NCT05289739|EXPERIMENTAL|Exercise group|Usual medical care + supervised exercise training during intensive medical treatment
62396104|NCT05289739|NO_INTERVENTION|Control group|Usual medical care
62396105|NCT05806450|EXPERIMENTAL|Intervention condition|Structured online intervention consists of three weekly sessions of cognitive therapy and psychoeducation about child sleep
62571346|NCT06368336||Sepsis case|Nationwide registry of patients admitted to ICU treatment for or with sepsis, in Sweden, older than18 years of age.
62002837|NCT04770376||Cohort A: patients treated with chemotherapy (I-II line) associated to bevacizumab|Quantification of biomarkers will be performed on 100 patients treated with bevacizumab through the collection of the following samples at different timepoints: 1 serum sample; 2 CTAD plasma samples; 2 K2EDTA plasma samples. The samples will be collected as follows: before the start of chemotherapy; 3 weeks after start of chemotherapy, before start of treatment with bevacizumab; 9 weeks after start of chemotherapy; 15 weeks after start of chemotherapy; 52 weeks after start of chemotherapy; at progression of disease.
62002838|NCT04770376||Cohort B: patients treated with chemotherapy (I-II line, not associated to antiangiogenic drugs)|Quantification of biomarkers will be performed on 50 patients treated with chemotherapy through the collection of the following samples at different timepoints: 1 serum sample; 2 CTAD plasma samples; 2 K2EDTA plasma samples. The samples will be collected as follows: before the start of chemotherapy; 3 weeks after start of chemotherapy, before start of treatment with bevacizumab; 9 weeks after start of chemotherapy; 15 weeks after start of chemotherapy; 52 weeks after start of chemotherapy; at progression of disease.
62002839|NCT06484153|EXPERIMENTAL|Treatment|"Pembrolizumab intravenous (IV) 200mg flat dose day 1 then every 3 weeks. Fruquintinib orally (PO) 3mg po qd.~Pirfenidone (Esbriet) orally (PO) with food according to this schedule:~two dose groups: 200mg, TID, po;500mg, TID ,po. Using 3-3 design, the observation period of DLT was 28 days."
62002840|NCT05963542|EXPERIMENTAL|ACT + sound therapy group|"The combined treatment group will receive Internet-delivered guided self-help tinnitus treatment based on ACT combined with customized sound therapy.~The online ACT program includes 8 modules of structured self-help material over 8 weeks. Each module includes information, exercises, and homework. The self-help material covers the six core processes of ACT: acceptance, cognitive defusion, being present, self-as-context, values, and committed action, emphasizing psychological flexibility.~Customized sound therapy will be provided by the Fudan Tinnitus Relieving System (FTRS) app. Participants will listen to tailor-made music through the app for more than two hours per day."
62002841|NCT05963542|ACTIVE_COMPARATOR|sound therapy group|The single treatment group will receive customized sound therapy provided by the FTRS app for more than two hours per day.
62002842|NCT01563575|EXPERIMENTAL|Intervention Group|fast-track implementation process
62002843|NCT01563575|NO_INTERVENTION|Control Group|Continue usual routine
62002844|NCT03613896|PLACEBO_COMPARATOR|conventional dentures|a complete denture made through conventional processing technique
62002845|NCT03613896|ACTIVE_COMPARATOR|3D printed dentures|a complete denture made through 3d printing
62188118|NCT03457974|EXPERIMENTAL|congenital heart disease|42 patients
62188119|NCT03457974|OTHER|helathy children|42 children
62396106|NCT05806450|ACTIVE_COMPARATOR|Active control condition|Psychoeducation about basic sleep structure and sleep hygiene
62396107|NCT05007366|ACTIVE_COMPARATOR|Real-time gait biofeedback (RTGBF)|The RTGBF regimen delivers biofeedback that cues a personalized target to normalize vertical ground reaction force (vGRF) of each limb.
62571347|NCT06368336||Control|Age and gender matched population controls.
62571348|NCT01278004|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62571349|NCT01278004|EXPERIMENTAL|Drug|
62002846|NCT01631474|EXPERIMENTAL|Low-dose active, BID|low dose of CB-03-01, 0.1% applied twice a day
62002847|NCT01631474|EXPERIMENTAL|Medium-dose active, BID|medium dose of CB-03-01, 0.5% applied twice a day
62002848|NCT01631474|EXPERIMENTAL|High-dose active, QD|high dose of CB-03-01, 1% applied once a day
62188120|NCT03596398||Young stroke|Patients with acute stroke aged 20 or over, and under 56 years old (Not included 56) .
62188121|NCT04483518||HBV patients|HBV patients with HBsAg positive and/or HBV DNA positive
62571350|NCT04203342|EXPERIMENTAL|Ketoconazole 2% cream (Douglas Pharmaceuticals America Ltd.)|Subject will be randomized to either test product/active comparator/placebo comparator. Test product is Ketoconazole 2% cream manufactured by Douglas Pharmaceuticals America Ltd.
62571351|NCT04203342|ACTIVE_COMPARATOR|Ketoconazole 2% cream (Teva Pharmaceuticals USA)|Subject will be randomized to either test product/active comparator/placebo comparator. Active comparator is Ketaconazole 2% cream manufactured by Teva Pharmaceuticals USA.
62396108|NCT05007366|SHAM_COMPARATOR|Sham real-time gait biofeedback (Sham RTGBF)|The Sham RTGBF regimen will receive biofeedback that cues their habitual step length determined during the accommodation period on the first session of treadmill walking.
62778338|NCT02825199|EXPERIMENTAL|Caffeine group|All participants underwent otoscopy and tympanometry, responded to the Profile of Mood State (POMS), submitted to the cVEMP, oVEMP and caloric tests in that order. After that they received caffeine capsule (300mg). After 45 minutes they again responded to the POMS, repeated the cVEMP, oVEMP and caloric test.
62002849|NCT01631474|EXPERIMENTAL|High-dose active, BID|high dose of CB-03-01, 1% applied twice a day
62396109|NCT05348785|EXPERIMENTAL|BIIB122 225 mg|"Participants will receive BIIB122, 225 mg tablets, by mouth, once daily (QD) for up to a minimum of 48 weeks and a maximum of 144 weeks.~Participants who received BIIB122 and completed the ET visit of study 283PD302 (NCT05418673) will continue to receive BIIB122, 225 mg tablets, by mouth, QD for up to a minimum of 48 weeks and a maximum of 144 weeks."
62396110|NCT05348785|PLACEBO_COMPARATOR|BIIB122 Matching Placebo|"Participants will receive BIIB122 matching placebo tablets, by mouth, QD for up to a minimum of 48 weeks and a maximum of 144 weeks.~Participants who received placebo and completed the ET visit of study 283PD302 (NCT05418673) will continue to receive BIIB122 matching placebo tablets, by mouth, QD for up to a minimum of 48 weeks and a maximum of 144 weeks."
62778339|NCT02825199|PLACEBO_COMPARATOR|Non caffeine group|All participants underwent otoscopy and tympanometry, responded to the Profile of Mood State (POMS), submitted to the cVEMP, oVEMP and caloric tests in that order. After that they received placebo capsule (maize starch). After 45 minutes they again responded to the POMS, repeated the cVEMP, oVEMP and caloric test.
62002850|NCT01631474|PLACEBO_COMPARATOR|Vehicle, QD or BID|vehicle cream, applied once or twice a day
62002851|NCT01340976|EXPERIMENTAL|LY2787106 Dose Escalation|Part A: Dose escalation starting at 0.3 milligram/kilogram (mg/kg), intravenously (IV), day one of up to three 21-day cycles.
62002852|NCT01340976|EXPERIMENTAL|10 mg/kg LY2787106|Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator.
62571352|NCT04203342|PLACEBO_COMPARATOR|Placebo (Douglas Pharmaceuticals America Ltd.)|Subject will be randomized to either test product/active comparator/placebo comparator. Placebo comparator is manufactured by Douglas Pharmaceuticals America Ltd.
62188122|NCT06131775|OTHER|Immunotherapy|"Patients with locally advanced/metastatic disease who are due to receive as a first attempt an immune checkpoint inhibitors immunotherapy-based treatment.~Blood sample collection : One blood draw of 10 mL will be realized before the initiation of immunotherapy. Any adverse event related to the blood draw will be recorded. A follow-up will be performed at 6 months to record the immune-related adverse events, a statement of the disease and any other cancer treatments received. A 24 months long term follow up will be performed to record patient vital status and any date of disease progression."
62188123|NCT06131775|OTHER|Curative surgery|"Patients newly diagnosed and naive of any anticancer treatment who are due to receive a curative surgery of their primitive tumor.~Blood samples collection : Three blood draws of 10 mL will be realized : one before the surgery, one after 3 months and one after 6 months. Any adverse event related to the blood draw will be recorded. A follow-up will be performed at 6 months to record the statement of the disease and any other cancer treatments received. A 24 months long term follow up will be performed to record patient vital status and any date of disease relapse."
62188124|NCT00672282|PLACEBO_COMPARATOR|A|
62188125|NCT00672282|ACTIVE_COMPARATOR|B|
62188126|NCT04546802|ACTIVE_COMPARATOR|Immediate treatment|This group will undergo immediate treatment of the HCV once HCC complete response (CR) has been confirmed
62188127|NCT04546802|ACTIVE_COMPARATOR|Delayed treatment|This group will delay commencement of the HCV treatment until 6 months after HCC complete response (CR) has been confirmed
62002853|NCT01340976|EXPERIMENTAL|10 mg/kg LY2787106+Iron|Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles with daily oral iron supplementation. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator.
62188128|NCT02577588|EXPERIMENTAL|re-activated T cells|Ten patients with CRC stage UICC IV under routine first line FOLFOX 6/Bevacizumab therapy are planned to receive a singular treatment with an autologous T cell product at a dose of 5x10\^7 (first three or six patients) or 5x10\^8 (last four or seven patients) cells.
62571353|NCT02734537|EXPERIMENTAL|Arm A (IMRT)|Patients undergo IMRT QD 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
62571354|NCT02734537|EXPERIMENTAL|Arm B (IMRT, cisplatin)|Patients undergo IMRT QD 5 days a week and receive cisplatin IV over 1-2 hours weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
62002854|NCT03341130|EXPERIMENTAL|Treatment Group|The treatment group will will be treated a mandibular advancement oral appliance following standard practices. The treatment group will also receive a mandibular repositioning splint to wear in the mornings for a minimum of 1 hour following removal of their mandibular advancement oral appliance, in an effort to reduce the side effects resulting from use of the mandibular advancement oral appliance.
62188129|NCT00020722|EXPERIMENTAL|therapeutic autologous lymphocytes|
62188130|NCT04434118||Rheumatoid Arthritis with COVID-19|
62188131|NCT04434118||Rheumatoid Arthritis without COVID-19|
62188132|NCT04632043|ACTIVE_COMPARATOR|Early intubation|Patients with COVID-19 suffering from severe acute hypoxemic respiratory failure (defined as the need for non-rebreather mask or high flow nasal oxygen with setting FiO2 of at least 90% or non-invasive mechanical ventilation to maintain a SpO2 \>92%) for at least 48 hours will undergo intubation.
62571355|NCT00651261|EXPERIMENTAL|Induction and consolidation chemotherapy plus midostaurin|Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and the experimental drug midostaurin. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with the experimental drug midostaurin. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with midostaurin for twelve (12) months.
62002855|NCT03341130|EXPERIMENTAL|Positive Control Group|The positive control group will will be treated a mandibular advancement oral appliance following standard practices. The positive control group will not receive any additional oral appliances. Side effects resulting from use of the mandibular advancement oral appliance will be managed using standard practices, including jaw stretching exercises as needed for comfort.
62002856|NCT03341130|NO_INTERVENTION|Negative Control Group|The negative control group is comprised of 15 healthy individuals recruited specifically from faculty members at the UBC Faculty of Dentistry. This group will undergo the same clinical data collection as the treatment group and the negative control group but will not receive any treatment.
62002857|NCT00222469|EXPERIMENTAL|1|3-agent treatment group
62002858|NCT06104267|EXPERIMENTAL|Medical Tai Chi Exercise Group|
62188133|NCT04632043|ACTIVE_COMPARATOR|Delayed intubation|Patients with COVID-19 suffering from severe acute hypoxemic respiratory failure (defined as the need for non-rebreather mask or high flow nasal oxygen with setting FiO2 of at least 90% or non-invasive mechanical ventilation to maintain a SpO2 \>92%) for at least 48 hours will continue to receive non-rebreather mask, high-flow nasal oxygen or non-invasive mechanical ventilation in an attempt to avoid intubation.
62214659|NCT02299180|EXPERIMENTAL|Intervention (ACP) arm|The patient and his/her family members will be referred to an ACP facilitator and will undergo ACP as an ongoing process, integrated with patient's care, from the facilitator, in coordination with a coordinator/nurse, and treating physician. The ACP facilitator will be certified in providing ACP and will possess sufficient knowledge of the risks, benefits, and harms of treatments and procedures available to the patient. The ACP facilitator will be supported by the physician with the specialized knowledge of treatment options, especially with regards to prognosis. Family members will be encouraged to be present during the ACP discussion so that the whole family unit will be able to explore goals, values and beliefs towards the patient's medical care.
62571356|NCT00651261|ACTIVE_COMPARATOR|Induction and consolidation chemotherapy plus placebo|Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and placebo. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with placebo. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with placebo for twelve (12) months.
62571357|NCT03309943|EXPERIMENTAL|Propranolol|Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions
62571358|NCT03309943|PLACEBO_COMPARATOR|Placebo|Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions
62188134|NCT05531071|ACTIVE_COMPARATOR|Biofeedback electrical stimulation|Use the PHENIX USB4 Pelvic Floor Rehabilitation Therapy Apparatus to enter the Stress Urinary Incontinence Treatment Module. The frequency of electrical stimulation was 50Hz, the pulse width was 250μs, and the current intensity increased from 0mA, generally not exceeding 50mA. For the 1st to 3rd treatments, intermittent bioelectrical stimulation mode was given.For the 4th to 10th treatments, the biofeedback mode with intermittent bioelectrical stimulation was given, and for the 11th to 15th treatments, the simple biofeedback mode was given. 3 times a week, 30 minutes each time, a total of 15 treatments. Instruct the patient to go home to perform pelvic floor muscle training, focusing on anal contractions. Each anal contraction takes 3-5s and relaxes for 5-10s. so repeatedly. 20 minutes each time, 3 times a day in the morning, noon and evening, 5 days a week, until the end of the treatment.
62188135|NCT05531071|ACTIVE_COMPARATOR|Acupuncture|A single-use sterile needle of Changchun Aikang brand was selected, with a size of 0.30 mm × 40 mm. Ding points: Guanyuan point, Qihai point, Zhongji point, Zusanli point, Sanyinjiao point, Yinlingquan point. Routine disinfection of the patient's skin is performed, and Guanyuan, Qihai, and Zhongji points are punctured obliquely downward, and the needle is inserted 1-1.2 cun; evenly lift, insert and twist to get qi. At the same time, the moxa column was ignited and placed in the moxibustion box, and the moxibustion box was placed above the three points of Guanyuan, Qihai, and Zhongji in the patient's abdomen, and the moxibustion was performed until the skin was red and the deep tissue was heated. 1 time a day, every Monday to Friday, 30 minutes each time, 10 times as a course of treatment. The patients were instructed to go home for pelvic floor muscle training, and the method was the same as that of group Biofeedback electrical stimulation.
62188136|NCT05531071|EXPERIMENTAL|Acupuncture combined with biofeedback electrical stimulation|Biofeedback electrical stimulation therapy combined with acupuncture and moxibustion were given to the patients. After 10 sessions of acupuncture, continue the unfinished biofeedback electrical stimulation treatment. The patients were instructed to go home for pelvic floor muscle training, and the method was the same as that of group Biofeedback electrical stimulation.
62188137|NCT04467645|EXPERIMENTAL|Reflexology|Reflexology Application: A total of twelve 30-minute reflexology sessions (2 per week)were administered to each patient.
62188138|NCT04467645|NO_INTERVENTION|No intervention|No intervention was applied to the postmenopausal women in the control group.
62188139|NCT01659671|ACTIVE_COMPARATOR|Uvulopalatopharyngoplasty|One arm is Uvulopalatopharyngoplasty(intervention group of 32 patients), one arm is expectancy (control group of 33 patients). After six months the controls have delayed surgery and then both groups are followed for two years
62188140|NCT01659671|ACTIVE_COMPARATOR|Control|After six months the controls have delayed surgery then are followed for 2 year
62188141|NCT00631345|EXPERIMENTAL|Lifestyle|This Group-Based Lifestyle Intervention (Phases 1 and 2) will be led by lay health counselors (LHCs). The 6-month Phase 1 includes weekly meetings on nutrition and physical activity, psychosocial factors related to health behaviors, and question and answer periods. The 18-month Phase 2 will consist of monthly group meetings and individual telephone contacts. Intervention participants who choose to participate in the study continuation (Phase 3) will be further randomized to receive either extended group or self-directed maintenance. Those who are randomized to receive Extended Group Maintenance (Phase 3) will continue attending monthly meetings; those who receive Self-Directed Maintenance (Phase 3) will no longer attend groups.
62188142|NCT00631345|OTHER|Comparison|The comparison condition exceeds the usual care provided to similar community members and is an individual education program that builds on an increased awareness of existing community resources. In the initial trial, these subjects will receive two individual sessions with the RD and a monthly newsletter. In the study continuation, comparison participants will receive biannual nutrition counseling and a monthly newsletter.
62188143|NCT05423483|EXPERIMENTAL|Text Message Intervention|Parents in the intervention arm will receive text message reminders to restrict lethal means for 6 months.
62188144|NCT05423483|NO_INTERVENTION|Treatment as Usual|Parents in the treatment as usual group will not receive the text message intervention.
62188145|NCT02113410|EXPERIMENTAL|Sit 'N' Fit Chair Yoga (SNFCY)|Willing and eligible subjects randomized to Sit 'N' Fit Chair Yoga attended twice-weekly 45-minute yoga sessions for 8 weeks, for a total of 16 sessions.
62571359|NCT06104254|NO_INTERVENTION|control group|The patient who assign to control group, they will give standard ward care before surgery and we measure their pain beliefs and pain level. After operation we will asses their pain beliefs and pain level. the last measure will be carried out after 30 days operation.
62571360|NCT06104254|EXPERIMENTAL|experimental group|The patient who assign to experimental group, we will measure their pain beliefs and pain level before surgery. After that a researcher will give an education before operation to these patients about pain, potential pain and pain management after surgery. we will asses these patients pain beliefs and pain level after surgery and 30 days later again.
62571361|NCT06253000|ACTIVE_COMPARATOR|Cryoablation|Cryoablation of the mouths of the pulmonary veins and the posterior wall of the left atrium.
62571362|NCT06253000|ACTIVE_COMPARATOR|Radiofrequency ablation|"Radiofrequency ablation of pulmonary veins according to the box isolation type using a non-fluoroscopic navigation system."
62571363|NCT04538833|EXPERIMENTAL|monosialic ganglioside|On the days -1, 1, and 2 of albumin-bound paclitaxel application, 80 mg of monosialic ganglioside were applied (monosialic ganglioside was a single infusion)
62571364|NCT04538833|PLACEBO_COMPARATOR|Placebo|The control group received placebo on days -1, 1, and 2 of albumin-bound paclitaxel application, (placebo as a single infusion)
62002859|NCT00481728|EXPERIMENTAL|Tolterodine|
62188146|NCT02113410|ACTIVE_COMPARATOR|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) will attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
62002860|NCT05287191|EXPERIMENTAL|Experimental arm|Intravenous magnesium sulphate as first line followed by digoxin IV loading as second line and then amiodarone IV as third line treatments for fast Atrial Fibrillation
62002861|NCT05287191|ACTIVE_COMPARATOR|Standard of care arm|Intravenous amiodarone as compactor group intervention
62002862|NCT01437553|OTHER|IVUS|Patients undergoing catheterization due to acute coronary syndrome will have IVUS done with grayscale and iMAP analysis performed.
62188147|NCT04777825|EXPERIMENTAL|HRV biofeedback training|During the inclusion visit, all patients will benefit from a psychoeducation session supervised by the psychologist. This group of patients will also benefit from the HRV biofeedback training.
62188148|NCT04777825|OTHER|control|During the inclusion visit, all patients will benefit from a psychoeducation session supervised by the psychologist.
62188149|NCT01792388|PLACEBO_COMPARATOR|Soya Bean oil|
62188150|NCT01792388|ACTIVE_COMPARATOR|Vitamin D|
62188151|NCT00777634||Binge eating disorder (BED)|Individuals who meet criteria for binge eating disorder.
62188152|NCT00777634||Without BED|Individuals who do not meet criteria for binge eating disorder.
62188153|NCT01636622|EXPERIMENTAL|Vemurafenib + Carboplatin + Paclitaxel|"All 3 study drugs will start on day 1 of cycle 1. Cycle defined as 3 weeks. On day 1, paclitaxel and carboplatin will be administered first, and the vemurafenib administration will start in the evening that day.~Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.~Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.~Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle."
62188154|NCT01585298|EXPERIMENTAL|Fingolimod|Fingolimod 0.5 mg by mouth once daily for 7 days.
62188155|NCT03499262|EXPERIMENTAL|Group Social ABcs|Participants receiving Group Social ABCs intervention
62188156|NCT02466243|EXPERIMENTAL|JBT-101|"Part A: JBT-101 20 mg capsule once a day on Days 1-28, then 20 mg capsule twice a day on Days 29-84.~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE."
62188157|NCT02466243|PLACEBO_COMPARATOR|Placebo|"Part A: Placebo capsule once a day on Days 1-28, then placebo capsule twice a day on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE."
62188158|NCT05125081|EXPERIMENTAL|LDP group|Liuwei Dihuang Pill (LDP）marketed product in China donated by pharmaceutical company.
62188159|NCT05125081|PLACEBO_COMPARATOR|placebo group|Same smell, color and shape as Liuwei Dihuang Pill (LDP）without herbs in capsules.
62188160|NCT06262178|EXPERIMENTAL|Parenting-STAIR|PSTAIR is a 23 session intervention which combines elements of two existing EBTs: Skills Training in Affective and Interpersonal Regulation (STAIR), targeting maternal trauma and emotion dysregulation, and dyadic Parent-Child Care (PC-CARE), targeting parenting. We propose to shorten PSTAIR into a 10-15 session modular intervention and individualize treatment using an adaptive decision rule and shared decision making (SDM).
62188161|NCT06262178|ACTIVE_COMPARATOR|Treatment As Usual|Participants in the comparison condition will be assigned to treatment as usual. All participating clinics offer Prolonged Exposure (PE) and Cognitive Processing Therapy (CPT), both trauma-focused EBTs. Though some differences have been noted, evidence suggests outcomes for PE and CPT are broadly equivalent. Participants in the comparison condition will receive PE or CPT, as determined by Cohen Veterans Network (CVN) clinics' standard treatment assignment procedures, and will participate in assessments on the same schedule as the treatment condition.
62778340|NCT04628988|EXPERIMENTAL|CC-90011 in combination with Abiraterone and Prednisone|Oral administration (PO) of CC-90011 monotherapy administered once per week (QW), for 4 weeks. From cycle 2 onwards, all participants will receive 60 mg of CC-90011 PO QW, in combination with 100 mg of abiraterone PO daily, and 5 mg of prednisone PO every 12 hours (10mg QD)
62002863|NCT01723228|EXPERIMENTAL|Rasagiline 1.0 mg/day|Rasagiline 1 mg oral tablets once daily for 24 weeks
62002864|NCT01723228|PLACEBO_COMPARATOR|Placebo|Placebo oral tablets once daily for 24 weeks
62002865|NCT04595487|EXPERIMENTAL|left ventricular septal pacing|Implantation of a pacemaker with the ventricular lead delivered transvenously through the interventricular septum (IVS) to the left ventricular (LV) septum.
62002866|NCT04595487|ACTIVE_COMPARATOR|right ventricular pacing|Implantation of a pacemaker with the ventricular lead placed in the RV.
62188162|NCT04457596|ACTIVE_COMPARATOR|Arm I (trastuzumab emtansine, placebo)|Patients receive T-DM1 IV over 30-90 minutes on day 1 and placebo PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
62188163|NCT04457596|EXPERIMENTAL|Arm II (trastuzumab emtansine, tucatinib)|Patients receive T-DM1 IV over 30-90 minutes on day 1 and tucatinib PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
62188164|NCT06289647|ACTIVE_COMPARATOR|Azithromycin Continuation|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. Oral azithromycin, 20 mg/kg for children and 1 g for adults, will be offered to all households identified on the preceding census in the communities randomized to continuing treatment. Study drug will be distributed by health extension workers and organized by PNSO. Individuals with a known macrolide allergy will be offered a two-week course of daily ophthalmic tetracycline ointment (two tubes).
62188165|NCT06289647|NO_INTERVENTION|Azithromycin Discontinuation|In study communities randomized to the Azithromycin Discontinuation arm, individuals will receive no treatment.
62571365|NCT02921724|EXPERIMENTAL|Cancer patients undergoing oral therapy|At the time of therapy prescription, patients candidate for oral therapy with capecitabine or sunitinib will be provided with informations on the side-effects of therapy and on the use and functions of the mobile diary app TreC-Onco. Patients are required to manually insert data into the mobile diary app at least once a day. Patients will be visited every 6 weeks. During the visit, the clinician will compare adherence and toxicity data entered into the mobile diary app with those directly reported by the patient and by drug accountability.
62571366|NCT05388279|EXPERIMENTAL|JS012|
62188166|NCT06487143|EXPERIMENTAL|3-month triptorelin|Triptorelin pamoate is administered via intramuscular injection once every three months
62188167|NCT06487143|ACTIVE_COMPARATOR|1-month triptorelin|Triptorelin acetate 3.75mg is administered via intramuscular injection once every four weeks.
62214660|NCT04285203|EXPERIMENTAL|Educational Video|Participants were exposed to 2 educational videos in addition to standard of care education.
62214661|NCT04285203|NO_INTERVENTION|Standard of Care|Participants received standard of care education.
62571367|NCT05388279|EXPERIMENTAL|JS012 combination with chemotherapy|
62778341|NCT06425432||CL first|Subject will present wearing habitual contact lenses for the aberrometry measurement. They will then remove their contact lenses and measurement repeated uncorrected.
62188168|NCT06416332|EXPERIMENTAL|in face to face live group|In the live therapeutic exercise group (group A) the program and its progression will be determined and performed for life according to the patient's progress, with a frequency of sessions twice a week, a session duration of 45 minutes, following the recommended dosage of exercise according to with the clinical instructions, while the total duration of the intervention will be eight weeks.
62188169|NCT06416332|EXPERIMENTAL|telerehabilitation program group|In the telerehabilitation program group (group B), the therapeutic exercise program will follow the same structure, with differences in the explanation of the exercises, their presentation, as well as the monitoring and information of the participants, as they will be done through a telerehabilitation platform and a special software data processing. The intervention time remains the same, with the physiotherapist in these 45 minutes of the session evaluating the data on the patient's progress by receiving the information through the software, and informing the patient of any changes in the progression of the exercise program. The remaining parameters of the intervention also remain the same, as in face to face live exercise.
62188170|NCT05364580|EXPERIMENTAL|PROTOXIN(Phase Ⅲ)|PROTOXIN will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL)
62188171|NCT05364580|ACTIVE_COMPARATOR|Botox® (Phase Ⅲ)|Botox® will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL).
62188172|NCT03548493|EXPERIMENTAL|Magnesium (M) group|Magnesium (M) group (n=17) , in which magnesium sulphate is given as adjuvant to propofol for sedation
62188173|NCT03548493|ACTIVE_COMPARATOR|Fentanyl (F) group|Fentanyl (F) group (n=17), in which fentanyl is given as adjuvant to propofol for sedation
62188174|NCT00664183|EXPERIMENTAL|1|
62188175|NCT00664183|EXPERIMENTAL|2|
62188176|NCT01151423|EXPERIMENTAL|Caplacizumab|Caplacizumab 10 mg once daily
62188177|NCT01151423|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62188178|NCT01932398||ADHD|A diagnosis of ADHD, classified by the DSM-IV.
62188179|NCT01932398||no ADHD|No diagnosis of ADHD, classified by the DSM-IV.
62188180|NCT02488083|EXPERIMENTAL|all subjects treated by UltraShape|all the patients undergo fat reduction treatment by UltraShape
62188181|NCT01466790|EXPERIMENTAL|Arm 1|30 patients will receive TMC435 (150 mg once a day) plus PSI-7977(GS7977) (400 mg once a day) with ribavirin (1000-1200 mg/day) for 24 weeks and followed by a 24-week follow-up phase.
62188182|NCT01466790|EXPERIMENTAL|Arm 2|15 patients wiil receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) for 24 weeks of and followed by a 24-week follow-up phase.
62188183|NCT01466790|EXPERIMENTAL|Arm 3|30 patients will receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) with ribavirin (1000-1200 mg/day) for 12 weeks and followed by a 36-week follow-up phase.
62188184|NCT01466790|EXPERIMENTAL|Arm 4|15 patients will receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) for 12 weeks and followed by a 36-week follow-up phase.
62188185|NCT04614571|OTHER|Gluten Challenge|
62396111|NCT06724237|ACTIVE_COMPARATOR|Arm I (observation)|Patients receive standard of care observation on study. Patients also undergo blood sample collection and optional bone marrow aspiration and biopsy on study, and CT or PET/CT throughout the study.
62571368|NCT06578832||Children with chronic kidney disease|It is a group of patients between the ages of 4 and 17 who have recently been diagnosed with jchronic kidney disease
62778342|NCT06425432||Glasses first|Subjects will refrain from contact lens wear on day of the visit. Initial aberrometry measurement will be performed uncorrected. They will be then asked to insert their contact lenses and aberrometry measurements repeated.
62778343|NCT04780464|ACTIVE_COMPARATOR|Standard doxorubicin|
62778344|NCT04780464|EXPERIMENTAL|Metronomic doxorubicin|
62778345|NCT04780464|EXPERIMENTAL|Metronomic oral cyclophosphamide + prednisolone or prednisone|
62778346|NCT01533142||surgical methods|Different methods are used among hospitals in Helse-Vest, and this allows us to compare different clinical and biological effects following bariatric surgery different methods) among a homogeneous population in the western part of Norway (Vestlandet
62002867|NCT06163066|EXPERIMENTAL|Web-based Group|The father's phone will be stolen and the father will record the researcher's phone number. After this stage, the researcher will apply a pre-test, make the father a member of the website and show the first video about basic newborn care to the father via his phone. The first access to the website will be made under the guidance of the researcher. For membership, individuals must have an internet connection and know how to use a phone. Even though the fathers made their first viewing before being discharged from the hospital, the web page will be open for 1 month and they will be able to watch the video they want whenever they want. Individuals who visit the page and agree to participate in the study will be given a posttest at the end of the 1st month and at the end of the 4th month.
62002868|NCT06163066|EXPERIMENTAL|Face-to-face Group|The father's phone will be stolen and the father will record the researcher's phone number. Then, before his wife is discharged from the hospital, the father will be interviewed and an appointment will be made to meet at the clinic at a convenient time. During this appointment, the researcher will apply a pre-test and explain information about basic newborn care (hygiene, safety and nutrition) face-to-face and in practice. In addition, brochures about baby care will be provided to fathers that they can use at any time. After this process, the final test will be applied at the end of the 1st month and at the end of the 4th month.
62002869|NCT06163066|NO_INTERVENTION|Control Group|The father's phone will be stolen and the father will record the researcher's phone number. After this stage, the researcher will perform a pre-test before the mother is discharged and will not have her perform any newborn care procedures. Fathers in the control group will continue to receive routine care. In Turkey, information about the basic care of the newborn is given only verbally by neonatal midwives and nurses before discharge. After these procedures, a final test will be applied to this group at the end of the 1st month and at the end of the 4th month.
62002870|NCT04237961|EXPERIMENTAL|Upper third interference|Botox \& brow lift
62002871|NCT04237961|EXPERIMENTAL|Middle third|Botox and fat injection
62188186|NCT00514800|EXPERIMENTAL|Intervention|"Patients will be given a home blood pressure monitor and taught how to use it and how to respond to the readings using a standardised protocol and blood pressure targets. The study nurse will follow up patients at home after a month with additional telephone support according to a defined protocol. Patients will consult their own GP for medication changes when above target.~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings."
62188187|NCT00514800|ACTIVE_COMPARATOR|Control|
62214662|NCT05833204|EXPERIMENTAL|Colporrhaphy with barbed absorbable suture|The colporrhaphy will be performed using a 0-caliber barbed absorbable suture (V-Loc ™, Covidien, Medtronic)
62214663|NCT05833204|ACTIVE_COMPARATOR|Colporrhaphy with standard absorbable suture|The colporrhaphy will be performed using a standard 0-caliber absorbable suture made of a coated braided thread (Vicryl; Ethicon Inc, Sommerville, NJ)
62571369|NCT06578832||Healthy patient group|Healthy children aged between 4 and 17 years, with no systemic diseases and not taking any regular medications.
62778347|NCT01533142||Morbid obesity|
62778348|NCT00241904|ACTIVE_COMPARATOR|Comprehensive Intervention Group|The NP/CHW intervention focused on behavioral interventions to affect therapeutic lifestyle changes and adherence to medications and appointments as well as the prescription and titration of medications for one year. The NP and CHW worked as a team. The NP oversaw the initial assessment and, in collaboration with the CHW, tailored the intervention plan, conducted the intervention including lifestyle modification counseling and medication titration and prescription, consulted with the physician, and supervised the CHW. Specific algorithms for drug treatment of hyperlipidemia, hypertension (HBP), hyperglycemia, ACE, and β-blocker therapy were developed for this study based on current guidelines and standards of care.
62778349|NCT00241904|ACTIVE_COMPARATOR|Less Intensive Intervention Group|Participants will receive usual care from their physicians and a Less Intensive (LI) intervention of feedback on cardiovascular disease (CVD) risk factors and guidelines to patients and their physicians. Patients and their providers in the received the results of baseline lipids, BP, and HbA1c along with the recommended goal levels and a pamphlet on controlling risk factors published by the American Heart Association. In addition, providers received copies of the AHA/ACC Guidelines for Secondary Prevention.
62778350|NCT06136130|EXPERIMENTAL|Positioning Material|"Preterm infants in Intervention group were placed in the nest with positioning material and placed in lateral and prone positions~The positioning material and hand-face maneuver were applied together to the preterm infants in the intervention group, and they were given lateral and prone positions in this way in the second day"
62778351|NCT06136130|NO_INTERVENTION|Standard Care|Standard care was used
62778352|NCT06192680|EXPERIMENTAL|liposomal irinotecan + capecitabine + bevacizumab|"liposomal irinotecan 70 mg/m², d1 + capecitabine 1000 mg/m² BID, d1\~10 + bevacizumab 5mg/kg, d1.~q2w"
62778353|NCT04575207|EXPERIMENTAL|caFFR-guided|Participants who are randomly assigned to caFFR-guided group will receive the detection of Coronary Angiography-Derived Fractional Flow Reserve (caFFR) Measurement System. The online caFFR value is used to guide the PCI strategy. If caFFR ≤ 0.80, PCI treatment will be performed in lesions and optimal medicine treatment will be performed when caFFR \> 0.80.
62778354|NCT04575207|ACTIVE_COMPARATOR|FFR-guided|Participants who are randomly assigned to FFR-guided group will receive the detection of pressure wire. The FFR value is used to guide the PCI strategy. If FFR ≤ 0.80, PCI treatment will be performed in lesions and optimal medicine treatment will be performed when FFR \> 0.80.
62778355|NCT01105377|EXPERIMENTAL|Treatment (entinostat, azacitidine)|Patients receive azacitidine subcutaneously on days 1-5 and 8-10 and oral entinostat on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62778356|NCT05861141|ACTIVE_COMPARATOR|Control Group|Patients will receive a selected physical therapy program only.
62778357|NCT05861141|EXPERIMENTAL|Study Group|Patients will receive the same selected physical therapy program as the control group in addition to aerobic exercise in the form of treadmill training.
62778358|NCT06051006||Patients|Minor patients from 8 years with cochlear implants for at least 1 year and followed at Hôpital Necker-Enfants malades.
62778359|NCT02933502|EXPERIMENTAL|DSXS topical product|treatment with DSXS once daily for 28 days
62002872|NCT04237961|EXPERIMENTAL|Lower third|Suspension suture
62778360|NCT03184285|EXPERIMENTAL|bariatric surgery|baseline alert 1; Anti-Trendelenburg-position (ATB); Anti-Trendelenburg-position (ATB) in narcosis; baseline in narcosis 1; passive leg raising; volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); baseline in narcosis 2; start capnoperitoneum; Anti-Trendelenburg-position (ATB) plus capnoperitoneum; ATB plus capnoperitoneum plus volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); ATB loss of capnoperitoneum; baseline in narcosis; baseline alert 2; torso position rising 30° at the beginning; torso position rising 30° at the end
62778361|NCT02321761|EXPERIMENTAL|study group|"Dosage (mg) Day days 0-14 no drug will be given days 15-21 dosage is 100 mg days 22-28 dosage is 200mg days 29-42 dosage is 400mg days 43-56 dosage is 200mg~days 57-70 no drug will be given"
62778362|NCT05215158|ACTIVE_COMPARATOR|Peribulbar dexmedetomidine|The peribulbar block will be done using a mixture of 4 ml Lidocaine 2%, 4 ml Bupivacaine 0.5%, and 2 ml normal saline containing 50 μg dexmedetomidine perineurally (30 patients).
62778363|NCT05215158|ACTIVE_COMPARATOR|Intravenous dexmedetomidine|The peribulbar block will be done using a mixture of 4 ml Lidocaine 2%, 4 ml Bupivacaine 0.5%, and 2 ml normal saline. Patients received 50 μg dexmedetomidine in 50 mL of normal saline administered as an infusion over 10 minutes, and given 10 minutes before the peribulbar block (30 patients).
62778364|NCT05901402|EXPERIMENTAL|The experimental group|The experimental group performed aerobic resistance exercise during pregnancy every day.
62778365|NCT05901402|NO_INTERVENTION|The control group|The control group was given traditional nursing.
62778366|NCT00930007||Hyperandrogenemic|Girls with elevated free testosterone concentrations
62778367|NCT00930007||Controls|Girls with normal free testosterone concentrations
62778368|NCT00597493|EXPERIMENTAL|Sorafenib + Temozolomide|"Subjects receive 400mg of Sorafenib twice daily and 50mg/m\^2 of Temozolomide once daily~Subjects continue to receive treatment until any of the following: progressive disease, unacceptable toxicity, non-compliance with study guidelines, withdrawal of patient consent, intercurrent non-cancer-related illness that prevents continuation of therapy or regular follow-up, general or specific changes in a subject's condition which render the patient unacceptable for treatment in the judgement of the investigator, or study closure"
62778369|NCT00486668|ACTIVE_COMPARATOR|Group 1: AC then paclitaxel + trastuzumab|AC followed by paclitaxel plus trastuzumab
62778370|NCT00486668|EXPERIMENTAL|Group 2: AC then paclitaxel + lapatinib|AC followed by paclitaxel plus lapatinib
62778371|NCT00486668|EXPERIMENTAL|Group 3: AC then paclitaxel + trastuzumab + lapatinib|AC followed by paclitaxel plus trastuzumab plus lapatinib
62778372|NCT01171391|EXPERIMENTAL|VA106483 1mg|
62002873|NCT00480636||One cohort of patients treated with dalteparin.|About 100 patients with deep-vein thrombosis and with or without pulmonary embolism will be included in the study.
62002874|NCT05441059||Patients treated with mepolizumab|Patients treated with mepolizumab
62002875|NCT04325529||remitted MDD|Unmedicated Remitted Participants with Past History of MDD
62778373|NCT01171391|EXPERIMENTAL|VA106483 2mg|
62778374|NCT01171391|EXPERIMENTAL|VA106483 4mg|
62778375|NCT01171391|PLACEBO_COMPARATOR|Sugar pill|
62002876|NCT04325529||Control subjects|healthy control subjects
62002877|NCT05395819|EXPERIMENTAL|Reverse Total Shoulder Arthroplasty (RTSA)|"Patient will undergo a RTSA as per standard technique. It uses a stemmed metal humeral component attached to the glenoid and the shallow glenoid component attached to the humerus. Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within \< 10 degrees of neutral glenoid version. Standard instruments including a spherical burr and power reamers will be used to achieve this."
62002878|NCT05395819|ACTIVE_COMPARATOR|Total Shoulder Arthroplasty (TSA)|Patients will undergo standard glenoid preparation and implantation of a TSA. It uses a stemmed metal humeral component to replace the arthritic head of humerus and a shallow polyethylene glenoid component to replace the arthritic glenoid surface. The degree of anterior- reaming will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
62002879|NCT00463060|EXPERIMENTAL|Treatment|Participants treated with chemotherapy and radiotherapy
62002880|NCT02110992|EXPERIMENTAL|Docetaxel + Stereotactic Radiation|Docetaxel 15mg/m2 IV weekly for 3 weeks. SBRT 25-40 Gy in 5 fractions given twice weekly with each treatment separated by \> 48 hours.
62778376|NCT04346849|EXPERIMENTAL|MTA pulpotomy|Teeth receiving pulpotomy using MTA
62778377|NCT04346849|EXPERIMENTAL|Biodentine pulpotomy|Teeth receiving pulpotomy using Biodentine
62778378|NCT04346849|EXPERIMENTAL|Bioceramic pulpotomy|Teeth receiving pulpotomy using Bioceramic
62778379|NCT02389439|EXPERIMENTAL|Pyronaridine-artesunate|"Pyronaridine-artesunate (Pyramax®, Shin Poong Pharmaceuticals). One tablet contains 60mg artesunate+ 180mg pyronaridine. Dosing will be according to body weight.~It will be taken orally with water, once daily for 3 days. Each dose will be administered under the supervision. A dose will be repeated in full if vomiting occurs within 30 minutes of administration of the first day of administration only.~20 - \< 24 kg = 1 tab 24 - \< 45 kg = 2 tabs 45 - \< 65 kg = 3 tabs 65 and above = 4 tabs"
62002881|NCT05567640|EXPERIMENTAL|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|"Digital, transdiagnostic, emotion-focused CBT intervention that consists of five core modules or components that have been shown to target temperamental characteristics (i.e., neuroticism) and resulting emotion dysregulation that are believed to underlie all anxiety, depressive, and emotional disorders. The core components of the program are psychoeducation, mindfulness, cognitive flexibility, behavioral strategies to counter emotion-driven behaviors, interoceptive, and emotion exposures."
62188188|NCT05563649|EXPERIMENTAL|Online Guided Self-Help-Family-based Treatment (GSH-FBT)|"GSH-FBT consists of 10 20-minute parent-only sessions over 9 months. The guidance portion is manualized and will be delivered by a clinician familiar with both the online modules and FBT, who acts as a coach. Sessions follow an online curriculum containing a total of 65 short videos. Each lecture series is comprised of a written introduction orienting the viewer to the videos, 5-9 short videos (\< 7 minutes each), and assigned reading from the parent education manual, Help Your Teenager Beat an Eating Disorder. In line with GSH approaches, coaches direct parents to watch or re-watch specific videos contained in the online platform related to their questions."
62188189|NCT05563649|ACTIVE_COMPARATOR|FBT via Videoconferencing (FBT-V)|15 60-minute sessions of 3-phase manualized FBT modified for videoconferencing will be delivered to participants randomized to this treatment by therapists trained in FBT. The first phase encourages parental management of weight restoration (approximately 8 weekly sessions); the second phase promotes a developmentally appropriate transition back to adolescent management of weight restoration and maintenance under parental supervision (approximately 4 bi-weekly sessions), and the third phase focuses on adolescent development (approximately 3 monthly sessions). Each session consists of 10 minutes with the adolescent individually to discuss progress and the adolescent's perspective on treatment, followed by 50 minutes with the entire family.
62188190|NCT03037047|PLACEBO_COMPARATOR|Control group|patients will be treated by 0.9% sodium chloride injection on the basis of conventional therapy for 14 days.
62188191|NCT03037047|EXPERIMENTAL|Experimental group|patients will be treated by salvianolate injection on the basis of conventional therapy for 14 days.
62188192|NCT02480478||intrahepatic cholestasis of pregnancy|5 ml whole blood sample is going to collect from intrahepatic cholestasis of pregnancy group for the assessment of serum autotaxin levels
62188193|NCT02480478||healthy control group|5 ml of whole blood is going to taken from healthy control group
62396112|NCT06724237|EXPERIMENTAL|Arm II (high dose chemotherapy and ASCT)|Patients receive stem cell mobilization and then undergo leukapheresis per standard of care. Patients also receive high dose chemotherapy followed by ASCT per standard of care. Additionally, patients undergo blood sample collection and optional bone marrow aspiration and biopsy on study, and CT or PET/CT throughout the study.
62396113|NCT05292378|EXPERIMENTAL|High CO2 Exposure first, then low CO2 exposure second.|At the first study visit the subject is exposed to 2500 ppm CO2 for 2.5 hours and at the second study visit the subject is exposed to 600 ppm CO2 for 2.5 hours.
62396114|NCT05292378|SHAM_COMPARATOR|Low CO2 Exposure first, then high CO2 exposure second.|At the first study visit the subject is exposed to 600 ppm CO2 for 2.5 hours and at the second study visit the subject is exposed to 2500 ppm CO2 for 2.5 hours.
62396115|NCT01151865|ACTIVE_COMPARATOR|Dexmedetomidine|"Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4."
62571370|NCT06578832||Children with chronic kidney disease receiving dialysis treatment|It is a group of patients aged between 4 and 17 who have recently been diagnosed with chronic kidney disease and are receiving dialysis treatment.
62571371|NCT06578832||Children with chronic kidney disease who have undergone a kidney transplant|It is a group of patients aged between 4 and 17 who have recently been diagnosed with chronic kidney disease and have undergone a kidney transplant.
62571372|NCT06578832||Children with stage 1-3 chronic kidney disease|It is a group of patients aged between 4 and 17 who have been diagnosed with stage 1-3 chronic kidney disease
62571373|NCT06578832||Children with stage 4-5 chronic kidney disease|It is a group of patients aged between 4 and 17 who have been diagnosed with stage 4-5 chronic kidney disease
62571374|NCT02312323|EXPERIMENTAL|Definitive 65 HPT|The Test product were the Definitive 65 (Filcon V4) lenses with Hydra PEG surface coating. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
62778380|NCT01108380|EXPERIMENTAL|1. CD34|"1. 4 days injection of G-CSF (10μg/kg, Subcutaneous infusion)~2. On 5th day, plasmapheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells)~3. CD 34 cells will be selected by CliniMACS (Miltenyi Biotec, Bergisch- Gladbach, Germany) (at least 1x10(7) of CD 34 cell)~4. In same day, right portal vein embolization with infusion of CD 34 cells into left portal vein will be performed."
62778381|NCT01108380|ACTIVE_COMPARATOR|2. Mononucelar cell|"1. 4 days injection of G-CSF (10μg/kg, Subcutaneous infusion)~2. On 5th day, plasma pheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells)~3. In same day, right portal vein embolization with infusion of mononuclear cells into left portal vein will be performed."
62778382|NCT01108380|OTHER|3. Control|Without infusion of G-CSF, patients will be performed just right portal vein embolization
62778383|NCT04378231|EXPERIMENTAL|high-dose group|patients take dry suspension of amoxicillin clavulanate potassium 45 mg/kg/ time (amoxicillin) orally twice a day, total daily dose not exceeding 2 g, and the course of treatment is two weeks.
62188194|NCT04679155|EXPERIMENTAL|eTRE|participants allocated to this group will be required to eat only between 0800h and 1600h.
62188195|NCT04679155|ACTIVE_COMPARATOR|lTRE|participants allocated to this group will be required to eat only between 1200h and 2000h
62188196|NCT05891652|ACTIVE_COMPARATOR|Blocked|Patients had bilateral M-TAPA block with 0.25% bupivacaine (total volume of 40 ml) at the end of the surgery for postoperative pain control.
62188197|NCT05891652|NO_INTERVENTION|Control|Patients did not have any block or infiltration anesthesia for their postoperative pain. They only received intravenous opioid analgesic (tramadol).
62188198|NCT01999777|EXPERIMENTAL|USL261|5 mg intranasal midazolam
62188199|NCT01999777|PLACEBO_COMPARATOR|Placebo|intranasal placebo
62188200|NCT02520310|EXPERIMENTAL|AVJ-514|The AVJ-514 system
62778384|NCT04378231|EXPERIMENTAL|standard dose group|patients take dry suspension of amoxicillin clavulanate potassium 30 mg/kg/ time (amoxicillin) orally twice a day, total daily dose not exceeding 2 g, and the course of treatment is two weeks.
62188201|NCT04485299|EXPERIMENTAL|bifluorid 10 varnish|Bifluorid 10 (NaF and CaF) lead to reduce the dentin hypersensitivity, the sodium fluoride (NaF) dissociates and releases F ions, that diffuse through the tubules and then precipitates as calcium fluoride as a consequence of the high of calcium content in saliva and dentinal fluid ,The calcium fluoride (CaF) present in the varnish composition diffuses into the tubules and block the canal with a semi-permanent protective layer.The calcium fluoride is added to block the dentin tubules mechanically, by the combination with the calcium fluoride resulted from the sodium fluoride reaction to the calcium of dentin.
62571375|NCT02312323|ACTIVE_COMPARATOR|Definitive 65|The Control product was the commercially available Definitive 65 (Efrofilcon A) lens. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
62778385|NCT04254094||Early onset dementias (EOD)|Prospective multicenter cohort of EOD patients with a three-year follow-up in tertiary Reference Memory centers
62188202|NCT04485299|ACTIVE_COMPARATOR|sodium fluoride varnish|Topical application of varnish fluoride (sodium fluoride NaF) effect on exposed dentine as a desensitizing agent, the varnish fluoride process is caused by the reaction between NaF and calcium ions resulting in calcium fluoride crystals being deposited on the openings of the dentinal tubules that decrease pain.
62188203|NCT03177681|EXPERIMENTAL|Group 1 - Antibiotics Taken During Past 2 Weeks|"Group 1: Participant was on antibiotics anytime during the past 2 weeks prior to the time of enrollment.~Tongue assessment, stool sample, and questionnaires done at baseline and once during Days 3-7 and once during Days 8-12.~Participants wear a Holter monitor for 20-24 hours at baseline and once during Days 3-7 and once during Days 8-12.~Participants given 2 tablespoons (33 cc) of yogurt each day for 12 days."
62188204|NCT03177681|EXPERIMENTAL|Group 2 - No Antibiotics Taken During Past 2 Weeks|"Group 2: Participant has not been on antibiotics in the past 2 weeks.~Tongue assessment, stool sample, and questionnaires done at baseline and once during Days 3-7 and once during Days 8-12.~Participants wear a Holter monitor for 20-24 hours at baseline and once during Days 3-7 and once during Days 8-12.~Participants given 2 tablespoons (33 cc) of yogurt each day for 12 days."
62188205|NCT02132117|EXPERIMENTAL|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 29 days.
62188206|NCT02132117|PLACEBO_COMPARATOR|Vehicle|Vehicle to Oxymetazoline HCL Cream applied to the face once daily for 29 days.
62188207|NCT04461769|EXPERIMENTAL|Slow Oscillation Synchronization with TES|Transcranial Electrical Stimulation, 0.5 Hz sine wave, 0.5 mA, between frontal (frontopolar and inferior lateral frontal) and posterior (mastoid and occipital) electrodes.
62188208|NCT04461769|SHAM_COMPARATOR|Sham Control|No current delivered.
62188209|NCT02813993|EXPERIMENTAL|Intervention Group|A five-minute video concerning age-related fertility decline, fertility risk factors, success of infertility treatments and emotional consequences of childlessness
62188210|NCT02813993|NO_INTERVENTION|Control|No intervention
62778386|NCT04942782|EXPERIMENTAL|lumbopelvic stabilization exercises|the patients will receive trunk stabilization exercise +strengthening exercises for the abdominal, back, and hip muscles three times/ week for three months
62778387|NCT04942782|EXPERIMENTAL|Pilates exercises|the patients will receive trunk pilates exercise +strengthening exercises for the abdominal, back, and hip muscles three times/ week for three months
62778388|NCT04942782|ACTIVE_COMPARATOR|conventional therapy|the patients will receive trunk stabilization exercise three times/ week for three months
62778389|NCT05464615|EXPERIMENTAL|Amoxicillin Graded Challenge|"1. Obtain baseline vitals (heart rate, O2 saturation, blood pressure and respiratory rate).~2. Administer 0.7 ml (56 mg) of amoxicillin 400 mg/ 5ml orally followed by 30 minutes of observation for allergy symptoms and other adverse reactions (e.g., itching, hives, swelling, coughing, wheezing, throat tightness, difficulty breathing, abdominal pain, vomiting, lightheadedness, hypotension, low oxygen saturation, tachycardia)~3. If no allergy or adverse symptoms are noted, administer 2.5 ml (200 mg) of amoxicillin followed by 90 minutes of observation"
62188211|NCT03596242|EXPERIMENTAL|High Blood Pressure Monitoring by Short Message Service (SMS)|Will receive the text message intervention and will be provided with a blood pressure cuff in addition to standard blood pressure control education received at clinic visits
62188212|NCT03596242|ACTIVE_COMPARATOR|Usual Care Plus Standard Blood Pressure Monitoring|Will receive standard blood pressure care and education, as well as a blood pressure cuff at their clinic visits
62188213|NCT02134366|EXPERIMENTAL|Clobazam|Subjects who are assigned the clobazam treatment group will receive a 10mg loading dose followed by a maintenance dose of 5-25 mg bid starting 12 hrs after the loading dose. If subjects are found to have failed to respond to treatment with clobazam, the physician investigator has the ability to either start another AED or increase the dose of clobazam depending on the clinical situation. Subjects still being treated with clobazam at discharge will be given a 30 day supply of clobazam.
62778390|NCT01324869|EXPERIMENTAL|Group A|Patients will receive an intravitreal injection of 0.5mg KH902 in the study eye at the first month, following the fixed injection, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.
62778391|NCT01324869|EXPERIMENTAL|Group B|Patients will receive continuously monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye; following the initial 3-month fixed-dosing phase of the trial, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.
62778392|NCT03576573||Primary Total Hip Arthroplasty|Single arm study of subjects previously implanted with any MicroPort Orthopedics or Wright Medical Technology femoral stems and PROCOTYL® C Acetabular Components
62188214|NCT02134366|ACTIVE_COMPARATOR|Clonazepam|Subjects who are assigned to the clonazepam treatment group will receive a dose of 1-2mg clonazepam dose tid. Following the initial treatment if a physician investigator determines that the subject's treatment has failed, the investigator has the option of treating the subject with clobazam at which point the individuals would be treated in the same method as those originally assigned to the clobazam treatment group.
62188215|NCT02134366|ACTIVE_COMPARATOR|Lorazepam|Subjects who are assigned to the lorazepam treatment group will receive a 1-2mg dose of lorazepam qid. Following the initial treatment if a physician investigator determines that the subject's treatment has failed, the investigator has the option of treating the subject with clobazam at which point the individuals would be treated in the same method as those originally assigned to the clobazam treatment group.
62778393|NCT01961063|EXPERIMENTAL|Treatment (gene therapy)|Patients receive busulfan IV over 3 hours on day -2 followed by lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells IV on day 0.
62778394|NCT02110797|OTHER|RETT patients|
62188216|NCT03552562|OTHER|30 patients with no signs of diabetic retinopathy|
62188217|NCT03552562|OTHER|30 patients with mild diabetic retinopathy|
62188218|NCT03552562|OTHER|30 patients with moderate to severe diabetic retinopathy|
62778395|NCT03761810|EXPERIMENTAL|S6G5T-3|Participants will topically apply S6G5T-3 cream, once daily to face for 12 weeks
62778396|NCT03761810|PLACEBO_COMPARATOR|S6G5T-8 Vehicle Cream|Participants will topically apply S6G5T-8 vehicle cream, once daily to face for 12 weeks.
62778397|NCT04945109|EXPERIMENTAL|Mankai beverage first|Two weeks of Mankai supplementation followed by two weeks of water supplement
62188219|NCT03552562|OTHER|30 healthy age-and sex- matched control subjects|
62188220|NCT00370110|EXPERIMENTAL|Itopride|
62188221|NCT00370110|OTHER|Placebo|
62188222|NCT04011293|EXPERIMENTAL|A|Single dose of CNCT19
62188223|NCT01003145|EXPERIMENTAL|H1N1 vaccine of 15 μg HA on Day 0|"15 μg HA (0.5 mL) per injection, 1 injection~50 adults (aged 18\~60 years) were assigned to receive one injection of H1N1 vaccine"
62188224|NCT01003145|EXPERIMENTAL|H1N1 vaccine of 15 μg HA on Day 0 and 21|"15 μg HA (0.5 mL) per injection, 2 injections~50 adults (aged 18\~60 years) and 50 elders (aged over 60 years) were assigned to receive two injections of H1N1 vaccine 3 weeks apart"
62188225|NCT01003145|EXPERIMENTAL|H1N1 vaccine of 30 μg HA on Day 0 and 21|"30 μg HA (1 mL) per injection, 2 injections~50 adults (aged 18\~60 years) and 50 elders (aged over 60 years) were assigned to receive two injections of H1N1 vaccine 3 weeks apart"
62188226|NCT04745520|EXPERIMENTAL|Rib fixation (medical devices)|Surgery and pain medication. The pain of patients will be treated with rib fixation and pain medication.
62188227|NCT04745520|ACTIVE_COMPARATOR|Pain medication (comparator treatment)|Pain medication only.
62188228|NCT00997711|EXPERIMENTAL|Cypher|Sirolimus-eluting stent
62188229|NCT05580198||BRH+|Acute ischemic stroke patients with brainstem raphe hypoechogenicity.
62188230|NCT05580198||BRH-|Acute ischemic stroke patients without brainstem raphe hypoechogenicity.
62188231|NCT00307164|ACTIVE_COMPARATOR|NucleomaxX|Participants received NucleomaxX for 48 weeks
62188232|NCT00307164|PLACEBO_COMPARATOR|Placebo|Participants received NucleomaxX placebo for 48 weeks
62778398|NCT04945109|EXPERIMENTAL|Mankai beverage last|Two weeks of water supplementation followed by two weeks of Mankai supplement
62778399|NCT01902472||FTC/TDF for PrEP|HIV-1 negative adults (any sex/gender, including transgender) who seroconvert while taking FTC/TDF for PrEP
62188233|NCT01991145|EXPERIMENTAL|UCB and EPO|UCB + EPO + Rehabilitation
62188234|NCT01991145|ACTIVE_COMPARATOR|UCB and placebo EPO|UCB + placebo EPO + Rehabilitation
62188235|NCT01991145|ACTIVE_COMPARATOR|placebo UCB and EPO|placebo UCB + EPO + Rehabilitation
62188236|NCT01991145|PLACEBO_COMPARATOR|placebo UCB and placebo EPO|placebo UCB + placebo EPO + Rehabilitation
62188237|NCT02682940|OTHER|Usual Care Patients on MDI or CSII|Usual care patients on multiple daily injections of insulin (MDI) or insulin pumps (CSII) will be their own controls against baseline and will use the Vigilant Diabetes Management Application in conjunction with a wireless blood glucose meter for three months.
62571376|NCT05063513|EXPERIMENTAL|Transplant arm|Experimental arm will undergo mobilisation with cyclophosphamide (CY) 4 g/m2 (in two divided doses), followed by Autologous Hematopoietic Stem Cell Transplantation using CY (200 mg/kg body weight given in 4 daily doses) plus ATG and unmanipulated autologous graft and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
62571377|NCT05063513|ACTIVE_COMPARATOR|Rituximab arm|Control arm will receive 4 successive weekly infusions of rituximab (antiCD20) 375 mg/m2 body surface area for four weeks and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
62188238|NCT06514573|EXPERIMENTAL|Butyrate|The butyrate groups (butyrate \<=20 kg, butyrate \>20 kg) will receive oral sodium butyrate (dose of 20 mg/kg body weight/daily in sachets, up to 800 mg/day maximum dose) plus ASD standard care.
62571378|NCT06205043|ACTIVE_COMPARATOR|Standard of care (SoC) based programming in Parkinson's disease patients|Patients will be programmed in a routine (Standard of Care) program. Based on the randomization the patient may receive this at the beginning or after the Stim search program (crossover)
62571379|NCT06205043|EXPERIMENTAL|StimSearchTM software based programing in Parkinson's disease patients|Patients will be programmed using StimSearch algorithm. Based on the randomization the patient may receive this at the beginning or after the Standard of Care program (crossover)
62188239|NCT06514573|PLACEBO_COMPARATOR|Placebo|The placebo groups (placebo \<=20 kg, placebo \>20 kg) will receive placebo (cornstarch) at the same dose and time plus ASD standard care.
62188240|NCT02171884||Group E1|Singletons born following ART via IVF/ICSI (short culture)
62188241|NCT02171884||Group EC1|Singletons born following ART via IVF/ICSI and freezing-thawing of the embryo
62188242|NCT02171884||Group T1|Singletons conceived naturally
62188243|NCT02171884||Group E2|Singletons born following ART with IVF/ICSI (prolonged culture)
62188244|NCT01314599|EXPERIMENTAL|Arm 1|PM01183 will be administered i.v. as a 1-hour infusion through a pump device at escalating doses according to the respective dose level, on Days 1 and 8 of each treatment phase.
62188245|NCT04388696|EXPERIMENTAL|Sisterhood 2.0|"Sisterhood 2.0 used a group format with activities that explore respect, nonviolence, healthy relationships, and sexuality, through 8 sessions (3 hours/session) over an 8 week period.~Sessions focus on gender, consider harmful messages around femininity and their image, healthy sexuality, healthy relationships and connections, understanding sexual abuse and assault, and self care."
62188246|NCT04388696|ACTIVE_COMPARATOR|Job Skills Training|The curriculum used for this program is an intensive 18-24 hour job readiness training curriculum distributed across 3 weeks, or up to 2 months.
62188247|NCT00527150|OTHER|Cohort 1|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
62188248|NCT00527150|OTHER|Cohort 2|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
62571380|NCT02159053|EXPERIMENTAL|Secukinumab 150 mg s.c. with loading|Secukinumab 150 mg at Baseline, Weeks 1, 2, and 3, followed by dosing every four weeks starting at Week 4.
62571381|NCT02159053|EXPERIMENTAL|Secukinumab 150 mg s.c. without loading|Secukinumab 150 mg at Baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2, and 3.
62571382|NCT02159053|PLACEBO_COMPARATOR|Placebo|Placebo at Baseline, Weeks 1, 2, 3, 4, 8, and 12, followed by dosing with Secukinumab 150 mg every four weeks starting at Week 16.
62571383|NCT02463851|ACTIVE_COMPARATOR|AF-Ablation with Multi-electrode catheter|Regular AF-ablation with a multi-electrode ablation catheter
62571384|NCT02463851|ACTIVE_COMPARATOR|AF-Ablation with Contact Force single-tip electrode|Regular AF-ablation with a regular Contact Force single-tip ablation catheter
62571385|NCT03395145|EXPERIMENTAL|Bio-Oss Collagen and Mucograft Seal|Bone volume Changes after socket preservation using Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal
62571386|NCT03395145|NO_INTERVENTION|Natural healing|Evaluation of Bone volume Changes after tooth extraction (natural healing)
61977843|NCT01085409||Artery disease|Subjects with mobility constraints as a results of severe artery disease which in some cases led to leg amputation.
62188249|NCT00527150|OTHER|Cohort 3|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
62188250|NCT00527150|OTHER|Optional Cohort 4|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
62571387|NCT05358054|EXPERIMENTAL|GROUP A|GROUP A
62571388|NCT05358054|EXPERIMENTAL|GROUP B|GROUP B
62188251|NCT00527150|OTHER|Optional Cohort 5|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
62188252|NCT03443414|EXPERIMENTAL|0.75 mg RPL554|
62188253|NCT03443414|EXPERIMENTAL|1.5 mg RPL554|
62188254|NCT03443414|EXPERIMENTAL|3 mg RPL554|
62188255|NCT03443414|EXPERIMENTAL|6 mg RPL554|
62188256|NCT03443414|PLACEBO_COMPARATOR|Placebo|
62188257|NCT01547221|ACTIVE_COMPARATOR|3% boric acid|control
62188258|NCT01547221|EXPERIMENTAL|1% clotrimazole ear drop|3% boric acid is set as control while 1% clotrimazole ear drop is set as intervention.
62188259|NCT01568385|EXPERIMENTAL|TAK-438 20 mg QD|
62188260|NCT05846698||control group|
62188261|NCT05846698||treatment group|
62188262|NCT01777490|ACTIVE_COMPARATOR|Arm 1: Control - Caregiver|Caregivers in the control arm will be referred to the VA Caregiver Support Program (usual care), as a resource for them as they care for the patient in the home.
62188263|NCT01777490|EXPERIMENTAL|Arm 2: HI FIVES - Caregiver|Caregivers will take part in three phone training sessions and will attend four group training sessions at the VA. They will also be given the option of participating in 2 booster phone training sessions post-group sessions. Caregivers will be asked to provide one in-person (baseline) and three phone assessments (3, 9, and 15 months). Patients will also be enrolled and contact will be limited to assessments
62188264|NCT01777490|ACTIVE_COMPARATOR|Arm 1: Control - Patient|The patient of each caregiver will also be enrolled and contact will be limited to assessments.
62571389|NCT06313619|EXPERIMENTAL|Digital Pharmacy Intervention|"A total of 39 pharmacy will be included in the intervention. The digital intervention named SmartAMR will be introduced among them. The participants will install the mobile app and use it to keep record of the antimicrobial sales in a central database."
62571390|NCT02836002|EXPERIMENTAL|Group 1 - SP low/SP high|"Group 1 will be treated with a course of subcurative sulfadoxine-pyrimethamine (SP) (SP low, 500mg/25mg) as treatment 1.~As treatment 2 (SP high) volunteers will receive a treatment with sulfadoxine-pyrimethamine (1000mg/50mg).~Group 1 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
62571391|NCT02836002|EXPERIMENTAL|Group 2 - SP low/Pip high|"Group 2 will be treated with a course of subcurative sulfadoxine-pyrimethamine (SP) (SP low, 500mg/25mg) as treatment 1.~As treatment 2 (Pip high) volunteers will receive a treatment with piperaquine (960mg).~Group 2 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
62571392|NCT02836002|EXPERIMENTAL|Group 3 - Pip low/Pip high|"Group 3 will receive piperaquine (Pip) in a low-dose (Pip low, 480 mg) as treatment 1.~As treatment 2 (Pip high) volunteers will receive a treatment with piperaquine (960mg).~Group 3 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
61977844|NCT01085409||Anxiety|Subjects with anxiety complaints
62188265|NCT01777490|EXPERIMENTAL|Arm 2: HI-FIVES - Patient|The patient of each caregiver will also be enrolled and contact will be limited to assessments.
62188266|NCT01993771||Males and females with alopecia|Males and females with alopecia scheduled for general anaesthesia.
62188267|NCT01475422|EXPERIMENTAL|Conversation Maps Diabetes Education|
62188268|NCT01475422|ACTIVE_COMPARATOR|Usual Care|
62188269|NCT04624945||SICU cohort|150 subjects with the admission diagnosis of neurological haemorrhage (e.g. subarachnoid haemorrhage, intracerebral haemorrhage etc), admitted to SICU of National University Hospital, Singapore, who are expected to stay for more than 48 hours, will be recruited and enrolled. Frequency of blood sampling will be stipulated atday 1/2/3/4/5 to draw clinical relevance. An additional 0.5 tablespoonful (7.7ml) of blood will be taken daily from each subject as well as residual blood from routine laboratory test blood samples.
62188270|NCT00969969|ACTIVE_COMPARATOR|Arthrodesis|Fusion
62188271|NCT00969969|EXPERIMENTAL|Cartiva|Synthetic Cartilage Implant
62188272|NCT05223972|EXPERIMENTAL|Scoliosis Treatment Group|For the scoliosis group treatment include schroth theraphy
62188273|NCT05223972|EXPERIMENTAL|Lyon Treatment|For the scoliosis group treatment include Lyon theraphy..
62188274|NCT03427983|OTHER|US-guided regular injection|US in-plane injection with corticosteroid and 1cc of lidocaine. Total of 2cc.
62188275|NCT03427983|OTHER|US-guided hydrodissection|US in-plane injection with corticosteroid and 1cc of lidocaine, and 3cc of saline. Total of 5cc.
62188276|NCT01947712|PLACEBO_COMPARATOR|milk chocolate|dosage form: orally given dosage:40 g milk chocolate (≤35% cocoa) frequency and duration: 40 g/day for one month
62188277|NCT01947712|ACTIVE_COMPARATOR|dark chocolate|dosage form: orally given dosage:40 g dark chocolate (≥85% cocoa) frequency and duration: 40 g/day for one month
62188278|NCT02188537|EXPERIMENTAL|Nelfinavir, Bortezomib, Dexamethasone|"The trial is designed as an add-on therapy, where nelfinavir is added to the approved bortezomib-containing therapy. Bortezomib and dexamethasone background treatment will be given in the Swissmedic-approved dose and schedule and according to international therapeutic standard."
62188279|NCT00002740|EXPERIMENTAL|Treatment - Carboplatin Chemotherapy|See detailed description.
62188280|NCT04721288|EXPERIMENTAL|Intervention Group|1 year of tailored communication with transplant care team through Reboot application in addition to standard of care communication system.
62188281|NCT04721288|SHAM_COMPARATOR|Standard of Care Group|1 year of generic communication through Reboot application with communication with transplant care team through standard of care communication system.
62188282|NCT01692093|EXPERIMENTAL|KM110329|Participants will receive KM110329 for eight weeks. Participants will take 2 tablets by mouth with water two times a day after meals.
62188283|NCT01692093|PLACEBO_COMPARATOR|Control|Participants will receive placebo drug for eight weeks. Participants will take 2 tablets by mouth with water two times a day after meals.
62188284|NCT03471364|EXPERIMENTAL|Arm I (ketoconazole)|Participants apply ketoconazole topically BID on days 1-28.
62188285|NCT03471364|PLACEBO_COMPARATOR|Arm II (placebo)|Participants apply placebo topically BID on days 1-28.
62188286|NCT01066715|PLACEBO_COMPARATOR|Placebo|
62188287|NCT01066715|EXPERIMENTAL|XOMA 052|
62188288|NCT04789343|EXPERIMENTAL|hand files with lateral condensation technique|Previously done root canal filling removed by hand files (Hedstrom file,VDW, Munich,Germany ) and shaped with the same files and after instrumentation, all canals were filled by AH Plus sealer (Dentsply De Tray, Costanz, Germany) and lateral condensation technique of gutta-percha.
62188289|NCT04789343|EXPERIMENTAL|Reciproc instrument with lateral condensation technique|Previous root canal filling removed by Reciproc instrument (VDW ,Munich, Germany )using Endomotor (VDW, Munich, Germany). After removal, root canal instrumented with the same instrument and obturated using AHPlus sealer with lateral condensation technique of gutta-percha.
62188290|NCT04789343|EXPERIMENTAL|Reciporoc instrument with continuous warmed condensation technique|Previous root canal removed by Reciproc instrument using Endomotor, shaped and obturated by AhPlus sealer with continuous gutta-percha technique (Diadent Dia-Duo (Diadent, Chongju, Korea).
62188291|NCT00412880|EXPERIMENTAL|BI 2536|Total Patients
62188292|NCT00005219||Exercise Study Participants|Data from the San Diego Health and Exercise Baseline survey conducted in 1986 were used to contact participants for the follow-up
62188293|NCT02354547|EXPERIMENTAL|SGT-53 with Topotecan/Cyclophosphamide|There will be 4-6 cycles (21 days/cycle) of therapy in this trial. In cycle 1, SGT-53 will be given as a single agent twice weekly starting at 1.4 mg/m² of DNA per infusion to evaluate single-agent toxicity. Pharmacokinetic studies will be performed. In the absence of dose limiting toxicity, patients will proceed to cycle 2 even if they have progressive disease. Starting in cycle 2, SGT-53 will be administered twice-weekly in combination with topotecan and cyclophosphamide administered daily for 5 days, days 1-5 of each cycle. Day 1 of each combination cycle is the first day on which topotecan and cyclophosphamide are administered with SGT-53. If a subject has at least stable disease after four cycles of therapy and is tolerating protocol therapy, two additional cycles may be considered.
62188294|NCT05594004||Oscillating-Rotating electric toothbrush|Twice daily brushing
62188295|NCT05594004||Sonic electric toothbrush|Twice daily brushing
62188296|NCT05594004||Manual toothbrush|Twice daily brushing
62188297|NCT03514381|OTHER|Patients starting a treatment with Doxorubicin and Ifosfamide|
62188298|NCT01242371|ACTIVE_COMPARATOR|Probiotic Supplement|Probiotic supplement 1 tablet by mouth daily for 14 weeks after 2 week placebo run-in
62188299|NCT01242371|PLACEBO_COMPARATOR|Identical-appearing Placebo|Identical appearing placebo 1 tablet by mouth daily for 14 weeks after 2 week placebo run-in
62188300|NCT01283022|EXPERIMENTAL|MVI 200|MVI 200 mcg vaginal insert
62188301|NCT04537871||Observational (physical assessment)|Patients undergo echocardiogram to assess cardiac function and mechanics, cardiopulmonary exercise test, pulmonary function test, musculoskeletal ultrasound, bioelectrical impedance analysis to measure total lean body mass and percent body fat), physical function tests, and collection of blood samples within 45 days from the start of conditioning therapy, and at 6 months, 1 year, and 2 years post-transplant.
62188302|NCT02063464||Cohort 1|Subjects w/ovarian, primary peritoneal or fallopian tube ca who are not currently on therapy and are screening for trials, being seen in consultation, or presenting for enrollment on a trial.
62188303|NCT03613324||Bladder outlet obstruction (BOO)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having BOO when Qmax was \<12 mL/s and PdetQmax was ≥25 cmH2O with sustained detrusor contraction during voiding cystometry.
62188304|NCT03613324||Detrusor underactivity (DU)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having DU when Qmax was \<12 mL/s and PdetQmax was \<10 cmH2O during voiding cystometry.
62571393|NCT02836002|EXPERIMENTAL|Group 4 - Pip low/SP high|"Group 4 will receive piperaquine (Pip) in a low-dose (Pip low, 480 mg) as treatment 1.~As treatment 2 (SP high) volunteers will receive a treatment with sulfadoxine-pyrimethamine (1000mg/50mg).~Group 4 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
62188305|NCT03613324||ND BOO/DU|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. This group revealed no demonstrated bladder outlet obstruction nor detrusor underactivity.
62188306|NCT04643093|ACTIVE_COMPARATOR|Pitavastatin|Pitavastatin
62188307|NCT04643093|ACTIVE_COMPARATOR|Ezetimibe|Ezetimibe
62188308|NCT04643093|EXPERIMENTAL|1PC111|1PC111
62188309|NCT05161741|EXPERIMENTAL|Uncontrolled diabetes requiring Insulin|
62188310|NCT01380977|EXPERIMENTAL|Impact of Crime group intervention|
62188311|NCT01380977|ACTIVE_COMPARATOR|Treatment as usual|
62188312|NCT04283227|EXPERIMENTAL|OTL-200 Gene Therapy|OTL-200 is an autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene.
62188313|NCT06464952|EXPERIMENTAL|Resistant potato starch|
62188314|NCT06464952|ACTIVE_COMPARATOR|Cellulose|
62188315|NCT04334616|ACTIVE_COMPARATOR|Conventional Laryngocope|Patients in this arm will be intubated with conventional Macintosh laryngoscope
62188316|NCT04334616|ACTIVE_COMPARATOR|Video Laryngocope|Patient in this arm will be intubated with Karl Storz Video Laryngoscope
62188317|NCT01937195|EXPERIMENTAL|AccuCath Intravenous Catheter System|AccuCath Intravenous Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal.
62188318|NCT03579238|NO_INTERVENTION|Distant|The clinician sits quietly 3 feet away from participant who is lying on a soft table at rest.This position is held for 5 minutes without moving.
62188319|NCT03579238|NO_INTERVENTION|close|The clinician sits at the head of the table with his arms on the table alongside the participant's head but not touching the resting patient who is lying at rest on the table. This position is held for 5 minutes without moving.
62188320|NCT03579238|SHAM_COMPARATOR|touching|"The clinician lifts the patient's head passively off the table in order to place his hands underneath the participant's head, palms facing upwards and in contact with the back of the head of the participant. The participant's head is gently lowered to rest upon the clinician's hands. No external force is provided by the clinician upon the participant's head as the head rests in the clinician's palms on the table. This position is held for 5 minutes without moving. This is called a touching intervention and is meant to be a sham. A five minute rest period follows in which the clinician removes his hands from underneath the participant's head and places them next to the patient on the table, but not in contact with the patient."
62188321|NCT03579238|EXPERIMENTAL|Occipital motion inhibition|"The clinician gently inhibits motion of the participant's occiput into flexion phase of the primary respiratory mechanism, and allows extension phase only. Upon sensing a still point, where no further flexion motion is palpated, the clinician will state to the research assistant now to indicate he feels a still point. This position is held for 5 minutes without moving. This is called a CV4 or modified CV4 intervention. A five minute rest period follows in which the clinician removes his hands from underneath the participant's head and places them next to the patient on the table, but not in contact with the patient."
62188322|NCT02900898|EXPERIMENTAL|Dynamic exercise and Mediterranean diet|"DE: divided in stretch: arms, hands, legs, knees, for 20 seconds (s), resting 5, warming and flexion: making small circles forward and backward for 20 s, resting 5, DE: resistance (contraction, twisting) using therapeutic leagues with 20 repetitions, resting 10 s. Aerobic part will perform in a treadmill by 20 minutes (monitoring blood pressure and heart rate) and relaxation: involved the stretching part.~MD: Individualized diet (energy expenditure) according to age, ideal weight and height. Distribution of macronutrients will be 50% carbohydrates, 30% lipids and 20% of proteins. This diet is according to the Mediterranean diet patterns and consist in five meals: breakfast, snack, principal meal, snack and dinner. All recommended meals include type of food and method of preparation."
62188323|NCT02900898|EXPERIMENTAL|Dynamic exercise|"DE: divided in stretch: arms, hands, legs, knees, for 20 seconds (s), resting 5, warming and flexion: making small circles forward and backward for 20 s, resting 5, DE: resistance (contraction, twisting) using therapeutic leagues with 20 repetitions, resting 10 s. Aerobic part will perform in a treadmill by 20 minutes (monitoring blood pressure and heart rate) and relaxation: involved the stretching part."
62188324|NCT02900898|EXPERIMENTAL|Mediterranean diet|MD: Individualized diet (energy expenditure) according to age, ideal weight and height. Distribution of macronutrients will be 50% carbohydrates, 30% lipids and 20% of proteins. This diet is according to the Mediterranean diet patterns and consist in five meals: breakfast, snack, principal meal, snack and dinner. All recommended meals include type of food and method of preparation.
62188325|NCT02900898|ACTIVE_COMPARATOR|Control|This group will not carry out interventions.
62188326|NCT03634839|EXPERIMENTAL|Sweet non-menthol, nicotine 36mg/ml|Sweet flavor non-menthol (Watermelon) with 36mg/ml Nicotine
62188327|NCT03634839|EXPERIMENTAL|Sweet menthol, nicotine 36mg/ml|Sweet flavor with menthol (Watermelon-menthol) with 36mg/ml Nicotine
62188328|NCT01765738|ACTIVE_COMPARATOR|Antibiotic coated PICC|Cook Medical Spectrum Turbo-Ject Minocycline/Rifampin Power-Injectable PICC (5fr double lumen or 6fr triple lumen)
62188329|NCT01765738|ACTIVE_COMPARATOR|Non-antibiotic coated PICC|Bard Access PowerPICC Power Injection PICCs (6fr double lumen or 6fr. triple lumen)
62188330|NCT04451837|ACTIVE_COMPARATOR|semaglutide|Patients randomized to add semaglutide (Ozempic) will receive injection training at the study site and inject 0.25 mg subcutaneously once weekly during the first four weeks, followed by 0.5 mg weekly for the subsequent four weeks and finally 1.0 mg weekly throughout the study.
62188331|NCT04451837|ACTIVE_COMPARATOR|dapagliflozin|Those randomized to dapagliflozin will receive 10 mg orally once daily in addition to metformin.
62188332|NCT04171947|EXPERIMENTAL|Matuzalem|Tea extract vaginal ovule daily for 7 consecutive days
62188333|NCT04171947|SHAM_COMPARATOR|Vehicle|Polyethylene glycol vaginal ovule daily for 7 consecutive days
62214664|NCT05138354|ACTIVE_COMPARATOR|Control group|Patients received a 4-week treatment program (12 treatment sessions, three times a week). Patients received the conservative treatment protocol comprised of ultrasound, hot pack application, and exercises.
62571394|NCT01401361|EXPERIMENTAL|Treatment Arm|Atrial Flutter RF Ablation treatment with the Contact Therapy Cool Path ablation catheter, 1500 T9 V1.43 RF Generator, Model 1611 connection cable, EnSite Velocity Contact™ Kit, and EnSite Velocity Contact software controlled via entitlement.
62571395|NCT03890432|EXPERIMENTAL|GLUCOSAFE 2|Insulin-therapy and nutrition support guided by the GLUCOSAFE 2 software.
62571396|NCT03890432|ACTIVE_COMPARATOR|Local protocol control group|Insulin-therapy and nutrition support guided by the local protocols (electronic or paper version) of the ICU/HUG.
62778400|NCT04977219||Prism Adaptation Training;|Patients who received prism adaptation training for treatment of spatial neglect during their inpatient rehabilitation admission
62188334|NCT00621192|EXPERIMENTAL|Meropenem|"These~Participants were subdivided into the following four groups based on Gestational Age (GA) and Postnatal Age (PNA):~Group 1: GA at birth below 32 weeks - PNA \<2 weeks; Group 2: GA at birth below 32 weeks - PNA ≥2 weeks and \<91 days; Group 3: GA at birth 32 weeks or older - PNA \<2 weeks; Group 4: GA at birth 32 weeks or older - PNA ≥2 weeks and \<91 days."
62571397|NCT03890432|OTHER|Historical control group|"Retrospective data with standard care before the beginning of the pilot study in order to minimize the cross-over effect due to the fact that caregivers are going to have in charge patients in both groups (intervention and control group) at the same time."
62002882|NCT05567640|ACTIVE_COMPARATOR|Space from Depression (SFD)|Digital CBT program designed to minimize the impact of depressive symptoms. This program emphasizes the use of cognitive behavioral strategies as well as mindfulness through a series of seven structured modules. The core components of the program include psychoeducation around the relationship between thoughts, feelings, and behaviors; cognitive behavioral practices aimed at restructuring negative beliefs; behavioral strategies to improve self-esteem; and mindfulness techniques that focus attention on the present moment.
62188335|NCT05923346|EXPERIMENTAL|Glutlearn|
62571398|NCT01077297|EXPERIMENTAL|Tezosentan|
62571399|NCT00016432|EXPERIMENTAL|Group 1|Exemestane
62571400|NCT00016432|PLACEBO_COMPARATOR|Group 2|Placebo
62778401|NCT04977219||Standard Care|Patients who received standard treatment of spatial neglect during their admission
62778402|NCT05648019|EXPERIMENTAL|Single Arm|CD19-directed CAR T-cell therapy for relapsed/refractory B-lineage leukaemia/lymphoma.
62778403|NCT05510674|EXPERIMENTAL|OWL-EVO1|OWL-EVO1 probe will be administered to those who are fully eligible, including those diagnosed with lung cancer and healthy volunteers
61977845|NCT01085409||Controls|Healthy controls
62214665|NCT05138354|EXPERIMENTAL|Intervention group|Patients received a 4-week treatment program (12 treatment sessions, three times a week). Patients received LLLT and myofascial release combined with the control intervention. the conservative treatment protocol comprised of ultrasound, hot pack application, and exercises
62571401|NCT02848144|OTHER|Children with infectious shock|Children aged from 1 month to \<18 years. In 3 stratified groups : \<2 years, 2-8 years, and \>8 years. About one third of the patients are expected in each age-group.
62571402|NCT02848144|OTHER|Control group: healthy children|Healthy children aged-matched to cases (same stratification group, about 20 per age group); They will be hospitalized for an elective surgery (dental, ENT, maxillofacial, urologic, hernia surgery, neurosurgery without massive hemorrhage) and without any infection.
62571403|NCT04273529|PLACEBO_COMPARATOR|Control group|placebo
62571404|NCT04273529|EXPERIMENTAL|Thalidomide group|thalidomide
62571405|NCT00566020|EXPERIMENTAL|Lamotrigine|study drug
62571406|NCT04938180|EXPERIMENTAL|Cohort A|Each subject will receive a low dose of AMB-05X every 2 weeks, for a total of 6 doses over the 12-week treatment period.
62778404|NCT06099834|OTHER|Patient selection|Patient selection criteria were as follows: absence of any systemic disease; not being in American Society of Anesthesiologists (ASA) Class 3 or 4 according to the ASA Physical Status Classification System (Doyle, 2017); being older than 20 years of age; the existence of panoramic and dental volumetric tomography images of the area to be implanted; the presence of a suitable recipient bone for implantation with dental implants of the desired length and diameter.
62778405|NCT06099834|OTHER|Dental Implant Application|Bredent SKY® dental implants were applied at a torque level of 30 N.cm as recommended by the manufacturer. The surgery and all measurements were performed by the same surgeon.
62571407|NCT06368271|EXPERIMENTAL|Intake of fatty acids|,Participants ingest a test drink containing 35g of MCT or LCT oil diluted in 100g of low-fat, low-carb cocoa milk) within five min. Blood and oxygen uptake are obtained frequently during the following 4 hours.
62571408|NCT02075203|EXPERIMENTAL|AERAS-404 (15 mcgH4/500 nmol IC31)|2 doses on Study Days 0 and 56
62571409|NCT02075203|ACTIVE_COMPARATOR|Bacillus Calmette-Guérin (BCG)|1 Dose on Study Day 0
62002883|NCT05567640|ACTIVE_COMPARATOR|Space for Resilience (SFR)|Digital program based on positive psychology principles and designed to promote resilience and well-being through a series of seven modules. The core components of the program include psychoeducation, values exploration, building relationships, promoting self-esteem and self-efficacy, and building gratitude and optimism.
62188336|NCT06301347|EXPERIMENTAL|Learning through Play Plus|"The proposed intervention is a combination of two interventions:~Learning through Play The 'Learning through Play' programme is intended to stimulate early child development. The central feature of the program is a pictorial calendar devised for parents, depicting eight successive stages of child development from birth to 3 years, with illustrations of parent-child play and other activities that promote parental involvement, learning, and attachment.~Culturally Adapted Cognitive Behavioral Therapy for Psychosis (CaCBTp) The CaCBTp interventions will follow the treatment manual developed by David Kingdom and David Tarkington and culturally adapted by Farooq Naeem. In CBT the general approach will be a collaborative understanding of the development of symptoms and further work toward reducing distress and disability in participants."
62571410|NCT02075203|PLACEBO_COMPARATOR|Placebo|2 Doses on Study Days 0 and 56
62571411|NCT05374317|ACTIVE_COMPARATOR|Standard Dose (Group 1)|Yellow Fever vaccine standard dose, 0.5mL.
62002884|NCT01715506|EXPERIMENTAL|Educational intervention|Educational intervention with two days of lecture/course for the whole staff in the selected department in each nursing home and six monthly sessions of counselling in smaller groups
62188337|NCT06301347|NO_INTERVENTION|Treatment-as-Usual|This group of patients will not be provided any intervention. They will be taking only treament as usual (which in Pakistan means attending the outpatient clinic at regular intervals and taking prescribed medication) and we will compare this group with LTP Plus group after three months.
62188338|NCT01183442|ACTIVE_COMPARATOR|vitamin D (Oleovit®)|vitamin D drops
62396116|NCT01151865|PLACEBO_COMPARATOR|Saline placebo|An identical syringe to that in the intervention arm, but which does not contain dexmedetomidine, will be provided. The initial rate of infusion and subsequent adjustments will be the same as in the dexmedetomidine group.
62396117|NCT06722586|EXPERIMENTAL|Treatment|Sirolimus two pills (1mg) per day
62396118|NCT06722586|PLACEBO_COMPARATOR|Control|Placebo two pills per day
62396119|NCT03641690||27 case|Twenty-seven patients were admitted to the ICU with severe pneumonia and with a high probability of viral infection or a previously confirmed diagnosis received Empirical antimicrobial therapy
62396120|NCT03641690||70 control|70 healthy subjects (HS) among blood donors attending the Regional Center for Blood Transfusion (Lille, France).
62396121|NCT04600518||SPRINT cohort|stage II and III advanced gastric cancer patients based on the 6th and 8th of the AJCC
62396122|NCT06126627|EXPERIMENTAL|Teachers/student teachers with vocal fatigue|Teachers/student teachers with vocal fatigue based on Vocal Fatigue Index (VFI, German). Pre-Screening and Screening. Experiment 1: MRI with MRI-compatible surface electrodes on the neck and audio recordings during MRI with and without stress induction. Prior to MRI, questionnaires on voice, personality, and stress and practice oft the tasks. During experiment, collection of saliva samples (before, during, and after MRI). During MRI, multiple subjective ratings of emotional state by the participants. Experiment 2 (approximately 2 weeks later): Speech tasks with surface electromyographic sensors applied to the neck with concurrent audio recordings. Prior to the experiment questionnaires on voice and practice of tasks. Subjective ratings of vocal and cognitive effort during the experiment by the participants.
62396123|NCT06126627|ACTIVE_COMPARATOR|Control group|Control participants without vocal fatigue based on Vocal Fatigue Index (VFI, German). Same experimental procedures as in arm 1.
62396124|NCT03927209|EXPERIMENTAL|BI 1467335 (low dose)|
62396125|NCT03927209|EXPERIMENTAL|BI 1467335 (high dose)|
62396126|NCT00906516|EXPERIMENTAL|Neuradiab in combination with Avastin|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
62571412|NCT05374317|EXPERIMENTAL|Fractional dose (Group 2)|Yellow Fever vaccine 1/5th standard dose, 0.1mL.
62571413|NCT05374317|EXPERIMENTAL|Fractional dose (Group 3)|Yellow Fever vaccine 1/10th standard dose, 0.05mL.
62571414|NCT06163885|EXPERIMENTAL|peer-supported training group|Peer-supported training groups consist of 36 people. Participants in this group will receive a four-hour stoma care skill training from their peers. The group's knowledge and skills in stoma care were evaluated by two independent observers
62002885|NCT04554511||Training cohort|Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.
62188339|NCT01183442|PLACEBO_COMPARATOR|Placebo|placebo drops
62188340|NCT01257399|EXPERIMENTAL|Asacol®|Import Mesalazine
62396127|NCT03495596||Videolaryngoscopy patients|The patients who were attempted to be intubated with videolaryngoscopy
62396128|NCT03188276|ACTIVE_COMPARATOR|CHC patients|32 treatment-naive CHC patients treated by Ledipasvir-Sofosbuvir or Daclatasvir-Sofosbuvir.
62571415|NCT06163885|EXPERIMENTAL|flipped classroom training group|flipped classroom training groups consist of 35 people. Participants in this group will receive a four-hour stoma care skill training from their educator. The group's knowledge and skills in stoma care were evaluated by two independent observers
62396129|NCT03188276|NO_INTERVENTION|Healthy controls|20 Healthy controls without any treatment
62396130|NCT04052425|EXPERIMENTAL|Double-Blind Period: Ruxolitinib cream 1.5% BID|Participants applied ruxolitinib 1.5% cream twice daily (BID) for 24 weeks.
62571416|NCT06163885|NO_INTERVENTION|Control group|Control training groups consist of 35 people. Participants in this group will receive a four-hour stoma care skill training from their educator. The group's knowledge and skills in stoma care were evaluated by two independent observers
62002886|NCT04554511||Validation Cohort|Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.
62002887|NCT03766100|EXPERIMENTAL|Intervention group|Cognitive Behavioural Therapy for Insomnia (CBT-i).
62002888|NCT03766100|NO_INTERVENTION|Control group|Insomnia is untreated.
62778406|NCT06099834|OTHER|Osseointegration and periodontal measurements|Following the operations, the stability of the dental implants was measured at the 1st (T1), 4th (T4), and 12th (T12) weeks using Periotest (Periotest M, Modautal/Germany) and Osstell (Osstell AB-W\&H, Sweden) devices. In accordance with the manufacturers' recommendations, the final implant stability quotient (ISQ) and Periotest values were determined by calculating the average of three measurements per implant. At the same time, periodontal index values of probing depth (PD-mm) and bleeding on probing (BOP-%) were recorded at the site of the dental implant at T4 and T12.
62002889|NCT01417832|EXPERIMENTAL|Treatment with Infiltrant/Adhesive|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
62188341|NCT01257399|ACTIVE_COMPARATOR|Mesalazine|Marketed Mesalazine
62188342|NCT04627415|EXPERIMENTAL|Face to Face Treatment|The F2F version of PEAK contains 10 BPE sessions (1.5 hours each). Session content includes: 1) Introduction to ADHD, 2) Attending, Rewards and Ignoring, 3) General Behavior Management Strategies, 4) Problem-Solving Approach, 5) Preventive Intervention, 6) Instructive Interventions, 7) Response Strategies, 8) Extending What Works to Community Settings, 9) Promoting Early Reading and Math Skills, and 10) Effective Communication Strategies. Each session contains didactic instruction and activities designed to enhance engagement. Sessions include video examples and interactive activities. Weekly homework is assigned for strategy practice. At the start of the following session, the leader checks in with families on the use of the chosen strategy. The session leader praises successes and troubleshoots challenges. The intervention also includes optimistic training which aims to identify/improve pessimistic thinking patterns that parents have about their parenting and child's behaviors.
62214666|NCT01757197|EXPERIMENTAL|All Patients|Toclizumab will be administered on Day 0. The administration of tocilizumab will be every 2 weeks for a total of 8 doses.
62002890|NCT01417832|PLACEBO_COMPARATOR|Placebo, placebo treatment|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with a placebo treatment: At baseline one caries lesion was cleaned with a microbrush for 30 seconds and the procedure was repeated after two minutes.
62188343|NCT04627415|EXPERIMENTAL|Online Treatment|For the online version of the program, in addition to content regarding an overview of ADHD, the initial session consists of brief video clips demonstrating how to access PEAK sessions on the Internet, and an orientation to online content (e.g., handouts, interactive chat sessions, research team contact links). Prior to the session, parents are provided with password-protected individual access codes. Similar to the F2F program, check-ins are provided weekly via each parent's preferred mode of communication (i.e., text, internet, phone) to query strategies implemented, praise success, and troubleshoot alternative strategies. Parents in the online condition will also receive supplemental optimistic training to improve pessimistic thinking patterns about their child and parenting.
62188344|NCT04627415|OTHER|Waitlist Control|The comparison condition is a waitlist control group that will receive no intervention throughout the intervention timeframe. Instead, participants will receive wellness information about typical child development and constructs unrelated to the intervention content. Subsequent to the 12-month follow-up assessment, they will be provided access to the online version of the program. To encourage ongoing participation in the absence of services, parents will be informed that, at the end of the intervention timeframe, they will receive support (i.e., weekly contact to answer questions) while they complete the online program.
62188345|NCT00664105|EXPERIMENTAL|Therapeutic Intervention|
62188346|NCT02985047|EXPERIMENTAL|Brief Admission|Participants randomised to Brief admission (BA) will have the possibility of admitting themselves to hospital for a maximum duration of three consecutive days at a maximum frequency of three times per month. Apart from BA they have access to all psychiatric care that they would have if they had not participated in the study (including general admission to hospital).
62396131|NCT04052425|PLACEBO_COMPARATOR|Double-Blind Period: Vehicle cream BID|Participants applied matching vehicle cream BID for 24 weeks.
62571417|NCT02215395|EXPERIMENTAL|CVR treatment cycle|Women who meet all inclusion and no exclusion criteria will be randomized to the first treatment cycle with the CVR alone followed by the second treatment cycle with the CVR and miconazole (one of three dosing regimens) or the first treatment cycle with the CVR and miconazole followed by the second treatment cycle with the CVR alone.
62188347|NCT02985047|NO_INTERVENTION|Control|Participants randomized to Treatment as Usual will receive no intervention from the study protocol, except the baseline assessments and repeated assessments administered on the same schedule as described above for the treatment group. They will not be given the evaluation measures that are specific to the intervention. Participants have access to all psychiatric care that they would have if they had not participated in the study (including general admission to hospital).
62188348|NCT05550571|EXPERIMENTAL|Patients treated with the device|
62188349|NCT06499688|EXPERIMENTAL|Treatment Group|Single injection with Rcombinant botulinum neurotoxin type A for injection(YY001) in glabellar lines
62002891|NCT01921829|NO_INTERVENTION|Usual Care|Participants randomized to the Usual Care group (control arm) will receive escalating diuretics and medical therapy per HF guidelines published by the American College of Cardiology (ACC)/American Heart Association (AHA) and Heart Failure Society of America (HFSA), dosed in variable fashion at the discretion of the treating cardiologist.
62188350|NCT06499688|ACTIVE_COMPARATOR|Active-Controlled Group|Single injection with BOTOX® in glabellar lines
62188351|NCT06499688|PLACEBO_COMPARATOR|Placebo-Controlled Group|Single injection with placebo in glabellar lines
62188352|NCT05196880||ARM 1|Patients with negative clinical suspicion of Biofilm containing wounds(CSB-).
62188353|NCT05196880||ARM 2|Patients with positive clinical suspicion of Biofilm containing wounds(CSB+)
62188354|NCT00607464|EXPERIMENTAL|1|Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
62188355|NCT00607464|NO_INTERVENTION|2|Standard care
62188356|NCT00920647|OTHER|Control|Untreated Patients
62188357|NCT00920647|EXPERIMENTAL|Idursulfase -IT (1 mg)|monthly using an intrathecal drug delivery device (IDDD)
62188358|NCT00920647|EXPERIMENTAL|Idursulfase-IT (10 mg)|monthly using an intrathecal drug delivery device (IDDD)
62188359|NCT00920647|EXPERIMENTAL|Idursulfase -IT (30 mg)|monthly using an intrathecal drug delivery device (IDDD)
62188360|NCT02612506|EXPERIMENTAL|Hepalatide|Hepalatide 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg
62188361|NCT02612506|PLACEBO_COMPARATOR|Placebo|Placebo 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg
62571418|NCT06261346|EXPERIMENTAL|PRGF group|Participants tissue will be incubated in plasma rich in growth factors prior to endothelial keratoplasty procedure. Participants will be followed up for up to 1 year.
62571419|NCT06261346|ACTIVE_COMPARATOR|Control group|Participants will undergo endothelial keratoplasty procedure. Participants will be followed up for up to 1 year.
62571420|NCT05392205|EXPERIMENTAL|68Ga-FAP-2286|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-2286, and undergo PET/CT imaging within the specified time.
62188362|NCT04502992|OTHER|Single Arm (pre-post, quasi-experimental)|Pre-post intervention, single arm. (Intervention was 4 weeks of Acceptance and Committment therapy, 2 times per week, 90 min per session, in a group setting).
62188363|NCT05332106|EXPERIMENTAL|Estradiol Valerate and Dienogest Test Product.|Participants will receive one tablet of the test formulation containing Estradiol Valerate and Dienogest 2 mg/ 2 mg.The tablet will be taken with water and in a fasting condition.
62188364|NCT05332106|ACTIVE_COMPARATOR|Estradiol Valerate and Dienogest Referent Product|Participants will receive one tablet of the marketed reference containing Estradiol Valerate and Dienogest 2 mg/ 2 mg. The tablet will be taken with water and in a fasting condition.
62571421|NCT03325634|EXPERIMENTAL|Treatment (SBRT)|Patients undergo Stereotactic Body Radiation Therapy (SBRT) every other day for 3 fractions.
62571422|NCT03741192|EXPERIMENTAL|Treatment Group|SPEAC System
62188365|NCT05762952|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10mg oral tablet.
62188366|NCT05762952|PLACEBO_COMPARATOR|Placebo|Placebo matching tablet.
62188367|NCT06456086||Stevens-Johnson syndrome/toxic epidermal necrolysis|
62188368|NCT06456086||healthy control group|
62188369|NCT06456086||Maculopapular Eruption|
62188370|NCT05649189||Participants testing positive for Food Addiction (FA)|these participants have tested positive for Food Addiction (FA) at a severe level using the YaleFAS-2 Food Addiction Scale.
62188371|NCT05649189||Participants testing negative for Food Addiction (FA)|these participants have tested negative for Addiction (FA) using the YaleFAS-2 Food Addiction Scale.
62188372|NCT03630406||Laser treatment|Female patients with either SUI of vaginal wall weakness and prolapse refered for an attempt at laser treatment.
62188373|NCT05920863|EXPERIMENTAL|Experimental|"1. TACE: pharmorubicin 30mg, oxaliplatin 50mg, cycle 4-5 week.~2. Tislelizumab: 200mg, cycle 3 week.~3. Lenvatinib: weight \<60kg, 8mg/day; weight ≥60kg, 12mg/day."
62188374|NCT02989090|EXPERIMENTAL|Group A (Intervention Group)|Receive Detailed ICD Information-electronic: Receive ICD Patient Notification Summary via MyChart Patient Portal Account - Receive training to familiarize yourself with using the ePHR, MyChart Complete baseline, 3 month and 6 months survey
62188375|NCT02989090|ACTIVE_COMPARATOR|Group B (Intervention Group)|Receive Detailed ICD Information-paper: Receive ICD Patient Notification Summary via paper Receive training to familiarize yourself with using the ePHR, MyChart Complete baseline, 3 month and 6 months survey
62188376|NCT02989090|NO_INTERVENTION|Group C (Control Group)|Receives Standard of Care-No Report Complete baseline, 3 month and 6 months survey
62188377|NCT05052502|EXPERIMENTAL|reactive focal mass drug administration (rfMDA)|Reactive FMDA (rfMDA) led by VMVs in response to cases in study area sub-district, in both villages and forest workers; quantitative G6PD testing for all individuals and 14-day PQ for G6PD non-deficient.
62188378|NCT05052502|ACTIVE_COMPARATOR|Control|Standard of care including case management through health facilities and malaria posts/VMVs; village-based RACD conducted by district staff in some areas.
62188379|NCT02561208|ACTIVE_COMPARATOR|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps and SMS text messages.
62188380|NCT02561208|NO_INTERVENTION|Usual Care Group|Women with HPV self-collected tests receive usual care.
62188381|NCT01350232|EXPERIMENTAL|HSCT|"Subjects receive the preparative regimen in 2 steps. The first step will be with fludarabine and cytarabine and a low dose of total body irradiation. This will be followed by the first step of the transplant graft - the donor lymphocytes. The second step of the chemotherapy will be two doses of cyclophosphamide. This will then be followed by the second step of the transplant graft - the stem cells.~Only subjects with prior alloimmunization against donor will receive desensitization. Subjects who demonstrate alloimmunization against the HLA of the donor will receive bortezomib and rituximab in combination with plasmapheresis prior to the admission for transplant."
62188382|NCT05070832|EXPERIMENTAL|Hyperthermia Group|The neoadjuvant therapy is hyperthermia combined with concurrent radiochemotherapy for this group.
62188383|NCT05070832|NO_INTERVENTION|Non-hyperthermia group|The neoadjuvant treatment is concurrent radiochemotherapy, which is standard treatment for LARC according to the guidelines.
62188384|NCT04662437||Covid-19 Patient Group|10 ml of venous blood was taken from the forearm venous vein from people in the Covid-19 Patient Group, and the level of parathyroid hormone, calcium, phosphorus, alkaline phosphatase was measured from this blood.
62188385|NCT04662437||Healthy Control Group|10 ml of venous blood will be taken from the forearm venous vein from the healthy control group and the parathyroid hormone, calcium, phosphorus, alkaline phosphatase level will be measured from this blood.
62188386|NCT02008071|EXPERIMENTAL|Daily step goal financial incentive|
62188387|NCT02008071|ACTIVE_COMPARATOR|Control, Standard of Care|
62188388|NCT00521976||Chest pain|Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).
62188389|NCT01278147|NO_INTERVENTION|controle|patient without fatigue education program
62571423|NCT03741192|NO_INTERVENTION|Standard of Care|
62188390|NCT01278147|EXPERIMENTAL|Education program|the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
62571424|NCT01213732|EXPERIMENTAL|L19TNFα plus melphalan|Subjects will be sequentially assigned to one of 2 dose levels of L19TNFα: 325 µg or 650 µg. All subjects will receive a single dose of L19TNFα and Melfalan (10mg/ L Limb volume).
62571425|NCT06176274|EXPERIMENTAL|the experimental group|a prehabilitation program will be applied before the surgery.
62188391|NCT05113797|ACTIVE_COMPARATOR|Control Group|Subjects will perform YBT-LQ practice tests using standardized set of verbal instructions provided in the YBT-LQ online manual prior to the testing condition.
62188392|NCT05113797|EXPERIMENTAL|OPTIMAL Motor Learning Group|Subjects will perform the YBT-LQ with the practice period altered to implement aspects of the three pillars of the OPTIMAL motor learning theory (promotion of autonomy support (AS), presence of an external focus (EF) of attention, and implementation of enhanced expectancies (EE) placed upon a task).
62188393|NCT00030823|EXPERIMENTAL|Vaccine|Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine with QS21 adjuvant subcutaneously weekly on weeks 1, 2, 3, 7, and 19.
62571426|NCT06176274|NO_INTERVENTION|The Control Group|he will receive standard nursing care procedure.
62188394|NCT04847245|ACTIVE_COMPARATOR|Pregabalin group|Pregabalin capsules were administered orally (75 mg, tid), combined administration of duloxetine.
62188395|NCT04847245|EXPERIMENTAL|0.125 mg/kg esketamine group|Intravenous administration of esketamine 0.125 mg/kg，and duloxetine is co- administered orally.
62188396|NCT04847245|EXPERIMENTAL|0.25 mg/kg esketamine group|Intravenous administration of esketamine 0.25mg/kg，and duloxetine is co- administered orally.
62571427|NCT05472025||Changes in blood pressure|Blood pressure assessment：The blood pressure and heart rate before induction and the blood pressure and heart rate per minute within 10 minutes after induction intubation were recorded. After induction of anesthesia, MAP \< 60 mmHg, or the decrease rate exceeded 30% of the baseline value, was defined as the occurrence of hypotension
62188397|NCT04847245|EXPERIMENTAL|0.50 mg/kg esketamine group|Intravenous administration of esketamine 0.50 mg/kg，and duloxetine is co- administered orally.
62396132|NCT04052425|EXPERIMENTAL|Treatment-Extension Period: Ruxolitinib cream 1.5% BID|Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied ruxolitinib cream 1.5% BID during the Double-Blind Period continued to apply ruxolitinib cream 1.5% BID for an additional 28 weeks in the Treatment-Extension Period.
62396133|NCT04052425|EXPERIMENTAL|Treatment-Extension Period: Vehicle cream to Ruxolitinib cream 1.5% BID|Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied vehicle cream BID during the Double-Blind Period applied ruxolitinib cream 1.5%m BID for 28 weeks in the Treatment-Extension Period.
62396134|NCT01288911|EXPERIMENTAL|Enzalutamide|Participants received enzalutamide 160 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.
62396135|NCT01288911|ACTIVE_COMPARATOR|Bicalutamide|Participants received bicalutamide 50 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.
62396136|NCT01768182|EXPERIMENTAL|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.
62571428|NCT06576544||High-risk|Individuals having chronic HTN, according to ACOG guidelines, as either SBP ≥140 mmHg or DBP ≥90 mmHg on at least 2 occasions, ≥4 hours apart, prior to 20 weeks gestation
62571429|NCT06576544||Intermediate-risk|"Individuals who are at risk of de novo PP HTN; these are individuals who are at risk for preeclampsia based on an adapted USPSTF algorithm but who did not develop HTN by the time of delivery. The algorithm is as follows:~-One or more of the following high risk conditions and/or two or more of the following moderate risk conditions for development of de novo postpartum hypertension: i. High risk conditions: pregestational diabetes mellitus, renal disease, autoimmune disease (systemic lupus erythematosus, antiphospholipid syndrome), multifetal gestation, gestational diabetes mellitus A2 (i.e. medication-dependent), history of preeclampsia in a prior pregnancy (not including the index pregnancy) ii. Moderate risk conditions: primiparity, obesity (BMI ≥ 35 kg/m2), age ≥ 35 years, Black or African-American race, family history of preeclampsia"
62571430|NCT06576544||Low-risk|Having no diagnosis of HTN/HDP by the time of delivery and not meeting criteria for increased risk of HDP or de novo PP HTN.
62571431|NCT00773825||1|Pregnancy after ICSI or IVF
62002892|NCT01921829|EXPERIMENTAL|Protocolized Diuretic Strategy|Participants randomized to the Protocolized Diuretic Strategy group will receive escalating diuretics according to an algorithm targeting a goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide). If UO is \< 3 L/day, diuretic regimen will be increased. If UO is 3-5 L/day, diuretic regimen will be continued at current doses. If UO is \> 5 L/day, diuretic regimen will be reduced.
62002893|NCT04260815|EXPERIMENTAL|anodal tDCS on the left inferior frontal gyrus (IFG)|
62002894|NCT04260815|EXPERIMENTAL|anodal tDCS on the right IFG|
62002895|NCT04260815|SHAM_COMPARATOR|sham tDCS|
62002896|NCT01126164|EXPERIMENTAL|parent handbook|parent handbook
62002897|NCT01126164|EXPERIMENTAL|peer basics|peer delivered basics
62002898|NCT01126164|EXPERIMENTAL|parent handbook and peer basics|parent handbook and peer basics
62002899|NCT03289728|EXPERIMENTAL|Strategy guided by ischemia imaging|"Non-invasive imaging (SPECT or DSE) will be performed. High-risk Patients judged to high risk by imaging (according to ESC guidelines (5)) will undergo coronary angiography aimed at myocardial revascularization and have optimal medical treatment, according to ESC guidelines.~- Low or intermediate risk patients will receive optimal medical treatment."
62002900|NCT03289728|ACTIVE_COMPARATOR|Systematic coronary angioplasty|Patients will routinely undergo invasive coronary angiography aimed at myocardial revascularization.
62002901|NCT00003724|EXPERIMENTAL|surgery|"Patients undergo open resection (thoracotomy, median sternotomy, or bilateral sternothoracotomy).~Patients with isolated recurrence in the chest should have the recurrence(s) resected if feasible. The original resection approach (open versus VATS) should be the preferred method for the second resection, but is not required.~Quality of life is assessed prior to randomization and then at 30 days, 3 months, and 6 months. Patients are followed every 3 months for 1 year and then every 6 months thereafter."
62188398|NCT00322686|EXPERIMENTAL|Oglemilast followed by placebo|
62188399|NCT00322686|EXPERIMENTAL|Placebo followed by Oglemilast|
62188400|NCT02496598|EXPERIMENTAL|In Vitro Follicle Activation (IVA)|Ovarian tissue will be removed and cultured in vitro with compounds to activate dormant follicles. Following activation, ovarian tissue will be auto-grafted and the patient monitored for follicular growth.
62188401|NCT01688310|ACTIVE_COMPARATOR|Open surgical circumcision|Open surgical techniques, which are commonly used for circumcision in Mozambique, require good surgical skills and minor complications are common.
62188402|NCT01688310|EXPERIMENTAL|Gomco clamp with tissue adhesive|Coupling removal of the foreskin with the Gomco clamp followed by wound sealing with tissue adhesive results in a procedure that can be performed by generalist doctors using the same technique in all age groups.
62188403|NCT00761956|ACTIVE_COMPARATOR|1|Study arm will consist of patients that are treated with the NexGen CR-Flex Fixed Bearing Knee.
62188404|NCT00761956|ACTIVE_COMPARATOR|2|Study arm will consist of patients that are treated with the NexGen CR Knee.
62188405|NCT03674762|EXPERIMENTAL|dental implants|microgrooved dental implants submerged
62188406|NCT03674762|EXPERIMENTAL|dentale implants|microgrooved dental implants nonsubmerged
62188407|NCT02706951|EXPERIMENTAL|Upadacitinib 30 mg|"Period 1: Participants receive upadacitnib 30 mg once daily and placebo to methotrexate once weekly for 14 weeks.~Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260."
62188408|NCT02706951|EXPERIMENTAL|Upadacitinib 15 mg|"Period 1: Participants receive upadacitnib 15 mg once daily and placebo to methotrexate once weekly for 14 weeks.~Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260."
62188409|NCT02706951|EXPERIMENTAL|Methotrexate / Upadacitinib 30 mg|"Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib once daily for 14 weeks.~Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260."
62188410|NCT02706951|EXPERIMENTAL|Methotrexate / Upadacitinib 15 mg|"Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib for 14 weeks.~Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260."
62188411|NCT02078414||Ulipristal acetate|Women choosing EllaOne as emergency contraception
62188412|NCT02078414||Copper IUD|Women choosing copper IUD as emergency contraception
62188413|NCT05353660||chronic kidney disease|
62188414|NCT05353660||maintenance hemodialysis|
62188415|NCT03258671|EXPERIMENTAL|Mutation+ concurrent|IMRT concurrent with EGFR-TKI on paticipants with known sensitive EGFR mutations.
62396137|NCT01768182|PLACEBO_COMPARATOR|Placebo|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.
62396138|NCT03880162|EXPERIMENTAL|Study intervention|Participants will follow an energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates) for minimum two weeks.
62396139|NCT03880162|ACTIVE_COMPARATOR|Control intervention|Participants will follow an energy deficient (30% deficit) standard diet (50% of carbohydrates) for minimum two weeks.
62396140|NCT06722157|EXPERIMENTAL|Arm A: BI 771716|
62396141|NCT06722157|EXPERIMENTAL|Arm B: BI 771716 and Sham comparator|
62002902|NCT00003724|EXPERIMENTAL|video-assisted surgery|"After spiral CT showing pulmonary nodules are amenable to video-assisted thoracic surgery (VATS) resection with curative intent, patients undergo minimally-invasive video-assisted resection.~Patients with isolated recurrence in the chest should have the recurrence(s) resected if feasible. The original resection approach (open versus VATS) should be the preferred method for the second resection, but is not required.~Quality of life is assessed prior to randomization and then at 30 days, 3 months, and 6 months. Patients are followed every 3 months for 1 year and then every 6 months thereafter."
62002903|NCT05242510|EXPERIMENTAL|Patching|
62002904|NCT05242510|EXPERIMENTAL|Prism Adaptation|
62002905|NCT01825408|ACTIVE_COMPARATOR|Doxycycline, 3 weeks|Subjects with chronic rhinosinusitis with nasal polyps (CRSwNP) will receive Doxycycline 100mg BID or if allergic to doxycycline, then Augmentin 875mg BID for 3 weeks duration. These patients will also receive a course of Prednisone (30mg x 3d, 20mg x 3d, 10mg x3d, 10mg every other day for 6 days (3 doses)) which is standard of care treatment for patients with chronic sinusitis with nasal polyps.
62002906|NCT01825408|ACTIVE_COMPARATOR|Doxycycline, 6 weeks|Subjects with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)will receive Doxycycline 100mg BID or if allergic to doxycycline, then Augmentin 875mg BID for 6 weeks duration. These patients will also receive a course of Prednisone (30mg x 3d, 20mg x 3d, 10mg x3d, 10mg every other day for 6 days (3 doses)) which is standard of care treatment for patients with chronic sinusitis with nasal polyps.
62188416|NCT03258671|EXPERIMENTAL|Mutation+ concomitant|IMRT concomitant with EGFR-TKI on paticipants with known sensitive EGFR mutations.
62188417|NCT05434585|EXPERIMENTAL|Test group 1: ABO1009-DP|Intramuscularly injecting 15 μg of ABO1009-DP into lateral deltoid of the upper arm of subjects on D0 and D28, respectively.
62188418|NCT05434585|EXPERIMENTAL|Test group 2: ABO-CoV.617.2|Intramuscularly injecting 15 μg of ABO-CoV.617.2 into lateral deltoid of the upper arm of subjects on D0 and D28, respectively.
62188419|NCT05434585|PLACEBO_COMPARATOR|Control group: Placebo|Intramuscularly injecting placebo into lateral deltoid of the upper arm of subjects on D0 and D28, respectively
62188420|NCT04142099|EXPERIMENTAL|skin to skin contact 60 min group|"1. Newborns are exposed to maternal and child skin within five minutes of birth.~2. Observe the time of newborn spent in suctioning the maternal nipple in 60 minutes of skin to skin contact.~3. No intervention or forced neonatal suction."
62188421|NCT04142099|ACTIVE_COMPARATOR|skin to skin contact 20 min group|"1. Newborns are exposed to maternal and child skin within five minutes of birth.~2. Observe the time of newborn spent in suctioning the maternal nipple in 20 minutes of skin to skin contact.~3. No intervention or forced neonatal suction."
62188422|NCT05834023|ACTIVE_COMPARATOR|Bupivacaine 0.25% plus Lidocaine 1%|Infraclavicular block with Bupivacaine and Lidocaine
62188423|NCT05834023|EXPERIMENTAL|Bupivacaine 0.5%|Infraclavicular block with Bupivacaine
62188424|NCT05586412|EXPERIMENTAL|exercise therapy group|Exercise therapy group; joint range of motion exercises including the upper extremity, strengthening, stretching, isometric and posture exercise program will be given. These exercises are in the form of a home program and will be asked to do 2 sets a day, 5 days a week, and 10 repetitions of each movement for 4 weeks.
62214667|NCT05775081|EXPERIMENTAL|Treated Dentine Matrix (TDM)|Participants treated with TDM paste
62214668|NCT05775081|EXPERIMENTAL|Platelet Rich Fibrin (PRF)|Participants treated with PRF
62214669|NCT04428372|EXPERIMENTAL|Mannitol|intravenous 20% mannitol, 0.25g/kg/hour (maximum 25g/hour; maximum 75g per session; maximum volume 375mL/session) as a continuous infusion during dialysis
62214670|NCT04428372|PLACEBO_COMPARATOR|Placebo|0.9% saline at a rate of 1.25mL/kg/hour (maximum volume 375mL) as a continuous infusion during dialysis
62396142|NCT06722157|ACTIVE_COMPARATOR|Arm C: Pegcetacoplan|
62571432|NCT00773825||2|Pregnancy after ovarian stimulation
62002907|NCT01825408|ACTIVE_COMPARATOR|Azithromycin, 3 weeks|Subjects with Chronic Rhinosinusitis without Nasal Polyps will receive Azithromycin 250mg daily, or if allergic to azithromycin, then Augmentin 875mg BID for 3 weeks duration.
62002908|NCT01825408|ACTIVE_COMPARATOR|Azithromycin, 6 weeks|Subjects with chronic Rhinosinusitis without Nasal Polyps will receive Azithromycin 250mg daily, or if allergic to azithromycin, then Augmentin 875mg BID for 6 weeks duration.
62002909|NCT00884234|EXPERIMENTAL|1|RT001 (Botulinum Toxin Type A Topical Gel)
62188425|NCT05586412|EXPERIMENTAL|vagus stimulation group|To the patients in the vagus stimulation treatment group; Auricular vagus nerve stimulation in the physical therapy and rehabilitation unit, 20 sessions in total, 5 days a week, and 30 minutes each session. will be applied. Patients will be treated in the form of daily arrival and departure. Vagus nerve stimulation will be performed using a TENS device with specially designed ear-shaped surface electrodes, the size of which can be selected according to any size ear. The electrodes will be placed on the inner and outer surface of the tragus and the concha. Waveform biphasic asymmetrical, pulse duration less than 500 microseconds and frequency of 10 hertz for 30 minutes. been applied continuously throughout and the amplitude will be adjusted according to the sensory threshold level.
62214671|NCT01543984|EXPERIMENTAL|Tailored Physical Activity|"Health guidance (1,5h) and Tailored Physical Activity (3\*50 min/week in 10 weeks)"
62396143|NCT03055208|EXPERIMENTAL|Radiosurgery|"Following intraoperative confirmation of glioblastoma (frozen section):~Early (24-72h post surgery) stereotactic ablation (gamma knife radiosurgery) of residual tumor (defined in early postoperative T1-weighted MRI scanning with and without contrast), followed by standard-of-care therapy (chemo-radiotherapy with 60 Gy external beam radiation therapy (EBRT) and 75 mg/m2/d temozolomide, followed by adjuvant chemotherapy with 150-200 mg/m2/d/cycle temozolomide in a 5/28 days schedule)."
62396144|NCT01648517|EXPERIMENTAL|Arm A|Genomic-driven dual agent chemotherapy Chemotherapy will consist of the assigned two drugs according to ERCC1 and RRM1 mRNA expression level A1: docetaxel + vinorelbine (DV) A2: gemcitabine + vinorelbine (GV) A3: docetaxel + carboplatin (DC) A4: gemcitabine + carboplatin (GC)
62396145|NCT01648517|ACTIVE_COMPARATOR|Arm B|standard of care All control arm patients received standard platinum-based doublet chemotherapy with docetaxel plus carboplatin
62571433|NCT00773825||3|natural pregnancy
62571434|NCT04195204|EXPERIMENTAL|Tropisetron|Patients allocated to this arm will receive intravenous Tropisetron (5mg) before anesthesia induction and once daily for 7 days after surgery.
62571435|NCT04195204|PLACEBO_COMPARATOR|Placebo|Patients allocated to this arm will receive an identical volume of normal saline before anesthesia and once daily for 7 days after surgery.
62571436|NCT05809232|ACTIVE_COMPARATOR|CARES-guided Group|The Intervention
62571437|NCT05809232|NO_INTERVENTION|Non CARES-Guided Group|The control - Participants randomized to the control arm will continue to have their routine Pre-Anesthesia Assessment on the electronic form, without the CARES calculator calculations, as per current practice
62002910|NCT00884234|PLACEBO_COMPARATOR|2|Vehicle Control
62214672|NCT01543984|OTHER|Reference group|Health Counselling (1,5h)
62396146|NCT04112862|EXPERIMENTAL|Intervention|three GLUT1DS patients with drug resistant epilepsy who tried the ketogenic diet without any benefits.
62396147|NCT04159558|EXPERIMENTAL|experimental hypertension|The subjects with Hypertension will be trained in the use of the personalized help tool and will use it during a period of 3 months.
62396148|NCT04159558|EXPERIMENTAL|experimental diabetes|The subjects with Diabetes will be trained in the use of the personalized help tool and will use it during a period of 3 months.
62396149|NCT04159558|EXPERIMENTAL|experimental heart failure|The subjects with Heart failure will be trained in the use of the personalized help tool and will use it during a period of 3 months.
62571438|NCT03321968|EXPERIMENTAL|Quadrivalent VLP Influenza Vaccine - Lot 1|Participants received one intramuscular (IM) injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.
62571439|NCT03321968|EXPERIMENTAL|Quadrivalent VLP Influenza Vaccine - Lot 2|Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.
62571440|NCT03321968|EXPERIMENTAL|Quadrivalent VLP Influenza Vaccine - Lot 3|Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.
62571441|NCT02155283|OTHER|Treatment Continuous Passive Motion|Single-arm; 3-week treatment plan using Kyrobak compared to baseline (before treatment)
62002911|NCT03400033|EXPERIMENTAL|Daprodustat|Subjects randomized to this arm will receive daprodustat tablets titrated doses from 2 to 48 milligrams orally three-times weekly along with saline by IV route for the 52 weeks treatment period.
62002912|NCT03400033|ACTIVE_COMPARATOR|Epoetin alfa|Subjects randomized to this arm will receive matching placebo tablets to daprodustat orally three-times weekly and Epoetin alfa by IV route for the 52 weeks treatment period.
62188426|NCT05586412|EXPERIMENTAL|exercise-vagus stimulation group|Exercise and vagus stimulation treatment group; Both the applications made to the patients in the vagus stimulation group and the same exercises given to the patients in the exercise therapy group will be given as a home program. Patients in all groups will be evaluated with different parameters twice, before and after the treatment.
62188427|NCT03468179|EXPERIMENTAL|Oatmeal|Subjects will arrive for study fasting. IV access will be obtained, and baseline blood drawn. They will be fed 80gm/100kg oatmeal, and blood levels will be drawn at 30, 60, 90, and 120 minutes.
62188428|NCT00936598|EXPERIMENTAL|zolpidem|Participants randomized to the zolpidem (intervention) group will receive the FDA approved dose of zolpidem, (10 mg for women \<65; 5 mg for women \> or = 65 years). For the purposes of this double-blind trial, zolpidem (e.g., Roxane Laboratories) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.
62188429|NCT00936598|PLACEBO_COMPARATOR|sugar pill|Participants randomized to the sugar pill (control) group will receive placebo. For the purposes of this double-blind trial, placebo (sugar) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.
62188430|NCT05438134|EXPERIMENTAL|SMART-3RP Group Intervention|Residents will participate in 9 structured weekly group sessions which incorporates stress management and relaxation training upon enrollment.
62188431|NCT05438134|ACTIVE_COMPARATOR|Waitlist Control Group Intervention|Residents will participate in 9 structured weekly group sessions which incorporates stress management and relaxation training after the final survey time point.
62188432|NCT03045913||Genoss DES|Subject implanted Genoss DES for coronary artery disease
62571442|NCT00597662|EXPERIMENTAL|1|
62571443|NCT00597662|ACTIVE_COMPARATOR|2|
62188433|NCT04742062|ACTIVE_COMPARATOR|ApTOLL single dose|ApTOLL is administered intravenously in a single ascending dose pattern in seven dose levels (0.7mg - 70mg). Levels 1 - 3 include one subject per level and levels 4 - 7 include six subjects per level (1 sentinel + 5 subjects).
62188434|NCT04742062|PLACEBO_COMPARATOR|Placebo single dose|Placebo is administered intravenously during seven dose levels. Levels 1 - 3 include one subject per level and levels 4 - 7 include two subjects per level (1 sentinel + 1 subject).
62188435|NCT04742062|ACTIVE_COMPARATOR|ApTOLL multiple dose|ApTOLL is administered intravenously every eight hours during 24h (21mg). This arm includes six subjects (1 sentinel + 5 subjects).
62188436|NCT04742062|PLACEBO_COMPARATOR|Placebo multiple dose|Placebo is administered intravenously every eight hours during 24h. This arm includes twosubjects (1 sentinel + 1 subject).
62188437|NCT00169845|EXPERIMENTAL|Alpha-Tocopherol and Beta-Carotene|Patients received a daily supplementation of alpha-tocopherol (one capsule of 400 IU dl-alpha-tocopherol) and beta-carotene (one capsule of 30 mg) for 3 years after the end of radiation therapy. Due to ethical concerns, the beta-carotene supplementation was stopped during the trial (after the randomization of 156 patients). See details in JNCI, 2005: 97 (7), 481-8.
62188438|NCT00169845|PLACEBO_COMPARATOR|Placebo|Patients received two capsules of placebos per day during 3 years. When the beta-carotene was stopped, they received only one capsule.
62188439|NCT06367634|EXPERIMENTAL|Ultra Deep|
62188440|NCT06367634|ACTIVE_COMPARATOR|Restylane|
62188441|NCT01550523|EXPERIMENTAL|18-mer oligodeoxynucleotide|
62188442|NCT00750451|EXPERIMENTAL|LMWH|Women in the LMWH arm are administered 1 mg/kg/day subcutaneously low molecular weight heparin after oocyte collection in addition to routine luteal phase support with vaginal progesterone
62571444|NCT06018675||Group 1|Kinesiotherapy
62571445|NCT06018675||Group 2|Dry needling
62571446|NCT06018675||Group 3|Lidocain injection
62188443|NCT00750451|ACTIVE_COMPARATOR|Control|Women in the control arm are administered routine luteal phase support without the addition of LMWH
62188444|NCT00594022|ACTIVE_COMPARATOR|"Group 1- VirtuSom - Stim"|Normal sleepers (7.5 - 9.0 hours), MSLT (multiple sleep latency test) \>=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with active device (electric stimulation of the Vestibular nerve).
62188445|NCT00594022|PLACEBO_COMPARATOR|"Group 2- VirtuSom- Sham"|Normal sleepers (7.5 - 9.0 hours), MSLT \>=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with placebo / sham device (NO electric stimulation of the Vestibular nerve).
62188446|NCT01299311|NO_INTERVENTION|Inactivity|4 days of inactivity, mainly sitting
62188447|NCT01299311|ACTIVE_COMPARATOR|NEAT|4 days of NEAT (everyday activities)
62188448|NCT01299311|ACTIVE_COMPARATOR|Exercise|4 days of inactivity combined with 1 hour of exercise
62188449|NCT01427049||renal denervation|Adults with a systolic BP ≥160 mmHg (≥150 mmHg for type 2 diabetics) with a stable drug regimen including 3 or more antihypertensive medications, including a diuretic, or inability to follow a stable drug regimen due to unacceptable side-effects of antihypertensive medication.
62188450|NCT03177109|ACTIVE_COMPARATOR|Fluoride Varnish Group|5% fluoride varnish (Acclean) applied topically
62188451|NCT03177109|ACTIVE_COMPARATOR|Arginine paste Group|8% arginine containing paste (Colgate® Sensitive Pro-Relief™) applied topically
62188452|NCT03177109|ACTIVE_COMPARATOR|Adhesive Resin Group|Self-adhesive resin (Seal and Protect, Dentsply) applied topically
62188453|NCT01434719||S.suis cases|This group consists of human cases with S.suis infection (confirmed or probable) admitted to National Hospital for Tropical Diseases in 2010.
62188454|NCT01434719||Sepsis controls|This group consists of hospital controls diagnosed with sepsis (not caused by S.suis) admitted to National Hospital for Tropical Diseases in 2010.
62188455|NCT01586481|ACTIVE_COMPARATOR|barouk|
62188456|NCT01586481|EXPERIMENTAL|sanidiab|
62188457|NCT06333977|EXPERIMENTAL|LC542019|oral dose, once daily.
62188458|NCT06333977|PLACEBO_COMPARATOR|Placebo|matching placebo capsules.
62188459|NCT02871583|ACTIVE_COMPARATOR|lichtenstein|lichtenstein procedure
62002913|NCT05581212|NO_INTERVENTION|Standard of Care (Control phase)|In the current standard of care in Thailand, at time of diagnosis and tuberculosis (TB) treatment initiation, TB patients are being advised to tell their household (HH) contacts to consult at the TB clinic for screening and provision of either curative or preventive treatment - according to the screening outcome.
62188460|NCT02871583|ACTIVE_COMPARATOR|Kugel|Kugel procedure
62021023|NCT02419157|ACTIVE_COMPARATOR|Clearfil SE Bond Etch (CSE-E)|"CSE-E (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Enamel margins were selectively etched with 36% phosphoric acid for 15s and subsequently thoroughly rinsed and air-dried. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~Selective enamel etching with 36% phosphoric acid"
62571447|NCT06166446|ACTIVE_COMPARATOR|a CAD/CAM-milled mandibular overdenture and a maxillary acrylic conventional complete denture|patients received lower denture fabricated by milling technique
62571448|NCT06166446|ACTIVE_COMPARATOR|3rd printed mandibular overdenture and a maxillary acrylic conventional complete denture|The denture base was fabricated by adding the material layer by layer
62188461|NCT02871583|NO_INTERVENTION|control|healthy volunteers
62188462|NCT01103232|EXPERIMENTAL|Electrical Muscle Stimulation|Electrical muscle stimulation of the right wrist flexor muscles was applied
62188463|NCT01103232|SHAM_COMPARATOR|Control|Transcutaneous electrical nerve stimulation was applied
62188464|NCT03447275||Controls|Apparently healthy subjects without type 2 diabetes
62188465|NCT03447275||Patients with type 2 diabetes|type 2 Diabetes since 5 years or longer
62188466|NCT05168098|EXPERIMENTAL|olfactory intervention group|
62188467|NCT05168098|ACTIVE_COMPARATOR|game comparison group|
62188468|NCT05168098|NO_INTERVENTION|control group|
62188469|NCT03385577|EXPERIMENTAL|Yoga Intervention|"The intervention, Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer, is a 10-week, manualized, group yoga program. Sessions are 60 minutes in duration, once a week, across the course of 10 weeks. The 10-week program is comprised of five modules, each of which will take two sessions to complete: (1) Getting Started, (2) Cultivating a Mindful Attitude, (3) Self-Care and Compassion, (4) Finding Peace and Acceptance, and (5) The Power of the Present Moment."
62188470|NCT00361036|EXPERIMENTAL|1|BeadBlock treatment arm
62188471|NCT00361036|ACTIVE_COMPARATOR|2|Embospheres control arm
62188472|NCT02991586|EXPERIMENTAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy (DBT) is a cognitive behavioral treatment that was originally developed to treat chronically suicidal individuals diagnosed with borderline personality disorder (BPD) and it is now recognized as the gold standard psychological treatment for this population. In addition, research has shown that it is effective in treating a wide range of other disorders such as substance dependence, depression, post-traumatic stress disorder (PTSD), and eating disorders. In this research DBT skills will be taught to parents of adolescents with high emotional instability
62188473|NCT02991586|NO_INTERVENTION|Control|"Control: The No intervention arm in this research is defined as follow:, sons and daughters are in their respective treatment but parents are nor receiving any DBT intervention"
62188474|NCT01775293|EXPERIMENTAL|Non-absorbable polypropylene mesh|"2 step procedures~* first step is insertion of Non-absorbable polypropylene mesh under the facial skin~* second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step"
62396150|NCT04159558|EXPERIMENTAL|experimental copd|The subjects with COPD will be trained in the use of the personalized help tool and will use it during a period of 3 months.
62396151|NCT04159558|EXPERIMENTAL|experimental asthma|The subjects with Asthma will be trained in the use of the personalized help tool and will use it during a period of 3 months.
62002914|NCT05581212|EXPERIMENTAL|Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack (Intervention phase)|"In the selected provinces, individuals (≥18 years) with newly detected bacteriologically confirmed pulmonary Tuberculosis (index TB case) will be sensitized on the importance of HH contact investigation for detection and prevention of TB and stigma reduction.~Index TB cases will be asked to enumerate all persons living in their HH for ≥1 month at the date of TB diagnostic (contact list), and provide their name/age/sex and relationship with the index case.~Screening will be offered to each HH contact, using screening invitation cards that will be provided to the index TB case, to be handed over to each HH contact (or caregiver for children \<13 years old).~Urban and Village Health Volunteers (U/VHV),will visit the HH to enhance awareness of the importance of screening for TB case-finding and prevention and facilitate liaison with the hospital.~If active tuberculosis has been formally excluded, they will be eligible to receive the Tuberculosis Preventive Treatment (TPT)."
62002915|NCT04497987|EXPERIMENTAL|Bamlanivimab (Part 1)|Participants received single Intravenous (IV) infusion of 4200 milligrams (mg) bamlanivimab.
62002916|NCT04497987|PLACEBO_COMPARATOR|Placebo (Part 1)|Participants received single IV infusion of Placebo.
62188475|NCT02306447|EXPERIMENTAL|rPMS and rTMS|"rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.~rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.~For stimulation we use MagPro X100 (Medtronic, Denmark)."
62188476|NCT02646735|EXPERIMENTAL|Fulvestrant|Fulvestrant 500 mg
62396152|NCT04159558|EXPERIMENTAL|experimental obesity|The subjects with Obesity will be trained in the use of the personalized help tool and will use it during a period of 3 months.
62571449|NCT06041854|EXPERIMENTAL|freeze-dried bone allograft combined with enamel matrix derivative|The intrabony defects will be treated by surgical treatment and the defects filled by freeze-dried bone allograft mixed with enamel matrix derivative.
62571450|NCT06041854|ACTIVE_COMPARATOR|freeze-dried bone allograft|The intrabony defects will be treated by surgical treatment and the defects filled by freeze-dried bone allograft.
62571451|NCT03259464|EXPERIMENTAL|BI 685509|Chinese \& Japanese subjects
62002917|NCT04497987|EXPERIMENTAL|Bamlanivimab (Part 2-Prevention)|Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
62002918|NCT04497987|EXPERIMENTAL|Bamlanivimab + Etesevimab (Part 2-Prevention)|Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
62002919|NCT04497987|PLACEBO_COMPARATOR|Placebo Comparator: Placebo (Part 2-Prevention)|Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
62002920|NCT04497987|EXPERIMENTAL|Bamlanivimab (Part 2 - Treatment)|Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
62002921|NCT04497987|EXPERIMENTAL|Bamlanivimab + Etesevimab (Part 2- Treatment)|Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
62002922|NCT04497987|EXPERIMENTAL|Bamlanivimab (Part 3)|"Part 3 of the study is exploratory, conducted to study exploratory objectives and is not reported in this record.~\[Participants received single IV infusion of 700 mg bamlanivimab.\]"
62002923|NCT04497987|EXPERIMENTAL|Bamlanivimab + Etesevimab (Part 3)|"Part 3 of the study is exploratory, conducted to study exploratory objectives and is not reported in this record.~\[Participants received single IV infusion of 700 mg bamlanivimab given with 1400 mg etesevimab.\]"
62188477|NCT02646735|ACTIVE_COMPARATOR|Exemestane|Exemestane 25mg
62396153|NCT01654666|EXPERIMENTAL|RIPC group|"Treatment:Patients in this group received standard medical therapy and remote ischemic preconditioning (RIPC) treatment.~Device:RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min,each patient in the RIPC group do it twice a day for at least two weeks before carotid artery stenting.~Procedure: Carotid Artery Stenting"
62396154|NCT01654666|ACTIVE_COMPARATOR|Control group|Treatment:Patients in this group received standard medical therapy alone. Procedure: Carotid Artery Stenting
61977846|NCT02902640||Acute Bronchitis Participants|Participants with acute bronchitis for whom the treating physician has decided to initiate treatment with Balsamic Bactrim, will be observed. Administration of Balsamic Bactrim will be according to physician's recommendation under local labeling. The study protocol does not enforce any treatment.
62188478|NCT02977286|EXPERIMENTAL|Naloxegol Oral Tablet|"Intervention: Naloxegol 25 mg (or 12.5 mg) tablet po (enteral) daily AND Docusate Sodium 100mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following:~1. Adverse event potentially attributable to the study drug.~2. Use of Relistor.~3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.~4. The participant has been administered 10 days of study medication.~5. The participant is discharged from the ICU.~6. The participant requires the initiation of a strong CYP3A4 inhibitor medication.~Other Name: Movantik"
62188479|NCT02977286|PLACEBO_COMPARATOR|Placebo Oral Tablet|"Intervention: Placebo tablet po (enteral) daily AND Docusate Sodium 100 mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following:~1. Adverse event potentially attributable to the study drug.~2. Use of Relistor.~3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.~4. The participant has been administered 10 days of study medication.~5. The participant is discharged from the ICU.~6. The participant requires the initiation of a strong CYP3A4 inhibitor medication.~Other Name: AstraZeneca provided Movantik placebo"
62188480|NCT02161406|ACTIVE_COMPARATOR|Abatacept|125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
62188481|NCT02161406|PLACEBO_COMPARATOR|Placebo|125mg Placebo
62002924|NCT03989297||NPC patients|Consecutive patients who were pathologically diagnosed with NPC and for whom fresh-frozen tissue samples were available were included.
62188482|NCT03630263|EXPERIMENTAL|Raw Corn Starch|Vehicle (apple sauce) will be spiked with 30 g of slowly digestible carbohydrate (raw corn starch)
62778407|NCT02036866|EXPERIMENTAL|Physical Therapy Positive Expectation|The physical therapist will read a script indicating that the intervention is an effective treatment for knee osteoarthritis and is expected to reduce pain and improve strength. Patients are then instructed on the home exercise program and how to operate the TENS (transcutaneous electrical nerve stimulation) unit. The duration of intervention is 1 week during which patients will wear then wear the TENS unit for 8 hours per day and perform no more than 3 sets of 10 repetitions of the physical therapy exercises daily.
62778408|NCT02036866|EXPERIMENTAL|Physical Therapy Neutral Expectation|The physical therapist will read a script indicating that the intervention may or may not be an effective treatment for knee osteoarthritis and may nor may not reduce pain and improve strength. Patients are then instructed on the home exercise program and how to operate the TENS unit. The duration of intervention is 1 week during which patients will wear then wear the TENS unit for 8 hours per day and perform no more than 3 sets of 10 repetitions of the physical therapy exercises daily.
62778409|NCT02036866|EXPERIMENTAL|Control- No Intervention|The patients in the control group will be reminded of their appointment in 1 week and instructed to maintain their usual activity level during that time.
62188483|NCT03630263|PLACEBO_COMPARATOR|No Raw Corn Starch|Vehicle (apple sauce) will not be spiked with 30 g of slowly digestible carbohydrate (raw corn starch)
62188484|NCT00511498|PLACEBO_COMPARATOR|Placebo Arm|Placebo nightly
62188485|NCT00511498|ACTIVE_COMPARATOR|Drug|Sildenafil 50mg nightly
62188486|NCT02516865|EXPERIMENTAL|Group 1|
62188487|NCT02516865|EXPERIMENTAL|Group 2|
62188488|NCT02516865|NO_INTERVENTION|Group 3|
62188489|NCT00684203|EXPERIMENTAL|Vorapaxar 20 mg/1 mg|Vorapaxar 20 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
62571452|NCT03259464|PLACEBO_COMPARATOR|Placebo|Chinese \& Japanese subjects
62571453|NCT06292741|EXPERIMENTAL|cognitive decline|comparison of autonomic parameters among subjects with different forms of cognitive decline
62778410|NCT05735249|EXPERIMENTAL|ARN-75039|Escalating single or multiple doses of ARN-75039 oral capsules
62778411|NCT05735249|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules in a same SAD and MAD dosing regimen as ARN-75039
62778412|NCT02253784|ACTIVE_COMPARATOR|Group I (ISB-P)|Four nerve blocks with perineural injection of dexamethasone 0.1 mg/kg and bupivacaine 0.5% - 45 ml
62778413|NCT02253784|ACTIVE_COMPARATOR|Group II (ISB-S)|Four nerve blocks with systemic injection of dexamethasone 0.1 mg/kg and bupivacaine 0.5% - 45 ml
62778414|NCT02253784|ACTIVE_COMPARATOR|Group III (ISB-C)|Four nerve blocks without dexamethasone
62778415|NCT03002714|EXPERIMENTAL|Exercise|Performance of two resistance exercise sessions
62778416|NCT03137498|EXPERIMENTAL|Lidocaine|Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes (active experimental) and normal saline 1ml intravenous push injection (placebo)
62002925|NCT05857605|ACTIVE_COMPARATOR|Standard Physical Therapy exercise instructions for Knee Osteoarthritis|"Participants enrolled in the control group will be provided standard physical therapy exercise instruction based on Arthritis Foundation guidelines for physical activity specific to individuals with knee osteoarthritis. During their first visit, the participants will meet the trained research staff to trial a series of therapeutic exercises for medial knee OA. They will be provided a handout with pictures of these exercises after they have demonstrated the ability to complete them at the initial visit. The participants will then complete this program on their own for 8 weeks; performing the exercises 3 times per week.~Apart from these home-based exercise sessions participants in this group will complete 3 separate evaluation sessions onsite at the beginning, interim, and end of the study where they will complete a series of functional tests and fill standard questionnaires evaluating their pain, symptoms and knee function followed by thigh muscle strength testing."
62002926|NCT05857605|EXPERIMENTAL|Standard Physical Therapy exercise instructions for Knee Osteoarthritis + seated elliptical device|"Participants in the intervention group will be provided physical therapy (PT) exercise instruction based on Arthritis Foundation guidelines for physical activity specific to individuals with knee OA. Participants will be provided a handout with pictures of these exercises after they have demonstrated the ability to complete them at the initial visit. They will then complete this program on their own for 8 weeks; performing the exercises 3 times per week. This group will also receive a compact seated elliptical device which they will be expected to use for a min of 30 min for 5 days per week in conjunction with PT exercise instruction.~Apart from these exercise sessions participants in this group will complete 3 separate evaluation sessions on-site at the beginning, interim, and end of the study where they will complete a series of functional tests and fill standard questionnaires evaluating their pain, symptoms, and knee function followed by thigh muscle strength testing."
62002927|NCT00333606|EXPERIMENTAL|Verum acupuncture|Acupuncture of specific acupuncture points
62002928|NCT00333606|SHAM_COMPARATOR|Sham acupuncture|Acupuncture of non-specific acupuncture points
62002929|NCT06091553|ACTIVE_COMPARATOR|Duloxetine alone (as monotherapy)|Duloxetine alone (as monotherapy)
62778417|NCT03137498|ACTIVE_COMPARATOR|Ketorolac|Ketorolac 30mg (1ml) intravenous push injection (active intervention) and Normal saline 50ml IVPB over 10 minutes (placebo)
62778418|NCT01289366||Patients with IBD|
62778419|NCT03541902|EXPERIMENTAL|Group 1 (cabozantinib)|Participants receive cabozantinib PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62778420|NCT03541902|EXPERIMENTAL|Group 2 (sunitinib malate)|Participants receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62778421|NCT02961946|ACTIVE_COMPARATOR|Sublingual Nitroglycerin spray|Sublingual Nitroglycerin spray of 0.8 mg
62778422|NCT02961946|ACTIVE_COMPARATOR|Sublingual Nitroglycerin tablet|Sublingual Nitroglycerin tablet of 0.8 mg
62778423|NCT02961946|ACTIVE_COMPARATOR|Nitroglycerin skin patch|Nitroglycerin skin patch of 0.8 mg/h
62778424|NCT04382378|NO_INTERVENTION|control group|Group that will receive a standard care from physiotherapy staff not involved in delivering the intervention whenever feasible.
62188490|NCT00684203|EXPERIMENTAL|Vorapaxar 20 mg/2.5 mg|Vorapaxar 20 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
62188491|NCT00684203|EXPERIMENTAL|Vorapaxar 40 mg/1 mg|Vorapaxar 40 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
62188492|NCT00684203|EXPERIMENTAL|Vorapaxar 40 mg/2.5 mg|Vorapaxar 40 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
62571454|NCT02283268|EXPERIMENTAL|Recombinant von Willebrand Factor (rVWF)|Surgery participants treated with Recombinant von Willebrand Factor (rVWF)
62778425|NCT04382378|EXPERIMENTAL|50 electrically evoked contractions|Group that will receive a standard care from physiotherapy staff plus neuromuscular electrical stimulation with the following parameters: pulsed current; freqeuncy 50Hz; pulse witdh 400 us, current intensity that get level 4/5 of evoked contractions proposed by Segers et al; on/off time and duration of therapy that allow 50 ellectrically evoked contractions with surface electrodes positioned on the quadriceps femoris.
62778426|NCT04382378|EXPERIMENTAL|100 electrically evoked contractions|Group that will receive a standard care from physiotherapy staff plus neuromuscular electrical stimulation with the following parameters: pulsed current; freqeuncy 50Hz; pulse witdh 400 us, current intensity that get level 4/5 of evoked contractions proposed by Segers et al; on/off time and duration of therapy that allow 100 ellectrically evoked contractions with surface electrodes positioned on the quadriceps femoris.
62778427|NCT04215874||Dorsal penile nerve block group|"Ultrasound (US) guided dorsal penile nerve block with in plane technique was done.~Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis."
62002930|NCT06091553|ACTIVE_COMPARATOR|Duloxetine augmented with gabapentin (as combined therapy)|Duloxetine augmented with gabapentin (as combined therapy)
62002931|NCT06091553|ACTIVE_COMPARATOR|Duloxetine augmented with amitriptyline (as combined therapy)|Duloxetine augmented with amitriptyline (as combined therapy)
62002932|NCT06091553|NO_INTERVENTION|control|control
62188493|NCT00684203|PLACEBO_COMPARATOR|Placebo|Placebo loading dose + daily placebo maintenance dose + standard of care (Aspirin + Ticlopidine)
62188494|NCT04561778|ACTIVE_COMPARATOR|HOT-CRT|Subjects randomized to HOT-CRT will undergo CRT as described below. His bundle pacing lead will be placed initially to achieve CRT. If complete resynchronization is achieved (BBB normalization) but capture thresholds are high (1.5-2V), the lead may be placed in the distal conduction system (left bundle branch area). If only partial QRS narrowing is achieved, a coronary sinus lead may be placed and LV timing may be optimized to achieve maximal resynchronization. This will be at the discretion of the implanting physician. Only FDA approved leads and devices will be used.
62188495|NCT04561778|ACTIVE_COMPARATOR|Biventricular Pacing|Subjects randomized to biventricular pacing will undergo left ventricular lead placement in the coronary sinus venous branches.Only FDA approved leads and devices will be used.
62571455|NCT03324620|EXPERIMENTAL|pre active HSCT|"Candidates for transplantation of hematopoietic progenitors since May 12, 2012, regardless of sex and age, who agree to participate in the study and sign informed consent.~In the pre-transplantation visit with the physiotherapist: Measures of muscle mass and strength, quality of life questionnaires, program presentation, fitness assessment and lifestyle determination. The exercises will be personalized, stimulating your practice before admission and involving the family. During admission, the team will encourage the patient to remain active by adapting to the symptoms. At discharge, measures of resistance, exercise tolerance and quality of life at discharge, in the month after discharge, 3 months after discharge, 6 months after discharge and 12 months after discharge."
62778428|NCT04215874||Caudal epidural block group|A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed 0.25% bupivacaine at a dose of 0.2 ml/kg was administered.
62188496|NCT05827770|EXPERIMENTAL|Toripalimab Combined With Temozolomide|Toripalimab Combined With Temozolomide
62396155|NCT01654666|SHAM_COMPARATOR|Sham RIPC group|"Treatment:Patients in this group received standard medical therapy and sham remote ischemic preconditioning treatment.~Device:Sham RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min, each patient in RIPC group do it twice a day for at least two weeks before carotid artery stenting.~Procedure: Carotid Artery Stenting"
62396156|NCT05766410|EXPERIMENTAL|Palbociclib/Letrozole|CDK4, 6 inhibitor and endocrine therapy
62396157|NCT05766410|ACTIVE_COMPARATOR|Ribociclib/Letrozole|CDK4, 6 inhibitor and endocrine therapy
62396158|NCT05766410|ACTIVE_COMPARATOR|Abemaciclib/Letrozole|CDK4, 6 inhibitor and endocrine therapy
62396159|NCT05571397|EXPERIMENTAL|Dexcom CGM|Dexcom G6
62571456|NCT03324620|NO_INTERVENTION|control group|"Patients' candidates for transplantation of hematopoietic progenitors prior to May 12, 2012, regardless of gender and age, who meet the inclusion criteria and are collected correlatively until completing 104 subjects.~Clinical history review to calculate the days of hospitalization in the different hospitalization units during the transplant. As well as the number and type of complications and the use of health resources. Status vitae. Baseline review of functional tests and exercise tolerance."
62396160|NCT05571397|NO_INTERVENTION|Historical Controls|Matched historical controls
62778429|NCT01729208|EXPERIMENTAL|Dual Focus Soft Contact Lens|Dual Focus Soft Contact Lens
62778430|NCT01729208|PLACEBO_COMPARATOR|Single Vision Soft Contact Lens|Single Vision Soft Contact Lens
62778431|NCT02252965|ACTIVE_COMPARATOR|Metformin IR|
62396161|NCT04369911|EXPERIMENTAL|Low Dose|Acupuncture treatment once per week for 5 weeks. Five total acupuncture treatments completed.
62396162|NCT04369911|EXPERIMENTAL|High Dose|Acupuncture treatment twice per week for 5 weeks. Ten total acupuncture treatments completed.
61977847|NCT04946539||Spondyloarthritis|
62188497|NCT04147195|EXPERIMENTAL|LYS006|LYS006 20 mg was administered orally twice per day (b.i.d) for 12 weeks
62396163|NCT03759340|EXPERIMENTAL|ATI 502 0.46% Topical Solution|Subjects will apply ATI-502 Topical Solution, 0.46% twice-daily for 24 weeks followed by a 4-week post-treatment follow up period.
62396164|NCT05056948||Control|Original 3D maxillary teeth model from subjects who fulfill inclusion/exclusion criteria
62396165|NCT05056948||Test|"3D maxillary teeth model from subjects who fulfill inclusion/exclusion criteria.~The right first molar (FDI number 16) will be removed in the computer and then designed by artificial intelligence (AI) system~AI system will be trained by~1. different algorithms such as Group 1) Voxel-based; Group 2) View-based; Group 3) Point-based; and Group 4) Fusion methods~2. Group i) maxillary model only and Group ii) with antagonist model"
62778432|NCT02252965|EXPERIMENTAL|Metformin XR|
62778433|NCT03695822|EXPERIMENTAL|Mirabegron|OAB female patients who will receive beta-3 agonist (mirabegron 2 mg) treatment
62188498|NCT04147195|EXPERIMENTAL|LYS006 + LJN452|LYS006 20 mg was administered orally twice per day (b.i.d) in addition to LJN452 200ug administered orally once daily for 12 weeks
62188499|NCT01630005|EXPERIMENTAL|Talk therapy|A cohort of 25 patients
62188500|NCT01154062|EXPERIMENTAL|low dose|Pazopanib tablet
62188501|NCT00927498|ACTIVE_COMPARATOR|Arm A Daunorubicin and Cytarabine|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4."
62778434|NCT03037983|ACTIVE_COMPARATOR|Active rTMS|Subjects will receive actual rTMS treatment.
62188502|NCT00927498|EXPERIMENTAL|Arm B Daunorubicin and Cytarabine and Mylotarg|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1."
62188503|NCT05692219|EXPERIMENTAL|Lifestyle medicine|The booklet-delivered multicomponent lifestyle medicine intervention includes six weekly sessions (i.e., participants are anticipated to access the intervention every day for 42 days) that are related to the following topics: (a) lifestyle psychoeducation, (b) exercise, (c) nutritional recommendations, (d) stress management, (e) sleep management, and (f) motivation and goal-setting techniques.
62002933|NCT05556122|EXPERIMENTAL|intercostal nerve block at the incision|General anesthesia and intercostal nerve block were performed.The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
62188504|NCT05692219|ACTIVE_COMPARATOR|Cognitive behavioural therapy|The booklet-delivered self-help CBT includes six weekly sessions (i.e., participants are anticipated to access the intervention every day for 42 days) that are related to psychoeducation of depression, cognitive behavioural techniques( e.g. behavioral activation, cognitive restructuring), stress management, mindfulness, goal-setting, and/or positive psychology.
62188505|NCT05692219|NO_INTERVENTION|Waitlist control|Participants in the waitlist control group will be asked to maintain their typical activities during the trial period, and they will be given the lifestyle medicine booklet or CBT booklet based on their preference following the completion of the 3-month follow-up assessment (Week 19).
62188506|NCT04158271|EXPERIMENTAL|Prone Position|Evaluation of Techniques for tracheal tube Exchange in prone position
62188507|NCT04158271|EXPERIMENTAL|Laryngeal tube|Evaluation of Techniques for tracheal tube Exchange in patients with laryngeal tube (LT)
62778435|NCT03037983|SHAM_COMPARATOR|Sham rTMS|Subjects will attend and sit through the session, but no rTMS treatment will be actually delivered to them.
62778436|NCT05607862|EXPERIMENTAL|Intervention Group|The intervention group will continue with its usual medical-pharmacological treatment, and will also receive a multi-component exercise program and health education guidelines.
62778437|NCT05607862|OTHER|Control Group|The control group will be given health education guidelines and will continue with their usual medical-pharmacological treatment.
62778438|NCT01706783|EXPERIMENTAL|NNC0195-0092 (somapacitan)|
62778439|NCT01706783|ACTIVE_COMPARATOR|Norditropin NordiFlex®|
62002934|NCT05556122|ACTIVE_COMPARATOR|lateral intercostal nerve block at costal angle|General anesthesia and intercostal nerve block were performed.The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
62002935|NCT05492058|EXPERIMENTAL|maternal touch|maternal touch
62002936|NCT05492058|EXPERIMENTAL|music group|music group
62002937|NCT05492058|EXPERIMENTAL|virtual reality group|virtual reality group
62002938|NCT05492058|NO_INTERVENTION|control|
62188508|NCT04158271|EXPERIMENTAL|Endotracheal tube Leackage|Evaluation of Techniques for tracheal tube Exchange in critical care patients with a endotracheal tube and a high leackage
62188509|NCT02671214|PLACEBO_COMPARATOR|Control|100 g high fibre flour
62188510|NCT02671214|ACTIVE_COMPARATOR|Active 1|85 g high fibre flour + 15 g legume flour
62188511|NCT02671214|ACTIVE_COMPARATOR|Active 2|98 g high fibre flour + 2 g guar gum
62778440|NCT05462418|ACTIVE_COMPARATOR|diathermy group|Patients' incisions are completed using the unipolar diathermy from Whiteline until we reach the parietal peritoneum (cutting the Whiteline then coagulating until reaching the peritoneum). The used diathermy frequency was 50-70 MHz.
62778441|NCT05462418|ACTIVE_COMPARATOR|scalpel|patients had their incisions completed using the surgical scalpel till we reach the parietal peritoneum.
62778442|NCT01979133|EXPERIMENTAL|icariin|Icariin will be given 100 mg/day. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 for participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
62188512|NCT02671214|ACTIVE_COMPARATOR|Active 3|88 g high fibre flour + 2 g guar gum + 10 g legume flour
62188513|NCT02671214|ACTIVE_COMPARATOR|Active 4|83 g high fibre flour + 2 g guar gum + 15 g legume flour
62188514|NCT02671214|ACTIVE_COMPARATOR|Active 5|96 g high fibre flour + 4 g guar gum
62188515|NCT02671214|ACTIVE_COMPARATOR|Active 6|86 g high fibre flour + 4 g guar gum + 10 g legume flour
62188516|NCT02671214|ACTIVE_COMPARATOR|Active 7|81 g high fibre flour + 4 g guar gum + 15 g legume flour
62188517|NCT02671214|ACTIVE_COMPARATOR|Active 8|94 g high fibre flour + 6 g guar gum
62188518|NCT02671214|ACTIVE_COMPARATOR|Active 9|98 g high fibre flour + 2 g konjac mannan
62188519|NCT02671214|ACTIVE_COMPARATOR|Active 10|96 g high fibre flour + 4 g konjac mannan
62188520|NCT02671214|ACTIVE_COMPARATOR|Active 11|100 g low fibre flour
62188521|NCT00734045||1|Subjects with diagnosed congestive heart failure
62188522|NCT00734045||2|Subjects not diagnosed with congestive heart failure
62188523|NCT02056002|ACTIVE_COMPARATOR|Usual Care|"* Standard CPAP educational training~* Educational Brochures~* Educational DVD videos mailed to participant"
62188524|NCT02056002|EXPERIMENTAL|Peer-Buddy System|"* Two 30-minute in person sessions with Peer Buddy~* Standard CPAP training~* Eight phone conversations with Peer Buddy over 3 months~* Subsequent 3 months use of phone system to contact Peer Buddy as needed~One Month Visit:~-Home visit to collect CPAP information~Three Month Visit:~* Questionnaires~* Psycho Motor Vigilance Test (PVT) Video Game~* Collect CPAP information~* Measure weight~* Measure blood pressure~Six Month Visit:~* Questionnaires~* PVT (Video game)~* Collect CPAP information~* Measure Weight~* Measure Blood Pressure~* Evaluate the program and Peer Buddy"
62002939|NCT03992807|EXPERIMENTAL|A patient decision aid|A patient decision aid that includes not only the standard general information, but also the quantitative risk information on the possible outcomes of cataract surgery as well as value clarification exercise.
62188525|NCT04016805|EXPERIMENTAL|ublituximab + umbralisib + ibrutinib|Participants were administered with ublituximab, 900 milligrams (mg), intravenous (IV) infusion once every cycle through cycle 6, then every three cycles upto 24 cycles; umbralisib, 800 mg, oral tablet, daily through Cycles 1-24; ibrutinib oral tablet daily (1 Cycle = 28 days).
62396166|NCT04668157|EXPERIMENTAL|TAK-536|TAK-536 granule formulation, orally once daily before or after breakfast. The initial dose of TAK-536 will be 0.1 mg/kg (not exceeding 2.5 mg/day). After the initial dose, TAK-536 will be titrated to 0.2 mg/kg (not exceeding 5 mg/day), 0.4 mg/kg (not exceeding 10 mg/day), and 0.8 mg/kg (not exceeding 20 mg/day) if the subjects do not achieve the target blood pressure and no concerns are found in safety and tolerability.
62002940|NCT03992807|ACTIVE_COMPARATOR|A usual education booklet|A traditional booklet with standard general information developed by the National Eye Institute (NEI) to help patients understand cataract.
62002941|NCT02386111|EXPERIMENTAL|Varlilumab and Sunitinib|
62002942|NCT05614245|EXPERIMENTAL|Group G1, Subgroup G1-A|10 participants aged 18-40 years to receive one dose of VBI-2901e at 5 µg spike protein and 1 µg E6020 per dose at Day 1
62188526|NCT04016805|EXPERIMENTAL|ublituximab + umbralisib + venetoclax|Participants were administered with ublituximab, 900 milligrams (mg), intravenous (IV) infusion once every cycle through cycle 6, then every three cycles upto 24 cycles; umbralisib, 800 mg, oral tablet, daily through Cycles 1-24; venetoclax oral tablet daily (1 Cycle = 28 days).
62188527|NCT04016805|EXPERIMENTAL|ublituximab + umbralisib + acalabrutinib|Participants were administered with ublituximab, 900 milligrams (mg), intravenous (IV) infusion once every cycle through cycle 6, then every three cycles upto 24 cycles; umbralisib, 800 mg, oral tablet, daily through Cycles 1-24; acalabrutinib oral capsule every 12 hours (1 Cycle = 28 days).
62778443|NCT04548518|ACTIVE_COMPARATOR|GPO Tri Fluvac vaccine|408 participants will receive a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020 (consisting of A/Brisbane/02/2018 (H1N1)pdm-09-like virus, A/South Australia/34/2019 (H3N2)-like virus, and B/Washington/02/2019-like (B/Victoria lineage) virus) produced by the Government Pharmaceutical Organization (GPO), Thailand. The vaccine to be administered by intramuscular (IM) injection.
62002943|NCT05614245|EXPERIMENTAL|Group G1, Subgroup G1-B|10 participants aged 18-40 years to receive two doses of VBI-901e at 5 µg spike protein and 1 µg E6020 per dose at Day 1 and Day 28
62002944|NCT05614245|EXPERIMENTAL|Group G2, Subgroup G2-A|10 participants aged 18-40 years to receive one dose of VBI-2901e at 5 µg spike protein and 3 µg E6020 per dose at Day 1
62002945|NCT05614245|EXPERIMENTAL|Group G2, Subgroup G2-B|10 participants aged 18-40 years to receive two doses of VBI-901e at 5 µg spike protein and 3 µg E6020 per dose at Day 1 and Day 28
62188528|NCT06484374|SHAM_COMPARATOR|Craniotomy|Traditional craniotomy, by opening the skull and thus removing the hematoma
62188529|NCT06484374|EXPERIMENTAL|Robot-assisted minimally invasive treatment|Minimally invasive hematoma removal with robotic assistance
62188530|NCT04776902|OTHER|Study Group|All patients will be enrolled in one arm
62188531|NCT04962373||Adolescents|Adolescents with a contract for Brief admission by self-referral
62188532|NCT04962373||Parents|Parents to adolescents with a contract for Brief admission by self-referral
62188533|NCT04962373||Staff|Health care providers who work with adolescents with a contract for Brief admission by self-referral
62188534|NCT01876147||Order of vision tests 1|Undergo testing with BRVT first, FrACT second.
62188535|NCT01876147||Order of vision tests 2|Undergo testing with FrACT first, BRVT second.
62188536|NCT05747612|OTHER|Patients with Bipolar Disorder|
62396167|NCT01629238||group 1|group 1 = consumers of marketed drinkable low fat fermented milk enriched with plant sterol
62188537|NCT06195462|SHAM_COMPARATOR|Laying on of hands with healing intent (LHHI)|The non-healers volunteers will move their hands in a longitudinal direction, starting at the top of the patient's head, slowly lowering their hands along the body, 5 times and asked to send thoughts of health and healing to the participant. Then, they will place their hands on the patient's head, distance about 10 to 15 cm, during 5 minutes. Weekly sessions.
62188538|NCT06195462|EXPERIMENTAL|"Laying on of hands by spiritist passe"|The healers will prepare before the start with prayer for connection with Good Spirits. Volunteers will move their hands in a longitudinal direction, starting at the top of the patient's head, slowly lowering their hands along the body, 5 times and asked to send thoughts of health and healing to the participant. Then, they will place their hands on the patient's head, distance about 10 to 15 cm, during 5 minutes. Weekly sessions.
62002946|NCT05614245|EXPERIMENTAL|Group G3, Subgroup G3-A|10 participants aged 18-40 years to receive one dose of VBI-2901e at 5 µg spike protein and 10 µg E6020 per dose at Day 1
62002947|NCT05614245|EXPERIMENTAL|Group G3, Subgroup G3-B|10 participants aged 18-40 years to receive two doses of VBI-901e at 5 µg spike protein and 10 µg E6020 per dose at Day 1 and Day 28
62188539|NCT06195462|OTHER|Without laying on of hands|The participants will not receive the laying on of hands. A volunteer will stand next to the patient with hands behind them and will mentally repeat the alphabet or do math for 5 minutes. Weekly sessions.
62188540|NCT01569009||Observational|Patients are asked to continue with their normal daily activities.
62188541|NCT02271230|EXPERIMENTAL|Vitamin D and fish oil|2000 IU per day and 1 g per day of fish oil
62778444|NCT04548518|ACTIVE_COMPARATOR|Licensed Influenza vaccine|408 will receive a Licensed Influenza vaccine (seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020 (consisting of A/Brisbane/02/2018 (H1N1) pdm-09-like virus, A/South Australia/34/2019 (H3N2)-like virus, and B/Washington/02/2019-like (B/Victoria lineage) virus) 0.5 mL administered intramuscularly (IM) in the deltoid muscle of the non-dominant arm.
62188542|NCT02271230|PLACEBO_COMPARATOR|Vitamin D alone|2000 IU Vitamin D and fish oil placebo
62188543|NCT02271230|EXPERIMENTAL|Fish oil (EPA/DHA) alone|1 g per day of fish oil and vitamin D placebo
62396168|NCT01629238||group 2|group 2 = non-consumers of marketed drinkable low fat fermented milk enriched with plant sterol
62778445|NCT06300268|OTHER|Interventional|AdvaPro Sirolimus Eluting Coronary Stent System
62778446|NCT05708339|ACTIVE_COMPARATOR|conventionally fabricated ear prosthesis|
62778447|NCT05708339|EXPERIMENTAL|virtually fabricated ear prosthesis|
62002948|NCT03561974|EXPERIMENTAL|Humidification|
62002949|NCT03561974|NO_INTERVENTION|Control group without humidification|
62002950|NCT03410979|EXPERIMENTAL|GLPG2737 single dose|Single doses of GLPG2737 oral suspension at up to 5 dose levels in ascending order
62002951|NCT03410979|PLACEBO_COMPARATOR|Placebo single dose|Single doses of Placebo oral suspension
62002952|NCT03410979|EXPERIMENTAL|GLP2737 multiple dose|Multiple doses of GLPG2737 oral suspension at up to 3 dose levels in ascending order
62002953|NCT03410979|PLACEBO_COMPARATOR|GLPG2737 multiple dose|Multiple doses of Placebo oral suspension
62002954|NCT05716035|EXPERIMENTAL|tocilizumab|Participants will receive tocilizumab 8mg/Kg administered intravenously (IV) on weeks 1,5,9 and 13 of the open-lable period.
62188544|NCT02271230|PLACEBO_COMPARATOR|Fish oil and vitamin D placebo|Placebo for both vitamin D and fish oil
62396169|NCT04784208||Arm 1-Healthy Volunteers|"Arm 1: Subjects from the general population who are naïve to their hypothyroid status.~The Subjects will be randomly selected and will be equally stratified between genders and socio-economics statuses from places where groups of general populations are located"
62778448|NCT04739579||Anastomotic Leak|
62778449|NCT04739579||Non-Anatomotic Leak|
62188545|NCT00459797|ACTIVE_COMPARATOR|Conventional Glidescope|
62778450|NCT02650102|EXPERIMENTAL|antipsychotics|This group was treated with one of 5 antipsychotics(risperidone/olanzapine/aripiprazole/quetiapine/ziprasidone) randomly.
62778451|NCT02650102|NO_INTERVENTION|health control|This group was treated with no invention
62778452|NCT04877977||Healthy Volunteers|Individuals who previously signed consent for ETPB research as healthy volunteers
62188546|NCT00459797|EXPERIMENTAL|Single-use Glidescope|
62778453|NCT04877977||Mood Disorder Patients|Individuals with mood disorders who previously signed consent for ETPB research
62778454|NCT03121703|EXPERIMENTAL|lumbar stabilization exercises group|diverse lumbar stabilization exercises
62778455|NCT03121703|OTHER|trunk muscle strengthening exercise|trunk muscle strengthening exercise
62778456|NCT00306709|EXPERIMENTAL|Teaching|
62778457|NCT00524615|ACTIVE_COMPARATOR|1|25 mg of Spironolactone oraly once daily
62778458|NCT00524615|PLACEBO_COMPARATOR|2|placebo oraly once daily
62778459|NCT04078984||Experimental|Experimental group is composed by patients that enter the weaning phase following a moderate to severe Acute Respiratory Distress Syndrome (ARDS) equiped with a nasogastric allowing measures of Electrical Activity of diaphragm (EAdi) will be included. Driving Pressure will be measured following the method used by Bellani et al. A weaning test will be conducted daily.
62778460|NCT02921087|OTHER|Test followed by control|Subjects will be randomized in a 1:1 ratio based on a randomization schedule according to sequentially assigned subject numbers to the test daily disposable soft contact lenses at the first visit. Subjects will crossover to the control daily disposable soft contact lenses at the second visit.
62778461|NCT02921087|OTHER|Control followed by test|Subjects will be randomized in a 1:1 ratio based on a randomization schedule according to sequentially assigned subject numbers to the control daily disposable soft contact lenses at the first visit. Subjects will crossover to the test daily disposable soft contact lenses at the second visit.
62188547|NCT03128671|EXPERIMENTAL|FAVoR Intervention Group|In the intervention group, scripted audio messages recorded by the patient's family (FAVoR intervention) will be played for the patient at hourly intervals during daytime hours. These messages will be personalized, delivered automatically, and provide information about the ICU environment. The FAVoR intervention, a standardized protocol developed and tested in preliminary work, will be delivered by audio recording for 5 consecutive days (120 hours), or until ICU discharge if discharge occurs within the first 5 days. The number of episodes of delirium during ICU stay is the primary outcome measure. Data will also be collected at 1 month and 6 months following hospital discharge for secondary aim 3.
62188548|NCT03128671|NO_INTERVENTION|Control Group|The control group will not receive the FAVoR intervention. The number of episodes of delirium during ICU stay is the primary outcome measure. Data will also be collected at 1 month and 6 months following hospital discharge for secondary aim 3.
62188549|NCT04806594|EXPERIMENTAL|Papix acne scar|Papix acne scar gel for 8 consecutive weeks, 2 times per day
62778462|NCT02211313|ACTIVE_COMPARATOR|Ureteral stent - soft, 6 French|Subjects randomized to soft stent, size 6 French
62778463|NCT02211313|ACTIVE_COMPARATOR|Ureteral stent - hydrophobic, 6 French|Subjects randomized to hydrophobic stent, size 6 French
62778464|NCT03369236|ACTIVE_COMPARATOR|Danicopan (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period)|"Danicopan was administered at a starting dose of 100 milligrams (mg) 3 times daily (TID) for the first 2 weeks, then dosage was to be increased to 200 mg TID for the remainder of the 6-month treatment period.~All participants who completed the double-blind treatment period were enrolled in the open-label extension period and were to receive danicopan 200 mg TID."
62778465|NCT03369236|PLACEBO_COMPARATOR|Placebo (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period)|"Placebo was administered TID during the 6-month treatment period.~All participants who completed the double-blind treatment period were enrolled in the open-label extension period and were to receive danicopan 200 mg TID."
62778466|NCT01545440|EXPERIMENTAL|lebrikizumab - highest dose|
62778467|NCT01545440|EXPERIMENTAL|lebrikizumab - lowest dose|
62778468|NCT01545440|EXPERIMENTAL|lebrikizumab - middle dose|
62778469|NCT01545440|PLACEBO_COMPARATOR|placebo|
62778470|NCT05768815|EXPERIMENTAL|Breaking the Cycle Intervention group|
62778471|NCT05768815|ACTIVE_COMPARATOR|Maxxine Wright Intervention group|
62778472|NCT01408342|OTHER|Rituximab, Alemtuzumab|
62778473|NCT03267914|EXPERIMENTAL|Tray group|Control intervention Patients will use the custom-made tray to apply the fluoride locally to the teeth and wear for 5 minutes each day.
62778474|NCT03267914|ACTIVE_COMPARATOR|Brush group|Patients will brush with the fluoride for 2 minutes each day.
62778475|NCT00562146||1|Successful progression of spiral tube to duodenum within 3 days
62778476|NCT00562146||2|Failure of progression to duodenum within 3 days
62778477|NCT01091818|ACTIVE_COMPARATOR|midazolam|
62778478|NCT01091818|EXPERIMENTAL|dexmedetomidin|
62778479|NCT03048877|EXPERIMENTAL|Apatinib|Apatinib Mesylate Tablets
62778480|NCT03048877|PLACEBO_COMPARATOR|Placebo|Placebo Tablets
62188550|NCT03616964|EXPERIMENTAL|2 milligram (mg) Baricitinib|Participants received one 2 mg baricitinib tablet and one placebo tablet matching 4 mg baricitinib administered orally once daily (QD) for 52 weeks.
62188551|NCT03616964|EXPERIMENTAL|4 mg Baricitinib|Participants received one 4 mg baricitinib tablet and one placebo tablet matching 2 mg baricitinib administered orally QD for 52 weeks.
62188552|NCT03616964|PLACEBO_COMPARATOR|Placebo|Participants received 2 placebo tablets: one placebo tablet matching 4 mg baricitinib and one placebo tablet matching 2 mg baricitinib administered orally QD for 52 weeks.
62778481|NCT04374955|EXPERIMENTAL|İnfantile colic|Mothers of babies diagnosed with infantile colic in the intervention group will receive routine care and start taking probiotic products after the first stool of the babies and blood is taken for intestinal permeability and will continue for 15 days.
62778482|NCT04374955|OTHER|Control|Mothers of babies diagnosed with infantile colic in the control group will receive routine care for 15 days after blood is taken for the first stool and intestinal permeability of the babies.
62778483|NCT06577415|EXPERIMENTAL|Mild Hepatic Impairment|Participants with mild hepatic impairment received single subcutaneous dose of 3 milligrams (mg) RAY1225.
62778484|NCT06577415|EXPERIMENTAL|Moderate Hepatic Impairment|Participants with moderate hepatic impairment received single subcutaneous dose of 3 mg RAY1225.
62778485|NCT06577415|ACTIVE_COMPARATOR|Normal Hepatic Function|Participants with normal hepatic function received single subcutaneous dose of 3 mg RAY1225.
62002955|NCT03897972|ACTIVE_COMPARATOR|Non-personalised general diet advice|Control group to receive non-personalised dietary advice based on general public health dietary recommendations for Northern Europe. Advice will be delivered to the participant via the eNutri web application.
62002956|NCT03897972|EXPERIMENTAL|Personalised diet advice|Intervention group to receive personalised dietary advice generated by the eNutri app from their actual dietary intakes and tailored according to their body mass index and food preferences. Advice will be delivered to the participant via the eNutri app web application and will be generated based on their adherence to an 11-item diet quality score suitable for Northern European populations.
62002957|NCT03632291|EXPERIMENTAL|UB-221 (0.2 mg/kg)|Intravenous infusion
62002958|NCT03632291|EXPERIMENTAL|UB-221 (0.6 mg/kg)|Intravenous infusion
62002959|NCT03632291|EXPERIMENTAL|UB-221 (2 mg/kg)|Intravenous infusion
62002960|NCT03632291|EXPERIMENTAL|UB-221 (6 mg/kg)|Intravenous infusion
62002961|NCT03632291|EXPERIMENTAL|UB-221 (10 mg/kg)|Intravenous infusion
62002962|NCT01831310|ACTIVE_COMPARATOR|Control (standard) (Kabiven)|an isocaloric and iso-nitrogenous standard parenteral nutrition (Kabiven)
62002963|NCT01831310|EXPERIMENTAL|Standard parenteral-glutamine (S-D)|alanine-glutamine (aln-gln) (Dipeptiven) supplemented parenteral nutrition (S-D group, n=8),
62002964|NCT01831310|EXPERIMENTAL|Standard-Omega-3 fatty acid (S-O)|Omega-3 fatty acid (Omegaven) supplemented parenteral nutrition (S-O group, n=8)
62002965|NCT01831310|EXPERIMENTAL|Standard-glutamine-omega 3 (S-D-O)|ala-gln and omega 3 fatty ascid supplemented parenteral nutrition (S-D-O group, n=10).
62002966|NCT06192225|EXPERIMENTAL|Slow PACE arm|The intervention consists of performance of pre-trained guided Slow PACE breathing by the patient at induction of anesthesia for breast cancer surgery.
62002967|NCT06192225|NO_INTERVENTION|Control arm|Care as usual
62002968|NCT02092090|NO_INTERVENTION|Control|Dietary advice at baseline only
62002969|NCT02092090|EXPERIMENTAL|Dietary sodium reduction|Dietary advice and reduced-sodium added-potassium salt substitute
62002970|NCT06341439|EXPERIMENTAL|Test Group|
62002971|NCT06341439|ACTIVE_COMPARATOR|Control Group|
62002972|NCT01973101|EXPERIMENTAL|Chemo-induction|Cisplatin plus Gemcitabine for 3 cycles followed by Cisplatin, radiotherapy and brachytherapy
62002973|NCT01973101|ACTIVE_COMPARATOR|Chemoradiotherapy|Cisplatin, radiotherapy and brachytherapy
62002974|NCT01874834|PLACEBO_COMPARATOR|Filtered air exposure|2 hr exposure to clean, filtered air with intermittent exercise
62002975|NCT01874834|EXPERIMENTAL|Ozone|2 hr exposure to 300 ppb ozone with intermittent exercise
62002976|NCT01874834|EXPERIMENTAL|Diesel Exhaust, No ozone|2 hr exposure to whole diesel exhaust (300 ug/m3; gases + particles) with intermittent exercise; no ozone
62002977|NCT01874834|EXPERIMENTAL|Ozone + Diesel Exhaust|2 hr exposure to a combination of 300 ppb ozone an 300 ug/m3 whole diesel exhaust with intermittent exercise
62002978|NCT00524979||Schizophrenia|People who are diagnosed as schizophrenic by DSM-IV
62002979|NCT00524979||Mental diseases|Patients who are deagnosed as having mental disease other then schizophrenia
62002980|NCT00524979||Mentally healthy|People who have no mental disease
62002981|NCT04041869|EXPERIMENTAL|MapTrek|
62002982|NCT01404468|ACTIVE_COMPARATOR|pulsed|
62002983|NCT01404468|SHAM_COMPARATOR|control|
62002984|NCT01404468|ACTIVE_COMPARATOR|continuous|
62002985|NCT05281250|EXPERIMENTAL|Supervised physical exercise|Supervised exercise (aerobic + strength + flexibility) depending on the functional capacity of each patient, during hospitalization
62002986|NCT05281250|NO_INTERVENTION|Control|Patients will receive recommendations about exercising during hospitalization.
62188553|NCT04783103|ACTIVE_COMPARATOR|Active adTMS|Subjects in the treatment arm receive 20 sessions of real adTMS . The sessions will be spread over the four succeeding days (5 sessions daily on Tuesday, Wednesday, Thursday and Friday).
62188554|NCT04783103|SHAM_COMPARATOR|Sham adTMS|Subject in the control/Placebo/Sham arm receive 20 sessions of sham adTMS. The sessions will be spread over the four succeeding days (5 sessions daily on Tuesday, Wednesday, Thursday and Friday).
62188555|NCT03831854|ACTIVE_COMPARATOR|lamotrigine|Patient will receive 300 mg of oral lamotrigine with small sips of water to reduce the psychologic side effects (measured by four key items of Brief Psychiatric Rating Scale: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) of intraoperative ketamine use.
62188556|NCT03831854|PLACEBO_COMPARATOR|Placebo|Patient will receive oral Placebo with small sips of water, to reduce the psychologic side effects (measured by four key items of Brief Psychiatric Rating Scale: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) of intraoperative ketamine use.
62188557|NCT02712164|EXPERIMENTAL|Experimental: Modified NPWT dressing|In the experimental group, a microporous silver-impregnated foam with a thin silicone contact layer (Mepilex Ag) will be applied. A macroporous foam layer (V.A.C. GranuFoam) and an occlusive dressing (V.A.C. Drape) will then be applied to cover the foam, plus 3-5cm border of intact skin. The occlusive dressing will then be pinched and a 2cm hole will be cut to apply the SensaT.R.A.C. Pad that supplies pressure from the NPWT unit. NPWT will be applied at 125mmHg throughout treatment using KCI's InfoV.A.C. Therapy Unit. The donor site dressing will be replaced on postoperative day 5-7 and a new occlusive dressing (Tegaderm) will be applied.
62188558|NCT02712164|ACTIVE_COMPARATOR|Control: Tegaderm|In the control group, the donor sites will be dressed with an occlusive dressing only (Tegaderm). The donor site dressings will be replaced on postoperative day 5-7 and a new occlusive dressing (Tegaderm) will be applied.
62188559|NCT02413814|EXPERIMENTAL|Anger Reduction Treatment|The treatment consists of eight 30-minute IBM sessions. Participants will be presented with ambiguous scenarios and asked imagine themselves in these situations. In the first task, the scenario will be followed by a benign interpretation of the situation. Participants will answer a comprehension question designed to have participants endorse this benign interpretation. In the second task, participants will be presented with a word denoting an interpretation with either a negative/hostile or positive/benign connotation. Following this word, an ambiguous scenario will appear. Participants will indicate whether the word and the scenario were related. They will receive feedback training them to endorse positive interpretations and reject negative interpretations.
62396170|NCT04784208||Arm 2- Hypothyroid treatment naïve patients|The subjects will be identified and selected from clinical settings such as hospitals, clinics and certified laboratories.
62396171|NCT03979924|OTHER|Interventional Step|The interventional step will comprise the same follow-up as the observational step, except for the addition of an early and preventive care, conducted by a specialized physiotherapist using an active exercise handbook elaborated with the patient's therapeutic education transversal Unit (Utep). This aims at increasing the patient's adhesion to the program and to limit the reduction of mouth opening and its consequences ( Trismus rehabilitation)
62571457|NCT02764281|EXPERIMENTAL|MEDA/Auto-HSCT|Patients will be initially treated with four cycles MEDA chemotherapy, followed by autologous hematopoietic stem cell transplantation (Auto-HSCT).
62571458|NCT02986022|EXPERIMENTAL|Resilience|Participants will receive four sessions covering Resilience intervention content
62778486|NCT01835834|EXPERIMENTAL|zirconia bridge restoration|"The device is a ceramic core made of shaded zirconium with an anatomic contour core with a minimum of 0.6 mm\*\* thickness and minimal connector size of 4.0 x 3.0 / 9.4 (height x width \[mm\] / area \[mm2\])\*\* of high strength zirconia framework providing homogenous veneering material thickness as an external coating with 1.0 - 2.0 mm\* wall thickness. The core is veneered with dental porcelain at the dental laboratory.~Intended use and indications:~NobelProceraTM Bridge Shaded Zirconia consists of an individualized, supporting substructure in a ceramic bridge construction for tooth/teeth replacement.~NobelProceraTM Bridge Zirconia is intended for patients in need of prosthetic oral reconstruction in order to restore chewing function. Zirconia bridges for natural tooth restorations are customized, designed, and milled from pre-sintered blanks of zirconia. The multi-unit restorations can be placed in all positions in the mouth."
62778487|NCT06525064|NO_INTERVENTION|Control Group|When clinics are in the control condition, patients will receive usual care. Before the visit eligible participants will receive a weblink to study information, and if agree to participate, the survey. The participants will not be presented Health-E You content and clinicians will not receive output to prime the visit; the participants will receive usual care as typical. Previously enrolled control males will not be enrolled during intervention periods to maintain the research study's integrity.
62778488|NCT06525064|EXPERIMENTAL|Intervention Group|"When clinics are in the intervention condition, all patients presenting for any reason will get a study weblink 24 hours before the visit; walk-ins will get a study link code in clinic. If the participants agree to participate and meet study criteria, the participants will get a survey link and then Health-E You content to complete before the visit. Previously enrolled males will not be enrolled again to maintain the research study's integrity. Thus, participants will only have one opportunity for administration to the Health-E You app.~Participants will be considered to have completed the Health-E You app if the participants answer all of the app's initial tailoring questions and receive recommendations for SRH topics to discuss with the clinician. As a technology-based intervention, no direct interactions with interventionists with participants are required."
62778489|NCT01086943|EXPERIMENTAL|device arm|
62778490|NCT02572622|EXPERIMENTAL|spinal decompression group|only 15 sessions of spinal decompression therapy were applied.
62571459|NCT02986022|ACTIVE_COMPARATOR|Resilience+Information|Participants will receive four sessions covering Resilience intervention and Information intervention contents.
62571460|NCT06392659|EXPERIMENTAL|Part A: Midazolam|Participants will receive a single dose of Midazolam in absence and presence of VX-993.
62571461|NCT06392659|EXPERIMENTAL|Part B: Itraconazole|Participants will receive a single dose of VX-993 on Day 1 and Itraconazole once daily (qd) on Days 7 through Day 15. On Day 10 participants will receive Itraconazole followed by VX-993.
62778491|NCT02572622|EXPERIMENTAL|combine group|10 patients participated in this group. for two weeks electrotherapy, deep friction massage and traction and last two weeks electrotherapy and exercise totally 15 session of treatment were applied.
62002987|NCT05233410|EXPERIMENTAL|Ruxolitinib|Ruxolitinib cream 1.5% twice daily (BID) for 16 weeks followed by ruxolitinib cream 1.5% BID for an additional 16-week treatment extension period.
62778492|NCT02572622|EXPERIMENTAL|exercise group|10 patients participated in this group. for two weeks electrotherapy, deep friction massage and last two weeks electrotherapy and exercise totally 15 session of treatment were applied whi
62778493|NCT00498576||1|kidney transplant with hypertension
62778494|NCT00498576||2|hypertensive patients with native kidneys
62778495|NCT00498576||3|healthy controls
62778496|NCT06168617|EXPERIMENTAL|Pilot phase|5 patients of both 3 groups will perform the parametric studying tasks. This phase aims at determine the feasibility of the tasks according to their parameters : Guided walk, visuo-manual task and posturography.
62778497|NCT06168617|EXPERIMENTAL|Validation phase|20 patients of both 3 groups will perform these performance tasks. This phase is designed to evaluate the performance tests executed by patients in real-life situations.
62778498|NCT03761069|EXPERIMENTAL|PTC299|PTC299 will be administered orally once daily (QD) for each 28-day cycle.
62778499|NCT05026203|EXPERIMENTAL|Ketamine|
62778500|NCT05026203|PLACEBO_COMPARATOR|Midazolam|
62778501|NCT02756494||Ischemic Stroke in Young Adults|Patients between 18 and 45 years of age with a first ever ischaemic stroke are eligible for this study from the Department of Beijing Chaoyang Hospital between January 1, 2016 and December 31, 2016. All patients were defined as a sudden loss of global or focal cerebral function that persisted with a probable vascular cause for 24h and confirmed by brain CT or MRI.
62778502|NCT02756494||matched control subjects|The age-, sex-, and time of enrollment-matched control cohort was randomly identified after eliminating the study subjects and those who had been given a diagnosis of any stroke at any time.
62778503|NCT00868907|EXPERIMENTAL|Treatment A|35 mg risedronate DR tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
62778504|NCT00868907|EXPERIMENTAL|Treatment B|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
62778505|NCT00868907|ACTIVE_COMPARATOR|Treatment C|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
62002988|NCT05233410|PLACEBO_COMPARATOR|Vehicle|Vehicle cream for 16 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 16-week treatment extension period.
62002989|NCT01086592|ACTIVE_COMPARATOR|Control|
62002990|NCT01086592|EXPERIMENTAL|Strengthening exercise|Strong progressive strengthening exercises of lower limbs.
62002991|NCT01086592|EXPERIMENTAL|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
62002992|NCT01086592|EXPERIMENTAL|Electrotherapy+weights|
62002993|NCT05240846|EXPERIMENTAL|Paramedian conventional palpation group|Patients in this group underwent conventional landmark guided paramedian spinal anesthetic. The spinal anesthesia will be administered based on conventional landmark-based paramedian approach.
62002994|NCT05240846|EXPERIMENTAL|Ultrasound assistance paramedian spinal group|This group will have their spinal anesthetic done based on Ultrasound assistance paramedian spinal.
62778506|NCT02645630|EXPERIMENTAL|Right Cervical Manipulation|Patients assigned to this group will receive a cervical spine manipulation targeting the C3/C4 segment on the right side.
62778507|NCT02645630|EXPERIMENTAL|Left Cervical Manipulation|Patients assigned to this group will receive a cervical spine manipulation targeting the C3/C4 segment on the left side.
62778508|NCT02645630|ACTIVE_COMPARATOR|Sham Cervical Manipulation|Patients assigned to this group will receive a sham cervical spine manipulation targeting the C3/C4 segment on both sides. No therapeuthic thrust will be applied.
62778509|NCT02706197|EXPERIMENTAL|IA No treatment except standard-of-care (SOC) surgery|Placement of OxyChip will be through a minimally invasive procedure (needle injection) and removal will be at the time of surgical resection. In Phase IA, patients will not have any cancer therapy prior to removal of the OxyChip and duration of implantation is typically less than 4 weeks but may be up to 52 weeks.
62002995|NCT03553316|EXPERIMENTAL|Sequence (1)|"Number of Subject: 24~Wash out Period: over 7 days (between each period)~Investigators Products(IPs) for Period1: A (Single)= PK101-002~IPs for Period2: B (Combination)= PK101-001, PK101-002"
62002996|NCT03553316|EXPERIMENTAL|Sequence (2)|"Number of Subject: 24~Wash out Period: over 7 days (between each period)~IPs for Period1: B (Combination)= PK101-001, PK101-002~IPs for Period2: A (Single)= PK101-002"
62396172|NCT05574959|EXPERIMENTAL|investigational Lens Device|investigational IOL Model DEN00V
62396173|NCT05574959|ACTIVE_COMPARATOR|Control Lens Device|control IOL Model ZCB00/DCB00
62778510|NCT02706197|EXPERIMENTAL|IB SOC adjuvant therapy and SOC surgery|Placement of OxyChip will be through a minimally invasive procedure (needle injection) and removal will be at the time of surgical resection. In Phase IB, patients will have standard of care neoadjuvant chemotherapy or pre-operative radiation therapy during the time that the OxyChip is within the tumor, which is typically 6 weeks but may be up to 52 weeks.
62002997|NCT02711800|EXPERIMENTAL|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by Dr. Patrick Seed from the department of pediatrics. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The intervention duration is 30 days.
62002998|NCT02584309|EXPERIMENTAL|Arm 1: Doxorubicin and Upfront Dexrazoxane|"* Dexrazoxane will be given intravenously on an outpatient basis over 15 minutes on each day that doxorubicin is given.~* Dexrazoxane should be given no more than 30 minutes prior to administration of doxorubicin, which is typically given on Day 1 of a 21-day cycle.~* Dosing is a 10:1 ratio of dexrazoxane to doxorubicin; doxorubicin is typically given at 75 mg/m2, so dexrazoxane dosing would be 750 mg/m2.~* In the event of a national shortage of dexrazoxane, 72-hour infusional doxorubicin can be used instead of dexrazoxane and bolus doxorubicin.."
62188560|NCT02413814|PLACEBO_COMPARATOR|Control Condition|Participants assigned to the control condition will complete eight computerized sessions consisting of psychoeducation on healthy behaviors (i.e., topics of exercise, diet, hygiene, social support, healthy activities, and sleep, taken from protocols developed from our ongoing research). These participants will also view relaxing videos consisting of brief guided meditation instructions, pictures of nature scenes, and soft music. These sessions (psychoeducation and relaxing videos) will be matched for time with the active treatment condition, lasting 30 minutes each.
62188561|NCT04291209|ACTIVE_COMPARATOR|Experimental arm with Intratympanic NAC injection|One ear will be randomly chosen for the experimental treatment and receive intratympanic NAC injections 60 minutes prior to their scheduled chemotherapy sessions
62188562|NCT04291209|NO_INTERVENTION|Control arm with No injection|The control ear will not receive any injections
62188563|NCT00988533|EXPERIMENTAL|0.5% Ivermectin Cream|
62188564|NCT04622098||patients with SEL|"Any patient with detected sub-epithelial lesion during upper endoscopy either symptomatized or accidently discovered.~Patients diagnosed by EUS, CT scan or surgically removed lesions."
62188565|NCT04329546||Cases|Cases are patients with COVID-19.
62571462|NCT06392659|EXPERIMENTAL|Part C: Gemfibrozil|Participants will receive a single dose of VX-993 on Day 1 and Gemfibrozil every 12 hours (q12d) on Days 7 through Day 15. On Day 10 participants will receive Gemfibrozil followed by VX-993.
62571463|NCT05282537||In person academic activities group|"University students of health sciences area returning to in person academic activities in Mexico.~All university students will return to in person academic activities in March, 2022, for that reason a limitation is that it is no possible to have a control group (Nobody is going to continue in virtual academic activities)."
62778511|NCT00988572|EXPERIMENTAL|Intervention group|Vestibular rehabilitation, twice a week for 9 weeks
62778512|NCT00988572|NO_INTERVENTION|Control group|The patients in the control group does nothing, except for normal treatment for their wrist fracture.
62188566|NCT04329546||Contacts|Contacts are household contacts of an index (case) patient.
62188567|NCT05194163|EXPERIMENTAL|10mg MW150 daily|10 mg MW150 daily (1 capsule of 10 mg daily)
62188568|NCT05194163|PLACEBO_COMPARATOR|placebo daily|placebo daily (1 capsule of matched placebo daily)
62188569|NCT05837299|EXPERIMENTAL|IMC008 dose 1-3|a certain number of IMC008 cell per kg will be infused
62571464|NCT01831076|ACTIVE_COMPARATOR|Treatment (exemestane, surgery)|Patients receive exemestane orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
62571465|NCT01831076|EXPERIMENTAL|treatment (exemestane, tamoxifen, surgery)|Patients receive exemestane plus tamoxifen orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
62778513|NCT03634254||primary caregivers of AAC users in New Taipei City|Satisfaction level of communication quality
62778514|NCT01652131|OTHER|Tetrastarch (130/0.4)|In obese patients candidates to laparoscopic gastrojejunal bypass an infusion of Tetrastarch (130/0.4)) of 15mL/kg (of corrected weight) will be initiated after protocoled induction of general anesthesia. Blood samples will be taken at time 0 (after induction of anesthesia and before initiating infusion) and then every 5 minutes for half an hour and then every 15 minutes up to 90 minutes. Blood samples will be processed in the Institution's laboratory. Urine will be measured at the end of the intervention. With these data kinetic parameters will be estimated for each patient.
62778515|NCT05254249|ACTIVE_COMPARATOR|Treatment Group|In the treatment group, intervention was given in the form of standard therapy and probiotic Lactobacillus plantarum IS 10605 in the amount of 2x1010 CFU for 12 weeks.
62778516|NCT05254249|PLACEBO_COMPARATOR|Placebo Group|In the placebo group, intervention was given in the form of standard therapy and placebo 2x1 sachets for 12 weeks.
62188570|NCT03703726|ACTIVE_COMPARATOR|Reference meal|50 g of Commercial Rice was cooked and 4 mg iron from Ferrous sulphate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
62188571|NCT03703726|EXPERIMENTAL|Test meal A|Commercial Rice was mixed with cold-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
62188572|NCT03703726|ACTIVE_COMPARATOR|Test meal B|Commercial Rice was mixed with warm-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
62188573|NCT03703726|EXPERIMENTAL|Test meal C|Commercial Rice was mixed with hot-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
62188574|NCT03703726|EXPERIMENTAL|Test meal D|Commercial Rice was mixed with cold-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
62188575|NCT03703726|ACTIVE_COMPARATOR|Test meal E|Commercial Rice was mixed with warm-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
62188576|NCT03703726|ACTIVE_COMPARATOR|Test meal F|Commercial Rice was mixed with hot-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
62188577|NCT03713320|EXPERIMENTAL|Cobomarsen|Cobomarsen will be administered by intravenous 2-hour infusion at a dose of 282 mg on Days 1, 3, 5, 8, and weekly thereafter
62396174|NCT05988619|ACTIVE_COMPARATOR|iCBT and TMS|All participants complete six weeks of TMS treatment (five days per week) within the UCLA TMS Clinic. Participants in this condition additionally access iCBT materials and attend a weekly session for 30 minutes with a trained mental health coach to discuss iCBT content.
62396175|NCT05988619|PLACEBO_COMPARATOR|Psychoeducation and TMS|All participants complete six weeks of TMS treatment (five days per week) within the UCLA TMS Clinic. Participants in this condition additionally access educational materials about mental health and attend a weekly session for 30 minutes with a trained mental health coach to discuss educational content.
62571466|NCT03577496|EXPERIMENTAL|Peppermint oil|A cotton ball with three drops of peppermint oil will be waved under the patient's nares upon arrival to the recovery room. The patients will be assessed for PONV for up to an hour in the post anesthesia care unit (PACU) or until their discharge, whichever is first.
62571467|NCT04033731||Controls|Participants will include 15 healthy men and women aged 18-40 years, right-hand dominant, Native English speakers, with normal or corrected-to-normal vision.
62571468|NCT01921101|OTHER|intensive medical nutrition|participants will receive intensive medical nutrition from hospital admission to discharge
62778517|NCT05254249|NO_INTERVENTION|Healty Control Group|Healthy control group was not given any treatment. Stool samples were taken to examine the gut microbiota profile.
62188578|NCT03713320|ACTIVE_COMPARATOR|Vorinostat|Vorinostat will be administered orally at a dose of 400 mg (four 100-mg capsules) once daily with food, at approximately the same time each day.
62188579|NCT01671306||Collateral, coronary disease|Patients are grouped into 2: Good and poor collateral development
62188580|NCT01671306||collateral|Patients are grouped into 2: Good and poor collateral development
62188581|NCT05282836|EXPERIMENTAL|Intervention|H2-O2 (66% hydrogen; 33% oxygen) inhalation. Patients in the treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) during a 7-day stay in the intensive care unit.
62188582|NCT05282836|NO_INTERVENTION|No intervention|Usual care refers to the standard-of-care (including oxygen therapy) recommended by guidelines.
62188583|NCT04044703|EXPERIMENTAL|Model-based vancomycin dosing|Participants will receive model-based intermittent intravenous vancomycin dosing as calculated by the dosing calculator available on a web application. Participants will then have routine therapeutic drug monitoring and linear dose adjustments.
62188584|NCT04692298|OTHER|Pulse|Participants will consume kidney beans, lentil, pinto beans, black-eyed pea, chickpea
62188585|NCT04695886|EXPERIMENTAL|CIME intervention|Community-delivered Integrated Malaria Elimination (CIME). The CIME intervention model integrates interventions for malaria, dengue, tuberculosis, childhood diarrhoea and RDT-negative fever.
62188586|NCT04695886|NO_INTERVENTION|ICMV standard of care|Integrated Community Malaria Volunteer (ICMV) model - this is the current standard of care. This model involves malaria volunteers undertaking additional screening and referral services for a range of other diseases including: dengue, lymphatic filariasis, tuberculosis, HIV/AIDS and leprosy.
62188587|NCT02335645||Body Weight Supported Treadmill|Post surgical ACL patients who will complete standard ACL protocol with the addition of body weight supported treadmill use.
62188588|NCT02931578|ACTIVE_COMPARATOR|Glucose100|Participants in this arm will randomly receive 100% glucose in the OGTT drink 3 out of 9 visits.
62188589|NCT02931578|ACTIVE_COMPARATOR|Glucose50|Participants in this arm will randomly receive 50% glucose in the OGTT drink 3 out of 9 visits.
62188590|NCT02931578|ACTIVE_COMPARATOR|Glucose42|Participants in this arm will randomly receive 42% glucose in the OGTT drink 3 out of 9 visits.
62188591|NCT05376345|EXPERIMENTAL|LCAR-BCDR cells product|Each subject will receive LCAR-BCDR cells
62396176|NCT00519090|EXPERIMENTAL|Nilotinib (AMN107)|
62396177|NCT00519090|ACTIVE_COMPARATOR|Imatinib|
62396178|NCT04738123|EXPERIMENTAL|KarXT|
62396179|NCT04738123|PLACEBO_COMPARATOR|Placebo|
62396180|NCT05039840|EXPERIMENTAL|Frexalimab|Frexalimab intravenous (IV) loading dose followed by subcutaneous (SC) doses, 24 weeks
62396181|NCT05039840|PLACEBO_COMPARATOR|Placebo|Placebo IV loading dose followed by SC, 24 weeks
62188592|NCT01007006|EXPERIMENTAL|TMRDU|Telepharmacy Robotic Medicine Delivery Unit (TMRDU) group will receive TMRDU plus medication management
62571469|NCT01921101|OTHER|control|participants will not receive intensive nutritional support from hospital admission to discharge
62002999|NCT02584309|ACTIVE_COMPARATOR|Arm 2: control (Doxorubicin and Standard of Care Dexrazoxane)|"* Doxorubicin is given as standard of care. Doxorubicin is typically given at 75 mg/m2 on Day 1 of a 21-day cycle.~* Starting with cycle 5, standard of care dexrazoxane (75 mg/m2) will be given for 4 cycles.~* The last 10 patients enrolled after completion of enrollment to Arm 1 will be enrolled to Arm 2."
62003000|NCT02584751|ACTIVE_COMPARATOR|Able-Bodied non-GERD|Able-bodied patients who are not diagnosed with GERD during screening will act as controls.
62003001|NCT02584751|ACTIVE_COMPARATOR|SCI non-GERD|SCI patients who are not diagnosed with GERD during screening will act as controls
62003002|NCT02584751|EXPERIMENTAL|SCI GERD|For those SCI subjects who are identified with GERD, they will undergo a 8week treatment of Omeprazole to reduce GERD
62571470|NCT05260567|EXPERIMENTAL|Exercise and Lifestyle Change|Exercise training and lifestyle change
62188593|NCT01007006|NO_INTERVENTION|Control|Control arm will receive only medication management, no TMRDU.
62188594|NCT01179503|ACTIVE_COMPARATOR|Calcium only|1200 mg Calcium per day
62188595|NCT01179503|EXPERIMENTAL|Vitamin D plus calcium|2000 IU vitamin D plus 1200 mg calcium per day
62188596|NCT05573581|EXPERIMENTAL|Botox injection group|Botox injection in anterior belly of digastric before mandibular advancement orthognathic surgery
62188597|NCT05573581|NO_INTERVENTION|placebo group|no injection before surgery
62571471|NCT05260567|OTHER|Standard Care|Patients will also receive specific advice to perform an unsupervised walking exercise according to NICE guideline.
62778518|NCT05697068|ACTIVE_COMPARATOR|Standard-of-Care|Patients who test positive will receive a call from the provider who conducted the test to notify them of the test result and provide standard-of-care counseling (e.g., health education, link them to resources). Index patients are entered into a COVID-19 patient registry in the Federally Qualified Health Center's electronic health record system (which also is linked to the clinic's COVID-19 dashboard) and monitored closely, with telemedicine follow-ups provided by skilled clinical staff every two-to-three days, and in-person follow-ups provided as needed.
62778519|NCT05697068|EXPERIMENTAL|Enhanced Standard-of-Care|In addition to the aforementioned standard-of-care actions, index patients in the enhanced standard-of-care group will receive tailored phone/mobile counseling (motivational interviewing) focused on implementing strategies to prevent immediate household spread of COVID-19, followed by weekly text messaging for a total of 6 weeks.
62778520|NCT02037906|EXPERIMENTAL|Escalating Energy SWL|50 Patients
62778521|NCT02037906|EXPERIMENTAL|Constant Energy SWL|50 Patients
62778522|NCT02037906|EXPERIMENTAL|Reduction Energy SWL|50 Patients
62778523|NCT04297605|EXPERIMENTAL|Experimental 1: pembrolizumab and Pemetrexed|"Treatment includes administration of pembrolizumab and chemotherapy, which are administered every 21 days~Pembrolizumab 200 mg and Pemetrexed 500 mg/m2 day 1 of 21 day cycle (for non-squamous only)"
62778524|NCT04297605|EXPERIMENTAL|Experimental 2: pembrolizumab and Nab-paclitaxel|"Treatment includes administration of pembrolizumab and chemotherapy, which are administered every 21 days~Pembrolizumab 200 mg and Nab-paclitaxel 100 mg/m2 days 1,8 of 21 day cycle x 4 cycles followed by pembrolizumab alone"
62778525|NCT02170181||OLIGOMETASTATIC ARM|SBRT to Oligometastases
62778526|NCT02170181||CONSOLIDATION ARM|SBRT as Consolidation to Residual Disease
62778527|NCT02170181||NORTON-SIMON ARM|SBRT to Debulk Gross Disease
62778528|NCT02170181||RE-IRRADIATION ARM|
62778529|NCT05767827|ACTIVE_COMPARATOR|Group R|0.35% ropivacaine 20ml, 1.5% lidocaine with adrenaline 10ml = 30 ml
62778530|NCT05767827|EXPERIMENTAL|Group RD|0.35% ropivacaine and 1mcg/ kg dexmedetomidine (20 ml), 1.5% lidocaine with adrenaline (10ml) = 30 ml
62778531|NCT04978818|ACTIVE_COMPARATOR|Vaxelis|165 infants will be randomized to the Vaxelis group, which is licensed for primary vaccination at 2, 4 and 6 months of age.
62778532|NCT04978818|ACTIVE_COMPARATOR|PedvaxHIB arm|165 infants will be randomized to the PedvaxHIB group, which is licensed for primary vaccination at 2 and 4 months of age.
62188598|NCT04885348|EXPERIMENTAL|Dental Home Visits and Dental Home Education Leaflets|Two trained dental home visitors made 6-monthly Dental Home Visits (DHVs) to families in the Intervention Group. Dental Home Education Leaflets (DHELs) and oral health messages were delivered through a personalized approach that avoids direct persuasion.
62188599|NCT04885348|ACTIVE_COMPARATOR|Dental Home Education Leaflets|Only Dental Home Education Leaflets were provided every six months for 2 years.
62188600|NCT04067349|ACTIVE_COMPARATOR|laparoscopic liver resection|Patients undergoing laparoscopic liver resection
62396182|NCT06601478|EXPERIMENTAL|Lifestyle Intervention|"Participants will undergo the MEDLIFE evaluation and will talk over their results and recommendations with the health care providers (cardiologists, nurses or dietitians) to improve habits identified as inadequate.~The intervention group will obtain access to the MEDLIFE online app and will receive personal text messages based on the MEDLIFE test to improve each of the items included in the tool. The available resources will be based on the recommendations for diet, physical activity, sleep and social interaction.~At the beginning and in each of the 4 visits, the following determinations will be done in both groups: anthropometric and biochemical measurements by trained stuff, arterial pressure, MEDLIFE scoring, sociodemographic questions, several questionnaires, and other relevant information obtained from medical histories."
62396183|NCT06601478|NO_INTERVENTION|Control, no Lifestyle Intervention|"Participants will undergo the MEDLIFE evaluation and will talk over their results and recommendations with the health care providers (cardiologists, nurses or dietitians) to improve habits identified as inadequate.~The control group will continue with their current lifestyle and will receive a handout with lifestyle recommendations.~At the beginning and in each of the 4 visits, the following determinations will be done in both groups: anthropometric and biochemical measurements by trained stuff, arterial pressure, MEDLIFE scoring, sociodemographic questions, several questionnaires, and other relevant information obtained from medical histories."
62396184|NCT06248762|EXPERIMENTAL|Intervention condition|Participants will use the app for 4 weeks, daily for 10-15 minutes
62396185|NCT06248762|OTHER|Waitlist control condition|Participants in the control condition will start using the app 4 months after the start (baseline)
62003003|NCT02584751|ACTIVE_COMPARATOR|Able-bodied GERD|For those AB subjects who are identified with GERD will act as controls. Note they will not receive treatment for GERD in this study. We will notify their primary care physician during the study so that they may receive treatment.
62778533|NCT02625714|OTHER|A group|Renexin® → SID142
62003004|NCT02051972||Indicated for a VVI(R) pacemaker|
62396186|NCT06209099|EXPERIMENTAL|Group A: Nonoperative Management|Patients who achieve Clinical complete response (cCR) or near-cCR when restaged at 16 weeks following IMRT plus consolidation CapeOX.
62778534|NCT02625714|OTHER|B group|SID142 → Renexin®
62778535|NCT02430987|ACTIVE_COMPARATOR|Metabolic syndrome|"The MetS diagnosis was determined by following the guidelines defined by the Adult Treatment Panel (ATP III) (8): (1) Abdominal circumference (AC) ?88cm; (2) HDL-cholesterol \< 50mg/dL; (3) triglycerides \> 150mg/dL; (4) arterial blood pressure (SAH) \> 130/85mmHg; and (5) fasting glucose \> 110mg/dL. The women considered as carrying MetS were those with at least three of the components described.~Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese"
62778536|NCT02430987|PLACEBO_COMPARATOR|Obesity|women were stratified into 3 groups by body mass index (BMI): Group 1: BMI of 18.5 to 24.9kg/m2 (Normal BMI Group), Group 2: BMI of 25 to 29.9kg/m2 (Overweight Group); Group 3: BMI of 30kg/m2 to 34.5kg/m2 or higher) (Obese Group Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese
62778537|NCT05819320||ALdakhla general hospital patients|patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease in renal unit of internal medicine of Eldakhla general hospital in New Vally
62778538|NCT05819320||Assuit University hospital adult renal unit|patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease in renal unit of internal medicine of Assuit University hospital (adult renal unit ) .
62778539|NCT05819320||Assuit University hospital pediatric renal unit|patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease in renal unit of internal medicine of Assuit University hospital (pediatric renal unit ).
62778540|NCT00935441|EXPERIMENTAL|Telemonitoring|Case management with home telemonitoring for blood sugar and blood pressure plus home HbA1c measurement
62778541|NCT00935441|ACTIVE_COMPARATOR|Usual case management|Case management
62778542|NCT02709876|EXPERIMENTAL|Stem Cells|Intravitreal Injection of bone marrow derived CD34+, CD133+, CD271+ stem cells.
62778543|NCT04530500||Arm 1|Males first tested positive for SARS-CoV-2 at the site (medical center) with CAG length \<24 (based on the CoVAST Test)
62778544|NCT04530500||Arm 2|Males first tested for SARS-CoV-2 at the site (medical center) with CAG length \>=24 (based on the CoVAST Test)
62003005|NCT03199378||Caucasian|English speaking Caucasian individuals
62003006|NCT03199378||African American|English speaking African American individuals
62003007|NCT03199378||Hispanic|Spanish speaking Hispanic individuals
62003008|NCT00699972|EXPERIMENTAL|1|
62003009|NCT00699972|EXPERIMENTAL|2|
62003010|NCT00699972|PLACEBO_COMPARATOR|3|
62188601|NCT04067349|ACTIVE_COMPARATOR|open liver resection|Patients undergoing open liver resection
62188602|NCT05663528||orotracheal intubation group|Composed of Patients who were intubated after 48 hours of admission to the intensive care unit
62188603|NCT05663528||non-intubated group|Composed of patients who were not intubated during their stay in the intensive care unit
62188604|NCT06030960|EXPERIMENTAL|Group 1|Patients with Chronic Low Back Pain (CLBP) who will receive Virtual Reality (VR) stabilization exercises, regular stabilization exercises and patient instructions and education
62188605|NCT06030960|ACTIVE_COMPARATOR|Group 2|Patients with Chronic Low Back Pain (CLBP) who will receive regular stabilization exercises and patient instructions and education
62188606|NCT04513743|EXPERIMENTAL|Healthy adults|UNEEG™ medical 24/7 EEG™ SubQ
62188607|NCT02314104|ACTIVE_COMPARATOR|Treatment TAP, placebo local injection|Treatment TAP block was 30 mL 0.5% ropivacaine bilaterally. Placebo local injection was 2 mL of 0.9% normal saline at each port site.
62188608|NCT02314104|ACTIVE_COMPARATOR|Placebo TAP, treatment local injection|Placebo TAP was 30 mL of 0.9% normal saline bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.
62571472|NCT04643977|EXPERIMENTAL|mesohyal ARGIBENONE|Name of the investigation medical device: mesohyal ARGIBENONE Code of the MD for the purpose of the clinical investigation: mARG-01-17 GMDN code: 59131 mARG-01-17 is a dermal filler recommended for cutaneous filling, facial wrinkle improvement and general condition of the skin, which is administered by intradermal injections. It encourages repair and restructuring of skin tissue, reducing the signs of aging.
62188609|NCT02314104|ACTIVE_COMPARATOR|Treatment TAP, treatment local injection|Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.
62571473|NCT04485325|ACTIVE_COMPARATOR|Tofacitinib|Tofacitinib (Xeljanz®; 5 mg twice daily, p.o.)
62778545|NCT01537822|EXPERIMENTAL|hysteroscopic morcellator|Women, randomized into getting a treatment with the hysteroscopic morcellator.
62188610|NCT03124147|ACTIVE_COMPARATOR|Anodal tDCS with motor training|20 minutes of anodal transcranial direct current stimulation applied to the ipsilesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
62571474|NCT04485325|ACTIVE_COMPARATOR|Etanercept|Etanercept (Enbrel®; 50 mg once per week, s.c.)
62571475|NCT00656825|ACTIVE_COMPARATOR|Panel I|The first 12 subjects will be selected and ranodmized in order to receive the first treatment dose of 100 μg/mL or placebo in a 8:4 ratio
62571476|NCT00656825|ACTIVE_COMPARATOR|Panel II|The second 12 subjects will be selected and randomized in order to receive the second treatment dose of 200 μg/mL or placebo in a 8:4 ratio
62571477|NCT00656825|ACTIVE_COMPARATOR|Panel III|The third 12 subjects will be selected and randomized in order to receive the third treatment dose of 300 μg/mL or placebo in a 8:4 ratio
62571478|NCT00656825|PLACEBO_COMPARATOR|Placebo|Patients from each panel will be given placebo in a 4:8 ratio.
62571479|NCT04572503|EXPERIMENTAL|Modified Anterior Palatoplasty|Barbed Suture Modified Anterior Palatoplasty In Management of Mild and Moderate Obstructive Sleep Apnea Syndromea using single resorbable polydioxanone barbed bidirectional size 0 monofilament suture
62571480|NCT03481868|EXPERIMENTAL|Chronic Myeloid Leukemia|Patients newly diagnosed for Chronic Myeloid Leukemia, according to inclusion and exclusion criteria
62571481|NCT04768816|PLACEBO_COMPARATOR|Placebo Comparator|Placebo 0.9% sodium chloride infusion any time after entering the Placebo Group, doses is 20-30ml. The infusion speed is 1ml/min.
62571482|NCT04768816|EXPERIMENTAL|Experimental|Autologous Umbilical Cord Blood Mononuclear Cells Therapy any time after the diagnosis of cerebral palsy, doses is 20-30ml (total Mononuclear cells#1\*10\^7/kg). The infusion speed is 1ml/min.
62778546|NCT01537822|ACTIVE_COMPARATOR|Resectoscope|Women, randomized into getting a treatment with the resectoscope.
62778547|NCT02879578|EXPERIMENTAL|Valbenazine (Children)|Children (6 to 11 years of age) received valbenazine 10 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 20 mg or continue with the participant's current dose for the remainder of the treatment period.
62778548|NCT02879578|EXPERIMENTAL|Valbenazine (Adolescents)|Adolescents (12 to 17 years of age) received valbenazine 20 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 40 mg or continue with the participant's current dose for the remainder of the treatment period.
62188611|NCT03124147|ACTIVE_COMPARATOR|Cathodal tDCS with motor training|20 minutes of cathodal transcranial direct current stimulation applied to the contralesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
62188612|NCT03124147|ACTIVE_COMPARATOR|Dual tDCS with motor training|20 minutes of anodal transcranial direct current stimulation applied to the ipsilesional hemisphere and cathodal transcranial direct current stimulation applied to the contralesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
62188613|NCT03124147|SHAM_COMPARATOR|Sham tDCS with motor training|20 minutes of sham transcranial direct current stimulation applied to the ipsilesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
62188614|NCT02999243|EXPERIMENTAL|HIV self-testing|HIV self-testing kits plus harm reduction education materials will be offered to the intervention group.
62188615|NCT02999243|PLACEBO_COMPARATOR|Education|Harm reduction educational materials will be offered to the control group.
62188616|NCT04584892||Haemophilia A|Patients enrolled will have Haemophilia A (any severity), needing turoctocog alpha prophylactic therapy.
62778549|NCT02879578|EXPERIMENTAL|Valbenazine (Adults)|Adults (18 to 64 years of age) received valbenazine 40 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 80 mg or continue with the participant's current dose for the remainder of the treatment period.
62778550|NCT02634827|EXPERIMENTAL|Treatment (decitabine, midostaurin)|Patients receive decitabine intravenously (IV) over 1 hour on days 1-5 and midostaurin orally (PO) twice daily (BID) on days 8-21 of courses 1 and 2, and on days 1-28 of each subsequent course. Patients failing to achieve complete response (CR)/complete response with incomplete recovery (CRi)/partial response (PR)/morphologic leukemia-free state by end of course 2 receive midostaurin PO BID on days 1-28. Patients achieving CR/CRi/PR/morphologic leukemia-free state by end of course 8 may continue on current regimen. Patients failing to achieve a CR/CRi/PR/ morphologic leukemia-free state in bone marrow blasts by end of course 8 go to event monitoring. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
62778551|NCT03922178|EXPERIMENTAL|Elective coronary surgery|The study will be conducted at the CHU Brugmann Hospital, with collaboration between cardiac surgery and anesthesiology wards. Subjects referred for elective coronary surgery will be prospectively included during the length of the study.
62778552|NCT02240602|EXPERIMENTAL|Oxycodone, 1.00 mg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 1.00 mg with lock out time of 10 min without basal infusion.
62778553|NCT02240602|EXPERIMENTAL|Oxycodone, 0.03 mg/kg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 0.03 mg/kg with lock out time of 10 min without basal infusion.
62778554|NCT02240602|EXPERIMENTAL|Oxycodone, 0.02 mg/kg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 0.02 mg/kg with lock out time of 10 min without basal infusion.
62778555|NCT05727514|OTHER|enrolled participants|participation in 4-session music composition program with optional viewing of performance at the end
62778556|NCT04508491|EXPERIMENTAL|Rhythm control|Rhythm control with medication or any procedure
62778557|NCT04508491|ACTIVE_COMPARATOR|Rate control|Rate control with medication or any procedure
62778558|NCT01643824|EXPERIMENTAL|Proton Beam Therapy|"* Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 \<40%, and/or RLV30 \<30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30\<50% and RLV30\<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30\<60%, and/or RLV30\<50%~* Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
62778559|NCT02437370|EXPERIMENTAL|Arm A (pembrolizumab, docetaxel)|pembrolizumab IV over 30 minutes on day 1 and docetaxel IV over 60 minutes on day 1.
62778560|NCT02437370|EXPERIMENTAL|Arm B (pembrolizumab, gemcitabine hydrochloride)|pembrolizumab IV as in Arm A and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8.
62778561|NCT03995706|EXPERIMENTAL|Breast Brain Metastasis and Glioblastoma|Sacituzumab Govitecan treatment will be initiated with a 10mg/kg standard dose without any dose escalation on day-1, prior to surgery. Sacituzumab govitecan and will continue to be administered by IV infusion over 3 hours on Days 1 and 8 of a 21 day cycle post-operatively until progression.
62778562|NCT00289081|ACTIVE_COMPARATOR|1|Rotating Platform Cruciate Retaining Knee implant
62778563|NCT00289081|ACTIVE_COMPARATOR|2|Rotating Platform Cruciate Substituting Knee implant.
62778564|NCT04286516|EXPERIMENTAL|Reaching with TMS|All participants enrolled in this group will receive TMS while performing reaching movements in a robotic system.
62778565|NCT02477189||Study Group|This was the group that received the penis implant, consented for participation and completed the follow-up questionnaire.
62778566|NCT00445770|EXPERIMENTAL|1|
62003011|NCT05340153|ACTIVE_COMPARATOR|Artemether-lumefantrine|Drug: Artemether-lumefantrine drug combination Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains a blister of 12 tablets. It will be administered each day as one, two or three tablets depending on the weight of the child.
62396187|NCT06209099|EXPERIMENTAL|Group B: Local Excision|Patients with near-cCR or residual tumor ≤ycT2N0 when reassessed at 16 weeks following IMRT plus consolidation CapeOX; or Patients with regrowth ≤ycT2N0 when reassessed during surveillance in NOM;
62778567|NCT00445770|EXPERIMENTAL|2|
62396188|NCT06209099|EXPERIMENTAL|Group C: Total Mesorectal Excision|"Patients with residual tumor \&gt;ycT2N0 when restaged at 16 weeks following IMRT plus consolidation CapeOX.~or Patients with regrowth \&gt;ycT2N0 when reassessed during surveillance in NOM; or Patients with any high-risk pathological factors following local excision (LE)"
62778568|NCT00445770|ACTIVE_COMPARATOR|3|
62778569|NCT05374330|EXPERIMENTAL|Electroacupuncture|Acupuncture needles will be inserted into the body at standardized acupuncture points. Electrical current will then be applied using 2 channels of electrical current for a total of 4 points receiving electroacupuncture
62778570|NCT05374330|SHAM_COMPARATOR|Sham acupuncture|Sham Acupuncture needles will be placed at standardized acupuncture points. Sham electrical current will then be applied using 2 channels / 4 points as in the electroacupuncture group. The electrical current will not be turned on.
62778571|NCT05374330|NO_INTERVENTION|Waitlist|The wait list group will be required to complete questionnaires at 4 separate time points over the 12 week study period.
62778572|NCT04511065|EXPERIMENTAL|Intervention Group|The intervention group will be provided with a survey to determine areas of interest to guide the 7-week literacy intervention plan of completing a newsletter. Students will complete the newsletter virtually using secure Zoom meetings 2x per week for 30 minutes per session. The results of the GORT 5 and TOC will be used to determine the baseline reading skills of the students and each researcher will use the results of the assessments to guide the intervention with the newsletter topic that is chosen by the student. For example, if the GORT 5 notes deficiency with reading accuracy, the focus of the intervention will be ensuring that reading accuracy is a focus of the summary that is crafted by the student for the newsletter.
62778573|NCT04511065|NO_INTERVENTION|Control Group|The control group will not participate in the newsletter creation for the 7-week study period. These students will engage in the after-school programs at the Center, some of which may be literacy-based, but not the prescriptive model that is being followed by the researchers.
62778574|NCT02145065|ACTIVE_COMPARATOR|Plain Balloon Angioplasty|Plain Balloon Angioplasty
62778575|NCT02145065|EXPERIMENTAL|microcrystalline Paclitaxel Coated Balloon (PAK)|plain balloon angioplasty followed by mcPCB dilation
62778576|NCT02748928|EXPERIMENTAL|UltraShape Power treatment to abdomen|"Eligible subjects will receive 3 treatments, 2 weeks interval, with the UltraShape Power device according to the study protocol and user manual.~The subject will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment, for total expected study duration of 16 weeks"
62188617|NCT01774305|EXPERIMENTAL|dexmedetomidine|We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously, for 10 min) at time of muscle layer closing.
62778577|NCT00615173|EXPERIMENTAL|1|tacrolimus(fk506) treatment in induction and maintenance phase
62778578|NCT00615173|ACTIVE_COMPARATOR|2|intravenous cyclophosphamide pulses treatment in induction phase; and Aza in the maintenance phase
62778579|NCT06216210||Group (A)|Opioid-free anesthesia group
62188618|NCT01774305|PLACEBO_COMPARATOR|saline|We administrate the saline single bolus (0.25ml/kg,intravenously, for 10 min) at time of muscle layer closing.
62188619|NCT04912713|ACTIVE_COMPARATOR|Arm 1|This group will be randomly immersed in ice water (2°C temperature) for preset times and instructed to remove their hand if they cannot withstand these times. In total there will be 5 attempts with durations of 90, 60, 60, 60, 90 and 60 s respectively. Between dive attempts they will be instructed to put their arm on a towel and immediately do the arithmetic task of counting backwards from the number 2043 as quickly and accurately as they can. Each time they make a mistake in the mental task, they will be given negative feedback and must start again from the number 2043. The duration of the 4 arithmetic tasks (between each of the 5 immersion attempts) will be fixed at 45, 60, 90 and 45 s respectively.
62778580|NCT06216210||Group (B)|Opioid-containing anesthesia group.
62396189|NCT04295629|ACTIVE_COMPARATOR|VAS (Visüel Analog Score)|VAS : 0-10 points 0 means: no pain 10 means: incredible pain
62396190|NCT04295629|ACTIVE_COMPARATOR|LANSS (Leeds Assessment of Neuropathic Symptoms and Signs)|LANSS 0-24 points \>12 points : has chronic neuropathic pain \<12 points: no chronic neuropathic pain
62778581|NCT02128412|ACTIVE_COMPARATOR|Stent oversize group|"Oversized stent deployed at low pressure:~A stent premounted on a balloon with a nominal diameter halfway between the lumen diameter and the true vessel diameter (approximated by external elastic lamina) as assessed by IVUS. This will be based on the smallest of the vessel reference diameters proximal and distal to the lesion. In addition the vessel diameter must be greater than this diameter throughout the length of the lesion. This stent will be implanted at an inflation pressure of 10 atmospheres or less for at least 15 seconds and a second IVUS will be performed to assess the end point."
62778582|NCT02128412|ACTIVE_COMPARATOR|High pressure group|"Stent deployed at high pressure:~A stent premounted on a balloon with a nominal diameter approximately equal to the vessel segment lumen reference diameter as previously assessed by IVUS will be used. This stent will be implanted at an inflation pressure of 14 atmospheres or more for at least 15 seconds and a second IVUS will be performed to assess the end point"
62778583|NCT04607369||Groups in General all were done under the wcgIRB, even those that were Practice groups|"Groups 1-3 were practice groups, gathering smartphone app installation, functional and usability feedback in preparation for later phase groups~Groups 4a and 4b Cohort 1 and 2 is the FDA application finalized and submitted study groups~Group 5-6 currently in continuing clinical trial during FDA application process"
62396191|NCT04843189||Da Vinci Robotic Surgery Group|Da Vinci Robotic Surgery Group
62396192|NCT04843189||Laparoscopy-assisted surgery group|Laparoscopy-assisted surgery group
62396193|NCT04672200|EXPERIMENTAL|Intervention arm|This group will receive the weekly group exercise which will be delivered online initially, and in the community clubs once they are allowed to reconvene according to government guidance. The duration of the intervention is 12 weeks.
62396194|NCT06425471|EXPERIMENTAL|KARL STORZ fetoscope arm|
62396195|NCT06679920|OTHER|Optical coherence tomography measurements during transurethral resection of a bladder tumour|Single arm
62396196|NCT05829018|ACTIVE_COMPARATOR|Dutch South Asian males|males of Dutch South Asian descent, as defined as having 4 grandparents that originally descended from either Surinam, Bangladesh, India, Nepal, Pakistan, Afghanistan, Bhutan or Sri Lanka
62571483|NCT03601598|EXPERIMENTAL|SHR-1210 + SHR6390|SHR-1210 was administered 200mg iv every 2 weeks in combination with SHR6390 150mg or 100mg oral daily with 3 weeks on and 1 week off
62778584|NCT04607369||1-3,5 Developmental team(1), Technician(2) and Non-Clinical Groups(3) 5. Retinal practice|Individuals on the developmental team, staff members and outside clinic people 5 Retinal Practice (to do after FDA approval)
62003012|NCT05340153|EXPERIMENTAL|Dihydroartemisinin-piperaquine|Drug: Dihydroartemisinin-piperaquine drug combination Dihydroartemisinin-piperaquine is formulated as tablets and will be provided in blister packs. Each tablet contains 40 mg dihydroartemisinin and 320 mg piperaquine. Every pack has a picture showing how the drug should be given and contains a blister of 6 tablets and given each day as half, one, two or three tablets depending on the weight of the child.
62188620|NCT04912713|ACTIVE_COMPARATOR|Arm 2|This group will not be falsely recorded or evaluated. They will be randomly immersed in warm water (35-37°C temperature) for preset times and instructed to remove their hand if they cannot withstand these times. In total there will be 5 attempts with durations of 90, 60, 60, 60, 90 and 60 s respectively. Between dive attempts they will be instructed to put their arm on a towel and immediately do the simple counting task, in which they will have to count consecutively from 1 to 25 at their own pace. If they reach 25 they must start again and will never be given negative feedback. The duration of the 4 arithmetic tasks (between each of the 5 immersion attempts) will be fixed at 45, 60, 90 and 45 s respectively
62396197|NCT05829018|ACTIVE_COMPARATOR|Dutch South Asian females|females of Dutch South Asian descent, as defined as having 4 grandparents that originally descended from either Surinam, Bangladesh, India, Nepal, Pakistan, Afghanistan, Bhutan or Sri Lanka
62188621|NCT01390350|PLACEBO_COMPARATOR|Placebo|
62396198|NCT05829018|ACTIVE_COMPARATOR|Dutch Europid males|males of Europid descent, as defined as having 4 grandparents from European origin
62003013|NCT03491150|PLACEBO_COMPARATOR|Parent Placebo|Participants (who were treated with Placebo in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).
62003014|NCT03491150|EXPERIMENTAL|Parent Crenezumab|Participants (who were treated with Crenezumab in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).
62003015|NCT06410872||Episodic cluster headache|Patients diagnosed according to ICHD3 criteria with episodic cluster headache
62003016|NCT06410872||Chronic cluster headache|Patients diagnosed according to ICHD3 criteria with chroniccluster headache
62396199|NCT05829018|ACTIVE_COMPARATOR|Dutch Europid females|females of Europid descent, as defined as having 4 grandparents from European origin
62003017|NCT06410872||Migraine|Patients diagnosed according to ICHD3 criteria with migraine (MA and MO)
62003018|NCT06410872||Healthy controls|Healthy controls, sex- and age-matched without current diagnosis of headache disorder
62003019|NCT05770037|EXPERIMENTAL|Treatment Arm 01: Alectinib|This alectinib treatment arm is for adult, teenage/young adult (TYA) and paediatric participants with ALK-positive cancers.
62003020|NCT02213939||CPB + Cytosorb|On pump myocardial revascularization with the use of the cytokine adsorbing circuit (Cytosorb)
62003021|NCT02213939||CPB / Control|Controll group; on pump myocardial revascularization
62003022|NCT02213939||OPCAB / Control|Controll Group; off-pump myocardial revascularization
62396200|NCT05762315|EXPERIMENTAL|Audio Storytelling|15 minutes transformative audio storytelling session
62778585|NCT04607369||4a. Cohort 1. FDA group|Patients in Neuro-Ophthalmology of Texas (NOT) PLLC practice which has referrals from multiple practices including retinal patients.
62778586|NCT04607369||4b. Cohort 2. FDA group|Patients in NOT practice
62778587|NCT04607369||6 At Home use of app in continuing clinical trial during FDA decision|Patients are educated on the app at home via app video clips and brochure, and as necessary, online training with COA (ophthalmic assistants/technicians or other trained educators) in order to do remote physiologic vision monitoring or preclinic near vision check.
62778588|NCT04607369||7a Cohort 1 FDA group responding to AI|Normal patients were tested with standard near vision tests compared with the smartphone app near vision tests. All patients were trained at home with app videos and by COA via telemedicine before coming to clinic.
62778589|NCT04607369||7b Cohort 2 FDA group responding to AI|Normal patients were tested with standard near vision tests compared with the smartphone app near vision tests. All patients were trained at home with app videos and by COA via telemedicine before coming to clinic.
62778590|NCT00724204|PLACEBO_COMPARATOR|A|Children that consumed a follow on formula without Lactobacillus salivarius CECT5713
62778591|NCT00724204|ACTIVE_COMPARATOR|B|Children that consumed a follow on formula with Lactobacillus salivarius CECT5713
62778592|NCT04933461|OTHER|Simulation of skin pricking by using Medlance Plus|Estimation of the true failure rate of the device. Estimation of the sharps' injury prevention feature of the tested safety lancets are effective in preventing needle stick injuries.
62778593|NCT04933461|OTHER|Simulation of skin pricking by using myLance|Estimation of the true failure rate of the device. Estimation of the sharps' injury prevention feature of the tested safety lancets are effective in preventing needle stick injuries.
62778594|NCT02798471|EXPERIMENTAL|Edoxaban|"Edoxaban treatment will be dispensed to the participant on a monthly visit schedule.~Edoxaban will be started orally at the age/weight/renal function appropriate dose, depending on the results of the ongoing U157 study (NCT02303431) for the Treatment Period."
62778595|NCT02798471|EXPERIMENTAL|Standard of Care|Standard of Care (SOC) treatment will be dispensed to the participant on a monthly visit schedule.
62188622|NCT01390350|EXPERIMENTAL|Canakinumab|
62778596|NCT04316676|OTHER|Three imaging techniques: PET-MPI, CT-MPI, and CT-FFR|Participants referred for a clinical PET-MPI will also have CT-MPI and CT-FFR imaging performed for analysis of myocardial perfusion.
62778597|NCT04316364|EXPERIMENTAL|Treatment group A|Neoadjuvant setting: Drug: SHR-1316 and carboplatin and Paclitaxel (Albumin Bound) 3 cycles; Adjuvant setting: Drug: SHR-1316 up to 16 cycles
62778598|NCT04316364|EXPERIMENTAL|Treatment group B|Neoadjuvant setting: Drug: SHR-1316 and platinum-based dual chemotherapy 3 cycles; Adjuvant setting: Drug: SHR-1316 up to 16 cycles
62778599|NCT04316364|PLACEBO_COMPARATOR|Treatment group C|Neoadjuvant setting: Drug: Placebo and platinum-based dual chemotherapy 3 cycles; Adjuvant setting: Drug: Placebo up to 16 cycles
62778600|NCT05790720|EXPERIMENTAL|Intervention|Patients older than 65 years of age will receive an intravenous infusion of Propofol with prespecified plasma targets. During its administration, registration of BIS values, frontal electroencephalography, and clinical signs of consciousness will be performed. Two models will be created and compared retrospectively: BIS (Eleveld Validation) and EEG Frontal Marker (New model).
62778601|NCT05767190|EXPERIMENTAL|MotivAir group|Subjects in the MotivAir group will follow an intervention - lasting approximately 45 minutes - based on motivational interviewing principles and techniques delivered by a trained nurse.
62778602|NCT05767190|NO_INTERVENTION|Treatment as usual|Participants assigned to the control group will receive a usual pulmonary rehabilitation program for patients with OSAS receiving CPAP therapy, which is a standard technical training comprising information regarding the use, maintenance and safety measures of the device, plus a home inspection delivered by a technician who has the only task of doing maintenance to the machinery.
62188623|NCT03557606||Alar treatment with BMC|Patients with CCJ instability that receive Alar treatment with BMC using anterior approach.
62778603|NCT04654078|EXPERIMENTAL|Group 1|Group 1
62778604|NCT04654078|EXPERIMENTAL|Group 2|Group 2
62778605|NCT04654078|EXPERIMENTAL|Group 3|Group 3
62778606|NCT04654078|EXPERIMENTAL|Group 4|Group 4
62188624|NCT00830609|ACTIVE_COMPARATOR|A|Patients in this arm will receive standard of care (Peginterferon alfa 2A 180 mcg/weeks SC plus ribavirin 800 mg/day for 24 weeks).
62396201|NCT05115630|EXPERIMENTAL|Cyclophosphamide|On Days 3 and 4, you will receive cyclophosphamide by vein over about 3 hours to help lower the risk of graft-versus-host disease
62778607|NCT04654078|EXPERIMENTAL|Group 5|Group 5
62778608|NCT04654078|EXPERIMENTAL|Group 6|Group 6
62778609|NCT02476006|EXPERIMENTAL|Alirocumab|Participants received Alirocumab 150 milligram (mg) subcutaneously (SC) once every two weeks (Q2W) or 75 mg SC Q2W added to stable LMT up to a maximum of 120 weeks. Alirocumab dose was either up-titrated from 75 to 150 mg Q2W or down-titrated from 150 to 75 mg Q2W, based on Investigator judgment and treatment response.
62778610|NCT06186986|EXPERIMENTAL|Part 1|In Part 1 of this side study a minimum of 5 eligible patients will undergo 89Zr-brentuximab-PET scans at 3 different time points (1, 4 and 7 days after tracer injection) either without (2 patients) or with preceding administration of 10 mg (3 patients) or more (n patients) of unlabeled brentuximab.
62778611|NCT06186986|EXPERIMENTAL|Part 2|In Part 2 of this side study the optimized imaging schedule from Part 1 will be used to investigate biodistribution and tumor uptake of 89Zr-brentuximab in 15 patients and correlate imaging data to baseline sCD30 serum levels, CD30 IHC and CD30 Gene Expression Profiling (GEP).
62778612|NCT06502704||Control|No pathology upon colonoscopy
62778613|NCT06502704||Small adenoma|\< 1cm size polyp upon colonoscopy
62396202|NCT05115630|EXPERIMENTAL|Mesna|On Days 3 and 4, You will also receive mesna by vein over 30 minutes every 4 hours for a total of 10 mesna doses.
62396203|NCT05115630|EXPERIMENTAL|Filgrastim|Starting on Day 7, you will begin to receive filgrastim as an injection under the skin 1 time a day.
62396204|NCT05115630|EXPERIMENTAL|Melphalan|On Day -7, you will receive melphalan by vein over about 30 minutes.
62778614|NCT06502704||Large adenoma|\> 1cm size polyp upon colonoscopy
62778615|NCT06502704||Cancer|Adenocarcinoma upon colonoscopy
62188625|NCT00830609|EXPERIMENTAL|B1|After a period of 4 weeks with peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day (Induction phase), these patients will be allocated according to negativity or positivity of RNA-HCV at week 4. If RNA-HCV negative, treatment with peginterferon alfa 2 a 180 mcg/week plus RBV 800 mg/day (SOC) will be continued over 20 additional weeks (Arm B1). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin \> 12g/dL.
62188626|NCT00830609|EXPERIMENTAL|B2|If RNA-HCV at week 4 remains positive after the induction phase, then peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day will be continued for 20 additional weeks (Arm B2). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin \> 12g/dL.
62188627|NCT01363310|ACTIVE_COMPARATOR|Quetiapine XR|
62396205|NCT05115630|EXPERIMENTAL|Fludarabine phosphate|On Days -7, -6, -5, and -4, you will receive fludarabine by vein about 1 hour.
62396206|NCT05115630|EXPERIMENTAL|Tacrolimus|Starting on Day 5, you will begin receiving tacrolimus to help lower the risk of GVHD. You will begin by receiving it nonstop by vein until you are able to take it by mouth. You will then take tacrolimus by mouth 2 times a day for about 3 months.
62396207|NCT05115630|EXPERIMENTAL|Mycophenolate mofetil|by mouth 3 times a day for 90 days or longer.
62396208|NCT05115630|EXPERIMENTAL|Total Body Irradiation One Dose|on Day -2, you may receive 1 dose of total body irradiation (TBI).
62396209|NCT06286293||bvYOD|Neuropsychological assessment and driving simulator task.
62396210|NCT06286293||non-bvYOD|Neuropsychological assessment and driving simulator task.
62396211|NCT06286293||Patients with frontal brain damage|Neuropsychological assessment and driving simulator task.
62396212|NCT06286293||Healthy controls|Neuropsychological assessment and driving simulator task.
62396213|NCT04716205|EXPERIMENTAL|Mulligan's bent leg raise Technique|Mulligan's bent leg raise Technique and Static Stretching
62396214|NCT04716205|ACTIVE_COMPARATOR|Static stretching|Static Stretching
62396215|NCT04882072|EXPERIMENTAL|Ustekinumab|"Double-blind (DB) Period: Participants will receive weight-ranged based ustekinumab (6 milligrams/kilogram\[mg/kg\]) as IV infusion at Week 0 followed by ustekinumab 90mg injection SC 8 weeks after initial IV dose, then every 8 weeks (q8w) thereafter until the end of the DB period with starting the protocol defined oral GC taper regimen from Week 2 visit.~Open Label Extension (OLE) period: Participants will receive ustekinumab SC injection at Week OL-0, followed by ustekinumab 90mg SC injection with oral GC taper at investigator's discretion for 52 weeks (Week OL-52) or until 32 weeks from first SC administration after end of DB period whichever is later.~Long-term Extension (LTE) Period: Participants who completed OLE period may be eligible to enter LTE and continue to receive ustekinumab 90mg SC injection q8w."
62584883|NCT04418128|EXPERIMENTAL|Conventional therapy + Nafamostat mesylate|"* The conventional therapy comprised, as necessary, Lopinavir/ritonavir, Hydroxychlorquine, supplemental oxygen, Non-invasive and invasive ventilation, antibiotic agents, renal-replacement therapy (e.g.: CRRT, HD), extracorporeal membrane oxygenation (ECMO).~* Nafamostat mesylate injection day), taking into account the severity and underlying disease of the clinical trial patient.~  * Method of administration: Nafamostat injection is mixed with 1,000 ml of 5% DW infusion, followed by continuous infusion over 24 hours.~ * Duration of administration: The researcher administers for 10-14 days considering the severity and underlying disease of the clinical trial patient."
62188628|NCT01363310|ACTIVE_COMPARATOR|Escitalopram|
62188629|NCT04355936|EXPERIMENTAL|TELMISARTAN|Patients in this group will receive 80 mg Telmisartan twice daily plus standard care.
62188630|NCT04355936|NO_INTERVENTION|CONTROL|Patients in this group will receive standard care.
62003023|NCT02659332|EXPERIMENTAL|TURBT|Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of1ms)
62003024|NCT02411331|EXPERIMENTAL|Experimental group|90 patients will receive 10 injections of ethanol lock solution in implantable venous access port during the first 10 days of the study.
62003025|NCT02411331|OTHER|control group|90 patients will receive 10 injections of vancomycin lock solution in implantable venous access port during the first 10 days of the study
62003026|NCT04884152|ACTIVE_COMPARATOR|Home Exercise Group|"The home Exercise program includes an educational training program about parafunctional activities of patients having bruxism with myofascial temporomandibular disorders. The program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises.~Relaxation: Relaxation exercises with diaphragmatic breathing Posture Exercise: Rest position of tongue and TMJ, head and neck posture correction exercises Stretching Exercises: Stretching exercises for chewing muscles, cervical muscles, and pectoral muscles Strengthening: The neck will consist of strengthening exercises for deep flexor muscles, suprahyoid and infrahyoid muscles, and scapular retractors."
62003027|NCT04884152|EXPERIMENTAL|Telerehabilitation Group|"The program includes the same stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises using telerehabilitation once a week by video call, and reminder messages will be sent to the patients 3 times a week.~Relaxation: Relaxation exercises with diaphragmatic breathing Posture Exercise: Rest position of tongue and TMJ, head and neck posture correction exercises Stretching Exercises: Stretching exercises for chewing muscles, cervical muscles, and pectoral muscles Strengthening: The neck will consist of strengthening exercises for deep flexor muscles, suprahyoid and infrahyoid muscles, and scapular retractors."
62003028|NCT02308670||RRMS changing from 20mg to 40mg GA|Relapsing-remitting Multiple Sclerosis patients who are switching from 20mg of glatiramer acetate (GA) to 40mg. The investigator is not influencing this clinical decision, just measuring its impact using MRI metrics.
62003029|NCT01337297|PLACEBO_COMPARATOR|sham-tDCS|the electrodes are positioned in the same manner as the active-tDCS, activated for 20 s (time to climb ramp of the current until reach the current intensity used in the experiment), enough to produce the sensation of itch, and turned off until the end of the session.
62003030|NCT01337297|EXPERIMENTAL|active-tDCS|low-intensity transcranial Direct Current Stimulation (tDCS)applied over the dorsolateral prefrontal cortex
62003031|NCT01043796|EXPERIMENTAL|Insecticide treated nets and wall liners|
62003032|NCT01043796|ACTIVE_COMPARATOR|Insecticide treated nets alone|
62003033|NCT01567488|EXPERIMENTAL|Everolimus + Octreotide LAR treatment|
62003034|NCT00094653|ACTIVE_COMPARATOR|1|Melanoma Peptide Vaccine (MDX-1379) (gp100) + Placebo
62003035|NCT00094653|EXPERIMENTAL|2|MDX-010 (ipilimumab) + MDX-1379 (gp100) (Melanoma Peptide Vaccine)
62584884|NCT04149782||Patients enrolled in differentiated service delivery models|
62778616|NCT01650272|EXPERIMENTAL|5%Minoxidil solution|"This arm AGA patient receive 5%Minoxidil solution ( Propylene glycol solvent ) to use for 6 month.~Record efficacy and safety as described."
62778617|NCT01650272|EXPERIMENTAL|5%Minoxidil milky lotion|This arm AGA patient receive 5%Minoxidil milky lotion to use for 6 month. Record efficacy and safety as described.
62003036|NCT00094653|ACTIVE_COMPARATOR|3|MDX-010 (ipilimumab) + Placebo
62003037|NCT04140734|EXPERIMENTAL|Hard Palate|Some patients who will already be undergoing lower eyelid retraction repair with a spacer graft will be randomized to use hard palate
62003038|NCT04140734|ACTIVE_COMPARATOR|Autologous Ear Cartilage|Some patients who will already be undergoing lower eyelid retraction repair with a spacer graft will be randomized to use autologous ear cartilage
62003039|NCT04140734|ACTIVE_COMPARATOR|Porcine Acellular Dermal Matrix|Some patients who will already be undergoing lower eyelid retraction repair with a spacer graft will be randomized to use porcine acellular dermal matrix
62584885|NCT04149782||Patients not enrolled in DSD models|
62778618|NCT06416410|EXPERIMENTAL|JAB-21822+JAB-3312|JAB-21822 tablet, 21 days as a treatment cycle; JAB-3312 tablet/capsule, 21 days as a treatment cycle
62778619|NCT06416410|ACTIVE_COMPARATOR|Tislelizumab combined with Pemetrexed + Carboplatin|Tislelizumab injection, 21 days as a treatment cycle; Pemetrexed injection, 21 days as a treatment cycle; Carboplatin injection, 21 days as a treatment cycle
62778620|NCT05941013|EXPERIMENTAL|Ultrasound detectable cuffed endotracheal tube (USD-ETT)|Intubation with a novel ultrasound-detectable endotracheal tube
62778621|NCT00392990|EXPERIMENTAL|Alternating doxil/Magrath regimen & rituximab/Magrath regimen|Patients are stratified between high risk and low risk disease status. Low risk patients receive 3 cycles of rituximab (500 mg/m2) R-CODOX-M chemotherapy IV over 2-4 hours with intrathecal chemotherapy (Regimen A). High risk patients receive 1 cycle of R-CODOX-M chemotherapy IV followed by R-IVAC chemotherapy over 30 minutes(Regimen B); regimens A and B are then repeated.
62778622|NCT00520260|ACTIVE_COMPARATOR|1|Active treatment arm bromfenac 0.09% BID for 6 weeks
62778623|NCT00520260|ACTIVE_COMPARATOR|2|ketorolac 0.4% BID for 6 weeks
62003040|NCT00528528|EXPERIMENTAL|Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet|Telaprevir tablets at the dose of 750 milligram (mg) orally administered every 8 hours (hr) for 12 weeks, in combination with standard treatment composed of pegylated interferon (Peg-IFN)-alfa-2a solution for subcutaneous injection at the dose of 180 microgram per week (mcg/week) and ribavirin (RBV) oral tablets at the dose of 1000-1200 mg/day up to 48 weeks.
62003041|NCT00528528|EXPERIMENTAL|Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule|Telaprevir tablets at the dose of 750 mg orally administered every 8 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2b solution for subcutaneous injection at the dose of 1.5 mcg/kilogram/week (mcg/kg/week) and RBV oral capsules at the dose of 800-1200 mg/day up to 48 weeks.
62003042|NCT00528528|EXPERIMENTAL|Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet|Telaprevir tablets at the dose of 1125 mg orally administered every 12 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2a solution for subcutaneous injection at the dose of 180 mcg/week and RBV oral tablets at the dose of 1000-1200 mg/day up to 48 weeks.
62188631|NCT05928949|ACTIVE_COMPARATOR|conventional physical therapy|Group A performed flexibility, strength, and endurance exercises that focused on the lower extremity and trunk muscles, exercise for postural stability in various positions and surfaces, including flexibility exercises for the hip, knee and calf muscle. Strengthening exercises included the core muscles, hip abductors, hip extensors hamstrings and quadriceps knee extension in high sitting. Postural control involved walking in all directions, exceeding the limits of stability in various positions such as kneeling, half kneeling, standing on rough and soft surfaces, Each session started with a warming up and cooling down of 5 minutes for each period and each session lasted for 45 minutes.
62188632|NCT05928949|EXPERIMENTAL|pilates exercises|group B received the same program of exercises given to group A in addition to 45 minutes of Pilates exercises to improve balance and gross motor coordination. Exercises were performed on a mat, a medical ball, and from a standing position, focusing on maintaining core contraction, spinal and pelvic alignment, and respiration rhythm. Ten repetitions of Pilates exercises will be performed with a 2-minute rest period between repetitions. Both groups will attend the intervention program three times/week for 3 months
62188633|NCT02906280|EXPERIMENTAL|19 Ga EBUS-TBNA needle|needle aspiration by a flexible 19 Ga needle (Olympus)
62188634|NCT02906280|ACTIVE_COMPARATOR|22 Ga EBUS-TBNA needle|needle aspiration by a 22 Ga needle (Olympus)
62778624|NCT06453291|EXPERIMENTAL|Conventional Therapy Group|"* Intervention: Participants will receive standard treatment for CLBP, including NSAIDs and physical therapy.~* Frequency: Daily NSAID use as prescribed, physical therapy sessions twice a week"
62778625|NCT06453291|EXPERIMENTAL|Neuromodulation + PRP Therapy Group|"* Intervention: Participants will undergo neuromodulation via the DRG and receive PRP injections.~* Frequency: Neuromodulation sessions once a week for the first month, followed by monthly maintenance sessions if needed. PRP injections will be administered once a week for the first three weeks."
62778626|NCT01595555|NO_INTERVENTION|Wait-list control|Group with no intervention. Only complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
62003043|NCT00528528|EXPERIMENTAL|Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule|Telaprevir tablets at the dose of 1125 mg orally administered every 12 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2b solution for subcutaneous injection at the dose of 1.5 mcg/kg/week and RBV oral capsules at the dose of 800-1200 mg/day up to 48 weeks.
62188635|NCT01233661|EXPERIMENTAL|short AVD pacing|short AVD pacing
62188636|NCT01233661|NO_INTERVENTION|prior (stable) programming|prior (stable) programming
62778627|NCT01595555|EXPERIMENTAL|Stress Free Now|Participate in the 8 week online stress management program Stress Free Now. Complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
62188637|NCT00288223|EXPERIMENTAL|1|telithromycin
62188638|NCT02895360|EXPERIMENTAL|Phase 1|Fixed 3+3 dose escalation of BAL101553 in patients with advanced solid tumors
62188639|NCT02895360|EXPERIMENTAL|Phase 2a|BAL101553 at MTD in patients with platinum-resistant/refractory ovarian cancer or recurrent glioblastoma
62778628|NCT01595555|EXPERIMENTAL|Stress Free Now + Social Media|Participate in the 8-week Stress Free Now program and a discussion board that provides peer and moderator support. Complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
62778629|NCT06256926|ACTIVE_COMPARATOR|Drug Product|Test Product: Curcuvail® 250 mg capsule
62778630|NCT06256926|PLACEBO_COMPARATOR|Placebo Product|Placebo Product
62778631|NCT05647785||cerena™|Subjects who took part in the cerena™ group during the original RESTORE study
62778632|NCT05647785||attune™|Subjects who took part in the attune™ group during the original RESTORE study
62778633|NCT01786252|EXPERIMENTAL|Drug: human chorionic gonadotropin (hCG)|"Drug: human chorionic gonadotropin (hCG). A single intrauterine infusion of 500IU hCG dissolved in IVF media (Global-trademark) will be administered to participants in the experimental group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic where a uterine lavage and an endometrial biopsy will be performed to obtain a sample of uterine secretory proteins and endometrial tissue, respectively, for research analysis."
62778634|NCT01786252|PLACEBO_COMPARATOR|"IVF media (Global-trademark)"|Placebo Comparator for hCG. A single intrauterine infusion of IVF media without hCG will be administered to participants in the control group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic and a sample of uterine secretory proteins and endometrial tissue, will be obtained via uterine lavage and endometrial biopsy, respectively, for research analysis.
62003044|NCT05514067|EXPERIMENTAL|Electro-acupuncture (EA) arm|Patients with stable CAD going for coronary artery bypass graft (CABG) surgery randomized to receive EA before surgery.
62188640|NCT06546059|OTHER|one group|
62188641|NCT05557071|EXPERIMENTAL|Intervention|An online, asynchronous, self-paced, 6-week long, physical activity intervention.
62003045|NCT05514067|NO_INTERVENTION|Standard Care arm|Patients with stable CAD going for coronary artery bypass graft (CABG) surgery.
62003046|NCT01172691|EXPERIMENTAL|Placebo and Study|
62003047|NCT04694196|EXPERIMENTAL|Locate occlusal plane|Use anatomical landmark to locate OP in dentulous subjects.
62003048|NCT06333795|EXPERIMENTAL|Active treatment|Active capsule FMT-treatment
62188642|NCT05557071|NO_INTERVENTION|Control|A waitlist control; continue with life/activity as usual. Control participants will receive access to the intervention at 6 weeks following all measurements.
62188643|NCT01076998|EXPERIMENTAL|Lubricant eye drop|Lubricant eye drop
62396216|NCT04882072|PLACEBO_COMPARATOR|Placebo|"DB period: Participants will receive placebo intravenous (IV) infusion at Week 0 followed by placebo subcutaneous (SC) injection administration, 8 weeks after the initial IV dose, then q8w thereafter until the end of DB period with starting the protocol defined oral GC taper regimen from Week 2 visit.~OLE period: Participants will receive ustekinumab SC at Week OL-0, followed by SC administration of ustekinumab with oral GC taper at investigator's discretion for 52 weeks (Week OL-52) or until 32 weeks from the first SC administration after the end of DB period, whichever is later.~LTE Period: Participants who complete their participation in OLE period may be eligible to enter the LTE and continue to receive 90 mg SC ustekinumab q8w."
62396217|NCT06109766|EXPERIMENTAL|Promoting First Relationships Home Visiting|"PFR-HV is a 10-week home-based parenting support program that promotes parental sensitivity and reduce the risk of maltreatment. PFR uses a curriculum, each week consisting of a theme for discussion and an activity. Sessions includes at least two handouts, one with new content and one titled Thoughts for the Week, which asks parents to think about a topic discussed in the session and apply it to their relationship with their child. On alternating weeks, the provider video records the parent-child dyad playing for 10 minutes. The following week the parent and provider view the video recording, and the provider guides the parent to reflect on their observation of the play. When the parent is sensitive to the child's needs, the provider acknowledges that with positive instructive comments. When there is tension between child and parent, the provider pauses the video and asks reflective questions, which allows parents to reconsider the meaning behind their child's behavior."
62396218|NCT06109766|EXPERIMENTAL|Promoting First Relationships Telehealth|"PFR-T is a 10-week telehealth parenting support program. PFR-T retains all of the core content features of PFR-HV: use of parent-child interaction during play as a way to reflect on the child's social and emotional needs, use of handouts and exercises to deepen the learning, and thoughts for the week. The parent-child video observations will be completed online over Zoom. The provider will mail the handouts to participants before starting PFR-T and send handouts by email as a backup. To discuss the handouts, the provider will use share screen. During five of the weekly sessions, the provider uses the record feature of Zoom to record playtime between parent and child. At the next visit, the PFR-T provider will use share screen to playback the video to offer positive instructive and reflective feedback and facilitate discussion. As is typical in PFR, the provider will be able to pause or rewind the recording as needed."
62584886|NCT05897710|ACTIVE_COMPARATOR|Center-Based Cardiac Rehab (CBCR)|Standard of care for participants' center-based cardiac rehabilitation program. Traditional 12-week, in-person program.
62778635|NCT03647267|ACTIVE_COMPARATOR|Pneumatic Vitreolysis|Participants randomized to the Pneumatic Vitreolysis arm will receive 0.3-mL intraocular injection of C3F8 gas.
62778636|NCT03647267|PLACEBO_COMPARATOR|Observation|Participants randomized to the observation group will receive a sham injection.
62778637|NCT03813992|ACTIVE_COMPARATOR|MED2005 0.2%|MED2005 0.2% w/w gel to deliver 0.6 mg dose of GTN applied topically prior to a sexual intercourse attempt
62778638|NCT03813992|ACTIVE_COMPARATOR|MED2005 0.4%|MED2005 0.4% w/w gel to deliver 1.2 mg dose of GTN applied topically prior to a sexual intercourse attempt
62778639|NCT03813992|ACTIVE_COMPARATOR|MED2005 0.6%|MED2005 0.6% w/w gel to deliver 1.8 mg dose of GTN applied topically prior to a sexual intercourse attempt
62003049|NCT06333795|PLACEBO_COMPARATOR|Placebo|Placebo capsules are given.
62003050|NCT01749891|EXPERIMENTAL|Arm 1.5 mg ALG - 1001|Arm 1.5 mg ALG- 1001 per 50ul
62188644|NCT01076998|ACTIVE_COMPARATOR|Refresh PM Ointment|Refresh PM Ointment
62188645|NCT04528823|NO_INTERVENTION|Standard care (control arm)|Strategy 1: Symptoms screen, CXR and TST (standard)
62584887|NCT05897710|EXPERIMENTAL|Virtual World-Based Cardiac Rehab (VWCR)|Telehealth delivery of cardiac rehabilitation via Second Life virtual world platform. 12-week, home-based program.
62188646|NCT04528823|ACTIVE_COMPARATOR|GeneXpert (GX)|Strategy 2: Symptoms screen, Genexpert and TST
62188647|NCT04528823|ACTIVE_COMPARATOR|CXR for all/NoTST|Strategy 3: Symptoms screen, CXR but NO TST
62188648|NCT02720211|ACTIVE_COMPARATOR|Gray tinted spectacle lenses|Subjects in this arm will be asked to wear a neutral gray tint that blocks all wavelengths equally
62188649|NCT02720211|EXPERIMENTAL|Thin-Film spectacle lenses|Subjects in this arm well be asked to wear a thin-film coating that specifically blocks 480-nm wavelength
62396219|NCT06109766|NO_INTERVENTION|Control, Resource Condition|For families randomized to the control group, they will not receive any intervention in the 3 month timeframe between the first two research visits. The research coordinator will maintain contact with the families in this group, and they will be emailed a resource packet with some information about services or programs that might be helpful for them based on the area they reside.
62188650|NCT01613963||Patients with ocular inflammation|Patients with ocular inflammation
62188651|NCT02781311|EXPERIMENTAL|Setipiprant|Setipiprant 1000 mg (2 X 500 mg) tablets, orally, BID at 12-hour intervals for 24 weeks.
62188652|NCT02781311|PLACEBO_COMPARATOR|Placebo|Two placebo tablets BID at 12-hour intervals for 24 weeks.
62396220|NCT05403502|EXPERIMENTAL|t:slim X2 insulin pump with Control-IQ technology utilizing insulin Lyumjev®|Current Control-IQ technology users with type 1 diabetes, age 6-80, will use the t:slim X2 insulin pump with Control-IQ technology 1.5 and Lyumjev insulin for 3-months of outpatient use.
62188653|NCT02781311|ACTIVE_COMPARATOR|Finasteride|Finasteride 1 mg tablet, orally, once daily for 24 weeks.
62188654|NCT04199468|EXPERIMENTAL|Active Delta-9-THC and Placebo Ketamine|Active IV Delta-9-THC and Placebo Ketamine
62188655|NCT04199468|EXPERIMENTAL|Active Delta-9-THC and Active Ketamine|Active IV Delta-9-THC and Active Ketamine
62188656|NCT04199468|EXPERIMENTAL|Placebo Delta-9-THC and Placebo Ketamine|IV Placebo Delta-9-THC and Placebo Ketamine
62188657|NCT04199468|EXPERIMENTAL|Placebo Delta-9-THC and Active Ketamine|IV Placebo Delta-9-THC and Active Ketamine
62188658|NCT04310332||1L-PEG|Hospitalized patients who are prescribed colonoscopy with 1L-polyethylene glycole (PEG) plus ascorbic acid as bowel preparation.
62396221|NCT02990273|ACTIVE_COMPARATOR|TEG|Blood transfusion
62396222|NCT02990273|ACTIVE_COMPARATOR|Prothrombin Time (PT)/International normalized ratio (INR)|Blood transfusion
62584888|NCT05911048|EXPERIMENTAL|Experimental group|Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)
62584889|NCT05911048|ACTIVE_COMPARATOR|Control group|Recombinant COVID-19 Vaccine (Sf9 Cell)(WSK-V101)
61977848|NCT04700982||Based on the length of hospital stay|Based on the length of hospital stay, patients were divided into two groups: hospital stays ≤ 3 months (Group 1) and \> 3 months (Group 2).
62188659|NCT04310332||4L-PEG|Hospitalized patients who are prescribed colonoscopy with 4L-polyethylene glycole (PEG) as bowel preparation.
62188660|NCT01509443|EXPERIMENTAL|Interventional|Participants will receive standard asthmatic treatment and breathing/mild physical exercise
62188661|NCT01509443|NO_INTERVENTION|Control Arm|The control arm will receive standard medical care for asthma
62188662|NCT01694888|EXPERIMENTAL|midwifery students|all midwifery students studying at last term (except one who was absent) (27) in Mashhad school of nursing and midwifery in April 2011
62188663|NCT02778464||Group A: Female IBD and RA (non-pregnant)|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All diaries and stool sample consumables for disease activity will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
62584890|NCT05943561||Concussion|Has an acute concussion
62584891|NCT05943561||Non-concussion|Does not have a concussion
62778640|NCT03813992|PLACEBO_COMPARATOR|Placebo vehicle|Placebo vehicle applied topically prior to a sexual intercourse attempt
62778641|NCT02969460|EXPERIMENTAL|Neurotrack Virtual Cognitive Health Program|This program is a multi-domain lifestyle intervention designed to prevent or delay cognitive decline and impairment in older at-risk adults. The first 6 months of the program emphasizes lifestyle change, while the last 6 months of the program emphasizes habit reinforcement. The program focuses on nutrition, physical exercise, and cognitive training.
62778642|NCT02023814||Study group|All patients who underwent stem cell mobilization after chemotherapy and G-CSF at our institution between 2002 and 2013
62778643|NCT03811301|EXPERIMENTAL|Interventional|Wireless Implantable Neurodevice Microsystem
62003051|NCT01749891|EXPERIMENTAL|Arm 2.5 mg ALG -1001|Arm 2.5 mg ALG -1001 per 50ul
62003052|NCT01749891|EXPERIMENTAL|Arm 4.0 mg ALG -1001|Arm 3 4.0 mg ALG -1001 per 50ul
62188664|NCT02778464||Group B: Female IBD|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All diaries and stool sample consumables for disease activity will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
62003053|NCT05800054|EXPERIMENTAL|NST intervenes throughout the process|"1. Nutritionists formulate nutritional programs and manage them in a refined manner.~   The nutritionist urges the patient to report daily to ensure that the patient's energy and protein are in place~2. Radiotherapy~3. chemotherapy"
62003054|NCT05800054|EXPERIMENTAL|Routine nutrition guidance group for esophageal cancer|"1. Patients perform their own nutrition regimen, and the nutritionist is not involved in management~2. Radiotherapy~3. chemotherapy"
62003055|NCT05088291||The new protection device|A total of 100 patients underwent continuous coronary angiography (CAG) or percutaneous coronary intervention (PCI). The first surgeon does not need to wear a lead dress to stand inside the new protective device (NPD) to perform all operations.
62003056|NCT05088291||The traditional lead clothing|A total of 100 patients underwent continuous coronary angiography (CAG) or percutaneous coronary intervention (PCI). The first surgeon wears the traditional lead clothing (TLC) to perform all operations.
62396223|NCT03347565||Adolescents with an Eating Disorder|Females between the ages of 14-17 currently diagnosed with an eating disorder (including ARFID, Anorexia Nervosa, Bulimia Nervosa, OSFED)
62778644|NCT02239315|EXPERIMENTAL|Tumor RNA Disruption Assay™ (RDA)|Tumor RNA Disruption Assay™ (RDA) to generate RDA score from fine needle aspiration biopsy samples of breast cancer obtained 7-14 days after the first, second and third cycles of neoadjuvant chemotherapy; and, if there is a change of chemotherapy regimen, after the first cycle of the new chemotherapy.
62778645|NCT01778101|EXPERIMENTAL|lansoprazole|lansoprazole 1mg/kg twice a day for 14days
62778646|NCT03954262||TCI group|Group I received TCI at 5-6 ug/ml target effect concentration (Ce)
62778647|NCT03954262||bolus group|groups II received an induction bolus of propofol (2-2.5mg/kg).
62778648|NCT01785823|EXPERIMENTAL|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr
61977849|NCT00129454|EXPERIMENTAL|Telemedicine treatment|Psychotherapy delivered by telephone
61977850|NCT00129454|ACTIVE_COMPARATOR|In-Person treatment|Psychotherapy delivered in-person
61977851|NCT00129454|NO_INTERVENTION|Assessment only|No intervention
61977852|NCT01516814|EXPERIMENTAL|Arm 1|
61977853|NCT01516814|ACTIVE_COMPARATOR|Arm 2|
61977854|NCT01516814|ACTIVE_COMPARATOR|Arm 3|
62396224|NCT03347565||Healthy Controls|Females between the ages of 14-17 with no psychiatric conditions
62778649|NCT01785823|ACTIVE_COMPARATOR|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the decremental rates of 6.0 ml/hr (D6-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr,
62571484|NCT05009693|EXPERIMENTAL|white light intervention group|Between the second and the eighth days of the application phase, the patients in the intervention group were administered a standard white light at 10,000 Lux intensity by an independent nurse (RA1) in their home environment using a Litebook Elite light source (The Litebook Company Ltd., Medicine Hat, AB). The distance between the light source and the patient's face was set at 50 cm, and the intensity of the light for each patient was checked using a Lux Meter. The intervention was applied between 07:00 and 10:00 in the morning for 30 minutes without interruption, and it was continued for seven successive days. The light application procedure was followed based on the previous studies on oncology patients. The second and third evaluations of the fatigue status of patients were completed on the 9th and 21st days.
62571485|NCT05009693|NO_INTERVENTION|Control group|
62188665|NCT02778464||Group C: Female - Healthy Pregnant|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All stool sample consumables will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
62396225|NCT00528125|ACTIVE_COMPARATOR|A|Active laser acupuncture
62396226|NCT00528125|PLACEBO_COMPARATOR|B|placebo laser acupuncture
61977855|NCT05706142|NO_INTERVENTION|Control group|No motor imagery will be shown to these students. The same massage will only be shown as practically at class.
62396227|NCT01371955||diabetic nephropathy group|patient with diabetic nephropathy, defined as Albuminuria \> 30 mg/day or urinary Albumine/ creatinine ratio \> 3 mg/mmol ; or GFR estimated by MDRD less than 60 ml/min.1,73m². With no other etiology of diabetic nephropathy.
62396228|NCT01371955||diabetic retinopathy group|patient with diabetic retinopathy defined as showing at least one micro aneurysm on retinography. Without nephropathy defined as above
62396229|NCT01371955||no complication group|patient without diabetic nephropathy or retinopathy
62396230|NCT02427334|ACTIVE_COMPARATOR|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
62396231|NCT02427334|ACTIVE_COMPARATOR|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
62396232|NCT02427334|PLACEBO_COMPARATOR|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
62003057|NCT04690127|EXPERIMENTAL|Plyometric Training Group|Individuals in the plyometric training group will receive plyometric training. In this training, individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery). Except for one session that will be applied every two weeks, all other trainings will be given on the basis of telerehabilitation via distance education tools.
62003058|NCT04690127|NO_INTERVENTION|Control Group|Volunteers in this group will not participate in any training.
62778650|NCT01785823|ACTIVE_COMPARATOR|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at at the decremental rates of 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr,
62778651|NCT01019369|EXPERIMENTAL|Self Administration of DMPA|Self administration of subcutaneous depot medroxyprogesterone acetate
62778652|NCT01019369|ACTIVE_COMPARATOR|Clinic administration of DMPA|Clinic administration (routine care) of DMPA
62778653|NCT03236987|ACTIVE_COMPARATOR|Clarithromycin 1000 MG|"The patient will received a combination of 3 antibiotics :~* Rifampicin (10mg/kg once daily)~* Ethambutol (15 to 20 mg/kg once daily)~* Clarithromycin (500 mg twice daily)"
62003059|NCT02498093|EXPERIMENTAL|Maximal strength training|Maximal strength training supervised by a physiotherapist
62003060|NCT02498093|ACTIVE_COMPARATOR|Control|Conventional rehabilitation supervised by a physiotherapist
62396233|NCT06077760|EXPERIMENTAL|V940 + Pembrolizumab|Participants will receive 1 mg of V940 via intramuscular (IM) injection once every 3 weeks for 9 doses PLUS 400 mg of pembrolizumab via intravenous (IV) infusion once every 6 weeks for up to 9 doses until disease recurrence or unacceptable toxicity or for a total treatment duration of up to approximately 1 year, whichever is sooner.
62778654|NCT03236987|EXPERIMENTAL|Azithromycin 250 MG|"The patient will received a combination of 3 antibiotics :~* Rifampicin (10mg/kg once daily)~* Ethambutol (15 to 20 mg/kg once daily)~* Azithromycin (250 mg once daily)"
62778655|NCT04361305|EXPERIMENTAL|tadalafil combined with dapoxetine|
62778656|NCT04361305|ACTIVE_COMPARATOR|tadalafil mono group|
62188666|NCT02778464||Group D: Female - RA Pregnant|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All stool sample consumables will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
62188667|NCT00002668|ACTIVE_COMPARATOR|Observation|Standard pain management interventions usually given by hospital staff
62188668|NCT00002668|EXPERIMENTAL|Educational Intervention and Behavioral Skills Training|Patients participated in a program including video presentations, written materials, and coaching in behavioral skills to improve pain control (not to reduce analgesic use).
62778657|NCT03098745|ACTIVE_COMPARATOR|Omafilcon A|Participants are randomized to wear omafilcon A lens pair bilaterally for 1 hour during the study.
62003061|NCT02505633|EXPERIMENTAL|2P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced at the behind site of the initial puncture site. And the needle is penetrated the nerve sheath with a direction of upward, and then the same process is performed and LA 15 mL is injected.
62188669|NCT04911478||Subjects from Adicet Bio allogeneic γδ CAR T cell interventional studies.|"This is a rollover protocol designed to provide long-term follow-up to all subjects previously enrolled in Adicet Bio allogeneic γδ CAR T cell study.~Patients will be followed for up to 15 years post treatment of Adicet Bio allogeneic γδ CAR T cell investigational products."
62188670|NCT03017547|EXPERIMENTAL|IC14|IC14 4 mg/kg IV on Study Day 1, then IC14 2 mg/kg IV once daily on Study Days 2-4.
62571486|NCT05460351|EXPERIMENTAL|BRJ+Nitrate|This arm underwent a 3 days a week, 10 weeks of resistance exercise training program and consumed for a 70 mL bottle of beetroot juice containing 380 mg of nitrate plus a 15 dose of whey protein after each exercise session.
62188671|NCT03017547|PLACEBO_COMPARATOR|Placebo|Placebo IV once daily on Study Day 1-4
62571487|NCT05460351|PLACEBO_COMPARATOR|Control|This arm underwent a 3 days a week, 10 weeks of resistance exercise training program and consumed for a 70 mL bottle of beetroot juice containing 0 mg of nitrate plus a 15 dose of whey protein after each exercise session.
62571488|NCT00511914|EXPERIMENTAL|cTIV (Adults)|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
62188672|NCT00632021|NO_INTERVENTION|1|Patients will receive usual care at hospital discharge, which generally includes physician reconciliation of medications and a nurse-provided explanation of how to take medications at the time of discharge.
62188673|NCT00632021|EXPERIMENTAL|2|Participants will receive pharmacist-led medication reconciliation, pharmacist counseling prior to discharge, a follow-up telephone call 1-4 days after discharge, and additional telephone support as needed.
62571489|NCT00511914|EXPERIMENTAL|cTIV (Elderly)|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
62188674|NCT04486976|EXPERIMENTAL|Normal|
62188675|NCT04486976|EXPERIMENTAL|Glaucoma|
62396234|NCT06077760|ACTIVE_COMPARATOR|Placebo + Pembrolizumab|Participants will receive V940-matched placebo via IM injection once every 3 weeks for 9 doses PLUS 400 mg of pembrolizumab via IV infusion once every 6 weeks for up to 9 doses until disease recurrence or unacceptable toxicity or for a total treatment duration of up to approximately 1 year, whichever is sooner.
62571490|NCT05978050|EXPERIMENTAL|nimotuzumab|Participants received nimotuzumab injection 600 mg for the first time, followed by 400 mg once a week until disease progression or inability to tolerate or withdrawal from the trial; At the same time, in combination with paclitaxel 80 mg/m2, it was administered on days 1, 8 and 15 of each treatment cycle (4 weeks) until the disease progressed or could not be tolerated or withdrew from the trial.
62188676|NCT04486976|EXPERIMENTAL|Cataract|
62571491|NCT05978050|PLACEBO_COMPARATOR|placebo|Participants received placebo 600 mg for the first time, followed by 400 mg once a week until disease progression or inability to tolerate or withdrawal from the trial; At the same time, in combination with paclitaxel 80 mg/m2, it was administered on days 1, 8 and 15 of each treatment cycle (4 weeks) until the disease progressed or could not be tolerated or withdrew from the trial.
62571492|NCT02099110|EXPERIMENTAL|Ertugliflozin 5 mg + sitagliptin 100 mg|Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
62571493|NCT02099110|EXPERIMENTAL|Ertugliflozin 15 mg + sitagliptin 100 mg|Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
62571494|NCT02099110|EXPERIMENTAL|Ertugliflozin 5 mg|Ertugliflozin 5 mg, oral, once daily for 52 weeks
62778658|NCT03098745|ACTIVE_COMPARATOR|Somofilcon A|Participants are randomized to wear somofilcon A lens pair bilaterally for 1 hour during the study.
62778659|NCT03098745|ACTIVE_COMPARATOR|Omafilcon A - Proclear (PC)|Participants are randomized to wear omafilcon A - PC lens pair bilaterally for 1 hour during the study.
62778660|NCT00698334|EXPERIMENTAL|HIV infected|HIV infected patients with active TB
62778661|NCT00698334|ACTIVE_COMPARATOR|HIV negative|HIV negative patients with active TB
62778662|NCT05030480||Chronic kidney disease|eGFR values of less than 60 mL/min/1.73 m2
62778663|NCT05030480||Non-Chronic kidney disease|eGFR values more than 60 mL/min/1.73 m2
62778664|NCT04883814|EXPERIMENTAL|Initial Staging|FES PET/CT will be compared to CT/bone scan for detection of unsuspected distant metastases in patients with ER-positive locally advanced breast cancer
62778665|NCT04883814|EXPERIMENTAL|Suspected disease recurrence|FES PET/CT will be compared to CT/bone scan for detection of unsuspected distant metastases in patients with ER-positive breast cancer and suspected disease recurrence
62003062|NCT02505633|ACTIVE_COMPARATOR|1P1I group|After subcutaneous injection of 1 mL of 2% lidocaine, a nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach from lateral to medial direction. After the needle is penetrated the nerve sheath, the nerve stimulator is then turned on, and the stimulation current starts at 0.5mA. If hand muscle twitching is observed even at 0.3 mA, local anesthetics 30 mL (lidocaine mixed with epinephrine) is injected.
62003063|NCT02745964|EXPERIMENTAL|LMA supreme|Anesthesia is maintained using LMA supreme during surgery.
62003064|NCT02745964|ACTIVE_COMPARATOR|I-gel|Anesthesia is maintained using I-gel during surgery.
62003065|NCT04054037||HBV-ACLF Group|Patients with HBV related acute on chronic liver failure
62003066|NCT02059148|EXPERIMENTAL|LY2835219 Standard|Single oral dose of LY2835219 given with a standard meal in one of three study periods.
62003067|NCT02059148|EXPERIMENTAL|LY2835219 Fasted|Single oral dose of LY2835219 given with no food in one of three periods.
62003068|NCT02059148|EXPERIMENTAL|LY2835219 High-Fat|Single oral dose of LY2835219 given with a high fat meal in one of three periods.
62003069|NCT05882227|EXPERIMENTAL|Video|"patients will watch a video with discharge information taken from the document Optimized hip replacement recovery program; information for patients, family members or caregivers."
62778666|NCT02126618||women with lower urinary tract symptoms|
62778667|NCT04591847|EXPERIMENTAL|Vitamin D supplemented group|Vitamin D2 20000 IU 1 tab oral weekly start at GA 18 -22 weeks until delivery
62778668|NCT04591847|EXPERIMENTAL|Placebo group|Placebo drug (Appearance same as Vitamin D2) 1 tab oral weekly start at GA 18 -22 weeks until delivery
62003070|NCT05882227|ACTIVE_COMPARATOR|Traditional information|"patients will receive discharge information will be provided through the document entitled Optimized Hip Replacement Recovery Program; Information for Patients, Family or Caregivers."
62778669|NCT05676216|ACTIVE_COMPARATOR|Diphenhydramine|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping
62188677|NCT04447157||Microspherophakia|This is a non-interventional study(NIS). All the patients diagnosed as microspherophakia are included in the study and recieved intraocular lens implantation
62188678|NCT01195207|EXPERIMENTAL|001|CNTO 3157 or placebo 0.003 mg/kg CNTO 3157 or placebo infusion
62188679|NCT01195207|EXPERIMENTAL|002|CNTO 3157 or placebo 0.01 mg/kg CNTO 3157 or placebo infusion
62188680|NCT01195207|EXPERIMENTAL|003|CNTO 3157 or placebo 0.03 mg/kg CNTO 3157 or placebo infusion
62188681|NCT01195207|EXPERIMENTAL|004|CNTO 3157 or placebo 0.1 mg/kg CNTO 3157 or placebo infusion
62778670|NCT05676216|EXPERIMENTAL|Sodium Bicarbonate|Sodium bicarbonate 66.4 mEq in 100 mL normal saline intravenous dripping
62003071|NCT05817396|EXPERIMENTAL|Cooperative Planning for Promoting PAHCO|"Participatively developed intervention concept by means of cooperative planning (Rütten, 1997) to promote physical activity-related health competence (PAHCO): A separate cooperative planning process will take place in each of the four schools in this study arm from April to November 2023. Within the framework of these processes, suitable interventions tailored to the target group and the school will be developed for the implementation of the curriculum content PAHCO with the participation of actors from science and practice (e.g., teachers, nursing students of the schools). The developed interventions will be implemented from December 2023 under the responsibility of the actors in the schools."
62778671|NCT05676216|EXPERIMENTAL|Diphenhydramine with Sodium Bicarbonate|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping with Sodium bicarbonate 66.4 mEq intravenous push
62188682|NCT01195207|EXPERIMENTAL|005|CNTO 3157 or placebo 0.3 mg/kg CNTO 3157 or placebo infusion
62778672|NCT02050087|ACTIVE_COMPARATOR|3 weeks with simple sling|Early motion after arthroscopic rotator cuff repair.
62003072|NCT05817396|EXPERIMENTAL|Expert-Based Intervention for Promoting PAHCO Delivered by External Physical Activity Specialists|"Expert-based intervention concept with external physical activity specialists to promote physical activity-related health competence (PAHCO). We will develop a specific intervention concept for the implementation of the curriculum content PAHCO at nursing schools in Bavaria from April to November 2023. Currently (March 2022), it is planned that the intervention will comprise 12 sessions with a duration of 45 or 90 minutes. The entire intervention will be specified during the different steps of intervention mapping (i.e., needs assessment, goal formulation, screening evidence-based intervention content). Physical activity specialists (e.g. sports scientists, physiotherapists) will be trained to implement this expert-based intervention concept from December 2023 to March 2024."
62188683|NCT01195207|EXPERIMENTAL|006|CNTO 3157 or placebo 1 mg/kg CNTO 3157 or placebo infusion
62188684|NCT01195207|EXPERIMENTAL|007|CNTO 3157 or placebo 3 mg/kg CNTO 3157 or placebo infusion
62188685|NCT01195207|EXPERIMENTAL|008|CNTO 3157 or placebo 10 mg/kg CNTO 3157 or placebo infusion
62188686|NCT05317507|EXPERIMENTAL|Randomization order 1|Participants receive placebo at visit 1, 50 mg CBD at visit 2, and 100 mg CBD at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
62778673|NCT02050087|ACTIVE_COMPARATOR|6 weeks with neutral brace|Delayed motion after arthroscopic rotator cuff repair.
62778674|NCT03291990|EXPERIMENTAL|5 fraction radiotherapy with standard temozolomide|5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide
62778675|NCT01288547|ACTIVE_COMPARATOR|theobromine|theobromine (700 mg) in capsule
62778676|NCT01288547|ACTIVE_COMPARATOR|caffeine|caffeine (120 mg) in capsule
62778677|NCT01288547|PLACEBO_COMPARATOR|Placebo capsule|no theobromine or caffeine
62778678|NCT01288547|ACTIVE_COMPARATOR|theobromine + caffeine|Combined theobromine and caffeine treatment, consisting of 700 mg theobromine and 120 mg caffeine
62778679|NCT05400993|EXPERIMENTAL|treatment group|Chidamide combined with EC -- T regimen was treated with 1 cycle every 21 days, followed by 4 cycles of EC followed by 4 cycles of T, a total of 8 cycles
62188687|NCT05317507|EXPERIMENTAL|Randomization order 2|Participants receive placebo at visit 1, 100 mg CBD at visit 2, and 50 mg CBD at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
62571495|NCT02099110|EXPERIMENTAL|Ertugliflozin 15 mg|Ertugliflozin, oral, once daily for 52 weeks
62003073|NCT05817396|EXPERIMENTAL|Expert-Based Intervention for Promoting PAHCO Delivered by Teachers|"Expert-based intervention concept with teachers as multipliers to promote physical activity-related health competence (PAHCO). We will develop a specific intervention concept for the implementation of the curriculum content PAHCO at nursing schools in Bavaria from April to November 2023. Currently (March 2022), it is planned that the intervention will comprise 12 sessions with a duration of 45 or 90 minutes. The entire intervention will be specified during the different steps of intervention mapping (i.e., needs assessment, goal formulation, screening evidence-based intervention content). Teachers of the participating nursing schools of this study arm will be trained to implement this expert-based intervention concept in their school from December 2023 to March 2024."
62003074|NCT05817396|NO_INTERVENTION|Regular Education and Health Promotion|"No systematic intervention concept: In the schools of this study arm, there is no systematic and scientifically supported intervention for the implementation of the curriculum content PAHCO."
62003075|NCT03111654|OTHER|Patients with pericardial closure of the auricle|
62003076|NCT03111654|OTHER|Patients without closure of the auricle|
62003077|NCT00826267|EXPERIMENTAL|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
62003078|NCT00826267|ACTIVE_COMPARATOR|Lapatinib|Lapatinib tablets 1500 mg daily.
62188688|NCT05317507|EXPERIMENTAL|Randomization order 3|Participants receive 50 mg CBD at visit 1, placebo at visit 2, and 100 mg CBD at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
62188689|NCT05317507|EXPERIMENTAL|Randomization order 4|Participants receive 50 mg CBD at visit 1, 100 mg CBD at visit 2, and placebo at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
62188690|NCT05317507|EXPERIMENTAL|Randomization order 5|Participants receive 100 mg CBD at visit 1, 50 mg CBD at visit 2, and placebo at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
62188691|NCT05317507|EXPERIMENTAL|Randomization order 6|Participants receive 100 mg CBD at visit 1, placebo at visit 2, and 50 mg CBD at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
62188692|NCT04683341|EXPERIMENTAL|Arm A - initial TAF treatment group|cirrhotic or non-cirrhotic CHB patients with hepatic decompensation and HBV NUC treatment naïve or experienced (except prior TAF) will receive initial treatment (Arm A) with TAF 25 mg/day.
62188693|NCT04683341|EXPERIMENTAL|Arm B - switch to TAF treatment group|cirrhotic or non-cirrhotic CHB patients with hepatic decompensation and currently under HBV NUC treatment (except TAF) with HBV DNA \< 20 IU/mL within 6 months prior screening will switch (Arm B) to TAF 25 mg/day
62778680|NCT01818284|EXPERIMENTAL|Filgrastim + Plerixafor|"Each donor receives Filgrastim 5 µg/kg subcutaneously in the morning daily for 4 days. The dose of Filgrastim based on the donor's actual body weight. Donors will continue Filgrastim until completion of apheresis. Each donor receives Plerixafor 240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization. The dose-volume of Plerixafor based on the donor's actual body weight. Apheresis procedure to start the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor. The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.~The apheresis procedure may continue beyond day 1 until the target dose of 4x106 cluster of differentiation 34 (CD34+) cells/kg (recipient's weight) is obtained."
62778681|NCT03287427|EXPERIMENTAL|TetMYB Vaccine & BGB-A317|
62778682|NCT00679172|EXPERIMENTAL|M01ZH09 Vaccine Candidate Cohort 1|Dose of 5.0 x 10\^9 colony forming units (CFU) S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
62188694|NCT01649557|EXPERIMENTAL|Open-label OPDC-34712|
62188695|NCT06155110|EXPERIMENTAL|Cardiomyopeptidin group|The Cardiomyopeptidin group received intravenous infusion 3 mg/(kg·d) of cardiomyopeptidin during the PCI until 3 days after operation
62003079|NCT00826267|ACTIVE_COMPARATOR|Trastuzumab|Trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly.
62003080|NCT05073406|EXPERIMENTAL|Hypobaric normoxia|Altitude exposure in hypobaric normoxic condition
62003081|NCT05073406|SHAM_COMPARATOR|Hypobaric hypoxia|Altitude exposure in hypobaric hypoxic condition
62003082|NCT02760134|OTHER|SMP with F14 sheath|Patients undergo Super-Mini Percutaneous Nephrolithotomy with F14 suction-evacuation sheath.
62188696|NCT06155110|NO_INTERVENTION|The control group|
62188697|NCT01190644|EXPERIMENTAL|Sotatercept|Participants will receive a single 35 mg dose of sotatercept by subcutaneous (SC) injection on Day 1, Day 43, and Day 85.
62188698|NCT04264975|EXPERIMENTAL|Fecal microbiota transplantation|Fecal microbiota transplantation in patients who have advanced solid cancer with primary (group 1) or secondary resistance (group 2) to immuno-oncology
62188699|NCT03639727|ACTIVE_COMPARATOR|Citric acid aerosol bronchial challenge|Inhaled citric acid aerosol. This study investigates the diagnostic accuracy of two cough provocation tests, one of which is citric acid aerosol challenge.
62188700|NCT03639727|ACTIVE_COMPARATOR|Mannitol aerosol bronchial challenge|Inhaled mannitol aerosol. This study investigates the diagnostic accuracy of two cough provocation tests, one of which is mannitol aerosol challenge.
62188701|NCT04415645|EXPERIMENTAL|VVZ-149 Injections|
62188702|NCT05846438|EXPERIMENTAL|Showering 48 hours after Surgery|Group 1 will be allowed to shower 48 hours after surgery with drain tubes still in place.
62778683|NCT00679172|EXPERIMENTAL|M01ZH09 Vaccine Candidate Cohort 2|Dose of 7.5 x 10\^9 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
62778684|NCT00679172|EXPERIMENTAL|M01ZH09 Vaccine Candidate Cohort 3|Dose of 1.1 x 10\^10 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
62778685|NCT00679172|EXPERIMENTAL|M01ZH09 Vaccine Candidate Cohort 4|Dose of of 1.7 x 10\^10 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
62003083|NCT02760134|OTHER|SMP with F12 sheath|Patients undergo Super-Mini Percutaneous Nephrolithotomy with F12 suction-evacuation sheath.
62778686|NCT03121755||Sangre Por Salud cohort members|Subjects entered in the Sangre Por Salud Biobank
62778687|NCT04318600|EXPERIMENTAL|human amniotic mesenchymal stem cell treatment group|
62778688|NCT04318600|NO_INTERVENTION|blank control group|
62778689|NCT00350012||1|Persons who have had a stroke and either have, or do not have, a pathological asymmetry of perception, attention and action causing functional disability (spatial neglect; Barrett and Burkholder, 2006).
62778690|NCT00350012||2|Healthy age- and education-matched volunteers
62003084|NCT01173302|EXPERIMENTAL|Post vaccination|All the subjects had been vaccinated with antirabies vaccine.
62003085|NCT04358497|EXPERIMENTAL|Interventional treatment plus best chronic medical treatment|Sandwich embolization ( 2% polidocanol + Coils) Diosmin hisperidin 1g twice a day for 6 months Ibuprofen 500mg 3 times a day for 6 months
62003086|NCT04358497|ACTIVE_COMPARATOR|Best chronic medical treatment alone|Diosmin hisperidin 1g twice a day for 6 months Ibuprofen 500mg 3 times a day for 6 months
62778691|NCT03620734||GAHT and PrEP|HIV-negative TGW will have HIV testing using the 4th generation immunoassays/nucleic acid testing (NAT) in acute HIV testing algorithm currently used at the Thai Red Cross Anonymous Clinic at week 5, 8, and 15. Creatinine clearance will be performed at week 15.
62188703|NCT05846438|NO_INTERVENTION|Showering after drain tubes are removed|Group 2 will not be allowed to shower until drain tubes are removed.
62396235|NCT06224491|SHAM_COMPARATOR|Placebo tactile stimulation|From a standardized starting position for 10 minutes tactile contact in the area outside the description of reflex zones in reflex locomotion according to Vojta.
62571496|NCT02099110|ACTIVE_COMPARATOR|Sitagliptin 100 mg|Sitagliptin 100 mg, oral, once daily for 52 weeks
62778692|NCT03620734||GAHT and ART|HIV-positive TGW on ART will have their plasma HIV RNA measured at the same day ART is initiated and at week 15 (12 weeks after ART provision). CD4 count will be measure at week 15.
62778693|NCT05825391|NO_INTERVENTION|control group|Continue to use the center's original antiplatelet regimen: oral aspirin 100 mg and clopidogrel 75 mg daily
62778694|NCT05825391|EXPERIMENTAL|test group|Use a guided antiplatelet regimen based on LTA testing
62778695|NCT02400021|EXPERIMENTAL|Prometrium|Prometrium (progesterone capsules) intervention
62778696|NCT02400021|NO_INTERVENTION|No treatment|no treatment arm
62778697|NCT05273463|EXPERIMENTAL|Video-Based Education Group|Approximately 4 weeks before scheduled surgery, participants will receive the video-based intervention regarding pre-and postoperative care for ACL reconstruction.
62778698|NCT05273463|EXPERIMENTAL|Virtual Classroom Course Group|Approximately 4 weeks before scheduled surgery, participants will receive the classroom-based intervention regarding pre-and postoperative care for ACL reconstruction.
62778699|NCT05273463|NO_INTERVENTION|Standard of Care Group|Participants will receive verbal and written pre-and postoperative instruction as typically received by all ACL reconstruction patients treated by the attending physicians before and after surgery.
62778700|NCT04343716|EXPERIMENTAL|White women|White women aged 65-75 with knee OA
62778701|NCT04343716|EXPERIMENTAL|Black women|Black women aged 65-75 with knee OA
62003087|NCT01740583|EXPERIMENTAL|annuloplasty|All patients will receive treatment with the Mitralign Percutaneous Annuloplasty System (MPAS).
62003088|NCT04519658|EXPERIMENTAL|CIN-107 0.5mg|Subjects received CIN-107 0.5 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
62003089|NCT04519658|EXPERIMENTAL|CIN-107 1mg|Subjects received CIN-107 1 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
62003090|NCT04519658|EXPERIMENTAL|CIN-107 2mg|Subjects received CIN-107 2 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
62003091|NCT04519658|PLACEBO_COMPARATOR|Placebo|Subjects received placebo tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
62003092|NCT01330758|ACTIVE_COMPARATOR|40 mg AZD8931 wet granulation tablet formulation|
62003093|NCT01330758|EXPERIMENTAL|40 mg AZD8931 roller compacted tablet formulation|
62003094|NCT02566915|NO_INTERVENTION|CPET submaximal without EPAP|Will be collected clinical and anthropometric data of the participants and they are packaged in self-evaluation form. Evaluation of pulmonary function at rest will be rescued from patient charts. When carried out for over six months, will be repeated by the researchers. Patients will conduct incremental CPET of 5-10W/min limited by symptoms (FEV1 \<1L-5W or FEV1\> 1L-10W) (Visit 1). After a period of 2-7 days the CPET will be performed submaximal with 75% of the peak load reached in the incremental CPET (visits 2-3). During the visit without EPAP will be maintained using the facial mask applied without resistance.
62003095|NCT02566915|EXPERIMENTAL|CPET submaximal with EPAP|Will be collected clinical and anthropometric data of the participants and they are packaged in self-evaluation form. Evaluation of pulmonary function at rest will be rescued from patient charts. When carried out for over six months, will be repeated by the researchers. Patients will conduct incremental CPET of 5-10W/min limited by symptoms (FEV1 \<1L-5W or FEV1\> 1L-10W) (Visit 1). After a period of 2-7 days the CPET will be performed submaximal with 75% of the peak load reached in the incremental CPET (visits 2-3). The application of EPAP (10cmH2O) via face mask (Vital RHDSON Signs®, New Jersey, USA) will be randomized with the help of opaque envelopes to be given in one visit. IC serial measurements will be carried out before, during and immediately after the exercise.
62003096|NCT05471362||Cases women who used IUD|Cases: women who had immediate Copper IUD inserted since October 2021 at the 4 public hospitals
62003097|NCT05471362||Control women who didn't use IUD|Controls: women who gave birth at the same hospitals and not using the immediate Copper IUD
62188704|NCT01774136|EXPERIMENTAL|Enhanced HIV and MCH training for CHW|The intervention includes two components: (1) a 2-week HIV/C-IMCI training for CCGs and their associated facilitators and supervisors, and (2) continuous support and supervision following the continuous quality improvement (CQI) framework, a low-technology approach to management and supervision of health programs.
62188705|NCT01774136|NO_INTERVENTION|Standard of Care|
62188706|NCT02250690|EXPERIMENTAL|experimental group - tDCS|The tDCS intervention occur at 10 sessions of intervention where electrodes are connected to head specifically in supplementary motor area placed at 2 cm in front of vertex. The clinical stimulator (NeuroConn, Germany) provided the direct current using two silicon-sponge electrodes with a surface area of 35 cm2 (5 × 7cm) embedded in a saline-soaked solution. Immediately after 13 minutes of tDCS application, patient was submitted to gait training three times a week during 4 weeks with visuals cues. The patients were asked to walk along at a 7 meters rubber carpet to at different speed, forward and backward gait, side walk during thirty minutes with three intervals of two minutes. The patient may be at on state of drug administration and the training is applied by another physiotherapist.
62188707|NCT02250690|SHAM_COMPARATOR|Control group (tDCS sham)|The sham character is ensured by the stimulation time, once the device is programmed to turn off 30 seconds after the beginning of stimulation. The current is switched in ascending ramp mode for 10 seconds until 2 mili ampere and a descending ramp similar also for 10 seconds will be used until the end of stimulation. The sham stimulation is commonly perceived by the patient as the actual treatment and all procedures for the application of the technique should be similar to those adopted for the active stimulation. Immediately after tDCS stimulation, the gait training consisting of a protocol based on sensory cues for 30 minutes is administered three times a week for four weeks. Sham stimulation will be held for 30 seconds in order to mimic the perceived lowering effect of ramp current.
62003098|NCT04361461|EXPERIMENTAL|Group 1|Hydroxychloroquine (400 mg)
62003099|NCT04361461|EXPERIMENTAL|Group 2|Hydroxychloroquine (400 mg) + azithromycin (500 mg)
62003100|NCT00729352||Control group|18-35 yr old healthy subjects with wild type genotype for NQO1.
62003101|NCT00729352||Case group|18-35 yr old healthy subjects who are homozygotic for minor allele of NQO1 Pro187Ser polymorphism
62003102|NCT00646412|EXPERIMENTAL|A|A-Part® Gel
62188708|NCT00848510|EXPERIMENTAL|EMD 525797|
62188709|NCT01536171||Shod versus Barefoot Running|two running conditions, with normal running shoes and barefoot
62003103|NCT00646412|NO_INTERVENTION|B|untreated control group
62003104|NCT06075485||Patient|Infants (from 5 months) and children up to 17 years of age follow up for drug resistant epilepsy
62003105|NCT01700179|EXPERIMENTAL|ACH-0143102 plus ribavirin daily|ACH-0143102 loading dose (225 milligrams \[mg\]) on Day 1, followed by maintenance doses (75 mg) on Days 2-84, plus weight-based ribavirin as per label on Days 1-84.
62003106|NCT01384058|ACTIVE_COMPARATOR|Ezetimibe 10mg/d|intake of ezetimibe 10mg per day for six weeks after wash-out
62778702|NCT03580226||Good glycemic control|Good glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c \< 7.0.
62003107|NCT01384058|ACTIVE_COMPARATOR|Simvastatin 20 mg per day|intake of simvastatin 20 mg per day for six weeks after wash-out
62188710|NCT03947008|EXPERIMENTAL|First Intuitive Eating Group (IE1)|IE1 will be the first group to participate in an intuitive eating program and will be required to attend five intuitive eating classes. The intuitive eating classes will be 60-minutes each week for 5 weeks. An initial assessment will be conducted during the first thirty minutes of the first intuitive eating class. A final assessment will be conducted during the last 30 minutes of the last intuitive eating class. This group will have an additional final assessment on the last day of the IE2's intuitive eating course. During the assessments, they will complete a questionnaire that will ask them about their body satisfaction and eating attitudes, and have their height and weight measured.
62778703|NCT03580226||Poor glycemic control|Poor glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c \>= 7.0.
62778704|NCT03887221|EXPERIMENTAL|Safinamide 50mg|The subjects will receive 50mg safinamide on Day 1 of Period 1 and on Days 8 to 14 in period 2.
62778705|NCT03887221|EXPERIMENTAL|Safinamide 100mg|The subjects will receive 100mg safinamide on Day 1 of Period 1 and on Days 8 to 14 in period 2.
62778706|NCT04992195||Vaccination Group|Citizens who received baseline cognitive assessment and evaluation of metabolic risk factors from the CUHK Brain Health Longitudinal Study. Baseline micro- and macro-cerebrovascular abnormalities were evaluated by MRI brain on recruitment and received COVID-19 vaccination (SinoVac or BioNTech).
62778707|NCT04992195||Control Group|Citizens who received baseline cognitive assessment and evaluation of metabolic risk factors from the CUHK Brain Health Longitudinal Study. Baseline micro- and macro-cerebrovascular abnormalities were evaluated by MRI brain on recruitment and have not received any COVID-19 vaccines nor clinically/serologically evident SARS-CoV-2 infection.
62003108|NCT01384058|ACTIVE_COMPARATOR|Ezetimibe 10 mg/d and Simvastatin 20mg/d|intake of ezetimibe 10 mg and simvastatin 20 mg per day for six weeks after wash-out
62003109|NCT04348513|EXPERIMENTAL|T3 solution for injection|T3 Solution for injection 10 μg/ml, each vial contains 150μg of liothyronine in a total volume of 15ml. The dose administered will be 0.8g/kg i.v. bolus starting within 60min after respiratory support and will be followed by an infusion of 0.113g. kg-1.h-1 i.v. for 48 hours (therapeutic dose). After the first 48h, a maintenance dose will be administered corresponding to 50% of the therapeutic dose (0.057g. kg-1.h-1 i.v.). Drug administration will stop after successful weaning or end of followup (maximum 30 days).
62003110|NCT04348513|PLACEBO_COMPARATOR|Placebo|Composition identical apart from the active substance. Same dosage.
62003111|NCT02259933|EXPERIMENTAL|KUC 7483 CL|increasing repeated oral doses
62003112|NCT02259933|PLACEBO_COMPARATOR|Placebo|
62003113|NCT02351869|ACTIVE_COMPARATOR|Nitrous oxide|N2O-condition participants will inhale an initial mixture of 10% N2O in oxygen (O2) for 5 minutes, followed by 25% N2O in O2 for 20 minutes. N2O-condition participants will also receive 5ml intravenous saline concomitantly with 10% N2O, and again with 25% N2O.
62396236|NCT06224491|EXPERIMENTAL|Reflex locomotion zone stimulation|From a standardized starting position tactile stimulation in the area of the zone in reflex locomotion according to Vojta for 10 minutes .
62778708|NCT01008449|ACTIVE_COMPARATOR|Absorbable Subcuticular Surgical Suture|Patients in this arm will receive absorbable subcuticular suture for wound closure of cesarean deliveries.
62003114|NCT02351869|PLACEBO_COMPARATOR|Midazolam|Inhaled room air plus intravenous midazolam bolus (total 2mg). Midazolam-condition participants will receive intravenous infusions of 0.5mg midazolam in 5ml saline (start of 1st inhalation epoch), followed by 1.5mg midazolam in 5ml saline (start of 2nd inhalation epoch).
62003115|NCT01964911|EXPERIMENTAL|Ropivacaïne|
62778709|NCT01008449|ACTIVE_COMPARATOR|Surgical staples|Patients in this arm will receive surgical staples for wound closure.
62003116|NCT00502697|EXPERIMENTAL|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic visits. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
62003117|NCT00502697|OTHER|Conventional prenatal/postpartum care|Women assigned to the control arm of the study received conventional prenatal and postpartum clinic care.
62396237|NCT06722014|EXPERIMENTAL|Cohort A: User Acceptability Testing|15 participants will be enrolled for this cohort. Participants will engage in a one-time interview with study staff or a focus group with other participants. Application testing and user acceptability testing will be completed by participants to provide feedback for refining the intervention.
62571497|NCT04891146||Inhalation anesthesia|Sevoflurane for opioid remifentanyl used
62571498|NCT04891146||Total Intravenous Anesthesia|Propofol for opioid remifentanyl used
62003118|NCT00352612|PLACEBO_COMPARATOR|cephalexin|
62214673|NCT03821779|EXPERIMENTAL|Group 1: Go-no-go phase|"The presence of significant prefrontal oscillations in the EEG recording 2-6Hz band during in vivo social exposure (oral presentation to examiners) will be assessed in 10 subjects with social anxiety disorder. EEG will be recorded immediately before, during and after oral presentations to examiners.~Psychometric evaluation will be performed prior to experimental sessions. Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods (wainting, presentation, recovery).~Results of EEG recordings in the first 10 subjects will lead to continuation (presence of significant slow prefrontal oscillations during anxiety) or interruption (absence of signification oscillation) of the study."
62396238|NCT06722014|EXPERIMENTAL|Cohort B: Pre-Pilot Testing|8 participants will be enrolled for this cohort and will engage in a 4-week testing period of the intervention followed by a one-time interview with study staff.
62571499|NCT06001710|ACTIVE_COMPARATOR|classic inferior alveolar nerve block anesthesia|Inferior alveolar nerve block (IANB) is a technique of dental anesthesia, used to produce anesthesia of the mandibular teeth, gingivae of the mandible and lower lip. The conventional IANB is the most commonly used the nerve block technique for achieving local anesthesia for mandibular surgical procedures using long needle
62571500|NCT06001710|EXPERIMENTAL|needleless jet injector anesthesia|Jet injection technology uses mechanical energy to force a liquid drug into subcutaneous tissues without a needle using infiltration technique
62571501|NCT06213584|EXPERIMENTAL|mulligan mobilization|Mulligan mobilization techniques
62571502|NCT06213584|EXPERIMENTAL|pnf|Proprioceptive neuromuscular fasciliation techniques
62571503|NCT06213584|EXPERIMENTAL|conservative rehabilitation|Conservative rehabilitation
62571504|NCT03259425|EXPERIMENTAL|Nivolumab and HF10, all participants|
62571505|NCT06444776||Head and neck cancer patients referred for radiation therapy|
62571506|NCT04856007|EXPERIMENTAL|Dapagliflozin 5mg + Metformin 500mg XR|co-administration of a single oral dose of a 5mg dapagliflozin (Forxiga® 5mg) tablet and a 500mg metformin XR (Glucophage XR®) tablet
62571507|NCT04856007|EXPERIMENTAL|Dapagliflozin/metformin XR FDC 5/500 mg|single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR subject
62571508|NCT04856007|EXPERIMENTAL|Dapagliflozin 10mg + Metformin 1000mg XR|co-administration of a single oral dose of a 10mg dapagliflozin (Forxiga® 10mg) tablet and two 500mg metformin XR (Glucophage XR®) tablets
62571509|NCT04856007|EXPERIMENTAL|Dapagliflozin/metformin XR FDC 10/1000 mg|ingle FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR
62003119|NCT00352612|ACTIVE_COMPARATOR|clindamycin|
62003120|NCT02684227|EXPERIMENTAL|Treatment (enzalutamide, paclitaxel, carboplatin)|Patients receive enzalutamide PO QD alone on days 1-28. Patients then receive enzalutamide PO QD on days 1-21, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6-9 cycles in the absence of disease progression or unacceptable toxicity.
62003121|NCT02531165|EXPERIMENTAL|Morphine|"* Pre-hospital Ticagrelor 180 mg loading dose orally.~* Morphine, initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required.~* Aspirin 500 mg loading dose orally (or intravenously).~* Unfractioned heparin 5'000 IU loading dose intravenously, additional doses to achieve an ACT \>250 sec during PCI are allowed.~* Primary PCI."
62778710|NCT05131230||CytoSorb group|
62778711|NCT04965662|EXPERIMENTAL|Arm A: Home PEPSE (Immediate)|Patients randomised to the immediate arm (ARM A) will receive a 5 day PEPSE 'Home pack' containing Truvada® (tenofovir disoproxil -as fumarate- 245 mg, emtricitabine 200 mg), ONE tablet OD and Maraviroc 300 mg, TWO tablets OD.
62778712|NCT04965662|NO_INTERVENTION|Arm B: Standard of Care (Deferred)|Standard of care antiretroviral therapy for PEPSE as per the British Association for Sexual Health and HIV (BASHH) guidelines.
62778713|NCT02760316|EXPERIMENTAL|AZD9567 oral suspension of 10 mg|Participants will receive oral supension of 10 mg dose strength
62003122|NCT02531165|EXPERIMENTAL|Fentanyl|"* Pre-hospital Ticagrelor 180 mg loading dose orally.~* Fentanyl, initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required.~* Aspirin 500 mg loading dose orally (or intravenously).~* Unfractioned heparin 5'000 IU loading dose intravenously, additional doses to achieve an ACT \>250 sec during PCI are allowed.~* Primary PCI."
62003123|NCT00880945||36-40 patients|patients with small peripheral lesions who need bronchoscopy for diagnostic purposes
62003124|NCT05902208|EXPERIMENTAL|Valaciclovir|
62003125|NCT05902208|PLACEBO_COMPARATOR|Placebo|
62003126|NCT02187302|EXPERIMENTAL|CRLX101 + bevacizumab|"CRLX101 in combination with bevacizumab:~* CRLX101 15 mg/m\^2 IV on days 1 and 15 of a 28-day cycle;~* bevacizumab 10 mg/kg IV on days 1 and 15 of a 28-day cycle."
62003127|NCT02187302|ACTIVE_COMPARATOR|Standard of Care|Standard of care treatment include one of the following agents to which the patient can have no prior exposure: sorafenib; everolimus; pazopanib; axitinib; bevacizumab; sunitinib, or other approved drug considered by the Medical Monitor to represent an acceptable standard of care therapy
62003128|NCT01514552|PLACEBO_COMPARATOR|Placebo gummy|Each 6 gram placebo gummy contains 79% corn syrup (Karo, ACH Food Companies, Memphis, TN), 20% wheat starch (Confectioners G, Tate and Lyle PLC., Decatur, IL), 1% artificial strawberry flavors (Kool-Aid Kraft Foods, East Hanover, NJ).
62396239|NCT06722014|EXPERIMENTAL|Cohort C: STAMP + CBT App|"Permutated-block randomization and a block size of 6 will be used to randomize 30 participants to this cohort, and participants will complete:~* Baseline in-person or remote visit with an introduction to the STAMP+CBT application.~* Surveys via the application 6 days per week.~* Day 7 check in with study team~* Day 14 survey~* Day 28 follow-up surveys~* Optional in-person or remote semi-structured, exit interview~* Day 42 (Week 6) follow-up survey"
62396240|NCT06722014|OTHER|Cohort D: Digital Cancer Pain Education Packet + Usual Care|"Permutated-block randomization and a block size of 6 will be used to randomize 30 participants to this cohort, and participants will complete:~* Baseline in-person or remote visit with introduction to the digital cancer pain education packet and pain tracker form.~* Completion of pain tracker~* Day 7 check in with study team~* Day 14 survey~* Day 28 surveys~* Optional in-person or remote semi-structured, exit interview to review the educational packet~* Day 42 (Week 6) follow-up survey"
62571510|NCT00648115|OTHER|Basic Vocational Services|Veteran receives basic vocational services
62571511|NCT00648115|ACTIVE_COMPARATOR|Self-Study|Veteran participates in self-study vocational program
62778714|NCT02760316|EXPERIMENTAL|AZD9567 oral suspension of 20 mg|Participants will receive oral suspension of 20 mg dose strength
62003129|NCT01514552|ACTIVE_COMPARATOR|Strawberry gummy|Each 6 gram strawberry gummy contains 45% freeze-dried fruit (California Strawberry Commission), 44% corn syrup (Karo, ACH Food Companies, Memphis, TN), 11% wheat starch (Confectioners G, Tate and Lyle PLC., Decatur, IL). With this formulation, daily fruit consumption is equivalent to 1 cup of whole strawberries. All ingredients (wheat starch, freeze-dried fruit, and high fructose corn syrup) will be purchased from a single lot. When a single lot is not available then the multiple manufacturing lots will be mixed into a single lot to be used for production of fruit gummies.
62003130|NCT05466396||Smokers with Pre-COPD|Smoking history ≥ 10 pack-years 0.7≤ FEV1/FVC\<0.8 and FEV1%pred ≥ 80% (post-bronchodilator)
62003131|NCT05466396||Smokers with Mild-COPD|Smoking history ≥ 10 pack-years FEV1/FVC\<0.7 and FEV1%pred ≥ 80% (post-bronchodilator)
62003132|NCT05466396||Non-Smokers with Pre-COPD|Smoking history \< 10 pack-years or never-smokers 0.7≤ FEV1/FVC\<0.8 and FEV1%pred ≥ 80% (post-bronchodilator)
62003133|NCT05466396||Non-Smokers with Mild-COPD|Smoking history \< 10 pack-years or never-smokers FEV1/FVC\<0.7 and FEV1%pred ≥ 80% (post-bronchodilator)
62003134|NCT05466396||Healthy Controls|Healthy volunteers without smoking history FEV1/FVC ≥ 0.8 and FEV1%pred ≥ 80% (post-bronchodilator)
62003135|NCT01345279||cisplatin|
62003136|NCT01345279||cisplatin + topotecan|
62003137|NCT01345279||cisplatin + paclitaxel|
62571512|NCT00648115|ACTIVE_COMPARATOR|Group program|Group based vocational program
62571513|NCT01615406|EXPERIMENTAL|Drug: 99mTc-MIP-1404|20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
62571514|NCT02108548|EXPERIMENTAL|Part 1: ASP7657 Single Ascending Dose|
62571515|NCT02108548|EXPERIMENTAL|Part 1: ASP7657 Single Ascending Dose - Food Effect|
62778715|NCT02760316|EXPERIMENTAL|AZD9567 oral suspension of 40 mg|Participants will receive oral suspension of 40 mg dose strength
62778716|NCT02760316|EXPERIMENTAL|AZD9567 oral suspension of 80 mg|Participants will receive oral suspension of 80mg dose strength
62003138|NCT04272398|ACTIVE_COMPARATOR|Treatment|Used dynamic elastomeric fabric orthoses with physiotherapy and rehabilitation program
62003139|NCT04272398|EXPERIMENTAL|Control|Only physiotherapy and rehabilitation program
62003140|NCT01723865||Conventional|Patients with heart failure having an ICD-CRT implanted, followed by conventional visits.
62003141|NCT01723865||Remote Monitoring|Patients with heart failure having an ICD-CRT implanted, followed by remote monitoring.
62003142|NCT00983281||Hextend|Patients that received Hextend as part of their fluid resuscitation.
62571516|NCT02108548|PLACEBO_COMPARATOR|Part 1: Placebo|
62571517|NCT02108548|EXPERIMENTAL|Part 2: ASP7657 Multiple Ascending Dose|
62003143|NCT00983281||Standard of Care|Patients that received standard fluid resuscitation but no Hextend.
62003144|NCT01374308|EXPERIMENTAL|NASVAC|NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
62003145|NCT01374308|ACTIVE_COMPARATOR|Pegylated interferon alpha 2b|Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
62003146|NCT03341052|ACTIVE_COMPARATOR|Obese Participants|Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
62003147|NCT03341052|ACTIVE_COMPARATOR|Normal Weight Participants|Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
62003148|NCT05453838|OTHER|New product - Original product|All subjects will receive first product A and then product B. In addition, the reference product will also be received (three times a glucose solution during the trial).
62003149|NCT05453838|OTHER|Original product - New product|All subjects will receive first product B and then product A. In addition, the reference product will also be received (three times a glucose solution during the trial).
62003150|NCT05572502|EXPERIMENTAL|Vegan diet|All participants will follow a low-fat vegan diet. There are no other study arms or control group.
62571518|NCT02108548|EXPERIMENTAL|Part 2: ASP7657 Multiple Ascending Dose Elderly|
62571519|NCT02108548|PLACEBO_COMPARATOR|Part 2: Placebo|
62396241|NCT06580106||AML participants who are receiving or are planned to receive azacitidine plus venetoclax|Buccal swabs for SNPs and pharmacogenomic analysis will be collected at baseline. Venetoclax peak and trough levels will be obtained during SOC Aza/Ven treatments. CYP3A activity will also be evaluated. Demographic and cancer related history will be acquired for each participant. During study participation, cancer treatment details including administration, dose modifications, delays, and reductions, including specific grade 3 toxicities, stem cell transplant status, symptom burden, disease response, and survival will be collected. Participants will be taken off study after three years.
62571520|NCT02108548|ACTIVE_COMPARATOR|Part 2: Naproxen|
62003151|NCT04433897||Oral estrogen + IUD|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + IUD
62003152|NCT04433897||Oral estrogen + hysterectomy|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + hysterectomy.
62003153|NCT04433897||Oral estrogen + oral progesterone|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + oral progesterone.
62003154|NCT04433897||Transdermal estrogen + IUD|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + IUD.
62003155|NCT04433897||Transdermal estrogen + hysterectomy|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + hysterectomy.
62003156|NCT04433897||Transdermal estrogen + oral progesteron|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + oral progesteron
62003157|NCT04433897||SERM|Women who opt to be treated for their postmenopausal symptoms using SERM's
62003158|NCT04433897||Aromatase inhibitor|Women who opt to be treated for their postmenopausal symptoms using aromatase inhibitor.
62003159|NCT04433897||Duavive|Women who opt to be treated for their postmenopausal symptoms using duavive.
62571521|NCT05738057|EXPERIMENTAL|Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and Camrelizumab|"D-TACE with cisplatin-eluting beads. More TACE can be done if clinically necessary.~Camrelizumab (200 mg, Intravenous drips (ivd), D1/3W) plus Gem (1000 mg/m2, ivd, D1\&8/3W) and Cis (25 mg/m2, ivd, D1\&8/3W). Three weeks are one cycle of treatment. Chemotherapy lasted for no more than 12 cycles."
62003160|NCT04433897||No treatment|Women who opt not to be treated for their postmenopausal symptoms.
62003161|NCT05117463||Healthy Younger Adults|Healthy younger adults without any neurological and orthopedic disorders.
62003162|NCT05117463||Healthy Older Adults|Healthy older adults without any neurological and orthopedic disorders.
62003163|NCT05117463||Older Adults with higher risk of falls|Older adults with a history of falls or poor balance based on the clinical balance and gait assessment.
62003164|NCT01387607|EXPERIMENTAL|Pregabalin|
62003165|NCT01387607|PLACEBO_COMPARATOR|Placebo|Matched placebo
62003166|NCT06478004|EXPERIMENTAL|Direct resin composite with the help of custom 3D printed templates|Directly restoring carious primary anterior teeth with resin composite with the help of custom 3D printed templates obtained from digitally waxed-up patients' dental models.
62003167|NCT06478004|ACTIVE_COMPARATOR|Direct resin composite using conventional strip crowns.|Directly restoring carious primary anterior teeth with resin composite using conventional strip crowns.
62003168|NCT01917071|EXPERIMENTAL|Matched Group|Receives thoracic spine manipulation in the direction of motion limitation.
62571522|NCT00162110|ACTIVE_COMPARATOR|1|
62571523|NCT03055299|EXPERIMENTAL|COMEX|Patients receive comprehensive exercise intervention
62778717|NCT02760316|ACTIVE_COMPARATOR|Prednisolone oral capsules of 20 mg|Participants will receive oral capsules of 5 mg dose strength
62778718|NCT02760316|EXPERIMENTAL|AZD9567 oral suspension of 125 mg|Participants will receive oral suspension of 125 mg dose strength
62778719|NCT02760316|EXPERIMENTAL|AZD9567 oral suspension of 155 mg|Participants will receive oral suspension of 155 mg dose strength
62778720|NCT02760316|ACTIVE_COMPARATOR|Prednisolone oral capsules of 5 mg|Participants will receive oral capsules of 5 mg dose strength
62778721|NCT02760316|ACTIVE_COMPARATOR|Prednisolone oral capsules of 40 mg|Participants will receive oral capsules of 5 mg dose strength
62778722|NCT00585273||1|Incident users of antipsychotics.
62003169|NCT05676892|EXPERIMENTAL|The experimental group in benign gallbladder disease|"inclusion criteria~* Patients who underwent elective gallbladder surgery (cholelithiasis, chronic cholecystitis, gallbladder polyps, gallbladder adenomyomatosis) ② Patients between the ages of 19 and 65 ③ A person who voluntarily signed a written consent form after hearing and understanding the explanation of this clinical trial~intravenous ibuprofen 800mg/8ml was used after surgery."
62003170|NCT05676892|EXPERIMENTAL|The controled group in benign gallbladder disease|"inclusion criteria~* Patients who underwent elective gallbladder surgery (cholelithiasis, chronic cholecystitis, gallbladder polyps, gallbladder adenomyomatosis) ② Patients between the ages of 19 and 65 ③ A person who voluntarily signed a written consent form after hearing and understanding the explanation of this clinical trial~normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) was used after surgery."
62003171|NCT01852292|EXPERIMENTAL|Buparlisib + weekly Paclitaxel|Patients who were randomized to this arm on a 1:1 randomization, took buparlisib 100 mg daily and paclitaxel 80 mg/m\^2 weekly.
62003172|NCT01852292|PLACEBO_COMPARATOR|Buparlisib matching placebo + Paclitaxel|Patients who were randomized to this arm on a 1:1 randomization, took buparlisib matching placebo 100 mg daily and paclitaxel 80 mg/m\^2 weekly.
62003173|NCT00864162|EXPERIMENTAL|A|Ramipril10 mg Capsules, single dose
62778723|NCT00585273||2|Non-users of antipsychotics
62778724|NCT02447978||PCR-positive pertussis cases|Cases will be all individuals who tested PCR-positive for pertussis and negative for parapertussis during the study period and who received 5 doses of DTaP vaccines (either manufactured by GSK or any brand, depending on study objective) through 84 months of age before testing PCR-positive.
62003174|NCT00864162|ACTIVE_COMPARATOR|B|Atlace® 10 mg capsules, single dose
62003175|NCT03582488|EXPERIMENTAL|Dementia with Lewy Bodies|18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology
62778725|NCT02447978||PCR-negative pertussis controls|Controls will consist of persons who tested PCR-negative for both pertussis and parapertussis and who received 5 DTaP doses (either manufactured by GSK or any brand, depending on study objective) before testing PCR negative.
62778726|NCT02447978||KPNC-matched controls|Controls will consist of all KPNC members of the same sex, age (year and quarter of birth), race or ethnic group (7 groups; 6 for reported, 1 for imputed), and medical centre as each pertussis case and who were members on the date the case tested PCR-positive (anchor date).
62778727|NCT04741763|PLACEBO_COMPARATOR|Placebo|Maltodextrin Placebo: Experimental is 1:2
62003176|NCT06023784|EXPERIMENTAL|left bundle branch area pacing|
62003177|NCT06023784|ACTIVE_COMPARATOR|right ventricular pacing|
62003178|NCT04452266||case group|Women with Lynch Syndrome and endometrial Cancer matched on age of endometrial cancer diagnosis
62003179|NCT04452266||control group|Women with Lynch Syndrome, without Cancer at Lynch Syndrome Diagnostic matched on their age at Lynch Diagnostic
62396242|NCT02425774|PLACEBO_COMPARATOR|Sham stimulation + Placebo|"* no stimulation~* 1 placebo tablet at two different timepoints before surgery"
62571524|NCT00424619|ACTIVE_COMPARATOR|1|50 000 IU Vitamin D2
62778728|NCT04741763|EXPERIMENTAL|Active|Eye Promise Visual Edge containing 8 mg zeaxanthin \& 4 mg lutein Placebo: Experimental is 1:2
62396243|NCT02425774|ACTIVE_COMPARATOR|Vagus stimulation + placebo|"* Stimulation at the beginning and the end of the surgery~* 1 placebo tablet at two different timepoints before surgery"
62396244|NCT02425774|ACTIVE_COMPARATOR|Prucalopride + sham stimulation|"* 1 prucalopride tablet at two different timepoints before surgery~* no stimulation"
62396245|NCT00142428|EXPERIMENTAL|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
62571525|NCT00424619|ACTIVE_COMPARATOR|2|100 000 IU Vitamin D2
62778729|NCT05961137|ACTIVE_COMPARATOR|After-phase: Incorporation of Rapid Fluid Infusion Device in Prehospital Suspected Sepsis Protocol|Modified protocol specifying intravenous crystalloid infusion Rapid Fluid Infusion Device. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
62778730|NCT05961137|ACTIVE_COMPARATOR|Before phase: Conventional Prehospital Suspected Sepsis Protocol|Conventional protocol employing intravenous crystalloid infusion via gravity or pressurized-bag. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
62778731|NCT02555384|ACTIVE_COMPARATOR|crowded drawing task|children will be asked to draw on a pattern presented under crowded viewing conditions.
62778732|NCT02555384|PLACEBO_COMPARATOR|uncrowded drawing task|children will be asked to draw on a pattern presented under uncrowded viewing conditions
62571526|NCT00424619|PLACEBO_COMPARATOR|3|Placebo
62584892|NCT01981954|EXPERIMENTAL|Solifenacin succinate|Children aged 6 months to less than 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods.
62778733|NCT04313478||Low Birth Weight Infants|They were as follows: being at 3 to 9 months' corrected age, gestational age of less than 36 weeks + 6 days, birth weight of 2000 g or less. Infants with any genetic, metabolic, orthopedic congenital abnormalities or chronic diseases and parents' rejection to participate in the study were excluded.
62778734|NCT04313478||Normal Weight Infants|They were as follows: being between 3 and 9 months of age, being full-term, had no complications during delivery. Infants that presented any type of sensory or motor disorder were excluded.
62778735|NCT03659877|EXPERIMENTAL|Heart failure patients|Patients will be required to perform a number of physical activity tasks such as laying down, sitting and walking. During these activities, acceleration, oxygen consumption, rating of perceived exertion and heart rate will be recorded.
62003180|NCT05049161|EXPERIMENTAL|Temelimab 18 mg/kg|Monthly IV repeated dose
62003181|NCT05049161|EXPERIMENTAL|Temelimab 36 mg/kg|Monthly IV repeated dose
62003182|NCT05049161|EXPERIMENTAL|Temelimab 54 mg/kg|Monthly IV repeated dose
62003183|NCT01594593|EXPERIMENTAL|Acceptance and Commitment Therapy|Group-based behavioral workshop to address cancer-related distress
62003184|NCT01594593|NO_INTERVENTION|treatment as usual|
62003185|NCT05738200|EXPERIMENTAL|Nordic Hamstring Exercise|A 4-week (10 session), progressive, Nordic Hamstring Exercise (NHE) protocol will be used for this study.
62584893|NCT05787561|EXPERIMENTAL|Avutometinib (VS-6766) and Defactinib|All enrolled patients will be treated with Avutometinib (VS-6766) 3.2 mg PO, twice weekly (e.g. M/Th,Tu/F, or W/Sa) + defactinib 200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle.
62584894|NCT06128044|EXPERIMENTAL|Dose Escalation of CB-012|Part A (Dose Escalation) of CB-012 with increasing doses using a 3+3 design, during which the MTD and/or RDE will be identified.
62003186|NCT05738200|NO_INTERVENTION|Control|Patients randomized to the control group will be instructed to avoid any changes to their normal routine (e.g., physical activity level, strength training, etc.). An investigator not involved in data collection will communicate with patients in the control group on a weekly basis to ensure they have not changed their physical activity level and do not have any questions. Patients randomized to the control group will participate in a minimum of 2 study visits at baseline and 4 weeks. These individuals will have the option to open enroll in the intervention group at the completion of their original 4-week study period. Those who choose to enroll in the intervention group at this time will return for 11 additional visits to complete the NHE protocol (visits 3-12) and final assessment (visit 13)
62003187|NCT02698358||K-EPIC|Patients with femoropopliteal artery disease undergoing endovascular therapy using Epic stent (Boston Scientific).
62003188|NCT00004031|ACTIVE_COMPARATOR|CHOP/CHOP-R x 3|Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Prednisone 100 mg/day PO Days 1-5 Vincristine 1.4 mg/m2 IV Day 1 Rituximab 375 mg/m2 IV Day 1 This regimen is repeated every 21 days for 8 cycles
62003189|NCT00004031|EXPERIMENTAL|CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant|Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Prednisone 100 mg/day PO Days 1-5 Vincristine 1.4 mg/m2 IV Day 1 Rituximab 375 mg/m2 IV Day 1 This regimen is repeated every 21 days for 6 cycles followed by autologous stem cell transplant.
62003190|NCT03892980|EXPERIMENTAL|Nipple Sparing Mastectomy|
62003191|NCT04734340|EXPERIMENTAL|EIT-guided group|Treatment based on EIT
62003192|NCT04734340|PLACEBO_COMPARATOR|Control group|Treatment based on ARDS-net Peep setting
62003193|NCT01166308|EXPERIMENTAL|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I Part of the Trial
62003194|NCT01166308|ACTIVE_COMPARATOR|Standard Treatment: Fractionated Stereotacitc Radiotherapy|Standard Precision Radiotherapy performed as Fractionated Stereotactic Radiotherapy (FSRT) up to 36 Gy in single dosis of 2 Gy
62003195|NCT01844258|EXPERIMENTAL|Modified technique for I/A group|"* In the modified cataract surgery procedure, the size of the capsulorhexis opening will be decreased to 1.0-1.5 mm in diameter.~* The capsulorhexis will be located in the peripheral area of the lens instead of the central area.~* A 0.9 mm phacoemulsification probe will be used to remove the cataractous lens.~* One drop of 0.5% or 1% atropine and an antibiotic/steroid ointment will be placed in the eye, which will then be patched."
62003196|NCT01844258|ACTIVE_COMPARATOR|Traditional technique for I/A group|• In traditional technique group, the cataractous lens will be removed through an anterior continuous curvilinear capsulorhexis (ACCC) that is about 5-6 mm in diameter.
62396246|NCT04854356|EXPERIMENTAL|HIE with BFR during exercise phase|BFR with 40% Arterial occlusive pressure cycling at 85% VO2max for 3 minutes and rest interval for 3 minutes (4 sets) each time during exercise
62396247|NCT04854356|ACTIVE_COMPARATOR|HIE with BFR during interval phase|BFR with 40% Arterial occlusive pressure cycling at 85% VO2max for 3 minutes and rest interval for 3 minutes (4 sets) each during the interval
62396248|NCT04854356|NO_INTERVENTION|HIE without BFR|Cycling at 85% VO2max for 3 minutes and rest interval for 3 minutes (4 sets) each time during exercise
62396249|NCT05512585|ACTIVE_COMPARATOR|awake prone positioning with room air|Participants will stay in the prone position
62396250|NCT05512585|EXPERIMENTAL|awake prone positioning with high-flow nasal cannula|Participants will stay in the prone position and breathe with high-flow nasal cannula
62396251|NCT05512585|EXPERIMENTAL|awake prone positioning with continuous positive airway pressure|Participants will stay in the prone position and breathe with continuous positive airway pressure via face mask
62396252|NCT05512585|NO_INTERVENTION|supine position with room air|Participants will stay in the supine position
62396253|NCT05512585|ACTIVE_COMPARATOR|supine position with high-flow nasal cannula|Participants will stay in the supine position and breathe with high-flow nasal cannula
62778736|NCT05095948||Supportive Care (questionnaire, clinic conversation)|Patients complete questionnaires over 15-20 minutes and undergo audio recording of clinic conversations between the oncology team or the specialist palliative care team. Patients' medical records are also reviewed.
62778737|NCT02047526||1|
62778738|NCT03954613|EXPERIMENTAL|Group A|Donepezil/Memantin Combination
62778739|NCT03954613|EXPERIMENTAL|Group B|Donepezil/Memantin Combination + Cognitive Exercises (BEYNEX Software)
62778740|NCT03954613|ACTIVE_COMPARATOR|Group C|Donepezil Mono
62778741|NCT03954613|ACTIVE_COMPARATOR|Group D|Donepezil Mono + Cognitive Exercises (BEYNEX Software)
62778742|NCT03954613|ACTIVE_COMPARATOR|Group E|Memantine Mono
62778743|NCT03954613|ACTIVE_COMPARATOR|Group F|Memantine Mono + Cognitive Exercises (BEYNEX Software)
62778744|NCT01910467|EXPERIMENTAL|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases \>5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
62778745|NCT01910467|OTHER|NIRS not visible and treatment as usual|NIRS measurements are not visible and the patients will be treated according to routine ('treatment as usual')
62778746|NCT01647334|EXPERIMENTAL|Shrinking Target Adaptive Radiotherapy|Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer
62778747|NCT05122299|OTHER|Negative control group|
62003197|NCT01782313|EXPERIMENTAL|Treatment (tivozanib)|Patients receive tivozanib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62003198|NCT03568942|EXPERIMENTAL|Female subjects with acute cystitis|Adult female subjects with suspected acute cystitis based on clinical presentation and pyuria (\>=10 WBC/mm\^3 or presence of leukocyte esterase) and/or nitrite will be included. Subjects will be administered 1500 mg gepotidacin BID for 5 days via the oral route.
62778748|NCT05122299|ACTIVE_COMPARATOR|Positive control group|
62778749|NCT05122299|EXPERIMENTAL|Study group|
62003199|NCT06538623|EXPERIMENTAL|Liposome Irinotecan Injection II via Hepatic Arterial Infusion Group|Liposome Irinotecan: 60 mg/m², Oxaliplatin: 85 mg/m², Fluorouracil: 2400 mg/m² Leucovorin: 400 mg/m², every 3 weeks (Q3W), administered via hepatic arterial infusion (HAIC); S-1: 40 mg per dose, twice daily for seven days, every 3 weeks (Q3W), taken orally.
62003200|NCT00443183|EXPERIMENTAL|Brief Negotiation Interview|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
62396254|NCT05512585|ACTIVE_COMPARATOR|supine position with continuous positive airway pressure|Participants will stay in the supine position and breathe with continuous positive airway pressure via face mask
62396255|NCT06287112|EXPERIMENTAL|PAC-ETGBD (Prevention of Acute Cholecystitis with ETGBD)|
62778750|NCT05987787||Obese patients underwent laparoscopic sleeve gastrectomy with suture reinforcement|Laparoscopic sleeve gastrectomy running seromuscular stitches at the proximal third of the stapled line using unidirectional 2/0 barbed sutures to invaginate the staple line completely.
62778751|NCT05987787||Obese patients underwent laparoscopic sleeve gastrectomy without suture reinforcement|Laparoscopic sleeve gastrectomy without staple line reinforcement.
62778752|NCT01440881|ACTIVE_COMPARATOR|Nesiritide|infuses at 0.01 MCG (micrograms)/KG (kilograms)/min (minute) for 48 hours
62003201|NCT00443183|PLACEBO_COMPARATOR|Discharge Instructions|Scripted discharge instructions to be read by emergency practitioner and designed to be less than 1 minute in length.
62396256|NCT03043287||BOTOX®|Participants who received 100 to 200 units (U) onabotulinumtoxinA (BOTOX®) as treatment for OAB. No study drug is administered in this study.
62396257|NCT04885582||Patients with biliary complications|patients with postoperative biliary fistula, biliary stenosis
62778753|NCT01440881|PLACEBO_COMPARATOR|Placebo|infuses at 0.01MCG/KG/min for 48 hours
62003202|NCT00554827|EXPERIMENTAL|Pralatrexate Injection (FOLOTYN,PDX,Pralatrexate(R|"Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or 4 weeks (depending on cohort), with 1 week of rest."
62003203|NCT00887900|EXPERIMENTAL|1|Submitted to deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
62003204|NCT00887900|ACTIVE_COMPARATOR|2|Submitted to regular penetrating keratoplasty
62003205|NCT02064738|NO_INTERVENTION|Normal diet|Two weeks of unaltered diet
62003206|NCT02064738|EXPERIMENTAL|Low omega-6/high omega-3 diet|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams
62003207|NCT03618797|EXPERIMENTAL|HL-PIF cap.160/2mg + Placebo|"* Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg~* once a day"
62003208|NCT03618797|ACTIVE_COMPARATOR|Livalo tab. 2mg + Placebo|"* Pitavastatin ca 2mg~* once a day"
62003209|NCT02431858|EXPERIMENTAL|Catheter Over Needle|"The femoral nerve catheter used will be the E-Catheter (Pajunk) device which is a novel catheter over needle system."
62003210|NCT02431858|ACTIVE_COMPARATOR|Catheter through needle|"The femoral nerve catheter used will be the Sonolong catheter (Pajunk) which is a traditional catheter through needle system."
62003211|NCT05036564|EXPERIMENTAL|Study population - PCNSL|"Patients (pts) with clinical and radiological suspicion of PCNSL or with confirmed diagnosis of PCNSL will be enrolled to the protocol. They will represent the Study population"
62003212|NCT05036564|OTHER|Control|"1. Pts with suspicion of secondary CNS lymphoma, that includes subjects with DLBCL and involvement of the CNS at presentation in association with systemic disease, or subjects with systemic DLBCL and CNS relapse during or after primary therapy.~2. Pts with histological diagnosis of systemic DLBCL at high risk of CNS relapse according to Institutional guidelines and patients with histological diagnosis of systemic high grade B cell lymphoma, according to 2017 WHO classification;~3. pts affected by neurological disorders that are usually differential diagnosis of PCNSL (i.e. neurodegenerative and neuroinflammatory disorders, toxic or infective encephalitis, other primary CNS tumors)."
62003213|NCT05515848||AORTLANTIC registry|Patients undergoing aortic root surgery with aortic valve conservation, using the inclusion technique described by Tirone David, between January 1, 2004 and December 31, 2021, at five centers (Nantes - Rennes - Brest - Angers - Tours University Hospital (UH))
62003214|NCT03962335|EXPERIMENTAL|VD group|Group that starts with Vegetarian diet (VD)
62003215|NCT03962335|EXPERIMENTAL|MD+Bt group|Group that starts with Mediterranean diet with oral supplementation with butyrate (MD+Bt)
62003216|NCT03962335|ACTIVE_COMPARATOR|MD group|Group that starts with Mediterranean diet (MD)
62003217|NCT01996670||<2h group|
62003218|NCT01996670||2-4h group|
62003219|NCT01996670||>4h group|
62003220|NCT06273176||Awake mapping|Awake mapping: Tumor resection with intraoperative awake motor or language mapping
62003221|NCT06273176||Asleep mapping|Asleep mapping: Tumor resection with intraoperative asleep motor mapping
62003222|NCT06273176||No mapping|No mapping: Tumor resection without intraoperative mapping
62003223|NCT05121584|EXPERIMENTAL|Kinder Krown|Anterior primary teeth which restored by a Kinder Krown zirconia crown as a final restoration
62003224|NCT05121584|ACTIVE_COMPARATOR|NuSmile|Anterior primary teeth which restored by a NuSmile zirconia crown as a final restoration
62003225|NCT05657028|EXPERIMENTAL|Group D (Dexmedetomidine)|In the Dexmedetomidine group, patients will be given IV bolus infusion of dexmedetomidine
62003226|NCT05657028|EXPERIMENTAL|Group L (Lidocaine)|In the Lidocaine group, the patients will be given an IV bolus infusion of lidocaine
62003227|NCT02117037|OTHER|study of PEC markers and chemokines/ chemokine recep|blood sample for dosage and study of PEC markers and chemokines/ chemokine receptors
62003228|NCT00849628||1|Constipation
62003229|NCT05780242||TCA|interviews based on a questionnaire established beforehand evoking the history of eating disorders and the experience of the participant
62003230|NCT05065125||LDLT cohort|Living-donor liver transplatation (LDLT) patients with anastomotic biliary stricture
62003231|NCT04696705|EXPERIMENTAL|Allogeneic γδT cell immunotherapy|Patients will receive 2 cycles of ex-vivo expanded allogeneic γδT cells treatments, at 14 days' intervals, each cycle has 2 infusions. Ex-vivo expanded γδT cells are transfused to patients in a dosage escalated manner (Dose escalation, 1×107, 3×107, 9×107 per kg of body weight).
62003232|NCT03646721|EXPERIMENTAL|[Part1] DA-1241 : 6 subjects in each cohort(Cohort 1-3)|Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).
62003233|NCT03646721|PLACEBO_COMPARATOR|[Part1] Placebo : 2 subjects in each cohort(Cohort 1-3)|Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).
62003234|NCT03646721|EXPERIMENTAL|[Part2] DA-1241 : 15 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
62003235|NCT03646721|PLACEBO_COMPARATOR|[Part2] Placebo : 5 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
62003236|NCT03646721|ACTIVE_COMPARATOR|[Part2] Sitagliptin : 5 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
62396258|NCT04885582||Patients without biliary complications|patients without postoperative biliary fistula and biliary stenosis
62003237|NCT02287896|EXPERIMENTAL|Roledumab Open-label IM|"- Planned antenatal prophylaxis: A single dose of 300 µg IM of Roledumab at 28 or 29 weeks of gestation.~- Antenatal prophylaxis following sensitizing events: One or more dose(s) of 300μg IM anti-RhD antibodies (Rhophylac or Roledumab) based on the Kleihauer-test as soon as possible and no later than 72 hours after event occurrence.~- Postnatal prophylaxis: Roledumab should be administered to the mother as soon as possible within 72 hours of delivery of an RhD positive infant.~The postnatal dose must still be given even when antenatal prophylaxis has been administered.~Before Roledumab 300μg IM postnatal administration, a Kleihauer-Betke test will be performed on maternal blood sample taken no earlier than 30 min after delivery in order to determine the volume of foetomaternal hemorrhage (FMH)."
62003238|NCT02287896|EXPERIMENTAL|Roledumab Open-label IV|"- Planned antenatal prophylaxis: A single dose of 300 µg IV of Roledumab at 28 or 29 weeks of gestation.~- Antenatal prophylaxis following sensitizing events: One or more dose(s) of 300μg IV anti-RhD antibodies (Rhophylac or Roledumab) based on the Kleihauer-test as soon as possible and no later than 72 hours after event occurrence.~- Postnatal prophylaxis: Roledumab should be administered to the mother as soon as possible within 72 hours of delivery of an RhD positive infant.~The postnatal dose must still be given even when antenatal prophylaxis has been administered.~Before Roledumab 300μg IV postnatal administration, a Kleihauer-Betke test will be performed on maternal blood sample taken no earlier than 30 min after delivery in order to determine the volume of foetomaternal hemorrhage (FMH)."
62003239|NCT03372512||Fluid overload (Liters) ≥ median|
62003240|NCT03372512||Fluid overload (Liters) < median|
62003241|NCT01826175|EXPERIMENTAL|Ticagrelor|Subjects receive 180 mg of ticagrelor immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
62003242|NCT01826175|ACTIVE_COMPARATOR|Clopidogrel|Subjects receive 600 mg of clopidogrel immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
62003243|NCT06382987||Participants that have initiated deucravacitinib treatment|
62003244|NCT06382987||Participants that have initiated apremilast treatment|
62003245|NCT06126484|OTHER|Neonates with congenital heart disease|Neonates with critical congenital heart diseases that require early catheter intervention
62003246|NCT00658112|EXPERIMENTAL|Benzoyl Peroxide 5%|Subjects will be given standard instructions in the use of topical benzoyl peroxide gel and will be provided with a supply of medication fitted with a Medication Event Monitoring System (MEMS) cap. This cap records dates and times the assembly is opened which can be downloaded at the final visit and tabulated with associated software. When the tubes are weighed, data from the MEMS Caps will be collected. Study coordinators will record adherence, while assessors are blinded to adherence rates. All subjects will be assigned to treatment with topical benzoyl peroxide to the entire face.
62778754|NCT06180707|EXPERIMENTAL|gel of pregabalin|The experimental 10% pregabalin gel (GPG) will be applied to the buccal surfaces of the central and lateral incisors, canines and upper and lower premolars, with an active microbrush, for 10 minutes. Subsequently, all groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whiteness HP, FGM). Sensitivity assessment will be carried out using a form consisting of a visual analogue scale (VAS), patients will be instructed to record tooth sensitivity daily, during the 21 days of follow-up. To measure color, the VITA Easyshade spectrophotometer (VITA, Germany) will be used at two times: baseline (Ti) and one week after the 3rd bleaching session (Tf).
62003247|NCT02434770|EXPERIMENTAL|BBIBP bOPV Lot 1|Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
62003248|NCT02434770|EXPERIMENTAL|BBIBP bOPV Lot 2|Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
62003249|NCT02434770|ACTIVE_COMPARATOR|BioFarma bOPV|Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
62003250|NCT02747069||NICU electronic stethoscope|Neonatal patients of any gestation admitted to the neonatal intensive care unit (NICU) and undergoing routine monitoring with ECG and pulse oximetry Heart rate will be evaluated using an electronic stethoscope
62003251|NCT02747069||Newborns <32 weeks and ECG|Neonatal patients \<32 weeks gestation Heart rate will be assessed at the time of delivery with both an electronic stethoscope and ECG using a pre placed lead system
62003252|NCT00095758|PLACEBO_COMPARATOR|A1|
62003253|NCT00095758|ACTIVE_COMPARATOR|A2|
62003254|NCT01507285|EXPERIMENTAL|NNC 90-1170|
62003255|NCT01507285|PLACEBO_COMPARATOR|Placebo|
62003256|NCT00956410|EXPERIMENTAL|CAD106|
62003257|NCT04508569|EXPERIMENTAL|Big Decisions|
62778755|NCT06180707|ACTIVE_COMPARATOR|gel with 5% potassium nitrate and 2% sodium fluoride|The gel with 5% potassium nitrate and 2% sodium fluoride (NKFG) will be applied to the buccal surfaces of the central and lateral incisors, canines and upper and lower premolars, with a microbrush actively, for 10 minutes. Subsequently, all groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whiteness HP, FGM). Sensitivity assessment will be carried out using a form consisting of a visual analogue scale (VAS), patients will be instructed to record tooth sensitivity daily, during the 21 days of follow-up. To measure color, the VITA Easyshade spectrophotometer (VITA, Germany) will be used at two times: baseline (Ti) and one week after the 3rd bleaching session (Tf).
62188711|NCT03947008|EXPERIMENTAL|Second Intuitive Eating Group (IE2)|IE2 will be the second group to will participate in an intuitive eating program and will be required to attend 5 intuitive eating classes. The classes will be 60-minutes each week for 5 weeks. An initial assessment will be conducted on the same day as IE1 but they will take the 5 week course once the first group completes the class. This group will have an additional initial assessment on the day they begin their curriculum. The initial assessment will occur during the first thirty minutes of the first intuitive eating class. A final assessment will be conducted during the last 30 minutes of the last intuitive eating class. During assessments, they will complete a questionnaire that will ask about body satisfaction and eating attitudes, and have their height and weight measured.
62188712|NCT02808247|EXPERIMENTAL|Experimental arm (arm A): Nintedanib|Nintedanib 200 mg twice daily orally. Nintedanib will be given continuously until clinically relevant disease progression according to the investigator's assessment or until other criteria for treatment discontinuation are met as specified in the protocol. Dosing beyond RECIST 1.1 progression is allowed for the oral agent if the patient still derives benefit from the treatment.
62778756|NCT06180707|PLACEBO_COMPARATOR|placebo gel (carbopol 1%)|The placebo gel (PG) will be applied to the buccal surfaces of the central and lateral incisors, canines and upper and lower premolars, with a microbrush actively, for 10 minutes. Subsequently, all groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whiteness HP, FGM). Sensitivity assessment will be carried out using a form consisting of a visual analogue scale (VAS), patients will be instructed to record tooth sensitivity daily, during the 21 days of follow-up. To measure color, the VITA Easyshade spectrophotometer (VITA, Germany)) will be used at two times: baseline (Ti) and one week after the 3rd bleaching session (Tf).
62778757|NCT02847104||dynamic insulin protocol|patients received intravenous insulin infusion according to a dynamic insulin protocol
62778758|NCT02847104||static insulin protocol|patients received intravenous insulin infusion according to a static insulin protocol
62778759|NCT05687019|EXPERIMENTAL|Patient undergoing prostate enucleation by Holmium Laser|It is based on a pulsed laser at a wavelength of 2140 nm, which penetrates the tissues over a very short distance. The prostate tissue must therefore be in contact with the laser fiber to be cut or vaporized, and hemostasis will take place nearby. The procedure lasts approximately one hour.
62003258|NCT04508569|ACTIVE_COMPARATOR|Youth Voices|
62003259|NCT03789552|EXPERIMENTAL|T89 low-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.~Subjects in this group will use three T89 capsules and one Placebo capsule each time by oral administration twice daily for 8 weeks."
62003260|NCT03789552|EXPERIMENTAL|T89 high-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~Subjects in this group will use four T89 capsules each time by oral administration twice daily for 8 weeks."
62188713|NCT02808247|ACTIVE_COMPARATOR|Standard arm (arm B): Ifosfamide|Ifosfamide 3 g/m2 intravenously on days 1, 2 and 3 every 21 days for up to a maximum of 6 cycles.
62188714|NCT06489275|EXPERIMENTAL|Intervention|Subjects receive a brief intervention consisting of 6 financial literacy classes designed to improve their financial literacy and financial wellness, followed by 3 one-on-one booster sessions to reinforce learning and provide support.
62003261|NCT03789552|PLACEBO_COMPARATOR|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 8 weeks.
62003262|NCT02034526|PLACEBO_COMPARATOR|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
62003263|NCT02034526|EXPERIMENTAL|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
62584895|NCT06128044|EXPERIMENTAL|Dose Expansion of CB-012|Part B (Dose Expansion) - participants will be enrolled to receive CB-012 at the RDE and/or MTD determined in Part A in order to the determine the RP2D.
62584896|NCT04523272|EXPERIMENTAL|TQB2450 + Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
62778760|NCT04230824|ACTIVE_COMPARATOR|Pre-workout plus and Protein recovery plus|"Pre-workout plus: a blend of caffeine, choline bitartrate, carbohydrate, HMB, vitamin D3 mixed with water and consumed within 30 minutes prior to exercise~Protein recovery plus: a blend of whey protein, caseinate, carbohydrate, vitamin C, alpha-tocopherol, vitamin D3, glucosamine mixed with water and consumed 15 minutes post exercise"
62003264|NCT02160366||Biomarker/Molecular Data Collection and Analyzation|Advanced cancer participants
62003265|NCT02957890|EXPERIMENTAL|Twice-annual influenza vaccination|Twice-annual influenza vaccination: administrations of inactivated influenza vaccine (Northern hemisphere formulation, NH) prior to the northern hemisphere winter, plus inactivated influenza vaccine (Southern hemisphere formulation, SH) prior to the northern hemisphere summer.
62003266|NCT02957890|PLACEBO_COMPARATOR|Once-annual influenza vaccination|Administrations of inactivated influenza vaccine (Northern hemisphere formulation, NH) prior to the northern hemisphere winter, plus placebo prior to the northern hemisphere summer.
62003267|NCT06084195|EXPERIMENTAL|Single arm|single arm
62003268|NCT04043195|EXPERIMENTAL|Nivolumab + Oxaliplatin + Ipilimumab|Cohort 1
62003269|NCT02388737|EXPERIMENTAL|Vonoprazan 10 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Vonoprazan 10 mg, tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg placebo-matching, capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing."
62003270|NCT02388737|EXPERIMENTAL|Vonoprazan 20 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Vonoprazan 20 mg, tablets, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg, placebo-matching capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing"
62188715|NCT06489275|ACTIVE_COMPARATOR|Services as Usual|Subjects receive routine mental health care.
62584897|NCT04523272|ACTIVE_COMPARATOR|Sunitinib Malate Capsules|Sunitinib malate capsule 50mg administered orally, once daily in 28-day cycle(14 days on treatment from Day 1-14, 14 days off treatment from day 15-28).
62188716|NCT05538247|EXPERIMENTAL|S. boulardii CNCM I-745 Group|Subjects will receive Indomethacin from day 2 to day 7 and S. boulardii CNCM I-745 from day 1 to day 14
62778761|NCT04230824|PLACEBO_COMPARATOR|Placebo|Non-caloric powder mixed with water and consumed within 30 minutes prior to exercise and within 15 minutes after exercise
62778762|NCT04230824|NO_INTERVENTION|Control|This arm will receive no intervention
62778763|NCT03742453|EXPERIMENTAL|Hepatic nodule group|This group meets eligibility criteria, and undergo contrast-enhanced ultrasound (CEUS) and scheduled gadoxetic acid MRI (gadoxetic acid-enhanced liver MRI; EOB-MRI; Gd-EOB-MRI)
62778764|NCT03178669|EXPERIMENTAL|Cobitolimod Dose 2x31 mg|Dose 31 mg of cobitolimod at 2 occasions, placebo at 2 occasions
62778765|NCT03178669|EXPERIMENTAL|Cobitolimod Dose 2x125 mg|Dose 125 mg of cobitolimod at 2 occasions, placebo at 2 occasions
62778766|NCT03178669|EXPERIMENTAL|Cobitolimod Dose 2x250 mg|Dose 250 mg of cobitolimod at 2 occasions, placebo at 2 occasions
62778767|NCT03178669|EXPERIMENTAL|Cobitolimod Dose 4x125 mg|Dose 125 mg of cobitolimod, at 4 occasions
62778768|NCT03178669|PLACEBO_COMPARATOR|Placebo|Placebo at four occasions
62003271|NCT02388737|ACTIVE_COMPARATOR|Lansoprazole 15 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Lansoprazole 15 mg, capsules, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing."
62188717|NCT05538247|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive Indomethacin from day 2 to day 7 and Placebo from day 1 to day 14
62778769|NCT02846649|EXPERIMENTAL|PIER Intervention|The program will help participants learn to recognize the presence of craving and how it can be reduced through environmental, self-regulatory and mood management. Each day, the PIER1 program sends (1) a morning reflection focused on positive thinking, (2) two random prompts assessing severity of craving, (3) feedback specific to managing withdrawal symptoms, mood management, and environmental triggers that are affecting craving, (4) evening assessments of drug use with feedback, (5) goal commitment prompt with feedback, and (6) user-triggered craving assessments with feedback
62396259|NCT02496715|EXPERIMENTAL|Treatment 1|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg. Single puff, twice daily (approximately every 12 hr) for 4 weeks
62778770|NCT05995899|EXPERIMENTAL|Patients with IBS-C|
62396260|NCT02496715|EXPERIMENTAL|Treatment 2|Advair 100/50 Diskus pMDI containing fluticasone propionate 100mcg / salmeterol 50 mcg. Single puff, twice daily (approximately every 12 hr) for 4 weeks
62778771|NCT02581969||Prophylaxis|Prophylaxis group: treatment is based on regularly repeated infusions of clotting factor, 20-30 IU/kg -3 times a week
62778772|NCT02581969||On-demand|On-demand group: treatment administered when bleeding episode occur
62778773|NCT00820417|EXPERIMENTAL|a|Dose-escalation
62778774|NCT00820417|EXPERIMENTAL|B|Maximum tolerated dose (MTD)
62778775|NCT04225793|ACTIVE_COMPARATOR|Eziklen®|potassium, magnesium and sodium sulphates-based laxative
62778776|NCT04225793|ACTIVE_COMPARATOR|Macrogol|Macrogol-3350 + Sodium Sulfate + Potassium Chloride+ Sodium Chloride + Ascorbic Acid-based and Sodium Ascorbate-based Moviprep
62778777|NCT01620944|EXPERIMENTAL|Arm1: ATV/RTVHS+3TC|
62778778|NCT01620944|ACTIVE_COMPARATOR|Arm2: ATV/RTVHS+TDF/FTC|
62778779|NCT00852501||Non-functioning pituitary macroadenoma|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
62778780|NCT02500446|ACTIVE_COMPARATOR|Intensification|Oral dolutegravir 50 mg once daily for 8 weeks added to their current ART regimen.
62778781|NCT02500446|PLACEBO_COMPARATOR|Placebo|Oral placebo once daily for 8 weeks added to their current ART regimen.
62778782|NCT03748459||Permanent suture|Subjects will have skin closure with permanent suture (prolene) (6-0 polypropylene) in open rhinoplasty.
62778783|NCT03748459||Resorbable suture|Subjects will have skin closure with Resorbable Suture (5-0 fast absorbing plain gut) in open rhinoplasty
62778784|NCT00288327|EXPERIMENTAL|1|Enhanced New Leaf Intervention
62778785|NCT00288327|OTHER|2|Minimum Intervention
62396261|NCT02496715|PLACEBO_COMPARATOR|Treatment 3|Placebo inhalation. Single puff, twice daily (approximately every 12 hr) for 4 weeks
62396262|NCT05814627|EXPERIMENTAL|Upadacitinib+ Adalimumab matching Placebo|Participants will receive upadacitinib once a day along with matching placebo for adalimumab at eow (every other week) in Period 1. Eligible participants will continue to receive same study treatment in Period 2 as assigned in Period 1.
62584898|NCT06012890||Automatic acquisition|Clinical MRI planning performed automatically by an AI-based software
62584899|NCT06012890||Manual Acquisition|Clinical MRI planning performed manually by a specialized radiology technician
62778786|NCT02501200|EXPERIMENTAL|TR group|CKD-391 and combination dose of Atrovastatin and Ezetimibe in order
62778787|NCT02501200|EXPERIMENTAL|RT group|combination dose of Atrovastatin and Ezetimibe and CKD-391 in order
62778788|NCT03256318||Children in Sports and Rec|Children with disabilities who enter the study between ages 5 and 10 who are participating in a Sports and Recreation Program. They will receive no intervention, only surveys.
62778789|NCT03256318||Comparison Children|Children with disabilities who enter the study between ages 5 and 10 and end participation in Sports and Recreation Program at a later date. They will receive no intervention, only surveys.
62778790|NCT00938691|EXPERIMENTAL|Tepha|
62778791|NCT00938691|ACTIVE_COMPARATOR|Vicryl|
62778792|NCT04353778|NO_INTERVENTION|PLWH|People living with HIV (HIV)
62778793|NCT04353778|NO_INTERVENTION|Healthy Controls|Healthy controls who do not have HIV
62778794|NCT04353778|ACTIVE_COMPARATOR|Pyridostigmine|PLWH on pyridostigmine 30mg PO TID
62778795|NCT04353778|PLACEBO_COMPARATOR|Placebo|PLWH on placebo
62778796|NCT04353778|OTHER|nVNS|PLWH to undergo non-invasive vagal nerve stimulation
62778797|NCT02126592||PCOS cohort|Women with PCOS
62778798|NCT02126592||Control cohort|Women without PCOS
62571527|NCT03286556|EXPERIMENTAL|Autoantibody Reductive Therapy|"Therapeutic Plasma Exchange (TPE) consisting of 1x estimated plasma volume exchanges for 3 successive days (1-3) and then, after a one day interval to enable equilibration of autoantibodies between intra- and extra-vascular spaces, again on days 5, 6, 9, 11, 13, and 15.~Rituximab: One gm i.v. will be administered on day 6 and day 15 after completion of the TPE on those days.~Intravenous immunoglobulin (IVIG): 0.5 gm/kg/day i.v. on days 16-19~All subjects in this trial, including patients in this arm, will receive identical empiric antibiotics and steroids. The steroid dose is: Prednisone 60 mg (p.o.) on day 1, followed by 20 mg/day on days 2-5, 7-14, and 16-19 (or the i.v. methylprednisolone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 6 and 15, as a premedication prior to the rituximab."
62584900|NCT03441802|ACTIVE_COMPARATOR|Cases|
62778799|NCT04611906||Stroke patient|Patients who have acute cerebral ischemic symptoms attributed by cSVD can be recruited into this study. Eligible patients will be screened by Neurologists based on the inclusion and exclusion criteria. The time window for recruitment of the patient is 4 weeks from the qualifying stroke.
62778800|NCT04541628|EXPERIMENTAL|SIG-001|Participants received a single dose of 50 milliliter (mL), 78.5 mL and 133 mL of SIG-001 spheres \[an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce B-Domain Deleted Human Factor VIII (BDD-hFVIII) producing Spheres\] administered laparoscopically into the peritoneal cavity.
62778801|NCT00119496|ACTIVE_COMPARATOR|Group 1|Inhaled beclomethasone (400mcg/day)
62778802|NCT00119496|ACTIVE_COMPARATOR|Arm 2|Rosiglitazone
62778803|NCT00119496|ACTIVE_COMPARATOR|Arm3|Oral theophylline
62778804|NCT00119496|ACTIVE_COMPARATOR|Arm 4|Oral theophylline and inhaled beclomethasone
62778805|NCT01651663|EXPERIMENTAL|Arbidol (Umifenovir)|
62778806|NCT01651663|PLACEBO_COMPARATOR|placebo|
62778807|NCT01651663|EXPERIMENTAL|Arbidol (Umifenovir) prophylaxis|
62778808|NCT01651663|PLACEBO_COMPARATOR|placebo prophylaxis|
62778809|NCT03491202||atrial fibrillation|Patients with a diagnosis of atrial fibrillation will be eligible for enrollment
62778810|NCT03697681|EXPERIMENTAL|Glutamine|Intravenous glutamine infusion perioperatively for 18 hours (8 hours before surgery and 10 hours after induction of anesthesia)
62778811|NCT03697681|PLACEBO_COMPARATOR|Placebo|placebo
62778812|NCT02861638|EXPERIMENTAL|Experimental group|Video of the exercises and conventional physiotherapy. 30 minutes twice a day, 5 days a week for 2 weeks.
62778813|NCT02861638|ACTIVE_COMPARATOR|Control group|Video of nature scenes and conventional physiotherapy. 30 minutes twice a day, 5 days a week for 2 weeks.
62778814|NCT06084221|NO_INTERVENTION|OFR Team Practice as Usual|Data are collected regarding standard OFR Team practice and outcomes before implementation of the FORTRESS Intervention
62778815|NCT06084221|EXPERIMENTAL|FORTRESS|Participating counties receive both training in data-driven decision making and inventory of overdose-prevention strategies
62778816|NCT03088813|EXPERIMENTAL|Part 1: Experimental Arm, dose level 1|Irinotecan liposome injection
62778817|NCT03088813|EXPERIMENTAL|Part 1: Experimental Arm, dose level 2|Irinotecan liposome injection
62778818|NCT03088813|EXPERIMENTAL|Part 2: Experimental Arm|Irinotecan liposome injection
62396263|NCT05814627|EXPERIMENTAL|Adalimumab + Upadacitinib matching Placebo|Participants will receive adalimumab at eow (every other week) along with matching placebo for upadacitinib once a day in Period 1. Eligible participants will continue to receive same study treatment in Period 2 as assigned in Period 1.
62778819|NCT03088813|ACTIVE_COMPARATOR|Part 2: Control Arm|Topotecan
62778820|NCT02123576|EXPERIMENTAL|Treatment|Pentoxyfylline 400mg three times a day or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR \<10 for 90 days in addition to standard AMO therapy
62778821|NCT02123576|PLACEBO_COMPARATOR|Placebo|This is a standard placebo pill.
62778822|NCT01781559|EXPERIMENTAL|phenolic acid + maltodextrin|phenolic acid + maltodextrin;
62778823|NCT01781559|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin
62778824|NCT01781559|ACTIVE_COMPARATOR|flavanol + maltodextrin|flavanol + maltodextrin
62778825|NCT01631396||Patients recieving Sugammadex|Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.
62396264|NCT03094468|EXPERIMENTAL|P-3058|
62396265|NCT03094468|PLACEBO_COMPARATOR|Vehicle|
62396266|NCT01694849|EXPERIMENTAL|GFT505 80mg|Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.
62778826|NCT01631396||Patients recieving Neostigmine|Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body.
62778827|NCT00333918|EXPERIMENTAL|1-bromfenac ophthalmic solution|sterile ophthalmic solution
62778828|NCT00333918|PLACEBO_COMPARATOR|2-placebo comparator|sterile ophthalmic solution
62778829|NCT03905850|EXPERIMENTAL|Somapacitan 5/10/10 mg|One dose of somapacitan 5 mg/1.5 ml followed by two doses of somapacitan 10 mg/1.5 ml. Each dose will be followed by a 3 week observation period.
62778830|NCT03905850|EXPERIMENTAL|Somapacitan 10/5/10 mg|One dose of somapacitan 10 mg/1.5 ml followed by a 5 mg/1.5 ml dose followed by a 10 mg/1.5 ml dose. Each dose will be followed by a 3 week observation period.
62778831|NCT03905850|EXPERIMENTAL|Somapacitan 10/10/5 mg|Two doses of 10 mg/1.5 ml somapacitan followed by a 5 mg/1.5 ml dose. Each dose will be followed by a 3 week observation period.
62778832|NCT05032885|EXPERIMENTAL|A|48-72 hours after hospital admission, following the baseline assessment of the patient, they will begin to receive physiotherapy treatment with respiratory techniques and motor training, adapted at all times to the clinical situation of the patient, until hospital discharge. If the patient's clinical condition worsens, treatment will be temporarily suspended until the patient improves to allow resumption of treatment.
62778833|NCT05032885|NO_INTERVENTION|B|48-72 hours after admission to the hospital, after the patient's baseline assessment, the patient will not receive physiotherapy and the usual referral to the Rehabilitation Service for physiotherapy treatment of hospitalized patients will be followed, if the patient's physician considers it necessary and requests it.
62003272|NCT06295718||Ambulatory Children with Duchenne Muscular Dystrophy|"Participants who meet the inclusion criteria will be evaluated synchronously online using the Zoom platform in terms of the functional performance and quality of life parameters specified below, after ensuring the presence of a suitable environment and a stable internet connection. During the online evaluation, patients will be asked to perform the specified functions in front of the camera. In addition, the survey questions necessary to evaluate the quality of life will be expressed verbally to the participants. Inter-rater reliability will be examined by comparing the scores after being performed separately by two different physiotherapists. The reliability and validity of the online assessment will be investigated by repeating the same assessments online and face-to-face.~* Timed Performance Tests~* Upper Extremity Functions~* Lower Extremity Functions~* Quality of Life"
62188718|NCT03494465|ACTIVE_COMPARATOR|MEDICAL TREATMENT GROUP|"Medical treatment will be used in a staggered manner and may also associate laser trabeculoplasty. If necessary, then surgical treatment would be indicated: trabeculectomy. or another filtering surgery.~Inadequate IOP control will be determined by the local ophthalmologist, and additional treatment will be indicated to achieve an target IOP."
62188719|NCT03494465|EXPERIMENTAL|INTERVENTION GROUP|"In lens extraction arm, patients will undergo lens phacoemulsification with intraocular lens implant (IOL) within 60 days after randomization.~If additional treatment is required, the same stepped sequence of therapy described for medical treatment group will be used and will be considered a therapeutic failure."
62188720|NCT01398696|ACTIVE_COMPARATOR|Patient Information Leaflets|Patient Information Leaflets (PIL) is given to the patient during consultation
62571528|NCT03286556|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|The same steroid regimen as described for the experimental arm, i.e., prednisone 60 mg (p.o.) on day 1, followed by 20 mg/day on days 2-5, 7-14, and 16-19 (or the i.v. methylprednisolone equivalent), and methylprednisolone 100 mg i.v. administered on days 6 and 15, as well as empiric antibiotics.
62571529|NCT03241862|EXPERIMENTAL|Restylane® Silk|All subjects enrolled in the study will undergo lip rejuvenation treatment with Restylane® Silk.
62571530|NCT04967482|EXPERIMENTAL|DEB-TACE|DEB-TACE will be performed for the patients who choose DEB-TACE as the primary treatment.
62571531|NCT04967482|ACTIVE_COMPARATOR|cTACE|cTACE will be performed for the patients who choose cTACE as the primary treatment.
62571532|NCT04720924|EXPERIMENTAL|AQCS-aided group|Patients in AQCS-aided group will go through white light EGD examination with assistance of AQCS.
62778834|NCT04967339|EXPERIMENTAL|Foot deformity correcting insole arm|"Patients allocated to the foot deformity correcting insole arm will receive insoles to correct their foot deformities (plano-valgus foot deformity)."
62778835|NCT04967339|ACTIVE_COMPARATOR|Lateral wedge insole arm|"Patient allocated to the Lateral wedge insole arm will receive conventional lateral wedge insole."
62778836|NCT05974319|NO_INTERVENTION|Control group|During the blood sample collection, the application was carried out in line with the routine care.
62778837|NCT05974319|EXPERIMENTAL|Dry heat application|The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. The researcher will heat the thermoregulated electric pad and set it to 42°C. After making sure that there are no contraindications in the application of the electric pad device, a dry heat of 42°C will be applied to the determined area with the electric pad for 5 minutes.
62778838|NCT05974319|EXPERIMENTAL|Dry cold application|The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. After the researcher is sure that there are no contraindications in the application of the gel pad, dry cold will be applied to the determined area with the gel pad for 3 minutes.
62778839|NCT06183333|EXPERIMENTAL|Intervention group|Web-based emotion regulation intervention
62778840|NCT06183333|NO_INTERVENTION|Waitlist control group|Eight-week waiting period
62778841|NCT02402413|EXPERIMENTAL|PCOS women|
62778842|NCT02986854|EXPERIMENTAL|Menveo-Menveo Group|Approximately 300 subjects, who were vaccinated with a single dose of Menveo 4 to 6 years before, will receive one dose of MenACWY-CRM at Day 1.
62188721|NCT01398696|PLACEBO_COMPARATOR|usual consultation without PIL|no particular intervention during consultation for the patient.
62396267|NCT01694849|EXPERIMENTAL|GFT505 120mg|Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.
62396268|NCT01694849|PLACEBO_COMPARATOR|Placebo|hard gelatin capsules, oral administration, 3 capsules per day before breakfast with a glass of water.
62571533|NCT04720924|NO_INTERVENTION|Control group|Patients in control group will go through white light EGD examination without AQCS.
62571534|NCT03364465|NO_INTERVENTION|GruopFix|one-lung ventilation with constant tidal volume
62571535|NCT03364465|ACTIVE_COMPARATOR|GroupVariable|one-lung ventilation with variable tidal volume Intervention: change of ventilatory settings
62571536|NCT04108468|EXPERIMENTAL|Golimumab & Methotrexate|
62571537|NCT04108468|ACTIVE_COMPARATOR|Methotrexate|
62571538|NCT05217810||Atectura inhalation capsule (150/80ug)|Indacaterol acetate/Mometasone furoate; 150/80ug
62571539|NCT05217810||Atectura inhalation capsule (150/160ug)|Indacaterol acetate/Mometasone furoate; 150/160ug
62584901|NCT03441802|OTHER|Controls|
62778843|NCT02986854|EXPERIMENTAL|Menactra-Menveo Group|Approximately 300 subjects, who were vaccinated with a single dose of Menactra 4 to 6 years before, will receive one dose of MenACWY-CRM at Day 1.
62778844|NCT02986854|ACTIVE_COMPARATOR|Naive Group|Aproximately 100 subjects, of similar age to subjects enrolled in other primed groups, who have not received any meningococcal vaccination, will receive one dose of MenACWY-CRM at Day 1.
62778845|NCT01315444|ACTIVE_COMPARATOR|PPI abrupt cessation|Abrupt cessation
62778846|NCT01315444|ACTIVE_COMPARATOR|PPI gradual step down cessation|Gradual cessation
62778847|NCT00848224|EXPERIMENTAL|2|
62778848|NCT04119596||Diagnosed Parkinson's disease|Patients with incident Parkinson's disease
62778849|NCT04119596||Control|Volunteers without diagnosed Parkinson's disease not meeting the exclusion criteria
62778850|NCT02122224|EXPERIMENTAL|Group 1|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
62778851|NCT02122224|EXPERIMENTAL|Group 2|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
62778852|NCT02122224|EXPERIMENTAL|Group 3|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
62778853|NCT02122224|EXPERIMENTAL|Group 4|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
62003273|NCT05639270|EXPERIMENTAL|low back pain|"The experimental intervention consists of vagal stimulation using the Tens Eco device with an auricular electrode and conductive gel.~The stimulation will have an intensity of 25 Hz, lasting 30 minutes, once a day, for 3 months.~An evaluation of the pain will be done every week by phone for the first month and then in consultation at one month and at 3 months."
62003274|NCT00240071|EXPERIMENTAL|Avastin|The patient will continue the same hormonal therapy used prior to study enrollment but will combine it with Avastin.
62003275|NCT04869735||With information about booster vaccination|Adults aged 25 years in 2020 without delivery of DTPolio vaccine in 2019 or 2020, to whom information concerning this vaccination is given
62003276|NCT04869735||Without information about booster vaccination|Adults aged 25 years in 2020 without delivery of DTPolio vaccine in 2019 or 2020, to whom information concerning this vaccination is not given.
62003277|NCT01454726|EXPERIMENTAL|experimental group|receiving both Diaoshi Jifa therapy and the Western medical treatment.
62003278|NCT01454726|OTHER|control group|receiving the Western medical treatment alone.
62003279|NCT03962803|EXPERIMENTAL|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
62396269|NCT05324800|EXPERIMENTAL|Curcuma longa L. extract mixture group|2 times a day, 2 capsule for 1 time, after breakfast and dinner meal (1.6 g/day, Curcuma longa L. extract mixture 1 g/day)
62778854|NCT05969340|EXPERIMENTAL|Experimental group|Patient diagnosed with Posterior canal BPPV
62778855|NCT05969340|PLACEBO_COMPARATOR|Control group|Patient who are scheduled for CT-imaging as part of standard clinical routine and do not have BPPV
62778856|NCT04602247|EXPERIMENTAL|SIC|100 mg sodium iron chlorophyllin (SIC) containing 6 mg 57 Fe.
62778857|NCT04602247|EXPERIMENTAL|SIC + AA combined|100 mg sodium iron chlorophyllin (SIC) containing 6 mg 57 Fe given with 40 mg Ascorbic Acid
62778858|NCT04602247|ACTIVE_COMPARATOR|FeSO4|6mg of FeSO4 given as 4 mg 56Fe and 2mg 58Fe
62778859|NCT04602247|ACTIVE_COMPARATOR|FeSO4 + AA combined|6mg of FeSO4 given as 4 mg 56Fe and 2mg 58Fe along with 40 mg Ascorbic Acid
62778860|NCT04602247|EXPERIMENTAL|EP + FeSO4 combined|100 mg of Chlorophyllin without the Magnesium central atom along with 6 mg FeSO4 as 54 Fe
62778861|NCT04602247|EXPERIMENTAL|EP + FeSO4 + AA combined|100 mg of Chlorophyllin without the Magnesium central atom along with 6 mg FeSO4 as 54 Fe along with 40 mg of Ascorbic Acid
62778862|NCT05562609|EXPERIMENTAL|Intramuscular TXA|1g TXA as 2 x 5 ml IM injections (100mg/ml) and slow IV injection of placebo (1 x 10 ml of 0.9% sodium chloride)
62778863|NCT05562609|ACTIVE_COMPARATOR|Intravenous TXA|1g TXA by slow IV injection and 2 x 5 ml IM injections of placebo
62778864|NCT05562609|PLACEBO_COMPARATOR|Placebo|Placebo by 1 x slow 10ml IV injection and 2 x 5 ml IM injections
62778865|NCT00147004|EXPERIMENTAL|1|hydrocortisone sodium succinate
62778866|NCT00147004|PLACEBO_COMPARATOR|2|Placebo
62778867|NCT04796350|EXPERIMENTAL|Treated group|Subject receives standard of care to repair the index hip fracture and AGN1 LOEP treatment on the target unfractured contralateral hip
62778868|NCT04796350|NO_INTERVENTION|Control group|Subject receives standard of care to repair the index hip fracture and no AGN1 LOEP treatment on the target unfractured contralateral hip
62778869|NCT02551419|EXPERIMENTAL|ketogenic drink|MCT ketogenic drink: ketogenic drink providing 30 g/d of MCT oil in 250 ml of lactose-free skim milk for 6 months supplementation
62778870|NCT02551419|PLACEBO_COMPARATOR|Placebo|Lactose-free skim milk-based placebo drink containing high-oleic sunflower oil of equivalent energy value to the active arm for a 6 months supplementation
62778871|NCT02027948|EXPERIMENTAL|nutritional management|The proposed study will be a prospective feasibility study of a nutritional management algorithm with risk-based guidelines in older adults (n=50) with newly diagnosed locally advanced esophageal cancer receiving preoperative or definitive chemoradiotherapy with an induction chemotherapy approach. Eligible patients must be age ≥ 65 years old. While all patients with esophageal cancer may benefit from this intervention, we wish to target the most vulnerable population (older patients who are at highest risk of malnutrition) in this pilot study.
62778872|NCT05727800|EXPERIMENTAL|Part A|Participants grouped in different cohorts will receive a single ascending dose of VX-668.
62778873|NCT05727800|PLACEBO_COMPARATOR|Placebo Part A|Participants will be randomized to receive placebo matched to VX-668.
62571540|NCT05217810||Atectura inhalation capsule (150/320ug)|Indacaterol acetate/Mometasone furoate; 150/320ug
62003280|NCT03962803|EXPERIMENTAL|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
62188722|NCT01296763|EXPERIMENTAL|Irinotecan, Cisplatin, Olaparib, then add Mitomycin-C|A 3+3 dose escalation design will be used starting with dose 1. The maximally tolerated dose is defined as the highest dose for which at most 1 out of 6 patients experiences a DLT. We will use 3 patients per dose cohort. If 0 of 3 patients have a DLT (see section 5a) then the escalation will be continued at the next dose level. If 1 of 3 patients have a DLT then three more patients will be enrolled at this dose. If 1 of 6 patients has a DLT then the dose escalation will continue. If 2 or more of the first 3 patients, or \>2 of 6 patients treated have a DLT at the dose level, we will reduce the dose to the previous dose level of Olaparib for the phase 2 and then test Mitomycin C (phase 1 dose 5). If DLTs are observed at our dose 1 regimen, we will reduce the duration of Olaparib from day 1 and day 8 to just day 1 (dose level -1) and we will not test Mitomycin C in the trial.
62571541|NCT05304728||Primary Objective: Severe Sepsis|The primary endpoint for this study is defined as the presence of sufficient data for SOWS training and algorithm development to proceed with subsequent validation. To provide sufficient data subsets (severe sepsis EHR encounters) for training and validation of the Sepsis Onset Warning System algorithm. There will not be any interventions administered.
62778874|NCT05727800|EXPERIMENTAL|Part B|Participants grouped in different cohorts will receive multiple doses of VX-668.The dose levels will be determined based on the data from Part A.
62778875|NCT05727800|PLACEBO_COMPARATOR|Placebo Part B|Participants will be randomized to receive placebo matched to VX-668.
62003281|NCT03962803|EXPERIMENTAL|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
62003282|NCT02410811||Age Stratum A|"* Age 6 to 13.99 years~* Cardiac magnetic resonance imaging (CMR)"
62571542|NCT03023618|NO_INTERVENTION|control group|patients before 2014, in which fluids were administered without FloTrac monitoring
62003283|NCT02410811||Age Stratum B|"* Age 14 to 20.99 years~* Detectible and quantifiable TRJV with reported value~* Cardiac magnetic resonance imaging (CMR)"
62003284|NCT02410811||Age Stratum C|"* Age ≥21 years~* Detectible and quantifiable TRJV with reported value~* Cardiac magnetic resonance imaging (CMR)"
62571543|NCT03023618|ACTIVE_COMPARATOR|case group|patients after 2014, after management of fluid therapy has been guided by FloTrac parameters as a standard clinical practice (NICE protocol)
62571544|NCT06378593|EXPERIMENTAL|Stage I - dose escalation|Dose escalation of 3HP-2827 in patients with advanced solid tumors.
62571545|NCT06378593|EXPERIMENTAL|Stage II - expansion|Expansion evaluating the recommended dose and schedule of 3HP-2827 identified from Stage I.
62778876|NCT01660503|PLACEBO_COMPARATOR|No SCF|Twice daily consumption of snack foods containing no SCF.
62778877|NCT01660503|EXPERIMENTAL|10 grams SCF|Twice daily consumption of snack foods, each containing 5 grams SCF
62778878|NCT01660503|EXPERIMENTAL|20 grams SCF|Twice daily consumption of snack foods, each containing 10 grams SCF
62003285|NCT02410811||Age Stratum D|"* Age ≥6 years.~* Current use of disease-modifying therapy \[hydroxyurea, chronic transfusions, or both (given concurrently, sequentially, or both)\] that was initiated at \<3 years of age, and for which there has been no interruption of therapy for \>6 consecutive months since the initiation of disease-modifying therapy.~* Cardiac magnetic resonance imaging (CMR)"
62003286|NCT02896400|EXPERIMENTAL|BNI+NRT+QL+Text|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
62003287|NCT02896400|EXPERIMENTAL|BNI+NRT+QL|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
62003288|NCT02896400|EXPERIMENTAL|BNI+NRT+Text|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
62003289|NCT02896400|EXPERIMENTAL|BNI+NRT|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
62188723|NCT04182113|EXPERIMENTAL|1 Hz rTMS Stimulation first, then 20 Hz rTMS Stimulation, then sham rTMS|Subjects will receive one session of each: low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of motor threshold (MT), for a total of 1200 pulses, high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minute, Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
62003290|NCT02896400|EXPERIMENTAL|BNI+QL+Text|Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
62003291|NCT02896400|EXPERIMENTAL|BNI+QL|Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL)
62003292|NCT02896400|EXPERIMENTAL|BNI+Text|Brief Negotiated Interview (BNI) Registration in SmokefreeText (Text)
62778879|NCT01218399|ACTIVE_COMPARATOR|Budesonide|"Combination of budesonide and formoterol. Medications are given according to the package insert and manufacturer's instructions.~Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Symbicort study arm."
62778880|NCT01218399|PLACEBO_COMPARATOR|Placebo Comparator: Budesonide|"Control of budesonide alone. Medication was given according to the package insert and manufacturer's instructions.~Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Budesonide study arm."
62778881|NCT04908865|EXPERIMENTAL|Pediatric participants receiving belimumab|
62003293|NCT02896400|EXPERIMENTAL|BNI only|Brief Negotiated Interview (BNI)
62571546|NCT03852953||Study 1: Under- and overdiagnosed group|Non-proportional stratified sample of women diagnosed with interval or screen-detected breast cancers after participation in BreastScreen Norway. This sample will include under- or overdiagnosed cancers, as well as cancers that were not under- or overdiagnosed.
62778882|NCT04434014||males from 20 to above 65 y|will be sub divided into 4 groups according to age sub group I from 20 - 35 sub group II from 36- 45 sub group III from 46- 65 sub group IV more than 65
62003294|NCT02896400|EXPERIMENTAL|NRT+QL+Text|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
62003295|NCT02896400|EXPERIMENTAL|NRT+QL|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
62003296|NCT02896400|EXPERIMENTAL|NRT+Text|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
62003297|NCT02896400|EXPERIMENTAL|NRT only|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
62003298|NCT02896400|EXPERIMENTAL|QL+Text|Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
62003299|NCT02896400|EXPERIMENTAL|QL only|Referral to CT Smokers Quitline (QL)
62003300|NCT02896400|EXPERIMENTAL|Text only|Registration in SmokefreeText (Text)
62003301|NCT02896400|NO_INTERVENTION|Control|Control arm, no intervention
62003302|NCT03895320|EXPERIMENTAL|Intervention Program|The intervention and control programs will consist of similar, but not identical components. The intervention will include a) a brief self-assessment (also called 'quiz'), b) score, and c) personalized messaging. For the intervention program, the self-assessment ('Sexual Health Quiz'), score ('Sexual Health Score') and messaging ('Sexual Health Messaging') will pertain to sexual and reproductive health. For the intervention program, the self-assessment, will include a valid clinical prediction tool, established to predict STI positivity. Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen after the risk score. The program will be delivered via tablet. All participants regardless of randomization group, will be offered a STI screening kit immediately after receipt of their respective program.
62396270|NCT05324800|PLACEBO_COMPARATOR|placebo group|2 times a day, 2 capsule for 1 time, after breakfast and dinner meal (1.6 g/day, Curcuma longa L. extract mixture 0 g/day)
62778883|NCT04434014||female from 20 to above 65 y|will be sub divided into 4 groups according to age will be sub divided into 4 groups according to age sub group I from 20 - 35 sub group II from 36- 45 sub group III from 46- 65 sub group IV more than 65
62396271|NCT06199479|OTHER|Arm 1|The tests and procedures done as part of your standard-of-care biopsy preparation, participants will also have advanced MRI and CT scans performed no later than 2 weeks before the biopsy. Typically, these scans are done within 1 or 2 days before surgery to provide the most accurate images to the surgeon.
62396272|NCT04984824|NO_INTERVENTION|No nap group|No nap opportunity will be given in this condition.
62571547|NCT03852953||Study 2: Rate of overdiagnosis group|Women residing in Norway, born between 1927 and 1934 (inclusive). This cohort will include women who have attended screening and who have not attended screening.
62571548|NCT03852953||Study 3: Awareness and knowledge group|Women aged 50-69, and practising family doctors aged 25-75, currently living in Norway.
62778884|NCT00652886|EXPERIMENTAL|A|Subjects received Kali's products under fasting conditions
62188724|NCT04182113|EXPERIMENTAL|1 Hz rTMS Stimulation first, then sham rTMS, then 20 Hz rTMS Stimulation|Subjects will receive one session of each: low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of motor threshold (MT), for a total of 1200 pulses, high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minute, Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
62396273|NCT04984824|EXPERIMENTAL|10 minute nap|Participants will be given a 10 minute nap.
62396274|NCT04984824|EXPERIMENTAL|30 minute nap|Participants will be given a 30 minute nap.
62396275|NCT04984824|EXPERIMENTAL|60 minute nap|Participants will be given a 60 minute nap.
62396276|NCT06445907|EXPERIMENTAL|Part 1 (Dose Escalation)|Participants receive Q702 orally (PO) once daily (QD) on days 1-7 and 15-21 of each cycle. Azacitidine intravenously (IV) over 10-40 minutes or subcutaneously (SC) on days 1-7 of each cycle and venetoclax PO QD on days 1-21 or days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants also undergo collection of blood samples and bone marrow aspiration and/or biopsy throughout the trial.
62571549|NCT06578442|EXPERIMENTAL|Treatment group|Magnetic Field Treatment was applied to the participants for 30 minutes a day, twice a week for 8 weeks, using an electromagnetic field therapy device, in a supine position, by placing circular magnetotherapy electrodes in the abdominal area, at 25 Hz and 30 Gauss power.
62778885|NCT00652886|ACTIVE_COMPARATOR|B|Subjects received BTG products under fasting conditions
62396277|NCT06445907|EXPERIMENTAL|Part 2 (Dose Expansion)|Participants receive Q702 orally (PO) once daily (QD) on days 1-7 and 15-21 of each cycle. Azacitidine intravenously (IV) over 10-40 minutes or subcutaneously (SC) on days 1-7 of each cycle and venetoclax PO QD on days 1-21 or days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants also undergo collection of blood samples and bone marrow aspiration and/or biopsy throughout the trial.
62778886|NCT03057782||Group A|"1. Plan for major surgery anticipated to cause pain and agitation (i.e. esophageal atresia treatment);~2. Patients who are anticipated to receive prolonged post-surgical neuromuscular blockade (NMB)~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. These subjects will also receive EMG monitoring. Subjects in this group will also have video recordings that may be used for novel analysis such as subdermal blood flow or micro-movement."
62778887|NCT03057782||Group B|"1. Plan for major surgery anticipated to cause pain and agitation (i.e. bowel surgery);~2. Patients who are not anticipated to receive acute post-surgical NMB~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
62778888|NCT03057782||Group C|"Plan for minor surgery anticipated to cause pain and agitation (i.e. hernia repair)~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
62778889|NCT03057782||Group D|"No plan for surgery~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
62778890|NCT04697732||Adult patients age above 18 years|ASA I-IV adult patients over 18 years of age who will receive general anesthesia and are scheduled to be extubated postoperatively, who can give informed consent, have no known psychological or psychiatric problems, and who are suitable for postoperative follow-up.
62778891|NCT05238883|EXPERIMENTAL|Dose Escalation - HFB200301 monotherapy|Participants will be administered HFB200301 at dose levels 1-5 as an intravenous infusion to determine the Recommended Dose for Expansion (RDE).
62778892|NCT05238883|EXPERIMENTAL|Dose Escalation - HFB200301 in combination with tislelizumab|Participants will be administered HFB200301 at dose levels 1-4 in combination with one dose level of tislelizumab as an intravenous infusion to determine the combination Recommended Dose for Expansion (RDE).
62396278|NCT04693858|EXPERIMENTAL|Child Anxiety Learning Modules (CALM)|Children randomly assigned to this condition will receive the CALM intervention.
62778893|NCT05238883|EXPERIMENTAL|Dose Expansion - HFB200301 monotherapy|Participants will be administered HFB200301 at monotherapy RDE as an intravenous infusion.
62571550|NCT06578442|EXPERIMENTAL|Control group|"The control group was given constipation coping training and asked to perform the taught methods every day for 8 weeks. Whether the individuals applied the methods was checked every day via telerehabilitation."
62571551|NCT02390921|ACTIVE_COMPARATOR|Liosomated iron therapy|Fisiogen Ferro Forte 28mg every day po, during 3 months
62571552|NCT02390921|EXPERIMENTAL|Endovenous Iron Therapy|Venofer 300mg endovenously every 3 months
62571553|NCT03033368|EXPERIMENTAL|opened label|Open-label, single-arm study, rilpivirine is the study drug
62571554|NCT01056471|EXPERIMENTAL|Low dose autologous mesenchymal cells|The dose of infused cells is 10e6 cells/Kg
62571555|NCT01056471|EXPERIMENTAL|High dose|The dose of infused cells is 4\*10e6 cells/Kg
62571556|NCT01056471|NO_INTERVENTION|Placebo Control|
62003303|NCT03895320|OTHER|Control Program|The intervention and control programs will consist of similar, but not identical components. The Control Program will include a) a brief self-assessment (also called 'quiz'), b) score, and c) personalized messaging. For the Control Program, the self-assessment ('Water Sugar Sweetened Beverages (SSB) Quiz'), score ('Water SSB Score') and messaging ('Water SSB Messaging') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment. However, based on the answers given on the control quiz, steps the control participant can take to meet the recommended daily intake of water and sugar sweetened beverages will be displayed on the screen after they complete the quiz. The control program will be delivered via tablet. All participants regardless of randomization group, will be offered a STI screening kit immediately after receipt of their respective program.
62003304|NCT01547884||1|Latent TB positive with helminth positive
62003305|NCT01547884||2|Latent TB positive with helminth negative
62396279|NCT04693858|ACTIVE_COMPARATOR|Child Anxiety Learning Modules--Relaxation (CALM-R)|Children randomly assigned to this condition will receive the CALM-R intervention.
62396280|NCT04693858|NO_INTERVENTION|Waitlist control|Within each nurse, 20% (1 in 5) children will be randomly assigned to wait a period of eight weeks prior to starting the intervention with their school nurse. During this period, the child is not prevented from seeing the school nurse, nor are they prevented from continuing to utilize stable doses of community treatment (i.e., therapy outside of school or medication); nurses are simply asked to provide normal support and avoid using techniques specific to CALM or CALM-R. After the 8 weeks, youth are re-evaluated and nurses begin delivering the intervention to the student.
62396281|NCT06662747||Healthy|Cervicovaginal microbiota, mycobiota, and HPV prevalence, and identify women with stable Lactobacillus-dominated microbiota, with no STIs and no evidence of genital inflammation.
62778894|NCT05238883|EXPERIMENTAL|Dose Expansion - HFB200301 in combination with tislelizumab|Participations will be administered HFB200301 in combination with tislelizumab at combination RDE as an intravenous infusion.
62778895|NCT04218591|ACTIVE_COMPARATOR|PRP|Intra-articular injection PRP
62778896|NCT04218591|PLACEBO_COMPARATOR|Saline|Intra-articular injection Saline
62778897|NCT06584227|EXPERIMENTAL|Adebrelimab and Chidamide Combined with Gemcitabine and S1|
62778898|NCT01716455|EXPERIMENTAL|SSP-004184 (Mild Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
62778899|NCT01716455|EXPERIMENTAL|SSP-004184 (Moderate Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
62778900|NCT01716455|EXPERIMENTAL|SSP-004184 (Severe Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
62778901|NCT01716455|EXPERIMENTAL|SSP-004184 (End Stage Renal Disease)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
62778902|NCT01716455|EXPERIMENTAL|SSP-004184 (Healthy Elderly Subjects)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
62778903|NCT01716455|EXPERIMENTAL|SSP-004184 (Matched Healthy Subjects)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1. Healthy subjects matched to renally impaired subjects in arms 1 through 4. (Note: One healthy subject can match more than one renally impaired subject.)
62778904|NCT00854035|EXPERIMENTAL|E|
62778905|NCT00854035|PLACEBO_COMPARATOR|P|
62778906|NCT03908918|EXPERIMENTAL|Active group|Mobile-app delivered mindfulness intervention. Dosage: 4 times per week for 4 weeks
62778907|NCT03908918|OTHER|Waitlist control|Waitlist control - receiving the app after 6 months
62003306|NCT00907920||Correlative studies|"Tumor DNA samples are examined by mutation analysis for germline and somatic mutations in the ALK tyrosine kinase domain. Samples are analyzed by whole genome amplification using polymerase chain reaction and then sequenced for DNA alterations in the entire ALK coding sequence. Samples are also examined for SNPs by polymorphism analysis. Exploratory multivariable analysis is performed to test for the prognostic ability of ALK mutations in the presence of other known prognostic variables (i.e., age, International Neuroblastoma Staging System stage, MYCN status, International Neuroblastoma Pathology Classification, and diploidy).~A subset of tumor DNA samples from high-risk patients will be resequenced for DNA alterations to determine whether or not additional regions in ALK, outside of the tyrosine kinase domain, are prone to mutations and should be sequenced in a larger panel."
62003307|NCT01610791|EXPERIMENTAL|Single Arm|
62003308|NCT04290091||Patients with CAD|Patients who have hemodynamically significant CAD.
62003309|NCT04290091||Patients without CAD|Patients who don't have hemodynamically significant CAD.
62003310|NCT06457022|EXPERIMENTAL|Group A|Receiving modified constraint induced movement therapy , for 30 minutes , in addition to conventional physiotherapy program for the other 30 minutes.
62778908|NCT03310177||COPD|The smokers who are diagnosed as chronic obstructive pulmonary disease according to GOLD guideline.
62778909|NCT03310177||healthy control|The healthy controls without chronic obstructive pulmonary disease
62188725|NCT04182113|EXPERIMENTAL|20 Hz rTMS Stimulation first, then 1 Hz rTMS Stimulation, then sham rTMS|Subjects will receive one session of each: low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of motor threshold (MT), for a total of 1200 pulses, high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minute, Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
62003311|NCT06457022|EXPERIMENTAL|Group B|Receiving dual task training (Cognitive-Motor) for 30 minutes, in addition to conventional physiotherapy program for the other 30 minutes.
62188726|NCT04182113|EXPERIMENTAL|20 Hz rTMS Stimulation first, then sham rTMS, then 1 Hz rTMS Stimulation|Subjects will receive one session of each: low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of motor threshold (MT), for a total of 1200 pulses, high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minute, Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
62188727|NCT04182113|EXPERIMENTAL|sham rTMS first, then 1 Hz rTMS Stimulation, then 20 Hz rTMS Stimulation|Subjects will receive one session of each: low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of motor threshold (MT), for a total of 1200 pulses, high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minute, Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
62396282|NCT05429268|EXPERIMENTAL|Tafasitamab and Lenalidomide|Tafasitamab and lenalidomide will be coadministered for up to 12 cycles (28 days per cycle).followed by tafasitamab monotherapy (in participants with stable disease or better) until treatment withdrawal criteria are met.
62778910|NCT02974049|ACTIVE_COMPARATOR|Standard Treatment|Albendazole 400 mg + Ivermectin 200 µg/kg body weight administered annually (at 0, 12 and 24 months)
62778911|NCT02974049|EXPERIMENTAL|ALB 400 mg x2 per year|Albendazole 400 mg given at 0, 6, 12, 18, 24 and 30 months
62778912|NCT02974049|EXPERIMENTAL|ALB 800 mg x2 per year|Albendazole 800 mg given at 0, 6, 12, 18, 24 and 30 months
62778913|NCT02974049|EXPERIMENTAL|ALB 400mg + IVM 200mcg/kg + DEC 6mg/kg|Albendazole 400 mg plus Ivermectin 200 µg/kg body weight plus Diethylcarbamazine 6 mg/kg body weight given one time only
62778914|NCT06155539||Pre-diabetes|Fasting blood glucose level of 5.6-6.9 mmol/L (impaired fasting blood glucose) or 2-hour postprandial blood glucose of 7.8-11.0 mmol/L (impaired glucose tolerance) or haemoglobin A1c (HBA1c) of 5.7-6.4%.
62778915|NCT06155539||Diabetes in the early stages|Fasting blood glucose is higher than 7.0mmol/L, 2 hours postprandial blood glucose is higher than 11.1mmol/L, random blood glucose is higher than 11.1mmol/L with classic symptoms of hyperglycemia, and the HbA1C is higher than 6.5%, but there is no obvious complication of heart, kidney and eyes.
62778916|NCT06155539||Diabetes in the middle and late stages|Includes diabetics with various degrees of complications. Among the minor complications are microalbuminuria and mild diabetic retinopathy (e.g. microaneurysms, mild haemorrhages). Mild to moderate complications included diabetic nephropathy without renal failure and diabetic retinopathy without proliferative diabetic retinopathy. Severe complications include hyperglycaemic crises such as diabetic ketoacidosis and hyperosmolar hyperglycaemic state, microvascular complications such as retinopathy (neovascularisation and vitreous or preretinal haemorrhage preretinal haemorrhage), nephropathy, cardiomyopathy, neuropathy (sensory lesions such as podiatry, autonomic neuropathies such as sexual dysfunction and gastroparesis), and macrovascular complications (coronary heart disease, cerebrovascular disease, proliferative diabetic retinopathy, peripheral arterial disease, amputations and foot ulcers).
62003312|NCT06457022|OTHER|Group C|Receiving only conventional physiotherapy program for 60 minutes.
62003313|NCT00043693|EXPERIMENTAL|1|Participants will undergo the Family Intervention for Dual Diagnosis (FIDD) program.
62003314|NCT00043693|ACTIVE_COMPARATOR|2|Participants will be placed in a family psychoeducation program.
62003315|NCT01278459|EXPERIMENTAL|Atorvastatin first|Participants receive 4 week treatment with atorvastatin 20mg/day, followed by 4 week washout, followed by 4 week treatment with placebo.
62003316|NCT01278459|EXPERIMENTAL|Placebo first|Participants receive 4 week treatment with placebo, followed by 4 weeks washout, followed by 4 weeks treatment with atorvastatin 20mg/day.
62188728|NCT04182113|EXPERIMENTAL|sham rTMS first, then 20 Hz rTMS Stimulation, then 1 Hz rTMS Stimulation|Subjects will receive one session of each: low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of motor threshold (MT), for a total of 1200 pulses, high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minute, Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
62188729|NCT02638688||2D ultrasound|2D-US measurements are the most accurate method for measuring fibroid volumes
62188730|NCT02638688||3D ultrasound|3D-US measurements are the most accurate method for measuring fibroid volumes
62188731|NCT02638688||postoperative|actual volume using change in water path measurements are the most accurate method for measuring fibroid volumes
62188732|NCT02909309|OTHER|ALL INCLUDED PATIENTS|"A single arm for this study. All the patients benefit of both systems. The participants are their own control.~Non invasive sensors are used to monitor and record data of those two systems in a synchron way ( JAWAC / Capnoline + Spo2)."
62188733|NCT04850235|EXPERIMENTAL|TPX neoadjuvant chemotherapy +CCRT|Patients receive neoadjuvant chemotherapy with Nab-PTX (150/175/200/225/250 mg/m2, D1) , cisplatin (75 mg/m2, D1) and capecitabine (1000 mg/m2, BID, D1-14) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100 mg/m2) concurrent every three weeks during radiotherapy (D1, D22, D43 of RT)
62188734|NCT04553445|EXPERIMENTAL|Chronotype|Determination whether monthly migraine load is affected by exercise in sync with chronotype
62188735|NCT04553445|EXPERIMENTAL|Green exercise|Determination whether monthly migraine load is affected by exercise in a natural environment
62188736|NCT01335906|EXPERIMENTAL|Evidence-based informed consent|
62571557|NCT02343939|EXPERIMENTAL|Entospletinib + daunorubicin + cytarabine (Group A)|"Dose Escalation: Entospletinib up to 400 mg for 14 days and then entospletinib up to 400 mg in combination with daunorubicin and cytarabine for up to two 14-day cycles.~Dose Expansion: Entospletinib 400 mg for 14 days and then entospletinib 400 mg in combination with daunorubicin and cytarabine for up to two 14-day cycles. Some participants will have the option to receive post-induction therapy with entospletinib 400 mg in combination with cytarabine/cytosine arabinoside (ARA-C). Participants may receive maintenance therapy with 28-day cycles of entospletinib 400 mg for up to twelve 28-day cycles, if the participant is not eligible for stem cell transplant."
62778917|NCT01088594|EXPERIMENTAL|1|pioglitazone 45 mg
62778918|NCT01088594|EXPERIMENTAL|2|Rosiglitazone 8 mg
62778919|NCT01088594|PLACEBO_COMPARATOR|3|Placebo
62778920|NCT05521321|EXPERIMENTAL|Receives the Stanford Cannabis Prevention and Awareness curriculum|Stanford Cannabis Prevention and Awareness curriculum administered
62778921|NCT05521321|NO_INTERVENTION|Does not receive Stanford Cannabis Prevention and Awareness curriculum|Receives another curriculum or no cannabis prevention curriculum
62778922|NCT05385588|EXPERIMENTAL|Single arm|290 PLHIV, aged 55 to 76 years old
62778923|NCT04966988||CAV 0(Not significant)|No detectable angiographic lesion
62188737|NCT01335906|NO_INTERVENTION|Usual information|
62188738|NCT01688817|OTHER|Physician's counseling|
62188739|NCT01688817|ACTIVE_COMPARATOR|Information leaflet|
62778924|NCT04966988||CAV 1 (Mild)|Angiographic left main (LM) \<50%, or primary vessel with maximum lesion of \<70%, or any branch stenosis \<70% (including diffuse narrowing) without allograft dysfunction
62188740|NCT02581059|EXPERIMENTAL|Regorafenib + Ginseng|Regorafenib will be administered 160 mg once daily for the first 21 days of each 28-day cycle. Subjects will receive 1,000 mg ginseng orally twice daily every day for 4 weeks (2 cycles).
62188741|NCT02581059|ACTIVE_COMPARATOR|Regorafenib Only|Regorafenib will be administered 160 mg once daily for the first 21 days of each 28-day cycle for 2 cycles.
62188742|NCT04120376|EXPERIMENTAL|Counseling Intervention|All participants will receive contraception counseling by study Advanced Practice Providers (APPs)
62188743|NCT01473615|EXPERIMENTAL|Treatment As Usual + Mindfulness Based Cognitive Therapy|Subjects randomized into the intervention group will receive, a manualized 8-week MBCT group skills program with sessions that each last 2 hours, in addition to their treatment as usual (TAU).
62188744|NCT01473615|NO_INTERVENTION|Treatment As Usual|Patients randomized into the TAU group will continue to receive their care as usual and be put on a waitlist. They will be offered the MBCT treatment after the completion of the study.
62188745|NCT06120946||Control arm|Patients randomised in the BHF PROTECT study to TAVI without Sentinel cerebral embolic protection
62188746|NCT06120946||Intervention arm|Patients randomised in the BHF PROTECT study to TAVI with Sentinel cerebral embolic protection
62778925|NCT04966988||CAV 2 (Moderate)|Angiographic LM \<50%; a single primary vessel≥70%, or isolated branch stenosis ≥70% in branches
62778926|NCT04966988||CAV 3 (Severe)|Angiographic LM≥50%, or two or more primary vessels ≥70% stenosis, or isolated branch stenosis≥70%in all 3 systems; or CAV1 or CAV2 with allograft dysfunction (defined as LVEF≤45% usually in the presence of regional wall motion abnormalities) or evidence of significant restrictive physiology
62778927|NCT04492163|EXPERIMENTAL|Experimental: TTFields|Patients receive continuous TTFields treatment using the Optune® System with high intensity transducer arrays.
62778928|NCT01679886|EXPERIMENTAL|Rubidium PET|Rubidium PET
62778929|NCT02542787|EXPERIMENTAL|Active|VSN16R (Canbex name for molecule) oral capsules, 50mg-400mg daily or twice daily, total exposure 26 days
62778930|NCT02542787|PLACEBO_COMPARATOR|Placebo|Placebo capsules, 50mg-400mg daily or twice daily, total exposure 26 days
62778931|NCT03473899|ACTIVE_COMPARATOR|rESWT + RP|Device: rESWT
62778932|NCT03473899|PLACEBO_COMPARATOR|sham-rESWT + RP|Device: sham-rESWT
62778933|NCT00857974|NO_INTERVENTION|Usual Care|No physical activity intervention will be prescribed for the Usual Care Arm.
62778934|NCT00857974|ACTIVE_COMPARATOR|Physical Activity|
62778935|NCT06222528|EXPERIMENTAL|Brief video intervention (Black Girl)|A brief social contact-based video with a Black girl protagonist
62778936|NCT06222528|EXPERIMENTAL|Brief video intervention (Black Boy)|A brief social contact-based video with a Black boy protagonist
62003317|NCT05053672|NO_INTERVENTION|Conventional therapy back pain treatment|Participants randomized to сonventional therapy group will receive complex rehabilitation program including physical exercise, phonophoresis with hydrocortisone, lumbar region massage, acupuncture within 2 weeks.
62396283|NCT06010576|ACTIVE_COMPARATOR|EUS-guided rendezvous group (EUS RV group)|In the EUS RV group, a linear array echoendoscope would be used to evaluate the common bile duct and left intrahepatic duct in order to identify the optimal route for biliary access by fine needle. Using a 19 gauge EUS needle, the dilated biliary tree will be accessed by either a transduodenal puncture to the common bile duct or a transgastric puncture to the left intrahepatic duct under direct EUS guidance. The optimal access route will be based on patient's anatomy after EUS assessment and left to the discretion of the investigator. Next, a guidewire would be advanced through the needle into the bile duct and out of the papillary orifice. The echoendoscope would then be exchanged to a duodenoscope for ERCP. The EUS rendezvous ERCP procedure will be completed by retrieving the rendezvous guidewire into the duodenoscope or by cannulation alongside the rendezvous guidewire to obtain biliary access.
62396284|NCT06010576|ACTIVE_COMPARATOR|Early precut papillotomy group (EPP group)|In the EPP group, the precut papillotomy would be performed with 1 of the following acceptable techniques per the usual practice of the study investigator and institution: 1) conventional precut papillotomy by needle knife, 2) precut fistulotomy by needle knife, or 3) transpancreatic precut papillotomy by papillotome
62003318|NCT05053672|ACTIVE_COMPARATOR|Conventional physiotherapy therapy back pain treatment + ReOxy-therapy|Participants randomized to Active Comparator group will receive complex rehabilitation program and 10 ReOxy-therapy sessions within 2 weeks (5 sessions per week).
62003319|NCT05053672|PLACEBO_COMPARATOR|Conventional physiotherapy therapy + Sham ReOxy-therapy|Participants randomized to Placebo Comparator group will receive complex rehabilitation program and 10 sham ReOxy-therapy sessions within 2 weeks (5 sessions per week).
62003320|NCT05851560|NO_INTERVENTION|Control|control group that does not use antiadhesive material
62003321|NCT05851560|EXPERIMENTAL|Oxidized regenerated cellulose(ORC) Group|The group that uses Oxidized regenerated cellulose(ORC) as antiadhesive material during thyroid surgery.
62396285|NCT05968157|EXPERIMENTAL|High Risk Participants--MIRAI|Patients who are deemed high risk on standard breast screening mammogram by the MIRAI model
62396286|NCT05968157|ACTIVE_COMPARATOR|High Risk Participants--non-MIRAI|Patients who are deemed high risk by Tyrer-Cuzick model but not MIRAI
62396287|NCT04446039||1. Escitalopram Cohort|
62003322|NCT05851560|EXPERIMENTAL|Hyaluronic acid(HA) Group|The group that uses Hyaluronic acid(HA) as antiadhesive material during thyroid surgery.
62003323|NCT02130050||OSA Patient|•male patients aged 30 to 65 yr who are newly diagnosed as severe OSA (AHI \>=30/hr)
62003324|NCT02130050||Control subjects:|•male control subjects are recruited from Heath Check-up Center. Subjects who are matched with OSA patients at age (+/-2 yrs), body height (+/-3cm) and body weight (\<100 kg: +/-3kg, \>100 kg: +/-4kg) are screened. Only subjects who are not sleepy (ESS\<10) and have no OSA (AHI\<5/hr PSG)
62778937|NCT06222528|EXPERIMENTAL|Brief video intervention (Latinx Girl)|A brief social contact-based video with a Latinx girl protagonist
62778938|NCT06222528|EXPERIMENTAL|Brief video intervention (Latinx Boy)|A brief social contact-based video with a Latinx boy protagonist
62778939|NCT06222528|EXPERIMENTAL|Brief video intervention (White Girl)|A brief social contact-based video with a White girl protagonist
62778940|NCT06222528|EXPERIMENTAL|Brief video intervention (White Boy)|A brief social contact-based video with a White boy protagonist
62003325|NCT00235989|ACTIVE_COMPARATOR|ET: IFNB-1b 250 mcg => 250 mcg|Extension Treatment 250 mcg continued
62003326|NCT00235989|EXPERIMENTAL|ET: IFNB-1b 500 mcg => 250 mcg|Extension Treatment 500 mcg reduced to 250 mcg
62003327|NCT00235989|EXPERIMENTAL|ET: IFNB-1b 500 mcg => 500 mcg|Extension Treatment 500 mcg continued
62003328|NCT00235989|EXPERIMENTAL|ET: IFNB-1b 250 mcg => 500 mcg|Extension Treatment 250 mcg increased to 500 mcg
62003329|NCT05669443|EXPERIMENTAL|conventional PEEP|Apply of PEEP 5
62003330|NCT05669443|ACTIVE_COMPARATOR|optimized PEEP|Apply of optimized PEEP derived using EIT (airtom®)
62396288|NCT04446039||2. Paroxetine Cohort|
62396289|NCT04446039||3. Fluoxetine Cohort|
62396290|NCT04446039||4. Mirtazapine Cohort|
62396291|NCT04446039||5. Duloxetine Cohort|
62396292|NCT04446039||6. Sertraline Cohort|
62778941|NCT06222528|EXPERIMENTAL|Brief video intervention (Nonbinary or transgender)|A brief social contact-based video with a nonbinary or transgender protagonist
62003331|NCT01690767|EXPERIMENTAL|Topical and intraurethral 2% lidocaine|2% lidocaine gel will be applied for 5 minutes to the external urethral opening. This will be followed immediately by 2% lidocaine gel administration into the urethra using a 24 gauge angiocath for 5 minutes prior to catheterization for urine specimen collection. Children \< 7 kg and \> 7 kg will receive 1 cc and 1.5 cc, respectively.
62778942|NCT06222528|ACTIVE_COMPARATOR|Control|A brief video control condition with psychoeducation on depression and help seeking
62003332|NCT01690767|ACTIVE_COMPARATOR|Standard of care|According to standard nursing practice, the urethra will be catheterized without anaesthetic gel but using lubricant gel only. Intervention is Health Care Lubricating Jelly.
62003333|NCT03706807|EXPERIMENTAL|Mindfulness-Based Intervention|"This group will be included in the eight-week mindfulness program following the Mindfulness-Based Health Promotion (MBHP) protocol. The group will have a weekly meeting of an hour and thirty minutes for eight weeks to perform the mindfulness-based interventions accompanied by plus four one-hour meetings through a maintenance group after conclusion of the program, totaling 16 hours. The training will be lead by a certified instructor and he will introduce practices such as mindfulness in breathing, body scan, mindful walking, mindful movements and 3-minutes of mindfulness and the concepts of first and second suffering and the Hi-Thanks-Bye."
62003334|NCT03706807|ACTIVE_COMPARATOR|Cognitive Stimulation|The basic workshop is considered a cognitive stimulation and the participants will receive an hour and thirty minutes class once a week during four months. The abilities learned at the workshop will be basic computer functions from development of the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks. The activities of the workshop are elaborated according to the development of each class and is participants.
62003335|NCT03706807|NO_INTERVENTION|Naïve|It's a waiting list group which will receive no intervention.
62003336|NCT06107491|OTHER|study group|mothers receiving routine education plus digital video disk before surgery
62003337|NCT06107491|OTHER|control group|mothers receiving routine education
62003338|NCT02419846|EXPERIMENTAL|Men over 40: Screening with intervention|Participants over the age of 40 complete an educational intervention comprising a 10-20 minute PowerPoint presentation given by an experienced healthcare professional that discusses prostate cancer facts, screening guidelines, risks, benefits, and consequences. Participants may undergo a screening exam comprising a prostate specific antigen level and digital rectal exam.
62003339|NCT02419846|EXPERIMENTAL|Men 18-39: Educational intervention|Participants between 18 and 39 complete an educational intervention comprising a 10-20 minute PowerPoint presentation given by an experienced healthcare professional that discusses prostate cancer facts, screening guidelines, risks, benefits, and consequences.
62003340|NCT04845737|OTHER|Fibromyalgia patient group|Sympathetic skin response measurements will be made in patients who meet the diagnosis criteria of fibromyalgia. Vitamin D levels will be measured and hemogram values will be checked in these patients.
62188747|NCT03318653||HD - Hemodialysis|Patients with end stage renal disease treated with hemodialysis
62396293|NCT04446039||7. Venlafaxine Cohort|
62396294|NCT04446039||8. Tianeptine Cohort|
62778943|NCT03576716|EXPERIMENTAL|Study Population|D6-25-hydroxyvitamin D3 with vitamin D3
62396295|NCT04446039||9. Vortioxetine Cohort|
62396296|NCT04446039||10. Desvenlafaxine Cohort|
62396297|NCT04446039||11. Bupropion Cohort|
62396298|NCT01693640|EXPERIMENTAL|abatacept|
62396299|NCT05937152|EXPERIMENTAL|Eptinezumab Group|Subjects diagnosed with diabetic polyneuropathy (DPN) will receive 2 infusions of eptinezumab during the 24 week-long placebo-controlled treatment period.
62778944|NCT04533867||Ondansetron|In Group B (n = 50): Intravenous injection of ondansetron 0.1 mg/kg diluted up to 5 mL with normal saline solution in a maximum dose of 8 mg is performed at the end of bariatric surgery while patients are in anesthesia. The drug is injected once.
61977856|NCT05706142|EXPERIMENTAL|Intervention Group|"Within the scope of motor imagery training, a presentation will be made to the students of pediatric rehabilitation lecture in the intervention group about what motor imagery is. PETTLEP model will be used for imagery training. In this model, imagery training will be prepared in accordance with our purpose, taking into account the physical, environmental, time, task, learning, emotion and personal subheadings. In the training sessions, relaxation exercises will be given for 5 minutes first. After the relaxation exercises, special colic massage imagery training will be given to newborns for 10 minutes. The massage will also be shown as practically at class."
61977857|NCT05160454|ACTIVE_COMPARATOR|patient|child with moyamoya
61977858|NCT05160454|ACTIVE_COMPARATOR|control|unaffected control
62188748|NCT03318653||PD - Peritoneal dialysis|Patients with end stage renal disease treated with peritoneal dialysis
62003341|NCT04845737|OTHER|Control Group|The participant in this group will be chosen from healthy volunteers. Sympathetic skin response will be measured of the participants. Vitamin D levels and hemogram values will be recorded.
62003342|NCT05449925|EXPERIMENTAL|TEST GROUP|i-PRF and Microneedling Procedure in thin gingiva followed by orthodontic treatment
62003343|NCT05449925|NO_INTERVENTION|CONTROL GROUP|no periodontal intervention
62003344|NCT05650372|EXPERIMENTAL|High intensity resistive exercise group|Participants of this group will be applied manual lymphatic drainage and compression bandaging and they will exercise for 25 minutes, three sets of each exercise at 80% intensity of 1 max repetition.
62396300|NCT05937152|PLACEBO_COMPARATOR|Placebo Group|Subjects diagnosed with diabetic polyneuropathy (DPN) will receive 2 infusions of placebo during the 24-week long placebo-controlled treatment period.
62396301|NCT05937152|EXPERIMENTAL|Open-label Eptinezumab Group|At the end of the placebo-controlled treatment period, all participants will have the option to continue into the 24-week long active study treatment period and will receive 2 infusions of eptinezumab.
62396302|NCT06629272|EXPERIMENTAL|D-THIO (Deprescribing Thyroid Hormone In Older Adults)|"D-THIO is an innovative adapted multilevel intervention.~Providers in the intervention arm will receive: 1) an introductory letter, and 2) the D-THIO pharmaceutical opinion via EMR-compatible correspondence.~After randomization of their treating providers, patients in the intervention arm will receive a study packet including: 1) introductory letter, and 2) the D-THIO patient brochure (educational EMPOWER brochure)."
62396303|NCT06629272|ACTIVE_COMPARATOR|Enhanced usual care|"This arm will receive enhanced usual care.~Providers in the control arm will receive: 1) an introductory letter signed by the PI and site-PIs, and 2) the ATA hypothyroidism pocket card via EMR.~Patients in the control arm will receive a study packet including: 1) introductory letter, and 2) the ATA patient brochure."
62778945|NCT04533867||Palonosetron|The antiemetics used are palonosetron in Group A (n = 50): Intravenous injection of Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution is performed at the end of bariatric surgery while patients are in anesthesia. The drug is injected once.
62778946|NCT05966948|EXPERIMENTAL|Hypertonic Dextrose Prolotherapy|This group received a Hypertonic dextrose intra articular is 25%, while extra articular 20% injection on day 1 and day 30 with same dose.
62778947|NCT05966948|PLACEBO_COMPARATOR|Normal Saline|This group received Normal Saline injection on day 1 and day 30.
62778948|NCT00830180|EXPERIMENTAL|Anti-NGF AB|
62778949|NCT06200623||Asthmatic patients presented to respiratory outpatient clinic|"All subjects will be subjected to Complete history taking including demographic data, residence, educational level, income level, and presence of first- or second-degree medical relative. The first onset age of asthma and duration of asthma will be recorded. Factors that can affect treatment adherence are collected as type and number of medications, cost, inclusion in the health insurance system, availability, asthma-related comorbidities, and choice of drug and device.~: To assess adherence we will use the Morisky Medication Adherence Scale (MMAS-8) as discussed above~To assess patient beliefs, we will use The Beliefs about Medicines Questionnaire as discussed above To obtain information on illness perception we will use The Brief Illness Perception Questionnaire (Brief IPQ) as discussed above To assess asthma control we will use the asthma control test as discussed above"
62778950|NCT01115374|ACTIVE_COMPARATOR|manual lymphatic drainage|Application of manual lymphatic drainage
62778951|NCT01115374|EXPERIMENTAL|low frequency sound waves|Application of low frequency sound waves
62003345|NCT05650372|ACTIVE_COMPARATOR|Low intensity resistive exercise group|Participants in this group will be applied manual lymphatic drainage and compression bandaging and they will exercise for 25 minutes, three sets of each exercise at 30% intensity of 1 max repetition.
62003346|NCT04820816||Posterior pelvic tilt group|"1. patients with chronic low back pain or repeated non-specific back pain for more than three months.~2. Both sex with posterior pelvic tilt (-0.7 ± 6.5°) and decreased lumbar lordosis~3. Their ages were ranged from 20-35 years~4. Body Mass Index from 18-25 Kg/m²"
62003347|NCT04820816||Normal anterior pelvic tilt group|"1. patients with chronic low back pain or repeated non-specific back pain for more than three months.~2. Both sex with anterior pelvic tilt (5° and 13°) and normal lumbar lordosis~3. Their ages were ranged from 20-35 years~4. Body Mass Index from 18-25 Kg/m²"
62003348|NCT04140461|EXPERIMENTAL|Trial|Amphotericin B 0.5 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 4 weeks
62003349|NCT04140461|ACTIVE_COMPARATOR|Control|Amphotericin B 0.7 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 2 weeks
62003350|NCT05054530|EXPERIMENTAL|GMA106|9 different dosages will be subcutaneously injected into the abdomen.
62003351|NCT05054530|PLACEBO_COMPARATOR|Matching placebo|9 different dosages will be subcutaneously injected into the abdomen.
62003352|NCT05124639|EXPERIMENTAL|Group self-management support|Group self-management support program for anxiety disorders developped by Relief (https://myrelief.ca/).
62188749|NCT05730998|EXPERIMENTAL|Intervention group|1 capsule (120 mg) of Anthocran phytosome will be taken 1 times a day, for 6 months, with control every 2 months and phone call every month of treatment.
62188750|NCT05730998|PLACEBO_COMPARATOR|Placebo group|1 capsule of placebo will be taken 1 times a day, for 6 months, with control every 2 months and phone call every month of treatment.
62188751|NCT00561717|EXPERIMENTAL|Arm 1|
62188752|NCT00561717|ACTIVE_COMPARATOR|Arm 2|
62188753|NCT00561717|ACTIVE_COMPARATOR|Arm 3|
62188754|NCT00561717|PLACEBO_COMPARATOR|Arm 4|
62188755|NCT05271344|PLACEBO_COMPARATOR|Placebo Group|Placebo products for probiotics, prebiotics, omega 3 and vitamin D
62188756|NCT05271344|EXPERIMENTAL|Treated Group|Omega 3 fatty acids for 7 days (before starting conventional oral immunonutrition supplement), Probiotics for 14 days before and after the operation, Prebiotics for 14 days before and after the operation, Vitamin D for 6 days before the operation.
62778952|NCT02536222|EXPERIMENTAL|Reactive case investigation : FT/FDA with DHA-PQ|All consenting household members eligible to receive DHA-PQ and living in a household where anyone in the household tests positive with a malaria rapid diagnostic test (RDT) will receive the age-appropriate treatment dose of DHA-PQ. If no one in the household tests RDT positive then no one in the household will receive DHA-PQ.
62778953|NCT02536222|NO_INTERVENTION|No Intervention: Standard of Care (Control)|The standard of care arm will have the standard of care offered by the Ministry of Health which applies to all arms. This includes available mosquito net coverage and passive case detection of individuals seeking treatment from a health provider at a health post or community.
62778954|NCT00903305|EXPERIMENTAL|Group II (SNIP)|Patients undergo SNIP comprising four visits over 2 months and four monthly telephone calls from the APN. The APN will provide 24 hour access during the study. Patients complete questionnaires about satisfaction with care, perceived preparedness with self-care, and helpfulness of patient teaching at baseline, 3 months and 6 months.
62778955|NCT00903305|ACTIVE_COMPARATOR|Group I (usual care intervention)|Patients undergo usual care and complete questionnaires about satisfaction with care, perceived preparedness with self-care, and helpfulness of patient teaching at baseline, 3 months and 6 months.
62188757|NCT04477993|EXPERIMENTAL|Experimental Group - ruxolitinib|Ruxolitinib 5 mg PO b.i.d. for 14 days
62188758|NCT04477993|PLACEBO_COMPARATOR|Placebo Group|
62188759|NCT05657756|OTHER|Atracrium group|
62188760|NCT05657756|OTHER|Rocoronium group|
62188761|NCT01636908|EXPERIMENTAL|Kinase inhibitor|Patients are cohort-wise treated with a registered (tyrosine) kinase inhibitor
62396304|NCT04688385|EXPERIMENTAL|Multipeptide Vaccine + XS 15|a personalizied multi-peptide vaccine in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes
62003353|NCT05124639|NO_INTERVENTION|Treatment-as-usual|Treatment-as-usual and a delayed intervention (if desired by participants) after the 12-month follow up
62003354|NCT05224492|EXPERIMENTAL|Sulforaphane Group|
62003355|NCT05224492|PLACEBO_COMPARATOR|Placebo Group|
62003356|NCT05703893||Syndromic TAA|Patients presenting either clinical or genetic phenotype referring to a syndrome related to Thoracic Aortic Aneurysms
62003357|NCT05703893||Non-syndromic TAA|Patients presenting Thoracic Aortic Aneurysms
62003358|NCT00167934|PLACEBO_COMPARATOR|Placebo|50% of participants will receive placebo
62003359|NCT00167934|EXPERIMENTAL|Experimental|50% of participants will receive Depakote ER
62003360|NCT04230096|EXPERIMENTAL|applied group|low level laser therapy applied in one group
62003361|NCT04230096|NO_INTERVENTION|controlled group|other group will be controlled in which low level laser will not be applied
62003362|NCT05225961|EXPERIMENTAL|Tirofiban|An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 10 ml (500 micrograms) of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters).
62188762|NCT04695652|EXPERIMENTAL|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
62188763|NCT04695652|PLACEBO_COMPARATOR|MVC-COV1901(Saline)|Saline/0.5 mL
62188764|NCT02787447|EXPERIMENTAL|1|After 3 mos TKI, patients showed stable disease take TKI, radiotherapy and thymosin alpha 1 till tumor progression.
62188765|NCT02690337|EXPERIMENTAL|DS-1123|This study will follow a modified Continual Reassessment Method (mCRM) + Escalation with Overdose Control (EWOC),design with a starting intravenous (IV) dose of 0.1 mg/kg.
62188766|NCT04451811|EXPERIMENTAL|OPL-002 SDD 20 mg|20 mg SDD formulation of OPL-002
62188767|NCT04451811|EXPERIMENTAL|OPL-002 5 mg Tablet|5 mg tablet formulation of OPL-002
62188768|NCT04451811|EXPERIMENTAL|OPL-002 20 mg Tablet|20 mg tablet formulation of OPL-002
62778956|NCT00803062|ACTIVE_COMPARATOR|Arm I (paclitaxel and cisplatin)|Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV on day 1 or 2.
62188769|NCT01206699|EXPERIMENTAL|corticoid|Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
62188770|NCT01206699|PLACEBO_COMPARATOR|physiological solution|Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
62571558|NCT02343939|EXPERIMENTAL|Entospletinib + decitabine (Group B)|"Dose Escalation: Entospletinib 400 mg for 14 days and then entospletinib 400 mg in combination with decitabine for 10 days beginning on Day 1 of every 28-day cycle (at least 2 cycles of induction therapy but no more than 4 cycles). Participants who are intolerant of decitabine may switch to entospletinib monotherapy maintenance at any time after completing the first 2 cycles.~Dose Expansion: Entospletinib 400 mg for 14 days for the safety run-in participants or Entospletinib 400 mg for 5 days for the randomization participants. Then entospletinib 400 mg in combination with decitabine or azacitidine (at least 2 cycles of induction therapy but no more than 4 cycles). Some participants will have the option to receive maintenance therapy with entospletinib in combination with decitabine or azacitidine. Participants who are intolerant of decitabine or azacitidine may switch to entospletinib monotherapy maintenance at any time after completing the first 2 cycles."
62188771|NCT03968068|EXPERIMENTAL|Exercise|
62188772|NCT03968068|EXPERIMENTAL|Remote Ischaemic Conditioning|
62188773|NCT05996978||Intensive Drug Therapy|Dual antiplatelet therapy (DAPT) (aspirin 100 mg per day and clopidogrel 75 mg per day were administered for 90 days, followed by aspirin 100 mg per day for long term) and atorvastatin (40 mg per day for 14 days, followed by 20 mg per day long term) after enrollment.
62188774|NCT04063046|ACTIVE_COMPARATOR|General anesthesia|General anesthesia involving intubation or supraglottic airway device insertion
62396305|NCT05275231|EXPERIMENTAL|Dyads|This is a pragmatic, pre-post, pilot study. Participants will meet in groups of 12 for the SMA intervention at the conference room at the Emory Family Medicine Center in Dunwoody, Georgia. The intervention will consist of bi-weekly sessions over a 16-week period, with phone check-ins for the remaining weeks. Each session will last 60-90 minutes, and participants will engage in a total of 6 televisit sessions. Sessions will consist of a group-based program for all participants, followed by a personalized care plan, led by a physician. In this dyad-based group, participant's social partner must commit to attend all in-person sessions.
62778957|NCT00803062|EXPERIMENTAL|Arm II (paclitaxel, cisplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV and bevacizumab IV over 30-90 minutes on day 1 or 2.
62778958|NCT00803062|EXPERIMENTAL|Arm III (topotecan hydrochloride and paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
62188775|NCT04063046|EXPERIMENTAL|peripheral nerve block|popliteal sciatic nerve block
62188776|NCT02429986|OTHER|ASV Arm|The measures are performed during the annual consultation required by the French Social Security for the renewal of the reimbursement of the ASV care.
62188777|NCT02265809|EXPERIMENTAL|Aldesleukin|Aldesleukin will be administered subcutaneously at varying doses and frequencies for a period of up to 98 days from first administration depending on the treatment assignment. The maximum dose allowed is 0.6 X 10\^6 IU/m2.
62778959|NCT00803062|EXPERIMENTAL|Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab)|Patients receive paclitaxel IV over 3 hours and bevacizumab IV over 30-90 minutes on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
62778960|NCT05797597|EXPERIMENTAL|Aspirin|Acard 300 mg (Acidum acetylsalicylicum). 1 tablet (300 mg) twice a day
62778961|NCT05797597|PLACEBO_COMPARATOR|Placebo|Placebo 1 tablet twice a day
62778962|NCT03561818|EXPERIMENTAL|Hospital-based group|2 months hospital-based pulmonary rehabilitation program
62778963|NCT03561818|EXPERIMENTAL|Home-based group|2 months home-based pulmonary rehabilitation program
62778964|NCT01139567||Standard Care Group|Subjects who will undergo only standard wound care management.
62778965|NCT01139567||Hyperbaric Oxygen Therapy Group|Subjects who are selected for adjunctive hyperbaric oxygen therapy in addition to standard wound care intervention.
62214674|NCT03821779|EXPERIMENTAL|Group 2.1|"In group 2.1, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after:~1. real exposure: oral presentation to a panel of examiners~2. virtual reality : oral presentation to virtual examiners~Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session.~Psychometric evaluation will be performed prior to experimental sessions."
62396306|NCT05275231|ACTIVE_COMPARATOR|Men Only|This is a pragmatic, pre-post, pilot study. Participants will meet in groups of 12 for the SMA intervention at the conference room at the Emory Family Medicine Center in Dunwoody, Georgia. the intervention will consist of bi-weekly sessions over a 16-week period, with phone check-ins for the remaining weeks. Each session will last 60-90 minutes, and participants will engage in a total of 6 televisit sessions. Sessions will consist of a group-based program for all participants, followed by a personalized care plan, led by a physician. In this group just the participant will receive the intervention.
62778966|NCT05880173|OTHER|Diagnostic FIB4|Only one arm because diagnostic study evaluating blood test using elastometry and liver biopsy as reference
62778967|NCT04534270|EXPERIMENTAL|Dapagliflozin treatment|
62778968|NCT00455143|EXPERIMENTAL|Dexmedetomidine|Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
62778969|NCT00455143|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively or until discharge from the PACU.
62778970|NCT01799824|EXPERIMENTAL|Active|ANT-1403
62778971|NCT01799824|PLACEBO_COMPARATOR|Vehicle|Vehicle
62778972|NCT03633266|EXPERIMENTAL|anti-VEGF|experimental group: vitreoretinal surgery combined with intraoperative anti-VEGF
62778973|NCT03633266|ACTIVE_COMPARATOR|PRP|Control group: vitreoretinal surgery combined with intraoperative PRP
62778974|NCT06583967|EXPERIMENTAL|Group 1 - Elliptical Trainer|15 MS subjects will be enrolled and assigned to group 1 and to be trained (Elliptical Trainer) twice a week for 12 weeks.
62778975|NCT06583967|EXPERIMENTAL|Group 2 - Treadmill|15 MS subjects will be enrolled and assigned to group 2 and to be trained (Treadmill) twice a week for 12 weeks.
62778976|NCT01133938||Closed reduction < 12 months of age|
62003363|NCT05225961|ACTIVE_COMPARATOR|Acetylsalicylic acid|A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. One vial of ASPIRINA ® in not more than 250 ml in 0.9% sodium chloride solution, 5% and 10% glucose solution, Ringer's solution or lactated Ringer's. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial.
62396307|NCT03698825|EXPERIMENTAL|Dose Escalation of TEW-7197|TEW-7191 will be given twice daily (BID) for 5 days followed by 2 days off with a cycle of 4 weeks
62396308|NCT04652245|EXPERIMENTAL|Treatment A (Dymista) and Treatment B (Placebo), separated by at least 14 days of wash-out period|Fixed drug combination of Azelastine hydrochloride 137 μg / Fluticasone propionate 50 μg nasal spray and Placebo nasal spray
62778977|NCT01133938||Open reduction < 12 months of age|
62778978|NCT01133938||Open reduction with concomitant osteotomies > 12 months fo age|
62778979|NCT04159792||stroke|Those with standard treatment as usual.
62778980|NCT02549131|ACTIVE_COMPARATOR|Suture|Randomizing to Suture closure of Cesarean Section wound. In woman meeting inclusion criteria and not meeting exclusion criteria.
62778981|NCT02549131|ACTIVE_COMPARATOR|Staples|"Women in this Arm will be assigned to Standard Surgical Staples closure of Cesarean section.~Women will have met inclusion criteria and not meet exclusion criteria and willing to consent to study. Intervention is the randomization to either Arm. Both are standard of care at this facility."
62778982|NCT02357589|ACTIVE_COMPARATOR|2D laparoscopic cholecystectomy|The normal laparoscopic cholecystectomy with two dimensional view
62778983|NCT02357589|EXPERIMENTAL|3D laparoscopic cholecystectomy|The normal laparoscopic cholecystectomy with three dimensional view
62778984|NCT01399320|EXPERIMENTAL|cyanoacrylate dressing,excesion|we excise the sinus tip then apply cyanoacrylate dressing and watch for healing
62778985|NCT04422704|EXPERIMENTAL|Retired people|People who are either ordinarily or early retired and who have previously held a paid employment.
62778986|NCT01750905|ACTIVE_COMPARATOR|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
61977859|NCT01465087|EXPERIMENTAL|Diagnosis|Diagnosis, breath and confounding factor
62778987|NCT01750905|PLACEBO_COMPARATOR|Placebo|Placebo: Vehicle (D5W) SQ
62778988|NCT06480149|EXPERIMENTAL|SMALC|After laparoscopic surgery, the pain levels of the patients were evaluated and appropriate shoulder massage was applied to the patients 2 times at 6 st intervals and the pain levels of the patients were evaluated again. On the morning of the 1st postoperative day, the sleep quality of the patients was evaluated with the Richard Campbell Sleep Scale.
62778989|NCT06480149|OTHER|control group|After laparoscopic surgery, the pain levels of the patients were evaluated at the same hours as the intervention group and massage was not applied. On the morning of the 1st postoperative day, the sleep quality of the patients was evaluated with the Richard Campbell Sleep Scale.
62778990|NCT03291652||Symptomatic stroke patient|"DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.~2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.~Diagnosis procedure: DSA/3DRA"
62396309|NCT04652245|EXPERIMENTAL|Treatment B (Placebo) and Treatment A (Dymista), separated by at least 14 days of wash-out period|Placebo nasal spray and Fixed drug combination of Azelastine hydrochloride 137 μg / Fluticasone propionate 50 μg nasal spray
62188778|NCT04457817||CRI Monitoring/Management|These patients are COVID-19 positive; ages \> 18 and \< 70 years old; require \> 2 liters of oxygen by nasal cannula to maintain SpO2 \> 90%; are admitted to the sixth floor at University Hospital, on one of two designated Hospitalist services (approximately 16 COVID-19 positive patients/service). Patients in the study cohort will also be monitored with a CipherOx CR T1 tablet in a continuous manner to determine if maintaining CRI vales between 0.9-0.7 will: 1) help guide IV fluid (e.g. crystalloid, colloids, blood products) and medication therapy (e.g. diuretics); 2) allows earlier identification of patients who are poorly compensating and will require ICU level care; 3) reduces AKI and/or need for CRRT; and 4) improves clinical outcomes.
62188779|NCT01038453|ACTIVE_COMPARATOR|Cholecalciferol (Vitamin D3) 35 µg|Dietary Supplement: Cholecalciferol (Vitamin D3) 35 µg per day
62188780|NCT01038453|ACTIVE_COMPARATOR|Cholecalciferol (Vitamin D3) 70 µg|Dietary supplement: Cholecalciferol (Vitamin D3) 70 µg per day
62188781|NCT01038453|PLACEBO_COMPARATOR|placebo|
62396310|NCT05151809||PBC population residing in Italy|"All PBC patients living in Italy and aged at least 18 years can be included in the database. According to well-established criteria, PBC is diagnosed in subjects who fulfill two of the three of following criteria:~1. elevated alkaline phosphatase and /or GGT;~2. positive anti-mitochondrial autoantibodies (titer ≥ 1:40) or PBC-specific antinuclear antibodies (gp-210 and sp100);~3. characteristic histological features of florid bile ducts lesions and granulomatous lesion."
62396311|NCT02918968|EXPERIMENTAL|Enzalutamide 160 mg 1st line AAT/Flutamide 375 mg 2nd line AAT|Participants received enzalutamide 160 mg capsules, orally once daily as 1st line of alternative antiandrogen therapy (AAT) until confirmed prostate-specific antigen (PSA) progression, other disease progression, or an intolerable adverse event. After confirmation of PSA progression, other disease progression, or an intolerable adverse event, participants received flutamide 125 mg tablets orally thrice daily after each meal as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
62396312|NCT02918968|EXPERIMENTAL|Flutamide 375 mg 1st line AAT/Enzaltumide 160 mg 2nd line AAT|Participants received flutamide 125 mg tablets orally thrice daily after each meal as 1st line of AAT until confirmed PSA progression, other disease progression, or an intolerable adverse event. After confirmed PSA progression, other disease progression, or an intolerable adverse event. participants received enzalutamide 160 mg capsules orally once daily as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
62396313|NCT06508593||AKI group|Patients developed AKI after cardiac surgery
62396314|NCT06508593||Delirium group|Patients developed delirium 5 days after cardiac surgery
62396315|NCT06508593||AKI and delirium group|Patients developed AKI and delirium after cardiac surgery
62396316|NCT06508593||Control group|Patients didn't develope AKI or delirium after cardiac surgery
62396317|NCT04348760|EXPERIMENTAL|Intervention|Subjects were then instructed to avoid the foods highlighted in their personal food profile in certain days of the week, and to assume them in 7 of the 21 meals of the week
62396318|NCT03542409|EXPERIMENTAL|Cohort 1, Group A (contrast enhancing tumor)|Group A patients will undergo standard tumor preoperative imaging and MR perfusion scan prior to surgical resection. Group A patients will undergo standard intraoperative imaging along with MR perfusion scan during surgical resection.
62571559|NCT02343939|EXPERIMENTAL|Entospletinib (Group C)|"Dose Escalation: Entospletinib up to 800 mg for 28-day cycles until the participant meets criteria for study treatment discontinuation per the study protocol.~Dose Expansion: Entospletinib 400 mg for 28-day cycles until the participant meets criteria for study treatment discontinuation per the protocol."
61977860|NCT01216527|EXPERIMENTAL|experimental group|Neo-adjuvant Chemoradiotherapy followed by Surgery
62778991|NCT03291652||Asymptomatic stroke patient|"DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.~2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.~Diagnosis procedure: DSA/3DRA"
62188782|NCT04739410|EXPERIMENTAL|Ivermectin|Ivermectin Prescribing protocol: Participants were prescribed Ivermectin 12mg stat per oral and then 12 mg per oral after 12 hours and 12mg per oral after 24 hours and we looked at the response at day 7 on follow up in terms of improvement of symptoms like (Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue. and any side effects of the drugs were noted as well.
62188783|NCT04739410|PLACEBO_COMPARATOR|SOC standard of care|These participants were given standard of care without Ivermectin standard of care only symptomatic treatment
62003364|NCT06522308||Cholelithiasis Group|It is determined whether there is an umbilical hernias in patients with cholelithiasis
62188784|NCT00404885|PLACEBO_COMPARATOR|Placebo|
62188785|NCT00404885|ACTIVE_COMPARATOR|LX211, 0.2 mg/kg|
62188786|NCT00404885|ACTIVE_COMPARATOR|LX211, 0.4 mg/kg|
62188787|NCT00404885|ACTIVE_COMPARATOR|LX211, 0.6 mg/kg|
62188788|NCT00883636||Focal Segmental Glomerulosclerosis|
62188789|NCT00883636||Non-Focal Segmental Glomerulosclerosis|
62188790|NCT00739115|EXPERIMENTAL|1|Heliox gas added to nasal CPAP for the first 72 hours of life
62188791|NCT00739115|NO_INTERVENTION|2|Conventional nasal CPAP for the first 72 hours of life
62188792|NCT05513183||Arm I (Severe neutropnia group),|After CRS followed by HIPEC using MMC of 35mg/m2, patients who had absolute neutrophil count (ANC) \< 1000/mm3 during the postoperative period are assigned as experimental group (Arm I, severe neutropnia group).
62188793|NCT05513183||Arm II (No severe neutropenia group)|After CRS followed by HIPEC using MMC of 35mg/m2, patients who had ANC ≥ 1000/mm3 during the postoperative period are assigned as the control group (Arm II: no severe neutropenia group).
62188794|NCT02833298|EXPERIMENTAL|Automated reminders|Patient will be contacted for automated reminders within one month before the six-month interval indicating they are due for HCC screening.
62188795|NCT02833298|EXPERIMENTAL|Patient navigation|The patient navigator will coordinate with the provider and subject to schedule the appropriate office visit and imaging for HCC screening as needed within one month before the test is due.
62188796|NCT00763594|ACTIVE_COMPARATOR|IPT|Interpersonal Psychotherapy for Major Depressive Disorder
62188797|NCT00763594|EXPERIMENTAL|BRT|Brief Relational Therapy adapted for treatment of Major Depressive Disorder
62188798|NCT04116268||Obesity|BMI \>23kg/m2
62188799|NCT04116268||Control|BMI 18-22.9kg/m2
62188800|NCT05495698|OTHER|Control group|multi-inhaler triple therapy (Qvar and Bevespi)
62188801|NCT05495698|OTHER|Intervention group 1|single-inhaler triple therapy (Trimbow)
62188802|NCT05495698|OTHER|Intervention group 2|single-inhaler triple therapy (Trimbow) + e-health applications
62188803|NCT03039998||HAP Patients|HAP, intubated and mechanically ventilated.
62188804|NCT05949645|EXPERIMENTAL|Apreo Implant Group|This group will undergo up to 2 procedures and will receive up to 3 implants in each lung.
62188805|NCT04543812|EXPERIMENTAL|PBF-1681 (ferric citrate)|PBF-1681 (ferric citrate) will be dosed two times a day with the 2 largest meals (preferred) or three times a day with meals.
62003365|NCT06522308||Umbilical Hernia Group|It is determined whether patients with umbilical hernia have cholelithiasis or not.
62003366|NCT06090110|ACTIVE_COMPARATOR|Intervention|transcutaneous auricular vagal nerve stimulation, for 8 weeks at least one hour a day
62003367|NCT06090110|PLACEBO_COMPARATOR|placebo|sham stimulation with a non-conducting electrode, for 8 weeks at least one hour a day
62003368|NCT04766749|EXPERIMENTAL|Experimental|40 minutes before PCI by the nurse to the patient RIPC operation (RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times), and then do regular PCI operation
62188806|NCT04543812|PLACEBO_COMPARATOR|Placebo|Matching placebo will be dosed two times a day with the 2 largest meals (preferred) or three times a day with meals.
62188807|NCT02391077|NO_INTERVENTION|Control Arm|Standard PrePex Procedure
62188808|NCT02391077|EXPERIMENTAL|Arm 1 - Maximal intervention|"1. Foreskin disinfection with Povidone-Iodine~2. Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus~3. Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days"
62188809|NCT02391077|EXPERIMENTAL|Arm 2 - Medium intervention|"1. Foreskin disinfection with Povidone-Iodine~2. Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus"
62188810|NCT05575817|EXPERIMENTAL|Patient online grief tutorial|Participants will be given access to an online 9-module interactive tutorial about grief to be used in conjunction with a course of Prolonged Grief Disorder Therapy.
62188811|NCT03234361|EXPERIMENTAL|High Phosphate Phase|All subjects will be on a low Pi diet containing 700mg/day of phosphate and 2 capsules of sodium phosphate with 500mg/day of phosphate for 4 weeks.
62188812|NCT03234361|PLACEBO_COMPARATOR|Low Phosphate Phase|All subjects will be on a low Pi diet containing 700mg/day of phosphate and 2 capsules of sodium chloride for 4 weeks.
62571560|NCT02910206|EXPERIMENTAL|etomidate|etomidate is given for maintenance of general anesthesia,combined with sufentanil and cisatracurium
62003369|NCT04766749|NO_INTERVENTION|Control|A standard cuff is placed on the patient's thigh by the nurse 40 minutes before PCI but it is not inflated. PCI is performed 40 minutes later
62003370|NCT04380857|EXPERIMENTAL|Dexamethasone ophthalmic insert 0.4 mg|Dexamethasone ophthalmic insert 0.4 mg
62003371|NCT04380857|ACTIVE_COMPARATOR|Topical prednisolone acetate ophthalmic drops|topical prednisolone acetate ophthalmic drops
62188813|NCT01013545|EXPERIMENTAL|JAE-EMT|The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist. This intervention condition uses spoken language as the mode of communication. Individual, single word targets will be selected based on the child's level of language production and specific interests. The targets are systematically modeled in response to child actions and attention during play. A sequence of milieu teaching prompts will also be used to elicit targets from the child when use of the target language is functional for the child.
62003372|NCT01234220||Adrenal Venous Sampling (AVS)|Patients with Primary Aldosteronism (PA) undergoing AVS to discriminate PA forms with unilateral from bilateral excess aldosterone production.
62188814|NCT01013545|EXPERIMENTAL|JAE-AAC|The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist. The mode of communication introduced in this intervention condition is a developmentally chosen augmentative communication device. These devices are provided with a set of individually selected visual-graphic symbols and a relevant lexicon. The use of the device is taught within natural communicative exchanges within play routines and daily activities.
62188815|NCT02543099|EXPERIMENTAL|policosanol|Patients will receive policosanol 20mg daily until the end of the trial.
62188816|NCT02543099|PLACEBO_COMPARATOR|placebo|Patients will receive placebo 20mg daily until the end of the trial;
62188817|NCT04762303|EXPERIMENTAL|MedReviewRx|During the intervention phase, MedReviewRx will be made available to nursing homes with the understanding that it will be used to facilitate medication reviews and prescription check-ups. MedReviewRx provides clinicians with access to individualized and prioritized deprescribing information from MedSafer which: a) identifies potentially inappropriate medications (PIMs), b) explains why the medication is potentially inappropriate and c) provides instructions on how to safely stop/taper the medication.
62188818|NCT04762303|NO_INTERVENTION|No MedReviewRx|During the control phase, MedReviewRx will not be accessible to health care professionals at the nursing homes. This serves to obtain baseline deprescribing levels for each nursing home.
62188819|NCT02722811|EXPERIMENTAL|Etanercept treatment group|Subcutaneous injection etanercept of 50 mg/w and Health education, exercise and diet guidance; treatment: 8 weeks
62188820|NCT02722811|PLACEBO_COMPARATOR|Routine care group|Health education, exercise and diet guidance; treatment: 8 weeks
62188821|NCT03229486|EXPERIMENTAL|Sugammadex Injection [Bridion]|reversal of neuromuscular blockade with sugammadex
62188822|NCT03229486|ACTIVE_COMPARATOR|Neostigmine+Glycopyrronium|reversal of neuromuscular blockade with neostigmine \& glycopyrrolate
62188823|NCT00415701|EXPERIMENTAL|1|Etomidate as a single induction dose
62188824|NCT00415701|ACTIVE_COMPARATOR|2|Propofol as a single induction dose
62188825|NCT00415701|OTHER|3|Hydrocortisone substitution or placebo (50-50%) in etomidate-group
62188826|NCT01834586|OTHER|Anesthetic Topical Adhesive Synera|"Anesthetic Topical Adhesive Synera. For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week."
62188827|NCT03069144|EXPERIMENTAL|HAT1 topical solution|HAT1 topical solution will come in a labeled spray bottle. This topical medicated solution will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
62188828|NCT03069144|ACTIVE_COMPARATOR|Calcipotriol ointment (0.005%)|Calcipotriol ointment (0.005%) will come in a labeled tube. The medicated cream will be be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
62396319|NCT03542409|EXPERIMENTAL|Cohort 1, Group B (non-enhancing tumor)|Group B patients will undergo standard tumor preoperative imaging and 2HG spectroscopy scan prior to surgical resection. Group A patients will undergo standard intraoperative imaging along with 2HG spectroscopy scan during surgical resection.
62003373|NCT03938116|EXPERIMENTAL|Healing Hearts Together|
62003374|NCT03938116|NO_INTERVENTION|Usual Care|
62188829|NCT00136370|EXPERIMENTAL|1|Chlorhexidine Vaginal Wipe
62188830|NCT00136370|PLACEBO_COMPARATOR|2|Sterile water external genital wipe
62188831|NCT04345380|ACTIVE_COMPARATOR|Acrysof Rotation|Implantation of the Acrysof SN60WF Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
62003375|NCT01657110|OTHER|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
62003376|NCT01398566|EXPERIMENTAL|SuperBetter Play|members of this group will play SuperBetter for 6 weeks (averaging 10 min per day of play for 6 week period)
62003377|NCT05878613|EXPERIMENTAL|treadmill training with KT group (TTKT group)|Participants will undergo treadmill training with kinesiotape applied on their trunk muscles/
62003378|NCT05878613|ACTIVE_COMPARATOR|treadmill training without KT group (TT group)|Participants will undergo treadmill training.
62003379|NCT01708772||Sepsis|Forty five patients developed septic complication during ICU stay (sepsis group).
62003380|NCT01708772||SIRS group|Forty five patients were critically ill without evidence of infectious organism (SIRS group).
62003381|NCT04634149|EXPERIMENTAL|Group A: Moderate Hepatic Impairment|
62003382|NCT04634149|EXPERIMENTAL|Group B: Severe Hepatic Impairment|
62188832|NCT04345380|ACTIVE_COMPARATOR|Tecnis Rotation|Implantation of the Tecnis ZCB00 Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
62188833|NCT04345380|ACTIVE_COMPARATOR|Envista Rotation|Implantation of the Envista MX60 Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
62188834|NCT02719041||Tissue samples|Tissue samples taken from women treated for ovarian cancer will be stained.
62571561|NCT02910206|EXPERIMENTAL|propofol|propofol is given for maintenance of general anesthesia,combined with sufentanil and cisatracurium
62003383|NCT04634149|EXPERIMENTAL|Group C: Normal Hepatic Function|
62003384|NCT00907283|EXPERIMENTAL|deferiprone|15 mg/Kg/twice for 1 year
62003385|NCT01598116||Hemangioma|Identify biomarkers in children with hemangiomas.
62003386|NCT01598116||Without Hemangioma|Age-matched controlled group without hemangioma.
62003387|NCT02009033|EXPERIMENTAL|Ringer's lactate|Fluid therapy during operation
62003388|NCT04316182|EXPERIMENTAL|Cabozantinib|Cabozantinib at 60 mg/day in monotherapy until symptomatic tumor progression, unacceptable adverse events, patient decision or death
62003389|NCT06093724|EXPERIMENTAL|Anatomy reorganization after vaginoplasty in transgender women (MtF)|The research consists of adding to the usual MtF transgender patient undergoing vaginoplasty care course, static and dynamic perineo-pelvic MRI before, and at 6 and 24 months. The aim is to assess perineo-pelvic static's evolution, based on the appearance of a rectocele.
62003390|NCT03279276|EXPERIMENTAL|Primoris|Total hip arthroplasty surgery using a Primoris® femur component, Exceed ® acetabular cup + E-poly liner ®.
62003391|NCT03279276|ACTIVE_COMPARATOR|Echo|Total hip arthroplasty surgery using a standard uncemented Echo® femur component, Exceed ® acetabular cup + E-poly liner ®.
62003392|NCT04527081|EXPERIMENTAL|Group A|
62003393|NCT04527081|EXPERIMENTAL|Group B|
62003394|NCT04527081|EXPERIMENTAL|Group C|
62571562|NCT01031680|EXPERIMENTAL|1|Dapagliflozin 10 mg tablet
62188835|NCT03685682|EXPERIMENTAL|VZV seronegative Transplant Patients|recombinant subunit Herpes zoster vaccine
62188836|NCT00737828|ACTIVE_COMPARATOR|A|Control - Standard Perioperative Pathway, clinician decides post-operative care environment (usual care)
62188837|NCT00737828|EXPERIMENTAL|B|Intervention - Perioperative care pathway guided by CPX Results i.e.anaerobic threshold \& ventilatory equivalents
62188838|NCT02927015|EXPERIMENTAL|Purple Majesty potato chips|Purple Majesty potato chips
62188839|NCT02927015|EXPERIMENTAL|Mountain Rose potato chips|Mountain Rose potato chips
62188840|NCT02927015|EXPERIMENTAL|White potato chips|White potato chips
62188841|NCT02927015|EXPERIMENTAL|Crackers|Crackers
62571563|NCT01031680|PLACEBO_COMPARATOR|2|Matching placebo tablet
61977861|NCT01216527|ACTIVE_COMPARATOR|control group|only Surgery
61977862|NCT04651088|PLACEBO_COMPARATOR|Metabolic diet|Controlled metabolic diet arm.
61977863|NCT04651088|ACTIVE_COMPARATOR|Potassium citrate|
61977864|NCT04651088|ACTIVE_COMPARATOR|Sodium Bicarbonate|
61977865|NCT04651088|ACTIVE_COMPARATOR|Litholyte arm|
62003395|NCT00203749|EXPERIMENTAL|1|Intervention communities will receive the community-based VCT intervention community mobilization, mobile VCT, and post-test support services), as well as standard clinic-based VCT
62003396|NCT00203749|ACTIVE_COMPARATOR|2|Comparison communities will receive standard clinic-based VCT
62003397|NCT03883204|ACTIVE_COMPARATOR|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
62003398|NCT03883204|ACTIVE_COMPARATOR|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
62003399|NCT01448850|PLACEBO_COMPARATOR|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
62003400|NCT01448850|EXPERIMENTAL|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 milligram (mg) as intravenous (IV) infusion on Day 1 followed by 300 mg injection subcutaneously (SC) every 4 weeks up to Week 53.
62003401|NCT05414903||Children with Normal Hearing|typically developing children with normal hearing (thresholds ≤ 20 dB HL from 0.25 to 8 kHz) age-matched to the children with hearing loss
62003402|NCT05414903||Children with hearing loss and normal vestibular function|Children with hearing loss will have a pure-tone average (PTA) \> 65 dB and normal vestibular evaluation.
62003403|NCT05414903||children with hearing loss and vestibular loss|Children with hearing loss will have a pure-tone average (PTA) \> 65 dB and and varying degree of vestibular loss (i.e., unilateral or bilateral).
62003404|NCT01285804|ACTIVE_COMPARATOR|Cuffed ETT|
62003405|NCT01285804|ACTIVE_COMPARATOR|Uncuffed ETT|
62571564|NCT06367504|ACTIVE_COMPARATOR|Doctor's Biome Medical Food (DBMF)|Once a day daily 30 minutes before lunch
62571565|NCT06367504|PLACEBO_COMPARATOR|Placebo|Once a day daily 30 minutes before lunch
62571566|NCT06443957|PLACEBO_COMPARATOR|Intranasal normal saline|The patient was given 1ml of normal saline intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
62188842|NCT02684123|ACTIVE_COMPARATOR|Apremilast|Apremilast 30mg twice daily
62188843|NCT02684123|PLACEBO_COMPARATOR|Placebo|Placebo pills twice daily
62188844|NCT03563313|EXPERIMENTAL|Closed Loop Control (CLC)|Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology \& Dexcom G6 CGM for 6 months.
62188845|NCT03563313|ACTIVE_COMPARATOR|Sensor-Augmented Pump (SAP)|Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
62188846|NCT04290611||Enzalutamide drug-induced toxicity|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by enzalutamide, with a chronology compatible with the drug toxicity
62571567|NCT06443957|EXPERIMENTAL|Intranasal insulin-20U|The patient was given 1ml of 20U insulin intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
62571568|NCT06443957|EXPERIMENTAL|Intranasal insulin-40U|The patient was given 1ml of 40U insulin intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
62778992|NCT05124171|EXPERIMENTAL|Comirnaty® (Pfizer-BioNTech)|Length of use : 1 day
62778993|NCT05124171|EXPERIMENTAL|CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK|Length of use : 1 day
62778994|NCT05124171|EXPERIMENTAL|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|Length of use : 1 day
62003406|NCT04587934|EXPERIMENTAL|iRes Warmer with ResusView|iRes Warmer with ResusView program with experimental electrocardiogram monitor will be used for heart rate monitoring in the first 10 minutes of life during routine care and and/or neonatal resuscitation.
62778995|NCT06319859|ACTIVE_COMPARATOR|Group A|patients will receive 0.1 mg morphine with 15 mg heavy bupivacaine intrathecally
62778996|NCT06319859|ACTIVE_COMPARATOR|Group B|patients will receive 15 mg heavy bupivacaine with 0.1 ml saline intrathecally
62003407|NCT04587934|ACTIVE_COMPARATOR|iRes Warmer without ResusView|An external non-experimental electrocardiogram monitor will be used for heart rate monitoring in the first 10 minutes of life during routine care and and/or neonatal resuscitation.
62778997|NCT04150952|EXPERIMENTAL|HRV-Group|Athletes will train according to their basal HRV scores. If the resting HRV is higher tan their basal HRV, they will perform a high or moderate intensity training. If the resting HRV is lower, they will perform a low intensity training. If the resting HRV still lower, they will rest. They will not accumulate two or more days of high-moderate intensity training, nor two or more days of rest.
62778998|NCT04150952|ACTIVE_COMPARATOR|TRAD-Group|Athletes will train according to their trainer plan. Training will not be guided by their basal HRV scores.
62778999|NCT00534833|EXPERIMENTAL|Group 1|DTaP-Hep B-PRP-T + OPV vaccine group
62779000|NCT00534833|ACTIVE_COMPARATOR|Group 2|Tritanrix-HepB/Hib™ + OPV vaccine group
62779001|NCT01773304|EXPERIMENTAL|Meal rich in dairy protein|
62779002|NCT01773304|EXPERIMENTAL|Meal rich in meat protein|
62003408|NCT01719692|EXPERIMENTAL|Rituximab A group|375mg/m2 for once
62003409|NCT01719692|ACTIVE_COMPARATOR|Rituximab B group|100mg/week for four weeks
62188847|NCT00760344|EXPERIMENTAL|SYR-472 3.125 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
62188848|NCT00760344|EXPERIMENTAL|SYR-472 12.5 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
62188849|NCT00760344|EXPERIMENTAL|SYR-472 50 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
62188850|NCT00760344|EXPERIMENTAL|SYR-472 100 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
62188851|NCT00760344|PLACEBO_COMPARATOR|Placebo QD|(with lifestyle modification and/or metformin stable dose therapy)
62188852|NCT00760344|ACTIVE_COMPARATOR|Sitagliptin 100 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
62188853|NCT04181489|EXPERIMENTAL|Sintilimab + R-CHOP|
62188854|NCT04438122|ACTIVE_COMPARATOR|Red Wine group|Participants of this group consumed 200ml of red wine along with a meal (lunch or dinner) every day for 8 weeks.
62188855|NCT04438122|ACTIVE_COMPARATOR|Ethanol group|Participants of this group consumed 69mL of tsipouro along with a meal (lunch or dinner) every day for 8 weeks.
62188856|NCT04438122|NO_INTERVENTION|Control group|Participants of this group consumed no alcohol along with a meal (lunch or dinner) every day for 8 weeks
62188857|NCT05553093|EXPERIMENTAL|Tirzepatide|Tirzepatide 5、10、15mg
62188858|NCT05553093|ACTIVE_COMPARATOR|Insulin Glargine|Insulin Glargine 6 international unit (IU)
62779003|NCT04846465||male|normal Sohag healthy male (≥18 \& ≤ 60 years)
62779004|NCT04846465||female|normal Sohag healthy female (≥18 \& ≤ 60 years)
62779005|NCT06256419|EXPERIMENTAL|efficacy difference of GLP-1RA|Responders group and non-responders group
62779006|NCT02787915|EXPERIMENTAL|dendritic cell vaccine|DC1-CTL cellular therapy
62003410|NCT04945434|EXPERIMENTAL|S53P4 BAG intervention group|Patients recruited and enrolled in study for treatment with S53P4 BAG
62188859|NCT05802771||enrolled patients|Non small cell lung cancer patients underwent surgical resection. We will use part of this cohort to built the predictive models and a second part to validate the creted models.
62188860|NCT06499662|ACTIVE_COMPARATOR|Vagus Nerve Neurodynamics and Guided Breathing with Manual Therapy|Participants in this arm will receive a combination of vagus nerve neurodynamics and guided breathing at a rate of 6 breaths per minute (bpm), along with manual therapy. The neurodynamics intervention involves passive movements in the cervical region to enhance vagus nerve function, synchronized with the guided breathing. The manual therapy will include suboccipital inhibition techniques to complement the intervention. The total duration of the intervention will be 15 minutes.
62188861|NCT06499662|ACTIVE_COMPARATOR|Guided Breathing with Manual Therapy|Participants in this arm will receive only guided breathing at a rate of 6 breaths per minute (bpm) along with manual therapy. The guided breathing will be diaphragmatic, following a recording that marks the times for inhalation and exhalation. The manual therapy will include suboccipital inhibition techniques applied during the breathing. The total duration of the intervention will be 15 minutes.
62188862|NCT01210378|EXPERIMENTAL|Nitroglycerin|
62188863|NCT02851849|ACTIVE_COMPARATOR|LGD-6972-5 mg|5 mg LGD-6972 QD
62188864|NCT02851849|ACTIVE_COMPARATOR|LGD-6972-10 mg|10 mg LGD-6972 QD
62188865|NCT02851849|ACTIVE_COMPARATOR|LGD-6972-15 mg|15 mg LGD-6972 QD
62188866|NCT02851849|PLACEBO_COMPARATOR|Placebo|Placebo QD
62188867|NCT04735783|EXPERIMENTAL|Very low-energy, viscous placebo breakfast|Participants will consumed a viscous breakfast meal from a standard bowl with a standard spoon. The volume of the meal will be 5 mL/kg body mass, consisting of 15% (0.75 mL/kg body mass) low-energy flavoured squash, with the remainder made up of tap water. To thicken the solution and increase the perception of energy intake, 0.1 g/kg xanthan gum (a soluble fibre often used as a low-energy thickening agent) will be added and the mixture will be blended thoroughly. An additional 3 mL/kg tap water will be consumed as a drink alongside the meal in this trial.
62188868|NCT04735783|ACTIVE_COMPARATOR|Typical, whole-food breakfast|Participants will consume a standardised meal consisting of puffed rice cereal, semi-skimmed milk, white bread, seedless strawberry jam, and apple juice. This meal will provide 20% of estimated energy requirements, determined by multiplying estimated resting metabolic rate by a physical activity level of 1.6. A measured volume of tap water will be consumed alongside this meal, in order to match total water content of the typical whole-food breakfast to the very low-energy, viscous placebo breakfast.
62188869|NCT04735783|ACTIVE_COMPARATOR|Water-only control|Participants will consume 8 mL/kg body mass of plain tap water to match the total water content of the typical whole-food breakfast and the very low-energy, viscous placebo breakfast.
62188870|NCT03834389|EXPERIMENTAL|Experimental Group|Experimental group: case-based teaching method applied
62188871|NCT03834389|NO_INTERVENTION|Control Group|Control group: classical teaching method applied
62188872|NCT04731350|EXPERIMENTAL|Shock wave(A)|subjects will recive radial extracorporeal shock wave (2000 shock/session, 10Hz and EFD 0.178 mJ/mm²) on knee joints once per week for four weeks in addition to strengthening exercise
62188873|NCT04731350|EXPERIMENTAL|Iontophoresis (B)|subjects will recive dexamethasone iontophoresis on knee joints once per week for four weeks in addition to strengthening exercise
62188874|NCT04731350|OTHER|Control (C)|stregnthening exercise;straight leg raising exercisein which the patients were positioned in the crook lying position with the unexercised limb was the flexed one then the patients were asked to contract the quadriceps muscle and elevate the limb to 45º and hold for 6 seconds, slowly lower the limb and then relax for 6 seconds, three sets of 10 repetitions were don ,Isometric quadriceps contraction (quadriceps drill) in full knee extension maintained for 5 seconds, followed by a 5-second rest; the exercise was performed for 20 repetitions per session .treatment once per week for four weeks
62188875|NCT06141200|EXPERIMENTAL|Study Group (Arm 1)|"The patient will receive NW Roselle capsules 1000 mg and placebo tablets. Patients will take two capsules of NW Roselle and one placebo tablet orally BID on an empty stomach with plenty of water 15 minutes before meals or one hour after meals.~A total dose of 2000 mg of NW Roselle will be administered per day."
62188876|NCT06141200|ACTIVE_COMPARATOR|Control Group (Arm 2)|"Captopril 25 mg tablets will be used. The patient will receive placebo capsules and Captopril 25 mg tablets. Patients will take two placebo capsules and one Captopril 25 mg tablet orally BID on an empty stomach with plenty of water 15 minutes before meals or one hour after meals.~A total dose of 50 mg of Captopril will be administered per day."
62188877|NCT05574777|OTHER|Gastric mucosal ablation|Participants receive submucosal injection followed by ablation of gastric mucosa using Hybrid argonplasma coagulation (HAPC).
62188878|NCT04380428||Cross section of the student body.|Matriculated students at Portuguese medical and dental faculties.
62188879|NCT04923945|EXPERIMENTAL|Savolitinib|NSCLC
62188880|NCT01628692|EXPERIMENTAL|Cohort 1: (Genotype 1b) Daclatasvir + Simeprevir|Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal for 12 weeks
62571569|NCT03019133|NO_INTERVENTION|Usual Care|Usual care will be provided.
61977866|NCT04651088|ACTIVE_COMPARATOR|Crystal Lite|
61977867|NCT04651088|ACTIVE_COMPARATOR|Potassium Bicarbonate|
61977868|NCT00937157|OTHER|1|Patients diagnosed with multiple sclerosis who have the presence of at least 1 or more Gd enhancing lesions and/or acute relapse.
61977869|NCT01052051|EXPERIMENTAL|vitamin D3 and calcium carbonate|Daily vitamin D3 2000 IU/day and calcium carbonate 1500mg/day supplementation
62003411|NCT04971564||Case|Patients with cerebral hypoxia victims of ischaemic stroke, acute parenchymal haemorrhage or subarachnoid haemorrhage
62003412|NCT04971564||Control|Patients without cerebral hypoxia
62003413|NCT00797953|EXPERIMENTAL|Low dose|2 capsules of T89 with 1 placebo capsule each time, twice daily. The daily dose is 250 mg.
62779007|NCT00898456||Group 1|Leukemia blast cells obtained from bone marrow aspirate or peripheral blood at diagnosis are used to study polymorphisms and haplotypes of ATP-binding cassette (ABC) B1, ABCC1, ABCG2, and other candidate genes. Multidrug resistance (MDR) protein expression and function are also analyzed using leukemia blast cells from patients enrolled on CALGB-9760.
62003414|NCT00797953|EXPERIMENTAL|High dose|3 capsules of T89 each time, twice daily. The daily dose is 375 mg
62003415|NCT00797953|PLACEBO_COMPARATOR|Placebo|3 placebo capsules (PC) each time, twice per day. The daily dose is 0 mg.
62003416|NCT02183441|EXPERIMENTAL|BI 1356 plus ritonavir|Treatment A: 3 days of ritonavir, 1 day BI 1356
62003417|NCT02183441|ACTIVE_COMPARATOR|BI 1356|Treatment B: BI 1356 alone
62003418|NCT04495088|EXPERIMENTAL|A (experimental arm)|The experimental arm A starts with 6 cycles of mFOLFOX or 4 cycles of XELOX. Surgery is scheduled four or six weeks after day 1 of the last mFOLFOX or XELOX cycle, respectively. No postoperative chemotherapy is planned
62003419|NCT04495088|ACTIVE_COMPARATOR|B (control arm)|In the standard arm B, patients undergo surgical resection of the primary tumor followed by stage- (risk-)adapted adjuvant chemotherapy 4-8 weeks after surgery according to recommendations of the S3 guidelines in analogy to colon cancer. Details of the recommended protocols are provided in the protocol.
62188881|NCT01628692|EXPERIMENTAL|Cohort 2: (Genotype 1b) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing \<75 kg received a total ribavirin dose of 1000 mg per day; those weighing \>=75 kg received 1200 mg per day) for 12 weeks.
62188882|NCT01628692|EXPERIMENTAL|Cohort 3: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing \<75 kg received a total ribavirin dose of 1000 mg per day; those weighing \>=75 kg received 1200 mg per day) for 12 weeks.
62003420|NCT03913949|EXPERIMENTAL|single-agent, open-label, Phase I study of APG-2575|The study consists of the dose escalation stage and the dose expansion stage
62003421|NCT05291299|OTHER|Standard of Care (Control Group)|Physicians will follow standard of care and instruct participants in the control group to follow a Mediterranean diet higher in vegetables and fruits\[19\]. Patients will be provided with a handout detailing the basics of the Mediterranean diet. At follow up visits, physicians will ask participants about how they have been eating and if they have been following the guidelines.
62003422|NCT05291299|EXPERIMENTAL|Anti-inflammatory Diet (Intervention Group)|"An 8-week nutrition program consisting of an individualized elimination diet and systematic food reintroduction implemented and supervised by a Registered Dietitian. Clinical trials have shown some benefit from elimination diets for individuals with autoimmune disease \[18\].~The specifics of the elimination diet including duration and foods included will be individual and up to the RDs discretion based on the patient's medical and diet history, willingness, current diet, preferences, goals, and ability. The initial diet instruction with a Registered Dietitian will be a one-hour, individual secure video call, with nutrition evaluation/assessment and education on elimination diet protocol. Follow up visits will be approximately 20-30 minutes for the subsequent 7 weeks."
62188883|NCT01628692|EXPERIMENTAL|Cohort 4: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing \<75 kg received a total ribavirin dose of 1000 mg per day; those weighing \>=75 kg received 1200 mg per day.
62003423|NCT01622205|EXPERIMENTAL|Active|Early supported discharge
62003424|NCT01622205|OTHER|Control|Ordinary rehabilitation
62003425|NCT00003255|EXPERIMENTAL|topotecan + carboplatin|Patients receive continuous intravenous infusions of topotecan and carboplatin for 5 days. Treatment repeats every 3-4 weeks during induction (two courses) and every 6-10 weeks during consolidation. No more than four courses of treatment are given. Patients are followed every 6 months for 5 years.
62188884|NCT03190512|ACTIVE_COMPARATOR|Test Group|"Psychological measurements were taken from periodontal disease patients before treatment and after 6 weeks.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and the Psychological questionnaires were filled."
62791773|NCT01800591|EXPERIMENTAL|Immediate gratification|In addition to the standard enrollment, 6-month, and completion incentives, the subject will be told that they can weigh in again any time before the study ends when they think they have lost 5% of their initial body weight. If they did meet their 5% goal, they will begin receiving a bi-weekly premium discount during the next pay period for a total duration of 12 months. Subjects that do not meet the 5% cut off during a weigh in are allowed to re-weigh themselves as many times as they like although they are encouraged to do so when they think they have met their target weight. Their premium goes back to normal price after this 12-month discount ends.
62396320|NCT03542409|EXPERIMENTAL|Cohort 2|"During the analysis for cohort 1, we found significant differences in the pre MRI samples and the post intraoperative MRI samples. Cohort 2, which will include 10 additional patients, has be created to confirm these differences. Unlike cohort 1, advanced imaging (2-HG spectroscopy and MR perfusion) is not needed to make this comparison. The standard of care intraoperative MRI sequences used routinely will be sufficient for these 10 new samples. The specific aim of Cohort 2 is:~1. Compare areas from initial surgery with that of extended resection after intraoperative SOC MRI in 10 additional subjects (Cohort 2)."
62003426|NCT04320940|ACTIVE_COMPARATOR|Phenobarbital Sodium Injection 20mg|Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 20 mg/kg (first/initial dose) followed by 20 mg/kg (if required).
62003427|NCT04320940|ACTIVE_COMPARATOR|Phenobarbital Sodium Injection 40mg|Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 40 mg/kg (first/initial dose) followed by 10 mg/kg (if required).
62003428|NCT03571516|EXPERIMENTAL|Teduglutide|Participants will receive 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection of teduglutide into abdomen or into either the thigh or arm once daily (QD) in addition to standard medical therapy for 24 weeks.
62003429|NCT03571516|OTHER|Standard of Care (SOC)|Participants will receive standard medical therapy for 24 weeks.
62396321|NCT03592251|PLACEBO_COMPARATOR|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
62396322|NCT03592251|ACTIVE_COMPARATOR|EPA-rich|3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA
62396323|NCT03592251|ACTIVE_COMPARATOR|DHA-Rich|3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA
62396324|NCT02024997|EXPERIMENTAL|Abdominal MRI|Subjects will undergo magnetic resonance imaging (MRI) with contrast. Magnetic resonance (MR)_freebreathing scan will be acquired. MR_inspiration scan will be acquired. MR_expiration scan will be acquired.
62396325|NCT06559033||Multiple myeloma (MM) patient group|patients with multiple myeloma (MM) (defined by a clonal proliferation of tumour plasma cells (\>10%), the presence of a monoclonal peak in the serum or urine (excluding non-secretory myeloma) and organ damage secondary to bone marrow invasion)
62396326|NCT06559033||Monoclonal gammopathy of undetermined significance (MGUS) patient group|patients with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g/L and no clinical involvement)
62396327|NCT06559033||Control group|patient with no pathology under study relating to the project
61977870|NCT01052051|PLACEBO_COMPARATOR|Placebo for vitamin D3 and calcium carbonate|Placebo for daily vitamin D3 and calcium carbonate
62003430|NCT00117143|EXPERIMENTAL|Romiplostim|Participants will receive a maximum of 2 administrations of romiplostim by subcutaneous injection, the first on day 1 of the study and the second on day 15 or 22 depending on the participant's platelet count. Romiplostim doses to be tested were 30, 100, 300, and 500 μg.
62003431|NCT05228782|EXPERIMENTAL|HOW RU Intervention delivered by telephone|Group Phone will receive the HOW RU? intervention over the telephone.
62003432|NCT05228782|EXPERIMENTAL|HOW RU Intervention delivered by video-call|Group Video will receive the HOW RU? intervention delivered over video-call using the aTouch Away platform.
62396328|NCT03783312|PLACEBO_COMPARATOR|placebo|250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
62396329|NCT03783312|ACTIVE_COMPARATOR|paracetamol|1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
62396330|NCT03783312|ACTIVE_COMPARATOR|ibuprofen|800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
62396331|NCT04888507|EXPERIMENTAL|Pozelimab+Cemdisiran|
62188885|NCT03190512|PLACEBO_COMPARATOR|Control Group|"Psychological measurements were taken from periodontal disease patients at the baseline and after 6 weeks without the periodontal treatment.~Intervention: The Psychological questionnaires were filled."
62188886|NCT01971281|EXPERIMENTAL|TTFilelds + gemcitabine|Patients will be treated continuously with the NovoTTF-100L device, in addition to Gemcitabine.
62188887|NCT01971281|EXPERIMENTAL|TTFields + gemcitabine+ nab-paclitaxel|Patients will be treated continuously with the NovoTTF-100L device, in addition to Gemcitabine plus nab-paclitaxel
62188888|NCT06164015||Recurrent Miscarriage group (study group)|Group of women who have experienced 2 or more pregnancy loss of less than 24 weeks gestation.
62188889|NCT06164015||Fertile population group (control group)|Group of women with proven fertility with at least one child born at full term
62188890|NCT06277180|EXPERIMENTAL|Newly diagnosed MTC that resect all 68Ga-TCR-FAPI-avid lesions|Newly diagnosed MTC (did not receive previous surgery, radiotherapy or target therapy) and all pre-surgically identified 68Ga-TCR-FAPI-avid lesions are/can be successfully resected.
62188891|NCT06277180|EXPERIMENTAL|Recurrent/persistent MTC that resect all 68Ga-TCR-FAPI-avid lesions|Recurrent/persistent MTC (underwent previous surgery with currently biochemical recurrent/residual disease) and all pre-surgically identified 68Ga-TCR-FAPI-avid lesions are/can be successfully resected.
62188892|NCT06277180|EXPERIMENTAL|Not all 68Ga-TCR-FAPI-avid lesions can be resected|Not all pre-surgically identified 68Ga-TCR-FAPI-avid lesions are/can be resected.
62188893|NCT01861977|EXPERIMENTAL|Cognitive Behavioral Therapy|Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.
62188894|NCT01861977|ACTIVE_COMPARATOR|Informational Workshop|Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
62188895|NCT00944229|ACTIVE_COMPARATOR|1 Drug Treatment - LOVAZA|Drug Treatment - LOVAZA 4 gm q24 for 8 weeks
62188896|NCT00944229|PLACEBO_COMPARATOR|2 placebo|Placebo 4 capsules q24 for 8 weeks
62188897|NCT00603811|EXPERIMENTAL|1|VAX102, a recombinant fusion protein that links the influenza A virus M2e antigen to S. typhimurium flagellin, a TLR5 ligand.
62188898|NCT00603811|PLACEBO_COMPARATOR|2|Vaccine buffer
62188899|NCT01403649|EXPERIMENTAL|Increasing flu vaccination|Collect from billing records in the 10 intervention practice sites to test for an increase in the rate of receipt of ≥1 influenza vaccine during the post-intervention year compared to the pre-intervention year among children 6 months to 18 years during the season. The interventions include: 1. Develop practice-based intervention strategies (like use of reminder-recall of children due for influenza,2. Develop Private/public collaboration to increase flu vaccination between the intervention practices, their county public health department and visiting nursing associations, and 3. Implement both practice-based and private-public collaborative strategies in the intervention practices while monitoring only in the control practices
62188900|NCT01403649|OTHER|Usual care|Patients in control practices will continue to receive usual care with no change in practice regarding influenza immunization delivery.
62188901|NCT04182347|OTHER|People with IDD and caregivers|
62188902|NCT00513747|EXPERIMENTAL|Arm I|Patients receive rituximab IV over 4 hours on days 1, 3, and 5 of week 1 and then on day 1 of weeks 5, 9, 13, 17, and 21. Patients also receive fludarabine phosphate IV over 30 minutes on days 1-5 of weeks 1, 5, 9, 13, 17, and 21. After completion of chemoimmunotherapy, patients are followed every 3 months until disease progression. At the time of disease progression, patients receive retreatment with chemoimmunotherapy as above or another treatment regimen.
62396332|NCT04039282|OTHER|Patient Participant|Patients will be asked to complete an 3 days worth of an online dietary recall prior to their out patient appointment with the dietitian
62003433|NCT05228782|NO_INTERVENTION|Wait-list Control Group|Control groups will be offered standard care through their referring service (i.e. their routine clinical follow-up). The control group will be offered HOW RU? telephone support outside of the main trial after their primary outcome assessment at 12 weeks
62188903|NCT00513747|ACTIVE_COMPARATOR|Arm II|Patients are followed every 3 months until disease progression. At the time of disease progression, patients receive rituximab and fludarabine phosphate as in arm I. Patients are then followed every 3 months until second disease progression. Patients with a second disease progression receive retreatment with chemoimmunotherapy as above or another treatment regimen.
62571570|NCT03019133|ACTIVE_COMPARATOR|Sound reduction|Use of noise reduction headphones. Pro For Sho safety ear muffs with a noise reduction rate of 34dB will be used.
62003434|NCT05678335|PLACEBO_COMPARATOR|Hydroxychloroquine monotherapy|Oral hydroxychloroquine 200mg twice daily for 12 weeks.
62188904|NCT03324971|EXPERIMENTAL|Diabetic patients with non-adherence and poly-pharmacy|Medications review. Elimination of all unnecessary prescription to cut down the number of medications to the least possible number.
62188905|NCT03659331|EXPERIMENTAL|unexplained elevation of liver enzymes|patients over the age of 18 referred for unexplained elevation of liver enzymes and carry a single mutation in the ATP7B gene. After a washout period of 3 months these patients will be re-checked for liver enzymes and if high will receive zinc therapy at a dose of 300 mg / day for 6 months, after which the liver enzymes will be checked again.
62188906|NCT01684618|EXPERIMENTAL|Cerebral NIRS oximetry + CPAP|Cerebral NIRS oximetry, using the INVOS Cerebral/Somatic Oximeter, and changes in regional cerebral oxygen saturation, rSO2, during induced changes in CPAP flow pressure
62188907|NCT05456347|EXPERIMENTAL|High-protein animal diet.|Low-calorie and high-protein diet (35% of total calories), mostly of protein coming from animal sources (75% of total protein).
62188908|NCT05456347|EXPERIMENTAL|High-protein vegetal diet.|Low-calorie and high-protein diet (35% of total calories), mostly of protein coming from plant sources (75% of total protein).
62188909|NCT05742048||traumatic patient suspect to have long bone fracture between 18 - 65 years old|
62188910|NCT01333111|EXPERIMENTAL|Prophylaxis, high dose (trial duration 52 weeks)|
62396333|NCT04039282|OTHER|Dietitian Participant|The Dietitian will be asked to review the patients completed dietary recalls prior to the patient attending their out patient appointment.
62779008|NCT02249182|EXPERIMENTAL|12 to < 18 Years Old|"Participants between 12 to \< 18 years of age weighing ≥ 45 kg will receive LDV/SOF FDC (90/400 mg tablet or 4 x 22.5 mg/100 mg tablets or 8 x 11.25/50 mg granules based on swallowability assessment during screening).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~* HCV genotypes (GT) 1, 4, 5, or 6 treatment-naive (TN) with or without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 treatment-experienced (TE) without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~* HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~* HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~* HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
62188911|NCT01333111|EXPERIMENTAL|Prophylaxis, low dose (trial duration 52 weeks)|
62188912|NCT01333111|EXPERIMENTAL|On-demand (trial duration 28 weeks)|
62188913|NCT01582698|EXPERIMENTAL|Seropersistence evaluation + 2nd booster vaccination|Blood will be drawn to assess the seropersistence of TBE virus antibodies at 82, 94, 106 and 118 months after the first booster vaccination with FSME-IMMUN 0.5ml administered during the first precursor study. Timing of the second booster vaccination will depend on the level of serum TBE antibodies observed during the study. Blood will be drawn 21 - 35 days after vaccination to assess the booster response.
62188914|NCT01144390|EXPERIMENTAL|CBT plus MMT|cognitive behavioral therapy for heroin addicts with methadone maintenance treatment
62188915|NCT01144390|ACTIVE_COMPARATOR|methadone maintenance treatment|methadone maintenance treatment for heroin addicts
62188916|NCT06395623||Patients with DOR|50 patients diagnosed with DOR will be recruited in this group to get detectionsof pain threshold, infrared thermal image, resistance, micro-circulation, and biological ultra-weak luminescence at the relevant body surface areas and meridian acupoints and the blood test of serum FSH(follicle-stimulating hormone) and AMH(Anti-Müllerian Hormone).
62188917|NCT06395623||Healthy participants|50 healthy participants in this group will achieve the same detections of biological characteristics and blood test as well.
62188918|NCT03545412|EXPERIMENTAL|Microfocused ultrasound with visualization|
62188919|NCT04909138|ACTIVE_COMPARATOR|DRG stimulation therapy at 20 Hz and 30 seconds ON, 90 seconds OFF|DRG stimulation therapy at 20 Hz (30 seconds ON, 90 seconds OFF)
62188920|NCT04909138|ACTIVE_COMPARATOR|DRG stimulation therapy at 5 Hz and 30 seconds ON, 90 seconds OFF|DRG stimulation therapy at 5 Hz (30 seconds ON, 90 seconds OFF)
62188921|NCT03667664|OTHER|Prevention of loss of autonomy|Lifestyle counseling for elderly people about physical exercises and nutrition in a preventive way
62571571|NCT03019133|ACTIVE_COMPARATOR|Sound masking|Use of headphones and relaxing music. Sennheiser HD 280 pro headphones will be used for sound masking.
62003435|NCT05678335|EXPERIMENTAL|Tacrolimus monotherapy|Oral tacrolimus 1-2mg twice daily for 12 weeks.
62779009|NCT02249182|EXPERIMENTAL|6 to < 12 Years Old|"Participants between 6 to \< 12 years of age weighing ≥ 17 kg and \< 45 kg will receive LDV/SOF FDC (45/200 mg as 2 x 22.5/100 mg tablets or 4 x 11.25/50 mg granules based on swallowability assessment during screening).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~* HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~* HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~* HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~* HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
62188922|NCT06454305|EXPERIMENTAL|Active cycle of breathing technique|Breathing control, thoracic expansion and forced expiratory training are the three components of ACBT. The purpose of the thoracic expansion phase is to facilitate the release of secretions, enhance ventilation, and supply the necessary volume for forced expiratory breathing
62188923|NCT06454305|ACTIVE_COMPARATOR|Blow Bottle Technique|1-liter plastic bottle was filled with water to a height of 10 centimeters for this intervention. The water in the bottle was filled using a 30-cm-long tube that was placed 8 cm down. The participants were instructed to sit on a bed with comfortable position, Hold the bottle with one hand and the tube with the other Blowing Technique, Put the tube in mouth by holding lips firmly,Breathing in through nose and out through mouth,Blowing enough water is bubbled,Short Breaks for 2 to 3 mints, When mucus rises up get out of by cough and huff
62188924|NCT05132855|EXPERIMENTAL|Booster group 1 (BNT162b2 30ug)|The participants in this group will receive BNT162b2 30ug as the booster dose.
62188925|NCT05132855|EXPERIMENTAL|Booster group 2 (mRNA-1273 50ug)|The participants in this group will receive mRNA-1273 50ug as the booster dose.
62188926|NCT05132855|EXPERIMENTAL|Booster group 3 (mRNA-1273 100ug)|The participants in this group will receive mRNA-1273 100ug as the booster dose.
62188927|NCT05132855|EXPERIMENTAL|Booster group 4 (MVC-COV1901 15ug)|The participants in this group will receive MCV COVID-19 vaccine 15ug as the booster dose.
62188928|NCT04692805|EXPERIMENTAL|EUS-guided treatment of varices|"Procedure: EUS-guided injection of coils with cyanoacrylate glue (CYA) and sclerosing agent.~First CT scan will be ordered to determine the patient having esophageal and gastric varices and splenomegaly.~Complete blood count (CBC) will be ordered to confirm the deficiency of one or more blood cell lines.~A standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient considered as a candidate will be treated with Coils plus CYA and sclerosing agent (Group A)."
62188929|NCT04692805|EXPERIMENTAL|EUS-guided partial splenic embolization + EUS-guided treatment of varices|"Procedure: EUS-guided partial splenic embolization + EUS-guided treatment of varices First CT scan will be ordered to determine the patient having esophageal and gastric varices and splenomegaly.~Complete blood count (CBC) will be ordered to confirm the deficiency of one or more blood cell lines.~A standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient considered as a candidate will be treated with coils plus CYA and sclerosing agent.~At the same procedure, a branch of splenic artery will be identified by EUS and implanted with coils plus CYA (Group B)."
62571572|NCT04126980||ED group|The ED group who had less than 72 hours of hospitalization (including the preparation period which commonly took approximately 1 day) for the surgery.
62571573|NCT04126980||Comparison group|The comparison group who were hospitalized for more than 72 hours but less than 12 days.
62188930|NCT02309671|EXPERIMENTAL|FE 999049 6 µg|
62188931|NCT02309671|EXPERIMENTAL|FE 999049 9 µg|
62188932|NCT02309671|EXPERIMENTAL|FE 999049 12 µg|
62571574|NCT05217134|EXPERIMENTAL|Dural Puncture Epidural Analgesia (DPEA)|A 27-Whitacre spinal needle puncture will be performed with confirmation of LCR return, before the introduction of epidural catheter.
62571575|NCT05217134|NO_INTERVENTION|Epidural Analgesia (EA)|Standard epidural anesthesia wil be performed.
62571576|NCT00815542|ACTIVE_COMPARATOR|double balloon catheter|Cervical ripening by double balloon catheter
62571577|NCT00815542|PLACEBO_COMPARATOR|prostaglandins E2|cervical ripening using prostaglandins E2
62571578|NCT02689193||Salmonella|Patients for whom blood cultures grew Salmonella species.
62571579|NCT02689193||No pathogen|Patients for whom blood cultures did not grow a pathogen and no pathogen was detected using other routine care diagnostics (e.g. malaria with the use of a malaria rapid test).
62571580|NCT02689193||Another pathogen|Patients for whom blood cultures grew with another pathogen or a pathogen was detected using other routine care diagnostics (e.g. malaria with the use of malaria rapid test).
62571581|NCT02689193||Healthy controls|Healthy controls. Patients without fever but from whom blood is drawn for another reason (e.g. check of cholesterol).
62188933|NCT02309671|ACTIVE_COMPARATOR|FOLLISTIM 150 IU|follitropin beta
62188934|NCT01602094||Adequate antimeales antibody levels|ELISA test OD \> 0.1
62188935|NCT01602094||Inadequate measles antibody levels|ELISA test OD \< 0.1
62188936|NCT05155943|EXPERIMENTAL|KALPA X|The KALPA™ and KALPA X™ systems will be used during the performance of the LAAC procedure that is performed using customary and conventional tools and imaging technologies as currently performed in the participating center.
62188937|NCT04903899|EXPERIMENTAL|177Lu-DOTATATE|A total of two doses of 177Lu-DOTATATE will be administered intravenously. The minimum time between treatments is 2 weeks.
62188938|NCT02140736||Patients with chemo-induced symptomatic anemia|
62571582|NCT04498182|EXPERIMENTAL|AR-15512 Ophthalmic Solution Higher Dose|AR-15512 Ophthalmic Solution 0.003%, one drop in each eye twice daily for 84 days. Both eyes will be treated.
62571583|NCT04498182|EXPERIMENTAL|AR-15512 Ophthalmic Solution Lower Dose|AR-15512 Ophthalmic Solution 0.0014%, one drop in each eye twice daily for 84 days. Both eyes will be treated.
62571584|NCT04498182|PLACEBO_COMPARATOR|Vehicle|AR-15512 Ophthalmic Solution Vehicle, one drop in each eye twice daily for 84 days. Both eyes will be treated.
62571585|NCT05234905|EXPERIMENTAL|Recombinant human adenovirus type 5+ Camrelizumab|"Recombinant human adenovirus type 5: one lesion was selected for intratumoral injection.Intratumoral injection of H101 was performed on day 1 and day 4 of each cycle, and was repeated once every 3 weeks. H101 dose:~① Tumor maximum diameter ≤5cm, 1.5×10\^12vp (3 injections) on day 1, 1.0×10\^12vp (2 injections) on day 4.~② Tumor maximum diameter \>5cm but ≤10cm, 3.0×10\^12vp (6 injections) on day 1 and 2.0×10\^12vp (4 injections) on day 4.~③ Tumor maximum diameter \>10cm, 4.5×10\^12vp (9 injections) on day 1 and 3.0×10\^12vp (6 injections) on day 4.~H101 intratumoral injection until the tumor is completely regressed to stop the drug, but not more than 5 cycles at most.~Camrelizumab: administered after H101 on day 1 of each cycle and repeated for 3 weeks. Camrelizumab dose: 200 mg IV."
62571586|NCT00845221|EXPERIMENTAL|Imatinib|
62571587|NCT06464718|EXPERIMENTAL|Fortibone|
62571588|NCT06464718|ACTIVE_COMPARATOR|Chewable Tablet|
62188939|NCT02548078|EXPERIMENTAL|GSK3390107A+Nimenrix Group|Subjects in the GSK3390107A+Nimenrix Group received the investigational GSK3390107A vaccine at the Day 0 visit and Nimenrix at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
62188940|NCT02548078|EXPERIMENTAL|Nimenrix+GSK3390107A Group|Subjects in the Nimenrix +GSK3390107A Group received Nimenrix at the Day 0 visit and the investigational GSK3390107A vaccine at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
62188941|NCT02779348|EXPERIMENTAL|Nebicapone plus warfarin|BIA 3-202 200 mg tid + Warfarin 25 mg
62188942|NCT02779348|EXPERIMENTAL|Warfarin|Warfarin 25 mg
62188943|NCT03482947|EXPERIMENTAL|TAP|ultrasonography-guided transversus abdominis plane block administration of (1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).
62188944|NCT03482947|EXPERIMENTAL|Caudal|Caudal epidural block administration of (1 mL/kg of bupivacaine 0.25% \&1 μ/kg dexmedetomidine
62188945|NCT05290012|EXPERIMENTAL|Dark Chocolate|Participants consumed 18 grams of dark chocolate (36 g/day, 400 mg/day of flavanols) twice daily.
62188946|NCT05290012|NO_INTERVENTION|Control|No intervention was made
62188947|NCT05739136||Exposed Cohort|Pregnant women with conditions for which relugolix combination therapy is prescribed, who are exposed to relugolix combination therapy at any time during pregnancy
62188948|NCT05739136||Unexposed Cohort|Pregnant women with conditions for which relugolix combination therapy could be prescribed, who are not exposed to relugolix combination therapy at any time during pregnancy
62188949|NCT05580497|EXPERIMENTAL|Soft Wearable Robotic Knee System|30 minutes gait training wearing the Soft Wearable Robotic Knee System
62188950|NCT01580683|EXPERIMENTAL|Ascorbic acid|
62188951|NCT01580683|PLACEBO_COMPARATOR|Placebo|
62188952|NCT04729842|ACTIVE_COMPARATOR|Group - B , Patients who recieved Bupivacaine|30 ml of 0.5% bupivacaine was injected equally divided and injected in four nerves (musculocutaneous, median, radial and ulnar nerves)
62188953|NCT04729842|ACTIVE_COMPARATOR|Group - R , Patients who received Ropivacaine|30 ml of a solution containing 0.5% ropivacaine was equally divided and injected in the four nerves (musculocutaneous, median, radial and ulnar nerves)
62188954|NCT01026129|EXPERIMENTAL|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of remifentanil 0.25 mcg/kg before emergence of a desflurane-based anesthesia.
62188955|NCT01026129|EXPERIMENTAL|Remifentanil 0.5 mcg/kg|Administration of a bolus dose of remifentanil 0.5 mcg/kg before emergence of a desflurane-based anesthesia.
62188956|NCT01026129|ACTIVE_COMPARATOR|Lidocaine|Bolus dose of intravenous remifentanil 1mg/kg given once before emergence of general anesthesia.
62188957|NCT03936959|EXPERIMENTAL|LY3434172|LY3434172 administered IV
62188958|NCT00243022|EXPERIMENTAL|Arm I (intervention)|Patients receive oral Boswellia serrata extract 4 times a day and oral cyanocobalamin (vitamin B 12) once a day for 6 months in the absence of unacceptable toxicity.
62188959|NCT00243022|ACTIVE_COMPARATOR|Arm II (control)|Patients in the control arm receive oral cyanocobalamin (vitamin B 12) once a day for 6 months.
62188960|NCT05170269|EXPERIMENTAL|BT097|Subjects will receive BT097 200 U per kg of maternal body weight intravenously every 2 weeks until at least GW 17
62188961|NCT00227123|ACTIVE_COMPARATOR|1|Quetiapine versus Risperidone
62188962|NCT00460668|EXPERIMENTAL|Pulmonary rehabilitation post-thoracotomy|Pulmonary rehabilitation post-thoracotomy
62188963|NCT00460668|NO_INTERVENTION|Control|Control
62188964|NCT02851342||MS|patients with multiple sclerosis
62188965|NCT02851342||CO|matched control subjects
62396334|NCT02630992|EXPERIMENTAL|amoxicillin-clavulanate potassium|amoxicillin-clavulanate potassium (600 mg/221.5 mg/5 mL; 28:1) administered prior to February 25, 2016 at 90/3.2 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 1) or administered as of February 25, 2016 at 80/2.85 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 2)
62188966|NCT02504749|ACTIVE_COMPARATOR|Group A: General anaesthesia group|-Standard rapid sequence induction with pre-oxygenation by 100 % OXYGEN FOR 3 MINUTES FOLLOWED BY 4-5 mg/kg thiopental and 100 mg succinylcholine,cricoid pressure was applied once necessary.After correct placement of tracheal tube was confirmed,anaesthesia was maintained with up to 1.5% isoflurane and oxygen,neuromuscular blockade was maintained with 0.4 mg/kg atracurium.
62571589|NCT05696990|EXPERIMENTAL|3/7 RT method|perform interval- type endurance exercise at high intensity and resistance training with the 3/7 method
62188967|NCT02504749|ACTIVE_COMPARATOR|Group B:Spinal anaesthesia group.|"Prehydration with 500 ml lactated ringer solution intravenous within 15 minutes in the sitting position.Low back was prepared and drapped in a sterile fashion with Betadine solution 10%.~Spinal anaesthesia performed at L 2-3 or L 3-4 intervertebral space using a fine needle size 22 G.Injection of local anaesthetics into the subarachnoid space,Bupivacaine(marcaine) 1.5 -3.5 ml used."
62188968|NCT05805839|EXPERIMENTAL|Healthy Control Group|Subjects without inflammatory-demyelinating diseases of the central nervous system
62188969|NCT05805839|EXPERIMENTAL|Multiple Sclerosis Group|Subjects with current diagnosis of Multiple Sclerosis or an InflammatoryDemyelinating Disease of the Central Nervous System will have a PET/CT scan with radiotracer drug C-11 PIB \& C-11 ER176
62188970|NCT03118167|EXPERIMENTAL|Tea polyphenols & Acrylamide|TP 0.05g, 0.1g, 0.2g (starches filled, up to 0.35g) capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
62188971|NCT03118167|EXPERIMENTAL|AOB-w & Acrylamide|AOB-w 0.35g capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
62571590|NCT05696990|ACTIVE_COMPARATOR|3X9 RT method|perform interval- type endurance exercise at high intensity and resistance training with the 3X9 method
62188972|NCT03118167|ACTIVE_COMPARATOR|Placebo & Acrylamide|Placebo (Starches) 0.35g capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
62188973|NCT03320395|EXPERIMENTAL|Small bowel RFA treatment|Five small bowel samples each of the duodenum, jejunum and ileum will be recruited treated.
61977871|NCT04275791|EXPERIMENTAL|hierarchized|Structured regional health organization, composed of trauma centers hierarchized in several levels according to their capacity to receive severe traumatized persons.
62571591|NCT02865304|EXPERIMENTAL|endostar; taxane|Endostar was administered at 7.5 mg/m2, d1-14, q21d and was continued until progressive disease, unacceptable toxicity, consent withdrawal, or completion of 24 months. In the same time,Taxane-based chemotherapy was continued until progressive disease, unacceptable toxicity, consent withdrawal, or up to 8 cycles.
62571592|NCT02882581|EXPERIMENTAL|11C-metformin|All participants allocated to the study will be included in this arm
62571593|NCT04970147|OTHER|there are not arm for this study.|there is not a control group for this study.
62571594|NCT05480072|ACTIVE_COMPARATOR|PEA 600 mg|PEA capsules (600 mg twice a day) will be administered for 21 days
62571595|NCT05480072|PLACEBO_COMPARATOR|Placebo|Placebo capsules (600 mg twice a day) will be administered for 21 days
62779010|NCT02249182|EXPERIMENTAL|3 to < 6 Years Old|"Participants between 3 to \< 6 years of age weighing ≥ 17 kg will receive LDV/SOF FDC (45/200 mg granules as 4 x 11.25/50 mg packets) and participants weighing \< 17 kg will receive LDV/SOF FDC (33.75/150 mg oral granules as 3 x 11.25/50 mg packets).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~* HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~* HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~* HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~* HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
62779011|NCT04294147|EXPERIMENTAL|Galcanezumab|Participants received a single subcutaneous (SC) dose of 240 milligram (mg) Galcanezumab.
62188974|NCT05286463|EXPERIMENTAL|group A|received low-intensity pulsed ultrasound using bee venom (BV) gel for 5 minutes for each session, three times a week, for three consecutive weeks postoperative and received regular medical care.
62188975|NCT05286463|SHAM_COMPARATOR|group B|received low-intensity pulsed ultrasound using only plain gel without BV gel for 5 minutes for each session, three times a week, for three consecutive weeks postoperative and received regular medical care.
62188976|NCT01651533|EXPERIMENTAL|Experimental: Mental Practice Group|
62188977|NCT01651533|ACTIVE_COMPARATOR|Active Comparator: Active Control Group|
62188978|NCT01969045|EXPERIMENTAL|Working channel|Patients will receive local anaesthetics via the working channel of the bronchoscope.
62188979|NCT01969045|EXPERIMENTAL|Enk Fiberoptic Atomizer|Patients will receive the local anaesthetics for the flexible bronchoscopy via the nebulizer Enk Fiberoptic Atomizer.
62188980|NCT03839810|EXPERIMENTAL|stochastic resonance|stochastic resonance electrical stimulation is applied to the upper extremity during the subjects perform upper extremity motor function.
62188981|NCT03839810|SHAM_COMPARATOR|sham stimulation|sham electrical stimulation (same electrode location, but no electrical current is applied) is applied to the upper extremity during the subjects perform upper extremity motor function.
62188982|NCT04009629|EXPERIMENTAL|Exercise - apolipoprotein e4 carrier|A single 15 minute bout of moderate intensity aerobic exercise for individuals with 1 or 2 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.
62188983|NCT04009629|EXPERIMENTAL|Exercise - apolipoprotein e4 non-carrier|A single 15 minute bout of moderate intensity aerobic exercise for individuals with 0 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.
62188984|NCT05716529|EXPERIMENTAL|accelerated rehabilitation protocol|It's a four phases rehabilitation protocol mainly based on the remodeling process of the graft., emphasizing full passive knee extension, immediate weight bearing as tolerated and functional exercises
62396335|NCT01621139|EXPERIMENTAL|Real acupuncture|Real acupuncture group
62396336|NCT01621139|SHAM_COMPARATOR|Sham acupuncture|Sham acupuncture group
62188985|NCT05716529|ACTIVE_COMPARATOR|conventional physical therapy program|Current conventional protocols were based mainly on biological tissue healing time frames. These protocols emphasize pain reduction, full passive knee extension, quadriceps strength training, immediate motion, immediate par¬tial weight bearing (only if there is a correct gait pattern without any complications), and functional exercises
62003436|NCT03653793|EXPERIMENTAL|LivRelief Varicose Veins Cream|"Intervention:~All subjects were provided with an adequate supply of the Natural Health Product LivRelief Varicose Veins cream for 6 weeks of at home use."
62188986|NCT04042077|EXPERIMENTAL|Delafloxacin|Delafloxacin IV, with the option to switch to delafloxacin oral
62188987|NCT04042077|ACTIVE_COMPARATOR|Best Available Therapy|"Cardiothoracic / related leg SSI~* Vancomycin IV~* Linezolid IV, with the option to switch to linezolid oral.~In case of suspicion of Gram-negative, additional therapy shall be added as per investigator's choice~Abdominal SSI~* Piperacillin/Tazobactam IV, OR~* Tigecycline IV~In case of suspicion of MRSA, if the pre-selected treatment is Piperacillin/Tazobactam, additional therapy shall be added as per investigator's choice."
62188988|NCT00706771|ACTIVE_COMPARATOR|Sodium bicarbonate|sodium bicarbonate: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr
62188989|NCT00706771|ACTIVE_COMPARATOR|Sodium chloride|sodium chloride: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr
62188990|NCT01667549|EXPERIMENTAL|1M0.5|"Mothers will receive the intervention for 1 month beginning when their infant is 0.5 months old.~Intervention: Timing of Diet and Flavor Experience"
62188991|NCT01667549|EXPERIMENTAL|1M1.5|"Mothers will receive the intervention for 1 month beginning when their infant is 1.5 months old.~Intervention: Timing of Diet and Flavor Experience"
62188992|NCT01667549|EXPERIMENTAL|3M0.5|"Mothers will receive the intervention for 3 months beginning when their infant is 0.5 months old.~Intervention: Timing of Diet and Flavor Experience"
62779012|NCT04294147|ACTIVE_COMPARATOR|Erenumab|Participants received a single SC dose of 140 mg Erenumab.
62779013|NCT02870530|EXPERIMENTAL|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A treatment for Morbid
62779014|NCT00494507|ACTIVE_COMPARATOR|HYP Dichlorphenamide|Hyperkalemic participants were randomized to Dichlorphenamide for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
62003437|NCT02515539|EXPERIMENTAL|CardiAQ TMVI System (Transapical & Transfemoral DS)|CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
62003438|NCT04099667|EXPERIMENTAL|Phase 2; Low Dose MYOBLOC|Low Dose MYOBLOC is a single treatment and will be compared to volume-matched placebo
62779015|NCT00494507|PLACEBO_COMPARATOR|HYP Placebo|Hyperkalemic participants were randomized to Placebo for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
62779016|NCT00494507|ACTIVE_COMPARATOR|HOP Dichlorphenamide|Hypokalemic participants were randomized to Dichlorphenamide for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
62779017|NCT00494507|PLACEBO_COMPARATOR|HOP Placebo|Hypokalemic participants were randomized to Placebo for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
62188993|NCT01667549|NO_INTERVENTION|Control|Mothers will not receive the intervention.
62188994|NCT03017937|EXPERIMENTAL|Q- collar|All subjects will wear 3 sizes of the q-collar and ultrasound images of the jugular vein will be measured with each collar. Also, each subject will wear a pressure collar and ultrasound images of the jugular vein will be captured at each pressure point (0.1-0.5)
62188995|NCT02689947|EXPERIMENTAL|Restylane Silk|open label no placebo control
62188996|NCT02542098|EXPERIMENTAL|HYD 20 - 120 mg|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets administered orally every 24 hours
62188997|NCT03236610|EXPERIMENTAL|tenofovir|
62188998|NCT03236610|ACTIVE_COMPARATOR|tenofovir plus entecavir|
62188999|NCT05881239||Subjective Cognitive Concerns (SCC)|The composition of the proposed study population will reflect that of subjects recruited through the Longitudinal Cohort of the Massachusetts Alzheimer's Disease Research Center and that of patients treated by neurologists at the Memory and Movement Disorders Clinics at MGH as well as participants from the community.
62189000|NCT05881239||Mild Cognitive Impairment (MCI)|The composition of the proposed study population will reflect that of subjects recruited through the Longitudinal Cohort of the Massachusetts Alzheimer's Disease Research Center and that of patients treated by neurologists at the Memory and Movement Disorders Clinics at MGH as well as participants from the community.
62189001|NCT05881239||Mild Behavioral Impairment [prominent apathy] (MBI)|The composition of the proposed study population will reflect that of subjects recruited through the Longitudinal Cohort of the Massachusetts Alzheimer's Disease Research Center and that of patients treated by neurologists at the Memory and Movement Disorders Clinics at MGH as well as participants from the community.
62189002|NCT05881239||Age-matched Controls|We will utilize community sampling to recruit 100 age-matched controls.
62189003|NCT05953831|EXPERIMENTAL|CDR132L 4.52 mg|Six times CDR132L 4.52 mg/kg body weight intravenous in single dose.
62189004|NCT05953831|PLACEBO_COMPARATOR|Placebo|Six times Placebo intravenous in single dose.
62189005|NCT06166212||Cases with high myopic astigmatism|Cases having myopic astigmatism more than 1.5 diopter
62189006|NCT06166212||Cases with not high astigmatism|Cases having astigmatism less than 1.5 diopter
62189007|NCT04402697|NO_INTERVENTION|Normal-weight (NW)|Individuals with BMI\<25 kg/m2
62189008|NCT04402697|EXPERIMENTAL|Overweight-Obese (OW-OB)|Individuals with BMI\>25 kg/m2, submitted to a nutritional intervention (hypocaloric balanced diet) during 6 months and prescription of physical activity to achieve weigh loss
62189009|NCT04402697|EXPERIMENTAL|Metabolically obese normal-weight (MONW)|Individuals with BMI\<25 kg/m2, with metabolic alterations related to obesity (hypertriglyceridemia, hypercholesterolemia, hyperglycaemia, hypertension or high waist-hip ratio), submitted to an intervention to improve dietary habits and physical activity in order to achieve a better body composition and metabolic health. Mediterranean diet will be and aerobic and strength exercises will be advised to these individuals.
62189010|NCT02267265|EXPERIMENTAL|Treatment intervention|The treatment group will complete a demographics questionnaire and the knowledge survey before the intervention. Participants will then view the 10 minute TMW-Newborn Intervention video around the time of the newborn hearing screening. Participants whose newborn does not pass the hearing screen will view an additional 3 minute video detailing the importance of following up for an outpatient re-screening. The participant will complete the knowledge survey again before discharge, and after approximately four to six weeks.
62189011|NCT02267265|ACTIVE_COMPARATOR|Control intervention|The control group will complete a demographics questionnaire and knowledge survey. Participants will subsequently view the 10-minute Safe Sleep for your Baby (SIDS) educational video. It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome. This will be around the time of the newborn hearing screening. Participants will complete the knowledge survey again before discharge, and after approximately four to six weeks.
62189012|NCT02369861|EXPERIMENTAL|ST266|Eye drops
62189013|NCT02369861|PLACEBO_COMPARATOR|Artificial tears|Refresh lubricant eye drops
62571596|NCT02069041|EXPERIMENTAL|Ramucirumab + FOLFOX4|"8 milligram/kilogram (mg/kg) ramucirumab given intravenously (IV) on Day 1 followed by FOLFOX4 (folinic acid + fluorouracil + oxaliplatin chemotherapy regimen) given IV on Day 1 of 2 week cycles:~FOLFOX4 every 2 weeks:~85 milligram per square meter (mg/m²) oxaliplatin IV on Day 1 200 mg/m² folinic acid(FA) IV on days 1 and 2 400 mg/m² 5-FU bolus on days 1 and 2 600 mg/m2 5-FU 22-h continuous infusion on Days 1 and 2~Participants may continue to receive treatment until discontinuation criteria are met."
62189014|NCT04268537|EXPERIMENTAL|PD-1 group|Anti-PD-1 antibody, 200mg, IV, one time
62003439|NCT04099667|EXPERIMENTAL|Phase 2; High Dose MYOBLOC|High Dose MYOBLOC is a single treatment and will be compared to volume-matched placebo
62189015|NCT04268537|EXPERIMENTAL|thymosin group|Thymosin, 1.6 mg sc qd, last for 5 days
62189016|NCT04268537|PLACEBO_COMPARATOR|control group|stand treatment
62189017|NCT02118298||Multiple Sclerosis|Ages 18 - 66, 10 years or less of MS,
62189018|NCT02118298||Demographically matched controls|Ages 18 - 66, No known neurological disorder, no learning disorder, and no psychiatric disturbance that is actually interfering with life.
62189019|NCT01928693|ACTIVE_COMPARATOR|Besivance 0.6% Ophthalmic Suspension|A topical fluoroquinolone antimicrobial indicated for the treatment of bacterial conjunctivitis.
62779018|NCT03253328|ACTIVE_COMPARATOR|Active Arm N-acetyl cysteine (NAC)|Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to a standard adult intravenous dose of NAC (1200mg twice a day) for 6 days post-amputation.
62779019|NCT03253328|PLACEBO_COMPARATOR|Placebo Arm|Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to placebo ½ normal saline infusion (twice a day) for 6 days post-amputation.
62779020|NCT03841370||endodontic|"The color of anterior (incisors and canines) and posterior (premolar) teeth treated at a private clinic in the city of Pelotas will be evaluated. Data will be collected regardless of technique, treatment time and sealer used.~The ΔE00 will be evaluated using the measurements obtained in the homologous tooth (without endodontic treatment) versus the measurement obtained from the tooth treated endodontically.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
62779021|NCT06393881|EXPERIMENTAL|UI059|
62003440|NCT04099667|PLACEBO_COMPARATOR|Phase 2; Placebo|Volume-matched placebo is a single treatment
62003441|NCT04099667|EXPERIMENTAL|Phase 3; MYOBLOC|MYOBLOC is a single treatment and will be compared to volume-matched placebo
62003442|NCT04099667|PLACEBO_COMPARATOR|Phase 3; Placebo|Volume-matched placebo is a single treatment
62003443|NCT05439603|EXPERIMENTAL|ANC-501|50 mg/day
62189020|NCT01928693|ACTIVE_COMPARATOR|Zymaxid 0.5% Ophthalmic Solution|A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis.
62779022|NCT06393881|ACTIVE_COMPARATOR|UIC202201|
62779023|NCT03113695|EXPERIMENTAL|obinutuzumab, lenalidomide, and HDMP|
62779024|NCT01248637||Pimonidazole hydrochloride|Oral pimonidazole is administered at a dose of 0.5gm/m2 once approximately 24 hrs prior to surgery
62779025|NCT02295605|EXPERIMENTAL|Land-based exercises|Land-based muscle strengthening exercises protocol
62779026|NCT02295605|EXPERIMENTAL|Water-based exercises|Water-based muscle strengthening exercises protocol
61977872|NCT04275791|NO_INTERVENTION|all-or-nothing|Structured regional health organization, composed of non-hierarchical trauma centers at different levels according to their capacity to receive severe trauma victims (all-or-nothing type).
62003444|NCT02915614|ACTIVE_COMPARATOR|PiMM patients|"COPD patients with the Alpha-1 antitrypsin genetic variant PiMM (Smoking-related COPD)"
62003445|NCT02915614|EXPERIMENTAL|PiZZ patients|COPD patients with alpha-1 antitrypsin deficiency (genotype PiZZ)
62003446|NCT02438228|OTHER|Cardiac output measurement|
62003447|NCT01217918|EXPERIMENTAL|Cohort 1|PH-797804
62003448|NCT01217918|EXPERIMENTAL|Cohort 2|PH-797804
62003449|NCT01217918|EXPERIMENTAL|Cohotr 3|PH-797804
62189021|NCT01928693|ACTIVE_COMPARATOR|Vigamox 0.5% Ophthalmic Solution|A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis.
62189022|NCT01939301|ACTIVE_COMPARATOR|Inhaled Nitric Oxide|Inhaled nitric oxide
62779027|NCT03218930|OTHER|Social marketing intervention|Participants will receive a total combination of four interventions.
62779028|NCT02394717|OTHER|Intervention|All YMCA programs will receive the Healthy Eating and Physical Activity Intervention throughout the study. All programs will receive the HEPA Strategies intervetion to assist them with achievement of the HEPA Standards.
62779029|NCT06289452|EXPERIMENTAL|IVB102 Treatment Arm（Low dose）|Intraocular injection of a single low dose of IVB102
62779030|NCT06289452|EXPERIMENTAL|IVB102 Treatment Arm（Intermediate dose）|Intraocular injection of a single intermediate dose of IVB102
62779031|NCT06289452|EXPERIMENTAL|IVB102 Treatment Arm（High dose）|Intraocular injection of a single high dose of IVB102
62189023|NCT01939301|PLACEBO_COMPARATOR|Placebo|Oxygen
62571597|NCT03383289|EXPERIMENTAL|R-REM training|3 module training for frontline staff in assisted living facilities related to recognizing and management of resident-to-resident elder mistreatment
62779032|NCT02528682|EXPERIMENTAL|Single arm|MiHA-loaded PD-L-silenced DC Vaccination
62779033|NCT04118894||Foot and Ankle Devices|The study subjects included are those treated with one or more approved or cleared Wright Medical products included in this study.
62779034|NCT05286216|EXPERIMENTAL|Experimental group|"Patient diagnosis form with CHB and related scales (Patient Diagnosis Form with Chronic Hepatitis B, Medication Adherence Report Scale-5), Medication Adherence Report Scale (MedTake Test), Chronic Liver Disease Quality of Life Scale 2.0 (Liver Disease Symptom Index 2.0 (LDSI 2.0), Health-Related Quality of Life Scale SF-12 (12 Item Short Form Health Survey) (Short Form 12 - SF 12), Patient Learning Needs Scale will be applied before the intervention. The training will be in two modules and two different sessions. The effectiveness of the training will be evaluated by re-applying the scales 12 weeks and 24 weeks after the training."
62779035|NCT05286216|NO_INTERVENTION|Control group|"Patient diagnosis form with CHB and related scales (Patient Diagnosis Form with Chronic Hepatitis B, Medication Adherence Report Scale-5), Medication Adherence Report Scale (MedTake Test), Chronic Liver Disease Quality of Life Scale 2.0 (Liver Disease Symptom Index 2.0 (LDSI 2.0), Health-Related Quality of Life Scale SF-12 (12 Item Short Form Health Survey) (Short Form 12 - SF 12), Patient Learning Needs Scale in the first evaluation, 12 weeks and 24 weeks later, the scales were re-applied and the education was improved. effectiveness will be evaluated."
62003450|NCT05218759|EXPERIMENTAL|arm A|Progressive disease (PD) after anlotinib administration
62003451|NCT05218759|EXPERIMENTAL|arm B|Stable disease (SD) after anlotinib administration
62003452|NCT06448234|ACTIVE_COMPARATOR|Control Group|Participants receive DS prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
62003453|NCT06448234|EXPERIMENTAL|AI-Guided Group|Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
62003454|NCT00499135|EXPERIMENTAL|Schedule A|Patients receive sunitinib malate PO QD in weeks 1-4. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
62003455|NCT00499135|EXPERIMENTAL|Schedule B|Patients receive sunitinib malate PO QD in weeks 1, 2, 4, and 5. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
62003456|NCT05126407||Olynth Nasal Saline Drops/Spray and Olynth Ectomed Nasal Spray|Participants who have personally used or administered the Olynth Nasal Saline Drops/Spray and Olynth Ectomed Nasal Spray to a child at least once within the past 6 months will provide feedback via electronic survey on the prior use of the Drop/Spray.
62779036|NCT03125772|EXPERIMENTAL|TAXUS Element™ Paclitaxel-Eluting System|The TAXUS® Element™ stent system is a multifunctional device providing a mechanical structure for vascular lumen support and a pharmacological agent targeted toward reducing or preventing the incidence of restenosis. The TAXUS Element™ stent is a balloon expandable, stainless steel platinum alloy stent, coated with paclitaxel in a slow-release system, pre-mounted on a high-pressure Monorail delivery catheter and is intended for use in the treatment of coronary artery disease. The pharmacological agent, paclitaxel, is incorporated into a triblock polymer matrix and applied to the surface of the stent. The polymer matrix provides controlled release of available paclitaxel. The TAXUS Element™ stent design is built upon the TAXUS Express and TAXUS Liberte design experience, but incorporates several improved stent design characteristics. The TAXUS Element™ stent also has a smaller tip profile, designed to enhance the ability to cross tighter and/or more complex lesions.
62779037|NCT03125772|ACTIVE_COMPARATOR|XIENCE PRIME™ ™ Everolimus-Eluting Stent System|The everolimus-eluting stent (EES, manufactured and distributed by Abbott Vascular, Santa Clara, CA, as XIENCE PRIME™ ) is a balloon expandable stent manufactured from a flexible cobalt chromium alloy with a multicellular design and 0.0032-in strut thickness which is coated with a thin (7.8 μm) nonadhesive, durable, biocompatible acrylic polymer and fluorinated copolymer releasing everolimus. Everolimus \[40-O-(2-hydroxyethyl)- rapamycin\], a semisynthetic macrolide immunosuppressant, inhibits growth factor-stimulated cell proliferation by causing cell-cycle arrest in the late G1 stage, thereby suppressing neointimal formation. Comparative analysis in an in vivo rabbit aortoiliac model has shown more rapid endothelialization with the EES compared to SES, PES, and ZES.
62779038|NCT03194113|ACTIVE_COMPARATOR|Trauma-Focused Treatment|Weekly sessions of prolonged exposure
62779039|NCT03194113|ACTIVE_COMPARATOR|Emotion Regulation Treatment|weekly sessions of emotion regulation and skills training.
62779040|NCT03194113|ACTIVE_COMPARATOR|Intensive Trauma-Focused Treatment|prolonged exposure, 3 sessions per week
62779041|NCT02173587|EXPERIMENTAL|Mussel oil capsules|Four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) per day for first two months and two mussel oil capsules (containing 400mg mussel oil and 400mg corn oil) per day thereafter for four months.
62779042|NCT02173587|PLACEBO_COMPARATOR|Corn oil capsuels|Four corn oil capsules (containing 1600mg corn oil) for first two months and two mussel oil capsules (containing 800mg corn oil) per day thereafter for four months.
62189024|NCT02306590|EXPERIMENTAL|Study Intervention|High caloric fatty diet for drinking (100% lipids, 4.5 kcal/ml) 405 kcal/90 ml/day in addition to daily food intake and standard of care; corresponding to an additional intake of 45 g fat per day
62779043|NCT05586841|EXPERIMENTAL|Dalpiciclib + Chidamide|Dalpiciclib will be administered in a dose of 100 mg/d or 125 mg/d. Chidamide shall be designed in a dose of 25 mg/BIW or 20 mg/BIW
62779044|NCT03986684||Non-NAFLD|
62779045|NCT03986684||NAFLD|
62779046|NCT04216576|ACTIVE_COMPARATOR|Standard of Care|Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care
62779047|NCT04216576|EXPERIMENTAL|Standard of Care + Intervention|Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care + unidirectional text messaging intervention
62779048|NCT00634062|ACTIVE_COMPARATOR|1|
62779049|NCT00634062|PLACEBO_COMPARATOR|2|
62779050|NCT02687581|EXPERIMENTAL|12-hour IO-therapy Glasses|wear IO-therapy glasses for 12-hour
62189025|NCT02306590|PLACEBO_COMPARATOR|Placebo|Placebo drinking solution 8 kcal/90ml/day in addition to daily food intake and standard of care
62189026|NCT01856517|PLACEBO_COMPARATOR|placebo|saline administration over 24 h following full optimization of patient according to current guidelines
62189027|NCT01856517|ACTIVE_COMPARATOR|clonidine|clonidine 1 mcg.kg-1.h-1 over 24 h following full optimization of the patient according to current guidelines
62189028|NCT05474547|EXPERIMENTAL|Meditation|Meditation for 30 min 10 days
62189029|NCT01150045|ACTIVE_COMPARATOR|Arm A - FOLFOX and placebo (12 treatments)|Patients receive FOLFOX every 2 weeks plus placebo every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
62189030|NCT01150045|EXPERIMENTAL|Arm B - FOLFOX and celecoxib (12 treatments)|Patients receive FOLFOX every 2 weeks plus celecoxib every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
62189031|NCT01150045|ACTIVE_COMPARATOR|Arm C - FOLFOX and placebo (6 treatments)|Patients receive FOLFOX every 2 weeks plus placebo every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
62189032|NCT01150045|EXPERIMENTAL|Arm D - FOLFOX and celecoxib (6 treatments)|Patients receive FOLFOX every 2 weeks plus celecoxib every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
62189033|NCT02398045|EXPERIMENTAL|Computerised CBT|Computerised CBT for OCD
62003457|NCT02752295|NO_INTERVENTION|Waiting list, intervention after EOS|control group / waiting list one week stress-coping intervention planned after end of study (EOS) without one week stress-coping intervention AND without an additional two days follow-up care
62003458|NCT02752295|ACTIVE_COMPARATOR|Stress-coping week without follow-up|active comparator with one week stress-coping intervention BUT without an additional two days follow-up weekend
62003459|NCT02752295|ACTIVE_COMPARATOR|Stress-coping week with follow-up|active comparator with one week stress-coping intervention AND with an additional two days follow-up weekend
62189034|NCT00013611|NO_INTERVENTION|Antiretroviral therapy alone|
62189035|NCT00013611|EXPERIMENTAL|Proleukin plus antiretroviral therapy|
62189036|NCT04631588|EXPERIMENTAL|Open Label BOTOX|Participants will receive BOTOX at Baseline (Day 1)
62189037|NCT04631588|EXPERIMENTAL|Double-Blind Randomized BOTOX|Participants will receive BOTOX at Baseline (Day 1)
62189038|NCT04631588|PLACEBO_COMPARATOR|Double Blind Randomized Placebo|Participants will receive placebo at Baseline (Day 1)
62189039|NCT06269159||Health care providers|10 health care providers: physiotherapist working with adults with overweight and obesity
62189040|NCT06269159||Adults with overweight and obesity|"Inclusion criteria~* Adults aged 25-64 years~* Active on the job market for at least 50 percent~* BMI ≥25kg/m²~Exclusion criteria~* Retirement and early retirement~* Unemployment~* Working for less than 50 percent~* Working in night shifts~* Physical (e.g. amputations, paralysis, recovering from stroke, osteoarthritis), cognitive (e.g. dementia, psychological disorders) and major medical (e.g. Chronic respiratory diseases, heart failure, cardiovascular diseases, cancer) conditions that obstruct daily functioning~* Diabetes diagnosed by a general practitioner~* Pregnancy~* Pregnancy \<1 year ago~* Currently involved in study specific weight loss interventions~* Post-surgery weight loss interventions~* Waitlist for weight loss surgery~* Hospitalized"
62189041|NCT03200652|EXPERIMENTAL|metabolic availability of lysine in wheat|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or a baked wheat bread with or without lentils, which will all be provided by the investigators."
62189042|NCT02119949|EXPERIMENTAL|Working memory training|
62189043|NCT02119949|PLACEBO_COMPARATOR|Placebo training|
62189044|NCT04444843|OTHER|Mycophenolate Mofetil Capsules|The dosage of mycophenolate mofetil (CellCept) will be decided by the investigator and should be adjusted according to clinical response or therapeutic drug monitoring. It is not allowed to switch to other MPAs. When MMF is discontinued but is not switched to other MPA, the patients will be followed until the end of study.
62189045|NCT00552864|ACTIVE_COMPARATOR|R|
62571598|NCT03383289|NO_INTERVENTION|Control condition|Usual care
62571599|NCT02920502|PLACEBO_COMPARATOR|Arm 1: Placebo|Normal Healthy Volunteers without any skin pathology, will receive placebo
62189046|NCT00552864|ACTIVE_COMPARATOR|L|
62189047|NCT03783689|ACTIVE_COMPARATOR|Group 1 (Treatment)|Subjects in Group 1 will have Leads placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
62189048|NCT03783689|SHAM_COMPARATOR|Group 2 (Control)|Subjects in Group 2 will have Leads placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Subjects will then have the option to crossover and receive stimulation therapy.
62189049|NCT03659383|EXPERIMENTAL|Optimal hypoglycemic treatment|The patients will receive optimal hypoglycemic treatments, including adjustment of insulin dose and oral antidiabetic agents
62189050|NCT00652483|EXPERIMENTAL|1|Brimonidine ophthalmic solution 0.1%
62779051|NCT02687581|ACTIVE_COMPARATOR|6-hour patching|wear the eye patch for 6-hour
62003460|NCT03930459|EXPERIMENTAL|Static cold storage (SCS)|Traditional method of organ preservation which involves flushing of cold preservation solution following complete dissection and interruption of blood supply to the donor organ. Although cold preservation slows metabolism by 10- to 12-fold, substantial anaerobic activity continues even at ice temperature. This lead to the generation of reactive oxygen species that are the basis of ischaemia-reperfusion injury, when the organ is re-exposed to oxygenated blood at the time of transplantation. This damage, exacerbated by any prior injury, limits the maximum safe preservation time of the donor organ.
62189051|NCT00652483|ACTIVE_COMPARATOR|2|Brimonidine ophthalmic solution 0.2%
62779052|NCT02104947|EXPERIMENTAL|idarucizumab|idarucizumab Only 1 treatment, no placebo or comparator
62779053|NCT04256252|EXPERIMENTAL|Rituximab|Intravenous rituximab was administered at a fixed dose of 100 mg once weekly for 3 weeks, followed by maintenance treatment with 100 mg rituximab every 6 months.
61977873|NCT01575665|EXPERIMENTAL|Partial Rebreathing Mask|A novel membrane breathing mask which facilitates a partial rebreathing of expired gas (thereby raising systemic CO2), while allowing a diffusion of oxygen from the atmosphere to the user, through the membranes.
61977874|NCT03917108|ACTIVE_COMPARATOR|retraction cord|
61977875|NCT03917108|OTHER|subgingival clamp|
61977876|NCT04404842||EvidenceQ Cohort|Adult subjects, aged over 18 years, male and female.
61977877|NCT01427894|EXPERIMENTAL|Maternal Singing|Maternal singing during Kangaroo Care of stable preterm infants
61977878|NCT01427894|NO_INTERVENTION|Kangaroo Care|Kangaroo Care without singing
61977879|NCT05474742|EXPERIMENTAL|Intervention group|Use of the Nori Health app during the study period, standard care
61977880|NCT05474742|NO_INTERVENTION|Control group|No use of the Nori Health app during the study period, standard care
61977881|NCT03533179|EXPERIMENTAL|Esmolol-placebo+glucagon 1 placebo (A)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+ Physiologic saline - glucagon dummy bolus 50 ml at time=0."
62189052|NCT01636583|EXPERIMENTAL|LSF water without meal|Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
62189053|NCT01636583|ACTIVE_COMPARATOR|LSF water and inhibitory meal|Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
62189054|NCT01636583|ACTIVE_COMPARATOR|Fortified inhibitory meal with water|Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
62189055|NCT03091322||SR-T group|single chamber pacemaker
62189056|NCT03091322||DR-T group|dual chamber pacemaker
62189057|NCT03091322||HF-T group|triple chamber pacemaker (IS-1 connector)
62189058|NCT03091322||HF-T QP group|triple chamber pacemaker (with IS4 connector) and a lead of the Sentus QP lead family
62189059|NCT02652195|PLACEBO_COMPARATOR|Placebo|Each participant will be studied using fMRI following self-administration of placebo.
62189060|NCT02652195|EXPERIMENTAL|Oxytocin|Each participant will be studied using fMRI following self-administration of oxytocin.
62189061|NCT05838690|NO_INTERVENTION|Pre-Intervention Phase|NICU Patients who are intubated without the PINS Bundle.
62189062|NCT05838690|ACTIVE_COMPARATOR|Post-intervention Phase|NICU Patients who are intubated after unit implementation of the PINS Bundle
62189063|NCT06395922|EXPERIMENTAL|Blockbuster LMA (Group BL)|The LMA was inserted using the recommended technique, with the patient's head in the sniffing position. The appropriate size was selected based on body weight (size 3 for 30-50 kg, size 4 for 50-70 kg).
62189064|NCT06395922|EXPERIMENTAL|Baska Mask (Group BM)|The BM was inserted by opening the mouth, avoiding the tongue, and negotiating the palatopharyngeal curve using the hand-tab.
62571600|NCT02920502|EXPERIMENTAL|Arm 2: cholecalciferol: 50,000 IU|Normal healthy Volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 50,000 IU.
62189065|NCT00676845|PLACEBO_COMPARATOR|1|A 3-week placebo run-in period.
61977882|NCT03533179|EXPERIMENTAL|Esmolol+glucagon 1 placebo (B)|"Esmolol intravenous solution (10 mg/ml esmolol hydrochloride) is administered as a loading dose (1.25 mg/kg/min esmolol) at baseline (time= -15 minutes). Continuous infusion (500-750 micrograms/kg/min) of esmolol/placebo is then administered until T=30 minutes.~+ Physiologic saline - glucagon dummy bolus (50 ml) at time=0."
62189066|NCT00676845|EXPERIMENTAL|2|Olmesartan medoxomil oral tablets, at lowest study dosage for 52-week double-blind treatment period
62189067|NCT00676845|EXPERIMENTAL|3|Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 48 weeks.
62189068|NCT00676845|EXPERIMENTAL|4|Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 4 weeks followed by the highest study dose for 44 weeks.
62189069|NCT01267240|EXPERIMENTAL|Arm I (capecitabine, vorinostat)|Patients receive capecitabine PO BID and vorinostat PO daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62189070|NCT03716765|EXPERIMENTAL|non-surgical periodontal regeneration|non-surgical periodontal regeneration using locally injected vitamin d to treat the infrabony defect
62189071|NCT03716765|ACTIVE_COMPARATOR|surgical peridoontal regeneration|surgical periodontal regeneration using bone graft and collagen barrier
62189072|NCT02246881|ACTIVE_COMPARATOR|Current Factor VIII|Optivate® (Human Coagulation Factor VIII)
62571601|NCT02920502|EXPERIMENTAL|Arm 3: cholecalciferol: 100,000 IU|Normal healthy volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 100,000 IU.
62189073|NCT02246881|EXPERIMENTAL|Optivate®|Optivate® (Human Coagulation Factor VIII)
62189074|NCT01010204|EXPERIMENTAL|Varenicline|We will be comparing Varenicline to placebo in a double-blind placebo controlled, randomized study.
62189075|NCT01010204|PLACEBO_COMPARATOR|Placebo|We will be using placebo in a randomized, controlled, and blinded trial to compare to varenicline in subjects with bipolar disorder.
62189076|NCT03784781||Asthmatic children|Severe uncontrolled asthma is defined by the need to maintain a treatment with high doses of inhaled corticosteroids and a long-acting bronchodilator (B2LDA) and/or an anti-leukotriene
62189077|NCT03784781||Controls|Non-asthmatic children, paired in age, requiring bronchial endoscopy with BAL and bronchial mucosa biopsy.
62189078|NCT05079594|NO_INTERVENTION|Routine Care Group|Before the application, the families will be informed by the researcher and the 'Informed Consent Form' will be signed. After the heel blood procedure, when the baby starts to cry, comfort will be provided with gentle touches. For ethical reasons, routine care will be provided when the baby cries.
62571602|NCT02920502|EXPERIMENTAL|Arm 4: cholecalciferol: 200,000 IU|Normal Healthy volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 200,000 IU.
62571603|NCT00810667|EXPERIMENTAL|Lu AE58054|
62571604|NCT00810667|PLACEBO_COMPARATOR|Placebo|
62571605|NCT05795543|ACTIVE_COMPARATOR|A|subtalar arthrodesis by single screw
62189079|NCT05079594|EXPERIMENTAL|White Noise|Since white noise is a humming and continuous monotonous sound, it is similar to the sound in the womb. It will be explained that this sound is very similar to the sound that the baby hears in the mother's womb by making the white noise recordings listen to the mothers who will have their babies listen to white noise. by Orhan Osman; Dr. From the album 'Kolik', which was created by making use of the album 'The Happiest Baby' prepared by Harvey Karp, which consists only of uterus sounds; The song 'Don't Let Your Baby Cry, PT.2' will be played to babies. In addition, infants will be excluded from the study even though they meet the criteria, if they are not sedated, the procedure takes more than 2 minutes, the procedure is disrupted because someone enters the room loudly, or the mother changes the baby's position.
62189080|NCT05079594|EXPERIMENTAL|Mother Voice|Auditory responses, fetal age 26-28. It develops in the auditory cortex and brain stem in weeks. Hearing is one of the first senses a fetus develops and is 24-33. can recognize and remember the mother's voice after weeks. The fetus memorizes the musical characteristics of the mother's voice, like tone, by listening to it. It is stated that newborns exposed to their own mother's voice have a lower heart rate, higher sucking rate, a more relaxed appearance, and less crying and body movements.
62189081|NCT05801445|EXPERIMENTAL|Occupational Arm|
62189082|NCT05801445|ACTIVE_COMPARATOR|Traditional Exercise Arm|
62779054|NCT05192434|EXPERIMENTAL|Expressive Writing + Contingency Management|A total of 180 WWID will be randomly assigned to the EW+CM (expressive writing + contingency management) intervention arm. To begin each session, participants will complete a brief battery of psychological measures. Then, in a private setting, they will be asked to write for 20 minutes about a major trauma that occurred three or more months in the past. WWID who prefer not to write (e.g., have lower literacy) will be provided the opportunity to talk aloud about the traumatic experience while being audio recorded, which yields comparable effects to writing. Next, women will respond to a prompt that encourages cognitive processing of the trauma for ten additional minutes. To complete the session, participants will answer the same brief battery of psychological measures for the purposes of identifying acute distress. Those exhibiting clinically elevated distress symptoms will engage in a brief de-escalation and evaluation session with study staff who will be trained.
62779055|NCT05192434|PLACEBO_COMPARATOR|Neutral Writing + Contingency Management|A total of 180 WWID will be randomly assigned to the attention-control arm which includes neutral writing + CM. Women in this group will complete the same pre/post psychological measures as the intervention group for the purposes of time matching. During the writing session, they will be asked to describe their schedule from the preceding day as if they were reporting facts, without discussing personal thoughts and feelings (e.g., describe what you did from the time you got up until the time you went to bed). Those with lower literacy can opt to talk aloud while being audio recorded. This is the same attention-control used our previous work which balances contact time and study incentives.
62779056|NCT01603095||Growth measurements|Approximately 500 patients will be enrolled. Patients from birth to \<= 17 years on the date of consent will be enrolled. Approximately equal numbers of boys and girls will be enrolled.
62779057|NCT04842981|EXPERIMENTAL|Interleukin 6 receptor antibody|Tocilizumab, 162 mg subcutaneous, once every week OR Sarilumab, 200 mg subcutaneous, once every two weeks.
62779058|NCT03074682|EXPERIMENTAL|Lifeflow|Participants in this arm will use the Lifeflow device to administer fluid in a simulation in a simulation setting.
62779059|NCT03074682|ACTIVE_COMPARATOR|Push/Pull|Participants in this arm will use the Push/Pull method to administer fluid in a simulation in a simulation setting.
62779060|NCT03074682|ACTIVE_COMPARATOR|Pressure Bag|Participants in this arm will use a Pressure Bag to administer fluid in a simulation in a simulation setting.
62779061|NCT02188849|EXPERIMENTAL|Creatine|Creatine 5 g/ day
62779062|NCT02188849|PLACEBO_COMPARATOR|Placebo|Maltodextrin 5 g/day to be dissolved in water
62779063|NCT00375518|ACTIVE_COMPARATOR|1|Atorvastatin
62779064|NCT00375518|PLACEBO_COMPARATOR|2|placebo
62779065|NCT03390309|OTHER|Partially Hydrolyzed Formula|Infant was identified and got 1 or more scores by using infant feeding \& stool pattern questionnaire at Visit 1 will be assigned into experimental group randomly
62779066|NCT03390309|PLACEBO_COMPARATOR|Normal Formula|Normal Formula
61977883|NCT03533179|EXPERIMENTAL|Esmolol+glucagon 1 (C)|"Esmolol intravenous solution (10 mg/ml esmolol hydrochloride) is administered as a loading dose (1.25 mg/kg/min esmolol) at baseline (time= -15 minutes). Continuous infusion (500-750 micrograms/kg/min) of esmolol/placebo is then administered until T=30 minutes.~+Glukagon 1 (50 μg/kg bolus - over 1-3 min from time=0 min in 50 ml isotonic fluid)"
62189083|NCT00636480|EXPERIMENTAL|CHG 2%-26 ml|Chlorhexidine gluconate in an aqueous base, 26 ml applicator
62189084|NCT00636480|ACTIVE_COMPARATOR|ChloraPrep 26 ml|ChloraPrep One-Step 26 ml Active drug contains chlorhexidine gluconate and alcohol
62189085|NCT00636480|PLACEBO_COMPARATOR|Sterile Saline|Sterile salt water administered topically.
62571606|NCT05795543|ACTIVE_COMPARATOR|B|subtalar arthrodesis by double screws
62779067|NCT03821116|EXPERIMENTAL|Milk|At least 500 ml of Swedish milk daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.
62779068|NCT03821116|EXPERIMENTAL|Soured milk (filmjölk)|At least 500 ml of Swedish soured milk (filmjölk) daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.
62779069|NCT01868386|EXPERIMENTAL|Dose Level 1|Hypofractionated therapy, 26 treatments at 2.5 Gy
62189086|NCT00003495|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62189087|NCT05980169|EXPERIMENTAL|Cohort A|In this arm, patients with newly diagnosed gynecologic cancer starting chemotherapy treatment with carboplatin and paclitaxel will receive up to 8 cycles of SensoniQ treatment along with their chemotherapy (weekly or every 21 days depending on the regimen).
62571607|NCT04415164|EXPERIMENTAL|Xueshuantong|Patients will receive intravenously administered Xueshuantong, combined with guidelines-based standard care.
62571608|NCT04415164|PLACEBO_COMPARATOR|Placebo|Patients will receive intravenously administered Xueshuantong placebo, combined with guidelines-based standard care.
62003461|NCT03930459|EXPERIMENTAL|Normothermic machine perfusion (NMP)|The main goal of NMP is to optimize graft preservation by mimicking physiological conditions. The perfused organ is supplied with nutrients and oxygen to maintain metabolic hemostasis. Under these conditions, ATP and glycogen reserves can be maintained or actively restored. At the same time, toxic products from the cellular milieu are continuously eliminated, so the cell-mediated injury phase of reperfusion injury can be minimized. Thus, ischemic injury is avoided and the activation of cell death cascades is prevented. This allows both hepatocellular and biliary protection.
62003462|NCT03536039|EXPERIMENTAL|NGR-hTNF + R-CHOP|Treatment includes one course of conventional R-CHOP followed by 5 courses of conventional R-CHOP (rituximab, Cyclophosphamide, vincristine, doxorubicin, prednisone) in conjunction with intravenous delivery of NGR-hTNF. Chemoimmunotherapy courses will be delivered every 3 weeks; day 22 is to be considered as day 1 of the subsequent course
62003463|NCT06249308||Ovarian cancer|Participants with new diagnosis of ovarian cancer, from whom a peripheral blood sample will be collected.
62003464|NCT00675857|PLACEBO_COMPARATOR|A|
62003465|NCT00675857|ACTIVE_COMPARATOR|B|
62003466|NCT02142452|EXPERIMENTAL|mobile health intervention|Behavioral intervention. Women with excessive weight gain in pregnancy will be recruited in their 3rd trimester. They will begin with a 5 week group session on weight management. After they deliver the baby, they will begin receiving text messages supporting behavior change they learned in their 3rd trimester. They will follow up at 6 weeks postpartum and 4 months postpartum.
62003467|NCT02142452|PLACEBO_COMPARATOR|Control Group|Women will receive usual prenatal care from their OB. Postpartum, they will receive a monthly newsletter relevant to the new mother on her nutrition and physical activity. They will be followed at 6 weeks postpartum and 4 months postpartum.
62003468|NCT02534792||Revalvulation time early|Early revalvulation by homograft or percutaneous valve
62003469|NCT02534792||Revalvulation time late|Late revalvulation by homograft or percutaneous valve
62003470|NCT04277988||Crossed leg position|Patients in this group will be randomly allocated to sit in crossed leg position first.Ultrasonography will be performed in this position to measure the best visualized length of posterior longitudinal ligament, ligamentum flavum and interlaminar distance at L3-4 lumbar level as by Operator 1 . These measurements will be recorded by Operator 2 using intrinsic caliper software.Operator 1 will not be told the measurements.
62189088|NCT05980169|EXPERIMENTAL|Cohort B|In this arm, gynecologic cancer patients with persistent neuropathy following treatment with platinum agent and paclitaxel will receive a 30 minute SensoniQ treatment twice weekly for 4 weeks.
62779070|NCT01868386|EXPERIMENTAL|Dose Level 2|Hypofractionated therapy, 20 treatments at 2.83Gy
62189089|NCT06129032|ACTIVE_COMPARATOR|Group Wound infiltration + Intraperitoneal local anaesthetic instillation|the surgeon will be given a solution containing 20 ml of 0.5% bupivacaine, 20 ml of 2% lidocaine and 1:200,000 epinephrine with a total volume of 40 ml. A volume of 10 millilitres of the solution will be administered through the drip technique into each of the four quadrants of the uterus prior to the subsequent closure of the parietal peritoneum or fascia. A total volume of 10 ml of the solution will be administered through infiltration at the edges of the rectus aponeurosis, while the remaining 20 ml will be infiltrated subcutaneously into the incision. Patients will receive 800mg of ibuprofen and 1g of paracetamol 30 minutes prior to the end of the procedure. Following the surgical procedure, each patient will get a dosage of 15 mg/kg paracetamol every 6 hours and 800 mg of ibuprofen every 8 hours for 24 hours.
62779071|NCT01868386|EXPERIMENTAL|Dose Level 3|Hypofractionated therapy,15 treatments at 3.36 Gy
62003471|NCT04277988||Standard Sitting position|Patients in this group will be randomly allocated to sit in standard position first.Ultrasonography will be performed in this position to measure the best visualized length of posterior longitudinal ligament, ligamentum flavum and interlaminar distance at L3-4 lumbar level as by Operator 1 . These measurements will be recorded by Operator 2 using intrinsic caliper software.Operator 1 will not be told the measurements.
62003472|NCT02098161|EXPERIMENTAL|Treatment (SMAC mimetic LCL161)|Patients receive SMAC mimetic LCL161 PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62779072|NCT01868386|EXPERIMENTAL|Dose Level 4|Hypofractionated therapy, 10 treatments at 4.26 Gy
62003473|NCT00782210|EXPERIMENTAL|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
62003474|NCT00782210|EXPERIMENTAL|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
62003475|NCT00782210|PLACEBO_COMPARATOR|Placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
62003476|NCT06129812||resectable PDAC with no contact to major vessels (R-no contact)|
62003477|NCT06129812||resectable PDAC with contact PV/SMV of ≤180° (R-contact)|
62003478|NCT06129812||borderline resectable PDAC with PV/SMV contact >180° and without arterial involvement (BR-V)|
62003479|NCT00827411|EXPERIMENTAL|1: Monitoring Arm|"First randomization:~Monitoring Arm: dose adjustment of both aspirin and clopidogrel in suboptimal responders identified based on a point of care assay (VerifyNow)."
62003480|NCT00827411|ACTIVE_COMPARATOR|2: Conventional Arm|"First randomization:~Conventional Arm: fixed dose regiment of both aspirin and clopidogrel in all patients following DES implantation according to international guidelines"
62003481|NCT00827411|EXPERIMENTAL|3: Pursuit Arm|"Second randomization after one year of follow-up:~Pursuit Arm: Pursuit of a dual oral antiplatelet therapy (aspirin and clopidogrel) beyond one year"
62003482|NCT00827411|ACTIVE_COMPARATOR|4: Interruption Arm|"Second randomization after one year of follow-up:~Interruption Arm: Interruption of clopidogrel therapy."
62003483|NCT03022617|EXPERIMENTAL|Study Group|Open-label drug administration group. No comparator.
62003484|NCT01221259|EXPERIMENTAL|Drug E2212|
62003485|NCT01221259|PLACEBO_COMPARATOR|Placebo|
62003486|NCT03074903||Early cycle insertion|Participants in this group have the intrauterine system inserted during the first seven days of their menstrual cycle.
62003487|NCT03074903||Late cycle insertion|Participants in this group have the intrauterine system inserted during the remainder of their cycle.
62003488|NCT05473533|PLACEBO_COMPARATOR|Arm 1|Placebo
62003489|NCT05473533|EXPERIMENTAL|Arm 2|PRS-220
62003490|NCT03587610|ACTIVE_COMPARATOR|Intervention arm|"* if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~* if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
62003491|NCT03587610|NO_INTERVENTION|Standard care|"* if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~* if the patients vaccinations are not up to date: the patient will be informed that a remedial vaccination is necessary and that he should contact his primary care provider after hospital discharge."
62003492|NCT00028756|ACTIVE_COMPARATOR|Arm I (immediate chemotherapy)|Beginning within 90 days of radical cystectomy, patients receive a total of 4 courses of adjuvant chemotherapy.
62003493|NCT00028756|EXPERIMENTAL|Arm II (deferred chemotherapy)|Beginning at the time of clinical relapse, patients receive a total of 6 courses of adjuvant chemotherapy.
62003494|NCT04429009|EXPERIMENTAL|Active Study Group|"Participants in this group will be prescribed to use the ZEPHYRx RT device for incentive spectrometer once every hour during waking hours to perform a series of 10 deep breaths. The novel ZEPHYRx RT system consists three components:~1. The Spirobank Smart Spirometer, which is a non-significant risk, FDA-cleared diagnostic spirometer made by Medical International Research (MIR) that connects via bluetooth to an Android tablet.~2. A Samsung 10-inch tablet provided by Pad-in-Motion Inc. that will be connected to the hospital GuestWiFi network.~3. The ZEPHYRx Respiratory Therapy video game application installed on the tablet. This application consists of seven games that have been created to combine traditional IS techniques with playing a breath controlled video game. The application will record data while playing the video games including date/time of use, game played, inhalation duration, and inhalation volume."
62003495|NCT04429009|ACTIVE_COMPARATOR|Control Group|Participants in this group will be prescribed to routine respiratory care, Routine respiratory care involves the use of a standard incentive spirometer that is not a digital device and does not include any built-in reminder. As per routine care, the nurse or respiratory therapist will remind the subjects to perform a series of at least 10 deep breaths every hour.
62003496|NCT05996861||Pre-sleep protocol group|Patients with inclusion criteria assessed before the implementation of the sleep protocol.
62003497|NCT05996861||Post-sleep protocol group|Patients with inclusion criteria after the implementation of the sleep protocol.
62003498|NCT02376192|EXPERIMENTAL|Bolus Phenylephrine/Ephedrine Treatment'|Initial MicroScan® (Microvision Medical) SDF measurement are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia. In the operating room participants will receive a standard spinal anesthetic (hyperbaric bupivacaine, fentanyl and preservative free morphine) followed by a second comparative MicroScan® (Microvision Medical) SDF measurement within 10 minutes of initiation of spinal anesthetic. Participants who experience hypotension will receive bolus phenylephrine and/or ephedrine treatment as needed.
62003499|NCT02376192|EXPERIMENTAL|Phenylephrine Infusion Group|Initial MicroScan® (Microvision Medical) SDF measurement are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia. In the operating room participants will receive a standard spinal anesthetic (hyperbaric bupivacaine, fentanyl and preservative free morphine) followed by a second comparative MicroScan® (Microvision Medical) SDF measurement within 10 minutes of initiation of spinal anesthetic. Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
62003500|NCT05147857|ACTIVE_COMPARATOR|Mesotac in mid trimester|Prostaglandin
62003501|NCT05147857|ACTIVE_COMPARATOR|Dilapan s in mid trimester|"is an osmotic hygroscopic dilator produced from a patented Aquacryl® hydrogel that guarantees consistency of action.~It is a rigid gel rod that increases in volume by absorbing fluids from the cervical canal, so it gradually dilates the cervix The thin 4 mm rod can expand up to 15 mm over a 12-24 hours period. This allows it to dilate and soften the cervix gradually."
62003502|NCT02827058|EXPERIMENTAL|G25 pencil point needle|healthy pregnant women who at (vaginal or cesarean section) delivery get spinal anesthesia administered with use of a 25 gauge pencil point needle
62003503|NCT02827058|ACTIVE_COMPARATOR|G27 pencil point needle|healthy pregnant women who at (vaginal or cesarean section) delivery get spinal anesthesia administered with use of a 27 gauge pencil point needle
62003504|NCT02669602||No intervention|No Intervention
62189090|NCT06129032|ACTIVE_COMPARATOR|Group QUADRATUS LUMBORUM BLOCK|In the QLB group, quadratus lumborum type 1 block will be applied bilaterally on both sides with a total of 40 ml of solution containing 20 ml of 0.5% bupivacaine + 20 ml of 2% lidocaine + 1:200.000 epinephrine, under ultrasound guidance. Patients will receive 800mg of ibuprofen and 1g of paracetamol 30 minutes prior to the end of the procedure. Following the surgical procedure, each patient will get a dosage of 15 mg/kg paracetamol every 6 hours and 800 mg of ibuprofen every 8 hours for 24 hours.
62189091|NCT05489562|OTHER|Single Arm Mouthguard|Subjects wearing mouthguard to access tolerability and comfort of the device
62189092|NCT01095159|ACTIVE_COMPARATOR|TVT-O|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).
62003505|NCT05066620|EXPERIMENTAL|Intervention group|Chinese herbal medicine FYTF-919: Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)
62003506|NCT05066620|PLACEBO_COMPARATOR|Control group|Placebo treatment: Oral liquid 33ml TID (or patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)
62003507|NCT03389646|ACTIVE_COMPARATOR|Treated with Device: Including sham|"Treated with CERAMENTTM\|G or V for filling of bone defects in the tibia and/or femur and/or the acetabulum."
62003508|NCT03389646|NO_INTERVENTION|Control|Control without CERAMENT device
62003509|NCT03693768|EXPERIMENTAL|Health coaching ARM|Participants in this ARM will undergo health coaching for 4 months.
62003510|NCT00772551|ACTIVE_COMPARATOR|1|
62003511|NCT00772551|ACTIVE_COMPARATOR|2|
62003512|NCT06402058|EXPERIMENTAL|DMSB01|mPEG-PLA
62189093|NCT01095159|ACTIVE_COMPARATOR|TVT-S|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
62189094|NCT02781649|EXPERIMENTAL|Donor genotype 1a no resistance or 1b|Participants who receive donors found to have hepatitis C genotype 1a without resistance Zepatier one tablet daily for 12 weeks
62189095|NCT02781649|EXPERIMENTAL|Donor genotype 1a with resistance|Participants who receive donors found to have hepatitis C genotype 1a with nonstructural protein 5A associated resistance mutations Zepatier one tablet daily for 16 weeks Ribavirin weight based dosing for 16 weeks
62189096|NCT02781649|EXPERIMENTAL|Donor genotype 2 or 3|Participants who receive donors found to have hepatitis C genotype 2 or 3 Zepatier one tablet daily for 12 weeks Sofosbuvir 400 mg daily for 12 weeks
62189097|NCT02903797||Endometrial Hyperplasia|The first group was formed of the patients diagnosed endometrial hyperplasia histopathologically
62189098|NCT02903797||Control group|The control group was formed of the patients who were healthy women admitted to the clinic just for annual examination without any complain and symptoms
62571609|NCT06577701||Traditional Chinese Medicine cohort|Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Continuous medication for more than 3 months per year, or intermittent medication for more than 6 months per year was the exposure group (TCM diagnosis and treatment plan cohort).
62003513|NCT06402058|ACTIVE_COMPARATOR|Rejuran®|PN
62003514|NCT01329081|EXPERIMENTAL|Six weeks strength training in teams and patient education|
62189099|NCT03569215||IVF/ICSI failure|These patients had prolonged infertility with one or more failure of IVF/ICSI cycles
62779073|NCT04029103|ACTIVE_COMPARATOR|used m-DAKBAS|"m-DAKBAS application was downloaded to the mobile phones of the participants who met the research criteria and accepted to participate in the study; the participants were given a username and a password for the confidentiality. They were instructed how to use the application after a number of trials.~The participants were asked to send their blood sugar levels each time they measured it and foot observations daily through the application. Using the admin panel, the researcher followed the participants' frequency of using the application and the data they sent throughout 24 weeks and tried to find solutions to the problems experienced (for example: hyperglycaemia, insulin dosage adjustments). The participants were provided with feedback in line with these data; SMS reminders were sent if the tasks were not completed."
62003515|NCT01329081|EXPERIMENTAL|Supervised home training with focus on activities|
62003516|NCT02539875|EXPERIMENTAL|AWARD, Brief leaflet, Referral leaflet, active referral|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit as soon as possible and not later than a quit date (which will qualify them for the QTW prizes), Refer smokers to smoking cessation services, and Do it again: to repeat the intervention. Brief innovative leaflet on health warning and smoking cessation. A 2-side color printed A4 leaflet will be designed to systematically cover the most important messages to motivate smoking cessation. A 2-side color printed A4 referral leaflet will be used for motivate and assist the smokers to use the smoking cessation services. the smokers will be active refer to various smoking cessation services in Hong Kong (using the referral leaflet) and motivate the smokers to use the smoking cessation services.
62003517|NCT02539875|EXPERIMENTAL|AWARD, Brief leaflet|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit as soon as possible and not later than a quit date (which will qualify them for the QTW prizes), Refer smokers to smoking cessation services, and Do it again: to repeat the intervention. Brief innovative leaflet on health warning and smoking cessation. A 2-side color printed A4 leaflet will be designed to systematically cover the most important messages to motivate smoking cessation.
62189100|NCT03569215||Prolonged infertility only|These patients had prolonged infertility without any trials of IVF/ICSI cycles
62189101|NCT05114369||Early (<4weeks), Intermediate (4-12 weeks) and Late (>12 weeks)|Interval between index cholecystectomy and radical re-resection with curative intent
62189102|NCT00002463|EXPERIMENTAL|Combination Chemotherapy|Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine
62779074|NCT04029103|EXPERIMENTAL|not used m-DAKBAS|The participants who met the research criteria and accepted to participate in the study were given training via verbal instruction about the information in the content of m-DAKBAS (definition of Diabetic Foot, risk factors, protective precautions, daily foot care)
62779075|NCT05977829||Breast cancer patients with abnormal uterine bleeding|"* Transvaginal ultrasonography~* Outpatient Hysteroscopy"
62003518|NCT02539875|ACTIVE_COMPARATOR|Smoking cessation booklet, general advices|"Participants will receive minimal intervention, including: (1) the 12-page smoking cessation booklet (provided by COSH); (2) very brief, minimal and general smoking cessation advice include: Please quit smoking for improving health and save money, Please refer to the booklet for the details about smoking cessation and Please call us if you have any enquiry."
62003519|NCT03067779|OTHER|Survey and mHealth Tool|"A survey has been designed that evaluates CRIC participants' computer and mobile phone usage, and perceived e-health literacy.~There is also a mobile health-based (mHealth) patient safety educational curriculum that evaluates CRIC participants' knowledge of patient safety hazards in CKD. The mHealth patient safety curriculum tool is also known as eCRIC."
62779076|NCT05977829||Breast cancer patients without abnormal uterine bleeding|"* Transvaginal ultrasonography~* Outpatient Hysteroscopy"
62779077|NCT02073019|EXPERIMENTAL|Cohort A|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
62779078|NCT02073019|EXPERIMENTAL|Cohort B|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
62003520|NCT02837432|OTHER|Healthy|Healthy individuals will receive both the placebo and hydrocortisone interventions in a randomized order
62189103|NCT03453723|EXPERIMENTAL|magic glove hypnosis|Magic glove hypnosis technique use before propofol infusion
62189104|NCT03453723|ACTIVE_COMPARATOR|lidocaine|extemporaneous mixture with lidocaine for propofol infusion
62189105|NCT04065126|EXPERIMENTAL|Physical activity Intervention|This arm receives ten two-hour group sessions with physical activity and psycho-educational components, held by a physiotherapist over a period of ten weeks.
62189106|NCT04065126|ACTIVE_COMPARATOR|Brief Psycho-education|This arm receives two brief lectures of psycho-education held by a physiotherapist.
62189107|NCT03062449|ACTIVE_COMPARATOR|L-Serine Gummy Arm|L-serine will be presented in gummies containing 1g serine each. Subjects randomized into the L-serine arm will take 15 grams of L-Serine (15 gummies containing 1g of L-serine) orally twice daily for 246 days after the initial ascending dose period to confirm tolerability of the dose.
62189108|NCT03062449|PLACEBO_COMPARATOR|Placebo Gummy Arm|Placebo gummies containing no L-serine will be packaged in the same manner as that of the L-Serine gummy arm and be given to patients to take two times a day.
62189109|NCT05703152|EXPERIMENTAL|Combined Exercise|Therapeutic exercise program
62189110|NCT01375751|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injection once every 4 weeks for 12 weeks.
62189111|NCT01375751|EXPERIMENTAL|Evolocumab 350 mg|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
62189112|NCT01375751|EXPERIMENTAL|Evolocumab 420 mg|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
62571610|NCT06577701||Non Traditional Chinese Medicine cohort|Other patients who did not fit into the TCM group.
62584902|NCT04214262|EXPERIMENTAL|Arm A (atezolizumab, SBRT)|Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Starting on day 1 cycle 3, patients also undergo SBRT for 3-8 treatments every 2 days or QD over 1-3 weeks. Patients undergo FDG-PET/CT during screening. Patients undergo blood sample collection and CT scans throughout the trial.
62779079|NCT02073019|EXPERIMENTAL|Cohort C|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
62003521|NCT02837432|OTHER|Depression|Individuals with depression will receive both the placebo and hydrocortisone interventions in a randomized order
62779080|NCT03300986||Functional Electrical Stimulation (FES) users|
62779081|NCT04777292|EXPERIMENTAL|Immediate-use|Immediate use of esTOCma mobile app. Participants will use the mobile application immediately after the baseline assessment (T0) during approximately 10 days or until app completion.
62779082|NCT04777292|ACTIVE_COMPARATOR|Delayed use|Delayed use of esTOCma mobile app. Participants will start using the app 10 days after the first assessment (T0), and immediately after the T1 assessment.
62779083|NCT02128074|EXPERIMENTAL|KRX-0502|KRX-0502 (ferric citrate)
62779084|NCT02793791|EXPERIMENTAL|Ablation|
62779085|NCT02793791|NO_INTERVENTION|Observation|
62779086|NCT03473795||healthy participants and participants diagnosed with NCDs|This protocol will entail prospective collection of data on healthy participants and participants diagnosed with NCDs managed at collaborating institutions in SSA. Information to be obtained includes socio-demographic data, risk factors, disease-specific data, investigation and treatment details, as well as findings during follow-up. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality. Follow-up data will be updated during clinic visits and also via phone calls.
62779087|NCT04849715|ACTIVE_COMPARATOR|Treatment Group A|Participants will be administered parsaclisib once daily and will receive Bendamustine and Rituximab periodically for 6 months.
62779088|NCT04849715|PLACEBO_COMPARATOR|Treatment group B|Participants will be administered placebo once daily and will receive Bendamustine and Rituximab periodically for 6 months.
62779089|NCT05329870||Normal Colonoscopy and Normal qFIT|Normal colonoscopy and qFIT \<10 micrograms haemoglobin
62779090|NCT05329870||Normal Colonoscopy and Raised qFIT|Normal colonoscopy and qFIT \>=10 micrograms haemoglobin
62779091|NCT01660620|EXPERIMENTAL|betaxolol|betaxolol 0.25% 2 per day for 3 weeks
62779092|NCT01660620|PLACEBO_COMPARATOR|placebo|masked labeling also 2 per day administration
62779093|NCT05244733|EXPERIMENTAL|Social Engage (S-ENGAGE)|S-ENGAGE is a skills-based psychotherapy that focuses on helping patients engage in meaningful rewarding social activities. Subjects will receive 10 one-hour individual sessions of S-ENGAGE over 10 weeks.
62003522|NCT00325234|EXPERIMENTAL|Pemetrexed/Carboplatin|"Pemetrexed 600 mg/m\^2 was administered intravenously over approximately 10 minutes on Day 1.~Carboplatin was given over approximately 30 minutes on Day 1 beginning after the end of the Pemetrexed infusion, consistent with a target of AUC (Area under the plasma drug concentration versus time curve) 5.0 mg\*min/mL. The cycle of treatment was 21 days."
62189113|NCT00080990|EXPERIMENTAL|Treatment (alvocidib with oxaliplatin, 5-FU, leucovorin)|"Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, the cohort is expanded and an additional 10 patients are treated at that dose."
62189114|NCT03904940|EXPERIMENTAL|Total Contact Insole Group|Ethyl vinyl acetate insole shaped in the cast of the patient's foot, every 6 months.
62189115|NCT03904940|SHAM_COMPARATOR|Flat Insole group|Flat insole made the same material ethyl vinyl acetate, every 6 months.
62189116|NCT02953509|EXPERIMENTAL|Magrolimab + Rituximab, Phase 1b Dose Escalation|Participants with B-cell non-Hodgkin's lymphoma will receive 1 mg/kg magrolimab priming dose on Day 1 of Cycle 1 followed by weekly maintenance doses of 10, 20, 30, or 45 mg/kg on Days 8, 15, 22 for Cycle 1 and Days 1, 8, 15, and 22 for each cycle to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose and schedule (RP2DS) in combination with rituxumab 375 mg/m\^2. Cycle length is 28 days.
62779094|NCT05244733|PLACEBO_COMPARATOR|The Healthy Lifestyles Education Program|The healthy lifestyles education program consists of a notebook containing evidence-based educational material on mental health, physical activity, and information on community resources. Study staff meet with participants once, individually, for 1 hour to review each section and answer questions participants might have.
62779095|NCT04113525|EXPERIMENTAL|Active Stimulation + Robotic Wrist Therapy|Two courses of five consecutive days of 20 minute trans-spinal and trans-peripheral nerve active stimulation (total of 10 sessions) combined with a six-week intensive wrist robotic training program.
62779096|NCT04113525|SHAM_COMPARATOR|Sham Stimulation + Robotic Wrist Therapy|Two courses of five consecutive days of 20 minute trans-spinal and trans-peripheral nerve sham stimulation (total of 10 sessions) combined with a six-week intensive wrist robotic training program.
62779097|NCT05244551|EXPERIMENTAL|ABSK061|Dose escalation of oral ABSK061 will be guided by the Bayesian optimal interval (BOIN) design based on safety data collected until a maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified. During the dose escalation part of the study, patients will receive a single dose of ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in the subsequent cycles. If the actual elimination half-life of ABSK061 is greatly exceeding that predicted, a run-in period with a single-dose and a longer drug-free observation period could be performed in subsequent patients after the Investigator and Sponsor have discussed and agreed.
62779098|NCT02547168|EXPERIMENTAL|iRhythm ZIO XT patch group|This is the only arm in the study and patients within it will have a small, pebble shaped device adhered to their chests. This is an ECG (electrocardiogram) monitor and will measure the incidence of atrial fibrillation. It will have to be worn for 14 days before and after the lung resection procedure
62779099|NCT04384523|EXPERIMENTAL|OsrHSA 20 mg/kg IV|
62779100|NCT04384523|EXPERIMENTAL|OsrHSA 40 mg/kg IV|
62779101|NCT04384523|EXPERIMENTAL|OsrHSA 80 mg/kg IV|
62779102|NCT04384523|EXPERIMENTAL|OsrHSA 140 mg/kg IV|
62779103|NCT04384523|EXPERIMENTAL|OsrHSA 200 mg/kg IV|
62779104|NCT06166108|ACTIVE_COMPARATOR|"Group M bupivacaine +normal saline +MgSO4"|will receive 25 ml volume on each side (20 ml of 0.25% bupivacaine plus 5 ml of normal saline containing 250 mg of MgSO4)
62779105|NCT06166108|ACTIVE_COMPARATOR|"Group D bupivacaine +normal saline +dexamethasone"|will receive 25ml volume on each side (20 ml of 0.25% bupivacaine plus 5 ml of normal saline containing 8 mg of dexamethasone)
62779106|NCT03044184|ACTIVE_COMPARATOR|Intervention|"Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage~AND~Patients will have 1gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) intravenously infused over 10 minutes within 3 hours of symptom presentation and another 1 gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) infused over 8 hours."
62779107|NCT03044184|NO_INTERVENTION|Control|"Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage~AND~Patients will 100ml of normal saline 0.9% intravenously infused over 10 minutes within 3 hours of symptom presentation and another 100ml of normal saline 0.9% infused over 8 hours."
62003523|NCT00325234|ACTIVE_COMPARATOR|Gemcitabine/Vinorelbine|Vinorelbine 30 mg/m\^2 was given over approximately 6-10 minutes on Day 1 and Day 8. Gemcitabine 1200 mg/m\^2 was given over approximately 30 minutes on Day 1 and Day 8 beginning after the end of the Vinorelbine infusion. The cycle of treatment was 21 days.
62003524|NCT06198192|ACTIVE_COMPARATOR|Balance Exercises|This group will receive conventional exercises for balance.
62003525|NCT06198192|EXPERIMENTAL|Pilates Exercises|This group will receive Pilate exercises along with Balance exercises
62003526|NCT04121325||Gastroparesis patients with abdominal pain|Patients with gastroparesis who have had an Enterra device in place for at least two months who continue to have moderate to severe abdominal pain.
62003527|NCT06481059||Head and neck cancer post-radiotherapy|Head and neck cancer patients who received radiotherapy after six months. fractions no. \[(32-35 fractions) 5700-7000 Gy\] addition chemotherapy \[(cisplatin or cetuximab) (2-3 doses)\].
62003528|NCT06409468|EXPERIMENTAL|Coronally Advanced Tunnel with NovoMatrix|Gingival Augmentation Procedure using NovoMatrix + Coronally Advanced Tunnel
62003529|NCT02252627||Group 1|Healthy volunteers
62003530|NCT05599178||Term gestation|
62189117|NCT02953509|EXPERIMENTAL|Magrolimab + Rituximab, Phase 2 Indolent Lymphoma|Participants with indolent lymphoma will receive magrolimab based on RP2DS from Phase 1b portion of the study in combination with rituxumab 375 mg/m\^2.
62189118|NCT02953509|EXPERIMENTAL|Magrolimab + Rituximab, Phase 2 Diffuse Large B-Cell lymphoma|Participants with diffuse large B-cell lymphoma (DLBCL) will receive magrolimab based on RP2DS from Phase 1b portion of the study in combination with rituxumab 375 mg/m\^2.
62189119|NCT02953509|EXPERIMENTAL|Magrolimab + R-GemOx, Phase 1b Safety Dose Escalation Phase|Autologous stem cell transplant (or transplantation) ineligible DLBCL participants will receive 1 mg/kg magrolimab priming dose on Day 1 for Cyle 1 followed by maintenance doses of 30 or 45 mg/kg on Days 8, 11, 15, 22, and 29 for Cycle 1, every week for Cycle 2, and every 2 weeks for each cycle to determine maximum tolerated dose (MTD) + rituxumab 375 mg/m\^2 + gemcitabine 1000 mg/m\^2 + oxaliplatin 100 mg/m\^2. Cycle length is 28 days.
62189120|NCT02953509|EXPERIMENTAL|Magrolimab + R-GemOx, Phase 1b Dose Expansion Phase|Autologous stem cell transplant (or transplantation) ineligible DLBCL participants will receive magrolimab at a dose determined from Phase 1b Safety Dose-Escalation Phase in combination with rituxumab 375 mg/m\^2 + gemcitabine 1000 mg/m\^2 + oxaliplatin 100 mg/m\^2.
62189121|NCT05739110||micronecrosis(+) group|Hepatocellular patients with tumor micronecrosis.
62189122|NCT05739110||micronecrosis(-) group|Hepatocellular patients without tumor micronecrosis.
62779108|NCT06289309|EXPERIMENTAL|NerveTrend|In operations with NerveTrend mode the i-IONM stimulator will be used to test vagal response at the beginning of surgery, map out and trace the RLNs during surgery by repetitive stimulations, and in case of loss of signal (LOS) it will be used to identify the type and site of neural injury (Type I vs. Type II). Final prognostication of postoperative neral function will be based on vagal stimulation at the end of each lobectomy. In addition, the EMG trending including amplitude and latency changes from initial vagal baseline will be evaluated using the NerveTrend mode at 3 - 5min intervals to assure almost real time EMG tracing and allow for modification of surgical maneuvers in case of occurrence of severe combined events (yellow zone) in order not to end up with the LOS (red zone).
62779109|NCT06289309|ACTIVE_COMPARATOR|NerveAssure|In operations with NerveAssure mode the i-IONM stimulator will be used to test vagal response at the beginning of surgery, map out and trace the RLNs during surgery by repetitive stimulations, and in case of loss of signal (LOS) it will be used to identify the type and site of neural injury (Type I vs. Type II). Final prognostication of postoperative neral function will be based on vagal stimulation at the end of each lobectomy. In addition, the APS electrode will be placed on the Vagus nerve to allow for Automatic Periodic Stimulation of the Vagus nerve to test the RLN condition throughout the surgery and allow for modification of surgical maneuvers in case of occurrence of severe combined events (yellow zone) in order not to end up with the LOS (red zone).
62779110|NCT01705678|ACTIVE_COMPARATOR|Krill oil|Krill oil will be compared to fish oil as an active comparator
62779111|NCT01705678|ACTIVE_COMPARATOR|Fish oil|Fish oil 500 mg of DHA/EPA
62779112|NCT01598597||Cohort|
62779113|NCT06482450|EXPERIMENTAL|Patient- and Provider-Facing CDS|Parents of patients with odd birthdates (e.g. April 13) and vaccines due at the index appointment who also have a MYchart account will receive a text message directing the parent to the LTS server with integration into the provider workflow
62779114|NCT06482450|EXPERIMENTAL|Patient-Facing CDS Only|Among patients without a MYchart account, those with odd birthdates will receive a link to the LTS website (patient-facing CDS) but no integration into the provider workflow.
62779115|NCT06482450|PLACEBO_COMPARATOR|Control (MYchart account)|"Patients with an even birthdate (e.g. April 14) who have a MYchart account will receive a regular text message and e-mail appointment reminder with a vaccine primer (e.g. Vaccines are due and reserved for the participant's child), but no patient- or provider-facing CDS."
62779116|NCT06482450|PLACEBO_COMPARATOR|Control (no MYchart account)|As in the other control group, those without a MYchart account and an even birthdate (e.g. April 14) will receive a text message and e-mail appointment reminder with a vaccine primer but no patient- or provider-facing CDS.
62779117|NCT01849419|EXPERIMENTAL|Single group|Healthy volunteers received all drug conditions (MDMA, oxytocin, and placebo) using a within-subjects design.
62779118|NCT03080363|ACTIVE_COMPARATOR|Quadratus Lumborum Block|Ultrasound guided Quadratus Lumborum Block with 10 ml %0.5 bupivacaine and 10 ml %2 lidocaine
62003531|NCT02170246|NO_INTERVENTION|Antiretroviral Therapy (ART) only|Acute HIV-infected subjects (n=7) will be randomly assigned to a group that will receive antiretroviral therapy (the current standard of care for HIV patients) for 72 weeks.
62003532|NCT02170246|EXPERIMENTAL|ART + Telmisartan|Acute HIV-infected subjects (n=14) will be randomly assigned to a group that will receive treatment with telmisartan in addition to ART. Subjects will receive 40mg telmisartan daily for 4 weeks, followed by 80mg telmisartan daily for 44 weeks, to be taken in conjunction with ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily. After telmisartan is stopped, subjects will continue to take ART for an additional 24 weeks (total 72 weeks).
62003533|NCT05026463|EXPERIMENTAL|Inspiratory support level with PMI equal to -2|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
62189123|NCT03253120|OTHER|Patient|Patients will drink 5dl of water.
62189124|NCT03253120|OTHER|Healthy volunteer|Healthy volunteers will drink 5dl of water.
62189125|NCT05890937|EXPERIMENTAL|Mental stress group|they were expected to take their exams just after the assessment and before measuring for the second time
62189126|NCT05890937|NO_INTERVENTION|Control group|they were expected to take nothing for 30 min just after the assessment and before measuring for the second time
62189127|NCT01335945|OTHER|Cryoablation|Freezing of the celiac plexus
62779119|NCT03080363|NO_INTERVENTION|Group Control|No intervention
62779120|NCT01153698||patients after hip or knee replacement|
62779121|NCT01748825|EXPERIMENTAL|ARM 1 AZD1775 200 mg Once Daily|
62779122|NCT01748825|EXPERIMENTAL|ARM 2 AZD1775 225 mg Once Daily|
62779123|NCT01748825|EXPERIMENTAL|ARM 3 AZD1775 225 mg Twice Daily|
62779124|NCT01748825|EXPERIMENTAL|ARM 4 AZD1775 225 mg Twice Daily (week 1-only dosing)|
62779125|NCT01748825|EXPERIMENTAL|ARM 5 AZD1775 250 mg Once Daily|
62779126|NCT01748825|EXPERIMENTAL|ARM 6 AZD1775 300 mg Once Daily|
62779127|NCT01748825|EXPERIMENTAL|ARM 7 AZD1775 300 mg Twice Daily|
62003534|NCT05026463|EXPERIMENTAL|Inspiratory support level with PMI equal to 0|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
62003535|NCT05026463|EXPERIMENTAL|Inspiratory support level with PMI equal to +2|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
62779128|NCT01748825|EXPERIMENTAL|ARM 8 AZD1775 400 mg Once Daily|
62003536|NCT00501202|PLACEBO_COMPARATOR|002|placebo twice daily for 4 weeks
62003537|NCT00501202|EXPERIMENTAL|001|RWJ-333369 (carisbamate) 200 mg tablet twice daily for 4 weeks
62003538|NCT00202904|EXPERIMENTAL|Arm 1|
62003539|NCT00202904|ACTIVE_COMPARATOR|Arm 2|
62003540|NCT05523531||Patients with characteristics of idiopathic neuropathic eye pain associated with dry eye|Previously included in the QUALVIDON study
62003541|NCT02577965|EXPERIMENTAL|Female Arm|Female gender diagnosed with ST segment Elevation Myocardial Infarction (STEMI). Interventions: Angiography, thrombus aspiration, optical coherence tomography and percutaneous coronary intervention, implantation of XIENCE PRIME Everolimus Eluting Coronary Stent. Angiography and Optical Coherence Tomography follow up at 9 months.
62189128|NCT00079339|EXPERIMENTAL|Treatment (radiation therapy and tipifarnib)|"PHASE I: Patients undergo radiotherapy 5 days a week for 6 weeks. Beginning 0-2 days before radiotherapy, patients receive oral tipifarnib twice daily until the completion of radiotherapy. Beginning 2 weeks after the completion of radiotherapy, patients receive oral tipifarnib twice daily in weeks 1-3. Treatment repeats every 4 weeks for up to 24 additional courses (total of 26 courses) in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients undergo radiotherapy and receive tipifarnib at the MTD as in phase I (closed to accrual as of 1/19/06). Treatment continues for up to 24 months (26 courses) in the absence of disease progression or unacceptable toxicity."
62189129|NCT06008223|EXPERIMENTAL|experimental group (vitamin B6)|
62189130|NCT06008223|PLACEBO_COMPARATOR|control group (0.9% sodium chloride solution)|
62189131|NCT02751749|EXPERIMENTAL|Unified Protocol|"CBT based Internet delivered treatment targeting transdiagnostic vulnerability and maintaining factors for chronic pain and emotional problems.~Since this is a new target Group, a replicated single case design was used and participants are their own Control Group (no other treatment arms)."
62584903|NCT04214262|ACTIVE_COMPARATOR|Arm B (SBRT)|Beginning 21 days after randomization, patients undergo SBRT for 3-8 treatments every 2 days or QD over 1-3 weeks. Patients undergo FDG-PET/CT during screening. Patients undergo blood sample collection and CT scans throughout the trial.
62779129|NCT01748825|EXPERIMENTAL|ARM 9 Expansion Cohort 1: AZD1775 225 mg Twice Daily|
62779130|NCT01748825|EXPERIMENTAL|ARM 10 Expansion Cohort 2: AZD1775 300 mg Once Daily|
62779131|NCT05312294|EXPERIMENTAL|FLU-M w/o/p|Volunteers were vaccinated with a single dose of the Flu-M vaccine (without preservative) intramuscularly in a dose of 0.5 mL.
62779132|NCT05312294|EXPERIMENTAL|FLU-M w/p|Volunteers were vaccinated with a single dose of the Flu-M vaccine (with preservative) intramuscularly in a dose of 0.5 mL.
62779133|NCT01255124||Health infants (ClinicalTrials.gov ID: NCT01183611)|The subjects participated in the clinical trial 'The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates' in 2007 (ClinicalTrials.gov ID: NCT01183611).
62779134|NCT01657734||HGG2003|"\*\*\*\* patients enrolled in the HGG 2003 HGG-IMMUNO 2003 trial~Patients, older than 3 and younger than 60 years with relapse of high-grade glioma (anaplastic astrocytoma WHO grade III or glioblastoma multiforme WHO grade IV), histologically diagnosed in the first stage of the disease as well as after relapse or relapse of glioma which was grade II in the First phase but grade III or IV upon relapse are treated with dendritic cell therapy (immunotherapy) as single treatment approach (No radiotherapy and/or chemotherapy)."
62779135|NCT01657734||HGG2010|"\*\*\*\* patients enrolled in the HGG 2010 HGG-IMMUNO 2010 trial~* prospective double blind placebo controlled randomised clinical trial HGG-2010 for patients with newly diagnosed glioblastoma in which immunotherapy is integrated in the current standard of care (concommitant radiochemotherapy)."
61977884|NCT03533179|EXPERIMENTAL|Esmolol-placebo+glucagon 2 (D)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+Glukagon 2 (50 μg/kg bolus - over 30 min in 50 ml isotonic fluid from time=0 min)"
62003542|NCT02577965|ACTIVE_COMPARATOR|Male Arm|Male Gender with diagnose of ST segment Elevation Acute Myocardial Infarction (STEMI). Interventions: Angiography, thrombus aspiration, optical coherence tomography and percutaneous coronary intervention, implantation of XIENCE PRIME Everolimus Eluting Coronary Stent. Angiography and Optical Coherence Tomography follow up at 9 months.
62003543|NCT04990986|OTHER|Intervention|The complex intervention will be co-developed during first phase of the study.
62003544|NCT04990986|NO_INTERVENTION|Control|Half of the group will be included as control and thus not exposed to the intervention.
62003545|NCT02473068|ACTIVE_COMPARATOR|Group 1|In random order, CPAP via a standard humidifier with chamber output temperature of 31°C, or CPAP with a prototype humidifier with chamber output temperature of 31°C.
62003546|NCT02473068|EXPERIMENTAL|Group 2|In random order, CPAP via a standard humidifier with chamber output temperature of 31°C, or CPAP with a prototype humidifier with chamber output temperature of 27°C.
62003547|NCT01894828|ACTIVE_COMPARATOR|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily
62003548|NCT01894828|NO_INTERVENTION|Control|Patients are asked to keep on to their normal diet. No supplementation is introduced
62003549|NCT00973791|ACTIVE_COMPARATOR|Prior crystalloid|Crystalloid (Ringer's Lactate) was given before spinal anesthesia
62003550|NCT00973791|ACTIVE_COMPARATOR|Posterior crystalloid|Crystalloid (Ringer's Lactate) was given after spinal anesthesia
62003551|NCT00973791|ACTIVE_COMPARATOR|Prior colloid|Colloid (6% hydroxyethyl starch) was given before spinal anesthesia
62003552|NCT00973791|ACTIVE_COMPARATOR|Posterior colloid|Colloid (6% hydroxyethyl starch) was given after spinal anesthesia
62003553|NCT02920268|EXPERIMENTAL|Intervention|Intervention with dance and yoga sessions, two times a week in 8 months.
62779136|NCT03358134|EXPERIMENTAL|Secukinumab|All patients will be treated with active treatment. (anti-IL17)
62003554|NCT02920268|NO_INTERVENTION|Controls|No intervention
62003555|NCT05429450|EXPERIMENTAL|Methotrexate|Periocular injections of methotrexate
62003556|NCT05429450|ACTIVE_COMPARATOR|Triamcinolone acetonide|Periocular injections of triamcinolone acetonide
62189132|NCT05570305|EXPERIMENTAL|Treatment order 1|Subjects will start with 4 weeks of placebo in treatment period one, then 4 weeks of zibotentan during treatment period two. The order of the first two treatment periods is random which means that patients can start with either placebo or zibotentan. Then in treatment period three, patients are randomized to either either placebo or dapagliflozin for 2 weeks followed immediately by 4 weeks of both zibotentan and dapagliflozin. Between treatment periods there is a 4-week wash-out.
62189133|NCT05570305|EXPERIMENTAL|Treatment order 2|Subjects will start with 4 weeks of dapagliflozine in treatment period one, then 4 weeks of zibotentan during treatment period two. The order of the first two treatment periods is random which means that patients can start with either dapagliflozine or zibotentan. Then in treatment period three, patients are randomized to either either placebo or dapagliflozin for 2 weeks followed immediately by 4 weeks of both zibotentan and dapagliflozin. Between treatment periods there is a 4-week wash-out.
62189134|NCT01377792|ACTIVE_COMPARATOR|5 ml|
62003557|NCT04647058|ACTIVE_COMPARATOR|Cubital tunnel release|The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.
62003558|NCT04647058|EXPERIMENTAL|Supercharged end-to-side (SETS) nerve transfer|The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
62003559|NCT04701775|EXPERIMENTAL|Lactobacillus rhamnosus GG Group|Participants received only 1x106 cfu Lactobacillus rhamnosus GG once a day for 8 weeks.
62003560|NCT04701775|EXPERIMENTAL|Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis Group|Participants recevied a combined Lactobacillus acidophilus 1x109 cfu and Bifidobacterium animalis subsp.lactis 1x109 cfu once a day for 8 weeks.
62003561|NCT04701775|PLACEBO_COMPARATOR|Placebo|Those participants received placebo capsule once a day for 8 weeks.
62189135|NCT01377792|ACTIVE_COMPARATOR|10 ml|
62003562|NCT01100008|EXPERIMENTAL|Magnetic resonance imaging|
62189136|NCT02866396||Pregabalin patients|Same dose of preoperative pregabalin 1h after surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration (PACU if NRS \> 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS\>3
62003563|NCT04948138|EXPERIMENTAL|MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) syndrome|Patients with MELAS syndrome that will receive oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations)
62189137|NCT02866396||Naive patients|Pregabalin 150mg PO initiated 1h before surgery and associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS \> 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS\>3
62189138|NCT06137612||Patients with SMA|Patients with SMA type II and III
62189139|NCT06137612||Healthy controls|Age- and sex-matched HC
62189140|NCT03124654||Education|
62003564|NCT06442501||MPXV infected pregnant women|MPXV infected pregnant women
62003565|NCT06442501||Not MPXV infected pregnant women|Not MPXV infected pregnant women
62584904|NCT04065971|EXPERIMENTAL|2LHERP® arm|Group N°1: 2LHERP® treatment (6 months of treatment)
62003566|NCT00677495|EXPERIMENTAL|Gluten-free diet|Gluten-free diet
62003567|NCT01430065|EXPERIMENTAL|Tacrolimus and ASP015K|
62003568|NCT02017587||Chronic HBV|chronic HBV strata: HBV tolerant, Chronic active HBe+ or HBe-, suppressed with antiviral therapy
62584905|NCT04065971|PLACEBO_COMPARATOR|Placebo arm|Group N°1: Placebo treatment (6 months of treatment)
62189141|NCT04658563|EXPERIMENTAL|Group 1: Yoga|High-density HY training; average 90-110 minutes, 2 sessions per week under the supervision of the physiotherapist, once a week as a home program, will be applied for a total of 8 weeks to the first group.
62189142|NCT04658563|NO_INTERVENTION|Group 2: Control|Individuals in the second group will not included in any exercise training program
62189143|NCT02281162||Weight Gain|No intervention. Will evaluate vitamin D levels and other biomarkers affecting weight with venous blood draw.
62779137|NCT04720300|ACTIVE_COMPARATOR|MaaS app|The Mobility-as-a-Service (MaaS) App will be provided to students in the Intervention Group and is intended to facilitate their use of alternative transportation modes such as public transit, ride-hailing, walking, biking, bike share, and e-scooter share to get to campus. The MaaS App will be downloaded to students' smartphones and will provide real-time, multimodal trip planning to students on demand when they open the app. This means, for instance, that a student can plan a trip that includes driving to a train station, taking the train, and then walking from the alighting train station to their final destination. The app will be white label, i.e. it will have a customized look and feel specific to the participating south Florida colleges, and it will have personalization features so that students can tailor the app to their travel patterns. Students in a cluster assigned to the MaaS group will also receive information concerning housing options. Students complete surveys
62003569|NCT03913143|EXPERIMENTAL|Group 1: Dose 1 sepofarsen (QR-110)|Initial loading dose, followed by maintenance doses at month 3 and every 6 months there after, administered by intravitreal injection (24 months duration of treatment). After 12 months treatment of the contralateral eye may be initiated
62584906|NCT06604624|EXPERIMENTAL|HD1916|HD1916 will be administered via subcutaneous injection once a week in subjects with obesity.
62779138|NCT04720300|PLACEBO_COMPARATOR|No app|Students receive no app, no housing information, students complete surveys.
62779139|NCT04651608|EXPERIMENTAL|manuel acupressure|In this group, manual acupress was applied to children receiving chemotherapy with moderate and high emetogenic effects.
62779140|NCT04651608|EXPERIMENTAL|sea-band acupressure|In this group, sea-band acupressure was applied to children receiving chemotherapy with moderate and high emetogenic effects.
62779141|NCT03846284|PLACEBO_COMPARATOR|Bupivacaine (B group)|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of 10 cm saline over 10 mins then, I.V infusion 50 cm saline with rate 10-20 ml/h according to child weight."
62779142|NCT03846284|EXPERIMENTAL|Magnesium sulfate caudal (MC group)|"caudal block with bupivacaine 0.25% 1mg/kg + Magnesium sulfate 50 mg diluted in 10 cm saline.~+ I.V injection of 10 cm saline over 10 mins then, I.V infusion of 50 cm saline with rate 10-20 ml/h according to child weight."
62003570|NCT03913143|ACTIVE_COMPARATOR|Group 2: Dose 2 sepofarsen (QR-110)|Initial loading dose, followed by maintenance doses at month 3 and every 6 months there after, administered by intravitreal injection (24 months duration of treatment). After 12 months treatment of the contralateral eye may be initiated
62003571|NCT03913143|SHAM_COMPARATOR|Group 3: Sham|Sham procedure (no experimental drug administered), Day 1, month 3 and every six months there after. After 12 months cross over to active study drug may be initiated
62003572|NCT01698229||Group 1|Study cohort is comprised of healthy children, ages 2yrs - 8yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
62003573|NCT00712088|EXPERIMENTAL|1: Group Intervention|Group level intervention
62003574|NCT00712088|ACTIVE_COMPARATOR|2: HCT|Offer of HIV counseling and testing
62003575|NCT03818022|EXPERIMENTAL|Experimental|Patients receiving Cryoneurolysis (Iovera) prior to total knee arthroplasty
62003576|NCT03818022|NO_INTERVENTION|Control|
62584907|NCT06604624|ACTIVE_COMPARATOR|semaglutide|semaglutide will be administered via subcutaneous injection once a week in subjects with obesity.
62584908|NCT01638312||HIV infection patient and health people|The study does not have intervention
62189144|NCT02281162||No Weight Gain|No intervention. Will evaluate vitamin D levels and other biomarkers affecting weight with venous blood draw.
62189145|NCT01803334|EXPERIMENTAL|Marking abdomen|If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.
62189146|NCT01803334|NO_INTERVENTION|Control|If she is randomized to the control group, then she will undergo traditional preoperative counseling by the same team without marking the abdomen.
62779143|NCT03846284|EXPERIMENTAL|Magnesium sulfate I.V (M V group)|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h."
62189147|NCT02830542|EXPERIMENTAL|SER-262|SER-262 \[Single dose: 10(4), 10(5), 10(6), 10(7) or 10(8) SCFUs; Multiple dose 10(6), 10(7), or 10(8) SCFUs\]
62189148|NCT02830542|PLACEBO_COMPARATOR|Placebo|Placebo
62189149|NCT05450536|OTHER|Autism College Students|Single subject design means subjects are their own control.
62779144|NCT04721743||Affected Participants|Participants with Uveitis
62779145|NCT02690714|EXPERIMENTAL|6.6 mg/kg Plasminogen (Human) Intravenous|6.6 mg/kg Plasminogen (Human) Intravenous given every 2 to 4 days by a 10- to 30-minute intravenous infusion
62779146|NCT04716101|EXPERIMENTAL|Patients with nonspecific low back pain|Patients will be randomized to receive either a massage technique or a sham massage technique.
62003577|NCT04257682|ACTIVE_COMPARATOR|Bupivacaine|The participant will receive Bupivacaine as anesthesia during his or her planned total hip or knee replacement surgery.
62003578|NCT04257682|ACTIVE_COMPARATOR|Ropivacaine|The participant will receive Ropivacaine as anesthesia during his or her planned total hip or knee replacement surgery.
62003579|NCT04257682|ACTIVE_COMPARATOR|Mepivacaine|The participant will receive Mepivacaine as anesthesia during his or her planned total hip or knee replacement surgery.
62003580|NCT05897177||Normal patients|
62003581|NCT05897177||Observational group|
62003582|NCT01255566||Medical therapy cohort|For patients electing continued medical therapy, medication was prescribed based on the disease process and the judgment of the treating rhinologist. Treatment was not specifically dictated or prescribed by the study protocol.
62003583|NCT01255566||Surgical cohort|For patients electing ESS, surgery was performed by the enrolling rhinologist. In addition, medical management was administered in the perioperative and postoperative periods as dictated by the disease process and the judgment of the treating rhinologist. Treatment was not specifically dictated or prescribed by the study protocol.
62003584|NCT04865497|EXPERIMENTAL|High dose Group|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
62003585|NCT04865497|EXPERIMENTAL|Low dose Group|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,5μg/dose
62003586|NCT04865497|OTHER|Adjuvant-free Group|Adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
62003587|NCT04865497|OTHER|Control Group|Haemophilus b Conjugate Vaccine,10μg/dose
62003588|NCT02403869||Group 1|MBC patients starting treatment with monochemotherapy for second line of quimiotherapy treatment for metastatic disease
62003589|NCT05979103|EXPERIMENTAL|Reggae Music|Group 1 (Reggae): Participants in this group will be told about he stereotype of reggae in making people more calm. They will listen to reggae music over the 4 weeks.
62003590|NCT05979103|ACTIVE_COMPARATOR|Nature Sounds|Group 2 (Nature): Participants in this group will listen to nature sounds over the 4 weeks and will not be told any stereotypes.
62003591|NCT05979103|NO_INTERVENTION|Waitlist Group|Music Waitlist Group: Participants in this group will serve as a control and will not receive any intervention until the study is completed. They will complete a baseline survey and a follow-up survey at four weeks. Some recordings will be sent to this group after the study is completed, without tracking their usage.
62003592|NCT01721590|PLACEBO_COMPARATOR|Control|Placebo，3 capsules/time，3times/day for 1 year
62003593|NCT01721590|EXPERIMENTAL|Tongxinluo|Tongxinluo 3 capsules/time 3times/day for 1 year
62003594|NCT06357988|EXPERIMENTAL|Treatment (Vismodegib)|Patients receive vismodegib orally (PO) daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or nuclear study during screening, tumor biopsy on study and CT scan, MRI and blood sample collection throughout the study.
62003595|NCT00514410|EXPERIMENTAL|Folic Acid|
62003596|NCT00514410|PLACEBO_COMPARATOR|Placebo|
62003597|NCT03132597|EXPERIMENTAL|Early Mindfulness exposure|six weeks of 2 hours class of mindfulness training and orientations for home training at the beginning of the first semester
62189150|NCT03118245|EXPERIMENTAL|AuraGain group|AuraGain is inserted for maintenance of general anesthesia. The size 1 is for children \<5kg, size 2 for 5-10kg, size 2 for 10-20kg, and size 2.5 for 20-30kg.
62189151|NCT03118245|EXPERIMENTAL|I-gel group|I-gel is s inserted for maintenance of general anesthesia. The size 1 is for children weighted 2-5kg, size 2 for 5-12kg, size 2 for 10-25kg, and size 2.5 for 25-35kg.
62189152|NCT05656612|EXPERIMENTAL|The Group Given Training 1-2 Weeks Before The Procedure|Participants received breast biopsy procedure training once. 1-2 weeks before the breast biopsy procedure.
62779147|NCT04716101|ACTIVE_COMPARATOR|Asymptomatic volunteers|Similarly, the volunteers will be randomized to receive either a massage technique or a sham massage technique.
62779148|NCT02300519||Volunteers|Blood sampling : 1 blood punction of 36.5 ml for each volunteer
62003598|NCT03132597|EXPERIMENTAL|Late Mindfulness exposure|six weeks of 2 hours class of mindfulness training and orientations for home training at the second half of the first semester
62189153|NCT05656612|EXPERIMENTAL|The group trained on the day of the procedure|Participants received one time breast biopsy procedure training. The day of the breast biopsy procedure.
62189154|NCT05656612|EXPERIMENTAL|Repetitive training group|Participants received twice breast biopsy procedure training. The first training is 1-2 weeks before the breast biopsy procedure. The second training is the day of the breast biopsy procedure.
62189155|NCT06171269|EXPERIMENTAL|Radiation therapy|Participants will receive MRI scan before starting Radiation treatment. The results of this scan will be used to identify areas of the prostate to receive low doses of radiation (areas that show no cancer cells seen by the MRI scan).
62189156|NCT04730674|EXPERIMENTAL|post-mastectomty seroma group|female patients with established diagnosis of post-mastectomy seroma following modified radical mastectomy, were treated by local injection of tetracycline after the seroma fluid was aspirated, then a crepe bandage was applied over the mastectomy area. Then after 5 days the patient were examined again for seroma re-collection or the presence of complications. The amount of seroma aspirated in each session.
62189157|NCT04421339|EXPERIMENTAL|Melatonin|
62189158|NCT04421339|PLACEBO_COMPARATOR|Placebo|
62189159|NCT01515852|OTHER|Stress level after general anesthesia|
62189160|NCT01515852|OTHER|Stress level after local anesthesia|
62779149|NCT03338153||controlled diabetes|diabetic patients with HbA1C level below 7.0%
62779150|NCT03338153||uncontrolled diabetes|diabetic patients with hbA1C level above 7%
62779151|NCT03338153||non-diabetic|patients who does not have diabetes at the time of PCI
62779152|NCT02237638|EXPERIMENTAL|hVEGF26-104/RFASE vaccination|hVEGF26-104/RFASE is investigated in dose escalation in which hVEGF26-104 is escalated from 62.5 ug to 500 ug and RFASE is given in a fixed dose of 20 mg. Three patients are treated at each dose level. If 0 of the 3 patients are observed to have DLT, the dose level is escalated one step for the next cohort. If 1 of the 3 patients shows DLT, 3 additional patients are treated at that dose level. If none of these show DLT, the dose level is escalated for the next cohort; otherwise, the prior dose level is defined as the MTD. At the highest dose level 6 patients will be treated. The recommended dose for a phase II trial will be the lowest dose that results in the most effective VEGF neutralization, together with acceptable safety and toxicity.
62779153|NCT01900743|EXPERIMENTAL|Arm A|Regorafenib (160 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.
62003599|NCT03132597|NO_INTERVENTION|Control (not exposed)|Students not exposed to the mindfulness mandatory course (not exposed to the intervention)
62003600|NCT06417086|EXPERIMENTAL|Acupuncture Treatment|Participants in this group will receive acupuncture treatment in combination with donepezil for 12 weeks.
62003601|NCT06417086|ACTIVE_COMPARATOR|Sham Acupuncture Treatment|Participants in this group will receive sham acupuncture treatment in combination with donepezil for 12 weeks.
62189161|NCT06153992|ACTIVE_COMPARATOR|Control group|The control group received exercise therapy (once a day, 40min/ times, 5 times/week), occupational therapy (once a day, 30min/ times, 5 times/week), low-frequency electricity (once a day, 20min/ times, 5 times/week), acupuncture therapy (once a day, 20min/ times, 5 times/week) .
62584909|NCT05475366|EXPERIMENTAL|Molecular screening for prediction of response|L1 chemotherapy regimen (FOLFIRINOX vs Gemcitabine plus nab-paclitaxel (GemnabP)) will be selected based on transcriptomic signatures applied to the pre-therapeutic biopsy of newly diagnosed PDAC patients.
62779154|NCT01900743|PLACEBO_COMPARATOR|Arm B|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
62779155|NCT06000410|EXPERIMENTAL|ASA|Participants receive a single IA injection of 2 mL of ASA (plus 2 mL of normal saline)
62779156|NCT06000410|PLACEBO_COMPARATOR|Placebo|Participants receive a single IA injection of 4 mL of normal saline
62779157|NCT01640899|OTHER|Single-arm study|This is a single-arm study. Just one group (i.e. the patients)
62003602|NCT05176093|ACTIVE_COMPARATOR|Engensis|Active Comparator: Engensis 64 mg Engensis per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
62189162|NCT06153992|ACTIVE_COMPARATOR|Traditional isokinetic treatment group|The treatment machine adopts the traditional isokinetic training machine, the treatment items and the treatment parameters are the same as the intelligent isokinetic treatment group.
62779158|NCT05321251|EXPERIMENTAL|Topical insulin|Topical insulin (Humulin R) will be compounded under sterile conditions at a local pharmacy at a concentration of 25 IU / ml in sterile balanced saline solution (0.9%). Topical insulin will be administered four times per day to the affected eye. A bottle of topical insulin can be used for 14 days. Any remaining topical insulin will be discarded as waste after 14 days.
62779159|NCT05321251|ACTIVE_COMPARATOR|Tarsorrhaphy|Patients in this group will receive a temporary, central tarsorrhaphy and will not use additional eye drops.
62779160|NCT01217372|EXPERIMENTAL|Lemon supplementation YES|60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
62571611|NCT06295874|ACTIVE_COMPARATOR|Intervention Group|After obtaining written and verbal permission from the families of the patients in the intervention group by signing the Informed Volunteer Consent Form, the patients were filled out the Patient Introduction Form, Patient Monitoring Form and Medication Monitoring Form by the nurses. The massage process, which was performed according to the application protocol of the aroma oil prepared for the patients (5 drops of lavender oil, 4 drops of thyme oil, 3 drops of eucalyptus oil and 20 ml of almond oil in 20 ml), was performed by the researcher by stroking the patient's back and chest, effleurage, re-effleurage, back massage. Deep caressing and stroking on the dorsal surface were performed in 6 consecutive steps.
62779161|NCT01217372|NO_INTERVENTION|Lemon supplementation NO|No lemon supplementation
62779162|NCT02253485||telbivudine treated entire pregnancy|mothers in this group were treated with antiviral therapy during entire pregnancy for hepatitis, and their infants receive standard immunoprophylaxis for preventing MTCT of HBV.
62779163|NCT02253485||telbivudine treated in late pregnancy|mothers with high serum HBV DNA load were treated with antiviral therapy in late pregnancy, and their infants receive standard immunoprophylaxis for preventing MTCT of HBV.
62003603|NCT05176093|PLACEBO_COMPARATOR|Placebo|Placebo Comparator: Placebo 32 mL of Placebo per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
62003604|NCT04284696|ACTIVE_COMPARATOR|Verum|"patients with emesis gravidarum who take a chewing gum with vitamin C (verum) ad libitum several times daily for 2 weeks"
62003605|NCT04284696|PLACEBO_COMPARATOR|Placebo|"patients with emesis gravidarum who take chewing gum without vitamin C (placebo) ad libitum several times daily for 2 weeks"
62779164|NCT02253485||HBV DNA positive control|infants in this group born to mother with high serum HBV DNA load and receive standard immunoprophylaxis or additional HBIG injection at 1 month after birth for preventing MTCT of HBV.
62779165|NCT02253485||HBV DNA negative control|infants in this group born to a HBsAg positive and serum HBV DNA negative mothers and receive standard immunoprophylaxis for preventing MTCT of HBV
62779166|NCT04390841|EXPERIMENTAL|Single Arm ( Qubic Stim Cardiac Stimulator )|There is only one Arm in this trial, the subjects who meet the inclusion and exclusion criteria will receive the intracardiac electrophysiological examination, during which the subjects will be subject to diagnostic electrical stimulation by the Qubic Stim Cardiac Stimulator. The subjects will also receive the clinical follow-up visit after cardiac electrical stimulation until they are discharged from the hospital.
62779167|NCT00868036||Patch testing|Patch testing on patients with chronic idiopathic dermatitis.
62003606|NCT04284696|NO_INTERVENTION|Nihil|patients with emesis gravidarum who do not use chewing gum during the study phase
62779168|NCT01083589|EXPERIMENTAL|Imatinib Mesylate + Docetaxel|Imatinib Mesylate (Gleevec) Oral 400 mg daily + Docetaxel (Taxotere) 60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
62779169|NCT02034851||Dexamethasone|Intervention group
62779170|NCT02034851||Control|Placebo group (physiological saline)
62779171|NCT02191813|EXPERIMENTAL|Seresis®|
62003607|NCT02263638|EXPERIMENTAL|Anakinra|One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time by a nurse during a five day period
62189163|NCT06153992|EXPERIMENTAL|Intelligent isokinetic treatment group|"In the intelligent isokinetic treatment group, isokinetic muscle strength training of hemiplegic lower limb flexion muscle group and knee extension muscle group was added to the treatment of the control group.~Intelligent isokinetic treatment to increase the above treatment hemiplegic lower limb flexion, knee extension muscle isokinetic strength training. The patient's seat back was adjusted to 85° and fixed with a belt and shoulder cross-strap. The thigh of the subject was fixed with a nylon buckle, the lateral condyle of the femur was the axis, the lever arm length was scale 12, and the distal leg was fixed above the ankle. Passive joint activities were performed on the knee and ankle before training. Avoid joint damage and perform three low-resistance warm-up exercises. Choose 60°/s, 90°/s, 120°/s angular speed isokinetic training according to the patient's specific conditions. Each angular speed training is 10 times, the interval rest is 15s.ect."
62189164|NCT01495910|EXPERIMENTAL|Abiraterone acetate|Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
62189165|NCT04785768|EXPERIMENTAL|PCA with continuous + bolus dose|（1）Intravenous PCA with hydromorphone after successful titration of 24 hours;（2）PCA hydromorphone with continuous infusion where dose/h was the total equianalgesic over the previous 24h divided by 24 and bolus dosage for breakthrough pain was 10%-20% of the total equianalgesic over the previous 24h；lockout time = 10 minutes；（3）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day; (4)The treatment regimen was continued for 7 days.
62189166|NCT04785768|EXPERIMENTAL|PCA with bolus-only dose|（1）Intravenous PCA with hydromorphone after successful titration of 24 hours; (2)PCA hydromorphone with bolus-only where dosage was 10%-20% of the total equianalgesic over the previous 24h administrated as needed;（3）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day; (4)The treatment regimen was continued for 7 days.
62189167|NCT04785768|ACTIVE_COMPARATOR|Oral opioid|（1）Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours；(2)Oral sustained-released morphine where total equianalgesic over the previous 24h/2×75% every 12h/day and immediate-release morphine for breakthrough pain was 10%-20% of the total equianalgesic over the previous 24h； (3)Evaluate every 24 hours and the dose for the next day is adjusted according to the dose of the previous day；(4)The treatment regimen was continued for 7 days.
62189168|NCT06212089|EXPERIMENTAL|TR-012001|Single dose of TR-012001
62189169|NCT06212089|OTHER|Placebo|Single dose of placebo
62189170|NCT05015725||Treated hypothyroidism|Patients with treated hypothyroidism
62189171|NCT00728000|EXPERIMENTAL|chemotherapy regimen|Gemcitabine and oxaliplatin are given intravenously (into the vein) every 2 weeks. Erlotinib is a pill that is taken by mouth daily.
62189172|NCT03562429|EXPERIMENTAL|TGF group (study group)|Use TGF to treat osteoarthritis of the knee, 5g/time, 3 times a day, for 12 weeks.
62396337|NCT03799198|EXPERIMENTAL|WMP + Rx|Participants will receive Cleveland Clinic's Integrated Medical WMP with medication for chronic weight management (Rx) for approximately one year. After discussing with the study doctor, participants will receive one of the following listed 5 drugs approved by the Food and Drug Administration (FDA) for long-term weight loss: 1) orlistat, 2) lorcaserin or lorcaserin extended-release, 3) phentermine/topiramate extended-release, 4) naltrexone/bupropion extended-release and 5) liraglutide 3.0 mg.
62396338|NCT03799198|ACTIVE_COMPARATOR|WMP alone|Participants will receive Cleveland Clinic's Integrated Medical WMP alone for approximately one year.
62779172|NCT02191813|PLACEBO_COMPARATOR|Placebo|
62396339|NCT05954559|EXPERIMENTAL|0.05 mmol/kg Elucirem|a group that receives 0.05 mmol/kg Elucirem
62396340|NCT05954559|EXPERIMENTAL|0.075 mmol/kg Elucirem|A group that receives 0.075 mmol/kg Elucirem
62396341|NCT06219499|PLACEBO_COMPARATOR|Placebo|
62396342|NCT06219499|EXPERIMENTAL|ONC-841|
62396343|NCT02452320|PLACEBO_COMPARATOR|Control|Subjects randomized into the control group will not receive study medication, they will receive a placebo administered at the same schedule as the active drug in the other arm.
62396344|NCT02452320|ACTIVE_COMPARATOR|Randomized|Subjects randomized into the active treatment group will receive intravenous acetaminophen
62396345|NCT05687149||Fanconi anemia|A prospective cohort of individuals with Fanconi anemia (FA) at very high risk of squamous cell carcinoma (SCC)
62396346|NCT05017116|EXPERIMENTAL|Part A，single dose group|Subjects will receive single dose RBD1016/placebo on D1 combined with antiviral drugs during the study period.
62779173|NCT04499989|EXPERIMENTAL|INH|3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.
62779174|NCT04499989|PLACEBO_COMPARATOR|Placebo Comparator|3 vaginal tablet of Placebo Comparator self-inserted by the patient 12 hours before IUD insertion.
62779175|NCT03270891|ACTIVE_COMPARATOR|Delayed intervention (control arm)|Patients in this arm will have PGx test results made available to physicians 3 months after study enrollment
62396347|NCT05017116|EXPERIMENTAL|Part B, multiple dose group|Subjects will receive two doses of RBD1016/placebo on D1 and D29 combined with antiviral drugs during the study period.
62003608|NCT05709821|EXPERIMENTAL|Phase 1 IMM60 dose escalation safety arm|3 dose levels of IMM60 will be assessed (1, 3, 9 and 36 mg/m\^2 administered IV every 3 weeks for up to 6 cycles)
62003609|NCT05709821|EXPERIMENTAL|Phase 1 IMM60 + pembrolizumab combination safety arm|Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles will be administered in combination with IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the IMM60 dose escalation safety cohort.
62003610|NCT05709821|EXPERIMENTAL|Phase 2 PD-L1 ≥50% NSCLC Cohort 1 (Randomized, IMM60 + pembrolizumab)|Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles will be administered in combination with IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation safety cohorts.
62003611|NCT05709821|ACTIVE_COMPARATOR|Phase 2 PD-L1 ≥50% NSCLC Cohort 1 (Randomized, pembrolizumab monotherapy)|Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles.
62003612|NCT05709821|EXPERIMENTAL|Phase 2 PD-L1 <1% NSCLC Cohort 2|Participants will be treated with one cycle of IMM60 with a tumor biopsy before and after, to determine any changes in PD-L1 expression. After this one cycle, the participants will receive the combination of IMM60 IV for up to 6 total cycles + pembrolizumab 200 mg every 3 weeks administered IV. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation cohorts.
62003613|NCT05709821|EXPERIMENTAL|Melanoma Cohort|IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation cohorts.
62003614|NCT02665975|EXPERIMENTAL|Experimental group: iCBT|CBT-based internet-intervention for tinnitus The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
62003615|NCT02665975|ACTIVE_COMPARATOR|Face-to-face clinical tinnitus care|Receive individual face-to-face tinnitus care, and follow-up appointments as required.
62003616|NCT03621137||Patients with moderate-to-severe atopic eczema|Adult and pediatric patients that start treatment with phototherapy or systemic immunomodulating therapy for their atopic eczema
62003617|NCT02307552|EXPERIMENTAL|All patients|All patients in the study will receive a scan of their prostate with the novel UreScan machine. All scans will be evaluated in their accuracy of detecting cancer loci within the prostate as compared to histopathological reviews of the prostate post robotic prostatectomy.
62003618|NCT00792610|EXPERIMENTAL|Hepatitis B booster|They receive 3 doses of hepatitis B vaccine (Engerix-B Injection, recombinant HBsAg, 20mcg/ml/vial, GSK) at 0, 1st, 6th month during follow-up. Their anti-HBs status were checked at baseline, one week, one month, sixth month, and seven months later after the first dose of hepatitis B vaccine.
62003619|NCT03275558|ACTIVE_COMPARATOR|Axitinib|A single dose of Axitinib - 1 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
62003620|NCT03275558|ACTIVE_COMPARATOR|Sunitinib|A single dose of Sunitinib- 5 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
62003621|NCT03275558|ACTIVE_COMPARATOR|Pazopanib|A single dose of Pazopanib-5 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
62003622|NCT01008111|ACTIVE_COMPARATOR|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
62003623|NCT01008111|PLACEBO_COMPARATOR|Dermabond-Placebo Comparator|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
62779176|NCT03270891|EXPERIMENTAL|PGx Test|Patients in this arm will have PGx test results made available to physicians as soon available after enrollment.
62003624|NCT03128697|EXPERIMENTAL|Satiating diet-Low satiety phenotype|Low satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.
62003625|NCT03128697|EXPERIMENTAL|Satiating diet-High satiety phenotype|High satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.
62003626|NCT03128697|ACTIVE_COMPARATOR|Control diet-Low satiety phenotype|Low satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.
62003627|NCT03128697|ACTIVE_COMPARATOR|Control diet-High satiety phenotype|High satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.
62779177|NCT04477655|ACTIVE_COMPARATOR|Standard oxygen therapy|Oxygen therapy through high flow nasal cannula (HFNC). Continuous monitoring of vital signs. Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%. Prone positioning will be allowed as a rescue therapy.
62779178|NCT04477655|EXPERIMENTAL|Awake prone positioning|Oxygen therapy through high flow nasal cannula (HFNC). Patients will be asked to remain in prone position throughout the day as long as possible, with breaks according to tolerance. Pillows will be offered for maximizing comfort at chest, pelvis and knees. Monitoring of vital signs will not be suspended. Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%.
62189173|NCT03562429|PLACEBO_COMPARATOR|TGFP group (placebo group)|Use TGFP to treat osteoarthritis of the knee, 5g/time, 3 times a day, for 12 weeks.
62571612|NCT06295874|PLACEBO_COMPARATOR|Placebo Control Group|After obtaining written and verbal approval from the families of the patients included in the placebo control group by signing the Informed Volunteer Consent Form, the patients were filled out the Patient Introduction Form, Patient Monitoring Form and Medication Monitoring Form by the nurses. According to the oil application protocol, the massage with almond oil was performed by the researcher in 6 consecutive steps by stroking the patient's back and chest, effleurage, re-effleurage, deep stroking of the back and stroking the back surface.
62779179|NCT01779635|ACTIVE_COMPARATOR|oXiris as first filter|Start off the first CRRT circuit with oXiris, then cross-over to M150, then oXiris, then back to M150
62779180|NCT01779635|OTHER|M150 as first filter|Patients in M150 arm will start off with M150 as first filter for CRRT, then cross-over to oXiris after the former clots, then back to M150, then to oXiris.
62779181|NCT03977493|ACTIVE_COMPARATOR|Xeomin®|Intramuscular IncobotulinumtoxinA (Xeomin®) injection under guidance (EMG and/or sonographic monitoring), 2.5 to 40 U in each muscle (max. 5 forearm- and/or hand muscles).
62779182|NCT03977493|PLACEBO_COMPARATOR|Placebo concentrate|Intramuscular Placebo injection under guidance (EMG and/or sonographic monitoring), in each muscle (max. 5 forearm- and/or hand muscles).
62779183|NCT02883101|ACTIVE_COMPARATOR|Pulmonary rehabilitation group|"Participants randomised to the PR group will receive exercise training and regular instruction in self-management of ACT along with standard care. Patients will be enrolled into the pulmonary rehabilitation programme, in the Department of Pulmonary Medicine and Sleep disorders, All India Institute of Medical Sciences.~The total duration of the programme would be 8 weeks, with thrice weekly sessions of exercise training of 1 hour duration each. Of these sessions, at least 2 will be supervised while one will be at home. The patient will be asked to maintain a personal log recording the date, time, duration and type of exercise performed to ensure compliance, and these will be regularly reviewed and monitored.~The Rehabilitation Programme will include the following:~i. Patient education ii. Exercise training iii. Ventilator and breathing exercises"
61977885|NCT03533179|EXPERIMENTAL|Esmolol-placebo+glucagon 1 (E)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+ Glukagon 1 (50 μg/kg bolus - over 1-3 min from time=0 min in 50 ml isotonic fluid)"
62003628|NCT04731844|EXPERIMENTAL|Prostate Cancer|Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
62003629|NCT04731844|EXPERIMENTAL|Smoldering Multiple Myeloma (SMM)|Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
62003630|NCT04731844|EXPERIMENTAL|Monoclonal Gammopathy of Unknown Significance (MGUS)|Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
62003631|NCT05770466|EXPERIMENTAL|Experimental group|Treated with P1101 (Ropeginterferon alfa-2b) plus standard of care (SOC)
62003632|NCT05770466|ACTIVE_COMPARATOR|Control group|Treated with SOC alone
62003633|NCT02036099|EXPERIMENTAL|Intervention|Participants in this arm will assess patients using the Driving in Mild Dementia Decision Tool.
62003634|NCT02036099|NO_INTERVENTION|Control|Participants in this arm will assess patients using their usual care strategies.
62189174|NCT05260593|EXPERIMENTAL|Group A (Vit. B12 Phonophoresis group)|Patients in group (A) will receive phonophoresis with Vitamin B12. Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of vitamin B12 gel will be applied over the wrist. The following parameters will be used: intensity of 1.0 W/cm2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the vitamin B12 gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
62571613|NCT01540201|ACTIVE_COMPARATOR|1:2 group|conventional I:E ratio group, inspiratory time : expiratory time = 1:1
62571614|NCT01540201|EXPERIMENTAL|1:1 group|inspiratory time : expiratory time = 1:1
62571615|NCT02761772||PEP-A|See detailed description
62779184|NCT02883101|NO_INTERVENTION|Standard care group|"Candidates randomized to the standard care group will receive standard care for bronchiectasis according to current guidelines. These participants will receive instruction and review of airway clearance therapy (ACT). Each participant will be provided with written information about bronchiectasis and education regarding self-management of the condition. Participants who have not been previously instructed in any ACT will be taught the active cycle of breathing technique. These participants will not receive any supervised exercise training."
62003635|NCT02409862|EXPERIMENTAL|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
62003636|NCT02409862|PLACEBO_COMPARATOR|Placebo spray|This group will receive the single dose of 24 IU saline, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
62003637|NCT04574947|ACTIVE_COMPARATOR|Intravenous lidocaine|
62189175|NCT05260593|PLACEBO_COMPARATOR|Group B (Placebo-Phonophoresis with Vitamin B12)|Patients in group (A) will receive placebo phonophoresis with Vitamin B12 gel. Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of Vitamin B12 gel will be applied over the wrist. The ultrasound probe will be held over the wrist using topical gel containing Vitamin B12 which was the same as in group A. Ultrasound device will seem to be working for 5 min period with light-off position. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
62003638|NCT04574947|EXPERIMENTAL|Topical lidocaine|
62003639|NCT04574947|PLACEBO_COMPARATOR|Placebo|
62003640|NCT00348205|EXPERIMENTAL|Technolas 217z Zyoptix System|Bausch \& Lomb Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software.
62189176|NCT03990636|EXPERIMENTAL|Metil 5-aminolevulinate arm|Metil 5-aminolevulinate arm with photo activation.
62189177|NCT03990636|PLACEBO_COMPARATOR|Placebo arm|Placebo (without metil 5-aminolevulinate) arm with photo activation.
62571616|NCT02761772||PEP-S|See detailed description
62571617|NCT04850352|EXPERIMENTAL|Heukcha Extracts|Take Heukcha Extracts capsule once daily for 8 weeks.
62571618|NCT04850352|PLACEBO_COMPARATOR|Placebo|Take placebo capsule once daily for 8 weeks.
62779185|NCT04326049|EXPERIMENTAL|LLETZ with videocolposcopy|The LLETZ procedure will be performed using a videocolposcopy
62779186|NCT04326049|ACTIVE_COMPARATOR|LLETZ with binocular colposcopy|The LLETZ procedure will be performed using a binocular colposcope
62003641|NCT04276350|EXPERIMENTAL|Acupuncture|"Acupuncture Regime:~2-3 sessions per week, each lasting an hour, over a period of 10 weeks (with deviation of 2 weeks for scheduling), total of 30 sessions"
62003642|NCT04276350|ACTIVE_COMPARATOR|Best medical therapy|"Best Medical Therapy Regime:~3 sessions to be completed over a period of 10 weeks (with deviation of 2 weeks for scheduling), with subjects learning and practicing biofeedback exercises daily"
62003643|NCT02088658|EXPERIMENTAL|Techonology Intensified|Subjects randomized to this group will receive: 1) the FORA system for self-monitoring; 2) weekly telephone-delivered diabetes education/skills training; 3) patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions); and 4) patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools). The intervention will be delivered by telephone once a week for 12 weeks with each session lasting \~30 minutes.
62189178|NCT03297476||high-risk group|"Selected by High-risk subtype detection panels"
62189179|NCT03297476||non high-risk group|"Selected by High-risk subtype detection panels"
62189180|NCT00959010|EXPERIMENTAL|Omega 3 Premium|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA
62189181|NCT00959010|PLACEBO_COMPARATOR|Placebo|capsules containing middle chain triglycerides
62189182|NCT00755417|EXPERIMENTAL|G-ER 1200 mg|Gabapentin extended-release (G-ER) 1200 mg
62189183|NCT00755417|EXPERIMENTAL|G-ER 1800 mg|Gabapentin extended-release (G-ER) 1800 mg
62189184|NCT00755417|PLACEBO_COMPARATOR|Sugar Pill|Placebo 1200 mg or 1800 mg
62189185|NCT03648528|EXPERIMENTAL|cholecaciferol|one 5000 IU tablet of 25VD taken during dialysis (3 pills per week) for a period of 12 weeks
62189186|NCT03648528|PLACEBO_COMPARATOR|placebo|one tablet of placebo taken during dialysis (3 pills per week) for a period of 12 weeks
62189187|NCT06486142|ACTIVE_COMPARATOR|Afatinib/Dacomitinib|
62189188|NCT06486142|ACTIVE_COMPARATOR|Osimertinib|
62189189|NCT03956693|EXPERIMENTAL|HEADS: UP|HEADS: UP is group-based mindfulness intervention based on the original mindfulness based stress reduction course, but adapted for people affected by stroke.
62189190|NCT00196391|EXPERIMENTAL|1|
62189191|NCT00196391|EXPERIMENTAL|2|
62189192|NCT00196391|EXPERIMENTAL|3|
62189193|NCT00196391|EXPERIMENTAL|4|
62189194|NCT00196391|EXPERIMENTAL|5|
62189195|NCT00196391|PLACEBO_COMPARATOR|6|
62571619|NCT02408835|ACTIVE_COMPARATOR|PICO™|Use of PICO™ system negative pressure wound therapy device on surgical wound for up to seven days.
62571620|NCT02408835|NO_INTERVENTION|Conventional wound care|Usual wound dressings will be used as comparison group.
62571621|NCT02687061||Chronic hepatitis B|Patients diagnosed with chronic hepatitis B
62571622|NCT02687061||Chronic hepatitis C|Patients diagnosed with chronic hepatitis C
62189196|NCT03299777||Control group|A control group will consist 100 normotensive women with normal pregnancy outcomes who were admitted to our fetal-maternal unit during the same period
62189197|NCT03299777||Preeclampsia group|All patients diagnosed with preeclampsia will undergo the fibroscan test.
62003644|NCT02088658|NO_INTERVENTION|Usual Care|Apart from study visits, patients will be followed by their primary care providers. The provider will be responsible for determining treatment parameters, making changes in the treatment regimen, and determining the timing of follow up visits. Between scheduled office encounters, contact between patient and provider will be patient initiated. The provider may use clinic nurses to follow up on problematic patients or patients with abnormal results. In essence, this group will receive the current standard of care at the study clinics.
62003645|NCT01971138||Surgical site infection registration|Is there a routine for SSI registration
62003646|NCT03012854|EXPERIMENTAL|short-myotomy|Short-POEM for patients with esophageal achalasia
62003647|NCT03012854|ACTIVE_COMPARATOR|long-myotomy|Long-POEM for patients with esophageal achalasia
62003648|NCT03012854|EXPERIMENTAL|full-thickness myotomy|Full-thickness-POEM for patients with esophageal achalasia
62003649|NCT03012854|ACTIVE_COMPARATOR|circular myotomy|Circular-POEM for patients with esophageal achalasia
62003650|NCT06380478||aspicio Monofocal IOL|A bi-aspheric monofocal IOL is implanted through preloaded IOL Delivery System in the capsular bag in the posterior chamber of the eye during cataract surgery
62003651|NCT01640730|EXPERIMENTAL|Kanglaite injection|
62003652|NCT04911725|EXPERIMENTAL|With device use|Volunteers included will use IMD during one of the two periods of the study.
62003653|NCT04911725|NO_INTERVENTION|Without device use|Volunteers included will not use IMD during the other period of the study (reverse of experimental)
62003654|NCT02277496|EXPERIMENTAL|HC toolkit intervention students|HC students will receiveeExperimental wellness education via a toolkit approach to address the 2010 Dietary Guidelines for reducing obesity in youth. The specific recommendations include: 1) reducing intake of sugary beverages, 2) increasing intake of fruits and vegetables, 3) increasing frequency of eating breakfast, 4) decreasing fast and junk food choices, 5) increasing physical activity to 1 hour/day, and 6) decreasing screen time to 2 hours per day.
62003655|NCT02277496|NO_INTERVENTION|Comparison Schools|During the 2014-2015 school year, control schools were utilized to compare outcomes.
62003656|NCT02559388|ACTIVE_COMPARATOR|montelukast|montelukast 10 milligram, daily for 30 days
62189198|NCT04443959|EXPERIMENTAL|PUMAS Treatment|Prenatal insomnia program that places behavioral sleep strategies within a mindfulness-based intervention framework that is geared toward pregnant women.
62189199|NCT02731911||Ozurdex® (dexamethasone intravitreal implant)|Patients who received Ozurdex® in the treatment of Diabetic Macular Oedema per local standard of care in clinical practice.
62189200|NCT02926924|ACTIVE_COMPARATOR|Wound Vac|Wound vac
62189201|NCT02926924|ACTIVE_COMPARATOR|Standard Dressing|Standard Dressing
62003657|NCT02559388|PLACEBO_COMPARATOR|placebo|Placebo one tablet for 30 days
62003658|NCT02295748|EXPERIMENTAL|Deflazacort|0.9 mg/kg oral deflazacort (between 2 to 12 x 6mg tablets based on body weight) will be administered daily.
62003659|NCT04242056|OTHER|Using image to diagnosis Multiple sclerosis (MS)|In current study, we will enroll 38 patients with MS and evaluate their clinical severity; measure the WM lesion and disease activity by magnetic resonance imaging (MRI); myelination state and amyloid deposition by amyloid PET scan; tau deposition by state of-art tau PET scan
62003660|NCT05980780|NO_INTERVENTION|The control group|no intervention
62003661|NCT05980780|EXPERIMENTAL|video game group|Children in this group will play a video game for disease management
62003662|NCT05980780|EXPERIMENTAL|Education booklet group|Children in this group will read an educational booklet for disease management.
62003663|NCT02652975|EXPERIMENTAL|Category 1|Examination of participants prior to chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
62189202|NCT03546816|EXPERIMENTAL|5 mg Serlopitant Tablets|
62189203|NCT03546816|PLACEBO_COMPARATOR|Matching Placebo Tablets|
62189204|NCT00368641|EXPERIMENTAL|Intervention|peritoneal dialysis
62189205|NCT00368641|NO_INTERVENTION|Standard of Care|
62189206|NCT01089296|OTHER|Individually customized physiotherapy|The intervention involves handling the infant and changing its position. It focuses on improving symmetry, muscle balance and movement in infants. The parent who is with the infant during the admission period will carry out the daily intervention after being taught by the physiotherapist.
62189207|NCT01089296|NO_INTERVENTION|Control|Ordinary follow up in the Neonatal Intensive Care Unit (NICU).
62189208|NCT05995652||ESWL sucess and failed gps|post ESWL 50 pt large gp will be devided into sucess gp and failed gp
62003664|NCT02652975|EXPERIMENTAL|Category 2|Examination of participants immediately after chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
62003665|NCT02652975|EXPERIMENTAL|Category 3|Examination of participants one year after chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
62003666|NCT05151939||Patients with normal mediastinal and abdominal organ/anatomic strictures|Adult patients with normal mediastinal and abdominal organ/anatomic strictures after imaging test and EUS assessment due to chronic dyspepsia.
62003667|NCT05028374|OTHER|"A single booster dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly"|The dose of Moderna mRNA vaccine to be administered is the same for all patients in all enrollment cohorts: 0.5 mL administered intramuscularly as a single dose, according to the manufacturer's package insert.
62003668|NCT04164147|ACTIVE_COMPARATOR|NexGen|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet NexGen prosthesis
62003669|NCT04164147|ACTIVE_COMPARATOR|Persona MC Retained PCL|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet Persona MC Retained PCL prosthesis
62003670|NCT04164147|ACTIVE_COMPARATOR|Persona MC Sacrificed PCL|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet Persona MC Sacrificed PCL prosthesis
62003671|NCT05068973|EXPERIMENTAL|Luciola|Bronchoscopic implantation of the fiducial marker NOVATECH® LUCIOLA™ EB prior to radiotherapy treatment.
62003672|NCT05112393||Development Cohort|Half of the data will be randomized into development cohort by using a random number generated in Microsoft Excel. This cohort aim to develop a new estimating Glomerular Filtration Rate (eGFR) equation that produce accurate eGFR specifically in Malaysian multiracial population.
62003673|NCT05112393||Validation Cohort|Half of the data will be randomized into development cohort by using a random number generated in Microsoft Excel. This cohort aim to validate the newly developed estimating Glomerular Filtration Rate (eGFR) equation.
62003674|NCT04707534|EXPERIMENTAL|Dexamethasone 20 mg|Dexamethasone 20 mg daily for 5 days, followed by dexamethasone 10 mg daily for 5 days
62189209|NCT04606147|EXPERIMENTAL|Group 1 ((Serratus Anterior Plane Block SAPB)) N=3o|Patients received Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml levobupivacaine 0.25%. Then patients were transferred to the operating room.
62189210|NCT04606147|EXPERIMENTAL|Group 2 ((Erector Spinae Plane Block ESPB)) N=3o|Patients received Ultrasound guided erector spinae plane block with injection of 30 ml levobupivacaine 0.25%. Then patients were transferred to the operating room.
62189211|NCT03330613|OTHER|Inhalational anesthesia|Inhalational anesthesia is an anesthesia procedure using by respiratory tract. PAEDS used to for postanesthesia pediatric patients.
62189212|NCT03330613|ACTIVE_COMPARATOR|Total intravenous anesthesia|Total intravenous anesthesia (TIVA) is an anesthesia procedure using vascular infusion method.PAEDS used to for postanesthesia pediatric patients.
62779187|NCT01123707|EXPERIMENTAL|Prior Aripiprazole/Escitalopram Combination Therapy|Aripiprazole capsules, orally at the daily dose of 3, 6, or 12 mg, in combination with escitalopram 10 or 20 mg orally, once daily in combination with escitalopram 10 or 20 mg (i.e., the final dose taken during the previous study), orally, once daily, for 36 weeks. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 1 if the initial 6 mg/day dose was tolerated. The dose adjustments were allowed for aripiprazole to establish the maximum tolerated dose (MTD) by Week 4. Participants who received aripiprazole/escitalopram combination therapy in the double-blind treatment period in previous studies were included in this group.
62003675|NCT04707534|ACTIVE_COMPARATOR|Dexamethasone 6 mg|Dexamethasone 6 mg daily for 10 days
62003676|NCT02733978|EXPERIMENTAL|ozone treated group|Therapeutic effects will be graded into 4 levels from grade 0 (no change) to grade 3 (wound healing). The wound sizes will be measured at baseline and day 20, respectively. Tissue biopsies will be performed at baseline and day 20, expressions of VEGF, ETAR and AT1R autoantibodies proteins will be determined by immune-histochemical examinations
62003677|NCT02733978|NO_INTERVENTION|non-ozone treated group|Therapeutic effects will be graded into 4 levels from grade 0 (no change) to grade 3 (wound healing). The wound sizes will be measured at baseline and day 20, respectively. Tissue biopsies will be performed at baseline and day 20, expressions of VEGF, ETAR and AT1R autoantibodies proteins will be determined by immune-histochemical examinations
62003678|NCT05539235|EXPERIMENTAL|2 week group|Drug injection adjustment interval is 2 weeks
62189213|NCT03835962|EXPERIMENTAL|Intervention Arm|All participants will be asked to attend one experimental session. During the session, participants will listen one auditory stimulus sequence including sounds and words while EEG activity is recorded using the NeuroCatch Platform™ device.
62189214|NCT01013688|EXPERIMENTAL|left atrial RF ablation groups|Excised the left atrial appendage Encircling the left pulmonary veins and an extension to the posterior mitral valve annulus From the left atrial appendage to the left superior pulmonary vein A connecting line between both islands of pulmonary veins From the middle of the mitral valve ablation line down towards the base of the atria ligament of Marshall
62779188|NCT01123707|EXPERIMENTAL|Prior Escitalopram|Aripiprazole capsules, orally at the daily dose of 3, 6, or 12 mg, in combination with escitalopram 10 or 20 mg orally, once daily in combination with escitalopram 10 or 20 mg (i.e., the final dose taken during the previous study), orally, once daily, for 36 weeks. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 1 if the initial 6 mg/day dose was tolerated. The dose adjustments were allowed for aripiprazole to establish the MTD by Week 4. Participants who received escitalopram in the double-blind treatment period in previous studies were included in this group.
62003679|NCT05539235|EXPERIMENTAL|4 week group|Drug injection adjustment interval is 4 weeks
62003680|NCT00140075|EXPERIMENTAL|B|"ET (8 cycles)~T = docetaxel or paclitaxel"
62003681|NCT00140075|EXPERIMENTAL|A|"EC (4 cycles) followed by T (4 cycles) for a total of 8 cycles~T = docetaxel or paclitaxel"
62003682|NCT01228968||Volunteers|Volunteers will have a range of body mass index from 19 - 45 kilogram per square meter. In order to fit in the magnetic resonance scanner subjects must weigh less than 300 pounds.
62779189|NCT01123707|EXPERIMENTAL|Prior Aripiprazole|Aripiprazole capsules, orally at the daily dose of 3, 6, or 12 mg, in combination with escitalopram 10 or 20 mg orally, once daily in combination with escitalopram 10 or 20 mg (i.e., the final dose taken during the previous study), orally, once daily, for 36 weeks. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 1 if the initial 6 mg/day dose was tolerated. The dose adjustments were allowed for aripiprazole to establish the MTD by Week 4. Participants who received aripiprazole in the double-blind treatment period in previous studies were included in this group.
62003683|NCT05444309|ACTIVE_COMPARATOR|Quadratus lumborum block group|"The child will be positioned in the lateral position, with the operative side non-dependent. Under complete aseptic precautions, QL block will be given by anterior approach at the level of L4. A linear high-frequency probe of Sonosite M Turbo ultrasonography will be applied vertically above the iliac crest, and a 22G, 80 mm spinal needle will be inserted in the plane from the posterior edge of the probe through the QL muscle in an anteromedial direction. The needle tip will be placed between the Psoas major (PM) muscle and the QL muscle.~After negative aspiration, injection of 0.5 mL of normal saline to the space between PM and QL muscles .~An injection of 0.5 mg/kg of 0.25% bupivacaine into the fascial plane and the local anesthetic appears to press down the PM muscle in the ultrasound image, the patients will be repositioned to a supine position immediately after the block."
62189215|NCT01013688|EXPERIMENTAL|Bi-atrial radiofrequency ablation group|In the basis of left atrial group,excised the right atrial appendage; from the amputated right atrial appendage towards the inferior vena cava; from the midterm of interatrial septum to the AV groove; ablation between the superior and inferior caval cannulation sites; radiofrequency ablation for Waterston's groove
62189216|NCT01013688|NO_INTERVENTION|Amiodarone group|No radiofrequency ablation procedure during the valve surgery; Amiodarone 200 mg/day for 12 months after surgery
62189217|NCT01514851|EXPERIMENTAL|Arm 1|750-2250mg/day, tid (three times a day), 8 weeks
62189218|NCT01514851|ACTIVE_COMPARATOR|Arm 2|1500-4500mg/day, tid, 8 weeks
62189219|NCT04074343|EXPERIMENTAL|TAS-102 and Irinotecan|Patients receive TAS-102 25 mg/m2 PO twice daily on days 1-5 and and Irinotecan 180mg/m2 IV on day 1 every 14 days.
62189220|NCT00004146|EXPERIMENTAL|Treatment (RT and CAI)|"Patients receive induction therapy consisting of radiotherapy once daily 5 days a week plus oral carboxyamidotriazole once daily for 6 weeks followed by carboxyamidotriazole alone daily for 4 weeks. Patients continue on oral carboxyamidotriazole once daily as maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for survival.~Other: pharmacological study, radiation therapy"
62189221|NCT00947232|EXPERIMENTAL|Motivational interviewing|Motivational interviewing for people aging with multiple sclerosis or spinal cord injury to increase physical activity and decrease depression.
62189222|NCT00947232|ACTIVE_COMPARATOR|Education|Education about physical activity for people aging with multiple sclerosis or spinal cord injury to decrease depression.
62189223|NCT01192789|OTHER|Intervention|Severe Pneumonia Treatment by LHWs with Amoxicillin at 90mg/kg/day for severe pneumonia
62189224|NCT01192789|OTHER|Control|LHWs refer the severe pneumonia case to local health facility or private practitioner.
62189225|NCT00919945|EXPERIMENTAL|1|The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed. Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms. Patients in arm 1 will receive continuous nasogastric formula feeding at time 1 and NPO at time 2 (12 hours later).
62779190|NCT01123707|EXPERIMENTAL|Prior Single-blind Escitalopram|Aripiprazole capsules, orally at the daily dose of 3, 6, or 12 mg, in combination with escitalopram 10 or 20 mg orally, once daily in combination with escitalopram 10 or 20 mg (i.e., the final dose taken during the previous study), orally, once daily, for 36 weeks. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 1 if the initial 6 mg/day dose was tolerated. The dose adjustments were allowed for aripiprazole to establish the MTD by Week 4. Participants who received escitalopram in the single-blind treatment period in previous studies were included in this group.
62571623|NCT00891020|EXPERIMENTAL|Tocilizumab 8 mg/kg Monotherapy|Participants received Tocilizumab 8 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions for 24 weeks. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
62189226|NCT00919945|EXPERIMENTAL|2|The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed. Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms. Patients in arm 2 will receive NPO at time 1 and crossover to continuous nasogastric formula feeding at time 2.
62189227|NCT02432963|EXPERIMENTAL|Treatment (p53MVA, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes followed by modified vaccinia virus Ankara vaccine expressing p53 SC at least 30 minutes later once in weeks 1, 4, and 7. Patients may receive additional doses of pembrolizumab in weeks 10, 13, 16, and 19, for a maximum of 7 doses if there are no signs of progressive disease. Treatment continues in the absence of disease progression or unacceptable toxicity.
62571624|NCT00891020|EXPERIMENTAL|Tocilizumab 4 mg/kg + DMARD|Participants received Tocilizumab (TCZ) 4 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions plus non-biologic disease-modifying antirheumatic drug (DMARD) of the investigator's choice for 24 weeks. Participants not achieving a 20% improvement from baseline in tender and swollen joint counts at Week 8 were to have their dosage increased to 8 mg/kg, per protocol. Beginning at Week 12 dosage increase to 8 mg/kg was at the discretion of the investigator. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
62779191|NCT06583746||Lower extremity evaluation of children with DCP within the framework of ICF|30 children with DCP were included. The lower extremity evaluations of these cases were made according to ICF. Modified Ashworth Scale (MAS) was used for body structure and functions, Gillette Functional Assessment Questionnaire (FAQ) was used for activity and Pediatric Functional Independence Measure (WeeFIM) was used for participation.
62779192|NCT05397639|EXPERIMENTAL|Low Dose Masupirdine Arm|Tablet
62779193|NCT05397639|EXPERIMENTAL|High Dose Masupirdine Arm|Tablet
62779194|NCT05397639|PLACEBO_COMPARATOR|Placebo|Tablet
62779195|NCT02202538|EXPERIMENTAL|Indego|Indego
62779196|NCT01351155|ACTIVE_COMPARATOR|polyurethane foam (Allewyn adesive)|Polyurethane foam is applied as skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
62779197|NCT01351155|ACTIVE_COMPARATOR|polyurethane film (Tegaderm)|The polyurethane film is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
62779198|NCT01351155|ACTIVE_COMPARATOR|Hydrocolloid (Duoderm)|Hydrocolloid is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
62779199|NCT01351155|NO_INTERVENTION|Control|In this no-intervention arm, any skin protective dressing devices is applied before NIV starting
62779200|NCT04787055|EXPERIMENTAL|Receiver in the canal hearing instrument 3 month|Group of subjects who will get the receiver in the canal hearing instrument and wear for period of three months.
62779201|NCT04787055|EXPERIMENTAL|Receiver in the canal hearing instrument 6 month|Group of subjects who will get the receiver in the canal hearing instrument and wear for period of six months.
62779202|NCT03312426|EXPERIMENTAL|BMS-986205 under fasted conditions then with high-fat meal.|Single, 100 mg dose of BMS-986205 under fasted conditions (Day 1) followed by single, 100 mg dose of BMS-986205 with a high-fat meal (Day 15).
62779203|NCT03312426|EXPERIMENTAL|BMS-986205 with high-fat meal then under fasted conditions.|Single, 100 mg dose of BMS-986205 with a high-fat meal (Day 1) followed by single, 100 mg dose of BMS-986205 under fasted conditions (Day 15).
62779204|NCT03312426|EXPERIMENTAL|BMS-986205 under fasted conditions then with light meal.|Single, 100 mg dose of BMS-986205 under fasted conditions (Day 1) followed by single, 100 mg dose of BMS-986205 with a light meal (Day 15).
62779205|NCT03312426|EXPERIMENTAL|BMS-986205 with light meal then under fasted conditions.|Single, 100 mg dose of BMS-986205 with a light meal (Day 1) followed by single, 100 mg dose of BMS-986205 under fasted conditions (Day 15).
62779206|NCT02268994|EXPERIMENTAL|KRX-0502 (ferric citrate)|1 g of KRX-0502 (ferric citrate) containing approximately 210 mg of ferric iron
62189228|NCT01013142|EXPERIMENTAL|MN-221|
62189229|NCT01013142|PLACEBO_COMPARATOR|MN-221 Placebo|
62189230|NCT03506347|ACTIVE_COMPARATOR|Vancomycin 15mg/kg IV|Will receive 15mg/kg based on actual body weight (maximum of 2g) of vancomycin via the systemic route at a rate of 15mg/kg as per hospital guidelines. Systemic IV vancomycin is given via a forearm vein, given over an infusion timed to finish immediately prior to surgery.
62779207|NCT02268994|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62779208|NCT03669237|EXPERIMENTAL|end-to-side anastomosis|All surgeries during the study were performed by the same experienced surgical team and were performed following TME principles. End-to-side anastomosis was used to perform colorectal anastomosis after primary tumor resection.
62779209|NCT03669237|NO_INTERVENTION|end-to-end anastomosis|All surgeries during the study were performed by the same experienced surgical team and were performed following TME principles. After resection of the primary tumor, end-to-end anastomosis was used for colorectal anastomosis.
62779210|NCT06549660|PLACEBO_COMPARATOR|Placebo PBMT|Placebo PBMT will be applied twice weekly (three to four days apart) for three consecutive weeks, resulting in six treatment sessions. The placebo treatment will be applied in three zones: a) inferior to transverse process at L3-L4 left; b) intervertebral spaces between L3-L4; and c) inferior to transverse process at L3-L4 right.
62189231|NCT03506347|EXPERIMENTAL|Vancomycin 500mg Intraosseous|Will have the limb exsanguinated and an above knee tourniquet inflated to 300 mmHg. Immediately following tourniquet inflation, Group B will receive 500mg of vancomycin, via an EZ-IO intraosseous cannula. The vancomycin would be administered in 150ml of saline solution. The intraosseous cannula would be placed into the epiphysis of the proximal tibia. The tourniquet will be left inflated for 10 minutes following completion of the IORA injection then deflated.
62779211|NCT06549660|EXPERIMENTAL|Active PBMT|Active PBMT will be applied twice weekly (three to four days apart) for three consecutive weeks, resulting in six treatment sessions. The active treatment will be applied in three zones: a) inferior to transverse process at L3-L4 left; b) intervertebral spaces between L3-L4; and c) inferior to transverse process at L3-L4 right.
62779212|NCT06545591||EVT-stroke group|Patients with ischemic stroke who received endovascular thrombectomy (EVT) treatment
62779213|NCT06545591||non--EVT stroke group|The non--EVT stroke group was composed of patients with ischemic stroke without endovascular thrombectomy (EVT) treatment during the same period
62779214|NCT06545591||non--stroke control group|The non--stroke control group was composed of randomly selected stroke--free, age--matched and sex--matched individuals recruited from the health examination center.
62189232|NCT00074295|EXPERIMENTAL|treatment|GVAX lung cancer vaccine
62189233|NCT01012245||patients with glaucoma and ocular hypertension|
62189234|NCT06319157|EXPERIMENTAL|minimal access group|
62779215|NCT03752749|EXPERIMENTAL|Prednisolone + Acute Intermittent Hypoxia|
62779216|NCT03752749|PLACEBO_COMPARATOR|Placebo + Acute Intermittent Hypoxia|
62779217|NCT00169091|EXPERIMENTAL|Clozapine|Clozapine 12.5-300 mg taken orally per day for 12 weeks in the acute phase of the study and up to 130 weeks (total) in the Follow-up portion of the study.
62779218|NCT00169091|ACTIVE_COMPARATOR|Haloperidol|Haloperidol 2-12 mg taken orally per day for 12 weeks in the acute phase of the study and up to 130 weeks (total) in the Follow-up portion of the study.
62189235|NCT06319157|OTHER|conventional group|
62779219|NCT03920930|EXPERIMENTAL|Early-intraoperative Local infiltration technique|"A distal regional anaesthesia is performed in which the nerves are blocked by a local anaesthetic in the tissue in the immediate vicinity of the operating area (tissue infiltration technique). The LIA is applied in a total of 4 steps during the preparation of the knee joint: 1. after the skin incision, 2. after the capsule incision, 3. after complete exposure of the knee joint, 4. when the posterior knee capsule is reached."
62189236|NCT04962451|EXPERIMENTAL|Intervention group|
62779220|NCT03920930|ACTIVE_COMPARATOR|Late-intraoperative Local infiltration technique|"A distal regional anaesthesia is performed in which the nerves are blocked by a local anaesthetic in the tissue in the immediate vicinity of the operating area (tissue infiltration technique). The LIA is applied after the preparation of the femur and tibia bone shortly before the prosthesis is inserted and during the retreat from the knee joint."
62779221|NCT04805710|NO_INTERVENTION|clopidogrel combined with aspirin arm|Patients selected in the clopidogrel combined with aspirin arm will receive clopidogrel 75 mg once daily and aspirin 100 mg once daily.
62003684|NCT05444309|ACTIVE_COMPARATOR|Pericapsular Nerve Group (PENG) block group|"PENG block will be done while the child in supine position. Then, a high-frequency (8-15 MHz) ultrasound linear probe of Sonosite M Turbo ultrasonography (FUJIFILM Sonosite, Inc., Bothell, WA, USA) will be placed over the anterosuperior iliac spine and then rotating it 45 degrees to acquire images from lateral to medial of the anterior inferior iliac spine, iliopubic eminence, psoas tendon, and the femoral artery.~Then, a 22G, 80 mm spinal needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly.~After negative aspiration and a test does (0.5 mL of normal saline), an injection of 0.5 mg/kg of 0.25% bupivacaine into the space between the psoas tendon and the iliopubic eminence."
62779222|NCT04805710|EXPERIMENTAL|clopidogrel combined with rivaroxaban arm|Patients selected in the clopidogrel combined with rivaroxaban arm will receive clopidogrel 75 mg once daily and rivaroxaban 10 mg once daily.
62779223|NCT00924508|EXPERIMENTAL|Patch + cream, patch alone, cream alone|This is a single arm study. Each subject will have 3 target lesions; one treated with TAC 0.1% cream and hydrogel patch (occlusion), the second treated with cream alone, and the third treated with occlusion alone.
62189237|NCT04962451|PLACEBO_COMPARATOR|Placebo group|
62189238|NCT01055236|PLACEBO_COMPARATOR|hydroxyzine|
62779224|NCT01545427|EXPERIMENTAL|Gleevec|Gleevec 200 mg bid for 6 months.
62779225|NCT01545427|PLACEBO_COMPARATOR|Placebo|Placebo coated to appear identical to Gleevec.
62779226|NCT05859243|EXPERIMENTAL|Traditional concurrent training|The subjects will perform two concurrent training sessions, of approximately one hour per week. Composed of strength exercises and aerobic exercise (walking outdoors and/or treadmill).
62779227|NCT05859243|EXPERIMENTAL|Concurrent training consisting of strength training combined with dance classes|The subjects will perform two concurrent training sessions associated with dance classes, of approximately one hour per week. Composed of strength exercises and dance classes.
62779228|NCT05859243|NO_INTERVENTION|Control|Subjects will be instructed to maintain their usual routine during the study period.
62571625|NCT00891020|EXPERIMENTAL|Tocilizumab 8 mg/kg + DMARD|Participants received Tocilizumab (TCZ) 8 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions plus non-biologic disease-modifying antirheumatic drug (DMARD) of the investigator's choice for 24 weeks. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
62571626|NCT02819037|EXPERIMENTAL|Gas chromatography and stool analysis|gas chromatography and stool analysis for detection of malabsorption
62779229|NCT00829959||Genetic Counseling|Women referred to the Clinical Cancer Genetics Program for discussion of Hereditary Breast And Ovarian Syndrome (HBOC).
62779230|NCT02593825|EXPERIMENTAL|START-Play intervention|Intervention incorporating cognitive factors and focusing on self-initiated movement toward achievement of skill in sitting and reaching to increase problem-solving skills, which will then improve overall developmental outcomes. Visits to home by physical therapist twice weekly with parent training, for 3 months.
62779231|NCT02593825|ACTIVE_COMPARATOR|Business as Usual|Early motor intervention provided as standard treatment in the home for infants with motor dysfunction who are just beginning to sit. Dosage and content of intervention may vary from infant to infant and geographically.
62779232|NCT02219074|EXPERIMENTAL|Sebacia microparticle and laser treatment|
62779233|NCT02219074|SHAM_COMPARATOR|Vehicle and laser treatment|
62003685|NCT05444309|NO_INTERVENTION|control group|The child will not receive any block.
62189239|NCT01055236|PLACEBO_COMPARATOR|placebo|starch tablet
62189240|NCT01727869|EXPERIMENTAL|Cohort 1|Dosing regimen 1: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
62779234|NCT03860363||Treatment Group|Patients selected to participate.
62779235|NCT01960153|EXPERIMENTAL|Tadalafil|Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.
62571627|NCT03215290|EXPERIMENTAL|Trans-parenchymal compressing suture|"TCS: After liver transection, check for active hemorrhage and visible sites of bile leakage of cutting surface by stainless gauze which covered up on the raw cutting surface for 5 minutes. For patients with any positive findings including bloodstain and (or) bile staining, the cutting surface was recognized as not good cutting surface and further trans-parenchymal compressing sutured, if possible, using a hepatic needle."
62779236|NCT01960153|PLACEBO_COMPARATOR|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
62189241|NCT01727869|EXPERIMENTAL|Cohort 2|Dosing regimen 2: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
62779237|NCT01399866|PLACEBO_COMPARATOR|Placebo|50 mg capsule,single dose, twice, one week apart, by mouth
62003686|NCT01180738|ACTIVE_COMPARATOR|Body weight supported treadmill training|
62189242|NCT01727869|EXPERIMENTAL|Cohort 3|Dosing regimen 3: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
62189243|NCT02574962|EXPERIMENTAL|Acthar® Gel|For the first two weeks participants will receive 1 mL of study drug subcutaneously every other day. After that, participants will received 1 mL of study drug twice a week for up to 6 months.
62189244|NCT02375451||Radioiodine|Patients with a history of childhood treatment with radioiodine will be assessed for symptoms of salivary function and measurement of saliva production. These data will be compared to a normal control group.
62189245|NCT02375451||Control|Patients who are similar in age to those in the Radioiodine group, but who did not recieve I-131 therapy.
62189246|NCT01268124|EXPERIMENTAL|Treatment|
62779238|NCT01399866|ACTIVE_COMPARATOR|D-cycloserine|50 mg capsule,single dose, twice, one week apart, by mouth
62189247|NCT01435707|EXPERIMENTAL|Caudal 40 group|subjects who undergo caudal epidural block with triamcinolone 40 mg
62189248|NCT01435707|EXPERIMENTAL|STE 20 group|subjects who undergo selective transforaminal block with triamcinolone 20 mg
62189249|NCT01435707|EXPERIMENTAL|Caudal 20 mg|subjects who undergo caudal epidural block with triamcinolone 20 mg
62189250|NCT01435707|EXPERIMENTAL|STE 40 group|subjects who undergo selective transforaminal block with triamcinolone 40 mg
62189251|NCT02665585|EXPERIMENTAL|C-Guard carotid stent|Carotid stenting procedure by C-Guard stent implantation (InspireMD, Boston, MA, USA)
62189252|NCT02665585|ACTIVE_COMPARATOR|Wallstent carotid stent|Carotid stenting procedure by Wallstent implantation (BostonScientific, Marlborough, MA, USA)
62779239|NCT05580068|EXPERIMENTAL|Intervention Group|The intervention to be carried out in the treatment group is the use of the therapy measures for the treatment of arterial hypertension, which is delivered through the iATROS medical device. The therapy by means of the medical device takes place over 90 days.
62779240|NCT05580068|NO_INTERVENTION|Control Group|For the duration of the in-life phase, the treatment of the control group will follow the standard-of-care except for the measures necessary for the conduct of the study.
62779241|NCT02051634|ACTIVE_COMPARATOR|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
62189253|NCT04045847|EXPERIMENTAL|CD147-CART|CD147-CAR modified T cells, intracavity injection, 3+3 design with de-escalation in half step, every 7 days for 3 weeks
62003687|NCT01180738|ACTIVE_COMPARATOR|Overground walking training|
62003688|NCT05956769|ACTIVE_COMPARATOR|Empirical 2: TXA administration|Tranexamic acid administration, regardless of the result of TEG6.
62189254|NCT03562390|EXPERIMENTAL|Experimental group|124 women with locally recurrent or metastatic breast cancer who will receive treatment at 17 research centers in Liaoning Province and Heilongjiang Province of China. Irinotecan is administered intravenously on days 1 and 8 of each 3-week cycle.
62189255|NCT05730114||OHCA/ECMO|Patient resuscitated from Out of Hospital Cardiac Arrest from acute coronary syndrome and on VA-ECMO.
62189256|NCT05730114||OHCA/nonECMO|Patient resuscitated from Out of Hospital Cardiac Arrest from acute coronary syndrome and without VA-ECMO.
62571628|NCT03215290|NO_INTERVENTION|Exposed surface (ES)|147 Patients with exposed surface (ES) were matched as control group. No TCS.
62003689|NCT05956769|EXPERIMENTAL|Goal-directed 1: Placebo administration|Normal saline administration, according to the result of TEG6. . Placebo administration, at LY30 \< 3% or MA \> 54 mm in CRT of TEG6
62003690|NCT05956769|EXPERIMENTAL|Goal-directed 2: TXA administration|Tranexamic acid administration, according to the result of TEG6. Placebo discard, at LY30\> 3% or MA\<54 mm in CRT of TEG6
62189257|NCT05730114||nonOHCA/nonECMO|Patient with acute coronary syndrome without Out of Hospital Cardiac Arrest from acute coronary syndrome and without VA-ECMO.
62189258|NCT04176289|ACTIVE_COMPARATOR|PPI-guided pain therapy|At the end of anesthesia a PPI targeted opioid pain therapy will be performed by gradual administration of piritramid in 3 mg steps up to a PPI score ≤ 3.
62189259|NCT04176289|NO_INTERVENTION|Non-PPI-guided pain therapy|The amount of administered piritramid in the OR will be left to the discretion of the anesthesiologist attending the participant.
62189260|NCT02071680|OTHER|Iodine-123 Meta-iodobenzylguanidine|123I-mIBG administration followed by nuclear imaging pre-ablation and post-ablation
62189261|NCT01018108|OTHER|I|Patients undergo acupuncture twice weekly for 2 weeks and then once weekly for 6 weeks. Patients undergo single photon emission computed tomography imaging with iodine 123-I ADAM before and after completion of acupuncture.
62189262|NCT03376035|ACTIVE_COMPARATOR|Unilateral breast reconstruction|Temperature measurements are obtained from the reconstructed breast and compared to the non-reconstructed breast.
62571629|NCT04132323|ACTIVE_COMPARATOR|hypertonic glucose|"* to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.~* to measure the maximum diameter of telangiectasia using the Dermatoscope scale.~* to inject the 75% glucose, with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
62003691|NCT04476030|ACTIVE_COMPARATOR|Placebo + Assigned ADT|Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42.
62003692|NCT04476030|EXPERIMENTAL|SAGE-217 + Assigned ADT|Participants received SAGE-217, 50 milligrams (mg), orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42.
62003693|NCT05550012|NO_INTERVENTION|standard-dose CT|those patients undergo standard-dose liver CT in portal vein and delayed phase
62003694|NCT05550012|EXPERIMENTAL|low-dose CT|those patients undergo low-dose liver CT in portal vein and delayed phase
62189263|NCT03376035|EXPERIMENTAL|Bilateral breast reconstruction|Temperature measurements are obtained from both reconstructed breasts and the core temperature is measured as well for comparison.
62571630|NCT04132323|ACTIVE_COMPARATOR|0.05% sodium tetradecyl sulfate|"* to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.~* to measure the maximum diameter of telangiectasia using the Dermatoscope scale.~* to inject the 0.05% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
62003695|NCT02788110|OTHER|NIV NAVA then NIPPV|Infants will receive 15 minute trials of noninvasive neurally adjusted ventilatory assist (NIV NAVA) and nasal intermittent positive pressure ventilation (NIPPV) in random order with the first 10 minutes after changing to be considered a washout period and the last 5 minutes used for data collection. This group will receive NIV NAVA then NIPPV.
62003696|NCT02788110|OTHER|NIPPV then NIV NAVA|Infants will receive 15 minute trials of noninvasive neurally adjusted ventilatory assist (NIV NAVA) and nasal intermittent positive pressure ventilation (NIPPV) in random order with the first 10 minutes after changing to be considered a washout period and the last 5 minutes used for data collection. This group will receive NIPPV then NIV NAVA.
62571631|NCT04132323|ACTIVE_COMPARATOR|0.1% sodium tetradecyl sulfate|"* to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.~* to measure the maximum diameter of telangiectasia using the Dermatoscope scale.~* to inject the 0.1% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
62779242|NCT02051634|PLACEBO_COMPARATOR|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
62571632|NCT04132323|ACTIVE_COMPARATOR|0.15% sodium tetradecyl sulfate|"* to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.~* to measure the maximum diameter of telangiectasia using the Dermatoscope scale.~* to inject the 0.15% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
62003697|NCT06408116|OTHER|Group 1, Surgery|cT1-2 N0, all histologies: primary surgical therapy
62779243|NCT05036967||Heart Failure (HF) patients|Patients diagnosed with incident HF, in an outpatient setting in Colombia during the time period of 01 JUN 2019 to 31 MAY 2020
62003698|NCT06408116|OTHER|Group 2, Chemotherapy and surgery|cT3-4 and/or N+, adenocarcinomas: neoadjuvant chemotherapy, surgical therapy
62003699|NCT06408116|OTHER|Group 3, chemotherapy, radiotherapy and surgery|cT3-4 and/or N+, squamous cell carcinomas: neoadjuvant radio(chemo)therapy, surgical therapy
62003700|NCT05018572|EXPERIMENTAL|"Personalised internet-based treatment I am"|"Personalised internet-based treatment I am."
62779244|NCT00604890|EXPERIMENTAL|1|Active cream, 3% AM \& PM
62779245|NCT00604890|PLACEBO_COMPARATOR|2|Placebo cream AM ; 3% active cream PM
62779246|NCT00604890|PLACEBO_COMPARATOR|3|Placebo cream AM; 1.5% active cream PM
62003701|NCT05018572|NO_INTERVENTION|Treatment As Usual|Treatment in primary care / Treatment As Usual (TAU), which is medical treatment
62003702|NCT05320029|EXPERIMENTAL|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|Disposable Powered Articulating Endoscopic Linear Cutter Stapler
62003703|NCT05320029|ACTIVE_COMPARATOR|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|ECHELON Flex Powered Articulating Endoscopic Linear Cutters
62003704|NCT01437228|OTHER|povidone iodine|30-second vaginal scrub with povidone- iodine solution.
62779247|NCT00604890|PLACEBO_COMPARATOR|4|Placebo AM and PM
62779248|NCT05178485|EXPERIMENTAL|The experimental group|At each clinic visit for a subject's injection, the study coordinator will inform the clinic nurse of the group assignment, and the nurse will draw up the corresponding 2 mL injectate (either the bupivacaine/triamcinolone mixture) and wrap the syringe in foil. The syringe will then be provided to the physician for the injection.
62779249|NCT05178485|PLACEBO_COMPARATOR|The control group|At each clinic visit for a subject's injection, the study coordinator will inform the clinic nurse of the group assignment, and the nurse will draw up the corresponding 2 mL saline and wrap the syringe in foil. The syringe will then be provided to the physician for the injection.
61977886|NCT05517382|EXPERIMENTAL|supportED group|Participants in this group will engage with the digital game for one session (\~45min) and will receive NIDA and NIMH pamphlets on substance misuse and mental health for youth at the end of the session. Participants will use a dedicated device (e.g., tablet, laptop, or desktop) to access their digital experience on the web. The research staff and a school-based provider will be present to monitor gameplay, to provide support, if needed, and to field questions in person.
62003705|NCT01437228|PLACEBO_COMPARATOR|CONTROL|
62189264|NCT03163706|EXPERIMENTAL|Schizophrenia patients|Patients with DSM-5 criteria of schizophrenia
62189265|NCT03163706|OTHER|Control group|Control, no schizophrenia
62189266|NCT03672175|PLACEBO_COMPARATOR|SAGE-217 Matched Placebo|Participants self-administered SAGE-217 matched placebo capsules, orally, once daily in the evening with food for 14 days.
62189267|NCT03672175|EXPERIMENTAL|SAGE-217 20 mg|Participants self-administered SAGE-217 20 milligrams (mg) capsules, orally, once daily in the evening with food for 14 days.
62189268|NCT03672175|EXPERIMENTAL|SAGE-217 30 mg|Participants self-administered SAGE-217 30 mg capsules, orally, once daily in the evening with food for 14 days.
62189269|NCT02573272||Epileptic patients with AEDs and eslicarbacepine|
62189270|NCT05809336|EXPERIMENTAL|inosine group|Participants will receive inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting,every 2 or 3 weeks, until the subject's disease progresses, death, intolerable adverse events, the investigator determines that there is no benefit from continued treatment or other termination criteria are met (pregnancy, individual patient reasons or co-morbidities), the subject requests withdrawal from the study, withdrawal of informed consent, and loss of visit
62189271|NCT05809336|ACTIVE_COMPARATOR|non-inosine group|Participants will receive PD-1/PD-L1 inhibitor ± chemotherapy/targeting, every 2 or 3 weeks .until the subject's disease progresses, death, intolerable adverse events, the investigator determines that there is no benefit from continued treatment or other termination criteria are met (pregnancy, individual patient reasons or co-morbidities), the subject requests withdrawal from the study, withdrawal of informed consent, and loss of visit
62189272|NCT03807609|EXPERIMENTAL|CON .|The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
62189273|NCT03807609|EXPERIMENTAL|EX -30.|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
62189274|NCT03807609|EXPERIMENTAL|EX-180|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their appetite feelings will be assessed at regular intervals.
62189275|NCT02994771|ACTIVE_COMPARATOR|Lymfactin® [1 x 10E10 vp]|Lymfactin® \[1 x 10E10 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.
62189276|NCT02994771|ACTIVE_COMPARATOR|Lymfactin® [1 x 10E11 vp]|Lymfactin® \[1 x 10E11 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.
62189277|NCT01214421|EXPERIMENTAL|Tolvaptan|Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 milligrams (mg) in the morning \[AM\]/15 mg in the evening \[PM\] titrated to 60 mg \[AM\]/30 mg \[PM\], then 90 mg \[AM\]/30 mg \[PM\] based on tolerability were given orally twice daily until the last participant originating from prior studies (either 156-04-251 or 156-04-250, 156-06-260, 156-09-284, 156-09-285, and 156-09-290) who was eligible for efficacy analysis completed the Month 24.
62189278|NCT03180944|EXPERIMENTAL|1.2% Lugol's solution|This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.
62189279|NCT03180944|EXPERIMENTAL|1.0% Lugol's solution|This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.
62189280|NCT03180944|EXPERIMENTAL|0.8% Lugol's solution|This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.
62779250|NCT04267081|EXPERIMENTAL|Arm 1 (de novo AML)|"This arm will recruit the patients with de novo AML unfit for conventional chemotherapy. In validation cohort all the participants will receive azacytidine-venetoclax. In study cohort the patients with ex vivo resistance to venetoclax will be excluded from the study therapy.~All patients in validation and study cohorts (ARM1 and ARM2) will receive azacytidine and venetoclax. The purpose for the validation cohort is to validate the specificity and sensitivity of the ex vivo drug testing. Patients exhibiting ex vivo sensitivity and receiving azacytidine-venetoclax in validation cohort are analyzed also for study cohort."
62003706|NCT01347190|EXPERIMENTAL|Liquid API|
62189281|NCT03180944|EXPERIMENTAL|0.6% Lugol's solution|This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.
62189282|NCT03180944|EXPERIMENTAL|0.4% Lugol's solution|This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.
62003707|NCT01347190|PLACEBO_COMPARATOR|Placebo|
62003708|NCT02041130|EXPERIMENTAL|Renal Denervation and standard medical management|"Renal Denervation (RDN) is a simple catheter procedure removing excess nerve signals to and from the kidneys. The renal denervation system consists of a small steerable treatment catheter and an automatically-controlled treatment delivery generator.~A guiding catheter is inserted through a tiny incision in the groin into the femoral artery to direct the treatment catheter to the renal arteries. The treatment catheter delivers high -frequency radio waves, called radiofrequency wavees, to 4-6 locations within each of the two renal arteries. the energy delivered is about 8 watts and aims to disrupt the nerves and lower blood pressure over a period of months. The procedure takes 40-60 minutes."
62189283|NCT01126697|NO_INTERVENTION|Enhanced standard of care|
62189284|NCT01126697|ACTIVE_COMPARATOR|Lisinopril|
62189285|NCT01126697|ACTIVE_COMPARATOR|Coenzyme Q10|
62189286|NCT01126697|ACTIVE_COMPARATOR|Coenzyme Q10 and Lisinopril|
62189287|NCT04434248|EXPERIMENTAL|Favipiravir, lower dose (pilot stage)|1600mg BID on the 1st day followed by 600mg BID for 13 days
62189288|NCT04434248|EXPERIMENTAL|Favipiravir, higher dose (pilot stage)|1800mg BID on the 1st day followed by 800mg BID for 13 days
62189289|NCT04434248|ACTIVE_COMPARATOR|Standard of care (pilot stage)|Based on approved clinical recommendations for treatment of COVID-19 in the Russian Federation (but not Favipiravir). Might include hydroxychloroquine, chloroquine, lopinavir/ritonavir or other recommended schemes.
62189290|NCT04434248|EXPERIMENTAL|Favipiravir, selected dose (pivotal stage)|The dose will be selected based on pilot study results.
62779251|NCT04267081|EXPERIMENTAL|Arm 2 (relapsed, refractory or secondary AML)|"This arm will recruit the patients with relapsed, refractory or secondary AML. In validation cohort all the participants will receive azacytidine-venetoclax. In study cohort the patients with ex vivo resistance to venetoclax will be excluded from the study therapy.~All patients in validation and study cohorts (ARM1 and ARM2) will receive azacytidine and venetoclax. The purpose for the validation cohort is to validate the specificity and sensitivity of the ex vivo drug testing. Patients exhibiting ex vivo sensitivity and receiving azacytidine-venetoclax in validation cohort are analyzed also for study cohort."
62779252|NCT03459638||Periodontitis|Screening for DM, ASCVD, MetS and OSAS in patients with periodontitis
62779253|NCT03459638||No periodontitis|'Screening for DM, ASCVD, MetS and OSAS in patients without periodontitis
62779254|NCT01699568|EXPERIMENTAL|Vulcano Actives|Implants 4mm x 10mm Vulcano Actives (anodized surface)(AR Torque Vulcano actives), Conexão Sistemas de Prótese, Arujá, Brasil)will be placed on edentulous area in maxilla
62003709|NCT02041130|NO_INTERVENTION|Contorl and Standard Medical Management|Continued medical management will comprise management of all cardiovascular risk factors (hypertension, diabetes, dyslipidaemia) in accord with international guidelines. Lifestyle and dietary counselling will also be part of the patient management. As there is no established evidence-based pharmacotherapy for HFPEF per se, therapy aimed at HF specifically will adopt treatments recommended for HFREF with prescription of diuretic, ACE inhibitor/ARB, beta blocker and mineralocorticoid antagonist accordingly.
62003710|NCT01234129||zoledronic acid or not zoledronic acid|patients with multiple myeloma will be treated with cytoreductive therapy following by zoledronic acid or not.
62779255|NCT01699568|ACTIVE_COMPARATOR|Porous|Implants 4mm x 10mm Porous (dual acid-etched surface treatment)(AR Torque Porous, Conexão Sistemas de Prótese, Arujá, Brasil)will be placed on edentulous area in maxilla
62779256|NCT01227863|EXPERIMENTAL|Test|Dexamethasone + neomycyn + polimixyn B
62779257|NCT01227863|ACTIVE_COMPARATOR|Comparator|Dexamethasone + neomycyn + polimixy B
62779258|NCT05552066|OTHER|front phase|The current circuit remains unchanged (medical or nursing validation to confirm chemotherapy administration). Patient satisfaction is collected at each visit to the day hospital unit for chemotherapy.
62779259|NCT05552066|OTHER|Post Phase|A short circuit is set up. If no contraindications are identified by the plateform with the remote PRO collection, patients will undergo chemotherapy directly the next day (without any medical validation). Patient satisfaction is also collected at each visit to the day hospital unit for chemotherapy.
62779260|NCT03028779|EXPERIMENTAL|Fast-track total hip or knee arthroplasty|Be able to return patient home on the same day of a total hip or knee surgery.
62779261|NCT04545710|EXPERIMENTAL|Single Arm, POC|"Single arm, POC Safety and Efficacy~Osimertinib 80 mg QD Abemaciclib 150mg BID"
62779262|NCT00723359|EXPERIMENTAL|BT062|BT062 single agent dose escalation
62779263|NCT06077032|EXPERIMENTAL|garlic extract|"Garlic will be collected from Medicinal Plant station, Pharmacognosy Department, Faculty of Pharmacy, Assiut University.~The fresh garlic bulbs will be crushed. Extraction will be done using maceration method with Ethanol for 24 h at room temperature.~Freeze-drying method will be used to remove solvent and give dry powder. Dry powder will be mixed with isopropyl alcohol in a ultrasonic bath to solve thoroughly.~The soluble garlic extract will be added to a mixture of Polyethylene Glycol. The topical garlic formulation will be prepared for each time for two weeks-use and will be kept in dark glass containers in refrigerator till prescription.~•Group 1: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with garlic extract (15%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks."
62571633|NCT04156711|EXPERIMENTAL|Remote Ischemic Preconditioning|Remote ischemic preconditioning is carried out before the induction of general anesthesia. All four cycles will be completed before general anesthesia. The blood pressure cuff is placed on the upper limb. The cuff is inflated to 200 mmHg (if systolic blood pressures exceeds 185 mmHg, the cuff will be inflated to at least 15 mmHg above the systolic blood pressure) resulting in a total occlusion of the blood flow to the limb. After 5 minutes of ischemia, the cuff is deflated, and the limb is reperfused for 5 minutes. This cycle is repeated 4 times. Pulse oximetry is performed on the RIPC limb to make sure that the blood flow is completely interrupted during ischemia
62779264|NCT06077032|EXPERIMENTAL|chlorhexidine|"Chlorhexidine 4% (Laries, manufactured by: Smartec Egypt) will be diluted with equal amount of distilled water to obtain a concentration of 2%.~•Group 2: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with topical chlorhexidine (2%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks."
62779265|NCT06077032|PLACEBO_COMPARATOR|group3|•Group 3: (control) will use normal saline 0.9% as a placebo (they will be treated later on after completion of the study using any of the standard therapies for non-genital warts).
62779266|NCT02547051|EXPERIMENTAL|Food allergy and vocal cord tension|To determine if dietary allergen responses and frequency and severity of vocal cord tension.
62779267|NCT04277039|EXPERIMENTAL|OMT+CT|It consists of 8 sessions of osteopathic treatment and two 20-min sessions of cognitive training per week per 2 months
62003711|NCT01234129||zoledronic acid or not zoledronic acid|patients with multiple myeloma will be treated with cytoreductive therapy following by stem cell transplant and did not received zoledronic acid
62189291|NCT04434248|ACTIVE_COMPARATOR|Standard of care (pivotal stage)|Based on approved clinical recommendations for treatment of COVID-19 in the Russian Federation (but not Favipiravir). Might include hydroxychloroquine, chloroquine, lopinavir/ritonavir or other recommended schemes.
62571634|NCT04156711|NO_INTERVENTION|Control|Will receive no intervention, but will go through same tests at the same time-points (endothelial function measured by reactive hyperemia index, blood samples, Heart rate variability and questionaires)
62189292|NCT02689453|EXPERIMENTAL|1A-Interleukin 15 (IL-15) Followed by Alemtuzumab|IL-15 for 10 doses over two weeks followed by alemtuzumab for 4 weeks per dosing schema to determine the maximum tolerated dose (MTD)
62189293|NCT02689453|EXPERIMENTAL|1B - Interleukin-15 (IL-15) Followed by Alemtuzumab at the Maximum Tolerated Dose|IL-15 for 10 doses over two weeks followed by alemtuzumab for 4 weeks at the maximum tolerated dose (MTD)
62189294|NCT00522743|EXPERIMENTAL|1|GH \& GNRHa treatment
62571635|NCT04576520|EXPERIMENTAL|pharmacopuncture therapy|The physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
62571636|NCT04576520|ACTIVE_COMPARATOR|physical therapy|The physicians will choose the type and time of physical therapy according to participants' conditions.
62779268|NCT04277039|ACTIVE_COMPARATOR|osteopathic treatment|It consists of 8 sessions of osteopathic treatment throughout the 2-month study period
62003712|NCT01234129||zoledronic acid|Patients with multiple treated with cytoreductive therapy following by stem cell transplant will be planned to received zoledronic acid
62003713|NCT01670929|ACTIVE_COMPARATOR|Progesterone group|progesterone (400 mg pessary, once daily)
62189295|NCT00522743|ACTIVE_COMPARATOR|2|GH treatment
62189296|NCT01670071|EXPERIMENTAL|Paliperidone extended-release|
62003714|NCT01670929|PLACEBO_COMPARATOR|Placebo group|Placebo (pessary, once daily)
62003715|NCT03638986||Swiss version first|This group will first complete the Swiss version and second the German version of the TFI
62003716|NCT03638986||German version first|This group will first complete the German version and second the Swiss version of the TFI
62003717|NCT01399359||Women who decide not to take a SERM|Women participate in the counseling session, questionnaire 1, and questionnaire 2, and the online questionnaire.
62189297|NCT01670071|ACTIVE_COMPARATOR|Risperidone immediate-release|
62189298|NCT03667118|EXPERIMENTAL|Food Supplement|Infants who received the active food supplement powder
62189299|NCT03667118|PLACEBO_COMPARATOR|Placebo|Infants who received the placebo powder
62189300|NCT03792347|EXPERIMENTAL|Arm 1|Arm 1:preoperative pembrolizumab with chemoradiotherapy group Participants will receive carboplatin (AUC=2) IV and paclitaxel (50mg/m²) IV on day 1,8,15,22,29. And radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week. Participants will also receive pembrolizumab (2mg/kg) IV on days 1 and 22. Surgery will be performed within 6 weeks after completion of preoperative therapy described above.
62189301|NCT01198483|ACTIVE_COMPARATOR|Micro|Microincision cataract surgery
62189302|NCT01198483|ACTIVE_COMPARATOR|Small|Smallincision cataract surgery
62571637|NCT02903940||CRT+NAVH|Surface ECG recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy and Negative Atrioventricular Hysteresis settings.
62571638|NCT05190770|EXPERIMENTAL|Triamcinolone + Oleogel-S10|25 participants will be randomized to triamcinolone 0.1% cream once every morning and topical Oleogel-S10 gel once prior to bedtime for a 3 week period.
62571639|NCT05190770|PLACEBO_COMPARATOR|Triamcinolone + Placebo|25 patients with breast cancer will be randomized to triamcinolone 0.1% cream once every morning (QAM) and vehicle gel once prior to bedtime for a 3 week period.
62571640|NCT03063060||total thyroidectomy|patients who underwent total thyroidectomy with available vitamin D levels before surgery, as well as pre and post-operative PTH and calcium levels.
62003718|NCT01399359||Women who decide to take a SERM|Women participate in the counseling session, questionnaire 1 and questionnaire 2.
62571641|NCT00448266|EXPERIMENTAL|2|1 course ddAc, 2 courses IAA with PBPC support
62571642|NCT00448266|ACTIVE_COMPARATOR|1|3 courses ddAC
62003719|NCT00700011|ACTIVE_COMPARATOR|10 mg/m2 group|Patients were treated with Clofarabine 10 mg/m2 daily x 5 days per cycle. Cycles were intended on being every 28 days but this was flexible due to the bone marrow neding to recover from each cycle before strting the next one. Neulasta was given on day 5 of each cycle. Patients were treated until disease progression, or intolerable toxicities.
62003720|NCT00700011|ACTIVE_COMPARATOR|5 mg/m2 group|Patients were treated with Clofarabine 5 mg/m2 daily x 5 days per cycle. Cycles were intended on being every 28 days but this was flexible due to the bone marrow neding to recover from each cycle before strting the next one. Neulasta was given on day 5 of each cycle. Patients were treated until disease progression, or intolerable toxicities.
62003721|NCT00774098|PLACEBO_COMPARATOR|Control Group|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
62003722|NCT00774098|EXPERIMENTAL|GICP|
62003723|NCT00200954|PLACEBO_COMPARATOR|placebo|placebo group
62571643|NCT03863639||Pre-Eclampsia|15 English-speaking women with severe pre-eclampsia
62779269|NCT04277039|OTHER|usual care|patients will continue the routine care as established by international guidelines
62003724|NCT00200954|ACTIVE_COMPARATOR|2|Probiotic bacteria group
62003725|NCT05371535|EXPERIMENTAL|Experimental group|Those in the experimental group will receive MatrixOssTM Bone Graft plus Bio-Gide membrane.
62571644|NCT03863639||Control|15 English-speaking pregnant controls with uncomplicated pregnancy matched by age and gestational age
62571645|NCT03095326|EXPERIMENTAL|Zinc Syrup 1.5 mg/kgbw/day|Patient were given zinc formula in the form of syrup with dosage of 1.5 mg/kg body weight/day with a maximum dose of 50 mg/day. The amount of syrup given is estimated to be enough for 4 weeks.
62571646|NCT03095326|PLACEBO_COMPARATOR|Sucrose syrup|Patient were given sucrose syrup as placebo. The syrup was made in the same flavor and consistency as the zinc syrup.
62571647|NCT03023917|ACTIVE_COMPARATOR|umbilical cord clamping immediately|"Umbilical cord was clamped immediately, or as close as possible, after delivery of the infant's shoulders. (This was standard practice in the study hospital, thus it served as the control group)."
62779270|NCT03507738|EXPERIMENTAL|Adult MT-5625 middle dose|Adult receiving intramuscular injection with either middle dose of MT-5625 or placebo
62779271|NCT03507738|EXPERIMENTAL|Adult MT-5625 high dose|Adult receiving intramuscular injection with either high dose of MT-5625 or placebo
62003726|NCT05371535|ACTIVE_COMPARATOR|Control group|Those in the control group will receive Bio-Oss Bone Graft plus Bio-Gide membrane
62003727|NCT05689840||0-1 week group|Patients who have been infected with Covid-19 with 0-1 week post-COVID interval before surgery.
62003728|NCT05689840||1-2 weeks group|Patients who have been infected with Covid-19 with 1-2 weeks post-COVID interval before surgery.
62003729|NCT05689840||2-3 weeks group|Patients who have been infected with Covid-19 with 2-3 weeks post-COVID interval before surgery.
62571648|NCT03023917|EXPERIMENTAL|umbilical cord milking|preterm baby were placed at or below level of the placenta and about 25cm of the umbilical cord was vigorously milked towards the umbilicus two to three times before clamping the cord. The milking speed was about 25cm/2 seconds
62571649|NCT05101889|EXPERIMENTAL|Immunonutrition|"Oral immunomodulating formula (Oral Impact®, Nestle) One sachet of Oral Impact® consisted of 74 g of powder providing 303 kilocalories.~Three ready-to-drink bottles contained 303 kilocalories/bottle per day, starting 5 days before each chemotherapy session."
62571650|NCT05101889|ACTIVE_COMPARATOR|Control|An isocaloric isonitrogenous standard enteral nutrition formula. Three ready-to-drink bottles contained 303 kilocalories/bottle per day, starting 5 days before each chemotherapy session.
62571651|NCT05495100|EXPERIMENTAL|Mitoxantrone liposome combined with Chidamide and Azacitidine|
62571652|NCT06574685|EXPERIMENTAL|Twinkle Eyez Supplementation|
62571653|NCT06574685|PLACEBO_COMPARATOR|Placebo control|
62779272|NCT03507738|EXPERIMENTAL|Toddler MT-5625 middle dose|Toddler receiving intramuscular injection with either middle dose of MT-5625 or placebo
62003730|NCT05689840||3-4 weeks group|Patients who have been infected with Covid-19 with 3-4 weeks post-COVID interval before surgery.
62003731|NCT05689840||4-5 weeks group|Patients who have been infected with Covid-19 with 4-5 weeks post-COVID interval before surgery.
62003732|NCT05689840||5-6 weeks group|Patients who have been infected with Covid-19 with 5-6 weeks post-COVID interval before surgery.
62003733|NCT05689840||over 6 weeks group|Patients who have been infected with Covid-19 with over 6 weeks post-COVID interval before surgery.
62003734|NCT01251133|EXPERIMENTAL|LBVH0101|
62003735|NCT01251133|ACTIVE_COMPARATOR|Hiberix|
62003736|NCT06178874|ACTIVE_COMPARATOR|group S|The random blood sugar in the patients in group S will be managed using regular insulin based on a sliding scale together with an Insulin Glargine, 0.2 units/kg , SC, initially to be titrated as per the clinical situation to be given at 9 PM
62189303|NCT03157908|EXPERIMENTAL|Smartphone app|All participants in this pilot study will install the smartphone app for testing
62571654|NCT03710837|EXPERIMENTAL|Pain neuroscience education|Intervention: Pain neuroscience education group. One-off, 70 minute duration session delivered by Dr Cormac Ryan.
62571655|NCT03710837|EXPERIMENTAL|Red flag education|Intervention: Red flags education group. One-off 70 minute duration session delivered by Dr Cormac Ryan.
62571656|NCT06123169|ACTIVE_COMPARATOR|Broad spectrum antibioprophylaxis|Antibioprophylaxis with Piperacillin-tazobactam during DPC.
62571657|NCT06123169|EXPERIMENTAL|Broad spectrum antibiotherapy|5 days Antibiotherapy (Piperacillin-tazobactam) from surgery.
62779273|NCT03507738|EXPERIMENTAL|Toddler MT-5625 high dose|Toddler receiving intramuscular injection with either high dose of MT-5625 or placebo
62779274|NCT03507738|EXPERIMENTAL|Infant MT-5625 low dose|Infant receiving intramuscular injection with either low dose of MT-5625 or placebo
62779275|NCT03507738|EXPERIMENTAL|Infant MT-5625 middle dose|Infant receiving intramuscular injection with either middle dose of MT-5625 or placebo
62189304|NCT02885792|EXPERIMENTAL|Debuting and chronic schizophrenia|"ILLNESS HISTORY:~* Existing psychiatric and somatic diagnosis and treatment~* Charlson co-morbidity~MEASURE OF SOCIAL CONDITIONS~- For example Lubben Social Network Scale-6 and Brief Trauma Questionnaire.~MEASURE OF PSYCHIATRIC CONDITION::~* Positive and Negative Syndrome Scale (PANSS)~* Clinical Global Impression Scale (CGI)~* Columbia Suicide Severity Rating Scale (C-SSRS)~* Beck Cognitive Insight Scale~* Birchwood Insight Scale~CARDIOVASCULAR MEASUREMENT:~CT Coronary angiography (CT-CAG)~* Echocardiography~* Heart rate variability (HRV)~* Pulmonary function test (PFT)~* Toe blood pressure (TBP)~* Blood test~* Body composition analysis~* CT scan of upper abdomen~* Cardiovascular magnetic resonance imaging (CMR)~* Adipose tissue biopsy"
62189305|NCT02885792|ACTIVE_COMPARATOR|Matched controls|"CARDIOVASCULAR MEASUREMENT:~* CT Coronary angiography (CT-CAG)~* Echocardiography~* Heart rate variability (HRV)~* Pulmonary function test (PFT)~* Toe blood pressure (TBP)~* Blood test~* Body composition analysis~* CT scan of upper abdomen~* Cardiovascular magnetic resonance imaging (CMR)~* Adipose tissue biopsy"
62189306|NCT02039245|EXPERIMENTAL|Canagliflozin/Metformin XR|Each patient will receive 2 tablets of CANA/MET XR combination of total dose 300/2000 mg
62189307|NCT02607098||Males diagnosed with male-factor infertility|This study will recruit a convenience sample of 10 men and their partners seeking consultation from a fertility urologist following the detection of male-factor infertility.
62189308|NCT02607098||Female partners|This study will recruit a convenience sample of 10 men and their partners seeking consultation from a fertility urologist following the detection of male-factor infertility.
62189309|NCT00640744|OTHER|A|An untreated carotid plaque will be obtained at the first endarterectomy. Atorvastatin 80mg will be administered for 3 months. The contralateral (treated) plaque will be obtained at the second endarterectomy. Hence, each patient will be his/her own control
62189310|NCT00512642||Patients at increased risk of lung cancer|Patients at increased risk of lung cancer
62189311|NCT02284009|EXPERIMENTAL|Albiglutide|Approximately 51 subjects will be assigned to albiglutide 30 mg weekly (with treatment-masked increase to 50 mg weekly at Week 6) + background insulin. The starting dose of albiglutide will be 30 mg once weekly and will be increased at Week 6 to 50 mg, once weekly, if the 30-mg weekly dose is tolerated.
62189312|NCT02284009|EXPERIMENTAL|Placebo|Approximately 17 subjects will be assigned to albiglutide matching placebo + background insulin
62189313|NCT05323630|OTHER|Procedure with the Renuvion APR System in the labia|The labia procedure utilizing the Renuvion APR system will be performed per the investigator's standard clinical practice.
62189314|NCT00938405|EXPERIMENTAL|Colesevelam HCl|Beginning at Visit 1, two weeks after screening, subjects in the active treatment group will take 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
62189315|NCT00938405|PLACEBO_COMPARATOR|Comparison group|Beginning at Visit 1, two weeks after screening, subjects in the comparison group will be administered placebo, taking 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
62189316|NCT02656550|EXPERIMENTAL|Uterine Transplant|Women will undergo uterine transplantation after IVF. Donor uterus will be from either a living donor or cadaveric.
62189317|NCT03230045|EXPERIMENTAL|Acupoint stimulation|Acupoint Zhongfu and Zusanli are stimulated by transcutaneous electrical stimulation
62189318|NCT03230045|SHAM_COMPARATOR|no treatment|Electrodes are attached to Acupoint Zhongfu and Zusanli, but no stimulation is given
62189319|NCT05717218|EXPERIMENTAL|Interventional|All patients included
62779276|NCT03507738|EXPERIMENTAL|Infant MT-5625 high dose|Infant receiving intramuscular injection with either high dose of MT-5625 or placebo
62779277|NCT03507738|ACTIVE_COMPARATOR|Rotarix|Infant receiving oral administration with Rotarix
62003737|NCT06178874|ACTIVE_COMPARATOR|Group L|The random blood sugar in the patients in group L will be managed using regular insulin based on a sliding scale together with an Insulin Degludec 0.2 units/kg, SC, initially to be titrated as per the clinical situation to be given at 9 PM
62003738|NCT06178874|ACTIVE_COMPARATOR|Group R|The random blood sugar in the patients in group R will be managed using regular insulin based on a sliding scale
62003739|NCT02175069|EXPERIMENTAL|Interscalene Nerve Block - 5ml|"ultrasound guided interscalene plexus block (UISB)~Ropivacaine 0.75%, 20ml Gadopentetate-Dimeglumine 0.05 mmol Shoulder Surgery"
62003740|NCT02175069|ACTIVE_COMPARATOR|Interscalene Nerve Block - 20ml|"ultrasound guided interscalene plexus block (UISB)~Ropivacaine 0.75%, 5ml Gadopentetate-Dimeglumine 0.0125 mmol Shoulder Surgery"
62189320|NCT03040947||Healthy Volunteer|Healthy Volunteers will undergo a cardiovascular magnetic resonance imaging scan.
62189321|NCT03040947||Diseased (Suspected or Known Cardiac Conditions)|Patients will undergo a cardiovascular magnetic resonance imaging scan.
62189322|NCT01667406|EXPERIMENTAL|Kisspeptin-54, 1.6 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 1.6 nmol/kg
62189323|NCT01667406|EXPERIMENTAL|Kisspeptin-54, 3.2 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 3.2 nmol/kg
62189324|NCT01667406|EXPERIMENTAL|Kisspeptin-54, 6.4 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 6.4 nmol/kg
62189325|NCT01667406|EXPERIMENTAL|Kisspeptin-54, 12.8 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 12.8 nmol/kg
62189326|NCT01667406|EXPERIMENTAL|Kisspeptin-54 OHSS, 3.2 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 3.2 nmol/kg
62189327|NCT01667406|EXPERIMENTAL|Kisspeptin-54 OHSS, 6.4 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 6.4 nmol/kg
62189328|NCT01667406|EXPERIMENTAL|Kisspeptin-54 OHSS, 9.6 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 9.6 nmol/kg
62189329|NCT01667406|EXPERIMENTAL|Kisspeptin-54 OHSS, 12.8 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 12.8 nmol/kg
62779278|NCT00524017|EXPERIMENTAL|Arm I (treatment)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.
62779279|NCT00524017|NO_INTERVENTION|Arm II (control)|Patients receive regular follow-up care
62003741|NCT04055194|ACTIVE_COMPARATOR|Tranexamic acid group|100 pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.
62003742|NCT04055194|PLACEBO_COMPARATOR|Placebo group|100 pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
62571658|NCT04917003|EXPERIMENTAL|RIC group|"Patients who are allocated into RIC group will undergo the first EDAS surgery combined 3-month remote ischemic conditioning (RIC) treatment. The opposite operation will be performed at 3 months after the first operation.~RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm.~EDAS involves placement of an external carotid artery branch beneath the dura in the ischemic territories. The superficial temporal artery (STA) was commonly used."
62003743|NCT06051058|EXPERIMENTAL|Experimental: Care Transitions App|Use of the Care Transitions App to support the care transition for patients hospitalized and discharged with multiple chronic conditions will be compared to usual care.
62779280|NCT04984382|EXPERIMENTAL|After receiving standardized training on Helicobacter pylori eradication|After the gastroenterologists receive standardized training to eradicate Helicobacter pylori, they recruit Helicobacter pylori-positive patients for treatment.
62779281|NCT04984382|NO_INTERVENTION|Before receiving standardized training on Helicobacter pylori eradication|Gastroenterologists recruited patients with Helicobacter pylori positive for treatment before receiving standardized training on Helicobacter pylori eradication.
62779282|NCT06514833|EXPERIMENTAL|Nap|The experimental group will receive lifestyle recommendations to nap regularly
62779283|NCT06514833|OTHER|No nap|The control group would not receive lifestyle recommendations to nap regularly
62779284|NCT06527443||acute kidney injury|
62003744|NCT06051058|NO_INTERVENTION|No Intervention: Usual Care|Usual care transition care for patients hospitalized and discharged with multiple chronic conditions.
62189330|NCT01667406|EXPERIMENTAL|Kisspeptin-54 OHSS, 9.6 + 9.6|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a trigger injection of Kisspeptin, dose of 9.6 nmol/kg and a further injection of Kisspeptin, dose of 9.6 nmol/kg 10 hours later
62584910|NCT00170625|EXPERIMENTAL|Relapse 6-12 months|"dose level 0: Topotecan 1mg/m2/d on day 1-3, q 21d (+ Carboplatin AUC 5 on day 3 after Topotecan application)~If dose limiting toxicity (DLT) is present then Topotecan dose will be reduced to dose level -1 (dose level -1: Topotecan 0.75 mg/m2/d on day 1-3, q 21d (+ Carboplatin AUC 5 on day 3 after Topotecan application))~A DLT is present if a patient has a postponement due to hematologic toxicity of more than 7 days within the first four courses at dose level 0."
62779285|NCT06527443||non acute kidney injury|
62779286|NCT06583291|EXPERIMENTAL|Low dose|MRI-guided bilateral stereotactic cell implantation
62779287|NCT06583291|EXPERIMENTAL|High dose|MRI-guided bilateral stereotactic cell implantation
62003745|NCT04460664||Subjects admitted to floor|COVID-19 patients admitted to the floor as initial place of hospitalization
62003746|NCT04460664||Subjects admitted or transferred to ICU|COVID-19 patients admitted to the ICU as initial place of hospitalization or transferred to ICU from floor
62779288|NCT00997594|ACTIVE_COMPARATOR|Adrenal radiofrquency (RF) ablation|Patients who wll receive adrenal RF ablation.
62779289|NCT00997594|ACTIVE_COMPARATOR|Abdominal RF ablation other than adrenal gland|Patients who will receive abdominal radiofrequency ablation other than adrenal gland.
62779290|NCT02158208||Patients with HD|
62779291|NCT02158208||Controls|
62779292|NCT02299284|EXPERIMENTAL|Hand-Arm Bimanual Intensive Therapy (HABIT)|HABIT, bimanual training, bilateral training, restraint therapy, PT, OT, rehab
62779293|NCT02299284|EXPERIMENTAL|Intensive Functional Lower-Limb Training|lower-limb function, strength training, balance, PT, OT, rehab
62779294|NCT05785936||Highly sensitized and desensitized kidney transplanted group|Patient that were HLA desensitized for kidney transplantation
62571659|NCT04917003|OTHER|control group|"Patients who are allocated into the control group will accept EDAS surgery twice. The second operation will be performed at 3 months after the first operation.~EDAS involves placement of an external carotid artery branch beneath the dura in the ischemic territories. The superficial temporal artery (STA) was commonly used. Under certain circumstances, depending on the territory at risk, the occipital artery was also used. The donor vessel with the strip of galea (the arterial bridge) was detached from the pericranium or the fascia below, and two burr holes are made beneath the proximal and distal ends of the arterial bridge. The burr holes, with an average size of 3.0 × 8.0 cm, were connected by mill to make an oval bone flap and the dura was exposed. The target artery was then sewn to the dura using 10-0 Prolene suture. The bone flap was closed after cutting out the entry and exit sites for the target artery."
62003747|NCT03595475||Psychiatric RBD cases|"1. Presence of REM sleep without atonia;~2. At least one of the followings is present: i). Dream enactment behaviors, SRIs, potentially injurious or disruptive behaviors by history; ii). Abnormal REM sleep behaviors documented during v-PSG monitoring;~3. Absence of electroencephalogram (EEG) epileptiform activity during REM sleep unless RBD can be clearly distinguished from any concurrent REM sleep related seizure disorder;~4. The sleep disturbance is not better explained by other sleep disorder (e.g., obstructive sleep apnea, medical or neurological disorder, mental disorder, medication use, or substance use disorder)"
62571660|NCT02923323|EXPERIMENTAL|Group 1 T1DM aged 12-18 years.|T1DM patients. Receiving regularly insulin. Interventions: performance of continuous EEG , CGMS, MRI of brain with DTI , actigraph, neurocognitive testing
62571661|NCT02923323|ACTIVE_COMPARATOR|Group 2 Healthy aged 12-18 years.|Healthy Interventions: performance of continuous EEG , CGMS, MRI of brain with DTI , actigraph, neurocognitive testing
62779295|NCT05785936||Highly sensitized and non-desensitized kidney transplanted group|Patient that were not HLA desensitized for kidney transplantation but were highly sensitized and received a kidney graft due to local priority system
62779296|NCT05785936||Healthy donors|
62779297|NCT04794127|EXPERIMENTAL|Trabectedin in combination with Pioglitazone|Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and Pioglitazone given continuously at the daily dose of 45 mg by oral route. Since Trabectedin has no cumulative toxicities, and Pioglitazone as well, the combination will be administered until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment, or medical decision by the responsible physician.
62003748|NCT03595475||Psychiatric control|"1. Age- and sex- matched with pRBD proband;~2. Concurrent psychiatric illnesses according to the Mini International Neuropsychiatric Interview( M.I.N.I);~3. Free of narcolepsy and other neurological diseases;~4. Absence of any RBD features as based on REM sleep behavior disorder questionnaire (RBDQ-HK) and v-PSG; 5) Free of neurodegenerative diseases"
62003749|NCT03595475||Healthy control|"1. Age- and sex- matched with pRBD proband;~2. Without lifetime psychiatric disorder according to Mini International Neuropsychiatric Interview( M.I.N.I);~3. Free of narcolepsy and other neurological diseases;~4. Absence of any RBD features as based on RBDQ-HK and v-PSG;~5. Free of neurodegenerative diseases"
62779298|NCT05464368|EXPERIMENTAL|Cohort 1: (A+; CDR = .5, 1; AD)|Unblinded and randomized to receive either 18F-RO948or 18F-MK6240 for PET Scan #1. PET scan #2 will be either 18F-RO948or 18F-MK6240 NOT received in PET scan #1. If a 3rdPET scanoccurs,this third scanwill always be \[18F\]GTP1.
62003750|NCT00224211||I|Stable premature infants
62003751|NCT03304379|EXPERIMENTAL|Dosing regimen 1|
62003752|NCT03304379|EXPERIMENTAL|Dosing regimen 2|
62003753|NCT03304379|EXPERIMENTAL|Dosing regimen 3|
62003754|NCT03304379|EXPERIMENTAL|Dosing regimen 4|
62571662|NCT05691582|EXPERIMENTAL|Single arm|All the subjects recruited have 4 access to GRAIL, in 4 different day, to test their tolerability to the proposals
62571663|NCT00315133|EXPERIMENTAL|Transplant arm|This is a single arm study. The intervention is immunosuppression and autologous stem cell transplantation.
62571664|NCT02861105|ACTIVE_COMPARATOR|LMWH supplementation|40 mg of enoxaparin injected subcutaneously every 24 hours starting the day of ovum pick-up to the documentation of fetal life by ultrasound at 7 weeks of gestation
62779299|NCT05464368|EXPERIMENTAL|Cohort 2: (A-; CDR=0; OC)|Unblinded and randomized to receive either 18F-RO948or 18F-MK6240 for PET Scan #1. PET scan #2 will be either 18F-RO948or 18F-MK6240 NOT received in PET scan#1.If a 3rdPET scan occurs, this third scan will always be \[18F\]GTP1.
62003755|NCT02470728|NO_INTERVENTION|Control Group|Those randomized into the control group will receive the current standard of care for pain management. This standard care pathway involves a pain management specialist consultation only at the request of the primary admitting team. The pain management consultation can occur at any time during the patient's inpatient stay and care by these specialists ends at discharge.
62779300|NCT05464368|EXPERIMENTAL|Cohort 3: (A+; CDR = 0, .5, 1; AD)|Unblinded and randomized to receive 18F-RO948or 18F-MK6240 or \[18F\]GTP1for PET Scan #1. PET scan #2 will be 18F-RO948or 18F-MK6240 or \[18F\]GTP1NOT received in PET scan #1. PET scan # 3 will be 18F-RO948or 18F-MK6240 or \[18F\]GTP1NOT received in PET scan #1 or #2. Efforts will be made to include about 1/3 CDR = 0; 1/3 CDR = .5; 1/3 CDR = 1 in Cohort 3. Efforts will also be made to completethe study with about equal numbers of subjects whose PET scan #1 start with each of the three tracers.
62779301|NCT04917913|EXPERIMENTAL|Intervention|Subjects will be administered 3 daily doses (one per meal) of digestive enzymes (50mg), in a capsule, for 30 days
62003756|NCT02470728|EXPERIMENTAL|Treatment Group|Subjects randomized into the treatment (early intervention) group will receive the New Clinical Pathway: pain management care coordinated by pain-management specialists from inpatient admission through 60 days after discharge.
62003757|NCT02021591|NO_INTERVENTION|Control|Control Arm: Study participants attending one of the 4 control arm centers will receive usual diabetes education provided by staff at the site; be provided with free test strips for their blood glucose meters during the 4-week intervention period; given access to the MODD application at the end of the study. Instructions on how to use the MODD will be provided by site staff.
62003758|NCT02021591|EXPERIMENTAL|Intervention|Intervention: Mobile Diabetes Detective (MoDD) Study participants attending one of the 4 Intervention sites will receive usual diabetes education provided by staff at the site and be given access to the MODD application and instructions for use for 4 weeks at the beginning of the study. After the initial 4 weeks of access to the MODD application, participants will be offered an option to continue using MODD for the duration of the study.
62003759|NCT01686243|EXPERIMENTAL|"echogenic 17G tuohy needles  Pajunk TuohySono"|Epidural will be placed with the aid of ultrasound and echogenic 17G Tuohy needles (Pajunk TuohySono).
62003760|NCT01686243|PLACEBO_COMPARATOR|standard epidural needles|Epidural will be placed in standard practice with standard needles.
62003761|NCT05957068|EXPERIMENTAL|Exercise|The exercise intervention group will undergo an aerobic exercise and strength training programme, comprising 3 sessions per week, spanning 24 weeks (total: 3x24=72 sessions).
62003762|NCT05957068|EXPERIMENTAL|Control|The usual care group.
62003763|NCT03982329|ACTIVE_COMPARATOR|nrTMS group|15 minutes low-frequency nrTMS (1 Hz) of the uneffected hemisphere at 7 consecutive days
62003764|NCT03982329|SHAM_COMPARATOR|sham group|15 minutes sham stimulation of the uneffected hemisphere at 7 consecutive days
62003765|NCT02753647|EXPERIMENTAL|Chidamide plus R-CHOP|Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Doxorubicin 50mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Chidamide 20mg/d PO d1, 4, 8, 11 Frequency every 21 days for 6 cycles
62571665|NCT02861105|PLACEBO_COMPARATOR|0.9% saline solution|0.9% saline injected subcutaneously every 24 hours starting the day of ovum pick-up to the documentation of fetal life by ultrasound at 7 weeks of gestation
62779302|NCT04917913|PLACEBO_COMPARATOR|Placebo|Subjects will be administered 3 daily doses (one per meal) of digestive enzymes (50mg), in a capsule, for 30 days
62003766|NCT06472349||Chronic shoulder pain group|
62779303|NCT04855656|EXPERIMENTAL|Phase 1: RP-6306 Single-Agent, Dose Escalation and Food-effect Study|Patients receive RP-6306 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.
62779304|NCT04855656|EXPERIMENTAL|Phase 1: RP-6306 in combination with RP-3500, Dose Escalation Study|Patients receive RP-6306 with RP-3500 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.
62003767|NCT06472349||Healthy control group|
62003768|NCT03983096||test group|Patients with invasive breast cancer diagnosed by menstrual histology in 2014-2018 and receiving neoadjuvant chemotherapy, or patients with invasive breast cancer diagnosed by menstrual histology in 2014-2016 and receiving adjuvant chemotherapy. That used Pegylated liposomal doxorubicin for treat.
62571666|NCT04505930|EXPERIMENTAL|Intervention Group with active education|The study team provides participants in the intervention group with interventional education, using interactive video watch and dynamic discussion.
62779305|NCT04855656|EXPERIMENTAL|Phase 1: RP-6306 in combination with Debio 0123, Dose Escalation Study|Patients receive RP-6306 with Debio 0123 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.
62189331|NCT01667406|EXPERIMENTAL|Kisspeptin-54 OHSS, 9.6 + saline|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a trigger injection of Kisspeptin, dose of 9.6 nmol/kg and a further injection of saline10 hours later
62396348|NCT06205225|ACTIVE_COMPARATOR|Enhanced usual care|Participants assigned to the usual care group will receive (1) standard care, (2) patient education about HF self-care, and (3) three connected health devices. Usual care includes follow-up appointments every 2-3 months with a multidisciplinary team at the outpatient HF clinic. Patient education includes resources about HF self-care from the American Heart Association and Heart Failure Society of America. Connected health devices include the Withings Weight Scale, Withings blood pressure monitor, and Fitbit Charge 6 activity tracker (wrist-based with heart rate sensor). Participants will receive the devices at baseline along with training by research staff on how to use the devices to perform daily self-monitoring of weight, blood pressure, and physical activity/inactivity. The Withings devices have a cellular antenna for automatic transmission of data to our study server (iCardia). Fitbit will be paired with the participant's smartphone.
62396349|NCT06205225|EXPERIMENTAL|Text4HF|Participants allocated to the Text4HF group will receive the same components and devices as the usual care group (usual care, patient education, and connected health devices), plus individually tailored Text Messages targeting health beliefs, HF-knowledge, and self-efficacy about HF self-care. Participants will receive 4-6 TMs/week during the induction phase (0 to 3 months), and 2-4 TMs per week during the adoption period (3 to 6 months).Tailoring of the TMs is guided by participants' responses to validated instruments assessing intervention target variables at baseline and 3 months
62779306|NCT01019850|OTHER|Treatment for All Patients|Patients on study will receive vorinostat orally once daily on days 1 to 14. The starting dose level is 180 mg/M2. The maximum dose is 400 mg. Patients will receive 131- I Metaiodobenzylguanidine on day 3, 1hr after vorinostat dosing. Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg. Peripheral Blood Stem Cell Infusion is planned for 2 weeks after MIBG infusion (day 17). The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing. Patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines.
62779307|NCT02979223|EXPERIMENTAL|PMC/PEG-Asc|Picolyte 1 bottle/170cc at one day before colonoscopy, 7 PM. And then, Intake Coolprep 1L at the day of colonoscopy, 5 AM
62779308|NCT02979223|ACTIVE_COMPARATOR|PEG-Asc/PMC|Intake Coolprep 1L at one day before colonoscopy, 7 PM. And then, Intake Picolyte 1 bottle/170cc at the day of colonoscopy, 5AM
62396350|NCT06205225|EXPERIMENTAL|MyApps|In addition to usual care and patient education resources, participants in the MyApps group will receive three commercially available apps (Heart Failure Storylines, Withings Health Mate, and Fitbit), and three connected health devices (Withings Body Cardio Scale, Withings BP monitor, and Fitbit activity tracker). The apps interface with the devices via Bluetooth offering patients a comprehensive set of mHealth tools that support the core elements of HF self-care (maintenance, self-monitoring, and self-management).
62396351|NCT06205225|EXPERIMENTAL|MyApps + Text4HF|Participants in this group will receive the MyApps and Text4HF intervention components, combined.
62396352|NCT06113458|ACTIVE_COMPARATOR|Standard and One-time Training|Patient level: Standard, automatic reminders Clinic level: One-time training
62396353|NCT06113458|EXPERIMENTAL|Standard and Practice Facilitation|Patient level: Standard, automatic reminders Clinic level: Regular, ongoing coaching
62396354|NCT06113458|EXPERIMENTAL|High-intensity and One-time Training|Patient level: Personalized feedback Clinic level: One-time training
62396355|NCT06113458|EXPERIMENTAL|High-intensity and Practice Facilitation|Patient level: Personalized feedback Clinic level: Regular, ongoing coaching
62396356|NCT01501019|NO_INTERVENTION|Sjogren and Myositis Control (no control for takayasu's)|
62396357|NCT01501019|EXPERIMENTAL|Sjogren, Myositis and Takayasu's Trained|
62396358|NCT04191590|OTHER|Patient with Chronic Rhinosinusitis (CRS)|Patients with endonasal surgery scheduled under general anesthesia for an indication of Chronic Rhinosinusitis (CRS)
62396359|NCT04191590|OTHER|Patient without Chronic Rhinosinusitis (CRS)|Patients with endonasal surgery scheduled under general anesthesia for an indication of endonasal surgery for nasal obstruction or patients requiring an endonasal surgical approach such as pituitary adenomas for example.
62003769|NCT03983096||control group|Patients with invasive breast cancer diagnosed by menstrual histology in 2014-2018 and receiving neoadjuvant chemotherapy, or patients with invasive breast cancer diagnosed by menstrual histology in 2014-2016 and receiving adjuvant chemotherapy. That used epirubicin for treat.
62189332|NCT06032507|EXPERIMENTAL|Pulsed lavagegroup|Bone cementation with previous high-pressure pulsatile lavage
62189333|NCT06032507|EXPERIMENTAL|Non-pulsed lavage group|Bone cementation with previous manual rinsing lavage
62189334|NCT00620269|EXPERIMENTAL|study arm 1|Induction (with Erlotinib X 3 cycles) -\> CCRT with Erlotinib (X 2 cycles) -\> continue Erlotinib (X 6 cycles)
62396360|NCT05822973|ACTIVE_COMPARATOR|would closure using absorbable sutures|patients randomized into the absorbable suture group will have their incisions closed with 3.0 monocryl sutures
62396361|NCT05822973|ACTIVE_COMPARATOR|would closure using non-absorbable sutures|Patients randomized into the nonabsorbable suture group will have their incisions closed with either a 3.0 nylon suture
62396362|NCT03737812|PLACEBO_COMPARATOR|Placebo|Participants randomized to receive placebo by intravenous infusion.
62396363|NCT03737812|EXPERIMENTAL|Elezanumab 400mg Dose|Participants randomized to receive 400mg of elezanumab by intravenous infusion.
62003770|NCT00676442|OTHER|1|PN400 administered after meal
62189335|NCT00620269|EXPERIMENTAL|study arm 3|Induction (IP X 3 cycles) -\> CCRT with IP (X 2 cycles)
62396364|NCT03737812|EXPERIMENTAL|Elezanumab 1800 mg Dose|Participants randomized to receive 1800mg of elezanumab by intravenous infusion.
62396365|NCT05926687|ACTIVE_COMPARATOR|Social Communication + Reduce Frequency|"Starting Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week~Secondary Intervention: Reduce Frequency of Social Communication Intervention Intervention: Social Communication Who: Parent \& Child \& Therapist Reduce Frequency: 1-hour once/week"
62396366|NCT05926687|ACTIVE_COMPARATOR|Social Communication + Add Tools|"Starting Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week~Secondary Intervention: Add Tools to Social Communication Intervention Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week Add: Video feedback"
62779309|NCT04994678|EXPERIMENTAL|Virtual Reality Training Group|VR training system will be setup in multidisciplinary lab of Foundation University Institute of Rehabilitation Sciences Foundation University Islamabad. Display will be provided on 55 inch LED TV with audio feedback. Display will be at height of 5 feet from floor and at distance of 6 feet from Subject. The Virtual reality based training group will receive a game based virtual reality training via XBOX 360 or wii fit balance games. Particiapants will be required to physically move to move avatar on screen to rapidly leaning away, squat to avoid overhead obstacles and try small jump to avoid lower obstacles, single leg stance, in addition person will required to do half squatting, side to side jumps and vertical jumps. Treatment will be provided 3 times a week for 6 weeks with each session lasting for 30-50 minutes. Progressively challenge will be increased.
62779310|NCT04994678|ACTIVE_COMPARATOR|Moderate Aerobic Exercise Training Group|Moderate aerobic exercise training will be provided using motorized tread mill and stationary/recombinent cycle. Treatment will be provided for 30-50 minutes 3 times a week for 6 weeks.
62779311|NCT06284512||Uveal Melanoma|Patients with uveal melanoma will undergo a routine diagnostic imaging with color fundus photography and sonography.
62779312|NCT03802591|EXPERIMENTAL|CS1001 monoclonal antibody|in combination with Oxaliplatin and Capecitabine
62779313|NCT03802591|PLACEBO_COMPARATOR|CS1001 placebo|in combination with Oxaliplatin and Capecitabine
62779314|NCT01969032|EXPERIMENTAL|2 consequent anthracycline-taxane based chemotherapy regimens|Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
62779315|NCT00767767|PLACEBO_COMPARATOR|Placebos|Saline Infusion
62003771|NCT00676442|OTHER|2|PN400 administered prior to meal
62003772|NCT00676442|OTHER|3|PN400 administered prior to meal
62189336|NCT00620269|ACTIVE_COMPARATOR|control arm|CCRT with IP (X 2 cycles) -\> consolidation IP (X 3 cycles)
62779316|NCT00767767|ACTIVE_COMPARATOR|Propofol 0.45mcg/mL|Anesthetic Drug Infusion
62779317|NCT00767767|ACTIVE_COMPARATOR|Propofol 0.90mcg/mL|Anesthetic Drug Infusion
62779318|NCT00767767|ACTIVE_COMPARATOR|Thiopental 1.5mcg/mL|Anesthetic Drug Infusion
62779319|NCT00767767|ACTIVE_COMPARATOR|Thiopental 3mcg/mL|Anesthetic Drug Infusion
62779320|NCT01835730|EXPERIMENTAL|PE0139 Injection|Single subcutaneous injection of PE0139, 40 mg/mL
62779321|NCT01835730|PLACEBO_COMPARATOR|Placebo|Single subcutaneous injection of 0.9% Sodium Chloride (NaCl) (Placebo)
62779322|NCT01160432|EXPERIMENTAL|Methadone naloxone combination product 2/0,04 mg/ml|Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml
62779323|NCT01160432|ACTIVE_COMPARATOR|Methadone 2 mg/ml|Normal treatment except the dilution of methadone solution (5 mg/ml → 2 mg/ml).
62779324|NCT00467233|EXPERIMENTAL|1|Laser Treatment
62779325|NCT00467233|EXPERIMENTAL|2|Acid peel
62779326|NCT05024903|ACTIVE_COMPARATOR|Control Group: (PWG 1.0)|Those randomized to PWG 1.0 would have already completed their serious illness medical planning. Further involvement in the trial will be solely for the purposes of the outcome data collection
62779327|NCT05024903|ACTIVE_COMPARATOR|Intervention group: PWG 2.0|Serious illness medical planning plus the novel e-health platform designed to help people more broadly think and plan ahead
62779328|NCT04167137|EXPERIMENTAL|Arm 1: SYNB1891 Monotherapy|SYNB1891 monotherapy was administered as an IT injection on Days 1, 8, and 15 of Cycle 1 and Day 1 of subsequent cycles for up to 24 months/35 cycles. The starting dose of SYNB1891 in the first cohort was 1 × 10\^6 live cells and was increased in approximately 3-fold increments in subsequent cohorts.
62003773|NCT00676442|OTHER|4|PN400 followed by fast
62571667|NCT04505930|ACTIVE_COMPARATOR|Control Group with handouts|The study team provides the participants in the control group with education, using only handouts of vaccinations including HPV, but not using interactive video watch and dynamic discussion
62571668|NCT03726047|NO_INTERVENTION|Control|Subjects will complete learning of a new walking pattern through distorted visual feedback and retention will be tested immediately after and 24 hours later (without visual feedback).
62003774|NCT01306617|EXPERIMENTAL|ABT-450/r (250/100 mg) and ABT-333 plus RBV in treatment-naïve|ABT-450/r (250/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID for 12 weeks in treatment-naïve participants.
62003775|NCT01306617|EXPERIMENTAL|ABT-450/r (150/100 mg) and ABT-333 plus RBV in treatment-naïve|ABT-450/r (150/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID for 12 weeks in treatment-naïve participants.
62779329|NCT04167137|EXPERIMENTAL|Arm 2: SYNB1891 in Combination with Atezolizumab|"SYNB1891 was administered as an IT injection on Days 1, 8, and 15 of Cycle 1 and Day 1 of subsequent cycles for up to 24 months/35 cycles. The dose of SYNB1891 in the first cohort was 1 × 10\^7 live cells and was increased in an approximately 3-fold increment to 3 × 10\^7 live cells in the second cohort.~Atezolizumab was administered in accordance with its recommended dose and schedule (1200 mg IV Q3W) on Day 1 of each cycle for up to 24 months/35 cycles. On days when atezolizumab and SYNB1891 were both administered, SYNB1891 was administered first, followed by at least 1 hour of observation prior to the atezolizumab infusion."
62779330|NCT03087292|ACTIVE_COMPARATOR|Resistance training group|"Patients to be randomly assigned to the resistance training group will have resistance training with vascular occlusion 2 times per week for a period of 8 weeks on unilateral leg extension machine. During each training, they will performed 3 sets of 15 repetitions at the intensity of 30% 1 RM (repetition maximum). Each training set will separated by a 30 second rest period."
62571669|NCT03726047|EXPERIMENTAL|Exercise|Subjects will complete learning of a new walking pattern through distorted visual feedback and retention will be tested immediately without visual feedback. This will be followed immediately by 5 minutes of high intensity exercise. Retention without visual feedback will them be tested again 24 hours later.
62003776|NCT01306617|EXPERIMENTAL|ABT-450/r (150/100 mg) and ABT-333 plus RBV in non-responders|ABT-450/r (150/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID in previous non-responders to pegylated interferon (pegIFN) and RBV.
62003777|NCT03537118|EXPERIMENTAL|Fluoroscopic + Ultrasound Guidance|
62571670|NCT01666626||Crohn's Inpatients|Crohn's Inpatients, with clinical small bowel obstruction All undergo ultrasound stiffness imaging (USI) of distal affected ileum.
62571671|NCT01666626||Crohn's Outpatients|Crohn's Outpatients, starting anti-TNF therapy All undergo ultrasound stiffness imaging (USI) at week 0, 6, 14
62779331|NCT03087292|NO_INTERVENTION|Control group|Patients to be randomly assigned to the control group (normal physical activity) will continue with their usual physical activity regime.
62779332|NCT02696239|ACTIVE_COMPARATOR|V-lock suture|V-lock absorbable Wound Closure Device, by Covidien
62779333|NCT02696239|ACTIVE_COMPARATOR|Vicryl suture|Vicryl suture by Ethicon
62003778|NCT03537118|NO_INTERVENTION|Fluoroscopic Guidance Alone|
62003779|NCT01087424|EXPERIMENTAL|R mini CHOP|Induction : 3 cycles every 3 weeks Consolidation :3 cycles every 3 weeks
62003780|NCT01532466|EXPERIMENTAL|Rocuronium, fentanyl-induced cough, normal saline|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
62003781|NCT01532466|NO_INTERVENTION|Normal saline|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
62003782|NCT00437034|EXPERIMENTAL|Treatment (antiangiogenesis therapy)|Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62003783|NCT01479803|ACTIVE_COMPARATOR|EchoTip HD ProCore 22 Gauge|first passage in the pancreatic tumor with the EchoTip HD ProCore 22 Gauge then with the EchoTip 22 Gauge
62003784|NCT01479803|ACTIVE_COMPARATOR|Echo Tip 22 Gauge|First passage through the tumor with the EchoTip 22 Gauge then with Echotip HD ProCore 22 Gauge
62003785|NCT01356433|OTHER|arm1, vitamin C treated first|Arm 1(50cases): intervention with oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.
62003786|NCT01356433|OTHER|Arm 2 control first|
62571672|NCT02945475||obese|Individuals ages 18 to 35 years of age with body mass index (BMI) 30-40 kg/m2
62571673|NCT02945475||lean|Individuals ages 18 to 35 years of age with BMI of 19-24.9 kg/m2
62779334|NCT02696239|ACTIVE_COMPARATOR|Lapra-Ty II|Lapra-Ty II, Absorbable Suture Clip, by Ethicon
62779335|NCT01300572|EXPERIMENTAL|Y-90-BC8 & Allogeneic Transplant|"PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.~GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180."
62003787|NCT03256552|ACTIVE_COMPARATOR|GP MDI 28.8 micrograms|Glycopyrronium Metered Dose Inhaler 28.8 micrograms
62571674|NCT02945475||overweight|Individuals ages 18 to 35 years of age with BMI of 25-29.9 kg/m2
62571675|NCT06576440|EXPERIMENTAL|Major depressive disorder|Patients with major depressive disorder will receive a subcutaneous injection of ghrelin (experimental) on one day and saline (placebo) on another day (order randomised; double-blind cross-over design).
62779336|NCT06264856|EXPERIMENTAL|bronchoscopic suction|Bronchoscopic suction is a medical procedure used to remove excess mucus, secretions, and foreign objects from the airways through a bronchoscope. The patient would receive bronchoscopic sputum suction every 24-48 hrs after randomization until leaving ICU.. The patient could still receive blind negative pressure aspiration suction as the usual medical routine(every 2-4 hrs sputum suction if needed).
62003788|NCT03256552|ACTIVE_COMPARATOR|GP MDI 14.4 micrograms|Glycopyrronium Metered Dose Inhaler 14.4 micrograms
62189337|NCT00620269|EXPERIMENTAL|study arm 2|Induction (Erlotinib X 3 cycles) -\> CCRT with IP (X 2 cycles) -\> recurrence -\> Erlotinib (until PD)
62189338|NCT04073342||Surgical Necrotizing enterocolitis|Cases of preterm infants with necrotizing enterocolitis need surgical intervention
62779337|NCT06264856|ACTIVE_COMPARATOR|blind negative pressure aspiration suction|Negative pressure aspiration suction is a medical procedure that uses suction to remove fluids, mucus, or other materials from the body by creating a negative pressure or vacuum. The procedure involves inserting a catheter into the airway and applying negative pressure to the catheter to suction out the secretions or fluids. The patient would receive blind negative pressure aspiration suction as the usual medical routine(every 2-4 hrs sputum suction if needed).
62003789|NCT03256552|ACTIVE_COMPARATOR|GP MDI 7.2 micrograms|Glycopyrronium Metered Dose Inhaler 7.2 micrograms
62003790|NCT03256552|PLACEBO_COMPARATOR|Placebo MDI|Placebo Inhalation Aerosol
62003791|NCT04973761|OTHER|Strip composite crowns|
62189339|NCT04073342||Non Necrotizing enterocolitis|babies with intestinal operations for non necrotizing enterocolitis pathologies like congenital intestinal obstruction.
62779338|NCT03245983|EXPERIMENTAL|Patient willing to participate|
62779339|NCT02964767||HIV mono infection|HIV Patients do not have active Mycobacterium Tuberculosis infection
62003792|NCT04973761|EXPERIMENTAL|Zirconium crowns|
62003793|NCT01886833||Mother-Infant Pair|"The study will involve consenting mother-infant pairs from Kamwala health facility in Lusaka where the Maternal Child Health (MCH). Those generally interested will be invited to the research clinic, where more detailed information about the study is offered. Motivated mothers will be recruited and taken through the written informed consent process by the study nurse.~Enrolled mother-infant pairs will undergo baseline procedures as earlier described. They will then be followed prospectively until about December 2016. They will be expected to come to the clinic for scheduled visits at baseline, 1, 3, 12, 15 and 42 months. They will be urged to come to the clinic for unscheduled visit should the infant be unwell at any time, and particularly each time the infant experiences diarrhoea."
62003794|NCT00805116|EXPERIMENTAL|1|Whale blubber oil
62003795|NCT00805116|ACTIVE_COMPARATOR|2|Cod liver oil
62003796|NCT05597007|EXPERIMENTAL|Treatment|Clinic participation
62003797|NCT03797638|EXPERIMENTAL|Patients with writer's cramp|Patients with writer's cramp
62189340|NCT01855347||Preterm infants|Preterm infants (32 to 36 weeks of postmenstrual age) will be evaluated with a Near infrared Spectroscopy monitor device.
62189341|NCT05834920|ACTIVE_COMPARATOR|Neurofeedback|
62189342|NCT05834920|EXPERIMENTAL|Transcranial pulse stimulation|
62189343|NCT05834920|NO_INTERVENTION|Waitlist|
62189344|NCT01674322|EXPERIMENTAL|Ibrutinib|All participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
62189345|NCT01769430||Community acquired respiratory infection|Measurement of exhaled breath aerosol
62189346|NCT02874599|EXPERIMENTAL|Patients|Patients who require multiple dental restorations. Teeth will be restored with commercial restorative composites
62779340|NCT02964767||HIV-Tb. co infection|Patients with HIV and MycobacteriumTuberculosis co infections
62779341|NCT01344070|ACTIVE_COMPARATOR|Reference formulation of each drug|Innovator formulation
62779342|NCT01344070|ACTIVE_COMPARATOR|generic formulation a|one of the several generic formulations in the market, randomly selected for each drug
62003798|NCT03797638|OTHER|Control subjects|Control subjects, without writer's cramp, matched with case subjects with age, gender and hand writing
62003799|NCT01833403|OTHER|Measurement of insulin sensitivity|All participants will undergo a hyperinsulinemic-euglycemic clamp to measure insulin sensitivity
62003800|NCT05074433|EXPERIMENTAL|casirivimab+imdevimab Initial + Q4W|Initial subcutaneous (SC) dose, then SC dose every 4 weeks (Q4W)
62003801|NCT05074433|EXPERIMENTAL|casirivimab+imdevimab Q4W|SC dose Q4W
62003802|NCT05074433|EXPERIMENTAL|casirivimab+imdevimab Q12W|SC dose every 12 weeks (Q12W)
62003803|NCT05074433|PLACEBO_COMPARATOR|Placebo|SC dose Q4W
62779343|NCT01344070|ACTIVE_COMPARATOR|generic formulation b|second of the several generic formulations in the market, randomly selected for each drug
62779344|NCT01344070|ACTIVE_COMPARATOR|generic formulation c|third of the several generic formulations in the market, randomly selected for each drug
62779345|NCT01707082|EXPERIMENTAL|Part A Cohort 1|
62779346|NCT01707082|EXPERIMENTAL|Part A Cohort 2|
62779347|NCT01707082|EXPERIMENTAL|Part A Cohort 3|
62189347|NCT04786418|ACTIVE_COMPARATOR|Control group|Participants will be given standard advice about healthy eating, physical activity and management of weight during the study visit, in line with current NHS practice. There will be a total of 9 study visits for this group.
62189348|NCT04786418|EXPERIMENTAL|Low-calorie diet intervention group|Participants will received a special diet involving 25 regular visits and intensive management. Participants will be given a supply of especially formulated soups and shakes, a special diet in a form of powder that need to be mixed with 200 ml water.
62189349|NCT05707884|ACTIVE_COMPARATOR|volatile sedation|Patients receive volatile sedation for the intended 72 hours of deep sedation after complex free flap surgery.
62189350|NCT05707884|NO_INTERVENTION|intravenous sedation|Patients receive intravenous sedation (e.g. propofol) for the intended 72 hours of deep sedation after complex free flap surgery.
62189351|NCT05571826||telerehabilitation|Assessments, no specific intervention
62189352|NCT02578888|ACTIVE_COMPARATOR|Palliative Therapy|EORTCQLQ-30 and FAMCARE questionnaire every 6 weeks for 3 visits.
62189353|NCT02578888|EXPERIMENTAL|Palliative Therapy+ idiographic|EORTC QLQ-30, and FAMCARE questionnaire every 6 weeks for 3 visits plus patients undergo idiographic assessment.
62779348|NCT01707082|EXPERIMENTAL|Part A Cohort 4|
62779349|NCT01707082|EXPERIMENTAL|Part A Cohort 5|
62779350|NCT01707082|EXPERIMENTAL|Part B Cohort 1|
62779351|NCT01707082|EXPERIMENTAL|Part B Cohort 2|
62779352|NCT02195141|ACTIVE_COMPARATOR|conventional fraction|Radiotherapy (25x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily
62779353|NCT02195141|EXPERIMENTAL|SIB|Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
62779354|NCT00360568|EXPERIMENTAL|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants received LCIG, delivered through a percutaneous endoscopic gastrostomy with jejunal extension (PEG-J), administered for up to 12 months (52 weeks).~Starting dose of LCIG was based on the participant's optimized oral levodopa-carbidopa dose that the subject was receiving just prior to randomization in Study S187.3.001 (NCT00357994) or Study S187.3.002 (NCT00660387), administered in the morning of the first day following Study Day 86 of either of these 2 previous studies. The LCIG infusion was expected to infuse over approximately16 hours each day with a rate of infusion within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances."
62779355|NCT05945160|EXPERIMENTAL|Nutritional Supplements Group|Alpha Lipoic Acid will be administered as two 300 mg capsules taken once daily CoQ-10 will be administered as two 200mg capsules daily.
62779356|NCT05945160|NO_INTERVENTION|Standard of Care Group|Standard of care treatment for vestibular function.
62779357|NCT03672526|EXPERIMENTAL|device compuflo|
62779358|NCT04541511|EXPERIMENTAL|Healthy subject|"Healthy subject will be asked to performed two 6-minutes walking test : one in a corridor and one on the non-motorized treadmill.~Oxygen saturation, heart rate and Borg score will be collected before and after each test."
62779359|NCT04541511|EXPERIMENTAL|Patients|Patients will be asked to to performed a 6-minutes walking test on the non-motorized treadmill and to answer a questionnaire regarding the acceptability and ease of use of the new method.
62189354|NCT01124097|EXPERIMENTAL|Eslicarbazepine acetate 800 mg once daily (QD)|
62779360|NCT04186871|EXPERIMENTAL|Systemic Lupus Erythematosus (SLE): branebrutinib|
62779361|NCT04186871|PLACEBO_COMPARATOR|SLE: placebo|
62189355|NCT01124097|EXPERIMENTAL|Eslicarbazepine acetate 1200 mg QD|
62189356|NCT01124097|EXPERIMENTAL|Eslicarbazepine acetate 1600 mg QD|
62779362|NCT04186871|EXPERIMENTAL|Primary Sjögren's Syndrome (pSS): branebrutinib|
62779363|NCT04186871|PLACEBO_COMPARATOR|pSS: placebo|
62779364|NCT04186871|EXPERIMENTAL|Rheumatoid Arthritis (RA): branebrutinib followed by abatacept|
62189357|NCT01124097|PLACEBO_COMPARATOR|Placebo|
62189358|NCT01183247|ACTIVE_COMPARATOR|Rapamycin|Rapamycin-MMF-tacrolimus
62189359|NCT01183247|ACTIVE_COMPARATOR|Everolimus|Everolimus - tacrolimus - MMF
62189360|NCT01183247|ACTIVE_COMPARATOR|Prednisone|tacrolimus - MMF -prednisone
62189361|NCT01562106|EXPERIMENTAL|ICG Dye|Fluorescence-guided sentinel lymph node detection
62189362|NCT06189209|EXPERIMENTAL|Single arm, Open label study|Single agent Tenalisib \[RP6530 (PI3k delta, gamma and SIK3 inhibitor)\]
62571676|NCT06576440|EXPERIMENTAL|Healthy control participants|Healthy control participants will receive a subcutaneous injection of ghrelin (experimental) on one day and saline (placebo) on another day (order randomised; double-blind cross-over design).
62779365|NCT04186871|PLACEBO_COMPARATOR|RA: placebo followed by abatacept|
62779366|NCT04899453|EXPERIMENTAL|Zanubrutinib/rituximab & intravitreal MTX|Experimental arm will be treated with rituximab plus zanubrutinib (ZR) regimen for 6 cycles and followed by zanubrutinib maintenance for 2 years, meanwhile, intravitreal methotrexate will be given as protocol during the 1st year of treatment.
62779367|NCT02277912|EXPERIMENTAL|Transcranial Magnetic Stimulation I|Intervention: Repetitive navigated Transcranial Magnetic Stimulation of the motor cortex
62779368|NCT02277912|EXPERIMENTAL|Transcranial Magnetic Stimulation II|Intervention: Repetitive navigated Transcranial Magnetic Stimulation of the secondary somatosensory cortex
62779369|NCT02277912|SHAM_COMPARATOR|Sham Stimulation|Intervention: Repetitive sham Transcranial Magnetic Stimulation with SHAM block of the motor cortex
62189363|NCT04952480|EXPERIMENTAL|Dose-escalated adaptive chemoradiotherapy|Concurrent with standard of care platinum doublet based chemotherapy (cisplatin + etoposide), radiation treatment plan will be delivered in three sequential phases with two scheduled replans during the treatment along with scaled dose limits for organs-at-risk: Phase 1 dose prescription = 14 Gy in 7 fractions; Phase 2 dose prescription = 10 Gy in 5 fractions starting the day after the final (7th) fraction is delivered; Phase 3 dose prescription = either a) 70 Gy in 35 fractions, or if this cannot be safely reached without exceeding the dose limit of an organ-at-risk, b) the maximum safe prescribe-able dose tolerance specified in the protocol. Either 3D conformal radiotherapy or IMRT planning and delivery techniques will be employed, including contouring relevant thoracic organs-at-risk. All CT simulation scans will be without contrast.
62189364|NCT00348387|EXPERIMENTAL|Group 1|
62189365|NCT00348387|ACTIVE_COMPARATOR|Group 2|
62189366|NCT00612352|ACTIVE_COMPARATOR|Family HIstory Positive|Subjects with a positive family history of alcoholism.
62189367|NCT00612352|ACTIVE_COMPARATOR|Family History Negative|Subjects with a negative family history of alcoholism.
62189368|NCT06097962|EXPERIMENTAL|Group A (low-dose group)|"NK510 will be administered once a week for a total of six weeks.1×10\^9 NK cells/dose.~PD-1 blockade will be administered every 3 weeks."
62779370|NCT01836926|ACTIVE_COMPARATOR|Open intersphincteric resection|surgical Instruments for open approach intervention: Open laparotomy through abdominal incision and mobilization of the colon and rectum up to the splenic flexure with high ligation of the inferior mesenteric vessels and mesorectal excision till the levator ani then the peranal approach to resect the distal margin of the rectum through high or low intersphincteric resection in the plane between internal and external anal sphincters.
62779371|NCT01836926|ACTIVE_COMPARATOR|laparoscopic intersphincteric resection .|"instruments used: 4 or 5 laparoscopic trocars (two or three (10-mm) trocar, Two 5-mm trocars and a 12-mm trocar with reducers),Three 5-mm fenestrated grasping forceps, Five-millimetre coagulating shears, a 5-mm straight grasping forceps, Harmonic scalpel, 5 or 10 mm, a 10-mm fenestrated forceps, a 10-mm dissector,5 mm Bipolar grasper, a 5-mm needle holder, Twelve-millimetre linear staplers~intervention:~1. Trocar Placement and Exposure~2. Rectosigmoid Mobilization and Control of Inferior Mesenteric Vessels~3. Taking Down the Splenic Flexure~4. rectal dissection till the levator ani muscle and resection of thye lateral ligaments~then the peranal phase as in the laparotomy approach."
62779372|NCT03294850|EXPERIMENTAL|NASH group|These are individuals that have been identified as having NASH by MRE. Confirmation with liver biopsy required for continuation in the longitudinal study.
62779373|NCT03294850|ACTIVE_COMPARATOR|Non-NASH (NAFLD or normal) group|These are individuals that do not have NASH. They either have normal liver physiology or only have evidence of hepatic steatosis. This group will be studied up until the day of their bariatric surgery and will serve as a comparator population with respect to baseline measurements.
62779374|NCT05691647|EXPERIMENTAL|Chronotherapy + treatment as usual|
62779375|NCT05691647|ACTIVE_COMPARATOR|Treatment as usual|medication, cognitive behavioral therapy, and other psychotherapies.
62779376|NCT05385250|OTHER|Bone sparring radiotherapy|Observational arm of bone-sparing radiotherapy
62779377|NCT03246659|EXPERIMENTAL|arm 1|111In-CP04
62779378|NCT03246659|EXPERIMENTAL|arm 2|111In-CP04 with co-administration of gelofusine/gelaspan
62779379|NCT00675220||A|
62779380|NCT00961714|EXPERIMENTAL|OsseoFix|Osseofix is an titanium expandable device similar to a vascular stent that is placed in the fractured vertebral body to provide a structure in which bone cement (polymethylmethacrylate) is inserted. It is intended to be used in the thoracolumbar spine between levels T6 through L5.
62779381|NCT01039493||Patients|
62779382|NCT01039493||Providers|
62003804|NCT05447949|EXPERIMENTAL|Group 1 (ESPB + Dexmedetomidine)|Patients received Ultrasound guided ESPB with addition of dexmedetomidine 1 Mcg/kg to 30 ml levobupivacaine 0.25%, N=30 (16)
62189369|NCT06097962|EXPERIMENTAL|Group B (medium-dose group)|"NK510 will be administered once a week for a total of six weeks.9×10\^9 NK cells/dose.~PD-1 blockade will be administered every 3 weeks."
62189370|NCT06097962|EXPERIMENTAL|Group C (high-dose group)|"NK510 will be administered once a week for a total of six weeks.12×10\^9 NK cells/dose.~PD-1 blockade will be administered every 3 weeks."
62189371|NCT00151398|EXPERIMENTAL|A|
62189372|NCT00151398|EXPERIMENTAL|B|
62779383|NCT00115232||1|Children without family history of early atherosclerosis
62779384|NCT00115232||2|Children with family history of early atherosclerosis.
62779385|NCT00115232||3|Parents of children without family history of early atherosclerosis
62779386|NCT00115232||4|Parents of children with family history of early atherosclerosis
62779387|NCT03300921|EXPERIMENTAL|Arm A|Arm A: 50mcg IV weekly
62779388|NCT03300921|EXPERIMENTAL|Arm B|Arm B: 12mcg PO daily
62779389|NCT04538079||Feasibility/Accuracy/Reproducibility|The first 20 participants will be analysed for feasibility and the first 40 ECHOs for accuracy/reproducibility of non-invasive Cardiac Output Monitoring with ECHO as reference Method.
62779390|NCT04538079||Prediction of Circulatory Failure|Together with the Feasibility/Accuracy/Reproducibility Cohort this group's results will be analysed for prediction of circulatory failure defined as an ultrasound abnormality (IVH grade 3 - 4) or death within the first two weeks of life.
62779391|NCT00051922|EXPERIMENTAL|1|Participants will receive vaccine and will be followed for 1 year
62779392|NCT03040986|EXPERIMENTAL|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate by mouth (PO) twice daily (BID). Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity
62779393|NCT03759106|OTHER|No Intervention: Usual care|All study participants in the control group will receive an 8-week written home exercise program (e.g. GRASP) , i.e. the usual care discharge home program.
62189373|NCT00151398|EXPERIMENTAL|C|
62189374|NCT00151398|ACTIVE_COMPARATOR|D|
62189375|NCT01936467|EXPERIMENTAL|Standard suction|These are patients who will have endoscopic ultrasound-guided fine needle aspiration using the standard suction FNA technique: 15 to-and-fro movements within the lesion will be performed with use of 10cc suction syringe.
62189376|NCT01936467|EXPERIMENTAL|Capillary suction|These are patients who will have endoscopic ultrasound-guided fine needle aspiration using the capillary suction FNA technique: 15 to-and-fro movements within the lesion will be performed with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
62189377|NCT03735953|EXPERIMENTAL|Retroflexion arm|Retroflexion in the total colon and slow withdrawal to the rectum and record all visible colon polyps and other colon related diseases
62189378|NCT03735953|NO_INTERVENTION|Forward view arm|Colonoscope is slowly withdrawn from the proximal colon to the the rectum have a forward view and record all visible colon polyps and other colon related diseases
62189379|NCT04786613|ACTIVE_COMPARATOR|20 mg, 1.0% hyaluronic acid injection groups|In the first group, 2 ml linearly linked 20 mg 1.0% hyaluronic acid injection in 5 sessions will be applied.
62189380|NCT04786613|ACTIVE_COMPARATOR|32 mg, 1.6% hyaluronic acid injection groups|In the second group, 2 ml linearly linked 32 mg 1.6% hyaluronic acid injection in 3 sessions will be applied.
62189381|NCT04786613|ACTIVE_COMPARATOR|48 mg, 2.0% hyaluronic acid injection groups|In the third group 2.4 ml linearly linked 48 mg 2.0% hyaluronic acid injection in a single sessions will be applied.
62189382|NCT01853189|OTHER|OMT + Usual Care|
62189383|NCT01853189|OTHER|Usual Care|
62003805|NCT05447949|EXPERIMENTAL|Group 2 (ESPB+ dexamethasone)|Patients received Ultrasound guided ESPB with addition of dexamethasone 10 mg to 30 ml levobupivacaine 0.25%, N=30 (16)
62003806|NCT05447949|ACTIVE_COMPARATOR|Group 3 (ESPB)|Patients received Ultrasound guided ESPB with 30 ml levobupivacaine 0.25%, N=30
62003807|NCT06364969||Healthy subjects|Healthy adult volunteers (aged 18-35 years)
62003808|NCT05107362||Symptomatic Adult and Pediatric Subjects|Untrained lay user to collect throat swab specimen and perform investigational test.
62189384|NCT01042249|EXPERIMENTAL|Treatment|Treated with Pelvic Floor Muscle Training in 12 weeks
62189385|NCT01042249|NO_INTERVENTION|Control|Receives standard rehabilitation after stroke
62189386|NCT01434745|PLACEBO_COMPARATOR|Placebo|placebo
62189387|NCT01434745|EXPERIMENTAL|Simvastatin|0.5 mg/kg body weight/day
62189388|NCT02089139|EXPERIMENTAL|DISCOGEL|Percutaneous intradiscal injection of Discogel
62189389|NCT02089139|ACTIVE_COMPARATOR|conventional treatment|conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to: medications (analgesics, NSAIDs, muscle relaxants), physical therapy, manual techniques, transcutaneous electrical nerve stimulation (TENS), blocks
62003809|NCT01389440|EXPERIMENTAL|Gemcitabine, Erlotinib and radiotherapy|Gemcitabine + Erlotinib follow by Gemcitabine + Erlotinib + radiotherapy
62003810|NCT00071812|PLACEBO_COMPARATOR|Placebo plus SOC|
62003811|NCT00071812|EXPERIMENTAL|Belimumab 1 mg/kg plus SOC|
62571677|NCT01113372|EXPERIMENTAL|Clopidogrel 3 months|Regime of dual antiplatelet therapy (DAPT) including aspirin+clopidogrel for 3 months.
62189390|NCT02025855|EXPERIMENTAL|Methadone|Methadone will be administered at a dose calculated from the subjects total daily opioid requirements, with a maximum methadone dose of 60 mg per day. The methadone will be administered every 8 hours as 5 mg capsules that will be given via an enteral feeding tube.
62189391|NCT02025855|PLACEBO_COMPARATOR|Placebo|This will be a capsule containing only lactose and will be given every 8 hours via an enteral feeding tube. The number of placebo capsules will be calculated based on the subjects opioid requirements. This will ensure the same number of capsules will be given despite which arm the patient is enrolled in.
62189392|NCT01425138||Psoriasis|Published data on moderate-to-severe plaque psoriasis.
62189393|NCT00119561|EXPERIMENTAL|Arm 1|Telephone support groups
62189394|NCT00119561|NO_INTERVENTION|Arm 2|Usual VA care
62571678|NCT01113372|ACTIVE_COMPARATOR|Clopidogrel 12 months|Regime of dual antiplatelet therapy (DAPT) including aspirin+clopidogrel for 12 months.
62571679|NCT04275739|EXPERIMENTAL|Experimental: Episodic Future Thinking|
62779394|NCT03759106|EXPERIMENTAL|Experimental: Telerehabilitation system|Participants in the experimental group will receive 8 weeks home exercise program using a virtual reality (VR) and telerehabilitation system. The intensity and choice of game for the home program will be determined by the therapist based on the patient's abilities, interests, motivation and fatigue. The patient's performance for the VR home program will be monitored asynchronously and synchronously and the program adapted to ensure it remains at an appropriate level for the patient.
62779395|NCT02714283||Non-CF bronchiectasis patients|Complete national 2006-2014 Medicare data from Part A, B and D will be obtained from CMS. We will use bronchiectasis ICD-9 codes 494.0 and 494.1 to identify patients with bronchiectasis within Medicare. From this identified bronchiectasis cohort, we will exclude patients with cystic fibrosis (ICD-9 codes 277.00-277.09), HIV infection (042), and a history of organ transplant (V42.0, V42.1, V42.6, V42.7, V42.8).
62779396|NCT01471925|EXPERIMENTAL|Esomeprazole (40mg) + Sodium Bicarbonate (721mg)|
62779397|NCT01471925|ACTIVE_COMPARATOR|Nexium®|
62189395|NCT02695147||TAVI via Subclavian approach|Any TAVI procedure using any valve type performed via the subclavian approach
62189396|NCT02695147||TAVI via Direct Aortic approach|Any TAVI procedure using any valve type performed via the direct aortic approach
62571680|NCT04275739|ACTIVE_COMPARATOR|Control: Vivid Memory Task|
62779398|NCT03779087|EXPERIMENTAL|10d TL quadruple therapy|esomeprazole 40 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
62779399|NCT03779087|ACTIVE_COMPARATOR|10d AL quadruple therapy|esomeprazole 40 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, amoxicillin 500 mg and metronidazole 250 mg q.i.d. for 10 days
62779400|NCT00294255|EXPERIMENTAL|Risperidone|patients will receive risperidone for up to 20 weeks
62571681|NCT06535334||intravenous chemotherapy|triweekly chemotherapy with carboplatin AUC=5\~6 + liposomal-doxorubicin 30\~40mg/m2 or paclitaxel 175mg/m2 0r docetaxel 60\~75mg/m2
62571682|NCT06535334||intraperitoneal chemotherapy|"Day 1 IV Paclitaxel 135 mg/m2 + IP Cisplatin 75-100 mg/m2 or IP carboplatin (AUC = 6) Day 8 IP Paclitaxel 60 mg/m2 Every 21 days \* 6 cycles~OR~Day 1 IP Carboplatin AUC=5 or IP Cisplatin 50-75mg/m2 Day 2 IV Liposomal doxorubicin 15 mg/m2 + IP Liposomal doxorubicin 15 mg/m2 Every 28 days \* 6 cycles"
62779401|NCT03649724|PLACEBO_COMPARATOR|Placebo|0.25 ml of sterile normal saline administered subcutaneously / 12 weeks
62779402|NCT03649724|EXPERIMENTAL|Leuprolide|Eligard 22.5mg administered subcutaneously / 12 weeks
62003812|NCT00071812|EXPERIMENTAL|Belimumab 4 mg/kg plus SOC|
62003813|NCT00071812|EXPERIMENTAL|Belimumab 10 mg/kg plus SOC|
62003814|NCT01712984|EXPERIMENTAL|QIV ID Vaccine Group|Participants will receive the intradermal quadrivalent influenza vaccine
62003815|NCT01712984|ACTIVE_COMPARATOR|TIV ID1 Vaccine Group|Participants will receive the trivalent influenza vaccine containing the B strain from the primary (Yamagata) lineage
62003816|NCT01712984|ACTIVE_COMPARATOR|TIV ID2 Group|Participants will receive the intradermal trivalent influenza vaccine containing B strain from the alternate (Victoria) lineage
62003817|NCT05313165|EXPERIMENTAL|Treated with LimFlow|Treatment with the LimFlow Stent Graft System
62003818|NCT02553681|EXPERIMENTAL|HPT treated|Hydra-PEG Treatment (HPT) treated RGP contact lenses made from roflufocon D
62003819|NCT02553681|ACTIVE_COMPARATOR|untreated|untreated RGP contact lenses made from roflufocon D
62003820|NCT05594342|EXPERIMENTAL|Ivabradine+ dobutamine infusion|Patients will receive ivabradine 7.5 mg twice daily via oral route after starting dobutamine infusion by 30 minutes.
62003821|NCT05594342|ACTIVE_COMPARATOR|Dobutamine infusion only|Patient will receive dobutamine infusion only for cardiogenic shock
62189397|NCT04732871|EXPERIMENTAL|RSV_annual Group|Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and 2 revaccination doses at 12 months post-Dose 1 and at 24 months post-Dose 1, respectively and are followed up until the study end (Month 60).
62189398|NCT04732871|EXPERIMENTAL|RSV_flexible revaccination Group|Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and 2 revaccination doses at 24 months post-Dose 1 and at 48 months post-Dose 1, respectively and are followed up until the study end (Month 60).
62189399|NCT04732871|EXPERIMENTAL|RSV_1dose Group|Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and are followed up until Month 36. At Month 36, participants in this group will be re-randomized in 2 groups (RSV_1dose_M36 and RSV_1dose_flexible groups), which will be followed up until the study end (Month 60).
62189400|NCT03554031|EXPERIMENTAL|rhGH injection/Jintropin AQ|Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.No control.
62571683|NCT00982332|ACTIVE_COMPARATOR|betamethasone|patients treated with a single intramuscular injection of betamethasone
62571684|NCT00982332|PLACEBO_COMPARATOR|isotonic sodium chloride solution|
62189401|NCT03783676|EXPERIMENTAL|Remifentanil group|Will receive remifentanil bolus and infusion guided by an algorithm
62189402|NCT03783676|PLACEBO_COMPARATOR|Control group|Will receive normal saline bolus and infusion guided by the remifentanil algorithm
62396367|NCT05926687|ACTIVE_COMPARATOR|Social Communication + Switch Intervention to Disruptive Behavior|"Starting Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week~Secondary Intervention: Switch to Disruptive Behavior Intervention Who: Parent \& Therapist only Frequency: 1-hour once/week"
62396368|NCT05926687|ACTIVE_COMPARATOR|Disruptive Behavior + Reduce Frequency|"Starting Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour once/week~Secondary Intervention: Reduce Frequency of Disruptive Behavior Intervention Intervention: Disruptive Behavior Who: Parent \& Therapist only Reduce Frequency: 1-hour every other week"
62396369|NCT05926687|ACTIVE_COMPARATOR|Disruptive Behavior + Add Tools|"Starting Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour once/week~Secondary Intervention: Add Tools to Disruptive Behavior Intervention Intervention: Disruptive Behavior Who: Parent \& Therapist \& Child Frequency: 1-hour once/week Add: Video feedback"
62571685|NCT06578104||Paroxysmal|Ablation using the PulseSelect™ PFA system
62189403|NCT01913899|EXPERIMENTAL|Mirror therapy|60 minutes of mirror therapy each day over a period of 14 days starting directly post surgically (24-48 hours after surgery)
62396370|NCT05926687|ACTIVE_COMPARATOR|Disruptive Behavior + Switch Intervention to Social Communication|"Starting Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour once/week~Secondary Intervention: Switch to Social Communication Intervention Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week"
62396371|NCT02850757|EXPERIMENTAL|U shaped Guedl's airway|
62396372|NCT02850757|EXPERIMENTAL|Modified William's airway(Fekry airway )|
62571686|NCT06578104||Persistent|Ablation using the PulseSelect™ PFA system
62571687|NCT02494869|EXPERIMENTAL|Nonlinear Aerobic Training (75 minutes/week) closed to accrual|The ultimate goal is for participants to complete 75 minutes/week of structured aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from the (CPETs performed at baseline, midpoint, and Study Follow-Up. The 75 min/wk will be achieved via 3 individual supervised aerobic training sessions at approximately 25 minutes/session.All other on- site participants in Arms A and B will be provided with a heart rate monitor to thank them for completing the study. This arm is closed to accrual.
62396373|NCT05332912|EXPERIMENTAL|Immediate|Participants will receive 16 weeks of spatial ability experience.
62396374|NCT05332912|PLACEBO_COMPARATOR|Delayed|Participants will receive 8 weeks of verbal ability experience prior to receiving 8 weeks of spatial ability experience.
62396375|NCT06297629|EXPERIMENTAL|Group 1|If participants test positive for minimal residual disease (MRD), participants will be enrolled in Group 1. MRD refers to small numbers of cancer cells that remain in the body during or after treatment. Participants in this group will receive ASTX727 and DLI. If participants are enrolled in Group 1, the participant will take ASTX727 on Days 1-4 of each cycle.
62396376|NCT06297629|EXPERIMENTAL|Group 2|If participants do not test positive for MRD, you will be enrolled in Group 2. Participants in this group will only receive ASTX727. If participants are enrolled in Group 2, the participant will take ASTX727 on Days 1-3 of each cycle.
62396377|NCT01376076|EXPERIMENTAL|1|Sequential, Multiple Dose, titration from 1.5mg to 18mg once daily dose of cariprazine
62571688|NCT02494869|EXPERIMENTAL|Nonlinear Aerobic Training (150 minutes/week)|The ultimate goal is for participants to complete 150 minutes/week of structured aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from the CTPETs test performed at baseline, midpoint, and Study Follow-Up. The 150 minutes/week will be achieved by completing 3 aerobic training sessions/week for approximately 50 minutes/session. All other on- site participants in Arms A and B will be provided with a heart rate monitor to thank them for completing the study.
62584911|NCT00170625|EXPERIMENTAL|Relapse >12 months|"dose level 0: Topotecan 1mg/m2/d on day 1-3, q 21d (+ Carboplatin AUC 5 on day 3 after Topotecan application)~If dose limiting toxicity (DLT) is present then Topotecan dose will be reduced to dose level -1 (dose level -1: Topotecan 0.75 mg/m2/d on day 1-3, q 21d (+ Carboplatin AUC 5 on day 3 after Topotecan application))~A DLT is present if a patient has a postponement due to hematologic toxicity of more than 7 days within the first four courses at dose level 0."
62189404|NCT01913899|ACTIVE_COMPARATOR|Occupational/ physical therapy|60 minutes of occupational/ physical therapy each day over a period of 14 days starting 24-48 hours post surgically
62189405|NCT06546540|EXPERIMENTAL|Telitacicept|
62189406|NCT06546540|NO_INTERVENTION|Conventional|
62189407|NCT00916305|EXPERIMENTAL|Modified Audio video|Participants will listen to an audio video modified to mimic noise induced hearing loss after one night at a loud club
62189408|NCT00916305|ACTIVE_COMPARATOR|Unmodified Audio video|Participants will listen to the same music as the other arm, but only the track with unaltered music.
62189409|NCT02528851|EXPERIMENTAL|Higher CPAP|Infants extubated to CPAP level 2cm H2O higher than extubation EAP
62189410|NCT02528851|ACTIVE_COMPARATOR|Equivalent CPAP|Infants extubated to CPAP equivalent to extubation EAP
62189411|NCT02484378|EXPERIMENTAL|CER-001|CER-001 infusion
62571689|NCT02494869|EXPERIMENTAL|Nonlinear Aerobic Training (300 minutes/week)|The ultimate goal is for participants to complete 300 minutes/week of aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from CPETs performed at baseline, midpoint, and Study Follow-Up. The 300 minutes/week will be achieved by completing 5 aerobic training sessions/week for approximately 60 minutes/session. A minimum of 3 sessions/week are required to be supervised while the remaining 2 sessions can be supervised or unsupervised home-based. Participants on all Arms will receive a heart rate monitor prior to beginning unsupervised home-based aerobic training sessions. Vital sign monitoring guidelines for unsupervised sessions, prescribed at lower intensities, will be advised by the exercise physiologist at the time the session plan is provided to the patient. Patients will be instructed to not begin an unsupervised session if their resting heart rate or blood pressure is outside the recommended guidelines.
62571690|NCT02494869|ACTIVE_COMPARATOR|General Physical Activity|Usual care patients will receive a home-based, general physical activity program. Specifically, all patients assigned to general physical activity will receive an initial, in-person consultation with staff exercise physiologist outlining a structured home-based aerobic walking program with a goal up to 150 minutes per week outside of their normal daily activity. Patients can be provided with a fitness tracker (e.g. FitBit) to evaluate exercise duration and intensity. Patients may also be provided with an exercise log to records type, duration, and average heart rate during sessions. The exercise log is provided as a guidance tool and may be, although is not required to be, returned to study staff. Staff exercise physiologists will contact patients to check progress and answer questions.
62571691|NCT05027451|EXPERIMENTAL|IXT-m200|3 g of IXT-m200 given once by 30-min intravenous infusion
62571692|NCT05027451|PLACEBO_COMPARATOR|Placebo|Normal saline
62779403|NCT04326088||head and neck cancer with free flap reconstruction|patients with head and neck cancer who underwent tumor wide excision and primary free flap reconstruction or secondary free flap reconstruction between March 2008 and February 2017
62779404|NCT02759081|ACTIVE_COMPARATOR|water exchange|The air was turned off at the beginning of colonoscopy. Water was infused and suctioned at the same time during insertion. The air was turned on when the colonoscope reached the cecum.
62571693|NCT06574711|PLACEBO_COMPARATOR|Control yogurt|Participants consumed a 200 g bottle of plain Yogurt with 3.5% unreplaced fat orally, daily, for 90 days
62189412|NCT02484378|PLACEBO_COMPARATOR|Placebo|Placebo infusion
62189413|NCT01512550|ACTIVE_COMPARATOR|instrumented hip guide technique|A mechanical device used to measure and decide how the hip prosthesis (ABG II modular) should be implanted
62779405|NCT02759081|EXPERIMENTAL|cap-assisted water exchange|Cap was mounted to the tip of the colonoscope when water exchange was performed.
62779406|NCT02860572|EXPERIMENTAL|follow-up without intervention|No intervention to increase the urine output within 2 hours will be done.
62779407|NCT02860572|ACTIVE_COMPARATOR|Standard group - fluid bolus|Patient will receive 500mL of balanced crystalloid intravenously over 30 minutes.
62779408|NCT04450095|ACTIVE_COMPARATOR|Treated group|Tab. Volibris 10mg given once a day for 5 days, starting 48 hours before surgery (in addition for the standard treatment for partial nephrectomy)
62189414|NCT01512550|NO_INTERVENTION|conventional measuring technique|Standard way of implanting the prosthesis (ABG II standard) without special measuring device or computer navigation technique
62571694|NCT06574711|EXPERIMENTAL|Sacha inchi oil yogurt|Participants consumed a 200 g bottle of Yogurt with 3.5% replacement of dairy fat for Sacha inchi oil, orally, daily, for 90 days
62571695|NCT06574711|EXPERIMENTAL|Hybrid palm oil yogurt|Participants consumed a 200 g bottle of Yogurt with 3.5% replacement of dairy fat for Hybrid Palm Oil, daily, for 90 days
62584912|NCT05748847|ACTIVE_COMPARATOR|Pocket ICRS|Patients in this group underwent 360-degree MyoRing implantation through a femtosecond laser-assisted corneal pocket creation for the management of their central keratoconus.
62189415|NCT01512550|ACTIVE_COMPARATOR|computer assisted navigation|A method to use computer navigation when positioning and sizing the hip prosthesis (ABG II modular).
62189416|NCT05298397|EXPERIMENTAL|Intervention - EAT|This study has one arm (it is an open trial). All participants will receive the intervention (EAT-PTSD adapted for youth).
62189417|NCT01928667||Microscopic Colitis|Group consists of subjects diagnosed with either collagenous of lymphocytic colitis between January 1, 2000 and December 31, 2012
62779409|NCT04450095|NO_INTERVENTION|Control group|Treated with the standard treatment for partial nephrectomy
62779410|NCT05876338|EXPERIMENTAL|CRCaSSM|CRCaSSM
62779411|NCT05876338|NO_INTERVENTION|Control|
62189418|NCT01928667||Healthy Controls|Control group consists of subjects with no history of microscopic colitis. Group is age and sex matched with the case-group
62189419|NCT02244138||Adolescent CDSS|Implementation clinic site for CDDS
62189420|NCT05116332||Obstetrics and Gynaecology (O&G)|"Trainees from ST3/ST4/ST5 grades (n=11) and ST6/ST7 grades (n=12). As O\&G training covers both Obstetrics \& Gynaecology curriculums, we will recruit trainees in their final two years of training (i.e. ST6 and ST7) with gynaecology special interest; undertaking at least one gynaecology Advanced Training Skills Modules (ATSM). These include advanced laparoscopic training, open and laparoscopic benign abdomen, urogynaecology, gynaecology-oncology and reproductive medicine.~To measure musculoskeletal (Electromyography) and cognitive fatigue (Electroencephalography): A total of 10 trainees had these measured; ST3/4/5 (n=5) and ST6/7 (n=5)."
62779412|NCT01032499|ACTIVE_COMPARATOR|oxytetracycline|
62779413|NCT01032499|EXPERIMENTAL|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
62571696|NCT02185326|EXPERIMENTAL|Microflare and growth hormone|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
62189421|NCT05116332||General Surgery (GS)|"Trainees from ST3/ST4/ST5 (n=11) and senior trainees from ST7/ST8 (n=11).~To measure musculoskeletal (Electromyography) and cognitive fatigue (Electroencephalography): A total of 10 trainees had these measured; ST3/4/5 (n=6) and ST7/8 (n=4)"
62779414|NCT06584305||AI-Screened Cosmetic Surgery Patients|This cohort consists of patients aged 18 years or older who are undergoing elective cosmetic surgery. All participants in this group have undergone an AI-powered Body Dysmorphic Disorder (BDD) screening, which includes the completion of the Body Dysmorphic Disorder Questionnaire (BDDQ) and additional psychological evaluations. The AI system provides a risk assessment for BDD, guiding the surgical decision-making process and identifying patients who may require psychological intervention before proceeding with surgery.
62779415|NCT06005519|OTHER|Type 2 diabetes|
62779416|NCT06005519|OTHER|healthy participants|
62189422|NCT03409731|OTHER|Absorb GT1 BVS|Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.
62189423|NCT00899977|PLACEBO_COMPARATOR|Placebo|Subjects may receive a single, oral dose of placebo (capsule) in one of 4 crossover periods. Also, subjects may receive placebo orally, twice daily for 14 days in the last phase of the study.
62189424|NCT00899977|EXPERIMENTAL|1 mg TC-5214|Subjects may receive a single, oral capsule of 1 mg TC-5214 in one of 4 crossover periods.
62189425|NCT00899977|EXPERIMENTAL|2 mg TC-5214|Subjects may receive a single, oral capsule of 2 mg TC-5214 in one of 4 crossover periods.
62396378|NCT01376076|PLACEBO_COMPARATOR|2A|Double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35
62189426|NCT00899977|EXPERIMENTAL|4 mg TC-5214|Subjects may receive a single, oral capsule of 4 mg TC-5214 in one of 4 crossover periods. Also, subjects may receive 4 mg TC-5214 orally, twice daily for 14 days in the last phase of the study.
62396379|NCT01376076|PLACEBO_COMPARATOR|2B|Double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35
62396380|NCT06724549|ACTIVE_COMPARATOR|Fasting-Fed|Patients will be administrated 600mg dose of BN104 tablets under fasting conditions and fed conditions in period 1 and 2 respectively. There will be a at least 7-day washout period between the first and second dose.
62396381|NCT06724549|ACTIVE_COMPARATOR|Fed-Fasting|Patients will be administrated 600mg dose of BN104 tablets under fed conditions and fasting conditions in period 1 and 2 respectively. There will be a at least 7-day washout period between the first and second dose.
62396382|NCT06011603|OTHER|Prineo naive group|All subject's receive the same dressing, this group is comprised of patients consented to the study and will receive the Prineo dressing but have not had previous joint replacement surgery. Therefore, we consider them Prineo-naive.
62396383|NCT06011603|OTHER|Prineo-exposed group|All subject's receive the Prineo dressing, this group is comprised of patients who have undergone previous joint replacement surgery (hip or knee) and have had a prineo dressing. This also includes patients who have had prior exposure to glue/mesh dressing either as a patient or healthcare worker.
62396384|NCT06412289|EXPERIMENTAL|US-guided percutaneous needle biopsy|Patients who are randomized into this arm will undergo US-percutaneous needle biopsy to sample the lesion. A convex probe is used to visualize the lung lesion and execute the percutaneous procedure. One hour after the end of the procedure, a chest x-ray is requested.
62779417|NCT04348006|EXPERIMENTAL|Induction Therapy|Bortezomib will be administered as part of VCD or VRD protocols
62779418|NCT03123991|EXPERIMENTAL|Experimental Group|UP-A adapted as a preventive intervention. Specifically, the Spanish version of The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a 9 sessions school-based preventive intervention. The intervention is delivered in nine weekly sessions (each session lasting around 55 minutes).
62779419|NCT03123991|OTHER|Wait-list Control Group|Same than experimental group (EG), after EG finishes. Specifically, classes in waitlist condition will be offered the same intervention than experimental group after EG finishes the three months follow-up.Before that, waitlist means that the classess work as usual with issues of mental health.
62189427|NCT00899977|EXPERIMENTAL|8 mg TC-5214|Subjects may receive a single, oral capsule of 8 mg TC-5214 in one of 4 crossover periods.
62189428|NCT06490601|EXPERIMENTAL|combination therapy (thalidomide and hydroxyurea)|In this group, participants were treated with combination therapy that includes thalidomide and hydroxyurea at the dose of 100mg/day at night with aspirin and 500mg /day respectively.
62003822|NCT06136221|NO_INTERVENTION|Enhanced Usual Care|Patients will undergo baseline interviews with study coordinators. All participants will be screened for malnutrition with the validated malnutrition screening tool (MST). At the baseline interview, patients will receive instructional handouts on dietary changes and recipes as per the updated 2019 European Society for Clinical Nutrition \& Metabolism (ESPEN) guidelines. Information on the resource CirrhosisCare.ca will also be provided. Participants in the control arm will receive Fitbits to monitor their steps. They will be asked to try and get up to 7000 steps per day, and no follow-up on their progress in terms of step counts will be given during the 12 weeks. All participants will be allowed to keep their Fitbit once they complete the study.
62189429|NCT06490601|ACTIVE_COMPARATOR|thalidomide alone|In this group, participants were treated with thalidomide at the dose of 100mg/day at night with aspirin.
62189430|NCT00406614|EXPERIMENTAL|1|Literacy-focused high blood pressure intervention. The intervention group will receive the health literacy -focused hypertension management intervention that will be delivered through 6 weeks of highly interactive group sessions in a classroom setting, followed by telephone counseling once a month for 12 months. Also, the intervention group will concurrently use home blood pressure monitoring with telephone transmission for 12 months.
62189431|NCT00406614|ACTIVE_COMPARATOR|2|Wait-list control group will initially receive usual care from a regular medical provider. Participants in the control group will take part in the intervention once the study has been completed.
62189432|NCT05478382|PLACEBO_COMPARATOR|Placebo|3 capsules of placebo drug are administered once prior to surgery and every 12 hours after surgery for 72 hours
62189433|NCT05478382|EXPERIMENTAL|Pregabalin 25mg|1 capsule of Kabalin 25mg Cap and 2 pills of placebo drug are administered once prior to surgery and every 12 hours after surgery for 72 hours
62189434|NCT05478382|EXPERIMENTAL|Pregabalin 50mg|2 capsules of Kabalin 25mg Cap and 1 pill of placebo drug are administered once prior to surgery and every 12 hours after surgery for 72 hours
62189435|NCT05478382|EXPERIMENTAL|Pregabalin 75mg|3 capsules of Kabalin 25mg Cap are administered once prior to surgery and every 12 hours after surgery for 72 hours
62189436|NCT03569592|EXPERIMENTAL|Overdose Prevention Intervention|The experimental group will receive a brief overdose prevention education intervention and be issues naloxone upon discharge from jail.
62189437|NCT01097499|ACTIVE_COMPARATOR|LED application|Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.
62189438|NCT01097499|NO_INTERVENTION|No LED application|These patients will receive conventional dental implant treatment without the application of the LED therapy.
62189439|NCT01339299|EXPERIMENTAL|recombinant luteinizing hormone|150 IU r-LH, recombinant luteinising hormone, from treatment day 1 (stimulation day 1) until day of r-hCG administration (normally treatment day 10 to 14)
62189440|NCT01339299|ACTIVE_COMPARATOR|recombinant human chorionic gonadotrofin|25 IU of r-hCG from treatment day 1 (stimulation day 1) until day of r-hCG administration (normally treatment day 10 to 14 )
62571697|NCT02185326|NO_INTERVENTION|Microflare protocol alone|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later
62571698|NCT03225209|EXPERIMENTAL|OPTIFAST|"Subjects meeting inclusion criteria will be receive OPTIFAST meal replacement (MR) in the following manner:~WK1-WK12 (5 MR/DAY)~WK13-14 (4 MR/DAY)~WK 15 (3 MR/DAY)~WK 16 (2 MR/DAY)~WK 17-18 (1 MR/DAY)~WK 19-24 (No MR)"
62189441|NCT02087215|ACTIVE_COMPARATOR|boron gel|diabetic foot ulcer care with formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v).
62189442|NCT02087215|PLACEBO_COMPARATOR|control gel|placebo gel containing polymer of carbopol ultrex (1%)
62189443|NCT05205070|EXPERIMENTAL|Rosnilimab (ANB030)|ANB030 biological humanized monoclonal antibody, SC injections every 4 weeks
62189444|NCT05205070|PLACEBO_COMPARATOR|Placebo solution|Placebo solution, SC injections every 4 weeks
62189445|NCT02772237|ACTIVE_COMPARATOR|Treatment group|Riboflavin 400mg daily
62189446|NCT02772237|PLACEBO_COMPARATOR|Placebo group|Placebo
62189447|NCT02950051|ACTIVE_COMPARATOR|Standard chemoimmunotherapy (SCIT)|"Patients up to age 65: 6 cycles (q28d) of Fludarabine + Cyclophosphamide + Rituximab (FCR)~Patients older than 65 years: 6 cycles (q28d) of Bendamustine + Rituximab (BR)"
62189448|NCT02950051|EXPERIMENTAL|Rituximab + Venetoclax (RVe)|6 cycles (q28d) of RVe + 6 cycles (q28d) of Venetoclax (alone)
62189449|NCT02950051|EXPERIMENTAL|Obinutuzumab + Venetoclax (GVe)|6 cycles (q28d) of GVe + 6 cycles (q28d) of Venetoclax (alone)
62189450|NCT02950051|EXPERIMENTAL|Obinutuzumab + Ibrutinib + Venetoclax (GIVe)|"6 cycles (q28d) of GIVe + 6 cycles (q28d) of Ibrutinib plus Venetoclax.~Administration of ibrutinib will be continued for a maximum of 36 months or until MRD negativity, start of new anti-CLL therapy or inacceptable toxicity, whatever occurs first."
62189451|NCT01306123|EXPERIMENTAL|Nascobal nasal spray (cyanocobalamin USP)|One single administration of intranasal cyanocobalamin (initially)
62189452|NCT01306123|ACTIVE_COMPARATOR|Vitamin B12-ratiopharm N, injection solution|One single injection of IM cyanocobalamin (initially)
62189453|NCT01592812|EXPERIMENTAL|electrical stimulation|Evaluation of the effect of calf stimulation on flow and tissue oxygenation
62189454|NCT02698306|EXPERIMENTAL|Dexamethasone|Dexamethasone: Dexametasone 4mg tablet every 8/8hs for 3 days
62189455|NCT02698306|ACTIVE_COMPARATOR|Diclofenac Sodium|Diclofenac Sodium: Diclofenac Sodium 50 mg tablet every 8/8 hs for 3 days
62571699|NCT02158325|ACTIVE_COMPARATOR|3.0-3.9 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0-3.9 mm in diameter)
62571700|NCT02158325|EXPERIMENTAL|4.0-5.0 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (4.0-5.0 mm in diameter)
62779420|NCT04814056|EXPERIMENTAL|Afatinib treatment group|This is an open-label, sing-arm phase IV clinical study
62779421|NCT04070612||children with autoimmune haemolytic anemia|A blood sample of 2 times 2 to 5 ml additional maximum
62779422|NCT04070612||Children with Evans syndrome|A blood sample of 2 times 2 to 5 ml additional maximum
62189456|NCT04581928||COVID-19|Highly educated people Low educated people
62189457|NCT04140266|EXPERIMENTAL|Group A: Dapivirine (DPV) Vaginal Ring (VR)-004|Mothers will use one DPV VR continuously for approximately one month, replacing the DPV VR each month for approximately three months.
62189458|NCT04140266|EXPERIMENTAL|Group B: Truvada Tablet|Mothers will take one Truvada oral tablet daily for approximately three months.
62189459|NCT03345147||Normal Vitamin A intake|Normal Vitamin A intake will be assessed by a questionnaire directed to the consumption of food items with high VA content on the 7 days prior to the questionnaire. The daily consumption will be assessed on average. A child is assigned to Normal Vit. A consumption if daily Vit. A is between 250 and 600 micrograms per day.
62189460|NCT03345147||High Vitamin A intake|High Vitamin A intake will be assessed by a questionnaire directed to the consumption of food items with high VA content on the 7 days prior to the questionnaire. The daily consumption will be assessed on average. A child is assigned to High Vit. A consumption if daily Vit. A is above 900 micrograms per day.
62189461|NCT01261247|EXPERIMENTAL|Arm I|Patients receive oral panobinostat 3 times weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62189462|NCT05566392||Coronavirus disease (COVID)|Pediatric patients who was diagnosed as COVID
62189463|NCT05566392||Healthy|Pediatric participants who hadn't been diagnosed COVID before
62571701|NCT02158325|ACTIVE_COMPARATOR|5.1-6.0 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (5.1-6.0 mm in diameter)
62779423|NCT04070612||Children with Immune thrombocytopenic purpura|A blood sample of 2 times 2 to 5 ml additional maximum
62189464|NCT00603083|ACTIVE_COMPARATOR|A|This group receive local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg 10 and 22 hours after the operation. The medicine solution is given in a catheter, wich is placed in the hip at the end of the operation.
62189465|NCT00603083|PLACEBO_COMPARATOR|B|This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, wich is placed in the hip at the end of the operation.
62189466|NCT01558323|EXPERIMENTAL|LCQ908 (mild renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with mild renal impairment and will receive a single 40 mg dose of LCQ908.
62189467|NCT01558323|EXPERIMENTAL|LCQ908 (moderate renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with moderate renal impairment and will receive a single 40 mg dose of LCQ908.
62189468|NCT01558323|EXPERIMENTAL|LCQ908 (severe renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with severe renal impairment and will receive a single 40 mg dose of LCQ908.
62189469|NCT04201587|EXPERIMENTAL|Henna application group|
62189470|NCT04201587|NO_INTERVENTION|Control group|
62779424|NCT04095091||Control Group|"Healthy volunteers will be asked to complete a single imaging session that will include acquiring simultaneous 4D ultrasound and 4D MRI scan.~A substudy including patients undergoing radiotherapy for malignancies of the abdomen and pelvis. They will also be asked to complete a single imaging session that will include acquiring simultaneous 4D ultrasound and 4D MRI scan."
62189471|NCT01841697|EXPERIMENTAL|Omarigliptin 25 mg once weekly|Participants receive omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continue pre-study stable dose of metformin (total daily dose ≥1500 mg) throughout the study. Participants may receive glimepiride (total daily dose of 1-6 mg) as rescue therapy.
62189472|NCT01841697|ACTIVE_COMPARATOR|Sitagliptin 100 mg once daily|Participants receive sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continue pre-study stable dose of metformin (total daily dose ≥1500 mg) throughout the study. Participants may receive glimepiride (total daily dose of 1-6 mg) as rescue therapy.
62189473|NCT04943471||All patients will be given a questionnaire|All patients will be given the Big Five Questionnaire
62189474|NCT01954433||Operated TSA Patients|Patients with glenohumeral arthritis and/or rotator cuff tear arthropathy who were operated and received a total shoulder prosthesis
62189475|NCT01954433||Non-operated TSA Patients|TSA-patients, indicated for treatment with a total shoulder prosthesis, who decided not to operate
62189476|NCT01954433||Operated RCR Patients|Patients with rotator cuff tear who were operated and received a rotator cuff reconstruction by arthroscopy
62189477|NCT01954433||Non-operated RCR Patients|RCR-patients, indicated for rotator cuff reconstruction by arthroscopy, who decided not to operate
62189478|NCT01954433||Operated TMC OA Patients|Patients with trapeziometacarpal (TMC) osteoarthritis who were operated and received a resection interposition suspension arthroplasty of the TMC joint
62396385|NCT06412289|EXPERIMENTAL|CT-guided percutaneous needle biopsy|Patients who are randomized into this arm will undergo CT-percutaneous needle biopsy. The procedure is done by using a CT scan to measure and identify the right point where the percutaneous biopsy will be executed. One hour after the end of the procedure, a chest x-ray is requested.
62396386|NCT00781027|ACTIVE_COMPARATOR|1|Torsional phacoemulsification
62189479|NCT01954433||Non-operated TMC OA Patients|TMC OA-patients, indicated for surgical treatment (resection interposition suspension arthroplasty), who decided not to operate
62189480|NCT05311722|EXPERIMENTAL|Dexmedetomidine|Inj.dexmedetomidine 0.5mcg/kg diluted in 10ml N/s given as iv infusion over 10 minutes
62189481|NCT05311722|EXPERIMENTAL|Ketamine|Inj.ketamine 0.5mg/kg diluted in 10ml N/s given as iv infusion over 10 minutes
62189482|NCT05311722|EXPERIMENTAL|Tramadol|Inj.tramadol 0.5mg/kg diluted in 10ml N/s given as iv infusion over 10 minutes
62189483|NCT01076790|ACTIVE_COMPARATOR|Dexmedetomidine|Analgo-sedative, adjuvant of propofol anesthesia
62396387|NCT00781027|ACTIVE_COMPARATOR|2|Longitudinal phacoemulsification
62571702|NCT05737524|EXPERIMENTAL|Telerehabilitation (VAST 2)|
62584913|NCT05748847|ACTIVE_COMPARATOR|Tunnel ICRS|Patients in this group are underwent 340-degree KeraRing implantation through a femtosecond laser-assisted corneal tunnel creation for the management of their central keratoconus.
62584914|NCT06685575|NO_INTERVENTION|Conventional Transforaminal Lumbar Interbody Fusion With Posterior Decompression Surgery|standard surgery for foraminal stenosis
62779425|NCT04095091||Patient Group|Patients receiving radiotherapy for malignancies of the abdomen and pelvis will be asked to complete two research visits lasting approximately one hour. Each visit will include a 30 minute combined 4D ultrasound and 4D MRI scan.
62003823|NCT06136221|EXPERIMENTAL|LiverWatch Intervention|"Patients will undergo symptom-based monitoring with targeted nutrition support. participants in Arm 2 will also receive educational text messages related to cirrhosis and physical activity. In summary, there are four components to the~* Remote Symptom Monitoring~* Targeted Nutrition Assessment and Intervention~* Physical Activity and Rewards Program~* Motivational Messages~Subjects will be enrolled in an online portal, Way to Health (W2H), which automates many of the research and monitoring functions of the intervention. Patients will receive remote symptom monitoring on a weekly basis, enhanced nutrition assistance through weekly education videos, and motivational messages on Mondays and Fridays that include education on diet, physical activity, and cirrhosis. Participants in this arm will also be encouraged to increase their step count using a rewards system built through the W2H."
62003824|NCT04407728|EXPERIMENTAL|precocious EchoMorpho-T1|Women whose fetus is at high risk of congenital heart disease after the 1st trimester screening echo (EchoT1), will benefit from an early morphological ultrasound centered on the heart (EchoMorpho-T1) by a sonographer referent between 11 and 14 weeks +/- of an early fetal heart ultrasound (EchoCoeur-T1) between 11 and 15 weeks by a cardio-pediatrician in the event of an abnormality with the EchoMorpho-T1.
62003825|NCT04593901|OTHER|Video and App Review|Single arm study in which home healthcare workers review and provide feedback on scripts and/or videos and on the usefulness, usability, and desirability of an interactive app in an iterative, participatory manner.
62003826|NCT00378014|EXPERIMENTAL|Everolimus|Basiliximab plus everolimus-based immunosuppressive regimen following the reduction and cessation of initial CNI regimen plus optional steroids according to local best practice
62003827|NCT00378014|ACTIVE_COMPARATOR|Calcineurin Inhibitor (CNI)|Basiliximab plus CNI-based immunosuppressive regimen according to local best practice plus optional steroids according to local best practice
62003828|NCT04749290|EXPERIMENTAL|Study Formula|a Cow's Milk Based Infant Formula Containing Both OPO and CPP for term infants (JunLeBao ZhiZhen)
62003829|NCT04749290|ACTIVE_COMPARATOR|Comparator Formula|Commercially available infant formula without OPO for term infants (JunLeBao LeChun)
62003830|NCT04749290|NO_INTERVENTION|Human Milk Reference Group|Human milk
62189484|NCT01912989|EXPERIMENTAL|Lifestyle counseling|NOURISH+ plus motivational interviewing
62003831|NCT01633944|PLACEBO_COMPARATOR|Placebo|Twice Daily Dosing
62003832|NCT01633944|EXPERIMENTAL|Buprenorphine HCl Buccal Film|Twice Daily Dosing
62003833|NCT02310191||Stenting|Carotid stenting
62003834|NCT05699070|EXPERIMENTAL|DWC202211|
62003835|NCT05699070|EXPERIMENTAL|DWC202212|
62003836|NCT05699070|EXPERIMENTAL|DWC202211 + DWC202212|
62003837|NCT06276725|EXPERIMENTAL|Writing Wrongs|Writing Wrongs is an adaptation of expressive writing, a prolonged exposure practice targeting symptoms resulting from stressful life events. Writing Wrongs is specifically tailored to microaggressions experienced by minoritized students at predominantly White institutions. The intervention includes three 20-minute writing sessions occurring on three consecutive days. The Writing Wrongs writing activity asks participants to reflect on the facts and feelings associated with a microaggression they experienced.
62003838|NCT06276725|NO_INTERVENTION|Assessment Control|The Assessment Control is administered the same measures during the same number of sessions as the Writing Wrongs condition without receiving the Writing Wrongs writing activity. The participants assigned to this arm of the study will receive the Writing Wrongs intervention following the completion of the study.
62003839|NCT03638817|EXPERIMENTAL|Eltrombopag|
62003840|NCT00449293|ACTIVE_COMPARATOR|1|
62003841|NCT00449293|ACTIVE_COMPARATOR|2|
62003842|NCT04659070|EXPERIMENTAL|Experimental : Ezetimibe / Rosuvastatin + Telmisartan|Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks
62003843|NCT04659070|ACTIVE_COMPARATOR|Active comparator1 : Ezetimibe / Rosuvastatin|Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks
62003844|NCT04659070|ACTIVE_COMPARATOR|Active comparator2 : Telmisartan|Telmisartan 80mg PO, Once daily for 8 weeks
62189485|NCT03702387|NO_INTERVENTION|Control Group|Patients in this group will have standard intravenous regional anesthesia (IVRA) performed before the start of their surgery.
62214675|NCT03821779|EXPERIMENTAL|Group 2.2|"In group 2.2, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after:~1. virtual reality : oral presentation to virtual examiners~2. real exposure: oral presentation to a panel of examiners~Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session.~Psychometric evaluation will be performed prior to experimental sessions."
62779426|NCT01975597||Bone marrow aspirates and biopsy|
62189486|NCT03702387|EXPERIMENTAL|Esmarch Reapplication Group|Patients in this group will have all the standard intravenous regional anesthesia (IVRA) procedures performed before the start of their surgery with one exception: After standard intravenous regional anesthesia (IVRA) is performed, The elastic Esmarch bandage will be reapplied again on the same arm then will be released. then the surgery will be initiated. the only difference between groups is that the Esmarch reapplied group will be applied the esmach two times. First time, at the standard standard intravenous regional anesthesia (IVRA) before the lidocaine injection and second time, after the injection is completed.
62779427|NCT03327558|EXPERIMENTAL|Apriso 0.375G ER CAP|Apriso 0.375G ER Cap
62779428|NCT03327558|ACTIVE_COMPARATOR|APRISO 375 mg extended-release capsules|APRISO 375 mg ER cap
62571703|NCT05520723|EXPERIMENTAL|Sacituzumab Govitecan + Loperamide + G-CSF|"Upon meeting all selection criteria, patients enrolled in the study will receive the combination of:~Sacituzumab govitecan :10 mg/kg, intravenously (IV) on Days 1 and 8 every 21-day cycle .~This treatment will continue until disease progression, unacceptable toxicity, or physician's/patient's decision.~Loperamide : 2 mg orally (PO), twice a day (BID), or 4 mg once a day (QD) during three consecutive days after administration of sacituzumab govitecan, (D2, D3, D4 and D9, D10, D11) during the first two cycles (consider extending to the next cycle at the discretion of the physician).~G-CSF : 30 MU subcutaneously (SC) QD during two consecutive days, 48 hours after administration of sacituzumab govitecan (D3, D4 and D10, D11) during the first two cycles (consider extending to the next cycle at the discretion of the physician)."
62003845|NCT02165111|EXPERIMENTAL|Onabotulinumtoxin A|"One hand of each patient will be randomly selected for injection of Botulinum Toxin A (Onabotulinumtoxin A, 20 units/mL).~Injections are performed using a 30 gauge insulin syringe through the dorsal surface in seven locations: adjacent to the 2nd, 3rd, and 4th common digital arteries through the web spaces (10 units each=0.5mL each), and the radial side of the index finger metacarpal head, the ulnar side of the small finger metacarpal head, and each side of the thumb metacarpal head (5 units each= 0.25mL each). Total treatment dose of Botulinum Toxin A will not exceed 50 units per hand."
62189487|NCT00680888||1|Children and adolescents with psychosis in outpatients setting on treatment with quetiapine started from january 2003 to june 2006
62189488|NCT01006525||Insomniacs|Primary insomniacs, ages 21-70, in good general health.
62396388|NCT03995758|ACTIVE_COMPARATOR|Standard laser lithotripsy|standard of care for stone fragmentation in ureteroscopy
62396389|NCT03995758|ACTIVE_COMPARATOR|MOSES laser lithotripsy|MOSES technology used for stone fragmentation in ureteroscopy
62396390|NCT05334615||Acute COVID-19|"Hospital admission for management of symptoms related to COVID-19. Laboratory confirmed infection with SARS-CoV-2 by either PCR or antigen testing within 4 weeks of hospital admission.~Age ≥18 years."
62396391|NCT05334615||Incidental COVID-19|"Hospital admission for indications unrelated to COVID-19 who are incidentally found to have infection with SARS-CoV-2.~Age ≥18 years."
62571704|NCT01701817||Patients with Atrial Fibrillation (AF)|(1) patients with new onset/first detected Atrial Fibrillation (AF) diagnosed within the 6 months preceding the baseline visit; or (2) patients with AF who had initiation or transition to a FXa (Factor Xa) inhibitor or a direct thrombin inhibitor within the preceding 3 months.
62571705|NCT01343810|EXPERIMENTAL|Meditation|Both arms will undergo 8-weeks of Mindfulness-Based Stress Reduction (MBSR) training. The experimental arm will be randomly assigned to practice meditation immediately following the emotional stress task in the lab during the post-MBSR lab visit.
62571706|NCT01343810|ACTIVE_COMPARATOR|No meditation|Both arms will undergo 8-weeks of Mindfulness-Based Stress Reduction (MBSR) training. The active comparator arm will be randomly assigned to not practice meditation, but rather listen to a non-meditative audio track of equal length, immediately following the emotional stress task in the lab during the post-MBSR lab visit.
62189489|NCT03496376|EXPERIMENTAL|Kinesio Taping Group|Kinesio Taping Group received three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set plus thoracic kinesio taping application.
62214676|NCT06529055|EXPERIMENTAL|Oral Nicotine Pouches|Single dose 3mg oral nicotine pouch
62214677|NCT06529055|EXPERIMENTAL|Oral Caffeine Pouches|Single dose 100mg oral caffeine pouch
62214678|NCT06529055|EXPERIMENTAL|Combination of oral nicotine and caffeine pouches|Single simultaneous doses of a 3mg oral nicotine pouch and a 100mg oral caffeine pouch
62214679|NCT06529055|PLACEBO_COMPARATOR|Placebo|Flavor, color, and appearance matched placebo
62214680|NCT01302067|EXPERIMENTAL|Fesoterodine 8mg|
62214681|NCT01302067|EXPERIMENTAL|Fesoterodine 4mg|
62779429|NCT01432990|EXPERIMENTAL|robotic gait training|conventional physical therapy plus robot gait training program for SCI patients.
62779430|NCT01432990|NO_INTERVENTION|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
62779431|NCT04090463|EXPERIMENTAL|IORT group|"Intraoperative administration of 10 to 20 Gy after surgery or as an in situ treatment in case resection will not be performed"
62779432|NCT02859441|EXPERIMENTAL|E10030 and Ranibizumab|Intravitreal injections of E10030 and Ranibizumab
62779433|NCT02089126|EXPERIMENTAL|Gemigliptin/Glimepiride combination|Gemigliptin 50mg qd added to ongoing Glimepiride as fix-dose combination. The subjects will take a total of 2 tablets, Gemigliptin/Glimepiride combination \& Placebo for Glimepiride.
62779434|NCT02089126|PLACEBO_COMPARATOR|Placebo|The subjects will take a total of 2 tablets, Placebo for Gemigliptin/Glimepiride combination \& Glimepiride.
62214682|NCT01302067|PLACEBO_COMPARATOR|Placebo|
62003846|NCT02165111|PLACEBO_COMPARATOR|Placebo|"One hand of each patient will be randomly selected for injection of sterile saline solution (placebo).~Injections are performed using a 30 gauge insulin syringe through the dorsal surface in seven locations: adjacent to the 2nd, 3rd, and 4th common digital arteries through the web spaces (0.5 mL each), and the radial side of the index finger metacarpal head, the ulnar side of the small finger metacarpal head, and each side of the thumb metacarpal head (0.25 mL each)."
62003847|NCT03683381|EXPERIMENTAL|intervention|Patients in the intervention group will receive a 6-week app-based intervention to treat insomnia
62189490|NCT03496376|ACTIVE_COMPARATOR|Control Group|Control Group received three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set.
62189491|NCT02191904|ACTIVE_COMPARATOR|Truview EVO2®|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively.
62189492|NCT02191904|ACTIVE_COMPARATOR|Airtraq®|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively
62189493|NCT02191904|ACTIVE_COMPARATOR|Direct laryngoscopy|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively
62396392|NCT05334615||Acute influenza|"Hospital admission for clinical management of symptoms related to influenza. Laboratory confirmed infection with influenza A or influenza B within 4 weeks of hospital admission.~Negative testing for SARS-CoV-2. Age ≥18 years."
62396393|NCT05929794|ACTIVE_COMPARATOR|Micropatch application + metronidazole 0.75% topical gel|Participants will have pre-treatment micropatch application followed by metronidazole 0.75% topical gel
62003848|NCT03683381|EXPERIMENTAL|patient education|Participants in the patient education group will receive weekly information on insomnia symptoms
62003849|NCT01440309|EXPERIMENTAL|allogenic mesenchymal stem cells (MSCs)|Patients who have primary biliary cirrhosis.
62189494|NCT00930956|ACTIVE_COMPARATOR|Dextrose|30 g of carbohydrate via Sun-Dex OGTT beverage
62396394|NCT05929794|ACTIVE_COMPARATOR|Metronidazole 0.75% topical gel|Participants will have metronidazole 0.75% topical gel applied without the pre-treatment micropatch application
62396395|NCT05929794|ACTIVE_COMPARATOR|Micropatch application + metronidazole 0.75% topical cream|Participants will have pre-treatment micropatch application followed by metronidazole 0.75% topical cream
62396396|NCT05929794|ACTIVE_COMPARATOR|Metronidazole 0.75% topical cream|Participants will have metronidazole 0.75% topical cream applied without the pre-treatment micropatch application
62396397|NCT06724822|EXPERIMENTAL|Study arm- RF Vapor Ablation arm|This is a single arm study. All enrolled patients will be included in this arm
62396398|NCT05784129|ACTIVE_COMPARATOR|Group 1: Guselkumab|Participants will receive Guselkumab Dose 1 subcutaneously (SC) followed by Dose 2 SC thereafter through Week 144. Participants with disease recurrence will receive guselkumab SC treatment.
62396399|NCT05784129|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will receive matching placebo injections subcutaneously. Participants with disease recurrence will receive guselkumab SC treatment.
62396400|NCT02335411|EXPERIMENTAL|Cohort 1: Pembrolizumab monotherapy, previously treated|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W)
62396401|NCT02335411|EXPERIMENTAL|Cohort 2: Pembrolizumab combination therapy, treatment naive|Participants receive pembrolizumab 200 mg IV each 3-week cycle (Q3W) + cisplatin 80 mg/m\^2 IV Q3W for up to 6 cycles + 5-FU 800 mg/m\^2 IV on Days 1-5 every 3 weeks or (Japan only) capecitabine 1000 mg/m\^2 orally, twice per day (BID) on Days 1-14 of each 3-week cycle
62571707|NCT06574581|EXPERIMENTAL|ADSC01|"1. Low-dose AD-MSC (1x10E6 cells/kg);~2. Medium-dose AD-MSC (2x10E6 cells/kg)~3. High-dose AD-MSC (3x10E6 cells/kg)"
62189495|NCT00930956|EXPERIMENTAL|RS Type 2|30g Resistant Starch Type 2 (Hi-Maize 260, National Starch)
62189496|NCT00930956|EXPERIMENTAL|RS Type 4 (cross linked)|30g of cross linked RS type 4 (Fibersym RW, MGP Ingredients, Inc.)
62189497|NCT03119883|EXPERIMENTAL|Group I (biospecimen collection)|EX-VIVO: After an overnight fast of 6 hours, patients undergo collection of bone marrow aspirate samples.
62189498|NCT03119883|EXPERIMENTAL|Group II (biospecimen collection, glutamine, glucose)|IN VIVO: After an overnight fast of 6 hours, patients receive 13-carbon labeled glutamine or 13-carbon-labeled glucose IV over 90 minutes. Patients also undergo collection of blood and bone marrow aspirate samples.
62189499|NCT02185547|EXPERIMENTAL|ICBT in combination with sertraline treatment|Internet cognitive behavioral therapy in combination with sertraline treatment
62396402|NCT02335411|EXPERIMENTAL|Cohort 3: Pembrolizumab monotherapy, treatment naive, PD-L1 positive|Programmed death-ligand 1 (PD-L1) positive participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle (Q3W)
62571708|NCT05602844|EXPERIMENTAL|PSI Lapidus|Design of PSI, 3D printing of PSI, PSI-assisted Lapidus Surgery.
62571709|NCT05602844|ACTIVE_COMPARATOR|Conventional Lapidus|Lapidus Surgery: exposure of the 1TMTJ via a 3-5cm medial longitudinal skin incision and capsulotomy. Freehand creation of the fusion surface with fluoroscopic assistance. Fixation of the Lapidus arthrodesis will be performed with two 3.5mm headless compression screws.
62571710|NCT00531115|EXPERIMENTAL|1|
62003850|NCT01440309|ACTIVE_COMPARATOR|ursodeoxycholic acid (UDCA)|Patients who have primary biliary cirrhosis.
62396403|NCT05599373|ACTIVE_COMPARATOR|Active rTMS over bilateral dorsolateral prefrontal cortex|Active rTMS over bilateral dorsolateral prefrontal cortex. Participants will receive up to 20 rTMS sessions within the 4-week treatment period.
62396404|NCT05599373|ACTIVE_COMPARATOR|Active rTMS over left dorsolateral prefrontal cortex|Active rTMS over left dorsolateral prefrontal cortex and sham rTMS over right dorsolateral prefrontal cortex. Participants will receive up to 20 rTMS sessions within the 4-week treatment period.
62584915|NCT06685575|EXPERIMENTAL|Endoscopic Foraminotomy Surgery|The new type of surgery to treat lumbar foraminal stenosis which does not lead to instability of the spine
62779435|NCT01179152|ACTIVE_COMPARATOR|Budicort|75 children will receive treatment with Budicort 200 mcg
62779436|NCT01179152|ACTIVE_COMPARATOR|Symbicort|75 children will receive treatment with Symbicort 160 mcg
62779437|NCT01179152|NO_INTERVENTION|counselling|75 children who will not treated as their request but will be folowedup
62779438|NCT03878901|SHAM_COMPARATOR|control group|Cotton Blanket Warming (CBW) starts 30 min preoperatively and then continues throughout the entire operation.
62779439|NCT03878901|EXPERIMENTAL|warm group|"Warm according to different hypothermia risk for low risk ---Forced-air warming(FAW) starts at least 30 min preoperatively and then Cotton Blanket Warming (CBW) continues throughout the entire operation.~moderate risk---Forced-air warming(FAW) starts at least 30 min preoperatively and then Cotton Blanket Warming (CBW) and fluid warming continues throughout the entire operation.~high risk ----Forced-air warming(FAW) starts at least 30 min preoperatively, FAW and fluid warming continues throughout the entire operation."
62779440|NCT00992823|ACTIVE_COMPARATOR|Group 1:iron weekly supplementation|
62779441|NCT00992823|ACTIVE_COMPARATOR|Group 2: cycle supplementation|two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
62779442|NCT03763136|EXPERIMENTAL|hPSC-CM Therapy|Procedure: Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
62779443|NCT03763136|SHAM_COMPARATOR|Control|Procedure: Coronary artery bypass grafting surgery only.
62779444|NCT02380040||Term|Normal Term Newborn Intervention: PPG
62779445|NCT02380040||Preterm|Preterm babies admitted to the NICU not suffering from the conditions to be studied Intervention: PPG
62779446|NCT02380040||PDA|Patent Ductus Arteriosus Intervention: PPG
62779447|NCT02380040||PPHN|Persistent Pulmonary Hypertension Intervention: PPG
62779448|NCT05655013|ACTIVE_COMPARATOR|First part (year 1): groups 1+2|Zoledronate will be administered as an infusion six months after the last injection of denosumab followed by zoledronate infusions 3 and 6 months thereafter
62779449|NCT05655013|ACTIVE_COMPARATOR|First part (year 1): groups 3+4|Zoledronate will be administered as an infusion six months after the last injection of denosumab followed by zoledronate infusions when bone turnover is increased (s-carboxy-terminal collagen crosslinks (p-CTX) \> 0.4 ug/l which corresponds to the upper 50 % of the normal range for premenopausal women).
62779450|NCT05655013|ACTIVE_COMPARATOR|Second part (year 2-3): groups 1+3|Patients will receive yearly infusions of zoledronate 5 mg
62779451|NCT05655013|PLACEBO_COMPARATOR|Second part (year 2-3): groups 2+4|Patients will receive yearly infusions of placebo.
62779452|NCT01113580|EXPERIMENTAL|Adults|Healthy volunteers aged 18 to 59 years
62396405|NCT05599373|SHAM_COMPARATOR|Sham rTMS over bilateral dorsolateral prefrontal cortex|Sham rTMS over bilateral dorsolateral prefrontal cortex. Participants will receive up to 20 rTMS sessions within the 4-week treatment period.
62779453|NCT01113580|EXPERIMENTAL|Older Adults|Healthy volunteers aged 60 years or older
62779454|NCT05825885||5-7 days E2 therapy|Patient group treated with e2 for 5-7 days
62779455|NCT05825885||8-10 days E2 therapy|Patient group treated with e2 for 5-7 days
62396406|NCT06723626|EXPERIMENTAL|ascorbic acid|The ascorbic acid group will receive 2g of vitamin C for every 8 hours after surgery.
62396407|NCT06723626|PLACEBO_COMPARATOR|placebo|The placebo group will receive 100ml NS or 5% GS for every 8 hours after surgery.
62571711|NCT06382064|EXPERIMENTAL|Contact Lens Wear Experience|Participants will be enrolled in the study for 4 weeks. Biweekly replacement contact lenses will be worn for the first 2 weeks. One-week replacement lenses worn for second 2 weeks.
62779456|NCT05825885||11-13 days E2 therapy|Patient group treated with e2 for 5-7 days
62189500|NCT02185547|ACTIVE_COMPARATOR|ICBT|Only Internet cognitive behavioral treatment, no additional depression treatment
62189501|NCT04128462|EXPERIMENTAL|MNK6105 + SoC|"Participants will receive standard of care (SoC), along with MNK-6105 delivered by continuous intravenous (IV) infusion as follows:~* Loading dose: 20 g infused over 6 hours~* Intermediate dose: 15 g infused over 18 hours~* Maintenance dose: 15 g infused over 24 hours for up to 4 days"
62779457|NCT03393949|EXPERIMENTAL|Group M|Patients in Group M received methylprednisolone 1mg•kg-1
62779458|NCT03393949|EXPERIMENTAL|Group C|Patients in Group C received isotonic saline 1mg•kg-1
62779459|NCT04887987|EXPERIMENTAL|Pilates exercise program + active PBMT (PIL+PBMT)|Participants will be submitted to a supervised 8-wk mat Pilates exercise program (2 x/week) and will receive active PBMT on the lumbar region (between L1 and L5) 10 min before and after exercise sessions (totaling 20 min), through a device containing 264 LEDs (132 red and 132 infrared.
62779460|NCT04887987|SHAM_COMPARATOR|Pilates exercise program + sham PBMT (PIL+SHAM)|Participants will be submitted to a supervised 8-wk mat Pilates exercise program (2 x/week) and will receive sham PBMT on the lumbar region (between L1 and L5) 10 min before and after exercise sessions (totaling 20 min), through a device containing 264 LEDs (132 red and 132 infrared.
62396408|NCT03830840||Adult Individuals with Type 2 diabetes|Individuals ≥18 years of Hispanic/Latino heritage with an established diagnosis of type 2 diabetes
62779461|NCT04887987|EXPERIMENTAL|Multicomponent exercise program + active PBMT (EX+PBMT)|Participants will be submitted to a supervised 8-wk multicomponent exercise program (3 x/week) and will receive active PBMT on the lumbar region (between L1 and L5) imediately before each workout, through a device containing 200 LEDs (100 red and 100 infrared).
62779462|NCT04887987|SHAM_COMPARATOR|Multicomponent exercise program + sham PBMT (EX+SHAM)|Participants will be submitted to a supervised 8-wk multicomponent exercise program (3 x/week) and will receive sham PBMT on the lumbar region (between L1 and L5) imediately before each workout, through a device containing 200 LEDs (100 red and 100 infrared).
62571712|NCT03793842|EXPERIMENTAL|Usual care then PEEP titration by Electrical Impedance Tomography (EIT)|Patients in the usual care first group will continue to receive mechanical ventilation according to the University of Michigan Acute Respiratory Distress Syndrome (ARDS) protocol high-PEEP arm
62571713|NCT03793842|EXPERIMENTAL|PEEP titration by EIT then usual care|Patients in the high PEEP titration by EIT first will have receive ventilation with a PEEP determined by EIT titration procedure.
62571714|NCT02875613|EXPERIMENTAL|Avelumab|Avelumab 10mg/kg IV infusion on days 1 and 15 of 28-day cycle
62571715|NCT06497530|EXPERIMENTAL|Experimental Treatment|"Induction phase：participants will receive Serplulimab on Day 1 of each 21-day cycle in combination with carboplatin on Day 1 and etoposide on Days 1, 2, and 3 of each 21-day cycle for 4 cycles.~Maintenance phase：participants will receive Serplulimab on Day 1 of each 21-day cycle in combination with Lurbinectedin on Day 1 of each 21-day cycle."
62003851|NCT03952169|EXPERIMENTAL|Probiotics group|Participants will be given capsules containing Lactobacillus paracasei once daily for 12 weeks followed by comprehensive physical and clinical examinations.
62189502|NCT04128462|PLACEBO_COMPARATOR|Placebo + SoC|Participants will receive SoC, along with continuous IV infusion of matching placebo for 5 days.
62189503|NCT01270828|EXPERIMENTAL|Pregablain CR tablet 82.5 to 660mg|
62189504|NCT01270828|PLACEBO_COMPARATOR|Placebo|
62779463|NCT01596036|EXPERIMENTAL|Early Appointment|Patients will receive an early appointment (within 10 days) from the time of their anticipated hospital discharge
62003852|NCT03952169|PLACEBO_COMPARATOR|Placebo group|Participants will be given capsules containing microcrystalline cellulose once daily for 12 weeks followed by comprehensive physical and clinical examinations.
62003853|NCT05168475|ACTIVE_COMPARATOR|Rituximab|
62003854|NCT05168475|ACTIVE_COMPARATOR|Infliximab|
62003855|NCT05168475|ACTIVE_COMPARATOR|Tocilizumab|
62189505|NCT05666362|ACTIVE_COMPARATOR|Group 1 : ( benoxinate hydrochloride 0.4% group )|They will receive benoxinate hydrochloride 0.4% immediately before fundus examination .
62189506|NCT05666362|PLACEBO_COMPARATOR|Group 2 : ( control group )|They will receive saline drops instead of benoxinate hydrochloride 0.4%. Randomization: simple randomization sampling using sealed envelope technique.
62189507|NCT00423072||1|children with cleft palate birth-24 months of age
62396409|NCT03830840||Adult Family member|Adult family members, ≥18 years, of the individual with type 2 diabetes
62396410|NCT03830840||Child family member with diabetes|Child, ≥7 years but \<18 years, family member with diabetes
62396411|NCT03830840||Child family member without diabetes|Child, ≥7 years but \<18 years, family member without diabetes
62396412|NCT05722327|EXPERIMENTAL|Stage 1 ( MRTX849 and Irinotecan)|Participants assigned to Stage 1, participants dose levels of MRTX849 and irinotecan will depend on when the participants joined the study. This study will also test 2 different dosing schedules: concurrent dosing or staggered dosing
62396413|NCT05722327|EXPERIMENTAL|Stage 2 ( MRTX849 and Irinotecan)|Participants assigned to Stage 2 will receive MRTX849 and irinotecan at the dose level that was recommended during Stage 1. This study will also test 2 different dosing schedules: concurrent dosing or staggered dosing
62396414|NCT03265808|EXPERIMENTAL|allogeneic human mesenchymal stem cells (allo-hMSCs)|Participants will be treated with a single administration of allogeneic hMSCs: 100 x 10\^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
62396415|NCT03265808|PLACEBO_COMPARATOR|Placebo|Participants will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
62396416|NCT05740982|ACTIVE_COMPARATOR|4|0.5 mL of 1 x 10\^8 (50% Tissue Culture Infectious Dose (TCID50) JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)) administered subcutaneously on adults ages 18-50 years on Days 1 and 29. N=135
62396417|NCT05740982|EXPERIMENTAL|5|0.5 mL of 1 x 10\^8 (50% Tissue Culture Infectious Dose (TCID50) JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)) administered subcutaneously on adolescents ages 12-17 years on Days 1 and 29. N=315
62396418|NCT04325126||RBP4 in diabetes|RBP4 in diagnosed diabetes.
62396419|NCT04325126||RBP4 in pre-diabetes (pre-DM)|RBP4 in pre-diabetes (pre-DM).
62396420|NCT04325126||RBP4 in DM-CVD|RBP4 in diabetic cardiovascular disease.
62003856|NCT05168475|PLACEBO_COMPARATOR|Placebo|Placebo may be to one of the active biologics (ie placebo to Rituximab, Placebo to Infliximab, placebo to Tocilizumab). Only 1 placebo is in a randomised sequence of interventions.
62003857|NCT00779766|EXPERIMENTAL|Cervarix Group|Subjects received 3 doses of Cervarix™ vaccine. Cervarix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
62189508|NCT05713162|EXPERIMENTAL|Children experimental group|Children who receive 10 sessions of the social skills training program
62189509|NCT05713162|EXPERIMENTAL|Adolescent experimental group|Adolescents who receive 10 sessions of the social skills training program
62189510|NCT05713162|NO_INTERVENTION|Children control group|Children in waiting list (do not receive 10 sessions of the social skills training program)
62189511|NCT05713162|NO_INTERVENTION|Adolescent control group|Adolescents in waiting list (do not receive 10 sessions of the social skills training program)
62189512|NCT04666363|EXPERIMENTAL|Lavender oil|On the first day (before intervention), the intensity of needle insertion-related pain was measured. The experimental group inhaled lavender essence (12 consecutive hemodialysis seasons).
62189513|NCT04666363|NO_INTERVENTION|Control group|The patients will not smell lavender oil.
62396421|NCT04325126||RBP4 in CVD|RBP4 in single coronary artery disease.
62396422|NCT04325126||RBP4 in NC|RBP4 in healthy controls.
62189514|NCT01180881||Proton Radiation Patients at MGH|Pediatric brain and central nervous system (CNS) tumor patients treated with proton beam radiation therapy
62189515|NCT04678778|EXPERIMENTAL|Combined, simultaneous physical and cognitive activity|The combined physical and cognitive activity VR arm will participate in our customized spatial navigation program that increases difficulty and length per trial over time. As described in the Game Design section, each session will consist of 5 trials. The first trial will be a long-delay free recall condition from the previous day's path. The next 4 trials will consist of learning, cued recall, and free recall. This VR-based spatial navigation program has been tested in our feasibility trial for safety and tolerability in older adults.
62003858|NCT00779766|PLACEBO_COMPARATOR|Placebo Group|Subjects received 3 doses of placebo. Placebo was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
62003859|NCT01592188|ACTIVE_COMPARATOR|MT|Mindfulness training. Participants will be provided with once per week training in mindfulness meditation.
62003860|NCT01592188|EXPERIMENTAL|CBCT|Cognitively-based compassion training. Participants in this arm will be provided with once weekly training on the cognitively-based compassion training program.
62189516|NCT00770198||alcoholic liver disease|alcoholic liver disease patients undergoing a transjugular liver biospy in our institution
62189517|NCT00770198||chronic HCV hepatitis|chronic HCV hepatitis patients undergoing a transjugular liver biopsy in our institution
62189518|NCT01338376|EXPERIMENTAL|Structured Education Group|Subjects received structured diabetes education
62189519|NCT01338376|ACTIVE_COMPARATOR|Conventional Care Group:|Subjects received conventional diabetes education
62189520|NCT06019065|EXPERIMENTAL|Cohort A1: Single ascending dose of AJA001|AJA001 active q.d. 2.2 mL oral dose level 1
62189521|NCT06019065|PLACEBO_COMPARATOR|Cohort A1: Single ascending dose of placebo|AJA001 placebo q.d. 2.2 mL oral dose level 1
62189522|NCT06019065|EXPERIMENTAL|Cohort A2: Single ascending dose of AJA001|AJA001 active q.d. ascending oral dose level 2
62189523|NCT06019065|PLACEBO_COMPARATOR|Cohort A2: Single ascending dose of placebo|AJA001 placebo q.d. ascending oral dose level 2
62189524|NCT06019065|EXPERIMENTAL|Cohort A3: Single ascending dose of AJA001|AJA001 active q.d. ascending oral dose level 3
62189525|NCT06019065|PLACEBO_COMPARATOR|Cohort A3: Single ascending dose of placebo|AJA001 placebo q.d. ascending oral dose level 3
62189526|NCT06019065|EXPERIMENTAL|Cohort A4: Single ascending dose of AJA001|AJA001 active q.d. ascending oral dose level 4
62189527|NCT06019065|PLACEBO_COMPARATOR|Cohort A4: Single ascending dose of placebo|AJA001 placebo q.d. ascending oral dose level 4
62189528|NCT06019065|EXPERIMENTAL|Cohort B1: Multiple ascending doses of AJA001|AJA001 active b.i.d. oral dose level 1
62003861|NCT04605575|EXPERIMENTAL|Pyrotinib plus vinorelbine|
62189529|NCT06019065|PLACEBO_COMPARATOR|Cohort B1: Multiple ascending doses of placebo|AJA001 placebo b.i.d. oral dose level 1
62003862|NCT00863642|EXPERIMENTAL|Early|In patients who present with mild to moderate gallstone pancreatitis, those randomized to the early arm will undergo laparoscopic cholecystectomy within 48 hours of admission, regardless of laboratory values normalization and resolution of abdominal pain.
62003863|NCT00863642|OTHER|Control|In patients in the control arm, laparoscopic cholecystectomy is delayed until laboratory values normalize and abdominal pain resolves.
62189530|NCT06019065|EXPERIMENTAL|Cohort B2: Multiple ascending doses of AJA001|AJA001 active b.i.d. oral dose level 2
62189531|NCT06019065|PLACEBO_COMPARATOR|Cohort B2: Multiple ascending doses of placebo|AJA001 placebo b.i.d. oral dose level 2
62189532|NCT06019065|EXPERIMENTAL|Cohort B3: Multiple ascending doses of AJA001|AJA001 active b.i.d. oral dose level 3
62189533|NCT06019065|PLACEBO_COMPARATOR|Cohort B3: Multiple ascending doses of placebo|AJA001 placebo b.i.d. oral dose level 3
62189534|NCT06019065|EXPERIMENTAL|Cohort B4: Multiple ascending doses of AJA001|AJA001 active b.i.d. oral dose level 4
62189535|NCT06019065|PLACEBO_COMPARATOR|Cohort B4: Multiple ascending doses of placebo|AJA001 placebo b.i.d. oral dose level 4
62189536|NCT04947514|OTHER|Treatment Side (Right or Left)|Each patient undergoing routine bilateral breast reduction will be randomized to receive the study drug (topical tranexamic acid) either to the right or left breast at the conclusion of the operation, prior to closure of the incisions. The other breast will receive topical saline.
62779464|NCT01596036|PLACEBO_COMPARATOR|Standard Referral|Patients will receive an appointment to cardiac rehabilitation at 5 weeks from the date of their anticipated hospital discharge. A routine referral to cardiac rehabilitation will also occur in parallel. Consequently, it is possible that some patients will attend cardiac rehabilitation earlier than their assigned 5 week appointment.
62779465|NCT02589535||septic|Group Gb: postoperative septic patients in intensive care unit (ICU)\] Gb1: the group of septic patients treated with extracorporeal hemoperfusion therapy and conventional therapy according to the Surviving Sepsis Campaign guidelines Gb2 group treated with conventional therapy according to the Surviving Sepsis Campaign guidelines
62779466|NCT02589535||no septic|Ga: postoperative patients in emergency surgical ward (ES)
62779467|NCT02589535||healthy|Healthy people
62779468|NCT04232111|SHAM_COMPARATOR|Thermoneutral|Neither heat nor vacuum applied to hand
62779469|NCT04232111|EXPERIMENTAL|Heat and Vacuum|Heat and vacuum applied to hand
62779470|NCT04232111|EXPERIMENTAL|Heat only|Only heat applied to hand
62779471|NCT02474953|EXPERIMENTAL|Dosing Sequence 1|Proprietary Curcumin Formulation administered first, Unformulated Comparator Curcumin Product administered second
62779472|NCT02474953|EXPERIMENTAL|Dosing Sequence 2|Unformulated Comparator Curcumin Product administered first, Proprietary Curcumin Formulation administered second
62779473|NCT04292223|EXPERIMENTAL|Drug - Pimavanserin|Pimavanserin 34 mg administered orally
62779474|NCT04565795|EXPERIMENTAL|Placement of ureteral stent post ureteroscopy|Subjects with unilateral ureteral or renal stone fragments who have undergone an uncomplicated ureteroscopy (UURS)
62779475|NCT03114631|EXPERIMENTAL|Dendritic cells lysate-pulsed group|Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with tumor lysate
61977887|NCT05517382|OTHER|Control group|Participants in this group will engage with a non-health-related game for one session (\~45min) and will receive NIDA and NIMH pamphlets on substance misuse and mental health for youth at the end of the session. Participants will use a dedicated device (e.g., tablet, laptop, or desktop) to access their digital experience on the web. The research staff and a school-based provider will be present to monitor gameplay, to provide support, if needed, and to field questions in person.
62189537|NCT04947514|OTHER|Non-Treatment Side (Right or Left)|Each patient undergoing routine bilateral breast reduction will be randomized to receive the study drug (topical tranexamic acid) either to the right or left breast at the conclusion of the operation, prior to closure of the incisions. The other breast will receive topical saline.
62189538|NCT01376154||Subjects prescribed lamivudine tablet|Subjects with hepatitis B virus-induced liver cirrhosis prescribed lamivudine tablet during study period
62189539|NCT03174782|ACTIVE_COMPARATOR|Treatment|Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.
62189540|NCT03174782|PLACEBO_COMPARATOR|Control|Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
62189541|NCT00464945|EXPERIMENTAL|1|
62779476|NCT03114631|NO_INTERVENTION|Control group|Patients treated according to clinical protocols
62189542|NCT00464945|ACTIVE_COMPARATOR|2|
62189543|NCT01907932|EXPERIMENTAL|normal and various degrees splenomegaly|"VScan Ultrasound (GE Healthcare, USA) all subjects will be measured by 5 different medical residents~Each resident will complete questionaire:~1. Adequacy of image quality~2. What is best view obtained~3. Greatest Longitudinal Measure~4. Diagnosis~5. Diagnostic Certainty~6. Time to Complete exam"
62779477|NCT03114631|EXPERIMENTAL|Dendritic cells peptide-pulsed group|Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with MUC-1/WT-1 peptides
62003864|NCT01403207||knee osteoarthritis|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
62396423|NCT04843098|EXPERIMENTAL|Single arm, open label|Phase 1a: All subjects receiving TL117 alone (20-120 mg); Phase 1b: All subjects receiving TL117 (MTD-1 or MTD) plus Paclitaxel; Phase 2: All subjects receiving TL117 in combination with Paclitaxel at RP2D
62779478|NCT06023043|NO_INTERVENTION|No Steroid (NS)|No Dexamethasone (NS)
62779479|NCT06023043|EXPERIMENTAL|With Steroid (WS)|With Dexamethasone (WS)
62779480|NCT05354687|NO_INTERVENTION|Control Group|No intervention will be given to participants. Students will be given pre-test and post-tests.
62779481|NCT05354687|EXPERIMENTAL|Small-group Teaching Group|Participants will be given training on the evaluation of pressure injuries with small-group teaching techniques.
62779482|NCT05354687|EXPERIMENTAL|Self-directed Learning Group|Participants will be given training on the evaluation of pressure injuries with self-directed learning technique.
62779483|NCT04517643|EXPERIMENTAL|Therasphere Therapy|All participants will receive the Therasphere Therapy.
62779484|NCT02808468|ACTIVE_COMPARATOR|Brief Cognitive Intervention|One in person session (90 minutes) of trauma focused cognitive therapy followed by 4 weekly coaching calls (20 minutes each) with the same study therapist
61977888|NCT02899910|EXPERIMENTAL|Yoga with health education|12 week yoga program coupled to standardized health education for weight loss
62003865|NCT01744210||CHF|
62003866|NCT06504030|EXPERIMENTAL|modified-DEP for HLH|modified-DEP for the treatment of non-EBV-HLH and EBV-HLH patients.
62003867|NCT00977067|EXPERIMENTAL|A|
62003868|NCT06232382|EXPERIMENTAL|Hypnosis Audio|20 minutes audio
62779485|NCT02808468|NO_INTERVENTION|Assessment Only|Assessment session followed by weekly completion of assessment measures
62779486|NCT00665964|EXPERIMENTAL|X-3|X-3 polyethylene which is a new highly cross-linked poly that is theorized to be more durable in vivo
62779487|NCT00665964|ACTIVE_COMPARATOR|N2Vac polethylene|conventional polyethylene
62779488|NCT03937492|EXPERIMENTAL|A group|In this group patients follow standard treatment after radius fracture plus GMI procol
62779489|NCT03937492|ACTIVE_COMPARATOR|B group|In this group patients follow standard treatment after radius fracture
62779490|NCT04772508|SHAM_COMPARATOR|Group A|15 sites received only scaling and root planing
62779491|NCT04772508|ACTIVE_COMPARATOR|Group B|15 sites received scaling and root planing with subgingival placement of amnion membrane
62003869|NCT06232382|EXPERIMENTAL|Mindfulness meditation|20 minutes audio
62003870|NCT06232382|PLACEBO_COMPARATOR|Natural text audio|20 minutes audio
62003871|NCT00280566|EXPERIMENTAL|Ziprasidone|Active treatment, double-blind, randomized arm
62003872|NCT00280566|PLACEBO_COMPARATOR|Placebo|Placebo treatment, double-blind, randomized arm
62779492|NCT04772508|ACTIVE_COMPARATOR|Group C|15 sites received scaling and root planing with subgingival placement of amnion membrane hydrated with Taurine
62779493|NCT04378114|EXPERIMENTAL|Subjects with diabetes wearing Guardian™ Sensor (3). C algorithm applied retrospectively|Subjects wear Guardian™ Sensor (3) over 7 days and undergo one frequent sample test (FST). C sensor algorithm applied retrospectively to raw sensor data.
62779494|NCT04378114|EXPERIMENTAL|Subjects with diabetes wearing Guardian™ Sensor (3). Zeus algorithm applied retrospectively|Subjects wear Guardian™ Sensor (3) over 7 days and undergo one FST. Zeus sensor algorithm applied retrospectively to raw sensor data.
62779495|NCT01707381|ACTIVE_COMPARATOR|Timolol Maleate|Timolol maleate ophthalmic solution 0.5% administered 1 drop BID once in morning and once in the evening for 4 weeks.
62779496|NCT01707381|EXPERIMENTAL|BOL-303259-X|BOL-303259-X topical ophthalmic solution administered 1 drop QD in the evening for 4 weeks.
62779497|NCT04044976|EXPERIMENTAL|Treated infants|Infants who will receive caffeine in the delivery room.
62779498|NCT03370666|EXPERIMENTAL|HFNT|HFNT performed with any available device. The flow will be initially set at 60 liters per minute and temperature at 37° C. The target will be an oxygen saturation (SpO2) of 88-92%. In case of patient not tolerating these settings, flow and temperature will be titrated to the maximum tolerated level.
62003873|NCT02533921|OTHER|Standard of Care|Usual care as in including both a Primary Care Physician (PCP) and neurologist.
61977889|NCT02899910|ACTIVE_COMPARATOR|Health education|Standardized health education for weight loss
62003874|NCT02533921|ACTIVE_COMPARATOR|Interdisciplinary outpatient palliative care|Usual care augmented by an outpatient interdisciplinary palliative care team.
62003875|NCT05055674|EXPERIMENTAL|Motherly App|Participants in this arm will have access to Motherly, a smartphone app that is designed to promote life habits that have been shown to improve depression and mental health in mothers.
62003876|NCT05055674|ACTIVE_COMPARATOR|COMVC App|Participants in this arm will have access to COMVC, a smartphone app designed to deliver only psychoeducational content and mental health monitoring.
62003877|NCT05927233|EXPERIMENTAL|Group M|IV Methylprednisolone
62003878|NCT05927233|PLACEBO_COMPARATOR|Group P|IV Normal Saline
62003879|NCT03750734||Idiopathic bronchiectasis|Idiopathic bronchiectasis participants
62779499|NCT03370666|ACTIVE_COMPARATOR|NIV|NIV must be delivered by full or oronasal mask with any available ventilator. The ventilator settings will be decided according to the usual practice: maximal tolerated inspiratory pressure to obtain a measured or estimated expired tidal volume of 6-8 mL·kg-1 of body weight and a positive end expiratory pressure (PEEP) between 3 and 5 cmH2O. An interface rotational strategy will be allowed among only different types of masks.
61977890|NCT01840709|EXPERIMENTAL|Psychotherapy treatment|The experimental group will be treated with Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks.
61977891|NCT01840709|NO_INTERVENTION|control group|the patients in this group will be just assessed with the same questionnaires at baseline and after 20 weeks, without psychotherapy.
61977892|NCT03326791|EXPERIMENTAL|Intervention group|Acetylsalicylic acid 160 mg once daily until recurrent disease or a total period of 3 years.
61977893|NCT03326791|PLACEBO_COMPARATOR|Control group|Placebo Oral Tablet once daily until recurrent disease or a total period of 3 years.
61977894|NCT00022633|EXPERIMENTAL|gemcitabine, paclitaxel|
61977895|NCT04320381||Group A|subjects in the hypertonic saline study randomized to discontinue or maintain therapy
61977896|NCT04320381||Group B|subjects in the dornase alfa study randomized to discontinue or maintain therapy
61977897|NCT04320381||Group C|subjects who were randomized but withdrew early from the SIMPLIFY Study.
61977898|NCT04320381||Group D|subjects in the hypertonic saline study randomized to discontinue or maintain therapy with FEV1% predicted between 40 and \<60%
61977899|NCT04320381||Group E|caregiver participants (parents and legal guardians of eligible patient participants less than 18 years of age who were randomized in the SIMPLIFY study)
61977900|NCT00982592|EXPERIMENTAL|Arm I (FOLFOX regimen and placebo)|Patients receive FOLFOX chemotherapy comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil bolus and then IV over 46-48 hours on day 1. Patients also receive placebo PO QD on days 1-14. Courses repeat every 2 weeks in the absence of unacceptable toxicity or disease progression.
61977901|NCT00982592|EXPERIMENTAL|Arm II (FOLFOX regimen and vismodegib)|Patients receive FOLFOX chemotherapy as in arm I. Patients also receive vismodegib PO on days 1-14. Courses repeat every 2 weeks in the absence of unacceptable toxicity or disease progression.
61977902|NCT04324554||MRI of the right knee|An MRI of the right knee will be done to define the role of imaging in the diagnosis of early femoro-patellar osteoarthritis.
61977903|NCT02054416|ACTIVE_COMPARATOR|Art Assist Device|The ArtAssist© (model AA1000) device is made by ACI Medical located in San Marcos, CA (http://acimedical.com/) and is cleared per FDA under K942530.The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
61977904|NCT02054416|SHAM_COMPARATOR|Sham Device|"Sham devices look identical to the actual ArtAssist© devices, but provide low-pressure and differ only in number-coded tubing. The study sham intervention will consist of one hour of IPC with the sham ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the sham device has an internal device that stores the usage data) to evaluate subject compliance."
61977905|NCT03022565|EXPERIMENTAL|Vorinostat|"Vorinostat:~* 400 mg orally, once daily for 15 days."
61977906|NCT05193656||Detecting bladder tumor|Patients with hematuria, or previous bladder tumor
62003880|NCT03750734||Healthy volunteers|Healthy volunteers
62003881|NCT03392636|EXPERIMENTAL|Group A|Mitchell Banks Herniotomy
62003882|NCT03392636|EXPERIMENTAL|Group B|Fergusson Gross Herniotomy
62189544|NCT03095170|EXPERIMENTAL|Computerized brain fitness training|"Will receive a 10 day intervention program (over 2 weeks) consisting of Computer Brain Fitness Training, Calendar Training and Support Group.~After the initial two week intervention, there will be an extended period during which participants will continue the computerized brain fitness for another 24 weeks.Participants are encouraged to do at least two hours per week."
62189545|NCT03095170|EXPERIMENTAL|Yoga|"Will receive a 10 day intervention program (over 2 weeks) consisting of Yoga, Calendar Training, and Support Group.~After the initial two week intervention, there will be an extended period during which participants will continue yoga for 24 weeks. Participants assigned to the yoga intervention will continue to meet with their group and their yoga instructor for one hour per week and will be expected to do at least an additional hour of yoga by themselves every week."
62189546|NCT03095170|ACTIVE_COMPARATOR|Wellness Education|Will receive a 10 day intervention program (over 2 weeks) consisting of Wellness Education, Calendar Training and Support Group.
62189547|NCT01237847|OTHER|Wait List|
62189548|NCT01237847|EXPERIMENTAL|2 phone sessions|
62189549|NCT01237847|EXPERIMENTAL|4 phone sessions|
62189550|NCT00085397|EXPERIMENTAL|Arm I|Patients undergo surgical harvesting of tumor cells for subsequent fusion. Patients receive vaccination comprising dendritic cells (DC) fused with autologous tumor cells subcutaneously on day 1. Treatment repeats every 21 days for 3 courses. Patients who achieve a partial (PR) or complete response (CR) may receive an additional 3 courses.
62189551|NCT00085397|EXPERIMENTAL|Arm II|Patients receive vaccination comprising DC pulsed with gp100 antigen IV on day 1. Treatment repeats every 21 days for 6 courses. Patients who achieve a PR or CR may receive an additional 6 courses.
62189552|NCT05069298|EXPERIMENTAL|INTERVENTION|Silibinin (A) for three months, with an administration regimen of 3 oral doses of 300 mg per day, before each main meal.
62189553|NCT05069298|PLACEBO_COMPARATOR|CONTROL|Similar treatment regimen, but with a placebo.
62396424|NCT05674461|EXPERIMENTAL|WhatsApp Group|"In the study, training modules including general information about the postpartum period, breastfeeding counseling, postpartum nutrition, puerperal psychology, family planning and postpartum exercises, consisting of 4 sessions, will be applied to the women in the experimental group.~Trainings will be sent to the women in the WhatsApp experimental group in the form of videos via the WhatsApp application. The videos will be prepared with the researchers' own voice and image. Each training video will be sent for 15-30 minutes (in the form of short videos, if necessary, divided into parts).~Women will be supported through messages in order to increase their motivation and provide counseling regarding their possible questions and problems."
61977907|NCT01647282|EXPERIMENTAL|Sc/RP with minocycline micropheres|Sc/RP is the subgingival mechanical removal of calculus and diseased cementum from the tooth root. Local application of minocycline microspheres will be done after scaling and root planing (Sc/RP) has been completed
62003883|NCT05196412|EXPERIMENTAL|Main study group|Normal subjects of at least 65 years of age
62003884|NCT05196412|EXPERIMENTAL|Endurance athlete group|Group consists of active endurance athletes of at least 50 years of age
62003885|NCT01114516|NO_INTERVENTION|control|emergent cerclage with no peri-operative antibiotics or indomethacin
62003886|NCT01114516|EXPERIMENTAL|indomethacin and antibiotics|perioperative antibiotics and indomethacin
62189554|NCT00926575|EXPERIMENTAL|orBec®|Investigational drug
62189555|NCT00926575|PLACEBO_COMPARATOR|Placebo|Control
62189556|NCT06087471|SHAM_COMPARATOR|Control snack|42 participants will be randomly assigned to the control snack. Snacks should be consumed twice per day, once as a mid-morning snack and again as a mid-afternoon snack.
62003887|NCT04416035|EXPERIMENTAL|TRS003|TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Paclitaxel will be administered at a dose of 200 mg/m\^2 by IV infusion Q3W on Day 1 of each cycle，carboplatin will be administered at an AUC 6 mg/mL/ min by IV infusion Q3W on Day 1 of each cycle. Each cycle is 3 weeks. Treatments will continue until disease progression, death, intolerable toxicity, withdrawal of consent, investigator decision, or completion of 4-6 cycles of therapy. Maintenance therapy may be given at the discretion of the patient's primary oncologist.
62189557|NCT06087471|EXPERIMENTAL|Experimental snack|42 participants (50%) will be randomly assigned to snack on the intervention snack. Snacks should be consumed twice per day, once as a mid-morning snack and again as a mid-afternoon snack.
62189558|NCT00332969|EXPERIMENTAL|Sandostatin|
62189559|NCT00884897|EXPERIMENTAL|Oxytocin|We will purchase OT from PharmaWorld, an international pharmacy located in Switzerland; the preparation of intranasal OT is manufactured by Novartis and sold under the trade name: Syntocinon. We have obtained an IND (number 78,246) for Syntocinon (intranasal oxytocin) manufactured by Novartis.
62189560|NCT00884897|PLACEBO_COMPARATOR|Placebo|We will be purchasing oxytocin placebo nasal spray through LABOSWISS located in Davos, Switzerland and distributed through PharmaWorld. LABOSWISS will manufacture the matching the placebo under GDP guidelines. The placebo will be in every way identical to the oxytocin formulation but will not contain OT.
62189561|NCT05979623||ZS-IB-NSCLC|A total of 971 NSCLC patients with pathological stage IB resected by surgery (R0) from January 2016 to December 2020 at Zhongshan Hospital of Fudan University
62189562|NCT02398032|EXPERIMENTAL|CPAP nasal|Nasal continuous positive airway pressure, during the night
62189563|NCT02398032|SHAM_COMPARATOR|sham CPAP nasal|Nasal sham continuous positive airway pressure, during the night
62189564|NCT06157528|EXPERIMENTAL|ovarian endometriomas|Patients received a single dose of 1OOmg abarelix injection with slow absorption, Cmax of (43.4±32.3)ng/mL, Tmax of (3.0±2.9) days. AUC0-∞ is (500 ±96) ng·d/mL, t1/2 is (13.2±3.2) days, CL/F is (208±48) L/d
62189565|NCT03777852|EXPERIMENTAL|Pre-surgery First Breast Q|Women with proven breast cancer diagnosis. Respond to the First Breast Q questionnaire..
62189566|NCT03777852|ACTIVE_COMPARATOR|Post-surgery Second Breast Q|The Second Breast Q questionnaire will be applied to this group that will be composed of the women of the first group submitted to reconstructive breast cancer surgery.
62003888|NCT04416035|ACTIVE_COMPARATOR|China-approved Bevacizumab|China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Paclitaxel will be administered at a dose of 200 mg/m\^2 by IV infusion Q3W on Day 1 of each cycle and carboplatin will be administered at an AUC 6 mg/mL/min (the maximum dose capped at 900 mg) by IV infusion Q3W on Day 1 of each cycle. Each cycle is 3 weeks. Treatments will continue until disease progression, death, intolerable toxicity, withdrawal of consent, investigator decision, or completion of 4-6 cycles of therapy. Maintenance therapy may be given at the discretion of the patient's primary oncologist.
62396425|NCT05674461|EXPERIMENTAL|Face-to-face Group|"In the study, training modules including general information about the postpartum period, breastfeeding counseling, postpartum nutrition, puerperal psychology, family planning and postpartum exercises, consisting of 4 sessions, will be applied to the women in the experimental group.~The trainings will be given to the women in the experimental group face-to-face by the researchers in the form of 15-30 minute trainings in their own home environment.~Women will be supported through messages in order to increase their motivation and provide counseling regarding their possible questions and problems."
62396426|NCT05674461|OTHER|Control|No intervention will be applied to the mothers in the control group.
62396427|NCT00499694|EXPERIMENTAL|Bevacizumab and Satraplatin|"Bevacizumab 10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)~Satraplatin 80 mg/m(2), Orally, Days 1-5, every 35 days"
62396428|NCT05144269|EXPERIMENTAL|Multimodal exercises group|Multimodal exercise-based telerehabilitation will be implemented with video conference method. For telerehabilitation, a program including pilates, breathing, progressive relaxation training, posture and pelvic floor strengthening exercises was created. Sessions consist of 45 minutes. Telerehabilitation will take place 2 days a week for 8 weeks.
62396429|NCT05144269|NO_INTERVENTION|Education group|30 minutes of training will be given about postpartum and exercises. As exercise, only aerobic walking exercise, which can be started for 15 minutes a day and 3 days a week according to the guide, gradually increasing, up to 30 minutes and up to 4 days a week will be applied. There will also be a warm-up and a cool-down period before the walking exercise. \*Exercise intensity is determined in the 12-14 score range according to the Borg Scale, and how to apply it will be explained.
62396430|NCT04564534||Study cohort|"Adult (\>18 years) patients with aortic stenosis in whom TAVI is planned and who perform their pre-TAVI work-up in our centre will be invited to undergo cognitive assessment using the MoCA at the time of their hospitalization for pre-TAVI work-up.~The MoCA will be administered by trained professionals with MoCA certification.~Clinical outcomes, as assessed by the VARC2 criteria, will be collected for all patients at 3 months after the TAVI procedure."
62396431|NCT00967356|EXPERIMENTAL|A|AZD5985
62396432|NCT00967356|PLACEBO_COMPARATOR|B|Placebo
62003889|NCT01815281|EXPERIMENTAL|Foot Mechanical Stimulation|The FMS stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland).
62189567|NCT01958242|NO_INTERVENTION|Preoperative blood harvesting|
62571716|NCT05331131|EXPERIMENTAL|Ketamine Mouthwash|"Enrolled patients with histologically confirmed squamous cell carcinoma of the head and neck undergoing definitive radiation therapy to 70Gy with concurrent cisplatin chemotherapy who develop grade 3+ toxicity will be prescribed ketamine mouthwash at a strength of 20mg/5mL in NovaFilm suspension with OraSweet flavoring agent via swish and spit route of administration. They will take the investigational drug four times daily."
62571717|NCT01531621||mCRC treatments|All used treatments for metastatic colorectal cancer
62571718|NCT01695174|EXPERIMENTAL|Xifaxan|Xifaxan 550 mg two times per day for three months
62571719|NCT05184595|ACTIVE_COMPARATOR|Carfilzomib delivered in OH only|"Patients receive the whole treatment in OH. Primary and secondary endpoints are collected at day 1 of cycle 3, 6, 9, 12, 18 and one month after.~Patients leave the protocol prematurely due to treatment failure, toxicity or patient wishes. For those patients, the end of study visit will be done one month after ending treatment."
62189568|NCT01008163|EXPERIMENTAL|1|YY-351, PO, 1T tid. / Placebo, 1T tid.
62571720|NCT05184595|EXPERIMENTAL|Carfilzomib delivered in OH and HaH combined|"Patients receive the first cycle of treatment in OH. Then, they are randomized between exclusive OH treatment and combined treatment in OH and at home with HaH services.~For the HaH patients group, the first injection of each cycle is delivered in OH. The rest of the cycle is delivered at home by HaH after a clinical examination (by nurse or general practitionner).~Primary and secondary endpoints are collected at day 1 of cycle 3, 6, 9, 12, 18 and one month after.~Patients leave the protocol prematurely due to treatment failure, toxicity or patient wishes. For those patients, the end of study visit will be done one month after ending treatment."
62571721|NCT01316003||Normal subjects|Thirty-seven eyes of 37 individuals without eye diseases
62571722|NCT05457855||Montelukast|Exposure group
62189569|NCT01008163|EXPERIMENTAL|2|YY-351. PO, 2T bid. / Placebo 2T qd.
62189570|NCT01008163|EXPERIMENTAL|3|YY-351, PO, 2T tid.
62189571|NCT01008163|PLACEBO_COMPARATOR|4|Placebo, PO, 2T tid.
62189572|NCT02755701|EXPERIMENTAL|BCAA group|Branched-chain amino acid, 4.15g, Tid
62189573|NCT02755701|PLACEBO_COMPARATOR|Placebo group|Placebo, 4.15g, Tid
62396433|NCT06722794|OTHER|Novel Technique for Fixating the Plate of Ahmed Valve to the Sclera Using a Single Flanged Prolene S|Novel Technique for Fixating the Plate of Ahmed Valve to the Sclera Using a Single Flanged Prolene Suture
62571723|NCT05457855||Fluticasone|Reference group
62571724|NCT03211884|EXPERIMENTAL|Problem-solving therapy|Couched within Bandura's social-cognitive theory, self-management refers to the process by which individuals accept responsibility for and take action to change their behaviors, obtain knowledge related to their situation (e.g., behavioral manifestations of a TBI) through increased awareness and use of effective personal resources (e.g., skill in every-day problem-solving). This ultimately enhances the caregivers' confidence that they can cope with caregiving and behavior-related stressors in the care recipient.
62571725|NCT03211884|NO_INTERVENTION|Usual Care|Usual care was defined as various military caregiver organizations, support groups and services available to all family caregivers of combat Veterans (e.g., Military OneSource; Operation We Are Here; Veterans Administration Program of Comprehensive Assistance for Family Caregivers; American Red Cross Military and Veteran Caregiver Network; Project New Hope; Wounded Veteran Family Care; Women for Wounded Warriors).
62571726|NCT06532721||developmental disabilities group|this group recruited children with developmental disabilities
62571727|NCT06532721||typical developmental group|This regoup recruited children with typical development
62571728|NCT00509951|ACTIVE_COMPARATOR|1|One-session exposure treatment (OST)
62571729|NCT00509951|EXPERIMENTAL|2|Family-enhanced (augmented) OST
62189574|NCT00940862|EXPERIMENTAL|adalimumab|A total of 20 patients will be randomized to adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
62189575|NCT00940862|ACTIVE_COMPARATOR|Non-systemic treatment.|A total of 10 patients will be randomized to non systemic therapy for psoriasis (topical treatments and/or UVB phototherapy).
62189576|NCT01601912||Atomoxetine NRI|We will modulate endogenous adrenergic pain inhibitory mechanisms by using a selective norepinephrine reuptake inhibitor (NRI).
62189577|NCT01601912||Citalopram SSRI|We will modulate serotonergic pain inhibitory mechanisms by using a selective serotonin reuptake inhibitor (SSRI)
62189578|NCT04636645|ACTIVE_COMPARATOR|Normal Treadmill|After completion of the baseline evaluation, Group A participants will exercise for 25 minutes under low-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at a 0-degree incline. For each session, 20% support will be given to participants
62396434|NCT01151085||Voriconazole|Subjects who are treated with voriconazole
62571730|NCT01149564|PLACEBO_COMPARATOR|IV ibuprofen|The first dose of either oral or IV ibuprofen will be given at the time the patient is randomized.The subsequent doses of indometacin or ibuprofen are also determined according to the echocardiographic PDA flow patterns at intervals of once every 24 hours from the last dose. The dosage of both oral ibuprofen (Ibuprofen suspension, 20 mg/ml, Yung Shing Co., Taiwan) and IV ibuprofen (PedeaR 20 mg/ml, developed by Orphan Europe and approved by the EMEA) are an initial dose of 10 mg/kg and then 5 mg/kg at 24-hour intervals as indicated by PDA flow pattern.
62571731|NCT01149564|ACTIVE_COMPARATOR|Oral ibuprofen|
62571732|NCT03510039|ACTIVE_COMPARATOR|"Before Group"|35 Thirds benefiting from the usual care
62571733|NCT03510039|EXPERIMENTAL|"After Group"|"Recruit 35 Thirds for the phase phase After : Early device / Follow up by nurses"
62571734|NCT01722825|EXPERIMENTAL|LY2157299|80 up to 150 milligrams of LY2157299 administered orally, twice daily for 14 days, followed by 14 days with no study drug (2 weeks on/2 weeks off schedule) for at least two 28 day cycles. Participants receiving clinical benefit may continue receiving treatment until discontinuation criterion is met.
62571735|NCT00789373|EXPERIMENTAL|pemetrexed + cisplatin followed by pemetrexed|pemetrexed plus cisplatin followed by pemetrexed plus best supportive care
62571736|NCT00789373|PLACEBO_COMPARATOR|pemetrexed + cisplatin followed by placebo|pemetrexed plus cisplatin followed by placebo plus best supportive care
62003890|NCT01815281|SHAM_COMPARATOR|Footh Mechanical Stimulation|The sham stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland).
62003891|NCT04541017|EXPERIMENTAL|Arm I (magrolimab, mogamulizumab), Phase Ib and Phase II|Patients receive magrolimab IV over 2-3 hours weekly during cycles 1-2, then Q2W during cycles 3-12. Patients also receive mogamulizumab IV over at least 60 minutes weekly during cycle 1, then Q2W during cycles 2-12. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT or diagnostic CT, blood sample collection, and may undergo a skin punch biopsy during screening and on study.
62003892|NCT04541017|ACTIVE_COMPARATOR|Arm II (mogamulizumab), Phase II|Patients receive mogamulizumab IV over at least 60 minutes weekly during cycle 1, then Q2W during cycles 2-12. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients who have received at least 2 full treatment cycles and have PD or have received at least 6 full treatment cycles and have SD may crossover to Arm I. Patients undergo PET/CT or diagnostic CT, blood sample collection, and may undergo a skin punch biopsy during screening and on study.
62189579|NCT04636645|EXPERIMENTAL|Anti-gravity treadmill with lower limb positive pressure|Group B participants will be exercised for 25 minutes under normal-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
62396435|NCT06660420|EXPERIMENTAL|Escalation Phase|The dose of PRAME-TCR-NK cells you receive will depend on when you join this study. Up to 5 dose levels of the study product will be tested. The first group of participants will receive the lowest dose level of the study product. Each new group will receive a higher dose of the study product than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose and recommended dose of the study product is found.
62396436|NCT06660420|EXPERIMENTAL|Expansion Phase|Participants will receive PRAME-TCR-NK cells at the recommended dose.All participants will receive the same dose level of fludarabine and cyclophosphamide
62571737|NCT04144894|OTHER|Healthy Controls|
62571738|NCT04144894|OTHER|Vascular Surgery Subjects|
62779500|NCT02409342|ACTIVE_COMPARATOR|(Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)|Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months). Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).
62003893|NCT05294107|EXPERIMENTAL|Group Crohn's disease|4 additional biopsies for 30 patients with Crohn's disease
61977908|NCT01647282|ACTIVE_COMPARATOR|Sc/RP alone|Sc/RP is the subgingival mechanical removal of calculus and diseased cementum from the tooth root
61977909|NCT01638806|EXPERIMENTAL|Group I: PPCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
62003894|NCT05294107|EXPERIMENTAL|Group ulcerative colitis|4 additional biopsies for 30 patients with ulcerative colitis
62189580|NCT04636645|EXPERIMENTAL|Anti-gravity treadmill with without lower limb positive pressure|Group C participants will be exercised for 25 minutes three times a week for 8 consecutive weeks on the normal treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
62571739|NCT06229561|EXPERIMENTAL|ADM and SCTG|ADM and SCTG
62571740|NCT06229561|EXPERIMENTAL|Acellular Dermal Matrix and soft tissue graft|12participatent in two groups
62571741|NCT06198309||Frequent exacerbation of COPD|
62571742|NCT06198309||Non-frequent exacerbation of COPD|
62571743|NCT05702931|ACTIVE_COMPARATOR|Semaglutide treated group|Oral semaglutide once-daily as add-on to standard-of-care for post-transplant hyperglycaemia
62571744|NCT05702931|PLACEBO_COMPARATOR|Placebo treated group|Oral placebo once-daily as add-on to standard-of-care for post-transplant hyperglycaemia
62003895|NCT05294107|ACTIVE_COMPARATOR|Group No MICI|4 additional biopsies for 30 patients out of Inflammatory Disease Chronic Bowel Disease
62003896|NCT04313920|EXPERIMENTAL|Nutritional Supplement|Ready to drink liquid
62003897|NCT00901875|EXPERIMENTAL|Suboxone, maximum 8mg|
62003898|NCT00901875|EXPERIMENTAL|Buprenorphine + naloxone|
62003899|NCT00901875|EXPERIMENTAL|Buprenorphine + naloxone (Suboxone)|
62003900|NCT02149433|EXPERIMENTAL|Prednisone versus placebo|Prednisone 2mg/kg orally once a day x 7 days, 1 mg/kg orally once a day x 7 days and then 0.5 mg/kg orally once a day x 7 days
62003901|NCT02420496|EXPERIMENTAL|Enteral fish oil|Infants will receive enteral fish oil at a dose of 1mg/kg/day divided in two daily doses given enterally.
62003902|NCT02420496|ACTIVE_COMPARATOR|UDCA (ursodeoxycholic acid)|Infants will receive UDCA at a dose of 10mg/kg/dose in two daily doses given enterally
62003903|NCT02420496|PLACEBO_COMPARATOR|Placebo|Infant will receive placebo in two daily doses given enterally
62396437|NCT03900975||Vulvar Paget Disease|Women with vulvar paget disease
62396438|NCT03387982||Balloon Cryotherapy Treatment Group|Subjects will undergo endoscopic balloon cryotherapy for dysplastic Barrett's Esophagus as per standard of care. The treatment type (balloon cryotherapy vs RFA) is determined by the endoscopy physician at the time of the procedure and is based on several clinical factors including co-existing medical conditions, the anatomy of the esophagus, and the length and amount of tissue affected with Barrett's.
62003904|NCT01207778||preterm ESA recipients|Former preterm infants 500-1250 grams who received erythropoietin (400 units/kg 3x/week) or darbepoetin (10 micrograms/kg 1x/week), from the first week of life through 35 weeks corrected gestation
62396439|NCT03387982||RFA Treatment Group|Subjects will undergo radio frequency ablation treatment for dysplastic Barrett's Esophagus as per standard of care. The treatment type (balloon cryotherapy vs RFA) is determined by the endoscopy physician at the time of the procedure and is based on several clinical factors including co-existing medical conditions, the anatomy of the esophagus, and the length and amount of tissue affected with Barrett's.
62779501|NCT02409342|EXPERIMENTAL|Atezolizumab|Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
62003905|NCT01207778||preterm controls|Former preterm infants 500-1250 grams who received placebo (sham dosing), from first week of life through 35 weeks corrected gestation
62396440|NCT01081002|ACTIVE_COMPARATOR|Anesthesia (=A) with lidocaine 10%|3 min before sedation 4 puffs of terbutaline diluted lidocaine solution (Xylocaine ® 10% spray, Astra Zeneca, London, UK) will be sprayed on the pharynx
62396441|NCT01081002|PLACEBO_COMPARATOR|A with diluted gentian root solution|3 min before sedation 4 puffs of highly diluted gentian solution will be sprayed on the pharynx
62396442|NCT02177227|EXPERIMENTAL|Total Knee Arthroplasty with PSI|Total Knee Replacement with the use of the Attune TruMatch (TM) Patient-Specific Instrumentation
62396443|NCT02177227|NO_INTERVENTION|Total Knee Replacement|Total Knee Replacement, as per Standard of Care
62396444|NCT03173950|EXPERIMENTAL|1/Experimental Therapy|Patients will receive nivolumab at standard dose of 240 mg IV every 2 weeks for cycles 1 through 2, then doses of 480 mg every 4 weeks for a total of 14 additional doses
62396445|NCT02797600||ARM I|Woman residing in Appalachian counties who have prevalent invasive cervical cancer. Invasive cervical cancer cases participants will include women previously and currently treated for ICC during the past 10 years. Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. Biological samples will be collected during a scheduled visit with the research staff.
62571745|NCT01050036|EXPERIMENTAL|HCT recipients|"1. Patient with CBF AML will be eligible in his/her 1st complete remission (CR1) status. Patients who have relapsed or have achieved 2nd complete remission should not be included in this study.~2. 1st postremission therapy after CR1 will be performed with high-dose cytarabine (HDAC) chemotherapy, consisting of intravenous cytarabine 3 g/m2 infusion during 3 hours twice a day on days 1, 3, and 5.~3. After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information."
62571746|NCT01903330|EXPERIMENTAL|(ERC1671/GM-CSF/Cyclophosphamide)+bevacizumab/bevacizumab biosimilar|"ERC1671 and GM-CSF will be intradermally administered, while cyclophosphamide is orally administered. GM-CSF dose is 500mcg fixed dose and cyclophosphamide dose is 50 mg/day. Bevacizumab or approved bevacizumab biosimilars are administered as standard of care at 10 mg/kg every 2 weeks.~The treatment will be repeated every 28 days until progression of disease or intolerance."
62779502|NCT00554372|EXPERIMENTAL|Low Dose|1e8 pfu (plaque forming units) total dose of JX-594 (recombinant vaccinia virus) on each of three (3) treatment days (2 weeks apart)
62779503|NCT00554372|EXPERIMENTAL|High Dose|1e9 pfu (plaque-forming units) total dose of JX-594 (recombinant vaccinia virus) on each of three (3) treatment days (2 weeks apart)
62779504|NCT04544579||Ascending aortic dissection patients|Ascending aortic dissection patients
62779505|NCT05019534|EXPERIMENTAL|Vemurafenib, Cetuximab Combined With Camrelizumab (VCC)|Cetuximab and Camrelizumab in the fixed dose Vemurafenib have two dose groups: 960mg qd or 960mg bid
62779506|NCT06200883|PLACEBO_COMPARATOR|Placebo|Placebo oral tablet. In the Placebo group the participants take vehicle (1 vial per os every 24 hours) for 4 weeks
62003906|NCT01207778||term controls|Former term infants with normal delivery
62003907|NCT05790434||Cases|Patients with septic arthritis
62003908|NCT05790434||Controls|Patients with osteoarthritis, rheumatoid arthritis
62003909|NCT03117387||moderate neuromuscular block, normal body mass index|Patients with normal BMI (\< 30) who will receive a moderate neuromuscular block (train of four 1-3 twitches)
62003910|NCT03117387||deep neuromuscular block, normal body mass index|Patients with normal BMI (\< 30) who will receive a deep neuromuscular block (post tetanic count of 1-2 twitches)
62003911|NCT03117387||moderate neuromuscular block, high body mass index|Patients with high BMI (\> 30) who will receive a moderate neuromuscular block (train of four 1-3 twitches)
62003912|NCT03117387||deep neuromuscular block, high body mass index|Patients with high BMI (\> 30) who will receive a deep neuromuscular block (post tetanic count of 1-2 twitches)
62003913|NCT02157766|ACTIVE_COMPARATOR|MNP with Asthma: Mindfulness Based Stress Reduction|
62003914|NCT02157766|NO_INTERVENTION|MNP w/ Asthma: Wait List Control|
62003915|NCT02157766|ACTIVE_COMPARATOR|MNP, no asthma - Mindfulness Based Stress Reduction|
62396446|NCT02797600||ARM II|Woman residing in Appalachian counties who are newly diagnosed with invasive cervical cancer(ICC). Newly diagnosed with ICC, and currently being treated for ICC. Questionnaires will be used to obtain Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. All biological samples will be collected during a scheduled clinic visit.
62003916|NCT02157766|ACTIVE_COMPARATOR|MNP, no asthma: Health Enhancement Program|
62003917|NCT02157766|NO_INTERVENTION|MNP, no asthma - Wait List Control|
62396447|NCT02797600||ARM III|Healthy controls (women without a diagnosis of any type of cancer. Healthy controls will be women who are coming into one of the participating clinic or physician practice for a routine Pap test. Questionnaires will be used to obtain Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. All biological samples will be collected at the time of the clinical Pap smear.
62779507|NCT06200883|ACTIVE_COMPARATOR|CERBRAIN|In the CEREBRAIN group the participants take CEREBRAIN (1 vial per os of 1.2 g every 24 hours) for 4 weeks
62779508|NCT01918059|EXPERIMENTAL|Non-absorbable suture skin closure|The superficial eyelid skin will be repaired with simple interrupted sutures with non-absorbable suture (6-0 polypropylene) after repair of any deep component of the laceration.
62779509|NCT01918059|EXPERIMENTAL|Absorbable suture skin closure|The superficial eyelid skin will be repaired with simple interrupted sutures with absorbable suture (surgical gut) after repair of any deep component of the laceration.
62779510|NCT01918059|EXPERIMENTAL|Tissue Adhesive skin closure|The superficial eyelid skin will be repaired with layers of tissue adhesive (octyl-2-cyanoacrylate) after repair of any deep component of the laceration.
62779511|NCT04956653||Patients diagnosed with Cervical Degenerative Disease|Patients who suffered from Cervical Degenerative Disease, treated by operation for the first time and aged 18 years old or over were assigned to CDD group.
62779512|NCT04956653||Patients diagnosed with Thoracic Degenerative Disease|Patients who suffered from Thoracic Degenerative Disease, treated by operation for the first time and aged 18 years old or over were assigned to TDD group.
62003918|NCT02157766|ACTIVE_COMPARATOR|Long Term Meditator|
62003919|NCT05620290|EXPERIMENTAL|Treatment Arm|Malignant Melanoma patients undergoing MRI-guided ultrasound-stimulated microbubble treatment plus radiation therapy
62003920|NCT02684006|EXPERIMENTAL|Avelumab in combination with axitinib|Avelumab administered at 10 mg/kg IV every two weeks in combination with axitinib, 5 mg PO BID.
62003921|NCT02684006|ACTIVE_COMPARATOR|Sunitinib|Sunitinib given at 50 mg PO QD on schedule 4/2
62003922|NCT06386952||With Double Dorsal Cervical Fat|T2DM with Double Dorsal Cervical Fat (Double Hump)
62003923|NCT06386952||Without Double Dorsal Cervical Fat|T2DM without Double Dorsal Cervical Fat (Double Hump)
62003924|NCT00000439|ACTIVE_COMPARATOR|sodium valproate|sodium valproate was added on treatment as usual and dose monitored by blood level measurements
62003925|NCT00000439|PLACEBO_COMPARATOR|placebo|Placebo comparator was added on treatment as usual and dose monitored by blood level measurements
62779513|NCT04956653||Patients diagnosed with Lumbar Degenerative Disease|Patients who suffered from Lumbar Degenerative Disease, treated by operation for the first time and aged 18 years old or over were assigned to LDD group.
62189581|NCT06255925|EXPERIMENTAL|Treatment Group|In this arm, participants would participate in in an intervention program that uses character strengths to improve job maintenance skills in young adults.
62779514|NCT00500825||1|Patients successfully resuscitated after cardiac arrest undergoing therapeutic hypothermia
62779515|NCT04255303|EXPERIMENTAL|iCPR group|Clinic personnel (Providers and Nurses) will receive online training that includes: 1) an overview of the project; 2) iCPR workflows including triage; 3) CPR component review and risk categories; 4) history and physical examination components of the CPRs. The online training will be followed by in-person training to reinforce the online training and teach additional skills. In-person training sessions led by study team will last approximately 60 minutes, and consist of four basic components: 1) a review of the iCPR ARI protocol and tools; 2) on-screen walk-throughs of common scenarios employing the new tools; 3) physical examination technique practice with simulated patients; A 60-minute in-person follow-up nurse training will take place 4-6 weeks after implementation of the intervention.
62779516|NCT04255303|NO_INTERVENTION|Control no intervention group|standard care will continue as usual.
62003926|NCT06020404|EXPERIMENTAL|Controls|Eligible patients will undergo the experimental protocol.
62003927|NCT06020404|EXPERIMENTAL|Patients|Eligible patients will undergo the experimental protocol.
62003928|NCT04922333|EXPERIMENTAL|Bisphosphonate|Participants in this arm will receive six months of 150 mg once monthly oral risedronate
62003929|NCT04922333|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive six months of placebo
62003930|NCT06097884|EXPERIMENTAL|Main study intervention- Salt substitute|Replacing usual salt with salt substitute in school meals
62003931|NCT06097884|PLACEBO_COMPARATOR|Main study control- Usual salt|Using usual salt in school meals
62003932|NCT06097884|EXPERIMENTAL|Ancillary study intervention- Meal tray|Replacing bowls with trays in school cafeteria
62003933|NCT06097884|PLACEBO_COMPARATOR|Ancillary study control- Bowl|Using bowls in school cafeteria
62003934|NCT02244333||Patients with symptomatic BPS|
62003935|NCT04469361||Ballerinas|Balerina students who have trained at least for 4 years
62003936|NCT04469361||Female students|Female students with sedentary lifestyle
62003937|NCT01204866|EXPERIMENTAL|Stage I|Three (3) healthy male or female volunteers aged 18-59 years, not previously exposed to Valortim and who do not have pre-existing allergies
62003938|NCT01204866|EXPERIMENTAL|Stage II|Up to 4 healthy male or female volunteers aged 18-59 previously exposed to intravenous (IV) Valortim in PharmAthene Study #0036-08-05
62003939|NCT01516879|EXPERIMENTAL|Evolocumab|Participants received evolocumab 420 mg subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
62003940|NCT01516879|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
62003941|NCT00466765|EXPERIMENTAL|Single Arm|Use Brava system for pre-expansion of breast prior to fat grafting
62003942|NCT05508061|EXPERIMENTAL|Lyumjev (insulin lispro)|Administration of Lyumjev for a 30-day study period (dosage and frequency is patient-dependent)
62003943|NCT05508061|ACTIVE_COMPARATOR|Humalog (insulin lispro)|Administration of standard used Humalog for a 30-day study period and 8-day wash-out period located between the two study periods (dosage and frequency is patient-dependent)
62003944|NCT04918680||EcoFit® Total Hip System with implacross® E Polyethylene|Subjects who meet the indications for use for the EcoFit® Total Hip System with implacross® E Polyethylene and are candidates for a primary hip replacement.
62003945|NCT00175903|EXPERIMENTAL|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
62003946|NCT00175903|ACTIVE_COMPARATOR|Older Antepileptic Drugs|Older AEDs consist of CBZ-CR 200 mg and 400 mg and VPA-ER 300 mg and 500 mg.
62003947|NCT05950568|ACTIVE_COMPARATOR|Quadratus lumborum block type II|A 22 gauge needle was positioned between the erector spinae muscle in the thoracolumbar fascia's middle layer
62003948|NCT05950568|ACTIVE_COMPARATOR|Quadratus lumborum block type III|A 22 gauge needle was positioned between the psoas and quadratus lumborum muscles at the anterior fascia lumbosacral
62003949|NCT05950568|ACTIVE_COMPARATOR|Transversus abdominis plane block|A 22 gauge needle was positioned between the internal oblique and transversus abdominis muscles
62003950|NCT01868633|ACTIVE_COMPARATOR|Dexamethasone & spinal morphine|intrathecal morphine administered at time of spinal anesthesia. After cesarean delivery 8mg (2ml) of Dexamethasone given intraoperatively
62189582|NCT06255925|NO_INTERVENTION|Control Group|In this arm, participants are services as usual and will participate in their regular activities.
62189583|NCT01120847||Veterans with PTSD|No intervention; this is an observational study.
62189584|NCT01120847||Control group w/out PTSD|No intervention; this is an observational study.
62189585|NCT01705405|EXPERIMENTAL|medical device|medical device to acquire ultrasound and endoscopic images during surgery
62003951|NCT01868633|PLACEBO_COMPARATOR|Placebo injection and spinal morphine|intrathecal morphine administered at time of spinal anesthesia. After cesarean delivery 2ml of placebo (Normal saline) drawn to mimic active drug given intraoperatively
62003952|NCT03148197||Admitted for allogeneic HSCT|Patients admitted for performance of an allogeneic HSCT after high dosis chemotherapy.
62003953|NCT03148197||First diagnosis AML|Patients admitted with a first diagnosis of an acute myeloid leukemia for chemotherapy. Depending on factors like age or molecular risk profile some of these patients will proceed to allogeneic HSCT.
62003954|NCT04070833|ACTIVE_COMPARATOR|Vitamin D + fish oil|
62003955|NCT04070833|ACTIVE_COMPARATOR|Vitamin D + fish oil placebo|
62189586|NCT02169557|EXPERIMENTAL|Fexinidazole|
62189587|NCT03231969|EXPERIMENTAL|Bilastine 0.2%|"Bilastine Ophthalmic solution 0.2%~1 drop in each eye at 3 separate times during a 25 day period."
62189588|NCT03231969|EXPERIMENTAL|Bilastine 0.4%|"Bilastine Ophthalmic solution 0.4%~1 drop in each eye at 3 separate times during a 25 day period."
62189589|NCT03231969|EXPERIMENTAL|Bilastine 0.6%|"Bilastine Ophthalmic solution 0.6%~1 drop in each eye at 3 separate times during a 25 day period."
62189590|NCT03231969|PLACEBO_COMPARATOR|Bilastine 0%|"Vehicle of Bilastine Ophthalmic Solution~1 drop in each eye at 3 separate times during a 25 day period."
62189591|NCT01991847|EXPERIMENTAL|Physical activity|Physical activity
62396448|NCT04634617||Observational (questionnaires)|Patients complete questionnaires over 45-60 minutes consisting of demographic, treatment, lifestyle, disease, and comorbidity questions, as well as multiple study instruments assessing quality of life as it pertains to common toxicities of uterine cancer treatment.
62189592|NCT04883060|EXPERIMENTAL|Intervention|Patients undergoing ventriculoperitoneal surgery where the midline localizer was used
62003956|NCT04070833|ACTIVE_COMPARATOR|Vitamin D placebo + fish oil|
62003957|NCT04070833|PLACEBO_COMPARATOR|Vitamin D placebo + fish oil placebo|
62003958|NCT02595736|PLACEBO_COMPARATOR|Placebo (SC)|Single subcutaneous (SC) dose of placebo
62003959|NCT02595736|EXPERIMENTAL|LY3200327 (SC)|Single escalating subcutaneous (SC) dose of LY3200327
62189593|NCT02868372|ACTIVE_COMPARATOR|Betadine group|Subcutaneous tissues of cesarean section wounds are swabbed with10% undiluted Povidone Iodine solution without mobbing before closure of subcutaneous tissues
62189594|NCT02868372|NO_INTERVENTION|No intervention group|No swabbing of subcutaneous tissue of cesarean section wounds
62189595|NCT03003806|EXPERIMENTAL|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
62584916|NCT01990131|EXPERIMENTAL|Intervention|The anxiety risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
62003960|NCT02595736|EXPERIMENTAL|LY3200327 (IV)|Single intravenous (IV) dose of LY3200327
62003961|NCT02595736|PLACEBO_COMPARATOR|Placebo (IV)|Single intravenous (IV) dose of placebo
62003962|NCT01558700|EXPERIMENTAL|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
62189596|NCT03003806|ACTIVE_COMPARATOR|Control group-medical guided recommendations|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
62189597|NCT01810276|PLACEBO_COMPARATOR|Saline|400 mL of Saline will be given intravenously over 2 hours once.
62189598|NCT01810276|ACTIVE_COMPARATOR|Platelets|2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
62003963|NCT01558700|PLACEBO_COMPARATOR|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
62003964|NCT04518891|EXPERIMENTAL|Cognitive Functional Therapy (CFT) Group|"There will be 3 main components in the intervention:~1. Making sense of pain: the cognitive component will focus on identifying the factors that contribute to pain during examination. This will include discussion on the multidimensional nature of persistent pain, individual beliefs, and how emotions and behaviours regarding movement and lifestyle can reinforce a vicious cycle of pain and disability.~2. Controlled exposure: specific functional training is designed to normalise maladaptive or provocative movement and posture. functional integration is directed at activities of daily life that are avoided by the patient. This will vary among individuals but should include basic activities such as rolling in bed, sitting, sitting to standing, walking, bending and lifting.~3. Lifestyle change: Physical activity and lifestyle. Patients will be advised to gradually increase physical activity based on their preference, while also focusing on sleep hygiene, stress and management strategies."
62003965|NCT04518891|SHAM_COMPARATOR|Sham intervention|Placebo group will be treated with detuned photobiomodulation device (904Nm Ibramed Infrared - no-visible beam), without any emission of therapeutic dose. Nine sites will be applicate on the patient's lumbar region: three central sites on top of the spinous processes (between T11 and T12, L2 and L3, L5 and S1); in the same direction, but laterally, three sites on the left and three on the right. Three minutes of fake stimulation will be administered, summing up 27 minutes. In addition, a neutral talking control therapy of at least 15 minutes will be provided to patients in each session. Maladaptive beliefs will not be challenged; however, the therapists will be trained to show interest and warmth, empathy and encouraging participants to discuss neutral topics such as hobbies, sports, and current affairs. No advice or problem solving will be given, and any attempt to talk about emotional issues will be kindly discouraged and the talking will be redirect to neutral tropics.
62003966|NCT00589108|ACTIVE_COMPARATOR|Mobile-Bearing Knee|Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
62003967|NCT00589108|ACTIVE_COMPARATOR|Modular-Metal-Backed Knee|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
62003968|NCT00589108|ACTIVE_COMPARATOR|All-Polyethylene Knee|Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray
62003969|NCT04447092|EXPERIMENTAL|Gemcitabine/Nab-paclitaxel|Gemcitabine/Nab-paclitaxel + pembrolizumab
62003970|NCT04447092|EXPERIMENTAL|FOLFIRINOX|FOLFIRINOX + pembrolizumab
62779517|NCT01960517|EXPERIMENTAL|Catheter placed|
62779518|NCT00789672|ACTIVE_COMPARATOR|Lower Dose (3-1) levodopa/carbidopa|Oral levodopa 0.51 mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation) combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam 9 weeks after starting medication.
62779519|NCT00789672|ACTIVE_COMPARATOR|Higher Dose (4.5-1) levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation) combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam 9 weeks after starting medication.
62779520|NCT03760679|ACTIVE_COMPARATOR|Laryngeal mask Supreme|Device: Laryngeal mask Supreme
62779521|NCT03760679|EXPERIMENTAL|i-gel|Device: i-gel
62779522|NCT04219644|OTHER|Breathing test or sleep study|To evaluate the usability of the device in non-clinical and clinical settings
62779523|NCT04956458|EXPERIMENTAL|Lumbar motion style acupuncture treatment|"The MSAT group will recieve 3 sessions of MSAT; on second, third, fourth day after hospitalization.~A trained doctor of Korean medicine with at least 3 years of clinical experience will conduct the MSAT.~The MSAT group will be also treated with other Korean medical treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine."
62779524|NCT04956458|ACTIVE_COMPARATOR|Korean medical treatment|The control group will be received Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine
62779525|NCT03526510|ACTIVE_COMPARATOR|Standard Fractionation|Using 2 sequential IMRT plans, the pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent boost to the prostate to a total dose of 78 Gy.
62779526|NCT03526510|EXPERIMENTAL|Hypofractionation|Using a one phase IMRT plan, the pelvic lymph nodes will be treated to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68 Gy in 25 fractions concomitantly (simulataneous integrated boost).
62189599|NCT03635736||Severe brain injury|ICU-patients suspect to severe brain injury, measurement with multiple-spectral-sonography as acustocerebrography (ACG
62189600|NCT02706847|EXPERIMENTAL|Upadacitinib 15 mg|"Period 1: Participants receive upadacitinib 15 mg once daily for 24 weeks.~Period 2: Participants will continue on upadacitinib 15 mg once daily from Week 24 to Week 260."
62189601|NCT02706847|EXPERIMENTAL|Upadacitinib 30 mg|"Period 1: Participants receive upadacitinib 30 mg once daily for 24 weeks.~Period 2: Participants continue on upadacitinib 30 mg once daily until implementation of Protocol Amendment 4, then participants begin to receive upadacitinib 15 mg once daily up to Week 260."
62189602|NCT02706847|PLACEBO_COMPARATOR|Placebo / Upadacitnib 15 mg|"Period 1: Participants receive placebo once daily for 12 weeks followed by upadacitinib 15 mg once daily for 12 weeks.~Period 2: Participants will continue on upadacitinib 15 mg once daily from Week 24 to Week 260."
62189603|NCT02706847|PLACEBO_COMPARATOR|Placebo / Upadacitnib 30 mg|"Period 1: Participants receive placebo once daily for 12 weeks followed by upadacitinib 30 mg once daily for 12 weeks.~Period 2: Participants continue on upadacitinib 30 mg once daily until implementation of Protocol Amendment 4, then participants begin to receive upadacitinib 15 mg once daily up to Week 260."
62189604|NCT06183242|EXPERIMENTAL|Group I-1|Intake of REMAXA, enteric-coated tablets, 2 tablets 3 times a day for 10 days
62189605|NCT06183242|EXPERIMENTAL|Group I-2|Intake of REMAXA, enteric-coated tablets, 2 tablets 2 times a day for 10 days
62189606|NCT06183242|EXPERIMENTAL|Group I-3|Intake of REMAXA, enteric-coated tablets, 2 tablets once a day for 10 days
62189607|NCT06183242|ACTIVE_COMPARATOR|Group I-4|Infusions of REMAXOL, solution for infusion, by intravenous drip, 400 ml once a day for 10 days.
62189608|NCT06183242|EXPERIMENTAL|Group II-1|Intake of REMAXA, enteric-coated tablets, during 10 days according to optimal dosing regimen established during stage I.
62189609|NCT06183242|ACTIVE_COMPARATOR|Group II-2|Infusions of REMAXOL, solution for infusion, by intravenous drip, 400 ml once a day for 10 days.
62189610|NCT06183242|PLACEBO_COMPARATOR|Group II-3|Intake of Placebo, enteric-coated tablets, during 10 days, analogous to dosing regimen in Group II-1
62189611|NCT02149524|ACTIVE_COMPARATOR|Herceptin (trastuzumab)|Intravenous administration
62189612|NCT02149524|EXPERIMENTAL|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
62189613|NCT05702541|OTHER|LID223194 MF, then AOHG MF|Lehfilcon A multifocal contact lenses worn first, followed by lotrafilcon B multifocal contact lenses, as randomized. Each product will be worn in both eyes for 2 days in a daily wear modality. CLEAR CARE will be used for daily cleaning and disinfection.
62189614|NCT05702541|OTHER|AOHG MF, then LID223194 MF|Lotrafilcon B multifocal contact lenses worn first, followed by lehfilcon A multifocal contact lenses, as randomized. Each product will be worn in both eyes for 2 days in a daily wear modality. CLEAR CARE will be used for daily cleaning and disinfection.
62189615|NCT01114490|EXPERIMENTAL|Part 1 - Group 1|Moderate Hepatic Patients
62189616|NCT01114490|EXPERIMENTAL|Part 1 - Group 2|Healthy Subjects
62189617|NCT01114490|EXPERIMENTAL|Part 2 - Group 1|Mild Hepatic Patients
62189618|NCT01114490|EXPERIMENTAL|Part 2 - Group 2|Healthy Subjects
62189619|NCT04064294||Statin Before Levodopa|Historical use of a statin BEFORE beginning levodopa
62189620|NCT04064294||Statin After Levodopa|Historical use of a statin AFTER beginning levodopa
62189621|NCT04064294||No Statin|No historical use of a statin
62189622|NCT05574868|OTHER|Experimental: Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis Group|Male subjects 21 years of age and older who are implanted with an Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis for erectile dysfunction.
62189623|NCT00887029|ACTIVE_COMPARATOR|DuoTrav|
62189624|NCT00887029|ACTIVE_COMPARATOR|Xalacom|
62189625|NCT03920098||Mother-infant dyads|Mother-infant dyads
62189626|NCT05435911|EXPERIMENTAL|Remimazolam with flumazenil|Patients allocated to remimazolam with flumazenil group receive remimazolam as the main anesthetics during general anesthesia and then flumazenil administration at the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.
62189627|NCT05435911|ACTIVE_COMPARATOR|Propofol-based total intravenous anesthesia|Patients allocated to the propofol-based total intravenous anesthesia group receive propofol as the main anesthetics during general anesthesia until the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.
62779527|NCT03615066|EXPERIMENTAL|Selgantolimod 3 mg + TAF|Participants with Hepatitis B e antigen (HBeAg)-positive CHB or HBeAg-negative CHB currently not on oral antiviral (OAV) treatment, will receive selgantolimod 3 mg (2 x 1.5 mg tablet) on the same day once weekly for 24 doses along with tenofovir alafenamide (TAF) 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/early discontinuation (ED). At Week 48, per Principal Investigator's (PI's) discretion, participants can continue in the Treatment Free Follow-Up (TFFU) phase for up to an additional 48 weeks.
62003971|NCT06097234|ACTIVE_COMPARATOR|Pelex Upp Device|Subjects will receive treatment with the Pelex Upp device, the device under study. The subjects will use the device for treatment four times a week, ten minutes a day, for four weeks.
62003972|NCT06097234|ACTIVE_COMPARATOR|Pelex Upp Device + Pelvic Floor Physical Therapy|"Subjects will receive treatment with the Pelex Upp device, the device under study. The subjects will use the device for treatment four times a week, ten minutes a day, for four weeks.~In addition, subjects will have four weekly virtual visits with a pelvic floor physical therapist, who will provide further care instructions and pelvic floor training."
62003973|NCT06097234|ACTIVE_COMPARATOR|Pelvic Floor Physical Therapy|Subjects will have four weekly virtual visits with a pelvic floor physical therapist, who will provide care instructions and pelvic floor training, as well as provide a weekly treatment schedule for Kegel exercises.
62003974|NCT00722917|EXPERIMENTAL|TAK-379 25 mg QD|
62779528|NCT03615066|EXPERIMENTAL|Selgantolimod 1.5 mg + TAF|Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) and placebo (1 tablet) on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
62779529|NCT03615066|PLACEBO_COMPARATOR|Placebo + TAF|Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive 2 tablets of placebo on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, placebo will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
62189628|NCT02760563|EXPERIMENTAL|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62189629|NCT03715868|ACTIVE_COMPARATOR|Non-milked derived protein source formula diet|Formula diet based on a non-milked derived protein source
62003975|NCT00722917|EXPERIMENTAL|TAK-379 100 mg QD|
62003976|NCT00722917|EXPERIMENTAL|TAK-379 200 mg QD|
62003977|NCT00722917|ACTIVE_COMPARATOR|Pioglitazone 30 mg QD|
62003978|NCT00722917|PLACEBO_COMPARATOR|Placebo|
62003979|NCT02729649|EXPERIMENTAL|ArmAssist therapy|The group will be treated with ArmAssist robot therapy.
62003980|NCT02729649|ACTIVE_COMPARATOR|Conventional therapy|The group will be treated with conventional therapy.
62003981|NCT02729649|ACTIVE_COMPARATOR|Extended Conventional therapy|The group will be treated with extended conventional therapy.
62003982|NCT03229564|EXPERIMENTAL|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
62003983|NCT03087201|EXPERIMENTAL|nabiximols, oromucosal spray|1-12 puffs nabiximols / day, Duration of treatment: 13 weeks
62003984|NCT03087201|PLACEBO_COMPARATOR|placebo, oromucosal spray|1-12 puffs placebo / day, Duration of treatment: 13 weeks
62003985|NCT01987323|EXPERIMENTAL|Lipolat|Subconjunctival injection of Lipolat into the superior bulbar conjunctiva of all enrolled participants
62003986|NCT01493271|PLACEBO_COMPARATOR|Placebo|
62003987|NCT01493271|EXPERIMENTAL|RO5093151|
62003988|NCT03388723||Arm 1: Discovery phase|"Approximately 150 women with Gestational Diabetes Mellitus (GDM) and 150 controls, and their offspring will be recruited in Pune (from KEM Hospital and Vadu). The objective will be:~1. Identification of epigenetic signatures~2. Measurements of B vitamins and 1-C metabolites in mothers' blood and cord blood~3. Glucose, insulin and lipids in mothers during pregnancy~4. Anthropometry and blood pressure"
62003989|NCT03388723||Arm 2: Validation phase|Approximately 200 women with Gestational Diabetes Mellitus (GDM) and 200 controls, and their offspring will be recruited in Punjab, and 150 stored cord blood samples of GDM offspring in Pune will be investigated to validate the epigenetic signatures discovered in Arm 1.
62189630|NCT03715868|NO_INTERVENTION|Milked derived protein source formula diet|Formula diet based on a milked derived protein source
62584917|NCT01990131|PLACEBO_COMPARATOR|Control|The control condition will be a combination of information about general health and wellness (e.g. diet, exercise etc.) plus an inert Cognitive Bias Modification (CBM-I) task.
62189631|NCT06076408|EXPERIMENTAL|SNAGS with Pilates|Sustained Natural Apophyseal glides and Pilates Exercises
62189632|NCT06076408|ACTIVE_COMPARATOR|SNAGS|Sustained Natural Apophyseal glides
62584918|NCT01011530|EXPERIMENTAL|MLN4924|MLN4924 via IV infusion
62003990|NCT03388723||Arm 3: Stability phase|"Approximately 500 offspring of women with Gestational Diabetes Mellitus (GDM) from Pune (\~ half below 10 years and the rest over 10 years) will be investigated to study:~1. Stability of epigenetic signatures in offspring through childhood and adolescence~2. Relation of these signatures with phenotype"
62003991|NCT02093572|EXPERIMENTAL|Control|Subjects randomized to this group will consume 3 standard meals/day during the 2 week intervention period of the study.
62003992|NCT02093572|EXPERIMENTAL|Breakfast skipping|Subjects randomized to this group will consume 2 meals/day (omit breakfast - with caloric intake equal to consuming 3 meals/day) during the 2 week intervention period of the study.
62003993|NCT01396863|ACTIVE_COMPARATOR|First treatment HDF|The patient will receive treatment with pre-dilution hemodiafiltration during the first examination day. During the second examination day the patient will receive treatment with low flux hemodialysis.
62003994|NCT01396863|ACTIVE_COMPARATOR|First treatment HD|The patient will receive treatment with low flux hemodialysis during the first examination day. During the second examination day the patient will receive treatment with pre-dilution hemodiafiltration.
62003995|NCT03373175|EXPERIMENTAL|Ventilator 1 vs Ventilator 2|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record Pressure Support 10 (PS 10)record Pressure Support 15 (PS 15) record Pressure Support 20 (PS 20) record
62003996|NCT03373175|EXPERIMENTAL|Ventilator 3 vs Ventilator 4|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed.Interventions: Basal record PS10 record PS15 record PS 20 record
62003997|NCT03373175|EXPERIMENTAL|Ventilator 5 vs Ventilator 6|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record PS10 record PS15 record PS 20 record
62003998|NCT03373175|EXPERIMENTAL|Ventilator 7 vs Ventilator 8|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record PS10 record PS15 record PS 20 record
62003999|NCT03901924|ACTIVE_COMPARATOR|Volume Support Mode Mechanical Ventilation|Volume support mode ventilation is a spontaneous mode where a target goal volume is set on the ventilator. This ventilatory strategy is dependent on patients spontaneously breathing and triggering (or activating) the ventilator to support the breath. The ventilator adjusts the amount of pressure support to deliver with each breath (i.e. if the patient's tidal volume is greater than the set target volume, then the ventilator will decrease the amount of pressure support in the subsequent breath to try to achieve the goal volume and vice versa). The respiratory rate is not set in this mode of ventilation and is dependent on the patient. For patients randomized to this mode, the goal tidal volume will be set at 6 cc/kg of ideal body weight (IBW).
62004000|NCT03901924|ACTIVE_COMPARATOR|Assist Control Mode Mechanical Ventilation|In assist control mode ventilation, the machine is programmed to deliver a set tidal volume and set respiratory rate. Patients can breathe over the set respiratory rate, but the volume of breath that they receive is fixed and delivered by the ventilator. For patients randomized to this mode, the tidal volume will be set at 6 cc/kg of ideal body weight (IBW).
62004001|NCT03509129|ACTIVE_COMPARATOR|TECH (Technology)|Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.
62004002|NCT03509129|EXPERIMENTAL|TECH+COMP (Technology + Competition)|Participants will receive the same intervention components as the TECH goup, as well as a study designed team competition.
62004003|NCT01546116|EXPERIMENTAL|Adefovir and lamivudine combination|
62004004|NCT03915288|EXPERIMENTAL|Group continuous training at moderate intensity|"Training program lasting 36 weeks with assistance 3 times a week with 70 minutes per intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity - MICT (60 -80% FCM), 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. And the last 10 minutes were for cooling (exercises coordination, balance, walking and breathing exercises).~Regarding the MICT training, this was done with fast walk or jog in endless band with the floor tilted to reach the desired intensity. Also by bicycle, rowing and elliptical. During the entire intervention the participants was monitored by a Polar Multisport RS800CX, oximetry and with the Borg scale to avoid exceeding the training intensity (60-80% FCM, 6 to 8 Borg)."
62189633|NCT00814411|EXPERIMENTAL|Group Counseling|Group family planning counseling
62189634|NCT00814411|ACTIVE_COMPARATOR|Individual Counseling|Individual family planning counseling with gynecological patients who have unmet need
62571747|NCT01903330|PLACEBO_COMPARATOR|(Placebo Injection/Placebo Pill) +Bevacizumab/bevacizumab biosimilar|"The control group will have the same study schedule except that the patients will be receiving the Oral Control on the Cyclophosphamide treatment days and the Injectable control on the GM-CSF + ERC1671 treatment days. The control group will receive bevacizumab or approved bevacizumab biosimilar just as the active treatment group above.~The treatment will be repeated every 28 days until progression of disease or intolerance."
62004005|NCT03915288|EXPERIMENTAL|Group high Intensity Interval Training|"Training program lasting 36 weeks with assistance 3 times a week with 70 minutes per intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity (60 -80% FCM), 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. And the last 10 minutes were for cooling (exercises coordination, balance, walking and breathing exercises).~Concerning the HIIT training, it consisted of an intensity of interval training. That is, the participants who underwent 30 minutes of aerobic exercise consisted of a protocol created for this experimental group, which we named 30-30. 30 seconds at moderate intensity (60-80% FCM) and 30 seconds at high intensity (80-90%)."
62004006|NCT03915288|ACTIVE_COMPARATOR|Group control|This group did not perform supervised exercise nor were they given exercise recipes or formal intervention programs. Only continued with the usual care and gave directions to maintain a healthy lifestyle based on proper nutrition and usual activities. It is highlighted that in the institutions where the patients of the 3 groups attended, there is not a physical training area supervised by a professional. Therefore, the intervention protocol was not excluded or denied to the participants of the control group, but continuity and supervision was given for investigative purposes to its process and treatment. In addition, none of the 3 groups stopped their medical treatment or that of the other professionals that make up the interdisciplinary team.
62004007|NCT02694224|EXPERIMENTAL|vismodegib plus chemotherapy|Vismodegib 150 mg orally during paclitaxel and then dose dense epirubicin + cyclophosphamide (EC) therapy (see active comparator arm)
62004008|NCT02694224|ACTIVE_COMPARATOR|chemotherapy|Paclitaxel 80 mg/m2 weekly on days 1, 8 and 15 each 21 days x 12 doses and then dose dense E (90 mg/m2) plus cyclophosphamide (CPA) 600 mg/m2 each 2 weeks x 4 doses
62004009|NCT01882127|ACTIVE_COMPARATOR|High dose-DEX|40 patients are enrolled to take dexamethasone orally at a dose of 40 mg daily for 4 days
62004010|NCT01882127|EXPERIMENTAL|ATRA & High dose-DEX|40 patients are enrolled to take Dexamethasone orally at 40mg a day for 4 days and all-trans retinoic acid at 10mg tablet every 8 hours a day for 12 consecutive weeks.
62571748|NCT03864757|EXPERIMENTAL|UVFP correction surgery|Short-term implantation of VOIS and evaluation of voice quality and glottal closure.
62571749|NCT05935397||patients with CAD undergoing PCI|patients with CAD undergoing PCI with second generation DES
62571750|NCT04757025|EXPERIMENTAL|Electrical Impedance Tomography|patient monitored by Electrical Impedance Tomography
62004011|NCT06084208|EXPERIMENTAL|Robotic Navigational Bronchoscopy|Patients undergoing biopsy with the Ion Endoluminal System
62004012|NCT02073422||Non-ST elevation myocardial infarction|Natural history study of non-ST elevation myocardial infarction and coronary physiology
62004013|NCT02141516|EXPERIMENTAL|Group A|Complement deficiency
62004014|NCT02141516|EXPERIMENTAL|Group B|asplenia/splenic dysfunction
62189635|NCT04088045|EXPERIMENTAL|Receiving PRP injections or PRP plus neural prolotherapy|"This experiment compares the effect of injecting PRP alone into the knee joint and pes anserinus complex with when dextrose solution is also injected to the genicular nerves.~The injection of dextrose solution is to decrease the inflammation of the genicular nerves, hoping to further effectively alleviate the knee pain condition. Therefore, upon the conclusion of this study, we can see whether the inclusion of dextrose injection in addition to PRP treatment can really be effective in treating patients with more severe degrees of knee OA."
62189636|NCT00516139|EXPERIMENTAL|Lamotrigine|Open-label lamotrigine
62571751|NCT04757025|ACTIVE_COMPARATOR|Peripheral arterial Saturation|patient monitored by Peripheral arterial Saturation alone
62571752|NCT03034447|OTHER|Asthma|Children and teenagers with persistent asthma will perform questionnaires, lung function test, and home sleep study
62571753|NCT05525013|EXPERIMENTAL|Simvastatin|Simvastatin as an intracanal medication
62571754|NCT05525013|ACTIVE_COMPARATOR|Calcium hydroxide|Calcium hydroxide intracanal medication
62004015|NCT02141516|ACTIVE_COMPARATOR|Group C|age-matched healthy controls
62571755|NCT03411499|EXPERIMENTAL|Early surgery|Surgery within 72 hours from endocarditis diagnosis
62571756|NCT03411499|ACTIVE_COMPARATOR|Conventional therapy|Medical treatment and a possible delayed surgical intervention according to the current guidelines
62571757|NCT01155908|EXPERIMENTAL|Amlodipine Besylate/Benazepril Hydrochloride|10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules of Dr.Reddy's Laboratories Limited
62571758|NCT01155908|ACTIVE_COMPARATOR|Lotrel|Lotrel® (10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules) of Novartis
62571759|NCT03855527|EXPERIMENTAL|Silver Diamine Fluoride (SDF) group|Atraumatic restorative technique will be performed. Then the cavities will be dried with a gentle flow of compressed air. One drop of silver diamine fluoride (Advantage Arrest Silver Diamine Fluoride 38% - Bottle) will be dispensed into a dappen dish. A micro brush will be bent, dipped into SDF and dabbed on the side of the dappen dish to remove excess liquid before application. SDF will be applied directly to affected tooth surface and dried with gentle flow of compressed air for 1 minute. Excess SDF will be removed with cotton roll. Teeth will be restored with glass ionomer cement (GC Fuji IX).
62571760|NCT03855527|ACTIVE_COMPARATOR|Chlorhexidine group|Atraumatic restorative treatment will be performed. Then, the cavities will be disinfected by placing a cotton pellet soaked in chlorhexidine solution (Consepsis®2% Chlorhexidine Antibacterial Solution) for 1 minute, air dried and restored using glass ionomer cement.
62189637|NCT01845805|EXPERIMENTAL|Arm A: CC-486|CC-486 (oral azacitidine), 300 mg total, taken daily on days 1-21 (of a 28 day cycle) for up to 12 cycles. Upon disease recurrence, subjects will start on a first-line chemotherapy.
62189638|NCT01845805|ACTIVE_COMPARATOR|Arm B: observation|Observation until disease recurrence. Upon disease recurrence, subjects will start on a first-line chemotherapy.
62189639|NCT04544865|EXPERIMENTAL|Gastric and thoracic staple line reinforcement|ECHELON ENDOPATH Staple Line Reinforcement is used during a gastric or thoracic procedure.
62189640|NCT05061199||ECA group|TCC with extracorporeal anastomosis (ECA)
62189641|NCT05061199||ICA group|TCC with intracorporeal anastomosis (ICA).
62189642|NCT02573649|ACTIVE_COMPARATOR|CLS-ON first|Closed-loop Stimulation on first
62189643|NCT02573649|ACTIVE_COMPARATOR|CLS-OFF first|Closed-loop Stimulation off first
62189644|NCT05749861|EXPERIMENTAL|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348(5) - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348(5) - A single oral dose of 1 tablet under fasting condition"
62189645|NCT05749861|EXPERIMENTAL|Sequence 2|"Period 1: CKD-348(5) - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348(5) - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
62189646|NCT04120142|EXPERIMENTAL|IMT goup|Inspiratory muscle training + aerobic exercice
62189647|NCT04120142|ACTIVE_COMPARATOR|Control group|aerobic exercice
62189648|NCT04416932||Post-operative patients who had total shoulder arthroplasty|Patients who have had a total shoulder replacement will be scheduled for an ultrasound at Duke Radiology. An ultrasound will be completed on the shoulder that has been replaced, which takes no more than an hour. This ends all study involvement.
62779530|NCT05532280|EXPERIMENTAL|Test Product (T)|subjects were administered a single tablet of 90 mg Etoricoxib with approximately 240 ml water after an overnight fast of 10 hours
62004016|NCT02035007|EXPERIMENTAL|LV-EF > 50%|PiCCO catheter analysis of patients with coronary heart disease without impaired left ventricular function \[LV-EF \> 50%\]
62004017|NCT05227924||SYMBOL medical devices|Patients undergoing total hip arthroplasty with at least one medical device from the SYMBOL range
62189649|NCT01408745|EXPERIMENTAL|Sternumfix|sternotomy closure with Sternumfix
62189650|NCT01408745|ACTIVE_COMPARATOR|Steel wire|sternotomy closure with steel wire
62189651|NCT04601597|EXPERIMENTAL|The catheter tip was placed in the subclavian vein.|The pre-placement catheter length measured through the body surface was greater than the actual length. Therefore, 2 cm was subtracted from the pre-puncture point to the ipsilateral sternoclavicular joint to calculate the effective catheter pre-placement length.
62189652|NCT04601597|EXPERIMENTAL|The tip of the catheter was placed in the axillary vein of the chest wall.|The pre-placement length of the catheter was measured by subtracting 3-4 cm from the distance between the puncture point and ipsilateral midclavicular line. This adjustment was intended to prevent the catheter tip from entering the subclavian vein.
62189653|NCT04601597|EXPERIMENTAL|the catheter tip was located distal to the axillary vein.|The measurement method of catheter pre-placement length was as follows: in cases where the catheter was punctured from the basilic and brachial veins, the distance from the pre-puncture point to the intermuscular sulcus of the ipsilateral deltoid muscle and pectoralis major muscle was measured (not surpassing the intermuscular sulcus and not reaching the axilla); however, the distance from the pre-puncture point to the ipsilateral sub shoulder or axilla was measured.
62189654|NCT02485899|EXPERIMENTAL|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|All 190-202 study subjects administered BMN 190 300 mg by continuous Intracerebroventricular (ICV) infusion at a rate of 2.5 mL/hour for approximately 4 hours) every 14 days.
62779531|NCT05532280|ACTIVE_COMPARATOR|Reference Product (R)|subjects were administered a single tablet of 90 mg Etoricoxib with approximately 240 ml water after an overnight fast of 10 hours
62189655|NCT05282251|EXPERIMENTAL|Intrapleural bupivacine nebulization|Intrapleural nebulization of bupivacine (10 ml of bupivacaine 0.5%) + Intravenous normal saline as a placebo
62189656|NCT05282251|ACTIVE_COMPARATOR|Intravenous paracetamol and ketorolac|Intravenous analgesia: paracetamol (one gram) and Ketorolac (30 mg) + Intrapleural normal saline (10 ml) as a placebo
62189657|NCT02474849|ACTIVE_COMPARATOR|Conventional cigarette|
62189658|NCT02474849|EXPERIMENTAL|First-generation e-cigarette|
62189659|NCT02474849|EXPERIMENTAL|Rechargeable cig-like e-cigarette|
62189660|NCT02474849|EXPERIMENTAL|Closed modular system e-cigarette A|
62189661|NCT02474849|EXPERIMENTAL|Closed modular system e-cigarette B|
62189662|NCT04470869|EXPERIMENTAL|OLAF group|The interventional group (OLAF) benefit from a psychiatric follow up, from virtual visiting of the patient and video interview with ICU team.
62189663|NCT04470869|PLACEBO_COMPARATOR|Control|The control group contains the relatives of patients hospitalized after the confinement measure but before the OLAF intervention. This group benefit from phone contact with the ICU team at the admission in ICU then two contact per week minimum to one contact per day maximum during the stay, excepting the specific phone calls associated with favorable or unfavorable evolution.
62189664|NCT04811326|ACTIVE_COMPARATOR|NB-UVB radiation|will expose to 2 sessions/week of NB-UVB radiation, for 3 months.
62571761|NCT03855527|SHAM_COMPARATOR|Atraumatic Restorative Treatment without Disinfection|Cavities will be cleaned according to the ART approach.The cavity will be enlarged if needed using sterile hatchet.The carious dentin will be removed with excavators starting at the enamel-dentine junction. The unsupported thin enamel will be fractured off with the hatchet. The caries will be removed carefully until firm dentin is reached (physically resistant to hand excavation). The cavity will be cleaned with wet cotton pellets. Cavities will be restored immediately using conventional glass ionomer cement. All the cavities in the 3 groups will be temporary restored with glass ionomer cement handled according to manufacturer's instructions, however acid etching will not be carried out in order to make sample collection easier following the experimental period.
62004018|NCT02219815|NO_INTERVENTION|Standard Care|Patients in the standard care group will receive care as is currently delivered to patients awaiting cardiac surgery at each site. At present, patients are advised to rest and participate in very light intensity physical activity while awaiting surgery. At 1-2 weeks prior to their scheduled surgical date, the patient attends a single three hour cardiac pre-assessment with a nurse practitioner and cardiac anesthesiologist. In addition, a cardiac nurse counsels each patient on healthy behaviors (e.g. smoking cessation, diet, exercise).
62779532|NCT02848391|EXPERIMENTAL|healthy subjects|three hour flight simulation
62779533|NCT02848391|EXPERIMENTAL|COPD normocapnic|three hour flight simulation
62779534|NCT02848391|EXPERIMENTAL|COPD hypercapnic|three hour flight simulation
62004019|NCT02219815|EXPERIMENTAL|Prehab Intervention|Patients in the Prehab group will receive, in addition to the standard of care, an eight-week comprehensive exercise therapy and education program at a community-based CR facility. Patients will be asked to complete at least two sessions of supervised, structured exercise class plus have the option to attend one additional exercise class per week for eight-weeks, with progression to a moderate to high-intensity interval program based on the supervised assessment of the patient's capabilities. Prehab participants will also attend four education sessions on topics such as risk factor reduction, medication use, cardiovascular physiology, smoking cessation, healthy eating, exercise, and stress management and promotion of self-managed care.
62571762|NCT03469856|OTHER|single arm|The ASET Pilot study is a multicenter, single arm, open-label trial of single antiplatelet therapy with prasugrel for patients undergoing successful and optimal PCI for chronic stable angina with normal cardiac biomarkers values. angiographic and/or findings from intracoronary imaging, only then patients will be enrolled in the study and loaded with prasugrel 60 mg and continued with prasugrel only (10 mg once a day) for three months. Aspirin and clopidogrel will be discontinued. At the 3-months follow-up visit, prasugrel (only) will be replaced by aspirin (only) or dual-antiplatelet therapy according to local standard of care.
62004020|NCT01504334|EXPERIMENTAL|Pirfenidone(200mg)|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
62189665|NCT04811326|ACTIVE_COMPARATOR|Latanoprost|latanoprost 0.005%, will be applied after microneedling, by using 1.5-2 mm needle length dermapen, of vitiligenous patches. The procedure will be repeated once weekly for 3 months (12 sessions).
62571763|NCT06148792|EXPERIMENTAL|TQRevised|Patients are treated with schizontocidal treatment plus a single weight-based oral dose of TQ (target dose 7.5mg/kg)
62571764|NCT06148792|ACTIVE_COMPARATOR|TQStandard|Patients are treated with schizontocidal treatment plus single fixed oral dose of 300mg TQ (TQStandard)
62571765|NCT06148792|EXPERIMENTAL|PQ7|Patients are treated with schizontocidal treatment plus oral high dose PQ (total dose 7 mg/kg) over 7 days (PQ7)
62004021|NCT01504334|PLACEBO_COMPARATOR|Placebo (without active ingredient)|
62004022|NCT00322335|EXPERIMENTAL|Menitorix/Pediarix Group|Subjects were primed with 3 doses of Pediarix™ co-administered intramuscularly with Menitorix™ in the right and left thigh respectively in the primary study (NCT00352963) at 2, 4 and 6 months of age. This was followed by a booster dose of Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
62189666|NCT04811326|ACTIVE_COMPARATOR|latanoprost + NB-UVB|(latanoprost + NB-UVB group): latanoprost 0.005%, will be applied after microneedling of vitiligenous patches in the same day of NB-UVB sessions in the same manner of group 2.
62189667|NCT04811326|NO_INTERVENTION|healthy individuals|healthy individuals as control group
62189668|NCT02538315||Surgery plus PET/CT imaging|Dopaminergic stem cell transplant and \[18F\]FDOPA PET/CT
62189669|NCT05068921|EXPERIMENTAL|TQB2858|TQB2858 injection: once every 3 weeks, 1800mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.
62189670|NCT04553588|ACTIVE_COMPARATOR|Opioid Disposal Pouch|an opioid disposal pouch to inactivate and dispose of unused opioid medication within the first 30 days after surgery
62189671|NCT04553588|NO_INTERVENTION|Usual Care|usual medication disposal includes multiple options as desired by patient; for example, flushing down toilet, giving to local pharmacist, giving to police department etc.
62189672|NCT05005299|EXPERIMENTAL|Dose Level A|Subjects will receive receive short-course venetoclax on day -11 to -6 \[venetoclax 100mg daily administered on day -11 to -6 (total venetoclax dose: 600mg)\], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
62571766|NCT04471688||patients|Preoperative patients needing transfusions
62779535|NCT05392036|EXPERIMENTAL|Group A|shockwave therapy
62779536|NCT05392036|OTHER|Group B|therapeutic ultrasound
62779537|NCT03936972||ilizarov circular frame|46 participants with open tibia fracture Gustillo type III only
62779538|NCT03936972||Ex. Fix|47 participants with open tibia fracture Gustillo type III only
62779539|NCT03216746|EXPERIMENTAL|Oral orientation and App for smartphone|The oral health educational method of this group comprised a total of 66 adolescents aged between 14 and 19 years who received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. The participants of this group also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
62779540|NCT03216746|EXPERIMENTAL|Oral orientation|The oral health educational method of this group comprised a total of 71 adolescents aged between 14 and 19 years who received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases.
62779541|NCT03216746|EXPERIMENTAL|Video orientation and App for smartphone|The oral health educational method of this group comprised a total of 63 adolescentes aged between 14 and 19 years who received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The participants of this group also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
62571767|NCT06188078|OTHER|Control|Babies in the control group will be fed only breast milk or formula, and a urine bag will be inserted after 25 minutes and they will be expected to urinate. The success of the transaction and the processing time will be recorded.
62779542|NCT03216746|EXPERIMENTAL|Video orientation|The oral health educational method of this group comprised a total of 63 adolescentes aged between 14 and 19 years who received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience.
62779543|NCT06089512|PLACEBO_COMPARATOR|Control group|group receiving general anesthesia only
62779544|NCT06089512|ACTIVE_COMPARATOR|paravertebral block group|received single-shot paravertebral block after induction of anesthesia.
62189673|NCT05005299|EXPERIMENTAL|Dose Level B|Subjects will receive receive short-course venetoclax on day -11 to -6 \[venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10 to -6 (total venetoclax dose: 1100mg)\], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
62189674|NCT05005299|EXPERIMENTAL|Dose Level C|Subjects will receive receive short-course venetoclax on day -11 to -6 \[venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10, 400mg daily administered on day -9 and 600mg daily administered on day -8 to -6 (total venetoclax dose: 2500mg)\], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
62571768|NCT06188078|EXPERIMENTAL|The bladder stimulation technique|"Newborns will be fed formula or pumped breast milk, depending on the baby's age and weight. A urine bag will be inserted 25 minutes after the feeding.~The newborn will be held under the armpit by the nurse, male infants will be held with their legs hanging down, and female infants will be held in the hip flexion position.~Newborns with spontaneous voiding during the period from the beginning of the investigation procedure to positioning the newborn will be excluded from the study.~The bladder stimulation technique will be repeated sequentially for 3 minutes until voiding begins.The success of the transaction and the processing time will be recorded."
62779545|NCT06089512|ACTIVE_COMPARATOR|mid transverse process block group|received a mid-transverse process -to- pleura block after induction of anesthesia.
62189675|NCT05005299|EXPERIMENTAL|Dose Level B'|Subjects will receive receive short-course venetoclax on day -11 to -6 \[venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10 and 400mg daily administered on day -9 to -6 (total venetoclax dose: 1900mg)\], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
62189676|NCT05952947|EXPERIMENTAL|HRYZ-T101 Injection|Patients will undergo lymphocytapheresis, then treatment with HRYZ-T101 TCR-T cells.
62189677|NCT01003262|EXPERIMENTAL|Emergency Department Observation|The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria
62189678|NCT01003262|ACTIVE_COMPARATOR|Unstructured, inpatient evaluation|
62189679|NCT00798304|EXPERIMENTAL|1|Dose level 1 of meningococcal B rLP2086 vaccine and routine childhood vaccines
62189680|NCT00798304|EXPERIMENTAL|2|Dose level 2 of meningococcal B rLP2086 vaccine and routine childhood vaccines
62189681|NCT00798304|EXPERIMENTAL|3|Control group
62189682|NCT06090162|EXPERIMENTAL|experimental diagnostic test|Lumbar punction at diagnosis. CSF and blood samples will be assessed by the two diagnostic tests (CSF ctDNA and conventional test (CC/FC))
62396449|NCT03099434|ACTIVE_COMPARATOR|Live Donor Champion + Facebook App|The LDC program consists of 6 monthly sessions of approx. 1 hour each. Each LDC session is led by a transplant physician or clinical coordinator. LDC sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LDC sessions are as follows: 1) education about ESRD, KT, and LDKT 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) encouraging candidate self-efficacy. At session 3, the the Facebook app will be incorporated and given to candidates. The Facebook app provides step-by-step instructions for creating a Facebook post that details each waitlist candidate's struggle with ESRD and their need for a live donor. The post is then uploaded to Facebook so it can be shared with the candidate's Facebook social network.
62004023|NCT00322335|ACTIVE_COMPARATOR|Infanrix hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group|Subjects were either primed in the primary study (NCT00352963) with 3 doses of Infanrix™ hexa administered intramuscularly in the right thigh at 2, 4 and 6 months of age and 2 doses of NeisVac-C™ administered intramuscularly in the left thigh at 2 and 4 months of age or with Engerix-B at birth intramuscularly in the right thigh, Infanrix™ hexa intramusculary in the right thigh at 2 and 6 months of age and NeisVac-C™ intramuscularly in the left thigh at 2 and 4 months of age, Infanrix™ IPV/Hib was administered intramuscularly in the right thigh at 4 months of age. All subjects were boosted with Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
62004024|NCT00322335|ACTIVE_COMPARATOR|Infanrix hexa/Meningitec Group|Subjects were primed with Infanrix™ hexa co-administered intramuscularly with Meningitec™ in the right and left thigh respectively at 2, 4 and 6 months of age during the primary study (NCT00352963), followed by a booster dose of Infanrix™ hexa intramuscularly in the right thigh between 13 and 14 months of age in study (NCT00323050). No vaccines were administered during this long-term persistence phase of the study.
62004025|NCT01205165|EXPERIMENTAL|Adefovir Dipivoxil 10mg|All enrolled subject were enrolled to adefovir dipivoxil 10mg arm.
62004026|NCT03306342|EXPERIMENTAL|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
62571769|NCT06188078|EXPERIMENTAL|Bath|Newborns will be fed formula or pumped breast milk, depending on the baby's age and weight. Babies will be bathed under running water 20 minutes after feeding.The bathing process will take 4 minutes in total. After bath, a urine bag will be inserted at the 25th minute of feeding. The success of the transaction and the processing time will be recorded.
62571770|NCT03885895|ACTIVE_COMPARATOR|Participants with freckles (one side of the face)|one randomized side of the face will be treated by Intradermal Tranexamic acid
62571771|NCT03885895|ACTIVE_COMPARATOR|Participants with freckles (other side of the face)|other side will be treated by Q switched KTP laser
62571772|NCT03168711|EXPERIMENTAL|Inosine|Subjects will be administered oral inosine daily. The dose of inosine will be titrated to obtain serum urate levels of 7 - 8 mg/dL.
62004027|NCT05082194||Balance in CAA|Each of the examined post-stroke patients (CAA) performed the given test twice, with the eyes open the first time and the eyes closed the second time. Moreover, both during the Unterberger functional test and the tests on the Biodex SD balance platform, the muscle tone was assessed in the subjects using the Luna EMG device. In both tests, the patients performed each of the tests 6 times, 3 with eyes open and 3 with eyes closed, on the same day.
62004028|NCT05082194||Balance in healthy participants|Each of the examined healthy participants performed the given test twice, with the eyes open the first time and the eyes closed the second time. Moreover, both during the Unterberger functional test and the tests on the Biodex SD balance platform, the muscle tone was assessed in the subjects using the Luna EMG device. In both tests, the subject performed each of the tests 6 times, 3 with eyes open and 3 with eyes closed, on the same day.
62004029|NCT05114603|EXPERIMENTAL|Dose-escalation stage|Iinvestigate the safety and determine the MTD of HLX208. Two dose levels of 600mg and 900 mg are planned for dose finding.
62004030|NCT05114603|EXPERIMENTAL|Dose-expansion stage|Patients with advanced melanoma will be enrolled in two expansion cohorts, at doses equal to or lower than the MTD, to better characterize the safety, tolerability, PK variability, and preliminary efficacy of single-agent HLX208.
62004031|NCT05927610|EXPERIMENTAL|Cohort A|Cohort A will consist of newly diagnosed patients with Glioblastoma. Eligibility for enrollment prior to pathology diagnosis will be determined by a consensus diagnosis of high grade glioma based on clinical and radiographic evidence between neuroradiologist, neurosurgeon and study PI.
62004032|NCT05927610|EXPERIMENTAL|Cohort B|Cohort B will consist of patients with a histologically confirmed diagnosis of IDH WT glioblastoma.
62004033|NCT03025724|NO_INTERVENTION|Control|After the surgical excision, subjects will be asked to fill out a satisfaction survey. They will not receive any PDT treatment.
62004034|NCT03025724|EXPERIMENTAL|Intervention Group|Subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours. At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals). Lastly, they will be asked to fill out a satisfaction survey.
62004035|NCT02730416|EXPERIMENTAL|A: Nintedanib|Nintedanib 200mg twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatin-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
62004036|NCT02730416|PLACEBO_COMPARATOR|B: Placebo|Placebo twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatib-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
62004037|NCT00720876|EXPERIMENTAL|Vorinostat and Rituximab|Vorinostat by mouth two times (2X) per day for two weeks followed by one week of rest. Rituximab intravenously once every three weeks .
62004038|NCT01910064|EXPERIMENTAL|GK530G|GK530G is the fixed-dose combination gel of Adapalene and Benzoyl Peroxide, BPO
62189683|NCT04246398|EXPERIMENTAL|Fecal microbiota transplant (FMT)|"10 capsules per dose for 6 consecutive weeks, twice a week, for a total of 120 capsules.~Each inoculum will be prepared from the feces of 1 donor and a dose of 10 capsules contains sieved, concentrated material derived from a mean of 10 grams of fecal matter. Donors are healthy, nonpregnant adults aged 18 to 50 years, taking no medications, and with a normal body mass index (18.5-25 \[calculated as weight in kilograms divided by height in meters squared\])."
62571773|NCT03168711|PLACEBO_COMPARATOR|Placebo|Subjects will be administered oral placebo daily. The dose of placebo will be titrated to obtain serum urate levels of 7 - 8 mg/dL.
62004039|NCT06374329|EXPERIMENTAL|Posterior crossbite and lack of space (Group A - Expansion)|Patients with at least one impacted maxillary canine, uni or bilateral posterior crossbite and lack of space in the upper arch will be treated with slow maxillary expansion with removable plates (GROUP A - expansion)
62189684|NCT04246398|PLACEBO_COMPARATOR|placebo|Placebo capsules will consist of a combination of saline/glycerol (same vehicle as FMT capsules). The inner capsules is dark (green colored), so the general appearance of the capsules is the same to the people who do not prepare them.
62189685|NCT03653247|EXPERIMENTAL|BIVV003|Participants will receive plerixafor as subcutaneous (SQ) administration followed by myeloablative conditioning therapy with intravenous (IV) busulfan. BIVV003 will then be administered as a 1-time IV infusion of autologous Cluster of Differentiation 34 + Hematopoietic Stem/Progenitor Cell (CD34+HSPC) transfected ex vivo with zinc finger nuclease (ZFN) messenger ribonucleic acid (mRNAs) targeting the B-cell lymphoma/leukemia 11A (BCL11A) locus.
62189686|NCT05203705|EXPERIMENTAL|Treatment group 1|SHR2285 tablet; dose 1
62189687|NCT05203705|EXPERIMENTAL|Treatment group 2|SHR2285 tablet; dose 2
62189688|NCT05203705|EXPERIMENTAL|Treatment group 3|SHR2285 tablet; dose 3
62189689|NCT05203705|EXPERIMENTAL|Treatment group 4|SHR2285 tablet; dose 4
62189690|NCT05203705|ACTIVE_COMPARATOR|Treatment group 5|Enoxaparin
62189691|NCT00372853|EXPERIMENTAL|Arm A|
62189692|NCT00372853|EXPERIMENTAL|Arm B|
62189693|NCT01846403|OTHER|Semi-quantitative pregnancy test|Semi-quantitative urine pregnancy test (dBest One Step hCG Panel Test Kit)
62189694|NCT04456647||Parenteral nutrition|
62189695|NCT05879003|EXPERIMENTAL|novel brace with neuromuscular electrical stimulation plus exercise group|The experimental group received additional NMES during exercise. According to a previous study, the unit's electronics created electrical impulses with an output frequency of 80 Hz and a duration of 200 ms. The synchronous (S) mode and asymmetrical rectangular wave-pulse were used throughout the experiment. The amplitude was set as muscle motor-level contraction with the self-perception of maximal tolerable intensity. A rise and fall time of 2s with a tetanic muscle stimulation lasting 8 seconds and a 3s duration between stimulations were used for all participants.
62189696|NCT05879003|ACTIVE_COMPARATOR|exercise control group|The exercise intervention consisted of scapular-focused exercises with theraband, including scapula row, serratus punch, and adduction exercises in a standing position. The scapula row exercise was performed with the arm straight and the shoulder flexed to 30°. Participants retracted their scapula and brought the theraband to the side of the body, then returned; the serratus punch exercise began with elbow flexion at 90° and held the theraband. Participants punched and protracted their scapula; the adduction exercise was conducted with arm straight, shoulder internal rotation, and abduction at 30°. Participants pull the theraband to the side of the body. Each was performed at 10 repetitions per set for 3 sets daily.
62189697|NCT00796393|EXPERIMENTAL|2|Subject with active product, not vaccinated against influenza.
62189698|NCT00796393|PLACEBO_COMPARATOR|3|Subject with placebo, vaccinated against influenza.
62189699|NCT00796393|PLACEBO_COMPARATOR|4|Subject with placebo, not vaccinated against influenza.
62189700|NCT00796393|EXPERIMENTAL|1|Subject with active product, vaccinated against influenza
62396450|NCT03099434|ACTIVE_COMPARATOR|Facebook App|The Facebook app provides step-by-step instructions for creating a Facebook post that details each waitlist candidate's struggle with ESRD and their need for a live donor. The post is then uploaded to Facebook so it can be shared with the candidate's Facebook social network. The Facebook App prompts users with specific questions to create a narrative. Links to supplemental resources are auto-populated into the post to provide anyone that views the post with vetted information about the risks, benefits, and process of live donation. Candidates using the Facebook app attend one focus group session held at the transplant center where they are provided with verbal instructions and visual demonstrations of installation and use of the Facebook app.
62396451|NCT03099434|NO_INTERVENTION|Standard of Care|Standard of Care does not include any of the interventions detailed above, but rather normal routine care as this is the control group.
62004040|NCT06374329|EXPERIMENTAL|No Posterior crossbite and lack of space (Group B - Expansion)|"Patients with at least one impacted maxillary canine, no uni or bilateral posterior crossbite and lack of space in the upper arch will be treated with slow maxillary expansion with removable plates (GROUP B - expansion) .~Inclusion in groups B and C will be randomized"
62004041|NCT06374329|NO_INTERVENTION|No Posterior crossbite and lack of space (Group C - Expansion)|Patients with at least one impacted maxillary canine, no uni or bilateral posterior crossbite and lack of space in the upper arch will receive no treatment and will be simply followed up (GROUP C - No intervention) Inclusion in groups B and C will be randomized
62004042|NCT05029141|EXPERIMENTAL|Chidamide+AZA+HHT+AraC+G-CSF group|The patients are randomized into the group. Patients whose last induction failure regimen is a demethylated agent combined with priming regimen enter the experimental group directly.
62004043|NCT05029141|PLACEBO_COMPARATOR|Placebo+AZA+HHT+AraC+G-CSF group|The patients are randomized into the group.
62004044|NCT05593718||FaceMask Ventilation (FMV)|During the period from January 1, 2015, to December 31, 2016, all panendoscopies performed with FMV, whether urgent or scheduled and regardless of indication, were included. Panendoscopies performed with any other oxygenation method were excluded.
62004045|NCT05593718||HFNO|During the period from January 1, 2018, to December 31, 2019, all panendoscopies performed with HFNO, urgent or scheduled and regardless of indication, were included. Panendoscopies performed with any other oxygenation method were excluded.
62004046|NCT03765307|EXPERIMENTAL|SyMap Bronchial Ablation Group|The experimental group is treated using SyMap Bronchial Radiofrequency Ablation system, including disposable bronchial radiofrequency ablation catheter (Model: BA125T) and Bronchial radiofrequency ablation instrument (Model: ELATION S3).
62004047|NCT03765307|ACTIVE_COMPARATOR|Boston Scientific Bronchial Thermoplasty Group|The control group is treated using Boston Scientific Alair System, including Bronchial radiofrequency ablation catheter Alair (Model: ATS2-5 ) and Bronchial radiofrequency ablation instrument (Model: ATS200)
62189701|NCT06028490|EXPERIMENTAL|Interleukin-4 receptor responders 1|Recombinant fully human anti-IL4Rα monoclonal antibody drug.
62189702|NCT06028490|EXPERIMENTAL|Interleukin-4 receptor responders 2|Recombinant fully human anti-IL4Rα monoclonal antibody drug.
62004048|NCT05186467|ACTIVE_COMPARATOR|Intraperitoneal magnesium sulfate (IP) group|They will receive 100 ml normal saline infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline intraoperatively then an intraperitoneal wash of 100 ml normal saline containing 30 mg/kg MgSO4 at the end of laparoscopy.
62004049|NCT05186467|ACTIVE_COMPARATOR|Intravenous magnesium sulfate (IV) group|They will receive 100 ml normal saline containing MgSO4 30 mg/kg infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline containing MgSO4 (8mg/kg) intraoperatively then intraperitoneal wash using 100 ml normal saline at the end of laparoscopy.
62004050|NCT02191189|ACTIVE_COMPARATOR|Treatment A, p.o.|50 mg Nevirapine administered orally in 100 mL water
62004051|NCT02191189|EXPERIMENTAL|Treatment B, ascending colon|50 mg Nevirapine administered to the ascending colon via Enterion™ capsule
62004052|NCT02191189|EXPERIMENTAL|Treatment C, jejunum|50 mg Nevirapine administered to the jejunum via Enterion™ capsule
62004053|NCT02191189|EXPERIMENTAL|Treatment D, ileum|50 mg Nevirapine administered to the ileum via Enterion™ capsule
62004054|NCT02191189|EXPERIMENTAL|Treatment E, descending colon|50 mg Nevirapine administered to the descending colon via Enterion™ capsule
62004055|NCT01234467|EXPERIMENTAL|Bendamustine, Rituximab|This is a single arm intervention where patients will receive bendamustine at a dose of 120 mg/m\^2 infused over 60 minutes in days 1 and 2 of each 21 day cycle along with rituximab 375 mg/m\^2 after bendamustine on day 1 of each cycle. Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 3 at baseline were allowed to receive bendamustine at a dose of 90 mg/m\^2 daily with a dose increase to 120 mg/m\^2 daily if their ECOG improved.
62189703|NCT06028490|PLACEBO_COMPARATOR|Placebo|Recombinant fully human anti-IL4Rα monoclonal antibody drug.
62004056|NCT04300296|EXPERIMENTAL|Cutaneous lichen planus secukinumab 300mg Q4W|Secukinumab 300 mg every 4 weeks provided in pre-filled syringe in cutaneous lichen planus patients
62004057|NCT04300296|PLACEBO_COMPARATOR|Cutaneous lichen planus placebo|Placebo in 1ml PFS in cutaneous lichen patients
62004058|NCT04300296|EXPERIMENTAL|Mucosal lichen planus secukinumab 300 mg Q4W|Secukinumab 300 mg every 4 weeks provided in pre-filled syringe in mucosal lichen planus patients.
62004059|NCT04300296|PLACEBO_COMPARATOR|Mucosal lichen planus placebo|Placebo 1 ml PFS in mucosal lichen planus patients
62004060|NCT04300296|EXPERIMENTAL|Lichen planopilaris secukinumab 300 mg Q4W|Secukinumab 300 mg every 4weeks provided in pre-filled syringe in lichen planopilaris patients.
62004061|NCT04300296|PLACEBO_COMPARATOR|Lichen planopilaris placebo|Placebo in 1ml PFS in lichen planopilaris patients
62004062|NCT04300296|EXPERIMENTAL|Cutaneous lichen planus placebo to secukinumab 300 mg Q2W|Non responder patients on placebo in TP 1 received secukinumab 300 mg Q2W in TP 2
62004063|NCT04300296|EXPERIMENTAL|Mucosal lichen planus placebo to secukinumab 300 mg Q2W|Non responder patients on placebo in TP 1 received secukinumab 300 mg Q2W in TP 2
62004064|NCT04300296|EXPERIMENTAL|Lichen planopilaris placebo to secukinumab 300 mg Q2W|Non responder patients on placebo in TP 1 received secukinumab 300 mg Q2W in TP 2
62189704|NCT01355978|EXPERIMENTAL|Noninvasive Open Ventilation System|Portable noninvasive open ventilator \& nasal interface.
62189705|NCT04564521|EXPERIMENTAL|Nitroglycerin|Intravenous nitroglycerin (0.5mcg/kg/min) is infused after the induction of general anesthesia and during intra-arterial chemotherapy.
62189706|NCT04564521|ACTIVE_COMPARATOR|Normal saline|Normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy.
62189707|NCT01383330|EXPERIMENTAL|Megace|800mg
62189708|NCT01383330|ACTIVE_COMPARATOR|DW-ES(A)|625mg
62189709|NCT01383330|ACTIVE_COMPARATOR|DW-ES(B)|625mg
62189710|NCT06119347||AntiVEGF|cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (AntiVEGF)
62189711|NCT06119347||ICIs|cancer patients receiving immune checkpoint inhibitors (ICIs).
62571774|NCT02322112|PLACEBO_COMPARATOR|Microcrystalline Cellulose (Control)|Microcrystalline cellulose will be used as a placebo control, as it is known to be an insoluble, non-viscous fiber that is essentially not fermented by the human gut microbiota. However, it is important to note that cellulose does have fermentation potential within the gastrointestinal tract and may be associated with improved health benefits; indicating a role as an active comparator.
62004065|NCT02961907|NO_INTERVENTION|Control|"The usual routine course includes :~* a clinico-biological evaluation of infertility causes~* a laboratory staff and decision of therapeutic strategy and decision of a therapeutic strategy~* collection of blood and sperm samples"
62004066|NCT02961907|EXPERIMENTAL|PEPCI group|In the PEPCI group, the standardized assessment of the periconceptional profile is used to adapt the additional standardized intervention.
62189712|NCT01026298|NO_INTERVENTION|Control Group|8 weeks, no intervention for OSA
62189713|NCT01026298|ACTIVE_COMPARATOR|CPAP group|8-week randomized-controlled period of CPAP treatment
62189714|NCT00174447|EXPERIMENTAL|A1|
62571775|NCT02322112|EXPERIMENTAL|Acacia Gum|Acacia gum is composed largely of arabinogalactan, and is considered to be a relatively non-viscous, soluble fiber this is highly fermented by the gut microbiota and well tolerated.
62571776|NCT02322112|EXPERIMENTAL|Resistant Starch Type 4|Cross-linked phosphorylated resistant starch (type IV) is generally insoluble and with low viscosity; yet it tends to have physiologic properties similar to soluble fibers, such as fermentability.
62189715|NCT04594733|ACTIVE_COMPARATOR|Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)|Participants will be randomized to 8 weeks of placebo, minimum 2 week washout period, and then 8 weeks of a combination minocycline (200 mg daily) and NAC (1200 mg daily) followed by a final 2 week washout
62189716|NCT04594733|ACTIVE_COMPARATOR|minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo|Participants will be randomized to 8 weeks of a combination minocycline (200 mg daily) and NAC (1200 mg daily), minimum 2 week washout period, and then 8 weeks of placebo followed by a final 2 week washout
62189717|NCT01150435||Maintenance Medication D, S- Methadon|
62189718|NCT01150435||Maintenance Medication S- Methadon|
62189719|NCT01150435||Buprenorphine|
62189720|NCT01150435||Buprenorphine+ Naloxone|
62189721|NCT00741832|EXPERIMENTAL|I|Patients breath while a conical positive expiratory pressure device during exercises
62189722|NCT00741832|ACTIVE_COMPARATOR|C|Patients (normal) breath during exercise
62189723|NCT02529189|ACTIVE_COMPARATOR|Nitrate-rich beetroot juice|70 ml of a beetroot juice concentrate containing \~5 mmol nitrate
62189724|NCT02529189|PLACEBO_COMPARATOR|Nitrate-deplete beetroot juice|70 ml of a beetroot juice concentrate that is nitrate-depleted
62189725|NCT02297685|SHAM_COMPARATOR|Sham Transcutaneous nerve stimulation|The group with sham TENS did not receive any current. Four surface electrodes (5×5 cm Prim-Trode®, Spain) were symmetrically placed over the L1 and L5 transverse processes with respect to the spine. The patients were informed that they may or may not feel any sensation at the application site of the electrodes.
62189726|NCT02297685|EXPERIMENTAL|Transcutaneous nerve stimulation|The group with TENS received current at a frequency of 80 Hz and with a pulse width of 150 μs with two channels, for 30 minutes over a period of 4 weeks, including a total of 12 sessions.
62189727|NCT02297685|EXPERIMENTAL|Interferential currents|The group with IC received a base frequency of 4000 Hz with AMF = 65 Hz, sweep = 95 Hz and slope of 1/1 in tetrapolar mode, for 30 minutes over a period of 4 weeks, including a total of 12 sessions.
62189728|NCT00846508|EXPERIMENTAL|ciaplantin,cancer,survival|
62189729|NCT03155854|ACTIVE_COMPARATOR|Pretendinous cord excision|Patients will undergo either a targeted palmar fasciectomy procedure in which the involved Dupuytren's fascia will be excised
62189730|NCT03155854|ACTIVE_COMPARATOR|Division/manipulation of the cord|patients will undergo either a targeted palmar fasciectomy procedure in which the involved Dupuytren's fascia will be incised.
62189731|NCT04749407||chemoradiotherapy|
62779546|NCT03704714|EXPERIMENTAL|Treatment (nivolumab and R-CHOP)|Participants receive nivolumab IV over 30 minutes on day 1. Participants also rituximab IV on day 2, cyclophosphamide IV on day 2, doxorubicin hydrochloride IV over 3-5 hours on day 2, vincristine sulfate IV over 30 minutes on day 2, and prednisone PO on days 2-6 of course 1 and rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV over 3-5 hours on day 1, vincristine sulfate IV over 30 minutes on day 1, and prednisone PO on days 1-5 of courses 2-6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62779547|NCT05118334|EXPERIMENTAL|IBI310 (anti-CTLA-4) 1mg/kg(Q3W until progressive disease)in combination with Sintilimab|The test group will be treated with IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
62779548|NCT05118334|EXPERIMENTAL|IBI310 (anti-CTLA-4) 1mg/kg(Q3W*4cycles)in combination with Sintilimab|The test group will be treated with IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W\*4cycles,and then Sintilimab 200 mg IV, Q3W single until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
62779549|NCT05118334|EXPERIMENTAL|IBI310 (anti-CTLA-4) 1mg/kg(Q6W)in combination with Sintilimab|The test group will be treated with IBI310 1mg/kg IV, Q6W+ Sintilimab 200 mg IV, Q3Wuntil progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
62189732|NCT05500781|EXPERIMENTAL|Coaching HER|Participants in the interventional condition will take part in an online program consisting of 6 modules over 2 weeks
62189733|NCT05500781|NO_INTERVENTION|Waitlist Control|Participants will not be explicitly told their study condition, although they will be made aware of the assessment time points and whether they receive the intervention between T1 and T2 (intervention) or after T2 (waitlist control). Following completion of post-intervention assessments (T2), the control condition will participate in the intervention; but, they will not be monitored or assessed.
62189734|NCT01398098|EXPERIMENTAL|COLOKIT®|
62189735|NCT04751136|ACTIVE_COMPARATOR|Intervention Arm|infants were given Cerebrolysin®, manufactured by Neuro Pharma Gmbh, in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).
62189736|NCT04751136|NO_INTERVENTION|Non-intervention Arm|No medication was given
62189737|NCT05332678|EXPERIMENTAL|SLS-005 - Once Weekly|"SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion). SLS-005 will be administered as a weight-based dose of 0.75 g/kg by IV infusion once a week over 60 ± 5 minutes for volumes \<600 mL or 90 minutes +5 min for volumes \>600 mL.~For 52 weeks."
62189738|NCT05332678|EXPERIMENTAL|SLS-005 - Twice Weekly|"SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion). SLS-005 will be administered as a weight-based dose of 0.75 g/kg by IV infusion twice a week over 60 ± 5 minutes for volumes \<600 mL or 90 minutes +5 min for volumes \>600 mL.~For 52 weeks."
62396452|NCT02593331|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to BFKB8488A.
62396453|NCT02593331|EXPERIMENTAL|BFKB8488A SC|Participants will receive single ascending SC dose of BFKB8488A in each dose escalation cohort.
62396454|NCT02593331|EXPERIMENTAL|BFKB8488A IV|Participants will receive single IV dose of BFKB8488A.
62004067|NCT05870527|EXPERIMENTAL|Vagal Nerve Stimulation during Cochlear Implantation Surgery|Participants undergoing cochlear implantation will receive electrical stimulation during the procedure to stimulate the Arnold's nerve to measure pupil dilation.
62004068|NCT05870527|NO_INTERVENTION|Vagal Nerve Stimulator Implantation|Control cohort undergoing vagal nerve stimulator implantation.
62004069|NCT00514267|EXPERIMENTAL|1. HRPC|
62004070|NCT00514267|EXPERIMENTAL|2. Solid Tumors|
62004071|NCT02320890|EXPERIMENTAL|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 3 days a week for 12 weeks (total of 36 applications)
62004072|NCT02320890|SHAM_COMPARATOR|sham-Yband (YDT-201N)|sham-tDCS application 3 days a week for 12 weeks (total of 36 applications)
62004073|NCT01099085|ACTIVE_COMPARATOR|XP/simvastatin|Capecitabine/cisplatin + simvastatin
62004074|NCT01099085|PLACEBO_COMPARATOR|XP/placebo|Capecitabine/cisplatin + placebo
62004075|NCT05703191||Nitric Oxide|Inhaled Nitric Oxide
62004076|NCT05907304|EXPERIMENTAL|Naporafenib + Trametinib|Naporafenib (ERAS-254) 200 mg twice daily (BID) Trametinib 1 mg once daily (QD)
62004077|NCT04782778|ACTIVE_COMPARATOR|Costoclavicular Block|US-guided lateral approach costoclavicular block with 1 mg/kg Bupivacaine (%0,25)
62004078|NCT04782778|ACTIVE_COMPARATOR|Ultrasound Guided Supraclavicular Block|US-guided supraclavicular block with 1 mg/kg Bupivacaine (%0,25)
62004079|NCT06274554|EXPERIMENTAL|IL-23 Therapy with Fluconazole|Fluconazole will be blindly administered as capsules for oral consumption. On the first day, 200 mg will be given. Subjects will then take 100 mg once daily for thirteen days.
62004080|NCT06274554|PLACEBO_COMPARATOR|IL-23 Therapy with Placebo|Placebo will be blindly administered as capsules for oral consumption. On the first day, 200 mg will be given. Subjects will then take 100 mg once daily for thirteen days.
62004081|NCT04567121|OTHER|Intensive intervention group|intensive life-style and care intervention
62004082|NCT04567121|OTHER|Standard intervention group|standard life-style and care intervention
62004083|NCT04737642|EXPERIMENTAL|Papillary ballon dilatation|
62004084|NCT06538688|EXPERIMENTAL|Participants|Patients with impacted mandibular third molar in close proximity to the inferior alveolar nerve
62004085|NCT03075644|EXPERIMENTAL|Somapacitan|
62004086|NCT03075644|ACTIVE_COMPARATOR|Norditropin|
62004087|NCT03152318|EXPERIMENTAL|Arm A- rQNestin|"Arm A is rQNestin34.5v.2 treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A.~* Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent.~* rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose"
62004088|NCT03152318|EXPERIMENTAL|Arm B- rQNestin+CPA|"Arm B is rQNestin34.5v.2 treatment with Cyclophosphamide (CPA) pre-treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A.~* Cyclophosphamide one intravenous injection 2 days prior to procedure.~* Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent.~* rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose"
62004089|NCT03152318|EXPERIMENTAL|Arm C- Multiple Dose rQNestin|"Arm C includes up to 6 intratumoral repeated doses of rQNestin34.5v.2, first in a cohort receiving 10\^8 pfus per time point, followed by a cohort receiving 10\^9 or 10\^7 pfus per time point.~* Arm C adds 2 cohorts of 12 subjects in an open-label clinical trial of rQNestin34.5v.2 administered at two dose levels~* The injections are planned for days 0, 15, 30, 60, 90, and 120~* Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent."
62004090|NCT01054703|EXPERIMENTAL|Ethmoid Sinus Spacer placement|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
62779550|NCT05118334|EXPERIMENTAL|IBI310 (anti-CTLA-4) 0.5mg/kg in combination with Sintilimab|The test group will be treated with IBI310 0.5mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
62004091|NCT03291912|EXPERIMENTAL|Chuna Manual Therapy (CMT)|"1. Chuna manual therapy (CMT), 2 sessions/week, 6 weeks (12 sessions in total)~2. Usual care therapy (UC), 2 sessions/week, 6 weeks (12 sessions in total)~   * Usual care consists of physical therapy and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~  * Patients will be educated about cause and risk factors of cervicogenic dizziness, general neck muscle functions, self-exercising for relieving the symptoms.~  * CMT and UC group will receive the same UC regimen."
62004092|NCT03291912|ACTIVE_COMPARATOR|Usual Care (UC)|"Usual care therapy (UC), 2 sessions/week, 6 weeks (12 sessions in total)~* Usual care consists of physical therapy and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~* Patients will be educated about cause and risk factors of cervicogenic dizziness, general neck muscle functions, self-exercising for relieving the symptoms.~* CMT and UC group will receive the same UC regimen."
62004093|NCT05483244||discontinuous weaning group|Patients of the discontinuous weaning group were disconnected from the respirator during the spontaneous breathing phases which could then take place via taken directly to the heat moist exchanger, high-flow therapy and/or speaking valve without pressure support by the respirator.
62004094|NCT05483244||continuous weaning group|In the case of continuous weaning, spontaneous breathing trial was supported by the respirator, but the positive endexpiratory pressure was lowered to an individual level (between 5 and 10 mbar) resulting in very little pressure support.
62004095|NCT01705288|ACTIVE_COMPARATOR|Control Group (Standard Laparotomy)|Patients undergoing standard anesthesia and standard exploratory laparotomy. Treatment will be per your surgeon's routine standards.
62004096|NCT01705288|EXPERIMENTAL|Rapid Recovery Group|"Protocol for rapid recovery laparotomy procedure involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), post-operative use of non-steroidal anti-inflammatory drugs, early eating after surgery, early walking, and certain goals for discharge from the hospital."
62004097|NCT06192602|EXPERIMENTAL|Acceptance-based, insight-inducing medication adherence therapy (AIM-AT)|Acceptance-based Insight-inducing and Medication Adherence Therapy (AIM_AT) consists of 10 weekly/biweekly, 2-hour sessions (4-months), based on the modified Kemp's model/manual of Adherence therapy and mindfulness-based psychoeducation program developed by the research team. The integrative AIM_AT program based on the principles of motivational-interviewing technique (MI) and mindfulness- and acceptance-based therapy, which have been tested in our previous controlled trials and increasingly been shown to reduce both positive and negative psychotic symptoms and ambivalent attitude towards medication adherence and inducing treatment/illness insight.
62004098|NCT06192602|ACTIVE_COMPARATOR|Conventional Psychoeducation Group program (CPG)|Psychoeducation groups (12-18 members/group) will be led by one trained psychiatric nurse in each center experienced in psychiatric rehabilitation, and are guided by a validated group-intervention protocol based on the research team's and McFarlane et al.'s psychoeducation programs for psychosis. The psychoeducation program consists of 10 two-hour sessions, weekly/biweekly (similarly, 4-month duration) and is comprised of six components: introduction and goal-setting; basic understanding of psychosis and symptom and emotion self-care; education workshop of psychosis care, treatment and community support services; learning about self-care skills; establishing social support and effective coping skills; and skills practices, review and future plan.
62189739|NCT06231537|NO_INTERVENTION|Control Group|Health professionals, including dentists (CD), dental hygienists (TSB), dental assistants (ASB), nurses, and general practitioners, will continue providing care to users in accordance with the existing Service Card protocols in the city of Rio de Janeiro. This ensures on-demand service for users seeking dental care. Additionally, they will continue to facilitate participation in the Tobacco Control Program for interested individuals, following the established protocol of the city of Rio de Janeiro. Notably, members of the control group will not partake in the qualification process conducted by this research project. However, in the event of positive results at the research's conclusion, consideration will be given to extending qualification opportunities to the control group as well.
62189740|NCT06231537|EXPERIMENTAL|Active Screening Group|"Health professionals (Community Health Agents, dentists, dental hygienists, dental assistants, nurses, and general practitioners) will undergo training focused on preventing OC, considering risk factors and highlighting the significance of preventive oral examinations for early diagnosis. Dentist and general practitioners will receive training to conduct oral examinations, enabling them to identify suspicious lesions and potentially malignant disorders. The qualification process will be conducted through face-to-face meetings and/or videoconferencing, supplemented by educational material delivered via the widely used messaging application (WhatsApp).~Following qualification, tobacco users and excessive alcohol users will be invited to visit the Family Clinic for oral preventive examination. After six months, in the event that a user does not attend the Family Clinic, the Health Team will conduct an active search, through home visits or community outreach in bars."
62214683|NCT02341729|OTHER|starting with ticagrelor|"Patients, after CPR because of an ACS, will receive 2 crushed tablets of ticagrelor (180mg) through a gastric tube. After this dose twice a day 90mg is given for the duration of 1 year. The 1st blood sample is taken before administration. In total 10 blood samples are taken for determination of platelet aggregation and plasma concentrations.~When patients receive a semi-urgent CABG, ticagrelor has been interrupted for 3 days. Postoperative the patients get crushed tablets of ticagrelor, the 1st dose will be 90mg, and every 12h 90mg is given, for the duration of 1 year. The 1st blood sample is taken before the 1st dose. In total 9 blood samples are taken for determination of platelet aggregation and plasma concentrations."
62779551|NCT05259839|EXPERIMENTAL|Arm A (ABBV-383 with Pomalidomide and Dexamethasone)|Participants with relapsed or refractory (R/R) multiple myeloma (MM) who meet the criteria outline in the protocol will receive ABBV-383 with Pomalidomide and Dexamethasone.
62779552|NCT05259839|EXPERIMENTAL|Arm B (ABBV-383 with Lenalidomide and Dexamethasone)|Participants with R/R MM who meet the criteria outline in the protocol will receive ABBV-383 with Lenalidomide and Dexamethasone.
62779553|NCT05259839|EXPERIMENTAL|Arm C (ABBV-383 with Daratumumab and Dexamethasone)|Participants with R/R MM who meet the criteria outline in the protocol will receive ABBV-383 with Daratumumab and Dexamethasone.
62779554|NCT05259839|EXPERIMENTAL|Arm D (ABBV-383 with Nirogacestat)|Participants with R/R MM who meet the criteria outline in the protocol will receive ABBV-383 with Nirogacestat.
62779555|NCT03485196||MSI-H group|We use the immunohistochemical expression of mismatch repair proteins (MutS protein homolog 2( MSH2),MutS protein homolog 6( MSH6) and PMS2（postmeiotic segregation increased 2 ）) to Determine the MSI status . When one antibodies or more show negative nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite instability high (MSI-H).
62779556|NCT03485196||MSI-L group|We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status . when all the four antibodies show positive nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite stable (MSI-L).
62779557|NCT03485196||MSS group|We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status . when all the four antibodies show positive nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite stable (MSS).
62779558|NCT02593318|EXPERIMENTAL|Part 1 - Oxaloacetate (OAA) 1 gram/day|Participants take 1 gram of OAA per day for period of 4 weeks
62779559|NCT02593318|EXPERIMENTAL|Part 2 - Oxaloacetate (OAA)2 gram/day|Participants take 2 grams of OAA per day for period of 4 weeks
62779560|NCT02481609|EXPERIMENTAL|NAC arm|Topical intranasal N-acetyl cysteine (NAC 200 mg/2 ml vials) BID for one month
62779561|NCT01052077|EXPERIMENTAL|Brexipiprazole + ADT|OPC-34712 Tablets, Oral, 1 - 3 mg OPC-34712 + ADT
62779562|NCT01052077|PLACEBO_COMPARATOR|Placebo + ADT|Placebo + ADT
62779563|NCT05172804|EXPERIMENTAL|Nursing students receiving progressive muscle relaxation|PMR (Smith Version) involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot. This tense-let go exercise is performed twice for each muscle group. The tensing up phase for each muscle group should last for 5 to 10 seconds and the letting go phase for 20-30 seconds. Simultaneously, the subjects will be asked to pay attention to the sensations of muscle tension and relaxation. After the tense-let go exercise, subjects are asked to systematically scan the muscle groups to notice and let go any remaining muscle tension. The entire exercise should take around 30 minutes, not counting instructions and times of measurement \[11\].
61977910|NCT01638806|NO_INTERVENTION|Conventional: Group II|Patients are treated as today: Admission to local hospital, Low-molecular-weight heparin (LMWH), Aspirin, ADP-blocker and within 72 hours transfer for angiography/angioplasty. Patients with a Grace score \> 140 will be transferred for angiography/angioplasty within 24 hours. Patients with refractory angina, severe heart failure, life-threatening ventricular arrhythmias or haemodynamic instability will be transferred acutely for angiography/angioplasty according to the european guidelines.
62396455|NCT01939236|EXPERIMENTAL|traditional Chinese medicine|Subjects were treated with TCM 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient with chronic heart failure is qi deficiency and blood stasis. He will take drug of qi deficiency and blood stasis 2 times per day for 28 days.
62396456|NCT01939236|PLACEBO_COMPARATOR|placebo (gummeline)|Subjects were treated with placebo 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient with chronic heart failure is qi deficiency and blood stasis. He will take drug of qi deficiency and blood stasis 2 times per day for 28 days.
62004099|NCT06192602|OTHER|Treatment-as-usual only (TAU)|Routine/Usual care only (control) group participants (and the two treatment groups) will receive usual community mental healthcare services. The main services provided by the four ICCMWs mainly include day-time occupational and living skills training workshops, family mutual support groups, public and mental health education, social and recreational services, supportive groups services on specific mental health problems, referrals to community psychiatric and social care services, and individual and family counseling service as needed. In addition, the center users will also receive community mental health services provided by public hospital and outpatient departments.
62004100|NCT05217797|EXPERIMENTAL|Glasses|Participants in the experimental arm are asked to wear glasses (sunglasses or other glasses) when outside their home and close to others (e.g. on public transport, in shopping centres etc.).
62396457|NCT06444399|EXPERIMENTAL|Pityriasis Rubra Pilaris|Subjects will receive Deucravacitinib, twice daily for 24 weeks
62396458|NCT04106674|NO_INTERVENTION|Non-surgical|No surgery
62396459|NCT04106674|ACTIVE_COMPARATOR|Surgical|Surgeons preference
62396460|NCT00405665|EXPERIMENTAL|1|
62571777|NCT06577740|OTHER|Otago Exercise Group|Participants in the study were given group otago exercises for 4 weeks, face to face, once a week for 30 minutes. They were also given brochures containing otago exercises twice a week and followed up remotely. They were asked to walk normally for 30 minutes, 2 days a week. Then they entered a 4-week cleansing period.
62571778|NCT06577740|EXPERIMENTAL|Dual Task Focused Otago Exercise Group|After a 4-week washout period, participants in the study were given group-based otago exercises and dual-task exercises once a week for 4 weeks. They were given a brochure containing otago exercises including dual-task exercises twice a week and were applied individually and monitored remotely. They were asked to walk normally 2 days a week.
62571779|NCT02137213|EXPERIMENTAL|Arm A: Naloxone then placebo|Subjects assigned to Arm A will receive methadone with naloxone for one week and then methadone with placebo for one week
62571780|NCT02137213|EXPERIMENTAL|Arm B: Placebo then naloxone|Subjects assigned to Arm B will receive methadone with placebo for one week and then methadone with naloxone for one week
62571781|NCT06449430|EXPERIMENTAL|Sedation with propofol|Atropine 0.4 mg intravenous bolus and intravenous propofol will be administered through a continuous infusion with a target plasma concentration between 4-6 micrograms/mL maintaining a BIS between 65-75, following the protocol used by Sánchez-Romero J et al. (doi:10.3390/jcm11030489). For this, an intravenous infusion pump (Agilia SP TIVA ES, Fresenius Kabi AG, Bad Homburg, Germany) will be used. After the administration of propofol, a period of 3 minutes will be waited before starting the procedure to ensure the target plasma concentration.
62004101|NCT05217797|NO_INTERVENTION|Not glasses|Participants in no interventions arm are asked to not wear glasses (sunglasses or other glasses) when outside their home and close to others (e.g. on public transport, in shopping centres etc.).
62004102|NCT01558882||10 patients|The patients included desire tubal sterilization via the ESSURE technique.
62004103|NCT06248983||Participants|Observational study, therefore no intervention that is administered.
62004104|NCT06664411|EXPERIMENTAL|Pola-ZR2P|Patients were treated by Pola-ZR2P as Induction Therapy
62396461|NCT00405665|EXPERIMENTAL|2|
62396462|NCT06191562|EXPERIMENTAL|Posterior Tympanostomy Tube Left|Patients in whom the left ear is randomized to receive a tympanostomy tube in the posterior-inferior quadrant (new location).
62396463|NCT06191562|EXPERIMENTAL|Posterior Tympanostomy Tube Right|Patients in whom the right ear is randomized to receive a tympanostomy tube in the posterior-inferior quadrant (new location).
62396464|NCT05644145|EXPERIMENTAL|Yellow fever seropositive vaccinated pediatric population in Argentina|Yellow fever seropositive pediatric population in Argentina after receiving the YF vaccine at 12-23 months of age.
62396465|NCT06300060|EXPERIMENTAL|Synbiotic|Participants receive the synbiotic for 6 weeks.
62396466|NCT06300060|PLACEBO_COMPARATOR|Placebo|Participants receive the placebo for 6 weeks.
62396467|NCT06528301|EXPERIMENTAL|UB-VV111|A single dose of UB-VV111 will be administered.
62396468|NCT06528301|EXPERIMENTAL|UB-VV111 + rapamycin|A single dose of UB-VV111 will be administered followed by treatment with rapamycin.
62396469|NCT04761770|EXPERIMENTAL|Geriatric participants with various blood disorders|"1. Geriatric assessment (GA) pre-transplant~2. Risk-adapted allocation of conditioning intensity based on GA~3. GA-directed, longitudinal supportive care management"
62779564|NCT05172804|EXPERIMENTAL|Nursing students receiving guided imagery|Guided imagery (Smith Version) involves creating in one's mind or imagining a passive relaxing places or activities. In sense imagery, one simply imagines sensations associated with a relaxing setting or activity. The relaxation approach involves the sense of sight, sound, touch, and smell. The categories of stimuli consist of: (1) Travel such as boats, plains, trains, balloons, horses, (2) outdoor nature settings such as mountains, gardens, and forest, (3) water such as rivers, lakes, ocean, beach, rain, and (4) indoor settings such as childhood home, castle, religious institution, and cabin \[11\].
62571782|NCT06449430|ACTIVE_COMPARATOR|bupivacaine|"A combined spinal-epidural anesthesia technique will be performed with a spinal dose of 5-7.5 mg of hyperbaric bupivacaine and 20 μg of intrathecal fentanyl, along with the placement of an epidural catheter, following the protocol used by Brogly N et al. in Protocols of the Obstetric Anesthesia Section of SEDAR, 2021. After the administration of epidural anesthesia, a period of 3 minutes will be waited before starting the procedure to ensure effective anesthesia."
62214684|NCT01796548|EXPERIMENTAL|Oxybutynin Extended-Release|Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
62396470|NCT04982224|EXPERIMENTAL|Phase 1. Dose Escalation|Cohorts A and B: REGN5093-M114 monotherapy. Cohort C: REGN5093-M114+cemiplimab combination.
62396471|NCT04982224|EXPERIMENTAL|Phase 2. Dose Expansion|Cohorts A and B: REGN5093-M114 monotherapy. Cohort C: REGN5093-M114+cemiplimab combination.
62396472|NCT06058039|EXPERIMENTAL|NMRA-335140 80 milligrams (mg) once daily (QD)|Participants will receive a NMRA-335140 tablet at a dose of 80 mg QD
62396473|NCT06058039|PLACEBO_COMPARATOR|Placebo|Placebo participants will receive matching placebo tablet once daily
62396474|NCT05397002|OTHER|Patient with class III malocclusion|
62396475|NCT04002297|EXPERIMENTAL|zanubrutinib plus rituximab|
62396476|NCT04002297|ACTIVE_COMPARATOR|bendamustine plus rituximab|
62396477|NCT05643573|EXPERIMENTAL|Asundexian|Participants will receive asundexian and apixaban matching placebo.
62396478|NCT05643573|ACTIVE_COMPARATOR|Apixaban|Participants will receive apixaban and asundexian matching placebo.
61977911|NCT01502423|ACTIVE_COMPARATOR|Current formulation adalimumab|One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
61977912|NCT01502423|EXPERIMENTAL|New formulation of adalimumab|One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe
61977913|NCT01373437||Intubate|
62214685|NCT00568724||1|Children referred to surgical treatment of congenital hydronephrosis
62214686|NCT00568724||2|15 age- and sex-matched controls
62214687|NCT00568724||Children with healthy pelvic tissue|Children referred to nephrectomy due to nephrotic syndrome
62214688|NCT00568724||Adults with healthy pelvic tissue|Adults referred to nephrectomy due to another cause than hydronephrosis
62214689|NCT04576403|ACTIVE_COMPARATOR|Intervention group|Activated mittens
62214690|NCT04576403|SHAM_COMPARATOR|Control group|Deactivated mittens
62571783|NCT04723927||Older adults|The data for motor function and gait pattern analysis was obtained.
62214691|NCT04490122||Inhalational|will receive inhalational anesthesia
62214692|NCT04490122||Total intravenous|will receive total intravenous anesthesia with propofol infusion(100-150 mcg/kg/min) and dexmedetomedine 0.3mcg/kg/h.
62214693|NCT01695031|EXPERIMENTAL|Tailored asthma management program|Teens randomized to the experimental arm will receive 4 sessions of web-based, tailored asthma management
62214694|NCT01695031|ACTIVE_COMPARATOR|Generic web-based education|Teens in the control group will receive generic, web-based asthma education.
62214695|NCT05439382||Langer & Langer technique|Participants undergoing Langer \& Langer surgical technique
62214696|NCT05439382||Nelson' modified technique|Participants undergoing Nelson' modified surgical technique
62214697|NCT05439382||Coronally advanced flap and subepithelial graft|Participants undergoing Coronally advanced flap and subepithelial graft surgical technique
62214698|NCT04361955|OTHER|PD with DBS on|intervention is EEG while at rest and performing tasks, on anti PD medications and off anti PD medications
62214699|NCT04361955|OTHER|PD with DBS off|intervention is EMG while at rest and performing tasks, on anti PD medications and off anti PD medications
62214700|NCT04361955|OTHER|ET with DBS on|intervention is EEG while performing tasks and at rest
62214701|NCT04361955|OTHER|ET with DBS off|intervention is EEG while performing tasks and at rest
62214702|NCT01353859|EXPERIMENTAL|Single Arm|
62214703|NCT02275975|EXPERIMENTAL|K-877|K-877
62189741|NCT06231537|EXPERIMENTAL|Campaign Group|"Health professionals (Community Health Agents, dentists, dental hygienists, dental assistants, nurses, and general practitioners) will be training focused on preventing OC, risk factors and highlighting the significance of preventive oral examinations for early diagnosis. Dentist and general practitioners will receive training to conduct oral examinations, enabling them to identify suspicious lesions and potentially malignant disorders. The qualification process will be conducted through face-to-face meetings or videoconferencing.~Following qualification, tobacco and excessive alcohol users will be invited to visit the Family Clinic for oral examination. After six months, a public awareness campaign, over one month, will be conducted in the Family Clinics. This campaign will provide guidance on risk factors, signs and symptoms, and the importance of oral examinations."
62189742|NCT05172492|EXPERIMENTAL|Endocare|
62410025|NCT06650956|ACTIVE_COMPARATOR|Comparison District|Standard HPV Vaccination (Comparison District) - In the comparison district, routine HPV vaccination services will be provided to girls aged 10-13 years. The vaccine is a single dose of recombinant Human Papilloma virus quadrivalent types, 6, 11, 16, and 18.; A school-based vaccination campaign will be conducted in 2024 November to promote and administer the HPV vaccine. Additionally, the vaccine will be available at health facilities starting in the same month. Outreach activities will also be conducted to ensure access to the vaccine for hard-to-reach populations and out-of-school girls. - Unlike the intervention district, there will be no additional training for nor service by healthcare providers on comprehensive sexuality education (CSE) or other sexual and reproductive health (SRH) services, and there will be no dedicated community outreach sessions on SRH topics.
62004105|NCT04608266|EXPERIMENTAL|Camostat mesylate|Camostat mesylate, oral administration 600mg/day
62189743|NCT05172492|ACTIVE_COMPARATOR|Digital control|
62189744|NCT05225207||All Participants|Participants with uHCC who are prescribed with Lenvima within the scope of the approved label for Korea under the medical judgment of the investigator will be enrolled and observed for up to 12 months.
62189745|NCT02378636|EXPERIMENTAL|600S|Modified 600C (axis marks) monofocal aspheric intraocular lens
62004106|NCT04608266|PLACEBO_COMPARATOR|Placebo|Placebo tablets, oral administration
62004107|NCT02691767|EXPERIMENTAL|pazopanib|pazopanib 800 mg will be administered orally daily every 3weeks
62004108|NCT03567850|EXPERIMENTAL|Intervention|Participants assigned to the intervention arm will receive Problem Solving Skills Training (PSST) consisting of eight one-hour individual weekly sessions.
62189746|NCT05247697|EXPERIMENTAL|Treatment|Mirtazapine 7.5 mg
62189747|NCT05247697|PLACEBO_COMPARATOR|Control|Matching placebo
62189748|NCT02905409|ACTIVE_COMPARATOR|4PD diameter of ILM peeling in surgery|Patients were stratified according to the macular hole closure index(MHCI) measured by OCT into 3 subgroup (MHCI\<0.5, 0.5≤MHCI\<0.7, MHCI≥0.7 ). And then randomized into 2 different intervention groups. If randomized into 4PD (papillary diameter) group, patients were given 4PD diameter of ILM (internal limiting membrane) peeling in surgery.
62189749|NCT02905409|EXPERIMENTAL|2PD diameter of ILM peeling in surgery|Patients were stratified according to the macular hole closure index(MHCI) measured by OCT into 3 subgroup (MHCI\<0.5, 0.5≤MHCI\<0.7, MHCI≥0.7 ). And then randomized into 2 different intervention groups. If randomized into 2PD (papillary diameter) group, patients were given 2PD diameter of ILM (internal limiting membrane) peeling in surgery.
62779565|NCT05172804|EXPERIMENTAL|Nursing student receiving mindfulness meditation|"Smith version of the mindfulness meditation will be used in the current study. The mindful mediators are neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each stimulus. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction... how interesting) \[11\]."
62779566|NCT05172804|ACTIVE_COMPARATOR|control Group|Participants in the control condition will be instructed to sit with their eyes closed during the intervention periods. Participants in the control group will follow an identical time periods as the experimental groups. For instance, when the experimental groups will practice for 30 minutes, the participants in the control group will be asked to sit with eyes closed and relax for 30 minutes.
62004109|NCT03567850|ACTIVE_COMPARATOR|Control Arm|Care As Usual Group (CAU): Participants randomized to the CAU group will be observed under naturalistic conditions. Both PSST and CAU participants and their clinicians (PCP and oncology providers) will be allowed to use any clinically appropriate medical and behavioral care without restriction (e.g., care management, rehabilitation, behavioral therapy, palliative care) or refer patients to social and community services (e.g., peer support, county cancer services program or aging services). The CAU participants will undergo the same evaluation protocol as the PSST group
62004110|NCT03819231|EXPERIMENTAL|Mindfulness and intranasal oxytocin|Given oxytocin through intranasal administration and self-directed mindfulness training.
62004111|NCT03819231|ACTIVE_COMPARATOR|Mindfulness and placebo|Given sterile saline through intranasal adminstration and self-directed mindfulness training.
62004112|NCT03819231|SHAM_COMPARATOR|Sham mindfulness and placebo|Given sterile saline through intranasal adminstration and sham self-directed mindfulness training.
62004113|NCT01056848||CK-LX3401|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia.
62004114|NCT01056848||CK-LX3405|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia
62004115|NCT01056848||CK-LX3430|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia
62004116|NCT03262948|EXPERIMENTAL|nab-paclitaxel plus carboplatin|nab-paclitaxel 260mg/m2,i.v., plus carboplatin AUC = 6,i.v., starting from randomization, once every 3 weeks, for 4-6 cycles, or progression, or intolerance,or death or start a new anti-tumor treatment, whichever occurs first.
62004117|NCT03262948|ACTIVE_COMPARATOR|Paclitaxel plus carboplatin|paclitaxel 175 mg/m2,i.v., plus carboplatin AUC = 6,i.v., starting from randomization, once every 3 weeks, for 4-6 cycles, or progression, or intolerance,or death or start a new anti-tumor treatment, whichever occurs first.
62004118|NCT05900427|EXPERIMENTAL|Liposomal Bupivacaine Group|10 mL (133 mg) Liposomal bupivacaine and 20 mL (50 mg) 0.25% bupivacaine and 6 mL of saline (183 mg)
62004119|NCT05900427|OTHER|Plain Bupivacaine Group|36 mL (180 mg) 0.5% bupivacaine
62004120|NCT03364049|EXPERIMENTAL|MK-7162 25 mg +Pembrolizumab (Pembro)|Participants receive MK-7162 25 mg via oral tablets once daily (QD) throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 25 mg orally QD PLUS pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (every 3 weeks \[Q3W\]).
62004121|NCT03364049|EXPERIMENTAL|MK-7162 50 mg + Pembro|Participants receive MK-7162 50 mg via oral tablets QD throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-71625 50 mg orally QD PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle Q3W
62004122|NCT03364049|EXPERIMENTAL|MK-7162 100 mg + Pembro|Participants receive MK-7162 100 mg via oral tablets QD throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 100 mg orally QD PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle Q3W
62004123|NCT03364049|EXPERIMENTAL|MK-7162 200 mg + Pembro|Participants receive MK-7162 200 mg via oral tablets QD throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 200 mg orally QD PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle Q3W
62004124|NCT02492906||Osteoarthrosis group|Patients with primary severe knee osteoarthrosis or with chronic knee pain.
62004125|NCT02492906||Healthy patients|Healthy patients
62004126|NCT02694081|EXPERIMENTAL|Uncut Roux-en-Y Reconstruction|Uncut Roux-en-Y Reconstruction will be used after laparoscopy-assisted distal gastrectomy for early gastric cancer.
62004127|NCT02694081|ACTIVE_COMPARATOR|Billroth II Reconstruction|Billroth II Reconstruction will be used after laparoscopy-assisted distal gastrectomy for early gastric cancer.
62004128|NCT01394575|EXPERIMENTAL|IMRT-SIB|
62004129|NCT05402527|OTHER|Fish nutrients - Whey protein - Maltodextrin|Participants will receive fish nutrients, whey protein, and maltodextrin in this order.
62189750|NCT00873327|ACTIVE_COMPARATOR|1|Open label -- 6 interval doses
62214704|NCT02275975|EXPERIMENTAL|K-877 with Fluconazole|K-877 with Fluconazole
62189751|NCT06118242|EXPERIMENTAL|Results Related to Ventilator-Associated Pneumonia in Patients|Use of 0.12% Chlorhexidine Gluconate,1% Chlorhexidine Gluconate, Sodium Bicarbonate, Ozonated Water and Hypochlorous Acid.
62779567|NCT05308771|EXPERIMENTAL|Epidural anesthesia using VPC syringe|Epidural anesthesia detection using VPC syringe
62779568|NCT02448589|EXPERIMENTAL|TAS-119 Monotherapy|"Dose Escalation:~A Monotherapy Dose-Escalation Phase Performed in Approximately 5 Dose Levels (3 to 12 Patients Per Dose Level) to Determine the MTD for TAS-119 Given Orally (PO), Twice-Daily (BID) in a 28-Day Treatment Cycle; and:~Dose Expansion:~A Monotherapy Expansion Phase in Which Approximately 40 Additional Patients will be Enrolled to Further Evaluate the Recommended Phase II Dose (RP2D)"
62779569|NCT06485466|EXPERIMENTAL|TACE plus camrelizumab and apatinib|"Procedure: TACE is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) and oxaliplatin (50-150mg) are considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol (5-20ml) and other embolic agent( blank microspheres/ PVA/gelatin sponge particles) were determined by diameter and blood supply type of HCC.~Camrelizumab+apatinib: camrelizumab 200mg intravenously every 3 weeks and apatinib 250 mg orally once daily."
62779570|NCT06485466|ACTIVE_COMPARATOR|Camrelizumab plus apatinib|Camrelizumab+apatinib: camrelizumab 200mg intravenously every 3 weeks and apatinib 250 mg orally once daily.
62779571|NCT06429774||TBI Group|"TBI patients recruited from neurosurgical departments at 50 medical centers in China have apparent clinical symptoms that are confirmed by computed tomography or magnetic resonance imaging.~The exclusion criteria are those who fulfill one of the following conditions:~1. patients ≥90 years of age;~2. patients who did not accept follow-up visits or were unable to complete follow-up assessments;~3. patients with incomplete information;~4. patients who did not obtain written informed consent;~5. patients with concomitant cancer or other serious illnesses."
62779572|NCT04924153||EIMFS and EOEE (Up to 2 years)|Participants who have been diagnosed with epilepsy of infancy with migrating focal seizures (EIMFS) and early-onset epileptic encephalopathy (EOEE) with duration of symptoms for up to 2 years will be enrolled.
62779573|NCT04924153||EIMFS and EOEE (More than 2 years)|Participants who have been diagnosed with EIMFS and EOEE with duration of symptoms for more than 2 years will be enrolled.
62779574|NCT04924153||SHE (Up to 2 years)|Participants who have been diagnosed with sleep-related hypermotor epilepsy (SHE) with duration of symptoms for up to 2 years will be enrolled.
62004130|NCT05402527|OTHER|Fish nutrients - Maltodextrin - Whey protein|Participants will receive fish nutrients, maltodextrin, and whey protein in this order.
62004131|NCT05402527|OTHER|Whey protein - Fish nutrients - Maltodextrin|Participants will receive whey protein, fish nutrients, and maltodextrin in this order.
62004132|NCT05402527|OTHER|Whey protein - Maltodextrin - Fish nutrients|Participants will receive whey protein, maltodextrin, and fish nutrients in this order.
62779575|NCT04924153||SHE (More than 2 years)|Participants who have been diagnosed with SHE with duration of symptoms for more than 2 years will be enrolled.
62779576|NCT05126628|ACTIVE_COMPARATOR|Active Comparator: Proxalutamide + Usual Care|Proxalutamide + usual care as determined by care provider
62779577|NCT05126628|PLACEBO_COMPARATOR|Placebo Comparator: Placebo + Usual Care|Placebo + usual care as determined by care provider
62779578|NCT00771524|EXPERIMENTAL|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
62779579|NCT00771524|NO_INTERVENTION|Control|Standard of care antibiotics prior to hip replacement surgery
62004133|NCT05402527|OTHER|Maltodextrin - Fish nutrients - Whey protein|Participants will receive maltodextrin, fish nutrients, and whey protein in this order.
62004134|NCT05402527|OTHER|Maltodextrin - Whey protein - Fish nutrients|Participants will receive maltodextrin, whey protein, and fish nutrients in this order.
62004135|NCT05549193|EXPERIMENTAL|Mild and Moderate-Severe Urinary Incontinence Group|10 sets of pelvic floor muscle training and 2 sets of abdominal muscle strengthening training were given every day for 6 weeks. All analyzes were conducted at the beginning and end of the 6-week training. The same training program was applied to both groups ( Group 1 (mild urinary incontinence) and Group 2 (moderate-severe urinary incontinence), and the effects were compared according to the severity of incontinence.
62004136|NCT04282356|EXPERIMENTAL|Intraperitoneal chemotherapy|Cisplatin 100mg/m2 during surgery IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel, 60mg/m2 on D8 after surgery with at least 3 courses performed (up to 4-6 allowed)
62004137|NCT05555433||active spondyloarthritis|subjects with active spondyloarthritis with a BASDAI greater than 4
62004138|NCT05555433||remission spondyloarthritis|subjects presenting with a remission spondyloarthritis defined by a BASDAI less than 4
62004139|NCT05555433||controls without spondyloarthritis|controls without spondyloarthritis or other chronic inflammatory rheumatism and without fibromyalgia
62004140|NCT05555433||fibromyalgia|subjects with fibromyalgia
62004141|NCT01706250|EXPERIMENTAL|MAXCLARITY II|MaxClarity II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam. Available over the counter. Each subject applies both arms (MaxClarity II and Proactiv) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
62004142|NCT01706250|ACTIVE_COMPARATOR|PROACTIV|Proactiv (2.5% BPO) Renewing Cleanser and Repairing Lotion and Revitalizing Toner. Available over the counter. Each subject applies both arms (MaxClarity II and Proactiv) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
62004143|NCT01153945||Hypothyroid|
62004144|NCT01153945||Non hypothyroid|
62004145|NCT01153945||Healthy subjects|
62004146|NCT02580370|EXPERIMENTAL|Dose A|Botulinum toxin type A
62779580|NCT03465995||NKI iPAS Diagnostic Protocol|Research participants who qualify for this study will put on EKG leads, and then a non-invasive device called iPAS, which will record heart rate and eye tracking data while participants perform a task on the screen of the device. The testing session will not exceed 30 minutes. Participants will take a total of 3 recordings over a period of roughly 5 weeks.
62779581|NCT06238206|EXPERIMENTAL|People post-stroke|The focus group discussion will assess the needs and requirements of this group.
62189752|NCT06118242|EXPERIMENTAL|Results Regarding the Oral Mucous Membrane Integrity of Patients|Use of 1% Chlorhexidine Gluconate, Sodium Bicarbonate, Ozonated Water and Hypochlorous Acid.
62189753|NCT00293345|EXPERIMENTAL|Treatment (gemcitabine hydrochloride, triapine)|Patients receive 3-AP (TriapineÃÂ®) IV over 24 hours followed by gemcitabine hydrochloride IV over 100-125 minutes on days 1 and 8. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
62189754|NCT02677077||Czech Republic|Approximately 230 participants with RRMS receiving commercial natalizumab in Czech Republic
62779582|NCT06238206|EXPERIMENTAL|Older adults with sarcopenia|The focus group discussion will assess the needs and requirements of this group.
62779583|NCT06238206|EXPERIMENTAL|Physiotherapists|The focus group discussion will assess the needs and requirements of this group.
62779584|NCT00580762|EXPERIMENTAL|ESRD|End-Stage Renal Disease (ESRD) patients on dialysis who meet the NIH guidelines and preoperative requirements for RYGB will undergo laparoscopic RYGB
62779585|NCT00580762|ACTIVE_COMPARATOR|Non-ESRD|Non-ESRD patients who meet the NIH guidelines and preoperative requirements for RYGB will undergo laparoscopic RYGB
62779586|NCT00880594|EXPERIMENTAL|Open label desipramine|
62779587|NCT05009667||IMR first group|In this group, IMR based on pressure wire and arterial physiological detector will be measured first, and then caIMR base on angiography images and pressure sensor will be measured secondly.
62779588|NCT05009667||caIMR first group|In this group, caIMR based on angiography images and pressure sensor will be measured first, and then IMR based on pressure wire and arterial physiological detector will be measured secondly.
62779589|NCT02333019|EXPERIMENTAL|Let's Talk About Sex|Participants assigned to the treatment condition viewed a multimedia web site designed to help parents of pre-adolescent children, aged 10 to 14 years old, build skills to communicate effectively about parental values and issues relating to sexuality, sex and relationships, and preventing pregnancy and sexually transmitted infections.
62779590|NCT02333019|ACTIVE_COMPARATOR|Websites; preventing teen pregnancy|Participants assigned to the control condition were emailed urls for websites with information similar to the Let's Talk about Sex program. Parents were directed to the parents section of the National Campaign to Prevent Teen and Unplanned Pregnancy and children were directed to Nemours' KidsHealth website.
62004147|NCT02580370|PLACEBO_COMPARATOR|Dose B|Placebo comparator
62004148|NCT01173562|EXPERIMENTAL|Mebendazole|
62004149|NCT00577122|EXPERIMENTAL|Cohort I (MPA)|Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.
62004150|NCT00577122|EXPERIMENTAL|Cohort II (MPA, low-dose chemotherapy)|"Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.~Cyclophosphamide will be administered orally as a single daily dose. Methotrexate will be administered twice daily on days 1 and 2 of each week."
62004151|NCT01348399||XIENCE PRIME stents|
62189755|NCT02677077||Belgium|Approximately 70 participants with RRMS receiving commercial natalizumab in Belgium
62189756|NCT01884103||EMS Providers|Field Triage Decision-making for older adult patients with potential TBI.
62189757|NCT03107507|ACTIVE_COMPARATOR|Levetiracetam|"Levetiracetam given in oral form via oro-gastric tube, first a bolus dose 40-50mg/kg then maintenance dose 10-30 mg/kg/day divided every 12 hours.~Duration: until seizure free"
62189758|NCT03107507|ACTIVE_COMPARATOR|Phenobarbital|"Phenobarbital given in IV form, loading dose 20mg/kg that can be repeated after a 20 minute interval not to exceed 40mg/kg then maintenance dose 2-4 mg/kg/day divided every 12 hours.~Duration: until seizure free"
62189759|NCT06547268||Home monitoring program patients|Patients enrolled in the study are those patients who are already enrolled in (or are being discharged with) home monitoring in an existing program
62189760|NCT04849377|EXPERIMENTAL|Group I - 50 Gy/200 mg/m2|Patient Characteristics: \<20 Pack-Years, HPV16, OP, T1,T2 N0 RT 5 days per week for 6 weeks and Cisplatin weekly for 5 weeks
62004152|NCT03264131|EXPERIMENTAL|Open-label, Multicenter, Single-Arm|This is a single-arm intervention where patients will receive concurrent therapy with BV+CHEP \[(brentuximab vedotin; 1.8 mg/kg IV, on D1 every 21 days) (cyclophosphamide 750 mg/m\^2 on D1; doxorubicin 50 mg/m\^2 on D1, etoposide 100 mg/m\^2 IV infusion on D1-3; prednisone 100 mg orally once daily on D1-5; cycle length every 21 days)\] for 2 to 6 cycles of induction therapy. After 6 cycles of BV + CHEP, responders (CR, PR or SD) who are not eligible for BMT and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV, every 21 days) until disease progression, withdrawal due to toxicity or death.
62189761|NCT04849377|EXPERIMENTAL|Group II - 54 Gy/200mg/m2|Patient Characteristics: \<20 Pack-Years, HPV16, OP, T1-T2, N1-N2b, T3 N0-N2b RT 5 days per week for 6 weeks and Cisplatin weekly for 6 weeks
62571784|NCT00550043|EXPERIMENTAL|Cohort 1: Treatment Group A|INCB018424 15 mg twice daily (BID) or matching placebo
62571785|NCT00550043|EXPERIMENTAL|Cohort 2: Treatment Group B|INCB018424 5 mg BID or matching placebo
62571786|NCT00550043|EXPERIMENTAL|Cohort 2: Treatment Group C|INCB018424 25 mg BID or matching placebo
62571787|NCT00550043|EXPERIMENTAL|Cohort 2: Treatment Group D|INCB018424 50 mg once daily (QD) or matching placebo
62571788|NCT00550043|PLACEBO_COMPARATOR|Placebo|Matching placebo, oral
62571789|NCT05106296|EXPERIMENTAL|Treatment Regimen|Patients will be treated with the 4-drug chemo-immunotherapy regimen. Cycles are a minimum of 28 days.
62571790|NCT00838656|EXPERIMENTAL|Arm I|Patients receive carboplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo treatment with paclitaxel and may also receive 6 more courses of neoadjuvant chemotherapy. Patients may then undergo surgery. After surgery, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62571791|NCT00838656|EXPERIMENTAL|Arm II|Patients receive carboplatin IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo treatment with paclitaxel and may also receive 6 more courses of neoadjuvant chemotherapy. Patients may then undergo surgery. After surgery, patients receive paclitaxel IV over 3 hours and gemcitabine hydrochloride IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62571792|NCT05737745|NO_INTERVENTION|Usual care|Endometrial cancer survivors will receive standard survivorship care including a one-time educational newsletter about survivorship physical activity and nutrition recommendations. Fitbits will be given to track physical activity.
62571793|NCT05737745|EXPERIMENTAL|FitEx-ECS|Endometrial cancer survivors and their support team members (as a group of one survivor and their team) will complete the FitEx-ECS intervention program, with a focus on walking. Fitbits will be given to track physical activity.
62571794|NCT05737745|EXPERIMENTAL|FitEx-ECS+ Yoga|Endometrial cancer survivors and their support team members (as a group of one survivor and their team) will complete the FitEx-ECS+yoga intervention program, with a focus on postures, breathwork, and mindfulness. Fitbits will be given to track physical activity.
61977914|NCT00549302|ACTIVE_COMPARATOR|20 mg tadalafil|20 milligram (mg) tadalafil taken once a day
62004153|NCT05991102|EXPERIMENTAL|TAS-102 and Bevacizumab and radiofrequency electromagnetic field treatment|"Each treatment cycle with TAS-102 will be 28 days in duration.~One treatment cycle consists of the following:~* Days 1: Bevacizumab (5 mg/m2/dose) intravenous.~* Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5.~* Days 6 through 7: Recovery~* Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~* Days 13 through 28: Recovery~* Days 15: Bevacizumab (5 mg/m2/dose) intravenously.~Radiofrequency electromagnetic field treatment using the EHY-2030 device starts within the first week of systemic therapy 2 times weekly (60 min each) with an interval of at least 48h. A modulated electric field with a carrier radiofrequency 13.56 MHz will be generated."
62189762|NCT04849377|EXPERIMENTAL|Group III - 60 Gy/240 mg/m2|Patient Characteristics: 20-40 Pack-Years, Non-HPV16, Non-OP, T1-T2, N1-N2b, T3 N0-N2b RT 5 days per week for 6 weeks and Cisplatin weekly for 6 weeks
62571795|NCT04181476|OTHER|Topical products and Untreated areas|The subject will serve as their own control. Four different products will be tested.
62571796|NCT01882660|EXPERIMENTAL|Decitabine treatment|Treatment with decitabine
62571797|NCT01574365|EXPERIMENTAL|RTA402|
61977915|NCT00549302|ACTIVE_COMPARATOR|40 mg tadalafil|40 mg tadalafil tablet taken once a day
62571798|NCT01574365|EXPERIMENTAL|RTA402 Low|
62571799|NCT01574365|EXPERIMENTAL|RTA402 Medium-low|
62571800|NCT01574365|EXPERIMENTAL|RTA402 Medium-high|
62571801|NCT02767024|EXPERIMENTAL|Sodium Nitroprusside|Dose titration will start at 25 μg/min and increased by 25 μg every 5 minutes to maximal dose of 400 μg/min while maintaining SBP ≥ 90 mmHg. Every 5 minutes, the Pulmonary Capillary Wedge Pressure (PCWP), SBP will be measured. If PCWP \> 16 mmHg while maintaining SBP ≥ 90 mmHg, the investigator will proceed to titrate dose with the goal to achieve the target of PCWP ≤ 16 mmHg and Cardiac Index (CI) \> 2.2 L·min-1·m-2, or maximal infusion dose has been reached, whichever comes earliest. Continuous intravenous furosemide infusion dose will be maintained by protocol.
62571802|NCT02767024|ACTIVE_COMPARATOR|Dobutamine|Dose titration will start at 2.5 μg/kg/min and increased to doses of 5, 7.5 and 10 μg/kg/min (maximal dose). Every 30 minutes, the investigator will collect Pulmonary Artery (PA) blood samples for PA sat measurement to calculate Cardiac Output (CO) and CI by Fick. If CI ≤ 2.2 L·min-1·m-2, the investigator will proceed to titrate dose until CI \> 2.2 L·min-1·m-2 or maximal infusion dose has been reached, whichever comes earliest. Continuous intravenous furosemide infusion dose will be maintained by protocol.
62004154|NCT02837887|EXPERIMENTAL|Group I (immediate treatment)|Patients undergo computerized cognitive behavior therapy consisting of 45-60 minute sessions once per week for 8 weeks. Patients also complete the PHQ-9 and GAD7 at weeks 1, 3, 5, 7 and 8 and complete other questionnaires for 15-30 minutes each that assess psychosocial and physical symptoms.
62004155|NCT02837887|EXPERIMENTAL|Group II (wait-list)|Patients are placed on an 8-week wait-list and then undergo computerized cognitive behavior therapy and receive questionnaires as in Group I.
62004156|NCT00494494|ACTIVE_COMPARATOR|Standard Treatment|topical antibiotic for 10 days and a topical corticosteroid for 1 month
62004157|NCT00494494|EXPERIMENTAL|Nepafenac|1 drop per study eye three times per day for 30 days in addition to standard care
62004158|NCT00458484|EXPERIMENTAL|Series 1: Stereotactic radiosurgery|Series I: Radiation will be delivered in 4 fractions. The initial dose level will be 6 Gy per fraction to a total dose of 24 Gy in 4 fractions. Doses will be escalated at 2 Gy per fraction increments to 12 Gy per fraction to a total dose of 48 Gy.
62004159|NCT00458484|EXPERIMENTAL|Series 2: Stereotactic radiosurgery|Series II: The initial dose level will be 48 Gy to the target volume (tumor) in 3 fractions of 16 Gy per fraction. If acute toxicity is acceptable, then the next four patients will be escalated to 54 Gy in 3 fractions of 18 Gy. Finally if a dose limit has not been reached, the last group of four patients will be treated to 60 Gy in 3 fractions of 20 Gy each.
62004160|NCT02402452|EXPERIMENTAL|Normal Renal Function|Participants will receive a single dose of voxilaprevir on Day 1.
62004161|NCT02402452|EXPERIMENTAL|Severe Renal Impairment|Participants will receive a single dose of voxilaprevir on Day 1.
62004162|NCT04505020|EXPERIMENTAL|3D Print + Conventional imaging|Patients in this group allocation will receive a 3D reconstruction of their hip in addition to conventional preoperative imaging (X-ray, CT, and MRI) only for the use of pre-operative and intra-operative planning for their hip arthroscopy (FAI) procedure.
62004163|NCT04505020|OTHER|Conventional Imaging|Patients in this group allocation will receive conventional preoperative imaging (X-ray, CT, and MRI) only for the use of pre-operative and intra-operative planning for their hip arthroscopy (FAI) procedure.
62004164|NCT04516122||Observational (biospecimen collection, DXA scan)|Patients undergo collection of blood samples after starting immunotherapy and then at 6 and 12 months. Patients also undergo DXA scan over 5-10 minutes after starting immunotherapy and at 12 months.
62004165|NCT05472259|ACTIVE_COMPARATOR|Arm A NALIRI|"Cycle length: 14 days~Day 1:~* Leucovorin: 400 mg/m² IV - Dilute in 250 mL DSW and administer over two hours~* Liposomal irinotecan (FBE): 70 mg/m² IV\* - Dilute in 500 mL DSW and administer over 90 min~* 5 FU: 2400 mg/m² IV - Dilute in 500 to 1000 mL 0,9% NS of DSW and administer as a continuous IV infusion over 46 hours. To accommodate an ambulatory pump for outpatient treatment can be administered undiluted (50 mg/mL) or the total dose diluted in 100 to 150 mL NS.~  * Patients who are known to be homozygous for UGT1A1\*28 should start treatment with 50 mg/m2 ONIVYDE. If they do not encounter drug related toxicities during the first cycle of therapy (started at a reduced dose of 50 mg/m2), they may have the dose of ONIVYDE increased to a dose of 70 mg/m2 in subsequent cycles based on individual patient tolerance."
62779591|NCT06344156|EXPERIMENTAL|Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy|(1)8 cycles of Gemcitabine +capecitabine (Gemcitabine d1,8 ,Capecitabine d1-14 q3w）；（2） two 200 mg intravenous dose of tislelizumab (d1,q3w)（3）five intravenous doses of neoantigen vaccines given as priming doses(d1,8,22,36,50）and two booster dose(d80,d110)
62189763|NCT04849377|EXPERIMENTAL|Group IV - TPF Induction followed by 60 Gy and Carboplatin AUC 1.5|Patient Characteristics: 20-40 Pack-Years, Non-HPV16, Non-OP, T4, N2c, \>3 nodes, ENE, or Matted Nodes Induction Therapy: Cisplatin, Docetaxel, Fluorouracil followed by RT 60 GY + Carboplatin AUC 9.0 Docetaxel every 21 days for 3 cycles, Cisplatin every 21 days for 3 cycles, Fluorouracil continuous infusion over 4 days (every 21 days for 3 cycles). Followed by RT 5 days per week for 6 weeks and Carboplatin weekly for 6 weeks.
62189764|NCT03662646||IBD patients|
62189765|NCT03662646||Healthy controls|
62189766|NCT01289210|OTHER|VTX-2337 plus radiation|
62396479|NCT04136769|EXPERIMENTAL|Intervention|"After trial enrolment, patients undergo visceral debranching.~After visceral debranching, patients proceed to neoadjuvant chemotherapy. The therapy as such is not a formal part of the trial protocol. The specific chemotherapy regimen and its duration are decided individually by treating physicians.~Tumor resection should be performed two to four weeks after completion of chemotherapy. Prior to resection, re-staging and verification of vascular reconstruction patency are carried out. The specific procedure for tumor resection and intestinal tract reconstruction is at the choice of the treating surgeon. It should follow oncological principles and aim at complete removal of the tumor and regional lymph nodes. Usually, resection will be done as pancreatoduodenectomy with or without distal gastrectomy (Whipple's procedure or pylorus-preserving Whipple's procedure), distal pancreatectomy with splenectomy, or total pancreatectomy with splenectomy."
62189767|NCT05295394|EXPERIMENTAL|single arm|dolutegravir 50 mg QD plus lamivudine 300 mg QD
62189768|NCT02416245|EXPERIMENTAL|Test beverage powder|Test beverage powder is fortified with micronutrients and Bacopa monnieri extract. Each sachet contains 32g of treatmemt product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
62396480|NCT02345902|EXPERIMENTAL|Haloperidol and non-pharmacologic|"Haloperidol 1.25mg PO q. d. during nine days~Non-pharmacologic measures:~A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)"
62396481|NCT02345902|ACTIVE_COMPARATOR|Placebo and non-pharmacologic|"Placebo 1.25 mg PO q.d during nine days.~Non-pharmacologic measures:~A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)"
62396482|NCT00508872|EXPERIMENTAL|FOLFOX-B|FOLFOX-B: 5-Fluorouracil 400 mg/m\^2 IV + Bevacizumab 5 mg/kg IV + Leucovorin 400 mg/m\^2 IV + Oxaliplatin 85 mg/m\^2 IV
62779592|NCT03504631||Breast cancer patients on tamoxifen|Patients currently on treatment with tamoxifen for at least 4 months.
62189769|NCT02416245|PLACEBO_COMPARATOR|Control beverage powder|Control beverage powder is the non-fortified isocaloric powder i.e. without micronutrients and Bacopa Monnieri extract. Each sachet contains 32g of placebo product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
62189770|NCT02339545||All Enrolled Subjects|All subjects will receive Coronary Flow Reserve (CFR) measurements post successful orbital atherectomy treatment and stenting.
62189771|NCT01656213|EXPERIMENTAL|visual-feedback handgrip exercise|Subjects allocated to treatment will be trained in the laptop-based exercise that takes 20 minutes/session. Subjects will be encouraged to perform the exercise 2-3 times per dialysis session
62189772|NCT01656213|NO_INTERVENTION|Control Arm|"60 similar ESRD stroke patients will be randomly assigned to the non-intervention arm. These patients will receive standard advice during dialysis (rest or gentle activity, e.g. reading).~Note that both groups of patients will also receive standard multidisciplinary rehabilitation care following a stroke, including therapy sessions at times other than receiving dialysis"
62189773|NCT01266018|EXPERIMENTAL|Cohort 1: Sensitive Disease|"Cohort 1 comprised subjects with sensitive disease, defined as subjects who were treated with 1 previous line of chemotherapy and maintained an appropriate response for 90 days or more. Subjects received 4 administrations of ADI-PEG 20 (320 IU/m\^2) followed by 1 week of follow-up in each treatment cycle."
61977916|NCT02581449|EXPERIMENTAL|omega-3 group|omega-3 soft gelatin capsules 1000 mg (500mg EPA+250mg DHA)once daily for four months
62189774|NCT01266018|EXPERIMENTAL|Cohort 2: Refractory Disease|"Cohort 2 comprised subjects with refractory disease, defined as subjects who either (a) were treated with 1 previous line of chemotherapy and either had no response or progressed \< 90 days after completing treatment or (b) required third-line therapy, i.e., had completed 2 previous lines of chemotherapy, regardless of response. Subjects received 4 administrations of ADI-PEG 20 (320 IU/m\^2) followed by 1 week of follow-up in each treatment cycle."
62571803|NCT05487443|EXPERIMENTAL|Chemotherapy combined with immunotherapy|Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors for first-line treatment of advanced biliary malignancies
62571804|NCT06325735||full term pregnancy|"Total Participants: The study included full-term pregnant women.~Exclusion Criteria: Participants were carefully selected, excluding those with specific conditions that could confound the study results. These conditions included gestational and pregestational diabetes, chronic hypertension, gestational hypertension, pre-eclampsia/eclampsia, intrauterine fetal growth restriction, preterm delivery, multiple pregnancies, and prenatally detected fetal abnormalities."
62189775|NCT04833478|EXPERIMENTAL|Application|Measuring anxiety level of the patients using Facial Image Scale and Pulse Oximeter
62189776|NCT04833478|EXPERIMENTAL|Dental Song|Measuring anxiety level of the patients using Facial Image Scale and Pulse Oximeter
62189777|NCT04833478|EXPERIMENTAL|Tell Show Do|Measuring anxiety level of the patients using Facial Image Scale and Pulse Oximeter
62189778|NCT02868671|EXPERIMENTAL|real acupuncture|Participants will receive treatment four times a week for two weeks and three times a week for two weeks. Participants will be treated with major points: Yintang, Du20 (Bai Hui), LI4 (He Gu), LR3 (Tai Chong), ST36 (Zusanli) (front treatment) or GB20 (Feng Chi), SP6 (Sanyinjiao), BL15 (Xin Shu), BL18 (Gan Shu), BL23 (Shen Shu) (back treatment). The position of the treatment will alternate between sessions such that the first session will be on the back, with the next session on the front. In addition to the 5 required points, acupuncturist will be allowed to choose 1-3 more points. The supplemental points may be chosen from the following: HT7 (Shenmen), PC6 (Neiguan), SI3 (Hou Xi), RN6 (Qi Hai), KI 3 (Taixi), KI 6 (Zhao Hai), SP10 (Xue Hai), BL14 (Jue Yin Shu), BL17 (Ge Shu), BL20 (Pi Shu).
62189779|NCT02868671|SHAM_COMPARATOR|sham acupuncture|Participants randomized to sham acupuncture will receive a 'placebo' acupuncture session. For sham acupuncture, Streitberger needles, which acted like stage dagger with the shaft of the needle retracting into the handle, were placed at non-acupuncture points with the same number of acupuncture points in the VA group. The needle guiding tube will be used to create sensations that mimic needle manipulation.
62571805|NCT05917184||Neurological Outpatients|Participants in this group will be recruited from the outpatient clinical population at participating MGNet sites. Treating physicians will make the initial determination of patients' potential eligibility to participate in the study.
62571806|NCT02484846|EXPERIMENTAL|60% TIB|Participants were to spend 60% of their normal time in bed on the night prior to the second visit.
62571807|NCT02484846|EXPERIMENTAL|70% TIB|Participants were to spend 70% of their normal time in bed on the night prior to the second visit.
62571808|NCT02484846|EXPERIMENTAL|80% TIB|Participants were to spend 80% of their normal time in bed on the night prior to the second visit.
62571809|NCT02484846|EXPERIMENTAL|90% TIB|Participants were to spend 90% of their normal time in bed on the night prior to the second visit.
62571810|NCT02484846|ACTIVE_COMPARATOR|100% TIB|Participants were to spend 100% of their normal time in bed (i.e., no change) on the night prior to the second visit.
62571811|NCT02484846|EXPERIMENTAL|115% TIB|Participants were to spend 115% of their normal time in bed on the night prior to the second visit.
62571812|NCT02484846|EXPERIMENTAL|130% TIB|Participants were to spend 130% of their normal time in bed on the night prior to the second visit.
62571813|NCT03800199|EXPERIMENTAL|Perceptive Rehabilitation (PR-group)|Perceptive rehabilitation group will receive a treatment that, as described by on Paolucci et al. (2015). This treatment will include small latex cones with different resistance. In each session there will be over 100 cones will be placed on a rigid wood with using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks. There will be in total 16 sessions.
62571814|NCT01571219|EXPERIMENTAL|CT-P13|
62571815|NCT03792399|EXPERIMENTAL|Immediate feedback counseling|Professional CGM calibrate blood glucose via a glucsoe-oxidase-impregnated membrane during a 5 day period. The patient wearing professional CGM is randomized to immediate feedback after data downloaded into computer.
62571816|NCT03792399|OTHER|Delayed feedback counseling|Professional CGM calibrate blood glucose via a glucsoe-oxidase-impregnated membrane during a 5 day period. The patient wearing professional CGM is randomized to delayed feedback (standard care, i.e., CGM graphs interpretation at scheduled 3 months outpatient visit).
62571817|NCT04508257|EXPERIMENTAL|Investigational Formula (Stage 1&2)|Investigational formula contains DHA，ARA and enriched whey protein (source of milk fat globule membrane) to support the healthy growth and Cognitive development of infants.
61977917|NCT02581449|PLACEBO_COMPARATOR|placebo group|empty soft gelatin capsules with matched size, color and shape once daily for four months
62189780|NCT02868671|NO_INTERVENTION|No Intervention|All participants in this study will not receive interventions.
62189781|NCT05284955|EXPERIMENTAL|CardioMEMS HF System group|Pharmacological heart failure treatment guided by an implanted wireless pulmonary artery hemodynamic monitor (CardioMEMS HF system)
62189782|NCT05284955|ACTIVE_COMPARATOR|Standard of care|Standard heart failure medical treatment
62189783|NCT00443209|EXPERIMENTAL|Telcagepant 280 mg/300 mg|Participants receive telcagepant 300 mg soft gel capsules or telcagepant 280 mg tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of telcagepant, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of telcagepant per month for up to 18 months.
62571818|NCT04508257|ACTIVE_COMPARATOR|Control formula (Stage 1&2)|Control formula have comparable macronutrients and micronutrients, but does not contain DHA，ARA and MFGM.
62571819|NCT04508257|OTHER|Breast feeding|Breast fed of human milk
62571820|NCT06478472|EXPERIMENTAL|OR|Orelabrutinib in combination with rituximab
62189784|NCT00443209|ACTIVE_COMPARATOR|Rizatriptan 10 mg|Participants receive rizatriptan tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of rizatriptan, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of rizatriptan per month for up to 18 months.
62189785|NCT01598103|PLACEBO_COMPARATOR|Placebo to SAF312|
62189786|NCT01598103|EXPERIMENTAL|SAF312|
62189787|NCT01354249|PLACEBO_COMPARATOR|water|Patients will receive water 3h before operation in the same volume of the study group
62189788|NCT01354249|EXPERIMENTAL|whey protein plus carbohydrate|The CHO-P group will receive 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
62189789|NCT06028165|ACTIVE_COMPARATOR|CAG group|Patients who underwent coronary artery bypass grafting based on conventional coronary angiography (quantitative coronary angiography)
62189790|NCT06028165|ACTIVE_COMPARATOR|CT-FFR group|Patients who underwent coronary artery bypass grafting based on cardiac computed tomography-derived fractional flow reserve
62189791|NCT06371586|EXPERIMENTAL|Experimental arm|Neoadjuvant Chemotherapy Plus Anti-angiogenesis Therapy and Immunotherapy
62189792|NCT01718951|ACTIVE_COMPARATOR|golimumab|golimumab 50mg subcutaneous every 4 weeks
62189793|NCT01718951|ACTIVE_COMPARATOR|pamidronate|Pamidronate (60mg) intravenously every 4 weeks
62189794|NCT03045809||Women at risk of urogenital infections|Adult women living in the city of Kigali who are at high risk of HIV/urogenital infections (defined as having had more than one sexual partner in the last 12 months OR having been treated for a sexually transmitted infection (STI) in the last 12 months) regardless of the presence of current urogenital symptoms. Women who are known to be HIV-positive and/or pregnant are not excluded. All eligible women will be offered urogenital infection point-of-care tests.
62396483|NCT04963517|EXPERIMENTAL|Exercise therapy|"8 weeks personalized, multi-modal exercise with focus on lower extremity~* Initial consultation with recommendations for general physical activity~* Brochure with exercise recommendations~* 2x per week multi-modal group-based and supervised exercise (endurance, strength, mobility, coordination)~* week 1 and 2 supervised, week 3 and 4 partially supervised, week 5 and 6 only one supervised session, week 7 and 8 last two sessions supervised"
62571821|NCT04291287||Triple antithrombotic therapy|patients taking Triple antithrombotic therapy (aspirin and a P2Y12 inhibitor, in addition to either a DOACs or warfarin/acenocumarol)
62571822|NCT04291287||Dual antithrombotic therapy|patients taking Dual antithrombotic therapy (aspirin or P2Y12 inhibitor in addition to either a DOACs or warfarin/acenocumarol)
62571823|NCT01964482|EXPERIMENTAL|Strength training|Supervised strength training daily during hospitalization and 3 times per week for 4 weeks after discharge in the participant's home
62189795|NCT05141396|EXPERIMENTAL|Intervention - Telehealth- enabled support plus usual audit and feedback for SAT/SBT adherence|Usual audit and feedback + telehealth-enabled support
62189796|NCT05141396|ACTIVE_COMPARATOR|Control - Usual audit/feedback for SAT/SBT adherence only|Usual audit and feedback
62189797|NCT02716363|EXPERIMENTAL|Device : Rotablator|We compare in-hospital and long-term efficacy or safety of elective Rotational Atherectomy versus bailout Rotational Atherectomy and low-volume operator versus high-volume operator in patients with severe calcified lesions treated.
62189798|NCT01335412||IXIARO exposed group|Male and female active duty U.S. military personnel ≥ 17 years of age who either received at least one dose of IXIARO
62189799|NCT01335412||Comparison group|Male and female active duty U.S. military personnel ≥ 17 years of age who either received at least one dose of JE-VAX
62189800|NCT03372590|EXPERIMENTAL|NICU-based rehabilitation bundle|Patients identified to be at high risk for cerebral palsy will be enrolled after parental consent is obtained to the NICU rehabilitation program. This program consists of maternal-driven evidence based intervention that include: vocal soothing, scent exchange, comforting touch, kangaroo care, and infant massage. These intervention will be provided at GA-appropriate intervals.
62189801|NCT03372590|OTHER|Standard of care|Infants not participating in the intervention study will be provided with standard or care. Interventions include kangaroo care, physical therapy and infant massage provided by NICU staff.
62396484|NCT04963517|ACTIVE_COMPARATOR|Information group|"* Initial consultation with recommendations for general physical activity~* Brochure with exercise recommendations."
62571824|NCT01964482|NO_INTERVENTION|Usual care|Usual care
62571825|NCT06370689|ACTIVE_COMPARATOR|NRM - Non-rebreather mask in children 6-12 yrs|Non-rebreather mask in children 6-12 yrs
62779593|NCT06355219||Metabolic Surgery|Patients aged 18 years to 75 years, who had a BMI ≥30 and T2DM at the time of surgery, and who underwent Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) at Cleveland Clinic Health System(CCHS) hospitals in Florida and Ohio between January 1, 2010, and December 31, 2017.
62189802|NCT05479474|EXPERIMENTAL|Platelet rich plasma treatment arm|After consent in obtained, the patient will undergo a blood draw (12 tsp) to prepare the PRP infusion. The use of a centrifuge and an Arteriocyte Magellan kit are necessary for the PRP preparation. After injection of local anesthesia, PRP will be injected into each testicle.
62779594|NCT06355219||GLP-1 RAs|Non-surgical patients at CCHS who at randomly assigned index dates had T2DM and obesity, follow-up of at least 30 days after the assigned index date, did not meet any of the exclusion criteria for surgical patients, and did not have metabolic surgery prior to the assigned index date, who continuously received GLP-1 RA for ≥2 years, defined by prescription order for GLP-1 RA placed between January 1, 2010, and December 31, 2017, as well as ≥ 3 documented prescription fills within 1 year before their assigned index date and ≥ 3 fills within 1 year after their index date.
62779595|NCT00952887|EXPERIMENTAL|ACE-031|8 dosing groups
62189803|NCT06487689||Hemodyalisis|
62189804|NCT06487689||Peritoneal dyalisis|
62396485|NCT05340465|ACTIVE_COMPARATOR|Group 1. Oral iron|Oral iron is started on day 7 of life if baby is feeding 100 mL/kg/day. Iron supplements of up to 12 mg/kg/day are given based on CBC, retic, ret-hgb, serum ferritin and zinc protoporphyrin to heme ratio (ZnPP/H). Iron supplements are adjusted every 2 weeks following iron studies.
62396486|NCT05340465|EXPERIMENTAL|Group 2|Infants randomized to this arm will receive Darbe 10 mcg/kg q week started on day 3 of life. In addition, beginning on day 7, they will receive LMW-ID: 10 mg/kg x 1, retreat if ferritin \< 76 mcg/L
62396487|NCT05340465|EXPERIMENTAL|Group 3|Infants randomized to this arm will receive Darbe 10 mcg/kg q week started on day 3 of life. In addition, beginning on day 7, they will receive LMW-ID: 20 mg/kg x 1, retreat if ferritin \< 76 mcg/L
62396488|NCT05340465|EXPERIMENTAL|Group 4|Infants randomized to this arm will receive Darbe 10 mcg/kg q week started on day 3 of life. In addition, beginning on day 7, they will receive FMX: 10 mg/kg x 1, retreat if ferritin \< 76 mcg/L
62396489|NCT05340465|EXPERIMENTAL|Group 5|Infants randomized to this arm will receive Darbe 10 mcg/kg q week started on day 3 of life. In addition, beginning on day 7, they will receive FMX: 20 mg/kg x 1, retreat if ferritin \< 76 mcg/L
62779596|NCT00952887|PLACEBO_COMPARATOR|Placebo|
62189805|NCT06487689||Pre-dyalisis|
62189806|NCT04066517|EXPERIMENTAL|Open Label|Non-randomized, open label clinical trial that intends to treat with SBRT 15 patients with refractory VT.
62189807|NCT03866369|EXPERIMENTAL|Experimental|IMP Under investigation
62189808|NCT03866369|PLACEBO_COMPARATOR|Placebo to Match|
62189809|NCT04404309||Population 1|Any patient admitted to a psychiatric ward with a clinical diagnosis of (unipolar) major depression
62189810|NCT04404309||Population 2|Any patient with a clinical diagnosis of a moderate or severe unipolar depressive disorder with suicidal tendencies that persist for at least 48 hours after admission
62779597|NCT04611451|EXPERIMENTAL|whole body vibration group|Patients in the WBV exercise group; 24 sessions of TVT exercise 3 days a week (with at least 1 day of rest between each session) was performed under the supervision of a physician for a total of 8 weeks. Patients in the WBV exercise group were also shown a classic lumbar home exercise program and they were asked to apply for 8 weeks
62779598|NCT04611451|ACTIVE_COMPARATOR|exercise|The second group (control) only received classical lumbar home exercise program.
62189811|NCT04404309||Population 3|Patients with moderate or severe unipolar depressive episodes validated by research interviews and suicidal tendencies that persist for at least 48 hours after admission who will be followed up for 6 months
62189812|NCT02121912|EXPERIMENTAL|FPH Pilairo Q CPAP mask|The Sleep Technician will fit the FPH Pilairo Q CPAP mask to the participant.
62189813|NCT02121912|ACTIVE_COMPARATOR|Any other market released nasal or nasal-pillow CPAP mask|The Sleep Technologist will fit the participant with any market released nasal or nasal-pillow CPAP mask
62189814|NCT06121804||Patients with organ transplantation|Patients who underwent SOTs between 2002 and 2013, specifically, kidney (ICD-9-CM code V42.0), liver (ICD-9-CM code V42.7), or lung (ICD-9-CM code V42.6) transplants.
62189815|NCT06121804||Patients without organ transplantation|The general patients were enrolled as the comparison. We used propensity score matching (PSM) to establish a matched cohort.
62189816|NCT04367207||Adult patients with COVID-19 referred to intensive care|Prospective observational cohort study of adult (≥18 years) patients referred to intensive care or high-care units in Africa with suspected or known COVID-19 infection in Africa
62189817|NCT03927898|EXPERIMENTAL|SBRT+Toripalimab|Participants received SBRT (BED\>80Gy) to oligometastatic lesions and then receive Toripalimab (240mg)/q3w till progression of disease.
62189818|NCT02559310|EXPERIMENTAL|Lefamulin|Intravenous lefamulin with potential step-down to oral lefamulin
62189819|NCT02559310|ACTIVE_COMPARATOR|Moxifloxacin +/- Linezolid|Intravenous moxifloxacin with potential step-down to oral moxifloxacin +/- linezolid
62189820|NCT01306006|ACTIVE_COMPARATOR|MV-for-all|Measles vaccine provided to all children aged 9 months -3 years of age
62189821|NCT01306006|NO_INTERVENTION|National policy|Measles vaccine provided to children aged 9-11 months, if there are sufficient children to open a measles vaccine vial.
62189822|NCT03282136|ACTIVE_COMPARATOR|incretin arm|T2DM with HF treated by CRTd participants will be assigned prospectively to an intervention (incretin therapy plus conventional hypoglycemic drug therapy) according to study protocol to evaluate the effect of the drug on cardiac deaths, all cause deaths, and hospital admission for heart failure.
62571826|NCT06370689|ACTIVE_COMPARATOR|BVM with PEEP in children 6-12 yrs|Bag valve mask with positive end-expiratory pressure (PEEP) in children 6-12 yrs
62779599|NCT04793334||Obese + OSA|"Inclusion Criteria:~* Men and women~* Ages \>= 18-65 years old~* BMI 35 kg/m2-above~* Scheduled for sleeve gastrectomy (bariatric surgery)~* OSA identified by PSG~Exclusion Criteria:~* Any cardiovascular, pulmonary or renal disease other than well-controlled hypertension or asthma.~* Pregnancy~* Currently smoking~* Any respiratory disorder other than OSA or well controlled asthma~* contraindication to MRI"
62004166|NCT05472259|EXPERIMENTAL|Arm B NALIRINOX|"Cycle length: 14 days~Day 1:~* Oxaliplatin 60 mg IV - Dilute in 500 mL D5W and administer over two hours (prior to leucovorin). Shorter oxaliplatin administration schedules (eg. 1mg/m2 per minute) appear to be safe.~* Leucovorin: 400 mg/m² IV - Dilute in 250 mL DSW and administer over two hours (after oxaliplatin)~* Nanoliposomal irinotecan (FBE): 50 mg/m² IV - Dilute in 500 mL D5W and administer over 90 min~* 5 FU: 2400 mg/m² IV - Dilute in 500 to 1000 mL 0,9% NS of DSW and administer as a continuous IV infusion over 46 hours. To accommodate an ambulatory pump for outpatient treatment can be administered undiluted (50 mg/mL) or the total dose diluted in 100 to 150 mL NS."
62004167|NCT02043015|OTHER|Comprehensive HIV prevention services|A comprehensive package of HIV prevention services, including condom choices, Condom-compatible lubricant choices, Couples HIV counseling and testing (CVCT), Staff and provider MSM and LGBT sensitization training, HIV Testing and Risk-reduction counseling, Linkage to care, Pre-exposure prophylaxis with FTC/TDF
62189823|NCT03282136|PLACEBO_COMPARATOR|conventional hypoglycemic drug arm|T2DM with HF treated by CRTd participants will be assigned prospectively to placebo comparator (placebo plus conventional hypoglycemic drug therapy) according to study protocol to evaluate the effect of the drug on cardiac deaths, all cause deaths, and hospital admission for heart failure.
62189824|NCT00791375|EXPERIMENTAL|Physical Activity Intervention|Participants in this arm will be given access to a website designed to help them increase their levels of physical activity
62004168|NCT01430585|EXPERIMENTAL|A|
62004169|NCT01430585|EXPERIMENTAL|B|
62004170|NCT01430585|ACTIVE_COMPARATOR|C|
62189825|NCT00791375|PLACEBO_COMPARATOR|Cancer Website Control Group|Participants in this arm will be given information on cancer-related websites (that do not provide information on physical activity)
62189826|NCT00459914|ACTIVE_COMPARATOR|1 CPAP|Nasal continuous positive airway pressure
62189827|NCT00459914|NO_INTERVENTION|2|Pharmacological treatment alone
62571827|NCT06370689|ACTIVE_COMPARATOR|BVM without PEEP in children 6-12 yrs|Bag valve mask without positive end-expiratory pressure (PEEP) in children 6-12 yrs
62571828|NCT06370689|ACTIVE_COMPARATOR|NRM - Non-rebreather mask in normal weight adults|Non-rebreather mask in normal weight adults
62571829|NCT06370689|ACTIVE_COMPARATOR|BVM with PEEP in normal weight adults|Bag valve mask with positive end-expiratory pressure (PEEP) in normal weight adults
62571830|NCT06370689|ACTIVE_COMPARATOR|BVM without PEEP in normal weight adults|Bag valve mask without positive end-expiratory pressure (PEEP) in normal weight adults
62571831|NCT06370689|ACTIVE_COMPARATOR|NRM - Non-rebreather mask in overweight/obese adults|Non-rebreather mask in overweight/obese adults
62004171|NCT06019975||Autoimmune Encephalitis patients|Patients with autoimmune encephalitis admitted to the centers, who underwent a brain FDG-PET during the course of their disease trajectory.
62004172|NCT05625477|EXPERIMENTAL|TNM002 low dose|Participants receive a single intramuscular injection of TNM002 with low dose on Day 1
62004173|NCT05625477|EXPERIMENTAL|TNM002 medium dose|Participants receive a single intramuscular injection of TNM002 with medium dose on Day 1
62004174|NCT05625477|EXPERIMENTAL|TNM002 high dose|Participants receive a single intramuscular injection of TNM002 with high dose on Day 1
62004175|NCT05625477|ACTIVE_COMPARATOR|Human Tetanus Immunoglobulin (HTIG)|Participants receive a single intramuscular injection of human tetanus immunoglobulin 250 IU on Day 1
62004176|NCT05625477|PLACEBO_COMPARATOR|Placebo|Participants receive a single intramuscular injection of placebo on Day 1
62004177|NCT00353366||Cohort Group|Subjects received two oral doses of the Rotarix vaccine at the age of 6 weeks
62004178|NCT04099862||ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
62004179|NCT04099862||EUS-BD|Endoscopic UltraSound Biliary Drainage
62004180|NCT06110676|EXPERIMENTAL|LZM012 Q4W|Patients receive 320mg of LZM012 treatment once every 4 weeks
62004181|NCT06110676|EXPERIMENTAL|LZM012 Q4W-Q8W|Patients receive 320mg of LZM012 treatment once every 4 weeks till 12th week, then once evey 8 weeks
62004182|NCT06110676|ACTIVE_COMPARATOR|Active control|Patients receive 300mg of secukinumab treatment once every 4 weeks
62004183|NCT02100891|EXPERIMENTAL|Allogeneic HCT + Donor NK Cell Infusion|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
62004184|NCT05984134|EXPERIMENTAL|Middle Dose|12 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
62004185|NCT05984134|EXPERIMENTAL|High Dose|12 hours after PCI: 1.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：1.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
62004186|NCT05984134|PLACEBO_COMPARATOR|Placebo|Patients in this treatment group will receive placebo respective. Continuous administration for 7 days.
62004187|NCT03429491|PLACEBO_COMPARATOR|Placebo|Protein-free, LC n-3 PUFA-free juice based supplement
62004188|NCT03429491|EXPERIMENTAL|Leucine-enriched protein|Juice based supplement containing leucine-enriched protein
62004189|NCT03429491|EXPERIMENTAL|Leucine-enriched protein + LC n-3 PUFA|Juice based supplement containing leucine-enriched protein and LC n-3 PUFA
62004190|NCT01945515|EXPERIMENTAL|Robot + anodal tDCS|Robotic-assisted gait training for 45 min after anodal tDCS on impaired motor cortex for 20 min
62396490|NCT05443802|EXPERIMENTAL|Experimental|Reduced dose of rapid-acting insulin of 0.05 IU/kg/h from randomization until resolution of DKA
62004191|NCT01945515|SHAM_COMPARATOR|Robot + sham tDCS|Robotic-assisted gait training for 45 min after sham tDCS on impaired motor cortex for 20 min
62004192|NCT03996785|ACTIVE_COMPARATOR|Urban|"Patients will go for a silent 60-minute walk in an urban setting. The walk will take place in the months of June, July, August and September between 10:00 to 11:00 am.~Participants will walk in groups of two to three participants accompanied by two research assistants trained in mental health (doctoral students in psychology). The urban walk will be located on Boulevard de la Vérendrye with large arteries with three to four lanes."
62396491|NCT05443802|OTHER|Control|Rapid-acting insulin dose of 0.10 IU/kg/h in accordance with usual recommendations until resolution of DKA
62004193|NCT03996785|EXPERIMENTAL|Nature|"Patients will go for a silent 60-minute walk in a nature park setting. The walk will take place in the months of June, July, August and September between 10:00 to 11:00 am.~Participants will walk in groups of two to three participants accompanied by two research assistants trained in mental health (doctoral students in psychology).~The nature walk will take place at Parc Angrignon, an area of 96 hectares, one of Montreal's largest green and biodiverse spaces with a forest of 20 000 trees and a pond surrounded by willow trees."
62004194|NCT06153290|EXPERIMENTAL|Genuine/real|15 participants receiving genuine/real chiropractic adjustment
62004195|NCT06153290|SHAM_COMPARATOR|Simulated/sham|"15 participants receiving simulated/sham adjustment"
62396492|NCT06066359|EXPERIMENTAL|Part A: Cell therapy with NY-ESO-1 TCR/IL-15 NK - INPATIENT|
62189828|NCT04292080|EXPERIMENTAL|Group TECFIDERA™|30 patients will receive oral administration of Dimethyl Fumarate (Tecfidera™) 120 mg twice a day for the first week and then 240 mg of Tecfidera twice a day for 51 weeks following approved standard treatment scheme.
62189829|NCT04292080|OTHER|No comparator|30 patients will receive no specific treatment (standard of care) up to 24 months following randomization.
62189830|NCT04912310|EXPERIMENTAL|Acute angle closure glaucoma|Argon laser peripheral iridoplasty
62189831|NCT03189147|EXPERIMENTAL|Biceps Tenodesis|Patients in this group will received biceps tenodesis intervention to address their labral lesion
62004196|NCT00623883|EXPERIMENTAL|1|All identified ACF eliminated by cold or hot colonoscopic biopsy forceps
62189832|NCT03189147|ACTIVE_COMPARATOR|Debridement|Patients in this group will received debridement intervention to address their labral lesion
62779600|NCT04793334||Obese without OSA|"Inclusion Criteria:~* Men and women~* Ages \>= 18-65 years old~* BMI 35kg/m2 and above~* Scheduled for sleeve gastrectomy (bariatric surgery)~* No OSA identified by PSG~Exclusion Criteria:~* Any cardiovascular, pulmonary or renal disease other than well-controlled hypertension or asthma.~* Pregnancy~* Currently smoking~* Any respiratory disorder other than OSA or well controlled asthma~* contraindication to MRI"
62779601|NCT00328861|EXPERIMENTAL|NK Cells + IL-2: Melanoma|Melanoma (skin cancer). Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7. Fludarabine 25 mg/m\^2 day intravenous on days -6 through -2. IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days. Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
62396493|NCT06066359|EXPERIMENTAL|Part A2: Cell therapy with NY-ESO-1 TCR/IL-15 NK - OUTPATIENT|
62004197|NCT00623883|SHAM_COMPARATOR|2|ACF quantified and observed, re-evaluated after one year
62004198|NCT04454450|EXPERIMENTAL|Imaged prior to primary debulking surgery|Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection. Concretely, in patients triaged to primary debulking surgery (PDS), PET/MRI will be obtained within 30 days preceding multi-region tissue collection at the time of PDS (already being done under IRB# 06-107).
62189833|NCT06074692|EXPERIMENTAL|Bone arm|Bone tumor subgroup (bone arm) includes high-grade osteosarcoma, chondrosarcoma, undifferentiated bone sarcoma and other rare bone sarcomas with complex genomic features..
62189834|NCT06074692|EXPERIMENTAL|Soft tissue arm|Soft tissue sarcoma subgroup (soft tissue arm) includes leiomyosarcoma, pleomorphic rhabdomyosarcoma, angiosarcoma, fibrosarcoma, epithelioid sarcoma, malignant peripheral nerve sheath tumor(MPNST) and other rare soft tissue sarcomas with complex genomic features.
62189835|NCT06074692|EXPERIMENTAL|UPS/DDLPS arm|Immune hot tumor subgroup (UPS/DDLPS arm) includes undifferentiated pleomorphic sarcoma (UPS), dedifferentiated liposarcoma (DDLPS).
62189836|NCT05167084|EXPERIMENTAL|Metyrapone And Hydrocortisone|During one of the study periods, subjects receive hydrocortisone 19.9 mg/d subcutaneously via a pump in a pulsed fashion (eight times/day) and metyrapone per os (starting with a dose of 500 mg/d, then the dose will be increased the next days until 2500mg/d is achieved).
62189837|NCT05167084|PLACEBO_COMPARATOR|Placebo|During the other study period, subjects receive placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion and the same dose of placebo tablets p.o instead of metyrapone.
62189838|NCT04454099||Fecal Occult Blood Test|People in this group will use four kind of fecal occult blood test, including quantitative and qualitative method, to detect Hb in stool before colonoscopy.
62189839|NCT03622255|OTHER|MINST|Minimally invasive non-surgical technique (MINST): Root instrumentation under local anesthesia using specific hand instruments (micro- curettes) and delicate piezon ultrasonic instruments in the area of intraosseous defect.
62189840|NCT03622255|ACTIVE_COMPARATOR|MINST with EMD|Minimally invasive non-surgical technique (MINST) with application of Enamel Matrix Derivative (EMD): Root instrumentation under local anesthesia using micro- curettes and delicate piezon ultrasonic instruments in the area of intraosseous defect. Experimental intervention by application of EDTA gel for 2 minutes on the root surface of the involved tooth, followed by rinsing with saline, drying and application of Enamel Matrix Derivative gel, to fill the defect.
62189841|NCT04652661|EXPERIMENTAL|Dexmedetomidine Group|30 children will be sedated with 2 μg/kg intranasal dexmedetomidine
62189842|NCT04652661|ACTIVE_COMPARATOR|Midazolam Group|30 children will be sedated with 0.3 mg/kg intranasal midazolam.
62396494|NCT06066359|EXPERIMENTAL|Part B: Cell therapy with NY-ESO-1 TCR/IL-15 NK - INPATIENT|
62396495|NCT06066359|EXPERIMENTAL|Part B2: Cell therapy with NY-ESO-1 TCR/IL-15 NK - OUTPATIENT|
62396496|NCT01708369|ACTIVE_COMPARATOR|Oseltamivir & Placebo|Oseltamivir 150 mg orally will be administered 15 minutes after subjects consume orange juice
62396497|NCT01708369|EXPERIMENTAL|Oseltamivir & Ethanol|Oseltamivir 150 mg and ethanol targeted to blood alcohol concentration 0.08 g/dl
62396498|NCT01708369|ACTIVE_COMPARATOR|Aspirin & Placebo|Aspirin 650 mg orally will be administered 15 minutes after subjects consume orange juice
62396499|NCT01708369|EXPERIMENTAL|Aspirin & Ethanol|Aspirin 650 mg and ethanol targeted to blood alcohol concentration 0.08 g/dl
62396500|NCT04739059|EXPERIMENTAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously
62396501|NCT04604067|EXPERIMENTAL|Arm with 4 cohorts|"Cohort A: MYD88 L265P and/or CD79A/B mutations at baseline Treatment: Acalabrutinib-R-CHOP for a total number of 6 cycles.~Cohort B, C D: Without MYD88 L265P and CD79A/B mutations at baseline:~Assignment of cohort B, C and D after 2 cycles of R-CHOP according to PET (Deauville score (DS)) and molecular response (MR) (\>2log10 reduction of ctDNA) results:~Cohort B: DS 4 and No MR Treatment: 2 cycles of acalabrutinib-R-CHOP. After PET3/ctDNA3: patients with DS 1-3 and no MR OR DS4 with MR will receive 2 additional cycles of acalabrutinb-R-CHOP and 2 cycles of acalabrutinib single agent.~Cohort C: DS 1-3 and MR Treatment: 2 additional cycles of R-CHOP (4x RCHOP in total) followed by 2 cycles of rituximab single agent.~Cohort D: DS 4 and no MR OR DS 1-3 and MR Treatment: 4 additional cycles of RCHOP (6 cycles in total).~Follow up: Patients off treatment will be followed for 5 years."
62004199|NCT04454450|EXPERIMENTAL|Imaged pre/postneoadjuvant chemotherapy (NACT)|In patients triaged to neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS), PET/MRI will be obtained at two time points, i.e. first within 30 days preceding NACT/ multi-region laparoscopic tissue sampling (already being done under IRB# 06-107) and, second, any time after completion of NACT and before multi-region tissue collection at the time of interval debulking surgery (already being done under IRB# 06-107).
62779602|NCT00328861|EXPERIMENTAL|NK Cells + IL-2: Renal Cell|Renal cell (kidney cancer). Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7. Fludarabine 25 mg/m\^2 day intravenous on days -6 through -2. IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days. Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
62571832|NCT06370689|ACTIVE_COMPARATOR|BVM with PEEP in overweight/obese adults|Bag valve mask with positive end-expiratory pressure (PEEP) in overweight/obese adults
62571833|NCT06370689|ACTIVE_COMPARATOR|BVM without PEEP in overweight/obese adults|Bag valve mask without positive end-expiratory pressure (PEEP) in overweight/obese adults
62189843|NCT05363332||COVID-19 Cohort|Patients with a diagnosis of moderate or severe pneumonia or ARDS secondary to COVID-19.
62396502|NCT06479850|EXPERIMENTAL|Treatment Group|In this arm, participants would participate in in an intervention program that uses character strengths to improve job maintenance skills in young adults.
62004200|NCT05459636|ACTIVE_COMPARATOR|High-resistance inspiratory muscle strength training|Participants will perform high-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
62004201|NCT05459636|SHAM_COMPARATOR|Very-low resistance inspiratory muscle strength training|Participants will perform very-low-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
62189844|NCT05363332||Non COVID-19 Cohort|Patients with a diagnosis of moderate or severe pneumonia or ARDS not secondary to COVID-19.
62189845|NCT05213442|OTHER|All inpatients in Vinatier psychiatric Hospital|All hospitalized patients can potentially be recruited. They will benefit from the usual clinical and paraclinical examinations as part of their hospitalization diagnostic work-up. For the determination of biological analyses, a blood sample will be taken following inclusion as well as a Fibroscan examination.
62396503|NCT06479850|NO_INTERVENTION|Control Group|In this arm, participants are services as usual and will participate in their regular activities.
62571834|NCT03240068|EXPERIMENTAL|Angiotensin-(1-7)|Subjects will receive intravenous infusion of five ascending doses of angiotensin-(1-7). The doses are: 1, 2, 4, 8, and 12 ng/kg/min. Each dose will be maintained for 10 minutes, for a total infusion period of 50 minutes.
62189846|NCT01550055|EXPERIMENTAL|CMAB009 plus Irinotecan|
62189847|NCT01550055|ACTIVE_COMPARATOR|Irinotecan-only and sequential-CMAB009|
62189848|NCT06371469|EXPERIMENTAL|Experimental|"PHeBAC is an acronym that defines multi-interventions to health behaviour against cancer.~The intervention group will receive PHeBAC with multiple interventions including education, guidance, counseling, and case management in line with the 12 European Codes Against Cancer to reduce cancer risk. The PHeBAC interventions will be 8 weeks long, with two face-to-face and three telephone interviews.~The first and the 4th week will be face-to-face with two different sessions of 45 minutes each; the 2nd, 6th, and 8th weeks will be phone calls of 15 minutes each."
62571835|NCT03240068|PLACEBO_COMPARATOR|Saline|Subjects will receive intravenous infusion of saline that is matched in volume to the angiotensin-(1-7) arm. Saline infusion will be maintained for a total infusion period of 50 minutes.
62571836|NCT01692041|ACTIVE_COMPARATOR|Ivy leave|active therapy arm with Ivy leave 5 ml twice daily p.o. for four weeks
62571837|NCT01692041|PLACEBO_COMPARATOR|Placebo|Ivy leave placebo 5 ml twice daily p.o. for four weeks
62571838|NCT02203461|EXPERIMENTAL|Group I|STRIBILD® Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat
62571839|NCT02203461|ACTIVE_COMPARATOR|Group II|Truvada®/Kaletra® Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir
62004202|NCT05728164|EXPERIMENTAL|STUDY GROUP|"The group (35 students) will be divided into 7 small groups of (5 students in each group). In addition to routine training provided for the control group, the students of the intervention group will be provided with micro learning content following the educational topics of the course in the form of short videos of cinematic films reinforcing values of resilience, empathy, and positive emotions in dealing with others.~• Pre-simulation activities will also be developed that required watching a tutorial video on how to create a plan of care for such cases. Students also will be provided with background on cinematic simulation and a summary of the characters. Learners will be assigned to one of the films characters and introduced to the assessment tool they would utilize. A pre-briefing discussion on patient confidentiality, nursing role expectations, and developing a plan of care also preceded the activity."
62004203|NCT05728164|NO_INTERVENTION|Cintrol group|They will receive usual training based on the educational objectives of routine methods of lectures, discussion.
62004204|NCT05491603|EXPERIMENTAL|DBI-001 Gel|Topical application of DBI-001 gel on foot/feet affected with onychomycosis.
62004205|NCT05491603|EXPERIMENTAL|DBI-002 Gel|Topical application of DBI-002 gel on foot/feet affected with onychomycosis.
62004206|NCT05491603|PLACEBO_COMPARATOR|Aqueous Gel|Topical application of aqueous gel on foot/feet affected with onychomycosis.
62004207|NCT03788733|EXPERIMENTAL|Melatonin|Melatonin ORAL FILM 3mg will be taken by the subject once a day for 8 weeks
62004208|NCT03788733|PLACEBO_COMPARATOR|placebo|ORAL FILM 3mg placebo will be taken by the subject once a day for 8 weeks
62004209|NCT03212703|ACTIVE_COMPARATOR|Waitlist control (WLC)|Observation surveys over an 8-week period.
62004210|NCT03212703|ACTIVE_COMPARATOR|Mindfulness-Based Skills Training (MBST)|Attendance at weekly 1.5-hour group sessions and surveys over an 8-week period.
62004211|NCT03265119|EXPERIMENTAL|AEVI-001|
62004212|NCT03265119|PLACEBO_COMPARATOR|Placebo|
62004213|NCT04596540|EXPERIMENTAL|SEL-212 low-dose|IV infusion of SEL-212 low-dose every 28 days for a total of up to 6 infusions
62004214|NCT04596540|EXPERIMENTAL|SEL-212 high-dose|IV infusion of SEL-212 high-dose every 28 days for a total of up to 6 infusions
62004215|NCT04596540|PLACEBO_COMPARATOR|Placebo|IV infusion of Normal Saline every 28 days for a total of up to 6 infusions
62189849|NCT06371469|ACTIVE_COMPARATOR|Control Group|"The active control group will be given brochures from the Ministry of Health on cancer prevention and cancer screening recommendations and their questions will be answered.~Contact information of the researchers will be given and they will be told that they can call if they have any questions."
62189850|NCT05994469|EXPERIMENTAL|Copenhagen Adduction Exercise Group|there is no control group, all teams can implement the intervention protocol that better fits their normal schedule, the intervention can consist of 1 or 2 Copenhagen Adduction Exercise sessions per week
62189851|NCT06394609|EXPERIMENTAL|double loaded knotted suture anchor|arthroscopic bankart repair by using double loaded knotted suture anchor
62004216|NCT05869929|EXPERIMENTAL|Vegetables|4-5 servings of vegetables daily, per USDA definition.
62004217|NCT05869929|NO_INTERVENTION|Normal diet|Participant maintains normal diet, no intervention
62004218|NCT00607945|PLACEBO_COMPARATOR|0 g CLA|Avandia (Rosiglitazone) 4-8mg/day OR other diabetes medication currently prescribed to participant, 0 g CLA, 8 g Placebo oil (based on typical American diet)
62004219|NCT00607945|EXPERIMENTAL|3.2 g CLA|Avandia 4-8mg/day OR other diabetes medication currently prescribed to participant, 3.2 g CLA, 4.8 g placebo oil (based on typical American diet)
62004220|NCT00607945|EXPERIMENTAL|6.4 g CLA|Avandia 4-8mg/day OR other diabetes medication currently prescribed to participant, 6.4 g CLA, 1.6 g placebo oil (based on typical American diet)
62004221|NCT00571259|ACTIVE_COMPARATOR|1|Catheter lock with heparin 1,000 units/mL
62004222|NCT00571259|ACTIVE_COMPARATOR|2|Catheter lock with gentamicin 320 micrograms/mL in sodium citrate 4%
62004223|NCT06007469||Critical Limb Threatening Ischaemia|Patients presenting with Critical Limb Threatening Ischaemia
62004224|NCT06007469||Non-limb threatening peripheral vascular disease|Patients presenting with non-limb threatening peripheral vascular disease
62004225|NCT02227524|EXPERIMENTAL|No Device|Assistive device conditions
62004226|NCT02227524|EXPERIMENTAL|Single Point Cane|Assistive device condition
62004227|NCT02227524|EXPERIMENTAL|Four-Point Cane|Assistive device condition
62004228|NCT02227524|EXPERIMENTAL|Trekking Pole|Assistive device condition
62004229|NCT06472804||Observational|Patients undergo medical chart review and complete a questionnaire on study.
62004230|NCT06095843|ACTIVE_COMPARATOR|implants in free vascularized fibular flap|placement of dental implants in free fibular flaps after mandibular reconstruction
62004231|NCT06095843|ACTIVE_COMPARATOR|implants in non-vascularized iliac crest grafts|placement of dental implants in non-vascularized iliac crest grafts after mandibular reconstruction
62189852|NCT03232606||Asthmatic children|Asthmatic children aged 6 to 17 year old coming to follow-up at asthma clinic
62189853|NCT00949676||Heart Failure|
62189854|NCT05592977|EXPERIMENTAL|Intra-oral Distalizing Appliance|"Two infra zygomatic mini-implants will be placed Bands will be cemented to upper first molars. The inner bow (1.2mm) is a modified version of the inner part of a conventional face bow. Two hooks were soldered onto the inner bow distal to the lateral incisor teeth regions, and U loop at 1st premolar region, and bends acting as mesial stop will be bent in front of the maxillary first molars.~Orthodontic force 300 mg per side Will be delivered by Niti closed coil spring which is attached from infra zygomatic mini screw to the hook soldered to the wire framework."
62004232|NCT05996081|NO_INTERVENTION|Control|Individuals in the HIV clinics randomised to the control or intervention group will attend a consultation session as a usual HIV care based on the Indonesian guideline for HIV care and treatment (Ministry of Health Regulation No. 23/2022). Although it may slightly vary by clinic, for every visit they will collect their medications and receive general information from the HIV care provider on the prescribed ART regimens, including the dose, time of administration, potential side effects and how to deal with them, and the importance of adherence. They will be followed-up at the same time points as those in the intervention group.
62189855|NCT05901155|EXPERIMENTAL|MedAL-mentor|"In health facilities allocated to the medAL-mentor arm, the intervention will consist in :~* Providing tablets with ePOCT+ and initial training for use by healthcare workers~* Access to medAL-mentor for healthcare workers and the monitoring team~* Regular (at least every 2 weeks) supportive messages sent by the monitoring team to healthcare workers providing feedback from medAL-mentor~* Targeted phone calls and health facilities visits by the monitoring team based on medAL-mentor review Monitoring will be performed by the study team."
62189856|NCT05901155|NO_INTERVENTION|Routine mentoring|"In health facilities allocated to the control arm, tablets with ePOCT+ will also be provided to healthcare workers with initial training, but subsequent mentoring will be conducted routinely:~* No access to medAL-mentor for healthcare workers or the monitoring team~* At least one message sent by the monitoring team to healthcare workers every two weeks, to inquire about any issues and trigger a site visit if needed~* At least one visit from the monitoring team in each health facility every two months Monitoring will be performed by the study team."
62189857|NCT04707950|ACTIVE_COMPARATOR|study group will be given tranexamic acid|"Participants will be divided into two groups: a study group \& a control group. In addition to the standard management, the study group will be given TXA 1 gm (100 mg/ml) slowly intravenous infusion during delivery after clamping of the cord (administered over 10 minutes at 1 ml/minute).~The second dose of TXA 1 g Intravenous can be given if:~* Bleeding continues after 30 minutes~* Bleeding restarts within 24 hours of completing the first dose While the control group will not be given TXA and we will compare the results in both groups (amount of blood loss during operation to assess the efficacy of TXA in the prevention of PPH and reduction of intraoperative and postoperative blood loss and to assess its safety and benefit in the reduction of incidence of hysterectomy or blood transfusion requirements)."
62189858|NCT04707950|PLACEBO_COMPARATOR|Control group|The control group will not be given Tranexamic acid but only the standard management ( Oxytocin )
62189859|NCT04692090|EXPERIMENTAL|Yoga Group|Hatha yoga will be practiced twice a week for 10 weeks
62189860|NCT04692090|NO_INTERVENTION|Control group|This group will not have any intervention.
62396504|NCT06628193|SHAM_COMPARATOR|Sham LIFU|Sham LIFU stimulation visit with memory tasks and neuropsychological assessments.
62571840|NCT02203461|EXPERIMENTAL|Group III|Truvada®/Prezista®/Norvir® Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir
62571841|NCT05858281||Online Survey|
62004233|NCT05996081|EXPERIMENTAL|Intervention|Individuals attending the HIV clinics that are randomised to the intervention group will receive an intervention over 12 months in addition to usual care. The intervention using an adherence toolkit will be delivered during regular clinic visits when they collect their medications.
62571842|NCT05858281||Focus group|
62004234|NCT02260427|EXPERIMENTAL|the i-gel group|After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
62571843|NCT05858281||Interviews|
62571844|NCT03404037||Group I|Fifty-five coronary artery disease patients without type 2 DM
62571845|NCT03404037||Group II|Fifty-five coronary artery disease patients with type 2 DM
62004235|NCT02260427|ACTIVE_COMPARATOR|the Air-Q sp group|After induction of general anesthesia, the air-Q sp will be inserted according to randomly allocated group.
62004236|NCT01655836|EXPERIMENTAL|Treatment (HDR brachytherapy, SBRT)|Patients undergo HDR brachytherapy on day 0 followed by SBRT on days 15-30
62004237|NCT01954485|EXPERIMENTAL|LaserLok abutment|Laser microtexturing dental implant abutment
62004238|NCT01954485|ACTIVE_COMPARATOR|3inOne abutment|Standard dental implant abutment
62004239|NCT00215826|ACTIVE_COMPARATOR|1|650 IU
62004240|NCT00215826|ACTIVE_COMPARATOR|2|1300 IU
62189861|NCT02686099|EXPERIMENTAL|SternaLock 360|Sternal closure performed with SternaLock 360 as a primary closure system
62396505|NCT06628193|EXPERIMENTAL|LIFU 1|LIFU stimulation with parameter set 1 visit with memory tasks and neuropsychological assessments.
62396506|NCT06628193|EXPERIMENTAL|LIFU 2|LIFU stimulation with parameter set 2 visit with memory tasks and neuropsychological assessments.
62396507|NCT06628193|EXPERIMENTAL|LIFU 3|LIFU stimulation with parameter set 3 visit with memory tasks and neuropsychological assessments.
62571846|NCT05169242|EXPERIMENTAL|Intervention group|In the intervention arm, one or more endoclips will be used to completely close the mucosal defect after polypectomy. Prophylactic clipping will be applied to all post-polypectomy sites. The total number of endoclips used will be recorded.
62571847|NCT05169242|NO_INTERVENTION|Control group|In the control arm, no endoclip will be applied to all post-polypectomy sites, with the exceptions of uncontrolled immediate PPB or pre-treatment in very large pedunculated polyps as specified above. The subjects with endoclips applied due to safety reasons will be included in the subsequent intention-to-treat analysis, but not the per-protocol analysis.
62571848|NCT00745342|EXPERIMENTAL|Teamwork Group|Families randomized to the Teamwork Group received the behavioral family teamwork intervention.
62571849|NCT00745342|NO_INTERVENTION|Standard Care|Families in the Standard Care group received standard diabetes care and equal attention from study staff between visits to schedule appointments and encourage regular diabetes follow-up care.
62571850|NCT02462772|EXPERIMENTAL|Cabotegravir|Women randomised to the cabotegravir arm will receive daily oral cabotegravir (30 mg tablets) for approximately 30 days and thereafter will receive intra-muscular gluteal injections of cabotegravir LA (800 mg, administered as two 400 mg injections) every 12 weeks
62396508|NCT06628193|EXPERIMENTAL|LIFU 4|LIFU stimulation with parameter set 4 visit with memory tasks and neuropsychological assessments.
62396509|NCT06628193|EXPERIMENTAL|LIFU 5|LIFU stimulation with parameter set 5 visit with memory tasks and neuropsychological assessments.
62189862|NCT02686099|ACTIVE_COMPARATOR|Wire Cerclage|Sternal closure performed with standard wire cerclage as a primary closure system
62571851|NCT02462772|PLACEBO_COMPARATOR|Placebo|Women randomised to the placebo arm will receive daily oral tablets (30 mg tablets) for approximately 30 days and thereafter will receive intra-muscular gluteal injections of Intralipid® 20% every 12 weeks
62779603|NCT04060966||Cohort 1: Stress Task|Participants in Cohort 1 randomized to the stress task will complete the Cold-Pressor Task (CPT), which requires the continuous submersion of the forearm in ice-water (0-4°C) for 3 minutes in the presence of an experimenter. After the CPT, participants will complete a decision-making task. During the decision-making task, participants will do one of the following: evaluate different features of foods/monetary prizes in 'rating trials', choose between pairs or bundles of snack foods in 'choice trials', bid for the chance to win foods/monetary prizes or bid to remove certain foods from their choice menu in 'auction trials', or choose between pairs of monetary lotteries in 'lottery trials'.
62779604|NCT04060966||Cohort 1: Control|Participants in Cohort 1 randomized to the Control group will complete a matching control task to the CPT, which involves continuous submersion of the forearm in warm water, \~30°C, for 3 minutes. After the control CPT, participants will complete a decision-making task. During the decision-making task, participants will do one of the following: evaluate different features of foods/monetary prizes in 'rating trials', choose between pairs or bundles of snack foods in 'choice trials', bid for the chance to win foods/monetary prizes or bid to remove certain foods from their choice menu in 'auction trials', or choose between pairs of monetary lotteries in 'lottery trials'.
62396510|NCT06628193|EXPERIMENTAL|LIFU 6|LIFU stimulation with parameter set 6 visit with memory tasks and neuropsychological assessments.
62396511|NCT06628193|EXPERIMENTAL|LIFU 7|LIFU stimulation with parameter set 7 visit with memory tasks and neuropsychological assessments.
62396512|NCT02011646|EXPERIMENTAL|Healthy Weight|intervention four times per week and consist of approximately 10 participants.
62396513|NCT02011646|ACTIVE_COMPARATOR|Controlled Intervention|Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web.
62396514|NCT02138227|ACTIVE_COMPARATOR|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills.
62396515|NCT02138227|ACTIVE_COMPARATOR|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
62396516|NCT05515341||Medical Device Therapy/Procedure for Chronic Pain|
62396517|NCT05044143||Women who remained undelivered after their first episode of threatened preterm labor|Women admitted to the hospital due to their first episode of threatened preterm labor (i.e onset of spontaneous labor \< 34 weeks gestation), who did not deliver prematurely as labor stopped (with or without interventions such as tocolysis). Those with a cervical length \< 25 mm at the time of hospital discharge are eligible to participate in the study
62396518|NCT02223208|EXPERIMENTAL|Ro-CHOEP-21|During the Phase I It will administered Romidepsin (dose escalation) and the combination of CHOEP-21. During the Phase II It will administered Romidepsin (dose according to phase I) and the combination of CHOEP-21.
62004241|NCT06343077|ACTIVE_COMPARATOR|Hiltonol (Poly-ICLC)|Enrolled study subjects will receive paired intramuscular (IM) and intertumoral. (IT) injections of the drug Poly-ICLC (Hiltonol®) as follows: Paired 1.5 mg IM (week 1), 1 mg IT once (week 2), followed by paired 1.5 mg IM weekly from weeks 3-through10, and at weeks 14, 18, 22, 26, 30, 34, 38, 42 and 46 with a 4-week rest period between IM injections.
62571852|NCT02913443|EXPERIMENTAL|Introductory Cohort - 400 μg RO7051790|Introductory cohort to ensure participant safety, prior to the dose escalation study. 400 μg of RO7051790 was administered to two (2) participants followed by a 21-day DLT observation period.
62571853|NCT02913443|EXPERIMENTAL|Dose Escalation - 1000 μg RO7051790|1000 μg of RO7051790 was administered to six (6) participants once every 3 weeks (Q3W).
62571854|NCT02913443|EXPERIMENTAL|Dose Escalation - 1300 μg RO7051790|1300 μg of RO7051790 was administered to seven (7) participants once every 3 weeks (Q3W).
62571855|NCT02913443|EXPERIMENTAL|Dose Escalation - 1900 μg RO7051790|1900 μg of RO7051790 was administered to three (3) participants once every 3 weeks (Q3W).
62571856|NCT05743829||Cardiac Surgery|Patients undergoing cardiac surgery - left atrial appendage excision
61977918|NCT04690751|EXPERIMENTAL|Treatment A|Treatment A: Oral Dose of cenobamate administered as a single 200 mg tablet under fasted conditions
62189863|NCT04810897||Parkinson's disease|The neurologists will inform the individuals with PD that we are doing this research and we will attach the research advertisement at Movement Disorder Clinic, Division of Neurology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand. Only individuals with PD who meet the inclusion and exclusion criteria will be invited to participate in the study. The researcher will inform participants about the purpose, procedure, and advantage of the study prior to participation in the study. Individuals with PD will be asked to sign an informed consent if they agree to participate in the study.
62189864|NCT01296009|EXPERIMENTAL|traditional Chinese medicine|The pregnancy rate in traditional Chinese medicine group is higher than the control group
62396519|NCT06246669|EXPERIMENTAL|Moderate Intensity|Treadmill walking at a rating of perceived exertion (RPE) of 13.
62396520|NCT06246669|EXPERIMENTAL|Light Intensity|Treadmill walking at a rating of perceived exertion (RPE) of 9.
62571857|NCT05743829||Thoracic Surgery|Patients undergoing lung resection - ostial pulmonary vein tissue
62004242|NCT06343077|NO_INTERVENTION|Control (Standard of Care)|
62396521|NCT01053143|EXPERIMENTAL|Study Group|Participants aged 18 years and older at enrollment.
62779605|NCT04060966||Cohort 2: Stress Task + fMRI|Participants in Cohort 2 randomized to the Stress task will complete the CPT, which requires the continuous submersion of the forearm in ice-water (0-4°C) for 3 minutes in the presence of an experimenter. After the CPT, participants will complete decision-making tasks while being scanned via functional MRI (fMRI). The tasks will involve attending to auditory and/or visual stimuli on a computer. On each trial, different food items and different amounts of time (1-60 minutes) will be presented and participants will be asked to indicate how much they would pay from their $10 study endowment to avoid spending the trial's stated amount of time with the snack food.
62004243|NCT01037790|EXPERIMENTAL|Arm 1 - Metastatic breast cancer|"Metastatic breast cancer~PD-0332991 Given orally, 125 mg QD on a 21-day"
62004244|NCT01037790|EXPERIMENTAL|Arm 2 - Metastatic colorectal cancer that harbors the Kras or BRAF mutation|"Metastatic colorectal cancer that harbors the Kras or BRAF mutation~PD-0332991 Given orally, 125 mg QD on a 21-day"
62004245|NCT01037790|EXPERIMENTAL|Arm 3 - Advanced or metastatic esophageal and/or gastric cancer|"Advanced or metastatic esophageal and/or gastric cancer~PD-0332991 Given orally, 125 mg QD on a 21-day"
62004246|NCT01037790|EXPERIMENTAL|Arm 4 - Cisplatin-refractory, unresectable germ cell tumors|"Cisplatin-refractory, unresectable germ cell tumors~PD-0332991 Given orally, 125 mg QD on a 21-day"
62004247|NCT01037790|EXPERIMENTAL|Arm 5 - CCND1amplification, CDK4/6mutation, CCND2amplification, OR other functional G1/S alterations|"Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation , CCND2 amplification OR any other functional alteration at the G1/S checkpoint.~PD-0332991 Given orally, 125 mg QD on a 21-day"
62004248|NCT00433992||ABC/3TC|HIV-infected subjects were given Abacavir-Lamuvidine
62189865|NCT02803099|EXPERIMENTAL|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62004249|NCT00433992||TDF/FTC|HIV-infected patients were given tenofovir DF-emtricitabine
62004250|NCT04379167|EXPERIMENTAL|YY-20394|YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3 kinase (PI3K-δ) which differs structurally from idelalisib, a PI3K-δ inhibitor approved for patients with relapsed chronic lymphocytic leukemia and indolent lymphoma.
62004251|NCT01701661|ACTIVE_COMPARATOR|conservative treatment|Compression stockings class II
62004252|NCT01701661|ACTIVE_COMPARATOR|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refloating trunk
62004253|NCT05233878||Cohort group|Patients over 18 with a confirmed diagnosis of one or multiple cervical paragangliomas
62004254|NCT00578565|EXPERIMENTAL|1|open label, all subjects will receive rituximab
62004255|NCT05198791|EXPERIMENTAL|Eplerenone|Patients with MINOCA and an index of microvascular resistance (IMR) greater than or equal to 25 will be randomised to receive eplerenone (starting dose 25 mg, uptitrated to 50mg after two weeks) for six months or standard of care and research protocol study visits. Patients who are screened, give informed consent but are not randomized will enter a followup registry.
62004256|NCT05198791|SHAM_COMPARATOR|Standard of care|Patients with MINOCA and an index of microvascular resistance (IMR) greater than or equal to 25 will be randomised to receive eplerenone (starting dose 25 mg, uptitrated to 50 mg after two weeks) for six months or standard of care and research protocol study visits. Patients who are screened, give informed consent but are not randomized will enter a followup registry.
62004257|NCT01870128|ACTIVE_COMPARATOR|Methotrexate|Single agent Methotrexate 15 to 25 mg PO per week
62004258|NCT01870128|ACTIVE_COMPARATOR|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
62004259|NCT01870128|EXPERIMENTAL|Combination Steroid|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day Methylprednisolone 1000 mg intravenous per day for 3 days
62004260|NCT05685797|EXPERIMENTAL|TN patients with intervention|Patients with TN receiving 2 times of trigeminal nerve block and radiofrequency thermocoagulation
62004261|NCT05685797|NO_INTERVENTION|Control group|Healthy volunteer without any intervention
62004262|NCT01561768|EXPERIMENTAL|Group 1|
62004263|NCT01561768|EXPERIMENTAL|Group 2|
62189866|NCT04334447|EXPERIMENTAL|Intervention Group Patients|All HF patients that experience a HF education session
62189867|NCT03837483|EXPERIMENTAL|Gene Therapy|OTL-103, Autologous CD34+ hematopoietic stem cells transduced ex vivo with a lentiviral vector encoding the human WAS gene
62189868|NCT00610727|EXPERIMENTAL|Inhaled prochlorperazine 0.625 mg vs IV|Prochlorperazine 0.5 mg IV over 5 sec crossover Inhaled prochlorperazine 0.625 mg
62189869|NCT00610727|EXPERIMENTAL|Inhaled prochlorperazine 1.25 mg|Inhaled Staccato prochlorperazine 1.25 mg
62189870|NCT00610727|EXPERIMENTAL|Inhaled prochlorperazine 2.5 mg|Inhaled Staccato prochlorperazine 2.5 mg
62779606|NCT04060966||Cohort 2: Control + fMRI|Participants in Cohort 2 randomized to the Control group will complete a matching control task to the CPT, which involves continuous submersion of the forearm in warm water, \~30°C, for 3 minutes. After the control CPT, participants will complete decision-making tasks while being scanned via functional MRI (fMRI). The tasks will involve attending to auditory and/or visual stimuli on a computer. On each trial, different food items and different amounts of time (1-60 minutes) will be presented and participants will be asked to indicate how much they would pay from their $10 study endowment to avoid spending the trial's stated amount of time with the snack food.
62004264|NCT01561768|EXPERIMENTAL|Group 3|
62004265|NCT01561768|EXPERIMENTAL|Group 4|
62004266|NCT01561768|EXPERIMENTAL|Group 5|
62004267|NCT01451424|EXPERIMENTAL|Proellex 12 mg PK group|Subjects receiving 12 mg Proellex administered vaginally, and completing a PK arm consisting of 1 x 24 hr PK of Proellex, 14 days of daily Proellex trough measurements, and 1 x 24 hr PK of Proellex after 14 days of daily dosing. 12 mg PK subjects will continue with the protocol as written after the first 2 week period and will be treated for a total of 16 weeks.
62004268|NCT01451424|EXPERIMENTAL|Proellex 12 mg per protocol|Subjects receiving 12 mg Proellex daily, vaginally for 12 weeks
62004269|NCT01451424|EXPERIMENTAL|Proellex 6 mg per protocol|Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks
62004270|NCT01451424|EXPERIMENTAL|Proellex 3 mg per protocol|Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.
62004271|NCT01451424|EXPERIMENTAL|24 mg Proellex|24 mg vaginal Proellex daily for 16 weeks
62004272|NCT03811730|EXPERIMENTAL|TEE group|Eligible patients would be conducted TEE examination by researcher A,The examination results are judged by A and provided to the physician of this patient,
62004273|NCT03811730|ACTIVE_COMPARATOR|TTE group|Eligible patients would be conducted TTE examination by researcher B,The examination results are judged by B and provided to the physician of this patient,
62004274|NCT02090816||Surgery of liver and lung|Patients carriers of both liver and right lung metastases in the same time
62189871|NCT00610727|EXPERIMENTAL|Inhaled prochlorperazine 5 mg|Inhaled Staccato prochlorperazine 5 mg
62189872|NCT00610727|EXPERIMENTAL|Inhaled prochlorperazine 10 mg|Inhaled Staccato prochlorperazine 10 mg
62189873|NCT00610727|PLACEBO_COMPARATOR|inhaled Placebo|inhaled Staccato Placebo (0 mg)
62189874|NCT04211389|ACTIVE_COMPARATOR|ARQ-151 cream 0.3%|Active comparator
62189875|NCT04211389|PLACEBO_COMPARATOR|ARQ-151 cream vehicle|Placebo comparator
62189876|NCT01258647|EXPERIMENTAL|Feeding group|The feeding group will include 20 mother/infant dyads. The infants will be between 8 and 10 months of age.
62189877|NCT04236232||Patients who will be diagnosed as Subclinical Hypothyroidism|50 pt who will be diagnosed as Subclinical Hypothyroidism by elevated level of TSH (TSH: \>4.5 mu/l) and normal T4
62189878|NCT04236232||Patients with normal thyroid function|50 pt with normal thyroid function (TSH \&T4)
62189879|NCT01639742|EXPERIMENTAL|All Participants|All participants who had new texture round breast implants surgically implanted.
62189880|NCT03598699|EXPERIMENTAL|AXR-159 Ophthalmic Solution 3 mg/mL|AXR-159 Low Dose
62189881|NCT03598699|EXPERIMENTAL|AXR-159 Ophthalmic Solution 30 mg/mL|AXR-159 Mid Dose
62189882|NCT03598699|EXPERIMENTAL|AXR-159 Ophthalmic Solution 50 mg/mL|AXR-159 High Dose
62189883|NCT03598699|PLACEBO_COMPARATOR|AXR-159 Ophthalmic Solution Vehicle|Control Group
62189884|NCT00709501|EXPERIMENTAL|1|"Participants in the intervention condition are encouraged to access the Achieve Together website at least once each week. During each login, the following activities will occur:~1. Users will enter their weight and height, how well their plan for a healthy weight has been going, and clarify their goal weight.~2. Users will answer questions about each habit they are using to lose weight~3. Users will receive automated feedback about each habit and will be encouraged to change or delete habits that are being used but not helpful, more consistently use habits that are helpful but not used being used and to continue to use habits that are helpful and being used consistently.~4. Users are encouraged to search for habits that have helped people of similar age and gender to themselves."
62189885|NCT00709501|NO_INTERVENTION|2|Participants in the control condition will have to wait 12 weeks before accessing the Achieve Together website. These participants will be a given a log where they can document weekly weight measurements (this part did not happen).
62189886|NCT03682198|OTHER|One strategy for all enrolled patients:|All patients will participate in three substudies, in which they also act as controls, with exposure to the same three interventions: 1) NIRS-measurement on skin, skull and dura, 2) Phenylephrine 0.1 mg iv., and 3) inspired oxygen fraction of 0.3 vs. 0.8
62189887|NCT06095531|EXPERIMENTAL|Cranial flap replacement following a craniotomy using Tetranite for Cranial Flap Fixation (TN-CFF)|All patients enrolled in study will receive the use of Tetranite (TN-CFF) for their cranial flap fixation following a craniotomy. The flap fixation will be assessed at various time points.
62189888|NCT01238536|EXPERIMENTAL|Epidural Steroid injection|"Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.~Intervention: Epidural steroid with local anesthetic injection~2cc of .25 - 1% lidocaine and glucocorticoid (Kenalog 40-120 mg, depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg)"
62189889|NCT01238536|ACTIVE_COMPARATOR|Epidural local anesthetic injection|Intervention: Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
62189890|NCT01710059|EXPERIMENTAL|Experimental: Intervention Group|"Experimental: Intervention Group~1) Asthma Supervision; 2) Mobile Phone with talking, texting, and data plan; 3) Inhaled Corticosteroid Mobile Phone Application to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated; and 4) Beta2-adrenergic agonist Mobile Phone Application to monitor real time patterns of use of beta2-adrenergic agonist medication for asthma."
62189891|NCT06401278|EXPERIMENTAL|Transcutaneous electrical acupoint stimulation (Group A):|"Transcutaneous electrical acupoint stimulation :It will be performed by using the TENS device on acupoint (TEAS) as the following:~The patients will be placed in a relaxed comfortable sitting position with their back well supported. for 40 min three times weekly for a total of 6 weeks.The adhesive electrodes of the TENS device will be placed on the selected acupoint bilaterally Nei-Guan (PC6), Taichong (LR3), and Sanyinjiao (SP6)"
62004275|NCT06399328||A group (normal coronary arteries)|A group: no signs of coronary calcium (\<75 percentile values of corresponding age and gender ) and no plaques (normal coronary arteries)
62004276|NCT06399328||B group (subclinical coronary atherosclerosis, stage 1)|B group: coronary calcium \>75 percentile of corresponding age and gender /or plaques on MSCT without stenosis
62189892|NCT06401278|EXPERIMENTAL|Transcutaneous electrical nerve stimulation(Group b):|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 min three times weekly for a total of 6 weeks.
62189893|NCT06401278|NO_INTERVENTION|Control|"Routine medical treatment: (Group c): receive only routine medical treatment (antihypertensive medication, instructions and education to control blood pressure)~* Nutrition Eat a diet that is high in fiber and potassium, and low in salt (sodium), added sugar, and fat.~* Lifestyle Do not use any products that contain nicotine or tobacco, such as cigarettes, and chewing tobacco.~* Identify your sources of stress and find ways to manage stress. This may include deep breathing or making time for fun activities.~* Do not drink alcohol"
62189894|NCT05382039|NO_INTERVENTION|Subjects without Pain|This group will include twenty participants with no neck and/or upper quadrant pain that will not receive transcutaneous electrical nerve stimulation treatment.
62004277|NCT06399328||C group ( subclinical/clinically evident coronary atherosclerosis,stage 2)|C group: atherosclerotic plaques of coronary artery with stenosis 50% and more, with or without chest pain
62004278|NCT05923424|EXPERIMENTAL|Cohort 1 Mid IV Dose|Randomized 6:2 for single ascending dose
62004279|NCT05923424|EXPERIMENTAL|Cohort 3 High IV Dose|Randomized 6:2 for single ascending dose
62004280|NCT05923424|EXPERIMENTAL|Cohort 5 Higher IV Dose|Randomized 6:2 for single ascending dose
62004281|NCT05923424|EXPERIMENTAL|Cohort 6 Low IV Dose|Randomized 6:2 for single ascending dose
61977919|NCT04690751|EXPERIMENTAL|Treatment B|Treatment B: Oral Dose of cenobamate administered as a single 200 mg/20 mL suspension under fasted conditions
62004282|NCT05923424|EXPERIMENTAL|Cohort 2 Mid SC Dose|Randomized 6:2 for single ascending dose
62004283|NCT05923424|EXPERIMENTAL|Cohort 4 High SC Dose|Randomized 6:2 for single ascending dose
62004284|NCT05923424|EXPERIMENTAL|Cohort 7 Low SC Dose|Randomized 6:2 for single ascending dose
62004285|NCT05923424|EXPERIMENTAL|Expansion Cohort 1|Randomized 3:1 for single ascending dose
62004286|NCT05923424|EXPERIMENTAL|Expansion Cohort 2|Randomized 3:1 for single ascending dose
62004287|NCT05923424|EXPERIMENTAL|Expansion Cohort 3|Randomized 3:1 for single ascending dose
62779607|NCT04060966||Cohort 3: M-Turk Survey|Participants in Cohort 3 will access the Amazon Mechanical Turk (M-Turk) platform, where they can search for available surveys ('HITs') to complete for payment on the M-Turk website. After completing the surveys, participants will complete the Stress and Adversity Inventory (STRAIN) questionnaire.
62779608|NCT01996124|EXPERIMENTAL|Indacaterol|Indacaterol Fumarate 150 mcg Breezehaler,Onbrez Novartis International AG, Basel Switzerland. Once daily.
62779609|NCT01996124|PLACEBO_COMPARATOR|Placebo|Placebo Breezehaler
62779610|NCT01882504|EXPERIMENTAL|gevokizumab|Solution for subcutaneous injection
62004288|NCT03837262|EXPERIMENTAL|Flash glucose monitoring|Flash glucose monitoring continuously for 6 weeks then once a month up to 24 weeks, with structured education
62004289|NCT05961891|EXPERIMENTAL|Patients with Finger Tip Amputations|Patients with Finger Tip Amputations
62004290|NCT00855140|PLACEBO_COMPARATOR|Sham acupuncture|Sham acupuncture at non-active acupuncture points, using the Park Sham Device
62189895|NCT05382039|NO_INTERVENTION|Subjects with Pain and No Intervention|This group will include twenty participants with neck and/or upper quadrant pain that will not receive transcutaneous electrical nerve stimulation treatment.
62189896|NCT05382039|EXPERIMENTAL|Subjects with Pain and Intervention|This group will include twenty participants with neck and/or upper quadrant pain that will receive transcutaneous electrical nerve stimulation treatment.
62189897|NCT01298882|EXPERIMENTAL|Diacerein|
62189898|NCT01298882|PLACEBO_COMPARATOR|Placebo|
62779611|NCT04957056||Study object|A young patient hospitalized in the Department of Neurosurgery of the Third Hospital of Beijing University of Medicine underwent CT examination of cervical vertebrae. The patient had no cervical bony deformity, no cervical degeneration, and no history of trauma
62779612|NCT03846609|EXPERIMENTAL|double balloon platform|Device: double balloon interventional platform (DiLumen)
62004291|NCT00855140|EXPERIMENTAL|Verum Acupuncture|Acupuncture following a specific TCM-based protocol
62004292|NCT01469325|ACTIVE_COMPARATOR|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil.
62189899|NCT02627378|ACTIVE_COMPARATOR|Extracorporeal Membrane Oxygenation|Patients received Extracorporeal Membrane Oxygenation (ECMO) support
62189900|NCT02627378|PLACEBO_COMPARATOR|Non Extracorporeal Membrane Oxygenation|Patients did not receive Extracorporeal Membrane Oxygenation (ECMO) support
62189901|NCT03747887|ACTIVE_COMPARATOR|School as Usual|School as usual comparison condition.
62189902|NCT03747887|EXPERIMENTAL|Daily Report Card|A coach will establish a Daily Report Card based on IEP goals and objectives with the parents/teachers of the child in this arm.
62189903|NCT01196819|ACTIVE_COMPARATOR|Xience V|Implantation of Xience V drug eluting stent
62189904|NCT01196819|EXPERIMENTAL|Firehawk|Implantation of Firehawk drug eluting stent
62779613|NCT03846609|ACTIVE_COMPARATOR|no double balloon platform|Device: no double balloon interventional platform (DiLumen)
62779614|NCT02214745||Mentally retarded Israeli Arab children|
62779615|NCT02214745||Israeli Arab children with cerebral palsy|
62779616|NCT02214745||Israeli Jewish children with cerebral palsy|
62779617|NCT02214745||Mentally retarded Israeli Jewish children|
62189905|NCT05759286|EXPERIMENTAL|aromatherapy group|Children in this group will receive IANB injection with a nasal mask (similar to a nitrous oxide mask), the way the mask work is by putting on its circular hole a 3d printed perforated box containing cotton balls loaded with lavender-neroli oils blend
62189906|NCT05759286|EXPERIMENTAL|music group|children in this group will receive IANB injections by listening to music as background from a recorder.
62189907|NCT05759286|EXPERIMENTAL|combination group music and aromatherapy|children in this group will receive aromatherapy using the nasal mask with an aromatherapy box as well as music for 5 minutes and through the injection
62189908|NCT05759286|PLACEBO_COMPARATOR|control group|children in this group will receive IANB injections with behavioral management techniques l
62189909|NCT05395923|EXPERIMENTAL|Palatal Pre-Suture (GPCS)|In the test group, GPCS (Silk, 4-0, 18 mm, 3/8 sharp needle) will be placed before the incision in the palatal region. GPCS will be taken one week after surgery.
62189910|NCT05395923|ACTIVE_COMPARATOR|No Palatal Suture (No GPCS) - Control|In the control group, no sutures will be applied before graft harvesting from the palate.
62779618|NCT03247127|OTHER|HA-WBRT|Patients with brain metastases outside a 5-mm margin around either hippocampus and are eligible to this study will receive hippocampal avoidance whole brain radiotherapy 30 gray (Gy) in 10 fractions. The primary endpoint is Wechsler Memory Scale (Chinese) and cognitive abilities screening instrument (CASI) at 4 months.
62779619|NCT02816463|EXPERIMENTAL|Ambu AuraGain (Group A)|Laryngeal mask Ambu AuraGain will be used, and oropharyngeal leak pressure (OLP) after insertion will be recorded as the primary outcome measure
62779620|NCT02816463|ACTIVE_COMPARATOR|LMA Supreme (Group S)|Laryngeal mask Supreme will be used, and oropharyngeal leak pressure (OLP) after insertion will be recorded as the primary outcome measure
62779621|NCT01852422||Pelvic prolapse|
62779622|NCT01364025|EXPERIMENTAL|uterosacral ligament suspension|uterosacral ligament suspension colpopexy sutures will be placed bilaterally at the time of hysterectomy
62779623|NCT01364025|NO_INTERVENTION|hysterectomy alone|
62004293|NCT01469325|SHAM_COMPARATOR|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
62779624|NCT06217003|EXPERIMENTAL|trilaciclib|Screening of eligible subjects for inclusion and application of trilaciclib before undergoing perioperative chemotherapy
62189911|NCT04665609|EXPERIMENTAL|Anlotinib and TQB2450 solution|Microwave ablation will be performed according to patients' tumor number, size and liver function. Oral anlotinib (12 mg/d) will be administered and its cycle is defined as 2 weeks on-treatment followed by 1 week off-treatment. Patients will be given 1200 mg TQB245 solution intravenously every 3 weeks. The treatment continues until disease progression or treatment intolerance. Anlotinib and TQB2450 solution will be given after 2 weeks of microwave ablation procedure.
62189912|NCT04665609|ACTIVE_COMPARATOR|TQB2450 Solution|Microwave ablation will be performed according to patients' tumor number, size and liver function. Patients will be given 1200 mg TQB245 solution intravenously every 3 weeks.TQB2450 solution will be given after 2 weeks of microwave ablation procedure.
62779625|NCT06137651|EXPERIMENTAL|Cohort I (radiation therapy, trotabresib, vinorelbine)|Patients CNS metastases or LMD undergo radiation therapy over 7 days in the absence of disease progression or unacceptable toxicity. Patients then receive trotabresib PO QD on days 1-4 and vinorelbine IV over 6-10 minutes on days 4, 11, and 18 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, CT, and collection of blood samples throughout the trial.
62779626|NCT06137651|EXPERIMENTAL|Cohort S (surgery, trotabresib, vinorelbine)|Patients who undergo tumor resection receive trotabresib PO QD on days 1-4 and vinorelbine IV on day 4. Patients then undergo standard of care surgery. Patients may undergo radiation therapy after surgery per standard of care. Patients may then receive trotabresib PO QD on days 1-4 and vinorelbine IV over 6-10 minutes on days 4, 11, and 18 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, CT, and collection of blood samples throughout the trial.
62779627|NCT03296150|NO_INTERVENTION|Control arm : Information|Patients will receive the usual standard information delivered to patients
62779628|NCT03296150|EXPERIMENTAL|Intervention arm : Therapeutic educational program|"Patients will receive the therapeutic educational program PRESTAGE"
62779629|NCT05910008|EXPERIMENTAL|O-Arm stereotactic imaging|Imaging is performing directly in the operating room.
62779630|NCT05910008|ACTIVE_COMPARATOR|Standard stereotactic imaging|Imaging is performing in Radiology department.
62189913|NCT02080546|ACTIVE_COMPARATOR|Cut/Coag|
62189914|NCT02080546|EXPERIMENTAL|V-mode|
62189915|NCT02414009|EXPERIMENTAL|CAPTEM|Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die bid from day 1 to day 14 every 28 days plus temozolomide 150 mg/mq/die bid starting on day 10 to 14 every 28 days. Treatment will continue for up to 6 cycles or up to disease progression, unacceptable toxicity or informed consent withdrawal.
62189916|NCT02414009|ACTIVE_COMPARATOR|FOLFIRI|"Patients in Arm B will receive FOLFIRI chemotherapy starting Day~1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU 7 (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days. Treatment will continue for up to 12 cycles in Arm B or up to disease progression, unacceptable toxicity or informed consent withdrawal."
62189917|NCT01783340|ACTIVE_COMPARATOR|CQ and falciparum immunization|"This arm will receive chloroquine prophylaxis, a placebo during immunizations and three times 5 infected mosquito-bites (immunizations). Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Placebo capsules daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
62214705|NCT01440998|EXPERIMENTAL|Treatment (dasatinib, paclitaxel, carboplatin)|Patients receive induction therapy comprising dasatinib PO QD for 14 days. \*Beginning 7 days later, patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1, and dasatinib PO QD on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62779631|NCT00527982|EXPERIMENTAL|Celecoxib treatment|600 mg orally (PO) daily
62779632|NCT00527982|NO_INTERVENTION|No treatment|
62779633|NCT03671915|ACTIVE_COMPARATOR|Usual System (Open-loop)|In open loop: sensor-augmented pump (SAP) therapy using standard insulin pump setting combined with the six-generation glucose sensor (Dexcom G6).
62779634|NCT03671915|EXPERIMENTAL|DIABELOOP System (Closed-loop)|"In the closed loop: Diabeloop software (an MPC-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleïdo insulin pump.~A remote monitoring system managed by specialized nurse on behalf diabetologist, is provided in closed-loop session."
62779635|NCT01406015|ACTIVE_COMPARATOR|Spironolactone|
62779636|NCT01406015|PLACEBO_COMPARATOR|Placebo|
62779637|NCT03870412|EXPERIMENTAL|PEG-rhG-CSF|Jin Youli(PEG-rhG-CSF):From the first cycle of chemotherapy, Jin Youli(PEG-rhG-CSF) was injected subcutaneously 24-72 hours after the end of chemotherapy, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight \<45 kg. Inject once every chemotherapy cycle.
62779638|NCT00810784||1|Patients cared for before our intervention.
62779639|NCT00810784||2|Patients cared for after our intervention.
62004294|NCT06184334|ACTIVE_COMPARATOR|Group A : patients will receive mirabegron|patients will receive mirabegron
62004295|NCT06184334|ACTIVE_COMPARATOR|Group B: patients will receive tadalafil 5mg|patients will receive tadalafil 5mg
62189918|NCT01783340|EXPERIMENTAL|CQ/AZM and falciparum immunization|"This arm will receive chloroquine and azithromycin prophylaxis and three times 5 infected mosquito-bites (immunizations).~Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
62189919|NCT01783340|PLACEBO_COMPARATOR|CQ and AZM control|"This arm will receive chloroquine and azithromycin prophylaxis and three times 5 uninfected mosquito-bites during immunization. Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
62189920|NCT03387813|EXPERIMENTAL|Randomized Arm - Treatment Group|"Management of subjects based on pulmonary artery (PA) pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
62189921|NCT03387813|EXPERIMENTAL|Randomized Arm - Control Group|"Management of subjects per standard of care (signs, symptoms, weight etc.) without knowledge of PA pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
62189922|NCT03387813|EXPERIMENTAL|Single Arm|"Management of subjects based on PA pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
62189923|NCT00283283|EXPERIMENTAL|Male, Age 18 -49, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
62779640|NCT00715858|ACTIVE_COMPARATOR|1 AD doxycycline + rifampin|Participants with AD allocated to doxycycline 100 mg bid od and rifampin 300 mg od for 12 months
62189924|NCT00283283|EXPERIMENTAL|Male, Age 50 -64, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
62189925|NCT00283283|EXPERIMENTAL|Female, Age 18 - 49, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
62189926|NCT00283283|EXPERIMENTAL|Female, Age 18 - 49, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
62189927|NCT00283283|EXPERIMENTAL|Male, Age 18 - 49, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
62189928|NCT00283283|EXPERIMENTAL|Male, Age 50 -64, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
62189929|NCT00283283|EXPERIMENTAL|Female, Age 50 -64, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
62779641|NCT00715858|ACTIVE_COMPARATOR|2 AD doxycycline|
62189930|NCT00283283|EXPERIMENTAL|Female, Age 50 -64, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
62779642|NCT00715858|ACTIVE_COMPARATOR|3 AD rifampin|Participants with AD allocated to rifampin 300 mg od od and placebo matched to doxycycline bid for 12 months
62189931|NCT01227616|EXPERIMENTAL|Ferumoxytol|Intravenous (IV) iron
62189932|NCT01227616|ACTIVE_COMPARATOR|IV Iron Sucrose|Intravenous (IV) iron
62189933|NCT03234946|NO_INTERVENTION|Group A|Relatives of patients with diabetes who will only attend sessions at the center along with the patients on all the interventions of the center (except psychology and psychiatry), receiving instructions from each area on the first and fourth visit. When the patient with diabetes is in the psychology or psychiatry consultation, the relative will also be evaluated in these areas in an analogue form.
62189934|NCT03234946|EXPERIMENTAL|Group B|Relatives who will receive multidisciplinary care at the center The subjects from group B will be asked to be accompanied by another relative. If they accept, they will be included as a patient of the CAIPaDi program to receive all the interventions of the second, third and fourth visits in an individual form, without following the patient with diabetes.
62189935|NCT00531726|SHAM_COMPARATOR|B|
62189936|NCT00531726|EXPERIMENTAL|A|
62214706|NCT06010329|EXPERIMENTAL|Single arm, Open label|Participants will receive sutetinib maleate capsule taken orally with (preferred) or without food, at the dose directed by the Investigators, 28 days for a cycle.
62396522|NCT05994989||Group 1|"Patients who have undergone coronary artery bypass surgery and received intravenous tranexamic acid either as a bolus or infusion during the intraoperative period will be included in the study. The cases collected over a period of 6 months will be divided into two groups and compared.~The first group will consist of patients who receive a 10 mg/kg i.v. bolus of tranexamic acid after anesthesia induction, followed by an 8-hour i.v. tranexamic acid infusion at a dose of 2 mg/kg/hour."
62396523|NCT05994989||Group 2|Group 2 will consist of patients who receive three doses of tranexamic acid, 10 mg/kg i.v. bolus after anesthesia induction, in the pump, and after protamine sulfate administration.
62779643|NCT00715858|PLACEBO_COMPARATOR|4 AD placebo|Participants with AD allocated to placebo matched to doxycycline and placebo matched to rifampin for 12 months
62779644|NCT00715858|NO_INTERVENTION|5 Control|Age-matched cognitively healthy participants (untreated)
62779645|NCT04421248|EXPERIMENTAL|Attention Deficit Hyperactivity Disorder (ADHD)|8 to 12 year old children diagnosed with ADHD. Randomized, blinded, single dose, placebo controlled, crossover trial.
62779646|NCT04421248|NO_INTERVENTION|Typically developing controls (TDC)|Typically developing controls - 8 to 12 year old children
61977920|NCT04690751|EXPERIMENTAL|Treatment C|Treatment C: Oral Dose of cenobamate administered at a single 200 mg/20 mL suspension under fed conditions
61977921|NCT00065507|EXPERIMENTAL|A1|
62004296|NCT06184334|ACTIVE_COMPARATOR|Group C: patients will receive solfenacin|patients will receive solfenacin
62004297|NCT00460941|PLACEBO_COMPARATOR|Placebo|sc weekly
62004298|NCT00460941|EXPERIMENTAL|Taspoglutide 20mg|sc weekly
62004299|NCT00460941|EXPERIMENTAL|Taspoglutide 20mg-30mg|sc weekly
62004300|NCT00460941|EXPERIMENTAL|Taspoglutide 20mg-40mg|sc weekly
62004301|NCT01263288|ACTIVE_COMPARATOR|Vitamin D3 (cholecalciferol) 400 IU|
62004302|NCT01263288|ACTIVE_COMPARATOR|Vitamin D3 (cholecalciferol) 1000 IU|
62779647|NCT03521479|EXPERIMENTAL|Group A|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8.
62004303|NCT01263288|PLACEBO_COMPARATOR|Placebo|
62189937|NCT03833362|EXPERIMENTAL|NVR/RTV + PEG-INF/RBV (Treatment Naive)|"Narlaprevir - 2 tablets once a day orally~Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
62779648|NCT03521479|EXPERIMENTAL|Group B|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8.
62779649|NCT03521479|ACTIVE_COMPARATOR|Group C|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0, month 3, and month 6.
62004304|NCT04924777|EXPERIMENTAL|Brisk walk|
62779650|NCT03521479|ACTIVE_COMPARATOR|Group D|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and month 6.
62004305|NCT04924777|EXPERIMENTAL|Aerobic Training|
62004306|NCT04924777|EXPERIMENTAL|Strength Training|
62004307|NCT05345210|ACTIVE_COMPARATOR|Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)|Vonoprazan Fumarate 20mg bid po Amoxycillin 1000mg bid po Clarithromycin 500mg bid po for 14 days
62004308|NCT05345210|EXPERIMENTAL|Vonoprazan Fumarate+Amoxycillin 14days (VA14)|Vonoprazan Fumarate 20mg bid po Amoxycillin 1000mg bid po for 14 days
62004309|NCT05345210|EXPERIMENTAL|Vonoprazan Fumarate+Amoxycillin 7days (VA7)|Vonoprazan Fumarate 20mg bid po Amoxycillin 1000mg bid po for 7 days
62004310|NCT05345210|EXPERIMENTAL|Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)|Vonoprazan Fumarate 20mg bid po Tetracycline 500mg tid po Furazolidone 100 bid po for 14 days
62004311|NCT05345210|EXPERIMENTAL|Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)|Vonoprazan Fumarate 20mg bid po Tetracycline 500mg tid po Furazolidone 100 bid po for 7 days
62004312|NCT01769885|EXPERIMENTAL|Treatment (tivozanib and surgery)|Patients receive tivozanib PO QD on days 1-21. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. 25 days after completion of tivozanib, patients undergo curative nephrectomy.
62004313|NCT01697657|EXPERIMENTAL|Detemir|
62004314|NCT01697657|ACTIVE_COMPARATOR|NPH|
62004315|NCT02373358|EXPERIMENTAL|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety \& boundaries, strength \& power, assertiveness, intuition, trust, \& community) using mindfulness, breath work, and physical yoga poses.
62004316|NCT01638338|EXPERIMENTAL|Web site|"A specific web site for randomization and risky alcohol consumption counseling will be beta tested and created. Risky drinkers allocated to this arm will receive web assisted brief motivational interview.~They will first be assessed towards risky alcohol consumption and Quality of life (AUDIT and EQ5D). Personal health status will also be assessed with a Likert scale. Brief Intervention will be administered following a consistent number of web pages reporting brief motivational interview Web assisted brief motivational interview on risky drinking"
62004317|NCT01638338|EXPERIMENTAL|Face to Face|Risky drinking brief motivational interview provided by the GP.
62004318|NCT02907359|EXPERIMENTAL|Guadecitabine|Participants received Guadecitabine 60 mg/m\^2, SC, on Days 1-5 of each 28-day cycle for at least 6 cycles in the absence of unacceptable toxicity or disease progression requiring alternative therapy. Participants received Guadecitabine treatment beyond 6 cycles as long as the participant continued to benefit based on investigator judgment and participant response and tolerability (or up to a maximum of 36 cycles).
62004319|NCT02907359|ACTIVE_COMPARATOR|Treatment Choice|"Participants received one of the three treatment choice options:~1. LDAC 20 mg/m\^2 SC/IV once daily for 14 days of each 28-day cycles for at least 4 cycles in absence of disease progression or unacceptable toxicity.Participants who were responding or had stable disease were to continue treatment as per standard institutional practice.~2. Standard IC of a 7+3 regimen:Cytarabine 100-200 mg/m\^2/day given as continuous infusion for 7 days and anthracycline(daunorubicin(45-60 mg)/idarubicin(9-12 mg)/mitoxantrone(8-12 mg)/m\^2) by IV infusion for 3 days of each 28-day cycles.~3. BSC as needed during the treatment included,but was not limited to,blood transfusions(RBCs or platelets),growth factors including erythropoiesis stimulating agents,granulocyte stimulating factors,iron chelating therapy,and broad-spectrum antibiotics and/or antifungals.~Duration for treatment choice was as per locally approved prescribing information and institutional standard practice or up to a maximum 30 cycles."
62004320|NCT03091803||Arm I (QSM, T1WI, gadobenate dimeglumine, GOCART DCE MRI)|Patients undergo standard of care QSM and T1WI. Patients then receive gadobenate dimeglumine IV and undergo GOCART DCE MRI over 60 minutes.
62004321|NCT03091803||Arm II (QSM, T1WI, gadoterate meglumine, GOCART DCE MRI)|Patients undergo standard of care QSM and T1WI. Patients then receive gadoterate meglumine IV and undergo GOCART DCE MRI over 60 minutes.
62004322|NCT02424240||IGF-I/ IGFBP-3 ratio group|
62004323|NCT02424240||IGF-1 and IGFBP-3|
62004324|NCT05162872|EXPERIMENTAL|PD-(L)1 naive patients, ≥1L of platinum-based chemotherapy|"Histologically confirmed recurrent or metastatic nasopharyngeal carcinoma (including recurrence and metastasis after radiotherapy, or a condition not suitable for surgery and radiotherapy judged by investigator)~≥ 1L of platinum-based chemotherapy at least 1 measurable lesion (RECIST 1.1) ECOG 0-1, PD-(L)1 naive patients, Niraparib 200 mg QD D1-21,Sintilimab 200 mg IV q3W, first step enroll N1=23 participants, if CR+PR≥3,then go to the second step, continue to enroll N2=39 participants, if CR+PR\<3，then do not go to the second step."
62004325|NCT05162872|EXPERIMENTAL|PD-(L)1 previously treated patients，≥1L of platinum-based chemotherapy|"Histologically confirmed recurrent or metastatic nasopharyngeal carcinoma (including recurrence and metastasis after radiotherapy, or a condition not suitable for surgery and radiotherapy judged by investigator)~≥ 1L of platinum-based chemotherapy at least 1 measurable lesion (RECIST 1.1) ECOG 0-1, PD-(L)1 previously treated patients, Niraparib 200 mg QD D1-21,Sintilimab 200 mg IV q3W, first step enroll N1=20 participants, if CR+PR≥1,then go to the second step, continue to enroll N2=17 participants, if CR+PR\<1，then do not go to the second step."
62779651|NCT01737853||Ganfort's Group|"Ganfort® QD for patients under Krytantek®~For patients assigned to the Ganfort's group, instructions for applying one drop QD (8:00 PM ± 30 minutes)"
62779652|NCT01737853||Krytantek's Group|"Krytantek® BID for patients under Ganforti®~For patients assigned to the Krytantek's group, application schedule will be BID (8:00 AM ± 30 minutes and 8:00 PM ± 30 minutes)"
62779653|NCT03440489|OTHER|six-minute walking test|physical performance of the muscle: measured by Gait speed test, Timed up and go test, six-minute walking test , 30 seconds chair stand test
62779654|NCT06583603||Survey|17-item electronic survey will be administered via google docs
62779655|NCT04623840|EXPERIMENTAL|Exercised group|.(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, in addition to 3 sessions, per week, of combined continuous and interval aerobic exercise for eight weeks
62779656|NCT04623840|ACTIVE_COMPARATOR|non-exercised group|(n=30) will be sedentary obese men with ED. All participants will receive only five milligrams of tadalafil, one time per day, for eight weeks.
62214707|NCT04601753||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
62779657|NCT03995355|EXPERIMENTAL|Test Eye Drops|Eligible subjects that are non-contact lens wearers will be randomized to the Test group throughout the duration of the study.
62004326|NCT01794104|EXPERIMENTAL|1|Open-label Phase I trial evaluating weekly administration of LMP400, on days 1, 8, and 15, in 28-day cycles.
62779658|NCT03995355|ACTIVE_COMPARATOR|Control Eye Drops|Eligible subjects that are non-contact lens wearers will be randomized to the Control group throughout the duration of the study.
62779659|NCT03419065|OTHER|Relaxation Intervention|Women hospitalized on bed-rest for high risk pregnancy participated in Relaxation Interventions.
62004327|NCT06662825||Crizanlizumab Cohort|Patients with sickle cell disease (SCD) who had received at least one dose of crizanlizumab between 2019 and 2022.
62004328|NCT04655911||ABO-101|Participants from prior interventional trials involving the administration of ABO-101.
62004329|NCT03413332|EXPERIMENTAL|E-Talkcare Group|use the web-based patient education tool
62004330|NCT03413332|PLACEBO_COMPARATOR|Usual Care Group|receive usual care
62004331|NCT00462956|EXPERIMENTAL|lapatinib 1500mg daily|Subjects will self-administer lapatinib 1500 mg orally once daily.
62004332|NCT03460522|EXPERIMENTAL|Induction Therapy with Inotuzumab Ozogamicin|Patients will receive up to 3 cycles Inotuzumab with applications on day 1, 8 and 15 in each cycle. First dose will be 0.8 mg/m² on Day 1. All subsequent doses will be 0,5 mg/m².
62004333|NCT03955042|EXPERIMENTAL|Pemetrexed|Pemetrexed
62214708|NCT04452968|EXPERIMENTAL|intermittent fasting|"Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.~Women were told about timed restricted feeding. They were required to fast for 16 hours and consume their allotted calories during the remaining 8 hours."
62779660|NCT01895946|EXPERIMENTAL|Part A: Formulation Switch|AZD5363 tablet twice daily followed by AZD5363 capsule twice daily on an intermittent regimen (4 days on, 3 days off).
62779661|NCT01895946|EXPERIMENTAL|Part B: Food effect|AZD5363 tablet twice daily on an intermittent regimen (4 days on, 3 days off) with/without food on one occasion
62779662|NCT02459678|OTHER|Standard of Care|The MOH-recommended approach is opt out HIV testing in pregnancy followed by immediate initiation of ART for HIV-infected pregnant women. ART initiation is accompanied with counseling geared to educate and prepare women to take up and be retained on ART lifelong. Women who do not return for clinical or drug refill visits are traced by phone or in person.
62779663|NCT02459678|EXPERIMENTAL|Enhanced adherence package|The enhanced adherence package will be designed on the basis of the results of formative research. The intervention will support women who are eligible for ART under Option B+.
62779664|NCT02164370||non-pregnant controls|Acid-base in healthy non-pregnant women in childbearing age
62779665|NCT02164370||healthy pregnant control group|healthy pregnant volunteers matched in gestational age to cases
62779666|NCT02164370||severe pre-eclampsia|Acid-base in severe pre-eclampsia
62779667|NCT05358574||Patients who received the Anatomical Shoulder Bipolar|Patients who received the Anatomical Shoulder Bipolar and were operated according to the product's IFU and surgical technique
62779668|NCT05378061|EXPERIMENTAL|PACAP-38|A time- and volume-controlled infusion pump is used to administer PACAP-38 by intravenous infusion over 20 minutes.
62779669|NCT05378061|PLACEBO_COMPARATOR|Placebo (isotonic saline)|A time- and volume-controlled infusion pump is used to administer placebo (isotonic saline) by intravenous infusion over 20 minutes.
62779670|NCT01289054||Cohort 1 - Pregnancy/Fetal Exposure|
62779671|NCT01289054||Cohort 2 - Interrupted TKI|
62779672|NCT03150628|EXPERIMENTAL|Study population|
62004334|NCT02177240|ACTIVE_COMPARATOR|GRS (GlideRite®)|GlideScope® intubation with GRS® stylet of a simulated difficult airway
62004335|NCT02177240|ACTIVE_COMPARATOR|FIS (Flex-it® )|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
62189938|NCT03833362|ACTIVE_COMPARATOR|PEG-INF/RBV (Treatment Naive)|"Placebo Narlaprevir - 2 tablets once a day orally~Placebo Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
62189939|NCT03833362|EXPERIMENTAL|NVR/RTV + PEG-INF/RBV (Treatment Failure)|"Narlaprevir - 2 tablets once a day orally~Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
62214709|NCT04452968|ACTIVE_COMPARATOR|caloric restriction|Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.
62396524|NCT00847002|ACTIVE_COMPARATOR|Standard Wound Care|Gentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment.
62779673|NCT05331794|EXPERIMENTAL|"Experimental: BIOFIT-Park outdoor fitness equipment"|"Refers to an arm that trains on the BIOFIT-Park line of outdoor fitness equipment that is currently under development and testing."
62779674|NCT05331794|EXPERIMENTAL|Experimental: Gym park equipment|Refers to an arm that trains on gym park equipment
62779675|NCT01338857|EXPERIMENTAL|Sorafenib (Nexavar)|Sorafenib will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.
62779676|NCT06584214|EXPERIMENTAL|Diagnostic test: Determine™ Syphilis Advanced test|Diagnostic test: Testing using the Determine™ Syphilis Advanced test will be conducted by study staff members.
62779677|NCT02207218||NovoEight®|
62779678|NCT05108558|ACTIVE_COMPARATOR|Control - Crossover to CCH|Men in this cohort would undergo baseline assessments followed by no treatment for 6 months and then repeat assessments. Men would then cross-over to CCH treatment and undergo up to 8 injections (or until curvature is \<15 degrees). Final assessments would then be performed 6 weeks following the final injection.
62779679|NCT05108558|EXPERIMENTAL|Collagenase Clostridium Histolyticum|Men in this cohort would undergo baseline assessments followed by up to 8 injections of CCH (or until curvature is \<15 degrees). Men would then undergo assessments 6 weeks later, followed by a 6-month no treatment phase and then final assessments.
62004336|NCT03550924|ACTIVE_COMPARATOR|Low flow Oxygen Group|low flow passive oxygenation during laryngoscopy with 10l/min oxygen via standard nasal prongs
62004337|NCT03550924|EXPERIMENTAL|THRIVE Group|high flow passive oxygenation during laryngoscopy with 120l/min oxygen via THRIVE system
62004338|NCT02232659|EXPERIMENTAL|Primary Arm|Use of the SynCardia 70cc TAH-t for Destination Therapy to support an HDE Application.
62779680|NCT03897842|EXPERIMENTAL|Interventional Arm|The initial phase of the study will utilize the Reprieve Cardiovascular System to support a treatment algorithm that maximizes diuretic administration while carefully monitoring patient physiologic and hemodynamic status to ensure safe decongestion.
62779681|NCT01298271|NO_INTERVENTION|Cyanoacrylate|Endoscopic Cyanoacrylate Injection treatment of primary prevention GVB
62004339|NCT02232659|EXPERIMENTAL|Secondary Arm|Use of the SynCardia 70cc TAH-t for Destination Therapy in a less-restrictive patient population to further characterize the use of the 70cc TAH-t for DT.
62214710|NCT03975959|OTHER|GLIOBLASTOMA|"One visit with collection :~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
62779682|NCT01298271|ACTIVE_COMPARATOR|Propranolol|Propranolol is used for primary prevention of GVB
62004340|NCT06038838|EXPERIMENTAL|Patients with Symptomatic MR (MR>=3+)|Subjects treated with the Tioga TMVR System
62004341|NCT01864291|EXPERIMENTAL|Non-NF2 ABI surgery|All subjects will be part of a single arm involving placement of the ABI541 Auditory Brainstem Implant (ABI) device. The Nucleus 24 was discontinued and is no longer available.
62004342|NCT01121211|ACTIVE_COMPARATOR|Testosterone|Testosterone x 24 weeks
62004343|NCT01121211|PLACEBO_COMPARATOR|Placebo|Placebo x 24 weeks
62004344|NCT03523559||Interstitial Cystitis|
62004345|NCT03523559||normal|
62779683|NCT01124591|EXPERIMENTAL|Treatment|Assessment and brief intervention
62779684|NCT06143982|EXPERIMENTAL|Brief Intensive Trauma Treatment|If allocated to the intervention group, participants follow the Brief Intensive Trauma Treatment (BITT).
62004346|NCT04751305|EXPERIMENTAL|ACE Remote Maintenance Program with Health Coaching|The participants received online delivered (over zoom) group based exercise classes (2x/wk for first 2 weeks; 1x/wk for the remaining weeks) followed by a 15 minute post workout social session. Participants also received a PDF of a home-based exercise program with embedded videos and a Garmin Vivosmart4 activity tracker. The accelerometer is not intended to be an active part of the intervention but is used to gather an objective measure of PA levels. Additionally, the health coaching intervention received weekly zoom calls that were focused on being participant-centered, built on a coach participant relationship, and included participant-determined goals, a self-discovery process to find solutions, patient accountability, and education.
62779685|NCT06143982|NO_INTERVENTION|Waitlist control group|When allocated to the WLCG, participants receive BITT after a 3 months waiting period. The WLCG receives no care during the treatment phase (one week) of the intervention group. Besides this week the WLCG can undergo every treatment including EMDR and TF-CBT during the 3 months waiting period.
62004347|NCT04751305|ACTIVE_COMPARATOR|Only ACE Remote Maintenance Program|The participants received online delivered (over zoom) group based exercise classes (2x/wk for first 2 weeks; 1x/wk for the remaining weeks) followed by a 15 minute post workout social session. Participants also participants received a PDF of a home-based exercise program with embedded videos and a Garmin Vivosmart4 activity tracker. The accelerometer is not intended to be an active part of the intervention but is used to gather an objective measure of PA levels.
62779686|NCT00856804|EXPERIMENTAL|1|thalidomide added to peg-interferon + ribavirina
62779687|NCT03245398|ACTIVE_COMPARATOR|Single dose of mebendazole|In day 1 each child in this treatment arm will receive a 500 mg tablet of mebendazole plus one 100 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the placebo. In day 2 and 3 each child will receive one placebo twice a day (in the morning and in the evening)
62779688|NCT03245398|ACTIVE_COMPARATOR|Multiple dose of mebendazole|In day 1 each child in this treatment arm will receive a 100 mg tablet of mebendazole plus one 500 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the 100 mg tablet of mebendazole. In day 2 and 3 each child will receive one 100 mg tablet of mebendazole twice a day (in the morning and in the evening).
62004348|NCT04992559|EXPERIMENTAL|Toripalimab Arm|Toripalimab consolidation therapy
62004349|NCT06345638||Females with SCD|
62004350|NCT06345638||Males with SCD|
62004351|NCT02142530|EXPERIMENTAL|Carfilzomib/ Belinostat|"Carfilzomib and Belinostat will be administered on a 28-day schedule.~* Carfilzomib will be given on days 1-2, 8-9, and 15-16 of each cycle, beginning at a dose of 20 mg/m2 (dose level 0).~* Belinostat will be given on days 1-5 beginning at a dose of 600 mg/m2.~* Belinostat dosing will precede carfilzomib dosing on days when both drugs are administered. In dose level 1 and beyond, carfilzomib will be given at a dose of 20mg/m2 with cycle 1, and then escalated with cycle 2~* A maximum of four dose levels are planned with carfilzomib escalated no higher than 20/36 mg/m2 and belinostat escalated no higher than 900 mg/m2."
62004352|NCT02720913|EXPERIMENTAL|COR-KNOT|The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.
62004353|NCT02720913|ACTIVE_COMPARATOR|Standard Suture Tying|Standard Suture Tying
62004354|NCT02553421|EXPERIMENTAL|Pilot|A non-alarming ivWatch device will monitor the IV sites of these subjects. The goal of this small pilot study is to give clinicians an opportunity to perform the protocol and operate the ivWatch device and to give researchers the ability to make adjustments prior to starting the subsequent non-alarming group.
62779689|NCT06069635|EXPERIMENTAL|Fatigue group|30 male players will be assessed for core endurance, balance and performance then fatigue protocol will be applied and measure for core endurance, balance and performance after fatigue
62779690|NCT06069635|SHAM_COMPARATOR|Control group|30 players will be assessed for core endurance, balance and performance. Players will be assessed at baseline then take rest drink water and then measure for core endurance, balance and performance again .
62779691|NCT02657902||Gamma 3 Nail|Fractures that were treated with a Gamma 3 nail
62779692|NCT02657902||Gamma 3 Nail + U-Blade|Fractures that were treated with a Gamma 3 nail and additional with antirotation U-blade lag screws.
62779693|NCT02209974|PLACEBO_COMPARATOR|Inhaled Placebo|Inhaled placebo administered to healthy (n=7) and to a half (n=8) of COPD patients
62779694|NCT02209974|EXPERIMENTAL|Inhaled corticosteroids (Fluticasone, 0.5 mg)|Inhaled corticosteroids administered to the other half (n=8) of COPD patients
62779695|NCT04230213|EXPERIMENTAL|Treatment Arm 1|Subcutaneous (SC) injection given every other week
62779696|NCT04230213|ACTIVE_COMPARATOR|Treatment Arm 2|SC injection given every other week
62779697|NCT00525096|PLACEBO_COMPARATOR|Placebo|Aromasin + placebo in place of Celebrex
62779698|NCT00525096|EXPERIMENTAL|Celebrex|Aromasin + Celebrex
61977922|NCT00065507|ACTIVE_COMPARATOR|A2|
61977923|NCT03964155|EXPERIMENTAL|Patients with SDRA|Patients within 24 hours from meeting the Berlin criteria for moderate or severe ARDS and receiving inhaled sedation with sevoflurane
61977924|NCT05309564|EXPERIMENTAL|Intervention|Intervention with single botulinum neurotoxin injection into masseter.
61977925|NCT05309564|NO_INTERVENTION|Control|No intervention
61977926|NCT03258190|EXPERIMENTAL|Lime Powder Regimen|Participants were asked to take LPR twice a day for 6 months
61977927|NCT03258190|PLACEBO_COMPARATOR|Placebo|Participants were asked to take Placebo twice a day for 6 months
61977928|NCT05327140||patients with axial spondyloarthritis|ASAS classification criteria which relies either on sacroiliitis on imaging plus one SpA feature (imaging arm) or HLA-B27 antigen plus two SpA features (clinical arm), in a patient with chronic back pain and age at onset of less than 45 years
61977929|NCT05327140||patients with mechanical back pain|Patients diagnosed as chronic (more than 3 months) mechanical back pain, the diagnosis has been made prior to the study by the treating specialist, these patients are herein as a control group
62571858|NCT03068390|EXPERIMENTAL|RICHH Intervention|The RICHH intervention is an educational-behavioral and counseling intervention that promotes caregivers' knowledge, skills and motivation to engage in CVD risk reduction. The intervention is delivered individually to caregivers in their homes using video-conferencing technology on mini-iPads that we provide for all participants. Participants keep the mini-iPads at the end of the study. The program consists of 12 weekly sessions \[30-45 minutes\] followed by 8 bi-weekly \[every other week\] booster sessions and 6 monthly booster sessions that will be held at the caregivers' preferred times using a video conferencing program. A cardiac psychiatric advanced practice nurse certified cognitive behavioral therapy will deliver the intervention.
62571859|NCT03068390|ACTIVE_COMPARATOR|Usual care|The usual care control group will receive an attention placebo intervention in which the caregivers will receive mini-iPads loaded with Caregiver and CVD risk reduction pamphlets in PDF format along with the associated links from the American Heart Association. Because the investigators may identify CVD risk factors in baseline testing in participants who do not know they have them, it would be unethical not to provide at least usual care for these. Thus, all individuals enrolled in the study and in whom the investigators identify CVD risk factors will receive referral to a primary care provider for management of the CVD risk factors identified.
62779699|NCT00924339|PLACEBO_COMPARATOR|Rapeseed oil|Control-Group (n = 15) : Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
62779700|NCT00924339|EXPERIMENTAL|Soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
62779701|NCT04891484|EXPERIMENTAL|Ondansetron group|Group O :patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia
62189940|NCT03833362|ACTIVE_COMPARATOR|PEG-INF/RBV (Treatment Failure)|"Placebo Narlaprevir - 2 tablets once a day orally~Placebo Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
62189941|NCT04967898|EXPERIMENTAL|bowen technique|group 1 will be treated with the Bowen technique and heating pad. this technique will be given to asymptomatic females. 22 subjects will be taken this treatment. treatment will be given thrice a week for 3 weeks. the subjects will come after 1 month for follow-up.
62189942|NCT04967898|ACTIVE_COMPARATOR|sustained stretching|group 1 will be treated with the sustained stretching technique and heating pad. this technique will be given to asymptomatic females. 22 subjects will be taken this treatment. treatment will be given thrice a week for 3 weeks. the subjects will come after 1 month for follow-up
62396525|NCT00847002|ACTIVE_COMPARATOR|Flexitouch system with Standard Wound Care|In addition to standard wound care, patients who have been randomized to this group will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis (FarrowWrap will be removed during the time they are using Flexitouch). The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action.
62779702|NCT04891484|PLACEBO_COMPARATOR|Control group|Group S:patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia
62571860|NCT01168232|EXPERIMENTAL|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62779703|NCT00742729|EXPERIMENTAL|Arm 1|Educational small group session with free FOBT kit
62189943|NCT04492813|EXPERIMENTAL|Obese patients|Severe and morbidly obese patients (35²≤BMI \<55)
62779704|NCT00742729|EXPERIMENTAL|Arm 2|Educational small group session with no FOBT kit
62779705|NCT00742729|SHAM_COMPARATOR|Arm 3|Control
62779706|NCT02277808|ACTIVE_COMPARATOR|Respirgard II|Determination of pulmonary deposition
62779707|NCT02277808|ACTIVE_COMPARATOR|Isoneb|Determination of pulmonary deposition
62779708|NCT00565136|EXPERIMENTAL|TOPAS|TOPAS AMS Pelvic Floor Repair System
62779709|NCT05694299|EXPERIMENTAL|Nasal bridle|Nasal bridle fixation after nasoenteral feeding tube placement.
62189944|NCT04492813|ACTIVE_COMPARATOR|Non Obese patients|Patients with normal weight or slightly overweight (19 \<BMI \<30).
62189945|NCT05859438|EXPERIMENTAL|Intervention group|
62571861|NCT05376774||Critically ill patients|Patients admitted to intensive care units
62571862|NCT01610674|EXPERIMENTAL|Tailored improvement strategy|In 3 hospitals a tailored strategy to improve perioperative diabetes care is performed
62571863|NCT01610674|NO_INTERVENTION|Usual perioperative diabetes care|Three hospitals that provide usual perioperative diabetes care serve as control hospitals
62571864|NCT01733940|EXPERIMENTAL|"Tegaderm CHG Dressing"|This arm is receiving a clorhexidine dressing for intravascular catheters.
62571865|NCT01733940|ACTIVE_COMPARATOR|"Tegaderm IV dressing"|Use of tegaderm iv dressings for intravascular catheters. Change each 7 days.
62571866|NCT06574438|EXPERIMENTAL|AIFIGA group|receives the AIFIGA program and uses it for 3 months
62571867|NCT06574438|NO_INTERVENTION|control group|receives only routine care
62779710|NCT05694299|ACTIVE_COMPARATOR|Nasal patch|Nasal patch fixation after nasoenteral feeding tube placement.
62779711|NCT02800980||Drainage and sclerotherapy.|Patients with symptomatic lymphocele who are managed with percutaneous drainage and sclerotherapy.
62779712|NCT02800980||Drainage alone.|Patients with symptomatic lymphocele who are managed with percutaneous drainage alone.
62571868|NCT05107817|EXPERIMENTAL|Aquatic Exercise group|Participants will engage in a single session of training consisting of 120 repetitions of a ball throwing and catching task in water.
62779713|NCT06397235|EXPERIMENTAL|DEB-TACE+HAIC|"For DEB-TACE, superselective catheterization is performed and CalliSpheres loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In patients with huge or bilobar multiple lesions, in order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session.~After each chemoembolization, the microcatheter is reserved at the main hepatic tumor-feeding artery. The RALOX-based regimen is intra-arterially administered.~During follow-up, the treatment will be repeated on demand (about 4-week interval) based on the evaluation of the follow-up laboratory and imaging examination."
62779714|NCT06397235|ACTIVE_COMPARATOR|DEB-TACE|Superselective catheterization is performed and CalliSpheres loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In patients with huge or bilobar multiple lesions, in order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session.
62189946|NCT00531622|EXPERIMENTAL|Saredudant/Escitalopram|Saredutant 100 mg and Escitalopram 10 mg once daily for a maximum of 8 weeks
62189947|NCT00531622|ACTIVE_COMPARATOR|Placebo and Escitalopram|Placebo for saredutant and Escitalopram 10 mg once daily for a maximum of 8 weeks
62189948|NCT00531622|PLACEBO_COMPARATOR|Placebo|Placebo for saredutant and Placebo for Escitalopram once daily for one week during the screening phase and for a maximum of 8 weeks during the active phase
62189949|NCT04340765|EXPERIMENTAL|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT
62396526|NCT06220929|SHAM_COMPARATOR|Control group|Patients were randomly divided into intervention and control groups, with both groups receiving standard treatment and care for sepsis (decided by the attending physician). On this basis, the following treatments were administered: Control group (n=20): intravenous saline drip/oral placebo tablets.
62571869|NCT05107817|ACTIVE_COMPARATOR|Land Exercise group|Participants will engage in a single session of training consisting of 120 repetitions of a ball throwing and catching task on dry land.
62571870|NCT03231813|EXPERIMENTAL|SLS irritation model and Treatment|SLS induced irritation on two sites each on forearms and back Emollient cream treatment
62571871|NCT03231813|PLACEBO_COMPARATOR|SLS irritation model and No Treatment|SLS induced irritation on two sites each on forearms and back No treatment
62189950|NCT04228198||Radical cystectomy|Patients with histologically confirmed diagnosis of bladder cancer undergoing radical cystectomy surgery at 28 Urology departments in Italy
62571872|NCT03231813|SHAM_COMPARATOR|Sham irritation and Treatment|Sham irritation (water) on two sites each on forearms and back Emollient cream treatment
62779715|NCT01453907|EXPERIMENTAL|ETI-204|ETI-204, Anthim
62779716|NCT01453907|SHAM_COMPARATOR|placebo|
62779717|NCT05313737|EXPERIMENTAL|Automated phone opt-in message|Audiocare message requiring Veteran to confirm that they would like to participate in screening and have consult sent
62779718|NCT05313737|EXPERIMENTAL|Opt-out scheduling|Consult automatically sent and Veteran called to schedule screening
62779719|NCT02600091|EXPERIMENTAL|MBCT Intervention|Participants in the Mindfulness-based Cognitive Therapy Intervention arm will receive an 8-week programme in mindfulness-based cognitive therapy
62779720|NCT02600091|NO_INTERVENTION|Waiting List Control|The participants who are allocated to the waiting list control group will receive usual care. They will receive the MBCT intervention 3 months after the intervention group complete their MBCT programme.
62779721|NCT01521377|PLACEBO_COMPARATOR|Placebo|Single inhalation from matching placebo dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin.
62779722|NCT01521377|ACTIVE_COMPARATOR|Moxifloxacin Positive|Single inhalation from matching placebo dry powder inhaler once daily on days 1-10. Single dose oral tablet moxifloxacin (400mg) on day 10.
62004355|NCT02553421|EXPERIMENTAL|Non-alarming|150 patients will be enrolled in the non-alarming group. The ivWatch device will monitor the IV sites but will not issue infiltration notifications.
62189951|NCT01389414|EXPERIMENTAL|Arm A- p-Gemox|"Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once Q2W.~GEMOX chemotherapy will be administered after the administration of panitumumab once Q2W.~Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle."
62189952|NCT01389414|ACTIVE_COMPARATOR|Arm B-GEMOX|Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
62410026|NCT05992207|ACTIVE_COMPARATOR|physical thertapy training|The Control group received the selected physical therapy program for one hour, three times weekly for three successive months including facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern
62004356|NCT02553421|EXPERIMENTAL|Alarming|150 patients will be enrolled in the alarming group. The IV sites will be monitored with the ivWatch Model 400 infiltration notifications enabled.
62189953|NCT02476942||Cohort A: Adults and Adolescents with FVIII Inhibitors|Adults and adolescents with hemophilia A of any severity with the presence of FVIII inhibitors will be observed.
62189954|NCT02476942||Cohort B: Children with FVIII Inhibitors|Children with hemophilia A of any severity with the presence of FVIII inhibitors will be observed.
62571873|NCT03231813|NO_INTERVENTION|Sham irritation and No Treatment|Sham irritation (water) on two sites each on forearms and back No treatment
62571874|NCT05350657|EXPERIMENTAL|Ketogenic Diet|Subjects will be provided with foods following a ketogenic diet for 15 consecutive days.
62571875|NCT01591278|EXPERIMENTAL|Pulp dressing agent|
62571876|NCT01591278|ACTIVE_COMPARATOR|Pulp dressing|MTA
62571877|NCT02556775||Alternative Product Arm|Participant stops HYQVIA treatment (if the participant is still treated) and a licensed human normal immunoglobulin other than HYQVIA for intravenous (IV) or subcutaneous (SC) infusion or an alternative treatment will be administered, as determined by the physician.
62189955|NCT02476942||Cohort C: Adults and Adolescents without FVIII Inhibitors|Adults and adolescents with severe hemophilia A without the presence of FVIII inhibitors will be observed.
62189956|NCT05790525|OTHER|Both gastric and oral Helicobacter pylori are positive|
62189957|NCT05790525|OTHER|Positive for Helicobacter pylori for gastric and negative for Helicobacter pylori for oral cavity|
62189958|NCT00728299|EXPERIMENTAL|1|
62189959|NCT00728299|PLACEBO_COMPARATOR|2|
62189960|NCT06486675|EXPERIMENTAL|education|"The pre-test data from the students in the experimental group were collected in the first lesson via the Google form created using the Personal Introduction Form, Adults' Perception Scale on Breast Milk (ASAÖ) and Iowa Infant Nutrition Attitude Scale (IOWA), and the first and The second will be sent to the students by the authors. The first question was asked, Are you willing to participate in this research? Those who say yes will read and fill out this form themselves. At the end of the 14-week course period, post-test data will be obtained using the same method."
62189961|NCT06486675|NO_INTERVENTION|control group|"640 / 5.000 The pre-test data from the students in the control group is a survey form created by the third author using the Personal Introduction Form, Adults' Perception Scale on Mother's Milk (ASAÖ) and Infant Nutrition Attitude Scale (IOWA) before a suitable lesson in the first week of the semester. The form link will be created and sent to the students by the third author via WhatsApp messaging application. The first question was asked, Are you willing to participate in this research? Those who say yes will read and fill out this form themselves. At the end of the 14-week course period, the post-test data will be obtained by the third author using the same method."
62189962|NCT02447653|EXPERIMENTAL|Hydroxyapatite Coating|G7 HA Acetabular component will be implanted
62189963|NCT02447653|ACTIVE_COMPARATOR|Plasma Porous Spray|G7 PPS Acetabular component will be implanted
62189964|NCT06421805||thymoma|mediastinal tumors_thymoma
62189965|NCT06421805||teratoma|mediastinal tumors_teratomas
62189966|NCT06421805||germ cell tumor|mediastinal tumors_germ cell tumors
62189967|NCT06421805||lymphoma|mediastinal tumor_lymphoma
62571878|NCT02556775||HYQVIA Arm|Participant continues to receive HYQVIA (Immune Globulin (Human) 10% with recombinant human hyaluronidase (rHuPH20)), according to her treatment regimen.
62779723|NCT01521377|EXPERIMENTAL|GSK573719 Supra-therapeutic dose|Single inhalation from GSK573719 (500 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral moxifloxacin.
62189968|NCT06421805||mediastinal neuroendocrine tumors (NETs)|mediastinal tumor_NETs, including neuroendocrine tumours and neuroendocrine carcinomas.
62189969|NCT06421805||neurinoma|mediastinal tumor_neurinoma
62189970|NCT06421805||thymic carcinoma|mediastinal tumor_thymic carcinoma
62189971|NCT06421805||others|mediastinal tumors_other tumors
62189972|NCT05515783|EXPERIMENTAL|Part I: safety, tolerability, biodistribution and dosimetry|PET imaging will begin at 30s (30s/bed), 15min (1min/bed), 30min (2 min/bed), 60min (2 min/bed) and 120min (2 min/bed) after injection
62189973|NCT05515783|EXPERIMENTAL|Part II: diagnostic efficacy|Participants with various types of cancer will have PET imaging 50-100 minutes after injection of 68Ga-FAP-RGD and another agent (68Ga-FAPI-02 or 18F-FDG).
62189974|NCT06001866|EXPERIMENTAL|Spaced Retrieval practice during verb learning|"Each child will learn 8 novel verbs referring to unfamiliar transitive actions (mape). Four verbs will be learned in a condition requiring spaced retrieval practice; four verbs will be learned in a standard study-only (no retrieval practice) condition. In the spaced retrieval condition, the number of other words intervening between hearing the target and an attempt to retrieve it will increase from 0 to 3 words. In the study-only condition, children will simply hear the verb used to describe the action."
62189975|NCT03423368|EXPERIMENTAL|Libramed|Each patient will be admistered 6 tablets/day (3 tablets before lunch, 3 tablets before dinner) of Libramed for 30 days
62189976|NCT03423368|PLACEBO_COMPARATOR|Placebo|Each patient will be admistered 6 tablets/day (3 tablets before lunch, 3 tablets before dinner) of placebo for 30 days
62189977|NCT02717741|EXPERIMENTAL|tafetinib|tafetinib administered daily for 2 weeks, followed by a 1-week off period
62189978|NCT01809899|EXPERIMENTAL|Enhanced Consent Procedure|Participants in this group will receive an enhanced consent that will be an hour longer than usual.
62189979|NCT01809899|ACTIVE_COMPARATOR|Consent as Usual Procedure|Participants in this group will receive a normal consent procedure to the study
62779724|NCT01521377|EXPERIMENTAL|GSK573719/Vilanterol Therapeutic dose|Single inhalation from GSK573719/Vilanterol (125/25 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin on day 10.
62779725|NCT01521377|EXPERIMENTAL|GSK573719/Vilanterol Supra-therapeutic dose|Single inhalation from GSK573719/Vilanterol (500/100 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin on day 10.
62779726|NCT01894022|EXPERIMENTAL|Ambrisentan Arm|All subjects will receive ambrisentan initially at a dose of 5 mg once daily (OD). Based on the investigator's best judgment, the subject may continue on 5 mg OD, or be up-titrated to 10 mg OD. The dose may also be adjusted back to 5 mg OD at investigator discretion.
62189980|NCT02022111|ACTIVE_COMPARATOR|Intervention Program of Care|"1. Patient Education and Behavioral Activation by a Care Coordinator;~2. Supporting Self-Care;~3. Psychiatrist and Diabetologist Reviews; and~4. Decision-support Electronic Health Record System"
62189981|NCT02022111|PLACEBO_COMPARATOR|Control Arm|Participants randomized to the control arm will receive the existing standard of care and treatment for their diabetes that is provided routinely at each Clinic Site and their care provider will be notified regarding their depressive symptoms. The physicians treating the control arm will also be provided with trainings regarding identification and care for people with depression. The control participants will have no contact with care coordinators and will only be contacted at 6-monthly intervals for assessment by the blinded outcomes assessor.
62779727|NCT04582955|EXPERIMENTAL|Arm A|Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks
62189982|NCT02675049|PLACEBO_COMPARATOR|0.9% saline|Patients were assigned to receive 0.9% saline intranasally 45 min before surgery using a computer-generated random number table.
62779728|NCT04599036|EXPERIMENTAL|Feasibility|To explore if the feasibility of adding an EMG controlled device to the acute rehabilitation for stroke subjects with severe arm deficit.
62189983|NCT02675049|EXPERIMENTAL|dexmedetomidine 1 µg.kg-1|Patients were assigned to receive 1µg.kg-1dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
62189984|NCT02675049|EXPERIMENTAL|dexmedetomidine 1.5 µg.kg-1|Patients were assigned to receive 1.5µg.kg-1 dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
62189985|NCT02675049|EXPERIMENTAL|dexmedetomidine 2 µg.kg-1|Patients were assigned to receive 2µg.kg-1 dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
62189986|NCT06385847|OTHER|Zo-LY|Arm Zo-LY: Zoladex 3.6 mg (s.c.)/4W ✖ 2 cycles, followed by LY01005 3.6 mg (i.m.)/4W ✖ 2 cycles
62571879|NCT02307422||Case|Diabetic patients undergoing coronary angiography (both sexes), who are age 18-90, and admitted in the Department of Cardiology in the University General Hospital of Ioannina and Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. Presence epicardial vessel stenosis (\>50%), and multi-vessel disease will be recorded. Excluded: previous history of revascularization procedure or moderate to severe stenosis. Patient samples will be evaluated for quantitative levels of the biomarkers Lp(a) and OXPL/apoB. IL-1 Genotypes, and other SNPs associated with CAD will be assessed in this group and related to levels of Lp(a) and oxidized phospolipids. No interventions other than the post-hoc DNA testing will be performed.
62571880|NCT02307422||Control|Non-diabeticpatients undergoing coronary angiography (both sexes), who are age 18-90, and admitted in the Department of Cardiology in the University General Hospital of Ioannina and Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. Presence epicardial vessel stenosis (\>50%), and multi-vessel disease will be recorded. Excluded: previous history of revascularization procedure or moderate to severe stenosis. Patient samples will be evaluated for quantitative levels of the biomarkers Lp(a) and OXPL/apoB. IL-1 Genotypes, and other SNPs associated with CAD will be assessed in this group and related to levels of Lp(a) and oxidized phospolipids. No interventions other than the post-hoc DNA testing will be performed.
62571881|NCT06534853|EXPERIMENTAL|PFS Group|"Group A along with Post facilitation stretch of quadratus lumborum will a comprehensive therapeutic regimen that includes a 10-minute session of hot pack therapy specifically targeted at the low back region. In addition to this, participants will receive trigger point release therapy to alleviate muscle tension. The treatment plan also incorporates a tailored exercise protocol designed to enhance back health and strength. This protocol includes:~1. Back isometric exercises~2. Bridging exercises~3. Cat and camel stretches~4. Prone press-ups~5. Abductor strengthening exercises"
62571882|NCT06534853|EXPERIMENTAL|RI Group|"Group B along with Reciprocal inhibition of quadratus lumborum will a comprehensive therapeutic regimen that includes a 10-minute session of hot pack therapy specifically targeted at the low back region. In addition to this, participants will receive trigger point release therapy to alleviate muscle tension. The treatment plan also incorporates a tailored exercise protocol designed to enhance back health and strength. This protocol includes:~1. Back isometric exercises~2. Bridging exercises~3. Cat and camel stretches~4. Prone press-ups~5. Abductor strengthening exercises"
62571883|NCT05565781|ACTIVE_COMPARATOR|ECG Smartwatch for up to 1 year|Cardiac monitoring with an ECG Smartwatch over 1 year after the acute phase of cryptogenic stroke. Simultaneously, a continuous cardiac monitoring will be performed using an Insertable Cardiac Monitor (ICM)
62571884|NCT05565781|ACTIVE_COMPARATOR|Holter monitoring for up to 1 year|Cardiac monitoring with an external holter device for 30 days after the acute phase of cryptogenic stroke and 15 additional days of extended use every 3 months up to 1 year
62571885|NCT05565781|OTHER|Control group|Regular cardiac monitoring with an external holter device for 30 days after the acute phase of cryptogenic stroke
62571886|NCT03289026|EXPERIMENTAL|aripiprazole group|Patients receive aripiprazole treatment
62571887|NCT02067845|OTHER|Pre-post test design|
62571888|NCT01067781|EXPERIMENTAL|1|Two vaccination regimen with an LT patch (no swabbing)
62571889|NCT01067781|EXPERIMENTAL|2|Two vaccination regimen with an LT patch (with swabbing)
62571890|NCT01067781|PLACEBO_COMPARATOR|3|Two vaccination regimen with a placebo patch (no swabbing)
62571891|NCT01067781|PLACEBO_COMPARATOR|4|Two vaccination regimen with a placebo patch (with swabbing)
62571892|NCT05060276|EXPERIMENTAL|STI-3258|Intravenous infusion to be given with prophylaxis for infusion reactions, evaluating up to five dose cohorts including: 8 mg/kg, 12 mg/kg, 16 mg/kg, 20 mg/kg, and 24 mg/kg.
62779729|NCT06583434|EXPERIMENTAL|Pilates-Training Group|Participants in this group will receive twice-weekly Pilates sessions focusing on core and lower extremity stabilization exercises. Each session will last for 50 minutes and the intervention will continue for 8 weeks. The goal of this intervention is to improve gait patterns and balance in women with flexible flatfoot.
62779730|NCT06583434|EXPERIMENTAL|Non-Training Group|Participants in this group will not receive any specific intervention during the study period. They will continue their usual activities without any additional exercises provided by the study
62189987|NCT06385847|OTHER|LY-Zo|Arm LY-Zo: LY01005 3.6 mg (i.m.)/4W ✖ 2 cycles, followed by Zoladex 3.6 mg (s.c.)/4W ✖ 2 cycles
62189988|NCT04502797|EXPERIMENTAL|Interventional: Electronic Patient Visit Assessment (ePVA)|Participants diagnosed with head and neck cancer randomized to Electronic Patient Visit Assessment intervention
62189989|NCT04502797|NO_INTERVENTION|Usual care|Participants diagnosed with head and neck cancer randomized to usual care.
62189990|NCT00034554|EXPERIMENTAL|1|0.1mg
62189991|NCT00034554|EXPERIMENTAL|2|0.5mg
62189992|NCT00034554|EXPERIMENTAL|3|2.0mg
62189993|NCT00034554|EXPERIMENTAL|4|4.0mg
62189994|NCT00034554|EXPERIMENTAL|5|8.0mg
62189995|NCT00166881|EXPERIMENTAL|A, 2, III|Weekly Docetaxel-Irinotecan for Inoperable Gastric Cancers After P-HDFL
62189996|NCT01347671|ACTIVE_COMPARATOR|25 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 25 µg GRT6005 per day
62189997|NCT01347671|ACTIVE_COMPARATOR|75 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 75 µg GRT6005 per day
62004357|NCT05120167|ACTIVE_COMPARATOR|Endocervical cytology performed by liquid-based cytology|Endocervical sample collected by brushing and preserved in a liquid base, and evaluated as cytology.
62189998|NCT01347671|ACTIVE_COMPARATOR|200 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 200 µg GRT6005 per day
62189999|NCT01347671|PLACEBO_COMPARATOR|Matching Placebo|Participants allocated to this treatment arm will receive a dose of matched placebo once a day.
62004358|NCT05120167|ACTIVE_COMPARATOR|Endocervical cell block from a canal sample preserved in a buffered formalin base|"Endocervical sample collected by brushing and preserved in a buffered formalin base for obtaining a cell block, and evaluated similarly as histology."
62004359|NCT05120167|ACTIVE_COMPARATOR|Endocervical curettage|Endocervical curettage sample preserved in buffered formalin and evaluated by histology.
62190000|NCT03432390|EXPERIMENTAL|CPAP|
62190001|NCT03432390|ACTIVE_COMPARATOR|Control|
62190002|NCT05140083|EXPERIMENTAL|68Ga-NOTA Evans Blue PET/CT in Patients with Lymphatic System Related Diseases|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA Evans Blue will be injected subcutaneously. PET/CT imaging will be performed at 5-30 min post- injection. Visual and quantitative method will be used to assess the PET/CT images.
62190003|NCT00848848|ACTIVE_COMPARATOR|1|
62571893|NCT06575283||PVWMI Infants aged 6 months to 2 years|Infants will be scanned by MRI at the age of 6 months to 2 years. The infants of periventricular white matter injury (PVWMI) will be enrolled.
62190004|NCT00848848|ACTIVE_COMPARATOR|2|
62396527|NCT06220929|EXPERIMENTAL|Intervention group|Patients were randomly divided into intervention and control groups, with both groups receiving standard treatment and care for sepsis (decided by the attending physician). On this basis, the following treatments were administered: Intervention group (n=20): intravenous drip of ceftriaxone sodium 1g per dose, twice daily (continuously for 14 days), mecobalamin injection 1mg per dose, once daily (on days 1, 2, 3, 5, 7, 9, 11, 13), with a half-hour interval between medications. From day 15 to 28, take mecobalamin tablets orally, 1mg per dose, three times a day.
62571894|NCT06022432|EXPERIMENTAL|Reducing Negative Expectations|This group will watch a video of a patient-therapist interaction. The testimonial of the patient is framed to reduce negative expectations about therapeutic treatment.
62396528|NCT02530034|EXPERIMENTAL|Treatment (Hu8F4)|Patients receive anti-PR1/HLA-A2 monoclonal antibody Hu8F4 IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62571895|NCT06022432|EXPERIMENTAL|Maximizing Positive Expectations|This group will watch a video of a patient-therapist interaction. The testimonial of the patient is framed to maximize positive expectations about therapeutic treatment.
62571896|NCT06022432|OTHER|Control Group|This group will explicate their current treatment expectations in a writing task.
62571897|NCT01450306|EXPERIMENTAL|D-cycloserine plus exposure therapy|Single session (up to 3 hr) of in vivo exposure therapy plus 50 mg oral d-cycloserine administered 1 hr prior to exposure therapy session
62004360|NCT01093404|EXPERIMENTAL|Thrombus aspiration|Thrombus aspiration is then followed by standard balloon angioplasty (PCI).
62004361|NCT01093404|ACTIVE_COMPARATOR|Standard balloon angioplasty (PCI)|
62004362|NCT02399150||Acute Abdominal Pain|patients presenting to the ED with acute abdomen
62004363|NCT00646204|EXPERIMENTAL|1-Active study drug|memantine 10 mg bid
62190005|NCT00848848|ACTIVE_COMPARATOR|3|
62190006|NCT00848848|ACTIVE_COMPARATOR|4|
62190007|NCT00848848|ACTIVE_COMPARATOR|5|
62190008|NCT00848848|ACTIVE_COMPARATOR|6|
62190009|NCT00848848|ACTIVE_COMPARATOR|7|
62190010|NCT00848848|ACTIVE_COMPARATOR|8|
62190011|NCT00848848|ACTIVE_COMPARATOR|9|
62190012|NCT00848848|ACTIVE_COMPARATOR|10|
62004364|NCT00646204|PLACEBO_COMPARATOR|2-placebo comparator|2 tabs bid
62190013|NCT00943787|OTHER|SMBG followed by clamp|One month of self-monitored blood glucose (SMBG) field data was used to calculate measures of glucose variability and risk of hypoglycemia, while the hyperinsulinemic, euglycemic and hypoglycemic clamp procedure was used to evaluate insulin sensitivity and epinephrine response during induced hypoglycemia.
62190014|NCT02922205||RYGB surgery|Obese patients eligible for laparoscopic Roux-en-Y gastric bypass (RYGB) surgery.
62190015|NCT01485107|EXPERIMENTAL|Ultherapy™ treatment on the décolleté|All enrolled subjects will receive the study treatment.
62190016|NCT05359055|EXPERIMENTAL|Cohort 1|SPH3127 tablet, Itraconazole
62190017|NCT05359055|EXPERIMENTAL|Cohort 2|SPH3127 tablet, Rifampin
62190018|NCT01309698|EXPERIMENTAL|Treatment Sequence 1|
62190019|NCT01309698|EXPERIMENTAL|Treatment Sequence 2|
62190020|NCT01309698|EXPERIMENTAL|Treatment Sequence 3|
62190021|NCT01309698|EXPERIMENTAL|Treatment Sequence 4|
62190022|NCT01309698|EXPERIMENTAL|Treatment Sequence 5|
62190023|NCT01309698|EXPERIMENTAL|Treatment Sequence 6|
62190024|NCT00776022|EXPERIMENTAL|1|Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories
62571898|NCT01450306|PLACEBO_COMPARATOR|Placebo plus exposure therapy|Single session (up to 3 hr) of in vivo exposure therapy plus oral placebo capsule administered 1 hr prior to exposure therapy session
62571899|NCT03046589|EXPERIMENTAL|Treatment Period 1|DP13 capsules (dose level 1 ) and placebo capsules
62571900|NCT03046589|EXPERIMENTAL|Treatment Period 2|DP13 capsules (dose level 2) and placebo capsules
62571901|NCT03046589|EXPERIMENTAL|Treatment Period 3|DP13 capsules (dose level 3) and placebo capsules
62571902|NCT03046589|EXPERIMENTAL|Treatment Period 4|DP13 capsules (dose level 4) and placebo capsules
62571903|NCT03046589|EXPERIMENTAL|Treatment Period 5|DP13 capsules (dose level 5) and placebo capsules
62571904|NCT03046589|EXPERIMENTAL|Treatment Period 6|DP13 capsules (dose level 6) and placebo capsules
62571905|NCT01905202|EXPERIMENTAL|Secretrol|Secretrol Capsules 80/80 once daily for 6 months
62571906|NCT04412655||STEMI patients treated in March April 2019|Patients with STEMI undergoing mecahnical revascularization from 1th March to 30th April 2019
62571907|NCT04412655||STEMI patients treated in March April 2020|Patients with STEMI undergoing mecahnical revascularization from 1th March to 30th April 2020
62571908|NCT06368479|EXPERIMENTAL|iStatis Testing Onsite|Capillary (fingerstick) blood samples are tested using iStatis HBsAg Test onsite.
62004365|NCT06042088|EXPERIMENTAL|Double Gloves:Regular Size|Procedure A: Double gloves, participants will wear both gloves in their surgical glove size.
62190025|NCT00776022|ACTIVE_COMPARATOR|2|Cetirizine Hydrochloride 10 mg tablet of Pfizer Labs
62190026|NCT01919515|OTHER|ZR Crown & Stainless Steel Crown|Each subject will have a maximum of one ZR Crown and one Stainless Steel Crown cemented on primary molars that are treatment planned for a crown.
62190027|NCT02333266||Candidemia|0
62190028|NCT02276534|EXPERIMENTAL|Theatre|The participants will receive 10 sessions of peer-mediated, theatre-based intervention.
62190029|NCT02276534|EXPERIMENTAL|No Intervention then Theatre|The participants will not receive the treatment for a period of time.
62190030|NCT06485336|ACTIVE_COMPARATOR|Atorvastatin 40mg|Each participant in this arm will receive 40mg atorvastatin once daily for 84 days.
62190031|NCT06485336|PLACEBO_COMPARATOR|Placebo|Each participant in this arm will receive placebo once daily for 84 days.
62190032|NCT01320878|ACTIVE_COMPARATOR|iloprost low dose group|iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
62190033|NCT01320878|ACTIVE_COMPARATOR|iloprost high dose group|iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
62190034|NCT01320878|PLACEBO_COMPARATOR|placebo group|distilled water 2 ml per session
62190035|NCT05780905|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo for 1 year.
62190036|NCT05780905|ACTIVE_COMPARATOR|Active|Subjects randomized to semaglutide for 1 year.
62571909|NCT06368479|EXPERIMENTAL|iStatis Testing In Lab|Venous whole blood collected in Ethylenediaminetetraacetic acid tube, plasma and serum samples are tested using iStatis HBsAg Test
62571910|NCT06368479|NO_INTERVENTION|Reference Test|Either serum or plasma sample will be tested on Abbott Architect HBsAg Qualitative Confirmatory Assay and ADVIA Centaur (depending on the test result outcome).
62571911|NCT01215396|PLACEBO_COMPARATOR|Carbohydrate Placebo|
62571912|NCT01215396|ACTIVE_COMPARATOR|Single Dose|"The Amino Vital Focus Zone is a dietary supplement of amino acid mixture, which also contains some minerals, vitamin C, flavour, and sweetener, and its appearance is clear to slightly opaque powder. The Amino Vital Focus Zone contains the five kind of amino acid (L-Leucine, L-Isoleucine, L-Valine, L-Arginine, and L-Glutamine), Citric acid, Vitamin C, some mineral, and sweetener.~Powdered treatments will be dissolved in water and administered orally. This treatment will contain 0.96 g of amino acids."
62779731|NCT06583499|EXPERIMENTAL|Intervention Group (educated about sustainable nutrition)|The research will be conducted in an Anatolian high school. The experimental group will be randomly selected from the students who meet the inclusion criteria and are willing to participate in the study. The experimental group will receive sustainable nutrition education programme based on the transtheoretical model. The training content will be applied face-to-face at most twice a week for five weeks.
62004366|NCT06042088|EXPERIMENTAL|Double Gloves: Regular Size and Half-Size Bigger|Procedure B: Double gloves, Participants will wear their own glove size and half-size bigger glove on top
62190037|NCT04092452|EXPERIMENTAL|Cohort 1|PF-06650833
62190038|NCT04092452|EXPERIMENTAL|Cohort 2|PF-6700841
62190039|NCT04092452|EXPERIMENTAL|Cohort 3|PF-06826647
62004367|NCT06042088|EXPERIMENTAL|Double Gloves: Half-Size Bigger and Regular Size|Procedure C: Double gloves, participants will wear a half-size big glove and their own glove size on top.
62004368|NCT06042088|NO_INTERVENTION|One Glove|Procedure D: Participants will wear only one glove.
62004369|NCT01018420|EXPERIMENTAL|Colchicine|
62004370|NCT01018420|ACTIVE_COMPARATOR|Moxifloxacin|
62190040|NCT04092452|PLACEBO_COMPARATOR|Cohort placebo|placebo
62190041|NCT00583271||1|subjects who are getting a celiac block for chronic pancreatitis
62190042|NCT00583271||2|subjects who are getting a celiac block for pancreatic cancer
62190043|NCT00723749||Suboxone|Patients for whom a drug dependence therapy with SUBOXONE® is planned and indicated, and who have already been pre-treated with SUBUTEX®, or another maintenance drug for at least 6 months.
62190044|NCT00302159|EXPERIMENTAL|Valproic Acid|Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.
62190045|NCT06407609|ACTIVE_COMPARATOR|CUBO and low FODMAP diet (Intervention)|Curcuma and Boswellia serrata extract plus a Low Fodmap Diet
62190046|NCT06407609|OTHER|LFD (Control)|Only Low Fodmap Diet
62190047|NCT03070704||Insulin degludec /liraglutide|
62190048|NCT04568863|EXPERIMENTAL|Melatonin|(12 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
62190049|NCT04568863|PLACEBO_COMPARATOR|Placebo|(6 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
62190050|NCT03624387|NO_INTERVENTION|Control Group( No Painting Sessions)|No Geriatric Inclusive Art session.
62190051|NCT03624387|EXPERIMENTAL|Intervention Group( Painting Session)|Painting sessions for participants
62190052|NCT05891145|EXPERIMENTAL|Remimazolam group|General anesthesia was induced with 0.1 mg/kg of remimazolam and maintained with 0.1 mg•kg-1•h-1 remimazolam.
62190053|NCT05891145|ACTIVE_COMPARATOR|Control group|General anesthesia was induced with 0.1 mg/kg midazolam.
62190054|NCT00590525||1|
62190055|NCT01150461|EXPERIMENTAL|losartan|Losartan 50 mg b.i.d.
62190056|NCT01150461|PLACEBO_COMPARATOR|placebo|Placebo b.i.d.
62190057|NCT02515006|EXPERIMENTAL|Homeopathy|Individualized homeopathy treatment as a supportive care
62190058|NCT02515006|NO_INTERVENTION|Control|Usual Care
62190059|NCT04487353|EXPERIMENTAL|Experiment Group|"The Labor Evaluation Information Scale (LEIS) was administered as a pre-test before applying to 30 students who had taken a course on childbirth. After the pre-test, the application was carried out with the Labor mechanism application developed with virtual reality technology (VRT-LMA). Immediately after the application, data were collected with the LEIS, sense of presence scale and cognitive load scale. Post-test was performed again with the Labor Evaluation Information Scale (LEIS) 5 weeks after the application."
62190060|NCT04487353|NO_INTERVENTION|Control Group|"Before the theory training, the Assessment Knowledge Scale (LEIS) was administered as a pre-test to 31 students in the control group who had taken a course on obstetrics. After the pre-test, theory training including birth knowledge was given. Labor mechanism application developed with virtual reality technology (VRT-LMA) was not applied to the control group. After 4 hours of theoretical training, the final test was performed using LEIS. After 5 weeks, the last test was repeated."
62004371|NCT01093339||No treatment|Subjects w/ condition and subjects w/o condition of GERD (gastroesophageal reflux disease)
62004372|NCT04171414|EXPERIMENTAL|"CT-P17 SC AI (adalimumab)"|CT-P17 Subcutaneous(SC) Autoinjector(AI) (adalimumab)
62004373|NCT04788914|OTHER|Active bamboo charcoal|In this proposal, investigators aim to determine the therapeutic impact of a carbonaceous oral adsorbent made of activated bamboo charcoal (ABC) with/without probiotics on the endothelial/vascular function, CV outcome and mortality in CKD patients with PAD. In addition, investigators hypothesize that circulating long noncoding RNA (lncRNA) expression profiles and metabolome may serve as a sensitive and reliable biomarker to predict the adverse CV outcomes and death in CKD patients with established PAD. In addition, it is hypothesized that circulating lncRNAs and linked to adverse CV outcomes in CKD patients with PAD are associated with dysbiosis of gut microbiota. Investigators also hypothesize that the administration of ABC could normalize the dysbiosis of gut microbiota, dysregulated circulating lncRNAs and metabolome that are linked to adverse CV/limb outcomes in CKD patients with PAD.
62004374|NCT04788914|OTHER|Probiotics|The therapeutic impact of probiotics on circulating long noncoding RNA (lncRNA) expression profiles and metabolome may serve as a sensitive and reliable biomarker to predict the adverse CV outcomes and death in CKD patients with established PAD. In addition, it is hypothesized that circulating lncRNAs and linked to adverse CV outcomes in CKD patients with PAD are associated with dysbiosis of gut microbiota.
62190061|NCT01071837|ACTIVE_COMPARATOR|Re-Irradiation|33% of the patients will be randomized to reirradiation (RT) alone. They will receive 36 Gy (2 Gy per fraction)
62779732|NCT06583499|NO_INTERVENTION|Control Group ( non-educated about sustainable nutrition)|In order to prevent any potential influence from peer interaction, the control group will be composed of students from another Anatolian high school with a similar socio-economic and educational background. The control group will be randomly selected from students who meet the inclusion criteria and are willing to participate in the study. The sustainable nutrition education programme will not be applied to this group.
62190062|NCT01071837|EXPERIMENTAL|Re-Irradiation + APG101|66% of the patients will be randomized to reirradiation (RT) + 400 mg APG101 weekly. They will receive 36 Gy (2 Gy per fraction) and 400 mg APG101 weekly as an intravenous infusion
62779733|NCT06474403|OTHER|standard Sugarbecker's operation|patients this group will receive the standard Sugarbaker parastomal hernia repair, a well-established technique involving the placement of as an IPOM mesh replacement to reinforce the abdominal wall.
62779734|NCT06474403|OTHER|modified Sugarbecker's operation|patients this group will undergo a modified technique where the mesh is positioned entirely within the extraperitoneal space
62190063|NCT02460055|ACTIVE_COMPARATOR|Endotracheal tube|Following routine inhalation induction with 8% sevoflurane in oxygen and nitrous oxide, 100% oxygen will be administered and intravenous access will be secured. Intravenous administration of Propofol 3mg/kg and Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation with an age appropriate endotracheal tube. Presence of an audible air leak around the endotracheal tube will be addressed by inflating the cuff with air until the audible leak is no longer appreciated. The endotracheal tube will not be lubricated prior to intubation. Other medications that will be administered during the procedure include Dexamethasone at a dose of 0.15mg/kg up to 20 mg and Ondansetron 0.15mg/kg up to 4mg.
62214711|NCT03975959|OTHER|glioma|"One visit with collection :~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
62004375|NCT04039061||ADPKD patients|Patients with a diagnosis, or suspected diagnosis, of ADPKD
62779735|NCT04788056|EXPERIMENTAL|Bupivacaine|PSPB catheters will be placed with 60mL of 0.2% bupivacaine and continue to infuse bupivacaine 0.125% at 10mL/hr through the catheter
62779736|NCT04788056|PLACEBO_COMPARATOR|Saline|PSPB catheters will be placed with 60mL of saline and continue to infuse saline through the catheters.
62779737|NCT03858530|EXPERIMENTAL|All Patients Enrolled|All patients will undergo limited abdominal US with Doppler and SWE once a week upon admission for conditioning until the patient day +30 BMT or discharge, whichever comes first. Additional ultrasounds will also be performed if SOS is suspected.
62779738|NCT02596945||Peritoneal Dialysis participants|Participants who are on peritoneal dialysis and have been prescribed with methoxy polyethylene glycol were observed for a period of 9 months.
62779739|NCT06021509|EXPERIMENTAL|NovoClasp system|
62004376|NCT01177033||Best endovascular treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
62004377|NCT01177033||Best surgical treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
62779740|NCT00223249|ACTIVE_COMPARATOR|Quetiapine|Quetiapine
62004378|NCT01690039||All study participants|Furosemide-Fludrocortisone-Test and Ammonium chloride-Loading Test will be performed in renal stone patients.
62779741|NCT00223249|PLACEBO_COMPARATOR|Placebo|Inactive ingredient matching the active medication in appearance
62779742|NCT03972878|ACTIVE_COMPARATOR|control snack|control snack
62779743|NCT03972878|EXPERIMENTAL|control cream|control spreadable cream
62779744|NCT03972878|EXPERIMENTAL|cream version 1|control spreadable cream, version 1
62004379|NCT02467725|EXPERIMENTAL|Dynamic Culture Platform|Embryos randomized to the dynamic arm will be placed on the NSSB-300 microvibration platform within the designated incubator. The platform will vibrate at a strength setting of 4 for 5 seconds every 60 minutes. The embryos will be placed on the platform at the two pronucleur stage of development and remain on the platform until the blastocyst stage of development at which time the embryos will be biopsied for preimplantation genetic screening and frozen.
62571913|NCT01215396|ACTIVE_COMPARATOR|Double Dose|"The Amino Vital Focus Zone is a dietary supplement of amino acid mixture, which also contains some minerals, vitamin C, flavour, and sweetener, and its appearance is clear to slightly opaque powder. The Amino Vital Focus Zone contains the five kind of amino acid (L-Leucine, L-Isoleucine, L-Valine, L-Arginine, and L-Glutamine), Citric acid, Vitamin C, some mineral, and sweetener.~Powdered treatments will be dissolved in water and administered orally. This treatment will contain 1.92 g of amino acids."
62004380|NCT02467725|NO_INTERVENTION|Static Culture|The embryos randomized to the static or control arm of the study will be placed directly into the incubator and will not have any additional vibration, per routine care. The embryos will be placed in the incubator at the two pronucleur stage of development and remain in the incubator until the blastocyst stage of development at which time the embryos will be biopsied for preimplantation genetic screening and frozen.
62004381|NCT01826500||Patients|"Patients having any of the following criteria:~* Patients with embryo transfer fresh or frozen~* Patients from an IVF cycle,~* Patients supported surgically for endometriosis"
62004382|NCT01826500||Controls|Controls
62004383|NCT06663709|EXPERIMENTAL|Balance Resistance Aerobic Cognitive Exercises (BRACE)|BRACE include combination of exercises including, Balance, Resistance, Aerobic, Cognition Exercises.
62004384|NCT06663709|EXPERIMENTAL|Task Oriented|Task Oriented protocol is combination of warm up, balance,,and cognition exercises.
62004385|NCT04409041|EXPERIMENTAL|Low-dose naltrexone group|All participants were prescribed low-dose naltrexone at 3mg oral daily.
62004386|NCT01420081|EXPERIMENTAL|B|PI3K Basal, IV Compound
62004387|NCT01420081|EXPERIMENTAL|C|PI3K Activated, Oral Compound
62004388|NCT01420081|EXPERIMENTAL|F|Japanese lead in cohort, IV compound
62004389|NCT05621564||early breast cancer|no requirements for therapy
62004390|NCT05621564||advanced breast cancer|no requirements for therapy
62004391|NCT03619421|EXPERIMENTAL|Supplement with food|Zinc supplement to be taken at time of breakfast consumption
62571914|NCT04596410|EXPERIMENTAL|LLLT applied every other day|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day
62004392|NCT03619421|EXPERIMENTAL|supplement prior to food|Zinc supplement to be taken 30-min before breakfast consumption
62004393|NCT03707288|OTHER|Spine exercise program|"The preclinical second year medical students will be prospectively randomized into two (2) groups, a control group (Group A) and an intervention group (Group B) that will be given a standardized spine exercise program. They will be asked to complete a Questionnaire B to evaluate changes in knowledge, attitude and practice towards musculoskeletal problem of the back and neck pain after intervention; the numeric rating scale (NRS), and the Cornell Musculoskeletal Discomfort Questionnaire (CMDQ) at eight (8) weeks.~The standardized spine exercise program will be provided in a handout and given only to the intervention Group B subjects, these are basic low back exercises to be done three (3) times per week for 20mins, as well as a few very brief stretching exercises to be done during periods of sitting for greater than sixty (60) minutes."
62004394|NCT02310672|EXPERIMENTAL|Macitentan|All patients take open-label macitentan 10mg o.d.
62214712|NCT03975959|OTHER|breast cancer|"One visit with collection :~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
62396529|NCT03373422|EXPERIMENTAL|BAY1128688 (dose 1)|One BAY1128688 tablet (lowest dose) in the morning, one placebo tablet in the evening
62004395|NCT04582552||Ovarian cancer patients treated with PARP inhibitors|PARP inhibitors therapy until disease progression
62004396|NCT03125369|EXPERIMENTAL|Duodenojejunal bypass|patients receive sleeve gastrectomy plus duodeno-jejunal bypass
62004397|NCT03125369|ACTIVE_COMPARATOR|Roux-en-Y gastric bypass|patients receive roux-Y gastric bypass
62214713|NCT03975959|OTHER|healthy|"One visit with collection :~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
62004398|NCT05907135|EXPERIMENTAL|Beet|Powdered beets with green tea extract, Camu Camu, Quinoa sprouts, 3 mushroom blend.
62004399|NCT05907135|PLACEBO_COMPARATOR|Placebo|Similar colored powder with no active ingredients.
62396530|NCT03373422|EXPERIMENTAL|BAY1128688 (dose 2)|One BAY1128688 tablet (first intermediate dose) in the morning, one placebo tablet in the evening
62396531|NCT03373422|EXPERIMENTAL|BAY1128688 (dose 3)|One BAY1128688 tablet (second intermediate dose) in the morning, one placebo tablet in the evening
62004400|NCT05120193|EXPERIMENTAL|Sphere-9 Catheter|Sphere-9™ Mapping and Ablation Catheter; Affera Mapping System; Affera Ablation System
62004401|NCT05120193|ACTIVE_COMPARATOR|THERMOCOOL SMARTTOUCH SF|THERMOCOOL SMARTTOUCH® SF Catheter; SMARTABLATE® System; CARTO® 3 System
62004402|NCT05521204|EXPERIMENTAL|Treatment Group|
62004403|NCT02040662|EXPERIMENTAL|Continuous Thoracic Paravertebral Block|"1. continuous thoracic paravertebral blockade 0,08 ml/kg/h with bupivacaine 0,25% + epinephrine 1:200.000~2. patient-controlled analgesia (morphine), bolus dose 2 mg, lockout time 10 min"
62190064|NCT02460055|ACTIVE_COMPARATOR|No Endotracheal tube|Those not receiving endotracheal intubation will undergo an inhalation induction, have intravenous access secured and intravenous propofol 3mg/kg with Fentanyl 1mcg/kg will be administered prior to placement of the nasal trumpet and connection to the anesthesia circuit.patients will receive a general anesthetic consisting of sevoflurane in oxygen and air at routine concentrations for maintenance of anesthesiaOther medications that will be administered during the procedure to both arms of patients include Dexamethasone which will be administered at a dose of 0.15mg/kg up to 20 mg and Ondansetron 0.15mg/kg up to 4mg for post operative nausea and vomiting prophylaxis.
62571915|NCT04596410|ACTIVE_COMPARATOR|LLLT applied daily|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every day
62571916|NCT06380114|ACTIVE_COMPARATOR|Communication Training|Practice personnel (providers and nurses) receive training in communication about HPV vaccination.
62571917|NCT06380114|EXPERIMENTAL|Communication Training + Standing Orders Training/Implementation|Practice personnel (providers and nurses) receive training in communication about HPV vaccination and training in the implementation of standing orders for HPV vaccination.
62004404|NCT02040662|EXPERIMENTAL|Continuous Thoracic Epidural Analgesia|"1. continuous thoracic epidural block 0,06 ml/kg/h with bupivacaine 0,25% + epinephrine 1:200.000~2. patient-controlled analgesia (morphine), bolus dose 2 mg, lockout time 10 min"
62190065|NCT00518856|EXPERIMENTAL|intervention|TBAs who receive training and supplies for the intervention
62190066|NCT00518856|ACTIVE_COMPARATOR|control|TBAs continuing with current standard of practice
62190067|NCT05869695||OSPRO-ROS: 100 patients presenting musculoskeletal pain|Patients between 18 and 75 years of age with primary complaints involving the cervical spine, lumbar spine, shoulder or knee. Were able to read and comprehend Spanish.
62571918|NCT00755599|ACTIVE_COMPARATOR|No Stirrups|Vaginal speculum examinations done without stirrups. The woman's feet will be placed onto the exam table allowing maximal repositioning by the woman.
62571919|NCT00755599|ACTIVE_COMPARATOR|Stirrups|Speculum examination with feet in stirrups. The woman's feet will be placed into obstetric stirrups which fix the feet in place.
62190068|NCT05869695||OSPRO-YF: 100 patients presenting musculoskeletal pain|Patients between 18 and 75 years of age with primary complaints involving the cervical spine, lumbar spine, shoulder or knee. Were able to read and comprehend Spanish.
62190069|NCT00216047|EXPERIMENTAL|Single Group Assignment|Trastuzumab + PTK787 for HER2 positive patients
62190070|NCT01787253||Irritable bowel syndrome (IBS)|
62190071|NCT01787253||Healthy controls|
62190072|NCT01787253||Microscopic Colitis (MC)|
62396532|NCT03373422|EXPERIMENTAL|BAY1128688 (dose 4)|One BAY1128688 tablet (second intermediate dose) in the morning and one in the evening
62396533|NCT03373422|EXPERIMENTAL|BAY1128688 (dose 5)|One BAY1128688 tablet (highest dose) in the morning and one in the evening
62396534|NCT03373422|PLACEBO_COMPARATOR|Placebo|One placebo tablet in the morning and one in the evening
62779745|NCT03972878|EXPERIMENTAL|cream version 2|control spreadable cream, version 2
62190073|NCT01787253||Irritable bowel disease (IBD)|
62190074|NCT03903497|OTHER|NBI assessment using the WASP classification|
62396535|NCT01914289|EXPERIMENTAL|Resection|To observe prognosis of resection of icc
62779746|NCT03972878|EXPERIMENTAL|cream version 3|control spreadable cream, version 3
62779747|NCT03972878|EXPERIMENTAL|control chocolate bar|control chocolate bar
62779748|NCT03972878|EXPERIMENTAL|chocolate bar version 1|control chocolate bar version 1
62779749|NCT01060046||Patients with previously implanted biologic mesh|All patients undergoing a repeat operation to repair a recurrent hernia or to revise a surgical site which has been previously repaired using a biologic mesh.
62396536|NCT01914289|ACTIVE_COMPARATOR|Radiotherapy|To observe the prognosis of radiotherapy treatment of icc
62190075|NCT01642953|EXPERIMENTAL|Early recovery|"Patients who enroll in this arm are supplied a liquid diet one day before surgery without bowel preparation.~After gastric cancer surgery, they start sips of water on postoperative first day, and they are discharged once they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination."
62190076|NCT02643628|EXPERIMENTAL|Microneedling Only|All eligible scars within the treatment areas on each side of the face will receive microneedling treatment. The device will be rolled in a horizontal direction with medium pressure. After every roll, the device will be lifted and positioned a few millimeters inferior to the previous starting point. Rolling will be repeated until the entire skin area has been treated. The device will then be reoriented vertically and rolling will be repeated in a vertical direction.
62396537|NCT06722313|EXPERIMENTAL|PGT-M|The couples intended for PGT-M without proband were recruited from Shanghai JiAi Genetics and IVF Institute, Obstetrics and Gynecology Hospital of Fudan University between January 2023 and December 2024, and were included in the study if they were expected to have difficulties in the identification of an embryo as proband.
62396538|NCT03373656|EXPERIMENTAL|low antibody titers|Antibody titers lower than protection level
62571920|NCT02686463|EXPERIMENTAL|the laparoscopy group|Patients who are randomized to the laparoscopy group.
62571921|NCT02686463|EXPERIMENTAL|the laparotomy group|Patients who are randomized to the laparotomy group.
62571922|NCT00244114||A|
62571923|NCT00244114||B|
62571924|NCT02223962|EXPERIMENTAL|Physical activity|The fitbit Ultra was used to provide real-time feedback on physical activity. An experienced physiotherapist contacted the subjects 3 times a week to receive information about the amount of steps from the previous days. In agreement with the patient, a new goal for the coming weeks was set and patients were motivated to achieve their individual goal.
62571925|NCT02223962|PLACEBO_COMPARATOR|Usual Care|During the hospital stay, the patients in the control group will be informed about the beneficial effects of being physically inactive.They will not receive feedback about their activities performed and will not be stimulated to become more active.
62571926|NCT03966417|ACTIVE_COMPARATOR|Exercise training group|"Patient to be randomized to exercise training group will have exercise training sessions 2 times per week for a period of 12 weeks. They will undergo moderate continuous exercise training at 75% of Vo2max."
62571927|NCT03966417|NO_INTERVENTION|Usual care group|"Patient to be randomized to usual care group will undergo standard care fo 12 weeks."
62004405|NCT01899469|EXPERIMENTAL|Electromagnetic therapy (EM)|The group had performed 20 sessions of EM therapy for 20 minutes and after had a 25 minutes from Back School intervention.
62004406|NCT01899469|EXPERIMENTAL|Transcutaneous Electrical Neurological Stimulation (TENS)|The group had performed 20 sessions of TENS therapy for 20 minutes and after had a 25 minutes from Back School intervention.
62004407|NCT01899469|EXPERIMENTAL|Back School (BS)|The group had performed 20 sessions of Back School therapy for 25 minutes.
62004408|NCT03904459||cases|Children with juvenile idiopathic arthritis
62004409|NCT03904459||controls|healthy children
62004410|NCT02259491|EXPERIMENTAL|Manuka Honey Dressing|Patient receive manuka honey dressings on skin graft and free flap donor sites
62004411|NCT02259491|NO_INTERVENTION|Tegaderm and xeroform gauze|Patient receive standard wound care on skin graft and free flap donor sites which includes a tegaderm over the STSG site and xeroform gauze covered with dry gauze, kerlex and a cast for the STSG recipient site
62004412|NCT05475184|EXPERIMENTAL|JPI-547|
62004413|NCT01860417|EXPERIMENTAL|Allogenic Mesenchymal Stromal Cells|Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intradiscal injection of 25 millions MSC in 2 ml of saline
62004414|NCT01860417|ACTIVE_COMPARATOR|Mepivacaine|Infiltration of paravertebral musculature close to the affected disc(s) with 2 ml of 1% Mepivacaine
62004415|NCT04748510|ACTIVE_COMPARATOR|Functionally aligned Total Knee Arthroplasty|Knee arthroplasty performed using a functional alignment theory
62004416|NCT04748510|ACTIVE_COMPARATOR|Mechanical axis aligned Total Knee Arthroplasty|Knee arthroplasty performed using a mechanical alignment theory
62004417|NCT01277588||Patient|
62779750|NCT01060046||Control patients|Any patient undergoing a surgical procedure where fascial biopsy would not compromise the integrity of the procedure.
62004418|NCT01277588||Physcician|
62004419|NCT01919424|ACTIVE_COMPARATOR|'The English-Wright nebulizer'|The English-Wright nebulizer will be used to perform a methacholine challenge.
62004420|NCT01919424|ACTIVE_COMPARATOR|Trudell AeroEclipse*II BAN nebulizer|The Trudell AeroEclipse\*II BAN nebulizer will be used to perform a methacholine challenge
62004421|NCT04871334|EXPERIMENTAL|Dose Escalation Cohort|Six dose levels of TWP-101 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.
62004422|NCT04871334|EXPERIMENTAL|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
62004423|NCT04631939|EXPERIMENTAL|study intervention|"The intervention consists of a puzzle adventure game, in which players have to explore the fantasy world Macu'ta. The puzzles are based on Metacognitive Training for Psychosis (MCT), an intervention using playful, entertaining exercises to increase awareness of reasoning biases in patients and 'sow the seeds of doubt' through corrective ('aha!') experiences. The tasks will address reasoning biases associated with the emergence and maintenance of delusions."
62004424|NCT04631939|SHAM_COMPARATOR|control intervention|The control intervention consists of a puzzles focused exclusively on dexterity and accuracy.
62004425|NCT00780221||control|patients without coronary artery disease
62004426|NCT00780221||case|patients with coronary artery disease
62004427|NCT02292628|EXPERIMENTAL|Mesenchymal stem cells|Autologous mesenchymal stem cells from the adipose tissue in an unique intralesional infusion with a dose of 40 million cells.
62004428|NCT02292628|PLACEBO_COMPARATOR|Ringer lactate solution|Ringer lactate solution
62779751|NCT06039358|EXPERIMENTAL|Control - caffeine - placebo.|The order of the assessed sessions will be first the control one, then the caffeine one, and then the placebo one.
62004429|NCT02364310|EXPERIMENTAL|Baroreceptor stimulation on top of the best medical care|Baroreceptor stimulation with Barostim Neo TM
62779752|NCT06039358|EXPERIMENTAL|Control - placebo - caffeine.|The order of the assessed sessions will be first the control one, then the placebo one, and then the caffeine one.
62004430|NCT02364310|NO_INTERVENTION|Best medical care|Best medical care
62004431|NCT00858390|NO_INTERVENTION|1 standard care|organ donors receiving standard care
62004432|NCT00858390|EXPERIMENTAL|2 Enteral Feeding|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
62004433|NCT00101101|EXPERIMENTAL|Vaccine and Conventional Therapy|"Patients were treated with 3-6 cycles of chemotherapy +/- rituximab, with type and duration at the discretion of the individual clinician.~Chemotherapy: 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.~Patients who achieve a partial or complete response after completion of chemotherapy proceed to autologous tumor cell-based vaccine therapy.~Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2.~Treatment continues in the absence of disease progression or unacceptable toxicity."
62004434|NCT00073671|EXPERIMENTAL|1= Cognitive behavioral prevention of depression program|Participants receive a group cognitive-behavioral prevention program, which involved 8 weekly sessions and 6 monthly sessions of CBT skills such as cognitive restructuring, problem-solving, assertivenss, and behavioral activation. Participants in this arm also were able to seek the same kinds of nonstudy treatments as described in the usual care arm.
62004435|NCT00073671|ACTIVE_COMPARATOR|2 = Usual care|Participants receive usual care, which involves any type of treatment (e.g., psychotherapy, counseling, pharmacotherapy).
62214714|NCT02963740|EXPERIMENTAL|Weight Loss Intervention Group|Participants will take part in supervised exercise and home-based exercise sessions. Participants will be asked to follow a specific diet. Participants will be asked to take part in weekly behavioral group phone calls.
62571928|NCT03799640|EXPERIMENTAL|Standard Yoga|Yoga will be performed using linear forward and backward movements.
62571929|NCT03799640|EXPERIMENTAL|Multi-directional Yoga|The multidirectional yoga training program will use both simple and complex movement sequences (asana or postures) that include a cognitive component. For example, participants will be taught a movement sequence that includes 16-20 yoga postures that increase in difficulty as the training progresses. .
62004436|NCT05369910|EXPERIMENTAL|Flash first|"Light exposure (Flash) first, light deprivation (Dark) second:~Both interventions (Flash and Dark) are administered for one hour on 7 consecutive days. During the light exposure, participants are seated 120 cm in front of a white curtain that is illuminated by an LED light source. During the light deprivation, participants are seated in the same room used for light exposure, but in complete darkness."
62004437|NCT05369910|EXPERIMENTAL|Dark first|"Light deprivation (Dark) first, Light exposure (Flash) second:~Both interventions (Flash and Dark) are administered for one hour on 7 consecutive days. During the light exposure, participants are seated 120 cm in front of a white curtain that is illuminated by an LED light source. During the light deprivation, participants are seated in the same room used for light exposure, but in complete darkness."
62190077|NCT02643628|EXPERIMENTAL|Microneedling followed by Bellafill treatment|Subjects undergo microneedling as described for the Microneedling Only group. Then at Week 12, all eligible scars within the treatment areas on each side of the face will be treated with Bellafill (injected using a standard tunneling technique). A touch-up treatment is allowed at Month 1 after initial treatment, if additional treatment is required to achieve optimal correction.
62190078|NCT01021709|EXPERIMENTAL|tDCS with alternative electrode montage|Treating major depression with either alternative tDCS electrode montage.
62190079|NCT01952847|PLACEBO_COMPARATOR|mTOR Inhibitor Patient Group - Placebo|Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
62190080|NCT01952847|EXPERIMENTAL|mTOR Inhibitor Patient Group - Glutamine|Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
62190081|NCT01952847|PLACEBO_COMPARATOR|Radiation Therapy to Esophagus Patient Group - Placebo|Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times.
62190082|NCT01952847|EXPERIMENTAL|Radiation Therapy to Esophagus Patient Group - Glutamine|Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times.
62396539|NCT03373656|OTHER|high antibody titers|Antibody titers higher than protection level
62396540|NCT05174013|EXPERIMENTAL|Participants receiving GSK3858279|
62779753|NCT05800275|EXPERIMENTAL|Tucatinib + Intrathecal Trastuzumab + Capecitabine|Intra-CSF trastuzumab: 150 mg weekly Tucatinib: 300 mg orally twice daily Capecitabine: 1000 mg/m² orally twice daily on days 1-14 of each 21-day cycle
62779754|NCT02861859|PLACEBO_COMPARATOR|Placebo Comparator|"Eligible patients at high personal risk of CIVN will receive Standard of Care Regimen: Aprepitant (125 mg PO OD day 1, 80mg OD days 2-3), ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine placebo (PO OD days 1-4).~Eligible patients at low personal risk of CIVN will receive Standard of Care Regimen: Ondansetron (8mg PO, BID on Day 1 of each cycle,), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine placebo (PO OD days 1-4)."
62779755|NCT02861859|ACTIVE_COMPARATOR|Olanzapine|"Eligible patients at high personal risk of CIVN will receive Standard of Care Regimen: Aprepitant (125 mg PO, OD day 1, 80mg OD days 2-3), ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine (5 mg PO OD days 1-4).~Eligible patients at low personal risk of CIVN will receive Standard of Care Regimen: Ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine (5 mg PO OD days 1-4)."
62779756|NCT01893775|EXPERIMENTAL|1|Hu-Mik-Beta-1 every 3 weeks
62004438|NCT05543785|PLACEBO_COMPARATOR|control|"will receive 50 ml normal saline in the intravenous regional cannula in the surgical limb with torniquet.~And receive intravenous 30 mg ketorolac diluted in 10 ml saline in the peripheral general circulation."
62004439|NCT05543785|ACTIVE_COMPARATOR|ketorolac|"will receive 15 mg ketorolac tromethamine diluted in normal saline in a total volume of 50 ml in the intravenous regional cannula in the surgical limb with torniquet.~And receive intravenous 10 ml saline in the peripheral general circulation."
62004440|NCT06192004||Prospective Cohort|NSCLC patients initiating an approved treatment with risk of pneumonitis/ILD.
62004441|NCT06026904|ACTIVE_COMPARATOR|Active Comparator: Real Stimulation|The active Stimulation of taVNS lasted 30 mins. The stimulation protocol is preset to a biphasic impulse frequency of 25 Hz with a stimulation duration of 30 s, followed by a 30 s off phase. Behavior and ERPs datasets should be acquired before the first taVNS session and after the last taVNS session.The electrical current is transmitted by a titanium electrode placed at the cymba conchae.
62190083|NCT05194033|EXPERIMENTAL|Probiotics|The intervention group consumes oral probiotics 1 time/day for 7 consecutive days.
62190084|NCT05194033|PLACEBO_COMPARATOR|Placebos|The placebo group consumes oral placebo 1 time/day for 7 consecutive days.
62190085|NCT01793636|EXPERIMENTAL|AZD2014|AZD2014- tablets, starting dose 50mg BD everyday, until disease progression or untolerable toxicity
62396541|NCT05174013|PLACEBO_COMPARATOR|Participants receiving placebo|
62396542|NCT00994045|ACTIVE_COMPARATOR|Fresh Frozen Plasma|
62396543|NCT00994045|EXPERIMENTAL|Fibrinogen concentrate|
62571930|NCT03799640|EXPERIMENTAL|Educational Control|Lectures on Health and Wellness
62571931|NCT03637881||Other|Daily or non-daily Consumers
62779757|NCT03869879|ACTIVE_COMPARATOR|Feedback-assisted physical therapy|During a visual feedback session, therapists will spend 30min per session using the Mobility Rehab system for gait training with patients. Therapists may select modality, overground walking and/or treadmill, tasks (dual task, head turns, etc. as above) as appropriate for each patient. They will additionally spend 15min on endurance, strength, and static and dynamic balance in functional tasks.
62004442|NCT06026904|SHAM_COMPARATOR|Sham Comparator: Sham Stimulation|The active Stimulation of taVNS lasted 30 mins. The stimulation protocol is preset to a biphasic impulse frequency of 25 Hz with a stimulation duration of 30 s, followed by a 30 s off phase. Behavior and ERPs datasets should be acquired before the first taVNS session and after the last taVNS session.The electrical current is transmitted by a titanium electrode placed at the earlobe of the midpoint of the outer ear margin.
62190086|NCT01793636|ACTIVE_COMPARATOR|Everolimus|Everolimus- tablets, starting dose 10mg OD everyday until disease progression or untolerable toxicity
62190087|NCT05563090||0HEA|Healthy or sub-healthy subject without clinically diagnosed chronic conditions such as diabetes, hypertension or dyslipidemia
62190088|NCT05563090||1PRE|Prediabetes with IFG of FPG 6.1-6.9 mmol/L, and/or IGT with 2hPG of 7.8-11.0 mmol/L
62190089|NCT05563090||2DIA|Diabetes with FPG of ≥ 7.0 mmol/L, 2hPG of ≥ 11.1mmol, or HbA1c of \> 6.5%
62190090|NCT05563090||3PREHD|Prediabetes with hypertension and dyslipidemia
62396544|NCT03799341|EXPERIMENTAL|Tangible Prize-Based Contingency Management (TangiblePBCM)|For participants assigned to TangiblePBCM, prize draws resulting in one or more small, large, or jumbo wins will result in access to a prize cabinet stocked with small, medium, large, and jumbo financial incentive items. Medium incentive items are included for selection in the event that a patient draws several small prize slips on the same day and are considered equivalent to 4 small prizes. Selection of specific prize items will be informed by patient preference and items will be restocked at least every 2 weeks. The prize cabinet will be open during TangiblePBCM sessions such that prize items are readily visible. Selection of prizes, maintenance of the prize cabinet, and policies regarding prize redemption will follow published guidance on administration of TangiblePBCM within the context of research protocols.
62396545|NCT03799341|EXPERIMENTAL|Voucher Prize-Based Contingency Management (VoucherPBCM)|For participants assigned to VoucherPBCM, prize draws resulting in one or more small, large, or jumbo wins will be reinforced with VA Canteen vouchers in the specified incentive range (i.e., small, large, or jumbo).
62779758|NCT03869879|PLACEBO_COMPARATOR|Traditional physical therapy|During a regular session, patients with gait impairment will work on gait with the following tasks for 30min: weights on ankles, dual tasks, UE support, partial body weight support, speed challenges, obstacles, and head turning. Therapists may select modality, overground walking and/or treadmill, tasks (dual task, head turns, etc. as above) as appropriate for each patient. They will additionally spend 15min on endurance, strength, and static and dynamic balance in functional tasks.
62190091|NCT05563090||4DIAHD|Diabetes with hypertension and dyslipidemia
62396546|NCT01749241|EXPERIMENTAL|Loteprednol etabonate ointment|This is the arm which contains loteprednol steroid
62396547|NCT01749241|OTHER|Vehicle Ointment|This arm contains vehicle only.
62779759|NCT04951700||Schizophrenia|Women and men, all races and ethnicities, aged 18-65 years, meeting diagnostic DSM-5 criteria for schizophrenia or schizoaffective disorder.
62004443|NCT04652128|EXPERIMENTAL|zoledronate|Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.
62004444|NCT04652128|PLACEBO_COMPARATOR|saline|Subject will receive a single infusion of physiological saline 100mL intravenously.
62004445|NCT00964808|EXPERIMENTAL|Buprenorphine|Double dummy; Group A: Active Buprenorphine and placebo oxycodone
62004446|NCT00964808|EXPERIMENTAL|Oxycodone|"Double Dummy:~Group B: Placebo Buprenorphine and Active Oxycodone"
62190092|NCT00992992|EXPERIMENTAL|Tositumomab and Iodine I 131 Tositumomab followed by CHOP|Tositumomab and Iodine I 131 Tositumomab followed by CHOP
62190093|NCT04517968|EXPERIMENTAL|immediate implant with customized healing abutment|
62190094|NCT01629212|EXPERIMENTAL|Tiropramide HCl|
62190095|NCT01629212|ACTIVE_COMPARATOR|Octylonium bromide|
62190096|NCT02880839|EXPERIMENTAL|Partial cervical lamina excision group|Patients in the cervical lamina partial excision group underwent partial cervical lamina excision and cervical pedicle screw internal fixation.
62190097|NCT02880839|EXPERIMENTAL|Pipeline-dredge discharge group|Patients in the pipeline-dredge discharge group underwent pipeline-dredge discharge and cervical pedicle screw internal fixation.
62190098|NCT02880839|EXPERIMENTAL|Digital navigation group|Patients in the digital navigation group underwent digital navigation-assisted cervical pedicle placement.
62396548|NCT05915455|EXPERIMENTAL|HCP resource evaluation|HCP will be provided with resources to evaluate
62004447|NCT00689481|EXPERIMENTAL|U0267 foam|U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
62004448|NCT00689481|PLACEBO_COMPARATOR|Vehicle foam|Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
62004449|NCT01333488|NO_INTERVENTION|Conventional Therapy|
62190099|NCT01530893|EXPERIMENTAL|Intervention group A: flavanones|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
62214715|NCT01791387|EXPERIMENTAL|Dovitinib|Dovitinib 500 mg taken orally once daily 5 days on / 2 days off, until disease progression
62004450|NCT01333488|EXPERIMENTAL|Hypothermia|Subjects will have their core body temperatures lowered to 34C.
62779760|NCT04951700||Healthy Controls|Women and men, all races and ethnicities, aged 18-75 years, without personal history of lifetime psychiatric disorders, or a family history of psychotic disorders in 1st- or 2nd-degree relatives.
62004451|NCT01333488|EXPERIMENTAL|Hypothermia plus supplemental magnesium sulfate infusion|
62004452|NCT02306980|EXPERIMENTAL|Colostrum|Colostrum administration
62004453|NCT02306980|NO_INTERVENTION|Control|Routine care
62004454|NCT00799149|ACTIVE_COMPARATOR|Gabapentin|Gabapentin (1200 mg) administered 30-90 min before the patient entered the operating room; Subsequent doses of Gabapentin (1200 mg)were administered on the mornings (08H00) of the first, second, and third postoperative days.
62004455|NCT00799149|ACTIVE_COMPARATOR|Etoricoxib|Etoricoxib (120 mg)administered 30-90 min before the patient entered the operating room; Subsequent doses of etoricoxib (120 mg)were administered on the mornings (08H00) of the first, second, and third postoperative days.
62004456|NCT00799149|PLACEBO_COMPARATOR|Sugar pill|Sugar pill administered 30-90 min before the patient entered the operating room. Subsequent doses of Sugar pill were administered on the mornings (08H00) of the first, second, and third postoperative days.
62004457|NCT05540366|EXPERIMENTAL|Intervention Group|"Myogenous temporomandibular subjects~Physical therapy combined with aerobic exercise: 30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a bike."
62004458|NCT05540366|ACTIVE_COMPARATOR|Control group|"Myogenous temporomandibular subjects~Physical Therapy: 30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the intervention group)"
62004459|NCT06208241|EXPERIMENTAL|Allocetra-OTS|Single IA dose of Allocetra-OTS cells in suspension
62396549|NCT03596385|EXPERIMENTAL|Beta-blocker therapy|"This is a strategy (pragmatic) trial. In patients allocated to Beta-blocker therapy, beta blocker agent and dose are decided by treating physician.~betablocker therapy chosen might be any of the following: atenolol bisoprolol carvedilol metoprolol nebivolol"
62190100|NCT01530893|EXPERIMENTAL|Intervention group B: isoflavones|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
62190101|NCT01530893|EXPERIMENTAL|Intervention group C: Flavan-3-ols|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
62190102|NCT01530893|EXPERIMENTAL|Intervention group D: Anthocyanins|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
62396550|NCT03596385|NO_INTERVENTION|Control (no beta-blocker therapy).|Do not receive beta -blocker therapy
62396551|NCT04322929|EXPERIMENTAL|Oral roflumilast|Oral roflumilast 250 microgram daily will be started at the baseline visit for 4 weeks. For those who can tolerate the initial 4-week treatment, roflumilast will be increased to 500 microgram daily, allowing subsequent dose reduction back to 250 microgram daily in case of CTCAE grade 3 or 4 toxicities.
62571932|NCT04679532|OTHER|Validation. Gx sweat collection patch|Left ventral forearm placement using Epicore Biosystems Gx patch
62779761|NCT02145351|ACTIVE_COMPARATOR|Pacing off first, then pacing on|No-pacing on for the first for 4 weeks, followed by 4 week washout period, and then cross-over to pacing on for an additional 4 weeks.
62779762|NCT02145351|EXPERIMENTAL|Pacing on first, then pacing off|Pacing on for the first for 4 weeks, followed by 4 week washout period, and then cross-over to pacing off for an additional 4 weeks
62779763|NCT05491434|NO_INTERVENTION|Control|The usual pre-surgical preparation and conditioning will be carried out, without providing nutritional supplements or increased physical activity
62779764|NCT05491434|EXPERIMENTAL|Experimental|In addition to the usual pre-surgical preparation and conditioning, a nutritional supplement and increased physical activity will be provided in a controlled manner for 3 weeks.
62779765|NCT01199562||Arm I|Patients receive standard antiviral infection prophylaxis and management comprising ganciclovir, valganciclovir, or foscarnet sodium for 2 weeks or until the plasma CMV DNA Q-PCR is negative. Patients may receive additional courses based on subsequent CMV reactivations.
61977930|NCT03772145||Tofacitinib|Adult patients, age 18 years or older, with UC, who within 2 weeks have been started on tofacitinib therapy for moderate to severe UC or who plan to start this therapy within the next 2 weeks. The start of the tofacitinib therapy must have been or be initiated in the setting of standard of care therapy
61977931|NCT05230537|EXPERIMENTAL|Iptacopan (LNP023)|Iptacopan (LNP023) oral use capsules
61977932|NCT05230537|PLACEBO_COMPARATOR|Placebo|Placebo matched to study drug, oral use capsules
62571933|NCT04679532|OTHER|Validation. Reference sweat collection patch|Right ventral forearm placement using a well-established methodology as published in peer-reviewed journals
62571934|NCT03039764|NO_INTERVENTION|Standard occupational therapy|This group will receiving standard occupational therapy for the treatment of acute stroke.
62571935|NCT03039764|EXPERIMENTAL|SOT plus VR Rapael|This group will receive virtual reality-based rehabilitation intervention wearing Rapael glove made by Neofect supplemented with standard occupational services per conventional protocols.
62571936|NCT02514720|OTHER|Fast Nicotine Metabolizers|Those in the upper tertile of NMR for cigarette/nicotine metabolism.
62571937|NCT02514720|OTHER|Slow Nicotine Metabolizers|Those in the lower tertile of NMR for cigarette/nicotine metabolism
62004460|NCT02129361|EXPERIMENTAL|Adapted Screening and Brief Intervention|Adapted Screening and Brief Intervention: Participants will be screened for substance use, receive education regarding the effects of substance misuse, participate in a motivation interview, and participate in a booster session one month later
62004461|NCT02129361|ACTIVE_COMPARATOR|Screening & Education Attention Control|Screening \& Education Attention Control: Participants will be screened for substance use, receive education regarding the effects of substance misuse, and participate in a booster session one month later
62004462|NCT01304485|EXPERIMENTAL|Sodium Acetate C11 PET Imaging|
62004463|NCT01918475|ACTIVE_COMPARATOR|Carbetocin first|Subjects receive carbetocin 0.1 mg intravenously in the first session and placebo (NaCl 0.9%) in the second session
62571938|NCT05630261|EXPERIMENTAL|Self-help CBT-I|Participants assigned to the CBT-I group will receive the self-help CBT-I intervention for six weeks (i.e., participants will access the intervention every day, for 42 days).
62571939|NCT05630261|ACTIVE_COMPARATOR|Self-help CBT-D|Participants assigned to the CBT-D group will receive the self-help CBT-D intervention for six weeks (i.e., participants will access the intervention every day, for 42 days).
62571940|NCT03787784|EXPERIMENTAL|AI visible group|
62571941|NCT03787784|NO_INTERVENTION|AI invisible group|
62571942|NCT02189031||Upper Extremity Amputee|Robust custom tactor to facilitate embodiment and proprioception
62571943|NCT02189031||Able Bodied|Bypass tactor
62004464|NCT01918475|ACTIVE_COMPARATOR|Placebo first|Subjects receive placebo (NaCl 0.9%) intravenously in the first session and carbetocin 0.1 mg in the second session
62004465|NCT03251248|EXPERIMENTAL|First MSB11455 Then Neulasta|
62004466|NCT03251248|EXPERIMENTAL|First Neulasta Then MSB11455|
62571944|NCT01072773|EXPERIMENTAL|Bortez/Cyc/Dex|Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.
62571945|NCT00554515|EXPERIMENTAL|HD IL2|Participants received high-dose (HD) IL2, 600,000 IU/kg/dose (Prometheus Laboratories Inc.) i.v. every 8 hours for 5 days (maximum of 14 doses) beginning on day 1 and again on day 15. One course generally consisted of 5 days of treatment, 9 days of rest, 5 more days of treatment, and 9 weeks of rest, followed by up to two additional courses of HD IL2 for patients who benefited and tolerated most of the planned IL2 doses. A treatment delay of up to 4 weeks was allowed for resolution of side effects between courses. Patients were eligible to receive a maximum of three courses of treatment.
62571946|NCT03474185||Single Cohort|"The intervention for the entire cohort will be Taking Charge of your Heart Health Cardiac Education Classes, delivered via four 2.5-hour group-based classes at TotalCardiology Rehabilitation in Calgary, Canada. Classes review physiology, risk factors, medications, nutrition, exercise, and stress management. Patients are required to complete these classes prior to starting CR exercise sessions."
62571947|NCT01610817||Patients with the InPAct intervention|The InPAct intervention will be presented to the last patients recruited by each general practitioner
62396552|NCT04780230|EXPERIMENTAL|real tDCS|A total of 60 Cantonese-speaking post-stroke patients who are suffering from dysarthria will be recruited and randomly divided into real tDCS and sham groups.
62004467|NCT04441294|EXPERIMENTAL|ACE-Plus|"ACE-Plus is a one-on-one dual-session intervention for males aged 16 to 20 within foster care or preventive services settings which promotes condom use and knowledge of dual methods of contraception. The goal of ACE-Plus is to promote correct and consistent condom use of male latex condoms during penile-vaginal sex and to promote male engagement (e.g., discussion, decision-making) with their female partners in the use of female-centered contraception methods.~Session one focuses on correct and consistent condom use for purposes of HIV/STD prevention including information and activities that address teen pregnancy prevention. Session two, which occurs within 10 to 14 days of the first session, promotes dual-method contraceptive use. Both sessions are one hour."
62004468|NCT04441294|NO_INTERVENTION|On Track|On Track was the alternative program provided to males randomly assigned to the control group. On Track seeks to assist participants in identifying their aptitudes and preferences regarding their careers and their values associated with employment, and to provide tools to prepare them for the work setting and future job interviews. Participants learn how to identify attitudes, values, preferences, and challenges surrounding a career path, receive an understanding of the documents required for employment, and develop an initial employment strategy and action plan. Trained foster care agency staff deliver the curriculum to participating youth in two one-on-one sessions at agencies. Each session is one hour in length. Session two occurs 10 to 14 days after session one.
62004469|NCT04073095|ACTIVE_COMPARATOR|Group T = mTLIP block group|In group T, mTLIP block will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).
62004470|NCT04073095|ACTIVE_COMPARATOR|Group E = ESPB group|In group E, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).
62004471|NCT04073095|NO_INTERVENTION|Group C = Control group|Patients in control group will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
62004472|NCT01900470|EXPERIMENTAL|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT CHWs conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
62396553|NCT04780230|SHAM_COMPARATOR|sham tDCS|A total of 60 Cantonese-speaking post-stroke patients who are suffering from dysarthria will be recruited and randomly divided into real tDCS and sham groups.
62396554|NCT01854502|EXPERIMENTAL|Oral hygiene and fluoride use|Parents of young children were given counseling of their own oral hygiene and the use of fluoride on their child's visit to public dental service. The child was given multi-faceted counseling for good oral health habits.
62396555|NCT01854502|NO_INTERVENTION|Control|"Control, The parents were not given any intervention on their child's visit to public dental service.~The child was given multi-faceted counseling for good oral health habits."
62396556|NCT01854502|EXPERIMENTAL|Diet and use of xylitol|Parents of young children were given counseling of their own diet and the use of xylitol on their child's visit to public dental service. The child was given multi-faceted counseling for good oral health habits.
62396557|NCT06502821||students|4th year students of physical therapy
62396558|NCT06502821||young physiotherapists|physiotherapists 1-3 years in the profession
62396559|NCT06502821||experienced physical therapist|physical therapists with over 10 years in profession
62396560|NCT06156774||Patients with Non-Hodgkin Lymphoma B cell|Patients with B-cell non-Hodgkin Lymphoma scheduled to received CAR-T cell product according to Agenzia Italiana del Farmaco (AIFA) indications and technical data sheet of the drug
62396561|NCT04107961|EXPERIMENTAL|Vaccine arm|Vaccine in 1 ml, single dose
62396562|NCT04107961|PLACEBO_COMPARATOR|Placebo|1 ml normal saline , single dose
62396563|NCT06112249|NO_INTERVENTION|Control Group|
62396564|NCT06112249|EXPERIMENTAL|Peer Intervention|Receives curriculum taught by Peer Interventionist
62396565|NCT06112249|EXPERIMENTAL|Staff Delivered|Receives curriculum taught by staff
62396566|NCT00790595|EXPERIMENTAL|Group A|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
62396567|NCT00790595|EXPERIMENTAL|Group B|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
61977933|NCT04723550|EXPERIMENTAL|Telemedicine|Diabetes education and support by telemedicine
61977934|NCT04723550|ACTIVE_COMPARATOR|Usual care|Diabetes education and support in person
62571948|NCT01610817||Patients without the InPAct intervention|The InPAct intervention will not be presented to the first patients recruited by each general practitioner
62571949|NCT03789760|EXPERIMENTAL|active group|take two pills (120 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
62779766|NCT04932642|EXPERIMENTAL|High-intensity interval training plus resistance training (HIIT+RT)|The HIIT+RT group, the HIIT section consisted of 60 seconds of maximum intensity exercise using a magnetic resistance static bicycle (OxfordTM Fitness, model BE-2701, Chile), followed by 60-120 seconds of passive recovery over the bicycle totally off. This was repeated four to seven times according to the weekly schedule. The intensity of the exercise was measured on the Borg scale of 1 to 10 of perceived exertion and the participants worked at a level of between 6 to 9 points. Second, in the RT section, three to out of four RT exercises were included (according to the planning week), targeting the following different muscle groups: (1) forearm, (2) knee flexors and extensors, (3) trunk, (4) chest, (5) shoulder elevators, (6) horizontal shoulder flexors, (7) extensors, and finally (8) plantar flexors. These exercises were performed in three 3 sets of as many repetitions as possible in 60 seconds, followed by 60 to 120 seconds of passive recovery.
62396568|NCT00790595|EXPERIMENTAL|Group C|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
62396569|NCT00790595|EXPERIMENTAL|Group D|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
62779767|NCT04932642|EXPERIMENTAL|Resistance training plus High-intensity interval training (RT+HIIT)|Firstly, in the RT section, three to out of four RT exercises were included (according to the planning week), targeting the following different muscle groups: (1) forearm, (2) knee flexors and extensors, (3) trunk, (4) chest, (5) shoulder elevators, (6) horizontal shoulder flexors, (7) extensors, and finally (8) plantar flexors. These exercises were performed in three 3 sets of 60 seconds, followed by 60 to 120 seconds of passive recovery, as previously reported. Secondly, in the HIIT+RT group, the HIIT section consisted of 60 seconds of maximum intensity exercise using a magnetic resistance static bicycle (OxfordTM Fitness, model BE-2701, Chile), followed by 60-120 seconds of passive recovery over the bicycle totally off. This was repeated four to seven times according to the weekly schedule. The intensity of the exercise was measured on the Borg scale of 1 to 10 of perceived exertion and the participants worked at a level of between 6 to 9 points.
62779768|NCT05241145|EXPERIMENTAL|IVMED-6Wk|In Group 1 (IVMED-6Wk), patients instilled IVMED-80 eye drops into their study eye twice a day for 6 weeks and were followed for an additional 20 weeks without treatment (total 26 weeks)
62779769|NCT05241145|EXPERIMENTAL|IVMED-16Wk|In Group 2 (IVMED-16Wk), patients instilled IVMED-80 eye drops into their study eye twice a day for 16 weeks and were followed for an additional 10 weeks without treatment (total 26 weeks)
62779770|NCT05241145|PLACEBO_COMPARATOR|Placebo|In Group 3 (Placebo), patients instilled IVMED-80 vehicle solution eye drops into their study eye twice a day for 16 weeks and were followed for an additional 10 weeks without treatment (total 26 weeks)
62190103|NCT02643147|EXPERIMENTAL|CA125 guided strategy|In this group loop diuretic (Furosemide) dosage will be guided by Carbohydrate Antigen 125 (CA125) plasma levels
62190104|NCT02643147|ACTIVE_COMPARATOR|Conventional strategy|Standard treatment strategy Therapy is based on established european guidelines
62571950|NCT03789760|PLACEBO_COMPARATOR|control group|take two pills (120 mg) of placebo each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
62571951|NCT03038867|EXPERIMENTAL|Duloxetine|Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week
62779771|NCT01506011|EXPERIMENTAL|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Dr. Reddy's Laboratories Ltd.
62779772|NCT01506011|ACTIVE_COMPARATOR|Lotrel|Lotrel® Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Novartis Pharmaceuticals
62779773|NCT03594812|EXPERIMENTAL|Experimental group|This group performed aerobic exercise just after radiofrequency therapy in the abdominal region.
62779774|NCT03594812|PLACEBO_COMPARATOR|Placebo group|This group performed aerobic exercise just after radiofrequency therapy in the abdominal region but the radiofrequency device was switched off- Radiofrequency without power.
62779775|NCT06330610|EXPERIMENTAL|Intermittent enteral nutrition|patients that receive intermittent enteral nutrition.
62779776|NCT06330610|NO_INTERVENTION|continuous enteral nutrition|patients that receive continuous enteral nutrition
62779777|NCT02698150||Remote monitoring|Active group of patients undergoing daily remote monitoring using sensors and wearables
62396570|NCT00790595|EXPERIMENTAL|Group E|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
62396571|NCT04176237|EXPERIMENTAL|Intervention|Schools receive 3 one hour lessons on sun safety, followed by a 1 hour UV dosimtery laboratory session.
62396572|NCT04176237|NO_INTERVENTION|Control|Schools receive 3 one hour lessons on sun safety.
62396573|NCT04176237|NO_INTERVENTION|Observation|Schools do not receive any lessons.
62571952|NCT03038867|PLACEBO_COMPARATOR|Placebo|Placebo
62571953|NCT02647190|EXPERIMENTAL|Erwinia Chrysanthemi asparaginase|This is a phase I trial designed to assess the safety of IV Erwinia Chrysanthemi asparaginase during initial induction in patients aged 60 years or older with newly diagnosed Ph-negative ALL. A total of 12 patients will be accrued to the study.
62571954|NCT05662072|EXPERIMENTAL|Motor imagery|Motor imagery of inspiratory and expiratory exercises, 10 series of 1 minute.
62396574|NCT02222792||Septic patient group|The septic patient group will be comprised of patients presenting with bone and joint prosthetic device infection confirmed by intraoperative microbiological culture (at least 2 deep positive samples for the same bacterial strain).
62004473|NCT01900470|NO_INTERVENTION|Usual Primary Care|Patients will be encouraged to make follow-up appointments as needed with their primary care clinic for support towards their health goals. During these appointments, clinicians will help patients determine progress made on existing proximal goals, adjust goals based on self-efficacy, and help patients to create new proximal goals as needed. They will also work with PCPs to adjust medications when appropriate, provide health behavior education and make referrals to community-based services based on patient need.
62396575|NCT02222792||Non-septic patient group|The non-septic patient group will be comprised of prosthetic patients presenting with symptoms of mechanical loosening, and whose deep intraoperative samples have all proved negative
62571955|NCT05662072|EXPERIMENTAL|Action observation|Action observation of inspiratory and expiratory exercises, 10 series of 1 minute.
62779778|NCT02698150||Control|Control group of patients undergoing standard follow up wth no remote monitoring
62396576|NCT02222792||Intermediate group|An intermediate group will be comprised of patients with only one deep positive sample.
62779779|NCT04685525|EXPERIMENTAL|Mycobiome Supporting Diet|Participants will be able to abide by the allowed and disallowed foods in MSD diet for at least four consecutive weeks prior to conditioning and up to 10 days after transplant. Participants will maintain a diary of foods they consume and any adverse effects they are experiencing and will self- collect fecal samples 28 days before transplant, 2 days before transplant and 10 days after transplant
62396577|NCT04408105||Primary Care Providers|400 eligible primary care providers (PCPs) will be recruited across the 7 participating sites to complete an anonymous survey. The survey will be distributed to eligible PCPs by the study site research coordinator via anonymous REDCap internet survey with 2 additional automated electronic reminders. There will also be opportunities for providers to complete a paper survey at PCP clinic meetings which will be collected by only the site research coordinator to maintain response anonymity.
62779780|NCT01984996|EXPERIMENTAL|Freedom ProFlor Inguinal Hernia Implant|
62779781|NCT02307162|PLACEBO_COMPARATOR|Dummy solution|Nebulised suspension to be administered as either a single dose (Part A) or 11 doses over 6 days (Parts B anc C)
62779782|NCT02307162|EXPERIMENTAL|RPL554 suspension|"Nebulised suspension to be administered as either a single dose (Part A) or 11 doses over 6 days (Parts B anc C).~Starting dose in Part A to be 1.5mg/mL with planned up to 2 fold increments. Doses in Part B will be selected from Part A. Doses in Part C to be selected from Part B"
62779783|NCT03262441|EXPERIMENTAL|Mycophenolate mofetil|Mycophenolate Mofetil 500mg Tablets once per day for one week as a lead in to limit drug-related side effects. Provided they are tolerating the drug at lower dose, they will then initiate Mycophenolate Mofetil 500mg Tablets twice daily orally for 22 months
62779784|NCT02068287|EXPERIMENTAL|ESMOLOL|Resuscitated, hyperkinetic septic shock patients are treated with esmolol in order to reduce heart rate of 20% during 6 hours. During the intervention period, multimodal macro and micro hemodynamic data are recorded.
62779785|NCT02754206||Control|Subjects who are collegiate level athletes who do not have a concussion and are currently playing a contact-collision sport.
62779786|NCT02754206||Concussed|Subjects who have recently suffered a sports-related concussion and are currently a collegiate athlete playing a contact-collision sport.
62004474|NCT02543931|PLACEBO_COMPARATOR|Placebo|Participants will take 4 placebo capsules twice a day for one month
62004475|NCT02543931|EXPERIMENTAL|Meriva, low dose|Participants will take 4 Meriva-250mg capsules twice a day for one month
62004476|NCT02543931|EXPERIMENTAL|Meriva, high dose|Participants will take 4 Meriva-500mg capsules twice a day for one month
62571956|NCT05662072|PLACEBO_COMPARATOR|Placebo Observation|Placebo visualization of nature video, 10 minutes.
62571957|NCT01208675||Mild cognitive impairment|550 patients with mild cognitive impairment or subjective cognitive symptoms at baseline.
62571958|NCT01208675||Healthy elderly subjects|650 elderly subjects, who are cognitively healthy at baseline.
62571959|NCT02011685|ACTIVE_COMPARATOR|Home BP Telemonitoring (HBPTM)|Participants will take home BP readings 3 days per week (morning and evening) for one week out of each month during the 12-month intervention.
62571960|NCT02011685|EXPERIMENTAL|HBPTM + Nurse Case Management (NCM)|Participants will complete the same Home BP Telemonitoring protocol and will also complete 20 counseling phone calls with a nurse case manager during the 12-month intervention.
62571961|NCT00754130|EXPERIMENTAL|Placebo/MK-0941 20mg|Participants received Placebo during Period 1 and MK-0941 20 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
62779787|NCT02490007||Allergy Cases|All participants appear on the Australian Childhood Immunisation Register (ACIR) and have received their first pertussis vaccination before the age of 16 weeks. They will have been born during the period of change over from whole cell pertussis vaccine to acellular pertussis vaccine (1997-1999). Allergy case participants have all attended allergy clinics associated with tertiary teaching hospitals. They have confirmed IgE-mediated food allergy as defined by the case description and as ascertained by their medical records.
62779788|NCT02490007||Controls|All participants appear on the Australian Childhood Immunisation Register (ACIR) and have received their first pertussis vaccination before the age of 16 weeks. They will have been born during the period of change over from whole cell pertussis vaccine to acellular pertussis vaccine (1997-1999).
62779789|NCT01627964||normal heart function|normal heart function
62779790|NCT01627964||abnormal heart function|abnormal heart function
62571962|NCT00754130|EXPERIMENTAL|MK-0941 5mg/Placebo|Participants received MK-0941 5 mg during Period 1 and Placebo during Period 2. There was a washout period of at least 8 days between the two treatment periods.
62004477|NCT04090567|EXPERIMENTAL|Arm I (olaparib plus cediranib)|Patients receive olaparib PO BID and cediranib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62004478|NCT04090567|EXPERIMENTAL|Arm II (olaparib plus ceralasertib)|Patients receive olaparib PO BID on days 1-28 and ceralasertib PO QD on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62004479|NCT01289925|EXPERIMENTAL|Selenium|
62004480|NCT01289925|PLACEBO_COMPARATOR|Sugar Pill|
62004481|NCT03417141|EXPERIMENTAL|Valchor treatment of Lichen Planopilaris|Once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.
62004482|NCT05312736||Vision Cohort 1|"Criteria that must be met in the better eye\* at the Screening Visit:~visual acuity ETDRS letter score of 54 or more (approximate Snellen equivalent 20/80 or better) and visual field\*\* diameter 10 degrees or more in every meridian of the central field~The better eye is defined as the eye with the better Screening Visit ETDRS visual acuity. However, if both eyes have the same visual acuity, which is defined as the same Snellen equivalent, then the determination will be made at investigator discretion. In this scenario, the investigator will consider the eye with better fixation or clearer ocular media to permit highest quality retinal imaging.~The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to the Screening Visit or performed on the day of the Screening Visit."
62004483|NCT05312736||Vision Cohort 2|"Criteria that must be met in the better eye\* at the Screening Visit:~visual acuity ETDRS letter score of 19-53 (approximate Snellen equivalent 20/100 - 20/400) OR visual acuity ETDRS letter score of 54 or more (approximate Snellen equivalent 20/80 or better) and visual field\*\* diameter less than 10 degrees in any meridian of the central field.~The better eye is defined as the eye with the better Screening Visit ETDRS visual acuity. However, if both eyes have the same visual acuity, which is defined as the same Snellen equivalent, then the determination will be made at investigator discretion. In this scenario, the investigator will consider the eye with better fixation or clearer ocular media to permit highest quality retinal imaging.~The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to the Screening Visit or performed on the day of the Screening Visit."
62004484|NCT05312736||Vision Cohort 3|"Criteria that must be met in the better eye\* at the Screening Visit:~visual acuity ETDRS letter score of 18 or less (approximate Snellen equivalent 20/500 or worse).~The better eye is defined as the eye with the better Screening Visit ETDRS visual acuity. However, if both eyes have the same visual acuity, which is defined as the same Snellen equivalent, then the determination will be made at investigator discretion. In this scenario, the investigator will consider the eye with better fixation or clearer ocular media to permit highest quality retinal imaging.~The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to the Screening Visit or performed on the day of the Screening Visit."
62004485|NCT03258372|EXPERIMENTAL|Cohort 1|Mifepristone 300 MG, 1 tablet
62396578|NCT04408105||Gastroenterologists|100 eligible gastroenterologists (GIs) will be recruited across the 7 participating sites to complete an anonymous survey. The survey will be distributed to eligible GIs by the study site research coordinator via anonymous REDCap internet survey with 2 additional automated electronic reminders. There will also be opportunities for GIs to complete a paper survey at provider clinic meetings which will be collected by only the site research coordinator to maintain response anonymity.
62571963|NCT00754130|EXPERIMENTAL|MK-0941 5mg/MK-0941 20mg|Participants received MK-0941 5 mg during Period 1 and MK-0941 20 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
62571964|NCT00754130|EXPERIMENTAL|Placebo/MK-0941 40mg|Participants received Placebo during Period 1 and MK-0941 40 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
62779791|NCT00923845|OTHER|Donors|A sibling who is 6/6 HLA --matched with the recipient. Donors undergo donor lymphocyte harvest and stem cell mobilization and harvest.
62004486|NCT03258372|EXPERIMENTAL|Cohort 2|Mifepristone 1500 MG, 5 tablets
62571965|NCT00754130|EXPERIMENTAL|MK-0941 10mg/Placebo|Participants received MK-0941 10 mg during Period 1 and Placebo during Period 2. There was a washout period of at least 8 days between the two treatment periods.
62779792|NCT00923845|OTHER|Recipients|Recipients undergo induction therapy, allogeneic stem cell therapy and GVHD prophylaxis.
62779793|NCT02291588|EXPERIMENTAL|AMG 811|AMG 811 administered as subcutaneous and intravenous doses
62190105|NCT02437357|EXPERIMENTAL|Metacognitive Training|D-MCT is conceptualized as a variant of cognitive behavioral therapy (CBT) that uses a metacognitive perspective to focus on the modification of cognitive biases by using creative and engaging strategies (e.g., multimedial presentation). The training seeks to enable group members to recognize and correct the often automatic and unconscious depressive thought patterns, in part by viewing this depressive thought process at a distance (i.e., depersonalizing). Besides dysfunctional assumptions about one's thought processes, more general cognitive biases, which have been identified by basic research are at the core of the D-MCT. Finally, dysfunctional coping-strategies (i.e., thought suppression, rumination as problem-solving) are discussed and modified.
62396579|NCT04408105||Patients|500 eligible patients will be recruited across the 7 participating sites to complete a survey. The survey will be distributed to eligible patients at the time of a clinic appointment, via telephone, or via a REDCap internet survey that will allow for 2 additional electronic phone call reminders and 1 email reminder.
62571966|NCT00754130|EXPERIMENTAL|MK-0941 10mg/MK-0941 40mg|Participants received MK-0941 10 mg during Period 1 and MK-0941 40 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
62571967|NCT04742361|EXPERIMENTAL|[18F]PSMA-1007|single intravenous administration of \[18F\]PSMA-1007 for Positron Emission Tomography (PET) scan
62571968|NCT01508091|EXPERIMENTAL|Calorie restricted|25 % calorie restriction respect measured total energy expenditure, using a Mediterranean diet
62571969|NCT01689454||IVF treatment ISM1|Embryo culture in ISM1 medium
62571970|NCT01689454||IVF treatment EG|Embryo culture in EmbryoGen medium
62571971|NCT02968173|EXPERIMENTAL|Children at High Risk of severe RSV Infection|A single IM injection every 30 days beginning at Day 0 for a total of 3-5 injections determined by when in the RSV season a participant was enrolled.
62396580|NCT04238117|EXPERIMENTAL|LA group|The participants in LAT group underwent 10 sessions of LAT over 2 weeks, using a gallium aluminum arsenide Laser Pen. The participants in the LAT group received 0.375 J of energy at each of the following acupoints bilaterally: BL23 (Shenshu, B2), BL25 (Dachangshu, B2), BL26 (Guanyuanshu, B2), BL40 (Weizhong, B2) and SP6 (Sanyinjiao, B2).
62779794|NCT02291588|PLACEBO_COMPARATOR|Placebo|No active drug
62779795|NCT03537196|OTHER|All patients|All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.
62779796|NCT03537196|OTHER|HIV/HCV co-infected patients|For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day (sofosbuvir 400 mg and daclatasvir 90 mg)
62779797|NCT03537196|OTHER|Cirrhosis|In case of cirrhosis : ribavirin will be added to sofosbuvir / daclatasvir 12 weeks
62779798|NCT03537196|OTHER|Cirrhosis with ribavirin contra-indication|In case of cirrhosis with ribavirin contra-indication : sofosbuvir and daclatasvir for 24 weeks
62779799|NCT03302637||Cases|subjects with histology-confirmed incident pancreatic cancer, with no prior history of cancer (except non-melanoma skin cancer), a valid consent, and pre-diagnostic oral wash samples.
62779800|NCT03302637||Control|selected by incidence density sampling63 among cohort members who had no cancer prior to selection, provided a valid consent and an oral wash. Controls were frequency matched to cases by cohort, age at cohort entry (5 year), sex, race, and calendar year of cohort entry.
62779801|NCT00306540|ACTIVE_COMPARATOR|1|Placebo Seroquel + existing therapy
62396581|NCT04238117|NO_INTERVENTION|Control group|The participants of the control group received standard obstetric care.
62396582|NCT02012894||Obese patients with preoperative GER|Obese patients selected for laparoscopic sleeve gastrectomy with preoperative GER at 24 H pH-monitoring (Group A)
62004487|NCT04520425|EXPERIMENTAL|Intervention|Participants will receive 5 standardized osteopathic manipulative treatments, two weeks apart. (To be considered a study completer, a participant must complete at least 3 of these treatments.) In addition to assessments at intake and during treatments, 1 and 3 months after their last treatment patients will be asked to provide follow-up data. Assessments include the HIT-6, MIDAS, and MSQ surveys, treatment satisfaction assessments, and a headache diary. Participants will also consent to an electronic medical record extraction of medication and healthcare services utilization.
62004488|NCT06662812||GRNDaD Cohort|Patients with sickle cell disease (SCD) who were included in the GRNDaD registry and received a disease modifying therapy (DMT).
62779802|NCT00306540|EXPERIMENTAL|2|Seroquel + existing therapy
62779803|NCT04666194|ACTIVE_COMPARATOR|Cold forceps|4-6mm polyps were removed with cold forceps
62779804|NCT04666194|ACTIVE_COMPARATOR|Cold snare|4-6mm polyps were removed with cold snare
62004489|NCT04085822|EXPERIMENTAL|Multiple Abdominal Injections|Ten injections per patient: 7 of SMA-001 and 3 of control device.
62396583|NCT02012894||Obese patients without preoperative GER|Obese patients selected for laparoscopic sleeve gastrectomy without preoperative GER at 24 H pH-monitoring (Group B)
62396584|NCT02839213|ACTIVE_COMPARATOR|group A (Hyoscine Butyl bromide group)|The women will be given Hyoscine Butyl bromide
62396585|NCT02839213|ACTIVE_COMPARATOR|group B (Saline group)|The women will be given saline
62396586|NCT06027658||Non participants|Individuals receiving the standard support for victims of sexual violence (e.g. medical, social, and legal assistance, individual psychotherapy)
62571972|NCT01091506|EXPERIMENTAL|L-methylfolate|L-methylfolate 15mg (a medical food)
62571973|NCT01091506|PLACEBO_COMPARATOR|Placebo|Placebo
62571974|NCT05484206|EXPERIMENTAL|Cohort 1: CPT-B (moderate HI) participants and matched healthy participants will be evaluated first|All participants in Cohort 1 will be receiving VIR-2218 monotherapy.
62779805|NCT04666194|ACTIVE_COMPARATOR|Hot snare|4-6mm polyps were removed with hot snare
62779806|NCT02853435|EXPERIMENTAL|Part1a: Gepotidacin 1500 mg-Sequence A-capsules, B-RC, C-HSWG|Subjects will be receive treatment sequence (ABC) which is a single dose of gepotidacin 1500 mg (three tablets of 500 mg) reference capsule (Treatment A) in Period 1, 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in Period 2 or 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 3, according to randomization. There will be a washout period of at least 3 days between doses.
62004490|NCT02405416|EXPERIMENTAL|IIVCC group|The portal triad and infrahepatic inferior vena cava are dissected and taped with a vessel loop, respectively. During liver parenchymal resection，portal triad and infrahepatic inferior vena cava clampings are performed at the specified transection depth from liver surface successively.
62004491|NCT02405416|ACTIVE_COMPARATOR|SHVE group|In this group, the portal triad clamping and selective hepatic vascular exclusion of major hepatic veins are used. Different major hepatic veins are occluded by clamping forcep depending on the site of tumors. The clamping timepoints are same as the IIVCC group.
62004492|NCT00461539|ACTIVE_COMPARATOR|2|Participants will receive treatment as usual
62004493|NCT00461539|EXPERIMENTAL|1|Participants will receive the behavioral health intervention
62004494|NCT02044536||Faculty doctors|Experienced endoscopists (\> 6000 cases). no intervention
62004495|NCT02044536||Trainees|Doctors on fellowship who are inexperienced endoscopists (\< 4 months of endoscopy training) no intervention
62004496|NCT01367808|PLACEBO_COMPARATOR|Placebo|
62004497|NCT01367808|ACTIVE_COMPARATOR|Vorikonazole|
62004498|NCT01367808|ACTIVE_COMPARATOR|Posakonazole|
62004499|NCT00728377|ACTIVE_COMPARATOR|Heath & Wellness|
62004500|NCT00728377|EXPERIMENTAL|Exercise|
62004501|NCT04604457|NO_INTERVENTION|Standard of Care|Palliative care specialists would not reach out to primary care providers. Palliative care needs would be met via existing mechanisms.
62004502|NCT04604457|EXPERIMENTAL|Predictive Model|Palliative care specialists review recommendations from the predictive model and contact a patient's primary care provider (PCP) when appropriate to recommend a palliative care consult.
62004503|NCT06087172||Hypertensive Individuals|Patients diagnosed with arterial hypertension
62004504|NCT04891939|EXPERIMENTAL|The intervention Arm|This arm will receive the novel intervention package for a period of three months to prevent smoking initiation and increase quit rate. The intervention will consist of 4 lessons which will be taught for about one hour each day. This will be segmented into two broad areas as knowledge and skill development. Under the knowledge-based program, participants will be taught, the global challenge of tobacco and tobacco products, correcting the erroneous impression about tobacco, the media and advertisement, and the harmful effects of smoking. The skill development program teaches about refusal skills (self-esteem, interpersonal relationship skills, and problem-solving skills). The participants will understand the tobacco advertising and marketing strategies; peer influence, and skills for resisting influences to smoke.
62190106|NCT02437357|ACTIVE_COMPARATOR|Positivity Training|"Positivity Training (PT) is a euthymic therapy group based on cognitive behavioral therapy (CBT) with a focus on the education and training of sensual enjoyment and pleasure. Aim of the training is to reduce depressive symptomatology by increasing the ability to enjoy and to (re-)install positive sensory experiences. Therefore, group members are informed about the impact of positive experiences on well-being and the awareness of the five senses is trained in different practical exercises (hearing, sight, smell, taste, and touch)."
62571975|NCT05484206|EXPERIMENTAL|Cohort 2: CPT-C (severe HI) participants and matched healthy participants|This arm is optional based on Cohort 1. All participants in Cohort 2 will be receiving VIR-2218 monotherapy.
62571976|NCT05484206|EXPERIMENTAL|Cohort 3: CPT-A (mild HI) participants and matched healthy participants|This cohort is optional. All participants in Cohort 3 will be receiving VIR-2218 monotherapy.
62004505|NCT04891939|ACTIVE_COMPARATOR|The Control Arm|The control arm will not receive novel intervention program but will continue with the usual School Health and Education program (SHEP) however, at the end of the intervention, all the materials will be sent to the control arm to also benefit from the lessons.
62004506|NCT06027281||Married women who had female genital mutilation|
62004507|NCT06027281||Married women who didn't have female genital mutilation|
62004508|NCT03097653|EXPERIMENTAL|Decision-aid|
62004509|NCT03097653|ACTIVE_COMPARATOR|Standard information|
62004510|NCT02383446|EXPERIMENTAL|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
62004511|NCT00865722|ACTIVE_COMPARATOR|RemotePostConditioning|Patients will receive pPCI and treatments according to guidelines for STEMI PLUS extrinsic cuff compression to the lower limb for 5 ' followed by 5' reperfusion for three cycles (30' in total) starting with myocardial reperfusion
62004512|NCT00865722|SHAM_COMPARATOR|Controls|pPCI and treatments according to guidelines for STEMI
62571977|NCT05484206|EXPERIMENTAL|Cohort 4: CPT-A (mild HI) participants and matched healthy participants|All participants in Cohort 4 will be receiving VIR-3434 monotherapy.
62779807|NCT02853435|EXPERIMENTAL|Part1a: Gepotidacin 1500 mg-Sequence C-HSWG, A-capsules, B-RC)|Subjects will receive treatment sequence (CAB) to receive a single dose of gepotidacin 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 1, 1500 mg (three tablets of 500 mg) reference capsule (Treatment A) in Period 2 or 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in Period 3 according to randomization. There will be a washout period of at least 3 days between doses.
62004513|NCT02827292|EXPERIMENTAL|Laparoscopic Surgery without music|Intervention: Headphones without music (Silent). A headphone will be applied peroperatively but no music will be played. Blood samples to assess the biomolecular inflammatory response and the post operative monitoring will be done as per the protocol.
62004514|NCT02827292|EXPERIMENTAL|Laparoscopic Surgery with music|Intervention: peroperative music via head phones. A headphone will be applied peroperatively and music will be played for the entire duration of the surgical procedure. Blood samples to assess the biomolecular inflammatory response and the post operative monitoring will be done as per the protocol.
62571978|NCT05484206|EXPERIMENTAL|Cohort 5: CPT-B (moderate HI) participants and matched healthy participants|All participants in Cohort 5 will be receiving VIR-3434 monotherapy.
62571979|NCT05484206|EXPERIMENTAL|Cohort 6: CPT-C (severe HI) participants and matched healthy participants|This arm is optional based on Cohort 5. All participants in Cohort 6 will be receiving VIR-3434 monotherapy.
62571980|NCT05484206|EXPERIMENTAL|Cohort 7: CPT-A (mild HI) and matched healthy participants|All participants in Cohort 7 will be receiving VIR-3434 and VIR-2218 combination therapy.
62004515|NCT02240381|EXPERIMENTAL|Diagnostic (OGTT, euglycemic hyperinsulinemic clamp)|Patients undergo OGTT and a standard 2-step euglycemic hyperinsulinemic clamp procedure prior to HCT. Patients then undergo repeat OGTT and a 2-step euglycemic hyperinsulinemic clamp procedure once after HCT between days 90-100.
62004516|NCT01263574|PLACEBO_COMPARATOR|Heparinized Saline|This group will maintain their central lines patent with heparinized saline.
62004517|NCT01263574|EXPERIMENTAL|Ethanol lock solution group|Administration of the 70% ethanol lock solution will occur between cycles of parenteral nutrition. Randomized lock solutions will be administered three days per week. When patients have completed their parenteral nutrition, their central venous catheters will be flushed with 5mL saline, per current standards
62004518|NCT06017661|EXPERIMENTAL|Nutridrink Skin Repair with a mixture of plant extracts rich in polyphenolic compounds|Group of 15 patients undergoing surgical resection of tumour
62004519|NCT06017661|ACTIVE_COMPARATOR|Nutridrink Skin Repair|Group of 15 patients undergoing surgical resection of tumour
62004520|NCT06390020|NO_INTERVENTION|Control|Participants instructed not to partake in any (similar) mindfulness or meditation training.
62004521|NCT06390020|EXPERIMENTAL|MBSR training|
62004522|NCT06089720|EXPERIMENTAL|Zinc oxide nanoparticle coated orthodontic molar tubes (experimental)|The nine orthodontic patients will receive 36 orthodontic molar tubes coated with ZnO nanoparticle in split-mouth cross quadrant manner, In each patient, two diagonal quadrants (i.e., upper right and lower left, or vice versa) will randomly assigned to each coated OMT and UOMT groups. evaluation will be after 2 weeks for microbial assessment biofilm in addition to plaque \& gingival index. patients will be follow up for 3 month to evaluation bond failure rate.
62004523|NCT06089720|PLACEBO_COMPARATOR|orthodontic molar tubes (control)|The nine orthodontic patients will receive 36 the non-coated orthodontic molar tube in split-mouth cross quadrant manner, In each patient, two diagonal quadrants (i.e., upper right and lower left, or vice versa) will randomly assigned to each coated OMT and UOMT groups. evaluation will be after 2 weeks for microbial assessment biofilm in addition to plaque \& gingival index. patients will be follow up for 3 month to evaluation bond failure rate.
62571981|NCT05484206|EXPERIMENTAL|Cohort 8: CPT-B (moderate HI) and matched healthy participants|All participants in Cohort 8 will be receiving VIR-3434 and VIR-2218 combination therapy.
62571982|NCT05484206|EXPERIMENTAL|Cohort 9: CPT-C (severe HI) and matched healthy participants|This arm is optional based on Cohort 8. All participants in Cohort 9 will be receiving VIR-3434 and VIR-2218 combination therapy.
62571983|NCT02490371|EXPERIMENTAL|(1) rTMS- PT Ex Group|"1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse (20 minutes) at 90% resting motor threshold (rMT) will conduct for 10 consecutive sessions (5 days per week for 2 weeks) and immediately followed by 30- minutes structured physiotherapy upper limb training.~After the 10 sessions of brain stimulation, the 30-minute structured physiotherapy upper limb training program will continue for another 12 weeks (2 sessions per week)"
62004524|NCT03611725|ACTIVE_COMPARATOR|Distal radial artery|"After subcutaneous injection of lidocaine, the distal radial artery around the bony surface area is punctured with a 20-gauge venipuncture catheter needle or steel needle according to the operator's discretion. After successful puncture, flexible, straight plastic 0.025 mini-guidewire is inserted through the hole of the puncture needle. Then, Radifocus® introducer sheath (Terumo, Tokyo, Japan) is inserted into the distal radial artery."
62004525|NCT03611725|PLACEBO_COMPARATOR|Radial artery|"After subcutaneous injection of lidocaine, the radial artery is punctured with a 20-gauge venipuncture catheter needle or steel needle according to the operator's discretion. After successful puncture, flexible, straight plastic 0.025 mini-guidewire is inserted through the hole of the puncture needle. Then, Radifocus® introducer sheath (Terumo, Tokyo, Japan) is inserted into the radial artery."
62004526|NCT00832208|ACTIVE_COMPARATOR|Ambisome control:|Ambisome, Total dose 21.0 mg given as 7 x 3mg on days 1,2,3,4,5, and 14 and 21
62004527|NCT00832208|EXPERIMENTAL|Ambisome test|Single dose Ambisome in sequence(7.5 / 10.0/ 12.5 / 15.0mg)
62571984|NCT02490371|PLACEBO_COMPARATOR|(2) Placebo- PT Ex Group|"placebo stimulation over contra-lesional M1 region will be conducted for 10 consecutive sessions (5 sessions per week for 2 weeks) of and immediately followed by 30- minutes of structured physiotherapy upper limb training.~Then, the structured physiotherapy upper limb training will continue for another 12 weeks (2 sessions per week)."
62004528|NCT03027466|EXPERIMENTAL|Baseline Affirmation and Affirmation Texts|"Participants will be given a Baseline Affirmation Quiz at the beginning of the study and will receive affirmation text messages throughout the study"
62004529|NCT03027466|ACTIVE_COMPARATOR|Baseline Affirmation and No Affirmation Texts|"Participants will be given a Baseline Affirmation Quiz at the beginning of the study but will not receive affirmation text messages throughout the study"
62190107|NCT02719743|ACTIVE_COMPARATOR|H5N1 Formulation 1 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 1 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered intramuscularly (IM) in anterolateral thigh.
62190108|NCT02719743|EXPERIMENTAL|H5N1 Formulation 2 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 2 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
62190109|NCT02719743|EXPERIMENTAL|H5N1 Formulation 3 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 3 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
62190110|NCT02719743|EXPERIMENTAL|H5N1 Formulation 4 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 4 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
62190111|NCT02719743|EXPERIMENTAL|H5N1 Formulation 5 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 5 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
62190112|NCT01392703|OTHER|Dasatinib, 100 mg as tablets + water|Treatment A. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
62190113|NCT01392703|OTHER|Dasatinib, 100 mg as liquid + water|Treatment B. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
62571985|NCT01045382|EXPERIMENTAL|Mensenchymal Stem Cells|"Efficacy of MSC infusion on one-year overall survival of patients transplanted with HLA-mismatched PBSC.~Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2 Gy total body irradiation.~MSC cells (1,5-3,0 x 10E6 MSC/Kg BW) will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
62190114|NCT01392703|OTHER|Dasatinib, 100 mg as tablets in orange juice + water|Treatment C. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
62190115|NCT04919070|EXPERIMENTAL|Connect for Caregivers|Connect for Caregivers is a single session behavioral intervention with three components: 1) psychoeducation on the importance of connectedness for health and well-being; a card sort-based discussion prioritization tool that systematizes and routinizes the process of identifying and prioritizing barriers to connectedness; 3) personalized resources to address the identified barriers and targets.
62190116|NCT01424462|EXPERIMENTAL|Firategrast XRA|Low extended release tablet
62190117|NCT01424462|EXPERIMENTAL|Firategrast XRB|Medium extended releast tablet
62190118|NCT01424462|EXPERIMENTAL|Firategrast XRC|High extended release tablet
62190119|NCT01424462|EXPERIMENTAL|Firategrast IR|Immediate Release reference tablet
62190120|NCT02187367|EXPERIMENTAL|EGF Vaccine|Patients in this arm will receive a low dose of cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51
62190121|NCT02187367|NO_INTERVENTION|Best Supportive Care|Patients in this arm will receive best supportive care
62779808|NCT02853435|EXPERIMENTAL|Part1a: Gepotidacin 1500 mg-Sequence B-RC, C-HSWG, A-capsules)|Subjects will receive treatment sequence (BCA) to receive a single dose of gepotidacin 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in period 1, 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 2, or 1500 mg (three tablets of 500 mg) (Treatment A) in Period 3 reference capsule according to randomization.. There will be a washout period of at least 3 days between doses.
62190122|NCT05205109|EXPERIMENTAL|ATG-037+Keytruda(Pembrolizumab, MK-3475)|Part I: Dose Escalation Phase of ATG-037 Monotherapy PartII: Dose Escalation Phase and Dose Expansion Phase of ATG-037 in Upfront Combination with Keytruda(Pembrolizumab, MK-3475)
62190123|NCT06242938|EXPERIMENTAL|Early intensive antihypertensive treatment group|"1. Treatment starts within 1 hour after randomization~2. SBP target:130-140 mmHg within 1 hour after treatment~3. Under the guidance of medication, the researchers can independently select oral + intravenous antihypertensive medications"
62190124|NCT06242938|NO_INTERVENTION|Standard antihypertensive treatment group|"1. Empirical antihypertensive treatment~2. SBP target: 140-180 mmHg after randomization"
62190125|NCT00113269|EXPERIMENTAL|Alemtuzumab High-Risk Patients|Alemtuzumab, tacrolimus, mycophenolate mofetil and steroids; High risk patients: Panel reactive antibody ≥ 20% or re-transplant or African American
62190126|NCT00113269|ACTIVE_COMPARATOR|Conventional High-Risk Patients|Rabbit anti-thymocyte globulin, tacrolimus, mycophenolate mofetil and steroids; High risk patients: Panel reactive antibody ≥ 20% or re-transplant or African American
62004530|NCT03027466|ACTIVE_COMPARATOR|No Baseline Affirmation and Affirmation Texts|"Participants will not be given a Baseline Affirmation Quiz but will receive affirmation text messages throughout the study"
62004531|NCT03027466|PLACEBO_COMPARATOR|No Baseline Affirmation and No Affirmation Texts|Participants will experience the Smoke Free United Kingdom (UK) app without any affirmation content Smoke Free UK app (no baseline affirmation quiz and no affirmation text messages)
62190127|NCT00113269|EXPERIMENTAL|Alemtuzumab Low- Risk Patients|Alemtuzumab, tacrolimus, mycophenolate mofetil and steroids; Low risk patients: Panel reactive antibody \< 20% and first transplant and non-African American
62190128|NCT00113269|ACTIVE_COMPARATOR|Conventional Low-Risk Patients|Basiliximab, tacrolimus, mycophenolate mofetil and steroids; Low risk patients: Panel reactive antibody \< 20% and first transplant and non-African American
62190129|NCT02888379|EXPERIMENTAL|TOP1288 200 mg Rectal Solution|TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks
62190130|NCT02888379|PLACEBO_COMPARATOR|Placebo Rectal Solution|Placebo (for TOP1288) Rectal Solution Once Daily for 4 Weeks
62004532|NCT02974985|EXPERIMENTAL|Women aged 40-50|"Intervention--Injections of volumizing products Restylane L and Restylane Lyft with endpoint  a dramatic result is seen that is agreed upon by both subject and injector. The number of injections will be determined (and quantified) by both the patient and the PI to achieve this endpoint."
62190131|NCT04539067|EXPERIMENTAL|HMG group|Induction of ovulation from 2nd day of cycle Follow diameter of follicle When follicle 18:22mm Receive HMG
62190132|NCT04539067|EXPERIMENTAL|H FSH plus HHMG|Follow up ovulation from the 2nd day to 5th of menstruation cycle When follicle diameter 18mm to 22mm made induction of ovulation
62190133|NCT03617068|ACTIVE_COMPARATOR|Coconut Oil Cream|This group consist of batik traditional workers who use coconut oil cream for 2 weeks.
62190134|NCT03617068|PLACEBO_COMPARATOR|Placebo Cream|This group consist of batik traditional workers who use placebo cream which contained the vehiculum of the cream; using for 2 weeks.
62571986|NCT01045382|PLACEBO_COMPARATOR|Placebo|"Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2Gy total body irradiation.~Isotonic solution will be injected will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
62190135|NCT02967276|EXPERIMENTAL|Metformin and HDdexamethasone|"Metformin XR is initially administered at a dose of 500mg / daily by oral administration for 7 days. Patients who have a good tolerance (lack of adverse events of grade 3 or 4) may be staggered metformin dose to 2500 mg / day.~Patients in turn receiving dexamethasone pulse prescription (HDdex). A dose of dexamethasona 40 mg / day taken in a daily for four days every 8 days from 1st to 2nd cycle every 35 days and 1x per week for 4 weeks every 28 days from the 3rd to 6th cycle. The dose will be administered at 4 mg tablets, which are to be swallowed whole by 30 minutes after a meal. Patients over age 75 used 20 mg / day."
62190136|NCT01786304||Fecal incontinence|Patient with fecal incontinence and referred for a treatment with sacral nerve stimulation
62190137|NCT00568841|EXPERIMENTAL|1|
62190138|NCT00784147|ACTIVE_COMPARATOR|Ibalizumab 800 mg|every 2 weeks, combined with an Optimized Background Regimen
62190139|NCT00784147|ACTIVE_COMPARATOR|Ibalizumab 2000 mg|every 4 weeks, combined with an Optimized Background Regimen
62190140|NCT03153813|EXPERIMENTAL|Drug|Up to 4 patches to cover a surface of 1200 cm2 will be applied to the painful area depending on the surface of pain during 60 minutes : capsaicin 8% patches (Qutenza)
62190141|NCT03153813|PLACEBO_COMPARATOR|Placebo|Up to 4 patches will be applied to the painful area depending on the surface of pain during 60 minutes : placebo
62190142|NCT03763045|EXPERIMENTAL|Sildenafil 25|Twenty hemodialysis patients will receive a dose of 25mg sildenafil daily for 3 months.
62190143|NCT03763045|EXPERIMENTAL|Sildenafil 50|Twenty hemodialysis patients will receive a dose of 50mg sildenafil daily for 3 months.
62190144|NCT03763045|PLACEBO_COMPARATOR|Placebo|Twenty hemodialysis patients will receive a placebo tablet daily for 3 months.
62190145|NCT06314139|ACTIVE_COMPARATOR|cTBS group|cTBS at 80% action motor threshold (AMT) with 600 pulses over bilateral M1 and cerebellum. Continuous theta-burst stimulation (cTBS) was performed with a CCY-I Magnetic Stimulator (YIRUIDE Medical Co., Wuhan, China) with an air-cooled, figure-of-eight 70 mm coil. The site of stimulation during the TMS treatment sessions was bilateral M1 and cerebellum.
62190146|NCT06314139|SHAM_COMPARATOR|sham group|Sham stimulation was performed with the same protocol using an inactive coil to mimic true stimulation sound effects, but does not stimulate the brain or produce neurophysiological changes in cerebello-thalamo-cortical (CTC) connections and eyeblink regulation.
62190147|NCT01224522|EXPERIMENTAL|Visionaire|the group who will be operated by the use of Visionaire patient matched cutting blocks
62190148|NCT01224522|ACTIVE_COMPARATOR|Standard Surgical technique|The group who will be operated by means fo standard surgical technique
62190149|NCT01266746||Macular hole|The patients of idiopathic macular hole enrolled in the study
62396587|NCT06027658||Participants|Individuals receiving the RECREATION program in addition to standard support for victims of sexual violence
62190150|NCT01266746||Macular hole retinal detachment|The patients of macular hole retinal detachment enrolled in the study
62190151|NCT01266746||Myopic traction maculopathy|The patients of macular hole with myopic traction maculopathy enrolled in the study
62190152|NCT06296004||adult patient with Behçet's Disease|. Adult BD patients who fulfilling the criteria for the diagnosis by International Team for the Revision of the International Criteria for Bechet's Disease .
62190153|NCT06296004||healthy subjects|apparently healthy subjects
62190154|NCT06495593|EXPERIMENTAL|RR-MS|Two doses of 300 mg i.v. ocrelizumab two weeks apart followed by 600 mg i.v. ocrelizumab six months later.
62190155|NCT04545528||Test group|100 Patients that were referred to our stone clinic for follow up with risk factors for stone recurrence like metabolic syndrome and diabetes, uric acid stones etc. In addition to seeing our urologist and nephrologist these patients will also be referred to a nutritionist in order to balance risk factors and will be followed for one year with our usual blood tests and imaging
62190156|NCT04545528||Control group|100 Patients that were referred to our stone clinic for follow up without risk factors for stone recurrence will see our urologist and nephrologist and will be followed for one year with our usual blood tests and imaging
62190157|NCT00097838|EXPERIMENTAL|1 x 10^5 IU dose|Vaccine dose of 1 x 10\^5 IU per injection
62190158|NCT00097838|EXPERIMENTAL|1 x 10^6 IU dose|Vaccine dose of 1 x 10\^6 IU per injection
62190159|NCT00097838|EXPERIMENTAL|1 x 10^7 IU dose|Vaccine dose of 1 x 10\^7 IU per injection
62190160|NCT00097838|EXPERIMENTAL|1 x 10^8 IU dose|Vaccine dose of 1 x 10\^8 IU per injection
62190161|NCT00097838|PLACEBO_COMPARATOR|Placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
62190162|NCT05289219|EXPERIMENTAL|Intervention Group|The duration of the program is 16-weeks, 3-times a week, for up to 50 minutes per session, starting 1 month after surgery, based on the recommendations of the WHO and the ACSM, because the guidelines for morbidly obese patients undergoing bariatric surgery are not defined. Information on exercises for morbidly obese adults is limited, so the exercise programs will follow the guidelines for adults aged 18 to 65 years healthy, with chronic diseases or disabilities
62190163|NCT05289219|NO_INTERVENTION|Control Group|
62190164|NCT06125899|EXPERIMENTAL|Age emhGAP-IG|"* Adapted emhGAP-IG;~* Adapted Problem-Solving Therapy (PST-PC)~* Support/supervision of lay providers~* Links to social support resources."
62190165|NCT06125899|ACTIVE_COMPARATOR|Generic emhGAP-IG|Psychoeducation and stress reduction
62214716|NCT00297427|EXPERIMENTAL|Acupuncture|Subjects will 12 acupuncture treatments over 6 weeks; treatment sessions occur twice a week. A total of 12 acupuncture needles will be inserted bilaterally at two leg points and four back points. Needles are manually inserted through a standard guide tube contained within a fitted sheath and the basal ring secured to the skin by double-sided tape. The needles remain in place for 25 minutes and are manually stimulated twice during each treatment.
62396588|NCT06027658||Long term participants|Individual receiving the RECREATION program for at least a month
62571987|NCT05648422|NO_INTERVENTION|FG (FOLLOW GROUP)|FG receive: Conventional diet (WHO).
62779809|NCT02853435|EXPERIMENTAL|Part1b: Gepotidacin 1500 mg-Sequence DE-fasted followed by fed|Subjects will receive treatment sequence (DE) according to randomization which is a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a under fasted condition (Treatment D) in Period 1 followed by fed conditions (Treatment E) in period 2. There will be a washout period of at least 3 days between doses.
62779810|NCT02853435|EXPERIMENTAL|Part1b: Gepotidacin 1500 mg-Sequence ED-fed followed by fasted|Subjects will be receive treatment sequence (ED) according to randomization which is single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a under fed condition (Treatment E) in period 1 followed by fasted conditions (Treatment D) in Period 2. There will be a washout period of at least 3 days between doses.
62571988|NCT05648422|EXPERIMENTAL|CG (CONTROL GROUP)|CG receive: Conventional diet (WHO), deworming (nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days), and probiotics (Saccharomyces Boulardii, 200 mg every 12 hours for 6 days at week 1, 5 and 9).
62571989|NCT05648422|EXPERIMENTAL|IG (INTERVENTION GROUP)|IG receive: Deworming (nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days), probiotics (Saccharomyces Boulardii, 200 mg every 12 hours for 6 days at week 1, 5 and 9), specific diet, and NSS envelope (glutamine, arginine, folic acid, PUFA-n3, vegetal protein, nicotinic acid, cobalamin, thiamine, pyridoxine, magnesium, zinc, selenium, cholecalciferol, resveratrol, ascorbic acid, Spirulina Máxima, and inuline) every 12 hours for 12 weeks.
62571990|NCT00357799|ACTIVE_COMPARATOR|VeinViewer Arm|Attempts at IV placement will be made with use of the VeinViewer Machine
62571991|NCT00357799|NO_INTERVENTION|Conventional Method|IV attempted with conventional method
62571992|NCT02161640||Control|Age/sex matched control participants, not suffering from inflammatory bowel disease or any other chronic inflammatory disease
62571993|NCT02161640||Inflammatory Bowel Disease|Patients with active or remissive inflammatory bowel disease
62571994|NCT01317095|ACTIVE_COMPARATOR|Wire closure is the intervention|Patients will have their sternum closed using stainless steel wires.
62571995|NCT01317095|ACTIVE_COMPARATOR|Rigid fixation|Patients will have their sternum closed by rigid fixation using Starnalock plates.
62571996|NCT02004366|EXPERIMENTAL|Linagliptin In-hospital|Linagliptin once daily+ correction doses of aspart or lispro if needed
62571997|NCT02004366|ACTIVE_COMPARATOR|Basal Bolus In-hospital|Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
62571998|NCT02004366|EXPERIMENTAL|Linagliptin on discharge|Patients with admission A1C \< 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
62779811|NCT02853435|EXPERIMENTAL|Part 2a: Gepotidacin 1500 mg (RC or HSWG)- Japanese subjects|Japanese subjects will receive a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a.
62779812|NCT02853435|EXPERIMENTAL|Part 2b: Gepotidacin 1500 mg (RC or HSWG)- Chinese subjects|Chinese subjects will receive a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a.
62571999|NCT02004366|EXPERIMENTAL|Linagliptin+50%Glargine dose on d/c|Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
62779813|NCT02424682||HER 2 positive metastatic breast cancer|HER 2 positive metastatic breast cancer treated with Herceptin as per registered indication, until disease progression.
62779814|NCT04137250|ACTIVE_COMPARATOR|Hamstring|It is the group in which the hamstrings are surgically removed to be used as an autograft for the reconstruction of the anterior cruciate ligament. The intervention will consist of make an incision on the medial side of the proximal portion of the leg approximately 3 centimeters to dissect by planes until the tendons of the hamstrings are located, which will be removed surgically with specialized instruments and the wound will be closed, for later These tendons be used as an autograft for the reconstruction of the anterior cruciate ligament.
62190166|NCT02636608||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
62190167|NCT01229774|EXPERIMENTAL|Etoricoxib|
62572000|NCT02004366|EXPERIMENTAL|Linagliptin+80%Glargine dose on d/c|Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
62572001|NCT03334344|EXPERIMENTAL|Intervention Arm|Subjects whose surgeon will be viewing VR models in connection with the in addition to the source CT/MR image
62190168|NCT01229774|ACTIVE_COMPARATOR|Diclofenac|
62190169|NCT01972945|EXPERIMENTAL|Vaginoscopy|Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.
62190170|NCT01972945|ACTIVE_COMPARATOR|Standard Hysteroscopy|Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
62190171|NCT05525247|EXPERIMENTAL|Monotherapy|SLC-3010 Intravenous infusion over 30 minutes on day 1 of each 21-day cycle
62572002|NCT03334344|NO_INTERVENTION|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case
62572003|NCT05661539||non-pregnant|negative b-hCG results 9 days after embryo transfer.
62572004|NCT05661539||pregnant with obstetric complications|Patients with a positive pregnancy result who develop obstetric complications such as preeclampsia, eclampsia, fetal growth restriction, oligohydramnios, polyhydramnios, preterm birth, gestational diabetes mellitus, antenatal bleeding and etc. after the 20th gestational weeks.
62572005|NCT05661539||pregnant without obstetric complications|Patients who have positive pregnancy results and do not have any obstetric complications such as preeclampsia, eclampsia, fetal growth restriction, oligohydramnios, polyhydramnios, preterm birth, gestational diabetes mellitus, antenatal bleeding and etc. during pregnancy.
62572006|NCT01981707|EXPERIMENTAL|F-Choline PET|The F-Choline-PET will be performed before and at 6 weeks of the beginning of treatment by abiraterone acetate or enzalutamide.
62572007|NCT02449486|ACTIVE_COMPARATOR|Ropivacaine|Ropivacaine 4 ml/h (8 mg/h) continuous infusion for 48 hours
62572008|NCT02449486|PLACEBO_COMPARATOR|Placebo|Saline infusion 4 ml/h for 48 hours
62190172|NCT05525247|EXPERIMENTAL|Gemcitabine combination|"SLC-3010 Intravenous infusion over 30 minutes on day 1 of each 21-day cycle~Gemcitabine 1000 ㎎/㎡ Intravenous infusion over 30 minutes on day 1 and 8 of each 21-day cycle"
62190173|NCT05472584|EXPERIMENTAL|Experimental: Non-invasive spinal cord stimulation|This arm will receive 30 minutes of transcutaneous spinal cord stimulation as participants rest.
62190174|NCT05472584|EXPERIMENTAL|Experimental: Activity-based training|This arm will perform 30 minutes of activity-based training using leg movements.
62190175|NCT05472584|EXPERIMENTAL|Experimental: Activity-based training wtih non-invasive spinal cord stimulation|This arm will receive transcutaneous spinal cord stimulation as participants perform 30 minutes of activity-based training using leg movements.
62190176|NCT05472584|EXPERIMENTAL|Experimental: Non-invasive spinal cord stimulation and strength training|This arm will receive transcutaneous spinal cord stimulation as participants perform strengthening exercises.
62572009|NCT03334240|EXPERIMENTAL|CLS003|Digoxin and Furosemide topical formulation
62572010|NCT03334240|PLACEBO_COMPARATOR|Vehicle|Inactive vehicle
62572011|NCT06068673|EXPERIMENTAL|Group A|Group I are patients who will receive clindamycin added-on therapy.
62572012|NCT06068673|ACTIVE_COMPARATOR|Group B|Group II patients will be managed with the standard regimen.
62779815|NCT04137250|EXPERIMENTAL|Quadriceps tendon|It is the group in which a portion of the quadriceps tendon will be surgically removed for later use as an autograft for the reconstruction of the anterior cruciate ligament. The intervention consisted in making an incision in the anterior aspect of the distal portion of the thigh of approximately 3 centimeters to dissect by planes until locating the membranous portion of the quadriceps tendon, from which will be removed a portion of surgical way with specialized instruments and the Wound will be closed, for later this tendon to be used as an autograft for the reconstruction of the anterior cruciate ligament.
62572013|NCT04353713|EXPERIMENTAL|Dextrose Gel|"Dextrose 40% gel will be given immediately following stabilization at birth via massage into the buccal membrane. This will be prior to transport from the Delivery Room to the Neonatal Unit.~A dose of 1 ml of gel (Dextrose) will be administered to infants born greater than or equal to 29+1 weeks gestation. Prior to administration, a single brief oral suction will be given if required.~Half the dose of gel (0.5 ml) will be squeezed onto the gloved finger of a person. This half dose will be given on one side of mouth. The remaining half dose (0.5 ml) of gel will be administered to the other side of the mouth.~A total dose of 0.5 ml of gel (Dextrose) will be administered to infants born less than or equal to 29+0 weeks gestation.~Half the dose of gel (0.25 ml) will be squeezed onto the gloved finger of administering person. This half dose will be given on one side of mouth. The remaining half dose (0.25 ml) of gel will be administered to the other side of the mouth."
62734598|NCT02457689|PLACEBO_COMPARATOR|Group 3 (Electroporation and Placebo)|Group 3 (Electroporation and Placebo) Participants will receive 1.0ml intramuscular injections of Sodium Chloride BP into the upper thigh using the ICHOR TriGridTM delivery system for intramuscular (TDS-IM) delivery with electroporation. Electroporation (EP) improves the delivery of the product into muscle cells, by delivering an electrical pulse with the injection using a hand held device that is pressed against your thigh. This will cause a muscle twitch with a sharp cramp-like feeling in the thigh lasting a few seconds. Once the procedure is carried out, the muscle will feel sore for up to 72 hours. The investigator will ask volunteers not to engage in any strenuous exercise for at least 24 hours after the procedure.
62004533|NCT02974985|EXPERIMENTAL|Women aged 50-60|"Intervention--Injections of volumizing products Restylane L and Restylane Lyft with endpoint  a dramatic result is seen that is agreed upon by both subject and injector. The number of injections will be determined (and quantified) by both the patient and the PI to achieve this endpoint."
62779816|NCT05077293||Best Practice Alert group|Providers will receive a BPA at the time of visit for patients with HFrEF who are not on MRA (and who do not have contraindication to MRA). This alert will be visible on the first screen displayed in the electronic health record and will display the patient's current HFrEF therapies, EF, blood pressure, potassium, and glomerular filtration rate. The alert will give access to an outpatient heart failure order set, and also provide links to the most recent guidelines.
62004534|NCT00333112|EXPERIMENTAL|1|
62004535|NCT00333112|PLACEBO_COMPARATOR|2|
62004536|NCT05973838|EXPERIMENTAL|"Peer-Delivered Behavioral Activation (Peer Activate)"|Participants in the Peer Activate intervention will receive a PRS-delivered behavioral activation intervention to address barriers to retention in methadone treatment and increase substance-free, positive reinforcement to support retention and reduce polysubstance use.
62004537|NCT05973838|NO_INTERVENTION|Treatment As Usual|Participants in the TAU group will receive enhanced treatment as usual, defined as MTU services as usual enhanced with additional community referrals and follow-ups on those referrals, in addition to regular meetings with an addiction medicine physician and PRS on the MTU. Standard PRS contact typically includes connection to local resources and general peer support as needed.
62004538|NCT05891236|EXPERIMENTAL|Part A: Single Ascending Dose (SAD): Dose escalation cohort 1: MAM01 and placebo Intravenous (IV)|2 sentinel participants will be randomized in a 1:1 ratio to receive MAM01 1.5 milligrams per kilogram (mg/kg) IV or placebo. Following at least a 24-hour safety review period, the 6 remaining participants of Cohort 1 will be randomized in a 5:1 ratio to receive MAM01 1.5 mg/kg IV or placebo.
62004539|NCT05891236|EXPERIMENTAL|Part A: SAD dosing: Dose escalation Cohort 2: MAM01 and placebo SC|7 participants will be randomly assigned in a 6:1 ratio to receive MAM01 5 mg/kg SC or placebo
62004540|NCT05891236|EXPERIMENTAL|Part A: SAD dosing: Dose escalation Cohort 3: MAM01 and placebo IV|7 participants will be randomly assigned in a 6:1 ratio to receive MAM01 5 mg/kg IV or placebo.
62779817|NCT05077293||In-Basket Message group|Providers will receive a biweekly in-basket messages linking to a list of patients who have been seen in the past year with HFrEF who are not on MRA (and who do not have contraindication to MRA). This list will display each patient's current hFrEF therapies, EF, blood pressure, potassium, glomerular filtration rate, and date of last visit. From the list, providers can access the patient's chart, order medications, and document communication with the patient.
61977935|NCT05544331|EXPERIMENTAL|Written exercise group|The exercise program will consist of core stabilization exercises, which target various trunk muscles to optimize segmental control, spinal stability, spinal stiffness, orientation and the interoperability of these features. The exercise program will be in writing form, which is a common home exercise program type.
62004541|NCT05891236|EXPERIMENTAL|Part A: SAD dosing: Dose escalation Cohort 4: MAM01 and placebo IV|8 participants will be randomly assigned in a 6:2 ratio to receive MAM01 10 mg/kg IV or placebo.
62004542|NCT05891236|EXPERIMENTAL|Part A: SAD dosing: Dose escalation Cohort 5: MAM01 and placebo IV|7 participants will be randomly assigned in a 6:1 ratio to receive MAM01 40 mg/kg IV or placebo
62004543|NCT05891236|EXPERIMENTAL|Part A: Multiple Ascending Dose (MAD) (Repeat dosing): MAM01|Participants from Cohort 2 and from Cohort 3 will receive 5 mg/kg MAM01 SC.
62004544|NCT05891236|EXPERIMENTAL|Part B: Dose Expansion Cohort 6: Group 1: MAM01|6 participants will receive a 450 mg SC dose of MAM01. The dose was selected by applying a PK-pharmacodynamic (PD) model from the Part A data to estimate a (data-driven) protection threshold at Controlled Human Malaria Infection (CHMI).
62004545|NCT05891236|EXPERIMENTAL|Part B: Dose Expansion Cohort 6: Group 2: MAM01|8 participants will receive a 600 mg SC dose of MAM01. The dose was selected by applying a PK-PD model from the Part A data to estimate a (data-driven) protection threshold at CHMI
62004546|NCT05891236|EXPERIMENTAL|Part B: Dose Expansion Cohort 6: Group 3: MAM01|8 participants will receive 900 mg SC dose of MAM01. The dose was selected by applying a PK-PD model from the Part A data to estimate a (data-driven) protection threshold at CHMI.
62004547|NCT05891236|EXPERIMENTAL|Internal Infectivity Controls|6 participants will be enrolled into a non-randomized group prior to CHMI. These participants will receive no treatment and act as infectivity controls
62004548|NCT05593224|EXPERIMENTAL|Intracranial Stent (Tonbridge)|Placement of Intracranial Stent (Zhuhai Tonbridge Medical Tech. Co., Ltd. ).
62190177|NCT05472584|EXPERIMENTAL|Experimental: Non-invasive spinal cord stimulation and precision training|This arm will receive transcutaneous spinal cord stimulation as participants perform precision-control and dexterity exercises.
62190178|NCT05472584|EXPERIMENTAL|Experimental: Long-term activity-based training with non-invasive spinal cord stimulation|This arm will receive 4 weeks of activity-based training with transcutaneous spinal cord stimulation
62779818|NCT05077293||Control group|Patients who will receive the current standard practice of care (no alerts)
61977936|NCT05544331|EXPERIMENTAL|Video based exercise group|The exercise program will consist of core stabilization exercises, which provide segmental control optimization, spinal stabilization, spinal stiffness, orientation and the interoperability of these features. The exercise program will be given patients as video records, which provide visual and auditory feedbacks.
62004549|NCT01109316|ACTIVE_COMPARATOR|Insulin Lispro 2 Day|
62779819|NCT01690806||dexamethasone|Patients who receive dexamethasone (8 mg; Decadron; Merck Sharp \& Dohme) intravenously 90 min before skin incision
62004550|NCT01109316|EXPERIMENTAL|Insulin Lispro 6 Day|
62004551|NCT01109316|ACTIVE_COMPARATOR|Insulin Aspart 6 Day|
62004552|NCT01502644|ACTIVE_COMPARATOR|Low Negative Affect (NA)|Participants with low NA (HADS score ≤5 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
62190179|NCT05549349||Cholecystectomy during hospitalization|In this group, patients will have their cholecystectomy during the initial hospitalization. We will look at the mode of feeding between the biliary crisis and the cholecystectomy.
62190180|NCT05549349||Delayed cholecystectomy|In this group, patients will have their cholecystectomy deferred from their initial hospitalization for various reasons. They will be seen again 3 months after leaving hospital. They will or will not have been cholecystectomized during this interval. Their mode of feeding as well as biliary events will be studied.
62190181|NCT05026268|EXPERIMENTAL|Intracorporeal anastomosis|A laparoscopic right colectomy will be performed according to the surgeons standard practice with the intracorporeal anastomosis performing.
62779820|NCT01690806||placebo|Patients who receive saline placebo intravenously 90 min before skin incision
62779821|NCT02374567|EXPERIMENTAL|Psychiatric drugs|
62779822|NCT00147316|EXPERIMENTAL|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
62779823|NCT01925248|ACTIVE_COMPARATOR|Whey protein group|Patients will be randomized to receive whey protein
62779824|NCT01925248|PLACEBO_COMPARATOR|Placebo group|Patients will be randomized to receive placebo
62779825|NCT02809378|EXPERIMENTAL|Sevoflurane|anesthesia induction with pentothal sodium (4-5 mg/kg), maintenance with sevoflurane(1.6-2.5 vol%)
62004553|NCT01502644|ACTIVE_COMPARATOR|Moderate NA|Participants with moderate NA (HADS score ≥6 to ≤8 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
62004554|NCT01502644|ACTIVE_COMPARATOR|High NA|Participants with high NA (HADS score ≥9 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
62004555|NCT05402943||Intervention Group|The group which interventions applied during study.
62004556|NCT05402943||Control Group|None intervention applied.
62190182|NCT05026268|NO_INTERVENTION|extracorporeal anastomosis|A laparoscopic right colectomy will be performed according to the surgeons standard practice.
62004557|NCT04935151|ACTIVE_COMPARATOR|holmium laser enucleation of the prostate|holmium laser enucleation of the prostate (HoLEP)
62396589|NCT06027658||Professionals|Professionals associated with long term participants, working with them for standard support
62004558|NCT04935151|ACTIVE_COMPARATOR|bipolar resection of the prostate|bipolar resection of the prostate (BPEP)
62396590|NCT04087005|EXPERIMENTAL|Hominis placental pharmacopuncture|The Hominis placental pharmacopuncture group will receive 10 sessions of Hominis placental pharmacopuncture at 2 sessions/week for 5 weeks. A trained doctor of Korean medicine with at least 2 years clinical experience will administer JHG002 pharmacopuncture with a disposable syringe (0.5ml) directly into the designated sites, using a standardized method.
61977937|NCT05544331|NO_INTERVENTION|Control group|The patients, who are referred and will wait for the exercise program in their routine daily life. Measurements will be performed at the same time frame in experimental group. After the 12 weeks of follow up period, they will join the exercise program.
62004559|NCT02777762|EXPERIMENTAL|Fun First|Strategies to promote enjoyment of physical activity
62004560|NCT02777762|ACTIVE_COMPARATOR|Close at Hand|Strategies to promote tracking of physical activity
62004561|NCT00650039|ACTIVE_COMPARATOR|Arm 1|
62004562|NCT00650039|ACTIVE_COMPARATOR|Arm 2|
62004563|NCT00650039|PLACEBO_COMPARATOR|Arm 3|
62004564|NCT00896545|EXPERIMENTAL|5-keys feeding program|Counseling in small groups aimed at enhancing children's self control over eating
62004565|NCT00896545|ACTIVE_COMPARATOR|Healthy lifestyle counseling|Counseling in small groups aimed at achieving healthy eating patterns aimed at both the family and young children
62004566|NCT01161758|ACTIVE_COMPARATOR|Passive cervical mobilisation|Grade III cervical mobilization technique as described by Maitland. Applied to left C5/6 Segment.
62004567|NCT01161758|PLACEBO_COMPARATOR|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique.
62004568|NCT01161758|NO_INTERVENTION|Non-contact control|Non-contact control, which involved the subject resting in the treatment position without any physical contact between the researcher and the subject.
62396591|NCT04087005|ACTIVE_COMPARATOR|Transcutaneous electrical nerve stimulation|The control group will receive 2 sessions/week of TENS for 5 weeks. A high-frequency, low-intensity stimulus of 50-100Hz and up to 15mA will be used, such that the patients feel a current but do not feel pain. At each treatment visit, a physiotherapist will administer the treatment to the bilateral temporomandibular joint for 15 minutes. Both centres will use the same TENS device-a BioTron-DX (D.M.C, Osan, South Korea).
62396592|NCT02707562|EXPERIMENTAL|GLPG1837 dose 1, GLPG1837 dose 2, GLPG1837 dose 3|GLPG1837 twice daily oral dosing - morning and evening, for 4 weeks
62396593|NCT06433271|EXPERIMENTAL|Transdiagnostic Behavior Therapy (TBT)|Participants will receive 6, 30-45-minute, manualized, individual therapy sessions.
62004569|NCT04671459|EXPERIMENTAL|TTFields and SRS based on MRI or FET-PET|All subjects will receive TTFields and radiosurgery plus/minus FET PET imaging to define tumor volume.
62004570|NCT03629015|EXPERIMENTAL|Stemchymal®|Biological: Stemchymal® ALF/ ACLF patients will receive low (0.5 x 10\^6 cells/kg) or high (2 x 10\^6 cells/kg) dose of Stemchymal® through intravenous infusion
62004571|NCT01110629|EXPERIMENTAL|Arm 1|
62004572|NCT01110629|PLACEBO_COMPARATOR|Arm 2|
62779826|NCT02809378|EXPERIMENTAL|sevoflurane, remifentanil, and propofol|anesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%)
62396594|NCT06433271|ACTIVE_COMPARATOR|Active Comparator: Treatment as Usual-Problem Solving Therapy (TAU-PST)|Participants will receive 6, 30-45-minute, manualized, individual therapy sessions.
62396595|NCT01921582|EXPERIMENTAL|Methylphenidate|"Methylphenidate (TEVA-METHYLPHENIDATE ER-C)~* Dosage: 18 mg/day at Week 1; 36 mg/day at Week 2; 54 mg/day at Week 3; 72 mg/day at Week 4. Dosage levels may be maintained or decreased to manage medication side effects.~* Dosage form: tablet~* Dosage frequency: daily~* Duration: 12 weeks total"
61977938|NCT06013540|EXPERIMENTAL|Group A TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)|
61977939|NCT06013540|EXPERIMENTAL|Group B Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)|
61977940|NCT04952142|EXPERIMENTAL|minimal water exchange|We suctioned the lumen and infused water by constant pressure on the air-water valve button of the endoscope at the rectum to open the lumen.
61977941|NCT04952142|NO_INTERVENTION|traditional water exchange colonoscopy|The water exchange colonoscopy reached the cecum through continuous infusion and suction of water in the whole colon via an additional flushing pump.
61977942|NCT04231539|EXPERIMENTAL|Low Nicotine (nicotine vapor) 24 mg.ml|After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours, 5-7 days apart. During each session, participants take 20 puffs over 10 minutes (one puff every 30 seconds) of vaporizer filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored, or salt-based nicotine e-liquid solution of tobacco flavor assigned in a random order.
62572014|NCT04353713|PLACEBO_COMPARATOR|Placebo|"2% carboxymethylcellulose gel will be given following stabilization at birth via buccal route. This will be prior to in-house transport from the Delivery Room to the Neonatal Unit.~A standard total dose of 1 ml of placebo gel will be administered to infants born greater than or equal to 29+1 weeks gestation. Prior to administration, a single brief oral suction will be given if required.~Half the dose of gel (0.5 ml) will be squeezed onto the gloved finger of person. This half dose will be given on one side of mouth. The remaining half dose (0.5 ml) of gel will be administered to the other side of the mouth.~A total dose of 0.5 ml of gel (Placebo) will be administered to infants born less than or equal to 29+0 weeks gestation.~Half the dose of gel (0.25 ml) will be squeezed onto the gloved finger of a person. This half dose will be given on one side of mouth. The remaining half dose (0.25 ml) of gel will be administered to the other side of the mouth."
62572015|NCT02588768|ACTIVE_COMPARATOR|Active PBMT|Active PBMT was applied employing MR4 Laser Therapy Systems outfitted with LaserShower 50 4D emitters (both manufactured by Multi Radiance Medical, Solon - OH, USA). The cluster style emitter contains 12 diodes comprising of four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode).
62779827|NCT02809378|EXPERIMENTAL|Sevoflurane, remifentanil, propofol, and palonosetron|anesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%), and palonosetron 75 ug administration prior to anesthesia induction.
62779828|NCT06386679|EXPERIMENTAL|AFCC injection|
62779829|NCT01300260|EXPERIMENTAL|LY2189265 then Placebo|"LY2189265 (Dulaglutide) then Placebo: A single 1.5 milligram (mg) subcutaneous (SC) injection of LY2189265 on Day 1 in Period 1, followed by a single SC injection of Placebo on Day 1 in Period 2.~On Day 3 of each period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose bolus (0.3 gram/kilogram \[g/kg\] over approximately 2 minutes). Three hours later, participants were administered a second IV dextrose bolus of 25 g of 50% dextrose or a suitably adjusted dose according to glycemic status (20 g of 50% dextrose for participants with 3-hour glucose between 5.2 and 10 millimole/liter \[mmol/L\] or 15 g of 50% dextrose for participants with 3-hour glucose \>10 mmol/L), followed by a 20% dextrose at the set infusion rate of 600 milliliter/hour \[mL/h\] for 35 minutes. Fifteen minutes after the start of the 20% dextrose infusion, an IV 1-mg glucagon bolus was administered.~There was a washout period of at least 28 days between Periods 1 and 2."
62004573|NCT06662565|ACTIVE_COMPARATOR|Behavioral modification group|They will be treated with behavioral modification for 8 weeks.
62004574|NCT06662565|EXPERIMENTAL|Pelvic floor down training and behavioral modification group|They will be treated with the same behavioral modification plus pelvic floor down training three times per week for 24 sessions for 8 weeks.
62004575|NCT04376034|OTHER|Mild Severity|Eligible to enroll in study and will be monitored for progression. Will not initially receive plasma.
62779830|NCT01300260|EXPERIMENTAL|Placebo then LY2189265|"Placebo then LY2189265 (Dulaglutide): A single subcutaneous injection of Placebo on Day 1 in Period 1, followed by a single 1.5 milligrams (mg) subcutaneous injection of LY2189265 on Day 1 in Period 2.~On Day 3 of each period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose bolus (0.3 gram/kilogram \[g/kg\] over approximately 2 minutes). Three hours later, participants were administered a second IV dextrose bolus of 25 g of 50% dextrose or a suitably adjusted dose according to glycemic status (20 g of 50% dextrose for participants with 3-hour glucose between 5.2 and 10 millimole/liter \[mmol/L\] or 15 g of 50% dextrose for participants with 3-hour glucose \>10 mmol/L), followed by a 20% dextrose at the set infusion rate of 600 milliliter/hour \[mL/h\] for 35 minutes. Fifteen minutes after the start of the 20% dextrose infusion, an IV 1-mg glucagon bolus was administered.~There was a washout period of at least 28 days between Periods 1 and 2."
62779831|NCT04872790|EXPERIMENTAL|Treatment (prednisone, dasatinib, venetoclax, rituximab)|See detailed description
62004576|NCT04376034|ACTIVE_COMPARATOR|Moderate Severity|"Adult patients will be treated with 1 unit (200mL) of convalescent plasma~Pediatric patients will be treated with 10mg/kg up to 1 unit of convalescent plasma."
62004577|NCT04376034|ACTIVE_COMPARATOR|Severe or Critical Severity|"Adult patients will be treated with up to 2 units of convalescent plasma~Pediatric patients will be treated with 10mg/kg up to 2 units of convalescent plasma."
62004578|NCT00013117|OTHER|Arm 1|
62004579|NCT03623516||Thyroid cancer|All subjects living in the Marne or Ardennes Departments of France and who were diagnosed with papillary thyroid cancer between 1975 and 2014.
62004580|NCT00080223|EXPERIMENTAL|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
62004581|NCT03940378|EXPERIMENTAL|One-drug Regimes|Basic drug : Anlotinib Hydrochloride Capsules
62004582|NCT03940378|EXPERIMENTAL|Two-Drug Regimens|Basic drug: Anlotinib Hydrochloride Capsules Add Intervention drug: Levamisole Hydrochloride
62004583|NCT04870892||Norepinephrine variation|Patients with septic shock, cardiac output monitoring device with the PICCO2 system and decision by the physician in charge to modify the norepinephrine dose.
62004584|NCT04870892||Fluid infusion|Patients with septic shock, cardiac output monitoring device with the PICCO2 system and decision by the physician in charge to give fluid infusion
62004585|NCT01829932|ACTIVE_COMPARATOR|High Factor Diet|Patients will be on a factor altered diet to see effects on their lactulose breath test and symptoms.
62004586|NCT01829932|ACTIVE_COMPARATOR|Low Factor Diet|Patients will be on a factor altered diet to assess its effects on symptoms and lactulose breath test.
62004587|NCT01588782|EXPERIMENTAL|Abiraterone acetate|All individuals will receive study treatment in the same sequence. Period 1 (Days 1 to 4) consists of a single oral dose of 1000 mg abiraterone acetate tablets on Day 1 only. Period 2 (Days 11 to 17) consists of a daily oral dose of 400 mg ketoconazole tablets on Days 11 to 16 and administration of a single dose of 1000 mg abiraterone acetate on Day 14.
62004588|NCT00591448|EXPERIMENTAL|Virtual Reality|Patients with burns participate in VR during occupational therapy (OT) or physical therapy (PT) sessions ranging from 2 to 9 min in length
62004589|NCT02863978|EXPERIMENTAL|Digi-NewB Cohort|Multimodal signal acquisitions
62004590|NCT03394014|ACTIVE_COMPARATOR|popliteal sciatic nerve block|injecting 25 ml of bupivacaine 0.5 % (Sunnypivacaine, 20 ml vial contains Bupivacaine HCL Monohydrate 105.5 mg eq. to 100 mg Bupivacaine HCL, Sunny Pharmaceutical, Badr city- Cairo- Egypt) once circumferentially around the sciatic nerve at the popliteal fossa using ultrasound device (S-Nerve ultrasound system, Fujifilm Sonosite Inc., Bothell, WA)
62004591|NCT03394014|ACTIVE_COMPARATOR|subgluteal sciatic nerve block|injecting 25 ml of bupivacaine 0.5 % (Sunnypivacaine, 20 ml vial contains Bupivacaine HCL Monohydrate 105.5 mg eq. to 100 mg Bupivacaine HCL, Sunny Pharmaceutical, Badr city- Cairo- Egypt) circumferentially around the sciatic nerve at the subgluteal region using ultrasound device (S-Nerve ultrasound system, Fujifilm Sonosite Inc., Bothell, WA).
62004592|NCT04032756||Group 1|UC-patients (age at enrollment: 18-80 years) receiving a newly introduced Tofacitinib therapy (n=360). Previous treatment(s) with biologics or immunosuppressants is (are) permitted. About 20-30% of the Tofacitinib patients will biologic-naiv.
62004593|NCT04032756||Group 2|UC-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy (n=120). Previous treatment(s) with biologics or immunosuppressants is (are) allowed.
62004594|NCT04677946|EXPERIMENTAL|Healthy Cookie Group|All participants in the study
62190183|NCT05874778|EXPERIMENTAL|Radiation Group|"Paients will be treated with 6-8 cycles (21 days per cycle) of standard R-CHOP chemotherapy.~After completing the standard immunochemotherapy, subjects will be randomly divided into the radiotherapy group or the non-radiotherapy group, and the curative effects will be evaluated every three months after the end of the treatment or after a patient's leaving the group, so as to obtain the relevant data including those for figuring up 2-year PFS and survival of subjects and any treatment-related side effects as well."
62004595|NCT05315271|ACTIVE_COMPARATOR|Group 1|All patients will be randomly allocated into two equal groups: each group will contain 30patients:
62004596|NCT05315271|ACTIVE_COMPARATOR|Group 2|All patients will be randomly allocated into two equal groups: each group will contain 30patients:
62004597|NCT00749931|ACTIVE_COMPARATOR|SOC|Standard of Care arm - standard of care lumpectomy procedure
62004598|NCT00749931|EXPERIMENTAL|Device + SOC|Use of the device in addition to the standard of care lumpectomy procedure.
62004599|NCT04913428|EXPERIMENTAL|Interdigital exercise group|"Interdigital exercises:~12 repetitions in 3 sets of 4 repetitions~Conventional Physical Therapy:~Incentive spirometer 3 - 4 times a day, Percussion twice a day, Mobilization of the patient Total session given was for 20 -30 minutes"
62004600|NCT04913428|ACTIVE_COMPARATOR|Blow-Bottle technique group|"Blow-Bottle technique:~12 repetitions in 3 sets of 4 repetitions~Conventional Physical Therapy:~Incentive spirometer 3 - 4 times a day, Percussion twice a day, Mobilization of the patient Total session given was for 20 -30 minutes"
62004601|NCT02340234|EXPERIMENTAL|Lebrikizumab 250 mg Single Dose + TCS Cream|Participants will receive lebrikizumab 250 milligrams (mg) SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
62004602|NCT02340234|EXPERIMENTAL|Lebrikizumab 125 mg Single Dose + TCS Cream|Participants will receive lebrikizumab 125 mg SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
62004603|NCT02340234|EXPERIMENTAL|Lebrikizumab 125 mg Q4W + TCS Cream|Participants will receive lebrikizumab 125 mg SC every 4 weeks (Q4W) for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
62004604|NCT02340234|PLACEBO_COMPARATOR|Placebo Q4W + TCS Cream|Participants will receive placebo Q4W for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
62004605|NCT01457872|EXPERIMENTAL|Strength-based case management|Case management plus referral (vs referral-only)
62190184|NCT05874778|ACTIVE_COMPARATOR|Non-radiation Group|Paients will be treated with 6-8 cycles (21 days per cycle) of standard R-CHOP chemotherapy, but after this treatment patients will not be further given radiation therapy.
62004606|NCT01457872|ACTIVE_COMPARATOR|Referral only|Referral only (no case management intervention)
62004607|NCT04152447|NO_INTERVENTION|Standard of care|This arm describes the standard protocol used to aid in orthopedic recovery.
62004608|NCT04152447|ACTIVE_COMPARATOR|VR device|Patients randomly assigned to the experimental arm of the study were provided an Oculus Go™ device for the duration of their hospitalization. The device featured a headset with a 1280 x 1440, 60 Hz refresh rate LCD display, spatial audio (via built-in speakers; headphones were not provided or used to our knowledge, despite compatibility) and the ability to track 3 degrees of rotational freedom; it was compatible with glasses and included a soft, adjustable strap for optimal, user-based fit. A single controller, capable of recognizing hand motion, pointing, and clicking was also included.
62004609|NCT01713868|OTHER|Safe Sleep Edu and Breastfeeding mHealth|Participants will receive Safe Sleep Nursery Education and Breastfeeding Mobile Health messaging
62190185|NCT00250432|ACTIVE_COMPARATOR|1|50 mg intravenous (IV) infusion (diluted with 9% saline) administered daily (following a 70-mg IV loading dose on Day 1), over the course of \~2 hrs. all patients should be treated with antifungal therapy for at least 14 days following both the improvement in clinical and radiographic signs of disease and the eradication of Candida from culture samples obtained from the invasive site of infection.
62190186|NCT00250432|EXPERIMENTAL|2|150 mg intravenous (IV) infusion (diluted with 9% saline) administered daily, over the course of \~2 hrs. all patients should be treated with antifungal therapy for at least 14 days following both the improvement in clinical and radiographic signs of disease and the eradication of Candida from culture samples obtained from the invasive site of infection.
62572016|NCT02588768|PLACEBO_COMPARATOR|Placebo PBMT|Placebo PBMT was applied using the same device that emitted the same sounds and light, but with no effective irradiation.
62572017|NCT01760304|EXPERIMENTAL|Budesonide / Formoterol|This is a crossover study, where every patient will receive in a blinded fashion either Budesonide/Formoterol (Symbicort ® ) or placebo
62572018|NCT01760304|PLACEBO_COMPARATOR|Placebo|This is a crossover study, where every patient will receive in a blinded fashion either Budesonide/Formoterol (Symbicort ® ) or placebo
62004610|NCT01713868|OTHER|Breastfeeding Edu and Safe Sleep mHealth|Participants will receive the Breastfeeding Nursery Education and the Safe Sleep Mobile Health messaging
62004611|NCT01713868|OTHER|Safe Sleep Edu and Safe Sleep mHealth|Participants will receive Safe Sleep Nursery Education and Safe Sleep Mobile Health messaging
62190187|NCT00511836|EXPERIMENTAL|VIVITROL 380 mg|
62190188|NCT00511836|PLACEBO_COMPARATOR|Placebo|
62004612|NCT01713868|OTHER|Breastfeed Edu and Breastfeed mHealth|Participants will receive Breastfeeding Nursery Education and Breastfeeding Mobile Health messaging
62004613|NCT01565135|EXPERIMENTAL|Intervention Practices|Intervention offices will adopt a multimodal vaccine program to increase their patients' vaccine rates.
62190189|NCT00430742|EXPERIMENTAL|1|Arm 1: MK0364 0.5 mg capsule once daily
62190190|NCT00430742|EXPERIMENTAL|2|Arm 2: MK0364 1 mg capsule once daily
62190191|NCT00430742|EXPERIMENTAL|3|Arm 3: MK0364 2 mg capsule once daily
62190192|NCT00430742|PLACEBO_COMPARATOR|4|Arm 4: Pbo capsule once daily
62190193|NCT04189055|EXPERIMENTAL|Cohort #1|Cetuximab monotherapy (500mg/m² IV, day 1)
62190194|NCT04189055|EXPERIMENTAL|Cohort #2|Cetuximab and irinotecan (cetuximab 500mg/m² IV, day 1; irinotecan 180mg/m² IV, day 1).
62190195|NCT04626804|EXPERIMENTAL|1 Test the usability, perceptions, and acceptability of R/S|Dyads will use the R/S unit for 90 days, unless they request it to be removed prior to the end of the study. . The primary outcome is a caregiver-assessed measure usability.
62190196|NCT01752010|ACTIVE_COMPARATOR|Acupuncture Treatment|Traditional Chinese acupuncture.
62190197|NCT01752010|ACTIVE_COMPARATOR|Tennant™ Biomodulator Treatment|
62190198|NCT01752010|ACTIVE_COMPARATOR|Transcutaneous electrical nerve stimulation (TENS) Treatment|
62190199|NCT01130168|EXPERIMENTAL|Placebo/ISMN ER/Amlodipine (Sequence 1)|Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.
62572019|NCT02019316|EXPERIMENTAL|BioSteel Sports Drink|Participants will ingest 500ml of BioSteel Sports Drink 3 times during an exercise session.
62572020|NCT02019316|PLACEBO_COMPARATOR|Isoenergetic Control|Participants will orally ingest 500ml of Isoenergetic Control (0.18 calories/kg body weight) 2 times separated by 60 minutes.
62572021|NCT04019782|EXPERIMENTAL|Collagen-PVP|Collagen-polyvinyl pyrrolidone (collagen-PVP).
62572022|NCT04019782|ACTIVE_COMPARATOR|Hylan G-F 20|Hylan G-F 20.
62572023|NCT05801783|EXPERIMENTAL|R130 Treatment Group|Every 7-14 days,1-4 ml R130 （concentration of 1x10\^6-1x10\^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral or Intraperitioneal in patients with relapsed/refractory ovarian cancer.
62572024|NCT03780439||infection group and non-infection group|patients were divided into 2 sub-groups according to the presence of infection or not after radical gastrectomy for gastric cancer.
62190200|NCT01130168|EXPERIMENTAL|ISMN ER/Amlodipine/Placebo (Sequence 2)|Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
62004614|NCT01565135|NO_INTERVENTION|Control Practices|Control offices will offer usual health care related to immunizations throughout the duration of the study.
62004615|NCT00653354|ACTIVE_COMPARATOR|Arm 1|
62004616|NCT00653354|ACTIVE_COMPARATOR|Arm 2|
62004617|NCT00653354|PLACEBO_COMPARATOR|Arm 3|
62004618|NCT02479854|EXPERIMENTAL|A Test|test drug (Asmakast)1 chewable tablet contains 5 mg Montelukast
62004619|NCT02479854|ACTIVE_COMPARATOR|B Reference|reference drug (Singulair) 1 chewable tablet contains 5 mg Montelukast
62004620|NCT03903666|EXPERIMENTAL|Cohort|47 Down syndrome patients age from 4 to 16
62190201|NCT01130168|EXPERIMENTAL|Amlodipine/Placebo/ISMN ER (Sequence 3)|Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
62779832|NCT04713501|EXPERIMENTAL|PARTS|The PARTS Program is a 16-week group intervention model, with 8 individual clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
62779833|NCT02923076|EXPERIMENTAL|Study treatment|Allogeneic transplantation with CCR5 delta32/delta32 hematopoietic cells from cord blood.
62190202|NCT01130168|EXPERIMENTAL|ISMN ER/Placebo/Amlodipine (Sequence 4)|Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.
62396596|NCT01921582|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy~* 12 individual 50-minute appointments over the course of up to 14 weeks~* According to Fairburn, Marcus, and Wilson (1993)"
62779834|NCT02661516||Vitamin K Antagonists|Vitamin K Antagonists dose as specified
62779835|NCT00446173|EXPERIMENTAL|Busulfan + Cyclophosphamide + G-CSF + GM-CSF|
62004621|NCT00791791|OTHER|1|increasing remifentanil administration
62004622|NCT00791791|OTHER|2|decreasing remifentanil concentration
62004623|NCT03979443|NO_INTERVENTION|Inpatient|patients staying in the hospital for 1-3 nights after surgery
62004624|NCT03979443|ACTIVE_COMPARATOR|Outpatient|discharge on the day of the surgery, usually within 6-8 hours after procedure
62190203|NCT01130168|EXPERIMENTAL|Placebo/Amlodipine/ISMN ER (Sequence 5)|Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
62396597|NCT06724445|EXPERIMENTAL|Thabo group|Participants will view a cartoon video featuring a Black seropositive protagonist
62779836|NCT01483911|EXPERIMENTAL|ALX-0171|
62004625|NCT02188381||Normal controls without hypertension|Control subjects will have a systolic BP \<140mmHg with no cardiovascular disease. These subjects will provide a one time stool sample and a blood sample.
62004626|NCT02188381||Controlled hypertension|Subjects with controlled hypertension will provide a one time stool sample and a blood sample.
62004627|NCT02188381||Resistant hypertension|Resistant hypertension subjects will have systolic blood pressure (BP) ≥140 mmHg despite ≥3 anti-hypertensive medications of different classes. These subjects will provide a one time stool sample and a blood sample.
62004628|NCT02188381||Prior enrolled in NCT 02133872|These subject will be asked to provide two stool samples and two blood samples. One at baseline and one after 3 months of therapy.
62004629|NCT02188381||Remodeled Resistent Hypertension|Subjects with controlled hypertension will provide a one time stool sample and a blood sample.
62004630|NCT02177266|PLACEBO_COMPARATOR|Placebo|A placebo pill (identical to the study drug Colchicine) will be given in a double-blinded fashion to study participants randomized to placebo.
62004631|NCT02177266|EXPERIMENTAL|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
62004632|NCT03528434|EXPERIMENTAL|Zinc|Dietary Supplement: Zinc 10mg dispersible zinc sulfate tablet
62004633|NCT03528434|PLACEBO_COMPARATOR|Placebo|Dispersible tablet with inert ingredients, identical to zinc in appearance
62004634|NCT04535128||COVID-19 Positive|Patients with positive COVID-19 PCR
62004635|NCT06074575|EXPERIMENTAL|Negative emotional condition|The participant will watch a short video-clip with negative emotional content.
62004636|NCT06074575|EXPERIMENTAL|Positive emotional condition.|The participant will watch a short video-clip with positive emotional content.
62004637|NCT06074575|EXPERIMENTAL|Neutral condition.|The participant will watch a short video-clip with neutral emotional content.
62004638|NCT06074575|EXPERIMENTAL|Control condition.|The participant will not watch a video-clip, but will wait without specific instructions about what to think about.
62004639|NCT01655667||Chronic Obstructive Pulmonary Disease|All patients with a coded diagnosis of COPD entered into their electronic clinical record between 1990 and 2009.
62779837|NCT01483911|PLACEBO_COMPARATOR|Placebo|
62004640|NCT00401011|EXPERIMENTAL|Phase II: Perifosine + Bortezomib|All patients will start with perifosine at bedtime daily and Bortezomib IV on days 1, 4, 8, and 11 q 21 days. Patients will be evaluated at q 3 weeks. If the patient has a CR, PR, MR or stable disease, they will continue treatment.
62190204|NCT01130168|EXPERIMENTAL|Amlodipine/ISMN ER/Placebo (Sequence 6)|Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule for 4 weeks during Period, with a 2-week washout between each period.
62396598|NCT06724445|ACTIVE_COMPARATOR|Steve group|Participants will view a cartoon video featuring a White seropositive protagonist
62779838|NCT03597594|ACTIVE_COMPARATOR|TCRα/β/CD19-depleted SCT|"A preparative regimen based on the type of SCID will be given followed by infusion of donor cells. Cells for infusion are prepared using the CliniMACS System~Regimen 1 - IL2RG, JAK 3 (Haplocompatible) and all MSD~ATG (rabbit) IV Days -9 -8 and -7, Rest Days -6 and -5, Busulfan IV Days -4, -3, and -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0~Regimen 2 - RAG1, RAG2 (Haplocompatible)~ATG (rabbit) IV Days -9 -8 and -7, Fludarabine IV Days -7, -6, -5 and -4, Busulfan IV Days -5, -4 and -3, Thiotepa IV twice daily, Day -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0~Regimen 3 - ADA, IL7R, CD45 deficiency, CD3 subunits (Haplocompatible)~ATG (rabbit) IV Days -9 -8 and -7, Fludarabine IV Days -7, -6, -5 and -4, Busulfan: IV Days -4, -3 and -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0"
62779839|NCT03597594|EXPERIMENTAL|Donor Lymphocyte Infusions|"Phase I:~On the Phase I portion of the study, up to 4 different dose levels will be evaluated: Dose level -1, Dose ≥0.1 to ≤0.3; Dose level 1, Dose \>0.3 to ≤0.56; Dose level 2, Dose \>0.56 to ≤1.8; Dose level 3, Dose \>1.80 to ≤3.0~Dosing is determined based on the number of CD3+CD45RA-cells/kg and the patient weight in kilograms.~Phase II:~Participants will receive the Phase I determined maximum tolerated dose (MTD) of DLI.~Cells for infusion are prepared using the CliniMACS System."
62779840|NCT03203291|EXPERIMENTAL|Tethered Pelvic Assist Device (TPAD) Treatment|All participants will receive 5 consecutive days of training with the TPAD (tethered pelvic assist device) with testing completed before training, on completion of training and at a 1-week follow up.
62779841|NCT04202133|EXPERIMENTAL|WW (formerly Weight Watchers)|16-weeks of the group-based WW program
62779842|NCT04202133|OTHER|Waitlist Control|16-weeks on waitlist then participants will be provided with 16-weeks of the group-based WW program
62779843|NCT05084898|ACTIVE_COMPARATOR|Intervention|Far-UVC light as an additional method of disinfection
62779844|NCT05084898|PLACEBO_COMPARATOR|Placebo|"Inactive fluorescent light (no additional disinfection)"
62779845|NCT03441230|ACTIVE_COMPARATOR|Circumference of 13 cm, sphere form (diameter of 4 cm)|
62396599|NCT06205251|EXPERIMENTAL|Inspiratory Muscle Training (IMT)|Participants will be asked to perform inspiratory muscle training (breathing exercise) 5 days per week for 6 weeks at home.
62779846|NCT03441230|ACTIVE_COMPARATOR|Circumference of 13 cm, cylinder form, length 11 cm|
62779847|NCT03441230|ACTIVE_COMPARATOR|Circumference of 16 cm, sphere form (diameter of 5 cm)|
62779848|NCT03441230|ACTIVE_COMPARATOR|Circumference of 16 cm, cylinder form, length 11 cm|
62779849|NCT03441230|ACTIVE_COMPARATOR|Circumference of 16 cm, cylinder form, length 18 cm|
62779850|NCT03441230|ACTIVE_COMPARATOR|Circumference of 19 cm, sphere form (diameter of 6 cm)|
62572025|NCT04283630|ACTIVE_COMPARATOR|Randomization and Dietary supplement Interventions|The dietary nitrate supplement was provided in the form of commercial beetroot juice (Sport Beet IT shot, Heartbeet Ltd) for all participants, whereas vitamin C and the placebo were provided as supplement capsules. Participants were asked to consume one dose/shot of sport Beet IT (70ml) that delivers on average 300-400mg of inorganic nitrate every day in the morning during the four-week study period, except for the test days and washout weeks. Accordingly, the participant were asked to consume the concentrated beetroot juice with breakfast meals, and then the vitamin C supplement (1000 mg)or placebo at the same time one-hour post beetroot juice supplementation
62004641|NCT00401011|EXPERIMENTAL|Phase II: Perifosine + Bortezomib + Dexa|If the patient shows progressive disease, dexamethasone 20 mg will be added on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
62004642|NCT00401011|EXPERIMENTAL|Phase I: Dose 1: Perifosine + Bortezomib|Perifosine 50 mg at bedtime and bortezomib 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks.
62004643|NCT00401011|EXPERIMENTAL|Phase I: Dose 2: Perifosine + Bortezomib|Perifosine 100 mg at bedtime and bortezomib 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
62004644|NCT00401011|EXPERIMENTAL|Phase I: Dose 3: Perifosine + Bortezomib|Perifosine 50 mg at bedtime and bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
62004645|NCT00401011|EXPERIMENTAL|Phase I: Dose 4: Perifosine + Bortezomib|Perifosine 100 mg at bedtime and bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
62004646|NCT01639027|ACTIVE_COMPARATOR|Drotaverine|Women who will receive 40 mg Drotaverine hydrochloride (Do-Spa) IV injection.
62004647|NCT01639027|PLACEBO_COMPARATOR|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V.
62004648|NCT02510911|EXPERIMENTAL|Caffeine (100 mg)|Verum 1 with 100 mg caffeine
62779851|NCT03441230|ACTIVE_COMPARATOR|Circumference of 19 cm, cylinder form, length 11 cm|
62779852|NCT03441230|ACTIVE_COMPARATOR|Circumference of 22 cm, sphere form (diameter of 7 cm)|
62004649|NCT02510911|EXPERIMENTAL|Caffeine (200 mg)|Verum 2 with 200 mg caffeine
62004650|NCT02510911|PLACEBO_COMPARATOR|corn starch (250 mg approx.)|approx. 250 mg corn starch as placebo
62779853|NCT03441230|ACTIVE_COMPARATOR|Circumference of 25 cm, sphere form (diameter of 8 cm)|
62190205|NCT01982175|EXPERIMENTAL|Alemtuzumab|Patients receive Alemtuzumab escalated from initial dose of 3mg/day then 10mg/day and up to 30mg/day by intravenous infusion(if tolerated). when stable dose of 30mg/day is tolerated, Alemtuzumab is administrated at 30mg by IV infusion 3 times per week for up to 12 weeks (including escalation and stable dose period). After completion of 12 weeks treatment, or discontinuation of treatment within 12 weeks due to disease progression, patients will be visited every 3 months up to 1 year from enrollment or to death, whichever occurs first.
62572026|NCT04283630|PLACEBO_COMPARATOR|Placebo|Vitamin C placebo was matched with the active vitamin c capsules in shape, color, and size.
62779854|NCT03441230|ACTIVE_COMPARATOR|Circumference of 28 cm, sphere form (diameter of 9 cm)|
62779855|NCT02832336|EXPERIMENTAL|Caffeine|"Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakefulness state.~Generic name :Vivarin(1,3,7-trimethylxanthine), 200 mg/day for one week, Form of Administration:Oral in veg white capsule form (size 1) Drug Class:Central nervous system (CNS) stimulants."
62779856|NCT02832336|PLACEBO_COMPARATOR|Fiber|Fiber powder will be used as placebo, Form of Administration:Oral in veg white capsule form (size 1)
62004651|NCT06287060|EXPERIMENTAL|patients with extrinsic staining will be treated with strawberry extract.|
62004652|NCT06287060|ACTIVE_COMPARATOR|patients with extrinsic staining will be treated with Hydrogen peroxide bleaching agent.|
62004653|NCT04084353||Delivered women|Maternal and perinatal outcomes will be collected prospectively on all patients that deliver in Government Medical College (GMC) Hospital before, during and after the training over the study period (8 months) in order to evaluate the impact of the training.
62004654|NCT02477475||NEXIUM|Oral dose 20mg/day
62004655|NCT04634292||Children with cerebral palsy 7-9 years|21 children
62004656|NCT04634292||Children with cerebral palsy 10-12 years|21 children
62004657|NCT04634292||Healthy children 7-9 years|21 children
62004658|NCT04634292||Healthy children 10-12 years|21 children
62004659|NCT06100991||Generalized Pustular Psoriasis (GPP)|Pts presenting to enrolling sites across the North America are invited to enroll if eligible
62004660|NCT03211741|OTHER|open label|
62004661|NCT02069561|EXPERIMENTAL|Eicosapentaenoic Acid|Subjects with long-standing ulcerative colitis and meeting the inclusion criteria will receive 2 g/day of Eicosapentaenoic Acid as a supplement for 90 days
62004662|NCT02069561|NO_INTERVENTION|Normal controls|Five patients undergoing screening colonoscopy and polypectomy using biopsy forceps. Six biopsies of healthy mucosa will be collected at the time of colonoscopy. Faeces, urine and blood samples will be collected prior to performing colonoscopy. The samples will serve as healthy reference for the basic studies.
62004663|NCT00909636|ACTIVE_COMPARATOR|1. ABT-333 Tablet|Three 400mg ABT-333 Tablets, BID
62004664|NCT00909636|ACTIVE_COMPARATOR|2. ABT-333 Tablet|Four 400mg ABT-333 Tablets, BID
62004665|NCT00909636|PLACEBO_COMPARATOR|3. Placebo|Three or four placebo tablets, BID
62004666|NCT00183872|EXPERIMENTAL|Arm 1 - Irinotecan and Docetaxel|Irinotecan given day 1 and 8 every 21 days Docetaxel given day 1 and 8 every 21 days
62190206|NCT02204098|ACTIVE_COMPARATOR|Cohort 1:Neoadjuvant endocrine therapy alone|"* Will be treated with standard of care adjuvant endocrine therapy as determined by their treating physician~* Optional biopsy approximately 14 days following initiation of neoadjuvant therapy"
62190207|NCT02204098|EXPERIMENTAL|Cohort 2:Neoadjuvant endocrine + mammaglobin-A DNA vaccine|"* Will be treated with standard of care adjuvant endocrine therapy~* Optional biopsy approximately 14 days following initiation of neoadjuvant therapy~* Treated with 4 mg of mammaglobin-A DNA vaccine at 3 time points (Days 28, 56, and 84)~* All study injections will be administered using a TriGrid electroporation device"
62190208|NCT02204098|ACTIVE_COMPARATOR|Cohort 3: Neoadjuvant chemotherapy alone|"* Will be treated with standard of care neoadjuvant chemotherapy as determined by their treating physician~* If archival tissue not sufficient, a research biopsy to obtain primary tissue must be done prior to day 28~* Subjects who begin neoadjuvant endocrine therapy but are determined to not be responding at the Day 14 biopsy may begin chemotherapy treatment, at the discretion of the treating physician. These subjects may be enrolled in cohort 3"
62190209|NCT02204098|EXPERIMENTAL|Cohort 4: Neoadjuvant chemotherapy + mammoglobin-A DNA vaccine|"* Will be treated with standard of care neoadjuvant chemotherapy as determined by their treating physician~* If archival tissue not sufficient, a research biopsy to obtain primary tissue must be done prior to day 28~* Treated with 4 mg of mammaglobin-A DNA vaccine at 3 time points (Days 28, 56, and 84)~* All study injections will be administered using a TriGrid electroporation device~* Subjects who begin neoadjuvant endocrine therapy but are determined to not be responding at the Day 14 biopsy may begin chemotherapy treatment, at the discretion of the treating physician. These subjects may be enrolled in either cohort 4"
62190210|NCT04052945|ACTIVE_COMPARATOR|SPA acupuncture|active SPG acupuncture plus rescue medication (AA group)
62190211|NCT04052945|SHAM_COMPARATOR|sham acupuncture|sham-SPG acupuncture plus rescue medication (SA group)
62190212|NCT02020746|ACTIVE_COMPARATOR|EscharEx|Enzymatic debridement
62190213|NCT02020746|PLACEBO_COMPARATOR|Gel Vehicle|Control arm
62396600|NCT02895386|ACTIVE_COMPARATOR|Treatment Group A|ROX Coupler implantation and continuing antihypertensive medications.
62572027|NCT05029375|EXPERIMENTAL|immediate parental involvement|Parental involvement in training is parallel to children's training
62572028|NCT05029375|EXPERIMENTAL|delayed parental involvement|Parental involvement in training will be given at the end of the children's training
62190214|NCT05144698|EXPERIMENTAL|Administration of RAPA-201 cells|RAPA-201 cells will be administered at a target flat dose of 400 x 10\^6 cells per infusion.
62572029|NCT03348007|EXPERIMENTAL|HEPAR|1L of Hépar + 0.5L of low-mineral water (Hépar group).
62779857|NCT05018104||Lower Limb Orthopedic Surgery Patients who Received Popliteal Sciatic Nerve Blocks|All patients undergoing lower limb surgery who received popliteal sciatic nerve blocks (with or without other peripheral nerve blocks) at St. Paul's Hospital from January 4, 2016 to November 1, 2019
62190215|NCT01937026|EXPERIMENTAL|Baricitinib|Single oral dose of 4 milligrams (mg) baricitinib on Day 1
62396601|NCT02895386|SHAM_COMPARATOR|Control Group B|Sham procedure and continuing current antihypertensive medications.
62572030|NCT03348007|ACTIVE_COMPARATOR|VITTEL Bonne Source|1.5L of low-mineral water (Vittel Bonne Source, control group)
62572031|NCT01562782|EXPERIMENTAL|South Asians|Participants in this group have only South Asian heritage. The intervention is Fructose + Glucose Beverage.
62572032|NCT01562782|ACTIVE_COMPARATOR|Caucasians|Participants in this group have only Caucasian heritage. The intervention is Fructose + Glucose Beverage.
62572033|NCT00415818|EXPERIMENTAL|Arm 1|MVA-MUC1-IL2 in combination with 1st line Chemotherapy
62572034|NCT00415818|ACTIVE_COMPARATOR|Arm 2|1st line Chemotherapy without a MVA-MUC1-IL2 combination
62572035|NCT02011633|EXPERIMENTAL|HCP1201, Part 1|Participants received a single oral dose of the HCP1201 500/10 mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
62572036|NCT02011633|ACTIVE_COMPARATOR|Metformin and Rosuvastatin, Part1|Participants received a single oral dose of coadministration of Metformin SR 500 mg and Rosuvastatin 10 mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
62572037|NCT02011633|EXPERIMENTAL|HCP1201, Part 2|Participants received a single oral dose of the HCP1201 500/10mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
62572038|NCT02011633|ACTIVE_COMPARATOR|Metformin and Rosuvastatin, Part 2|Participants received a single oral dose of coadministration of Metformin SR 500mg and Rosuvastatin 10mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
62190216|NCT01937026|EXPERIMENTAL|Baricitinib + Probenecid|Oral doses of 1000 mg probenecid once daily on Days 3 through 7, with a single oral dose of 4 mg baricitinib co-administered on Day 5
62190217|NCT05006326|EXPERIMENTAL|68Ga-PSMA PET/MR|The investigators selected patients with a high clinical suspicion of HCC, or patients with confirmed HCC without tumour-related treatment who were to be biopsied or surgically resected to obtain pathological results. Patients signed an informed consent form and underwent 68Ga-PSMA PET/MR imaging (or PET/CT imaging if the patient had a contraindication to MR imaging).
62190218|NCT01988298|EXPERIMENTAL|Ibuprofen|Experimental: Ibuprofen 400 mg each 8 hours for 2-3 days.
62190219|NCT01988298|ACTIVE_COMPARATOR|Acetaminophen|Acetaminophen 1 g oral each 6 hours, 2-3 days.
62190220|NCT06050447||Patients with right-sided colon cancer|Tumors located anywhere from the cecum to the proximal transverse colon.
62190221|NCT06050447||Patients with left-sided colon cancer|Tumors located anywhere from the distal transverse colon to the rectosigmoid junction
62190222|NCT06050447||Patients with rectal cancer|Tumors located in rectosigmoid junction and in the rectum with/without the external sphincter or the levator muscles invasion
62190223|NCT06050447||Patients with right- and left-sided colon cancer (primary multiple cancer)|Patients with primary multiple cancer tumors
62572039|NCT01188330|EXPERIMENTAL|WITH Comprehensive Geriatric assessment|Conventional haematological management of patients and Comprehensive Geriatric assessment (CGA) at diagnosis followed by interventions according to disabilities detected and planned monthly follow up by a nurse practitioner during 6 months.
62004667|NCT03641378|EXPERIMENTAL|Inpatient Palliative Care Intervention|"* Patients and Caregivers will complete baseline self-report assessments at the time of obtaining informed consent~* Palliative Care Intervention~* Therapeutic Relationship~  --Develop a strong therapeutic relationship with patients and caregivers~* Assessment and Treatment of Patient Symptoms~  --Clarify the symptoms the patient will likely experience and offer reassurance about the methods for reporting and treating symptoms~* Managing Patients and Caregivers Expectations~  --Address early on patients and caregivers' concerns about the trajectory of illness during HCT and treatment side effects~* Coping with Illness and HCT --Introduce strategies to help improve adjustment (e.g., behavioral, cognitive, and spiritual approaches; accepting illness while maintaining hope; social support)"
62004668|NCT03641378|EXPERIMENTAL|Transplant Care Alone|"* Patients and Caregivers will complete baseline self-report assessments at the time of obtaining informed consent.~* Standard Transplant Care"
62004669|NCT01506531|ACTIVE_COMPARATOR|primary closure of gastroschisis|Attempt primary skin closure of gastroschisis shortly after birth
62004670|NCT01506531|ACTIVE_COMPARATOR|silo for gastroschisis|Surgical placement of silo over gastroschisis shortly after birth
62004671|NCT00495716|ACTIVE_COMPARATOR|Episodic Treatment Arm|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
62004672|NCT00495716|ACTIVE_COMPARATOR|Suppressive Therapy Arm|400 mg acyclovir orally twice daily for 1 year
62004673|NCT05925894|ACTIVE_COMPARATOR|Group 1: Mydriatic Eyedrops|Group 1 patients included instillation of one drop each of tropicamide 0.5% and phenylephrine 10% ( VISUMIDRIATIC FENILEFRINA) at 30, 20, and 10 min prior to surgery.
62190224|NCT02280512||elderly with fractures|patients more than 65 years old accepting surgeries for lower extremities fracture
62190225|NCT02109666||RA patients treated with Abatacept|RA patients are treated with Abatacept IV according Summary of Product Characteristics (SmPC) in Europe and Product Monograph in Canada
62190226|NCT06351462|OTHER|Patients transplanted from allogeneic HLA-compatible sibling donor or from sibling cord blood unit|
62572040|NCT01188330|ACTIVE_COMPARATOR|Conventional|Conventional haematological management of patients
62190227|NCT06351462|OTHER|Controlled patients - not transplanted|
62396602|NCT04881149|EXPERIMENTAL|All Study Participants|The TempSure will be used on the flanks during this study. Subjects will receive 1 biopsy in the treatment area on the flank. Subjects will also receive 1 biopsy sample on the contralateral side, where they did not receive treatment. Each subject had 1 control sample (tissue that was taken from an area where no treatment was received), and 1 treatment sample (tissue taken from an area that had been subjected to the treatment).
62779858|NCT02568592|EXPERIMENTAL|High Fat|High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
62572041|NCT05976321|EXPERIMENTAL|Cohort 1, Moderate HI: TAK-279 50 mg|Participants with moderate HI will receive a single oral dose of TAK-279 50 mg, on Day 1 in Part A of the study.
62396603|NCT06641141|EXPERIMENTAL|Induction of Labour between 38 weeks + 0 days and 38 weeks + 6 days|Induction of Labour between 38+0 weeks and 38+6 weeks.
62396604|NCT06641141|NO_INTERVENTION|Expectant Management|Expectant management without intervention until spontaneous labour, or earlier at the discretion of the attending healthcare provider.
62572042|NCT05976321|EXPERIMENTAL|Cohort 2, Normal Hepatic Function: TAK-279 50 mg|Participants with normal hepatic function will receive a single oral dose of TAK-279 50 mg, on Day 1 in Part A of the study. Based on an evaluation of the results from Part A, additional participants with normal hepatic function may be enrolled in Part B of the study.
62572043|NCT05976321|EXPERIMENTAL|Cohort 3, Mild/Severe HI: TAK-279 50 mg|Participants with mild/severe HI will receive a single oral dose of TAK-279 50 mg, on Day 1 in Part B of the study based on an evaluation of the results from Part A.
62779859|NCT02568592|EXPERIMENTAL|Normal|Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
62779860|NCT02568592|EXPERIMENTAL|Normal + Extra Fat|Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORM (Normal), with an additional 30% extra energy coming from fat.
62779861|NCT04462965|EXPERIMENTAL|Test group|Toripalima Combined with Temozolomide and Cisplatin. Toripalima3 mg/kg intravenous infusion, administered once every 2 weeks (1 treatment cycle every 2 weeks) for a maximum of 1 year. Temozolomide, Oral 200mg/m2 1-5 days and Cisplatin, Iv infusion 25 mg/m2/d for a period of 1 to 3 days, 28 days for 1 cycle, lasting 6 cycles;
62004674|NCT05925894|EXPERIMENTAL|Group 2: Insert Device Mydriasert®|Group 2 patients had the Mydriasert® (Phenylephrine Hydrochloride,Tropicamide) device placed in the inferior conjunctival sac at least 1 h before surgery
62396605|NCT04114955|ACTIVE_COMPARATOR|Intervention|Intervention condition comprised of two components designed to address intersectional stigma: 1) a group-level, peer-led intervention and 2) an individual-level peer navigation program to increase uptake of HIV testing and PrEP.
62396606|NCT04114955|OTHER|Wait-list control|Control participants will receive the intervention after a one-year waiting period.
62190228|NCT02164019|ACTIVE_COMPARATOR|long-stem cemented hemiarthroplasty (LSCH)|"(LSCH), Hip, Ball, Rod and Cement Replace the ball of the hip joint with a metal ball and a rod that is placed inside the thigh bone with cement to keep the implant in place. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary."
62190229|NCT02164019|ACTIVE_COMPARATOR|intramedullary nailing (IMN)|"Intramedullary nailing (IMN), Rod and Screws A metal rod is placed inside your thigh bone and secured in place by metal screws just below the hip and above the knee. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary."
62190230|NCT01240889|ACTIVE_COMPARATOR|montelukast|luekotriene inhibitor
62190231|NCT01240889|ACTIVE_COMPARATOR|Fluticasone|Nasal steroid
62190232|NCT02830529|EXPERIMENTAL|MAD DASH|Mindfulness based stress reduction and diet education delivered in 8 sessions lasting 2.5 hours each. Mindfulness conducted by a certified trainer. Participants were given homework and meditation CD. Dietitian delivered diet education and conducted interactive food demonstrations. Participants were given option complete weekly diet diary for the dietitian to provide feedback.
62190233|NCT02830529|EXPERIMENTAL|DASH diet education|Dietary approaches to stop hypertension sessions were delivered by a registered dietitian in 8 sessions lasting 1 hour each. Dietitian delivered diet education and conducted interactive food demonstrations. Participants were given option complete weekly diet diary for the dietitian to provide feedback.
62190234|NCT02830529|NO_INTERVENTION|Usual Care-DASH Pamphlet Only|Dietary approaches to stop hypertension pamphlet was mailed to each participant. They continued receiving usual care from their health care provider.
62004675|NCT05925894|EXPERIMENTAL|Group 3: Intracameral Anesthesia Mydrane®|Group 3 patients received 0.2 mL intracameral Mydrane®(0.2 mg/ml + 3.1 mg/ml + 10 mg/ml tropicamide, lidocaine hydrochloride, phenylephrine hydrochloride) immediately following the clear corneal incision; the surgeon allowed 45-60 s for adequate pupil dilation before performing continuous curvilinear capsulorhexis (CCC)
62004676|NCT00354224|EXPERIMENTAL|Oxaliplatin + Capecitabine|Patients will receive Oxaliplatin 85 mg/m2/d on day 1, given as a 2-hour infusion in 250 mL of dextrose 5% repeated every 2 weeks. Capecitabine will be administered orally at a dose of 850 mg/m2 twice a day.
62190235|NCT03965676|OTHER|Adult patients with a tophaceous gout|Adult patients with a tophaceous gout but no urate-lowering treatment or treatment but target not reached (target = uricemia \< 360µmol/L).
62004677|NCT06010394|ACTIVE_COMPARATOR|control group|commensal physiotherapy will be applied
62004678|NCT06010394|EXPERIMENTAL|exercise group|exercises will be given
62190236|NCT02219698|EXPERIMENTAL|Symptomatic treatment|
62779862|NCT04462965|PLACEBO_COMPARATOR|Placebo group|Placebo Combined with Temozolomide and Cisplatin. Toripalima3 mg/kg intravenous infusion, administered once every 2 weeks (1 treatment cycle every 2 weeks) for a maximum of 1 year. Temozolomide, Oral 200mg/m2 1-5 days and Cisplatin, Iv infusion 25 mg/m2/d for a period of 1 to 3 days, 28 days for 1 cycle, lasting 6 cycles;
62190237|NCT02744339|EXPERIMENTAL|Riociguat|Riociguat up-titrated to a maximum of 1.5mg TID
62190238|NCT02744339|PLACEBO_COMPARATOR|Placebo|Placebo sham-titrated TID
62779863|NCT05533970|EXPERIMENTAL|0.375% ropivacaine+0.5ug/kg Dexmedetomidine 30 ml|H-FICB under ultrasound guidance before general anesthesia, given 0.375% ropivacaine+0.5ug/kg Dexmedetomidine 30 ml
62779864|NCT05533970|EXPERIMENTAL|0.375% ropivacaine+1ug/kg Dexmedetomidine 30 ml|H-FICB under ultrasound guidance before general anesthesia, given 0.375% ropivacaine+1ug/kg Dexmedetomidine 30 ml
62004679|NCT06010394|EXPERIMENTAL|massage group|massage will be done
62004680|NCT02379585|ACTIVE_COMPARATOR|HER2 negative breast cancer|Doxorubicin and cyclophosphamide every two weeks for four cycles (one cycle is defined as 14 days). After completing fourth cycle, paclitaxel every two weeks for an additional four cycles. The appropriate surgery will be done three to six weeks after completing the last cycle of paclitaxel.
62004681|NCT02379585|ACTIVE_COMPARATOR|HER2 positive breast cancer|Docetaxel, trastuzumab, and pertuzumab every three weeks for four cycles. Pegfilgrastim after docetaxel. Surgery three to six weeks after completing the last docatexel. If additional chemotherapy is needed patients will receive both doxorubicin and cyclophosphamide every three weeks for four cycles and after the fourth cycle then trastuzumab for one year
62004682|NCT03040297|ACTIVE_COMPARATOR|TGI 6 L/min|Tracheal gas insufflation 6 L/min
62004683|NCT03040297|ACTIVE_COMPARATOR|TGI 11 L/min|Tracheal gas insufflation 11 L/min
62190239|NCT05987098|EXPERIMENTAL|Malignant Tumors|BBPA in suspected malignant tumors. This arm investigates the metabolic characteristics of BBPA in suspected malignant tumor patients who consider for surgical operations. A single dose of 0.10 mCi/kg BBPA will be intravenously injected and PET examination will carry out 30 minutes later. Surgical operations, if recommended after multiple examination, will be carried out within 1 week after BBPA PET scan.
62190240|NCT02328586|EXPERIMENTAL|Group Acupuncture|Participants will then be invited to participate in an 8-week, group-based acupuncture treatment intervention delivered by a licensed acupuncturist. The group will meet weekly for 8 consecutive weeks, each session lasting about 75 minutes.
62190241|NCT04592497|EXPERIMENTAL|QDOT|will undergo the AF ablation procedure with assistance THERMOCOOL SMARTTOUCH SF-5D QDOT system
62190242|NCT04592497|ACTIVE_COMPARATOR|standard|will undergo the AF ablation procedure with assistance standard Thermocool Smartouch SF system
62004684|NCT03040297|ACTIVE_COMPARATOR|TGI 0 L/min|Tracheal gas insufflation catheter, without gas flow
62190243|NCT00691600|ACTIVE_COMPARATOR|oral trimethoprim/sulfamethoxazole|subjects with abscesses less than 5cm will be randomized to either study med or placebo
62190244|NCT00691600|PLACEBO_COMPARATOR|placebo|Placebo after incision and drainage of abscess less than 5 cm.
62190245|NCT05874310|EXPERIMENTAL|Low dose FT-002|Intraocular injection of a single low dose of FT-002
62190246|NCT05874310|EXPERIMENTAL|Intermediate dose FT-002|Intraocular injection of a single Intermediate dose of FT-002
62190247|NCT05874310|EXPERIMENTAL|High dose FT-002|Intraocular injection of a single High dose of FT-002
62190248|NCT01390441|EXPERIMENTAL|Part A: MK-8808 500 mg/m^2 / Extension A: MK-8808 1000 mg|"During the Treatment Period, participants receive one course of MK-8808 (500 mg/m\^2) administered intravenously (IV) on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~During the Extension Period, participants receive open-label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, subcutaneously (SC), or intramuscularly (IM) for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
62190249|NCT01390441|ACTIVE_COMPARATOR|Part A: MabThera® 500 mg/m^2 / Extension A: MK-8808 1000 mg|"During the Treatment Period, participants receive one course of MabThera® (500 mg/m\^2) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~During the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
62190250|NCT01390441|EXPERIMENTAL|Part B: MK-8808 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of MK-8808 (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) adminstered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
62396607|NCT03335189|EXPERIMENTAL|ASyMS-Can|TParticipants assigned to the experimental group will be provided with the encrypted, secure, pre-programmed ASyMS-Can android phone, and instructed of its use; how to report their symptomatology on a twice daily basis using the CTAQ for the first 14 days of each treatment cycle until end of the final cycle of treatment (or up to 16 weeks).
62572044|NCT02767466||G|"All participants were randomly exposed to two different treatments:~* Conventional physical therapy (no specific device used)~* Robotic assisted gait training (Lokomat, Hocoma AG, Switzerland)~We consider the study as observational, since the both interventions of the study (physical therapy, robotic assisted gait training) did not change in the patients' usual therapy plan, as they received both interventions daily.~We only added diagnostic interventions to assess the affective responses."
62572045|NCT00934336|EXPERIMENTAL|preprandial injection|pre-prandial injection of an ultra-fast-acting analog during 3 months, then post-prandial injection of an ultra-fast-acting analog during 3 other months.
62572046|NCT00934336|EXPERIMENTAL|post-prandial injection|post-prandial injection of an ultra-fast-acting analog during 3 months then pre-prandial injection of an ultra-fast-acting analog during 3 other months.
62779865|NCT05533970|EXPERIMENTAL|0.375% ropivacaine+0.25ug/kg Dexmedetomidine 30 ml|H-FICB under ultrasound guidance before general anesthesia, given 0.375% ropivacaine+0.25ug/kg Dexmedetomidine 30 ml
62779866|NCT04829253|EXPERIMENTAL|b-DBT (Brief Dialectical Behavioral Therapy)|3 months of and intensive modified DBT intervention.
62004685|NCT06467266|EXPERIMENTAL|Intervention|Patients will undergo cardiac imaging with a cardiac MRI and echocardiogram prior to the haemodynamic study. The haemdynamic study will be performed in the catheter lab. During that study patients will undergo a temporary pacing procedure with pacing of multiple sites of the heart and multiple haemodynamic recordings. This will be conducted under local anaesthetic and sedation. Total procedure time will be approximately 2 hours.
62004686|NCT02376166|EXPERIMENTAL|Metformin|850 mg PO once daily for 4 weeks
62004687|NCT06354153|OTHER|group of first-line nurse managers|First-line nurse managers received a polarity training program
62004688|NCT06354153|OTHER|intervention group|60 first-line nurse managers received a polarity training program
62004689|NCT03918343|OTHER|All patients|
62004690|NCT02488785|NO_INTERVENTION|Control|Patients in this group will attend regular clinical and education appointments as offered by the clinic for their diabetes care.
62004691|NCT02488785|EXPERIMENTAL|Intervention|Patients in this group will be part of a Virtual Diabetes Self-Care and Education Program. They will receive a phone to communicate with a diabetes educator for 6 months. They will connect with the diabetes educator for weekly video conferences of up to 30 minutes for twelve consecutive weeks, followed by 7 phone calls. Additionally, they will receive a weekly text message about diabetes for 6 months.
62004692|NCT01950546|EXPERIMENTAL|Nanosilver fluoride|This product is a solution composed of: 390 mg / ml 9nm silver nanoparticles ;21 mg / ml chitosan ; 22 mg / ml NaF.The cariostatic agent, nanosilver fluoride, was formulated in a similar way to silver diamine fluoride, so that this new formulation contained 5% nanosilver fluoride, while commercial diamine silver fluoride contains 30% silver fluoride. It will be applied once with a microbrush on tooth surfaces to check if it prevents the growth of S. mutans biofilms on dental surfaces.
62004693|NCT04564625||Fracture and Vitamin D assessment|All patients between 18 and 25 years treated for fractures at Methodist Dallas Medical Center (MDMC) with an index admission vitamin D assessment will be enrolled. This study will consider any patients with an index admission occurring between February 2016 and February 2020. No changes to care or intervention will occur and this study will be conducted completely via chart review. The aim is to identify 100 subjects with a one-year follow-up appointment for their injury to determine the rate of nonunion and vitamin D levels. As patients receive vitamin D supplementation as standard of care if index values are low, impact will be assessed through relative deficiency and clinical outcomes. Data collected from subjects without need for supplementation may be used to generate a threshold.
62004694|NCT03192150|EXPERIMENTAL|ISV-305|0.1% dexamethasone in DuraSite® 2
62004695|NCT03192150|PLACEBO_COMPARATOR|Vehicle|DuraSite® 2 vehicle
62190251|NCT01390441|ACTIVE_COMPARATOR|Part B: MabThera® 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of MabThera® (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
62779867|NCT04829253|ACTIVE_COMPARATOR|s-DBT (standard Brief Dialectical Behavioral Therapy)|6 months of a standard DBT intervention (this is a shorter version of the original 12-month DBT, but includes all four active components delivered over 6 months)
62004696|NCT06048484|EXPERIMENTAL|Arm A: Safety run-in|Prior to resection: SBRT 40 Gy over 5 fractions, zimberelimab (AB122) 240 mg intravenously (IV) every 2 weeks for 7 weeks (4 doses), quemliclustat (AB680) 100 mg IV every 2 weeks for 7 weeks (4 doses) and etrumadenant (AB928) 150 mg PO daily for 7 weeks. After resection: mFOLFIRINOX (4 cycles)
62004697|NCT06048484|ACTIVE_COMPARATOR|Arm B: SBRT with Zimberelimab (AB122) Alone (Control Arm)|Prior to resection: SBRT 40 Gy over 5 fractions, 240 mg IV zimberelimab (AB122) every 2 weeks for 7 weeks (4 doses) prior to surgery. After resection: mFOLFIRINOX (4 cycles)
62004698|NCT06048484|EXPERIMENTAL|Arm C: SBRT, Zimberelimab with quemliclustat (AB680)|Prior to resection: SBRT 40 Gy over 5 fractions, 240 mg IV zimberelimab (AB122) every 2 weeks for 7 weeks (4 doses) prior to surgery in combination with quemliclustat IV at the recommended therapeutic dose (RTD)every 2 weeks for 7 weeks (4 doses) prior to surgery. After resection: mFOLFIRINOX (4 cycles)
62004699|NCT06048484|EXPERIMENTAL|Arm D: SBRT, Zimberelimab with AB680 and Etrumadenant (AB928)|Prior to resection: SBRT 40 Gy over 5 fractions, 240 mg IV zimberelimab (AB122) every 2 weeks for 7 weeks (4 doses) prior to surgery in combination with quemliclustat IV at the RTD every 2 weeks for 7 weeks (4 doses) and etrumadenant (AB928) PO at the RTD daily for 7 weeks prior to surgery. After resection: mFOLFIRINOX (4 cycles)
62004700|NCT01589822|EXPERIMENTAL|EVICEL Fibrin Sealant: Randomized|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen.
62190252|NCT01390441|EXPERIMENTAL|Part B: Rituxan® 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of Rituxan® (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
62004701|NCT01589822|NO_INTERVENTION|Standard of Care|Standard surgical technique for GI anastomosis.
62190253|NCT01804010|ACTIVE_COMPARATOR|Ivabradine|Single and repeated oral administrations of 3 doses of ivabradine
62779868|NCT00971295|EXPERIMENTAL|Treatment Sequence A|Eslicarbazepine acetate + Metformin period followed by washout period followed by Metformin period
62779869|NCT00971295|EXPERIMENTAL|Treatment Sequence B|Metformin period followed by washout period followed by Eslicarbazepine acetate + Metformin period
62190254|NCT01804010|PLACEBO_COMPARATOR|Placebo|Placebo administration
62004702|NCT01589822|EXPERIMENTAL|Experimental: EVICEL Fibrin Sealant: Non-Randomized|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen
62572047|NCT01767246|EXPERIMENTAL|PFS algorithm treatment|The Patellofemoral Syndrome algorithm is designed to determine what deficits a patient may have and addressing these sequentially. This subgrouping first assesses a patient fear avoidance beliefs, flexibility, body mechanics, and then strength and functional ability. The reason for sequential treatment is that there is evidence that without adequate flexibility a patient will be unable to perform exercises with proper body mechanics, and without proper mechanics strengthening and functional activity can cause increased stress on the patellofemoral joint. Progression through each specific subgroup is based on objective goals. Once the patient has met these goals they are progressed to the next treatment subgroup until discharge.
62004703|NCT01486017|EXPERIMENTAL|Treatment A|ASP015K oral dose low strength
62572048|NCT01767246|ACTIVE_COMPARATOR|Multimodal Treatment|Patients randomized to the this treatment group will be treated in a manner consistent with a Multimodal treatment approach previously described in literature that has been found effective in treating Patellofemoral Syndrome (Lowry, 2008). Treatment consists of strengthening, flexibility and manual treatments aim to improve patients knee pain.
62572049|NCT03423173|PLACEBO_COMPARATOR|Placebo|TDV placebo matching injection, subcutaneously (SC) once on Day 1, and Day 90.
62572050|NCT03423173|EXPERIMENTAL|TDV Lot 1|Participants were administered TDV lot 1, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.
62004704|NCT01486017|EXPERIMENTAL|Treatment B|ASP015K oral dose medium strength
62004705|NCT01486017|EXPERIMENTAL|Treatment C|ASP015K oral dose high strength
62004706|NCT04989049|ACTIVE_COMPARATOR|intervention group or case group|topical folic acid on oral ulcers will be applied for 7 days and patients will be asked to visit after 7 days for follow up
62572051|NCT03423173|EXPERIMENTAL|TDV Lot 2|Participants were administered TDV lot 2, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.
62004707|NCT04989049|PLACEBO_COMPARATOR|control group|placebo drug for oral ulcers
62004708|NCT01211275|EXPERIMENTAL|arm 2|axitinib + cisplatin + premetrexed
62004709|NCT01211275|ACTIVE_COMPARATOR|arm 1|cisplatin + premetrexed
62004710|NCT01947400||Hospitalists|AIDET Training
62004711|NCT02537418|EXPERIMENTAL|durvalumab ± tremelimumab|"durvalumab; Day 1 every 3 weeks or 4 weeks~tremelimumab; every 3-6 weeks for a total of 1-6 doses"
62190255|NCT04058002|EXPERIMENTAL|Experimental|Multiprofessional treatment and Educational Program Associated (EPA+C+BCAA) with supplementation of creatine and BCAA.
62190256|NCT04058002|ACTIVE_COMPARATOR|Control group|Multiprofessional treatment and Educational Program Associated (EPA+C) with supplementation of creatine only.
62572052|NCT03423173|EXPERIMENTAL|TDV Lot 3|Participants were administered TDV lot 3, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection once on Day 1, and Day 90.
62572053|NCT03478644|EXPERIMENTAL|Experimental Denture Wipe|Participants of this arm were instructed to use the experimental wipe to clean their dentures up to 4 times daily.
62572054|NCT03478644|PLACEBO_COMPARATOR|Tap Water|Participants of this arm were instructed to use running tap water to clean their dentures up to 4 times daily.
62572055|NCT02815332|PLACEBO_COMPARATOR|BPX-01 Vehicle Topical Gel|Approximately 1 gram applied once daily for 12 weeks
62004712|NCT03218111|OTHER|Healthy Normal Subjects|Healthy normal subjects 20-80 years old. All subjects will undergo the same procedures: intrathecal injection, using CT-guidance, with an MRI contrast. After injection subjects will undergo six sessions of MR imaging over a 10-12 hour period
62190257|NCT03220997|EXPERIMENTAL|Interventional|Mothers will be given six sachets of carbohydrate powder to be mixed in water . Instructions will be given to have two sachets in 800ml water at 10pm the night before and one sachet in 400ml water at 6 am on the morning of surgery. The order of the list will be decided at 8.45am on the morning of surgery by the surgical team. Mothers scheduled to have surgery later than 11am will be given a further sachet at 9.30am. Mothers scheduled for surgery after 1pm will be given a sachet at 9am and 11am.
62396608|NCT03335189|NO_INTERVENTION|Control|Control group will be asked to complete the study questionnaires at your clinic visits. Also, research staff will contact participants at 1 to 14 days following each chemotherapy, mid and end of each chemotherapy appointment and again within week 8 and 16 of your participation to collect information about participants' symptoms.
62779870|NCT02629003|ACTIVE_COMPARATOR|[11C]Cimbi-36|"\[11C\]Cimbi-36~Maximum of 600 Mega Becquerel (MBq) or 1.5 micrograms, single dose intravenous (I.V.)"
62004713|NCT01971827|NO_INTERVENTION|Control|No intervention
62004714|NCT01971827|EXPERIMENTAL|MOVI-KIDS Program|Intervention group
62004715|NCT06168526|EXPERIMENTAL|Acute physical activity|The participants in the experimental activity groups will perform an interval physical activity of different intensity for 16 minutes. The intensity will be controlled during the test by the monitorization of their heart rate using a heart rate monitor. Subsequently, participants will perform an active break in the classroom after finishing one of their usual theory sessions at the intensity of physical activity that proves to have the greatest benefits for cognition and well-being.
62004716|NCT03112161|EXPERIMENTAL|Eucaloric|Participants will consume a eucaloric diet with a macronutrient composition of 20% protein, 30% fat and 50% carbohydrate for 4 days (Eucaloric Feeding Period). The caloric value of the diet will be calculated based on lean body mass plus an activity factor to ensure energy and macronutrient balance.
62396609|NCT04978129|EXPERIMENTAL|Online and Text Message Intervention|Participants randomized to the intervention will receive a link to the online intervention following baseline completion. The online and Text Message intervention, and its delivery, will be designed and adapted based on the results of the formative focus groups and cognitive interviews and is meant to be non-confrontational in tone, seeks to increase motivation to increase the quality use of PBS and decrease motivations for non-use of PBS. Intervention participants will receive personalized PBS Text Messages 3x per week (based on self-selections from the interactive online intervention) for 8 consecutive weeks timed to occur on a random weekday as well as Friday and Saturday.
62396610|NCT04978129|NO_INTERVENTION|Wait List Control|The wait-list control condition will not receive any intervention content during the 8-week period of data collection, but will complete baseline, 2-month, and daily surveys according to the same schedule as the intervention group in order to assess event-level PBS use, PBS non-use, alcohol and marijuana use, CAM and SAM use, and related consequences for up to 24 days over an 8-week period. All wait-list control participants will receive the intervention at the end of the 8-week period of data collection for the pilot study.
62396611|NCT05292352|EXPERIMENTAL|Low Free Sugar Diet (LFSD) Intervention|The 1-year dietary intervention will be accomplished by adapting and extending a Social Cognitive Theory (SCT) guided low sugar intervention. SCT is a framework that helps explain how people regulate their behavior through control and reinforcement to achieve goal-directed behavior that can be maintained over time.
62779871|NCT02629003|ACTIVE_COMPARATOR|[11C]Cimbi-36-5|"\[11C\]Cimbi-36-5~Maximum of 600 Mega Becquerel (MBq) or 1.5 micrograms, single dose intravenous (I.V.)"
62004717|NCT03112161|EXPERIMENTAL|Overfed|Following 3 days of eucaloric feeding, participants will complete a 1-day overfeeding period (Overfeeding Feeding Period), during which their diet will have a daily energy value of 40% greater than the eucaloric diet (Eucaloric Arm), although the macronutrient composition will remain the same (20% protein, 30% fat, 50% carbohydrate).
62004718|NCT03112161|EXPERIMENTAL|Underfed|Following 3 days of eucaloric feeding, participants will complete a 1-day underfeeding period (Underfeeding Feeding Period), during which their diet will have a daily energy value of 40% less than the eucaloric diet (Eucaloric Arm), although the macronutrient composition will remain the same (20% protein, 30% fat, 50% carbohydrate).
62004719|NCT02672371|EXPERIMENTAL|active eMNS|Subjects with receive active eMNS for 20 minutes.
62004720|NCT02672371|SHAM_COMPARATOR|sham eMNS|Subjects with receive sham eMNS for 20 minutes.
62004721|NCT06341127|EXPERIMENTAL|Placebo-Fluoxetine-Placebo|placebo (medical grade cornstarch in a gel capsule, 1 capsule daily), followed by blinded randomized cross-over moment to active fluoxetine (2.5 then 5 mg po daily), followed by blinded randomized cross-over moment back to placebo
62004722|NCT03700359|EXPERIMENTAL|Anlotinib/Lobaplatin/Etoposide|EL regimen for 4 cycles followed by Anlotinib Hydrochloride maintenance therapy
62004723|NCT03700359|ACTIVE_COMPARATOR|Lobaplatin/Etoposide|EL regimen for 4 cycles
62396612|NCT05292352|NO_INTERVENTION|Usual Care Control|Usual Care (Control group): Parents of enrolled children in the usual care group will be provided printed material on healthy family lifestyle at the beginning of the study. The control group will complete all of the same research visits and assessments as the intervention group.
62779872|NCT03092635|EXPERIMENTAL|OPC|During weeks 1- 12, subjects will take one OPC tablet in the morning and in the evening, about 12 hours apart.
62779873|NCT05167591|EXPERIMENTAL|Study group|Measurements of paracetamol concentration
62779874|NCT04558359|ACTIVE_COMPARATOR|Standard of Care Cohort|Patients in this group will receive standard of care treatment.
62779875|NCT04558359|EXPERIMENTAL|Angiotensin II Cohort|Patients in this group will receive angiotensin II.
62779876|NCT02973308|OTHER|Treadmill-Test operator A|Randomised to motorised treadmill group A for inter reliability, observer A will perform both exercise tests
62779877|NCT02973308|OTHER|Treadmill-Test operator B|Randomised to motorised treadmill group B for intra reliability, observer A will perform one exercise test, followed by observed B
62190258|NCT03220997|NO_INTERVENTION|Standard Care|"Standard fasting instructions will given to mother:~Food until midnight before surgery 800ml water at 10pm night before surgery 400ml water at 6 am morning of surgery The order of the list will be decided at 8.45am on the morning of surgery by the surgical team.~Mothers scheduled to have surgery later than 11am will be given a further 400ml water at 9.30am. Mothers scheduled for surgery after 1pm will be given 400ml water at 9am and 11am."
62190259|NCT00543062|OTHER|Treatment Sequence ABCD|Treatment Sequence ABCD where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
62190260|NCT00543062|OTHER|Treatment Sequence BDAC|Treatment Sequence BDAC where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
62779878|NCT02973308|OTHER|Cycle-Test operator A|Randomised to cycle group B for inter reliability, observer A will perform both exercise tests
62779879|NCT02973308|OTHER|Cycle-Test operator B|Randomised to cycle group B for intra reliability, observer A will perform one exercise test, followed by observed B
62779880|NCT00267852||1.0|As per routinary clinical practice
62004724|NCT05476562||First-line Therapy|A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database)
62004725|NCT05476562||Second-line Therapy|A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database)
62004726|NCT05476562||Third-line Therapy|A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database)
62004727|NCT05476562||Fourth-line Therapy|A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database)
62004728|NCT03722329|EXPERIMENTAL|SB12|SB12 (proposed eculizumab biosimilar)
62004729|NCT03722329|ACTIVE_COMPARATOR|EU Soliris|EU sourced Soliris (eculizumab)
62004730|NCT03722329|ACTIVE_COMPARATOR|US Soliris|US sourced Soliris (eculizumab)
62004731|NCT06021886||patient without scar|history of euploid embryo transfer
62004732|NCT06021886||patient with cs scar no Niche|history of euploid embryo transfer
62190261|NCT00543062|OTHER|Treatment Sequence CABD|Treatment Sequence CABD where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
62004733|NCT06021886||patient with cs scar with niche|history of euploid embryo transfer
62004734|NCT01999621||lung cancer|Each lung cancer patient with organ failure, admitted in emergency, thoracic oncology or directly in ICU
62004735|NCT05854693|EXPERIMENTAL|Active tDCS|The intervention consisted of 10 daily 20-min sessions of bilateral prefrontal tDCS (anodal-right/cathodal-left, 2mA; 1 × 1 Mini-CT)
62190262|NCT00543062|OTHER|Treatment Sequence DCBA|Treatment Sequence DCBA where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
62190263|NCT03304756|EXPERIMENTAL|CAP|Cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
62190264|NCT01052363|EXPERIMENTAL|CA4P + Avastin|
62190265|NCT01052363|EXPERIMENTAL|Avastin + CA4P|
62190266|NCT01512498||Patients who underwent allogeneic HSCT|Patients who underwent allogeneic HSCT before the age of 18, who are 18 years or older at the time of the study and who are alive.
62190267|NCT04906265|ACTIVE_COMPARATOR|Intervention|The intervention comprises of standard rehabilitation and continuous measures of body positions and movements 24 hour a day with an IMU. Standard rehabilitation comprises of home-visits by a PT, where an individualized rehabilitation plan is outlined together with the patient. The plan includes individually tailored functional exercises. The plan also includes individually tailored walking exercises, indoor and outdoor when possible. At each home visit, the PT provides feedback to the participant based on the data from the IMU, i.e. body positions (time spent in sitting, standing, lying down) and body movements (steps per day, step length, walking speed).
62190268|NCT04906265|ACTIVE_COMPARATOR|Control|Standard rehabilitation alone
62190269|NCT04135508|EXPERIMENTAL|BAT1406|Adalimumab, 40 mg/0.8 mL/vial, subcutaneously 1 vial every two weeks, up to a maximum of 6 months treatment.
62004736|NCT05854693|SHAM_COMPARATOR|Sham tDCS|The sham group consisted of 10 daily 20-min sessions of sham stimulation
62190270|NCT04135508|ACTIVE_COMPARATOR|Humira|Adalimumab, 40 mg/0.8 mL/vial, subcutaneously 1 vial every two weeks, up to a maximum of 6 months treatment.
62190271|NCT02676843|EXPERIMENTAL|18F-AV-1451|Subjects who are microtubule associated protein tau (MAPT) family carriers and non-carriers will receive 18F-AV-1451 by injection, and undergo a Positron Emission Tomography (PET) scan, which will then be qualitatively analyzed to examine tau deposition in the brain.
62779881|NCT03582995|ACTIVE_COMPARATOR|Flap Surgery for root coverage with Alloderm and xenograft|Root coverage surgery using a flap technique
62779882|NCT03582995|EXPERIMENTAL|Tunnel Surgery for root coverage with Alloderm and xenograft|Root coverage surgery using a tunnel technique
62190272|NCT03922022|EXPERIMENTAL|EIM group|patients will go to different classes: (i) Hypertension basic exercise class (ii) Hypertension advanced exercise class (iii) diabetes basic exercise class (iv) diabetes advanced exercise class; if the patient has normal BMI AND reported some regular exercise, they will be prescribed the advanced level class. There is no control group for this pilot study
62190273|NCT02922283|EXPERIMENTAL|IL2-PET scan|\[18F\]FB-IL2 PET scan, Tumor biopsy, CT scan, Biopsy of non-target tissue
62779883|NCT05788497|EXPERIMENTAL|Hemorrane® Plus|Daily application of Hemorrane Plus (Hemorrane® + benzocaine) 10 mg/g rectal ointment + 30 mg/g benzocaine for 7 days.
62190274|NCT03306004||Health Care Providers|Providers answer questionaires
62190275|NCT03306004||Mothers|Mothers answer questionaires
62190276|NCT05264701|EXPERIMENTAL|Physiotherapist Supervised Exercise Training Group|Physiotherapist supervised exercise training in patients with coronary artery disease
62190277|NCT05264701|EXPERIMENTAL|Exercise Training Tracking from Phone-app Group|Exercise training tracking from phone app in patients with coronary artery disease
62190278|NCT05264701|EXPERIMENTAL|Control Group|General physical activity recommendations for home
62190279|NCT01699737|EXPERIMENTAL|JTT-851 Dose 1|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
62190280|NCT01699737|EXPERIMENTAL|JTT-851 Dose 2|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
62190281|NCT01699737|EXPERIMENTAL|JTT-851 Dose 3|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
62190282|NCT01699737|ACTIVE_COMPARATOR|Glimepiride Dose 1|Active Comparator Capsule and Placebo Tablets, administered once daily for 12 weeks
62190283|NCT01699737|PLACEBO_COMPARATOR|Placebo active & Placebo comparator|Placebo Tablets for study drug and Placebo Capsule for active comparator, administered once daily for 12 weeks
62190284|NCT04207645||African|patients originating from Nigeria and Sudan (11 centres)
62779884|NCT05788497|ACTIVE_COMPARATOR|Hemorrane®|Daily application of Hemorrane 10 mg/g rectal ointment for 7 days.
62779885|NCT05788497|PLACEBO_COMPARATOR|Placebo|Daily application of placebo for 7 days.
62779886|NCT03046030|EXPERIMENTAL|Healthy Volunteers|In this experiment, we will apply a crossover design in healthy subjects. Each subject will receive four treatments in four separate sessions: 1) VGAIT, 2) VGAIT control condition, 3) real acupuncture, and 4) sham acupuncture. Each session will be separated by at least 7 days. Subjects will participate in five experimental sessions: a training and familiarity behavioral session and four fMRI sessions during which the subject will receive one of the four treatments.
62779887|NCT03432559|OTHER|endoscopy|endoscopy of the upper GI tract
62779888|NCT01354366||Control|Marketed hypoallergenic infant formula containing a probiotic
62779889|NCT01354366||Experimental 1|An investigational hypoallergenic infant formula with a different protein content, containing the same probiotic as the control
62190285|NCT04207645||Latin American|patients originating from Mexico (5 centres)
62190286|NCT04207645||South Asian|patients originating from India and Pakistan (10 centres)
62190287|NCT04207645||European|patients originating from Spain (11 centres).
62779890|NCT01354366||Experimental 2|An investigational hypoallergenic infant formula with a different protein content, without a probiotic
62779891|NCT04255641||frozen embryos|
61977943|NCT04231539|EXPERIMENTAL|High Nicotine (nicotine vapor) 42 mg.ml|After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours, 5-7 days apart. During each session, participants take 20 puffs over 10 minutes (one puff every 30 seconds) of vaporizer filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored, or salt-based nicotine e-liquid solution of tobacco flavor assigned in a random order.
61977944|NCT05072574|EXPERIMENTAL|Experimental: nutritional education program|Specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program
62190288|NCT04853498|EXPERIMENTAL|TQB3720 tablets|TQB3720 tablets administered orally, once daily in 28-day cycle.
62190289|NCT06258954|EXPERIMENTAL|3D group|Using automatic comparison software for 3D reconstruction to determine the size of DLT.
62190290|NCT06258954|PLACEBO_COMPARATOR|control group|The size of DLT is based on patient's sex and height.
62190291|NCT03845712|EXPERIMENTAL|doxecitine and doxribtimine|This is an open label study with all participants in a single arm. Study participants will take doxecitine and doxribtimine up to a maximum of 800 mg/kg/day (400 mg/kg/day doxecitine and 400 mg/kg/day doxiribtimine).
62190292|NCT04375267|EXPERIMENTAL|177Lu-DOTA-TATE and olaparib|
62190293|NCT02706249|ACTIVE_COMPARATOR|A: Standard Dose Enoxaparin|"Participants will receive Enoxaparin 40 mg subcutaneously once daily. On study Enoxaparin will be administered for up 14 days during hospitalization.~After the day 14 assessment, treatment arms will be un-blinded in order to appropriately schedule a bilateral lower extremity ultrasound for participants enrolled onto Arm A at day 17."
62190294|NCT02706249|ACTIVE_COMPARATOR|B: Weight Adjusted Enoxaparin|"Participants will receive Enoxaparin at 1mg/kg subcutaneously once daily with maximum dose of 100 mg daily. Participants who weigh more than 100kg will be capped at 100mg.~On study Enoxaparin will be administered for up 14 days during hospitalization."
62396613|NCT05546515|ACTIVE_COMPARATOR|Suvorexant|20mg Suvorexant
62779892|NCT04674488|EXPERIMENTAL|TILs intervention|
62779893|NCT00099866|EXPERIMENTAL|Vildagliptin|
62779894|NCT00099866|ACTIVE_COMPARATOR|Metformin|
62779895|NCT03079219|EXPERIMENTAL|Experimental|Aprepitant, Ondansetron, Dexamethasone and Olanzapine
62779896|NCT03079219|OTHER|Standard|Aprepitant, Ondansetron, Dexamethasone
62190295|NCT03518242|EXPERIMENTAL|Treatment (Specimen collection, chemotherapy)|"SPECIMEN COLLECTION: Patients undergo collection of tumor tissue and peripheral blood samples for analysis via next generation sequencing to identify novel pathways in the pathogenesis of breast cancer.~TREATMENT: Patients are invited to participate in a treatment study. Patients receive cyclophosphamide PO daily on days 1-21, methotrexate PO QD on days 1, 8, and 15, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity."
62190296|NCT03253263|EXPERIMENTAL|OHB-607|Participants will receive continuous IV infusion of OHB-607 through from birth up to PMA 29 weeks +6 days.
62190297|NCT03253263|NO_INTERVENTION|Standard Neonatal Care|Standard neonatal care alone will be provided.
62190298|NCT04749355|EXPERIMENTAL|BST-236|BST-236 Intravenous, 4.5 g/m\^2/d or 2.3 g/m\^2/d, for 6 days
62190299|NCT01339962||Non-Interventional Study|Outcomes Research Study
62190300|NCT00637468|EXPERIMENTAL|1|Local intra-arterial fibrinolysis (LIF)
62190301|NCT00637468|ACTIVE_COMPARATOR|2|Conservative standard therapy
62190302|NCT03218566|OTHER|Single Arm|Single Arm - Use of Indigo Aspiration System (mechanical thrombectomy) to treat pulmonary embolism
62190303|NCT01236352|EXPERIMENTAL|Phase 1 (Cohort 1): BMS-911543 (5 mg)|BMS-911543 5 mg capsule by mouth twice daily for 12 months or greater depending on response
62190304|NCT01236352|EXPERIMENTAL|Phase 1 (Cohort 2): BMS-911543 (10 mg)|BMS-911543 10 mg capsule by mouth twice daily for 12 months or greater depending on response
62190305|NCT01236352|EXPERIMENTAL|Phase 1 (Cohort 3): BMS-911543 (20 mg)|BMS-911543 20 mg capsule by mouth twice daily for 12 months or greater depending on response
62190306|NCT01236352|EXPERIMENTAL|Phase 1 (Cohort 4): BMS-911543 (40 mg)|BMS-911543 40 mg capsule by mouth twice daily for 12 months or greater depending on response
62190307|NCT01236352|EXPERIMENTAL|Phase 1 (Cohort 5): BMS-911543 (80 mg)|BMS-911543 80 mg capsule by mouth twice daily for 12 months or greater depending on response
62396614|NCT05546515|PLACEBO_COMPARATOR|Placebo|Placebo oral capsules
62779897|NCT03854383|SHAM_COMPARATOR|Misoprostol alone|Enrolled women will receive 25 πg of misoprostol which will be placed intravaginally 4 hourly, maximum up to 5 doses
62572056|NCT02815332|EXPERIMENTAL|BPX-01 1% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
62190308|NCT01236352|EXPERIMENTAL|Phase 1 (Cohort 6): BMS-911543 (120 mg)|BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response
62779898|NCT03854383|ACTIVE_COMPARATOR|Isosorbide mononitrate with misoprostol|Enrolled women will receive 25 πg of misoprostol together with 40 mg isosorbide mononitrate which will be placed intravaginally 4 hourly, maximum up to 5 doses
62190309|NCT01236352|EXPERIMENTAL|Phase 1 (Cohort 7): BMS-911543 (160 mg)|BMS-911543 160 mg capsule by mouth twice daily for 12 months or greater depending on response
62190310|NCT01236352|EXPERIMENTAL|Phase 1 (Cohort 8): BMS-911543 (200 mg)|BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response
62190311|NCT01236352|EXPERIMENTAL|Phase 1 (Cohort 9): BMS-911543 (240 mg)|BMS-911543 240 mg capsule by mouth twice daily for 12 months or greater depending on response
62190312|NCT01236352|EXPERIMENTAL|Phase 1 (Cohort 10): BMS-911543 (320 mg)|BMS-911543 320 mg capsule by mouth twice daily for 12 months or greater depending on response
62190313|NCT01236352|EXPERIMENTAL|Phase 2 (Cohort 11): BMS-911543 (120 mg)|BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response
62396615|NCT03684343|OTHER|Atopic Dermatitis patients|Filmed consultation with a dermatologist. Laterality and tactile sensitivity test.
62779899|NCT03940118|ACTIVE_COMPARATOR|Catheter secretion suctioning|Secretions are aspirated with a catheter at -120 to -150 mBar
62396616|NCT03684343|OTHER|Healthy patients|Filmed consultation with a dermatologist. Laterality and tactile sensitivity test.
62779900|NCT03940118|EXPERIMENTAL|Secretion suctioning + hypertonic saline|Hypertonic saline is nebulized prior to aspiration of secretions.
62779901|NCT03940118|EXPERIMENTAL|Ins-exsufflation|Mechanical insufflation-exsufflation with device programmed at 50/-50 mmHg
62779902|NCT03940118|EXPERIMENTAL|Ins-exsufflation + Hypertonic Saline|Mechanical insufflation-exsufflation and hypertonic saline
62190314|NCT01236352|EXPERIMENTAL|Phase 2 (Cohort 12): BMS-911543 (200 mg)|BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response
62190315|NCT01690468|EXPERIMENTAL|Triciribine & Carboplatin|"Phase I/II: 25mg/m\^2 Triciribine and Carboplatin AUC 4. Triciribine escalated to 30, 35, 45mg/m\^2 if toxicities are not encountered.~Phase II: Recommended phase II dose of triciribine and carboplatin."
62190316|NCT01322009|EXPERIMENTAL|Drug|Probenecid and N-acetyl cysteine will be administered at standard doses for the first 4 days after TBI.
62190317|NCT01322009|PLACEBO_COMPARATOR|Placebo|Placebos will be prepared for the two experimental drugs and administered at identical time periods.
62396617|NCT02626962|EXPERIMENTAL|Nivolumab and Ipilimumab|Nivolumab and Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
62396618|NCT02812823|OTHER|High resolution anorectal manometry|All subjects will be investigated by high-resolution anorectal manometry. At the beginning the anorectal cather will be used to record conventional parameters and after that 3D high-definition anorectal manometric catheter will be inserted in order to measure conventional parameters and 3D picture of anorectum.
62572057|NCT02815332|EXPERIMENTAL|BPX-01 2% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
62572058|NCT03115437|EXPERIMENTAL|Hard cushioned running shoes|Running shoes with cushioned properties among the hardest of the market benchmark (Stiffness: +/- 90 N/mm)
62572059|NCT03115437|EXPERIMENTAL|Soft cushioned running shoes|Running shoes with cushioned properties among the softest of the market benchmark (Stiffness: +/- 57 N/mm)
62572060|NCT04075214|SHAM_COMPARATOR|delayed-active tAN|
62572061|NCT04075214|EXPERIMENTAL|active tAN|
62572062|NCT01741688||Tocilizumab|Participants with moderate to severe rheumatoid arthritis (RA), according to the American College of Rheumatology (ACR) criteria and the Disease Activity Score Based on 28 Joints (DAS28), in whom the attending physician has decided to start treatment with tocilizumab (according to the local label).
62779903|NCT06172725|EXPERIMENTAL|High-Protein Vegetarian Diet|High-protein vegetarian diet (no meat/fish)
62779904|NCT06172725|ACTIVE_COMPARATOR|High-Protein Omnivorous Diet|High-protein omnivorous diet
62779905|NCT01717326|EXPERIMENTAL|A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk|GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally once daily (QD) for 12 weeks, Elbasvir 20 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally twice daily (BID) for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
62779906|NCT01717326|EXPERIMENTAL|A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally BID for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
62396619|NCT03176979|EXPERIMENTAL|Diagnostic (CESM with DBT)|Patients undergo a clinical breast examination and a diagnostic mammogram with or without targeted breast ultrasound to the index cancer as part of their standard of care preoperative work-up. As part of the research study, patients receive contrast agent IV and then undergo a CESM with DBT over 30 minutes. Patients also receive a contrast agent, gadolinium, IV and undergo bilateral breast CE-MRI over 10 minutes.
62190318|NCT03191071|EXPERIMENTAL|UltraPro|"General practitioners randomly assigned to the UltraPro arm will be responsible to recruit patients fulfilling the inclusion criteria and manage them using the UltraPro algorithm.~The UltraPro algorithm combines the result of a procalcitonin point-of-care test with lung ultrasound result to decide on antibiotic prescription. Blood sampling will be performed to identify potential novel biomarkers. Naso-pharyngeal swabs as well as sputum culture will allow for microbiologic identification of aetiological agents."
62190319|NCT03191071|EXPERIMENTAL|Procalcitonin|"General practitioners randomly assigned to the procalcitonin arm will be responsible to recruit patients fulfilling the inclusion criteria and manage them using the procalcitonin algorithm.~The procalcitonin point-of-care test will be performed, as described above, to decide on antibiotic prescription. Blood sampling will be performed to identify potential novel biomarkers. Naso-pharyngeal swabs as well as sputum culture will allow for microbiologic identification of aetiological agents."
62190320|NCT03191071|ACTIVE_COMPARATOR|Usual Care|"General practitioners randomly assigned to the usual care arm will be responsible to recruit patients fulfilling the inclusion criteria and will manage and treat these patients as they usually do. Only general practitioners who do not use procalcitonin and lung ultrasonography routinely will be included in the usual care arm.~Naso-pharyngeal swabs as well as sputum culture will be performed to allow for microbiologic identification of aetiological agents."
62190321|NCT02219399|EXPERIMENTAL|300 mg DHA|300 mg DHA
62190322|NCT02219399|PLACEBO_COMPARATOR|Placebo|olive oil or high oleic acid sunflower oil placebo
62190323|NCT02219399|EXPERIMENTAL|600 mg DHA|600 mg DHA
62190324|NCT06205654||Intervention|innovative lighting designs are implemented in the living area.
62396620|NCT05300256|EXPERIMENTAL|Peripheral Heating|Peripheral Heating
62396621|NCT05300256|SHAM_COMPARATOR|Sham|Sham
62190325|NCT06205654||Control|no significant modifications to their lighting conditions are implemented in the living area
62396622|NCT06723847||Patient underwent robotic pancreaticoduodenectomy|All patients undergoing robotic pancreaticoduodenectomy regardless of the pathology for which they underwent it
62396623|NCT06300281|EXPERIMENTAL|Neuromuscular Exercise Group|A 12-week Neuromuscular exercise program consisting of sensorimotor system training, postural stability and control, global and local joint stabilization, balance training, muscle strength, breathing, and functional movement patterns will be created for the participants in Group 1.
62396624|NCT06300281|EXPERIMENTAL|Aquatic Exercise Group|Group 2 will undergo a 12-week aquatic exercise program at Alanya Alaaddin Keykubat University in a 140 cm deep pool and 32-degree water temperature.
62396625|NCT04474171|EXPERIMENTAL|SCI&U Intervention|The SCI\&U online platform has a resource library, secure videoconferencing, and tools to support one-on-one health coaching. Health coaches are certified in motivational interviewing and have lived in the community with SCI for more than five years. In the first session, participants identify priority issues related to their health and target management of secondary conditions specific to SCI. They will work through goal setting, problem solving activities and create action plans for behaviour change, which will be securely stored. The intervention will be a maximum of 14 sessions over 6 months. Each session will cover a health-related topic (bladder, bowel, skin, pain, healthy eating, physical activity or stress, anxiety and depression) and a self-management skill topic (action planning, goal setting, problem-solving, mood management, navigating the health care system and communicating with health care providers) with an expected duration of 30 to 45 minutes.
62396626|NCT04474171|NO_INTERVENTION|Waitlist Control|Usual health care and be offered the SCI\&U program at the end of the 12-month follow-up period (wait-list control)
62396627|NCT01475942|ACTIVE_COMPARATOR|Probiotic|Lactobacillus
62396628|NCT01475942|PLACEBO_COMPARATOR|Placebo|Sucrose
62190326|NCT05638737|EXPERIMENTAL|AZD4831|AZD4831
62190327|NCT05638737|PLACEBO_COMPARATOR|Placebo|Placebo
62396629|NCT04487275|EXPERIMENTAL|Drug|MLC901 capsules three times per day over 6 months
62396630|NCT04487275|PLACEBO_COMPARATOR|Placebo|Placebo capsules three times per day over 6 months
62396631|NCT04831957|OTHER|Patient underwent TAVI procedure|- Elderly patients who will undergo a TAVI procedure coming to the geriatric day hospital
62396632|NCT05839691||Mothers|Mothers enrolled in Home Visiting Programs that have or will be participating in past or future projects.
62396633|NCT05839691||Home Visitors|Home Visitors/Educators employed by Home Visiting Programs that have or will be participating in past or future projects.
62396634|NCT05839691||Supervisors|Supervising staff of Home Visiting Programs that have or will be participating in past or future projects.
62779907|NCT01717326|EXPERIMENTAL|A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1b only participants receive Grazoprevr 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
62396635|NCT06722937||Keratoconus group of children|
61977945|NCT05072574|NO_INTERVENTION|Control Group|Dietary and general lifestyle recommendations
61977946|NCT05766644|NO_INTERVENTION|Control|Usual care, with no guide on app use. Surveys are administered via Short Message Services links.
61977947|NCT05766644|EXPERIMENTAL|Education|Enrolled in a mobile app-based education program, with guidance from a healthcare professional. All educational materials and surveys are provided via the app.
62190328|NCT03893747|EXPERIMENTAL|the first batch vaccine producted by 40 L reactor|500 subjects will be randomly received the first batch vaccine producted by 40 L reactor
62190329|NCT03893747|EXPERIMENTAL|the second batch vaccine producted by 40 L reactor|500 subjects will be randomly received the second batch vaccine producted by 40 L reactor
62190330|NCT03893747|EXPERIMENTAL|the third batch vaccine producted by 40 L reactor|500 subjects will be randomly received the third batch vaccine producted by 40 L reactor
62190331|NCT03893747|EXPERIMENTAL|the first batch vaccine producted by 150 L reactor|500 subjects will be randomly received the first batch vaccine producted by 150 L reactor
62190332|NCT03893747|EXPERIMENTAL|the second batch vaccine producted by 150 L reactor|500 subjects will be randomly received the second batch vaccine producted by 150 L reactor
62190333|NCT03893747|EXPERIMENTAL|the third batch vaccine proudected by 150 L reactor|500 subjects will be randomly received the third batch vaccine producted by 150 L reactor
62190334|NCT03178045||Team Monitoring|Team Monitoring is the current standard of care for patients at Josie Robertson Surgery Center (JRSC).
62190335|NCT03178045||Enhanced Feedback|The electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity.
62190336|NCT03543605|EXPERIMENTAL|PROA Experimental|"It consists of the intervention measures described in the general antimicrobial stewardship program (PROA Control) plus clinical advice.~* The clinical assessments have been adapted for this project to the unique characteristics of infectious diseases in nursing homes.~* These are individual training activities whose main objective is to modify prescribing behaviors when they are inadequate and reinforce them when they are correct.~* They are carried out between the medical adviser, an expert in infectious diseases, and the doctor of the nursing home, through the structured review of a case attended by the doctor in the last 24 hours. The recommendations are not compulsory, and do not seek to change the decisions made in that patient, but the future ones in the case that is necessary.~* The counseling will be done by video-conference, with an approximate duration of 10 minutes. Each of the doctors will receive two monthly assessments during the intervention period."
62190337|NCT03543605|OTHER|PROA Control|"The intervention of the general antimicrobial stewardship program (PROA) contains the following set of measures:~* Creation of the local team of the PROA: one of the Family Physicians responsible for the patients and the pharmacist of the reference hospital of the center.~* Presentation of the project by the local team in its own center.~* Choice of the Aljarafe guide as a reference document for the diagnosis and treatment of infectious diseases. It is an accredited guide and widely disseminated among primary care and hospital doctors.~* Permanent information of the project (poster with its synthesis, a pocket triptych with the guide for the clinical management of the main clinical syndromes of infections in the residents of the nursing homes).~* Feedback of the results that will serve each center to know the evolution of its results, and to stimulate the comparison with the other centers."
62190338|NCT05673733|EXPERIMENTAL|Group A|Exergaming training combined with Scapular stabilization exercises will be performed for 6 weeks for 3 times per week.
62190339|NCT05673733|ACTIVE_COMPARATOR|Group B|Exergaming training will be performed for 6 weeks for 3 times per week.
62779908|NCT01717326|EXPERIMENTAL|B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight
62190340|NCT03113383|EXPERIMENTAL|Primary Arm|Use of the thoracic bifurcation and the visceral manifold to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy.
62396636|NCT06722937||Keratoconus group of adult|
62190341|NCT03113383|EXPERIMENTAL|Expanded Selection Arm|Use of the thoracic bifurcation and the visceral manifold to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy.
62190342|NCT00909532|PLACEBO_COMPARATOR|Placebo|Subjects who received placebo every 12 hours (q12h) for up to 48 weeks.
62572063|NCT05220449|ACTIVE_COMPARATOR|Cf-tACS (V1-Alpha_V5-Gamma)|
62396637|NCT06722937||Control group of children|
62396638|NCT06722937||Control group of adult|
62396639|NCT03174028|ACTIVE_COMPARATOR|laparoscopic group|laparoscopic pull-through
62396640|NCT03174028|SHAM_COMPARATOR|posterior sagittal group|posterior sagittal anorectoplasty
62396641|NCT06472934|EXPERIMENTAL|Pausing group|Subjects in the pausing group will stop their B-blocker medication 72h before the scheduled transcatheter aortic valve replacement (TAVR) procedure. Post-procedural B-blocker therapy will be resumed 72h after the procedure using the same type and dosage as prescribed before.
62396642|NCT06472934|OTHER|Control group|Subjects in the control group will keep their B-blocker medication in their prescribed dose during the scheduled TAVR procedure.
62396643|NCT02810210||Cohort 1|Monitoring of children born without congenital anomalies to mothers with biologically confirmed ZIKV's infection during the pregnancy
61977948|NCT01938378|OTHER|Pediatric patients undergoing TPE|octaplas™
62396644|NCT02810210||Cohort 2|Monitoring of children born with congenital anomalies to mothers with biologically confirmed ZIKV's infection during the pregnancy
62396645|NCT02810210||Cohort 3|Monitoring of children born without congenital anomalies to mothers with no biologically confirmed ZIKV's infection during the pregnancy
62396646|NCT06564779||group intervention|patients benefiting from the new memory assessment
62572064|NCT05220449|EXPERIMENTAL|Cf-tACS (V1-Gamma_V5-Alpha)|
62572065|NCT02821754|EXPERIMENTAL|1/A1-Durvalumab + Tremelimumab|Durvalumab + Tremelimumab
62572066|NCT02821754|EXPERIMENTAL|2/A2 - Durvalumab + Tremelimumab + Trans-arterial Catheter Chemoembolization (TACE)|Durvalumab + Tremelimumab + TACE
62572067|NCT02821754|EXPERIMENTAL|3/A3 - Durvalumab + Tremelimumab+ Radiofrequency Ablation (RFA)|Durvalumab + Tremelimumab+ RFA
62572068|NCT02821754|EXPERIMENTAL|4/A4 - Durvalumab + Tremelimumab+ Cryoablation|Durvalumab + Tremelimumab+ Cryoablation
62572069|NCT05958628|OTHER|Control group|Participants in this group will receive a conventional physiotherapy program 3 times a week for 5 weeks, each session lasting 1 hour.
62779909|NCT01717326|EXPERIMENTAL|B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
62004737|NCT05702320|EXPERIMENTAL|Reference Group|Patients in this group will be warmed for 15 minutes with a full-body blanket belonging to the air-blown heater device before surgery. The heating will be Decelerated until he is taken to the operating table, and after the preparations are completed, the lower extremities will continue to be heated with a half-body blanket belonging to the heating device. After the patient is taken to the post-anesthesia care unit, the soaked blankets will be removed and the whole body will continue to be warmed with a blanket as in the preoperative period. When the patient's body temperature rises above 36 °C, the heating process will be terminated and when he meets the criteria for being transferred to the clinic, his transfer to the clinic will be provided in accordance with the institution's policy.
62004738|NCT05702320|EXPERIMENTAL|intervention group|The patients in this group will be wrapped with a reflective blanket from the neck to the whole body with the reflective side facing the patient for 15 minutes before the operation, so that only the surgical gown is on the patients in this group. After a layer of operating room cover is placed on the patient's lower extremities on the operating table in accordance with the hospital procedure, a reflective blanket will be wrapped on it with the reflective side facing the patient. After the patient is taken to the post-anesthesia care unit, the soaked covers will be removed and the entire body of the patient will be wrapped with a reflective blanket, as in the preoperative period. When the patient's body temperature rises above 36 °C and he meets the criteria for being transferred to the clinic, his transfer to the clinic will be provided in accordance with the institution's policy.
62190343|NCT00909532|EXPERIMENTAL|150 mg Ivacaftor q12h|Subjects who received 150 mg of ivacaftor q12h for up to 48 weeks.
62572070|NCT05958628|EXPERIMENTAL|Intervention group|Participants in this group will receive Robotic Hand Exoskeleton System for 10 minutes in addition to 50 minutes of conventional physiotherapy 3 times a week for 5 weeks.
62572071|NCT06155955|EXPERIMENTAL|low dose emicizumab|2 mg per kilograms per dose in first month, loading every 2 weeks then every 4 weeks
62572072|NCT06155955|NO_INTERVENTION|low dose factor VIII prophylaxis|factor VIII prophylaxis
62572073|NCT00457197|PLACEBO_COMPARATOR|Placebo|This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
61977949|NCT03349112|ACTIVE_COMPARATOR|Anesthetized|A study team member will apply 1 mL of 2% viscous lidocaine to each nares prior to the passage of the catheter, Participants in this group will additionally receive .8 mL of a 4% Lidocaine spray to both nares prior to HRPM.
62190344|NCT06120868|EXPERIMENTAL|Surefil one Self-adhesive bulk fill restorative (SABF)|
62190345|NCT06120868|ACTIVE_COMPARATOR|Filtek One Bulk Fill (FOBF)|
62190346|NCT01898780|EXPERIMENTAL|horizontal mattress|pancreaticojejunostomy with horizontal mattress suture
62190347|NCT01898780|EXPERIMENTAL|interrupted suture|pancreaticojejunostomy with interrupted suture
62190348|NCT00585871|EXPERIMENTAL|Clonidine therapy group|clonidine 0.1 TID
62190349|NCT00585871|ACTIVE_COMPARATOR|Metoprolol control group|metoprolol 25 TID
62190350|NCT00487032|EXPERIMENTAL|1|Prazosin 1mg challenge to block alpha 1 adrenoreceptors
62190351|NCT00487032|PLACEBO_COMPARATOR|2|Placebo to Prazosin
62190352|NCT05932147|EXPERIMENTAL|Pilates group|This group includes 34 patients who have axillary web syndrome will receive Pilates exercise with traditional physical therapy exercise program (strength, core stability, flexibility, muscle control, posture and breathing). Patients will receive 3 sessions per week for 9 weeks; time of session is 30 minutes.
62190353|NCT05932147|EXPERIMENTAL|Manual lymphatic massage group|This group includes 34 patients who axillary web syndrome will receive Manual lymphatic drainage massage with traditional physical therapy exercise program (strength, core stability, flexibility, muscle control, posture and breathing). Patients will receive 3 sessions per week for 9 weeks; time of session is 30 minutes.
62190354|NCT04417569||stimulated cycles|Patients will have blood drawn on five separate occasions: before and following hCG trigger on the day of final oocyte maturation and day of egg collection
62190355|NCT00827554|EXPERIMENTAL|LMWH plus TACE|50 HCC patients will be allocated to receive Nadroparin 4100 AXa iu twice daily 3 days after TACE which lasted for 6 weeks
62396647|NCT01254734|EXPERIMENTAL|Arm I|Patients undergo transoral robotic microsurgery.
62396648|NCT05248685|EXPERIMENTAL|Dual CD33/CLL1 CAR T|All patients who receive Dual CD33/CLL1 CAR T Cell infusion
62396649|NCT02956226|EXPERIMENTAL|Cannabinoids - 99% pure cannabinoids mix|Oral cannabinoids mix \[cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio\] at 1 mg/kg cannabidiol per day, up-titrated until intolerance or to a maximum dose of 10 mg/kg CBD per day, divided to 3 daily doses, for 3 months.
62396650|NCT02956226|PLACEBO_COMPARATOR|Placebo|Oral olive oil and flavors that mimic in texture and flavor the cannabinoids' solution.
62396651|NCT02956226|EXPERIMENTAL|Cannabinoids - whole plant extract|Oral cannabinoids mix \[cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio\] at 1 mg/kg cannabidiol per day, up-titrated until intolerance or to a maximum dose of 10 mg/kg CBD per day, divided to 3 daily doses, for 3 months
62396652|NCT02380417||Single lung transplant paravertebral catheter placement|Those patients who underwent single lung transplant either right or left.
62396653|NCT02380417||bilateral lung transplant paravertebral catheter placement|those patients who underwent bilateral lung transplantation
62396654|NCT03420456|EXPERIMENTAL|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy and the light energy may activate under-stimulated brain regions.
62396655|NCT04522635|ACTIVE_COMPARATOR|albumin|albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
62396656|NCT04522635|PLACEBO_COMPARATOR|normal saline|0.9% sodium chloride (normal saline (NS)) given intravenously at the start of IHD
61977950|NCT03349112|PLACEBO_COMPARATOR|Non-Anesthetized|A study team member will apply 1 mL of 2% viscous lidocaine to each nares prior to the passage of the catheter. Randomized participants in this group will not receive .8 mL of a 4% Lidocaine spray prior to HRPM .
62190356|NCT00827554|ACTIVE_COMPARATOR|TACE alone|50 HCC patients randomly assigned to receive TACE without LMWH
62396657|NCT01693042|ACTIVE_COMPARATOR|Single intracoronary cell application|Single intracoronary application of autologous bone marrow derived mononuclear cells
62396658|NCT01693042|ACTIVE_COMPARATOR|repeated (2 times) intracoronary cell application|2 times (interval 4 months) intracoronary application of autologous bone marrow derived mononuclear cells
62190357|NCT05196971|EXPERIMENTAL|HS-10345 84mg|Participants will self-administer intranasal HS-10345 84mg on Days 1, 4, 8, and 11 during the double-blind phase
62396659|NCT04743024||Household|Household carer-child pairs will be included according to age and consent criteria
62396660|NCT05949177|EXPERIMENTAL|Graded Exposure and Mindfulness Meditation|The participants randomized to the GEMM group will complete 1) written exposure and 2) in vivo exposure and will be asked to rate their task specific fears after baseline tests. Tasks identified to be fearful will be used to develop the graded-hierarchy of fearful situations, and these fearful situations will be addressed in the GEMM. Participants will be instructed to watch a 30-min video that provides education on the rationale of cognitive behavioral therapies, specifically the benefits of exposure therapy and mindfulness meditation. Participants randomized into the GEMM group will also complete 5-weeks of Mobile Mindfulness Meditation. Participants randomized into the GEMM group will be guided through 4, 10-minute Mobile Mindfulness Meditation per week (20 total sessions) via the Headspace mobile application where they will learn the fundamentals of mindfulness meditation and how to apply mindfulness meditation to sports rehabilitation.
62572074|NCT00457197|ACTIVE_COMPARATOR|Quetiapine|This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
62779910|NCT01717326|EXPERIMENTAL|B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
62779911|NCT01717326|EXPERIMENTAL|B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant
62779912|NCT01717326|EXPERIMENTAL|B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
62779913|NCT01717326|EXPERIMENTAL|B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
62779914|NCT01717326|EXPERIMENTAL|B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
62779915|NCT01717326|EXPERIMENTAL|B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
62779916|NCT01717326|EXPERIMENTAL|B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
62779917|NCT01717326|EXPERIMENTAL|B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
62779918|NCT01717326|EXPERIMENTAL|B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
62779919|NCT01717326|EXPERIMENTAL|B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
62779920|NCT01717326|EXPERIMENTAL|B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
62572075|NCT03834688|EXPERIMENTAL|Induction|Venetoclax, bendamustine and rituximab as induction therapy for 6 cycles of 28 days.
62779921|NCT01717326|EXPERIMENTAL|C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, and RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight.
62779922|NCT01717326|EXPERIMENTAL|C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk|GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks and Elbasvir 50 mg capsule orally QD for 8 weeks
62779923|NCT01717326|EXPERIMENTAL|D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT3 participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, and RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
62572076|NCT06297018|NO_INTERVENTION|1|No intervention: This group includes liver transplant recipients and no intervention is applied to this group. Depression, anxiety and stress levels are measured in the pre-test. No intervention is implemented. As a post-test, depression, anxiety and stress levels are measured again.
61977951|NCT03342690||Eplerenone|Patients with CHF receiving Selara (eplerenone)
62190358|NCT05196971|PLACEBO_COMPARATOR|Placebo|Participants will be self-administered on Days 1, 4, 8, and 11 during the double-blind phase
62779924|NCT01717326|EXPERIMENTAL|D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk|GT3 participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, and RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
62779925|NCT00950742|EXPERIMENTAL|BIBW 2992 + Trastuzumab|Find maximum tolerated dose of the non-marketed substance:BIBW 2992 given orally with fixed weekly infusion doses of 2mg/kg Herceptin. Escalating doses of BIBW 2992 starting at 20mg daily.
62779926|NCT01255995||Control Patients|Controls without PXF who require cataract surgery
62779927|NCT01255995||Pseudo Exfoliation patients|PXF subjects with or without glaucoma who require cataract surgery
62779928|NCT02604914|EXPERIMENTAL|ND0612L (LD/CD solution)|3 doses of the investigational ND0612L (LD/CD solution) for subcutaneous (SC) infusion 0.24ml per hour.
62190359|NCT00390078|ACTIVE_COMPARATOR|1|20 Subjects, 1x 10E8_TCID50 MVA-mBN32
62190360|NCT00390078|PLACEBO_COMPARATOR|2|10 Subjects 1x 10E8_TCID50 IMVAMUNE
62190361|NCT02399397|ACTIVE_COMPARATOR|Control group|Adult patients(18-50 years old) ASA I-II without sepsis submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
62190362|NCT02399397|EXPERIMENTAL|Sepsis group|Adult patients (18-50 years old) ASAII and III with sepsis, systemic inflammatory response syndrome or septic shock submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
62190363|NCT02399397|EXPERIMENTAL|Elderly group|Elderly patients (\> 65 years old) ASA I-II without sepsis submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
62190364|NCT00611169|EXPERIMENTAL|1|Aspirin, clopidogrel, unfractionated heparin plus tirofiban infusion at high bolus dose
62190365|NCT00611169|NO_INTERVENTION|2|Aspirin, clopidogrel, unfractionated heparin
62190366|NCT03672799|EXPERIMENTAL|Rehabilitation Planning Consult (RPC)|"The RPC is a trans-disciplinary, consultative intervention. In the RPC, individualized rehabilitation needs are established, goals are set, strategies to achieve the goals are developed, and follow-through with strategies and goal attainment is facilitated by a rehabilitation professional who consults and collaborates with the survivor. The Rehabilitation Consultant does not provide hands-on treatment, but rather determines the survivors' priority individualized rehabilitation goals, and then helps devise a plan for the survivor to meet those goals independently.~Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consultant and second consultation 2 to 12 weeks later."
62190367|NCT03672799|ACTIVE_COMPARATOR|Wait list control (WLC)|"There is no standard rehabilitation care for survivors of head and neck cancer at the Princess Margaret Cancer Centre.~Participants allocated to WLC will enter a 12 week waiting period after which they will crossover to the RPC group."
62190368|NCT03135106|EXPERIMENTAL|Treatment A: Erdafitinib alone|Participants will receive single 4 milligram (mg) oral dose of erdafitinib on Day 1 in a fasted state.
62190369|NCT03135106|EXPERIMENTAL|Treatment B: Erdafitinib + Fluconazole|Participants will receive 400 mg fluconazole once daily orally from Day 1 to Day 11 in a fasted state and on Day 5, a single 4-mg oral dose of erdafitinib will be administered 30+/-10 minutes after the intake of 400 mg fluconazole dose.
62396661|NCT05949177|PLACEBO_COMPARATOR|Waitlist Control|Participants will be randomized to a waitlist control group. Participants will receive an email stating that they will receive access to 5-weeks of Headspace after 5-weeks. Participants will be also asked to not change their normal routines or download apps for relaxation, meditation, or sleep during 5-weeks. After completion of the outcome assessments at 5-weeks, participants in this group will receive access to 5-weeks of Headspace.
62396662|NCT04686773|EXPERIMENTAL|AZD1222 5×10^10 vp + rAd26-S (1.0±0.5) х 10^11vp|Subjects will receive 1 intramuscular (IM) injection of 5×10\^10 viral particles (nominal) of AZD1222 on Day 1 followed by rAd26-S 1×10\^11 viral particles (nominal) on Day 29 of the study.
62396663|NCT01858402|ACTIVE_COMPARATOR|Paracetamol|15 mg/kg paracetamol, IV (in the vein)(premixed with 0.9% sodium chloride to a total of 50 ml)single dose
62572077|NCT06297018|EXPERIMENTAL|2|Bioenergy group: This group includes liver transplant recipients and recipients who underwent intervention. Depression, anxiety and stress levels are measured in the pre-test. Bioenergy is then applied. As a post-test, depression, anxiety and stress levels are measured again.
62779929|NCT02604914|EXPERIMENTAL|ND0612H (LD/CD solution)|3 doses of the investigational ND0612H (LD/CD solution) for subcutaneous (SC) infusion 0.64ml per hour.
62779930|NCT02604914|ACTIVE_COMPARATOR|LCIG (Levodopa-carbidopa intestinal gel)|Active Comparator: LCIG subjects who completed the ND0612H arm will be administered with 3 doses of LCIG, directly to the jejunum.
61977952|NCT03045328|EXPERIMENTAL|Treatment (ibrutinib, venetoclax)|Patients receive ibrutinib PO QD beginning on week 1 day 1. Treatment with ibrutinib continues in the absence of disease progression or unacceptable toxicity. Patients also receive venetoclax PO QD beginning on week 9 day 1. Treatment with venetoclax continues up to week 61 day 7 in the absence of disease progression or unacceptable toxicity.
61977953|NCT03181087|EXPERIMENTAL|Umbilical cord MSCs Group|1\*10\^7 Umbilical cord Mesenchymal Stem Cells (MSCs)
62190370|NCT03135106|EXPERIMENTAL|Treatment C: Erdafitinib + Itraconazole|Participants will receive 200 mg itraconazole once daily orally from Day 1 to Day 11 and on Day 5, a single 4-mg oral dose of erdafitinib will be administered 30+/-10 minutes after the intake of 200 mg itraconazole dose.
62190371|NCT03437135||Witness patients|Healthy Volunteers
62190372|NCT03437135||Type 1 diabetic patients|patients with type 1 diabetes
62190373|NCT03437135||Type 2 diabetic patients|patients with type 2 diabetes
62190374|NCT01228877|EXPERIMENTAL|Exercise|Adduction, Abduction and Squat exercise three times a week for 16 weeks
62190375|NCT02075853||Bovine Xenograft|Patients in this group received a bovine xenograft in their Evans calcaneal lengthening procedure. Up until April 2014, patients were randomized into receiving the bovine graft or allograft. However, the bovine xenograft will no longer be manufactured, so no future patients will receive the bovine xenograft during the procedure.
62190376|NCT02075853||Iliac Crest Allograft|Patients in this group received an iliac crest cadaver allograft (bicortical or tricortical) in their Evans calcaneal lengthening procedure. Up until April 2014, patients were randomized into receiving the bovine graft or allograft. However, the bovine xenograft will no longer be manufactured, so all future patients will receive the allograft during the procedure.
62190377|NCT04049981|EXPERIMENTAL|Facial Engagement|This group will receive a version of Superpower Glass that targets specific areas of social deficits associated with autism.
62190378|NCT04049981|EXPERIMENTAL|Emotion Recognition|This group will receive a version of Superpower Glass that targets different areas of social deficits associated with autism.
62190379|NCT04197167|EXPERIMENTAL|Women undergoing hysteroscopy|Patients scheduled to undergo hysteroscopy for the evaluation of abnormal bleeding or abnormal cervical or uterine findings.
62190380|NCT04127903|EXPERIMENTAL|the Length of Right Main Stem Bronchus >=15mm|
62190381|NCT04127903|EXPERIMENTAL|the Length of Right Main Stem Bronchus <15mm|
62190382|NCT02503826|EXPERIMENTAL|1.5 SF|Sufentanil,1.5mcg/kg
62396664|NCT01858402|ACTIVE_COMPARATOR|Dipyrone|15 mg/kg IV (in the vein)dipyrone received (premixed with 0.9% sodium chloride to a total of 50 ml), single dose
62396665|NCT01595139||NF-1 without evidence of glioma|
62396666|NCT01595139||NF-1 with evidence of glioma|
62004739|NCT05702320|NO_INTERVENTION|control group|No heating procedure will be performed by the researcher in this group of patients during the perioperative period, only the number of covers provided for heating in the post-anesthesia care unit will be recorded. The duration of stay in the post-anesthesia care unit, the transfer of the patient to the clinic and the follow-up in the clinic will be carried out according to the hospital procedure.
62190383|NCT02503826|EXPERIMENTAL|2.0 SF|Sufentanil, 2.0mcg/kg
62190384|NCT02503826|EXPERIMENTAL|2.5 SF|Sufentanil, 2.5mcg/kg
62190385|NCT02630706|EXPERIMENTAL|Ertugliflozin 5 mg|Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
62190386|NCT02630706|EXPERIMENTAL|Ertugliflozin 15 mg|Ertugliflozin 15 mg (ertugliflozin 5 mg + ertugliflozin 10 mg) administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
62190387|NCT02630706|PLACEBO_COMPARATOR|Placebo|Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
62190388|NCT01758744|EXPERIMENTAL|Treprostinil|Inhaled prostanoid therapy with Treprostinil
62190389|NCT01852188|OTHER|Nonsterile|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
62190390|NCT01852188|OTHER|Sterile|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
62190391|NCT03874936|EXPERIMENTAL|A; Dexamethasone twice|24mg intravenous Dexamethasone (Dexavital®, Vital Pharma) 4mg/ml just before the operation and repeated after 24 hours.
62396667|NCT00902590||1|Patients with urothelial cancer
62396668|NCT00902590||2|unrelated adults accompanying patients to clinic
62396669|NCT06527157||Benign|sample collection from females with benign causes of AUB/PMB
62396670|NCT06527157||Malignant|sample collection from females with malignant causes of AUB/PMB
62396671|NCT05214131|EXPERIMENTAL|gogoband alarm|patients will be assigned to the novel bedwetting alarm
62396672|NCT05214131|ACTIVE_COMPARATOR|standard nocturnal enuresis alarm (SNEA) group|this is the standard bedwetting alarm that is presently available through out the world
62779931|NCT05850338|EXPERIMENTAL|Experimental|the autogenic relaxation exercise would be performed to intervention group. In the first interview, the introductory characteristics form was filled and the Menopause Specific Quality of Life Scale was completed. In addition, women were given training in line with the training booklet about the menopause period, autogenic relaxation exercise and cold pillow. After the training, autogenic relaxation exercise was taught accompanied by the autogenic relaxation exercise CD. The woman was informed about performing autogenic relaxation exercises 3 times a day and using a cold pillow when she experienced vasomotor symptoms. The autogenic relaxation exercise and cold pad application follow-up chart, which was prepared for the purpose of recording the applications, was given. The women were evaluated by being invited to the hospital at 4 and 8 weeks, and they filled out the Menopause Specific Quality of Life Scale during the follow-ups. The intervention was implemented for 8 weeks.
62004740|NCT02932891|EXPERIMENTAL|DSXS topical|active treatment
62190392|NCT03874936|EXPERIMENTAL|B; Dexamethasone once|24mg intravenous Dexamethasone just before the operation and placebo which is 6ml of isotonic sodium chloride (9mg/ml, 'normal' saline) after 24 hours
62190393|NCT03874936|PLACEBO_COMPARATOR|C; Placebo twice|placebo intravenous just before the operation and repeated after 24 hours
62190394|NCT01747863||Mild NE|Infants with evidence of a perinatal event and NE who do not qualify for therapeutic hypothermia.
62190395|NCT04775147|EXPERIMENTAL|Intervention group|Achieving SBP level of \<120mmHg within 1 hour after successful recanalization, and maintaining this level at least 72 hours.
62190396|NCT04775147|NO_INTERVENTION|Control group|Maintaining SBP level of \<140mmHg within 1 hour after successful recanalization, and maintaining this level at least 72 hours.
62190397|NCT02412449|EXPERIMENTAL|Treatment A|AKB-6548
62396673|NCT05778617|ACTIVE_COMPARATOR|Ambroxol hydrochloride|"Participants will receive ambroxol hydrochloride (tablets) for 104 weeks (blinded treatment period). Participants will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the blinded treatment period. Participants will then enter the open-label extension and will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the open-label extension phase.~n=165"
62396674|NCT05778617|PLACEBO_COMPARATOR|Placebo|"Participants will receive ambroxol hydrochloride matching placebo (tablets) for 104 weeks (blinded treatment period). Participants will receive ambroxol hydrochloride matching placebo 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the blinded treatment period. Participants will then enter the open-label extension and will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the open-label extension phase.~n=165"
62004741|NCT03052582|ACTIVE_COMPARATOR|Team 1: skimmed/whole|Milktype: 3 weeks with skimmed milk followed by 3 weeks with whole milk
62004742|NCT03052582|ACTIVE_COMPARATOR|Team 2: whole/skimmed|Milktype: 3 weeks with whole milk followed by 3 weeks with skimmed milk
62004743|NCT00937638|EXPERIMENTAL|Modified-DASH Diet|
62004744|NCT00937638|EXPERIMENTAL|BOLD diet|
62004745|NCT00937638|EXPERIMENTAL|BOLD-X|
62004746|NCT02904811|EXPERIMENTAL|Intervention group|"Testing for Ct infection immediately~Participants will perform self-taken vaginal samples.~The positive results for Ct will be examined and treated and their partner will also be informed to do so."
62004747|NCT02904811|EXPERIMENTAL|Control group|Testing for Ct infection at the end of the study
62004748|NCT02358746|EXPERIMENTAL|combined endo/epicardial approach|combining endocardial scar homogenization with epicardial scar homogenization in the first VT ablation approach
62004749|NCT02358746|ACTIVE_COMPARATOR|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
62004750|NCT01406821|SHAM_COMPARATOR|Dry needling|Blood will be drawn, and tendon will be penetrated with dry needle. Nothing will be injected into the tendon.
62004751|NCT01406821|EXPERIMENTAL|Platelet-rich plasma (PRP)|Blood will be drawn, and platelet-rich plasma will be injected into the tendon.
62004752|NCT03662100|EXPERIMENTAL|Test 1: 250 mg LY3074828|Participants received 250 mg LY3074828 solution formulation (1 x 2-mL 125-milligram/milliliter \[mg/mL\]) administered subcutaneously (SC) via an auto-injector (AI) in arm.
62004753|NCT03662100|EXPERIMENTAL|Test 2: 250 mg LY3074828|Participants received 250 mg LY3074828 solution formulation (1 x 2-mL 125-mg/mL) administered SC via an AI in thigh.
62004754|NCT03662100|EXPERIMENTAL|Test 3: 250 mg LY3074828|Participants received 250 mg LY3074828 solution formulation (1 x 2-mL 125-mg/mL) administered SC via an AI in abdomen.
62004755|NCT03662100|EXPERIMENTAL|Reference 1: 250 mg LY3074828|"Participants received 250 mg LY3074828 solution formulation (2 x 1-mL 125-mg/mL) in pre-filled syringe (PFS) administered as subcutaneous (SC) injection in arm.~The second injection was administered 20 (±2) minutes after the first injection."
62190398|NCT02412449|EXPERIMENTAL|Treatment B|AKB-6548
62190399|NCT02412449|EXPERIMENTAL|Treatment C|AKB-6548
62190400|NCT01262092|ACTIVE_COMPARATOR|Gabapentin|Buprenorphine will be given along with 2 capsules of gabapentin in the morning and 2 take-home capsules of gabapentin for night.
62190401|NCT01262092|PLACEBO_COMPARATOR|Placebo|Buprenorphine will be given, with 2 capsules of placebo in the morning and 2 take-home capsules of placebo in the evening
62190402|NCT05161793||CGM-Tele-monitoring Type 1|Tele-CGM-monitoring: Subjects are remotely monitored daily through a continuous glucose monitoring (CGM) system (Libre 2) that communicates via smart phone to a Libreview designed dashboard. Alerts set for: ≥4 hours without CGM signal, ≥2 hours 54-70 mg/dl, and 15 minutes \<54 mg/dl. Libreview dashboard automatically emails daily alerts to the Certified Diabetes Care and Education Specialist (CDCES). If alerts occurred, the CDCES performed telemedicine outreach based on type of alert.
62396675|NCT00874718|ACTIVE_COMPARATOR|Action group|
62396676|NCT00874718|OTHER|Control group|Non-specific educational program for general health.
62190403|NCT05161793||CGM-Tele-monitoring Type 2|Tele-CGM-monitoring: Subjects are remotely monitored daily through a continuous glucose monitoring (CGM) system (Libre 2) that communicates via smart phone to a Libreview designed dashboard. Alerts set for: ≥4 hours without CGM signal, ≥2 hours 54-70 mg/dl, and 15 minutes \<54 mg/dl. Libreview dashboard automatically emails daily alerts to the Certified Diabetes Care and Education Specialist (CDCES). If alerts occurred, the CDCES performed telemedicine outreach based on type of alert.
62190404|NCT01531101|EXPERIMENTAL|Individual PDT with TW|Individual Psychodynamic psychotherapy with transference work (TW).
62190405|NCT01531101|ACTIVE_COMPARATOR|Individual PDT without (TW)|Individual Psychodynamic psychotherapy without focus on transference work (TW).
62190406|NCT00727506|EXPERIMENTAL|BIBW 2992|BIBW 2992 once daily
62190407|NCT00727506|ACTIVE_COMPARATOR|TMZ|TMZ 21/28 days
62190408|NCT00727506|EXPERIMENTAL|BIBW 2992 plus TMZ|BIBW 2992 once daily plus TMZ 21/28 days
62190409|NCT06545318|ACTIVE_COMPARATOR|Density Gradient Centrifugation|A density gradient of is formed in 15 mL conical tubes as follows: 1 mL of lower gradient (90%) medium is placed at the bottom, 1 mL of upper (45%) gradient medium is placed on top of the bottom layer, and 1 mL of semen sample is layered above the gradient. Tubes are centrifuged for 10 minutes at 1,200 x g at room temperature. The pellet containing the viable cells is separated, resuspended in 1 mL of HTF-HEPES medium, and centrifuged at room temperature for 10 minutes at 1,200 x g to remove traces of gradient medium. The supernatant is then removed, 500 µL of HTF-HEPES medium are added to the sperm pellet, carefully mixed, and cells are counted
62190410|NCT06545318|EXPERIMENTAL|CA0 chamber|One mL of semen is placed in the base, then the intermediate part is placed on the base, taking care to match the notches that assemble both parts. Subsequently, 900 µL of HTF-HEPES medium are placed in the intermediate part, the cover is placed and the device is incubated at 37°C for 30 minutes. Subsequently, a 500-µL aliquot is recovered and cells are counted
62190411|NCT05995847|EXPERIMENTAL|harmonica combination group|These patients will participate in a six-month harmonica playing program, in addition to receiving basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for six months.
62779932|NCT05850338|NO_INTERVENTION|Control|After the women to be included in the control group were determined, individual interviews were conducted with the women in a separate room for orogenic relaxation. In the first interview, the introductory characteristics form was filled and the Menopause Specific Quality of Life Scale was completed. The women were evaluated by being invited to the hospital at 4 and 8 weeks, and they filled out the Menopause Specific Quality of Life Scale during the follow-ups. The women were followed for 8 weeks. No other intervention was applied to the women other than the standard care they received at the hospital. The women were called every week and their vasomotor symptoms were questioned.
62779933|NCT06320314|EXPERIMENTAL|mild to moderate melasma|adult patients suffering from mild to moderate melasma (Investigator's Global Assessment (IGA) 1 or 2)
62779934|NCT06320314|EXPERIMENTAL|mild to moderate acne induced PIHP|adult patients suffering from mild to moderate acne-induced PIHP (IGA 1 or 2) without active acne (i.e., less than 10 inflammatory lesions)
62779935|NCT06320314|EXPERIMENTAL|solar lentigo|adult patients suffering from solar lentigo with a pigmentation score \> 5
62779936|NCT00810992|ACTIVE_COMPARATOR|1 Program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
62779937|NCT00810992|EXPERIMENTAL|2 Program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
62779938|NCT04132674|OTHER|B/F/TAF|Switching participants who are currently on multi-tablet HIV antiretroviral therapy, including multi-tablet regimens and/or two drug combinations (dual therapy) to one oral tablet of B/F/TAF once-daily for 72 weeks
62779939|NCT02353728|EXPERIMENTAL|All Patients|Nilotinib at a dose of 300 mg P.O. twice a day (BID) daily
62779940|NCT04985669|EXPERIMENTAL|prucalopride group|prucalopride group will receive prucalopride 2 mg once daily
62004756|NCT03662100|EXPERIMENTAL|Reference 2: 250 mg LY3074828|"Participants received 250 mg LY3074828 solution formulation (2 x 1-mL 125-mg/mL) in PFS administered as SC injection in thigh.~The second injection was administered 20 (±2) minutes after the first injection."
62004757|NCT03662100|EXPERIMENTAL|Reference 3: 250 mg LY3074828|"Participants received 250 mg LY3074828 solution formulation (2 x 1-mL 125-mg/mL) in PFS administered as SC injection in abdomen.~The second injection was administered 20 (±2) minutes after the first injection."
62004758|NCT03997318|EXPERIMENTAL|AMDC-USR|AMDC-USR is the study product (Autologous Muscle Derived Cells for Urinary Sphincter Repair).
62004759|NCT03997318|PLACEBO_COMPARATOR|Placebo|Placebo control is the vehicle solution used for the study product.
62004760|NCT03746522|EXPERIMENTAL|Setmelanotide (Double-Blind)|Participants received once daily SC injection of setmelanotide for 14 weeks in a double-blind placebo-controlled treatment period (Period 1). Participants ≥16 years of age started on setmelanotide 2.0 mg with dose escalation to 3.0 mg. Participants \<16 years of age started on setmelanotide 1.0 mg with dose escalation to 3.0 mg.
62004761|NCT03746522|PLACEBO_COMPARATOR|Placebo (Double-Blind)|Participants received once daily SC injection of placebo (matching setmelanotide) for 14 weeks in a double-blind placebo-controlled treatment period (Period 1).
62190412|NCT05995847|ACTIVE_COMPARATOR|basic-PR-care group|These patients will receive basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for six months.
62396677|NCT06722950|EXPERIMENTAL|AC591+CAPEOX|AC591 granules (3 times a day) + CAPEOX chemotherapy
62779941|NCT04985669|ACTIVE_COMPARATOR|Lubiprostone group|lubiprostone group will receive lubiprostone 8 microgram twice daily
62779942|NCT01943240|EXPERIMENTAL|Group A|Paravertebral peripheral nerve blockade with with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of 0.375% ropivacaine for pectoral nerve block
62779943|NCT01943240|ACTIVE_COMPARATOR|Group S|Paravertebral peripheral nerve blockade with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of normal saline for pectoral nerve block.
62004762|NCT03746522|EXPERIMENTAL|Setmelanotide (Open-label)|After the initial 14-week double-blind treatment period, all participants immediately transitioned to open-label setmelanotide once daily SC injection for 38 weeks (Period 2) and then continued to receive setmelanotide in the 14-week open-label treatment period (Period 3).
62004763|NCT01049724||PRK|Those patients undergoing photorefractive keratectomy
62004764|NCT01049724||LASIK|Those undergoing Laser-assisted insitu keratomileusis
62190413|NCT06029608||Magnetically-controlled Capsule endoscopy group|Using magnetic-controlled capsule gastroscopy for postoperative assessment in elderly patients and patients with underlying diseases
62190414|NCT06029608||Conventional endoscopy group|Using conventional endoscopy for postoperative assessment in elderly patients and patients with underlying diseases
62190415|NCT06300983|ACTIVE_COMPARATOR|Experimental group|The intervention consisted of 5 sessions, with each lasting 100 minutes and delivered on a weekly basis.
62190416|NCT06300983|PLACEBO_COMPARATOR|Control group|The control group, which do not receive any psychoeducative intervention
62396678|NCT06722950|PLACEBO_COMPARATOR|Placebo+CAPEOX|Placebo (3 times a day) + CAPEOX chemotherapy
62396679|NCT05273515|EXPERIMENTAL|Pilot|3D scanning of participants. Images used to created 3D reconstruction of 15% and 25% total body weight loss. These are shown to participants using virtual reality. Qualitative outcomes measured using group discussion and questionnaires.
62396680|NCT01813682|NO_INTERVENTION|control group|preterm infants of this group with iron-free TPN for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
62396681|NCT01813682|EXPERIMENTAL|treatment group1|preterm infants of this group with iron supplementation of 200μg/kg/d for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
62396682|NCT01813682|EXPERIMENTAL|treatment group2|preterm infants of this group with iron supplementation of 400μg/kg/d for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
62004765|NCT06469008|EXPERIMENTAL|BL-B16D1|Participants receive BL-B16D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62004766|NCT06026891|EXPERIMENTAL|MG-K10 Humanized Monoclonal Antibody Injection|Every four weeks, subcutaneous injection ，total of 52W
62004767|NCT06026891|PLACEBO_COMPARATOR|MG-K10 placebo|Every four weeks, subcutaneous injection，The drug was transferred to the trial after 16 weeks
62004768|NCT03200613|EXPERIMENTAL|Apixaban|Apixaban 2.5 mg orally twice daily
62004769|NCT03200613|ACTIVE_COMPARATOR|Low Molecular Weight Heparin|Either enoxaparin 40 mg or dalteparin 5000 units subcutaneously once daily
62004770|NCT03917134|EXPERIMENTAL|cephalosporin + Metronidazole|In this arm, patients randomly selected, will receive cephalosporin in doses of 2 grams administered intravenously before surgery. metronidazole vaginal ovules of 500mg twice a day for 5 days after surgery
62004771|NCT03917134|PLACEBO_COMPARATOR|cephalosporin + placebo|In this arm, patients randomly selected, will receive cephalosporin in doses of 2 grams administered intravenously before surgery. placebo vaginal ovules twice a day for 5 days after surgery
62004772|NCT01067703|ACTIVE_COMPARATOR|RIPC|
62004773|NCT01067703|SHAM_COMPARATOR|CONTROL|
62004774|NCT04919967|EXPERIMENTAL|Virtual implementation protocol|Participants assigned to the virtual implementation protocol plus e-learning/toolkit group will take the e-learning course an also receive support through the Virtual Implementation Protocol.
62004775|NCT04919967|ACTIVE_COMPARATOR|E-learning/toolkit alone|Participants assigned to the e-learning/toolkit alone group will only complete the e-learning course/receive the e-learning toolkit.
62004776|NCT04919967|NO_INTERVENTION|Treatment as usual|Participants assigned to this group will not be provided any additional training or implementation assistance. They will be able to take trainings outside of study protocol if they would otherwise plan or want to do so. They will be offered the study-specific training and implementation assistance after they have completed the final study assessments.
62004777|NCT00628550|EXPERIMENTAL|1|Pediatric patients that experience in-hospital CPA who remain in cardiac arrest despite CPR and an initial, standard dose of epinephrine (0.01 mg/kg), will be randomly assigned to receive vasopressin (0.8 units/kg) rescue as the second vasopressor medication.
62004778|NCT00628550|ACTIVE_COMPARATOR|2|Pediatric patients that experience in-hospital CPA who remain in cardiac arrest despite CPR and an initial, standard dose of epinephrine (0.01 mg/kg), will be randomly assigned to receive standard dose epinephrine (0.01 mg/kg)rescue as the second vasopressor medication.
62190417|NCT00557531|EXPERIMENTAL|BL-1040|
62190418|NCT03024996|EXPERIMENTAL|Atezolizumab|Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (q3w) for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
62779944|NCT04844528|EXPERIMENTAL|Treatment: all patients|Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) for 1 year or oral placebo 1 tablet twice daily for 1 year. Patients will be stratified according to CLL therapy and the number of prior NMSC. At the end of 1 year, patients will undergo dermatologic examination and the number of new NMSC will be quantified. The number of patients who develop new NMSC in each arm will be documented. At this time, patients will be unblinded and all patients will receive Nicotinamide 500 mg BID for an additional year. At the end of this second year, patients will again undergo dermatologic examination, and the number of new NMSC will be quantified. The number of patients who develop NMSC will be documented. Skin biopsies will be taken for correlative studies.
62190419|NCT03024996|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to atezolizumab q3w for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
62190420|NCT04864366||Treatment naive patients|"1. HBV DNA\> 20000 IU/ml~2. ALT\>2×ULN；or ALT\>1×ULN，but liver biopsy showed inflammation greater than or equal to G2, or/and liver fibrosis greater than or equal to S2~3. No treatment with NA or/or αIFN within 1 year"
62190421|NCT04864366||ETV treatment experienced patients|"1. ETV treatment for 1 to 2 years before~2. HBsAg\>3000IU/mL~3. HBV DNA\<20IU/mL~4. ALT\<1×ULN~5. No other NA therapy prior to entecavir treatment~6. Patients had a desire to convert to TAF therapy"
62190422|NCT01011699|ACTIVE_COMPARATOR|sevelamer|"Titration phase with sevelamer (Renagel) with the aim of phosphatemia control in 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week)."
62190423|NCT01011699|ACTIVE_COMPARATOR|nicotinamide|"Titration phase with nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of nicotinamide dose up to 4 tablets, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week)."
62190424|NCT01174264|EXPERIMENTAL|Arm I (vismodegib on empty stomach)|Patients receive a single dose of vismodegib PO on an empty stomach. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28.
62190425|NCT01174264|EXPERIMENTAL|Arm II (vismodegib after high fat meal)|Patients receive a single dose of vismodegib PO after eating a high fat meal. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28.
62190426|NCT01174264|EXPERIMENTAL|Arm III (vismodegib after low fat meal)|Patients receive a single dose of vismodegib PO after eating a low fat meal. Beginning 7 days later, patients receive vismodegib PO after eating a meal daily on days 1-28.
62190427|NCT00298675|EXPERIMENTAL|Iniparib|
62190428|NCT00298675|EXPERIMENTAL|Iniparib/irinotecan|
62190429|NCT05907317|EXPERIMENTAL|Cerebral oximetry + usual care|
62572078|NCT06576518|EXPERIMENTAL|Exercise group|Patients with established CKD (1-4) and MS were treated with individualised incremental exercise (aerobic and resistance) for 6 months.
62190430|NCT05907317|OTHER|Usual care|The control group will receive mechanical ventilation without access to cerebral oximetry and the SafeBoosC treatment guideline. If the newborn is cared for outside the neonatal unit at any time, e.g. during surgery, cerebral oximetry may or may not be used, as decided by the responsible physician there
62190431|NCT05608031||bariatric surgery|A cross-sectional study was conducted among patients that underwent bariatric surgery (laparoscopic sleeve gastrectomy). Sleep quality was assessed using the Pittsburgh sleep quality index (PSQI) scale preoperatively and at the 6th postoperative month.
62190432|NCT04333732|EXPERIMENTAL|M-M-R II ®|Education and surveillance plus M-M-R II ® Single dose, 0.5 mL subcutaneous injection of M-M-R II ®
62190433|NCT04333732|PLACEBO_COMPARATOR|Placebo|Education and surveillance plus placebo Single dose, 0.5 mL subcutaneous injection of 0.9% saline
62190434|NCT00358644|EXPERIMENTAL|1|
62190435|NCT05597423|EXPERIMENTAL|Massage|The massage will be applied twice a week for a period of four weeks, 10 minutes after the end of lower limb training.
62190436|NCT05597423|PLACEBO_COMPARATOR|Placebo|The massage cream will be applied twice a week for a period of four weeks, 10 minutes after the end of lower limb training.
62190437|NCT05597423|NO_INTERVENTION|Control|The control group after 10 minutes of the end of lower limb training will remain at rest for 16 minutes.
62190438|NCT05301998|OTHER|Study Group|"Measurements of elasticity and thickness will be performed for each of the 200 patients.~Among the 200 patients, 10 will have a breast MRI in 3 different positions"
62190439|NCT05500079|ACTIVE_COMPARATOR|Wrist splint group|The group to be treated with a wrist splint
62190440|NCT05500079|ACTIVE_COMPARATOR|Transcutaneous pulsed RF group|The group to be treated with transcutaneous pulsed RF
62190441|NCT02119338|EXPERIMENTAL|5-ala preoperatively|A dose of 5-ala will be taken by mouth approximately 3 hours before going to surgery.
62190442|NCT05442346|EXPERIMENTAL|γ-globin reactivated autologous hematopoietic stem cells|each subject will accept one dose of γ-globin reactivated autologous hematopoietic stem cells
62190443|NCT02712970||stage-I|Single pit in the midline, no lateral extension. Pit-picking technique will be performed.
62190444|NCT02712970||Stage-II|\>1 pits in the midline, no lateral extension. Pit-picking and Bascom cleft lift techniques will be performed.
62572079|NCT00542009|EXPERIMENTAL|CE-326,597 100 mg QD|
62572080|NCT00542009|EXPERIMENTAL|CE-326,597 50 mg QD|
62572081|NCT00542009|EXPERIMENTAL|CE-326,597 25 mg QD|
62572082|NCT00542009|PLACEBO_COMPARATOR|Placebo|
62572083|NCT00542009|EXPERIMENTAL|CE-326,597 5mg QD|
62572084|NCT02110303|EXPERIMENTAL|18F-F Positive - Ticagrelor|Ticagrelor oral tablets, one (90mg) tablet, twice daily, 12 month duration
62572085|NCT02110303|PLACEBO_COMPARATOR|18F-F Positive - Placebo|Identical placebo, one tablet, twice daily, 12 month duration
62572086|NCT02110303|EXPERIMENTAL|18F-F Negative - Ticagrelor|Ticagrelor oral tablets, one (90mg) tablet, twice daily, 12 month duration
62190445|NCT02712970||Stage-III|Midline pit/pits plus lateral extension in one direction. Bascom cleft lift technique will be performed.
62190446|NCT02712970||Stage-IV|Midline pit/pits plus lateral extension in both directions. Rhomboid excision with the Limberg Flap will be performed.
62190447|NCT02712970||Stage-R|Recurrent PSD following any type of treatment. Other flap techniques such as V-Y advancement flap, Z-Plasty will be performed.
62190448|NCT03843398|EXPERIMENTAL|Minilaparotomy Group|Participants in this arm undergo colorectal cancer resection via minilaparotomy.
62190449|NCT03843398|ACTIVE_COMPARATOR|Laparoscopy Group|Participants in this arm undergo laparoscopic colorectal cancer resection.
62190450|NCT01632189|EXPERIMENTAL|Varenicline|Varenicline will be used at the same dosage regimen as used for smoking cessation, i.e. 0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily. The total duration of Varenicline treatment will be three months.
62190451|NCT04211025|EXPERIMENTAL|Modest|This approach is feasible to integrate into workflows of a wide-range of clinics, and should have a minimal impact on human resources. Materials and strategies to support staff in this work will be provided. .
62190452|NCT04211025|EXPERIMENTAL|Intensive|This approach is more robust, and requires a greater commitment of human resources.
62190453|NCT03617289|EXPERIMENTAL|Treatment|Receiving Magnesium Sulfate
62396683|NCT06406452|EXPERIMENTAL|Bioresorbable Tracheobronchial Splint|Participants are admitted to the hospital for this assessment and placement of the splint.
62396684|NCT03517150|EXPERIMENTAL|Experimental group|This group will use an oral appliance for treatment of obstructive sleep apnea. The oral appliance is custom-made and its titration is attained by means of progressive mandibular advancement that incrementally moves the mandible forward. This group of patients will use the oral appliance for 45 days.
62396685|NCT03517150|ACTIVE_COMPARATOR|Control group|This group will use a single adjustable silicone appliance in maxillar for 45 days, in order to compare to the experimental group.
62396686|NCT06405750|OTHER|LAA closure|All patients included in the study undergo closure of the Left Atrial Appendage
62396687|NCT06481215|EXPERIMENTAL|GNR-068 (JSC GENERIUM, Russia)|ustekinumab biosimilar
62190454|NCT03617289|PLACEBO_COMPARATOR|Placebo|Receiving Dextrose 5% in Water (D5W)
62190455|NCT01816347||Routine PCI patients|
62396688|NCT06481215|ACTIVE_COMPARATOR|Stelara® (manufacturer Silag AG, Switzerland, holder of authorisation Johnson & Johnson)|ustekinumab
62396689|NCT00883402|ACTIVE_COMPARATOR|CEA|Carotid endarterectomy
62572087|NCT02110303|PLACEBO_COMPARATOR|18F-F Negative - Placebo|Identical placebo, one tablet, twice daily, 12 month duration
62190456|NCT00447590|EXPERIMENTAL|LAP-BAND|All subjects who received the LAP-BAND System.
62214717|NCT00297427|SHAM_COMPARATOR|Sham acupuncture|Subjects will receive 12 sham acupuncture treatments (delivered twice a week) over 6 weeks. The sham needle is blunted needle whose shaft telescopes into the handle when tapped. While the needle appears to have been inserted, it does not actually penetrate the skin. It is held in place by the same standard guide tube used in the true acupuncture group. The acupuncture points and duration of treatment are the same as for the true acupuncture group.
62214718|NCT04175080||Control|
62214719|NCT04175080||HFpEF group|
62214720|NCT04175080||Hypertensive group|Patients in which the results of BNP/NT-proBNP did not confirm the diagnosis of HFpEF were classified as hypertensive group.
62214721|NCT05686538|EXPERIMENTAL|Innate donor lymphocyte infusion (iDLI)|TCRab/CD19 depleted DLI day 14 after routine allogeneic stem cell transplantation
62214722|NCT05686538|NO_INTERVENTION|Standard of care|Routine allogeneic stem cell transplantation
62214723|NCT00927030|EXPERIMENTAL|Pharmacokinetic|We hope to target 12 of the 30 children to be enrolled for this study to participate in a pharmacokinetic arm of the study. These 12 children would be receiving overnight sleep studies prior to receiving the first dose of melatonin and again at about every 3 week intervals each time the dose increases until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. During the sleep studies an intravenous catheter will be placed in the child's arm to sample small amounts of blood throughout the day (about 3 teaspoons of blood)to allow us to look at how melatonin is produced in children with autism who have sleep problems.
62396690|NCT00883402|ACTIVE_COMPARATOR|CAS|Carotid Artery Stenting
62396691|NCT03593031|ACTIVE_COMPARATOR|CI OBVAT|Patients with Convergence Insufficiency in Active Vision Therapy
62396692|NCT03593031|SHAM_COMPARATOR|CI Sham therapy|CI Sham therapy
62396693|NCT03593031|ACTIVE_COMPARATOR|Controls OBVAT|Control receive active therapy
62396694|NCT03593031|SHAM_COMPARATOR|Controls Sham|Subjects with Normal Binocular Vision will receive a therapy that appears to be therapeutic but does not have any binocular coordination benefits.
62396695|NCT05239741|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years).
62004779|NCT03794843|EXPERIMENTAL|Nimodipine Injection (II)|The specification of this injection is 5 ml: 4 mg , which is administered by constant infusion intravenously with an infusion pump. The injection and 0.9% sodium chloride injection is simultaneously infused at a ratio of 1:16 (injection: combined infusion). The rate of intravenous drip was started at 0.5 mg/h for 2 hours, and the rate of intravenous drip was 1.0 mg/h after 2 hours, and continuous infusion for 12 hours, for a total of 11 mg of nimodipine.
62004780|NCT03794843|EXPERIMENTAL|Nimodipine Injection|The specification of this injection is 50 ml: 10 mg ,which is administered by constant infusion intravenously with an infusion pump. The injection and 0.9% sodium chloride injection is simultaneously infused at a ratio of 1:4 (injection: combined infusion). The rate of intravenous drip was started at 0.5 mg/h for 2 hours, and the rate of intravenous drip was 1.0 mg/h after 2 hours, and continuous infusion for 12 hours, for a total of 11 mg of nimodipine.
62572088|NCT05647564|OTHER|Intrinsic Resistance Cohort (Cohort A)|Participants assigned to Cohort A have advanced prostate cancer and are scheduled to start a second-generation AR-targeted (such as enzalutamide, abiraterone, darolutamide, or apalutamide) or PSMA directed (e.g. Lu177-PSMA) therapies .
62779945|NCT04844528|PLACEBO_COMPARATOR|Arm 2: Placebo|Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) for 1 year or oral placebo 1 tablet twice daily for 1 year. Patients will be stratified according to CLL therapy and the number of prior NMSC. At the end of 1 year, patients will undergo dermatologic examination and the number of new NMSC will be quantified. The number of patients who develop new NMSC in each arm will be documented. At this time, patients will be unblinded and all patients will receive Nicotinamide 500 mg BID for an additional year. At the end of this second year, patients will again undergo dermatologic examination, and the number of new NMSC will be quantified. The number of patients who develop NMSC will be documented. Skin biopsies will be taken for correlative studies.
62779946|NCT05699564|EXPERIMENTAL|Early biomarker-based cardiological assessment and structured feedback in the EHR|We will perform cardiac biomarker testing with NT-proBNP and hs-cTnT measurements on emergency department admission in all participants, regardless of randomization status. The results will be provided in the patient's EHR, regardless of randomization status. For patients randomized to the intervention group, we will provide a note in the patient's EHR that includes assessment of probability that myocardial injury or dysfunction are the underlying pathophysiology responsible for tachypnea, as evaluated by the cardiac biomarker algorithm of the study. We will inform on general recommendations for work up and treatment.
62779947|NCT05699564|NO_INTERVENTION|Standard of care|Routine standard of care according to the treating physician
62779948|NCT03615339|EXPERIMENTAL|Molkosan|"Consumption of Molkosan (fermented whey) 20ml to be diluted in 200ml water prior to use twice a day (morning \& evening).~Total duration was 6 weeks."
62779949|NCT06583694||0 to 5 year-olds|Participants aged between 0-5 year-olds
62779950|NCT06583694||6- 14 year-olds|Participants aged between 6-14 year-olds
62779951|NCT06583694||15-21 year-olds|Participants aged between 15-21 year-olds
62779952|NCT06583694||22-59 year-olds|Participants aged between 22-59 year-olds.
62779953|NCT06583694||equal to and more than 60 year-olds|Participants aged equal to and more than 60 year-olds
62779954|NCT06372496|EXPERIMENTAL|Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI)|
62779955|NCT06372496|ACTIVE_COMPARATOR|Inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA)|
62779956|NCT04772781|EXPERIMENTAL|S (+) - Ibuprofen|
62779957|NCT04772781|ACTIVE_COMPARATOR|Ibuflex® - ibuprofen|
62779958|NCT06050785||Vancomycin group|
62779959|NCT06050785||Gentamycin group|
62779960|NCT05346653|ACTIVE_COMPARATOR|SGLT2i|Participants will be treated with a SGLT2i during their ICU stay. The SGLT2i and heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
62779961|NCT05346653|ACTIVE_COMPARATOR|No SGLT2i|Participants will not be treated with a SGLT2i during their ICU stay. Heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
62779962|NCT01440205|EXPERIMENTAL|Easy list of healthy habits|"In this condition, participants will be prompted to think about a list of healthy behaviors and check off (privately - they will never send this flyer back or show it to anyone) whether yes they conform to the healthy habit or no they do not. The list of healthy behaviors is a list that most people will find fairly easy, and thus most participants will answer yes to each habit. The final question will be a prompt to get a flu shot. The hope is that when people realize how healthy their habits are, it will seem natural to them to engage in yet another healthy habit and receive a flu shot."
62004781|NCT03218722|EXPERIMENTAL|PCC treatment|Conventional strategy for ATC management in addition to of intravenous Pro-Thrombin Concentrate Complex (25IU/kg factor IX)
62004782|NCT03218722|PLACEBO_COMPARATOR|Placebo treatment|Conventional strategy for ATC management without PCC (NaCl 0.9%)
62004783|NCT03356210|NO_INTERVENTION|Treatment as usual (TAU)|This control group will receive treatment as usual; conventional counseling
62190457|NCT03700905|EXPERIMENTAL|Neoadjuvant/adjuvant Nivolumab and Ipilimumab|"* Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery~* Surgical resection of primary tumor including neck dissection according to standard of care~* 6-7 weeks risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only), start within 6 weeks post-surgery~Arm Ia:~• Adjuvant administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months~Arm Ib:~• Adjuvant administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months"
62190458|NCT03700905|ACTIVE_COMPARATOR|Surgical resection + adjuvant radio(-chemo)therapy|"* Surgical resection of primary tumor including neck dissection according to standard of care~* 6-7 weeks risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43 or Cisplatin once weekly (40mg/m2) in high risk patients), start within 6 weeks post-surgery~* Standard follow-up"
62190459|NCT01929876|EXPERIMENTAL|Cobimetinib + Itraconazole|
62190460|NCT03060382|EXPERIMENTAL|balanced buttress absorbable spacer|For the patients of study group, a balanced buttress absorbable spacer was placed into tibia.
62190461|NCT03060382|PLACEBO_COMPARATOR|total knee arthroplasty|For the patients of control group, total knee arthroplasty was conducted.
62190462|NCT02132715|ACTIVE_COMPARATOR|Resistance exercise|Traditional isotonic lower-extremity resistance training
62190463|NCT02132715|EXPERIMENTAL|KAATSU exercise|Lower-extremity exercise with blood flow mildly restricted
62572089|NCT05647564|OTHER|Acquired Resistance Cohort (Cohort B)|Participants are assigned to Cohort B if they have advanced prostate cancer, are already on a second-generation AR-targeted therapy, and have shown an increase in their PSA (prostate-specific antigen) levels.
62779963|NCT01440205|EXPERIMENTAL|Challenging list of healthy habits|"In this condition, participants will be prompted to think about a list of healthy behaviors and check off (privately - they will never send this flyer back or show it to anyone) whether yes they conform to the healthy habit or no they do not. The list of healthy behaviors is a list that most people will find fairly difficult, and thus most participants will answer no to each habit. The final question will be a prompt to get a flu shot. The hope is that when people realize how unhealthy their habits are, it will seem wise to engage in one healthy habit that is easy (to make up for other bad behaviors) and receive a flu shot."
62004784|NCT03356210|EXPERIMENTAL|Neurofeedback + TAU|20 sessions of symptom-based NF training in conjunction with traditional therapy
62004785|NCT01644318||authoimmıne thyroiditis and habitual abortus|
62004786|NCT01644318||authoimmune thyroiditis|
62004787|NCT01644318||healthy controls|
62004788|NCT01916304|EXPERIMENTAL|Levothyroxine sodium new formulation|Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.
62004789|NCT01107470||Group A1|Age 18-34y (with short protocol)
62004790|NCT01107470||Group A2|age 35-42y ( with short protocol)
62004791|NCT01107470||Group B1|age 18-34y ( with long protocol)
62004792|NCT01107470||Group B2|age 35-42y ( with long protocol)
62004793|NCT03801616|EXPERIMENTAL|Virtual Reality|Every participant is provided with a VR headset
62190464|NCT03830762|EXPERIMENTAL|Cohort 1 / Cohort 2 (Active)|20mg or 30mg capsules of Xanamem respectively, to be administered PO once daily.
62190465|NCT03830762|PLACEBO_COMPARATOR|Cohort 1 / Cohort 2 (Placebo)|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily.
62190466|NCT01428752||Family history|30- to 49-year-old asymptomatic subjects with a first relative history of colorectal cancer
62004794|NCT01800292|EXPERIMENTAL|sildenafil therapy|Subjects will have 2D-Echocardiogram measuring left ventricular strain and strain rate using speckle tracking techniques, have 6 minute walk test, World Health Organization functional class (I-IV)assignment, and BNP lab result at baseline and at 3 months. Subjects will be started on sildenafil at 20 mg by mouth three times per day at the baseline visit. Each individual will serve as his/her own control.
62190467|NCT01321892||Squamous cell carcinoma|Patients included in this study will be receiving surgical treatment for their biopsy-proven squamous cell carcinoma.
62190468|NCT01562262||CTR|Control group
62190469|NCT01562262||ASS|Apnea without complaints group
62190470|NCT01562262||ACS|SAOS Group
62572090|NCT06231888||Press|
62572091|NCT06231888||Vacuum|
62572092|NCT01405339|EXPERIMENTAL|Budesonide via MAD|The current standard of care at St. Paul's Sinus Centre is to administer budesonide via the Mucosal Atomization Device (MAD). Its believed that MAD is a better device than the standard nasal lavage (Budesonide diluted in saline and delivered via Nasal Irrigation Bottle)because its fine mist and higher concentration enhances absorption and improves bioavailability.
62572093|NCT01405339|ACTIVE_COMPARATOR|Budesonide via Sinus Rinse Bottle|Budesonide via Sinus Rinse Bottle is the most commonly used delivery method.
62779964|NCT01440205|EXPERIMENTAL|Control|A control condition with no list of healthy behaviors.
62779965|NCT01953913|EXPERIMENTAL|Afatinib|Patient will receive afatinib once daily
62004795|NCT00850200|EXPERIMENTAL|Proton Radiation Plan|
62779966|NCT00999297|PLACEBO_COMPARATOR|Sugar pill (Placebo o mg/d)|0 mg/d sugar pill
62004796|NCT00850200|ACTIVE_COMPARATOR|Conventional Photon Radiation Plan|
62004797|NCT00850200|ACTIVE_COMPARATOR|Intensity Modulated Radiation Plan|
62004798|NCT05035017|EXPERIMENTAL|Test Lens, then Control Lens|Participants wore Test Lens for 2 days, and then Control Lens for 2 days
62004799|NCT05035017|ACTIVE_COMPARATOR|Control Lens, then Test Lens|Participants wore Control Lens for 2 days, and then Test Lens for 2 days
62004800|NCT00373243|EXPERIMENTAL|Subjects receiving GW406381|Subjects will receive single oral dose of 20 milligram (mg) of GW406381.
62004801|NCT04035720|EXPERIMENTAL|Quantitative risk estimation|Participants will be exposed to case-scenarios. Each case scenario provides a description of the current clinical situation (e.g. patient age, current treatment, number of relapses, current EDSS, MRI findings, etc). In addition, participants will see a squared box indicating the probability of risk progression (20%, 25%, 85%, 90%). This information may or may not be accurate to reflect potential errors of risk prediction tools.
62004802|NCT04035720|ACTIVE_COMPARATOR|Qualitative risk estimation|Participants will be exposed to the same case-scenarios as the intervention arm. Each case scenario provides a description of the current clinical situation (e.g. patient age, current treatment, number of relapses, current EDSS, MRI findings, etc). In addition, participants will see a squared box indicating a qualitative probability of risk progression (low, high). This information may or may not be accurate to reflect potential errors of risk prediction tools.
62004803|NCT04528758|EXPERIMENTAL|Dosimetry group|Patients in the dosimetry group will be imaged with the radio-pharmaceutical Rhodamine 6G at different time points. 0-120, 30-150, 60-180
62004804|NCT04528758|ACTIVE_COMPARATOR|Stable Heart Patients|Stable heart patients will be given a rest/stress PET/CT with Rhodamine 6G myocardial perfusion study to determine myocardial blood flow
62779967|NCT00999297|ACTIVE_COMPARATOR|Dihydrocapsiate|Drug 3 mg/d or 9 mg/d including Placebo
62004805|NCT03211195|EXPERIMENTAL|Sotagliflozin - Commerical|Healthy volunteers will be administered a single dose Sotagliflozin (SAR439954) tablet (Commercial formulation) by mouth under fasted conditions
62004806|NCT03211195|ACTIVE_COMPARATOR|Sotagliflozin -Development|Healthy volunteers will be administered a single dose Sotagliflozin (SAR439954) tablet (Development formulation) by mouth under fasted conditions - Type: Active Comparator
62004807|NCT01860261|EXPERIMENTAL|Aerobic and Strength Training|Participants in the Aerobic and Strength Training intervention group will receive a standardized aerobic and strength training exercise program for 12 weeks, including paid gym membership, personal training, and 3 workshops in ChiWalkRun technique.
62004808|NCT01860261|NO_INTERVENTION|Control (delayed onset of intervention)|After 12 weeks of active observation, this group will receive a modified version of the exercise intervention consisting of a free gym membership for 12 weeks, with limited personal training.
62004809|NCT01836484||Surgically staged endometrial and cervical carcinoma|
62779968|NCT00999297|ACTIVE_COMPARATOR|3 mg/d or 9 mg/d Dihydrocapsiate|Drug including Placebo
62779969|NCT06197620|EXPERIMENTAL|Thread Embedding Acupuncture and Standard Therapy|The patients are pre-operative laparoscopic living donor nephrectomy patients that receive standard analgetic drug treatment according to post-operative kidney donor transplant protocol and receive thread embedding acupuncture. All patients are also given standard therapy after surgery in the form of intravenous Paracetamol 1000 mg, 3 times a day.
62779970|NCT04001283|EXPERIMENTAL|sodium nitrite 24hours before|10umol/min intravenous sodium nitrite for 30minutes at 1ml/min over a period of 30minutes, 24 hours prior to CABG surgery
62779971|NCT04001283|EXPERIMENTAL|sodium nitrite 30minutes before|10umol/min intravenous sodium nitrite for 30minutes at 1ml/min over a period of 30minutes, 30 minutes prior to CABG surgery
62004810|NCT03710278||LPat Device|Performing Lumbar Puncture assisted by LPat
62004811|NCT02748577|EXPERIMENTAL|Migraine|Participants with migraines will complete one study visit where they will complete several questionnaires and will also complete Quantitative Sensory Testing (QST) Pain Measurements. They must be migraine-free during the visit and no migraine within 48 hrs of study visit
62779972|NCT04001283|PLACEBO_COMPARATOR|0.9% sodium chloride|Intravenous normal (0.9%) sodium chloride infused at 1ml/min
62779973|NCT03010280|EXPERIMENTAL|Immunonutrition|Patients receiving a preoperative balanced energy high-protein formula, enriched with Omega - 3 fatty acids (Immunonutrition formula)
62779974|NCT03010280|ACTIVE_COMPARATOR|Balanced high-protein formula|Patients receiving a preoperative balanced energy high-protein formula, without including Omega - 3 fatty acids
62779975|NCT01088022|EXPERIMENTAL|Aprepitant, Palonosetron, dexametasone|
62779976|NCT01088022|PLACEBO_COMPARATOR|Placebo, Palonosetron, Dexamethasone|
62779977|NCT05155774|ACTIVE_COMPARATOR|Control group, controlled every 6th week|"This group was controlled every 6th week, in accordance with what is deemed to be golden standard for treatment with a Twin Block orthodontic appliance."
62779978|NCT05155774|EXPERIMENTAL|Test group, controlled every 4th week|This group was controlled every 4th week, testing if a more frequent control interval would increase compliance with a Twin block orthodontic appliance.
62004812|NCT02748577|ACTIVE_COMPARATOR|Healthy Controls|Healthy Controls will complete one study visit where they will complete several questionnaires and will complete Quantitative Sensory Testing (QST) Pain Measurements.
62190471|NCT02561247|EXPERIMENTAL|Prismaflex HF20 CRRT|Patients included in this arm will be treated for a minimum period of 20 of the first 24 hours and up to 72 hours with each Prismaflex® HF 20 Set with BUN, creatinine and bicarbonate being measured for statistical analysis at 12 hour intervals during CRRT treatment.
62190472|NCT06377956||BMI≥18.5, age between 18-40 years old, 100subjects（50 female and 50 man）|"He Shuang(Polyethylene Glycol Electrolytes Powder):1/1.5 sachets of PEG(68.56-102.84g dissolved in water with1/1.5L ) were provided to volunteers based on body weight(BW): BW\<60 kg, 1 sachet , BW≥60 kg, 1.5 sachets, drinking an average of 200/250 mL every 15 minutes. It will cause frequent bowel motions or diarrhoea for a couple of hours afterwards.~Raceanisodamine Hydrochloride Injection: intramuscular injection of Raceanisodamine Hydrochloride Injection with 10mg. It may cause dry mouth, red face and blurred vision. The half-life of the medicine is 40 minutes and most of the above symptoms disappear within 1 to 3 hours."
62190473|NCT04650399|EXPERIMENTAL|Active|VLA1553
62004813|NCT05053984|EXPERIMENTAL|Neuromodulation|This study has only 1 arm and the control group is their baseline data
62004814|NCT01983657|EXPERIMENTAL|D1|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~If the treatment is effective, participants may be entered into low-dose group(D1)(rhGM-CSF administration 1.25 ug/kg/d, qd, sc, for 2 months，then rhGM-CSF administration 1.25 ug/kg/d, qod, sc, for 3 months), when the chest CT absorption≥25% , and /or the PaO2 elevated by 5 mm Hg."
62004815|NCT01983657|EXPERIMENTAL|D2|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~When the treatment is ineffective, and anti-GM-CSF antibody titers level ≥1:1000，the dose will be increased to 2.5 ug/kg/d. After 2 months, if the clinical response was optimal, that dose is continued for 3 months, and defined as group 2(D2)."
62190474|NCT04650399|PLACEBO_COMPARATOR|Placebo|Placebo
62190475|NCT02844530|EXPERIMENTAL|RIT|The experimental treatment will consist on 2 injections of 370 MBq/m2 of 90Y-epratuzumab tetraxetan fractionated RIT at day 1 and day 8. The first infusion of 90Y-epratuzumab tetraxetan will be co-injected for the six first patients in Nantes with 111In-epratuzumab tetraxetan for dosimetry purpose.
62190476|NCT02844530|ACTIVE_COMPARATOR|chemotherapy/ immunotherapy|"chemotherapy/ immunotherapy regimen will be assigned per investigator's choice to one of the following chemotherapy/ immunotherapy regimens:~1. FLAG +- anthracycline based regimen For subject's \>60 years : idarubicin 5 mg/m2 day 1,3, fludarabine 20 mg/m2 days 1-5, cytarabine 1 g/m2 days 1-5.~2. Clofarabine or clofarabine based regimens. Clofarabine use as a single agent should follow the recommended prescribing information. Clofarabine combination based regimens should use \>=20mg/m2/day for up to 5 days.~3. Hyper-C-VAd regimen: hyperfractionated cyclophosphamide 300 mg/m2 intravenously(i.v.) every 12 hours for 6 doses Days 1 to 3 + vincristine 2 mg i.v.Days 4 and 11; doxorubicin 50 mg/m2 i.v. over 24 hours via central venous catheter Day 4; and dexa-methasone 40 mg daily Days 1 to 4 and 11 to 14.~4. Blinatumomab (Blincyto®) : 28-day continuous infusion (9µg/d for days 1-7; 28µg/d thereafter, followed by 2 weeks of rest for up to 2 cycles."
62004816|NCT01983657|EXPERIMENTAL|D3|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~When the treatment is ineffective, and anti-GM-CSF antibody titers level ≥1:1000，the dose will be increased to 2.5 ug/kg/d. After 2 months, if the clinical response was not optimal, the patients will receive whole lung lavage(WLL), who are defined as group 3(D3)."
62190477|NCT04879264|EXPERIMENTAL|Patients irradiated for breast cancer|Participants with breast cancer who receive adjuvant radiotherapy following breast-conserving surgery or mastectomy.
62190478|NCT01176461|EXPERIMENTAL|A1 - Phase I Dose Escalation|Cohorts 1 through 5. Each treatment cycle is comprised of 6 doses of BMS-936558 and 6 peptide vaccines administered every 2 weeks for 12 weeks (cohort 6 has no peptides) (Cycle 1: Weeks 1, 3, 5, 7, 9, and 11; Cycle 2: Weeks 13, 15, 17, 19, 21, and 23) with tumor response assessments at the end of each cycle (during Weeks 12 and 24).
62190479|NCT01176461|ACTIVE_COMPARATOR|A2 - BMS-936558 Without Peptide Vaccine|Cohort 6. Each treatment cycle is comprised of 6 doses of BMS-936558 administered every 2 weeks for 12 weeks (cohort 6 has no peptides) (Cycle 1: Weeks 1, 3, 5, 7, 9, and 11; Cycle 2: Weeks 13, 15, 17, 19, 21, and 23) with tumor response assessments at the end of each cycle (during Weeks 12 and 24).
62779979|NCT00733681|EXPERIMENTAL|PFC Sigma RP TC3 Revision Knee System|Revision knee surgery with the PFC Sigma RP TC3 Revision Knee System (mobile bearing).
62004817|NCT01983657|ACTIVE_COMPARATOR|D4|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~When the treatment is ineffective, and anti-GM-CSF antibody titers level \<1:1000，the patients will receive whole lung lavage(WLL), then give rhGM-CSF administration (1.25 ug/kg/d) for 3 months, which belong to group4(D4)."
62004818|NCT01885481|ACTIVE_COMPARATOR|ESI-1|epidural steroid injection using dexamethasone
62190480|NCT04670770|EXPERIMENTAL|SHR1459|SHR1459
62190481|NCT02978677|EXPERIMENTAL|Grade II tumors (macroscopic)|Radiotherapy 68 Gy(RBE)
62190482|NCT02978677|EXPERIMENTAL|Grade III tumors (macroscopic)|Radiotherapy 72 Gy(RBE)
62190483|NCT02978677|ACTIVE_COMPARATOR|Grade II/III tumors (completely resected)|Radiotherapy 60 Gy(RBE)
62779980|NCT01500668|ACTIVE_COMPARATOR|Treatment|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
62004819|NCT01885481|EXPERIMENTAL|ESI-2|epidural steroid injection using betamethasone
62004820|NCT01873482|EXPERIMENTAL|Movement with rhythm|Subjects will move for 1 hour in time to the Congolese rhythm called Zebola.
62190484|NCT02757820|ACTIVE_COMPARATOR|LMA classic|Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
62190485|NCT02757820|ACTIVE_COMPARATOR|I-gel|Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
62190486|NCT02757820|ACTIVE_COMPARATOR|Air-Q|Patients will be anesthetized using Air-Q_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
62190487|NCT00431613|EXPERIMENTAL|1|DG -\> RT
62190488|NCT00431613|EXPERIMENTAL|2|DG -\> RT -\> DCarbo
62190489|NCT04810468|OTHER|Children in primary school|anthropometric measurment will take from each participiant in study to asses wheight ,height ,BMl and also use aquestionnaire yo asses the Sociodemographic data,dietary habits ,hygiene information
62004821|NCT01888497|EXPERIMENTAL|Arm A|
62190490|NCT01209598|EXPERIMENTAL|Palbociclib 200mg|This is a phase II study of Palbociclib in patients with advanced / metastatic liposarcoma. A one-stage design is used to determine whether patients treated with Palbociclib achieved a PFS rate of ≥ 40% at 12 weeks.
62190491|NCT01209598|EXPERIMENTAL|Palbociclib 125mg|This is a phase II study of Palbociclib in patients with advanced / metastatic liposarcoma. A one-stage design is used to determine whether patients treated with Palbociclib achieved a PFS rate of ≥ 40% at 12 weeks.
62396696|NCT05239741|ACTIVE_COMPARATOR|Standard of Care Chemotherapy|Participants receive 1 of 6 possible standard chemotherapy regimens at the discretion of the investigator: (1) mFOLFOX6; (2) mFOLFOX6+bevacizumab 5 mg/kg IV on Day 1 of each 14-day cycle (Q2W); (3) mFOLFOX6+cetuximab 400 mg/m\^2 IV over 2 hours then 250 mg/m\^2 over 1 hour weekly Q2W; (4) FOLFIRI; (5) FOLFIRI+bevacizumab 5 mg/kg IV on Day 1 Q2W; OR (6) FOLFIRI+cetuximab 400 mg/m\^2 IV over 2 hours then 250 mg/m\^2 over 1 hour weekly Q2W. Participants with documented disease progression following chemotherapy can receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years).
62779981|NCT01500668|PLACEBO_COMPARATOR|Control|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
62004822|NCT01888497|EXPERIMENTAL|Arm B|
62004823|NCT01888497|ACTIVE_COMPARATOR|Arm C|
62190492|NCT00202046||Patients with lymphedema|Identification of risk factors for lymphedema in women who have had axillary surgery for breast cancer.
62190493|NCT00202046||Control patients without lymphedema|Controls matched on type of axillary surgery and surgery date for comparison in quality of life (QOL) ratings from women who have lymphedema.
62190494|NCT01821937|EXPERIMENTAL|faldaprevir(high dose)|10 subjects (approximate sex ration: 1:1) will be assigned to trial by single and multiple dose.
62190495|NCT01821937|EXPERIMENTAL|Faldaprevir(low dose)|10 subjects (approximate sex ration: 1:1) will be assigned to trial by single and multiple dose.
62190496|NCT00440245|OTHER|salbutamol|There are two groups, asthma and COPD, which are being compared with respect to bronchoprotection from an active treatment (salbutamol).
62190497|NCT03436303|EXPERIMENTAL|CEE 0.625 mg/MP 100mg|CEE 0.625 mg/micronized progesterone (MP) 100 mg daily for the last 12 days of every 28 days for two years
62190498|NCT03436303|EXPERIMENTAL|CEE 0.3 mg/MP 100mg|CEE 0.3mg/micronized progesterone (MP) 100 mg daily for the last 12 days of every 28 days for two years
62190499|NCT03436303|EXPERIMENTAL|CEE 0.625 mg/dydrogesterone 10mg|CEE 0.625 mg/dydrogesterone 10 mg daily for the last 12 days of every 28 days for two years
62190500|NCT04921579|EXPERIMENTAL|En masse retraction|six anterior teeth are retracted by en masse technique using a crimpable hook distal to upper lateral incisor and a power chain.
62190501|NCT04921579|EXPERIMENTAL|two step retraction|six anterior teeth are retracted by two step technique by canine retraction followed by four anterior teeth retraction using a crimpable hook distal to upper lateral incisor and a power chain.
62190502|NCT00583947|OTHER|ARF/LEV|"Cross-over phase: one day active treatment with arformoterol 7.5 microgram per nebulization followed by a 7 day washout. Then a one day active treatment with levalbuterol 0.63 milligram per nebulization.~Open-label phase: Following another 7 day washout, one day treatment with arformoterol 15 micrograms per nebulization."
62190503|NCT00583947|OTHER|LEV/ARF|"Cross-over phase: one day active treatment with levalbuterol 0.63 milligram per nebulization followed by a 7 day washout. Then a one day active treatment with arformoterol 7.5 micrograms per nebulization.~Open-label phase: Following another 7 day washout, one day treatment with arformoterol 15 micrograms per nebulization."
62190504|NCT02209181|EXPERIMENTAL|JNJ-10450232 250 mg|
62004824|NCT01888497|PLACEBO_COMPARATOR|Arm D|
62004825|NCT04404959|ACTIVE_COMPARATOR|fascia iliaca compartment block with ropivacaine|in this arm, the fascia iliaca compartment block will be performed with 40 mL ropivacaine 0.25%
62004826|NCT04404959|PLACEBO_COMPARATOR|fascia iliaca compartment block with placebo|in this arm, the fascia iliaca compartment block will be performed with 40 mL normal saline
62004827|NCT04623164|NO_INTERVENTION|1 Group (Control)|ten students with healthy periodontium
62190505|NCT02209181|EXPERIMENTAL|JNJ-10450232 1000 mg|
62190506|NCT02209181|PLACEBO_COMPARATOR|Placebo|
62190507|NCT02209181|ACTIVE_COMPARATOR|Acetaminophen 1000 mg|
62190508|NCT04788342||Patients with and without left ventricular systolic dysfunction|Patients with different pathologies of the cardiovascular system (coronary artery disease, hypertension, valvular heart disease, heart failure) will be performed pulse wave recording using a CardioQvark cardiomonitor and echocardiography.
62779982|NCT03727906|OTHER|Non-insomnia Group|"Non-insomnia participants will not meet criteria for current DSM-5 Insomnia Disorder or have a past history of insomnia.~Interventions (order is randomly assigned):~1. no pre-sleep arousal manipulation night;~2. pre-sleep arousal down-regulation night~3. pre-sleep arousal up-regulation night."
62779983|NCT03727906|OTHER|Insomnia Group|"Insomnia Group participants will have to meet DSM-5 criteria for current Insomnia Disorder.~Interventions (order is randomly assigned):~1. no pre-sleep arousal manipulation night;~2. pre-sleep arousal down-regulation night~3. pre-sleep arousal up-regulation night."
62004828|NCT04623164|EXPERIMENTAL|2 Group|ten patients receiving standard non-surgical periodontal treatment (NSPT)
62004829|NCT04623164|EXPERIMENTAL|3 Group|ten patients receiving standard non-surgical periodontal treatment NSPT + 28-day chronotherapy with complex phytoadaptogens (CFA)
62004830|NCT02601040|EXPERIMENTAL|Attenuated Hepatitis A Vaccine, H2 Strain|Health subjects received attenuated Hepatitis A vaccine intramuscularly in the deltoid region.
62004831|NCT02601040|EXPERIMENTAL|Inactivated Hepatitis A Vaccine, Lu8 Strain|Health subjects received inactivated Hepatitis A vaccine intramuscularly in the deltoid region.
62004832|NCT02601040|PLACEBO_COMPARATOR|Group A Meningococcal Polysaccharide vaccine|Health subjects received Group A Meningococcal Polysaccharide vaccine intramuscularly in the deltoid region.
62004833|NCT04643106|EXPERIMENTAL|Hemostatic agent group|During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL® Fibrin Sealant, Ethicon, USA), which consist of thrombin and coagulating proteins, mainly fibrinogen and fibronectin. If hemostasis is not fulfilled enough by using it, a additional intervention such as electrocoagulation with bipolar forceps and barbed suture is required to stop bleeding.
62004834|NCT04643106|ACTIVE_COMPARATOR|Suturing group|During operation, barbed suture will be applied to the inner surface of ovarian parenchyme where ovarian endometriosis was attached. In this group, if bleeding is continued after suturing, additional electrocoagulation with bipolar forceps will be conducted.
62004835|NCT06019858|EXPERIMENTAL|Vitamin Energy Shot|Participants will take one bottle daily of the Vitamin Energy® shot, in the morning.
62004836|NCT04182581|EXPERIMENTAL|CAR-T treatment group|The patients will receive one dose of BCMA/CD19 dual-target CAR-T. BCMA/CD19 dual-target CAR-T dosage ranges from 5×10\^4 to 3×10\^5 CAR+T/Kg.
62004837|NCT01487005||elderly subjects|Healthy
62004838|NCT04548882|EXPERIMENTAL|Calypso Knee System|Calypso Knee System
62004839|NCT05993728|EXPERIMENTAL|Clinician-led Body Project|Participants randomized to this condition will take part in virtual Body Project groups led by clinicians.
62190509|NCT03144544||Pediatric specialist hospitals|Free-standing hospitals providing tertiary pediatric referral services and performing pediatric surgical procedures
62190510|NCT03144544||Non-pediatric specialist hospitals|Other hospitals performing pediatric surgical procedures
62190511|NCT04468230|EXPERIMENTAL|Nicotine Transdermal Patch Administration|Each patient will complete two 14-day treatment conditions, for 7 mg nicotine transdermal patch administration with a washout period in between (≥ 14 days and up to 21 days), then 14 mg nicotine transdermal patch administration (14 days).
62190512|NCT05129332|EXPERIMENTAL|Vaginal Dilator Intervention|Patients assigned to the vaginal dilator group will be provided the device, vaginal moisturizer, an adherence calendar, and standardized verbal and written instructions from a trained health professional to apply the moisturizer and use the dilator for 15 minutes daily. Standard medical grade vaginal dilators and pure Vitamin E oil will be provided for each study participant. They have the option of purchasing a dilator and/or moisturizer of a similar nature if they choose to.
62190513|NCT05129332|OTHER|Control (Vaginal Moisturizer Only)|Patients assigned to vaginal moisturizer alone will receive pure Vitamin E oil and similar standardized instructions on daily use and an adherence calendar. They will apply a dime-sized amount of Vitamin E oil every day. They have the option of purchasing their own moisturizer if they choose to.
62004840|NCT05993728|EXPERIMENTAL|Peer-led Body Project|Participants randomized to this condition will take part in virtual Body Project groups led by peers.
62004841|NCT05993728|ACTIVE_COMPARATOR|Educational control|Participants randomized to the educational control group will receive educational videos on body image and eating disorders
62004842|NCT02873013||Prostate Cancer|About 20,000 patients who have received a histopathological diagnosis of prostate cancer from ten countries in Asia.
62004843|NCT02156427|EXPERIMENTAL|VITICELL|In this arm, lesions will be treated by autologous epidermal cells suspension (containing hyaluronic acid) obtained after VITICELL kit's use, a class III medical device.
62004844|NCT02156427|PLACEBO_COMPARATOR|PLACEBO|In this arm, lesions will be treated by a suspension of hyaluronic acid without epidermal cells.
62004845|NCT00940303|EXPERIMENTAL|1|
62004846|NCT03604055|OTHER|Endobronchial hamartomas treatment|After removal of endobronchial lesions, cryotherapy is applied to the area of origin. Recurrences are followed. Recurrences are recorded as poor results, compared with good results.
62004847|NCT05410652||Fecal kit group|Collect stool samples from patients who meet the inclusion criteria. DNA was extracted from fecal samples. After that, the extracted DNA was sequenced by first generation sequencing. Finally，the mutation sites of extracted DNA were detected by fecal gene detection kit.
62004848|NCT05410652||Sanger Sequencing group|Detection of gyrA and 23S rRNA mutations in H. pylori isolated from Gastric Mucosa by Sanger Sequencing
62779984|NCT05082311||Patients with Pheochromocytoma/Paraganglioma (secretory, extra adrenal pheochromocytoma)|"Patients included in this cohort (n=50) are those who are diagnosed of Pheochromocytoma / Paraganglioma, willing to consent for the study and not on α-blockade at the time of recruitment into study, while can be on any other anti hypertensives~Patients in this group, besides the usual evaluation of Pheochromocytoma / Paraganglioma, will also undergo detailed cardiac and vascular evaluation, which will be done at diagnosis, at 7- 10 days of α-blockade, and 7 days, 3 and 6 months post adrenalectomy/ Paraganglioma excision The cardiovascular evaluation includes 2D-echocardiography, speckle tracking Echo (for measuring global longitudinal strain), serum NT-proBNP estimation and flow mediated vasodilatory studies by Doppler Ultrasonography of the brachial artery to assess the endothelial dependent and smooth muscle dependent vasodilatory responses"
62779985|NCT05082311||Essential Hypertensive Groups|This is a contemporary age- and gender-matched control group This group includes 10 newly detected (within 3 months) Essential Hypertensive patients, who will undergo treatment with standard anti- HT medications Cardiac evaluation will be done at baseline and after 3 months of anti hypertensive medications
62004849|NCT05410652||Drug sensitivity test group|Gastroscopy was performed on patients who met the inclusion and exclusion criteria to obtain samples of gastric mucosa. Helicobacter pylori culture and drug sensitivity test were performed on gastric mucosa samples in vitro. Finally, the drug sensitivity test results were collected.
62190514|NCT03958006|EXPERIMENTAL|Cochlear implantation|Simultaneous cochlear implantation with tumor resection
62190515|NCT04513353|EXPERIMENTAL|Digital Healthcare System Rehabilitation|
62190516|NCT04513353|ACTIVE_COMPARATOR|Conventional Rehabilitation|
62190517|NCT00462605|EXPERIMENTAL|Arm I|Patients receive oral MS-275 on days 1, 8, 15, and 22. Patients also receive sargramostim (GM-CSF) subcutaneously once daily on days 1-42 in courses 3 and 5 and on days 1-35 in courses 1, 2, 4, and 6. Treatment repeats every 6 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. After completion of 2 courses of study therapy, patients who achieve a complete or partial response may receive an additional 4 courses. Patients who maintain stable disease for more than 2 months after completion of 6 courses of study therapy may receive an additional 6 courses at the time of disease progression, provided they meet original eligibility criteria.
62190518|NCT02181907|EXPERIMENTAL|UH-AC 62 XX tablet|
62190519|NCT02181907|ACTIVE_COMPARATOR|UH-AC 62 XX capsule|
62004850|NCT02214147|EXPERIMENTAL|Alisertib: Normal Hepatic Function|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 50 mg, orally, twice daily (BID) for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 50 mg, BID for 7 days, followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Normal hepatic function includes participants with total bilirubin ≤ upper limit of the normal range \[ULN\] and alanine aminotransferase \[ALT\] level ≤ ULN.
62779986|NCT05082311||Healthy Individuals|This is a contemporary age- and gender-matched control group This group includes 10 Healthy individuals (normal in physical examination, ECG , Echo), that include hospital staff nurses, technicians, doctors whom would be requested to volunteer Cardiac evaluation will be done at the start of study and after 6 months
62779987|NCT05160129|EXPERIMENTAL|Circuit-selective DBS|People suffering from severe obsessive-compulsive disorder (OCD)
62004851|NCT02214147|EXPERIMENTAL|Alisertib: Moderate Hepatic Impairment|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by alisertib 30 mg, BID for 7 days (Cycle 1 Day 8 to 14), followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 30 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Moderate hepatic impairment includes participants with total bilirubin \> 1.5-3 x ULN and any ALT level.
62190520|NCT01177761|ACTIVE_COMPARATOR|exercise|endurance,balance, power, resistance type exercise
62190521|NCT01177761|NO_INTERVENTION|sedentary control|Subjects were instructed to do not relevantly change their lifestyle
62190522|NCT01715207|EXPERIMENTAL|Atenolol & Aliskiren|Atenolol tablet and Aliskiren 150mg or 300mg tablet by mouth per day for 6month
62190523|NCT01715207|OTHER|Atenolol|Atenolol tablet(Negative controls, Open-label)
62190524|NCT02530788|ACTIVE_COMPARATOR|Selenium Supplement (sodium selenite)|Active arm receiving Selenium in form of sodium selenite
62190525|NCT02530788|PLACEBO_COMPARATOR|Placebo|Placebo arm receiving Sodium Chloride solution
62190526|NCT01646385||etanercept|adult rheumatoid arthritis patients initiating therapy with etanercept as their first biologic therapy
62190527|NCT01646385||nbDMARD|biologic-naive adult rheumatoid arthritis patients with DAS28 \>4.2 treated with non-biologic anti-rheumatic drugs(s).
62190528|NCT02968706|EXPERIMENTAL|High flow cannula arm|Patients in the experimental arm (the high flow nasal cannula group) will receive heated humidified high flow oxygen of 50L/min at FiO2 of 40% throughout the colonoscopy. A patient satisfaction survey will be administered after procedure.
62190529|NCT02968706|ACTIVE_COMPARATOR|Conventional cannula arm|Participants in control arm (the conventional nasal cannula group) will receive an oxygen flow of 2-5 L /min. A patient satisfaction survey will be administered after procedure.
62190530|NCT02422732|OTHER|Children with reading disability|Children with NF1, with reading disability if their performances on reading assessment (Alouette Test) present a delay of at least 18 months, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis
62190531|NCT02422732|OTHER|Children without reading disability|Children with NF1, without reading disability if their performances on reading assessment (Alouette Test) present a less than 18-month delay, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis.
62190532|NCT00167232|ACTIVE_COMPARATOR|Naltrexone 150mg/day|
62190533|NCT00167232|PLACEBO_COMPARATOR|Placebo Sugar Pill|
62190534|NCT02412579||Hepatocellular Carcinoma with Cirrhosis|Subjects with hepatocellular carcinoma and cirrhosis.
62190535|NCT02412579||Cirrhosis without Hepatocellular Carcinoma|Subjects with only cirrhosis.
62779988|NCT05096312|ACTIVE_COMPARATOR|Zinc gluconate group|"interventions: Zinc gluconate (200g/capsule) one capsule once in the morning after breakfast for 60 days.~Adapalene 0.3% + benzoyl peroxide 2.5% gel to be applied once at night for 60 days."
62779989|NCT05096312|PLACEBO_COMPARATOR|Placebo group|interventions: Placebo capsule, one capsule once in the morning after breakfast for 60 days. Adapalene 0.3% + benzoyl peroxide 2.5% gel to be applied once at night for 60 days.
62004852|NCT02214147|EXPERIMENTAL|Alisertib: Severe Hepatic Impairment|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 20 mg, BID for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 20 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Severe hepatic impairment includes participants with total bilirubin \> 3 x ULN and any ALT level.
62004853|NCT05004259|EXPERIMENTAL|Arm 1|Six weekly doses of subcutaneous daratumumab 1,800mg and hyaluronidase 30,000U.
62190536|NCT03043430|EXPERIMENTAL|Ketamine|Ketamine 100 mg/mL concentration administered in a single 1.0 mg/kg dose with a maximum of 50mg intranasal via mucosal atomization device.
62190537|NCT03043430|ACTIVE_COMPARATOR|Midazolam|Midazolam 5 mg/mL concentration administered in a single administered in a single 0.3 mg/kg dose with a maximum of 5mg intranasal via mucosal atomization device.
62190538|NCT05815537|EXPERIMENTAL|Low-Reverberation|Participants perform psychoacoustic tasks under a low-reverberant environment and a control environment without reverberation.
62190539|NCT05815537|EXPERIMENTAL|High-Reverberation|Participants perform psychoacoustic tasks under a high-reverberant environment and a control environment without reverberation.
62190540|NCT02414126|ACTIVE_COMPARATOR|Children with dilated cardiomyopathy with an ejection fraction|
62190541|NCT02414126|ACTIVE_COMPARATOR|Children with univentricular congenital heart disease|
62190542|NCT02414126|ACTIVE_COMPARATOR|Children with left valvulopathy|
62410027|NCT05992207|ACTIVE_COMPARATOR|motor imaginary training|The study group received the selected physical therapy program for one hour, three times weekly for three successive months in addition to motor imagery program for 30 minutes as the following. Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semireclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise
62779990|NCT05441865||cognitive trajectory cohort|Th cognitive trajectory cohort, based on CLHLS dataset, will be used to evaluate the influence of cardiovascular risk factors on the cognitive trajectories among cognitively intact older adults
62779991|NCT05441865||neuroiming sample|The neuroiming sample, including cognitively intact older adults with MRI data, will be used to explore the potential mechanism of the cardiovascular risk factors and cognitive function.
62779992|NCT01660880||aripiprazole|Patient group who is treated with aripiprazole
62779993|NCT03797456|EXPERIMENTAL|ICP-022|
62779994|NCT05151757|EXPERIMENTAL|To test the effectiveness of a training course to improve graders ability to detect glaucoma|"Study design: This is an uncontrolled interventional experimental before and after study in which a minimum of 42 non-physician graders shall be trained to screen for glaucoma using optic nerve photos obtained for diabetic retinopathy (DR) screening in Vietnam.~The standard image training set will consist of about 50 normal optic nerve images of people without glaucoma and about 50 images of people with glaucoma, obtained from the on-going ORBIS CAFÉ DR screening programme (in which the graders are working), population-based eye studies in the UK (NICOLA) and the standard Glaucomatous Optic Neuropathy Evaluation (GONE) set of images. (https://gone-project.com/newgone/). The test set contains 60 normal and glaucomatous optic disc images."
62779995|NCT02294734|EXPERIMENTAL|GSK2269557 repeat dose|Participants will receive 2 inhalation of GSK2269557 dry powder once daily via DISKUS™ 'device' (DISKUS is a trademark of the GSK group of companies)
62779996|NCT02294734|PLACEBO_COMPARATOR|Matching placebo repeat dose|Participants will receive 2 inhalation matching placebo dry powder once daily via DISKUS 'device'
62190543|NCT00721812|OTHER|Part A|Single dose escalation
62190544|NCT00721812|OTHER|Part B|14 day repeat dose escalation
62410028|NCT01053169||Prophylaxis Cohort|Patients with coagulopathy due to liver disease or other condition requiring correction of coagulopathy who require surgical or diagnostic intervention
62190545|NCT00721812|OTHER|Part C|Fixed dose food effect
62190546|NCT04196543|EXPERIMENTAL|écho-doppler with ultrasonar Sonovue® injection|
62190547|NCT01780298||Group 1: COPD GOLD Stage 1-2|Sixty subjects with a clinical diagnosis of COPD, according to the GOLD guidelines (Stages 1-2), who are current smokers with at least a 10 pack-year smoking history.
62190548|NCT01780298||Group 2: Current Cigarette Smokers|Sixty subjects who are current smokers with at least a 10 pack-year smoking history and matched to the COPD cases by ethnicity, gender and age (within 5 years).
62190549|NCT01780298||Group 3: Ex-Smokers|Sixty subjects who are ex-smokers with at least a 10 pack-year smoking history who have not smoked for at least one year and matched to the COPD cases by ethnicity, gender and age (within 5 years).
62190550|NCT01780298||Group 4: Never Smokers|Sixty subjects who have never smoked (non-smokers) and matched to the COPD cases by ethnicity, gender and age (within 5 years).
62190551|NCT04237285|EXPERIMENTAL|Lavender 15|Participant who inhalates lavender oil for 15 minutes.
62410029|NCT01053169||Treatment Cohort|Patients experiencing acute bleeding perioperatively
62410030|NCT03184402|EXPERIMENTAL|DWJ1252|
62410031|NCT03184402|ACTIVE_COMPARATOR|Gasmotin|
62410032|NCT03940742|ACTIVE_COMPARATOR|Normal Hepatic Function|Participants with normal hepatic function received single subcutaneous dose of 5 milligrams (mg) tirzepatide.
62410033|NCT03940742|EXPERIMENTAL|Mild Hepatic Impairment|Participants with mild hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.
62572094|NCT06576245|EXPERIMENTAL|Combination Treatment: Quantum Molecular Resonance (QMR) and Intense Pulsed Light (IPL)|Participants in this arm will receive a combination treatment consisting of Quantum Molecular Resonance (QMR) therapy and Intense Pulsed Light (IPL) therapy. The treatment protocol includes 4 sessions of QMR and 3 sessions of IPL over a period of 6 weeks. QMR and IPL will be combined in certain weeks, with additional sessions of QMR and IPL performed separately in other weeks. The effectiveness of this combination therapy will be evaluated through various clinical endpoints, including improvements in tear film stability and dry eye symptoms over a 3-month follow-up period.
62572095|NCT06578208|EXPERIMENTAL|Male Gruop|The patient was placed in the lateral decubitus position by the therapist. The foot was placed on the popliteal fossa of the lower leg while the upper knee was flexed. Once the patient was in this position, the therapist performed high velocity and low amplitude thrusts (HVLA; high velocity - low amplitude) on the vertebra with dysfunction.
62572096|NCT06578208|EXPERIMENTAL|Female Group|The patient was placed in the lateral decubitus position by the therapist. The foot was placed on the popliteal fossa of the lower leg while the upper knee was flexed. Once the patient was in this position, the therapist performed high velocity and low amplitude thrusts (HVLA; high velocity - low amplitude) on the vertebra with dysfunction.
62410034|NCT03940742|EXPERIMENTAL|Moderate Hepatic Impairment|Participants with moderate hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.
62572097|NCT02391415|EXPERIMENTAL|HIV-unexposed infants VPM1002|HIV-unexposed infants vaccinated with VPM1002
62779997|NCT01618149||severe knee OA who are indicated for total knee arthroplasty|the woman who are indicated for TKR and are post menopausal will be recruited in this study. We will excluded the patients who had immune disease ,previous fracture of femur and end stage of renal disease
62190552|NCT04237285|EXPERIMENTAL|Lavender 60|Participant who inhalates lavender oil for 60 minutes.
62190553|NCT04237285|PLACEBO_COMPARATOR|Jojoba|Participant who inhalates jojoba oil for 15 minutes.
62190554|NCT05421468|ACTIVE_COMPARATOR|Pre-Iftar (Breaking the fast)|To take thyroxine at breaking of fast with sip of water then wait 30-60 miuntes to eat iftar (breakfast).
62572098|NCT02391415|ACTIVE_COMPARATOR|HIV-unexposed infants BCG|HIV-unexposed infants vaccinated with BCG
62572099|NCT02391415|EXPERIMENTAL|HIV-unexposed infants VPM1002(Hyg+)|HIV-unexposed infants vaccinated with VPM1002(Hyg+)
62572100|NCT02391415|ACTIVE_COMPARATOR|HIV-exposed infants BCG|HIV-exposed infants vaccinated with BCG
62572101|NCT02391415|EXPERIMENTAL|HIV-exposed infants VPM1002|HIV-exposed infants vaccinated with VPM1002
62572102|NCT04668495||Cangrelor Group|This is the study cohort that the blood sample will be obtained from. There are no interventions
62572103|NCT03337087|EXPERIMENTAL|Treatment (nal-IRI, leucovorin, fluorouracil, rucaparib)|"PHASE Ia: Patients receive liposomal irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV over 46 hours on days 1 and 15. Patients also receive rucaparib PO BID on days 4-13 and 18-27. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity.~PHASE Ib/II: Patients receive liposomal irinotecan IV over 90 minutes and fluorouracil IV over 46 hours on days 1 and 15. Patients also receive rucaparib PO BID on days 4-13 and 18-27. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity."
62779998|NCT02406404|EXPERIMENTAL|spirometer training group|incentive spirometer training group
62190555|NCT05421468|EXPERIMENTAL|Pre-Fajr (Starting the fast)|To take thyroxine immediately before start of fast at predawn time regardless of last meal time.
62572104|NCT03782753||Group A|25 LRRK2-PD patients
62779999|NCT02406404|NO_INTERVENTION|No intervention group|no intervention group
62780000|NCT04318925||1|Persons with diagnosed or suspected tick-borne disease age \>=18 years
62572105|NCT03782753||Group B|25 idiopathic PD patients
62410035|NCT03940742|EXPERIMENTAL|Severe Hepatic Impairment|Participants with severe hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.
62572106|NCT03782753||Group C|25 HC subjects
62572107|NCT02682693|EXPERIMENTAL|Denosumab|Denosumab every 4 weeks for 6 cycles.
62780001|NCT06508840||Pulmonary Rehab Programme|"Pulmonary Rehab Programme staff and patients. The five physiotherapists who deliver the programmes will receive Verbal Health Literacy training and implementation support.~Patients will enrol and complete the Pulmonary Rehab programme as usual. That is two sessions a week for six weeks."
62780002|NCT06508840||Weight Management Programme|"Six out of twelve Health Improvement Advisors, who deliver the programmes, will receive Verbal Health Literacy Training and implementation support.~Service users will attend the programme as usual. That is one session a week for 12 weeks."
62780003|NCT06242015|EXPERIMENTAL|Carbohydrate-first meal|
62780004|NCT06242015|EXPERIMENTAL|Carbohydrate-last meal|
62190556|NCT02961478|EXPERIMENTAL|Iohexol plasmatic clearance|
62780005|NCT05885802||ERAS group|Routine spine surgical patients receiving ERAS protocol that complies with current guidelines.
62780006|NCT04465292|EXPERIMENTAL|Intervention|Participants will receive Tildrakizumab 100mg at Weeks 0, 4, 16; three doses; a 16-week treatment course and 24-week followup
62780007|NCT00488696|EXPERIMENTAL|Interventional|Endovascular Bifurcated Stent Graft: The investigational operation involves placing a stent-graft over the aortic aneurysm.
62190557|NCT05679999||Control group|31 male volunteers who did not have erectile dysfunction
62190558|NCT05679999||Patient group|150 patients with erectile dysfunction
62190559|NCT00511186|EXPERIMENTAL|Bovine Intestinal AP|"Bovine Intestinal Alkaline Phosphatase (BIAP) Intravenous administration of 10 bolus (67,5U/kg) and 48h continuous infusion (132,5U/kg)"
62190560|NCT00511186|PLACEBO_COMPARATOR|2|"Placebo Intravenous administration of 10 bolus and 48h continuous infusion"
62190561|NCT05784610|ACTIVE_COMPARATOR|TOF/PTC|Non-automated neuromuscular blockade monitoring (TOF/PTC). As the NMB monitoring is depending on anesthesiologist usual practice and so only TOF measure is systematic, it is necessary to include a blind anesthesiologist measurement with the ATP mode in order to compare with data obtained during Time 2.
62190562|NCT05784610|EXPERIMENTAL|ATP|Automated neuromuscular blockade monitoring (ATP). TOF and PTC stimulations are regularly performed, and PTC is systematically performed if TOF = 0/4. If PTC = 10/10, a TOF stimulation is automatically performed.
62190563|NCT05230719||dTRA group|Investigators perform percutaneous coronary intervention by dTRA for patients
62190564|NCT05230719||TRA group|Investigators perform percutaneous coronary intervention by conventional TRA for patients
62190565|NCT02365103|OTHER|Test meal I (given with water)|Test meal with water
62190566|NCT02365103|OTHER|Test meal II (simultaneously with tea)|Test meal with tea (simultaneously)
62190567|NCT02365103|OTHER|Test meal III (1 hour after test meal)|Test Meal with tea given 1 hour after test meal
62190568|NCT02365103|OTHER|Reference Iron Dose|Reference iron dose administered
62190569|NCT05308277|OTHER|Single Arm - Leo Device Monitoring|Child's respiratory impedance will be continuously recorded using the Leo device during hospital/ED stay after consent and enrollment, and then during 7 days at home after discharge. The Leo device provides no intervention, and will only monitoring chest impedance for the worn period. Oscillometry and spirometry testing and flow volume assessment using PNT will be performed during study visits with Leo device attached.
62190570|NCT04174209|EXPERIMENTAL|Cohort 1|70 patients are involved and will perform the three conditions.
62190571|NCT01712269|EXPERIMENTAL|Weight-loss (bariatric) surgery|All subjects enrolled will undergo bariatric surgery to assist weight-loss
62190572|NCT00583466|ACTIVE_COMPARATOR|1 Normal saline arm|Polypectomy with normal saline injected for submucosal cushion creation
62190573|NCT00583466|ACTIVE_COMPARATOR|2 HPMC arm|Polypectomy after injection of hydroxypropyl methylcellulose (HPMC) to create submucosal cushion
62190574|NCT00583466|EXPERIMENTAL|3 Blood arm|Polypectomy after injection of autologous blood
62190575|NCT04131764||Optic neuritis diagnosis only|Patients who have a diagnosis of optic neuritis, without a diagnosis of MS or NMOSD.
62190576|NCT04131764||ON and multiple sclerosis|Patients who have a diagnosis of optic neuritis AND multiple sclerosis.
62190577|NCT04131764||ON and NMOSD|Patients who have a diagnosis of optic neuritis and neuromyelitis optica spectrum disorder.
62190578|NCT02607787|EXPERIMENTAL|Exercise Group|As well as usual care, this group receive a behavioural change session and intervention information regarding the exercise programme. The home-based walking and strengthening intervention is individually tailored for each participant. They receive a booklet, diary and pedometer to guide them as well as weekly phone calls for 12 weeks to monitor their progress.
62190579|NCT02607787|OTHER|Control Group|This group attends and participates in the same assessment outcomes as the intervention group and receives usual care for the duration of the study. However they are not given any exercise instructions and do not receive the intervention information until their final assessment at week 24. They are aware of their group allocation throughout the duration of the study.
62780008|NCT02220712|EXPERIMENTAL|Drug: OPC-14597 IMD|
62190580|NCT05021445|EXPERIMENTAL|plates based exercise|This will consists of 12 elderly participants who receive intervention protocol of Plates- based exercises program in which total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
62780009|NCT06312319|EXPERIMENTAL|Respiratory training added to orofacial exercises|Home-based respiratory training of the inspiratory and expiratory muscles using a device added to standard treatment including orofacial exercises.
62780010|NCT06312319|ACTIVE_COMPARATOR|Orofacial exercises|Standard treatment including orofacial exercises.
62780011|NCT05651815|EXPERIMENTAL|Graphene adjuvant therapy combined with conventional therapy group (treatment group)|Graphene adjuvant therapy combined with conventional therapy group (treatment group)：Contrasted to the control groups, the treatment groups will undergo 30-min of graphene adjuvant therapy every day for 7 d.
62780012|NCT05651815|NO_INTERVENTION|Conventional therapy group (control group)|Conventional therapy group (control group)：Patients will only receive the conventional treatment for COVID-19.
62780013|NCT01940536|ACTIVE_COMPARATOR|Tranexamic Acid|1g tranexamic acid, intravenous, at time of sudy enrollment and again a surgical incision
62780014|NCT01940536|PLACEBO_COMPARATOR|Placebo Injection|Placebo injection (normal saline) a time of study enrollment and again at time of surgical incision
62190581|NCT05021445|ACTIVE_COMPARATOR|conventional treatment|this will consists of 12 elderly participants who will receive intervention protocol of Conventional balance training exercises in which total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
62190582|NCT00490698|EXPERIMENTAL|Zoledronate + Atorvastatin|Zoledronate 4 mg intravenous (IV) once every 4 Weeks + Atorvastatin 20 mg orally (PO) daily
62190583|NCT04127071|ACTIVE_COMPARATOR|Surgical I&D Procedure|The abscess cavity will be evaluated thoroughly with ultrasonography. The site will be prepared and draped. The skin surface will be infiltrated with local anesthetic with a 25-gauge needle. The treating clinician may provide ultrasound-guided regional anesthesia for procedural analgesia at their discretion. Incision of the skin surface with a number 11-blade scalpel will be performed over the largest area of infection; the incision will be extended into the abscess cavity. A blunt instrument will then be used to break up internal loculations if present. Repeated instrumentation through the initial incision or extension of the original incision will be performed if needed. Lastly, iodoform packing will be inserted through the incision into the cavity. The decision to send the abscess contents for microbiological culture and susceptibility analysis will be at the discretion of the treating clinician.
62190584|NCT04127071|EXPERIMENTAL|Ultrasound-guided Needle Aspiration Procedure|The abscess cavity will be evaluated thoroughly with US. The site will be prepared and draped. The skin surface and anticipated needle track will be infiltrated with local anesthetic with a 25g needle. The treating clinician may provide ultrasound-guided regional anesthesia for procedural analgesia at their discretion. Under direct US-guided visualization, a 14g 2in steel needle attached to a 40mL syringe will be advanced into the abscess cavity with manual negative pressure. The needle tract will be extended obliquely 2-3 cm between the skin and abscess to prevent fistulization. Purulent material will be aspirated until no further purulence can be aspirated. Multiple aspiration attempts on the initial visit will be permitted to maximally drain the abscess cavity. Additionally, irrigation of the abscess cavity with sterile saline will be permitted to break up internal loculations if present, as has reported previously for trunk and breast abscesses.
62190585|NCT02145169|EXPERIMENTAL|Nitrous Oxide arm|Patients will receive a 50/50 mixture of Oxygen and Nitrous oxide via non breather mask
62190586|NCT02287233|EXPERIMENTAL|Phase 1: 600 mg Venetoclax + LDAC|"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 50 mg (Day 2) and increased up to 600 mg by Day 6. Beginning with Cycle 2, 600 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received low-dose cytarabine (LDAC; 20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.~Participants could continue receiving treatment until disease progression or until discontinuation criteria were met."
62410036|NCT06516653|EXPERIMENTAL|End to side fistula supported with VasQ|Patients receiving an end to side arteriovenous fistula, supported by VasQ, for fistula access
62410037|NCT06516653|ACTIVE_COMPARATOR|Standard of care end to side fistula|Patients receiving an end to side arteriovenous fistula, for fistula access
62410038|NCT03541356|PLACEBO_COMPARATOR|Placebo|
62410039|NCT03541356|ACTIVE_COMPARATOR|L-dopa 35 mg|
62572108|NCT02682693|EXPERIMENTAL|nab-Paclitaxel weekly|nab-Paclitaxel weekly for 12 weeks. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab. Patients with triple-negative tumors receive Carboplatin in parallel to nab-paclitaxel.
62780015|NCT04405076|EXPERIMENTAL|mRNA-1273: Dose 50 microgram (ug) - Participants Aged 18-54 years|"Part A: Participants aged 18-54 years will receive 1 intramuscular (IM) injection of 50 ug mRNA-1273 on Day 1 and on Day 29.~Part B: Participants aged 18-54 years who choose to be unblinded and received 50 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1."
62780016|NCT04405076|EXPERIMENTAL|mRNA-1273: Dose 50 ug - Participants Aged 55+ years|"Part A: Participants aged 55+ years will receive 1 IM injection of 50 ug mRNA-1273 on Day 1 and on Day 29.~Part B: Participants aged 55+ years who choose to be unblinded and received 50 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1."
62780017|NCT04405076|EXPERIMENTAL|mRNA-1273: Dose 100 ug - Participants Aged 18-54 years|"Part A: Participants aged 18-54 years will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29.~Part B: Participants aged 18-54 years who choose to be unblinded and received 100 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1."
62780018|NCT04405076|EXPERIMENTAL|mRNA-1273: Dose 100 ug - Participants Aged 55+ years|"Part A: Participants aged 55+ years will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29.~Part B: Participants aged 55+ years who choose to be unblinded and received 100 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1."
62572109|NCT02682693|EXPERIMENTAL|nab-paclitaxel 2 of 3 weeks|nab-Paclitaxel day 1,8 q22 for 12 weeks. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab. Patients with triple-negative tumors receive Carboplatin weekly in parallel to nab-paclitaxel.
62572110|NCT02682693|EXPERIMENTAL|EC every two weeks or every three weeks|Epirubicin and Cyclophosphamide 600mg/m² for 4 times. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab.
62572111|NCT06485050|EXPERIMENTAL|Photodynamic therapy with ciclopirox 8%|
62572112|NCT02170974|EXPERIMENTAL|BIBR 1048 MS polymorph II|
62572113|NCT02170974|ACTIVE_COMPARATOR|BIBR 1048 MS polymorph I|
62572114|NCT01489436|ACTIVE_COMPARATOR|Single port cholecystectomy|In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary; this device is placed percutaneously without the need for a trocar. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port, adequate hemostasis is ensured, the umbilical trocar removed, and the single operative site will be closed and sterile dressings applied (four Band-Aids).
62572115|NCT01489436|ACTIVE_COMPARATOR|Four-port laparoscopic cholecystectomy|The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder. Trocar sites will be closed and sterile dressings applied (four Band-Aids).
62572116|NCT05753020|EXPERIMENTAL|CKM Jumpstart Tool|Receives intervention
62572117|NCT05753020|NO_INTERVENTION|Control|Does not receive intervention
62572118|NCT06067906|PLACEBO_COMPARATOR|control group|
62572119|NCT06067906|EXPERIMENTAL|innovative group|
62572120|NCT05747326|EXPERIMENTAL|Study group|The eligible patients were enrolled to receive oral metronomic vinorelbine 40 mg on day 1, day 3, day 5 every week (Monday, Wednesday, and Friday) and capecitabine 500mg three times daily (tid) after meals every 3 weeks. Until disease progression or unacceptable toxicity occurred, or the patient refused medication, vinorelbine and capecitabine were administered continuously without drug-free periods over 21-day cycles.
62572121|NCT01690858||females with medical history of repeated foetal losses|The females can be pregnant
62572122|NCT01690858||females without medical history of repeated foetal losses|The females can be pregnant
62572123|NCT03194971||TTField at Recurrence|
62572124|NCT03194971||TTField at New Diagnosis|
62572125|NCT00904358||cross sectional area|internal jugular cross sectional area measured by ultrasound
62572126|NCT04305457|EXPERIMENTAL|Nitric Oxide inhalation|Nitric Oxide will be delivered through a non invasive CPAP system (with minimal pressure support to decrease discomfort due to the facial mask) or through a non-rebreathing mask system.
62780019|NCT04405076|PLACEBO_COMPARATOR|Placebo (Part A) and mRNA-1273 100 ug (Part B) - Participants Aged 18-54 years|"Part A: Participants aged 18-54 years will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29.~Part B: Participants aged 18-54 who choose to be unblinded and received mRNA-1273-matching placebo during Part A, will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and Day 29."
62780020|NCT04405076|PLACEBO_COMPARATOR|Placebo (Part A) and mRNA-1273 100 ug (Part B) - Participants Aged 55+ years|"Part A: Participants aged 55+ years will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29.~Part B: Participants aged 55+ years who choose to be unblinded and received mRNA-1273-matching placebo during Part A, will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and Day 29."
62780021|NCT04405076|EXPERIMENTAL|mRNA 1273.351 20 ug (Part C)|Part C: Participants will receive 1 IM booster dose of 20 ug of mRNA 1273.351 on Day 1.
62572127|NCT04305457|NO_INTERVENTION|Control|Patients assigned to the control group will not receive any gas therapy.
62572128|NCT04305457|EXPERIMENTAL|Nitric Oxide Inhalation (Non-Randomized)|All subjects part of this arm will receive nitric oxide gas either as an inpatient or outpatient. Nitric Oxide will be delivered through a non invasive CPAP system (with minimal pressure support to decrease discomfort due to the facial mask) or through a non-rebreathing mask system. Patients in this arm will not be randomized, so that all patients receive the study medication.
62780022|NCT04405076|EXPERIMENTAL|mRNA 1273.351 50 ug (Part C)|Part C: Participants will receive 1 IM booster dose of 50 ug of mRNA 1273.351 on Day 1.
62780023|NCT04405076|EXPERIMENTAL|mRNA-1273/mRNA-1273.351 mixture (Part C)|Part C: Participants will receive 1 IM booster dose of 50 ug of mRNA-1273/mRNA-1273.351 mixture on Day 1.
62190587|NCT02287233|EXPERIMENTAL|Phase 1: 800 mg Venetoclax + LDAC|"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 100 mg (Day 2) and increased up to 800 mg by Day 6. Beginning with Cycle 2, 800 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received LDAC (20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.~Participants could continue receiving treatment until disease progression or until discontinuation criteria were met."
62410040|NCT03541356|ACTIVE_COMPARATOR|L-dopa 70 mg|
62780024|NCT01541449||RA patients treated with plaquenil|
62410041|NCT03541356|ACTIVE_COMPARATOR|L-dopa 140 mg|
62780025|NCT01541449||Patients who do not use plaquenil|
62780026|NCT05330091||Healthy Women|Once Daily Women's Probiotic Placebo
62780027|NCT06395259||Hypovitaminosis Group|Patients who at the end of surgery have sub-optimal plasma ascorbic acid levels, i.e. with concentrations lower than 28 µmol/L
62780028|NCT06395259||Normal Range Group|Patients who at the end of surgery have plasma ascorbic acid levels equal to or greater than 28 µmol/L
62780029|NCT01297725|EXPERIMENTAL|Right sharp, left blunt|Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
62780030|NCT01297725|EXPERIMENTAL|Right blunt, left sharp|Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.
62780031|NCT00986362|EXPERIMENTAL|Ocriplasmin|
62780032|NCT00986362|PLACEBO_COMPARATOR|Placebo|
62572129|NCT03793114|EXPERIMENTAL|Detectable levels of adrenal hormones|Patients with detectable serum levels of adrenal hormones will go through cosyntropin stimulation testing.
62572130|NCT03793114|ACTIVE_COMPARATOR|Controls with undetectable hormone levels|Twenty patients without detectable serum levels of adrenal hormones will serve as controls in cosyntropin stimulation testing.
62572131|NCT03793114|NO_INTERVENTION|Undetectable levels of adrenal hormones|Patients without detectable serum levels of adrenal hormones. Cosyntropin stimulation testing will not be performed.
62572132|NCT03793114|OTHER|Congenital adrenal hyperplasia (CAH) control group|Mapping adrenal steroid profile in patients with congenital adrenal hyperplasia (CAH) with confirmed total deficiency of 21-hydroxylase.
62004854|NCT01345084|EXPERIMENTAL|Radiation therapy, cisplatin and nimotuzumab|"Nimotuzumab - (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes. Pre-drugs are optional, at the investigator's discretion)- 200 mg, IV, weekly doses during the radiation therapy until completing 6 months.~Radiation therapy- 66 -70 Gy, external,fractions of 2 Gy per day, 5 days a week~Cisplatin - 75 mg/m2, IV, Doses every 3 weeks (a total of three doses)"
62396697|NCT03793517|EXPERIMENTAL|Decitabine plus mBU/CY for HLA-mismatched HSCT|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD at the time of HLA-mismatched HSCT.~Details:~The conditioning therapy for human eukocyte antigen (HLA)-mismatched HSCT patients was decitabine plus modified BU/CY and ATG,consisting of decitabine 100mg·m-2·d-1 q12h on days-12 and -11,cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, simustine (Me-CCNU, 250 mg/m2), orally once on day -3, and ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2."
62396698|NCT03793517|EXPERIMENTAL|Decitabine plus mBU/CY for matched sibling transplant|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD at the time of matched sibling transplant.~Details:~In matched sibling transplantations, patients received decitabine 100mg·m-2·d-1 q12h on days-12 and -11,hydroxycarbamide (80 mg/kg) orally on day -10 and a lower dose of Ara-C (2 g·m-2·d-1) on day -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, simustine (Me-CCNU, 250 mg/m2), orally once on day -3."
62396699|NCT05237804|NO_INTERVENTION|Control group|The randomized centres in this group will not change their practices.
62780033|NCT02371031|EXPERIMENTAL|Arm 1: FDOPA-PET/MRI|"* Patients with known or suspected brain gliomas that are non-enhancing or have substantial non-enhancing regions will undergo FDOPA-PET/MRI within 2 weeks prior to planned standard of care surgical resection and/or stereotactic biopsy. In the same planning session, the MRI alone will be reviewed and then the FDOPA-PET data will be added to the planning.~* In the event that a patient cannot undergo MRI or PET/MRI is not available (e.g. due to maintenance), FDOPA-PET/CT can be performed instead at the discretion of the responsible physician.~* When feasible and at the discretion of the neurosurgeon performing the resection, areas of suspected tumor identified on the FDOPA-PET/MRI study but not the MRI alone will undergo tissue sampling."
62780034|NCT04735146|EXPERIMENTAL|Experimental Group|The Experimental Group will be involved in 1 weekly session of adapted physical activity lasting 1 hour for 6 weeks within the normal cycle of accompanying birth meetings provided by the University Hospital of Bologna.
62396700|NCT05237804|EXPERIMENTAL|Patient component|"The randomized centres in this group will be required to present patients with:~* A short introductory video, viewed on a tablet during hospitalization for coronary angiography,~* A paper booklet,~* A website."
62396701|NCT05237804|EXPERIMENTAL|Organisational component|The randomized centres in this group will be provided with a list of organisational changes to be implemented to improve patient care times.
62396702|NCT05237804|EXPERIMENTAL|Patient and organisational components|The randomized centres in this group will have to implement the two components.
62396703|NCT03127072|EXPERIMENTAL|Arm A|RFA plus chemotherapy ± target therapy
62572133|NCT03793114|OTHER|Bilaterally adrenalectomized control group|Mapping adrenal steroid profile in patients who are bilaterally adrenalectomized.
62572134|NCT03793114|EXPERIMENTAL|Diurnal variation in residual adrenocortical hormone levels|Patients with detectable serum levels of adrenal hormones will go through a 30-hour ambulatory sampling of interstitial fluid for mapping of any diurnal variation in endogenous adrenocortical secretion.
62572135|NCT03793114|EXPERIMENTAL|Repeated cosyntropin testing in newly diagnosed patients|Newly diagnosed patients will be invited to go through repeated cosyntropin testing to delineate the natural progression of adrenocortical failure.
62572136|NCT03793114|ACTIVE_COMPARATOR|Cardiovascular and inflammatory biomarkers|Compare cardiovascular and inflammatory biomarker profiles in patients with and without residual production of adrenocortical steroids
62190588|NCT02287233|EXPERIMENTAL|Phase 2: 600 mg Venetoclax + LDAC|"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 50 mg, and increased up to 600 mg by Day 6. Beginning with Cycle 2, 600 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received LDAC (20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.~Participants could continue receiving treatment until disease progression or until discontinuation criteria were met."
62190589|NCT00370370|ACTIVE_COMPARATOR|1|Injection of intravitreal bevacizumab
62190590|NCT00370370|ACTIVE_COMPARATOR|2|Injection of bevacizumab + triamcinolone acetonide
62780035|NCT04735146|NO_INTERVENTION|Control Group|The control group is expected to participate in 6 birth accompaniment meetings held online, 1 hour of which will be dedicated to the topic of exercise and physical activity recommendations in pregnancy.
62780036|NCT02922179||Diabetes Type 1|Individuals diagnosed with type 1 diabetes exposed to Long- and intermediate- acting insulins
62780037|NCT02922179||Diabetes Type 2|Individuals diagnosed with type 2 diabetes exposed to Long- and intermediate- acting insulins
62780038|NCT00180011|EXPERIMENTAL|omaluzimab|
62190591|NCT05470270|EXPERIMENTAL|New formulation of hydroxycarbamide|Single arm study with a single administration of hydroxycarbamide
62190592|NCT04714398|EXPERIMENTAL|Opt-In Recruitment|All recruitment messaging will be framed for patients as they must opt-in to participate in the remote monitoring program.
62396704|NCT03127072|ACTIVE_COMPARATOR|Arm B|chemotherapy ± target therapy
62780039|NCT03383380|EXPERIMENTAL|Rapamycin|Treatment for patients with activated phosphoinositide 3-kinase δ syndrome
62780040|NCT01900808||Patients with chronic liver disease|
62396705|NCT01636102|EXPERIMENTAL|Arm 1|
62396706|NCT04606797|EXPERIMENTAL|Nicotine Replacement Therapy|
62396707|NCT04606797|NO_INTERVENTION|Control|
62396708|NCT06326203|EXPERIMENTAL|EMBRYONIC STEM CELLS|Cellular Therapy Treatment: The treatment will consist of \*\*20 participants (n=20) who will receive treatment with expanded mesenchymal stem cells (MSCs). The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive MSC application via perilesional injections and a biocovering produced by the study team, also containing the same cells (single session - the MSC-containing dressing will remain in contact with the ulcer for 7 days). After removal of the biological dressing, the ulcer will receive local care with a topical hydrogel dressing, dry gauze, and a crepe bandage, with a minimum of one change per day.
62396709|NCT06326203|ACTIVE_COMPARATOR|CONVENTIONAL DRESSING (Control Group)|The control group will consist of 20 participants (n=20) who will receive local care for the ulcer. The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive the application of a conventional dressing with Hydrogel, dry gauze, and a crepe bandage. The patient will be instructed to change the dressing at least once a day.
62572137|NCT00927862|ACTIVE_COMPARATOR|Standard IWPC warfarin dosing algorithm|Standard International Warfarin Pharmacogenetics Consortium (IWPC) warfarin dosing algorithm.
62572138|NCT00927862|EXPERIMENTAL|Modified IWPC warfarin dosing algorithm|Modified International Warfarin Pharmacogenetics Consortium (IWPC) warfarin dosing algorithm
62780041|NCT02335593|EXPERIMENTAL|Zinc group|Zinc Sulphate Hard Gel Capsules 110 mg once daily for three months plus Epoetin alfa 2000-4000 IU solution for injection andIron Hydroxide Saccharate Complex Solution for injection.
62780042|NCT02335593|ACTIVE_COMPARATOR|Placebo group|Corn starch filled Hard Gel capsules once daily plus 'Epoetin alfa 2000-4000 IU solution for injection and Iron Hydroxide Saccharate Complex Solution for injection.
62780043|NCT03410121|OTHER|Standard 1 : Thoracic location|The intervention is characterized by the randomization into thoracic arm which means that patients will have an implantable Venous Access Device implanted into thoracic location
62780044|NCT03410121|OTHER|Standard 2 : Humeral location|The intervention is characterized by the randomization into humeral arm which means that patients will have an implantable Venous Access Device implanted into humeral location
62780045|NCT01844778|ACTIVE_COMPARATOR|TIS/TIP|During the first cycle of treatment, participants received nebulized TIS, 300 mg twice per day for 28 days followed by 28 days off-treatment. During the second cycle, participants received 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
62780046|NCT01844778|ACTIVE_COMPARATOR|COLI/TIP|During the first cycle, participants received nebulized COLI, 1 million or 2 million units twice or thrice per day (or the participant's usual dose and regimen) for 56 days (no off-treatment period) or 28 days on-treatment followed by 28 days off-treatment (cycling regimen), depending on local treatment guidelines. During the second cycle, participants received TIP, 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
62780047|NCT01844778|ACTIVE_COMPARATOR|TIP/TIP|During the first and second cycles, participants received TIP, 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
62780048|NCT04915417|EXPERIMENTAL|Resectable Pancreatic Ductal Adenocarcinoma (PDAC)|10 Resectable PDAC patients will receive a hybrid PET/MRI before SABR and DCE-CT before SABR, 6 hours after the first SABR fraction, and 4 weeks after the last fraction of SABR (before surgery)
62780049|NCT04915417|EXPERIMENTAL|Borderline Resectable Pancreatic Ductal Adenocarcinoma (PDAC)|20 Borderline Resectable PDAC patients will receive a DCE-CT scan prior to neoadjuvant chemotherapy, a PET/MRI and DCE-CT after neoadjuvant chemotherapy and before SABR, DCE-CT at 6 hours after the first SABR fraction, and 4 weeks after the last fraction of SABR (before surgery)
62190593|NCT04714398|EXPERIMENTAL|Opt-Out|All recruitment messaging will be framed as though participation is the default, and patients must opt-out of participating in the remote monitoring program.
62190594|NCT04714398|NO_INTERVENTION|Usual Care|Patients in the usual care arm will not be contacted by study staff, they will not receive a blood pressure cuff, and they will not be asked to participate in any component of the blood pressure monitoring program.
62190595|NCT03157245||participant|
62190596|NCT03097406||Osteoarthritis group|Patients with osteoarthritis (2017-2019) at Herlev Hospital treated with Global Unite total shoulder arthroplasty
62396710|NCT06001177|EXPERIMENTAL|Group 1|All eligible participants will receive 3 intravenous (IV) infusions of KAN-101
62004855|NCT01345084|ACTIVE_COMPARATOR|Radiation therapy and cisplatin|"Radiation therapy: 66- 70 Gy, fractions of 2 Gy per day, 5 days a week~Cisplatin:75 mg/m2, IV, doses every 3 weeks (a total of three doses)"
62004856|NCT02298738||New onset Atrial fibrillation|New-onset AF was defined as patients with hypertension and atrial fibrillation which was identified for the first time by an electrocardiogram or ambulatory holter monitoring.
62004857|NCT02298738||control|Hypertensive patients without atrial fibrillation.
62004858|NCT06114862|NO_INTERVENTION|Control|Of the individuals identified in the screener survey endorsing past year mental health symptoms, half will be randomized into the control group. The control group will not be contacted. The investigators will passively monitor their posts on RallyPoint for the duration of the study (6 months).
62004859|NCT06114862|EXPERIMENTAL|Intervention|Of the individuals identified in the screener survey endorsing past year mental health symptoms, half will be randomized into the intervention group. Participants in the intervention group will be recruited using a banner or pop-up message on their RallyPoint homepage or through a message on the RallyPoint site which will ask them if they have time to answer a few questions about their experiences on the RallyPoint site. If participants decline to answer these questions, a message will appear stating that they will be contacted again later, and the investigators will wait several days before contacting the potential participant again. After three attempts, participants will not be re-contacted. Participants' posts on RallyPoint will be passively monitored for 6 months after completing the intervention.
62004860|NCT00723606|EXPERIMENTAL|Intramuscular ziprasidone|
62004861|NCT00723606|ACTIVE_COMPARATOR|Intramuscular haloperidol|
62004862|NCT03240575|EXPERIMENTAL|Tiotropium + Olodaterol fixed dose combination|
62190597|NCT03097406||Osteoarthritis control group|Patients with osteoarthritis (2013-2016) at Herlev Hospital treated with a Global Advantage
62190598|NCT03097406||Fracture group|Patients with a fracture of the proximal humerus (2017-2019) at Køge and Herlev Hospital treated with Global Unite hemiarthroplasty
62396711|NCT06001177|PLACEBO_COMPARATOR|Group 2|All eligible participants will receive 3 intravenous (IV) infusions of placebo
62780050|NCT03265782|EXPERIMENTAL|ibuprofen group|treatment of pda with oral ibuprofen with a loading dose 10 mg/kg/ds in the first day followed by 5 mg/kg/ds in the second ant third days then a follow up echo is done
62004863|NCT03240575|ACTIVE_COMPARATOR|Fluticasone propionate + Salmeterol fixed dose combination|
62004864|NCT02517905|EXPERIMENTAL|EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration
62004865|NCT02517905|PLACEBO_COMPARATOR|Placebo|10 mL normal saline injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration
62190599|NCT03097406||Fracture control group|Patients with a fracture of the proximal humerus (2013-2016) at Køge and Herlev Hospital treated with Global FX hemiarthroplasty
62396712|NCT06525337|EXPERIMENTAL|STANDARDCARE (STAND) group|Participants will download the Apnimed App for daily sleep ring data collection, using it nightly and syncing data each morning. They will receive weekly video health coaching sessions for 6 weeks, focusing on sleep, nutrition, and CPAP adherence. Surveys will be completed at baseline, 6 weeks, and 3 months.
62396713|NCT06525337|EXPERIMENTAL|CONTROL (CON) group|Participants in this group will receive no device and no health coaching.
62780051|NCT03265782|EXPERIMENTAL|paracetamol group|treatment of pda with oral paracetamol with dose of 15 mg/kg/ds every 6 hours for 3 days then a follow up echo is done
62190600|NCT02754193|EXPERIMENTAL|Moderate hypothermia|Moderate hypothermia :Patients with cardiogenic shock treated with arteriovenous ECMO to a strategy of moderate hypothermia during 24 hours (Temperature at 33°C≤ T°C ≤34°C) associated with usual care
62190601|NCT02754193|NO_INTERVENTION|Normothermia|Normothermia: Patients with cardiogenic shock treated with arteriovenous ECMO to a strategy of normothermia (36°C≤ T°C ≤37°C) associated with usual care
62190602|NCT06171035|ACTIVE_COMPARATOR|Traditional model group|Received a regular learning
62190603|NCT06171035|EXPERIMENTAL|3D-printed high-fidelity craniofacial manikin model presention group|Received a regular learning plus 3D printing model
62190604|NCT05921097||T1DM|People with type 1 diabetes
62396714|NCT03503617|EXPERIMENTAL|RehabTouch Exercise Program|Participants will perform targetted movement exercises by interacting with the RehabTouch pucks, as described and monitored on a computer. Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks.
62780052|NCT03478735|EXPERIMENTAL|Ultrasound Guided GON Block at C2|Ultrasound Guided Greater Occipital Nerve Block at C2
62780053|NCT03478735|ACTIVE_COMPARATOR|Landmark based GON Block|Landmark-Based Greater Occipital Nerve Block
62780054|NCT01996085|EXPERIMENTAL|Hemodynamic group|"The treatment choice based on hemodynamic parameters established with ICG method.~Monotherapy or combined therapy in case of 1/ complex hemodynamic disturbances and/or 2/ office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg"
62780055|NCT01996085|ACTIVE_COMPARATOR|Empiric Group|"The treatment choice based on current guidelines (blinded to ICG).~Monotherapy or combined therapy in case of office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg"
62780056|NCT03025243|EXPERIMENTAL|50 micron|surgical guide constructed with 3D printing with printing layer thickness 50 micron
62780057|NCT03025243|ACTIVE_COMPARATOR|100 micron|surgical guide constructed with 3D printing with printing layer thickness 100 micron
62004866|NCT03337633|ACTIVE_COMPARATOR|Experiment 1 Easy|"For the first experiment, subjects in this arm received the easy menu during the protocol."
62004867|NCT03337633|ACTIVE_COMPARATOR|Experiment 1 Hard|"For the first experiment, subjects in this arm received the hard menu during the protocol."
62004868|NCT03337633|ACTIVE_COMPARATOR|Experiment 2 Easy|"For the second experiment, subjects in this arm, who qualified as restrained eaters and were asked to fast for 8 hours overnight, received the easy menu during the protocol."
62004869|NCT03337633|ACTIVE_COMPARATOR|Experiment 2 Hard|"For the second experiment, subjects in this arm, who qualified as restrained eaters and were asked to fast for 8 hours overnight, received the hard menu during the protocol."
62004870|NCT00013130|OTHER|Arm 1|
62004871|NCT02111252|EXPERIMENTAL|TAK-850 0.5 mL|A single dose of 0.5 mL TAK-850 (15 µg of hemagglutinin \[HA\] antigen per strain) is injected into the deltoid muscle.
62004872|NCT05862025|OTHER|Echocardiography intervention|"Patients will undergo mandatory transthoracic echocardiography during assessment of Staphylococcus aureus bacteremia.~Later, they will also undergo mandatory transesophageal echocardiography.~Both test will be performed during the first 14 days from bacteremia onset."
62004873|NCT01856543|PLACEBO_COMPARATOR|Eucerin|Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve application of the cream. Patients will be instructed to apply cream to the upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner quadrant, as well as irradiated nodal fields. They will be instructed to apply cream in a thin, uniform layer twice a day, in the morning and evening, and not within the immediate 4 hours prior to radiation treatment. Patients will be informed that application immediately following radiation treatment is acceptable for those scheduled to receive morning treatments. Patients will be provided diaries to record the date and time they applied the study cream. Pts should return the completed diaries on their weekly status checks and at the 2 weeks +/- 2 business days following the completion of RT.
62190605|NCT03602586|EXPERIMENTAL|Treatment (epacadostat, pembrolizumab)|Patients receive epacadostat PO BID and pembrolizumab IV over 30 minutes Q3W. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62780058|NCT03160885|EXPERIMENTAL|Initial treatment period - Tralokinumab Q2W|"Week 0 to Week 16~Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks"
62190606|NCT00976690|ACTIVE_COMPARATOR|1|Azathioprine : 2mg/kg/day
62190607|NCT00976690|ACTIVE_COMPARATOR|2|Mesalazine : 4g/day
62190608|NCT04576845||Study Group|The study will be performed on Caucasian origin children who are among 2 to 6 years of age. The study group will be composed of children (n=31) who had CMA (Ig E-mediated and/or non-Ig E-mediated and/or mixed type) proved with oral food challenge tests in their early childhood (in ages of 0-2). The inclusion criteria to the study group will be to undergo a Cow's milk elimination (CME) diet or took a hypoallergenic formula in 0-2 years of age for at least 3 months or longer due to CMA allergy and improved afterward, and/or to eliminate other nutrients (e.g., eggs, potatoes, wheat flour, soybean, etc.) other than cow's milk between the ages of 0-2 for at least 3 months or longer, and/or to add these nutrients back to their diet in the last 3 months, and/or not receiving hypoallergenic formula for the last 3 months, not to be on the CME diet at present. Thus, no children in the study and control groups will be on a dietary restriction during the study.
62190609|NCT05407077||females with isolated patellofemoral arthritis|those with anterior knee pain
62780059|NCT03160885|PLACEBO_COMPARATOR|Initial treatment period - Placebo|"Week 0 to Week 16 (Initial treatment period):~Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks"
62780060|NCT03160885|EXPERIMENTAL|Maintenance treatment period - Tralokinumab Q2W|"Week 16 to Week 52~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks"
62780061|NCT03160885|EXPERIMENTAL|Maintenance treatment period - Tralokinumab Q4W|"Week 16 to Week 52~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.~Participants in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks"
62780062|NCT03160885|PLACEBO_COMPARATOR|Maintenance treatment period - Placebo|"Week 16 to Week 52~Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks"
62780063|NCT03160885|PLACEBO_COMPARATOR|Maintenance treatment period - Placebo (tralokinumab naive)|"Week 16 to Week 52~Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks"
62190610|NCT05407077||healthy females|those without anterior knee pain
62190611|NCT06378697|EXPERIMENTAL|AK111|AK111 150 mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week 48.
62190612|NCT06378697|PLACEBO_COMPARATOR|placebo|Placebo+AK111 placebo subcutaneous injection at week 0,1, 4,8 and 12 follow AK111 4-weekly thereafter until week 48.
62190613|NCT03302390||Biopsy of Skin with Psoriasis|Shave biopsy of psoriasis lesion
62190614|NCT00534053|EXPERIMENTAL|1|400 patients will be given a mailed educational reminder 10 days after picking up their FOBT cards from the VA laboratory.
62190615|NCT00534053|NO_INTERVENTION|2|400 patients will not receive a mailed educational reminder to return their FOBT cards after they have picked up the FOBT cards from the VA laboratory
62004874|NCT01856543|EXPERIMENTAL|Mometasone Furoate 0.1%|Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve application of the cream. Patients will be instructed to apply cream to the upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner quadrant, as well as irradiated nodal fields. They will be instructed to apply cream in a thin, uniform layer twice a day, in the morning and evening, and not within the immediate 4 hours prior to radiation treatment. Patients will be informed that application immediately following radiation treatment is acceptable for those scheduled to receive morning treatments. Patients will be provided diaries to record the date and time they applied the study cream. Patients should return the completed diaries on their weekly status checks and at the 2 weeks +/- 2 business days following the completion of RT.
62004875|NCT02006238|EXPERIMENTAL|Farabloc|The participants will sleep on Farabloc fabric nightly for a week.
62190616|NCT00718471|EXPERIMENTAL|1|Enoxaparin
62572139|NCT00927862|OTHER|Historical controls|The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records database of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic (PG)-guided cohorts (July 2008 through December 2010). Patients ≥18 years old initiating warfarin therapy with a baseline and at least 1 follow-up international normalized prothrombin time ratio (INR) level between days 3-14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG based.
62004876|NCT02006238|PLACEBO_COMPARATOR|Nylon Fabric|The participants will sleep on Nylon fabric nightly for week.
62190617|NCT00718471|ACTIVE_COMPARATOR|2|UFH
62190618|NCT04692467|EXPERIMENTAL|Intervention (Early hypertension)|Participants randomized to the early HTN treatment arm will initiate 5mg daily of amlodipine immediately, increasing to 10 mg if SBP \>130 mmHg after 1 month.
62190619|NCT04692467|NO_INTERVENTION|Standard of Care|Participants randomized to the SOC arm will not be initiated on any medications initially. They may be initiated on amlodipine only if they develop HTN (SBP ≥140 or DBP ≥90 mm Hg).
62190620|NCT01199978|OTHER|Fractionated Proton Radiation|Single arm study, delivering fractionated radiation with a technique (proton therapy) that may be associated with reduced side effects
62190621|NCT00853372|EXPERIMENTAL|Trebananib 10 mg/kg + Sunitinib|Trebananib 10 mg/kg intravenously (IV) once weekly (QW) plus sunitinib 50 mg orally (PO) once daily (QD) 4 weeks on/2 weeks off
62190622|NCT00853372|EXPERIMENTAL|Trebananib 15 mg/kg + Sunitinib|Trebananib 15 mg/kg IV QW plus sunitinib 50 mg PO QD 4 weeks on/2 weeks off
62190623|NCT04430166|EXPERIMENTAL|PD-1 monoclonal antibody|
62190624|NCT03469726|OTHER|Patients with (suspected) PDAC|"Patients with (suspected) pancreatic cancer will undergo additional Contrast-enhanced Diffusion-weighted MRI (CE-DW-MRI) within two weeks from the CECT.~Suspected liver lesions on CECT and/or CE-DW-MRI will be biopsied to obtain histopathology as reference standard. For liver lesions without histopathologic proof of metastases a paired follow-up CECT and CE-DW-MRI serve as a composite reference standard. Follow up CECT and CE-DW-MRI will be performed in all patients at 3, 6, and 12 months."
62190625|NCT06066151|EXPERIMENTAL|Minayo Yeast Drink Product|"Minayo Iron-rich Yeast Drink with SOD, 385 pieces, 25ml/piece, each piece contains 13mg of iron.~Main ingredients: Water, erythritol, jujube juice concentrate, Wolfberry juice concentrate, ferrous gluconate, olive powder, SOD yeast powder, yeast extract (including glutathione), artichoke, etc."
62190626|NCT06292390|EXPERIMENTAL|Intervention Group|Pet therapy was applied to the individuals in the intervention group for 6 weeks in addition to their normal routine lives. This therapy was applied every 20 minutes, 2 days a week. Repeated measurements were made before therapy, at the end of therapy and 4 weeks after the end of therapy. The scales were collected by the questionnaire by face-to-face interview method.
62190627|NCT06292390|NO_INTERVENTION|Control Group|The elderly in this group have not been given any treatment, they have received routine nursing home care and necessary treatments if any. The first evaluation of the elderly in the control group, 6.week and 10.the necessary measurements were made with the scales three times a week in total. The scales were collected by the questionnaire by face-to-face interview method.
62190628|NCT01263249|ACTIVE_COMPARATOR|Catheter Anterior to Femoral Nerve|Each subject will have one lower extremity (Right or Left) randomized to receive a perinural catheter, placed anterior to the femoral nerve, with a continuous infusion of local anesthetic and then the outcomes will be measured.
62410042|NCT03541356|ACTIVE_COMPARATOR|L-dopa 70 mg/carbidopa 7 mg|
62780064|NCT03160885|EXPERIMENTAL|Open-label treatment - Tralokinumab 300 mg Q2W + optional TCS|"Week 16 to Week 52~Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered tralokinumab subcutaneous (SC) injection + optional TCS\* regimen Q2W~OR~Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS regimen Q2W~• TCS = topical corticosteroids"
62780065|NCT01575925|EXPERIMENTAL|4 mg Oral POM + 40 mg Oral DEX|Oral POM at 4 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle
62780066|NCT01575925|EXPERIMENTAL|2 mg Oral POM + 40 mg Oral DEX|Oral POM at 2 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle
62004877|NCT03357406|EXPERIMENTAL|edentulism side 1|ultrasound implant site preparation
62004878|NCT03357406|ACTIVE_COMPARATOR|edentulism side 2|conventional implant site preparation
62780067|NCT01881568|EXPERIMENTAL|Experimental|"1. Topical administration of 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride) as follow:~   * 50mL by irrigation before wound closure~  * 50mL by intraarticular administration (Drenofast) after wound closure.~2. Intravenous administration of Normal saline (0.9% sodium chloride) as follow:~   * 100mL before tourniquet realised~  * 100mL 3 hours after surgery"
62780068|NCT01881568|ACTIVE_COMPARATOR|Comparator|"1. Topical administration of Normal saline (0.9% sodium chloride) as follow:~   * 50mL by irrigation before wound closure~  * 50mL by intraarticular administration (Drenofast) after wound closure~2. Intravenous administration of two dosis of Tranexamic Acid as follow:~   * 15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), before tourniquet realised~  * 15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), 3 hours after surgery"
62004879|NCT03641573|EXPERIMENTAL|[14C] ASN002|\[14C\] ASN002
62190629|NCT01263249|ACTIVE_COMPARATOR|Catheter Posterior to Femoral Nerve|Each subject will have the opposite lower extremity (Right or Left) randomized to receive a perinural catheter, placed posterior to the femoral nerve, with a continuous infusion of local anesthetic and then the outcomes will be measured.
62190630|NCT02980523|EXPERIMENTAL|PRO-157 BID (2 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~1. instill one drop in each eye of PRO-157 (pazufloxacin), every 12 hours per day (BID), for 7 days~2. instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%)every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
62572140|NCT05034211|ACTIVE_COMPARATOR|Programmed intermittent Bolus Epidural technique|10ml ropivacaine 0,2% and 1,5 mcg/ml fentanyl, will be administered every 60 minutes via an epidural catheter placed for labor analgesia on L2-L3/L3-L4 level
62572141|NCT05034211|ACTIVE_COMPARATOR|Provider administered bolus epidural technique on patient request|10ml ropivacaine 0,2% and 1,5 mcg/ml fentanyl, will be administered by the provider on patient request
62004880|NCT04520945|ACTIVE_COMPARATOR|Active Participant of Phase 2B Clinical Study Chondrogen|50 participants will receive the investigational drug (Chondrogen and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.
62190631|NCT02980523|EXPERIMENTAL|PRO-157 TID (3 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~1. instill one drop in each eye of PRO-157 (pazufloxacin), every 8 hours per day (TID), for 7 days~2. 15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
62396715|NCT03503617|ACTIVE_COMPARATOR|Conventional tabletop exercise program|Conventional tabletop exercise program is a traditional exercise program described in a booklet similar to what is typical provided to stroke patients upon their discharge from the hospital. Participants will be asked to perform these exercises at least 3 hours per week for 3 consecutive weeks.
62572142|NCT06393309||Levetiracetam|Patients with idiopathic generalized epilepsy who were under treatment with levetiracetam
62572143|NCT06393309||Sodium valproate|Patients with idiopathic generalized epilepsy who were under treatment with valproate
62780069|NCT04496011|EXPERIMENTAL|Experimental Group|In this group the exercise program will be based on the protocol of Control Group, without the exception of walking training, adding aerobic capacity training using the bicycle ergometer, model CBL11 Classic® from ACT®.
62572144|NCT06578403|ACTIVE_COMPARATOR|control|minimally invasive non-surgical technique (MINST) in management of periodontitis stage III patients.
62572145|NCT06578403|EXPERIMENTAL|external intervention|minimally invasive non-surgical technique (MINST) with external microneedle (EMN) periodontitis stage III patients.
62190632|NCT02980523|EXPERIMENTAL|PRO-157 QID (4 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~1. instill one drop in each eye of PRO-157 (pazufloxacin), every 6 hours per day (QID), for 7 days~2. 15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
62396716|NCT06427577|EXPERIMENTAL|Allergic rhinitis|"ZhenQi FuZheng granules (ShiDaiYangGuang)~1 bag at a time, twice a day. Oral for 4 weeks."
62572146|NCT06578403|EXPERIMENTAL|internal intervention|minimally invasive non-surgical technique with an internal microneedle (IMN) on periodontitis stage III patients.
62572147|NCT02541513|EXPERIMENTAL|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for 3 days followed by an injection of Paliperidone 150 mg injection on Day 8
62572148|NCT06574750|EXPERIMENTAL|New HA filler (Curea)|The left/right assignment was sealed in a nontransparent envelop.
62572149|NCT06574750|ACTIVE_COMPARATOR|Juvederm|The left/right assignment was sealed in a nontransparent envelop.
62572150|NCT00175149|ACTIVE_COMPARATOR|1|Given alfacalcidiol. Dose adjusted after PTH level
62572151|NCT00175149|NO_INTERVENTION|2|The untreated arm
62572152|NCT03512054|EXPERIMENTAL|Experimental procedure|
62572153|NCT02840123|EXPERIMENTAL|Autologous dendritic cells|
62572154|NCT03355131|EXPERIMENTAL|Adapted NASA's Mission X program|Adapted NASA's Mission X program for the intervention group
62572155|NCT03355131|NO_INTERVENTION|Mission X Control|no intervention
62572156|NCT05390775|EXPERIMENTAL|Written Exposure Therapy|
62572157|NCT05390775|PLACEBO_COMPARATOR|Non-emotional Writing|
62572158|NCT02203227|PLACEBO_COMPARATOR|Placebo|Capsule containing 250 mg of placebo, two times a day
62572159|NCT02203227|EXPERIMENTAL|BioTurmin|Capsule containing 250 mg of BioTurmin (Curcuma longa rhizomes extract), two times a day
62572160|NCT02203227|EXPERIMENTAL|BioTurmin-WD|Capsule containing 250 mg of BioTurmin-WD (water dispersible curcuminoids), two times a day
62572161|NCT02203227|EXPERIMENTAL|MaQxan|Capsule containing 10 mg of MaQxan (Tagetes erecta flower extract), two times a day
62572162|NCT05832684|EXPERIMENTAL|Experimental|Dose escalation and expansion of ZVS101e. All patients enrolled in the study will receive a single subretinal injection of ZVS101e in one eye.
62004881|NCT04520945|PLACEBO_COMPARATOR|Placebo Participant of Phase 2B Clinical Study Chondrogen|50 participants will receive the placebo (Saline and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.
62004882|NCT03436368|ACTIVE_COMPARATOR|CSA group|Continuous Spinal Anesthesia
62004883|NCT03436368|ACTIVE_COMPARATOR|GA group|General Anesthesia
62004884|NCT04269603|OTHER|30 healthy adult volunteers|Healthy adult volunteers without hemorrhagic diathesis.
62190633|NCT02980523|ACTIVE_COMPARATOR|Moxifloxacin (Vigamox®)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~1. instill one drop in each eye of Moxifloxacin, every 8 hours per day, for 7 days.~2. 15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day for 7 days. (Can be applied 15 minutes after moxifloxacin)"
62190634|NCT02980523|ACTIVE_COMPARATOR|Gatifloxacin (Zymar®)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~1. instill one drop in each eye of Gatifloxacin, every 8 hours per day, for 7 days.~2. 15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day for 7 days.one drop 4 times a day for 7 days in each eye.(Can be applied 15 minutes after gatifloxacin)"
62190635|NCT02992847||Dotarem|At least 5 injection with Dotarem exclusively
62572163|NCT05772949|EXPERIMENTAL|Experimental group|The experimental group will use the smart hearing aid for 6 weeks.
62572164|NCT05772949|EXPERIMENTAL|Wait-list control group|The wait-list control group will follow existing practice (i.e. using no hearing aids or using hearing aids other than the smart hearing aids) for 6 weeks and then use the smart hearing aids for 6 weeks.
62572165|NCT05905315|ACTIVE_COMPARATOR|Primary chemoradiation|Patients included in the standard treatment arm will receive a combination of weekly cisplatin combined with 30 fractions of external beam radiotherapy on the primary tumour with a total dose of 64.5 Gy. Cisplatin will be given for six weeks intravenously with a dose of 40 mg/m2, if possible on the first day of the week. On day 1 until day 5 the patient will receive external beam radiotherapy. This will be repeated for a six-week period.
62572166|NCT05905315|EXPERIMENTAL|NACT (3-weekly carboplatin and paclitaxel) followed by surgery|Patients included in the experimental arm will be treated with intravenous infusion of paclitaxel 175 mg/m2, followed by carboplatin 5 area under the curve (AUC). This will be administered in a 3-weekly scheme with preferably 3 and a maximum of 4 courses, with evaluation after two courses of chemotherapy by physical examination. NACT will be subsequently followed by radical surgery in responding patients. A four to six weeks interval after the last course of chemotherapy needs to be respected before surgery, to allow sufficient physical recovery.
62572167|NCT01541332|EXPERIMENTAL|Pomalidomide + PLD + Dexamethasone|Pomalidomide + Pegylated Liposomal Doxorubicin + Dexamethasone in an open label, dose escalation study
62572168|NCT06336902|EXPERIMENTAL|Treatment (botensilimab, balstilimab, FMD, vitamin C)|Patients receive botensilimab IV over 30 minutes on day 1 of each cycle for up to 4 cycles. Patients receive balstilimab IV over 30 minutes and vitamin C IV over 30 minutes on days 1, 15 and 29 of each cycle. Patients undergo a FMD on days -4 to -1 of each cycle. Cycles repeat every 42 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT scans and MRI throughout the study.
62190636|NCT02992847||Multihance|At least 5 injection with Multihance exclusively
62780070|NCT04496011|NO_INTERVENTION|Group Control|"In this group the exercise program is based on the standard physiotherapy protocol that is part of the care routines performed at the bone marrow transplant service.~It includes essential components of a rehabilitation program: range of motion, balance training, gait and strength of the upper and lower limbs"
62780071|NCT03295773||Symptomatic stroke patient|Patients who are found signal void in a relevant intracranial internal carotid artery or middle cerebral artery (stenosis \>60%) will proceed to a 3-Dimensional rotational angiography (3DRA) at baseline and in 12 months. All recruited patients will receive dual antiplatelet agents for 4 weeks, followed by aspirin alone. The investigator or neurologists shall regularly review the patients and treat the conventional cardiovascular risk factors based on four pre-specified goals, for example, LDL \<1.8, HbA1c \<6.0, blood pressure \<140/90 and no smoking. The morphologic changes of the cerebral plaques with the intensity of the risk factor control in pre and post will be correlated.
62004885|NCT05689385|EXPERIMENTAL|eHealth-based cardiac rehabilitation|Participants receive a 12-wk case manager-led eHealth-based cardiac rehabilitation program with follow-up at 12 week, 6 months and 12 months.
62004886|NCT05689385|NO_INTERVENTION|Usual care|Participants receive usual care.
62004887|NCT04340882|EXPERIMENTAL|Treatment (docetaxel, ramucirumab, pembrolizumab)|Patients receive docetaxel IV over 60 minutes, ramucirumab IV over 60 minutes, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62004888|NCT05496725|EXPERIMENTAL|Micafungin (Product name:Myfungin)|Single dose micafungin 50mg
62004889|NCT05496725|ACTIVE_COMPARATOR|Micafungin (Product name:Mycamine)|Single dose micafungin 50mg
62004890|NCT06406062||AI-assisted group|Group with AI assistance
62190637|NCT03645148|EXPERIMENTAL|iNeo-Vac-P01|"Personal Cancer Vaccine: iNeo-Vac-P01 (peptides)+ GM-CSF;~Peptides: 4 x 100 mcg per peptide given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses;~GM-CSF: 4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses"
62410043|NCT00352664|ACTIVE_COMPARATOR|Donepezil|Oral Donepezil 5 mg daily x 7 days
62410044|NCT00352664|PLACEBO_COMPARATOR|daily x 7 days|Placebo tablet daily x 7 days
62410045|NCT00560573|EXPERIMENTAL|1|
62572169|NCT03497520|EXPERIMENTAL|scoliosis patients|scoliosis patients who have cobb angle over 10 degree perform asymmetric spinal stabilization exercise
62572170|NCT05172284||Psoriasis|
62004891|NCT06406062||Control group|Group without AI assistance
62572171|NCT05172284||Psoriatic arthritis|
62572172|NCT05172284||Atopic dermatitis|
62190638|NCT05950100|NO_INTERVENTION|Control group|Participants in the control group will not receive the intervention with virtual reality, but they will also receive, on the first postoperative day, the physiotherapeutic care offered by the institution, carried out by the hospital's physiotherapist and with the same duration as the other group (GRV), and constituted by the physiotherapeutic procedures commonly used in the hospital (respiratory physiotherapy maneuvers, kinesiotherapy and walking). During each physiotherapy session, in both groups, the visual analogue scale will be applied.
62004892|NCT06641856||Young Healthy Volunteers Group|"Age Range: 20-35 years Health Status: Participants in this group must be in good overall health, as determined by medical history, physical examination, and results of a routine health check-up within the past year.~Body Mass Index (BMI): Must be between 19-26 kg/m² (inclusive), with a minimum weight of 50 kg for males and 45 kg for females.~Sample Size: 150 participants (including equal representation of males and females).~Geographic Representation: Both permanent residents of Shanghai and non-residents who have been in the city for less than 30 days will be included. The proportion of local residents to non-residents will range from 1:1 to 2:1."
62004893|NCT06641856||Elderly Healthy Volunteers Group|"Age Range: 60-75 years Health Status: Participants in this group must have good respiratory health and be generally healthy based on medical history, physical examination, and a health check-up within the past year.~Body Mass Index (BMI): Must be between 19-26 kg/m² (inclusive), with a minimum weight of 50 kg for males and 45 kg for females.~Sample Size: 150 participants (including equal representation of males and females).~Geographic Representation: Similar to the young group, the elderly group will include both permanent residents of Shanghai and non-residents, with the same proportion of local residents to non-residents (1:1 to 2:1)."
62004894|NCT04015219|EXPERIMENTAL|Treatment Arm|PROKERA SLIM + Standard of Care
62004895|NCT04015219|ACTIVE_COMPARATOR|Control Arm|Standard of Care
62190639|NCT05950100|EXPERIMENTAL|Virtual reality group|Participants will receive the same care provided by the hospital, in addition to the application of the use of virtual reality
62190640|NCT02872389|EXPERIMENTAL|Sevoflurane|Anesthesia was maintained with sevoflurane.
62190641|NCT02872389|EXPERIMENTAL|Desflurane|Anesthesia was maintained with desflurane.
62572173|NCT05172284||Chronic urticaria|
62780072|NCT04194073|EXPERIMENTAL|Pulse oximeter calibration population|All subjects within this single arm of the study will undergo the calibration experiment as described in the Detailed Description
62780073|NCT03508609|EXPERIMENTAL|Autologous CD34 cells|Open label active treatment arm. Subjects receive autologous CD34 cells.
62004896|NCT05994729|EXPERIMENTAL|Candidates to RDN with ascertained CMD|Patients that are candidates to receive RDN for resistant/difficult to control hypertension, who also have documented coronary microvascular dysfunction
62190642|NCT05668299|EXPERIMENTAL|TrachFlush group|Patients in this arm received the intervention.
62190643|NCT02660515|ACTIVE_COMPARATOR|ORIF|The operation has to be performed within 3 weeks after the initial trauma. According to the current standard, antibiotic prophylaxis (Cefazoline, 1000 milligram intravenous) will be administered thirty minutes preoperatively. The distal radius will be approached according to Henry, which beholds an incision between the tendon of the flexor carpi radialis and the arteria radialis. After the fracture site is exposed, the fracture will be reduced and an appropriate volar locking plate will be positioned. The type and brand of the plate are at discretion of the treating surgeon. When a dorsal approach is deemed necessary the distal radius will be approached between the third and fourth dorsal extensor tendon compartments. To evaluate the quality of articular reduction, fluoroscopic images will be obtained. Wound closure will be performed using standard techniques.
62190644|NCT02660515|ACTIVE_COMPARATOR|ORIF with additional wrist arthroscopy|Surgery will be performed by a certified trauma surgeon, with experience in wrist arthroscopy. A delay of minimal 5 days before performing arthroscopy is mandatory to enable visualisation due to the organisation of the hematoma. During wrist arthroscopy, the forearm will be positioned upright and in neutral position, the elbow flexed by 90° and axial traction of 4-6 kg will be performed. Four portal entrees are created by superficial stab incisions and blunt preparation through the joint capsule; one midcarpal radiair and one midcarpal ulnar portal and the 3-4 and 6-R portal. A shaver is used for removal of fracture haematoma and osteocartilaginous debris. Cartilage damage will be graded using the Outerbridge classification system. With the 1 mm hook probe assessment of the quality of reduction and ligamentous injuries (TFCC, scapholunate and lunotriquetral) will be performed. Wound closure will be performed using standard techniques.
62190645|NCT01275742|NO_INTERVENTION|Usual Care|
62190646|NCT02520700|EXPERIMENTAL|Study participants|This was split scalp design - so each patient had one half of scalp treated with daylight PDT and one side treated with the artificial white light PDT - a surgical light (Maquet Power 500 LED surgery light)
62572174|NCT05172284||Suppurative hydrosadenitis|
62572175|NCT05172284||Systemic lupus erythematosus|
62572176|NCT05172284||Acne vulgaris|
62780074|NCT03433352||Control group|30 healthy volunteers were included in the healthy control group
62572177|NCT05172284||Rosacea|
62572178|NCT05172284||Seborrheic dermatitis|
62572179|NCT05172284||Contact dermatitis|
62572180|NCT05172284||Chronic eczema of the hands|
62572181|NCT05172284||Vitiligo|
62572182|NCT02012361|ACTIVE_COMPARATOR|Control Group|This group will be treated as any other patient would. Their anesthesia will be conducted as per routine with a target Fraction of inspired oxygen concentration (FiO2) of 0.25. During the course of the operation a small muscle biopsy will be collected.
62780075|NCT03433352||Recrudescence group|30 GD patients who received recurrence within 2 years after treatment with Methimazole Pill or propylthiouracil pill
62780076|NCT03433352||No recrudescence group|30 GD patients who did not receive recurrence within 2 years after treatment with Methimazole Pill or propylthiouracil pill
62190647|NCT03480113|EXPERIMENTAL|Mindfulness-based Intervention|1 session of health education regrading the harms from smoking and 6 sessions of Mindfulness-based intervention, 1 hour each session.
62572183|NCT02012361|ACTIVE_COMPARATOR|Single-Dose Heliox Group|This group will be treated with a single dose of inspired 75/25 heliox (75% helium 25% oxygen) breathed continuously for 15 minutes prior to the inflation of the surgical tourniquet. During the course of the operation a small muscle biopsy will be collected.
62190648|NCT03480113|ACTIVE_COMPARATOR|Physical Fitness intervention|1 session of health education regrading the harms from smoking and 6 sessions of physical fitness and stretch exercise, 1 hour each session.
62190649|NCT01087515|OTHER|Blood donation|
62190650|NCT03184506|SHAM_COMPARATOR|control group|
62190651|NCT03184506|ACTIVE_COMPARATOR|pre-warming group|
62190652|NCT02111863|EXPERIMENTAL|Lymphocyte Depleting Prep Regimen|Patients will receive a lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of 4-1BB selected tumor infiltrating lymphocytes (TIL) plus IV aldesleukin.
62190653|NCT05019170|EXPERIMENTAL|Best Practices + Incentives group|Participants assigned to this condition will receive the best practices treatment plus the financial incentives intervention.
62190654|NCT05019170|ACTIVE_COMPARATOR|Best Practices|Participants assigned to this condition will receive the best practices treatment alone.
62190655|NCT03316807|EXPERIMENTAL|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
62190656|NCT03316807|EXPERIMENTAL|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
62190657|NCT02102412|EXPERIMENTAL|single arm|single arm patients underwent colonoscopy with aer-o-scope followed by conventional colonoscopy to assess if any mucosal damage occurred with the experimental device.
62190658|NCT02846493|ACTIVE_COMPARATOR|bromocriptine group|Rectal bromocriptine (2.5 mg, qd) for 7 days
62572184|NCT00931528|EXPERIMENTAL|Tadalafil|Tadalafil
62572185|NCT00931528|PLACEBO_COMPARATOR|Placebo|Placebo
62572186|NCT03653962|ACTIVE_COMPARATOR|only informed consent|The first group was given verbal-written informed consent and a 15 question quiz about the informed consent content afterwards.
62780077|NCT02731443||ESx|Epilepsy patients undergoing elective surgical resection of brain tissue; study group: epilepsy surgery=ESx.
62780078|NCT02731443||DE|Epilepsy patients undergoing elective depth electrodes insertion in general anesthesia; control group: depth electrodes=DE.
62780079|NCT00346229|EXPERIMENTAL|Thermodox|ThermoDox20-40mg/m2 every 21-35 days followed by Chest Wall Hyperthermia
62780080|NCT02777827|EXPERIMENTAL|Abediterol dry powder inhaler 0.156 μg|Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)
62780081|NCT02777827|EXPERIMENTAL|Abediterol dry powder inhaler 2.5 μg|Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).
62190659|NCT02846493|EXPERIMENTAL|dexamethasone group|Oral take dexamethasone(3mg,qd)for 7 days
62190660|NCT02466347|EXPERIMENTAL|Synflutide HFA MDI, 250/25 mcg/dose|Synflutide HFA MDI(Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
62190661|NCT02466347|ACTIVE_COMPARATOR|SeretideTM EvohalerTM, 250/25 mcg/dose|SeretideTM EvohalerTM (Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
62190662|NCT00856245|OTHER|Rituximab|Patients will be treated IV with rituximab at the rate of 50 milligrams per hour (mg/hour) for 1 hour. If patient tolerates the infusion, the rate is increased by increments of 50 mg/hour every 30 minutes to a maximum of 400 mg/hour. If patient has a severe reaction, the infusion is stopped temporarily and the infusion rate is decreased by 50%. Subsequent infusions are started at the rate of 100 mg/hour, increased by 100 mg/hour every 30 minutes to a maximum of 400 mg/hour if tolerated. Vital signs are monitored every 15 minutes for 2 hours and every 30 minutes thereafter.
62190663|NCT01772563|EXPERIMENTAL|Volasertib + itraconazole then volasertib|Administration of volasertib in combination with itraconazole (Cycle 1) and afterwards alone (Cycle 2 and beyond).
62190664|NCT05247008|OTHER|Thyme honey interventional arm in geriatric patients having end-stage renal disease.|Thyme honey used as mouth rinse in treatment of xerostomia in geriatric patients with end-stage renal disease.
62190665|NCT01979419||cognitively normal|MRI scans, PET scans, lumbar puncture
62190666|NCT01979419||mild cognitive impairment|MRI scans, PET scans, lumbar puncture
62190667|NCT01979419||Alzheimer's Disease|MRI scans, PET scans, lumbar puncture
62190668|NCT01979419||vascular MCI|MRI scans, PET scans, lumbar puncture
62190669|NCT01979419||subcortical ischemic vascular dementia|MRI scans, PET scans, lumbar puncture
62572187|NCT03653962|EXPERIMENTAL|video assisted group|The second group got an additional information video presentation and then the same quiz.
62572188|NCT03693183|EXPERIMENTAL|Ketorolac/HPMC|"Drug: Ketorolac/HPMC Ophthalmic Solution~1 drop administered in each eye 4 times per day for 2 days"
62572189|NCT03693183|ACTIVE_COMPARATOR|HPMC|"Drug: 0.80% Hydroxypropyl Methylcellulose(HMPC) Ophthalmic Solution~1 Drop administered in each eye 4 times per day for 2 days"
62572190|NCT03693183|PLACEBO_COMPARATOR|Vehicle|"Drug: Vehicle Ophthalmic Solution~1 drop administered in each eye 4 times a day for 2 days"
62572191|NCT00997373|EXPERIMENTAL|Letrozole|letrozole 2.5 mg PO daily for 2-3 weeks prior to hysterectomy.
62572192|NCT00997373|NO_INTERVENTION|control|no treatemtn prior to hysterectomy
62780082|NCT02777827|EXPERIMENTAL|Abediterol pressurised metered-dose inhaler 0.05μg|Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).
62190670|NCT04075786||Gynecologists|Gynecologists in active clinical practice and resident (in training) gynecologists.
62190671|NCT01249508|EXPERIMENTAL|implemented nutrition label|A one-group pre-/post-design is used for the evaluation of the university canteen-based nutrition labeling program. This means that all participants of the program are exposed to the nutrition label implemented in the university canteen. The subject essentially serves as its own control based on pre-test behaviour. The nutrition label implemented is a star rating label calculated and assigned to each meal offered at the university canteens and based on the content of energy, saturated fat, sodium and fibre (expressed as vegetable portion).
62190672|NCT02519946|EXPERIMENTAL|On-Line Diet and Exercise Intervention|
62190673|NCT01758705||Cohort 1|Cohort 1
62396717|NCT00756379|EXPERIMENTAL|Intensive lifestyle modification|P.E.T. guided comprehensive therapy program. The study intervention is Comprehensive therapy program for risk factor modification. The Comprehensive program of atherosclerotic risk factor modification involves treatment to target lipid levels, blood pressure and diabetes control, smoking cessation, very low fat diet and aerobic exercise program. This is in addition to standard current medical therapy as provided by primary physician. No experimental medications or procedures will be used.
62190674|NCT03197025|EXPERIMENTAL|1/Arm 1 - Dose Escalation|Patients will undergo leukapheresis, then treatment with E6 T Cell Receptor (TCR) cells (at escalating doses) + aldesleukin
62572193|NCT04445038|EXPERIMENTAL|610 group|Participants will be administered with 0.03mg/kg, 0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 5.0mg/kg, 7.5mg/kg of 610 by subcutaneous injection. Subjects will be followed for 84 days.
62572194|NCT04445038|PLACEBO_COMPARATOR|controll group|Participants will be administered with 0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 5.0mg/kg, 7.5mg/kg placebo once by subcutaneous injection. Subjects will be followed for 84 days.
62572195|NCT05858580|EXPERIMENTAL|Intervention Group|"Intervention participants will receive approximately 25 hours of programming (over a 6-month period) related to the promotion of physical activity and healthy diet through:~1. 16 self-contained, parent-guided activity kits,~2. 9 one-on-one health coach/support sessions in-person or virtual by a trained health coach,~3. unlimited access to a resource toolbox."
62780083|NCT02777827|EXPERIMENTAL|Abediterol pressurised metered-dose inhaler 0.156 μg|Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).
62780084|NCT02777827|EXPERIMENTAL|Abediterol pressurised metered-dose inhaler 2.5μg|Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).
62190675|NCT03197025|EXPERIMENTAL|2/Arm 2 - Maximum Tolerated Dose (MTD)|Patients will undergo leukapheresis, then treatment with E6 T Cell Receptor (TCR) cells (at the MTD) + aldesleukin
62190676|NCT01708434|EXPERIMENTAL|Ulthera® treatment of the knees|Bilateral treatment of the knees using the Ulthera® System
62396718|NCT00756379|NO_INTERVENTION|Current standard of care|Current standard of care medical management as provided by primary physician.
62396719|NCT05538507|ACTIVE_COMPARATOR|Group I severe AD|Patients over 40 years of age and eligible for NIA-AA 2011 probable severe AD will be given donepezil 10 mg, memantine 20 mg and smart soup
62396720|NCT05538507|SHAM_COMPARATOR|Group II severe AD|Patients over 40 years of age and eligible for NIA-AA 2011 probable severe AD will be given donepezil 10 mg, memantine 20 mg and placebo
62572196|NCT05858580|NO_INTERVENTION|Control Group|"Control group programming consists of:~1. 6 parent-guided activity kits focused on STEM activities,~2. 6 monthly check-in calls to support retention.~The investigators will use Home Science Lab STEM kits designed for English- and Spanish-speaking children aged 6-11 years. The STEM kits do not include any physical health content. Kits will be mailed monthly to the participants' home. To maximize retention in the control group, staff will contact participants each month to confirm the kit was received, encourage completion of the kits, ask about their experience, and answer questions."
62780085|NCT02777827|PLACEBO_COMPARATOR|Placebo|Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).
62780086|NCT03796351|EXPERIMENTAL|MT10107(botulinum toxin type A)|Subjects will be administered a single equivalent dose of MT10107 by intramuscular injection to the EDB muscles of contralateral feet in five treatment group.
62004897|NCT05178849|EXPERIMENTAL|Hypnosis + local anesthasia|"As part of this project, local anesthesia will be supported by hypnosis in patients randomized to the hypnosis + AL arm, and started as soon as the patient is in prone position.~Hypnosis is a particular psychological state marked by the functioning of the individual at a level of attention other than the ordinary state of consciousness. It can, under certain conditions, give the appearance of sleep or sleepwalking without sharing all of its characteristics.~As part of care, hypnosis is widely used for pain control. The side effects reported are nil. One of its main benefits is improved patient comfort. One of its main benefits is improved patient comfort.~For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%."
62004898|NCT05178849|ACTIVE_COMPARATOR|Local anesthesia|For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%.
62004899|NCT01689896|ACTIVE_COMPARATOR|Testosterone Gel|Testosterone Gel
62004900|NCT01689896|PLACEBO_COMPARATOR|Placebo Gel|Placebo Gel
62396721|NCT05538507|ACTIVE_COMPARATOR|Group III Mild or moderate AD|Patients over 40 years of age and eligible for NIA-AA 2011 probable mild or moderate AD will be given donepezil 10 mg and smart soup
62572197|NCT00343044|EXPERIMENTAL|Treatment|Subjects received standard topotecan with the addition of bevacizumab. Cycles were 28 days and continued until toxicity, progression or subject wish to discontinue treatment. Topotecan administered 4 mg/m2 IV on days 1, 8 and 15 and bevacizumab IV 10 mg/kg, days 1 and 15 of each cycle.
62004901|NCT05498636|EXPERIMENTAL|SPEL|
62004902|NCT00431457|ACTIVE_COMPARATOR|Implantation intracranial electrode with immediate stimulation|
62004903|NCT00431457|PLACEBO_COMPARATOR|Implantation intracranial electrode without stimulation|
62004904|NCT00431457|ACTIVE_COMPARATOR|Resective surgery: amygddohyppocampertomy|
62780087|NCT03796351|ACTIVE_COMPARATOR|BOTOX® 50U(botulinum toxin type A)|Subjects will be administered a single equivalent dose of BOTOX® 50U by intramuscular injection to the EDB muscles of contralateral feet in five treatment group.
62780088|NCT01277484|EXPERIMENTAL|Decitabine, MDS treatment, IV injection|For the patients who achieve remission after allogeneic BMT and meet the enrollment criteria, decitabine will be given at a dose of 5mg/kg/day \~ 15mg/kg/day iv over 1 hour for 5 consecutive days starting 42-90 days after transplantation. The drug will be repeated every 4 weeks for up to 12 cycles.
62780089|NCT02505113||CTPV without Montelukast|Patients with CTPV do not receive the treatment of Montelukast.
62780090|NCT02505113||CTPV treated with Montelukast|Patients with CTPV treated with Montelukast (10mg, q.d., p.o.).
62780091|NCT00642447|EXPERIMENTAL|1|
62780092|NCT02676934|EXPERIMENTAL|Et group|applying end tidal concentration as a control target for delivery of sevoflurane
62780093|NCT02676934|NO_INTERVENTION|FGF group|using Fresh gas control for sevoflurane delivery
62780094|NCT03001687|EXPERIMENTAL|vitamin D +|"Patients in the vitamin D group will receive enteral supplementation with vitamin D, blood collection 3mL is performed in the first 24 hours after admission and one week later for serum hepcidin measurement"
62780095|NCT03001687|PLACEBO_COMPARATOR|vitamin D -|"Patients in vitamin D - group do not receive enteral supplementation with vitamin D and represent the control group, blood collection 3mL is performed in the first 24 hours after admission and one week later for serum hepcidin measurement"
62780096|NCT02359227|EXPERIMENTAL|Cenderitide|Cenderitide will be administered as four, 48-hour, continuous, subcutaneous infusion rates of 0.5, 1.0, 2.0 and 3.0 ng/kg/min totaling up to eight sequential days of dosing.
62004905|NCT05668767|EXPERIMENTAL|study group|Single-arm Surufatinib Durvalumab EP/EC
62004906|NCT03865290|EXPERIMENTAL|Healthy Control Ondansetron 8 mg|Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.
62004907|NCT03865290|EXPERIMENTAL|Diabetic (DM) gastroenteropathy Ondansetron 8 mg|"Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.~Oral Ondansetron 8 mg administered three times a day for weeks 3-6"
62004908|NCT03865290|EXPERIMENTAL|Non-ulcer dyspepsia (NUD) Ondansetron 8 mg|"Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.~Oral Ondansetron 8 mg administered three times a day for weeks 3-6"
62396722|NCT05538507|SHAM_COMPARATOR|Group IV Mild or moderate AD|Patients over 40 years of age and eligible for NIA-AA 2011 probable mild or moderate AD will be given donepezil 10 mg and placebo
62572198|NCT03617380|EXPERIMENTAL|PHARMD-TOC i|PharmD Follow-Up Post Discharge
62572199|NCT03617380|ACTIVE_COMPARATOR|USUAL CARE|Usual Post Discharge Procedures
62780097|NCT05211817|EXPERIMENTAL|Complex Intervention with Carnosine|Obese middle aged individuals will be subjected to 3 month complex lifestyle intervention including exercise (3 times per week) nutritional (weekly consultation) and psychological (monthly) interventions combined with oral administration of carnosine in dose 2g per day.
62780098|NCT05211817|EXPERIMENTAL|Complex Intervention with placebo|Obese middle aged individuals will be subjected to 3 month complex lifestyle intervention including exercise (3 times per week) nutritional (weekly consultation) and psychological (monthly) interventions combined with oral administration of identically looking placebo.
62780099|NCT05211817|EXPERIMENTAL|Without complex intervention with carnosine|Obese middle aged individuals will be subjected to standard clinical procedure without lifestyle interventions. Oral administration of carnosine in dose 2g per day will be provided.
62780100|NCT05211817|NO_INTERVENTION|Without complex intervention with placebo|Obese middle aged individuals will be subjected to standard clinical procedure without lifestyle interventions. Oral administration of identically looking placebo will be provided.
62780101|NCT04260945|EXPERIMENTAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
62780102|NCT00847197|EXPERIMENTAL|1|MK1903
62004909|NCT03865290|PLACEBO_COMPARATOR|Healthy Control Placebo|Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.
62780103|NCT00847197|PLACEBO_COMPARATOR|2|Placebo to MK1903
62190677|NCT04543383|EXPERIMENTAL|Part 1|Participants will receive two oral doses of milvexian (on Days 1 to 3), one in the morning and one in the evening. On Day 4, participants will only receive the morning dose of milvexian. On Day 4, four hours after the morning dosing of milvexian, each participant will receive an intravenous (IV) infusion of 4-Factor Prothrombin Complex Concentrate (4F-PCC) or matching placebo as per the treatment sequence AB and BA; in treatment period 1 and treatment period 2 where Treatment A=Dose 2 of milvexian + Dose 1 of 4F-PCC; Treatment B=Dose 2 milvexian + Placebo. A washout period of 14 days to 21 days will be maintained between each treatment period 1 and 2.
62396723|NCT05538507|ACTIVE_COMPARATOR|Group V MCI|Patients over 40 years of age and eligible for NIA-AA 2011 probable MCI will be given smart soup
62396724|NCT05538507|SHAM_COMPARATOR|Group VI MCI|Patients over 40 years of age and eligible for NIA-AA 2011 probable MCI will be given placebo
62396725|NCT02564094|EXPERIMENTAL|Epoetin beta|Participants with hematologic or solid malignancies will receive epoetin beta for a treatment period of approximately 20 weeks.
62780104|NCT05448391|EXPERIMENTAL|RIST4721 400 mg|RIST4721 400 mg: 4 active (100 mg) tablets once daily for 12 weeks
62780105|NCT02990676|EXPERIMENTAL|Computerised cognitive training group|Participants will be asked to complete the training programme provided using HAPPYneuron software for a minimum of 30 minutes 3 times a week for 12 weeks. The intervention will be completed in participant homes with the help of email or telephone reminders, as preferred.
62780106|NCT02990676|NO_INTERVENTION|Control group|Asked to continue as normal
62396726|NCT00038571|EXPERIMENTAL|Arm A (mantle-cell lymphoma)|
62396727|NCT00038571|EXPERIMENTAL|Arm B (other B-cell lymphomas)|
62396728|NCT02117466|OTHER|Standard dose cetuximab|Uptake of 89Zr-cetuximab: continue standard dose (500mg/m2 bsa) (standard care)
62396729|NCT02117466|EXPERIMENTAL|Dose escalation cetuximab|No 89Zr-cetuximab uptake: dose escalation in a 3x3 cohort design (with maximal 50% dose increase each cohort; with a maximum of 2000 mg/m2 bsa every two weeks)
62396730|NCT06666608|EXPERIMENTAL|Bone Stimulator Treatment|In addition to the standard of care treatment at Houston Methodist for spondylolysis (provision of a back brace and prescribed physical therapy regimen), participants assigned to this group will be provided a bone stimulator wherein they will be asked to wear their device for a minimum of 30 minutes a day for 12 weeks with no maximum usage time. The device will track compliance, and will be worn when at rest.
62396731|NCT06666608|ACTIVE_COMPARATOR|Standard of Care Treatment|Participants assigned to this group will undergo the standard of care treatment for spondylosis which is physical therapy and the usage of a back brace.
62396732|NCT06482515|EXPERIMENTAL|Time-restricted eating|
62396733|NCT06482515|ACTIVE_COMPARATOR|Time-unrestricted eating|
62396734|NCT00917943|EXPERIMENTAL|Tailored Counseling Intervention Arm|Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
62396735|NCT00917943|NO_INTERVENTION|Control Arm|Women randomized to the control arm receive the booklet, Forever Free for Baby and Me: A Guide to Remaining Smoke Free and usual prenatal and postpartum care.
62396736|NCT04726787|EXPERIMENTAL|Bridging Radiotherapy|Disease areas requiring effective long-term control will receive full-dose radiotherapy (20-30Gy/5-15#); other areas will receive low dose (4Gy/2#)
62396737|NCT02724189||Patients attending the preoperative assessment clinic|Patients in preoperative assessment clinic
62396738|NCT04312711|EXPERIMENTAL|intervention|All participants received 3D-TOF-MRA and ultrasound examination, and DSA is used as golden reference
62004910|NCT03865290|PLACEBO_COMPARATOR|Diabetic (DM) gastroenteropathy Placebo|"Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.~Oral matched placebo administered three times a day for weeks 3-6"
62572200|NCT06335381|EXPERIMENTAL|MOMs High Touch (MOMs-HT)|Participants randomized to the MOMs-HT arm will receive close clinical and behavioral health monitoring via weekly chats (text or email) using chatbot technology and navigation to timely clinical, behavioral health, and/or social care services by the MOMs team throughout the prenatal and postpartum periods; 12 bi-weekly self-management support telehealth visits with a MOMs care management coordinator (CMC) or registered nurse (RN) during the prenatal period; home blood pressure monitor to measure their blood pressure regularly; Fitbit to track physical activity; and bi-weekly telehealth visits with navigation to clinical, behavioral, and social services as needed by the MOMs team up to 6 weeks postpartum.
62572201|NCT06335381|ACTIVE_COMPARATOR|MOMs Low Touch (MOMs-LT)|Participants randomized to the MOMs-LT arm will receive close clinical and behavioral health monitoring via weekly chats (text or email) using chatbot technology and navigation to timely clinical, behavioral health, and/or social care services by the MOMs team throughout the prenatal and postpartum periods; bi-weekly telehealth visits with navigation to clinical, behavioral, and social services as needed by the MOMs team up to 6 weeks postpartum; and a Fitbit to track physical activity.
62190678|NCT04543383|EXPERIMENTAL|Part 2 (Group 1)|Participants will receive an oral dose of milvexian in morning in fed state on Day 1 and IV injection of Recombinant Human Factor VIIa (rFVIIa) or placebo matching to rFVIIa on Day 1 after 4 hours post morning milvexian dose in the following treatment sequence: DEF1, EF1D, F1DE, EDF1, F1ED and DF1E; in treatment period 1, treatment period 2 and treatment period 3 respectively where Treatment D=Dose 1 of milvexian +Dose 1 of rFVIIa; Treatment E=Dose 3 of milvexian+Dose 1 of rFVIIa; Treatment F1=Dose 3 of milvexian+Placebo; Treatment F2=Dose 1 of milvexian+Placebo. A washout period of 4 days will be maintained between each treatment period 1, 2 and 3.
62396739|NCT04535544|EXPERIMENTAL|Immediate Active Treatment arm: JNJ-73763989 + NA|Participants will receive JNJ-73763989 subcutaneous (SC) injection every 4 weeks (Q4W) along with NA (entecavir \[ETV\], tenofovir disoproxil, or tenofovir alafenamide \[TAF\]) once daily for 144 Weeks in Part 1 and for at least 96 weeks in Part 2.
62572202|NCT02034734|EXPERIMENTAL|1: ASP3652|Multiple doses of ASP3652
62572203|NCT05129865|EXPERIMENTAL|LYT-300 in healthy volunteers LYT-300, Doses TBD|Subjects will crossover across 3 dosing periods in which they will receive placebo and two experimental dose levels
62572204|NCT05129865|EXPERIMENTAL|LYT-300 in healthy volunteers LYT-300|LYT-300, Dose TBD with and without food, separated by 7-day washout
62572205|NCT05129865|EXPERIMENTAL|LYT-300, Dose TBD QAM every 24 h for 7 days|
62572206|NCT05129865|PLACEBO_COMPARATOR|Placebo QAM every 24 h for 7 days|
62572207|NCT05129865|PLACEBO_COMPARATOR|Placebo QHS every 24 h for 7 days|
62572208|NCT05129865|EXPERIMENTAL|LYT-300 in healthy volunteers LYT-300, Dose TBD QHS every 24 h for 7 days|
62572209|NCT05129865|EXPERIMENTAL|LYT-300|
62780107|NCT02436954|PLACEBO_COMPARATOR|CO2 insufflation at intra-abdominal pressure 8 mmHg|CO2 insufflation with intra-abdominal pressure 8 mmHg during deep-NMB
62780108|NCT02436954|ACTIVE_COMPARATOR|CO2 insufflation at intra-abdominal pressure 12 mmHg|CO2 insufflation with intra-abdominal pressure 12 mmHg during deep-NMB
62780109|NCT04286815|EXPERIMENTAL|Experimental Group|a lentiviral vector to transfer IL2RG complementary DNA to bone marrow stem cells in ten children with genetic diagnosed X-SCID（severe combined immune deficiency）.
62572210|NCT05129865|PLACEBO_COMPARATOR|Placebo|
62572211|NCT04390503|EXPERIMENTAL|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Participants randomized to the experimental arm will receive 2 units (approximately 200 to 250 mL per unit, total 400-500mL) of convalescent plasma that was collected from a volunteer who recovered from COVID-19 disease.
62780110|NCT02687087|EXPERIMENTAL|Visco-ease|Visco-ease is a suspension of multilamellar vesicles comprising lipids in ratios which mimic the lipidic composition of endogenous extra-alveolar lamellar bodies. Visco-ease is suspended in physiological saline (0.9% NaCl) to provide a final dose concentration of 19.6 mg/mL. Visco-ease is a white to off-white turbid suspension. The device under evaluation in this clinical investigation is Visco-ease at a concentration of 19.6 mg/mL.
62572212|NCT04390503|ACTIVE_COMPARATOR|Control (albumin 5%)|Participants randomized to the control arm will receive 2 units of 250 mL (500mL total) of albumin (human) 5% infusion. The albumin will be prepared in bags that are identical to the bags used for plasma. The similar appearance of albumin and plasma will facilitate maintaining the blinded status of subjects and most of the study staff.
62572213|NCT03367182||Weekly paclitaxel + bevacizumab|
62572214|NCT03367182||Topotecan + bevacizumab|
62572215|NCT03367182||Pegylated liposomal doxorubicin + bevacizumab|
62572216|NCT01623310|EXPERIMENTAL|OPN-375 400 μg BID|OPN-375 400 μg BID for 12 months
62572217|NCT04301869|ACTIVE_COMPARATOR|Intravenous therapy|Intravenous antibiotics administered for pleural space infection
62572218|NCT04301869|ACTIVE_COMPARATOR|Oral therapy|Oral antibiotics administered for pleural space infection
62780111|NCT02687087|PLACEBO_COMPARATOR|RIX-Placebo|Physiological Saline (sodium chloride 0.9% (w/v)
62780112|NCT06583993|EXPERIMENTAL|HNF4α srRNA treatment|The subjects with advanced ICC will be treated by HNF4α srRNA intravenously via a peripheral vein.
62780113|NCT06017869|EXPERIMENTAL|Autologous CD34+ cells enriched with allogenic placenta-derived mitochondria|
62780114|NCT05175742|EXPERIMENTAL|40µg PTX-COVID19-B Open-label|Participants, 15 healthy adults 18 to 64 years of age will receive 1 intramuscular (IM) injection of 40µg PTX-COVID19-B vaccine on Day 1, followed by a second dose on Day 28.
62780115|NCT05175742|EXPERIMENTAL|40µg PTX-COVID19-B|Participants, 360 healthy adults 18 to 64 years of age, will receive 1 intramuscular (IM) injection of 40µg PTX-COVID19-B vaccine on Day 1, followed by a second dose on Day 28. Participants will receive a placebo dose on Day 21.
62780116|NCT05175742|ACTIVE_COMPARATOR|Pfizer-BioNTech COVID-19 vaccine|Participants, 190 healthy adults 18 to 64 years of age, will receive 1 intramuscular (IM) injection of Pfizer-BioNTech COVID-19 vaccine on Day 1, followed by a placebo dose on Days 21. Participants will receive a placebo dose on Day 28.
62004911|NCT03865290|PLACEBO_COMPARATOR|Non-ulcer dyspepsia (NUD) Placebo|"Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.~Oral matched placebo administered three times a day for weeks 3-6"
62004912|NCT04431362|NO_INTERVENTION|Baseline|Participants will not listen to music for 5 to 15 days based on the baseline duration they were assigned.
62004913|NCT04431362|EXPERIMENTAL|Intervention|Participants will listen to music for 3 weeks.
62004914|NCT04955106|OTHER|Sample for reliability|Reliability and validity of SEM Scanner : intra rater, inter rater and inter novice/trained 8(2 trained rater, 2 novice rater, each one performed twice)measured will be performed on each patient.
62004915|NCT03126097|EXPERIMENTAL|JNJ-64155806+COCP+JNJ-64155806 with COCP|Participants will receive JNJ-64155806 150 milligram (mg) twice daily (BID) under fed conditions on Days 1 to 7 \[JNJ-64155806 Alone Phase\] followed by a 10-day washout phase; followed by Ethinylestradiol/drospirenone 0.02 mg/3 mg given as a combined oral contraceptive pill (COCP) once daily (QD) on Days 18 to 41 and COCP placebo QD on Days 42 to 45 \[COCP Lead-in Phase\]; further followed by COCP QD on Days 46 to 69 (on Days 59 to 66 under fed condition), JNJ-64155806 150 mg BID (under fed conditions) on Days 60 to 66, and COCP placebo QD on Days 70 to 73 \[JNJ-64155806 + COCP Co-administration Phase\].
62004916|NCT01994304|NO_INTERVENTION|No safe childbirth checklist|The selected control districts include Bharatpur, Pali, Jhunjhunu, and Nagaur
62396740|NCT04535544|PLACEBO_COMPARATOR|Deferred Active Treatment arm: Placebo+NA+JNJ-73763989+NA|Participants will receive matching placebo to JNJ-73763989 SC injection Q4W along with NA (ETV, tenofovir disoproxil, or TAF) once daily for 52 Weeks followed by JNJ-73763989 SC injection Q4W along with NA once daily for 96 weeks in Part 1 and for at least 48 weeks in Part 2.
62396741|NCT04529031|ACTIVE_COMPARATOR|RFPP group intervention|The focus of RFPP is on enhancing contextual discrimination and emotional regulation, and promoting the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices.
62396742|NCT04529031|SHAM_COMPARATOR|attentional control condition (group process)|Subjects will receive progressive muscle relaxation and other relaxation techniques as well as education about PTSD and supportive psychotherapy. Parents will receive 4 sessions of relaxation techniques.
62396743|NCT05598411|EXPERIMENTAL|Oral Glucocorticoids group|Intervention Period：oral glucocorticoids（methylprednisolone 24mg qd, 2-week duration）+nasal spray （Budesonide Nasal Spray 64ug per Nostril, bid, 2-week duration） follow-up period：nasal spray（Budesonide Nasal Spray 64ug per Nostril, bid, 24-week duration）
62004917|NCT01994304|ACTIVE_COMPARATOR|Safe Childbirth Checklist|The selected districts for SCC intervention include Alwar, Jalore, Sirohi, Sikar, Dausa, and Churu
62396744|NCT05598411|PLACEBO_COMPARATOR|Placebo group|Intervention Period：oral placebo+nasal spray（oral placebo 24mg qd, 2-week duration）+nasal spray （Budesonide Nasal Spray 64ug per Nostril, bid, 2-week duration） follow-up period：nasal spray（Budesonide Nasal Spray 64ug per Nostril, bid, 24-week duration）
62410046|NCT05393635|EXPERIMENTAL|Cohort 1|Participants with cervical cancer whose disease has progressed during or after treatment with platinum-based chemotherapy. Participants with combined positive score ≥ 1 should also have disease that has progressed during or after treatment with CPI.
62410047|NCT05393635|EXPERIMENTAL|Cohort 2|Participants with head and neck squamous-cell carcinoma (HNSCC) whose disease has progressed during or after platinum-based chemotherapy and previous CPI.
62780117|NCT01516398||Preterm infants|No interventions were performed. Group consisted of preterm infants enrolled in the study.
62780118|NCT01516398||Term control infants|No interventions were performed. Group consisted of term infants enrolled in the study to serve as controls for the preterm infant group.
62780119|NCT03327194|EXPERIMENTAL|ADHEAR Audio processor|
62780120|NCT02464514|OTHER|Healthy obese children|High carbohydrate meal High fat meal
62780121|NCT02464514|OTHER|Children with Prader Willi Syndrome|High carbohydrate meal High fat meal
62004918|NCT00179647|OTHER|Lenalidomide 5-25 mg, w/wo dexamethasone|single-arm, open-label, lenalidomide, 5-25 mg, 21/28 days, with/without dexamethasone
62004919|NCT02041598|EXPERIMENTAL|Full CHW Intervention|5 monthly group educational sessions, 2 1v1 Visits with CHW, Phone Calls as Needed
62780122|NCT03993522|EXPERIMENTAL|CTO Exerciser|"2x Symptom limited cardiopulmonary exercise tests~1x Sub-maximal cardiopulmonary exercise test (20 minutes)"
62780123|NCT03238833|EXPERIMENTAL|luteal ovarian stimulation|The controlled ovarian stimulation in in vitro fertilization cycle was started since luteal phase.
62780124|NCT03238833|ACTIVE_COMPARATOR|follicular ovarian stimulation|The controlled ovarian stimulation in in vitro fertilization cycle was started since early follicular phase phase.
62780125|NCT06440551|EXPERIMENTAL|Healthy Eating and Physical Activity - Intervention|Participants will attend virtual classes on increasing healthy eating, increasing physical activity, and decreasing sedentary behaviors.
62780126|NCT06440551|ACTIVE_COMPARATOR|General Health Topics - Control|Participants will attend virtual classes on general health topics.
62780127|NCT02314832|ACTIVE_COMPARATOR|Continuous femoral nerve block|patients receiving continuous femoral nerve block for analgesia after total knee arthroplasty
62780128|NCT02314832|ACTIVE_COMPARATOR|adductor canal block|adductor canal block group will receive adductor canal block for analgesia after TKA
62780129|NCT01669083|EXPERIMENTAL|Cohort 1: GSK557296 10 mg|GSK557296 10 mg single dose on Day 1 followed by repeat dosing (4 times a day) on Days 2-6
62780130|NCT01669083|EXPERIMENTAL|Cohort 2: GSK557296 150 mg|GSK557296 150 mg as a single dose on Day 1 followed by repeat nominal dosing of the same dose (either 2, 3 or 4 times a day based on half-life demonstrated in treatment A) on Days 9-13
62780131|NCT01669083|EXPERIMENTAL|Cohort 3|This study had an adaptive design and additional cohorts may be added depending on the PK profiles of Cohort 1 and Cohort 2. Subjects in this optional Cohort 3 will receive GSK557296 (dose to be determined) as a single dose on Day 1 followed by repeat nominal dosing of the same dose (either 2, 3 or 4 times a day based on half-life demonstrated in Cohort 1 and Cohort 2) on Days 2-6
62780132|NCT01669083|EXPERIMENTAL|Cohort 4|This study had an adaptive design and additional cohorts may be added depending on the PK profiles of Cohort 1 and Cohort 1. Subjects in this optional Cohort 4 will receive GSK557296 (dose to be determined) by PK of prior doses, 10-150 mg single dose on Day 1 followed by repeat dosing (either 2, 3 or 4 times a day dependent on half-life demonstrated in prior groups) on Days 2-6
62780133|NCT02428205|EXPERIMENTAL|Propranolol arm|Propranolol will be administered in the form of a liquid dose via oral syringe by the participants' parent/caregiver an hour before each EIBI session. To minimize risk, the bodyweight adjusted minimum dose of propranolol used safely for test anxiety in healthy adults (10mg) will be used: participants weighing \> 30 kg will be given 4 mg, participants weighing 22.5 - 30 kg will be given 3 mg, participants weighing 15 - 22.5 kg will be given 2 mg. Participants weighing \< 15 kg will be excluded for safety reasons.
62780134|NCT02428205|PLACEBO_COMPARATOR|Placebo arm|Placebo will be administered in the form of a liquid dose via oral syringe by the participants' parent/caregiver an hour before each EIBI session.The same bodyweight adjusted doses specified in the propranolol arm will be used for this arm.
62780135|NCT01184417|ACTIVE_COMPARATOR|Phenobarbital group|10 mg/kg IV phenobarbital in 100 ml saline
62004920|NCT02041598|NO_INTERVENTION|Control: Intro to Diabetes Session Only|One-time, Introduction to Diabetes educational session only
62004921|NCT06366971|EXPERIMENTAL|Experimental Group|The experimental group will receive exercise training consisting of pelvic PNF techniques in addition to patient education which consisting of basic lumbar stabilization exercises 3 days a week for 6-weeks.
62780136|NCT01184417|PLACEBO_COMPARATOR|Placebo group|100 ml saline
62004922|NCT06366971|ACTIVE_COMPARATOR|Control Group|The control group will receive patient education consisting of basic lumbar stabilization exercises 3 days a week for 6-weeks.
62004923|NCT05023694||Newborn reanimated video recordings|Newborns, requiring stabilization at birth in Delivery Room, prior authorization by verbal and written informed consent
62004924|NCT03059381||Fycompa-treated epilepsy participants|Adolescent epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa
62004925|NCT06198907|EXPERIMENTAL|Part A Dose escalation|Dose escalation part Golidocitinib in combination with sintilimab
62004926|NCT06198907|EXPERIMENTAL|Part B Dose expansion cohort 1 (PD-L1 TPS ≥ 50%)|Dose expansion cohort 1, Golidositinib plus Sintilimab following Sintilimab
62004927|NCT06198907|EXPERIMENTAL|Part B Dose expansion cohort 2 (PD-L1 TPS 1-49%)|Dose expansion cohort 2, Golidositinib plus Sintilimab following Sintilimab + chemotherapy
62004928|NCT04194775|EXPERIMENTAL|Nofazinlimab (CS1003)|
62004929|NCT04194775|PLACEBO_COMPARATOR|Nofazinlimab (CS1003) placebo|
62004930|NCT03932942|EXPERIMENTAL|Point-of-care testing of respiratory pathogens on admission|Point-of-care testing of respiratory pathogens on admission. The subjects will receive the point-of-care testing of respiratory pathogens at pediatric emergency room. The results are ready within 1 one hour.
62004931|NCT03932942|NO_INTERVENTION|Routine ED protocol|Diagnostic tests for respiratory pathogens will be obtained according to clinical judgement and tested on microbiological laboratory. The results are ready on the next office day.
62572219|NCT05481697|EXPERIMENTAL|UWL and GRAIL Galleri Testing|"Enrolled participants will have an initial blood sample taken and record their weights weekly on a FitBit Aria scale for three years to detect for UWL~Those who unintentionally lost lost ≥5% from their baseline weight will be identified and have a GRAIL Galleri blood test, physical examination, imaging, and cancer screenings to test for malignancy"
62572220|NCT06048861|EXPERIMENTAL|Individuals with Carpal Tunnel Syndrome|
62572221|NCT06048861|EXPERIMENTAL|Healthy Controls|
62572222|NCT02380833|ACTIVE_COMPARATOR|MyPlate|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations for eight weeks.
62004932|NCT05329597||100mg|After 15 consecutive days of takeing 100mg Umorestat capsule of each participant, 2 mL of peripheral venous blood is collected at 3 h, 8 h and 24 h (D16) on the 15th day into the vacuum blood collection tube via EDTA anticoagulation for genotyping and metabolite determination.
62004933|NCT05329597||200mg|After 15 consecutive days of takeing 200mg Umorestat capsule of each participant, 2 mL of peripheral venous blood is collected at 3 h, 8 h and 24 h (D16) on the 15th day into the vacuum blood collection tube via EDTA anticoagulation for genotyping and metabolite determination.
62004934|NCT05329597||400mg|After 15 consecutive days of takeing 400mg Umorestat capsule of each participant, 2 mL of peripheral venous blood is collected at 3 h, 8 h and 24 h (D16) on the 15th day into the vacuum blood collection tube via EDTA anticoagulation for genotyping and metabolite determination.
62004935|NCT05329597||600mg|After 15 consecutive days of takeing 600mg Umorestat capsule of each participant, 2 mL of peripheral venous blood is collected at 3 h, 8 h and 24 h (D16) on the 15th day into the vacuum blood collection tube via EDTA anticoagulation for genotyping and metabolite determination.
62004936|NCT01579396|EXPERIMENTAL|septeX|septeX CVVH for 12h after cardiac surgery
62004937|NCT01579396|OTHER|standard therapy|standard therapy according to local practice
62004938|NCT04055116|EXPERIMENTAL|Unbuffered Lidocaine, then Buffered Lidocaine|Subjects will receive an injection of non-buffered 2% lidocaine with 1:100,000 epinephrine on one occasion; they will be randomized to this group. After a minimum of one week, subjects will receive the alternate solution.
62004939|NCT04055116|EXPERIMENTAL|Buffered Lidocaine, then Unbuffered Lidocaine|"Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion.Subjects will receive an injection of this buffered 2% lidocaine with 1:100,000 epinephrine on one occasion; they will be randomized to this group. After a minimum of one week, subjects will receive the alternate solution.~We will use 8.4% Sodium Bicarbonate manufactured by Hospira, Inc. Lake Forest, IL"
62004940|NCT04542070|ACTIVE_COMPARATOR|Biktarvy (BIK)|Participants with HIV-1 received BIK tablet orally until month 12. BIK was a fixed dose combination of 50 mg Bictegravir (BIC) + 200 mg Emtricitabine (FTC) + 25 mg Tenofovir alafenamide (TAF).
62572223|NCT02380833|ACTIVE_COMPARATOR|MyPlate + Exercise|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
62572224|NCT02380833|ACTIVE_COMPARATOR|Paleolithic|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations for eight weeks.
62004941|NCT04542070|EXPERIMENTAL|Oral lead-in phase (OLI)|Participants with human immunodeficiency viruses (HIV)-1 who chose oral lead in (OLI) received oral 30 milligram (mg) Cabotegravir (CAB) tablet + 25 mg Rilpivirine (RPV) tablet once daily (QD) for one month. At the month 1 visit, the last dose of oral CAB + RPV was given, followed by the first 600 mg CAB long-acting (LA) + 900 mg RPV LA intramuscular injection (IM), and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections once every 2 months (Q2M) until Month 12 (Maintenance Phase). The participants had the option to continue the regimen in the Extension Phase
62572225|NCT02380833|ACTIVE_COMPARATOR|Paleolithic + Exercise|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
62572226|NCT06101797|EXPERIMENTAL|Remote supervised exercise group|The intervention will last 12 weeks and consist of muscle-strengthening exercises for the lower extremities supervised remotely by video call.
62572227|NCT06101797|EXPERIMENTAL|In-person supervised exercise group|The intervention will last 12 weeks and consist of muscle-strengthening exercises for the lower extremities supervised in person at a physiotherapy clinic.
62004942|NCT04542070|EXPERIMENTAL|Direct to injections (D2I)|Participants with HIV-1 who chose direct to injections (D2I) received the first injections of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading doses at Day 1 one month, followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and month 3 followed by Q2M until Month 11. The participants had the option to continue the regimen in the Extension Phase.
62004943|NCT04542070|ACTIVE_COMPARATOR|Switch Q2M Group|Eligible participants with HIV-1 who received BIK tablet orally switched treatment after month 12 (Extension Phase) to CAB LA 600 mg + RPV LA 900 mg regimen, administered once every 2 months.
62004944|NCT04127760|NO_INTERVENTION|control|Follow-up at several time frames
62004945|NCT04127760|EXPERIMENTAL|treatment|Radiotherapy would be carried out. Follow-up at the same time frames as the control arm
62780137|NCT00721838||1|Surgery group
62004946|NCT04522024|ACTIVE_COMPARATOR|Mei Mini Maze|Mei Mini Maze procedure (Unilateral thoracoscopic epicardial ablation by radiofrequency energy from left side)
62396745|NCT03833609|EXPERIMENTAL|Online yoga training (Group A)|Participants will receive an e-pamphlet on physical exercise developed by The Arthritis Society, and will be invited to complete a yoga training program. The yoga training program is a structured low-intensity Vishwas-Raj. Participants will be asked to complete three individual 1-hour sessions per week for 12 consecutive weeks by watching a previously filmed session led by a qualified yoga instructor and posted on Facebook. They will also take part in a 1-hour virtual group session per week using a video-conferencing platform. Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
62410048|NCT05393635|EXPERIMENTAL|Cohort 3|Participants with non-small cell lung cancer (NSCLC) whose disease has progressed during or after platinum-based chemotherapy and a CPI. Participants with targetable mutations (e.g. EGFR/ALK) are required to have disease which has progressed on targeted therapy and platinum-based chemotherapy.
62780138|NCT00721838||2|Control - Lifestyle modification program
62004947|NCT04522024|EXPERIMENTAL|Mei Mini Maze plus epicardial cryoablation|Epicardial focal cryoablation during Mei Mini Maze procedure
62004948|NCT03560323|ACTIVE_COMPARATOR|Group I Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 0.4 mg/kg.min for 20 minutes and then at a constant rate of 0.2 mg/kg.min until study end
62004949|NCT03560323|ACTIVE_COMPARATOR|Group II Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 1.5 mg/kg.min for 20 minutes and then at a constant rate of 0.75 mg/kg.min until study end
62004950|NCT03560323|ACTIVE_COMPARATOR|Group III Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 4.0 mg/kg.min for 20 minutes and then at a constant rate of 2.0 mg/kg.min until study end
62004951|NCT03384251|EXPERIMENTAL|Intervention group|This group shall be given a comprehensive sex education in approximately six sessions.
62004952|NCT03384251|NO_INTERVENTION|Control group|This group will not be given any form of education.
62004953|NCT04181918|EXPERIMENTAL|AOT|This group will observe videos depicting daily actions and afterwards they will execute the seen actions
62004954|NCT04181918|EXPERIMENTAL|MI|This group will imagine motorically the same action as the first group and afterwards they will execute the imagined actions
62190679|NCT04543383|EXPERIMENTAL|Part 2 (Group 2)|Participants will receive an oral dose of milvexian in morning in fed state on Day 1 and IV injection of rFVIIa or placebo matching to rFVIIa on Day 1 after 4 hours post morning milvexian dose in the following treatment sequence: DEF2, EF2D, F2DE, EDF2, F2ED and DF2E; in treatment period 1, treatment period 2 and treatment period 3 respectively where Treatment D=Dose 1 of milvexian+Dose 1 of rFVIIa; Treatment E=Dose 3 of milvexian+Dose 1 of rFVIIa; Treatment F1=Dose 3 of milvexian+Placebo; Treatment F2=Dose 1 of milvexian+Placebo. A washout period of 4 days will be maintained between each treatment period 1, 2 and 3.
62190680|NCT04767724|EXPERIMENTAL|Extracorporeal shock wave|Participants received three ESWT sessions once per week for three consecutive weeks. The probe of the ESWT machine (FT-174; Swiss Dolor Class; Switzerland) was placed perpendicularly on the patient's palm over the median nerve on the carpal tunnel after application of the ultrasound gel as a coupling agent. Afterward, the ESWT was administered with 1000 shots, 1.5 bar of pressure, and a frequency of 6 Hz
62410049|NCT01975129|EXPERIMENTAL|Vagitocin (Oxytocin)|
62572228|NCT02892890|EXPERIMENTAL|patients with CIDP|
62004955|NCT04181918|NO_INTERVENTION|Control|This group will neither observe nor imagine actions, but simply observe videos with no motor content. Afterwards they will execute the same actions as in AOT and MI.
62780139|NCT04166617|ACTIVE_COMPARATOR|Conventional therapy|Conventional physical therapy for upper limb in stroke patients
62780140|NCT04166617|EXPERIMENTAL|Leap motion plus conventional therapy|Leap motion plus conventional physical therapy for upper limb in stroke patients
62780141|NCT06258408|EXPERIMENTAL|BB102 monotherapy|The study is composed of fasted dose cohorts and fed dose cohort. BB102 will be administered orally daily alone as monotherapy in all cohorts. In the fasted dose cohorts, the subjects will receive once daily of BB102 monotherapy fasted across approximately 6 ascending dose levels. The starting dose is 50mg/day. In the fed dose cohort, the subjects will receive once daily of BB102 monotherapy in a fed condition. The dose selected for fed dose cohort must be deemed safe as assessed by safety monitoring committee (SMC).
62780142|NCT05148104||Patients receiving shoulder arthroplasty|Patients receiving shoulder arthroplasty that have an intact glenoid prior to the procedure. Ideally the glenoid surface should be visible and intact during imaging.
62780143|NCT05526898|EXPERIMENTAL|SyntrFuge System|Adipose tissue microsized via the SyntrFuge System
62004956|NCT05585216|EXPERIMENTAL|PRP combined with leg swing and quadriceps strengthening exercise|Group A received twice intra-articular injection of platelet-rich plasma (2 ml, 2 weeks apart) and regular leg swing and quadriceps strengthening exercise for three months.
62004957|NCT05585216|ACTIVE_COMPARATOR|intra-articular combination injections of PRP and HA|Group B received twice intra-articular combination injections of PRP (2 ml) and HA (2 ml) every 2 weeks.
62004958|NCT00773097|EXPERIMENTAL|MUC1 Poly-ICLC|
62780144|NCT05526898|OTHER|Standard of Care|Steroid Injection
62780145|NCT00064792|PLACEBO_COMPARATOR|OraPlus|
62780146|NCT00064792|ACTIVE_COMPARATOR|Simvastatin Susp|
62780147|NCT01505816|NO_INTERVENTION|Toric|Multifocal Toric IOL implantation
62190681|NCT04767724|ACTIVE_COMPARATOR|Local corticosteroid injection|A single injection of one mL (40 mg) of betamethasone into the region surrounding the median nerve.
62190682|NCT00607581|EXPERIMENTAL|1|"The participants receive up to 9 28-day cycles of~* cyclophosphamide: 500 mg orally on days 1, 8, 15;~* lenalidomide: 15 mg orally on days 1-21;~* dexamethasone: 40 mg orally on days on days 1, 8, 15, 22."
62190683|NCT04361812|EXPERIMENTAL|HS632|HS632 150mg for a single subcutaneous injection
62190684|NCT04361812|ACTIVE_COMPARATOR|Omalizumab (Xolair®)|Omalizumab 150mg for a single subcutaneous injection
62190685|NCT01062269|ACTIVE_COMPARATOR|Cholestyramine 4 grams|
62190686|NCT01062269|ACTIVE_COMPARATOR|Cholestyramine 12 grams|
62190687|NCT01062269|PLACEBO_COMPARATOR|Tang|
62190688|NCT02833961|EXPERIMENTAL|ISCHEMIC STROKE|ischemic stroke admitted in the Pitié Salpêtrière Stroke unit in Paris
62190689|NCT02833961|ACTIVE_COMPARATOR|HEALTHY SUBJECTS|Age and gender-matched healthy volunteers
62190690|NCT04225741|EXPERIMENTAL|training group|The single-session training lasted for approximately 40-45 minutes and was conducted in the training room of Sıtmapınarı family health center, as a suitable environment. The health belief model predicts the determinants of preventive health behaviors and explains inadequate participation in disease prevention and screening programs.22,23 Furthermore, this model not only explains behavior regarding screening, but also evaluates the cognitive factors that facilitate health-promoting behaviors.22-24
62572229|NCT03963232|PLACEBO_COMPARATOR|Placebo|"* Double-blind treatment phase: Participants received placebo once per month subcutaneously (SC) for 3 months.~* Open-label treatment phase: After completion of double-blind phase, participants could enter open-label treatment phase where they received 240 milligram (mg) loading dose of galcanezumab SC (2 injections of 120 mg) in the first month followed by 120 mg per month for 2 months.~* Follow-up phase: After completion or discontinuation from double-blind or open-label treatment phases, participants entered follow-up phase where they were observed for 4 months. No treatments administered."
62190691|NCT04225741|NO_INTERVENTION|Control Group|None of the interventions described above were applied to the control group.
62572230|NCT03963232|EXPERIMENTAL|Galcanezumab 120 mg|"* Double-blind treatment phase: Participants received 240 mg loading dose of galcanezumab SC (2 injections of 120 mg) in the first month followed by 120 mg per month for 2 months.~* Open-label treatment phase: After completion of double-blind phase, participants could enter open-label treatment phase where they continued to receive 120 mg galcanezumab SC per month for 3 months.~* Follow-up phase: After completion or discontinuation from double-blind or open-label treatment phases, participants entered follow-up phase where they were observed for 4 months. No treatments administered."
62572231|NCT01599260|EXPERIMENTAL|Resistance Exercise|Subjects will participate in a 16 week long resistance exercise program which will consist of 2 30-minute individually supervised sessions per week.
62572232|NCT05796219|OTHER|Low dose mammogram|Low dose mammo to compare with standard mammo
62190692|NCT01796054|EXPERIMENTAL|Stress Free Now with group support|Randomized participants have access to online stress reduction program, Stress Free Now. Participants will log in to online program, read daily lessons and practice therapeutic exercises. They will also attend weekly group support session during 6-week program
62190693|NCT01796054|EXPERIMENTAL|Stress Free Now|Randomized participants have access to online stress reduction program, Stress Free Now, for 6 weeks. Participants will log into online program, read daily lessons and practice therapeutic exercises.
62190694|NCT01796054|NO_INTERVENTION|Control|Randomized participants do not have access to online stress reduction program, Stress Free Now, nor do they attend weekly group support sessions.
62572233|NCT00264719|ACTIVE_COMPARATOR|A|Mothers with pre-term deliveries will receive metoclopramide 10 mg three times a day for the first 7 days and 2 times a day for the 8th to 10th day, and once a day for the 11th to 12th day
62572234|NCT00264719|PLACEBO_COMPARATOR|B|Mothers with pre-term deliveries will receive metoclopramide 10 mg 3 times a day, 2 times a day from 8th to 10th day and once a day from 11th to 12th day
62572235|NCT00264719|ACTIVE_COMPARATOR|C|Mothers with full term deliveries will receive 10 mg metoclopramide, 3 times a day for the first 7 days, 2 times a day from 8th to 10th day, and once a day for day 11 to 12
62572236|NCT00264719|PLACEBO_COMPARATOR|D|Mothers with full term deliveries will receive the placebo 10 mg three times a day, for 7 days, and two times a day from day 8 to day 10, and once a day from 11th to 12th day
62572237|NCT02412163||IM HTO Nail|Implant with the Ellipse IM HTO Nail
62190695|NCT04250779|PLACEBO_COMPARATOR|Control Group|In this arm, patients are provided with standard-of-care instructions on using MDIs correctly and regularly at home. The MDI usage is recorded using CapMedic device with active guidance turned off.
62190696|NCT04250779|ACTIVE_COMPARATOR|Treatment Group|In this arm, patients are provided with active guidance from CapMedic device on using MDIs correctly and regularly at home. The MDI usage is recorded using CapMedic device with active guidance turned on.
62190697|NCT02314351|ACTIVE_COMPARATOR|Intravenous metoclopramide|Intravenous metoclopramide, 10 mg (2 mL) in 98 mL 0.9% normal saline solution (total 100 mL)
62190698|NCT02314351|PLACEBO_COMPARATOR|Placebo|0.9% normal saline solution (total 100 mL)
62190699|NCT00698282|EXPERIMENTAL|1|
62190700|NCT00698282|EXPERIMENTAL|2|
62190701|NCT00698282|PLACEBO_COMPARATOR|3|
62190702|NCT01788475|ACTIVE_COMPARATOR|Dexamethasone implant up to every 3 Mo.|"Ozurdex (dexamethasone) 0.7 mg implant will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.~Re-implantation of Ozurdex (dexamethasone) may occur at any time \> 3 months following last injection in group 1 if any of the following conditions are met:~1. Increase of \> 50 microns from the best previous CRT measurement~2. Recurrence of intraretinal cystic edema~3. Persistent intraretinal cystic edema"
62190703|NCT01788475|ACTIVE_COMPARATOR|Dexamethasone implant up to every 6 Mo.|"Ozurdex (dexamethasone) 0.7 mg implant will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.~Re-implantation of Ozurdex (dexamethasone) may occur at any time \>6 months following last injection in group 2 if any of the following conditions are met:~1. Increase of \> 50 microns from the best previous CRT measurement~2. Recurrence of intraretinal cystic edema~3. Persistent intraretinal cystic edema"
62004959|NCT02188368|EXPERIMENTAL|A: POM 4mg+Steroids+(CFZ, BTZ, CY or CLA)|"POM 4 mg PO days 1-21 Steroids at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~BTZ (bortezomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~CFZ (carfilzomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~CLA (clarithromycin) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~CY (cyclophosphamide) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject)."
62004960|NCT02188368|EXPERIMENTAL|B: POM 3mg+PLD with or without steroids|"POM 3 mg PO days 1-21 Steroids (if the patient had received them) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~PLD at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject)."
62190704|NCT01788475|SHAM_COMPARATOR|Sham Implant|"Sham Procedure will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit. Also, at 13 months, patients in the sham group will be eligible for Ozurdex (dexamethasone) 0.7 mg implantation if initial inclusion/exclusion criteria are met. These patients would follow re-implantation guidelines of group 2.~Sham implantation may occur at any time \> 6 months following last sham injection in group 3 if any of the following conditions are met:~1. Increase of \> 50 microns from the best previous CRT measurement~2. Recurrence of intraretinal cystic edema~3. Persistent intraretinal cystic edema"
62396746|NCT03833609|EXPERIMENTAL|Online aerobic dance training (Group B)|Participants will receive the e-pamphlet on physical exercise and will be invited to complete an aerobic dance program. The aerobic dance program is a low to moderate intensity level program and will also use a video. The video, adapted for youth with JIA, was developed with feedback from a JIA patient with experience in aerobic dance and a physiotherapist with experience in pediatric rheumatology. The aerobic dance program will have the same characteristics in terms of frequency, total number of sessions and total duration as the yoga program (i.e., three 1-hour individual sessions and one 1-hour virtual group session per week for 12 weeks). Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
62396747|NCT03833609|NO_INTERVENTION|Wait list control (Group C)|Participants will receive the e-pamphlet on physical exercise and will be instructed to continue with their current medical care while they are on the wait list (12 weeks). After the completion of the study, the yoga and aerobic dance training videos will be available to all participants including those in the control group. In recruitment documents, this group will be termed the e-pamphlet group.
62396748|NCT05852301||HI-ART|People living with HIV with CD4+ T cells \> 800 c/uL on ART initiation
62396749|NCT05852301||HI-ART control|People living with HIV with CD4+ T cells between 500-800 c/uL on ART initiation
62572238|NCT05976997|EXPERIMENTAL|Duvelisib-Chidamide|Patients with newly diagnosed PTCL were treated with a combination of Duvelisib and Chidamide. The dose of Duvelisib was 25mg twice a day. Every 4 weeks (28 days) is a cycle with a total of 2 cycles.
62572239|NCT00684320|ACTIVE_COMPARATOR|2 Placebo Condition (PC)|The placebo, group will complete the PC procedure, which is identical to the ADT procedure except that during the presentation of the trials where a disgust or angry face is present, the probe will appear with equal frequency in the position of disgust or angry and neutral face. Thus, disgust, angry nor neutral face will have signal value regarding the position of the probe.
62572240|NCT00684320|EXPERIMENTAL|1 Attention Disengagement Training (ADT)|Those assigned to ADT condition will receive a computer delivered attention retraining protocol designed to enhance attention disengagement from socially threatening stimuli. The ADT protocol includes eight 30-min sessions delivered over a 6-week period (i.e., bi-weekly sessions). During each session, participants will see 320 trials that consist of the various combinations of probe type (E or F) probe position (top or bottom), and emotion type (Neutral, Disgust, Anger). 256 trials will include one neutral face and one disgust face or one angry face: 2 (probe type) X 2 (probe position) X 16 (person) X 4 (repetitions). On trials where participants see one neutral face and one disgust or angry face (i.e., 80% of the trials), the probe will always follow the neutral face.
62780148|NCT06303219|EXPERIMENTAL|TRADITIONAL MODERATE INTENSITY TRAINING|
62004961|NCT02188368|EXPERIMENTAL|C: POM MTD + other drugs|"Phase 1:~POM at escalating doses of 2 mg (Cycle 1), 3 mg (Cycle 2) or 4 mg (Cycle 3+) All other agents at the same dose and on the same days as the patients were receiving them in the lenalidomide-containing regimen they had failed~Phase 2:~POM at the MTD All other agents, at the same dose and on the same days as phase 1"
62004962|NCT03339375||control|Monitoring arterial pressure, central venous pressure and pulse pressure variation
62004963|NCT03339375||esophagela Doppler|Monitoring arterial pressure, central venous pressure Insertion of esophageal Doppler probe to patient Monitoring stroke volume, cardiac output, corrected flow time from esophageal Doppler Use stroke volume optimization goal directed therapy protocol
62004964|NCT00742976|ACTIVE_COMPARATOR|1|8 weeks of insulin Detemir, then cross over to 8 Weeks of Insulatard, then cross over to 1 week of Detemir
62004965|NCT00742976|ACTIVE_COMPARATOR|2|8 weeks of Insulin Insulatard, then cross over to 8 weeks of insulin Detemir, then crossover to 1 week of Insulin Insulatard
62004966|NCT05418556|ACTIVE_COMPARATOR|Conventional Arm|After PCI, patients are prescribed aspirin at a daily dose of 100 mg PO plus a P2Y12 inhibitor \[clopidogrel or ticagrelor or prasugrel according to the clinical diagnosis\] for 12 months after the index PCI.
62780149|NCT06303219|ACTIVE_COMPARATOR|HIGH INTENSITY INTERVAL TRAINING|
62780150|NCT05684029||Near-infrared Step|1. Use near-infrared equipment to detect surgical specimens; 2. Timing near-infrared equipment detects parathyroid glands and takes photography; 3. recording the positive tissue in NIRAF; 4. analyzing the accuracy of NIR equipment to see positive points.
62004967|NCT05418556|EXPERIMENTAL|Tailored Arm|The antiplatelet regimens post-PCI are 1-month DAPT (aspirin plus clopidogrel) followed by 11-months clopidogrel alone for CCS, and 3-months DAPT (aspirin plus P2Y12 inhibitor \[ticagrelor, prasugrel\]) followed by 9-months P2Y12 inhibitor alone for ACS.
62396750|NCT05852301||Hyper|People living with HIV with CD4+ T cells \>800 c/μL on ART initiation, but increase to \>1000c/μL within 48 months of ART initiation
62190705|NCT05426993||Patients diagnosed with lymphedema with metabolic syndrome|"Demographic information of the patients (age, height, weight, occupation, history), comorbid diseases (hypertension, diabetes, cardiac problems, circulatory problems, thyroid dysfunction), operation date, operation type, affected extremity, type of lymphedema will be recorded. In addition to these, mental status, edema and quality of life assessments will also be made.~As a treatment, extremity volume and quality of life evaluations will be made before and after the first phase of CDT (manual lymphatic drainage, skin care, compression therapy and exercises) for 3 weeks."
62190706|NCT05426993||Patients diagnosed with lymphedema without metabolic syndrome|"Demographic information of the patients (age, height, weight, occupation, history), comorbid diseases (hypertension, diabetes, cardiac problems, circulatory problems, thyroid dysfunction), operation date, operation type, affected extremity, type of lymphedema will be recorded. In addition to these, mental status, edema and quality of life assessments will also be made.~As a treatment, extremity volume and quality of life evaluations will be made before and after the first phase of CDT (manual lymphatic drainage, skin care, compression therapy and exercises) for 3 weeks."
62004968|NCT02041026|EXPERIMENTAL|probiotic yoghurt|the subject will be given 200ml of yogurt daily for 28 days
62004969|NCT04216862|EXPERIMENTAL|Strengthening exercise treatment|This exercise targets the deep flexor muscles of the upper cervical region the longus capitis and longus colli muscles.
62190707|NCT04510298|EXPERIMENTAL|SP-624|SP-624 oral capsule, 20 mg once daily
62190708|NCT04510298|PLACEBO_COMPARATOR|Placebo|Placebo oral capsule, once daily
62190709|NCT00616824|ACTIVE_COMPARATOR|Traditional Method|Arm which uses the Serratus Anterior muscle mobilization for lateral coverage of the tissue expander
62190710|NCT00616824|EXPERIMENTAL|Dermamatrix Arm|Arm which uses Dermamatrix as the lateral expander coverage
62190711|NCT05728190|EXPERIMENTAL|Lavender essential oil|In the intervention group, five days, seven drops of lavender essential oil were dripped onto a 5x5 gauze pad in the morning and evening, for 20 minutes, 10 cm away from the nose, and sniffed.
62190712|NCT05728190|PLACEBO_COMPARATOR|Steril/Salin water|Five days seven drops of saline/sterile water were dripped onto a 5x5 gauze pad in the morning and evening, and they were put to sniff for 20 minutes, 10 cm away from the nose.
62190713|NCT02719288|EXPERIMENTAL|CLARIX® CORD 1K|Applied in addition to standard of care tendon repair surgery.
62190714|NCT02719288|NO_INTERVENTION|Standard of care tendon repair surgery only|
62190715|NCT05526365|NO_INTERVENTION|Control|Participants in the control group will receive an initial 12 question baseline test (same as intervention). They will after two weeks receive a second test that is linguistically the same as the national GPhC exam.
62780151|NCT05684029||Senior Surgeon Step|1. Senior Surgeon inspects for parathyroid glands in postoperative thyroid specimens with the naked eye; 2. Timing senior doctors with parathyroid glands; 3. PTH test strips confirm all suspicious tissues. 4. all analyzing the accuracy of the positive points of senior doctors.
62190716|NCT05526365|EXPERIMENTAL|Intervention|Participants in the intervention group will receive an initial 12 question baseline test (same as control). They will after two weeks receive a second test that is reduced in idea density by around 10% overall.
62190717|NCT04278586|EXPERIMENTAL|Live-Online Mindful Recovery OUD Care Continuum|Live-Online Mindful Recovery OUD Care Continuum (M-ROCC) builds on other mindfulness interventions for addictive disorders, but is specifically designed for patients with OUD prescribed buprenorphine to be delivered in a live-online environment. It focuses on integration of mindfulness practice for living well through stress, anxiety, depression, pain and addiction recovery. The live-online M-ROCC curriculum has three primary components, including a low-dose mindfulness phase, an intensive mindfulness training phase and then a mindfulness maintenance check-in support group.
62780152|NCT04454242|EXPERIMENTAL|L-EMST|"At 30% of the maximum expiratory pressure (MEP), 25 breaths, 7 days / week, a total of 8 weeks will be trained once a day with a 1-minute rest cycle in 5 breaths.~Patients will be invited to control every 2 weeks. MEP measurements will be repeated and the training value will be adjusted in 30% of the new measurement."
62190718|NCT04278586|ACTIVE_COMPARATOR|Live-Online Control|A time- and attention-matched live online control group. The manualized control intervention developed for the basic group-based opioid treatment group in primary care uses 16 core modules and 8 elective modules that are common to eclectic approach in treatment as usual addiction recovery groups (including engagement and group development activities with a mix of basic CBT skills, twelve-step facilitation, community reinforcement, and motivational interviewing). As an active group control, this method will help to isolate mindfulness as the putative mechanism of action by controlling for the therapeutic aspects of group without any reference to mindfulness.
62190719|NCT01493037|OTHER|PICSO|PICSO treatment for 90 minutes
62190720|NCT00561899|EXPERIMENTAL|1|SP+AQ
62572241|NCT04124211|EXPERIMENTAL|FMT Arm|10 Participants will be enrolled in this arm to receive FMT treatment
62780153|NCT04454242|ACTIVE_COMPARATOR|H-EMST|"In 60% of the maximum expiratory pressure (MEP), 25 breaths a day, 7 days / week, a total of 8 weeks will be trained with a 1-minute rest cycle in 5 breaths.~Patients will be invited to control every 2 weeks. MEP measurements will be repeated and the training value will be adjusted in 60% of the new measurement."
62004970|NCT04216862|ACTIVE_COMPARATOR|Stretching exercise treatment|The subject's forearm is stabilized by a vertical plane before the trunk is rotated in the opposite direction. Therefore the arm on the involved side is externally rotated and abducted to 90.
62004971|NCT00219375|EXPERIMENTAL|E1|This arm is conducted as a separate study (12-601-0001)
62004972|NCT00219375|EXPERIMENTAL|E2|This arm is conducted as a separate study (12-603-0001).
62190721|NCT00561899|EXPERIMENTAL|2|Piperaquine plus SP arm
62190722|NCT00561899|EXPERIMENTAL|3|Du-Cotecxin
62396751|NCT05852301||Hyper control|People living with HIV with CD4+ T cells \<500 c/μL on ART initiation and reconstituted to 500-1000c/μL within 48 months of ART initiation
62396752|NCT02790476|EXPERIMENTAL|Letter intervention|The intervention arm will involve letters sent to prescribers in San Diego County.
62396753|NCT02790476|NO_INTERVENTION|Control|The control group will involve prescribers not receiving letters
62572242|NCT05446857|EXPERIMENTAL|Active Drug|All enrolled participants will receive Glecaprevir/Pibrentasvir
62190723|NCT02315768|EXPERIMENTAL|GA101+ibrutinib|"Ibrutinib 420 mg (140 mg capsules 3 times) orally once daily for up to 6 cycles.~GA101 (Obinutuzumab) by Intravenous infusion for up to 6 cycles (28 day cycles) as follows:~* Cycle 1, Day 1,100 mg GA101 obinutuzumab will be administered.~* Cycle 1, Day 2, 900 mg of GA101 obinutuzumab will be administered.~* Cycle 1, Days 8 and 15,1,000 mg of GA101 obinutuzumab will be administered.~* Cycles 2-6, Day 1, 1,000 mg of GA101 obinutuzumab will be administered."
62190724|NCT00705601||1|
62004973|NCT00219375|NO_INTERVENTION|conventional therapy|This arm is conducted as a separate study (12-602-0001)
62004974|NCT03448003|EXPERIMENTAL|Group I (IO prevention program)|Patients attend IO prevention program consisting of 1-2 physical activity, nutrition and diet, and mind-body practice sessions over 60 minutes weekly for 12 weeks. Patients also attend a behavioral counseling session once weekly for up to 26 weeks. Patients complete exercises over 30-60 minutes 3-5 times weekly for 12 weeks.
62004975|NCT03448003|ACTIVE_COMPARATOR|Group II (no intervention)|Patients receive no intervention. After 26 weeks, patients may crossover to Group I.
62004976|NCT03191539|EXPERIMENTAL|Apremilast|30 mg of Apremilast twice a day during 52 weeks. During the first 6 days will be a dose escalation as the following: Day 1: 10 mg daily Day 2: 10 mg day- 10 mg night Day 3: 10 mg day- 20 mg night Day 4: 20mg day- 20mg night Day 5: 20 mg day- 30 mg night Day 6: 30 mg day- 30 mg night
62004977|NCT03613207|EXPERIMENTAL|Dermal pharmacokinetic measurement|"Measurement of dermal pharmacokinetic (PK) parameters (AUC, Cmax) within each subject.~For dermal PK measurement cutaneous interstitial fluid will be sampled using dermal open flow microperfusion (dOFM). Additionally 8 blood samples will be drawn to rule out systemic appearance of lidocaine/prilocaine.~Each subject will have 9 test sites in total which are treated with:~* 2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~* 2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~* 2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~* test sites: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)~* 2 test sites: untreated test site"
62396754|NCT04492514|EXPERIMENTAL|Mavrilimumab|Mavrilimumab Treatment infusion
62780154|NCT01860950|ACTIVE_COMPARATOR|anodal tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder (Brand Phoresor-II Auto) . BCI entails listening to a 3-minute audio recording designed to mimic key components of cognitive behavioral therapy (CBT) for pain.
62780155|NCT01860950|ACTIVE_COMPARATOR|anodal tDCS plus pain-education|"Participants were provided pain education during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder.~Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing."
62004978|NCT02404363|EXPERIMENTAL|Clopidogrel|Clopidogrel tablets 75 mg for six months:
62004979|NCT02404363|PLACEBO_COMPARATOR|Comparator|Placebo tablet 75 mg for six months:
62190725|NCT04449237|OTHER|volunteer|40 volunteer will not accept any treatment
62396755|NCT04492514|PLACEBO_COMPARATOR|Placebo|Placebo infusion
62780156|NCT01860950|EXPERIMENTAL|cathodal tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode attached to the right shoulder and the cathode electrode placed over the left DLPFC. BCI entails listening to a 3-minute audio recording designed to mimic key components of cognitive behavioral therapy (CBT) for pain.
62190726|NCT04449237|PLACEBO_COMPARATOR|patients with unmodified music group|40 participants in this group will listen to music without any modification
62190727|NCT04449237|EXPERIMENTAL|patients with modified tinnitus relieving music|40 participants in this group will listen to the music modified according to the matched dominant tinnitus pitch
62190728|NCT03508947|EXPERIMENTAL|WVE-210201 (Dose A) or placebo|
62190729|NCT03508947|EXPERIMENTAL|WVE-210201 (Dose B) or placebo|
62396756|NCT03433443|ACTIVE_COMPARATOR|Control group|Usual physical rehabilitation group
62396757|NCT03433443|EXPERIMENTAL|Intervention group|Case manager assisted rehabilitation
62572243|NCT02890576||telemedicine|Setting up of a new organization of medical monitoring (ussing telemedicine) of patient having a cochlear implant
62572244|NCT00940615|EXPERIMENTAL|1|participants in the aerobic exercise intervention
62572245|NCT00940615|ACTIVE_COMPARATOR|2|participants in the stretching/toning control condition
62572246|NCT01346059|PLACEBO_COMPARATOR|Saline|The saline arm will receive normal saline through the catheter as a placebo.
62190730|NCT03508947|EXPERIMENTAL|WVE-210201 (Dose C) or placebo|
62396758|NCT06012149|EXPERIMENTAL|Braining|A 12 week program where participants are encouraged to participate in physical exercise at the psychiatric unit.
62396759|NCT06012149|ACTIVE_COMPARATOR|Structured advice on physical activity|Health interview and a 12 week program where participants are encouraged to engage in physical exercise outside the psychiatric setting.
62396760|NCT06248203|EXPERIMENTAL|Tealeaf - Adolescent|The Tealeaf-A arm will have three randomized schools. Teachers in the Tealeaf-A arm will receive six days of training and then supervision every 2 weeks to deliver care.
62396761|NCT06248203|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|The EUC arm will have three randomized schools and will be used as an ethical comparator for the Tealeaf-A arm. Teachers will receive two days of training, all materials, and no supervision.
62572247|NCT01346059|EXPERIMENTAL|Vancomycin|The vancomycin arm will receive vancomycin solution through the catheter.
62572248|NCT00552643|EXPERIMENTAL|1|Treatment with Polyheal 1
62572249|NCT00552643|ACTIVE_COMPARATOR|2|Saline
62572250|NCT04689035|EXPERIMENTAL|Cohort 1|AVLX-144_dose1
62780157|NCT01860950|EXPERIMENTAL|cathodal tDCS plus pain-education|Participants were provided pain education during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode attached to the right shoulder and the cathode electrode was placed over the left DLPFC. Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing.
62004980|NCT05487963|EXPERIMENTAL|CGB-500 topical ointment, 1% tofacitinib|
62004981|NCT05487963|PLACEBO_COMPARATOR|Vehicle topical ointment|
62004982|NCT04102475|EXPERIMENTAL|eatline group|
62004983|NCT04102475|SHAM_COMPARATOR|control group|
62396762|NCT04593082||Pediatric MS Subjects|Subjects with pediatric MS will undergo fasting lab work, non-contrasted MRI, DEXA scan, and surveys.
62396763|NCT04593082||Healthy controls|Non-MS pediatric control subjects who will undergo fasting lab work, DEXA scan, and surveys for comparison to control group.
62396764|NCT02760680|PLACEBO_COMPARATOR|Polysomnography|"The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines."
62004984|NCT01636895|EXPERIMENTAL|SP-IPTp efficacy|Efficacy of suphladoxine/pyrimethamine as IPTp
62572251|NCT04689035|EXPERIMENTAL|Cohort 2|AVLX-144_dose2
62572252|NCT04689035|EXPERIMENTAL|Cohort 3|AVLX-144_dose3
62572253|NCT04689035|EXPERIMENTAL|Cohort 4|AVLX-144_dose4
62572254|NCT04689035|EXPERIMENTAL|Cohort 5|AVLX-144_dose5
62572255|NCT04689035|EXPERIMENTAL|Cohort 6|AVLX-144_elderly
62572256|NCT04848051|EXPERIMENTAL|CRC screening reminder|Participants randomized to the CRC Reminder arm will receive reminder that they are due/overdue for CRC screening
62780158|NCT01860950|SHAM_COMPARATOR|sham tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session.
62780159|NCT01860950|SHAM_COMPARATOR|sham tDCS plus pain-education|Participants were provided pain education during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session. Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing.
62190731|NCT03508947|EXPERIMENTAL|WVE-210201 (Dose D) or placebo|
62190732|NCT03508947|EXPERIMENTAL|WVE-210201 (Dose E) or placebo|
62572257|NCT04848051|EXPERIMENTAL|CRC Reminder & Short message|Participants randomized to the CRC Reminder \& short message arm will receive reminder that they are due/overdue for CRC screening and short message to encourage screening
62572258|NCT04848051|EXPERIMENTAL|CRC Reminder and Navigation Program|Participants randomized to the CRC reminder and navigation program arm will receive reminder that they are due/overdue for CRC screening and short message to participate in the health navigation program that will connect participants to individually tailored resources and assistance
62780160|NCT00705146|ACTIVE_COMPARATOR|Comfort Cool Splint|Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks.
62780161|NCT00705146|ACTIVE_COMPARATOR|Hybrid Custom-made splint|The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks.
62780162|NCT04783077|ACTIVE_COMPARATOR|FRD Control|
62780163|NCT04783077|ACTIVE_COMPARATOR|VNRBD Control|
62780164|NCT04783077|EXPERIMENTAL|FRD WhatsApp|
62780165|NCT04783077|EXPERIMENTAL|VNRBD WhatsApp|
62780166|NCT04783077|EXPERIMENTAL|Docudrama|
62780167|NCT03116256|OTHER|VLCD only|Very low calorie diet (VLCD) only group- participants in this group will receive complete meal replacement for 6 weeks.
62780168|NCT03116256|ACTIVE_COMPARATOR|VLCD+RET|VLCD+RET group- participants in this group will receive complete meal replacement for 6 weeks and resistance exercise training 3 times every week for 6 weeks.
62780169|NCT03116256|ACTIVE_COMPARATOR|VLCD+HIIT|VLCD+HIIT group- participants in this group will receive complete meal replacement for 6 weeks and High intensity interval training 3 times every week for 6 weeks.
62780170|NCT05029739|EXPERIMENTAL|E-intervention group|Participants will be instructed to download a life-style-changing mobile app to which they will have access for 12 weeks. After the first week of the program, participants who smoke will be offered to incorporate smoking cessation support into their PAD program. These changes are minor and not intended to divide the intervention group in two but instead to personalize the study experience. The program aims to empower positive lifestyle change by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed. Beyond this, all patients in the interventional arm will also receive standard of care as defined below for the control arm.
62572259|NCT04848051|EXPERIMENTAL|CRC Reminder & CRC education|Participants randomized to the CRC reminder and CRC education program arm will receive reminder that they are due/overdue for CRC screening and offered short educational program conducted online
62780171|NCT05029739|ACTIVE_COMPARATOR|Standard of care - control group.|All patients in the control arm will receive best medical therapy including start or optimization of secondary preventive pharmacotherapy, smoking cessation advise and advise on modifiable risk factors. The control arm will also receive an information leaflet about relevant lifestyle modifications for PAD. After the baseline measurements and data collection, there will be no scheduled visits to a health care provider until week 12.
62572260|NCT00083759|ACTIVE_COMPARATOR|natalizumab|
62572261|NCT00083759|PLACEBO_COMPARATOR|placebo|
62572262|NCT06266195||GRUPPO CIRROSI|32 soggetti uomini o donne, \>18 anni con diagnosi di cirrosi epatica di differente eziologiA
62780172|NCT06195410|ACTIVE_COMPARATOR|Comparator: Intervention Group|
62780173|NCT06195410|SHAM_COMPARATOR|Comparator|
62780174|NCT02741427|PLACEBO_COMPARATOR|G1 (group 1) - Conventional toothpaste|G1 used a conventional toothpaste in daily oral regimen
62780175|NCT02741427|EXPERIMENTAL|G2 (group 2) - Whitening toothpaste|G2 used a whitening toothpaste containing blue pigment in daily oral regimen
62780176|NCT02741427|ACTIVE_COMPARATOR|G3 (group 3) - 10 % Carbamide peroxide|G3 made an at-home tooth bleaching with 10 % Carbamide peroxide
62780177|NCT00391625|EXPERIMENTAL|GA-GCB|15-60 U/kg every other week via intravenous infusion
62780178|NCT02479139|PLACEBO_COMPARATOR|Vehicle|Vehicle for botulinum toxin Type A topical liniment (ANT-1207) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
62572263|NCT06266195||GRUPPO HCC|32 pazienti uomini o donne, con diagnosi di neoplasia primitiva del fegato
62780179|NCT02479139|EXPERIMENTAL|ANT-1207 Dose 1|Botulinum toxin Type A topical liniment (ANT-1207) Dose 1 (lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
62780180|NCT02479139|EXPERIMENTAL|ANT-1207 Dose 2|Botulinum toxin Type A topical liniment (ANT-1207) Dose 2 (second lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
62780181|NCT02479139|EXPERIMENTAL|ANT-1207 Dose 3|Botulinum toxin Type A topical liniment (ANT-1207) Dose 3 (mid-level dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
62780182|NCT02479139|EXPERIMENTAL|ANT-1207 Dose 4|Botulinum toxin Type A topical liniment (ANT-1207) Dose 4 (second highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
62004985|NCT02128295|EXPERIMENTAL|Primiparous mothers|Mother who are primiparous
62004986|NCT02128295|EXPERIMENTAL|Multiparous mothers|Mothers who are multiparous
62004987|NCT04482569|EXPERIMENTAL|Single Ascending Dose Study|Six XNW4107 doses ( 50-1250 mg ), each administered as a single dose with 60-minute IV infusion
62004988|NCT04482569|EXPERIMENTAL|Multiple Ascending Dose Study|Three XNW4107 doses (167-500 mg), each administered as 60-minute IV infusion every 6 hours for 7 days
62004989|NCT04482569|EXPERIMENTAL|Multiple Dose Study of XNW4107 +Imipenem/Cilastatin|500 mg XNW4107 co-administered with imipenem/cilastatin as 60-minute IV infusion every 6 hours for 14 days
62004990|NCT02107703|EXPERIMENTAL|Abemaciclib + Fulvestrant|Abemaciclib 150 milligram (mg) administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.
62004991|NCT02107703|PLACEBO_COMPARATOR|Placebo + Fulvestrant|Placebo administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.
62004992|NCT05276804|EXPERIMENTAL|Sugammadex|Prospective cohort of patients undergoing laparoscopic inguinal hernia repair will receive Sugammadex. Sugammadex will be used for reversal of their neuromuscular blockade. The dosing for Sugammadex is 4mg/kg for a deep reversal and a 2mg/kg for a standard reversal, which will be more common for this study. Sugammadex comes in 200mg/2mL and 500mg/5mL vials. Because of the variability in weight of the patients and the type of reversal needed (deep vs standard), 140 5mL vials will be required.
62004993|NCT05276804|NO_INTERVENTION|Retrospective cohort|Retrospective cohort of patients who did not receive Sugammadex
62004994|NCT06141629|ACTIVE_COMPARATOR|Accu-Chek Aviva Expert.|Accu-Chek Aviva Expert. This is a glucometer with boluscalculator.
62004995|NCT06141629|PLACEBO_COMPARATOR|Accu check Nano|Accu check Nano
62004996|NCT03568422|EXPERIMENTAL|CFI-402257 + Paclitaxel|Oral CFI-402257 on intermittent schedule:\* days 1, 2, 8, 9, 15 \& 16 q4w Plus Paclitaxel 80 mg/m2 IV days 1, 8 \& 15 every 28 days
62004997|NCT02093546||Ancillary-correlative (Biospecimen collection)|Patients undergo collection of blood at screening, between days 3 and 5, 28, and 56. Patients also undergo collection of tumor biopsy at screening and day 28.
62004998|NCT01441193|EXPERIMENTAL|HIV-1 Tat/delta-V2 Env combined vaccine|Tat 7.5 microg and delta-V2 Env 100 microg associated proteins administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at weeks 24 and 36
62004999|NCT01441193|ACTIVE_COMPARATOR|HIV-1 delta-V2 Env vaccine|delta-V2 Env 100 microg administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at week 24 and 36
62005000|NCT01441193|ACTIVE_COMPARATOR|HIV-1 Tat vaccine 7.5 microg|Tat 7.5 microg administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at week 24 and 36
62005001|NCT01441193|ACTIVE_COMPARATOR|HIV-1 Tat vaccine 30 microg|Tat 30 microg administered i.d. at week 0, 4 and 8
62005002|NCT04389411|EXPERIMENTAL|Montelukast|10mg Oral Montelukast once daily for 60 days
62005003|NCT04389411|PLACEBO_COMPARATOR|Placebo|Placebo.
62005004|NCT05318638|OTHER|Study group|All participants in the study will perform arm/hand movement tasks in both of two conditions (with and without soft-robotic glove), so they constitute 1 study arm, but all receiving both intervention conditions (experimental - with glove and control - without glove).
62005005|NCT00556842|ACTIVE_COMPARATOR|1|Participants will undergo total hip arthroplasty.
62005006|NCT00556842|ACTIVE_COMPARATOR|2|Participants will undergo hemi-arthroplasty.
62780183|NCT02479139|EXPERIMENTAL|ANT-1207 Dose 5|Botulinum toxin Type A topical liniment (ANT-1207) Dose 5 (highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
62780184|NCT02193308|EXPERIMENTAL|Telmisartan/Amlodipine FDC|
62780185|NCT02193308|ACTIVE_COMPARATOR|Telmisartan + Amlodipine mono|
62780186|NCT04952246||multiple sclerosis group|
62780187|NCT04952246||non-prognosis group|
62780188|NCT05009329|EXPERIMENTAL|Phase 1 Dose Exploration|Dose escalation of JAB-21822 to determine maximum tolerated dose.
62190733|NCT05638347|EXPERIMENTAL|HRS-7085 tablets Cohort 1|Part 1- HRS-7085 tablets
62190734|NCT05638347|EXPERIMENTAL|HRS-7085 tablets Cohort 6|Part 1- HRS-7085 tablets
62190735|NCT01941238||Insulin pump|
62572264|NCT02909335|ACTIVE_COMPARATOR|Tacrolimus group|Tacrolimus + mycophenolate mofetil + corticosteroids
62572265|NCT02909335|EXPERIMENTAL|Everolimus group|Everolimus + mycophenolate mofetil + corticosteroids
62572266|NCT02264626|EXPERIMENTAL|acutely ill patients|administration of remifentanil at the infusion rate by 0.025 μg kg-1 min-1 to a maximum of 0.10 μg kg-1 min-1.
62572267|NCT05235412||Chinese mothers with the intention to breastfeed, and their infants.|Observational study.
62190736|NCT01941238||MDI|
62190737|NCT01114451|EXPERIMENTAL|Early Staple Removal|Skin staple removal on post-operative day #3
62190738|NCT01114451|EXPERIMENTAL|Delayed Staple Removal|Skin staple removal on post-operative day 7-10
62190739|NCT05121389|EXPERIMENTAL|study group|Patients of study group will receive intravenous normal saline 30cc per kilogram of body weight, one fifth of which will be given as a bolus followed by delivery of the remaining four fifth as a constant infusion over a period of 12 hours.
62190740|NCT05121389|SHAM_COMPARATOR|control group|Patients of control group will receive intravenous normal saline 10cc per kilogram of body weight as a constant infusion in the first 12 hours.
62190741|NCT04565262|EXPERIMENTAL|NAs+IFN-α|NAs+IFN-α/ 96w
62190742|NCT04565262|OTHER|NAs+(IFN-α+ NAs )|NAs/48w+(IFN-α+ NAs)/96w
62190743|NCT01457274|EXPERIMENTAL|"light sedation"|"In this study the depth of sedation will be guided by the Bispectral Index monitor (BIS monitor). A BIS value of 70-80 will be targeted in the light sedation arm."
62190744|NCT01457274|ACTIVE_COMPARATOR|"deep sedation"|"In this study the deep sedation arm will have a BIS value of less than 60 targeted."
62190745|NCT01337362|ACTIVE_COMPARATOR|Patients with hypoglycemia awareness|Patients who have symptoms when the blood sugar level is low
62190746|NCT01337362|EXPERIMENTAL|patients with hypoglycaemic unawareness.|Patients who do not feel any symptoms when the blood sugar levels are low
62572268|NCT00912743|EXPERIMENTAL|1|MSI - H arm
62190747|NCT05057247|EXPERIMENTAL|Duvelisib plus Docetaxel chemotherapy|"Participants will receive duvelisib by mouth twice daily,dosage per protocol continuously (days 1-21 of a 21-day cycle) with a 7-day lead-in planned prior to the start of taxane therapy.~Docetaxel at via IV will be delivered on day 1 of each 21-day cycle.~Treatment will continue for 24-months or until unacceptable toxicity, progression, or death."
62190748|NCT02214680|EXPERIMENTAL|Combination of Brimonidine and Timolol|On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.
62572269|NCT04290221|EXPERIMENTAL|Percutaneous electrolysis in the lumbar nerv|This group will be treated with intratissue percutaneous electrolysis using a needle G32 with galvanic current as a cathodic flow electrode in the posterior nerve root of L3, L4 and L5, bilaterally (one times per week / 3 weeks). The intervention will be guided by ultrasound equipment medically certified (Directive 93/42 / EEC) device (EPI Advanced Medicine, Barcelona, Spain).
62572270|NCT04290221|ACTIVE_COMPARATOR|Electrical dry needling in trigger points|It consists in apply the electrical dry needling on active and/or latent TPs in the gluteus medius, quadratus lumborum, and erector spinae muscles of the subjects L3 (one times per week / 6 weeks).
62190749|NCT01831037||Regression of fibrosis|Group conformed by patients experiencing improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
62190750|NCT01831037||No regression of fibrosis|Group conformed by patients not showing the predefined improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
62190751|NCT00575042|EXPERIMENTAL|Patients treated with Fenofibrate|Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) 160 mg table per day for 1 year
62190752|NCT00755729|EXPERIMENTAL|OCH|fast from midnight the night before surgery, and consume 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
62572271|NCT06092788|EXPERIMENTAL|NTP42:KVA4 Capsule|
62572272|NCT06092788|ACTIVE_COMPARATOR|NTP42:KVA4 Oral Suspension|
62572273|NCT05245526|EXPERIMENTAL|Healthy adult participants|All participants are enrolled in the test group and receive the noninvasive adhesive reprocessed pulse oximeter sensors.
62190753|NCT00755729|NO_INTERVENTION|FSD|fast from midnight the night before surgery, and no preoperative oral carbohydrate loading
62190754|NCT02405897|EXPERIMENTAL|Cup forceps|4 biopsies (transbronchial lung biopsy) with Cup forceps
62190755|NCT02405897|ACTIVE_COMPARATOR|Alligator forceps|4 biopsies (transbronchial lung biopsy) with Alligator forceps
62190756|NCT00652509|EXPERIMENTAL|1|IDEA
62190757|NCT00652509|ACTIVE_COMPARATOR|2|IE
62190758|NCT00652509|NO_INTERVENTION|3|UC: Patients receive no research intervention.
62190759|NCT06056089|ACTIVE_COMPARATOR|Control Group|1 sachet (535 kcal) of RUSF per day
62572274|NCT05841563|EXPERIMENTAL|PM54|"Phase Ia (dose escalation) stage: Patients will receive PM54 i.v. at a starting dose of 0.3 mg/m2.~Phase Ib (expansion) stage: Patients will receive PM54 i.v. at the RD determined during the Phase Ia stage."
62190760|NCT06056089|EXPERIMENTAL|MAM Experimental A|1 sachet (500 kcal) of RUTF per day
62190761|NCT06056089|EXPERIMENTAL|MAM Experimental B|2 sachets (1000 kcal) of RUTF per day
62190762|NCT06398990|EXPERIMENTAL|Cognitive Exercise Therapy Approach|Cognitive exercise therapy sessions will consist of exercises including various movements in one session and the exercises will be worked with respiratory control, accompanied by a physiotherapist.
62190763|NCT06398990|EXPERIMENTAL|Yoga Programme|Yoga sessions will consist of exercises including various movements in one session and the exercises will be practised with respiratory control, accompanied by a physiotherapist.
62190764|NCT06398990|OTHER|Routine Medical Treatment|Individuals in this group will receive medical treatment recommended by the relevant physician.
62190765|NCT04727983|NO_INTERVENTION|Pelvic Floor Muscle Function|Pelvic floor muscle function will be evulated with the Modified Oxford Scale
62572275|NCT02901210|EXPERIMENTAL|Modified Delorme|Modified technique for delorme procedure done in mild to moderate rectal prolapse as the investigator destroy use the electrocautery to peal the mucosa with less intraoperative bleeding ,avoiding stripping of the mucosa done in classic delorme that induce major bleeding intraoperative .
62005007|NCT00841438|ACTIVE_COMPARATOR|Provisional use of Clotinab|Provisional use of clotinab
62572276|NCT01591135|ACTIVE_COMPARATOR|Cisplatin|Chemoradiotherapy with cisplatin and 5-fluorouracil for 2 cycles followed by adjuvant chemotherapy for 2 cycles.
62572277|NCT01591135|EXPERIMENTAL|Paclitaxel|Patients randomized in Arm B will receive chemoradiation with weekly paclitaxel and 5-fluorouracil for 5 weeks followed by adjuvant chemotherapy with paclitaxel and 5-fluorouracil for 2 cycles.
62572278|NCT04335890|EXPERIMENTAL|DC IKKb|Vaccination with IKKb matured RNA loaded Dendritic Cells
62572279|NCT00529620|ACTIVE_COMPARATOR|1|sulfalene pyrimethamine plus amodiaquine
62572280|NCT00529620|ACTIVE_COMPARATOR|2|dihydroartemisinin piperaquine
62572281|NCT00529620|ACTIVE_COMPARATOR|3|sulfadoxine-pyrimethamine plus piperaquine
62572282|NCT05106140||Stroke Participants|This group will include stroke survivors from the Calgary Stroke Program who are over 18 years of age.
62572283|NCT05106140||Control Participants|This group will include healthy individuals from the community who are matched for age and sex to stroke participants.
62572284|NCT04607564|EXPERIMENTAL|No comparison pilot group|Attendance at ten Ntombi Vimbela workshops running for a total 35 hours over six weeks.
62780189|NCT05009329|EXPERIMENTAL|Phase IIa Dose Expansion|Patients with KRAS p.G12C mutant advanced non small cell lung cancer or other solid tumors will be enrolled and treated at the monotherapy RP2D to evaluate the safety and preliminary efficacy.
62780190|NCT05009329|EXPERIMENTAL|Phase IIb|Patients with KRAS p.G12C mutant advanced non small cell lung cancer will be enrolled and treated at the monotherapy RP2D to evaluate the safety and efficacy.
62780191|NCT01745042||android postmenopausal women|Clinical exams
62780192|NCT01745042||gynoid postmenopausal women|Clinical exams
62005008|NCT00841438|EXPERIMENTAL|Upstream use of clotinab|early upstream use of clotinab
62572285|NCT04010760||PE confirmed|Patients admitted with confirmed pulmonary embolism.
62572286|NCT04010760||PE suspected|Patients admitted with suspected, but not confirmed pulmonary embolism.
62572287|NCT04010760||Controls|Healthy controls same gender and age (within af range of 10 years) as PE patients
62005009|NCT02839499|EXPERIMENTAL|mixed food|experimental group with RU sleeping®, autonomy scale (ADL and AGGIR) and various activity scale (IADL)
62005010|NCT02839499|OTHER|normal texture food|control group with RU sleeping®, autonomy scale (ADL and AGGIR) and various activity scale (IADL)
62005011|NCT01158625|NO_INTERVENTION|Morning dosing of antihypertensive drugs|
62005012|NCT01158625|ACTIVE_COMPARATOR|Nighttime dosing of antihypertensive drugs|
62005013|NCT02189187|EXPERIMENTAL|Mindfulness Based Stress Reduction (MBSR) program|Mindfulness Based Stress Reduction (MBSR) is an 8-week program that consists of training in mindfulness practices, the application of mindfulness to daily life, and information about healthy living and the role played by thoughts and emotions in health.
62005014|NCT02189187|ACTIVE_COMPARATOR|Healthy Living Course (HLC)|Healthy Living Course (HLC) an 8-week psycho-educational program that consists of lectures and discussion on healthy living, stress management, time management, and unhealthy behaviors (e.g. smoking, drinking).
62005015|NCT03076138|EXPERIMENTAL|Test group|Bone grafting with gene-activated matrix (OCP + plasmid DNA with VEGF gene)
62005016|NCT02703103|EXPERIMENTAL|Standard cardiopulmonary resuscitation|standard CPR (30:2) according to European Resuscitation Council 2015 guidelines for cardiopulmonary resuscitation.
62005017|NCT02703103|EXPERIMENTAL|asynchronous cardiopulmonary resuscitation|asynchronuos CPR according to European Resuscitation Council 2015 guidelines for cardiopulmonary resuscitation.
62005018|NCT00179413|ACTIVE_COMPARATOR|PEG-Intron|PEG-Intron 0.5mcg/kg once a week SC
62005019|NCT00179413|ACTIVE_COMPARATOR|Colchicine|0.6mg twice a day
62005020|NCT00803127||no treament|
62005021|NCT03252522|EXPERIMENTAL|Intervention|Capsules of broad spectrum micronutrients: a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants.
62005022|NCT03252522|PLACEBO_COMPARATOR|Placebo|Capsules of inactive placebo.
62005023|NCT03252522|EXPERIMENTAL|Open Label|All participants have the option to participate in an 8-week, naturalistic, open label follow-up in which the child will take the active micronutrient treatment; capsules of broad spectrum micronutrients.
62005024|NCT02327429|EXPERIMENTAL|A Chinese menu plan for type 2 diabetes|All participants will be in the intervention arm for this pilot study
62005025|NCT05571059|EXPERIMENTAL|Ifetroban Sodium|Drug: Ifetroban Oral capsule, 250 mg, once daily for 12 months
62005026|NCT05571059|PLACEBO_COMPARATOR|Placebo|Drug: Placebo Matching placebo, oral capsule, once daily for 12 months
62005027|NCT05892627|EXPERIMENTAL|PoZibio|PoZibio, twice daily (50 x 10\^9 CFUs/ CAPSULE) for 6 weeks
62005028|NCT05892627|PLACEBO_COMPARATOR|Placebo|Placebo, twice daily for 6 weeks
62572288|NCT02557282||Predicate software|Olea Sphere PACS with CT Perfusion Module
62572289|NCT02557282||Investigational software|Vue PACS 12.1.5 Computed Tomography (CT) Perfusion
62780193|NCT03492801||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood samples at baseline and every 12 weeks for up to 6 times.
62780194|NCT05621174|OTHER|Magisterial Dexamphetamine|Magisterial Dexamphetamine
62005029|NCT03784950|EXPERIMENTAL|Rating tool only|Rating eConsults from peer specialists in first phase
62005030|NCT03784950|EXPERIMENTAL|Feedback only|Receiving feedback from peer specialists in first phase
62005031|NCT03784950|EXPERIMENTAL|Rating Tool plus Feedback|Both rating and feedback in second phase.
62005032|NCT04524273|EXPERIMENTAL|Inebilizumab, (AChR-Ab+) MG|"Participants will receive inebilizumab administered intravenously (IV) on Days 1, 15, and 183 of the RCP.~Participants who elect to enter the open label phase (OLP) will receive inebilizumab administered IV on OLP Days 1, IV placebo on OLP Day 15 (to avoid potential unblinding), and inebilizumab IV on OLP Days 183, 365, 547, 729, and 911."
62005033|NCT04524273|PLACEBO_COMPARATOR|Placebo, (AChR-Ab+) MG|"Participants will receive placebo administered IV on Days 1, 15, and 183 of the RCP.~Participants who elect to enter the OLP will receive inebilizumab administered IV on OLP Days 1,15, 183, 365, 547, 729, and 911."
62005034|NCT04524273|EXPERIMENTAL|Inebilizumab, (MuSK-Ab+) MG|"Participants will receive inebilizumab administered IV on Days 1 and 15 of the RCP.~Participants who elect to enter the OLP will receive inebilizumab administered IV on OLP Day 1, IV placebo on OLP Day 15 (to avoid potential unblinding), and inebilizumab IV on OLP Days 183, 365, 547, 729, and 911."
62190766|NCT04727983|NO_INTERVENTION|Bladder function|Bladder function will be evulated with the urinary diary for 3 days
62190767|NCT04727983|NO_INTERVENTION|Incontinence Symptoms|Incontinence Symptoms will be evulated with The International Incontinence Consultation Questionnaire-Short Form (ICIQ-SF) and the Coital Incontinence Score (CIS)
62190768|NCT04727983|NO_INTERVENTION|Quality of Life|Quality of life will be evulated with the King Health Questionnaire (KHQ)
62190769|NCT04727983|NO_INTERVENTION|Sexual Function|Sexual Function will be evaluated with Pelvic Organ Prolapse / Urinary Incontinence Sexual Questionnaire (PISQ-12).
62005035|NCT04524273|PLACEBO_COMPARATOR|Placebo, (MuSK-Ab+) MG|Participants will receive placebo administered IV on Days 1 and 15 of the RCP. Participants who elect to enter the OLP will receive inebilizumab administered IV on OLP Days 1,15, 183, 365, 547, 729, and 911.
62005036|NCT01849705||All subjects|No intervention
62005037|NCT02956213|EXPERIMENTAL|ARM 1 MERV17 first|"This group will receive a portable HEPA air filtering device with MERV17 air filter for the first part of the study. At cross over, this group will receive the placebo or no high-efficiency filter."
62005038|NCT02956213|ACTIVE_COMPARATOR|ARM 2 MERV17 second|This group will receive a HEPA portable air filter with no high efficiency air filter for the first part of the study. At cross over, this group will receive the high-efficiency MERV17 air filter.
62005039|NCT01448668||Test group with Iscador® Qu|The test group will receive the mistletoe extract Iscador® Qu as supportive treatment in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
62005040|NCT01448668||Control group|The parallel control group will receive no mistletoe but only post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
62005041|NCT05168007|EXPERIMENTAL|Cariprazine 3mg/day|WID-RGC20(Cariprazine) 3 mg/day
62005042|NCT05168007|EXPERIMENTAL|Cariprazine 6mg/day|WID-RGC20(Cariprazine) 6 mg/day
62005043|NCT05168007|PLACEBO_COMPARATOR|Placebo|Placebo for WID-RGC20(Cariprazine) 3 mg/day or 6mg/day
62005044|NCT00228891|ACTIVE_COMPARATOR|2|Patients with diagnosed diabetic neuropathy will receive objective baseline testing and follow up testing every six months after the start of Pulsatile intravenous insulin therapy to monitor and assess diabetic neuropathy.
62005045|NCT00228891|PLACEBO_COMPARATOR|1|Control patients with diabetic neuropathy will receive objective testing at baseline and every six months to compare and measure results with patients who are receiving pulsatile intravenous insulin therapy.
62005046|NCT05000645|NO_INTERVENTION|Women, Infants, and Children (WIC)|Usual WIC counseling and food benefits for use in person at approved grocery stores.
62005047|NCT05000645|EXPERIMENTAL|WIC + grocery delivery|Usual WIC counseling and food benefits, as well as twice-monthly home deliveries of WIC-approved foods.
62190770|NCT04727983|EXPERIMENTAL|NMES group|The first group will be given Neuromuscular Electrical Stimulation (NMES) and lifestyle suggestions (LSS)
62190771|NCT04727983|SHAM_COMPARATOR|SHAM ES group|The second group will be given sham NMES in addition to LSS
62572290|NCT00873392|EXPERIMENTAL|1|Experimental drug
62572291|NCT00873392|ACTIVE_COMPARATOR|2|Usual treatment
62780195|NCT05621174|OTHER|Tentin|Tentin
62005048|NCT05000645|EXPERIMENTAL|WIC + grocery delivery + unsweetened beverage delivery|Usual WIC counseling and food benefits as well as twice-monthly home deliveries of WIC-approved foods PLUS unsweetened beverages to replace their current sugar-sweetened beverages (SSB) intake.
62190772|NCT04727983|NO_INTERVENTION|End of Treatment Special Evaluations|Subjective perception of improvement and treatment satisfaction of the patients will be questioned
62780196|NCT05506527|EXPERIMENTAL|study group 1|Study group A: will receive combined plyometric exercises and sensorimotor program
62780197|NCT05506527|EXPERIMENTAL|study group 2|Study group B: will receive sensorimotor program alone
62780198|NCT00753363|EXPERIMENTAL|Arm 1|6 months of aerobic exercise training
62780199|NCT00753363|EXPERIMENTAL|Arm 2|6 months of weight loss
62780200|NCT06429800|EXPERIMENTAL|Cohort LN: ATA3219 Dose Level -1|Participants will receive a single IV infusion of ATA3219 Dose Level -1 (if required) on Day 1 of a 28-day dose limiting toxicity (DLT) observation period.
62780201|NCT06429800|EXPERIMENTAL|Cohort LN: ATA3219 Dose Level 1|Participants will receive a single IV infusion of ATA3219 Dose Level 1 on Day 1 of a 28-day DLT observation period.
62780202|NCT06429800|EXPERIMENTAL|Cohort LN: ATA3219 Dose Level 2|Participants will receive a single IV infusion of ATA3219 Dose Level 2 on Day 1 of a 28-day DLT observation period.
62780203|NCT06429800|EXPERIMENTAL|Cohort LN: ATA3219 Dose Level 3|Participants will receive a single IV infusion of ATA3219 Dose Level 3 on Day 1 of a 28-day DLT observation period.
62780204|NCT06429800|EXPERIMENTAL|Cohort ERL: ATA3219 Dose Level -1|Participants will receive a single IV infusion of ATA3219 Dose Level -1 (if required) on Day 1 of a 28-day DLT observation period.
62780205|NCT06429800|EXPERIMENTAL|Cohort ERL: ATA3219 Dose Level 1|Participants will receive a single IV infusion of ATA3219 Dose Level 1 on Day 1 of a 28-day DLT observation period.
62780206|NCT06429800|EXPERIMENTAL|Cohort ERL: ATA3219 Dose Level 2|Participants will receive a single IV infusion of ATA3219 Dose Level 2 on Day 1 of a 28-day DLT observation period.
62780207|NCT06429800|EXPERIMENTAL|Cohort ERL: ATA3219 Dose Level 3|Participants will receive a single IV infusion of ATA3219 Dose Level 3 on Day 1 of a 28-day DLT observation period.
62780208|NCT05284344||patients with newly diagnosed type 2 diabetes|Newly diagnosed, drug-naïve, Chinese patients with type 2 diabetes.
62780209|NCT05284344||Non-diabetic control subjects|
62780210|NCT06501612|EXPERIMENTAL|CGM plus Undermyfork group|Participants will be provided continuous glucose monitors (Dexcom G7) to monitor blood glucose for the entire duration of this study (i.e., one new device every 10 days for a total of 2 devices) and will be instructed to use the mobile food diary application. A post-Undermyfork satisfaction qualitative interview will be administered and compensation provided when the CGM is removed and survey completed.
62780211|NCT06501612|ACTIVE_COMPARATOR|CGM Only group|Participants will be provided continuous glucose monitors (Dexcom G7) to monitor blood glucose for the entire duration of this study (i.e., one new device every 10 days for a total of 2 devices).
62780212|NCT00293020|EXPERIMENTAL|1|BEMA Fentanyl
62780213|NCT00562991||FeNO group|asthma patients, exhaled NO is used to monitor asthma
62780214|NCT00562991||Symptom group|asthma patients, exhaled NO is not used to monitor asthma
62190773|NCT04686292||Suspected infection|All patients admitted to the emergency department with suspected infections assessed by the receiving physician
62190774|NCT00632502|EXPERIMENTAL|Navarixin|Navarixin (MK-7123, SCH 527123) 30 mg capsule, to be taken by mouth once daily in the morning for 4 weeks
62190775|NCT00632502|PLACEBO_COMPARATOR|Placebo|Placebo capsule to match navarixin, to be taken by mouth once daily in the morning for 4 weeks
62190776|NCT01191554|EXPERIMENTAL|High dosage|A loading dose of 30 mg/kg and a maintenance infusion of 16 mg/kg through out the operation, and 2 mg/kg into the cardiopulmonary bypass (CPB) prime volume.
62190777|NCT01191554|EXPERIMENTAL|Low dosage|A loading dose of 10 mg/kg and a maintenance infusion of 1 mg/kg through out the operation, and 1 mg/kg into the cardiopulmonary bypass (CPB) prime volume.
62190778|NCT03264690||Microbial composition measured from IBD and non-IBD groups|Participants with inflammatory bowel disease (IBD) and non-IBD will be measured for microbial composition.
62190779|NCT01782521|NO_INTERVENTION|Primer|Metal brackets bonded with primer
62190780|NCT01782521|EXPERIMENTAL|No primer|Metal brackets bonded without primer
62190781|NCT02786004|EXPERIMENTAL|Full Field Digital Mammography|2-dimensional breast imaging
62572292|NCT00674648|EXPERIMENTAL|1|This is a non-randomized single institution phase I dose escalation trial, designed to evaluate the toxicity and anti-viral activity of CMV-pp65 peptide-specific T cell lines, generated in vitro from CMV seropositive normal HSCT and 3rd party donors, when adoptively transferred to treat recipients of these transplants who have a CMV infection or persistent CMV antigenemia and are therefore at high risk of a life-threatening CMV infection.
62572293|NCT00880113||Acute stroke|Patients over 18 years of age with acute stroke symptoms of less then 9 hours duration and no hemorrhage on non-contrast CT.
62572294|NCT03426306|EXPERIMENTAL|4DCT-ventilation|The patient will undergo 4DCT imaging. The 4DCT imaging data along with image processing techniques will be used to generate a 4DCT-ventilation map. All surgical decisions will be based on the current standard of care imaging (VQ scans) and not on the 4DCT imaging results.
62572295|NCT00351702|ACTIVE_COMPARATOR|Isoniazid|Isoniazid (300mg) daily for 36 months
62572296|NCT00351702|EXPERIMENTAL|Isoniazid + Ethambutol|Isoniazid (300 mg) + Ethambutol (800 mg) daily for 6 months
62190782|NCT02786004|EXPERIMENTAL|Digital Breast Tomosynthesis|3-dimensional breast imaging
62190783|NCT05253768|EXPERIMENTAL|intervention|Patients who receive a fecal microbiota transplantation via a nasointestinal tube.
62190784|NCT05253768|PLACEBO_COMPARATOR|placebo|Patients who receive a placebo FMT via a nasointestinal tube.
62190785|NCT06402942|EXPERIMENTAL|Experimental group|Gamified occupational therapy programme group
62190786|NCT06402942|OTHER|Control group|Classic occupational therapy group
62572297|NCT03809338||flight attendant women|Assesment antral follicle count on day 3 5ml blood sample to be taken
62572298|NCT03809338||day working women|Assesment antral follicle count on day 3 5ml blood sample to be taken
62572299|NCT00954772||Staged Bilateral STN DBS|
62572300|NCT00954772||Simultaneous Bilateral STN DBS|
62190787|NCT02036437|EXPERIMENTAL|Cases|A dose of 20ug is required obtained by dissolving the 200ug tablet (Misotac® Sigma Pharmaceutical Industries) in 200 ml water (1ug per ml), the solution is shaked well before each administration. The solution will be orally administrated every two hours (max. 12 hrs) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy.
62190788|NCT02036437|ACTIVE_COMPARATOR|Control|Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
62190789|NCT01807429|EXPERIMENTAL|Ketamine-midazolam|300 to 500 mcg/kg ketamine plus 0.03 mg/kg midazolam
62190790|NCT01807429|ACTIVE_COMPARATOR|Morphine|0.05 to 0.1 mg/kg morphine
62572301|NCT02318680|EXPERIMENTAL|Intervention|Review of follow home visits after discharge from Nykøbing Falster Hospital
62572302|NCT02318680|NO_INTERVENTION|Control|Standard health care and discharge services
62190791|NCT00661843|EXPERIMENTAL|1|Intervention group: Intervention constitutes of 2 supervised yoga classes per week incorporating gentle Yoga postures, relaxation and meditation sequences In addition: daily home based sessions of yogic relaxation and meditation using a pre-recorded audio CD
62190792|NCT00661843|NO_INTERVENTION|2|Control in waiting to be crossed over after control phase completed. Participants of this group studied using same objective and subjective outcome measures.
62190793|NCT01322737|EXPERIMENTAL|SUMO Tissue Access and Resection System|
62190794|NCT02367430|EXPERIMENTAL|Critical Time Intervention for Hoarding Disorder|Patients with Hoarding Disorder received CTI Model
62190795|NCT06130072|ACTIVE_COMPARATOR|Hysteroscopic tubal occlusion using iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil|Group 2 including 20 patients with hydrosalpinx refaired for hysteroscopic tubal occlusion prior to IVF using iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil.
62572303|NCT01028014|ACTIVE_COMPARATOR|Pseudoephedrine|Pseudoephedrine 120mg extended release tablets
62572304|NCT01028014|ACTIVE_COMPARATOR|Solifenacin|Solifenacin 5mg capsule
62572305|NCT01028014|ACTIVE_COMPARATOR|Tamsulosin|Tamsulosin 0.4mg capsule
62572306|NCT01028014|ACTIVE_COMPARATOR|Imipramine|Imipramine 25mg tablet
62572307|NCT01028014|ACTIVE_COMPARATOR|Cyclobenzaprine|Cyclobenzaprine 10mg tablet
62572308|NCT01028014|PLACEBO_COMPARATOR|Lactose capsules|Sham
62572309|NCT01065337|NO_INTERVENTION|control group|patients received standard of care wound treatment according guideline of the American Diabetes Association (ADA)
62572310|NCT01065337|ACTIVE_COMPARATOR|bone marrow stem cells intraarterial|bone marrow stem cells administered intraarterial
62572311|NCT01065337|ACTIVE_COMPARATOR|tissue repair cells intramuscular|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intramuscular
62572312|NCT01065337|ACTIVE_COMPARATOR|tissue repair cells intraarterial|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intraarterial
62190796|NCT06130072|ACTIVE_COMPARATOR|Hysteroscopic tubal occlusion using only iso-amyl- 2-cyanoacrylate|Group 1 including 25 patients with hydrosalpinx refaired for hysteroscopic tubal occlusion prior to IVF using iso-amyl- 2-cyanoacrylate .
62190797|NCT03091582|EXPERIMENTAL|Cognitive behavioral therapy|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive factors and behavioral factors on affective distress.
62190798|NCT03091582|EXPERIMENTAL|Behavioral Activation|Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
62190799|NCT06034795||Patients|"32 patients with Familial mediterranenan fever will participate. In these patients we will check bone mineral density using the dexa method.~Blood tests will also be taken to assess calcium metabolism. All patients will be treated with colchicine."
62190800|NCT06034795||Control group|Healthy children will be used as control group. MEFV gene will be checked to exclude diagnosis of FMF. In these patients we will check bone mineral density using the dexa method. Blood tests will also be taken to assess calcium metabolism. The results from the two groups will be compared.
62190801|NCT01498315||Women following hysterecomy|
62190802|NCT02063581|EXPERIMENTAL|Sequence 1: Tablet followed by Capsule|
62190803|NCT02063581|EXPERIMENTAL|Sequence 2: Capsule followed by Tablet|
62190804|NCT01565317|EXPERIMENTAL|Intensive Treatment (Why WAIT)|Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
62190805|NCT01565317|NO_INTERVENTION|Control Group|Matched control group will be recruited from obese patients with diabetes followed at Joslin Clinic. This group will receive the routine standard diabetes care.
62190806|NCT01762332|ACTIVE_COMPARATOR|Low opioid level|Base level of remifentanil effect side concentration: 2ng/ml Stopped recruitment (May 2014)
62190807|NCT01762332|ACTIVE_COMPARATOR|High opioid level|Base level of remifentanil effect side concentration: 4ng/ml Stopped recruitment (May 2014)
62190808|NCT01762332|OTHER|chronic beta-blocker treatment|"Patients with chronic beta-blocker treatment prior to surgery and study. Will all be allocated to the high opioid level arm without randomization.~Continue recruitment."
62190809|NCT00012662|OTHER|Arm 1|
62190810|NCT05678283|EXPERIMENTAL|Part 1: CC-90010 followed by [14C]CC-90010|
62190811|NCT05678283|EXPERIMENTAL|Part 2: CC-90010|
62190812|NCT05311553|EXPERIMENTAL|Zona pellucida thinning|thinning will be performed without reaching the inner membrane of the Zona pellucida thickness.
62190813|NCT05311553|EXPERIMENTAL|Zona pellucida drilling|an opening will be made from the outside to the inside of the Zona pellucida.
62190814|NCT01336205|EXPERIMENTAL|1|Oral Treatment
62572313|NCT01065337|ACTIVE_COMPARATOR|bone marrow stem cells intramuscular|bone marrow stem cells administered intramuscular
62780215|NCT02992509|OTHER|Treatment|This pilot study group is a prospective observational study. It is not blinded and there is no control. This is a single arm study (treatment group) which will receive intravesical electrical stimulation with a total of 8 therapy sessions, each lasting 15 minutes. The sessions will be done in a serial fashion, 2 per week for 4 consecutive weeks.
62005049|NCT01486563|ACTIVE_COMPARATOR|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing radical prostatectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
62005050|NCT01486563|PLACEBO_COMPARATOR|Sodium Chloride 9 mg/ml|Patients undergoing radical prostatectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
62005051|NCT02771639||Femoral neck fractures|Patients admitted to Sundsvall hospital for a displaced femoral neck fracture and treated with a hip arthroplasty
62005052|NCT00110812|NO_INTERVENTION|No IL-2|Participants will receive no aldesleukin or HAART
62005053|NCT00110812|EXPERIMENTAL|IL-2 without ART|Participants will receive aldesleukin under the skin twice daily for 5 consecutive days every 8 weeks for 3 cycles, then as needed to maintain CD4 counts at or above a goal level. Some Group 2 participants may take part in additional cycles of aldesleukin if they meet certain study criteria.
62190815|NCT01336205|ACTIVE_COMPARATOR|2|Oral treatment
62190816|NCT02788266|ACTIVE_COMPARATOR|connective tissue graft+composite resin|connective tissue graft plus composite resin
62190817|NCT02788266|ACTIVE_COMPARATOR|connective tissue graft+ glass ionomer|connective tissue graft plus resin modified glass ionomer cement
62190818|NCT02788266|ACTIVE_COMPARATOR|connective tissue graft+giomer|connective tissue graft plus giomer
62190819|NCT02977247||Women undergoing routine diagnostic breast evaluation|Non-Interventional: Women presenting to enrollment sites for diagnostic examinations of symptoms or imaging findings, as recommended by a physician, and assigned BI-RADS category 4 or 5 (biopsy indicated).
62190820|NCT04410276||Patients with enterococcal bloodstream infections|Adult patients (≥ 18 years of age) with ≥ 1 positive blood cultures with Enterococcus during hospitalization and who have repeat blood culture(s) within 7 days from the first positive culture will be included.
62190821|NCT02106364|EXPERIMENTAL|LY2605541|LY2605541 administered by subcutaneous (SQ) injection once daily for 52 weeks. Initial dose is 10 units (10 U) and is titrated by investigator. Participants may continue oral antihyperglycemic medication (OAM) as prescribed by their personal physician.
62190822|NCT02106364|ACTIVE_COMPARATOR|Insulin Glargine|Insulin glargine administered by SQ injection once daily for 52 weeks. Initial dose is 10 U and is titrated by investigator. Participants may continue OAM as prescribed by their personal physician.
62190823|NCT04226092|EXPERIMENTAL|Subjects with atopic dermatitis|
62396765|NCT02760680|ACTIVE_COMPARATOR|Diagnostic Device (WatchPAT 200 (TM))|The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
62396766|NCT06416462|PLACEBO_COMPARATOR|Simulation of antimicroial Photodynamic therapy group|Participants in the control group will be treated in exactly the same way as the aPDT group, however the light treatment will be simulated. The device will be placed in position, however it will be switched off. After three weeks of monitoring in the control group, the patient will be informed that they were in the placebo group and will be offered treatment with aPDT and irradiation, for ethical reasons.
62572314|NCT02273063|EXPERIMENTAL|Transcranial Magnetic Stimulation|Stimulation at pulse frequency of 5Hz delivered over L DLPFC. Intensity: 120% of Motor Threshold, 5 Sec Train, 14 Sec Inter-Train Interval, Frequency: 5Hz, Total Pulses: 3000/session. Sessions delivered once/day on weekdays for up to 40 sessions.
62005054|NCT00110812|EXPERIMENTAL|IL-2 with pericycle HAART|Participants will receive aldesleukin under the skin twice daily for 5 consecutive days every 8 weeks for 3 cycles, then as needed to maintain CD4 counts at or above a goal level; Group 3 participants will also take HAART for 3 days prior to the start of each aldesleukin cycle, throughout the 5-day aldesleukin cycle, and for 2 days after the end of each aldesleukin cycle (for a maximum of 10 days with each aldesleukin cycle). Some Group 3 participants may take part in additional cycles of aldesleukin if they meet certain study criteria. HAART is not supplied by the study, and choice of drugs is left to the participant and physician. The HAART regimen should include at least one protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors.
62005055|NCT06573502|EXPERIMENTAL|prp with prf group|Pt will recievd prp with prf
62005056|NCT06573502|ACTIVE_COMPARATOR|prp group|Pt will recieve prp only
62005057|NCT06573502|ACTIVE_COMPARATOR|prf group|Pt will recieve prf only
62190824|NCT04226092|EXPERIMENTAL|Control subjects|
62190825|NCT04072705||1. Poor and intermediate metabolizer group|Poor and intermediate metabolizer group: acute ischemic stroke patients with poor and intermediate metabolizer genotype of cytochrome P450 2C19 for clopidogrel.
62396767|NCT06416462|ACTIVE_COMPARATOR|Antimicrobial Photodynamic therapy group|In the experimental group (aPDT), 1% methylene blue applied with the aid of a syringe will be used as a photosensitizer (with a pre-irradiation time of 5 minutes, 6 J of red laser will be applied.
62005058|NCT01714310|EXPERIMENTAL|Adjunctive fluoxetine|Participants previously titrated with open-label lisdexamfetamine randomized to adjunctive fluoxetine at end of study week 4.
62005059|NCT01714310|PLACEBO_COMPARATOR|Adjunctive placebo|Participants previously titrated with open-label lisdexamfetamine randomized to adjunctive placebo at end of study week 4.
62005060|NCT01714310|OTHER|Open Lisdexamfetamine Titration|All participants initially titrated with open-label lisdexamfetamine from baseline to end of study week 4.
62005061|NCT01632371|EXPERIMENTAL|Paclitaxel Eluting Balloon + Scoring Balloon|Dilatation of the lesion with an Paclitaxel Eluting Balloon before the utilization of a Scoring Balloon
62005062|NCT01632371|ACTIVE_COMPARATOR|Paclitaxel Eluting Balloon|Paclitaxel Eluting Balloon
62005063|NCT05380375||Short-course|Group with short treatment of antibiotic of \<= 5 days
62005064|NCT05380375||Very short-course|Group with short treatment of antibiotic of \<= 3 days
62005065|NCT01942941|EXPERIMENTAL|geko™ electrical stimulation|Applied to stimulate peroneal nerve unilaterally
62005066|NCT01527552|EXPERIMENTAL|Formulation A|
62005067|NCT01527552|EXPERIMENTAL|Formulation B|
62005068|NCT03949075|EXPERIMENTAL|Enalapril treatment|
62005069|NCT03949075|PLACEBO_COMPARATOR|Placebo treatment|
62005070|NCT03966274||Delirium positive|
62005071|NCT03966274||Delirium negative|
62190826|NCT04072705||2. Extensive metabolizer group|Extensive metabolizer group: acute ischemic stroke patients with Extensive metabolizer genotype of cytochrome P450 2C19 for clopidogrel.
62190827|NCT03225898|EXPERIMENTAL|Resistance Exercise with Blood flow restriction|Subjects will perform 4 sets with 30, 15, 15, 15 repetitions at 30% 1RM.
62190828|NCT03225898|ACTIVE_COMPARATOR|High-intensity resistance exercise|Subjects will perform 4 sets of 8 repetitions at 70% 1RM.
62190829|NCT00064142|EXPERIMENTAL|Arm I (halofuginone hydrobromide)|Patients apply topical halofuginone hydrobromide ointment to each of 6 lesions twice a day for 12 weeks.
62190830|NCT00064142|PLACEBO_COMPARATOR|Arm II (placebo)|Patients apply topical placebo ointment to each of 6 lesions twice a day for 12 weeks.
62190831|NCT00909129|EXPERIMENTAL|HIV-1 HCV coinfected patients|HIV-1 HCV coinfected patients undergoing HCV therapy
62190832|NCT04676113||Pediatric Patients with Sickle Disease who are overweight/obese|Pediatric Patients age 10-19 years diagnosed with Sickle cell disease who have a BMI of \>85%ile.
62190833|NCT04676113||Pediatric Patients with Sickle Cell Disease who are underweight/normal weight|Pediatric Patients age 10-19 years diagnosed with Sickle Cell disease who have a BMI\<85%ile.
62190834|NCT04476940|EXPERIMENTAL|COVID BF-Support|COVID-19 breastfeeding guideline education and support for pregnant women.
62190835|NCT04560647||Psoriasis|Subjects diagnosed with psoriasis.
62005072|NCT03743948|EXPERIMENTAL|Expectant couple at risk of transmitting a monogenic disease.|Expectant couple (pregnant woman from 9 weeks of gestation and spouse) at risk of transmitting a monogenic disease among the genes included in the trusight one expanded sequencing kit (Illumina).
62396768|NCT05645146|ACTIVE_COMPARATOR|Group 1: Standard Treatment|Participants will receive a connection to the Tobacco Free Florida Quitline and a 12 week supply of nicotine replacement therapy (the patch and lozenges)
62005073|NCT02714452|OTHER|Intervention|Person-centred care
62190836|NCT04560647||Control|Subjects who do not have psoriasis.
62190837|NCT05260099||Retrospective|Patients not treated with LPS Adsorber
62190838|NCT05260099||Prospective|Patients treated with LPS Adsorber
62190839|NCT06114992||Servo-n HFOV treatment|As this study is single-armed (non-controlled), all patients in this study receive the same treatment, i.e. Servo-n HFOV treatment. There are however two subgroups, elective HFOV and rescue HFOV treatment
62396769|NCT05645146|EXPERIMENTAL|Group 2: Motivation and Problem Solving (MAPS) counseling|Participants will receive a 12 week supply of nicotine replacement therapy (the patch and lozenges) along with the MAPS intervention, which consists of 6 MAPS counseling calls over 12 months, and individually tailored SMS text content driven by monthly smartphone delivered check-ins for 24 months
62780216|NCT05672550|EXPERIMENTAL|Bayesian based dose adjustment|"Optimization of the enoxaparin dose using a bayesian program in order to prevent patients from complications due to the renal transplantation.~A first recommended dose of enoxaparin (50 IU/kg) is administered subcutaneously during transplantation or within the first 24 hours.~Then, in the experimental group, the dose is adjusted following a bayesian program integrated in the electronic Case Report Form which is based on each patient's data as the Anti-Xa activity"
62005074|NCT02714452|NO_INTERVENTION|Control|Conventional care
62190840|NCT01838954|ACTIVE_COMPARATOR|Short-wave diathermy|Short-wave diathermy device turned on
62190841|NCT01838954|PLACEBO_COMPARATOR|control|Short-wave diathermy device turned off
62190842|NCT00861822|ACTIVE_COMPARATOR|RBC|Advance RBC transfusion' (ART) group
62190843|NCT00861822|OTHER|Standard Care|Standard-of-care RBC transfusion (SRT) group
62190844|NCT05457166|EXPERIMENTAL|patients|patients in a before/after experimental design to assess the value of using the KASPARD technology compared to the conventional management of patients with falls in nursing homes
62190845|NCT00807703|EXPERIMENTAL|1|Select Stim: see summary
62190846|NCT05969678|EXPERIMENTAL|Intervention group ( breathing training with incentive spiromete)|The experimental group will receive the breathing training of abdominal diaphragmatic breathing method combined with incentive spiromete.
62190847|NCT05969678|NO_INTERVENTION|control group|The control group is only taught the breathing training of abdominal diaphragmatic breathing.
62396770|NCT06493214|EXPERIMENTAL|Calendars + Pings + Coaching|Intervention is administered online (electronic calendars and text message pings) and virtually (coaching).
62396771|NCT06493214|EXPERIMENTAL|Calendars + Pings + Tailored Calendar|Intervention is administered online (electronic calendars and text message pings).
62396772|NCT06493214|EXPERIMENTAL|Calendars + Pings + Pings|Intervention is administered online (electronic calendars and text message pings).
62005075|NCT00431249|OTHER|one|
62005076|NCT00220025|EXPERIMENTAL|NBUVB|
62190848|NCT00624013|PLACEBO_COMPARATOR|Placebo|Placebo 50 mg up to 100 mg daily for 6 months
62190849|NCT00624013|ACTIVE_COMPARATOR|Sertraline (Zoloft)|Sertraline (Zoloft) 50 mg up to 100 mg daily for 6 months
62190850|NCT04147858|EXPERIMENTAL|NYX-2925 50 mg|NYX-2925 50 mg administered orally.
62190851|NCT04147858|EXPERIMENTAL|NYX-2925 100 mg|NYX-2925 100 mg administered orally.
62190852|NCT04147858|PLACEBO_COMPARATOR|Placebo|Placebo administered orally.
62190853|NCT02503098|EXPERIMENTAL|Recovery Record adaptive smartphone application (RR-A)|Participants will have access to all Recovery Record standard functions and will additionally receive tailored, algorithm-generated content targeting cognitive distortions.
62190854|NCT02503098|ACTIVE_COMPARATOR|Recovery Record standard smartphone application (RR-S)|Participants will have access to all Recovery Record standard functions, including meal monitoring, motivational enhancement, social support, and coping skill strategies.
62190855|NCT02566564|EXPERIMENTAL|open label, single arm|Open label, single arm, dose escalating
62190856|NCT00891046|EXPERIMENTAL|Canakinumab|Canakinumab
62190857|NCT01377298|EXPERIMENTAL|Pazopanib|Single arm study, pazopanib
62190858|NCT01828086|EXPERIMENTAL|CJM112|CJM112 in different doses; single ascending and multiple ascending
62190859|NCT01828086|PLACEBO_COMPARATOR|Placebo|Placebo to match
62190860|NCT01828086|ACTIVE_COMPARATOR|Secukinumab|Active investigational drug.
62190861|NCT02442193|EXPERIMENTAL|Individual Placement and Support|Individual Placement and Support
62190862|NCT02442193|NO_INTERVENTION|Treatment as Usual|Treatment as Usual is comprised of routine clinical care.
62190863|NCT02001909|EXPERIMENTAL|Regorafenib|
62190864|NCT02001909|EXPERIMENTAL|Neomycin|
62190865|NCT04524767|EXPERIMENTAL|SBIRT|SBIRT will involve screening with the Patient Health Questionnaire-9 (PHQ-9); brief intervention with Motivational Interviewing (MI); and referral to specialty treatment, as needed for subjects with persistent depressive symptoms.
62190866|NCT04524767|ACTIVE_COMPARATOR|Referral As Usual|Referral as Usual will involve distributing depression educational materials (e.g., from the National Institute of Mental Health) and contact information for treatment providers in our target community
62190867|NCT01042210||Mothers, preeclampsia|Mothers with preeclampsia diagnosed according to the Guidelines by the Czech Society of obstetrics and gynecology as development of hypertension after the 20th week of pregnancy (systolic blood pressure, ≥140 mmHg; and/or diastolic blood pressure, ≥90 mmHg; measured at rest on two consecutive occasions at least 24 h apart) in previously normotensive women, and the onset of proteinuria (\>300 mg of urinary protein/L over 24 h).
62190868|NCT01042210||Newborns, physiological pregnancy-delivery|The newborns from the physiological pregnancies with spontaneous, uncomplicated delivery.
62005077|NCT05567731|EXPERIMENTAL|ultrashort GnRHa|the patients used the ultrashort protocols with GnRH agonist (GnRH-a, and recombinant FSH for controlled ovarian hyperstimulation (COH). Form the second day of menstrual cycle, 0.1 mg/d GnRH agonist will be injected by subcutaneous injection for 3-4 d.
62190869|NCT01042210||Newborns, pregnancy with preeclampsia|Newborns from the pregnancies complicated by preeclampsia.
62190870|NCT01042210||Mothers, Physiological pregnancy-labour|The cohort of non-preeclamptic mothers with physiological, uncomplicated conception, pregnancy and delivery.
62396773|NCT06493214|EXPERIMENTAL|Calendar + Tailored calendars + Pings|Intervention is administered online (electronic calendars and text message pings).
62005078|NCT05567731|EXPERIMENTAL|short GnRHa|Buserelin acetate 100 mg five times daily and FSH will be started on the 2nd day of the menstrual cycle as short application. The dose of gonadotropin hormone will be individualized according to the patient's age and previous stimulation history or response to stimulation. Cycles will be monitored by transvaginal ultrasonography and serum E2 levels.
62190871|NCT02453984|EXPERIMENTAL|1|89Zr-MPDL3280A-PET scan
62396774|NCT06493214|EXPERIMENTAL|Calendar + Tailored calendars + Coaching|Intervention is administered online (electronic calendars) and virtually (coaching).
62572315|NCT05189977|ACTIVE_COMPARATOR|Sertraline alone at steady state|To assess the hemodynamic changes associated with the effects of a single dose of prazosin or propranolol in the presence of brexpiprazole + sertraline at steady state compared with a single dose of prazosin or propranolol in the presence of sertraline alone at steady state.
62190872|NCT03215953|ACTIVE_COMPARATOR|Group A|cast shoe plus standard wound care
62190873|NCT03215953|ACTIVE_COMPARATOR|Group B|removable walker plus standard wound care
62190874|NCT01453023|ACTIVE_COMPARATOR|Fluticasone Furoate|One of two study treatments subjects will receive. Given to allow comparison of FF exposure in combination versus as mono therapy.
62190875|NCT01453023|EXPERIMENTAL|Fluticasone Furoate/Vilanterol|One of two study treatments subjects will receive. FF/VI combined is being tested and compared to fluticasone furoate.
62190876|NCT05803148|EXPERIMENTAL|Experimental group: Cardioneuroablation|In this arm, the catheter ablation of the GPs will be performed in the order of LSGP, LIGP, RIGP, left atrial RAGP and right atrial RAGP. Patient education includes fully informing patients of the benign prognosis of vasovagal syncope, and educating patients to avoid triggering factors as much as possible. At the same time, the patient should be taught how to cope with the impending syncope with physical counter-pressure maneuvers and dietary suggestions that emphasize fluid and sodium intake.
62190877|NCT05803148|ACTIVE_COMPARATOR|Control group: Midodrine|In this arm, Midodrine will be applied without the following contraindications: hypertension, chromaffin cell carcinoma, acute nephritis, severe renal dysfunction, glaucoma, prostatic hyperplasia with urinary retention, mechanical urinary obstruction, hyperthyroidism. Patient education includes fully informing patients of the benign prognosis of vasovagal syncope, and educating patients to avoid triggering factors as much as possible. At the same time, the patient should be taught how to cope with the impending syncope with physical counter-pressure maneuvers and dietary suggestions that emphasize fluid and sodium intake.
62396775|NCT06493214|EXPERIMENTAL|Calendar + Tailored calendars|Intervention is administered online (electronic calendars).
62190878|NCT00675584|ACTIVE_COMPARATOR|Placebo Budesonide|Participants will receive 0.5 mg of ICS (budesonide as Pulmicort Respules®) once a day at night, except during respiratory tract illnesses. During respiratory tract illnesses, participants will receive placebo each morning and 0.5 mg of budesonide each night for 7 days.
62396776|NCT06493214|EXPERIMENTAL|Calendars + Pings|Intervention is administered online (electronic calendars and text message pings).
62396777|NCT06493214|EXPERIMENTAL|Calendars + Tailored calendar|Intervention is administered online (electronic calendars).
62396778|NCT06493214|EXPERIMENTAL|Calendars|Intervention is administered online (electronic calendars).
62396779|NCT03159455|EXPERIMENTAL|BI 1467335|
62396780|NCT03159455|PLACEBO_COMPARATOR|Placebo|
62005079|NCT05567731|EXPERIMENTAL|long GnRHa|In the long protocol, daily SC injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium \< 5 mm and low E2 \< 50 and LH \< 5IU/l with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany) in a starting dose of 150-300 IU/day according to women age, day 3 FSH,AMH and previous gonadotropin response then adjustment of the dose according to ovarian response monitored by serum E2 and ultrasound evaluation. All patients were followed up by Transvaginal ultrasound scan daily or on alternate days according to the ovarian response to treatment starting on treatment cycle day for folliculometry and endometrial thickness and pattern.
62780217|NCT05672550|ACTIVE_COMPARATOR|Treatment as usual (empirical dose adjustment)|Anti-Xa activity is measured and twice-daily enoxaparin empirical dose-adjustment is performed according to the usual practices in the investigating centers
62190879|NCT00675584|EXPERIMENTAL|Budesonide|Participants will receive 1 mg of ICS (budesonide as Pulmicort Respules®) twice a day for 7 days at the onset of a respiratory tract illness; they will receive placebo ICS once a day at all other times during the study.
62190880|NCT02683499|EXPERIMENTAL|Ultrasonic tips|Prepared surfaces will be finished with ultrasonic tips
62190881|NCT02683499|NO_INTERVENTION|Conventional|Prepared surfaces will be finished with ordinary burs
62190882|NCT00823836|EXPERIMENTAL|ropinirolePR-PR group|
62190883|NCT00823836|ACTIVE_COMPARATOR|ropiniroleIR-PR group|
62190884|NCT06492772|EXPERIMENTAL|Experimental Group|The experimental group will be provided with smoking cessation training based on the transtheoretical model.Individuals will be required to use the mobile application for 6 months. Measurements will be made at 1, 3, and 6 months.
62396781|NCT01393444|EXPERIMENTAL|Direct Brain Interface Users|"All participants enrolled in the study will undergo Implantation of ECoG sensors on the brain surface to record neural activity. There is no control group. There are no other arms."
62410050|NCT03710759|EXPERIMENTAL|Assistive Autogenic Drainage|Autogenic drainage (AD) is a breathing technique that uses controlled breathing and least amount of coughing to clear secretions from your chest. It involves you hearing and feeling your secretions as you breathe out and controlling the urge to cough until secretions are high up and easily cleared with little effort.
62190885|NCT06492772|OTHER|Control Group|The control group will be given ordinary smoking cessation information. Measurements will be made at 1, 3, and 6 months.
62190886|NCT01500993|ACTIVE_COMPARATOR|5-Fluorouracil (5-FU)|Drug - 5FU based chemoradiotherapy and chemotherapy
62190887|NCT01500993|EXPERIMENTAL|Capecitabine|Drug - Capecitabine-based radiochemotherapy and chemotherapy
62190888|NCT01746147||Patients with MDS and AML prior to allogeneic SCT|
62190889|NCT02024295|EXPERIMENTAL|Ademethionine|ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
62190890|NCT02024295|ACTIVE_COMPARATOR|Polyene Phosphatidyl choline|Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
62190891|NCT05258591|EXPERIMENTAL|Axem Home|Patients receive at-home access to Axem Home system for duration of the study period.
62190892|NCT05617963|EXPERIMENTAL|Durvalumab treatment|"Patients will receive durvalumab intravenously 1500 mg every 4 weeks until disease progression, unacceptable toxicity, death or patient's decision for a maximum of 24 months. For patients receiving prophylactic cranial irradiation as per standard of care, the first dose of durvalumab may be delayed by up to 42 days from the end of the CRT. Radiological assessments will be planned every 12 weeks (± 7 days) of maintenance treatment.~The first dose of durvalumab should be administered within 3 days of inclusion."
62190893|NCT05617963|NO_INTERVENTION|Surveillance|Surveillance as per standard of care. Patients will perform radiological assessment every 12 weeks (± 7 days) from randomization.
62410051|NCT01710007|EXPERIMENTAL|1PC002|2 mg 1PC002 once daily for 12 weeks.
62410052|NCT01710007|ACTIVE_COMPARATOR|Lipitor|10 mg atorvastatin once daily for 12 weeks.
62410053|NCT04391686||COVID intensive care unit|
62780218|NCT04391803|EXPERIMENTAL|Pipeline™ Flex Embolization Device with Shield Technology™|This is a prospective, single-arm study in which subjects have consented and deployment of the Pipeline™ Flex Embolization Device with Shield Technology™ is attempted.
62780219|NCT04584242|EXPERIMENTAL|Pioglitazone|
62780220|NCT04584242|EXPERIMENTAL|Evogliptin|
62410054|NCT04391686||intensive care unit|
62410055|NCT04391686||obesity|
62396782|NCT03083795|EXPERIMENTAL|Social relationships intervention|"Participants randomized to the social interaction cohort will be split into two groups of 12. Each group of 12 will meet together once a month for a two-hour support group. Each participant will be allowed five minutes to check-in with the support group. During the 5 minute period the participant is encouraged to share their innermost thoughts and feelings in the knowledge that this information will not be shared outside the group.~Participants will additionally be paired with another study participant in the same cohort and will be asked to meet outside group sessions once a week for a minimum of 45 minutes. The pairing process will take place by study investigators and will be sensitive to gender, age, and neighbourhood of residence. Participants who find that their paired partner is not suitable may ask the facilitators to help find a more suitable match.~These participants will continue to receive BC Diabetes standard care."
62572316|NCT05189977|ACTIVE_COMPARATOR|Sertraline + brexpiprazole at steady state|To assess the hemodynamic changes associated with the effects of a single dose of prazosin or propranolol in the presence of brexpiprazole + sertraline at steady state compared with a single dose of prazosin or propranolol in the presence of sertraline alone at steady state.
62572317|NCT04016389|EXPERIMENTAL|Neo-Adjuvant Chemotherapy, Surgery, and Adjuvant Chemotherapy|"Participants will receive neo-adjuvant treatment cisplatin or carboplatin with paclitaxel, intravenously, either once every cycle or once a week, for three (21-day) cycles.~After neo-adjuvant treatment, depending on their status, participants may have the trachelectomy done.~Adjuvant treatment may include standard chemotherapy and radiotherapy, or a hysterectomy may need to be done."
62572318|NCT03055455||Sepsis|Children with severe sepsis or septic shock
62005080|NCT03407872|EXPERIMENTAL|PART A|6 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.
62005081|NCT03407872|EXPERIMENTAL|PART B|4 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.
62005082|NCT03407872|EXPERIMENTAL|PART C|4 cohorts will receive multiple dose of Esketamine DPI in two weeks' time administered with dose escalation between cohorts.
62005083|NCT03407872|PLACEBO_COMPARATOR|PART C placebo|4 cohorts will receive multiple dose of matching placebo in two weeks' time.
62005084|NCT05208216|EXPERIMENTAL|Intervention arm|Application of the Geko device for mechanical VTE prophylaxis up until day 10 / discharge form critical care (whichever comes sooner).
62005085|NCT05208216|ACTIVE_COMPARATOR|Usual care arm|Application of our usual intermittent pneumatic compression devices for mechanical VTE prophylaxis up until day 10 / discharge form critical care (whichever comes sooner).
62005086|NCT06051773||SSc patients|
62005087|NCT04960228|EXPERIMENTAL|Altruism Video Intervention|Participants will watch a 3-minute video about COVID-19 vaccination that elicits altruistic motives. The role of this arm is to test whether altruistic themes are an effective way to promote COVID-19 vaccination amongst young people and whether a video format is preferable for this group.
62005088|NCT04960228|ACTIVE_COMPARATOR|Informational Text Intervention|Participants will read a brief informational text including information drawn from the Public Health Agency of Canada website (https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/prevention-risks.html#self). The purpose of this arm is to provide an active comparator with information about COVID-19 preventative health behaviors that has been strongly recommended to the public since the beginning of the pandemic. By doing this, we will assess if the video intervention changes vaccination intentions more than a presentation of general, well-known COVID-19 related information.
62005089|NCT02469610|EXPERIMENTAL|study|In the study group the surgeon will perform an intercostal Bupivacaine block of 100ml over five intercostal spaces which include the operation cuts. The block will be done in the beginning of the surgery right after the insertion of the video camera to the pleural space.
62005090|NCT02469610|OTHER|control|In the control group the surgeon will perform the same intercostal block at the end of the surgery just before closing the operation cuts. this approach is used today in our department.
62005091|NCT01081808|OTHER|Armed Activated T Cells|Activated T Cells (ATC) armed with the bispecific antibody OKT3 x Cetuximab (EGFRBi). ATC will be expanded for 14 days from a leukapheresis product, armed with EGFRBi, cryopreserved and infused in 8 divided doses. Patients will also receive low dose subcutaneous IL-2(3000,000 IU/m2/day) and GM-CSF (250ug/m2 twice per week)
62572319|NCT04124601|OTHER|Neoadjuvant Chemoradiotherapy|Neoadjuvant Chemoradiotherapy (50 Gy in 2 Gy fractions + Capecitabine 1650 mg/m2/d over 25 working days)
62572320|NCT04124601|EXPERIMENTAL|Neoadjuvant Chemoradiotherapy, Ipilimumab, Nivolumab|Neoadjuvant Chemoradiotherapy (50 Gy in 2 Gy fractions + Capecitabine 1650 mg/m2/d over 25 working days) with sequential Ipilimumab (1 mg/kg IV on day 7) and Nivolumab (3 mg/kg IV on day 14, 28 and 42)
62190894|NCT03866096|EXPERIMENTAL|Experimental|Each session will last 20 minutes, taking place during 2 days a week, in a period of 6 weeks. The intervention will be made prior to the training session. The subjects of the experimental group will receive an intervention through neuromuscular training and a CORE strengthening program
62190895|NCT03866096|ACTIVE_COMPARATOR|Control|Each session will last 20 minutes, taking place during 2 days a week, in a period of 6 weeks. The intervention will be made prior to the training session. The subjects of the experimental group will receive an intervention through neuromuscular training.
62190896|NCT03451409||OCD Proband|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
62190897|NCT03451409||OCD Siblings|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
62190898|NCT03451409||Healthy Controls|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
62190899|NCT01854606|EXPERIMENTAL|AEB071 and EVEROLIMUS|AEB071 and EVEROLIMUS will be taken together in this open-label non-randomized study
62190900|NCT02148510|EXPERIMENTAL|Monobloc|Treatment with an appliance that holds the lower jaw in a fixed protruded position
62190901|NCT02148510|ACTIVE_COMPARATOR|Bibloc|Bibloc device where a maxillary splint is connected to a mandibular splint by a connector allowing a slight opening of the jaw without compromizing the protrusion (Narval)
62190902|NCT02578498|PLACEBO_COMPARATOR|High carbohydrate diet|high carbohydrate intake
62190903|NCT02578498|ACTIVE_COMPARATOR|Low carbohydrate diet|low carbohydrate intake
62190904|NCT02646709|EXPERIMENTAL|Ketamine 1|Ketamine 1 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
62396783|NCT03083795|NO_INTERVENTION|Control cohort|Patients in the control group will receive BC Diabetes standard care.
62396784|NCT02058849|EXPERIMENTAL|Beetroot|Beetroot 10 grams concentrated organic beetroot crystals
62396785|NCT02058849|PLACEBO_COMPARATOR|Placebo|Placebo
62396786|NCT05119738||Three doses of BNT162b2.|Cancer patients on active cytotoxic treatment who received three doses of BNT162b2.
62396787|NCT05119738||Two doses of Coronavac and one of BNT162b2.|Cancer patients on active cytotoxic treatment who received two doses of Coronavac and one dose of BNT162b2.
62005092|NCT04990895|NO_INTERVENTION|Control group|Participants in the control group will have a planned clinic follow-up visit prior to each scheduled chemotherapy appointment. Although they will not be asked to complete PROs in between clinic visits, they will be asked to respond to a series of HRQOL questionnaires at baseline, at 6 months (±2 weeks) from enrollment, and at completion of neoadjuvant/adjuvant systemic therapy if this date differs from the 6-month time point by more than 4 weeks. A satisfaction questionnaire will also be administered at the end of study.
62190905|NCT02646709|EXPERIMENTAL|Ketamine 1.5|Ketamine 1.5 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
62190906|NCT02646709|EXPERIMENTAL|Ketamine 2|Ketamine 2 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
62190907|NCT05841589|EXPERIMENTAL|Green tea extract mouth rinse|group green tea extract
62190908|NCT05841589|EXPERIMENTAL|Garlic with lime extract mouth rinse|garlic with lime extract
62190909|NCT05841589|EXPERIMENTAL|Pomegranate extract mouth rinse|pomegranate extract
62190910|NCT05841589|EXPERIMENTAL|Chlorhexidine mouth rinse|chlorhexidine
62190911|NCT00550212|EXPERIMENTAL|1|240 mg
62396788|NCT06672445|EXPERIMENTAL|ARO-ATXN2|ARO-ATXN2 Injection
62396789|NCT06672445|PLACEBO_COMPARATOR|Placebo|(0.9% NaCl)
62396790|NCT04920786|EXPERIMENTAL|TB006 70 mg - 5000 mg IV|TB006 infused intravenously over 1 hour
62396791|NCT04920786|PLACEBO_COMPARATOR|Placebo|0.9% normal saline infused intravenously over 1 hour
62396792|NCT06269484|PLACEBO_COMPARATOR|Treatment Group 1|Participants will receive once daily dose of placebo matching zibotentan capsule + placebo matching dapagliflozin tablet for 6 weeks
62396793|NCT06269484|EXPERIMENTAL|Treatment Group 2|Participants will receive once daily zibotentan capsule + placebo matching dapagliflozin tablet for 6 weeks
62396794|NCT06269484|EXPERIMENTAL|Treatment Group 3|Participants will receive once daily zibotentan capsule + dapagliflozin tablet 10 mg for 6 weeks
62572321|NCT03685253|PLACEBO_COMPARATOR|Placebo|Participants randomized to placebo will take 2 capsules by mouth twice a day for 6 months. The placebo capsules are matched to the NR capsules.
62190912|NCT06096584|EXPERIMENTAL|Group TIPS|patients will receive double level subsartorial block and suprasartorial LA injection at the level of the distal FT after induction of general anesthesia (GA)
62190913|NCT06096584|ACTIVE_COMPARATOR|Group Dual|patients will receive double level subsartorial canal block after induction of GA
62190914|NCT05572749|EXPERIMENTAL|Arm 1|Participants of Arm 1 are going to be administered Crocus Kozanis for 12 weeks (30mg twice per day), wash-out period for 12 weeks and metformin (1000mg once per day) for 12 weeks.
62190915|NCT05572749|EXPERIMENTAL|Arm 2|Participants of Arm 2 are going to be administered metformin (1000mg once per day) for 12 weeks, wash-out period for 12 weeks and Crocus Kozanis (30mg twice per day) for 12 weeks.
62190916|NCT05572749|PLACEBO_COMPARATOR|Arm 3|Participants of Arm 3 are going to be administered placebo (5ml twice per day) for 12 weeks
62190917|NCT02016378|SHAM_COMPARATOR|sham retraining|Participants in this condition will participate in a computerized task wherein the size of pictures of drug and non-drug related stimuli are increased or decreased based on the tilt (left or right) of the pictures, but without regard to the content (i.e., drug or non-drug).
62396795|NCT05666804|EXPERIMENTAL|Personalized regimen arm|1\~3 x 4-week loading injections and one 8-week injection, followed by Treat-and-extend (T\&E) regimen up to Week 56
62396796|NCT05666804|ACTIVE_COMPARATOR|Standard regimen arm|3 x 4-week loading injections and disease activity assessment at week 16 followed by q12w/q8w up to Week 56
62396797|NCT04548401||Antiplatelet-N group|Patients with ruptured aneurysm underwent coiling alone, without post-treatment antiplatelet therapy
62190918|NCT02016378|ACTIVE_COMPARATOR|Bias retraining|Participants in this condition will participate in 6 sessions of a computerized bias retraining.
62190919|NCT06222242|EXPERIMENTAL|mychoiceTM intervention|Single arm study - all participants receive mychoiceTM
62190920|NCT03478137|EXPERIMENTAL|CPAP intervention|Over the course of 4-7 months, participants will have to wear the CPAP every night, at least 4 hours per night.
62190921|NCT03478137|NO_INTERVENTION|Control 1|Eligible participants who declined to participate in the study. Their main study visit data will be used to compare with the intervention group.
62190922|NCT03478137|NO_INTERVENTION|Control 2|Eligible participants who were not approached, hence not given the opportunity to accept or decline. Their main study visit data will be used to compare with the intervention group.
62190923|NCT05906797|EXPERIMENTAL|Periodontitis|Subjects diagnosed with periodontitis according to the most recent international guidelines and without cardiovascular diseases.
62190924|NCT05906797|NO_INTERVENTION|Healthy|Subjects without periodontitis and with good gingival health.
62190925|NCT05036954||no arm|
62190926|NCT06463236|EXPERIMENTAL|Intervention group|Standardized guidance for anemia treatment by grassroots doctors using the maintenance hemodialysis renal anemia management process
62190927|NCT06463236|ACTIVE_COMPARATOR|control group|Experiential treatment by grassroots doctors
62190928|NCT04642547|EXPERIMENTAL|Combination therapy with Lenvatinib and Gefitinib|First week: Gefitinib 125mg/day, Lenvatinib 8mg/day if body weight ≤ 60Kg and 12mg/day if body weight \> 60Kg. If the patient is well tolerated, the dose of Gefitinib will be adjusted to 250 mg/day after one week, and the dose of Lenvatinib will remain the same (8mg/day for weight ≤ 60Kg and 12mg/day for weight \> 60Kg). Route of administration: Oral.
62190929|NCT06133634|ACTIVE_COMPARATOR|Fisetin|Fisetin will be administered in an intermittent manner with two, three-day dosing periods at a dose of 2 mg/kg/day separated by two weeks.
62190930|NCT06133634|PLACEBO_COMPARATOR|Placebo|Placebo capsules identical in appearance to fistin capsules will be administered in an intermittent manner with two, three-day dosing periods separated by two weeks.
62005093|NCT04990895|EXPERIMENTAL|Intervention|Participants in the intervention group will also have a planned clinic follow-up visit prior to each scheduled chemotherapy appointment. They will be asked to complete a series of HRQOL questionnaires at baseline, at 6 months, and at completion of neoadjuvant/adjuvant chemotherapy to evaluate their HRQOL and satisfaction levels with their care. In addition, however, they will also receive an email reminder at the mid-way point between scheduled clinic visits to prompt them to enter ePROs via the REDCap online system, including measures such as the ESASr, the EORTC-QLQ C30 and EORTC-BR23 or EORTC-CR29 and specific symptom questionnaires.
62190931|NCT00738439||Operative|Diagnosis of adult degenerative or idiopathic scoliosis with a curvature of the spine measuring greater than or equal to 20 degrees requiring surgery.
62190932|NCT00738439||Nonoperative|Diagnosis of adult degenerative or idiopathic scoliosis with a curvature of the spine measuring greater than or equal to 20 degrees not requiring surgery.
62190933|NCT05442450|EXPERIMENTAL|Diet+excercise+oral semaglutide|Participants will receive individual counselling sessions for reduced-calorie diet and physical activity (with 150 minutes per week of physical activity, such as walking). Participants in this group will receive oral Semaglutide drug along with diet and exercise. Treatment will be initiated with the 3 mg once-daily dose. The dose will be increased to 7 mg and then maximum of 14mg per day in 2-4weeks interval based on your symptoms (nausea, vomiting, constipation etc)
62190934|NCT05442450|NO_INTERVENTION|Diet+excercise|Participants in this group will receive individual counselling sessions for reduced-calorie diet and increased physical activity (with 150 minutes per week of physical activity, such as walking).
62190935|NCT02671110|EXPERIMENTAL|Transforming Your Life|The TYL program emphasized: 1) helping participants develop and maintain healthy habits and disrupt unhealthy habits, 2) enabling participants to create a personal food and exercise environment that increases exposure to healthy eating and physical activity and encourages automatic responding to goal-related cues, and 3) facilitating participants' weight loss motivation.
62190936|NCT02671110|ACTIVE_COMPARATOR|Diabetes Prevention program|The DPP recommends that participants set a weight loss reduction goal of 7% or more of their baseline body weight, reduce consumption of high fat foods as a means to reduce caloric intake, and engage in brisk walking or other moderate intensity physical activity for 150 minutes per week. Sessions include information on changing energy intake and energy output through diet and exercise, and addressing psychological, social, environmental, and motivational challenges to health behavior change.
62190937|NCT03840265|OTHER|Carotid endarterectomy|All patients in this study will undergo carotid endarterectomy procedure
62190938|NCT02838537||Triptan Arm|"Users of triptan defined as at least one recorded dispensing of any drug during the follow up, with no recorded of any of these drugs during the previous 6 months (new or incident users)"
62190939|NCT02838537||Ergot Arm|"Users of ergot derivative defined as at least one recorded dispensing of any drug during the follow up, with no recorded of any of these drugs during the previous 6 months (new or incident users)"
62190940|NCT02161042||fresh blood Transfusion|
62190941|NCT02161042||Old blood transfusion|
62190942|NCT04368845|ACTIVE_COMPARATOR|Experimental Intervention Arm: Telerehabilitation|The treatment arm will be given up to 1-hour resistive training exercises, breathing exercises and aerobic exercises administered by an expert physiotherapist via teleconference (telerehabilitation). Every ten days one physiotherapist will record the individualized exercise program, will reevaluate the magnitude of exercise for each patient and reinforce to continue or increase exercise magnitude.
62190943|NCT04368845|NO_INTERVENTION|No Intervention: Conventional teleconference|The usual care arm will receive standard communication via teleconference every ten days for a six-month period without any specific recommendations and exercise prescription for home training. The control arm will be subject to the same assessments as the experimental arm at the start, and at the 3 and 6 months period.
62190944|NCT03450668|ACTIVE_COMPARATOR|standard incubator|routinely used standard incubator already used in the neonatal unit
62190945|NCT03450668|EXPERIMENTAL|mOm incubator|new test incubator
62190946|NCT00484601|EXPERIMENTAL|Ifosfamide and Doxorubicin|Single arm treatment with Ifosfamide and Doxorubicinin patients with Refractory Nasopharyngeal Carcinoma
62190947|NCT02432833|EXPERIMENTAL|Envarsus® (tacrolimus)|prolonged-release tablets once daily and orally
62396798|NCT04548401||Antiplatelet-Y group|Patients with ruptured aneurysm underwent stent assisted coiling, with post-treatment antiplatelet therapy (aspirin and/or clopidogrel or ticagrelor)
62190948|NCT02432833|ACTIVE_COMPARATOR|Prograf or Advagraf|Prograf® hard capsules, twice daily, oral formulation or Advagraf® prolonged-release hard capsules, once daily, oral formulation
62190949|NCT05931445|EXPERIMENTAL|Monitoring group|ePRO monitoring will be conducted once weekly after study enrollment, along with standard care of treatment.
62780221|NCT05825560|ACTIVE_COMPARATOR|Control group|"Analgesia combines paracetamol (1g every 6 to 8 hours according to age and weight recommendations) and remifentanil, adapted according to a tiered administration system depending on the Behavior Pain Scale (BPS) and the theoretical ideal weight. Remifentanil doses are adjusted so that the patient has a BPS score of 4 or less. Reassessment of analgesia will be carried out every 30 minutes until analgesic adaptation is complete, then every 2 hours as is usually done in our department.~If the BPS is less than or equal to 4, the therapeutic de-escalation will be done with a reverse algorithm until the analgesic drugs are stopped.~After the sedation balance phase, the patient's BPS will be assessed every 2 hours."
62190950|NCT05931445|NO_INTERVENTION|Non-monitoring group|Standard care of treatment will be given without ePRO monitoring.
62396799|NCT05661006|PLACEBO_COMPARATOR|Control group|Subjects taking control product
62396800|NCT05661006|EXPERIMENTAL|Active group|Subjects taking active product
62780222|NCT05825560|EXPERIMENTAL|OFA Group|"A fixed combination of nefopam and tramadol will be initiated at daily doses. An initial dose of 50mg tramadol and 20mg nefopam IV over 30 min. will be administered. Reassessment of analgesia will be performed every 30 min. for two hour and then every 2 hours.~* If BPS is \> 4, administration of ketamine with an initial bolus of 0.15mg/kg followed by continuous administration at a dose of 0.15mg/kg/hour.~* If the BPS is \< 4, remifentanil is introduced at the minimum effective dose, in a stepwise fashion according to the theoretical ideal weight~* In the event of maximum pain requiring the full range of therapies in the algorithm the total dose of tramadol will be 450mg/day and nefopam 120mg/day, in accordance with summaries of product characteristics.~* If the BPS \< or = 4, the therapeutic de-escalation will be done with a reverse algorithm until the analgesic drugs are stopped, according to the following scheme: remifentanil, ketamine, tramadol and then nefopam."
62396801|NCT04358809|EXPERIMENTAL|Suspension of Mw + Standard therapy of COVID-19|0.3 ml (0.1ml x 3 Injection) of intradermal Mw for 3 consecutive days + Standard therapy of COVID-19
62396802|NCT04358809|PLACEBO_COMPARATOR|Placebo|0.3 ml (0.1ml x 3 Injection) of intradermal Placebo for 3 consecutive days + Standard therapy of COVID-19
62572322|NCT03685253|EXPERIMENTAL|Niagen®|Participants randomized to Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will take 250 mg capsules. Participants will take 2 capsules by mouth twice a day (1000 mg) for 6 months
62572323|NCT06482398|EXPERIMENTAL|Sericin extract and turmeric extract cream|Apply the sample 2 times a day for 8 weeks
62572324|NCT06482398|ACTIVE_COMPARATOR|Triamcinolone acetonide 1% cream|Apply the sample 2 times a day for 8 weeks
62572325|NCT05943093||ALL patients|
62572326|NCT05943093||control group free from the disease|
62780223|NCT02337881|ACTIVE_COMPARATOR|nifedipen and sildenafil|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours, at the same time sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
62780224|NCT02337881|ACTIVE_COMPARATOR|nifedipen only|nifedipine alone in the same regimen and duration described before.
62780225|NCT04420663|EXPERIMENTAL|Manometer Group|"Therapeutic thoracentesis will be performed in a sitting position. wide bore catheter as a pleural catheter will be inserted into the pleural cavity. simple water manometer will be connected to the pleural catheter via 3-way adapter.connected to the infusion lines with one draining into the drainage collection bottle and the other pre-flushed with normal saline hanging down till 40 cm below the puncture site and then rising up (forming a U) with the ascending arm taped to the IV stand. baseline pleural pressure will be registered before the beginning of pleural fluid withdrawal. Pleural pressure curve will subsequently be registered after the withdrawal of each 200 ml of pleural fluid up to a total volume of 1000 ml."
62005094|NCT04894981|EXPERIMENTAL|Immersive condition|Performance driving wheelchair in immersive condition (in Cave automatic environment or with HMD)
62005095|NCT04894981|EXPERIMENTAL|Non Immersive condition|Performance driving wheelchair in non immersive condition (with screen and physical simulator or screen only)
62005096|NCT06034054|EXPERIMENTAL|Nursing counseling|The individuals included in nursing counseling group were given counseling by the research nurse for 6 months.
62005097|NCT06034054|NO_INTERVENTION|Control|Individuals included in control group were followed up routinely in the outpatient clinic for 6 months.
62005098|NCT01956110|EXPERIMENTAL|A|Follitropin Delta (FE 999049)
62005099|NCT01956110|ACTIVE_COMPARATOR|B|Follitropin Alfa (GONAL-F)
62005100|NCT01674686|EXPERIMENTAL|A|Sarpogrelate versus placebo
62005101|NCT01674686|EXPERIMENTAL|B|Atorvastatin 80mg versus no statin or simvastatin 20 mg if LDL \> 130 mg/dl
62005102|NCT05157100|EXPERIMENTAL|Ingrezza|Participants will receive Ingrezza orally once daily for 12 weeks.
62005103|NCT04832373|OTHER|Humanoid Robot|
62005104|NCT04976192|EXPERIMENTAL|TEV-45779-300 mg Main Treatment period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
62005105|NCT04976192|ACTIVE_COMPARATOR|Xolair-300 mg Main Treatment Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
62005106|NCT04976192|EXPERIMENTAL|TEV-45779-150 mg Main Treatment period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
62005107|NCT04976192|ACTIVE_COMPARATOR|Xolair-150 mg Main Treatment Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
62005108|NCT04976192|EXPERIMENTAL|TEV-45779-300 mg Main / TEV45779-300 mg Transition Period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to TEV-45779-300 mg in the Main Treatment period.
62572327|NCT06049563||Enrolled subjects|An additional MRI scan of the upper abdomen will be performed on all the subjects with the low-field 0.4 T MRI system.
62780226|NCT04420663|NO_INTERVENTION|Conventional Group|Therapeutic thoracentesis will be performed in a sitting position. The skin will be cleaned with betadine antiseptic solution. Pleural aspiration should take place in a clean area using full aseptic techniques. 5-10 cc Lidocaine 2% will be given as local anesthetic in the site of puncture. the IV cannula is advanced till fluid is aspirated. Then, the needle is withdrawn and the catheter is fixed to two 3-way adapters fixed in series placed in between. connected to the infusion lines with one draining into the drainage collection bottle.
62780227|NCT02513472|EXPERIMENTAL|Eribulin Mesylate + Pembrolizumab|Participants with mTNBC previously treated with 0 (stratum 1) or 1 to 2 (stratum 2) lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting.
62005109|NCT04976192|EXPERIMENTAL|Xolair-300 mg Main / TEV45779-300 mg Transition Period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
62190951|NCT01114776||Sickle Cell Disease (SCD)|Patients with sickle cell diseases, 16 years or older with 10-20 years of transfusion (defined as 0.2-0.6mg Fe/kg/day exposure with annual ferritin levels greater than 2500 in at least 60% of years of chronic transfusion); 0 to 9 years old at the initiation of chronic transfusions; no exchange transfusions in the previous 6 months; and iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months or ferritin level greater than 1500mg/dl.
62190952|NCT01114776||Thalassemia Major (TM)|Patients with β-thalassemia major and transfusion-dependent E-beta THAL. 16 years or older with 10-20 years of chronic transfusion (defined above), 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
62396803|NCT05608707|EXPERIMENTAL|Personalised diet plus physical activity intervention|"A personalised diet intervention involving the incorporation of the developed plant-based protein and fibre product.~Participants will also undertake 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise"
62396804|NCT05608707|EXPERIMENTAL|Usual diet plus physical activity|Participants will consume their usual diet and undertake 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise
62005110|NCT04976192|ACTIVE_COMPARATOR|Xolair-300 mg Main / Xolair-300 mg Transition Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
62005111|NCT04976192|EXPERIMENTAL|TEV-45779-150 mg Main / TEV-45779-150 mg Transition Period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to TEV-45779-150 mg in the main treatment period.
62005112|NCT04976192|EXPERIMENTAL|Xolair-150 mg Main / TEV-45779-150 mg Transition Period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR-150 mg in the main treatment period.
62005113|NCT04976192|ACTIVE_COMPARATOR|Xolair-150 mg Main / Xolair-150 mg Transition Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR -150 mg in the main treatment period.
62396805|NCT05608707|EXPERIMENTAL|Personalised diet plus usual physical activity|A personalised diet intervention involving the incorporation of the developed plant-based protein and fibre product.
62396806|NCT05608707|NO_INTERVENTION|Control (usual diet and physical activity)|This arm will not be given any nutritional or physical activity support. They will be instructed to carry on with their usual activities.
62396807|NCT06032091||Participants|Persons with dementia
62780228|NCT01356199|EXPERIMENTAL|ARTRONAT|
62780229|NCT01356199|PLACEBO_COMPARATOR|PLACEBO|
62780230|NCT02747368|OTHER|Wet age related macular degeneration|Ocusweep system is compared to results of conventional devices.
62005114|NCT04001153||Upper primary first molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
62190953|NCT01114776||Diamond Blackfan Anemia (DBA)|Patients with DBA, 16 years or older with 10-20 years of transfusion, 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
62190954|NCT01114776||Controls|
62190955|NCT05064579||Patients with asthma|Children and adolescents aged 8 to 17 years old with a doctor's diagnosis of asthma and controller asthma treatment
62190956|NCT05064579||Holders of parental authority|Holders of parental authority of patients with asthma described in group A
62190957|NCT05064579||Doctors|Doctors caring for patients with asthma described in group A
62005115|NCT04001153||Lower primary first molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
62005116|NCT04001153||Upper primary second molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
62005117|NCT04001153||Lower primary second molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
62190958|NCT04430803|EXPERIMENTAL|Hydrogen-rich water|"Hydrogen-rich water (Rejuvenation, HRW Natural Health Products Inc.)~* 8 ppm of hydrogen~* Administered one dose two times per day on an empty stomach in the morning and at the evening"
62396808|NCT06723613|NO_INTERVENTION|Placebo group|"Mothers in the control group will not exercise and will receive routine breastfeeding counseling.~In the 8th and 14th weeks after birth, mothers will be subjected to; Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF), LATCH- Breastfeeding Charting system, IMDAT: a tool for assessing the level of maternal milk intake scales."
62396809|NCT06723613|EXPERIMENTAL|Intervention Group|Primiparous mothers assigned to the exercise group will attend classes in groups of 8-10. Mothers will be given 1 hour (120 minutes) of exercises to increase breast milk three times a week for 6 weeks. The total training time is 18 hours. Each session will include 60 minutes of warm-up and stretching exercises and 30 minutes of relaxation exercises.
62396810|NCT04994938|EXPERIMENTAL|Peer led diet and exercise intervention|participation in two-times per week diet and exercise peer led interventions.
62396811|NCT06672237|EXPERIMENTAL|nexiguran ziclumeran|nexiguran ziclumeran 55 mg by single IV infusion
62780231|NCT02834247|EXPERIMENTAL|Part 1: Advanced Solid Tumors|TAK-659 60 milligram (mg), tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 milligram per kilogram (mg/kg), infusion over 60 minutes, intravenously (IV), on Days 1 and 15 in each 28 day treatment cycle until PD or unacceptable toxicity. Dose escalation of TAK-659 to 100 mg may be done using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or RP2D.
62780232|NCT02834247|EXPERIMENTAL|Nivolumab Fixed Dose Cohort|After RP2D of TAK-659 has been identified, based on evaluation of combination with weight-based dose of nivolumab (3 mg/kg), RP2D may be evaluated in combination with a fixed dose of 240 mg IV nivolumab after discussion between investigator and sponsor for all types of advanced solid tumors. For single-agent nivolumab, fixed dose is expected to have equal exposure, safety, and efficacy as weight-based (3 mg/kg) dose. If nivolumab fixed dose is evaluated with TAK-659 RP2D, 3 participants will be initially enrolled into cohort. Following evaluation of safety, efficacy, and any available PK data, along with discussions between investigator and sponsor, 3 additional participants may be enrolled into cohort for a total of 3 to 6 participants. If \>=1 out of 6 participants experiences dose-limiting toxicity (DLT) in Cycle 1, or significant safety issues are seen in Cycle 2 and beyond, re-evaluation of TAK-659 RP2D when administered with a fixed dose of nivolumab is permitted.
62005118|NCT01862172|OTHER|additional MRI|
62005119|NCT05537233|EXPERIMENTAL|Semaglutide|Participants in this group will receive semaglutide once weekly injection in addition to their standard closed-loop therapy
62005120|NCT05537233|PLACEBO_COMPARATOR|Control|Participants in this group will receive placebo once weekly injection in addition to their standard closed-loop therapy
62005121|NCT05681429|PLACEBO_COMPARATOR|Opioid-based Anaesthesia|This arm will be given drugs for standard opioid-based anaesthesia.
62005122|NCT05681429|EXPERIMENTAL|Opioid-free Anaesthesia|"This experimental arm will be given drugs for opioid-free anaesthesia as stated below to replace opioids used:~Intravenous (IV) Lignocaine (1.5 mg/kg) Intravenous Infusion (IVI) Dexmedetomidine (0.2-0.7 mcg/kg/h) \& volatile (sevoflurane) \~ Minimum Alveolar Concentration (MAC) 0.9-1.0 IV Paracetamol 1 gm (give after scalp block) IV Parecoxib 40 mg (give 30 minutes before end of surgery) IV Ondansetron 4 mg (give 30 minutes before end of surgery) IV Metoclopramide 10 mg (rescue)"
62005123|NCT05049148|OTHER|Patients requirering brain/medullary tumors excision|All patients requirering a surgery for brain or medullar excision
62005124|NCT00726219|OTHER|1|Insertion distance of femoral catheter: 3cm
62396812|NCT06672237|PLACEBO_COMPARATOR|Normal Saline|Placebo; Normal saline (0.9% NaCl) by single IV infusion
62396813|NCT01823575|EXPERIMENTAL|Silicone-covered metallic ureteral stent|Deployment of a silicone-covered metallic ureteral stent for malignant ureteral obstruction and compare the results with placement of a double-J stent in terms of primary patency rate at 3 month follow-up (primary end point)
62005125|NCT00726219|OTHER|2|Insertion distance of femoral catheter: 7cm
62396814|NCT01823575|ACTIVE_COMPARATOR|Double-J stent|Placement of a double-J stent for malignant ureteral obstruction and compare these results to deployment of a silicone-covered metallic stent in terms of primary patency rate at 3 month follow-up.
62572328|NCT01715532|EXPERIMENTAL|Huachansu + TACE|Patients in this arm will receive Huachansu tablets each 3 and 3 times a day orally, as well as transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment.
62005126|NCT05649605|ACTIVE_COMPARATOR|Active comparator arm|Active treatment
62005127|NCT05649605|PLACEBO_COMPARATOR|Placebo comparator arm|Placebo treatment
62190959|NCT04430803|PLACEBO_COMPARATOR|Control water|"Tap water~* 0 ppm of hydrogen~* Administered one dose two times per day on an empty stomach in the morning and at the evening"
62190960|NCT02806843|EXPERIMENTAL|Stroke survivors and healthy subjects|Stroke survivors greater than 18 years of age with hemiplegia and varying levels of impairment as well as healthy subjects greater than 18 years old with no motor disabilities will be asked to interact with a therapist. The Patient-Therapist interactions will be recorded using the Rehab Intercap System and 3D Kinect Device.
62190961|NCT00356811|EXPERIMENTAL|Single arm|Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
62396815|NCT04991753|PLACEBO_COMPARATOR|Group 1: Placebo|Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 10 along with standard-of-care background therapy.
62396816|NCT04991753|EXPERIMENTAL|Group 2: Nipocalimab|Participants will receive nipocalimab IV q2w through Week 10 along with standard-of-care background therapy.
62005128|NCT04540432|EXPERIMENTAL|Profile AB|Patients on non-steroidal anti-inflammatory drugs followed by biotherapy.
62005129|NCT04540432|EXPERIMENTAL|Profile AM|Patients on non-steroidal anti-inflammatory drugs followed by treatment with methotrexate.
62005130|NCT04540432|EXPERIMENTAL|Profile AMB|Patients on non-steroidal anti-inflammatory drugs followed by treatment with methotrexate and then biotherapy if there is no improvement with methotrexate.
62005131|NCT04540432|EXPERIMENTAL|Profile A|Patients on non-steroidal anti-inflammatory drugs.
62005132|NCT04540432|EXPERIMENTAL|Profile M|methotrexate alone
62005133|NCT04540432|EXPERIMENTAL|Profile B|biotherapy alone
62005134|NCT02562313|EXPERIMENTAL|BioChaperone insulin lispro|
62190962|NCT06258213|PLACEBO_COMPARATOR|Placebo|
62190963|NCT06258213|ACTIVE_COMPARATOR|ABP-745|
62005135|NCT02562313|ACTIVE_COMPARATOR|Humalog®|Insulin lispro
62005136|NCT00391352||MS|MS patient is matched to healthy volunteer
62005137|NCT00391352||Control|
62396817|NCT01977651|EXPERIMENTAL|Enzalutamide 160 mg|Participants received 160 mg of enzalutamide orally once a day, for 4 months. At the end of the 4-month treatment period, participants who were assessed as deriving benefit from enzalutamide treatment continued in the extension period. The total study drug treatment duration for the extended period depended on individual clinical benefit. If a participant experienced a Grade 3 or higher toxicity that was attributed to enzalutamide and could not be ameliorated by the use of adequate medical intervention, treatment with enzalutamide was allowed to be interrupted for 1 week or until the toxicity grade improved to Grade 2 or lower severity. Subsequently, enzalutamide was restarted at the original dose 160 mg per day or a reduced dose 120 or 80 mg per day in consultation with the medical monitor.
62396818|NCT04398797|EXPERIMENTAL|Intervention|Use of notification algorithm and nurse follow-up
62396819|NCT04398797|NO_INTERVENTION|Control|Standard regime (usual care)
62572329|NCT01715532|ACTIVE_COMPARATOR|TACE|Patients in this arm will receive transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment.
62780233|NCT02834247|EXPERIMENTAL|Part 2: Metastatic Triple-negative Breast Cancer (TNBC)|Participants with metastatic TNBC will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
62572330|NCT02042014|EXPERIMENTAL|QTI571|Participants will receive QTI571 during 3 years.
62572331|NCT02366689|ACTIVE_COMPARATOR|Toothpaste|Triclosan/fluoride toothpaste
62572332|NCT02366689|ACTIVE_COMPARATOR|Toothpaste + mouthwash|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
62396820|NCT06248216|EXPERIMENTAL|Virtual reality arm|In the virtual reality intervention, participants will complete the scheduled educational module five times in the week of the intervention. This VR is assisting users in using immersive reality to reduce pain, learning cognitive and behavior self-coping skills and retraining the pain pathways. There are several sessions, which will be delivered using an all-in-one head-mounted display. Each session varies in duration approximately from 3 to 15 minutes.
62396821|NCT06248216|PLACEBO_COMPARATOR|Audio Mp4 arm|In the audio intervention, participants will complete the scheduled module 5 times a week of the intervention. The content is similar to that of the VR, which will be delivered by the audio player. Each session varies in duration approximately from 3 to 15 minutes.
62190964|NCT02605746|EXPERIMENTAL|2-4 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 2-4 hours prior to craniotomy for tumor resection.
62190965|NCT02605746|EXPERIMENTAL|4-8 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 4-8 hours prior to craniotomy for tumor resection.
62190966|NCT02605746|EXPERIMENTAL|22-26 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 22-26 hours prior to craniotomy for tumor resection.
62396822|NCT00596466|EXPERIMENTAL|1|
62396823|NCT06713928|EXPERIMENTAL|Oral hygiene with dog therapy|use the DAT to support the oral hygiene procedures provided.
62396824|NCT06713928|NO_INTERVENTION|Oral hygiene without dog therapy|make oral hygiene without any type of support
62791774|NCT01800591|EXPERIMENTAL|Financial incentive with frequent feedback|In addition to the standard enrollment, 6-month, and completion incentives, the subject will be asked to weigh in on the IncentaHEALTH scales everyday they are at work. These subjects will participate in a daily lottery with the possibility of winning the same amount as the discount in Arms 2 and 3 over the course of the study. The subject can choose to select or be designated a two digit number that ranges from 00 to 99. Each day a lottery will be held and the subject will be given a 1% chance of matching both digits or an 18% chance of matching one digit. In order to get the lottery winnings, the subject must meet a weight goal that consistently decreases to accumulate to a 5% weight loss by the 6 month mark. After 6 months, the subject will receive the lottery winnings if they maintain that target weight (initial weight minus 5%) until the end of the 12-month study.
62396825|NCT04890054|ACTIVE_COMPARATOR|SMARTER CRC Intervention Year 1|In year 1, patients receive mailed FITs from CCO, screening reminders from clinics, and patient navigation as appropriate; Health record data collected.
62396826|NCT04890054|ACTIVE_COMPARATOR|SMARTER CRC Intervention Year 2|In year 2, patients receive mailed FITs from CCO, screening reminders from clinics, and patient navigation as appropriate; Health record data collected.
62396827|NCT04063748|EXPERIMENTAL|Experimental|Participants are asked to train (at least) 5 times a week during 15 - 20 mins. The first 4 sessions are training sessions, the fifth session is an in-training test session (DTT and phoneme discrimination).
62396828|NCT04063748|OTHER|Placebo|CI-users: Participants are asked to train (at least) 5 times a week during 15 - 20 mins. The first 4 sessions are training sessions, and the fifth session is an in-training test session (DTT and phoneme discrimination).
62396829|NCT04063748|PLACEBO_COMPARATOR|Passive Control|HA users: Participants do not receive an intervention.
62572333|NCT02366689|PLACEBO_COMPARATOR|Fluoride only Toothpaste + mouthwash|Fluoride only toothpaste + Fluoride only Mouthwash
62396830|NCT06723379||Healthy surgical patients|Healthy surgical patients who are undergoing surgical procedures with projected moderate postoperative pain.
62396831|NCT01205464|ACTIVE_COMPARATOR|Doxycycline|Treatment with Capsule Doxycycline 200 mg, once daily, for 21 days.
62396832|NCT01205464|PLACEBO_COMPARATOR|Sugar pill|Capsule Placebo, 200 mg, once daily, for 21 days.
62396833|NCT03539627||patients with hypertension, CAD and diabetes|Patients with hypertension associated with stable CAD and diabetes on azilsartan medoxomil (Edarbi) therapy
62396834|NCT04811079|EXPERIMENTAL|Spectacle Filter Sequence 1|(419nm, 437nm, 373nm, 456nm, 476nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 1.
62396835|NCT04811079|EXPERIMENTAL|Spectacle Filter Sequence 2|(437nm, 456nm, 419nm, 476nm, 373nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 2.
62396836|NCT04811079|EXPERIMENTAL|Spectacle Filter Sequence 3|(456nm, 476nm, 437nm, 373nm, 419nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 3.
62396837|NCT04811079|EXPERIMENTAL|Spectacle Filter Sequence 4|(476nm, 373nm, 456nm, 419nm, 437nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 4.
62005138|NCT06172335|EXPERIMENTAL|Intervention (Cetoleic acid)|6 x capsules intervention oil (oil = mix of fish oils, olive oil, high-oleic sunflower oil and rapeseed oil) with high content of cetoleic acid (1780 mg/day, estimated: 29,76%) every morning for 4 weeks.
62190967|NCT05777109|EXPERIMENTAL|HS-20090|Subcutaneously injection of HS-20090 (120mg/1.7mL) once on the first day
62396838|NCT04811079|EXPERIMENTAL|Spectacle Filter Sequence 5|(373nm, 419nm, 476nm, 437nm, 456nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 5.
62572334|NCT04410107||Severe Pneumonia|"Presence of fever or suspected lower respiratory infection, plus one of the following criteria:~1) respiratory rate\> 30 movements / min; 2) severe respiratory distress 3) Pulse oximetry (SpO2) ≤93% in room air; and/or 3) Pulmonary infiltrates\> 50% on chest imaging within 24-48hrs of symptom onset."
62572335|NCT04410107||Acute respiratory distress syndrome (ARDS)|"* Onset: acute, i.e. within 1 week of known clinical insult or new or worsening respiratory symptoms; and~* Chest imaging (e.g. X-ray or CT scan): bilateral opacities, not fully explained by effusions, lobar/lung collapse or nodules; and~* Origin of pulmonary edema: respiratory failure not fully explained by cardiac failure or fluid overload; and~* Degree of hypoxemia: arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) ≤ 300 mm Hg with positive end-expiratory pressure ≥ 5 cm H2O."
62572336|NCT00463047|EXPERIMENTAL|Fentanyl Buccal Tablets (FBT)|This study includes a screening period, 2 open-label dose titration periods (in randomized order), and 2 double-blind treatment periods (in randomized order).
62572337|NCT00463047|ACTIVE_COMPARATOR|Oxycodone|This study includes a screening period, 2 open-label dose titration periods (in randomized order), and 2 double-blind treatment periods (in randomized order).
62572338|NCT05573022|EXPERIMENTAL|Arm A1: Breast cancer patients|
62572339|NCT05573022|ACTIVE_COMPARATOR|Arm B1: Breast cancer patients|
62190968|NCT05777109|ACTIVE_COMPARATOR|Xgeva®|Subcutaneously injection of Xgeva® (120mg/1.7mL) once on the first day
62572340|NCT05573022|EXPERIMENTAL|Arm A2: Colorectal cancer patients|
62572341|NCT05573022|ACTIVE_COMPARATOR|Arm B2: Colorectal cancer patients|
62572342|NCT04835662|OTHER|Complementary feeding promotion|Intervention
62572343|NCT03056638|EXPERIMENTAL|Degarelix in conjunction with stereotactic body radiosurgery|Degarelix monthly for 6 months SBRT 8 Gy x 5
62572344|NCT03056638|EXPERIMENTAL|stereotactic body radiosurgery (SBRT)|SBRT 8 Gy x 5
62572345|NCT02028767|EXPERIMENTAL|Fixed Dose Combination (FDC)|12.5 mg Empagliflozin / 500mg metformin fixed dose combination
62780234|NCT02834247|EXPERIMENTAL|Part 2: Metastatic Non-small Cell Lung Cancer (NSCLC)|Participants with metastatic NSCLC will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1.disease or unacceptable toxicity. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
62780235|NCT02834247|EXPERIMENTAL|Part 2: Metastatic HNSCC|Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
62780236|NCT04125277|EXPERIMENTAL|Imaging|One visit to either the UMCG or Amsterdam UMC-location VUMC is required for the FES-PET scan, and possibly one additional visit for an FDG-PET. A FES- or FDG-PET scan plus low dose CT will each induce an extra radiation burden of about 6.1 mSv (210 MBq injected for an average patient of 70 kilogram body weight).
62780237|NCT05293626|EXPERIMENTAL|NR082 injection|"Potential doses at the dose-finding stage:~* 0.5E9 vg, 0.05 mL/eye/dose (low dose)~* 1.5E9 vg, 0.05 mL/eye/dose (starting dose)~* 3.0E9 vg, 0.05 mL/eye/dose (intermediate dose)~* 4.5E9 vg, 0.05 mL/eye/dose (high dose)"
62791775|NCT03701672||Opioid Analgesic Treatment|Chronic paint patients receiving opioid treatment at a Multidisciplinary Pain Center following local SOPs
62005139|NCT06172335|PLACEBO_COMPARATOR|Control oil|6 x capsules control oil (oil= mix of fish oils, olive oil, high-oleic sunflower oil and rapeseed oil) with low content of cetoleic acid (35 mg/day, estimated 0.58%) every morning for 4 weeks.
62190969|NCT02155049|EXPERIMENTAL|Prostaglandin Analogues|The patients will receive a single daily drop of bimatoprost for six months.
62190970|NCT02577003|EXPERIMENTAL|Ipragliflozin + Sitagliptin|Ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
62190971|NCT02577003|ACTIVE_COMPARATOR|Placebo + Sitagliptin|Placebo to ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
62190972|NCT01445795|EXPERIMENTAL|200 mg INX-08189 Fasted|Cohort 1: 200 mg INX-08189 QD fasted for seven days
62572346|NCT02028767|ACTIVE_COMPARATOR|Separate tablets|Empagliflozin and Metformin tablets
62572347|NCT05057598|EXPERIMENTAL|Intervention group on diet and lifestyles|The arm consists to provide survivors with evidence-based recommendations and to promote improved nutrition and physical activity through videos and lectures available on the website (theoretical lectures on preventive strategies, and practical videos on cooking techniques and specific physical exercises).
62572348|NCT01257334|EXPERIMENTAL|Treatment Group|BI 10773 10 mg, 25 mg administered once daily
62572349|NCT01257334|PLACEBO_COMPARATOR|Control Group|Placebo administered once daily
62396839|NCT04811079|EXPERIMENTAL|Spectacle Filter Sequence 6|(476nm, 456nm, 373nm, 437nm, 419nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 6.
62396840|NCT04811079|EXPERIMENTAL|Spectacle Filter Sequence 7|(373nm, 476nm, 419nm, 456nm, 437nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 7.
62396841|NCT04811079|EXPERIMENTAL|Spectacle Filter Sequence 8|(419nm, 373nm, 437nm, 476nm, 456nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 8.
62572350|NCT02484456|EXPERIMENTAL|AV 101 (4-chlorokynurenine), then Placebo|After a two-week drug-free period, participants received daily oral dose of AV 101 (4-chlorokynurenine) monotherapy 1,080mg/day for seven days, then dose increased to AV 101 1,440mg/day for next seven days followed by a two-week washout period; then crossover to placebo phase with daily dose of placebo pill for two weeks.
62005140|NCT05924035|NO_INTERVENTION|Control Group|Control Group will participate in standardized, prescribed exercise 4 days per week and perform countermovement jumps on a force plate both before and after daily workouts (standard of care summer athletic training)
62572351|NCT02484456|EXPERIMENTAL|Placebo, then AV 101 (4-chlorokynurenine)|After a two-week drug-free period, participants received daily dose of placebo pill for two weeks followed by two-week washout period; then crossover to AV 101 treatment phase with daily oral dose of AV 101 (4-chlorokynurenine) monotherapy 1,080mg/day for seven days, then dose increased to AV 101 1,440mg/day for next seven days.
62190973|NCT01445795|PLACEBO_COMPARATOR|Placebo QD Fasted|Cohort 1: Placebo QD fasted for seven days
62572352|NCT04171336|EXPERIMENTAL|Animal-assisted group therapy|
62572353|NCT01022307||Group 1: no history of TBI|184 participants with no history of traumatic brain injury (TBI).
62572354|NCT01022307||Group 2: with a history of TBI|28 patients with a history of TBI. Most of these patients had suffered mild TBI.
62572355|NCT00558701|ACTIVE_COMPARATOR|Microcurrent Stimulator + Silverlon|Patients receiving active electrical stimulation (15-50 microamps) during treatment of skin donor sites with Silverlon wound contact dressing. Intervention is active electrical stimulation via microcurrent stimulator.
62572356|NCT00558701|SHAM_COMPARATOR|Silverlon alone|Patients receiving treatment of skin donor sites with Silverlon wound contact dressing alone (i.e., without active electrical stimulation)
62572357|NCT00210418|EXPERIMENTAL|Preventive targeting|This arm targeted pregnant and lactating women as well as children 6-23.9 months of age to receive BCC and food assistance. A total of 27 months of enrollment in this program arm was possible.
62572358|NCT00210418|ACTIVE_COMPARATOR|Recuperative targeting|This arm targeted pregnant and lactating women as well as mothers of malnourished children (WAZ \<-2 zscores) between 6 and 59 months of age. A total of 18 months of enrollment was possible in this program arm.
62572359|NCT01598493|ACTIVE_COMPARATOR|Control|Flamazine is applied on the wound in the control group instead and then covered with sterile gauze
62572360|NCT01598493|EXPERIMENTAL|BCT Antimicrobial Dressing|The wound in the experimental group is first cleansed with normal saline and then applied with BCT Antimicrobial Dressing and covered by sterile gauze, and dressings will be changed every 3 days.
62572361|NCT04200989|EXPERIMENTAL|Treatment|Peanut ILIT
62005141|NCT05924035|EXPERIMENTAL|HBOT Treatment|HBOT Treatment Group will receive HBOT Treatment in addition to standardized, prescribed exercise 4 days per week and perform countermovement jumps on a force plate both before and after daily workouts (standard of care summer athletic training)
62005142|NCT01646697|EXPERIMENTAL|Diagnostic (cytopathologic evaluation)|Patients undergo cytopathologic sample collection during pancreatic resection during which slides are gently pressed against the cut edge of the pancreas, the surgical bed, and along the superior mesenteric artery, and finally against the tumor itself.
62005143|NCT01479621|EXPERIMENTAL|Fp MDPI 12.5 mcg|"Fluticasone propionate (Fp) 12.5 mcg per dose twice a day (for a total daily dose of 25 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
62396842|NCT04811079|EXPERIMENTAL|Spectacle Filter Sequence 9|(437nm, 419nm, 456nm, 373nm, 476nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 9.
62396843|NCT04811079|EXPERIMENTAL|Spectacle Filter Sequence 10|(456nm, 437nm, 476nm, 419nm, 373nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 10.
62396844|NCT03660657|EXPERIMENTAL|Ozone Group:|Standard treatment + Ozone therapy (O3/O2)
62396845|NCT03660657|PLACEBO_COMPARATOR|Control Group:|Standard treatment + Oxygen (O2)
62572362|NCT02589626|EXPERIMENTAL|empagliflozin 10 mg|empagliflozin 10 mg tablet and placebo matching empagliflozin 25 mg tablet
62572363|NCT02589626|EXPERIMENTAL|empagliflozin 25 mg|empagliflozin 25 mg tablet and placebo matching empagliflozin 10 mg tablet
62572364|NCT03368092|EXPERIMENTAL|Dornase alfa|Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.
62572365|NCT03368092|PLACEBO_COMPARATOR|Placebo|NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.
62572366|NCT01826513|EXPERIMENTAL|Unblinded Investigational Arm|Participants participated in an unblinded investigational phase of the trial prior to, and separate from, the single-blind cross-over phase of the trial. Data was collected from the his phase to aid the final development of the algorithm before proceeding to algorithm validation (ie. cross-over phase).
62780238|NCT01796821|PLACEBO_COMPARATOR|Vehicle gel|vehicle gel is used as a control group. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
62005144|NCT01479621|EXPERIMENTAL|Fp MDPI 25 mcg|"Fluticasone propionate (Fp) 25 mcg per dose twice a day (for a total daily dose of 50 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
62005145|NCT01479621|EXPERIMENTAL|Fp MDPI 50 mcg|"Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
62005146|NCT01479621|EXPERIMENTAL|Fp MDPI 100 mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
62005147|NCT01479621|EXPERIMENTAL|Placebo MDPI|Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.
62190974|NCT01445795|EXPERIMENTAL|100 mg INX-08189 with Ribavirin|Cohort 2: 100 mg INX-08189 100 mg dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID, the AM dose will be taken 4 hours after INX-08189 so it may be taken with food)
62190975|NCT01445795|ACTIVE_COMPARATOR|Placebo QD dosed with ribavirin|Cohort 2: Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
62190976|NCT01445795|EXPERIMENTAL|100 mg INX-08189 with a low-fat meal|Cohort 3: 100 mg INX-08189 with a low-fat meal QD x7 days
62190977|NCT01445795|PLACEBO_COMPARATOR|Placebo with low-fat meal|Cohort 3: Placebo administered with a low-fat meal QD for 7 days
62190978|NCT01445795|EXPERIMENTAL|100 mg INX-08189 Fasted|Cohort 4: 100 mg INX-08189 BID fasted x7 days
62190979|NCT01445795|PLACEBO_COMPARATOR|Placebo BID Fasted|Cohort 4: Placebo BID fasted x7 days
62780239|NCT01796821|ACTIVE_COMPARATOR|SR-T100 gel with 1.0 % SM|SR-T100 contains 1.0% SM. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
62780240|NCT01796821|ACTIVE_COMPARATOR|SR-T100 gel with 2.3% SM|SR-T100 contains 2.3% SM. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
62190980|NCT01727661||type 1 diabetes mellitus|"1. exercise testing with near-infrared spectroscopy~2. lung function testing~3. quality of life"
62190981|NCT01727661||healthy controls|"1. exercise testing with near-infrared spectroscopy~2. lung function testing~3. quality of life"
62572367|NCT01826513|ACTIVE_COMPARATOR|Standard AutoSet algorithm|Participants first received therapy with the Standard AutoSet algorithm for one night, and then received therapy with the Modified AutoSet algorithm (an AutoSet device with an algorithm developed for sleep breathing parameters specific to females) the following night.
62572368|NCT01826513|EXPERIMENTAL|Modified AutoSet algorithm|Participants first received therapy with the Modified AutoSet algorithm (an AutoSet device with an algorithm developed for sleep breathing parameters specific to females) for one night, and then received therapy with the standard AutoSet algorithm the following night.
62005148|NCT01479621|EXPERIMENTAL|Flovent Diskus 100mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
62005149|NCT01191710|EXPERIMENTAL|Antagonist group|Antagonist protocol for IVF
62005150|NCT01191710|ACTIVE_COMPARATOR|Agonist group|Long Agonist protocol for IVF
62396846|NCT05144646|EXPERIMENTAL|HEALTHY SUBJECTS|With healthy subjects in a randomised, open experimental design, in an intrasubject control group (application of HFA / EVOO on one heel, using the contralateral heel as a control and evaluating oxygenation and tissue perfusion in both cases). This intervention would correspond to phase 1
62005151|NCT03294603|EXPERIMENTAL|[14C]-CC-220 solution|A single oral dose of 1 mg \[14C\]-CC-220 solution, containing approximately 1.4 μCi of radioactivity, will be administered on Day 1 under fasted conditions.
62005152|NCT06319599|EXPERIMENTAL|Routine therapy+Stellate ganglion block|"The study lasts 10d for each patient. During the treatment, All the participants are provided with the routine rehabilitation therapy.~Based on the invention above, the patients in the experimental group were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)"
62005153|NCT06319599|PLACEBO_COMPARATOR|Routine therapy+placebo|The study lasts 10d for each patient. During the treatment, All the participants are provided with the routine rehabilitation therapy.
62396847|NCT05144646|EXPERIMENTAL|PATIENTS|With hospitalised patients and patients from social and health centers an experimental, randomised, open design, also with an intrasubject control group (application of HFA / EVOO on one heel, using the contralateral heel as a control and evaluating oxygenation and tissue perfusion in both cases). This intervention would correspond to phase 2.
62396848|NCT02708524|EXPERIMENTAL|Senofilcon C Wearers|Senofilcon C Wearers will wear the Senofilcon C Contact Lenses as daily wear for 30 (-2/+6) days.
62572369|NCT06295458|EXPERIMENTAL|Flicker Exposure (Treatment Group)|Participants will be instructed to take home the stimulation equipment. Participants and their study partners (if applicable) will be trained on how to use the device before leaving the facility. Each device case also includes an instruction document. Participants and/or study partners (if applicable) will keep a manual log of daily operation, including the time of day used, whether the participant felt drowsy or, was able to complete the entire session, or if the participant was unable to complete the therapy that day. Finally, study staff will contact participants monthly every 2 weeks to ensure compliance, assess adverse events, and log concomitant medications.
62572370|NCT06295458|SHAM_COMPARATOR|Control Group|Participants will receive sham stimulation. Participants and/or study partners (if applicable) will keep a manual log of daily operation, including the time of day used, whether the participant felt drowsy or, was able to complete the entire session, or if the participant was unable to complete the therapy that day. Finally, study staff will contact participants monthly every 2 weeks to ensure compliance, assess adverse events, and log concomitant medications.
62005154|NCT01097837||Epilepsy|Cohort is comprised of women with epilepsy between 18 and 47.
62005155|NCT04879160||1/ Cohort 1A|Clinician raters familiar with NF1
62005156|NCT04879160||2/ Cohort 1B|Clinician raters without specific NF1 familiarity
62005157|NCT04879160||3/ Cohort 2A|Non-clinician raters familiar with NF1
62005158|NCT04879160||4/ Cohort 2B|Non-clinician raters without specific NF1 familiarity
62005159|NCT04879160||5/ Cohort 3|Subjects with NF1
62005160|NCT02085564||GEJ-cancer patients consideres resectable|All patients have biopsy verified GEJ-cancer, and has been considered for intend curative resection by a multidisciplinary panel of specialists.
62005161|NCT00357370|EXPERIMENTAL|Cohort 1|20 mg
62005162|NCT00357370|EXPERIMENTAL|Cohort 2 - Arm 1|10 mg
62005163|NCT00357370|EXPERIMENTAL|Cohort 2 - Arm 2|20 mg
62005164|NCT00357370|PLACEBO_COMPARATOR|Cohort 2 - Arm 3|
62005165|NCT05883605|OTHER|one population of normotensive and hypertensive|treated and untreated normotensive and hypertensive patients
62396849|NCT02708524|ACTIVE_COMPARATOR|Comfilcon A Wearers|Comfilcon A Wearers will wear the Comfilcon A Contact Lens as daily wear for 30 (-2/+6) days.
62396850|NCT02708524|ACTIVE_COMPARATOR|Lotrafilcon B Wearers|Lotrafilcon B Wearers will wear the Lotrafilcon B Contact Lens as daily wear for 30 (-2/+6) days.
62396851|NCT02708524|ACTIVE_COMPARATOR|Samfilcon A Wearers|Samfilcon A Wearers will wear the Samfilcon A Contact Lens as daily wear for 30 (-2/+6) days.
62396852|NCT04029246|NO_INTERVENTION|Letter only|
62396853|NCT04029246|ACTIVE_COMPARATOR|Letter plus phone call|
62396854|NCT04029246|ACTIVE_COMPARATOR|Letter plus incentive|
62396855|NCT04503655|EXPERIMENTAL|Intervention group|"The randomized centres in this group will be follow a training dedicated on implementation of organizational and therapeutic measures (for prevention and management of complications) to reduce lenght-of-stay after TF TAVI."
62190982|NCT05784922||Digital Outreach: Patient Gateway|"Participants who list Patient Gateway as the preferred mode of contact in the electronic health record (EHR) system. Patient Gateway is an online patient portal that gives patients access to securely message their Mass General Brigham provider, request routine appointments, prescriptions and referral authorizations as well as view test results that were processed at a Mass General Brigham facility. Participants will receive the digital educational lung cancer screening video via their patient gateway account."
62190983|NCT05784922||Digital Outreach: Text|"Participants who list Text as the preferred mode of contact in the electronic health record (EHR) system. Participants will receive the digital educational lung cancer screening video via a text message sent directly to their cell phone."
62396856|NCT04503655|NO_INTERVENTION|Control group|The randomized centres in this group will not change their practices.
62396857|NCT06013579|ACTIVE_COMPARATOR|Continuous Moderate Exercise (CME)|Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak172, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
62780241|NCT03515642|EXPERIMENTAL|HIIT group|The HIIT modality consisted of 30-40 minutes (min) of steady-state, high-intensity training 3 d/wk on a stationary bicycle at the target heart rate (HR) range equivalent to 85% to 95% of the individual's maximum oxygen consumption rate (VO2max). Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6-weeks.
62780242|NCT03515642|ACTIVE_COMPARATOR|SIT group|The SIT modality consisted of 6 to 10 repetitions of a 30 s segment of all-out exercise interspersed with 2 min of recovery, 3 d/wk on a stationary bicycle at the target heart rate (HR) range equivalent to 90% to 95% of the individual's maximum oxygen consumption rate (VO2max).
62780243|NCT00951652|EXPERIMENTAL|CBT plus supportive listening|14 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques and the second hour will be supportive listening
62780244|NCT00951652|ACTIVE_COMPARATOR|CBT plus Interpersonal and emotional processing therapy|14 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques and the second hour will be Interpersonal and emotional processing therapy
62190984|NCT05784922||Digital Outreach: Email|"Participants who list Email as the preferred mode of contact in the electronic health record (EHR) system. Participants will receive the digital educational lung cancer screening video directly to the email they have listed."
62190985|NCT02818998|EXPERIMENTAL|Aflibercept 2 mg fixed|Participants received fixed dosing of 2 mg aflibercept at injection intervals of 8 weeks
62190986|NCT02818998|EXPERIMENTAL|Aflibercept 2 mg flexible|Participants received flexible dosing of 2 mg aflibercept at injection intervals of ≥8 week
62190987|NCT02818998|EXPERIMENTAL|Aflibercept 2 mg PRN|Participants received monthly monitoring with 2 mg aflibercept injection pro re nata (PRN, as needed)
62190988|NCT01210651|EXPERIMENTAL|Hatha Yoga Practice Group|Participants in this group practiced 90-minute sessions of hatha yoga exercises twice weekly for a total of 8 weeks.
62190989|NCT01210651|ACTIVE_COMPARATOR|Attention Control Education Group|Participants in this group attended 90-minute educational seminars on yoga history twice weekly for a total of 8 weeks.
62780245|NCT05455502|EXPERIMENTAL|Sequence 1|Participants will receive VX-548 reference tablet (TF1) under fasted condition in dosing period 1, then VX-548 test tablet (TF2) under fasted condition in dosing period 2, and finally VX-548 test tablet (TF2) under fed condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
62780246|NCT05455502|EXPERIMENTAL|Sequence 2|Participants will receive VX-548 TF1 under fasted condition in dosing period 1, then VX-548 TF2 under fed condition in dosing period 2, and finally VX-548 TF2 under fasted condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
62780247|NCT05455502|EXPERIMENTAL|Sequence 3|Participants will receive VX-548 TF2 under fasted condition in dosing period 1, then VX-548 TF1 under fasted condition in dosing period 2, and finally VX-548 TF2 under fed condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
62780248|NCT05455502|EXPERIMENTAL|Sequence 4|Participants will receive VX-548 TF2 under fasted condition in dosing period 1, then VX-548 TF2 under fed condition in dosing period 2, and finally VX-548 TF1 under fasted condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
62780249|NCT05455502|EXPERIMENTAL|Sequence 5|Participants will receive VX-548 TF2 under fed condition in dosing period 1, then VX-548 TF1 under fasted condition in dosing period 2, and finally VX-548 TF2 under fasted condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
62780250|NCT05455502|EXPERIMENTAL|Sequence 6|Participants will receive VX-548 TF2 under fed condition in dosing period 1, then VX-548 TF2 under fasted condition in dosing period 2, and finally VX-548 TF1 under fasted condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
62780251|NCT05018663||Prospective enrollment|All subjects will be enrolled prospectively. Subjects will be included in the study after eligibility is assessed and informed consent is obtained. The slide scanner will scan the slides on site and the images will be securely saved and sent for interpretation by the AI software at a different location. The results of the AI interpretation of the slides will be blinded to the on-site procedure team including the endoscopist and cytopathologist until the final pathology report is complete.
62190990|NCT03237169||Prospective cohort|Prospective cohort of patients with stable or stabilized coronary artery disease and de novo coronary lesions, in whom functional evaluation is performed, according do standard clinical indications.
62396858|NCT06013579|ACTIVE_COMPARATOR|High-Intensity Interval Training (HIIT)|Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
62396859|NCT05081791|EXPERIMENTAL|Exercise Training|This group will engage in a 12-week exercise training program
62396860|NCT05081791|NO_INTERVENTION|Control group|Usual care. Patients in this group will be offered the same program at the end of the study
62396861|NCT03116789|ACTIVE_COMPARATOR|VGA-1(Probiotics)|Lactobacillus rhamnosus and Lactobacillus acidophilus.
62396862|NCT03116789|ACTIVE_COMPARATOR|VGA-2(Probiotics)|Lactobacillus rhamnosus and Lactobacillus plantarum.
62396863|NCT05885958|EXPERIMENTAL|Immediate|Patients will be given up to 30 minutes to void during the active void trial postoperatively.
62396864|NCT05885958|EXPERIMENTAL|Extended|Patients will be given up to 60 minutes to void during the active void trial postoperatively.
62572371|NCT00775801|EXPERIMENTAL|Treatment|FLD
62005166|NCT06202638||The arterial pressure and HPI course in 7 time-windows cohorts in one-lung ventilated patients|60 consecutive adult patients qualified for open-chest lung resection procedures under general anesthesia with one-lung ventilation will be monitored during the operation using standard invasive hemodynamic monitoring with arterial pressure transducer and concomitantly with HemoSphere monitor with the HPI software attached to the Acumen IQ transducer (Edwards LifeSciences, Irvine, CA, USA). The clinicians will be blinded to the output of the HemoSphere monitor. Hemodynamic waveforms and HPI prediction data will be recorded from the time of arterial cannula insertion until leaving the operation room. HPI values and intraoperative hemodynamic course including intraoperative hypotensive events (IOH) will be recorded at all stages of the procedure.
62005167|NCT04261270|EXPERIMENTAL|ASC09F+Oseltamivir|
62572372|NCT00775801|ACTIVE_COMPARATOR|Control|
62005168|NCT04261270|EXPERIMENTAL|Ritonavir+Oseltamivir|
62780252|NCT01868477|EXPERIMENTAL|Erythropoietin alpha|Patients will receive erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be switched to the combination arm. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study.
62780253|NCT01868477|EXPERIMENTAL|Deferasirox + Erythropoietin alpha|Patients will receive deferasirox dispersible tablet (DT) 10 mg/kg/day or deferasirox film-coated tablet (FCT) 7 mg/kg/day in combination with erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, erythropoietin dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be discontinued from the study. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study. Patients will continue deferasirox treatment.
62780254|NCT05373342||iCount Device|A novel external device which can count the swabs and surgical tampons used during childbirth in an objective and validated manner.
62005169|NCT04261270|EXPERIMENTAL|Oseltamivir|
62005170|NCT02204254|EXPERIMENTAL|Radiofrequence|3 sessions of radiofrequency at 3 weeks intervals V1, V2 (W3 or W4) and V3 (between W6 and W8), with clinical examination, evaluation of tolerance, adverse events report, photos, surface biopsy (SSSB), and confocal microscopy (V1 and V3). Follow up visit V4 (M6) with clinical evaluation, photos, SSSB, confocal microscopy, adverse events report and treatment satisfaction.
62005171|NCT02204254|PLACEBO_COMPARATOR|Doxycycline|doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
62005172|NCT05256017|ACTIVE_COMPARATOR|Acoziborole|Single dose administration of 3 tablets of 320 mg
62005173|NCT05256017|PLACEBO_COMPARATOR|Placebo|Single dose administration of 3 tablets of 320 mg
62005174|NCT05216367|EXPERIMENTAL|Cohort 1 (healthy subjects)|8 healthy subjects with normal hepatic function will receive a single dose of 5 mg (1x5 mg) fruquintinib
62005175|NCT05216367|EXPERIMENTAL|Cohort 2 (moderate hepatic impairment)|8 subjects with moderate hepatic impairment will receive a single dose of 2 mg (2 x 1 mg) fruquintinib
62005176|NCT05216367|EXPERIMENTAL|Cohort 3 (mild hepatic impairment)|8 subjects with mild hepatic impairment will receive a single dose of 5 mg (1 x 5 mg) fruquintinib
62190991|NCT01984567|EXPERIMENTAL|Vitamin E|
62572373|NCT01962012|EXPERIMENTAL|AcceleDent Aura|AcceleDent Aura device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
62572374|NCT01962012|SHAM_COMPARATOR|Sham Device|Sham devices will look identical to active devices but will not deliver vibration to the patient.
62190992|NCT01984567|EXPERIMENTAL|Lipoic acid|
62190993|NCT01984567|PLACEBO_COMPARATOR|Control|
62396865|NCT03626935|EXPERIMENTAL|3D-printed customized guide plate|3D-printed customized guide plate will be used to guide the Kirschner wires in ankle arthrodesis.
62396866|NCT03044327|OTHER|LPS challenge|LPS inhalation and bronchial instillation
62396867|NCT06078813|EXPERIMENTAL|Low baseline VCF risk|"All of:~* No VCF~* Predominantly sclerotic lesion (as determined by the Investigator based on MRI)~* Normal spinal alignment~* \<50% vertebral body involvement"
62572375|NCT01159041|EXPERIMENTAL|Family Focused Treatment (FFT)|15 session family-based treatment emphasizing improving relationship skills to combat depression symptoms and support recovery.
62572376|NCT01159041|ACTIVE_COMPARATOR|Individual Treatment (IP)|15 session individually-based treatment to assist children in understanding the causes of their symptoms.
62572377|NCT01760135|EXPERIMENTAL|low calory|15kcal/kg caloric supplement
62780255|NCT05373342||User Feedback Survey|"Feedback will be taken from 20 users including midwives/ doctors.~Users will be emailed an online survey or given the same survey as a printout to complete.~All 20 users will also then also be approached to have a semi-structured interview.~10 of the users who first express interest will be interviewed."
62780256|NCT05254327|EXPERIMENTAL|Arm A|Short Chemo-Radiation Therapy (SCRT) + BMX-001
62780257|NCT05254327|NO_INTERVENTION|Arm B|Short Chemo-Radiation Therapy (SCRT)
62005177|NCT02591628|ACTIVE_COMPARATOR|Intervention|"Intervention is HCTZ prescription conversion to chlorthalidone. Intervention patients are defined as patients of physicians randomized to intervention. All these patients will have their current prescription of hydrochlorothiazide (HCTZ) switched to an equipotent dose of Chlorthalidone. These patients can choose to decline this intervention, and will be followed for 9 months with no other intervention to observe primary and secondary outcomes."
62005178|NCT02591628|NO_INTERVENTION|Usual Care|"Usual care patients are defined as patients of physicians randomized to usual care. All these patients will keep their current prescription for HCTZ and work with their physician like normal. These patients will be followed for 9 months with no intervention to compare primary and secondary outcomes to the intervention group."
62005179|NCT02880982|ACTIVE_COMPARATOR|Intervention|Softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3) to be taken orally once per week for 3 years
62005180|NCT02880982|PLACEBO_COMPARATOR|Placebo|Softgel capsule of identical taste and appearance to active comparator, but containing no cholecalciferol, to be taken orally once per week for 3 years
62005181|NCT05755828|EXPERIMENTAL|ASCT+CAR-T Cell Infusion|CD19 CAR-T cells were prepared from peripheral lymphocytes of NHL patients with PR after 3 to 4 courses of chemotherapy, and autologous stem cells were collected and frozen after mobilization of patient stem cells by granulocyte stimulating factor (10μg/kg/d\*5d). BEAM pretreatment was performed. Autologous stem cells were injected 24 h after pretreatment, and the number of CD34+ cells was \> 2\*106/kg. On the 6th day after transplantation, autologous Anti-CD19 CAR T cells were transfused, and the dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. The patients were given constant intravenous drip/push infusion for 30 minutes.
62005182|NCT06562140||Colorectal cancer patients|Patients aged 18 to 80 years with a diagnosis of colorectal carcinoma
62005183|NCT06562140||Anal cancer patients|Patients aged 18 to 80 years with a diagnosis of anal carcinoma
62005184|NCT05000749|EXPERIMENTAL|DBT-SG plus VHA treatment as usual|Dialectical Behavior Therapy Skills Group (DBT-SG) in addition to VHA treatment as usual. Group is 24 weekly sessions teaching skills in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness.
62005185|NCT05000749|ACTIVE_COMPARATOR|VHA treatment as usual|VHA treatment as usual for Veterans at risk for suicide attempt
62005186|NCT03132948|EXPERIMENTAL|Physical Activity|Single arm study where patients choose from physical activities after baseline assessment by PT. Activities include the following: Nintendo WII fit console, Xbox Kinect fit console and other sport activities.
62005187|NCT03228680|EXPERIMENTAL|Follitropin delta|FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. The daily FE 999049 dose was fixed throughout the stimulation period. The minimum allowed daily FE 999049 dose was 6 μg and maximum allowed daily dose was 12 μg. Dosing continued until the criterion for triggering of final follicular maturation was met. Participants could be treated for a maximum of 20 days.
62005188|NCT03228680|ACTIVE_COMPARATOR|Follitropin beta|FOLLISTIM was administered as single daily subcutaneous injections in the abdomen. The starting dose of FOLLISTIM was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 375 IU. Dosing continued until the criterion for triggering of final follicular maturation was met. Participants could be treated for a maximum of 20 days.
62005189|NCT04142437||GI|adult patients with gastrointestinal (GI) cancer
62005190|NCT04142437||H&N|adult patients with head and neck (H\&N) cancer
62780258|NCT05254327|EXPERIMENTAL|Arm C|Long Course Chemo-Radiation Therapy (LCCRT) + BMX-001
62005191|NCT04142437||STS|adult patients with soft tissue sarcoma (STS)
62005192|NCT04142437||CNS|adult patients with primary central nervous system (CNS) cancer
62005193|NCT04142437||Lung|adult patients with lung cancer
62005194|NCT04142437||Melanoma|adult patients with melanoma
62005195|NCT04142437||Pediatric|all pediatric patients regardless of tumor type will be enrolled under this cohort
62780259|NCT05254327|NO_INTERVENTION|Arm D|Long Course Chemo-Radiation Therapy (LCCRT)
62780260|NCT05501951|EXPERIMENTAL|right DLPFC tDCS|Participants in this group will receive 10 sessions of right DLPFC tDCS
62780261|NCT05501951|EXPERIMENTAL|right OFC tDCS|Participants in this group will receive 10 sessions of right OFC tDCS
62005196|NCT04142437||other|patients with other tumor types
62005197|NCT00087633|EXPERIMENTAL|1|
62005198|NCT00087633|NO_INTERVENTION|2|
62005199|NCT00770120|EXPERIMENTAL|Everolimus|Daily oral Everolimus 10 mg/day
62396868|NCT06078813|EXPERIMENTAL|High baseline VCF risk|"Any of:~* Pre-existing VCF~* Predominantly lytic lesion (as determined by the Investigator based on MRI)~* Spinal deformity~* ≥50% vertebral body involvement"
62780262|NCT05501951|SHAM_COMPARATOR|Control group|Participants in this group will receive 10 sessions of sham stimulation
62780263|NCT06168266|ACTIVE_COMPARATOR|Control group|Undergoing conventional treatment
62396869|NCT05947981|NO_INTERVENTION|Control group|Patients will be fasted and not receiving any pre-operative fluids
62190994|NCT05078177|EXPERIMENTAL|AHSCT + intrathecal Rituximab|AHSCT with reduced intensity condition regimen (RIC). Lumbar puncture with intrathecal injection of 25 mg Rituximab will be performed once from about D+12 to D+14 AHSCT, depending on the duration of cytopenia.
62190995|NCT04099654|EXPERIMENTAL|Core-Stabilization Exercise|
62190996|NCT04099654|EXPERIMENTAL|Counseling of physical activity|
62396870|NCT05947981|ACTIVE_COMPARATOR|Dextrose group|Patients will take 100ml/HR of clear fluids (apple juice) during the fasting hours till 2 hrs before the operation and will receive dextrose 5% infusion at a rate of 1ml/kg/h 2hrs before the operation and till the end of the operation
62396871|NCT05947981|PLACEBO_COMPARATOR|Normal saline group|Patients will take 100ml/HR of water during the fasting hours till 2 hrs before the operation and will receive normal saline 0.9% at a rate of 1ml/kg/h (group NS) intravenously (IV)2hrs before the operation and till the end of the operation
62396872|NCT00556140|EXPERIMENTAL|Major Depression with Psychotic Features|
62396873|NCT05999227|EXPERIMENTAL|Immunotherapy|"Patients with rectal cancer will receive short-course radiotherapy and neoadjuvant chemotherapy plus immunotherapy.~68Ga-FAPI-04 and 18F-FDG PET will be performed at baseline and after short-course radiotherapy and 2 cycles of neoadjuvant chemotherapy plus immunotherapy. The two imaging intervals will be completed two days apart."
62396874|NCT05868187|EXPERIMENTAL|Exercise, Problem-Solving and Education|Individualized exercise program Weekly Goals setting and problem-solving session to create a weekly action plan Four Assigned interactive educational modules
62396875|NCT05868187|NO_INTERVENTION|Usual Care|Participants will complete their daily routines as they typically do.
62396876|NCT04530227|EXPERIMENTAL|Camrelizumab combined with chemotherapy|"Participants receive camrelizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 18 cycles PLUS Investigator's choice of chemotherapy.~Interventions:~Biological: Camrelizumab"
62396877|NCT06285019|EXPERIMENTAL|Combination therapy|TOMOX-HAIC combined with Sintilimab and bevacizumab biosimilar
62396878|NCT01985555|EXPERIMENTAL|Volitinib(HMPL-504)|There are 5 dose cohorts,including600 QD,800QD and 400BID mg,500BID in the dose escalation stage and HMPL-504 will be administered orally to patients once daily for each dose cohort., in the dose expansion stage 500BID will be administered orally to patients.
62396879|NCT05617014||Cognitively Normal (CN)|700 participants with no apparent memory problems, which is anticipated to include 250 newly enrolled participants and 450 rollover participants from the prior ADNI3 study without apparent memory problems.
62396880|NCT05617014||Mild Cognitive Impairment (MCI)|450 participants with mild cognitive impairment (MCI), which is anticipated to include 250 newly enrolled participants and 200 rollover participants from the prior ADNI3 study with MCI.
62396881|NCT05617014||Dementia (DEM)|350 participants with mild dementia (DEM), which is anticipated to include 250 newly enrolled participants and 100 participants followed from the prior ADNI3 study with dementia.
62396882|NCT06723782|EXPERIMENTAL|AMTRIX-D|Surgical release of the tendon and wrapping of the released tendon with desiccated amniotic membrane (AMTRIX-D)
62396883|NCT02735382|EXPERIMENTAL|EHR-based referral to quit line|"Clinics will use an EHR-based fully-electronic HIPAA-compliant tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication.~Intervention: Behavioral: Tobacco quitline EHR referral"
62396884|NCT02735382|ACTIVE_COMPARATOR|Fax-based referral to quit line|"Clinics will use a paper fax tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication.~Intervention: Behavioral: Tobacco quitline Fax referral"
62396885|NCT02735382|EXPERIMENTAL|EHR-based Clinic Staff|Clinics will use an EHR-based fully-electronic HIPAA-compliant tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication. Staff in these clinics will complete surveys to address Aim 4 of the study.
62396886|NCT02735382|ACTIVE_COMPARATOR|Fax-based referral to quit line Clinic Staff|Clinics will use a paper fax tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication. Staff in these clinics will complete surveys to address Aim 4 of the study.
62396887|NCT04393259||Participants|Women attending an antenatal service using the Rainbow Clinic model of care.
62190997|NCT00254969|EXPERIMENTAL|1|
62190998|NCT05578430|EXPERIMENTAL|TACE+Cadonilimab+Surgery|After appropriate screening and randomization, patients enrolled will receive TACE plus 2-cycle of Cadonilimab treatment before surgery. Four weeks later after surgery, Cadonilimab treatment will be followed up to 16 cycles.
62396888|NCT01590628|EXPERIMENTAL|NiCord|NiCord: NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
62396889|NCT05507346|EXPERIMENTAL|Dayspring, Non-Pneumatic Active Compression Device (NPCD)|The Dayspring, an Non-Pneumatic Active Compression Device (NPCD) Active Wearable Compression Device is an FDA cleared calibrated active gradient pressure compression garment that is segmental and programmable and applies controlled sequential pressure from the distal to proximal-end of the limb in a cyclic manner.
62572378|NCT01760135|ACTIVE_COMPARATOR|high calory|25kcal/kg
62396890|NCT05507346|ACTIVE_COMPARATOR|Advanced Pneumatic Compression Device (APCD)|A commercially available advanced pneumatic compression device that is FDA-cleared for the same indication for use as the Dayspring Wearable Compression Device.
62396891|NCT04868188||Voriconazole administration to adult patients with suspected fungal disease, receiving ECMO support|Adult (\>18 years) patients with severe influenza / Covid-19 supported on ECMO and with confirmed or suspected aspergillosis infection.
62396892|NCT05638594|EXPERIMENTAL|Pyrotinib +trastuzumab+dalpiciclib+letrozole|Every 4 weeks for 5 cycles. Cumulative 20 weeks of treatment. Premenopausal patients need to receive ovarian function suppression
62396893|NCT05638594|ACTIVE_COMPARATOR|Trastuzumab + pertuzumab + docetaxel + carboplatin|Every 3 weeks for 6 cycles. Cumulative 18 weeks of treatment
62396894|NCT04826042|ACTIVE_COMPARATOR|contrast group|injection of contrast medium 6 cc during thoracic epidural catheterization
62396895|NCT04826042|PLACEBO_COMPARATOR|normal saline group|injection of normal saline 6 cc during thoracic epidural catheterization
62396896|NCT06536569|EXPERIMENTAL|Sharkskin Group|25g Grieshaber Sharkskin ILM Forceps with Reflex Handle
62396897|NCT06536569|ACTIVE_COMPARATOR|Standard Group|25g Grieshaber standard ILM
62396898|NCT02914873|ACTIVE_COMPARATOR|Current clinical practice for active surveillance|In this arm, patients are monitored according to current clinical practice for active surveillance at the trial centre. Repeat biopsies (and/or other examinations) and curative treatment are performed according to the urologist's judgement.
62005200|NCT01825369|EXPERIMENTAL|IV L-carnitine|L-carnitine (25, 50, or 100mg/kg IV) will be given, 30-60 minutes prior to the initiation of CPB, and a second dose \~2 hr. following separation from CPB (with a minimum of 4 hrs from initial dose). The first 5 subjects will receive 25 mg/kg, with an escalation of dose after each 5 subjects enrolled. The study drug will be brought to the operating room and administered over 5 minutes by the anesthesiologist after an IV has been placed. Prior to the administration of the study drug, and again 24 and 48 hrs after CPB, 3.0 ml of blood will be collected for determinations of carnitine levels (free, total, and acylcarnitine), mitochondrial function, ROS and bioavailable NO as described in Aim 3A. Additional blood (0.5-1.0 ml) will be obtained to determine carnitine levels before CPB, and then before and 0.5, 1.5, 3, 5, 9, 12, and 24h after the second dose.
62572379|NCT02068508||Pioglitazone|Pioglitazone 15 mg to 30 mg, orally, once daily
62396899|NCT02914873|EXPERIMENTAL|Standardized triggers for initiation of treatment with curative intent|In this arm, patients are monitored according to a standardized active surveillance protocol with specific triggers for treatment. Repeat biopsies and curative treatment are only initiated if/when specific criteria are fulfilled.
62396900|NCT01143558|EXPERIMENTAL|1|All cohorts undergo the same intervention with the study device.
62572380|NCT02449798|EXPERIMENTAL|"AccuCath 2.25 BC Intravascular Catheter"|"Use of AccuCath 2.25 BC peripheral IV device for difficult IV access in emergency room patients who have had 2 previous attempts, identified as difficult IV access from patient history or non-palpable, non-visible veins."
62572381|NCT06534593|ACTIVE_COMPARATOR|Control Group|The Control group will receive standard treatment for the management of discogenic low back pain.
62572382|NCT06534593|EXPERIMENTAL|Experimental Group|The Physical Therapy group will receive Physical Therapy for the management of discogenic low back pain.
62572383|NCT00450099|EXPERIMENTAL|1|Epidural, bupivacaine
62572384|NCT00808912|ACTIVE_COMPARATOR|1|Subjects will exercise in a high air pollutant environment after ingesting a standard dose of sildenafil.
62780264|NCT06168266|EXPERIMENTAL|Intervention Group: eccentric cycling exercise|Received eccentric cycling exercise
62780265|NCT05391256|EXPERIMENTAL|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally six drone systems are setup to be deployed in suspected OHCA cases as a complement to EMS. This is a single-arm intervention evaluating referral of bystanders during 112-calls to retrieve drone delivered AEDs in suspected OHCA.
62780266|NCT06510010|EXPERIMENTAL|Oxaliplatin With S-1 （SOX）Combined H. Pylori Eradication|Subjects randomized to the trial group will receive 3-4 cycles of Oxaliplatin With S-1 （SOX）+ H. pylori eradication (a 14-day quadruple regimen: amoxicillin + clarithromycin + omeprazole + bismuth potassium citrate) before surgery. One of the SOX regimens will be every 3 weeks (Q3W), with a tumor response assessment at the end of the neoadjuvant therapy course. Patients will continue to receive 4-5 cycles of SOX adjuvant chemotherapy after surgery for a total of 8 cycles of SOX regimen treatment. Patients in the trial group will undergo H. pylori eradication at the time of the first cycle of the SOX regimen. H. pylori eradication will be determined by postoperative pathology, and those who are H. pylori-positive by postoperative pathology will be treated with remedial eradication therapy after recovery from surgery (except for patients with total gastric resection).
62005201|NCT04438928|EXPERIMENTAL|Healthy pregnant women - Supplement|"Supplementation with micronutrients plus docosahexaenoic acid (DHA) preparation (Multimicronutrients and docosahexaenoic acid (MMS) soft gel capsules) during 2nd and 3rd trimesters of pregnancy.~Subgroup: Healthy pregnant women with Caesarean section \[A subset of subjects (approximately 10 subjects per study arm) undergoing elective Caesarean section (for reasons independent from the study)\]"
62190999|NCT04767334|EXPERIMENTAL|Gait training on Lower body positive pressure|"All participants will have gait training for 40 minutes a day, for three days a week, for six weeks. On session one, the lower body positive pressure chamber will be set to unload 50% of patient's body weight.On the following sessions, the percentage of unload patient's body weight will be decrease depends on the patient's comfort.~The physical therapist assistance and treadmill speed will be evaluated and altered based on the patient's capacity. The participants can take a rest whenever his/her need during walking. The rest time will be measured and documented."
62005202|NCT04438928|OTHER|Healthy pregnant women - Non-Supplement|"Control study group~Subgroup: Healthy pregnant women with Caesarean section \[A subset of subjects (approximately 10 subjects per study arm) undergoing elective Caesarean section (for reasons independent from the study)\]"
62005203|NCT00757575||1|
62191000|NCT01059305|EXPERIMENTAL|Erlotinib|150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
62191001|NCT05429593|EXPERIMENTAL|Part 1 sequence A|Semaglutide followed by Semaglutide/dapagliflozin
62572385|NCT00808912|ACTIVE_COMPARATOR|2|Subjects will exercise in a low pollutant environment after ingesting a standard dose of sildenafil.
62005204|NCT00869648|ACTIVE_COMPARATOR|Neutralposition|Head placed in neutral position
62191002|NCT05429593|EXPERIMENTAL|Part 1 sequence B|Semaglutide/dapagliflozin followed by Semaglutide
62191003|NCT05429593|EXPERIMENTAL|Part 2 sequence A|Dapagliflozin followed by Semaglutide/dapagliflozin
62572386|NCT00808912|PLACEBO_COMPARATOR|3|Subjects will exercise in a high pollutant environment after ingesting a placebo.
62005205|NCT00869648|ACTIVE_COMPARATOR|Extension|Head placed in extension
62005206|NCT00869648|ACTIVE_COMPARATOR|Anaesthesiologist's position|Head placed in position deemed optimal by an anaesthesiologist
62005207|NCT02714049|EXPERIMENTAL|flibanserin|Subjects meeting inclusion/exclusion criteria who respond to flibanserin will have a total of 20 weeks of open label drug
62005208|NCT02714049|EXPERIMENTAL|flibanserin and sex therapy|Subjects meeting inclusion/exclusion criteria who respond to flibanserin will have a total of 20 weeks of open label drug as well as 9 sex therapy visits
62005209|NCT06097507|EXPERIMENTAL|Asthma patients|"Low risk educational intervention. The consented patients will be given an information packet containing an infographic about the climate impact of inhalers, a letter explaining the option of changing inhalers (which clearly outlines that the Bricanyl Turbuhaler will not cost them more money than the Ventolin) and a pre-filled prescription for Bricanyl Turbuhaler.~Also 5 selected asthma providers will be asked to fill a questionnaire on their perspectives on the climate impact of inhalers and their approach to inhaler rotation. This may also be supplemented with a phone interview"
62005210|NCT06316466||the high Lp (a) groups and the low Lp (a) groups|The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups.
62005211|NCT06316466||the low Lp (a) groups|The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups.
62191004|NCT05429593|EXPERIMENTAL|Part 2 sequence B|Semaglutide/dapagliflozin followed by dapagliflozin
62572387|NCT00808912|PLACEBO_COMPARATOR|4|Subjects will exercise in a low pollutant environment after ingesting a placebo.
62572388|NCT04697446||Patients from the BLU-667-1101 (ARROW) study|Patients with Non-Small Cell Lung Cancer (NSCLC) who received treatment with pralsetinib as part of the BLU-667-1101 (ARROW) study
62005212|NCT01624727|NO_INTERVENTION|Usual care|Those randomized to usual care will continue to follow the care provided by their cardiologist. They will have all the follow-up phone calls, visits and testing which the intervention group has.
62005213|NCT01624727|ACTIVE_COMPARATOR|Lovaza (Omega 3 ethyl esters)|
62005214|NCT01357993|EXPERIMENTAL|001|JNS001 18 mg 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
62005215|NCT03144180|NO_INTERVENTION|Control|The Q-cup will not be used to collect umbilical cord blood.
62005216|NCT03144180|ACTIVE_COMPARATOR|Study Group|The Q-cup will be used to collect umbilical cord blood.
62005217|NCT01288534|EXPERIMENTAL|Radiation Treatment|
62005218|NCT02808845||microalbuminuria with eGFR≥60ml/min|microalbuminuria group with estimated glomerular filtration rate (eGFR) ≥60ml/min.
62005219|NCT02808845||normal-albuminuria group with eGFR≥60ml/min|normal-albuminuria group with estimated glomerular filtration rate (eGFR) ≥60ml/min.
62005220|NCT02808845||microalbuminuria group with eGFR<60ml/min|microalbuminuria group with estimated glomerular filtration rate (eGFR) \<60ml/min.
62005221|NCT02808845||normal-albuminuria group with eGFR<60ml/min|normal-albuminuria group with estimated glomerular filtration rate (eGFR) \<60ml/min.
62005222|NCT01775696||sporadic AD|80 sporadic AD patients (40 at the stage of MCI, 40 at the stage of mild or moderate dementia)
62191005|NCT03652350|EXPERIMENTAL|Use CT-guided microwave ablation in Ground Glass Nodules ≤ 3cm|Patients with Ground Glass Nodules ≤ 3cm were treated with CT-guided microwave ablation
62191006|NCT02498262|EXPERIMENTAL|Virtual Reality Training System|
62191007|NCT01677299|ACTIVE_COMPARATOR|1000 mg EFB0026 (metformin immediate-release)|BID
62191008|NCT01677299|EXPERIMENTAL|1000 mg EFB0027 (metformin delayed-release)|BID
62191009|NCT01677299|EXPERIMENTAL|500 mg EFB0027 (metformin delayed-release)|BID
62572389|NCT04697446||External Control Group|Patients with Non-Small Cell Lung Cancer (NSCLC) that received best available therapy
62572390|NCT04687839|EXPERIMENTAL|Healthy adult subjects|"It's a randomized intra-individual comparative study with two injured study areas (treated and untreated) for each subject.~The randomization will determine the application side on which the tested product will be applied (RIGHT or LEFT forearm).~Twice daily application on the treated area."
62191010|NCT01677299|EXPERIMENTAL|500 mg EFB0026 + 1000 mg EFB0027|BID
62191011|NCT02320994||stroke patients|post-rehabilitation stroke patients
62191012|NCT06017908|EXPERIMENTAL|PPPD patients|Virtual Reality will be used to execute the RDT and OKAN in PPPD patients.
62191013|NCT06017908|EXPERIMENTAL|Healthy patients|Virtual Reality will be used to execute the RDT and OKAN in healthy PPPD patients.
62396901|NCT06377449|EXPERIMENTAL|Medical management based on results of ultrasound lungs examination|Based on the degree/ presence of interstitial pulmonary edema (number of B-lines) and presence of postoperative pleural effusion, identified by regularly performed ultrasound examination of the lungs, medical therapy will be modified in each particular patient to improve clinical status and outcome. Administration of the following drug groups can be made/ doses can be adjusted: Diuretics (furosemide/ Hypothiazide/ spironolactone), Non-steroid antiinflammatory (Ibuprofen), Glucocorticoids.
62396902|NCT06377449|ACTIVE_COMPARATOR|Medical management based on routine clinical and X-ray diagnostic methods|Ultrasound examination of the lungs will be performed in all patients in this group, but the attending physician will not be informed about it's results and findings. Any changes in medical therapy/ treatment strategy will be based on standard clinical and X-ray diagnostic methods.
62396903|NCT03742895|EXPERIMENTAL|Olaparib|Participants with HRRm or HRD-positive advanced cancer will receive oral olaparib, 300 mg twice daily (BID).
62396904|NCT05530499|EXPERIMENTAL|Almond|Participants in this group will be instructed to consume 57 grams of whole almonds every day for six weeks.
62396905|NCT05530499|ACTIVE_COMPARATOR|Cookie|Participants in this group will be instructed to consume cookies equivalent to the energy content of 57 grams of whole almonds every day for six weeks.
62791776|NCT04872595|EXPERIMENTAL|P-rATG with total body irradiation, thiotepa, cyclophosphamide|"P-rATG days (always starting on Day -12 to -10)~* Hyper fractionated total body irradiation (1375 - 1500cGy\*) Day -9 to -6~* Thiotepa (5mg/kg/day x 2 day) Day -5 to -4~* Cyclophosphamide (60mg/kg/day x 2 days) Day -3 to -2~* GCSF Day +7 \*TBI dose in 125cGy fractions (with lung shielding) and total dose to be determined by treating physician/radiation oncology and is based off age, stage of disease, and anesthesia requirements."
62791777|NCT04872595|EXPERIMENTAL|P-rATG with busulfan, melphalan and fludarabine|"P-rATG days (Appendix A - always starting on Day -12 to -10)~* Busulfan -Day -9 to -7~* Initial dose per table in Appendix B; doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg\*h/L Melphalan (70mg/m2/day x 2 days) Day -6 to -5~* Fludarabine (25mg/m2/day x 5 days) Day -6 to -2~* GCSF Day +7"
62791778|NCT02814175|ACTIVE_COMPARATOR|Part 1: MTX Escalated Dose|Methotrexate (MTX) escalated to 20 - 25 mg or highest tolerable dose every week (ew)
62791779|NCT02814175|EXPERIMENTAL|Part 1: ADA + MTX|Adalimumab (ADA) 40 mg every other week (eow) in combination with MTX 15 mg ew
62005223|NCT01775696||familial forms of AD|15 familial forms of AD caused by APP, PSEN1 or PSEN2 mutations
62791780|NCT02814175|ACTIVE_COMPARATOR|Part 2: MTX Escalated Dose|Participants achieving minimal disease activity (MDA) at Week 16 on MTX escalated to 20 -25 mg or highest tolerable dose ew, continued with the same MTX dose
62791781|NCT02814175|ACTIVE_COMPARATOR|Part 2: ADA + MTX Escalated Dose|Participants not achieving MDA at Week 16 on MTX escalated to 20 - 25 mg or highest tolerable dose ew, received ADA 40 mg eow in combination with MTX 20 - 25 mg or highest tolerable dose ew
62791782|NCT02814175|EXPERIMENTAL|Part 2: ADA|Participants achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had MTX completely withdrawn at Week 16 and continued receiving ADA as monotherapy
62791783|NCT02814175|EXPERIMENTAL|Part 2: ADA ew + MTX|Participants not achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had ADA escalated to 40 mg ew in combination with MTX 15 mg ew
62791784|NCT06027008|EXPERIMENTAL|Mechanical Insufflation-Exsufflation|Invasively ventilated patients will receive MI-E until successful extubation or for a maximum of 7 days. MI-E will be given in the morning and afternoon each calendar day. Patients will be pre-oxygenated with FiO2 100% prior to disconnection from the ventilator; additional 15 litres oxygen can be added; A pre-set program is used: three times three cycles with a 2-second insufflation and an immediate 2-second exsufflation. The cycles of the MI-E session will be performed with a positive and negative pressure of 40 cmH2O. The program is set up with the possibility of auto-triggering by the patient.
62791785|NCT06027008|NO_INTERVENTION|Standard airway care|Patients in the control group will receive usual airway care which includes endotracheal suctioning and manual hyperinflation used when indicated based on clinical signs as part of regular airway care. Care protocols for endotracheal suctioning and manual hyperinflation are predefined. As with the intervention arm, there will be no use of saline instillation during suctioning. Manual hyperinflation technique is described in the care protocol of the intensive care unit and ICU nurses are trained to perform this technique.
62791786|NCT02741141|ACTIVE_COMPARATOR|Classical partograph|Labour dystocia is diagnosed when cervical dilation is less than 1 cm per hour or after 3 hours at complete cervical dilation without engagement of the presentation. In this case, active management of labour is started with introduction of oxytocin, artificial rupture of membranes and supportive therapy.
62791787|NCT02741141|EXPERIMENTAL|New partograph|The second strategy is based on the partograph developped by Neal and Lowe. An active management of labour is started when crossing the dystocia line or when there are no cervical modifications after 4 hours beyond 5 cm of cervical dilation. In this case, active management of labour is started with introduction of oxytocin, artificial rupture of membranes and supportive therapy.
62791788|NCT01010971|EXPERIMENTAL|Ciclesonide HFA Nasal Aerosol 160 μg|160 μg once daily
62791789|NCT01010971|EXPERIMENTAL|Ciclesonide HFA Nasal Aerosol 80 μg|80 μg once daily
62791790|NCT01010971|PLACEBO_COMPARATOR|Placebo|Placebo
62791791|NCT05846815|EXPERIMENTAL|TD|Children of 8-13 years of age without any neuropsychiatric diagnose (typically developed)
62791792|NCT05846815|EXPERIMENTAL|ADHD|Children of 8-13 years of age with previously diagnosed ADHD symptoms
62791793|NCT04158583|EXPERIMENTAL|Part A: Cohort 1 RO7296682 0.3 mg Q3W|Participants with non-small cell lung cancer (NSCLC), melanoma (MEL), head and neck squamous cell carcinoma (HNSCC), ovarian cancer (OvC), triple-negative breast cancer (TNBC), and esophageal carcinoma (EsC) received RO7296682 0.3 milligram (mg) intravenous (IV) infusion on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, every 3 weeks (Q3W). Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade \>=4, IRR; Grade \>=4, immune-mediated adverse events; Grade \>=4) were discontinued from study treatment.
62005224|NCT01775696||asymptomatic relatives|30 asymptomatic relatives to familial AD patients
62191014|NCT01181791|EXPERIMENTAL|probiotic group|Lactobacillus reuteri will be given at a dose of 1x108 colony forming units (CFU)/day
62191015|NCT01181791|PLACEBO_COMPARATOR|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present.
62191016|NCT03203837||HCC patients|HCC patients treated with radioembolization. Plasma collection will be performed at 7 timepoints in relation to treatment.
62191017|NCT05997342|EXPERIMENTAL|TQB3912 tablets|TQB3912 tablets, 28 days as a treatment cycle.
62191018|NCT00959777|EXPERIMENTAL|DA-3031|
62005225|NCT01775696||controls|40 controls
62005226|NCT01775696||genetic FTD|5 genetic forms of FTD
62005227|NCT04155996||data collection|20 patients
62005228|NCT04838366|EXPERIMENTAL|Intervention|The study group will be intervened with carbohydrate loading as the protocol made by ERAS(Li et al., 2021). We will provide glucose-D.
62191019|NCT00959777|ACTIVE_COMPARATOR|filgrastim|
62396906|NCT06588855|EXPERIMENTAL|RO7790121|Participants will receive RO7790121 intravenously (IV) followed by RO7790121 subcutaneous (SC) injection.
62396907|NCT06588855|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo IV followed by placebo SC.
62396908|NCT03772574|EXPERIMENTAL|THRIVE|THRIVE preoxygenation (tidal volume breathing with the OptiFlow system applied at 100% oxygen).
62396909|NCT03772574|ACTIVE_COMPARATOR|Facemask|Facemask preoxygenation (tidal volume breathing via a face mask set at 100% oxygen).
62396910|NCT06589271|EXPERIMENTAL|hUC-MSCs transplantation group|Human Umbilical Cord Mesenchymal Stem Cells
62396911|NCT06589271|ACTIVE_COMPARATOR|control group|suspension transplantation
62005229|NCT04838366|NO_INTERVENTION|Usual care|The control group will be kept in fasting condition from midnight as a traditional practice in existence.
62191020|NCT01090011|EXPERIMENTAL|combination arm|patients to receive medium BIBW 2992 once daily plus biweekly cetuximab infusion at low, median and high dose level
62191021|NCT01090011|EXPERIMENTAL|sequential arm|patients to receive BIBW 2992 once daily, upon progression add biweekly cetuximab
62396912|NCT02369380|EXPERIMENTAL|Hyaluronic acid|Injections of hyaluronic acid under metatarsal heads
62396913|NCT00556088|EXPERIMENTAL|Part 1|"Part I Phase I dose escalation trial. LBH589 will be administered orally on Monday and Thursday or Tuesday and Friday each week (twice weekly). Paclitaxel and carboplatin will be administered intravenously every 21 days.~Part II LBH589, paclitaxel, and carboplatin dosing will be determined in the first phase of this study (Phase I). The drug dosages to be administered will be reduced one level from the determined Maximum Tolerated Dose (MTD). In addition, bevacizumab 15 mg/kg will be added to the second portion of this trial."
62005230|NCT06187545|ACTIVE_COMPARATOR|Control group|5-hour period in which patients will continue to be routinely sedated in the critical care unit
62396914|NCT02426359|EXPERIMENTAL|Q301 Cream|Q301 Cream
62396915|NCT02426359|PLACEBO_COMPARATOR|Vehicle|Vehicle
62396916|NCT03426774|EXPERIMENTAL|YG ( 25-59yrs) -GJogger|Gentle Jogger applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
62396917|NCT03426774|EXPERIMENTAL|OG (Greater than 60 yrs)-GJogger|Gentle Jogger applied to each individual in (1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
62005231|NCT06187545|EXPERIMENTAL|Experimental group|5-hour period in which patients will be sedated through the closed-loop system
62005232|NCT02074124||Adenosine Vasodilation test|Group scanned with CT perfusion during adenosine vasodilation test.
62005233|NCT02074124||Reference group|Group scanned twice without adenosine vasodilation test for a reference. No randomization.
62005234|NCT04687956|EXPERIMENTAL|LYMPHA|LYMPHA procedure is performed in which the lymphatic vessels drained from the arm and the axillary vein are micro-bonded to the side branches.
62005235|NCT04687956|ACTIVE_COMPARATOR|Control|No LYMPHA procedure is performed
62005236|NCT05857657|EXPERIMENTAL|lower leg kinesiotaping|Kinesiotaping will be applied on tibialis anterior for 30 minutes for one session
62005237|NCT05857657|EXPERIMENTAL|propriocepticve neuromuscular facilitation|:Proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
62396918|NCT03426774|EXPERIMENTAL|YG ( 25-59yrs) -GJumper|Gentle Jumper applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
62396919|NCT03426774|EXPERIMENTAL|OG (Greater than 60 yrs)-Gjumper|Gentle Jumper applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
62396920|NCT03426774|SHAM_COMPARATOR|YG ( 25-59yrs) -GJogger Sham|A Sham Gentle Jogger is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
62005238|NCT05857657|ACTIVE_COMPARATOR|propriocepticve neuromuscular facilitation with lower leg kinesiotaping|Kinesiotaping will be applied on tibialis anterior for 30 minutes with proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
62005239|NCT04490434|EXPERIMENTAL|Cohort 1, A (DWP14012/Celecoxib)|Patients treated with DWP14012, Celecoxib will be enrolled. DDI will be evaluated.
62005240|NCT04490434|EXPERIMENTAL|Cohort 1, B (DWP14012/Celecoxib)|Patients treated with DWP14012, Celecoxib will be enrolled. DDI will be evaluated.
62005241|NCT04490434|EXPERIMENTAL|Cohort 2, C (DWP14012/Naproxen)|Patients treated with DWP14012, Naproxen will be enrolled. DDI will be evaluated.
62005242|NCT04490434|EXPERIMENTAL|Cohort 2, D (DWP14012/Naproxen)|Patients treated with DWP14012, Naproxen will be enrolled. DDI will be evaluated.
62005243|NCT04490434|EXPERIMENTAL|Cohort 3, E (DWP14012/Meloxicam)|Patients treated with DWP14012, Meloxicam will be enrolled. DDI will be evaluated.
62396921|NCT03426774|SHAM_COMPARATOR|OG (Greater than 60 yrs)- GJogger-Sham|A Sham Gentle Jogger is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
62396922|NCT03426774|SHAM_COMPARATOR|YG ( 25-59yrs) -GJumper- Sham|A Sham Gentle Jumper is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
62005244|NCT04490434|EXPERIMENTAL|Cohort 3, F (DWP14012/Meloxicam)|Patients treated with DWP14012, Meloxicam will be enrolled. DDI will be evaluated.
62005245|NCT03030027|EXPERIMENTAL|Connecting Through Caregiving|This arm focuses on perspective-taking reappraisal procedures.
62005246|NCT03030027|OTHER|Basic Skills Building|This arm focuses on skill building.
62005247|NCT05410834||Individuals with polycystic ovarian syndrome|Individuals with a documented diagnosis of polycystic ovarian syndrome
62005248|NCT05410834||Individuals without polycystic ovarian syndrome|Individuals without a known diagnosis of polycystic ovarian syndrome but with regular menstrual cycles
62005249|NCT03161275||nirs|The cerebral oxymetry saturation was monitored continuously, using a non-invasive method. The cerebral saturation was monitored intraoperatively with near infrared spectroscopy (INVOS 4100; Somanetics Inc, Troy, MI). Data acquired from the device were automatically and continuously recorded in 10-second intervals throughout the anaesthesia. A lead for the cerebral saturation monitoring was placed on degreased skin on the patient's forehead, on the right side, some 1 cm over the eyebrow. The baseline value was determined before induction of anaesthesia. The following criteria were accepted as significant reduction of the cerebral oxygenation (saturation) value: reduction of the cerebral oxymetry by over 25% in relation to the baseline; the absolute value of cerebral oxymetry below 50%.
62005250|NCT03161275||cognitive function|Upon the day preceding the actual surgery, and again at 5 days after the surgery, the Mini Mental State Examination test was completed, with a view to assessing the chang-es in the patients' cognitive function. The difference between score in Mini Mental State Examination higher than 2 points defined a diagnosis of cognitive dysfunction.
62005251|NCT04163393|EXPERIMENTAL|R-One|Patients treated with robotic assistance
62005252|NCT05062668||iStent|POAG patient operated at the CHU of Amiens or the CH of Saint-Quentin of a combined cataract and iStent inject or inject W surgery from January 2018 to September 2020.
62005253|NCT05062668||cataract only|POAG patients operated only on cataract from January 2018 to September 2020.
62005254|NCT04448470||patients with a clinical suspicion of sleep apnea (n=150)|patients with a clinical suspicion of sleep apnea
62005255|NCT04448470||healthy subjects (n=10)|healthy subjects
62005256|NCT06205927|ACTIVE_COMPARATOR|Standard treatment arm|The standard treatment arm will receive carbon ion beam radiotherapy of 77Gy (RBE equivalent) per 22 fractions for gross tumor volume.
62005257|NCT06205927|EXPERIMENTAL|Boost arm|Boost arm will receive 77Gy (RBE equivalent) per 22 fractions for gross tumor volume and a simultaneously dose boost of 83.6Gy (RBE equivalent) per 22 fractions for hypoxic lesions detected by 18F-Misonidazole PET/CT
62005258|NCT05498948|EXPERIMENTAL|Probiotic mixture|Dietary Supplements: Probiotic mixture supplementation The Probiotic mixture supplementation contains Lactobacillus acidophilus, Lactobacillus lactis, and Streptococcus lactis.
62005259|NCT05498948|PLACEBO_COMPARATOR|Placebo|Dietary Supplement: Placebo The placebo product will be orally take.
62396923|NCT03426774|SHAM_COMPARATOR|OG (Greater than 60 yrs)-GJumper Sham|A Sham Gentle Jumper is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
62005260|NCT04240899|EXPERIMENTAL|Tele-yoga|This is a single group study, therefore all subjects will be included in this single arm and will undergo the same telerehabilitation yoga intervention delivered through videoconferencing.
62005261|NCT04330079|EXPERIMENTAL|Dapagliflozin|
62005262|NCT04330079|OTHER|Lifestyle modification|
62396924|NCT05555134|NO_INTERVENTION|CONTROL|receive usual care
62396925|NCT05555134|EXPERIMENTAL|EXPERIMENTAL|receive the educational intervention, along with usual care
62396926|NCT02503969||Screened|Those who received an adequate screen for colorectal cancer.
62005263|NCT00901940|ACTIVE_COMPARATOR|MenACWY Plain Polysaccharide (ACWY Vax)|The MenACWY Plain Polysaccharide Vaccine, which is already licensed and is used as a travel vaccine, is known as the MenACWY plain polysaccharide (ACWY Vax). Participants in this arm will receive 1 dose of the MenACWY plain polysaccharide (ACWY Vax) and 1 dose of the MenACWY conjugate (MenACWY).
62005264|NCT00901940|ACTIVE_COMPARATOR|MenACWY conjugate|The MenACWY conjugate vaccine was licensed in the UK in March 2010, and is known as the MenACWY conjugate vaccine (Menveo). Participants in this arm will receive 2 doses of the MenACWY conjugate vaccine.
62005265|NCT02456922|OTHER|Group A|Subjects wearing Harmony 1 Sensor for up to 10 days.
62005266|NCT00259857|EXPERIMENTAL|1 Alendronate, Calcium, Vitamin D|Crossover study. Year-1, 10 participants will take study medication, calcium and vitamin D supplements and other 10 participants will take placebo, calcium and vitamin D supplements. Year-2, they will crossover to the second arm of the study. Those who took study medication and supplements in year-1, will take placebo and supplements in the year-2, and those 10 participants who took placebo and supplements in the year-1, will take study medications and supplements in the year-2.
62005267|NCT00259857|PLACEBO_COMPARATOR|2 Placebo, Calcium and Vitamin D|Year-1, 10 participants will take Alendronate (study medication)and calcium and vitamin D supplement). Another 10 participants will take placebo, calcium and vitamin D. In year-2 they will crossover. Those who took alendronate in the first year, will take Placebo, calcium and vitamin D for 12 months and those who took Placebo in the first year, will take Alendronate, calcium and vitamin D in the second year (12 months).
62396927|NCT02503969||Not Screened|Those who received an adequate screen for colorectal cancer.
62396928|NCT04348123|EXPERIMENTAL|Outreach educational program|"Participants will be given a survey to elucidate beliefs and barriers around breast health and mammography.~A brief, culturally-appropriate educational session about breast health and mammography will follow and will be delivered by a female public health educator.~After education, eligible women will be offered a free on-site mammogram"
62396929|NCT03604198|EXPERIMENTAL|relacorilant (CORT125134)|
62396930|NCT03007472|EXPERIMENTAL|CI532/N7 study group|All subjects will receive a CI532 cochlear implant (intervention) and be fit with the CP1000 sound processor
62396931|NCT01224288|EXPERIMENTAL|DCE-CT Scans|DCE-CT = Dynamic contrast enhanced CT - DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
62396932|NCT03166891|EXPERIMENTAL|chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
62396933|NCT04311515|ACTIVE_COMPARATOR|30 mg PU AD|75 subjects will be treated with active PU-AD on a 1:1 ratio qd
62396934|NCT04311515|PLACEBO_COMPARATOR|30 mg Placebo|75 subjects will be treated with placebo SyrSpend on a 1:1 ratio qd
62396935|NCT04790630|EXPERIMENTAL|Computerized Cognitive Remediation of Executive Functioning (CCR-EF)|"Initially 10 hours of processing speed exercises from Brain HQ, (the 3 exercises are auditory tone sweep, visual processing \[Double Decision\], visual sweep).~Following the 8-10 hours of Brain HQ, participants complete 8-10 hours of Ultimate Word Master before completing 16-20 hours of Neurogrow (formerly called Catch the Ball).~Participants are asked to complete approximately 28-42 hours of computerized brain training over 4-6 weeks."
62396936|NCT04790630|ACTIVE_COMPARATOR|Active Control|Patients in the active control arm will complete three activities according to a standard protocol: 1) play a visuospatially oriented computer game (Myst), 2) watch computer-based educational programs on art, history, literature, and 3) play computer games online through the Brain HQ platform; games include crossword puzzles, soduko, paddleboard, and word search. Participants will complete a total of 32-42 hours of training over 4-6 weeks. Time spent on each task will be evenly divided (15 minutes of each task everday).
62396937|NCT03762187|EXPERIMENTAL|Self-affirmation|Participants completed a written self-affirmation manipulation before completing the standard counseling provided by the clinic.
62396938|NCT03762187|ACTIVE_COMPARATOR|Positive living counseling|Participants completed the standard counseling provided by the clinic (treatment as usual control condition).
62396939|NCT06420115|EXPERIMENTAL|mpMRI target prostate biopsy with 16 gauge needle|
62396940|NCT06420115|EXPERIMENTAL|mpMRI target prostate biopsy with 18 gauge needle|
62396941|NCT05058599||facial videos dataset|facial videos collected from Zhongshan Ophthalmic Center of Sun Yat-sen University.
62396942|NCT06315634|ACTIVE_COMPARATOR|Heavy Bupivacaine plus normal saline|2.5 ml of 0.5% hyperbaric Bupivacaine plus 0.5 ml 0.9 % saline
62396943|NCT06315634|EXPERIMENTAL|Heavy Bupivacaine plus dexmedetomidine|2.5 ml of 0.5% hyperbaric Bupivacaine plus 5 micrograms dexmedetomidine in 0.5 ml 0.9 % saline
62396944|NCT06315634|EXPERIMENTAL|Heavy Bupivacaine plus midazolam|2.5 ml of 0.5% hyperbaric Bupivacaine plus 2 milligrams midazolam in 0.5 ml 0.9 % saline
62005268|NCT06103513|ACTIVE_COMPARATOR|Arm 1: Growth hormone 0.2 mg/kg/week|Twenty-five subjects will initiate rhGH therapy at 0.2 mg/kg/week for the first 12 months of treatment
62396945|NCT06576934|EXPERIMENTAL|Transjugular intrahepatic portosystemic shunt (TIPS)|Patients will receive TIPS implantation if ascites as the first single decompensating event with grade 2 ascites and MELD ≥ 15 OR grade 3 ascites occurs.
62005269|NCT06103513|ACTIVE_COMPARATOR|Arm 2: Growth hormone 0.3 mg/kg/week|Twenty-five subjects will initiate rhGH therapy at 0.3 mg/kg/week for the first 12 months of treatment
62005270|NCT04162951|EXPERIMENTAL|Ordinary approach group|The patients in this group will receive ordinary ultrasound-guided thoracic paravertebral block. by local anesthetic mixture at a volume of 0.2 ml/kg composed of plain bupivacaine 0.25% and Fentanyl 2 ug/ml.
62005271|NCT04162951|EXPERIMENTAL|Retro-laminar approach group|The patients in this group will be receive real ultrasound-guided Retrolaminar thoracic paravertebral block by local anesthetic mixture at a volume of 0.2 ml/kg composed of plain bupivacaine 0.25% and Fentanyl 2 ug/ml.
62005272|NCT05566340||isolated aortic valve replacement group|Isolated aortic valve replacement surgery.
62005273|NCT05566340||aortic valve replacement with mitral valve repair group|Aortic valve replacement with mitral valve repair
62005274|NCT01982422|EXPERIMENTAL|Dietary Intervention|A whole food, nutrient-dense dietary intervention which restricts processed foods high in food additives and optimizes micronutrient intake.
62005275|NCT01982422|PLACEBO_COMPARATOR|Standard-of Care Group|This group will receive normal standard-of-care for pregnancy.
62005276|NCT05825482|ACTIVE_COMPARATOR|Arm 1|Partial mastectomy with Savi Scout® localization and routine cavity shave margins
62191022|NCT01607541|EXPERIMENTAL|Peer-driven intervention|"The PDI entails structured intervention sessions including a computerized CARE for Prevention tool and HIV pre-test and post-test counseling, the opportunity to educate three peers on core education messages, and navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and six months of navigation)"
62191023|NCT01607541|ACTIVE_COMPARATOR|Control|The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
62005277|NCT05825482|ACTIVE_COMPARATOR|Arm 2|Partial mastectomy with Savi Scout® localization and selective shave margins.
62005278|NCT03354494||DSG-CTP|
62191024|NCT02478645|EXPERIMENTAL|ramosetron 0.3|
62191025|NCT02478645|ACTIVE_COMPARATOR|ramosetron 0.45|
62572391|NCT01256489|OTHER|Infliximab|Every patient enrolled in the study will receive monthly infusions of Infliximab throughout the term of the study. Infliximab will be administered intravenously.
62572392|NCT02435537|ACTIVE_COMPARATOR|Intrathecal Bupivacaine|intrathecal injection of 10 mg hyperbaric bupivacaine 0.5% in 2 ml volume and 1ml of saline 0.9%
62572393|NCT02435537|ACTIVE_COMPARATOR|Intrathecal Morphine|intrathecal injection of 10mg bupivacaine 0.5% in 2ml volume intrathecal injection of 0.5 mg morphine in 1ml volume
62005279|NCT01859715|ACTIVE_COMPARATOR|Oxycodone group|Subjects given either oxycodone 5mg by ED provider decision or by triage nurse randomization.
62005280|NCT01859715|ACTIVE_COMPARATOR|Nausea-observational group|Patients given ondansetron 4mg by ED provider decision or by triage nurse. This is an observational cohort only.
62005281|NCT01859715|ACTIVE_COMPARATOR|Hydrocodone/Acetaminophen group|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
62005282|NCT01912248||Heart failure|strength training
62005283|NCT01912248||Heart Transplant recipients|strength training
62005284|NCT01912248||patients with ischemic heart disease|strength training
62005285|NCT05716711|EXPERIMENTAL|GROUP 1|"GROUP 1~1st GROUP LAVENDER OIL EXTRACT WILL BE APPLIED TO 20 PATIENTS WITH COLOSTOMY FOR 1 MONTH WITH 20 DROPS A DAY INTO THE STOMA BAG"
62005286|NCT05716711|EXPERIMENTAL|GROUP 2|2nd GROUP MINT OIL EXTRACT WILL BE APPLIED TO 20 PATIENTS WITH COLOSTOMY DURING 1 MONTH.
62005287|NCT05716711|NO_INTERVENTION|CONTROL GROUP|20 PATIENTS WITH COLOSTOMY WITH NO INTERVENTION
62005288|NCT02020668|EXPERIMENTAL|Physiotherapy|Physiotherapy included joint protection strategies, performance of therapeutic exercises and patient education.
62005289|NCT02020668|OTHER|Wait list control|Wait list control received standard care and were invited to join the physiotherapy once intervention period is finished.
62005290|NCT01271543|ACTIVE_COMPARATOR|MacIntosh group|
62005291|NCT01271543|EXPERIMENTAL|Shikani optical stylet|
62005292|NCT03395431|ACTIVE_COMPARATOR|FAB group|Arm A - Finger prick autologous blood (FAB) plus conventional treatment The patients will use FAB alongside conventional therapy as recommended by their treating ophthalmologist. A fingertip of the hand will be wiped with an alcohol steret and self-pricked using a standard diabetic lancet. The drop of blood is produced as normal and applied to the lower fornix of the affected eye(s) with the lower lid pulled down slightly by the patient. The blood will be applied 4 times a day. A fresh finger should be used for each eye. FAB should be applied at least 15 minutes after any artificial tears and no other drops applied for at least half an hour afterwards
62005293|NCT03395431|NO_INTERVENTION|Control group|Arm B - Conventional treatment only The patients will use conventional therapy (artificial tears, cyclosporin drops and punctal plugs/cautery) as recommended by their treating ophthalmologist
62191026|NCT02478645|ACTIVE_COMPARATOR|ramosetron 0.6|
62191027|NCT04413370||Severe Group|This group of subjects needed a referral to the hospital for further treatments.
62191028|NCT04413370||Mild group|This group of subjects was diagnosed with dry eye but can use artificial tears instead of further treatment.
62572394|NCT02435537|ACTIVE_COMPARATOR|Intrathecal Morphine-Dex|intrathecal 10mg bupivacaine 0.5% in 2 ml volume intrathecal 0.5 mg morphine intrathecal 5 µg of dexmedetomidine in 1ml volume .
62572395|NCT03978663|EXPERIMENTAL|Neoadjuvant radiotherapy|3 doses of stereotactic radiotherapy administered prior to neoadjuvant chemotherapy in high-risk breast cancers.
62572396|NCT02073929|ACTIVE_COMPARATOR|Active|Liraglutide s.c. 1,8mg daily for 26 weeks
62572397|NCT02073929|PLACEBO_COMPARATOR|Placebo|Placebo s.c. daily for 26 weeks
62572398|NCT01288677|EXPERIMENTAL|001|TMC649128 Escalated doses
62572399|NCT05344443|EXPERIMENTAL|Active Treatment|Participants randomized into this arm will receive Lemborexant (5-10mg).
62191029|NCT04413370||Follow-up group|This group of subjects had no dry eye symptoms and signs and belonged to the normal control group.
62191030|NCT02718261|EXPERIMENTAL|Verum (pantoprazole)|
62396946|NCT06576934|NO_INTERVENTION|Standard medical treatment|Patients in this group will receive standard medical treatment according to the current EASL guidelines (salt restriction, diuretic treatment, carvedilol, large-volume paracentesis if necessary, albumin substitution if more than 5 litre of ascites is removed)
62396947|NCT01479777|EXPERIMENTAL|FES Stepping|For the next 8 weeks, we will ask you to come to the ICSCI twice (2) time per week during which you will perform FES Stepping.
62396948|NCT06722287|EXPERIMENTAL|CAMMA Intervention|Mobile application intervention that provides family caregivers with self-care tools, care management tools, and online support group
62572400|NCT05344443|PLACEBO_COMPARATOR|Placebo Treatment|Participants randomized into this arm will receive a placebo medication which appears the same as the active treatment.
62572401|NCT03747133|EXPERIMENTAL|Stereotactic Ablative Radiotherapy|Adult patients with Kidney mass (either primary or metastasis) amenable to SABR
62572402|NCT05780125|EXPERIMENTAL|FibCLOT|Patients randomized to the FibCLOT arm will receive 30 mg/kg, approximated to the closest between 2 and 3 grams, of FibCLOT (LFB, Puteaux, France).
62572403|NCT05780125|ACTIVE_COMPARATOR|RiaSTAP|Patients randomized to the RiaSTAP arm will receive 30 mg/kg, approximated to the closest between 2 and 3 grams, of RiaSTAP (King of Prussia, PA, USA).
62572404|NCT03028207||COPD|Subjects with FEV1/FVC score less than 0.70 post-bronchodilator test will be allocated to COPD group and the prevalence of COPD will be evaluated. Subjects in this group will be categorized in 4 groups namely GOLD I - IV depending on the disease severity.
62572405|NCT03028207||Non-COPD|Subjects with FEV1/FVC score greater than or equal to 0.70 post-bronchodilator test will be allocated to non-COPD group.
62780267|NCT06510010|ACTIVE_COMPARATOR|Oxaliplatin With S-1 （SOX）|Subjects randomized to the control group will receive 3-4 cycles of neoadjuvant therapy with the Oxaliplatin With S-1（SOX）regimen before surgery. The SOX regimen will be administered every 3 weeks (Q3W). A tumor response assessment will be performed at the end of the treatment course. Control patients were treated with H. Pylori eradication after recovery from surgery based on postoperative pathologic H. Pylori results: if H. Pylori-positive, they received H. Pylori eradication plus 4-5 cycles of SOX adjuvant chemotherapy (except for patients who underwent total gastric resection); if H. Pylori-negative, they received 4-5 cycles of SOX adjuvant chemotherapy only.
62780268|NCT05938127|EXPERIMENTAL|Lymphoma Survivors IMST|Participants will undergo a version of the BfitBwell Cancer Exercise Program physical assessment, which assesses physical fitness and function.
62780269|NCT05938127|EXPERIMENTAL|Lymphoma Survivors sham IMST|Participants will undergo a version of the BfitBwell Cancer Exercise Program physical assessment, which assesses physical fitness and function.
62780270|NCT06304779|PLACEBO_COMPARATOR|Control group|Patients receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.
62780271|NCT06304779|EXPERIMENTAL|Lidocaine group|Patients receive a loading dose of 1.5 mg/kg 2% lidocaine at anesthesia induction, followed by continuous intravenous infusion at 1.5 mg/kg/h until 24 hours postoperatively.
62005294|NCT00774995|EXPERIMENTAL|Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig)|Subjects who previously received HBV vaccine at 0, 1, 6 and 60 months (4 doses) and HBIg concomitantly at Month 0, and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
62005295|NCT00774995|EXPERIMENTAL|Engerix(3-dose)+HBIg|Subjects who previously received HBV vaccine at 0, 1, 6 months (3 doses) and HBIg concomitantly at Month 0, and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
62005296|NCT00774995|EXPERIMENTAL|Engerix(4-dose)|Subjects who previously received HBV vaccine at 0, 1, 6 and 60 months (4 doses) and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
62191031|NCT02718261|PLACEBO_COMPARATOR|Placebo|0.9% saline
62191032|NCT03236532|EXPERIMENTAL|Glutamine and exercise|Glutamine dipeptide (20g/day) in 300 ml of water and ingest it after lunch during 7 days. In case of forgetfulness, they were suggested to ingest it soon after dinner. All participants were instructed to maintain their routine eating habits throughout the duration of the study. On the seventh and last day of supplementation, they were submitted to the resistance training session.
62396949|NCT03665558|NO_INTERVENTION|Aortic dP/dt in sinus rhythm|Left ventricular and aortic dP/dt values were recorded at baseline condition while patients are on sinus rhythm.
62780272|NCT02868229|EXPERIMENTAL|COR-001|
62780273|NCT02868229|PLACEBO_COMPARATOR|Placebo|
62396950|NCT03665558|ACTIVE_COMPARATOR|Aortic dP/dt during DDD pacing|Patients will be their own control. Aortic and ventricular pressures will be recorded under temporary DDD pacing again and these data collected at every pacing steps will be compared to the pressures recorded at baseline condition.
62396951|NCT01878708|EXPERIMENTAL|PEG-L-asparaginase/Dexamethasone|Patients will receive Oncaspar® (PEG-asparaginase) at a dose of 2,000 IU/m2 administered intramuscularly on day 3 of each 3 week cycle, with dexamethasone 40mg given orally on days 1-4.
62396952|NCT03457701|EXPERIMENTAL|rhEPO+57Fe followed by Daprodustat+58Fe|Participants will be randomly assigned to remain on their current therapy (either epoetin alfa or darbepoetin alfa) in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (57Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive Daprodustat in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (58Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: Histamine \[H2\] receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
62191033|NCT03236532|PLACEBO_COMPARATOR|Maltodextrin and exercise|Maltodextrin (20g/day) in 300 ml of water and ingest it after lunch during 7 days. In case of forgetfulness, they were suggested to ingest it soon after dinner. All participants were instructed to maintain their routine eating habits throughout the duration of the study. On the seventh and last day of supplementation, they were submitted to the resistance training session.
62191034|NCT00787072|EXPERIMENTAL|1|
62396953|NCT03457701|EXPERIMENTAL|rhEPO+58Fe followed by Daprodustat+57Fe|Participants will be randomly assigned to remain on their current therapy (either epoetin alfa or darbepoetin alfa) in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (58Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive Daprodustat in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (57Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
62572406|NCT03996005|EXPERIMENTAL|MRI Guided Transurethral Ultrasound|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
62572407|NCT00562172|EXPERIMENTAL|1|
62572408|NCT00562172|ACTIVE_COMPARATOR|2|
62780274|NCT01298765|EXPERIMENTAL|BEMA Buprenorphine|buprenorphine buccal soluble film
62780275|NCT05028270||Balloon technology|The femoral artery is introduced after the patient is fully anesthetized. First, the 5F-VETERBRAL is introduced under the guidance of the guidance. The common carotid artery and internal carotid artery will be received laterally. After whole-body heparinization, micro-catheter and guide wire technology are used. In the figure below, the proximal end of the 4mm super-form occlusion ball is marked far away from the eye, plugged and sealed, and the guide tube is pushed around in the internal carotid artery. When the occlusion is finished, the internal carotid artery and the ophthalmic artery are not accompanied far away, and the plot is good. The guiding catheter drives the injection of drugs, topotecar, and topotecan for 5 minutes (the suction balloon is opened and blocked, and the infusion is continuous) to complete the infusion.
62191035|NCT00787072|PLACEBO_COMPARATOR|2|
62780276|NCT05028270||Microcatheter technology|The tip of the Marathon microcatheter is placed at the opening of the ophthalmic artery. After the contrast agent is confirmed by hand, the chemotherapeutic drugs The femoral artery is introduced after the patient is fully anesthetized. First, the 5F-VETERBRAL is introduced under the guidance of the guidance. Maphalan, carboplatin, and topotecan are injected sequentially for 30 minutes. Make sure that the tip position of the catheter is not maintained during the injection process. verb: move. After the operation is completed, the blocking balloon is pulled out under the guidance of the guide wire, the arterial sheath is removed, and the femoral artery puncture point is pressed to stop bleeding.
62005297|NCT00774995|EXPERIMENTAL|Engerix(3-dose)|Subjects who previously received HBV vaccine at 0, 1, 6 months (3 doses) and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
62005298|NCT02804503|EXPERIMENTAL|Calorie Labels|A menu with rank ordered calorie labels and a statement on the energy needs per meal.
62005299|NCT02804503|EXPERIMENTAL|Exercise Labels|A menu with rank ordered exercise labels showing minutes of brisk walking necessary to burn the food calories.
62005300|NCT02804503|ACTIVE_COMPARATOR|No Labels|A menu with no labels
62005301|NCT02707614||Robotic vs open prostastectomy|One group is operated by open prostatectomy the other by robotic assistance
62005302|NCT02961426|EXPERIMENTAL|sofosbuvir + ravidasvir|12 weeks for non-cirrhotic patients, 24 weeks for cirrhotic patients
62005303|NCT02047110|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.
62005304|NCT02047110|EXPERIMENTAL|Risankizumab 18 mg|Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks
62005305|NCT02047110|EXPERIMENTAL|Risankizumab 90 mg|Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period
62005306|NCT02047110|EXPERIMENTAL|Risankizumab 180 mg|Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period
62005307|NCT05765968|EXPERIMENTAL|Double Stimulation Protocol|Double stimulations were performed during the follicular and luteal phases in the same cycle by rFSH\&hmg.
62005308|NCT05765968|ACTIVE_COMPARATOR|Antagonist Stimulation Protocol|The classical antagonist protocol were performed by rFSH,hmg and antagonist.
62005309|NCT01800903|ACTIVE_COMPARATOR|Sequence 1|SpeediCath catheter then ZN-D catheter then ZN-C catheter
62191036|NCT04258657|EXPERIMENTAL|Paclitaxel-albumin and S-1|
62005310|NCT01800903|EXPERIMENTAL|Sequence 2|SpeediCath catheter then ZN-C catheter then ZN-D catheter
62005311|NCT01800903|EXPERIMENTAL|Sequence 3|ZN-D catheter then SpeediCath catheter then ZN-C catheter
62005312|NCT01800903|EXPERIMENTAL|Sequence 4|ZN-D catheter then ZN-C catheter then SpeediCath catheter
62005313|NCT01800903|EXPERIMENTAL|Sequence 5|ZN-C catheter then SpeediCath catheter then ZN-D catheter
62005314|NCT01800903|EXPERIMENTAL|Sequence 6|ZN-C catheter then ZN-D catheter then SpeediCath catheter
62005315|NCT06664476|EXPERIMENTAL|Study group|The study group for this research consists of 45 oncology nurses who are actively involved in the care and management of patients with implanted Port-A-Catheters for chemotherapy. These nurses are recruited from the Oncology and Nuclear Medicine Center at Kasr Elini hospital, which includes outpatient clinics. The nurses in this study play a critical role in handling long-term venous access devices, particularly Port-A-Catheters, which are essential for the administration of chemotherapy and other related treatments.
62191037|NCT04718636|EXPERIMENTAL|Administration of OC alone, then progress to OC in combination with CC-99677|Oral Contraceptive (OC) and CC-99677 will be administered daily
62191038|NCT02903303|OTHER|Treatment|There will be only one arm for this pilot study. All participants will follow 4 hypnosis sessions, and then the facet block.
62396954|NCT03457701|EXPERIMENTAL|Daprodustat+57Fe followed by rhEPO+58Fe|Participants will be randomly assigned to receive Daprodustat in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (57Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive rhEPO (either epoetin alfa or darbepoetin alfa) in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (58Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
62410056|NCT06650111||Patients|"Patients whose biopsy of the care revealed tubulointerstitial nephritis in the foreground and retained as the main cause of renal dysfunction after etiological investigation.~The biopsies concerned were carried out between 01/01/2010 and 31/12/2019. The clinical follow-up data of the patients from whom the biopsies were taken will be collected until the date of the last follow-up (before 31/12/2021)."
62410057|NCT05356546||Participants with a previous TYRX™ Absorbable Antibacterial Envelope implant|Participants who previously underwent a transvenous CIED implantation with the market released TYRX™ Absorbable Antibacterial Envelope, used for approved indications per country/region, and are returning for a CIED replacement procedure at least 12 months from the prior CIED implantation will be evaluated in this study.
62572409|NCT05576935|EXPERIMENTAL|Intervention|"The intervention task consists of a 60 minute Stroop task. In this task, four coloured words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the colour of the word, ignoring the meaning of the word itself. If, however, the ink colour of the word is red, the button to be pressed will be the button linked to the real meaning of the word. The word presented and its ink colour will be randomly selected by a computer (100% incongruent), with all incongruent word-colour combinations being equally common. Subjects will be instructed to respond as quickly and accurately as possible. To assess performance both ACC and reaction time (RT) will be collected and averaged every block."
62005316|NCT03362515|EXPERIMENTAL|Furosemide|
62572410|NCT05576935|ACTIVE_COMPARATOR|Control|In the control task subjects will have to watch a documentary of 60 min.
62780277|NCT03036618|PLACEBO_COMPARATOR|Wheat|Test wheat bread roll (approximately 160g weight) without quinoa.
62780278|NCT03036618|EXPERIMENTAL|Quinoa|Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
62005317|NCT03362515|PLACEBO_COMPARATOR|Placebo|
62005318|NCT03302702|OTHER|Exercise program|Treatment group
62005319|NCT00590304||EU, LV, MA, EL, DU|The population will consist of 120 English-speaking participants ages 4-17 years from four rural schools with physician-diagnosed asthma or symptoms of asthma in the previous 12 months. As of June 2008, an additional rural school has been added to the population criteria, making a total of five rural schools.
62005320|NCT04607408|EXPERIMENTAL|Part A, Group 1: CH505TF gp120 + GLA-SE|Participants will receive 20 mcg Stable CH505TF gp120 admixed with 2.5 mcg GLA-SE, to be administered as a 0.25 mL intramuscular (IM) injection into either thigh at Weeks 0, 8, 16, 32, and 54.
62005321|NCT04607408|PLACEBO_COMPARATOR|Part A, Group 2: Placebo|Participants will receive Placebo to be administered as a 0.25 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
62005322|NCT04607408|EXPERIMENTAL|Part B, Group 3: CH505TF gp120 + GLA-SE|Participants will receive 20 mcg Stable CH505TF gp120 admixed with 5 mcg GLA-SE, to be administered as a 0.5 mL IM injection into either thigh at Weeks 0, 8, 16, 32, and 54.
62005323|NCT04607408|PLACEBO_COMPARATOR|Part B, Group 4: Placebo|Participants will receive Placebo to be administered as a 0.5 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
62005324|NCT04607408|EXPERIMENTAL|Part C, Group 5: CH505TF gp120 + GLA-SE|Participants will receive 20 mcg Stable CH505TF gp120 admixed with 5 mcg GLA-SE, to be administered as a 0.5 mL IM injection into either thigh at Weeks 0, 8, 16, 32, and 54.
62005325|NCT04607408|PLACEBO_COMPARATOR|Part C, Group 6: Placebo|Participants will receive Placebo to be administered as a 0.5 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
62005326|NCT04607408|EXPERIMENTAL|Part C, Group 7: CH505TF gp120 + GLA-SE|Participants will receive 5 mcg Stable CH505TF gp120 admixed with 5 mcg GLA-SE, to be administered as a 0.5 mL IM injection into either thigh at Weeks 0, 8, 16, 32, and 54.
62005327|NCT04607408|PLACEBO_COMPARATOR|Part C, Group 8: Placebo|Participants will receive Placebo to be administered as a 0.5 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
62005328|NCT05024565|EXPERIMENTAL|prolonged intravenous infusion of β-lactams Antibiotics|Administer according to the PK/PD optimized regimen with the goal of increasing T\>MIC. (1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours.
62191039|NCT04787237|EXPERIMENTAL|Vestibulart socket therapy and immediate implants|A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators (. Implant fixture were then inserted . A flexible cortical membrane shield that is made of cortical bone of heterologous origin was introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a membrane tack or a micro screw to the alveolar bone apical to the base of the socket . The socket gap between the implant and the shield was then packed thoroughly with particulate bone graft
62191040|NCT04787237|ACTIVE_COMPARATOR|Buser's technique and early implant placement|In Buser's group early implant placement, the failing tooth was extracted atraumatically using a periotome. A collagen plug was placed to stabilize the wound clot. A healing period of 4-8 weeks was followed. Then an open flap implant surgery using a triangular flap design was cut. Implant was then placed under the crest of the palatal bone. A healing abutment was then attached. Contour augmentation was done using autogenous bone chips mixed with saline and bone conditioned medium (BCM) added to bioss bone granules to activate it.
62191041|NCT02099448||Elective Cardiac Catheterization|
62191042|NCT02885662|EXPERIMENTAL|CS-3150|CS-3150 2.5 to 5.0 mg , orally, once daily after breakfast for 12 weeks.
62191043|NCT03883464|EXPERIMENTAL|Low fat intake|Patients who underwent cholecystectomy and were instructed to have a low fat diet.
62191044|NCT03883464|NO_INTERVENTION|Regular diet|Patients who underwent cholecystectomy and were instructed to have a regular diet.
62191045|NCT06146192||Colchicine|
62191046|NCT06146192||No colchicine|
62191047|NCT05396937|EXPERIMENTAL|T+A+RAD|
62191048|NCT03575676|EXPERIMENTAL|Group A|Administration of SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks, SOM3355 100mg BID for 6 weeks and placebo BID for 6 weeks.
62191049|NCT03575676|EXPERIMENTAL|Group B|Administration of placebo BID for 6 weeks, SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks and SOM3355 100mg BID for 6 weeks.
62191050|NCT01476605|ACTIVE_COMPARATOR|PrT-DMS|1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.
62191051|NCT01476605|EXPERIMENTAL|PrT-D|PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine
62191052|NCT01476605|NO_INTERVENTION|Waitlist|
62191053|NCT01476605|ACTIVE_COMPARATOR|Platelet rich plasma|
62191054|NCT01932268|EXPERIMENTAL|Rifampicin|experimentally check a change of the colchicine concentration from baseline at 1,2,4,8,24 hours after taking Rifampicin
62191055|NCT03292445|EXPERIMENTAL|Immune tolerance after kidney transplant|Immune tolerance after kidney transplant will be induced by transfusion of enriched donor blood stem cells and T cells to initiate blood cell mixed chimerism in patients conditioned with total lymphoid irradiation and rabbit anti-thymocyte globulin after kidney transplant. Patients will receive corticosteroids for 14 weeks with gradual dose reduction. They will also receive 12 months of mycophenolate mofetil and 18 months of tacrolimus with dose tapering beginning 9 months post-transplant and continuing as long as mixed chimerism is maintained and there is no evidence of graft versus host disease and no kidney rejection evident. Patients losing chimerism will continue on low dose immunosuppressive drug doses unless additional kidney rejection therapy is needed.
62191056|NCT05142930|ACTIVE_COMPARATOR|Intermittent ultrasound|Patients with coccydynia will receive 10 sessions of physical therapy, 5 days a week for 2 weeks. Intermittent ultrasound will be used as a physical therapy agent. Intermittent ultrasound treatment will be applied to the muscles of the bilateral coccyx region at a dose of 1.0W/cm², at a frequency of 1 Megahertz, for 3+3 minutes.
62191057|NCT05142930|ACTIVE_COMPARATOR|Continuous ultrasound|Patients with coccydynia will receive 10 sessions of physical therapy, 5 days a week for 2 weeks. Continuous ultrasound will be used as a physical therapy agent. Continuous ultrasound treatment will be applied to the muscles of the bilateral coccyx region at a dose of 1.0W/cm², at a frequency of 1 Megahertz, for 3+3 minutes.
62191058|NCT04910633||Solid Tumor and COVID-19|Patients with a solid tumor followed by an oncologist of Lyon University Hospital Cancer Institute (LUHCI) who have been hospitalized at LUHCI for the COVID-19 between March and May 2020 and who didn't oppose the reuse of their medical file data for research purpose.
62191059|NCT02415647||Child Proband with Psychiatric Disorder|Affected group of child probands with psychiatric disorders (ages 6-12 years).
62191060|NCT02415647||Normal Comparison Group|Non-disordered psychiatrically normal comparison group (ages 6-12 years).
62191061|NCT05198726|ACTIVE_COMPARATOR|Active tACS plus active SoP|Active alpha range tACS plus Speed of Processing Training
62191062|NCT05198726|ACTIVE_COMPARATOR|Active tACS plus sham SoP|Active alpha range tACS plus sham Speed of Processing Training
62191063|NCT05198726|ACTIVE_COMPARATOR|Sham tACS plus active SoP|Sham alpha range tACS plus Speed of Processing Training
62191064|NCT02472054|EXPERIMENTAL|hemophagocytic lymphohistiocytosis (HLH)|"Alemtuzumab (CAMPATH®)~1. Initial Treatment (D1 to D3) D1: 0.5 mg / kg / day Alemtuzumab combined with 2 mg /kg/d of IV Methylprednisolone (MP) or PO Prednisolone, and IVC or PO cyclosporine (CSA) (target rate from 150 to 200 ng / ml in the absence of renal failure) D2 and D3: 1 mg / kg / day Alemtuzumab combined with 2 mg / kg / d of IV MP or PO Prednisolone and IVC or PO CSA (target rate 150-200 ng / ml)~   The maximum dose of Alemtuzumab is limited to 30 mg per day (1 vial).~2. Maintenance treatment (D4 to D14)~   * MP/Prednisolone progressive tapering starting at D4 (2 mg / kg / day) to reach the dose 0.5 mg / kg / day at D14~  * CSA IVC or PO at a target rate of 150-200 ng / ml"
62191065|NCT01360385||Central Retinal Vein Occlusion|CRVO-patients with planned treatment with intravitreal injections of ranibizumab, who receive three monthly injections of ranibizumab and a 3 month follow-up period, during which ranibizumab injections are provided as needed.
62191066|NCT04088864|EXPERIMENTAL|R/R B-ALL|"Subjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide followed by infusion of CD22 CAR T cells on Day0.~Lymphodepletion:~* Fludarabine 25 mg/m2 per day IV for days 4, 3, -2~* Cyclophosphamide 900 mg/m2 per day IV on day -2~Autologous CD22 CAR T cells will be administered intravenously at Dose level 1 (1 x 10\^6 transduced T cells/kg (± 20%))."
62191067|NCT04088864|EXPERIMENTAL|Lymphoma|"Subjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide followed by infusion of CD22 CAR T cells on Day0.~Lymphodepletion:~* Fludarabine 25 mg/m2 per day IV for days 4, 3, -2~* Cyclophosphamide 900 mg/m2 per day IV on day -2~Autologous CD22 CAR T cells will be administered intravenously at Dose level 1 (1 x 10\^6 transduced T cells/kg (± 20%))."
62191068|NCT03012243|ACTIVE_COMPARATOR|Cholecystostomy|Percutaneous cholecystostomy, leaving drain in situ
62191069|NCT03012243|EXPERIMENTAL|Gallbladder aspiration|Gallblader aspiration without drain
62191070|NCT05360628|EXPERIMENTAL|D-0120 plus Allopurinol|D-0120 dosing followed by Allopurinol and combination treatment
62191071|NCT05360628|EXPERIMENTAL|Allopurinol plus D-0120|Allopurinol dosing followed by D-0120 and combination treatment
62780279|NCT02540668|EXPERIMENTAL|Warfarin|Single oral dose of 15 mg warfarin on Day 1.
62005329|NCT05024565|NO_INTERVENTION|short-term intravenous infusion of β-lactams Antibiotics|The daily allowable dose is calculated according to the creatinine clearance rate. The carbapenems, cephalosporins and β-lactamase inhibitor compound preparations are administered in accordance with the dosage and usage required by the instructions, and the injection is generally 30 minutes.
62005330|NCT02863224||Healthy control|
62005331|NCT02863224||Ocular hypertension|
62005332|NCT02863224||Primary open angle glaucoma|
62005333|NCT02863224||Normal tension glaucoma|
62780280|NCT02540668|EXPERIMENTAL|Lanabecestat + Warfarin|Lanabecestat administered orally once daily on Days 8 to 27, with a single oral dose of 15 mg warfarin co-administered on Day 22.
62191072|NCT04698746|ACTIVE_COMPARATOR|Ultrasound guided pericapsular nerve group block|Injection of 15 ml 0.5% bupivacaine + 2 mg dexamethasone + 14.5 ml isotonic saline mixture between iliopubic eminentia and psoas tendon under ultrasound guidance
62780281|NCT03071289|ACTIVE_COMPARATOR|The control group (Group A)|In Group A, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method A. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
62780282|NCT03071289|EXPERIMENTAL|The experiment group (Group B)|In Group B, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method B. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
62005334|NCT02514252|EXPERIMENTAL|Fentanyl Sublingual Spray (FSS)|Hospitalized participants asked to complete a number of surveys at baseline. Participants then receive one single dose of intravenous opioid rescue for their first episode of breakthrough pain, and then receive up to 4 doses of FSS for subsequent episodes of breakthrough pain. Initial FSS starting dose is proportional to the patient's morphine equivalent daily dose (MEDD). Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose. At the time of discharge, if FSS was helpful in controlling participant's pain, they are then able to continue with FSS use for 1 month. Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
62005335|NCT03096522|ACTIVE_COMPARATOR|Phenytoin 2% spray|Patients undergoing anal fistulotomy with postoperative topical phenytoin therapy
62005336|NCT03096522|ACTIVE_COMPARATOR|Anal fistulotomy|Patients undergoing anal fistulotomy without postoperative topical therapy
62005337|NCT00961324|EXPERIMENTAL|IDeg|
62005338|NCT00961324|EXPERIMENTAL|IGlar|
62005339|NCT03032003|ACTIVE_COMPARATOR|Cysticlean arm|Cysticlean (2 BID for 15 days)
62005340|NCT03032003|PLACEBO_COMPARATOR|Placebo arm|Placebo (2 BID for 15 days)
62005341|NCT00203203|EXPERIMENTAL|Stem Cell Therapy|Subject is randomized to receive Stem Cell Therapy (intramyocardial injection of stem cells) via NOGA mapping.
62780283|NCT01238328|EXPERIMENTAL|Transplantation|
62005342|NCT00203203|OTHER|Control, then Stem Cell Therapy|"Subject is randomized to receive a NOGA mapping and no injections at time of active enrollment.~At 6 months, subject is offered stem cell therapy."
62005343|NCT01898793|EXPERIMENTAL|Phase I Dose Level 1: 0.5 x 10^6/kg CIML NK cells|"* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.~* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.~* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)"
62005344|NCT01898793|EXPERIMENTAL|Phase I Dose Level 2: 1.0 x 10^6/kg CIML NK cells|"* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.~* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.~* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)"
62005345|NCT01898793|EXPERIMENTAL|Phase I Dose Level 3: Maximum NK cell/number kg|"* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.~* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.~* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)"
62780284|NCT02508909|EXPERIMENTAL|Videoscopic ilioinguinal lymphadenectomy for melanoma|Melanoma groin lymph node metastasis.
62780285|NCT02610452|EXPERIMENTAL|The study population|"The study population consists of adult patients treated in the Palliative Care Unit of the University Hospital of Nimes, regardless of their original condition. In 2013 the proportion of stays connected with diagnostics for cancer was 70.16%.~Intervention: Clown therapy"
62191073|NCT04698746|ACTIVE_COMPARATOR|Intra-articular local anesthetic injection|At the end of the surgical case, a total of 10 ml 0.5% bupivacaine + 2 mg dexamethasone + 9.5 ml isotonic saline injection intra-articularly.
62791794|NCT04158583|EXPERIMENTAL|Part A: Cohort 2 RO7296682 1 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 1 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade \>=4, IRR; Grade \>=4, immune-mediated adverse events; Grade \>=4) were discontinued from study treatment.
62005346|NCT01898793|EXPERIMENTAL|Phase II (IL-2): Maximum NK cell/number kg|The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
62780286|NCT04840134|EXPERIMENTAL|From Hardship to Hope: Financial Wellness Intervention|"From Hardship to Hope: A Peer-led intervention to reduce financial hardship and suicide risk~Over the course of this study, the investigators will develop and pilot a financial wellness intervention to work in tandem with clinical treatment. The intervention will support individuals experiencing financial hardship and suicide risk to address their financial difficulties (e.g., debt, inability to meet basic needs) by coaching them on financial management techniques, facilitating a financial wellness plan, and connecting them with community-based financial supports (e.g., free financial counseling). The intervention will be facilitated by trained peer specialists, who are individuals with lived experience of financial hardship and suicidal ideation or suicidal behaviors who are state certified peer specialists (having met formal training and experience requirements)."
62780287|NCT05972837|EXPERIMENTAL|SES combined with telemedical support|SES device for personal use will be provided for participants in addition to remote medical support.
62005347|NCT01898793|EXPERIMENTAL|Lead-in Cohort & Phase II (ALT-803): Maximum NK cell/number kg|"* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.~* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.~* Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5)."
62005348|NCT01898793|EXPERIMENTAL|Pediatric Cohort: Maximum NK cell/number kg|"* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1~* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0~* Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses"
62780288|NCT05972837|ACTIVE_COMPARATOR|SES|Participants in this group will also attend an appointment via a video call with a rehabilitation doctor in the first week but no weekly telehealth visits. Only SES device for personal use and a user manual will be provided.
62396955|NCT03457701|EXPERIMENTAL|Daprodustat+58Fe followed by rhEPO+57Fe|Participants will be randomly assigned to receive Daprodustat in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (58Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive rhEPO (either epoetin alfa or darbepoetin alfa) in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (57Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
62780289|NCT05972837|NO_INTERVENTION|No intervention|Participants in this group will not be provided either SES device or weekly telehealth visits. They are only required to attend a session of video call with a rehabilitation doctor in the first week.
62780290|NCT02941666||Collapse ON group|This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with post collapse osteonecrosis.
62780291|NCT02941666||Pre-collapse group|This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with pre-collapse osteonecrosis.
62191074|NCT00624910|EXPERIMENTAL|1|A total of three 5 × 5-cm bupivacaine sponges implanted at specified layers in the wound prior to wound closure
62396956|NCT05040282|OTHER|Etonogestrel 68 mg implant|Women will be subjected to etonogestrel 68 mg implant insertion (Implanon NXT; Organon, USA Inc) according to manufacture instructions. The insertion will be within the first 5 days of the menstrual cycle
62572411|NCT01906216|ACTIVE_COMPARATOR|Sorafenib|All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). Sorafenib may be taken either with a low/moderate fat meal or without food. Subjects are to continue sorafenib according to the study protocol if the adverse events could be safely controlled.
62191075|NCT00624910|PLACEBO_COMPARATOR|2|A total of three 5 × 5-cm collagen sponges implanted at specified layers in the wound prior to wound closure
62191076|NCT00624910|NO_INTERVENTION|3|The patient will recieve the standard of care, but no implant during surgery
62572412|NCT01906216|EXPERIMENTAL|Sorafenib combined with TACE|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). In addition, the subjects in this arm will receive the treatment of conventional transarterial chemoembolization. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents(doxorubicin) and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads.
62005349|NCT01898793|NO_INTERVENTION|Donors|-The haploidentical donor identified by HLA matching of the immediate family members (parents, siblings, and children) will undergo non-mobilized leukapheresis on Day -1. Peripheral blood mononuclear cells (PBMCs) will be collected using standard collection techniques.
62005350|NCT05553925|EXPERIMENTAL|Intervention Implementation|At least 5,000 patients from the participating BWH practices/sites will receive the combined intervention (online weight management program with patient navigator support and personalized coaching) as part of standard of care for overweight and obesity.
62005351|NCT05061160|EXPERIMENTAL|Interval Aerobic Exercise training Group|Interval Aerobic Exercise for 4 weeks
62780292|NCT02941666||FAI group|This control group will be selected in patients undergoing hip arthroscopy for femoral/acetabular impingement.
62191077|NCT02758743|EXPERIMENTAL|Acetium Lozenge|Acetium lozenge (L-cysteine 3mg) is used in context of each cigarette smoked.
62780293|NCT05905731|EXPERIMENTAL|HBV-TCR T cell infusion|Autologous HBV specific TCR redirected T cells
62191078|NCT02758743|PLACEBO_COMPARATOR|Placebo|Identical in appearance with Acetium lozenge, placebo lozenges will be used in the same manner as in experimental arm.
62191079|NCT05693909|EXPERIMENTAL|Cohort 1|SP-420, 28 mg/kg, three times weekly for 48 weeks
62191080|NCT05693909|EXPERIMENTAL|Cohort 2|SP-420, 56 mg/kg, three times weekly for 48 weeks
62191081|NCT05693909|EXPERIMENTAL|Cohort 3|SP-420, 84 mg/kg, three times weekly for 48 weeks
62191082|NCT04928807|EXPERIMENTAL|Short course radiotherapy sequential camrelizumab and chemotherapy|"Radiotherapy will employ conformal or intensity-modulated radiation therapy, with a pelvic irradiation dose of 25 Gy/5 Fractions/1 week. Then rest for 1 week after radiotherapy and begin to receive neoadjuvant chemotherapy CAPOX and camrelizumab, for 2 cycles.~The patients were operated within 10 weeks after the last radiotherapy, and the surgical method is total mesorectal excision.~Postoperative adjuvant therapy will be started 4-6 weeks after surgery, and the adjuvant regimen was the same as that before operation (CAPOX + camrelizumab) for 6 cycles"
62191083|NCT04928807|ACTIVE_COMPARATOR|Long term concurrent chemoradiotherapy and sequential chemotherapy|"The patients received neoadjuvant therapy of CAPOX 2 weeks after long-term concurrent chemoradiotherapy (28\*1.8Gy, during the same period, capecitabine was 825 mg / m2, twice a day, 5 days a week).~The patients were operated within 10 weeks after the last radiotherapy. Adjuvant therapy should begin within 4-6 weeks after surgery, and the adjuvant regimen was the same as that before operation (CAPOX) for 6 cycles"
62191084|NCT03214445|EXPERIMENTAL|resin composite with nanofiller.|30 restorations of resin composite occlusal, molars or premolars, with values of 3 or 4 for the parameter marginal adaptation according to the FDI criteria randomized assigned in this group
62191085|NCT03214445|ACTIVE_COMPARATOR|sealant based on resin|30 restorations of resin composite occlusal, molars or premolars, with values of 3 or 4 for the parameter marginal adaptation according to the FDI criteria randomized assigned in this group
62780294|NCT03772665|EXPERIMENTAL|Emixustat|10 mg
62780295|NCT03772665|PLACEBO_COMPARATOR|Placebo|Includes identical tablets with only inactive ingredients (0 mg).
62191086|NCT03214445|NO_INTERVENTION|Control|The restorations were evaluated without treatment about defective restoration that was considered clinically acceptable.
62191087|NCT06547307|ACTIVE_COMPARATOR|Caffeine 2 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform one exercise test (10 km cycling time trial).
62191088|NCT06547307|ACTIVE_COMPARATOR|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform one exercise test (10 km cycling time trial).
62191089|NCT06547307|PLACEBO_COMPARATOR|Placebo|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform one exercise test (10 km cycling time trial).
62191090|NCT02465151|EXPERIMENTAL|No Protein|
62191091|NCT02465151|EXPERIMENTAL|Low Protein|
62191092|NCT02465151|EXPERIMENTAL|Medium Protein|
62191093|NCT02465151|EXPERIMENTAL|High Protein|
62191094|NCT04119843|EXPERIMENTAL|Mangoral|All participants will receive a single dose of Mangoral (equivalent to 800 mg Manganese (II) chloride tetrahydrate \[MnCl2 4H2O\]).
62191095|NCT06324045|NO_INTERVENTION|Control arm|Includes patients who will receive usual ambulatory, and at discharge care
62780296|NCT04580095|EXPERIMENTAL|With AI algorithm|"In the With AI algorithm arm, the sonographer will perform the echocardiographic exam using the AI algorithm."
62780297|NCT04580095|NO_INTERVENTION|Without AI algorithm|"In the Without AI algorithm, the echocardiographic exam will be performed without the use of the AI algorithm."
62780298|NCT01162811|NO_INTERVENTION|Control group|The control group receives conventional care and treatment
62780299|NCT01162811|EXPERIMENTAL|Intervention group|the intervention group receives visualization and relaxation exercises together with structured behavioural attention
62005352|NCT05061160|ACTIVE_COMPARATOR|Continuous Aerobic Exercise training Group|Continuous aerobic exercise for 4 weeks
62005353|NCT03766503|OTHER|Intervention|The main study intervention is the daily witnessing of participants while they self-administer their medications by trained pharmacy staff to ensure compliance. The staff in question will be provided by Leila pharmacy and will in addition provide support so that individuals can transition back into living independently through reminders to attend regularly scheduled medical appointments and counseling on correct use of prescribed medications.
62191096|NCT06324045|EXPERIMENTAL|Intervention arm|Includes patients who will receive a structured deprescribing intervention by the multidisciplinary team during patients' time at the center, and discharge (as applicable)
62191097|NCT05111405|OTHER|Trapezial excision with or without soft tissue interposition and /or ligament reconstruction|The participating surgeon will perform their usual version of a trapeziectomy and thumb metacarpal using either FCR tendon or abductor hallucis longs (APL) tendon. Tendon interposition will be left to the surgeon's discretion.
62572413|NCT06055517|EXPERIMENTAL|Pulsed low dose-rate radiotherapy (pLDRT)|
62005354|NCT03161561|OTHER|capacity of primary phagocytes|capacity of primary phagocytes isolated from COPD patients' blood to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
62005355|NCT02806479||Case: Hypertrophic cardiomyopathy|HCM patients at high risk for ventricular arrhythmia
62191098|NCT05111405|OTHER|Suture button suspension arthroplasty (SBS)|Dorso-radial incision, capsulotomy between extensor pollicis brevis (EPB) and APL protecting the radial artery. A second incision is made on dorsum of hand between the 2nd and 3rd MCs. A cannulated drill with suture passer is passed from base of 1st MC to mid 2nd MC. The TightropeTM is passed from 1st to second MC with one button on the base of the 1st MC. Trapeziectomy is then performed using a cruciate osteotomy and rongeurs. The thumb is adducted against index MC to avoid excessive tightening and the suture is tied over a second button on the 2nd MC. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
62191099|NCT06509360|OTHER|Feelee app|Following a Single Case Experimental Design, all participants will follow a ABA baseline: 2-weeks baseline phase without intervention (A), 4-weeks intervention phase using the Feelee app (B) and a 2-weeks follow-up phase without intervention again (B).
62191100|NCT02498236|EXPERIMENTAL|Oxytocin 6-84 IU|Subjects will be randomly assigned to one of eight doses of intranasal oxytocin.
62191101|NCT02498236|PLACEBO_COMPARATOR|Placebo|Subjects will be administered intranasal placebo using the same spray volume as experimental condition
62191102|NCT00580489|ACTIVE_COMPARATOR|Arm C Morphine|Morphine given to trauma patients transported by helicopter
62191103|NCT00580489|ACTIVE_COMPARATOR|Arm D Fentanyl|Fentanyl given to trauma patients transported by helicopter
62191104|NCT02825251|EXPERIMENTAL|Faster-acting insulin aspart CSII|
62191105|NCT02825251|ACTIVE_COMPARATOR|NovoRapid® CSII|
62191106|NCT05716022||Hiatal Hernia Group|The subject has a history of acid reflux and/or hiatal hernia undergoing surgical repair by thoracic surgery at the University of Virginia.
62191107|NCT05716022||Control Group|Patients undergoing bronchoscopy for clinical purposes at the University of Virginia endoscopy suite without a clinical diagnosis of hiatal hernia and/or pulmonary fibrosis.
62191108|NCT00333749|EXPERIMENTAL|1|55 children \< 5 years with acute oral ulcer disease.
62191109|NCT00333749|PLACEBO_COMPARATOR|2|55 Children \< 5 years with acute oral ulcer disease.
62191110|NCT02994784|EXPERIMENTAL|Evomela|Propylene Glycol-Free Melphalan Hydrochloride (Evomela) administered intravenously at 70-100 mg/m2/day on Days -3 and -2 prior to autologous stem cell transplantation
62572414|NCT06564675||OHCA patients|"OHCA patients, randomized to STEPCARE Trial. The patients are recruiten to this substudy in selected centers with access to the Brainstatus device for recording of cEEG.~Adult patients who remain comatose after sustained ROSC after OHCA are eligible to the STEPCARE Trial. Exclusion criteria are pregnancy, previous randomization to STEPCARE, trauma or hemorrhage as reasons for arrest, suspected or confirmed intracranial hemorrhage, and specifically for this study allergy to adhesive material and injured skin in the frontal-temporal area, that prevents adhesion of the Brainstatus electrode."
62780300|NCT02486965|EXPERIMENTAL|training group|"The training program consists of three sessions of 45 minutes of physical activity per week for 2 years. During the first 6-9 months, two individual workouts, supervised by a physiotherapist and a session in Living.~Depending on the capacity and exercise tolerance of the patient, patients realize the second phase of training until 2 years of the study: three exercise sessions from 45 to 60 minutes per week of which group session led by a professor of Adapted Physical Activity (APA) and 2 autonomous sessions.~Thermal stimulation with test thermode Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms"
62005356|NCT02806479||Control I: Healthy|Healthy Controls
62005357|NCT02806479||Control II: Post-MI with arrhythmogenic substrate|Ischemic cardiomyopathy patients with documented history of ventricular tachyarrhythmia and left ventricular hypertrophy
62005358|NCT02806479||Control III: VT/VF-free ischemic cardiomyopathy|Ischemic cardiomyopathy patients without ventricular arrhythmia, as proven by non-inducibility and history of freedom from ventricular tachyarrhythmia during at least one ICD generator life
62005359|NCT01993108|EXPERIMENTAL|Healthy Controls|Healthy individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
62005360|NCT01993108|EXPERIMENTAL|Adult Attention-Deficit/Hyperactivity Disorder|ADHD individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
62191111|NCT01874509|ACTIVE_COMPARATOR|Check Your Drinking screener|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
62191112|NCT01874509|EXPERIMENTAL|Alcohol Help Centre|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
62191113|NCT03329729||Hyperlipidemic patients|
62191114|NCT02417649|EXPERIMENTAL|Ismigen|Treatment over 3 successive months. One sublingual tablet every day on the first ten days of each month, followed by twenty days of rest.
62191115|NCT02417649|PLACEBO_COMPARATOR|Placebo|Treatment over 3 successive months. One sublingual tablet every day on the first ten days of each month, followed by twenty days of rest.
62191116|NCT03210649|EXPERIMENTAL|CKD-519 400mg(PartⅠ: 1day)|CKD-519 400mg(100mg x 4tabs) or placebo
62191117|NCT03210649|EXPERIMENTAL|CKD-519 400mg(PartⅡ: 14days)|CKD-519 400mg(100mg x 4tabs) or placebo
62191118|NCT01592396|EXPERIMENTAL|Tralokinumab 300 mg|Participants aged 12 to 14 years and 15 to 17 years will receive a single dose of tralokinumab (CAT-354) 300 milligram (mg), subcutaneously on Day 1.
62191119|NCT00520845|EXPERIMENTAL|Treatment Arm|Either docetaxel or pemetrexed given with celecoxib
62191120|NCT04292470|EXPERIMENTAL|Amitriptyline|Amitriptyline 10 mg daily
62191121|NCT03042364|NO_INTERVENTION|No intervention|Standard treatment
62191122|NCT03042364|EXPERIMENTAL|Intervention|Endometrial scratching before standard treatment
62191123|NCT05395364|NO_INTERVENTION|Control|No intervention will occur.
62191124|NCT05395364|EXPERIMENTAL|Intervention|An intervention program based on the promotion of health literacy and lifestyles, specifically on children's: 1-health literacy and infodemic resilience; 2- lifestyles (e.g. dietary intake, 24h-movement behaviour); 3-overweight and obesity; 4-blood pressure.
62396957|NCT06198179|EXPERIMENTAL|Experimental group|"these individuals will receive the upper limb children action-observation training (UP-CAT) with visual feedback~UP-CAT:~* Individual tasks like modelling compound,board games,cards,magnets,glass bead to do bracelets,painting and crafting (making a grass man,making musical instruments with cardboard),cooking (making juice cocktails,fruit skewers,chocolate fondue),building towers, making puzzles \& water games including filling a bucket with a sponge/bottle,filling \& throwing water balloons.~* To maximize the variety of the actions we included different objects (e.g.coins,bottles, stamps,modelling compound) to be grasped with different grasp types (whole hand,pinch, tripod grasp) and in different orientations of the wrist.~Visual feedback:~Mirror in front of patient will be used. After the baseline assessment,the patient in the experimental group will receive the upper limb children action-observation training with visual feedback Time of rehabilitation will be 1 hour/subject."
62191125|NCT02906722|EXPERIMENTAL|Experimental group|Patients receive simultaneously nebulized colimycin every 8 h and intravenous placebo administered once, twice or 3 times per day according to renal function
62191126|NCT02906722|ACTIVE_COMPARATOR|Control group|Patients receive simultaneously intravenous colimycin administered once, twice or 3 times per day according to function renal and nebulized placebo every 8 h
62191127|NCT06263439||Children with hand, foot and mouth disease or herpangina|Children with hand, foot and mouth disease or herpangina will be proposed to have a throat or buccal swab collected to do the diagnosis of an enterovirus infection.
62191128|NCT06355323|EXPERIMENTAL|Patients|
62191129|NCT03451708|EXPERIMENTAL|Optimization of OKS|Crossover study examining various OKS protocols on improving symptoms of hemispatial neglect
62191130|NCT03451708|EXPERIMENTAL|Safety and efficacy study|Randomized study assessing the safety and efficacy of OKS in treating hemispatial neglect
62191131|NCT03451708|EXPERIMENTAL|Effect of repetitive stimulation|Benefits of daily, repetitive OKS in treating hemispatial neglect
62191132|NCT03451708|EXPERIMENTAL|OKS and gait|Effect of OKS on gait and balance
62191133|NCT01426347|PLACEBO_COMPARATOR|placebo group|"RA Patients with vitamin D deficiency will be randomized to placebo and active intervention arms.~Patients in the placebo arm will receive I placebo pill per week for 16 weeks. After completing this arm, they will cross-over to the active treatment arm."
62191134|NCT01426347|ACTIVE_COMPARATOR|Ergocalciferol|Patients with vitamin D deficiency will be randomized to either active or placebo group. In the active group, patients will receive ergocalciferol 50,000 IU per week for 16 weeks.
62191135|NCT05075512|EXPERIMENTAL|experimental group|anlotinib combined with fulvestrant
62191136|NCT01472029|EXPERIMENTAL|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab|
62191137|NCT03439618|OTHER|continuous feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h
62396958|NCT06198179|OTHER|Control group|"This will receive the upper limb children action-observation training (UP-CAT).~UP-CAT:~Following tasks will be performed by children~* Individual tasks like modelling compound,board games,cards,magnets,glass bead to do bracelets,painting and crafting (making a grass man,making musical instruments with cardboard),cooking (making juice cocktails,fruit skewers,chocolate fondue),building towers, making puzzles \& water games including filling a bucket with a sponge/bottle,filling \& throwing water balloons~* To maximize the variety of the actions we included different objects (e.g. coins,bottles, stamps,modelling compound) to be grasped with different grasp types (whole hand,pinch, tripod grasp) \& in different orientations of the wrist.After the baseline assessment,the patient in the experimental group will receive the UL children action-observation training with visual feedback Time of rehabilitation will be 1 hour per subject."
62396959|NCT06423118||Healthy Older Adults|"* Age 55-85~* 8+ years of education~* No frank cognitive impairment or dementia"
62780301|NCT02486965|PLACEBO_COMPARATOR|control group|A training program supervised by physical therapists and teachers in Adapted Physical Activity, identical to the active program in its follow-up, but the intensity of the sessions is lower than that of the training group
62780302|NCT05270798|EXPERIMENTAL|Patients with low triiodothyronine levels who received triiodothyronine|
62005361|NCT02052479|OTHER|Polycystic Ovary Synrome, PCOS, Caucasian, No treatment|Frequently Sampled Intravenous Glucose Tolerance Test with minimal model analysis (MINMOD FSIVGTT)
62191138|NCT03439618|OTHER|time-restricted feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 6h (7:00-9:00,11:00-13:00,17:00-19:00).
62191139|NCT01146977|EXPERIMENTAL|Autologous HCT|"5.1.3. After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.~5.1.3.1. If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue."
62191140|NCT01146977|ACTIVE_COMPARATOR|HDAC chemotherapy|If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.
62191141|NCT02383992|ACTIVE_COMPARATOR|Hydrogen Peroxide|Post-operative wound will be treated with 3% H2O2 solution, Subjects will also clean the sutured wounds with 3% H2O2 solution or twice daily then dress the wounds with petroleum jelly and a bandage.
62780303|NCT05270798|PLACEBO_COMPARATOR|Patients with low triiodothyronine levels who received placebo|
62780304|NCT05270798|EXPERIMENTAL|Patients with low triiodothyronine and low tetraiodothyronine levels who received triiodothyronine|
62191142|NCT02383992|ACTIVE_COMPARATOR|Saline|Post-operative wound will be treated with 0.9% normal saline. Subjects will also clean the sutured wounds with normal saline twice daily then dress the wounds with petroleum jelly and a bandage.
62191143|NCT00118612|EXPERIMENTAL|Therapeutic Regimen|
62191144|NCT00118612|EXPERIMENTAL|Intermediate dose|
62191145|NCT00118612|EXPERIMENTAL|Low dose|
62191146|NCT00118612|PLACEBO_COMPARATOR|Placebo|
62191147|NCT00707499|EXPERIMENTAL|1|
62396960|NCT02033642|EXPERIMENTAL|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child.
62396961|NCT02033642|EXPERIMENTAL|Maintenance|The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors at home.
62396962|NCT04081246|EXPERIMENTAL|Modified en bloc resection|For patients undergoing modified en bloc resection, piecemeal resection of the exophytic part of the bladder tumour will be performed, followed by en bloc resection of the tumour base.
62396963|NCT06723860||Retrospective control cohort|Retrospectively collected data on a group of intensive care survivors who were not referred for a post-ICU clinic visit.
62396964|NCT06723860||Intervention cohort|Patients meeting FICM criteria who are referred for a CCRP clinic visit and consent to participation in research
62005362|NCT02052479|OTHER|Polycystic Ovary Synrome, PCOS, African-American, No treatment|Frequently Sampled Intravenous Glucose Tolerance Test with minimal model analysis (MINMOD FSIVGTT)
62005363|NCT01797328|ACTIVE_COMPARATOR|cold provocation|cold arm
62396965|NCT00848965|PLACEBO_COMPARATOR|Placebo|
62396966|NCT00848965|EXPERIMENTAL|Fluticasone propionate 25ug|
62396967|NCT00848965|EXPERIMENTAL|Fluticason propionate 50ug|
62396968|NCT00848965|EXPERIMENTAL|Fluticasone propionate 100ug|
62396969|NCT00848965|EXPERIMENTAL|Flutciasone propionate 200ug|
62396970|NCT05577819|EXPERIMENTAL|Patients 65 and older with Heart Failure with Preserved Ejection Fraction|Patients 65 years and older presenting to Massachusetts General Hospital with a known diagnosis of HFpEF and without a diagnosis of amyloidosis in the ambulatory (outpatient) setting will undergo a 99Tc-Pyrophosphate Scan to identify Cardiac Amyloidosis
62005364|NCT01797328|ACTIVE_COMPARATOR|to avoid feeling cold|warm arm
62396971|NCT06063538|EXPERIMENTAL|CardiaMend Pericardial and Epicardial Reconstruction Matrix used in combination with amiodarone|Patients randomized to this study arm includes the CardiaMend which will be used according to the instructions for use. It will be patted dry to facilitate implantation. Pieces will be cut to cover the right and left atria. The remaining piece will be contoured to close the anterior pericardial space. Four ampules of amiodarone (150mg/3ml; 12cc total volume) will be drawn into a syringe. 2cc will be dripped over the right atrium and a small CardiaMend patch placed to cover this area. Another 2cc will be used over the left atrium and covered with the CardiaMend. The anterior pericardial space will be closed without putting pressure on the underlying structures using the CardiaMend attached to the native pericardium utilizing running 4-0 monofilament suture.
62396972|NCT06063538|NO_INTERVENTION|University of Chicago's standard of care in patients undergoing isolated CABG or valve surgery|The standard of care for this study at The University of Chicago is to ligate the left atrial appendage (LAA) during the proposed cardiac surgery (intra-operative) to reduce the occurrence of post operative atrial fibrillation (A-FIB) in combination with amiodarone injections (if applicable).
62005365|NCT03945877||English-speaking Community Members|Survey respondents
62396973|NCT04888936||NCI RASopathies Clinical Center Cohort|includes Proband, Other carriers in family, Family Controls
62396974|NCT04888936||NCI RASopathies Field Cohort|includes Proband, Other carriers in family, Family Controls
62396975|NCT00239694|EXPERIMENTAL|1|Previously vaccinated
62005366|NCT03945877||Spanish-speaking Community Members|Survey respondents
62396976|NCT00239694|EXPERIMENTAL|2|Never vaccinated
62396977|NCT02370173|EXPERIMENTAL|PTSD wavelength-1 bright light|30 minutes of daily light exposure for 6 weeks
62396978|NCT02370173|PLACEBO_COMPARATOR|PTSD wavelength-2 bright light|30 minutes of daily light exposure for 6 weeks
62396979|NCT06724120||Survival Group|
62396980|NCT06724120||Non-survival Group|
62780305|NCT05270798|PLACEBO_COMPARATOR|Patients with low triiodothyronine and low tetraiodothyronine levels who received placebo|
62396981|NCT04187066||Obese|severe obesity
62396982|NCT04187066||Control|Control group with normal weight
62396983|NCT04344431|EXPERIMENTAL|HBO group|
62396984|NCT04344431|NO_INTERVENTION|Non-HBO group|
62780306|NCT02999412|ACTIVE_COMPARATOR|Comprehensive medication review (I1)|
62780307|NCT02999412|ACTIVE_COMPARATOR|Comprehensive medication review with active follow-up (I2)|
62780308|NCT02999412|OTHER|Usual care (Control)|
62780309|NCT04523597||toracic hyperkyphosis|children with COBB angle ≥ 45˚
62780310|NCT04523597||control|children with kyphosis index \< 13 measured using the flexicurve ruler
62780311|NCT05629468|ACTIVE_COMPARATOR|Azithromycin and Topical|group A (n=25) received tab. azithromycin 250mg oral on alternate days and topical cream benzoyl peroxide 4% twice a day daily for a period of 3 months
62780312|NCT05629468|EXPERIMENTAL|Probiotics and Topical|group B (n=25) received Probiotic sachet oral once a day everyday and topical cream benzoyl peroxide 4% twice a day daily for a period of 3 months
62780313|NCT05629468|OTHER|Azithromycin and Probiotics and Topical|combination group C (n=25) received tab. azithromycin 250mg oral on alternate days, Probiotic sachet oral once a day everyday and topical cream benzoyl peroxide 4% twice a day daily for a period of 3 months
62780314|NCT00746434|ACTIVE_COMPARATOR|1|Roflumilast cream 0.5%
62780315|NCT00746434|PLACEBO_COMPARATOR|2|Placebo cream
62005367|NCT03945877||Arabic-speaking Community Members|Survey respondents
62005368|NCT01257204|ACTIVE_COMPARATOR|Control|Placebo + Pegylated interferon alfa-2a + Ribavirin
62005369|NCT01257204|EXPERIMENTAL|12 Week Cohort|Daclatasvir + Pegylated interferon alfa-2a + Ribavirin
62005370|NCT01257204|EXPERIMENTAL|16 Week Cohort|Daclatasvir + Pegylated interferon alfa-2a + Ribavirin
62005371|NCT00685932|NO_INTERVENTION|Control|This arm will be randomly assigned to have conventional retractions (ie Rich retractors and similar) used in the usual fashion during the cesarean procedure.
62191148|NCT02906020|EXPERIMENTAL|GZ/SAR402671|Part 1: Increasing doses of GZ/SAR402671 were administered once per day. Part 2: A dose of GZ/SAR402671 (determined in Part 1) was administered once per day.
62396985|NCT03107273||Diagnostic patient|
62396986|NCT03107273||Control|
62396987|NCT00457951|EXPERIMENTAL|Open Label|Initial six subjects treated with ODSH open-label to confirm safety in subjects with an acute exacerbation of COPD; six additional patients will be enrolled following safety review.
62396988|NCT00457951|PLACEBO_COMPARATOR|0.9% Sodium Chloride|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride Solution bolus; dose of 0.375mg/kg/hr over 96 hours.
62396989|NCT00457951|ACTIVE_COMPARATOR|Randomized, Blinded, ODSH Arm|Subjects will receive standard of care treatment. ODSH is administered in bolus doses estimated to inhibit inflammatory mediators randomized 1:1 to ODSH 8mg/kg or placebo. The continuous infusion dose will be 0.375 mg/kg/hr over 96 hours.
62005372|NCT00685932|EXPERIMENTAL|Mobius|This arm will be randomized to have the providers who are performing the cesarean section use the Mobius retractor during the cesarean section procedure after the peritoneal cavity is opened.
62005373|NCT06413810|EXPERIMENTAL|Food ingredient|
62005374|NCT06413810|PLACEBO_COMPARATOR|Placebo|
62005375|NCT04543552||Bladder Scan|Subjects who are scheduled to undergo urodynamic studies.
62005376|NCT02193594|EXPERIMENTAL|CCRT group|The patient in CCRT group will receive the preoperative concurrent chemoradiotherapy for 5 weeks and sequential radical D2 total gastrectomy and postoperative adjuvant chemotherapy of 6 cycles.
62005377|NCT02193594|ACTIVE_COMPARATOR|CT group|The patient in CT group will receive radical D2 total gastrectomy and postoperative adjuvant chemotherapy of 8 cycles.
62005378|NCT01575327|ACTIVE_COMPARATOR|Fixed oxygen flow delivery|Oxygen flow delivery is adjusted by respiratory therapists. Standard medical treatment.
62005379|NCT01575327|EXPERIMENTAL|FreeO2 system|FreeO2 is a new system that automatically adjusts the oxygen flow delivered to patients in a closed-loop based on the SpO2 signal. This system is intended to maintain SpO2 in a predefined target and to adapt oxygen flow to patient's needs.
62005380|NCT04002765|OTHER|New RA patients|"* Adults aged 18 to 90 years-old~* Diagnosis of rheumatoid arthritis (RA) based on ACR-EULAR 2010 criteria~* Onset of disease duration at least 1 year and at most 10 years prior to inclusion"
62005381|NCT05023590|ACTIVE_COMPARATOR|cryo ablation|cryo ablation of left atrium during mitral valve open chest intervention
62005382|NCT05023590|ACTIVE_COMPARATOR|radio frequency ablation|radio frequency ablation of left atrium during mitral valve open chest intervention
62005383|NCT06539026|EXPERIMENTAL|IVCCI-guided fluid therapy|"the participants in this group will receive crystalloids according to the IVCCI assessment as follows:~1. If ≥ 50 % a bolus will be given 300 ml by dripping within 30 minutes, the fluid will be repeated by half the amount if needed to reach equal or less than 40% collapsibility.~2. If \< 50 % or B line finding in lung ultrasound no bolus will be given."
62005384|NCT06539026|NO_INTERVENTION|Conventional fluid therapy|the participants in this group will receive the standard regimen; no routine additional fluid within half an hour before surgery only the fixed maintenance of 80-100 ml/hr.
62005385|NCT02168166|ACTIVE_COMPARATOR|Executive Function Training|"Two weeks of training of cognitive domain of executive functioning~Using online program (Scientific Brain Training Pro)~Four exercises"
62005386|NCT02168166|PLACEBO_COMPARATOR|Placebo Training|"Two weeks of training with exercises not affecting working memory, information processing speed, or cognitive load~Exercises maintain other traditional progressive aspects to preserve appearance of dynamic titration of difficulty levels~Using online program (Scientific Brain Training Pro)~Four exercises"
62005387|NCT06078046|EXPERIMENTAL|Mindful yoga intervention|The intervention, comprising six 90-minute sessions, will be delivered by a trained mindful yoga instructor in group format. The intervention is based on our previously tested mindfulness yoga programme for people with PD (31). Following a universal Hatha Yoga practice, the session comprises mindfulness practice of yoga sequence, breathing exercise, and guided meditation. Both face-to-face and home-based online modes of delivery are available.
62005388|NCT06078046|EXPERIMENTAL|Arts-based therapy intervention|Participants in the six 90-minute sessions in this intervention will be engaged in art-making processes through multiple art modalities such as visual arts, dance/ movement, music, drama, and creative writing. Each section is usually structured with Filling-in - greetings and check-in, Bridging - warm-up, Decentering - arts making and appreciation, Harvesting - sharing and response, and Closure. Both face- to-face and home-based online modes of delivery are available.
62005389|NCT00279708|ACTIVE_COMPARATOR|Intervention Arm (Atorvastatin)|Atorvastatin: Subjects were assigned to the treatment intervention by way of double blind masking. Atorvastatin 80 mg/day was the initial treatment given, as tolerated for a 12 month period. During the study, a 50% dose reduction was applied for subjects meeting pre-specified criteria.
62191149|NCT02906020|PLACEBO_COMPARATOR|Placebo|A matching placebo for Parts 1 and 2 was administered once per day.
62396990|NCT04575909|EXPERIMENTAL|Explicit Expressive Prosody Intervention|Explicit cues will be provided to help participants improve expression of targeted affective prosody.
62396991|NCT04575909|EXPERIMENTAL|Implicit Expressive Prosody Intervention|Implicit cues will be provided to help participants improve expression of targeted affective prosody.
62396992|NCT04575909|EXPERIMENTAL|Explicit Receptive Prosody Intervention|Explicit cues will be provided to help participants improve recognition of targeted affective prosody.
62191150|NCT01814072|EXPERIMENTAL|Condition 1|1) Lifestyle Core; 2) 12 Telephone Coaching Sessions; 3) Report to Primary Care Physician
62780316|NCT06471075|EXPERIMENTAL|Mindfulness Pain Management|
62191151|NCT01814072|EXPERIMENTAL|Condition 2|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendations to use meal replacements; 5) Buddy training via webinars
62396993|NCT04575909|EXPERIMENTAL|Implicit Receptive Prosody Intervention|Implicit cues will be provided to help participants improve recognition of targeted affective prosody.
62396994|NCT04575909|ACTIVE_COMPARATOR|No-Intervention|Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention \[if relevant\]), hobbies, and other similar topics.
62005390|NCT00279708|PLACEBO_COMPARATOR|Control Arm (Placebo)|Placebo: In a double-blind fashion, subjects were assigned to receive the sham intervention which appeared the same as the intervention agent. For subjects meeting pre-specified criteria, a 50% dose reduction was applied during the 12 month treatment phase of the study: Placebo vs. Atorvastatin
62396995|NCT05788484|EXPERIMENTAL|CDX-585|"Dose-escalation phase: Eligible patients will receive treatment, based on cohort assigned, in 2-week cycles until progression or intolerance.~Expansion phase: Patients enrolled in the expansion phase of the study will receive CDX-585 at the dose level chosen during the escalation phase."
62780317|NCT06471075|ACTIVE_COMPARATOR|Pain Psychoeducation|
62780318|NCT06261359|EXPERIMENTAL|CEND-1+ nab-paclitaxel + gemcitabine|Participants will receive nab-paclitaxel 125mg/m2; CEND1 3.2mg/kg IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
62780319|NCT06261359|PLACEBO_COMPARATOR|Placebo+ nab-paclitaxel + gemcitabine|Participants will receive nab-paclitaxel 125mg/m2; placebo IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
62780320|NCT04995549|EXPERIMENTAL|Measures using Cutiscan® CS 100|
62780321|NCT03651609|EXPERIMENTAL|UNE at HUA_HUA release|Patients with UNE under the HUA randomly distributed for simple decompression of the ulnar nerve. Patients will also receive pictured recommendations with descriptions, which limb positions should be avoided. Control neurological examination will be performed every 3 months and identical protocol as at the time of diagnostic evaluation at 1 year follow-up.
62005391|NCT06193538|EXPERIMENTAL|Intratumoral injection of NV-A01 adenovirus|
62005392|NCT04550624|EXPERIMENTAL|Interventional Arm|This is an open-label, multi-center, phase II trial of lenvatinib in combination with pembrolizumab in patients with Advanced Biliary Tract Carcinoma (BTC) who have progressed on standard systemic therapy. All participants will be administered Pembrolizumab 200mg IV on day 1 and Lenvatinib 20mg PO daily days 1-21 of each cycle (21 days).
62005393|NCT04118010|ACTIVE_COMPARATOR|Vitamin D3 and Inulin|Vitamin D3 50,000 IU/week and 12 g/day chicory-derived prebiotic inulin for 12 weeks
62005394|NCT04118010|ACTIVE_COMPARATOR|Vitamin D3 and placebo Inulin|Vitamin D3 50,000 IU/week and 12 g/day corn-derived maltodextrin/day as the prebiotic placebo for 12 weeks
62005395|NCT04118010|ACTIVE_COMPARATOR|Placebo vitamin D3 and Inulin|Matching to Vitamin D3 placebo capsules, and 12 g/day chicory-derived prebiotic inulin for 12 weeks
62005396|NCT04118010|PLACEBO_COMPARATOR|Placebo vitamin D3 and placebo Inulin|Matching to Vitamin D3 placebo capsules, and 12 g/day corn-derived maltodextrin/day as the prebiotic placebo for 12 weeks
62005397|NCT03169491|EXPERIMENTAL|Therapeutic|Continuous positive airway pressure (CPAP) with automatic pressure from 4 to 15 cmH2O every night for one week, afterwards use of CPAP at the P90 of pressure determinated during automatic use for one week, via oronasal interface.
62005398|NCT03169491|SHAM_COMPARATOR|Suboptimal|Continuous positive airway pressure (CPAP) every night for two weeks at fixed pressure of 4 cmH2O, via oronasal interface.
62005399|NCT03169491|OTHER|Severe OSAS|Continuous positive airway pressure (CPAP) with automatic pressure from 4 to 15 cmH2O every night for one week, afterwards use of CPAP at the P90 of pressure determinated during automatic use for one week, via oronasal interface.
62005400|NCT02354638|EXPERIMENTAL|Tobacco users: behavioural counseling|The cab drivers using tobacco will be invited to participate in the tobacco cessation programme at the TCC and will receive three monthly follow-up for one year. Thus intervention will be in the form of behavioural therapy and pharmacotherapy (if required)
62005401|NCT02354638|NO_INTERVENTION|Non Users|The cab drivers who are not using tobacco in any form will not receive any type of intervention
62005402|NCT00700791|PLACEBO_COMPARATOR|Group I Single Site Randomization|Patients with 1 surgical scar will be given both oral placebo and topical cream placebo
62005403|NCT00700791|ACTIVE_COMPARATOR|Group II Single Site Randomization|Single surgical site will be given oral placebo and topical TCT
62005404|NCT00700791|ACTIVE_COMPARATOR|Group III Single Site Randomization|Patients with 1 surgical scar will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream
62005405|NCT00700791|ACTIVE_COMPARATOR|Group IV Single Site Randomization|Patients with 1 surgical scar will be given both Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT).
62005406|NCT00700791|PLACEBO_COMPARATOR|Group I: Bilateral Site Randomization|Patients with bilateral surgical scars will be given both oral placebo and topical cream placebo on one surgical site.
62005407|NCT00700791|ACTIVE_COMPARATOR|Group II: Bilateral Site Randomization|Patients with bilateral surgical scars will be given oral placebo and Natural Vitamin E Tocotrienol Cream (TCT) to one of the surgical sites.
62191152|NCT01814072|EXPERIMENTAL|Condition 3|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages; 5) Buddy training via webinars
62396996|NCT02461173|ACTIVE_COMPARATOR|Stimulated IUI|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3nd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
62572415|NCT06572059||study/1(Assesments will be done for once)|"It will consist of individuals with MS (\>18years old). who were followed up in the Multiple Sclerosis clinic of the Neurology Department of Kahramanmaraş Sutcu Imam University (KSU) Health Practice and Research Hospital. Patients who meet the inclusion criteria will be evaluated using the following parameters, respectively:~* EDSS score (patient reports recorded by the physician will be used.)~* Demographic information~* Fatigue Severity Scale (FSS)~* Beck Depression Inventory (BDI)~* Kinesthetic and Visual Imagery Questionnaire (KVIQ)~* Mental Chronometer Test (Nine-Hole Peg Test (DDPT) will be used.)~* Jebson-Taylor Hand Function Test (JHEFT)~* Manual Ability Test (MAM-36)~* Multiple Sclerosis Impact Scale (MSIS-29) Assesments will be done for once."
62005408|NCT00700791|ACTIVE_COMPARATOR|Group III: Bilateral Site Randomization|Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream on one surgical site.
62191153|NCT01814072|EXPERIMENTAL|Condition 4|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages
62572416|NCT06572059||healthy control/2 (Assesments will be done for once)|"It will consist of individuals with healthy volunteers with the similar age (\>18years old).~Healthy volunteers who meet the inclusion criteria will be evaluated using the following parameters, respectively:~* EDSS score (patient reports recorded by the physician will be used.)~* Demographic information~* Fatigue Severity Scale (FSS)~* Beck Depression Inventory (BDI)~* Kinesthetic and Visual Imagery Questionnaire (KVIQ)~* Mental Chronometer Test (Nine-Hole Peg Test (DDPT) will be used.~* Jebson-Taylor Hand Function Test (JHEFT)~* Manual Ability Test (MAM-36)~* Multiple Sclerosis Impact Scale (MSIS-29) Assesments will be done for once."
62572417|NCT03347305|EXPERIMENTAL|Patients Group DPA|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
62572418|NCT03347305|EXPERIMENTAL|Healthy Volunteers|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
62572419|NCT05729789|EXPERIMENTAL|Group Written Exposure Therapy|"Patients will be invited to participate in group Written Exposure Therapy (described in the Interventions section)."
62005409|NCT00700791|ACTIVE_COMPARATOR|Group IV: Bilateral Site Randomization|Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT) on one surgical site.
62005410|NCT00700791|NO_INTERVENTION|Normal Skin and Adipost Tissue Group|Normal human skin and adipose tissue will be collected
62005411|NCT04921358|EXPERIMENTAL|Arm A: Tislelizumab in combination with Sitravatinib|tislelizumab 200 mg intravenously once every 3 weeks in combination with sitravatinib 100 mg orally once a day
62191154|NCT01814072|EXPERIMENTAL|Condition 5|1) Lifestyle Core; 2) 12 telephone sessions; 3) Buddy training via webinars
62396997|NCT02461173|ACTIVE_COMPARATOR|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
62396998|NCT02461173|ACTIVE_COMPARATOR|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
62396999|NCT01718574|EXPERIMENTAL|Self-help book|
62397000|NCT01718574|NO_INTERVENTION|Usual Care Control|
62397001|NCT00421928|EXPERIMENTAL|001|tapentadol (CG5503) 50 100 150 200 250mg twice a day (BID) during 15 weeks
62397002|NCT00421928|ACTIVE_COMPARATOR|002|oxycodone 10 20 30 40 50mg twice a day (BID) during 15 weeks
62572420|NCT05633160|EXPERIMENTAL|67Cu-SAR-BBN|"In the dose escalation phase:~64Cu-SAR-BBN: Patients will receive up to 2 administrations of 200MBq~67Cu-SAR-BBN: Cohorts 1 - 3: Single administration (dose will be determined based on cohort allocation).~Cohort 4: 2 administrations at the recommended dose (determined by cohorts 1-3).~In the cohort expansion phase:~Patients will receive up to 3 administrations of 200MBq of 64Cu-SAR-BBN and 2 administrations at the recommended dose level of 67Cu-SAR-BBN, determined through the dose escalation.~Additional administrations: (up to a maximum total of 4) may be offered to those participants, in either the dose escalation or cohort expansion, with radiological non-progression."
62572421|NCT02134054||Biologic|Patients on treatment with biologics (infliximab or adalimumab)
62005412|NCT04921358|ACTIVE_COMPARATOR|Arm B: Docetaxel|docetaxel 75 mg/m2 intravenously once every 3 weeks
62005413|NCT02208791|ACTIVE_COMPARATOR|Tacrolimus/MPS/Prednisone|This arm will be maintained with current conventional triple immunosuppression. Sirolimus will not be added to this arm
62191155|NCT01814072|EXPERIMENTAL|Condition 6|1) Lifestyle Core; 2) 12 telephone coaching sessions; 3) Recommendations to use meal replacements
62191156|NCT01814072|EXPERIMENTAL|Condition 7|1) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages
62191157|NCT01814072|EXPERIMENTAL|Condition 8|1) Lifestyle Core; 2) 12 telephone sessions; 3) Recommendation to use meal replacements; 4) Regular text messages, 5) Buddy training via webinars
62191158|NCT01814072|EXPERIMENTAL|Condition 9|1) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Report to Primary Care Physician
62397003|NCT00421928|PLACEBO_COMPARATOR|003|placebo matching placebo twice a day (BID) during 15 weeks
62397004|NCT04647006|OTHER|Conventional Thyroidectomy|Conventional Thyroidectomy
62397005|NCT04647006|ACTIVE_COMPARATOR|Transoral endoscopic thyroidectomy vestibular approach|Transoral endoscopic thyroidectomy vestibular approach
62397006|NCT06724315||GOLD B; OR GOLD E|Criteria: CAT ≥10 or MMRC ≥ 2 ; OR 2 exacerbations/year or 1 exacerbation leading to hospitalization
62397007|NCT06724315||GOLD 3 OR 4|Criteria: FVE1 \< 50%
62397008|NCT06724328|NO_INTERVENTION|Control Group|In this group, preterm infants will be recorded with a camera for 20 minutes between 13:00-13:20, 19:00-19:20, and 01:00-01:20, after their routine care and feeding have been completed, with no interventions applied to the baby.
62780322|NCT03651609|ACTIVE_COMPARATOR|UNE at HUA_conservative treatment|Patients with UNE under the HUA randomly distributed for conservative treatment. Patients will receive pictured recommendations with descriptions, which limb positions should be avoided. In order to prevent deterioration in conservatively treated group of patients with UNE at HUA control neurological examination will be performed every 3 months. Criteria for surgical HUA release will be clinical deterioration or lack of clinical improvement after 12 months. Prior to surgical HUA release and at 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
62780323|NCT03651609|EXPERIMENTAL|UNE at RTC_HUA release|Patients with UNE in the RTC groove randomly distributed for simple decompression of the ulnar nerve. Patients will also receive pictured recommendations with descriptions, which limb positions should be avoided. At 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
62780324|NCT03651609|ACTIVE_COMPARATOR|UNE at RTC_conservative treatment|Patients with UNE in the RTC groove randomly distributed for conservative treatment. Patients will receive pictured recommendations with descriptions, which limb positions should be avoided. At 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
62780325|NCT01227005|ACTIVE_COMPARATOR|Whole Blood|Whole Blood plus pooled platelets
62191159|NCT01814072|EXPERIMENTAL|Condition 10|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Buddy training via webinars
62191160|NCT01814072|EXPERIMENTAL|Condition 11|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages; 5) Buddy training via webinars
62397009|NCT06724328|EXPERIMENTAL|Maternal Heartbeat|Researchers will schedule a time with the mother within 48 hours after the baby's birth to record the heartbeat. The recording of the mother's heartbeat will be done when the mother's mood is stable and the environment is quiet. A Doppler fetal heart monitor will be used to detect the mother's heartbeat. After ensuring a regular and stable heart rate, the mother's heartbeat will be recorded for 15 minutes using a recording device.
62780326|NCT01227005|ACTIVE_COMPARATOR|Component Therapy|Red blood cells, plasma, platelets
62780327|NCT04598412||Mexican sample|Aged \>60 years (n = 187)
62780328|NCT04598412||German sample|Aged \>75 years (n = 97)
62780329|NCT04598412||Northamerican sample|Aged \>60 years (n = 200)
62780330|NCT04598412||British sample|Aged \>70 years (n = 38)
62780331|NCT03298763|EXPERIMENTAL|Phase 1 - RP2D finding study|Phase I of the trial aims to establish the recommended MSCTRAIL dose when given in combination with cisplatin/pemetrexed chemotherapy in metastatic non-small cell lung cancer (NSCLC) patients
62005414|NCT02208791|EXPERIMENTAL|Sirolimus/Low Tacrolimus/MPS/Prednisone|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid..
62005415|NCT01342562|EXPERIMENTAL|DXM-bupivacaine|
62005416|NCT01342562|PLACEBO_COMPARATOR|saline-bupivacaine|
62005417|NCT04708327|PLACEBO_COMPARATOR|Placebo|Dosing Period 1: Placebo (five capsules) Dosing Period 2: Placebo (one capsule)
62005418|NCT04708327|EXPERIMENTAL|STAT-205|Dosing Period 1: 22.5 mg STAT-205 (five 4.5 mg capsules) Dosing Period 2: 4.5 mg STAT-205 (one capsule)
62005419|NCT05973747|EXPERIMENTAL|Calcium Gluconate|Infused intravenously over 10 minutes upon umbilical cord clamping. First 10 assigned patients received 2 grams per protocol. Subsequent 13 patients received 1.5 grams, dose recalibrated per protocol.
62005420|NCT05973747|ACTIVE_COMPARATOR|Calcium Chloride|0.5mg calcium chloride, infused intravenously over 10 minute infusion beginning upon umbilical cord clamping
62005421|NCT05941026|EXPERIMENTAL|Arms|Nursing students who were in the experimental group during the application phase of the study were given training to develop their intercultural sensitivity levels based on Leninger's Intercultural Nursing Theory. Data were collected at the beginning of the four-week online training, at the end of the training, and one month after the training.
62005422|NCT05941026|NO_INTERVENTION|Control groups|No application was made to the control group within the scope of the research. Data were collected simultaneously with only the experimental group.
62005423|NCT05268471|EXPERIMENTAL|Positional Device (PD)|Vibrating positional device (Nightbalance, Philips) to treat positional obstructive sleep apnea
62005424|NCT05268471|ACTIVE_COMPARATOR|Continuos Positive Airway Pressure (CPAP)|Continuos Positive Airway Pressure (standard treatment) to treat obstructive sleep apnea
62005425|NCT03551470||Synchronous colorectal cancer and liver metastases|Robotic (Da Vinci) one-stage colorectal and liver resection
62005426|NCT03886064|NO_INTERVENTION|Control group|Only measurement of clinical endpoints at time zero, then at 6, 12, 18 and 24 months and minimal counseling.
62005427|NCT03886064|OTHER|Interventional group|Measurement of clinical endpoints at time zero, then at 6, 12, 18 and 24 months and minimal counseling followed by multi-behavioral intervention adapted to local resources.
62005428|NCT02529384||malignant group|The lesion which is malignant tumors in breast
62005429|NCT02529384||begin group|The lesion which is begin lesion in breast
62005430|NCT02529384||The control group|Patient's ipsilateral or contralateral normal breast parenchyma were collected as a control group
62005431|NCT06005025|EXPERIMENTAL|REMİNDER MESSAGE|"All participants will be given one-hour training on breast cancer, modifiable and non-modifiable risk factors for breast cancer, symptoms of breast cancer, screening programmes and breast self-examination. In addition to the presentation, breast self-examination will be applied one-to-one with a breast examination model. This group will be counselled for 6 months after the training and a reminder message will be sent via SMS on Monday every week as Check your modifiable risk factors for breast cancer and their feedback will be received."
62005432|NCT06005025|NO_INTERVENTION|CONTROL GROUP|All participants will be given one-hour training on breast cancer, modifiable and non-modifiable risk factors for breast cancer, symptoms of breast cancer, screening programmes and breast self-examination. In addition to the presentation, breast self-examination will be applied one-to-one with a breast examination model. There will be no additional practice outside the training.
62005433|NCT01745029||Ulcerative Colitis|
62005434|NCT03337724|EXPERIMENTAL|Ipatasertib + Paclitaxel|
62191161|NCT01814072|EXPERIMENTAL|Condition 12|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages
62005435|NCT03337724|EXPERIMENTAL|Placebo + Paclitaxel|
62191162|NCT01814072|EXPERIMENTAL|Condition 13|1) Lifestyle Core; 2) 24 telephone sessions; 3) Buddy training via webinars
62191163|NCT01814072|EXPERIMENTAL|Condition 14|1) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Recommendation to use meal replacements
62191164|NCT01814072|EXPERIMENTAL|Condition 15|1) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages
62191165|NCT01814072|EXPERIMENTAL|Condition 16|1) Lifestyle Core; 2) 24 telephone sessions; 3) Recommendation to use meal replacements; 4) Regular text messages, 5) Buddy training via webinars
62397010|NCT06724328|EXPERIMENTAL|Gentle Human Touch|GHT will be applied to the babies at the designated times.
62397011|NCT06724328|EXPERIMENTAL|Maternal Heartbeat and Gentle Human Touch|For this group, maternal heartbeat will be played and GHT steps will be applied simultaneously at the designated times. Camera recording will start 2 minutes before the intervention and continue for an additional 2 minutes after the intervention.
62397012|NCT04941768||Avelumab + Axitinib|There will not be any study-specific interventions in this study. Participants with advanced RCC receiving 800 milligrams (mg) of Avelumab intravenously every 2 weeks in combination with 5 mg of Axitinib orally twice per day in accordance with the terms of marketing authorization for the first-line therapy as per the current clinical practice will be observed for 24 months in this study.
62005436|NCT02487589|NO_INTERVENTION|Control group|"In Italy, medical risks and patients risk behaviour are not systematically registered and addressed by hospital physicians, specialists and general practitioners (GPs).~Patients allocated in control group will receive by the hospital staff tailored recommendations based on their own risk profile. The same information will be sent to their GPs. No restrictions on co-interventions will be placed."
62005437|NCT02487589|EXPERIMENTAL|Treated group|Telephone support, telemonitoring and tele-exercise
62005438|NCT01813565|EXPERIMENTAL|Additional instillation of hyaluronic acid/chondroitin sulfate|Transurethral resection of bladder ulcer + instillation of hyaluronic acid/chondroitin sulfate
62191166|NCT01814072|EXPERIMENTAL|Condition 17|1) Lifestyle Core; 2) 12 Telephone Coaching Sessions
62572422|NCT03738436|ACTIVE_COMPARATOR|traditional neuromuscular training, NMT|Eight-week physical therapy program consisted of neuromuscular training (NMT) starting from 4 weeks post-surgery. The NMT program includes re-position exercise, strengthening, stretching, landing and balance training.
62572423|NCT03738436|EXPERIMENTAL|modified visual feedback, MVF|Starting from 4 weeks post-surgery, eight-week physical therapy program consisted of traditional neuromuscular training (as in NMT group), but with modified visual feedback by eyes closed, reduced lighting or wearing strobe goggles.
62572424|NCT05740566|EXPERIMENTAL|Tarlatamab|Participants will receive tarlatamab as an intravenous (IV) infusion.
62005439|NCT01813565|ACTIVE_COMPARATOR|Transurethral resection of bladder ulcer|Transurethral resection of bladder ulcer
62191167|NCT01814072|EXPERIMENTAL|Condition 18|1) Lifestyle Core; 2) 12 telephone sessions; 3) Recommendations to use meal replacements; 4) Buddy training via webinars
62191168|NCT01814072|EXPERIMENTAL|Condition 19|1) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages; 4) Buddy training via webinars
62191169|NCT01814072|EXPERIMENTAL|Condition 20|1) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages; 4) Recommendation to use meal replacements
62191170|NCT01814072|EXPERIMENTAL|Condition 21|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Buddy training via webinars
62191171|NCT01814072|EXPERIMENTAL|Condition 22|1) Lifestyle Core; 2) 12 telephone coaching sessions; 3) Report to Primary Care Physician; 4) Recommendations to use meal replacements
62191172|NCT01814072|EXPERIMENTAL|Condition 23|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages
62397013|NCT06417801||Cohort 1 (N=30)|Locally-advanced/metastatic HR+/HER2- breast cancer, either treatment naive or previously exposed to adjuvant therapies, no prior palliative therapy, candidates to receive first-line hormone therapy, primary tumor tissue available.
62397014|NCT06417801||Cohot 2 (N=40)|Locally-advanced/metastatic HR+/HER2- breast cancer, progression during hormone therapy plus CDK inhibitor; primary tumor tissue available.
62572425|NCT05740566|ACTIVE_COMPARATOR|Standard of Care|Participants will receive treatment per local standard of care (SOC).
62572426|NCT02194283|EXPERIMENTAL|Ambroxol - in single rising doses|
62572427|NCT02194283|PLACEBO_COMPARATOR|Placebo|
62572428|NCT02097745|EXPERIMENTAL|MabThera/Rituxan|
62191173|NCT01814072|EXPERIMENTAL|Condition 24|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages, 6) Buddy training via webinars
62191174|NCT01814072|EXPERIMENTAL|Condition 25|1) Lifestyle Core; 2) 24 telephone coaching sessions
62191175|NCT01814072|EXPERIMENTAL|Condition 26|1) Lifestyle Core; 2) 24 telephone sessions; 3) Recommendation to use meal replacements; 4) Buddy training via webinars
62191176|NCT01814072|EXPERIMENTAL|Condition 27|1) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages; 4) Buddy training via webinars
62191177|NCT01814072|EXPERIMENTAL|Condition 28|1) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages; 4) Recommendation to use meal replacements
62572429|NCT05939960||Normal group|GCT time within normal range；Normal coagulation function
62191178|NCT01814072|EXPERIMENTAL|Condition 29|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Buddy training via webinars
62191179|NCT01814072|EXPERIMENTAL|Condition 30|1) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements
62191180|NCT01814072|EXPERIMENTAL|Condition 31|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages
62397015|NCT05183633||One single trial|
62397016|NCT05228873||Investigational arm|Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days plus the Standard of Care (SOC) for the treatment of COVID-19 acute stage based on the Vietnam Ministry of Health guideline at this time
62397017|NCT05228873||• Controlled arm|Patient who receive the Standard of Care (SOC) for the treatment of COVID-19 acute stage based on the Vietnam Ministry of Health guideline at this time
62397018|NCT02257502|EXPERIMENTAL|aflibercept|intravitreal injection of aflibercept (EYLEA)
62397019|NCT00823771||Reviewed by radiation oncologist|
62397020|NCT00823771||Reviewed by general practitioner|
62397021|NCT04272320|NO_INTERVENTION|Group C|
62397022|NCT04272320|ACTIVE_COMPARATOR|Group TFP|Transversalis fascia plane block, before the surgical procedure.
62572430|NCT05939960||hypercoagulable group|GCT time reduction； Normal coagulation function,
62005440|NCT05009251|NO_INTERVENTION|No-Contact Control|Subjects in the no-contact control arm will receive no additional pro-vaccination intervention beyond the health system's normal efforts. Although some patients are currently targeted for flu vaccination encouragement due to a conventional non-ML assessment that they are at high risk for complications, these patients are not told that they are at high risk or that they have been targeted.
62397023|NCT05959551|EXPERIMENTAL|left DLPFC stimulation|HD-tDCS will be used to deliver direct current to the target via rubber electrodes and HD-tDCS gels. The 9 electrodes (8 channels + 1 ground) positions and current intensity will be determined based on computer simulation using HDTargets software (Soterix Inc.) that results in maximum focal current on the left dorsolateral prefrontal cortex (DLPFC; x=-44, y=10, z=30) with inward field orientation. The peak current will not exceed 2 mA. A constant current will be delivered for 20 minutes.
62397024|NCT05959551|EXPERIMENTAL|right DLPFC stimulation|HD-tDCS will be used to deliver direct current to the target via rubber electrodes and HD-tDCS gels. The 9 electrodes (8 channels + 1 ground) positions and current intensity will be determined based on computer simulation using HDTargets software (Soterix Inc.) that results in maximum focal current on the right dorsolateral prefrontal cortex (DLPFC; x=+42, y=+14, z=+30) with inward field orientation. The peak current will not exceed 2 mA. A constant current will be delivered for 20 minutes.
62397025|NCT05959551|EXPERIMENTAL|left IPL stimulation|HD-tDCS will be used to deliver direct current to the target via rubber electrodes and HD-tDCS gels. The 9 electrodes (8 channels + 1 ground) positions and current intensity will be determined based on computer simulation using HDTargets software (Soterix Inc.) that results in maximum focal current on the left intraparietal lobe (IPL; x=-50, y=-36, z=+42) with inward field orientation. The peak current will not exceed 2 mA. A constant current will be delivered for 20 minutes.
62397026|NCT05959551|EXPERIMENTAL|VLPFC-PCC stimulation|HD-tDCS will be used to deliver direct current to the target via rubber electrodes and HD-tDCS gels. The 9 electrodes (8 channels + 1 ground) positions and current intensity will be determined based on computer simulation using HDTargets software (Soterix Inc.) that results in maximum focal current on the left ventrolateral prefrontal cortex (VLPFC; x=-50, y=+26, z=+8) and posterior cingulate cortex (PCC; x=1, y=-61, z=38) with inward field orientation. The peak current will not exceed 2 mA. A constant current will be delivered for 20 minutes.
62397027|NCT05959551|SHAM_COMPARATOR|Sham stimulation|One of the above three targets will be randomly selected. The current will be applied for 30 seconds ramp-up followed by 30 seconds ramp-down.
62397028|NCT04642326|EXPERIMENTAL|Test Group: experimental - UVC Therapy applied|Test: Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy
62397029|NCT04642326|NO_INTERVENTION|Control Group|Control: Antiviral + Antimalarial + Antibiotic Treatment
62572431|NCT03444181|EXPERIMENTAL|Music lessons|
62572432|NCT03444181|ACTIVE_COMPARATOR|Training intervention|
62572433|NCT03444181|NO_INTERVENTION|No intervention|
62005441|NCT05009251|EXPERIMENTAL|Reminder Control|Subjects in the reminder control arm will receive messages reminding them to get the flu shot without being advised of their risk status.
62005442|NCT05009251|EXPERIMENTAL|High Risk Only|Subjects in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications, without specifying how or why the health system believes this to be the case.
62005443|NCT05009251|EXPERIMENTAL|High Risk with Explanation Based on Medical Records|Subjects in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications via review of their medical records and will be provided a human-understandable short list of the top factors from their medical record that explain their risk.
62005444|NCT05009251|EXPERIMENTAL|High Risk with Explanation Based on Algorithm|Subjects in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records by a computer algorithm and will be provided a human-understandable short list of the top factors from their medical record that explain their risk.
62005445|NCT03057691||No depression/anxiety|patients suffered from ACS who have undergone PCI without depression or anxiety
62005446|NCT03057691||Depression|patients suffered from post-ACS depression who have undergone PCI
62005447|NCT03057691||Anxiety|patients suffered from post-ACS anxiety who have undergone PCI
62005448|NCT03057691||Depression with anxiety|patients suffered from post-ACS depression with anxiety who have undergone PCI
62191181|NCT01814072|EXPERIMENTAL|Condition 32|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages, 6) Buddy training via webinars
62191182|NCT03720223|EXPERIMENTAL|Liposomal Bupivacaine|20ml Liposomal Bupivacaine 1.3% (13.3mg/mL), injected to the buccal mucosal graft harvest site.
62005449|NCT02756793|ACTIVE_COMPARATOR|Standard of Care Treatment|"Patient treatment may include the following 3 options, at the discretion of the treating physicians:~* Continue with current systemic agent(s)~* Observation~* Switch to next-line treatment"
62005450|NCT02756793|EXPERIMENTAL|Stereotactic Ablative Radiotherapy (SABR)|SABR is delivered to all sites of progressive disease with continuation of current systemic agents. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in Arm 1.
62005451|NCT01800916|EXPERIMENTAL|Treatment sequence 1|"The subjects randomised to Treatment sequence 1 are going to test~1. Coloplast Adhesive baseplate A (A)~2. Coloplast Adhesive baseplate B (B)~3. SenSura 1-piece (S)~The subjects test the three test products in a randomised order: ABS; BSA; SAB"
62191183|NCT03720223|NO_INTERVENTION|Control|No local anesthetics injected to the buccal mucosal graft harvest site
62397030|NCT01249482||Late eradication|Group B (n=100) will be given rabeprazole 20 mg qd for 8 weeks and discontinued for 2 weeks. Then, H. pylori eradication with triple therapy will be given for one week, followed by rabeprazole 20 mg qd for 7 weeks.
62397031|NCT01249482||Negative HP|For patients with negative H. pylori infection (n=100), proton-pump inhibitor with rabeprazole 20 mg qd will be given for 8 weeks and discontinued.
62397032|NCT01249482||Early eradication|Group A (n=100) will be given initial H. pylori eradication with triple therapy for one week, followed by proton-pump inhibitor with rabeprazole 20 mg qd for 7 weeks.
62005452|NCT01800916|EXPERIMENTAL|Treatment sequence 2|"The subjects randomised to Treatment sequence 2 are going to test~1. Coloplast Adhesive baseplate B (B)~2. Coloplast Adhesive baseplate C (C)~3. SenSura 1-piece (S)~The subjects test the three test products in a randomised order: CBS; BSC; SCB"
62191184|NCT02840864|EXPERIMENTAL|Arm 1|Sonographically assisted breast surgery
62191185|NCT02840864|ACTIVE_COMPARATOR|Arm 2|Conventional breast surgery
62397033|NCT05882045|EXPERIMENTAL|Retatrutide Dose 1|Participants will receive retatrutide subcutaneously (SC).
62397034|NCT05882045|EXPERIMENTAL|Retatrutide Dose 2|Participants will receive retatrutide SC.
62397035|NCT05882045|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62397036|NCT02561689|EXPERIMENTAL|Fissure sealant material 1|Fissure sealing with Delton FS+ Fissure sealing withClinpro Sealant Fissure sealing withGrandio Seal Fissure sealing withControl Seal Fissure sealing withUltraSeal XT+ UltraSeal XT hydro
62397037|NCT02561689|EXPERIMENTAL|Fissure sealant material 2|Fissure sealing with Delton FS+ Fissure sealing withClinpro Sealant Fissure sealing withGrandio Seal Fissure sealing withControl Seal Fissure sealing withUltraSeal XT+ UltraSeal XT hydro
62397038|NCT02173470|NO_INTERVENTION|Control|Routine clinical care (which includes a conventional chest X-ray).
62005453|NCT01800916|EXPERIMENTAL|Treatment sequence 3|"The subjects randomised to Treatment sequence 3 are going to test~1. Coloplast Adhesive baseplate A (A)~2. Coloplast Adhesive baseplate B (C)~3. SenSura 1-piece (S)~The subjects test the three test products in a randomised order: ACS; CSA; SAC"
62005454|NCT03595371|EXPERIMENTAL|dapansutrile capsules|Hard gelatin capsules containing 100 mg of dapansutrile (API)
62191186|NCT05895708|EXPERIMENTAL|Specified strengthening and stretching|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretching (cervical extensors and pectoral muscles) exercises based on Harman and Mostafa et al's approach. This exercise program will be repeated 4 times per week for 10 weeks, and each session lasted for 30 minutes.
62191187|NCT05895708|SHAM_COMPARATOR|General Exercise group|The program will consist of regular general postural exercises such as postural awareness exercises as well as general strengthening exercises such as range of motion exercises for the upper quadrant. The program will also be repeated 4 times per week for 10 weeks, with each session lasting 30 minutes
62191188|NCT03564197|OTHER|Nivolumab|nivolumab containing treatment according to label
62191189|NCT02453061|PLACEBO_COMPARATOR|Placebo group|Subjects will receive safflower oil at 1g/kg/day for 6 months (months 0 - 6) and triheptanoin oil at 1g/kg/day for 6 months (months 7 - 12)
62191190|NCT02453061|ACTIVE_COMPARATOR|Triheptanoin group|Subjects will receive triheptanoin oil at 1g/kg/day for 6 months (months 0 - 6) and triheptanoin oil at 1g/kg/day for 6 months (months 7 - 12)
62191191|NCT03563625|ACTIVE_COMPARATOR|Caudal block|Caudal block with 1mg/kg bupivacaine 0.25%.
62191192|NCT03563625|ACTIVE_COMPARATOR|Wound infiltration|Local wound infiltration with 1mg/kg bupivacaine 0.25%.
62191193|NCT00807105|EXPERIMENTAL|depressive patients|patients suffering from deppresion
62191194|NCT04360785|EXPERIMENTAL|Methotrexate + Adalimumab|Experimental group : patients will receive 2 subcutaneous injections of methotrexate in addition of the usual adalimumab
62191195|NCT04360785|NO_INTERVENTION|Adalimumab|Reference group : patient will receive adalimumab as usual to treat spondyloarthritis
62191196|NCT04530604|EXPERIMENTAL|Defibrotide|
62780332|NCT03298763|ACTIVE_COMPARATOR|Phase 2 Intervention Arm|"Cisplatin 75mg/m2 and Pemetrexed 500mg/m2 on day 1 followed by MSCTRAIL (at the recommended phase 2 dose) on day 2. This schedule will be repeated after 21 days for 3 cycles.~Patients will then receive a further 1-3 cycles of pemetrexed/ cisplatin alone. They may then be eligible for maintenance pemetrexed according to clinical response as directed by their Oncologist in line with local standard of care."
62005455|NCT02223767|EXPERIMENTAL|Verum transcranial magnetic stimulation (TMS)|10 Hz TMS over medial prefrontal cortex
62005456|NCT02223767|EXPERIMENTAL|Sham transcranial magnetic stimulation (TMS)|10 Hz sham TMS over medial prefrontal cortex
62005457|NCT00678691|EXPERIMENTAL|A,1|armodafinil
62780333|NCT03298763|PLACEBO_COMPARATOR|Phase 2 Control Arm|"cisplatin 75mg/m2 and pemetrexed 500mg/m2 on day 1 and placebo on day 2. This will be repeated after 21 days for up to 3 cycles.~Patients will then receive a further 1-3 cycles of pemetrexed/ cisplatin alone. They may then be eligible for maintenance pemetrexed according to clinical response as directed by their Oncologist in line with local standard of care."
62780334|NCT05917171|EXPERIMENTAL|painTRAINER intervention|40 Spanish speaking Hispanic and Latine participants will participate in an 8 week online pain coping skills training program designed to address cancer-related pain.
62780335|NCT06153472|EXPERIMENTAL|VR-based sensory stimulation|Participants in the experimental group will receive VR-based sensory stimulation.
62780336|NCT06153472|NO_INTERVENTION|Usual care|Participants in the control group will receive usual care.
62005458|NCT00678691|PLACEBO_COMPARATOR|A,2|placebo
62191197|NCT02165995|EXPERIMENTAL|Navigated Transcranial Magnetic Stimulation (nTMS)|Participant assessed by nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Motor mapping and speech mapping performed at these visits. This should take about 1½-2 hours to complete.
62191198|NCT02407210|EXPERIMENTAL|azilsartan group|Once-daily oral administration of 20 or 40 mg tablet before or after breakfast
62191199|NCT02407210|ACTIVE_COMPARATOR|olmesartan medoxomil group|Once-daily oral administration of 20 or 40 mg tablet before or after breakfast
62191200|NCT03473210|ACTIVE_COMPARATOR|Amniopatch group|in which women were subjected to active treatment included prophylactic antibiotics and antenatal corticosteroids with an effort to seal the ruptured membranes using the amniopatch technique.
62191201|NCT03473210|ACTIVE_COMPARATOR|control group|in which women were subjected to conservative management with prophylactic antibiotics and antenatal corticosteroids
62191202|NCT00825305|EXPERIMENTAL|Zagreb (2-1-1)|Rabies PCEC vaccine was applied according Zagreb schedule with 2 vaccinations on day 0, 1 vaccination on day 7 and day 21, respectively
62191203|NCT00825305|ACTIVE_COMPARATOR|Essen (1-1-1-1-1)|Rabies PCEC vaccine was applied according Essen schedule, i.e. 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.
62191204|NCT02242643|EXPERIMENTAL|FluLaval™ Quadrivalent Group|"Subjects in this group received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of FluLaval™ Quadrivalent vaccine.~The vaccine was administered intramuscularly into the anterolateral region of the thigh (subjects below 12 months of age) or in the deltoid muscle of the non-dominant arm (subjects ≥12 months of age)."
62191205|NCT02242643|ACTIVE_COMPARATOR|Fluzone® Quadrivalent Group|"Subjects in this group received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluzone® Quadrivalent vaccine.~The vaccine was administered intramuscularly into the anterolateral region of the thigh (subjects below 12 months of age) or in the deltoid muscle of the non-dominant arm (subjects ≥12 months of age)."
62397039|NCT02173470|EXPERIMENTAL|CT scan|Routine clinical care, which includes a chest x-ray, with an additional ultra low-dose non contrast enhanced chest CT with IR (performed preoperatively).
62397040|NCT04149145|EXPERIMENTAL|M4344+Niraparib|all PARP resistant, recurrent ovarian cancer
62572434|NCT06314672|EXPERIMENTAL|Phase I (interview, discussion, review, AEP, education)|Community members, clinic staff, and providers undergo in-depth interview for intervention development on study. Researchers review baseline data on referral patterns and accrual of racial and ethnic minorities to clinical trials in each clinic site. Providers, clinical staff, and research team participate in implementation discussion. AEP strategies developed and initiated in one OSUCCC/James clinic. Providers and community members participate in educational sessions on study. (Year 1)
62005459|NCT05835453|ACTIVE_COMPARATOR|Conventional tray|Two simple randomizations will be performed using a software program freely available online (www.sealedenvelop.com). For the first randomization, for each participant, the group (type of tray) will be randomized and it will always be applied to the participant's right hemiarch (n=40) according to the model: conventional tray or clear aligner. Subsequently, the second randomization will be carried out, which will define the alternate days for the use of the tray and the aligner: Monday, Wednesday and Friday or Tuesday, Thursday and Saturday.
62191206|NCT04231045||Patients on PiCCO monitoring system|ALL intensive care patients on PiCCO monitoring system and over 18 years old and on PiCCO for more than 24 hours. Those medical or surgical patients admitted in a UK NHS unit, elective, semi-elective or emergency admission.
62191207|NCT06420050|EXPERIMENTAL|Instagram Intervention|
62191208|NCT06420050|NO_INTERVENTION|Control|
62005460|NCT05835453|ACTIVE_COMPARATOR|Clear aligner|The patients will use the clear aligner on their right hemiarch and according to the second randomization it will be applied on Monday, Wednesday and Friday or Tuesday, Thursday and Saturday.
62005461|NCT00145509|ACTIVE_COMPARATOR|Asenapine|Asenapine
62191209|NCT01390155||1|Patients undergoing temporary myocardial ischemia produced by a one-minute balloon occlusion of the proximal left anterior descending coronary artery.
62572435|NCT06314672|EXPERIMENTAL|Phase II (AEP, education, interviews)|Participants participate in the AEP in the remaining clinics at OSUCCC/James and community clinics on study. Community members and providers participate in culturally tailored educational activities. Providers, patients, and community members participate in interviews to explore current barriers to referral and participation on study. (Years 2-4)
62191210|NCT01390155||2|Patients undergoing temporary myocardial ischemia produced by a one-minute balloon occlusion of the proximal left circumflex artery.
62572436|NCT06314672|EXPERIMENTAL|Phase III (interview)|Providers, clinic staff, patients, and community members participate in interviews to explore current barriers to referral and participation. (Year 5)
62005462|NCT00145509|PLACEBO_COMPARATOR|Placebo|Placebo
62191211|NCT01390155||3|Patients undergoing temporary myocardial ischemia produced by a one-minute occlusion of the proximal right coronary artery.
62191212|NCT01390155||4|Patients undergoing temporary myocardial ischemia produced by a one-minute occlusion of the target vessel.
62191213|NCT05760521|EXPERIMENTAL|Arm A: Provider Educational Intervention|Providers receiving education/support from neurology teams, Adult Gerontological Nurse Practitioner (AGNP) assessments/recommendations, and training of office staff regarding ADRD and community resources support for patients/caregivers.
62191214|NCT05760521|NO_INTERVENTION|Arm B: Provider Control|Providers receiving AGNP assessments/recommendations only.
62191215|NCT04025268|ACTIVE_COMPARATOR|pregnant women receiving group prenatal care (GPNC)|Overweight/obese pregnant women will be recruited from the prenatal care clinic at the Lyndon B Johnson Tropical Medical Center (LBJTMC) in Pago Pago, American Samoa. These women will be randomized to receive the 10-session GPNC intervention.
62780337|NCT00912457|EXPERIMENTAL|Donepezil|Donepezil-treated sleep apnea patients
62780338|NCT00912457|PLACEBO_COMPARATOR|Placebo|Placebo-treated sleep apnea patients
62780339|NCT01949610|EXPERIMENTAL|14C-JNJ26489112|
62005463|NCT04465045||Unique cohort|All women, 18 to 43 years, operated from laparoscopy-hysteroscopy for unexplained infertility in montpellier university hospital
62191216|NCT04025268|ACTIVE_COMPARATOR|pregnant women receiving standard of care (SOC)|Overweight/obese pregnant women will be recruited from the prenatal care clinic at the Lyndon B Johnson Tropical Medical Center (LBJTMC) in Pago Pago, American Samoa. These women will be randomized to continue with standard of care (SOC) prenatal care visits.
62191217|NCT05563389|PLACEBO_COMPARATOR|PLACEBO|placebo formula
62191218|NCT05563389|ACTIVE_COMPARATOR|statin|atorvastatin tablets
62191219|NCT06413719||No Intervention|Children with probable or definite sensory processing challenges per the SSP-1
62397041|NCT04502862|EXPERIMENTAL|Dupilumab|Participants received a loading dose of 400 mg of dupilumab (2 injections × 200 mg) SC on Day 1, followed by 200 mg Q2W for 12 weeks.
62397042|NCT04502862|PLACEBO_COMPARATOR|Placebo|Participants received an initial loading dose of matching placebo (2 injections of placebo) SC on Day 1, followed by 1 injection of placebo Q2W for 12 weeks.
62397043|NCT03948061|EXPERIMENTAL|Cherry juice followed by placebo|Sweet cherry juice concentrate will be consumed twice daily for 6 weeks, followed by consumption of placebo beverage twice daily for 6 weeks.
62397044|NCT03948061|EXPERIMENTAL|Placebo beverage followed by cherry juice|Placebo beverage will be consumed twice daily for 6 weeks, followed by consumption of sweet cherry juice concentrate twice daily for 6 weeks.
62397045|NCT03007680|EXPERIMENTAL|Core muscle activation|Core muscle will be activated by physical fitness using plank, crunch and leg extension.
62397046|NCT03007680|NO_INTERVENTION|No core muscle activation|
62397047|NCT04236986|NO_INTERVENTION|Baseline [11C]PBR28 PET Scan|Subjects will complete a 120-minute baseline \[11C\]PBR28 PET scan.
62397048|NCT04236986|EXPERIMENTAL|Post-LPS [11C]PBR28 PET Scan|Subjects will complete a second120-minute \[11C\]PBR28 PET scan 3-hours after LPS administration (1.0ng/kg; IV)
62005464|NCT04046471|OTHER|Individual In-Person|
62005465|NCT04046471|OTHER|Group Remote|
62397049|NCT02928900|EXPERIMENTAL|Intervention period|In this stepped-wedge trial design, the experimental arm refers to the time period when the study sites receive the clinician training intervention. The intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care providers who serve HIV-positive adolescents and youth.
62397050|NCT02928900|NO_INTERVENTION|Control period|In this stepped-wedge trial design, the no intervention arm refers to the time period before the study sites receive the clinician training intervention, during which standard of care is provided.
62397051|NCT02735772|OTHER|cystocele|"Arm: Patients with paravaginal defect cystocele~Intervention: transobturator approach for paravaginal repair"
62191220|NCT02609542||STOL group|"STOL children will be recruited in the neuropediatric unit at the GHICL in Lille. Children will be followed and we will determine if capacities of verbal memory of the children presenting STOL diagnosed at an early stage of their development (before 6 years) are predictive of the evolution of the disorder according to their cognitive profile and more specifically, their language profile as well as their tests performances. The participants' eye movements ( visual world paradigm or eye tracking) will be recorded in order to determine the interplay between linguistic and visual information processing.~Patients with a persistent STOL will be identified at the end of the follow up."
62397052|NCT06209268|ACTIVE_COMPARATOR|paricalcitol group|
62397053|NCT06209268|PLACEBO_COMPARATOR|placebo group|
62397054|NCT01992146|PLACEBO_COMPARATOR|Placebo|Change in Pain Ratings (NRS) at the surgical site and at the mirror-site in the contralateral groin six to eight weeks after unilateral herniotomy following administration of placebo.
62397055|NCT01992146|EXPERIMENTAL|Target-controlled naloxone-infusion (total dose: 3.25 mg/kg)|Change in Pain Ratings (NRS) at the surgical site and at the mirror-site in the contralateral groin six to eight weeks after unilateral herniotomy following administration of naloxone.
62397056|NCT02363504||Healthy older controls|7 Tesla MRI with memory task and non-invasive neurostimulation
62397057|NCT02363504||Prodromal Alzheimer's disease patients|7 Tesla MRI with memory task and non-invasive neurostimulation
62397058|NCT06234501|EXPERIMENTAL|Vitamin-B6|Participants will consume one high-dose Vitamin B6 100 mg tablet orally once daily for one month. Vitamin B6 will be provided as Pyridoxal-5'-Phosphate (PLP)
62397059|NCT06234501|PLACEBO_COMPARATOR|Placebo|Participants will consume a Placebo tablet matching the appearance of the Vitamin B6 tablets in the Experimental arm orally once daily for one month.
62397060|NCT03360695|EXPERIMENTAL|Proactive Psychiatry Consultation (PPC) - PILOT|"Proactive Psychiatry Consultation and Case Management is:~1. Patient-centered: Based on the patient's needs, the team aims to build a relationship, increase engagement, and promote continuity.~2. Team-based: A psychiatrist and case manager identify goals for cancer treatment, assess psychiatric history and symptoms with a focus on impact on cancer care, collaborate with community-based clinicians and caregivers, and address barriers to care.~3. Integrated into cancer care delivery: The psychiatry and oncology teams collaborate starting at cancer diagnosis to support patient through cancer treatment.~4. Systematic: The team monitors psychiatric and cancer-related symptoms and cancer care delivery to measure progress toward goals and rapidly adjust treatment as needed."
62397061|NCT03360695|EXPERIMENTAL|Proactive Psychiatry Consultation (PPC) - Randomized Trial|"Proactive Psychiatry Consultation and Case Management is:~1. Patient-centered: Based on the patient's needs, the team aims to build a relationship, increase engagement, and promote continuity.~2. Team-based: A psychiatrist and case manager identify goals for cancer treatment, assess psychiatric history and symptoms with a focus on impact on cancer care, collaborate with community-based clinicians and caregivers, and address barriers to care.~3. Integrated into cancer care delivery: The psychiatry and oncology teams collaborate starting at cancer diagnosis to support patient through cancer treatment.~4. Systematic: The team monitors psychiatric and cancer-related symptoms and cancer care delivery to measure progress toward goals and rapidly adjust treatment as needed."
62397062|NCT03360695|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC) - Randomized Trial|Study staff will send a templated email to the treating oncologist at enrollment informing the oncologists of the psychiatric diagnosis and available psychosocial services. Study staff will also inform the patient and caregiver of available psychosocial services.
62780340|NCT02119390|OTHER|Standard Care|Participants in the Standard Care group will complete a demographic questionnaire at the time of consent as well as other questionnaires during the course of the study. They will receive standard clinical care.
62005466|NCT04309435|EXPERIMENTAL|Self-esteem intervention|"The self-esteem intervention involves 6 x 1-hour therapy sessions, each of which will be provided by a fully trained and supervised psychological therapist over an 8-week period (to allow for cancelled appointments etc). It will involve the following elements:~* Engagement and listening~* Positive regard and empathy~* Collaboration~* Development of a shared understanding of low self-esteem (a 'psychological formulation')~* Provision of written or audio-visual information relating to low self-esteem~* Between-session activity for participant~* Provision of structured self-help material relating to low self-esteem~* Testing of beliefs related to low self-esteem~* Practicing new strategies related to low self-esteem~* Development of a shared plan to maintain gains in self-esteem"
62005467|NCT04309435|PLACEBO_COMPARATOR|Self-esteem control group|'Assessment and support' for participants with low self-esteem will also involve 6 x 1-hour sessions with a psychological therapist, over a period of 8 weeks. However, in these meetings, the therapist will work in collaboration with the person to complete a more detailed assessment of factors which help or hinder their decision-making capacity. They will provide engagement, listening, positive regard and empathy, but they will not develop a psychological formulation, nor will they provide the person with information relating to their problems. They will also not provide self-help material, or encourage the person to test their beliefs, practice new strategies or develop a shared plan for the future. Once the trial is over, however, the therapist will offer to meet with the person to share the results of the assessment and develop a psychological formulation. With the participant's consent, this information will also be shared with the clinical team.
62191221|NCT02609542||Control group|Children with no language development disorder willing to participate in the study will be recruited at school. The participants' eye movements ( visual world paradigm or eye tracking) will be recorded in order to determine the interplay between linguistic and visual information processing.
62191222|NCT02637102||Patients undergoing cardiac or vascular surgery|
62780341|NCT02119390|EXPERIMENTAL|Pill Trial+|Participants in the Pill Trial+ group will complete a demographic questionnaire at the time of consent as well as other questionnaires during the course of the study. They will receive standard clinical care plus three 25-minute individualized, behavioral, staff-delivered intervention sessions at HAART initiation, and 1-, and 3-month follow-up visits. Two brief booster sessions will also be provided following sessions 1 (in clinic) and 2 (by phone).
62191223|NCT02335905|EXPERIMENTAL|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if \> 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour). The dose may vary with age.
62191224|NCT05038540|EXPERIMENTAL|Virtual reality application|Application of virtual reality glasses during scaling and root planning to a quadrant.
62191225|NCT05038540|ACTIVE_COMPARATOR|No application|No application of virtual reality glasses during scaling and root planning to a quadrant.
62191226|NCT01776164||Patient with FRDA|Patients affected by Friedreich's ataxia
62572437|NCT01548040|EXPERIMENTAL|quadriceps NMES using Kneehab XP|All subjects in the treatment group will receive quadriceps Neuro Muscular Electrical Stimulation (NMES) using Kneehab XP on the affected leg, 20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.group will also complete the standard TKA post-surgery rehabilitation program used at the Hawkins Foundation
62005468|NCT04309435|EXPERIMENTAL|Self-stigma intervention|"The self-stigma intervention involves 6 x 1-hour therapy sessions, each of which will be provided by a fully trained and supervised psychological therapist over an 8-week period (to allow for cancelled appointments etc). It will involve the following elements:~* Engagement and listening~* Positive regard and empathy~* Collaboration~* Development of a shared understanding of high self-stigma (a 'psychological formulation')~* Provision of written or audio-visual information relating to self-stigma~* Between-session activity for participant~* Provision of structured self-help material relating to self-stigma~* Testing of beliefs related to self-stigma~* Practicing new strategies related to self-stigma~* Development of a shared plan to maintain reductions in self-stigma"
62191227|NCT01776164||Healthy controls|Healthy volunteers age- and gender-matched with no neurological disease identified.
62191228|NCT00832468|PLACEBO_COMPARATOR|sham ear acupressure|
62191229|NCT00832468|EXPERIMENTAL|ear acupressure|
62191230|NCT04715555||Atrial Fibrillation|Participants with a diagnosis of atrial fibrillation (AF) who exhibited AF in previous AF screening (as part of the SAFER Programme).
62191231|NCT04715555||Non-Atrial Fibrillation|Participants without a diagnosis of atrial fibrillation (AF) who have previously undergone AF screening (as part of the SAFER Programme).
62191232|NCT04945447|EXPERIMENTAL|Intervention group - Medical clinics|Medical clinics receiving the pharmacist intervention described in the intervention group for patient level
62397063|NCT04291885|EXPERIMENTAL|Avelumab|6 months of Avelumab at a dose of 800mg as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)
62191233|NCT04945447|NO_INTERVENTION|Control group - medical clinics|All medical clinics that are enrolled in the trial will eventually receive the intervention at some point. As some medical clinics act as the control group to being with.
62191234|NCT04945447|EXPERIMENTAL|Intervention group - patient level|"The intervention consists of two subgroups: Intervention pharmacist and intervention proposals. As the pharmacist conducts medication reviews of the polypharmacy patients in the medical clinic they can make a note to the physician about fx a specific medication the physician needs to pay attention to. These polypharmacy patients are enrolled in the group intervention proposals and are asked to complete questionaries at baseline and follow-up. Ultimately, it is up to the physician to react to the note in the polypharmacy patients medical record. Therefore the pharmacist only makes a note in the journal of the patient and does nothing else.~The group intervention pharmacist is polypharmacy patients where the pharmacist conducts a medication review and develops suggested interventions proposals for each participant"
62397064|NCT04291885|PLACEBO_COMPARATOR|Placebo|6 months of Placebo as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)
62005469|NCT04309435|PLACEBO_COMPARATOR|Self-stigma control group|'Assessment and support' for participants with high self-stigma will also involve 6 x 1-hour sessions with a psychological therapist, over a period of 8 weeks. However, in these meetings, the therapist will work in collaboration with the person to complete a more detailed assessment of factors which help or hinder their decision-making capacity. They will provide engagement, listening, positive regard and empathy, but they will not develop a psychological formulation, nor will they provide the person with information relating to their problems. They will also not provide self-help material, or encourage the person to test their beliefs, practice new strategies or develop a shared plan for the future. Once the trial is over, however, the therapist will offer to meet with the person to share the results of the assessment and develop a psychological formulation. With the participant's consent, this information will also be shared with the clinical team.
62191235|NCT04945447|NO_INTERVENTION|Control group - patient level|The control group will have access to usual care and other health services within the healthcare systems. Participants randomised to the control group are invited to participate in the evaluation of the current treatment in the primary health care sector
62397065|NCT00649220|EXPERIMENTAL|Memantine|
62397066|NCT04338685|EXPERIMENTAL|Part A1-1 mg RO7119929|Participants received 1mg RO7119929 every week in 3-week cycles.
62397067|NCT04338685|EXPERIMENTAL|Part A1-3 mg RO7119929|Participants received 4 mg RO7119929 every week in 3-week cycles
62397068|NCT04338685|EXPERIMENTAL|Part A1 - 6 mg RO7119929|Participants received 6 mg RO7119929 every week in 3-week cycles
62397069|NCT04338685|EXPERIMENTAL|Part A1 -9 mg RO7119929|Participants received 9 mg RO7119929 every week in 3-week cycles
62397070|NCT04338685|EXPERIMENTAL|Part B1-5 mg RO7119929|Participants with both available and evaluable tumor biopsy samples received 5 mg RO7119929 on Cycle 1 Day 1 to month 12
62397071|NCT04338685|EXPERIMENTAL|Part A2- 2/5/5 mg RO7119929|Participants received RO7119929 QW with step-up dosing of 2/5/5 mg during Cycle 1.
62191236|NCT00902798|EXPERIMENTAL|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
62191237|NCT00902798|ACTIVE_COMPARATOR|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.~Time commitment: about 1 hour per week; Location: Pittsburgh, PA only"
62191238|NCT01022411|EXPERIMENTAL|A|Brown rice
62191239|NCT01022411|PLACEBO_COMPARATOR|B|White rice
62191240|NCT04699968|EXPERIMENTAL|Treatment group A|
62191241|NCT04699968|EXPERIMENTAL|Treatment group B|
62191242|NCT00356759|SHAM_COMPARATOR|12-weekly INR|Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times
62780342|NCT01364389|EXPERIMENTAL|ACZ885|On day 1, patients received a single intravenous dose of ACZ885 3mg/kg along with a placebo intravenous infusion in a double dummy manner to maintain the blind. On day 15, partial and complete responders continued in the open label phase of this treatment arm where they were eligible to receive one re-dose of ACZ885 upon confirmed disease flare. Non-responders started a 20 mg dose cycle of prednisone or prednisolone followed by standard steroid tapering.
62780343|NCT01364389|EXPERIMENTAL|AIN457|On day 1, patients received a single intravenous dose of AIN457 3mg/kg along with a placebo intravenous infusion in a double dummy manner to maintain the blind. On day 15, partial and complete responders continued in the open label phase of this treatment arm where they were eligible to receive one re-dose of AIN457 upon confirmed disease flare. Non-responders started a 20 mg dose cycle of prednisone or prednisolone followed by standard steroid tapering.
62191243|NCT00356759|NO_INTERVENTION|Standard management|Dosing warfarin every 4 weeks, all INRs true values
62191244|NCT02557126|EXPERIMENTAL|URC102|URC102
62005470|NCT04309435|EXPERIMENTAL|Jumping to conclusions intervention group|"The 'jumping-to conclusions' (JTC) intervention involves 6 x 1-hour therapy sessions, each of which will be provided by a fully trained and supervised psychological therapist over an 8-week period (to allow for cancelled appointments etc). It will involve the following elements:~* Engagement and listening~* Positive regard and empathy~* Collaboration~* Development of a shared understanding of role of JTC (a 'psychological formulation')~* Provision of written or audio-visual information relating to JTC~* Between-session activity for participant~* Provision of structured self-help material relating to JTC~* Testing of beliefs related to JTC~* Practicing new strategies related to reducing JTC~* Development of a shared plan to maintain reductions in JTC"
62191245|NCT02557126|PLACEBO_COMPARATOR|Placebo|Placebo
62191246|NCT02106195|EXPERIMENTAL|Belumosudil 200 mg|Belumosudil 200 mg (two 100 mg capsules) orally once daily for 28 days
62397072|NCT04338685|EXPERIMENTAL|Part A2- 2/5/6 mg RO7119929|Participants received RO7119929 QW with step-up dosing of 2/5/6 mg during Cycle 1.
62191247|NCT01206400||pioglitazone vs placebo|15 patients in pioglitazone group and 15 in placebo group
62191248|NCT04860856|EXPERIMENTAL|Hematoma block|Fracture site injection of 20 mL of 0.5% ropivacaine with an 18-gauge needle (150 mm length).
62191249|NCT04860856|PLACEBO_COMPARATOR|Normal saline injection|Fracture site injection of 20ml of normal saline.
62191250|NCT03054337|EXPERIMENTAL|Vadadustat, Dose 1|Daily oral dose
62397073|NCT04338685|EXPERIMENTAL|Part A3-4 mg RO7119929|Participants received tocilizumab pre-treatment on Cycle 1 Day 1, approximately 2 hours prior to RO7119929 administration and 4 mg RO7119929 every week in 3-week cycles
62191251|NCT03054337|EXPERIMENTAL|Vadadustat, Dose 2|Daily oral dose
62191252|NCT03054337|EXPERIMENTAL|Vadadustat, Dose 3|Daily oral dose
62191253|NCT03054337|PLACEBO_COMPARATOR|Placebo|Daily oral dose
62191254|NCT01341847|ACTIVE_COMPARATOR|Water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of the colonoscope during insertion since the scope is inserted into the anus until reach the cecum. Water will be infused as needed under endoscopist judgement through the adaptor on biopsy channel with endoscopic washer pump. The usual air insufflation will be used during colonoscope withdrawal to facilitate mucosal examination and perform any other intervention, such as biopsy
62191255|NCT01341847|OTHER|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
62191256|NCT03537235|EXPERIMENTAL|Libramed|3 tablets of Libramed 2 twice a day 15 minutes before meals for 3 months.
62191257|NCT03537235|PLACEBO_COMPARATOR|Placebo|3 tablets of Placebo 2 twice a day 15 minutes before meals for 3 months.
62191258|NCT05592184||Dual task|Exercise (elastic resistance) with dual task The dual task will be self-regulated and will consist of subtracting 3 by 3 from 100, and performing the maximum number of repetitions possible.
62191259|NCT05592184||Single task|exercise (elastic resistance) without dual task
62191260|NCT06099119|EXPERIMENTAL|experimental arm|Creon 35.000 Ph.U (R) at a fixed dose of 3 capsules orally with main meals (breakfast, lunch and dinner) and 2 capsules with snacks over 6 months post randomization.
62191261|NCT06099119|OTHER|control arm|Creon 35.000 Ph.U (R) at a fixed dose of 3 capsules orally with main meals (breakfast, lunch and dinner) and 2 capsules with snacks during the last 3 months post randomization.
62191262|NCT05129410|EXPERIMENTAL|A single-arm open-label pilot observational study|Patients were received prednisone(0.5mg-1mg/kg/day) and a combination with MMF (1.5g-2.0g/d).
62191263|NCT02760901|ACTIVE_COMPARATOR|Mannitol group|patients received mannitol 20 % 100 ml half an hour before cisplatin and saline hydration.
62397074|NCT02185729|ACTIVE_COMPARATOR|Healthy Volunteer|Subjects receive 24 hours of infusion of 0.9% normal saline, dextrose (sugar) without fat, ClinOleic (olive oil-based), and Intralipid (soybean-derived fat)
62397075|NCT05040373||Patisiran|Pregnant women exposed to commercial patisiran-LNP (ONPATTRO) during the 12 weeks prior to their last menstrual period (LMP) or at any time during pregnancy.
62005471|NCT04309435|PLACEBO_COMPARATOR|Jumping to conclusions control group|'Assessment and support' for participants who demonstrate the JTC bias will also involve 6 x 1-hour sessions with a psychological therapist, over a period of 8 weeks. However, in these meetings, the therapist will work in collaboration with the person to complete a more detailed assessment of factors which help or hinder their decision-making capacity. They will provide engagement, listening, positive regard and empathy, but they will not develop a psychological formulation, nor will they provide the person with information relating to their problems. They will also not provide self-help material, or encourage the person to test their beliefs, practice new strategies or develop a shared plan for the future. Once the trial is over, however, the therapist will offer to meet with the person to share the results of the assessment and develop a psychological formulation. With the participant's consent, this information will also be shared with the clinical team.
62005472|NCT05104372|EXPERIMENTAL|Intervention|"Intervention Group HSNIG started within 5 days of symptom onset Number of times HSNIG should be done: As many times as needed (but not more than 12 times/day) PLUS~Standard personal, household hygiene and social distancing advice:~http://www.covid.gov.pk/prevention"
62005473|NCT05104372|PLACEBO_COMPARATOR|Control|"Control Group~Standard personal, household hygiene and social distancing advice:~http://www.covid.gov.pk/prevention"
62005474|NCT02052739|EXPERIMENTAL|SAGE-547 Standard Dose|Participants received SAGE-547 IV loading infusion of 286.6 micrograms per kilogram per hour (μg/kg/hr) for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5.
62005475|NCT02052739|EXPERIMENTAL|SAGE-547 High Dose|Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5.
62005476|NCT00787410|EXPERIMENTAL|1|
62005477|NCT01482780|EXPERIMENTAL|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion), a special coronary sinus catheter will be introduced after induction of anaesthesia until going on bypass.
62005478|NCT01482780|NO_INTERVENTION|Control|normal procedure of preparing Bypass grafts. Equivalent time before going on Bypass is determined as control period
62005479|NCT05439850|ACTIVE_COMPARATOR|Control Group|Surgical treatment alone, consisting of arthroscopic rotator cuff repair. Ultrasound postoperatively at 1 year.
62005480|NCT05439850|EXPERIMENTAL|Study Group|Identical surgical treatment as control group plus bio-inductive patch implant. Ultrasound postoperatively at 1 year.
62005481|NCT03721198|ACTIVE_COMPARATOR|Acidulated phosphorous flouride|Acidulated phosphorous flouride used once at the first of the study
62005482|NCT03721198|EXPERIMENTAL|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish (CLINPRO XT ) is used once at the first of the study only
62005483|NCT05717595|OTHER|high fructose|high fructose (\>100 gram fructose / day) for 4 weeks
62005484|NCT05717595|OTHER|low fructose|low fructose diet (\<30 gram fructose intake per day isocaloric correction with dextrose) for 4 weeks
62005485|NCT01684384|EXPERIMENTAL|No treatment|CT-scans will be taken in the study. The EC of the University hospital antwerp considers this as an intervention.
62005486|NCT00002495|EXPERIMENTAL|Nodal RT|subtotal nodal irradiation will consist of mantle and periaortic/spleen fields treated sequentially. Total dose 3600-4000 cGy over 20 fractions.
62005487|NCT00002495|EXPERIMENTAL|Chemotherapy + Nodal RT|3 cycles (28 days each) of chemotherapy (doxorubicin 25 mg/m\^2 on days 1 and 15, vinblastine 6 mg/m\^2 on days 1 and 15). Four weeks after last cycle, subtotal nodal irradiation (total dose 3600-4000 cGy over 20 fractions) will be given as described for the Nodal RT arm.
62005488|NCT04237077|EXPERIMENTAL|"Group with telephone coaching program ."|subjects aged 75 years or more living at home, with telephone coaching program
62005489|NCT04237077|ACTIVE_COMPARATOR|"Group without telephone coaching program."|subjects aged 75 years or more living at home, without telephone coaching program
62005490|NCT01866709|ACTIVE_COMPARATOR|Sodium Polystyrene Sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
62005491|NCT01866709|PLACEBO_COMPARATOR|Silicified microcrystalline cellulose|Oral suspension of placebo blended with pigment to have the same appearance, taste, odor and mode of administration as SPS.
62005492|NCT06147011|EXPERIMENTAL|3D medical education model group|Received a regular learning plus 3D printing model
62005493|NCT01976845|EXPERIMENTAL|Propofol|Propofol 20 mg IV (2 ml)
62005494|NCT01976845|ACTIVE_COMPARATOR|Midazolam|Midazolam 2 mg IV (2 ml)
62005495|NCT01976845|PLACEBO_COMPARATOR|Saline|Saline 2 ml
62005496|NCT01479907|ACTIVE_COMPARATOR|Synbiotics|"A specific multistrain/multifi ber synbiotic composition of prebiotics and probiotics (Synbiotic Forte™, IONIA Pharmaceuticals, Athens, Greece) was administered at the active comparator arm of the study. It contained 10 \[11\] of each of four lactic acid bacteria (LAB): Pediococcus pentosaceus 5-33:3, Leuconostoc mesenteroides 32-77:1, Lactobacillus paracasei ssp. paracasei 19, and Lactobacillus plantarum 2362, and 2.5 g of each of the four fermentable fibers (prebiotics): b-glucan, inulin, pectin and resistant starch. The synbiotics were delivered in sachets and then mixed with water (12 g in 250 mLof water once daily). Th e treatment started on the day patients tolerated per os liquid intake (2nd-4th POD). The intervention period lasted 15 days."
62005497|NCT01479907|PLACEBO_COMPARATOR|Placebo|The patients belonging to the placebo comparator arm received only the 4 fi bers and no LAB (12 gin 250 mLof water once daily for 15 days). All the subjects were interviewed by a dedicated research fellow (KP) and reactions to the product, and any adverse events occurring in the 15-day period were recorded.
62005498|NCT02962037|NO_INTERVENTION|Base line|the subject will take the tests in the morning and the evening
62005499|NCT02962037|EXPERIMENTAL|After treatment|the subject will take the tests in the morning and the evening
62005500|NCT05844696|SHAM_COMPARATOR|Sham stimulation|
62005501|NCT05844696|EXPERIMENTAL|continuous tDCS|
62005502|NCT05844696|EXPERIMENTAL|slow-oscillatory tDCS|
62005503|NCT05246605|EXPERIMENTAL|From supine to prone to supine position|Prone position
62191264|NCT02760901|ACTIVE_COMPARATOR|ACTZ group|patients received acetazolamide 250 mg half an hour before cisplatin with saline hydration.
62191265|NCT02760901|ACTIVE_COMPARATOR|NAC group|patients received acetylcysteine NAC (600 mg every 12 hours) for 4 doses beginning 24 hours before cisplatin with saline hydration.
62572438|NCT01548040|SHAM_COMPARATOR|quadriceps TENS|The sham device will look identical to the Kneehab XP device. All subjects in the control group will receive quadriceps Transcutaneous Electrical Nerve Stimulation (TENS) at a minimal sensory input using Kneehab XP on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.group will also complete the standard TKA post-surgery rehabilitation program used at the Hawkins Foundation
62572439|NCT00674960|EXPERIMENTAL|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
62397076|NCT06187064|OTHER|Study cohort|The investigators will enroll 50 female-identifying people who present to the clinical van for care and follow them for 6 months. The investigators will assess uptake of PrEP and buprenorphine; POC STI testing and treatment completion rates; sustained use of PrEP and buprenorphine at months 3 and 6 (n=50). The investigators will conduct surveys to assess and characterize the acceptability and feasibility of venue-based primary and HIV prevention care among women who inject drugs (WWID).
62397077|NCT03200041|OTHER|Low Risk|350 Low risk The only intervention is a 20 ml blood sample will be taken from each participant.
62780344|NCT01364389|OTHER|Prednisone|On day 1, patients received daily oral doses of prednisone 20 mg along with daily oral placebo doses to in a double-dummy manner to maintain the blind. On day 15, partial and complete responders continued in the study and tapered their steroid treatment according to standard care. Non-responders were discontinued from the study.
62005504|NCT04721002||Participants With Multiple Myeloma|Participants with newly diagnosed and relapsed/refractory multiple myeloma will receive standard of care. Bone marrow and blood samples will be collected.
62005505|NCT05546333||Patients receiving CTA|Patients who will receive a CTA due to clinical need will be imaged with electrical impedance tomography in addition to the CTA.
62005506|NCT02118428|EXPERIMENTAL|Mirasol|Transfusions with Mirasol-treated whole blood
62397078|NCT03200041|OTHER|High Risk|150 High Risk going onto invasive diagnostic procedure. The only intervention is a 20 ml blood sample will be taken from each participant.
62397079|NCT04690673|EXPERIMENTAL|Study group|All healthy volunteers are in this group. They receive 1g paracetamol orally. Saline-, urine-, venous blood and fingerprick samples will be collected at timely intervals.
62005507|NCT02118428|ACTIVE_COMPARATOR|Control|Transfusions with untreated whole blood
62005508|NCT01443442|ACTIVE_COMPARATOR|Bepreve|1.5% bepotastine besilate, drops, twice per day, for two weeks
62005509|NCT01443442|ACTIVE_COMPARATOR|Alrex|treatment with 0.2 % loteprednol etabonate, drops, four times per day
62005510|NCT01643720||Autism Spectrum Disorders|Children with Autism Disorders and their parents
62005511|NCT01643720||Typically Developing|Typically Developing children and their parents
62005512|NCT02796807|EXPERIMENTAL|68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT|
62005513|NCT03268967|ACTIVE_COMPARATOR|Structured Admission procedure|After implementation of a structured admission procedure to all ICU patients inspired by principles of Crisis Resource Management, Closed loop communication, action cards, and staff simulation training
62397080|NCT02896686|ACTIVE_COMPARATOR|Control|Abdominal wall closure will be done by continuous polydioxanone (PDS) suture following a SL:WL ratio of 4:1, and the skin will be closed using a subcutaneous purse-string closure
62572440|NCT00381862|EXPERIMENTAL|Aprepitant and Palonosetron|
62780345|NCT00697710|EXPERIMENTAL|Cohort A|50 mg S-777469 or Placebo, BID
62005514|NCT03268967|NO_INTERVENTION|Standard Care|Randomly admission procedure to all ICU patients based on the clinicians' evaluation prior implementation of the intervention.
62005515|NCT02063997|EXPERIMENTAL|Arhalofenate 600 mg|
62005516|NCT02063997|EXPERIMENTAL|Arhalofenate 800 mg|
62005517|NCT02063997|ACTIVE_COMPARATOR|Allopurinol 300 mg; colchicine 0.6 mg|
62005518|NCT02063997|ACTIVE_COMPARATOR|Allopurinol 300 mg|
62005519|NCT02063997|PLACEBO_COMPARATOR|Placebo|
62005520|NCT00614796|EXPERIMENTAL|1|5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
62191266|NCT01046045|ACTIVE_COMPARATOR|Everolimus|before and after everolimus; in other words, comparison of specified outcome before and after treatment with everolimus
62780346|NCT00697710|EXPERIMENTAL|Cohort B|200 mg S-777469 or Placebo, BID
62780347|NCT00697710|EXPERIMENTAL|Cohort C|800 mg S-777469 or Placebo, BID
62780348|NCT03496805|EXPERIMENTAL|MGE group|Patients will be randomized to muscadine grape extract (MGE). The patients will take 4 capsules by mouth BID (twice daily). Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
62191267|NCT01046045|ACTIVE_COMPARATOR|Calcineurin-inhibitor immunosuppression|Cyclosporin-based immunosuppression without everolimus
62780349|NCT03496805|PLACEBO_COMPARATOR|Placebo group|Patients will be randomized to placebo. The patients will take 4 capsules by mouth BID (twice daily). Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of placebo.
62780350|NCT01336023|EXPERIMENTAL|IDeg|
62780351|NCT01336023|EXPERIMENTAL|IDegLira|
62005521|NCT00614796|NO_INTERVENTION|2|daily physical activity is assessed at baseline, 3 months, 9 months and 15 months. No counseling.
62005522|NCT01356511|EXPERIMENTAL|Prednisone group|Patients in the PDN arm received PDNorally at 1.0mg/kg body weight daily for 4 consecutive weeks.
62191268|NCT01276769|ACTIVE_COMPARATOR|ET|The control arm receive the paclitaxel plus epirubicin
62191269|NCT01276769|EXPERIMENTAL|PC|the experimental arm which receive the paclitaxel combined with carboplatin
62191270|NCT00167154|EXPERIMENTAL|risperidone|risperidone
62191271|NCT00167154|PLACEBO_COMPARATOR|placebo|placebo comparator
62191272|NCT02368938||Several communities in the north of Shanghai|
62191273|NCT02704013|OTHER|Intervention|Patients with overactive bladder will receive anticholinergic therapy: oral oxybutynin in daily dose 0.2-0.5 mg/kg divided in two daily doses for 3 to 6 months depending on treatment outcome assessed 3 months after start of intervention.
62780352|NCT01336023|EXPERIMENTAL|Lira|
62780353|NCT01722435||OST completers|Patients who are likely to complete OST during the next 12 or 18 months
62780354|NCT05664802|EXPERIMENTAL|e-HERO 2.0|The e-HERO intervention includes 10 modules, totaling approximately 2.5 hours of content. Across these modules, e-HERO uses diverse delivery methods to address HIV and STI knowledge, behavioral skills, HIV and STI testing intention, and instill self-efficacy to primary and secondary prevention behaviors. Those in the intervention condition will also engage in three virtual group discussion sessions with peer mentors.
62191274|NCT03257098|EXPERIMENTAL|allo-APZ2-CVU|Application of IMP on patients wound
62191275|NCT05132881|ACTIVE_COMPARATOR|Transcutaneous Auricular Vagal Nerve Stimulation Intervention Group Distressed Healthcare Workers|"Two subgroups will be included in fMRI in the Active Comparator Group where scans performed during the initial evaluation period (pre) and at 3 months (post). Subgroup I of 30 subjects will undergo fMRI scans that will include structural imaging and functional imaging with Blood Oxygen Level Dependent Imaging (BOLD) scan and two arterial spin labeling (ASL) scans. This same imaging protocol, which takes a total of about 45 minutes, will be performed initially and then after the 3 month TaVNS program or the waitlist period. All scans will be co-registered and comparable slices of the cerebral cortex will be examined.~Subgroup II will consist of 10 study subjects all receiving the TaVNS program who will undergo fMRI initially and then again at 3 months. This group will be scanned while wearing the TaVNS system (a special one that can be used in the MRI environment) and the fMRI will be used to evaluate the direct effects of the TaVNS while turned on and off in the scanner."
62191276|NCT05132881|ACTIVE_COMPARATOR|Waitlist Control Distressed Healthcare Workers Delayed TaVNS Group|After baseline and 3 month imaging is completed. The waitlist control subgroups will be included in fMRI scans performed during the initial evaluation period (pre) and at 3 months (post). Subgroup I of 30 subjects will undergo fMRI scans that will include structural imaging and functional imaging with Blood Oxygen Level Dependent (BOLD) scan and two arterial spin labeling (ASL) scans. a typical morning waking up). This same imaging protocol, will be performed initially and then after the 3 month waitlist period. All scans will be co-registered and comparable slices of the cerebral cortex will be examined. After the waitlist imaging is completed the subjects will be offered the TaVNS health device.
62191277|NCT05132881|OTHER|Healthy Controls: Group II and III|The Investigators will also plan to recruit 10 healthy controls with no reports of psychological distress (i.e. less than 2 on the SUDS). These 10 healthy controls will have the TaVNS placed while receiving two fMRI scans approximately 3 months apart. These control subjects will be used to compare the subgroup of study subjects to ensure that any changes are not associated with test-retest effects.the Investigators also plan to recruit 50 additional healthy controls with no reports of psychological distress (i.e. less than 2 on the SUDS.) These 50 controls will have the TaVNS placed while receiving one fMRI scan sequence in one day while wearing a non-metalllic set of the TaVNS ear buds to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device.
62191278|NCT05177692|ACTIVE_COMPARATOR|Intervention group - Vguard|Intervention group will be fitted with a Vguard system Patients will have double ICP monitoring using the intraventricular drainage and and intraparenchymal ICP monitoring device
62191279|NCT05177692|NO_INTERVENTION|Control group - regular intra-ventricular drainage|Control group will be fitted with a standard system for drainage of ventricular fluid Patients will have double ICP monitoring using the intraventricular drainage and and intraparenchymal ICP monitoring device
62191280|NCT00953316||at-risk infants|Includes all children born at less than 37 weeks gestation and other high risk newborns such as those with a history of breathing problems and/or low tone.
62572441|NCT06369454|EXPERIMENTAL|Treatment Sequence 1|Ritlecitinib 100 mg solution (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule with 153Sm2O3 (fasted, Period 2), and followed by ritlecitinib 100 mg MR capsule with 153Sm2O3 (fed, Period 3).
62780355|NCT05664802|ACTIVE_COMPARATOR|e-HERO 1.0|e-HERO 1.0 contains the same number of modules as e-HERO. The control arm reflects HIV and STI information that is currently publicly available.
62780356|NCT01335269|EXPERIMENTAL|Treatment arm|BI 853520 once daily in a dose escalation schedule
62397081|NCT02896686|EXPERIMENTAL|Reinforcement with Mesh|"Abdominal wall closure will be done by continous polydioxanone (PDS) suture following a SL:WL ratio of 4:1.~The incision is reinforced with onlay placement of a light polypropylene mesh (3 cm wide and the length corresponding to the incision), fixed to the aponeurosis with interrupted polyglactin (Vycril) suture.~The skin will be closed using a subcutaneous purse-string closure"
62005523|NCT01356511|EXPERIMENTAL|Dexamethasone group|DXM was administered orally at 40 mg daily for 4 consecutive days and then stopped
62397082|NCT06084312||This registry will not target any specific populations|
62397083|NCT02889861|EXPERIMENTAL|Regimen 1|IMCgp100 (77 kDa bi-specific protein) weekly dosing regimen (QW)
62005524|NCT03552887||Postoperative patients|Cohort of patients undergoing cardiac surgery, aged ≥ 18 years old, who had received any physiotherapy intervention
62005525|NCT00795691|EXPERIMENTAL|Low-carbohydrate diet|The low-carbohydrate diet was based on the Atkins weight loss diet. The daily intake goals were to restrict intake of carbohydrate to 20-25 grams for the first 2-week phase. If body weight decreased, the daily goal for carbohydrate was increased by 5 grams. If body weight increased, the daily goal for carbohydrate intake was decreased by 5 grams. The minimum goal for carbohydrate intake was 20 grams per day and the maximum goal was 50 grams per day.
62005526|NCT00795691|ACTIVE_COMPARATOR|Low-fat diet|The low-fat diet was based on the algorithm used to restrict fat and calorie intake in the Diabetes Prevention Program. The daily goals for fat intake was based on an algorithm to reduce total calorie intake to achieve a one pound weight loss per week with 25% of calories from fat.
62005527|NCT00856024||Group 1: Naïve patients|Patients, from Brazil, with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin and who previous to this treatment had not been treated with peginterferon alfa-2b.
62005528|NCT00856024||Group 2: Re-treatment|Patients, from Brazil, with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin and who previous to this treatment had been considered nonresponders or relapsing to prior treatment for chronic hepatitis C.
62005529|NCT00856024||Group 3: HIV/HCV co-infected patients|Patients, from Brazil, with confirmed chronic hepatitis C and infected with Humman Immunodeficiency Virus (HIV) who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin.
62005530|NCT04190186|ACTIVE_COMPARATOR|Biotronik ICM-guided AF management|ICM obtained data will be actively used to guide and monitor treatment .
62780357|NCT01764958||preterm infants and their mothers|"Inclusion criteria are: preterm infants born between 26-34 weeks of gestation, whose mothers speak and write Hebrew fluently. Exclusion criteria are: preterm infants who suffer from perinatal asphyxia, genetic or metabolic diseases, necrotizing colitis that requires operation, intra uterine growth retardation, deafness, retinopathy of prematurity (ROP) or major congenital defects.~Infants and their mothers will be recruited from child developmental centers and Pediatric Clinics of Maccabi. No intervention is included in the research."
62780358|NCT04088591|EXPERIMENTAL|Treatment arm|The study drug is ascorbic acid is 200mg/kg/day divided over 4 doses per day and delivered in 50 ml of 5% dextrose in water intravenously over a total duration of 96 hours.
62780359|NCT04088591|PLACEBO_COMPARATOR|Placebo arm|The placebo is 50ml of 5% dextrose in water and will be administered 4 doses per day over a total duration of 96 hours
62780360|NCT00527904|EXPERIMENTAL|PN 400 (VIMOVO)|500 mg delayed release naproxen/20 mg immediate release esomeprazole
62780361|NCT04478604||pregnant women|last trimester pregnant women and gave birth in the same hospital
62780362|NCT01073930|EXPERIMENTAL|PICOPREP|"Split Dose method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day, during the morning prior to the colonoscopy."
62780363|NCT01073930|ACTIVE_COMPARATOR|HalfLytely|HalfLytely and Bisacodyl Tablets Bowel Prep Kit was used according to the approved labeled dosage and administration instructions. The two bisacodyl tablets were taken the day prior to the procedure and the HalfLytely was taken following the first bowel movement or 6 hours after the bisacodyl tablets.
62780364|NCT01135095|EXPERIMENTAL|low-dose imaging|low dose versus standard dose imaging
62780365|NCT01320202|ACTIVE_COMPARATOR|Soluble Ferric Pyrophosphate (SFP) in dialysate|11 micrograms (µg) of iron / deciliter (dL) of dialysate.
62780366|NCT01320202|PLACEBO_COMPARATOR|Standard Dialysate|0 micrograms (µg) of iron / deciliter (dL) of dialysate.
62780367|NCT01646242|EXPERIMENTAL|Cold snare polypectomy|
62780368|NCT01646242|EXPERIMENTAL|Double biopsy polypectomy|
62780369|NCT03550417||2011 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010.
62780370|NCT03550417||2013 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010. Comparison of 2011, 2013 cohorts \& July16/June17.
62780371|NCT03550417||July2016/Jun17 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010 \& 2014. Comparison of 2011, 2013 cohorts \& July16/June17.
62780372|NCT05336149|EXPERIMENTAL|Whole-tooth dentin graft|The extracted tooth will be prepared as whole-tooth dentin graft and inserted in the extraction socket.
62780373|NCT05336149|ACTIVE_COMPARATOR|Particulate dentin graft|The extracted tooth will be prepared as particulate dentin graft and inserted in the extraction socket.
62780374|NCT01853605|EXPERIMENTAL|Augmentation|Women undergoing breast augmentation.
62780375|NCT01853605|EXPERIMENTAL|Reconstruction|Women undergoing breast reconstruction.
62397084|NCT04784806|EXPERIMENTAL|Consumption of ground beef|Consuming 106g of cooked ground beef (85% lean) to deliver 20g of protein.
62397085|NCT04784806|EXPERIMENTAL|Consumption of ground pork|Consuming 118g of cooked ground pork (72% lean) to deliver 20g of protein.
62397086|NCT04784806|EXPERIMENTAL|Consumption of tofu burger|Consuming 113g of cooked tofu to deliver 20g of protein.
62397087|NCT04784806|EXPERIMENTAL|Consumption of Beyond Meat burger|Consuming 113g of Beyond Meat burger to deliver 20g of protein.
62397088|NCT05642091|ACTIVE_COMPARATOR|transudate effusion|
62005531|NCT04190186|NO_INTERVENTION|Conventional AF Management|Treating physicians/nurses will be blinded to the AF episodes data from the monitor, but will be provided information on asystole, or ventricular arrhythmia events (for safety).
62005532|NCT01150695|EXPERIMENTAL|Group A (DVC-LVS)|Single dose of the Dynport Vaccine Company Live Vaccine Strain (DVC-LVS) product in one arm and normal saline (NS) control in the other arm on Day 0.
62005533|NCT01150695|EXPERIMENTAL|Group B (USAMRIID-LVS)|Single dose of the United States Army Medical Research Institute of Infectious Diseases Live Vaccine Strain (USAMRIID-LVS) product in one arm and normal saline (NS) control in the other arm on Day 0.
62005534|NCT04921930|EXPERIMENTAL|Artesunate|"Dose escalation of oral artesunate:~Step 1: 25 mg daily (1 tablet) during one week Step 2: 50 mg daily (2 tablets) during one week (if no effect on biomarker and no adverse reaction at step 1) Step 3: 75 mg daily (3 tablets) during one week (if no effect on biomarker and no adverse reaction at step 2) Step 4: 100 mg daily (4 tablets) duing one week (if no efficacy and no adverse reaction at step 3)"
62397089|NCT05642091|ACTIVE_COMPARATOR|exudative effusion|
62397090|NCT05117658|EXPERIMENTAL|HA121-28|Patients will receive HA121-28 tablets at 450 mg once daily (QD) for 21 days on a 28-day treatment cycle.
62397091|NCT06187454|EXPERIMENTAL|Active tDCS|
62397092|NCT06187454|SHAM_COMPARATOR|Sham tDCS|
62397093|NCT06709612|EXPERIMENTAL|active AMT-143 hydrogel|"6 participants in the first cohort will receive 1 mL AMT-143 hydrogel containing 385 mg ropivacaine.~6 participants in the second cohort will receive 2 mL AMT-143 hydrogel containing 770 mg ropivacaine.~6 participants in the third cohort will receive 3 mL AMT-143 hydrogel containing 1,155 mg ropivacaine"
62397094|NCT06709612|ACTIVE_COMPARATOR|Ropivacaine solution|"2 participants in the first cohort will receive 5 mL Ropivacaine 10 mg 1% solution.~2 participants in the second cohort will receive 5 mL Ropivacaine 10 mg 1% solution.~2 participants in the third cohort will receive 5 mL Ropivacaine 10 mg 1% solution."
62397095|NCT06709612|PLACEBO_COMPARATOR|Placebo|2 participants in the first cohort will receive 1 mL saline placebo. 2 participants in the second cohort will receive 1 mL saline placebo. 2 participants in the third cohort will receive 1 mL saline placebo.
62397096|NCT02028182|EXPERIMENTAL|Positive reactions, Concordance with reference allergen|Subjects were patch tested with an experimental allergen panel containing ascending doses of Lyral (0.10 mg/cm2, 0.20 mg/cm2 and 0.40 mg/cm2) and a negative control. A second panel containing 20 mg of 5% Lyral in petrolatum was applied for evaluation of concordance. The panels were worn for approximately 48 hours. Skin reactions were assessed at 3, 4 and 21 days following application.
62397097|NCT01451203|PLACEBO_COMPARATOR|PBO + MTX|Participants who received placebo subcutaneously every two weeks (Q2W) at Weeks 0, 2, and 4; followed by placebo subcutaneously Q2W from Week 6 to Week 50 and an oral dose of MTX administered from Week 0 onwards
62397098|NCT01451203|EXPERIMENTAL|CZP + MTX|Participants who certolizumab pegol (CZP) subcutaneously at a loading dose of CZP 400 mg every 2 weeks (Q2W) at Weeks 0, 2, and 4; followed by a dose of CZP 200 mg subcutaneously Q2W from Week 6 to Week 50 and an oral dose of MTX administered from Week 0 onwards
62780376|NCT01853605|EXPERIMENTAL|Revision-Augmentation|Women undergoing revision of previous breast augmentation.
62191281|NCT00999739|EXPERIMENTAL|two vaccines|people allocated to arm two vaccines will receive one dose of heptavalent pneumococcal conjugate vaccine at day 0 and 23-valent polysaccharide vaccine at week4 , 110 HIV-infected people will be included Intervention: administration of two vaccines
62191282|NCT00999739|EXPERIMENTAL|One vaccine|people allocated to arm one will receive only one doses of pneumococcal polysaccharide 23-valent vaccine. 110 HIV-infected adults will be included in this arm Intervention: administration of one vaccine
62191283|NCT02080403|EXPERIMENTAL|Treatment|Treatment, 2.5 mg Chlorhexidine Gluconate chip (PerioChip®) inserted every two weeks starting at Baseline for the first 3 months, plus mechanical Subgingival Debridement at Baseline and 3 months.
62005535|NCT02007356|EXPERIMENTAL|allogeneic HSCT|"The present study will evaluate and validate in a single-center, open-label, single arm fashion the safety and feasibility of direct infusions of donor-derived pathogen-specific IFN-γ positive T-cells in recipients of HSCT with post-transplant viral infection according to the previously clinically certified CCS® \[3-6\]. The Investigator will first generate and apply IFN-γ positive selected T-cells to recipients of HSCT with CMV, EBV or adenovirus as previously published. The Investigator aim is to include 6 patients from the University Hospital of Basel.~With confirmed safety the investigator will in the future perform an efficacy study and extend this treat-ment for other clinically relevant pathogens including human herpesvirus (HHV)-6, HHV-8, polyomaviruses JC and BK and fungi including Aspergillus fumigatus and Candida albicans, to other immunosuppressed patients such as solid organ transplant (SOT) recipients."
62005536|NCT01468662||STEMI|
62005537|NCT03318848|EXPERIMENTAL|Video during simulation|The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
62005538|NCT03318848|NO_INTERVENTION|Simulation without video|The students of the control group performed the simulation of the bed bath procedure, with the aid of a tutor.
62005539|NCT03427918|EXPERIMENTAL|patient-partner|patients and their partners will receive a weekly Mindfulness-Based Sex Therapy program. The treatments will deliver by a group of facilitators to groups of women consisting of 4-7 women.
62005540|NCT03427918|EXPERIMENTAL|patient-partner and health care providers|patients and their partners as well as health care providers will receive a weekly Mindfulness-Based Sex Therapy program. Th treatments will deliver by a group of facilitators to groups of women consisting of 4-7 women.
62005541|NCT03427918|NO_INTERVENTION|Control group|The control group will receive a routine counseling
62005542|NCT02694341|ACTIVE_COMPARATOR|Bakri Balloon with abdominal traction stitch|bakri balloon will be inserted with abdominal traction stitch
62005543|NCT02694341|EXPERIMENTAL|Bakri Balloon without abdominal traction stitch|bakri balloon will be inserted with no performance of abdominal traction stitch
62005544|NCT03612622|ACTIVE_COMPARATOR|Transcranial Magnetic Stimulation-Real|Participants will receive active TMS once daily for two weeks
62005545|NCT03612622|PLACEBO_COMPARATOR|Transcranial Magnetic Stimulation-Sham|Participants will receive sham TMS once daily for two weeks
62191284|NCT02080403|NO_INTERVENTION|Control|Mechanical Subgingival Debridement at Baseline and 3 months.
62191285|NCT02509455||Normal 1|SwayStar device used 1st, Sensoro used 2nd
62191286|NCT02509455||Normal 2|Sensoro device used 1st, SwayStar used 2nd
62191287|NCT02928731||Children with cancer|"Children met the criteria below were invited to fill in the questionnaires set 1.~(1) all children should be ages 9-16 years, (2) they should be able to speak and read Chinese, (3) they should have been diagnosed with cancer for at least 2 months and be currently undergoing active treatment, and (4) they should aware of their diseases (cancer)."
62191288|NCT02928731||Healthy children|"Children met the criteria below were invited to fill in the questionnaires set 2.~(1) all children should be ages 9-16 years, (2) they should be able to speak and read Chinese, and (3) they should not have cancer or any other chronic illness."
62191289|NCT04980079|ACTIVE_COMPARATOR|group A -undergo primary ureteroscopy URS|Thirty children with calicular anuria will undergo primary ureteroscopy URS
62780377|NCT01853605|EXPERIMENTAL|Revision-Reconstruction|Women undergoing revision of previous breast reconstruction.
62005546|NCT05443997|EXPERIMENTAL|A&T- intensive|"1. Capacity building will involve offsite training conducted by Vitamin Angels and short capsule trainings delivered by government staff~2. Supportive supervision will involve training and handholding of supervisors on use of job aids and mobile application~3. Strategic use of data will involve setting up processes to review key data, review meetings and short trainings on gap areas.~4. Engagement of Panchayati Raj Institutions (PRI) around convergence where PRI members will be equipped with job aids, including an App~5. Improved food supplements where THR offering for pregnant and lactating women and children 6 months and older will be revisited and improved solutions will be explored."
62191290|NCT04980079|ACTIVE_COMPARATOR|the group B(30 patients) will undergo deferred ureteroscopy URS|group B (30) patients will be admitted to do urinary drainage through the insertion of a double-J stent or percutaneous nephrostomy (PCN) at first , then a deferred ureteroscopy URS will be done
62191291|NCT01450293|EXPERIMENTAL|Group A|5 to 12 months old infants; AdCh63 ME-TRAP, MVA ME-TRAP
62191292|NCT01450293|EXPERIMENTAL|Group B|5 to 12 months old infants; AdCh63 ME-TRAP, MVA ME-TRAP
62191293|NCT01450293|NO_INTERVENTION|Group C|5 to 12 months old infants; no vaccination
62191294|NCT01450293|EXPERIMENTAL|Group D|10 week old babies; AdCh63 ME-TRAP, MVA ME-TRAP
62191295|NCT01450293|EXPERIMENTAL|Group E|10 week old babies; AdCh63 ME-TRAP, MVA ME-TRAP
62191296|NCT01450293|NO_INTERVENTION|Group F|10 week old babies; no vaccination
62191297|NCT03196323||Initial Cohort|"In Aim 1, the investigators will evaluate psychometrically RettBe 1.0 following, in part, previous studies including our examination of anxiety instruments and adaptation of the Anxiety, Depression and Mood Scale (ADAMS) for RTT, and their adaptations of the Aberrant Behavior Checklist-Community (ABC-C) for fragile X syndrome and Down syndrome. In Aim 1, the investigators will also refine RettBe 1.0 by adding new missing items based on parental input or clinician (PIs of sites involved) feedback. The resulting instrument, RettBe 2.0 will be tested in Aim 2."
62191298|NCT03196323||Validation Cohort|Testing of RettBe 2.0 will be carried out with a new (naïve) validation cohort of 300 subjects and two raters (preferentially both parents/caregivers, alternatively one teacher or therapist), to determine inter-rater reliability. One rater, preferentially a parent, will be asked to also complete three other behavioral measures (RSBQ, ADAMS, ABC-C) for comparisons. Scores for RettBe 2.0 will be analyzed in terms of psychometric properties, as performed for RettBe 1.0. However, in addition to structure (construct validity) and content validity, the investigators will also examine convergent and discriminant validity by correlating domain RettBe 2.0 scores with those of comparable and non-comparable domain scores of the RSBQ, ADAMS, and ABC-C, respectively.
62191299|NCT04460833|EXPERIMENTAL|Test group|All children will have the 6 feedback modalities + the control given randomly
62191300|NCT06471712|EXPERIMENTAL|18F-LNC1007 Injection|a single dose of 18F-LNC1007 Injection will be administered
62191301|NCT02265666|EXPERIMENTAL|BIIL 284 BS Tablet FF|
62191302|NCT02265666|ACTIVE_COMPARATOR|BIIL 284 BS tablet C|
62191303|NCT03510767|EXPERIMENTAL|TQ-B3525|
62005547|NCT05443997|NO_INTERVENTION|A&T-non intensive|Only receives standard government services
62191304|NCT02001142|EXPERIMENTAL|Exercise|
62191305|NCT02001142|NO_INTERVENTION|Sedentary Control|
62191306|NCT03543553||SZ|Individuals with a diagnosis of schizophrenia
62191307|NCT03543553||HC|Healthy control participants
62191308|NCT04268056||RT patients|100 patients with breast cancer undergoing radiation therapy
62191309|NCT02547441|EXPERIMENTAL|Treatment|CLS001 (Omiganan) gel applied once daily
62005548|NCT03521492|EXPERIMENTAL|caries group|
62005549|NCT03521492|EXPERIMENTAL|free caries group|
62191310|NCT02547441|PLACEBO_COMPARATOR|Vehicle Gel|Vehicle gel applied once daily
62191311|NCT02547272||Nasal and rectal samples|ICU patients with nasal and rectal bacterial samples for the presence of S Aureus
62191312|NCT02342145|ACTIVE_COMPARATOR|group A|The patients were used cycloaporine A:2mg/kg combined with methotrexate 15mg/m2 +1d，10mg/m2 +3,+6,+11d,mycophenolate mofetil: 0.25g/d, -1d to 90d and basiliximab: 10mg each time, 0d and +4 d for prevention of graft-versus-host-disease.
62191313|NCT02342145|EXPERIMENTAL|group B|The patients were used cyclosporine A 2mg/kg,methotrexate,15mg/m2 +1d，10mg/m2 +3,+6,+11d,mycophenolate mofetil: 0.25g/d, -1d to 90d for prevention of graft-versus-host-disease.
62191314|NCT02697838|EXPERIMENTAL|Experimental: Apatinib plus chemotherapy|
62191315|NCT05097937|SHAM_COMPARATOR|Sham intervention|The needle will be inserted for 90 seconds without galvanic current.
62191316|NCT05097937|EXPERIMENTAL|Low intensity percutaneous electrolysis|Galvanic current will be applied with an intensity of 0.3 mA for 90 seconds.
62191317|NCT05097937|EXPERIMENTAL|High intensity percutaneous electrolysis|Participants will receive three impacts of galvanic current with an intensity of 3 mA for 3 seconds each.
62191318|NCT02872012|EXPERIMENTAL|Cryoanesthesia Device -5 degrees Celsius for 10 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
62191319|NCT02872012|EXPERIMENTAL|Cryoanesthesia Device -5 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
62397099|NCT06300047|NO_INTERVENTION|Usual Care Group|No intervention group used as a control leading into the intervention for comparative analysis. Patients in this arm receive care as usual with no changes and are not aware of the intervention group.
62005550|NCT05050643|ACTIVE_COMPARATOR|CACP-EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy for EBP #1, Comprehensive Assessment and Care Planning (CACP) for High-Risk Veterans.
62191320|NCT02872012|EXPERIMENTAL|Cryoanesthesia Device -7 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
62191321|NCT02872012|EXPERIMENTAL|Cryoanesthesia Device -10 degrees Celsius for 10 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
62191322|NCT02872012|EXPERIMENTAL|Cryoanesthesia Device -10 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
62191323|NCT02872012|ACTIVE_COMPARATOR|Lidocaine|"Participants randomized to this arm will have their other eye receive anesthesia via the current standard of care treatment method (lidocaine) prior to receiving an intravitreal injection.~Lidocaine: Lidocaine will be applied to the non-cryoanesthesia eye."
62191324|NCT03945643|ACTIVE_COMPARATOR|Sildenafil administration|Administration of 50mg sildenafil one time, one hour prior to measurements
62191325|NCT03945643|PLACEBO_COMPARATOR|Placebo administration|Administration of 50mg placebo one time, one hour prior to measurements
62191326|NCT05834868|EXPERIMENTAL|THDB0206 Injection|
62572442|NCT06369454|EXPERIMENTAL|Treatment Sequence 2|Ritlecitinib 100 mg solution (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule with 153Sm2O3 (fed, Period 2), and followed by ritlecitinib 100 mg MR capsule with 153Sm2O3 (fasted, Period 3).
62191327|NCT05834868|ACTIVE_COMPARATOR|Insulin Lispro Injection|
62191328|NCT05781165|EXPERIMENTAL|Intervention|Participants in the intervention arm will be able to access the augmented reality page in the web app to perform the HIV self-test
62572443|NCT04027530|EXPERIMENTAL|Ertugliflozin 15mg once daily|Once daily treatment with oral ertugliflozin (steglatro) 15mg for 4 consecutive weeks.
62572444|NCT04027530|PLACEBO_COMPARATOR|Placebo|Once daily treatment with a placebo pill for 4 consecutive weeks.
62572445|NCT05176821|EXPERIMENTAL|High-dose dual therapy group|esomeprazole 20mg qid plus amoxicillin 750mg qid were used in the high-dose dual therapy group
62005551|NCT05050643|ACTIVE_COMPARATOR|CACP-EBQI-LC|Learning collaboratives (LC) are widely used in healthcare settings, as an effective implementation strategy. The LC will be used to increase uptake of EBP #1, Comprehensive Assessment and Care Planning (CACP) for High-Risk Veterans.
62005552|NCT05050643|ACTIVE_COMPARATOR|HCMA-EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy for EBP # 2,Phone-Based Health Coaching for Medication Adherence (HCMA).
62005553|NCT05050643|ACTIVE_COMPARATOR|HCMA-EBQI-LC|Learning collaboratives (LC) are widely used in healthcare settings, as an effective implementation strategy. The LC will be used to increase uptake of EBP # 2,Phone-Based Health Coaching for Medication Adherence (HCMA).
62005554|NCT05769894||Fracture neck of femur|"Trauma and Orthopaedics wards and the Emergency department will be screened for new admissions with fractured neck of femur proven by X-ray on admission, thereby identifying 20 participants according to eligibility criteria.~Suitable patients will be approached about the study and given an information sheet. Later, when they have had enough time to consider, they will be enrolled if they are happy to provide written informed consent.~Blood samples will be taken on the ward on admission, 24, 48 and 72 hours from admission and at 1 month.~Blood will be collected in 4 tubes on each occasion. (1 x2ml 3.2% sodium citrate vacutainer, 1 x 6ml lithium heparin vacutainer. 2 x 5ml SST tubes for Inflammatory markers.) A detailed description of this is laid out below."
62005555|NCT05769894||Patients > 70 years age admitted with chest infection|"The Emergency department, Acute Medical Unit and medical wards will be screened for eligible participants whose primary diagnosis is chest infection (Acute bronchitis or Pneumonia). Aiming to recruit 20 participants.~Acute Bronchitis is a lower respiratory tract infection causing inflammation in the bronchial airways It is a clinical diagnosis characterised by a cough with no evidence of pneumonia. The chest X-ray can be normal.~Pneumonia is an infection of the lung tissue in which the air sacs in the lungs become filled with microorganisms, fluid and inflammatory cells, affecting the function of the lungs. 39 Patients will be selected according to symptoms, clinical diagnosis +/- Chest X-ray findings (Pneumonia only)."
62005556|NCT05769894||Healthy volunteers following COVID booster|Aiming to recruit 20 participants due to have a COVID vaccine at Southampton General Hospital. We are aiming to recruit 20 healthy volunteers meeting the criteria as per study eligibility.
62005557|NCT05769894||Patient admitted with AMI within 6 weeks of inflammatory condition|Screening will include patients admitted with Type 1 or Type 2 MI or myocardial injury, as defined by the 4th Universal Definition, if they are within 6 weeks of one of the inflammatory conditions listed above.40 Suitable patients will be approached about the study and given an information sheet.
62005558|NCT05769894||AMI secondary to stent thrombosis|"Eligible patients will have been admitted with definite stent thrombosis according to the Academic Research Consortium definition. 41 Stent thrombosis is a complete occlusion of the artery secondary to thrombus inside the stent. ARC (Academic research consortium) has identified stent thrombosis detected by angiography as Definite stent thrombosis (ST). They also categorised stent thrombosis as early (up to 30 days from deployment), or late (30 days to 12 months from deployment).~Suitable patients will be approached about the study and given an information sheet."
62005559|NCT03058068|EXPERIMENTAL|Safety Run-In: Treatment 1 Allo-hMSCs|Treatment 1: 1 subject will receive a single administration of allogeneic MSCs: 20 x 10\^6 MSCs (20 million) cells delivered via peripheral intravenous infusion.
62005560|NCT03058068|EXPERIMENTAL|Safety Run-In: Treatment 2 Allo-hMSCs|2 subjects will receive a single administration of allogeneic MSCs: 100 x 10\^6 MSCs (100 million) cells delivered via peripheral intravenous infusion.
62005561|NCT03058068|EXPERIMENTAL|Randomized: Cohort 1 Allo-hMSCs|Cohort 1 (5 subjects): 20 million MSCs A single peripheral intravenous infusion of 20 x 10\^6 MSCs (20 million cells) will be administered to each subject.
62005562|NCT03058068|EXPERIMENTAL|Randomized: Cohort 2 Allo-hMSCs|Cohort 2 (5 subjects): 100 million MSCs A single peripheral intravenous infusion of 100 x 10\^6 MSCs (100 million cells) will be administered to each subject.
62005563|NCT03058068|PLACEBO_COMPARATOR|Randomized: Cohort 3 Allo-hMSCs|Cohort 3 (5 subjects): Placebo A single peripheral intravenous infusion of placebo (PlasmaLyte A containing 1% HSA) will be administered to each subject.
62005564|NCT02199418|EXPERIMENTAL|Paclitaxel and Cisplatin|"Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.~Trastuzumab (only for human epidermal growth factor receptor-2(HER2)-positive patients): Loading dose: 4 mg/kg, Maintenance dose: 2 mg/kg, day 1 q day 8 for 16 weeks. Post-surgery: up to a total duration of 1 year"
62005565|NCT02897739||TTC Patients|Patients diagnosed with Tako-tsubo cardiomyopathy.
62005566|NCT02897739||Health Volunteers|Participants who have normal hearts.
62005567|NCT00560261|EXPERIMENTAL|1:Children with sickle cell disease|"NO-CO inhalation and expiration:~Children with sickle cell disease"
62005568|NCT00560261|ACTIVE_COMPARATOR|2: Healthy volunteers|"NO-CO inhalation and expiration:~Healthy volunteers"
62191329|NCT05781165|NO_INTERVENTION|Control|Participants in the control arm will be asked to follow the instruction sheet to perform the HIV self-test
62780378|NCT05772013|ACTIVE_COMPARATOR|Continuous azithromycin|Participants in this arm will continue with their standard of care (i.e. continuous dose of azithromycin according to their standard prescription) throughout the trial.
62005569|NCT05644327|EXPERIMENTAL|Cardiovascular training (CT)|Cardiovascular training (CT) will be performed on a recumbent stepper. CT will start at low intensity, and, through a linear progression, will reach vigorous intensity; then, this intensity will be maintained until the end of the training period. Each session will include five minutes of warm-up and cool-down performed at the beginning and at the end of the training, respectively. Furthermore, five minutes of stretching will be performed after the cool-down. CT's sessions will last approximately 45 minutes (30 to 50 minutes) and will be interspersed with 48 hours of recovery.
62005570|NCT05644327|EXPERIMENTAL|Resistance training (RT)|Resistance training (RT) intensity will be estimated using the percentage of one-maximal repetition (1-RM) defined as the maximal weight liftable for ten maximal repetitions with proper form. The program will include five exercises (leg press, lat machine, leg extension, leg curl, bench press) and will start at high-volume low intensity. RT will follow a periodization to reach high-intensity low-volume at the end of the intervention (week 12). The training sessions will start and end with five-minute of warm-up and cool-down, which will include exercise on a recumbent stepper and stretching, respectively. RT's sessions will last approximately 45 minutes (40 to 50 minutes) and will be interspersed with 48 hours of recovery.
62005571|NCT05644327|EXPERIMENTAL|Multimodal training (MT)|Multimodal training (MT) will combine cardiovascular and resistance training interventions using the modalities described previously, but each component will be shortened to match the overall training duration (i.e., volume) among groups. The first part of each training session will always include three resistance exercises, which will be followed by 15-20 minutes of cardiovascular training performed on the total body recumbent stepper. Periodization will follow the same progression previously described for cardiovascular and resistance training, respectively, reaching vigorous intensity towards the end of the training period. Training sessions will include a five-minute warm-up and cool-down on the total body recumbent stepper. MT's sessions will approximately last 45 minutes (40 to 50 minutes) and will be interspersed with 48 hours of recovery.
62572446|NCT05176821|ACTIVE_COMPARATOR|Furazolidone-based quadruple therapy|furazolidone 100mg bid + amoxicillin 1000mg bid + esomeprazole 20mg bid + bismuth potassium citrate 1000mg(220mg of bismuth) bid were used in the Furazolidone-based quadruple therapy
62572447|NCT01438398|OTHER|Submucosal Endoscopic Mucosal Flap Technique|Submucosal Endoscopic Mucosal Flap Technique
62005572|NCT05644327|NO_INTERVENTION|Control condition (CON; waiting list)|The control condition (CON; waiting list) will receive no intervention (i.e., exercise) but usual care. Participants in the CON will be required to go about their normal life, maintaining their current physical activity levels until the end of the study. Then, they will be offered to join one of the training programs/condition.
62005573|NCT02521012|ACTIVE_COMPARATOR|Vitamin D 10 micrograms|"Vitamin D supplementation 10 micrograms/day given to depressed individuals, defined as reference"
62005574|NCT02521012|EXPERIMENTAL|Vitamin D 100 micrograms|Vitamin D supplementation 100 micrograms/day given to depressed individuals
62005575|NCT01872871|PLACEBO_COMPARATOR|local anasthetic drops|topical anaesthetic drop with placebo
62005576|NCT01872871|ACTIVE_COMPARATOR|Paracetamol|Topical anaesthetic drop with Paracetamol
62397100|NCT06300047|EXPERIMENTAL|Intervention Group|Patients in this arm receive access to and support from a Transition coordinator who will meet with them prior to transition from pediatric to adult care and follow up with them every 2 months throughout the first year of their transition period utilizing phone, text, email, social media.
62572448|NCT06573684||Type II Diabetic Mellitus without comorbidities|Patient who suffered diabetic neuropathy and history of type II diabetic mellitus without comorbidities
62572449|NCT06573684||Type II Diabetic Mellitus with hypertension|Patient who suffered diabetic neuropathy and history of type II diabetic mellitus with hypertension
62780379|NCT05772013|OTHER|Seasonal azithromycin|"Azithromycin will be taken by participants during the autumn-winter (October - March).~Matched placebo will be taken by the participants in the spring-summer (April - September)."
62780380|NCT05772013|PLACEBO_COMPARATOR|Complete Discontinuation of azithromycin|Participants will take continuous matched placebo throughout the trial.
62780381|NCT00543335|EXPERIMENTAL|Sorafenib + Radiation Therapy|Sorafenib starting dose 200 mg orally daily + 45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
62780382|NCT03892239|EXPERIMENTAL|Intervention|Monitoring and suggestion of training progress. Behaviour change strategy based on increasing knowledge.
62780383|NCT03892239|ACTIVE_COMPARATOR|Control|Monitoring and suggestion of training progress.
62780384|NCT01012544|ACTIVE_COMPARATOR|stent thrombosis patients|Patients with a history of a stent thrombosis
62780385|NCT01012544|ACTIVE_COMPARATOR|Patients without a history of a stent thrombosis|Patients without a history of stent thrombosis
62191330|NCT05675462|EXPERIMENTAL|H101 + Tislelizumab+ Lenvatinib|"(Dose escalation and cohort expansion) H101 administered by intratumoral injection in combination with Tislelizumab administered intravenously (IV), and Lenvatinib administered orally.~H101 intratumorally injection starts at day 0. Tislelizumab plus lenvatinib will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks plus a lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."
62397101|NCT01604642|OTHER|cachectic versus no cachectic patients|blood tests, muscular biopsies
62397102|NCT04140942|EXPERIMENTAL|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual, participants will participate in Virtual Reality Job Interview Training.
62397103|NCT04140942|ACTIVE_COMPARATOR|Services as Usual|Study participants will be receiving their Vocational Village services as usual that may include but not limited to vocational skill training, and social skill training.
62572450|NCT06573684||Type II Diabetic Mellitus with hypertension and dyslipidemia|Patient who suffered diabetic neuropathy and history of type II diabetic mellitus with hypertension and dyslipidemia
62572451|NCT04754932|EXPERIMENTAL|Community Site 1|CST Implementation community site
62397104|NCT04823663||BSC Product Use|"Subject fulfilling one of the following conditions:~a. prospectively scheduled for a procedure involving i. use of a BSC EP Ablation product or BSC Capital Equipment product or ii. a BSC CRM product implant or b. retrospectively enrolled no more than 10 days after the index procedure and and all data necessary for appropriate reporting of all past visits is available and complete including i. the procedure where being diagnosed or treated with at least 3 separate BSC EP Ablation products/components or BSC Capital Equipment products/components or ii.the BSC CRM product implant."
62397105|NCT04751851|EXPERIMENTAL|A.1: Medium duration withdrawal programme with ACT|Medium duration withdrawal programme with Acceptance and Commitment Therapy
62397106|NCT04751851|EXPERIMENTAL|A.2: Long duration withdrawal programme with ACT|Long duration withdrawal programme with Acceptance and Commitment Therapy
62397107|NCT04751851|ACTIVE_COMPARATOR|B.1: Medium duration withdrawal programme without ACT|Medium duration withdrawal programme without Acceptance and Commitment Therapy
62572452|NCT04754932|EXPERIMENTAL|Community Site 2|CST Implementation community site
62572453|NCT04754932|EXPERIMENTAL|Community Site 3|CST Implementation community site
62572454|NCT04754932|EXPERIMENTAL|Community Site 4|CST Implementation community site
62572455|NCT04754932|EXPERIMENTAL|Community Site 5|CST Implementation community site
62572456|NCT04871048|EXPERIMENTAL|active tDCS stimulation|Transcranial direct current stimulation tDCS-Stimulation will be performed using a Neurocan DC-Stimulator Plus
62572457|NCT04871048|SHAM_COMPARATOR|sham tDCS stimulation|Transcranial direct current stimulation tDCS-The control group will receive the sham stimulation following the same regimen, using the sham procedure .
62572458|NCT03596112|EXPERIMENTAL|polyacrylate wound pad|Use of cellulose and distinct layers of sodium-polyacrylate pad for wound care; frequency: twice a week
62572459|NCT03596112|ACTIVE_COMPARATOR|hydrocellular foam pad|Use of standard foam pad for wound care; frequency: twice a week
62572460|NCT06576986|PLACEBO_COMPARATOR|Capecitabine alone control|n the Control Group, patients received Maltodextrin as supplementation
62397108|NCT04751851|ACTIVE_COMPARATOR|B.2: Long duration withdrawal programme without ACT|Long duration withdrawal programme without Acceptance and Commitment Therapy
62572461|NCT06576986|EXPERIMENTAL|Capecitabine alone synbiotic|In the Intervention Group, patients received the symbiotic Simbioflora as supplementation.
62572462|NCT06576986|PLACEBO_COMPARATOR|Capecitabine associated with control Oxaliplatin|n the Control Group, patients received Maltodextrin as supplementation
62572463|NCT06576986|EXPERIMENTAL|Capecitabine associated with synbiotic Oxaliplatin|In the Intervention Group, patients received the symbiotic Simbioflora as supplementation.
62397109|NCT04285957||pre-test Group|"Consecutive recruitment of 10 post-stroke patients undergoing intensive rehabilitation treatment at the Neurological Rehabilitation Unit, Foundation don Gnocchi Scientific Institute.~Inclusion criteria: age 18-90, stroke occurred within 3 months from enrollment; clinical stability (SIC = 0). The exclusion criteria are: stroke recurrence; visual and / or hearing disorders; cognitive decline (MMSE \<21) and/or severe aphasia, which would limit the the patients' understanding of and the reliable answering to the two assessment tools"
62397110|NCT04285957||Validation Group|Recruitment of 60 post-stroke patients undergoing intensive rehabilitation treatment at the Neurological Rehabilitation Unit, Foundation don Gnocchi Scientific Institute.Inclusion criteria: age 18-90, stroke occurred within 8 months from enrollment; clinical stability (SIC = 0). If the following criteria are present: visual and / or hearing disorders; cognitive decline (MMSE \<21) and/or severe aphasia, which would limit the patients' understanding of and the reliable answering to the two assessment tools, the interview shall be carried out with a proxy
62572464|NCT02112383|EXPERIMENTAL|Internet-based cognitive behavior therapy|
62572465|NCT02112383|EXPERIMENTAL|Cognitive behavior group therapy|
62572466|NCT01095562|EXPERIMENTAL|ABT-126 Dose 1|
62572467|NCT01095562|EXPERIMENTAL|ABT-126 Dose 2|
62572468|NCT01095562|PLACEBO_COMPARATOR|Sugar Pill|
62572469|NCT01749475||midazolam|
62572470|NCT01749475||hypnosis|
62572471|NCT05921578|NO_INTERVENTION|Routine diagnostic workup|
62397111|NCT04533672|EXPERIMENTAL|Single study arm|
62572472|NCT05921578|EXPERIMENTAL|Routine diagnostic workup + pre-operative CBCT-based planning|
62005577|NCT06572592||Adult-type diffuse gliomas|"Inclusion Criteria:~1. First diagnosis of glioma, with no preoperative radiotherapy or chemotherapy.~2. Underwent multiparametric MRI examination in our hospital before surgery.~3. Tumor resection or biopsy was performed within 3 weeks after MRI examination.~4. Pathological examination confirmed glioma.~Exclusion Criteria:~1. Inability to cooperate during MRI examination, resulting in poor image quality that prevents image analysis.~2. Surgery or biopsy specimens were unqualified and could not be analyzed pathologically."
62397112|NCT02704858|EXPERIMENTAL|NEO100 Phase 1|Intranasal delivery of NEO100 (perillyl alcohol) four times a day, escalation up to four different doses to determine maximum tolerated dose.
62572473|NCT06576531|EXPERIMENTAL|Exercise group|The experimental group will receive an ad hoc designed stepped exercise intervention supported by adherence monitoring.
62572474|NCT06576531|NO_INTERVENTION|Control group|The control group will follow standard lifestyle recommendations according to clinical practice.
62572475|NCT05881564|ACTIVE_COMPARATOR|Blood prime for cardiopulmonary bypass|
62791795|NCT04158583|EXPERIMENTAL|Part A: Cohort 3 RO7296682 2 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 2 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade \>=4, IRR; Grade \>=4, immune-mediated adverse events; Grade \>=4) were discontinued from study treatment.
62005578|NCT02456831|ACTIVE_COMPARATOR|Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
62005579|NCT02456831|EXPERIMENTAL|Experimental Infant Formula 1|Experimental Ready-to-Feed Soy Formula
62005580|NCT02456831|EXPERIMENTAL|Experimental Infant Formula 2|Experimental Ready-to-Feed Soy Formula
62005581|NCT02456831|EXPERIMENTAL|Experimental Infant Formula 3|Experimental Ready-to-Feed Soy Formula
62005582|NCT06211816|OTHER|Nurse prior to intervention|
62005583|NCT03967470|PLACEBO_COMPARATOR|Placebo arm|Placebo spray used during one month
62005584|NCT03967470|ACTIVE_COMPARATOR|Treatment arm|Bacteria spray used during one month
62191331|NCT03815253|EXPERIMENTAL|Acupuncture group|"Body electro-acupuncture will be conducted for 2 sessions per week over 8 consecutive weeks.~Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points.~We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes."
62191332|NCT03815253|PLACEBO_COMPARATOR|sham-acupuncture group|"As to the participants allocated to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to act as sham control at the same acupoints with same stimulation modality. However, the needles will be only adhered to the skin instead of insertion. The validity and credibility of this model has been well demonstrated."
62397113|NCT02704858|EXPERIMENTAL|NEO100 Phase 2A|Intranasal delivery of NEO100 (perillyl alcohol) four times a day. Treatment of total of 25 patients at maximum tolerated dose.
62572476|NCT05881564|ACTIVE_COMPARATOR|clear prime for cardiopulmonary bypass|
62572477|NCT03349879||Vitamin D deficiency|serum 25(OH)D \< 30 nmol/L
62572478|NCT03349879||Vitamin D insufficiency|serum 25(OH)D between 30 and 49 nmol/L
62005585|NCT02922452|EXPERIMENTAL|BMS-986141 and Dilitazem|
62005586|NCT01621399|PLACEBO_COMPARATOR|Vehicle|Treatment with the vehicle (placebo)
62005587|NCT01621399|EXPERIMENTAL|Product 55394|Treatment with product 55394
62572479|NCT03349879||Vitamin D sufficiency|serum 25(OH)D ≥ 50 nmol/L
62572480|NCT00002837|EXPERIMENTAL|Doxorubicin, Paclitaxel + Cyclophosphamide with PBPC|
62572481|NCT04992806||patients accepted hip arthroscopy|patients with hip diseases and accepted hip arthroscopy in Peking University Third Hospital
62572482|NCT02989038|EXPERIMENTAL|NNC, INC, VLNC|Normal Nicotine Content (NNC), Intermediate Nicotine Content (INC), Very Low Nicotine Content (VLNC)
62572483|NCT02989038|EXPERIMENTAL|NNC, VLNC, INC|Normal Nicotine Content, Very Low Nicotine Content, Intermediate Nicotine Content
62191333|NCT04217772|EXPERIMENTAL|Eyes post-lensectomy|Eyes of children after cataract surgery
62191334|NCT04217772|NO_INTERVENTION|Healthy Eyes|Eyes of healthy volunteers
62191335|NCT01672138|ACTIVE_COMPARATOR|Control|Pulmonary Vein Antrum Isolation (PVAI) + isolation of left atrial posterior wall
62572484|NCT02989038|EXPERIMENTAL|INC, VLNC, NNC|Intermediate Nicotine Content, Very Low Nicotine Content, Normal Nicotine Content
62572485|NCT02989038|EXPERIMENTAL|INC, NNC, VLNC|Intermediate Nicotine Content, Normal Nicotine Content, Very Low Nicotine Content
62572486|NCT02989038|EXPERIMENTAL|VLNC, NNC, INC|Very Low Nicotine Content, Normal Nicotine Content, Intermediate Nicotine Content
62572487|NCT02989038|EXPERIMENTAL|VLNC, INC, NNC|Very Low Nicotine Content, Intermediate Nicotine Content, Normal Nicotine Content
62005588|NCT06155617|OTHER|Single Arm Clinical Trial|Participants with various upper extremity disorders are provided treatment/interventions and evaluated at baseline, 3-6 weeks, and at discharge using the PRESS to Function Approach
62005589|NCT04985253||Operable breast neoplasm cohort|Operable breast cancer (OBC) ER +/Her2 neg or triple negative breast cancer patients diagnosed and treated at Tata Memorial Centre, Mumbai from 01 Jan 2010 to 31 Dec 2013 with a five-year follow up or events within the 5 years.
62005590|NCT03685994||the patients who will undergo TIPS|
62005591|NCT01223716|EXPERIMENTAL|Perceptual learning|
62005592|NCT01223716|EXPERIMENTAL|Video Game|
62005593|NCT01223716|EXPERIMENTAL|Occlusion Therapy|
62005594|NCT02002234|OTHER|Medical Treatment Arm|Received standardized medical therapy in an intensive care unit (ICU), which included elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L. Hyperglycemia, hyperthermia and hypotension were avoided or corrected when present.
62005595|NCT02002234|OTHER|Surgery with Medical Treatment Arm|Aside from receiving standardized medical therapy, decompressive hemicraniectomy was performed by removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank. Cranioplasty was performed during a separate admission on an elective basis not earlier than 6 months from the initial surgery.
62005596|NCT01482104|EXPERIMENTAL|MAL-PDT re-treatment|1 treatment of MAL-PDT with re-treatment of non-complete responders
62005597|NCT01482104|ACTIVE_COMPARATOR|usual MAL-PDT|2 MAL-PDT treatments 1 week apart
62005598|NCT03824197|OTHER|EVOO-phenol high|Extra-virgin olive oil rich with oleocanthal and other phenolic compounds that will be added to daily diet
62005599|NCT03824197|OTHER|OO-phenol low|Olive oil with low phenolic content that will be added to daily diet
62005600|NCT01530191||Abdominal|- Participants undergoing surgeries with an abdominal approach will be given a Morphine PCA at a dose of 2mg every 10 minutes with a 12mg/hour lockout. They will also be given IV Toradol at 30mg every 6 hours as needed for a maximum of four doses.
62005601|NCT01530191||Vaginal|- Participants undergoing surgeries with a vaginal approach will be given hydrocodone/acetaminophen at a dose of 5/325 (1-2 tablets every four hours as needed), and provided with Ibuprofen 800mg every 8 hours as needed.
62005602|NCT03779412|EXPERIMENTAL|ACT self-help book condition|Participants in this condition will be assigned to read The Happiness Trap by Harris (2008), a self-help book based on acceptance and commitment therapy.
62572488|NCT06329349|EXPERIMENTAL|Intervention|Exercise intervention
62572489|NCT06329349|NO_INTERVENTION|Control|No intervention.
62572490|NCT04936100|EXPERIMENTAL|"Visual acuity assessment using Vision Screening module of Easy Vision application"|
62572491|NCT04936100|EXPERIMENTAL|"Visual acuity assessment using Test Yourself module of Easy Vision application"|
62005603|NCT03779412|ACTIVE_COMPARATOR|MBSR self-help book condition|Participants in this condition will be assigned to read A Mindfulness-Based Stress Reduction Workbook by Stahl and Goldstein (2010), a self-help book based on Mindfulness-Based Stress Reduction.
62005604|NCT02554110|EXPERIMENTAL|Stimulator Active Device|Intervention: This intervention arm will use a Stimulator Active Device peripheral nerve stimulation. Participants will receive a cutaneous stimuli in response to oxygen desaturations in postoperative surgical patients.
62005605|NCT02554110|SHAM_COMPARATOR|Stimulator Sham Device|No intervention: This arm will use a Stimulator Sham Device peripheral nerve stimulation.Participants will not receive a cutaneous stimuli in response to oxygen desaturations in postoperative surgical patients.
62005606|NCT00779675||Infliximab 5 mg/kg|
62005607|NCT01184469||Fresh embryo transfers|Patients who received fresh blastocyst transfer
62572492|NCT04936100|EXPERIMENTAL|"Visual acuity assessment using Peek Acuity application"|
62005608|NCT01184469||Thawed embryo transfers|Patients who received transfers of frozen/thawed embryos
62780386|NCT05320003|OTHER|Adults with pes planus|Detailed clinical examination of cases with pes planus will be performed. Inky foot analysis of both feet will be performed to confirm the diagnosis of pes planus in the subjects included in the study. Staheli arch index and Chippaux-Smirak Index will be calculated for each foot based on the footprints obtained. According to the Staheli Arc Index 1 and above, according to the Chippaux-Smirak Index 0.45 and above will be considered as pes planus, static foot pressure measurement will be performed with a pedobarography device in all cases. Peak pressure, maximum force and total foot area values will be obtained. Balance assessment of the patients will be performed with a computerized static posturography device. Individuals will be graded according to the fall index results, as low, medium and high risk. It will be determined whether there is a fall risk with the Timed Up and Go Test, which is one of the clinical balance tests.
62005609|NCT01988571|ACTIVE_COMPARATOR|Arm 1 - Atorvastatin|One 40 mg Atorvastatin tablet each morning by mouth for 24 months
62005610|NCT01988571|PLACEBO_COMPARATOR|Arm 2 - Placebo|One placebo tablet each morning by mouth for 24 months.
62572493|NCT04936100|OTHER|Visual acuity assessment using the conventional methods|
62572494|NCT04634344|EXPERIMENTAL|DZD2269 as monotherapy|
62780387|NCT03466736||cognitively intact older adults|Each subject will receive an amyloid PET scan with \[18F\]flutemetamol
62780388|NCT03466736||Mild Cognitive Impairment|Each subject will receive an amyloid PET scan with \[18F\]flutemetamol
62780389|NCT03466736||Alzheimer's disease|Each subject will receive an amyloid PET scan with \[18F\]flutemetamol
62780390|NCT04673539||Single group|Instrument validation in stroke patients
62780391|NCT06366230|EXPERIMENTAL|Urea dialysate|Patients who had urea added to the final dialysis fluid
62780392|NCT04660396||Outpatients following discharge for treatment of heart failure|Daxor Corporation's commercially available Blood Volume Analyzer, BVA-100, will be performed at 5 timepoints for each patient.
62780393|NCT03720288|EXPERIMENTAL|Acetazolamide|All patients will receive an initial dose of intravenous furosemide of 1mg / kg, subsequently descaled to 0.5mg / kg of 6 / 6h, associated with oral hydrochlorothiazide 25mg / day and spironolactone 25mg / day orally. When the patient is randomized to the acetazolamide group, he / she will start using the adjuvant medication as acetazolamide drug capsule at the daily dose of 250 mg / day (oral) during the first three days of treatment.
62005611|NCT04316624|EXPERIMENTAL|C-CAR066|Autologous C-CAR066 (CD20-directed CAR T-cell) administered by intravenous (IV) infusion
62005612|NCT04341974||surgical patients|Adult patients undergoing major elective general abdominal surgery for ontological disease
62005613|NCT05758740|EXPERIMENTAL|E-health enhanced behavioural change intervention|The investigators will administer e-health behavioural change techniques (e.g., automated advice, tele-counselling, digital-tailored advice) on top of the conventional behavioural change techniques (e.g., information provision, goal setting) via digital devices (i.e., smartphone) to promote moderate-to-vigorous physical activity of the participants.
62005614|NCT05758740|ACTIVE_COMPARATOR|Conventional behavioural change intervention|The investigators will administer conventional behavioural change techniques (e.g., information provision, goal setting) via conventional methods (i.e., face-to-face meetings) to promote moderate-to-vigorous physical activity of the participants.
62005615|NCT03307330||Obstructive Sleep Apnea|Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) \>=5
62005616|NCT03307330||Non-Obstructive Sleep Apnea|Non-Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) \< 5
62005617|NCT01947504|EXPERIMENTAL|education and support intervention|education and support intervention
62191336|NCT01672138|ACTIVE_COMPARATOR|Study I|PVAI+ scar homogenization
62191337|NCT01672138|ACTIVE_COMPARATOR|Study II|PVAI + isolation of left atrial posterior wall + non-PV triggers ablation
62191338|NCT04500028|EXPERIMENTAL|INH|3 vaginal tablet of isonicotinic acid hydrazide (900mg) ( inserted by the study nurse 4 hours before IUD insertion.
62572495|NCT01435460|EXPERIMENTAL|Alrex|Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2%
62572496|NCT01435460|ACTIVE_COMPARATOR|Patanol|Ophthalmic solution containing olopatadine, 0.1%
62572497|NCT02283684|ACTIVE_COMPARATOR|Greenlight laser PVP|Greenlight (532-nm) laser Photoselective vaporization of the prostate using (XPS) 180W system
62572498|NCT02283684|ACTIVE_COMPARATOR|Bipolar TUVP|Bipolar transurethral vaporization of the prostate using bipolar system
62572499|NCT04944914|EXPERIMENTAL|Camrelizumab Plus Stereotactic Body Radiotherapy|Patients receive camrelizumab(200mg, iv drip for over 60min) every 2 weeks from 2 weeks before radiotherapy, and then receive stereotactic body radiotherapy until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision or the upper limit of treatment duration of 1 year.
62572500|NCT04944914|ACTIVE_COMPARATOR|Camrelizumab|Patients receive camrelizumab(200mg, iv drip for over 60min) every 2 weeks until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision or the upper limit of treatment duration of 1 year.
62572501|NCT06578260|EXPERIMENTAL|The effect and outcomes in the intervention schools|The intervention schools will use the Support Group intervention regarding bullying and exclusion.
62191339|NCT04500028|PLACEBO_COMPARATOR|Placebo Comparator|one tablet of placebo inserted by the study nurse 4 hours before IUD insertion.
62191340|NCT01115608|EXPERIMENTAL|Pharmacist follow-up|"The patients will receive pharmaceutical follow-up during one year after discharge from the hospital. Three meetings are arranged, one at discharge, one after three months and the last after one year. Patients will be called up for arrangement of consultation. Written information concerning drugs used will be supplied."
62191341|NCT01115608|NO_INTERVENTION|Control group|The control group receives no follow-up from the pharmacist, but will after one year, when they are out of the study, receive one follow-up visit and drug review.
62191342|NCT01854307|EXPERIMENTAL|Pneumoperitoneum and SVV/PPV|
62191343|NCT00104767|EXPERIMENTAL|celecoxib|
62191344|NCT04331483|EXPERIMENTAL|Physical activity intervention|"The intervention consists of an adapted physical activity (APA) program defined at baseline, incorporating supervised sessions with an APA teacher, as well as autonomous sessions. The program is individualized according to age, aerobic capacity, and PA preferences.~The total duration of the intervention is a maximum of 3 months (during the period of hospitalization in a sterile room)."
62191345|NCT00491621|OTHER|1|surgery or biopsy of the kidney tumor
62191346|NCT04803747|ACTIVE_COMPARATOR|Tranexamic acid (TXA) Arm|TXA 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
62191347|NCT04803747|PLACEBO_COMPARATOR|Placebo Arm|Placebo 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
62191348|NCT01907698||Vaginal coitus group|Pregnant women assigned to have vaginal coitus at least twice a week
62191349|NCT01907698||Control group|Pregnant women assigned to have no vaginal intercourse
62191350|NCT05210075|EXPERIMENTAL|A wait list controlled|A wait list controlled
62572502|NCT06578260|NO_INTERVENTION|The outcomes in the control schools|The control schools will implement the same measures as they normally do regarding bullying and exclusion.
62572503|NCT01379768|ACTIVE_COMPARATOR|Lotrafilcon A|Lotrafilcon A contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon A contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
62572504|NCT01379768|ACTIVE_COMPARATOR|Lotrafilcon B|Lotrafilcon B contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon B contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
62572505|NCT01379768|NO_INTERVENTION|No lens wear|No contact lens wear for the duration of the study. One 8-hour sleep at 1 week, followed by an 8-hour sleep 4 weeks later.
62572506|NCT04740671|EXPERIMENTAL|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody
62572507|NCT04740671|ACTIVE_COMPARATOR|Ranibizumab|Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
62005618|NCT01947504|NO_INTERVENTION|waiting list|waiting list and regular medical follow-up
62005619|NCT05660928|EXPERIMENTAL|Intervention|"Eighteen primary care centers will be randomized to the intervention arm, which consists of a multidimensional strategy, with a multidisciplinary approach, for the management of patients with hypertension and diabetes in the primary care setting. It is going to include:~1. Telehealth tools: clinical decision support system for primary care professionals to support the care of patients with hypertension and diabetes; clinical decision support system to support community health agents (ACS), for use in home visits; asynchronous teleconsultations; telediagnosis for digital electrocardiogram and retinography reports; text messages to patients, to provide information, education, improve adherence to treatment and encourage patients to promote health;~2. Continued education for health professionals;~3. Strengthening the educational groups and promotion of lifestyle changes, with a focus on promoting healthy eating and reducing sedentary behavior."
62005620|NCT05660928|NO_INTERVENTION|Usual care|Seventeen primary care centers will be randomized to usual care.
62780394|NCT03720288|EXPERIMENTAL|Placebo|All patients will receive an initial dose of intravenous furosemide of 1mg / kg, subsequently descaled to 0.5mg / kg of 6 / 6h, associated with oral hydrochlorothiazide 25mg / day and spironolactone 25mg / day orally. When the patient is randomized to the placebo group, he / she will start using the placebo drug capsule during the first three days of treatment.
62005621|NCT04196556|EXPERIMENTAL|Active Families|Usual care plus intervention active families. This intervention, based on the methodology of meaningful learning, will have two components: group education directed to parents (caregivers) and education directed to children in the reviews in consultation. The group intervention will consist of 6 sessions, with a biweekly / monthly frequency, will be taught as determined in the program monitoring annex, in the 3 months after the initial assessment. The content of the sessions is defined in attached annex. Regarding the proposed methodology, it has nuances and tools different from the traditional ones to achieve significant learning in the field of health. It is based on participatory methods and a more profound modification of knowledge, skills, emotions and attitudes than the brief advice that is used in family intervention in scheduled consultations.
62191351|NCT04251039||PCI with pre-treatment with P2Y12 inhibitors|"SCAD patients undergoing complex PCI with pre-treatment with P2Y12 inhibitors will undergo:~* Assessment of platelet reactivity (Time 0, T0) (VFN)~* PCI (start = T1; end= T2)"
62780395|NCT03408184|ACTIVE_COMPARATOR|Lumbar paravertebral group|After general anesthesia, the patient is placed prone. To establish the level of the block, we used US-counting of vertebrae. After determining the lumbar one level, the block performed at a parallel line 2 cm lateral to the spinous process, the transducer is moved until the corresponding transverse process is identified. Utilizing an in-plane approach from lateral to medial, a spinal needle is advanced until contact with the transverse process. The needle is withdrawn and redirected caudally under the transverse process helped by the loss of resistance technique. the solution is slowly injected after negative aspiration for blood.
62005622|NCT04196556|ACTIVE_COMPARATOR|Control group|"Usual care:~The activities included in the Service for Attention to Patients with Childhood Obesity will be carried out in the Madrid's Primary Healthcare Standardized Service portfolio, which establishes a monthly follow-up in the first 6 months and bimonthly of month 6 to 12. To this At least the child and the primary caregiver, the child's educational agent, will be consulted and will receive support documentation to exercise and reinforce their role."
62005623|NCT03459196|EXPERIMENTAL|Treatment Group|A novel radiofrequency ablation catheter combining microelectrodes, thermocouples, porous tip irrigation and contact force sensing nMARQ Multi-Channel RF Generator with Software including TGA mode (Temperature Guided Ablation).
62005624|NCT06272747|EXPERIMENTAL|Experimental: A (XH-S003)|Participants will receive XH-S003 once or twice daily on scheduled day(s)
62191352|NCT04251039||PCI with treatment with P2Y12 inhibitors only after procedure.|"SCAD patients undergoing complex PCI with treatment with P2Y12 inhibitors only after procedure will undergo:~* Administration of Cangrelor (bolus + infusion of at least 2 hours and at least until end of PCI) or decision to not administer (T0)~* Assessment of platelet reactivity (Time 0, T0) (VFN)~* PCI (start of PCI= T1; end of infusion of Cangrelor= T2)"
62191353|NCT04443478||Laparoscopic Surgery|Lower Mediastinal Lymphadenectomy should be finished via laparoscopic method.
62191354|NCT04443478||Open Surgery|Lower Mediastinal Lymphadenectomy should be finished via open method.
62005625|NCT06272747|PLACEBO_COMPARATOR|Placebo Comparator: B (Placebo)|Participants will receive matching placebo once daily on scheduled day(s)
62005626|NCT01087385||Troponin T elevation|
62005627|NCT01087385||No troponin T elevation|
62780396|NCT03408184|ACTIVE_COMPARATOR|The field block group|The ilioinguinal nerve block was done at one fingerbreadth from the anterior superior iliac spine in a line with the pubic tubercle, The injection was done after the bob of the needle after passing the external oblique aponeurosis and muscle and 5ml of the solution is injected. The rest of the solution is injected in the incision line.
62005628|NCT05510323|ACTIVE_COMPARATOR|CS|low-dose corticosteroids monotherapy
62005629|NCT05510323|ACTIVE_COMPARATOR|CS+CTX|low-dose corticosteroids combined with cyclophosphamide
62780397|NCT05825976|EXPERIMENTAL|Intervention group 1|Supplementation with 2 gel-capsules (each containing 720 mg eicosapentaenoic acid (EPA) and 480 mg docosahexaenoic acid (DHA))
62780398|NCT05825976|EXPERIMENTAL|Intervention group 2|Supplementation with 2 gel-capsules (each containing 320 mg eicosapentaenoic acid (EPA) and 200 mg docosahexaenoic acid (DHA))
62005630|NCT04706624|ACTIVE_COMPARATOR|A - High intensity Contingency management + SMS reminders|Participants who respond to the high intensity contingency management (frontline intervention) receive the adaptive intervention of SMS reminders.
62005631|NCT04706624|ACTIVE_COMPARATOR|B - High intensity Contingency management + Matrix only|Participants who do not respond to the high intensity contingency management are randomized into the Matrix only group.
62005632|NCT04706624|ACTIVE_COMPARATOR|C - High intensity Contingency management + (Matrix + CM)|Participants who do not respond to the high intensity contingency management are randomized into the Matrix plus contingency management group.
62005633|NCT04706624|ACTIVE_COMPARATOR|D - Low intensity Contingency management + SMS reminders|Participants who respond to the low intensity contingency management (frontline intervention) receive the adaptive intervention of SMS reminders.
62005634|NCT04706624|ACTIVE_COMPARATOR|E - Low intensity Contingency management + Matrix only|Participants who do not respond to the who intensity contingency management are randomized into the Matrix only group.
62005635|NCT04706624|ACTIVE_COMPARATOR|F - Low intensity Contingency management + (Matrix+CM)|Participants who do not respond to the who intensity contingency management are randomized into the Matrix plus contingency management group.
62005636|NCT00125827|EXPERIMENTAL|1|Single-arm, dose escalation
62005637|NCT01000246|EXPERIMENTAL|influenza vaccine day 4|influenza vaccine day 4 of chemotherapy
62780399|NCT05825976|ACTIVE_COMPARATOR|Control|Supplementation with 2 gel-capsules (each containing 1000 mg extra virgin olive oil)
62005638|NCT01000246|EXPERIMENTAL|influenza vaccine day 16|influenza vaccine day 16 of chemotherapy
62005639|NCT01000246|ACTIVE_COMPARATOR|influenza vaccine|influenza vaccine in patients with heartfailure
62005640|NCT00545831|EXPERIMENTAL|A|Use of taurolidine in prevention of bloodstream infection related to central venous access
62005641|NCT00545831|PLACEBO_COMPARATOR|B|Use of Physiologic Serum to compare to arm A
62005642|NCT01545817|EXPERIMENTAL|Pazopanib followed by everolimus|First line pazopanib, followed by second line everolimus
62005643|NCT04894617|ACTIVE_COMPARATOR|Amantadine|The intervention group will receive a dose at day 1 of amantadine 100 mg followed by 100 mg amantadine after 6 hours. The following 4 consecutive days, study participants will receive a daily dose of 200mg amantadine, 100 mg (1 capsule) morning and 100 mg (1 capsule) evening, yielding 5 days of treatment in total (10 capsules in total).
62005644|NCT04894617|PLACEBO_COMPARATOR|Placebo|The control group will receive placebo treatment with lactose monohydrate; 1 capsule, followed by 1 capsule after 6 hours on day 1. The following 4 consecutive days, study participants will receive 1 capsule morning and 1 capsule evening, yielding 5 days of treatment in total (10 capsules in total).
62005645|NCT05329740|EXPERIMENTAL|Glucocorticoid group|
62005646|NCT05329740|NO_INTERVENTION|Control Group|
62005647|NCT02842502|EXPERIMENTAL|Skin graft pellet|This group concerns patients who are recruited for skin graft procedure leading to the collection of supernumerary biopsies.
62005648|NCT00895375||Psoriasis patients|40 subjects (male or female) age 18 or older with psoriasis covering \>10% BSA and without a diagnosis of depression.
62005649|NCT00895375||Patients without psoriasis|40 subjects without psoriasis matched for age, sex and BMI, as a control population.
62191355|NCT02069197|ACTIVE_COMPARATOR|Ketogenic diet, lifestyle counseling|ketogenic diet consisted of 3:1\[fat\]:\[protein+carbohydrate\] weight ratio with 1600kcal restriction.
62780400|NCT06358092||Training cohort|To explore the cut-off value of LSM and SSM by 2D-SWE for assessment of CSPH in cirrhosis.
62780401|NCT06358092||Validation cohort|To validate the cut-off value of LSM and SSM by 2D-SWE for assessment of CSPH in cirrhosis.
62397114|NCT06347458|EXPERIMENTAL|BG1805|"Dose escalation: Three dose levels were designed, and if the maximum tolerated dose (MTD) was not found at the highest level, no further dose escalation was to be performed. Approximately 12-18 subjects were planned to be enrolled in the dose-escalation phase to evaluate the safety and tolerability of BG1805 injection and to determine the MTD and/or the recommended phase II dose (RP2D).~Dose Expansion: During or after the dose escalation process, if a certain dose group is determined to have preliminary anti-tumor effects and controllable safety, it can be extended at this dose level to further evaluate the tolerance and safety of BG1805 injection, and to preliminarily evaluate its effectiveness."
62397115|NCT04939805|EXPERIMENTAL|Selective CRP apheresis as an adjunct to standard of care|Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.
62397116|NCT04939805|NO_INTERVENTION|Standard of care according to current guideline recommendations|
62397117|NCT06520046|EXPERIMENTAL|Motor control group|"Basketball players aged between 10-18 years old who play regularly in one of the basketball sports clubs in the city of Salamanca.~The study will be carried out in 20 sessions. As for the proprioception and balance work, a simple proposal of exercises will be made, increasing the difficulty from the fifth session onwards. From the 10th session onwards, unstable surfaces will be introduced as long as our athletes are capable of achieving the task of less complexity. If it is not possible to progress in intensity, the same level will be maintained."
62397118|NCT06520046|ACTIVE_COMPARATOR|Control|"Basketball players aged between 10-18 years old who play regularly in one of the basketball sports clubs in the city of Salamanca.~These participants shall carry out their usual treatment"
62780402|NCT03094715|ACTIVE_COMPARATOR|Thrombectomy|Endovascular thrombectomy and best medical care
62005650|NCT06663605|EXPERIMENTAL|PALI-2108|Part A - Single Ascending oral doses of PALI-2108 in healthy adult subjects. Part B - Single oral dose crossover of PALI-2108 in healthy adult subjects. Part C - Multiple Ascending oral Doses of PALI-2108 in healthy adult subjects. Part D - (open-label) Multiple oral Doses of PALI-2108 in Ulcerative Colitis patients.
62005651|NCT06663605|PLACEBO_COMPARATOR|PALI-2108 Placebo|Part A - Single Ascending oral Dose of matching placebo in healthy adult subjects. Part B - Single Ascending oral Dose of matching placebo crossover of PALI-2108 in healthy adult subjects. Part C - Multiple Ascending oral Doses of matching placebo in healthy adult subjects. Part D - (open-label) Multiple Ascending oral Doses of matching placebo in Ulcerative Colitis patients.
62005652|NCT01539382|EXPERIMENTAL|Cerebral oxygenation intervention|Cerebral oxygenation levels for people in this group will be monitored and maintained above 60%. If levels decrease to below 60%, a protocol is followed to guide possible interventions to increase cerebral oxygenation levels above 60%
62191356|NCT02069197|ACTIVE_COMPARATOR|Orlistat, Lifestyle counseling|Orlistat 120 mg TID, standardized diet and lifestyle-modification counseling based on the LEARN (Life, Exercise, Attitudes, Relationships,and Nutrition) program with recommended caloric goal of 1600 kcal/day.
62005653|NCT01539382|NO_INTERVENTION|Cerebral oxygenation control|Cerebral oxygenation levels for people in this group will be masked and thus doctors and care staff will not use the cerebral oxygenation levels to make any interventions. If the cerebral oxygenation levels drop to below 40%, the cerebral oxygenation levels will be unmasked so that doctors can follow the protocol to increase levels to above 60%.
62005654|NCT04224766|EXPERIMENTAL|suprascapular nerve block with costoclavicular infraclavicular|Single shot US-guided suprascapular nerve block (SSNB) with 5 mL bupivacaine 0.5%, then single shot US-guided costoclavicular block (CCB) with 10 ml bupivacaine 0.5%.
62005655|NCT04224766|ACTIVE_COMPARATOR|Interscalene brachial plexus block|Single shot US-guided interscalene brachial plexus block (ISBPB) with 15 mL bupivacaine 0.5%.
62005656|NCT05137652|OTHER|Control group|single needle approach for 40 patients in which nerve is traditionally been targeted.
62191357|NCT02069197|ACTIVE_COMPARATOR|Standartized diet, Lifestyle counseling|Standardized diet and lifestyle-modification counseling based on the LEARN (Lifestyle, Exercise, Attitudes, Relationship, Nutrition) program with recommended caloric goal of 1600kcal/day.
62191358|NCT04816123|EXPERIMENTAL|[14C]Donafenib|
62191359|NCT05891951|EXPERIMENTAL|B-Carotid ultrasound guided fluid therapy|Participants will use carotid ultrasound to assess volume status. If volume is insufficient, fluid therapy will be selected until volume is sufficient, anesthesia will be then induced. If volume is sufficient, anesthesia will be directly induced.
62191360|NCT05891951|NO_INTERVENTION|C-No intervention|No carotid ultrasound will be used to assess the volume status of the patients, and anesthesia will be directly induced.
62780403|NCT03094715|OTHER|Best medical care|Best medical treatment
62005657|NCT05137652|EXPERIMENTAL|Study group|40 patients will receive the three needle approach.
62005658|NCT03869125||Obstructive sleep apnoea group|Blood pressure measurement
62191361|NCT02761447|EXPERIMENTAL|Treatment Traditional and Motor Imaginary Program|"Amputees patients also conservative protocol will undergo physiotherapy techniques work Motor Imaginary Program, based on a system of two videos that allow the patient to recreate the normal way. The first video will include two sequences of a harmonic gear that will allow the patient to examine, with the physiotherapist, the characteristics of the different body segments involved in locomotion and place the member in space. The second video include an analysis in five phases. This protocol will be applied 3 days a week (25-30minutos) for one month."
62191362|NCT02761447|ACTIVE_COMPARATOR|Treatment Traditional and Mirror Therapy|Amputees patients also conservative protocol will undergo physical therapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
62191363|NCT01973140|OTHER|Tolvaptan and Hypertonic saline infusion|Tolvaptan 60 mg or 30 mg tablet by mouth for the first part of the study. A week later, infusion of hypertonic saline.
62397119|NCT05943132|EXPERIMENTAL|MISC-CBO|MISC-CBO is a year-long semi-structured, manualized video-feedback caregiver intervention that targets key components in caregiver-child interactions known to improve caregiving quality and child outcomes. These components include emotional and cognitive components shown to improve socio-emotional and cognitive developmental outcomes in children.
62397120|NCT05943132|OTHER|Treatment as Usual|TAU at CBOs include provision of meals, counselling services mostly focused on social support, financial assistance, and healthcare counseling - all which promote the mental health of OVC, but does not include a specific focus on caregiving quality.
62572508|NCT02200172|ACTIVE_COMPARATOR|Melatonin|A single daily sublingually administered tablet of 3mg non-animal synthetic source melatonin (immediate-release) at 21.00 hours (±1 hour), starting on Study Day 1 and stopping on Study Day 28 of admission or earlier in the event of death or discharge.
62572509|NCT02200172|PLACEBO_COMPARATOR|Placebo|A single daily sublingually administered tablet of placebo at 21.00 hours (±1 hour), starting on Study Day 1 and stopping on Study Day 28 of admission or earlier in the event of death or discharge.
62572510|NCT04079179|EXPERIMENTAL|Patients < 21 years with recurrent LCH (Grp1)|Children (≥ 6 months) and young adults (\<21 years) with recurrent active LCH lesions (may also have LCH-ND).
62572511|NCT04079179|EXPERIMENTAL|Patients of any age with LCH-ND (Grp2)|Patients of any age (≥ 6 months) with progressive LCH Neurodegenerative Disease (LCH-ND) without other sites of active LCH.
62005659|NCT01895751|NO_INTERVENTION|Conservative therapy|"Conservative therapy group involves optimal medical therapy according to local hospital protocols with selective invasive management as clinically appropriate. Patients assigned to the conservative group may be referred for invasive management if the patient meets one of the following pre-specified criteria:~Recurrent or refractory (class III or IV) angina with documented ischaemic ECG changes while on optimal medical therapy.~New ST segment elevation in two contiguous leads without Q waves or T wave inversion greater than 3 mm or development of hemodynamic instability Deterioration in heart failure status (defined as Killip class 3 or 4)."
62005660|NCT01895751|ACTIVE_COMPARATOR|Invasive management|Invasive management is timed as appropriate according to local NHS protocols. Usually, invasive management is expected to be performed in line with contemporary guidelines.
62005661|NCT04209088|EXPERIMENTAL|Pulmonary ultrasounds|All patients will be included in the experimental arm
62005662|NCT05263661|EXPERIMENTAL|LIFT|ligation of interesphincteric fistula tract
62005663|NCT05263661|ACTIVE_COMPARATOR|FLAP|Rectal advancement flap
62005664|NCT06027827||experimental group|In addition to the central bone graft of the fusion cage, the lateral bone graft of the fusion cage was added.
62005665|NCT06027827||control group|Conventional bone grafting in the center of the fusion
62005666|NCT04463381||Group 1|sharp choledochotomy by a scalpel or scissor
62005667|NCT04463381||Group 2|choledochotomy by a diathermy hook
62005668|NCT04463381||Group 3|choledochotomy by an ultrasonic device
62005669|NCT06024876|EXPERIMENTAL|CS-101|CS-101: Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
62005670|NCT01573624|ACTIVE_COMPARATOR|Fluticasone Furoate (FF)|100mcg, inhaled
62005671|NCT01573624|ACTIVE_COMPARATOR|Fluticasone Furoate /Vilanterol (VI)|100/25mcg inhaled
62005672|NCT01573624|EXPERIMENTAL|Fluticasone Furoate/GSK573719|100/15.6-250mcg inhaled
62005673|NCT05166213||Chronic back pain|
62005674|NCT05166213||Clinically significant menopausal complaints|
62005675|NCT05166213||Parkinson's disease|
62005676|NCT05166213||Migraine|
62005677|NCT05166213||Cancer-related emesis/nausea|
62005678|NCT04595006|EXPERIMENTAL|Cold Stimulation (CS)|Subjects will undergo a mild cold stimulation of about 14 degrees Celsius by wearing a cooling vest for approximately an hour daily for the next 12 weeks or 3 months.
62572512|NCT04079179|EXPERIMENTAL|Patients <21 years with other histiocytic disorders (Grp3)|Newly diagnosed or relapsed/refractory children (≥ 6 months) and young adults (\<21 years) with other histiocytic disorders including juvenile xanthogranuloma, Erdheim-Chester disease, histiocytic sarcoma and Rosai-Dorfman disease.
62572513|NCT04079179|EXPERIMENTAL|Patients ≥ 21 years with LCH/histiocytic disorders (Grp4)|Adults (≥21 years) with LCH or other histiocytic disorder with recurrent active lesions (may also have LCH-ND).
62005679|NCT04595006|EXPERIMENTAL|Browning Nutraceutical (BN)|Subjects will consume 2000mg of curcumin daily for the next 12 weeks or 3 months.
62005680|NCT04595006|EXPERIMENTAL|Cold Stimulation and Browning Nutraceutical (CSBN)|Subjects will undergo a mild cold stimulation of about 14 degrees Celsius by wearing a cooling vest for approximately an hour and consume 2000mg of curcumin daily for the next 12 weeks or 3 months.
62005681|NCT04488705|EXPERIMENTAL|Single ascending dose|
62005682|NCT04488705|EXPERIMENTAL|Repeat dose - 7 days|
62005683|NCT04488705|EXPERIMENTAL|Repeat dose - 14 days|
62005684|NCT04488705|EXPERIMENTAL|Repeat dose - 7 days with SABA|
62005685|NCT02625493||study population|All patients who underwent elective coronary procedures belonged to the one group, they received standard care without any additional interventions, but were asked to fill in a questionnaire.
62572514|NCT01920412|EXPERIMENTAL|Left Atrial Appendage Occluder|Adopted non-comparative arm on Left Atrial Appendage Occluder.
62005686|NCT00384813|EXPERIMENTAL|1: Home-based family intervention|Home-based family intervention
62005687|NCT00384813|ACTIVE_COMPARATOR|2: ETAU|Enhanced Treatment As Usual (1 home visit)
62005688|NCT05525819|EXPERIMENTAL|Control group|Cases will be subjected to spinal anesthesia with hyperbaric bupivacaine 10 mg.
62005689|NCT05525819|EXPERIMENTAL|Intrathecal group|Cases will be subjected to the same anesthetic mixture as controls with adding dexmedetomidine 5 μg.
62005690|NCT05525819|EXPERIMENTAL|Intravenous group|Cases will receive hyperbaric bupivacaine (10 mg), in addition to IV dexmedetomidine (1 μg/kg loading dose, followed by 0.4 μg/kg/h maintenance dose).
62005691|NCT01297673||Spinal cord injury|Patients with neurogenic lower urinary tract dysfunction due to spinal cord injury with regular urodynamic examination
62005692|NCT00808288|EXPERIMENTAL|PF-00610355|
62005693|NCT00808288|EXPERIMENTAL|PF- 00610355|
62005694|NCT00808288|EXPERIMENTAL|PF - 00610355|
62005695|NCT00808288|PLACEBO_COMPARATOR|Placebo|
62005696|NCT00808288|ACTIVE_COMPARATOR|Salmeterol|
62005697|NCT06663566||high-FAPI+|"FAPI Nuclear Medicine Cardiac Imaging stronge Positive in English."
62005698|NCT06663566||low-FAPI+|"FAPI Nuclear Medicine Cardiac Imaging Weak Positive in English."
62005699|NCT06663566||No FAPI+|FAPI nuclear medicine cardiac imaging negative
62005700|NCT02357576|EXPERIMENTAL|Reduced Lipid|Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
62005701|NCT02357576|ACTIVE_COMPARATOR|Standard Lipid|Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
62572515|NCT02361463|EXPERIMENTAL|3D group|Will practice under 3D vision conditions on a laparoscopic virtual reality simulator
62572516|NCT02361463|ACTIVE_COMPARATOR|2D group|Will practice under 2D vision conditions on a laparoscopic virtual reality simulator
62005702|NCT01932216|ACTIVE_COMPARATOR|Single-site robotic cholecystectomy|Single-site cholecystectomy using da Vinci robotic assisted surgery
62005703|NCT01932216|ACTIVE_COMPARATOR|Multi-port laparoscopic cholecystectomy|Multi-port cholecystectomy using laparoscopic surgery
62005704|NCT01818362|EXPERIMENTAL|Group 2|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 52 weeks later.
62005705|NCT01818362|EXPERIMENTAL|Group 3|MVA NP+M1 1.5 x 10⁸pfu followed by ChAdOx1 NP+M1 2.5 x 10¹⁰vp 8 weeks later.
62005706|NCT01818362|EXPERIMENTAL|Group 4|MVA NP+M1 1.5 x 10⁸pfu followed by ChAdOx1 NP+M1 2.5 x 10¹⁰vp 52 weeks later.
62005707|NCT01818362|EXPERIMENTAL|Group 1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 8 weeks later.
62005708|NCT01818362|EXPERIMENTAL|Group 5|ChAdOx1 NP+M1 2.5 x 10¹⁰vp
62005709|NCT01818362|EXPERIMENTAL|Group 6|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 8 weeks later.
62005710|NCT02484105|EXPERIMENTAL|Comforting Conversation|Conversation according to the initital qualitative study.
62005711|NCT02484105|ACTIVE_COMPARATOR|Standard Communication|Standard information prior to and during endoscopy.
62005712|NCT03285321|EXPERIMENTAL|Arm 1|Nivolumab 480mg IV every 4 weeks for up to 6 cycles
62005713|NCT03285321|EXPERIMENTAL|Arm 2|Nivolumab 240mg IV every 2 weeks PLUS Ipilimumab 1mg/kg IV every 6 weeks for up to 4 cycles (12 doses Nivolumab and 4 doses of Ipilimumab)
62005714|NCT06387329|ACTIVE_COMPARATOR|3 day arm|Subjects will be given a 3 day twice daily course of 100mg nitrofurantoin by mouth starting at the time of intradetrusor injection of 100u onabotulinumtoxinA
62005715|NCT06387329|EXPERIMENTAL|Single dose arm|Subjects will be given a single dose of 100mg nitrofurantoin by mouth at the time of intradetrusor injection of 100u onabotulinumtoxinA
62005716|NCT00808600|OTHER|resource-activating training, intensified exercise training|combination of the two interventions: resource-activating behavioural training and intensified exercise training
62005717|NCT00808600|OTHER|resource-activating training, moderate exercise training|combination of the two interventions: resource-activating training and moderate exercise training
62005718|NCT00808600|OTHER|relaxation training, intensified exercise training|combination of the two interventions: relaxation training and intensified exercise training
62005719|NCT00808600|OTHER|relaxation training, moderate exercise training|combination of the two interventions: relaxation training and moderate exercise training
62005720|NCT01546948|EXPERIMENTAL|Methadone|Patients in the methadone group will be administered 0.3 mg/kg of methadone intraoperatively: two-thirds of the dose (6 cc or 0.2 mg/kg of methadone) on induction of anesthesia as a bolus. The remainder of the dose (3 cc or 0.1 mg/kg of methadone) will be administered at approximately 1.5-2 hours before the end of the procedure.
62005721|NCT01546948|ACTIVE_COMPARATOR|Hydromorphone|Patients in the hydromorphone group will receive 0.03 mg/kg of hydromorphone; two-thirds the dose (6 cc or 0.02 mg/kg) on induction of anesthesia, and the remainder of the hydromorphone (3 cc or 0.01 mg/kg) will be bolused 1.5-2 hours before surgery concludes.
62005722|NCT02143843|EXPERIMENTAL|13 mg Bimatoprost Ocular Insert|13 mg Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new 13 mg Bimatoprost Ocular Insert and used continuously for another 6 months.
62005723|NCT01529528|PLACEBO_COMPARATOR|Placebo of CWP-0403 100mg|Placebo of CWP-0403 100mg
62005724|NCT01529528|EXPERIMENTAL|CWP-0403 200mg|CWP-0403 200mg
62572517|NCT04519268||Elective Surgical Adult Patients|Adult patients scheduled for an elective general surgical operation.
62572518|NCT03807479|EXPERIMENTAL|Ponatinib|Patients in this treatment arm receive Ponatinib: starting dose 30 mg once-daily. Doses may be increased in case of inappropriate response and reduced to manage drug-related adverse events (AEs) and may be re-escalated once events resolve.
62005725|NCT01529528|EXPERIMENTAL|CWP-0403 100mg|CWP-0403 100mg
62005726|NCT05321303|EXPERIMENTAL|Experimental: Serious game Experimental group|"The participants spend on one MetaHospital scenario in which Nursing Care (management of diabetic ketoacidosis)."
62005727|NCT05321303|EXPERIMENTAL|Experimental: Standardized Patients Control group|The participants spend one scenario 10 minutes; on a scenario designed to train Nursing Care (management of diabetic ketoacidosis).
62005728|NCT03461627|EXPERIMENTAL|Salmeterol Xinafoate and Fluticasone Propinate Powder|Salmeterol Xinafoate and Fluticasone Propinate Powder for inhalation (50ug/250ug) 50ug/250ug 1 puff twice a day for 4 weeks
62005729|NCT03461627|ACTIVE_COMPARATOR|Seretide|50ug/250ug 1 puff twice a day for 4 weeks
62005730|NCT04554433|ACTIVE_COMPARATOR|Intervention|A ) Treatment group will receive a combination of Asprin in anti - inflammatory dose and controlled ethanol vapor inhalation in concentraions and technique according to their medical condition .
62005731|NCT04554433|NO_INTERVENTION|Control|B ) Control group : will receive the standard protocol . Data collection will include : sociodemographic data , clinical history , results of follow up ( daily or according to clinical situation ) Follow up : to record any side effects of drugs , and swab will be taken for PCR .
62191364|NCT03313141|EXPERIMENTAL|Subjects|Only one arm is considered
62191365|NCT00777998|EXPERIMENTAL|A|Auto-Allo Tandem Stem cell Transplantation plus maintenance therapy with Thalidomide and DLI
62572519|NCT03058562|EXPERIMENTAL|Crossover Sequence A|"Each in the fasting state:~Period 1: Single-dose matching placebo~Period 2: Single-dose ABX-1431"
62572520|NCT03058562|EXPERIMENTAL|Crossover Sequence B|"Each in the fasting state:~Period 1: Single-dose ABX-1431~Period 2: Single-dose matching placebo"
62005732|NCT03411525|EXPERIMENTAL|Commitment invitation at time 1|In the stepped wedge cluster randomized design, the first clinic will remain in the control period (no intervention) for 1 month, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 8 months.
62005733|NCT03411525|EXPERIMENTAL|Commitment invitation at time 2|In the stepped wedge cluster randomized design, the second clinic will remain in the control period (no intervention) for 2 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 7 months.
62191366|NCT00777998|ACTIVE_COMPARATOR|B|Auto-Auto Tandem stem cell Transplantation plus maintenance therapy with Thalidomide
62191367|NCT03004404|EXPERIMENTAL|SRD part-Dose group 1: BI 730357 PfOS 2 mg Fasted|"Participants were administered on Day 1 a single oral dose of 2 milligram (mg) of BI 730357 powder for reconstitution of an oral solution (PfoS) reconstituted in solvent for oral solution 2 milliliter (mL) (Macrogol 400 (Polyethylene glycol 400) together with about 240 milliliter (mL) of water in fasted state.~One authorized employee of the trial site was witness of the administration of the trial medication."
62397121|NCT04926337||Tight fitting facemask|Preoxygenation with tight facemask, 100% oxygen.
62191368|NCT03004404|PLACEBO_COMPARATOR|Placebo|This arm comprises all placebo treated participants in trial part SRD, regardless of the dose group in which they were treated. Participants of the first cohort of each dose group (DG) were not randomized. In the second cohort of each DG participants were assigned to active treatment or placebo in a 3:1 allocation ratio.
62572521|NCT03058562|EXPERIMENTAL|Crossover Sequence C|"Each with a standard high fat meal:~Period 3: Single-dose matching placebo~Period 4: Single-dose ABX-1431"
62005734|NCT03411525|EXPERIMENTAL|Commitment invitation at time 3|In the stepped wedge cluster randomized design, the third clinic will remain in the control period (no intervention) for 3 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 6 months.
62005735|NCT03411525|EXPERIMENTAL|Commitment invitation at time 4|In the stepped wedge cluster randomized design, the fourth clinic will remain in the control period (no intervention) for 4 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 5 months.
62191369|NCT03004404|EXPERIMENTAL|SRD part-Dose group 2: BI 730357 PfOS 8 mg Fasted|"Participants were administered on Day 1 a single oral dose of 8 milligram (mg) of BI 730357 powder for reconstitution of an oral solution (PfoS) reconstituted in solvent for oral solution 8 milliliter (mL) (Macrogol 400 (Polyethylene glycol 400) together with about 240 milliliter (mL) of water in fasted state.~One authorized employee of the trial site was witness of the administration of the trial medication."
62191370|NCT03004404|EXPERIMENTAL|SRD part-Dose group 3: BI 730357 tablet 25 mg Fasted|Participants were administered on Day 1 a single oral dose of 25 milligram (mg) of BI 730357 film-coated tablet together with about 240 milliliter (mL) of water in fasted state. One authorized employee of the trial site was witness of the administration of the trial medication.
62191371|NCT03004404|EXPERIMENTAL|SRD part-Dose group 4: BI 730357 tablet 50 mg Fasted|Participants were administered on Day 1 a single oral dose of 50 milligram (mg) of BI 730357 film-coated tablet together with about 240 milliliter (mL) of water in fasted state. One authorized employee of the trial site was witness of the administration of the trial medication.
62397122|NCT04926337||High flow nasal oxygen|Preoxygenation with high flow nasal oxygen, 100% oxygen
62397123|NCT00403429|EXPERIMENTAL|Capecitabine|
62005736|NCT03411525|EXPERIMENTAL|Commitment invitation at time 5|In the stepped wedge cluster randomized design, the fifth clinic will remain in the control period (no intervention) for 5 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 4 months.
62191372|NCT03004404|EXPERIMENTAL|SRD part-Dose group 5: BI 730357 tablet(s) 100 mg Fasted|Participants were administered on Day 1 a single oral dose of 100 milligram (mg) of BI 730357 film-coated tablets (2x50mg) together with about 240 milliliter (mL) of water in fasted state. One authorized employee of the trial site was witness of the administration of the trial medication.
62397124|NCT02123186||newborns testing for SMA|
62397125|NCT02546193|EXPERIMENTAL|Outpatient Foley catheter (Randomized & Prospective)|"This arm reflects enrolled women who were (A) randomized to the outpatient Foley catheter group (RCT design) or (B) chose the outpatient Foley catheter group (Modified Prospective study design).~Participants underwent basic history review, fetal nonstress testing, ultrasound for presentation and amniotic fluid index, and cervical exams the evening before their scheduled induction in the Family Birth Center. A Foley catheter was placed for cervical ripening. After fetal monitoring, they were dismissed to home, to return to the Family Birth Center in the morning for continuation of their labor inductions in the inpatient setting."
62572522|NCT03058562|EXPERIMENTAL|Crossover Sequence D|"Each with a standard high fat meal:~Period 3: Single-dose ABX-1431~Period 4: Single-dose matching placebo"
62572523|NCT06575985|EXPERIMENTAL|Heat acclimation and exercise group|Experimental group who will complete an exercise training intervention under hot conditions
62572524|NCT06575985|ACTIVE_COMPARATOR|Thermo-neutral exercise training group|Control group who will complete an exercise training intervention under thermo-neutral conditions
62572525|NCT03792100|EXPERIMENTAL|SmofKabiven emulsion for infusion|SmofKabiven emulsion for infusion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drug is 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%.
62191373|NCT03004404|EXPERIMENTAL|SRD part-Dose group 6: BI 730357 tablet(s) 200 mg Fasted|Participants were administered on Day 1 a single oral dose of 200 milligram (mg) of BI 730357 film-coated tablets (4x50mg) together with about 240 milliliter (mL) of water in fasted state. One authorized employee of the trial site was witness of the administration of the trial medication.
62005737|NCT03411525|EXPERIMENTAL|Commitment invitation at time 6|In the stepped wedge cluster randomized design, the sixth clinic will remain in the control period (no intervention) for 6 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 3 months.
62397126|NCT02546193|ACTIVE_COMPARATOR|Inpatient usual care (Randomized & Prospective)|"This arm reflects enrolled women who were (A) randomized to the inpatient usual care group (RCT design) or (B) chose the inpatient usual care group (Modified Prospective study design). No participants in the modified Prospective study design were accrued due to screen failure.~Participants presented to the Family Birth Center in the evening for their scheduled induction of labor. They underwent basic history review, fetal nonstress testing, ultrasound for presentation and amniotic fluid index, and cervical exam. Cervical ripening commenced with either a Foley catheter or vaginal misoprostol per the discretion of the managing obstetric team. They remained in the inpatient setting throughout their entire labor induction course."
62005738|NCT03411525|EXPERIMENTAL|Commitment invitation at time 7|In the stepped wedge cluster randomized design, the seventh clinic will remain in the control period (no intervention) for 7 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 2 months.
62397127|NCT02976909|EXPERIMENTAL|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
62397128|NCT00895999|EXPERIMENTAL|1|Female patients (n=30) who meet criteria for major depression and chronic pelvic pain will be randomly assigned to 8 individual sessions of IPT adapted for depression and pain.
62397129|NCT00895999|OTHER|2|Female patients (n=30) who meet criteria for major depression and chronic pelvic pain will be randomly assigned to Enhanced Support and Connection to Counseling (ESCC).
62005739|NCT03411525|EXPERIMENTAL|Commitment invitation at time 8|In the stepped wedge cluster randomized design, the eighth clinic will remain in the control period (no intervention) for 8 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 1 month.
62780404|NCT01999725|EXPERIMENTAL|EDP-788|Single doses with dose escalation to continue in successive cohorts
62005740|NCT02489227|ACTIVE_COMPARATOR|Humira (adalimumab)|Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be assigned (1:1) to CHS-1420 or continue adalimumab treatment, 1 dose every 2 weeks for weeks 17-23. The assignments for treatment sequences (Treatment Period 1 and Treatment Period 2) were made randomly at the beginning of Treatment Period 1. At week 24 subjects will switch to CHS-1420 open label until study end.
62005741|NCT02489227|EXPERIMENTAL|CHS-1420|CHS-1420 40mg 2 doses at Week 0/Day 0 then 1 dose every 2 weeks starting at Week 1 for 23 weeks. At Week 24 subjects will continue on to CHS-1420 open label until study end.
62005742|NCT01464320|EXPERIMENTAL|ABT-614|
62397130|NCT01002846|EXPERIMENTAL|traditional acupuncture|Procedure : ST 36 and PC 6 are selected, subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth
62780405|NCT01999725|PLACEBO_COMPARATOR|Placebo|Single dose with matching placebo
62780406|NCT03463603||Asian racial identity|"Those who self-report Asian or related terms as their racial identity."
62780407|NCT03463603||South Asian racial identity|"Those who self-report South Asian or related terms as their racial identity."
62780408|NCT03463603||Other racial identity|"All others, who self-report neither Asian, South Asian or their related terms as their racial identity."
62780409|NCT03420885|EXPERIMENTAL|Ba Duan Jin Group|Ba Duan Jin plus health education. Participants take part in 16-week program. The health education is conducted as the Health Education Group. Besides, the participants attended two 90-minute sessions of group-based Ba Duan Jin training per week and practiced at least three 30-minute Ba Duan Jin sessions at home per day.
62780410|NCT03420885|ACTIVE_COMPARATOR|Health Education Group|Health education. Participants take part in 16-week program. The health education includes work, rest, diet and other basic programs according to the different conditions of participants.
62005743|NCT01464320|PLACEBO_COMPARATOR|Placebo Comparator|
62005744|NCT04026906|EXPERIMENTAL|Skin Glue|Patients in the intervention group will receive standard peripheral intravenous catheter (PIVC) securement (with cloth-bordered transparent polyurethane dressing (Tegaderm® I.V. Advanced) and tape). In addition they will receive a drop of cyanoacrylate glue (Dermabond® topical skin adhesive) at both the PIVC insertion site and under the hub of the catheter.
62191374|NCT03004404|EXPERIMENTAL|SRD part-Dose group 7: BI 730357 tablet(s) 400 mg Fasted|Participants were administered on Day 1 a single oral dose of 200 milligram (mg) of BI 730357 film-coated tablets (8x50mg) together with about 240 milliliter (mL) of water in fasted state. One authorized employee of the trial site was witness of the administration of the trial medication.
62191375|NCT03004404|EXPERIMENTAL|SRD part-Dose group 8-9: BI 730357 tablet(s) 400 mg Fed|"The same participants conformed the Dose group (DG) 8 and DG 9. DG 8: Participants were administered on Day 1 a single oral dose of 200 milligram (mg) of BI 730357 film-coated tablets (8x50mg) together with about 240 milliliter (mL) of water, 30 minutes (min) prior dose administration the participants consumed a standard continental breakfast.~DG 9: Participants were administered on Day 1 a single oral dose of 200 milligram (mg) of BI 730357 film-coated tablets (8x50mg) together with about 240 milliliter (mL) of water, 30 minutes (min) prior dose administration the participants consumed a standard high fat breakfast.~Both treatment periods were separated by a wash-out phase of at least 14 days between drug administration of DG 8 and DG 9. One authorized employee of the trial site was witness of the administration of the trial medication."
62191376|NCT03004404|EXPERIMENTAL|SRD part-Dose group 10: BI 730357 tablet(s) 800 mg Fed|Participants were administered on Day 1 a single oral dose of 200 milligram (mg) of BI 730357 film-coated tablets (16x50mg) together with about 240 milliliter (mL) of water, 30 minutes (min) prior dose administration the participants consumed a standard high fat breakfast. One authorized employee of the trial site was witness of the administration of the trial medication.
62005745|NCT04026906|PLACEBO_COMPARATOR|Standard Care|Patients in the control group will receive standard PIVC placement with cloth-bordered transparent polyurethane dressing (Tegaderm® I.V. Advanced) and tape.
62005746|NCT02710604|ACTIVE_COMPARATOR|CMX157 5mg versus TDF|CMX157, 5mg tablet, 28 days versus TDF(tenofovir disoproxil fumerate) 300mg tablet, 28 days
62005747|NCT02710604|ACTIVE_COMPARATOR|CMX157 10mg versus TDF|CMX157, 10mg tablet, 28 days versus TDF 300mg tablet, 28 days
62005748|NCT02710604|ACTIVE_COMPARATOR|CMX157 25mg versus TDF|CMX157, 25mg tablet, 28 days versus TDF 300mg tablet, 28 days
62005749|NCT02710604|ACTIVE_COMPARATOR|CMX157 50mg versus TDF|CMX157, 50mg tablet, 28 days versus TDF 300mg tablet, 28 days
62005750|NCT02710604|ACTIVE_COMPARATOR|CMX157 100mg versus TDF|CMX157, 100mg tablet, 28 days versus TDF 300mg tablet, 28 days
62005751|NCT02093637|PLACEBO_COMPARATOR|Placebo acupuncture|Placebo acupuncture up to 5 acupuncture needles\* in each ear (up to 10 needles total) at points identified by point-finder to have no electrical conductance) plus usual operative and post-operative care (narcotic and non-narcotic pain medication).
62005752|NCT02093637|EXPERIMENTAL|Battlefield Acupuncture|Usual operative and post-operative care (narcotic and non-narcotic pain medication) plus Battlefield Acupuncture (up to 5 acupuncture needles\* in each ear (up to 10 needles total), identified by a point-finder.
62005753|NCT02093637|NO_INTERVENTION|standard therapy|standard therapy
62005754|NCT06078735|EXPERIMENTAL|LockeT|These are the patients assigned for LockeT device arm to close the access site wound.
62005755|NCT06078735|NO_INTERVENTION|Manual compression|These are the patients assigned for Manual Compression arm to close the access site wound.
62005756|NCT02309281|OTHER|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
62005757|NCT04514991|EXPERIMENTAL|Treatment|Surgical sites (osteotomy) assigned to this group received endodontic microsurgery procedure+ Foundation (J. Morita USA).
62005758|NCT04514991|NO_INTERVENTION|Control|Surgical sites (osteotomy) assigned to this group receives endodontic microsurgery procedure only.
62005759|NCT00847496|EXPERIMENTAL|1|AWBAT
62005760|NCT00847496|ACTIVE_COMPARATOR|2|BIOBRANE(R)
62397131|NCT01002846|SHAM_COMPARATOR|sham acupuncture|Procedure : Beside 1cm of ST 36 and PC 6 are selected( not meridian point), subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
62397132|NCT06724874|NO_INTERVENTION|control group|
62397133|NCT06724874|EXPERIMENTAL|Web-based deep relaxation exercise|
62780411|NCT03945149|ACTIVE_COMPARATOR|Turmipure Gold™|30 subjects will be randomized under active arm and will receive Active Product at V1 and until V2 (5 weeks of treatment).
62005761|NCT00160316|EXPERIMENTAL|1|
62005762|NCT02999958|NO_INTERVENTION|Control|Sequential culture media without addition of antioxidants
62005763|NCT02999958|ACTIVE_COMPARATOR|Treatment|Sequential culture media with the addition of antioxidants
62005764|NCT02821884|EXPERIMENTAL|Combination of tDCS and NMES|Both tDCS and NMES conduct simultaneously for 30 minutes.
62005765|NCT02821884|ACTIVE_COMPARATOR|Combination of tDCS and sham NMES|Both tDCS and sham NMES conduct simultaneously for 30 minutes. Sham NMES electrodes are placed away from all motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation.
62005766|NCT02821884|SHAM_COMPARATOR|Combination of sham tDCS and sham NMES|"Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Shame tDCS is started in a ramp-like fashion but fade out slowly after 30 seconds.~Sham NMES electrodes are placed away from all motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation."
62005767|NCT06218004|EXPERIMENTAL|Group A: Neoadjuvant treatment group|envafolimab: 150 mg once every 1 week for 8 doses subcutaneously on day 1 Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.
62191377|NCT03004404|EXPERIMENTAL|BA Part: R/T2/T1|"Participants were orally administered 25 mg of BI 730357 as film-coated tablet (Reference treatment R) in fasted state.~Followed by 25 mg of BI 730357 film-coated tablet in a fed state (test treatment T2), a high-fat, high-calorie breakfast was served 30 min before dose administration.~Participants received 25 mg of BI 730357 powder for reconstitution of an oral solution (PfOS) reconstituted in solvent for oral solution 2.5 milliliter (mL) (Macrogol 400 (Polyethylene glycol 400) (test treatment T1) in fasted state.~The 3 treatments were administered with 240 mL of water and were separated by a washout period of at least 8 days. One authorized employee of the trial site was witness of the administration of the trial medication."
62397134|NCT05957315|EXPERIMENTAL|Mobile Cardiac Outpatient Telemetry Device (MCOT)|These participants will be randomized into receiving the Philips/BioTel MCOT device in addition to usual care.
62780412|NCT03945149|PLACEBO_COMPARATOR|Placebo|30 subjects will be randomized under Placebo arm and will receive placebo Product at V1 and until V2 (5 weeks of treatment).
62005768|NCT06218004|EXPERIMENTAL|Group B: Conversion therapy group|envafolimab: 150 mg once every 1 week for 8 doses subcutaneously on day 1 Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.
62005769|NCT01282216|ACTIVE_COMPARATOR|Donor PCV13|Donors receive PCV13 prior to bone marrow donation.
62005770|NCT01282216|ACTIVE_COMPARATOR|Donor Havrix|Donors receive Havrix prior to bone marrow donation.
62005771|NCT01282216|ACTIVE_COMPARATOR|Recipient vaccine|Recipients receive Havrix and PCV13 post bone marrow transplant.
62005772|NCT05177198|EXPERIMENTAL|Test group (M-MIST + Clindamycin augmented PRF)|Patients will be selected with probing pocket depth PD ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm, with vertical defects as detected in periapical radiographs will be treated with modified minimally invasive surgical technique with Clindamycin (at concentration of 150 mg/ml) augmented platelet-rich fibrin.
62005773|NCT05177198|EXPERIMENTAL|Control group (M-MIST + PRF)|Patients will be selected with probing pocket depth PD ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm, with vertical defects as detected in periapical radiographs will be treated with modified minimally invasive surgical technique with platelet-rich fibrin alone .
62005774|NCT06663618|PLACEBO_COMPARATOR|short-term glucocorticoid monotherapy|Oral prednison starts at 0.6-0.8mg/kg/d, then tapered and withdrawal in 6 months.
62005775|NCT06663618|EXPERIMENTAL|short-term glucocorticoid combined with Mycophenolate mofetil|Oral prednison starts at 0.6-0.8mg/kg/d, then tapered and withdrawal in 6 months. Oral Mycophenolate mofetil 0.75g bid for 6 months.
62005776|NCT00686491||1|Triathletes
62005777|NCT00686491||2|Cold air athletes
62005778|NCT00686491||3|Swimmers
62005779|NCT00686491||4|Other sports elite athletes
62005780|NCT00686491||5|Control subjects
62005781|NCT05631496||Patients with Knee Disorders|Patients with knee disorders such as traumatic meniscal and ligament injuries,fractures,osteoarthritis,patellofemoral joint pain
62191378|NCT03004404|EXPERIMENTAL|BA Part: R/T1/T2|"Participants were orally administered 25 mg of BI 730357 as film-coated tablet (Reference treatment R) in fasted state.~Participants received 25 mg of BI 730357 powder for reconstitution of an oral solution (PfOS) reconstituted in solvent for oral solution 2.5 milliliter (mL) (Macrogol 400 (Polyethylene glycol 400) (test treatment T1) in fasted state.~Followed by 25 mg of BI 730357 film-coated tablet in a fed state (test treatment T2), a high-fat, high-calorie breakfast was served 30 min before dose administration.~The 3 treatments were administered with 240 mL of water and were separated by a washout period of at least 8 days. One authorized employee of the trial site was witness of the administration of the trial medication."
62572526|NCT03792100|ACTIVE_COMPARATOR|"Hospital compounded All in one emulsion for PN"|"Hospital compounded All in one emulsion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drugs will be 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%."
62397135|NCT05957315|NO_INTERVENTION|Standard Treatment Group|These participants will be randomized into only receiving usual care and will not receive the MCOT device.
62572527|NCT02830503|EXPERIMENTAL|Intervention|Feeding tube daily replacement
62191379|NCT03004404|EXPERIMENTAL|BA Part: T2/R/T1|"Participants were orally administered 25 mg of BI 730357 film-coated tablet in a fed state (test treatment T2), a high-fat, high-calorie breakfast was served 30 min before dose administration.~Followed by 25 mg of BI 730357 as film-coated tablet (Reference treatment R) in fasted state.~Participants received 25 mg of BI 730357 powder for reconstitution of an oral solution (PfOS) reconstituted in solvent for oral solution 2.5 milliliter (mL) (Macrogol 400 (Polyethylene glycol 400) (test treatment T1) in fasted state.~The 3 treatments were administered with 240 mL of water and were separated by a washout period of at least 8 days. One authorized employee of the trial site was witness of the administration of the trial medication."
62191380|NCT03004404|EXPERIMENTAL|BA Part: T2/T1/R|"Participants were orally administered 25 mg of BI 730357 film-coated tablet in a fed state (test treatment T2), a high-fat, high-calorie breakfast was served 30 min before dose administration.~Participants received 25 mg of BI 730357 powder for reconstitution of an oral solution (PfOS) reconstituted in solvent for oral solution 2.5 milliliter (mL) (Macrogol 400 (Polyethylene glycol 400) (test treatment T1) in fasted state.~Followed by 25 mg of BI 730357 as film-coated tablet (Reference treatment R) in fasted state.~The 3 treatments were administered with 240 mL of water and were separated by a washout period of at least 8 days. One authorized employee of the trial site was witness of the administration of the trial medication."
62005782|NCT03734198|EXPERIMENTAL|Ibrutinib + daratumumab|"Prephase (D-27 to D0): ibrutinib 420 mg/day~Cycle 1 (4 weeks): ibrutinib 420 mg/day from D1 to D28 + daratumumab 8 mg/kg D1 and D2, then 16 mg/kg at D8, D15, D22.~Cycle 2 (4 weeks): ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1, D8, D15 and D22.~Cycles 3 to 6 (4 weeks) : ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1 and D15.~Cycles ≥ 7 (4 weeks) : ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1."
62005783|NCT02837536|ACTIVE_COMPARATOR|Horizontal iCare|In the horizontal iCare arm, these patients were randomized to have their IOP measured with the iCare tonometer held in the horizontal position first and then their IOP measured with the iCare tonometer held in the vertical position.
62397136|NCT03270280|PLACEBO_COMPARATOR|Normal Saline|The group contains healthy individuals with chronic periodontitis who will receive Normal Saline as placebo
62005784|NCT02837536|ACTIVE_COMPARATOR|Vertical iCare|In the vertical iCare arm, these patients were randomized to have their IOP measured with the iCare tonometer held in the vertical position first and then their IOP measured with the iCare tonometer held in the horizontal position.
62005785|NCT02397356|EXPERIMENTAL|Ketamine first AB|Patients in this group will first receive a dose of ketamine in the nebulised form when they ask for pain relief. The second time they ask for pain relief, they will receive physiological salt in the nebulised form.
62005786|NCT02397356|ACTIVE_COMPARATOR|Placebo first BA|Patients in this group will first receive physiological salt in the nebulised form form when they ask for pain relief. The second time they ask for pain relief, they will receive a dose of ketamine in the nebulised.
62005787|NCT03527212|EXPERIMENTAL|SJP-0035 0.001% (ophthalmic solution)|
62005788|NCT03527212|PLACEBO_COMPARATOR|Placebo (ophthalmic solution)|
62005789|NCT03592641|EXPERIMENTAL|Treatment (savolitinib)|Patients receive savolitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62005790|NCT05264324|EXPERIMENTAL|High altitude 2500 m above sea level (high altitude)|Maximum Exercise Capacity in high altitude
62005791|NCT05264324|ACTIVE_COMPARATOR|Low altitude 470 m above sea level (low altitude)|Maximum Exercise Capacity in low altitude
62005792|NCT02461420||Phelan-McDermid Syndrome|Phelan-McDermid Syndrome
62005793|NCT06451523|EXPERIMENTAL|Alliance180 Program|Participants will attend the 3-day Alliance180 Program.
62005794|NCT06513585||Superselective adrenal artery embolization group|Superselective adrenal artery embolization for primary aldosteronism
62005795|NCT06513585||adrenalectomy group|adrenalectomy for primary aldosteronism
62005796|NCT04035785|EXPERIMENTAL|Kangfu anti-inflammatory suppository|"Kangfu Xiaoyan Suppository was used for 21 days, while levofloxacin + metronidazole for 10 days, levofloxacin + metronidazole for 4 days.~One of the levofloxacin quinolones has broad-spectrum antimicrobial activity and strong antimicrobial activity.~Metronidazole is mainly used to treat or prevent systemic or local infections caused by the above-mentioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
62005797|NCT04035785|PLACEBO_COMPARATOR|antibiotics alone group|"One of the levofloxacin quinolones has broad-spectrum antimicrobial activity and strong antimicrobial activity. It has strong antimicrobial activity against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and Haemophilus influenzae, Legionella pneumophila, Neisseria gonorrhoeae and other gram-negative bacteria. Bacterial activity.~Metronidazole is mainly used to treat or prevent systemic or local infections caused by the above-mentioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
62005798|NCT04686097|EXPERIMENTAL|experimental group (electrocoagulation)|Participants in the experimental group will receive ultrasound-guided puncture of coagulation incompetent perforator veins.
62397137|NCT03270280|EXPERIMENTAL|Nigella Sativa|The group contains healthy individuals with chronic periodontitis who will receive Nigella sativa Oil as intervention
62572528|NCT02830503|NO_INTERVENTION|Control|Feeding tubes replaced as normal practice in the department (normally once a week).
62572529|NCT01580605||Users of somatropin|
62005799|NCT04686097|ACTIVE_COMPARATOR|control group (sclerotherapy)|Participants in the control group will receive an ultrasound-guided sclerosing agent injected.
62191381|NCT03004404|EXPERIMENTAL|BA Part: T1/R/T2|"Participants received 25 mg of BI 730357 powder for reconstitution of an oral solution (PfOS) reconstituted in solvent for oral solution 2.5 milliliter (mL) (Macrogol 400 (Polyethylene glycol 400) (test treatment T1) in fasted state.~Followed by 25 mg of BI 730357 as film-coated tablet (Reference treatment R) in fasted state.~Participants were orally administered 25 mg of BI 730357 film-coated tablet in a fed state (test treatment T2), a high-fat, high-calorie breakfast was served 30 min before dose administration.~The 3 treatments were administered with 240 mL of water and were separated by a washout period of at least 8 days. One authorized employee of the trial site was witness of the administration of the trial medication."
62780413|NCT05185414|OTHER|RNA sequencing in genetically solved lissencephaly cases|RNA expression patterns in lissencephalies. RNA sequencing will be applied to the genetically solved lissencephaly cases. The acquired information on RNA expression patterns will be implemented in unsolved lissencephaly cases.
62005800|NCT05478174|EXPERIMENTAL|HSK3486|HSK3486 for general anesthesia induction
62005801|NCT05478174|ACTIVE_COMPARATOR|Propofol|Propofol for general anesthesia induction
62005802|NCT02624102|EXPERIMENTAL|Cognitive therapy|Major depressive disorder treated with cognitive therapy (Trial Based Cognitive Therapy plus Drug).
62005803|NCT02624102|EXPERIMENTAL|Behavioral Therapy|Major depressive disorder treated with behavioral therapy (Behavioral Activation plus drug).
62005804|NCT02624102|OTHER|Antidepressants|Major depressive disorder treated only with antidepressants (Drug alone).
62005805|NCT04135716|EXPERIMENTAL|Exposed group|Patients will receive colonoscopy with assistance of Endo.Angel
62005806|NCT04135716|SHAM_COMPARATOR|Non-exposed group|Patients will receive colonoscopy without assistance of Endo.Angel
62005807|NCT05301335|EXPERIMENTAL|Therapeutic Arm|
62397138|NCT02515890|EXPERIMENTAL|Dexmedetomidine Only|All subjects receive saline (control), followed by a dexmedetomidine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
62397139|NCT02515890|EXPERIMENTAL|Midazolam Only|Subjects receive saline (control), followed by midazolam infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
62397140|NCT02515890|EXPERIMENTAL|Ketamine Only|All subjects receive saline (control), followed by ketamine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
62780414|NCT05185414|OTHER|RNA sequencing in genetically unsolved lissencephaly cases|Obtain a genetic diagnosis in unsolved lissencephaly cases by implementation of RNA expression patterns obtained in arm 1.
62005808|NCT05301335|SHAM_COMPARATOR|Sham Arm|
62005809|NCT05902390|EXPERIMENTAL|hydrogel spacer|The Subjects randomized to the treatment group underwent placement of hydrogel spacer.
62005810|NCT05902390|NO_INTERVENTION|Control|The Subjects randomized to the control group did not receive injection of the hydrogel spacer.
62780415|NCT05475236|SHAM_COMPARATOR|Sham Stimulation|Participants will undergo 30 seconds of 2 mA electrical current to the head through saline soaked electrodes.
62780416|NCT05475236|EXPERIMENTAL|Transcranial Direct Current Simulation|Participants will undergo 20 minutes of 2 mA electrical stimulation to the head through saline soaked electrodes.
62780417|NCT06228859|EXPERIMENTAL|Group I (LOA): Patients were given overdentures with locator attachments.|locater groups or overdenture attachment
62005811|NCT02384603|EXPERIMENTAL|GPR and CBT|Global postural reeducation associated with cognitive behavioral therapy; 01 session per week for 10 weeks
62005812|NCT02384603|ACTIVE_COMPARATOR|SMSE and CBT|Segmental muscle stretching exercises associated with cognitive behavioral therapy; 01 session per week for 10 weeks
62005813|NCT02988063|EXPERIMENTAL|Compression plus PEM|Patients will receive 4-5 weeks of compression therapy, followed by treatment with 1% polidocanol endovenous microfoam (PEM) and 12 additional weeks of compression therapy. If the treating physician determines that the vein is not closed after a subjective assessment of vein patency via standard-of-care limited duplex imaging, patients will be re-treated with PEM on Day 4.
62005814|NCT01823029|EXPERIMENTAL|erythropoietin,injection of iron and enteral nutrition|The patients receive treatment of erythropoietin,injection of iron and enteral nutrition.
62005815|NCT01823029|EXPERIMENTAL|erythropoietin and enteral nutrition.|The patients receive treatment of erythropoietin and enteral nutrition.
62005816|NCT04777890|ACTIVE_COMPARATOR|suboccipital inhibition technique group|
62005817|NCT04777890|EXPERIMENTAL|INYBI group|Participants in this group will be treated with the INYBI, an instrument designed for treating the suboccipital area, in a more precise way than the manual technique.
62397141|NCT02515890|EXPERIMENTAL|Saline/Midazolam/Saline/Ketamine|"All subjects receive saline (control), followed by midazolam infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.~Subjects then returned at least 1 week later for another set of experimental sessions with the same design, however the saline was followed by ketamine infusion."
62397142|NCT02515890|EXPERIMENTAL|Saline/Ketamine/Saline/Midazolam|"All subjects receive saline (control), followed by ketamine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.~Subjects then returned at least 1 week later for another set of experimental sessions with the same design, however the saline was followed by midazolam infusion."
62780418|NCT06228859|EXPERIMENTAL|Group II (TIA): Patients were given overdentures with TITACH attachment.|TITACH groups for overdenture attachment
62397143|NCT03160131|ACTIVE_COMPARATOR|Intervention|All participants receive NVT course training and are tested at baseline and at the end of the study for primary and secondary endpoints.
62397144|NCT03160131|NO_INTERVENTION|Control|All participants receive no NVT course training and are tested at baseline and at the end of the study for primary and secondary endpoints.
62397145|NCT05127642||Postpartum hemorrhage patients|
62397146|NCT05127642||Controls (non postpartum hemorrhage patients)|
62572530|NCT03616574|EXPERIMENTAL|Dose Escalation - CA102N Monotherapy|0.36, 0.54, and 0.72 mg/kg of nimesulide equivalents of CA102N on Days 1 and 15 of a 28-day cycle
62780419|NCT03387358||Historical Comparison Group|This group includes patients who were admitted to St. Paul's Hospital ICU (Vancouver BC, Canada) from September 2014 to September 2015, and had a small bore feeding tube in place at some point during their ICU admission, and were matched to key variables to the prospective observational treated group.
62005818|NCT04777890|EXPERIMENTAL|combined treatment group|Participants in this group will be first treated with the INYBI and then receive an upper cervical manipulation
62397147|NCT05881538|EXPERIMENTAL|Exercise group|"16 weeks of a High Intensity Interval Training exercise program conducted telematically with real time supervision twice a week.~The exercise program consists of a circuit of exercises aiming to achieve a target heart rate for each fitness level."
62572531|NCT03616574|EXPERIMENTAL|Dose Escalation - CA102N plus LONSURF|0.36, 0.54, and 0.72 mg/kg of nimesulide equivalents of CA102N on Days 1 and 15 in combination with 35 mg/m2/dose of LONSURF orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle
62572532|NCT03616574|EXPERIMENTAL|Dose Expansion - CA102N plus LONSURF|The preliminary RP2D of CA102N on Days 1 and 15 in combination with 35 mg/m2/dose of LONSURF orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle
62791796|NCT04158583|EXPERIMENTAL|Part A: Cohort 4 RO7296682 6 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 6 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade \>=4, IRR; Grade \>=4, immune-mediated adverse events; Grade \>=4) were discontinued from study treatment.
62005819|NCT00333229|EXPERIMENTAL|Zoledronic Acid|Patients randomized into the Zometa arm received a total of 8 study drug infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.
62005820|NCT00333229|PLACEBO_COMPARATOR|Placebo|Patients randomized into the Placebo Arm received a total of 8 placebo infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.
62791797|NCT04158583|EXPERIMENTAL|Part A: Cohort 5 RO7296682 18 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 18 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade \>=4, IRR; Grade \>=4, immune-mediated adverse events; Grade \>=4) were discontinued from study treatment.
62005821|NCT06086184|EXPERIMENTAL|ACT group therapy|High-frequency inpatient ACT group therapy program for patients with psychosis spectrum disorder.
62005822|NCT02321982|NO_INTERVENTION|Separate-day preoperative consultation|Patients referred for Mohs surgery for non-melanoma skin cancer will have a preoperative consultation in advance of the day of the procedure.
62005823|NCT02321982|EXPERIMENTAL|Same-day preoperative consultation|Patients referred for Mohs surgery for non-melanoma skin cancer will have a preoperative consultation on the day same day as the procedure.
62005824|NCT00466960|EXPERIMENTAL|Treatment (colony stimulating factor and chemotherapy)|"INDUCTION THERAPY: Patients receive GM-CSF SC once daily on days 16-26. Patients also receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 14 days after last GM-CSF injection, patients receive GM-CSF SC once daily on days 1-15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
62005825|NCT00648531|EXPERIMENTAL|1|Balsalazide Disodium Capsules 750 mg
62005826|NCT00648531|ACTIVE_COMPARATOR|2|Colazal® Capsules 750 mg
62005827|NCT02966171|EXPERIMENTAL|HMPL-453|Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, untill disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 25, 50, 100, 200, 300, 400, and 500 mg/day.
62005828|NCT05796128|ACTIVE_COMPARATOR|LISA with NCPAP|In this group, infants will receive NCPAP during LISA procedure.
62005829|NCT05796128|EXPERIMENTAL|LISA with NIPPV|In this group, infants will receive NIPPV during LISA procedure.
62005830|NCT01285765|EXPERIMENTAL|Early-PET-result-adapted treatment|4 to 6 RCHOP21
62005831|NCT01285765|ACTIVE_COMPARATOR|standard treatment|6 RCHOP21
62005832|NCT05247190|EXPERIMENTAL|Treating self-criticism|8-session group intervention targeting self-criticism given 2-hrs/week with booster session after 3-months.
62005833|NCT02100267|EXPERIMENTAL|Asthma patients|
62005834|NCT02100267|EXPERIMENTAL|Healthy volunteers|
62005835|NCT05373511||bronchial asthma|"Inclusion criteria:~Participants over the age of 18 who have had mild to moderate bronchial asthma since childhood and have been referred by a pulmonologist or physician~Exclusion criteria:~Participants with other health issues such as cardiorespiratory issues, neurological deficits or diseases such as nerve compressions, any chronic diseases or suffering from respiratory tract infections, participants with a history of previous serious injuries to the musculoskeletal system, which may result in body posture disturbances Any disease that impairs one's sense of balance"
62005836|NCT05373511||non-asthmatic control group:|"Inclusion and Exclusion criteria for non-asthmatic control group:~Inclusion criteria:~For the healthy subjects referred by a consultant pulmonologist/physician, age- and gender-matched volunteers were recruited from the community~Exclusion criteria:~Other health issues, such as cardiorespiratory issues, neurological deficits, musculoskeletal problems, and peripheral vascular diseases\& pregnancy may affect test performance."
62005837|NCT05913219||Participants with long-term conditions affecting movement|A total number of 120 people with long-term conditions affecting their movement include people with Parkinson's (N=60), stroke (N=30), those living with arthritis (N=30).
62005838|NCT05913219||Healthy control|A total number of 30 healthy people with no condition impacting their movement and walking ability.
62397148|NCT05881538|NO_INTERVENTION|Control group|Routine physician recommendations for physical activity.
62780420|NCT03387358||Prospective Observational Treated Group|This group includes all patients who were admitted to St. Paul's Hospital ICU from Nov. 2017 to Dec. 2018, and nasal bridle securement device for small bore feeding tubes at some point during their ICU admission. The clinical indicators for a nasal bridle securement device outlined in our nursing practice standards include one or more of the following: recurrent nasoenteric tube dislodgement; confused and/or agitated patients; fluoroscopically or endoscopically placed nasoenteric tube; history of difficult tube placement; facial burn victims with nasoenteric tube; and/or oily skin causing decreased adhesion of traditional securement.
62780421|NCT03104257||Cannabis Dependent Subjects|Subjects who are frequent cannabis users
62005839|NCT02136875|EXPERIMENTAL|Double dose of Advair for AECOPD|Double dose of Salmeterol + Fluticasone Propionate (Advair) Self-administered prescription Self-management education on the use of a self-administered prescription
62780422|NCT03104257||Healthy Controls|Subjects with no current cannabis use
62780423|NCT02332291|ACTIVE_COMPARATOR|Blinded Escitalopram / Open-Label Bupropion|8 weeks of blinded escitalopram, followed by 8 weeks of open-label bupropion xl for nonremitters
62780424|NCT02332291|PLACEBO_COMPARATOR|Blinded Placebo / Open-Label Bupropion|8 weeks of blinded placebo, followed by 8 weeks of open-label bupropion xl for nonremitters.
62780425|NCT00156390|EXPERIMENTAL|1|echo-guided LV lead placement
62005840|NCT02995395||Mucosal Impedance Balloon catheter|At the conclusion of the endoscopy, all fluids will be aspirated from the esophagus. The endoscope will then be left in place in the mid-esophagus and a custom Mucosal Impedance (MI) balloon assembly four axial arrays of 10 sensors (total of 40 sensors) will be positioned along the esophageal mucosal wall under direct visualization to directly measure MI at uniform intervals. Once in place, impedance readings will be recorded for a total of 2 minutes. At this point both the endoscope and impedance catheter will be withdrawn simultaneously.
62005841|NCT00554749|OTHER|1 Behavioral intervention|Behavioral intervention in all seven subjects Weekly sessions in the home and the kindergarten using defocused communication and stimulus fading interventions
62005842|NCT00705575|EXPERIMENTAL|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|
62214724|NCT00927030|PLACEBO_COMPARATOR|flavored inert liquid|Of the 30 targeted participants, 18 will be randomized at the first three week dosing period {1mg of melatonin}. The randomization will be single blind to the parent in a 5:1 ratio (15 children will receive melatonin, and 3 children will receive a flavored placebo at the first 3-week period only). After the initial 3-week dose cycle of 1 mg, all children randomized to placebo will begin 3 mg of melatonin and will continue in dose increase (6mg, 9 mg)until they meet the criteria of falling asleep within 30 minutes of bedtime 5/7 nights per week. No child will take more than 9 mg.
62780426|NCT00156390|OTHER|2|LV lead placement as per standard of care (without echo-guidance)
62005843|NCT00705575|ACTIVE_COMPARATOR|Aliskiren (300 mg)|
62005844|NCT01322204|EXPERIMENTAL|1|Neonates 0-30 days, no more than 2,000 grams, receiving mechanical ventilation.
62005845|NCT01544972|ACTIVE_COMPARATOR|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days
62005846|NCT01544972|ACTIVE_COMPARATOR|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
62005847|NCT00414661||Study group|All enrolled subjects
62005848|NCT05626881|ACTIVE_COMPARATOR|PRP group|It will include patients with melasma treated with PRP sessions every two weeks for three monthsPRP is injected intralesionally at the site of melasma using a 30 G hypodermic needle through an insulin syringe. A maximum of 2.0 ml of PRP will be injected into the dermis (about 1.5-2.0 mm deep) about 1 cm apart to raise dermal papules
62005849|NCT05626881|ACTIVE_COMPARATOR|Silymarin group|It will include patients with melasma applying with topical Silymarin cream. Silymarin cream will be prepared in the Faculty of Pharmcy according to the following formulation: stearic acid 15 g, glycerin 5 g, KOH 0.72 g, H2O 79 g, sodium benzoate (0.1%), and Tween-80 (1%). Silymarin was manufactured with concentration of 1.4%. Silymarin will be applied twice daily. The duration of treatment will be 3 months.
62780427|NCT00186901|PLACEBO_COMPARATOR|1A|Nutritional counseling + placebo
62780428|NCT00186901|EXPERIMENTAL|1B|Nutritional counseling + supplementation with calcium, 1000mg/day + vitamin D, 800 units/day, for a 2 year period
62780429|NCT01068769|EXPERIMENTAL|Regorafenib|Regorafenib adminstered orally, 160 mg per day on days 1 through 21 of a 28 day cycle
62780430|NCT06016868||Interventional|
62780431|NCT04929080|EXPERIMENTAL|JS004 200mg, Q3W until to 2 years|Part A: phase I: 3-6; phase II: 66.
62780432|NCT04929080|EXPERIMENTAL|JS004 600mg, Q3W until to 2 years|Part A: phase I: 3-6; phase II: 66.
62780433|NCT04929080|EXPERIMENTAL|240mg JS001+100mg JS004, Q3W until to 2 years|Part B: phase I: 6; phase II: 68.
62780434|NCT04929080|EXPERIMENTAL|240mg JS001+200mg JS004, Q3W until to 2 years|Part B: phase I: 6; phase II: 68.
62397149|NCT01614028|ACTIVE_COMPARATOR|Total Hip Arthroplasty using Fitmore femoral stem|
62397150|NCT01614028|ACTIVE_COMPARATOR|Total Hip Arthroplasty using M/L Taper Femoral stem|
62397151|NCT04038411|EXPERIMENTAL|PD-1 Antibody, chidamide, lenalidomide and etoposide|PD-1 Antibody: 240mg, d1, Chidamide: 20mg, twice a week, Lenalidomide: 25mg, d1-14 Etoposide:100mg/m2, d1-3 and 21 days made one treatment cycle.
62397152|NCT06420206|OTHER|Acute Cancer Care Center|In Group 1, participants will receive the usual standard of care, during your emergency room visit, provided by the Acute Cancer Care Center (ACCC) treating doctor who will address symptoms and other medical problems that brought the participant to the emergency room.
62791798|NCT04158583|EXPERIMENTAL|Part A: Cohort 6 RO7296682 35 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 35 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade \>=4, IRR; Grade \>=4, immune-mediated adverse events; Grade \>=4) were discontinued from study treatment.
62397153|NCT06420206|OTHER|Goals of Care|In Group 2, participants will receive the above usual standard of care plus goals of care (GOC) intervention.
62397154|NCT06377488|EXPERIMENTAL|Test Arm|Eligible subjects who are habitual soft contact lens wearers will be fit with the TEST lens in both eyes, to wear the lens for a minimum of 6 hours a day, every day, between visits for approximately 2 weeks.
62397155|NCT06176092||Younger Adults (ages 20-39)|The study will examine age differences in learning to trust using laboratory tasks and surveys.
62397156|NCT06176092||Older Adults (60 and older)|The study will examine age differences in learning to trust using laboratory tasks and surveys.
62572533|NCT05707468|ACTIVE_COMPARATOR|A (hormone)|The patients in arm A with oligometastatic PCa will receive long-term ADT combined with abiraterone.
62572534|NCT05707468|EXPERIMENTAL|B (neoadjuvant hormone and RT)|The patients in arm B with oligometastatic PCa will receive 1 month of naADT, followed by metastasis-directed radiation and abdominal or pelvic radiotherapy. Then, radical prostatectomy will be performed at intervals of 5-15 weeks after radiotherapy, and long-term ADT will be continued.
62397157|NCT02078141|EXPERIMENTAL|18F-deoxyglucose (FDG)|18F-deoxyglucose (FDG)
62397158|NCT06724042|EXPERIMENTAL|Part 1 Dose escalation|An open-label dose escalation of ISM5939 administered orally as a single agent in patients with advanced or metastatic solid tumors.
62397159|NCT06724042|EXPERIMENTAL|Part 2 Dose optimization|ISM5939 will be administered orally as a single agent in patients with advanced or metastatic solid tumors in 2 selected dose levels to determine RP2D of ISM5939 monotherapy.
62397160|NCT06724042|EXPERIMENTAL|Part 3 Dose expansion|This will be an open-label evaluation of ISM5939 administered orally in combination with cisplatin, docetaxel, or pembrolizumab in patients with selected advanced solid tumors. Each of the combination cohort will start with safety run-in dose escalation for ISM5939. Subsequent subjects will then be enrolled in combination expansion cohorts with a fixed dose of ISM5939 selected by safety review committee.
62397161|NCT06076902|EXPERIMENTAL|Treatment group with patch augmentation|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented with a synthetic polyester patch
62397162|NCT06076902|ACTIVE_COMPARATOR|Comparison group without patch augmentation|Arthroscopic rotator cuff reconstruction using fixation with anchors and no augmentation with a synthetic polyester patch
62397163|NCT06469216|ACTIVE_COMPARATOR|30 ml of Hyaluronic Acid (HA) enema will be given to the patients|All patients will be prospectively randomized into two groups; either the treatment (HA) group or the control group. In this study protocol, 30 ml of HA enema and 30 ml of placebo enema (identical to treatment group enema but without HA) will be given to the patients as they lie on their left side with their right knee pulled up to the chest.
62572535|NCT06576700|EXPERIMENTAL|Active supplement|Treatment: the capsules contains Grape Seed Extract GSE-0001- Proanthocyanidins \<95%)
62572536|NCT00640757|ACTIVE_COMPARATOR|Low Methionine 1|Methionine deficient diet
62572537|NCT00640757|PLACEBO_COMPARATOR|Placebo 2|Placebo comparator methionine complete diet
62572538|NCT04856306||Myomectomy|After routine patient counseling on fibroid treatments, this group chooses surgical myomectomy of any type (abdominal/laparoscopic/hysteroscopic)
62572539|NCT04856306||Uterine artery embolization|After routine patient counseling on fibroid treatments, this group chooses uterine artery embolization procedure.
62191382|NCT03004404|EXPERIMENTAL|BA Part: T1/T2/R|"BA Part: T1/T2/R Participants received 25 mg of BI 730357 powder for reconstitution of an oral solution (PfOS) reconstituted in solvent for oral solution 2.5 milliliter (mL) (Macrogol 400 (Polyethylene glycol 400) (test treatment T1) in fasted state.~Participants were orally administered 25 mg of BI 730357 film-coated tablet in a fed state (test treatment T2), a high-fat, high-calorie breakfast was served 30 min before dose administration.~Followed by 25 mg of BI 730357 as film-coated tablet (Reference treatment R) in fasted state.~The 3 treatments were administered with 240 mL of water and were separated by a washout period of at least 8 days. One authorized employee of the trial site was witness of the administration of the trial medication."
62397164|NCT06469216|PLACEBO_COMPARATOR|30 ml of placebo enema (identical to treatment group enema but without HA) will be given to patients|All patients will be prospectively randomized into two groups; either the treatment (HA) group or the control group. In this study protocol, 30 ml of HA enema and 30 ml of placebo enema (identical to treatment group enema but without HA) will be given to the patients as they lie on their left side with their right knee pulled up to the chest.
62397165|NCT05282901|EXPERIMENTAL|Metastatic Uveal MElanoma patients|Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of metastatic uveal melanoma (UM)
62397166|NCT01263652|ACTIVE_COMPARATOR|IMmed|Patients receiving intra-muscular medication and oral placebo
62397167|NCT01263652|ACTIVE_COMPARATOR|POmed|Patients receiving intra-muscular placebo and oral medication
62005850|NCT05626881|ACTIVE_COMPARATOR|PRP + silymarin group|It will be treated by using both PRP sessions and applying topical Silymarin cream. Silymarin will be applied twice daily, while PRP sessions every 2 weeks.
62005851|NCT05010174||Observational, long-term safety follow-up of patients who have received MDR product|Only patients who have received treatment with MDR product will be eligible for this study.
62005852|NCT06663787||Continuing anti-HER2 treatment|Breast cancer patients who are continuing complete response (CR) or partial response (PR) for more than two years of anti-HER2 treatment (trastuzumab, pertuzumab, T-DM1, and T-DXd)
62191383|NCT05105048|EXPERIMENTAL|mRNA-1647|CMV-seronegative or CMV-seropositive participants will receive mRNA-1647 vaccine by intramuscular (IM) injection in a 0-, 2-, and 6-month schedule.
62191384|NCT05105048|PLACEBO_COMPARATOR|Placebo|CMV-seronegative or CMV-seropositive participants will receive placebo matching to mRNA-1647 vaccine by IM injection in a 0-, 2-, and 6-month schedule.
62191385|NCT05616377||target therapy + local therapy group vs target therapy alone group|
62397168|NCT03878576|ACTIVE_COMPARATOR|REFERENCE: white bread - BGL0 [RP]|Participants consume a meal of bread BGL0 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
62397169|NCT03878576|EXPERIMENTAL|TEST: b-glucan enriched bread - BGL2 [IP1]|Participants consume a meal of bread BGL2 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
62397170|NCT03878576|EXPERIMENTAL|TEST: b-glucan enriched bread - BGL3 [IP2]|Participants consume a meal of bread BGL3 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
62397171|NCT03878576|EXPERIMENTAL|TEST: b-glucan enriched bread - BGL4 [IP3]|Participants consume a meal of bread BGL4 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
62397172|NCT01258751|EXPERIMENTAL|PF-05212377|
62191386|NCT05616377||local therapy before target therapy group vs local therapy after target therapy group|
62191387|NCT01337206|EXPERIMENTAL|Stenting Arm|Stenting Arm
62191388|NCT01337206|ACTIVE_COMPARATOR|Dilation Arm|Dilation Arm
62191389|NCT05776290|EXPERIMENTAL|Hyaluronic acid injection|The hyaluronic acid will be injected into the implant socket before implantation.
62397173|NCT04983927||Ischemic stroke positive|Patients diagnosed with acute ischemic stroke after a brain CT scan
62780435|NCT05126849|EXPERIMENTAL|Haploidentical allogeneic hematopoietic stem cell transplantation.|"1. Conditioning regimen Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day-1)~2. Stem cell source Bone Marrow~3. GVHD Prophylaxis Rabbit ATG dosed at 0.5 mg/kg on day -9 and 2 mg/kg on days -8 and -7, Cyclophosphamide 50 mg/Kg/day at D+3 and D+4, Tacrolimus (residual 8-12 microg/L) and mycophenolate (MMF) from D+5. In absence of GvHD, MMF will be stopped at D35 and tacrolimus at day 365.~4. Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT, Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine."
62780436|NCT05463250|EXPERIMENTAL|Smart Watch, then no intervention|Physicians will be asked to wear a Smartwatch for 6 months, and then will be monitored for the following 6 months without wearing a Smartwatch. Physicians will complete surveys about their experiences
62780437|NCT05463250|EXPERIMENTAL|No intervention, then Smart Watch|Physicians will be monitored for the first 6 months without wearing a Smartwatch, and then will be asked to wear a Smartwatch for the following 6 months. Physicians will complete surveys about their experiences
62780438|NCT00691743||1|Primary care
62780439|NCT01161537|EXPERIMENTAL|VX-770|"Part A: Subjects received placebo tablets matched to VX-770 150 milligram (mg) orally twice daily from Day 1 to 14 (Placebo run-in period), followed by VX-770 150 mg tablets orally twice daily from Day 15 to 42 (VX-770 treatment period), and then placebo tablets matched to VX-770 150 mg orally twice daily from Day 43 to 57 (Placebo washout period) during Part A of the study.~Part B: Subjects received VX-770 150 mg tablets orally twice daily for 48 weeks during Part B of the study. Part B included subjects from Part A and newly enrolled subjects."
62780440|NCT01301859|ACTIVE_COMPARATOR|TIP Adherence Intervention|The TIP program is a brief, individualized intervention designed as an adjunct to pharmacotherapy for depression prescribed by a primary care physician. The key to the intervention is the involvement of the older adult in creating an adherence strategy tailored to his/her barriers and needs.
62780441|NCT01301859|PLACEBO_COMPARATOR|Usual Care|Treatment as usual in a primary care setting
62780442|NCT00741442|EXPERIMENTAL|1|RDEA806 400 mg qd
62191390|NCT05776290|NO_INTERVENTION|Traditional treatment|The socket will be prepared in the normal manner without being injected with any material.
62191391|NCT02029768||Women with burn injury|
62780443|NCT00741442|EXPERIMENTAL|3|RDEA806 400 mg bid
62780444|NCT00741442|PLACEBO_COMPARATOR|2|Placebo QD
62780445|NCT00741442|PLACEBO_COMPARATOR|4|Placebo BID
62780446|NCT02681315|EXPERIMENTAL|6 liter/min group|Infants will be extubated to a HHHFNC (Fisher and Paykel Healthcare , Auckland, New Zealand) at ﬂow rate of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
62191392|NCT02029768||Men with burn injury|
62191393|NCT01343251||HeRO Graft|patients who are evaluated and receive a HeRO Graft implant for hemodialysis
62191394|NCT01343251||Control|control group of non-HeRO patients who are evaluated but do not receive a HeRO Graft for any reason
62191395|NCT04855942|EXPERIMENTAL|Focused Extracorporeal Shock Wave Therapy (ESWT)|2000 impulses of 5 Hz and 0.32 mJ/mm2 , twice per week for 3 weeks
62191396|NCT04855942|ACTIVE_COMPARATOR|Physiotherapy|therapeutic ultrasound, 12 times in 3 weeks
62191397|NCT01020214|EXPERIMENTAL|1|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
62191398|NCT01020214|ACTIVE_COMPARATOR|2|Benicar HCT® Tablets 40 mg/25 mg
62397174|NCT04983927||Ischemic stroke negative with other brain disease|Patients who has not been diagnosed with acute ischemic stroke after a brain CT scan, but has been diagnosed with other brain diseases.
62397175|NCT04983927||Ischemic stroke negative and no brain disease|Patients who has not been diagnosed with acute ischemic stroke after a brain CT scan and has not been diagnosed with other brain diseases.
62397176|NCT05705310|EXPERIMENTAL|Intervention Group|
62397177|NCT05705310|NO_INTERVENTION|Control Group|Individuals in the control group will receive usual care
62397178|NCT04765761|ACTIVE_COMPARATOR|PLMA with Introducer'|PLMA placed in position with the help of the introducer-tool and then the introducer-tool retained in place throughout the institution and duration of positive pressure ventilation.
62780447|NCT02681315|ACTIVE_COMPARATOR|3 liter/min group|Infants will be extubated to HHHFNC (Fisher and Paykel Healthcare , Auckland, New Zealand) a ﬂow rate of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
62780448|NCT04649177|OTHER|study group|There is only one study group in this study. All subjects will receive the OCT scanning and PROSE lens fitting.
62191399|NCT05280197|EXPERIMENTAL|liposomal bupivacaine plus free bupivacaine|
62191400|NCT05280197|PLACEBO_COMPARATOR|normal saline|
62397179|NCT04765761|ACTIVE_COMPARATOR|PLMA without Introducer|PLMA placed in position with the help of the introducer-tool and then the introducer-tool removed before institution of positive pressure ventilation.
62397180|NCT00028496|EXPERIMENTAL|Treatment (vaccine therapy, sargramostim, vaccine adjuvant)|"The first three cohorts of 3-12 patients receive escalating doses of recombinant fowlpox-CEA-TRICOM vaccine (fCEA-TRI) until the maximum tolerated dose (MTD) is determined. fCEA-TRI is administered intradermally every 2 weeks for 4 doses and then every 2 months thereafter (beginning on day 56) in the absence of disease progression or unacceptable toxicity.~The fourth and fifth cohorts of 6 patients receive fCEA-TRI at the MTD in the same manner as the first three cohorts combined with escalating doses of sargramostim (GM-CSF). GM-CSF is administered subcutaneously once daily beginning on the day of each vaccination and continuing for a total of 4 days.~The sixth through eighth cohorts of 6 patients receive fCEA-TRI at the MTD in the same manner as the first three cohorts combined with escalating doses of recombinant fowlpox-GM-CSF (rF-GM-CSF)."
62191401|NCT06164808|OTHER|Active device engagement|All subjects will wear either the Holter monitor and the HeartWatch.
62005853|NCT06663787||Follow up (stop anti-HER2 treatment)|Breast cancer patients who stopped anti-HER2 treatment with complete response (CR) or partial response (PR) after more than two years of anti-HER2 treatment(trastuzumab, pertuzumab, T-DM1, and T-DXd)
62191402|NCT01301599|EXPERIMENTAL|combination group|combination therapy of alpha blocker and 5-alpha-reductase inhibitor medication
62397181|NCT04798560||Patients undergoing Whipple operation|After Whipple operation patients will be observed for complications and emphasis will be given on the presence of postoperative pancreatic fistula (POPF) according to the ISGPF 2016 definition. There will be to arms of patients. The first will include patients that do not develop POPF or either develop Biochemical Leak (Grade A). The second group consist of patients that develop either Grade B or Grade C POPF
62191403|NCT01301599|ACTIVE_COMPARATOR|alpha blocker group|alpha blocker monotherapy
62191404|NCT01301599|ACTIVE_COMPARATOR|5 ARI group|5 alpha-reductase inhibitor group
62191405|NCT03828890|OTHER|Single Arm Trial|Intervention includes screening eye exam using Optos technology
62191406|NCT06161337|EXPERIMENTAL|Experimental group|60 young (age 18-65), healthy, normal body mass index subjects for this study.
62191407|NCT06515704||A representative sample of Polish young adults|"Polish young adults, aged 18-29, living in Poland during this period (2020-2023:~COVID-19, lockdown, economic crisis, political changes, climate changes, and the war in Ukraine). Intervention: psychological tests and psychosocial questionnaires Assessment of psychological functioning (including quality of life, mental health conditions, coping skills- adaptation to stress, global crisises, developmental crisis; resilience; postformal thinking; relationships with parents/ partners/ friends), and socio-demographics, academic performance, home, general health, habits, and attitudes."
62397182|NCT05146193||All subjects are diagnosed of having a spinal deformity|Routine care of patients with spinal deformities
62397183|NCT03911401|EXPERIMENTAL|0.3% OPA-15406|Twice daily
62397184|NCT03911401|EXPERIMENTAL|1% OPA-15406|Twice daily
62397185|NCT03911401|PLACEBO_COMPARATOR|Placebo|Twice daily
62397186|NCT02873806|OTHER|2 micro-bypass stents & travoprost|"Two iStent inject micro-bypass stents and topical travoprost~Intervention:~* Implantation of two iStent inject micro-bypass stents~* Tobramycin~* Dexamethasone"
62397187|NCT04548349|EXPERIMENTAL|Altreno Group|
62780449|NCT06002516|EXPERIMENTAL|RELIEF pathway|Patients in the intervention group (RELIEF-pathway) will receive access to the web-based education tool before visit of the outpatient clinic of Surgery or Gastroenterology.
62780450|NCT06002516|NO_INTERVENTION|Usual care|Patients assigned to the control group will receive the usual care given at participating centers. During the first visit at the surgery or gastroenterology outpatient clinic subjects are seen by a random medical specialist, who will assess history, examine the patient, and review investigations. Diagnostic and treatment decisions will be based on the physician's preference and experience and on the patients' preferred choice of treatment.
62005854|NCT01043965|ACTIVE_COMPARATOR|Diabetes|Type 2 diabetes patients without obstructive coronary disease. Interventional group: lifestyle changes and treatment with metformin.
62005855|NCT01043965|NO_INTERVENTION|Control|Control group - normal, healthy individuals.
62005856|NCT05430789|EXPERIMENTAL|Intervention group|5As brief advice + Self-help ebooklet + Nurse-led mHealth intervention
62005857|NCT05430789|ACTIVE_COMPARATOR|Control group|5As brief advice + Self-help ebooklet + Text messaging
62397188|NCT04548349|EXPERIMENTAL|BPO Group|
62191408|NCT04990778|EXPERIMENTAL|Treatment (eprenetapopt, venetoclax)|Patients receive eprenetapopt IV over 6 hours on days 1-4 and venetoclax PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62397189|NCT04548349|NO_INTERVENTION|Control Group|During the entire study period, the subjects in the control group will not be allowed to use any antibacterial wash, other than approved OTC cleansers.
62397190|NCT06146010||german leptomeningeal disease register|The aim of the leptomeningeal disease register is to establish an internet-based cancer register in which patients with leptomeningeal disease are recorded at the time of diagnosis and after appropriate information and consent to data collection. Due to the rapid progression of the disease and potential rapid deterioration, inclusion must take place at the time of diagnosis. The course of the disease in individual patients is then documented retrospectively on the basis of routine clinical care data for the entire duration of the study or until the death of the participating patients.
62780451|NCT04412707|ACTIVE_COMPARATOR|Arm A|Melflufen 40 mg iv Day 1 of each 28 day cycle. Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle, if \> 75 years of age 20 mg. Cycle 1 will be administered via a Peripheral Venous Catheter (PVC) and cycle 2 and onwards melflufen will be administered via a Central Venous Catheter (CVC).
62191409|NCT03865953|ACTIVE_COMPARATOR|LAT8881|1 x 30 mg capsule of LAT8881 taken by mouth, twice daily (morning and evening) during the four-week treatment period.
62191410|NCT03865953|PLACEBO_COMPARATOR|Placebo|1 x 30 mg capsule of placebo, taken by mouth, twice daily (morning and evening) during the four-week treatment period.
62191411|NCT02386839|EXPERIMENTAL|Antecedent Standard of Care|Participants who were treated with standard neonatal care in study ROPP-2008-01 (NCT01096784) were enrolled in this group for assessment of rhIGF-1/rhIGFBP-3 long-term efficacy and safety outcomes.
62005858|NCT02158026||infertility without polycystic ovarian syndrome|1000 women with infertility without polycystic ovarian syndrome who are already decided to be treated with ICSI will be recruited
62005859|NCT00548860|EXPERIMENTAL|Ferric Carboxymaltose (FCM)|Undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg)
62397191|NCT02326909|EXPERIMENTAL|optical coherence tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
62780452|NCT04412707|ACTIVE_COMPARATOR|Arm B|Melflufen 40 mg iv Day 1 of each 28 day cycle. Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle, if \> 75 years of age 20 mg. Cycle 1 will be administered via a Central Venous Catheter (CVC) and cycle 2 will be administered via a Peripheral Venous Catheter (PVC). From cycle 3 and onwards melflufen will be administered via CVC.
62780453|NCT06423131|NO_INTERVENTION|Traditional Haplo identicle HCT|Beijing haploidenticla HCT is the routinely traditional way used for haploidentical HCT
62780454|NCT06423131|EXPERIMENTAL|TCRαβ Depleted haploidentical HCT|TCRαβ Depleted haploidentical HCT is experimental used to decrease GVHD and obtain better qulity of life for children with haploidentical HCT.
62191412|NCT02386839|EXPERIMENTAL|Antecedent rhIGF-1/rhIGFBP-3|Participants who were treated with rhIGF-1/rhIGFBP-3 in study ROPP-2008-01 (NCT01096784) were enrolled in this group for assessment of rhIGF-1/rhIGFBP-3 long-term efficacy and safety outcomes.
62191413|NCT05861765|EXPERIMENTAL|Papaverine|Slowly inject 10ml of papaverine hydrochloride solution (30mg/10ml) through the successfully implanted radial artery sheath, and continuously drip papaverine hydrochloride solution (60mg/500ml, 4ml/min) through the artery sheath during the operation. The compatible solutions are normal saline(0.9%);
62191414|NCT05861765|PLACEBO_COMPARATOR|Placebo|After inserting the radial artery sheath, slowly inject 10ml normal saline(0.9%) through the artery sheath, and continuously drip normal saline(0.9%, 500ml, 4ml/min) through the artery sheath during the operation.
62397192|NCT04668482|EXPERIMENTAL|SCS off|SCS is switched off
62397193|NCT04668482|EXPERIMENTAL|SCS on|SCS is switched on
62572540|NCT04856306||Elagolix|After routine patient counseling on fibroid treatments, this group chooses the following medication: every morning (AM), 300mg elagolix, 1mg estradiol, and 0.5mg norethindrone acetate capsules taken in one combined capsule and every evening (PM), 300mg elagolix capsule. In our study, this medication will be administered for 12 months unless the subject withdraws from the study. It is FDA-approved for continuous use of up to 24 months.
62780455|NCT02327988|EXPERIMENTAL|Cryotherapy|To the cryotherapy group a 1kg ice pack was strapped over the entire brachial biceps muscle and adjacent muscles of the arm under study using a bandage, and the application lasted 25 minute laser
62005860|NCT00548860|ACTIVE_COMPARATOR|Standard Medical Care (SMC)|Varied as determined by the Investigator
62005861|NCT06146387|EXPERIMENTAL|Investigational Formula|"Feihe Investigational Formula~1. Contains 2 kinds of HMOs~2. 5 kinds of phospholipid content reached the level of breast milk~3. DHA\&ARA reaches the content and proportion of breast milk in China~4. Comprehensive nutrition: OPO, probiotics, lactoferrin, CPP, nucleotide, choline, inositol, taurine, L-carnitine, GOS, lutein"
62005862|NCT06146387|ACTIVE_COMPARATOR|Control Formula|Control formula contains comparable macronutrients and micronutrients, but does not contain HMO, DHA and ARA.
62005863|NCT06146387|OTHER|Breastfeeding|breastmilk-feeding
62191415|NCT03186586|EXPERIMENTAL|Ulipristal acetate 5mg/day/five days|Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Ulipristal acetate at 5mg/day/five days Ulipristal 5mg daily for 5 days at the bleeding episode
62191416|NCT03186586|PLACEBO_COMPARATOR|Placebo 1 pill/day/five days|Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Placebo at 1pill/day/five days Placebo one pill a day for 5 days at the bleeding episode
62191417|NCT03219762|EXPERIMENTAL|Nab-paclitaxel|Nab-paclitaxel (30-min infusion) 100 mg/sqm weekly on days 1, 8, 15 q 28 days.
62191418|NCT02605369|EXPERIMENTAL|Intervention arm: An integrated package|Pregnant women in the intervention clusters will receive an integrated package consisting of peer support for facility based births by pregnancy buddies, mama kits and mobile phone messages. These components will all aim at mitigating the three delays and increasing the proportion of facility based births.
62397194|NCT01020812|EXPERIMENTAL|Stereotactic body radiotherapy (SBRT)|"SBRT will be delivered on Varian's linear accelerator with On-Board Imaging (OBI) capabilities. The tumor will be tracked with the ethiodol material from the TACE procedure, and respiratory gating will be used to minimize motion due to respiration. Treatment will be given in either 3 or 5 fractions . SBRT will take place after the treatment planning and within 12 weeks of the last TACE procedure.~Doses: 45 Gy at 15 Gy/fraction , 36 Gy at 12 Gy/fraction, 45 Gy at 9 Gy/fraction, 40 Gy at 8 Gy/fraction"
62005864|NCT05074550|EXPERIMENTAL|PPMX-T003|This drug should be administered within 48 hours after the phlebotomy. In addition, as a dose escalation design, 4 doses of 0.25 mg/kg, 0.4 mg/kg, 0.64 mg/kg, and 1 mg/kg are administered to the same subject, when the next phlebotomy required during observation period after the 1st administration.
62572541|NCT03871751|EXPERIMENTAL|Safe and Sound Protocol|All child participants will participate in 1 pre-intervention assessment and 1 post-intervention assessment. The auditory intervention (i.e., Safe and Sound Protocol, SSP) will last for 1 hour per day, for 5 consecutive days.
62572542|NCT06204263|NO_INTERVENTION|Control Group|Babies in the control group will be given only routine ward care (breast milk or formula via tube without stimulation of the pacifier or mother's finger).
62572543|NCT06204263|EXPERIMENTAL|Experimental Group|The baby will be allowed to suck his father's finger for five minutes three times a day before nasogastric feeding.
62572544|NCT00649922|PLACEBO_COMPARATOR|Double Blind|
62191419|NCT02605369|NO_INTERVENTION|Control arm: Standard of care|Pregnant women in the control clusters will continue to receive the standard of care for pregnant women according to Ugandan Ministry of Health guidelines
62191420|NCT02419768|EXPERIMENTAL|Physical Exercise|All patients will receive a circuit-group training including a specific work of balance, posture, gait, fitness, dual tasks and stretching.
62191421|NCT02419768|NO_INTERVENTION|Control|All patients will not change their physical activities
62005865|NCT01122511|EXPERIMENTAL|700 ug dexamethasone and ranibizumab|Intravitreal injection of 700 ug dexamethasone and ranibizumab into study eye
62005866|NCT01122511|ACTIVE_COMPARATOR|ranibizumab and sham|Intravitreal injection of ranibizumab and Sham into study eye
62005867|NCT03675048|EXPERIMENTAL|Intervention group|The intervention group will receive 5 drops (10\^8 cfu Lactobacillus reuteri DSM 17938) twice daily during feeding for 4 weeks.
62191422|NCT04058834|EXPERIMENTAL|NNC0385-0434|Healthy volunteers will be randomised to one of three cohorts. In each cohort of 8 participants, 6 will receive active drug and 2 will receive placebo. Following safety observation, patients with hypercholesterolaemia will enter a fourth cohort. There will be 15 participants in this cohort.
62191423|NCT04058834|PLACEBO_COMPARATOR|Placebo (NNC0385-0434)|Healthy volunteers will be randomised to one of three cohorts. In each cohort of 8 participants, 6 will receive active drug and 2 will receive placebo.
62191424|NCT03294824||patients who reactivate CMV or AdV after allogeneic HSCT|allotransplanted patients who reactivated respectively CMV (n=30) and AdV (n=10)
62191425|NCT03294824||Control group: allogeneic HSC transplanted patients|allotransplanted patients who didn't reactivate CMV
62572545|NCT00649922|EXPERIMENTAL|Open Label|
62572546|NCT03066713|EXPERIMENTAL|Experimental: A|Skin On French Fry - breakfast Skin On French Fry - lunch Mashed Potatoes - dinner
62572547|NCT03066713|EXPERIMENTAL|Experimental: B|Skin Off French Fry - breakfast Skin Off French Fry - lunch Mashed Potatoes - dinner
62572548|NCT03066713|EXPERIMENTAL|Experimental: C|Hash brown - breakfast Hash brown - lunch Mashed Potato - dinner
62572549|NCT03066713|EXPERIMENTAL|Experimental: D|Pancake - breakfast Pretzels - lunch Macaroni - dinner
62572550|NCT02402387|ACTIVE_COMPARATOR|Neutral|The patient's head will be in neutral position.
62572551|NCT02402387|EXPERIMENTAL|Flexed|The patient's head will be flexed.
62572552|NCT02402387|EXPERIMENTAL|Extended|The patient's head will be extended.
62572553|NCT02402387|EXPERIMENTAL|Rotated|The patient's head will be rotated.
62572554|NCT03111680|EXPERIMENTAL|intervention|this arm received an environmental intervention to make healthy eating and activity easier for residents
62572555|NCT03111680|NO_INTERVENTION|control|the control participants received no interventions
62572556|NCT03813680|ACTIVE_COMPARATOR|PVM group|This group included 30 participants. Passive vertebral mobilization was given along with routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care
62572557|NCT03813680|ACTIVE_COMPARATOR|PNF group|This group included 30 participants. PNF exercise in the form of diagonal pattern neck movements was along with routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care
62572558|NCT03813680|ACTIVE_COMPARATOR|RPT(Routine Physiotherapy) group|This group included 30 participants.Routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care.
62780456|NCT02327988|EXPERIMENTAL|Laser therapy|The laser therapy group received laser application to the muscle belly of the non-dominant upper limb brachial biceps at four different points.
62005868|NCT03675048|PLACEBO_COMPARATOR|Placebo group|The placebo group will receive 5 drops twice daily during feeding for 4 weeks. Placebo composition will be identical to that of the study drug but will not contain L. reuteri.
62191426|NCT03294824||Healthy donors group|healthy donors serologically + for CMV
62191427|NCT01641679||Suspected recurrent DTC|100 patients with biochemically suspected recurrent DTC
62191428|NCT05297344|EXPERIMENTAL|direct pulp capping|If a pulp exposure occurred, direct pulp capping will be performed according to the parents' wishes
62191429|NCT05297344|ACTIVE_COMPARATOR|pulpotomy|If a pulp exposure occurred, pulpotomy will be performed according to the parents' wishes
62191430|NCT04001335||CL suspicion|Patients with skin lesions suspected to be cutaneous leishmaniasis
62214725|NCT06162962||age groups|The general characteristic of patients and clinical data including age, Enneking stage, surgical methods, type of prosthesis, primary tumor location were recorded.
62214726|NCT06162962||surgical methods|The general characteristic of patients and clinical data including age, Enneking stage, surgical methods, type of prosthesis, primary tumor location were recorded.
62214727|NCT06162962||type of prosthesis|The general characteristic of patients and clinical data including age, Enneking stage, surgical methods, type of prosthesis, primary tumor location were recorded.
62214728|NCT06162962||primary tumor location|The general characteristic of patients and clinical data including age, Enneking stage, surgical methods, type of prosthesis, primary tumor location were recorded.
62780457|NCT02327988|NO_INTERVENTION|Control|The control group did not undergo any intervention and remained at rest for 25 minutes.
62780458|NCT06583954||healthy adults with refractive error|
62572559|NCT04644432|EXPERIMENTAL|A - for patients with a DNA mutation that match a targeted treatment|"Listed below are the possible study drugs and dosages:~Erlotinib 150 mg once a day for 4 weeks.~Osimertinib 80 mg once a day for 4 weeks.~Alectinib 600 mg twice a day for 4 weeks~Dabrafenib 150 mg twice a day combined with Trametinib 2 mg once a day for 4 weeks~Trastuzumab-emtansin iv infusion 3.6 mg/kg every 3rd week~Olaparib 400 mg twice a day for 4 weeks~Pembrolizumab iv infusion 2 mg/kg every 3rd week~Cabozantinib 60 mg once a day for 4 weeks~Crizotinib 250 mg twice a day for 4 weeks~Palbociclib 125 mg once a day in3 weeks, hereafter pause for one week~Imatinib 400 mg once a day for 4 weeks~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
62005869|NCT03675048|NO_INTERVENTION|Control group|The infants from the control group will comply with the same requirements and will undergo the same procedures as participants from the main group except for randomization and treatment.
62005870|NCT00797992|EXPERIMENTAL|1|Myopic eyes with retinal neovascularization
62005871|NCT02390583|ACTIVE_COMPARATOR|control|CBT treatment of internet dependence each two weeks during 3 months
62005872|NCT02390583|EXPERIMENTAL|intervention|CBT treatment of internet dependence plus CBT treatment of sleep disorders during 3 months
62005873|NCT04458714|ACTIVE_COMPARATOR|CO2 group (treatment arm)|This arm included 32 patients who were randomized for using CO2 as the contrast medium for aortoiliac angiolplasty.
62005874|NCT04458714|ACTIVE_COMPARATOR|ICM group (control arm)|This arm involved 32 patients who were randomized for using iodine contrast medium (ICM) for aortoiliac angiolplasty.
62005875|NCT06462690|EXPERIMENTAL|Experimental Group|After determining the patients who meet the inclusion criteria and are willing to participate in the study, their consent is obtained and the protocol is applied by the researcher one day before the application, when the patient feels ready, using the face-to-face interview technique (PIF), (DLQI), (GCS), (SEF). Pre-test data is collected by applying it. Vital signs are taken and recorded. Skin moisture is measured with the DMM device. Braden Risk Assessment Scale is applied. After the measurements, the patient is given care according to the care protocol, measurements are made again in between, and then (DLQI), (GCS) is applied, and the skin moisture and vital signs are measured, and the process is concluded.
62191431|NCT04214327|ACTIVE_COMPARATOR|Strengthening Families Program Online eLearning Game|This arm of the study receives a 10-session online family-based intervention with separate, but intersecting, tracks for parents and youth. Each lesson contains 3 mini-lessons per week and includes behavioral skills training and interactive multimedia lessons with video vignettes that target parenting skills, family cohesion, organization, communication, social skills, and drug prevention for youth. The youth track is highly gamified to stimulate engagement and reinforce the core active ingredients. There are self-correcting quizzes to assess learning, and process evaluation to determine program fidelity and engagement. There are learning theory instructional design elements with scaffolding, stealth learning, and theoretical principles of social learning, social interactional, and family systems theory. There is a highly animated game families can play upon successful completion of each lesson, using game points they earned through quizzes and practices. There is a 3-month follow-up.
62214729|NCT06162962||Enneking stage|The general characteristic of patients and clinical data including age, Enneking stage, surgical methods, type of prosthesis, primary tumor location were recorded.
62214730|NCT04811131|ACTIVE_COMPARATOR|Active IP and Active Phototherapy|ARQ-252 cream 0.3% BID with phototherapy.
62397195|NCT04281966|EXPERIMENTAL|Experiment|For young people from schools randomly assigned to the experimental ASEP condition will participate in the ASEP intervention. The ASEP intervention is a Third-Party Policing partnership that involves a partnership between police and school, an ASEP conference and follow up which is organized and led by a conference facilitator with the young person, their parent (or guardian), a school representative (e.g., teacher), and a uniformed school-based police officer. The police and school representatives will be trained by the facilitator to utilize procedurally just dialogue during the entirety of the conference. The ASEP conference script will utilize a procedurally just dialogue to increase both the young person and their parents' perceptions and knowledge of the legitimacy of the truancy laws, police, and schools in order to gain willing compliance to follow the rules.
62572560|NCT04644432|EXPERIMENTAL|B - for patients with an angiogen profile|"Study drug: Sunitinib peroral tablet 50 mg once a day for 4 weeks, hereafter pause for 2 weeks (4/2 schedule or 2/1 schedule).~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
62397196|NCT04281966|NO_INTERVENTION|Control|"Participants allocated to the control condition will be given the business-as-usual' approach to handling school non-attendance. The control participants will be sanctioned in the usual manner for engaging in truancy through the requirements denoted in the Queensland Education (General Provisions) Act (2006)."
62397197|NCT05115682|EXPERIMENTAL|Morning First|Participants will complete a single bout of exercise at 09:00, and after at least a one-week washout perform another exercise bout at 16:00.
62397198|NCT05115682|EXPERIMENTAL|Afternoon First|Participants will complete a single bout of exercise at 16:00, and after at least a one-week washout perform another exercise bout at 09:00.
62397199|NCT04276493|EXPERIMENTAL|Cohort 1- Zanidatamab + Docetaxel|Zanidatamab intravenous (IV) infusion followed by docetaxel IV infusion first-line therapy once every three weeks (Q3W) in female participants with metastatic breast cancer
62397200|NCT04276493|EXPERIMENTAL|Cohort 2- Zanidatamab + Tiselizumab + Chemotherapy|Zanidatamab intravenous (IV) infusion followed by tislelizumab IV infusion and CAPOX chemotherapy (oral capecitabine + IV oxaliplatin) first-line therapy once every three weeks (Q3W) in participants with metastatic gastric / GEJ adenocarcinoma
62780459|NCT01959438|EXPERIMENTAL|Selenite treatment|In the first part of the study, cohorts of 3 patients receive sodium selenite iv, starting with a dose of 0.5 mg/m2. If no serious adverse event the next cohort is treated according to a dose escalation schedule and this part has been completed. In the modified protocol, a continuous infusion over 2 days will be administered.
62780460|NCT01776723|EXPERIMENTAL|I: Dose Escalation - Ruxolitinib|"Phase I: Dose Escalation. In Phase I, participants will be allocated to dose levels starting at 10 mg/d (twice a day \[BID\] dosing) according to the rolling six Phase I design."
62780461|NCT01776723|EXPERIMENTAL|II: Maximum Tolerated Dose - Ruxolitinib|Phase II: Treatment at Maximum Tolerated Dose (MTD).
62005876|NCT06462690|NO_INTERVENTION|Control Group|After the patients who meet the inclusion criteria and are willing to participate in the study are determined, their consent will be obtained and pre-test data will be collected by applying face-to-face interview techniques (PIF), (DLQI), (GCS) at a time when the patient feels ready. Vital signs will be taken and recorded. Skin moisture measurement will be made with a DMM device. Braden Risk Assessment Scale will be applied. After the measurements, according to the care protocol, the patients will not be given care, they will receive routine care, then (DLQI), (GCS) will be applied, skin moisture and vital signs will be measured and the procedure will be terminated.
62005877|NCT03957538|NO_INTERVENTION|Standard care|Standard consent and explanation
62005878|NCT03957538|EXPERIMENTAL|Virtual reality|Addition of VR headset
62005879|NCT06348511|EXPERIMENTAL|Immediate and contingent reward (ICR)|Tic suppression directly affects gameplay, with participants informed that suppressing tics weakens opponents and improves card acquisition. Daily sessions end with feedback on suppression performance relative to that day's baseline.
62214731|NCT04811131|ACTIVE_COMPARATOR|Active IP and Sham Phototherapy|ARQ-252 cream 0.3% BID with sham phototherapy
62214732|NCT04811131|PLACEBO_COMPARATOR|Vehicle and Active Phototherapy|ARQ-252 Vehicle cream BID with active phototherapy
62397201|NCT02843282|EXPERIMENTAL|Cognitive training|Advanced reasoning training
62397202|NCT04893174|EXPERIMENTAL|UMC119-06-05|Human Umbilical Cord Derived-Mesenchymal Stem Cells. Subjects will receive a single-dose intra-articular (IA) injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.
62397203|NCT02929017|OTHER|Intervention|Group will receive SUPPORT, an intervention that provides information about the disease, self-management strategies, and introduction to advanced care planning in a format with enhanced content available across multiple domains (face-to-face, printed material, and digitally (via use of a tablet) delivered by an interventionist.
62397204|NCT02929017|OTHER|Usual Care|Group will receive usual standard-of-care, and be provided with currently available printed material for information about their illness.
62397205|NCT06623032|EXPERIMENTAL|Healthy Participants|
62397206|NCT06623032|EXPERIMENTAL|MCADD Patients|
62397207|NCT02433015|ACTIVE_COMPARATOR|Tobacco Cigarette Group|This group will not receive an electronic cigarette and will continue to smoke combustible tobacco cigarettes as previously.
62780462|NCT04976361|EXPERIMENTAL|Diabetic Patients with PDR|PRP for each diabetic patient included in this study.
62780463|NCT04138290|EXPERIMENTAL|Predictix Antidepressant Software tool|Predictix Antidepressant Software tool will be used when prescribed with a medication for their MDD, by their treating physician.
62780464|NCT02211066|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 75 mg will be administered daily for 1 year
62005880|NCT06348511|ACTIVE_COMPARATOR|Delayed reward (DR)|The gameplay does not depend on performance, but participants still receive end-of-session feedback on tic suppression.
62005881|NCT00222937|EXPERIMENTAL|A|Patients are enrolled in Lessac-Madsen Resonant Voice Therapy.
62005882|NCT00222937|EXPERIMENTAL|B|Patients are enrolled in Casper Based Confidential Flow Therapy.
62214733|NCT04811131|PLACEBO_COMPARATOR|Vehicle and Sham Phototherapy|ARQ-252 Vehicle cream BID with sham phototherapy
62214734|NCT06431308|EXPERIMENTAL|Nutritional intervention group|Nutrition guidance before AOM treatment by registered dietitian (RD) followed by nutrition and behavioral recommendations according to reported gastrointestinal symptom(s).
62397208|NCT02433015|EXPERIMENTAL|Electronic Cigarette Group|This group will receive an electronic cigarette to use for the duration of the study.
62397209|NCT06694935|EXPERIMENTAL|QX1206|
62397210|NCT06118840|EXPERIMENTAL|True-AI-integrated intracranial aneurysms diagnosis strategy|For patients who underwent head CTA and assigned to True-AI group, they will be diagnosed by a radiologist who are aided by the True-AI-integrated intracranial aneurysms diagnosis strategy.
62780465|NCT02211066|EXPERIMENTAL|Ticagrelor|Ticagrelor 90 mg will be administered daily for 1 year
62780466|NCT06526091||Preterm infants|Preterm infants born at less than 34 completed weeks gestation
62780467|NCT06077942||Subjects|Subjects implanted with the shoulder replacement medical devices manufactured by FX Shoulder Solutions and distributed by FX Shoulder Solutions.
62780468|NCT04790071|ACTIVE_COMPARATOR|Conventional therapy|It covers the classical physical therapy modalities that patients will take for shoulder pain.
62780469|NCT04790071|ACTIVE_COMPARATOR|Conventional therapy plus dry needling|It covers the classical physical therapy modalities that patients will take for shoulder pain. It also refers to the dry needling treatment to be applied.
62572561|NCT04644432|EXPERIMENTAL|C - for patients with an immune profile|"Study drug: Nivolumab iv infusion 6 mg/kg (max 480 mg) every 4th week.~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
62572562|NCT04644432|EXPERIMENTAL|D - for patients that have neither mutations nor an immune- or angiogen profile|"Study drug: Nivolumab iv infusion 6 mg/kg (max 480 mg) every 4th week.~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
62572563|NCT05149625|EXPERIMENTAL|Dexcom G6|
62005883|NCT06404177|EXPERIMENTAL|Dexketoprofen|Patients receive a perfusion of Dexketoprofen in intraveinous with an injection of istonic saline IM injection
62191432|NCT04214327|ACTIVE_COMPARATOR|SFP Home-use DVD/video series|"This arm of the study receives an 11-session home-use DVD or coupon code for viewing the SFP videos online at home that contains the same SFP skills and lesson content as the online condition. However, the lesson material is not animated and involves simply viewing the videos at home. This arm represents an attention-control condition as the requirements of participation and exposure to the intervention will match the online condition, as participants use the Internet or a DVD player to view lesson material in a self-paced format. There are no differences in recruitment for this condition; all assignment to experimental conditions is based on their recruiter's location using a randomized control trial design. Participants in this condition will be provided a hyperlink URL to answer pre- and posttest assessments and at the 3-month follow-up. Process evaluation materials will be delivered via a hyperlink to a commercial survey vendor during the trial and at the conclusion."
62397211|NCT06118840|SHAM_COMPARATOR|Sham-AI-integrated intracranial aneurysms diagnosis strategy|For patients who underwent head CTA and assigned to Sham-AI group, they will be diagnosed by a radiologist who are aided by the Sham-AI-integrated intracranial aneurysms diagnosis strategy. To mimic the True-AI, the Sham-AI had a sensitivity close to 0% and a similar specificity to the True-AI.
62397212|NCT06510322|ACTIVE_COMPARATOR|Sildeanfil|Participants in this arm will receive sildenafil 20mg every 8 hours for 1 week and then dose will be up titrated to 40mg every 8 hours for the duration of the study period.
62397213|NCT06510322|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive matching placebo, which serves as a negative control to understand changes in small and large blood vessels.
62572564|NCT05149625|NO_INTERVENTION|Traditional self-blood glucose measurement|
62572565|NCT01019759|NO_INTERVENTION|No add-on AF-surgery|patient undergoing only scheduled valve and/or coronary bypass surgery
62572566|NCT01019759|EXPERIMENTAL|PV isolation|patient undergoing add-on epicardial microwave energy pulmonary vein isolation
62572567|NCT03952273|ACTIVE_COMPARATOR|Combo|PCI with COMBO stent
62572568|NCT03952273|ACTIVE_COMPARATOR|BioMatrix Alpha|PCI with BioMatrix Alpha stent
62572569|NCT05617157|NO_INTERVENTION|Control|
62572570|NCT05617157|EXPERIMENTAL|Stair stepping|
62572571|NCT05654961||Heart failure patients|According to the eligibility criteria specified below.
62572572|NCT01549587|ACTIVE_COMPARATOR|Regular Oral Hygiene|toothpaste, toothbrush and dental floss
62572573|NCT01549587|EXPERIMENTAL|Advanced Oral Hygiene plus counseling|toothpaste, toothbrush, mouth rinse and dental floss plus specialized education
62572574|NCT02192996|OTHER|Probiotics supplementation|"Five very low birth weight (VLBW) infants enrolled within 2 days of birth, with a weight \< 1300 g and gestational age \< 29 weeks and without any malformation or metabolic disease at birth were supplemented with two daily doses of a mixture of Bifidobacterium breve and Lactobacillus salivarius , probiotic strains isolated from human milk during their first weeks of life. The lyophilized powder has contained at least 1x10\^9 colony forming units (CFU) per doses of each one of the probiotic bacteria."
62572575|NCT01353560||New patients of Osher Clinical Center|
62005884|NCT06404177|ACTIVE_COMPARATOR|Piroxicam|Patients receive an intramuscular injection of piroxicam with an intravenous isotonic saline
62005885|NCT04689737|EXPERIMENTAL|Experimental group|Doravirine (Pifeltro, MSD) will be added to participant's cART (100 mg once daily) for 5 days
62005886|NCT02661438|OTHER|Placebo to Ciprofloxacin DPI|Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
62005887|NCT04961892||surgical treatment|Patients with CAI undergoing surgical treatment
62005888|NCT04961892||conservative treatment|Patients with CAI undergoing conservative treatment
62005889|NCT00584038|NO_INTERVENTION|1 Standard Care (SC)|Participants receive usual contraceptive care administered by clinic provider.
62572576|NCT02407925||Endoscopists|Approximately 35 endoscopists whom are certified to perform colonoscopies on FIT-positive patients in the Dutch population screening program
62572577|NCT02407925||Colonoscopies|Colonoscopies on FIT-positive patients in the Dutch population screening program
62572578|NCT02407925||Device|Olympus colonoscopes with Narrow Band Imaging
62572579|NCT01796535||PerX360º System™|Patients treated with PerX360º System™
62572580|NCT04953442|EXPERIMENTAL|Intervention|Fitbit Device Self-Determination Theory Text Messages
62572581|NCT04953442|NO_INTERVENTION|Wait List Control|Informational flyer of evidence-based strategies on engaging in healthy physical activity and sleep lifestyle habits.
62780470|NCT00983385|EXPERIMENTAL|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol immediate release (IR) tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
62780471|NCT02221388|ACTIVE_COMPARATOR|BI 671800 ED capsules|
62005890|NCT00584038|OTHER|2 Standard Care + Educational (SCE)|Participants receive standard contraceptive care from clinic provider, followed by 45-minute educational intervention.
62005891|NCT00584038|OTHER|3 Standard Care + Educational + Phone Calls (SCEP)|Participants receive standard contraceptive care from clinic provider, followed by phone calls weekly until onset of menses and monthly thereafter for six consecutive months.
62005892|NCT02579616|EXPERIMENTAL|24 mg Lenvatinib|Participants with unresectable BTC and disease progression or failure following one prior gemcitabine-based doublet chemotherapy regimen (combination of gemcitabine and cisplatin, or gemcitabine and other platinum agent/fluoropyrimidine agent).
62005893|NCT03829735|EXPERIMENTAL|Children and their mothers|Human biological samples from children aged 9 to 12 months and their mothers. Capillary and venous blood samples.
62005894|NCT03787316|EXPERIMENTAL|Experimental group|4-weeks use of specially produced shock absorbing insoles and the daily home exercise program during this 4 weeks. Daily exercises include M. gastrocnemius, soleus, tibialis anterior, tibialis posterior stretching, strengthening of the anterior, lateral, posterior compartmental and foot intrinsic muscles of the foot, eccentric exercise of gastrocnemius and soleus.
62191433|NCT04214327|ACTIVE_COMPARATOR|Wait-Listed Control|"This arm of the study receives no active intervention for the initial intervention period of 11 weeks; however, following conclusion of the initial trial the wait-listed control sites are then administered the 10-session SFP Online intervention. During the initial trial of 11 weeks, participants in this condition receive weekly email reminders that contain riddles and puzzles for youth and parents receive nutritional information and food preparation recipes. The intent of these weekly emails is to stimulate continued participation and reduce attrition.~Individual families will be randomly assigned to one of the three interventions with a computerized random number generator."
62005895|NCT00548808|EXPERIMENTAL|Insulin lispro low mixture|Insulin lispro low mixture (1, 2 or 3 daily injections)
62780472|NCT02221388|EXPERIMENTAL|BI 671800 HEA tablet in fasted state|
62005896|NCT00548808|ACTIVE_COMPARATOR|Insulin glargine|Insulin glargine (alone or with 1, 2 or 3 daily injections of insulin lispro)
62191434|NCT04214327|NO_INTERVENTION|SFP Group Norms|This arm of the study provides a means to conduct a non-inferiority trial contrasting the active intervention conditions (SFP Online and Home-use DVD/videos) to the traditional 14-session in-person group-delivery format, which serves as a benchmark of effectiveness for SFP. There is no data collection as the Group Norms are part of an existing database of families that already took SFP classes. All effect size comparisons are conducted using secondary data analysis. The expected margin of equivalence is set at 10% so that any condition that exceeds another in the magnitude of effect size is considered as 'good as' the comparison condition. All effect sizes will be adjusted for demographic and site-specific factors to control for clustering and within-site contextual factors that can influence program outcomes.
62005897|NCT02130401|EXPERIMENTAL|TNM (thermoneuromodulation device)|A standardized active thermal neuromodulation waveform will be used for all patients. The device is non-invasive and does not use electrical stimulation.
62005898|NCT03808896|ACTIVE_COMPARATOR|bougie-assisted intubation|use bougie as guide, intubation with loading endotracheal tube under direct or video laryngoscopy
62191435|NCT02161471||Aortic coarctation|Patients after repair of coarctation of the aorta
62191436|NCT02161471||Tetralogy of Fallot|Patients after repair of tetralogy of Fallot
62191437|NCT02161471||TGA atrial switch|Patients with transposition of the great arteries after atrial switch (Senning procedure)
62191438|NCT02161471||TGA arterial switch|Patients with transposition of the great arteries after arterial switch operation
62005899|NCT03808896|ACTIVE_COMPARATOR|intubation with epiglottic lifting|Lifting of epiglottis with stylet-equipped endotracheal tube to assist intubation under direct or video laryngoscopy
62005900|NCT03808896|NO_INTERVENTION|Traditional intubation|intubation under direct or video laryngoscopy without epiglottis lifting nor bougie-assited
62005901|NCT06182267|EXPERIMENTAL|Group I|toothpaste containing 8% L-arginine
62191439|NCT02161471||Normal|Normal controls
62191440|NCT00003564|EXPERIMENTAL|Arm I (Procarbazine + Isotretinoin)|Arm I: Oral procarbazine once daily on days 1-14 every 28 days, and Oral isotretinoin every 12 hours on days 15-28 every 28 days; 6 courses of combined therapy, then continue oral isotretinoin alone on days 15-28 of each 28 day course.
62191441|NCT00003564|EXPERIMENTAL|Arm II (Procarbazine Alone)|Arm II: Oral Procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses of treatment.
62572582|NCT02752243|EXPERIMENTAL|CIK-Cells|IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
62780473|NCT02221388|EXPERIMENTAL|BI 671800 HEA EC tablet in fasted state|
62780474|NCT02221388|EXPERIMENTAL|BI 671800 HEA tablet in fed state|
62780475|NCT02221388|EXPERIMENTAL|BI 671800 HEA EC tablet in fed state|
62780476|NCT02221388|EXPERIMENTAL|BI 671800 HEA, 50 mg tablet in fasted state|
62005902|NCT06182267|ACTIVE_COMPARATOR|Group II|toothpaste containing 0.24% sodium fluoride
62005903|NCT06086535||BRILMA block|Patients receiving BRILMA blockade. BRILMA blockade will be performed at the end of surgery at the level of the 3rd, 4th and 5th intercostal spaces of the right hemithorax.
62005904|NCT06086535||Intercostal nerve cryoanalgesia|Patients receiving intercostal nerve cryoanalgesia. The cryoanalgesia technique will be performed by the surgeon before the closure of the minithoracotomy, at the level of the 3rd, 4th and 5th intercostal spaces on the right hemithorax.
62005905|NCT03906669|ACTIVE_COMPARATOR|Letrozole|Letrozole 2.5mg PO daily for 14 days between diagnosis of breast cancer and definite surgery
62005906|NCT03906669|EXPERIMENTAL|Letrozole and Prometrium|Letrozole 2.5mg PO daily and Prometrium 300mg PO daily for 14 days between diagnosis of breast cancer and definite surgery
62005907|NCT03906669|EXPERIMENTAL|Tamoxifen and Prometrium|Tamoxifen 20mg PO daily and Prometrium 300mg PO daily for 14 days between diagnosis of breast cancer and definite surgery
62005908|NCT01178229|EXPERIMENTAL|Physiotherapy|group of bruxist children that received physiotherapy to change the head posture
62780477|NCT04152798|ACTIVE_COMPARATOR|ProGrip™ mesh repair|Laparoscopic hiatal hernia repair with ProGrip™ mesh
62780478|NCT04152798|ACTIVE_COMPARATOR|Primary crural repair|Primary posterior crura repair
62780479|NCT06584019|EXPERIMENTAL|Range Of Motion applied group|Children with cancer were given Range Of Motion exercises once a day for 5 days for approximately 20 minutes.
62780480|NCT06584019|NO_INTERVENTION|Control group|Children with cancer in this group received no intervention.
62397214|NCT03035331|EXPERIMENTAL|Treatment (pembrolizumab, dendritic cell therapy, cryosurgery)|Patients receive pembrolizumab IV on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive dendritic cell therapy IT on days 2, 8, and 15 of cycles 2 and 3, and day 2 of cycles 4 and 5. Patients undergo cryosurgery on day 2 of cycle 2 and receive pneumococcal 13-valent conjugate vaccine by injection on day 2 of cycles 2-5. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients who are CR, PR, or SD after completion of therapy, may receive pembrolizumab for an additional 18 cycles in the absence of disease progression or unacceptable toxicity.
62397215|NCT02491918|ACTIVE_COMPARATOR|In the bag IOL|Cataract surgery with IOL implantation in the capsular bag
62780481|NCT03296943|EXPERIMENTAL|Essential oil|Essential oil is prepared from the product of Thailada with manufacture standard ID 1087/2548 by Thailand Ministry of Industry. Essential oil is extracted by a cold compressed method from the lavandula angustifolia (lavender) grown in Australia.
62005909|NCT01178229|NO_INTERVENTION|Control|Group of bruxist children that did not receive treatment
62005910|NCT05746546|EXPERIMENTAL|Transdermal Nicotine Patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. Participants will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
62005911|NCT03228134|EXPERIMENTAL|Hanxiao treatment group|80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.
62005912|NCT03228134|SHAM_COMPARATOR|Hanxiao control group|80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule placebo oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.
62397216|NCT02491918|ACTIVE_COMPARATOR|Optic Capture of IOL|intraocular lens implantation in the capsular bag with posterior optic capture
62005913|NCT03228134|EXPERIMENTAL|Xuxiao treatment group|80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.
62005914|NCT03228134|SHAM_COMPARATOR|Xuxiao control group|80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule placebo oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.
62005915|NCT06382623||The peritendinous steroid group|A 1 ml mixture of corticosteroid (2 mg + 5 mg/ml betamethasone) and 1 ml of local anesthetic agent (20 ml 2% prilocaine) was injected peritendinously between the A1 pulley and the flexor tendon sheath at the metacarpophalangeal joint level under ultrasound guidance.
62191442|NCT04396847|EXPERIMENTAL|Lorcaserin first, then placebo|Participants first receive lorcaserin (10 mg BID) for 7 days. After a washout period of 7 days, they then receive placebo tablets (BID) for 7 days.
62191443|NCT04396847|PLACEBO_COMPARATOR|Placebo first, then lorcaserin|Participants first receive placebo (BID) for 7 days. After a washout period of 7 days, they then receive lorcaserin (10 mg BID) for 7 days.
62397217|NCT05679401|EXPERIMENTAL|Imlifidase and Standard-of-Care (SoC)|"* Imlifidase is administered IV as one dose of 0.50 mg/kg over 30 minutes.~* SoC consists of a standardized combination of PLEX, CYC, and glucocorticoids."
62572583|NCT02095639||ECT and Treatment Resistant Depression|Subjects will be those with diagnosis of major depressive disorder that have not responded to many different treatments and who are planning to take electroconvulsive therapy (ECT). This group will receive two \[18F\]FEPPA PET scans, one baseline and one after an average of 2.5 weeks of ECT treatments.
62572584|NCT02087540|EXPERIMENTAL|Telmisartan 80mg & Rosuvastatin 20mg|PO, Once Daily, 8 weeks
62572585|NCT02087540|EXPERIMENTAL|Telmisartan 80mg & Rosuvastatin 10mg|PO, Once Daily, 8weeks
62572586|NCT02087540|ACTIVE_COMPARATOR|Telmisartan placebo & Rosuvastatin 20mg|PO, Once Daily, 8 weeks
62572587|NCT02087540|ACTIVE_COMPARATOR|Telmisartan Placebo & Rosuvastatin 10mg|PO, Once Daily, 8 weeks
62572588|NCT02087540|ACTIVE_COMPARATOR|Telmisartan 80mg & Rosuvastatin placebo|PO, Once Daily, 8 weeks
62780482|NCT03296943|SHAM_COMPARATOR|Perfume|Perfume is the synthetic perfume of lavender flavor without essential oil.
62780483|NCT01114438|EXPERIMENTAL|Device|
62780484|NCT06584032|EXPERIMENTAL|Experimental group|Patients will be treated with a planned dose of fruquintinib and sintilimab every three weeks until an IRC (independent review committee)-confirmed PD(disease progression) or meeting other discontinuation criteria.
62191444|NCT06234553||training set and validation set|Retrospective study focusing on the diagnosis and treatment outcomes of pituitary adenomas
62191445|NCT02493842|EXPERIMENTAL|Invasive nerve stimulation|"Invasive nerve stimulation using the following experimental devices~1. Transverse Intrafascicular Multichannel Electrode for human (TIME-4H)~2. The STIMEP stimulator~3. The EPIONE Psychophysical Testing Platform software for stimulator control~Nerve stimulation therapy is provided while providing visual guidance to the subject and without the use of hand prosthetic devices"
62191446|NCT03959852|ACTIVE_COMPARATOR|Sub-Dissociative Ketamine alone|0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
62191447|NCT03959852|ACTIVE_COMPARATOR|Fentanyl alone|1 mg/kg of Fentanyl IV administered over at least 1 minute
62191448|NCT03959852|EXPERIMENTAL|Sub-dissociative Ketamine and Fentanyl|Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute
62005916|NCT06382623||The percutaneous A1 pulley release group|In the A1 pulley release group, 1 ml of local anesthetic agent (20 ml 2% prilocaine) was injected into the pulley-associated subcutaneous tissue using a 27 G needle under ultrasound guidance. The metacarpophalangeal joint was brought into slight hyperextension. Subsequently, a 20 G 0.9x38mm needle, modified by bending approximately 40-45 degrees from the proximal 1/3 of the needle with the aid of a cap, was used. The needle was advanced in-plane from distal to proximal along the midline, with simultaneous movement towards the palmar surface, aiming to cut or loosen the pulley between the tendon and A1 pulley. The loosening procedure was repeated from the distal to proximal aspect of the pulley until the sensation of resistance at the needle tip disappeared.
62005917|NCT03545607|EXPERIMENTAL|MultiStem|1.2 billion cells
62005918|NCT03545607|PLACEBO_COMPARATOR|Placebo|
62005919|NCT02840292||Cases|Late preterm neonates (\>34weeks but \<37weeks of gestation) with maternal hemoglobin \< 11gm/dl
62005920|NCT02840292||Controls|Late preterm neonates (\>34weeks but \<37weeks of gestation) with maternal haemoglobin ≥ 11gm/dl
62005921|NCT06038591|EXPERIMENTAL|Sleep Intervention|The sleep intervention focuses on enhancing young children's sleep by providing parents with behavioral strategies and support. Interventionists will work with parents on establishing consistent soothing bedtime routines; behavioral regulation to manage bedtime resistance and nighttime wakings; goal setting, problem solving, and action planning; self-monitoring via daily sleep logs; and stimulus control of child's sleep environment.
62005922|NCT06038591|NO_INTERVENTION|Comparison/control|The comparison arm is a no-contact control group. Parents and children will not receive any intervention. They will be placed on a wait-list, and then offered the sleep intervention once the post-assessments are complete.
62005923|NCT00668681|ACTIVE_COMPARATOR|Endorefix|Evaluation of EndoRefix Endovascular Delivery System and Staple
62005924|NCT03296163|EXPERIMENTAL|MB02 (Bevacizumab Biosimilar Drug)|MB02 (Bevacizumab Biosimilar Drug) + Carboplatin/Paclitaxel
62005925|NCT03296163|ACTIVE_COMPARATOR|EU-approved Avastin®|EU-approved Avastin® + Carboplatin/Paclitaxel
62005926|NCT01994512|EXPERIMENTAL|Decompression without fusion|Surgery of the stenotic spinal segments with decompression of the neural elements without concommitant fusion.
62005927|NCT01994512|EXPERIMENTAL|Decompression with fusion|Surgery of the stenotic spinal segments with decompression of the neural elements with concommitant fusion.
62005928|NCT06218043|OTHER|Iodine intake intervention balance experiment|Replace subjects' iodized salt with non-iodized salt.
62005929|NCT06165068|ACTIVE_COMPARATOR|Antiplatelet drug|In this study, antiplatelet drugs are medications that patients take to treat their underlying condition, such as aspirin 81 mg/day or clopidogrel 75 mg/day.
62005930|NCT06165068|EXPERIMENTAL|Antiplatelet drug with antioxidant|Antiplatelet drugs are medications that patients take to treat their underlying condition, such as aspirin 81 mg/day or clopidogrel 75 mg/day combined with N-acetylcysteine 600 mg/day.
62005931|NCT06165068|NO_INTERVENTION|No medication|Patient with no medication used.
62191449|NCT05588583|EXPERIMENTAL|Supportive Care with Mepilex Up|All Subjects will use a soft, silicone, non-bordered, adhesive, foam dressing called Mepilex Up as the absorbent primary dressing.
62191450|NCT01893047|NO_INTERVENTION|no music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
62005932|NCT02290587|EXPERIMENTAL|Patient|MS diagnosis according to McDonald criteria (Polman et al., 2005). Relapsing-remitting MS (RRMS) according to Lublin et al. (1996);
62005933|NCT02290587|EXPERIMENTAL|Control|healthy subject
62005934|NCT01585142|EXPERIMENTAL|BabyNes system formula|
62005935|NCT05690295|EXPERIMENTAL|CLIMHEALTHY|All postmenopausal women without breast cancer will be subjected to 12 weeks of full body resistance exercise training (3 times per week)
62005936|NCT05690295|EXPERIMENTAL|CLIMCANCER|All postmenopausal women survivors of breast cancer without or with Hormone Therapy (pecifically Aromatase Inhibitor or Tamoxifen) will be subjected to 12 weeks of full body resistance exercise training (3 times per week)
62005937|NCT04024475||A: Opportunistic screening & benign prostate syndrome (BPS)|Asymptomatic men offered screening (PSA testing) with prostate biopsy (A1). Or patients with lower urinary tract symptoms from benign prostatic hyperplasia undergoing: no treatment (A2), medical therapy (A3), or transurethral resection of the prostate (A4)
62191451|NCT01893047|EXPERIMENTAL|live music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
62005938|NCT04024475||B: Localized/locally advanced PCa with curative intent|B0: Patients under active surveillance (B0, closed group); B1: radical prostatectomy (RP) or RP followed by (adjuvant) external beam radiation; B2: external beam radiation therapy (EBRT) without androgen deprivation therapy (ADT); B3: external beam radiation therapy with ADT
62005939|NCT04024475||C: Biochemical relapse|Patients with PSA progression after RP with or without systemic therapy
62191452|NCT01893047|EXPERIMENTAL|recorded music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
62191453|NCT04041973|EXPERIMENTAL|ACT arm|Artemether-lumefantrine (AL) x 3 days followed by 1 day per week
62191454|NCT04041973|ACTIVE_COMPARATOR|Multivitamin arm|Multivitamin x 3 days followed by 1 day per week
62397218|NCT05679401|ACTIVE_COMPARATOR|Standard-of-Care (SoC)|SoC consists of a standardized combination of PLEX, CYC, and glucocorticoids.
62191455|NCT00360477|ACTIVE_COMPARATOR|1|Floseal
62191456|NCT00360477|ACTIVE_COMPARATOR|2|Cope-Loop/Nephrostomy Tube
62397219|NCT06297603|EXPERIMENTAL|Retatrutide Dose 1|Participants will receive retatrutide administered subcutaneously (SC).
62397220|NCT06297603|EXPERIMENTAL|Retatrutide Dose 2|Participants will receive retatrutide administered SC.
62397221|NCT06297603|EXPERIMENTAL|Retatrutide Dose 3|Participants will receive retatrutide administered SC.
62397222|NCT06297603|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo administered SC.
62572589|NCT02087540|PLACEBO_COMPARATOR|Telmisartan placebo & Rosuvastatin placebo|PO, Once Daily, 8 weeks
62572590|NCT03278327|OTHER|Endoscopic resection|
62397223|NCT01406548|EXPERIMENTAL|BPS804 dosing frequency 1|Subjects dosed 20mg/Kg BPS804 monthly
62572591|NCT02134015|EXPERIMENTAL|Placebo + erlotinib|Placebo infusion every 3 weeks and oral erlotinib 150 mg/day
62572592|NCT02134015|EXPERIMENTAL|Patritumab + erlotinib|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks) and oral erlotinib 150 mg/day
62005940|NCT04024475||D: Metastatic PCa but hormone sensitive|Metastatic PCa without curative treatment but hormone sensitive disease, treated with ADT (medical or surgical), with or without additive treatments. Oligometastatic PCa.
62572593|NCT04145180|EXPERIMENTAL|Manual Therapy|Manual Therapy-based intervention
62005941|NCT04024475||E: Metastatic castration resistant prostate cancer (mCRPC)|Metastatic castration resistant prostate cancer (mCRPC). Oligometastatic PCa.
62005942|NCT06444477||Patients with a definite diagnosis of both ITP and cancer|
62572594|NCT04145180|NO_INTERVENTION|Control|Patients waiting list
62005943|NCT01045226|EXPERIMENTAL|Arm I|Patients undergo proton radiotherapy once daily 5 days a week for approximately 9 weeks in the absence of disease progression or unacceptable toxicity.
62572595|NCT04644302||non-COVID sepsis|Patients admitted to ICU with sepsis of non-COVID origin
62572596|NCT04644302||COVID sepsis|Patients admitted to ICU with sepsis of COVID origin
62191457|NCT00360477|ACTIVE_COMPARATOR|3|Fascial Stitch
62191458|NCT05811299|EXPERIMENTAL|Abdominal Exercises and KT intervention|(Group A ) will receive kinesio taping with abdominal exercises. 8 sessions for 4 weeks and 2 session will be given in a week.
62191459|NCT05811299|ACTIVE_COMPARATOR|Abdominal exercises|(Group B) will receive abdominal exercises 8 sessions for 4 weeks and 2 session will be given in a week.
62191460|NCT02325362|EXPERIMENTAL|Miglustat then placebo|10 patients will received Miglustat then the placebo
62191461|NCT02325362|EXPERIMENTAL|Placebo then Miglustat|10 patients will received Placebo then Miglustat
62191462|NCT05750836|EXPERIMENTAL|Specific nursing support|The caregivers benefit from specific nursing support.
62191463|NCT05750836|ACTIVE_COMPARATOR|No specific nursing support|Caregivers do not receive any specific support from the nurses.
62191464|NCT03334877||β -human chorionic gonadotropin|Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation to predict preterm labour in asymptomatic high risk patients
62191465|NCT03833895|EXPERIMENTAL|Group 1 Elements|Continuously infusion of 0.05ug/kg/min Norepinephrine during the Cesarean Section operation
62191466|NCT03833895|EXPERIMENTAL|Group 2 Elements|Continuously infusion of 0.25ug/kg/min phenylephrine during the Cesarean Section operation
62397224|NCT01406548|PLACEBO_COMPARATOR|placebo dosing frequency 1|Subjects dosed with matching placebo to 20mg/Kg BPS804 monthly
62397225|NCT01406548|EXPERIMENTAL|BPS804 dosing frequency 2|Subjects dosed with 20mg/Kg BPS804 quarterly
62397226|NCT01406548|PLACEBO_COMPARATOR|placebo dosing frequency 2|Subjects dosed with matching placebo to 20mg/Kg BPS804 every 3 months
62397227|NCT01406548|EXPERIMENTAL|BPS804 dosing frequency 3|Subjects dosed with 20mg/Kg BPS804 weekly
62397228|NCT01406548|PLACEBO_COMPARATOR|Placebo dosing frequency 3|Subjects dosed with matching placebo to 20mg/Kg BPS804 weekly
62397229|NCT06058013|EXPERIMENTAL|NMRA-335140 80 milligrams (mg) once daily (QD)|Participants will receive a NMRA- 335140 tablet at a dose of 80 mg once daily (QD)
62572597|NCT03431831|ACTIVE_COMPARATOR|Intervention Control|All participants will receive diet/physical intervention. One arm will receive diet/physical activity intervention alone as a Intervention/usual care condition.
62005944|NCT05451576|ACTIVE_COMPARATOR|Sodium selenite|200μg/d intravenous sodium selenite was dissolved in 100 ml 0.09% NaCl run 30 minutes, will be given on day 1-5, day 8-12, day 15-19, day 22-26, day 29-33, day 36-40, day 43-47 during concurrent chemoradiotherapy.
62191467|NCT03833895|PLACEBO_COMPARATOR|Group 3 Elements|In the placebo-control group, 3 ml/kg/min of LR was administrated according to standard weight.
62191468|NCT04565002|EXPERIMENTAL|EG|The TEDS protocol will consist of the following parameters: a) frequency of 30 Hz; b) pulse width of 0.4 ms; c) respiratory rate of 15 irpm; d) holding time of 1 s; e) rise time of 1 s; f) 2 s descent time; and g) 2 s non-stimulus time. Phrenics equipment (Dualpex 961, Quark®) will be used. The positioning of the electrodes will be performed according to a study by Cancelliero et al. (2012), who proposed the placement of two electrodes in the right and left paraxiphoid regions, and two others in the direction of the axillary midline, over the seventh intercostal space, also on the right and left sides.
62780485|NCT06584032|ACTIVE_COMPARATOR|Control group|Patients will be treated with TPC (chemotherapy of treating physician's choice, paclitaxel or doxorubicin) every three or four weeks until IRC-confirmed PD or meeting other discontinuation criteria.
62005945|NCT05451576|PLACEBO_COMPARATOR|Placebo|100 ml intravenous 0.09% NaCl run 30 minutes, will be given on day 1-5, day 8-12, day 15-19, day 22-26, day 29-33, day 36-40, day 43-47 during concurrent chemoradiotherapy.
62005946|NCT05703919|EXPERIMENTAL|Titrated Oxygen|"If the treating EMT or paramedic finds indications for inhaled bronchodilators, this will be done with compressed air 6-8 l/min. as the driver for the nebulizer. The patient will have a Bi-nasal EtCO2 (end-tidal carbon dioxide) meter placed under the nebulizer. This will measure the EtCO2 during the treatment and at the same time oxygen can be titrated through this to a target SpO2 of 88-92%. Repeated treatment will be at the discretion of the treating EMT or paramedic according to SOP (standard operating procedures).~Following scenarios regarding SpO2 can occur during treatment:~SpO2 \<88%: Supplemental oxygen via the EtCO2-meter up to 10 l/min, if higher oxygen levels are needed oxygen will be used as driver for the nebulizer. If the SpO2 remains under 88% additional oxygen can be added via the EtCO2-meter.~SpO2 88-92%: No intervention.~SpO2 \>92%: No intervention.~If repeated treatment is not indicated the patient receives oxygen to SpO2 88-92% according SOP."
62191469|NCT04565002|NO_INTERVENTION|CG|The control group will undergo the same assessments as the experimental group, but the TEDS will not be applied.
62191470|NCT05385237|EXPERIMENTAL|4D-MRI assessment for patients with liver diseases|patients with chronic liver diseases, acute liver inflammation or cardiac blood congestion to the liver will be assessed by MRI
62191471|NCT05385237|EXPERIMENTAL|4D-MRI assessment for healthy volunteers (control group)|healthy control subjects will be assessed by MRI
62780486|NCT06203769|EXPERIMENTAL|Experimental group|14-day antibiotic therapy after removal of infected material
62191472|NCT01246089|EXPERIMENTAL|Ranabizumab|Myopic eyes with retinal neovascularization
62191473|NCT01759147|EXPERIMENTAL|Surgery|Surgical repair of acromioclavicular dislocation.
62191474|NCT00696488|EXPERIMENTAL|Fluorouracil 0.5%|each subject will receive the study medication: Carac® 0.5% Fluorouracil, a standard treatment for actinic keratoses. Carac® will be dispensed to the subjects in the original tube with MEMS electronic monitoring caps attached. Subjects will be asked to apply the medication daily to AK lesions
62191475|NCT02931305|EXPERIMENTAL|Epimedium Prenylflavonoids Extract|Single oral doses of EP (370 mg, 740 mg and 1110 mg) capsules would be orally administered.
62191476|NCT02931305|PLACEBO_COMPARATOR|Placebo|Single oral doses of Placebo (370 mg, 740 mg and 1110 mg) capsules would be orally administered.
62191477|NCT02518815|EXPERIMENTAL|Prewarming group|Prewarmed for 20 minutes prior to OR using 3M Bair Paws System, a forced air warming blanket. This warming blanket was then used intraoperatively throughout the case.
62191478|NCT02518815|NO_INTERVENTION|Control group|Patients received standard care, which is no active prewarming prior to OR. A full body, forced air warming blanket (same as treatment group) was used intraoperatively throughout the case.
62005947|NCT05703919|ACTIVE_COMPARATOR|Standard Oxygen|"If the treating EMT or paramedic finds indication for inhaled bronchodilators, this will be done with oxygen 6-8 l/min. as the driver for the nebulizer. The patient will have a Bi-nasal EtCO2 meter placed under the nebulizer. This will measure the EtCO2 during the treatment and at the same time mask the patient for group allocation. Repeated treatment will be at the discretion of the treating EMT or paramedic according to SOP.~Following scenarios regarding SpO2 can occur during treatment:~SpO2 \<88%: Supplemental oxygen via the EtCO2 -meter up to 10 l/min.~SpO2 88-92%: No intervention.~SpO2 \>92%: No intervention.~If repeated treatment is not indicated the patient receives oxygen to SpO2 88-92% according SOP."
62005948|NCT03667339||outpatients group|Patient schedulded to undergo outpatient Direct Anterior Total Hip Arthroplasty
62005949|NCT03667339||inpatients group|Patient schedulded to undergo inpatient Direct Anterior Total Hip Arthroplasty
62191479|NCT01844726|EXPERIMENTAL|GLYX-13|Single IV infusion of GLYX-13, 5mg/kg,
62191480|NCT01844726|PLACEBO_COMPARATOR|Placebo|Single IV administration of placebo
62191481|NCT05625932|NO_INTERVENTION|Control Arm|Those patients allocated in the control arm will receive no interventions related to VTE risk. No placebo will be administered to avoid discomfort of these patients who are already under treatment for their cancer.
62214735|NCT06431308|NO_INTERVENTION|Control group|"* Usual nutrition care treatment for patients treated with Wegovy© (RCT).~* Prior to the initiation of AOM treatment, participant will receive general nutrition guidance based on national recommendations according to the Mediterranean diet."
62397230|NCT06058013|PLACEBO_COMPARATOR|Placebo|Placebo participants will receive matching placebo tablet once daily.
62397231|NCT05136989||Professionals from the seven least coercive facilities|Volunteer professionals selected on the basis of their experience in reducing the use of coercion.
62780487|NCT06203769|ACTIVE_COMPARATOR|control group|28-day antibiotic therapy after removal of infected material
62780488|NCT03603106|EXPERIMENTAL|Part I (Phase I)|In each dose group (0.025, 0.05, 0.075, 0.1, 0.2 and 0.3 mmol/kg), 9 healthy subjects were to be included: 6 subjects received P03277 and 3 subjects received placebo in one single intravenous administration.
62780489|NCT03603106|EXPERIMENTAL|Part II (Phase IIA)|In each dose group (0.05, 0.075, 0.1 and 0.2 mmol/kg), all 3 patients received one single intravenous administration of P03277.
62780490|NCT01150565|EXPERIMENTAL|LiRIS low dose|The first dose group of approximately 10 patients receive low dose LiRIS on Day 1 to Day 14.
61977954|NCT04262505|EXPERIMENTAL|Mediterranean Diet Group (Group A)|The intervention is based on components of the traditional Mediterranean diet which is primarily a plant based diet and emphasises intakes of vegetables, whole grains and fruit with the main added fat being extra virgin olive oil.The diet will be modified and tailored to cultured preferences by the registered dietitian. Participants will be informed of their diet allocation group during the baseline teleconsultation and will commence the diet the following day or as soon as is feasible for 12 weeks. Participants will be provided with resources specifically designed to explain the components of the Mediterranean diet and how it will be followed.
62005950|NCT01395472|EXPERIMENTAL|TBI - Experimental Sample|TBI patients will be submitted to two acute physical exercise protocols in a cycloergometer with one weak of interval (until voluntary exhaustion and 30 minutes in ventilatory threshold I)
62005951|NCT01395472|ACTIVE_COMPARATOR|Healthy Controls|healthy volunteers will be submitted to two acute physical exercise protocols in a cycloergometer with one weak of interval (until voluntary exhaustion and 30 minutes in ventilatory threshold I)
62005952|NCT01395472|ACTIVE_COMPARATOR|TBI Controls|Patients will be submitted to a protocol of stretching for 30 minutes
62005953|NCT01434823|EXPERIMENTAL|Intervention - nocturnal coverage|Nocturnal coverage from intensivists will be randomized by week. The weeks that have intensivists in the MICU during the 7pm to 7am shift are the intervention weeks.
62005954|NCT01434823|NO_INTERVENTION|Control - standard of care|The weeks that are not randomized, the intervention arm will retain the current standard of care in the HUP MICU: attending intensivist availability by phone (home call).
62005955|NCT06319196|EXPERIMENTAL|Anti-PD-1/LAG-3 (Opdualag/BMS-986213)|
62005956|NCT06319196|ACTIVE_COMPARATOR|Anti-PD-1 ( Nivolumab)|
62005957|NCT05741918|EXPERIMENTAL|Pediatric Intensive Care Units Patients|Patients under 18 admitted in pediatric intensive care unit
62005958|NCT05586399|EXPERIMENTAL|Exercise intervention|Participants performing a rehabilitation program for 5 times a week in a total of 4 weeks in one of two rehabilitation centers in Trondheim, Norway. The aim is to perform a total of 20 maximal strength training interventions supervised by one or more health professionals. Maximal strength training will be performed with 4 repetitions and 4 series at 90-95% of one repetition maximum.
62005959|NCT02734017|OTHER|standard course|group not receiving medication review
62191482|NCT05625932|EXPERIMENTAL|Experimental arm|"Those patients allocated to the experimental arm will receive prophylactic Tinzaparin at a fixed dose according to their weight:~Patients \< 80 kg will receive a fixed dose of 4500 IU daily. Patients between 80-100 kg will receive a fixed dose of 6000 IU daily. Patients \> 100 kg will receive a fixed dose of 8000 IU daily.~Accordingly, the effective dose of tinzaparin is estimated to be in the range of 56-90 IU/kg. Tinzaparin dose will be adjusted according to the dose levels specified above in patients who experience changes in body weight greater than 10% during treatment period."
62191483|NCT00610909|EXPERIMENTAL|1|Those in the active treatment group will receive doses of Paxil CR in increments of 12.5 mg daily for the first week and increased at 12.5 mg increments at visit weeks to a maximum of 50 mg daily, as determined by the investigator. The investigator will adjust dosage based on clinical response. Following the completion of the double-blind phase, patients on placebo and non-responders to the study drug will be tapered off the study drug back to 0 over 2 weeks, and they will be referred to their Primary Care Physician, Internist or Gastroenterologist to be prescribed treatment for Irritable Bowel Syndrome.
62005960|NCT02734017|OTHER|pharmacist-led standardized medication review|"pharmacist-led standardized medication review including :~* Medical and pharmaceutical admission medication reconciliation and treatment review~* Medical and pharmaceutical medication reconciliation at discharge and treatment review~* Medication Liaison Service"
62005961|NCT01570023|NO_INTERVENTION|Standard Clinical Care|Standard swallowing intervention is that which is identified by the SLP as appropriate to treat the patient's dysphagia and is in common clinical practice. Such treatment would consist of dietary or postural compensatory strategies (i.e., chin down posture while swallowing).
62005962|NCT01570023|EXPERIMENTAL|Standard Clinical Care Plus Isometric Lingual Exercise|Standard Clinical Care Plus 8-week Isometric Lingual Exercise Regimen. The isometric tongue exercises will be completed using the Madison Oral Strengthening Therapeutic (MOST) device. Baseline maximum lingual pressure will be obtained at the anterior and posterior sensors independently by gathering two sets of data (3 MOST device trials) at each site (anterior and posterior) that differ by less that 5%. During week one of the regimen, the target value of each repetition will be 60% of the maximum baseline pressure. For the remaining seven weeks of the program, the target value will be increased to 80% of the maximum. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.
62005963|NCT06034366|EXPERIMENTAL|study group|Participants in the study group will use 0.01% atropine (3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks,
62005964|NCT06034366|OTHER|placebo eye drops|participants in the control group will utilize placebo eye drops (0.9% sodium chloride, 3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks.
62005965|NCT01159301|EXPERIMENTAL|Treatment (entinostat, sorafenib tosylate)|Patients receive oral entinostat once daily on days 1 and 15 and oral sorafenib tosylate twice daily on days 1-28 (days 15-28 only of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62191484|NCT00610909|PLACEBO_COMPARATOR|2|Same shape placebo
62191485|NCT01256671|EXPERIMENTAL|DHEA|0.5% DHEA (intravaginal)
62397232|NCT05136989||Voluntary ex-patients|Voluntary ex-patients who were hospitalized in these establishments in the two years preceding the survey and whose condition is stabilized
62397233|NCT05169567|EXPERIMENTAL|Arm A: Abemaciclib plus Fulvestrant|Abemaciclib administered orally in combination with fulvestrant administered intramuscularly (IM).
62005966|NCT06663176|EXPERIMENTAL|Part 1-1 (Active)|RESP303 Single Ascending Dose Phase followed by Multiple Daily Dosing (28-days)
62005967|NCT06663176|EXPERIMENTAL|Part 2-1 (Active)|RESP302 TID Single Ascending Dose Phase followed by Multiple Daily Dosing (28-days)
62397234|NCT05169567|ACTIVE_COMPARATOR|Arm B: Placebo plus Fulvestrant|Placebo administered orally in combination with fulvestrant administered IM.
62397235|NCT06722105|EXPERIMENTAL|2 infusions of MSC|
62397236|NCT06722105|EXPERIMENTAL|1 infusion of MSC|
62397237|NCT06722105|PLACEBO_COMPARATOR|Placebo|
62005968|NCT06663176|EXPERIMENTAL|Part 2-2 (Active)|RESP303 BID Single Ascending Dose Phase followed by Multiple Daily Dosing (28-days)
62005969|NCT06663176|EXPERIMENTAL|Part 2-3 (Active)|RESP303 TID Single Ascending Dose Phase followed by Multiple Daily Dosing (28-days)
62191486|NCT05869045||Patients with Diaphragmatic dysfunction (DD)|Patients with diaphragmatic dysfunction measured by point-of-care ultrasound using the diaphragm shortening fraction (DSF) method, which resulted in values lower than 10%. DSF is calculated by the formula: diaphragmatic thickness at the end of inspiration - diaphragmatic thickness at the end of expiration/diaphragmatic thickness at the end of expiration×100
62191487|NCT05869045||Patients without Diaphragmatic dysfunction (DD)|Patients without diaphragmatic dysfunction measured by point-of-care ultrasound using the DSF method, which resulted in values higher than 10%.
62397238|NCT06380985|EXPERIMENTAL|Personalized VR Alcohol Approach Bias Modification (ApBM) Condition|The Personalized VR ApBM will consist of 9 cognitive training sessions, each session lasting approximately 20 minutes completed on separate days over 3 weeks. Each session requires the participant to respond to 240 visual stimuli using a push or pull motion as quickly as possible.
62005970|NCT00484302|EXPERIMENTAL|CapOpus|
62005971|NCT00484302|ACTIVE_COMPARATOR|Treatment as usual|
62005972|NCT04709965|OTHER|Main Study|Patients attending routine genetic clinic/paediatric clinic appointments for diagnosis of a multiple anomaly syndrome where distinctive facial features form part of their presenting pattern.
62397239|NCT06380985|SHAM_COMPARATOR|Sham Condition|Sham training will consist of 9 cognitive training sessions, each session lasting approximately 20 minutes completed on separate days over 3 weeks. Each session requires the participant to respond to 240 visual stimuli using a push or pull motion as quickly as possible.
62005973|NCT04709965|OTHER|Faces Sub Study|Patients eligible to be recruited to the Faces Sub Study will have biochemically or genetically confirmed diagnosis of inborn disorder of metabolism where no well described dysmorphic facial features are known to be associated with disorder.
62397240|NCT02958449|EXPERIMENTAL|Test - Standard Closure with TissuGlu Surgical Adhesive|Standard closure plus treatment with TissuGlu
62572598|NCT03431831|EXPERIMENTAL|Counselling|These participants will receive usual care and counseling in the form of motivational interviewing weekly with goal setting for the first 5 weeks and monthly intervention for the final 5 months.
62572599|NCT03431831|EXPERIMENTAL|Contrave|These participants will receive usual care and prescription of Contrave for weight loss. They will be seen weekly for the first 5 weeks and monthly for the final 5 months.
62005974|NCT03837899|EXPERIMENTAL|Durvalumab / Tremelimumab Combination Therapy|"Part 1 (dose finding) Durvalumab + tremelimumab Combination Treatment. Durvalumab and tremelimumab are initially administered at dose level 1 and dose escalated based on results from PK modeling and tolerance to determine the RP2D. Both drugs are administered every 4 weeks as intravenous infusions. Tremelimumab is only administered with durvavalumab for 4 doses, from cycles 2-5. (sarcoma, NB and NHL)~Part 2 (dose expansion phase) Durvalumab + tremelimumab Combination Treatment. Durvalumab and tremelimumab are administered at the RP2D, every 4 weeks as intravenous infusions. Tremelimumab is only administered with durvalumab for 4 doses, from cycles 1-4. Tremelimumab may be added for 4 doses at time of progressive disease. Cohorts: solid tumors, sarcomas, NHL restricted to PMBCL and ALCL subtypes)"
62005975|NCT06055426|EXPERIMENTAL|bed bath|"Bed bath application stages:~* Environmental elements (ambient temperature, airflow and curtain-screen) are taken under control in the clinic (Ensure that the ambient temperature is 23-24℃)."
62191488|NCT03167853|EXPERIMENTAL|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg per 2 weeks until disease progresses or unacceptable tolerability occurs.
62191489|NCT06319183|EXPERIMENTAL|Salbutamol|
62191490|NCT02923505||SDB+COPD|Patients with sleep-disordered breathing and concomitant chronic obstructive pulmonary disease
62191491|NCT02923505||SDB+HF|Patients with sleep-disordered breathing and concomitant heart failure
62191492|NCT02923505||SDB+COPD+HF|Patients with sleep-disordered breathing and concomitant chronic obstructive pulmonary disease and heart failure
62191493|NCT05951023|EXPERIMENTAL|Eszopiclone|Subjects will be asked to take their study drugs nightly at bedtime and use their CPAP during sleep as much as possible
62397241|NCT02958449|NO_INTERVENTION|Control - Standard Closure|Standard closure with no intervention
62397242|NCT05889780|ACTIVE_COMPARATOR|Pantry only|Referrals to onsite food pantry or emergency food boxes from partner pantry if onsite pantry is not open by 2024.
62397243|NCT05889780|EXPERIMENTAL|Nutritious, no-prep meals|Participants will receive up to 12 nutritious no-prep meals per month (three meals per week) for three-months.
62397244|NCT05889780|EXPERIMENTAL|Vouchers|Participants will receive $75 vouchers each month for three-months.
62780491|NCT01150565|EXPERIMENTAL|LiRIS high dose|The second dose group of approximately 10 patients receive high dose LiRIS on Day 1 to Day 14.
62780492|NCT01879943|EXPERIMENTAL|PillCam COLON 2 and Standard Colonoscopy|"Patients will have videocapsule colonoscopy after bowel preparation, followed by standard colonoscopy the next day.~Interventions:~* Device: PillCam COLON 2 on D0~* Procedure: Standard colonoscopy on D1"
62005976|NCT06341465|EXPERIMENTAL|Exercise group|For 12 weeks, participants will receive rotational breathing, correction techniques, positioning, mobilization, and three-dimensional exercises specific to their curvature twice a week.
62005977|NCT06341465|EXPERIMENTAL|Exercise and taping group|For 12 weeks, participants will schroth exercises including receive rotational breathing, correction techniques, positioning, mobilization and three dimensional exercises specific to their curvature and kinesiological taping. Kinesiological taping will be applied as a tone enhancer or tone reducer according to the concave and convex sides of the curve.
62005978|NCT06341465|NO_INTERVENTION|Healthy people|Healthy individuals without scoliosis will be included.
62191494|NCT05951023|PLACEBO_COMPARATOR|Placebo|Subjects will be asked to take their study drugs nightly at bedtime and use their CPAP during sleep as much as possible
62191495|NCT03206268||healthy eyes|
62191496|NCT03206268||uveitis eyes|
62191497|NCT02970097|ACTIVE_COMPARATOR|single shot IBP block|Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
62191498|NCT02970097|ACTIVE_COMPARATOR|local infiltration|Subjects will receive local infiltration into portal space and joint space with 10ml of 0.5% ropivicaine given intraoperatively to help with operative and postoperative pain
62005979|NCT05172505|ACTIVE_COMPARATOR|Active prefrontal tDCS 2mA 6 weeks 5x/week|
62191499|NCT01843777|ACTIVE_COMPARATOR|Standard-of-Care|"The standard-of-care control group will review and practice with the audiologist content such as: 1) information on hearing-aid batteries and how to change them, 2) cleaning/daily care of the hearing aids, and 3) inserting and removing the hearing aids."
62191500|NCT01843777|EXPERIMENTAL|Treatment|The treatment group, on the other hand, will use a motivational tool (exploring importance) in a manner that is consistent with the spirit of motivational interviewing.
62191501|NCT01468077|EXPERIMENTAL|Tocilizumab, Normal Administration|Tocilizumab 8 mg/kg infusion of 60 minutes duration every 4 weeks for 6 infusions (up to 24 weeks)
62191502|NCT01468077|EXPERIMENTAL|Tocilizumab, Fast Administration|Tocilizumab 8 mg/kg infusion of 31 minutes duration every 4 weeks for 6 infusions (up to 24 weeks). The first infusion was 1 hour. If an infusion reaction occurred during any treatment, 1 hour infusions were used for all subsequent infusions
62780493|NCT04014569|EXPERIMENTAL|MPSA Algorithm|Insulin dosing will be adjusted using the MPSA algorithm
62005980|NCT05172505|SHAM_COMPARATOR|Sham prefrontal tDCS 6 weeks 5x/week|
62191503|NCT01292304|EXPERIMENTAL|Tolvaptan|Tolvaptan 15 mg tablet once daily for 7 days followed by Tolvaptan 30 mg (two 15 mg tablets) once daily according to efficacy and tolerability
62191504|NCT04428008|EXPERIMENTAL|Active arm|1.6 mg thymalfasin in 1 mL subcutaneous injection twice weekly after dialysis for 8 weeks
62191505|NCT04428008|NO_INTERVENTION|Control arm|Standard care
62780494|NCT06426914|EXPERIMENTAL|Interventional|Pilates Clinical (Introductory program)
62005981|NCT01267903|EXPERIMENTAL|320U /0.5ml in young adults|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 20 young adults aged 16-22 years old on day0,28
62191506|NCT04970719|EXPERIMENTAL|Remdesivir plus Baricitinib|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course
62780495|NCT06426914|ACTIVE_COMPARATOR|Control|Cardiac Rehabilitation
62191507|NCT04970719|ACTIVE_COMPARATOR|Remdesivir plus Dexamethasone|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5 -day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
62191508|NCT00844597|EXPERIMENTAL|Cohort 1 - 0.5 mg/kg/wk|Subjects in this group will receive a 0.5 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
62191509|NCT00844597|EXPERIMENTAL|Cohort 2 - 1.0 mg/kg/wk|Subjects in this group will receive a 1.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
62191510|NCT00844597|EXPERIMENTAL|Cohort 3 - 2.0 mg/kg/wk|Subjects in this group will receive a 2.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
62191511|NCT00844597|EXPERIMENTAL|Cohort 4 - 4.0 mg/kg/wk|Subjects in this group will receive a 4.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
62191512|NCT00844597|EXPERIMENTAL|Cohort 5 - 10.0 mg/kg/wk|Subjects in this group will receive a 10.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
62005982|NCT01267903|EXPERIMENTAL|640U /0.5ml in young adults|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 20 young adults aged 16-22 years old on day0,28
62780496|NCT03273309|ACTIVE_COMPARATOR|Vibratory Perineal Stimulus|It's thought that the vibratory perineal stimulation can produces afferent nerve impulses that goes to the sacral spinal cord (S2-S4) via the pudendal nerve and stimulates the sacral somatic response which will cause the pelvic muscle contraction.
62780497|NCT03273309|ACTIVE_COMPARATOR|Transvaginal Electrical Stimulation|Transvaginal electrical stimulation can produces direct and reflex responses of the pelvic floor muscles, being more effective in patients who can't voluntarily contract this musculature. In addition, it increases blood flow to the muscles, restores neuromuscular connections and improves muscle fiber function.
62005983|NCT01267903|EXPERIMENTAL|160U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 20 children aged 5-15 years old on day0,28
62005984|NCT01267903|EXPERIMENTAL|320U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 20 children aged 6-15 years old on day0,28
62005985|NCT01267903|EXPERIMENTAL|640U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 20 children aged 6-15 years old on day0,28
62005986|NCT03757182||Wearable activity monitor|Continuous activity monitoring with Fitbit Charge HR from baseline to up to 1 year from end-of-study.
62191513|NCT00844597|EXPERIMENTAL|Cohort 6 - 20.0 mg/kg/wk|Subjects in this group will receive a 20.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
62191514|NCT03678623||Office-based workers|Individuals working in an office environment with their main tasks involving use of a computer, reading, phoning, making presentations and participating in meetings, who perform more than 30 hours per week mostly sitting at a computer.
62191515|NCT02780297||Primary Hyperoxaluria Patients|Patients with confirmed diagnosis of Primary Hyperoxaluria.
62191516|NCT02780297||Dent Disease Patients|Patients with confirmed diagnosis of Dent Disease.
62191517|NCT02780297||Cystinuria Patients|Patients with confirmed diagnosis of Cystinuria.
62191518|NCT02780297||APRT deficiency Patients|Patients with confirmed diagnosis of adenine phosphoribosyltransferase deficiency (APRTd)
62191519|NCT02780297||Lowe Syndrome or Dent 2 patients|Patients with confirmed diagnosis of Lowe Syndrome or Dent 2.
62572600|NCT03431831|EXPERIMENTAL|Contrave and counseling|These participants will receive usual care of diet and physical activity recommendations and Contrave prescription and counseling (motivational interviewing interventions weekly for the first 5 weeks and then monthly for 5 months.
62780498|NCT03524638|ACTIVE_COMPARATOR|ARM A|Colorectal surgery with administration of Visbiome
62780499|NCT03524638|ACTIVE_COMPARATOR|ARM B|Colorectal Surgery alone
62780500|NCT02056327||Oral appliance with monitoring suite|Subjects will sleep with a standard oral appliance with the newly developed monitoring suite embedded within it for 1-2 nights while being monitored with standard in lab polysomnography or home sleep testing.
62780501|NCT00446082|EXPERIMENTAL|SOM230 LAR|
62780502|NCT05477797|EXPERIMENTAL|Ixazomib DX|Id: Ixazomib 4mg po d1,8,15; Dexamethasone 20mg po d1,8,15,22; （28 days /cycle）. The treatment will be maintained for 2 years （if no disease progression or intolerant side effects appear）.
62780503|NCT05477797|PLACEBO_COMPARATOR|Lenalidomide DX|Rd: Lenalidomide 25mg qd d1-21; Dexamethasone 20mg po d1,8,15,22; （28 days /cycle）. The treatment will be maintained for 2 years （if no disease progression or intolerant side effects appear）.
61977955|NCT04262505|EXPERIMENTAL|Healthy Eating Group (Group B)|Participants assigned to the Healthy Eating group will be advised to adhere to the current healthy eating guidelines and will be provided with resources to inform them of these guidelines and sample meal plans that are readily available on the Healthy Ireland website.
62191520|NCT02780297||Dent 1 carriers|Patients with confirmed diagnosis of Dent 1. Dent 1 carriers
62191521|NCT02780297||Enteric Hyperoxaluria Patients|Patients with confirmed diagnosis enteric hyperoxaluria.
62191522|NCT00455897|EXPERIMENTAL|GMCSF-RCHOP|
62191523|NCT06546722|NO_INTERVENTION|Placebo|This group receives standard analgesic treatment and no Transversus Thoracic Plane Block is performed
62191524|NCT06546722|ACTIVE_COMPARATOR|Transversus Thoracic Plane Block pre|This group receives standard analgesic treatment and Transversus Thoracic Plane Block is performed before surgery
62191525|NCT06546722|ACTIVE_COMPARATOR|Transversus Thoracic Plane Block post|This group receives standard analgesic treatment and Transversus Thoracic Plane Block is performed at the end of surgery
62191526|NCT05963009|EXPERIMENTAL|Baxdrostat oral solution|5 mg CIN-107 oral solution in a fasted state
62780504|NCT00577499||Only group|adult cystic fibrosis patients who are not at goal body mass index and have started lubiprostone therapy within one month of study enrollment
62780505|NCT02655575|EXPERIMENTAL|BI + VR + CBT|"Brief Intervention (BI) consists of an individual clinical examination, education/information and advice about being active Vestibular Rehabilitation (VR) includes active exercises that provokes dizziness, Balance exercises and body awareness exercises in a group format.~Cognitive Behavioral Therapy (CBT) includes conversation and reflection about factors that may be a barrier to Activity and participation"
62191527|NCT05963009|EXPERIMENTAL|Baxdrostat tablet (fasted state)|5 mg CIN-107 tablet(s) in a fasted state
62191528|NCT05963009|EXPERIMENTAL|Baxdrostat tablet (fed state)|5 mg CIN-107 tablet(s) in a fed state (standard high fat meal)
62191529|NCT04817423||Model training and test group|Data set will be split into training group and test group, where training group will be used for model building, and test group for subsequent evaluation and verification.
62191530|NCT02777645||Study group|Study group(n=50) included CP children with chewing disorder. Growth, feeding evaluation will be done.
62191531|NCT02777645||Control group|Control group(n=35)= healthy children without chewing disorder Growth, feeding evaluation will be done.
62191532|NCT06370442|ACTIVE_COMPARATOR|Lorazepam|
62191533|NCT06370442|ACTIVE_COMPARATOR|Haloperidol|
62191534|NCT06370442|EXPERIMENTAL|IN Dex|
62191535|NCT05888610|EXPERIMENTAL|Digital Outpost|
62572601|NCT03297645|EXPERIMENTAL|Arm 1|school + asthma education + home environment remediation
62572602|NCT03297645|EXPERIMENTAL|Arm 2|asthma education + home environment remediation
62780506|NCT02655575|ACTIVE_COMPARATOR|BI + phone calls|Brief Intervention (BI) consists of an individual clinical examination, education/information and advice about being active Phone Calls as follow-up at week 2 and 6 to reassure
62572603|NCT03297645|ACTIVE_COMPARATOR|Arm 3|enhanced standard of care
62572604|NCT01686464|EXPERIMENTAL|Magnetic - Oxygen|Magnetic and Oxygen Treatment for Bell's Palsy
62780507|NCT06481566|EXPERIMENTAL|Almonertinib plus SABR group|Take first-line Almonertinib for 2-4 months, then deliver SABR to residual primary lung lesions; after that, go on Almonertinib maintenance treatment
62005987|NCT06130176|EXPERIMENTAL|Single-step Functional Sinus Endoscopy and Transoral Surgery|The patients who will be included in this study will be treated by functional sinus endoscopy and transoral surgery to remove the dental cause in the same visit to treat odontogenic sinusitis. The functional sinus endoscopy will be performed by the otolaryngologist, while the transoral surgery will be performed by oral and maxillofacial surgeon.
62005988|NCT06130176|ACTIVE_COMPARATOR|Functional sinus endoscopy|The patients who will be included in this study will be treated by functional sinus endoscopy to treat odontogenic sinusitis, and it will be performed by the otolaryngologist.
62191536|NCT00131963||Regimen 1|Patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.
62191537|NCT00131963||Regimen 2|Patients receive doxorubicin and cyclophosphamide as in regimen 1. Patients then receive paclitaxel IV over 1 hour once weekly for 12 weeks.
62572605|NCT01686464|ACTIVE_COMPARATOR|prednisone - valacyclovir|prednisone and valacyclovir treatments for bell palsy
62005989|NCT06130176|ACTIVE_COMPARATOR|Trans oral Surgery|The patients who will be included in this study will be treated by transoral surgery to treat odontogenic sinusitis, and it will be performed by by oral and maxillofacial surgeon
62005990|NCT05756764||Patients with obesity on pharmacotherapy|Before initiation of pharmacotherapy (as part of the standard-of-care treatment) and 6 months after initiated medication
62005991|NCT03544983|EXPERIMENTAL|Proactive Outreach + Web Counseling|Web + Streamlined Telephone Genetic Information
62005992|NCT03544983|NO_INTERVENTION|Usual Care|Participants in the usual care arm will not be provided with access to the web-based intervention nor will they have access to streamlined genetic counseling. They can pursue clinical genetic counseling on their own.
62191538|NCT05350488||Stroke Survivors <1 year|Group A will include participants that are less than 1 year out from their most recent stroke.
62191539|NCT05350488||Stroke Survivors >1 year|Group B will include participants that are greater than 1 year out from their most recent
62191540|NCT05350488||Caregivers|Group C will include participants' identified caregivers.
62191541|NCT00519545|EXPERIMENTAL|1|scripted prayer group (intervention group)
62191542|NCT00519545|NO_INTERVENTION|2|no prayer intervention group (non-intervention group)
62572606|NCT04725162||Epilepsy patients|Pediatric patients with focal epilepsy.
62572607|NCT04725162||Control|Age-matched controls who underwent 18F-FDG PET/CT examination for diseases outside brains.
62572608|NCT04725162||Validation|Children who underwent 18F-FDG PET/MRI to examine extracranial tumors.
62572609|NCT02589639|EXPERIMENTAL|empagliflozin 10 mg|
62005993|NCT05645627|PLACEBO_COMPARATOR|Group 1|Participants receive placebo through week 16,placebo participants will cross over to receive IBI112 through week 48
62005994|NCT05645627|EXPERIMENTAL|Group 2|Participants receive Dose 1 IBI112 through week 16 ,and then will receive Dose 2 IBI112 through week 48
62005995|NCT05645627|EXPERIMENTAL|Group 3|Participants receive Dose 1 IBI112 through week 16 ,and then will receive Dose 3 IBI112 through week 48
62191543|NCT03850275|EXPERIMENTAL|Experimental: Placebo, then caffeinated placebo, then e+shots|Participants received placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the caffeinated placebo and tested for 108 minutes. After another 48 hour washout period they received the e+shot and were tested for 108 minutes
62191544|NCT03850275|EXPERIMENTAL|Experimental: Caffeinated placebo, then placebo, then e+shots|Participants received caffeinated placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the placebo and tested for 108 minutes. After another 48 hour washout period they received the e+shot and were tested for 108 minutes
62191545|NCT03850275|EXPERIMENTAL|Experimental: placebo, then e+shots, then caffeinated placebo|Participants received placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received e+shots and tested for 108 minutes. After another 48 hour washout period they received the caffeinated placebo and were tested for 108 minutes.
62191546|NCT03850275|EXPERIMENTAL|Experimental: caffeinated placebo, then e+shots, then placebo|Participants received caffeinated placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the e+shots and tested for 108 minutes. After another 48 hour washout period they received the placebo and were tested for 108 minutes.
62191547|NCT03850275|EXPERIMENTAL|Experimental: e+shots, then caffeinated placebo, then placebo|Participants received e+shots and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the caffeinated placebo and tested for 108 minutes. After another 48 hour washout period they received the placebo and were tested for 108 minutes.
62191548|NCT03850275|EXPERIMENTAL|Experimental: e+shots, then placebo, then caffeinated placebo|Participants received e+shots and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the placebo and tested for 108 minutes. After another 48 hour washout period they received the caffeinated placebo and were tested for 108 minutes.
62191549|NCT05226676|EXPERIMENTAL|Real rTMS group|Repetitive TMS at 20Hz frequency over the M1 will be performed for five consecutive days for 2 weeks (using 90% of the resting motor threshold/total of 500 pulses). The rTMS will be applied through a figure-8 coil connected to a magnetic stimulator, which provides a biphasic pulse. This protocol was developed in accordance with the guidelines for the safe use of rTMS.
62191550|NCT05226676|SHAM_COMPARATOR|Sham group|Sham stimulation will be performed for five consecutive days for 2 weeks (using 90% of the resting motor threshold/total of 500 pulses). For the sham stimulation a sham coil will be used.
62191551|NCT04539483|EXPERIMENTAL|HDIT101|Topical application of HDIT101 solution to orolabial herpes lesion (4 times over 2 days). Blinded study drug will be applied to 2 lesions in the study
62572610|NCT02589639|EXPERIMENTAL|empagliflozin 25 mg|
62572611|NCT02589639|PLACEBO_COMPARATOR|placebo|
62572612|NCT00640913||I|Twenty consecutive patients operated on with low anterior resection of the rectum for cancer with a defunctioning stoma who accept participation.
62572613|NCT06577233|EXPERIMENTAL|Investigative Treatment|During the surgery, the investigative treatment group will have 5cc of diluted 0.25% Bupivacaine Hydrochloride injected into the superficial retroperitoneal area over the superior hypogastric nerve plexus.
62572614|NCT06577233|PLACEBO_COMPARATOR|Placebo|During the surgery, the placebo group will have 5cc of 0.9% normal saline injected into the superficial retroperitoneal area over the superior hypogastric nerve plexus.
62572615|NCT02761421||patients with IOPD|observation all patients with IOPD
62191552|NCT04539483|PLACEBO_COMPARATOR|Placebo to HDIT101|Topical application of placebo solution to orolabial herpes lesion (4 times over 2 days). Blinded study drug will be applied to 2 lesions in the study
62191553|NCT01957540|EXPERIMENTAL|Ticagrelor|Ticagrelor 90mg bid for 15 days
62191554|NCT01957540|ACTIVE_COMPARATOR|Prasugrel|Prasugrel 10mg od for 15 days
62191555|NCT02000128|EXPERIMENTAL|bioimpedance monitoring group|patients whose fluid status will be monitored and guided by bioimpedance analysis
62191556|NCT02000128|OTHER|clinical monitoring group|patients whose fluid status will be monitored and guided by clinical experience
62191557|NCT05147337|EXPERIMENTAL|Cohort 1: E2511 10 mg or Placebo|Non-Japanese adult (greater than or equal to \[\>=\] 18 years and less than \[\<\] 55 years old) participants will receive 10 milligram (mg) E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
62191558|NCT05147337|EXPERIMENTAL|Cohort 2: E2511 20 mg or Placebo|Non-Japanese adult participants will receive 20 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
62191559|NCT05147337|EXPERIMENTAL|Cohort 3: E2511 40 mg or Placebo|Non-Japanese adult participants will receive 40 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
62191560|NCT05147337|EXPERIMENTAL|Cohort 4: E2511 80 mg or Placebo|Non-Japanese adult participants will receive 80 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
62191561|NCT05147337|EXPERIMENTAL|Cohort 5: E2511 20 mg or Placebo|Japanese adult (\>=20 years and \<55 years old) participants will receive 20 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
62191562|NCT05147337|EXPERIMENTAL|Cohort 6: E2511 40 mg or Placebo|Japanese adult participants will receive 40 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
62572616|NCT06534099|PLACEBO_COMPARATOR|Control|Without changing their original lifestyle habits, weekly follow-ups were conducted by the experimenters via telephone or face-to-face interviews to ensure that the participants did not engage in other forms of regular fitness activities.
62572617|NCT06534099|EXPERIMENTAL|Experimental|The Wuqinxi exercise regimen was conducted under the guidance of a professional Wuqinxi instructor, where the experimental group practiced the five animal forms of the exercise, which include the Tiger, Deer, Bear, Ape, and Bird forms. The exercise period was 24 weeks, with the first 4 weeks designated as the learning phase and weeks 5 to 24 as the consolidation and reinforcement phase. The frequency of exercise was three times per week, with each session lasting 70 minutes, including 10 minutes for warm-up and relaxation activities.
62191563|NCT05147337|EXPERIMENTAL|Cohort 7: E2511 80 mg or Placebo|Japanese adult participants will receive 80 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
62191564|NCT05147337|EXPERIMENTAL|Cohort 8: E2511 40 mg or Placebo|Non-Japanese older (\>=55 years and less than or equal to \[\<=\] 85 years old) participants will receive 40 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
62191565|NCT05736419|EXPERIMENTAL|Participants with Sickle Cell Disease or β-Thalassemia|Participants will have severe sickle cell disease or transfusion-dependent β-thalassemia.
62191566|NCT04171349|ACTIVE_COMPARATOR|Group A|Patients received ultrasound guided supraclavicular block with 40 ml of Articaine hydrochloride 2%
62191567|NCT04171349|EXPERIMENTAL|Group AD|Patients received ultrasound guided supraclavicular block with 40 ml articaine 2% mixed with dexmedetomidine (1 µg/kg).
62572618|NCT05253469||Cryopreserved Aortic Homograft|"Include patients who received CAH for native (NVE) or prosthetic valve endocarditis (PVE).~The CAH are implanted using miniroot procedure. For extended aortic valve infection, aortic root replacement and reconstruction of regional contiguity is the recommended approach. Complicated aortic IE may present with destruction of a large portion of the aortic annulus, annular abscess and colonization of infected foci in contiguous cardiac structures (eg. Aortic root and intervalvular fibrosa).~Use of homograft in first time aortic valve replacement for IE decreased over time (9,4% to 5,6%) and in reoperation (37,5% to 28,5%) in a report from STS database between 2005-2011 (6). Nevertheless, the homograft was used more often in reoperations than in primary interventions (32.2% vs 7.0%, p \< 0.0001) in both valve replacements (14,6%) and for root replacements (53,2%) (6)."
62191568|NCT01021371|EXPERIMENTAL|Patient interview and communication to GP from hospital|Intervention group: The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group about their rehabilitation needs and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus.
62191569|NCT01021371|NO_INTERVENTION|Control group: Usual practice, no intervention|
62191570|NCT04030689||Axis 2|Each patient diagnosed HIV positive following VihTest test will be invited to participate to ALSO-Parcours; This program aimed to decribe the link to care for this population and to make a descriptive analysis of this HIV+ patients.
62191571|NCT02775305|NO_INTERVENTION|Not frail|Source of these participants will be the same as those who screen into the study; patients with chronic kidney disease receiving care at the San Francisco Veteran Affairs Medical Center. Based on initial screening if participants do not meet criteria for frailty, baseline screening data will be used for comparative analysis as the no intervention arm.
62191572|NCT02775305|EXPERIMENTAL|Frail|Source of these participants will be the same as those who screen into the study; patients with chronic kidney disease receiving care at the San Francisco Veteran Affairs Medical Center. Based on initial screening if participants meet criteria for frailty participants will be enrolled in the intervention arm. Participants who are ambulatory regardless of co-morbidities will not be excluded from the study.
62191573|NCT02346929|EXPERIMENTAL|ultrasound-guided hematoma block|Patients in this arm will receive a bed-side ultrasound guided hematoma block with analgesia (0.25% bupivacaine)
62191574|NCT02346929|NO_INTERVENTION|traditional hematoma block|Patients in this arm will have the hematoma block of the distal radius fracture with no ultrasound for guidance with analgesia (0.25% bupivacaine)
62191575|NCT02312206|EXPERIMENTAL|NEOD001|24 mg/kg (maximum dose of 2500 mg) of NEOD001 administered once every 28 days.
62397245|NCT04201223|EXPERIMENTAL|FLARE Intervention|Participants will be randomized to receive an intervention that works with melanoma survivors and their children as a family unit to improve melanoma preventive behaviors.
62397246|NCT04201223|NO_INTERVENTION|Standard Education|Participants will be randomized to receive information on child sun protection that is publicly available.
62780508|NCT03067623|EXPERIMENTAL|PRP-infusion|PRP will be obtained from a fresh whole blood collected from a peripheral vein; the blood sample will be centrifuged at 1500g (RCF) for 10 minutes and the repeated reversal of the tube will allow obtaining the PRP at the concentration required. Then 0,5-1ml of PRP will be infused into the uterine cavity through a Tomcat catheter. The endometrial thickening will be evaluated by ultrasonography 24-48h after the instillation and, if the endometrial lining reaches 7mm the Embryo-transfer will be arranged.
62780509|NCT01069705|EXPERIMENTAL|Tobramycin Inhalation Powder (TIPnew)|Participants received four capsules of 28 mg TIPnew (112 mg), inhaled twice a day (b.i.d.) in the morning and the evening given in a cycle of 28 days on treatment followed by 28 days off treatment for three consecutive cycles.
62780510|NCT01948063|PLACEBO_COMPARATOR|Control|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
62780511|NCT01948063|EXPERIMENTAL|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg of Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
62780512|NCT01463202|ACTIVE_COMPARATOR|DMPA postpartum|Depot medroxyprogesterone acetate postpartum
62780513|NCT01463202|ACTIVE_COMPARATOR|DMPA at 4-6 weeks after delivery|Depot medroxyprogesterone acetate at 4-6 weeks after delivery
62780514|NCT01512992|EXPERIMENTAL|Home telehealth|
62780515|NCT01512992|NO_INTERVENTION|Usual care|
62780516|NCT06583486|EXPERIMENTAL|Treatment Group|Five sites will be repeatedly injected with Rcombinant botulinum neurotoxin type A for injection (YY001) at 0.05 mL each, 2 sites in corrugator muscle of each side and 1 site in the procerus muscle, for a total dose of 20U.The study period is up to 64 weeks, divided into 5 treatment cycles.
62191576|NCT02312206|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as a 250 mL bag of normal saline once every 28 days.
62191577|NCT04467892|ACTIVE_COMPARATOR|Group A|. Group A 120 patients, received high dose (30 mg/kg) methylprednisolone slowly intravenous in 250 ml normal saline every 8 hours for only 4 days
62191578|NCT04467892|ACTIVE_COMPARATOR|Group B|group B 120 patients, included received 1 mg/kg/day methylprednisolone divided to three doses given every 8 hours for two weeks.
62191579|NCT00886353|ACTIVE_COMPARATOR|APN01|Healthy volunteers will receive APN01
62191580|NCT00886353|PLACEBO_COMPARATOR|Placebo|Physiological saline administrated i.v.
62191581|NCT05336175|EXPERIMENTAL|Ang-(1-7)|30 participants will take 100 micrograms of Ang-(1-7) a day via subcutaneous injection for 90 days
62191582|NCT05336175|PLACEBO_COMPARATOR|Saline Placebo|10 participants will take 100 micrograms of saline placebo a day via subcutaneous injection for 90 days
62191583|NCT05733416|EXPERIMENTAL|Intensive Cancer Screening|Usual care plus PDG PET/CT
62397247|NCT06117163|EXPERIMENTAL|Collaborative Care Model (CCM)|"The investigators propose a CCM called Tunawiri, meaning thrive in Kiswahili, that will be integrated within an existing multidisciplinary team of clinicians, mentor mothers, and other clinic staff in Kenyan antenatal care clinics. CCM includes: 1) clinic-level sensitization and integration, 2) Screening for CMD including anxiety, depression and trauma symptoms, 3) Problem-solving type cognitive behavioral therapy delivered by lay health workers, 4) Decision Support and monitoring via an Electronic Health Registry, and 5) Psychiatrist case review and nurse-managed mental health medication."
62397248|NCT05147831|EXPERIMENTAL|Remote Ischemic Preconditioning Protocol|
62397249|NCT05147831|NO_INTERVENTION|Sham Preconditioning Protocol|
62780517|NCT04038567|OTHER|App introduction to intervention|Introduction to intervention via the mobile app itself.
62780518|NCT04038567|OTHER|Therapist introduction to intervention|Introduction to intervention via a call from the study therapist.
62572619|NCT05253469||Stented/Non stented xenograft|Stented/Non stented xenograft may be inserted using separate or continuos stich with or without teflon pledget. The use of biological valves increased from 57% to 67% for primary the operation during which the use of mechanical valves decreased from 30% to 24%. For reoperations, the use of biologic valves increased from 38% to 52% compared to the warning use of mechanical valves from 20% to 17%. A homograft was used in only 2.5% of valve replacements, while a biological valve was used in 68.7% of the cases. This trend is reversed both in NVE and PVE the aortic root was involved (6). In the presence of peri-annular abscess formation and mitro-aortic discontinuity, conventional stented /non stented xenograft are used in combination with synthetic patch for both NVE and PVE.
62572620|NCT05253469||Mechanical valve prostheses|Mechanical prostheses may be inserted using separate or continuos stich with or without teflon pledget. Prior to 2000, mechanical valves were used in 50% of patients compared to 14% since 2009. Analysis of the STS Database (6) showed that from 2005 to 2011 a progressive shift in favour of biological valves both as the primary operation (NVE) (73%) and in the reoperation (PVE) (27%) compared to mechanical prosthesis. For extended aortic valve infection, aortic root replacement and reconstruction of regional contiguity is the recommended approach. Complicated aortic IE may present with destruction of a large portion of the aortic annulus, annular abscess and colonization of infected foci in contiguous cardiac structures (eg. aortic root and intervalvular fibrosa). In the presence of peri-annular abscess formation and mitro-aortic discontinuity, conventional mechanical prostheses are used in combination with synthetic patch for both NVE and PVE
62572621|NCT03532425|EXPERIMENTAL|B/F/TAF|"B/F/TAF + Atripla Placebo~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks"
62572622|NCT03532425|ACTIVE_COMPARATOR|Atripla|"Atripla + B/F/TAF Placebo~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks"
62572623|NCT04222998|EXPERIMENTAL|Intervention group|Household receives the home-based growth chart
62572624|NCT04222998|ACTIVE_COMPARATOR|Control group|Household does not receive the home-based growth chart
62572625|NCT01822093|EXPERIMENTAL|Cytovir-ADV|Adenovirus-specific T-cells
62572626|NCT03459560|EXPERIMENTAL|PolyPill|Single daily dose of PolyPill and minimal care.
62572627|NCT03459560|NO_INTERVENTION|Control|Only minimal care
62005996|NCT04054648|ACTIVE_COMPARATOR|Bedtime Antihypertensive Medications|The LTC facility's pharmacist will switch all once daily antihypertensive medications, one at a time as tolerated, to bedtime. Blood pressure lowering medications taken more than once per day are left alone.
62191584|NCT05733416|OTHER|Usual Care|Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care)
62191585|NCT01921361|ACTIVE_COMPARATOR|Intravenous|Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous dexmedetomidine (dexmedetomidine diluted 1mcg/ml and than 1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)
62191586|NCT01921361|ACTIVE_COMPARATOR|Intrathecal|Intrathecal (3 ml) 15 mg levobupivacaine + (0.3 ml) 3 mcg dexmedetomidine (dexmedetomidine diluted 10 mcg/ml) and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)
62191587|NCT01921361|PLACEBO_COMPARATOR|Control|Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion).
62191588|NCT01240915|EXPERIMENTAL|Cohort 1|The first 9 subjects will be recruited into Cohort 1 and will receive either placebo (n=3) or MultiStem low dose (n=6) as an intravenous infusion on Day 1. The first five patients enrolled constitute a subgroup of Cohort 1 and these patients will receive multiple doses, once every day for 7 days for 3 doses (Day 1 and Weeks 1 \& 2).
62191589|NCT01240915|EXPERIMENTAL|Cohort 2|This group will receive either placebo (n=3) or MultiStem high dose (n=6) as an intravenous infusion on Day 1. The subjects then receive the opposite dose of study medication at Week 8.
62397250|NCT05231785|EXPERIMENTAL|Part A: ALN-APP|Participants will be administered a single dose of ALN-APP.
62397251|NCT05231785|PLACEBO_COMPARATOR|Part A: Placebo|Participants will be administered a single dose of placebo.
62397252|NCT05231785|EXPERIMENTAL|Part B:|Participants will be administered multiple doses of ALN-APP.
62572628|NCT04071210|EXPERIMENTAL|Experimental|Probiotic tablets (containing a mix of Lactobacillus rhamnosus PB01, DSM 14869 and Lactobacillus curvatus EB10, DSM 32307, 1\*10(9) CFU) 2 times/day for 12 weeks
62780519|NCT04038567|OTHER|Standard dose|Standard dose of meditation time (once a day).
62780520|NCT04038567|OTHER|High dose|High dose of meditation time (twice a day).
62005997|NCT04054648|NO_INTERVENTION|Morning Antihypertensive Medications|No change to blood pressure medication timing is made. By default, most patients are using once daily antihypertensive medications in the morning at baseline.
62191590|NCT01240915|EXPERIMENTAL|Cohort 3|These subjects (total n=88 evaluable patients) will receive either Placebo or MultiStem (1:1 randomization) as an intravenous infusion on Day 1. In addition all subjects in Cohort 3 will receive a single infusion of either MultiStem or Placebo at Week 8, depending on their randomization schedule. A total of \~22 patients will receive an additional infusion of MultiStem, \~44 patients will receive the alternative blinded therapy to that which they received for Day 1 infusion, and \~22 patients will receive an additional infusion of placebo.
62191591|NCT04535245||LCI testing|LCI testing will be performed on all study subjects
62397253|NCT05962463||Canal adductor blockade|After surgical cleaning of the anteromedial thigh, all participants in this group received single shot ultrasound guided canal adductor blockade with 14 ml 0,25% levobupivacaine and 100 mcg clonidine mixed in the same syringe. Investigators previously scanned the adductor canal and chose the middle of the canal as the entry point of the 10 cm echogenic ultrasound needle. After the blockade, all participants were monitored in our ambulance for the next hour.
62397254|NCT05962463||Pulsed radiofrequency therapy|After surgical cleaning of the anteromedial thigh, all participants in this group received ultrasound-guided pulsed radiofrequency therapy. Investigators previously scanned the adductor canal and chose the middle of the canal as the entry point of the RF 10 cm needle with a 1 cm free tip. After sensory and motor checking all patients have gotten 6 minutes of therapy divided into 3 sequences of 2 minutes of 50 V current and 42. Before starting the PRF therapy all participants have gotten 2 ml 0,25% levobupivacaine through the needle for preventing discomfort during the procedure. After the treatment, all participants were monitored in our ambulance for the next hour.
62572629|NCT04071210|PLACEBO_COMPARATOR|Placebo Comparator|Placebo tablets 2 times/day for 12 weeks
62005998|NCT05724602|EXPERIMENTAL|Radiotherapy + Xevinapant|3 cycles of xevinapant (200 mg/day from Day 1 to 14, per 21-day cycle) + IMRT followed by 3 cycles of xevinapant in monotherapy (200 mg/day from Day 1 to 14, per 21-day cycle)
62191592|NCT03541681|ACTIVE_COMPARATOR|Glucocorticoid Injections|A series of three cervical transforaminal local anesthetic (0,5 ml Bupivacain) injections with glucocorticoid (1 ml Dexamethasone) within 3 months.
62191593|NCT03541681|ACTIVE_COMPARATOR|Local Anesthetic Injections|A series of three cervical transforaminal local anesthetic (0,5 ml Bupivacain) injections without glucocorticoid (Dexamethasone) within 3 months.
62397255|NCT02045940|EXPERIMENTAL|Cohort 1|Participants will receive one of the following four treatment sequences in four study period (one treatment per period). Sequence 1=Placebo, dose level (DL) 2, DL3, and DL4. Sequence 2=DL1, placebo, DL2, and DL4. Sequence 3=DL1, DL2, placebo, and DL4. Sequence 4=DL1, DL2, DL3, and placebo
62397256|NCT02045940|EXPERIMENTAL|Cohort 2|Participants will receive one of the following four treatment sequences in four study period (one treatment per period). Sequence 5=Placebo, DL5, DL6, and DL7. Sequence 6=DL4, placebo, DL6, and DL7. Sequence 7=DL4, DL5, placebo, and DL7. Sequence 8=DL4, DL5, DL6, and placebo
62572630|NCT03684707|ACTIVE_COMPARATOR|Metformin Hcl 500Mg 24Hr Sa Tab|Metformin Hcl 500Mg 24Hr Sa Tab drug is given to the patient
62572631|NCT03684707|PLACEBO_COMPARATOR|control|starch tablets
62572632|NCT04558801|EXPERIMENTAL|Mobile application-based lifestyle change program|"This arm receives the mobile application-based lifestyle change program at baseline. The mobile application-based lifestyle change program consists of twice a week content for the first 6 months, continuing with less frequent content for the following 6 months. The follow-up period is 6 months. Weight is measured and blood samples (lipids, glucose and metabolic syndrome measures) are collected at 0, 6, 12, and 18 months.~The mobile application-based counselling contains aspects of cognitive behavior therapy and persuasive system design and consists of twice a week reminders, tasks, self-monitoring, and reflection."
62572633|NCT04558801|ACTIVE_COMPARATOR|"The waiting-list control"|"The waiting-list control arm will receive mobile application-based lifestyle change program after 6 months, following same principles as Mobile application-based lifestyle change program-arm, excluding follow-up period (6 months of waiting list, 6 months of more intense and 6 months of less intense application use)."
62572634|NCT05720338|ACTIVE_COMPARATOR|Standard of care|Intraperitoneal drain will be placed near the pancreatic resection margin, which is the routine standard of care.
62191594|NCT01729845|EXPERIMENTAL|Treatment (decitabine, MEC)|"Patients receive decitabine IV on days -9 to -5 (dose level 1), days -11 to -5 (dose level 2), or days -14 to -5 (dose level 3).~INDUCTION THERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-5, etoposide IV on days 1-5, and cytarabine IV on days 1-5. Patients achieving CR or CR with CRp may receive up to 2 courses of induction therapy and up to 2 courses of consolidation therapy."
62191595|NCT04394884||COVID-19 -|will receive BTK therapy for other reasons
62397257|NCT02045940|EXPERIMENTAL|Cohort 3|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A
62572635|NCT05720338|NO_INTERVENTION|Omitting Standard of Care|No intraperitoneal drain will be placed in the participants, which omits the routine standard of care.
62780521|NCT04038567|OTHER|App response to symptoms|Mobile app response to elevated psychological distress symptoms during intervention period.
62005999|NCT05724602|PLACEBO_COMPARATOR|Radiotherapy + Placebo|3 cycles of placebo (from Day 1 to 14, per 21-day cycle) + IMRT followed by 3 cycles of placebo in monotherapy (from Day 1 to 14, per 21-day cycle).
62006000|NCT01931267|EXPERIMENTAL|Tablet Computer Motivated Instruction|Using Tablet Computer Motivated Instruction to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects.
62006001|NCT01931267|ACTIVE_COMPARATOR|systematic instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
62191596|NCT04394884||COVID-19 + BTK|will receive BTK therapy
62191597|NCT04394884||COVID-19 + No BTK|will not receive BTK therapy
62397258|NCT02045940|EXPERIMENTAL|Cohort 4|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A and preceding repeat dose Cohort
62397259|NCT02045940|EXPERIMENTAL|Cohort 5|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A and preceding repeat dose Cohorts
62397260|NCT02654405|EXPERIMENTAL|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
62006002|NCT03623737|EXPERIMENTAL|paclitaxel plus cisplatin|A. T: Paclitaxel 50 mg/m2, 1h IVF, weekly, week 1 to week 5 during CRT. B. P: Cisplatin 30 mg/m2, 2 h IVF, weekly following paclitaxel, week 1 to week 5 during CRT.
62006003|NCT03623737|ACTIVE_COMPARATOR|cisplatin plus 5-fluorouracil|A. P: Cisplatin 75 mg/m2, 2 h IVF, on day 1 of week 1 and week 5 during CRT. B. F: 5-FU 1,000 mg/m2, 24 h IVF, on day 1, 2, 3, 4 of week 1 and week 5 during CRT.
62397261|NCT02654405|PLACEBO_COMPARATOR|Placebo|Placebo capsule with 2 mg of sodium butyrate for making taste or odor, (9 mg/day)
62006004|NCT03833284|EXPERIMENTAL|Participant Barriers to TVU Screening|Patients with a history of pre-term birth will be identified through a review of their medical history. Patients will then be asked to complete a survey assessing their knowledge of transvaginal ultrasound screening. Patients will then be asked to attend in-person or online workshops designed to increase patient knowledge of TVU screening guidelines and benefits. Finally, patients will complete exit surveys to determine whether their attitudes and beliefs towards screening have changed over time.
62006005|NCT03833284|EXPERIMENTAL|Provider Barriers to TVU Screening|Obstetric and Gynecologic Providers will be identified based on prior working relationships with the University of Kentucky outreach programs. Chosen providers will be asked to complete a survey assessing their attitudes towards TVU screening. Following completion, providers will be asked to attend either in-person or online workshops designed to increase provider knowledge of TVU screening guidelines and benefits. Finally, providers will complete exit surveys to determine whether their attitudes and beliefs toward screening have changed over time.
62006006|NCT06383299||1|untreated group
62006007|NCT06383299||2|cpap treatment group
62006008|NCT04953767|EXPERIMENTAL|Blue light therapy|The participants receive blue light therapy for 1 hours, between 8am to 12pm in the morning.
62006009|NCT04953767|SHAM_COMPARATOR|White light|The participants receive white light for 1 hour, between 8am to 12pm in the morning.
62397262|NCT04116073|EXPERIMENTAL|INCMGA00012 (PD-1 antibody)|All participants will receive the interventional study drug; INCMGA00012.
62572636|NCT03510845|EXPERIMENTAL|Repairable ACL tear|Patients whose ACL found to be avulsed from its femoral insertion or has a proximal tear, and intra-operatively, found to have a good tissue quality, will undergo arthroscopic ACL primary repair using fiberwires and SwiveLock screw to anchor the ligament into its origin, in the femoral condyle.
62572637|NCT03510845|OTHER|Irreparable ACL tear|Patients whose ACL cannot be repaired, will undergo arthroscopic ACL reconstruction using hamstring tendons.
62006010|NCT02967952|ACTIVE_COMPARATOR|supraglottic airway (SGA)|Adult patients with non-trauma causes of OHCA who are resuscitated by emergency medical technician paramedic (EMTP) in the prehospital setting and received airway management of supraglottic airway (SGA).
62006011|NCT02967952|ACTIVE_COMPARATOR|endotracheal intubation (ETI)|Adult patients with non-trauma causes of OHCA who are resuscitated by emergency medical technician paramedic (EMTP) in the prehospital setting and received airway management of endotracheal intubation (ETI).
62006012|NCT01437514|EXPERIMENTAL|lower risk group with pSRT|the patients that was divided into the lower risk group that the mesorectum involvement less than 5mm, and no lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients accept the preoperative short-course radiotherapy before the surgery
62006013|NCT01437514|NO_INTERVENTION|lower risk group with operation only|the patients that was divided into the lower risk group that the mesorectum involvement less than 5mm, and no lymph node larger than 8mm,according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.
62006014|NCT01437514|EXPERIMENTAL|higher risk group with pSRT|the patients that was divided into the higher risk group that the mesorectum involvement more than 5mm, or with lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.these patients have the preoperative short-course radiotherapy before the surgery.
62006015|NCT01437514|NO_INTERVENTION|higher risk group with operation directly|the patients that was divided into the higher risk group that the mesorectum involvement more than 5mm, or with lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.
62006016|NCT06117267|EXPERIMENTAL|Anatase Spine Surgery Navigation System|Using the navigation system during surgery
62397263|NCT03730259|EXPERIMENTAL|WebTIPS|A Tailored Program for Perioperative Anxiety and Pain (WebTIPS) aims at reducing perioperative anxiety and pain in children via an internet and mobile platform with short message service (SMS) two-way communication between a healthcare provider and patient/parent. The Web-based Tailored Intervention Preparation for Surgery (WebTIPS) program is developed using the conceptual framework of the Triple Aim that evaluates the intervention within the context of clinical efficacy, improved child and parent surgical experience, and reduced resource utilization during the surgical episode.
62006017|NCT05242497|EXPERIMENTAL|pharmacopuncture group|The physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
62006018|NCT05242497|ACTIVE_COMPARATOR|conservative treatment group|The physicians will choose the type and time of physical therapy and if needed, pharmacological treatment according to participants' conditions.
62397264|NCT03730259|NO_INTERVENTION|Control|Subjects in this attention control group, the Web-based Information (WebINFO) group will not be provided tailored content or access to two-way communication. Instead, this group will only receive basic information regarding the management of perioperative anxiety and postoperative pain via the internet and/or mobile platform.
62006019|NCT03633435|EXPERIMENTAL|assisted home hemodialysis patients|all patients starting assisted home hemodialysis during the study period
62006020|NCT02872922|ACTIVE_COMPARATOR|Endothelial function after CWUT|Endothelial function of the all patients before and after application continuous waveform of ultrasound therapy (CWUT) measured by technique flow-mediated dilation (FMD).
62006021|NCT02872922|ACTIVE_COMPARATOR|Endothelial function after PWUT|Endothelial function of the all patients before and after application pulsed waveform of ultrasound therapy (PWUT) measured by technique flow-mediated dilation (FMD).
62006022|NCT02872922|ACTIVE_COMPARATOR|Endothelial function after PLACEBO|In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off. Endothelial function of the all patients before and after application placebo waveform of ultrasound therapy measured by technique flow-mediated dilation (FMD)
62006023|NCT06608069|EXPERIMENTAL|Educational councelling and Reminder.|Enrolled participants will be counselled and educated by pharmacist on the therapy and benefits of adherence.
62006024|NCT06608069|NO_INTERVENTION|DOTS therapy|Enrolled patient will be given the DOT therapy for TB.
62397265|NCT05333432|OTHER|Men at high genetic risk of prostate cancer|Cohort of unaffected men from 40 to 70 years olds with high risk of prostate cancer (PC) defined as being a member from a family that meets hereditary PC criteria or by carrying a mutation of a DNA repair gene or a gene specific to PC.
62397266|NCT02924922|ACTIVE_COMPARATOR|Laparoscopic partial nephrectomy|"1. Inclusion criteria fulfilled:~   * Baseline Abdomen CT/MRI~  * Patient Age, Weight, Height, Co-Medication~  * Informed Consent~  * Baseline renal function (eGFR, renal scintigraphy, sCreatinine, creatinine clearance)~2. During hospitalization, one day before laparoscopic partial nephrectomy:~   * eGFR~  * sCreatinine~  * Hemoglobin~3. After surgery:~   * Assessment of eGFR 4 days after operation~  * Hb assessment every 6 H in the first 48 H~  * Assessment of adverse events~  * Histological Results~4. 6, 12, 24 months after intervention:~   * Creatinine Clearance (only performed at 6 months follow-up)~  * Tc-99m MAG3Dynamic Scintigraphy (only performed at 6 months follow-up)~  * eGFR~  * Assessment of adverse events~  * Assessment of possible recurrence~  * Assesment of kidney volume variation"
62214736|NCT03237572|EXPERIMENTAL|Arm A: 1st dose of pembrolizumab after HIFU|Pembrolizumab (200 mg) administered intravenously, days 22, 43, 64, followed by day 1 of each ensuing 3 -week cycle. Focused ultrasound tumor ablation day 15. High-intensity focused ultrasound ablation will target 50% of the tumor, up to 3 cubic centimeters.
62572638|NCT05236205|EXPERIMENTAL|Control Group|This group will receive the treatment of caries removal with a lowspeed drill (conventional treatment).
62572639|NCT05236205|EXPERIMENTAL|Papacarie|In this group, partial caries removal with Papacarie will be performed.
62572640|NCT05236205|EXPERIMENTAL|Papacarie and Bixa orellana extract|In this group, partial caries removal with Papacarie and the application of Bixa orellana extract (20%) will be performed.
62780522|NCT04038567|OTHER|Therapist response to symptoms|Therapist call in response to elevated psychological distress symptoms during intervention period.
62780523|NCT06130462|ACTIVE_COMPARATOR|LPT aluminium|Investigation of participants with aluminium allergy versus healthy controls. Aluminium in different concentrations are added to the blood samples to elicit a response
62780524|NCT06130462|PLACEBO_COMPARATOR|LPT control|Tetanus toxoid was added to blood samples as control substance.
62780525|NCT05845853|EXPERIMENTAL|interventinal group|28 subject will receive a program of scapular motor control exercises using PNF technique in addition to the conventional treatment for 18 sessions (3 sessions per week for six weeks)
62780526|NCT05845853|NO_INTERVENTION|control group|28 subject will receive conventional physical therapy program (heat-TENS) for 18 sessions (3 sessions per week for six weeks)
62780527|NCT05533320|EXPERIMENTAL|Supportive care (PSCS)|Patients undergo scalp cooling using the PSCS 30 minutes before, during, and for up to 2 hours after completion of chemotherapy for 6 chemotherapy sessions.
62780528|NCT03665272|EXPERIMENTAL|fixation by tissue adhesive|In this group, deepithelialized gingival grafts were fixed by tissue adhesive without any suture.
62780529|NCT03665272|EXPERIMENTAL|fixation by sutures|In this groups, deepithelialized gingival grafts were fixed by 4.0 round vicryl sutures.
62780530|NCT05360719|EXPERIMENTAL|Group Tele-exercise Class|Volunteers will be asked to participate in the group online exercise class 2 times per week for 8 weeks. Each activity session will last about 60 minutes and will focus on mind-body practices, tailored to physical and emotional needs of individuals with SCI. Class will be taught by a physical therapist who is an experienced community exercise instructor. Class will be co-led by a person who is living with SCI (one of our community partners). Classes will take place over a secure virtual platform (Zoom). Before beginning and after completion of the program, participants will be asked to participate in small group interviews to share expectations and experiences of the study
62780531|NCT05360719|OTHER|Waitlist Control|The waitlist control group will complete all quantitative measures as a baseline (baseline-control) and will be instructed to continue their activities as usual, with measures obtained again at 8-weeks (post-control/pre-program). Following the initial 8-week baseline, each waitlist group will participate in pre-intervention semi-structured interview or small focus group with the post-control measures as pre-intervention assessment. They will join the tele-exercise intervention with all measures at 8-weeks (post-intervention) and with leisure time physical activity and quality of life assessed at 16-weeks following initiation of the program.
62191598|NCT05979428|EXPERIMENTAL|Part A Single ascending dose (SAD) cohorts in healthy participants:|Healthy participants, randomized in 3:1 ratio in each of the cohorts will receive single ascending dose of either NNC0491-6075 or placebo in 5 cohorts (Cohort A1, A2, A3, A4 and A5). In cohorts A1, A2 and A3, the participants will receive subcutaneous injection, whereas in cohorts A4 and A5 the administration will be performed intravenously.
62397267|NCT02924922|ACTIVE_COMPARATOR|Robot assisted partial nephrectomy|"1. Inclusion criteria fulfilled:~   * Baseline Abdomen CT/MRI~  * Patient Age, Weight, Height, Co-Medication~  * Informed Consent~  * Baseline renal function (eGFR, renal scintigraphy, sCreatinine, creatinine clearance)~2. During hospitalization, one day before robot assisted partial nephrectomy:~   * eGFR~  * sCreatinine~  * Hemoglobin~3. After surgery:~   * Assessment of eGFR 4 days after operation~  * Hb assessment every 6 H in the first 48 H~  * Assessment of adverse events~  * Histological Results~4. 6, 12, 24 months after intervention:~   * Creatinine Clearance (only performed at 6 months follow-up)~  * Tc-99m MAG3Dynamic Scintigraphy (only performed at 6 months follow-up)~  * eGFR~  * Assessment of adverse events~  * Assessment of possible recurrence~  * Assesment of kidney volume variation"
62397268|NCT02278874||Multiple gestation high risk pregnancies|women pregnant with twins or triplets at high risk for aneuploidy
62397269|NCT05003206|EXPERIMENTAL|PD,DBS|Patients with idiopathic PD before and after DBS surgery
62397270|NCT06216600|EXPERIMENTAL|WE RISE Intervention|Participants will undergo WE RISE intervention: twice a week for 8 week combination delivery of acceptance and commitment therapy + exercise + social suppot.
62397271|NCT06216600|ACTIVE_COMPARATOR|Control|Participants will receive standard of care which would be referrals to local opportunites for therapy, exercise and social support.
62397272|NCT06216600|EXPERIMENTAL|Observational|Observational study of participants undergoing WE RISE adapted for sustainability.
62397273|NCT03198559|EXPERIMENTAL|Experimental|"Participants current ART regimen:~2 grams disulfiram by mouth per day for a total of 28 days~400mg vorinostat by mouth per day on days 8, 9,10 and days 22, 23, 24"
62791799|NCT04158583|EXPERIMENTAL|Part A: Cohort 7 RO7296682 70 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 70 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade \>=4, IRR; Grade \>=4, immune-mediated adverse events; Grade \>=4) were discontinued from study treatment.
62572641|NCT05236205|EXPERIMENTAL|Partial removal with aPDT|In this group, partial removal of the carious tissue will be performed, with Papacarie and the application of Bixa orellana extract (20%) with blue LED (aPDT).
62780532|NCT01605110|EXPERIMENTAL|Hyperbaric oxygen therapy|We propose to study the effects of two HBOT treatments (one before and one after surgery) with patients who have undergone upper eyelid surgery. Reduction in swelling and bruising will be assessed at 3, 10, 21, 30 and 90 days post-surgery to determine if healing is accelerated by HBOT. Patients that volunteer to participate in this study will be exposed to two treatments of 100% oxygen at 2.0 atmospheres absolute (ATA) or air (sham) 1.2 ATA inside mono-place chambers for 90 minutes. By comparing oxygen treatment groups with a matched control group, we can accurately assess the effectiveness of this treatment for patients. By participating in this study, patients will help in establishing the best treatment practices of using HBOT to accelerate healing and reduce cost in surgical recovery.
62780533|NCT01605110|SHAM_COMPARATOR|Air sham|We propose to study the effects of two HBOT treatments (one before and one after surgery) with patients who have undergone upper eyelid surgery. Reduction in swelling and bruising will be assessed at 3, 10, 21, 30 and 90 days post-surgery to determine if healing is accelerated by HBOT. Patients that volunteer to participate in this study will be exposed to two treatments of 100% oxygen at 2.0 atmospheres absolute (ATA) or air (sham) 1.2 ATA inside mono-place chambers for 90 minutes. By comparing oxygen treatment groups with a matched control group, we can accurately assess the effectiveness of this treatment for patients. By participating in this study, patients will help in establishing the best treatment practices of using HBOT to accelerate healing and reduce cost in surgical recovery.
62006025|NCT03182348||Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
62006026|NCT01276899||Neoadjuvant setting|
62397274|NCT02463526|EXPERIMENTAL|Group 1 - MWM condition/Sham condition|Subjects will receive treatment for 4 times with Mulligan's Mobilization with Movement (MWM) condition, and after 72 hrs, will be treated 4 times with the sham condition.
62397275|NCT02463526|EXPERIMENTAL|Group 2 - Sham condition/MWM condition|Subjects will receive treatment for 4 times with sham condition, and after 72 hrs, will be treated 4 times with the Mulligan's Mobilization with Movement (MWM) condition.
62397276|NCT03975465|EXPERIMENTAL|Expiratory Muscle Strength Training|Patients randomized to the EMST arm will use the EMST150 device as packaged, i.e. following package instructions
62191599|NCT05979428|EXPERIMENTAL|Part B Multiple ascending dose (MAD) cohorts in dyslipidemia participants|Participants with dyslipidemia, randomized in the ratio 2:1 in each of the cohorts will receive multiple ascending dose of either NNC0491-6075 or placebo in 3 cohorts (Cohort B1,B2 and B3). Participants will receive subcutaneous injections of either NNC0491-6075 or placebo once weekly for 4 weeks.
62397277|NCT03975465|ACTIVE_COMPARATOR|Pharyngeal Muscle Strengthening Exercises|Patients randomized to Standard Care will receive swallowing exercises designed to strengthen muscles that contribute to pharyngeal phase motor events and increase structural range of motion
62397278|NCT03151200|ACTIVE_COMPARATOR|binocular treatment|Active treatment group will receive five days of one hour visual binocular training by playing a specifically designed falling blocks video game on a computer screen that will be individually calibrated for each person with red-green glasses with treatment effect.
62397279|NCT03151200|SHAM_COMPARATOR|sham treatment|Sham treatment group will receive five days of one hour sham visual binocular training by playing a specially designed falling blocks video game on a computer screen with polarized glasses with no treatment effect.
62397280|NCT03679117|EXPERIMENTAL|Mindfulness Training|Phone-delivered mindfulness training
62006027|NCT01276899||Metastatic setting|
62006028|NCT02206126|EXPERIMENTAL|Energy restriction group|The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
62006029|NCT02206126|NO_INTERVENTION|Control group|The control group was advised not to change their food intake.
62006030|NCT06251713|EXPERIMENTAL|VeXUS score guided fluid management|"Fluid management:~* Restrictive intake~* Diuretic-induced fluid removal aiming for a diuresis of 2-4mL/Kg/h if VeXUS score \> 1~* During 24 to 48 hours"
62006031|NCT06251713|OTHER|Usual care|"Fluid management:~* Usual care~* at the discretion of the attending physician"
62006032|NCT01149798|EXPERIMENTAL|Abraxane and Cisplatin combination|Abraxane and Cisplatin combination
62191600|NCT05979428|EXPERIMENTAL|Part C: Single ascending dose (SAD) cohorts in healthy Japanese participants:|Healthy Japanese participants, randomized in the ratio 3:1 in each of the cohorts will receive single ascending dose of either NNC0491-6075 or placebo in 3 cohorts (Cohort C1,C2 and C3). The route of administration will be subcutaneous or intravenous.
62191601|NCT04554745|OTHER|Non-scared uterus of pregnant women|
62780534|NCT01978223||Cases|Children hospitalised for SGE, aged 12 weeks to \< 5 years at the time of hospital admission/ED stay and whose stool samples test positive for RV by enzyme linked immunosorbent assay (ELISA) at a GSK designated laboratory.
62006033|NCT01440946|EXPERIMENTAL|rFIXFc Prophylaxis|"At Baseline and at Day 1, participants receive a single intravenous (IV) injection of prestudy FIX and rFIXFc, respectively, over 10 (±5) minutes at a dose of 50 IU/kg. Immediately after the last PK sampling, the first prophylactic dose of approximately 50 to 60 IU/kg will be administered in clinic as an IV injection.~Dose could be increased or decreased in increments of 10 IU/kg; increases to a maximum of 100 IU/kg and frequency of administration to a maximum of twice weekly, were allowed as indicated."
62006034|NCT04577690|EXPERIMENTAL|PECS block|A PECS block of 0.25 % bupivacaine with epinephrine 1:200000 (below the toxic dose limit of 3 mg/kg) in divided doses to cover the fascial planes identified in PECS I and PECS II. At the completion of surgery, the wound will be infiltrated with up to 0.2 ml/kg of 0.25 % bupivacaine into the wound.
62006035|NCT04577690|ACTIVE_COMPARATOR|Infiltration|At the completion of surgery, the EP cardiologist will infiltrate the wound with up to 0.8 ml/kg of 0.25 % bupivacaine with epinephrine 1:200000.
62397281|NCT03679117|NO_INTERVENTION|Treatment as Usual|Prenatal care
62397282|NCT05620186|OTHER|Original PROSPECT|Original, distributed PROSPECT where trainees learn at their own pace in between, before/after clinical activities
62397283|NCT05620186|OTHER|Massed PROSPECT|Massed, bootcamp-style training form of PROSPECT where trainees are exempt from clinical duties
62780535|NCT01978223||Controls|Children hospitalised for SGE, aged 12 weeks to \< 5 years at the time of hospital admission/ ED stay, whose stool samples test negative for RV by enzyme linked immunosorbent assay at a GSK designated laboratory and who will be matched to the cases by date of birth and the hospital of admission/ ED stay.
62006036|NCT04805307|EXPERIMENTAL|Part A, Dose escalation|CMG901 will be administered in treatment cycles once every 3 weeks (Q3W). Dose escalation will be carried out according to a modified 3+3 dose-escalation design. Accelerated dose titration design will be used for the first 2 dose levels (0.3mg/kg and 0.6mg/kg), and then traditional 3+3 dose escalation design will be used for the following levels (1.2mg/kg, 1.8mg/kg, 2.2mg/kg, 2.6mg/kg and 3.0mg/kg).
62006037|NCT04805307|EXPERIMENTAL|Part B, Dose expansion _GC_ MTD level|"This cohort will comprise subjects with Claudin 18.2 positive GC or GEJ adenocarcinoma with prior failure of, progression on, or intolerance to, standard therapy.~The starting dose of CMG901 for Expansion will be derived from the MTD determined during Dose Escalation."
62006038|NCT04805307|EXPERIMENTAL|Part B, Dose expansion _PC_ MTD level|"This cohort will comprise subjects with Claudin 18.2 positive pancreatic cancer with prior failure of, progression on, or intolerance to, standard therapy.~The starting dose of CMG901 for Expansion will be derived from the MTD determined during Dose Escalation."
62006039|NCT04805307|EXPERIMENTAL|Part B, Dose expansion _GC_ MTD-1 level|"This cohort will comprise subjects with Claudin 18.2 positive GC or GEJ adenocarcinoma with prior failure of, progression on, or intolerance to, standard therapy.~The starting dose of CMG901 for Expansion will be derived from the MTD-1 level determined during Dose Escalation."
62191602|NCT04554745|OTHER|Scared uterus of pregnant women|
62397284|NCT03813316|EXPERIMENTAL|Interventional Arm|Adding a DPP-4i (sitagliptin) and/or an SGLT2i (ertugliflozin) to metformin after receiving extra training on individualized care.
62397285|NCT03813316|EXPERIMENTAL|Control Arm|Adding a DPP-4i (sitagliptin) and/or an SGLT2i (ertugliflozin) to metformin as per standard care/Diabetes Canada guidelines.
62397286|NCT03982381|ACTIVE_COMPARATOR|Metformin|Metformin 1000-3000 mg per day according to clinical guidelines. Split into 2-3 doses per day.
62397287|NCT03982381|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10 mg once daily
62780536|NCT03612765|EXPERIMENTAL|Intervention group|Participants in the intervention group will receive face-to-face intervention sessions that include interviews, discussions and didactic teaching.
62780537|NCT03612765|NO_INTERVENTION|Control group|Participants in the control group will receive usual care that normally includes three monthly outpatient doctor consultations and when necessary, heart failure nurse referral.
62397288|NCT05660070|EXPERIMENTAL|mobile Social Interaction Therapy by Exposure (mSITE)|mSITE is a blended intervention that integrates brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching.
62191603|NCT01160237|EXPERIMENTAL|Group A|Subjects previously vaccinated with a vaccine against the pandemic H1N1 strain
62397289|NCT00489411|EXPERIMENTAL|Arm I/Group A (Duloxetine then Placebo)|Patients receive oral duloxetine hydrochloride once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive an oral placebo once or twice daily in weeks 8-13.
62397290|NCT00489411|EXPERIMENTAL|Arm II/Group B (Placebo then Duloxetine)|Patients receive an oral placebo once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive oral duloxetine hydrochloride once or twice daily in weeks 8-13.
62397291|NCT06116916|EXPERIMENTAL|Arm A|KHK4951 High dose
62397292|NCT06116916|EXPERIMENTAL|Arm B|KHK4951 Middle dose
62397293|NCT06116916|EXPERIMENTAL|Arm C|KHK4951 Low dose
62006040|NCT04805307|EXPERIMENTAL|Part B, Dose expansion _PC_ MTD-1 level|"This cohort will comprise subjects with Claudin 18.2 positive pancreatic cancer with prior failure of, progression on, or intolerance to, standard therapy.~The starting dose of CMG901 for Expansion will be derived from the MTD-1 level determined during Dose Escalation."
62572642|NCT06120426||Total en bloc spondylectomy for spinal oligometastases|Based on the medical history, physical signs, and imaging examination results, a definitely diagnosis of spinal oligometastasis tumor was made and perform a Total en bloc spondylectomy.
62006041|NCT02537964|EXPERIMENTAL|Chlorhexidine bath|Intervention: All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
62780538|NCT01623869|EXPERIMENTAL|Treatment (trebananib)|Patients receive 30 mg/kg trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62780539|NCT01642108|OTHER|Sitagliptin|
62006042|NCT02537964|NO_INTERVENTION|Standard bathing|Standard bathing with water +/- mild soap according to age and gestational week
62006043|NCT05118594|EXPERIMENTAL|Pre-treatment recommendations|Therapists receive automatized feedback at the beginning of the treatments with recommendations regarding the most appropriate interventions to use with their patients based on a machine learning algorithm developed on a previous study.
62780540|NCT02446080|EXPERIMENTAL|Probiotic Group|Milk drink with probiotic culture (150 mL/daily) for 60 days.
62006044|NCT05516251|ACTIVE_COMPARATOR|Topiramate|
62397294|NCT01560806|NO_INTERVENTION|Conventional Healthcare services|People with high blood pressure detected during screening survey or opportunistically during study period will be referred to receive the conventional health care services for hypertension at district hospital or local commune health station
62397295|NCT01560806|EXPERIMENTAL|Commune Hypertension Management|People with high blood pressure were managed in commune-based hypertension management programme
62397296|NCT05028569|EXPERIMENTAL|Double-Blind, Placebo-Controlled Phase: BOTOX Dose A|Participants will receive BOTOX Dose A on Week 0 and Week 12.
62397297|NCT05028569|EXPERIMENTAL|Double-Blind, Placebo-Controlled Phase: BOTOX Dose B|Participants will receive BOTOX Dose B on Week 0 and Week 12.
62397298|NCT05028569|PLACEBO_COMPARATOR|Double-Blind, Placebo-Controlled Phase: Placebo|Participants will receive placebo on Week 0 and Week 12.
62397299|NCT05028569|EXPERIMENTAL|Open-Label Phase: BOTOX Dose A|Eligible participants will receive BOTOX Dose A on Week 24 and Week 36.
62572643|NCT06120426||Separation surgery combined with radiotherapy for spinal oligometastases|Based on the medical history, physical signs, and imaging examination results, a definitely diagnosis of spinal oligometastasis tumor was made and perform a Separation surgery. After surgical recovery, take a radiotherapy.
62572644|NCT02645474|ACTIVE_COMPARATOR|Paravertebral block with ropivacaine|Patients are treated with an older technique (paravertebral block with ropivacaine), somehow established in treating pain after breast surgery. This technique has been shown to be effective but has an intrinsic risk of iatrogenic pneumothorax and is considered technically demanding.
62572645|NCT02645474|EXPERIMENTAL|PECS block with ropivacaine|Patients are treated with PECS block, which has been already adopted in common clinical practice as an alternative to paravertebral block for postoperative pain treatment after breast surgery. This technique is thought to be somehow simpler to perform and safer with regard to pneumothorax, however no studies have been done yet to statistically compare the two blocks with regard to safety and effectiveness.
62572646|NCT00600912|EXPERIMENTAL|1-SMOFlipid®|lipid emulsion based on soybean oil, medium-chain triglycerides, olive oil and fish oil SMOFlipid®-Group (n = 21)
62780541|NCT02446080|ACTIVE_COMPARATOR|Control Group|Milk drink (150 mL/daily) for 60 days.
62006045|NCT05516251|EXPERIMENTAL|Transcutaneous Supraorbital Nerve Stimulator|
62006046|NCT02130765|NO_INTERVENTION|Drug with ICD/CRT-D|Implantable cardioverter defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D) with routine drug therapy
62006047|NCT02130765|ACTIVE_COMPARATOR|Cardiac catheter ablation with ICD/CRT-D|Cardiac catheter ablation with ICD/CRT-D with routine drug therapy
62780542|NCT02202369|EXPERIMENTAL|Multimodal Analgesia (MMA) Treatment|
62006048|NCT06572839|NO_INTERVENTION|No intervention: Standard of Care|Debridement, offloading, and proper moisture balance dressings
62397300|NCT01958944|EXPERIMENTAL|Nitric oxide + standard treatment|Inhalation of 160 ppm NO for 30 minutes, 3 times daily, for a duration of 10 working days with the exclusion of weekend days (Friday \& Saturday) in which no treatment under this study will be provided.
62780543|NCT02202369|ACTIVE_COMPARATOR|Standard of Care Pain Managment Protocol|
62780544|NCT03669289|EXPERIMENTAL|Enhanced model of primary care|
62006049|NCT06572839|EXPERIMENTAL|Amnio-Maxx as an addition to standard of care|Device exposure is estimated to be a maximum of 12 weeks
62006050|NCT02178033|OTHER|low-volume (2L) PEG|All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®\*, Norgine, Harefield, United Kingdom); Bowel cleansing preparation is divided into two equal doses (each MOVIPREP® sachet dissolved in one liter of water, according to manufacturer's instruction). Each dose must be followed by at least 0.5 L of clear fluid at each administration, and should be taken in a maximum time of 2 hours. In this arm, both doses are taken the day before colonoscopy, starting on the evening at about 18:00. Solution intake should be completed before 22.00 h.
62006051|NCT02178033|ACTIVE_COMPARATOR|Split dose low-volume PEG solution|All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®\*, Norgine, Harefield, United Kingdom); Bowel cleansing preparation is divided into two equal doses (each MOVIPREP® sachet dissolved in one liter of water, according to manufacturer's instruction). Each dose must be followed by at least 0.5 L of clear fluid at each administration, and should be taken in a maximum time of 2 hours. In this arm, the first dose is taken on the evening before colonoscopy (at about 20:00 h), the second one is taken early in the morning on the day of the procedure, starting about 4 h before the scheduled procedure time.
62006052|NCT03184792|ACTIVE_COMPARATOR|Transcutaneous spinal stimulation & Physical therapy|Transcutaneous cervical electrical stimulation combined with physical therapy that targets rehabilitation of upper extremity functions
62191604|NCT01160237|EXPERIMENTAL|Group B|Subjects previously vaccinated with a vaccine against the pandemic H1N1 strain
62006053|NCT03184792|ACTIVE_COMPARATOR|Physical therapy only|Physical therapy that targets rehabilitation of upper extremity functions
62191605|NCT01160237|ACTIVE_COMPARATOR|Group C|Subjects not previously vaccinated with a vaccine against the pandemic H1N1 strain
62191606|NCT02392754|EXPERIMENTAL|Screening|The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
62572647|NCT00600912|ACTIVE_COMPARATOR|2-ClinOleic 20%®|olive and soybean oil-group (n=21)
62006054|NCT05592015|EXPERIMENTAL|Treatment (ruxolitinib)|Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity. Patients who achieve a response (CR or PR) may receive an additional 12 months of ruxolitinib, for a maximum of 24 months.
62572648|NCT02980068|EXPERIMENTAL|15N Nitrate|single 1,000mg dose of 15N nitrate with 3g of conjugated linoleic acid (CLA).
62572649|NCT02980068|EXPERIMENTAL|14N Sodium Nitrate|single 1,000mg dose of 14N sodium nitrate with 3g of conjugated linoleic acid (CLA)
62572650|NCT01174823|EXPERIMENTAL|Bepotastine Besilate Ophthalmic Solution|
62572651|NCT01174823|PLACEBO_COMPARATOR|Placebo|
62006055|NCT02596529|EXPERIMENTAL|Fixation|Patients with a medium-sized posterior fragment which will be treated by open reduction and internal fixation of all fractured malleoli.
62006056|NCT02596529|ACTIVE_COMPARATOR|No fixation|Patients with a medium-sized posterior fragment which will be treated bij open reduction and internal fixation of lateral and medial malleolus alone. No fixation of the posterior malleolus take place.
62572652|NCT02491840|EXPERIMENTAL|Gastric and cardia adenocarcinomas|Biopsy of Gastric and cardia adenocarcinomas
62572653|NCT02043444|EXPERIMENTAL|secretory azoospermia|110 men with secretory azoospermia will have FDG PET-CT
62006057|NCT01715103|OTHER|Healthy women volunteers|Healthy women volunteers with vaginal swabs by washing and cytobrush
62006058|NCT01715103|OTHER|HIV-1 infected women|HIV-1 infected women with vaginal swabs by washing and cytobrush
62572654|NCT02043444|ACTIVE_COMPARATOR|excretory azoospermia|30 men with secretory azoospermia will have FDG PET-CT
62572655|NCT02043444|PLACEBO_COMPARATOR|normospermia|20 men with secretory azoospermia will have FDG PET-CT
62780545|NCT06187077|EXPERIMENTAL|DHA-Enhanced FAITH! App|This group will use the FAITH! App with guided support from a Digital Health Advocate (DHA) within their church.
62006059|NCT03440879|EXPERIMENTAL|ADT group|Prostate cancer patients currently receiving androgen deprivation therapy (Zoladex)
62780546|NCT06187077|OTHER|FAITH! App|This group will use the FAITH! App on their own, with no DHA support.
62780547|NCT01041521|EXPERIMENTAL|Lovaza (omega three fatty acid)|"Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.~Other Names:~Lovaza was previously known as Omacor (omega-3-acid ethyl esters) capsules"
62006060|NCT03440879|NO_INTERVENTION|No-ADT group|Prostate cancer patients without any history of receiving any form of androgen deprivation therapy
62006061|NCT05848388||1|older than 9-year-old patients, with panoramic radiographic images showing the first permanent molars
62006062|NCT00613600|EXPERIMENTAL|1|Two 665 mg capsules of glucomannan three times a day for eight weeks
62006063|NCT00613600|PLACEBO_COMPARATOR|2|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
62572656|NCT00767455|SHAM_COMPARATOR|Positive, Negative Controls|
62006064|NCT06499701||Ringer's Lactate|Adult patients admitted in the intensive care unit (ICU) with sepsis, as defined by the Sepsis-3 criteria and exhibiting sepsis-induced hypoperfusion prior to the administration of adequate volume resuscitation (i.e., 30 ml/kg crystalloid).
62006065|NCT02869971|EXPERIMENTAL|Embolization|Prostatic Arteries Embolization
62572657|NCT00433394|EXPERIMENTAL|Stratum 1: No Consent for personal identification|Data to be collected for this stratum include histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries.
62006066|NCT02869971|ACTIVE_COMPARATOR|Combined Therapy|Combodart® : dutasteride 0.5 mg/tamsulosin 0.4 mg per day
62572658|NCT00433394|EXPERIMENTAL|Stratum 2: Consent for personal identification - No Contact|Data will be collected for this study include:child's name, parent's name, address, telephone number, child's date of birth, race, ethnicity, histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries. No contact for future to ask me to consider taking part in Research Network approved studies
62572659|NCT00433394|EXPERIMENTAL|Stratum 3: Consent for personal identification - Contact|Data will be collected for this study include:child's name, parent's name, address, telephone number, child's date of birth, race, ethnicity, histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries Someone from the Childhood Cancer Research Network may contact me in the future to ask me to consider taking part in Research Network approved studies
62572660|NCT06575673|EXPERIMENTAL|DBT-ST group|Participants in the intervention group will receive the DBT-ST by means of a free video-communication app. Over the next 14 weeks from the baseline, participants will receive two individual sessions (30-45 mins) and 12 group therapy sessions (120-minute)
62780548|NCT01041521|NO_INTERVENTION|sugar pill|"Dietary Supplement: sugar pill~2 capsules given twice daily Arms: sugar pill"
62780549|NCT06526559|EXPERIMENTAL|Barbed suture group|Pyeloplasty done using barbed absorbable sutures
62780550|NCT06526559|ACTIVE_COMPARATOR|PGA group|Pyeloplasty done using conventional PGA (Polyglactin) sutures
62780551|NCT05042284|EXPERIMENTAL|NE PERT|Non-enteric coated pancreatic enzyme capsules containing 30,000U of protease will be provided three times a day along with food (breakfast, lunch and dinner)
62780552|NCT05042284|PLACEBO_COMPARATOR|Placebo|Similar appearing glucose capsules will be provided three times a day along with food (breakfast, lunch and dinner)
62780553|NCT00411814|PLACEBO_COMPARATOR|Placebo|Saline
62780554|NCT00411814|ACTIVE_COMPARATOR|Active|GSK679586
62780555|NCT00695422||Specimen Collection|Blood collection, anal cytology and biopsy of observed lesions. Additional cervical cytology and biopsy for females.
62006067|NCT02281721||Single Group; Surpass Flow Diverter(s)|Individuals using the Surpass Flow Diverter(s)
62006068|NCT01187082|EXPERIMENTAL|bladdertraining group|Cognitive training in groups at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
62006069|NCT01187082|ACTIVE_COMPARATOR|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
62006070|NCT03272594|EXPERIMENTAL|Breastfeeding|
62006071|NCT03272594|ACTIVE_COMPARATOR|24% oral sucrose|
62006072|NCT02163291|EXPERIMENTAL|paclitaxel liposome|S-1 plus paclitaxel liposome
62006073|NCT00691236|ACTIVE_COMPARATOR|A|standard chemotherapy which is Adriamycin, Cisplatinum and Ifosfamide
62780556|NCT03916081|ACTIVE_COMPARATOR|Roflumilast Cream 0.05%|Participants apply roflumilast cream 0.05% QD for 28 days.
62006074|NCT00691236|EXPERIMENTAL|B|zoledronic acid prior to standard chemotherapy
62006075|NCT00691236|EXPERIMENTAL|C|zoledronic acid alone 4mg IV 3 weekly for 6 doses
62780557|NCT03916081|ACTIVE_COMPARATOR|Roflumilast Cream 0.15%|Participants apply roflumilast cream 0.15% QD for 28 days.
62780558|NCT03916081|PLACEBO_COMPARATOR|Vehicle Cream|Participants apply vehicle cream QD for 28 days.
62397301|NCT06382428|EXPERIMENTAL|TR-PFMT group|In the TR-PFMT group, the PFMT program was carried out via a synchronous online platform (Skype™ program). Participants were asked to install Skype™ software on their personal computers or phones and create a personal account. In the first evaluation session, participants were taught how to use the hardware and software. Additionally, they were asked to place their cameras at an average distance of 1-1.5 meters so that their entire body could be seen. At the beginning of each session, they were informed that their information was kept confidential and their audio and video images would not be shared with another person.
62191607|NCT02392754|NO_INTERVENTION|Control|The control group receives standard care for 6 months (including a pulse check and heart auscultation by a physician at 6 months).
62191608|NCT05009199|EXPERIMENTAL|[18F]MNI-444|After a wash-out of caffeine of at least 24 hours, each participant will receive a single injection of \[18F\]MNI-444 followed by brain PET imaging of up to 90 minutes to establish baseline A2A receptor binding.
62397302|NCT06382428|ACTIVE_COMPARATOR|S-PFMT group|In the S-PFMT group, the PFMT program was conducted as a face-to-face session in groups of 4 people.
62397303|NCT02064491|EXPERIMENTAL|Erlotinib and Chemotherapy|Intercalated erlotinib in combination with chemotherapy for four to six cycles followed by continuous erlotinib maintenance
62397304|NCT02064491|ACTIVE_COMPARATOR|Chemotherapy|Chemotherapy for four to six cycles
62397305|NCT04115202||posterior spinal approach group|Lumbar arthrodesis performed by a posterior spinal approach.
62397306|NCT04115202||anterior spinal approach group|Lumbar arthrodesis performed by a anterior spinal approach.
62397307|NCT04274985||1|Patients with temporomandibular disorders
62397308|NCT06445959|EXPERIMENTAL|Part 1|"Participants enrolled in Part 1, the dose of venetoclax/decitabine you receive will depend on when you join this study. Up to 3 dose levels will be tested. Up to 6 participants will be enrolled at each dose level.~- All participants will receive the same dose level of olutasidenib."
62397309|NCT06445959|EXPERIMENTAL|Part 2|"Participants enrolled in Part 2, you will receive venetoclax/decitabine at the recommended dose that was found in Part 1.~- All participants will receive the same dose level of olutasidenib."
62397310|NCT01491802|EXPERIMENTAL|LAMA alone, then LAMA/LABA combination|Participants will first receive an inhaled long-acting muscarinic antagonist (LAMA) once daily for 4 weeks. After a 2 week washout period, they will then receive the fixed-dose combination product \[LAMA plus long-acting beta2-agonist (LABA)\] once daily for 4 weeks.
62397311|NCT01491802|EXPERIMENTAL|LABA/LAMA combination, then LAMA alone|Participants will first receive a long-acting muscarinic antagonist (LAMA) plus long-acting beta2-agonist (LABA) combination product once daily for 4 weeks. After a 2 week washout period, they will then receive the LAMA single product once daily for 4 weeks.
62397312|NCT03937531|EXPERIMENTAL|Retrograde-fill void trial (RVT)|Subjects will leave the operating room with a urinary catheter inserted. Subjects should be recovered from anesthesia effects (2-3 hours after surgery) before voiding trial. First, the bladder will be completely drained into the Foley bag then the bag will be detached from the catheter. The bladder will be back-filled with sterile water (300 mL). After the catheter is removed, subjects are expected to void at least 2/3 (200 mL) of the total instilled amount within 30 minutes of filling. Post-void residual (PVR) will be measured by both subtraction of the voided volume from 300cc and by using a bladder scanner.
62780559|NCT02012712|EXPERIMENTAL|Personal Health Record (PHR)|Subjects were sent an invitation to use an online Personal Health Record (PHR)
62780560|NCT02012712|NO_INTERVENTION|Usual care|Subjects received usual care (no invitation or access to the study PHR)
62780561|NCT03735108||pregnancy loss group|the times of pregnancy loss more than or equal to twice
62780562|NCT03735108||normal control group|no history of pregnancy loss
62780563|NCT00557453||A|Antibiotic treatment
62191609|NCT04771377|EXPERIMENTAL|standard protein supplementation (SPS)|0.8g protein/ IBW/ day
62780564|NCT00557453||B|Non antibiotic treatment
62780565|NCT06356389|EXPERIMENTAL|JX11502MA|JX11502MA 1.5 mg; JX11502MA 3 mg; JX11502MA 6 mg;
62780566|NCT06356389|PLACEBO_COMPARATOR|Placebo|Placebo
62791800|NCT04158583|EXPERIMENTAL|Part A: Cohort 8 RO7296682 100 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 100 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade \>=4, IRR; Grade \>=4, immune-mediated adverse events; Grade \>=4) were discontinued from study treatment.
62191610|NCT04771377|EXPERIMENTAL|High protein supplementation (HPS)|1.2g protein/ IBW/ day
62572661|NCT06575673|OTHER|TAU|Participants in the control group will receive a smoking cessation booklet published by the Hong Kong Council on Smoking and Health that provided information on the negative health consequences of smoking, reasons to quit, strategies for quitting, smoking cessation services available in Hong Kong, and a public Quitline number (usual care). Participants will also receive a monthly health education for three months that provides general health information and sharing sessions, which is one of the routine care for smokers during the first 3-4 months after they seek help for smoking problem (waiting period for further intervention).
62572662|NCT02866292||non-pregnant nulliparous|Nulliparous without previous gestation. Pelvic floor muscle evaluation by means of vaginal palpation and vaginal squeeze pressure (perineometer), and evaluation of the sexual function by the Female Sexual Function Index (FSFI) questionnaire.
62572663|NCT02866292||primigravid|Pregnant women on her first pregnancy and gestational age above 14 weeks. Pelvic floor muscle evaluation by means of vaginal palpation and vaginal squeeze pressure (perineometer), and evaluation of the sexual function by the Female Sexual Function Index (FSFI) questionnaire.
62572664|NCT03188289|PLACEBO_COMPARATOR|Placebo gel|The placebo gel is used by all patients on one side of the mouth and serves as a control group.
62572665|NCT03188289|ACTIVE_COMPARATOR|Clorhexidine gel|Chlorhexidine gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
62572666|NCT03188289|ACTIVE_COMPARATOR|Clorhexidine-Chitosan gel|Clorhexidine-chitosan gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
62572667|NCT03188289|ACTIVE_COMPARATOR|Hyaluronic acid gel|Hialuronic acid gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
62572668|NCT04445272|EXPERIMENTAL|Tocilizumab|"Patients will receive IV tocilizumab as per clinical practice and at the discretion of treating investigator, following the posology indicated in the SmPC, or the recommendations proposed by the Spanish Ministry of Health:~The recommended posology by the SmPC is 8 mg per kg in patients weighing greater than or equal to 30 kg or 12 mg per kg in patients weighing less than 30 kg. If no clinical improvement in the signs and symptoms up to 3 additional doses of tocilizumab may be administered. The interval between consecutive doses should be at least 8 hours.~The recommendations of the Spanish Ministry of Health:~Patients more than 80 kg: first dose 600 mg; second dose 600 mg. Patients less than 80 kg: first dose 600 mg; second dose 400 mg.~A third dose might be considered 16 to 24 hours after if: fever persists or a worsening of the laboratory parameters~Given the exceptionality of the situation modification of doses according to the physician experience will be allowed."
62191611|NCT04771377|EXPERIMENTAL|HPS + PA|1.2g protein/ IBW/ day + PA 3 times a week/ 12 weeks
62572669|NCT00204919|PLACEBO_COMPARATOR|1|
62572670|NCT00204919|ACTIVE_COMPARATOR|2|
62572671|NCT06273514|EXPERIMENTAL|TECAR|TECAR therapy is a non-invasive method for treating musculoskeletal system disorders based on the application of high-frequency current (300 kHz - 1 MHz)
62572672|NCT06273514|EXPERIMENTAL|Dry needling|Dry needling, a form of intramuscular stimulation, is a therapeutic intervention employed in physiotherapy and sports medicine. It entails the precise insertion of fine needles into specific myofascial trigger points, taut bands of skeletal muscle, or connective tissue without the administration of pharmacological agents.
62572673|NCT05373732|EXPERIMENTAL|Transcendental Meditation|The Transcendental Meditation (TM) technique is described as a simple, natural technique that is practiced twice a day for 20 minutes while sitting comfortably with eyes closed. There are no required changes in lifestyle, beliefs or philosophy. Instruction in the TM technique involves a seven-step course over five sessions (90-minute meetings).
62572674|NCT05373732|ACTIVE_COMPARATOR|Health Education|The health education (HE) intervention provided behavioral instructions for CVD risk factor prevention . This group received written materials, structured presentations, didactic instructions and group support for modifying the major cardiovascular risk factors including salt restriction, weight reduction, aerobic exercise, alcohol and smoking cessation.
62572675|NCT05887440|EXPERIMENTAL|3 assessments|The randomisation provides for 3 assessments of baseline
62191612|NCT04695704|EXPERIMENTAL|Montelukast|10mg oral montelukast once daily for 28 days.
62572676|NCT05887440|EXPERIMENTAL|4 assessments|The randomisation provides for 4 assessments of baseline
62191613|NCT04695704|PLACEBO_COMPARATOR|Placebo|oral placebo once daily for 28 days.
62191614|NCT05736172|EXPERIMENTAL|Pain group education|In this group, the education session will be provided in a face-to-face group setting.
62191615|NCT05736172|ACTIVE_COMPARATOR|Pain material education|In this group the same education session will be provided in written form by means of a leaflet.
62191616|NCT04412525|ACTIVE_COMPARATOR|27 gauge needle vitrectomy surgery|ultra-small gauge
62191617|NCT04412525|ACTIVE_COMPARATOR|larger than 27 gauge (23G or 25G) needle vitrectomy surgery|23-gauge and 25-gauge instruments are a little larger in size
62191618|NCT02389322|EXPERIMENTAL|5μg/ml ESAT6-CFP10 after BCG immunization|A within group paired comparison of 5μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 5μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after BCG immunization, according to a randomisation scheme .
62191619|NCT02389322|EXPERIMENTAL|10μg/ml ESAT6-CFP10 after BCG immunization|A within group paired comparison of 10μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 10μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after BCG immunization, according to a randomisation scheme .
62191620|NCT02389322|PLACEBO_COMPARATOR|5μg/ml ESAT6-CFP10 after placebo immunization|A within group paired comparison of 5μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 5μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after placebo controlled immunization, according to a randomisation scheme .
62191621|NCT02389322|PLACEBO_COMPARATOR|10μg/ml ESAT6-CFP10 after placebo immunization|A within group paired comparison of 10μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 10μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after placebo controlled immunization, according to a randomisation scheme.
62191622|NCT01356771|OTHER|Control Group|
62191623|NCT01356771|OTHER|Tailored Intervention|We will mail three separate pamphlets created specifically for the participant. The information in the pamphlets will be based on answers from the first survey.
62191624|NCT04296747|EXPERIMENTAL|Induction therapy|patients would accept toripalimab combined with chemotherapy as induction therapy, then radical treatment(surgery or chemoradiotherapy) according to whether the tumor could be resectable or the evaluation result according to RECIST1.1. Ones with PD after induction therapy will enter survival follow-up directly
62191625|NCT01915797||Patient having a cancer and abnormal development|Patient having developed a cancerous pathology and presenting one or several anomalies of the development.
62191626|NCT02097186|EXPERIMENTAL|Remote ischaemic preconditioning|Remote ischaemic preconditioning will be performed in the same manner as several previous trials. Immediately after induction of anaesthesia, a standard, CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
62191627|NCT02097186|NO_INTERVENTION|Control to remote preconditioning group|Patients randomised to this group will receive routine pre-operative, peri-operative and post operative care.
62191628|NCT01807182|EXPERIMENTAL|Treatment (TIL, combination chemotherapy, aldesleukin)|Patients receive cyclophosphamide IV on days -7 to -6 and fludarabine phosphate IV on days -5 to -1. Patients undergo TIL infusion over 30-60 minutes on day 0 and receive aldesleukin IV every 8 hours on days 1-5 for up to a maximum of 14 doses.
62191629|NCT05837988||MHD patients|Cross sectional survey, no intervention measures involved
62191630|NCT00966264|ACTIVE_COMPARATOR|LNG-IUS|Levonorgestrel releasing intrauterine system
62191631|NCT00966264|OTHER|Hysterectomy|Hysterectomy
62191632|NCT05345730||Mitral valve insufficiency patients undergoing mitral valve repair surgery|The research population consists of mitral valve insufficiency patients scheduled for elective surgical mitral valve repair (N=20) according to the current European guideline criteria. These patients will undergo a cardiac MRI scan 2 weeks prior to surgery and 3 months after surgery.
62791801|NCT04158583|EXPERIMENTAL|Part A: Cohort 9 RO7296682 165 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 165 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade \>=4, IRR; Grade \>=4, immune-mediated adverse events; Grade \>=4) were discontinued from study treatment.
62191633|NCT05562661||M89PF/standard skin care|use of M89PF on one side of the face standard skin care products on the other side of the face
62191634|NCT01883284|EXPERIMENTAL|Cystic Fibrosis patients (CF)|Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects
62191635|NCT01883284|OTHER|Control subjects (non CF)|Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects
62191636|NCT04195347|EXPERIMENTAL|CM4620 Treatment|"Phase I:~Cohort 1 patients receive CM4620 IV at dose level 1 on days 1-4. Cohort 2 patients receive CM4620 IV at dose level 2 on days 1-4. Cohort 3 patients receive CM4620 IV at either dose level 1 or 2 on days 1-4~Phase II:~Patients will receive CM4620 IV on days 1-4 at the recommended Phase II dose (RP2D) as determined in Phase I."
62191637|NCT00688220||1|Those wearing garments fabricated with Celliant
62191638|NCT00688220||2|Those not wearing garments fabricated using Celliant (placebo).
62191639|NCT06216652|ACTIVE_COMPARATOR|downhill walking|All participants received a conventional physiotherapy program. In addition to this program, the first group performed downhill walking exercise on the treadmill
62191640|NCT06216652|ACTIVE_COMPARATOR|uphill walking|All participants received a conventional physiotherapy program. In addition to this program, the second group performed uphill walking exercise on the treadmill
62191641|NCT06216652|ACTIVE_COMPARATOR|walking with no incline|All participants received a conventional physiotherapy program. In addition to this program, the third group performed walking with no incline exercise on the treadmill
62572677|NCT05887440|EXPERIMENTAL|5 assessments|The randomisation provides for 5 assessments of baseline
62191642|NCT00786643|EXPERIMENTAL|Stratum 1|Patients in stratum 1 have not received prior chemotherapy in the metastatic setting.
62191643|NCT00786643|EXPERIMENTAL|Stratum 2|Patients in stratum 2 have received 1-2 prior chemotherapy regimens in the metastatic setting.
62191644|NCT00304772|ACTIVE_COMPARATOR|1|
62191645|NCT00304772|ACTIVE_COMPARATOR|2|
62191646|NCT03379545|OTHER|3D MR and 3D CT Imaging|All shoulder arthroplasty candidates with glenohumeral osteoarthritis will be receiving both 3D computed tomography (CT) and 3D non-contrast magnetic resonance (MR) imaging.
62191647|NCT00797888|EXPERIMENTAL|Telephonic|Tailored telephonic intervention to improve HbA1c for participants in the diabetes registry
62191648|NCT00797888|ACTIVE_COMPARATOR|Standard registry|People with diabetes who are in the A1c registry may receive letters from the DOHMH to promote improved A1c and also give lists of bronx resources for healther foof and activites
62572678|NCT04160234||Elderly patient|Preoperative elderly patients, who are planned for a surgical intervention
62191649|NCT04871347|EXPERIMENTAL|Dose Escalation Cohort|Three dose levels of TWP-101 will be tested by a conventional 3 + 3 study design.
62572679|NCT05261516|ACTIVE_COMPARATOR|Propofol|"In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given.~In patients in the propofol group, anesthesia will be induced and maintained with a total intravenous anesthesia pump following the model of Schnider et al, at a targeted effect-site concentration of 4 +/- 1 mcg/ml.~In patients in all groups, after induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TetraGraph device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital."
62021024|NCT02419157|ACTIVE_COMPARATOR|Xeno V+ Etch (XV-E)|"XV-E (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Enamel margins were selectively etched with 36% phosphoric acid for 15s and subsequently thoroughly rinsed and air-dried. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~Selective enamel etching with 36% phosphoric acid"
62780567|NCT03364738|EXPERIMENTAL|rhPTH(1-84)|Participants will receive rhPTH(1-84) subcutaneous (SC) injection in the thigh (alternate thigh every day) once daily (QD) of an escalating dose from 50 microgram (mcg) to a maximum of 100 mcg increased in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining albumin-corrected serum calcium (ACSC) levels in the range of 2-2.25 millimoles per liter (mmol/L) (8.0-9.0 milligrams per deciliter \[mg/dL\]). Once a participant achieves a stable ACSC (2-2.25 mmol/L \[8.0-9.0mg/dL\]) and has minimized supplement doses, they will be maintained at that dose of rhPTH(1-84). If ACSC is greater than (\>) 2.25 mmol/L (\>9.0 mg/dL), a starting dose of 25 mcg will be administered.
62572680|NCT05261516|EXPERIMENTAL|Isoflurane|"In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given. After induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TetraGraph device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital.~The anesthesia will be maintained with the agent specified by randomization: isoflurane in this group."
62780568|NCT05094908|ACTIVE_COMPARATOR|Regime 1 (30 days)|Regimen 1: arnica tincture applied 3 times a day for 30 days (group 1). For both regimens, the participant applies the tincture in the morning, afternoon and evening, that is, three times a day.
62780569|NCT05094908|ACTIVE_COMPARATOR|Regime 2 (45 days)|Regimen 2 arnica tincture applied 3 times a day for 45 days (group 2). For both regimens, the participant applies the tincture in the morning, afternoon and evening, that is, three times a day.
62780570|NCT00627055|EXPERIMENTAL|1|LPV/r monotherapy
62780571|NCT00627055|ACTIVE_COMPARATOR|2|LPV/r + 2NRTIs (TDF/FTC or TDF/3TC)
62780572|NCT05080374|EXPERIMENTAL|HVLA + exercise Group|Spinal manipulation (HVLA) + trunk exercise program
62780573|NCT05080374|EXPERIMENTAL|HVLA + kinesiotaping group|Spinal manipulation (HVLA) + Kinesiotaping (lumbar)
62780574|NCT05080374|EXPERIMENTAL|HVLA + Respiratory exercise group|Spinal manipulation (HVLA) + respiratory exercise program
62780575|NCT03366467|EXPERIMENTAL|SADE first|SADE first will initially be treated under SADE (Time 1) and receive RDE on the second encounter (Time 2)
62780576|NCT03366467|EXPERIMENTAL|RDE first|RDE first will initially be treated under RDE (Time 1) and receive SADE on the second encounter (Time 2)
62780577|NCT06526052|EXPERIMENTAL|Mindfulness Program|The Mindfulness Program is an online, coached intervention that teaches mindfulness activities such as calm breathing, listening, acceptance, gratitude, and compassion. Participants meet with their coach weekly for nine 30-minute, weekly sessions in which they learn mindfulness skills and practice using the mindfulness exercises between sessions. Meetings are done remotely (e.g., Zoom).
62780578|NCT06526052|ACTIVE_COMPARATOR|Supportive Active Comparison|The Supportive Active condition involves participants meeting remotely (e.g., Zoom) with a coach for nine 30-minute, weekly sessions during which teens discuss their thoughts and feelings about things going on in their life. Coaches are instructed to use active listening, open-ended questions, empathy, reflection, and unconditional positive regard. Between sessions, teens use expressive writing to describe and understand their thoughts and feelings about situations in their life.
62780579|NCT06526052|NO_INTERVENTION|Control|This is an assessment only control condition. Participants complete all of the same measures as do youth in the other two conditions at the same time points (i.e., baseline, post-intervention (about 10 weeks after baseline) and at a six-month follow-up.
62780580|NCT02776254|EXPERIMENTAL|START|The START model aims to deliver a higher intensity of treatment services by offering same-day CD4 testing and results, streamlined adherence counseling, and quicker initiation of life-long ART to patients enrolling in HIV care and treatment services.
62780581|NCT02776254|EXPERIMENTAL|FAST Track|In the FAST-TRACK model a pharmacy technician will dispense drugs) and lay health care workers will provide brief symptom screening to identify patients in need of higher-level care. If there is no need of higher-level care, then the clinic visit is over.
62006076|NCT04184076|NO_INTERVENTION|Dietary counseling alone|"1. Controls will be instructed to maintain their weight throughout the trial, and not to change their eating or physical activity habits. Controls will visit the research center on a weekly basis for weigh-ins. Body composition and metabolic disease risk variables will be assessed in control subjects every 12 weeks.~2. Subjects will complete a 3-d food record (2 regular day and 1 holiday) each week during the experiment.~3. The blood draws will be taken at approximately 11:00 am. The following analyzes will be measured in plasma samples: ketones, fasting glucose, fasting insulin, hemoglobin A1c, liver function, renal function, albumin, lipid profiles, MMP-9, IL-6, TNF-alpha, exosome markers (phospho-IRS1, phospho-Tau, Abeta1-42). Metabolomic and lipidomic analyses will be performed on the baseline and 3-month time point plasma samples."
62572681|NCT05261516|EXPERIMENTAL|Desflurane|"In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given. After induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TetraGraph device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital.~The anesthesia will be maintained with the agent specified by randomization: desflurane in this group."
62572682|NCT05261516|EXPERIMENTAL|Sevoflurane|"In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given. After induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TetraGraph device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital.~The anesthesia will be maintained with the agent specified by randomization: sevoflurane in this group."
62572683|NCT01289860|ACTIVE_COMPARATOR|Blueberry drink|30g of blueberry powder (equivalent to 200g fresh blueberries) and 300ml of semi-skimmed milk
62572684|NCT01289860|PLACEBO_COMPARATOR|Control drink|29g of powder consisting of sugars and vitamin C, values of which were matched to that of the blueberry drink, with 1 g of citric acid to match for taste.
62780582|NCT02776254|EXPERIMENTAL|CAG (intervention)|CAG intervention, consists of facilitated groups of six people based on geographic proximity of home address and patient preference. This group of six people, will meet monthly at a designated place in the community to provide support and receive medications. Each month one of the members will rotate visiting the clinic for their routine medical visit and will pick up medications for the entire CAG and bring them back to the community. This rotation schedule will recur every six months. Lay health care workers will provide brief symptom screening to identify patients in the group that need of higher-level care.
62780583|NCT02776254|ACTIVE_COMPARATOR|CAG (comparison)|Eligible patients at control sites will be approached for willingness to participate in the study. Those who are willing will be enrolled in the study and consent will be obtained to use patient data within SmartCare to evaluate the primary outcome of retention.
62780584|NCT02776254|EXPERIMENTAL|UAG (intervention)|Urban sites will be eligible for the UAG model in which patients will be joined into a UAG group consisting of 30 people. Each UAG group will meet every two to three months at a designated site (either at the clinic facility or another site in the community). Patients will receive (a) group adherence counseling led by a lay HCW (b) two to three month supply of ART medications via a pharmacy tech (c) attendance record and symptom assessment. As in the CAG model, patients may be referred up-referred for care based on acute illness or patient preference. Patients will continue to visit the facility for a routine medical visit with a professional HCW every six months.
62780585|NCT02776254|ACTIVE_COMPARATOR|UAG (comparison)|Eligible patients at control sites will be approached for willingness to participate in the study. Those who are willing will be enrolled in the study and consent will be obtained to use patient data within SmartCare to evaluate the primary outcome of retention.
62780586|NCT03182907|EXPERIMENTAL|Bezlotoxumab|Participants receive 10 mg of bezlotoxumab per kg body weight via a single 60-minute (±10 minutes) intravenous (IV) infusion on Day 1. Additionally, participants receive background antibacterial drug treatment (ABD) for 10-21 days per institutional guidelines, at the investigator's discretion. Dose may then be changed based on results from initial 12 participants.
62780587|NCT03182907|PLACEBO_COMPARATOR|Placebo|Participants receive placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose via a single 60-minute (±10 minutes) IV infusion on Day 1. Additionally, participants receive background ABD for 10-21 days per institutional guidelines, at the investigator's discretion.
62191650|NCT04871347|EXPERIMENTAL|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
62191651|NCT04923308||Intervention group|
62191652|NCT04923308||Control group|
62191653|NCT00398281|EXPERIMENTAL|Arm I|Patients receive oral dutasteride once daily on days 1-14.
62191654|NCT00398281|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo once daily on days 1-14.
62780588|NCT03534622|EXPERIMENTAL|Delafloxacin|"Dosing will be initiated on Day 1. All participants will receive 300-mg delafloxacin as a~1-hour intravenous infusion every 12 hours (± 15 minutes) for a total of 7 doses."
62780589|NCT05791240|NO_INTERVENTION|Pre-Intervention|The medical team will use standard interpreter practices with this group.
62780590|NCT05791240|EXPERIMENTAL|Interventional|This arm will be given interpreter tablets in order to allow them to call interpreter themselves.
62780591|NCT04635514||Study group of 32 subjects|"Thirty-two women who presented with symptomatic lateral vaginal prolapse (deep dyspareunia, sensation of vaginal fulness, and heaviness) composed the study's group.~The surgical lateral vaginal reconstruction (lateral colporrhaphy) of the lateral vaginal wall was administered."
62191655|NCT05227781|EXPERIMENTAL|L-Citrulline|L-Citrulline: 10 grams/day
62791802|NCT04158583|EXPERIMENTAL|Part A: Cohort 10 RO7296682 20 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 20 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade \>=4, IRR; Grade \>=4, immune-mediated adverse events; Grade \>=4) were discontinued from study treatment.
62191656|NCT05227781|PLACEBO_COMPARATOR|Placebo|Maltodextrin: 10 grams/day
62191657|NCT04996940|EXPERIMENTAL|Tobacco then Menthol|A 30-minute session with tobacco flavor then a 30-min session with menthol flavor
62191658|NCT04996940|EXPERIMENTAL|Menthol then tobacco|A 30-minute session with menthol flavor then a 30-min session with tobacco flavor
62191659|NCT02019862||TRJ®|
62191660|NCT02751047|PLACEBO_COMPARATOR|Manual ventilation|During anesthetic induction, facemask ventilation is performed by manual bagging, after setting adjustable pressure limiting (APL) valve at 13 cmH2O. During mask ventilation, gastric ultrasonography is continuously performed to detect gastric insufflation.
62191661|NCT02751047|ACTIVE_COMPARATOR|Pressure controlled mechanical ventilation|During anesthetic induction, facemask ventilation is performed with mechanical ventilator by pressure controlled mode, with inspiratory pressure of 13 cmH2O. During mask ventilation, gastric ultrasonography is continuously performed to detect gastric insufflation.
61977956|NCT01772706|EXPERIMENTAL|laser low-level energy functional|The material used will be a diode laser of 100 mW, with a wavelength of 658 nm. Application will be made after each radiotherapy session in an adapted room (low light intensity, possibility of ENT examination) on all grade superior or equal to 2 stomatitis injuries. The energetic dose delivered will be 4 J/cm2. The duration of the treatment for one will be determined by an abacus.
62191662|NCT01318876||BC Children's and Women's Hospital, Vancouver.|
62191663|NCT01318876||University of British Columbia, Vancouver.|
62191664|NCT01318876||Health care workers in Halifax|
62191665|NCT01318876||Health care workers from CHUQ hospitals|
62572685|NCT05024188|EXPERIMENTAL|Antibiotics + FMT|7 days of antibiotics- Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day. After antibiotics administration, participants will receive 10 aFMT capsules for three consecutive days (a total of 30 capsules).
62572686|NCT05024188|PLACEBO_COMPARATOR|Placebo|7 days of cellules pills. After cellules pills administration, participants will receive 10 agarose capsules for three consecutive days (a total of 30 capsules).
62572687|NCT05668416|EXPERIMENTAL|experiment|The intervention group will include parents who were trained in the preoperative period. The training includes brochures and oral training prepared by the researchers in line with the literature and the training given in the hospital.
62780592|NCT00085449|EXPERIMENTAL|Regimen A + B|"Conditioning regimen A: Patients receive alemtuzumab IV over 2 hours on days -14 to -12; fludarabine IV over 30 minutes on days -7 to -3; and melphalan IV over 20-30 minutes on day -2.~Conditioning regimen B: Patients receive oral or IV cyclosporine twice daily and oral or IV mycophenolate mofetil twice daily on days -15 to 0. Patients also receive alemtuzumab, fludarabine, and melphalan as in conditioning regimen A. Patients undergo low-dose total body irradiation twice daily on days -2 and -1.~All patients undergo allogeneic, T-cell-depleted, CD34-positive peripheral blood stem cell transplantation on day 0. Patients receive sargramostim (GM-CSF) subcutaneously beginning on day 1 and continuing until blood counts recover.~Patients are followed every 3 months for 1 year and then every 6 months for 5 years."
62780593|NCT02518373|EXPERIMENTAL|G17DT & Omeprazole|"* A 14-day washout period~* An Omeprazole Treatment Period 1 (Day -15 to Day -1)~* A G17DT treatment period (Day 0 to Day 85)~* An Omeprazole Treatment Period 2 (Day 86 to Day 100)"
62021025|NCT02419157|ACTIVE_COMPARATOR|Clearfil SE Bon Non-etch (CSE-NE)|"CSE-NE (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~No selective enamel etching with 36% phosphoric acid"
62191666|NCT01318876||Health care workers from Toronto|
62572688|NCT05668416|NO_INTERVENTION|control|The control group will be the oral information group that is in the hospital routine. Parents in this group will be informed verbally when they come to the hospital for anesthesia and file procedures the day before the surgery.
62780594|NCT04623229|EXPERIMENTAL|MCS|
62780595|NCT04623229|EXPERIMENTAL|ReLACS Early|
62191667|NCT01318876||Centre hospitalier et universitaire de Sherbrooke|
62191668|NCT01318876||The Ottawa General Hospital, Ottawa|
62780596|NCT04623229|EXPERIMENTAL|ReLACS Standard|
62780597|NCT03964688|EXPERIMENTAL|Vitamin C|vitamin C intravenous during hospitalization, followed with vitamin C oral
62780598|NCT03964688|EXPERIMENTAL|Placebo|placebo intravenous during hospitalization, followed with placebo oral
62780599|NCT05977088|EXPERIMENTAL|Interventional|"Power Mag TMS device will be used throughout the study, and the excitations will be made with the help of an 8 shaped coil (diameter: 70 mm) with internal cooling. The right-left DLPFC, which is the application area, will be determined with the help of the primary motor hand area and the 10/20 EEG system.~A resting state EEG (eyes open-closed) will be taken i in the Faraday cage."
62780600|NCT05977088|SHAM_COMPARATOR|Sham|The same treatment procedures will be applied to the control group with a sham coil.
62006077|NCT04184076|EXPERIMENTAL|Time-restricted feeding (TRF) with dietary counseling|"1. Subjects will be instructed to eat ad libitum from 10:00 to 18:00 h daily, and fast from 18:00 to 10:00 h daily. During the 8-h feeding window, there will be no restrictions on types or quantities of foods consumed. During the fasting period, subjects will be encouraged to drink plenty of water and will be permitted to consume energy-free beverages.~2. Subjects will complete a 3-d food record (2 regular day and 1 holiday) each week during the experiment.~3. The blood draws will be taken at approximately 11:00 am, especially prior to the first consumption of food by subjects in the TRF group. The following analyzes will be measured in plasma samples: ketones, fasting glucose, fasting insulin, hemoglobin A1c, liver function, renal function, albumin, lipid profiles, MMP-9, IL-6, TNF-alpha, exosome markers (phospho-IRS1, phospho-Tau, Abeta1-42). Metabolomic and lipidomic analyses will be performed on the baseline and 3-month time point plasma samples."
62780601|NCT05061628|EXPERIMENTAL|JS006 as Monotherapy|"1. JS006 as Monotherapy dose-escalation：5 proposed dose levels（18mg, 60mg, 180mg, 600mg, 1800mg).~2. JS006 as Monotherapy dose-extension：1 or 2 proposed dose levels, to be determined."
62006078|NCT06251076|EXPERIMENTAL|Cohort 1|Give teclistamab step-up dosing at Princess Margaret Cancer Centre as per product monograph.
62006079|NCT06251076|EXPERIMENTAL|Cohort 2|Give teclistamab step-up dosing at Princess Margaret Cancer Centre with the addition of one dose of prophylactic tocilizumab prior to step-up dose 1.
62006080|NCT06251076|EXPERIMENTAL|Cohort 3|Give teclistamab step-up dosing at Southlake Regional Cancer Centre in the outpatient setting using the best method(s) as determined from Cohorts 1 and 2.
62006081|NCT06251076|NO_INTERVENTION|Caregiver Cohort|Caregivers of participants in Cohorts 1, 2, and 3 will complete various questionnaires to assess impact.
62006082|NCT00219934||Group A|acute or early in the course of HIV-1 infection, independent of decisions regarding therapy with HAART.
62006083|NCT00219934||Group B|subjects who were diagnosed with acute HIV-1 infection in the past and have been participating in an ADARC/Rockefeller University Hospital treatment protocol for acute HIV-1 infection, and currently have a viral load consistently less than 50 copies/ml on current treatment
62006084|NCT01389297|ACTIVE_COMPARATOR|Face-to-face SMART Recovery meetings|Participants in this arm will be asked to attend face-to-face SMART Recovery meetings.
61977957|NCT01772706|PLACEBO_COMPARATOR|laser low-level energy nonfunctional|The procedure is identical to the one used in arm A but the laser will not be functional. The period of application will be around one minute.
61977958|NCT05491330|ACTIVE_COMPARATOR|R reference (first dose)|Reference drug (Paxlovid) Nirmatrelvir 150 mg + Ritonavir 100 mg tablets
61977959|NCT05491330|EXPERIMENTAL|T test|Test drug (Copaxid) Nirmatrelvir 150 mg + Ritonavir 100 mg tablets
62006085|NCT01389297|EXPERIMENTAL|Overcoming Addictions web app|Participants in this condition will use the Overcoming Addictions web application and not attend face-to-face SMART Recovery meetings.
62006086|NCT01389297|EXPERIMENTAL|Web app + meetings|Participants in this condition will be asked to use both the Overcoming Addictions web application and attend face-to-face SMART Recovery meetings.
62006087|NCT06664749|EXPERIMENTAL|Three stair position pillow group|Three stair position pillows were used for preterm infants.
62006088|NCT06664749|EXPERIMENTAL|Positioning material group|Positioning materials were used for preterm infants.
62780602|NCT05061628|EXPERIMENTAL|JS006 in combination with Toripalimab|"1. JS006 in combination with Toripalimab dose-escalation：2 or 3 proposed dose levels, to be determined.~2. JS006 in combination with Toripalimab dose-extension：1 or 2 proposed dose levels, to be determined.~3. JS006 in combination with Toripalimab indications expansion: 2 to 4 specific tumor types are selected for indication expansion after the combination dose-expansion is completed."
62780603|NCT00459654|EXPERIMENTAL|Radium-223 dichloride (Xofigo, BAY88-8223)|Each subject receives local filed external beam radiotherapy (EBR) and repeated injections of the investigational drug radium-223 (EBR+Radium-223)
62006089|NCT04095000|EXPERIMENTAL|FACE-TC SP|The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
62191669|NCT04582305|ACTIVE_COMPARATOR|Bleomycin jet-injections|This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be given per 1 cm2, with a maximum of 20 injections per treatment. The maximum dosage of bleomycin per treatment will be 2 mL, corresponding to 2 USP-E (units) of bleomycin. The maximum cumulative dosage of bleomycin will be 6 USP-E in this study.
62780604|NCT00459654|PLACEBO_COMPARATOR|Saline|Each subject receives local filed external beam radiotherapy (EBR) and repeated injections of saline (EBR+placebo)
62780605|NCT01323140|EXPERIMENTAL|TMTS treatment|Following a lead-in dose-proportionality phase (Days 1-2) and a site-to-site bioavailability phase (Days 2-9), subjects were dosed for efficacy analysis beginning on Day 9 at dose level B (a single 48 cm2 testosterone matrix transdermal system). Based on pharmacokinetic (PK) analysis of blood samples drawn on Day 16, on Day 22 subjects could be dose-titrated up to dose level C (one 28 cm2 plus one 48 cm2 TMTS), down to dose level A (one 28 cm2 TMTS), or remain at dose level B. Subjects at all dose levels were pooled for primary efficacy analysis on Days 29/30.
62780606|NCT02731612|EXPERIMENTAL|Lurasidone|Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.
62780607|NCT02731612|PLACEBO_COMPARATOR|Placebo|Placebo added to current treatment for 6 weeks
62780608|NCT05890469|EXPERIMENTAL|Zirconia surface implant and guided bone regeneration (Test)|Zirconia surface implant (Straumann PURE®, Basel, Switzerland) and guided bone regeneration (GBR) with a porcine collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland) and a deproteinized bovine bone substitute (Bio-Oss Collagen®, Geistlich, Wolhusen, Switzerland).
62780609|NCT05890469|OTHER|Hydrophilic titanium surface implant and guided bone regeneration (Control)|Hydrophilic titanium surface implant (Straumann Standard Plus (SP) Tissue level, SLActive®, Basel, Switzerland) and guided bone regeneration (GBR) with a porcine collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland) and a deproteinized bovine bone substitute (Bio-Oss Collagen®, Geistlich, Wolhusen, Switzerland).
62780610|NCT06584162|NO_INTERVENTION|Control|Continuing subcutaneous vedolizumab every other week
62780611|NCT06584162|EXPERIMENTAL|Intervention|Therapeutic drug monitoring guided de-escalation
62780612|NCT03936647|ACTIVE_COMPARATOR|Standard conventional treatment (surgical or endovascular)|Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.
62780613|NCT03936647|EXPERIMENTAL|WEB embolization device|Endovascular treatment with WEB, including standard management of thrombo-embolic risk
62780614|NCT04651127|EXPERIMENTAL|Toripalimab + Chidamide Arm|
62780615|NCT01770015|EXPERIMENTAL|ventilated patient|"all patients underwent the same diagnostic test . cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization.~HLA DR antigen, cytokines (IL 6 and 10), B-glucan. fungi and bacteria endotracheal aspiration"
62780616|NCT06118957|EXPERIMENTAL|Enoxaparin|Participants will receive weight-based dosing of enoxaparin at 0.5 mg/kg rounded to the nearest 10 mg every 12 hours based on delivery admission weight. Participants will receive therapy for 14 days.
62780617|NCT06118957|NO_INTERVENTION|No treatment|Participants will receive no enoxaparin treatment.
62780618|NCT01366729|EXPERIMENTAL|TheraTogs|
62780619|NCT01366729|ACTIVE_COMPARATOR|Cane walking|
62780620|NCT02518191|EXPERIMENTAL|GnRHa group|Eligible patients with breast cancer treated with GnRHa while receiving chemotherapy.
62780621|NCT02518191|NO_INTERVENTION|None GnRHa group|Eligible patients with breast cancer treated without GnRHa while receiving chemotherapy.
62780622|NCT03170193|EXPERIMENTAL|AMG 529|Participants received a single dose of AMG 529 at ascending dose levels by either subcutaneous or intravenous injection.
62780623|NCT03170193|PLACEBO_COMPARATOR|Placebo|Participants received a single dose of placebo matching to AMG 529 by either subcutaneous or intravenous injection.
62780624|NCT03784807||Infected|Patients with prosthetic joint or osteoarticular infection
62780625|NCT03784807||Not infected|Patients with implant failure not due to infection
62572689|NCT03193853|EXPERIMENTAL|Tak + cisplatin and nab paclitaxel|Patients with metastatic TNBC who meet the enrollment criteria will receive TAK-228 and TAK-117 until disease progression followed by nab paclitaxel plus cisplatin for six cycles. Patients who did not progress may continue nab paclitaxel under treating physicians discretion.
62780626|NCT05145244||Patients with newly diagnosed non-small cell lung cancer|"Approximately 1800 patients who are initiating~* Standard of care, including targeted therapy based on PD-L1 status, EGFR, ALK or ROS1 (routine biomarkers)~* Active clinical trials in the clinics after informed consent"
62780627|NCT05145244||Patients with metastatic breast cancer|"Approximately 600 patients who are initiating~* Standard of care, including targeted therapy based on HER2 status and ER status (routine biomarkers)~* Active clinical trials in the clinics after informed consent"
62191670|NCT04582305|PLACEBO_COMPARATOR|Placebo jet-injections|This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be given per 1 cm2, with a maximum of 20 injections per treatment. The maximum dosage of normal saline per treatment will be 2 mL.
62191671|NCT01511497|EXPERIMENTAL|PF-04427429|
62780628|NCT03964402||Control|Control arm, i.e., as per standard procedures
62780629|NCT03964402||Experimental|Experimental arm, i.e. investigational product
62780630|NCT01616368|EXPERIMENTAL|MEAL|Participation in an 8-week mindful eating course
62780631|NCT05700227|EXPERIMENTAL|Daily Adaptive External Beam Radiation Therapy|Daily adaptive radiation therapy delivered with Varian Ethos treatment system
62780632|NCT00377364|EXPERIMENTAL|Acetaminophen|Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days.
62780633|NCT00377364|PLACEBO_COMPARATOR|Placebo|Participants will be given an identical appearing placebo (two 500 mg tablets) four times daily for 7 days.
62780634|NCT05392803|EXPERIMENTAL|Active then Sham Treatment|"Application of 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy, 7 day washout, 30 days of sham."
62191672|NCT01511497|PLACEBO_COMPARATOR|Placebo|Normal saline
62191673|NCT05113706||Bystander not emotional distressed|If caller is not emotional distressed the first minute of the call
62191674|NCT05113706||Bystander emotional distressed|If caller is emotional distressed the first minute of the call
62191675|NCT00455741|ACTIVE_COMPARATOR|Young postmenopausal women|Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women.
62191676|NCT00455741|ACTIVE_COMPARATOR|Older postmenopausal women|Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women..
62572690|NCT03084120|OTHER|Gastric bypass surgery|"Pregnant women having undergone a Gastric bypass surgery before the pregnancy.~* Collection of bloods samples for the mother.~* Retrieval of umbilical cord blood.~* Retrieval of placenta.~* Collection of newborn's and mother's lock of hair.~* Dietetic patient outcomes questionnaires for the mother.~* Parental questionnaires : ASQ (Ages \& Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
62572691|NCT03084120|OTHER|Reference group|"Pregnant women having a body mass index \<25 kg/m2 at the early pregnancy.~* Collection of bloods samples for the mother.~* Retrieval of umbilical cord blood.~* Retrieval of placenta.~* Collection of newborn's and mother's lock of hair.~* Dietetic patient outcomes questionnaires for the mother.~* Parental questionnaires : ASQ (Ages \& Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
62780635|NCT05392803|EXPERIMENTAL|Sham then Active Treatment|"Application of 30 days of a nonfunctional sham device, 7 day washout, then 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy"
62780636|NCT03739515|EXPERIMENTAL|HSCP team|Patients in this arm will receive comprehensive assessment and/or pre-discharge services by an ED-based HSCP team
62780637|NCT03739515|ACTIVE_COMPARATOR|Routine care|Patients in this arm will receive routine ED care
62006090|NCT04095000|ACTIVE_COMPARATOR|Treatment As Usual|Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
62006091|NCT00079274|EXPERIMENTAL|Arm A (combination chemotherapy)|Patients received oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46-48 hours on days 1. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
62006092|NCT00079274|EXPERIMENTAL|Arm B (combination chemotherapy)|Patients received irinotecan IV over 2 hours on day 1 and leucovorin calcium and fluorouracil as in arm A. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
62006093|NCT00079274|EXPERIMENTAL|Arm C (combination chemotherapy)|Patients received the same treatment as in arm A for 6 courses followed by the same treatment as in arm B for 6 courses (total of 12 courses). Treatment continues in the absence of unacceptable toxicity or recurrent disease.
62006094|NCT00079274|EXPERIMENTAL|Arm D (combination chemotherapy, monoclonal antibody)|Patients received cetuximab IV over 1 hour on days 1 and 8 and oxaliplatin, leucovorin calcium, and fluorouracil as in arm A. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
62006095|NCT00079274|EXPERIMENTAL|Arm E (combination chemotherapy, monoclonal antibody)|Patients received cetuximab as in arm D and irinotecan, leucovorin calcium, and fluorouracil as in arm B. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
62572692|NCT03084120|OTHER|Overweight|"Pregnant women having a body mass index 25-30 kg/m2 at the early pregnancy.~* Collection of bloods samples for the mother.~* Retrieval of umbilical cord blood.~* Retrieval of placenta.~* Collection of newborn's and mother's lock of hair.~* Dietetic patient outcomes questionnaires for the mother.~* Parental questionnaires : ASQ (Ages \& Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
62572693|NCT03084120|OTHER|Obesity|"Pregnant women having a body mass index \> 30 kg/m2 at the early pregnancy.~* Collection of bloods samples for the mother.~* Retrieval of umbilical cord blood.~* Retrieval of placenta.~* Collection of newborn's and mother's lock of hair.~* Dietetic patient outcomes questionnaires for the mother.~* Parental questionnaires : ASQ (Ages \& Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
62006096|NCT00079274|EXPERIMENTAL|Arm F (combination chemotherapy, monoclonal antibody)|Patients received cetuximab as in arm D and chemotherapy as in arm C.
62572694|NCT04986345|EXPERIMENTAL|Rest, HIIT-4, HIIT-10|"Both arms start with the rest condition and the order of the two other conditions (HIIT-4 and HIIT-10) is determined at random.~This arm's sequence of intervention is : 1-Rest; 2- HIIT-4 and 3- HIIT-10."
62572695|NCT04986345|EXPERIMENTAL|Rest, HIIT-10, HIIT-4|"Both arms start with the rest condition and the order of the two other conditions (HIIT-4 and HIIT-10) is determined at random.~This arm's sequence of intervention is : 1- Rest; 2- HIIT-10 and 3- HIIT-4."
62572696|NCT02535767|EXPERIMENTAL|A: 0.40 mg/kg PQ G6PDd|0.40 mg/kg of primaquine (as a single dose) in G6PD-deficient individuals
62572697|NCT02535767|EXPERIMENTAL|B: PQ in G6PDd|A single dose of primaquine in G6PD-deficient men, exact dose to be decided by DSMB based on findings in previous dose group. The minimum change in dose from the last study dose is 0.05 mg/kg, and the maximum change is 0.20 mg/kg of primaquine). Dose is not to exceed 0.75 mg/kg primaquine.
62780638|NCT05172089||Diabetic Foot Ulcer study|405 clinically diagnosed Diabetic Foot Ulcer (DFU) patients who are suspected to be infected will be recruited . Wound swab for culture obtained. Baseline digital imaging of target wound(s). SF-12 Health survey, Visual Analogue Pain scale, Cardiff wound impact questionnaires. Wound site evaluation including TcOM/TBI/ankle brachial index (ABI) will be completed for subjects with wounds below the knee, if not already completed per standard of care within the previous 12 months. Hemoglobin A1c point of care testing will be drawn for diabetic subjects who do not have an A1c available within 90 days prior to enrollment; 3mm biopsy tissue or debrided tissue will be collected. Ideally, two tissue samples will be obtained; the subject's medical records will be reviewed and followed for up to 16 weeks or until their wound has closed, whichever comes first. The research staff will also call the patient or care facility as needed to check for wound closure.
62780639|NCT01710098||Degarelix|adult male patients with advanced hormone dependent prostate cancer who receive 240 mg as a start dose and then monthly 80mg Firmagon® for one year
62780640|NCT02458443|SHAM_COMPARATOR|IHG 5% Un-medicated|Participants with high blood pressure (greater than 120/80) who are not medicated for blood pressure control will conduct isometric handgrip (IHG) exercise at 5% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
62780641|NCT02458443|SHAM_COMPARATOR|IHG 5% BB|Participants with high blood pressure (greater than 120/80) who are currently taking beta blockers for blood pressure control will conduct isometric handgrip exercise at 5% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
62191677|NCT02522988|EXPERIMENTAL|Group 1a|During the first 3-week period of the study, Group 1 will serve as the experimental arm and will receive the open-label placebo intervention. Group 1 participants will take 2 placebos in the morning and 2 placebos in the evening for 21 days.
62191678|NCT02522988|NO_INTERVENTION|Group 2a|During the first 3-week period of the study, Group 2 will serve as the comparator arm.
62191679|NCT02522988|NO_INTERVENTION|Group 1b|During the last 3-week period of the study, Group 1 will serve as the comparator arm.
62191680|NCT02522988|EXPERIMENTAL|Group 2b|During the last 3-week period of the study, Group 2 will serve as the experimental arm and will receive the open-label placebo intervention.Group 2 participants will take 2 placebos in the morning and 2 placebos in the evening for 21 days.
62191681|NCT04943354|ACTIVE_COMPARATOR|Study of single-nucleotide polymorphisms in women diagnosed with premature ovarian failure|Study of genes affecting single nucleotide polymorphisms: Reninangiotensin-aldosterone system (AGT, ACE), endothelial dysfunction (NOS3, EDN1), thrombosis-associated (ITGB3, ITGA2, FGB, GPIBA, SERPINE PAI1), proinflammatory (CRP, IL17A, IL2, IL10 1, IL10 2, TNFα, CRP 4, IL6, TLR2, TLR3, TLR4, TLR6, TLR9) in the study group of women diagnosed with premature ovarian failure.
62006097|NCT00079274|OTHER|Arm G (Locally directed therapy)|Patients determined to have mutated KRAS (or KRAS not evaluable) were assigned to an event monitoring arm in which adjuvant therapy was determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification was the responsibility of the treating oncologists.
62780642|NCT02458443|EXPERIMENTAL|IHG 30% Un-medicated|Participants with high blood pressure (greater than 120/80) who are not medicated for blood pressure control will conduct isometric handgrip exercise at 30% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
62780643|NCT02458443|EXPERIMENTAL|IHG 30% BB|Participants with high blood pressure (greater than 120/80) who are currently taking beta blockers for blood pressure control will conduct isometric handgrip exercise at 30% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
62780644|NCT06523244|EXPERIMENTAL|test group|PDT with chitosan nanoparticles enriched ICG
62780645|NCT06523244|ACTIVE_COMPARATOR|Control group|PDT with ICG
62780646|NCT04077931|EXPERIMENTAL|Aerobic exercises|She asked to start walking with the speed of the machine was adjusted at 0.8 km/hour, so her resting pulse rate increases, then we increased the speed by 0.2 km/hour gradually every 2 minute (to give a time for adjustment of heart rate) till reaching our target heart rate (not less than 60% and not more than 75% of target heart rate). So the intensity of exercises can be increase or decrease only by changing the speed of treadmill according to target heart rate \[13\]
62780647|NCT04077931|EXPERIMENTAL|Deep breathing exercises|Technique of breathing exercises: Regular aerobic exercises in a form breathing exercises included duration of 30 min. at 40-70% VO2 max. performed 2-3 per week. Each woman practiced deep breathing exercises 30 min. in the of form (diaphragmatic breathing exercises, 15 min. and lateral costal breathing exercises 15 min.) 3 times per week for 12 weeks.
62780648|NCT03102268||cholangiocarcinoma patients|cholangiocarcinoma patients without any anti-cancer therapy
62780649|NCT03102268||benign biliary stricture patients|benign biliary stricture patients without any therapy targeting the stricture
62780650|NCT03172130|EXPERIMENTAL|Straight CPAP|Patients randomized to straight CPAP will receive 10 cm of air pressure, or as determined by the results of polysomnography, for 6 weeks. Following the 6-week visit, patients will be placed on straight CPAP with equipment approved by insurance for an additional 6 weeks.
62780651|NCT03172130|SHAM_COMPARATOR|Sham CPAP|Patients randomized to sham CPAP will receive 1-2 cm of air pressure for 6 weeks. Following the 6-week visit, patients will be placed on straight CPAP with equipment approved by insurance for an additional 6 weeks.
62780652|NCT04798716|EXPERIMENTAL|Escalating Dose First Cohort|"First Cohort:~Five patients will receive an escalating dose every other day for a period of 5 days, with a minimum of 24 hours between doses recorded. Dose escalation will begin at 2 x 10\^9 exosomes"
62191682|NCT04943354|ACTIVE_COMPARATOR|Study of single-nucleotide polymorphisms in a control group of healthy women|Study of genes affecting single nucleotide polymorphisms: Reninangiotensin-aldosterone system (AGT, ACE), endothelial dysfunction (NOS3, EDN1), thrombosis-associated (ITGB3, ITGA2, FGB, GPIBA, SERPINE PAI1), pro-inflammatory (CRP, IL17A, IL2, IL10 1, IL10 2, TNFα, CRP 4, IL6, TLR2, TLR3, TLR4, TLR6, TLR9) in a control group of healthy women .
62191683|NCT05090189|EXPERIMENTAL|Exercise training|The experimental arm will enroll in a 6-month, twice-weekly, home-based, remotely monitored exercise training program, the emphasis of which will be to improve musculoskeletal health and function.
62191684|NCT05090189|NO_INTERVENTION|Control|The control group will receive standard medical care.
62191685|NCT02168322|EXPERIMENTAL|collagen membranes|collagen barrier that help in isolating unwanted tissues in periodontal regneration
62191686|NCT06016699||Chemoradiation with protons|HNSCC patients treated with standard-of-care chemoradiation with protons.
62191687|NCT06016699||Chemoradiation with photons|HNSCC patients treated with standard-of-care chemoradiation with photons.
62191688|NCT06016699||Radiation with protons|HNSCC patients treated with standard-of-care radiation with protons.
62191689|NCT06016699||Radiation with photons|HNSCC patients treated with standard-of-care radiation with photons.
62191690|NCT04569019||Health care workers|The study will be conducted among UCKWUM healthcare professionals, i.e. doctors, nurses, paramedics, laboratory workers, pharmacists, and administration workers. Based on previous research, the group should include at least 200 participants
62191691|NCT01015677|EXPERIMENTAL|MK-6913 75 mg|MK-6913 75 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 1 and Stage 2)
62191692|NCT01015677|ACTIVE_COMPARATOR|17-β estradiol 1 mg|17β-estradiol 1 mg tablet and matching placebo for MK-6913 75 mg capsule once daily for 4 weeks (Stage 1 and Stage 2)
62397313|NCT03937531|ACTIVE_COMPARATOR|Spontaneous void trial (SVT)|"Subjects will leave the operating room without a urinary catheter. Participants are allowed up to 6 hours after surgery for spontaneous voiding. After voiding, the voided volume will be noted. PVR will be measured using a bladder scanner.~In both groups, if PVR \>=100 mL on a bladder scanner, an indwelling urinary catheter will be placed and the actual PVR will be documented. Subjects who failed voiding trial will be instructed to return to clinic within 2-4 days for the second void trial. Prophylactic antibiotics will NOT be given. The time to discharge will be measured for each subject. This will be determined by calculating the time between arrival to the PACU and the time of discharge using documentation from EPIC."
62397314|NCT04392531|ACTIVE_COMPARATOR|Group A (control)|The control group will consist on the standard treatment that patients will receive according to hospital standard of care protocol.
62397315|NCT04392531|EXPERIMENTAL|Group B (experimental)|The experimental group will consist on cyclosporine added to the standard treatment that patients will receive according to hospital standard of care protocol.
62397316|NCT06005792|EXPERIMENTAL|Plaque Psoriasis|
62397317|NCT06005792|EXPERIMENTAL|Atopic Dermatitis|
62191693|NCT01015677|PLACEBO_COMPARATOR|Placebo|Matching placebo for MK-6913 75 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 1 and State 2)
62191694|NCT01015677|EXPERIMENTAL|MK-6913 25 mg|MK-6913 25 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 2)
62191695|NCT01798342|ACTIVE_COMPARATOR|Maltodextrin|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin
62191696|NCT01798342|EXPERIMENTAL|Glutamine|The same volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of glutamine
62572698|NCT02535767|EXPERIMENTAL|C: PQ in G6PDd|A single dose of primaquine in G6PD-deficient men, exact dose to be decided by DSMB based on findings in previous dose group. The minimum change in dose from the last study dose is 0.05 mg/kg, and the maximum change is 0.20 mg/kg of primaquine). Dose is not to exceed 0.75 mg/kg primaquine.
62572699|NCT02535767|EXPERIMENTAL|D: PQ G6PDn|A single dose of primaquine in G6PD-normal men, at the highest tolerable dose determined by the DSMB, from previous dose groups.
62572700|NCT06510270|ACTIVE_COMPARATOR|Symptomatic heart failure|Patients with clinical manifictations of heart failure but preserved ejection fraction by echocardiography.
62191697|NCT03810651|OTHER|Renal tumors|Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care. Patients may receive an investigation drug for Wilms or CCSK given concurrently or within the first four weeks of the first fraction of proton therapy administration.
62191698|NCT04646369|ACTIVE_COMPARATOR|"screening as usual"|"Participants in the screening as usual' group will have a symptoms scores report of results sent to their provider based on their Screening Wizard responses."
62191699|NCT04646369|EXPERIMENTAL|Screening Wizard 2.0|Participants in the Screening Wizard 2.0 Report group will have a symptoms scores report of results and treatment preferences, barriers, and recommendations sent to their provider based on their Screening Wizard responses.
62191700|NCT04646369|EXPERIMENTAL|Screening Wizard 2.0 + SOVA|Participants in the Screening Wizard 2.0 + SOVA group will have a symptoms scores report of results and treatment preferences, barriers, and recommendations sent to their provider based on their Screening Wizard responses. This group will also receive access to the SOVA website aimed at addressing perceptions about mental health providing support to teens through peer interaction.
62191701|NCT01368237||Patients|Patients awaiting invasive coronary angiography
62191702|NCT05261412|ACTIVE_COMPARATOR|Standard Consent (Control)|Standard consent (written patient information leaflet (PIL) + verbal discussion with the responsible surgeon) for EVTA followed by signing of consent.
62191703|NCT05261412|EXPERIMENTAL|Digital health education tool (dHET)|dHET for EVTA + verbal discussion with the responsible surgeon followed by signing of consent.
62191704|NCT05038553||Patients with early rheumatoid arthritis|
62191705|NCT04751682|EXPERIMENTAL|BBV154: Single Dose|Group 1 (Single dose group): In this group, 70 participants will be recruited and administered with vaccine (BBV154) on day 0 and with placebo on day 28 via intranasal route.
62191706|NCT04751682|EXPERIMENTAL|BBV154: Two Dose|Group 2 (Two-dose group): In this group, 70 participants will be recruited and administered with vaccine (BBV154) on both day 0 and on day 28 via intranasal route.
62191707|NCT04751682|PLACEBO_COMPARATOR|Placebo|Group 3 (Placebo): In this group, 35 participants will be recruited and administered with placebo on both day 0 and day 28 via intranasal route.
62572701|NCT06510270|PLACEBO_COMPARATOR|Asymptomatic Diastolic dysfunction|Patients with diastolic dysfunction grade II or more by Echocardiography but with out any heart failure manifictation.
62572702|NCT02254590|EXPERIMENTAL|IEDL|Endoscopic decompression of spinal stenosis
62572703|NCT03956563|ACTIVE_COMPARATOR|Active treatment arm|Youlaser MT: sequential 10600+1540 nm with vaginal (2 passes) and intritus (1 pass) treatment
62191708|NCT02153905|EXPERIMENTAL|Phase 1 - Dose Escalation/De-Escalation|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MAGE-A3- A1 transduced peripheral blood lymphocytes (PBL) + high-dose aldesleukin
62191709|NCT02153905|EXPERIMENTAL|Phase II - Maximum Tolerated Dose|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MAGE-A3- A1 transduced peripheral blood lymphocytes (PBL) + high-dose aldesleukin
62191710|NCT03050190|EXPERIMENTAL|Therapeutic 4SCAR19 cells|Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.
62572704|NCT03956563|SHAM_COMPARATOR|Control arm|Youlaser MT: no laser emission with vaginal (2 passes) and intritus (1 pass) treatment
62572705|NCT01672541|EXPERIMENTAL|Dating Matters Comprehensive Approach|Schools randomly assigned to the comprehensive approach will: implement 6th, 7th, and 8th grade student curricula in English to all the students in these grades; offer parent programs for parents of 6th, 7th, and 8th graders;implement a communications campaign involving brand ambassadors, a text message campaign, and social media campaign;encourage all educators to take an online training about teen dating violence for educators;be supported in assessing and informing local school or community policies relevant to teen dating violence.
62572706|NCT01672541|ACTIVE_COMPARATOR|Standard of Care Safe Dates Approach|Schools randomly assigned to the standard of care approach will implement Safe Dates as it is published in their schools 8th grade classes.
62572707|NCT05868330|ACTIVE_COMPARATOR|Interscalene Catheter|One of the current standard of care for shoulder replacement surgery at our institution is to receive an interscalene catheter for pre-operatively
62191711|NCT04737837||children|Children aged 4\~16 years with focal onset seizures
62191712|NCT04737837||Adult|Adults aged \>16 years with focal onset seizures
62191713|NCT00813982|EXPERIMENTAL|Experimental Lotrafilcon A Contact Lens|Lotrafilcon A experimental contact lens randomly assigned to one eye
62572708|NCT05868330|ACTIVE_COMPARATOR|Exparel Single Shot Interscalene Block|One of the current standard of care for shoulder replacement surgery at our institution is to receive a pre-operative single shot interscalene block with Exparel
62572709|NCT06296758|EXPERIMENTAL|SIFI local anesthesia|Subjects randomized to the SiFi arm will have an ultrasound-guided suprainguinal fascia iliaca single shot block performed preoperatively in the anesthesia block room with 40ml of 0.2% ropivacaine local anesthetic. This will be reduced to 30 ml in patients under 60 kg.
62006098|NCT06236958||Transnasal jejunal tube enteral nutrition group|Naso-jejunal tube was placed to the distal 15cm of Traitz ligament during the operation; short peptide enteral nutrient solution was heated by enteral nutrition pump and infused slowly and continuously 24 hours after the operation; during the period of infusion, the gastrointestinal tolerance of the patients was evaluated dynamically, and attention was paid to the absence of abdominal pain, diarrhea, constipation, vomiting, regurgitation, and misaspiration. According to the results of regular review of nutritional indicators, including hemoglobin, albumin, electrolytes, liver and kidney function, etc., increase the dosage of enteral nutrients in patients in appropriate amounts; patients with no abdominal distension after exhaustion and fluid intake, that is, the removal of nasojejunal tube, and replaced by oral intake of food.
62191714|NCT00813982|ACTIVE_COMPARATOR|Commercial Lotrafilcon A Contact Lens|Lotrafilcon A commercial contact lens randomly assigned to one eye
62191715|NCT00564148|EXPERIMENTAL|A,1, II|
62572710|NCT06296758|ACTIVE_COMPARATOR|FNB local anesthesia|Subjects randomized to the FNB arm will have an ultrasound-guided femoral nerve single shot block performed preoperatively in the anesthesia block room with 20ml of 0.5% ropivacaine local anesthetic. This will be reduced to 15ml in patients under 60 kg.
62191716|NCT04596176|NO_INTERVENTION|Business As Usual|Families who were involved in the child welfare services
62191717|NCT04596176|ACTIVE_COMPARATOR|Intensive Supportive Housing for Families|Families who were randomly assigned in this group
62780653|NCT04798716|EXPERIMENTAL|Escalating Dose Second Cohort|"Second Cohort:~Five patients will receive an escalating dose every other day for a period of 5 days, with a minimum of 24 hours between doses recorded. Dose escalation will begin at 4 x 10\^9 exosomes."
62780654|NCT04798716|EXPERIMENTAL|Escalating Dose Third Cohort|Five patients will receive a treatment dose of 8 X 10\^9 exosomes every other day for a period of 5 days, with a minimum of 24 hours between doses recorded.
62191718|NCT04596176|ACTIVE_COMPARATOR|Program Supportive Housing for Families|Families who were randomly assigned in this group
62191719|NCT02600078|ACTIVE_COMPARATOR|Moderate Hypoxia|Subjects will be exposed to moderate hypoxia and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
62191720|NCT02600078|SHAM_COMPARATOR|Sham|Subjects will be exposed to sham and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
62191721|NCT02600078|ACTIVE_COMPARATOR|Mild Hypoxia|Subjects will be exposed to mild hypoxia and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
62191722|NCT05956067|EXPERIMENTAL|Equal energy white stimulus|Equal energy white light at 500 lux. The International Commission on Illumination (CIE) coordinates of this light are (x=y=0.33), indicating that the stimulus appears uniformly white which means that the activation of each of the three classes of photoreceptors are equivalent, thus silencing any chromatic opponency. The stimulus will be delivered by a portable battery-operated ganzfeld light stimulation device for 2 hours per day for 5 consecutive days.
62191723|NCT05956067|EXPERIMENTAL|Green light stimulus|Green light at 500 lux. Participants will view 545 nm green light delivered via a portable battery-operated ganzfeld light stimulation device for 2 hours per day for 5 consecutive days.
62191724|NCT05956067|EXPERIMENTAL|S-cone modulating white light|The S-cone modulating light stimulus will alternate between two light conditions at 500 lux that will activate the S-cones by about 100x differentially between the two conditions while maintaining the L- an M-cones at constant activation between the two alternating conditions using 427 nm versus 545 nm light. The stimulus will be delivered by a portable battery-operated ganzfeld light stimulation device for 2 hours per day for 5 consecutive days.
62191725|NCT03634397|EXPERIMENTAL|Less-Impaired Arm Training|Intervention condition includes therapy of the less-impaired (ipsilesional) arm.
62191726|NCT03634397|SHAM_COMPARATOR|Contralesional Arm Comparison|Comparison control condition includes therapy of the paretic (contralesional) arm.
62780655|NCT04798716|PLACEBO_COMPARATOR|Treatment Dose Fourth Cohort Randomized control ratio 1:3|"Fourth Cohort:~Randomized Cohort Up to 40 patients may be enrolled in this phase of the trial. For those receiving the placebo (\~25%), 3 doses will be given over the 5 day period, dispensed from identical vials with physician and patient blinded. The full dose of 8 X 10\^9 exosomes will be given to 75% of the patients in 3 doses over the course of 5 days, with one dose occurring every other day."
62780656|NCT01407445|PLACEBO_COMPARATOR|Placebo|1 tablet of placebo/ oral/ 3 times a day for three months
62780657|NCT01407445|ACTIVE_COMPARATOR|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for three months
62214737|NCT03237572|EXPERIMENTAL|Arm B: 1st dose of pembrolizumab before HIFU|Pembrolizumab (200 mg) intravenously, days 1, 22, 43, 64, followed by day 1 of each ensuing 3 -week cycle. Focused ultrasound tumor ablation day 15. High-intensity focused ultrasound ablation will target 50% of the tumor, up to 3 cubic centimeters.
62397318|NCT06379854|EXPERIMENTAL|chest physiotherapy|we take 2 groups in one group only chest physiotherapy introduce
61977960|NCT05491330|ACTIVE_COMPARATOR|R reference (second dose)|Reference drug (Paxlovid) Nirmatrelvir 150 mg + Ritonavir 100 mg tablets
62191727|NCT02755129|OTHER|single arm|"Single arm, all the patients enrolled will perform the same walking exercises.~On arrival to the rehabilitation center subjects will have the Reveal LINQ, the 3D-accelerometers (one on the chest by medical-grade adhesives and a second at the level of the waist over the top of a medical grade adhesive) and the Holter attached externally. Then, they will be asked to perform the following exercises:~* Walking Exercises-4 Meter Gait Speed (4MGS) Test Walking exercises - Six Minute Walk (6MW) Test~* Walking exercises - 4 Meter Gait Speed (4MGS) Test~* Walking Exercises - Five Times Sit to Stand (FTSTS) Test~* Walking Exercises - Expanded Timed Get-Up-and-Go (ETGUG) Test"
62006099|NCT06236958||Transvenous parenteral nutrition group|Nutrient solution was evenly titrated starting 24 hours after surgery. Configuration of nutritional solution: glucose and medium/long-chain fat emulsion as the main energy substances to provide calories, diabetic patients depending on the blood glucose level to adjust the pancreatic glucose ratio, and then assisted by subcutaneous injection of insulin to control blood glucose, if necessary, pay attention to the total amount of rehydration fluids, electrolytes, vitamins and micronutrient supplementation. Nutritional solution was evenly mixed in the laminar flow clean table and infused through the intravenous route, and oral feeding was started after exhaustion.
62780658|NCT03546088|EXPERIMENTAL|awake naso-tracheal intubation|The patients with obstructive oro and hypo-pharynx tumours will have their airway secured through awake fiberoptic naso-tracheal intubation with light sedation and topical anaesthesia with lidocaine. The sedation will be provided in small boluses until the desired level will be achieved not exceeding 0.05 mg/kg of midazolam and 3 mcg/kg fentanyl. The dose of lidocaine will be to a maximum of 7 mg/kg. The reinforced intubating tube will be lubricated with lidocaine gel.
62191728|NCT00508495|EXPERIMENTAL|Test drug|
62006100|NCT01743092|OTHER|Tutorial Workbook|Tutorial Workbook Group only receives a Tutorial Workbook Group
62006101|NCT01743092|EXPERIMENTAL|Tutorial Workbook Group plus webinar|Tutorial Workbook Group plus webinar will receive in addition, a webinar as an additional resource.
62191729|NCT00508495|ACTIVE_COMPARATOR|Reference drug|
62191730|NCT00508495|PLACEBO_COMPARATOR|Placebo|
61977961|NCT01657279|EXPERIMENTAL|Randomized clinical scenarios|Clinicians are randomized to a sequence of 5 clinical scenarios
61977962|NCT02031731|EXPERIMENTAL|4 mg/kg Onartuzumab (MetMAb)|
62191731|NCT02714712||HCV group (Peginterferon alfa-2a)|A total of 156 chronic HCV genotype 1 or 2 patients who received Peginterferon alfa-2a (Peg-IFN alfa-2a) plus ribavirin therapy were consecutively enrolled from the gastroenterological clinics.
62191732|NCT02714712||Control Group|There were 153 healthy controls negative for anti-HCV enrolled simultaneously from the database of Health Management Center.
62191733|NCT02920840|ACTIVE_COMPARATOR|Intermittent theta-burst stimulation|Intervention: application of 200 TMS triplet bursts (at 100 Hz, inter-burst interval 200ms) over left dorsolateral prefrontal cortex
62780659|NCT01209221|EXPERIMENTAL|1|
62780660|NCT01209221|EXPERIMENTAL|2|
62780661|NCT01209221|PLACEBO_COMPARATOR|3|
62780662|NCT01209221|PLACEBO_COMPARATOR|4|
62780663|NCT05243589|EXPERIMENTAL|group A/ routine physical therapy and proprioceptive training|Routine physical therapy and proprioceptive training is performed
62191734|NCT02920840|EXPERIMENTAL|Negative-peak-triggered-TMS|Intervention: application of 200 brain-state dependent 100 Hz TMS triplet bursts triggered at the negative peak phase of the ongoing endogenous alpha-band oscillation (as detected by surface EEG over left dlPFC)
62780664|NCT05243589|ACTIVE_COMPARATOR|Group B/ routine physical therapy|Routine physical therapy
62191735|NCT02920840|ACTIVE_COMPARATOR|Open-loop replay TMS|"Intervention: application of the same sequence of TMS pulses as in condition Negative-peak-triggered-TMS, i.e. irrespective of ongoing brain state over left dlPFC"
62191736|NCT02904785|EXPERIMENTAL|Extracorporeal Shock Waves|Focused shock waves delivered by an electromagnetic generator with a focus of 5.0cm deep on the affected knee in three different positions. A total of 7000 pulses will be delivered on a weekly session for four weeks.
62191737|NCT02904785|SHAM_COMPARATOR|Sham Extracorporeal Shock Waves|Sham focused shock waves delivered by an electromagnetic generator on the affected knee in three different positions. A total of 7000 pulses will be delivered on a weekly session for four weeks. A foam will be placed in the probe as to stop the energy to be transmitted to the patient's knee, so no focused shockwaves will be delivered.
62780665|NCT01727336|EXPERIMENTAL|Dalantercept 0.9 mg/kg plus axitinib|Subcutaneous (SC) injection of dalantercept 0.9 mg/kg once every 3 weeks and oral axitinib 5 mg BID for continuous dosing.
62191738|NCT04661943|EXPERIMENTAL|Arm A|Chidamide Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)
62191739|NCT06510062|EXPERIMENTAL|SAM Ultrasound Device and Diclofenac Patch 1|Patients receive treatment from the SAM Ultrasonic Diathermy Device 1 hour with 2.5% diclofenac ultrasound gel patch on right forearm. The SAM device emits continuous ultrasound at 3-megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
61977963|NCT02031731|EXPERIMENTAL|15 mg/kg Onartuzumab (MetMAb)|
62780666|NCT01727336|PLACEBO_COMPARATOR|Placebo plus axitinib|Subcutaneous injection of normal saline once every 3 weeks and oral axitinib 5 mg BID for continuous dosing
62780667|NCT01727336|EXPERIMENTAL|Dalantercept 0.6 mg/kg|Part 1 dose escalation arm 0.6 mg/kg dalantercept once every 3 weeks
62780668|NCT01727336|EXPERIMENTAL|Dalantercept 0.9 mg/kg|Part 1 dose escalation arm 0.9 mg/kg dalantercept once every 3 weeks
62191740|NCT06510062|EXPERIMENTAL|SAM Ultrasound Device and Diclofenac Patch 2|Patients receive treatment from the SAM Ultrasonic Diathermy Device 1 hour with 2.5% diclofenac ultrasound gel patch on left forearm. The SAM device emits continuous ultrasound at 3-megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
62780669|NCT01727336|EXPERIMENTAL|Dalantercept 1.2 mg/kg|Part 1 dose escalation arm 1.2 mg/kg dalantercept once every 3 weeks
62780670|NCT01727336|EXPERIMENTAL|Dalantercept 1.5 mg/kg|Part 1 dose escalation arm 1.5 mg/kg dalantercept once every 3 weeks
62780671|NCT03642730|EXPERIMENTAL|Scanned patients|Scanned patients TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors
62780672|NCT03642730|EXPERIMENTAL|Non-expert scanning volunteers|Non-expert scanning volunteers (among the medical staff at the clinical site) TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors
62780673|NCT02013245|EXPERIMENTAL|MTBVAC group 1|Intervention: MTBVAC live vaccine (low dose 5 x 10E03 CFU/0.1mL)
62780674|NCT02013245|EXPERIMENTAL|MTBVAC Group 2|Intervention: MTBVAC live vaccine (middle dose 5 x 10E04 CFU/0.1mL)
62780675|NCT02013245|EXPERIMENTAL|MTBVAC Group 3|Intervention: MTBVAC live vaccine (high dose 5 x 10E05 CFU/0.1mL)
62780676|NCT02013245|ACTIVE_COMPARATOR|BCG Control Group|Intervention: Commercially available BCG live vaccine (dose 5 x 10E05 CFU/0.1mL)
62780677|NCT05433597|PLACEBO_COMPARATOR|Control group|"Chemotherapy: 5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle; Cisplatin: 80mg/m2, used on the 1st and 28th day of each cycle; Q60d; Every 2 months for a treatment cycle, use 2 cycles, a total of 4 months.~Radiotherapy: Radiotherapy was initiated on day 15 of the first cycle of chemotherapy GTV: 6810cGy (227 cGy/30f) Or 6996 cGy (212 cGy/ 33F); CTV: 5400-6000 cGy (180-200 cGy/f); Radiotherapy once a day, 5 times a week, a total of 30-33 times, a total of about 6 weeks.~Placebo: Normal saline 1-2ml, intramuscular injection, QD, 30 days in the first and third months, once a day."
62780678|NCT05433597|ACTIVE_COMPARATOR|Experimental group|"Chemotherapy: 5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle; Cisplatin: 80mg/m2, used on the 1st and 28th day of each cycle; Q60d; Every 2 months for a treatment cycle, use 2 cycles, a total of 4 months.~Radiotherapy: Radiotherapy was initiated on day 15 of the first cycle of chemotherapy GTV: 6810cGy (227 cGy/30f) Or 6996 cGy (212 cGy/ 33F); CTV: 5400-6000 cGy (180-200 cGy/f); Radiotherapy once a day, 5 times a week, a total of 30-33 times, a total of about 6 weeks.~Tianenfu (recombinant human tumor necrosis factor for injection) : 1 million IU (BSA\<2.0m2) or 1.5 million IU (BSA≥2.0m2), dissolved in normal saline 1-2mL, intrascularization, QD, 30 days in the first and third months, once a day."
62780679|NCT05800912|EXPERIMENTAL|Narrative photography group|Students in the NP group performed training activities on empathy and care for patients undergoing heart transplantation.
62780680|NCT05800912|ACTIVE_COMPARATOR|Traditional learning group|Students in the TL group performed a conventional intervention without real patients.
62780681|NCT01534195|EXPERIMENTAL|Prednisolone|Prednisolone Sodium Phosphate Ophthalmic Solution, 1%
62780682|NCT01534195|PLACEBO_COMPARATOR|Placebo|Tears Naturale II Ophthalmic Solution, 1%
62780683|NCT02101489|ACTIVE_COMPARATOR|Intraop Foley catheter measurement|20 women will have intraoperative Foley catheter measurement of the urethral length
62780684|NCT02101489|NO_INTERVENTION|Without intraop Foley cath measurement|20 women without intraoperative Foley catheter measurement of the urethral length
62780685|NCT05763771|EXPERIMENTAL|Part 1|Participants will use the app for 4 weeks, during which participants will follow a smoking schedule on the app to help you reduce your cigarette consumption
61977964|NCT02031731|EXPERIMENTAL|30 mg/kg Onartuzumab (MetMAb)|
61977965|NCT02753101|EXPERIMENTAL|Single Arm|\[18F\]-FTC-146
61977966|NCT01349790|EXPERIMENTAL|NewGam|Each participant received 1 g/kg NewGam intravenously on 2 consecutive days.
61977967|NCT03695562|EXPERIMENTAL|implant placement using sequential drilling|patient with vitamin D deficiency using sequential drilling technique
61977968|NCT03695562|ACTIVE_COMPARATOR|implant placement using single drilling|Patient with vitamin D deficiency using single drilling technique
61977969|NCT02946645|ACTIVE_COMPARATOR|Manual Physiotherapy|TMD patients will treat with orofacial physiotherapy by one expert operator according to literature
61977970|NCT02946645|ACTIVE_COMPARATOR|Neuromuscular Bite|TMD patients will receive an intraoral neuromuscular bite according to literature
61977971|NCT02946645|PLACEBO_COMPARATOR|Placebo|TMD placebo group.
61977972|NCT00671502|EXPERIMENTAL|Carisoprodol 700mg|tablet sustained release (SR)
61977973|NCT00671502|EXPERIMENTAL|Carisoprodol 500mg|sustained release(SR) tablet
61977974|NCT00671502|PLACEBO_COMPARATOR|Placebo|tablet
61977975|NCT06408623|EXPERIMENTAL|Treatment group|
61977976|NCT01182545|PLACEBO_COMPARATOR|The normoventilation group|15 minutes prior to CO2 insufflation, the patients' lungs were ventilated with a tidal volume (TV) of about 8 mL.kg-1 and respiratory rate (R.R) owas adjusted to maintain an end-tidal CO2 (ETCO2) of 4.6-6 kPa throughout the procedure.
61977977|NCT01182545|ACTIVE_COMPARATOR|The hyperventilation group|15 minutes prior to CO2 insufflation, the patients' lungs were ventilated with a TV of 8 mL.kg-1 with the adjustment of the R.R to maintain an ETCO2 of 4-4.6 kPa, until the end of anaesthesia.
61977978|NCT01558830|PLACEBO_COMPARATOR|sugar pill|one pill twice daily, uptitrated to two pills twice daily to mirror ranolazine prescription strategy
62780686|NCT05763771|EXPERIMENTAL|Part 2|"Participants will also use the app for the duration of the study (about 3 months).~Participants will be asked to record your smoking using the app and complete online surveys"
62780687|NCT05852860|NO_INTERVENTION|Usual Care|Clinicians and patients will receive no further interventions beyond usual practice.
62780688|NCT05852860|EXPERIMENTAL|Clinician Nudge|Clinicians will receive a nudge via a Best Practice Alert within the electronic medical record.
62780689|NCT05852860|EXPERIMENTAL|Patient Nudge|Patients will receive a message sent through the patient portal or via text.
62780690|NCT05852860|EXPERIMENTAL|Combined Nudge: Clinician and Patient Nudge|Both the clinician nudge and the patient nudge will be used.
62780691|NCT04048408||Obstructive lung diseases group|
62780692|NCT04048408||Healthy group|
62780693|NCT00873184|OTHER|1|A prospective, single-arm intervention study, potential participants will be identified and screened for eligibility via medical record review of patient scheduled for their post surgical primary adjuvant treatment consultation at DUMC.
62006102|NCT03148548||Patients with iliofermoral thrombosis without rekanalisation|subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did not undergo recanalisation
62191741|NCT06510062|EXPERIMENTAL|SAM Ultrasound Device and SAM Patch 1|Patients receive treatment from the SAM Ultrasonic Diathermy Device 1 hour with standard ultrasound gel patch on right forearm. The SAM device emits continuous ultrasound at 3-megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
62191742|NCT06510062|EXPERIMENTAL|SAM Ultrasound Device and SAM Patch 2|Patients receive treatment from the SAM Ultrasonic Diathermy Device 1 hour with standard ultrasound gel patch on left forearm. The SAM device emits continuous ultrasound at 3-megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
62191743|NCT03758495||Patients with Schizophrenia|Individuals who have been previously diagnosed with schizophrenia and meet our research criteria for symptoms indicative of schizophrenia within their lifetime.
62191744|NCT03758495||Patients with Major Depressive Disorder|Individuals who have been previously diagnosed with major depressive disorder and meet our research criteria for symptoms indicative of major depressive disorder within their lifetime.
62397319|NCT06379854|ACTIVE_COMPARATOR|trunk rotation exercises,deep diaphragmatic also chest physiotherapy|But in 2nd group chest physiotherapy with trunk rotation exercises and deep diaphragmatic breathing exercises alo introduce.
62397320|NCT06567340|EXPERIMENTAL|StratCare|Treatment recommendation made by the StratCare-2 App using stratified care principles.
62397321|NCT06567340|NO_INTERVENTION|Usual Stepped Care|Treatment recommendation made using usual stepped care principles.
62397322|NCT01390376|EXPERIMENTAL|BE 1|DAAOI-1 1g
62397323|NCT01390376|EXPERIMENTAL|BE 2|DAAOI-1 2g
62397324|NCT01390376|PLACEBO_COMPARATOR|starch pill|
62397325|NCT04705259|ACTIVE_COMPARATOR|ENGAGEMENT bundle|A multimodal bundle of interventions to optimise antibiotic prescribing in residential aged care facilities. The bundle includes education for nurses and general practitioners caring for residents, telehealth support and implementation of state-wide guidelines.
62780694|NCT02918357|EXPERIMENTAL|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
61977979|NCT01558830|ACTIVE_COMPARATOR|Ranolazine|500 mg twice daily, titrated to 1000 mg twice daily if needed for relief of anginal symptoms
62780695|NCT01659684|EXPERIMENTAL|standard intravenous immunoglobulin|Single arm evaluation of neurological consequences of congenital CMV infection in comparison with historical untreated controls.
62780696|NCT02403401|EXPERIMENTAL|Levonorgestrel (BAY98-7196)|Vaginal ring containing 170 mg levonorgestrel
62780697|NCT04445337|EXPERIMENTAL|Open Label SGB|Initial perineural bolus injection - clonidine 100 mcg, Decadron PF 5mg, and 0.25% bupivacaine 5 ml will be used for SGB block.
62791803|NCT02717143||Acute myocarditis|"Patients with a clinical picture suggestive of acute myocarditis: increase of troponin above the threshold defined by the pathological laboratory, associated with at least one of the three following criteria:~1. prolonged chest pain \> 10 minutes,~2. recent infectious context \<7 days~3. young subject and / or absence of cardiovascular risk factors and / or absence of significant coronary lesion~Patients will be included after completion of MRI confirm the diagnosis. They will be followed for 3 years, every year, by the doctor who included them in the study.~This is an observational study that does not affect the management of patients."
62006103|NCT03148548||Patients with ilifermoral thrombosis with rekanalisation|subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did undergo recanalisation
62006104|NCT03567863|ACTIVE_COMPARATOR|Group A|"The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)~20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®"
62006105|NCT03567863|ACTIVE_COMPARATOR|Group B|"The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)~22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®"
62006106|NCT00624117|EXPERIMENTAL|A|
62006107|NCT05294705||Autism Spectrum Disorder|During Screening Visits, the Autism Diagnostic Observational Schedule (ADOS) will be administered to confirm diagnosis. Criteria for group inclusion is: diagnosis of Autism Spectrum Disorder based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the Autism Diagnostic Observation Schedule (ADOS-G), Brief Observation of Symptoms of Autism (BOSA), Childhood Autism Rating Scale-2(CARS-2) and the Autism Diagnostic Interview-Revised, short form (ADI-R). Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
62006108|NCT05294705||Typical Development|Typically Developing (TD) participants from each site will be roughly matched by age and sex to the ASD group.
62006109|NCT04341038|EXPERIMENTAL|Intervention|"Methylprednisolone pulses 120mg/day for 3 consecutive days (if they were not previously administered) with Tacrolimus at the necessary dose to achieve plasma levels of 8-10 ng/ml.~In addition, these patients can receive all the treatments considered necessary for their clinical management."
62397326|NCT04705259|PLACEBO_COMPARATOR|Usual care|Usual facility practices with regards to antibiotic prescribing and review
62397327|NCT04111913|EXPERIMENTAL|anlotinib and chemoradiotherapy|"anlotinib: 12 mg, po, qd, on day1-14 of a 21 days cycle; anlotinib will be administrated to 2 cycles for induction before the 2 cycles of chemoradiation and anlotinib will be administrated up to 1year or disease progression for maintenance treatment.~EP regimen: cisplatin 50mg/m2, d1, 8, 29, 36; etoposide 50mg/m2, d1\~5, d29\~33. Radiotherapy program: 2 Gy / time / d, 5 d / week;PTV radiotherapy 60\~66Gy/30\~33 times/6\~7 weeks."
62397328|NCT01559649||Group 1|Veterans admitted to MEDVAMC with a suspected ischemic or hemorrhagic stroke will be recruited. Individuals with a history of neurological disease other than stroke, head and neck structural surgery, or history of dysphagia unrelated to the current stroke will be excluded from participation. Individuals who are obtunded, medically unstable, greater than 5 days post-admission will be excluded. Patients with language or cognitive deficits who are judged by the attending neurologist to not have capacity to provide informed consent will be eligible to participate, but they must have an authorized representative available within 24 hours of admission to provide consent. Patients will undergo swallowing screening and videofluoroscopic swallowing study to establish validity of screening items
62397329|NCT01559649||Group 2|Stroke ward nurses. The nurses will administer and interpret the swallowing screening items. Speech pathologists will also make blinded, simultaneous interpretations of the screening items. Nurse and speech pathologist interpretation will be used to establish nursing reliability.
62006110|NCT04341038|NO_INTERVENTION|Usual care|These patients can receive all the treatments considered necessary for their clinical management, except cyclosporine and tacrolimus.
62006111|NCT02316717|EXPERIMENTAL|Treatment Arm A|IMM-124E, 600 mg three times daily, orally plus matching placebo
62006112|NCT02316717|EXPERIMENTAL|Treatment Arm B|IMM-124E, 1200 mg three times daily, orally
62006113|NCT02316717|PLACEBO_COMPARATOR|Treatment Arm C|Matching placebo, three times daily, orally
62006114|NCT02310542|EXPERIMENTAL|MARS-SPAD|Patients will receive first the MARS albumin dialysis system and then, in a second time, the SPAD albumin dialysis system.
62006115|NCT02310542|EXPERIMENTAL|SPAD-MARS|Patients will receive first the SPAD albumin dialysis system and then, in a second time, the MARS albumin dialysis system.
62006116|NCT04906434|EXPERIMENTAL|ABSK011 60mg cohort|60mg cohort：1 patient will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, the patient will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.
62006117|NCT04906434|EXPERIMENTAL|ABSK011 120mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
62006118|NCT04906434|EXPERIMENTAL|ABSK011 180mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
62006119|NCT04906434|EXPERIMENTAL|ABSK011 240mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
62191745|NCT03758495||Healthy Controls|Individuals who have not met criteria for a psychiatric disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric disorder.
62397330|NCT05637931||adult polymyositis and dermatomyositis|
62397331|NCT05637931||juvenile dermatomyositis|
62791804|NCT00952393|OTHER|Pharmacokinetic|This single arm examines the pharmaco-kinetics of the release of 3-2,4 dimethoxy-benzilidene anabaseine in a hypomellose sustained release formulation.
62397332|NCT05637931||healthy controls|
62006120|NCT04906434|EXPERIMENTAL|ABSK011 320mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
62006121|NCT04906434|EXPERIMENTAL|ABSK011 400mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
62006122|NCT01470287|EXPERIMENTAL|Arm 1|
62006123|NCT04661345||Septic group|The septic group is composed of patients with prosthetic joint infection mediated by coagulase-negative Staphylococci (CoNS)
62006124|NCT04661345||Aseptic group|The aseptic group is composed of patients with implant failure unrelated to infection.
62191746|NCT02367352|EXPERIMENTAL|Cohort 1 (Dose Escalation Phase)|Alisertib 15 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m\^2, intravenous (IV), on Days 1, 8, and 15 in a 28-day cycle until disease progression or unacceptable toxicity (Up to 22 Cycles).
62780698|NCT04130698|EXPERIMENTAL|Distress Tolerance|"Treatment rationale: RAs will explain that there are 3 (not 2 as in the control) key factors that maintain smoking behavior and excess weight: 1) learned habits, 2) the addictive properties of smoking and food, and 3) a way to manage distress. Therefore, to be effective, an intervention designed to simultaneously treat smoking cessation and weight loss must address all 3 key factors. This condition includes both key factors in the control but introduces the third key factor distress tolerance (DT). Toward that end, modules will include: a values discussion; experiential avoidance; distress tolerance; and mindfulness-based ways to manage distress.~Module 1: Orientation \& ACT; Module 2: Avoidance; Module 3: Cognitive Fusion vs. Defusion; Module 4: Self-As-Context; Module 5: Present-Moment-Awareness; and Module 6: Values and Committed Action."
62780699|NCT04130698|ACTIVE_COMPARATOR|Active Health Control|"Treatment rationale: RAs will explain that there are 2 key factors that maintain smoking behavior and excess weight: 1) learned habits and 2) the addictive properties of smoking and food. Therefore, to be effective, an intervention designed to simultaneously treat smoking cessation and weight loss must address both key factors. Toward that end, modules will include standard treatment on: the dangers of smoking, excess weight, unhealthy diets and sedentariness; the importance of healthy behaviors; and relaxation exercises to manage stress. These are all key aspects of standard treatment for smoking cessation and weight loss.~Module 1: Orientation and Health; Module 2: Game Plan; Module 3: Stress and Coping Strategies; Module 4: Physical Activity; Module 5: Changes in Activities, Habits and Lifestyle; and Module 6: Long-Term Rewards."
62780700|NCT03668093|EXPERIMENTAL|ICCMS|Intervention
62780701|NCT03668093|ACTIVE_COMPARATOR|CAMBRA|Comparator
62006125|NCT01670357|EXPERIMENTAL|DA-6034 Low dose|DA-6034 3%
62006126|NCT01670357|EXPERIMENTAL|DA-6034 High dose|DA-6034 5%
62006127|NCT01670357|PLACEBO_COMPARATOR|Placebo|DA-6034 Placebo
62191747|NCT02367352|EXPERIMENTAL|Cohort 2 (Dose Escalation Phase)|Alisertib 25 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m\^2, intravenous (IV), on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity. Dose of alisertib will be de-escalated to 20 mg if ≥ 2 participants experience a dose limiting toxicity (DLT).
62780702|NCT02331017|EXPERIMENTAL|Bimodal users|"Bilateral-bimodal users with moderate-to-severe hearing loss who use hearing aids for at least 75% of their waking hours.~Administration of Speech perception tests and self-rating questionnaire"
62191748|NCT02367352|EXPERIMENTAL|Dose Expansion Cohort|Alisertib, MTD/RP2D determined in Dose Escalation Phase, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m\^2, IV on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity.
62191749|NCT05794243|EXPERIMENTAL|LY3493269 (Part A)|LY3493269 administered orally as test or reference formulations in participants who are in a fasted state.
62191750|NCT05794243|EXPERIMENTAL|LY3493269 (Part B)|LY3493269 administered orally as test or reference formulations in participants who are either in a fasted or fed state.
62191751|NCT00648687|EXPERIMENTAL|I|this group will receive oral water and glucose prior to eye exam
62191752|NCT00648687|NO_INTERVENTION|II|this group is the control group.
62006128|NCT00084695|EXPERIMENTAL|Regimen A|Patients undergo total body irradiation (TBI) two times daily on days -7 to -4. Patients receive cyclophosphamide IV over 30-60 minutes on days -3 and -2 and anti-thymocyte globulin (ATG) IV over at least 6 hours on days -3 to -1.
62006129|NCT00084695|EXPERIMENTAL|Regimen B (patients who do not receive TBI)|Patients receive oral busulfan 4 times daily on days -8 to -5, and ATG IV over at least 6 hours and melphalan IV over 15-20 minutes on days -4 to -2.
62191753|NCT06486337|EXPERIMENTAL|CMOP±R|All enrolled patients. All patient who signed the consent form for participation to the study.
62006130|NCT00084695|EXPERIMENTAL|Regimen C (patients with Fanconi's anemia/related disorders)|Patients undergo TBI on day -6. Patients receive ATG IV over at least 6 hours and methylprednisolone IV on days -5 to -1 and fludarabine IV over 30 minutes and cyclophosphamide IV over 30-60 minutes on days -5 to -2.
62780703|NCT03249987|OTHER|Electronic bladder diary|Participants will be asked to complete the electronic diary for three days before crossing over to the paper diary. Patients will be asked to record the time and volume of voids, any incontinence or urgency episodes and sleep-wake times. Patients will be asked to complete a short questionnaire regarding their opinions
62780704|NCT03249987|OTHER|Paper bladder diary|Participants will be asked to complete the paper diary for three days before crossing over to the electronic diary. Patients will be asked to record the time and volume of voids, any incontinence or urgency episodes and sleep-wake times. Patients will be asked to complete a short questionnaire regarding their opinions
62780705|NCT05377944|EXPERIMENTAL|BAT2306|Patients will receive subcutaneous treatment of 300 mg BAT2306 (2 injections of 150 mg/1 ml) via PFS at weeks 0, 1, 2, 3, and 4 followed by dosing every 4 weeks, thereafter up to Week 40.
62006131|NCT00084695|EXPERIMENTAL|Regimen D|Patients receive oral or IV busulfan 4 times daily on days -9 to -5, ATG IV over at least 6 hours on days -5 to -3, and cyclophosphamide IV over 30-60 minutes on days -5 to -2.
62191754|NCT04330690|EXPERIMENTAL|Artesunate|Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care
62191755|NCT04330690|EXPERIMENTAL|Imatinib|Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care
62780706|NCT05377944|ACTIVE_COMPARATOR|EU-approved Cosentyx|Patients will receive subcutaneous treatment of 300 mg EU-approved Cosentyx (2 injections of 150 mg/1 ml) at weeks 0, 1, 2, 3, and 4 followed by dosing every 4 weeks, thereafter up to Week 40.
62780707|NCT05406869|EXPERIMENTAL|pulsed sonic balloon dilatation catheter and pulsed sonic generater|All subjects will receive treatment from the pulsed sonic balloon dilatation catheter
62780708|NCT05329064|OTHER|10mcg of BNT162b2 (Pfizer-BioNTech/Comirnaty®)|10mcg of BNT162b2 (Pfizer-BioNTech/Comirnaty®) for each dose. Two doses will be given at 2 months apart between doses.
62780709|NCT03235089|ACTIVE_COMPARATOR|Test lens|Each subjects will wear a test lens in one eye and the control lens in the other as an unmatched pair, per predetermined randomization schedule (to determine which eye receives test/control lens).
62780710|NCT03235089|ACTIVE_COMPARATOR|nelfilcon A lens (control)|Each subjects will wear a test lens in one eye and the control lens in the other as an unmatched pair, per predetermined randomization schedule (to determine which eye receives test/control lens).
62780711|NCT01563172|EXPERIMENTAL|Experimental dentifrice 0.5g, 45 seconds brushing group|Participants brush twice a daily for 45 seconds with experimental dentifrice.
62780712|NCT01563172|EXPERIMENTAL|Experimental dentifrice 1.5g, 45 seconds brushing group|Participants brush twice a daily for 45 seconds with experimental dentifrice.
62780713|NCT01563172|EXPERIMENTAL|Experimental dentifrice 0.5g, 2 minutes brushing group|Participants brush twice a daily for 2 minutes with experimental dentifrice.
62780714|NCT01563172|EXPERIMENTAL|Experimental dentifrice 1.5g, 2 minutes brushing group|Participants brush twice a daily for 2 minutes with experimental dentifrice.
62780715|NCT01563172|ACTIVE_COMPARATOR|Contol group|Participants brush twice a daily for 2 minutes with controll dentifrice.
62780716|NCT05788913|ACTIVE_COMPARATOR|Reference Drug|Healthy participants using intravenous Heparin Sodium Injection, USP (Fresenius Kabi) to assess the pharmacodynamic profile
62780717|NCT05788913|EXPERIMENTAL|Test Drug|Healthy participants using intravenous Heparin Test to assess the pharmacodynamic profile
62780718|NCT06276166||Older adults|Older adults without clear diagnosis of any type of dementia, neurological diseases, and mental disorders that affecting cognitive function.
62780719|NCT02470884|EXPERIMENTAL|FAST|Subjects treated with the Boston Scientific Fully Absorbable Scaffold
62780720|NCT02077400|NO_INTERVENTION|no antibiotic|
62780721|NCT02077400|ACTIVE_COMPARATOR|Cephazolin|cefazoline
62780722|NCT03513627||Implant|Post-occlusive reactive hyperaemia test (PORH test) in the gingiva at a dental implant born crown in the front region of the jaw
62780723|NCT03513627||Tooth|Post-occlusive reactive hyperaemia test (PORH test) in the gingiva at the contralateral natural tooth
62780724|NCT04981210||suspect LOPD|
62780725|NCT06175624|ACTIVE_COMPARATOR|Clinical Healthy|Our study will include 25 people with clinically healthy patients.
62780726|NCT06175624|EXPERIMENTAL|Gingivitis|Our study will include 25 people with gingivitis patients.
62006132|NCT03447171||Refractive Error|
62191756|NCT04330690|EXPERIMENTAL|Infliximab|Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care
62191757|NCT04330690|EXPERIMENTAL|Dexamethasone|Subjects will be randomized between Dexamethasone vs standard of care.
62780727|NCT06175624|EXPERIMENTAL|Periodontitis|Our study will include 25 people with periodontitis patients.
62780728|NCT02854748|EXPERIMENTAL|Empagliflozin / Lobeglitazone / Empa.+Lobe.|Period 1: Empagliflozin 25 mg QD for 5 days Period 2: Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days
62780729|NCT02854748|EXPERIMENTAL|Empagliflozin / Empa.+Lobe. / Lobeglitazone|Period 1: Empagliflozin 25 mg QD for 5 days Period 2: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 3: Lobeglitazone 0.5 mg QD for 5 days
62780730|NCT02854748|EXPERIMENTAL|Lobeglitazone / Empagliflozin / Empa.+Lobe.|Period 1: Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg QD for 5 days Period 3: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days
62780731|NCT02854748|EXPERIMENTAL|Lobeglitazone / Empa.+Lobe. / Empagliflozin|Period 1: Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg QD for 5 days
62191758|NCT04330690|EXPERIMENTAL|LSALT Peptide|Subjects will be randomized between LSALT vs standard of care.
62191759|NCT04330690|NO_INTERVENTION|Control (Standard Care)|This arm will receive standard supportive care guidelines for COVID-19. It is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
62191760|NCT00662922||1|patients with hypoglycemia during intensive care
62191761|NCT00662922||2|patients without hypoglycemia during intensive care
62191762|NCT05302245||Caregivers of ABI survivors|Unpaid caregivers of acquired brain injury survivors living in Nova Scotia
62191763|NCT02968238|ACTIVE_COMPARATOR|CBT preference arm|CBT preference arm consists of participants who are randomized to the preference condition and choose to receive cognitive-behavioral therapy (CBT). CBT consists of 10 weeks of weekly treatment.
62191764|NCT02968238|ACTIVE_COMPARATOR|Yoga preference arm|Yoga preference arm consists of participants who are randomized to the preference condition and choose to receive yoga. Yoga consists of 10 weeks of bi-weekly treatment (total = 20 treatments).
62572711|NCT00728260||Menactra Vaccine Recipients|"Children 2 years through 10 years of age who received Menactra vaccine within Kaiser Permanente during the study period. They served as their own controls for evaluation of acute (Days 0-30) events. Rates of events occurring during Days 0-30 following vaccination were compared to rates of events occurring during Days 31-60 following vaccination.~Six-month surveillance: For each individual receiving Menactra vaccine, the rate of an event in the 30-day follow-up period was compared with the rate of the same event in the 31-180-day follow-up period using age, sex, and seasonality as covariates in Cox regression analyses.~Menactra vaccine was administered according to routine clinical practice."
62780732|NCT02854748|EXPERIMENTAL|Empa.+Lobe. / Empagliflozin / Lobeglitazone|Period 1: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg QD for 5 days Period 3: Lobeglitazone 0.5 mg QD for 5 days
62780733|NCT02854748|EXPERIMENTAL|Empa.+Lobe. / Lobeglitazone / Empagliflozin|Period 1: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 2: Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg QD for 5 days
62780734|NCT01979458|EXPERIMENTAL|PSE|Patients whose distal colon is imaged using the PSE device. This is a pilot trial of 30 patients.
62780735|NCT01006642||Healthy controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
62191765|NCT02968238|ACTIVE_COMPARATOR|CBT randomized arm|CBT randomized arm consists of participants who are randomized to the random condition and are randomized to receive cognitive-behavioral therapy (CBT). CBT consists of 10 weeks of weekly treatment.
62191766|NCT02968238|ACTIVE_COMPARATOR|Yoga randomized arm|Yoga randomized arm consists of participants who are randomized to the random condition and are randomized to receive yoga. Yoga consists of 10 weeks of bi-weekly treatment (total = 20 treatments).
62191767|NCT02250599|ACTIVE_COMPARATOR|carboplatin and paclitaxel|carboplatin and paclitaxel :paclitaxel 175 mg/m2 IV and carboplatin AUC 6 IV on Day 1 of each 3-week cycle
62191768|NCT02250599|EXPERIMENTAL|AVASTIN and carboplatin and paclitaxel|AVASTIN and carboplatin and paclitaxel: Bevacizumab(AVASTIN) 7.5 mg/kg intravenously (IV) infusion on Day 1 of each 3-week cycle; paclitaxel 175 mg/m2 IV and carboplatin AUC 6 IV on Day 1 of each 3-week cycle
62191769|NCT06311643|EXPERIMENTAL|Study group|Postpartum Back Massage is done to puerperal women just after 4 hours of delivery and for 1 month with rate of 3 sessions per week and routine postnatal care
62191770|NCT06311643|NO_INTERVENTION|Control group|Puerperal women just have routine post natal care for 1 month
62191771|NCT06008847||Lower Gastrointestinal Symptoms|Participant aged over 18 with referred lower gastrointestinal symptoms
61977980|NCT00551733|EXPERIMENTAL|Arm I|Patients receive paclitaxel poliglumex IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62191772|NCT00848796|OTHER|Heparin|Compare two market brands of Heparin
62191773|NCT02053883|PLACEBO_COMPARATOR|Placebo|Fibrin sealant only.
62191774|NCT02053883|EXPERIMENTAL|Cethrin (BA-210) - Low Dose|Low dose of Cethrin in a fibrin sealant.
62191775|NCT02053883|EXPERIMENTAL|Cethrin (BA-210) - High Dose|High dose of Cethrin in a fibrin sealant.
62780736|NCT01006642||Functional dyspepsia-EPS|Functional dyspepsia-EPS(epigastric pain syndrome) Patients admitted to outpatient department with symptoms meeting ROME III criteria
62780737|NCT01006642||Functional dyspepsia-PDS|Functional dyspepsia-PDS(postprandial distress syndrome) Patients admitted to outpatient department with symptoms meeting ROME III criteria
62780738|NCT03483545|EXPERIMENTAL|Follitropin delta and HP-hMG|Follitropin delta combined with highly purified human menopausal gonadotrophin
62780739|NCT03360058|EXPERIMENTAL|Immediate access to STBD training|Immediate access to training materials and print pieces to support implementation
62780740|NCT03360058|PLACEBO_COMPARATOR|Delayed access to STBD training|Delayed access to training materials and print pieces
62780741|NCT00837850|ACTIVE_COMPARATOR|1|
62780742|NCT00837850|ACTIVE_COMPARATOR|2|
62780743|NCT05134480|ACTIVE_COMPARATOR|Cornea from donor with diabetes|Participant will be assigned a cornea recovered from a donor with diabetes.
62780744|NCT05134480|ACTIVE_COMPARATOR|Cornea from donor without diabetes|Participant will be assigned a cornea recovered from a donor without diabetes.
62780745|NCT00901121|EXPERIMENTAL|BoneCeramic|Straumann BoneCeramic is a fully synthetic bone graft substitute of medical grade purity in particulate form composed of biphasic calcium phosphate - a mixture of 60% hydroxylapatite and of 40% of the beta form of tricalcium phosphate (beta-TCP).
62780746|NCT00901121|ACTIVE_COMPARATOR|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
62780747|NCT01453608|EXPERIMENTAL|Ferinject (ferric carboxymaltose)|
62780748|NCT01453608|PLACEBO_COMPARATOR|Placebo (saline)|
62780749|NCT01189591|EXPERIMENTAL|Sleep deprivation|Slow-wave sleep deprivation for one night as an experimental treatment for major depressive disorder
62780750|NCT04341948|ACTIVE_COMPARATOR|Group 1 (Treatment)|Participants in Group 1 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
62572712|NCT03152877|EXPERIMENTAL|Liposomal bupivacaine treatment group|20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, in subjects in the experimental arm, following completion of the surgical repair.
62780751|NCT04341948|SHAM_COMPARATOR|Group 2 (Control)|Participants in Group 2 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Participants will then have the option to crossover and receive stimulation therapy.
62780752|NCT04369950|ACTIVE_COMPARATOR|2 percent Lidocaine with epinephrine and epidural morphine|
62780753|NCT04369950|EXPERIMENTAL|3 percent 2-Chloroprocaine and epidural morphine|
62780754|NCT04369976|EXPERIMENTAL|SHORT ARM HUMAN CENTRIFUGE|SHORT ARM HUMAN CENTRIFUGE IN COMBINATION WITH EXERCISE INTERMITTENT CENTRIFUGATION TOTAL TIME 30 MINUTES
62572713|NCT03152877|ACTIVE_COMPARATOR|0.25% plain bupivacaine treatment group|20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, in subjects in the active comparator arm, following completion of the surgical repair.
62780755|NCT05194527||Patients with Acute Mesenteric Ischemia|Patients that are diagnosed with Acute mesenteric Ischemia
62006133|NCT02970838|EXPERIMENTAL|Intervention|Patients take part in a structured weight-loss program over 15 weeks including a fasting phase with formula diet over six weeks
62780756|NCT05194527||Patient with another underlying disease/condition|Patients that are diagnosed not with acute mesenteric ischemia, but with a other underlying disease/condition
62780757|NCT01912339|EXPERIMENTAL|Treatment|Treatment: Rezūm System
62780758|NCT01912339|OTHER|Control|Control: Rigid Cystoscopy
62780759|NCT04794075|EXPERIMENTAL|Experimental group with the therapeutic education and nursing support program|In addition to the conventional oncology follow-up, patients will participate in an initial educational assessments day.
62780760|NCT04794075|NO_INTERVENTION|Control group|Patients will have the conventional oncology follow-up.
62780761|NCT05551884||Training cohort|Training cohort was set to develop the novel non-invasive model based on metabolomics technology for HVPG.
62006134|NCT04912024||Tablo Hemodialysis System|Participants who were prescribed acute intermittent renal replacement therapy on the Tablo Hemodialysis System at a dialysate flow rate of 300 mL/min
62006135|NCT04912024||Conventional Hemodialysis System|Participants who were prescribed acute intermittent renal replacement therapy on conventional hemodialysis systems (Non-Tablo) with dialysate flow rates of ≥ 500 mL/min
62780762|NCT05551884||Validation cohort|Validation cohort was set to validate the novel non-invasive model based on metabolomics technology for HVPG.
62780763|NCT01496820|EXPERIMENTAL|GO2KA1|
62780764|NCT01496820|PLACEBO_COMPARATOR|Placebo|
62780765|NCT01423734||MRI|Patients will be consented for a second MRI without additional intravenous contrast, referred to from now on as 'research MRI', to be performed later on the same day as their clinical liver MR examination, on one of two 3.0 Tesla MR 750 GE scanners at the Breast and Imaging Center. The research MRI will consist only of the localizer and diffusion weighted imaging (DWI) sequences, with acquisition parameters identical to our clinical MRI. The reproducibility of DWI is best assessed in separate MR imaging sessions, although the examinations can be performed the same day.
62780766|NCT01704404|EXPERIMENTAL|Dose 1 TD-4208|22 µg
62780767|NCT01704404|EXPERIMENTAL|Dose 2 TD-4208|44 µg
62780768|NCT01704404|EXPERIMENTAL|Dose 3 TD-4208|88 µg
62780769|NCT01704404|EXPERIMENTAL|Dose 4 TD-4208|175 µg
62780770|NCT01704404|EXPERIMENTAL|Dose 5 TD-4208|350 µg
62780771|NCT01704404|EXPERIMENTAL|Dose 6 TD-4208|700 µg
62780772|NCT01704404|PLACEBO_COMPARATOR|Placebo|Placebo
62780773|NCT06339931|EXPERIMENTAL|SMWLM combined Spinal traction with belt|Group A (Spinal traction with belt plus SMWLM) as per Mulligan rule of three SMWLM on affected lumbar vertebrae. Spinal traction with belt for 10 mins.
62780774|NCT06339931|ACTIVE_COMPARATOR|SMWLM combined Spinal traction without belt|Group B (Spinal traction without belt plus SMWLM) as per Mulligan rule of three SMWLM on affected lumbar vertebrae. Manual spinal traction technique without belt.
62780775|NCT04505579||Tether|Patients who have received The Tether HUD for treatment of idiopathic scoliosis.
62572714|NCT06439875|EXPERIMENTAL|L-arginine (arm 1)|Participants in this arm of the study will have an oral supplementation of l-arginine and liposomial vitamin C on a daily basis for 28 days.
62572715|NCT06439875|PLACEBO_COMPARATOR|Placebo (arm 2)|This arm will be given a placebo comparator on a daily basis for 28 days.
62572716|NCT04994340||Children|From a cross-sectional perspective, children will fill out questionnaires related to their subjective physical activity levels (PAQ-C), levels of sedentary activity (YLSBQ), and socio-economic status (Family Affluence Scale III) during school hours. Two sessions of physical education will be used to measure the health-related physical fitness of children through the ALPHA-Fitness battery test. The sequence to administer this battery will be: 1. Weight and height (BMI); 2. Waist circumference; 3. Skin folds; 4. Hand grip strength, long jump with feet together, and 4x10 m shuttle run test (these tests could be carried out alternately or simultaneously since there will always be 2 or more evaluators); 5. 20 m Course Navette test.
62572717|NCT04994340||Adolescents|From a cross-sectional perspective, adolescents will fill out questionnaires related to their subjective physical activity levels (PAQ-A), levels of sedentary activity (YLSBQ), and socio-economic status (Family Affluence Scale III) during school hours. Two sessions of physical education will be used to measure the health-related physical fitness of adolescents through the ALPHA-Fitness battery test. The sequence to administer this battery will be: 1. Weight and height (BMI); 2. Waist circumference; 3. Skin folds; 4. Hand grip strength, long jump with feet together, and 4x10 m shuttle run test (these tests could be carried out alternately or simultaneously since there will always be 2 or more evaluators); 5. 20 m Course Navette test.
62572718|NCT04547985|PLACEBO_COMPARATOR|Placebo|24 randomized patients will take placebo daily for 8 weeks.
62572719|NCT04547985|ACTIVE_COMPARATOR|Naltrexone|24 randomized patients will take naltrexone daily for 8 weeks
62572720|NCT03866512|EXPERIMENTAL|Acipimox ingestion during immobilization|Oral ingestion of Acipimox during 2 days of forearm immobilization
62572721|NCT03866512|EXPERIMENTAL|B-agonist during immobilization|Oral ingestion of salbutamol during 2 days of forearm immobilization
62572722|NCT03866512|PLACEBO_COMPARATOR|Placebo ingestion during immobilization|Oral ingestion of a placebo 2 days of forearm immobilization
62572723|NCT01215591|ACTIVE_COMPARATOR|Gradual wean from Nasal CPAP|Nasal CPAP for gradual wean group it was cycled off for 3 hours alternating with 3 hours on for first 48 hours, if successful the cycle was extended to 6 hours off and 3 hours on for the next 48 hours. If the baby tolerated this regime the prongs were removed and CPAP was kept off.
62572724|NCT01215591|NO_INTERVENTION|Sudden wean from Nasal CPAP|Usual practice to wean the preterm neonates from nasal CPAP
62780776|NCT03750331|ACTIVE_COMPARATOR|traditional patient follow-up|a group of renal transplant outpatients consulting their Transplant Centre following a traditional schedule (every other week up to 6 months post-transplant, once a month up to year 1, every three months up to year 2 and every 6 months thereafter)
62006136|NCT05828628||Patients with a new diagnosis of primary or secondary CNS lymphoma|
62191776|NCT01013961|ACTIVE_COMPARATOR|Arm A (standard dose)|"Patients receive alemtuzumab subcutaneously (SC) on days 1-3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 and standard-dose rituximab 375 mg/m\^2/week intravenously (IV) on days 8, 15, 22, and 29 in cycle 1 (33-day cycle). In cycle 2 and subsequent cycles (28-day cycle), patients receive alemtuzumab SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 and standard-dose rituximab IV on days 3, 10, 17, and 24. Treatment repeats every 28 days for up to 3 cycles.~Alemtuzumab dose for cycle 1 week 1 requires a 'dose ramp' (3 mg day 1, 10 mg day2, and 30 mg day 3 of cycle 1) and then is 30 mg 3 times a week."
62572725|NCT03384030|EXPERIMENTAL|adapted STMST|Participants are subjected to the adapted STMST to induce emotional sweating.
62572726|NCT01945723||Healthy volunteers|Healthy volunteers
62572727|NCT03823170|EXPERIMENTAL|Laser therapy|The low-power, infrared (808nm wavelength) diode laser with a power of 100mW (Therapy EC, DMC) will be used. The mode of irradiation is punctual, in contact and perpendicular to the dental surface. Three points on the crown of multiradicular teeth (mesial and distal of the cervical region and central part of the tooth lesion) and two points on the crown of unirradicular teeth (central point of the cervical region and central part of the tooth lesion) will be irradiated for 10s per point , 1J per point, with a 72-hour interval between treatment sessions. The distance between the irradiation points will be about 2 mm. The tip of the laser equipment will be positioned perpendicular to the application site.
62572728|NCT03823170|ACTIVE_COMPARATOR|Fluorotherapy|The treatment will be carried out with the application of fluoride varnish (Duraphat), with the aid of a microbrush. After the application, water will be dripped onto the applied varnish in order to promote its drying. Fluorotherapy will be performed once a week, totaling 4 sessions.
62572729|NCT03823170|EXPERIMENTAL|Laser therapy and fluorotherapy|The teeth will be treated first with the laser (same specifications as Laser therapy), followed by application of fluoride varnish (same specifications as Fluorotherapy).
62572730|NCT02174510|EXPERIMENTAL|20mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
62572731|NCT02174510|EXPERIMENTAL|40mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
62780777|NCT03750331|EXPERIMENTAL|medically-tailored follow-up with Ap'Telecare|a group of patients assisted by Ap'Telecare and consulting their Transplant Centre following a less stringent schedule of consultations (every month up to 6 months, every other month up to year 1, every six months up to year 2 and once a year thereafter).
62006137|NCT01218997|EXPERIMENTAL|Medisorb naltrexone 380 mg (VIVITROL)|
62780778|NCT06299462|EXPERIMENTAL|Matched-sibling donor transplants|Matched sibling transplants will receive PTCy + ATG2.5 ± ATG1.5
62780779|NCT06299462|EXPERIMENTAL|Matched unrelated donor transplants|Unrelated transplants will receive PTCy + ATG5.0
62006138|NCT01218997|ACTIVE_COMPARATOR|Oral naltrexone 50 mg|
62006139|NCT05241223|SHAM_COMPARATOR|Control group|This group will receive an education program which will cover information regarding asthma, physical activity and sedentary behavior.
62214738|NCT01348568|EXPERIMENTAL|Low glycemic index diet with canola oil bread|Subjects will be given whole wheat bread which includes canola oil, and advised to follow a diabetic diet using low glycemic index foods.
62214739|NCT01348568|ACTIVE_COMPARATOR|high fiber diet|Subjects will be given whole wheat bread, and advised to follow a healthy high fiber diabetic diet.
62780780|NCT01710631|EXPERIMENTAL|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
62780781|NCT01710631|PLACEBO_COMPARATOR|placebo|placebo tablet
62780782|NCT04888013|PLACEBO_COMPARATOR|control group|Routine care for childbirth
61977981|NCT00551733|ACTIVE_COMPARATOR|Arm II|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
61977982|NCT06141590|EXPERIMENTAL|UI068|
61977983|NCT06141590|EXPERIMENTAL|UIC202205, UIC202206|
61977984|NCT03707327|EXPERIMENTAL|Game Ready group|the participants performed cryotherapy by compression with Game Ready
62191777|NCT01013961|EXPERIMENTAL|Arm B (low dose)|"Patients receive alemtuzumab SC on days 1-3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 and low-dose rituximab at 20 mg/m\^2 IV on days 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 in cycle 1 (33-day cycle). In cycle 2 and subsequent cycles (28-day cycle), patients receive alemtuzumab SC and low-dose rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 3 cycles.~Alemtuzumab dose for cycle 1 week 1 requires a 'dose ramp' (3 mg day 1, 10 mg day2, and 30 mg day 3 of cycle 1) and then is 30 mg 3 times a week."
62191778|NCT04816864|ACTIVE_COMPARATOR|ECANS started from the right vagus nerve|superior ECANS and ultrasonography guided inferior ECANS
62191779|NCT04816864|ACTIVE_COMPARATOR|ECANS started from the left vagus nerve|superior ECANS and ultrasonography guided inferior ECANS
62191780|NCT03527641|EXPERIMENTAL|Salud sin Barreras, Health without Barriers|"Salud sin Barreras is a manualized community-delivered program tailored for Latino families and their adolescent children at-risk for type 2 diabetes. Salud sin Barreras is based upon a lifestyle intervention called the Healthy Living Program (HeLP), which includes 6 weekly 2-hour nutrition/cooking sessions and 6 weekly 2-hour Multidisciplinary Sessions that include parent education on nutrition, fitness, goal-setting, parenting, and a brief mindfulness curriculum, a teen group physical fitness class, and a teen mindfulness curriculum called Learning 2 BREATHe. In between sessions, participants are encouraged to practice brief mindfulness skills in their daily lives and to complete the homework assignments, such as an audio-guided body scan. Participants have access to home-practice audio-recordings and will be queried about their completion of home-practice assignments."
62397333|NCT06408103|EXPERIMENTAL|Multi-component, transdisciplinary and multifocal intervention (intercog-group)|"This group will receive a multi-component intervention that includes cognitive training, physical exercise, and nutritional counseling; dually and simultaneously. This intervention will be carried out at the patient's home for 12 weeks, with professional support twice a week plus a recommendation to walk 30 minutes/day.~Furthermore, in the family component, caregivers of the patients will also receive a training component to accompany the intervention and prepare for the caregiver role. This component will be delivered by healthcare professionals in a group format (n=10 per group) over 12 weeks, with weekly sessions lasting 2 hours each. Each session is organized into five parts: opening, activation, education, practice, and explanation of the activities for the next week."
61977985|NCT03707327|EXPERIMENTAL|Ice pack|the participants performed cryotherapy for ice pack
61977986|NCT00820131|EXPERIMENTAL|1|
61977987|NCT00820131|ACTIVE_COMPARATOR|2|
62191781|NCT03527641|ACTIVE_COMPARATOR|La Vida Saludable, Healthy Living|The Health Living Program (HeLP) is a manualized community-delivered program tailored specifically for Latino families and children at-risk for adult obesity. HeLP includes 6 weekly 2-hour nutrition/cooking sessions and 6 weekly 2-hour Multidisciplinary Sessions, that include parent education on nutrition, fitness, goal-setting, and parenting, a teen group physical fitness class, and a teen health knowledge curriculum derived from a health education curriculum called Hey DURHAM.
62191782|NCT02586415|ACTIVE_COMPARATOR|endovascular thrombectomy therapy|"Treatment with one or more thrombectomy devices (only the devices listed in this protocol are approved for use in DEFUSE 3) plus standard medical therapy for patients who have evidence of an ICA or MCA M1 occlusion and a Target Mismatch Profile.~Devices approved for use in DEFUSE 3:~* Trevo Retriever~* Solitaire™ FR Revascularization Device~* Penumbra thrombectomy system~* Covidien MindFrame Capture Revascularization Device"
62191783|NCT02586415|NO_INTERVENTION|Medical Management|standard medical therapy alone
62191784|NCT03060018|EXPERIMENTAL|All included patients|All included patients will undergo the intervention of transcutaneous sensor placement
62191785|NCT01508637|EXPERIMENTAL|Diesel Exhaust + Terazosin|
62191786|NCT01508637|EXPERIMENTAL|Diesel Exhaust + placebo|
62191787|NCT01508637|SHAM_COMPARATOR|Filtered Air + terazosin|
62191788|NCT01508637|SHAM_COMPARATOR|Filtered air + placebo|
62191789|NCT03005990|EXPERIMENTAL|Exercise training group|Exercise group will attend a supervised aerobic plus resistance exercise training class 3 times a week totally for 24 weeks.
62191790|NCT03005990|NO_INTERVENTION|Control group|Control group only provide standard outpatient care program.
62214740|NCT04135690|EXPERIMENTAL|HAIC plus toripalimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Toripalimab 240mg intravenously every 3 weeks.
62214741|NCT04135690|ACTIVE_COMPARATOR|HAIC plus sorafenib|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Sorafenib 400mg twice daily (Bid) oral dosing.
62397334|NCT06408103|NO_INTERVENTION|Usual care plus active control|The conventional management of patients with mild cognitive impairment focuses on therapies such as cognitive rehabilitation, occupational therapy, and physical exercise, with medical monitoring as needed according to the patient's needs. Additionally, they will receive information about infectious diseases such as dengue, pneumonia, tuberculosis, Chagas disease, leishmaniasis, COVID-19, leprosy, urinary tract infection, rabies, superficial and cutaneous mycoses, and hepatitis one topic per week through an infographic and video sent to the cell phone.
62397335|NCT02500732|PLACEBO_COMPARATOR|Placebo|Placebo capsule to be given the night before the study tilt, and the morning of the study tilt test.
62780783|NCT04888013|EXPERIMENTAL|experimental 2|Building childbirth environment
62780784|NCT04888013|EXPERIMENTAL|experimental 1|Building childbirth environment and labor delivery recovery room
61977988|NCT01575496|ACTIVE_COMPARATOR|Active tDCS|Subjects will receive 20 minutes of active tDCS.
61977989|NCT01575496|SHAM_COMPARATOR|Sham tDCS|Subjects will receive 20 minutes of sham tDCS.
62191791|NCT02043834|EXPERIMENTAL|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
62191792|NCT02043834|NO_INTERVENTION|Control|The control group will keep their normal activity without receiving any intervention.
62191793|NCT02347995|PLACEBO_COMPARATOR|Resistive Training|Participants will drink a placebo beverage after each resistance training session.
62191794|NCT02347995|EXPERIMENTAL|Resistive Training + Protein|Participants will drink 30 grams of whey protein after each resistance training session.
62191795|NCT02891642||Malignancy, Serous effusion|Analysis of serous effusion through immunomagnetic detection device
62191796|NCT00475644|EXPERIMENTAL|Enzastaurin|Enzastaurin: 1125 milligram (mg) loading dose then 500 mg, oral daily, up to 3 years
62191797|NCT01536587|OTHER|Single Arm|Inhalation of salmeterol 50 µg twice daily over 4 weeks
62397336|NCT02500732|ACTIVE_COMPARATOR|Atomoxetine|Atomoxetine 40mg PO to be given the night before the study tilt, and the morning of the study tilt test.
62397337|NCT06403540||diaphragm contraction fraction|Diaphragm muscle contraction fraction measured before and after surgery
62191798|NCT01288209|EXPERIMENTAL|TMC435 100 mg 12 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment will be stopped at Week 24 if participants achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \< 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
62191799|NCT01288209|EXPERIMENTAL|TMC435 100 mg 24 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin ( PR) for 24 weeks (Wks). Treatment will be stopped at Week 24 if participants achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \< 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
62191800|NCT01265043|EXPERIMENTAL|OHI|Patients provided with oral hygiene instruction and electric toothbrush
62397338|NCT06429722|EXPERIMENTAL|NMRA-335140 80 milligrams (mg) once daily (QD)|Participants will receive a NMRA-335140 tablet at a dose of 80 mg QD.
62397339|NCT06429722|PLACEBO_COMPARATOR|Placebo|Placebo participants will receive matching placebo tablet once daily.
62397340|NCT02226276|EXPERIMENTAL|Diagnostic (copper Cu 64-DOTA-trastuzumab PET)|Patients undergo whole body fludeoxyglucose F 18 PET/CT. Patients then receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV and then undergo PET scans at 24 and 48 hours. Patients then receive ado-trastuzumab emtansine IV every 3 weeks until complete response or disease progression at the discretion of the treating oncologist. Patients undergo restaging by whole body fludeoxyglucose F 18 PET/CT every 6 weeks after initiation of treatment until disease progression.
62397341|NCT05998304|EXPERIMENTAL|[14C] Yiqibuvir|Eligible healthy male subjects received a single oral 600 mg (radioactivity of 100µCi) dose of \[14C\] Yiqibuvir
62397342|NCT01111058|EXPERIMENTAL|Everolimus (RAD001)|Subjects will receive Everolimus 10 mg daily
62397343|NCT01111058|EXPERIMENTAL|Placebo|Subjects will receive double-blind placebo
62191801|NCT01265043|EXPERIMENTAL|OHI + CHX mouthrinse|Patients provided with oral hygiene instruction and Corsodyl mouthrinse
62191802|NCT01265043|EXPERIMENTAL|OHI + CHX mouthrinse + assisted brushing|Oral hygiene instruction, Corsodyl mouthrinse, and assisted brushing
62397344|NCT06108531||pancreatic patients|Cases will be the patients with newly-diagnosed pancreatic.
62397345|NCT06108531||The controls|Controls will be selected from patients with pancreatitis from the same hospital as the case, matched by gender, race and age (1:1).
62397346|NCT04056325|EXPERIMENTAL|Phase 2a - Arm A|2 mg Moxidectin at day 0 administered orally
62397347|NCT04056325|EXPERIMENTAL|Phase 2a - Arm B|4 mg Moxidectin at day 0 administered orally
62397348|NCT04056325|EXPERIMENTAL|Phase 2a - Arm C|6 mg Moxidectin at day 0 administered orally
62397349|NCT04056325|EXPERIMENTAL|Phase 2a - Arm D|8 mg Moxidectin at day 0 administered orally
62780785|NCT03420833|EXPERIMENTAL|CRT-On first, then CRT-Off|Subjects will be randomized to have the cardiac resynchronization therapy pacemaker (CRT-P) programmed on in the first intervention period, and after six months the CRT function will be turned off in the second intervention period.
62780786|NCT03420833|EXPERIMENTAL|CRT-Off first, then CRT-On|Subjects will be randomized to have the cardiac resynchronization therapy pacemaker (CRT-P) programmed off in the first intervention period, and after six months the CRT function will be turned on in the second intervention period.
62191803|NCT04031196|ACTIVE_COMPARATOR|QLB group, Quadratus Lumborum Block group|the patient placed in the lateral decubitus position, the low-frequency convex probe of Sonosite M Turbo ultrasonography was placed in the anterior axillary line midway between subcostal margin and iliac crest to identify the abdominal muscle layers, then the probe was moved to the posterior axillary line to visualize the quadratus lumborum muscle attached to the transverse process of the L4, With the psoas major muscle placed anteriorly, the erector spinae muscle posteriorly, a 22-gauge, 80 mm needle was inserted in-plane into the posterior aspect of QL muscle (between quadratus lumborum and erector spinae muscle), and then 0.5ml/kg of 0.25% levobupivacaine local anesthetic was injected behind the muscle as a bolus dose. The block was performed bilaterally.
62397350|NCT04056325|EXPERIMENTAL|Phase 2a - Arm E|10 mg Moxidectin at day 0 administered orally
62572732|NCT02174510|EXPERIMENTAL|80mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
62780787|NCT02906267|OTHER|Manual-controlled|Patient in the manual ventilation group will receive facemask ventilation to get a tidal volume of 8-10ml/kg with a respiratory rate of 15/min. The pop-off valve will be set to 20 cm H2O.
62006140|NCT05241223|EXPERIMENTAL|Experimental group|In addition to the educational program, this group will receive weekly individual and/or group online sessions for 12 weeks of motivation-based on behavior change intervention to promote physical activity and reduce sedentary behavior, based on both self-determination theory and transtheoretical model. They will also receive a pedometer with specific strategies related to it.
62191804|NCT04031196|ACTIVE_COMPARATOR|TAP block group,Transversus Abdominis Plane Block group|patient placed in the supine position, a linear multifrequency 6-13 MHz probe of Sonosite M Turbo ultrasonography was placed posterior to the midaxillary line at the midpoint between the inferior costal margin and the iliac crest, a 22-gauge, 50 mm needle was placed using an in-plane technique between the internal oblique and transversus abdominis muscle then local anesthetic was injected in a bolus dose 0.5ml/kg of 0.25% levobupivacaine, the block was done bilaterally.. after ultrasound Identification of the plane between the internal oblique and transversus abdominis muscle,
62397351|NCT04056325|EXPERIMENTAL|Phase 2a - Arm F|12 mg Moxidectin at day 0 administered orally
62572733|NCT02714439|EXPERIMENTAL|High-Resolution Microendoscopy (HRME)|After standard colposcopy examination performed, participants undergo a high-resolution microendoscopy imaging procedure. Proflavine 0.01% is applied to the cervix, then high-resolution microendoscopy imaging procedure performed. Standard colposcopy procedure will then continue.
62572734|NCT04582539|EXPERIMENTAL|INCB000928|INCB000928 will be administered in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.
62572735|NCT04316871|PLACEBO_COMPARATOR|Group D|A total volume of 10 mL injection 5 mL of bupivacaine hydrochloride 0.125% diluted in 5 mL preservative-free normal saline by the hospital pharmacist.
62006141|NCT06117462||Age above 60 eldery|group will be assessed using the Clinical Frailty Scale (CFS) giving patients who are very fit score one and those who are terminally ill score nine.
62006142|NCT06117462||age between 18:60 young|group will be assessed using the Clinical Frailty Scale (CFS) giving patients who are very fit score one and those who are terminally ill score nine.
62006143|NCT01229475|ACTIVE_COMPARATOR|Stepwise approach|Stepwise approach for repeat AF ablation
62006144|NCT01229475|ACTIVE_COMPARATOR|Linear ablation|Linear ablation for repeat procedure in patients with recurrent atrial fibrillation
62006145|NCT04295889|ACTIVE_COMPARATOR|Group A|"Group A will receive an invitation for home based albuminuria screening using a more conventional urine collection device (known as Peespot Test)."
62397352|NCT04056325|PLACEBO_COMPARATOR|Phase 2a - Arm G|matching Placebo tablet(s) at day 0 administered orally
62780788|NCT02906267|OTHER|Volume-controlled|mechanical breath will be delivered by a Primus ventilator (Dräger, Lubeck, Germany) at a frequency of 15 breath/min. Tidal volume will be set to 8-10 ml/min.
62780789|NCT02906267|OTHER|Pressure-controlled|mechanical breath will be delivered by a Primus ventilator (Dräger, Lubeck, Germany) at a frequency of 15 breath/min. Pressure will be adjusted to obtain a tidal volume of 8-10 ml/min.
62780790|NCT00534976|EXPERIMENTAL|Montelukast Sodium|"Participants 4-5 years: A single dose of 4 mg Montelukast chewable tablet daily, crossing over to matching placebo (Pbo) after a 3- to 7-day washout period (no participants 4-5 years were enrolled)~Participants 6-14 years: A single dose of 5 mg Montelukast chewable tablet daily, crossing over to matching Pbo after a 3- to 7-day washout period"
62191805|NCT04901832|EXPERIMENTAL|Experimental Group|The intervention in this group is stretching exercises with the aim of prevention and reduction of leg muscle cramps among patients undergoing hemodialysis
62191806|NCT04901832|NO_INTERVENTION|Control Group|The participants in this group used as reference group
62191807|NCT05994976||Healthy volunteers|Healthy adults
62191808|NCT05994976||Acne|Adult subjects aged 18 to 45 years old with acne
62191809|NCT05994976||AD|Adult subjects with Atopic Dermatitis (AD)
62191810|NCT05994976||CHE|Adult subjects with Chronic Hand Eczema (CHE)
62191811|NCT05994976||HS|Adult subjects with Hidradenitis suppurativa (HS)
62191812|NCT05994976||PPP|Adult subjects with Palmoplantar pustulosis (PPP)
62191813|NCT05994976||Psoriasis|Adult subjects with Psoriasis
62397353|NCT04056325|EXPERIMENTAL|Phase 2b - Arm A|"the recommended dose moxidectin (i.e. the most promising dosage identified in phase 2a; between 2-12 mg) at day 0 administered orally~+ Ivermectin placebo, corresponding to Phase 2b - Arm B"
62397354|NCT04056325|ACTIVE_COMPARATOR|Phase 2b - Arm B|"200 µg/kg ivermectin at day 0 administered orally~+ Moxidectin placebo, corresponding to Phase 2b - Arm A"
62572736|NCT04316871|ACTIVE_COMPARATOR|Group A|A total volume of 10 mL injection: 5 mL of bupivacaine hydrochloride 0.125% with 1.5 mg of preservative-free morphine diluted in 5 mL preservative-free normal saline by the hospital pharmacist.
62006146|NCT04295889|ACTIVE_COMPARATOR|Group B|"Group B will receive an invitation for home based albuminuria screening using an app (internet application) and an ACR dipstick test (known as ACR\| EU Test)."
62191814|NCT02471456||EVH|Patients that have undergone Endoscopic Vein Harvesting (EVH)
62191815|NCT02471456||OVH|Patients that have undergone open vein harvest (OVH)
62191816|NCT00768495||One Cohort|
62191817|NCT04417205|ACTIVE_COMPARATOR|Carbohydrate rich breakfast|Participants will be provided with 28-days worth of pre-weighed carbohydrate rich breakfast materials to consume before 1000h daily.
62191818|NCT04417205|EXPERIMENTAL|Whey protein enriched breakfast|Participants will be provided with 28-days worth of pre-weighed whey protein enriched rich breakfast materials to consume before 1000h daily.
62191819|NCT04417205|NO_INTERVENTION|Extended morning fast|Participants will be asked to remain fasted (i.e. to not consume breakfast) until 1200h daily for 28-days.
62191820|NCT02562820|EXPERIMENTAL|Ketamine|Subjects will receive intravenous infusion of a 0.1, 0.5, 1.0, 2.0 or 4.5 mg/kg dose over the course of 40 minutes
62191821|NCT02562820|PLACEBO_COMPARATOR|Placebo|Subjects will receive an intravenous infusion of normal saline over the course of 40 minutes
62191822|NCT01130649||Epilepsy patients, electronic diary|Cohort of epilepsy patient using an electronic diary system to record all seizures, side effects, and medication compliance
62191823|NCT01130649||Epilpesy patient, no electronic diary|Group of epilepsy patients who are followed using the standard of care, which is a paper diary and routine outpatient follow up visits
62191824|NCT05068947|EXPERIMENTAL|Study drug: GV101|400 mg (10 mL liquid), 800 mg (20 mL liquid), 1600 mg (40mL liquid) of GVS101 will be administered once, orally to subjects in the treatment group, cohort 5 to 7.
62191825|NCT05068947|PLACEBO_COMPARATOR|Placebo|Matched placebo control 400 mg (10 mL liquid), 800 mg (20 mL liquid), 1600 mg (40mL liquid) of GVS101 will be administered once, orally to subjects in the control group, cohort 5 to 7.
62397355|NCT02876211|EXPERIMENTAL|paricalcitol plus epoetin beta|Paricalcitol 2 capsules /three times per week \& epoetin
62397356|NCT02876211|PLACEBO_COMPARATOR|placebo plus epoetin beta|Placebo 2 capsules/three times per week \& epoetin
62572737|NCT04316871|ACTIVE_COMPARATOR|Group B|A total volume of 10 mL injection: 5 mL of bupivacaine hydrochloride 0.125% with 3 mg of preservative-free morphine diluted in 5 mL preservative-free normal saline by the hospital pharmacist.
62397357|NCT05972681|EXPERIMENTAL|Local Anesthesia arm|Bupivicaine and Epinephrine
62397358|NCT05972681|SHAM_COMPARATOR|Normal saline sham arm|
62006147|NCT00424372|EXPERIMENTAL|pregabalin|
62006148|NCT03912233|PLACEBO_COMPARATOR|Part 1: Placebo|Participants received placebo matched to VX-121/TEZ/VX-561 triple combination (TC) for 4 weeks in the treatment period and placebo matched to TEZ/VX-561 for 18 days in the washout period.
62006149|NCT03912233|EXPERIMENTAL|Part 1: VX-121/TEZ/VX-561 TC - Low Dose|Participants received VX-121 5 milligram (mg) once daily (qd)/TEZ 100 mg qd/VX-561 150 mg qd TC for 4 weeks in the treatment period and TEZ 100 mg qd/VX-561 150 mg qd for 18 days in the washout period
62006150|NCT03912233|EXPERIMENTAL|Part 1: VX-121/TEZ/VX-561 TC - Medium Dose|Participants received VX-121 10 mg qd/TEZ 100 mg qd/VX-561 150 mg qd TC for 4 weeks in the treatment period and TEZ 100 mg qd/VX-561 150 mg qd for 18 days in the washout period.
62006151|NCT03912233|EXPERIMENTAL|Part 1: VX-121/TEZ/VX-561 TC - High Dose|Participants received VX-121 20 mg qd/TEZ 100 mg qd/VX-561 150 mg qd TC for 4 weeks in the treatment period and TEZ 100 mg qd/VX-561 150 mg qd for 18 days in the washout period.
62006152|NCT03912233|ACTIVE_COMPARATOR|Part 2: TEZ/IVA|Following run-in period with TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) for 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the treatment period and TEZ 100 mg/IVA 150 mg q12h for 4 weeks in the washout period.
62006153|NCT03912233|EXPERIMENTAL|Part 2: VX-121/TEZ/VX-561 TC - High Dose|Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received VX-121 20 mg qd/TEZ 100 mg qd/VX-561 150 mg qd TC for 4 weeks in the treatment period and TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the washout period.
62006154|NCT00261924|EXPERIMENTAL|Intercept Platelets|Study patients receiving platelets that have been processed with the INTERCEPT pathogen inactivation system
62006155|NCT00261924|ACTIVE_COMPARATOR|Conventional Platelets|Study patients receiving platelets processed by standard method without the INTERCEPT pathogen inactivation system
62006156|NCT01973634|ACTIVE_COMPARATOR|Minimal surgical margin 1 mm, conventional arm: seq boost|Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost).
62006157|NCT01973634|EXPERIMENTAL|Minimal surgical margin of 1 mm, experimental arm with SIB|Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
62006158|NCT01973634|ACTIVE_COMPARATOR|Minimal surgical margin <1 mm, conventional arm: seq boost|Minimal surgical margin \< 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
62006159|NCT01973634|EXPERIMENTAL|Minimal surgical margin < 1 mm, experimental arm with SIB.|Minimal surgical margin \< 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
62006160|NCT02672735|EXPERIMENTAL|Corrective Exercise Program|Participants in the Corrective Exercise Program (CEP) group (n = 28) will be given a four-week corrective exercise programming intervention.
62006161|NCT02672735|NO_INTERVENTION|Control|The participants in the Control (CON) group (n = 28) will have their four-week corrective exercise programming intervention deferred for 4 weeks, and as such, will serve as the comparative group for the CEP group.
62006162|NCT02908529|PLACEBO_COMPARATOR|Placebo|Placebo 2 hours before bedtime
62006163|NCT02908529|ACTIVE_COMPARATOR|Combination product of Atomoxetine and Oxybutynin|Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
62006164|NCT02678039|EXPERIMENTAL|Fluoroscopy|"Real-time fluoroscopic X-ray guidance to confirm placement of an epidural catheter in the spinal epidural space at the desired location.~Following epidural catheter placement, 1/8% bupivacaine is infused at 4ml/hr into the epidural catheter during and after surgery for pain control."
62006165|NCT02678039|ACTIVE_COMPARATOR|Traditional|"The traditional approach for placement of an epidural catheter is used with indirect indicators of placement including palpation of spine and 'loss-of-resistance' to fluid injection.~Following epidural catheter placement, 1/8% bupivacaine is infused at 4ml/hr into the epidural catheter during and after surgery for pain control."
62006166|NCT01201681||Post-operativeTooth Pain|
62006167|NCT00441337|EXPERIMENTAL|0.3 mg/kg MDX-1106 drug|0.3 milligrams (mg) MDX-1106 drug (nivolumab) per kilogram (kg) of body weight (mg/kg) was administered in a single intravenous (IV) infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
62006168|NCT00441337|EXPERIMENTAL|1 mg/kg MDX-1106 drug|1 mg MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
62006169|NCT00441337|EXPERIMENTAL|3 mg/kg MDX-1106 drug|3 mgs MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
62006170|NCT00441337|EXPERIMENTAL|10 mg/kg MDX-1106 drug|10 mgs MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
62006171|NCT03074721|OTHER|PCI with PCI Suite Software|
62006172|NCT03074721|OTHER|conventional PCI|
62006173|NCT04925297||Non-NS ( Non-neurological sequelae) group|Patients who do not develop neurological dysfunction after acute carbon monoxide poisoning
62006174|NCT04925297||NS (Neurological sequelae) group|Patients who develop neurological dysfunction after acute carbon monoxide poisoning
62006175|NCT02210585|ACTIVE_COMPARATOR|Kneehab®|5 sessions per week
62006176|NCT02210585|PLACEBO_COMPARATOR|Placebo|5 sessions per week
62006177|NCT04708197|OTHER|aphasic patients|post stroke aphasic patients will receive 10 sessions of high frequency rTMS 3 times per week over the damaged hemisphere without language therapy
62006178|NCT03779997|EXPERIMENTAL|Video-based DOT Application|
62006179|NCT03779997|NO_INTERVENTION|Treatment as Usual (TAU)|
62006180|NCT01650181|ACTIVE_COMPARATOR|Metformin|Patients treated with diet, exercise and metformin
62006181|NCT01650181|ACTIVE_COMPARATOR|Suplement|Patients treated with diet, exercise and metformin plus Siliphos (140mg) + Selenium (15mcg) -Methionine 3mg + Alpha Lipoic Acid (200mg).
62191826|NCT01620970|EXPERIMENTAL|PF03446962|Investigational study drug, administered intravenously every 2 weeks until disease progression or unacceptable toxicity.
62191827|NCT04748536|EXPERIMENTAL|Group 1: Dose A IRL201104 or placebo|IRL201104 IV once daily for 5 days OR Placebo IV once daily for 5 days
62191828|NCT04748536|EXPERIMENTAL|Group 2: Dose B IRL201104 or placebo|IRL201104 IV once daily for 7 days OR Placebo IV once daily for 7 days
62006182|NCT04929301|EXPERIMENTAL|AME Hand-Expression|Participants in the antenatal milk expression (AME) group will learn hand-expression from a certified lactation consultant beginning at 37 weeks of pregnancy. At the same visit, the PI or RA will also provide oral and written instructions for AME at home, specifically instructing participants to do AME 1-2 times per day for no longer than 10 minutes.
62397359|NCT05489432|EXPERIMENTAL|prehabilitation group|care as usual and pre habilitation intervention
62006183|NCT04929301|ACTIVE_COMPARATOR|Education|Participants in the education group will receive a weekly educational hand-out on varying breastfeeding topics (e.g., latch).
62397360|NCT05489432|NO_INTERVENTION|control group|care as usual
62780791|NCT00534976|EXPERIMENTAL|Placebo|"Participants 4-5 years: A single dose of 4 mg Pbo chewable tablet daily, crossing over to Montelukast 4 mg chewable tablet after a 3- to 7-day washout period (no participants 4-5 years of age were enrolled)~Participants 6-14 years: A single dose of 5 mg Pbo chewable tablet daily, crossing over to Montelukast 5 mg chewable tablet after a 3- to 7-day washout period"
62780792|NCT03797300|EXPERIMENTAL|Primary|
62006184|NCT04579913||iTind subjects|Patient who participated previously in the MT-03 study in the iTind arm
62191829|NCT02419417|EXPERIMENTAL|Monotherapy Treatment|Patients treated at various doses and schedules
62191830|NCT02419417|EXPERIMENTAL|Combination Therapy|Patients treated at selected doses and schdules
62191831|NCT04382235||Covid-19 related Pneumonia patients|The cohort is defined by subjects with a diagnosis of COVID 19-related pneumonia requiring non-invasive ventilatory support.
62191832|NCT05632822||SBT failure|The SBT was considered to be a failure if at least one the following criteria was present: (1) blood oxygen saturation (SpO2) of \<90 % with a fraction of inspired oxygen (FiO2) of≥50 %; (2) acute respiratory distress (RR≥40/min, agitation, cyanosis); (3) systolic arterial blood pressure of ≥180 mmHg; (4) cardiac arrhythmias; (5) respiratory acidosis \[pH\<7.32 with an arterial carbon dioxide tension (PaCO2) of ≥50 mmHg\].
62191833|NCT05632822||SBT success|If none of these failure criteria was present, the SBT was considered as successfully completed.
62780793|NCT01158391|EXPERIMENTAL|NTrainer® Intervention|NTrainer® Intervention - Infants in the experimental group will receive the NTrainer System patterned synthetic orocutaneous stimulation during the first 30 minutes of a tube (gavage) feeding session. The intervention may be provided up to 4 times daily to achieve an average of 30 sessions distributed over a two week period.
62780794|NCT01158391|SHAM_COMPARATOR|Control Intervention|Control Intervention - Infants in the Control group will be provided orocutaneous stimulation with a 'quiet pacifier' during the first 30 minutes of a tube (gavage) feeding session. The intervention may be provided up to 4 times daily to achieve an average of 30 sessions distributed over a two week period.
62780795|NCT06405477|EXPERIMENTAL|Sun|We are blind and don't know which group is which.
62780796|NCT06405477|PLACEBO_COMPARATOR|Moon|We are blind and don't know which group is which.
62191834|NCT01660256|EXPERIMENTAL|OPC-12759 ophthalmic solution|OPC-12759 ophthalmic solution
62191835|NCT01660256|PLACEBO_COMPARATOR|Placebo|OPC-12759 ophthalmic solution 0%
62191836|NCT01660256|ACTIVE_COMPARATOR|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension
62397361|NCT01348828|OTHER|Single Arm|All patients meet study criteria receives a single use Ventana Fenestrated System, which requires administration of intravascular contrast. Catheter advancement is performed under fluoroscopic guidance and Ventana Fenestrated System is placed.
62397362|NCT05502406|EXPERIMENTAL|IASTM|The participants of the respective group will receive myofascial release using a C shaped glider, by the help of gentle horizontal strokes the targeted soft tissue restrictions will be relieved over the cervicodorsal fascia
62397363|NCT05502406|EXPERIMENTAL|MMFR|The participants of the respective group will recieve manual soft tissue release over the cervicodorsal fascia using velvet glove technique for a period of 5 to 7 mins inorder to set free any adhesion in the underlying myofascia
62397364|NCT06236373||Cancer Survivors|Cancer Survivors
62397365|NCT06236373||Cancer Survivors Caregiver|Family members or/and caregivers
62397366|NCT06236373||Cancer Survivors Stakeholders|Health professionals, patients associations
62397367|NCT05630638|EXPERIMENTAL|Delstrigo|doravirine/lamivudine/tenofovir disoproxil 100 mg/ 300 mg/ 245 mg film coated tablets, dosed 1 tablet once daily for the duration of the study
62397368|NCT05630638|ACTIVE_COMPARATOR|Standard of care|dolutegravir/lamivudine/tenofovir disoproxil 50 mg/300 mg/245 mg film coated tablets, dosed 1 tablet once daily for the duration of the study
62780797|NCT05532904|OTHER|Intervention|"This 6-week program of care will include:~* group education sessions including a psycho-education component (1 session / week)~* a personalized exercise training protocol (from 1 session of supervision to 3 sessions of guided exercise per week) adapted to the results of the VO2max exercise test.~* if dysfunctional health beliefs are identified (SSD-12 score ≥ 26): a group protocol of cognitive and behavior therapy (2 sessions per week, including at least 1 in person).~* if cognitive complaints and/or neuropsychological impairment: a cognitive remediation protocol (1 group session plus 2 home sessions per week)"
62780798|NCT05532904|NO_INTERVENTION|Control|Usual care (waiting list)
62791805|NCT04886713||Obese HFpEF|Left ventricular-EF ≥ 50%, N-terminal-pro-brain natriuretic peptide (NT-proBNP) ≥ 125ng/l, evidence of structural heart diseases (diastolic dysfunction, Left ventricular-hypertrophy or Left atrial-dilatation) BMI ≥30 kg/m²
62006185|NCT03306264|EXPERIMENTAL|MDS or CMML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727|Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.
62006186|NCT03306264|EXPERIMENTAL|MDS or CMML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727|Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days) followed by ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.
62191837|NCT02505893|EXPERIMENTAL|Treated|The investigational treatment will be islet transplant in the presence of induction with ATG/G-CSF and rapamycin treatment for one month. One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver. ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant. Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion. Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
62191838|NCT06442696|EXPERIMENTAL|Intervention Group|10-14 years old adolescent are given health education Health education was given
62191839|NCT06442696|NO_INTERVENTION|Control Group|10-14 years old adolescent are not given health education
62191840|NCT05252936|EXPERIMENTAL|Spanish language content|Social media campaign content with Spanish language voiceover
62191841|NCT05252936|EXPERIMENTAL|K'iche' language content|Social media campaign content with K'iche' language voiceover
62191842|NCT05252936|EXPERIMENTAL|Kaqchikel language content|Social media campaign content with Kaqchikel language voiceover
62191843|NCT05252936|ACTIVE_COMPARATOR|Control|A control group that is not exposed to any of the social media campaign content will serve as control to allow for comparison of outcomes with treatment arms.
62191844|NCT06415097||Type 1 Diabetes MDI Smart Pen Users|Individuals with type 1 diabetes receiving multiple daily doses of insulin (MDI), utilizing glucose monitoring devices, and using or having used insulin smart pens.
62191845|NCT06415097||Type 1 Diabetes MDI Smart Pen Non-Users|Patients with type 1 diabetes receiving multiple daily doses of insulin (MDI) and using glucose monitoring devices.
62397369|NCT05606523||Cachectic patients with pancreatic cancer|Measurements and sample collection at one timepoint.
62572738|NCT04316871|ACTIVE_COMPARATOR|Group C|A total volume of 10 mL injection: 5 mL of bupivacaine hydrochloride 0.125% with 4 mg of preservative-free morphine diluted in 5 mL preservative-free normal saline by the hospital pharmacist.
62572739|NCT04168723|EXPERIMENTAL|Group A-MD1003|Group A=32 subjects Placebo for MD1003 on Day -1. Daily dose of 1200 mg of MD1003 from Day 1 to Day 8 Placebo for moxifloxacin on Day 1 and Day 9
62191846|NCT04817605|EXPERIMENTAL|Exercise Therapy|
62191847|NCT04200222||Preeclampsia|The diagnosis of L-PrE, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), is established based on the presence of proteinuria (urinary excretion of protein ≥300 mg in a 24-h urine specimen, or proteinüria ≥1+ in dipstick) and a blood pressure level of ≥90/140 mmHg (two blood pressure measurements 6 h apart) that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure \<110/160 mm Hg, it was accepted as mild; and in case these values exceeded this level, it was accepted as severe. The study population consisted of 50 late-onset preeclampsia patients as study group and 50 patients with normal pregnancies as control group.
62397370|NCT05606523||Non-cachectic patients with pancreatic cancer|Measurements and sample collection at one timepoint.
62397371|NCT05606523||Healthy volunteers|Measurements and sample collection at one timepoint.
62397372|NCT02330406|ACTIVE_COMPARATOR|Anagliptin|Anagliptin 100 mg bid for 52 weeks. Can increase to 200 mg bid if needed.
62397373|NCT02330406|ACTIVE_COMPARATOR|Sitagliptin|Sitagliptin 50 mg qd for 52 weeks. Can increase to 100 mg qd if needed
62397374|NCT01319422|EXPERIMENTAL|Pomalidomide 2 mg/d on 28 days/28 day cycle|
62397375|NCT01319422|EXPERIMENTAL|Pomalidomide 4 mg/d on 21 days/28 day cycle|
62397376|NCT00442741|EXPERIMENTAL|Patupilone + Midazolam|
62397377|NCT00442741|EXPERIMENTAL|Patupilone + Omeprazole|
62397378|NCT05557266|EXPERIMENTAL|Mindfulness-based intervention (MBI)|A 8-week mindfulness-based intervention. From 15 to 30 minutes of practice per session, three times/week through audio guided meditations.
62791806|NCT04886713||Obese controls|No history of heart failure, Left ventricular-EF \> 50% and NT-pro-BNP \<125ng/l, BMI ≥ 30kg/m²
62791807|NCT04886713||Lean control|No history of heart failure, Left ventricular-EF \> 50% and NT-pro-BNP \<125ng/l, BMI \< 30kg/m²
62397379|NCT05557266|ACTIVE_COMPARATOR|Physical exercise (PE)|A 8-week physical exercise intervention. From 15 to 30 minutes of practice per session, three times/week through workout videos.
62006187|NCT03306264|EXPERIMENTAL|AML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727|Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
62006188|NCT03306264|EXPERIMENTAL|AML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727|Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days) followed by ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
62397380|NCT05557266|NO_INTERVENTION|Wait list (WL)|The participants will continue their work activity as usual. This arm will be invited to a mindfulness training once the study finished.
62397381|NCT04544592|EXPERIMENTAL|I: Dose Escalation|First 3-21 subjects enrolled. Treated with escalating doses of therapy until the RP2D is determined.
62397382|NCT04544592|EXPERIMENTAL|II: Dose Expansion|22-40 additional subjects treated at the RP2D, including those treated within the phase 1 portion of the trial.
62397383|NCT05602558|EXPERIMENTAL|LYB001|
62397384|NCT05602558|PLACEBO_COMPARATOR|Placebo|
62397385|NCT04129879|EXPERIMENTAL|1|all patients treated by conventional bare eye technique and then the use of methylene blue contrast technique to visualize endometriotic lesions perioperatively
62397386|NCT01730222|EXPERIMENTAL|PAXG regimen|cisplatin at 30 mg/m2 on days 1 and 15, nab-paclitaxel at the RP2D on days 1 and 15, capecitabine at 1250 mg/ m2 days 1-28, gemcitabine at 800 mg/ m2 on days 1 and 15 every 4 weeks
62780799|NCT04059120|EXPERIMENTAL|Experimental group|The physical load will be organized as follows: The experimental group (EG) will perform muscle strength exercises with intensities of 45 to 90% of 1RM in combination with specific stretching exercises, and aerobic resistance with efforts of 60 to 90% of the theoretical maximum heart rate, which will be controlled with a Polar brand heart rate monitor model FT7.
62780800|NCT04059120|ACTIVE_COMPARATOR|Control group|The physical load will be organized as follows: The control group (CG) will perform muscle strength exercises with intensities of 45 to 90% of 1RM in combination with single or general stretching exercises, and aerobic resistance with efforts of 60 to 90% of the theoretical maximum heart rate, which will be controlled with a Polar brand heart rate monitor model FT7.
62006189|NCT02561507||American College of Surgeons members|Survey participants
62006190|NCT00028028|EXPERIMENTAL|Arm I|Patients receive low-dose CCI-779 IV over 30 minutes once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
62006191|NCT00028028|EXPERIMENTAL|Arm II|Patients receive high-dose CCI-779 as in arm I.
62006192|NCT04546854|EXPERIMENTAL|Conservative - Binding Appeal|
61977990|NCT05620004|EXPERIMENTAL|Bifidobacterium Bifidum Oral Product|patients with advanced hepatocellular carcinoma who will be treate with carrilizumab and apatinib mesylate plus Bifidobacterium Bifidum Oral Product daily
62006193|NCT04546854|EXPERIMENTAL|Liberal - Individulizing Appeal|
62397387|NCT01730222|ACTIVE_COMPARATOR|gemcitabine + nab-paclitaxel|gemcitabine at 1000 mg/ m2 on days 1, 8 and 15 every 4 weeks + nab-paclitaxel at 125 mg/ m2 on days 1, 8 and 15 every 4 weeks
62397388|NCT04225117|EXPERIMENTAL|Cohort 1: HR+/HER2- breast cancer|"Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.~HR+/HER2- = Hormone receptor-positive/ human epidermal growth factor receptor 2-negative"
62397389|NCT04225117|EXPERIMENTAL|Cohort 2: Triple negative breast cancer (TNBC)|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
62397390|NCT04225117|EXPERIMENTAL|Cohort 3: Squamous non-small cell lung cancer|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
62397391|NCT04225117|EXPERIMENTAL|Cohort 4: Non-squamous non-small cell lung cancer|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
62397392|NCT04225117|EXPERIMENTAL|Cohort 5: Head and neck cancer|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
62397393|NCT04225117|EXPERIMENTAL|Cohort 6: Gastric or GEJ or esophageal cancer|"Participants enrolled into Cohort 6 will be reallocated based on disease type and histology into Cohorts 7 or 8.~GEJ= gastroesophageal junction"
62397394|NCT04225117|EXPERIMENTAL|Cohort 7: Gastric and esophageal adenocarcinoma (EAC) including GEJ adenocarcinoma|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
62780801|NCT01805557|ACTIVE_COMPARATOR|R-DHAP|R-DHAP x 2, restaging, mobilization and harvest of peripheral stem cell + R-DHAP x 2, restaging with PET evaluation
62780802|NCT01805557|EXPERIMENTAL|BR-DHAP|Bortezomib + R-DHAP x 2, restaging, mobilization and harvest of peripheral stem cell + Bortezomib + R-DHAP x 2, restaging with PET evaluation
62780803|NCT03509259||Asthma|"If the doctor has been diagnosed with asthma and one or more of the following criteria is met;~1. FEV1 (Forced expiratory volume in 1 second) increased more than 12% \& 200 mL after 10-20 minutes of inhalation of short-acting bronchodilator (200-400 mg salbutamol)~2. Positive bronchial provocation tests (methacholine, mannitol, exercise, aspirin, etc.)~3. FEV1 Increased more than 12% \& 200 mL from baseline FEV1 after anti-inflammatory treatment for 4 weeks or longer.~They can have concomittent COPD or not"
62780804|NCT03509259||Healthy control|Subjects who performed coronary artery calcium scoring CT for health checkup purpose.(retrospective group = historical control group)
62006194|NCT03457012||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
62006195|NCT01797536|EXPERIMENTAL|Mild Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with mild hepatic insufficiency, defined as a score of 5 to 6 on the Child-Pugh scale
62780805|NCT02349685|EXPERIMENTAL|14 day bismuth based quadruple therapy (PBMT) group|Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
62191848|NCT04200222||Control|Pregnant women with uncomplicated pregnancies were randomly selected to serve as controls. Healthy subjects who had a normal pregnancy and outcomes without any fetal-neonatal complications were accepted into the control group.
62191849|NCT06229249|EXPERIMENTAL|Experimental group|The participants in this group received carpal ligament self-myofascial stretching along with conventional physical therapy.
62191850|NCT06229249|ACTIVE_COMPARATOR|Control group|The participants in this group received conventional physical therapy.
62191851|NCT02395419|ACTIVE_COMPARATOR|Totaltrack|OTI with TotalTrack
62191852|NCT02395419|ACTIVE_COMPARATOR|Airtraq|OTI with Airtraq
62397395|NCT04225117|EXPERIMENTAL|Cohort 8: Esophageal squamous cell carcinoma (ESCC)|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
62780806|NCT02349685|EXPERIMENTAL|14 day Moxifloxacin containing triple therapy (MEA) group|PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.
62397396|NCT04225117|EXPERIMENTAL|Cohort 9: Head and neck squamous cell carcinoma (HNSCC)|Participants will receive enfortumab vedotin as an IV infusion on days 1 and 8 of each 21-day cycle. Pembrolizumab will be administered as an IV infusion on day 1 of each 21-day cycle.
62191853|NCT01495676|ACTIVE_COMPARATOR|Radiotherapy + cisplatin|
62191854|NCT01495676|EXPERIMENTAL|Radiotherapy + cisplatin + gemcitabine|
62191855|NCT00573456|OTHER|1|
62191856|NCT01587482||drug eluting balloon|"In this observationnal study, the intervention of interest is the use of drug eluting balloon in stent restenosis.~Only the treated patients were included in this cohort."
62191857|NCT04797390|ACTIVE_COMPARATOR|Advanced Pneumatic Compression Device (APCD)|Daily self-administered treatment with the Flexitouch® Plus system (FT)
62397397|NCT03010046|EXPERIMENTAL|ANX005 Monotherapy|ANX005 intravenous infusion
62397398|NCT03010046|EXPERIMENTAL|ANX005 and IVIg Combination Therapy|ANX005 intravenous infusion in combination with intravenous immunoglobulin (IVIg)
62191858|NCT04797390|ACTIVE_COMPARATOR|Usual Care|Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
62397399|NCT03010046|PLACEBO_COMPARATOR|Placebo|Placebo intravenous infusion
62397400|NCT03246685|EXPERIMENTAL|Pembrolizumab Failures|Imprime PGG + Pembrolizumab
62397401|NCT03246685|EXPERIMENTAL|Active Stable Disease on Pembrolizumab|Imprime PGG + Pembrolizumab
62572740|NCT04168723|ACTIVE_COMPARATOR|Group B-Moxifloxacin|"Subjects in Group B will be further randomized to Subgroups B1 and B2 in a ratio of 1:1.~Subgroup B1: 16 subjects Placebo for MD1003 on Day -1 Placebo for MD1003 from Day 1 to Day 8 Moxifloxacin 400 mg on Day 1 and Placebo for moxifloxacin on Day 9 Subgroup B2: 16 subjects Placebo for MD1003 on Day -1 Placebo for MD1003 from Day 1 to Day 8 Placebo for moxifloxacin on Day 1 and Moxifloxacin 400 mg on Day 9"
62006196|NCT01797536|EXPERIMENTAL|Moderate Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with moderate hepatic insufficiency, defined as a score of 7 to 9 on the Child-Pugh scale
62191859|NCT06544369||Vaccinated group|all criteria are accepted for study
62191860|NCT06544369||Non-vaccinated group|all criteria are accepted for study
62191861|NCT01784523|NO_INTERVENTION|Standard treatment|patients randomized to standard treatment will not receive hydroxychloroquine.
62397402|NCT05246852|EXPERIMENTAL|intervention group|
62397403|NCT05246852|NO_INTERVENTION|control group|
62780807|NCT02349685|ACTIVE_COMPARATOR|14 day tailored therapy group|based on H. pylori culture and antimicrobial sensitivity, select the 2nd rescue regimen between 14 days of bismuth-based quadruple therapy or 14 days moxifloxacin-containing triple therapy according to antibiotics susceptibility.
62780808|NCT02292706||SOF+RBV|Participants who were previously treated with sofosbuvir (SOF) along with ribavirin (RBV) will be followed up to 5 years.
62780809|NCT02292706||LDV/SOF|Participants who were previously treated with ledipasvir/sofosbuvir (LDV/SOF) will be followed up to 5 years.
62780810|NCT02292706||LDV/SOF+RBV|Participants who were previously treated with LDV/SOF along with ribavirin will be followed up to 5 years.
62780811|NCT02292706||SOF/VEL|Participants who were previously treated with sofosbuvir/velpatasvir (SOF/VEL) will be followed up to 5 years.
62191862|NCT01784523|EXPERIMENTAL|Hydroxychloroquine|Patients will be randomized to receive standard of care or standard of care + hydroxychloroquine. Dose will be weight-adjusted: 200 mg daily for patients weighing \<60kg; and 400 mg daily (200 mg twice a day)for patients weighing \>60kg.
62191863|NCT00373451|EXPERIMENTAL|Abciximab+UFH|Abciximab and unfractionated heparin as bolus given during PCI and abciximab-perfusion for 12 hours after PCI
62191864|NCT00373451|ACTIVE_COMPARATOR|Bivalirudin|Bivalirudin given only during PCI
62006197|NCT01797536|EXPERIMENTAL|Severe Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with severe hepatic insufficiency, defined as a score of 10 to 15 on the Child-Pugh scale
62397404|NCT02473341|EXPERIMENTAL|Bovine colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.~+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
62572741|NCT02189005|EXPERIMENTAL|PreCrea|Study dietary supplement (Precrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification program.
62780812|NCT02292706||SOF/VEL+RBV|Participants who were previously treated with SOF/VEL along with RBV will be followed up to 5 years.
62006198|NCT01797536|EXPERIMENTAL|Healthy Participants|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants matched to the mean of all hepatic insufficiency participants for age, gender, and weight
62191865|NCT01081275|ACTIVE_COMPARATOR|CI Therapy|CI therapy involves repetitive practice with the more-affected hand on typical daily living activities (such as stacking objects, pouring, moving objects) for 3.5 hours per day, along with physical restraint of the better hand to keep it from assisting, and home practice exercises.
62191866|NCT01081275|ACTIVE_COMPARATOR|CAM treatments|CAM treatments are holistic physical treatments designed to work on the entire body to improve quality of life and overall health. This study will use yoga, relaxation exercises, aquatherapy (pool therapy), and massage.
62191867|NCT03228147|EXPERIMENTAL|Supportive Care (nutrition supplement)|Patients receive 10 different nutrition supplements PO and complete questionnaires based on each sample in a single session over 60-90 minutes.
62191868|NCT00778245|EXPERIMENTAL|1|cefprozil 500mg tablets of Ranbaxy
62191869|NCT00778245|ACTIVE_COMPARATOR|2|CEFZIL ® 500 mg tablets of Bristol-Myers Squibb Company, USA
62191870|NCT05729308|ACTIVE_COMPARATOR|Group (CE): Patients receiving caudal epidural block|
62191871|NCT05729308|ACTIVE_COMPARATOR|Group (ESP): Patients receiving bilateral erector spinae plane block.|
61977991|NCT05620004|NO_INTERVENTION|without Bifidobacterium Bifidum Oral Product|patients with advanced hepatocellular carcinoma who will be treate with carrilizumab and apatinib mesylate without Bifidobacterium Bifidum Oral Product daily
61977992|NCT05443867||MPX-Assess|Contacts of MPX index cases
61977993|NCT03164200|EXPERIMENTAL|High fat breakfast|45% fat 35% Carbohydrate 20% protein
61977994|NCT03164200|EXPERIMENTAL|Higher carbohydrate breakfast|60% carbohydrate 20% fat 20% protein
62191872|NCT05729308|ACTIVE_COMPARATOR|Group (C): Control group, patients receiving general anesthesia with intravenous analgesia.|
62191873|NCT04312932|EXPERIMENTAL|Long chain polyunsaturated fatty acid (LCPUFA) Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of gamma-linoleic acid (GLA) + eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) as Omega 3-6 oil to be administered twice per day by mouth for 90 days
62191874|NCT04312932|PLACEBO_COMPARATOR|Canola Oil|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
62214742|NCT04135690|OTHER|Patients receiving TKI plus ICI|Patients, who meet the inclusion criteria but withdraw consent or reject this study, receive systemic treatment according to the doctor. Systemic treatment include atezolizumab+bevacizumab, camrelizumab+apatinib, sintilimab+bevacizumab and so on.
62214743|NCT00836745||1|Non Interventional
62214744|NCT05170061|ACTIVE_COMPARATOR|Nebivolol|Nebivolol, 20 mg daily for 1 week followed by 40 mg daily for 3 weeks, followed by 1 week down-titration to 20 mg daily
62214745|NCT05170061|ACTIVE_COMPARATOR|Valsartan|Valsartan, 160 mg daily for 1 week followed by 320 mg daily for 3 weeks, followed by 1-week down-titration to 160 mg daily
62214746|NCT05170061|ACTIVE_COMPARATOR|Nebivolol/valsartan|Combination of nebivolol/valsartan 20/160 mg daily for 1 week followed by 40/320 mg daily for 3 weeks, followed by 1-week down-titration to 20/160 mg daily
62214747|NCT01602107|NO_INTERVENTION|Control|Participants in the control group will not receive therapist-supervised intervention. An exercise sheet briefly describing pelvic floor muscle exercises will be provided, as would be the standard practice from most physicians.
62214748|NCT01602107|EXPERIMENTAL|Pelvic Floor Therapy|Participants in the experimental group undergo and assessment and treatment by a registered physiotherapist. Treatments will include two sessions of biofeedback training, therapist-assisted strengthening exercises, and will a prescribed home exercise program to strengthen their pelvic floor muscles.
62397405|NCT02473341|PLACEBO_COMPARATOR|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
62397406|NCT05814367|EXPERIMENTAL|Test/Control|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to receive 1-2 drops on each eye (right eye followed by left eye) over soft spherical contact lenses, over two wear periods (test then control). A washout period of 90 minutes between eyedrop instillations will occur. The second eyedrop as per the randomization schedule will follow the same procedure as previously stated.
62397407|NCT05814367|EXPERIMENTAL|Control/Test|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Control/Test sequence, to receive 1-2 drops on each eye (right eye followed by left eye) over soft spherical contact lenses, over two wear periods (control then test). A washout period of 90 minutes between eyedrop instillations will occur. The second eyedrop as per the randomization schedule will follow the same procedure as previously stated.
62397408|NCT02104726|ACTIVE_COMPARATOR|Blind Steroid Injection|Blind Steroid Injection for patients with OA deemed qualified for it clinically
62397409|NCT02104726|ACTIVE_COMPARATOR|Fluoroscopy guided steroid injection|Fluoroscopy guided Steroid Injection for patients with OA deemed qualified for it clinically. We want to see which one is better.
62397410|NCT04798664|NO_INTERVENTION|Basic Usual Care|Participants receive the usual care approach, Ask-Advise-Refer (AAR), which is a standard approach in which non-study clinicians ask smokers about their desire to quit smoking, advise them to quit, and provide informational resources such as hotlines, specialized clinics, or smoking cessation classes.
62572742|NCT02189005|PLACEBO_COMPARATOR|Placebo 600 mg capsules|Placebo was given to patients twice daily 30 mins before food for 90 days along with lifestyle modification program.
62572743|NCT01218087|EXPERIMENTAL|Cranial cup device and Moldable positioner device|The cranial cup for 12/24 hours and the moldable positioner device was used for positioning infants the remainder of the 24 hours
62572744|NCT01218087|ACTIVE_COMPARATOR|Moldable positioner device|Moldable positioner device was used for positioning infants for 24/24 hours
62572745|NCT01040637|EXPERIMENTAL|TD-1211 dose level 1|Ascending doses
62572746|NCT01040637|EXPERIMENTAL|TD-1211 dose level 2|Ascending doses
62572747|NCT01040637|EXPERIMENTAL|TD-1211 dose level 3|Ascending doses
62214749|NCT03534128|EXPERIMENTAL|Spatial navigation evaluation|
61977995|NCT05829486||ketaprop|At the beginning of anesthesia, 0.25 mg/kg ketamine and 0.75 mg/kg propofol will be administered.
61977996|NCT05829486||remiprop|At the beginning of anesthesia, 1 mcg/kg of remifentanil and 0.75 mg/kg propofol will be administered.
62021026|NCT02419157|ACTIVE_COMPARATOR|Xeno V+ Non-etch (XV-NE)|"XV-NE (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~No selective enamel etching with 36% phosphoric acid"
62214750|NCT00621777|ACTIVE_COMPARATOR|Randomized Phase: Varenicline|Varenicline is a partial agonist at alpha4beta2 nicotinic acetylcholine receptors (nAChRs) and a full agonist at alpha 7 nAChRs that has been shown to be effective for smoking cessation compared with placebo and bupropion, with effects on abstinence rates for up to one year. Varenicline has demonstrated safety when dosed at 1 mg twice per day for up to one year. Because varenicline, at a dose of 1 mg twice per day, may be a more effective treatment for sustained abstinence than bupropion, it was chosen as the medication intervention for this study.
62214751|NCT00621777|PLACEBO_COMPARATOR|Randomized Phase: Placebo|
62214752|NCT02370927|PLACEBO_COMPARATOR|Control|100% Wheat Flour
62214753|NCT02370927|EXPERIMENTAL|Cereal w/ pea protein|Pea protein
62214754|NCT02370927|EXPERIMENTAL|Cereal w/ pea starch|Pea starch
62214755|NCT02370927|EXPERIMENTAL|Cereal w/ pea starch + pea fibre|Pea starch + pea fibre: 5g
62214756|NCT02370927|EXPERIMENTAL|Cereal w/ pea protein + pea starch|Pea protein + pea starch: 10g
62214757|NCT02370927|EXPERIMENTAL|Cereal w/ pea protein + pea fibre + pea starch:|Pea protein + pea fibre + pea starch: 20g
62214758|NCT05014711|EXPERIMENTAL|remifentanil group|After enrollment, remifentanil will be used for analgesia. Duration of mechanical ventilation, incidences of adverse events, interval from SBT to extubation, dosages and costs of analgesics and sedatives drugs will be observed.
62214759|NCT05014711|ACTIVE_COMPARATOR|fentanil group|After enrollment, fentanil will be used for analgesia. Duration of mechanical ventilation, incidences of adverse events, interval from SBT to extubation, dosages and costs of analgesics and sedatives drugs will be observed.
62214760|NCT00685906|EXPERIMENTAL|1|
62214761|NCT00685906|ACTIVE_COMPARATOR|2|
62214762|NCT02235389||Administration of thrombolytic treatment with PHARAOH|Pre-Hospital Alteplase Remote Advice of Hospital (PHARAOH)
62214763|NCT02235389||Standard therapy with thrombolytic treatment in Hospital|
62214764|NCT00741364|ACTIVE_COMPARATOR|1|vitamin D3 (400 IU/d)
62214765|NCT00741364|ACTIVE_COMPARATOR|2|vitamin D3 (10,000 IU/d)
62214766|NCT00741364|ACTIVE_COMPARATOR|3|vitamin D3 (40,000 IU/d)
62214767|NCT00336700|EXPERIMENTAL|Gemcitabine and Erlotinib|Erlotinib (oral) 150 mg/day x 12 months Gemcitabine 1500 mg/m2 IV over 150 minutes q 2 weeks x 4 months
62214768|NCT06381544|EXPERIMENTAL|Aromatherapy|Aromatherapy Group Aromatherapy will be carried out by spreading the essential oil in the laboratory with the help of a censer. For each censer, 6drops of essential oil mixture (oil mixture ratio, lemon, orange, frankincense oils; 2:2:2 ratio) and two censers will be used. Students will fill out the Introductory Information Form and State Anxiety Scale before being admitted to the laboratory. Students in the experimental group will be taken to the laboratory where aromatherapy is applied, intravenous catheter application will be demonstrated on a simulation model by the researcher during skill training, and each student will practice on the model once. At the end of the application, after students fill out the State Anxiety Scale again, they will be taken to a different room/laboratory and evaluated for skill learning.
62191875|NCT03498469|ACTIVE_COMPARATOR|No Parenting program|Participants assigned to this comparison arm will receive a standardized reintegration package that includes individualized case management support and a reunification cash grant. Individualized case management will consist of a caseworker-developed individualized care plan with routine caseworker visits at the household level. At a minimum, each family will be visited on a monthly basis during the first 6 months post-placement and then every other month for the next 9 months. For the cash grant, the family of each enrolled child will receive a reunification cash grant in the Ugandan Shilling equivalent of $125, administered in two equal disbursements. It is designed to offset the cost of child care.
62191876|NCT03498469|EXPERIMENTAL|Parenting program|Those in the intervention arm will receive an enhanced reintegration package of services that consist of the standard package (case management and cash grant) plus a parenting program called 'Esanyu Mu Maka' or Happiness in the Home. The parenting curriculum used will be an adaptation of the evidence-based Sinovuyo Kids curriculum, tailored for caregivers of children age 1 to 13 years. It will have specifically designed components to address parenting challenges under reunification/reintegration conditions and to support the child and caregiver in building their relationship. It will be delivered at the household level by project trained parenting facilitators. The program will consist of approximately 13 bi-weekly sessions, which will be delivered over the course of 7 months.
62191877|NCT05763199|EXPERIMENTAL|Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®)|AHCC 3g PO Daily
62191878|NCT05763199|PLACEBO_COMPARATOR|Placebo|Placebo PO Daily
62191879|NCT02075619|EXPERIMENTAL|Sequence 1|Four subjects (2 Chinese and 2 Caucasian) will receive one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 1; one GSK3074477 Fixed dose combination (FDC) formulation-1 tablet in Period 2 and one GSK3074477 FDC formulation-2 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
62191880|NCT02075619|EXPERIMENTAL|Sequence 2|Four subjects (2 Chinese and 2 Caucasian) will receive one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 1; one GSK3074477 FDC formulation-2 tablet in Period 2 and one GSK3074477 FDC formulation-1 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
62780813|NCT02292706||SOF/VEL/VOX|Participants who were previously treated with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) with or without RBV will be followed up to 5 years.
62780814|NCT02292706||Other SOF-Based|Participants who previously received other SOF based regimen will be followed up to 5 years.
62191881|NCT02075619|EXPERIMENTAL|Sequence 3|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-1 tablet in Period 1, one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 2; and one GSK3074477 FDC formulation-2 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
62191882|NCT02075619|EXPERIMENTAL|Sequence 4|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-1 tablet in Period 1; one GSK3074477 FDC formulation-2 tablet in Period 2; and one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
62397411|NCT04798664|ACTIVE_COMPARATOR|Enhanced Usual Care|Participants receive the basic usual care of Ask-Advise-Refer as well as free access to nicotine replacement therapy (NRT) and/or reimbursement of up to $300 for any smoking cessation medications (varenicline/Chantix or bupropion/Zyban) prescribed by non-study clinicians.
62397412|NCT04798664|ACTIVE_COMPARATOR|Enhanced Usual Care plus Financial Incentives|Participants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively.
62397413|NCT04798664|ACTIVE_COMPARATOR|Enhanced Usual Care plus Financial Incentives plus Mobile Health Application|"Participants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the future is now between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner."
62572748|NCT01040637|EXPERIMENTAL|TD-1211 dose level 4|Ascending doses
62572749|NCT01040637|EXPERIMENTAL|TD-1211 OIC dose level 1|Ascending doses
62780815|NCT02292706||Enrolled From Ineligible Parent Treatment Group|Participants were enrolled from ineligible parent treatment group.
62780816|NCT06253169||Not participating in screening|All women over 30 years of age who are not participating in screening or have not had a screening visit in less than 5 years.
62780817|NCT06253169||Participating in the screening|All women over 30 years of age who regularly participate in screening but have not had an HPV test in the last 3 years.
62780818|NCT05253781|EXPERIMENTAL|Intervention|Low dose aspirin (LDA) group will receive 100mg aspirin daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
62780819|NCT05253781|PLACEBO_COMPARATOR|Control|Placebo group will receive one tablet of the placebo which has same shape, size, thickness and colour as the LDA daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
62021027|NCT03637998|EXPERIMENTAL|PROPEL|The Problem-solving Pain to Enhance Living Well (PROPEL) intervention entails each participant watching 10 video modules via REDCap. These modules include: (1) pain neurophysiology, (2) catastrophizing, (3) stress reactivity, (4) fear of movement, (5) progressive relaxation, (6) deep breathing, (7) guided imagery, (8) heat, ice and stretching, (9) strategies for physical activity self-activation and (10) problem-solving.
62780820|NCT05196087||NIP IT!|Patients with early stage or locally advanced disease that is planned for or have undergone curative treatment will have next-generation sequencing (NGS)-based ctDNA analysis performed on blood samples to determine minimal residual disease (MRD). Blood samples, stool samples, and additional archival/fresh tumor specimens will be collected for banking and future research purposes.
62791808|NCT04473027||Patients with advanced melanoma|Patients receiving anti-PD-1 monotherapy (Nivolumab or Pembrolizumab) in the first-line setting
62191883|NCT02075619|EXPERIMENTAL|Sequence 5|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-2 tablet in Period 1; one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 2; and one GSK3074477 FDC formulation-1 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
62191884|NCT02075619|EXPERIMENTAL|Sequence 6|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-2 tablet in Period 1; one GSK3074477 FDC formulation-1 tablet in Period 2; and one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
62191885|NCT02850042|EXPERIMENTAL|Occupation-based practice|Occupation-based intervention (OBP) is a form of activity-based therapy consisting of client-directed occupations that match client-identified goals. OBP group will participate in activities such as wood working, scrap booking, higher level dressing (don/doffing a bra, zipping coat), hair care, opening doors, using bathroom stalls, typing, cooking, tying shoes, washing dishes, carrying dirty dish carts, clearing dirty dishes and raking. Repetition of the tasks are not the focus in the OBP group. Each session lasted 55-minute and it was delivered twice a week for 4 weeks (8 sessions).
62191886|NCT02850042|ACTIVE_COMPARATOR|Modified-constraint induced therapy|Modified-constraint induced therapy (m-CIT) group will target functional goals (eg, activities of daily living) or goal subcomponents (eg, pinching, grasp/release, or functional reach patterns). Tasks were repeated at rate of approximately 10 to 50 repetitions each session according to the demands of the task. No physical constraint of the less-affected UE will be applied, but training compelled highly repetitive use of the more-affected upper extremity. Subjects will attempt tasks with progressive difficulty. Each session lasted 55-minute and it was delivered twice a week for 4 weeks (8 sessions).
62191887|NCT06152679||Patients|Patients who have undergone day-case bladder tumour resection or bladder outflow obstruction surgery (prostate resection or enucleation) within the past 6 weeks.
62191888|NCT03422445|EXPERIMENTAL|Apatinib plus Temozolomide|this trial is designed single arm. all the subjects enrolled will receive the experimental intervention,apatinib+temozolomide.
62191889|NCT05550753|EXPERIMENTAL|Intervention|Will be offered the BT coaching intervention during of 4-months (February 1st 2023- May 31st 2023).
62191890|NCT05550753|PLACEBO_COMPARATOR|Control|Will NOT be offered the BT coaching intervention during of 4-months (February 1st 2023- May 31st 2023). Will be offered the coaching intervention after the study completion (from September 1st 2023 - December 31st 2023).
62191891|NCT01521247|NO_INTERVENTION|Control group|Usual care.
62191892|NCT01521247|OTHER|Asthma Transition Program|Asthma Transition Program
62191893|NCT04629456|EXPERIMENTAL|group 1|A total of eight electrodes were placed on the quadriceps femoris muscles (four on each leg): two on the vastus medialis, one on the rectus femoris muscle, and one on the vastus lateralis muscle. The stimulation protocol of the NMES consisted of a symmetrical biphasic square pulse at 75 Hz, a duty cycle of 6 seconds (sec.) on and 29 sec. off, a pulse time of 410 sec. during a session lasting 20 min. The intensity was increased to maximum individual toleration. The muscle contractions were visible and palpable.
62397414|NCT03351426|ACTIVE_COMPARATOR|Active tDCS Group|Subjects will receive a total of eight tDCS sessions: 1st week five daily sessions (Monday to Friday), followed by 2nd week three sessions only (Monday, Wednesday, Friday). tDCS sessions will consist of 20 minutes stimulation at 2mA. Target: left dorsolateral prefrontal cortex (DLPFC). Montage: 5x5 sponge electrodes placed over EEG 10:20 system location F3 (anode) and right supraorbital area (cathode).
62397415|NCT03351426|SHAM_COMPARATOR|Sham tDCS Group|Subjects will receive a total of eight tDCS sessions: 1st week five daily sessions (Monday to Friday), followed by 2nd week three sessions only (Monday, Wednesday, Friday). tDCS sessions will be sham stimulation (30-second ramp up and down). Target: left dorsolateral prefrontal cortex (DLPFC). Montage: 5x5 sponge electrodes placed over EEG 10:20 system location F3 (anode) and right supraorbital area (cathode).
62397416|NCT04936646|EXPERIMENTAL|Classic rTMS Stimulation using the B65 Coil|
62397417|NCT04936646|EXPERIMENTAL|Deeper rTMS Stimulation using the B70 Coil|
62397418|NCT04936646|SHAM_COMPARATOR|control group with a sham stimulation using a sham coil|
62397419|NCT06718413|EXPERIMENTAL|Hyaluronidase plus saline (Treatment Arm)|hyaluronidase plus saline injection
62397420|NCT06718413|EXPERIMENTAL|Saline injection (Control Arm)|normal saline injection
62397421|NCT02398292|OTHER|M3 Program|Non-randomized experimental group. The program is a six-week multi-modal intervention, including nutrition education and cooking classes, physical activity, and mindfulness. Outcomes will be compared to a non-randomized control group.
62397422|NCT02398292|OTHER|Control|Non-randomized control group. Outcomes will be compared at same time points (baseline, 6 weeks, 12 weeks).
62397423|NCT06724250|ACTIVE_COMPARATOR|Biofeedback therapy group|Patients with dyssynergic defecation underwent biofeedback training program in the form of six sessions over one month
62572750|NCT01040637|EXPERIMENTAL|TD-1211 OIC dose level 2|Ascending doses
62572751|NCT01040637|EXPERIMENTAL|TD-1211 OIC dose level 3|Ascending doses
62572752|NCT01040637|EXPERIMENTAL|TD-1211 OIC dose level 4|Ascending doses
62397424|NCT06724250|ACTIVE_COMPARATOR|Botox injection group|Participants in this group received 100 international unit of botulinum toxin type A that was injected injections into the puborectalis muscle to alleviate dyssynergic defecation by reducing muscle overactivity and improving coordination.
62397425|NCT00999453|EXPERIMENTAL|LDL-cholesterol 70 mg/dL or lower|'Experimental arm' is defined as patients treated to lower the level of low-density lipoprotein to 70 mg/dl or lower. 'Control arm' is defined as patients treated to lower low-density lipoprotein to a level of 100 mg/dl or lower.
62572753|NCT01040637|EXPERIMENTAL|TD-1211 OIC dose level 5|Ascending doses
62572754|NCT01040637|PLACEBO_COMPARATOR|Placebo|Ascending doses
62572755|NCT05361577|ACTIVE_COMPARATOR|Active astimulation|Active sessions will last 1 hour each. The following parameters will be used for electric stimulation: low frequency (20 Hz), low current intensity (2 mA), with a small pulse width of 25-170 microseconds.
62572756|NCT05361577|SHAM_COMPARATOR|Sham stimulation|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
62572757|NCT03924180|EXPERIMENTAL|GMP - Dietary Supplement for PKU patients|Glycomacropeptides -GMP Glytactin
62191894|NCT04629456|EXPERIMENTAL|Group 2|The chair-seated exercises were used in the early stages of the program because the participants were frail adults. Repetitions of toe raises, heel raises, knee lifts, knee extensions, and others were performed while seated on a chair. Hip flexions, lateral leg raises, and repetitions of other exercises were performed standing upright behind the chair and holding the back of the chair for stability. To strengthen lower extremities, a fixed weight was placed on the ankle while participants performed strengthening exercises. Weights of 0.50, 0.75, 1.00, and 1.50 kg were used in accordance with each participant's strength level as the resistance progressively increased. The exercises performed using these ankle weights included seated knee flexion and extension and standing knee flexion and extensions. Exercises using a resistance band: Resistance bands were used to strengthen lower body. Lower body exercises included leg extension and hip flexion(24).
62191895|NCT05352945|NO_INTERVENTION|control arm|"conventional anaesthesia~The botulinum toxin injection procedure will be carried out in the standard way, according to the recommendations applicable in France, and after local anaesthesia."
62191896|NCT05352945|EXPERIMENTAL|interventional arm|"conventional anaethesia and use of the self-hypnosis mask~The mask and the helmet are positioned and activated 10 minutes before the procedure, with the travel to india programme chosen because it was developed for pain management and its duration is compatible with the procedure (25 minutes)."
62191897|NCT00947323|PLACEBO_COMPARATOR|placebo|
62191898|NCT00947323|EXPERIMENTAL|Simvastatin|Treatment arm.
62191899|NCT04386070|NO_INTERVENTION|Control (normal practice)|Treatment without the trial intervention. Patients will be treated as per hospital routine practice. The control arm may change over the course of the trial and will be monitored by the TMG and DMC
62191900|NCT04386070|EXPERIMENTAL|RESP301|RESP301 is administered quickly (8-10 minutes) via an easy-to-use, vibrating mesh nebuliser. The recommended nebulisers used to administer this intervention are available in all participating countries. The intervention will be administered using a nebuliser according to standard local practice; where permitted for patients to self-administer, a member of the clinical team will ensure that the patient has viewed the intervention administration training video, and will also oversee the patient for the first trial dose to ensure proper administration.
62191901|NCT00760747|EXPERIMENTAL|Slow Switching Group|Slow Switching Group (switch from full stimulant dose to atomoxetine, 1.2 mg/kg/day, orally (PO), during 10 weeks then continue treatment up to 1.8 mg/kg/day, PO to 14 weeks
62191902|NCT00760747|EXPERIMENTAL|Fast Switching Group|Fast Switching Group (switch from full stimulant dose to atomoxetine 1.2 mg/kg/day, PO, during 2 weeks then continue treatment up to 1.8 mg/kg/day, PO to 14 weeks
62191903|NCT03055169||intensive care patients|patients with a least one organ dysfunction
62191904|NCT03242668|EXPERIMENTAL|PVB using PVC for PCA in VATS|The VATS was performed.Paravertebral space was identified by loss of resistance technique combined with video-assisted inside thoracic space before chest close.PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA with background rate 3ml/h, bolus dose 2ml was infused through PVC.
62191905|NCT01030432|EXPERIMENTAL|Phase 2a: Arm 1|
62191906|NCT01030432|PLACEBO_COMPARATOR|Phase 2a: Arm 2|
62191907|NCT01030432|EXPERIMENTAL|Phase 2b: Arm 1|
62191908|NCT01030432|PLACEBO_COMPARATOR|Phase 2b: Arm 2|
62191909|NCT01949636||lean adolescents|
62191910|NCT00617929|EXPERIMENTAL|Conditioning for Graft Failure|Primary or secondary graft failure after hematopoietic stem cell transplantation defined as a \> 50% loss of previously best donor chimerism or less than 25% donor chimerism beyond day +42 with pancytopenia and no evidence of relapse. Patients with any diagnosis, type of donor, hematopoietic cell graft or conditioning regimen should be considered for this study. Patients receive anti-thymocyte globulin, rituximab, and clofarabine.
62191911|NCT02422680||Patients referred to a colonoscopy|A min. of 800 patients referred to colonoscopy at Aalborg University Hospital. The 800 patients are from the out patient clinic. A mix of screening and non-screening patients.
62191912|NCT04067843|EXPERIMENTAL|Photodynamic treatment|Skin microbiome after photodynamic treatment before and after skin antisepsis
62191913|NCT01689363|EXPERIMENTAL|Arm H|Intradermal injection of Amphadase (hyaluronidase 150 USP units/mL)
62191914|NCT01689363|ACTIVE_COMPARATOR|Arm P|Intradermal injection of Histatrol (histamine base 0.1 mg/mL)
62572758|NCT03924180|ACTIVE_COMPARATOR|Control -Amino acids mixtures|Mixtures of conventional amino acids.
62572759|NCT05775393|EXPERIMENTAL|Group A|Serratus anterior plane block using 30ml of (bupivacaine 0 .25 % and dexamethasone 4 mg)
62191915|NCT01689363|PLACEBO_COMPARATOR|Arm N|Intradermal injection of saline (0.02 mL)
62191916|NCT04407936||coronary angiography|The investigators recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention
62397426|NCT00999453|ACTIVE_COMPARATOR|LDL-cholesterol 100 mg/dL or lower|'Experimental arm' is defined as patients treated to lower the level of low-density lipoprotein to 70 mg/dl or lower. 'Control arm' is defined as patients treated to lower low-density lipoprotein to a level of 100 mg/dl or lower.
62397427|NCT02106715|ACTIVE_COMPARATOR|Training|Two exercises for training of core stability and mobility.
62572760|NCT05775393|EXPERIMENTAL|Group B|Serratus anterior plane block using 30ml of (bupivacaine 0.25% and dexamethasone 4mg with ketamine 50 mg).
62191917|NCT03509246|EXPERIMENTAL|Pegylated liposomal doxorubicin plus Bortezomib combination|At BRCA wild-type platinum-resistant recurrent ovarian cancer patients, Pegylated liposomal doxorubicin and Bortezomib combination therapy for six cycles.
62191918|NCT05585918|ACTIVE_COMPARATOR|SEL Only|"SEL Only Condition supports include:~* School wide support for implementation of Second Step curriculum (e.g., technical assistance professional development, facilitated professional learning communities)~* Support to Positive Behavioral Intervention and Supports (PBIS) and Multi Tiered System of Supports (MTSS) and equity teams with alignment of initiatives~* Individualized technical assistance with Second Step SEL implementation"
62191919|NCT05585918|EXPERIMENTAL|SEL + Equity|"SEL + Equity (Second Step + Equity) supports include supports from the SEL Only condition plus:~* Training and implementation support for teachers to deliver 6 equity literacy lessons tailored to each grade level (4th and 5th for elementary schools; 6th - 8th for middle schools) and aligned with Second Step core content~* Five 45-minute school-wide equity focused Professional Development (PD) sessions to complement AACPS Equity PD~* Individualized teacher coaching to support implementing equity practices and equity-focused classroom lessons"
62191920|NCT06545279|EXPERIMENTAL|Hall Crown Technique|preformed metal crowns (PMCs) cemented with no local anesthesia, caries removal or tooth preparation in one side.
62191921|NCT06545279|EXPERIMENTAL|Modified Hall Technique|preformed metal crowns (PMCs) cemented with no local anesthesia, caries removal but with prior interproximal slicing on other side
62191922|NCT01497106|EXPERIMENTAL|Calorie restriction|Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks.
62191923|NCT01497106|ACTIVE_COMPARATOR|Control|Participants will continue their normal living for entire time of the study, totaling 16 weeks.
62397428|NCT02106715|NO_INTERVENTION|Control|Control group without training
62397429|NCT01977066|EXPERIMENTAL|Six months supervised exercise training|
62397430|NCT01977066|EXPERIMENTAL|Six months home-based exercise training|
62397431|NCT01977066|NO_INTERVENTION|Control group|
62397432|NCT06722040||Before pediatric triage track|The dyads of children and their caregivers calling the Medical Helpline 1813 before the implementation of the pediatric triage unit (January 1, 2022 - June 30, 2022)
62397433|NCT06722040||After pediatric Triage track|The dyads of children and their caregivers calling the Medical Helpline 1813 after the implementation of the pediatric triage unit (January 1, 2023-June 30, 2023)
62572761|NCT04458402|EXPERIMENTAL|Hypofractionated Whole-Pelvis Radiotherapy|Hypofractionated WPRT Cohort 1: 41.25 Gy in 15 fx Cohort 2: 38 Gy in 10 fx
62791809|NCT02255461|EXPERIMENTAL|Treatment (palbociclib isethionate)|Patients receive palbociclib isethionate PO QD on days 1-21. Treatment repeats every 4 weeks for 26 courses in the absence of disease progression or unacceptable toxicity.
62006199|NCT06416748|OTHER|single arm|Patients with SHAPE inclusion criteria (FIGO 2018 stage IA2 and IB1 up to 2 cm, with limited stromal invasion: \&amp;amp;lt; 10 mm on LEEP/cone and \&amp;amp;lt; 50% depth on imaging) should undergo conization with surgical margins free from invasive disease or conization with involved surgical margins followed by MRI scan or expert ultrasound scan showing no residual disease. In case of residual disease at post conization imaging still fitting inclusion criteria, another conization is recommended. After these steps minimally invasive (laparoscopy or robotic) simple hysterectomy is performed with sentinel lymph node biopsy algorithm. Adjuvant therapy is given only in case of positive surgical margins, metastatic lymph nodes, and extensive LVSI with depth of stromal infiltration over 2/3.
62006200|NCT05839665|ACTIVE_COMPARATOR|Humidified high-flow oxygen|Humidified high-flow nasal oxygen delivered via the Optiflow device. Repeated series with 100% oxygen with flows varying between 30 to 50 l/min. Volunteers will also be pre-oxygenated with both opened and closed mouth.
62006201|NCT05839665|EXPERIMENTAL|Standard nasal cannula|Standard nasal cannula connected to an oxygen rotameter Repeated series with 100% oxygen with flows varying between 15 to 50 l/min. Volunteers will also be pre-oxygenated with both opened and closed mouth.
62006202|NCT05839665|ACTIVE_COMPARATOR|Facemask|"Tight-fitting facemask. Two series will be done where pre-oxygenation will be performed with four minutes of tidal volume breathing and eight vital capacity breaths.~This arm is not randomised. All study subjects will start with facemask pre-oxygenation and are thereafter randomised to standard nasal cannula or humidified high-flow nasal cannula."
62006203|NCT03243968||Ischemic patient - IP|25 participants with myocardial ischemia detected by scintigraphy and normal coronarography
62006204|NCT03243968||Control group - CG|25 healthy non-ischemic individuals
62006205|NCT05022823|ACTIVE_COMPARATOR|Standard of Care|Group A (Control). Home decongestive exercise regimen + daytime use of a compression sleeve (12 hours per day)
62006206|NCT05022823|EXPERIMENTAL|DPRE + compression sleeve during exercise|Group B. Decongestive Progressive Resistance Exercise + compression sleeve use during exercise + daytime use of a compression sleeve (12 hours per day)
62006207|NCT05022823|EXPERIMENTAL|DPRE + AC garment during exercise|Group C. Decongestive Progressive Resistance Exercise + Adjustable Compression (AC) garment use during exercise + daytime use of a compression sleeve (12 hours per day).
62006208|NCT03128879|EXPERIMENTAL|Treatment (venetoclax, ibrutinib, acalabarutinib)|Patients receive venetoclax PO QD and ibrutinib PO QD and acalabrutinib PO BID. Treatment repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unaccepted toxicity.
62006209|NCT02753894|EXPERIMENTAL|4.5 g/day group|Three times a day
62006210|NCT02753894|EXPERIMENTAL|6.0 g/day group|Three times a day
62006211|NCT02753894|EXPERIMENTAL|7.5 g/day group|Three times a day
62006212|NCT00622635|EXPERIMENTAL|Indacaterol 300 μg - placebo to indacaterol - salmeterol 50 μg|In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62021028|NCT06175728|EXPERIMENTAL|Use of S-Press|Use of the S-Press during in patient stay alongside usual physiotherapy sessions
62191924|NCT01760798|ACTIVE_COMPARATOR|Daily Teriparatide group|This group will recieve 20µg of teriparatide by subcutaneous route daily at 8 pm for 1 year
62191925|NCT01760798|EXPERIMENTAL|Weekly Teriparatide group|This group will recieve 60µg of teriparatide by subcutaneous route weekly at 8pm on Sunday for 1 year
62191926|NCT00590564|EXPERIMENTAL|1|All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal.
62191927|NCT04802304|EXPERIMENTAL|Treatment|
62397434|NCT04468139|EXPERIMENTAL|Quercetin|Quercetin 500 g of quercetin Quercetin will be administered orally once daily, in the morning before breakfast for 5-10 days or patient improves or discharged
62397435|NCT04678180|EXPERIMENTAL|Virtual tic training|A combination of treatment using virtual tic training and training at the hospital. In total nine sessions using a combined training of HRT and ERP. In four of the nine sessions (session 3, 5, 6, 7) training is performed as a virtual training. All sessions last 60 minutes
62191928|NCT04802304|NO_INTERVENTION|Control|
62397436|NCT04678180|EXPERIMENTAL|Video tic training|A combination of treatment using self-instructive videos and training at the hospital. In total nine sessions using a combined training of HRT and ERP. Four of the nine sessions are completed at the hospital (session 1 and 2 are combined 120 minutes, session 4: 60 minutes, session 8: 60 minutes and session 9: 60 minutes). For all sessions, self-instructive videos have been recorded instructing the child and their families how they should perform the training
62397437|NCT02327897||asthmatic|study group
62397438|NCT02327897||non-asthmatic|controls
62191929|NCT02358447||SPECT/CT before/after navigated TKR|SPECT/CT in patients before and after navigated TKR (assessment of bone tracer uptake, 3D CT component position)
62191930|NCT02358447||SPECT/CT before/after conventional TKR|SPECT/CT in patients before and after conventional TKR (assessment of bone tracer uptake, 3D CT component position)
62191931|NCT05584605|EXPERIMENTAL|aerobic treadmill training|Progressive graded, high-intensity aerobic treadmill training is delivered over 36 sessions at a frequency of 3x per week for 30-50 minutes of training per session over a period of 3 months. If possible, the training intensity is progressed from 40% to 80% of heart rate reserve, according to the supervising therapist.
62191932|NCT05584605|ACTIVE_COMPARATOR|stretching exercise|The control intervention includes stretching exercise therapy similarly heart rate controlled within limits up to 20% of heart rate reserve over 36 sessions at a frequency of 3x per week for 30 minutes.
62397439|NCT06722404|ACTIVE_COMPARATOR|standard therapeutic food group|The control group received standard therapeutic foods (F-75, F-100 and Plumpy'nuts)
62397440|NCT06722404|EXPERIMENTAL|therapeutic foods plus synbiotics group|the intervention group received therapeutic foods plus synbiotics containing Oligomate that was fortified in F75 at the rate of 7.5 g/L containing 4.1 g/L GOS for 1 g/100 kcal dose and at the rate of 11.5 g/L containing 6.1 g/L GOS for 1.5 g/100 kcal dose while in F100 and Plumpy'nuts it was fortified at the rate of 10 g/L containing 5.5 g/L GOS for 1 g/100 kcal dose and at the rate of 15 g/L containing 8.25 g/L GOS for 1.5 g/100 kcal dose and Resiton (Lactobacillus paracasei sbsp. paracasei) 3 billion cfu/day and 6 billion cfu/day that were mixed in different combinations.
62397441|NCT02491463|EXPERIMENTAL|GSK3389245A_LD GROUP|Subjects in this group will receive 2 doses, one month apart of the GSK3389245A vaccine low dose
62397442|NCT02491463|EXPERIMENTAL|GSK3389245A_HD GROUP|Subjects in this group will receive 2 doses, one month apart, of the GSK3389245A vaccine high dose
62397443|NCT02491463|ACTIVE_COMPARATOR|Bexsero Group|Subjects in this group will receive 2 doses, one month apart, of Bexsero
62397444|NCT02491463|PLACEBO_COMPARATOR|Placebo Group|Subjects in this group will receive 2 doses, one month apart, of placebo
62397445|NCT06724562||Anti-IL1 Observational Arm|FOP patients that are treated with Anti-IL1 Therapy
62397446|NCT06724562||Optional Non-Treatment Observational Arm|FOP patients unable to obtain Anti-IL1 therapy
62397447|NCT06722378|EXPERIMENTAL|Access to notes on a tablet|Participants will be provided a tablet and will be able to access their child's medical notes while in the hospital.
62397448|NCT06722378|NO_INTERVENTION|Care as usual|Participants will not have access to a table to view their child's medical notes while in the hospital.
62791810|NCT03177928|ACTIVE_COMPARATOR|study group|patients with myeloproliferative neoplasms and reveal cardiac complications by using echocardiogram, intervention by using transthorathic echocardiography for all patients.
62021029|NCT06560541|EXPERIMENTAL|Diabetes Patients Cohort Red Rice (DPC-RR)|
62021030|NCT06560541|PLACEBO_COMPARATOR|Diabetes Patients Cohort White Rice (DPC-WR)|
62191933|NCT01722747|EXPERIMENTAL|Intervention Condition|Tobacco Free Teachers, Tobacco Free Society (TFT/TFS)
62191934|NCT01722747|NO_INTERVENTION|Delayed Intervention Control condition|Receives abbreviated 3-month delayed intervention after final data collection time point
62191935|NCT03293836|EXPERIMENTAL|Radiofrequency treatment|Radiofrequency ablation of insufficient saphenous and perforating veins plus multilayer compressive bandage treatment
62191936|NCT03293836|ACTIVE_COMPARATOR|Multilayer Compressive Bandage only|Receive only compressive treatment
62397449|NCT06091891|ACTIVE_COMPARATOR|Control|
62397450|NCT06091891|EXPERIMENTAL|ROTEM-guided|
62397451|NCT05025891|NO_INTERVENTION|Arm 1: control|Patients continue consultations as usual in HDJA or at UMIT.
62397452|NCT05025891|EXPERIMENTAL|Arm 2: teleconsultation alone|Patients are directed to the tele-monitoring platform without specific accompaniment.
62397453|NCT05025891|EXPERIMENTAL|Arm 3: teleconsultation and mediation|Patients are referred to the tele-monitoring platform with specific support with mediation.
62397454|NCT02709980|PLACEBO_COMPARATOR|Sleep Education|6 sessions of sleep education.
62397455|NCT02709980|ACTIVE_COMPARATOR|Cognitive Behavior Therapy for Insomnia|6 sessions of cognitive behavioral therapy for insomnia (CBT-I).
62397456|NCT01405989|EXPERIMENTAL|Treatment arm A|darexaban, wash-out, ketoconazole + darexaban
62397457|NCT01405989|EXPERIMENTAL|Treatment arm B|ketoconazole + darexaban, wash-out, darexaban
62397458|NCT04081727|EXPERIMENTAL|Test Article - Zip-stitch Clips|Zip-stitch clips for vaginal cuff closure during laparoscopic hysterectomy
62397459|NCT04081727|OTHER|Reference Group - V-Loc Barbed Suture|Will not be comparative against the test article, but will be performed for reference and safety.
62397460|NCT02672748|EXPERIMENTAL|Gardening|Receiving two years of technical, labor and financial support in starting, growing, and harvesting from a home food garden.
62397461|NCT02672748|NO_INTERVENTION|Control|The control families receive a garden as a delayed intervention after two years.
62397462|NCT05186688|EXPERIMENTAL|Physical activity|Patients are encouraged to participate in physical exercise at the psychiatric unit
62397463|NCT05866757|NO_INTERVENTION|Continuation - Group 1: Detectable disease|Continuing Maintenance Therapy- Patients with biochemically detectable disease who have failed to achieve Complete remission (CR) or Very good Partial Remission (VGPR) by IMWG criteria and/or MRD-positive and/or high risk features. They will continue maintenance therapy until disease progression with monitoring every 3 months as per standard of care (SOC), or more often if required. In case of disease progression these patients will be switched to a different treatment and withdraw from the study. QOL will be assessed.
62397464|NCT05866757|NO_INTERVENTION|Continuation - Group 2 Subgroup A: Remission|"Continuing Maintenance Therapy- Patients in biochemical remission, who meet IMWG criteria for very good partial response (VGPR) or complete response (CR and and sustained MRD (defined as MRD-negative at two time points that are at least 1 year apart) without high risk features. High-risk cytogenetics abnormalities defined as per IMWG criteria (del(17p) and/or t(4;14) and/or t(14;16)) , or any other features suggestive of high risk disease: extramedullary disease, poor response to first line therapy, plasma cell leukaemia, organomegaly secondary to infiltration by multiple myeloma.~Maintenance will continue until disease progression, monitored every 3 months as per SOC or more often if required. In case of disease progression these patients will be switched to a different treatment and withdraw from the study. QOL will be assessed."
62780821|NCT01204216|ACTIVE_COMPARATOR|Aim 1|Subjects in this arm will be 10 people without diabetes as well as 10 people with diabetes and stable glycemic control. Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
62780822|NCT01204216|ACTIVE_COMPARATOR|Aim 2|For Aim 2, 10 additional subjects with diabetes in poor glycemic control will be studied initially and then again in improved glycemic control after at least 8 months (with up to 5 additional subjects entered as needed to ensure 10 completed paired studies) to assess the potential role of MRBC variation in the discordances seen between HbA1c and blood glucose testing. Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
62780823|NCT05407857|EXPERIMENTAL|On-site|The on-site multi-modal intervention will be actively involved in management with nutrition, exercise and cognitive programs. The on-site intervention group requires subjects to participate in prescribed place according to the protocol.
62572762|NCT05005195|OTHER|Abdominal CT Scan|A policy of invitation to a targeted community-based non-contrast CT screening of the abdomen in those at risk of kidney cancer.
62780824|NCT05407857|ACTIVE_COMPARATOR|Remote|The remote intervention group is designed for reducing the chances of person-to-person contact response to the current COVID-19 pandemic and development of digital internet. It uses innovative technology combining wearable devices with inertial measurement units, blue-tooth equipment, apps, feedback technology and artificial intelligence based remote comprehensive training programs.
62780825|NCT05407857|PLACEBO_COMPARATOR|Control|The control group will also receive the same health evaluation and education as all intervention groups.
62780826|NCT03147443|EXPERIMENTAL|Individualized Decoction|"It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.~The Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
62780827|NCT03147443|PLACEBO_COMPARATOR|placebo|"Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The placebo and test drug have no differences in dosage form, appearance, color, specification, label, and so forth.~The placebo is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
62780828|NCT03147443|ACTIVE_COMPARATOR|Tested drug minus heat-clearing herbs|"It is the decoction of the Individualized Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.~This control Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
62780829|NCT01058629|EXPERIMENTAL|SynergEyes A2 Hybrid Contact Lens|
62021031|NCT06560541|EXPERIMENTAL|Healthy Control Cohort Red Rice (HCC-RR)|
62780830|NCT05688020|EXPERIMENTAL|Tranexamic acid|During the ER procedure, de-identified injectate solution will be introduced. Study group: 9 ml of standart solution for injection \[Consisit of: 6 ml indigo carmine + 500 ml succinylated gelatin 4% (Gelofusine; B. Braun, Crissier, Switzerland)\] + 1 ml (100mg) of TXA (tranexamic acid).
62021032|NCT06560541|PLACEBO_COMPARATOR|Healthy Control Cohort White Rice (HCC-WR)|
62021033|NCT06112210|EXPERIMENTAL|HBOT group|
62021034|NCT06112210|PLACEBO_COMPARATOR|CON group|
62572763|NCT01015365|OTHER|Surgical revision|Surgical cementless One-stage revision of the chronic infected hip arthroplasty
62191937|NCT01111240||Psoriatic Arthritis|Participants with Psoriatic Arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 24 months.
62191938|NCT05765201||High IOP|Eyes in this arm will maintain an IOP of 65mmHg throughout the cataract surgery.
62191939|NCT05765201||Low IOP|Eyes in this arm will maintain an IOP of 28mmHg throughout the cataract surgery.
62191940|NCT06417034|EXPERIMENTAL|Music-based game training|Subjects will be asked to press their finger while a series of archery target continuously drop down and pass by the bottom line follow the beats of music melody on Tipr.
62191941|NCT06417034|ACTIVE_COMPARATOR|Non music-based game training|The background music will be disabled. Subjects need to press equally amount of force in certain tolerance that been set by only the visual cue on Tipr.
62191942|NCT03343093|EXPERIMENTAL|Intervention Evaluation Control Group|Surveys at 3 month intervals
62191943|NCT03343093|EXPERIMENTAL|Intervention Evaluation Test Group|We will evaluate the effects of an educational, tailored, online rehabilitation program addressing sexual and urinary outcomes after treatment by surveying at 3 month intervals
62191944|NCT03329300|OTHER|All participants|Family-based Behavioral Treatment (FBT)
62191945|NCT01857726|EXPERIMENTAL|The TACE/TACI combination group|Transarterial chemoembolization with doxorubicin/transarterial chemoinfusion with cisplatin combination
62191946|NCT01857726|ACTIVE_COMPARATOR|The TACE-only group|Transarterial chemoembolization with doxorubicin
62191947|NCT06547788|EXPERIMENTAL|Mitral valve repair with creation of an 8m inter-atrial shunt|
62191948|NCT06547788|ACTIVE_COMPARATOR|Mitral valve repair without a shunt|
62191949|NCT04484584||Complex Decongestive Therapy Group (CDT)|"Complex Decongestive Therapy Group: The treatment was applied by a specialist therapist who received CDT training. The study group rehabilitation and CDT application is 1 hour. CDT Treatment Protocol:~Deep abdominal technique application Neck region CDT application (supraclavicular fossa circular motion-Eflöraj) Circular movements on ipsilateral Axillar lymph nodes Circular movements on bottle neck cubital fossa Front arm bucket pumping pump push MLD application of dorsal and palmar face of the hand to ulnar and radial bundles~Bandage Treatment (Fingers and hand and forearm bandage): Patients can stay for 6-8 hours or until the next day.~Patients can do exercises in bandages. The patient is given home education.~The treatment was made for approximately 30-45 minutes. Patients were given exercise training at home. Orthopedic rehabilitation is the same as the control group."
62191950|NCT04484584||Orthopedic Rehabilitation Group (OR)|"Orthopedic Rehabilitation Group: The treatment was made for approximately 30-45 minutes. Patients were given exercise training at home.~Orthopedic Rehabilitation Treatment Protocol:~Exercises to be done at 4 to 6 weeks: Wrist NEH (at the pain limit),active exercise,Grasp exercise~Exercises to be done at 6 to 8 weeks: Wrist NEH (at the pain limit),Active assistive / active exercise, Grasp exercise,Supination-pronation exercise. (Opposite baths and classical massage are recommended from orthopedics)~Exercises to be done at 8 to 10 weeks: Stretching exercises,Finger strengthening spring with Digiflex spring, Power web combo hand finger arm amplifier, Msd theraflex hand exercise dough, Theraband flevbar exercise bar.~Exercises to be done at 10 to 12 weeks Wrist strengthening exercises, Resistant exercises to all muscles."
62191951|NCT06051071|EXPERIMENTAL|Treatment|tDCS stimulation arm
62191952|NCT00683059|EXPERIMENTAL|Nab-paclitaxel|
62191953|NCT04649671|NO_INTERVENTION|Standard care|Hepatocellular carcinoma (HCC) patients with insulin resistance who underwent hepatic resection or radiofrequency ablation (RFA) will be enrolled. Patients included in the control arm will receive a booklet including information about physical activity recommendations and practice (education). After 12 weeks, they will also be provided mobile application and wearable device and perform exercise for 12 weeks.
62191954|NCT04649671|ACTIVE_COMPARATOR|Mobile health|HCC patients with insulin resistance who underwent hepatic resection or RFA will be enrolled. Patients included in the intervention arm will receive both booklet and mobile health program. They will perform exercise daily with mobile application and wearable device (warm-up, stretching, aerobic, and strengthening) for 24 weeks.
62780831|NCT05688020|ACTIVE_COMPARATOR|Epinephrine|During the ER procedure, de-identified injectate solution will be introduced. 9 ml of standart solution for injection \[Consisit of: 6 ml indigo carmine + 500 ml succinylated gelatin 4% (Gelofusine; B. Braun, Crissier, Switzerland)\] + 1 ml epinephrine 1:100,000 + 1 ml saline 0.9%.
62780832|NCT06437470|SHAM_COMPARATOR|conventional physical therapy program|participants will receive the conventional physical therapy program while using non-inflated cuff as a sham treatment during exercising.
62780833|NCT06437470|EXPERIMENTAL|blood flow restriction combined to conventional physical therapy program|participants will receive the conventional physical therapy program with the use of BFR cuff which will be inflated to reach 80% of limb occlusive pressure
62780834|NCT04132596|EXPERIMENTAL|Motor Complete Tetraplegia|C4-T1 American Spinal Injuries Association (ASIA) Impairment Scale Classification A or B spinal cord injury tscs with activity based therapy intervention
62780835|NCT04132596|EXPERIMENTAL|Motor Complete Paraplegia|T2-12 ASIA Impairment Scale A or B spinal cord injury tscs with activity based therapy intervention
62780836|NCT04132596|EXPERIMENTAL|Motor incomplete SCI|C4-T12 ASIA Impairment Scale C or D spinal cord injury tscs with activity based therapy intervention
62191955|NCT06082570|EXPERIMENTAL|All the subjects enrolled will receive the experimental intervention, c610 injection|
62191956|NCT03278743||low to moderate tea consumption|consumption of 0.4 to 4.6 cups of tea (200 ml) per day (n=463)
62191957|NCT03278743||High tea consumption|consumption of 4.6 to 11.9 cups of tea (200 ml) per day (n=213)
62191958|NCT05511337|OTHER|Control|Caloric restriction
62191959|NCT05511337|EXPERIMENTAL|Intervention A|Caloric restriction and control oxalate and citrate food
62191960|NCT05511337|EXPERIMENTAL|Intervention B|Real-life intervention, control of oxalates and citrates without restriction of kilocalories.
62191961|NCT02825186|EXPERIMENTAL|Loteprendol|Topical Loteprendol used after strabismus surgery
62191962|NCT02825186|EXPERIMENTAL|Dexamethasone|Topical Dexamethasone used after strabismus surgery
62191963|NCT01520337||patients undergoing outpatient colonoscopy|
62572764|NCT01563042|EXPERIMENTAL|Cohort 1 GSK2434735|Cohort 1: Single intravenous administration of GSK2434735 and Pharmacokinetic (PK) and Immunogenicity assessments up to 42 days post dose.
62191964|NCT04413422||propofol|Those patients planned for general surgery, who received propofol as an induction agent for general anesthesia.
62780837|NCT00496288|EXPERIMENTAL|prophylactic irradiation|prophylactic contralateral breast irradiation
62191965|NCT04413422||etomidate|Those patients planned for general surgery, who received etomidate as an induction agent for general anesthesia.
62780838|NCT00496288|NO_INTERVENTION|controls|Those that do not opt for prophylactic irradiation or mastectomy
62780839|NCT03581838||Acitve EoE|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals who have EoE who have not been treated or have not achieved remission from treatment.
62780840|NCT03581838||Remission EoE|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals who have EoE who are have achieved remission from treatment.
62191966|NCT04413422||thiopental|Those patients planned for general surgery, who received thiopental as an induction agent for general anesthesia.
62191967|NCT00136279|EXPERIMENTAL|School plus parent|Adolescents receive school-based curriculum (either Project TNT or Making a Difference) and mothers receive the Linking Lives curriculum
62780841|NCT03581838||Controls|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals without EoE.
62780842|NCT04078581|EXPERIMENTAL|healthy controls|Questionnaire and fecal sample collection
62006213|NCT00622635|EXPERIMENTAL|Placebo to indacaterol - salmeterol 50 μg - indacaterol 300 μg|In treatment period 1, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); and in treatment period 3, patients received indacaterol 300 μg once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62006214|NCT00622635|EXPERIMENTAL|Salmeterol 50 μg - indacaterol 300 μg - placebo to indacaterol|In treatment period 1, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); in treatment period 2, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); and in treatment period 3, patients received placebo to indacaterol once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62006215|NCT00622635|EXPERIMENTAL|Placebo to indacaterol - indacaterol 300 μg - salmeterol 50 μg|In treatment period 1, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received indacaterol 300 μg once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62021035|NCT00961974|NO_INTERVENTION|Standard Care|"* Routine diabetes support and education from diabetes health care team~* Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
62191968|NCT00136279|ACTIVE_COMPARATOR|School-only|Adolescents receive school-based curriculum and parents received a control curriculum on helping their child choose a high school
62191969|NCT00136279|EXPERIMENTAL|Parent-Only|In the sex risk reduction portion of the study only, a second experimental group consisted of parents receiving the Linking Lives intervention and adolescents receiving no in-school intervention
62191970|NCT01348152|PLACEBO_COMPARATOR|Placebo|Placebo TID
62191971|NCT01348152|EXPERIMENTAL|DAIKENCHUTO (TU-100) 15 g/day|TU-100 5g TID
62191972|NCT05224843|EXPERIMENTAL|Older adults in Primary Care setting|Elder mistreatment in the Primary Care setting.
62191973|NCT06201546|ACTIVE_COMPARATOR|TAP block|Transversus Abdominal Plane Block aplied after LSG. In TAP block local anesthetic(%0,25 bupivacaine-20ml)will be administrated the between the transversus abdominis muscle and the internal abdominal muscle fascia.
62191974|NCT06201546|ACTIVE_COMPARATOR|m-TAPA block|Modified-Thoracoabdominal Plane Block-pericondrial approach aplied after LSG. In m-TAPA block local anesthetic (0.25% bupivacaine-20ml) will be administrated between the transversus abdominis muscle and the internal abdominal muscle fascia under the costochondrial region.
62191975|NCT05803083|ACTIVE_COMPARATOR|Hyaluronic Acid 150 mg|Take 150 mg/day of hyaluronic acid.
62191976|NCT05803083|ACTIVE_COMPARATOR|Hyaluronic Acid 100 mg|Take 100 mg/day of hyaluronic acid.
62191977|NCT05803083|PLACEBO_COMPARATOR|Placebo|Take 0 mg/day of hyaluronic acid.
62397465|NCT05866757|OTHER|Discontinuation - Group 2 Subgroup B|Patients who prefer to discontinue maintenance therapy. Patients who have discontinued maintenance therapy earlier than 2 years due to side effects but also achieved sustained MRD negative CR might be also included in this subgroup. This subgroup will be monitored and per SOC with blood tests, and BM MRD by NGF. In case of detectable disease in any of the samples (blood or BM) they will be offered to restart on maintenance therapy. Changing to a different type of treatment could be also offered to these patients, after discussion with treating physician. In case of being switched to a different treatment patient will withdraw from the study. QOL will be assessed
62397466|NCT04742868|EXPERIMENTAL|Arm 1 QUADRICEPS TENDON WITH BONE GRAFT|Quadriceps tendon with bone will be used as graft for the surgery.
62397467|NCT04742868|EXPERIMENTAL|Arm 2 HAMSTRING TENDON GRAFT|Hamstring tendon with bone will be used as graft for the surgery
62397468|NCT04742868|EXPERIMENTAL|Arm 3. QUADRICEPS TENDON WITHOUT BONE GRAFT|Quadriceps tendon without bone will be used as graft for the surgery.
62572765|NCT01563042|EXPERIMENTAL|Cohort 2 GSK2434735|Cohort 2: Single subcutaneous administration of GSK2434735 and Pharmacokinetic (PK) and Immunogenicity assessments up to 42 days post dose.
62572766|NCT02770794|EXPERIMENTAL|All patients|Discontinue infliximab; Receive infliximab when relapse
62572767|NCT02407613|EXPERIMENTAL|MR-HIFU ablation|Ten patients undergo MR-HIFU ablation with the Sonalleve MR-HIFU Breast Tumor Therapy System (Profound Medical). According to a treat-and-resect protocol, these patients also undergo standard therapy consisting of breast cancer surgery 1 to 2 weeks after MR-HIFU treatment (+/- radiotherapy).
62572768|NCT02276755|ACTIVE_COMPARATOR|Intervention: 1|Dietary Supplement: Cholecalciferol (vitamin D3)
62791811|NCT03177928|ACTIVE_COMPARATOR|control group|patients with hematological disorders including myeloproliferative neoplasms without cardiac affection by using echocardiogram. Intervention will be in the form of using transthorath echocardiography with all patients to reveal any cardiac abnormalities.
62006216|NCT00622635|EXPERIMENTAL|Indacaterol 300 μg - salmeterol 50 μg - placebo to indacaterol|In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); and in treatment period 3, patients received placebo to indacaterol once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62006217|NCT00622635|EXPERIMENTAL|Salmeterol 50 μg - placebo to indacaterol - indacaterol 300 μg|In treatment period 1, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); and in treatment period 3, patients received indacaterol 300 μg once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62006218|NCT00972491|OTHER|0 sec, 60 sec, 90 sec|LMA will be inserted at 0, 60, and 90 seconds after eyelash reflex disappears
62006219|NCT00627679|EXPERIMENTAL|Treatment sequence: A, B, D, C|Treatment visits were separated by a 48-72 hour washout period. Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 2; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 3; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 4; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 5
62006220|NCT00627679|EXPERIMENTAL|Treatment sequence: B, C, A, D|Treatment visits were separated by a 48-72 hour washout period. Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 2; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 3; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 4; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 5
62006221|NCT00627679|EXPERIMENTAL|Treatment sequence: C, D, B, A|Treatment visits were separated by a 48-72 hour washout period. Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 2; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 3; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 4; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 5
62191978|NCT02778672||Infants with potential pneumonia|
62191979|NCT04771364||Standard care|"Patients aged \>65 years old scheduled for hip fracture between January 1st 2017 and December 31th 2019.~Standard anesthesiology cares were performed, as usual in our hospital institution."
62191980|NCT04771364||ASAP cohort|"Patients aged \>65 years old scheduled for hip fracture between January 1st 2020 and December 31th 2022.~Standard anesthesiology cares were performed, as usual in our hospital institution, but the investigator focused the attention on these cares' adaptation: early geriatrician's advice, prefer locoregional anesthesia techniques where possible, early surgical therapy and medical adaptation on chronic therapy."
62191981|NCT00460902|EXPERIMENTAL|Deep TMS stimulation|
62191982|NCT00460902|EXPERIMENTAL|DTMS with positive cognitive-emotional provocation|
62191983|NCT00460902|EXPERIMENTAL|DTMS with negative cognitive-emotional provocation|
62572769|NCT02276755|PLACEBO_COMPARATOR|Placebo Comparator: 2|Dietary Supplement: Placebo
62572770|NCT05736120||Phase I|Online bulletin boards (OBB)
62572771|NCT05736120||Phase II|Virtual focus groups (real-time)
62572772|NCT04440215|OTHER|Control|Usual rehabilitation care (no telerehabilitation, interdisciplinary meetings not systematically organized and/or not involving a complete team of professionals)
62572773|NCT04440215|EXPERIMENTAL|Telerehabilitation|A mix of home or rehabilitation center visits, telerehabilitation and interprofessional shared decision making process.
62006222|NCT00627679|EXPERIMENTAL|Treatment sequence: D, A, C, B|Treatment visits were separated by a 48-72 hour washout period. Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 2; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 3; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 4; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 5
62006223|NCT06408285|EXPERIMENTAL|TQC3927 powder for inhalation|TQC3927 powder for inhalation is administered as a single dose
62006224|NCT06408285|PLACEBO_COMPARATOR|TQC3927 powder for inhalation placebo|TQC3927 powder for inhalation placebo is administered as a single dose
62021036|NCT00961974|EXPERIMENTAL|Care Plus|"* Routine diabetes support and education from diabetes health care team~* Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
62191984|NCT00859976|ACTIVE_COMPARATOR|Plasma-sprayed shell|Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
62191985|NCT00859976|EXPERIMENTAL|BoneMaster coated shell|Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
62397469|NCT05219110|EXPERIMENTAL|Hyperhydration|"In this study arm, all eligible children are admitted for the administration of intravenous fluids.~The following specifics will form the basis of the fluid management protocol:~1. Reversal of dehydration: Initial ED rehydration strategies should focus on rapidly reversing dehydration.~2. Infusion of 200% of maintenance fluids x 24 hours~3. If hematocrit reduction \< 20% from initial value, repeat step #2 \[infusion of 200% maintenance fluids x 24 hours\].~4. Oral fluids permitted ad lib.~5. Once the target hematocrit reduction is achieved (20% decrement in initial HCT) AND a 10% weight gain, adjust total IV fluid volume to maintain targeted weight gain: insensible plus output (i.e., urine plus stool)."
62572774|NCT05369065|EXPERIMENTAL|Ablation Treatment|The participants randomized to this arm will receive Neurotronic ablation treatment.
62572775|NCT05369065|SHAM_COMPARATOR|Sham Treatment|The participants randomized to this arm will have a sham procedure (angiography only)
62572776|NCT05369065|EXPERIMENTAL|Single Arm non-Randomized Treatment|The participants treated in this arm will receive the Neurotronic ablation treatment
62572777|NCT00715273|ACTIVE_COMPARATOR|1 - single therapy group|Participants will receive atorvastatin, placebo niacin, and placebo colesevelam. The treatment target for LDL-C will be ≤80 mg/dl for the single therapy group.
62572778|NCT00715273|EXPERIMENTAL|2 - double therapy group|Participants will receive atorvastatin, niacin, and placebo colesevelam. The treatment target for LDL-C will be ≤80 mg/dl for the double therapy group.
62572779|NCT00715273|EXPERIMENTAL|3 - triple therapy group|Participants will receive atorvastatin, niacin, and colesevelam. The treatment target for LDL-C will be ≤60 mg/dl for the triple therapy group
62572780|NCT01775059|EXPERIMENTAL|Integrated sensor and infusion set.|
62780843|NCT01100775|EXPERIMENTAL|Galantamine, then Placebo|Participants took lead-in 3 days of 4mg/ twice a day of galantamine followed by 8 mg on the 4th day, the day of testing. Then, after a period of at least one month, participants took lead-in 3 days of 4mg/ twice a day of placebo followed by 8 mg on the 4th day, the day of testing.
62780844|NCT01100775|EXPERIMENTAL|Placebo, then Galantamine|Participants took lead-in 3 days of 4mg/ twice a day of placebo followed by 8 mg on the 4th day, the day of testing. Then, after a period of at least one month, participants took lead-in 3 days of 4mg/ twice a day of galantamine followed by 8 mg on the 4th day, the day of testing.
62780845|NCT04223908||FCS|patient with genetically documented familial chylomicronemia syndrome
62780846|NCT04223908||MCS|patient with genetically or phenotypically documented multifactorial chylomicronemia syndrome
62780847|NCT02300740|EXPERIMENTAL|low dose|500 mg nicotinamide riboside oral
62780848|NCT02300740|EXPERIMENTAL|high dose|1000 mg nicotinamide riboside oral
62191986|NCT02484989||Retinopathy of prematurity|Any baby with ROP who is treated or referred to another unit for treatment either in the form of laser therapy, cryotherapy, antiVEGF agent or vitrectomy/scleral buckling (or a combination of above treatments)
62191987|NCT04853615||Group 1|1st group will receive normal saline 10ml/kg over 6 hours before and 6 hours after radiocontrast
62572781|NCT02056184|ACTIVE_COMPARATOR|Adalimumab, masked ultrasound|Adalimumab and blinded ultrasound.
62572782|NCT02056184|EXPERIMENTAL|Adalimumab, unmasked ultrasound|Adalimumab and open ultrasound.
62780849|NCT02445066|OTHER|Open label|Vitamin D3 - 4,000 IU/day for 4 months
62780850|NCT03700437|EXPERIMENTAL|Fasting-Mimicking Diet (FMD)|"Participants randomized to the intervention arm (FMD) will be provided with Chemolieve®, a plant-based FMD that provides \~300 calories/fasting day and includes all the food to be consumed during the dietary intervention including supplements~Subjects will start the diet 3 days prior to chemo-immunotherapy and continue on the first day of chemo-immunotherapy for the first 4 cycles of therapy."
62191988|NCT04853615||Group 2|2nd group will receive allopurinol 300 mg and linagliptin 5 mg once daily
62191989|NCT04853615||Group 3|3rd group will receive the SGLT2i empagliflosin 25 mg once daily
62397470|NCT05219110|ACTIVE_COMPARATOR|Conservative Fluid Management|The conservative fluid management arm has been designed to align and integrate into existing local practice patterns. Implementation of this approach will allow institutions and their practitioners to choose their management of protocol eligible children. All children will undergo a protocolized baseline evaluation that includes reversal of dehydration (if present) and follow-up plan (see Pre-Pathway care). The fluid management decision in the ED (i.e., to treat dehydration) will be at the discretion of the clinical care team. In the absence of evidence of microangiopathy (i.e., normal urinalysis, LDH, hemoglobin and platelet counts, and creatinine concentrations), the decision to admit the child to hospital or discharge the child to home will be at the discretion of the clinical care team. If microangiopathy is present (i.e., abnormal urinalysis, LDH, hemoglobin or platelet counts, or creatinine concentrations) admission for monitoring will be required.
62191990|NCT04853615||Group 4|4thwill receive allopurinol and empagliflosin.
62397471|NCT01431599|EXPERIMENTAL|short-course|
62397472|NCT05836649|EXPERIMENTAL|Active VR then Passive VR|Participant will conduct the experiment using active VR first and then passive VR
62397473|NCT05836649|EXPERIMENTAL|Passive VR then Active VR|Participant will conduct the experiment using passive VR first and then active VR
62397474|NCT05707806||healthy controls|generally healthy volunteers
62397475|NCT06724354|ACTIVE_COMPARATOR|intervention group|The patients in the experimental group were applied a care package protocol. Before the surgery; ensuring that the patient takes a shower, the necessity of shaving, the application of appropriate surgical prophylaxis, and the provision of preoperative glycemic control were applied to the experimental group. During the surgery; ensuring appropriate surgical hand hygiene, complying with aseptic technique, preparing the skin with appropriate antiseptic solution, keeping the patient's body temperature above 36°C during the surgery, repeating antibiotic prophylaxis in prolonged surgeries, and ensuring optimum oxygenation were applied. After the surgery; ensuring aseptic technique during dressing, ensuring hand hygiene before and after each intervention to the wound, not opening the wound for the first 48 hours, not continuing surgical antibiotic prophylaxis for more than 24 hours after the surgery, and the provision of postoperative glycemic control were applied.
62397476|NCT06724354|NO_INTERVENTION|control group|The infection prevention package parameters were not applied and the routine practice of the clinic was continued.
62397477|NCT05364554|EXPERIMENTAL|Group 1: JNJ-77242113 Dose 1 Once Daily (QD)|Participants originally randomized to JNJ-77242113 Dose 1 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 QD from Week 0 through Week 36 in this study.
62397478|NCT05364554|EXPERIMENTAL|Group 2: JNJ-77242113 Dose 2 QD|Participants originally randomized to JNJ-77242113 Dose 2 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 2 QD from Week 0 through Week 36 in this study.
62397479|NCT05364554|EXPERIMENTAL|Group 3: JNJ-77242113 Dose 3 QD|Participants originally randomized to JNJ-77242113 Dose 3 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.
62191991|NCT06136026||Rectal cancer cohort|20,000 patients with rectal cancer will be included in this cohort and followed for five years.
62397480|NCT05364554|EXPERIMENTAL|Group 4: JNJ-77242113 Dose 1 Twice Daily (BID)|Participants originally randomized to JNJ-77242113 Dose 1 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 BID from Week 0 through Week 36 in this study.
62397481|NCT05364554|EXPERIMENTAL|Group 5: JNJ-77242113 Dose 3 BID|Participants originally randomized to JNJ-77242113 Dose 3 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 BID from Week 0 through Week 36 in this study.
62397482|NCT05364554|EXPERIMENTAL|Group 6: JNJ-77242113 Dose 3 QD|Participants originally randomized to placebo in originating Study 77242113PSO2001 will receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.
62397483|NCT05600855|EXPERIMENTAL|The group of daGOAT model prevention|"Model-predicted high-risk patients: ruxolitinib 5mg bid po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted moderate-risk patients: ruxolitinib 2.5mg bid p po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted low risk: regular aGVHD prophylactic regimens."
62397484|NCT06464081||Inter-rater reliability and intra-rater reliability|"Tongue protrusion, elevation and swallowing measurements will be assessed at three time points, each interspersed by a one-week to one-month interval.~Assessments will be conducted by the same rater during two of these time points, whereas another independent rater will conduct the assessments of the third time point."
62397485|NCT05623319|EXPERIMENTAL|Pembrolizumab/Olaparib|Patients will be treated with pembrolizumab plus chemotherapy during the Induction Phase. In case of responsive or stable disease, patients will enter the Maintenance Phase and will be treated with pembrolizumab plus olaparib until progression or up to a maximum of 35 cycles.
62191992|NCT06136026||Colon cancer cohort|20,000 patients with colon cancer will be included in this cohort and followed for five years.
62191993|NCT06136026||Colorectal adenoma cohort|10,000 patients with colorectal adenomas will be enrolled in this cohort and followed for five years.
62214769|NCT06381544|NO_INTERVENTION|Control|No Intervention: Routine practices Students will fill out the Introductory Information Form and State Anxiety Scale before being admitted to the laboratory. First, the students in the control group will be taken to the laboratory, during the skills training, the intravenous catheter application will be demonstrated on a simulation model by the researcher, and each student will practice on the model once. At the end of the application, after students fill out the State Anxiety Scale again, they will be taken to a different room/laboratory and evaluated for skill learning. The evaluation will be carried out by the researchers for each student individually and with a standard check-list.
62214770|NCT02138175||Patients at risk for bleeding|Patients at risk for bleeding
62397486|NCT00462501|EXPERIMENTAL|Chemotherapy and Bevacizumab With or Without Radiation|FOLFOX/Bevacizumab will be given for 4 cycles over 8 weeks; FOLFOLX6 without Bevacizumab will be given for an additional 2 cycles over 4 weeks. Oxaliplatin will be given on Day 1 of each cycle over 2 hours at 85 mg/m2 IV. Leucovorin will be given Day 1 of each cycle over 2 hours at 400 mg/m2 IV. Fluorouracil will be given on Day 1 of each cycle at 400 mg/m2 IVP, then Fluorouracil will be given at 1200 mg/m2 IVCI over Day 1 and 2. Bevacizumab will be given at 5mg/kg over 10 minutes on day 1. Patients will undergo re-staging within 3 weeks of completing their 6th cycle of FOLFOX. If the reassessment reveals that there has been no disease progression as compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection. If the surgical oncologist's reassessment is that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous infusional 5-fluorouracil.
62006225|NCT04410926|PLACEBO_COMPARATOR|control group|"Corrective exercises The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes. Each exercise was performed for 30 repetitions holding each repetition for 5 seconds (about three minutes).~Neuromuscular electrical stimulation The control group received placebo NMES with no current stimulation. In another words, the current intensity was set at 0mA while standing on both feet for 30 minutes."
62006226|NCT04410926|EXPERIMENTAL|intervention group|"Corrective exercises The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes. Each exercise was performed for 30 repetitions holding each repetition for 5 seconds (about three minutes).~Neuromuscular electrical stimulation~The experimental group received NMES aiming to reinforce the planter intrinsic foot muscles. High-voltage pulsed current was set at frequency of 85 Hz with 5 seconds contraction time and 12 seconds rest time while the ramp-up and ramp-down time were 0.3 and 0.7 respectively. The current intensity was adjusted based on the individual tolerance without reporting pain or discomfort while standing on both feet. The stimulation time lasted each session for 30 minutes."
62006227|NCT02573610|EXPERIMENTAL|DE-108|High concentration / Antibacterial Ophthalmic Solution
62397487|NCT02036892|EXPERIMENTAL|Lifestyle counseling with smartphones|Lifestyle counseling assisted by smartphones
62397488|NCT02036892|ACTIVE_COMPARATOR|Lifestyle counseling|Lifestyle counseling
62397489|NCT06715761|EXPERIMENTAL|Myofascial release group (MRG)|
62397490|NCT06715761|ACTIVE_COMPARATOR|Cupping therapy group (CTG)|
62397491|NCT06715761|NO_INTERVENTION|Control group (CG)|Wait-and-see
62572783|NCT02043795|OTHER|Treated with BVS|Symptomatic patients would be screened with a duplex ultrasound as per clinical practice prior to intervention. After informed consent for a standard angiography/intervention, the patient will undergo a planned intervention under general or local anaesthesia in an angiographic facility.
62572784|NCT04537234|EXPERIMENTAL|Group 1: High-Dose Quadrivalent Influenza Vaccine (QIV-HD)|Participants received a single injection of 0.7 milliliters (mL) QIV-HD, intramuscularly (IM) at Day 0.
62572785|NCT04537234|ACTIVE_COMPARATOR|Group 2: Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD)|Participants received a single injection of 0.5 mL QIV-SD, IM at Day 0.
62006228|NCT02573610|ACTIVE_COMPARATOR|Levofloxacin 0.5%|Low concentration / Antibacterial Ophthalmic Solution
62006229|NCT05448664|EXPERIMENTAL|Families HBM- mobile messaging|Family- and HBM-based behavioral intervention using mobile messaging
62006230|NCT05448664|ACTIVE_COMPARATOR|Adolescents HBM- mobile messaging|Student- and HBM-based behavioral intervention using mobile messaging
62006231|NCT05448664|PLACEBO_COMPARATOR|Adolescents e-pamphlets|Prevailing oral health education by e-version of pamphlets through mobile messaging
62006232|NCT04935307|EXPERIMENTAL|Patients with multiple chemical sensitivity (MCS)|MCS is characterized by odour intolerance and various somatic symptoms attributed to the influence of toxic environmental chemicals in low usually harmless doses.
62397492|NCT05789901|OTHER|MARVIN: a Chatbot for HIV patients|Co-construction of the chatbot, Usability study, Implementation, Evaluation of outcomes and Continuous improvements
62397493|NCT05789901|OTHER|MARVIN: a Chatbot for Community Pharmacists|Co-construction of the chatbots, Usability study, Implementation, Evaluation of outcomes and Continuous improvements
62572786|NCT03319732|EXPERIMENTAL|AERT 80 mg|Arbaclofen extended release tablet, 20 mg
62191994|NCT02802397|OTHER|Cases|"Cases and controls will benefit, as usual in France concerning infertility etiology examinations, of a follicle antral count by transvaginal ultrasound and AMH measurement.~At baseline, physicians will complete a short questionnaire to check the inclusion criterion, the results of the measurement of follicle count and hormone measurement (including AMH). Cases and controls will respond to self-administered questionnaire at inclusion with information about their medical history, their demographics, their tobacco and alcohol consumption, their occupation and products handled in the workplace. Blood samples (for measure of persistent organic pollutants and heavy metals) and urine (for measure of metabolites of glycol ethers) will be collect at baseline. Occupational exposures to solvents will be defined using job exposures matrices. The risk of decreased ovarian reserve will be analyzed using logistic regressions for each exposure of interest adjusting for potential confounders."
62397494|NCT05789901|OTHER|MARVINA: a Chatbot for Breast Cancer Patients|Co-construction of the chatbots, Usability study, Implementation, Evaluation of outcomes and Continuous improvements
62572787|NCT04707521|EXPERIMENTAL|3M tape ship-shaped combined with strap fixing method|"1. Cutting method of 3M adhesive tape of ship shape: cut a piece of 20cm×3cm elastic adhesive tape, fold it in half to form a rectangle of 10cm×3cm, cut 5cm straight line from the middle point of the crease, cut it at an Angle of 45°, fold and open the 3M elastic adhesive tape in half, which is the adhesive tape required for fixing. The final shape is similar to that of a ship, and it is named as 3M adhesive tape of ship shape.~2. Fixation method: The ship shape with 3M adhesive tape was pasted upward on the opposite cheek (near zygomatic), and the endotracheal intubation was wound around for two rounds and then glued to the near cheek (near zygomatic).Put the tooth pad next to the endotracheal intubation and wrap the tooth pad and catheter together for two turns with a short 3M adhesive tape of 12cm×1.5cm.Finally, fasten it with a lacing."
62572788|NCT04707521|NO_INTERVENTION|traditional X-shaped tape and string fixing|traditional X-shaped tape and string fixing
62572789|NCT06210113|EXPERIMENTAL|Mindfulness|8-week mindfulness-based stress reduction training
62006233|NCT04935307|EXPERIMENTAL|Patients with multi-systemic functional somatic disorders (FSD)|Based on empirical research, a phenotype of multi-systemic FSD or multi-organ bodily distress syndrome (multi-organ BDS) has been identified in the most severely affected patients who have symptoms from multiple organ systems, thus fulfilling the criteria for multiple FSS. Multi-organ BDS is a research diagnosis, and the terms FSD and BDS are used as synonyms. This diagnosis is defined by an identifiable physical symptom pattern with symptoms from four groups (a cardiopulmonary, a gastrointestinal, a musculoskeletal, and a general symptom group).
62397495|NCT05789901|OTHER|MARVIN CHAMP: a Chatbot for Pediatric Infectious Conditions|Co-construction of the chatbots, Usability study, Implementation, Evaluation of outcomes and Continuous improvements
62572790|NCT06210113|NO_INTERVENTION|Placebo|received usual care
62572791|NCT00203619|EXPERIMENTAL|1|Wireless capsule endoscopy
62006234|NCT04935307|EXPERIMENTAL|Healthy controls|Healthy participants
62006235|NCT01509794|ACTIVE_COMPARATOR|Low Valence|Participants in the low valence condition will participate in photo-based simulations. They will see a photo of the patient and hear affectively flattened audio. The script and clinical information remain the same as the high valence condition.
62397496|NCT00207831|EXPERIMENTAL|Tegafur uracile + radiotherapy|
62397497|NCT00207831|ACTIVE_COMPARATOR|radiotherapy|
62397498|NCT02210026|EXPERIMENTAL|Experimental|Infants will be assessed on standard bubble nasal CPAP, then on Seattle-PAP bubble nasal CPAP, then again on standard bubble nasal CPAP.
62397499|NCT06724744|ACTIVE_COMPARATOR|Manual diaphragmatic release group|30 elderly diabetic women participating in manual diaphragmatic release plus aerobic training
62572792|NCT00203619|ACTIVE_COMPARATOR|2|Standard care
62006236|NCT01509794|EXPERIMENTAL|High Valence|Participants in the high valence condition will participate in video-based simulations. They will see a rich multimedia presentation of the clinical encounter, with affectively enhanced audio. The script and clinical information remain the same as the low valence condition.
62006237|NCT04341480||Chemotherapy group|Routine chemotherapy every 3 weeks for 2 cycles, and follow up for 2 weeks after discharge from hospital. Total observation duration is 6 weeks.
62572793|NCT02090348|EXPERIMENTAL|dimethyl fumarate|DMF at a dose of 120 mg twice a day (BID) for the first 7 days and 240 mg BID for the remainder of study period (up to 12 months)
62191995|NCT02802397|OTHER|Controls|"Cases and controls will benefit, as usual in France concerning infertility etiology examinations, of a follicle antral count by transvaginal ultrasound and AMH measurement.~At baseline, physicians will complete a short questionnaire to check the inclusion criterion, the results of the measurement of follicle count and hormone measurement (including AMH). Cases and controls will respond to self-administered questionnaire at inclusion with information about their medical history, their demographics, their tobacco and alcohol consumption, their occupation and products handled in the workplace. Blood samples (for measure of persistent organic pollutants and heavy metals) and urine (for measure of metabolites of glycol ethers) will be collect at baseline. Occupational exposures to solvents will be defined using job exposures matrices. The risk of decreased ovarian reserve will be analyzed using logistic regressions for each exposure of interest adjusting for potential confounders."
62397500|NCT06724744|ACTIVE_COMPARATOR|Control group|30 elderly diabetic women participating in aerobic training only
62397501|NCT05365828||Gestational parents|The study is composed of a sample of LGBTQIA+ and cisgender, heterosexual parents who are receiving antenatal care at the participating hospitals.
62572794|NCT05944848|EXPERIMENTAL|1mg group|Single oral dose of 1 mg CL-197 capsules or CL-197 placebo
62572795|NCT05944848|EXPERIMENTAL|10mg group|Single oral dose of 10 mg CL-197 capsules or CL-197 placebo
62572796|NCT05944848|EXPERIMENTAL|30mg group|Single oral dose of 30 mg CL-197 capsules or CL-197 placebo
62572797|NCT05944848|EXPERIMENTAL|60mg group|Single oral dose of 60 mg CL-197 capsules or CL-197 placebo
62780851|NCT06260306|ACTIVE_COMPARATOR|Hip Activation Group|The hip activation HEP group will receive a combination of hip musculature activation exercises used by previous researchers that show an increase in hip muscle recruitment.
62006238|NCT04341480||Control group|No treatment, based on patient's choice. Total observation duration is 6 weeks.
62397502|NCT05653388||Enrolled Subjects|Once enrolled subjects will provide Optional Archival Tissue, Optional Fresh tumor for a biopsy and blood collections at baseline, optional day 8 of cycle 1, day 1 of cycles 2-6 and at progression
62397503|NCT05751421|EXPERIMENTAL|primary total knee replacement + Zynrelef|Patients undergoing primary total knee replacement with Extended Relief Bupivacaine and Meloxicam (Zynrelef)
62397504|NCT05751421|ACTIVE_COMPARATOR|primary total knee replacement + adductor canal block (ACB)|Patients undergoing primary total knee replacement with routine adductor canal block
62397505|NCT05859334|EXPERIMENTAL|Treatment (erdafitinib)|Patients receive erdafitinib PO QD in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI, OCT, and collection of blood samples throughout the trial.
62397506|NCT05653882|EXPERIMENTAL|AB248 Monotherapy Dose-Escalation|AB248 will be administered intravenously as a single agent
62397507|NCT05653882|EXPERIMENTAL|AB248 + pembrolizumab Combination Dose-Escalation|AB248 and pembrolizumab will be administered intravenously
62397508|NCT05653882|EXPERIMENTAL|AB248 Monotherapy Indication Expansion|AB248 will be administered intravenously as a single agent in disease specific cohorts
62572798|NCT05944848|EXPERIMENTAL|100mg group|Single oral dose of 100 mg CL-197 capsules or CL-197 placebo
62572799|NCT06096779|EXPERIMENTAL|Cohort A: Atezolizumab+Bevacizumab|Participants will receive Atezolizumab plus Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62572800|NCT06096779|EXPERIMENTAL|Cohort B: Atezolizumab|Participants will receive Atezolizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62572801|NCT06556433|EXPERIMENTAL|Rewards Group|Index participants in the Rewards Group will be scheduled to complete smoking status check-ins six times during the 6-month Treatment Phase: weekly for four weeks, then at three and six months. At each check-in, cigarette smoking abstinence will be assessed. Participants in the Rewards Group will receive informational materials on smoking cessation.
62572802|NCT06556433|NO_INTERVENTION|Comparison Group|Index participants in the Comparison Group will be scheduled to complete smoking status check-ins six times during the 6-month Treatment Phase: weekly for four weeks, then at three and six months. At each check-in, cigarette smoking abstinence will be assessed. Participants in the Comparison Group will receive informational materials on smoking cessation.
62572803|NCT02921984|EXPERIMENTAL|Docetaxel arm|Concurrent chemotherapy with Docetaxel if genetic testing show that the patient should be sensitive to this drug.
62572804|NCT02921984|EXPERIMENTAL|Pemetrexed arm|Concurrent chemotherapy with Pemetrexed if genetic testing show that the patient should be sensitive to this drug.
62572805|NCT02921984|EXPERIMENTAL|Cisplatin arm|Concurrent chemotherapy with Cisplatin if genetic testing show that the patient was nor sensitive to neither Pemetrexed nor Docetaxel
62572806|NCT04164966||New onset Type 1 Diabetes|
62572807|NCT04164966||Healthy Normal Volunteers (HNV)|
62780852|NCT06260306|EXPERIMENTAL|Combined Hip Activation and Core Stabilization Group|The hip activation plus core stabilization HEP group will receive the same hip exercises as the other group, plus core stabilization exercises used by previous researchers.
62791812|NCT03177928|ACTIVE_COMPARATOR|control group 2|healthy people from the same age and sex will be investigated using echocardiogram. Intervention will be in the form of using transthorathic echocardiography.
62780853|NCT05119400||COVID-19 group|"COVID-19 group will be made up of 30 patients that have a past diagnosis of COVID-19 with confirmed positive SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) PCR (polymerase chain reaction) test in their electronic medical record and were previously hospitalized at NYP/WCM (NewYork Presbyterian/ Weill Cornell Medicine) between March 1 and December 31, 2020 for a minimum of three days.~Administration of study instruments, including self-report measures of mood, anxiety, post-traumatic stress and adjustment, and objective neuropsychological tests of cognitive function will be done via telephone interview, videoconference interview, and/or Redcap survey for both groups."
62006239|NCT04301167|EXPERIMENTAL|Single group|An AB single-case experimental design will be used. An RCT would be inappropriate since the befriending intervention is known to improve wellbeing. As such participants will have data collected in a pre- and post-intervention phase, for a maximum of 13 time points. This approach has been identified by What Works Clearinghouse as an acceptable empirical design to include in evidence based practice reviews (Kratchowill et al., 2010).
62191996|NCT04719299|EXPERIMENTAL|smart phone application|Behavior modification of patients will be done by showing them smartphone application game. The game demonstrates the use of common dental equipment like mirrors, ultrasonic scalers, handpieces and suction tips, etc. in the form of animated pictures with visual and sound effects. The dentist will play the game to show the child the dental procedure that will be performed on him later.
62397509|NCT05653882|EXPERIMENTAL|AB248 + pembrolizumab Combination Indication Expansion|AB248 and pembrolizumab will be administered intravenously in disease specific cohorts
62397510|NCT00407979||People with Atopic Dermatitis|
62397511|NCT00407979||People with Psoriasis|
62572808|NCT02914613|EXPERIMENTAL|SF0166 low dose BID|SF0166 low dose instilled in study eye BID for 28 days of treatment.
62780854|NCT05119400||Comparison group|"The subjects in comparison group will be 30 patients previously hospitalized at NYP/WCM between March 1 and December 31, 2020 for a minimum of three days. The recruited subjects would have undergone hospitalization secondary to a medical diagnosis that was not COVID-19.~Administration of study instruments, including self-report measures of mood, anxiety, post-traumatic stress and adjustment, and objective neuropsychological tests of cognitive function will be done via telephone interview, videoconference interview, and/or Redcap survey for both groups."
62780855|NCT06525090||298 school children aged 9-10 years|298 school children aged 9-10 years.
62006240|NCT02755831|EXPERIMENTAL|Sleep Study + CPAP group|Pregnant women in early pregnancy may be randomized to this arm and be assigned Sleep study + CPAP treatment
62006241|NCT02755831|OTHER|Standard Prenatal Care group|Pregnant women in early pregnancy may be randomized to this arm and will receive standard prenatal care without CPAP treatment.
62006242|NCT06335771|NO_INTERVENTION|Lean Individuals|No intervention will be administered.
62006243|NCT06335771|EXPERIMENTAL|Metabolically abnormal obese Individuals (obesity with normoglycemia and abnormal liver fat content)|Participants will undergo a dietary weight loss intervention to achieve 10% weight loss over about 6 months.
62006244|NCT06335771|EXPERIMENTAL|Metabolically normal obese Individuals (obesity with normoglycemia and normal liver fat content)|Participants will undergo a dietary weight loss intervention to achieve 10% weight loss over about 6 months.
62006245|NCT06335771|EXPERIMENTAL|Individuals with Type 2 Diabetes Mellitus|Participants will undergo a dietary weight loss intervention to achieve 10% weight loss over about 6 months.
62191997|NCT04719299|ACTIVE_COMPARATOR|traditional behavior management technique|Using traditional behavior management techniques (Tell-Show-Do) which will be applied prior to local anesthesia administration
62191998|NCT03088774|EXPERIMENTAL|New web-application|Information material developed in a participatory design together with patients.
62191999|NCT03088774|EXPERIMENTAL|Patient Handbook|Public available information.
62192000|NCT04897204|EXPERIMENTAL|Left Atrial Appendage Electrical Isolation with One-stop treatment of atrial fibrillation|The patients received routine catheter ablation of atrial fibrillation with left atrial appendage occlusion and additional left atrial appendage electrical isolation operation.
62192001|NCT04897204|OTHER|One-stop treatment of atrial fibrillation|The patients received routine catheter ablation of atrial fibrillation with left atrial appendage occlusion.
62192002|NCT02449057|EXPERIMENTAL|JUST|Juveniles Under Supervision and Treatment. This entails swift, certain, and modest sanctions for violations of terms of community supervision.
62192003|NCT02449057|NO_INTERVENTION|Probation-as-Usual|Juvenile probation-as-usual.
62397512|NCT00407979||Generally healthy people|
62397513|NCT00407979||People with Atopic Dermatitis and Eczema Herpeticum|
62397514|NCT01556503||Pigmented Lesion|Patients identified as having a concerning pigmented lesion and the physician believes it is appropriate to biopsy to rule out melanoma.
62397515|NCT05732961|EXPERIMENTAL|Participants with gene mutations other than SF3B1|Participants with lower risk MDS or non-proliferative MDS/MPN with somatic splicing gene mutations other than SF3B1
62397516|NCT05732961|EXPERIMENTAL|Participants with SF3B1 mutation|Participants with lower risk MDS or non-proliferative MDS/MPN with SF3B1 mutation who had received hypomethylating agents and or lenalidomide.
62397517|NCT03504059|NO_INTERVENTION|Control|The usual educational program is applied
62572809|NCT02914613|EXPERIMENTAL|SF0166 high dose BID|SF0166 high dose instilled in study eye BID for 28 days of treatment.
62572810|NCT02353546|EXPERIMENTAL|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
62572811|NCT02353546|NO_INTERVENTION|Usual Care|
62397518|NCT03504059|ACTIVE_COMPARATOR|Short Intervention|A two-year specially designed educational program is applied. This program aims to encourage a healthy lifestyle through gamification, including diet education, physical activity and self esteem.
62780856|NCT03761342|NO_INTERVENTION|Control|A control arm that mirrors a traditional web-grocery store with no but with no FOP labels.
62780857|NCT03761342|EXPERIMENTAL|Multiple Traffic Light Labels|Similar to Arm 1, with Multiple Traffic Light labels displayed on all products FOP. A 60-second introductory video briefly explaining the MTL scheme will be shown before each shop in this Arm.
62780858|NCT03761342|EXPERIMENTAL|Nutri-Score|Similar to Arm 2, with Nutri-Score labels instead of MTL labels displayed on all products FOP. A 60-second introductory video briefly explaining the NS scheme will be shown to shoppers in this condition.
62780859|NCT04791085||general surgeons|General surgeons who work at general or private hospitals in Greece
62780860|NCT05184816|EXPERIMENTAL|Deferoxamine (DFO)|This study is an open-label, non-randomized, single-center, dose escalation phase 1a study of intrathecal deferoxamine (IT-DFO) in patients with leptomeningeal metastases (LM) from solid tumor malignancies, followed by a phase 1b dose expansion cohort at the recommended phase 2 dose (RP2D) in patients with LM from solid tumor malignancies. Study objectives will include safety (1a/1b), pharmacokinetics (PK) and pharmacodynamics (PD) of IT-DFO (1a), and preliminary anti-tumoral efficacy in patients with LM solid tumor malignancies (1b).
62780861|NCT01433094|EXPERIMENTAL|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving
62791813|NCT06546046|EXPERIMENTAL|ECG monitoring by telemetry device and patch-type ECG monitor at the same time|The patient undergoes electrocardiogram monitoring simultaneously through a telemetry device and a patch-type electrocardiograph.
62006246|NCT04581499|EXPERIMENTAL|DynamiCare Motivation Support Program|Intervention Group members will receive 32 weeks of remote Contingency Management (CM; financial motivational incentives), Recovery Coaching, substance testing, appointment reminding/tracking, and in-app Cognitive Behavioral Therapy (CBT). After 32 weeks, coaching, testing, appointment tracking and CBT will continue until an overall 12 months in the project is completed.
62006247|NCT04581499|OTHER|Untreated or Routine Care Control Group|Control participants will receive substance tests at the same frequency as Intervention participants, and the same incentive amounts for tests as treatment participants. Controls' payments, however, will not be contingent on positive/negative results, but rather only on valid, on-time submission. Controls will not receive coaching, CBT or rewards for appointments.
62006248|NCT03857802|EXPERIMENTAL|Sleep hygiene intervention|In the experimental group will proceed to the explanation of sleep hygiene measures to improve the quality of sleep. After 3 months, at the next health check, the quality of sleep questionnaire will be carried out together with the blood extraction.
62397519|NCT03504059|ACTIVE_COMPARATOR|Long Intervention|A four-year specially designed educational program is applied. This program aims to encourage a healthy lifestyle through gamification, including diet education, physical activity and self esteem.
62397520|NCT04881669|EXPERIMENTAL|low group|low thickness group
62006249|NCT03857802|NO_INTERVENTION|No sleep hygiene intervention|In the no intervention group, the same follow-up visits and the same blood extractions will be carried out, but no educational activity on sleep will be carried out.
62006250|NCT02866877||Subarachnoid Hemorrhage|
62021037|NCT00961974|EXPERIMENTAL|Care Ultra|"* Routine diabetes support and education from diabetes health care team~* Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
62397521|NCT04881669|EXPERIMENTAL|moderate group|moderate thickness group
62397522|NCT04881669|EXPERIMENTAL|high group|high thickness group
62192004|NCT06297044||Right Hemispheric Stroke|"Specific inclusion criteria for this participants' group are:~- unilateral right hemispheric lesion after an ischemic or hemorrhagic stroke.~There are no specific exclusion criteria for this participants' group (see general exclusion criteria).~Participants will undergo a detailed neuropsychological assessment as detailed in the study's detailed description and outcome measures sections."
62192005|NCT06297044||Left Hemispheric Stroke|"Specific inclusion criteria for this participants' group are:~- unilateral left hemispheric lesion after an ischemic or hemorrhagic stroke.~There are no specific exclusion criteria for this participants' group (see general exclusion criteria).~Participants will undergo a detailed neuropsychological assessment as detailed in the study's detailed description and outcome measures sections."
62192006|NCT06297044||Traumatic Brain Injury|"Specific inclusion criteria for this participants' group are:~* presence of a traumatic brain injury episode~* absence of previous neurological and psychiatric conditions.~There are no specific exclusion criteria for this participants' group (see general exclusion criteria).~Participants will undergo a detailed neuropsychological assessment as detailed in the study's detailed description and outcome measures sections."
62397523|NCT02141776|SHAM_COMPARATOR|Sham Controlled Arm|The subjects randomized to this group will not receive stimulation daily for four weeks.
62397524|NCT02141776|ACTIVE_COMPARATOR|Transcranial direct current stimulation (t-DCS)|The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
62397525|NCT05372614|EXPERIMENTAL|Treatment (neratinib, trastuzumab deruxtecan)|Patients receive neratinib PO QD on days 1-21 (days 8-21 of cycle 1, then days 1-21 in cycles thereafter for PD study) of each cycle and trastuzumab deruxtecan IV over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, CT scan and echocardiograpahy or MUGA scan throughout study. Additionally, patients may undergo a tissue biopsy at baseline.
62397526|NCT06515834|PLACEBO_COMPARATOR|Placebo|
62397527|NCT06515834|ACTIVE_COMPARATOR|FE 999301|
62397528|NCT05791201|EXPERIMENTAL|VX-264|
62397529|NCT06374511||Cohort|Inpatients diagnosed with decompensated cirrhosis form the Hepatology Unit, Nanfang Hospital, China. All patients with clinically verified diagnosis, irrespective of disease stage and etiology is included.
62397530|NCT02889926|EXPERIMENTAL|a swab according to the method of Levine|
62397531|NCT02889926|EXPERIMENTAL|Bacteriological referred to biopsy|
62397532|NCT06722638|EXPERIMENTAL|VR Arm|Pain and anxiety management in this arm will include: topical numbing cream 30 minutes prior to the scheduled procedure, option for a 0.05mg/kg (max 2 mg) oral/IV dose of lorazepam. VR headsets will be donned. After sterile cleaning of the lumbar spine area, lidocaine will be injected between L3-4 or L4-5 for local anesthetic. A 22-gauge needle of appropriate length (1.5, 2.5, 3.5 inch) will be used to access the intrathecal space. Cerebral spinal fluid will be collected for evaluation (standard procedure) and IT chemotherapy will be administered.
62397533|NCT06722638|NO_INTERVENTION|GA Arm|Pain and anxiety in this arm will be managed with general anesthesia, usually propofol, which is the current standard of care at Children's National Hospital.
62397534|NCT05930210|EXPERIMENTAL|ENERGI-F703 GEL|ENERGI-F703, topical application, 2 times daily for 16 weeks
62397535|NCT05930210|PLACEBO_COMPARATOR|ENERGI-F703 matched vehicle|ENERGI-F703 matched vehicle, topical application, 2 times daily for 16 weeks
62397536|NCT06724055||AIP|
62397537|NCT06724055||PPL|
62397538|NCT06724055||PDAC|
62397539|NCT00934661|EXPERIMENTAL|Extended Release Epidural Morphine|Four mg (0.4 ml) of EREM will be delivered to the epidural space and flushed with 1 ml of saline
62397540|NCT00934661|PLACEBO_COMPARATOR|Placebo Group|The epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
62397541|NCT05428176|EXPERIMENTAL|Arm I (high intensity e-Health program)|Patients and parents receive the high intensity eHealth intervention through the interactive website and via videoconferencing for 30-50 minutes once every 3 to 4 weeks for up to 5 sessions over 6 months. Patients and parents also receive usual care. After 6 months, parents attend booster sessions at months 7, 9, and 11.
62397542|NCT05428176|ACTIVE_COMPARATOR|Arm II (usual care)|Patients and parents receive usual care.
62397543|NCT06723249|ACTIVE_COMPARATOR|Intervention group|The participants under intervention group will receive stingless bee honey. At the same time, they will continue treatment as usual, their pharmacological like antidepressants or psychotherapy
62397544|NCT06723249|NO_INTERVENTION|Control group|The participants in the control group will not receive stingless bee honey. They will continue treatment as usual, their pharmacological like antidepressants or psychotherapy
62397545|NCT05586204|EXPERIMENTAL|Facilitate action narrowly|
62397546|NCT05586204|EXPERIMENTAL|Facilitate action broadly|
62397547|NCT05586204|EXPERIMENTAL|Boost intentions only|
62572812|NCT04028609|EXPERIMENTAL|Intervention|Subjects receive an intervention with 4 components: development of a personal health plan; review and support for medication adherence; connection with primary care provider within 30 days; and education about clinical indicators that call for immediate intervention.
62780862|NCT01433094|ACTIVE_COMPARATOR|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
62006251|NCT02333578|EXPERIMENTAL|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
62397548|NCT05586204|EXPERIMENTAL|Boost intentions and facilitate action narrowly|
62572813|NCT04028609|ACTIVE_COMPARATOR|Services as Usual|Subjects receive medical services as usual.
62192007|NCT06297044||Right Hemispheric Brain Tumor|"Specific inclusion criteria for this participants' group are:~- unilateral right hemispheric brain tumor.~There are no specific exclusion criteria for this participants' group (see general exclusion criteria).~Participants will undergo a detailed neuropsychological assessment as detailed in the study's detailed description and outcome measures sections."
62780863|NCT01303926|ACTIVE_COMPARATOR|Cisplatin and Pemetrexed|
62192008|NCT06297044||Left Hemispheric Brain Tumor|"Specific inclusion criteria for this participants' group are:~- unilateral left hemispheric brain tumor.~There are no specific exclusion criteria for this participants' group (see general exclusion criteria).~Participants will undergo a detailed neuropsychological assessment as detailed in the study's detailed description and outcome measures sections."
62397549|NCT05586204|EXPERIMENTAL|Boost intentions and facilitate action broadly|
62397550|NCT05586204|NO_INTERVENTION|Holdout|
62397551|NCT01263366|EXPERIMENTAL|Norepinephrine|
62397552|NCT05482776|ACTIVE_COMPARATOR|classic training group|The classic training group followed their routine of both physical and cognitive exercises that were recorded for their control. Balance exercises, strength and aerobic exercise. They were assessed at the beginning and at the end of the 10 weeks.
62006252|NCT06073925|ACTIVE_COMPARATOR|chronic ITP children with VD level less than 30 ng/ml.|will receive VD 3 50000 IU per week for 3 months beside their treatment for ITP.
62397553|NCT05482776|EXPERIMENTAL|HIFT group|The experimental group performed 10-weeks training program consisted in Warm-up phase and HIFT training. They were assessed at the beginning and at the end of the 10 weeks.
62397554|NCT05057975|EXPERIMENTAL|Sunrise|Home Sleep Test, OSA diagnosis based on mandibular movements recording
62397555|NCT05057975|ACTIVE_COMPARATOR|PSG|Polysomnography, OSA diagnosis based on local scoring by center
62572814|NCT03557619|EXPERIMENTAL|Ethinyl estradiol/Levonorgestrel and Venetoclax|Ethinyl estradiol/levonorgestrel is administered on Period 1 Day 1 and then again on Period 3 Day 1. Venetoclax is administered on Period 2 Day 1 and then daily thereafter.
62572815|NCT06235021|EXPERIMENTAL|Saffron|The experimental group will receive scaling and root debridement and will be instructed to use a mouthwash containing aqueous extract of saffron twice a day for 6 weeks.
62572816|NCT06235021|PLACEBO_COMPARATOR|chlorhexidine mouthwash.|The control group will receive scaling and root debridement and gargle their mouth with commercial product of 0.2% chlorhexidine mouthwash.
62780864|NCT01303926|ACTIVE_COMPARATOR|Carboplatin paclitaxel bevacizumab|
62780865|NCT02685904|EXPERIMENTAL|ENIA11|25 mg of ENIA11 subcutaneously administered twice weekly
62780866|NCT02685904|PLACEBO_COMPARATOR|Placebo|25 mg of Placebo subcutaneously administered twice weekly
62780867|NCT01794676||Family 1|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
62780868|NCT01794676||Family 2|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
62780869|NCT01794676||Family 3|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
62780870|NCT01620762|EXPERIMENTAL|Cat-Pad Treatment 1|Cat-PAD Treatment 1
62780871|NCT01620762|EXPERIMENTAL|Cat-PAD Treatment 2|Cat-PAD Treatment regimen 2
62780872|NCT01620762|PLACEBO_COMPARATOR|Placebo|Placebo
62780873|NCT00118950|ACTIVE_COMPARATOR|4|Metformin plus placebo-Repgalinide. Double-masked, randomized. Duration: Four months.
62780874|NCT00118950|ACTIVE_COMPARATOR|2|Repaglinide plus Placebo-Metformin. Double-masked, randomized. Duration: Four months.
62780875|NCT00118950|OTHER|1|Run-in period: Treatment: Diet-only. Duration: One month.
62780876|NCT00118950|OTHER|3|Wash-out period: Treatment: Diet-only: Duration: One month.
62780877|NCT05196555|EXPERIMENTAL|microscopic surgical repair of cleft palate with intravelar veloplasty (IVVP)|
62791814|NCT00526591|EXPERIMENTAL|Low-dose Everolimus Cohort|5mg Everolimus daily continuously for 8 weeks and conventional surgery
62397556|NCT06661603|EXPERIMENTAL|GSY Yoga Intervention|"GSY Goodbye Stress with Yoga Protocol Full body warm-up and light stretching exercise 15 min Performing various yoga postures - including standing, sitting, prone, and supine yoga postures (Asanas) 50 min Breathing exercises = (Pranayama)10 min and Meditation15 min~\*The development of the yoga protocol, named GSY Goodbye Stress with Yoga Protocol, was a collaborative effort involving a certified yoga trainer, a medical researcher, and experienced yogis from India."
62780878|NCT03588936|EXPERIMENTAL|Nivolumab (0.25 mg/kg) and Tocilizumab|"Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.25 mg/kg based on dose escalation design).~Nivolumab will be given every \~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on \~Day 29 on the same day as Dose # 3 of Nivolumab."
62780879|NCT03588936|EXPERIMENTAL|Nivolumab (0.5 mg/kg) and Tocilizumab|"Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.5 mg/kg based on dose escalation design).~Nivolumab will be given every \~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on \~Day 29 on the same day as Dose # 3 of Nivolumab."
62006253|NCT06073925|ACTIVE_COMPARATOR|chronic ITP children with VD level more than 30 ng/ml.|will receive VD 3 50000 IU per week for 3 months beside their treatment for ITP.
62397557|NCT06661603|NO_INTERVENTION|Control Group|The participants who don't receive any kind of therapy, which means the control group with standard care and without any treatment or intervention.
62397558|NCT04109573|EXPERIMENTAL|Anorectal function post anal laser|"Intervention:~Device: laser"
62397559|NCT06083038||Metastatic breast cancer starting alpelisib|
62397560|NCT02040415|EXPERIMENTAL|DW-1030(eperisone HCl)|DW-1030(eperisone HCl) 75mg BID
62397561|NCT02040415|ACTIVE_COMPARATOR|Myonal Tab.(eperisone HCl)|Myonal Tab.(eperisone HCl) 50mg TID
62397562|NCT04620356|EXPERIMENTAL|DryNites arm|"Participants in this arm use DryNites every night for 4 weeks (run-in period), an additional 4 weeks (intervention core trial period), and an optional additional 4 weeks (extension period). All participants in this arm also receive absorbent bad mats to use every night."
62397563|NCT04620356|NO_INTERVENTION|No Pants arm|"Participants in this arm use DryNites every night for 4 weeks only during the initial run-in period. Thereafter, participants in this arm do not use DryNites during the 4 week intervention core trial period or the optional additional 4 weeks extension period. All participants in this arm also receive absorbent bad mats to use every night."
62397564|NCT00684658|EXPERIMENTAL|1|TeenCope: Internet-based Coping Skills Training
62397565|NCT00684658|ACTIVE_COMPARATOR|2|Managing Diabetes: Internet-based Diabetes Education
62006254|NCT06073925|NO_INTERVENTION|Placebo|will receive their treatment for ITP.
62006255|NCT03501797|EXPERIMENTAL|Early singing intervention (AB)|Participants receive a 16 weeks of singing-based rehabilitation and standard care (SC) followed by 16 weeks of SC only.
62006256|NCT03501797|EXPERIMENTAL|Late singing intervention (BA)|Participants receive a 16 weeks of SC only followed by 16 weeks of singing intervention and SC.
62006257|NCT02472756||Follicular Lymphoma Participants|Previously treated adult participants with relapsed/refractory FL will receive rituximab in combination with chemotherapy regimen. All treatments prescribed during the observation period will be at the treating physician's discretion. Participants will be followed up for safety and efficacy evaluation in accordance with routine practice, up to 30 months.
62006258|NCT00192075|EXPERIMENTAL|A+FFG|Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid
62780880|NCT05282433|EXPERIMENTAL|Research Group|Patients with advanced hepatocellular carcinoma who had failed previous standard 1/2-line therapy and could not tolerate or reject existing therapies.
62780881|NCT04995861|ACTIVE_COMPARATOR|Group A (adductor canal only)|Will recieve adductor canal block only
62006259|NCT00192075|ACTIVE_COMPARATOR|A+FOLFOX 4|Avastin + Oxaliplatin + 5-Fluorouracil (5FU)/Folinic Acid
62006260|NCT04892485||CF patients|
62006261|NCT04892485||Controls|
62006262|NCT02538926|EXPERIMENTAL|Treatment (DA-EPOCH-A)|Patients receive etoposide, doxorubicin hydrochloride, and vincristine sulfate IV continuously over days 1-4, cyclophosphamide IV over 1 hour on day 5, and prednisone PO BID on days 1-5. Patients also receive asparaginase IM or IV over 1-2 hours every 2-3 days, beginning day 7 of each course. Patients who are CD20 positive and Philadelphia chromosome negative also receive rituximab IV on day 1 or 5. Patients who are Philadelphia chromosome positive also receive imatinib mesylate PO on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
62006263|NCT05942248|OTHER|Acne vulgaris|Inflammatory and non-inflammatory lesion counts
62006264|NCT05942248|OTHER|Rosacea|Inflammatory lesion count
62780882|NCT04995861|ACTIVE_COMPARATOR|Group AB (adductor canal + IPACK)|Will recieve both adductor canal block and IPACK
62780883|NCT01329939|EXPERIMENTAL|Obese atopic asthmatics, montelukast|Obese/overweight (BMI 85%ile or above for children and \> 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive montelukast in a double blinded fashion.
62780884|NCT01329939|PLACEBO_COMPARATOR|Lean atopic asthmatics, placebo|Normal weight (BMI less than 85%ile or above for children and \< 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive placebo in a double blinded fashion.
62780885|NCT01329939|ACTIVE_COMPARATOR|Lean atopic asthmatics, montelukast|Normal weight (BMI less than 85%ile or above for children and \< 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive montelukast in a double blinded fashion.
62780886|NCT01329939|PLACEBO_COMPARATOR|Obese atopic asthmatics, Placebo|Obese/overweight (BMI 85%ile or above for children and \> 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive placebo in a double blinded fashion.
62006265|NCT05942248|OTHER|Melasma|Pigment intensity and distribution with use of Melasma Area Severity Index
62780887|NCT03488277|EXPERIMENTAL|LE: leg elevation group|the patients of this group will be positionned in supine with 15° left tilt and will have a leg elevation with a 30 cm pillow positionned under the heels. this position will be hold immediately after spinal anesthesia until fetal extraction
62780888|NCT03488277|NO_INTERVENTION|CG: Control group|The patients of this group will be positiooned in supine with 15° left tlit after spinal anesthesia. no leg elevation
62780889|NCT02006849|OTHER|Acthar 40 units|Acthar 40 units subcutaneously three times a week for patients with sub-nephrotic proteinuria.
62780890|NCT02006849|OTHER|Acthar 80 units|Acthar 80 units subcutaneously twice a week for patients with nephrotic proteinuria.
62780891|NCT02036008|OTHER|Liver MRI with EcGd and with Gdfos|All participants will receive two contrast-enhanced MRI studies of the liver: one with gadofosveset trisodium (Gdfos) and one with gadobutrol (EcGd) at a dose of 0.1 mL/kg body mass up to 10 mL.
62780892|NCT03992443|EXPERIMENTAL|CUSA-081|Participants received 1 or 2 doses of CUSA-081, 0.70 milligrams (mg) per 2 milliliter (mL) directly into the catheter lumen. Participants received the first dose at minute (min) 0, and the second dose, if needed, at min 90. Assessments were performed at min 30, 60, 90, 120, 150, and 180.
62780893|NCT04090619||Observational (questionnaires)|Participants complete 8 questionnaires about appetite, quality of life, symptoms, history of weight loss, nutritional status, body image, and nutritional support over 30 minutes.
62780894|NCT04942405|EXPERIMENTAL|TURKOVAC SARS-COV-2 Vaccine|600 Subunit of SARS-CoV-2 virus antigen, intramuscular injection, two doses given 28 days apart.
62006266|NCT05942248|OTHER|Seborrheic Dermatitis|Grading of seborrheic dermatitis with Seborrheic Dermatitis Area Severity Index score
62006267|NCT01777997|EXPERIMENTAL|FTC/RPV/TDF|
62006268|NCT05637645|ACTIVE_COMPARATOR|Group M|It will involve participants who are given spinal anesthesia through midline approach.
62192009|NCT06297044||Mild Cognitive Impairment|"Specific inclusion criteria for this participants' group are:~* MCI diagnosis according to Petersen et al., 2006 criteria~* absence of previous neurological and psychiatric conditions.~There are no specific exclusion criteria for this participants' group (see general exclusion criteria).~Participants will undergo a detailed neuropsychological assessment as detailed in the study's detailed description and outcome measures sections."
62780895|NCT04942405|ACTIVE_COMPARATOR|CoronaVac|600 Subunit of SARS-CoV-2 virus antigen, intramuscular injection, two doses given 28 days apart.
62780896|NCT03208088|EXPERIMENTAL|Sequence 1|etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 4 (experimental)
62006269|NCT05637645|ACTIVE_COMPARATOR|Group P|It will involve participants who are given spinal anesthesia through paramedian approach.
62006270|NCT05637645|ACTIVE_COMPARATOR|Group T|It will involve participants who are given spinal anesthesia through Taylors approach.
62780897|NCT03208088|EXPERIMENTAL|Sequence 2|etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Control Lens (Active Comparator)
62780898|NCT03208088|EXPERIMENTAL|Sequence 3|etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 1 (experimental)
62780899|NCT03208088|EXPERIMENTAL|Sequence 4|etafilcon A Test Lens 4 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 1 (experimental)
62780900|NCT03208088|EXPERIMENTAL|Sequence 5|etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental)
62780901|NCT03208088|EXPERIMENTAL|Sequence 6|etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 2 (experimental / etafilcon A Test Lens 1 (experimental)
62780902|NCT03208088|EXPERIMENTAL|Sequence 7|etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental)
62006271|NCT03160924|ACTIVE_COMPARATOR|Enhanced Recovery After Surgery (ERAS)|"In this arm, the ERAS perioperative care program will be applied.~1. Preoperative counselling by surgeon, dietician and physiotherapist~2. Preoperative carbohydrate-loaded drink 800ml 12.5% Carbohydrate drink 8h before surgery 400ml 12.5% Carbohydrate drink 4h before surgery (Omit 4h drink if patient has DM)~3. Fluid restriction, avoid opioids, use of Cox-II inhibitors as analgesics~4. Avoid use of drains~5. Early resumption of diet~6. Early mobilisation with physiotherapist~7. Dietary counselling by dietician~8. Early discharge if fulfil discharge criteria.~Discharge criteria:~Adequate pain control with oral analgesics Ability to tolerate soft diet Passage of flatus Mobilization~Patients will be called by doctors every day after discharge to monitor their clinical status. There will be a low threshold for readmitting patients. Patients will also be given a hotline to call if they feel unwell. They will be seen in clinic on post-operative D7 and D14."
62780903|NCT03208088|EXPERIMENTAL|Sequence 8|etafilcon A Test Lens 1 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 4 (experimental / etafilcon A Test Lens 3 (experimental)
62780904|NCT03208088|EXPERIMENTAL|Sequence 9|etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 3 (experimental / etafilcon A Control Lens (Active Comparator) /etafilcon A Test Lens 4 (experimental)
62780905|NCT03208088|EXPERIMENTAL|Sequence 10|etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 1 (experimental / etafilcon A Control Lens (Active Comparator)
62780906|NCT03997110|ACTIVE_COMPARATOR|Arm A Or Control Arm- Long course palliative treatment.|Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
62780907|NCT03997110|EXPERIMENTAL|Arm B or Experimental Arm-Short course palliative radiation.|Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
62780908|NCT03800511||repeated caesarean section|full term pregnant women with singleton baby with a history of at least previous one caesarean section
62780909|NCT04957368|EXPERIMENTAL|Nitrous Oxide + saline solution|
62780910|NCT04957368|ACTIVE_COMPARATOR|Oxygen + Midazolam|
62780911|NCT02213484||Marfan syndrome|Individuals with a clinical diagnosis of Marfan syndrome
62780912|NCT02213484||Aortopathy syndrome|Individuals with one of the following clinical diagnoses: Loeys-Dietz syndrome, Turner syndrome, Ehlers-Danlos type IV syndrome, Thoracic Aortic Aneurysm and Dissection syndromes.
62780913|NCT04085913|ACTIVE_COMPARATOR|Current Practice|Thyroid or parathyroid surgery with local injection of lidocaine and epinephrine preincision, as is current practice.
62780914|NCT04085913|EXPERIMENTAL|Bupivicaine HCL|Thyroid or parathyroid surgery with local injection of bupivicaine HCL and Epinephrine preincision.
62780915|NCT04085913|EXPERIMENTAL|Exparel Injection|Thyroid and parathyroid surgery with local injection of lidocaine and epinephrine preincison and Exparel postincision
62780916|NCT02683863|OTHER|Group 1|"There will be 4 CSF sampling groups at the Week 6 visit for PK assessment:~1. Four subject for CSF samples 3 hours after dosing"
62780917|NCT02683863|OTHER|Group 2|2. Four subjects for CSF samples 5 hours after dosing
62780918|NCT02683863|OTHER|Group 3|3. Four subjects for CSF samples 7 hours after dosing
62780919|NCT02683863|OTHER|Group 4|4. Four subjects for predose CSF samples
62780920|NCT00119821|EXPERIMENTAL|I|Behavioral Weight Reduction
62780921|NCT00119821|OTHER|II|Exercise
62021038|NCT05036122|EXPERIMENTAL|Whole-body exercise in healthy adults (Aim 1)|Subjects will have blood \[lactate\] measurement obtained with the LabClasp device while completing an exercise stress test on a treadmill or bicycle.
62572817|NCT00841386|EXPERIMENTAL|Cross-linking treatment|Topical anesthesia (lidocaine jelly 2%) will be used. The central 9 mm of corneal epithelium will be removed cautiously with an Amoils brush. Riboflavin 0.1% solution will be applied (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) to the cornea every 2-3 minutes for 15 minutes and then every 5 minutes thereafter. The UV source will be from the CBM VEGA X-linker (CSO, Florence, Italy). A wavelength of 370 nm will be used to direct 5.4 J/cm2 to the area of cornea debrided for 30 minutes. The distance from the UV source to the cornea will be 1.5 to 5.4 cm.
62780922|NCT00119821|OTHER|III|Smoking Cessation
62780923|NCT03706183||Study Group|The IMA levels will be determined and the association of the IMA and Hearing thresholds will be evaluated.
62192010|NCT06297044||Healthy Individuals|"Specific inclusion criteria for this participants' group are:~- absence of neurological and psychiatric conditions.~There are no specific exclusion criteria for this participants' group (see general exclusion criteria).~Participants will undergo a detailed neuropsychological assessment as detailed in the study's detailed description and outcome measures sections."
62780924|NCT03706183||Control Group|The IMA levels will be determined.
62572818|NCT00841386|SHAM_COMPARATOR|Sham treatment group|Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and a 2% methylcellulose solution combined with 1% fluorescein dye will be applied to the cornea every 5 minutes for 30 minutes. The patient will be placed under the UV device, but instead of the UV light, the LED aiming beam will be applied for 30 minutes.
62006272|NCT03160924|NO_INTERVENTION|Conventional perioperative program|"In this arm, the conventional preoperative program will be applied.~1. No preoperative counselling~2. No Preoperative carbohydrate-loaded drink~3. Routine anaesthesia, no specific protocol on fluid restriction, opioids will be used as usual. Tramadol would be used as postoperative pain control.~4. Routine use of drains~5. Diet will be resumed when there is flatus clinically~6. Mobilisation as per patient's wish~7. Dietary counselling by dietician~8. Discharge if fulfil discharge criteria.~Discharge criteria:~Adequate pain control with oral analgesics Ability to tolerate soft diet Passage of flatus Mobilization~Patients will be seen in clinic on post-operative D14."
62006273|NCT01651572|EXPERIMENTAL|Cisatracurium|"Induction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl.~Cisatracurium (Nimbex):~* initial dose: 0.2 mg/kg~* maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)~At the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg.~Patients will be extubated with a TOF-Ratio of at least 0.90."
62572819|NCT04832594|EXPERIMENTAL|Supplemental MRI|Women randomized to MRI will be examined using a shortened MRI protocol on a Signa Premier 3T MRI scanner. The MRI examination will be reviewed by two radiologists and assigned BI-RADS score. Appropriate clinical work-up will follow according to the BI-RADS score. BI-RADS 3 or higher at initial MRI will be recalled for a second look ultrasound.
62572820|NCT04832594|NO_INTERVENTION|No MRI (standard-of-care)|"Standard-of-care. Both arms will have had a regular screening mammography examination prior to randomization. The No MRI arm will have no further intervention."
62572821|NCT04477148|ACTIVE_COMPARATOR|Metallic Reusable(MR)|Patients in this group were intubated with reusable metallic blades
62780925|NCT03640221|EXPERIMENTAL|Experimental|will receive two bottles of Ertugliflozin 15mg tablets (active drug) and a placebo for hydrochlorothiazide.
62780926|NCT03640221|ACTIVE_COMPARATOR|Active Comparator|will receive two bottles of Placebo for ertugliflozin and hydrochlorthiazide 12.5mg capsules (active drug)
62780927|NCT01183455|EXPERIMENTAL|Aralast NP|Participants will receive Aralast NP (90mg/kg) intravenously once a week for 12 weeks.
62780928|NCT01183455|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo intravenously once a week for 12 weeks.
62780929|NCT05768035|EXPERIMENTAL|Patients with acute leukemia or myelodysplastic syndrome and eligible for an haplo PT-Cy HSCT|"Segment 1: 3 dose-level SMART101 cells/infusion~1. 1.5 x 106 CD7+ cells per kg of body weight~2. 4.5 x 106 CD7+ cells per kg of body weight~3. 9.0 x 106 CD7+ cells per kg of body weight~Segment 2:~2 cohorts of patients will be included in the study based on the type of conditioning regimen:~* The cohort A will include up to 17 patients receiving a myeloablative conditioning (MAC).~* The cohort B will include up to 17 patients receiving a reduced intensity conditioning (RIC).~* Enrollment of patients in each cohort will be done in parallel."
62780930|NCT05755802|ACTIVE_COMPARATOR|Group A (PENG block)|Ultrasound-guided PENG block will be performed under strict aseptic precautions and patient's arm will be placed in external rotation and abducted at 45 degrees.
62780931|NCT05755802|ACTIVE_COMPARATOR|Group B (Shoulder block)|Ultrasound-guided shoulder block will be performed under strict aseptic precautions with patient in semi-recumbent position with the operating arm on the contra-lateral shoulder.and then, the patients will be positioned in a semi-recumbent position with the arm slightly flexed and adducted at the elbow for axillary nerve block.
62780932|NCT03845959|EXPERIMENTAL|TD0019.6cap|estimated dose, 2 oral capsules/time x 3 times/day
62780933|NCT03845959|EXPERIMENTAL|TD0019.9cap|1.5 times of estimated dose 2 oral capsules/time x 3 times/day
62780934|NCT03845959|PLACEBO_COMPARATOR|Placebo|Placebo 2 placebo oral capsules /time x 3 times/day
62780935|NCT02317978||Subfertility without polycystic ovarian syndrome|The records of all women with infertility who had IVF/ICSI without polycystic ovarian syndrome (PCO) will be reviewed
62780936|NCT02898298|EXPERIMENTAL|Immediate|Immediate group receives the Positive Emotion Regulation training immediately.
62780937|NCT02898298|ACTIVE_COMPARATOR|Waitlist control group|Waitlist control group receives the Positive Emotion Regulation training 4 weeks later.
62780938|NCT00995657|ACTIVE_COMPARATOR|High dose ICS|Fluticasone Propionate 250mcg bid
62192011|NCT00884559|ACTIVE_COMPARATOR|Technical|Technical Instructions
62192012|NCT00884559|EXPERIMENTAL|Leadership|Leadership-Instructions
62192013|NCT01371071||CIS or early relapsing-remitting MS|
62192014|NCT01496365|EXPERIMENTAL|DS-5565 5mg nighttime|DS-5565 5 mg/day (one 5 mg tablet at bedtime)
62572822|NCT04477148|ACTIVE_COMPARATOR|Metallic Disposable(MD)|Patients in this group were intubated with disposable metallic blades
62780939|NCT00995657|ACTIVE_COMPARATOR|Low dose ICS|Fluticasone propionate 50mcg bid
62780940|NCT04380805|EXPERIMENTAL|AK104|AK104 monotherapy
62780941|NCT02807870|EXPERIMENTAL|Methylphenidate-psychoeducational group|Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments) and weekly psychoeducational groups for parents during 8 weeks.
62780942|NCT02807870|EXPERIMENTAL|Parental training-placebo pill|Weekly parental training conducted by behavioral psychologists and placebo pill during 8 weeks.
62780943|NCT02807870|PLACEBO_COMPARATOR|Psychoeducational group-placebo pill|Weekly psychoeducational groups for parents and placebo pill during 8 weeks.
62780944|NCT05315089|EXPERIMENTAL|Interventional Group|Virtual reality games +conventional exercises
62780945|NCT05315089|ACTIVE_COMPARATOR|control Group|Conventional exercises
62780946|NCT05150938||Cancer patients with VTE|Cancer patients who received anticoagulation treatment.
62780947|NCT00659230|PLACEBO_COMPARATOR|Placebo|Arm 1
62780948|NCT00659230|ACTIVE_COMPARATOR|Nepicastat|Arm 2
62192015|NCT01496365|EXPERIMENTAL|DS-5565 10 mg at bedtime|DS-5565 10 mg/day (one 10 mg tablet at bedtime)
62192016|NCT01496365|EXPERIMENTAL|DS-5565 15 mg at bedtime|DS-5565 15 mg/day (one 5 mg tablet plus one 10 mg tablet at bedtime)
62192017|NCT01496365|EXPERIMENTAL|DS-5565 20 mg total per day|DS-5565 20 mg/day (one 10 mg tablet in the morning and one 10 mg tablet at bedtime)
62006274|NCT01651572|EXPERIMENTAL|Rocuronium|"Induction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl~Rocuronium (Esmeron):~* initial dose: 0.6 mg/kg~* maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)~At the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg.~Patients will be extubated with a TOF-Ratio of at least 0.90."
62006275|NCT06664307||All patients attending the hepatology clinic or hospitalized with a diagnosis of liver cirrhosis|"All patients attending outpatient clinics or hospitalized with a diagnosis of viral etiology or alcohol-related liver cirrhosis will be evaluated for the indication of primary prophylaxis with NSBB according to Baveno VII guidelines.~The choice of NSBB type was mainly based on clinical parameters, regardless of the presence of an acute hemodynamic response. In patients who did not show signs of circulatory dysfunction or refractory ascites, carvedilol was preferred, as it has been shown to be more potent in decreasing portal pressure. Carvedilol was initiated at a dose of 6.25 mg/day and, if tolerated, was subsequently increased to a target dose of 12.5 mg/day. Higher doses of carvedilol were only used in cases of concomitant hypertension. For propranolol users, the dose was progressively increased until the heart rate decreased to approximately 55 beats per minute. In patients with significant ascites, a maximum dose of 80 mg/day of propranolol was administered."
62021039|NCT05036122|EXPERIMENTAL|ICU patients susceptible to developing sepsis (Aim 2)|Subjects will have blood \[lactate\] measurement obtained with the LabClasp device as frequently as required for clinical purposes
62780949|NCT04313114|ACTIVE_COMPARATOR|PRIME CRC|Patients will receive a plain language, literacy appropriate, actionable printed CRC screening handout emphasizing the benefits of CRC screening and screening options; as well as plain language, literacy appropriate handouts on the CRC screening test they choose - colonoscopy or FIT. Patients will also receive automated reminder calls and texts for both screening options to encourage screening.
62572823|NCT04477148|ACTIVE_COMPARATOR|Plastic Disposable(PD)|Patients in this group were intubated with disposable plastic blades
62572824|NCT00827216|PLACEBO_COMPARATOR|Physiologic saline|
62572825|NCT00827216|ACTIVE_COMPARATOR|Erythromycine|
62572826|NCT05835440||staff stakeholders|The potential stakeholders are a diverse population and will include managers, emergency department clinicians and practitioners, radiologists, radiographers, administrative staff and surgeons. A maximum total of 4 staff stakeholder interviews shall be undertaken.
62572827|NCT05835440||patient participants|The patient population are adults who have sustained a traumatic wrist injury with normal X-rays and have been treated by NHS services.
62780950|NCT04313114|ACTIVE_COMPARATOR|Enhanced Usual Care|Patients will receive a plain language, literacy appropriate, actionable printed CRC screening handout emphasizing the benefits of CRC screening and screening options; as well as plain language, literacy appropriate handouts on the CRC screening test they choose - colonoscopy or FIT. Patients will receive no reminder calls.
62780951|NCT00061633|EXPERIMENTAL|Telavancin|
62780952|NCT00061633|ACTIVE_COMPARATOR|Standard of care for cSSSI|cSSSI - complicated skin and skin structure infections
62780953|NCT03274518|ACTIVE_COMPARATOR|Online Hemodiafiltration|"The olHDF technique combines diffusion with high convection rates in which the dialysis fluid, free of toxins and pyrogens, is used to prepare the replacement fluid.~The online module of dialysis machine prepares the replacement fluid by a cold sterilization process. There is a cross-flow water preparation, in order to avoid the accumulation of possible contaminants. The addition of bicarbonate and acid solutions to water follows the process. Next, the ready-for-infusion dialysis solution is passed through another ultrafilter prior to being infused into patients."
62791815|NCT00526591|ACTIVE_COMPARATOR|High-dose Everolimus Cohort|10mg Everolimus daily continuously for 8 weeks and conventional surgery
62791816|NCT02411019||Observational group|Subjects in the period less than 24 weeks after the final administration of GX-188E
62572828|NCT05516680|EXPERIMENTAL|Experiment group|electro-acupuncture and MRI-navigated rTMS
62572829|NCT05516680|ACTIVE_COMPARATOR|Control group|MRI-navigated rTMS
62572830|NCT00000412|ACTIVE_COMPARATOR|Group A|Group A active alendronate (10 mg/day) and placebo calcitriol.
62572831|NCT00000412|PLACEBO_COMPARATOR|Group B|We will give Group B placebo alendronate and active calcitriol (0.25 micrograms BID).
62006276|NCT02984397|EXPERIMENTAL|KF group|In each study visit, patients will receive enough pills for the next month. At the first visit, patients receiving ketotifen (KF) will receive four vials sequentially numbered (1 to 4) containing enough pills for one week each, and will be instructed by the clinician and by the pharmacist to use vial 1 for the first week (0.5 mg of KF BDI), vial 2 for the second week (1mg of KF BDI), vial 3 for the third week (2 mg of KF BDI), and vial 4 for the fourth week (3mg of KF BDI). As for weeks 4, 8 and 12 visits, patients treated with KF will receive four equal vials containing enough pills for one week each (3 mg of KF BDI)
62006277|NCT02984397|PLACEBO_COMPARATOR|Placebo group|Patients participating in the placebo group will also receive sequentially numbered vials at the first visit. Similarly, patients taking placebo will also receive four equal vials of pills on the next visits.
62006278|NCT02984397|ACTIVE_COMPARATOR|SOC|Standard of care - patients who refuse to participate in the study but allow us to compare their clinical data to that of participants of the study
62192018|NCT01496365|EXPERIMENTAL|DS-5565 30 mg total per day|DS-5565 30 mg/day (one 5 mg tablet plus one 10 mg tablet in the morning and one 5 mg tablet plus one 10 mg tablet at bedtime)
62192019|NCT01496365|ACTIVE_COMPARATOR|Pregabalin 300 mg total per day|Pregabalin 300 mg/day (two 150 mg capsules, in the morning and at bedtime)
62192020|NCT04799769|EXPERIMENTAL|Test Device|Investigational Device Arm
62397566|NCT06658041|EXPERIMENTAL|JoyAge stepped-care intervention|Participants are provided with specified interventions (cognitive behavioural therapy-based) according to their depressive symptom severity at the primary care setting provided by trained clinical social workers, and may be stepped-up or stepped-down according to their response.
62397567|NCT06658041|ACTIVE_COMPARATOR|Care-as-usual|Participants will continue with their usual care at their district-based primary care centre without JoyAge intervention, which may entail services such as stress management or health-related programmes but without symptom-specific psychological interventions or stepped-care.
62397568|NCT06665009|EXPERIMENTAL|Manually Opened and Device-Opened|
62397569|NCT06724393|ACTIVE_COMPARATOR|Control|This group with undergo online low-intensity resistance training twice per week
62780954|NCT03274518|EXPERIMENTAL|Expanded Hemodialysis|More recently, membranes with high cutoff values, but with tight pore size distribution have been developed. The main concept is to keep both cutoff and retention onset values close to each other, but with a cutoff value lower than of albumin. This should allow removal of middle-to-high weight range uremic toxins, with very low albumin leak. Thus, these membranes, denominated high retention onset (HRO) membranes, allow performing both diffusive and convective processes in a conventional hemodialysis machine.
62780955|NCT04083157|EXPERIMENTAL|Intradermal hepatitis B vaccine with imiquimod|Subjects in the study arm will receive 20 mcg intradermal Engerix-B at two separate sites (10 mcg/0.5 ml) with topical imiquimod ointment pre-treatment 5 minutes before injection.
62397570|NCT06724393|EXPERIMENTAL|Blood flow restriction|This group with undergo online low-intensity resistance training with blood flow restriction twice per week
62397571|NCT05056909|ACTIVE_COMPARATOR|Standard of care|CKD care, as routinely provided in the respective nephrology outpatient clinic.
62192021|NCT01289132|PLACEBO_COMPARATOR|Placebo|
62192022|NCT01289132|EXPERIMENTAL|Azilsartan 5 mg QD|
62397572|NCT05056909|EXPERIMENTAL|Intervention|standard of care + Kidney ACTion AI-supported software for chronic kidney disease care.
62397573|NCT02452892|SHAM_COMPARATOR|LFMS Sham|For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered. Low field magnetic stimulation (no magnetic field for sham) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
62397574|NCT02452892|ACTIVE_COMPARATOR|LFMS 20 minutes|LFMS 20 minutes + Sham 40 min.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
62397575|NCT02452892|ACTIVE_COMPARATOR|LFMS 60 minutes|LFMS 60 minutes.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
62397576|NCT02452892|OTHER|LFMS 120 min|Week 2 subjects may be re-randomized to receive LFMS 120 minutes. Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
62780956|NCT04083157|ACTIVE_COMPARATOR|Intramuscular hepatitis B vaccine with aqueous cream|Subjects in the control arm will receive 20 mcg intramuscular Engerix-B at two separate sites (10 mcg/ 0.5 ml) with topical placebo aqueous cream pretreatment 5 minutes before injection.
62192023|NCT01289132|EXPERIMENTAL|Azilsartan 10 mg QD|
62192024|NCT01289132|EXPERIMENTAL|Azilsartan 20 mg QD|
62192025|NCT01289132|EXPERIMENTAL|Azilsartan 40 mg QD|
62192026|NCT01289132|EXPERIMENTAL|Azilsartan 80 mg QD|
62192027|NCT01289132|ACTIVE_COMPARATOR|Candesartan Cilexetil 8 mg titrated to12 mg QD|
62397577|NCT06366191|EXPERIMENTAL|Prevention algorithm|Patient will have the current support for psychotrauma and psychotrauma prevention algorithm.
62572832|NCT03926832|EXPERIMENTAL|Patients with Sarcoidosis|Participants with Sarcoidosis. This arm will complete baseline questionnaires assessing daytime sleepiness (Epworth Sleepiness Scale - ESS) and fatigue (Fatigue Assessment Scale - FAS). All participants will perform home polygraphy and will be treated with CPAP for three months if moderate-to-severe OSA has been diagnosed and re-assessed with the same questionnaires along with a complete analysis of CPAP adherence by analyzing the compliance report of the device.
62780957|NCT03287362|EXPERIMENTAL|ST-arm|one-third of the patients is randomized to schema therapy
62192028|NCT01951768|EXPERIMENTAL|Garamycin Sponge (Gentamicin-Collagen Sponge)|Garamycin Sponge (Gentamicin-Collagen sponge) applied daily plus systemic antibiotic and standard ulcer care
62397578|NCT06366191|ACTIVE_COMPARATOR|Current support for psychotrauma|Patient will have the current support for psychotrauma.
62572833|NCT02898428||New mothers|New mothers with type 1 diabetes
62780958|NCT03287362|ACTIVE_COMPARATOR|CBT-arm|one-third of the patients is randomized to cognitive behavioral therapy
62780959|NCT03287362|PLACEBO_COMPARATOR|IST-arm|one-third of the patients is randomized to individualized supportive therapy
62780960|NCT01873651|EXPERIMENTAL|Delta III|Implantation of a Delta III Prosthesis
62780961|NCT03939936|ACTIVE_COMPARATOR|Test Group|"Psoriatic measurements and saliva samples were taken from periodontal disease patients before treatment and after 8 weeks.~Intervention: Non-surgical periodontal treatment was performed and the Psoriasis Area and Severity Index (PASI) was filled, saliva samples were taken."
62780962|NCT03939936|PLACEBO_COMPARATOR|Control Group|"Psoriatic measurements and saliva samples were taken from periodontal disease patients at the baseline and after 8 weeks without the periodontal treatment.~Intervention: Psoriasis Area and Severity Index (PASI) was filled, saliva samples were taken."
62006279|NCT04524403|EXPERIMENTAL|Miricorlilant 600 mg|Patients who meet the entry criteria will be randomized to receive 600 mg miricorilant for 26 weeks.
62006280|NCT04524403|EXPERIMENTAL|Miricorlilant 900 mg|Patients who meet the entry criteria will be randomized to receive 900 mg miricorilant for 26 weeks.
62192029|NCT01951768|ACTIVE_COMPARATOR|Systemic Antibiotic|Systemic antibiotic therapy and standard ulcer care
62192030|NCT02813902|ACTIVE_COMPARATOR|Heliocare|240 mg administered orally daily
62192031|NCT02813902|PLACEBO_COMPARATOR|Sugar pill|a sugar pill matching the Heliocare tablet in look and weight will be administered orally daily
62192032|NCT03540745|EXPERIMENTAL|TES Treatment|Where subject is randomized to TES.
62192033|NCT03540745|PLACEBO_COMPARATOR|TES-SHAM Treatment|Where subject is randomized to a SHAM condition
62397579|NCT06023927||Newly-diagnosed mild OSA - initiating CPAP treatment|Subjects with newly-diagnosed mild obstructive sleep apnea being treated with CPAP undergoing clinical observation/diagnostic evaluation for detection and tracking of NTG.
62397580|NCT06023927||Newly-diagnosed moderate OSA - initiating CPAP treatment|Subjects with newly-diagnosed moderate obstructive sleep apnea being treated with CPAP undergoing clinical observation/diagnostic evaluation for detection and tracking of NTG.
62397581|NCT06023927||Newly-diagnosed severe OSA - initiating CPAP treatment|Subjects with newly-diagnosed severe obstructive sleep apnea being treated with CPAP undergoing clinical observation/diagnostic evaluation for detection and tracking of NTG.
62572834|NCT02898428||Control group|Non-pregnant, non-breastfeeding women with type 1 diabetes matched for age and BMI
62572835|NCT03382834|EXPERIMENTAL|Arm A: Tamoxifen + Vorinostat|From Day 0 to Day 38, participants will receive tamoxifen orally once a day. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
62572836|NCT03382834|ACTIVE_COMPARATOR|Arm B: Vorinostat alone|Day 0 to Day 38 will be an observation period with no tamoxifen. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
62572837|NCT04013672|EXPERIMENTAL|Arm A - Have not received immunotherapy|Arm A is patients with first recurrence of glioblastoma who have failed prior chemotherapy and radiation but have not received any immunotherapy.
62780963|NCT01209078|EXPERIMENTAL|Regimen 1|GSK1322322 1500mg and Placebo Linezolid given twice a day (BID) for 10 days
62780964|NCT01209078|ACTIVE_COMPARATOR|Regimen 2|Linezolid 600mg and placebo GSK1322322 given BID for 10 days
62780965|NCT00680797|EXPERIMENTAL|+T +E|+Testosterone, +Estrogen
62780966|NCT00680797|EXPERIMENTAL|+T -E|+Testosterone, -Estrogen
62780967|NCT00680797|EXPERIMENTAL|-T +E|-Testosterone, +Estrogen
62572838|NCT04013672|EXPERIMENTAL|Arm B - Have failed prior anti-PD1 therapy|Arm B is an exploratory arm of 10 patients who have failed prior anti-PD1 therapy.
62572839|NCT00410813|EXPERIMENTAL|Arm I|Patients receive oral dasatinib once daily.
62780968|NCT00680797|NO_INTERVENTION|-T -E|-Testosterone, -Estrogen
62780969|NCT06134843|EXPERIMENTAL|DERMASEAL|"DERMASEAL will be placed to completely cover the donor site wound. The entire site will then be covered with a transparent film dressing (TegadermTM, 3M) with at least 3 cm margin of normal skin under the film dressing before securing it with kerlix gauze and an ace wrap bandage placed circumferentially around the extremity.~The dressing will be left on the donor site wound until the wound is completely closed or changed at the discretion of the treating team."
62791817|NCT02197663|EXPERIMENTAL|Acupuncture|The total course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.
62006281|NCT04524403|PLACEBO_COMPARATOR|Placebo|Patients who meet the entry criteria will be randomized to receive placebo for 26 weeks.
62021040|NCT05015153|EXPERIMENTAL|Intervention group|20 sessions of Pulmonary rehabilitation will be performed over a period of 3 months
62192034|NCT01755676|EXPERIMENTAL|Orlistat 60 mg|
62006282|NCT03188965|EXPERIMENTAL|Part A: single-agent dose-escalation|Patients with histologically confirmed solid tumors or non-Hodgkin's lymphoma (NHL) receive BAY1895344 in a 21-day cycle.
62006283|NCT03188965|EXPERIMENTAL|Part A.1: Single-agent dose escalation with alternative dosing schedule|Patients with histologically confirmed solid tumors or NHL known to be positive for ATM loss and/or ATM deleterious mutations receive BAY1895344 in a 28-day cycle.
62006284|NCT03188965|EXPERIMENTAL|J-arm of Part A: dose escalation cohort in Japanese patients|Japanese patients with histologically confirmed solid tumors receive BAY1895344 at two dose levels: MTD-1 and MTD.
62006285|NCT03188965|EXPERIMENTAL|Part B: single-agent expansion|Patients with a) DDR deficiency biomarker-positive advanced solid tumors: castration-resistant prostate cancer (CRPC), HER2-negative breast cancer (BC), colorectal cancer (CRC), and gynecological tumors; OR b) histologically confirmed advanced cancer and loss of ATM regardless of the cancer type receive BAY1895344 at MTD determined at the end of dose escalation.
62006286|NCT03188965|EXPERIMENTAL|Part B.1: single-agent expansion with alternative dosing schedule|Patients with histologically confirmed relapsed or refractory MCL receive BAY1895344 at a dose determined after evaluation of multiple BAY1895344 doses in Part A.1
62006287|NCT00338195|NO_INTERVENTION|Delayed intervention control|
62006288|NCT03795922|EXPERIMENTAL|MT10109L|MT10109L will be injected into the GL: initial double-blind treatment on Day 1, and up to 2 open-label study interventions during the retreatment period.
62006289|NCT03795922|PLACEBO_COMPARATOR|Placebo|Placebo will be injected into the GL: initial double-blind treatment on Day 1.
62006290|NCT06351605||Photobiomodulation (PBM)|Valeda Light Delivery System The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
62192035|NCT01755676|PLACEBO_COMPARATOR|Placebo|
62192036|NCT02209844|EXPERIMENTAL|BI 44847 powder|single rising dose reconstituted with natrosol solution
62192037|NCT02209844|PLACEBO_COMPARATOR|Placebo|reconstituted with natrosol solution
62572840|NCT00410813|EXPERIMENTAL|Arm II|Patients receive oral dasatinib twice daily.
62572841|NCT01709682|ACTIVE_COMPARATOR|AAD therapy|Recurrent episodes were pharmacologically managed by conventional AAD therapy (propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure) according to AF management guidelines.
62780970|NCT06134843|NO_INTERVENTION|Standard of Care|"The donor site wound is covered with a transparent film dressing (TegadermTM, 3M) with at least 3 cm margin of normal skin under the film dressing. The dressing is then secured with kerlix gauze and ace wrap bandage placed circumferentially around the extremity.~The dressing will be left on the donor site wound until the wound is completely closed or changed at the discretion of the treating team."
62791818|NCT02197663|SHAM_COMPARATOR|sham acupuncture|The total course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen.
62006291|NCT02438566|ACTIVE_COMPARATOR|Oral Tranexamic Acid (OTA)|Subjects will be randomized 1:1 to receive either IVTA or OTA with corresponding placebos. OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
62006292|NCT02438566|ACTIVE_COMPARATOR|Intravenous Tranexamic Acid (IVTA)|Subjects will be randomized 1:1 to receive either IVTA or OTA with corresponding placebos. IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
62006293|NCT03057145|EXPERIMENTAL|Prexasertib Combine with Olaparib|"* Olaparib will be administered orally on an intermittent schedule during each 28-day cycle. Exact administration schedule will depend on assigned dose level.~* Prexasertib will be administered intravenously on Days 1 and 15 of a cycle"
62021041|NCT05015153|NO_INTERVENTION|Control group|No Pulmonary rehabilitation
62021042|NCT00661492|EXPERIMENTAL|Arm 1|Erbitux (cetuximab) and Novantrone (mitoxantrone)
62021043|NCT00661492|EXPERIMENTAL|Arm 2|Novantrone (mitoxantrone)
62192038|NCT06391437||Control group|Sex- and age-matched approximate-health children without sepsis will be recruited as a control group.
62192039|NCT06391437||Studied group|All pediatric Patients from 29 days to 16 years old who were admitted to the pediatric intensive care unit (PICU) with sepsis as defined by International pediatric sepsis consensus conference will be consecutively recruited in this study.
62192040|NCT06544603||Control group|
62192041|NCT06544603||LA 3 month group|"Laser acupuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy). In LA group, we choose 5 acupoints on the affected side. It includes ST2(Si Bai), ST4(Di Cang), ST6(Jia Che), GB14(Yang Bai), GB20(Feng chi). We choose 6 acupoints, including LI4 (He Gu), LI11(Qu Chi), ST25 (Tian Shu), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), LR3 (Tai Chong).~Laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm), 1500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, 36 times total treatment."
62192042|NCT06544603||LA 6 month group|"Laser acupuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy). In LA group, we choose 5 acupoints on the affected side. It includes ST2(Si Bai), ST4(Di Cang), ST6(Jia Che), GB14(Yang Bai), GB20(Feng chi). We choose 6 acupoints, including LI4 (He Gu), LI11(Qu Chi), ST25 (Tian Shu), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), LR3 (Tai Chong).~Laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm), 1500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, 72 times total treatment."
62192043|NCT03105063|EXPERIMENTAL|US GROUP|All patients will first undergo ultrasound scan of the hip in attempt to recognize the AIIS, on the same day , the true morphology of the AIIS will be evaluated using 3d imaging
62192044|NCT01076764|EXPERIMENTAL|Otamixaban - 0.080 mg/kg bolus + 0.100 mg/kg/h infusion|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:~* Drug A: Otamixaban (0.080 mg/kg bolus followed by 0.100 mg/kg/h infusion)~* Drug B: Placebo (for UFH)~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:~* Drug C: Placebo (for Eptifibatide)"
62192045|NCT01076764|EXPERIMENTAL|Otamixaban - 0.080 mg/kg bolus + 0.140 mg/kg/h infusion|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:~* Drug A: Otamixaban 0.080 mg/kg bolus followed by 0.140 mg/kg/h infusion)~* Drug B: Placebo (for UFH)~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:~* Drug C: Placebo (for Eptifibatide)"
62192046|NCT01076764|ACTIVE_COMPARATOR|UFH + Eptifibatide|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:~* Drug A: Placebo (for Otamixaban)~* Drug B: UFH (60 IU/kg bolus followed by 12 IU/kg/h infusion)~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:~* Drug C: Eptifibatide (180 mcg/kg bolus followed by 2 mcg/kg/min infusion)"
62572842|NCT01709682|ACTIVE_COMPARATOR|re-ablation procedure|"Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s.~The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity. Only in patients with induced left atrial flutter, additional RF ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs."
62572843|NCT02748213|EXPERIMENTAL|Herceptin + Taxotere|Participants will receive dual therapy with Herceptin and Taxotere until disease progression, unmanageable toxicity, or withdrawal.
62572844|NCT02748213|EXPERIMENTAL|Herceptin + Taxotere + Xeloda|Participants will receive triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal.
62791819|NCT04922606|OTHER|US of GSV|Ultrasound of the Great Saphenous Vein
62192047|NCT01642433|PLACEBO_COMPARATOR|Sugar pills|
62791820|NCT03683342|ACTIVE_COMPARATOR|Ankle Block|Ankle block will be performed under ultrasound guidance.
62021044|NCT04554862|ACTIVE_COMPARATOR|the intervention group (M) magnesium sulfate|a 6ml of magnesium sulfate 10% (600mg) will be added to 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block
62006294|NCT02399085|EXPERIMENTAL|Tafasitamab (MOR00208) + lenalidomide (LEN)|"MOR00208:~MOR00208 was administered via IV infusion at a dose of 12 mg/kg. For the first three cycles (Cycles 1 to 3) of the study each cycle consisted of a MOR00208 infusion on Day 1, Day 8, Day 15 and Day 22 of the cycle.~Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter MOR00208 was administered on a bi-weekly (every 14 days) basis with infusions on Day 1 and Day 15 of each 28-day cycle.~LEN:~Participants self-administered a starting dose of 25 mg oral LEN daily on Days 1-21 of each cycle, for up to 12 cycles in total. LEN dose could be modified in a de-escalating fashion or discontinued based upon clinical and laboratory findings.~On days when both study drugs were given together, LEN was administered prior to MOR00208."
62192048|NCT01642433|ACTIVE_COMPARATOR|Prazosin pills|
62192049|NCT05428527||Breast cancer patients with Cancer-related fatigue treatment|Breast cancer patients who approved to use NHI to pay for Cancer-related fatigue treatment drug
62192050|NCT05521711|EXPERIMENTAL|Active low dose oral immunotherapy and Placebo sublingual immunotherapy|
62192051|NCT05521711|EXPERIMENTAL|Placebo low dose oral immunotherapy and Active sublingual immunotherapy|
62192052|NCT05521711|EXPERIMENTAL|Placebo low dose oral immunotherapy and Placebo sublingual immunotherapy|
62192053|NCT01717079|ACTIVE_COMPARATOR|Effective arm|Effective coil
62192054|NCT01717079|PLACEBO_COMPARATOR|Placebo arm|Placebo coil
62192055|NCT01132469|EXPERIMENTAL|Endoscopic Submucosal Dissection|Single-arm for ESD procedure and retrospective surgical procedure(Laparoscopy, Open surgery)data collection
62192056|NCT02925845|EXPERIMENTAL|Neuromuscular electrostimulation|Patients assigned to the group NMS, following the visit Day Hospital, in the first two hours of each HD session will perform a program of neuromuscular electrostimulation of the limb with the RC-AVF performed in the reference position of the flexors and extensors forearm at the tip intervened in each HD session on the stage previously established in the protocol (duration according to established program).
62780971|NCT04417231|EXPERIMENTAL|Apheresis group|"10 patients receive a maximum of 3 apheresis treatments at intervals of 24 ± 12 hours each (from the beginning of the preceding treatment). The first treatment starts within 72 hours after infarction or, in case of an unclear time window, within presumed 72 hours after the patient was last seen free of symptoms. No further treatments are carried out if the CRP concentration before the start of a treatment is \<10 mg/l or if the patient has been discharged from hospital.~For each treatment, 1.5 - 2.5 times the plasma volume is processed. The duration of each treatment is approximately 4-6 hours."
62780972|NCT04417231|NO_INTERVENTION|Control group|10 patients of the control group receive the same examinations as arm 1 (verum group) but no apheresis treatments after ischemic stroke.
62780973|NCT00646399|PLACEBO_COMPARATOR|Placebo|Phosphate Buffered Saline
62780974|NCT00646399|EXPERIMENTAL|Pagibaximab 50 mg/mL|Pagibaximab at 100 mg/kg intravenously at Days 0, 1, 2, 9, 16 and 23.
62791821|NCT03683342|ACTIVE_COMPARATOR|Popliteal sciatic nerve block (PSNB)|PSNB will be performed under ultrasound guidance, along with a saphenous nerve block at the ankle
62006295|NCT02049489|EXPERIMENTAL|ICT-121 DC vaccine|Autologous dendritic cells pulsed with peptide antigens
62006296|NCT03780179|EXPERIMENTAL|MMRvaxpro|
62006297|NCT03780179|PLACEBO_COMPARATOR|Placebo|
62021045|NCT04554862|ACTIVE_COMPARATOR|the intervention group (K) ketorolac|a 2ml of ketorolac (30mg) will be added to 4ml of normal saline and 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block
62021046|NCT01597206|EXPERIMENTAL|Removable partial denture Group|Patients with a reduced posterior dental arch will be randomized into one of 2 Groups Group A will receive a removable partial denture prosthesis
62192057|NCT02925845|NO_INTERVENTION|Isometric exercises|They will perform isometric exercises operated limb on an outpatient basis (repeated pressure rubber balls, heavy lifting 1-2 kg).
62192058|NCT01938313|ACTIVE_COMPARATOR|ERAS perioperative cares|Patients planned to undergoing laparoscopic gastrectomy, following the ERAS protocols.
62192059|NCT01938313|ACTIVE_COMPARATOR|Conventional perioperative cares|Patents will be managed by our hospital's critical pathways.
62192060|NCT01149122|ACTIVE_COMPARATOR|Gemcitabine/Oxaliplatin with Erlotinib|
62192061|NCT01149122|ACTIVE_COMPARATOR|Gemcitabine/Oxaliplatin without Erlotinib|
62192062|NCT01458522|ACTIVE_COMPARATOR|fPHT 20mg|fPHT treatment arm, a bolus of 20 mg PE/kg will be administered at a rate of no greater than 75 mg PE/minute. If a further bolus is required, 5 mg PE/kg will be administered. The daily maintenance dose for fPHT will be 5 mg PE/kg divided into 2 doses.
62192063|NCT01458522|EXPERIMENTAL|LCM 400mg|LCM treatment arm, a bolus of 400 mg will be administered over 30 minutes. If a further bolus is required, 200 mg will be administered. Regardless of whether the subject received a rebolus, he or she will begin receiving a maintenance dose 12 hours after the initial dose. The daily maintenance dose will be the same as the total bolus (400 mg or 600 mg) divided into 2 doses.
62192064|NCT03796078|ACTIVE_COMPARATOR|Bimaxillary surgery (MMA)|Bimaxillary Orthognathic Surgery. MMA
62192065|NCT03796078|ACTIVE_COMPARATOR|monomaxillary surgery (Isolated MaxS)|Monomaxillary surgery (Isolated MaxS)
62192066|NCT03796078|ACTIVE_COMPARATOR|monomandibullary surgery (Isolated MandS)|Monomandibular surgery (Isolated MandS)
62791822|NCT03255577|EXPERIMENTAL|Sentinel Lymph Node Biopsy (SLNB)|The patients will undergo SLNB with dual tracer mapping using technetium-99m sulfur colloid and isosulfan blue dye, as is standard practice at our institution for cN1 patients. Than the SLNB procedure will be performed
62006298|NCT03178058||Parturients for CS|"Parturients presenting for Cesarean section will be enrolled preoperatively. Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
62006299|NCT06158737|EXPERIMENTAL|Experimental: JS010 injection|
62006300|NCT06158737|PLACEBO_COMPARATOR|Placebo|
62006301|NCT04302467|EXPERIMENTAL|GDFT group|Fluid maintenance with 2 ml/kg/h of Ringer's solution of sodium acetate, when SVV\>13%, 4 mL/kg bolus of hydroxyethyl starch will be infused within 5 min. If SVV falls below 13%, the bolus will be suspended. If SVV is still more than 13%, 100 μg of phenylephrine will be administered when CI is more than 2.5 L/min/m2, 1 mg of dopamine will be administered when CI is less than 2.5 L/min/m2. When SVV\<13%, but mean arterial pressure (MAP)\<65 mmHg, 8 μg of norepinephrine will be administered. The hemodynamic status will be repeatedly measured every 10 min.
62006302|NCT04302467|EXPERIMENTAL|restrictive fluid therapy group|fluid maintenance with 2 ml/kg/h of Ringer's solution of sodium acetate, hydroxyethyl starch will be infused to supply blood loss, the ratio of hydroxyethyl starch to blood loss is 1:1. 0.01-0.1 μg/kg/min of norepinephrine will be administered to maintain MAP\>65 mmHg.
62006303|NCT06387303|ACTIVE_COMPARATOR|Intrathecal Morphine|250 mcg Intrathecal Injection prior to incision
62006304|NCT06387303|EXPERIMENTAL|Intravenous Methadone|0.2 mg / kg Intravenous delivery prior to incision
62192067|NCT02781805|EXPERIMENTAL|Alendronate|Subjects will take the study drug alendronate, a nitrogenous bisphosponate, for approximately one to three weeks before their breast surgery.
62192068|NCT02394249|EXPERIMENTAL|Sitting regime|The subjects will follow the sitting regime during four days. Each day: 14 hours sitting, 1 hour walking and 1 hour standing and 8 hours sleeping.
62192069|NCT02394249|EXPERIMENTAL|Sit Less regime|Subjects will follow the sit less regime during four days. Each day will consist of 9 hours sitting, 4 hours walking, 3 hours standing and 8 hours sleeping. The walking and standing will be done in a minimum of eight bouts with a time interval of \>1 hour. The subjects will be instructed to walk on a slow pace, i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.
62192070|NCT04201145|EXPERIMENTAL|Run in cohort: pembrolizumab only|"Treatment with pembrolizumab as a single agent for 56 days~- 2 doses during treatment cycle, intravenous, at predetermined protocol dose"
62192071|NCT04201145|EXPERIMENTAL|Cohort 1: pembrolizumab + defactinib 12 days|"Treatment with Defactinib in combination with Pembrolizumab for 12 days~* Defactinib oral, twice daily, per predetermined dose for 12 days of treatment in combination~* Pembrolizumab via infusion, twice per cycle, per predetermined dose"
62397582|NCT05078658|EXPERIMENTAL|Low-carbohydrate diet|The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories but the amount of carbohydrates would be limited to provide only 15% (+/- 5%) of the recommended energy a day.
62397583|NCT05078658|ACTIVE_COMPARATOR|Recommended carbohydrate diet|The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories with 50% (+/- 5%) of the recommended energy from carbohydrates.
62397584|NCT01670552|EXPERIMENTAL|Nimesulide + Pantoprazole|Nimesulide + Pantoprazole- 1 tablet each 12 hours for 14 days
62397585|NCT01670552|ACTIVE_COMPARATOR|Naproxen + Esomeprazole|Naproxen + Esomeprazole - 1 tablet each 12 hours for 14 days
62397586|NCT00287261|EXPERIMENTAL|zometa|3-weekly infusion of zometa (zoledronic acid) 4 mg
62192072|NCT04201145|EXPERIMENTAL|Cohort 2: pembrolizumab + defactinib 35 days|"Treatment with defactinib in combination with pembrolizumab to 35 days~* Defactinib oral, twice daily, per predetermined dose for 35 days of treatment in combination~* Pembrolizumab via infusion, twice per cycle, per predetermined dose"
62192073|NCT04201145|EXPERIMENTAL|Expansion cohort|Tolerated phase IA regimen will be administered in a phase IB expansion cohort
62397587|NCT06724731||children patients Cholestatic Liver Disease|evaluate the diagnostic value of the Combi-Elasto technique in assessing liver fibrosis in children with cholestatic liver disease
62780975|NCT03570801|EXPERIMENTAL|Expert Panel Review|"For patients who are randomized to receive an expert panel review, de-identified lumbar MRI (sagittal and key axial images), 36-inch standing plain radiographs (if available), and flexion and extension radiographs will be uploaded into a web-based platform and reviewed. These will be submitted for an Expert Panel Review.~Images will be reviewed through a Spine Expert's Network, consisting of physicians involved in this study who will each offer their opinion as to which of two surgical treatment groups (decompression alone or decompression with fusion) they would choose for the patient. The results of this review will be discussed between the patient and the patient's physician. Together, they will determine the best surgical approach."
62780976|NCT03570801|NO_INTERVENTION|No Expert Panel Review|For patients not receiving the expert panel review, they will discuss with their surgeon the best surgical option and proceed as they would in standard of care.
62397588|NCT04920097|EXPERIMENTAL|Auricular Point Acupressure (APA)|The APA arm will receive in-person weekly treatments and a self-guided smartphone application with videos for understanding and administering APA. The APA arm will receive one in-person seed placement and a training for the participant or their caregiver to place the seeds on the ear points, as well as one zoom meeting 1 week after the first visit to coach participant and/or caregiver on seed placement.
62397589|NCT04920097|EXPERIMENTAL|Virtual Auricular Point Acupressure (vAPA)|The vAPA arm will self-administer APA by placing the seeds according to the video instruction found in the self-guided smartphone application for understanding and administering APA. Participant and/or a caregiver will follow the video instruction on seed placement and will receive one zoom session for APA coaching one week after the baseline visit.
62397590|NCT04920097|ACTIVE_COMPARATOR|Usual Care Control|Usual Care arm will continue with their usual care.
62780977|NCT02868047||Suspected Chronic Pancreatitis|Included patients will be those scheduled for an upper endoscopic ultrasound examination with suspected chronic pancreatitis
62397591|NCT06056505|EXPERIMENTAL|Partial kidney nephrectomy with aid of 3D model|The patient information (before intervention) and the surgery (partial nephrectomy) will be performed with the aid of 3D modelling of the kidney.
62397592|NCT06056505|ACTIVE_COMPARATOR|Partial kidney nephrectomy with aid of 2D model|The patient information (before intervention) and the surgery (partial nephrectomy) will be performed with the aid of 2D modelling of the kidney.
62397593|NCT06722027|EXPERIMENTAL|CCSH-TI Group|4-session intervention of 60- minutes each delivered every other week by healthcare chaplains to mixed-role inter-professional teams that includes mindfulness and compassion-based approaches to bolster resilience, compassion for self and others, and psychological safety.
62397594|NCT06722027|ACTIVE_COMPARATOR|TAU (treatment as usual) group|Participants in this group will have access to all well-being resources and activities available to them as employees.
62780978|NCT02868047||NOT Suspected Chronic Pancreatitis|Included patients will be those scheduled for an upper endoscopic ultrasound examination without suspected chronic pancreatitis.
62780979|NCT01876693|NO_INTERVENTION|control|nutrition counselling with nasogastric tube insertion in the cases of weight loss more than 10% or severe mucositis developed during chemoradiotherapy
62780980|NCT01876693|EXPERIMENTAL|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
62006305|NCT03830294|EXPERIMENTAL|Self-adhesive Group|The participants used the adhesive breast prosthesis that adheres to the skin.
62006306|NCT03830294|ACTIVE_COMPARATOR|Conventional Group|The participants used the conventional breast prosthesis that was placed inside a bra and did not directly adhere to the skin.
62397595|NCT05728710||Perforation|all patients with immediate or delayed perforation identified from the FECCO (NCT04592003)
62397596|NCT05028894||IPF|Participants diagnosed with idiopathic pulmonary fibrosis
62397597|NCT06068790|ACTIVE_COMPARATOR|HoLEP surgery with 22Fr|HoLEP will be performed per standard clinical care with the instruments assigned at randomization - 22Fr or 28Fr.
62397598|NCT06068790|EXPERIMENTAL|HoLEP surgery with 28Fr|HoLEP will be performed per standard clinical care with the instruments assigned at randomization - 22Fr or 28Fr.
62397599|NCT04620005||ECMO|The first group will include practitioners who work in intensive care unit with ECMO services
62006307|NCT02488629|EXPERIMENTAL|SCB01A|This study is a single arm, open-label, Phase II trial
62006308|NCT06580158||Patients who are completing an outpatient electrocardiogram (ECG) at the Mayo Clinic.|
62006309|NCT06144073|EXPERIMENTAL|Intervention (Mandala art therapy) group|Students with premenstrual syndrome who were included in the mandala art therapy group by randomization method will be made to practice mandala.
62006310|NCT06144073|NO_INTERVENTION|Control|Control group is the group without any intervention.
62397600|NCT04620005||Non-ECMO|The second group will include practitioners who work in non-ECMO inventive care unit
62397601|NCT05955651||Pelvic washings|Three Samples of peritoneal washings will be collected and send to pathology. looking for myometrial cell spillage at three designated points in surgery. 1st before hysterectomy, 2nd after hysterectomy, and 3rd after morcellation and extraction of the uterus out of the abdominal cavity.
62397602|NCT06616857|EXPERIMENTAL|NUDGE|
62780981|NCT02130505|ACTIVE_COMPARATOR|T2DM|Patients with type 2 diabetes mellitus, defined as having met the diagnostic criteria as outlined by the World Health Organization
62780982|NCT02130505|ACTIVE_COMPARATOR|FCH|Patients with familial combined hyperlipidemia, defined as familial hyperlipidemia with a dominant inheritance pattern, elevated plasma apolipoprotein (apo) B concentrations (\>1.2 g/L) and elevated triglyceride (TG) levels (\>1.7 mmol/L) at the time of diagnosis
62397603|NCT06616857|ACTIVE_COMPARATOR|Education|
62397604|NCT06171659||Open Surgical Procedure (Arthroplasty)|"PPSP subjects who have undergone hip (or knee) joint arthroplasty (i.e., open surgical procedure for joint replacement).~* 6 month post-op scans~* 12 month post-op scans~* 18 month post-op scans"
62397605|NCT06171659||Less Invasive Procedure (Arthroscopy)|"PPSP subjects who have undergone hip (or knee) arthroscopy (i.e., less invasive joint surgical procedure involving scopes and lower profile surgical tools)~- 6 month post-op scans"
62397606|NCT06171659||Asymptomatic: Had Total Joint Replacement (Arthroplasty)|"Asymptomatic subjects who have undergone total hip or total knee arthroplasty.~- single scan during one study visit (up to 3.5 hours)"
62397607|NCT06171659||Asymptomatic: Less Invasive Procedure (Arthroscopy)|"Asymptomatic subjects who have undergone hip or knee arthroscopy.~- single scan during one study visit (up to 3.5 hours)"
62572845|NCT03254745|EXPERIMENTAL|Pharmacist intervention|"1. Disease education (General education about rheumatoid arthritis in a verbal and written manner)~2. Dietary and lifestyle modifications (General recommendations as well as specific ones based on patients' baseline health status)~3. Counseling regarding adherence (General lecture on adherence to medications and physical rehabilitation in rheumatoid arthritis as well as specific advice based on patients health status)~4. Advice on medication use (General counseling on medication use as well as patient centered counseling)."
62006311|NCT05624099|EXPERIMENTAL|drug|"1. camrelizumab 200mg intravenous drip d1q3w~2. Paclitaxel: 150mg/m2 d1 q3w~3. Platinum: Cisplatin, carboplatin, nedaplatin and other platinum drugs~4. Radiotherapy dose: 5040cGy/28f radiotherapy efficacy evaluation after 2-3 cycles of chemotherapy PR/SD received local radiotherapy."
62397608|NCT06175871|EXPERIMENTAL|Otago exercises|"OTAGO program - based on very specific exercises for balance, force, and muscular endurance as well as on education about the risk of falling. The program is considered as home care (exercises to be done at home) but will be done as a group and with supervision, at CIUSSS or from outdoor and nature intervention (recreactional parks). OTAGO session lasts for 30-40 minutes and will be done twice a week at sites with progression. The program is comprised of 5 muscle strengthening exercises and 12 postural balance exercises. Participants will also be invited to walk 2 times per week for 30 minutes (can be divided into shorter periods, for example 3 blocs of 10 minutes) from outdoor sites or recrative parks. According to each person's strength and mobility, exercises will be increased with the use of free weights (for example during squats) and/or by increasing the number of repetitions. Total duration of the program will be 3 months (i.e., a duration adapted to the site)."
62397609|NCT06175871|ACTIVE_COMPARATOR|Conventional physiotherapy at Hospital|This group will be for the conventional type of intervention already in place in geriatric services from La Baie Hospital. This therapy used for physiotherapists at site, including mobility exercices.
62572846|NCT03254745|NO_INTERVENTION|Usual care|Patients will not be counseled by pharmacist and will be allowed to take usual care.
62192074|NCT03194867|EXPERIMENTAL|Isatuximab/cemiplimab (Regimen 1)|"Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression.~Cemiplimab on Days 1 and 15 in 28-day cycle up to disease progression."
62192075|NCT03194867|EXPERIMENTAL|Isatuximab/cemiplimab (Regimen 2)|"Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression.~Cemiplimab on Day 1 in 28-day cycle up to disease progression."
62192076|NCT03194867|ACTIVE_COMPARATOR|Isatuximab|Isatuximab on Days 1, 8, 15 and 22, then Day 1 and 15 in 28-day cycles up to disease progression.
62192077|NCT05021471|EXPERIMENTAL|Group A|Twenty nine (29) patients will be treated stretching of hamstring with pressure biofeedback.
62192078|NCT05021471|ACTIVE_COMPARATOR|Group B|Twenty nine (29) patients will be treated stretching of hamstring without pressure biofeedback.
62572847|NCT05096364|EXPERIMENTAL|AK111 Regimen 1|AK111 Regimen 1 - subcutaneous injection every 4 weeks up to 60 weeks
62780983|NCT02130505|ACTIVE_COMPARATOR|FH|Patients with familial hyperlipidemia, defined as having met the diagnostic criteria as outlined by the world Health Organization
62780984|NCT02130505|ACTIVE_COMPARATOR|Healthy controls|Healthy controls
62780985|NCT01590654|EXPERIMENTAL|0.3mg GS-9620|
62780986|NCT01590654|EXPERIMENTAL|1mg GS-9620|
62780987|NCT01590654|EXPERIMENTAL|2mg GS-9620|
62780988|NCT01590654|EXPERIMENTAL|4mg GS-9620|
62780989|NCT01590654|EXPERIMENTAL|0.3mg GS-9620 QW x 2 doses|
62780990|NCT01590654|EXPERIMENTAL|1mg GS-9620 QW x 2 doses|
62780991|NCT01590654|EXPERIMENTAL|2mg GS-9620 QW x 2 doses|
62780992|NCT01590654|EXPERIMENTAL|4mg GS-9620 QW x 2 doses|
62006312|NCT05301205|ACTIVE_COMPARATOR|group I|will be received oral gabapentin capsule 1200 mg 2h pre-operatively.
62192079|NCT05625347|EXPERIMENTAL|Arm 1: I-ASA 100mg, then C-ASA 162mg tablet|"Treatment A: Single dose of 100 mg ASA powder for oral inhalation (I-ASA) via DPI.~Treatment B: Single dose of 162 mg chewable non-enteric-coated Aspirin (C-ASA) tablets."
62192080|NCT05625347|EXPERIMENTAL|Arm 2: C-ASA 162mg tablet, then I-ASA 100mg|"Treatment A: Single dose of 162 mg chewable non-enteric-coated Aspirin (C-ASA)tablets.~Treatment B: Single dose of 100 mg ASA powder for oral inhalation (I-ASA) via DPI."
62572848|NCT05096364|EXPERIMENTAL|AK111 Regimen 2|AK111 Regimen 2 - subcutaneous injection every 4 weeks up to 60 weeks
62006313|NCT05301205|ACTIVE_COMPARATOR|group II|will be received oral gabapentin capsule 600 mg 2h pre-operatively.
62006314|NCT05301205|NO_INTERVENTION|Group III|will be received placebo capsules at 2 hours preoperatively.
62006315|NCT03360292|EXPERIMENTAL|Higher target range|Infants will be targeted to 92-97% oxygen saturation
62192081|NCT00346853|EXPERIMENTAL|1|
62192082|NCT00346853|PLACEBO_COMPARATOR|2|saline
62192083|NCT03515447||Before period|During this period no patient received Romiplostim.
62192084|NCT03515447||After period|"Application of the transfusion saving strategy protocol through Romiplostim treatment.~The first subcutaneous injection of 1.5 to 2 µg/kg of romiplostim was administered in the post-operative periods. An algorithm based on patient weight and platelet count was established to determine romiplostim doses. One injection per week was performed. Romiplostim posology was adjusted between 2 and 5µg/kg every week according to platelet count with a maximum of 4 administrations in the ICU."
62192085|NCT02582268|EXPERIMENTAL|TAS guided IUD insertion|the female will be asked to be full bladder. the trans-abdominal probe will be placed by an assistant on the suprapubic region. under speculum examination, the intrauterine device IUD (TCu 380A) will be placed till it reaches the fundus of the uterus and then released.
62192086|NCT02582268|EXPERIMENTAL|Traditional IUD insertion|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound. the trans-abdominal probe will also be placed by an assistant on the suprapubic region ( the image would be on freeze mode) as it is not actually used , it is just to make the same settings for the participant females.
62192087|NCT05732805|EXPERIMENTAL|BCD-217 (nurulimab + prolgolimab)|BCD-217 followed by prolgolimab 1 mg/kg monotherapy.
62192088|NCT05732805|ACTIVE_COMPARATOR|BCD-100 (prolgolimab)|Prolgolimab monotherapy.
62572849|NCT05096364|EXPERIMENTAL|AK111 Regimen 3|AK111 Regimen 3 - subcutaneous injection every 4 weeks up to 60 weeks
62572850|NCT05096364|EXPERIMENTAL|AK111 Regimen 4|AK111 Regimen 4 - subcutaneous injection every 4 weeks up to 60 weeks
62572851|NCT05096364|PLACEBO_COMPARATOR|Placebo to AK111|Placebo to AK111-Placebo subcutaneous injection, then 1:1 randomized to AK111 Regimen 3 or Regimen 4 at week 12
62006316|NCT03360292|NO_INTERVENTION|Standard target range|Infants will be targeted to 90-95% oxygen saturation, which is the range used as routine in the Neonatal Unit involved in the study
62780993|NCT02353390|ACTIVE_COMPARATOR|Oral Water Hydration|Subjects will be given up to 15 minutes to drink up to 500 mL of water prior to the first IM vaccination.
62780994|NCT02353390|NO_INTERVENTION|Usual Care|Subjects will receive usual care prior to the first IM vaccination. No water or food will be offered.
62780995|NCT02624531|OTHER|fertility-sparing surgery|NACT with Taxane combined with cisplatin and Fertility-sparing Treatment Strategy
62780996|NCT03479710|EXPERIMENTAL|FMT infusion|FMT will be performed using frozen donor stool samples obtained from the stool bank of CUHK. 100-200ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via OGD.
62780997|NCT03479710|NO_INTERVENTION|Control|No FMT infusion.
62780998|NCT01087216|ACTIVE_COMPARATOR|Group Laser = Arm As A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
62780999|NCT01087216|PLACEBO_COMPARATOR|Bras B : the control group|patient to accept habitual treatment of corticoid
62781000|NCT06388317|EXPERIMENTAL|Adaptive Step Goal (Intervention)|After the 1-week run-in period, participants in the control group will be provided with constant daily step goals that were set to 10,000 steps per day through the Sprout app. Participants will receive a push notification at 8 AM every day that provides that day's step goal (10,000 steps), and if the participant achieves the goal before 8 PM, then another push notification will be sent to congratulate the participant on reaching their step goal (of 10,000 steps) for the day.
62781001|NCT06388317|ACTIVE_COMPARATOR|Static Step Goal (Control)|After the 1-week run-in period, participants in the control group will be provided with constant daily step goals that were set to 10,000 steps per day through the Sprout app. Participants will receive a push notification at 8 AM every day that provides that day's step goal (10,000 steps), and if the participant achieves the goal before 8 PM, then another push notification will be sent to congratulate the participant on reaching their step goal (of 10,000 steps) for the day.
62781002|NCT04569357|EXPERIMENTAL|Prospekta|One tablet per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablet should be held in mouth until completely dissolved.
62006317|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 1 mg/kg Q2W|Single-agent LAG525 1 mg/kg Q2W
62192089|NCT01844713|EXPERIMENTAL|Experimental: Workbook|Distribution of the sun protection educational workbook
62192090|NCT01844713|NO_INTERVENTION|Control|Distribution of general skin care information
62192091|NCT04685447|EXPERIMENTAL|Expanded Hemodialysis|Hemodialysis modality performed by using a medium cut-off membrane
62192092|NCT04685447|EXPERIMENTAL|Protein-leaking hemodialysis|Hemodialysis modality performed by using a membrane with accentuated absorption capacities.
62192093|NCT03344068|EXPERIMENTAL|Experimental Group|The patients in the Experimental Group are allocated to receive radical radiotherapy with or without chemotherapy plus Nutren® Optimum of 7 scoops tid at begin of radiotherapy.
62192094|NCT03344068|ACTIVE_COMPARATOR|Controlled Group|The patients in the Controlled Group are allocated to receive radical radiotherapy with or without chemotherapy plus routine diet guidance at begin of radiotherapy.
62192095|NCT03265015|EXPERIMENTAL|cTBS|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern.
62192096|NCT03265015|ACTIVE_COMPARATOR|iTBS|Transcranial Magnetic Stimulation delivered in an intermittent Theta Burst Stimulation (iTBS) pattern.
62192097|NCT03080142|EXPERIMENTAL|Group 1|Single injection of Exparel
62192098|NCT03080142|ACTIVE_COMPARATOR|Group 2|Injection of Ropivicaine (Naropin) bolus and placement of Ropivicaine catheters
62192099|NCT04349007|ACTIVE_COMPARATOR|Standard meal|local porridge with a vitamin and mineral sprinkle powder that will be mixed in
62192100|NCT04349007|EXPERIMENTAL|School food ready-to-use|peanut-based school food ready-to-use
62192101|NCT04349007|EXPERIMENTAL|School food ready-to-use plus Milk|peanut-based school food ready-to-use with milk
62192102|NCT04940364|EXPERIMENTAL|Cohort 1|Pozelimab: Single-dose SC on day 1
62192103|NCT04940364|EXPERIMENTAL|Cohort 2|Pozelimab: Single-dose IV on day 1
62192104|NCT04940364|EXPERIMENTAL|Cohort 3|Pozelimab: Single-dose SC on day 29 Cemdisiran: Single-dose SC on day 1
62781003|NCT04569357|PLACEBO_COMPARATOR|Placebo|One tablet per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablet should be held in mouth until completely dissolved.
62781004|NCT02372981|EXPERIMENTAL|DG-HAL with mucopexy|Mucopexy with DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
62006318|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 3 mg/kg Q2W|Single-agent LAG525 3 mg/kg Q2W
62006319|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 5 mg/kg Q2W|Single-agent LAG525 5 mg/kg Q2W
62006320|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 10 mg/kg Q2W|Single-agent LAG525 10 mg/kg Q2W
62006321|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 15 mg/kg Q2W|Single-agent LAG525 15 mg/kg Q2W
62006322|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 240 mg Q2W|Single-agent LAG525 240 mg Q2W
62006323|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 400 mg Q2W|Single-agent LAG525 400 mg Q2W
62192105|NCT04940364|EXPERIMENTAL|Cohort 4|Pozelimab: Single-dose SC on day 1 Cemdisiran: Single-dose SC on day 1
62192106|NCT04940364|EXPERIMENTAL|Cohort 5|Optional Pozelimab: Single-dose SC on day 1 or day 29 Cemdisiran: Single-dose SC on day 1
62192107|NCT04940364|EXPERIMENTAL|Cohort 6|Pozelimab: Single-dose IV on day 1
62192108|NCT02907437|ACTIVE_COMPARATOR|Minocycline treatment|Intervention: Drug: Minocycline (200 mg/day)
62192109|NCT02907437|PLACEBO_COMPARATOR|Placebo treatment|Placebo Intervention: Drug: Placebo (200 mg/day)
62192110|NCT05176691|EXPERIMENTAL|Treatment|All patients to receive HMPL-760 daily.
62192111|NCT05428280|EXPERIMENTAL|Muscle Energy Techniques|"Following physiotherapy will be given to the participants in this group for 4 weeks, 3 times a week:~1. Muscle Energy Technique"
62006324|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 3 mg/kg Q4W|Single-agent LAG525 3 mg/kg Q4W
62006325|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 5 mg/kg Q4W|Single-agent LAG525 5 mg/kg Q4W
62006326|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 10 mg/kg Q4W|Single-agent LAG525 10 mg/kg Q4W
62006327|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 400 mg Q4W|Single-agent LAG525 400 mg Q4W
62572852|NCT05385263|EXPERIMENTAL|NIVOLUMAB|All patients enrolled will be given nivolumab ( 3mg/kg IV) on day +5 Patients with CAR-T expansion\<100 cells/microL on day +7 will be given 1 additional dose of nivolumab (3mg/kg IV) on day +19 (two weeks after first dose of nivolumab).
62781005|NCT02372981|ACTIVE_COMPARATOR|mucopexy alone|Mucopexy without DG-HAL is performed using the same specific device consisting of a proctoscope equipped with a Doppler probe and a light source as described above.
62781006|NCT03229941|EXPERIMENTAL|Restrictive|Transfusion trigger: Hb\<7gm/dl
62781007|NCT03229941|EXPERIMENTAL|Liberal|Transfusion trigger: Hb\<10gm/dl
62781008|NCT02606058|NO_INTERVENTION|Early cord clamping (Control Arm)|Immediate cord clamping (\< 10 seconds after birth). The cord is clamped 6 cm from the umbilicus within ten seconds of delivery of the baby.
62781009|NCT02606058|EXPERIMENTAL|Deferred cord clamping|Deferred cord clamping. Investigator/Research personnel holds the baby as low as possible below the level of the introitus or placenta for 60 seconds and not to exceed 80 seconds, then clamps the cord about 6 cm from the umbilicus.
62781010|NCT03140462||liver transplant patients and donors|To study clinical and genetic factors on tacrolimus dose normalized trough concentration.
62781011|NCT04832880|EXPERIMENTAL|Control arm (dexamethasone arm)|IV dexamethasone 6 mg for 10 days
62781012|NCT04832880|EXPERIMENTAL|Remdesivir arm|IV dexamethasone 6 mg for 10 days + remdesivir IV 200 mg on day 1, followed by 100 mg die until day 10
62781013|NCT04832880|EXPERIMENTAL|Baricitinib arm|IV dexamethasone 6 mg for 10 days + baricitinib 4 mg die for 10 days. For patients aged \> 75 years or estimated GFR \< 60 ml/min\*1.73m2, baricitinib dose is reduced to 2 mg for 10 days.
62006328|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W|Combination LAG525 0.3 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
62192112|NCT05428280|ACTIVE_COMPARATOR|Myofascial Mobilization Techniques|"Following physiotherapy will be given to the participants in this group for 4 weeks, 3 times a week:~1. Myofascial Mobilization"
62781014|NCT04832880|EXPERIMENTAL|Remdesivir + baricitinib arm|"IV dexamethasone 6 mg for 10 days + remdesivir IV 200 mg on day 1, followed by 100 mg die until day 10 + baricitinib 4 mg die for 10 days.~For patients aged \> 75 years or estimated GFR \< 60 ml/min\*1.73m2, baricitinib dose is reduced to 2 mg for 10 days."
62781015|NCT02235545||St. Jude Medical Optisure Lead|Patients implanted with St. Jude Medical Optisure Lead
62781016|NCT05324228||Preschool children|10 preschool healthy children aged 3-5,9 years.
62781017|NCT05324228||Children of younger school age|10 children of younger school age aged 6-10,9 years.
62781018|NCT05324228||Children in puberty|10 children in puberty aged 11-14,9 years
62781019|NCT05324228||Postpubertal adolescents|10 postpubertal adolescents aged 15-18,9 years.
62781020|NCT04248088|NO_INTERVENTION|Educational Control Group|Education provided for optional use
62781021|NCT04248088|EXPERIMENTAL|Gentle Stretching and Education|Gentle Stretching for 60 minutes twice weekly for 6 months
62006329|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W|Combination LAG525 1 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
62006330|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W|Combination LAG525 80 mg + PDR001 80 mg (Q2W/Q2W)
62006331|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W|Combination LAG525 80 mg + PDR001 240 mg (Q2W/Q2W)
62006332|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W|Combination LAG525 240 mg + PDR001 240 mg (Q2W/Q2W)
62192113|NCT00980590|EXPERIMENTAL|Airway Scope|Intubation with Airway Scope
62781022|NCT01299116|OTHER|Preference SARC|Participants received one of a variety of oral contraceptives or DMPA
62781023|NCT01299116|EXPERIMENTAL|Randomized LARC|"Participants receive one of the following interventions:~Implanon® or Nexplanon®; ParaGard®; Mirena®"
62781024|NCT01299116|ACTIVE_COMPARATOR|Randomized SARC|Participants received one of a variety of oral contraceptives or DMPA
62781025|NCT00411632|EXPERIMENTAL|Bexarotene + Erlotinib|Bexarotene 400 mg/m\^2 by mouth daily x 28 Days. Erlotinib 150 mg by mouth daily x 28 Days.
62781026|NCT01509911|EXPERIMENTAL|TL-118 with standard of care Gemcitabine|
62781027|NCT01509911|ACTIVE_COMPARATOR|Gemcitabine with out TL-118|
62006333|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 240 mg + PDR001 300 mg (Q3W/Q3W)
62006334|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W)
62006335|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 600 mg + PDR001 300 mg (Q3W/Q3W)
62006336|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W|Combination LAG525 80 mg + PDR001 240 mg (Q4W/Q4W)
62006337|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W|Combination LAG525 400 mg + PDR001 400 mg (Q4W/Q4W)
62192114|NCT00980590|ACTIVE_COMPARATOR|Macintosh laryngoscope|Intubation with Macintosh laryngoscope
62781028|NCT01211821|OTHER|metoprolol|Treatment A
62572853|NCT05668208|EXPERIMENTAL|extraperitoneal surgery group - TEP inguinal hernia repair|The external sheath of the rectus muscle was seen by passing through the skin and subcutaneous tissue with a mini incision made from the umbilicus edge. A 10 mm trocar was placed in the preperitoneal area and CO2 insufflation was performed. The pressure was set to 14 mmHg. Two more 5 mm trocars were inserted between the umbilicus and the sympisis pubis under the laparoscope. The preperitoneal inguinal area was dissected with a laparoscopic dissector and grasper. The hernia sac was released. A 10x15 cm prolene mesh was spread and fixed to cover the femoral, direct and indirect hernia areas. The trocars were removed by evacuating the CO2 gas. The skin was closed and the operation was terminated.
62572854|NCT05668208|ACTIVE_COMPARATOR|transperitoneal surgery group - laparoscopic cholecystectomy|With a mini incision made under the umbilicus, the abdomen was entered with a 10 mm trocar. Pneumoperitoneum was created with CO2 gas. Intra-abdominal pressure was set to 14 mmHg. Under the guidance of the laparoscope, one 10 mm trocar from the subxiphoid area and two more 5 mm trocars from the subcostal area were inserted. The cystic artery and cystic duct were clipped and cut by exposing the Callot triangle. Then the gallbladder was separated from the liver bed and taken out of the abdomen. The CO2 in the abdomen was evacuated and the trocars were removed. The fascia defect and skin were closed and the operation was terminated.
62572855|NCT01661335|EXPERIMENTAL|Ondansetron, dexamethasone, aprepitant|Arm A: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
62572856|NCT01661335|PLACEBO_COMPARATOR|Ondansetron, Dexamethasone, placebo|Arm B: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
62572857|NCT00802035|ACTIVE_COMPARATOR|IR am|30 mg, single dose, morning administration (immediate release \[IR\])
62572858|NCT00802035|EXPERIMENTAL|ER am|30 mg; single dose; morning administration (extended release \[ER\])
62781029|NCT01211821|EXPERIMENTAL|BMS-914392 + metoprolol|Treatment B
62006338|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W|Combination LAG525 800 mg + PDR001 400 mg (Q4W/Q4W)
62192115|NCT01443923|ACTIVE_COMPARATOR|1-HCV|Hepatitis C Mono-infected
62572859|NCT00802035|EXPERIMENTAL|ER pm|30 mg; single dose; evening administration
62572860|NCT00802035|ACTIVE_COMPARATOR|IR pm|30 mg; single dose; evening administration
62781030|NCT06457698|PLACEBO_COMPARATOR|HA injection|After TMJ double-puncture arthrocenthesis under local anesthesia, hyaluronic acid (Suplasyn®, 20 mg/ml) will be injected in the joint with the first portal.
62781031|NCT06457698|ACTIVE_COMPARATOR|HA + PRP injection|"32ml of venous blood per joint will be collected and added to four 8ml-collection tubes containing sodium citrate. Then, blood will be centrifugated at 800rpm for 8 minutes at room temperature. 3 layers are perceptible: (1)layer with platelet-rich plasma and growth factors; (2)layer with white blood cells; (3)layer corresponding to red blood cells. Then, the total plasma volume will be calculated, and the plasma corresponding to the first fraction (low platelet fraction) aspirated. The second fraction of the first layer corresponding to PRP, above the white blood cell layer, will be removed and transferred to new tubes.~10 minutes before the mixing with HA, a calcium chloride-rich activator (Endoret ®, BTI Biotechnology Institute, Vitoria-Gasteiz, Álava, Spain) will be added to the PRP. The mixture of PRP with HA was then carried out at a ratio of 1cc of low molecular weight HA (Suplasyn®, 20 mg/ml) +1cc of PRP and introduced in the joint with the first portal."
62572861|NCT02425566|EXPERIMENTAL|Study day with trimethaphan|After baseline measurements, autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min.
62192116|NCT01443923|ACTIVE_COMPARATOR|2 HCV/HIV|Hepatitis C and HIV co-Infected
62006339|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W|Combination LAG525 1000 mg + PDR001 400 mg (Q4W/Q4W)
62006340|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W|Combination LAG525 80 mg + PDR001 400 mg (Q2W/Q4W)
62192117|NCT02546947|NO_INTERVENTION|Appropriate clinical group|group of patients with clinical dose adjustment
62192118|NCT02546947|ACTIVE_COMPARATOR|TOF adapted group|group with an objective of less than 2 responses to TOF stimulation monitored
62192119|NCT02376647|EXPERIMENTAL|Driving pressure limited ventilation|Driving pressure limited ventilation (≤13cmH2O)
62192120|NCT02376647|ACTIVE_COMPARATOR|Conventional ventilation|Mechanical ventilation with limited tidal volume (8mL/kg of predicted body weight) and plateau pressure (≤30cmH2O)
62397610|NCT02679560|ACTIVE_COMPARATOR|Liposomal Bupivacaine|In patients with femur or hip fractures, a fascia iliaca compartment block using liposomal bupivacaine will be administered
62006341|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W|Combination LAG525 240 mg + PDR001 400 mg (Q2W/Q4W)
62006342|NCT02460224|EXPERIMENTAL|Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W|Combination LAG525 300 mg + PDR001 400 mg (Q2W/Q4W)
62006343|NCT02460224|EXPERIMENTAL|Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1
62006344|NCT02460224|EXPERIMENTAL|Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W|Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1
62006345|NCT02460224|EXPERIMENTAL|Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1
62006346|NCT05520671|EXPERIMENTAL|TESLA-G|Participants will be randomised into the two arms with a 1:1 allocation ratio stratified by year of study. There will be 25 participants in this arm.
62006347|NCT05520671|ACTIVE_COMPARATOR|Control|Participants will be randomised into the two arms with a 1:1 allocation ratio stratified by year of study. There will be 25 participants in this arm.
62192121|NCT02453243|NO_INTERVENTION|Baseline|Retrospective Chart Reviews will be conducted for the period between the original ED-SAFE and the new study to test the long-term sustainability of nurse administered universal screening implemented in the original study.
62397611|NCT02679560|PLACEBO_COMPARATOR|Ropivacaine HCL|In patients with femur or hip fractures, a fascia iliaca block using using 0.2% ropivacaine will be administered
62397612|NCT03378921|EXPERIMENTAL|donors feces|Fecal microbiota transplantation (FMT) is performed by experienced endoscopists through flexible endoscopy into the afferent limb. The second FMT is installed via transanal catheter into the pouch 4 weeks after the first FMT.
62397613|NCT03378921|PLACEBO_COMPARATOR|patients own feces|Fecal microbiota transplantation (FMT) is performed by experienced endoscopists through flexible endoscopy into the afferent limb. The second FMT is installed via transanal catheter into the pouch 4 weeks after the first FMT.
62006348|NCT00434096|EXPERIMENTAL|1|
62006349|NCT00434096|PLACEBO_COMPARATOR|2|
62006350|NCT03065465|OTHER|Standard endoscopic treatment|For those assigned to the standard endoscopy group, endoscopic hemostasis is performed using usual CURE hemostasis therapy for the focal GI lesions: injection of dilute (e.g. 1: 20,000) epinephrine (in 1-2 cc aliquots in 4 quadrants next to the SRH) of active bleeding or adherent clots (prior to snaring them off); coaptive coagulation with multipolar electrocautery (MPEC) probe and/or standard through the endoscope hemoclips along the course of the underlying artery as detected by DEP. Hemostasis is performed until active bleeding stops and/or the SRH is obliterated. Residual blood flow after visually guided hemostasis is recorded, but not used as a guide for additional hemostasis in this study.
62006351|NCT03065465|EXPERIMENTAL|Over-the-scope hemoclipping device|For those assigned OTSC, prior to use of the OTSC in UGI lesions with active bleeding or adherent clots, dilute epinephrine (1: 20,000) is injected around the SRH in 1-2 cc aliquots and the clots are cold guillotined off, as previously described (2, 4, 17). As a brief additional description, after initial diagnosis and preparation of the lesion and SRH (as described for standard hemostasis), the therapeutic sized endoscope is removed and this or a diagnostic panendoscope will be affixed with the OTSC of appropriate size for the endoscope and the target lesion. The endoscope is re-introduced and passed to the bleeding site. The SRH is centered in the field of view and within the cap of the OTSC device. Using high suctioning and firm pressure to center the SRH, the lesion and SRH is captured into the cap and the OTSC is deployed by rotating the handle and thereby compressing the bleeding lesion and surrounding tissue with mechanical hemostasis.
62006352|NCT00203450|EXPERIMENTAL|Zonegran|Zonegran
62006353|NCT00203450|PLACEBO_COMPARATOR|Placebo|Placebo pill
62006354|NCT01455116|EXPERIMENTAL|Mild induced hypothermia|Induced hypothermia to 32-34 degrees Celsius (90 - 93 degrees Fahrenheit)
62006355|NCT01455116|NO_INTERVENTION|Fever Respect|Standard of care septic shock therapy according to Surviving Sepsis Campaign guidelines
62192122|NCT02453243|OTHER|Intervention|"1. Safety Plan Intervention: Clinician training in safety planning, and~2. A Lean Implementation Strategy: The Implementation of the safety planning guided by Lean~Combine, this is expected to increase safety planning by clinicians."
62192123|NCT02453243|NO_INTERVENTION|Maintenance|Test sustainability of safety planning during the Maintenance phase.
62192124|NCT00665093||A|
62397614|NCT03158532|PLACEBO_COMPARATOR|Placebo I/Placebo II|0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
62397615|NCT03158532|EXPERIMENTAL|Nitroglycerin I/Placebo II|500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
62397616|NCT03158532|ACTIVE_COMPARATOR|Placebo I /Nitroglycerin II|0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
62192125|NCT00665093||B|
62192126|NCT03785106|EXPERIMENTAL|1HP|4-week daily regimen of weight-based RPT and INH, plus pyridoxine (vitamin B6)
62192127|NCT03785106|ACTIVE_COMPARATOR|3HP|12-weekly INH/RPT regimen, plus pyridoxine (vitamin B6)
62192128|NCT04669145|EXPERIMENTAL|Continuous Regional Anesthesia Lower Limb Surgery|Various types of regional anesthesia blocks will be performed based on the patient's injuries including fascia iliaca plane blocks, femoral nerve blocks, adductor canal blocks, popliteal approach sciatic nerve blocks, and saphenous nerve blocks A catheter will be placed for the given block for 48 hours. Those patients undergoing lower limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia.
62192129|NCT04669145|EXPERIMENTAL|Single Shot Regional Anesthesia Lower Limb Surgery|"Various types of regional anesthesia blocks will be performed based on the patient's injuries including fascia iliaca plane blocks, femoral nerve blocks, adductor canal blocks, popliteal approach sciatic nerve blocks, and saphenous nerve blocks. These blocks will be given via a single dose or single shot. Those patients undergoing lower limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia."
62781032|NCT06329206|EXPERIMENTAL|GH2616 GROUP|"Dose Escalation: Dose Escalation Cohorts Subjects will be enrolled at various doses of GH2616. These Dose Escalation Cohorts will be utilized to To determine the maximum tolerated dose (MTD) and/or recommended dose for expansion(s) (RDEs) for Dose Expansion. Dose Escalation: Backfill Cohorts 2 \~ 3 dose cohorts are allowed to be backfilled.These Backfill Cohorts will be utilized to build additional data to support selection of doses and/or tumor types for further study in Dose Expansion.~Dose Expansion: Expansion Cohorts 2 \~ 3 dose cohorts are planned.Subjects with advanced solid tumors harboring TP53 mutation and whole genome duplication (WGD+) will be enrolled.These Cohorts will be utilized to to determine the recommended Phase II dose (RP2D) of GH2616 Tablet."
62781033|NCT02858063||Pending chemotherapy +/- trastuzumab|In the 1st group (chemotherapy), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
62192130|NCT04669145|EXPERIMENTAL|Continuous Regional Anesthesia Upper Limb Surgery|Various types of regional anesthesia blocks involving the brachial plexus will be performed based on the patient's injuries. A catheter will be placed for the given block for 48 hours. Those patients undergoing upper limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia.
62572862|NCT02425566|EXPERIMENTAL|Radionuclide Study day with nitroglycerin|Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements. Outcome measurements will be repeated within 10 min after the nitroglycerin has dissolved
62192131|NCT04669145|EXPERIMENTAL|Single Shot Regional Anesthesia Upper Limb Surgery|Various types of regional anesthesia blocks involving the brachial plexus will be performed based on the patient's injuries. A catheter will be placed for the given block for 48 hours. Those patients undergoing upper limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia.
62192132|NCT01372007|EXPERIMENTAL|Lanreotide Autogel 120mg|
62192133|NCT01372007|PLACEBO_COMPARATOR|Placebo|
62192134|NCT03364777||lumbar surgery patients|patients undergoing lumbar surgery with or without anxiety or depression emotional state
62006356|NCT02439775|EXPERIMENTAL|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
62192135|NCT05917132|EXPERIMENTAL|Single|All participating subjects will undergo 3 feeding phases : 3 days of a run-in diet, 2 days of a polyunsaturated fatty acid (PUFA) diet and 2 days of a saturated fatty acid (SFA) diet.
62397617|NCT03158532|EXPERIMENTAL|Nitroglycerin I /Nitroglycerin II|500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
62397618|NCT02502994|OTHER|Intervention|Single arm of the castration resistant prostate cancer
62572863|NCT06577194|EXPERIMENTAL|Experimental group|Experimental arm
62781034|NCT02858063||pending trastazumab +/- hormone therapy|In the 2nd group (trastazumab), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
62006357|NCT02439775|SHAM_COMPARATOR|Sham Procedure|Renal angiography
62006358|NCT04465175|ACTIVE_COMPARATOR|Second dose magnesium sulphate|Second dose magnesium sulphate 50 mg/kg infused over one hour
62006359|NCT04465175|PLACEBO_COMPARATOR|Placebo|Normal saline (2.5 ml/kg) infused over one hour
62781035|NCT02858063||pending hormone therapy alone|In the third group (hormone therapy), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
62781036|NCT02858063||pending afercare period|In the last group (aftercare), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
62397619|NCT00938457|EXPERIMENTAL|Arm I|Patients undergo either percutaneous placement of metallic fiducial markers within the liver or respiratory-correlated cone-beam computed tomography for stereotactic targeting and planning. Patients then undergo single-fraction stereotactic body radiotherapy over approximately 1 hour within 1 week of the marker placement.
62397620|NCT06649929|EXPERIMENTAL|Couples-based treatment- Patient|In this group, couples will attend 3-telehealth based sessions with a community health worker for education and interventions to improve communication, sleep quality and PAP use
62397621|NCT06649929|EXPERIMENTAL|Couples-based treatment- Partner|In this group, couples will attend 3-telehealth based sessions with a community health worker for education and interventions to improve communication, sleep quality and PAP use
62572864|NCT02801513|EXPERIMENTAL|Brief Mindfulness Training|The brief mindfulness training comprised of three 1.5-hour weekly individual sessions and included intensive daily home practice. Participants were asked to engage in formal meditation practice for about 25 minutes twice per day on six out of seven days of each week using recorded guided meditations. Practices were shorter in duration than the practices in Mindfulness-Based Cognitive Therapy (MBCT, Segal et al., 2002) in order to allow for more flexibility in scheduling the practices, but followed the standard sequence of mindfulness-based interventions.
62781037|NCT05037617|EXPERIMENTAL|Intervention site (Foothills Medical Centre): Continuation of Oxytocin|Participants in this arm will receive a blinded vial of oxytocin once a patient is found to be \>= 6 cm dilated.
62781038|NCT05037617|PLACEBO_COMPARATOR|Intervention site (Foothills Medical Centre): Discontinuation of oxytocin|Participants in this arm will receive a blinded vial of saline solution once a patient is found to be \>= 6 cm dilated.
62781039|NCT01454765||Sperm sample from healthy volunteers|
62781040|NCT03468647|EXPERIMENTAL|FRAGIL-IT testing group|FRAGIL-IT tools : connected soles, connected weighting machine and measure of gripping force
62781041|NCT02464722|EXPERIMENTAL|Dexmedetomidine|"1. Before induction of Anesthesia, 1 mcg/kg iv loading dose of dexmedetomidine over 10 minutes.~2. Anesthesia was induced with propofol 2 mg kg-1 , rocuronium 0.6 mg kg-1~3. After Mask ventilation with 6 vol% desflurane in 100% oxygen for 3 minutes, tracheal intubation was done~4. Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min. The infusion rate was adjusted according to the patient's response, to achieve a mean arterial pressure between 60 and 80 mmHg.~5. Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.~6. At the end of surgery, discontinuation of desflurane and dexmedetomidine, sending recovery room."
62791823|NCT00595491|EXPERIMENTAL|allergic asthmatic, allergic nonasthmatic, healthy|Adults who are allergic asthmatics, allergic nonasthmatics, or healthy controls will receive segmental allergen challenge to the lung
62006360|NCT03427385|EXPERIMENTAL|Minimum Effective dose|Local anesthetic Ropivacaine 0.5% injection for adductor canal block
62006361|NCT02942979||MISSION Implementation as Usual|Passive implementation or, IU for MISSION-Vet is comprised of a two-hour webinar training, along with key information on how to access and use the MISSION-Vet Treatment Manual and Consumer Workbook. The manual is posted on the web and available inside the VA on the National Center for Homelessness Among Veterans website or at missionmode.org. This passive implementation strategy has been used in previous studies
62006362|NCT02942979||Facilitation Implementation of MISSION|Facilitation is a comprehensive approach in which implementation experts partner with local staff to support implementation planning and to tailor adoption strategies to the local context. Facilitation gives attention to addressing individual- and organizational-level factors that can influence successful implementation of an evidence based practice with good fidelity.
62006363|NCT02898194||1/Patient Surrogates|Any eligible participant who have acted as a surrogate medical decision-maker.
62192136|NCT05196451|ACTIVE_COMPARATOR|Short-time rehabilitation|The intervention consists of an individualized numbers of outpatient encounters (min. 2, max. 8) with medical doctors and physiotherapists at Kysthospitalet, Stavern, Norway. The encounters aim to foster a rehabilitation process based upon principles from Cognitive Behavioral Therapy (CBT)
62192137|NCT05196451|NO_INTERVENTION|Care as usual|
62397622|NCT06649929|ACTIVE_COMPARATOR|Information Control- Patient|In this group, couples will recieve a standardized packet of insomnia about obstructive sleep apnea and starting positive airway pressure.
62397623|NCT06649929|ACTIVE_COMPARATOR|Information Control- Partner|In this group, couples will recieve a standardized packet of insomnia about obstructive sleep apnea and starting positive airway pressure.
62397624|NCT04855539||wave 1|
62397625|NCT04855539||wave 2|
62572865|NCT02801513|ACTIVE_COMPARATOR|Resting Control Training|The resting control training comprised of three 1.5-hour weekly individual sessions and included intensive daily home practice. Participants were asked to schedule regular rest periods as a means of deliberately retreating from the activities of the day. Length and frequency of the rest periods mirrored the time demands of the meditation training. Participants received a plausible rationale for the control training that linked acute depression to stress and suggested rest, relaxation, and disengagement from negative thinking as an initial and preliminary step towards recovery.
62572866|NCT03661619|EXPERIMENTAL|Control Group|Envelope technique + sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure
62572867|NCT03661619|EXPERIMENTAL|Test Group|Envelope technique + sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure
62572868|NCT01569971||Adolescents|Adolescents with SCD (all genotypes) age 12 years old up to 18 years old and currently receiving services through the St. Jude Children's Research Hospital Sickle Cell Disease Transition Program.
62572869|NCT01569971||Caregivers|Caregiver of an adolescent with SCD who has resided with the adolescent for at least two years prior.
62572870|NCT01569971||Young Adults|Young adults with SCD (all genotypes) age equal to 18 years up to and equal to 30 years of age who have transitioned to adult care.
62006364|NCT02203591|EXPERIMENTAL|3M CHG/IPA Prep C|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
62572871|NCT05029791|OTHER|Metastatic melanoma|Patients with stage III or IV melanoma eligible for an immunotherapy or targeted therapy
62572872|NCT02790567||HIT study group|The HIT study group will include all patients admitted in our surgical intensive care unit (ICU) during the study period if the clinician in charge of the patient suspects the diagnosis of HIT. The HEP score, the 4Ts score, the immuno-diffusion particle gel immunoassay (ID-PaGIA) and the HIT-Ab(PF4-H) test will be done for each patient the day the diagnosis of HIT will be suspected.
62572873|NCT06113419|EXPERIMENTAL|Early cholecystectomy|Early laparoscopic cholecystectomy (within 72 hours after randomization)
62572874|NCT06113419|ACTIVE_COMPARATOR|Interval cholecystectomy|Interval laparoscopic cholecystectomy (30 +/- 5 days after randomization).
62572875|NCT00326716|EXPERIMENTAL|Treatment|
62192138|NCT04489108|EXPERIMENTAL|Tranexamic Acid with Standard Medical Treatment|Arm A will Tranexamic Acid 1g iv bolus as loading dose followed by 3g Tranexamic Acid infused over next 24 hours along with standard medical and interventional (Endoscopy) therapy.
62572876|NCT00650013|EXPERIMENTAL|1|Midodrine HCl Tablets 5 mg
62572877|NCT00650013|ACTIVE_COMPARATOR|2|ProAmatine® Tablets 5 mg
62572878|NCT03456804|EXPERIMENTAL|Treatment ESK981|Patients receive pan-VEGFR/TIE2 (Vascular Endothelial Growth Factor Receptor/angopoeitin receptor2) tyrosine kinase inhibitor CEP-11981 PO QD for 5 days (Monday-Friday). Treatment repeats for up to 8 weeks in the absence of disease progression or unacceptable toxicity. If treatment is successful after 8 weeks, patients may receive up to 6 months of pan-VEGFR/TIE2 tyrosine kinase inhibitor CEP-11981.
62572879|NCT05557162|EXPERIMENTAL|Notification of the AI ECG algorithm and the A3E scores|Provider-facing recommendation report that alerts to provider for positive AI ECG Amyloid Score, standardized amyloid order set, diagnostic algorithm and reminders
62572880|NCT05557162|NO_INTERVENTION|Usual Care|No alerts to provider for positive AI ECG Amyloid Score, standardized amyloid order set, diagnostic algorithm and reminders
62791824|NCT04383782|ACTIVE_COMPARATOR|Expectancy Challenge|The expectancy challenge intervention will involve two brief videotaped testimonials in which former smokers discuss their experiences with smoking-related health conditions. Participants will be encouraged to reflect back on the content of each video once per week leading up to the follow-up assessment.
62397626|NCT00679692||3:|three arms for study
62397627|NCT03802747|EXPERIMENTAL|Y-90, SBRT, and Durvalumab Alone|Six patients will be enrolled in cohorts of three to be administered Y-90, SBRT, and Druvalumab.
62397628|NCT03802747|EXPERIMENTAL|Y-90, SBRT, and Durvalumab + Tremelimumab|Six patients will be enrolled in cohorts of three to be administered Y-90, SBRT, and Druvalumab + Tremelimumab.
62397629|NCT04499118|EXPERIMENTAL|Arm a(HR+/HER2-,HRD-）|Participants receive AT regimen for neoadjuvant therapy
62397630|NCT04499118|EXPERIMENTAL|Arm b(TNBC, HRD-)|Participants receive TP regimen for neoadjuvant therapy
62397631|NCT04499118|EXPERIMENTAL|Arm c(HER2-,HRD+)|Participants receive AT regimen for neoadjuvant therapy
62572881|NCT02846181|EXPERIMENTAL|Healthy|
62572882|NCT05924789||Cohort A|120 patients with histological diagnosis of gastric and gastroesophageal junction cancer.
62572883|NCT05924789||Cohort B|80 patients histological diagnosis of pancreatic cancer.
62572884|NCT04657588|EXPERIMENTAL|Anal insert|This group will be asked to use anal inserts to help manage their faecal incontinence during the treatment period
62572885|NCT04657588|SHAM_COMPARATOR|Care as usual|This group will be asked to continue with their care as usual (e.g. incontinence pads)
62006365|NCT02203591|EXPERIMENTAL|3M CHG/IPA Prep CH|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
62192139|NCT04489108|ACTIVE_COMPARATOR|Placebo + Standard Medical treatment|Arm B will receive similar volume of isotonic solution (saline) along with standard medical and interventional (Endoscopy) therapy.
62397632|NCT04499118|EXPERIMENTAL|Arm d(HER2-, HRD+)|Participants receive TP regimen for neoadjuvant therapy
62397633|NCT02045017|EXPERIMENTAL|Pomalidomide and low dose Dexamethasone|Pomalidomide 4mg, and low dose Dexamethasone, starting at 40mgs(≤ 75 years old) or 20 mg/day (\> 75 years old)
62397634|NCT06381947|EXPERIMENTAL|PCSK9 inhibitors plus ezetimibe and bempedoic acid|Patients in therapy with PCSK9 inhibitors, bempedoic acid and ezetimibe
62572886|NCT01514292|EXPERIMENTAL|Real Time Continuous Glucose Monitoring System|7 day use of real time continuous glucose monitoring system
62781042|NCT02464722|ACTIVE_COMPARATOR|Remifentanil|"1. Anesthesia was induced with propofol 2 mg kg-1 , rocuronium 0.6 mg kg-1~2. Mask ventilation with 6 vol% desflurane in 100% oxygen for 2 minutes.~3. After 1 mcg/kg iv loading dose of remifentanil over a period of 1 minutes. tracheal intubation was done.~4. Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min. The infusion rate was adjusted according to the patient's response, to achieve a mean arterial pressure between 60 and 80 mmHg.~5. Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.~6. At the end of surgery, discontinuation of desflurane and remifentanil, sending recovery room."
62192140|NCT05032404|EXPERIMENTAL|BNT103|All participants receive BNT103. BNT103 provides 10 sessions over approximately 10 weeks.
62192141|NCT02990468|EXPERIMENTAL|Radiation Therapy, Cisplatin and BMX-001|In Phase 1, safety and tolerability of BMX-001 will be assessed using a Continual Reassessment Method and a maximum tolerated dose (MTD) will be determined using a single arm design. In Phase 2, the severity of radiation-induced mucositis and xerostomia will be assessed using a single arm design.
62192142|NCT04181112|EXPERIMENTAL|Fecal microbiota transplantation|
62192143|NCT04181112|EXPERIMENTAL|Fecal microbiota transplantation with antibiotic pre-treatment|
62192144|NCT04181112|NO_INTERVENTION|No intervention follow-up|
62397635|NCT06381947|EXPERIMENTAL|PCSK9 inhibitors plus ezetimibe|Patients in therapy with PCSK9 inhibitors and ezetimibe
62006366|NCT02203591|ACTIVE_COMPARATOR|ChloraPrep|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
62192145|NCT05244369|ACTIVE_COMPARATOR|Acupuncture+TENS group|Acupuncture application twice a week - a total of 8 sessions, and rehabilitation program consisting of joint range of motion, stretching and strengthening exercises for 30 minutes for 5 days a week for 4 weeks, current frequency 60-100 Hz to stump tip, impulse duration 100 microseconds transcutaneous electrical nerve stimulation (TENS) will be applied.
62397636|NCT02688881|EXPERIMENTAL|sirolimus|sirolimus 1mg will be administered orally daily
62192146|NCT05244369|OTHER|Only TENS group|A rehabilitation program consisting of joint range of motion, stretching, and strengthening exercises for 30 minutes, 5 days a week for only 4 weeks, and transcutaneous electrical nerve stimulation (TENS) with a current frequency of 60-100 Hz and an impulse duration of 100 microseconds will be applied.
62192147|NCT03293069|EXPERIMENTAL|Deferiprone|Half of participants will receive twice-daily oral deferiprone taken over 12 months.
62192148|NCT03293069|PLACEBO_COMPARATOR|Placebo|Half of participants will receive the placebo Twice-daily oral placebo taken over 12 months
62781043|NCT02574689|EXPERIMENTAL|HIPP Intervention|The physical activity intervention emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals), and includes regular mailings (three mailings in month 1, two mailings in months 2 and 3, one mailing in months 4, 5, 6, 8, and 10) of physical activity manuals that are matched to the participant's current level of motivational readiness and individually-tailored computer expert system feedback reports.
62192149|NCT01699841||HIV+ and HIV- mothers and their infants|
62192150|NCT05988242|EXPERIMENTAL|primrose oil|primrose oil
62192151|NCT05988242|EXPERIMENTAL|lavender oil|lavender oil
62192152|NCT05988242|PLACEBO_COMPARATOR|the placebo group|took the same bottle of oil which didn't contain the active substances but have the same shape, same oder, same color.
62006367|NCT02203591|PLACEBO_COMPARATOR|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
62006368|NCT00917813|EXPERIMENTAL|KD-247|
62006369|NCT00917813|PLACEBO_COMPARATOR|Placebo|
62192153|NCT05175196|EXPERIMENTAL|Pediatric Participants with GAS|"Children age 5-17 years old diagnosed via standard Rapid Antigen Detection Test with acute pharyngitis caused by Group A Streptococcus (GAS), along with their parent or legal guardian (aka caregiver)."
62192154|NCT02595372|EXPERIMENTAL|High dose omeprazole treatment|Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until surgery.
62192155|NCT01696786|EXPERIMENTAL|Oocyte cryopreservation|
62192156|NCT02454504|ACTIVE_COMPARATOR|sugammadex|this arm will receive sugammadex at the end of the surgery
62192157|NCT02454504|ACTIVE_COMPARATOR|neostigmine|this arm will receive neostigmine at the end of the surgery
62192158|NCT02339870|EXPERIMENTAL|Arm I (expressive disclosure)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about their emotions pertaining to managing and providing care for the cancer patient.
62192159|NCT02339870|EXPERIMENTAL|Arm II (benefit finding)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about any benefits that have arisen because of the cancer diagnosis.
62006370|NCT06573190||Chronic hepatitis B patients|Patients aged 18 years and older with HBsAg positivity for more than six months and HBV-DNA level \>2,000 IU/ml
62006371|NCT01307241||one cohort|Adult patients with ALL attending at the Instituto Nacional de Cancerologia Mexico.
62006372|NCT03754257|EXPERIMENTAL|Experimental Electrical Stimulation|Experimental Electrical Stimulation for 40 minutos + conventional physiotherapy, during seven days.
62006373|NCT03754257|SHAM_COMPARATOR|Sham Electrical Stimulation|Sham Electrical Stimulation for 40 minutes + conventional physiotherapy, during seven days.
62006374|NCT04920851||Covid with sepsis|Covid patient with sepsis
62006375|NCT04920851||covid without sepsis|Covid patient without sepsis
62006376|NCT01132521|EXPERIMENTAL|ulinastatin group|Regular treatments plus ulinastatin. Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
62006377|NCT01132521|PLACEBO_COMPARATOR|placebo group|Regular treatment plus placebo. Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
62021047|NCT01597206|ACTIVE_COMPARATOR|Reduced Posterior Dental Arch Group|Patients with a reduced posterior dental arch and not receiving any Intervention will be compared to the removable partial denture group
62192160|NCT02339870|SHAM_COMPARATOR|Arm III (control)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about an emotionally neutral topic.
62192161|NCT06292923|EXPERIMENTAL|Nasal Foralumab 50 μg|Each patient will receive nasal foralumab 50 μg per dosing day (25 μg per nostril).
62192162|NCT06292923|EXPERIMENTAL|Nasal Foralumab 100 μg|Each patient will receive nasal foralumab 100 μg per dosing day (50 μg per nostril).
62192163|NCT06292923|PLACEBO_COMPARATOR|Nasal placebo (acetate buffer)|Each patient will receive placebo on each dosing day in divided doses, in each nostril.
62214771|NCT06122844|EXPERIMENTAL|Social, Emotional, and Ethical Development (SEED) curriculum|The kindergartens, teachers, and children will receive the training and SEED curriculum. Upon informed consent from the school principals and parents, parents, teachers, and children will complete pre-, post-, and 4-week follow-up assessments. Focus group interviews will be conducted with teachers to understand their acceptability, demand, practicality, integration, and efficacy of the teacher training at post-teacher training and delivery of the SEED curriculum for children at post-intervention. Another focus group interviews will be conducted with SEED trainers to get information about teachers' participation rate in the training session.
62192164|NCT03326362|EXPERIMENTAL|High intensity resistance training (HIRT)|"12 weeks of two weekly training sessions, with at least 48 hours of interval between sessions. The HIRT performed the squat, deadlift and lunge exercises, as these exercises induce high core muscles activity. HIRT started with two weeks of low intensity exercises emphasizing the activation of core muscles (pelvic elevation with feet on the floor, superman, static supine bridge on bosu), and the technique of the selected resistance exercises (e.g. squat, deadlift, and lunges). Participants performed 3 sets of 10 repetitions per exercise. In the third and forth weeks, participants performed the exercises from the previous weeks and also static unipedal forward flexion on bosu and dynamic unipedal forward flexion and the main exercises with a load corresponding to (50% of the 1 RM load (Brzycki, 1993).~From the 5th to the 12th week, participants performed only the selected resistance exercises with progressive higher intensities (from 12RM to 8RM)."
62192165|NCT03326362|ACTIVE_COMPARATOR|Low intensity resistance training (LIRT)|12 weeks of two weekly training sessions, with at least 48 hours of interval between sessions.The LIRT group performed very low intensity and volume exercises (i.e. 1 set per exercise). Exercises started with participants lying on a firm surface, with the back supported, knees bent and feet flat on the floor. Then, participants performed the following exercises: 1) inhaling and exhaling and then isometrically contract in gluteal and abdominal muscles for 20 seconds and relax; 2) raising the head, lifting the chin and shoulders toward the chest for 20 seconds and relax; 3) raising one knee towards the chest and raising the head and shoulders likewise in the second exercise for 20s, relaxing, and changing the leg.; 4) raising both knees towards the chest in the same time that raise the head and shoulder off the floor during 20 seconds and relax.
62192166|NCT01782768|EXPERIMENTAL|Effect of different NPPV mode on NRD|13 hypercapnic recovering AECOPD patients were placed on different mode of noninvasive positive pressure ventilation(NPPV,such as the PAV or PSV mode) randomly.For each mode, three levels (PA-, PA, PA+or PS-, PS, PS+), ) of support were applied.PS and PA are set for the patient's comfort . On the basis of these two levels, 25% increase and reduction assisted level of pressure were set both for PS and PA (PA-, PA+or PS-, PS+). At each level, the patients were ventilated at least 20 minutes until the breathing was stable.
62192167|NCT05355168|EXPERIMENTAL|Neoadjuvant treatment|Neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab
62192168|NCT04214353|EXPERIMENTAL|Experimental arm|Salivary duct carcinoma patients with R/M disease, who will start androgen deprivation therapy as standard of care will receive PET/CT scans before and after ADT.
62006378|NCT03446703|EXPERIMENTAL|SCIT Social cognition interactive|Psychosocial intervention based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs \& Penn; Lahera \& Benito, in press).
62006379|NCT03446703|ACTIVE_COMPARATOR|TAR Training in affect recognition|Training in Affect Recognition it is a 12-session training on facial affect recognition over a period of 6 weeks.
62192169|NCT01791413|ACTIVE_COMPARATOR|depot medroxyprogesterone acetate|
62192170|NCT01791413|NO_INTERVENTION|No depot medroxyprogesterone acetate|
62192171|NCT01103921|OTHER|Glucose|
62192172|NCT01103921|OTHER|Fructose|
62192173|NCT01103921|OTHER|High-Fructose Corn Syrup|
62192174|NCT01103921|OTHER|Aspartame|No sugar
62192175|NCT04912154|EXPERIMENTAL|Traditional rehabilitation protocol|Traditional rehabilitation protocol after the surgery will be conducted
62192176|NCT04912154|ACTIVE_COMPARATOR|Accelerated rehabilitation protocol|Accelerated rehabilitation protocol under ultrasonic monitoring after the surgery will be conducted
62397637|NCT04373720|EXPERIMENTAL|Diagnostic (MRE, standard of care MRI)|Patients undergo MRE over 10 minutes and then undergo standard of care MRI of the brain with and without contrast at baseline. Within 4 weeks after the initial MRI and MRE scans, patients may undergo standard of care biopsy to check the status of the disease. Within 48 hours after biopsy, patients undergo standard of care MRI to check the status of the disease. Patients who do not undergo biopsy undergo standard of care MRI 4-8 weeks after MRE scan to check the status of the disease.
62397638|NCT03642639|OTHER|Coils|MICRUSFRAME and GALAXY coils
62397639|NCT00354991|EXPERIMENTAL|1|Losartan/HCTZ
62021048|NCT05928325|EXPERIMENTAL|Supportive Care (GA-guided intervention)|Patients complete geriatric assessments at baseline, 6 months, and 12 months later. Based on the assessments, patients may receive further intervention at survivorship visit. Patients also receive survivorship care educational materials and wear a wearable activity tracking device for 1 year on study.
62192177|NCT05399368|EXPERIMENTAL|RPT193 400 mg|RPT193 400 mg oral tablet administered daily for 16 weeks
62192178|NCT05399368|EXPERIMENTAL|RPT193 200 mg|RPT193 200 mg oral tablet administered daily for 16 weeks
62192179|NCT05399368|EXPERIMENTAL|RPT193 50 mg|RPT193 50 mg oral tablet administered daily for 16 weeks
62192180|NCT05399368|PLACEBO_COMPARATOR|Placebo|Matching placebo oral tablet administered daily for 16 weeks
62397640|NCT03853993|EXPERIMENTAL|Experimental group-phase I|Quadrivalent influenza vaccine
62397641|NCT03853993|EXPERIMENTAL|Experimental group-phase III|Quadrivalent influenza vaccine
62397642|NCT03853993|ACTIVE_COMPARATOR|Control group-1-phase III|Trivalent influenza vaccine (contains B/Victoria strain)
62397643|NCT03853993|ACTIVE_COMPARATOR|Control group-2-phase III|Trivalent influenza vaccine (contains B/Yamagata strain)
62781044|NCT02574689|ACTIVE_COMPARATOR|Wellness Contact Control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the ACS website (www.cancer.org) will be mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
62397644|NCT05035810|EXPERIMENTAL|Social Incentives and Gamification, Corticosteroid AB|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
62397645|NCT05035810|ACTIVE_COMPARATOR|No Incentive, Corticosteroid AB|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
62397646|NCT05035810|EXPERIMENTAL|Social Incentives and Gamification, Corticosteroid BA|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
62781045|NCT00960479|EXPERIMENTAL|1|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)
62397647|NCT05035810|ACTIVE_COMPARATOR|No Incentive, Corticosteroid BA|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
62397648|NCT04982497|EXPERIMENTAL|Video game based intervention|The participants in the experimental group will receive a cognitive-behavioral intervention for active aging via an interactive online multimedia video game with a complementary App. The intervention will consist of 8 modules each approximately 70 (±25) minutes long that will be administered at a rate of 1 per week with between-session homework.
62397649|NCT04982497|ACTIVE_COMPARATOR|Control group|Individuals assigned to this group will receive online therapeutically inactive information about active aging.
62397650|NCT01045902|EXPERIMENTAL|Arm 1|
62397651|NCT01045902|ACTIVE_COMPARATOR|Arm 2|
62397652|NCT04582331||COVID-19 positive|Patients with suspected COVID-19 based on presence of at least one newly emerged relevant symptom that has emerged at most 10 days prior to enrollment. COVID-19 positive status is confirmed by diagnostic testing and clinical diagnosis.
62781046|NCT00960479|ACTIVE_COMPARATOR|2|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)
62781047|NCT00773747|EXPERIMENTAL|Vorinostat + Bortezomib|Participants will receive vorinostat four 100 mg capsules (400 mg total) orally 0-30 minutes after a meal on Days 1-14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.
62021049|NCT02948985||RAS and B-raf wild type mCRC|patients with histologically confirmed RAS and B-raf wild type mCRC treated with FOLFIRI±cetuximab
62021050|NCT01847508|ACTIVE_COMPARATOR|PHILOS +|Proximal Humeral Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
62572887|NCT02940756|EXPERIMENTAL|artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
62781048|NCT00773747|PLACEBO_COMPARATOR|Placebo + Bortezomib|Participants will receive four placebo capsules orally 0-30 minutes after a meal on Days 1-14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.
62192181|NCT00047255|EXPERIMENTAL|Herceptin plus docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
62192182|NCT00047255|EXPERIMENTAL|Docetaxel, Carboplatin, and Herceptin|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
62192183|NCT06411509|EXPERIMENTAL|TC plus active rTMS|
62781049|NCT00367835|EXPERIMENTAL|SPD503 (Guanfacine hydrochloride)|
62781050|NCT00367835|PLACEBO_COMPARATOR|Placebo|
62781051|NCT06246578|OTHER|Within patient comparison|Simultaneous glucose measurement with Libre 2 sensor and Contour Next One in patients using Dexcom G7
62781052|NCT00569764||observational|patients with schizophrenia who want to change an antipsychotics due to metabolic side effect
62006380|NCT05608785|EXPERIMENTAL|HER2 protein positive 3+ or FISH amplification or HER protein 2+ but FISH amplification|"Initial treatment (4-6 cycles): IBI315 injection, oxaliplatin, capecitabine~* IBI315: 1200 mg per cycle d1 dosing, intravenous drip, 3 weeks as one treatment cycle.~* Oxaliplatin: 130 mg/m2, d1 per cycle, intravenous drip, 3 weeks as a treatment cycle.~* Capecitabine: 1000 mg/m2 orally twice daily (1 dose in the morning and 1 dose in the evening), d1-d14 per cycle, 2 weeks off 1 week, 3 weeks cycle.~Patients with CR/PR/SD enter maintenance therapy: IBI315 monotherapy maintenance~- IBI315: 1200 mg IV drip per cycle d1 for 3 weeks."
62781053|NCT01057563|ACTIVE_COMPARATOR|BMS group|Patients undergoing PCI with BMS implantation
62781054|NCT01057563|ACTIVE_COMPARATOR|PRE-DEB group|Patients undergoing PCI with BMS implantation after lesion predilation with DEB
62781055|NCT01057563|ACTIVE_COMPARATOR|POST-DEB group|Patients undergoing PCI with BMS implantation followed by postdilation with DEB
62781056|NCT03803436|EXPERIMENTAL|Study arm|Liver transplant
62781057|NCT03803436|ACTIVE_COMPARATOR|Parallel arm|Chemotherapy
62781058|NCT02728388|EXPERIMENTAL|PDT Treatment|"Each subject will have either placebo or Levulan Kerastick topical application applied to matched sets of neurofibromas. Each subject will have both sets, in order to serve as his/her own control subject.~16 to 24 hours post study drug treatment, both sets of neurofibromas, Levulan and placebo treated, will be irradiated with red light (630 nm) from an Omnilux Revive light device at 100 mW/cm2 for 1000 seconds (16.7 minutes)."
62781059|NCT01281033|ACTIVE_COMPARATOR|thrombus-aspiration group|In patients in the thrombus-aspiration group, the thrombus-aspiration is manually performed.
62572888|NCT02940756|EXPERIMENTAL|artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to \<15 kg, two tablets twice daily for those weighing 15 to \<25 kg and three tablets twice daily for those weighing 25 to \< 35 kg, for three days."
62021051|NCT01847508|ACTIVE_COMPARATOR|PHILOS|Proximal Humeral Internal Locking System (PHILOS)
62572889|NCT02940756|EXPERIMENTAL|Dihydroartemisinine-piperaquine|Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to \<7 kg, one tablet once daily for those weighing 7 to \<13 kg, and two tablets once daily for those weighing 13 to \<24 kg, for three days.
62781060|NCT01281033|EXPERIMENTAL|AngioJet Rheolytic Thrombectomy|AngioJet Rheolytic Thrombectomy (RT) System consists of a drive unit console, disposable pump set, and disposable catheter.
62781061|NCT00802893|EXPERIMENTAL|Experimental Drug|
62781062|NCT00802893|PLACEBO_COMPARATOR|Placebo Comparator|
62781063|NCT02516592|EXPERIMENTAL|QVA149 110/50 micrograms|QVA149 110/50 micrograms o.d. Capsules for inhalation
62781064|NCT02516592|ACTIVE_COMPARATOR|salmeterol/fluticasone 50/500 micrograms|salmeterol/fluticasone 50/500 micrograms b.i.d. Dry inhalation powder
62781065|NCT03458689|OTHER|Left hemicolectomy without nerve blocks|Left hemicolectomy, laparoscopic technique Enteral and parenteral analgesics such as paracetamol and oksykodon
62781066|NCT03458689|ACTIVE_COMPARATOR|Left hemicolectomy with TAP block|Left hemicolectomy, laparoscopic technique TAP block bilateral with Naropin 3,75 mg/ml, 2 x 20 ml
62781067|NCT03458689|ACTIVE_COMPARATOR|Left hemicolectomy with QL block|Left hemicolectomy, laparoscopic technique QL block bilateral with Naropin 3,75 mg/ml, 2 x 20 ml
62781068|NCT03875664|ACTIVE_COMPARATOR|Intervention|Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
62781069|NCT03875664|PLACEBO_COMPARATOR|Placebo|Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
62781070|NCT05492357|EXPERIMENTAL|Advanced platelet-rich fibrin plus + Liquid platelet-rich fibrin|A-PRF plus + Liquid-PRF are prepared from the patient's blood.
62006381|NCT05608785|EXPERIMENTAL|Positive for Claudin 18.2 protein|"Initial treatment (4-6 cycles): PD-L1 monoclonal antibody, TST001 injection, oxaliplatin, capecitabine~* TST001: 3mg, 4.5mg and 6mg dose levels for hill climbing trial, dose per cycle d1, IV drip, 3 weeks for one treatment cycle. 3-6 patients were enrolled in each dose level (3 patients were enrolled if no DLT was present, if present extended to 6 patients)~* TQB2450 injection: 1200 mg per cycle d1 dosing, IV drip, 3 weeks as a treatment cycle.~* Oxaliplatin: 130 mg/m2 per cycle d1 dosing, intravenous drip, 3 weeks as a treatment cycle.~* Capecitabine: 1000 mg/m2 orally twice daily (1 dose in the morning and 1 dose in the evening), d1-d14 per cycle, 2 weeks off 1 week, 3 weeks cycle.~Patients with CR/PR/SD enter maintenance therapy: TQB2450 injection + TST001~* TST001: maintenance at the dose level used (3mg/4.5mg/6mg), dosed d1 per cycle, IV drip, 3 weeks as a treatment cycle.~* TQB2450 injection: 1200mg, dosed d1 per cycle, intravenous drip, 3 weeks as a treatment cycle."
62006382|NCT05608785|EXPERIMENTAL|Her2 protein, Claudin18.2 protein were negative|"Initial treatment (4-6 cycles): TQB2450 injection, Anrotinib, Oxaliplatin, Capecitabine~* TQB2450 injection: 1200mg per cycle d1 dosing, intravenous drip, 3 weeks as a treatment cycle.~* Anrotinib: 1 capsule (10 mg) once daily, dosed every cycle d1-d14, stopping for 2 consecutive weeks, 3 weeks as a treatment cycle~* Oxaliplatin: 130 mg/m2, d1 per cycle, intravenous drip, 3-week treatment cycle.~* Capecitabine: 1000 mg/m2 orally twice daily (1 dose in the morning and 1 dose in the evening), d1-d14 per cycle, 2 weeks off 1 week, 3 weeks as a treatment cycle.~Patients with CR/PR/SD enter maintenance therapy: PD-L1 inhibitor, anlotinib~* PD-L1 monoclonal antibody (TQB2450): 1200 mg d1 per cycle, intravenous drip, 3 weeks as a treatment cycle.~* Anlotinib: 1 capsule (10mg) once daily, d1-d14 per cycle, stopping for 2 weeks, 3 weeks as a treatment cycle."
62006383|NCT06085898|EXPERIMENTAL|Stryphnodendron Adstringens (Barbatimão)|Intimate Soap
62397653|NCT04582331||COVID-19 negative, symptomatic|Patients with suspected COVID-19 based on presence of at least one newly emerged relevant symptom that has emerged at most 10 days prior to enrollment. COVID-19 negative status is confirmed by diagnostic testing and clinical diagnosis.
62397654|NCT04582331||Normal Healthy Volunteers|Asymptomatic healthy participants recruited from hospital staff or co-living family members, or co-living family member of a COVID-19 positive study participant.
62006384|NCT04160260|EXPERIMENTAL|Omadacycline: Omadacycline Tablets|
62006385|NCT04688281|ACTIVE_COMPARATOR|GUARDIX-SG®|Treat GUARDIX-SG 5ml prefilled syringe after surgery
62006386|NCT04688281|EXPERIMENTAL|Medicurtain®|Treat Medicurtain® 5ml prefilled syringe after surgery
62006387|NCT02592473|EXPERIMENTAL|Embozene Microspheres|Embozene Microspheres are spherical particles consisting of a hydrogel core and a poly nanocoat that will be used during study procedure, Prostatic Artery Embolization (PAE) to reduce or eliminate bloodflow to the prostate.
62006388|NCT00574405|ACTIVE_COMPARATOR|1|MDI = 3-4+ insulin injections/day, using split-mix NPH insulin + regular insulin or Lantus + Novolog® (or Humalog®).
62006389|NCT00574405|EXPERIMENTAL|2|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
62006390|NCT00674141|OTHER|1|only one experimental treated group
62006391|NCT05613439||Day-surgery group|Patients having hip or knee replacement as day-surgery with successful discharge to own home on day of surgery
62006392|NCT05613439||High-risk patients|Patients evaluated to be at increased risk of postoperative complications. These patients will receive relevant additional attention based on type of comorbidity. I.e. preoperative evaluation of iron status and i.v. iron treatment in case of preoperative anaemia, increased focus on avoidance of NSAIDs and adequate fluid therapy in patients with renal disease etc.
62006393|NCT05613439||Main group|"Patients who are not scheduled for day-surgery and without comorbidities qualifying as high-risk. These patients go through a standard fast-track procedure with discharge to own home when fulfilling functional discharge criteria."
62192184|NCT06411509|SHAM_COMPARATOR|TC plus sham rTMS|
62192185|NCT06411509|EXPERIMENTAL|TC-alone|
62192186|NCT06411509|ACTIVE_COMPARATOR|Low-intensity physical exercise|
62192187|NCT03566979|EXPERIMENTAL|Test naproxen sodium tablet|Single dose of 440 mg of naproxen sodium administered as two Test Naproxen Sodium 220 mg tablets (Test NPX)
62781071|NCT05492357|EXPERIMENTAL|Advanced platelet-rich fibrin plus alone|A-PRF+ is prepared from the patient's blood.
62781072|NCT02172404|EXPERIMENTAL|HandiHaler® vs. MDI|sequence during treatment phase: first Placebo capsule administered via HandiHaler then Ipratropium metered dose inhaler
62192188|NCT03566979|ACTIVE_COMPARATOR|Commercial naproxen sodium tablet|Single dose of 440 mg of naproxen sodium administered as two commercial naproxen sodium 220 mg tablets
62781073|NCT02172404|EXPERIMENTAL|MDI vs. HandiHaler®|sequence during treatment phase: first Ipratropium metered dose inhaler then Placebo capsule administered via HandiHaler Ipratropium metered dose inhaler
62006394|NCT04646616|EXPERIMENTAL|Community popular opinion leader (POL)|After successful completion of the new COVID-19 training module, POLs will reach out to members of their social networks to model and diffuse social norms to reduce the risk of COVID-19 infection and transmission, screen for symptoms and counsel regarding COVID-19, SAVAME syndemic factors, and refer at-risk or affected individuals to appropriate community services (e.g. free COVID-19 testing and treatment, mental health services, substance use services, violence prevention, support groups, etc.). As in other POL based interventions and pragmatic trials, POLs be asked to follow up with their community contacts to monitor their situation and provide additional support, but there will be flexibility with the frequency and number of follow up contacts depending on their needs identified and the preferences of the community contact. POLs will be continually supported by the research team via face-to-face biweekly booster sessions (if COVID-19 situation requires it) or by zoom.
62781074|NCT05612425|EXPERIMENTAL|Safety Behavior Fading|Individuals randomly assigned to the safety behavior fading condition will receive instructions to decrease or eliminate their endorsed appearance-related safety behaviors. In addition, they will receive daily reminders via text message to decrease these behaviors, along with a safety behavior monitoring checklist in which the participant indicates the extent to which they decreased and/or eliminated each safety behavior over the previous day.
62006395|NCT02426281|EXPERIMENTAL|nab-paclitaxel in combination with gemcitabine|nab-paclitaxel in combination with gemcitabine nab- paclitaxel 125mg/m2 in combination with gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
62006396|NCT05836610|ACTIVE_COMPARATOR|Standard dose hydrocortisone|The standard dose of hydrocortisone therapy in neonates for hypotension is 0.5 mg/kg every 6 hours.
62006397|NCT05836610|ACTIVE_COMPARATOR|Modified dose hydrocortisone|The modified dose of hydrocortisone therapy will be determined based on the pharmacokinetic results.
62006398|NCT05372016|EXPERIMENTAL|Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha),0.5mL, three doses, 0,2,6 months
62006399|NCT05372016|ACTIVE_COMPARATOR|GARDASIL ®9|GARDASIL®9 (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) ,0.5mL, three doses, 0,2,6 months
62006400|NCT03100825|EXPERIMENTAL|QVM149|All eligible patients take QVM149 150/50/160 μg once daily over 52 weeks.
62781075|NCT05612425|ACTIVE_COMPARATOR|Unhealthy Behavior Fading|Individuals randomly assigned to the unhealthy behavior fading condition will receive instructions to decrease or eliminate unhealthy behaviors that are unrelated to appearance. They will also receive daily reminders via text message to decrease these behaviors, along with a behavior monitoring checklist in which the participant indicates the extent to which they decreased and/or eliminated each behavior over the previous day.
62006401|NCT05112497||Crohn's Disease|"1. Pregnant CD patients~2. Newborn of pregnant CD patients~3. Father of the newborn~4. Non-pregnant CD women"
62006402|NCT05112497||Healthy Control|"1. Pregnant women without CD~2. Newborn of pregnant women without CD~3. Father of the newborn"
62006403|NCT04613180|PLACEBO_COMPARATOR|Group I (control group)|40 patients with obstructive bronchitis who received placebo
62006404|NCT04613180|ACTIVE_COMPARATOR|Group II|40 patients who received oral montelukast sodium oral, at a dosage of 0.2-0.4 mg/kg/day
62006405|NCT04065919|ACTIVE_COMPARATOR|Exparel|"administration of liposomal bupivacaine 266mg/20mL+ 40 mL bupivacaine 0.25% bupivacaine~."
62006406|NCT04065919|ACTIVE_COMPARATOR|Standard of Therapy|administration of 0.25% bupivacaine with epinephrine at 1cc/kg total dose
62006407|NCT01703481|EXPERIMENTAL|Part 1|Dose Escalation, Part 1: Participants will be enrolled in sequential cohorts to determine recommended Phase 2 doses (RP2D).
62006408|NCT01703481|EXPERIMENTAL|Part 2|Dose Confirmation, Part 2: Tumor biopsy cohorts will confirm RP2D.
62006409|NCT01703481|EXPERIMENTAL|Part 3, Cohort A|First dose expansion, Part 3: Participants with squamous non-small cell lung cancer.
62006410|NCT01703481|EXPERIMENTAL|Part 3, Cohort B|First dose expansion, Part 3: Participants with small cell lung cancer.
62006411|NCT01703481|EXPERIMENTAL|Part 3, Cohort C|First dose expansion, Part 3: Participants with breast cancer.
62192189|NCT03566979|ACTIVE_COMPARATOR|Commercial naproxen sodium liquid gels capsule|Single dose of 440 mg of naproxen sodium administered as two 220 mg commercial liquid gels capsules
62006412|NCT01703481|EXPERIMENTAL|Part 3, Cohort D|First dose expansion, Part 3: Participants with solid tumors (consisting of one of the following: gastric, head and neck, lung adenocarcinoma, urothelial, glioblastoma multiforme \[GBM\], ovarian or prostate).
62192190|NCT03566979|PLACEBO_COMPARATOR|Placebo tablet|Single dose of two Placebo tablets
62006413|NCT01703481|EXPERIMENTAL|Part 4, Cohort E|Second dose expansion, Part 4: Participants with non-small cell lung cancer.
62781076|NCT02376803|EXPERIMENTAL|Morning warfarin ingestion|Patients switch from taking warfarin in the evening to taking warfarin in the morning.
62781077|NCT02376803|ACTIVE_COMPARATOR|Evening warfarin ingestion|Patients continue taking warfarin in the evening as per their usual routine.
62006414|NCT01703481|EXPERIMENTAL|Part 4, Cohort F|Second dose expansion, Part 4: Participants with solid tumors (consisting of one of the following: breast, urothelial, GBM).
62781078|NCT00383942|ACTIVE_COMPARATOR|Misoprostol|Patients randomized to this arm will receive 25 micrograms of misoprostol every four hours.
62006415|NCT01601834|EXPERIMENTAL|Cohort 1: Experimental intervention: PF-06273340 or placebo|Subjects in Cohort 1 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated.
62006416|NCT01601834|EXPERIMENTAL|Cohort 2: Experimental intervention: PF-06273340 or placebo|Subjects in Cohort 2 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated.
62192191|NCT03969498||1- Obstetric APS women (oAPS)|No intervention, pure observational study.
62192192|NCT03969498||2-Women positive for F5rs6025 or F2rs1799963 polymorphis|No intervention, pure observational study.
62781079|NCT00383942|EXPERIMENTAL|EASI Catheter|Patients randomized to this arm will receive extra amniotic saline infusion (EASI) administered via catheter
62006417|NCT01795924|EXPERIMENTAL|PD-616 plus low-dose Cytarabine|Patients will receive low-dose cytarabine (20 mg/m2) subcutaneously (SC) once daily (QD), followed by a 1-hour intravenous (IV) infusion of PD-616 for 5 consecutive days during Week 1 (D1 to D5) and Week 2 (D8 to D12) of a 28-day treatment cycle. Cytarabine is to be administered approximately 30 minutes before PD-616. In Phase 1 part, the starting dose of PD-616 is 0.0875 mg/m2, with sequential increments of 0.0375 mg/m2, to 0.125, and 0.1625 mg/m2. The dose of PD-616 to be administered in Phase 2 part will be the maximum tolerated dose (MTD)determined from Phase 1 part of the study.
62192193|NCT03969498||3-Women with negative thrombophilia screening (Control group|No intervention, pure observational study.
62192194|NCT01602510|EXPERIMENTAL|Lamotrigine CD|lamotrigine chewable dispersible tablets 25mg, 50mg, 100mg
62192195|NCT01602510|PLACEBO_COMPARATOR|Placebo|Placebo
62192196|NCT06134947||Group A|group A=75 patients as case group (children with Chronic Respiratory Disease)
62006418|NCT01678534|PLACEBO_COMPARATOR|Placebo|In patients randomly assigned to the placebo arm will receive a intravenous solution (containing the vehicle) with the same appearance as the drug under investigation. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.
62192197|NCT06134947||Group B|group B=75 children as control group (children with no Chronic Respiratory Disease).
62192198|NCT06109610|EXPERIMENTAL|Intervention group|Taking Behavioral Therapy
62192199|NCT06109610|NO_INTERVENTION|Control group|Do not taking Behavioral Therapy
62192200|NCT01657747|NO_INTERVENTION|Not applicable (imaging study)|
62192201|NCT04056793|EXPERIMENTAL|Parturients in situation of dystocia|Positioning of the parturients in an optimized birthing position
62192202|NCT00915083|EXPERIMENTAL|Amrubicin 40mg/m^2|Amrubicin 40mg/m\^2 given as a 5 minute IV infusion on Days 1, 2 \& 3 of a 21 day cycle
62192203|NCT01776359|ACTIVE_COMPARATOR|High Protein|High Protein
62192204|NCT01776359|PLACEBO_COMPARATOR|Low Protein|Low Protein
62192205|NCT02446613|OTHER|Nasal allergen challenge|Subjects do not receive study medication in this study 204509. Subjects who carried from study TL7116958 treatment group GSK2245035 will undergo NAC with pollen allergen extract.
62781080|NCT01636128|EXPERIMENTAL|Sulindac first (Treatment Sequence B)|Sulindac alone, washout, DFMO alone, then combination of sulindac and DFMO
62781081|NCT01636128|EXPERIMENTAL|DFMO first (Treatment Sequence A)|DFMO alone, followed by washout, sulindac alone, then combination of DFMO and sulindac
62781082|NCT01853878|EXPERIMENTAL|GSK2302032A Group|The patients received 13 administrations GSK2302032A product, as per the following schedule: For the first five doses: 1 dose every 3 weeks. For the remaining 8 doses: 1 dose every 12 weeks.
62781083|NCT01853878|PLACEBO_COMPARATOR|Placebo group|The patients received 13 administrations of a placebo, as per the following schedule: For the first five doses: 1 dose every 3 weeks. For the remaining 8 doses: 1 dose every 12 weeks.
62572890|NCT04386330|EXPERIMENTAL|Narrative Exposure Therapy|Firefighters will receive distance-delivered NET administered by a paraprofessional.
62781084|NCT00372697|EXPERIMENTAL|Octreotide 30 mg every 21 days|Patients received octreotide 30 mg every 21 days intramuscularly (im) for 6 months, a total of 8 doses. At each study visit, octreotide was administered only after completion of all scheduled efficacy and safety evaluations for that visit. Octreotide was injected im into the right or left gluteal regions. The injections were initially administered by a trained and authorized member of the investigational team. When no study visit at the investigational site was required, the injections were given by a trained nurse or the family doctor.
62781085|NCT00372697|EXPERIMENTAL|Octreotide 60 mg every 28 days|Patients received octreotide 60 mg every 28 days intramuscularly (im) for 6 months, a total of 6 doses. Octreotide mg was administered as two 30 mg injections. At each study visit, octreotide was administered only after completion of all scheduled efficacy and safety evaluations for that visit. Octreotide was injected im into the right or left gluteal regions. The injections were initially administered by a trained and authorized member of the investigational team. When no study visit at the investigational site was required, the injections were given by a trained nurse or the family doctor.
62006419|NCT01678534|EXPERIMENTAL|Allogeneic stem cells from adipose tissue|The experimental drug is a solution of mesenchymal stem cells from adipose tissue. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.Dose: 1 million units/kg
62006420|NCT04125108|EXPERIMENTAL|pulmonary rehabilitation group|The experimental group was to participate in a 12-week pulmonary rehabilitation program supplemented with an individualized and supervised exercise-training program.
62006421|NCT04125108|NO_INTERVENTION|control group|The control group was to participate in a 12-week conventional rehabilitation program.
62006422|NCT02886585|EXPERIMENTAL|Previously Untreated Brain Metastases-Cohort A|"- Previously Untreated Brain Metastases~* Baseline Brain MRI and PET CT~* For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.~* Brain MRI and PET/CT"
62572891|NCT04446013|EXPERIMENTAL|Group General Anesthesia|C-Section under general anesthesia
62192206|NCT04773925|EXPERIMENTAL|Mindfulness group|As this is a pilot feasibility trial, there is only one arm. All subjects will receive the mindfulness intervention if they consent to participate in the study.
62006423|NCT02886585|EXPERIMENTAL|Progressive Brain Metastases-Cohort B|"- Progressive Brain Metastases~* Baseline Brain MRI and PET CT~* For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.~* Brain MRI and PET/CT"
62006424|NCT02886585|EXPERIMENTAL|Neoplastic Meningitis-Cohort C|"* Neoplastic Meningitis~* Histologically confirmed solid malignancy~* Positive Cytology~  * Baseline Brain MRI~ * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.~ * Brain MRI and PET/CT"
62192207|NCT02630407|EXPERIMENTAL|Hyaluronic acid group|Single injection of 3 ml HA (product name: Hymovis, Fidia Spa, Padova, Italy) the day after ACL reconstruction (after drainage removal)
62192208|NCT02630407|PLACEBO_COMPARATOR|Placebo group|Single injection of 3 ml saline solution the day after ACL reconstruction (after drainage removal)
62192209|NCT05864677|NO_INTERVENTION|Group S - standard treatment|Patients will be treated in accordance with the current recommendations. Patients with every postoperative complication (severe postoperative bleeding, wound infection, hemodynamically unstable) and those undergoing reoperation will be excluded from this study.
62192210|NCT05864677|ACTIVE_COMPARATOR|Group CER - treatment with Cerebrolysin|Patients will be treated in accordance with the current recommendations and receiving additional treatment with Cerebrolysin.
62572892|NCT04446013|EXPERIMENTAL|Grup Spinal Anesthesia|C-Section under spinal anesthesia
62572893|NCT02858583|EXPERIMENTAL|Intervention (CC+SI)|"Infants randomized into the CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression. The SI will be delivered over a period of 45 seconds. This will be followed by PEEP of 5-8 cm water to perform an assessment of the newborn's heart rate. If heart rate is \>60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains \<60/min continue with CC+SI for another 45sec at which time a further assessment should be performed. If heart rate remains \<60/min continue with CC+SI."
62572894|NCT02858583|ACTIVE_COMPARATOR|Control (3:1 C:V)|"Infants randomized into the 3:1 C:V group will receive CC at a rate of 90/min and 30 ventilations/min in a 3:1 C:V ratio as recommended by the current resuscitation guidelines."
62572895|NCT02917382||Waiting list for liver transplant|Patients on the waiting list for liver transplant treated at ambulatory liver transplant of Hospital of Clinics of the Federal University of Minas Gerais
62572896|NCT02917382||Undergoing liver transplantation|Patients undergoing liver transplantation treated at ambulatory liver transplant of Hospital of Clinics of the Federal University of Minas Gerais
62006425|NCT02886585|EXPERIMENTAL|1-4 Brain Metastases from Melanoma Cohort D|"* 1-4 Brain Metastases from Melanoma~* Clinical indication for stereostatic radiosurgery~* Evaluable extracranial focus~  * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. In Cohort D, cycle 1 and 2 of pembrolizumab will be administered 3 weeks apart and stereotactic radiosurgery will be administered between cycles. Treatment will be administered on an outpatient basis.~ * Brain MRI and PET CT"
62006426|NCT06572657|EXPERIMENTAL|cognitive stimulation group|cognitive stimulation
62006427|NCT06572657|EXPERIMENTAL|physical exercise group|physical exercise
62006428|NCT06572657|NO_INTERVENTION|control group|no intervention
62572897|NCT04431258|EXPERIMENTAL|Arm A) ABTL0812 + FOLFIRINOX|"FOLFIRINOX will be dosed according to the standard following regimen:~* oxaliplatin 85 mg/m2, administered as 2-hour iv infusion~* leucovorin 400 mg/m2, administered as 2-hour iv infusion~* irinotecan 180 mg/m2, administered as 1.5-hour iv infusion~* fluorouracil 2400 mg/m2, administered as 46-hour iv infusion every 2 weeks (=1 cycle) until disease progression or unacceptable toxicities.~ABTL0812 will be administered daily at its RP2D. ABTL0812 will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, ABTL0812 will be maintained once chemotherapy is discontinued, if ABTL0812 is tolerated and if the patient is in response or stable disease."
62572898|NCT04431258|EXPERIMENTAL|Arm B) PLACEBO + FOLFIRINOX|"FOLFIRINOX will be dosed according to the standard following regimen:~* oxaliplatin 85 mg/m2, administered as 2-hour iv infusion~* leucovorin 400 mg/m2, administered as 2-hour iv infusion~* irinotecan 180 mg/m2, administered as 1.5-hour iv infusion~* fluorouracil 2400 mg/m2, administered as 46-hour iv infusion every 2 weeks (=1 cycle) until disease progression or unacceptable toxicities.~Placebo will be administered at the same volume than ABTL0812 in arm A) FOLFIRINOX, then daily during chemotherapy cycles. Also, placebo will be maintained once chemotherapy is discontinued."
62006429|NCT06461520|EXPERIMENTAL|Maze Balance Board|Every child will have their balance evaluated using the SWOC tool, CTSIB, and Pediatric Balance Scale. Patients performed a range of proprioceptive exercises, such as static one-leg standing, board balancing, squatting, and 20 minutes of straight-line walking on a hard surface before moving to a foam surface. For 20 minutes each session, proprioceptive exercises were conducted with open eyes first, followed by closed ones. The training program for the maze balancing board will next take place. There will be seven phases to the maze balance board training; each stage will last for two days and there will be three sessions per day, each lasting an hour.
62006430|NCT06461520|ACTIVE_COMPARATOR|Proprioceptive training|This group will get proprioceptive training. For a total of ten weeks, the intervention will be carried out three times a week for forty minutes each. Without maze-balance board training, the training schedule will consist of three sessions each week, lasting ten minutes each for preparatory, twenty minutes for proprioceptive, and ten minutes for restorative activities. Every meeting ended with a 10-minute cool-down and 10-minute warm-up to signify the quality of work.
62006431|NCT05699668|EXPERIMENTAL|older premature children born at a term ≤28 weeks of amenorrhea without dysplasia bronchopulmonary|OCT Angiography
62572899|NCT03146455||Health adults|(1) 18\< Age \<65, and Han Chinese residents living in Hunan more than 3 years. (2) Health examination population who physical examination, assistant examination and serological examination were normal; Not suffer from other diseases last 3 months; Not take any medication last 7 days.
62572900|NCT00836225|EXPERIMENTAL|A|50 mg ISIS 388626 vs Placebo, s.c. injection
62781086|NCT03413709|ACTIVE_COMPARATOR|Treatment Group (n=350)|The sample for the treatment group for the impact evaluation will only include fathers who are receiving the full 240 hour Family Formation Program (and not the abbreviated 80 hour program). The treatment group will receive FSC's Family Formation Program, which is a six week, 240 hour program implementing a set of curricula focusing on responsible parenting, healthy relationships,and economic stability and mobility. In addition, participants will receive case management and a variety of employment, legal and support services for up to one year following the completion of the curriculum.
62781087|NCT03413709|NO_INTERVENTION|Comparison Group (n=350)|The sample comparison group will receive only the abbreviated 80 hour program. Which consist of economic stability and mobility only. These participants will receive employment case management and legal services for up to one year following the completion of the curriculum.
62781088|NCT05808413|ACTIVE_COMPARATOR|Informational Video|Participants will watch a 1-minute video detailing the impact vaccination has had on the COVID-19 pandemic, where accurate information on vaccination can be found, and the convenience of vaccination.
62781089|NCT05808413|EXPERIMENTAL|Informational + Altruistic Video|Participants will first watch the 1-minute informational video before watching an additional 40-second video eliciting altruistic motivations for vaccination. The purpose of this arm is to test whether altruistic messages are efficacious to increase vaccine intentions beyond providing only vaccine information.
62006432|NCT05699668|EXPERIMENTAL|older premature children born at a term ≤28 weeks of amenorrhea with dysplasia bronchopulmonary|OCT Angiography
62006433|NCT05699668|EXPERIMENTAL|patients in the control group without prematurity without BPD|OCT Angiography
62006434|NCT04257058|EXPERIMENTAL|Electronic educational material|Participants will complete an online pre-test survey via REDCap. One week after the pre-test survey is completed, AYAs will be sent electronic media via email to review on their own. Study staff will confirm receipt and review of material and schedule a post-test survey to be completed in REDCap two weeks after material is reviewed.
62006435|NCT00401336|EXPERIMENTAL|Magnetic Resonance Imaging|New magnetic resonance imaging multiecho gradient-echo sequence
62006436|NCT02059928|EXPERIMENTAL|Intraosseous device placement|Intraosseous device
62192211|NCT04547023|EXPERIMENTAL|Fasting before gestational diabetes screen|Fasting for at least 6 hours prior to the 1-hour gestational diabetes screen.
62572901|NCT00836225|EXPERIMENTAL|B|100 mg ISIS 388626 vs Placebo, s.c. injection
62572902|NCT00836225|EXPERIMENTAL|C|200 mg ISIS 388626 vs Placebo, s.c. injection
62572903|NCT00836225|EXPERIMENTAL|D|400 mg ISIS 388626 vs Placebo, s.c. injection
62572904|NCT00836225|EXPERIMENTAL|AA|50 mg ISIS 388626, 3x over 1 week s.c. injection, weekly s.c. injection for 5 weeks vs Placebo
62572905|NCT00836225|EXPERIMENTAL|BB|100 mg ISIS 388626, 3x over 1 week s.c. injection, weekly s.c. injection for 5 weeks vs Placebo
62006437|NCT02125539|EXPERIMENTAL|Navigating my Journey program|Client participants of counselors who were randomized to the experimental condition will receive the following intervention: The online Navigating my Journey relapse prevention program is an adjunct to outpatient treatment. We will ask client participants to complete at least 12 Navigating my Journey sessions and discuss them with their counselors.
62006438|NCT02125539|ACTIVE_COMPARATOR|Attention Control|Client participants of counselors who were randomized to the control condition will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
62192212|NCT04547023|ACTIVE_COMPARATOR|Fed before gestational diabetes screen|Liberal per oral intake within 2 hours of the 1-hour gestational diabetes screen.
62192213|NCT06022445||Patients with septic shock after allo-HSCT|patients who underwent allo-HSCT and experienced septic shock
62192214|NCT06252012|EXPERIMENTAL|Mobile Application Group|Within the scope of the mobile application, information modules on cervical cancer screening tests, cervical cancer risk factors, ways to prevent cervical cancer, types of HPV, and HPV vaccine will be provided. A parallel-group pretest-posttest randomized controlled trial design will be used in the second stage of the study.
62192215|NCT06252012|NO_INTERVENTION|Control Group|The relevant brochures of the Ministry of Health on the prevention of cervical cancer will be given to the experimental and control groups.
62572906|NCT00836225|EXPERIMENTAL|AAA|50 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
62781090|NCT05808413|EXPERIMENTAL|Informational + Altruistic + Individualistic Video|Participants will watch the 1-minute informational video, the 40-second altruistic video, and an additional 40-second video eliciting individualistic motivations for vaccination. This arm will be used to test if combined altruistic and individualistic messages provide a greater effect than providing only vaccine information.
62572907|NCT00836225|EXPERIMENTAL|BBB|100 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
62572908|NCT00836225|EXPERIMENTAL|CCC|200 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
62006439|NCT01930058|EXPERIMENTAL|Panel A: HCV GT3 MK-8876 150 mg|Participants infected with HCV GT3 received 150 mg MK-8876 once daily (q.d.) by mouth for 7 days.
62006440|NCT01930058|EXPERIMENTAL|Panel B: HCV GT3 MK-8876 800 mg|Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days.
62006441|NCT01930058|EXPERIMENTAL|Panel E: HCV GT1a MK-8876 800 mg|Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.
62006442|NCT01639170|EXPERIMENTAL|subjects undergoing abdominal surgery|"Subjects who undergone abdominal intervention and reported major symptoms and signs suggestive of gastrointestinal perforation (abdominal pain, leukocytosis, fever) within the third postoperative day.~Exclusion criteria: inability to consent to the study, age ≤18 yr, certain or probable pregnancy, inability to remain in upright position for more than 10 minutes."
62192216|NCT02192593|EXPERIMENTAL|Computer CBT|A 10-session computerized cognitive-behavioral therapy intervention
62192217|NCT02192593|NO_INTERVENTION|Usual Care|
62192218|NCT05099289|EXPERIMENTAL|AtaCor EV-ICD Lead System|Subjects inserted with the AtaCor EV-ICD Lead Model AC-7000
62572909|NCT00836225|EXPERIMENTAL|FFF|50 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
62781091|NCT02364934||Propofol|Propofol is intravenously administrated during anesthesia maintenance in patients (18-65 years old)
62781092|NCT02364934||Sevoflurane|Sevoflurane (inhalation) is administrated during anesthesia maintenance in patients (18-65 years old)
62781093|NCT02364934||Propofol (elderly)|Propofol is intravenously administrated during anesthesia maintenance in patients (≥65 years old)
62006443|NCT01813981|PLACEBO_COMPARATOR|High roast coffee|110mg caffeine with 108 mg chlorogenic acid at start of study
62572910|NCT06362915|ACTIVE_COMPARATOR|Group A:Lidocaine group|will receive blind local infiltration in femoral region on the operation side by an experienced anesthesiologist using 20 ml lidocaine 1%
62572911|NCT06362915|ACTIVE_COMPARATOR|Group B:Bupivacaine group|will receive ultrasound-guided ilioinguinal/iliohypogastric nerve block using 20 ml Bupivicane 0.25% by an experienced anesthesiologist
62572912|NCT05577013|EXPERIMENTAL|(Kinesiotaping and motor relearning program group|"The experimental group will receive kinesiotaping; Instructions before applying kinesiotape~* Patients' skin must be clean, free of dirt, oil or sweat.~* Long hair must be removed for proper adhesion to the skin.~* Leave the tape upstretched 2-3 cm at start and end point of tape over the skin"
62781094|NCT02364934||Sevoflurane (elderly)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in patients (≥65 years old)
62781095|NCT02364934||Propofol (men)|Propofol is intravenously administrated during anesthesia maintenance in men (18-65 years old)
62781096|NCT02364934||Sevoflurane (men)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in men (18-65 years old)
62781097|NCT02364934||Propofol (women)|Propofol is intravenously administrated during anesthesia maintenance in women (18-65 years old)
62006444|NCT01813981|ACTIVE_COMPARATOR|Low roast coffee|110 mg caffeine with 235 mg chlorogenic acid at start of the study
62192219|NCT02926911|ACTIVE_COMPARATOR|Surgery|DCIS - Surgery +/- radiation choice for endocrine therapy (MMG q 12 months x 5 years usual care for recurrent disease)
62192220|NCT02926911|EXPERIMENTAL|Active Monitoring|DCIS - Choice for endocrine therapy (MMG q 6 months x 5 years GCC for invasive progression)
62006445|NCT01813981|PLACEBO_COMPARATOR|Control|110 mg caffeine at start of study
62006446|NCT04333680|ACTIVE_COMPARATOR|Phased Array|Operators who will be using a phased array-type transducer to perform the FAST exam on a healthy normal volunteer.
62781098|NCT02364934||Sevoflurane (women)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in women (18-65 years old)
62781099|NCT02157961||General Practitioner / Family Physician in German Primary care|
62006447|NCT04333680|ACTIVE_COMPARATOR|Curvilinear|Operators who will be using a curvilinear array-type transducer to perform the FAST exam on a healthy normal volunteer.
62006448|NCT04720859|EXPERIMENTAL|Patients with PHH following Roux-en-Y-gastric bypass (cases)|Patients diagnosed with PHH following Roux-en-Y-gastric bypass.
62006449|NCT04720859|NO_INTERVENTION|Healthy individuals (controls)|Healthy normoweight individuals, matched by age and gender with the cases.
62006450|NCT04515186|OTHER|Meglumine Antimoniate|Meglumine Antimoniate, 20 mg/kg/day for 20 days parenterally. This trial arm was discontinued after protocol amendment 7. However, patients assigned to this arm before protocol amendment 7 becomes effective will continue in the study and will receive complete treatment as initially planned.
62006451|NCT04515186|ACTIVE_COMPARATOR|Miltefosine monotherapy|Miltefosine monotherapy 2.5 mg/kg/day for 28 days orally
62006452|NCT04515186|EXPERIMENTAL|Thermotherapy + miltefosine|"Thermotherapy (one session, 50⁰C for 30 applications\*) + miltefosine 2.5 mg/kg/day for 21 days orally."
62006453|NCT01514318||Revelation|Subjects who received the Revelation Hip Stem prior to 2002 and have agreed to come into the office for a single visit.
62006454|NCT01155895|EXPERIMENTAL|Amlodipine Besylate/Benazepril Hydrochloride|10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules of Dr.Reddy's Laboratories Limited
62192221|NCT03513744|EXPERIMENTAL|infant formula containing five HMOs|
62192222|NCT03513744|NO_INTERVENTION|infant formula|
62192223|NCT03513744|NO_INTERVENTION|breast milk group|
62192224|NCT03708237|PLACEBO_COMPARATOR|Placebos|Placebo Dose: Not Applicable Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
62006455|NCT01155895|ACTIVE_COMPARATOR|Lotrel|Lotrel® (10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules) of Novartis
62006456|NCT02751983|EXPERIMENTAL|Treatment as usual plus ACT|Participants in this condition will be enrolled in the ACT for Life intervention and still able to engage in treatment as usual.
62006457|NCT02751983|ACTIVE_COMPARATOR|Treatment as usual|Participants in this condition will not be enrolled in ACT for Life, but will continue to participate in treatment as usual (e.g., inpatient and outpatient mental health care).
62006458|NCT05508113|NO_INTERVENTION|Control|No intervention was given to this group of patients
62006459|NCT05508113|EXPERIMENTAL|20-40ug/ml ozone|ozone autohemotherapy
62192225|NCT03708237|EXPERIMENTAL|Ropinirole|Drug: ropinirole Dose: 0.25 - 2 mg as tolerated Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
62192226|NCT03708237|EXPERIMENTAL|Gabapentin|Drug: gabapentin Dose: 100 - 300 mg as tolerated Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
62192227|NCT00345475||AED treatment|Women being treated with UCB AEDs while pregnant.
62192228|NCT03452683|NO_INTERVENTION|Usual Care|Participants randomized to the Usual Care arm will receive educational handouts.
62397655|NCT06357832|EXPERIMENTAL|Investigational stimulation group|The experimental group will receive the new investigational deep TMS protocol
62397656|NCT06357832|ACTIVE_COMPARATOR|Standard-of-care stimulation group|The control group will receive the currently FDA-cleared standard-of-care deep TMS protocol.
62397657|NCT04672434|EXPERIMENTAL|Sym024 Dose Level 1|Part I, Sym024 monotherapy dose level 1
62397658|NCT04672434|EXPERIMENTAL|Sym024 Dose Level 2|Part I, Sym024 monotherapy dose level 2
62397659|NCT04672434|EXPERIMENTAL|Sym024 Dose Level 3|Part I, Sym024 monotherapy dose level 3
62397660|NCT04672434|EXPERIMENTAL|Sym024 Dose Level 4|Part I, Sym024 monotherapy dose level 4
62397661|NCT04672434|EXPERIMENTAL|Sym024 Dose Level -1|Part I, Sym024 monotherapy dose level -1. Evaluate only if needed based on tolerability
62397662|NCT04672434|EXPERIMENTAL|Sym021+Sym024 Dose Level 2|Part II, Sym021 in combination with dose level 2 of Sym024
62397663|NCT04672434|EXPERIMENTAL|Sym021+Sym024 Dose Level 3|Part II, Sym021 in combination with dose level 3 of Sym024
62397664|NCT04672434|EXPERIMENTAL|Sym021+Sym024 Dose Level 4|Part II, Sym021 in combination with dose level 4 of Sym024
62397665|NCT04672434|EXPERIMENTAL|Sym021+Sym024 Dose Level 5|Part IIa, Sym024 monotherapy and in combination with Sym021
62397666|NCT04672434|EXPERIMENTAL|Sym021+Sym024 Dose Level 1|Part II, Sym021 in combination with dose level 1 of Sym024. Evaluate only if needed based on tolerability
62397667|NCT04672434|EXPERIMENTAL|Dose Expansion Sym021 (+Sym024)|Part III, dose expansion Sym024 and/or Sym021+Sym024
62397668|NCT01021423|EXPERIMENTAL|Lenalidomide|Lenalidomide - 15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
62397669|NCT01021423|EXPERIMENTAL|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
62397670|NCT04274569|ACTIVE_COMPARATOR|Sodium fluoride (NaF)|Group 1: Quarterly application of a 5% NaF varnish (Duraphat® Varnish, Colgate-Palmolive Ltd, (UK) Ltd., Guildford, Surrey, UK)
62397671|NCT04274569|EXPERIMENTAL|NaF plus tricalcium phosphate (TCP )|Group 2: Quarterly application of 5% NaF-TCP (ClinproTM White Varnish; 3M ESPE, St Paul, MN, USA)
62781100|NCT02157961||Medical Specialists|Working in the ambulatory setting
62572913|NCT05577013|ACTIVE_COMPARATOR|motor relearning program group|"The control group will receive motor relearning programme exercises for 40 minutes.~1. Hitting a target on table from flexed elbow to extension of elbow~2. Hitting a target on front of table with shoulder flexion (reaching fwd)~3. Hitting a target on table with wrist extension~4. Pronation to supination while holding a bottle of water.~5. Rolling ball on table in forward, backward and sideways~6. Holding polystyrene cup and placing it on other side~7. Picking up blocks and placing them to other side~8. Holding polystyrene cup and placing them above and below level of sitting to front and sideways~9. Holding polystyrene cup and placing them above and below level of standing to front and sideways~10. pick small objects from one container to another"
62572914|NCT04827953|EXPERIMENTAL|Investigational treatment|Conventional Chemotherapy (Gemcitabine + nab-paclitaxel) plus NLM-001 plus Zalifrelimab
62006460|NCT03652298|EXPERIMENTAL|Experimental arm|In the experimental group, participants will perform vagal breathing (VB), followed by the MSI, followed again by VB. The VB component will guide participants how to perform deep slow vagal breathing by inhaling and counting 1-5, holding their breath and counting 1-2, and exhaling and counting 1-5, during 2-5 minutes. The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).
62006461|NCT03652298|OTHER|Control Arm|Participants in the control group will receive support and attention (usual care) and will be invited to recall announcement of the incurable disease progression. More precisely, they will be invited to express their associated thoughts and feelings, being free to talk about their experience, and the psychologist will react with empathy and support.
62006462|NCT02548988|EXPERIMENTAL|Healthy|Healthy women are submitted to selective neuromuscular electrical stimulation on VMO.
62006463|NCT02548988|EXPERIMENTAL|Patellofemoral pain syndrome|Women with patellofemoral pain syndrome are submitted to selective neuromuscular electrical stimulation on VMO.
62006464|NCT04777409|EXPERIMENTAL|Oral semaglutide 14 mg|Participants are given oral semaglutide once daily
62006465|NCT04777409|PLACEBO_COMPARATOR|Placebo (semaglutide)|Participants are given oral placebo once daily
62006466|NCT01500148|EXPERIMENTAL|Intevention-PMVr Procedure|
62572915|NCT04573049|EXPERIMENTAL|Levosimendan|Levosimendan 0.1µg/kg/min will last for 24h after the valve is released.
62572916|NCT04573049|PLACEBO_COMPARATOR|Placebo|5% glucose 0.1µg/kg/min administration will continue for 24h after the valve is released.
62572917|NCT03476187|EXPERIMENTAL|µCor wearers|Wear the µCor device
62781101|NCT06136065|EXPERIMENTAL|Arm 1|100 patients with solid tumor and 18-Fluorine-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose Positron emission tomography / Computerized tomography scan dubious
62781102|NCT05124132|EXPERIMENTAL|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) as delivered in the parent study (Protocol ID #201410093) consisted of a brief introductory meeting, eight weekly 2.5-hour classes, and a retreat, followed by monthly booster sessions for approximately 15 months. Content included instruction in mindfulness meditation practices, gentle mindful movement, and exercises to enhance mindfulness in everyday life. For the current study, participants will continue monthly approximately 2.5 hour booster sessions covering similar content for the duration of the study. Participants will be encouraged to maintain daily formal meditative activities at home.
62781103|NCT05124132|EXPERIMENTAL|Exercise|The exercise protocol in the parent study (Protocol ID #201410093) was optimal for improving aerobic fitness and insulin sensitivity in older adults, as well as improving strength and balance and reducing indices of frailty. It consisted of classes twice weekly for 6 months, building up to 1.5 hr, under the direct supervision of trained exercise instructors, followed by once weekly classes for 12 months. For the current study, participants will continue monthly approximately 1.5 hour classes focused on functional training for the duration of the study. Participants will be encouraged to continue between-session engagement in aerobic and resistance training activities at home.
62781104|NCT05124132|EXPERIMENTAL|Mindfulness-Based Stress Reduction + Exercise|This condition will receive both MBSR and exercise as described. Participants in this condition will attend monthly sessions with encouragement to complete at-home mindfulness practice as well as at-home exercise for the duration of the study.
62006467|NCT01585766|EXPERIMENTAL|MEDI-551 30 MG-IV|Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
62006468|NCT01585766|EXPERIMENTAL|MEDI-551 60 MG-SC|Participants received SC injection of 60 mg MEDI-551 on Day 1.
62006469|NCT01585766|EXPERIMENTAL|MEDI-551 100 MG-IV|Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
62006470|NCT01585766|EXPERIMENTAL|MEDI-551 300 MG-SC|Participants received SC injection of 300 mg MEDI-551 on Day 1.
62006471|NCT01585766|EXPERIMENTAL|MEDI-551 600 MG-IV|Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
62006472|NCT01585766|PLACEBO_COMPARATOR|PLACEBO-IV-SC|Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1.
62006473|NCT04942275|EXPERIMENTAL|Intervention : Lung perfusion PET/CT using Ga68-MAA and SBRT planification|"All patients included for treatment with stereotactic radiotherapy for non-small cell lung cancer or lung metastasis will benefit from a pre-therapeutic functional assessment including:~* The standard functional assessment recommended before performing an SBRT.~* A perfusion PET/CT scan~The treatment planning will be carried out in 2 stages:~* First, an anatomical planning will be carried out, blinded to the PET results.~* Then, a functional planning, respecting the standard constraints applied during anatomical planning, but also incorporating a new functional lung volume constraint defined by pulmonary PET, will then be carried out.~A follow-up will be carried out for 12 months, including repeated perfusion PET/CT imaging at 3 and 12 months"
62572918|NCT04454047||Extracapsular method group|50 patients with refractory tennis elbow who received extracapsular arthroscopic surgery.
62572919|NCT02333344|EXPERIMENTAL|Zoledronic acid 5mg|interventional group which receive yearly Zoledronic acid 5mg/100ml infusion treatment for two years
62572920|NCT02333344|NO_INTERVENTION|blank|blank group
62192229|NCT03452683|EXPERIMENTAL|Movn Mobile App|Participants randomized to the Movn Mobile App arm will have the Movn app downloaded to their cell phone. Participants will enter in their weight and symptoms into the app every day.
62397672|NCT04274569|EXPERIMENTAL|NaF plus CPP-ACP|Group 3: Quarterly application of a 5% NaF plus casein phosphopeptide-stabilized amorphous calcium phosphate complexes (CPP-ACP) (MI Varnish TM; GC corporation, Itabashi-Ku, Tokyo, Japan)
62397673|NCT00929227||1|Stress MRI perfusion, and cardiac CT will have observed sensitivity, specificity, and accuracyof at least 0.80 in predicting CAD in a patient population with prior equivocal stress testing.
62397674|NCT06199193|NO_INTERVENTION|Control Human patient (non-Alzheimer) with routine normal diet|Control human patients (60),non suffering from Alzheimer, will continue with their normal dietary habits and samples will be collected.
62397675|NCT06199193|SHAM_COMPARATOR|Alzheimer patients with routine normal diet and dietary counseling|Alzheimer patients (60) will continue with their routine normal diet and samples will be collected.
62572921|NCT01985841|EXPERIMENTAL|Bevacizumab/FEC/Docetaxel|Bevacizumab plus 5-Fluorouracil/Epirubicin/Cyclophosphamide (FEC) -\> Bevacizumab plus Docetaxel
62572922|NCT06535945|EXPERIMENTAL|30 g/L or below|Receive Human Albumin 20% Solution when albumin serum concentration is at 30 g/L or below
62572923|NCT06535945|ACTIVE_COMPARATOR|20 g/L or below|receive Human Albumin 20% Solution when albumin serum concentration is at 20 g/L or below
62572924|NCT06369363|PLACEBO_COMPARATOR|Placebo|
62781105|NCT05124132|ACTIVE_COMPARATOR|Health Education|The health education control condition is based on a chronic disease self-management program developed at Stanford University and was used as an attentional control in the parent study (Protocol ID #201410093). This control intervention was designed to be time-equivalent to MBSR, with 8 weeks of 2.5 hour weekly group classes followed by monthly booster sessions for approximately 15 months. For the current study, participants will continue monthly approximately 1.5 hour sessions covering similar content for the duration of the study.
62781106|NCT05417087|EXPERIMENTAL|SF001 administered without water|test product administered without water
62781107|NCT05417087|EXPERIMENTAL|SF001 administered with water|test product administered with water
62781108|NCT05417087|EXPERIMENTAL|Trintellix|Reference product administered with water
62006474|NCT04620148|EXPERIMENTAL|TAK-242|Patients will be administered TAK-242 as a continuous IV infusion with standard care starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 7 days
62006475|NCT04620148|PLACEBO_COMPARATOR|Placebo|Patients will be administered placebo as a continuous IV infusion with standard care starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 7 days
62006476|NCT01852890|EXPERIMENTAL|50g Ascorbate|"This arm is the initial starting dose. The first study participant will be assigned the 50g ascorbate arm.~* Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~* Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~* Ascorbate: 50 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
62397676|NCT06199193|EXPERIMENTAL|Alzheimer patients with personalized diet|Alzheimer patients (30) will be given personalized diet, with supplements based on the gut microbiota (elaborated through AI analyses) or a standard supplement (n=30) Samples will be collected.
62397677|NCT04260360|EXPERIMENTAL|NanoDoce|Intratumoral injection of NanoDoce (2.0 to 6.0 mg/mL) at a volume not to exceed 5.0 mL. NanoDoce will be administered on up to two occasions with at least 4 weeks between doses.
62397678|NCT02076646|EXPERIMENTAL|Ph I: L19IL2 + DTIC|"Cohorts of 3-6 patients will receive escalating doses of L19-IL2 until MTD is reached.~L19-IL2 will be administered on days 1, 8 \& 15 of each 21-day-cycle. Dacarbazine will be given at a fixed dose on day 1 of each 21-day cycle, 30 minutes after the end of the L19-IL2 infusion."
62397679|NCT02076646|EXPERIMENTAL|Ph II - ARM 1: L19IL2 at RD + DTIC|During the phase II part of this study, 60 patients with Stage IV M1a and M1b melanoma will be randomized in a 1:1 ratio: 30 patients assigned to Arm 1 will receive L19IL2 at the RD + DTIC at a fixed dose.
62397680|NCT02076646|ACTIVE_COMPARATOR|Ph II - ARM 2: DTIC monotherapy|During the phase II part of this study, 60 patients with Stage IV M1a and M1b melanoma will be randomized in a 1:1 ratio: 30 patients assigned to Arm 2 will receive DTIC at a fixed dose as monotherapy.
62397681|NCT05587933|EXPERIMENTAL|operative|
62397682|NCT06161766||Patients with HRS-AKI or HRS-AKI-like syndrome and chronic kidney disease|Patients with clinical suspicion of HRS-AKI or HRS-AKI-like syndrome in case of previously diagnosed chronic kidney disease (CKD) who who receive vasoactive treatment for the management of HRS, as defined by the administration of terlipressin or noradrenalin plus albumin.
62572925|NCT06369363|EXPERIMENTAL|Estradiol|
62572926|NCT04917822|EXPERIMENTAL|Emotion regulation arm|The emotion regulation arm aims at improving emotional regulation skills among parents and children.
62572927|NCT04917822|ACTIVE_COMPARATOR|Information provision arm|The information provision arm aims at providing information about Hong Kong, such as education, community resources, medical care, employment, housing, and job-seeking among parents and children.
62572928|NCT01692925|EXPERIMENTAL|Lot A|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
62572929|NCT01692925|EXPERIMENTAL|Lot B|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
62572930|NCT01692925|EXPERIMENTAL|Lot C|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
62572931|NCT01692925|EXPERIMENTAL|Lot D|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
62781109|NCT02370797|EXPERIMENTAL|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
62781110|NCT02651220|EXPERIMENTAL|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w|
62781111|NCT02651220|ACTIVE_COMPARATOR|Epiduo® Forte Gel 0.3%/2.5% w/w|
62781112|NCT02651220|PLACEBO_COMPARATOR|Placebo (vehicle) Topical Gel|
62781113|NCT02831517|EXPERIMENTAL|Part 1|48 participants: Cohorts 1,2 and 3 (Single Ascending Dose of BIIB074 or placebo) in a 6:2 ratio
62781114|NCT02831517|EXPERIMENTAL|Part 2|16 participants: Multiple Ascending Dosing of BIIB074 or placebo in a 6:2 ratio; 3 times daily \[TID\] in cohort 4 for 6 days and one time (QD) for 1 day and 2 times daily \[BID\] in cohort 5 for 6 days and QD for 1 day
62781115|NCT05933343|ACTIVE_COMPARATOR|Ethibond suture|Patients with complex anal fistula will undergo placement of Ethibond™ 1 suture as a drainage seton
62006477|NCT01852890|EXPERIMENTAL|75g Ascorbate|"If the 50g arm is tolerated, the study opens the 75g arm.~* Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~* Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~* Ascorbate: 75 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
62006478|NCT01852890|EXPERIMENTAL|100g Ascorbate|"If the 75g arm is tolerated, the study opens the 100g arm.~* Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~* Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~* Ascorbate: 100 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
62006479|NCT01852890|EXPERIMENTAL|25g Ascorbate|"This study arm will only be used if participants cannot tolerate the 50g arm. If participants cannot tolerate 50 grams of Ascorbate, the 25g arm is opened.~* Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~* Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~* Ascorbate: 25 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
62006480|NCT06050408|EXPERIMENTAL|Acute stroke group|Patients receive treatment 6-12 weeks after stroke.
62006481|NCT06050408|EXPERIMENTAL|Subacute stroke group|Patients receive treatment 16-20 weeks after stroke.
62006482|NCT06050408|EXPERIMENTAL|Chronic stroke group|Patients receive treatment 52+ weeks after stroke.
62006483|NCT03892720|EXPERIMENTAL|Treatment (SBRT)|Patients undergo stereotactic body radiation therapy with either standard radiation treatment software or HyperArc software technology for 2-3 fractions per week over a 2-week period for 5 fractions.
62006484|NCT05305794|EXPERIMENTAL|Semaglutide|
62006485|NCT05305794|ACTIVE_COMPARATOR|Control|
62006486|NCT01835249|EXPERIMENTAL|Intensive BP Arm|"Participants randomized into the Intensive BP arm will have a goal of SBP \<120mmHg. Drugs will be added and/or titrated at each visit (monthly) to achieve SBP \<120 mmHg. At periodic milepost visits, addition of another drug will be required if not at goal."
62781116|NCT05933343|ACTIVE_COMPARATOR|Vessel loop|Patients with complex anal fistula will undergo placement of vessel loop as a drainage seton
62006487|NCT01835249|ACTIVE_COMPARATOR|Standard BP Arm|Participants randomized into the Standard arm will have a goal of SBP \<140 mm Hg. Intensify therapy if SBP ≥160 mmHg @ 1 visit; ≥140 mmHg @ 2 consecutive visits; Down-titration if SBP \<130 mmHg @ 1 visit; \<135 mmHg @ 2 consecutive visits.
62006488|NCT06572605|EXPERIMENTAL|Treatment (EDM-EBRT, talquetamab)|"STEP-UP PERIOD: Patients undergo EMD-EBRT QD for 5 treatment fractions on weekdays (Monday to Friday), and receive talquetamab SC starting after the first fraction of EMD-EBRT and continuing every 2-4 days for up to 3 step-up doses in the absence of unacceptable toxicity.~SUBSEQUENT TREATMENT: Starting 2-7 days after step-up dose 3, patients receive talquetamab SC on days 1 and 15 of each cycle. Cycles repeat every 28 days for up to a maximum of 13 total cycles in the absence of disease progression or unacceptable toxicity.~Patients also undergo CT and/or PET/CT and collection of blood samples throughout the trial and undergo image-guided EMD biopsy at screening and on study. Patients undergo bone marrow biopsy/aspiration at screening and optionally at end of treatment."
62006489|NCT03022149|EXPERIMENTAL|Doctormate® (200mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) once daily for 6 months
62006490|NCT03022149|SHAM_COMPARATOR|Doctormate® (60mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (60mmHg) once daily for 6 months
62006491|NCT03244228|EXPERIMENTAL|Part 1a SAD HTL0016878/Placebo|In Part 1a, single ascending doses of HLT0016878 or matching placebo will be administered to groups of 12 subject each (9 active, 3 placebo). Each subject will have up to four treatment sessions separated by an appropriate wash-out. Healthy, young, male subjects.
62397683|NCT06456346|EXPERIMENTAL|Bomedemstat|Participants will receive active bomedemstat and hydroxyurea placebo daily for up to approximately 52 weeks. Dosage will be adjusted either up or down within specified time parameters for each participant to the dose that provides sufficient exposure to safely inhibit thrombopoiesis to decrease platelet counts to the target range. Participants who complete treatment at Week 52 will be eligible to continue treatment in the extended treatment phase. Unblinding will occur and placebo discontinued once all participants have completed at least 52 weeks of therapy or otherwise discontinued.
62572932|NCT04070001|ACTIVE_COMPARATOR|Ibuprofen group|Ibuprofen group received 1-dose 400-mg Ibuprofen 1 hour before elastomeric separator placement
62572933|NCT04070001|ACTIVE_COMPARATOR|Laser group|Laser groups received a single irradiation of low-level laser immediately after elastomeric separator placement.
62781117|NCT04897763|EXPERIMENTAL|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
62781118|NCT04438291|EXPERIMENTAL|Intervention schools|A 2-hour education session with multicomponent interventions including education sessions with small group dialogues with a registered nurse and trained healthcare and lay volunteers and educational computer games
62781119|NCT04438291|OTHER|Control schools|Control and usual care
62006492|NCT03244228|EXPERIMENTAL|Part 1b single dose HTL0016878|In Part 1b, a single dose of HTL0016878 will be administered to 6 subjects on two occasions: once in the fasted and once the fed state. This will be open-label. Healthy, young, male or female subjects.
62006493|NCT03244228|EXPERIMENTAL|Part 1c single dose HTL0016878|In Part 1c, a single dose of HTL0016878 will be administered to up to 6 (optional up to 12) healthy elderly subjects This will be open-label. Healthy, elderly, male subjects.
62192230|NCT02166970|EXPERIMENTAL|Single stent deployment|Metallic stent deployment in hilar obstruction. Insertion of metallic stent to the dominant targeted duct such as right anterior (segments V and VIII), right posterior (segments VI and VII) or left (segments II-IV).
62192231|NCT02166970|ACTIVE_COMPARATOR|Multiple stent deployment|Metallic stent deployment in hilar obstruction. Insertion of multiple metallic stent to the dominant targeted duct such as right anterior (segments V and VIII), right posterior (segments VI and VII) or left (segments II-IV).
62192232|NCT02039648|ACTIVE_COMPARATOR|Rumex acetosa L. extract|Rumex acetosa L. extract mouthrinse, 10 ml, tid, 3 min, 7 days
62192233|NCT02039648|PLACEBO_COMPARATOR|Placebo|Placebo mouthrinse, 10 ml, tid, 3 min, 7 days
62192234|NCT01928238|EXPERIMENTAL|Arm 1|"Patients will have two 20-minute noninvasive periods :~Noninvasive neurally adjusted ventilatory assist (NIV-NAVA) and then Noninvasive pressure support ventilation (NPSV)"
62192235|NCT01928238|EXPERIMENTAL|Arm 2|"Patients will have two 20-minute noninvasive periods :~Noninvasive pressure support ventilation (NPSV) and then Noninvasive neurally adjusted ventilatory assist (NIV-NAVA)"
62192236|NCT00009906|EXPERIMENTAL|Arm I (imatinib mesylate)|Patients receive oral imatinib mesylate once daily.
62192237|NCT00009906|EXPERIMENTAL|Arm II (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily.
62192238|NCT06485583|OTHER|Constraint-Induced Movement Therapy|The rehabilitation plan involves several components to promote the recovery of the affected limb. Initially, we will immobilize the unaffected limb using a constraint device such as a mitt or sling for about 90% of waking hours over a period of six weeks.
62781120|NCT02358226|EXPERIMENTAL|Soccer League (SL)|In the SL arm, participants will be invited to participate in a Soccer League, led by coaches who meet the criteria of: 1) soccer skills, 2) being a role model, and 3) social competence. Coaches will undergo intensive training in ethics; role-playing the delivery of health messages; conducting brief interventions for alcohol; how to acquire information on HIV, TB, alcohol use and employment; linkages to local clinics, data collection; and Street Smart, an evidence-based intervention for high-risk youth. Coaches will provide pre- and post-game talks, incorporating the topics of alcohol and drugs; interacting positively with health care providers, partners and family members; HIV, diabetes; daily routines; healthy social networks; making and saving money; loyalty and national success.
62006494|NCT03244228|EXPERIMENTAL|Part 2a MAD HTL0016878/Placebo|In Part 2a, multiple doses of HTL0016878 will be administered to up to 5 cohorts (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
62006495|NCT03244228|EXPERIMENTAL|Part 2b MAD HTL0016878/Placebo|In Part 2b, multiple doses of HTL0016878 will be administered to up to 3 cohorts of healthy, elderly subjects (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
62006496|NCT04453124|NO_INTERVENTION|Soap and Water|Standard of care using soap and water
62006497|NCT04453124|EXPERIMENTAL|Ficus Septica Sap|Ficus Septica Sap, topical cream, 50ul, daily, for 2 days
62006498|NCT04453124|ACTIVE_COMPARATOR|Chlorhexidine (Topical)|Chlorhexidine, topical solution, 50ul, daily, for 2 days
62006499|NCT05022810|EXPERIMENTAL|Test Drug|Participants will receive a single oral dose of either New Paracetamol Oral Suspension (24 mg/ml) or Panadol B\&I Oral Suspension (24 mg/ml paracetamol) on Day 1 (Period 1) and Day 4 (Period 2) under fasting conditions as per the randomization schedule. A wash out period of at least 72-hour will be maintained between each treatment period.
62006500|NCT05022810|ACTIVE_COMPARATOR|Reference Drug|Participants will receive a single oral dose of either New Paracetamol Oral Suspension (24 mg/ml) or Panadol B\&I Oral Suspension (24 mg/ml paracetamol) on Day 1 (Period 1) and Day 4 (Period 2) under fasting conditions as per the randomization schedule. A wash out period of at least 72-hour will be maintained between each treatment period
62006501|NCT01280773|NO_INTERVENTION|PSV weaning|Patinens in the PSV group will be weaned using PSV mode.
62192239|NCT06485583|OTHER|neurodevelopmental treatment|The rehabilitation approach includes hands-on techniques to guide the patient through normal movement patterns. By providing sensory input, we aim to improve motor control and postural alignment, using techniques such as handling, guiding, and assisting movements.
62192240|NCT04218474|OTHER|patient lost sensation ant half of lower lip|patient with injured inferior alveolar nerve at one side
62192241|NCT02900235|EXPERIMENTAL|MT-3995|\[14C\]-MT-3995 after a single oral dose
62006502|NCT01280773|EXPERIMENTAL|NAVA weaning|Patients in NAVA group will eb weaned using NAVA mode.
62192242|NCT03990740||Cases|Patients suffering from keratoconus and requiring a first optical corneal transplant
62192243|NCT03990740||Controls|Patients with an indication of orbital exenteration operation due to an orbital tumor
62192244|NCT00003058|EXPERIMENTAL|Troglitazone|Patients received troglitazone 800 mg oral once-daily. Treatment continued as long as patient was responding or in stable disease clinically and ended if patient experienced progression or unacceptable toxicity.
62397684|NCT06456346|ACTIVE_COMPARATOR|Hydroxyurea|Participants will receive active hydroxyurea and bomedemstat placebo daily for up to 52 weeks. Dosage will be adjusted either up or down within specified time parameters for each participant to the dose that provides sufficient exposure to safely inhibit thrombopoiesis to decrease platelet counts to the target range. Participants who complete treatment at Week 52 will be eligible to continue treatment in the extended treatment phase. Unblinding will occur and placebo discontinued once all participants have completed at least 52 weeks of therapy or otherwise discontinued.
62397685|NCT01992926|ACTIVE_COMPARATOR|interactive educational intervention|Physicians will use an interactive educational worksheet during the standard-of-care clinic visit.
62192245|NCT03697694|EXPERIMENTAL|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
62572934|NCT04070001|PLACEBO_COMPARATOR|Control group|Control group received placebo lactose tablets 1 hour before elastomeric separator placement.
62006503|NCT01108575|EXPERIMENTAL|Inspiratory muscle strength training|
62006504|NCT01108575|SHAM_COMPARATOR|Sham Inspiratory muscle strength training|
62192246|NCT03697694|PLACEBO_COMPARATOR|500mg of placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
62397686|NCT01992926|NO_INTERVENTION|control group|Physicians will conduct the standard-of-care clinic visit as usual.
62397687|NCT05538442|OTHER|group|Healthy trailer
62781121|NCT02358226|EXPERIMENTAL|Soccer League/Vocational Training (SL-V)|The SL-V arm will include both the SL intervention as well as access to Vocational Training through either Silulo Ulutho Technologies, which offers computer courses, or Zenzele Training and Development programs, which provides training in woodwork and wielding. Both programs are located in Khayelitsha, which is close to participants' homes, thus avoiding transport-related barriers. Additionally, the training programs occur in a mentor-mentee context so that participants can develop the interpersonal skills required for employment.
62006505|NCT06100250|EXPERIMENTAL|Telehealth intervention|Participants will receive an MI-based telehealth intervention for bacterial STI screening.
62397688|NCT05278663|EXPERIMENTAL|Cohort 1: E6742 100 mg or Placebo|Participants will receive E6742 100 milligram (mg) tablet or E6742-matched placebo tablet, orally, twice daily for up to 85 days.
62781122|NCT02358226|NO_INTERVENTION|Control Condition (CC)|Participants in the CC arm will routinely receive flyers with picture stories regarding HIV prevention strategies and how to access these strategies: HIV testing, circumcision, HIV treatment, including ARV, condoms and sexually transmitted diseases.
62006506|NCT00679341|EXPERIMENTAL|Trastuzumab emtansine|Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) administered over 30-90 minutes every 3 weeks on Day 1 of each 21-day cycle.
62006507|NCT00679341|ACTIVE_COMPARATOR|Trastuzumab + docetaxel|Patients received a loading dose of trastuzumab 8 mg/kg IV + docetaxel 75 or 100 mg/m\^2 IV on Day 1 of Cycle 1 followed by trastuzumab 6 mg/kg IV + docetaxel 75 or 100 mg/m\^2 IV on Day 1 of all subsequent 21-day cycles.
62006508|NCT04099524|EXPERIMENTAL|active tDCS|We will apply the stimulation for 20 minutes using current at 1.5mA with a ramp up and ramp down period of 30 seconds at the start and end of the session.
62397689|NCT05278663|EXPERIMENTAL|Cohort 2: E6742 200 mg or Placebo|Participants will receive E6742 200 mg tablets (two tablets of each 100 mg) or E6742-matched placebo tablets, orally, twice daily for up to 85 days.
62397690|NCT05642325|EXPERIMENTAL|Arm A|Participants will receive 4 high-dose vamikibart intravitreal (IVT) injections every 4 weeks (Q4W) to Week 12, followed by as-needed (PRN) dosing from Week 20 to Week 48.
62397691|NCT05642325|EXPERIMENTAL|Arm B|Participants will receive 4 low-dose vamikibart IVT injections Q4W to Week 12, followed by PRN dosing from Week 20 to Week 48.
62397692|NCT05642325|SHAM_COMPARATOR|Arm C|Participants will receive 4 sham injections Q4W to Week 12, followed by PRN sham dosing from Week 20 to Week 48.
62397693|NCT03012035|EXPERIMENTAL|experimental group|Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
62006509|NCT04099524|SHAM_COMPARATOR|sham tDCS|tDCS will ramp up for 30 seconds with 1 mA current and then ramp off within 10 seconds. As 30 seconds is too short for tDCS to have any effects, this will be the control condition. tDCS is on for 30 seconds because that is usually the only time individuals would experience tingling and itching - a factor we aim to equate between experimental and control conditions.
62006510|NCT01172548|EXPERIMENTAL|imatinib mesylate|
62006511|NCT06653946|ACTIVE_COMPARATOR|Hemorragic transformation group|262 acute ischemic stroke (AIS) patients who had a hemorrhagic transformation of brain infarction after 24-36 hours of receiving alteplase.
62192247|NCT03531554|EXPERIMENTAL|ketone ester drink|Oral intake of ketone ester drink muscle biopsy exercise muscle biopsy Magnetic Resonance imaging
62572935|NCT03424811|EXPERIMENTAL|Intervention Group|Includes core behavior change strategies and behavioral skills training designed to promote healthy eating behaviors.
62572936|NCT03424811|NO_INTERVENTION|Control Group|Information provided will mimic what families may receive during a routine well-child visit.
62572937|NCT05498129|ACTIVE_COMPARATOR|No school meal|
62006512|NCT06653946|ACTIVE_COMPARATOR|non-hemorragic transformation group|454 acute ischemic stroke (AIS) patients did not have a hemorrhagic transformation of brain infarction after 24-36 hours of receiving alteplase
62572938|NCT05498129|EXPERIMENTAL|School meal|
62572939|NCT05498129|EXPERIMENTAL|School meal plus micronutrient powder|
62192248|NCT03531554|PLACEBO_COMPARATOR|carbohydrate drink|Oral intake of isocaloric carbohydrate drinkmuscle biopsy exercise muscle biopsy Magnetic Resonance imaging
62781123|NCT04292743|EXPERIMENTAL|Eryaspase plus FOLFIRINOX|"Eryaspase will be administered on day 1 and 15 of a 4 week cycle (intravenous infusion) in dose escalating/reduction depending on the cohort the patient is assigned to~mFOLFIRINOX dosing will include 5-fluorouracil 2400 mg/m² over 46 hours, oxaliplatin 85 mg/m², Irinotecan 150 mg/m² (intravenous infusion) on Day 1 and 15 of the 4 weeks cycle for a maximum of 12 cycles."
62192249|NCT02596698||Adolescents with Mood Disorders|Teens aged 13-18 with a diagnosis of a mood disorder.
62192250|NCT02596698||Adolescents with no Mental Health Diagnoses|13-18, no psychiatric d/o diagnosis
62192251|NCT02552459|ACTIVE_COMPARATOR|sufentanil|sufentanil 150μg，intravenous administration during the following 72 hours after operation.
62192252|NCT02552459|EXPERIMENTAL|sufentanil&dexmedetomidine 1|sufentanil 150μg，dexmedetomidine 0.05μg/kg/h，intravenous administration during the following 72 hours after operation.
62192253|NCT02552459|EXPERIMENTAL|sufentani&dexmedetomidine 2|sufentanil 150μg，dexmedetomidine 0.1μg/kg/h，intravenous administration during the following 72 hours after operation.
62192254|NCT02552459|EXPERIMENTAL|sufentanil&dexmedetomidine 3|sufentanil 150μg，dexmedetomidine 0.15μg/kg/h ，intravenous administration during the following 72 hours after operation.
62781124|NCT03028935|EXPERIMENTAL|Prevention (exercise, nutrition education program)|Exercise Intervention \& Nutritional Intervention. Participants undergo instructor-led exercise and nutrition education classes for 60 minutes twice a week for 12 weeks.
62781125|NCT01447186||Patient Decision Aid for Spanish Speaking Men|Spanish-Language Slide Set
62192255|NCT05616598|ACTIVE_COMPARATOR|Pateint group|Men with HCV
62781126|NCT04840329|EXPERIMENTAL|Education Arm|
62781127|NCT04840329|NO_INTERVENTION|Waitlist Control Arm|
62781128|NCT04751877|EXPERIMENTAL|Isatuximab/Lenalidomide/Dexamethasone/Bortezomib|
62781129|NCT04751877|ACTIVE_COMPARATOR|Isatuximab/Lenalidomide/Dexamethasone|
62781130|NCT03064919|EXPERIMENTAL|Curriculum Testing|Test an evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals.
62781131|NCT03156374|EXPERIMENTAL|Ovulation test use|Use of both ovulation tests and standardised care
62781132|NCT03153995|EXPERIMENTAL|sub-periosteal soft tissue expansion|Eight patients will receive osmotic hydrogel expanders prior to bone augmentation procedures. All expanders will be placed in sub-periosteal positions using the tunnel technique.
62781133|NCT03153995|ACTIVE_COMPARATOR|periosteal releasing incision|periosteal releasing incision will be performed for Eight patients during ridge augmentation surgery .
62192256|NCT05616598|NO_INTERVENTION|Control group|Men without HCV
62192257|NCT00903825|ACTIVE_COMPARATOR|Manual palpation|Local anesthetic before femoral artery puncture will be injected with the classic manual palpation technique
62192258|NCT00903825|EXPERIMENTAL|Ultrasound guidance|Local anesthetic before femoral artery puncture will be performed with the use of duplex ultrasound guidance
62192259|NCT00127842|OTHER|Etanercept|Open-label etanercept administered by subcutaneous injection at a dose of 50 mg/week for 24 months.
62192260|NCT02305745||Preeclampsia- observational|45 women with preeclampsia
62192261|NCT02305745||No preeclampsia- observational|10 women without preeclampsia
62192262|NCT04324190|EXPERIMENTAL|Online support program|Guided online support program, consisting of modules (structured in chapters) aiming at reduce stress related to the COVID-19 pandemic.
62192263|NCT04324190|ACTIVE_COMPARATOR|Waiting period (WHO recommendation)|"Waiting period (2 weeks duration) during which subjects are provided with the WHO recommendations Coping with stress during the 2019 nCoV outbreak. Following the 2 weeks waiting period, subjects are provided with the guided online support program outlined in the arm 'online support program'."
62781134|NCT03190460|EXPERIMENTAL|Intervention|
62781135|NCT03190460|OTHER|Education|
62781136|NCT04887896|EXPERIMENTAL|GS500 flexible dose|3, 2, or 4 GS500 capsules 2 times per day
62781137|NCT04887896|PLACEBO_COMPARATOR|Placebo flexible dose|3, 2, or 4 placebo capsules 2 times per day
62781138|NCT02697435|EXPERIMENTAL|Patient-Centered Care|Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain.
62781139|NCT02697435|PLACEBO_COMPARATOR|Imaging-Directed Care|Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
62781140|NCT01970969||Cardiac arrhythmia symptoms|All subjects enrolled in the study will have an iRhythm Zio patch placed and a blood sample obtained.
62781141|NCT05435417|EXPERIMENTAL|Manual segmentation technique of CBCT images of the condyles.|Using the manual edition built in tool, first a brush of small size will be used to demarcate the outline of the condyle in the sagittal cuts. Then shading the demarcated condylar area with a brush of larger size in each slice. The outline of the condyle will be refined on all cuts. The software built in tool 'create surface' will be used to create the segmented 3D volume
62397694|NCT03012035|OTHER|comparator group|The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
62397695|NCT05156749|EXPERIMENTAL|short-arm fiberglass cast|"salter harris fractures of the distal radius/forearm in children are usually treated with fiberglass long-arm casts. The investigators were able to demonstrate that in distal metaphyseal forearm fracture, treatment with a short-arm cast is not inferior to a long-arm cast.~Patients are going to receive a short-arm cast for fracture treatment."
62397696|NCT05156749|ACTIVE_COMPARATOR|long-arm fiberglass cast|"salter harris fractures of the distal radius/forearm in children are usually treated with a fiberglass long-arm cast.~Patients are going to receive a long-arm cast for fracture treatment."
62572940|NCT02653781|EXPERIMENTAL|Realistic simulation; Performance|Student participation in the study will happen on demand by enrollment in activities of dialogue-exhibition (workshop) on realistic simulation in the context of patient safety. Check the performance of students in face of simulation workshop for test realistic simulation.
62781142|NCT05435417|EXPERIMENTAL|Semiautomatic segmentation technique of CBCT images of the condyles.|Using the water shed built in tool, first a brush of small size will be used to demarcate the outline of the condyle by the 'background' option in all planes. Then using the 'foreground' option, a brush of larger size will be used to shade the condylar area. The software built in tool 'expand water shed' will be used to include the whole condyle. At last, 'create surface' option will be used to create the segmented 3D volume.
62006513|NCT02224872|EXPERIMENTAL|Bone marrow transplant|Thymoglobulin on days -9 to -7 Fludarabine on days -6 to -2 Cyclophosphamide on days -6, -5, 3, 4 TBI on day -1 BMT on day 0 Mesna on days 3, 4 Tacrolimus on days 5-365 Mycophenolic acid mofetil on days 5-35
62006514|NCT06018961||Adult patients with digestive surgery|Patients who have planned abdominal surgery
62006515|NCT00804882||1|Mexican Americans with heart failure and metabolic syndrome
62006516|NCT00804882||2|Mexican Americans with heart failure without metabolic syndrome
62006517|NCT00804882||3|Non-Hispanic White Americans with heart failure and metabolic syndrome
62006518|NCT00804882||4|Non-Hispanic White Americans with heart failure without metabolic syndrome
62006519|NCT00772096|EXPERIMENTAL|Verum|
62192264|NCT04324190|NO_INTERVENTION|No intervention (natural course)|"This non-randomised arm (recruited separately; anticipated sample size of 500 subjects, not counted in the overall anticipated sample size) consists of subjects not intending to participate in the Selfapy online support program. Assessment points in this arm are comparable to those in the arm Online support program (in the 'No intervention (natural course)' arm, T1 refers to time of study inclusion)."
62192265|NCT01692509||Patients requiring NIV|Patients requiring NIV because of acute respiratory failure
62192266|NCT00785954|EXPERIMENTAL|A1: KAI-9803|
62192267|NCT00785954|EXPERIMENTAL|A2: KAI-9803|
62192268|NCT00785954|EXPERIMENTAL|A3: KAI-9803|
62006520|NCT00772096|NO_INTERVENTION|No treatment|
62006521|NCT05403554|EXPERIMENTAL|NI-1801 Single Agent|NI-1801 will be evaluated in patients with MSLN-expressing advanced, metastatic solid tumors
62192269|NCT00785954|PLACEBO_COMPARATOR|A4: Placebo|
62192270|NCT03756376||IRRIV and RFR|Enrolled patients will receive IRRIV test and RFR assessment. RFR will be evaluated through a protein loading test. (1.2 g of protein/Kg of body weight) performed with cooked beef. The RFR was then defined as the difference between the highest CrCl obtained after the protein load and the baseline CrCl measured on rest conditions. Concerning the IRRIV test, a weight of 10% of the patient's body weight is applied on the abdominal wall. RRIs is recorded in a middle interlobular artery, every minute for 10 minutes during the echo-renal stress test. The lowest RRI reached is taken as reference (stress RRI). The IRRIV is defined as the percentage difference between baseline RRI and stress RRI
62006522|NCT05403554|EXPERIMENTAL|NI-1801 in Combination with Pembrolizumab|NI-1801 will be evaluated in patients with MSLN-expressing advanced, metastatic solid tumors in combination with anti-PD-1 antibody
62006523|NCT05403554|ACTIVE_COMPARATOR|Randomized cohort|In the randomized, open-label cohort design, the experimental arm will receive the investigational drug NI-1801 at the P2RD in combination with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles.
62006524|NCT06192342||Patients with acute neurological injury|Patients ≥ 16 years of age with ANI requiring mechanical ventilation for neurological causes, without baseline lung injury, defined by a PaO2/FiO2 ≥ 300 and with a normal chest x-ray
62006525|NCT00523185|ACTIVE_COMPARATOR|2|
62006526|NCT00523185|ACTIVE_COMPARATOR|1|
62006527|NCT01872572|OTHER|Cohort 1|Cohort 1: 6 subjects received Subcutaneous RB006 0.5 mg/kg and 2 subjects received SC placebo
62006528|NCT01872572|OTHER|Cohort 1-A|Cohort 1-A: 4 subjects received open-label Subcutaneous RB006 0.5 mg/kg
62006529|NCT01872572|OTHER|Cohort 2|Cohort 2: 6 subjects received Subcutaneous RB006 1.0 mg/kg and 2 subjects received SC placebo
62006530|NCT01872572|OTHER|Cohort 3|Cohort 3: 6 subjects received Subcutaneous RB006 3.0 mg/kg and 2 subjects received SC placebo
62006531|NCT01872572|OTHER|Cohort 4|"8 subjects received subcutaneous RB006 2.0 mg/kg as well as the following:~* 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~* 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration"
62006532|NCT05955560|OTHER|Treatment Sequence 1|PureWick™ Male External Catheter is used first, followed by cross-over to Sage PrimoFit.
62006533|NCT05955560|OTHER|Treatment Sequence 2|The Sage PrimoFit™ is used first, followed by cross-over to PureWick MEC.
62192271|NCT01111253|ACTIVE_COMPARATOR|Conservative strategy with antibiotics|"* Hospital admission~* Intravenous fluids and at least 48 hours of intravenous antibiotics and subsequently switch to oral antibiotics if tolerated (otherwise continuation i.v.) to complete a full 10-day treatment duration~* Adequate pain relief~* Oral intake as tolerated~* Daily monitoring"
62192272|NCT01111253|NO_INTERVENTION|Liberal strategy without antibiotics|"* Admission only if discharge criteria are not met~* No initial antibiotics~* Intravenous fluids only for those not tolerating oral liquids~* Adequate pain relief~* Oral intake as tolerated~* Daily monitoring when admitted to the hospital~* Self-monitoring at home (Patient diary with temperature and VAS pain score until full recovery)"
62192273|NCT03838523|EXPERIMENTAL|OLP group|"At baseline, patients are given an explanation about why placebos without deception might be effective.~Women allocated to this group receive an 4-week Open Label Placebo treatment. After 4 weeks, they are randomized again to either continue or discontinue the OLP treatment for another 4 weeks."
62192274|NCT03838523|NO_INTERVENTION|No-treatment group|"At baseline, patients are given an explanation about why placebos without deception might be effective.~Women assigned to the no-treatment group do not receive any treatment as part of the study."
62192275|NCT05337423|EXPERIMENTAL|Group 1|Moisturizing cream indicated and provided by the hospital (with urea) + LED treatment.
62192276|NCT05337423|SHAM_COMPARATOR|Group 2|Moisturizing cream indicated and provided by the hospital (with urea) + LED sham treatment.
62192277|NCT04699760|PLACEBO_COMPARATOR|Placebo|Nutritional supplement without fish oil
62192278|NCT04699760|ACTIVE_COMPARATOR|Fish oil|Nutritional supplement with fish oil
62192279|NCT00362375|EXPERIMENTAL|Healthy Love Workshop|Single-session, small-group HIV prevention intervention
62192280|NCT00362375|ACTIVE_COMPARATOR|HIV101|Single-session, small-group intervention providing facts regarding HIV/AIDS
62192281|NCT03450499|EXPERIMENTAL|analgesic effects of ketamine|the experimental group will receive ketamine intravenously at 0.25 mg per kg before skin incision.
62192282|NCT03450499|PLACEBO_COMPARATOR|placebo|they will receive same volume of 0.9% normal saline as calculated for experimental group before skin incision.
62192283|NCT01240538|EXPERIMENTAL|Treatment (virus and chemotherapy)|Patients receive wild-type reovirus IV over 60 minutes QD on days 1-5. Some patients also receive cyclophosphamide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62192284|NCT02339597|EXPERIMENTAL|APAP Lab|standard Initiation of APAP therapy in sleep laboratory.
62192285|NCT02339597|EXPERIMENTAL|APAP Home|initiation of APAP therapy in homely environment with additional continuous telemetric support.
62192286|NCT01003535||[123I]5-IA-85380 SPECT|
62192287|NCT05488288|EXPERIMENTAL|Mesh group|"ventral hernia repair with non absorbable mesh placement concomitant to bariatric procedure (sleeve gastrectomy or by-pass).~In this group, the repair technique and the type of mesh are left to the choice of the center, as there are no strong data to demonstrate which technique is the best for VH repair in this population."
62192288|NCT05488288|ACTIVE_COMPARATOR|Suture group|"suture repair of ventral hernia concomitant to bariatric procedure (sleeve gastrectomy or by-pass).~In this group, the hernia sack is resected through an open approach, and the fascial defect is systematically closed with a slowly absorbable monofilament suture."
62192289|NCT02653209|EXPERIMENTAL|Sitagliptin - DPP4i|
62781143|NCT05435417|NO_INTERVENTION|Actual physical measurements of the condyles on the dry mandibles|"For linear measurements, actual physical measurements will be done on the dry mandibular condyles, using digital caliper, as mentioned before.~For volumetric measurements, water displacement technique will be used. The mandibular condyle will be immersed in a graduated beaker containing water till the level of the glued gutta percha. The volume of the displaced water will be measured and will represent the actual volume of the condyle"
62006534|NCT01424488|EXPERIMENTAL|sugammadex group|4 mg/kg of sugammadex for reversal of pipecuronium-induced neuromuscular blockade
62781144|NCT04036500|EXPERIMENTAL|Estradiol|Subjects will take estradiol 1 mg orally after time 0 blood draw. They will get 7 blood draws at hours 0,1,2,3,4,6,8. A wash-out period of at least one week will allow for complete clearance of the exogenous oral estradiol before testing the pharmacokinetics of sublingual estradiol on the same ten patients in the same manner. On day 2 of study, subject will take estradiol 1 mg sublingually after time 0 blood draw, supervised by a research team member to ensure proper dissolution. Blood will be drawn at hours 0,1,2,3,4,6,8 as on day 1 of study.
62006535|NCT01424488|PLACEBO_COMPARATOR|placebo group|3 ml of saline (placebo) for reversal of pipecuronium-induced neuromuscular blockade
62006536|NCT02422433|EXPERIMENTAL|OFDI Capsule Marking and Imaging|Subject will swallow the OFDI capsule, marking will be performed by making superficial cautery marks on the tissue. This will be followed by imaging using the OFDI Imaging system.
62006537|NCT06662552|EXPERIMENTAL|whole body vibration group|Fifteen patients will receive whole body vibration and traditional physical therapy program (splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises) on quadriceps muscle (3 times per week, for 6 weeks), plus medical treatment
62006538|NCT06662552|ACTIVE_COMPARATOR|pulsed electromagnetic field (PEMF) group|Fifteen patients will receive pulsed electromagnetic field (PEMF) and traditional physical therapy program (splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises) on quadriceps muscle (3 times per week, for 6 weeks), plus medical treatment.
62006539|NCT06479109|OTHER|Providers use a job aid (information sheet) during ANC counseling about supplement adherence.|Providers in intervention sites use an information sheet that serves as a job aid to counsel women about the benefits of the supplements.
62006540|NCT06479109|OTHER|Pregnant women receive a behavioral intervention in IFAS or MMS sites during antenatal care visits.|Pregnant women in intervention clinics will receive antenatal care counseling assisted with an information sheet for providers to use.
62006541|NCT06479109|NO_INTERVENTION|Pregnant women receive standard antenatal care visits in IFAS or MMS sites|Pregnant women in control clinics will receive standard counseling from health providers during the antenatal care visits.
62006542|NCT06573021||Patients with a clinical and radiological diagnosis of acute cholecystitis|Patients with a clinical and radiological (abdominal ultrasound and/or computed tomography) diagnosis of acute cholecystitis based on the revised Tokyo guidelines who underwent laparoscopic cholecystectomy within 24-72 hours from the onset of symptoms and patients with American Society of Anesthesiologists (ASA) score of 0-3. Near-infrared fluorescent cholangiography was performed at three time points during laparoscopic cholecystectomy: (i) following exposure of Calot's triangle, prior to any dissection; (ii) after partial dissection of Calot's triangle; (iii) after complete dissection of Calot's triangle.
62006543|NCT06055088|EXPERIMENTAL|exercise with massage ball|The exercise group will participate in home-based hand and foot exercises for 8 weeks. The exercise program will start the week the first neuropathy symptom appears and continue for 8 weeks. The exercises, which will last for 8 weeks, will be performed 3 times a day and at least 3 times a week. A detailed exercise brochure will be given to the exercise group. Patients in the massage ball group will be given a massage ball to be used in exercises.
62006544|NCT06055088|EXPERIMENTAL|exercise with stress ball|The exercise group will participate in home-based hand and foot exercises for 8 weeks. The exercise program will start the week the first neuropathy symptom appears and continue for 8 weeks. The exercises, which will last for 8 weeks, will be performed 3 times a day and at least 3 times a week. A detailed exercise brochure will be given to the exercise group. Patients in the stress ball group will be given a stress ball to be used in exercises
62006545|NCT06055088|NO_INTERVENTION|control|No intervention will be applied to the patients in the control group during the follow-up period, only data collection forms will be applied.
62192290|NCT02653209|EXPERIMENTAL|Canagliflozin - SGLT2i|
62192291|NCT02653209|EXPERIMENTAL|Pioglitazone - TZD|
62192292|NCT01780597||Organ Donors (declared Brainstem-Dead)|This group of subjects is defined as those who have previously expressed their future wish to organ donation and who have suffered events leading to declaration of brainstem-death. Furthermore these subjects will have had their hearts declined for heart transplantation on the basis of poor function.
62192293|NCT02375347|EXPERIMENTAL|Chickpea Enhanced Diet|Fed an enhanced Chickpea diet over a short term period (Chickpea Enhanced Diet Short Term)
62192294|NCT05764551|EXPERIMENTAL|DNA methylation|The enrolled individuals with HCC would receive serum DNA methylation test before their treatment (including all kinds of recommened HCC treatment). Then regularly serum DNA methylation test would be done at 4th\~8th weeks, 16th week, 32th week and 48th week. If the enrolled patients did not have HCC recurrence during at 48th week. The regular check of serum DNA methylation would be canceled. The enrolled patients would be observed till 96th week. If there is any recurrence during 48\~96th week, one time of serum DNA methylation would be checked at the time of recurrence. The observation and intervention would be completed at 96th week.
62192295|NCT00574418|OTHER|1|
62192296|NCT05323045|EXPERIMENTAL|BYON3521|c-MET targeting Antibody-Drug Conjugate
62192297|NCT04908345|EXPERIMENTAL|Methadone|Methadone 0,075mg/kg for induction and half of induction dose of boluses as needed during surgery
62192298|NCT04908345|ACTIVE_COMPARATOR|Fentanyl|Fentanyl 3 mcg/kg for induction and half of induction dose of boluses as needed during surgery
62192299|NCT06385925|EXPERIMENTAL|Phase 1: Dose-finding/evaluation of TSN1611 monotherapy|The phase 1 part will evaluate the prespecified sequential dose levels of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors to determine the recommended dose of TSN1611 for further investigation.
62192300|NCT06385925|EXPERIMENTAL|Phase 2: Dose expansion of TSN1611 monotherapy|Phase 2 part will evaluate the efficacy and safety of TSN1611 as monotherapy at the recommended dose level in separate groups of patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer, or other solid tumors, harboring KRAS G12D mutations.
62192301|NCT01790295|EXPERIMENTAL|Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)|Ruxolitinib (INC424) tablets will be started 62 days (day -67) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
62192302|NCT06265324|EXPERIMENTAL|Control|
62192303|NCT00759122|ACTIVE_COMPARATOR|1|VENLAFAXINE
62192304|NCT00759122|PLACEBO_COMPARATOR|2|
62397697|NCT03672136|EXPERIMENTAL|Concurrent Chemoradiotherapy+Anlotinib|"1. Radiotherapy: Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy. If radiotherapy and chemotherapy are conducted in the same day, chemotherapy should be priority to radiotherapy.~2. Chemotherapy: Platinum based dual drug regime determined by researcher.After finishing concurrent chemoradiotherapy, there is no need of maintenance chemotherapy.~3. Anlotinib: Combined with 12mg/d QD Anlotinib on the first, second weeks and fourth, fifth weeks of radiotherapy, that is on the day1\~14, day22\~36.~4. Maintenance therapy: One month after finishing concurrent chemoradiotherapy, 12mg/d QD Anlotinib can be administrated, each cycle is defined as 2 weeks on-treatment followed by 1 week off-treatment. The treatment can continue until disease progression or treatment intolerance, but should not exceed 24 months.~5. During the course of study, it's not allowed to receive other anti-tumor therapy."
62397698|NCT05167669|OTHER|Prospective, interventional, single-center, feasibility pilot study.|10 patients with radiologically confirmed bone metastases and eligible for a course of palliative EBRT. Eligible patients will be mainly discussed and recruited in a dedicated tumor-board for bone metastases performed in a weekly basis at HUG.
62397699|NCT05239390|EXPERIMENTAL|SCI -110|SCI -110 (Previously known as THX-110): a combination of THC (Doses: 2.5 mg - 12.5 mg per daily dose) and PEA (Dose: 800 mg per daily dose), administered together as separate pills, orally, twice daily (morning and evening - except for the initial titration dose, of 2.5 mg THC+800 mg PEA given once a day, in the morning.
62572941|NCT02653781|OTHER|theoretical-practical classes|Will be to give a theoretical-practical classes for students of control group the provision of similar opportunities
62572942|NCT00918411|EXPERIMENTAL|Ramosetron group|oral
62192305|NCT04135612|EXPERIMENTAL|Smartphone group|"application installed to their smartphones. This application will be in Hebrew language, simple to use, and specifically designed to the needs of the current study.~Each patient will document each evening her lactation performance during the day, and the App will generate a daily report transmitted by email every evening to our computerized research database. Every evening the patient will receive via email an individualized feedback from our team regarding her lactation. This feedback could include: reassurance and positive feedback and lactation tips in attempt to optimize specific obstacles. In addition, patients will be encouraged to use the platform to ask questions and receive immediate answers regarding any aspect lactation. As per the study protocol, medical treatment will only be initiated in a formal clinic appointment and not via the application."
62192306|NCT04135612|NO_INTERVENTION|Control group|The routine prenatal care provided by our institute includes lactation consulting during the 48-72 hour postpartum hospitalization.
62192307|NCT02997332|EXPERIMENTAL|Patients with squamous cell carcinoma of the oral cavity,|The aim is to evaluate safety, PK and pharmacodynamics of durvalumab in adult patients with squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx previously untreated, with indication of induction chemotherapy.
62192308|NCT02209103|EXPERIMENTAL|Citrus flavonoid|Citrus flavonoid
62192309|NCT02209103|EXPERIMENTAL|Citrus flavonoid formulation|Citrus flavonoid formulation
62192310|NCT02209103|PLACEBO_COMPARATOR|Placebo|Placebo
62192311|NCT03002142|EXPERIMENTAL|Patients treated with hearing aids|Patients fitted with functional hearing aids (Phonak Audéo BR)
62192312|NCT03002142|PLACEBO_COMPARATOR|Patients treated with placebo device|Patients fitted with non-functional hearing aids
62572943|NCT00918411|PLACEBO_COMPARATOR|Placebo group|oral
62572944|NCT04956601|EXPERIMENTAL|VBT|CT image guided high-dose-rate vaginal brachytherapy, 30Gy/6f, 2f/w.
62572945|NCT04956601|ACTIVE_COMPARATOR|EBRT|Pelvic external beam radiotherapy，IMRT/VAMT，IGRT suggested，DT 45Gy/25f.
62572946|NCT05047211|ACTIVE_COMPARATOR|Oral Iron group|"Ferrous sulfate 325 mg (65 mg elemental iron) by mouth for a total of 6 weeks three times daily.~Intravenous placebo in sodium chloride 0.9% 500mL IV infusion will be given before discharge home over 1 hour preceded by placebo test dose IV infusion of 100mL 0.9% sodium chloride."
62192313|NCT02957955|EXPERIMENTAL|Interventional|Group 1. Usual care + High-Intensity Interval Training, Nutritional Workshop, Stress Management Course.
62192314|NCT02957955|NO_INTERVENTION|Non interventional|Group 2. Usual care. Patients are encouraged to remain physically active, although they do not participate in a regular structured exercise training program.
62192315|NCT06499389|EXPERIMENTAL|Intensive instrumental and early respiratory physiotherapy|Patients in this arm will receive instrumental and intensive respiratory physiotherapy strategy from inclusion to day 7, 3 times a day, before and after extubation. Instrumental physiotherapy will be protocolized and cough strength and efficacy of bronchial secretions clearance will be evaluated
62006546|NCT00599937|NO_INTERVENTION|ATRA ->Chemo|Patients 65 years of age with a WBC count less than 5,000 were randomized to receive the reference ATRA treatment of our previous trial (APL91 trial), ie, 45 mg/m2/d ATRA followed by CT or ATRA plus CT (ATRA+CT). In the ATRA followed byCT group, patients received 45 mg/m2/d ATRA orally until CR, with a maximum of 90 days. After CR achievement, they received a course of 60 mg/m2/d daunorubicin (DNR) for 3 days and 200 mg/m2/d AraC for 7 days (course I). However, course I was added to ATRA if the WBC count was increased to greater than 6,000, 10,000, or 15,000 by day 5, 10, and 15 of ATRA treatment, respectively, because, from our experience, patients were at risk of ATRA syndrome above those thresholds.
62006547|NCT00599937|EXPERIMENTAL|ATRA+CT|Patients randomized to the ATRA+CT group received the same combination of ATRA and CT, with course I of CT starting on day 3 of ATRA treatment. This 48-hour interval before onset of CT was based on our previous report, because it allowed correction of coagulopathy.
62006548|NCT00599937|NO_INTERVENTION|High WBC|Patients with a WBC count greater than 5,000 at presentation (irrespective of their age) and patients 66 to 75 years of age with a WBC count 5,000 were not randomized but received ATRA plus CT course I from day 1 (high WBC group) and the same schedule as in the ATRA-\>CT group (elderly group), respectively.
62006549|NCT00599937|NO_INTERVENTION|no maintenance|No maintenance
62006550|NCT00599937|EXPERIMENTAL|maintenance ATRA|Intermitent ATRA as maintenance
62006551|NCT00599937|EXPERIMENTAL|maintenance Cxt|continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally) as maintenance
62006552|NCT00599937|EXPERIMENTAL|maintenance both|continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally) AND ATRA as maintenance
62006553|NCT04841564|ACTIVE_COMPARATOR|ultrasound group|serratus anterior plane block will be done through ultrasound guidance
62006554|NCT04841564|EXPERIMENTAL|Open group|serratus anterior plane block will be done after mastectomy through the open wound
62006555|NCT04556305|EXPERIMENTAL|Mind - BrainHQ cognitive training intervention|The Mind intervention uses the evidence-based BrainHQ computerized cognitive training program. BrainHQ focuses on improving memory, attention, sensory function, and working memory, and has demonstrated efficacy in improving memory among healthy older adults and adults with heart failure. BrainHQ is tailored to the individual, and program difficulty automatically progresses based on performance. Training occurs during three 30-minute sessions per week, for a total of 36 hours. Participants will complete the BrainHQ program on an iPad tablet, which will be provided to them.
62006556|NCT04556305|EXPERIMENTAL|Move - lifestyle physical activity intervention|"The Move intervention is a 24-week evidence-based program based on social cognitive theory. It was originally developed for midlife women and successfully maintained increased physical activity. It has since been tailored for older women with CVD to prevent or delay cognitive decline, and includes: (1) education on the importance of lifestyle physical activity for brain health, (2) increasing lifestyle physical activity while considering CVD, and (3) including a goal for increasing Fitbit active minutes (≥ 3 METs or moderate-intensity physical activity) to ensure participants are obtaining the beneficial aerobic fitness effects during periods of lifestyle physical activity. Core elements include a personal lifestyle physical activity goal and five group meetings."
62397700|NCT02278042|ACTIVE_COMPARATOR|9% Fuctose|Milk Sweetened with fructose in an amount that the added fructose contributes 9% of the calories required for weight maintenance.
62192316|NCT06499389|ACTIVE_COMPARATOR|Protocolized standard-of-care respiratory physiotherapy|Patients in this group will receive standardized and protocolized respiratory physiotherapy, i.e. 1 to 2 sessions of manual respiratory physiotherapy (not assisted by an instrumental technique) per day until the day of successful extubation, or until day 7 if necessary.
62192317|NCT04578288|ACTIVE_COMPARATOR|Standard Blood Pressure management|The standard blood pressure management is maintenance of intraprocedural pre-recanalization SBP between 140-180 mmHg for all patients who receive endovascular thrombectomy for acute ischemic stroke in anterior circulation.
62192318|NCT04578288|EXPERIMENTAL|Individualized Blood Pressure management|The study intervention would be maintaining the intraprocedural pre-recanalization blood pressure in individualized SBP target ranges depending on the systolic blood pressure of the patient at presentation (=baseline SBP or bSBP).
62192319|NCT01177956|EXPERIMENTAL|Cetuximab + Cisplatin + 5-Fluorouracil (5-FU)|
62192320|NCT00746629|ACTIVE_COMPARATOR|Prescribed Skills|Behavioral skills are all prescribed and considered necessary tools expected to be used consistently, completely, and uniformly by all participants throughout treatment
62192321|NCT00746629|EXPERIMENTAL|Self-Directed Skills|Behavioral skills are considered a tool box from which families are encouraged to select skills that best apply to that family's situation in attempts to help their child make eating and activity change.
62397701|NCT02278042|ACTIVE_COMPARATOR|18% Sucrose|Milk Sweetened with sucrose in an amount that the added sucrose contributes 18% of the calories required for weight maintenance.
62397702|NCT02278042|ACTIVE_COMPARATOR|18% High fructose corn syrup|Milk Sweetened with High fructose corn syrup (HFCS) in an amount that the added HFCS contributes 18% of the calories required for weight maintenance.
62572947|NCT05047211|EXPERIMENTAL|IV Iron group|"Low molecular weight iron dextran (infed) 1000mg in sodium chloride 0.9% 500mL IV infusion over 1 hour preceded by test dose 25 mg IV low molecular weight iron dextran infusion in 100mL 0.9% sodium chloride.~Oral placebo will be given by mouth for a total of 6 weeks TID."
62572948|NCT01453270|EXPERIMENTAL|NICOM and PLR|A systematic approach to resuscitation started in the ED and using a step-wise approach to optimize cardiac preload, afterload, and contractility, thus optimizing oxygen delivery to the tissues will be applied to the intervention group using the Non-Invasive Cardiac Output Monitor (NICOM) and passive leg-raising (PLR) maneuver.
62781145|NCT00615030|EXPERIMENTAL|Indacaterol Morning,Indacaterol Evening, Salmeterol|In period I, indacaterol 300 μg once a day in the morning delivered via single dose dry powder inhaler (SDDPI) with a placebo to salmeterol delivered via dry powder inhaler (DPI). Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, Salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and second dose in the evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
62006557|NCT04556305|EXPERIMENTAL|MindMoves - cognitive training and lifestyle physical activity|Participants who are assigned to this condition will complete both the Move lifestyle physical activity program and the Mind BrainHQ cognitive training intervention simultaneously for 24 weeks (see Move and Mind descriptions). Participants will receive both a Fitbit and iPad tablet to complete the combined MindMoves intervention.
62192322|NCT00922415||cases|patients at least 18 years of age, with confirmed Crohn's disease undergoing intestinal resection for complicated Crohn's disease
62397703|NCT02278042|ACTIVE_COMPARATOR|9% Glucose|Milk Sweetened with glucose in an amount that the added glucose contributes 9% of the calories required for weight maintenance.
62397704|NCT02278042|ACTIVE_COMPARATOR|Unsweetened Milk|Unsweetened milk consumed in amount the contributes 18% of the calories required for weight maintenance.
62397705|NCT03313297|ACTIVE_COMPARATOR|AZD4017|400mg oral AZD4017 twice daily for 35 days
62397706|NCT03313297|PLACEBO_COMPARATOR|Placebo|A placebo tablet containing microcrystalline cellulose and sodium stearyl fumarate to match the active tablets in size, shape and colour.
62572949|NCT01453270|ACTIVE_COMPARATOR|Usual care|
62572950|NCT05627505||Pneumonia group|Patients in the MICU after lung transplantation were enrolled, and alveolar lavage fluid was obtained within 48 hours of the patient's surgery, divided into aliquots, and subjected to macrogenomic sequencing, routine microbiological testing and cytokine testing. Patients will be divided into pneumonia group if they had a co-infection at the time of sampling.
62006558|NCT04556305|NO_INTERVENTION|Usual Care|Participants in the usual care group do not receive any Mind- or Move-related intervention, and will receive their usual care from their cardiology provider.
62006559|NCT00767676|OTHER|1|
62192323|NCT06542939|EXPERIMENTAL|Community Health Workers (CHW) treatment group|There is a 6-month intervention period immediately following recruitment. Participants enrolled in the intervention will complete 5 educational sessions and attend 2 one-on-one virtual meetings.
62397707|NCT01546311||lower limb amputees|
62397708|NCT03730051|ACTIVE_COMPARATOR|Gadoterate meglumine contrast|0.2 mL/kg (0.1 mmol/kg) administered as a single IV bolus injection at a rate of 2 mL/second. The FDA-approved product labeling provides weight-adjusted dose volumes as follows: 30 kg: 6 mL; 40 kg: 8 mL; 50 kg: 10 mL; 60 kg: 12 mL; 70 kg: 14 mL; 80 kg: 16 mL; 90 kg: 18 mL; 100 kg: 20 mL; 110 kg: 22 mL; 120 kg: 24 mL; 130 kg: 26 mL; 140 kg: 28 mL; 150 kg: 30 mL.
62397709|NCT03730051|EXPERIMENTAL|Gadobutrol contrast|0.1 mL/kg (0.1 mmol/kg) administered as a single IV bolus injection by power injector. Imaging may begin after administration and then repeat sequentially to determine peak intensity and wash-out. The manufacturer provides weight-based dose volumes as follow: 35 kg: 3.5 mL; 40 kg: 4 mL; 45 kg: 4.5 mL; 50 kg: 5 mL; 60 kg: 6 mL; 70 kg: 7 mL; 80 kg: 8 mL; 90 kg: 9 mL; 100 kg: 10 mL; 110 kg: 11 mL; 120 kg: 12 mL; 130 kg: 13 mL; 140 kg: 14 mL.
62006560|NCT04587622|EXPERIMENTAL|Group 1 - Healthy subjects with normal hepatic function|Healthy subjects with normal hepatic function - Control
62006561|NCT04587622|EXPERIMENTAL|Group 2 - Mild Hepatic Impairment|Mild hepatic impairment: Child-Pugh A (Score 5-6)
62006562|NCT04587622|EXPERIMENTAL|Group 3 - Moderate Hepatic Impairment|Moderate hepatic impairment: Child-Pugh B (Score 7-9)
62006563|NCT04587622|EXPERIMENTAL|Group 4 - Severe Hepatic Impairment|Severe hepatic impairment: Child-Pugh C (Score 10-15)
62781146|NCT00615030|EXPERIMENTAL|Indacaterol Evening,Indacaterol Morning, Placebo|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
62006564|NCT06188416||Cases with CAI|Cases that reported previous experience of chronic ankle instability
62006565|NCT06188416||Cases without CAI|Cases that did not report any previous experience of chronic ankle instability
62006566|NCT03860896|EXPERIMENTAL|GB004|GB004 for oral administration daily
62006567|NCT03860896|PLACEBO_COMPARATOR|Placebo|Placebo for oral administration daily
62192324|NCT06542939|ACTIVE_COMPARATOR|Control group|The control participants will complete only the first educational session. The control arm will receive usual care from their primary care physician (PCP) during the first 12 months of data collection. After 12 months they will be invited to attend remaining group sessions.
62192325|NCT04058470|EXPERIMENTAL|TR follow by R-CHOP|"TR follow by R-CHOP:~TR: Toripalimab,Rituximab, R-CHOP: Rituximab, Cyclophosphamide,Doxorubicin,Vincristine,Prednisone"
62192326|NCT06447649||study group|We included stroke patients aged between 20 and 85. inclusion criteria for this study; having received a diagnosis of hemiplegia following a cerebrovascular accident (CVA), having experienced a first-time stroke, having unilaterally affected, having stage 3 or above Brunnstrom upper limb stage, not having any other neurological/orthopedic problems in addition to hemiplegia, not having any shoulder problems on the same side (affected side) before the stroke, scoring 25 or above on the Mini Mental Test.
62192327|NCT06009042|EXPERIMENTAL|IVIG 20g/d|Participants will receive IVIG (intravenous immunoglobulin) 20g/d for 6 days. They also receive conventional liquid therapy and symptomatic supportive treatment.
62006568|NCT05996250|OTHER|Immersive virtual reality task|"The immersive virtual reality task, specifically designed for this research, is an adaptation to humans of Morris Pool. The virtual environment is composed of a circular arena 22 virtual meters in diameter, delimited by a low wall. It features two visual landmarks and an invisible object to find. The activity includes a control training sequence, an evaluation sequence and a delayed recall performed approximately 20 minutes after the end of the evaluation sequence.~The immersive reality task is performed once by the participants (the study consists on one visit)."
62006569|NCT03113682|EXPERIMENTAL|Intervention (CBT-RD)|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-RD. There is no control group.
62006570|NCT02353481||Heart Failure|All patients in the audit that meets the eligibility criteria
62006571|NCT06531863|EXPERIMENTAL|Curcumin and EGCG Supplementation|Participants in the intervention group with consume 1,500mg/day curcumin with 300mg/day EGCG.
62006572|NCT06531863|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo to consume everyday.
62006573|NCT02468466|EXPERIMENTAL|Multi-level suicide prevention programs|The study team, including staff members from the intervention municipalities, provided each municipality with a standardized form of the work plan used in our study. The intervention municipality autonomously conducted the intervention program during the implementation period.
62006574|NCT02468466|ACTIVE_COMPARATOR|Community intervention as usual|Suicide prevention program as usual
62006575|NCT05493995|EXPERIMENTAL|Penpulimab+Anlotinib+Nab-paclitaxel+Gemcitabine|
62006576|NCT00170079|EXPERIMENTAL|Step care vs. regular care|Participants were randomized either to (1) Step care intervention, where smokers who failed to quit or who relapsed received increasingly intensive smoking cessation interventions; vs. (2) Regular care, where smokers who failed to quit or who relapsed received repeated intervention.
62006577|NCT03225794||Controls|Adults living in rural area of Cameroon, not infected with simian foamy viruses
62192328|NCT06009042|ACTIVE_COMPARATOR|IVIG 10g/d|Participants will receive IVIG (intravenous immunoglobulin) 10g/d for 6 days. They also receive conventional liquid therapy and symptomatic supportive treatment.
62214772|NCT06122844|NO_INTERVENTION|Waitlist control group|One kindergarten will be assigned to the waitlist control condition. Teachers in the waitlist control schools will wait for at least 12 weeks before they receive the training, and children in the waitlist control group will receive SEED curriculum after the teachers' training. Upon informed consent from the school principals and parents, parents, teachers, and children will also complete pre- and post-test assessments.
62006578|NCT03225794||Simian Foamy virus infection|Adults living in rural area of Cameroon, infected with simian foamy viruses
62006579|NCT03374826|EXPERIMENTAL|Dedicated axillary hybrid PET-MRI axilla|
62006580|NCT01015846|EXPERIMENTAL|Intervention|
62006581|NCT01015846|ACTIVE_COMPARATOR|Core stability exercise|Traditional core stability exercise
62192329|NCT01667809|ACTIVE_COMPARATOR|Cognitive Behavior Therapy|As the trial will include several different common subclinical mental disorders, the cognitive behavior therapy used in the study will be based on the protocols with best empirical support. Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
62006582|NCT04400097|EXPERIMENTAL|hidden-knot group|
62006583|NCT04400097|ACTIVE_COMPARATOR|two-knot group|
62006584|NCT04400097|ACTIVE_COMPARATOR|multi-knot group|
62192330|NCT01667809|EXPERIMENTAL|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
62781147|NCT00615030|EXPERIMENTAL|Salmeterol, Placebo, Indacaterol Morning|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose was in the evening along with placebo matching indacaterol delivered by SDDPI. In period II, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
62006585|NCT01035879|EXPERIMENTAL|MBX-2982 25 mg|
62006586|NCT01035879|EXPERIMENTAL|MBX-2982 100 mg|
62006587|NCT01035879|EXPERIMENTAL|MBX-2982 300 mg|
62006588|NCT01035879|ACTIVE_COMPARATOR|Sitagliptin 100 mg|
62006589|NCT01035879|PLACEBO_COMPARATOR|Placebo|
62006590|NCT03522376||Chronic obstructive pulmonary disease|Subjects with the diagnosis of chronic obstructive pulmonary disease, stable clinically, has no infection or acute exacerbation in the previous four weeks, and can cooperate with the measurements of this study, loaded inspiratory muscle test.
62006591|NCT04544449|EXPERIMENTAL|Fenebrutinib|Participants will receive oral fenebrutinib and intravenous (IV) ocrelizumab-matching placebo.
62006592|NCT04544449|ACTIVE_COMPARATOR|Ocrelizumab|Participants will receive intravenous (IV) ocrelizumab and oral fenebrutinib-matching placebo.
62006593|NCT01117727|EXPERIMENTAL|Pilot Testing|
62006594|NCT05649163||Cohort1|Cohort1: About 186 patients with histologically or cytologically confirmed gastric/gastroesophageal junction (GEJ) adenocarcinoma with HER2 overexpression who received a regimen containing Disitamab Vedotin;
62006595|NCT05649163||Cohort2|Cohort2: About 80 patients with histologically or cytologically confirmed HER2-overexpressed gastric cancer /GEJ adenocarcinoma who received an investigator-selected regimen in addition to Disitamab Vedotin;
62006596|NCT05649163||Cohort3|Cohort3: Approximately 40 patients with other advanced solid tumors histologically or cytologically confirmed with HER2-overexpression and receiving a regimen containing Disitamab Vedotin.
62006597|NCT05869227|EXPERIMENTAL|Capecitabine combined with toripalimab maintenance group|Capecitabine, 1000 mg/m2/dose, twice a day, days 1-14; 21 days/cycle toripalimab, 240mg, intravenously, day 1 and 21 days/cycle
62006598|NCT05869227|PLACEBO_COMPARATOR|Placebo combined with toripalimab maintenance group|Placebo, 1000 mg/m2/dose, twice a day, days 1-14; 21 days/cycle toripalimab, 240mg, intravenously, day 1 and 21 days/cycle
62006599|NCT01164852|NO_INTERVENTION|Expectant management|Expectant management: refers to pregnancy prolongation during which time women and fetuses are carefully monitored for indications for delivery.
62006600|NCT01164852|ACTIVE_COMPARATOR|Interventionist management|Interventionist management: in which blood pressure is stabilized, corticosteroids are given for acceleration of fetal maturity and delivery is planned within 48-72 hours.
62006601|NCT03240627|EXPERIMENTAL|LH-8 cutaneous solution|LH-8 cutaneous solution (0.126 mL per spray) applied to the whole scalp:
62006602|NCT03240627|PLACEBO_COMPARATOR|Placebo cutaneous solution|Placebo cutaneous solution (0.126 mL per spray) applied to the whole scalp:
62006603|NCT03191916|EXPERIMENTAL|Experimental group|The experimental group will receive 2 milliamps of anodal transcranial direct current stimulation for 20 minutes daily for 5 days.
62006604|NCT03191916|SHAM_COMPARATOR|Sham group|The sham group will be connected to the anodal transcranial direct current stimulation device daily for 5 days. During the 20 minute sessions, the participant will only receive stimulation for a 30-second ramp up period, at which point the stimulation will be discontinued for the remainder of the time.
62006605|NCT05596526|EXPERIMENTAL|MS patients on anti-CD20|Participants aged 18 and above will receive two doses of the recombinant Zoster vaccine (Shingrix®)
62006606|NCT05596526|EXPERIMENTAL|Healthy controls|Healthy participants aged 50 to 59 will receive two doses of the recombinant Zoster vaccine (Shingrix®)
62006607|NCT04991480|EXPERIMENTAL|Part A1|Part A1 will evaluate ART4215 monotherapy administered in 21 day cycles. Up to 90 participants will participate in this dose escalation arm.
62006608|NCT04991480|EXPERIMENTAL|Part A2|Part A2 will evaluate ART4215 given in combination with talazoparib in 21 day cycles. Up to 50 participants will participate in this dose escalation arm.
62006609|NCT04991480|EXPERIMENTAL|Part B1|In Part B1 dose expansion, up to 30 participants with solid cancers that have been treated with a PARP inhibitor for an approved indication will receive ART4215.
62006610|NCT04991480|EXPERIMENTAL|Part B2|In Part B2 dose expansion, up to 20 participants with solid cancers with characteristics indicative of sensitivity to pol theta inhibition will receive ART4215.
62006611|NCT04991480|EXPERIMENTAL|Part B3|In Part B3, approximately 120 participants with HER2 negative BRCA breast cancers will be randomized 1:1 to either ART4215 in combination with talazoparib or talazoparib alone.
62006612|NCT04991480|EXPERIMENTAL|Part A3|Part A3 will evaluate ART4215 given in combination with niraparib in 21-day cycles. Up to 30 participants will participate in this dose escalation arm.
62781148|NCT00615030|EXPERIMENTAL|Placebo, Salmeterol, Indacaterol Evening|In period I, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, salmeterol 50 μg twice daily delivered via dry powder inhaler (DPI). One of the two daily doses of salmeterol was administered in the morning and the second dose was in the evening along with placebo matching indacaterol delivered by SDDPI. In period III, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via dry DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
62781149|NCT00615030|EXPERIMENTAL|Indacaterol Morning, Placebo, Indacaterol Evening|In period I, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, During morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, Patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
62192331|NCT06456476||patints with obstructive jaundicep|The patients, clinically diagnosed as suffering from obstructive jaundice and referred to the Department of Internal Medicine for further evaluation.
62192332|NCT03339271|ACTIVE_COMPARATOR|Technology-Enhanced Group|Family caregivers will have daily visits from the study nurse while the patient is in the hospital and will receive weekly technology-enhanced support (video chats) from the study nurse for 8 weeks after the patient is discharged from the hospital.
62192333|NCT03339271|ACTIVE_COMPARATOR|Usual Care Group|Family caregivers will have usual care support from the doctors and nurses to plan for taking care of the patient upon return home and will receive a weekly telephone call for 8 weeks after the patient is discharged from the hospital.
62192334|NCT02403518|ACTIVE_COMPARATOR|Back Pain Only|Pain localized to the low back or buttocks.
62572951|NCT05627505||control group|Patients in the MICU after lung transplantation were enrolled, and alveolar lavage fluid was obtained within 48 hours of the patient's surgery, divided into aliquots, and subjected to macrogenomic sequencing, routine microbiological testing and cytokine testing. Patients will be divided into non-pulmonary infection （control）group if they had no co-infection at the time of sampling.
62781150|NCT00615030|EXPERIMENTAL|Indacaterol Evening,Salmeterol, Indacaterol Morning|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period II, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
62192335|NCT02403518|ACTIVE_COMPARATOR|Leg Pain Only|Pain localized to unilateral pain of the leg (thigh, knee, calf, or foot).
62192336|NCT02403518|ACTIVE_COMPARATOR|Back and Leg Pain|Pain localized to both the low back and legs (back, buttocks, thigh, knee, calf, or foot).
62192337|NCT02313389|EXPERIMENTAL|maintenance chemotherapy|"Clinical examination and MRI will be performed every 3 months for 2 years and then every 6 months until tumor progression.~Neurocognitive tests will be performed at randomization and annually. Quality of life questionnaires at randomisation and every 3 months"
62006613|NCT04053374||DMD treatment naive CIS or RRMS patients|Newly presenting Clinically Isolated Syndrome (CIS) or Relapsing and Remitting Multiple Sclerosis (RRMS) patients not treated before with Disease Modifying Drugs (DMD) Additional analysis of CSF and CSF cells will be performed in this cohort on a voluntary basis.
62006614|NCT04053374||Secondary Progressive Multiple Sclerosis (SPMS)|People with confirmed diagnosis of SPMS
62006615|NCT04053374||Primary Progressive Multiple Sclerosis (PPMS)|People with confirmed diagnosis of PPMS
62006616|NCT04053374||DMD-treated with stable disease|People with Multiple Sclerosis (MS) who are treated with DMD who have had stable disease symptoms for at least 3 months
62006617|NCT04053374||Disease controls|People who undergo lumbar puncture due to clinical suspicion of neurological condition, but brain Magnetic Resonance Imaging (MRI) and CSF examination exclude MS diagnosis.
62192338|NCT02313389|NO_INTERVENTION|observation|"Clinical examination and MRI will be performed every 3 months for 2 years and then every 6 months until tumor progression.~Neurocognitive tests will be performed at randomization and annually. Quality of life questionnaires at randomisation and every 3 months"
62397710|NCT03970603|ACTIVE_COMPARATOR|Early Weight-Bearing|Being directed to bear weight on the affected ankle two weeks from suture button fixation for syndesmotic disruption
62781151|NCT00615030|EXPERIMENTAL|Salmeterol, Indacaterol Evening, Placebo|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
62781152|NCT00615030|EXPERIMENTAL|Placebo, Indacaterol Morning, Salmeterol|In period I, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via dry powder inhaler DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
62006618|NCT04053374||Healthy donors|Age, sex and ethnicity matched healthy donors will also be recruited from university and hospital staff and patient friends after informed consent has been obtained. Healthy donors will be asked to provide a blood sample and demographic information but will NOT be asked to provide CSF samples.
62006619|NCT02471521|EXPERIMENTAL|Neuromuscular blocker|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed with after rocuronium administration in children while continuous gastric auscultation and abdominal sonography are performed.
62192339|NCT01275599|EXPERIMENTAL|Open-Label Arm|"The treatment period will include 3 phases:~* 14 day run-in period~* 7 day co-administration period~* 31 day follow-up period"
62397711|NCT03970603|ACTIVE_COMPARATOR|Delayed/Late Weight-Bearing|Being directed to bear weight on the affected ankle six weeks from suture button fixation for syndesmotic disruption
62397712|NCT06724172|EXPERIMENTAL|Self-Management|A self-management intervention through direct provision of social needs supports (grocery, physical activity, and transportation support) with self-directed behavior change tools and usual care.
62397713|NCT06724172|EXPERIMENTAL|Community-Based|A community-based intervention for active social needs referrals assistance with health coaching and active lifestyle intervention and usual care.
62192340|NCT05921669|EXPERIMENTAL|Experimental Group 1: The group in which breastfeeding training was given to mothers and fathers|"Face-to-face theoretical breastfeeding training and then practical training (breastfeeding techniques, burping, changing diapers, milking by hand or pump, etc.) will be given by the researcher to the mothers and fathers. This training is planned to take 30-45 minutes. Then, an additional 15-30 minutes of father-supported breastfeeding training will be given to fathers. At the end of the training, the Breastfeeding Booklet prepared by the researchers will be given to the parents."
62397714|NCT06724172|NO_INTERVENTION|Usual Care|Patients randomized to the usual care control group will not receive the study interventions. Instead, these patients will receive usual care which includes social needs screening in the clinical setting, targeted community service and program referrals, clinical decision support tools for social needs support in the electronic health record, and routine clinical care with provider-based lifestyle counseling.
62781153|NCT00615030|EXPERIMENTAL|Indacaterol Morning, Salmeterol, Placebo|In period I, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
62397715|NCT05672459|EXPERIMENTAL|Dose Escalation (Part 1) and Expansion (Part 2 )|Participants will receive IVS 3001 at the selected dose Participants will receive IVS 3001 at the recommended phase 2 dose
62781154|NCT00615030|EXPERIMENTAL|Indacaterol Evening, Placebo, Salmeterol|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via dry powder inhaler DPI. In period II, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
62397716|NCT04431856|EXPERIMENTAL|Immediate Condition|Participants in the Immediate Condition group will receive a total of 4 sessions of Unified Protocol for COVID-19 Parenting Stress (UP-COVID) intervention
62397717|NCT04431856|ACTIVE_COMPARATOR|Delayed Condition|Participants in the Delayed Condition group will receive the Self Help Guide (SHG) by the National Child Traumatic Stress Network (NCTSN). They will then receive the UP-COVID intervention following their week 6 assessment
62006620|NCT02471521|ACTIVE_COMPARATOR|Non-neuromuscular blocker|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed without rocuronium in children while continuous gastric auscultation and abdominal sonography are performed.
62572952|NCT03444428||Non Invasive Ventilation|"* Age, height, weight~* History and Physical Examination~* Evaluation of dyspnoea: mMRC, Borg scale (Seated-Supine)~* Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)~* Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5)~* 24h Blood Pressure monitor~* Spirometry - FEV1 and FVC~* Respiratory muscle strength - MIP, MEP, and SNIP~* Arterial Blood Gases~* Carotid-femoral pulse wave velocity~* Breath CO exhale"
62572953|NCT03444428||Without Non Invasive Ventilation|"Age, height, weight~* History and Physical Examination~* Evaluation of dyspnoea: mMRC, Borg scale (Seated-Supine)~* Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)~* Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5)~* 24h Blood Pressure monitor~* Spirometry - FEV1 and FVC~* Respiratory muscle strength - MIP, MEP, and SNIP~* Arterial Blood Gases~* Carotid-femoral pulse wave velocity~* Breath CO exhale"
62006621|NCT01427296|ACTIVE_COMPARATOR|OsmoPrep Tablets|
62192341|NCT05921669|EXPERIMENTAL|Experimental Group 2: The group in which breastfeeding training was given only to the mother|"Only mothers will receive face-to-face theoretical breastfeeding training followed by practical training (breastfeeding techniques, flatulence, changing diapers, milking by hand or pump, etc.). This training is planned to take 30-45 minutes. At the end of the training, mothers will be given a Breastfeeding Booklet prepared by the researchers."
62572954|NCT05185037||Caesarian Section Patient|Obstetric patient
62572955|NCT04901247||day 3|embryo grading and culture refreshment will be done 67-69 hours post insemination
62572956|NCT04901247||day 5|embryo grading and culture medium refreshment will be done 114-118 hours post insemination
62572957|NCT03549728|EXPERIMENTAL|Group A|Group A (N=44): women will receive intrauterine infusion of granulocyte colony-stimulating factor on the day of ovum-pick up during IVF cycle.
62572958|NCT03549728|PLACEBO_COMPARATOR|Group B|Group B (N=44): women will receive placebo intrauterine infusion of normal saline on the day of ovum-pick up during IVF cycle.
62781155|NCT00615030|EXPERIMENTAL|Salmeterol, Indacaterol Morning, Indacaterol Evening|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
62781156|NCT00615030|EXPERIMENTAL|Placebo, Indacaterol Evening, Indacaterol Morning|In period, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
62781157|NCT01891474|EXPERIMENTAL|U-health care|voice inception technique based U-healthcare service
62781158|NCT01891474|NO_INTERVENTION|control|conventional treatment
62781159|NCT03043651|EXPERIMENTAL|Oral treprostinil|Sustained-release tablets for TID administration
62781160|NCT05963997|EXPERIMENTAL|Cohort 1|Up to 6 evaluable participants will receive samuraciclib 240 mg in combination with elacestrant 300 mg in cycles of 28 days (Cycle 1 to 6), 56 days (Cycle 7 to 9) and up to 84 days (Cycles 10 onwards).
62006622|NCT01427296|ACTIVE_COMPARATOR|HalfLytely and Bisacodyl Tablet|
62006623|NCT03393611|EXPERIMENTAL|CPX-351 Salvage Therapy and Transplant|Subjects will receive CPX-351 salvage chemotherapy on Day -21, -19, and -17 as a bridge to allogeneic stem cell transplantation using a Fludarabine/Melphalan/rATG conditioning regimen and a haplo-cord graft.
62192342|NCT05921669|NO_INTERVENTION|Control Group: No intervention was made, group receiving routine hospital care)|No additional training will be given to this group by the researcher, apart from the trainings included in the routine procedures of the hospital.
62572959|NCT05664152|EXPERIMENTAL|MG1111|Participants will be administered subcutaneously with a single dose(0.5 mL dose) of the BARYCELA inj.(MG1111) on the upper arm (brachia lateral).
62572960|NCT05528796|EXPERIMENTAL|Pregnancies where the fetus has been diagnosed with NIHF|"The unit of analysis will be the proband, i.e. pregnancy/fetus affected with non-immune hydrops fetalis (NIHF).~Pregnant individuals receiving care at one of the participating sites whose fetus has been diagnosed with NIHF of unknown etiology will be eligible for recruitment and enrollment in this study. Biological fathers of the fetus with NIHF will also be enrolled when available in order to determine inheritance of fetal genetic variants when identified."
62781161|NCT05963997|EXPERIMENTAL|Cohort 2|Up to 6 evaluable participants will receive samuraciclib in combination with elacestrant at the SRC recommended dose (anticipated 360mg samuraciclib, 300 mg elacestrant) in cycles of 28 days (Cycle 1 to 6), 56 days (Cycle 7 to 9) and up to 84 days (Cycles 10 onward).
62006624|NCT03430752||Survivors of Childhood Solid Tumors|Survivors of Childhood Solid Tumors were invited to fill in a set of questionnaires.
62572961|NCT01288937|EXPERIMENTAL|Milnacipran|Patients will receive Milnacipran
62572962|NCT01288937|PLACEBO_COMPARATOR|Placebo|Patients will receive Placebo
62006625|NCT03430752||Survivors of Childhood Leukemia|Survivors of Childhood Leukemia were invited to fill in a set of questionnaires.
62192343|NCT00905034|EXPERIMENTAL|MOAD|Chemotherapy regimen of methotrexate, rituximab, vincristine, pegylated L-asparaginase and dexamethasone (MOAD).
62781162|NCT05963997|EXPERIMENTAL|Cohort 3|Up to 6 evaluable participants will receive samuraciclib in combination with elacestrant at the SRC recommended dose (anticipated 360mg samuraciclib, 400 mg elacestrant) in cycles of 28 days (Cycle 1 to 6), 56 days (Cycle 7 to 9) and up to 84 days (Cycles 10 onward).
62781163|NCT05963997|EXPERIMENTAL|Cohort 4 Expansion|Up to 30 evaluable participants will receive samuraciclib in combination with elacestrant at the SRC recommended dose (anticipated 360mg samuraciclib, 400 mg elacestrant) in cycles of 28 days (Cycle 1 to 6), 56 days (Cycle 7 to 9) and up to 84 days (Cycles 10 onward).
62781164|NCT00820716|EXPERIMENTAL|CA|Exercise training with alternate load
62781165|NCT00820716|ACTIVE_COMPARATOR|CC|Exercise training with constant load
62781166|NCT06128603||LPD group|Cases who had underwent laparoscopic pancreaticoduodenectomy
62781167|NCT02106494|EXPERIMENTAL|APF530 500 mg SC|APF530 500 mg (granisetron 10 mg) SC and ondansetron placebo IV (0.15 mg/kg) and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1 in association with HEC
62781168|NCT02106494|ACTIVE_COMPARATOR|ondansetron 0.15 mg/kg IV|Ondansetron 2 mg/mL solution to be administered at 0.15 mg/kg IV (up to a maximum of 16 mg) and APF530 placebo SC and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1
62781169|NCT06321770|EXPERIMENTAL|Bioactive collagen peptide|The active treatment group included 40 women who received the bioactive collagen peptide-based food supplement orally
62781170|NCT06321770|PLACEBO_COMPARATOR|Placebo|"Oral suspension and sealed in sachets that were identical in appearance and odor.~ingredients, which were also contained in the placebo, were 467 mg lemon flavour, 150 mg citric acid, 8.5 mg sucralose and 7.1 mg stevia (97%). The placebo did not contain any nutrients."
62781171|NCT02541734|EXPERIMENTAL|gelofusine and 111In-exendin 4 SPECT/CT|subjects will receive a gelofusine injection before the injection of the radiopharmaceutical (111In-exendin 4)
62006626|NCT00799617|ACTIVE_COMPARATOR|AndroGel® (testosterone gel)|The initial dose of AndroGel will be 5.0 g (containing 50 mg of testosterone) once a day. Participants will apply AndroGel once daily to the shoulders, abdomen or upper arms. The serum testosterone concentration will be measured monthly for the first three months, then at months 6, 9 and 12. If the testosterone concentration is not between 500 and 800 ng/dL at any time point, the dose will be either increased by increments of 1.25-2.5 g/day, up to a maximum of 15 g/day or decreased by increments of 1.25-3.75 ng/day. Participants will be taught how to apply the gel and they will be provided with written instructions and precautions. This information will be reviewed at each contact and visit.
62006627|NCT00799617|PLACEBO_COMPARATOR|Placebo gel|Placebo gel is identical to the testosterone gel and is supplied in an identical pump bottle container. It is applied to the shoulders, abdomen or upper arms once a day. Participants will be taught how to apply the gel and they will be provided with written instructions and precautions. This information will be reviewed at each contact and visit.
62006628|NCT00098839|EXPERIMENTAL|Reinduction Chemoimmunotherapy with Epratuzumab once weekly|Four weekly doses of epratuzumab (360 mg/m2/dose) IV days 1, 8, 15, 22. Also received vincristine sulfate, prednisone, pegaspargase, doxorubicin hydrochloride, dexrazoxane hydrochloride, etoposide, cyclophosphamide, filgrastim, high-dose (HD) methotrexate with Leucovorin calcium rescue, L-asparaginase, cytarabine, IT cytarabine, IT methotrexate (CNS-negative), Intrathecal triple therapy (ITT) (methotrexate, cytarabine, therapeutic hydrocortisone for CNS-positive) during the 3 blocks of reinduction therapy.
62006629|NCT00098839|EXPERIMENTAL|Reinduction Chemoimmunotherapy with Epratuzumab twice weekly|Eight 8 twice-weekly doses of epratuzumab (360 mg/m2/dose) IV days 1, 4, 8, 11, 15, 18, 22 \& 25. Also received vincristine sulfate, prednisone, pegaspargase, doxorubicin hydrochloride, dexrazoxane hydrochloride, etoposide, cyclophosphamide, filgrastim, high-dose (HD) methotrexate with Leucovorin calcium rescue, L-asparaginase, cytarabine, IT cytarabine, IT methotrexate (CNS-negative), Intrathecal triple therapy (ITT) (methotrexate, cytarabine, therapeutic hydrocortisone for CNS-positive) during the 3 blocks of reinduction therapy.
62006630|NCT02326142|EXPERIMENTAL|OBE001|
62006631|NCT02326142|PLACEBO_COMPARATOR|Placebo|
62006632|NCT01767792|EXPERIMENTAL|Bevacizumab|Follow participant for 2 years and assess hearing response rates
62192344|NCT06065137|EXPERIMENTAL|POH patients|incremental administration of investigated anesthetics up to full therapeutic dose in POH patients.
62781172|NCT02541734|PLACEBO_COMPARATOR|saline and 111In-exendin 4 SPECT/CT|As a control, subjects will receive an injection of saline before the injection of the radiopharmaceutical (111In-exendin 4)
62781173|NCT04522349|ACTIVE_COMPARATOR|Greifer then Axon-Hook|T0 + 2 weeks: evaluation with Greifer. T1 + 2 weeks: evaluation with Axon-Hook
62781174|NCT04522349|ACTIVE_COMPARATOR|Axon-Hook then Greifer|T0 + 2 weeks: evaluation with Axon-Hook. T1 + 2 weeks: evaluation with Greifer
62781175|NCT01906528|EXPERIMENTAL|Males vs females|Constant-rate IV infusions of Mivacurium, range 1.0 - 3 micro/kg/min, duration 150 - 180 min
62781176|NCT05541445|EXPERIMENTAL|Experimental arm|Immunotherapy combined with chemotherapy and radiotherapy
62781177|NCT00490074|EXPERIMENTAL|3 DNA-C + 1 NYVAC-C|
62781178|NCT00490074|ACTIVE_COMPARATOR|2 DNA-C + 2 NYVAC-C|
62006633|NCT02321865|EXPERIMENTAL|NPC-02|
62006634|NCT02690285|OTHER|Part 1: glutathione transferase zeta 1 (GSTZ1) haplotyping|The participants will have blood collection and cheek cell collection after signing the informed consent, to determine GSTZ1 haplotype.
62006635|NCT02690285|EXPERIMENTAL|Part 2: Dichloroacetate (DCA) Kinetics|Eight study participants will be administered oral Dichloroacetate (DCA) 25 mg/kg daily for 5 days. On the fifth day frequent blood samples will be obtain over the following 24 hours. Study participants will complete a DCA kinetic study on day 5, at the Clinical Research Clinic (CRC).
62192345|NCT03544645|ACTIVE_COMPARATOR|control group|"This group received a printed material brochure as an educational material"
62192346|NCT03544645|EXPERIMENTAL|intervention group|"This group received an audiovisual material video as an educational material"
62192347|NCT04467047|EXPERIMENTAL|Intervention|Intravenous 1\*10E6 MSCs/kg body weight Mesenchymal Stromal Cells infusion
62192348|NCT06270277|EXPERIMENTAL|Inflammatory bowel disease group|Adolescents with Inflammatory bowel diseases will be administered Pediatric Quality of Life Inventory (PedsQL) and Strengths and Difficulties Questionnaire (SDQ).
62192349|NCT06270277|ACTIVE_COMPARATOR|Control group|Adolescents without known diseases in same age group will be administered Pediatric Quality of Life Inventory (PedsQL) and Strengths and Difficulties Questionnaire (SDQ) as control group
62192350|NCT06202768||Main population|History of cesarean section Vertex singleton gestation At term (at least 37 weeks of gestation)
62192351|NCT04434001|EXPERIMENTAL|ZEPLAST|"In case of bleeding and:~* CT INTEM \> CT HEPTEM by 25% : give protamine 0.25 mg/kg;~* MCF FIBTEM \< 8 mm : give Fibrinogen Concentrate 30 mg/kg;~* CT EXTEM \> 100 s : give Prothrombin Complex Concentrate 20 mg/kg."
62006636|NCT00968175|ACTIVE_COMPARATOR|Group 1: CPN + analgesic therapy|Receives ultrasound guided celiac plexus neurolysis (CPN) in addition to standard analgesic therapy
62192352|NCT04434001|ACTIVE_COMPARATOR|Control|"In case of bleeding and:~* CT INTEM \> CT HEPTEM by 25% : give protamine 0.25 mg/kg;~* fibrinogen and/or thrombin generation deficiency : give FFP 10-20 ml/kg."
62192353|NCT05233709|OTHER|OTf + FeSO4|OTf + FeSO4 - This is the experimental arm where Ferrous sulfate will be given to the participants along with apo-Ovotransferrin, a potential iron absorption enhancer. They will be given as solutions that will be spread on bread with butter and honey, a breakfast meal.
62192354|NCT05233709|OTHER|Lf+ FeSO4|Lf + FeSO4 - This is the experimental arm where Ferrous sulfate will be given to the participants along with lactoferrin, a potential iron absorption enhancer. They will be given as solutions that will be spread on bread with butter and honey, a breakfast meal.
62572963|NCT01736644|PLACEBO_COMPARATOR|Electrocautery|Use of electrocautery in tourniquet and without tourniquet total knee replacement surgery.
62781179|NCT02620488|ACTIVE_COMPARATOR|Healthy Control|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
62192355|NCT05233709|OTHER|FeSO4|FeSO4 - This is the control arm where Ferrous sulfate will be given in the form of a solution that will be spread on bread with butter and honey, as a breakfast meal
62781180|NCT02620488|EXPERIMENTAL|Sickle Cell Disease|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
62192356|NCT00883298|EXPERIMENTAL|Open Label|temozolomide plus bevacizumab administered as open label single arm treatment
62397718|NCT00148109|ACTIVE_COMPARATOR|EGFR positive|The EGFR positive group will be conducted in a 2-stage minimax trial design to determine the rate of four-month progression free survival in this patient population treated with cetuximab
62397719|NCT00148109|ACTIVE_COMPARATOR|EGFR Negative|The EGFR negative group will help us explore the possibility of benefit of cetuximab in a patient whose tumor does not express or minimally expresses EGFR. If benefit in progression-free survival or in another surrogate such as tumor response or a molecular event is seen in this group it would provide rationale to study this group further in subsequent trials
62781181|NCT03779581|EXPERIMENTAL|Exercise Group|The experimental group received active self-correction exercises to restore movements in different planes as close as possible to physiologically normal.
62781182|NCT03779581|ACTIVE_COMPARATOR|Control Group|All patients were prescribed a spinal orthosis (TLSO) and got a preliminary evaluation for orthosis design and manufacturing based on the curve type categorization from Ross and Weiss during the first appointment (Rigo et al., 2010).
62781183|NCT02755896|OTHER|Arm 1 - 600 cGY x 5 fractions|Patients will receive 600 cGY x 5 fractions of radiation therapy over 5 consecutive days.
62781184|NCT02755896|OTHER|Arm 2 - 800 cGY x 3 fractions|Patients will receive 800 cGY x 3 fractions of radiation therapy every other day for 3 days.
62006637|NCT00968175|NO_INTERVENTION|Analgesic therapy alone|Will not receive ultrasound guided celiac plexus neurolysis (CPN); only standard analgesic therapy for pain management
62006638|NCT05219136|ACTIVE_COMPARATOR|Conventional Fasting Group|In this parallel group, subjects are performed a conventional fasting protocol which requires 6-8h fasting for solid, 2h for clear liquids.
62781185|NCT05100446|ACTIVE_COMPARATOR|Treatment with Pylera (r) + esomeprazole 40mg|
62572964|NCT01736644|ACTIVE_COMPARATOR|Bipolar Sealer Aquamantys|Use of bipolar sealer Aquamantys in tourniquet and tourniquetless total knee replacement surgical procedures.
62572965|NCT03346135|EXPERIMENTAL|Treatment (ASCT, melphalan, daratumumab)|Patients undergo standard of care ASCT with a conditioning regimen of melphalan. Beginning 60-120 days after ASCT, patients receive daratumumab IV every week for 8 weeks, every 2 weeks for 16 weeks, and then every 4 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
62192357|NCT05472103|EXPERIMENTAL|treatment|administration of Surgical ergonomics workshop
62192358|NCT05472103|NO_INTERVENTION|control|no intervention
62192359|NCT03404544|ACTIVE_COMPARATOR|Carbetocin bolus|Patients in this arm will receive both syringes : the 3 ml and the 10 ml. The carbetocin 100 mcg will be in the 3 ml syringe over 2 sec and the 10 ml syringe will contain only normal saline given as infusion over 10 min.
62781186|NCT05100446|ACTIVE_COMPARATOR|Treatment with high-dose amoxicillin + esomeprazole 40mg|
62006639|NCT05219136|EXPERIMENTAL|Modified Fasting Group|"In this test group, a new protocol of 4h fasting for rice porridge, 2h for clear liquids is applied to subjects.~The rice porridge is commercially available (New Rice Porridge®, Charm Kitchen Food Co., Ltd., Q/NBBD0001S). The volume is 300ml, with the energy as 105kJ per 100g, and it can be eaten after being heated or at room temperature."
62192360|NCT03404544|EXPERIMENTAL|Carbetocin infusion|Patients in this arm will receive both syringes : the 3 ml and the 10 ml. The carbetocin 100 mcg will be in the 10 ml syringe as an infusion over 10min and the 3 ml syringe will contain only normal saline given iv over 2 sec as a bolus.
62192361|NCT04264546|EXPERIMENTAL|Experimental Adult Group - High dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of high dosage investigational sIPV Intervention: Biological: one-dose regimen of high dosage investigational sIPV
62192362|NCT04264546|EXPERIMENTAL|Experimental Children Group - High dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of high dosage investigational sIPV Intervention: Biological: one-dose regimen of high dosage investigational sIPV
62397720|NCT05635110|EXPERIMENTAL|Part A|Participants will receive a single dose of VX-548 on Day 1 and a single dose of omeprazole once daily (qd) on Days 10 through Day 12. On Day 13, participants will receive omeprazole followed by VX-548 under fasted conditions.
62397721|NCT05635110|EXPERIMENTAL|Part B|Participants will receive a single dose of VX-548 on Day 1 followed by rifampin qd on Days 10 through Day 27. On Day 19, participants will be co-administered rifampin and VX-548 under fasted conditions.
62192363|NCT04264546|EXPERIMENTAL|Experimental Infant Group - High dosage|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of high dosage investigational sIPV Intervention: Biological: Three-dose regimen of high dosage investigational sIPV
62192364|NCT03243435||Native 1,5 Tesla breast MRI group|From all patients a 1,5 Tesla MRI of the breast will be obtained
62192365|NCT03267810|EXPERIMENTAL|Active TENS|Participants are given 30 minutes of TENS therapy twice a week for 8 weeks.
62397722|NCT03235674|EXPERIMENTAL|High-intensity stair climbing exercise|3 x 60 seconds of stair climbing, at a vigorous pace as described by rating of perceived exertion, separated by 60 seconds of rest. Subjects will complete supervised sessions 3 times/week for 2 weeks, and then continue unsupervised for the following 10 weeks.
62397723|NCT03235674|NO_INTERVENTION|standard cardiac rehabilitation exercise|Subjects will complete the traditional cardiac rehabilitation program, combination of aerobic and resistance exercise 2 times/week for 2 weeks, and then continue unsupervised for the following 10 weeks.
62397724|NCT06723210||Patients|The patients were assigned to the same group because the study´s design only demands to create one group of patients.
62397725|NCT03165227|EXPERIMENTAL|BI 685509 Dose 1|
62397726|NCT03165227|EXPERIMENTAL|BI 685509 Dose 2|
62397727|NCT03165227|EXPERIMENTAL|BI 685509 Dose 3|
62397728|NCT03165227|PLACEBO_COMPARATOR|Placebo|
62572966|NCT04601077|ACTIVE_COMPARATOR|Nitric Oxide|Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days
62572967|NCT04601077|PLACEBO_COMPARATOR|Placebo|Placebo of Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days
62397729|NCT05225701|EXPERIMENTAL|Transdiagnostic guided internet-delivered intervention with synchronous assistance|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules. The duration of the intervention program may vary between users; however, the participant will have access permits for a maximum period of 12 weeks. In order to monitor the participant's progress, each user will be assigned an advisor who will be health personnel (psychologists, social workers, and gerontologists) to get an a weekly personalized synchronous assistance and psychological counseling.
62572968|NCT01680536|EXPERIMENTAL|Maraviroc, darunavir, ritonavir|Single-arm,assessing cerebrospinal fluid inflammatory markers after addition of maraviroc to patients stable on monotherapy darunavir/ritonavir
62781187|NCT04897178||Fetuses with normal anatomy|Fetuses with normal anatomy scan who demonstrate no structural abnormalities of different systems (CNS, chest and heart, abdomen, skeletal system)
62781188|NCT04897178||Fetuses with abnormal anatomy|Fetuses with abnormal anatomy scan who demonstrate any structural abnormalities that can be detected with ultrasound
62006640|NCT00621426||Observation|Patients with end-stage renal disease (ESRD) treated with hemodialysis three (3) times per week for at least 3 continuous months
62006641|NCT03768739||CICU extubated patients|Participants will undergo a Fiberoptic Endoscopic Evaluation of Swallowing (FEES)
62192366|NCT03267810|SHAM_COMPARATOR|Sham TENS|Electrodes are placed on participants for 30 minutes twice a week for 8 weeks without TENS stimulation.
62397730|NCT05225701|ACTIVE_COMPARATOR|Transdiagnostic self-guided internet-delivered intervention|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules. The duration of the intervention program may vary between users; however, the participant will have access permits for a maximum period of 12 weeks. All modules are sequential, allowing the user to go step by step. This arm does not have personalized online assistance.
62781189|NCT04129892|EXPERIMENTAL|Course participants|Students that enroll in the Resilience-based course during their Bachelor of science or Bachelor of social studies.
62781190|NCT04129892|NO_INTERVENTION|Control group- no intervention|Students in their Bachelor of science or Bachelor of social studies that did not attend the course, but agreed to fill out the study questionnaires.
62781191|NCT04305561|OTHER|Ultrasound + Contrast-enhanced ultrasound|"Patients are offered a contrast-enhanced ultrasound (CEUS) examination in addition to conventional imaging. All included patients undergo both CEUS and conventional imaging, enabling them to act as their own controls.~Pilot study: 60 patients Main study: 112 patients"
62781192|NCT04305561|NO_INTERVENTION|Conventional imaging|"Dual-tracer 99mTechnetium-pertechnetate/ 99mTechnetium-sestamibi subtraction scintigraphy with single-photon emission computerised tomographic/CT fusion imaging (SPECT/CT) combined with conventional ultrasound.~Pilot study: 60 patients Main study: 112 patients"
62781193|NCT03052049|EXPERIMENTAL|Prostate Artery Embolization|There is only one arm of this study where patients receive Prostate Artery Embolization
62781194|NCT05393973|EXPERIMENTAL|Core stability exercises along with conventional physical therapy|Core stability exercises
62781195|NCT05393973|EXPERIMENTAL|Swiss ball exercises along with the conventional physical therapy protocol|Swiss ball exercises
62192367|NCT02400008|EXPERIMENTAL|Patient with bilateral vocal fold paralysis|Patient with bilateral vocal fold paralysis in a closure position between 6 months to 36 months before et who has been treated by endoscopic treatment without satisfying result (voice or breathing).
62192368|NCT02882997|EXPERIMENTAL|Duck Duck Punch|"Community dwelling stroke survivors: Stroke survivors will install an interactive computer game in their home. Subjects will be instructed to play the computer game as much as you want to every day for 7 days. Inpatient stroke patients: The interactive computer game will be installed at a local inpatient stroke rehabilitation hospital. Subjects will be instructed to play this game as much as you want to during non-therapy hours (evenings and weekends) over the next 7 days."
62192369|NCT02882997|ACTIVE_COMPARATOR|Standard activities|"Community dwelling stroke survivors: Subjects will receive a hard-copy handout of an arm home exercise program and given the instructions to do these exercises as many times as you can daily. Inpatient stroke patients: Subjects will be encouraged to participate in standard evening/weekend recreational activities and to remember to use the paretic arm as much as you can."
62397731|NCT05225701|NO_INTERVENTION|waiting list|Participants on the waiting list will be assigned to the intervention after 2 months after randomization and will join the Transdiagnostic guided internet-delivered intervention with synchronous assistance.
62781196|NCT03970291|EXPERIMENTAL|Nociceptive-Level (NOL)|Analgesic component of anesthesia (fentanyl) will be guided using NOL
62781197|NCT03970291|NO_INTERVENTION|Standard Clinical Care (SCC)|Standard Clinical Care guided fentanyl administration
62781198|NCT01513122|ACTIVE_COMPARATOR|Arm 1. Lopinavir / ritonavir + 2-3N(t)RTI|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3N(t)RTI
62781199|NCT01513122|ACTIVE_COMPARATOR|Arm 2. Lopinavir /ritonavir + raltegravir|
62781200|NCT06572852||Cases with both endometriosis and adenomyosis|100 women diagnosed with both endometriosis and adenomyosis (cases). These participants are part of couples seeking fertility treatment at Assisted Reproduction Centers. The diagnosis of both endometriosis and adenomyosis will be made through ultrasound imaging at the IVF centers. The recruitment involves the collection of blood for genetic and epigenetic analysis, and acquiring ultrasound images for machine learning analysis.
62781201|NCT06572852||Cases with only endometriosis|15 women diagnosed exclusively with endometriosis (cases): This subgroup consists of women who have been diagnosed with endometriosis but show no ultrasound evidence of adenomyosis. The recruitment involves the collection of blood for genetic and epigenetic analysis, acquiring ultrasound images for machine learning analysis, and collecting uterine fluid samples to study gene expression profiles through uterine fluid extracellular vesicles (UF-EVs).
62781202|NCT06572852||Cases with only adenomyosis|15 women diagnosed exclusively with adenomyosis (cases): This subgroup includes women diagnosed solely with adenomyosis, without any ultrasonographic signs of endometriosis. The recruitment involves the collection of blood for genetic and epigenetic analysis, acquiring ultrasound images for machine learning analysis, and collecting uterine fluid samples to study gene expression profiles through uterine fluid extracellular vesicles (UF-EVs).
62781203|NCT06572852||Controls|400 women from couples seeking fertility treatment at infertility clinics (controls): These participants, who will be part of couples attempting to conceive, will be actively seeking treatment for infertility or other gynecological symptoms. Crucially, these individuals will have undergone ultrasound screenings that have excluded the presence of endometriosis or adenomyosis. The recruitment involves the collection of blood for genetic and epigenetic analysis, and acquiring ultrasound images for machine learning analysis.
62781204|NCT06572852||Cases of endometriosis with pre-existing genotyping data|This group will consist of 300 DNA biobanked samples from women diagnosed with endometriosis. These samples come with pre-existing genotyping data, which will be integrated into the study to provide a robust genetic baseline for comparative analyses.
62006642|NCT05731934|EXPERIMENTAL|HX301|Study treatment: during each cycle (28 days), HX301 is dosed QD for 3 weeks (21 days) followed by 1 week (7 days) off therapy.
62006643|NCT05411510|EXPERIMENTAL|Densah bur|According to the protocol for densah burs. The direction was reversed and the cutting speed was raised to 1200 rpm after the initial perforation close to the sinus floor. After that, two densifying burs were used in succession to elevate the sinus membrane by 2 mm and prepare the implant hole to the desired implant size.
62006644|NCT05411510|ACTIVE_COMPARATOR|Ostetome|Flat end osteotome of appropriate size will be introduced through the osteotomy to infracture the floor of the sinus by light malleting.
62192370|NCT02264262|EXPERIMENTAL|Sympathetic nerve activity|Healthy volunteers will undergo microneurography, and non invasive sympathetic nerve activity by EKG analysis at baseline and in response to stress.
62397732|NCT03234023|ACTIVE_COMPARATOR|INTERVENTION GROUP|The participants of this group will follow recommendations of food, physical exercise, control of consumption of drugs and consumption of alcohol and tobacco.
62397733|NCT03234023|NO_INTERVENTION|CONTROL GROUP|The participants of this group are submitted to the standard intervention.
62397734|NCT05697445|EXPERIMENTAL|Cranial Mobilization and Exercises Group|
62397735|NCT05697445|ACTIVE_COMPARATOR|Exercises Group|
62781205|NCT00082199|ACTIVE_COMPARATOR|A1|
62006645|NCT05197049|EXPERIMENTAL|Group 1: Guselkumab|Participants will receive guselkumab (Dose 1) injection subcutaneously followed by guselkumab (Dose 2) injection subcutaneously.
62006646|NCT05197049|EXPERIMENTAL|Group 2: Guselkumab|Participants will receive guselkumab (Dose 1) injection subcutaneously followed by guselkumab (Dose 3) injection subcutaneously.
62006647|NCT05197049|PLACEBO_COMPARATOR|Group 3: Placebo|Participants will receive placebo injection subcutaneously.
62781206|NCT00082199|PLACEBO_COMPARATOR|A2|
62006648|NCT02432716|EXPERIMENTAL|Insulin (glulisine), then Placebo|Participants first receive one dose of Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril). After a washout period of 2 weeks, they then received one dose of placebo, Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril).
62006649|NCT02432716|EXPERIMENTAL|Placebo, then Insulin (glulisine)|Participants first receive one dose of placebo, Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril). After a washout period of 2 weeks, they then received one dose of Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril).
62192371|NCT02466698|EXPERIMENTAL|Intestinal Lavage|A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
62192372|NCT02466698|ACTIVE_COMPARATOR|Usual Care|Patients will receive usual care for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The usual care group will receive the same antibiotic doses as the experimental arm of the study. For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
62192373|NCT00913523|EXPERIMENTAL|Tampon with GML|Regular and Super Tampon with GML added to the cover
62192374|NCT00913523|SHAM_COMPARATOR|Tampon without GML|Regular and Super Tampon without GML
62192375|NCT00913523|SHAM_COMPARATOR|Tampon Normally Used|Type and Size of Tampon Normally Used by Subjects
62192376|NCT06030869||Cohort-A: Patients with actionable targets|In the OncoKB(Precision Oncology Knowledge Base) database, the gene alteration has a variant of clinical evidence in this tumor or other tumor types and is considered to be an interventional variant. Cohort-A may include different observation subgroups. For example, substudy-A1: monotherapy/combination therapy for patients with A1-relative. Substudy-Ax: monotherapy/combination therapy for patients with Ax-relative.
62397736|NCT02931331||Observational|Patients undergoing standard of care (PET stress testing followed by mechanical revascularization) are undergoing an additional PET stress test to determine the impact of revascularization.
62781207|NCT05768984|EXPERIMENTAL|Experimental group|Empowerment program will be implemented.
62781208|NCT05768984|NO_INTERVENTION|Control group|No program will be implemented.
62397737|NCT04255433|EXPERIMENTAL|Tirzepatide|Tirzepatide administered subcutaneously (SC) once a week.
62006650|NCT05552313|EXPERIMENTAL|kinesio taping with thoracic manipulation and conventional treatment|experimental group will be given kinesio taping with thoracic manipulation and conventional treatment
62781209|NCT00724633|OTHER|1|standard dialysate Na 140 mEq/L
62781210|NCT00724633|ACTIVE_COMPARATOR|2|dialysate sodium equal to patient's predialysis serum Na
62006651|NCT05552313|SHAM_COMPARATOR|sham kinesio taping with thoracic manipulation and conventional treatment|control group will be given sham kinesio taping with thoracic manipulation and conventional treatment
62006652|NCT05236309||JGF (Jing-Guan-Fang): Traditional Chinese Medicine Decoction|JGF group: 100ml JGF decoction per day at least 1 week
62006653|NCT05236309||NO JGF|NO JGF group: None use traditional Chinese medicine(JGF)
62397738|NCT04255433|ACTIVE_COMPARATOR|Dulaglutide|Dulaglutide administered SC once a week.
62781211|NCT00724633|ACTIVE_COMPARATOR|3|dialysate sodium lower than patient's predialysis plasma sodium
62781212|NCT06551259|EXPERIMENTAL|Intervention group: dexmedetomidine|Intravenous infusion of 0.6μg/kg load dose of dexmedetomidine within 10 minutes after intubation, followed by continuous infusion at a rate of 0.4 μg/kg/h until 30 minutes before the end of surgery
62781213|NCT06551259|PLACEBO_COMPARATOR|Control group|Provide equal volume of physiological saline
62781214|NCT03549715|EXPERIMENTAL|ARM A: durvalumab + ddMVAC|Durvalumab + ddMVAC Durvalumab 1500 mg IV D1 every 28 days Durvalumab will be administered at the hospital every 28 days prior to administration of ddMVAC on D1.
62781215|NCT03549715|EXPERIMENTAL|ARM B: durvalumab + tremelimumab+ ddMVAC|"durvalumab + tremelimumab + ddMVAC Tremelimumab 75 mg IV D1 every 28 days Tremelimumab will be administered first, with durvalumab infusion starting approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion.~Infusion of ddMVAC will start approximately 1 hour after completion of durvalumab."
62006654|NCT03916627|EXPERIMENTAL|Cohort A1|Cemiplimab prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC) Not open for accrual
62006655|NCT03916627|EXPERIMENTAL|Cohort A2|Cemiplimab and platinum doublet prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC) Not open for accrual
62006656|NCT03916627|EXPERIMENTAL|Cohort A3|Platinum doublet prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC) Not open for accrual
62006657|NCT03916627|EXPERIMENTAL|Cohort B|Cemiplimab prior to surgery; cemiplimab post surgery (HCC)
62006658|NCT03916627|EXPERIMENTAL|Cohort C|Cemiplimab prior to surgery; standard of care radiation and/or chemotherapy followed by cemiplimab post surgery (HNSCC) Not open for accrual
62006659|NCT03916627|EXPERIMENTAL|Cohort B2|SBRT 8 Gy X 3 fractions followed by cemiplimab prior to surgery; cemiplimab post surgery (HCC)
62006660|NCT03916627|EXPERIMENTAL|Cohort B3|Cemiplimab and fianlimab before and after surgery (HCC)
62214773|NCT04203459||Pancreatic cancer patient|(1) patients with pancreatic cancer confirmed by imaging, pathology and body fluid biopsy, or patients who recovered well one month after operation but still had residual lesions, recurrence or metastasis. ② age ≥ 30 and ≤ 75. ③ no chemotherapy, radiotherapy or targeted drugs were used before admission. ④ patients who had used immunosuppressive drugs, hormones, antibiotics and probiotics one month before admission were excluded. ⑤ patients with HIV positive and active hepatitis B or C infection were excluded. ⑥ exclude the previous history of other malignant tumors or the current combination of other malignant tumors. The patients with serious cardiopulmonary disease and liver and kidney dysfunction were excluded. ⑧ patients with obstructive jaundice were excluded.
62781216|NCT01962870|PLACEBO_COMPARATOR|Placebo|Placebo Nasal Spray
62781217|NCT01962870|ACTIVE_COMPARATOR|Vasopressin|Vasopressin Nasal Spray
62006661|NCT06409624||Pulmonary hypertension|Patients with diagnosed PH by right heart catheterization with or without PH-specific treatment
62006662|NCT06409624||No pulmonary hypertension|Patients in whom PH was excluded by right heart catheterization
62006663|NCT02037711|ACTIVE_COMPARATOR|Chirocaine group (levobupivacaine )|
62006664|NCT02037711|SHAM_COMPARATOR|Control group|
62006665|NCT04537806|PLACEBO_COMPARATOR|Placebo|Participants receiving mechanical ventilation as standard of care were randomized to receive a 60-hour single continuous intravenous (IV) infusion of brexanolone-matching placebo.
62006666|NCT04537806|EXPERIMENTAL|Brexanolone|Participants receiving mechanical ventilation as standard of care were randomized to receive a 60-hour single continuous IV infusion of brexanolone at 70 micrograms per kilogram per hour (mcg/kg/h) for 58 hours followed by a 2-hour taper of brexanolone at 35 mcg/kg/h.
62006667|NCT00820924|EXPERIMENTAL|LAPATINIB|LAPATINIB 1500MG ORAL ONCE DAILY
62006668|NCT03748940|PLACEBO_COMPARATOR|Part A: Placebo|Placebo administered subcutaneously (SC)
62006669|NCT03748940|EXPERIMENTAL|Part A: LY3074828|LY3074828 administered SC
62006670|NCT03748940|PLACEBO_COMPARATOR|Part B: Placebo|Placebo administered SC
62006671|NCT03748940|EXPERIMENTAL|Part B: LY3074828|LY3074828 administered SC
62006672|NCT03748940|EXPERIMENTAL|Part B: LY900021|LY900021 (LY3074828 + LY9999QS) administered SC
62781218|NCT01805037|EXPERIMENTAL|Treatment (brentuximab vedotin, rituximab)|"INDUCTION: Patients receive brentuximab vedotin IV over 30 minutes once weekly for 3 weeks and rituximab IV once weekly for 4 weeks. Patients unable to achieve CR may receive additional optional consolidation therapy identical to induction therapy.~MAINTENANCE THERAPY: Patients receive brentuximab vedotin IV once every 3 weeks and rituximab IV once every 6 weeks. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
62781219|NCT00999518|EXPERIMENTAL|Group 1|
62781220|NCT00999518|EXPERIMENTAL|Group 2|
62781221|NCT00999518|EXPERIMENTAL|Group 3|
62781222|NCT00999518|EXPERIMENTAL|Group 4|
62781223|NCT00999518|PLACEBO_COMPARATOR|Group 5|
62781224|NCT05887531|EXPERIMENTAL|Prehabilitation|
62781225|NCT02940639||Cohort 1|Participants with advanced/metastatic renal cell cancer (RCC) starting nivolumab monotherapy after prior therapy
62192377|NCT06030869||Cohort-B: Patients with potential actionable targets|In cohort-B, the gene alteration that MTB combines with clinical practice and literature reports that can match targeted therapy is considered to be potential actionable targets. Cohort-B also includes different observation subgroups and clinical trials may conduct in each subgroup. For example, substudy-B1(TP53 as driver gene), substudy-B2(RAS as driver gene), substudy-B3(MAP2K1 as driver gene), substudy-B4(PTEN Loss as driver gene), substudy-B5(11q13 co-amplification as driver genes), Substudy-B6(concomitant actionable alterations), substudy-B7(other driver genes). MTB-guided therapy was defined as having a clinical benefit if the PFS ratio between the longest PFS on MTB-guided therapy and the PFS on the last therapy before MTB-guided therapy was ≥1.3 (i.e., using patients as their own controls) for each substudy. To meet the primary objective, at least 35% of participants had to achieve a PF2S/PFS1 ≥ 1.3 in a sample population of 25 evaluable patients.
62192378|NCT06030869||Cohort-C: Patients with non-actionable targets|MTB combined with clinical practice and literature reports can not match the gene alteration of targeted therapy, which is considered as an irreversible gene alteration.
62192379|NCT05646147|OTHER|Diagnostic Cohort Study|All patients will underwent full diagnostic testing.
62192380|NCT02497846|EXPERIMENTAL|TEOSYAL® PureSense Redensity [I]/MicronJet®|"injection of the acid hyaluronic gel with lidocaine as an anesthetic and a dermo-restructuring complex (including 8 amino acids , 3 antioxidants Acid, vitamin B6 and 2 minerals).~Product will be injected in a unique device group:~* in crow's feet in order to cover the zone to be treated. Quantity of product injected will be determined by the injector and noted (up to 1 ml by side). A subject can be injected in the left or/and right side.~* using a MicronJet microneedle for the superficial wrinkles."
62192381|NCT05559632|ACTIVE_COMPARATOR|conventional drilling group|drilling the other contralateral sites of bone using the conventional sequential drilling system according to the manufactural instruction.
62192382|NCT05559632|EXPERIMENTAL|osseodensification drilling group|bone preparation was performed using tapered multifluted burs (Densah Bur; Versah, MI, USA) at 800- 1200 rpm counterclockwise rotation under saline irrigation. Drilling to the desired depth using the tapered densah pilot drill with speed of 800-1200 rpm with copious irrigation without any lateral pressure with clock wise motion.
62192383|NCT02227797|EXPERIMENTAL|Voriconazole|
62192384|NCT03723577|EXPERIMENTAL|Fibrillar Collagen Powder Dressing|
62192385|NCT00815113||1|First degree relative of gastric cancer patient
62192386|NCT00815113||2|Consecutive gastro-esophageal reflux patients
62192387|NCT00312585|EXPERIMENTAL|Acupuncture|
62192388|NCT00312585|SHAM_COMPARATOR|Sham Acupuncture|
62192389|NCT00312585|NO_INTERVENTION|Usual care only|
62192390|NCT03795168|EXPERIMENTAL|Transcranial vibrating system effect|"Participants will be enrolled for a 4 week period and will have 2 vestibular physical therapy (PT) visits per week. During the first 2 weeks (4 visits), 20 participants will perform their PT exercises (30 minutes or less if the participant is too dizzy to finish) wearing the transcranial vibration system (TCVS) and the other 20 participants without. The following 2 consecutive weeks (4 visits), participants will perform their PT exercises wearing the TCVS if they weren't previously, or won't wear the device during their PT exercises if they were previously.~Outcomes measured:~* at every visit: dizziness at the end of PT exercise (with dizziness symptom scale DSS); duration of PT exercise~* at the first and last visit: force plate system assessment (balance)"
62781226|NCT02940639||Cohort 2|Participants with advanced/metastatic RCC starting 1st line therapy with nivolumab and ipilimumab combination therapy, in intermediate/poor risk participants
62397739|NCT05299060|ACTIVE_COMPARATOR|Control|After cannulation of a midline catheter or peripherally inserted central venous catheter with modified micro-Seldinger technique, the control group underwent standard care.
62781227|NCT05133661||HPV positive women|"Women aged 25-49 years seeking offered HPV testing (either self-collection or clinician collection of samples) and treatment of precancerous lesions as part of service package in study facilities will be enrolled in the study and interviewed at different time points.~A subset of the women screened will be selected for in-depth interview to gather data on: ease of use of self-collection kits for cervical cancer screening, receipt of the test results, and treatment for precancer. Another subset of women will be selected after HPV screening to participate in client exit interview."
62781228|NCT06101277|EXPERIMENTAL|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
62781229|NCT01955538|ACTIVE_COMPARATOR|Control|Psychiatric treatment as usual for 6 months according to best clinical practice: 10 consultations with a medical doctor (medication and psycho-education) as well as 16 consultations with a psychologist.
62214774|NCT04203459||Healthy person|(1) no history of digestive tract diseases, infectious diseases or immune diseases.(2) no history of smoking or drinking.(3) did not take antibiotics and other drugs and probiotics for 1 month before enrollment.
62214775|NCT00379288|EXPERIMENTAL|MF/F 200/10 mcg BID|
62214776|NCT00379288|EXPERIMENTAL|MF/F 400/10 mcg BID|
62006673|NCT02443376||Hemodialysis patients|Stable end-stage renal disease patients on maintenance conventional hemodialysis received 4-5 hours of treatment thrice weekly. Pulse wave velocity and central aortic pressure was measured before and after the midweek dialysis session.Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM) was measured before the midweek dialysis session just after Complior device
62006674|NCT02443376||Healthy subjects|Medical staff: medical doctors, nurses
62006675|NCT06277934|EXPERIMENTAL|RGT001-075 Group|Patients will receive once daily dose of study drug for a total of 12 weeks
62006676|NCT06277934|PLACEBO_COMPARATOR|Placebo Group|Patients will receive once daily dose of matching placebo for a total of 12 weeks
62006677|NCT05052229|PLACEBO_COMPARATOR|Placebo|Inhaled medical grade normoxic gas (FiO2 = 0.21; DIN 02238755 Air Liquide Healthcare, Montreal, Quebec, Canada).
62006678|NCT05052229|ACTIVE_COMPARATOR|Nitric Oxide|Inhaled 40 ppm nitric oxide from a KINOX gas cylinder system (Air Liquid Healthcare, Montreal, Quebec, Canada; DIN 02451328).
62192391|NCT03795168|SHAM_COMPARATOR|Vs transcranial vibrating system sham|"40 participants will be enrolled for a 4 week period and will have 2 vestibular physical therapy (PT) visits per week. Participants will perform their PT exercises (30 minutes or less if the participant is too dizzy to finish) wearing the transcranial vibration system (TCVS) at optimal vibrating frequency or wearing the TCVS at irrelevant vibrating frequency (sham). The TCVS and TCVS sham will be labeled A or B by the sponsor. The investigators and participants will not know which TCVS is optimal or sham. The sponsor will randomly assign participants TCVS A or B.~Outcomes measured:~* at every visit: dizziness at the end of PT exercise (with dizziness symptom scale DSS); duration of PT exercise~* at the first and last visit: force plate system assessment (balance)"
62006679|NCT03466034||Endometriod|Type I (endometrioid and mucinous carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.
62006680|NCT03466034||Serous|Type II (serous and clear cell carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.
62006681|NCT02825511||A cohort of basal cell carcinoma|A cohort of surgically treated BCC, primitive clinically suspected or previously biopsied on a 4-month period, an expected number of 3 200 cases. The management of the BCC will be consistent with current recommendations. BCC recurrence and those who received prior medical treatment will be excluded.
62006682|NCT03087279|EXPERIMENTAL|Texas I-CAN Active Math Lessons|Texas I-CAN Active math lesson in academic classroom
62006683|NCT03087279|EXPERIMENTAL|Texas I-CAN Active Language Arts Lessons|Texas I-CAN Active language arts lessons in academic classroom
62006684|NCT03087279|NO_INTERVENTION|Control|Regular, Sedentary academic lessons in math and language arts
62192392|NCT03432468|ACTIVE_COMPARATOR|postmenopausal hypertensive women|
62397740|NCT05299060|EXPERIMENTAL|Intervention|After cannulation of a midline catheter or peripherally inserted central venous catheter with a modified micro-Seldinger technique, the intervention group underwent the standard treatment plus application of cyanoacrylate tissue adhesive (SecurePortIV®) at the puncture site.
62781230|NCT01955538|EXPERIMENTAL|Basic Body Awareness Therapy|Standard psychiatric treatment + Basic Body Awareness Therapy for 20 weeks, 1 hour/week.
62781231|NCT01955538|EXPERIMENTAL|Mixed physical activity|Standard psychiatric treatment + Mixed physical activity for 20 weeks, 1 hour/week.
62006685|NCT01406691|EXPERIMENTAL|Light|one hour of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during hour immediately prior to desired waketime
62006686|NCT01406691|PLACEBO_COMPARATOR|Fake light|during hour immediately prior to desired waketime, subjects will receive one light flash (insufficient to cause phase shift)
62006687|NCT03359733|EXPERIMENTAL|TAK-659 100 mg Fasted + TAK-659 100 mg Fed|TAK-659 100 milligram (mg), tablet, orally under fasted state, once on Day 1, followed by TAK-659 100 mg, tablet, orally under fed state, once on Day 8 of a 15-day food effect treatment period.
62006688|NCT03359733|EXPERIMENTAL|TAK-659 100 mg Fed + TAK-659 100 mg Fasted|TAK-659 100 mg, tablet, orally under fed state, once on Day 1, followed by TAK-659 100 mg, tablet, orally under fasted state, once on Day 8 of a 15-day food effect treatment period.
62006689|NCT02611167|EXPERIMENTAL|Bone marrow-derived MSC transplantation (1 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
62006690|NCT02611167|EXPERIMENTAL|Bone marrow-derived MSC transplantation (3 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
62781232|NCT03771274|EXPERIMENTAL|Tecnis ZLB00 & Symfony IOL|The Tecnis multifocal ZLB00 and the Symfony IOLs are presbyopia correcting lenses designed to improve the vision at distance, intermediate and near reducing the need for glasses in patients undergoing cataract surgery.
62781233|NCT02283788|EXPERIMENTAL|Treatment Sequence ABCD|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
62781234|NCT02283788|EXPERIMENTAL|Treatment Sequence BDAC|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
62192393|NCT03432468|PLACEBO_COMPARATOR|age-matched hypertensive male patients|
62192394|NCT04042753|EXPERIMENTAL|Pituitary Cancer|Participants will have a pituitary adenoma/carcinoma of any histology
62192395|NCT03922152|EXPERIMENTAL|Short course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation and 2D-technique.
62192396|NCT02232399|ACTIVE_COMPARATOR|Milrinone|In this arm the patients will receive Milrinone as an inotrope agent. Concentration: 0.2 mg/mL Infusion rate: 0.12 mL / kg / hr = Dose delivered 0.4 μg / kg / min --- Bolus dose: 1.44 ml / kg / hr in ten minutes (a maximum volume 0.24 ml / kg) = 48 μg / kg
62214777|NCT00379288|ACTIVE_COMPARATOR|F/SC 250/50 mcg BID|
62214778|NCT00379288|ACTIVE_COMPARATOR|F/SC 500/50 mcg BID|
62397741|NCT02184312|EXPERIMENTAL|Nevirapine XR low dose|
62397742|NCT02184312|EXPERIMENTAL|Nevirapine XR medium dose|
62397743|NCT02184312|ACTIVE_COMPARATOR|Nevirapine XR high dose|
62397744|NCT02184312|ACTIVE_COMPARATOR|Nevirapine (VIRAMUNE®)|commercial product
62397745|NCT05342870|EXPERIMENTAL|Dexmedetomidine|
62781235|NCT02283788|EXPERIMENTAL|Treatment Sequence CADB|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
62572969|NCT04054115|EXPERIMENTAL|Treatment Arm|"1. Baseline cardiac catheterization under GA. (Standard of Care, SOC)~2. Transfer patient to MRI unit~3. Baseline MRI~   1. Obtain ABG for pCO2 from existing femoral arterial access.~  2. Repeat pressure measurements with existing catheters at the SVC, RA and Aorta.~  3. MRI phase contrast imaging for flow measurements(SOC).~4. During the MRI, Alprostadil infusion will be started and titrated to the target dose 0.1mcg/kg/min, provided there is a less than 20% drop in blood pressure from baseline.~5. Post alprostadil infusion~   1. 1ml blood sample taken from existing femoral venous access for prostaglandin level.~  2. Repeat pressure measurements with existing catheters left at the SVC, RA and Aorta.~  3. Repeat MRI flow measurements~7.Return to cath lab if further intervention required. 8.Recovery and monitoring for 4 to 6 hours prior to discharge(SOC)."
62572970|NCT00602836|EXPERIMENTAL|PCR-Lenalidomide|Pentostatin, Cyclophosphamide, Rituximab + Lenalidomide
62572971|NCT04429789|EXPERIMENTAL|Active-Alert Hypnosis|
62572972|NCT04429789|EXPERIMENTAL|Traditional Hypnosis|
62006691|NCT02611167|EXPERIMENTAL|Bone marrow-derived MSC transplantation (6 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
62006692|NCT02611167|EXPERIMENTAL|Bone marrow-derived MSC transplantation (10 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
62006693|NCT04143412|ACTIVE_COMPARATOR|Tritace (Ramipril)|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Tritace (Ramipril) 10 mg/ day. Full doses will be reached by forced titration after 4 weeks
62397746|NCT04201652|ACTIVE_COMPARATOR|Superficial|Intervention: Superficial local anesthetic infiltration.
62397747|NCT04201652|ACTIVE_COMPARATOR|Deep|Intervention: Superficial and deep local anesthetic infiltration.
62397748|NCT06522763|EXPERIMENTAL|Test Product: 500/25mg Sulfadoxine / Pyrimethamine Dispersible tablets.|A single oral dose of 500/25 mg sulfadoxine/pyrimethamine dispersible tablets will be administered.
62397749|NCT06522763|ACTIVE_COMPARATOR|Reference Product: SPAQ-CO® Dispersible tablets.|A single oral dose of 500/25 mg sulfadoxine/pyrimethamine dispersible tablet from the SPAQ-CO® will be administered.
62397750|NCT00777582|EXPERIMENTAL|Treatment A|300mg bid (twice daily) tablet dose
62397751|NCT00777582|EXPERIMENTAL|Treatment B|400 mg twice daily (bid) capsule dose
62781236|NCT02283788|EXPERIMENTAL|Treatment Sequence DCBA|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
62781237|NCT02971553|EXPERIMENTAL|Upright Resuscitator with PEEP|Ventilation with the Upright Resuscitator with PEEP
62781238|NCT02971553|ACTIVE_COMPARATOR|Upright Resuscitator|Ventilation with the Upright Resuscitator (without PEEP)
62781239|NCT02764684|EXPERIMENTAL|HIV-infected patients|Probiotics (lactobacillus rhamnosus)
62781240|NCT04119011|EXPERIMENTAL|Probiotic|Probiotic in powder form containing lactobacillus and bifidobacterium strains, sugar, milk powder and flavoring, taken 2 sachets daily for 3 months
62781241|NCT04119011|PLACEBO_COMPARATOR|Placebo|Placebo in powder form containing sugar, milk powder, flavoring, taken 2 sachets daily for 3 months
62781242|NCT00924443|EXPERIMENTAL|Clofarabine|Clofarabine 30 mg/m\^2/day intravenously over 1 hour for 5 days every 28 to 42 days (one cycle), then 20mg/m\^2/day intravenously over 1 hour for 5 days every 29 to 43 days for the second and subsequent cycles, up to a maximum of 3 cycles.
62781243|NCT02690649|EXPERIMENTAL|Health Messaging (Non-Procedural)|"PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.~Training on the use of MyChart and the AdhereTech smart pill bottle, medication adherence monitored with Surescripts e-prescribing software and AdhereTech smart pill bottle use."
62397752|NCT00777582|EXPERIMENTAL|Treatment C|400mg bid (twice daily) tablet dose
62397753|NCT06212310||In-person genetic counseling|Patients referred for standard of cancer genetic counseling are seen in-person with a genetic counselor for service.
62397754|NCT06212310||Telephone genetic counseling|Patients referred for standard of cancer genetic counseling are on the telephone with a genetic counselor for service.
62397755|NCT04717986|EXPERIMENTAL|Intervention Group|Dapagliflozin 10 mg every 24 hours for 12 months
62397756|NCT04717986|PLACEBO_COMPARATOR|Control Group|1 placebo tablet every 24 hours for 12 months
62006694|NCT04143412|ACTIVE_COMPARATOR|Eraloner (Eplerenone)|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Eraloner (Eplerenone) 50 mg/ day. Full doses will be reached by forced titration after 4 weeks
62006695|NCT04143412|ACTIVE_COMPARATOR|Tritace/Eraloner (Ramipril/Eplerenone)combination therapy|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Tritace/Eraloner (Ramipril 10 mg / Eplerenone 50 mg ) / day. Full doses will be reached by forced titration after 4 weeks
62006696|NCT03265093|ACTIVE_COMPARATOR|experimental; Corticosteroid|Intralesional corticosteroid administration
62006697|NCT03265093|EXPERIMENTAL|Experimental; Injectable Platelet rich fibrin|Injectable Platelet rich fibrin
62006698|NCT03692546|EXPERIMENTAL|Liposomal Bupivacaine (LB)|Administration of 20 ml of LB diluted with an additional 40 ml of saline was injected into a triangular soft tissue surgical field block, along with standard bupivacaine interscalene block
62397757|NCT03391063|EXPERIMENTAL|reinforced polyamide denture base|metal reinforced polyamide denture base
62397758|NCT03391063|ACTIVE_COMPARATOR|conventional acrylic resin denture base|conventional heat cured acrylic resin denture base
62006699|NCT03692546|NO_INTERVENTION|Interscalene Block Alone (ISB)|Administration of 20mL of 0.5% standard bupivacaine interscalene block with no additional soft tissue surgical field block
62192397|NCT02232399|EXPERIMENTAL|Levosimendan|In this arm the patients will receive Levosimendan as an inotrope agent. Concentration: 0.05 mg/mL Infusion rate: 0.12 mL / kg / hr = Dose delivered 0.1 μg / kg / min --- Bolus dose: 1.44 ml / kg / hr in ten minutes (a maximum volume 0.24 ml / kg) = 12 μg/kg
62192398|NCT01781832|EXPERIMENTAL|(ARFI)-Derived Shear Wave Velocities|"This is an ultrasound-based new technique using Acoustic Radiation Force Impulse (ARFI). Shear Wave speeds are derived using ARFI.~During ultrasound scanning a sound wave is sent towards tissue. The tissue's movement in response to the wave is measured in Shear Wave Velocity, which can estimate tissue stiffness. This technique may help detect bladder wall thickness and fibrosis (thickening) in the urinary bladder of pediatric patients."
62781244|NCT02690649|NO_INTERVENTION|No Health Messaging|"No PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.~Standard care, training on the use of MyChart and the AdhereTech smart pill bottle, medication adherence monitored with Surescripts e-prescribing software and AdhereTech smart pill bottle use"
62192399|NCT05405699|NO_INTERVENTION|Control|
62572973|NCT04429789|NO_INTERVENTION|Wait-List Control|Participants in this arm will continue their usual care for fatigue. The therapist will notify participants assigned to Usual Care via the participant's preferred mode of communication (phone, U.S. mail, or email). People assigned to usual care will be encouraged to continue using the health care services available to them to address their fatigue. The study therapist will emphasize the importance of completing the outcome assessments. Following the completion of their final assessment (3 month follow-up); these individuals will be offered their choice of the two hypnosis treatments.
62006700|NCT06192745|EXPERIMENTAL|Group 1|"Children will participate in 2 exposure conditions in their own homes (i.e., experimental and internal negative control), facilitated by research staff (one week apart, counterbalanced to control for possible order effects). The internal negative control will be the same for all groups, but the experimental exposure will differ. Both exposures will take place for 1 hour before bed in room lighting (40-50 lux).~Experimental exposure: children in Group 1 will be exposed to a tablet with unfiltered bright screen light and exciting media content (BL/EC).~Internal negative control exposure: children will participate in non-screen-based quiet activities"
62572974|NCT04670952|EXPERIMENTAL|Low Pressure Laparoscopic Cholecystectomy|"LPLC refers to Low Pressure Laparoscopic Cholecystectomy. In this arm, the pneumoperitoneum pressure is set as 10mmHg."
62572975|NCT04670952|OTHER|Standard Pressure Laparoscopic Cholecystectomy|"This is taken as the control group. SPLC refers to Standard Pressure Laparoscopic Cholecystectomy. In this arm, the pneumoperitoneum pressure is set as 14 mmHg."
62572976|NCT05333302|EXPERIMENTAL|CD19 CAR-T cells immunotherapy|After a cycle of lymphodepleting chemotherapy a patient receive locally produced autologous CD19 CAR-T cells
62781245|NCT03934853|OTHER|No arm|There is no arm for this study.
62006701|NCT06192745|EXPERIMENTAL|Group 2|"Children will participate in 2 exposure conditions in their own homes (i.e., experimental and internal negative control), facilitated by research staff (one week apart, counterbalanced to control for possible order effects). The internal negative control will be the same for all groups, but the experimental exposure will differ. Both exposures will take place for 1 hour before bed in room lighting (40-50 lux).~Experimental exposure: children in Group 2 will be exposed to a tablet with unfiltered bright screen light and calming media content (BL/CC).~Internal negative control exposure: children will participate in non-screen-based quiet activities"
62192400|NCT05405699|EXPERIMENTAL|Intervention|
62192401|NCT01820884|EXPERIMENTAL|Total Hysterectomy (TH)|Patients may receive total hysterectomy (TH) and bilateral pelvic and para-aortic lymph node dissection (BPLND).
62192402|NCT01820884|ACTIVE_COMPARATOR|TH and bilateral salpingo-oophorectomy (TH/BSO)|Patients may receive total hysterectomy, bilateral salpingo-oophorectomy (BSO) and bilateral pelvic and para-aortic lymph node dissection.
62192403|NCT01939353|EXPERIMENTAL|Centanafadine SR 100-500 mg|Following a 1-week SB placebo run-in treatment, participants with \<30% improvement and ≥28 total score on Adult ADHD-RS-IV scale score received centanafadine (CTN) 100 mg, sustained release (SR) tablet, once daily (1 tablet in the morning) on Days 1 and 2, followed by 200 mg, SR tablets, twice daily (1 tablet in the morning and 1 tablet 5 hours later) on Days 3 and 4, followed by 300 mg, SR tablets, twice daily (2 tablets in the morning and 1 tablet 5 hours later) on Days 5, 6, and 7. After 1 week of treatment, CTN doses were maintained or titrated in 100-mg increments up to the maximum of 500 mg daily or reduced based on the safety and tolerability, as judged by the investigator at Weeks 2, 3 and 4.
62192404|NCT03230825|EXPERIMENTAL|Oral contraceptives|Oral contraceptive agent, given for free, for 3 weeks and a follow up visit a week after treatment withdrawal.
62192405|NCT03230825|SHAM_COMPARATOR|Expectant management|Expectant management for 3 weeks and a follow up visit a week later.
62214779|NCT05599945|EXPERIMENTAL|Single Dose 1: NNC0581-0001 10 milligram (mg)|Part A: Healthy participants will receive a single dose of NNC0581-0001 10 mg or matching placebo injection subcutaneously.
62397759|NCT05794204|EXPERIMENTAL|Patients randomized to dose 1 study drug|Approximately 25 patients randomized to dose 1 of RMP-A03
62572977|NCT04769089|EXPERIMENTAL|Pulse Dye Laser|Treatment with PDL alone.
62572978|NCT04769089|EXPERIMENTAL|CO2 Laser|Treatment with CO2 alone.
62781246|NCT04856904|PLACEBO_COMPARATOR|Trifarotene Vehicle Cream|
62397760|NCT05794204|EXPERIMENTAL|Patients randomized to dose 2 of study drug|Approximately 25 patients randomized to dose 2 of RMP-A03
62397761|NCT05794204|PLACEBO_COMPARATOR|Patients randomized to placebo|Approximately 25 patients randomized to placebo.
62781247|NCT04856904|EXPERIMENTAL|Trifarotene (CD5789) 50 mcg/g Cream|
62781248|NCT02409719|ACTIVE_COMPARATOR|Control - Verbal information and Booklet|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given.
62006702|NCT06192745|EXPERIMENTAL|Group 3|"Children will participate in 2 exposure conditions in their own homes (i.e., experimental and internal negative control), facilitated by research staff (one week apart, counterbalanced to control for possible order effects). The internal negative control will be the same for all groups, but the experimental exposure will differ. Both exposures will take place for 1 hour before bed in room lighting (40-50 lux).~Experimental exposure: children in Group 3 will be exposed to a tablet with filtered dim screen light and exciting media content (DL/EC).~Internal negative control exposure: children will participate in non-screen-based quiet activities"
62006703|NCT06192745|EXPERIMENTAL|Group 4|"Children will participate in 2 exposure conditions in their own homes (i.e., experimental and internal negative control), facilitated by research staff (one week apart, counterbalanced to control for possible order effects). The internal negative control will be the same for all groups, but the experimental exposure will differ. Both exposures will take place for 1 hour before bed in room lighting (40-50 lux).~Experimental exposure: children in Group 4 will be exposed to a tablet with filtered dim screen light and calming media content (DL/CC).~Internal negative control exposure: children will participate in non-screen-based quiet activities"
62006704|NCT05447442||Study group|Patients with anemia will be checked whether they would be assessed by protocol.
62006705|NCT01291927|EXPERIMENTAL|Pancreas-sparing duodenectomy|
62006706|NCT01291927|ACTIVE_COMPARATOR|Pancreaticoduodenectomy|
62006707|NCT02880566|EXPERIMENTAL|Treatment|Full scalp block performed with a total of 30 ml of levobupivacaine 0.33 %.
62192406|NCT03223051|EXPERIMENTAL|Evaluation|"Included patients will be invited to participate in 1 session, to be evaluated with the Motor Function Measure and the new test of space exploration, during 2 hours maximum, to compare scores with these 2 tests.~An occupational therapist will be required to install the patient in front of the table and to give the instructions."
62192407|NCT04845490|EXPERIMENTAL|Drug group 1|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with Mitomycin): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: Mitomycin 30 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
62192408|NCT04845490|EXPERIMENTAL|Drug group 2|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with lobaplatin): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
62781249|NCT02409719|EXPERIMENTAL|Study - Verbal information, Booklet & Schedule.|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
62781250|NCT01417455||Rheumatoid Arthritis|Active Rheumatoid Arthritis patients
62006708|NCT02880566|PLACEBO_COMPARATOR|Control|Full scalp block performed with a total of 30 ml of normal saline.
62006709|NCT02285985|EXPERIMENTAL|Saxagliptin|Saxagliptin (trade-name ONGLYZA™) is used along with diet and exercise to lower blood sugar levels in patients with Type II diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Saxagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amount of insulin produced by the body after meals when blood sugar is high As the blood sugar returns towards normal, the medication effect on insulin is decreased.
62006710|NCT02285985|PLACEBO_COMPARATOR|Placebo|Sugar pill
62006711|NCT00537446|ACTIVE_COMPARATOR|High-level ventilation|Each subject will spend 2 hours receiving high-level noninvasive ventilation.
62006712|NCT00537446|ACTIVE_COMPARATOR|Low-level ventilation|Each subject will receive 2 hours of low-level noninvasive positive pressure ventilation.
62006713|NCT01045291|ACTIVE_COMPARATOR|Fusion Pacing OFF|Subjects initially randomized to the Fusion Pacing OFF Arm will receive the Fusion Pacing software download at the implant visit, but the Fusion Pacing software will be programmed OFF. At 4 months subjects in this arm will crossover to the Fusion Pacing ON Arm.
62006714|NCT01045291|EXPERIMENTAL|Fusion Pacing ON|Subjects initially randomized to the Fusion Pacing ON Arm will receive the Fusion Pacing software download at the implant visit, and the Fusion Pacing software will be programmed ON. At 4 months subjects in this arm will crossover to the Fusion Pacing OFF Arm.
62781251|NCT01417455||Ankylosing Spondylitis|Active Ankylosing Spondylitis
62006715|NCT02674022|ACTIVE_COMPARATOR|Mothers of Children with ASD|Initial treatment with standard prenatal supplement in mothers with abnormal homocysteine levels; additional treatment with optimized prenatal supplement in mothers not responding adequately to initial treatment.
62006716|NCT02674022|ACTIVE_COMPARATOR|Mothers of Typically Developing Children|Initial treatment with standard prenatal supplement in mothers with abnormal homocysteine levels; additional treatment with optimized prenatal supplement in mothers not responding adequately to initial treatment.
62006717|NCT03363230|EXPERIMENTAL|Mindfulness skills|
62006718|NCT03363230|ACTIVE_COMPARATOR|Interpersonal effectiveness skills|
62006719|NCT05617846||Intervention group|Patients who received antiosteoporosis therapy after bone tumor resection
62006720|NCT05617846||Control group|Patients who underwent bone tumor resection without antiosteoporosis therapy
62006721|NCT02057107|OTHER|SBRT + Cetuximab + Docetaxel followed by Cetuximab + Docetaxel|Previously Treated With Cetuximab - Group A; No Previous Cetuximab - Group C
62192409|NCT04845490|NO_INTERVENTION|Control group|"hyperthermic intraperitoneal therapy (HIPET) (no drug) : Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: no drug. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
62397762|NCT00957736||Allogeneic stem cell transplant|Stem cells from a genetically non-identical donor transplanted into a patient.
62397763|NCT06526026|EXPERIMENTAL|Mental Health Virtual Ward|Admission to the Mental Health Virtual Ward
62397764|NCT05747157|EXPERIMENTAL|Administration of Metabolically Armed CD19 CAR-T cells|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. A dose of metabolically armed CD19 CAR-T cells will be infused on day 0.
62572979|NCT04769089|EXPERIMENTAL|Combination|Treatment with both PDL and CO2 laser.
62572980|NCT04769089|ACTIVE_COMPARATOR|No treatment|No laser treatment.
62572981|NCT03147690|EXPERIMENTAL|All Study Participants|All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL
62572982|NCT03090334|EXPERIMENTAL|De-escalation|"In this group, investigators will manage the antifungal therapy according to the BG levels as follows:~1. antifungal therapy will be stopped immediately after the BG response in case of serum BG \<80 pg/ml in presence of clinical stability (CS);~2. antifungal therapy will be continued until further BG determination, both for BG levels between 80-200 pg/ml and for BG \<80 pg/ml in patients without CS. In these cases, if the following BG value is \<80 pg/ml antifungal therapy will be stopped independently from the CS achievement.~3. antifungal therapy will be continued until day 10 for BG levels \>200 pg/ml"
62006722|NCT02057107|OTHER|SBRT + Cetuximab followed by Cetuximab|Previously Treated with Cetuximab - Group B; No Previous Cetuximab - Group D
62006723|NCT00808938|EXPERIMENTAL|Active Treatment|
62006724|NCT01006902||Individuals age 65 or older|Individuals age 65 or older receiving chemotherapy for cancer or short term androgen deprivation therapy for individuals 65 or older with prostate cancer.
62006725|NCT04452188|EXPERIMENTAL|Normoxia|"On bypass, goal PaO2 on cardiopulmonary bypass of 60-100 mm Hg using lower fraction of inspired oxygen (FiO2) (blended sweep gas) via oxygenator~Post-bypass, goal of PaO2 \<100 mm Hg by anesthesia and in ICU via oxygen titration via mechanical ventilator for 24 hours post-op."
62006726|NCT04452188|ACTIVE_COMPARATOR|Standard of care|Frequent blood gases will be checked per protocol on bypass and correlated with the blood parameter monitoring system to maintain a PaO2 of 200-300 per standard practice
62006727|NCT05611086|EXPERIMENTAL|NAC Group|Participants of this group was given capsules containing 600mg N-acetylcysteine
62006728|NCT05611086|PLACEBO_COMPARATOR|Placebo|Participants of this group was given capsules containing lactose
62006729|NCT01021124||QFT (+) vs QFT (-)|
62006730|NCT05986552|ACTIVE_COMPARATOR|Individual Schema Therapy (IST)|IST will follow the revised protocol described by Arntz \& van Genderen. In the first year, 2 sessions (of 50-60 minutes each) per week will be provided, with at least one day in between. In the second year, the frequency will be reduced to once a week for the first 6 months, for the next 3 months to once every two weeks, and for the last 3 months three (booster) sessions will be offered. Therapists need to be trained at least at the junior level of the Dutch ST Association, or of the International ST society (ISST), or having successfully completed the basic IST training and delivering the trial treatments under supervision of a recognized ST supervisor.
62397765|NCT05813925|EXPERIMENTAL|CagriSema 2.4 mg/2.4 mg|Participants will receive 2.4 milligrams (mg) cagrilintide and 2.4 mg semaglutide subcutaneously (s.c.) once-weekly (OW) after a dose escalation period of 16 weeks (0.25 mg of cagrilintide and 0.25 mg of semaglutide from weeks 0-4, 0.5 mg of cagrilintide and 0.5 mg of semaglutide from weeks 5-8, 1 mg of cagrilintide and 1 mg of semaglutide from weeks 9-12 and 1.7 mg of cagrilintide and 1.7 mg of semaglutide from weeks 13-16) during the maintenance period for 52 weeks
62397766|NCT05813925|ACTIVE_COMPARATOR|Semaglutide 2.4 mg|Participants will receive semaglutide s.c. 2.4 mg and placebo matched to semaglutide OW after a dose escalation period of 16 weeks (0.25 mg for weeks 0-4, 0.5 mg for weeks 5-8, 1 mg for weeks 9-12 and 1.7 mg for weeks 13-16) during the maintenance period for 52 weeks
62572983|NCT03090334|NO_INTERVENTION|Standard of care|"In this group antifungal treatment will be continued until clinician's decision.~Investigators will be blinded to the BG levels of patients enrolled in this arm, The BG results will be faxed directly to the coordinating center."
62572984|NCT00454246|EXPERIMENTAL|methoxy polyethylene glycol-epoetin beta|"120-360 micrograms methoxy polyethylene glycol-epoetin beta subcutaneous (sc) monthly starting dose, for a minimum of 5 months to a maximum of 18 months.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
62572985|NCT00454246|ACTIVE_COMPARATOR|Epoetin alfa|"Patients randomized to the reference arm continued to receive their standard of care dose and regimen of epoetin alfa subcutaneous once per week for a minimum of 5 months to a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
62006731|NCT05986552|ACTIVE_COMPARATOR|Combined Individual-Group Schema Therapy (IGST)|"In IGST individual sessions (45-60 min) are provided weekly in the first year, and once every 2 weeks in the first three quarters of the second year, after which 3 monthly booster sessions are offered. Group sessions take place once per week for 1.5 years. After 1.5 years, patients leave the group but continue with IST during the last .5 year. If slots are available, new patients can enter the ST group every 10 weeks.~GST is provided as semi-closed group format developed from the closed format as developed by Farrell \& Shaw. IST is based on Arntz \& van Genderen, with the addition that IST and GST are coordinated at weekly peer supervision meetings, and that problems related to the patient's participation in the group are put on the IST agenda.~GST therapists don't need to be IST therapist of their patients. The same training requirements hold as in the IST arm. Additionally, GST-therapists completed GST training and receive(d) at least 10 GST supervisions."
62192410|NCT04312256|EXPERIMENTAL|Dominant Hand and great toe|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand and great toe.
62214780|NCT05599945|EXPERIMENTAL|Single Dose 2: NNC0581-0001 30 mg|Part A: Healthy participants will receive a single dose of NNC0581-0001 30 mg or matching placebo injection subcutaneously.
62572986|NCT00454246|ACTIVE_COMPARATOR|Darbepoetin alfa|"Patients randomized to the reference arm continued to receive their standard of care dose and regimen of darbepoetin subcutaneous once every two weeks for a minimum of 5 months and a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
62006732|NCT03524027|EXPERIMENTAL|Congenital Thoracolumbar Kyphoscoliosis|Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS) Spinal Deformity by Posterior Vertebral Column Resection (PVCR) Surgical Technique
62006733|NCT00806468|EXPERIMENTAL|Desmopressin|Desmopressin 0,2 mg once daily and Desmopressin 0,2 mg bid for one week each.
62397767|NCT04162717|EXPERIMENTAL|The Effect of Telephone Symptom Triage Protocols|"Intervention group received symptom triage application with telephone, which consisted of guiding in line with symptom triage protocols. The patients who were included in the intervention were followed up by telephone on the 3rd, 7th and 10th day of after chemotherapy total of nine times during three chemotherapy cycles.~Symptom management, quality of life and self-maintenance were assessed by scales at the first interview and 3 months later."
62006734|NCT05317975|EXPERIMENTAL|Add-on telerehabilitation combined with usual home-based rehabilitation|Add-on telerehabilitation combined with usual home-based rehabilitation
62006735|NCT05317975|EXPERIMENTAL|Stand-alone usual home-based rehabilitation|Stand-alone usual home-based rehabilitation
62006736|NCT05317975|NO_INTERVENTION|Usual care|Usual care
62006737|NCT01730495|EXPERIMENTAL|Etanercept|
62006738|NCT03676452|EXPERIMENTAL|Intervention group|Participants of the intervention group train for 16 weeks (three times per week) with a multicomponent virtual reality-based exergame at their home. The Active@Home exergame contains strength training with Tai Chi-based exercises, balance training with dancing and a cognitive training with specific cognitive-motor games. Each training session lasts about 30 to 40 minutes.
62006739|NCT03676452|NO_INTERVENTION|Control group|Participants of the control group go on with their usual daily life. After post-measurements, they get the Active@Home exergame to use the training system at home. They don't have to follow a specific training plan.
62006740|NCT06572514|EXPERIMENTAL|experimental arm|Eligible patients received two cycles of pembrolizumab immunotherapy in combination with albumin-bound paclitaxel and cisplatin induction chemotherapy, followed by definitive concurrent radiochemotherapy.
62006741|NCT04506151|EXPERIMENTAL|Sleep-Opt|12-week intervention that includes self-monitoring, goal setting, motivational enhancement.
62006742|NCT04506151|ACTIVE_COMPARATOR|Healthy Living|12-week intervention that includes weekly telephone contact, didactic content equal in time and attention to intervention group.
62006743|NCT03935035|EXPERIMENTAL|internet-Cognitive Therapy for PTSD|This is a single-arm study. All participants will receive the same therapist supported, internet-delivered intervention.
62397768|NCT04162717|NO_INTERVENTION|Control group|The control group received standard nursing care applied at the hospital
62397769|NCT00943007|ACTIVE_COMPARATOR|Conventional Neuronavigation|Standard form of neuronavigation: based on preoperative MRI without intraoperative correction for brain shift
62572987|NCT03726970|EXPERIMENTAL|Tube Potential difference|Different kVp values of the CBCT machine 70, 80 ,90 kVp
62572988|NCT03726970|EXPERIMENTAL|MAR tool|MAR option in the software off and on
62572989|NCT06576453||All of the participants|"Parents participate in the PEPPS program (Parental psychoeducation program for suicide risk prevention) This is a group family psychoeducation program for parents child under 15 years 6 months having been urgently assessed at Robert University Hospital discharged for suicidal ideation or attempted suicide.~This program is built according to a global model based on:~* A support program for parents of Resourceful adolescents: parent of adolescents support program not specific to the theme of suicidal risk taking place in 3 to 4 sessions of 2 hours.~* The global program of the Suicide Prevention Intervention Center at the Children Hospital of Philadelphia which offers a multi-family group intervention (parents and children).~* The recommendations of the High Authority of Health which recommend an intervention psychoeducation type."
62781252|NCT01417455||Controls|Healthy donors age and sex matched to the patients
62781253|NCT02021630||Patient|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
62006744|NCT05355636|EXPERIMENTAL|experiment group|patient receiving counseling
62006745|NCT05355636|NO_INTERVENTION|control group|patient without counseling
62006746|NCT01020916|EXPERIMENTAL|Target Temperature 33°C|
62214781|NCT05599945|EXPERIMENTAL|Single Dose 3: NNC0581-0001 90 mg|Part A: Healthy participants will receive a single dose of NNC0581-0001 90 mg or matching placebo injection subcutaneously.
62397770|NCT00943007|EXPERIMENTAL|Intraoperative MRI|Standard neuronavigation plus intraoperative MRI to correct for brain shift
62397771|NCT01393652|EXPERIMENTAL|Cohort 1: Experimental intervention: PF-05105679 or placebo|Cohort 1
62397772|NCT01393652|EXPERIMENTAL|Cohort 2: Experimental intervention: PF-05105679 or placebo|Cohort 2
62781254|NCT02021630||Spouse/Partner|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
62006747|NCT01020916|ACTIVE_COMPARATOR|Target Temperature 36°C|
62006748|NCT04958694|EXPERIMENTAL|CEDARS- Active Intervention|Using an adapted stress-reduction intervention called the CEDARS, the investigators will pilot the intervention in adolescents (N=20) to determine the feasibility and acceptability of CEDARS implementation and to investigate adolescent stress reduction.
62006749|NCT04958694|OTHER|CEDARS- Waitlisted Control|The investigators will use a wait-listed control for the pilot intervention in adolescents (N=20) to determine the feasibility and acceptability of CEDARS implementation and to investigate adolescent stress reduction.
62006750|NCT01934634|EXPERIMENTAL|LCL161 +Gemcitabine +nab-Paclitaxel|LCL161 (tablets): 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days nab-paclitaxel IV: 100 or 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
62006751|NCT00775437|EXPERIMENTAL|Adalimumab|Adalimumab 24 mg/m\^2 body surface area (BSA) up to a total dose of 20 mg administered every other week (eow) by parent or designee as a single dose via subcutaneous injection at approximately the same time of day, for a minimum of 24 weeks. Participants could continue in the study until age 4 and 15 kg (US and Puerto Rico) or for up to 1 additional year after reaching age 4 and 15 kg (EU). Visits beyond Week 24 occurred every 12 weeks for those participants who continued in the study.
62006752|NCT01647867|EXPERIMENTAL|Met analysis|Met analysis on tissue and blood Western Blot Immunohistochemistry ELISA test
62397773|NCT01393652|ACTIVE_COMPARATOR|Cohort 3: Experimental intervention PF-05105679 or placebo and|Cohort 3
62192411|NCT03113747|EXPERIMENTAL|ALLO-ASCs|The patients receive ALLO-ADSCs. Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging
62192412|NCT03113747|NO_INTERVENTION|The standard treatment|"All patients will be subjected to standard stepped treatment of burn wounds:~* Infusion therapy aimed to eliminate disorders of homeostasis during burn shock and burn toxemia;~* Systemic antibiotic therapy for preventing infectious complications;~* Adequate analgesia and sedation;~* Decompression necrotomy in the first 24 hours following the burn trauma;~* Necrectomy simultaneously with imposition of lyophilized xenografts performed in the first 1-5 days after applying burn;~* Autologous skin grafting 3-5 days after performed xenografts with the perforation coefficient 1:3"
62192413|NCT06445088||Diagnosis cohort|The participant has signs or symptoms suggestive of nasopharyngeal carcinoma, or has a condition that needs to be differentiated from nasopharyngeal carcinoma
62192414|NCT03502577|EXPERIMENTAL|Treatment (Chemotherapy, BCMA-specific CAR T-cells, LY3039478)|Participants receive fludarabine and cyclophosphamide on days -4 to -2. Participants then receive BCMA-specific CAR T-cells IV over 20-30 minutes on day 0 and LY3039478 PO on days 2, 4, 7, 9, 11, 14, 16, and 18.
62192415|NCT00064649|ACTIVE_COMPARATOR|2|Transurethral Needle Ablation (TUNA)
62192416|NCT00064649|ACTIVE_COMPARATOR|3|finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
62192417|NCT00064649|ACTIVE_COMPARATOR|1|Transurethral Microwave Thermotherapy (TUMT)
62192418|NCT05802927|OTHER|Experimental: Diabetes-specific formula|
62192419|NCT05802927|OTHER|Experimental: Breakfast 1 Noodle Soup|
62192420|NCT05802927|OTHER|Experimental: Breakfast 2 Glutinous rice|
62192421|NCT06062524|EXPERIMENTAL|WeFlow-EndoSeal Aorta Vascular Plug System|WeFlow-EndoSeal Aorta Vascular Plug System
62192422|NCT01163474|EXPERIMENTAL|Arm 1 - All study participants|Evaluate video clinic visit prior to Face-to-Face usual care visit
62192423|NCT03753243|EXPERIMENTAL|Intervention|Treatment will be planned for a total of 14 to 16 weeks. Pembrolizumab will be administered every 3 weeks via IV infusion with a dose of 200 mg per infusion. Enzalutamide will be given orally and dispensed to the patient on the date of their first infusion. The dosage of Enzalutamide will be 160 mg, administered once daily for approx. 16 weeks. GNRH agonist therapy will be administered as a standard of care therapy and will follow a standard dosage to maintain castrate levels.
62192424|NCT04194047||RBC group|Patients who received RBC transfusion
62192425|NCT04194047||crystalloids group|Patients who received fluid resuscitation with crystalloids
62572990|NCT06576453||Participants - qualitative interview|"Semi-structured interviews (qualitative) will be carried out with parents who have followed either all or part of the sessions of the band. The parents interviewed will be chosen based on the wealth of information they will be likely to contribute to the study.The sampling method will follow the snowball model, described by Kathy Charmaz. According to this, the characteristics of new participants will be determined according to the results of the analysis of the first interviews until data saturation. We will conclude with the latter when no new information emerges from the data collection."
62192426|NCT04194047||control group|Patients not receiving RBC nor crystalloids
62192427|NCT03576417|ACTIVE_COMPARATOR|RT+ cisplatin|100 mg/m2 of cisplatin on days 1, 22,43 of RT
62192428|NCT03576417|EXPERIMENTAL|RT+ cisplatin + nivolumab|"* 240 mg of nivolumab 3 weeks before RT-Cisplatin~* 360 mg of nivolumab on days 1, 22,43 of -RT-cisplatin~* 480 mg of nivolumab for maintenance"
62192429|NCT05741190||myope|Patients with myopia
62192430|NCT05741190||Hypermetrope|Patients with hypermetropia
62192431|NCT05741190||Astigmatic|Patients with Astigmatism
62192432|NCT04107753|EXPERIMENTAL|Intervention: Brief counseling based on the 5As model|The intervention group received a brief counseling based on the 5As model. It mainly consists of the following steps: ask, advice, asses, assist, arrange. It is performed by the nurse who take clinical care of the patient. The patients receive an information card about the Smoke cessation center's (CTT) and the patients who agree are contacted by the CTT's staff.
62192433|NCT04107753|NO_INTERVENTION|Control group|"No other intervention than the usual care (range between the not mentioning the subject at all, to a general advice to quit without bringing any evidence or any structured counseling)."
62192434|NCT05558436||Case group|Patients with colorectal cancer and advanced adenoma.
62192435|NCT05558436||Control group|Healthy participants and patients with benign colorectal disease.
62192436|NCT03124693|EXPERIMENTAL|Test Group|All subjects are enrolled into the test group and all subjects received the Rainbow DCI pulse oximeter sensor.
62781255|NCT02021630||Child(ren)|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
62192437|NCT02738528|EXPERIMENTAL|Experimental Group|Mental practice and brushing guidance in patients with Parkinson Disease
62192438|NCT02738528|NO_INTERVENTION|Control group|Brushing guidance in patients without Parkinson Disease
62192439|NCT04561947|ACTIVE_COMPARATOR|TT+CTG|The combined connective tissue graft (CTG) with tunnel technique (TT)
62192440|NCT04561947|EXPERIMENTAL|TT+CGF|The combined concentrated growth factor (CGF) membrane with tunnel technique (TT)
62192441|NCT02083601|EXPERIMENTAL|Psychological Support|The intervention group will participate in the 2-day, in-person Parent Forum and receive monthly phone calls from a mental health professional for 12 months.
62192442|NCT02083601|OTHER|No Psychological Support|This comparison group will attend the 2-day, in-person Parent Forum but will not receive long-term psychological support.
62192443|NCT00005964|EXPERIMENTAL|Chemotherapy + prednisone + filgrastim|Patients receive doxorubicin IV, etoposide IV, vincristine IV, and cyclophosphamide IV continuously over days 1-4. Patients also receive oral prednisone twice daily on days 1-5 and filgrastim (G-CSF) subcutaneously beginning on day 6 until blood counts recover. Treatment continues every 21 days for a maximum of 8 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
62192444|NCT01108315|EXPERIMENTAL|Intervention|The participant used the web and/or phone-based PRO reporting symptoms to enter symptoms twice a week at minimum.
62192445|NCT01108315|NO_INTERVENTION|Usual Care|The participants on this arm do not record their symptoms. They report symptoms as they would under usual care.
62397774|NCT00877526||A|
62572991|NCT05091905|ACTIVE_COMPARATOR|Continuous Infusion|Patients will receive a continuous infusion of Ropivacaine 0.2% (6 mL/hr popliteal-sciatic and 8 mL/hr infraclavicular, 4 mL patient controlled bolus with 30-minute lockout).
62572992|NCT05091905|EXPERIMENTAL|Titratable Automated Boluses|Patients will receive patient-titratable intermittent boluses of Ropivacaine 0.2% (8 mL popliteal-sciatic or 11 mL infraclavicular automated bolus every 120 minutes, 4 mL patient controlled bolus with 30-minute lockout).
62006753|NCT01257594|EXPERIMENTAL|No cytoreductive surgery planned|Patients who are not candidates for surgery as part of their routine care will enroll into the medical arm of the trial. They will initiate pulsatile erlotinib dosing and continue therapy until either disease progression or intolerable toxicity.
62006754|NCT01257594|EXPERIMENTAL|Cytoreductive surgery planned|"Patients scheduled for salvage resection as part of their routine care will be considered for this cohort. They will receive 1 pre-operative dose of 2000 mg erlotinib. Resection will occur ≤ 3 hours after the pre-operative dose. After recovery from surgery, patients will resume pulsatile erlotinib dosing."
62006755|NCT03833076|EXPERIMENTAL|GROUP A: Medical Device Procto|"Medical device Procto presents itself as a translucent green gel with a typical smell; it is intended for topical use.~Posology: external or internal use by means of the provided rectal applicator and following the instructions on the package insert. It can be applied when needed, after intimate cleansing, at any time."
62006756|NCT03833076|PLACEBO_COMPARATOR|GROUP B: Matching placebo|"Investigational Product (IP) placebo presents itself as a translucent green gel with a typical smell; it is intended for topical use.~Posology: external or internal use by means of the provided rectal applicator and following the instructions on the package insert. It can be applied when needed, after intimate cleansing, at any time."
62006757|NCT04088682||All hospitals|"All hospitals will take the treatment quality improvement strategies and tools into implementation.~Intervention: Behavioral: Quality improvement strategies and tools"
62006758|NCT01665365|EXPERIMENTAL|1. Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention (intervention group).
62006759|NCT01665365|NO_INTERVENTION|2.|Primary percutaneous coronary intervention (control group).
62192446|NCT05445063|EXPERIMENTAL|Participants receiving intervention|Participants will receive autologous transplantation of induced pluripotent stem cell-derived retinal pigment epitheliums.
62192447|NCT00147277|ACTIVE_COMPARATOR|8 pulses|8 pulses Anti-Tachycardia Pacing (ATP) delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)
62192448|NCT00147277|EXPERIMENTAL|15 pulses|15 pulses Anti-Tachycardia Pacing (ATP) delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)
62006760|NCT04616781|ACTIVE_COMPARATOR|Ketone ester with alcohol consumption|Drink a single dose of ketone ester 1.9 kcal/kg, complete 1 hour MRI scan, drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
62006761|NCT04616781|PLACEBO_COMPARATOR|Isocaloric dextrose placebo drink with alcohol consumption|Drink a single dose of Isocaloric dextrose placebo drink, complete 1 hour MRI scan, drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
62006762|NCT03101475|EXPERIMENTAL|immunotherapy + local tumor ablation|Patients with unresectable colorectal liver metastases which show at least stable disease or partial remission after 4-6 months will receive treatment with durvalumab and tremelimumab plus local tumor ablation (Radiofrequency ablation RFA or Sterotactic body radiation therapy SBRT) of selected liver lesions, followed by maintenance treatment with durvalumab.
62192449|NCT05438836||Online adaptive radiotherapy|Daily online adaptive radiotherapy
62192450|NCT03774290|EXPERIMENTAL|PBF-680 10 mg|10 mg of PBF-680 once a day
62192451|NCT03774290|PLACEBO_COMPARATOR|Placebo oral capsules|Placebo once a day
62397775|NCT06094075|EXPERIMENTAL|DSI-based training group|This group will perform resistance exercises based in their DSI values.
62397776|NCT06094075|ACTIVE_COMPARATOR|Normal training group|This group will perform a normal, typical resistance exercise program
62572993|NCT02458248|EXPERIMENTAL|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all post-randomisation visits, targeting sodium intake of \<100mmol/day (\<2.3g/day).
62572994|NCT02458248|NO_INTERVENTION|Usual care|For all participants, standard care will be provided at the nephrology clinic at GUH or by local general practitioners, and includes treatment of hypertension, underlying comorbidities and optimizing the metabolic profile. Participants randomized to usual care will also attend a dietitian-developed healthy eating guidance session but will not receive specific recommendations targeting sodium intake.
62192452|NCT05333874|ACTIVE_COMPARATOR|Neoadjuvant chemotherapy|"If Circulating tumor DNA (ctDNA) blood test is positive, change in treatment can be made. Participants will be monitored with ctDNA at 60days, 3 months, 6 months, 9 months, 12 months, 18months and 24months from surgery.~The participant's core biopsy specimens will be sent to NateraTM to sequence the primary tumor. The baseline blood work for ctDNA will be collected prior to the initiation of systemic therapy. Subsequently, ctDNA will be collected prior to each cycle of neoadjuvant chemotherapy. Participants will undergo surgery and ctDNA needs to be collected fourteen days post-surgery The treating oncologist will complete a questionnaire to determine how ctDNA impacts treatment decisions in the adjuvant setting once the results from the fourteen day ctDNA is available and at the time of ctDNA re-emergence. Participants will complete participant questionnaire at 3 months, 6months, 12months and 24 months post-operatively."
62397777|NCT06191757|EXPERIMENTAL|experimental group|The sample consisted of n=57 premature infants, n=27 in the study group and n=30 in the control group. Data were collected in two stages. In the first stage, mothers sang lullabies to the infants in the study group three times a week and touched them tenderly. In the second stage, developmental support program (GEDEP) was applied to the same infants for three months starting from the 40th week of gestation. The infants in the control group were given routine care. In data collection, Mother and Newborn Descriptive Information Form, Premature Infant Comfort Scale (PICS), Developmental Support Program Evaluation Form, GEDEP user guide form and Sound Decibel Measurement Device were used.
62572995|NCT02473250|EXPERIMENTAL|Bipolar depressed|Bipolar depressed subjects will have neuroimaging and treatment with fluoxetine in combination with a mood stabilizer (valproate)
62572996|NCT03496896|EXPERIMENTAL|"TARGET intervention"|The intervention group will receive a standardized transition care intervention by a trained nurse composed of a pre-discharge component and 2 post-discharge follow-up phone calls 3 days and 14 days after discharge.
62572997|NCT03496896|NO_INTERVENTION|Control|The group control will receive usual care without additional intervention.
62572998|NCT03482453|EXPERIMENTAL|Part 1 Cohort 1: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1.
62572999|NCT03482453|EXPERIMENTAL|Part 1 Cohort 2: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 1.
62573000|NCT03482453|EXPERIMENTAL|Part 1 Cohort 3: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 2.
62573001|NCT03482453|EXPERIMENTAL|Part 1 Cohort 4: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 3.
62573002|NCT03482453|EXPERIMENTAL|Part 1 Cohort 5: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 4.
62006763|NCT06320470|EXPERIMENTAL|Education|"Prior to the educational sessions, study participants will be given access to educational materials (e.g., handouts, videos) that provide an overview of information regarding cannabis products, effects, and pain. These materials will be developed with insight from the study team and the Community Advisory Board.~Educational content will include known side effects of cannabis (e.g., common effects like dizziness or sedation, rare side effects like hallucinations or vomiting) as well as specific risks associated with administration routes, such as respiratory harm from smoking or unregulated vaporized concentrate products, and the delayed onset of edible products. Sessions will help the participants appropriately select products for use."
62006764|NCT04072484|NO_INTERVENTION|Room Air|The reduced oxygen breathing device will be set to deliver room air. (i.e., no oxygen is removed from the gas mixture. The subject will perform CPR while breathing through mask and tubing that is connected to the device.
62573003|NCT03482453|EXPERIMENTAL|Part 2: TAK-788 Fed + TAK-788 Fasted|TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fed conditions with low-fat meal (Treatment A), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fasted conditions (Treatment B). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.
62573004|NCT03482453|EXPERIMENTAL|Part 2: TAK-788 Fasted + TAK-788 Fed|TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fed conditions with low-fat meal (Treatment A). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.
62573005|NCT03482453|EXPERIMENTAL|Part 3: TAK-788 DiC (reference) + TAK-788 DiC (test)|TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of Intervention Period 2.
62573006|NCT03482453|EXPERIMENTAL|Part 3: TAK-788 DiC (test) + TAK-788 DiC (reference)|TAK-788 160 mg, DiC B (test), orally, under fasted condition, once, on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 2.
62573007|NCT06539156||Medical Patients|
62006765|NCT04072484|EXPERIMENTAL|Hypoxia|The reduced oxygen breathing device will be set to deliver a gas mixture with15% oxygen. (Equivalent to the partial pressure of oxygen at 2,438 meters.) The subject will perform CPR while breathing through mask and tubing that is connected to the device.
62006766|NCT05234515||Patients with intestinal failure or an enterocutaneous fistula undergoing elective surgery.|Adult patients with a diagnosis of intestinal failure (IF) or an enterocutaneous fistula (ECF) undergoing planned surgery in our unit.
62006767|NCT03904979|EXPERIMENTAL|Therapeutic Writing Prompts|Participants will be given writing prompts that discuss events that have been perceived as stressful in their lives and how they may or may not have cultivated resilience and coping strategies because of it.
62006768|NCT03904979|PLACEBO_COMPARATOR|General Writing Prompts|"Participants will be given writing prompts that discuss neutral topics unrelated to their life stress, resilience, or coping."
62214782|NCT05599945|EXPERIMENTAL|Single Dose 4: NNC0581-0001 250 mg|Part A: Healthy participants will receive a single dose of NNC0581-0001 250 mg or matching placebo injection subcutaneously.
62573008|NCT06539156||Surgical Patients|
62573009|NCT05907564|EXPERIMENTAL|Single Arm|Device: Aventus Thrombectomy System
62573010|NCT04253483|EXPERIMENTAL|Arm I (HDR)|Patients undergo HDR.
62573011|NCT04253483|EXPERIMENTAL|Arm II (SABR)|Patients undergo SABR every other day for 5 treatments.
62573012|NCT01934582|EXPERIMENTAL|Open label extension|
62192453|NCT05333874|OTHER|Observational|Observation for triple negative breast cancer (TNBC): No adjuvant chemotherapy. Patients may complete checkpoint inhibitor from neoadjuvant setting. human epidermal growth factor receptor 2 (HER2) positive breast cancer: complete twelve months of anti-HER2 therapy, which was initiated in neoadjuvant setting), participants in the observation arm, will be monitored for Circulating tumor DNA (ct-DNA) re-emergence and systemic therapy can be added at the time of ctDNA re-emergence.
62573013|NCT02014311|EXPERIMENTAL|CTA+CTP guided treatment strategy|Patients with adenosine stress induced regional myocardial hypoperfusion (CT perfusion imaging) in combination with a corresponding epicardial coronary vessel with \>50% stenosis (Coronary CT angiography) will be referred for invasive investigation within 30 days after study inclusion - CTP-INTERVENTION
62006769|NCT03904979|NO_INTERVENTION|No Writing|Participants will not be given writing prompts during their prenatal care. They will be given blank journals that will NOT contain any instructions or writing prompts.
62397778|NCT06191757|EXPERIMENTAL|control group|"The data of the control group were collected in two stages. No intervention was made to the control group by the researcher.~First stage application steps:~* Before starting the application, the Mother and Newborn Information Form (Annex 1) was filled out by the researcher.~* The babies in the control group were cared for and their daily care (hygienic care (oral care, eye care, body care, diaper cleaning, etc.), feeding, taking vital signs, other follow-ups) were carried out by the nurse.~Approximately 10-15 minutes and 20-25 minutes after the care was completed, the baby's responses were evaluated by the researcher with the premature comfort scale.~Second stage: When the babies in the control group reached their first corrected month, developmental evaluations were made by the researcher using the GEDEP evaluation form every four weeks for a total of three months."
62397779|NCT01694095||Patients with geographic atrophy|
62397780|NCT06723977|EXPERIMENTAL|intervention group|Auditory Hallucination Based Voice Hearing Simulation application was applied to the intervention group and an information brochure was given. Auditory Hallucination Based Voice Hearing Simulation was applied only once to caregivers of individuals diagnosed with schizophrenia. The application took an average of 45 minutes.
62397781|NCT06723977|NO_INTERVENTION|control group|The control group continued the routine practices of the clinic and was given an information brochure.
62397782|NCT04806178|ACTIVE_COMPARATOR|BCG intradermal vaccine|Intradermal BCG Group (n=16): 0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
62397783|NCT04806178|PLACEBO_COMPARATOR|Placebo|Placebo group (n = 16): 0.9% saline solution in the same volume as BCG vaccine in a single dose.
62397784|NCT06096857|ACTIVE_COMPARATOR|Active|Roseomonas and Cardamom seeds
62397785|NCT06096857|PLACEBO_COMPARATOR|Placebo|Sucrose
62397786|NCT02613910|EXPERIMENTAL|Ofatumumab|t the Baseline (Bln) and wk 4 visits, Subjects will receive 40mg ofatumumab sc (Oft) (as two 20mg sc inj) and as 1 Oft 20mg sc inj every 4 wks from wk 8 through wk 56. Subjects will return to clinic 4 wks after the last dose for a follow-up (f/u) visit (wk 60). Antihistamine 10 mg and Acetaminophen/paracetamol (A/P) 1 grams(g) will be given 1-2 hours(h) before and 4 h after each dose of Oft. A/P 1 g will be supplied for self administration if needed. Prednisone/Prednisolone dose will continue to be tapered during core study period (CSP) by 1 dose level every 2 wks to \<= 10 mg/day from Bln through wk 60. Upon completion of the CSP, subjects will enter Individualized f/u Period, where subjects will monitored every 12 wks for a minimum of 1 yr and for up to 2 yr, until CD19+ B-LC or IgG recover to lower limit of normal (LLN) or to the subject's Bln value from Study OPV116910 (if \<LLN) or if study withdrawal criteria are met or for a maximum of 2 yr after the last dose of Oft.
62397787|NCT02788981|EXPERIMENTAL|Nab-Paclitaxel+Mifepristone|Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle)
62397788|NCT02788981|PLACEBO_COMPARATOR|Nab-Paclitaxel+Placebo|Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle)
62397789|NCT04827992|EXPERIMENTAL|Medical Marijuana + Prescription Opioid Taper Support (POTS) behavioral treatment|This group can begin using medical marijuana immediately and will participate in the POTS treatment groups.
62397790|NCT04827992|ACTIVE_COMPARATOR|Prescription Opioid Taper Support (POTS) treatment alone|This group must abstain from marijuana use and will participate in the POTS behavioral treatment alone.
62397791|NCT05726617|EXPERIMENTAL|Experimental: Avatar Intervention|The Avatar Intervention will take place over 8 consecutive weeks, with one session per week. Each session will last approximately 60 minutes. The goal of the intervention will be to help you reduce cravings related to your cannabis use with the use of virtual reality and avatars.
62397792|NCT06722560|ACTIVE_COMPARATOR|GLP-1 hormone|
62397793|NCT06722560|PLACEBO_COMPARATOR|Placebo|
62573014|NCT02014311|ACTIVE_COMPARATOR|CTA guided treatment strategy|Patients with at least one epicardial coronary artery stenosis \>50% (Coronary CT angiography) will be referred for invasive investigation within 30 days after initial discharge from the hospital - CONTROL
62573015|NCT01019694|EXPERIMENTAL|Combivent Respimat 20/100 microgram(mcg)|patient to take 1 inhalation 4 times a day
62573016|NCT01019694|ACTIVE_COMPARATOR|Combivent CFC-MDI 36/206 microgram-mcg|patient to take 2 inhalations 4 times a day
62573017|NCT01019694|ACTIVE_COMPARATOR|Atrovent HFA 42 mcg + Albuterol HFA|patient to take 2 inhalations of each 4 times a day
62573018|NCT05033717|EXPERIMENTAL|Group A|Tissue Flossing Technique
62573019|NCT05033717|ACTIVE_COMPARATOR|Group B|Static Stretching exercises
62006770|NCT03031288|EXPERIMENTAL|"Start feeding with Device A, standard"|Alternatively feeding with standard feeding bottle (Device A) and vented base feeding bottle (Device B)
62006771|NCT03031288|EXPERIMENTAL|"Start feeding with Device B, vented"|Alternatively feeding with vented base feeding bottle (Device B) and standard feeding bottle (Device A)
62006772|NCT00215774|NO_INTERVENTION|No antiarrhythmic treatment|Control group
62397794|NCT06724926|EXPERIMENTAL|Dose Determination followed by Dose Expansion|"Patients with leptomeningeal metastasis from a solid tumor or primary CNS high-grade glioma will be enrolled and start Azeliragon 7 days prior to CSI, during CSI, and for 7 days days after completion of CSI (Dose Determination). Patients will be monitored for dose limiting toxicities during protocol therapy.~Once the recommended dose is identified, additional patients will be treated with Azeliragon at recommended dose in combination with craniospinal irradiation (Dose Expansion)."
62397795|NCT05847023|EXPERIMENTAL|Immediate LUNA intervention|LUNA intervention between T1 and T2. No treatment between T2 and T3. LUNA intervention comprises 20hrs of face-to-face treatment, 2 sessions per week of 60 minutes each, for 10 weeks. One session is delivered by a qualified speech and language therapist; the other session is delivered by an assistant (student or volunteer) following guidance and under distance supervision. Both therapist and assistant will receive LUNA training. The treatment is specified in the TIDIER checklist. In brief, it aims to improve spoken discourse production, using personal narratives as assessment and treatment stimulate, and by integrating word, sentence and discourse level tasks. Treatment is manualised and has been codesigned with key stakeholders (providers and users).
62397796|NCT05847023|EXPERIMENTAL|Delayed LUNA intervention|Wait between T1 and T2. LUNA between T2 and T3. LUNA intervention as above
62006773|NCT00215774|EXPERIMENTAL|B-Flecainide treatment|4 weeks treatment with flecainide
62006774|NCT00215774|EXPERIMENTAL|C-Flecainide treatment|6 months flecainide treatment
62006775|NCT03419091|ACTIVE_COMPARATOR|Reusable Ureteroscope|Standard ureteroscope.
62006776|NCT03419091|EXPERIMENTAL|single-use flexible digital ureteroscope (LithoVue)|Disposable ureteroscope being tested.
62006777|NCT04380207|EXPERIMENTAL|QPX7728|antibiotic
62006778|NCT04380207|PLACEBO_COMPARATOR|Placebo|Matched placebo
62006779|NCT04380207|EXPERIMENTAL|QPX2014|antibiotic
62006780|NCT05641740|EXPERIMENTAL|Radiofrequency Therapy Group|The experimental group will receive a single-session of radiofrequency in their hands that has vasodilator action.
62192454|NCT00866489|NO_INTERVENTION|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min.
62192455|NCT00866489|EXPERIMENTAL|RIPC|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
62397797|NCT06172166|EXPERIMENTAL|Transdisciplinary Care for Transition|
62397798|NCT06172166|NO_INTERVENTION|Standard Clinical Care|
62397799|NCT00984100|EXPERIMENTAL|Notes Transvaginal Cholecystectomy|Patients who undergo a NOTES Transvaginal cholescystectomy.
62573020|NCT01566539|EXPERIMENTAL|Healthy Volunteers - Intranasal Vasopressin (AVP)|The AVP group of healthy volunteers will self-administer vasopressin solution prior to completing the PD task.
62573021|NCT01566539|EXPERIMENTAL|Healthy Volunteers - Intranasal Oxytocin (OT)|The OT group of healthy volunteers will self-administer oxytocin solution prior to completing the PD task.
62573022|NCT01566539|PLACEBO_COMPARATOR|Healthy Volunteers - Intranasal Placebo|The placebo group of healthy volunteers will self-administer a placebo spray prior to completing the PD task.
61977997|NCT00681655|EXPERIMENTAL|Responses to alcohol|Each subject completed a total of 2 2.8 hr-long clamping sessions.Within each session, procedures differed only by the content of the infusate. In one session, 6% ethanol was infused. In the other session, only vehicle was infused, quantifying the placebo response for every subject. The order of alcohol or placebo sessions was counterbalanced; subjects were blind to which session was which; sessions were scheduled to occur about 2 weeks apart. Measures were collected before, and at beginning and end of infusion, and included subjective perceptions, EMG, EEG, stop-signal performance, eye movements, and auditory responses. Design allowed analysis of effect of alcohol vs placebo, initial effect of alcohol and acute tolerance to alcohol.
62006781|NCT05641740|PLACEBO_COMPARATOR|Placebo Comparator: Control Group|The placebo group will receive a single placebo radiofrequency session with the machine in pause mode.
62006782|NCT00385970|ACTIVE_COMPARATOR|1|UFT+LV Group: The group treated with UFT and LV
62192456|NCT00781937|EXPERIMENTAL|Lira 3.0 mg|A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liraglutide 3.0 mg, once daily, injected subcutaneously and instructed to follow a standard energy-restricted diet in the 56-week main trial period. Subjects discontinued treatment in the 12-week follow-up period. The starting dose of liraglutide was 0.6 mg, with weekly increments of 0.6 mg every 7 days until the target dose of 3.0 mg was reached
62192457|NCT00781937|PLACEBO_COMPARATOR|Placebo|A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liraglutide placebo, once daily, injected subcutaneously for 56 weeks and instructed to follow a standard energy-restricted diet in the 56-week main trial period. Subjects discontinued treatment in the 12-week follow-up period
62192458|NCT01502592|EXPERIMENTAL|Cryoablation alone|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
62397800|NCT02763566|EXPERIMENTAL|Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)|Abemaciclib given orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.
62397801|NCT02763566|EXPERIMENTAL|Placebo + NSAI|Placebo given orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.
62397802|NCT02763566|EXPERIMENTAL|Abemaciclib + Fulvestrant|Abemaciclib given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
62397803|NCT02763566|EXPERIMENTAL|Placebo + Fulvestrant|Placebo given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
62397804|NCT06722820|EXPERIMENTAL|Cohort 1|LPH-5_dose 1, single dose
62397805|NCT06722820|EXPERIMENTAL|Cohort 2|LPH-5_dose 2, single dose
62397806|NCT06722820|EXPERIMENTAL|Cohort 3|LPH-5_dose 3, single dose
62006783|NCT00385970|EXPERIMENTAL|2|UFT+PSK Group: The group treated with of UFT and PSK
62006784|NCT04102358||Single injection|Patients who received an infraclavicular block with a single injection technique were included in Group-S.
62006785|NCT04102358||Triple injection|Patients who received an infraclavicular block with a triple injection technique were included in Group-T.
62006786|NCT03952793|EXPERIMENTAL|Experimental|Extended biopsy
62192459|NCT01502592|EXPERIMENTAL|Ipilimumab alone|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
62192460|NCT01502592|EXPERIMENTAL|Ipilimumab & Cryoablation|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
62192461|NCT03513068|NO_INTERVENTION|Standard Of Care (SOC)|Standard of care long-term oxygen therapy
62397807|NCT06722820|EXPERIMENTAL|Cohort 4|LPH-5_dose 4, single dose
62397808|NCT06722820|EXPERIMENTAL|Cohort 5|LPH-5_dose 5, single dose
62397809|NCT06722820|EXPERIMENTAL|Cohort 6|LPH-5_dose 6, single dose
62397810|NCT01388946|ACTIVE_COMPARATOR|Ropivacaine 0.75|Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
62397811|NCT01388946|PLACEBO_COMPARATOR|Normal saline|Continuous infusion of normal saline 2 ml/h for 24 hours
62397812|NCT06724913|EXPERIMENTAL|Arm 1|Subjects of this arm will receive the following sequence of products: day 1 - ice cream with brazzein, maltitol and oligofructose, day 2 - ice cream with brazzein, erythritol, maltitol and inulin; day 3 - standard ice cream
62397813|NCT06724913|EXPERIMENTAL|Arm 2|Subjects of this arm will receive the following sequence of products: day 1 - ice cream with brazzein, erythritol, maltitol and inulin; day 2 - ice cream with brazzein, maltitol and oligofructose, day 3 - standard ice cream
62397814|NCT06724913|EXPERIMENTAL|Arm 3|Subjects of this arm will receive the following sequence of products: day 1 - standard ice cream; day 2 - ice cream with brazzein, maltitol and oligofructose, day 3 - ice cream with brazzein, erythritol, maltitol and inulin
62397815|NCT02248272|EXPERIMENTAL|Polycystic Ovary Syndrome|40 women with PCOS followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (40% carbohydrates, 25% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
62397816|NCT02248272|EXPERIMENTAL|Impaired Glucose Tolerance|35 individuals with Impaired Glucose Tolerance (IGT) followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (45% carbohydrates, 20% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
62397817|NCT02248272|EXPERIMENTAL|Type 2 Diabetes|12 individuals diagnosed with type 2 diabetes followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (45% carbohydrates, 20% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
62397818|NCT06163768|OTHER|insulin|This is a prospective study, without intervention in the clinical treatment plan at the hospital
62192462|NCT03513068|EXPERIMENTAL|SOC + POC (Portable Oxygen Concentrator)|Standard of care long-term oxygen therapy + POC
62192463|NCT00633945|EXPERIMENTAL|Lenalidomide|Open label lenalidomide received.
62006787|NCT02797262|EXPERIMENTAL|Intervention|"Building on the available Proteus devices, the investigators will design and create a Proteus digital health feedback (PDHF) system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).~The investigators will test overall utility (including feasibility, acceptability and sustainability) of the PDHF system, its accuracy for measuring adherence and its impact on enhancing patients' level of adherence and the effect on virologic and clinical outcomes (exploratory), the retention of its impact on keeping up with adherence and improvement of plasma HIV RNA and CD4 cell count after the 16-week usage of the PDHF system."
62006788|NCT02797262|NO_INTERVENTION|Control|UC is chosen as the control condition because it meets ethical and moral requirements to attempt treatment. Eligible patients will be randomized to one of the two conditions using a stratified urn randomization procedure to increase the likelihood of balanced allocation of prognostic variables at baseline.
62192464|NCT00633945|EXPERIMENTAL|Lenalidomide 2|Open label lenalidomide received.
61977998|NCT04207385|ACTIVE_COMPARATOR|A group: Routine treatment group|Routine dosage of venlafaxine during the first 4 weeks.
62006789|NCT04772092||Seniors|70 years of age and over, inpatients or outpatients
62781256|NCT00719888|EXPERIMENTAL|Treatment (myeloablative UCBT)|"Patients receive myeloablative conditioning comprising fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 and -6, and undergo high-dose TBI BID on days -4 to -1. Patients then undergo single- or double-unit UCBT on day 0.~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred \> day 30) after engraftment if there continues to be no evidence of acute GVHD."
62781257|NCT00719888|EXPERIMENTAL|Arm II (myeloablative UCBT)|"Patients receive myeloablative conditioning comprising fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 2-4 hours on days -5 and -4, and middle-intensity TBI QD on days -2 and -1. Patients then undergo single- or double-unit UCBT on day 0.~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred \> day 30) after engraftment if there continues to be no evidence of acute GVHD."
62781258|NCT06303063|EXPERIMENTAL|SINOMED IAS Stent System|The SINOMED IAS Stent System is intended for use with occlusive devices in the treatment of intracranial aneurysms.
62006790|NCT01196767|EXPERIMENTAL|ropivacaine|
62192465|NCT02812992|ACTIVE_COMPARATOR|GO-GO arm|Nab-paclitaxel 125 mg/m\^2 i.v. over 30 minutes followed by gemcitabine infusion 1000 mg/m\^2 on days D1, D8, D15 of a 28-day cycle.
62192466|NCT02812992|ACTIVE_COMPARATOR|SLOW-GO arm|Gemcitabine 1000 mg/m\^2 i.v. on days D1, D8, D15 of a 28-day cycle.
62781259|NCT06303063|ACTIVE_COMPARATOR|Neuroform Atlas Stent System|The Neuroform Atlas Stent System is intended for use with occlusive devices in the treatment of intracranial aneurysms.
62781260|NCT00166530|ACTIVE_COMPARATOR|1|Arm 1: Active comparator
62781261|NCT00166530|EXPERIMENTAL|2|Arm 2: Drug
62781262|NCT02583555|ACTIVE_COMPARATOR|Active patient support|Interview followed by frequent telephone support Questionnaire every 3 months
62781263|NCT02583555|NO_INTERVENTION|Controls|Questionnaire every 3 months
62781264|NCT00644436|EXPERIMENTAL|1|Single topical application
62781265|NCT00644436|ACTIVE_COMPARATOR|2|Single topical application
61977999|NCT04207385|EXPERIMENTAL|B group: PGx-guided group|The PGx test results guide the dosage of venlafaxine during the first 4 weeks.
62192467|NCT02812992|ACTIVE_COMPARATOR|FRAIL arm|Best supportive care as determined by the investigator.
62192468|NCT04160377|EXPERIMENTAL|melancholic depression|patients with melancholic depression undergo the treatment of Fluvoxamine
62192469|NCT04160377|EXPERIMENTAL|non-melancholic depression|patients with non-melancholic depression undergo the treatment of Fluvoxamine
62192470|NCT01296555|EXPERIMENTAL|Phase I, Stage 1: GDC-0032 as Single Agent|Participants with locally advanced or metastatic solid tumors will receive increasing doses of GDC-0032 administered orally daily in 28-day cycles. Dose escalation decisions will be based upon the observed incidence of DLTs.
62192471|NCT01296555|EXPERIMENTAL|Phase I, Stage 2: GDC-0032 + Fulvestrant|Participants (Cohorts F, J, K, L, and M) will receive GDC-0032 in combination with fulvestrant until disease progression.
62192472|NCT01296555|EXPERIMENTAL|Phase I, Stage 2: GDC-0032 + Letrozole|Participants (Cohorts E, N, P, Q, R, and S) will receive GDC-0032 in combination with letrozole until disease progression.
62192473|NCT01296555|EXPERIMENTAL|Phase I, Stage 2: GDC-0032 as Single Agent|Participants (Cohorts A, B, C, D, G, H, T, T2, and X) will receive GDC-0032 until disease progression.
62192474|NCT01296555|EXPERIMENTAL|Phase I, Stage 2: GDC-0032 + Midazolam|Participants (Cohort C) will receive GDC-0032 in combination with midazolam.
62573023|NCT01566539|EXPERIMENTAL|Within Subject Group|Some healthy volunteer participants who received drug in their first session will receive placebo in their second session and vice-versa prior to completing the PD task. For each gender, half will receive AVP in one session and placebo in the other session, and half will receive OT in one session and placebo in the second session. In each group, half of the subjects will receive drug first and half will receive placebo first. Additionally, a group of subjects who receive placebo the first time will receive placebo the second time.
62781266|NCT04870372|EXPERIMENTAL|Selegiline|Subjects who meet all of the inclusion and none of the exclusion criteria will be received Selegiline.The study medication dosage will be escalated from 5mg/daily to the target dose(5\~10mg/daily) in 2 weeks and then maintained for the remaining 6 weeks.
61978000|NCT04207385|ACTIVE_COMPARATOR|C group: Routine PGx-guided group|The PGx test results guide the dosage of venlafaxine between 4th and 8th weeks.
61978001|NCT04207385|ACTIVE_COMPARATOR|D group: The combination of PGx and TDM group|The PGx and TDM test results guide the dosage of venlafaxine between 4th and 8th weeks.
61978002|NCT02315378|OTHER|ARTAT|A one-session intervention targeting at-risk individuals (those continuing to experience peritraumatic panic following a trauma) and designed to reduce peritraumatic anxiety and enhance self-efficacy.
62006791|NCT01196767|OTHER|normal saline|
61978003|NCT02315378|OTHER|TAU|Treatment as Usual
62006792|NCT00405574|EXPERIMENTAL|High Dose|ATN-224 dose 300mg
62006793|NCT00405574|EXPERIMENTAL|Low Dose|ATN-224 dose: 30mg
61978004|NCT01577329|EXPERIMENTAL|mindfulness meditation class|Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
62006794|NCT02572050|EXPERIMENTAL|Robotic Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy (RDG) with D2 LND for patient with stage II or III gastric cancer The primary efficacy endpoint of number of dissected lymph nodes in the N2 area (which is #7, #8a, #9, #11p and #12a according to the JRSSGC) after oncologic resection for clinical stage II or III gastric adenocarcinoma.assessment.
62006795|NCT06430372|EXPERIMENTAL|Bev-ICG NIR-II Endoscopy|The patients will receive a topical administration of probe (Bev-ICG) during the endoscopy. Then fluorescence imaging will be performed to guide the detection.
62006796|NCT03477500|EXPERIMENTAL|HSCT (Cyclophosphamide and ATG)|"Day 1: Cyclophosphamide 2.0 g/m2 body surface area Days 5-10: Granulocyte colony stimulating factor (filgrastim) 5 mcg/kg body weight/day sc.~Day 11 and until apheresis is discontinued: Granulocyte colony stimulating factor (filgrastim) 5 mcg/kg body weight x 2 sc/day.~HSCT days -5 to -2: Cyclophosphamide 50 mg/kg/day. HSCT days -5 to -1: Anti-thymocyte globulin (ATG-rabbit, Thymoglobuline®) 0.5 mg/kg body weight iv on day -5, 1.0 mg ATG-rabbit/kg will be given iv on day -4, and 1.5 mg ATG-rabbit /kg will be given iv on days -3,-2 and -1 over 10 hours.~HSCT day 0: Reinfusion of a minimum of 3,0 x 106 CD 34+ cells/kg body weight."
62006797|NCT03477500|ACTIVE_COMPARATOR|Alemtuzumab, Cladribine or Ocrelizumab|Alemtuzumab, Cladribine or Ocrelizumab administered after the label of the study drug.
62006798|NCT05588596|EXPERIMENTAL|Intervention group|Access to routine hospital care and outpatient services. Patients received relevant health counseling provided by the investigator. In addition, Patients received Trauma Resiliency Mindfulness-Informed Intervention, including Mindfulness awareness, body scanning, walking awareness, mindful breathing, etc.
62006799|NCT05588596|NO_INTERVENTION|Waitlist group|Access to routine hospital care and outpatient services. In addition, the patient received relevant health counseling provided by the investigator, including AIDS related knowledge counseling, diet advice, etc. At the end of the study, patients in the waitlist group were provided with intervention.
62006800|NCT01163604|EXPERIMENTAL|Argatroban group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive continuous infusions of argatroban for 2 days before and 3 days after stenting, with accompanied aspirin and clopidogrel treatment.
62006801|NCT01163604|EXPERIMENTAL|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
62006802|NCT01362907|OTHER|Delefilcon A / etafilcon A|Delefilcon A contact lenses worn first, with etafilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
62006803|NCT01362907|OTHER|Etafilcon A / delefilcon A|Etafilcon A contact lenses worn first, with delefilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
62006804|NCT05086692|EXPERIMENTAL|MDNA11|"MDNA11 is a long-acting beta-only recombinant interleukin-2 (rIL-2) albumin fusion"
62006805|NCT05682482|ACTIVE_COMPARATOR|LT4/LT3 combination therapy|The intervention group is treated with once daily a LT4 tablet and twice daily a LT3 tablet with a LT4:LT3 ratio 16:1.
62006806|NCT05682482|PLACEBO_COMPARATOR|LT4/placebo therapy|The control group is treated with once daily a LT4 tablet and twice daily a placebo tablet.
62006807|NCT06000878|EXPERIMENTAL|experimental group|The experimental group received a one-hour e-book course plus one month of first aid e-book intervention and regular training
62006808|NCT06000878|NO_INTERVENTION|control group|The control group only received one month of regular training.
62006809|NCT00128180|ACTIVE_COMPARATOR|Active|Methylprednisolone
62006810|NCT00128180|PLACEBO_COMPARATOR|Placebo|Placebo
62006811|NCT01652456|EXPERIMENTAL|Group A|
62006812|NCT01652456|NO_INTERVENTION|Group B|
62006813|NCT05668793||Positive group|The positive group is composed of patients with hepatocellular carcinoma of different stages and pathological types.
62781267|NCT06414577|EXPERIMENTAL|Irinotecan Liposomes combined With Nituzumab|
62781268|NCT02346617|EXPERIMENTAL|allogeneic HSCT|The present study will investigate in a single-center (Samsung Medical Center), open-label, single arm by direct infusions of donor-derived CMV-spefic IFN-γ positive T-cells for the treatment of refractory CMV infection in allogeneic hematopoietic stem cell transplant (HSCT) recipients.
62006814|NCT05668793||Negative group|"1. Patients with other digestive system malignancies (including stomach cancer, esophageal cancer, colorectal cancer, pancreatic cancer, gallbladder/duct cancer, etc.), patients with non-digestive system malignancies (including lung cancer, thyroid cancer, cervical cancer, endometrial cancer, breast cancer, prostate cancer, urothelial cancer, etc.).~2. Patients with benign liver diseases (such as cirrhosis, hepatitis, fatty liver, liver adenoma, liver cyst, etc.)."
62397819|NCT03921008|EXPERIMENTAL|Paclitaxel and Radiation|"* All patients will receive standard of care induction chemotherapy with 6 weekly cycles of paclitaxel at 80 mg/m\^2. They will then receive 6 weekly cycles of paclitaxel at 80 mg/m\^2 concurrently with radiation therapy. Patients will be receiving paclitaxel as part of their routine care, but in order to participate in this study, their induction chemotherapy regimen must be paclitaxel. Radiation therapy is 50.4 Gy in 28 fractions delivered within 7 weeks. A radiation therapy boost of 10-16.2 Gy over 5-9 fractions is allowed at the discretion of the treating physician.~* Standard of care surgery ideally within 6 weeks after completing concurrent chemotherapy and radiation therapy"
62397820|NCT00919620|EXPERIMENTAL|case management (4 yrs)|4-year case management and standard care
62397821|NCT00919620|ACTIVE_COMPARATOR|case management (2 yrs) and standard care (2 yrs)|2-year case management and standard care
62397822|NCT00919620|NO_INTERVENTION|standard care (4 yrs)|standard care for 4 years
62397823|NCT00496782|OTHER|Single|
62397824|NCT04062097||dabigatran-group|Patients with the anticoagulating therapy dabigatran and onset of clinically symptomatic intracranial hemorrhage, that is treated with idarucizumab.
62397825|NCT04062097||VKA-group|Patients under effective treatment with VKA and with intracranial hemorrhage.
62397826|NCT00287612|ACTIVE_COMPARATOR|1|Arms:Lap. Fundo. with Mobilization of the Esophageal Junction
62397827|NCT00287612|EXPERIMENTAL|2|
62397828|NCT04337762||Healthy|Healthy adult individuals residing in the United States with no history of COVID-19
62397829|NCT04337762||COVID-19 Confirmed|United States adults that have tested positive for SARS-CoV-2 virus which causes the human disease COVID-19 (IE novel coronavirus) or those that have been exposed to a confirmed case and are awaiting testing
62397830|NCT00705471||Infliximab|Because of the difficulty of finding subjects with exactly the same disease severity, information will be recorded for the time period for up to three years before and for one year after their initial infliximab infusion for comparison of health care costs and utilization prior to infliximab and post infliximab use.
62397831|NCT00707551|EXPERIMENTAL|1|Ketoconazole tablet + AZD1305 Extended Release tablet
62397832|NCT00707551|EXPERIMENTAL|2|Verapamil Extended Release tablet + AZD1305 Extended Release tablet
62781269|NCT00966550|ACTIVE_COMPARATOR|Tomato|Tomato with high carb/fat meal
62397833|NCT00707551|EXPERIMENTAL|3|AZD1305 Extended Release tablet
62397834|NCT03319160||All LifeVest Users|Patients who were prescribed and used a LifeVest in France
62397835|NCT04918251||Controls|Individuals from the Irish population with no psychiatric, psychological, neurological or muscular disease diagnosis
62397836|NCT04918251||Amyotrophic lateral sclerosis patients|
62397837|NCT04918251||Multiple sclerosis patients|
61978005|NCT01577329|NO_INTERVENTION|wait list|Subjects assigned to the control group will continue with medical treatment as usual and be allowed to attend the mindfulness meditation class after week eight.
62397838|NCT04918251||Frontotemporal dementia patients|
62397839|NCT01325376|NO_INTERVENTION|Self directed|
62006815|NCT03579199|EXPERIMENTAL|exploration of abdominal cavity using a NIR/ICG camera|
62006816|NCT03968458|EXPERIMENTAL|Obese adolescents|18 adolescents with obesity are involved and will perform the three conditions.
62214783|NCT05599945|EXPERIMENTAL|Single Dose 5: NNC0581-001 600 mg|Part B: Participants with hepatic steatosis will receive a single dose of NNC0581-0001 600 mg or matching placebo injection subcutaneously.
62397840|NCT01325376|ACTIVE_COMPARATOR|Technology assisted health behavior|The intervention arm will have access to a dynamic online environment with social networking and device data uploads that include activity data, weight data and laboratory data at frequent intervals to nudge optimal health behavior.
61978006|NCT04774874|EXPERIMENTAL|FOL- 005 (0.1 %)|topical formulation
62397841|NCT04771130|EXPERIMENTAL|Parts 1 and 2: AML Cohorts|Participants with AML will receive BGB-11417 and azacitidine on a 28-day cycle.
62397842|NCT04771130|EXPERIMENTAL|Parts 1 and 2: MDS Cohorts|Participants with MDS will receive BGB-11417 and azacitidine on a 28-day cycle.
61978007|NCT04774874|EXPERIMENTAL|FOL -005 (0.5 %)|topical formulation
61978008|NCT04774874|EXPERIMENTAL|FOL -005 (1.5 %)|topical formulation
62397843|NCT04771130|EXPERIMENTAL|Part 3: AML and MDS Cohorts|Participants with AML and MDS will receive BGB-11417 and azacitidine on a 28-day cycle. A subset of the participants will receive a modified second cycle of treatment to explore drug-drug interactions (DDI) with posaconazole.
62397844|NCT04771130|EXPERIMENTAL|Part 3: AML and MDS Cohort|Participants with MDS and R/R AML (China only) will receive BGB-11417 on a 28-day cycle.
62397845|NCT05478473|EXPERIMENTAL|Chidamide combined with Toripalimab|
62397846|NCT05796401|ACTIVE_COMPARATOR|Treatment as usual (TAU)|
62397847|NCT05796401|EXPERIMENTAL|TAU + cognitive training|
62397848|NCT05796401|EXPERIMENTAL|TAU + personalized neuroprotective strategies|
62397849|NCT05796401|EXPERIMENTAL|TAU + personalized neuroprotective strategies + cognitive training|
62397850|NCT06281236|EXPERIMENTAL|prednisolone + SPI-62|Participants will receive prednisolone throughout the trial and SPI-62 on days 3-16.
62397851|NCT06040905|EXPERIMENTAL|Coenzyme Q10|Coenzyme Q10 300 mg/day (150 mg/b.i.d.)
62397852|NCT06040905|PLACEBO_COMPARATOR|Placebo|Placebo (dextrin)
62781270|NCT00966550|PLACEBO_COMPARATOR|Non-Tomato|Non-tomato with high carb/fat meal
62781271|NCT03229733|EXPERIMENTAL|Experimental group|Patients randomized to the experimental group participate in exergames training with Kinect. The supervised OT chooses different games according to the patient's needs and abilities. During therapy patients are at sitting position. The game program will be adjusted when patients got improvement. After 30 minutes of exergames training, participants will receive a 30-minutes of traditional occupational therapy.
62781272|NCT03229733|ACTIVE_COMPARATOR|Control group|Patients in the control group will receive individually tailored traditional occupational therapy consisting of the similar movement and dose as the experimental group doing by using the traditional equipment, such as climbing bar.
62781273|NCT03068767|EXPERIMENTAL|Vitamin D group|Patients receiving vitamin D supplement (2000 IU/day) for 2 months
62781274|NCT03068767|NO_INTERVENTION|Control group|Patients without receiving vitamin D supplement
62781275|NCT03138161|EXPERIMENTAL|Phase 1|"Phase 1: 3-6 will be treated with escalating doses of Trabectedin every 3 weeks up to 18 doses. Dose Level 1 is 1.0 mg/m2; Dose Level 2,1.2 mg/m2; Dose Level 3,1.5 mg/m2. Beginning 2 weeks after the first dose of Trabectedin, all patients will be treated with Ipilimumab at 1 mg/kg every 12 weeks up to 5 doses, and Nivolumab at 3 mg/kg every 2 weeks up to 26 doses.~Phase 2: All patients will be treated with the maximum tolerated dose of Trabectedin every 3 weeks. Beginning 2 weeks after the first dose of Trabectedin, all patients will be treated with Ipilimumab at 1 mg/kg every 12 weeks up to 5 doses, and Nivolumab at 3 mg/kg every 2 weeks up to 26 doses."
62781276|NCT01647776||Individuals without colon polyps|
62781277|NCT01647776||Individuals with colon polyps|
62781278|NCT02333786|EXPERIMENTAL|Infant|Radial artery or posterior tibial artery of patients younger than 1 year old are either cannulated with short-axis/out-of-plane or long-axis/in-plane US-guided arterial catheterization technique.
62781279|NCT02333786|EXPERIMENTAL|Preschool child|Radial artery or posterior tibial artery of patients older than 1 year old and younger than 5 years old are either cannulated with long-axis/in-plane or short-axis/out-of-plane US-guided arterial catheterization technique.
62781280|NCT05870878|EXPERIMENTAL|Standard care and additional lifestyle program|3 lifestyle group sessions (1 physical and 2 online) and additional online platform and individual consultation given at the research center by trained employees
62781281|NCT05870878|OTHER|Standard care|Individual consultation given at the research center by trained employees
62781282|NCT06351254|EXPERIMENTAL|Sine sound waves treatment|sine sound waves
62781283|NCT06351254|EXPERIMENTAL|Kinesthetic exercises|Head to neutral head position test and head to target repositioning test
62781284|NCT06351254|EXPERIMENTAL|Sine sound waves plus kinesthetic exercises|Combination of sine sound waves and kinesthetic exercises
62781285|NCT06315127|EXPERIMENTAL|Human Donor Milk|All infants in this group will receive pasteurized donor milk from Rogers Hixon Ontario Human Milk Bank if they need extra feeding.
62781286|NCT06315127|ACTIVE_COMPARATOR|Formula supplement|All infants in this group will receive formula which is the standard of care if they need extra feeding.
62781287|NCT01091012|OTHER|Sildenafil 20mg oral|
62781288|NCT01091012|OTHER|Sildenafil 10mg intravenous|
62781289|NCT01024842|EXPERIMENTAL|Low dose vaccinees|Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10\^8 pfu.
62781290|NCT01024842|EXPERIMENTAL|High dose vaccinees|Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10\^8 pfu.
62781291|NCT01024842|PLACEBO_COMPARATOR|Low dose placebo|Individuals will receive three intramuscular injections of low dose placebo
62781292|NCT01024842|PLACEBO_COMPARATOR|High dose placebo|Individuals will receive three intramuscular injections of high dose placebo
62781293|NCT01829022||E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
61978009|NCT04774874|PLACEBO_COMPARATOR|Vehicle|topical formulation
62006817|NCT04719416|ACTIVE_COMPARATOR|Active Treatment with Relaxation|This subgroup comprises of patients who are currently receiving active treatment for their cancer diagnosis. They will be completing the pre-recorded relaxation audio therapy twice weekly prior to falling asleep.
62781294|NCT04185389||Control|Women in the original HPV FOCAL control arm who completed the 48 month exit screen (HPV/LBC co-test) and who had no CIN2+ detected during the trial or at trial exit will be invited to submit another LBC sample for HPV and cytology co-testing.
62781295|NCT01630889|EXPERIMENTAL|Roxadustat|Participants previously randomized to roxadustat will receive roxadustat at the same dose and frequency assigned at the last dose in the previous FibroGen study. Dose adjustments will be implemented (up to a maximum roxadustat dose of 3.0 mg/kg or 400 mg, whichever is lower) every 4 weeks to maintain Hb levels at 10.0-12 grams (g)/deciliter (dL). However, if a participant, at any dose, experiences an event of excessive hematopoiesis then the participant's dose will be immediately reduced, or an event of rapidly declining Hb then the participant's dose will be immediately increased. Participants will be permitted to receive roxadustat for up to 8 years.
62781296|NCT04433065|EXPERIMENTAL|Primary Cohort|Device: Intrepid TTVR System
62781297|NCT01401608||Treatment|Ablation of VT/PVCs using a magnetic RF ablation catheter
62781298|NCT04988009||Observational (survey, medical chart review)|Patients complete a survey related to their perceived quality of care via telephone and have their medical chart reviewed prospectively.
62781299|NCT02122367|EXPERIMENTAL|stroke volume variation, pleth variability index|"stroke volume variation: recorded using the FloTrac/Vigileo system (Edwards Lifesciences)~pleth variability index: recorded using the Masimo Radical-7 monitor (Masimo Corporation, Irvine, CA, USA)"
62573024|NCT01566539|EXPERIMENTAL|Faces Task - Vasopressin (AVP)|Healthy volunteers between the ages of 21-30 years will receive Faces Intranasal Vasopressin (AVP) prior to completing the Faces task during fMRI scanning.
62781300|NCT01054625|EXPERIMENTAL|zalutumumab 4 mg/kg|zalutumumab 4 mg/kg iv single infusion week 1,3, 4 and 5
62006818|NCT04719416|ACTIVE_COMPARATOR|Remission with Relaxation|This subgroup comprises of patients who are currently in remission for their cancer diagnosis. They will be completing the pre-recorded relaxation audio therapy twice weekly prior to falling asleep.
62006819|NCT04719416|NO_INTERVENTION|Active Treatment without|This subgroup comprises of patients who are currently receiving active treatment for their cancer diagnosis. They will not be asked to complete any additional relaxation therapy.
62006820|NCT04719416|NO_INTERVENTION|Remission without|This subgroup comprises of patients who are currently in remission for their cancer diagnosis. They will not be asked to complete any additional relaxation therapy.
62397853|NCT02354040|EXPERIMENTAL|Talking Rx|Assigned to receive Health Literacy and Reminder Updates via the IT based intervention Talking Rx, in addition to Usual Care for patients in the intervention group. The physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
62397854|NCT02354040|NO_INTERVENTION|Usual Care, Prescriptions and Counselling|Assigned to receive a standard prescription and Counselling only, there are no cointerventions in this group
62573025|NCT01566539|PLACEBO_COMPARATOR|Faces Task - Placebo|Healthy volunteers between the ages of 21-30 years will receive placebo prior to completing the Faces task during fMRI scanning.
62781301|NCT01054625|EXPERIMENTAL|zalutumumab 8 mg/kg|zalutumumab 8 mg/kg iv single infusion week 1, 3, 4 and 5
62573026|NCT01566539|EXPERIMENTAL|Empathy Task - Oxytocin (OT)|Healthy volunteers between the ages of 18-30 years will receive placebo at scan 1 and OT at scan 2 prior to completing an empathy task.
62573027|NCT01566539|PLACEBO_COMPARATOR|Empathy Task - Placebo|Healthy volunteers between the ages of 18-30 years will receive placebo at scan 1 and placebo at scan 2 prior to completing an empathy task.
62573028|NCT01566539|EXPERIMENTAL|Anxious and Depressed Subjects - OT|Depressed or anxious men between the ages of 18 and 22 will receive intranasal OT prior to completing the Prisoner's Dilemma game task and MRI scan.
62573029|NCT01566539|PLACEBO_COMPARATOR|Anxious and Depressed Subjects - Placebo|Depressed or anxious men between the ages of 18 and 22 will receive intranasal placebo prior to completing the Prisoner's Dilemma game task and MRI scan.
62573030|NCT01566539|EXPERIMENTAL|Healthy Volunteers - Lorazepam|Healthy normal men between the ages of 18 and 22 will receive lorazepam prior to completing the Prisoner's Dilemma game task and MRI scan.
62573031|NCT01131364|EXPERIMENTAL|F16IL2 in combination with doxorubicin|
62781302|NCT01054625|EXPERIMENTAL|zalutumumab 16 mg/kg|zalutumumab 16 mg/kg iv single infusion week 1, 3, 4 and 5
62781303|NCT01622777|EXPERIMENTAL|Rosuvastatin|20 mg daily of oral rosuvastatin
62781304|NCT01622777|PLACEBO_COMPARATOR|Placebo|
62006821|NCT06423716|EXPERIMENTAL|Intervention|Duloxetine 60mg OD for 2 weeks preoperatively then 60mg OD for 6 weeks post-surgery.
62006822|NCT06423716|PLACEBO_COMPARATOR|Control|Placebo OD for 2 weeks preoperatively then OD for 6 weeks post-surgery.
62006823|NCT02373124|EXPERIMENTAL|open-label|52 minute infusion of NMDA antagonist
62006824|NCT02148003|ACTIVE_COMPARATOR|RFA at 90 degrees Celsius|Radiofrequency ablation (RFA) of the lumbar facets nerve supply will be performed at 90 degrees Celsius
62006825|NCT02148003|ACTIVE_COMPARATOR|RFA at 80 degrees Celsius|Radiofrequency ablation (RFA) of the lumbar facets nerve supply will be performed at 80 degrees Celsius
62781305|NCT04356716|ACTIVE_COMPARATOR|Standard of Care Sildenafil|Medical record review for participants that are prescribed Sildenafil off-label as part of standard of care treatment for disease.
62781306|NCT04356716|ACTIVE_COMPARATOR|Sildenafil|Participants are prescribed sildenafil 40-80 mg daily.
62781307|NCT05880498|EXPERIMENTAL|Mindfulness Intervention|"6 week smartphone-based self-guided mindfulness training using a customized version of the Healthy Minds app.~Participants were instructed to listen to at least one activity per day for 5 days per week, for 6 weeks. Activities that were part of the structured curriculum consisted of alternating mindfulness didactic 'lessons' (each up to 7 minutes in length) and mindfulness 'practices' (either 10 minutes or 15 minutes in length- as chosen by the participant)."
62781308|NCT05880498|NO_INTERVENTION|Wait-List Control (WLC)|No intervention was administered during the 6-week wait list control period.
62781309|NCT06232785|EXPERIMENTAL|Ibuprofen Group|Participants received 0.8g ibuprofen intravenously 30 minutes before the end of the procedure
62192475|NCT01296555|EXPERIMENTAL|Phase II: GDC-0032 + Fulvestrant|Post-menopausal females with locally advanced or metastatic HER2-negative, hormone receptor-positive breast cancer will receive GDC-0032 in combination with fulvestrant until disease progression.
62192476|NCT03805477|EXPERIMENTAL|Nintedanib|Nintedanib 150 mg Kps bid (oral)
62192477|NCT04821817|PLACEBO_COMPARATOR|Group C (Control group)|Patients in this group will receive peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 2 ml normal saline.
62397855|NCT04462328|EXPERIMENTAL|Phase I Dose Level 1: Durvalumab + Acalabruitinib|"* Acalabrutinib 100 mg twice per day by mouth on days 1-28~* Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle"
62781310|NCT06232785|PLACEBO_COMPARATOR|Sufentanil Group|Participants received 0.2ug/kg of sufentanil intravenously 30 minutes before the end of the procedure
62781311|NCT02220426|OTHER|Xenon inhalation|Inhalation of 5 doses of 750ml of hyperpolarized 129Xe gas
62397856|NCT04462328|EXPERIMENTAL|Phase I Dose Level 2: Durvalumab + Acalabruitinib|"* Acalabrutinib 200 mg twice per day by mouth on days 1-28~* Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle"
62781312|NCT05236244|EXPERIMENTAL|İntervention group|Diaphragmatic breathing exercises: First Evaluation + (1 week break) + Motor imagery protocol + Second Evaluation + 8 weeks of diaphragmatic breathing exercises +Third Evaluation +(1 week interval) + Motor imagery protocol + Fourth Evaluation
62781313|NCT05236244|NO_INTERVENTION|Control Group|First Evaluation + (1 week break) + Motor imagery protocol + Second Evaluation + 8 weeks break +Third Evaluation +(1 week interval) + Motor imagery protocol + Fourth Evaluation
62781314|NCT04112394|EXPERIMENTAL|ESP Group|In addition to routine standard perioperative and postoperative analgesia protocol patients will receive a single shot of local anesthetic injection at the erector spinae plane.
62397857|NCT04462328|EXPERIMENTAL|Expansion Cohort: Durvalumab + Acalabrutinib|"* Acalabrutinib 100 mg or 200 mg (depends on tolerable dose found in Phase I portion of study) twice per day by mouth on days 1-28~* Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle"
62192478|NCT04821817|EXPERIMENTAL|Group R (rocuronium group)|Patients in this group will receive peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 0.06 mg/kg of rocuronium in 2 ml normal saline.
62397858|NCT02632773|EXPERIMENTAL|Parent Learning Style 1|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
62397859|NCT02632773|EXPERIMENTAL|Parent Learning Style 2|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
62397860|NCT02632773|OTHER|Learning Style 1 (Parent)|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
62397861|NCT02632773|OTHER|Learning Style 2 (Parent)|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
62781315|NCT04112394|OTHER|Control|Patients will receive standard perioperative and postoperative analgesia protocol.
62781316|NCT00692419|EXPERIMENTAL|Symptom management nurse intervention|This arm of the study will have a symptom management nurse facilitate the management of pain, sexual dysfunction and depression. The nurse will work with the patient's renal provider to implement appropriate symptom alleviating treatment. The intervention is patient specific and entirely dependent on the treatment recommendation made by the symptom management nurse.
62781317|NCT00692419|ACTIVE_COMPARATOR|Feedback intervention|This arm of the study will have pain, sexual dysfunction and depression assessed monthly with feedback given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider. The intervention on symptoms is at the discretion of the renal provider. The interventions implemented were patient specific and consisted of therapies the patient's renal provider decided to implement.
62781318|NCT05526339|EXPERIMENTAL|High-flow nasal oxygenation combined with nasopharyngeal airway|High-flow nasal oxygenation combined with nasopharyngeal airway was used in obese patients who are scheduled to undergo gastrointestinal endoscopy procedures sedated with propofol.
62192479|NCT02547376||Eligible patients with Soft Tissue Sarcoma|Primary Soft Tissue Sarcoma group
62192480|NCT04689880||XLIF Decade Plate|
62192481|NCT05306249|EXPERIMENTAL|CBD LGP 50 group|Patients will receive CBD LGP 50 at a dose of 1 mg/kg twice a day in the form of oil dispensed through a graduated pipette until the end of week 12.
62192482|NCT05306249|PLACEBO_COMPARATOR|Control group|Patients will receive the MCT oil placebo without CBD until the end of week 12.
62397862|NCT06079606||Group A|Term children born with caesarean section (their mothers received intra-operative antibiotics)
62192483|NCT05276271||epileptic children|epileptic children who had been diagnosed with epilepsy with at least two focal seizures within a year, and treated with levetiracetam monotherapy for at least 12 months
62781319|NCT05526339|ACTIVE_COMPARATOR|Regular nasal cannula combined with nasopharyngeal airway|Regular nasal cannula combined with nasopharyngeal airway was used in obese patients who are scheduled to undergo gastrointestinal endoscopy procedures sedated with propofol.
62192484|NCT05276271||healthy controls|healthy controls who was without an exposure to levetiracetam
62781320|NCT02978950|EXPERIMENTAL|Surveillance arm|Bilateral duplex ultrasound surveillance
62192485|NCT05664789|ACTIVE_COMPARATOR|N-acetylcysteine|12 week administration of active study compound
62192486|NCT05664789|PLACEBO_COMPARATOR|Placebo|12 week administration of matched placebo
62192487|NCT03363347||Radioiodine refractory papillary thyroid cancer|Patients with radioiodine refractory papillary thyroid cancer who received redifferentiation therapy with retinoid acid.
62192488|NCT03363347||Radioiodine sensitive papillary thyroid cancer|Patients who were in remission after one or two radioiodine therapies.
62781321|NCT02978950|ACTIVE_COMPARATOR|No surveillance arm|no duplex ultrasound surveillance
62781322|NCT02919527|EXPERIMENTAL|Self-Myofascial-Release|Two 60 seconds bouts of Self-Myofascial-Release performed at the anterior thigh; anticipated intensity of 7/10 on a 10 point numeric rating scale (0 representing no discomfort and 10 representing maximal discomfort)
62781323|NCT02919527|ACTIVE_COMPARATOR|Stretching|Two 60 seconds bouts of static stretching performed at the anterior thigh; anticipated intensity of 7/10 on a 10 point numeric rating scale (0 representing no discomfort and 10 representing maximal discomfort)
62781324|NCT02919527|NO_INTERVENTION|Control|No Intervention
62192489|NCT02337621||pectus excavatum surgical candidates|Any person who is eligible to undergo the Nuss procedure for surgical correction of pectus excavatum
62781325|NCT02673684|SHAM_COMPARATOR|Sham Neurostim System (Sham NSS)|In this arm, the subject will receive the standard-of-care with regard to his pain management (which may or may not include opioids such as morphine). Additionally, the subject will receive a sham Neuro-Stim System device that will only be active for five minutes. Identical to the active device in placement, labeling, and packaging. It will remain on the subject's ear for 5 days at which point the subject may discard the device.
62781326|NCT02673684|EXPERIMENTAL|Working Neurostim System (Working NSS)|In this arm, the patient will receive the standard-of-care with regard to his pain management (which may or may not include opioids such as morphine). Additionally, the subject will receive an active Neuro-Stim System that generates electrical impulses that stimulate the neurovascular bundles in the ear. It will remain on subject's ear for 5 days at which point the subject may discard the device.
62781327|NCT05795153|EXPERIMENTAL|LOU064 (remibrutinib)|Open label single arm trial.
62192490|NCT04415827|EXPERIMENTAL|Athletes with community-acquired pneumonia|man and women, athletes, age 17-25, patients with community-acquired pneumonia
62781328|NCT06121024||Simple Tracheal Stenosis|Simple stenosis was defined as lesions with a vertical extension \<1 cm (short segment) with endoluminal occlusion, without tracheomalacia or loss of cartilage support.
62192491|NCT04415827|EXPERIMENTAL|Untrained people with community-acquired pneumonia|man and women, untrained people, age 17-25, patients with community-acquired pneumonia
62192492|NCT04415827|EXPERIMENTAL|Athletes with bronchitis|man and women, athletes, age 17-25, patients with bronchitis
62192493|NCT04415827|EXPERIMENTAL|Untrained people with bronchitis|man and women, untrained people, age 17-25, patients with bronchitis
62192494|NCT04415827|EXPERIMENTAL|Athletes with chronic obstructive pulmonary disease|man and women, athletes, age 17-25, patients with with chronic obstructive pulmonary disease
62192495|NCT04415827|EXPERIMENTAL|Untrained people with chronic obstructive pulmonary disease|man and women, untrained people, age 17-25, patients with with chronic obstructive pulmonary disease
62192496|NCT04415827|EXPERIMENTAL|Athletes with acute respiratory infections|man and women, athletes, age 17-25, patients with acute respiratory infections
62006826|NCT01611571|ACTIVE_COMPARATOR|Active Risedronate Placebo Teriparatide|Active Risedronate + Placebo Teriparatide for 18 months / Active Risedronate for 6 months
62006827|NCT01611571|ACTIVE_COMPARATOR|Active Risedronate Active Teriparatide|Active Risedronate + Active Teriparatide for 18 months / Active Risedronate for 6 months
62006828|NCT01611571|ACTIVE_COMPARATOR|Placebo Risedronate Active Teriparatide|Placebo Risedronate Active Teriparatide for 18 months / Active Risedronate for 6 months
62006829|NCT01751503|ACTIVE_COMPARATOR|Interosseous route of TPTT|The investigators will have two groups of patients, one who had their tendon transfer using the extra membranous route and other group which had their tendon transfer through the interosseous route. Patients will be randomized to either groups before the surgery and both the patients and the assessors will be blinded to the technique used. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors.
62006830|NCT01751503|ACTIVE_COMPARATOR|Extra membranous route of TPTT|Extramembranous or circumtibial route of Tibialis Posterior tendon transfer.Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
62192497|NCT04415827|EXPERIMENTAL|Untrained people with acute respiratory infections|man and women, untrained people, age 17-25, patients with acute respiratory infections
62006831|NCT03697811|EXPERIMENTAL|DE-117 Ophthalmic Solution 0.002%|Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
62006832|NCT00835497|EXPERIMENTAL|Glipizide Metformin|Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in first period followed by Metaglip® 5/500 mg Tablet (reference) dosed in second period
62006833|NCT00835497|ACTIVE_COMPARATOR|Metaglip®|Metaglip® 5/500 mg Tablet (reference) dosed in first period followed by Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in second period
62006834|NCT00115596|EXPERIMENTAL|Intervention Arm|"'Formal Curriculum; Low-Fidelity Simulation'~Residents randomized to the intervention arm will receive the study skills training curriculum (the intervention)."
62006835|NCT00115596|NO_INTERVENTION|Control|Residents randomized to the control arm will receive standard pediatric training.
62192498|NCT06031636||Oncolytic adenovirus(H101) combined with PD-1 inhibitors|This study observed 2-4 treatment cycles. For the convenience of statistics, this project stipulated that the first combined medication (v1) after the patient was enrolled in this study was administered with oncolytic virus (recombinant human adenovirus type 5) by intratumoral injection or intrapleural injection on the 1-3 days. On the 4th or 5th day, PD-1 injection was administered once per cycle. The completion of two visits in this study is considered a completed case, and subsequent treatment is determined jointly by the researcher and the subject.
62192499|NCT01155414|EXPERIMENTAL|Investigational infant formula A|Investigational Protein Hydrolysate formula
62192500|NCT01155414|ACTIVE_COMPARATOR|Hydrolysate based Infant Formula|
62192501|NCT01155414|EXPERIMENTAL|Investigational Infant Formula B|Investigational Protein Hydrolysate Formula
62397863|NCT06079606||Group B|Term vaginally born children and their mothers received intra-partum antibiotics
62781329|NCT06121024||Complex Tracheal Stenosis|Complex stenosis were defined as lesions ≥1 cm and varying degrees of cartilage involvement or circumferential contractile scar or tracheal stenosis associated with malacia and inflammation.
62781330|NCT04816058||Ankle Instability Group|Patients with a history of ankle instability or injury.
62006836|NCT01479634|ACTIVE_COMPARATOR|Arm A|Treatment for HIV in participants with CD4+ cell counts 250-350 cells/uL
62006837|NCT01479634|ACTIVE_COMPARATOR|Arm B|Treatment for HIV in participants with CD4+ cell counts \>350 cells/uL
62192502|NCT00092053|PLACEBO_COMPARATOR|Placebo|Participants will receive 3 placebo tablets once a month, for 3 months, on the first day of each treatment cycle.
62192503|NCT00092053|EXPERIMENTAL|ibandronate 100 mg|Participants will receive 2 ibandronate 50 mg tablets and 1 placebo tablet once a month, for 3 months, on the first day of each treatment cycle.
62192504|NCT00092053|EXPERIMENTAL|ibandronate 150 mg|Participants will receive 3 ibandronate 50 mg tablets once a month, for 3 months, on the first day of each treatment cycle.
62192505|NCT06543563|PLACEBO_COMPARATOR|DEX|A loading dose of DEX 0.3 µg/kg was infused intravenously at a constant speed within 10 min after the patients entered the operating room, and the DEX maintenance dose was infused at 0.3µg/kg/h until the end of the first stage (deep-brain stimulation implantation) of the operation. After the craniotomy, normal saline is infused at a rate of 3 ml/kg/h until the completion of electrode implantation, prior to microelectrode recording (MER) and electrode insertion. Blood pressure and heart rate of the patient are closely monitored after drug administration to maintain circulatory stability.
62214784|NCT05599945|EXPERIMENTAL|Single Dose 6: NNC0581-001 1000 mg|Part B: Participants with hepatic steatosis will receive a single dose of NNC0581-0001 1000 mg or matching placebo injection subcutaneously.
62397864|NCT06079606||Group C|Term vaginally born children that received systemic antibiotics during the first week of life for at least 48 hours
62397865|NCT06079606||Group D (Control group)|Term vaginally born children that had not received systemic antibiotics at the time of recruitment
62781331|NCT04816058||Healthy Group|Participants without a history of ankle injury
62781332|NCT04870918|EXPERIMENTAL|self-care intervention|First, health education will be carried out by the nurse. The consultations will be individual, weekly (Wednesdays), the others, therefore, will be biweekly, extending to the 30/30 days the following, individually in order to observe the difficulties and doubts of each patient. Counting the meetings in a total of 12 in the first 6 months.
62006838|NCT04563312|NO_INTERVENTION|Balance Assessment|The Flamingo Balance Test and Y Balance Test were used to evaluate static and dynamic balance, respectively.
62006839|NCT04563312|NO_INTERVENTION|Coordination Assessment|Coordination was assessed using the Hexagon Test.
62006840|NCT04563312|NO_INTERVENTION|Lower Extremity Functional Performance Assessment|Lower extremity functional performance was evaluated using the Single Leg Hop Test.
62192506|NCT06543563|EXPERIMENTAL|DEX-KET|A loading dose of DEX 0.3 µg/kg was infused intravenously at a constant speed within 10 min after the patients entered the operating room, and the DEX maintenance dose was infused at 0.3µg/kg/h until the end of the first stage (deep-brain stimulation implantation) of the operation. After the craniotomy, esketamine (0.1mg/ml) is infused at a rate of 3ml/kg/h until the completion of electrode implantation, prior to microelectrode recording (MER) and electrode insertion. Blood pressure and heart rate of the patient are closely monitored after drug administration to maintain circulatory stability.
62192507|NCT00566813|ACTIVE_COMPARATOR|Group 1 (Islet Cell Transplant)|1-3 Islet transplants by the Edmonton Protocol of Steroid Free Immunosuppression using daclizumab 1 mg/kg IV immediately pre-transplant and 2, 4, 6, and 8 weeks after transplant; sirolimus dosed to maintain serum trough levels 12-15 ng/mL for three months post-transplant and 7-10 ng/mL therafter; tacrolimus dosed to maintain serum trough levels 3-6 ng/mL throughout the study.
62192508|NCT00566813|ACTIVE_COMPARATOR|Group 2 (Islet Cell Transplant plus)|1-3 islet transplants by the Edmonton Protocol of Steroid Free Immunosuppression using daclizumab 1 mg/kg IV immediately pre-transplant and 2, 4, 6, and 8 weeks after transplant; sirolimus dosed to maintain serum trough levels 12-15 ng/mL for 3 months post-transplant and 7-10 mg/mL thereafter; tacrolimus dosed to serum trough levels 3-6 ng/mL throughout the study; etanercept 50 mg IV pre-transplant, 25 mg subcutaneously post-transplant Days 3, 7, 10; exenatide 5-mcg subcutaneously twice daily for I week, then up to 10-mcg twice daily for 6 months after the last islet transplant.
62192509|NCT01791777|EXPERIMENTAL|Purveyor|"The purveyor arm will include SafeCare Coaching that is conducted by a Training Specialists from the National SafeCare Training and Research Center (NSTRC), a GSU (Georgia State University)-Center that conducts training and research on the SafeCare model."
62192510|NCT01791777|EXPERIMENTAL|Local|"The the local are will receive SafeCare Coaching that is provided by a staff member who works for the local social service agency."
62192511|NCT03181659|EXPERIMENTAL|Group 1: patients with NSCLBP who do not seek care|Manual Therapy, Therapeutic Education, Therapeutic Exercice
62192512|NCT03181659|EXPERIMENTAL|Group 2: patients with NSCLBP who do not seek care|Therapeutic Education, Therapeutic Exercice
62192513|NCT03181659|EXPERIMENTAL|Group 3: patients with NSCLBP who seek care|Manual Therapy, Therapeutic Education, Therapeutic Exercice
62192514|NCT03181659|EXPERIMENTAL|Group 4: patients with NSCLBP who seek care|Therapeutic Education, Therapeutic Exercice
62397866|NCT05216302|NO_INTERVENTION|Usual Care|Patients allocated to this arm will continue with their schedule chemotherapy with no additional intervention
62397867|NCT05216302|EXPERIMENTAL|Prehabilitation|Patients allocated to this arm will participate in a weekly group-based exercise intervention (nordic walking) and receive health education through a booklet, videos of the exercises and face-to-face sessions prior to each nordic walking session. Chemotherapy will continue as scheduled.
62781333|NCT04870918|NO_INTERVENTION|usual care|The control group will go through medical consultations as instructed by the doctor and will not receive intervention for health education by the nurse.
62781334|NCT00839761|EXPERIMENTAL|iron fortified rice group|
62781335|NCT00839761|PLACEBO_COMPARATOR|iron drop group|
62006841|NCT04563312|EXPERIMENTAL|Exercise|Nine different clubs and sport centers were screened and 18- to 35-year-old individuals regularly engaged in MT or BB for the last 6 months were invited to join the study.
62006842|NCT05352022|EXPERIMENTAL|Monthly Unconditional Financial Incentive|Individuals assigned to this group will receive diabetes education and a monthly incentive to supplement income and enhance ability to purchase healthy food options.
62006843|NCT05352022|EXPERIMENTAL|Monthly Unconditional Plus Healthy Food Purchasing Financial Incentive|Individuals assigned to this group will receive diabetes education, a monthly incentive to supplement income and enhance ability to purchase healthy food options, and an additional weekly incentive if receipt for purchase of healthy food items from a grocery store is provided.
62006844|NCT05352022|EXPERIMENTAL|Monthly Unconditional Plus Healthy Food Purchasing Plus Glycemic Control Financial Incentive|Individuals assigned to this group will receive diabetes education, a monthly incentive to supplement income and enhance ability to purchase healthy food options, an additional weekly incentive if receipt for purchase of healthy food items from a grocery store is provided, and an incentive at the end of the study based on absolute drop in HbA1c.
62006845|NCT06466954||Group of Primary Dysmenorrhea|Females with Primary Dysmenorrhea
62006846|NCT06466954||Group Without Primary Dysmenorrhea|Females without Primary Dysmenorrhea
62006847|NCT03427658|EXPERIMENTAL|Increase sweet food consumption|Participants are asked to increase their consumption of sweet foods throughout their diet. Participants will be supported through an individual dietary interview where sweet foods will be highlighted and additional sweet food consumption recommended.
62192515|NCT01726569|EXPERIMENTAL|film and trained counseling|Subjects will be asked to watch a 5-10 min film and participate in a 10-15 min pre-operative counseling session with a trained doctor/nurse. Subjects will also participate in a 5 min post-operative counseling session and follow up counseling after operation 1 week and 6 weeks
62397868|NCT00945815|EXPERIMENTAL|treatment|AraC 1 g/m2/d IV Days 1-5 clofarabine 40 mg/m2/d IV Days 2-6 epratuzumab 360 mg/m2/d IV Days 7, 14, 21, 28 acetaminophen 650 mg/d PO Days 7, 14, 21, 28 diphenhydramine 50 mg/d IV Days 7, 14, 21, 28 IT methotrexate 12 mg IT at least 1 wk apart during induction All give 1 cycle
62781336|NCT03090204|OTHER|ultrasound measurements|ultrasound measurements of myocardial deformation of free wall right ventricle during a sharp decline of right ventricle preload induced during a session of Intermittent hemodialysis.
62781337|NCT00193921|EXPERIMENTAL|A|Vinorelbine + cisplatin + high-dose palliative radiotherapy
62397869|NCT06541665|EXPERIMENTAL|Tirabrutinib + R-MPV in patients with newly diagnosed, treatment naïve PCNSL|
62397870|NCT06722807|EXPERIMENTAL|Clampless, sutureless robotic partial nephrectomy|
62397871|NCT02221882|EXPERIMENTAL|LY3164530|LY3164530 in escalating dose cohorts given intravenously (IV) once on Days 1 and 15 or on Days 1, 8, 15, and 22 of a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
62781338|NCT00193921|ACTIVE_COMPARATOR|B|Gemcitabine + high-dose palliative radiotherapy
62006848|NCT03427658|ACTIVE_COMPARATOR|Decrease sweet food consumption|Participants are asked to decrease their consumption of sweet foods throughout their diet. Participants will be supported through an individual dietary interview where sweet foods will be highlighted and substitutions for sweet food consumption will be recommended.
62006849|NCT02087462|EXPERIMENTAL|Electroacupuncture (EA)|Use Electroacupuncture only
62192516|NCT01726569|OTHER|traditional counseling|Subjects will be participate or not participate in pre-operative counseling and/or post-operative counseling with a rural hospital's doctor/nurse.
62192517|NCT00922168||Cardiac Surgeries: CABG, valve replacements|
62192518|NCT04034849|EXPERIMENTAL|Test group|Low-Level Laser Therapy was applied in the test group with a Diode Laser Fox (A.R.C. Laser, Italy) using these parameters: a wavelength of 810 nm, a power of 0.6 W, a power density of 1.2 W/cm2, a beam area of 0.08 cm2 and an energy of 6 J with an application time per point of 10 seconds in 56 points (3 in the vestibular mucosa of the 4 quadrants, 6 in each of the two buccal mucosa, 6 in the hard palate, 4 in each lateral of the tongue, 6 in the dorsum of the tongue and 4 sublingual points) with a distance between points of 2mm. It was applied, therefore, a dose of 12 J/cm2 in a continuous mode in a total of 10 sessions, 2 sessions per week for 5 weeks.
62006850|NCT02087462|OTHER|EA + Traction|Use electroacupuncture and traction together
62006851|NCT02087462|OTHER|EA + Traction + Oral Medication|Combine electroacupuncture, traction and oral medication (Voltaren and Vitamin B1) together for treatment
62006852|NCT02459314|PLACEBO_COMPARATOR|soymilk|Soymilk (SM) contained 5 gm soy protein and 6.5 gm sugar per 180 mL package.
62192519|NCT04034849|PLACEBO_COMPARATOR|Placebo group|Low-Level Laser Therapy was applied in the placebo group with a Diode Laser Fox (A.R.C. Laser, Italy) turned off with an application time per point of 10 seconds in 56 points (3 in the vestibular mucosa of the 4 quadrants, 6 in each of the two buccal mucosa, 6 in the hard palate, 4 in each lateral of the tongue, 6 in the dorsum of the tongue and 4 sublingual points) with a distance between points of 2mm. It was applied, therefore, a dose of 12 J/cm2 in a continuous mode in a total of 10 sessions, 2 sessions per week for 5 weeks.
62192520|NCT02229227|EXPERIMENTAL|Albiglutide + Insulin Glargine Arm|During standardization period, subjects will transit from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. During treatment period, subject will receive Albiglutide 30 milligrams (mg) weekly subcutaneous (SC) injection and insulin lispro dose will be downtitrated to half that used in the standardization period. At Week 4, Albiglutide will be uptitrated to 50 mg weekly SC injection and insulin lispro will be stopped for the remainder of the treatment Period. Insulin lispro may be re-introduced after Week 8 according to pre-defined hyperglycemia thresholds. Insulin will be adjusted according to protocol-defined insulin titration algorithms
62397872|NCT06722196|EXPERIMENTAL|Experimental|patients will receive 2 patches soaked in cordarone hydrochloride (150 mg/3 ml each)
62397873|NCT06722196|SHAM_COMPARATOR|Sham|patients will receive 2 patches soaked in saline solution (3 ml each)
62397874|NCT01623518|EXPERIMENTAL|ChAdOx1-NP+M1|
62397875|NCT03280576||Sepsis|Patients with sepsis
62397876|NCT03280576||Cardiac Surgery|Patients undergoing cardiac surgery
62397877|NCT03280576||Healthy controls|Normal individuals
62397878|NCT03737617|EXPERIMENTAL|Active arm|Weekly subcutaneous immunoglobulin therapy (0.1g/Kg) Cuvitru 20% Injectable Solution for 1 Year
62397879|NCT03737617|NO_INTERVENTION|Control|Standard Care arm without immunoglobulin replacement therapy
62006853|NCT02459314|ACTIVE_COMPARATOR|sterol/fiber-enriched soymilk|PLant sterol and soluble fiber-enriched soymilk (SFSM) contained 1 gm free plant sterol, 5 gm inulin (soluble fiber), 5 gm soy protein and 6.5 gm sugar per 180 mL package
62006854|NCT06161792|PLACEBO_COMPARATOR|I placebo capsule|"Subjects will be enrolled to about 14-days of placebo-run-in period.~Other Names:~RCN3028 placebo"
62006855|NCT06161792|EXPERIMENTAL|II RCN3028 0.8 mg capsule|"Subjects will be enrolled to about 14-days of placebo-run-in period. Treatment started at 0.4 mg, titrated to 0.8 mg for maintenance phase.~Other Names:~RCN3028 0.8 mg capsule"
62006856|NCT03913078|ACTIVE_COMPARATOR|Group Fitness|Subjects will be offered several sessions per week of a traditional group fitness program led by a trained group leader.
62006857|NCT03913078|ACTIVE_COMPARATOR|PlayFit|Subjects will be offered several sessions per week of a modified sports fitness program, led by a trained group leader.
62006858|NCT04983394|EXPERIMENTAL|Virtual Realty|Participants will play a motion-controlled video game with Microsoft XBox One Kinect for 30 minutes, three days a week, for 8 weeks and lower and upper extremity stretching, strengthening and endurance exercises
62006859|NCT04983394|ACTIVE_COMPARATOR|Conventional|Participants will do aerobic exercises for 30 minutes, three days a week, for 8 weeks and lower and upper extremity stretching, strengthening and endurance
62006860|NCT01375218|ACTIVE_COMPARATOR|Plastizote Brace|
62006861|NCT01375218|ACTIVE_COMPARATOR|Pavlik Brace|
62006862|NCT04169295|EXPERIMENTAL|Intervention group|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's, and couple's personalized IVF-prognosis
62006863|NCT04169295|SHAM_COMPARATOR|Control group|At the time of their fresh embryo transfer couples will receive a document with a photo of their transferred embryo(s) and the number of cryopreserved embryos.
62397880|NCT01539512|ACTIVE_COMPARATOR|Idelalisib + rituximab|Participants will receive idelalisib plus rituximab
62006864|NCT05894850|EXPERIMENTAL|With automatic surveillance system reminding through telephone and message|Patients were reminded of the surveillance time by an automatic surveillance system after the endoscopic and pathological results were available and before the surveillance time through telephone and message.
62006865|NCT05894850|EXPERIMENTAL|With automatic surveillance system reminding through message|Patients were reminded of the surveillance time by an automatic surveillance system after the endoscopic and pathological results were available and before the surveillance time through message.
62192521|NCT02229227|EXPERIMENTAL|Insulin Glargine + Insulin Lispro Arm|During standardization period, subjects will transit from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. During treatment period, subject will continue with the same doses as at the end of the standardization period and doses will be adjusted according to protocol-defined insulin titration algorithms
62192522|NCT01931982|ACTIVE_COMPARATOR|victoza|The study is a cross over study. Patients randomised to start with victoza are treated with victoza for 10 weeks. After a wash out period of 2 weeks they cross over to 10 weeks of no treatment
62781339|NCT00773773|EXPERIMENTAL|Patients undergoing prostatic biopsy|This study will enroll two groups of 250 patients who are to undergo prostatic biopsy as part of their routine medical care because of suspicion of prostate cancer (elevated PSA between 2 and 10 ng/ml, abnormal rectal examination, or both). The first group will contain 250 patients of African-American descent and the second will contain 250 Caucasian men.
62006866|NCT05894850|EXPERIMENTAL|With manual reminder|Patients were reminded of the surveillance time by manual reminder after the endoscopic and pathological results were available and before the surveillance time.
62006867|NCT05894850|NO_INTERVENTION|Normal group|The patients in the control group were observed in the clinical natural state of surveillance without automatic surveillance system or manual reminder.
62006868|NCT04135703|EXPERIMENTAL|Risk Prevention Services +Housing|Opioid and related prevention services including Strengths-Based Outreach and Advocacy (SBOA), MI, HIV risk and suicide prevention (CTSP) as well as rental and utility assistance for 6 months.
62006869|NCT04135703|EXPERIMENTAL|Risk Prevention Services Only|Opioid and related prevention services including Strengths-Based Outreach and Advocacy (SBOA), MI, HIV risk and suicide prevention (CTSP).
62006870|NCT00736203||A|non-smokers
62006871|NCT04545177|EXPERIMENTAL|Tissue Preservation System (TPS)|Tumor tissue will be obtained, processed, and then transported remotely to undergo multiple tests, including gene panel DNA sequencing, DNA methylation array, and bulk as well as single-cell transcriptome analyses (RNA-seq)
62192523|NCT01931982|NO_INTERVENTION|No treatment|
62192524|NCT04340934|EXPERIMENTAL|Use of REZUM system|Surgery of benign prostatic hyperplasia by REZUM system
62397881|NCT01539512|PLACEBO_COMPARATOR|Placebo + rituximab|Participants will receive placebo to match idelalisib plus rituximab
62573032|NCT02445638|ACTIVE_COMPARATOR|Whole egg|Subjects will be provided with a daily breakfast meal containing the equivalent of 2 whole eggs for 4 weeks.
62006872|NCT01854021|EXPERIMENTAL|inhalational anesthesia|inhalational anesthesia
62006873|NCT01854021|EXPERIMENTAL|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
62006874|NCT01854021|EXPERIMENTAL|intravenous anesthesia|intravenous anesthesia
62006875|NCT03580096|EXPERIMENTAL|Experimental group|Patients were included in a core stability intervention. It will be done with different stages and increasing gradually.
62006876|NCT03580096|ACTIVE_COMPARATOR|Control group|Standard intervention consisting of exercises aimed at improving balance.
62006877|NCT04019912|EXPERIMENTAL|Gait Training plus music|Patients will be randomly assigned to the rehabilitation group through gait trainer3 with Rhythmic Auditory Stimulation (RAS). All patients will undergo a complete clinical and neurophysiological evaluation at baseline. The training program consist of 45 minutes of treadmill training with RAS. The daily training program will be practiced once a day at the same time of day (from 9:00 am to 1:00 pm), five times a week for eight consecutive weeks. RAS treadmill sessions will be performed individually in the same position and under the supervision of physiotherapists with 2 years of RAS training.
62192525|NCT01906619||Febrile illness WITH febrile seizure|The cohort comprises children aged between 3 months and 5 years who had a febrile seizure during the actual febrile disease.
62397882|NCT05346887|EXPERIMENTAL|Home-based Therapy|
62397883|NCT05999292|OTHER|68Ga-R8760 Dose Selection (Part 1)|
62397884|NCT05999292|OTHER|68Ga-R8760 Expansion Cohort (Part 2)|
62397885|NCT03431688|ACTIVE_COMPARATOR|PAM|treatment with PPI, metonidazole, amoxicillin
62781340|NCT04751188|EXPERIMENTAL|Bezafibrate and Ursodeoxycholic acid|Bezafibrate 200 mg every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 6 months.
62781341|NCT04751188|PLACEBO_COMPARATOR|Placebo and Ursodeoxycholic acid|Placebo tablet every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 6 months.
62192526|NCT01906619||Febrile illness WITHOUT febrile seizure|The cohort comprises children aged between 3 months and 5 years with a febrile illness who had never a febrile seizure.
62192527|NCT01164111|EXPERIMENTAL|Preoperative resistance training|preoperative resistance training: Duration 8 weeks. Intensity: 3 sets of 80 % of 1 repetition max (1 RM) in each exercise. Frequency: 2 times/week
62397886|NCT03431688|ACTIVE_COMPARATOR|PBMT|treatment with PPI, metonidazole, bismuth, tetracyclin
62397887|NCT06723028|EXPERIMENTAL|Positive regulation of craving training|"Participants randomized into the active mROC-T intervention (mROC-T+) will:~1. Read a brief essay about the social justice benefits of eating healthy foods~2. Participants complete six free-response questions to ensure that they understood the essays.~3. Participants are instructed to use the information from the essay. They are shown a cue matching the essay: Think Positive~4. They are shown an image of a healthy food (no added sugar and \< 2g/serving saturated fat) OR an image of an unhealthy food (contain added sugar and/or \>4.5g/serving saturated fat).~5. The participant is asked to rate how strong their craving is for the pictured food. The participant indicates their craving on a VAS from 1 (No craving at all) to 5 (Very high craving)"
62397888|NCT06723028|EXPERIMENTAL|Critical regulation of craving training|"Participants randomized into the active mROC-T intervention (mROC-Tc) will:~1. Read a brief essay about the social justice consequences of eating unhealthy foods (CIRITCAL, mROCTc)~2. Participants complete six free-response questions to ensure that they understood the essays.~3. Participants are instructed to use the information from the essay. They are shown a cue matching the essay: Think Critical~4. They are shown an image of a healthy food (no added sugar and \< 2g/serving saturated fat) OR an image of an unhealthy food (contain added sugar and/or \>4.5g/serving saturated fat).~5. The participant is asked to rate how strong their craving is for the pictured food. The participant indicates their craving on a VAS from 1 (No craving at all) to 5 (Very high craving)"
62573033|NCT02445638|PLACEBO_COMPARATOR|Yolk-free egg|Subjects will be provided with a daily breakfast meal containing the equivalent of 2 yolk-free eggs for 4 weeks.
62573034|NCT00880854|EXPERIMENTAL|1|BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 in combination with CP-675,206 I.V. week 3, week 1
62781342|NCT01078844|PLACEBO_COMPARATOR|Placebo|Treatment as usual plus placebo
62781343|NCT01078844|ACTIVE_COMPARATOR|memantine|Treatment as usual plus memantine
62781344|NCT01340573||Genotype 1 CHC Participants|
62781345|NCT01340573||Non-genotype 1 CHC participants|
62006878|NCT04019912|ACTIVE_COMPARATOR|Traditional Gait Training|Patients will be randomly assigned to the non-Rhythmic Auditory Stimulation (RAS) treadmill walking group. All patients will undergo a complete clinical and neurophysiological evaluation at baseline.The daily training program consist of 45 minutes of conventional gait training using a non-RAS treadmill. The daily training program will be practiced once a day at the same time of day (from 9:00 am to 1:00 pm), five times a week for eight consecutive weeks. Non-RAS treadmill sessions will be performed individually in the same position and under the supervision of physiotherapists.
62006879|NCT02335138|PLACEBO_COMPARATOR|Control Arm|Each participant will receive an at-home test kit and will be asked to test and return results to investigator.
62006880|NCT02335138|ACTIVE_COMPARATOR|Intervention Arm|Each participant will receive an at-home test kit and will be asked to take the test in conjunction with an online CHTC session.
62006881|NCT01900613|EXPERIMENTAL|Intervention|Niños Sanos Familia Sana consists of CBPR developed nutrition education and economic vouchers for fruit and vegetable purchase in Firebaugh supermarket
62006882|NCT01900613|ACTIVE_COMPARATOR|Comparison|Comparison community of San Joaquin
62006883|NCT04048603||idiopathic REM sleep behavior disorder|Subjects with the diagnosis of idiopathic REM sleep behavior disorder
62006884|NCT04048603||Controls without iRBD|Healthy controls without the diagnosis of idiopathic REM sleep behavior disorder
62006885|NCT04147338|EXPERIMENTAL|Reference Device: Guselkumab|Participants will receive subcutaneous (SC) injections of guselkumab in reference device.
62006886|NCT04147338|EXPERIMENTAL|Test Device 1: Guselkumab|Participants will receive SC injections of guselkumab in test device 1.
62006887|NCT04147338|EXPERIMENTAL|Test Device 2: Guselkumab|Participants will receive SC injections of guselkumab in test device 2.
62006888|NCT05916157||ABBV-951|Participants will receive ABBV-951 as prescribed by their physician.
62006889|NCT00293384|EXPERIMENTAL|Aprepitant, Dexamethasone, Cytoxan & Kytril|"Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally, 1 hour prior to cyclophosphamide administration.~Cyclophosphamide 4gm/m2 I.V. over 90 - 120 minutes.~Days 2 \& 3: Aprepitant 80 mg once daily in the morning."
62006890|NCT05951244|ACTIVE_COMPARATOR|Transcranial Direct Stimulation|20 epilepsy patients who were eligible and gave consent according to the inclusion criteria. For active group, tDCS treatment will be 2 mA current strength for 30 minutes.
62006891|NCT05951244|SHAM_COMPARATOR|Sham-Transcranial Direct Current Stimulation|"20 epilepsy patients who were eligible and gave consent according to the inclusion criteria.~For the sham group, the current will increase to 2mA in 10 seconds, continue for the 30s, then decrease to 0 in 10 seconds and cut off."
62006892|NCT03763994||Control group 1|Never low back pain in the last 3 months
62006893|NCT03763994||Control group 2|occasionally (1-30days) low back pain in the last 3 months
62006894|NCT03763994||Low back pain group 3|frequently (31-60days) low back pain in the last 3 months
62006895|NCT03763994||Low back pain group 4|daily (61-90days) low back pain in the last 3 months
62006896|NCT01929668|ACTIVE_COMPARATOR|polyethylene glycol|4L polyethylene glycol
62006897|NCT01929668|EXPERIMENTAL|polyethylene glycol with ascorbic acid|2L polyethylene glycol and ascorbic acid
62006898|NCT05391217||Transgender people with history of cancer|Self-reported cancer history and/or treatment for cancer within the last 5 years.
62006899|NCT05391217||Transgender people without history of cancer|People living with other chronic conditions
62006900|NCT03194048|EXPERIMENTAL|Functional Chewing Training|Children with CP and have tongue thrust included this group.
62006901|NCT03194048|ACTIVE_COMPARATOR|Control|Children with CP and have tongue thrust included this group.
62192528|NCT01164111|NO_INTERVENTION|Control|Standard preoperative track.: No training intervention. Standard preoperative information.
62192529|NCT05250427||People / Person Living with Obesity (PLwO)|From online, general population consumer panels
62006902|NCT00475007|EXPERIMENTAL|1|The experimental group will have an investigational medical device implanted in their lungs with an instrument known as a bronchoscope. This procedure is done without an incision
62006903|NCT00475007|SHAM_COMPARATOR|2|The sham comparator group will be tested, treated and followed in an identical manner as the experimental group, except that no valves will be placed during the diagnostic bronchoscopy, the sham procedure.
62006904|NCT02054364|EXPERIMENTAL|FBT and CRT|Family-Based Treatment combined with Cognitive Remediation Therapy (15 sessions of each)
62006905|NCT02054364|EXPERIMENTAL|FBT and art therapy|Family-Based Treatment combined with art therapy (15 sessions of each)
62006906|NCT05956418|EXPERIMENTAL|Centhaquine (Dose: 0.01 mg/kg) + Standard of care|Centhaquine will be administered intravenously after enrollment to hypovolemic shock patients with systolic arterial blood pressure ≤ 90 mmHg at presentation and continue to receive standard shock treatment. Centhaquine will be administered at a dose of 0.01 mg/kg of body weight, as an intravenous (IV) infusion over 1 hour in 100 mL of normal saline. Second dose of centhaquine will be administered if SBP falls below or remains below or equal to 90 mmHg but not before 4 hours of the previous dose and total doses per day (in 24 hours) will not exceed 3 doses. Centhaquine administration if needed will continue for two days post-enrollment. A minimum of 1 dose or maximum of 6 doses of centhaquine will be administered within first 48 hours post-enrollment. Each patient will be monitored closely throughout his/her hospitalization and will be followed until discharge or day 7 (whichever is earlier) from enrollment.
62006907|NCT02544893|ACTIVE_COMPARATOR|bupivacaine|0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on paravertebral block
62006908|NCT02544893|ACTIVE_COMPARATOR|dexmedetomidine|100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on paravertebral block
62397889|NCT06723028|SHAM_COMPARATOR|Control|"Participants randomized to the control (CRO) group will:~1. Read a brief essay about fun food trivia (unrelated to any aspects of perceived healthiness). The essays are matched on structure/word count to the mROC-T essays.~2. Participants complete six free-response questions to ensure that they understood the essays.~3. Participants are instructed to use the information from the essay. They are shown a cue matching the essay, either: Think Relaxed or Think Serene.~4. They are shown an image of a healthy food (no added sugar and \< 2g/serving saturated fat) OR an image of an unhealthy food (contain added sugar and/or \>4.5g/serving saturated fat).~5. The participant is asked to rate how strong their craving is for the pictured food. The participant indicates their craving on a VAS from 1 (No craving at all) to 5 (Very high craving)"
62397890|NCT03319368|EXPERIMENTAL|Intervention: Targeted gown and glove use|Additional gowns and gloves used for high risk care activities
62397891|NCT06453473|EXPERIMENTAL|training on the PerStBiRo with pertubation (PerTSBR)|The experimental group will pedall on the PerStBiRo system like the active comparator group but will receive additional roll- and pitch-angles balance perturbations.
62781346|NCT02537184|OTHER|Group 1 - Recall Interval of 4 months|"Oral clinical conditions:~Only at baseline all childrens will receive 5% sodium FV (Duraphat, Colgate Oral Pharmaceuticals). Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment Procedure/Surgery: Oral clinical conditions Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
62781347|NCT02537184|OTHER|Group 2 - Recall Interval of 8 months|"Oral clinical conditions:~Only at baseline all childrens will receive 5% sodium FV (Duraphat, Colgate Oral Pharmaceuticals). Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment Procedure/Surgery: Oral clinical conditions Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
62781348|NCT06478303||TMS Experimental group|
62397892|NCT06453473|ACTIVE_COMPARATOR|unperturbed training on the PerStBiRo (TSBR)|The active comparator group will pedall on the PerStBiRo system without perturbations.
62397893|NCT06044168|EXPERIMENTAL|Intervention group|Receive leucine on a daily basis for 10 weeks.
62397894|NCT03836079|EXPERIMENTAL|ADHF Patients|Treatment with preCARDIA System
62781349|NCT06478303||fMRI Experimental group|
62781350|NCT06478303||Experimental ccPAS group|
62781351|NCT06478303||Sham ccPAS group|
62006909|NCT02544893|ACTIVE_COMPARATOR|serum phsyologic|0,9% 21 ml serum physiologic
62006910|NCT05411406||Study cohort|Patients undergoing ENT or OMS surgery with general anesthesia with facemask ventilation and tracheal intubation (observational)
62006911|NCT02130375|EXPERIMENTAL|stress urinary incontinence|Women with stress urinary incontinence
62006912|NCT02224365|EXPERIMENTAL|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
62006913|NCT02224365|PLACEBO_COMPARATOR|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
62192530|NCT05250427||Health Care Professionals (HCPs)|HCPs treating people who have obesity
62781352|NCT06478303||control group|
62781353|NCT01153555||Intermediate coronary lesions|"Diagnostic device: FFR~Diagnostic device: IVUS RF~At participating centers, FFR and IVUS are standard of care diagnostic procedures for patients with intermediate (40-80% angiographic stenosis by visual estimate). Both modalities were used regularly for such patients whether or not they are participants in this clinical study. In FIRST, the decision to perform percutaneous coronary intervention (PCI) was left to the discretion of the investigator, and was not dictated by the clinical protocol."
62781354|NCT03725761|EXPERIMENTAL|Sacituzumab Govitecan Treatment|Subjects enrolled in this study will receive Sacituzumab Govitecan in addition to their single agent ARSI as treatment for Castrate-Resistant Prostate Cancer. Dose will be calculated per protocol in milligrams based on the subject's body weight at the beginning of each cycle or more frequently if weight changes \>10%. Subjects will be treated on days 1 and 8 in a 21-day cycle, minimum 3 cycles.
62781355|NCT05532891||Pre-pandemic|Patients that underwent elective bariatric surgery in a control period prior to the pandemic (one year from 1st September 2018).
62781356|NCT05532891||Pandemic|Patients that underwent elective bariatric surgery during the pandemic (one year from 1st April 2020)
62781357|NCT02818049|EXPERIMENTAL|Bronchoalveolar Lavage|BAL was performed in accordance with current practice. Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure. Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor. O2 saturation (SpO2) is monitored continuously by pulse oximetry.
62781358|NCT04790292|ACTIVE_COMPARATOR|group M|group M 10mg morphine +0.25% bupivacaine
62781359|NCT04790292|ACTIVE_COMPARATOR|group MD|group MD 10mg morphine + 8mg dexamethasone +0.25% bupivacaine
62006914|NCT04990726||Observational (assessment, blood collection, questionnaire)|Patients undergo medical assessments and blood sample collection and complete questionnaires at baseline, 1, 3, 6, 12, 18, and 24 months.
62006915|NCT04990726||Treatment (assessment, blood collection, questionnaire)|Patients undergo medical assessments and blood sample collection and complete questionnaires at baseline (prior to C1 infusion), 2, 4, 7 infusion, at end of treatment, and 18 and 24 months after completion of treatment.
62006916|NCT03704181|EXPERIMENTAL|colchicine|colchicine 0,5 milligram tablet by mouth every 12 hours, for 1 year
62006917|NCT03704181|ACTIVE_COMPARATOR|placebo|"placebo tablet by mouth every 12 hours, for 1 year~pill manufactured to mimic coclchicine 0,5 mg tablet"
62006918|NCT04535284|EXPERIMENTAL|Coaching|"Health Coaching-in-Context includes coaching by trained coaches up to 10 sessions over teleconference."
62006919|NCT04535284|NO_INTERVENTION|Usual Care|The usual care group does not get any intervention but continues with any of their usual activities that would otherwise would have been provided to them.
62006920|NCT06574230|EXPERIMENTAL|dart training|The exercise group participated in dart training for 12 weeks, with sessions held three times per week, each lasting 90 minutes. During the first week of the program, participants received both theoretical and practical instruction on game rules, breathing techniques, and throwing techniques. The training focused on breathing control, throwing techniques, scoring strategies, and involved practicing a set number of exercises.
62006921|NCT06574230|NO_INTERVENTION|control group|the control group did not engage in any dart-related activities during this period and were instructed to continue with their regular daily activities at school.
62006922|NCT00478400||Participants who have had a TBI|"(recruited by invitation only)~1. Must be between 1- and 6-years post-injury~2. Closed head injury~3. Evidence of loss of consciousness~4. Must have an informant (friend, spouse, child etc.)~5. Audit-C \< 7, PCL \< 65 and PHQ-9 \< 15"
62006923|NCT00478400||Participants with No history of TBI|"(Recruited by invitation only)~1. No history of TBI~2. Must have an informant (friend, spouse, child etc.)"
62006924|NCT00478400||Veterans with History of TBI|"1. Must be between 1- and 6-years post-injury~2. Closed head injury~3. Evidence of loss of consciousness~4. Must have an informant (friend, spouse, child etc.)~5. Audit-C \< 7, PCL \< 65 and PHQ-9 \< 15"
62006925|NCT00478400||US Veterans with No history of TBI|"1. No history of TBI~2. Must have an informant (friend, spouse, child etc.)"
62006926|NCT05142358|ACTIVE_COMPARATOR|left-sided breast cancer|Participants will come in for their regularly scheduled radiation planning and treatment. Participants will undergo three scans (with and without DIBH (i.e., free-breathing), with CPAP). Participants will also use the CPAP device before the CT scan, for which they will be educated and trained.
62006927|NCT05142358|ACTIVE_COMPARATOR|Lung SBRT|Participants will come in for their regularly scheduled radiation planning and treatment. Participants will undergo three scans (with and without DIBH (i.e., free-breathing), with CPAP). Participants will also use the CPAP device before the CT scan, for which they will be educated and trained.
62006928|NCT01799356|ACTIVE_COMPARATOR|moxifloxacin Group|Treatment at uPID with moxifloxacin
62006929|NCT01799356|PLACEBO_COMPARATOR|Ofloxacin Group|Treatment at uPID with Ofloxacin plus metronidazole
62006930|NCT04931225|EXPERIMENTAL|Landiolol injection|Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.
62006931|NCT04931225|NO_INTERVENTION|Usual tachycardia management|No treatment, usual tachycardia management.
62006932|NCT05446350|EXPERIMENTAL|Experiment 1|The aim of Experiment 1 is to understand how tACS operates on the neural level
62006933|NCT05446350|EXPERIMENTAL|Experiment 2|The aim of Experiment 2 is to increase efficacy of tACS and, consequently, its potential to play an important role in research and everyday life applications
62006934|NCT05446350|EXPERIMENTAL|Experiment 3|The aim of Experiment 3 is to reveal how tACS can boost speech perception in a multi-speaker scenario.
62006935|NCT05446350|EXPERIMENTAL|Experiment 4|The aim of Experiment 4 is to combine established techniques to create novel opportunities to improve speech perception
62397895|NCT06280079|EXPERIMENTAL|Ultra-high-caloric fatty diet|ultra-high-caloric, high-fat, fluid nutritional supplement oral intake of 4 times 35 ml per day in addition to normal food intake, corresponding to +630 kcal and +70g fat per day
62397896|NCT06280079|PLACEBO_COMPARATOR|Placebo|placebo, fluid nutritional supplement oral intake of 4 times 35 ml per day in addition to normal food intake, corresponding to +50 kcal and +3,5g fat per day
62397897|NCT01641952||Rituximab|Participants who had an inadequate response or intolerance to one anti- tumor necrosis factor (anti-TNF) agent received rituximab (Mabthera) at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
62397898|NCT05142904|EXPERIMENTAL|Radiofrequency ablation|Patients allocated to the radiofrequency ablation (RFA) arm will undergo RFA under local anaesthesia with the moving-shot technique.
62397899|NCT05142904|ACTIVE_COMPARATOR|Radioactive iodine, study protocol|Patients allocated to this arm will undergo treatment with radioactive iodine (I-131) according to a standardized dose-calculation.
62397900|NCT05142904|OTHER|Radioactive iodine, cohort|This group contains patients who are not randomized and have given informed consent undergo treatment with radioactive iodine (I-131) according to local standard (e.g. fixed dose or dose-calculation based on iodine uptake and thyroid nodule mass).
62397901|NCT02218866||Group 1|All participants will be examined by a neurologist to test sensation, reflexes, and strength and complete a few questionnaires. Tests will be performed to measure nerve function and small punch skin biopsies will be taken to assess nerve fiber density. Blood and urine tests will measure various markers of interest. Participants will be seen before and after their bariatric surgery.
62397902|NCT02218866||Group 2|"In addition to the procedures described for Group 1, participants in Group 2 will have the following procedures:~* During bariatric surgery, a small biopsy from the liver and abdominal fat will be taken to examine how fat is processed within the body.~* At the first visit, after a skin biopsy is taken, a small capsaicin patch will be placed on the lower thigh. The patch will remain in place for 48 hours and will cause the nerves in the immediate area to pull back from the skin. A biopsy will be taken from the patch area 48 hours, 1 month, and 3 months after the initial biopsy. This procedure will be repeated after surgery.~* MRIs may be performed before and after bariatic surgery.~* Participants may be asked to complete additional tests to evaluate nerve function"
62397903|NCT02218866||Group 3|Group 3 will comprise of individuals who are not overweight. Participants in this group will undergo a similar evaluation to Group 2.
62397904|NCT06018389|EXPERIMENTAL|Structural Only|The Structural Only condition consists of (1) school policies for school-based social events; and (2) an information-based interactive parent meeting. Interventions in this arm are targeting the school and parent level.
62397905|NCT06018389|EXPERIMENTAL|Structural+Group MI|"The Structural+Group MI condition consists of the elements described in Structural Only and group MI. Interventions in this arm are targeting all three levels: school, parent and student level."
62397906|NCT06018389|NO_INTERVENTION|Control|The Control condition is an assessment-only condition. During the period under study, it includes the same assessments (surveys) as the other two conditions. After the last follow-up (August 2024), control schools can opt-in to receive any of the intervention programs.
62397907|NCT03635541||observational group of NAFLD|Liver biopsy proved NAFLD patients, observational study. Oral advice on lifestyle would be given at each visit.
62397908|NCT00722462|EXPERIMENTAL|1|Active acupuncture
62397909|NCT00722462|SHAM_COMPARATOR|2|Sham Acupuncture- acupuncture at neutral points
62397910|NCT00722462|NO_INTERVENTION|3|Embryo transfer with no acupuncture
62397911|NCT03707106|EXPERIMENTAL|VR based cue exposure smoking cessation|an established CBT intervention for smoking cessation supported by cue exposure in virtual reality
62397912|NCT03707106|ACTIVE_COMPARATOR|PMR supported smoking cessation|an established CBT intervention for smoking cessation supported supported by specific stress reduction (Progressive Muscle Relaxation, Jacobson)
62397913|NCT02062541|EXPERIMENTAL|Funct. assessment+fast rehabilitation|Funct. assessment+fast rehabilitation
62006936|NCT01487616||Women with previous preterm birth|Women with history of preterm birth (birth of a baby of less than 37 weeks gestational age, where labour was spontaneous) regardless of past pregnancy history.
62397914|NCT02062541|EXPERIMENTAL|Funct. assessment+usual rehabilitation|Funct. assessment+usual rehabilitation
62397915|NCT02062541|EXPERIMENTAL|usual assessment+fast rehabilitation|usual assessment+fast rehabilitation
62397916|NCT02062541|NO_INTERVENTION|usual assessment+usual rehabilitation|usual assessment+usual rehabilitation
62397917|NCT05122364|ACTIVE_COMPARATOR|Telerehabilitation group|Group of cochlear implanted children who will take sessions online by the Arabic online program that will be designed
62397918|NCT05122364|PLACEBO_COMPARATOR|Face to Face group|Group of cochlear implanted children who will take sessions face to face in the classical way (control group)
62397919|NCT06180655|EXPERIMENTAL|Diabetes Self-Management Education and Support (DSMES) plus Tai Chi Easy (TCE)™|Participants will be asked to attend 45 minutes of DSMES and 45 min of TCE twice a week for 6 weeks. All classes will be recorded and available online and can viewed at a time when it is most convenient to accommodate working adults.
62397920|NCT02861157|EXPERIMENTAL|TX Condition: Planet T1D Intervention|Families participating in the TX condition will be asked to attend a one-hour orientation session, during which study expectations and tasks will be explained. Families will be asked to watch a short 2-minute study overview video that summarizes study requirements and expectations. Parents and their children will then have the opportunity to provide informed consent/assent prior to their participation in the study. Youth participants will then receive a mobile phone preloaded with the Planet T1D app and a brief orientation to the app and associated website. Participants in the TX condition will receive immediate access to the Planet T1D application and website following the orientation session and will have four months to freely use the application. The TX group will be provided with a mobile phone for the full 2-months of the study.
62781360|NCT04767984|EXPERIMENTAL|Arm I (atorvastatin, biospecimen collection)|Patients receive atorvastatin PO QD for 12 months. Patients also undergo colonoscopy with biopsy, and collection of blood on the trial.
62192531|NCT05920993||Healthy adults|Measures of tongue function were collected from two groups of individuals(healthy adults and stroke patients with dysphagia ). The items of measurement about healthy adults are the maximal tongue pressure, tongue endurance, and lingual swallowing pressures of saliva, 3-ml water, IDDSI 2, IDDSI3, and IDDSI 4 liquids.
62006937|NCT01487616||Women with previous miscarriage|Women with history of miscarriage (spontaneous pregnancy loss before 24 weeks of gestation), regardless of past pregnancy history.
62192532|NCT05920993||Stroke patients with dysphagia|The items of measurement about stroke patients with dysphagia are the maximal tongue pressure, tongue endurance, and lingual swallowing pressures of saliva.
62397921|NCT02861157|NO_INTERVENTION|CO Condition: Treatment-As-Usual|A national sample of type 1 diabetes participants will be recruited through a partnership with Medikidz Ltd. Because of the inability to meet with remotely located participants for orientation and distribution of phones, these participants will be assigned to the treatment-as-usual, online control (CO) condition. For recruitment of the online control group, youth and parents interested in participating will be asked to complete a brief eligibility survey. Participants in the treatment-as-usual CO condition will not receive access to the Planet T1D app and website but will receive email reminders to complete surveys online at each time point.
62397922|NCT05602623|EXPERIMENTAL|770 +/- 9nm/ 830 +/- 15nm/ 900 +/- 15nm|Eligible subjects will be randomized to wavelength sequence 770 +/- 9nm/ 830 +/- 15nm/ 900 +/- 15nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
62397923|NCT05602623|EXPERIMENTAL|770 +/- 9nm/ 900 +/- 15nm/ 830 +/- 15nm|Eligible subjects will be randomized to wavelength sequence 770 +/- 9nm/ 900 +/- 15nm/ 830 +/- 15nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
62397924|NCT05602623|EXPERIMENTAL|830 +/- 15nm/ 770 +/- 9nm/ 900 +/- 15nm|Eligible subjects will be randomized to wavelength sequence 830 +/- 15nm/ 770 +/- 9nm/ 900 +/- 15nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
62397925|NCT05602623|EXPERIMENTAL|830 +/- 15nm/ 900 +/- 15nm/ 770 +/- 9nm|Eligible subjects will be randomized to wavelength sequence 830 +/- 15nm/ 900 +/- 15nm/ 770 +/- 9nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
62397926|NCT05602623|EXPERIMENTAL|900 +/- 15nm/ 830 +/- 15nm/ 770 +/- 9nm|Eligible subjects will be randomized to wavelength sequence 900 +/- 15nm/ 830 +/- 15nm/ 770 +/- 9nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
62397927|NCT05602623|EXPERIMENTAL|900 +/- 15nm/ 770 +/- 9nm/ 830 +/- 15nm|Eligible subjects will be randomized to wavelength sequence 900 +/- 15nm/ 770 +/- 9nm/ 830 +/- 15nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
62397928|NCT02662348|EXPERIMENTAL|Interleukin-2 Transfusion|Patients receive low-dose Recombinant Human Interleukin-2 SC daily beginning 3 days before the first HER2Bi armed T cell infusions infusion.
62192533|NCT01889069|EXPERIMENTAL|Rituximab|Participants will receive at least 4 doses of rituximab 1400 mg SC once a month during the Induction period, and at least 6 doses of rituximab 1400 mg SC once every two months during the Maintenance period, in addition to standard chemotherapy. Standard chemotherapy regimen included cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP); or cyclophosphamide, vincristine and prednisone (CVP); or bendamustine as per standard local practice.
62192534|NCT03790709|EXPERIMENTAL|High dose ANAVEX2-73|High dose active once daily orally
62192535|NCT03790709|EXPERIMENTAL|Mid dose ANAVEX2-73|Mid dose active once daily orally
62006938|NCT01487616||Women with previous term births|Women with previous term births (37 or more weeks of gestation)
62192536|NCT03790709|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo dose once daily orally
62006939|NCT02145039|EXPERIMENTAL|Haploidentical stem cell transplant|This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
62006940|NCT05588024||Head Up CPR based bundle of care|All patients in the registry receive the Head Up CPR based bundle of care.
62192537|NCT05631743|EXPERIMENTAL|VR-CBT|A trained psychotherapist provides CBT-VR for up to 10 sessions over 10 weeks.
62006941|NCT04917094|EXPERIMENTAL|Below the knee compression stocking|
62006942|NCT01470469|ACTIVE_COMPARATOR|SPD503|
62006943|NCT01470469|PLACEBO_COMPARATOR|Placebo|
62192538|NCT05631743|ACTIVE_COMPARATOR|Self-management|Participants use a commercial VR application at home for guided self-management at their own pace over 10 weeks.
62192539|NCT04700683|ACTIVE_COMPARATOR|Noninvasive Peripheral Nerve Stimulation|NPNS device programmed to deliver active stimulation.
62192540|NCT04700683|SHAM_COMPARATOR|Sham control|NPNS device programmed to deliver sham stimulation.
62192541|NCT01357642|EXPERIMENTAL|Arm T|Arm T is the experimental treatment arm consisting of 2 x 125 mcg/inhalations of E004, QID, with 4-6 hr intervals
62006944|NCT04252105|EXPERIMENTAL|Antioxidant rich diet|
62006945|NCT04252105|NO_INTERVENTION|Regular diet|
62006946|NCT06374433|EXPERIMENTAL|Occipital tACS at IAF-2Hz|Transcranial alternating current stimulation (tACS) at occipital sites to modulate the occipital brain areas' activity at a frequency below the individual alpha frequency (IAF-2 Hz).
62006947|NCT06374433|EXPERIMENTAL|Occipital tACS at IAF+2Hz|Transcranial alternating current stimulation (tACS) at occipital sites to modulate the occipital brain areas' activity at a frequency above the individual alpha frequency (IAF+2 Hz).
62006948|NCT06374433|EXPERIMENTAL|Frontal tACS at 4-7 Hz|Transcranial alternating current stimulation (tACS) at frontal sites to modulate the frontal brain areas' activity at a frequency within the theta band (4-7 Hz).
62006949|NCT06374433|SHAM_COMPARATOR|Sham/placebo tACS|Transcranial alternating current stimulation (tACS) is applied only in the first and the last 30 seconds of the experimental procedure, thus resulting ineffective.
62006950|NCT06374433|EXPERIMENTAL|Occipital tRNS|Stimulation at occipital sites with transcranial random noise stimulation (tRNS) to modulate occipital brain areas plasticity
62006951|NCT06374433|EXPERIMENTAL|Frontal tRNS|Stimulation at frontal sites with transcranial random noise stimulation (tRNS) to modulate frontal brain areas plasticity
62006952|NCT06374433|SHAM_COMPARATOR|Sham/placebo tRNS|Transcranial random noise stimulation (tRNS) is applied only in the first and the last 30 seconds of the experimental procedure, thus resulting ineffective.
62006953|NCT03106727|ACTIVE_COMPARATOR|Zalewa|Household Model Intervention introduced first - March 2017
62006954|NCT03106727|ACTIVE_COMPARATOR|Ligowe and Magaleta|Household Model Intervention to be introduced in June 2017
62006955|NCT03106727|ACTIVE_COMPARATOR|Neno District Hospital and Neno Parish|Household Model Intervention to be introduced in September 2017
62006956|NCT03106727|ACTIVE_COMPARATOR|Matope|Household Model Intervention to be introduced in December 2017
62006957|NCT03106727|ACTIVE_COMPARATOR|Matandani and Nsambe|Household Model Intervention to be introduced in March 2018
62006958|NCT03106727|ACTIVE_COMPARATOR|Luwani, Nkula, and Midzemba|Household Model Intervention to be introduced in June 2018
62006959|NCT02530294|EXPERIMENTAL|glycopyrronium|glycopyrronium Topical Wipes
62006960|NCT02530294|PLACEBO_COMPARATOR|Vehicle|glycopyrronium Topical Wipes, Vehicle
62006961|NCT04612634|EXPERIMENTAL|Research Group 1|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun Institute of Biological Products Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
62006962|NCT04612634|ACTIVE_COMPARATOR|Research Group 2|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang Pukang Biotechnology Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
62006963|NCT04612634|ACTIVE_COMPARATOR|Research Group 3|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. at the age of 18-24 months old, 1.0 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
62006964|NCT00129233|ACTIVE_COMPARATOR|Valsartan|Valsartan group treated with 80-160mg daily valsartan without Ca channel blockers or ACE inhibitors.
62006965|NCT00129233|ACTIVE_COMPARATOR|Amlodipine|Amlodipine group treated with 5-10mg daily amlodipine without ACE inhibitors or angiotensin receptor blockers.
62006966|NCT00512096|EXPERIMENTAL|Cisplatin + Ifosfamide + Paclitaxel|Cisplatin 25 mg/m\^2 IV Days 1-3; Ifosfamide 1200 mg/m\^2 IV Days 1-3; Paclitaxel 175 mg/m\^2 IV Day 1
62006967|NCT03814694|EXPERIMENTAL|CRHP Diet|Hypo-energetic carbohydrate-reduced high-protein (CRHP) dietary intervention with a controlled 5-7% loss in body weight.
62006968|NCT03814694|ACTIVE_COMPARATOR|CD Diet|Hypo-energetic conventional diabetes (CD) dietary intervention with a controlled 5-7% loss in body weight.
62006969|NCT02594722|EXPERIMENTAL|One single arm group|"COPD included in a pulmonary rehabilitation program~Intervention:~Investigators used a bedside cycloergometer with electrical stimulation. COPD perform 2 measure of oxygen uptake during exercise for compare aerobic capacities:~* Functional Electrical Stimulation Cycling (FES-cycling)~* Classic Cycloergometer endurance training with a sham electrical stimulation"
62006970|NCT03464344|OTHER|Patients with cortical superficial siderosis.|During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
62006971|NCT03464344|OTHER|Patients without cortical superficial siderosis|During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
62006972|NCT00830193|ACTIVE_COMPARATOR|N-acetylcysteine|Intravenous fluid administration was administered as soon as possible following randomization (not to exceed 12 hours prior to anticipated contrast exposure) and continued for 12 hours post CT. Patients randomized to the experimental arm received intravenous normal saline plus NAC 10 grams IV (5 g pre and 2.5 g at 6 and 12 hours post-exposure) for a total of 3 doses.
62006973|NCT00830193|PLACEBO_COMPARATOR|Placebo|Intravenous fluid administration was administered as soon as possible following randomization (not to exceed 12 hours prior to anticipated contrast exposure) and continued for 12 hours post CT. Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g in 100 cc D5W (pre-CT dose) or 2.5 g in 50 cc D5W (post-CT doses). The placebo was D5W and was colour and consistency matched by pharmacy. Patients randomized to placebo received intravenous normal saline plus 3 doses of placebo.
62006974|NCT02423265|ACTIVE_COMPARATOR|Ranolazine|500mg bd ranolazine for 1 week then uptitrated to 1000mg bd to continue for 8 weeks
62192542|NCT01357642|PLACEBO_COMPARATOR|Arm P|Placebo comparator as 2×Placebo QID, with 4-6 hr intervals
62192543|NCT01357642|ACTIVE_COMPARATOR|Arm A|Active comparator, Primatene Mist, 2×220 mcg/inhalation, QID, with 4-6 hr intervals
62192544|NCT02147847|EXPERIMENTAL|Video game based training 1|Video Game play with training strategy 1
62192545|NCT02147847|EXPERIMENTAL|Video game based training 2|Video Game play with training strategy 2
62192546|NCT05072652|EXPERIMENTAL|Immobilization|Participants in the immobilization groups will undergo one week of unilateral knee joint immobilization of the left leg.
62192547|NCT05072652|NO_INTERVENTION|Control|The control group will not undergo any intervention.
62573035|NCT04028050|EXPERIMENTAL|Atezolizumab + Carboplatin + Etoposide|Participants will receive intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min), followed by intravenous infusion of etoposide 100 milligrams per square meter (mg/m\^2) on days 1 through 3 of each cycle during the induction phase (21-day cycle for four/six cycles). On Days 2 and 3, participants will receive etoposide alone. After the induction phase, participants will begin maintenance therapy with atezolizumab every 3 weeks until PD, unacceptable toxicity, loss of clinical benefit or study termination by the Sponsor.
62781361|NCT04767984|PLACEBO_COMPARATOR|Arm II (placebo, biospecimen collection)|Patients receive placebo PO QD for 12 months. Patients also undergo colonoscopy with biopsy, and collection of blood on the trial.
62781362|NCT04003987|ACTIVE_COMPARATOR|ESP Block|For the ESP block the ultrasound is positioned in a parasagittal fashion, 2-3 inches lateral to the spinous process. This approach visualizes the transverse process. The needle is inserted cranial-to-caudal to make contact with the shadow of the transverse process, with the needle tip deep to the fascial plane of the erector spinae muscle. Injection of saline confirms the location of the needle, and the anesthetic is injected (40 ml into each side; 20 ml injected at T8 and 20 ml injected at T12)
62781363|NCT04003987|ACTIVE_COMPARATOR|TAP Block|For the TAP block, the ultrasound probe is placed transverse to the abdominal wall, between the iliac crest and the costal margin. The needle is placed in the plane of the probe and advanced until it is between the internal oblique and the transversus abdominis muscles. Once in the plane, 2 mL of saline is injected to confirm needle position, then the local anesthetic solution is injected (40 ml into each side; 20 ml injected for subcostal TAP and 20 ml injected for posterior TAP).
62781364|NCT05801614|OTHER|Low Carb diet|Participants will have acces to a plattform with recepies containing 30 g carbohydrate / day during the first three months and thereafter recepies containing 80 g carbohydrate/ day during the remaining 12 months
62781365|NCT05801614|OTHER|Low Calori diet|Participants will be asked to by low caloric diet replacement containing 850 kCal/day during the first 3 months, aiming for a weight loss of 10 kg during and thereafter will have access to recepies containing less calorie for weight maintenance during the remaining 12 months
62781366|NCT04715698|EXPERIMENTAL|ICG-guided|anti-hypertensive drug selection based on physician's experience and hemodynamic profiling by measured ICG
62781367|NCT04715698|ACTIVE_COMPARATOR|Empirical|anti-hypertensive drug selection based on physician's experience only
62781368|NCT05987956|EXPERIMENTAL|Alectinib - Usual|"* Usual ALECENSA - Alectinib~* Chemotherapy (NDC...01)~* Usual ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily~* Usual Approach Group (NDC...01)~* ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
62781369|NCT05987956|EXPERIMENTAL|Alectinib - Study|"* Study ALECENSA - Alectinib~* Chemotherapy (NDC...86)~* Study ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily~* Study Approach Group (NDC...86)~* ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
62006975|NCT02423265|PLACEBO_COMPARATOR|Placebo|Matching placebo, with up titration after 1 week as in active treatment arm
62192548|NCT03836573|EXPERIMENTAL|E-cigarette only decision aid|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of information on e-cigarettes only. Patients will only be enrolled in this group in phase II if they self-identify as 'uninterested in quitting cigarettes'. During the physician encounter will be given harm-reduction guidance.
62192549|NCT03836573|EXPERIMENTAL|E-cigarette and Standard Smoking Cessation Group|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of standard smoking cessation and e-cigarette options. Patients will only be enrolled in this group in phase II if they self identify as 'interested in quitting and using e-cigarettes'. During the physician encounter will be given e-cigarette cessation guidance.
62192550|NCT03836573|EXPERIMENTAL|Standard Smoking Cessation Group|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of standard smoking cessation and e-cigarette options. All patients in phase I will be enrolled in this group. In addition, patients in phase II who self-identify as 'interested in quitting but do not use e-cigarettes' will also be enrolled in this group. During the physician encounter will be given standard smoking cessation guidance.
62192551|NCT05933785||transanal endoscopic ISR|
62192552|NCT05933785||traditional ISR|
62192553|NCT01632410||Study group 1|"Post hemispheral ischemic stroke cognitively intact. Exclusion: Subjects with severe visual or hearing impairments, stroke location brain steam.~The group will be divided in to 4 goups acording to stroke specific location as demonstrated in MRI."
62192554|NCT01632410||Control|Control: Healthy subjects resemble in age and sex
62192555|NCT01632410||Study -3|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
62192556|NCT01632410||Stydy -2|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
62192557|NCT01632410||Stydy- 4|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
62214785|NCT01763398||non-Hodgkin's lymphoma|Patients with non-Hodgkin's lymphoma, high risk group for neutropenic fever, treated by CHOP-like regimen and primary G-CSF prophylactic therapy
62397929|NCT02662348|EXPERIMENTAL|T Cells Transfusion|Patients receive HER2Bi-Armed T Cells IV weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62192558|NCT00824330|OTHER|Control Phase; Exercise Phase|"Participants act as their own control.~Control Phase:~Participants will not change their activity during the 3 month control phase (defined as no strength training and less than 30 minutes brisk walking/moderate exercise per week, no vigorous exercise) Baseline measures will be obtained.~Exercise Phase:~This phase will consist of a Titration phase followed by an Intervention Phase. During the Titration phase, under the guidance of a trainer, subjects will increase their number of steps by 20% per week until they have reached 10,000 steps or 3 months have passed. During the Intervention Phase subjects will continue to walk 10,000 steps (or the number of steps they reached in the Titration phase)."
62192559|NCT02846064|OTHER|Ovarian tissue cryopreservation|
62192560|NCT04614090||99 warfarin patients|warfarin patients were operated within 24 h with a cephalomedullary nail due to a trochanteric or subtrochanteric hip fracture. All patients on warfarin were reversed if necessary to INR≤1.5 before surgery using vitamin K and/or four-factor prothrombin complex concentrate (PCC)
62192561|NCT04614090||99 patients without anticoagulants|As a 1:1 ratio control group matched for age, gender and surgical implant. All patients were operated within 24 h with a cephalomedullary nail due to a trochanteric or subtrochanteric hip fracture.
62192562|NCT00268372|ACTIVE_COMPARATOR|cisplatin/RT alone|cisplatin and radiation therapy
62192563|NCT00268372|EXPERIMENTAL|induction chemo followed by cisplatin/RT|docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by surgery and/or cisplatin and radiation therapy
62192564|NCT02842437|EXPERIMENTAL|Dexmedetomidine|25 patients receive a loading infusion of dexmedetomidine (1ug/kg) for 10min follow by a maintenance infusion (0.5ug/kg·h) continued until the end of the surgery
62192565|NCT02842437|PLACEBO_COMPARATOR|Placebo|25 patients receive matching placebo （normal saline）
62192566|NCT03553381||obese without MS|BMI 25- 35 Kg/mq without metabolic syndrome (MS) submitted to hypocaloric balanced diet
62192567|NCT03553381||obese with MS|BMI 25- 35 Kg/mq with metabolic syndrome submitted to hypocaloric balanced diet
62192568|NCT04669743|EXPERIMENTAL|Study Population|Subjects will be recruited and consented following screening. Subjects will be characterized into cohorts based on presence of COPD and smoking status. All subjects enrolled will be undergoing the same interventions: 1st Bronchoscopy (3 wks pre-exposure), Ozone Exposure, 2nd Bronchoscopy (1 day post-exposure), 3rd Bronchoscopy (5 days post-exposure). Ozone exposure will take place in an exposure chamber.
62192569|NCT01077128||Patients with psoriasis|All eligible patients with psoriasis treated with Adalimumab
62192570|NCT01672593|EXPERIMENTAL|PRFG treatment|As described in our previous study, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the autologous PRFG(platelet-rich fibrin glue) group and then frozen at -20°C for storage. Prior to application, frozen cryoprecipitate and thrombin stored were thawed in a 37°C water bath. Aminomethylbenzoic Acid (1ml: 1mg, Sigma-Aldrich, St Louis, MO) was added into the cryoprecipitate in the volume ratio of 1:10.
62397930|NCT02821975|EXPERIMENTAL|Cognitive computer training|This is the intervention group receiving cognitive computer training three times a week for three months.
62192571|NCT01672593|ACTIVE_COMPARATOR|Bioseal treatment|The commercial fibrin sealants used in the study were purchased from Guangzhou Bioseal Biotech Co. Ltd, Guangzhou, China. Upon application, two components, fibrinogen and thrombin, were placed separately in two syringes which were joined by a Y-shaped connector. The trunk of the Y-shaped connecter was connected to a single lumen catheter.
62192572|NCT03035669|EXPERIMENTAL|Mindfulness group|Mindfulness based stress reduction: 8 week program, including meditation, body-awareness, and yoga practices. Daily assignments and home practices during 50 minutes per day.
62192573|NCT03035669|ACTIVE_COMPARATOR|Reading group|Reading and sharing group: 8 week program, including readings, interpersonal exchanges, group discussion, listening and role playing exercises. Daily assignments and home practices during 50 minutes per day.
62192574|NCT05030051|EXPERIMENTAL|SkinPen Precision System|This proof of concept study is being conducted over the course of 60 days followed by a 3-month post-treatment visit to assess the efficacy and tolerability of the Sponsor's SkinPen device when used to treat men and women with signs of aging on the dorsum of the hands. Overall assessment of clinical outcome and safety will be based on the evaluation of pre- and post-treatment photos comparing baseline to final visit. The subject's assessment of satisfaction will also be evaluated at Visit 3 and Visit 4. Finally, both the clinician's and subject's assessment will be characterized using a clinician assessment scale at the 3 month post-treatment visit.
62397931|NCT02821975|NO_INTERVENTION|cogntrol group|The control group do not receive cognitive computer training for three months
62397932|NCT01754363|EXPERIMENTAL|Attune Primary Total Knee Replacement|"Subjects will receive one of the following Attune total knee implants:~Cruciate retaining fixed bearing (CR FB) Cruciate retaining rotating platform (CR RP) Posterior stabilized fixed bearing (PS FB) Posterior stabilized rotating platform (PS RP)"
62397933|NCT05579509|EXPERIMENTAL|High Pain Catastrophizing|Based on the Pain Catastrophizing Scale (PCS)
62397934|NCT05579509|EXPERIMENTAL|Low Pain Catastrophizing|Based on the Pain Catastrophizing Scale (PCS)
62397935|NCT06008938||HEMGENIX|Patients with hemophilia B treated with HEMGENIX in countries where HEMGENIX is approved for commercial use.
62192575|NCT00726271|EXPERIMENTAL|active|"Subjects will complete the Zung Depression and Anxiety Scales. At the first visit the subject's medication list, weight, height, and waist measurement will be obtained. The goal is to recruit a minimum of 20 patients.~Subjects will receive light olive oil, and capsules of fish oil and flaxseed oil, to take daily at home with weight based dosing, based on the doses recommended in Dr. Roberts' work. Doses are within the recommended dietary ranges to improve intermediate outcomes for coronary artery disease subjects.~They will return weekly for measurement of weight, waist measurements, discussion of any problems with the oils, and dose adjustment of the oils."
62397936|NCT06008938||FIX Prophylaxis|Patients with hemophilia B on FIX prophylaxis and enrolled in American Thrombosis and Hemostasis Network (ATHN) Transcends (A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People with Non-Neoplastic Hematologic Disorders) Hemophilia Cohort, or a similar registry.
62573036|NCT05664022|EXPERIMENTAL|Global postural reeducation approach|The patient will receive 15 sessions of the Global Postural Re-education approach performed 2times/week for 1 hour including patient education. Each treatment will be individualized for every patient and for his/her pain-related limitation. Each session includes only 2-3 postures to increase the standardization of treatment.
62573037|NCT05664022|ACTIVE_COMPARATOR|Conventional treatment|The patient will receive the conventional treatment in form of exercise program of(abdominal and pelvic floor strengthening)and (stretching exercise of back and hip flexor muscles)to improve pain and function in chronic low back pain patients.
62573038|NCT00781729|EXPERIMENTAL|1|Yoga, one hour class, 3 times per week, for 24 weeks
62573039|NCT00781729|PLACEBO_COMPARATOR|2|Luncheon Seminar Series, once per month, for 24 weeks
62192576|NCT05735665|EXPERIMENTAL|study group: the bowel Ultrasound-based treat to target arm|"At W12 ± 4 and W24 ± 4, subjects will perform FC and bowel US and PRO will be recorded.~If rectal bleeding \> 2 + stool frequency \> 2 AND FC \> 250 mcg/g AND/OR MUC \> 6.2, treatment will be changed according to GCP and international guidelines."
62192577|NCT05735665|OTHER|control group: the routine Colonoscopy treat to target arm.|"At W12 ± 4 and W24 ± 4, subjects will perform FC and PRO will be recorded for all patients.~If rectal bleeding \> 2 + stool frequency \> 2 AND FC \> 250 mcg/g, treatment will be changed according to GCP and international guidelines. If rectal bleeding \> 0 + stool frequency \> 2 AND FC will be ≥ 50 mcg/g and ≤ 250 mcg/g, a RSS will be done in order to decide any treatment switch."
62192578|NCT04831047|EXPERIMENTAL|Upneeq Group|Participants in this group will receive a one-time dosing of oxymetazoline hydrochloride 0.1% (1 drop applied to ocular surface of each eye of patients in the treatment group)
62192579|NCT04831047|SHAM_COMPARATOR|Control Group|Participants in this group will receive a one-time dosing of balanced saline solution (1 drop applied to ocular surface of each eye of patients in the control group)
62192580|NCT01142167|ACTIVE_COMPARATOR|Standard Colonoscopy|Colonoscopy with standard instrument
62192581|NCT01142167|EXPERIMENTAL|Ultra-thin colonoscopy|New prototype scope
62192582|NCT05236647|EXPERIMENTAL|Intravenous morphine infusion|"Morphine 10 mg/ml or morphine 20 mg/ml will be diluted with normal saline to 5 mg/ml or 10 mg/ml. Both active study medication and placebo will be prepared in 100 ml drug containers suitable for the infusion pump.~The patient will have two similar infusion pumps. Morphine infusion connected to an i.v. line, placebo (normal saline) connected to a s.c line. Bolus dose will initially be equal to dose/hour. The nurse will administer bolus doses on both pumps (placebo and morphine pump) simultaneously. Patient reported pain intensity (NRS 0-10) and whether the bolus dose was initiated by the patient or the nurse will be recorded before each bolus dose. Bolus dose will be equally increased if/when the infusion rate is increased. If the bolus dose is ineffective, the bolus dose can be increased in steps of 0.1 ml until an effective dose is reached."
62214786|NCT01389505|ACTIVE_COMPARATOR|Panretinal photocoagulation|Group 1: Panretinal photocoagulation treatment (PRP) at month-0 that can be repeated after month-3.
62214787|NCT01389505|EXPERIMENTAL|Bevacizumab + Panretinal Photocoagulation (PRP)|Group 2: Bevacizumab intravitreous injections plus PRP
62214788|NCT03228745|EXPERIMENTAL|pre-operative MBSR|Pre-operative MBSR is a condition where individuals will receive a pre-operative 8-week community-based MBSR course, which includes group classes lasting 2.5 hours a week, 45-minutes of home practice 6 days per week, a 1-hour orientation session at the beginning, and a full-day silent retreat at the end. During the orientation, participants will complete the study measures for this study.
62214789|NCT03228745|NO_INTERVENTION|treatment-as-usual (TAU)|The individuals in the TAU group will receive their treatment as usual.
62214790|NCT06610513|EXPERIMENTAL|Guided imagery group|Guided imagery will be applied to risky pregnant women in addition to normal nursing care.
62214791|NCT06610513|NO_INTERVENTION|control group|Only routine nursing care will be provided to risky pregnant women.
62214792|NCT01869816||Acute coronary syndrome (ACS)|Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Acute myocardial infarction or unstable angina.
62214793|NCT01869816||Stable angina pectoris (SAP)|Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Stable angina.
62214794|NCT01869816||Control|Who were recruited from the participants for a routine health check-up in the Health Promotion Center of Korea University Guro Hospital.
62214795|NCT02807818|EXPERIMENTAL|Nurse home visits|Nurse biweekly home visit.
62214796|NCT02807818|NO_INTERVENTION|Usual care|Usual care.
62214797|NCT03248492|EXPERIMENTAL|DS-8201a Low Dose|T-DM1 resistant/refractory (R/R) patients in the low dose treatment group
62214798|NCT03248492|EXPERIMENTAL|DS-8201a Medium Dose|T-DM1 resistant/refractory (R/R) patients in the medium dose treatment group
62214799|NCT03248492|EXPERIMENTAL|DS-8201a High Dose|T-DM1 resistant/refractory (R/R) patients in the high dose treatment group
62214800|NCT03248492|OTHER|Exploratory Arm|In Part 2b- Continuation Stage, about 10 T-DM1 Intolerant patients will receive the DS-8201a recommended dose (RD) as an exploratory arm
62214801|NCT05132127|EXPERIMENTAL|Sutimlimab|Participants with body weight greater than or equal to (\>=) 39 kilograms (kg) to less than (\<) 75 kg and who had completed Part B of CARDINAL or CADENZA study were enrolled in the current study and received sutimlimab (BIVV009) 6.5 grams as intravenous (IV) infusion on Day 0, Day 7, Day 21 and thereafter every 2 weeks (maximum duration: 49 weeks) in the current study.
62397937|NCT05685355||Gingivitis samples|"Inclusion criteria:~1. Adult subjects attending PPDH can give informed consent.~2. Subjects who are diagnosed to have gingivitis only and have 24 or more teeth.~3. Subjects who are otherwise medically healthy.~4. Subjects who can attend multiple dental visits.~Exclusion criteria~1. Subjects who are in acute dental infection or in pain.~2. Subjects who have oral mucosal diseases that preclude retraction of soft tissues for photos.~3. Subjects who are in the fixed appliance for orthodontic treatment.~4. Subjects who are pregnant, or medically unfit for periodontal charting or require antibiotic coverage (e.g. risk of infective endocarditis)"
62397938|NCT01794221|ACTIVE_COMPARATOR|Stitches only|Stitches only closing circumcision wound
62397939|NCT01794221|EXPERIMENTAL|Stitches and skin adhesive|application of 2-octyl cyanoacrylate skin adhesive.
62573040|NCT04568915|EXPERIMENTAL|Dry Needling-Group|Tens, Stretching, Strengthening(girdle), Neck Isometrics, DN
62573041|NCT04568915|ACTIVE_COMPARATOR|Maitland-Group|Tens Stretching, Strengthening(girdle), Neck Isometrics, Maitland joint mobilization
62573042|NCT04917159|EXPERIMENTAL|ACT Group|The ACT intervention was structured to take place over one month on a weekly basis via Tencent's VooV platform. Each roughly 2-hour session will consist of a group-based ACT (1.5 hours) and a brief health education talk on CHF self-management (0.5 hours). Each training session will serve about 4-8 dyads. In addition, each participant will receive one set of session handouts on CHF education, ACT skills, and a homework assignment.
62573043|NCT04917159|ACTIVE_COMPARATOR|HE group|The participants of the control group will receive four weekly 2-hour sessions of structured health education on CHF self-management over four consecutive weeks via Tencent's VooV platform, delivered by a registered nurse. Each session will includea a review of the previous session (except the first session), a CHF education talk and a Q\&A section to evaluate the participant's understanding of the key concepts. Each session will be offered to 4-8 patient-caregiver dyads. In addition, each participant will receive session handouts on the main topic related to CHF self-management and homework assignments.
62573044|NCT00302328|NO_INTERVENTION|macular hole operation no peeling|
62006976|NCT03497559|EXPERIMENTAL|Music|Patients will received 30 minutes of classical music 3 times per day . Music will be delivered with noise cancellation headphones.
62006977|NCT03497559|SHAM_COMPARATOR|Noise cancellation|Patients will received 30 minutes of silent recording 3 times per day . Music will be delivered with noise cancellation headphones.
62006978|NCT03497559|NO_INTERVENTION|Control|Patients will receive standard of care.
62006979|NCT00785486|OTHER|Midazolam alone|Baseline midazolam and 1-hydroxy-midazolam pharmacokinetics. One day 1 after a fast of at least 10 hours patients received a single oral dose of midazolam 2 mg. Blood was drawn at times sufficient to characterize the pharmacokinetics of midazolam and its main metabolite.
62214802|NCT02099045||Ultrasound examination|All patients over the age of 18 presenting in the emergency department.
62214803|NCT04059302|EXPERIMENTAL|Online CBT-I|Fully-automated, internet-delivered cognitive behavioral therapy for insomnia program that consists of 6 therapy cores delivered weekly over 6 weeks.
62214804|NCT04059302|NO_INTERVENTION|Wait-List Control|Wait-list control group will receive no intervention until after the trial period is completed. During the trial period they will complete all study assessments, but receive no active treatment.
62006980|NCT00785486|OTHER|Qualaquin (quinine) alone steady state|On the morning of day 9 after taking Qualaquin (quinine) capsules 324 mg orally every 8 hours for the prior 5 days, and following a fast of at least 10 hours all study participants received their usual morning dose of Qualaquin (quinine) 324 mg. Blood was drawn at times sufficient to determine the steady state Cmax and AUC 0-tau for Qualaquin (quinine).
62214805|NCT02185001|ACTIVE_COMPARATOR|Surgical Treatment Group|Direct Medial Patellofemoral Ligament (MPFL) Repair
62214806|NCT02185001|ACTIVE_COMPARATOR|Conservative Treatment Group|Immobilization, stabilization bracing, and physical therapy
62214807|NCT05129228|EXPERIMENTAL|OCT-guided saphenous vein graft coronary artery bypass graft surgery|Optical Coherence Tomography (OCT) provides high quality intravascular images by using infrared light. OCT will assess the harvested saphenous vein conduit in Coronary Bypass Graft Surgery (CABG). Abnormalities found in the harvested conduits via OCT, at the discretion of the surgeon, will not be utilized for CABG.
62214808|NCT05129228|NO_INTERVENTION|Visual inspection-guided saphenous vein graft coronary artery graft surgery|Harvested saphenous vein conduits will be assessed visually and will undergo a blinded OCT.
62214809|NCT04534153|EXPERIMENTAL|Fexofenadine without SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride and 101 mg microcrystalline cellulose
62214810|NCT04534153|EXPERIMENTAL|Fexofenadine and 3 mg SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 3 mg SLS and 101 mg microcrystalline cellulose
62214811|NCT04534153|EXPERIMENTAL|Fexofenadine and 30 mg SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 30 mg SLS and 101 mg microcrystalline cellulose
62214812|NCT04552899|EXPERIMENTAL|Zinpentraxin Alfa|Participants will receive intravenous (IV) infusions of Zinpentraxin Alfa over 50-70 minutes on Days 1, 3 and 5, then followed by infusions every 4 weeks (Q4W) to Week 48.
62214813|NCT04552899|PLACEBO_COMPARATOR|Placebo|Participants will receive IV infusions of placebo over 50-70 minutes on Days 1, 3 and 5, followed by infusions Q4W to Week 48.
62214814|NCT00439231|EXPERIMENTAL|Lenalidomide (Revlimid) subjects|Lenalidomide regimen testing to determine efficacy for CLL/ SLL subjects
62214815|NCT02852070|ACTIVE_COMPARATOR|control group|Bronchoscopy examination with 120ml sterile saline solution for bronchoalveolar lavage
62214816|NCT02852070|EXPERIMENTAL|observation group|Bronchoscopy examination with 60ml sterile saline solution for bronchoalveolar lavage
62397940|NCT02978625|EXPERIMENTAL|Treatment (talimogene laherparepvec, nivolumab)|Patients receive talimogene laherparepvec IT and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycle 1 then every 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo, CT scan or PET/CT on study. Patients also undergo blood sample collection and biopsies on study.
62192583|NCT05236647|ACTIVE_COMPARATOR|Subcutaneous morphine infusion|"Morphine 10mg/ml or morphine 20 mg/ml will be diluted with normal saline to 5 mg/ml or 10 mg/ml. Both active study medication and placebo will be prepared in 100 ml drug containers suitable for the infusion pump.~The patient will have two similar infusion pumps. Morphine infusion connected to a s.c. line, placebo (normal saline) connected to a i.v. line. Bolus dose will initially be equal to dose/hour. The nurse will administer bolus doses on both pumps (placebo and morphine pump) simultaneously. Patient reported pain intensity (NRS 0-10) and whether the bolus dose was initiated by the patient or the nurse will be recorded before each bolus dose. Bolus dose will be equally increased if/when the infusion rate is increased. If the bolus dose is ineffective, the bolus dose can be increased in steps of 0.1 ml until an effective dose is reached."
62192584|NCT00729638|EXPERIMENTAL|Single arm|Single arm phase I study
62192585|NCT04539223|ACTIVE_COMPARATOR|Drug (Evolocumab)|Individuals randomized to this arm will administer Evolocumab subcutaneously (SC) every two weeks (Q2W) for 26 weeks.
62192586|NCT04539223|NO_INTERVENTION|No Drug (Standard of Care)|Individuals randomized to this arm will not administer a placebo.
62192587|NCT00727740|EXPERIMENTAL|1|Indomethacin liquid suspension 100 mg (25 mg/5ml) which is 20 cc of suspension instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
62397941|NCT04463719|EXPERIMENTAL|Intervention group|Counseling using the electronic conversation aid
62397942|NCT04463719|ACTIVE_COMPARATOR|Control Group|Routine counseling only
62397943|NCT01441089||1/ Patients with cancer, other tumors, or possible genetic tumor|Patients enrolled on IRB approved NIH Intramural Research Program (IRP) therapeutic clinical trials
62397944|NCT05798663|EXPERIMENTAL|Arm A: Atezolizumab|79 participants will be randomized 1:1 to Arm A. Participants in Arm A will receive induction immunotherapy with atezolizumab on Day 1 of each cycle, concurrent chemoradiotherapy, and adjuvant atezolizumab Day 1 of each cycle.
62397945|NCT05798663|EXPERIMENTAL|Arm B: Atezolizumab and Tiragolumab|79 participants will be randomized 1:1 to Arm B. Participants in Arm B will receive induction immunotherapy with atezolizumab plus tiragolumab on Day 1 of each cycle, concurrent chemoradiotherapy, and adjuvant atezolizumab plus tiragolumab on Day 1 of each cycle.
62397946|NCT05798663|EXPERIMENTAL|Arm C: Atezolizumab and Tiragolumab|"An additional pilot cohort of 20 patients will be accrued at selected sites towards the end of the overall accrual period and after initial safety evaluations of the addition of tiragolumab to atezolizumab before and after chemoradiotherapy.~Participants enrolled to Arm C will receive induction immunotherapy with atezolizumab plus tiragolumab on Day 1 of each cycle, concurrent atezolizumab plus tiragolumab with chemoradiotherapy, and adjuvant atezolizumab plus tiragolumab on Day 1 of each 21 cycle."
62397947|NCT02645682|EXPERIMENTAL|anti-infection CVC (Certofix®protect)|intervention group
62397948|NCT02645682|ACTIVE_COMPARATOR|normal CVC (Certofix®)|control group
62397949|NCT04551248||PCV13 recipients (children)|Children \< 5 years who had received PCV10 or PCV13 from May, 2014 to December, 2018 under the national childhood immunization program in South Korea.
62397950|NCT04551248||PPSV23 recipients (elderly adults)|Persons 65 years or older who had received at least one dose of PPSV23 between January, 2014 and December, 2018 under the national immunization program in South Korea.
62397951|NCT04551248||Influenza vaccine recipients (elderly adults)|Persons 65 years or older who had received at least one dose of influenza vaccine (as comparator) between January, 2014 and December, 2018 under the national immunization program in South Korea.
62397952|NCT04456816|EXPERIMENTAL|100 mg AP1189|100 mg AP1189. The treatment is a 12-weeks treatment. Each daily dose will be administered as a tablet
62397953|NCT04456816|EXPERIMENTAL|Placebo|Placebo. The treatment is a 12-weeks treatment. Each daily dose will be administered as a tablet
62397954|NCT03798652||Patients referred for CABG|Patients with known coronary artery disease referred for isolated surgical revascularisation, who will be invited to attend our facility for a research CMR scan, a research 3D transthoracic echocardiogram and a 6 minute walk test
62397955|NCT04802759|ACTIVE_COMPARATOR|Cohort 1: Giredestrant Monotherapy|
62573045|NCT00302328|ACTIVE_COMPARATOR|Macular hole operation ICG peeling|
62573046|NCT00302328|EXPERIMENTAL|Macular hole operation TB peeling|
62006981|NCT00785486|EXPERIMENTAL|Midazolam with Qualaquin (quinine)|On day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen, all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg. Blood was drawn sufficient to characterize the steady state kinetics of quinine and the kinetics of midazolam and 1-hydroxy-midazolam in the presence of each other.
62573047|NCT04129957||Patients who underwent placement of dental implants|The study only includes one cohort. That is the patients who underwent placement of dental implants at baseline.
62006982|NCT02459691|ACTIVE_COMPARATOR|Usual Care Only|Patients assigned to this group will continue medical care as usual.
62006983|NCT02459691|EXPERIMENTAL|Vida Sana|Patients assigned to this group will continue medical care as usual and in addition will receive the culturally adapted intervention.
62573048|NCT02156037|EXPERIMENTAL|dashboard team care intervention|Dashboard team
62397956|NCT04802759|EXPERIMENTAL|Cohort 1: Giredestrant + Abemaciclib|
62397957|NCT04802759|EXPERIMENTAL|Cohort 1: Giredestrant + Ipatasertib|
62573049|NCT02156037|ACTIVE_COMPARATOR|usual diabetes team control|usual clinical diabetes team with no access to the diabetes dashboard
62573050|NCT03938350|EXPERIMENTAL|Dialectical Behavior Therapy (DBT) Skills Training|Participants in this group will receive 8 weeks of Dialectical Behavior Therapy (DBT) Skills Training.
62573051|NCT03938350|NO_INTERVENTION|Treatment as Usual|Participants in this study arm will receive treatment as usual consisting of routine prenatal care with any mental health assessment, social work involvement or mental health service provision based on clinician referral or self-referral.
62006984|NCT00630422||64|All Patients
62397958|NCT04802759|EXPERIMENTAL|Cohort 1: Giredestrant + Inavolisib|
62397959|NCT04802759|EXPERIMENTAL|Cohort 1: Giredestrant + Ribociclib|
62397960|NCT04802759|EXPERIMENTAL|Cohort 1: Giredestrant + Everolimus|
62781370|NCT04180566|OTHER|Weekly antenatal testing|Women with BMI 30-40 between 20 and 34.6 weeks of gestation will receive weekly antenatal testing (biophysical profile) starting at 34 weeks as well as growth ultrasound every 4 weeks.
62192588|NCT00727740|PLACEBO_COMPARATOR|2|Placebo suspension in the same volume (20 cc) which is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. The placebo suspension is also flushed with 5 cc of normal saline.
62397961|NCT04802759|EXPERIMENTAL|Cohort 1: Giredestrant + Samuraciclib|
62397962|NCT04802759|EXPERIMENTAL|Cohort 1: Giredestrant + Atezolizumab|
62397963|NCT04802759|EXPERIMENTAL|Cohort 1: Giredestrant + Abemaciclib + Atezolizumab|
62397964|NCT04802759|ACTIVE_COMPARATOR|Cohort 2: Giredestrant + PH FDC SC|
62192589|NCT00625300|ACTIVE_COMPARATOR|1|Active treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
62192590|NCT00625300|SHAM_COMPARATOR|Placebo|Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (sham) over the motor cortex and the prefrontal cortex.
62192591|NCT01593930|EXPERIMENTAL|1 Articaine(Infiltration)|Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
62192592|NCT01593930|EXPERIMENTAL|2 Articaine(Infiltration)|Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine
62192593|NCT01593930|EXPERIMENTAL|Lidocaine(IANB)+1Articaine(Infiltration)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
62192594|NCT01593930|EXPERIMENTAL|Lidocaine(IANB)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine
62397965|NCT04802759|EXPERIMENTAL|Cohort 2: Giredestrant + PH FDC SC + Abemaciclib|
62397966|NCT04802759|EXPERIMENTAL|Cohort 2: Giredestrant + PH FDC SC + Palbociclib|
62397967|NCT04347460||COVID 19|Patients requiring ICU treatment due to severe COVID 19 interstitial pneumonia or otherwise COVID-19 related disease
62192595|NCT04199286|ACTIVE_COMPARATOR|Asymmetrical surgery|This asymmetrical horizontal muscle surgery done as recess-resect in one eye or 3 muscle surgery
62781371|NCT04180566|OTHER|Growth ultrasound examination every 4 weeks|Women with BMI 30-40 between 20 and 34.6 weeks of gestation will receive ultrasound examination (growth ultrasound) every 4 weeks starting at 34 weeks.
62192596|NCT04199286|ACTIVE_COMPARATOR|Symmetrical|This symmetrical horizontal muscle surgery includes bilateral medial rectus recession in esotropia cases or bilateral lateral rectus recession in exotropia
62192597|NCT04613245||Patient with asthma|
62192598|NCT02901847|OTHER|Intervention|PAD tailored care
62397968|NCT05782504|EXPERIMENTAL|Treatment arm|4 treatment sessions, each lasting 60 minutes, within a 4-week perioperative period, with 2 preoperative (in the last 2 weeks before surgery) and 2 postoperative (in the first 2 weeks after surgery) sessions.
62781372|NCT04730531|EXPERIMENTAL|Treatment Arm|Local infiltration with 0.25% bupivacaine and epinephrine
62781373|NCT04730531|PLACEBO_COMPARATOR|Control Arm|Placebo of equal volume injectable saline
62192599|NCT02568670|EXPERIMENTAL|according to clinical signs|removal the peripheral catheter according to clinical signs
62192600|NCT02568670|NO_INTERVENTION|sistematically every 96 hours|removal the peripheral catheter every 96 hours
62192601|NCT04016012|EXPERIMENTAL|Intervention arm|Participants in the intervention group will receive local zambian foods and standard health care for eight (8) weeks.
62192602|NCT04016012|NO_INTERVENTION|Control arm|The control group will have their usual (standard) diet in their home and receive standard health care for eight (8) weeks.
62192603|NCT06155097|NO_INTERVENTION|Control Group|Patients will not receive any regional injections
62192604|NCT06155097|ACTIVE_COMPARATOR|The transversus thoracis muscle plane block (TTP) group|Patients will receive the TTP block with administration of 20 ml volume of local anesthetics (Lidocaine 2% + Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone) bilaterally
62192605|NCT06155097|ACTIVE_COMPARATOR|The parasternal intercostal nerve block (PSI block) group|Patients will receive the PSI block with administration of 20 ml volume of local anesthetics (Lidocaine 2% + Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone) bilaterally
62192606|NCT05000047||All participants|All study participants who have bilateral earmold impressions completed using both a 3D ear scanner and the conventional procedure using silicone impression material.
62397969|NCT04176172|ACTIVE_COMPARATOR|Varenicline & Standard Cessation Counseling|varenicline plus standard behavioral smoking cessation treatment
62397970|NCT04176172|EXPERIMENTAL|NMR-Tailored Medication & Standard Cessation Counseling + MAPS|varenicline or nicotine patch plus standard behavioral smoking cessation treatment with Managed Problem Solving adherence intervention
62397971|NCT03326882|ACTIVE_COMPARATOR|Glidescope|A device for endotracheal intubation
62397972|NCT03326882|ACTIVE_COMPARATOR|Macintosh laringoscope|A device for endotracheal intubation
62397973|NCT05626556|EXPERIMENTAL|older adults|Older adults with mild to moderate chronic illness
62397974|NCT04932980|ACTIVE_COMPARATOR|Aflibercept ® rapid treatment extension (T&E)|Early treat and extend (T\&E) with Aflibercept ®. First IVT followed by control after 3 weeks and 2nd IVT after 6 weeks (= shortest treatment interval). Treatment will be adjusted according to morphologic response by adaptation of treatment intervals in +/- two-week increments.
62397975|NCT04932980|ACTIVE_COMPARATOR|Brolucizumab ® rapid treatment extension (T&E)|Early treat and extend (T\&E) with Brolucizumab ®. First IVT followed by control after 3 weeks and 2nd IVT after 6 weeks (= shortest treatment interval). Treatment will be adjusted according to morphologic response by adaptation of treatment intervals in +/- two-week increments.
62397976|NCT02784730|EXPERIMENTAL|Iterative PICC placement|New PICC placement at each chemotherapy cycle (removed after treatment administration)
62781374|NCT01378468||Patients with first ischemic stroke|
62781375|NCT03124082|ACTIVE_COMPARATOR|opioid|remifentanil 0,15-0,25 mcg/kg/h
62192607|NCT03193463|EXPERIMENTAL|Predominantly enhancing mass with volume of 8 cc or less|Only 1 Cleveland Multiport Catheter (CMC) will be placed and CED will be performed intra-operatively only in a magnetic resonance imaging (MRI) equipped Operating Room. Topotecan infusion will be performed over a 4-hour period, with the goal of complete tumor coverage. The initial rate will be 1.20 ml/hour and infusion will be monitored by intermittent MRI imaging. The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent. Following completion of the 4-hour infusion, the CMC will be removed. The initial rate for each subsequent patient may be adjusted upwards in increments of up to 1.20 ml/hour based upon the tumor coverage and safety characteristics of the previously treated patients.
62573052|NCT03618160|EXPERIMENTAL|Part 1: SAD (Cohort 1 to 3)|Participants in Cohorts 1 to 3 will receive a single Subcutaneous (SC) low, medium, and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety, tolerability review to determine safe and maximum well tolerated dose.
62192608|NCT03193463|EXPERIMENTAL|Predominantly enhancing mass with volume of > 8 cc|2 Cleveland Multiport Catheter (CMCs) will be placed and the total infusion rate of Topotecan per CMC to be used for the first 24 hours for the first patient will be 0.834 ml/hour (3.48 microliters/minute/microcatheter). The rate used for the second 24 hours of the infusion will be 1.668 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.834 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the enhancing tumor by the infused Gadopentetic acid (Gd-DTPA), or 2) rate-limiting toxicity.
62192609|NCT03193463|EXPERIMENTAL|Predominantly non-enhancing mass|The total infusion rate of Topotecan per Cleveland Multiport Catheter (CMC) to be used for the first 24 hours for the first patient will be 0.29 ml/hour. The rate used for the second 24 hours of the infusion will be 0.58 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.29 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the non-enhancing tumor by the infused Gd-DTPA, or 2) rate-limiting toxicity.
62192610|NCT02046512|EXPERIMENTAL|Probiotic|Patients randomized to probiotic therapy will receive 1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
62192611|NCT02046512|PLACEBO_COMPARATOR|Sugar Pill|Patients randomized to placebo therapy will receive an identical appearing placebo capsule on a twice-daily basis
62214817|NCT06396364|EXPERIMENTAL|Cryotherapy|Patients were treated with a third-generation cryotherapy device (Z- One®, Zamar) which was applied daily for 2 hours two times a day up to the day of surgery. The leg was immobilized in a walking boot which was removed when the cryotherapy device was applied.
62214818|NCT06396364|ACTIVE_COMPARATOR|Immobilization and elevation|The leg was immobilized into a half cats and elevation of the injured limb was indicated before surgery.
62573053|NCT03618160|EXPERIMENTAL|Part 2: MAD (Cohort 4 to 6)|Participants in Cohorts 4 to 5 will receive weekly multiple SC low and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. If multiple high dose is judged as not tolerable, additional optional Cohort 6 will be added to Part 2 to investigate the safety, tolerability and PK after administration of multiple medium dose of JNJ-64565111 in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety and tolerability review to determine safe and maximum well tolerated dose.
62573054|NCT03618160|EXPERIMENTAL|Part 3: Single Dose (Cohort 7)|Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 which may be started (as early as) in parallel with Cohort 3 in Part 1 on Day 1, under fasted conditions in healthy Caucasian male participants. Based on the results from Cohort 1 to 3 in Part 1, the dose of Cohort 7 may be reduced to low dose or increased to high dose.
62573055|NCT01644071|EXPERIMENTAL|arm 1|application of three treatments and three masurements within 3 weeks
62573056|NCT01527656|EXPERIMENTAL|Formulation A|
62573057|NCT01527656|EXPERIMENTAL|Formulation B|
62006985|NCT06411548|ACTIVE_COMPARATOR|InsuLearn→Usual Care|During the first 24 hours of the hotel admission (visit 6), participants' insulin dose will be calculated by the InsuLearn, MD approved, report. The second 24 hours of the hotel admission (visit 7), participants will use their usual care method to calculate their insulin dose.
62006986|NCT06411548|ACTIVE_COMPARATOR|Usual Care→InsuLearn|During the first 24 hours of the hotel admission (visit 6), participants' insulin dose will be calculated by their usual care method. The second 24 hours of the hotel admission (visit 7), participants will use the InsuLearn, MD approved, report to calculate their insulin dose.
62006987|NCT03661515|EXPERIMENTAL|Fludarabine-Idarubicine-Cytarabine- Selinexor|"fludarabine 30 mg/m2/day intravenously on days 1 to 4, idarubicin 10 mg/m2/day intravenously on days 1 to 3, cytarabine 2 g/m2/day intravenously on days 1 to 4, G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5. This schedule will be combined with oral selinexor (KPT-330) for three weeks at days and dose according to escalation level:~* Level -1: Selinexor 40 mg/day, once weekly~* Level 1: Selinexor 60 mg/day, once weekly~* Level 2: Selinexor 80 mg/day, once weekly~* Level 3: Selinexor 100 mg/day, once weekly"
62006988|NCT06013371|EXPERIMENTAL|PF-07038124|PF-07038124 0.02% ointment once daily for 8 weeks
62006989|NCT06013371|PLACEBO_COMPARATOR|Placebo|Placebo Ointment
62006990|NCT00596011|ACTIVE_COMPARATOR|Polyphenon E Treatment|Polyphenon E, 200 mg epigallocatechin gallate (EGCG) twice a day (BID)
62006991|NCT00596011|PLACEBO_COMPARATOR|Placebo Administration|Matching placebo BID
62006992|NCT00326911|EXPERIMENTAL|cetuximab + bevacizumab + gemcitabine|Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks, and gemcitabine 1000 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks. All medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab, bevacizumab, and gemcitabine. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.
62006993|NCT00326911|ACTIVE_COMPARATOR|cetuximab + bevacizumab|Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks. Both medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab and bevacizumab. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.
62781376|NCT03124082|EXPERIMENTAL|opioid free|ketamine bolus 0,5 mg/kg + infusion 0,25 mg/kg/h lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h clonidine 4 mcg/kg
62006994|NCT00864474||Maraviroc Tablets|Patients administered.
62006995|NCT03756766||RSV positive ARTI|"RSV point of care testing will be performed (if result not already available) to confirm RSV positive status. Individuals with confirmed acute respiratory tract infection (ARTI) secondary to RSV (Group 1- active) will have nasopharyngeal swabs, blood samples, urine samples and stool samples taken at the time of recruitment and again at 7 weeks (convalescence).~Group 1 participants are categorised into 4 groups as follows:~Group 1a and 1b participants are healthy infants with an RSV infection either requiring hospitalisation for at least 12 hours or not requiring hospitalisation respectively.~Group 1c \& 1d are infants with an RSV infection with any co-morbidity that would exclude them from Group 1a and 1b either requiring hospitalisation for at least 12 hours or not respectively."
62192612|NCT03453047||1|Healthy volunteers. Liver donor groups; Course of the research: Blood samples from all groups shall be taken for S100β and NSE in preoperative period, in the operating room and after 1 and 6 months in postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients who were transplanted liver with S100β and NSE. Demographic data of the patients, accompanying diseases, American Society of Anesthesia classification, etiology, Model For End-Stage Liver Disease score, Child classification, sodium, potassium, total bilirubin, alanine aminotransferase, aspartate aminotransferase, Alkaline phosphatase, International Normalized Ratio, creatinine and urea shall be recorded. Intraoperative medicine administration and fluid balance, duration of operation, graft hot ischemia and graft cold ischemia durations, initial pulmonary artery pressure, blood component transplantations shall be recorded.
62192613|NCT03453047||2|Liver transplant groups;Course of the research Blood samples from all groups shall be taken for S100β and NSE in preoperative period, in the operating room and after 1 and 6 months in postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients who were transplanted liver with S100β and NSE. Demographic data of the patients, accompanying diseases, American Society of Anesthesia classification, etiology, Model For End-Stage Liver Disease score, Child classification, sodium, potassium, total bilirubin, alanine aminotransferase, aspartate aminotransferase, Alkaline phosphatase, International Normalized Ratio, creatinine and urea shall be recorded. Intraoperative medicine administration and fluid balance, duration of operation, graft hot ischemia and graft cold ischemia durations, initial pulmonary artery pressure, blood component transplantations shall be recorded.
62781377|NCT03295617||spinal thoracic herniation|
62781378|NCT02083497|EXPERIMENTAL|No banding|The volunteers who make up this group, held 18 kicks, 9 with the dominant leg and 9 with the non-dominant lower limb, without the intervention of any kind of bandage.
62781379|NCT02083497|EXPERIMENTAL|Group with Rigid Bandage|Volunteers carry out the same protocol described above, however, using rigid bandage. The bandage will be used for tape, Cremer brand and will be applied ankle support member of the individual, in order to limit the movement of the joint inversion.
62781380|NCT02083497|EXPERIMENTAL|Group with elastic bands|The protocol will be maintained, however, a brand elastic bandage Kinesio Sport applied to the lower support member of the individual, also in order to limit the movement of the joint inversion is used.
62781381|NCT06167707|EXPERIMENTAL|Treatment Sequence 1|Period 1: SC Period 2: IV
62781382|NCT06167707|EXPERIMENTAL|Treatment Sequence 2|Period 1: IV Period 2: SC
62781383|NCT00005818|EXPERIMENTAL|Treatment (irinotecan hydrochloride, semaxanib)|Patients receive irinotecan IV over 90 minutes on day 1 of weeks 1-4 and SU5416 IV over 60 minutes on days 1 and 4 of weeks 1-6. Treatment continues every 6 weeks in the absence of unacceptable toxicity or disease progression.
62781384|NCT00662545|EXPERIMENTAL|A|Entecavir 1 mg for 24 weeks in addition to continued standard of care antiretroviral therapy containing tenofovir in addition to emtricitabine or lamivudine
62781385|NCT00662545|ACTIVE_COMPARATOR|B|continued standard of care antiretroviral therapy which will include tenofovir in addition to emtricitabine or lamivudine
62781386|NCT04583956|ACTIVE_COMPARATOR|Remdesivir + Placebo|200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 1200-mg IV risankizumab placebo infusion (300-mg x 4 vials) once on Day 1. N=100.
62397977|NCT02784730|ACTIVE_COMPARATOR|Long term implantable device|Port-a-cath inserted prio first chemotherapy cycle and maintained throughout the study
62397978|NCT06522373|EXPERIMENTAL|Escalation Adults: MT-0169|
62397979|NCT06522373|EXPERIMENTAL|Escalation Pediatrics: MT-0169|
62397980|NCT06522373|EXPERIMENTAL|Expansion Adults: MT-0169|
62397981|NCT06522373|EXPERIMENTAL|Expansion Pediatrics: MT-0169|
62397982|NCT06725004|EXPERIMENTAL|Oxytocin|Participants will receive injection oxytocin 10 mg intramuscular as trigger for ovulation induction
62006996|NCT03756766||Healthy controls|"This group will include healthy infants (Group 2) who do not have an RSV positive respiratory tract infection and have been asymptomatic in the week preceding and following recruitment.~This group will have nasopharyngeal swabs, a blood test and a stool and urine sample taken at enrolment only."
62192614|NCT04558164|EXPERIMENTAL|Active TBS|Theta burst stimulation (TBS) will be delivered at 100% of motor threshold (MT).
62006997|NCT01446562|EXPERIMENTAL|Y90 Ibritumomab Tiuxetan|Addition of Y90 Ibritumomab Tiuxetan RIT to CHOP-R treatment for follicular lymphoma-patients also receive maintenance Rituximab every 3 months for 2 years after the Y90 Ibritumomab Tiuxetan
62192615|NCT04558164|SHAM_COMPARATOR|Sham TBS|Sham stimulation will be delivered at 0% of motor threshold (MT), with all other parameters matching the active TBS condition.
62192616|NCT02659098|EXPERIMENTAL|Open-Label Safety Run-in Phase: Treatment Group|Participants will receive CNTO 2476 3.0 x 10\^5 cells in 50 microliter (mcL). CNTO 2476 will be delivered using the custom-designed Delivery System.
62192617|NCT01341249|EXPERIMENTAL|DW224aa|DW224aa given by oral administration
62397983|NCT06725004|ACTIVE_COMPARATOR|Human Chorionic Gonadotropin|Participants will receive injection Human Chorionic Gonadotropin 5000 IU intramuscular as trigger for ovulation induction
62397984|NCT00245492|EXPERIMENTAL|1|Chromocolonoscopy
62397985|NCT01724723|EXPERIMENTAL|Entecavir group|Study treatment for only treatment group: entecavir (BARACLUDE®) 0.5 mg per day during and within 6 months after anti-tuberculous treatment.
62397986|NCT01724723|NO_INTERVENTION|Control group|Not receiving entecavir (BARACLUDE®)
62397987|NCT05534620|EXPERIMENTAL|Treosulfan and Fludarabine|Participants will receive treosulfan 10 gram per square meter (g/m\^2), intravenous (IV) infusion, given over 2 hours once daily on three consecutive days (day -4 to day -2), followed by fludarabine, 30 milligram per square meter (mg/m\^2) IV infusion once daily on 5 consecutive days (days -6 to -2), preceding allogeneic haematopoietic stem cell transplantation (alloHSCT) on Day 0.
62192618|NCT01341249|ACTIVE_COMPARATOR|DW224a|DW224aa given by oral administration
62192619|NCT04403542|EXPERIMENTAL|LID018869 (OD) / Biofinity (OS)|Lehfilcon A contact lens worn in the right eye, with comfilcon A contact lens worn in the left eye, as randomized, for approximately 1 week of continuous wear
62192620|NCT04403542|ACTIVE_COMPARATOR|Biofinity (OD) / LID018869 (OS)|Comfilcon A contact lens worn in the right eye, with lehfilcon A contact lens worn in the left eye, as randomized, for approximately 1 week of continuous wear
62397988|NCT01315158|ACTIVE_COMPARATOR|Propofol+Benzo/Opioids|"If the patient is randomized into this arm the recommended Versed and Fentanyl doses are standardized:~1. Recommended Versed:~   a. Prior to intubation~  * patient is \< 50 kg = 1 mg Versed~  * patient is 50-75 kg = 1.5 mg Versed~  * patient is \> 75 kg = 2 mg Versed~2. Recommended Fentanyl~   1. Prior to intubation = 0.5 ug/kg~  2. Total procedural dose = 1 ug/kg"
62397989|NCT01315158|ACTIVE_COMPARATOR|Propofol Alone|"The patients randomized into the sedation with propofol alone are able to cross over if they are unable to be successfully sedated under propofol alone. The the recommended doses before considering crossover are standardized:~* Induction Dose: 2-2.5 mg/kg~* Maintenance Dose: 0.1-0.2 mg/kg/min"
62397990|NCT06165471|EXPERIMENTAL|Blended learning group|The Intervention group will adopt the mode of online and offline blended learning based on the Chaoxing mobile application (Chaoxing app). The researchers will create surgical nursing practice courses on the Chaoxing app, and the experimental group will be subjected to 2 months of online and offline blended teaching intervention using the Chaoxing app.
62397991|NCT06165471|ACTIVE_COMPARATOR|Traditional teaching group|The control group will adopt the traditional face-to-face teaching method for the surgical nursing practice course. The teacher will demonstrate the process, and the students will practice. The teacher demonstrates each step, and the students practice each step.
62397992|NCT05471154|EXPERIMENTAL|Active HD-tDCS|Half of all subjects will receive active HD-tDCS (randomly assigned): anodal stimulation on the right dorsolateral prefrontal cortex. Stimulation will consist of 20 minutes 2mA anodal stimulation of the right dorsolateral prefrontal cortex.
62573058|NCT02006589|EXPERIMENTAL|Arm 1 Test then Reference|Subjects will be randomized and receive the following two treatments administered orally in a fasting state A= Single dose of candesartan cilexetil (Test formulation) 8mg; B = Single dose of candesartan cilexetil (Reference treatment) 8mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
62006998|NCT01785602|EXPERIMENTAL|QAW039|Participants received QAW039 450 mg daily by mouth.
62006999|NCT01785602|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo to QAW039.
62192621|NCT04429282|EXPERIMENTAL|ibuprofen( 400mg group)|Patients were randomly divided into the group received respectively IV ibuprofen 400 mg .
62192622|NCT04429282|EXPERIMENTAL|ibuprofen( 800mg group)|Patients were randomly divided into the group received respectively IV ibuprofen 800 mg.
62192623|NCT04429282|PLACEBO_COMPARATOR|placebo group|Patients were randomly divided into the group received respectively IV placebo,.
62192624|NCT02211547|NO_INTERVENTION|Control|No treatment to be rendered following separator placement.
62192625|NCT02211547|PLACEBO_COMPARATOR|Placebo|Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
62192626|NCT02211547|EXPERIMENTAL|Treatment|Single blind laser treatment (the laser will be positioned and operated, and energy transfer will take place).
62192627|NCT02441868|EXPERIMENTAL|Intervention|all participants will receive the training
62397993|NCT05471154|SHAM_COMPARATOR|Sham HD-tDCS|Half of all subjects will receive sham HD-tDCS (randomly assigned). A ramp-up of 1 minute will be used to induce the same feelings as during the active tDCS, but will then stop the stimulation. A short ramp up is repeated in the last minute of the protocol.
62192628|NCT04420429||Cohort|All patients
62781387|NCT04583956|EXPERIMENTAL|Remdesivir + Risankizumab|200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 1200-mg IV risankizumab infusion (300-mg x 4 vials) once on Day 1. N=100.
62781388|NCT01025830|EXPERIMENTAL|Generic|generic fixed dose combination of Stavudine, Lamivudine and Nevirapine (Triomune)
62007000|NCT04582422|EXPERIMENTAL|Touch Therapy|"The main purpose is to provide Touch Therapy intervention measures, the degree of fear of dental treatment for preschool children.~Use the chip chip tool (PCT) to ask the children's degree of fear of dental treatment. The control group uses questionnaires to ask the caregiver's age, social and economic status, education, past dental experience, etc. In the intervention group, the questionnaire was used to ask the caregiver's age, socioeconomic status, education, past dental experience, etc. During the waiting process, first follow the touch flow chart and perform the touch in the waiting area for 10 minutes. When visiting the treatment chair, the companion will be asked to touch the child's unilateral hand for 5 minutes during the consultation process. A small chair is provided to accompany the child for a total of 15 minutes. The two groups will use the chip tool again after the consultation , Ask the children how scared they are after seeing a doctor,"
62007001|NCT04582422|NO_INTERVENTION|dental education|The Chip Chip Tool (PCT) asked the children how scared they were about dental visits. The control group used questionnaires to ask the caregiver 's age, socioeconomic status, education, past dental experience, etc. before the visit to provide routine dental care, provide dental health education, how to use toothbrush Dental floss education,
62007002|NCT02871375|OTHER|DT1 MF, then Habitual|Delefilcon A multifocal contact lenses in Period 1, followed by subject's habitual multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.
62007003|NCT02871375|OTHER|Habitual, then DT1 MF|Subject's habitual multifocal contact lenses in Period 1, followed by delefilcon A multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.
62007004|NCT02669290|EXPERIMENTAL|Guided|Guided LV lead placement for CRT.
62007005|NCT02669290|ACTIVE_COMPARATOR|Non-Guided|Non-guided LV lead placement for CRT.
62397994|NCT04265794|EXPERIMENTAL|Intervention|6-week community-based behavioral program consisting of 12 group-based weekly sessions (1-hour sessions twice a week) delivered by trained staff in the Boys and Girls Club setting. The intervention targets knowledge, attitudes, and skills related to sugar-sweetened beverage consumption and water consumption, with reduction in sugar-sweetened beverage consumption and increase in water consumption being the primary behavioral targets.
62397995|NCT04265794|NO_INTERVENTION|Comparison|Parent-child pairs in comparison sites will receive usual care (standard Boys and Girls Club programming) during the study and the intervention upon study completion.
62007006|NCT06139913|EXPERIMENTAL|aerobic exercise|aerobic exercise using treadmill
62007007|NCT03370029||Primary ciliary dyskinesia patients|Primary ciliary dyskinesia patients will be included in study. Inclusion and exclusion criteria were considered.
62007008|NCT03370029||Healthy individuals|Those without diagnosed chronic disease will be included in study. Inclusion and exclusion criteria were considered.
62007009|NCT06174441|ACTIVE_COMPARATOR|Test group 1 (CPMSM)|Investigational product 1: daily dose 25 mL contains: Hydrolyzed fish collagen 5 g, methylsulphonylmethane (MSM) 1,5 g, Biotin 150 μg, Vitamin B6 1,6 mg, Zinc 2 mg, Vitamin C 120 mg.
62007010|NCT06174441|ACTIVE_COMPARATOR|Test group 2 (HC+)|"Investigational product 2: daily dose 25 mL contains: Niacin 16 mg, Pantothenic acid 6 mg, Biotin 500 μg, Vitamin B6 1,4 mg, Folic acid 200 μg, Zinc 2 mg, Pea sprout extract 100 mg, Horsetail aerial parts extract 70 mg, Ashwagandha root extract 40 mg, Saw palmetto fruit extract 40 mg, Nettle leaves extract 30 mg, Grape seed extract 10 mg.~Intervention: Dietary Supplement: Placebo Placebo group (PG) will receive placebo product without any of the active ingredients (PL, daily dose 25 mL: no active ingredients)."
62007011|NCT06174441|PLACEBO_COMPARATOR|Placebo group|placebo product without any of the active ingredients, daily dose 25 mL: no active ingredients.
62192629|NCT04769375||Group 1: Pregnant women diagnosed with GDM (first pregnancy)|This group will consist of women with gestational diabetes mellitus according to routine control tests in their first pregnancy.
62397996|NCT06345573||Female Sex|Healthy volunteer women aged between 50-75 years old, in post-menopausal status.
62397997|NCT06345573||Male Sex|Healthy volunteer men aged between 50-75 years old.
62397998|NCT04357431||study group|Health care providers include physicians, nurses, and health officers both medical and nursing subjects.
62397999|NCT04985916|PLACEBO_COMPARATOR|Vehicle|Vehicle, topical liniment, administered once at baseline
62398000|NCT04985916|EXPERIMENTAL|ET-01, Dose 1|Dose 1 of botulinum toxin, Type A, topical liniment, administered once at baseline. 250µm microneedle length
62398001|NCT04985916|EXPERIMENTAL|ET-01, Dose 2|Dose 2 of botulinum toxin, Type A, topical liniment, administered once at baseline. 250µm microneedle length
62398002|NCT03428139|ACTIVE_COMPARATOR|Group I|Each patient in this group was treated with pulsed radiofrequency on the affected dorsal root ganglion at 42°C for 120 seconds
62781389|NCT01025830|ACTIVE_COMPARATOR|Brand|3 separate single pills of Zerit (Stavudine)Epivir (Lamivudine) Viramune (Nevirapine)
62781390|NCT06579846|EXPERIMENTAL|Cytisinicline and exercise|Smokers who will receive directed physical exercise and brief counseling while undergoing treatment according to the care process.
62781391|NCT06579846|ACTIVE_COMPARATOR|Cytisinicline|Smokers who will receive an informational leaflet and brief counseling when they begin cytisinicline treatment, according to the care process.
62781392|NCT03424603|EXPERIMENTAL|STRO-001|intravenous
62007012|NCT06662929||Adult aged 18 years or above, and receiving radiotherapy for the HNC.|A non-interventional, questionnaire-based cross-sectional study for Arabic-speaking males and females, aged 18 years or above who is planned for receiving and who is currently receiving and who had already received radiotherapy for the Head \& Neck Cancer at King Saud University Medical City.
62007013|NCT06663865|EXPERIMENTAL|Bioactive whey protein concentrate containing dairy phospholipids|40g pre weighed powder to be mixed with 350ml of water. Consumed one daily for 12 weeks alongside their fattiest meal of the day.
62007014|NCT06663865|PLACEBO_COMPARATOR|Placebo Powder|Placebo powder matched for macro-nutrient and caloric content containing pea protein around 40g powder mixed with 350ml of water consumed once daily for 12 weeks alongside fattiest meal of the day.
62007015|NCT03326427|EXPERIMENTAL|Skill Training Group|A twelve sessions protocol of the Skill Training Group of the Dialectical Behavior Therapy.
62007016|NCT03326427|ACTIVE_COMPARATOR|Treatment as Usual|Patients will have one psychiatric session to control their medication adherence.
62573059|NCT02006589|EXPERIMENTAL|Arm 2 Reference then Test|Subjects will be randomized and receive the following two treatments administered orally in a fasting state: A=Single dose of candesartan cilexetil (Reference treatment) 8mg; B= Single dose of candesartan cilexetil (Test formulation) 8mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
62573060|NCT03137238||Early_PD|People with Parkinson's disease in the early stages with low doses of antiparkinsonian medication and no motor fluctuations.
62573061|NCT03137238||Advanced_PD|People with advanced Parkinson's disease with motor fluctuations.
62573062|NCT03137238||Early_controls|Healthy participants matched for age and gender to the 'Early_PD' group.
62573063|NCT03137238||Advanced_controls|Healthy participants matched for age and gender to the 'Advanced_PD' group.
62573064|NCT01009450|ACTIVE_COMPARATOR|LC was done using traditional method|LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
62573065|NCT01009450|ACTIVE_COMPARATOR|LC was done using harmonic ACE|LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
62573066|NCT00409487|EXPERIMENTAL|1|8 weeks of Valsartant treatment, 4 weeks of washout, 8 weeks of CPAP and 8 weeks of Valsartant plus CPAP treatments
62573067|NCT00409487|EXPERIMENTAL|2|8 weeks of CPAP , 4 weeks of washout, 8 weeks of Valsartant treatment and 8 weeks of Valsartant plus CPAP treatments
62781393|NCT02828020|EXPERIMENTAL|Ubrogepant 50 mg|1 ubrogepant 50 mg tablet and 1 placebo-matching ubrogepant 50 mg tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, 2 placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
62781394|NCT02828020|EXPERIMENTAL|Ubrogepant 100 mg|2 Ubrogepant 50 mg tablets, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, 2 placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
62007017|NCT03940209|NO_INTERVENTION|Usual care|Medicaid beneficiaries in this arm will have all the usual resources available to them through their health plan including access to a physician network, case management resources, and other educational and health-focused resources and activities.
62007018|NCT03940209|EXPERIMENTAL|Basic needs navigation|Medicaid beneficiaries in this arm will have all the usual resources available to them through their health plan (usual care) as well as a navigator for 6 months to address any unmet basic needs, provide instrumental and emotional social support, and improve self-management capabilities.
62007019|NCT05933434|ACTIVE_COMPARATOR|Intervention|"Single intraarticular knee injection with allogenic adipose derived mesenchymal stem cells (AD-MSC)~20 million AD-MSC in 10 mL saline"
62007020|NCT05933434|PLACEBO_COMPARATOR|Control|"Single intraarticular knee injection with saline alone~10 mL saline"
62781395|NCT02828020|PLACEBO_COMPARATOR|Placebo|2 placebo-matching ubrogepant 50 mg tablets, orally for treatment of a qualifying migraine attack. Participants had the option to take 2-placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
62781396|NCT01674777|EXPERIMENTAL|under fasting condition group|Subjects will receive a single dose of ASP1941 under fasting condition
62781397|NCT01674777|EXPERIMENTAL|before meal group|Subjects will receive a single dose of ASP1941 before meal
62007021|NCT06028711|EXPERIMENTAL|Education program and Pulmonary rehabilitation|Conventional pulmonary rehabilitation coupled with original education program.
62007022|NCT06028711|OTHER|Pulmonary rehabilitation|Conventional pulmonary rehabilitation
62007023|NCT05463224|EXPERIMENTAL|Lazertinib group|Lazertinib 240mg daily (1 cycle of 21 days)
62573068|NCT03907748|EXPERIMENTAL|Music Intervention|The music intervention will be provided to participant dyads (people with dementia and their cohabiting family caregivers) allocated to the first intervention. Caregivers will be trained to use the music intervention in three 2-hour training sessions with an intervention trainer (a music therapist). Training will take place at the dyad's home. The caregiver will then be asked to deliver the music intervention to the person with dementia at least 5x per week for 30 minutes.
62573069|NCT03907748|ACTIVE_COMPARATOR|Reading Intervention|The reading intervention will be provided to participant dyads (people with dementia and their cohabiting caregivers) allocated to the second intervention. Caregivers will be trained to use the reading intervention in three 2-hour training sessions with an intervention trainer. Training will take place at the dyad's home. The caregiver will then be asked to deliver the reading intervention to the person with dementia at least 5x per week for 30 minutes.
62781398|NCT01674777|EXPERIMENTAL|after meal condition|Subjects will receive a single dose of ASP1941 after meal
62007024|NCT05943444|ACTIVE_COMPARATOR|Parks technique|patients receive coloanal anastomosis operation
62192630|NCT04769375||Group 2:Pregnant women diagnosed with GDM (2nd or 3rd pregnancy)|This group will consist of women with gestational diabetes mellitus according to routine control tests in their second or third pregnancy.
62007025|NCT05943444|EXPERIMENTAL|Bacon technique|patients receive coloanal pull-out anastomosis operation
62007026|NCT05526872|EXPERIMENTAL|Arm I (PReVenT intervention)|Participants receive usual care as well as a portal message reminder to schedule a SM and a callback link if they need assistance. Participants who have not or do not schedule their SM at the time of the first reminder receive a reminder text-message one week later with a link to receive assistance with scheduling.
62192631|NCT04769375||Group 3: Healthy pregnant women (first pregnancy)|This group will consist of women who do not have gestational diabetes mellitus according to routine control tests in their first pregnancy.
62007027|NCT05526872|ACTIVE_COMPARATOR|Arm II (enhanced usual care)|Participants receive usual care as well as portal and text messages one week apart with educational materials about healthy eating.
62007028|NCT01731704|ACTIVE_COMPARATOR|Stereotactic Radiosurgery (SRS)|Radiation Therapy: Radiosurgical (SRS) technique via Gamma Knife Perfexion radiosurgical system
62007029|NCT01731704|ACTIVE_COMPARATOR|Whole Brain Radiation Therapy (WBRT)|whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
62007030|NCT05856305|EXPERIMENTAL|Chlorophyllin|Drug name: Sodium Copper Chlorophyllin Dosage form: Tablet Dosage: 750 mg Route of administration: Oral Frequency: Once daily in the morning before food. Duration: From 10-14 days before radiotherapy up to 3 months after the last dose of cytotoxic therapy
62007031|NCT05856305|PLACEBO_COMPARATOR|Placebo|Drug Name: Placebo Dosage form: 1 Tablet Route of administration: Oral Frequency: Once daily in the morning before food. Duration: From 10-14 days before radiotherapy up to 3 months after the last dose of cytotoxic therapy
62007032|NCT02867605|OTHER|Healthy Controls ages 18-45 with BMI of 19-25 or 30-35|Single Arm study
62192632|NCT04769375||Group 4:Healthy pregnant women (2nd or 3rd pregnancy)|This group will consist of women who do not have gestational diabetes mellitus according to routine control tests in their second or third pregnancy.
62573070|NCT03907748|NO_INTERVENTION|Standard Care|Participant dyads (people with dementia and their cohabiting caregivers) allocated to the standard care group will not receive any training or be asked to deliver an intervention.
62007033|NCT05314946|ACTIVE_COMPARATOR|Percutaneous enteral access|Feeding tube, either gastrostomy (G-) tube or gastrojejunostomy (GJ-) tube (placed by Interventional Radiology) or J-tube (surgically placed)
62007034|NCT05314946|EXPERIMENTAL|No percutaneous enteral access|No feeding tube placed.
62007035|NCT06273553|EXPERIMENTAL|RG002 Injection|In Part A, subjects with histologically confirmed Cervical Intraepithelial Neoplasia Grade 2 or 3 (CIN2/3) associated with Human Papillomavirus (HPV) 16 or 18, will be allocated to three dose cohorts that are 25µg,75µg and 150µg. In Part B, subjects with histologically confirmed Cervical Intraepithelial Neoplasia Grade 2 or 3 (CIN2/3) associated with Human Papillomavirus (HPV) 16 or 18, will be allocated to 1 or 2 dose levels according to the results of Part A. All subjects will receive a total of three RG002 Injections, administered intramuscularly at assigned dose level, with a dosing frequency of every 2 weeks (D1, D15, and D29).
62007036|NCT04879745|EXPERIMENTAL|Decision Aid Users|Patients with a rheumatic disease who are given access to the MyVoice:Rheum decision aid
62192633|NCT05418413|ACTIVE_COMPARATOR|Conventional Twin-block appliance|The patients in this control group will be treated using the conventional Twin-block appliance (CTB).
62398003|NCT03428139|ACTIVE_COMPARATOR|Group II|Each patient in this group was treated with pulsed radiofrequency as in group I plus oral alpha lipoic acid (ALA) 600 mg.
62398004|NCT05549804|EXPERIMENTAL|Dose Escalation|KL340399 weekly on Days 1, 8 and 15 on repeated 21-day cycles in escalating doses.
62573071|NCT01908075||BDP/FOR|Patients receiving ICS/LABA therapy as FP/SAL (Seretide®) who, at an index prescription date (IPD): Change their therapy to BDP/FOR (Fostair®) at same or lower BDP-equivalent ICS dose
62573072|NCT01908075||FP/SAL|Patients receiving ICS/LABA therapy as FP/SAL (Seretide®) who, at an index prescription date (IPD) : Remain on FP/SAL at the same BDP-equivalent ICS dose
62573073|NCT05131217|EXPERIMENTAL|Acute bout of Continuous Moderate Intensity Exercise|
62573074|NCT05131217|EXPERIMENTAL|Acute bout of High Intensity Interval Training (HIIT)|
62573075|NCT05131217|EXPERIMENTAL|Control|
62007037|NCT04879745|ACTIVE_COMPARATOR|Pamphlet Users|Patients with a rheumatic disease who are given access to a widely-accessible pamphlet about family planning
62007038|NCT06052774|ACTIVE_COMPARATOR|Stage I grade B periodontitis patients|Nonsurgical periodontal debridement was performed on patients using an ultrasonic scaler and universal curettes (2R - 2L and 4R- 4L). Oral Hygiene measures were instructed following treatment and maintenance visits were given to them.
62007039|NCT06052774|ACTIVE_COMPARATOR|Stage II grade B periodontitis patients|Nonsurgical periodontal debridement was performed on patients using an ultrasonic scaler and universal curettes (2R - 2L and 4R- 4L). Oral Hygiene measures were instructed following treatment and maintenance visits were given to them.
62007040|NCT06052774|NO_INTERVENTION|Periodontally healthy individuals|No intervention
62192634|NCT05418413|EXPERIMENTAL|Esthetic Twin-block appliance|the patients in this experimental group will be treated using the esthetic Twin-block appliance (ETB).
62192635|NCT05790005|EXPERIMENTAL|Intervention group|A therapeutic play will be played for 20 minutes after the warm-up play for 10 minutes before the first surgical dressing to be applied after the surgery with children in the 7-12 age groups. There will be 46 children in the intervention group.
62398005|NCT05999747|EXPERIMENTAL|White Light/near-infrared fluorescence - Adults with normal renal function or mild renal impairment|Adult participants with normal renal function or mild renal impairment will receive a single dose of ASP5354
62398006|NCT05999747|EXPERIMENTAL|White Light - Adults with normal renal function or mild renal impairment|Adult participants with normal renal function or mild renal impairment will receive a single dose of ASP5354
62573076|NCT04183296|EXPERIMENTAL|TIVA(Total Intravenous Anesthesia and Volatile Anesthesia )|In the TIVA group, anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
62192636|NCT05790005|NO_INTERVENTION|Control group|Therapeutic play will be not played for 20 minutes after the 10-minute warm-up game before the first surgical dressing to be applied after the surgery with children in the 7-12 age group. The routine procedure applied in the service before the dressing process will be applied. There will be 46 children in the control group.
62781399|NCT03579641||Implantable Cardiac device with HeartLogic feature|Patients with Heart Failure, implanted with Boston Scientific Implantable Cardioverter Defibrillator or Defibrillator with Cardiac Resynchronization device with HeartLogic feature
62781400|NCT02168608|EXPERIMENTAL|Remote ischemia precondition|patients in this arm accepted RIPC procedure after induction of anesthesia
62781401|NCT02168608|EXPERIMENTAL|None remote ischemia precondition|patients in this arm didn't accept RIPC procedure after induction of anesthesia
62007041|NCT03307148|EXPERIMENTAL|ATRA in combination with Gemcitabine and Nab-Paclitaxel|Patients will receive ATRA, Gemcitabine and nab-Paclitaxel in 28 day cycles. ATRA will be administered for 6 cycles whereas Gemcitabine/nab-Paclitaxel will be administered until disease progression.
62007042|NCT01733381||Barefoot runners|This group of individuals will run in minimally shod foot ware. For the purposes of this study we have defined this to be Vibram Five Finger shoes. Participants will be runners who consistently run in these shoes at least 20 miles per week.
62007043|NCT01733381||Shoed runners|This group of individuals will run in normal running shoes. Participants will be runners who consistently run in regular running shoes (that are not considered by industry standards to be minimal shoes) at least 20 miles per week.
62192637|NCT02689570||type 1 diabetic patients|Adult T1DM patients, aged 18-75 years, regularly attending the out-patient diabetes clinic of the Antwerp University Hospital are recruited starting from June 2011. Patients had to have a diabetes duration of ≥5 years and be in general good health to be included. Exclusion criteria were a history of a major adverse cardiovascular event (myocardial infarction, stroke), other cardiovascular complaints, pregnancy or a glomerular filtration rate ≤30 ml/min/1.73 m2.
62192638|NCT00981539|ACTIVE_COMPARATOR|treatment : receives pre operative enema|one arm will receive pre operative enema
62192639|NCT00981539|NO_INTERVENTION|no enema|this group will not receive pre operative enema
62192640|NCT03122470|EXPERIMENTAL|MRI guided biopsy + TRUS biopsy|Patients will undergo an MRI guided biopsy and standard trans-rectal ultrasonography-guided (TRUS) biopsy. Results will be compared to see which can more accurately diagnose and manage prostate cancer
62192641|NCT01982409|EXPERIMENTAL|Live Attenuated Varicella Vaccine|use the arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
62192642|NCT04069585|EXPERIMENTAL|RHA® Redensity with new anesthetic agent|"Split-face injection of RHA® Redensity with new anesthetic agent in the perioral rhytids on one side of the mouth and RHA® Redensity with lidocaine in the perioral rhytids in the other side of the mouth.~Up to 3 mL injected per side."
62192643|NCT04069585|EXPERIMENTAL|RHA® Redensity with lidocaine|"Split-face injection of RHA® Redensity with lidocaine in the perioral rhytids on one side of the mouth and RHA® Redensity with new anesthetic agent in the perioral rhytids in the other side of the mouth.~Up to 3 mL injected per side."
62192644|NCT01175759|EXPERIMENTAL|Healthy control group|
62573077|NCT04183296|ACTIVE_COMPARATOR|Inhalation|Arm Description: In the volatile group, anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration \[Ce\] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
62781402|NCT02572765||Normotensive|Normotensive subjects
62781403|NCT02572765||Hypertensive|Hypertensive subjects
62007044|NCT05181007|ACTIVE_COMPARATOR|MFA|mefanamic acid
62007045|NCT05181007|ACTIVE_COMPARATOR|VPA|valproate
62007046|NCT05889052||Active cohort control|Children (aged 6-9 months) in the control arm will receive the standard of care: 5 doses of SP at EPI visits (at 10 weeks, 14 weeks, 6 months, 9 months and 15 months).
62192645|NCT01175759|EXPERIMENTAL|UPRL|
62192646|NCT05182307|EXPERIMENTAL|Treatment|DurAVR™ THV System
62192647|NCT03998722|EXPERIMENTAL|Vagivital|Vagivital once Daily for 12 weeks
62192648|NCT01913977|EXPERIMENTAL|Treatment with mechanical ventilation|Abylcap system with the oxygenator Lilliput2 as CO2 remover (Bellco, Italy).
62573078|NCT06322641||Nephrologist|Nephrologist with ASCVD and CKD patients
62781404|NCT01824433|ACTIVE_COMPARATOR|venlafaxine|venlafaxine 75-225mg qd
62781405|NCT01824433|ACTIVE_COMPARATOR|fluoxetine|fluoxetine 20-60mg qd
62781406|NCT01511081|EXPERIMENTAL|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
62781407|NCT01511081|EXPERIMENTAL|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
62781408|NCT02343809|EXPERIMENTAL|Intervention Group|Actual Diacutaneous Fibrolysis and Protocolized Physiotherapy
62781409|NCT02343809|SHAM_COMPARATOR|Placebo Group|Sham Diacutaneous Fibrolysis and Protocolized Physiotherapy
62781410|NCT02343809|OTHER|Control Group|Protocolized Physiotherapy
62781411|NCT03092505||Females|Females participants who are about to start first line antiretroviral therapy.
62781412|NCT01992211|EXPERIMENTAL|Treatment Sequence 1(ABC)|"Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 15Day."
62781413|NCT01992211|EXPERIMENTAL|Treatment Sequence 2(ACB)|"Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 15Day."
62007047|NCT05889052||Active cohort intervention|Children (aged 6-9 months) in the intervention arm with receive PMC: 8 doses of SP at EPI visits (at the same contacts as group 1 plus at 12 months, 18 months and 24 months)
62007048|NCT02283502|EXPERIMENTAL|Intervention: MRgHIFU, Surgery|Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
62007049|NCT04774510|OTHER|Optimized C-ARM CBCT|An optimized C-arm CBCT evaluation with a different acquisition geometry and a novel software for the rapid, quality improved and less-artefacts assessment of brain parenchyma and angiogram.
62007050|NCT06207279||Major Depressive Disorder|Patients meeting the diagnostic criteria for Major Depressive Disorder (MDD) according to DSM-5.
62007051|NCT06207279||Chronic Insomnia Disorder|Patients meeting the diagnostic criteria for Chronic Insomnia Disorder according to ICSD-3.
62007052|NCT06207279||Health Control|Healthy population.
62007053|NCT06207279||Attention Deficit and hyperactivity Disorder|Patients meeting the diagnostic criteria for Attention Deficit and hyperactivity Disorder (ADHD) according to DSM-5.
62007054|NCT00095784|EXPERIMENTAL|Treatment (decitabine)|Patients receive decitabine SC on days 1-5 and 8-12. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.
62007055|NCT00947297|EXPERIMENTAL|HPN-100|Patients who were treated with HPN-100
62007056|NCT03653754||typically developing|Intervention: Measurement of growth and body composition. Growth (height, body weight), and body composition was measured at school.
62007057|NCT03653754||neurodisabilities|Intervention: Measurement of growth and body composition. Growth (height, body weight), and body composition was measured at school.
62007058|NCT01245855|NO_INTERVENTION|PGE1 group and control group|the control group: received only the conventional medications, the PGE1 group: received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
62007059|NCT02826889|EXPERIMENTAL|Fluid loading group|
62007060|NCT03372148|EXPERIMENTAL|pHRMi in evaluation of swallowing function|Pharyngeal High Resolution Manometry and Impedance (pHRMi) evaluation of swallowing function at baseline, 3 months post radiation, then at 9 months
62007061|NCT04731441|EXPERIMENTAL|Exercise Group|Exercise Program Subjects randomized to the intervention arm should have 6 weeks of home exercise prior to surgery, with a minimum of 5 weeks and not more than 7 weeks. The program will begin with an exercise consultation appointment with a certified fitness professional. During this consultation participants will receive an exercise manual for individualized home-based exercise and a practical introduction by an exercise and cancer specialist. PowerBlock adjustable dumbbells will be used for resistance training exercises and walking or jogging will be the primary type of aerobic training. The current program design was developed and successfully used with women with breast cancer. Thus, some components may need modification for this group of patients with advanced GI cancer.
62007062|NCT04731441|ACTIVE_COMPARATOR|Education Group|Subjects randomized to the control arm will receive education and a handbook on the benefits of exercise and will be encouraged to have adequate protein in their diet and provided with the list of high protein foods and nutritional information. These subjects will undergo the same assessments as the intervention arm at all time points. Control subjects will be offered a 6-week home exercise program 3 months after CRS/HIPEC. Results and outcomes will not be recorded.
62007063|NCT02316197|EXPERIMENTAL|MSC2490484A 100 mg QD|Participants received MSC2490484A capsules 100 milligram (mg) orally, once daily (QD) from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
62007064|NCT02316197|EXPERIMENTAL|MSC2490484A 200 mg QD|Participants received MSC2490484A capsules 200 mg orally, QD from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
62007065|NCT02316197|EXPERIMENTAL|MSC2490484A 150 mg BID|Participants received MSC2490484A capsules 150 mg orally, twice daily (BID) from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
62007066|NCT02316197|EXPERIMENTAL|MSC2490484A 200 mg BID|Participants received MSC2490484A capsules 200 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
62007067|NCT02316197|EXPERIMENTAL|MSC2490484A 300 mg BID|Participants received MSC2490484A capsules 300 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
62192649|NCT04812743|EXPERIMENTAL|Colorectal Health Research Champion trainees|Colorectal Health Research Champion (CHRC) trainees receive 5 education sessions on colorectal cancer, clinical research, biospecimen donation, ethics, and presentation skills. The CHRCs will invite others in their social networks to present to them this educational information, following the train the trainer model of health education.
62007068|NCT02316197|EXPERIMENTAL|MSC2490484A 400 mg BID|Participants received MSC2490484A capsules 400 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
62007069|NCT02316197|EXPERIMENTAL|MSC2490484A 400 mg BID RP2D|Participants received MSC2490484A capsules 400 mg recommended Phase II dose (RP2D) orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
62192650|NCT00820261||Diarrhea|children and infants (less than 5 years of age) presenting with severe diarrhea will be enrolled
62007070|NCT01294995|EXPERIMENTAL|Tea-flavor Liquor, taken with meal|including 12 males and 11 females
62007071|NCT01294995|PLACEBO_COMPARATOR|Guizhou Meijiao Liquor, taken with meal|including 11 males and 11 females
62007072|NCT03009097|ACTIVE_COMPARATOR|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with DFDBA
62007073|NCT03009097|ACTIVE_COMPARATOR|DFDBA with Atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with DFDBA in combination with Atorvastatin gel.
62007074|NCT05942456||sB7-H3 of treatment-naive osteosarcoma patients|Before delivering neoadjuvant chemotherapy, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood
62192651|NCT02634424|EXPERIMENTAL|MyPKFiT|Personalized prophylaxis : Treatment is adjustment according to PK modeling
62398007|NCT05999747|EXPERIMENTAL|White Light/near-infrared fluorescence - Adults with moderate or severe renal impairment|Adult participants with moderate or severe renal impairment will receive a single dose of ASP5354
62398008|NCT05324774|EXPERIMENTAL|9MW0813|
62398009|NCT05324774|ACTIVE_COMPARATOR|aflibercept|
62398010|NCT05493748|OTHER|Frequency|Main symptom: Increased daytime urinary frequency: complaint that micturition occurs more frequently during waking hours than previously deemed normal by the woman.
62398011|NCT05493748|OTHER|Nocturia|Main symptom: Complaint of interruption of sleep one or more times because of the need to micturate.
62398012|NCT01751490|ACTIVE_COMPARATOR|physiotherapy alone|patients undergoing physiotherapy only
62398013|NCT01751490|ACTIVE_COMPARATOR|surgery and physiotherpay|patients receiving surgical treatment followed by physiotherapy
62398014|NCT02369874|EXPERIMENTAL|MEDI4736|MEDI4736 monotherapy
62781414|NCT01992211|EXPERIMENTAL|Treatment Sequence 3(BAC)|"Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 1Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 15Day."
62007075|NCT05942456||sB7-H3 after neoadjuvant chemotherapy for osteosarcoma patients|After neoadjuvant chemotherapy and before definitive surgery, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood
62398015|NCT02369874|EXPERIMENTAL|MEDI4736 + Tremelimumab|MEDI4736 + tremelimumab combination therapy
62398016|NCT02369874|ACTIVE_COMPARATOR|Standard of Care|Standard of Care
62398017|NCT05333549|EXPERIMENTAL|Usual care plus istradefylline|Participants will receive usual care, and in addition, will be asked to take istradefylline daily for 26 weeks.
62398018|NCT01493440|OTHER|Atosiban|
62573079|NCT04138953|EXPERIMENTAL|TMS over premotor cortex (PMC)|Noninvasive brain stimulation in the premotor cortex
62573080|NCT04138953|EXPERIMENTAL|TMS over primary motor cortex (M1)|Noninvasive brain stimulation in the motor cortex
62781415|NCT01992211|EXPERIMENTAL|Treatment Sequence 4(BCA)|"Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 8Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 15Day."
62007076|NCT03465293||SUDD post-menopausal female|Post-menopausal women with non-specific left side pain and altered bowel habit who are having mechanical bowel preparation for a colonoscopy
62007077|NCT05044234|PLACEBO_COMPARATOR|Placebo|Participants received placebo capsules for cedirogant orally once daily (QD) for 16 weeks.
62007078|NCT05044234|EXPERIMENTAL|75 mg Cedirogant|Participants received 75 mg cedirogant orally once daily (QD) for 16 weeks.
62007079|NCT05044234|EXPERIMENTAL|150 mg Cedirogant|Participants received 150 mg cedirogant orally once daily (QD) for 16 weeks.
62007080|NCT05044234|PLACEBO_COMPARATOR|375 mg Cedirogant|Participants received 375 mg cedirogant orally once daily (QD) for 16 weeks.
62007081|NCT01148953|ACTIVE_COMPARATOR|ALN-TTR01|
62192652|NCT01850030|EXPERIMENTAL|Dydrogesterone 30 mg|
62192653|NCT01850030|EXPERIMENTAL|Micronized Progesterone 600 mg|
62192654|NCT04790864|EXPERIMENTAL|Online large-group one-session treatment with post-treatment exercise targeting expectancy violation|
62192655|NCT04790864|ACTIVE_COMPARATOR|Online large-group one-session treatment with post-treatment control exercise|
62398019|NCT00682539|ACTIVE_COMPARATOR|Avastin|15 patients with clinical significant macular edema receive an injection of 2,5 mg Avastin every month. After three initial injections of Avastin re-injection is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns a sham injection is performed.
62398020|NCT00682539|ACTIVE_COMPARATOR|Triamciolone|30 patients with a clinical significant diabetic macular edema receive an intraocular injection of 8mg triamcinolone at baseline under sterile conditions. 1 and 2 month after the baseline injection, patients receive a sham injection. After three month re-injection of 8mg Triamcinolone is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns patients will receive a sham injection. In between two injection of 8mg Triamcinolone must be an temporal interval of at least 3 months.
62398021|NCT00682539|ACTIVE_COMPARATOR|Lucentis|15 patients with clinical significant macular edema receive an injection of 0,5 mg Lucentis every month. After three initial injections of Lucentis re-injection is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns a sham injection is performed.
62398022|NCT05696184|ACTIVE_COMPARATOR|GERD patients with complaint of regurgitation and supra-esophageal reflux disease (SERD)|GERD patients with complaint of regurgitation and one of the following supra-esophageal symptoms attributed to reflux of gastric content: chronic cough, frequent throat clearing, history of non-deglutitive aspiration pneumonia, hoarse voice, chronic sinusitis and dental erosion i.e. SE-GERD. Patients will undergo endoscopic evaluation of reflux and upper esophageal sphincter (UES) manometric testing.
62398023|NCT05696184|ACTIVE_COMPARATOR|Age and gender matched healthy controls|Controls will undergo endoscopic evaluation of reflux and upper esophageal sphincter (UES) manometric testing.
62398024|NCT05696184|ACTIVE_COMPARATOR|Age and gender matched patient controls (GERD without regurgitation and supra-esophageal complaint)|Age and gender matched patient controls (GERD without regurgitation and supra-esophageal complaint). Patients will undergo endoscopic evaluation of reflux and upper esophageal sphincter (UES) manometric testing.
62398025|NCT05696184|ACTIVE_COMPARATOR|Asthma patients with and without supra-esophageal symptoms|Asthma patients with and without supra-esophageal symptoms (these symptoms include chronic cough, frequent throat clearing, history of non-deglutitive aspiration pneumonia, hoarse voice, chronic sinusitis, and dental erosion). Patients will undergo endoscopic evaluation of reflux and upper esophageal sphincter (UES) manometric testing.
62573081|NCT04138953|SHAM_COMPARATOR|Sham TMS|Sham brain stimulation
62781416|NCT01992211|EXPERIMENTAL|Treatment Sequence 5(CAB)|"Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 1Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 15Day."
62781417|NCT01992211|EXPERIMENTAL|Treatment Sequence 6(CBA)|"Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 8Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 15Day."
62192656|NCT01910883|EXPERIMENTAL|Group 1|Single doses of 200, 400 and 600 mg finafloxacin i.v.
62192657|NCT01910883|EXPERIMENTAL|Group 2|Single doses of 800 and 1000 mg finafloxacin i.v.
62781418|NCT01478906||elderly ,adult|
62781419|NCT03786471|ACTIVE_COMPARATOR|Health Systems-Based Dementia Care|Dementia care that is based in the health care system, which partners with community-based organizations to provide comprehensive, coordinated, patient-centered care. The health system-based dementia care arm uses a Dementia Care Specialist (Nurse Practitioner or Physician Assistant) supervised by a physician to tailor and facilitate dementia care delivery in collaboration with the primary care physician (co-management). The Health Systems-Based Dementia Care arm is based on UCLA's Alzheimer's and Dementia Care Program.
62781420|NCT03786471|ACTIVE_COMPARATOR|Community-Based Dementia Care|Dementia care that is based in community organizations, which gives equal attention to patients and their primary family or friend caregivers. The community-based dementia care arm uses Care Consultants (social workers, nurses, or licensed therapist). Patients with dementia are engaged in the program whenever possible. Caregivers can be the sole program participant, when patients are too impaired. The program establishes a long-term relationship between Care Consultants and families. The exact content of assistance provided is tailored to the preferences of individual patients and caregivers, and is holistic in the range of potential concerns of problems addressed. The Community-Based Dementia Care arm is based on the Benjamin Rose Institute on Aging's Care Consultation Program.
62781421|NCT03786471|OTHER|Usual Care|Dementia care that most closely corresponds to traditional care. This arm will also receive standardized educational materials (hard copies and internet-based resources), referral to the Alzheimer's Association 1-800 national helpline to speak to a master's level consultant for decision-making support, crisis assistance, and caregiver education, as well as referral to local programs and services.
62781422|NCT02643732|EXPERIMENTAL|Methylphenidate|"Methylphenidate 10mg (one tablet) twice daily, increasing to 20mg (two tablets) twice daily following assessment 2 weeks into trial.~24 weeks duration"
62781423|NCT02643732|PLACEBO_COMPARATOR|Placebo|"Identical, over-encapsulated placebo tablets manufactured to be identical to the experimental tablets. One tablet twice daily, increased to two tablets twice daily following assessment 2 weeks into trial.~24 weeks duration."
62781424|NCT01111279|PLACEBO_COMPARATOR|Placebo|
62781425|NCT01111279|EXPERIMENTAL|gpASIT+TM|
62192658|NCT01910883|EXPERIMENTAL|Group 3|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 600 mg i.v.
62192659|NCT01910883|EXPERIMENTAL|Group 4|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 600 mg i.v. (additional to Group 3)
62192660|NCT01910883|EXPERIMENTAL|Group 5|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 800 mg i.v.
62192661|NCT01910883|EXPERIMENTAL|Group 6|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 1000 mg i.v.
62192662|NCT01137669|PLACEBO_COMPARATOR|Placebo|10 subjects to receive placebo subcutaneously.
62573082|NCT02089373|EXPERIMENTAL|Probe-based confocal laser endomicroscopy|
62007082|NCT01148953|PLACEBO_COMPARATOR|Sterile Normal Saline (0.9% NaCl)|
62192663|NCT01137669|EXPERIMENTAL|ZOSTAVAX®|30 subjects to receive 0.65 mL ZOSTAVAX® subcutaneously.
62007083|NCT01494311|ACTIVE_COMPARATOR|Placebo patch and lidocaine injection|Fourty-five patients were randomly assigned to receive a placebo patch, looking identically to the Rapydan patch and subsequent subcutaneous injection of 0.5 ml of lidocaine 1%.
62007084|NCT01494311|EXPERIMENTAL|Lidocaine/tetracaine patch|Fourty-five patients were randomly assigned to receive a lidocaine/tetracaine patch, followed by subcutaneous injection 0.5 ml of normal saline solution.
62007085|NCT05928442||"Endometriosis patients"|"Patient with a formal endometriosis diagnosed by clinical examination and imaging.~At least 20 patients"
62192664|NCT01082237|ACTIVE_COMPARATOR|escitalopram|All subjects will receive escitalopram (ESC), brand name Lexapro (Forest Laboratories, Inc., New York) throughout the study. Dosing will start at 5 mg/d, be titrated to 10 mg after 4 days, and continue at 10 mg/d thereafter; an additional dose titration to 20 mg will be pursued at week 8 for those not significantly better (\<50% improvement on IDS-30 at week 8 visit) and as tolerated.
62192665|NCT04988776|ACTIVE_COMPARATOR|group A|Patients received ultrasound-guided Intercostobrachial nerve block with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl ) .
62192666|NCT04988776|ACTIVE_COMPARATOR|group B|patients received ultrasound-guided pectoral nerves block type II with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl )
62192667|NCT04321122|EXPERIMENTAL|Ultrasound cyclo plasty(UCP)|Ultrasound cyclo plasty treatment for primary open-angle glaucoma patients.
62192668|NCT04955899|EXPERIMENTAL|Active Stimulation|Active stimulation for 12 weeks
62192669|NCT05655923|PLACEBO_COMPARATOR|Group I|ten patients will be subjected to place bone substitute mixed with Olive oil in intra bony defect. ( Control group)
62573083|NCT02089373|ACTIVE_COMPARATOR|White light endoscopy|
62573084|NCT00459277|EXPERIMENTAL|Nasalfent, Fentanyl Citrate Nasal Spray|
62573085|NCT00459277|PLACEBO_COMPARATOR|Placebo Spray|
62573086|NCT03969823|EXPERIMENTAL|Osimertinib|Osimertinib at 80mg dose will be administered orally once daily.
62573087|NCT04795648|EXPERIMENTAL|Spatial Repellent|Transfluthrin
62573088|NCT04795648|PLACEBO_COMPARATOR|Placebo|Inert ingredients
62573089|NCT00726973|EXPERIMENTAL|1|Reduced fluence (3300mW/cm2-50% standard fluence) PDT + ranibizumab
62573090|NCT00726973|ACTIVE_COMPARATOR|2|Ranibizumab monotherapy
62781426|NCT01111279|EXPERIMENTAL|gpASIT+TM/adjuvant|
62192670|NCT05655923|ACTIVE_COMPARATOR|Group II|ten patients will be subjected to place bone substitute mixed with ozonated olive oil in intra bony defect without further application of ozonated oil.
62781427|NCT01313338||Acute coronary syndrome|
62007086|NCT05928442||"Discordants patients"|"Patient with suspected endometriosis for whom the diagnosis is the source of a discrepancy between clinical examination and imaging data, AND a surgical indication.~At least 20 patients"
62192671|NCT05655923|ACTIVE_COMPARATOR|Group III|ten patients will be subjected to place bone substitute mixed with ozonated olive oil in intra bony defect with further weekly application of ozonated olive oil until third week
62007087|NCT05928442||"Surgery patients"|"Patient with a gynaecological indication for surgery of the small pelvis AND symptoms suggestive of endometriosis.~At least 20 patients"
62192672|NCT01896726|EXPERIMENTAL|Baricitinib + Microgynon|Microgynon \[30 micrograms (µg) ethinyl estradiol and 150 µg levonorgestrel\] administered orally, once daily (QD), on Days 1 and 29. Baricitinib, 10 milligrams (mg), administered orally QD on Days 23 through 30.
62192673|NCT01461889|EXPERIMENTAL|High INR|Transfuse plasma to High INR target. Plasma will be transfused to reach a target INR=2.5 for 48 hours while patient is actively bleeding.
62192674|NCT01461889|ACTIVE_COMPARATOR|Low INR|Transfuse plasma to Low INR target. Plasma will be transfused to reach a target INR=1.8 for 48 hours while patient is actively bleeding.
62192675|NCT05614518|EXPERIMENTAL|18F-NaF-PET/CT|"Patients undergo an 18F-NaF-PET/CT scan and an 99mTc-MDP-BS±SPECT scan within a time frame of 7 days.~Generic Name: Sodium Fluoride F-18 injection Dosage Form: Injection Dosage: Administer 5-10 mCi as an intravenous injection Frequency and Duration: Single dose"
62192676|NCT05614518|ACTIVE_COMPARATOR|99mTc-MDP-BS±SPECT|"Patients undergo an 18F-NaF-PET/CT scan and an 99mTc-MDP-BS±SPECT scan within a time frame of 7 days.~Generic Name: Technetium\[99mTc\] Methylenediphosphonate Injection Dosage Form: Injection Dosage: Administer 10-25 mCi as an intravenous injection Frequency and Duration: Single dose"
62192677|NCT02968615|EXPERIMENTAL|fiber & protein|A single dietary change condition that focuses exclusively on increasing fiber and protein.
62192678|NCT01121705|NO_INTERVENTION|A1. standard duration|Patients were randomly assigned in a 1:1 ratio to two treatment arms. In the standard treatment group (A1), patients were treated for 24 weeks irrespective of the HCV RNA status at week 4 with Peg-interferon alfa-2b at a dose of 1.5 mcg per kilogram of body weight weekly in combination with oral ribavirin administered at a dose of 1000 mg/day for patients with a weight \<75 kg or 1200 mg/day for those with a weight of ≥75 kg. Patients enrolled in Arm A1 will be treated for standard 24 weeks duration of treatment with standard dosages of PegInterferon alpha 2b and weight-based dosages of ribavirin.
62192679|NCT01121705|EXPERIMENTAL|B 1 I or II|In the variable treatment group, patients with a virologic response at week 4 will receive treatment for 12 weeks and those without a virologic response at 4 weeks treatment for 36 weeks. Patients without RVR will be treated for 24 or 36 weeks and labelled (B1I) or (B1II, respectively Intervention: different durations of treatment for patients without RVR
62007088|NCT01567189|EXPERIMENTAL|Hospital cardiac rehabilitation|The patients will perform physical training sessions in the hospital
62192680|NCT04829123|EXPERIMENTAL|Single dose of 0.5 mg HEC88473|Healthy subjects, receiving a single dose of 0.5 mg HEC88473 (N=6) or placebo(N=2) after meal.
62192681|NCT04829123|EXPERIMENTAL|Single dose of 1.7 mg HEC88473|Healthy subjects, receiving a single dose of 1.7 mg HEC88473 (N=6) or placebo(N=2) after meal.
62192682|NCT04829123|EXPERIMENTAL|Single dose of 5.1 mg HEC88473|Healthy subjects, receiving a single dose of 5.1 mg HEC88473 (N=6) or placebo(N=2) after meal.
62781428|NCT05249244||observation group|huachansu oral preparation (tablet, capsule) was used.
62781429|NCT05249244||control group|huachansu was not used.
62781430|NCT06156241|EXPERIMENTAL|4x10^6 Cells/kg Dose Group|This is a adaptive Baysian dose escalation study. The first 3 subjects will receive one stem cell infusion of 4x10\^6 Cells/kg. If no infusion related AE/SAE are found, the next cohort will receive the next highest stem cell dose.
62192683|NCT04829123|EXPERIMENTAL|Single dose of 10.2 mg HEC88473|Healthy subjects, receiving a single dose of 10.2 mg HEC88473 (N=6) or placebo(N=2) after meal.
62192684|NCT04829123|EXPERIMENTAL|Single dose of 17.0 mg HEC88473|Healthy subjects, receiving a single dose of 17.0 mg HEC88473 (N=6) or placebo(N=2) after meal.
62192685|NCT04829123|EXPERIMENTAL|Single dose of 25.5 mg HEC88473|Healthy subjects, receiving a single dose of 25.5 mg HEC88473 (N=6) or placebo(N=2) after meal.
62192686|NCT04829123|EXPERIMENTAL|Single dose of 34.0 mg HEC88473|Healthy subjects, receiving a single dose of 34.0 mg HEC88473 (N=6) or placebo(N=2) after meal.
62192687|NCT04829123|EXPERIMENTAL|Single dose of 44.2 mg HEC88473|Healthy subjects, receiving a single dose of 44.2 mg HEC88473 (N=6) or placebo(N=2) after meal.
62192688|NCT04829123|EXPERIMENTAL|Multiple doses of 1.7 mg HEC88473|Healthy subjects, receiving a weekly dose of 1.7 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
62192689|NCT04829123|EXPERIMENTAL|Multiple doses of 5.1 mg HEC88473|Healthy subjects, receiving a weekly dose of 5.1 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
62192690|NCT04829123|EXPERIMENTAL|Multiple doses of 10.2 mg HEC88473|Healthy subjects, receiving a weekly dose of 10.2 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
62781431|NCT06156241|EXPERIMENTAL|6x10^6 Cells/kg Dose Group|"The next cohort of 3 subjects will receive one stem cell infusion of 6x10\^6 Cells/kg.~If no infusion related AE/SAE are found, the next cohort will receive the next highest stem cell dose."
62781432|NCT06156241|EXPERIMENTAL|8x10^6 Cells/kg Dose Group|"The next cohort of 3 subjects will receive one stem cell infusion of 8x10\^6 Cells/kg.~If no infusion related AE/SAE are found, the next cohort will receive the next highest stem cell dose."
62781433|NCT06156241|EXPERIMENTAL|10x10^6 Cells/kg Dose Group|The last cohort of 3 subjects will receive one infusion of 10x10\^6 Cells/kg.
62781434|NCT04381650|EXPERIMENTAL|Dose Escalation: TAK-981 + Pembrolizumab (Fixed Dose)|Escalating doses of TAK-981 with starting dose of 40 mg, intravenous (IV) infusion, on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle and pembrolizumab 200 mg, IV infusion, as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle until RP2D is determined (for a maximum of 24 months).
62398026|NCT05696184|ACTIVE_COMPARATOR|Age and gender matched patient controls for diagnosed Barrett's esophagus patients|Patient controls for diagnosed Barrett's esophagus patients. Patients will undergo endoscopic evaluation of reflux and upper esophageal sphincter (UES) manometric testing.
62398027|NCT01624818|EXPERIMENTAL|Group 2, 6-7 years|18 children (6-7 years) with heart disease participating in a rehabilitation programme in Geilomo childrens hospital
62398028|NCT01624818|EXPERIMENTAL|Group 1, 11-12 years|18 children(11-12 years) with heart disease participating in a rehabilitation programme at Geilomo childrens hospital.
62398029|NCT01144858||patients with persistent atrial fibrillation ablation|
62398030|NCT03775642|EXPERIMENTAL|Intervention video|The intervention video will employ debiasing strategies to correct women's misinformation about the safety of the IUD and implant safety.
62398031|NCT03775642|PLACEBO_COMPARATOR|Control video|The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration.
62398032|NCT03222180|EXPERIMENTAL|Website|Participants will be provided with password-protected access to use of the online resource created during the first phase of the project during the one year randomized controlled trial. Participants' children with T1D will receive Usual Care for T1D as described below.
62398033|NCT03222180|NO_INTERVENTION|Usual Care|Participants' children with T1D will receive care for T1D at their respective institutions equivalent to that received by comparable patients who do not enroll in the trial. At all sites, Usual Care is designed to be consistent with the current American Diabetes Association Standards of Care for T1D in this clinical population.
62398034|NCT01753765|EXPERIMENTAL|Treatment|Study treatment with Cryo-Touch III device at Day 0.
62398035|NCT04815005||HoFH|Patients diagnosed with HoFH by their physicians, either based on clinical or genetic criteria.
62398036|NCT04086511||Children with PKU|
62398037|NCT04086511||Age- and sex-matched non-PKU comparison subjects|
62398038|NCT05715190|OTHER|nurse-led education|
62398039|NCT06722963|EXPERIMENTAL|Fentanyl group|Fentanyl used as an adjuvant to bupivacaine for intraperitoneal instillation during laparoscopic cholecystectomy, a dose is 50 micrograms is commonly added to the local anesthetic solution.
62007089|NCT01567189|ACTIVE_COMPARATOR|Home cardiac rehabilitation|The patients will perform physical training sessions at home
62007090|NCT01228240|EXPERIMENTAL|Metformin, Apo-metformin|Participants under treatment with non-generic Metformin (manufactured by Apotex Canada).
62007091|NCT01228240|ACTIVE_COMPARATOR|Metformin, Pars Minoo|Participants under treatment with generic Metformin (manufactured by Pars Minoo).
62192691|NCT02204020|EXPERIMENTAL|5-azacytidine|5-aza SC or IV 32mg/m2 - 75mg/m2 (based on dose escalation)
62007092|NCT03454438|EXPERIMENTAL|Algorithm|Use of electronic structured referral sheets using the algorithms for rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.
62007093|NCT03454438|EXPERIMENTAL|Triage|Triage by rheumatologist in a primary care setting.
62007094|NCT03454438|NO_INTERVENTION|Usual care|Control group consisting of usual care.
62007095|NCT03723694|ACTIVE_COMPARATOR|650 mg of Cocoapro flavanols|Daily, each subject will consume either two cocoa flavanol-containing capsules twice a day with a meal.
62007096|NCT03723694|PLACEBO_COMPARATOR|0mg Cocoapro flavanols|Daily, each subject will consume either ttwo placebo-containing capsules twice a day with a meal.
62007097|NCT02306967|ACTIVE_COMPARATOR|Standard Resection|Oral resection will be guided by usual practice. This involves identifying the tumour with white light and then marking surgical margins and resection the primary cancer.
62007098|NCT02306967|EXPERIMENTAL|FV Guided Resection|The oral resection will be guided by fluorescent visualization (FV).
62007099|NCT00917332|EXPERIMENTAL|intervention|"55 third trimester women will receive a CD of relaxation and guided imagery (of safe place), to practice daily at home until childbirth"
62007100|NCT00917332|NO_INTERVENTION|control|55 third trimester women who does not receive the relaxation and guided imagery CD.
62007101|NCT02231242|EXPERIMENTAL|Intrathecal Autologous Bone Marrow TNC|Procedure/Surgery: Intrathecal Autologous Bone Marrow TNC. Other Names: Autologous Stem Cell Transplantation Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) (10mcgr/kg of body weight) for 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the autologous TNC concentrate of 10 mL will be infused intrathecally.
62007102|NCT02231242|NO_INTERVENTION|Control group|"Patients will be evaluated with the Gross Motor Functional Classification System initially, at one, three and six months, and then cross to the intervention arm."
62007103|NCT02007928|OTHER|rispéridone, aripiprazole, olanzapine...|"Study:~We propose a prospective, interventional multicenter study.~Method:~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
62007104|NCT02513589|EXPERIMENTAL|Experimental arm|
62007105|NCT01166594|EXPERIMENTAL|Bevacizumab|Tested Drug
62007106|NCT01166594|PLACEBO_COMPARATOR|Control|Control - BSS
62007107|NCT04617093|EXPERIMENTAL|Total Patient Population|The planned PrismaLung+ treatment period for this study is 24 hours. Neuromuscular blockade and sedation will be required for the first 24 hours of ECCO2R treatment and thereafter, will be used at the discretion of the attending physician. Patients will require systemic anticoagulation with heparin during ECCO2R treatment. Blood warming during ECCO2R treatment will occur using the TherMax blood warmer.
62192692|NCT05393089|EXPERIMENTAL|AGN-190584|Participants will receive one drop of AGN-190584 instilled in each eye once daily for 14 days.
62192693|NCT05393089|PLACEBO_COMPARATOR|Vehicle|Participants will receive one drop of vehicle instilled in each eye once daily for 14 days.
62398040|NCT06722963|EXPERIMENTAL|Nalbuphine group|patients will receive Nalbuphine in a Doses ranging from 10 mg have been studied as adjuvants to bupivacaine
62398041|NCT01663688||Normative Data Collection|
62192694|NCT05688163|ACTIVE_COMPARATOR|traditional cognitive stimulation|The control group will carry out the programme based on traditional cognitive stimulation. Individual cognitive skills such as attention, memory, executive functions, orientation, praxis, calculation, visual perception and reasoning will be trained. The materials and media used will be a cognitive stimulation notebook created for the study which includes cards in printed paper format to be completed by the participants.
62398042|NCT02185443|EXPERIMENTAL|SBRT|
62398043|NCT04117282|ACTIVE_COMPARATOR|control group|15 children received the regular exercise program including classical gait training for diplegic children (30 minutes exercises + 30 minutes gait training)
62192695|NCT05688163|EXPERIMENTAL|programme based on everyday cognition|The experimental group, on the other hand, will carry out a programme based on everyday cognition, i.e. the use of cognitive functions to solve real everyday problems that occur in our daily lives and that allow us to be autonomous in our homes, such as preparing food, taking care of the house, using transport, shopping, using the telephone, medication, financial management and access to information and current affairs. As material for use as for the traditional cognitive stimulation sessions, a training booklet on everyday cognition has been created which includes all the sessions mentioned above.
62192696|NCT01934751|OTHER|Opioid dependent|Subjects with a possible opioid use disorder, as determined by positive responses on the eligibility form: has used opioids within the past 30 days, opioid use has been a problem, and at least one harmful consequence of opioid use has been present (eg. withdrawal symptoms, or problems with family, friends, work, money etc.).
62192697|NCT01934751|OTHER|Alcohol dependent|Patients who indicate they have a problem with alcohol will be asked to complete the AUDIT, a validated, 10-item instrument that measures the severity of an alcohol problem. The AUDIT enquires about core features of alcohol dependence, such as failure to fulfill obligations. A score of 8 or more indicates possible alcohol dependence.
62192698|NCT03757871|EXPERIMENTAL|Laser Stimulation|laser pen acupuncture projecting an infrared beam with a wavelength of 905nm bilaterally for 30 seconds on each point.
62192699|NCT03757871|PLACEBO_COMPARATOR|Placebo|The placebo group will have an application of the pen according to the same extinguished laser criteria.
62192700|NCT04832295|EXPERIMENTAL|Intervention|Photo-supported conversations about well-being, in addition to care as usual
62398044|NCT04117282|EXPERIMENTAL|study group|15 diplegic child received the same exercise program including the use of the antigravity shoes for gait training (30 minutes exercises + 30 minutes gait training)
62398045|NCT05721482|EXPERIMENTAL|MIM-DASH|A trained MIM provider and dietitian will deliver the MIM DASH group intervention in eight weekly 1-hour sessions via telehealth.
62781435|NCT04381650|EXPERIMENTAL|Dose Expansion Phase: Cohort A: Non-squamous NSCLC|TAK-981 as IV infusion in participants with non-squamous non-small cell lung cancer (NSCLC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
62781436|NCT04381650|EXPERIMENTAL|Dose Expansion Phase: Cohort B: Cervical Cancer|TAK-981 as IV infusion in participants with cervical cancer on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
62781437|NCT04381650|EXPERIMENTAL|Dose Expansion Phase: Cohort C: MSS-CRC|TAK-981 as IV infusion in participants with microsatellite stable colorectal cancer (MSS-CRC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
62192701|NCT04832295|ACTIVE_COMPARATOR|Control|Care as usual
62192702|NCT04361383|PLACEBO_COMPARATOR|Control group|patients will be operated under general anesthesia.
62192703|NCT04361383|ACTIVE_COMPARATOR|QLB group|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
62192704|NCT04361383|ACTIVE_COMPARATOR|ESPB group|patients will receive ultrasound-guided erector spinae plane block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
62398046|NCT05721482|NO_INTERVENTION|Attention Control|A trained interventionist will deliver the Caregiver Training. Participants in this group will attend eight 1-hour group lessons via telehealth for 8 weeks. We will use Alzheimer's Association caregiver training resources on topics such as Healthy Living for Your Brain and Body: Tips from the Latest Research; Dementia Conversations: Driving, Doctors Visits, Legal and Financial Planning; and Understanding and Responding to Dementia-Related Behavior. Similar to the MIM DASH group, participants will receive educational materials so they can follow along using videoconferencing or phone.
62398047|NCT01161173||Erlotinib|Participants received erlotinib (Tarceva) at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics. The recommended daily dose of erlotinib is 150 mg orally once daily.
62573091|NCT01398969|EXPERIMENTAL|Fresh FMT|Participants in this arm will receive Fresh FMT via rectal administration. They will be followed for 13 weeks to assess the cure or recurrence of CDI. All other procedures between the two arms will be identical.
62192705|NCT01749254||Acute Coronary Syndrome|40 patients admitted with ACS (NSTEMI/STEMI) will be recruited undergo 18F NaF PET, 18F FDG and CTCA within 1 month of the event.
62192706|NCT01749254||Stable angina cohort|40 patients with previously diagnosed coronary artery disease and listed to undergo elective coronary angiogram will be recruited. VH-IVUS will be attempted in all patients. Selected patients will undergo PET scan after stent implantation.
62573092|NCT01398969|EXPERIMENTAL|Frozen-and-Thawed FMT|Participants in this arm will receive Frozen-and-Thawed FMT via rectal administration. They will be followed 13 weeks to assess the cure or recurrence of CDI. All other procedures between the two arms will be identical.
62573093|NCT05369897|EXPERIMENTAL|VR training|VR training for at least 10 minutes at least three days per week, resulting in a total of at least 36 sessions (at least \~12 hours of training in total) for each participant, spread across three months. Each session will focus on cognitive training.
62573094|NCT05369897|SHAM_COMPARATOR|VR activity|VR activity for at least 10 minutes at least three days per week, resulting in a total of at least 36 sessions (at least \~12 hours of training in total) for each participant, spread across three months, with 360º images and videos but without the interactive cognitive training.
62398048|NCT04961190|ACTIVE_COMPARATOR|Prolonged Exposure Therapy|8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
62007108|NCT01848990|EXPERIMENTAL|Commercial Hylenex Recombinant (Formulation 1)|Hylenex Formulation 1: For 6 months, participants received their regular treatment of rapid-acting continuous subcutaneous insulin infusion (CSII) (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the commercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).
62007109|NCT01848990|EXPERIMENTAL|Precommercial Hylenex Recombinant (Formulation 2)|Hylenex Formulation 2: For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the precommercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).
62007110|NCT01848990|ACTIVE_COMPARATOR|Standard Rapid-Acting Insulin CSII|Participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.
62398049|NCT04961190|ACTIVE_COMPARATOR|Pharmacotherapy|20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily
62398050|NCT04961190|ACTIVE_COMPARATOR|Combined treatment (Prolonged Exposure and Pharmacotherapy)|8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders AND 20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily
62573095|NCT02476578|EXPERIMENTAL|Intervention Email|An email is sent, alerting the primary care providers about low values of BMI, HbA1c% or cholesterol and advising to consider appropriate dietary and medical revision.
62573096|NCT02476578|NO_INTERVENTION|Control|No email is sent.
62007111|NCT06232733|EXPERIMENTAL|Immediate Intervention|Access to HELP e-intervention from 0 to 6 months with kinesiology support.
62398051|NCT02960191|OTHER|healthy volunteers|subject with no current or past personal history of psychiatric disorders and about never having carried out suicide attempt
62573097|NCT03594981|EXPERIMENTAL|CMV/AdV /EBV/BKV specific T cells|CMV/AdV /EBV/BKV specific T cells will be thawed and transferred to a syringe given by slow intravenous injection over 1-2 minutes. Three dose levels will be explored. The lowest dose level will be 1x107cells/m2 and the highest will be 5x107/m2.
62398052|NCT02960191|OTHER|emotional witness|subject having had a personal history of unipolar or bipolar depressive disorder and who have never done in his life attempted suicide
62398053|NCT02960191|OTHER|patient suicide|subject having had a personal history of unipolar or bipolar depressive disorder and having realized in his life at least one suicide attempt
62398054|NCT00339482||American Indians|Residents of the Gila River Indian Community
62573098|NCT03220269||Out-of-hospital cardiac arrest (OHCA)|An OHCA is defined as cessation of cardiac mechanical activity that occurs outside of the hospital setting and is confirmed by the absence of signs of circulation.
62573099|NCT03220269||In-hospital cardiac arrest (IHCA)|An IHCA is defined as cessation of cardiac mechanical activity that occurs inside of the hospital setting and is confirmed by the absence of signs of circulation.
62573100|NCT05002257|EXPERIMENTAL|Experimental Arm|
62573101|NCT05002257|ACTIVE_COMPARATOR|Control arm|
62573102|NCT00383760|EXPERIMENTAL|Treatment (eribulin mesylate)|Patients receive E7389 IV on days 1 and 8.
62398055|NCT02919709|EXPERIMENTAL|thoracic or abdominal aortic aneurysm|
62573103|NCT01509313|EXPERIMENTAL|Uterine polypectomy using morcellator|A new instrument using a mechanical cutting edge has come to market for uterine polypectomy. In patients having a general anaesthesia the mechanical cutting instrument has been shown to be easier to learn, more effective at completely removing polyps and quicker than current techniques. However, the instrument is slightly larger, which could potentially cause more discomfort and prolong the procedure in the outpatient setting.
62573104|NCT01509313|ACTIVE_COMPARATOR|Electical Resection|At present the most commonly used device for removing the uterine polyps in the outpatient setting is by electrical resection. This will provide comparison for the morcellator device being tested
62007112|NCT06232733|ACTIVE_COMPARATOR|Delayed Intervention|Access to HELP e-intervention from 6 to 12 months with kinesiology support.
62007113|NCT03266562|OTHER|FES vs FDG|All patients will undergo two PEM studies, one with F-18 FDG and the second with F-18 FES. Co-registration of the PEM images from F-18 FDG and F-18 FES will be used to assess the heterogeneity of uptake of the F-18 FES relative to that of F-18 FDG. Heterogeneity of ER expression in the tumor will be determined by immunohistochemistry on the pathologic tissue
62007114|NCT00200226|PLACEBO_COMPARATOR|1|Vitamin B6
62007115|NCT00200226|ACTIVE_COMPARATOR|2|misoprostol
62007116|NCT02492451|ACTIVE_COMPARATOR|Endometrial Injury|Endometrial injury in luteal phase of preceding IUI cycle
62007117|NCT02492451|ACTIVE_COMPARATOR|Luteal Phase Support|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
62007118|NCT02492451|NO_INTERVENTION|Control group|Only IUI
62007119|NCT01996969|OTHER|Regorafenib|This study is a single arm study with biomarker analysis
62007120|NCT02919670|EXPERIMENTAL|Enterade and Standard Supportive Care|"* Two 8 oz. bottles of Enterade will be administered daily~* Enterade will be given orally from admission until day +14 or until discharge~* Standard Supportive Care will be administered according to institution's practice"
62007121|NCT02919670|PLACEBO_COMPARATOR|Placebo and Standard Supportive Care|"* Two 8 oz. bottles of Placebo will be administered daily~* Placebo will be given orally from admission until day +14 or until discharge~* Standard Supportive Care will be administered according to institution's practice"
62573105|NCT00833105|EXPERIMENTAL|AMES treatment|The subject will receive 25 treatment sessions, conducted 2-3 times per week on the AMES device. Each session will consist of testing followed by 30 minutes of wrist and finger rehabilitation using the AMES device.
62007122|NCT05920941|EXPERIMENTAL|[14C]JAB-21822|Single oral dose of 800mg 14C\]JAB-2182 suspension
62007123|NCT03069027|PLACEBO_COMPARATOR|Group I(control)|patients allocated for external nasal nerve block with saline adrenaline 1/200,000 (placebo)
62007124|NCT03069027|ACTIVE_COMPARATOR|Group II(block)|'External nasal nerve block by Xylocaine, adrenaline'
62007125|NCT05459493|EXPERIMENTAL|TJAOA101|Once enrolled, participants will be administrated TJAOA101 and followed by a 3-month medication cycle. The usage of this herbal compound is to take orally twice a day(two sacks per). Add it to about 200ml warm water and take it half an hour before breakfast in the morning and half an hour before bedtime in the evening except menstrual period.
62007126|NCT05230251|ACTIVE_COMPARATOR|High Dose Radiation (HDR) arm|Patients in the HDR arm will receive two fractions of HDR brachytherapy. HDR brachytherapy will be administered as per local practice and as previously described. All procedures will be conducted under general anesthesia in a dedicated brachytherapy suite using transrectal three dimensional ultrasound for image guidance. For all HDR fractions at least 10Gy will be delivered to the entire prostate with a boost to 13.5Gy to the involved prostate as determined by biopsy and PSMA PET/MRI results. In instances of multi-focal/diffuse involvement of the prostate, the entire prostate will receive 13.5Gy/fraction (respecting OAR constraints).
62007127|NCT05230251|EXPERIMENTAL|Lutetium Arm|Patients in Lutetium Arm will receive 1 cycle of 177Lu-PSMA radioligand therapy plus 1 fraction of HDR brachytherapy.
62007128|NCT00527813|EXPERIMENTAL|A|prone position for at least 16 hours per day
62007129|NCT00527813|NO_INTERVENTION|B|semi-recumbent position
62007130|NCT02526992|OTHER|patients with anti-TNF therapy|patients with rheumatoid polyarthritis inadequately controlled by a conventional treatment, occurring during the first 12 months of initiation of an anti-TNF therapy
62007131|NCT02483234|EXPERIMENTAL|Psoriasis/Psoriatic arthritis|Patients with Psoriasis and inflammatory and/or structural lesions and/or erosions in the MRI/HR-qCT scan will be treated with Secukinumab. Patients with psoriatic arthritis will be treated with Secukinumab. Bone changes will be evaluated influenced by IL-17 blockade
62007132|NCT05041088|EXPERIMENTAL|Experimental Group (ALL participants)|This group will be taking plamalogen supplement (ProdromeNeuro) and be followed through the study with neuropsychological testing, serology, and follow up MRI data. They will be administered 2mL per day for 6 months
62007133|NCT01857258|EXPERIMENTAL|Green Tea|Participants will be provided a confection containing green tea concentrate
62007134|NCT01857258|ACTIVE_COMPARATOR|Control|Participants will be provided a confection devoid of green tea concentrate
62007135|NCT03341624|EXPERIMENTAL|cataract surgery cataract extraction and intraocular implanta|
62573106|NCT01935232||Men|140 Men
62573107|NCT01935232||Female|500 Female
62573108|NCT06307132||test preparation|
62573109|NCT06307132||reference preparation|
62573110|NCT02946372|EXPERIMENTAL|ILMT|internal limiting membrane autologous transplantation (ILMT)
62573111|NCT02933554|EXPERIMENTAL|NASH- Left gastric artery embolization|Embospheres Microspheres as artificial embolic agent for left gastric artery embolization
62573112|NCT04545008|EXPERIMENTAL|Low Dose N-Acetyl Cysteine Alone|N-Acetyl Cysteine 600 mg three times daily
62573113|NCT04545008|EXPERIMENTAL|Medium Dose N-Acetyl Cysteine|N-Acetyl Cysteine 1,200 mg three times daily
62781438|NCT04381650|EXPERIMENTAL|Dose Expansion Phase: Cohort D: Cutaneous Melanoma|TAK-981 as IV infusion in participants with cutaneous melanoma on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
62781439|NCT04381650|EXPERIMENTAL|Dose Expansion Phase: Cohort E: Squamous NSCLC|TAK-981 as IV infusion in participants with squamous non-small cell lung cancer (NSCLC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
62781440|NCT04381650|EXPERIMENTAL|Dose Expansion Phase: Cohort F: CPI Refractory Squamous or Nonsquamous NSCLC|TAK-981 as IV infusion in participants with checkpoint inhibitors (CPI) refractory squamous or nonsquamous NSCLC on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
62192707|NCT00794170|EXPERIMENTAL|Telephone and print based intervention|The I-SIGHT intervention consists of twelve interactive voice recognition (IVR) phone calls over a nine-month period and accompanying printed materials that are mailed to participants following each call. The phone call messages and print materials are tailored to individuals' circumstances using data from the screening and baseline interviews. The intervention is based on theoretical constructs from Social Cognitive Theory and the Health Belief Model, and emphasizes self-efficacy, medication taking skills, outcome expectancies, facilitators and barriers to compliance, and social support. The treatment group receives the tailored telephone intervention and mailed, printed materials.
62398056|NCT04130165|EXPERIMENTAL|Matched donor human milk|Infants randomized to the matched donor human milk arm, will receive donor human milk which is matched to their mother's secretor status.
62781441|NCT01029847|PLACEBO_COMPARATOR|Placebo|
62781442|NCT01029847|ACTIVE_COMPARATOR|Adalimumab|TNF-alpha inhibitor
62781443|NCT01226576|EXPERIMENTAL|Treatment|ExAblate Treatment Arm
62781444|NCT03625999|EXPERIMENTAL|Training Group|Parents and children selected for the Training group will be lent a laptop for the duration of the at-home training, and assisted in opening the video game training exercise. Parents and children will be shown the game's operation and controls, including a home visit to the family's house to help them establish the game as part of routine. Parents will be asked to engage their children in the video game training exercise (on the laptop) for a minimum of 20 minutes, 3 times a week, for 4 weeks. The app will log all responses as well as time spent playing.
62781445|NCT03625999|NO_INTERVENTION|Wait-List Control|The families assigned to the wait-list control group will not receive access to the game until after 4 weeks and completion of the secondary round of testing at the lab. After the second lab visit and completion of the testing, families will be given access to the video game training exercise (on a loaned laptop), walked through the game's operation and controls, and encouraged to use it as often as they or their child like. If the child plays the game for a minimum of 20 minutes, 3 times per week, for 4 weeks, the family will be invited back to CARE for post-testing.
62781446|NCT06347263|EXPERIMENTAL|Test group|Procedure:Entire papilla preservation technique with autogenous bone and injectable platelet rich fibrin
62007136|NCT04458064|ACTIVE_COMPARATOR|i gel|I gel LMA was inserted for all patients
62007137|NCT04458064|ACTIVE_COMPARATOR|Air Q LMA|Air Q LMA was inserted for all patients
62007138|NCT04803929|EXPERIMENTAL|Anti-ILT3 CAR-T cells|All subjects were intravenous administrated with anti-ILT3 CAR-T cells
62007139|NCT02360618|EXPERIMENTAL|Metformin and Simvastatin Treatment|Patients in this group will receive 850 mg of Metformin and 20 mg of Simvastatin daily from the time they are enrolled in the study until the day before their surgery (approximately 12 weeks), in the absence of any safety or tolerability concerns.
62007140|NCT04140747||non-pregnant women|Samples will be collected from 30 healthy, non-pregnant women in the reproductive age: blood, urine, stool, saliva, oral swabs, vaginal swabs
62398057|NCT04130165|NO_INTERVENTION|Standard issue donor human milk|Infants randomized to the standard issue donor human milk arm, will receive donor human milk which is prepared without consideration of secretor status as per standard practice.
62192708|NCT00794170|NO_INTERVENTION|Usual care|The control group received usual care at each clinical site and interacted with study personnel only for data collection.
62007141|NCT04140747||pregnant women delivering vaginally|"From 30 healthy, pregnant women giving vaginal birth, samples will be collected shortly before, during and after birth from maternal and newborn sites:~maternal blood, urine, stool, saliva, oral swabs, vaginal swabs; cord blood, colostrum, meconium, infant oral swabs"
62007142|NCT04140747||pregnant women undergoing C-section|"From 30 healthy, pregnant women giving vaginal birth, samples will be collected shortly before, during and after birth from maternal and newborn sites:~maternal blood, urine, stool, saliva, oral swabs, vaginal swabs; amniotic fluid, cord blood, colostrum, meconium, infant oral swabs"
62007143|NCT03126981|EXPERIMENTAL|Whole, natural almonds|1.5 oz of whole, natural almonds
62007144|NCT03126981|PLACEBO_COMPARATOR|Low-fat, high refined starches/sugars|Low-fat foods,high in refined starches and added sugars
62007145|NCT04047290|EXPERIMENTAL|AK112|AK112 IV every 2 weeks (q2w) or every 3 weeks (q3w)
62007146|NCT03668652|EXPERIMENTAL|Focal prostate cancer treatment by HIFU|Patients with target lesion distance \< 30 mm from the rectum will be treated with High Intensity Focused Ultrasound (HIFU) applied by FocalOne HIFU device and patients with lesion \> 30 mm from the rectum will be treated with TULSA applied by TULSA-PRO.
62398058|NCT05731726|EXPERIMENTAL|Serplulimab+CAPEOX+celecoxib|articipants will receive serplulimab 300 mg every 3 weeks (Q3W) concurrently with CAPEOX regimen: Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine, 1000mg/m2, PO, BID, day1-14, q3w and celecoxib, 200mg, PO, BID, day1-21, q3w. Treatment repeats every 3 weeks for 6-8 cycles followed by surgery (total mesorectal excision, TME).
62192709|NCT02934204|EXPERIMENTAL|MTX and Temozolomide|"Induction therapy:~Methotrexate 3.5g/m2 ivgtt d1 2weeks/cycle，total 8 cycles Temozolomide 150mg/m2 po d1-5 4weeks/cycle, total 4 cycles~Consolidation therapy:~PCNSL patients achieve CR,Temozolomide 150mg/m2 po d1-5 4weeks/cycle, total 12 cycles"
62781447|NCT06347263|ACTIVE_COMPARATOR|Control group|Procedure: Entire papilla preservation technique alone.
62007147|NCT03668652|ACTIVE_COMPARATOR|Radical Prostatectomy|Robot assisted laparoscopic radical prostatectomy or open retro-pubic radical prostatectomy will be performed using validated radical prostatectomy technique. Nerve sparing surgery on side of cancer free prostate lobe will be performed and type of nerve sparing procedure will be specified.
62192710|NCT06001151|EXPERIMENTAL|Experimental Arm|Patients will receive cadonilimab (10mg/kg) plus pemetrexed(500mg/m2) and carboplatin (AUC=5) every 3 weeks for 4 cycles, follwed with cadonilimab (10mg/kg) plus pemetrexed (500mg/m2) every 3 weeks as maintenance therapy.
62192711|NCT04700059|EXPERIMENTAL|Intervention|10 perinatal home visits
62192712|NCT04700059|NO_INTERVENTION|Usual care|Routine medical care for mother and infant. Access to online resources.
62192713|NCT06283342||Iron deficiency group|Patients with a ferritin level below 12 mg/L were considered to have Iron deficiency group.
62007148|NCT04239534|OTHER|Single Arm|In this Single Arm Study, Epicardial linear lesions will be created endoscopically using the EPi-Sense-AF Guided Coagulation System with VisiTrax throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access. Followed by the sue of an endocardial ablation catheter that will be used to ablate endocardially to connect lesions at the reflections, complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter.
62007149|NCT02215070|EXPERIMENTAL|Pasireotide + Preparatory Regimen|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
62007150|NCT04996303|OTHER|Routine|Routine steroid administration group
62007151|NCT04996303|OTHER|Pulse|Steroid pulse therapy group
62007152|NCT02433834|EXPERIMENTAL|GP MDI 28.8 μg|GP MDI (PT001) 28.8 μg
62007153|NCT02433834|EXPERIMENTAL|GP MDI 14.4 μg|GP MDI (PT001) 14.4 μg
62007154|NCT02433834|EXPERIMENTAL|GP MDI 7.2 μg|GP MDI (PT001) 7.2 μg
62007155|NCT02433834|EXPERIMENTAL|GP MDI 3.6 μg per|GP MDI (PT001) 3.6 μg
62007156|NCT02433834|EXPERIMENTAL|GP MDI 1.9 μg|GP MDI (PT001) 1.9 μg
62192714|NCT06283342||Not iron deficiency group|Patients with a ferritin level above 12 mg/L were considered to have not iron deficiency group.
62192715|NCT06283342||Iron deficiency anemia group|Patients with ferritin level below 12 mg/L and hemoglobin (Hb) value below 11 g/dL were considered to have IDA.
62192716|NCT06283342||Not iron deficiency anemia group|Patients with ferritin level below 12 mg/L and hemoglobin (Hb) value above 11 g/dL were considered to have Not iron deficiency anemia group.
62781448|NCT03659136|EXPERIMENTAL|Xentuzumab/everolimus/exemestane|
62007157|NCT02433834|PLACEBO_COMPARATOR|Placebo|Placebo
62007158|NCT02433834|ACTIVE_COMPARATOR|Serevent® Diskus® 50 μg per inhalation|Serevent® Diskus® 50 μg per inhalation
62007159|NCT02948842|EXPERIMENTAL|Treatment Group|Patients will undergo instillation of local anesthesia (20 mL of 2% urethral lidocaine jelly), the patient will undergo cystoscopy, transurethral injection (via a 70 cm 4.8 Fr flexible cystoscopic needle with a 23 gauge needle tip manufactured by Laborie®, Ontario, Canada) of 0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture.
62192717|NCT00798434|ACTIVE_COMPARATOR|Placebo|Flexible dose regimen of placebo once daily. The dose can be increased after 4 weeks if clinically indicated. Subsequently the dose can be reduced to the original dose if clinically indicated.
62192718|NCT00798434|ACTIVE_COMPARATOR|Fesoterodine|Flexible dose regimen of fesoterodine fumarate 4mg once daily. The dose can be increased to 8mg once daily after 4 weeks if clinically indicated. Subsequently the dose can be reduced to 4mg if clinically indicated.
62192719|NCT03102489|EXPERIMENTAL|BP101|Treatment with BP101
62192720|NCT03102489|PLACEBO_COMPARATOR|Placebo|Treatment with placebo
62192721|NCT00466609|EXPERIMENTAL|Quetiapine (fluoxetine plus quetiapine)|fluoxetine up to 40mg once a day plus Quetiapine up to 200mg once a day, during 12 weeks
62781449|NCT03659136|PLACEBO_COMPARATOR|Placebo/everolimus/exemestane|
62781450|NCT01278797|ACTIVE_COMPARATOR|Telmisartan/Amlodipine Fixed Dose|Telmisartan/Amlodipine medium fixed dose combination tablet once daily.
62007160|NCT02679586|EXPERIMENTAL|Diffusion weighted MRI Group|"All patients will receive a double baseline diffusion weighted MRI (performed on the same day as the Baseline MRI).~Patients participating in Part I will receive another MRI approximately 1 week (day 8-11) after the first dose of Chemotherapy (chemotherapy will be determined by the treating physician and is not assigned as part of this trial).~Patients participating in Part II will receive a single MRI 1-2 weeks after the first dose of Chemotherapy A (chemotherapy will be determined by the treating physician and is not assigned as part of this trial). A second MRI will be repeated within 2 weeks prior to the start of Chemotherapy B."
62192722|NCT00466609|ACTIVE_COMPARATOR|Clomipramine (fluoxetine plus clomipramine)|Fluoxetine up to 40mg once a day plus clomipramine up to 75mg once a day, during 12 weeks
62192723|NCT00466609|PLACEBO_COMPARATOR|Placebo (fluoxetine plus placebo)|Fluoxetine up to 80 mg once a day plus placebo 3 pills once a day, during 12 weeks
62398059|NCT01934842|EXPERIMENTAL|TAP20-C|TAP20-C
62398060|NCT01934842|ACTIVE_COMPARATOR|SAFE-T-FILL|SAFE-T-FILL
62398061|NCT06723067|OTHER|Wearable wireless pump provided in week one|Provision of a wearable, wireless pump in week one with support from a lactation specialist, standard of care in week two.
62781451|NCT01278797|ACTIVE_COMPARATOR|Amlodipine Monocomponent|Amlodipine Monocomponent 10mg tablet once daily
62781452|NCT05040074|EXPERIMENTAL|SQ-Kyrin TMVr Feasibility Study|Experimental group is allocated to use the transcatheter edge-to-edge valve repair system of Shanghai Shenqi Medical Technology Co., Ltd.
62781453|NCT00622388|EXPERIMENTAL|Ofatumumab|8 weekly intra-venous (I.V.) infusions, 1 x 300mg and 7 x 1000mg
62007161|NCT03899610|EXPERIMENTAL|Neoadjuvant chemotherapy+Durvalumab+Tremelimumab|"1. Neoadjuvant treatment:~   Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)~2. Interval debulking surgery~3. Adjuvant treatment:~Standard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)"
62781454|NCT03304873|EXPERIMENTAL|Retapamulin|Thin layer of ointment applied twice a day for five days. Study drug will be applied to the nares and peri-rectal area twice a day for 5 consecutive days.
62781455|NCT03304873|PLACEBO_COMPARATOR|Placebo|The placebo used will be a triple purified pharmaceutical grade white petrolatum
62007162|NCT04971031|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.|
62192724|NCT05344677|EXPERIMENTAL|trendlenburg position group|in which the women will be positioned in a Trendelenburg position (20 °) once fully awake and cooperative in the recovery room and will remain in this posture for the first 24 hrs postoperatively. The maximum time allowed in a straight-up position will be three 15-min intervals over a 24-h period
62192725|NCT05344677|EXPERIMENTAL|warm pad application group|in this group warm pad (38◦C -40◦C) will be applied on the shoulder after four hours postoperatively for a period of 5-10 minutes. Each woman will be asked to place heat pads when needed during the first 24 hours.
62192726|NCT05344677|EXPERIMENTAL|deep breathing group|the researcher will instruct women after the end of surgery and upon consciousness to take slowly deep breathing while observing her chest and hold her breath for about 5 seconds and then exhale slowly, repeating this deep breathing technique five times after full vigilance within the first 3 hours after surgery. Then, the process will be repeated 6, 12, and 24 h later. The patient will be instructed about this type of breathing before surgery by researchers
62192727|NCT06029777||Retrospective cohort|"The retrospective cohort will include 2190 patients who underwent a clinically indicated cCTA between 2017 and 2019 at the Radiology Unit of San Raffaele Hospital.~No other interventions will be performed. Patients will be solely contacted via a telephone call to assess their clinical status."
62192728|NCT02932553|EXPERIMENTAL|BVS and OMT|Optimal medical treatment + BVS implantation
62192729|NCT01019239|EXPERIMENTAL|Laparoscopic Washout|Two 5mm ports will be placed in the suprapubic and right lower quadrants to facilitate triangulation of instruments during manipulation and lavage. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. Peritoneal lavage will be performed in all four quadrants using at least 4 litres of warmed saline until the drainage is clear. Two non-suction Penrose drains will be placed. Intravenous antibiotics will be continued for a minimum of 72hours and oral antibiotics will be continued for one week. Oral fluids will be commenced on the first postoperative day and diet will be introduced subsequently, depending on clinical status. Early mobilisation will be encouraged.
62192730|NCT01019239|ACTIVE_COMPARATOR|Conventional Treatment|Operative procedure will be similar to that previously described.Patients randomised to the second arm will undergo standard management (according to local preference) which will consist of Hartmanns Procedure or Primary resection of the diseased segment and anastomosis. Post operative care will be standardised between arms as described in the protocol
62398062|NCT06723067|OTHER|Wearable wireless pump provided in week two|Standard of care in week one, provision of a wearable, wireless pump in week two with support from a lactation specialist.
62781456|NCT06536192|EXPERIMENTAL|Intervention (Model) group|"1. Process: Theoretical knowledge will be given to students, and then different types of gynecological examinations will be explained practically on a model in the laboratory environment.~2. Process: The learner guide will be filled out.~3. Process: After 15 days, students will be taken back to the laboratory environment to fill out the learner guide again. In addition, Self-Confidence Scale (SCS) and Student Satisfaction and Self-Confidence in Learning Scale (SSSLS) will be filled out for the last exam."
62781457|NCT06536192|NO_INTERVENTION|Control group|"1. Procedure: The stages of gynecological examination evaluation for students, its purpose, the process of preparing the patient and evaluating them will be provided with theoretical knowledge.~2. Procedure: Pre-tests will be administered.~3. Procedure: Two weeks later, Self-Confidence Scale (SCS); Learner's Guide (LG) and (Student Satisfaction and Self-Confidence in Learning Scale) SSSCLS will be filled out for the final test."
62781458|NCT00168454|PLACEBO_COMPARATOR|Placebo|Placebo (normal saline) injected into detrusor on Day 1
62781459|NCT00168454|EXPERIMENTAL|BOTOX 50 U|botulinum toxin Type A 50 U injected into detrusor on Day 1
62781460|NCT00168454|EXPERIMENTAL|BOTOX 100 U|botulinum toxin Type A 100 U injected into detrusor on Day 1
62007163|NCT04971031|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution administered 7 times over two consecutive days.|
62007164|NCT04103294|EXPERIMENTAL|cowpea variety #1|25g of cowpea daily for days 6-10, 50g of cowpea daily for days 11-15 and then 75g of cowpea daily for days 16-20. The pregnant women will receive 50g of cowpea daily for days 6-10, 100g of cowpea daily for days 11-15 and then 150g of cowpea daily for days 16-20
62007165|NCT04103294|EXPERIMENTAL|cowpea variety #2|25g of cowpea daily for days 6-10, 50g of cowpea daily for days 11-15 and then 75g of cowpea daily for days 16-20. The pregnant women will receive 50g of cowpea daily for days 6-10, 100g of cowpea daily for days 11-15 and then 150g of cowpea daily for days 16-20
62007166|NCT05404516|EXPERIMENTAL|Sorafenib|"Induction cycle(s):~IA3+7. Patients will receive sorafenib 400 mg BID on days 8-21.~Consolidation Cycle 1:~IA3+3. Patients will receive sorafenib 400 mg BID on days 1-21.~Consolidation Cycles 2-4:~MDAC. Patients will receive sorafenib 400 mg BID on days 1-21.~Maintenance therapy:~Single agent sorafenib 400 mg BID for one year."
62007167|NCT05404516|ACTIVE_COMPARATOR|Standard therapy|"Induction cycle(s):~IA3+7.~Consolidation Cycle 1:~IA3+3.~Consolidation Cycles 2-4:~MDAC."
62007168|NCT04555135|EXPERIMENTAL|Colonoscopy Procedure with EndoVigilant Software|Colonoscopy Procedure is performed with EndoVigilant Software assisting the gastroenterologist during colonoscopy procedure.
62192731|NCT04554641|EXPERIMENTAL|BioKult Advanced|This is a single arm study, all participants will take Bio-kult Advanced for 56 days (+/- 2days). Participants will be required to take 4 capsules daily.
62192732|NCT05339347|ACTIVE_COMPARATOR|Active Comparator: Active Photoneuromodulation|Active stimulation with light fields as described in the intervention
62192733|NCT05339347|SHAM_COMPARATOR|Sham Comparator: Sham Photoneuromodulation|The blinding will be done with sham light, which consists of fields that do not reproduce light, but which have the same size and thickness as the true one.
62192734|NCT01004523||Single group|Previously preserved paraffin-embedded tissue blocks are obtained and used for biomarker studies. Blood samples obtained during treatment are also obtained. Loss of heterozygosity of specific chromosomal regions are performed using PCR analysis of microsatellite repeats (41,118-120) on DNA extracted from the paraffin-embedded archival specimens. FISH and flow cytometry may also be used to assess chromosomal loss of deletion. Immunohistochemistry is also performed.
62192735|NCT01295203|NO_INTERVENTION|Control group|The control group were not given access to the intervention website and received no additional information.
62192736|NCT02807974|EXPERIMENTAL|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally, once daily after breakfast for 12 weeks
62192737|NCT04992754||Pregnant women over 18 years old coming to consult at the gynecology department|Pregnant women over 18 years old coming to consult at the gynecology department in the Montpellier's hospital
62192738|NCT03815864||D2SA+|Median fluoresce intensity \> or = 1000 on Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
62192739|NCT03815864||D2SA-|Median fluoresce intensity \< 1000 on Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
62192740|NCT04814498|EXPERIMENTAL|Geneva cocktail (less fexofenadine) & BLD-0409|Following an overnight fast of at least 10 hours, subjects will be administered IP in a fixed sequence.
62192741|NCT04367480|EXPERIMENTAL|Group I (Active TENS)|Patients wear an active wireless TENS device 5 hours daily for up to 6 weeks in the absence of unacceptable toxicity.
62192742|NCT04367480|PLACEBO_COMPARATOR|Group II (Placebo TENS)|Patients wear a placebo wireless TENS device 5 hours daily for up to 6 weeks in the absence of unacceptable toxicity.
62192743|NCT04702516|EXPERIMENTAL|Semaglutide|Ozempic 1 mg (or highest tolerated dose) s.c. once weekly for 52 weeks (incl. titration)
62192744|NCT04702516|PLACEBO_COMPARATOR|Placebo|Placebo (saline) 1 mg (or highest tolerated dose) s.c. once weekly for 52 weeks (incl. titration)
62781461|NCT00168454|EXPERIMENTAL|BOTOX 150 U|botulinum toxin Type A 150 U injected into detrusor on Day 1
62007169|NCT04555135|NO_INTERVENTION|Colonoscopy Procedure without EndoVigilant Software|Colonoscopy Procedure is performed without EndoVigilant Software assisting the gastroenterologist during colonoscopy procedure.
62192745|NCT04324216|EXPERIMENTAL|Experimental group|3D virtual reality and hands-on aromatherapy
62192746|NCT04324216|NO_INTERVENTION|Control group|No intervention
62192747|NCT05261477|EXPERIMENTAL|Intervention group|Intervention group receives one in person education session using the 1stBIEN booklet, video education via mobile phones and care coordination from a bilingual Patient Navigator-PN for 3-months. PN follow up patients weekly for the first month and once a month for two months. Video education is done weekly. Videos cover problem solving training, brain injury concepts, rehabilitation treatments and school resources individualized to patient and family needs. PNs facilitate transition to outpatient care, follow-up with specialists and primary care providers; use of community resources; and communication with teachers and school administrators. PN provides observational and experiential learning opportunities for parents, using three way calls for scheduling of services and interactions with clinics and schools. PN calls use a problem-solving training format, to reinforce parental experiential learning and improve self-efficacy. Expert MD providers (Co-investigators) will supervise PNs.
62214819|NCT05680623||study population|"Subgroups based on the ISGPS diagnostic criteria and the grading system of PPAP:~1. Without PPAP or POH: Patients without POH nor imaging consistent with AP.~2. POH: sustained postoperative serum hyperamylasemia neither clinically relevant nor consistent imaging~3. PPAP: requiring the fulfilment of three criteria:~   * POH: sustained serum hyperamylasemia greater than the institutional upper limit of normal persisting on postoperative days 1 and 2;~  * macroscopic radiologic features of AP~  * clinically relevant complications. PPAP severity will be classified into grades B and C, with progressive clinical deterioration."
62781462|NCT00168454|EXPERIMENTAL|BOTOX 200 U|botulinum toxin Type A 200 U injected into detrusor on Day 1
62781463|NCT00168454|EXPERIMENTAL|BOTOX 300 U|botulinum toxin Type A 300 U injected into detrusor on Day 1
62007170|NCT04420702|EXPERIMENTAL|Early Detection Cohort (MRI with DBSI)|"* Magnetic resonance imaging (MRI) with DBSI analysis prior to prostate biopsy~* Standard of care prostate biopsy will be performed within 12 weeks of MRI~* Some participants may go on to receive standard of care radical prostatectomy and those participants may have their prostatectomy specimens scanned via MRI with DBSI imaging"
62007171|NCT04420702|EXPERIMENTAL|Active Surveillance Cohort (MRI with DBSI)|"* Magnetic resonance imaging (MRI) with DBSI analysis prior to prostate biopsy~* Standard of care prostate biopsy will be performed within 12 weeks of MRI~* Some participants may go on to receive standard of care radical prostatectomy and those participants may have their prostatectomy specimens scanned via MRI with DBSI imaging"
62781464|NCT04600583|ACTIVE_COMPARATOR|Alignment according to Functional Alignment philosophy|Patients randomized to this group will undergo a TKA (total knee arthroplasty) to receive a Triathlon Total Knee System aligned according to Functional Alignment philosophy. This method of implant alignment is defined by a patient's native joint line as well as the soft tissue envelope. Triathlon Total Knee System components will be positioned relative to intra-operative soft tissue laxity assessment. A mobile application (KneeBalancer) will be used to assist surgeon decision making during the dynamic joint balancing surgical step.
62192748|NCT05261477|NO_INTERVENTION|Attention Control group|Attention Control group receives one in person education session using the 1stBIEN booklet, monthly well-child texts and usual post-injury care including routine follow-up by specialists and primary care providers, per guidelines at each recruiting institution. Control patients have access to a list of community resources included in the 1stBIEN booklet. While education using the 1stBIEN booklet is not part of the current usual care at participating institutions, providing all families with initial education at the time of discharge addresses ethical and practical considerations. It standardizes discharge processes at participating institutions while delineating differences in the intensity of education and care coordination activities.
62398063|NCT05405621|EXPERIMENTAL|Cohort 1|Experimental: BAT8009 for Injection 0.6 mg/kg (frequency: Q3W)
62398064|NCT05405621|EXPERIMENTAL|Cohort 2|Drug: BAT8009 for Injection 1.2 mg/kg (frequency: Q3W)
62007172|NCT00594256|EXPERIMENTAL|Sodium oxybate|Active treatment
62007173|NCT02089750|ACTIVE_COMPARATOR|Orthotics|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period.
62007174|NCT02089750|ACTIVE_COMPARATOR|Orthotics Plus Chiropractic Care|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period in addition to receiving Chiropractic Care 1-4 times per week during the first 6 weeks of the 12 week study period.
62007175|NCT02089750|OTHER|Wait List|The group serves as a cross-over control group. Subjects are asked to avoid any new therapies for the first 6 weeks of the 12 week study and during the last six weeks they are fitted for the custom-made shoe orthotics.
62007176|NCT02857127|EXPERIMENTAL|Intervention Group|A group of people who participated in the walking program during a six month period. This group also received an educational material and attended meetings for behavioral change strategies.
62007177|NCT02857127|NO_INTERVENTION|Control Group|A group of people who did not receive the educational material and did not participated in any of the activities offered by the research team, such as walking classes and meetings for behavioral change.
62007178|NCT01507493||mutant alleles|grouped by SCN9A mutant alleles including 3312T, 1719R, 1150W.
62007179|NCT01507493||wild-type alleles|grouped by SCN9A wild-type alleles including 3312G, 1719C, 1150R.
62007180|NCT03444142|ACTIVE_COMPARATOR|Drug: Exenatide LAR|Exenatide LAR 2 mg, once weekly subcutaneously before breakfast during 4 weeks.
62007181|NCT03444142|ACTIVE_COMPARATOR|Drug: Dulaglutide|Dulaglutide .75 mg, once weekly subcutaneously Before breakfast during 4 weeks.
62007182|NCT06310434||University adolescents|"Adolescents attending a public university that belongs to the same health area with similar population characteristics in each province. The inclusion criteria will be students enrolled in different undergraduate studies in a public University (18-23 years old), who don´t need curricular adaptation. We will exclude health science studies because we suppose that they are students who may have worked more on compassionate awareness."
62007183|NCT06310434||High school adolescents|"The inclusion criteria will be students enrolled in public secondary schools (12-17 years old), that belong to the same health area. We also include families and teachers because we understand that their knowledge of the context can support the interventions of change proposals and are consistent with the participatory nature of the project. The inclusion criteria for families are parents, mothers, or legal tutors of minors with communication skills to participate in a group. Finally, all the teachers in every center will be invited to participate in the study."
62007184|NCT05512221|EXPERIMENTAL|Phase I|GBAT+I and GBAT+E groups
62007185|NCT05512221|EXPERIMENTAL|Phase 2a|Watchful Waiting, GBAT+I, and GBAT+E groups
62007186|NCT05512221|EXPERIMENTAL|Phase 2b|GBAT+IE groups
62007187|NCT00501540|EXPERIMENTAL|Lithium|Lithium carbonate will be dosed on a flat scale of mg/day and not by weight or body surface area (BSA). Lithium carbonate will be provided as a 300mg tablet and will be taken daily without breaks in treatment.
62007188|NCT05440682|EXPERIMENTAL|CP group|Pre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI
62007189|NCT02986204|OTHER|removal of ENG implant group|20 women who have an ENG implant that is difficult to feel on exam and would like to have it removed.
62007190|NCT02986204|OTHER|continuation of ENG implant|20 women who have are continuing to use their ENG implant.
62007191|NCT00827372|EXPERIMENTAL|Pazopanib Treatment|Pazopanib 800 mg orally once each day (maximum total duration of treatment = 24 weeks)
62007192|NCT05040763|EXPERIMENTAL|COVID-19 Swab Collection|All participants will receive standard of care COVID-19 testing in addition to buccal swab COVID-19 testing
62007193|NCT02167581||epithelial odontogenic tumours|
62007194|NCT00349596|EXPERIMENTAL|Decitabine|Decitabine administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
62398065|NCT05405621|EXPERIMENTAL|Cohort 3|Drug: BAT8009 for Injection 2.4 mg/kg (frequency: Q3W)
62007195|NCT00802217|ACTIVE_COMPARATOR|Cohort 1|Civamide liquid filled softgel capsule 5 mg
62007196|NCT00802217|ACTIVE_COMPARATOR|Cohort 2|Civamide liquid filled soft gel capsules 2 x 5 mg
62398066|NCT05405621|EXPERIMENTAL|Cohort 4|Drug: BAT8009 for Injection 3.6mg/kg (frequency: Q3W)
62007197|NCT03643822|ACTIVE_COMPARATOR|Dexamethasone vs. Control comparison|Freezing + dexamethasone(4mg)+1 ml of saline
62007198|NCT03643822|ACTIVE_COMPARATOR|Dexmedetomidine vs. Control comparison|Freezing + dexmedetomidine(50ug) + 1.5 ml of saline
62007199|NCT03643822|ACTIVE_COMPARATOR|Dexamethasone and Dexmedetomidine|Freezing+dexamethasone(4mg)+dexmedetomidine(50ug) + 0.5 ml of saline
62007200|NCT03643822|SHAM_COMPARATOR|Control Group-Placebo|Freezing + 2ml saline
62007201|NCT02200705|OTHER|single arm, open label|Early stage Breast cancers up to 1.5cm
62007202|NCT02610868|EXPERIMENTAL|MYOBLOC Injection|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections over the course of 1 year.
62007203|NCT04232163|EXPERIMENTAL|Immediate Treatment Group|Participants will receive the intervention right away
62007204|NCT04232163|NO_INTERVENTION|Delayed Treatment Group|Participants will receive usual care (no intervention), however, they will receive the intervention after a 3 week delay
62007205|NCT01236404|EXPERIMENTAL|PB1023 Injection|Subcutaneous injection PB1023
62214820|NCT05772273|EXPERIMENTAL|Camrelizumab, Azacitidine and low-dose Donor lymphocyte infusion|Patients are given azacytidine for 7 days, followed by 4 DLI treatments on Days 10, 17, 24 and 31, with the dose of DLI and Camrelizumab adjusted according to the donor source. Camrelizumab infusions were given 3 hours after completion of the 1st and 3rd DLIs, respectively.
62398067|NCT05405621|EXPERIMENTAL|Cohort 5|Drug: BAT8009 for Injection 4.8mg/kg (frequency: Q3W)
62007206|NCT01236404|PLACEBO_COMPARATOR|Placebo (0.9% Sodium Chloride Injection)|Subcutaneous Injection Placebo
62781465|NCT04600583|ACTIVE_COMPARATOR|Alignment to the patient's natural Mechanical axis|Patients randomized to this group will undergo a TKA (total knee arthroplasty) to receive a Triathlon Total Knee System neutrally aligned to the Mechanical axis. More specifically, the femoral component and tibial component are aligned 0° to the mechanical axis of each respective limb. Femoral component rotation is fixed to the trans-epicondylar axis. Soft tissue releases are performed at the discretion of the surgeon to achieve balance and full range of motion.
62007207|NCT06257784||Acute Respiratory Failure|Every patient admitted in Emergency department with any acute respiratory failure will be screened according to inclusion and exclusion criteria to being recruited in the study
62007208|NCT04631497||Healthcare workers|The study will cover employees of the Intensive Care Unit - nurses and doctors working with patients with COVID-19 infection. Test takers will be over the age of 18 and under the age of 70, female and male.
62007209|NCT05268250|EXPERIMENTAL|R2D2 mHealth treatment for diabetes distress|This is a mHealth supported, cognitive behavioral treatment for parents and school-age children who were identified with clinically relevant levels of diabetes distress as part of a clinic screening program
62007210|NCT05268250|NO_INTERVENTION|Standard Care Control|Parents and school-age children who were identified with clinically relevant levels of diabetes distress as part of a clinic screening program will receive local resources (print or electronic).
62007211|NCT01433263|EXPERIMENTAL|30mg/kg BYM338|
62007212|NCT01433263|PLACEBO_COMPARATOR|Placebo / late 30mg/kg BYM338|
62781466|NCT01816867||Patients with a ventral hernia|
62007213|NCT03560713|EXPERIMENTAL|FES + combined exercise|The Functional Electrical Stimulation (FES) + combined exercise group will receive 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant) and receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
62007214|NCT03560713|SHAM_COMPARATOR|FES sham|The Functional Electrical Stimulation (FES) sham + combined exercise group will receive 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes and receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
62007215|NCT01888289|EXPERIMENTAL|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
62007216|NCT01888289|ACTIVE_COMPARATOR|ACCUTANE|ACCUTANE 40 mg of Roche Laboratories Inc
62007217|NCT01295606|NO_INTERVENTION|Cefazolin, antibiotic prophylaxis|All included patients will received iv cefazolin
62007218|NCT04794543||e-cigarettes and/or e-liquid vaping smokers|actively use e-cigarettes or vape
62007219|NCT04794543||cigarette smokers|actively smoke combustible tobacco and/or marijuana (cannabis)
62007220|NCT04794543||Non-smokers|no use of e-cigarettes or vape or active smoking in the past 5 years (and less than a total of 10 pack-years lifetime use)
62007221|NCT04947397|NO_INTERVENTION|Group 1|Traditional deep extubation at 1.5 minimum alveolar concentration (MAC)
62007222|NCT04947397|EXPERIMENTAL|Group 2|Deep extubation guided by pupillometry -- at \< 0.5 MAC of vapor + propofol and fentanyl
62214821|NCT05191472|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62007223|NCT02778581|ACTIVE_COMPARATOR|Lipidic Blend 1|Glass bottle with 45 ml of vegetal mixture oil. 1 bottle per day
62007224|NCT02778581|ACTIVE_COMPARATOR|Lipidic Blend 2|Glass bottle with 45 ml of vegetal mixture oil. 1 bottle per day
62007225|NCT02778581|PLACEBO_COMPARATOR|Placebo|Glass bottle with 45 ml of Olive oil. 1 bottle per day
62398068|NCT05405621|EXPERIMENTAL|Cohort6|Drug: BAT8009 for Injection 6.0mg/kg (frequency: Q3W)
62007226|NCT04877262|EXPERIMENTAL|early time-restricted eating (eTRE)|Participants will be provided a weight-maintenance diet for 9 consecutive days and will consume all meals and snacks in a 6-h window in the morning hours (e.g., 8:00 AM - 2:00 PM)
62192749|NCT02661633||Injured and Matched Control Subject Pool|Injured subjects consist of athletes who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, balance/sway measurement, and clinical symptoms/assessments. In addition, a subset of injured and matched control subjects will receive advanced MRI/DTI neuroimaging at time of injury and following RTP.
62192750|NCT02661633||Pre-Season and Post-Season Subject Pool|This subject pool will consist of uninjured (not head injured) contact and non-contact athletes and will be tested at two time points - pre-season and post-season. These subjects will perform the same BrainScope Battery as the injured and matched control subjects at each time points.
62192751|NCT02094898|EXPERIMENTAL|Ketamine infusion|This trial was conducted in 2 phases. During the acute-phase, i.v. ketamine was administered thrice-weekly for up to 2 weeks.Those who achieved depressive symptom remission received continuation-phase treatment that consisted of once-weekly i.v. ketamine infusions for 4 additional weeks. Remission could occur after any of the 6 acute-phase infusions, at which point the next infusion was the first (of four) continuation-phase infusions. Individuals who remitted during acute-phase and completed continuation-phase treatment had 4 additional weekly post-continuation follow-up visits.
62192752|NCT02844777|PLACEBO_COMPARATOR|Placebo|Excipeint alone
62192753|NCT02844777|EXPERIMENTAL|5% VDA-1102|Active study medication
62192754|NCT02844777|EXPERIMENTAL|10% VDA-1102|Active study medication
62192755|NCT00351377|EXPERIMENTAL|Enteric-coated Mycophenolate Sodium|Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily in a dose that was equimolar to the dose of Mycophenolate mofetil the participant was taking at the time of study entry. The planned duration of treatment 6 to 8 weeks.
62192756|NCT05698732||Coronary Artery Disease (CAD) and high risk of bleeding|
62192757|NCT05698732||Coronary Artery Disease (CAD)|
62192758|NCT02162498|EXPERIMENTAL|Feeding buddies intervention|Sites receiving a comprehensive feeding buddy program implemented by the Window of Opportunity program.
62192759|NCT02162498|NO_INTERVENTION|Standard of care|Sites from Window of Opportunity program who are not yet receiving the comprehensive feeding buddies program and are only receiving standard of care PMTCT support.
62192760|NCT00925392|EXPERIMENTAL|Doripenem 500 mg|
62192761|NCT00925392|EXPERIMENTAL|Doripenem 1000 mg|
62192762|NCT02286453|EXPERIMENTAL|1|Benjakul
62192763|NCT02286453|ACTIVE_COMPARATOR|2|diclofenac
62781467|NCT02980133|PLACEBO_COMPARATOR|Placebo MDPI|Participants received matching placebo via multidose dry powder inhaler (MDPI) for 12 weeks.
62007227|NCT04877262|EXPERIMENTAL|control eating schedule (CON)|Participants will be provided a weight-maintenance diet for 9 consecutive days and will consume all meals and snacks in a 12-h window in the morning hours (e.g., 8:00 AM - 8:00 PM)
62007228|NCT00626262|EXPERIMENTAL|1|20mg oral
62007229|NCT00626262|EXPERIMENTAL|2|20mg IV
62007230|NCT00989729|ACTIVE_COMPARATOR|Methylprednisolone|75 patients will receive a single preoperative dosage of Methylprednisolone
62192764|NCT06305442|EXPERIMENTAL|Microbiota Directed Food (MDF)|Each participant will receive 12 weeks of MDF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-week period.
62192765|NCT06305442|ACTIVE_COMPARATOR|Ready-to-Use Supplementary Food (RUSF)|Each participant will receive 12 weeks of RUSF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-week period.
62192766|NCT05828758|EXPERIMENTAL|Study group|Children receiving amoxicillin
62192767|NCT05828758|PLACEBO_COMPARATOR|Comparison group|Children receiving placebo
62192768|NCT01080300|EXPERIMENTAL|Gabapentin Extended Release|Active treatment
62192769|NCT01080300|OTHER|Placebo|Placebo
62192770|NCT00869947|EXPERIMENTAL|Prosthesis|Powered ankle-foot prosthesis and passive-elastic prosthesis
62192771|NCT00869947|EXPERIMENTAL|Non-amputee|Non-amputee
62192772|NCT01558817|ACTIVE_COMPARATOR|Informational brochure|Patients receive an informational brochure
62192773|NCT01558817|EXPERIMENTAL|Intervention|Patients receive physician-directed informed assent intervention regarding CPR and informational brochure.
62192774|NCT04325633|EXPERIMENTAL|1: Naproxen|Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
62192775|NCT04325633|PLACEBO_COMPARATOR|2: Standard of care|Standard of care
62214822|NCT06065683||T2 hour|
62214823|NCT06065683||T12 hour|
62214824|NCT06065683||T24 hour|
62214825|NCT06065683||T48 hour|
62214826|NCT06065683||T72 hour|
62214827|NCT05599659|EXPERIMENTAL|Palliative care|Participants will receive palliative care.
62214828|NCT00614965|EXPERIMENTAL|1|IC
62214829|NCT00614965|EXPERIMENTAL|2|PC
62398069|NCT05405621|EXPERIMENTAL|Cohort 7|Drug: BAT8009 for Injection 7.2mg/kg (frequency: Q3W)
62192776|NCT02098447|EXPERIMENTAL|auricular vagal nerve stimulation|"Study participants (healthy and diabetics) are treated with auricular vagal nerve stimulation using four needle electrodes connected to an electrical stimulation device (PrimeStim). After an acclimatization phase the stimulation is turned on for 20 minutes followed by 20 minutes of paused stimulation, 20 minutes of stimulation, and another 10 minutes paused stimulation. This intervention is repeated on four consecutive days. Needle electrodes stay fixed over the whole study period.~Two different stimulation schemes are tested, each being assessed twice in random order. Stimulation amplitudes are adjusted with respect to a distinct but comfortable sensation at the auricle.~During the described protocol various biosignals are continuously recorded, including ECG, respiration, blood perfusion, oxygen saturation, transcutaneous oxygen tension, blood pressure and skin temperature."
62007231|NCT00989729|PLACEBO_COMPARATOR|Physiological Saline|75 patients will receive a single preoperative dosage of Physiological Saline
62398070|NCT05405621|EXPERIMENTAL|Cohort 8|Drug: BAT8009 for Injection 8.4mg/kg (frequency: Q3W)
62781468|NCT02980133|EXPERIMENTAL|Fp MDPI 25 mcg BID|Participants received 1 inhalation of 25 mcg fluticasone propionate (Fp) via MDPI twice daily (BID) (total daily dose: 50 mcg) for 12 weeks.
62781469|NCT02980133|EXPERIMENTAL|Fp MDPI 50 mcg BID|Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks.
62007232|NCT05862857|ACTIVE_COMPARATOR|Aim 1: HIV-focused mobilization|Patrons and workers at drinking venues will be given a recruitment card for free HIV testing at the local clinic.
62007233|NCT05862857|EXPERIMENTAL|Aim 1: Multi-disease-focused mobilization|Patrons and workers at drinking venues will be given a recruitment card for free multi-disease testing at the local clinic, including: diabetes, hypertension, HIV, malaria, TB, pregnancy.
62007234|NCT02845661|EXPERIMENTAL|group 1|patients in group 1, aged 20\~60, were accepted an initial dose of 0.9μg/kg dexmedetomidine over 15 min.
62007235|NCT02845661|EXPERIMENTAL|group 2|patients in group 2, aged 20\~60, were accepted an initial dose of 1.0μg/kg dexmedetomidine over 15 min.
62007236|NCT02845661|EXPERIMENTAL|group 3|patients in group 3, aged 20\~60, were accepted an initial dose of 1.1μg/kg dexmedetomidine over 15 min.
62192777|NCT00672451|EXPERIMENTAL|rhubarb extract|will receive rhubarb extract
62192778|NCT00672451|PLACEBO_COMPARATOR|placebo|receive placebo
62192779|NCT01446146|EXPERIMENTAL|IDM intervention|Will receive a 40 minute intervention session with a clinician, learning about PTSD treatment options and choosing a preferred treatment.
62781470|NCT02980133|EXPERIMENTAL|FS MDPI 50/12.5 mcg BID|Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol (FS) via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks.
62192780|NCT01446146|PLACEBO_COMPARATOR|Treatment as usual plus placebo session|Will work with provider to select a treatment plan and will receive a 40 minute session without IDM intervention.
62192781|NCT04670445|EXPERIMENTAL|Refine Intervention and Study Procedure|"Small open pilot (n=10) to refine the intervention and study procedures.~* The study will involve three surveys (one before first infusion, one after, and one six weeks later).~* An educational video regarding the risks, benefits, and potential outcomes of immunotherapy treatment and reviewing an immunotherapy-focused QPL prior to ICI initiation or PDF alternative to the video~* Question-prompt list (QPL) -list of suggested questions that participant can choose to raise with the oncology team."
62398071|NCT02049476|EXPERIMENTAL|Dexamethasone Pellet|This is a proof of concept study; therefore all enrolled patients will receive the intervention according to its FDA-approved indication.
62398072|NCT03892967|EXPERIMENTAL|Supportive care (interview)|Patients randomized to E2C2 intervention participate in an interview over 30-45 minutes. Providers and stakeholders also participate in an interview over 15-30 minutes.
62398073|NCT05656729|PLACEBO_COMPARATOR|Placebo|Placebo 8-week daily administration
62781471|NCT03578328||Cardiac arrest with targeted temperature management|
62781472|NCT03342118|EXPERIMENTAL|Phloroglucin group|patients taken Phloroglucin(Flospan®)
62007237|NCT05232448|NO_INTERVENTION|Control Group|Data collection forms will be applied to the students in the control group first. They will then continue their normal education.
62781473|NCT03342118|PLACEBO_COMPARATOR|Normal saline placebo group|patients taken normal saline placebo
62781474|NCT03219346|EXPERIMENTAL|Oral hygiene|
62781475|NCT03596580||Dehydrated participants|125 participants ≥ 65 years of age at the moment of the interviews; hospitalized in General Medicine; osmolarity ≥ 296 mOsm/L
62007238|NCT05232448|EXPERIMENTAL|Intervention Group|Data collection forms will be applied to the students in the intervention group first. Afterwards, cognitive-behavioral therapy training will be implemented as four modules, lasting 1 month in total.
62007239|NCT01491321|EXPERIMENTAL|Bee Venom Acupuncture & Loxoprofen|
62007240|NCT01491321|PLACEBO_COMPARATOR|Sham Bee Venom Acupuncture & Loxoprofen|
62007241|NCT05388890||MLD|Modified Liujunzi Decoction,1 package twice daily,6 months
62007242|NCT05388890||WFC|Weifuchun,three times a day, four at a time,6months
62007243|NCT00281840|EXPERIMENTAL|bevacizumab with docetaxel and radiation therapy|
62007244|NCT02451566||Fast-Track Group|Includes subject who complete the Fast-Track EVAR protocol.
62398074|NCT05656729|ACTIVE_COMPARATOR|Multistrain probiotic|Dietary Supplement: Multistrain Probiotic 12-week daily administration
62398075|NCT01698606|ACTIVE_COMPARATOR|Secondary lifestyle intervention arm|6-month wait list group. Second arm to receive multidisciplinary, family-centered lifestyle intervention with behavioral counseling, following of completion of main 6-month intervention for arm 1.
62398076|NCT01698606|EXPERIMENTAL|Primary lifestyle intervention arm|First arm to receive multidisciplinary, family-centered lifestyle intervention with behavioral counseling
62781476|NCT03596580||Hydrated participants|97 participants ≥ 65 years of age at the moment of the interviews; hospitalized in General Medicine; osmolarity \< 296 mOsm/L
62781477|NCT03618316|EXPERIMENTAL|Open-label imeglimin + cimetidine|Day 1: single oral dose of 1,500 mg imeglimin Day 5 to Day 10 inclusive: repeated doses of 400 mg cimetidine twice daily Day 8: second 1,500 mg dose of imeglimin together with the morning dose of cimetidine
62781478|NCT02021955|NO_INTERVENTION|usual care|Primary care providers treat their patients discharged from hospital for a COPD exacerbation as usual.
62781479|NCT02021955|EXPERIMENTAL|guideline treatment recommendations|Primary care clinicians receive treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
62007245|NCT02451566||Standard P-EVAR Group|Includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are completed with bilateral percutaneous access.
62007246|NCT02451566||Standard EVAR Group|Includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are not completed with bilateral percutaneous access (i.e. converted to femoral cutdown or open surgical repair).
62007247|NCT06250101|EXPERIMENTAL|Grammar treatment including semantic support|Children receiving grammatical treatment will also receive a simple explanation concerning the meaning of verbs used to elicit grammatical forms.
62007248|NCT06250101|ACTIVE_COMPARATOR|Grammatical treatment excluding semantic support|Children receiving grammatical treatment will not receive any explanation concerning the meaning of verbs used to elicit grammatical forms.
62007249|NCT02381080|EXPERIMENTAL|Part 1: Ibrutinib+Erythromycin+Voriconazole|Participants will receive oral treatment in six, 28-days cycles. In Cycle 1, participants will take ibrutinib 560 milligram (mg) (4\*140 mg capsules) once daily (QD) from Days 1- 4; on Days 5-11 ibrutinib 140 mg capsule QD in combination with erythromycin 500 mg tablet 3 times daily (TID); on Days 12-13 ibrutinib 140 mg capsule QD; on Days 14-18 ibrutinib 560 mg (4\*140 mg capsules) QD; on Days 19-25 ibrutinib 140 mg capsule QD in combination with voriconazole 200 mg tablet twice daily (BD); on Days 26-27 ibrutinib 140 mg capsule orally QD; and on Day 28 and in subsequent treatment Cycles (2-6) participants will continue oral treatment with ibrutinib 420 mg or 560 mg QD (depending on the subtype of B-cell malignancy).
62007250|NCT02381080|EXPERIMENTAL|Part 2: Ibrutinib+ Erythromycin+Voriconazole|Participants will receive oral treatment in six, 28-days cycles. In Cycle 1, participants will take ibrutinib 560 mg (4\*140 mg capsules) QD from Days 1- 4; on Days 5-18 ibrutinib 560 mg (4\*140 mg capsules) QD in combination with either erythromycin 500 mg tablet TID (Group 1) or voriconazole 200 mg tablet BD (Group 2); on Day 19 and in subsequent treatment Cycles (2-6) participants will continue oral treatment with ibrutinib 420 mg or 560 mg QD (depending on the subtype of B-cell malignancy).
62007251|NCT03722017|NO_INTERVENTION|Control--usual care|"Medication History: All participants / surrogates will receive a structured interview and chart review by the study Pharmacist or Nurse Practitioner at enrollment to determine:~Medications: Medications will include ANY medication with the potential for continuation at the time of hospital discharge to include pre-hospital medications, \[OTC medications\] and active in-hospital medications. Pre-hospital \[and OTC\] medications will be confirmed by Veteran/surrogate interview and pharmacy refills. If a Veteran is admitted from SNF (short-term stay), the investigators will request a copy of the Medication Administration Record (MAR) for the past 30 days. Current medications will be defined as those taken within 30 days prior to the index (enrollment) hospitalization event."
62192782|NCT04670445|EXPERIMENTAL|Educational Video and QPL List|"Randomized into Intervention Arm~* The study will involve three surveys (one before first infusion, one after, and one six weeks later).~* An educational video regarding the risks, benefits, and potential outcomes of immunotherapy treatment and reviewing an immunotherapy-focused QPL prior to ICI initiation or PDF alternative to the video~* Question-prompt list (QPL) -list of suggested questions that participant can choose to raise with the oncology team.~* Audio Recorded Conversation with oncologist"
62192783|NCT04670445|ACTIVE_COMPARATOR|Usual Care|"Randomized into Usual Care Arm~* The control group will have three surveys (one before first infusion, one after, and one six weeks later)~* Audio Recorded Conversation with oncologist"
62192784|NCT03463551|EXPERIMENTAL|ABL-101 IV as per dosing cohort + Supplementary O2 for 24h|"Patients will receive either ABL-101 or placebo (equivalent volume of 0.9% Sodium Chloride) within ascending dose groups of 6 patients each (4 to ABL-101, 2 to placebo).The starting cohort will be Cohort 1: 0.5mL/kg.~In the event that the start dose of Cohort 1 is considered intolerable in the opinion of the iDMC based on incidence of patients experiencing dose-limiting toxicities (DLTs), the iDMC will have the option of recommending a lower dose cohort (Cohort -1) of 0.25ml/kg (to a maximum of 25ml) be undertaken.~Cohort 1: 0.5 mL/kg to a maximum of 50ml; Cohort 2: 1.5mL/kg to a maximum of 150ml; Cohort 3: 3.0mL/kg to a maximum of 300ml.~All patients will receive Oxygen 60% by face mask (8l/min) for approximately 24h after ABL-101 or placebo administration."
62192785|NCT03463551|PLACEBO_COMPARATOR|IV 0.9% NaCl as per dosing cohort + supplementary O2 for 24h|"Cohort 1: Volume matched to the calculation used for ABL-101 using patient weight; Cohort 2: Volume matched to the calculation used for ABL-101 using patient weight; Cohort 3: Volume matched to the calculation used for ABL-101 using patient weight.~All patients will receive Oxygen 60% by face mask (8l/min) for approximately 24h after ABL-101 or placebo administration."
62192786|NCT02397447|EXPERIMENTAL|Momordica charantia|Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days
62398077|NCT03596645|EXPERIMENTAL|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab through Week 50. Doses will be based on body surface area. Following the Week 54 evaluations (end of main pivotal study) participants who are benefiting from golimumab at the discretion of the investigator may continue to receive SC golimumab in an extension period until end of study.
62398078|NCT03596645|EXPERIMENTAL|Group 2: Infliximab|Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
62781480|NCT04415411|NO_INTERVENTION|Control group|Routine nursing care
62192787|NCT02397447|PLACEBO_COMPARATOR|Placebo|Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days
62192788|NCT04382846|EXPERIMENTAL|Nitazoxanide|Nitazoxanide with standard protocol of treatment
62192789|NCT04382846|NO_INTERVENTION|Control group|Standard protocol alone
62398079|NCT03297463|EXPERIMENTAL|Phase Ib (Dose Escalation)|
62398080|NCT03297463|EXPERIMENTAL|Phase II (Dose Expansion)|
62781481|NCT04415411|EXPERIMENTAL|Intervention group|Nursing care based on the Theory of Human Caring
62781482|NCT02223806|ACTIVE_COMPARATOR|Self-assessment of uterine tonus|Uterine tonus assessment every 15 minutes for 2 hours by educated patient, which is standard-of-care.
62781483|NCT02223806|EXPERIMENTAL|Midwife uterine tonus assessment|Uterine tonus assessment every 15 minutes for 2 hours by midwive.
62781484|NCT02767661|EXPERIMENTAL|Capecitabine+Aromatase inhibitor|Capecitabine, 500mg, orally three times daily in combination with an aromatase inhibitor (Anastrozole 1 mg, orally once daily or Letrozole 2.5mg, orally once daily or Exemestane 25mg, orally once daily)
62007252|NCT03722017|EXPERIMENTAL|Intervention--deprescribing protocol|"In addition to a medication history, a study Pharmacist or Nurse Practitioner will review the reconciled total enrollment medication list. The following information will be ascertained for each medication: (1) Medication Indication; and, (2) Deprescribing rationale: Rationales for deprescribing (i.e., stopping or reducing dose) will be assessed for each medication.~Deprescribing Recommendations: For each medication recommended for deprescribing, the deprescribing action will be specified as: (1) Stop prior to hospital discharge without need for monitoring; (2) Stop prior to hospital discharge with symptoms/physiologic monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until medication is stopped; (5) Reduce to lower dose without need for monitoring; (6) Reduce to lower dose with symptoms/physiologic monitoring."
62192790|NCT02127125|PLACEBO_COMPARATOR|Type2 Diabetes Mellitus - Placebo|Type 2 Diabetes Mellitus subjects will receive maltodextrin (placebo)
62007253|NCT05159843|EXPERIMENTAL|Diabetes Self-Management education|"Participants randomized to this arm receive therapeutic education during four sessions of four consecutive days. An advanced practice nurse who specializes in diabetes will teach these sessions. The sessions will have small groups of five patients and it will last of one hour each day. The outline of the session is as follow (Figure 1):~First session: Insulin administration and blood glucose self-analysis Second session: Management of hypoglycemia and hyperglycemia Third session: Healthy diet adapted to the diabetic patient Four session: Physical exercise"
62007254|NCT05159843|EXPERIMENTAL|Usual care|Participants in control group receive usual services offered in University Hospital and other local health systems for patients with diabetes, which include regular visits with a diabetes provider (primary care or endocrine) and standard Spanish Diabetes Society information pamphlets. Consultation care is centralized in the pharmacological treatment regimen, dosage and guidelines.
62192791|NCT02127125|PLACEBO_COMPARATOR|Obese with NGT - Placebo|Obese (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) subjects will receive maltodextrin (placebo)
62192792|NCT02127125|PLACEBO_COMPARATOR|Lean with NGT -Placebo|Lean (BMI\< 26 kg/m2) normal glucose tolerant (NGT) will receive maltodextrin (placebo)
62192793|NCT02127125|ACTIVE_COMPARATOR|Type2 Diabetes Mellitus - Synbiotic|Type 2 Diabetic subjects will receive synbiotic
62192794|NCT02127125|ACTIVE_COMPARATOR|Type2 Diabetes Mellitus - Sevelamer|Type 2 Diabetic subjects will receive sevelamer
62781485|NCT02767661|ACTIVE_COMPARATOR|Aromatase inhibitor|Aromatase inhibitor (Anastrozole 1 mg, orally once daily or Letrozole 2.5mg, orally once daily or Exemestane 25mg, orally once daily)
62781486|NCT05024708|EXPERIMENTAL|ARVC patients|
62781487|NCT05024708|ACTIVE_COMPARATOR|Endurance athletes with a dilated RV|
62781488|NCT05024708|ACTIVE_COMPARATOR|Endurance athletes with normal RV|
62007255|NCT01844635|EXPERIMENTAL|2.5 mg/kg/day of Thymoglobulin for 5 days|2.5 mg/kg/day of Thymoglobulin for 5 days
62007256|NCT01844635|ACTIVE_COMPARATOR|3.5 mg/kg/day of Thymoglobulin for 5 days|3.5 mg/kg/day of Thymoglobulin for 5 days
62573114|NCT04545008|EXPERIMENTAL|Low Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 20 mg three times daily
62192795|NCT02127125|ACTIVE_COMPARATOR|Obese with NGT - Synbiotic|Obese (BMI = 30-37 kg/m2) normal glucose tolerant subjects (NGT) will receive Synbiotic
62192796|NCT02127125|ACTIVE_COMPARATOR|Obese with NGT - Sevelamer|Obese subjects (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer
62192797|NCT02127125|ACTIVE_COMPARATOR|Lean with NGT - Synbiotic|Lean (BMI\< 26 kg/m2) normal glucose tolerant (NGT) will receive Synbiotic
62192798|NCT02127125|ACTIVE_COMPARATOR|Lean with NGT - Sevelamer|Lean (BMI\< 26 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer
62192799|NCT05907798|ACTIVE_COMPARATOR|Group PECS|placing the ultrasound probe in the midclavicular line and in the parasagittal plane, After identifying the second and third ribs by sliding the ultrasound probe caudally, the lower end will be rotated towards the axilla to make the probe parallel to the deltopectoral groove. Combined with the in-plane technique, this rotation provides better extension to the intercostobrachial nerve. The tip of the needle will be inserted into the interpectoral fascial plane (between pectoralis major and minor). The needle will be advanced from the interpectoral fascial plane to the fascial plane between the pectoralis minor and the serratus anterior. 10 mL of local anesthetic (Bupivacaine) will be applied to the PECS I area and 20 mL to the PECS II area.
62573115|NCT04545008|EXPERIMENTAL|High Dose N-Acetyl Cysteine Alone|N-Acetyl Cysteine 1,800 mg three times daily
62573116|NCT04545008|EXPERIMENTAL|Medium Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 20 mg three times daily
62573117|NCT04545008|EXPERIMENTAL|Low Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 40 mg three times daily
62573118|NCT04545008|EXPERIMENTAL|High Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 20 mg three times daily
62573119|NCT04545008|EXPERIMENTAL|Medium Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 40 mg three times daily
62573120|NCT04545008|EXPERIMENTAL|Low Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 80 mg three times daily
62781489|NCT05024708|EXPERIMENTAL|Untrained subject with normal RV|
62781490|NCT00837343|EXPERIMENTAL|Quetiapine Fumarate arm|Quetiapine Fumarate arm
62781491|NCT02703480|EXPERIMENTAL|All Study Participants - d-PTFE|The proposed study design is a randomized controlled trial, split mouth design, to compare the two different vertical augmentation procedures: Titanium mesh (Ti-mesh) technique and Guided Bone Regeneration (GBR) technique with a high-density polytetrafluoroethylene (d-PTFE) membrane.
62192800|NCT05907798|ACTIVE_COMPARATOR|Group SA|It will be positioned to stand at the head of the patient or to one side of the patient and to see the ultrasound screen easily. High-frequency linear probe and 80 mm blunt-tipped needle will be placed cauda-cranially or cranially-caudal with in-plane technique. The injection site is found by placing the ultrasound probe under the clavicle in a parasagittal manner and counting from the second rib. By moving the probe laterally towards the mid or posterior axillary line, the serratus anterior muscle is seen as a layer of muscle over the anechoic shadow of the rib. It extends over the latissimus dorsi serratus anterior muscle and appears thicker and more prominent in the posterior axillary line. 30 mL of local anesthetic (bupivacaine) will be administered to the fascial plane by advancing the needle superficially or deeply into the serratus anterior muscle.
62192801|NCT05907798|SHAM_COMPARATOR|Group K (Control group)|The patient, who was taken to the operating table with his consent, will be monitored. ECG monitoring, SpO2 monitoring, invasive artery monitoring will be performed. General Anesthesia will be applied(Induction with 2 mg/kg propofol, 0.6mg/kg rocuronium bromide, 2µcg/kg fentanyl, 2MAC sevoflurane + 40% air mixture and maintenance with 2L/min) Routine coronary artery bypass grafting surgery will be performed without any peripheral blocking and LIMA blood flow will be measured.
62398081|NCT05807477||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
62398082|NCT03095365|ACTIVE_COMPARATOR|Dry needling|Received Dry needling in the neck muscles.
62398083|NCT03095365|ACTIVE_COMPARATOR|Conventional treatment|the participants received the conventional treatment for non-specific neck pain.
62398084|NCT03095365|EXPERIMENTAL|Dry needling and pain neuroscience education|Received the same treatment as dry needling group and pain education.
62398085|NCT06515886||Dental implants|"Intra-oral photograph~Sample of Peri-implant Crevicular fluid~Clinical Examination~Peri-apical x-ray"
62398086|NCT04102761|PLACEBO_COMPARATOR|Trigger Point Needling|The first group will receive a deep trigger point injection of saline into deep tissue.
62398087|NCT04102761|ACTIVE_COMPARATOR|Platelet Rich Plasma Injection|The Platelet Rich Plasma group will receive an injection of approximately 1-2 mL of Platelet Rich Plasma into the painful disc/discs.
62573121|NCT04545008|EXPERIMENTAL|High Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 40 mg three times daily
62573122|NCT04545008|EXPERIMENTAL|Medium Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 80 mg three times daily
62573123|NCT04545008|EXPERIMENTAL|High Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 80 mg three times daily
62573124|NCT02920008|EXPERIMENTAL|guadecitabine|Guadecitabine will be given SC at a dose of 60 mg/m\^2 in 28-day cycles (delayed as necessary to allow blood count recovery).
62573125|NCT02920008|ACTIVE_COMPARATOR|Treatment Choice (TC)|"1. High intensity~2. Low intensity~3. Best supportive care (BSC)."
62573126|NCT01157104|EXPERIMENTAL|IDX320 + PBO → IDX320 + IDX184|400 mg IDX320 and IDX184 matching placebo (PBO) once daily for 7 days; followed by 400 mg IDX320 and 100 mg IDX184 once daily for 7 days
62573127|NCT01157104|EXPERIMENTAL|IDX184 + PBO → IDX184 + IDX320|100 mg IDX184 and IDX320 matching PBO for 7 days; followed by 100 mg IDX184 and 400 mg IDX320 for 7 days
62573128|NCT01157104|PLACEBO_COMPARATOR|IDX320 PBO + IDX184 PBO|IDX320 matching PBO + IDX184 matching PBO for 14 days
62573129|NCT01534039|ACTIVE_COMPARATOR|Sur-Fit Natura/FormaFlex|Subject will be on Surfit Moldable for 2 weeks then crossover to Formaflex
62573130|NCT01534039|ACTIVE_COMPARATOR|FormaFlex/Sur-Fit Natura|Subject will be on Formaflex for 2 weeks then crossover to Surfit Moldable
62192802|NCT02562157|EXPERIMENTAL|Patients with antro duodenal obstructions|NOTES gastroenteric anastomosis
62398088|NCT04102761|ACTIVE_COMPARATOR|Bone Marrow Aspirate Injection|The third group will receive an injection of approximately 1-2 mL of Bone Marrow Concentrate into the painful disc/discs.
62398089|NCT06291909|PLACEBO_COMPARATOR|Condensed Program Group|Identification of optimal time use with comparison to current time use. No research staff supported goal setting, provision of lifestyle information resources through website (no other website functionality available).
62398090|NCT06291909|EXPERIMENTAL|Extended Program Group|Identification of optimal time use with comparison to current time use, complete access to the Small Steps digital interface, frequent one-on-one support from research staff, supported goal setting and behaviour change choices.
62398091|NCT04142697|ACTIVE_COMPARATOR|Healthy subjects|
62398092|NCT04142697|ACTIVE_COMPARATOR|Vestibular Disease patients|
62398093|NCT06722001|ACTIVE_COMPARATOR|Traditional group|The traditional group members will obtain traditional paper leaflets and oral health education.
62573131|NCT06401473|NO_INTERVENTION|Control|Patients received no intervention during cortisone injection.
62781492|NCT02703480|EXPERIMENTAL|All Study Participants - Ti-mesh|The proposed study design is a randomized controlled trial, split mouth design, to compare the two different vertical augmentation procedures: Titanium mesh (Ti-mesh) technique and Guided Bone Regeneration (GBR) technique with a high-density polytetrafluoroethylene (d-PTFE) membrane
62781493|NCT02019875|PLACEBO_COMPARATOR|Water|200 mL of water once a day for 14 days
62192803|NCT03960853|EXPERIMENTAL|pressure-controlled ventilation-volume guaranteed|patients will be allocated to pressure-controlled ventilation volume guaranteed in operation
62781494|NCT02019875|ACTIVE_COMPARATOR|Rifampin|Rifampin 600 mg once a day for 14 days
62781495|NCT02019875|ACTIVE_COMPARATOR|Grapefruit Juice|200 mL of grapefruit juice once a day for 14 days
62781496|NCT02019875|ACTIVE_COMPARATOR|Grapefruit Juice Plus Rifampin|200 mL of grapefruit juice once a day for 8 days plus rifampin 600 mg once a day for 14 days
62781497|NCT02019875|ACTIVE_COMPARATOR|Clarithromycin|Clarithromycin 250 mg twice a day for 14 days
62781498|NCT02019875|ACTIVE_COMPARATOR|Clarithromycin Plus Rifampin|Clarithromycin 250 mg twice a day for 14 days plus rifampin 600 mg once a day for 14 days
62781499|NCT00994643|EXPERIMENTAL|Treatment (Interleukin Therapy, Monoclonal Antibody)|Patients receive interleukin-2 SC twice weekly and rituximab IV once weekly in weeks 5-8 and 25-28. Courses repeat every 4 weeks for up to 7 months in the absence of disease progression or unacceptable toxicity.
62781500|NCT04534881|ACTIVE_COMPARATOR|progesterone|subjects on active drug (progesterone)
62781501|NCT04534881|PLACEBO_COMPARATOR|placebo|subjects on placebo
62007257|NCT05931848|EXPERIMENTAL|Otago exercise group|"The treatment program, which will last for 16 weeks, 3 days a week, a total of 48 sessions will be held. The program will be held one day a week with a maximum of 8 participants per group, under the supervision of a physiotherapist, in the Kadikoy Municipality Social Life Center, in the form of group exercise training, and two days a week at the participants' homes, with the implementation of the Otago Home Exercise Program non-supervised. Participants will be informed that the program should be implemented on non-consecutive days. All warm-up and strengthening exercises will be applied in combination with breathing. While the home exercise program is being taught to the patients, information will be given about the situations where the exercise is contraindicated and should be stopped.~Within the scope of group exercise training, it is planned to implement a structured program of approximately 45-60 minutes, including warm-up, strengthening, balance and cool-down exercises."
62192804|NCT03960853|PLACEBO_COMPARATOR|volume controlled ventilation|patients will be allocated to volume controlled ventilation in operation
62192805|NCT02221999|ACTIVE_COMPARATOR|Chemotherapy only|Paclitaxel injection 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle；Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle； for 4 cycles
62192806|NCT02221999|EXPERIMENTAL|GnRHa|Paclitaxel 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle; Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle; for 4 cycles Gonadotropin-releasing hormone agonist （GnRHa）11.25 mg every 3 months or 3.6mg every month subcutaneously
62192807|NCT02221999|EXPERIMENTAL|letrozole|Paclitaxel 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle; Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle; for 4 cycles Letrozole 2.5mg/day
62192808|NCT01937975|EXPERIMENTAL|Participants with End Stage Renal Disease on Hemodialysis|Participants with End Stage Renal Disease on hemodialysis received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days..
62192809|NCT01937975|EXPERIMENTAL|Participants with Severe Renal Impairment|Participants with Severe Renal Impairment (estimated glomerular filtration rate \<30 mL/min/1.73 m\^2) received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days.
62192810|NCT01937975|EXPERIMENTAL|Healthy Participants|Healthy participants (estimated glomerular filtration rate \>=80 mL/min/1.73 m\^2) received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days.
62192811|NCT01115686|ACTIVE_COMPARATOR|Branched-chain aminoacids|Branched-chain aminoacids are natural constituents of the food. Branched-chain aminoacids will be orally administered in the form of capsules.
62192812|NCT01115686|PLACEBO_COMPARATOR|placebo|The placebo will be orally administered in the form of capsules
62214830|NCT04869007||Patients with a history of cesarean section and a hysterosonographically diagnosed isthmocoele|"For patients who agreed to participate in the study, a specific measurement is made during the hysterosonography examination in order to determine the presence or absence of an isthmocele. Inclusion in the study is validated after a successful hysterosonography examination that confirms the presence or absence of an isthmocele. The patients are then attributed either to the: isthmocele + group or isthmocele - group."
62781502|NCT01085292|EXPERIMENTAL|Group A|
62781503|NCT01085292|EXPERIMENTAL|Group B - D|
62781504|NCT00769457|EXPERIMENTAL|1|Arm with activated OptiVol / Carelink-system, event-triggered physician alert and physician access to Cardiac Compass data
62781505|NCT00769457|NO_INTERVENTION|2|Arm with standard ICD - CRT-D therapy, no OptiVol and no Carelink
62781506|NCT05945251||FAPDs|Children 8-17 years with FAPDs
62781507|NCT05945251||Controls|Children 8-17 years without FAPDs
62781508|NCT02205528|PLACEBO_COMPARATOR|Treatment Period: Placebo QD|Participants will receive daily SC placebo injections during the 12-week, double-blind treatment period.
62781509|NCT02205528|EXPERIMENTAL|Treatment Period: NNC0090-2746 QD|Participants will receive daily 1.8-mg SC injections of NNC0090-2746 during the 12-week, double-blind treatment period.
62781510|NCT02205528|ACTIVE_COMPARATOR|Treatment Period: Liraglutide QD|Participants will receive open-label liraglutide via SC injection during the 12-week treatment period. The dose scheme will be as follows: 0.6 milligrams (mg) each day during Week 1, followed by 1.2 mg each day during Week 2, and 1.8 mg each day from Weeks 3 to 12.
62781511|NCT03214042|EXPERIMENTAL|trial group|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years.
62781512|NCT03752658||Tenofovir alafenamide (TAF)|Male or female HBeAg positive or negative patients (above 18 years of age) who were mono-infected with HBV, either NA treatment-naïve or treatment-experienced, but TAF naïve will be enrolled in this study, and they will be treated with TAF, alone or in combination with anti-HBV agents.
62573132|NCT06401473|SHAM_COMPARATOR|Distraction|Patients were instructed on a sham motor distraction task on the contralateral upper limb and performed this task during cortisone injection.
62781513|NCT04439981|PLACEBO_COMPARATOR|Control Group|treated by ice cream without any Curcuma extract supplementation
62781514|NCT04439981|EXPERIMENTAL|Treatment Group|treated by ice cream supplemented by Curcuma extract
62398094|NCT06722001|EXPERIMENTAL|"Brief insomnia intervention group"|"The Brief insomnia intervention group will study the interactive e-book."
62398095|NCT04188639|EXPERIMENTAL|Treatment with emicizumab|
62398096|NCT01438281|EXPERIMENTAL|SYL1001|
62398097|NCT06619587|EXPERIMENTAL|Phase I Arm A|Dose escalation and expansion arm
62398098|NCT06619587|EXPERIMENTAL|Phase I Arm B|Dose escalation and expansion arm
62398099|NCT06724458|EXPERIMENTAL|80% knee extension/80% barbell curl 1RM|The load will be set to 80% of 1RM for the knee extension and 80% 1RM for the barbell curl
62398100|NCT06724458|EXPERIMENTAL|40% knee extension/70% barbell curl 1RM|The load will be set to 40% of 1RM for the knee extension and 70% 1RM for the barbell curl
62398101|NCT06724458|EXPERIMENTAL|30% knee extension/60% barbell curl 1RM|The load will be set to 30% of 1RM for the knee extension and 60% 1RM for the barbell curl
62398102|NCT06724458|EXPERIMENTAL|25% knee extension/55% barbell curl 1RM|The load will be set to 25% of 1RM for the knee extension and 55% 1RM for the barbell curl
62573133|NCT06401473|EXPERIMENTAL|Experimental|Patients were instructed on the experimental task, involving scratching the upper limb ipsilateral to the site of the injection, and they performed this task during cortisone injection.
62573134|NCT06285864|EXPERIMENTAL|Interoception-based intervention|The interoception-based intervention group will receive the intervention, which consists of 8 weekly sessions, of 1h30 hour, in groups (4-8 participants in each group).
62573135|NCT06285864|NO_INTERVENTION|Waiting list|The waiting list group will maintain their treatments as usual and receive the interoception-based intervention, at the end of the study.
62398103|NCT06724458|EXPERIMENTAL|20% knee extension/50% barbell curl 1RM|The load will be set to 25% of 1RM for the knee extension and 50% 1RM for the barbell curl
62398104|NCT06724458|EXPERIMENTAL|15% knee extension/45% barbell curl 1RM|The load will be set to 15% of 1RM for the knee extension and 45% 1RM for the barbell curl
62398105|NCT06724458|EXPERIMENTAL|80% knee extension/80% barbell curl 1RM both with blood flow occlusion|The load will be set to 80% of 1RM for the knee extension and 80% 1RM for the barbell curl with both being under peripheral blood flow occlusion
62398106|NCT06724458|EXPERIMENTAL|40% knee extension/60% barbell curl 1RM both with blood flow occlusion|The load will be set to 40% of 1RM for the knee extension and 60% 1RM for the barbell curl with both being under peripheral blood flow occlusion
62398107|NCT06724458|EXPERIMENTAL|30% knee extension/60% barbell curl 1RM both with blood flow occlusion|The load will be set to 30% of 1RM for the knee extension and 60% 1RM for the barbell curl with both being under peripheral blood flow occlusion
62781515|NCT03719989|EXPERIMENTAL|Treatment arm|This study is sing-arm study. Therefore, all enrolled patients will be treated with azacitidine plus R-GDP regimen
62781516|NCT05582174|ACTIVE_COMPARATOR|PPI infusion|esomeprazole 80mg iv bolus followed by 8mg per hour for 72 hours
62781517|NCT05582174|EXPERIMENTAL|Vonoprazan|Vonoprazan 40 mg bid orally for 72 hours, and from day 4-30 VPZ 20 mg daily
62781518|NCT00477152|EXPERIMENTAL|HYLENEX-augmented subcutaneous (SC ) rehydration|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
62781519|NCT00232856|OTHER|1|Cypher™ sirolimus-eluting stent
62781520|NCT02363296|EXPERIMENTAL|EEG phase-triggered PAS|TMS triggered to a specific phase of the EEG mu rhythm
62781521|NCT01670773|EXPERIMENTAL|CAT-1004 Dose #1|Single dose #1
62192813|NCT04840342|EXPERIMENTAL|Eplerenone Arm|We posit that individuals who carry the LSD1 risk allele have increased mineralocorticoid receptor activity, which results in hypertension. Thus, our mechanistic clinical study will assess whether hypertensive LSD1 risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the LSD1 risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
62192814|NCT04840342|EXPERIMENTAL|Amlodipine Arm|We posit that individuals who carry the LSD1 risk allele have increased mineralocorticoid receptor activity, which results in hypertension. Thus, our mechanistic clinical study will assess whether hypertensive LSD1 risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the LSD1 risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
62192815|NCT04394195||patients with COVID-19 infection|patients with COVID-19 infection
62192816|NCT01943682|EXPERIMENTAL|CPX-351|CPX-351 is made up of two chemotherapy drugs that patients may have already received called cytarabine and daunorubicin that are now packaged together. Subjects will receive a single course of CPX-351 administered on Days 1, 3, and 5.
62192817|NCT02790879||Transition|Patients who switched from pediatric cystic fibrosis care center to an adult cystic fibrosis care center during 2013 or 2014, regardless of their clinical status.
62192818|NCT02383251|EXPERIMENTAL|Pazopanib/Paclitaxel association|"Arm 1 :~Pazopanib alone during 1 week at 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.~Then:~* Pazopanib 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.~* Paclitaxel 65 mg/m2 i.v. on days 1, 8, 15 every 28 days until progression of disease or toxicity"
62192819|NCT02383251|ACTIVE_COMPARATOR|Paclitaxel alone|"Arm 2 :~* Paclitaxel 80mg/m2 i.v. on days 1, 8, 15~* every 28 days until progression of disease or toxicity"
62398108|NCT06724458|EXPERIMENTAL|25% knee extension/55% barbell curl 1RM both with blood flow occlusion|The load will be set to 25% of 1RM for the knee extension and 55% 1RM for the barbell curl with both being under peripheral blood flow occlusion
62398109|NCT06724458|EXPERIMENTAL|20% knee extension/50% barbell curl 1RM both with blood flow occlusion|The load will be set to 20% of 1RM for the knee extension and 50% 1RM for the barbell curl with both being under peripheral blood flow occlusion
62573136|NCT06577142|EXPERIMENTAL|Group A|51 participants will be in experimental group giving them ''Burn 2 Learn'' program consisted of high intensity interval training activities such as lunges, jumping jacks, boxing, dancing and sports activities for ten weeks, measuring all values before giving them protocol and after protocol.
62781522|NCT01670773|ACTIVE_COMPARATOR|Salsalate + DHA|Single dose #2
62781523|NCT01670773|PLACEBO_COMPARATOR|Placebo|Single Dose #3
62781524|NCT04859816|EXPERIMENTAL|Roux-en-Y gastric bypass operated participants|Roux-en-Y gastric bypass operated participants in weight stable phase \> 1 year from surgery
62781525|NCT04859816|EXPERIMENTAL|Control participants|Age, sex, and BMI-matched un-operated participants.
62781526|NCT04930094|EXPERIMENTAL|Secukinumab 300 mg|Secukinumab 300 mg s.c. at BSL, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4. Secukinumab will be given in combination with a specified 26-week prednisone taper regimen. After the 26-week prednisone taper, participants will continue to receive placebo to prednisone until Week 52.
62781527|NCT04930094|PLACEBO_COMPARATOR|Placebo|Placebo to secukinumab s.c. at BSL, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4. Placebo will be given in combination with a specified 52-week prednisone taper regimen.
62007258|NCT05931848|NO_INTERVENTION|control group|The control group will not be included in any exercise program, and they will be informed that they can participate in the same program after 16 weeks if they prefer. At the same time, a one-session training will be given to all participants of intervention and control groups at the Kadıköy Municipality Social Life Center, where information about the factors that increase the risk of falling and house arrangements will be provided.
62192820|NCT05058053|EXPERIMENTAL|Cold application group|"After starting amiodarone treatment, cold application was applied a total of 12 times on the infused PVC with cold gel packs for 15 minutes at 2-hour intervals. At all stages of the study, the researcher closely monitored the patients. During the treatment, the development of phlebitis after cold application during the 24-hour infusion was evaluated every 2 hours by the researcher using the Visual Infusion Phlebitis Scale and recorded. After starting the amiodarone infusion, the patients were observed for the development of phlebitis for 24 hours until the end of the procedure and for 2 hours after the end of the treatment."
62398110|NCT06724458|EXPERIMENTAL|15% knee extension/45% barbell curl 1RM both with blood flow occlusion|The load will be set to 15% of 1RM for the knee extension and 45% 1RM for the barbell curl with both being under peripheral blood flow occlusion
62192821|NCT05058053|NO_INTERVENTION|Control group|"the patients who were started on amiodarone infusion were observed for the development of phlebitis, receiving no intervention. During the treatment, phlebitis development was evaluated and recorded by the researcher using the Visual Infusion Phlebitis Scale every 2 hours during the 24-hour infusion. After starting the amiodarone infusion, the patients were observed for the development of phlebitis for 24 hours until the end of the procedure and for 2 hours after the end of the treatment."
62192822|NCT03484494|OTHER|Active first|Subjects receive active Low Field Magnetic Stimulation in the first imaging visit and sham in the second.
62192823|NCT03484494|OTHER|Sham first|Subjects receive sham Low Field Magnetic Stimulation in the first imaging visit and active in the second.
62192824|NCT00980746|EXPERIMENTAL|ESL 400 mg BID|ESL 400 mg twice daily (BID)
62398111|NCT03313700|EXPERIMENTAL|Robotic Distal Gastrectomy|Robotic Distal Gastrectomy will be performed for the treatment of patients assigned to this group.
62398112|NCT03313700|ACTIVE_COMPARATOR|Laparoscopic Distal Gastrectomy|Laparoscopic Distal Gastrectomy will be performed for the treatment of patients assigned to this group.
62398113|NCT05718921|EXPERIMENTAL|Part A, Active dose A and Low body surface area|The intervention is YR001 Dose A on low body surface area, low dose YR001 for single topical administration
62398114|NCT05718921|EXPERIMENTAL|Part A, Active dose A and Middle body surface area|The intervention is YR001 Dose A on middle body surface area, low dose for single topical administration
62398115|NCT05718921|EXPERIMENTAL|Part A, Active dose A and High body surface area|The intervention is YR001 Dose A on high body surface area, low dose for single topical administration
62398116|NCT05718921|EXPERIMENTAL|Part A, Active dose B and Low body surface area|The intervention is YR001 Dose B on low body surface area, high dose YR001 for single topical administration
62007259|NCT01296724|OTHER|newborn with digestive pathology|Preterm or term newborn admitted in paediatric intensive care unit with an urethral catheter and digestive pathology
62007260|NCT01296724|OTHER|Newborn without digestive pathology|Preterm or term newborn admitted in paediatric intensive care unit with an urethral catheter and without digestive pathology
62007261|NCT06176833|ACTIVE_COMPARATOR|Early Intervention|Additional training will begin no more than 60 days following spinal cord injury
62007262|NCT06176833|ACTIVE_COMPARATOR|Sub-acute Intervention|Additional training will occur 3 months following spinal cord injury
62007263|NCT06176833|ACTIVE_COMPARATOR|Chronic Intervention|Additional training will occur 6-12 months following SCI
62007264|NCT06176833|NO_INTERVENTION|Standard of Care|This group only receives standard of care treatment but is assessed at the same time points as the other groups
62573137|NCT06577142|EXPERIMENTAL|Group B|51 participants will be in control group participating in their routine school physical activities, sports games or any exercise routines for ten weeks, measuring all values before giving them protocol and after protocol.
62007265|NCT02490137|EXPERIMENTAL|Game Players|Participants that will play video game
62007266|NCT02490137|NO_INTERVENTION|Control|No video game experience
62007267|NCT01985737||Infants with infected PICC line|After informed consent the subjects that develop a PICC line infection in the NICU will serve as the cases.
62007268|NCT01985737||Infants without infected PICC line|After informed consent the subjects that do not develop a PICC line infection in the NICU will serve as the controls.
62007269|NCT01907633||Domperidone/ a proton pump inhibitor/metoclopramide users|Study patients had at least one prescription for domperidone, a proton pump inhibitor, or metoclopramide. Proton pump inhibitors observed in this study are: omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole.
62007270|NCT01061554|EXPERIMENTAL|Gastric stable emulsion|A gastric stable emulsion vehicle for administration of tri-glyceride based omega-3 oils
62007271|NCT01061554|ACTIVE_COMPARATOR|Soft gel capsule (TG)|Soft gel capsule for administration of tri-glyceride based omega-3 oils
62007272|NCT01061554|ACTIVE_COMPARATOR|Soft gel capsules (MPL)|Soft gel capsule for administration of marine phospholipids based omega-3 oils
62007273|NCT03929835|EXPERIMENTAL|Avidekel Oil|The cannabis oil, sort T1/C20 CBD as categorized by the MOH guidelines will be made from Avidekel strain and olive oil extract. Avidekel oil contains Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.
62007274|NCT03929835|PLACEBO_COMPARATOR|Placebo|Patients in the control group will receive placebo oil containing olive oil and Chlorophyll.
62007275|NCT03697200|ACTIVE_COMPARATOR|Auricular Point Acupressure (APA)|Patients with active points related to Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS). The points for AIMSS include (1) points corresponding to body pain location and (2) three points known for alleviating stress and pain (i.e., shenmen, sympathetic, and nervous subcortex)
62007276|NCT03697200|SHAM_COMPARATOR|Sham APA control|The same procedure of APA will be applied but the tapes/seeds will be placed on different points (points not related to AIMSS). Participants in the Sham APA Control will receive APA on the five ear points comprising mouth, stomach, duodenum, internal ear, and tonsils. These points are chosen for the Sham APA Control for two reasons: First, they are distinct from the zones of the ear (and the points therein) associated with AIMSS and correspond to body regions in which BCS (Breast Cancer Survivors) are usually pain-free; second, they are equivalent in number to those points used in the APA treatment group and no negative impacts have been observed among these points in our pilot study.
62192825|NCT00980746|EXPERIMENTAL|ESL 800 mg QD|ESL 800 mg once-daily (QD)
62192826|NCT00980746|EXPERIMENTAL|ESL 600 mg BID|Eslicarbazepine 600 mg twice daily
62192827|NCT00980746|EXPERIMENTAL|ESL 1200 mg QD|Eslicarbazepine acetate 1200 mg once daily
62573138|NCT02743936|EXPERIMENTAL|NIPPV with nasal cannula|Non-invasive positive pressure ventilation with nasal cannula in place
62573139|NCT02743936|ACTIVE_COMPARATOR|NIPPV without nasal cannula|Non-invasive positive pressure ventilation without nasal cannula
62192828|NCT00980746|EXPERIMENTAL|ESL 800 mg BID|Eslicarbazepine acetate 800 mg twice daily
62781528|NCT04930094|EXPERIMENTAL|Secukinumab 150 mg|Secukinumab 150 mg s.c. at BSL, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4. Secukinumab will be given in combination with a specified 26-week prednisone taper regimen. After the 26-week prednisone taper, participants will continue to receive placebo to prednisone until Week 52.
62781529|NCT00604045|EXPERIMENTAL|1 Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
62192829|NCT00980746|PLACEBO_COMPARATOR|Placebo|Placebo
62398117|NCT05718921|EXPERIMENTAL|Part A, Active dose B and Middle body surface area|The intervention is YR001 Dose B on middle body surface area, high dose YR001 for single topical administration
62398118|NCT05718921|EXPERIMENTAL|Part A, Active dose B and High body surface area|The intervention is YR001 Dose B on high body surface area, high dose YR001 for single topical administration
62398119|NCT05718921|PLACEBO_COMPARATOR|Part A, Placebo and Low body surface area|The intervention is Placebo on low body surface area, Placebo for single topical administration
62398120|NCT05718921|PLACEBO_COMPARATOR|Part A, Placebo and Middle body surface area|The intervention is Placebo on middle body surface area, Placebo for single topical administration
62398121|NCT05718921|PLACEBO_COMPARATOR|Part A, Placebo and High body surface area|The intervention is Placebo on high body surface area, Placebo for single topical administration
62398122|NCT05718921|EXPERIMENTAL|Part B, Active dose A and High body surface area|The intervention is YR001 Dose A on high body surface area twice daily, low dose YR001 for multiple topical administration
62398123|NCT05718921|EXPERIMENTAL|Part B, Active dose B and High body surface area|The intervention is YR001 Dose B on high body surface area twice daily, high dose YR001 for multiple topical administration
62192830|NCT01821105|EXPERIMENTAL|Preoperative PET and CT Scans|Patients undergo preoperative whole-body PET scans and CT scans of the abdomen and pelvis. Patients then receive fluoro-deoxyglucose (FDG)IV 60-90 minutes prior to surgery and undergo intraoperative CT scans using a handheld probe and computer navigation system.
62192831|NCT04665752||Affected Participants|Participants previously diagnosed with COVID-19.
62192832|NCT05519553|EXPERIMENTAL|Experimental group|30 MS (Multiple sclerosis, relapsing-remitting) patients
62192833|NCT05519553|NO_INTERVENTION|Control group|30 MS (Multiple sclerosis, relapsing-remitting) patients
62192834|NCT01225497|ACTIVE_COMPARATOR|Standard eccentric exercise|Participants randomised to this group shall complete 180 repetitions a day of Alfredsons heel drop protocol. This has been accepted as standard management for mid-portion Achilles pain in the first instance.
62192835|NCT01225497|EXPERIMENTAL|Eccentric exercise as able|Participants randomised to this group shall carry out exactly the same eccentric exercises as per Alfredsons heel drop protocol. However, these individuals will be instructed to do what they can.
62192836|NCT03614806|EXPERIMENTAL|Patients tested for hyperventilation|Simultaneous Transcutaneous and End-tidal CO2 measurements. Eligible patients will be first invited to fill in the Nijmegen questionnaire. Then, in an hyperventilation test, transcutaneous Carbon Dioxide Pressure will be recorded simultaneously with the standard End-tidal Carbon Dioxide Pressure measurement.
62192837|NCT04374747|EXPERIMENTAL|Dietary Intervention|Intensive dietary counseling and fruit and vegetable box delivery.
62192838|NCT04374747|NO_INTERVENTION|Information|Control condition of information on healthy eating during breastfeeding
62192839|NCT00891033|EXPERIMENTAL|Cohort 1|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 5 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
62192840|NCT00891033|EXPERIMENTAL|Cohort 2|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 10 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
62192841|NCT00891033|EXPERIMENTAL|Cohort 3|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 15 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
62192842|NCT00891033|EXPERIMENTAL|Cohort 4|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 20 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
62192843|NCT01880242||Orsiro DES|"Subjects requiring coronary revascularization with Drug Eluting Stents (DES). subgroups: Subjects presenting with~1. Diabetes (all types)~2. Small vessels (≤2.75 mm)~3. Chronic total occlusion (CTO)~4. Acute Myocardial Infarction (incl. STEMI and NSTEMI)"
62192844|NCT05918276|EXPERIMENTAL|OBG|
62192845|NCT05044923|EXPERIMENTAL|Targeted Epidural Spinal Stimulation|Participants will undergo surgery to implant devices that will be used for Targeted Epidural Spinal Stimulation (TESS).
62192846|NCT04218747|EXPERIMENTAL|VA 365 Demonstration Benefits|Children in treatment schools received: (1) three meals during the school day and food packages for weekends and school breaks; (2) $60 monthly Electronic Benefit Transfer (EBT) benefits during summer months if they were eligible for FRP meals; and (3) nutrition education for their parents.
62192847|NCT04218747|NO_INTERVENTION|Control Group|"Schools in the control group operated under business as usual."
62192848|NCT01834612|ACTIVE_COMPARATOR|Blood draw|CM1500 with blood draw
62192849|NCT01834612|SHAM_COMPARATOR|No blood draw|CM 1500 with no blood draw
62192850|NCT04975503||Young Women|Young women, aged 18 to 50 years, with documented atherosclerotic cardiovascular disease
62192851|NCT04975503||Older Women|Older women, aged \>50 years, with documented atherosclerotic cardiovascular disease
62192852|NCT06202053||The experimental group (patients received the periareolar incision)|
62573140|NCT06431932|EXPERIMENTAL|Single-arm open-label study in healthy volunteers|Healthy volunteers will receive fisetin.
62192853|NCT06202053||The control group (patients underwent the axillary incision)|
62573141|NCT06431932|EXPERIMENTAL|RCT - Treatment group|Older patients with multimorbidity will receive fisetin.
62573142|NCT06431932|PLACEBO_COMPARATOR|RCT - Placebo group|Older patients with multimorbidity will receive placebo.
62573143|NCT04349228|EXPERIMENTAL|Hydroxychloroquine (HCQ)|Exposed health care professionals working in the intensive care unit
62573144|NCT04349228|PLACEBO_COMPARATOR|Placebo|Exposed health care professionals working in the intensive care unit
62007277|NCT03697200|OTHER|Education Control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Educational sessions are intended to reflect usual standard medical care per guidelines from the American Society of Clinical Oncology (ASCO), while also meeting the needs of trial participation, including (1) the knowledge of hormonal therapy and side effects; (2) assessment and management of physical long-term and late effects; (3) assessment and management of psychological long-term and late effects; and (4) dietary (developed by Co-I, van Londen) and physical activity in Breast Cancer Survivors (BCS) (developed by Co-I, Stearns). These materials have been used by the research team, and clinical practice. Materials will be tailored so that they can be delivered within 15 minutes for each session.
62192854|NCT00730613|EXPERIMENTAL|Treatment (therapeutic autologous lymphocytes)|Patients receive an infusion of autologous antigen-specific CD8+ cytotoxic T-lymphocyte clones over 5-10 minutes on days 1, 3, and 5 of weeks 1 and 2. Treatment repeats every 3 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity.
62192855|NCT01189110|ACTIVE_COMPARATOR|Arm 1|Stimulation of auriculotherapy points on both ears with functioning Stim Flex 400A TENS unit once a week for 5 weeks.
62192856|NCT01189110|PLACEBO_COMPARATOR|Arm 2|Stimulation of auriculotherapy points on both ears with disabled Stim Flex 400A TENS unit once a week for 5 weeks.
62192857|NCT03035110|EXPERIMENTAL|Dialectical Behavioural Therapy (DBT) skills group|Four group sessions, based on DBT, over two weeks, with a group of four to eight participants in attendance located on the hospital ward where the participant is a patient.
62192858|NCT03673995|EXPERIMENTAL|Myo-inositol+L-tyrosine|One sachet per day containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid for improving PCOS symptoms.
62192859|NCT02816359|OTHER|head-bed position|Head-bed position at 0° for 30 minutes then head-bed position at 30° for 30 minutes
62573145|NCT01519375||1|Patients with Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis, 18 years or older
62007278|NCT03675958|EXPERIMENTAL|GJPS + S|Experimental group: (GJPS + S) : Application Johnstone´s Pressure Splint plus Stretching in in 4 different treatment postures.
62573146|NCT02362802|ACTIVE_COMPARATOR|Antitachycardia Pacing|Implantable cardioverter defibrillator placement with Antitachycardia Pacing. Apart from that usual standard of care.
62007279|NCT03675958|ACTIVE_COMPARATOR|GS|Control group (GS): Just Stretching in 4 different treatment postures.
62007280|NCT05651009|EXPERIMENTAL|Control group|Cementless Triathlon Tritanium 3D printed TKA
62573147|NCT02362802|NO_INTERVENTION|No Antitachycardia Pacing|"Implantable cardioverter defibrillator placement without Antitachycardia Pacing.~Apart from that usual standard of care."
62573148|NCT02129166|PLACEBO_COMPARATOR|Dasatinib|In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
62573149|NCT02129166|ACTIVE_COMPARATOR|Dasatinib+Imatinib|"In this group, subjects will take imatinib prior to dasatinib administration.~Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose"
62573150|NCT02218047|ACTIVE_COMPARATOR|Best available therapy (BAT)|Best available therapy, as chosen by the investigator for patients who had been on HU in the 1 Year PROUD-PV study
62573151|NCT02218047|EXPERIMENTAL|Pegylated-Proline-interferon alpha-2b|AOP2014 for those patients who had been on AOP2014 in the PROUD-PV study
62007281|NCT05651009|EXPERIMENTAL|Study group|GMK Sphere cementless 3D printed TKA
62007282|NCT02268981|EXPERIMENTAL|Oxymizer® compared to CNC|"From 7am to 7pm oxygen saturation is measured by a pulse oximeter. One day with conventional nasal cannula, one day with Oxymizer®, one day with Oxymizer® and reduced Oxygen flow (-1l/min). The order of these days is randomized in 6 groups.~The intervention will be performed on consecutive days and twice during study period."
62007283|NCT03126799|ACTIVE_COMPARATOR|A: Erlotinib only|"Standard therapy arm:~Erlotinib 150mg. po, qd, daily, q 3weeks"
62007284|NCT03126799|EXPERIMENTAL|B: Erlotinib plus Bevacizumab|Study treatment arm; Erlotinib 150mg, po. qd, daily, q 3weeks plus Bevacizumab 15mg/kg, iv, on D1, q 3weeks.
62007285|NCT05353192|EXPERIMENTAL|Recombinant human growth hormone|Recombinant human growth hormone Injection (15IU/5mg/3ml/bottle)；0.05 mg/kg/d by subcutaneous injection for 52 weeks
62007286|NCT01322373||Healthy control subjects (HC)|Subjects who met criteria as healthy control subjects and completed Orasi Protocol ADG-08-01.
62007287|NCT01322373||Alzheimer's disease subjects (AD)|Subjects with a diagnosis of DAT according to DSM-IV-TR criteria who completed Orasi Protocol ADG-08-01.
62573152|NCT02299232|ACTIVE_COMPARATOR|dexmedetomidine 3mcg/kg|dexmedetomidine 3 mcg/kg intranasal 50 minutes before MRI
62573153|NCT02299232|ACTIVE_COMPARATOR|dexmedetomidine 4mcg/kg|dexmedetomidine 4 mcg/kg intranasal 50 minutes before MRI
62007288|NCT06046638|EXPERIMENTAL|Cyclopofol|For patients in the cyclopofol group, cyclopofol will be given as induction of anesthesia (0.4 mg/kg) followed by a continuous infusion (0.8 mg/kg/h) until the end of surgery.
62573154|NCT00669097|EXPERIMENTAL|TKI258|
62573155|NCT00676364|ACTIVE_COMPARATOR|4% lidocaine topical anesthetic cream|This group received topical 4% lidocaine anesthetic cream under occlusive dressing for 15 minutes prior to needle stick.
62573156|NCT00676364|PLACEBO_COMPARATOR|Placebo|This group received matching placebo cream under occlusive dressing for 15 minutes prior to needle stick.
62573157|NCT01470248|EXPERIMENTAL|Arsenic Trioxide Treatment|This is a single arm study. All patients will be treated with the investigational agent, Arsenic Trioxide, according to the dose and schedule indicated in the protocol.
62573158|NCT02694926|OTHER|adrenal insufficiency|
62781530|NCT00604045|PLACEBO_COMPARATOR|2 Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
62781531|NCT04050813|EXPERIMENTAL|Control|"The program is performed 2 times per week using resistance equipment in a physiotherapy clinic. Each session consists of on 2-legged loaded exercises for hamstring, quadriceps, gluteus maximun and core. The patients complete 3 or 4 sets in each exercise with a 2- to 3-minute rest between sets and a 5-minute rest period between the 4 exercises.~The number of repetitions decreases, and load gradually increases, every week. The repetitions and loads are as follows: 3 set of 12-repetition maximum (12RM), in week 1 and 2; 3 set of 10 RM, in week 3 and 4; 4 set of 10RM, in weeks 5 and 6; and 4 set of 8RM, in weeks 7 to 8."
62192860|NCT03151746|PLACEBO_COMPARATOR|Placebo|Placebo pill administered 1 hour before planned surgical procedure
62781532|NCT04050813|EXPERIMENTAL|Intervention|Experimental: Inertial flywheel resistance training The program is performed 2 times per week using resistance equipment in a physiotherapy clinical. Inertial flywheel resistance is a type of strength training; which is based on the increasing demands on eccentric action (breaking) after a concentric action (acceleration), due to the inertial load caused during the return movement. The patients complete 16 repetition maximum (RM) with moment inertia 0.05 m² from week 1-2, 24 repetition maximum (RM) with moment inertia = 0.10 m² from week 3 to 4. 32 repetition maximum (RM) with moment inertia = 0.10 m² from week 5 to 6 and 32 repetition maximum (RM) with moment inertia = 0.13 m² in a flywheel hamstring curl devise.
62781533|NCT03034824|EXPERIMENTAL|Scaling and root planing (SRP)-Control|Only non-surgical initial periodontal treatment (scaling and root planing)
62781534|NCT03034824|EXPERIMENTAL|SRP+940±15 nm diode laser|In addition to non-surgical initial periodontal treatment (scaling and root planing), individuals received 940±15 nm Diode laser
62781535|NCT03034824|EXPERIMENTAL|SRP+Er,Cr:YSGG laser|In addition to non-surgical initial periodontal treatment (scaling and root planing), individuals received Er,Cr:YSGG laser
62781536|NCT03963427|OTHER|Irradiated women|Irradiated women are randomized to reconstruction with a latissimus Dorsi flap and an implant or a deep inferior epigastria perforator flap.
62781537|NCT03963427|OTHER|Non-irradiated women|Non-irradiated women are randomized to reconstruction with a thoracodorsal flap with an implant or with an expander and later a permanent implant in two stages.
62781538|NCT02409771|EXPERIMENTAL|Intervention arm|Bilateral implantation with PRECIZON Presbyopic intraocular lens
62781539|NCT02556060|EXPERIMENTAL|lamotrigine|lamotrigine extended release up to 200 mg/day,
62781540|NCT02556060|PLACEBO_COMPARATOR|Placebo|Identical Placebo
62781541|NCT01840527||Advanced Melanoma|For patients in the advanced melanoma cohort, a one-time blood sample will be obtained prior to the commencement of systemic therapy at a time when standard-of-care blood will be drawn. While it is ideal to obtain samples prior to any systemic therapy, participants who have previously received therapy, have progressed, and are in need of additional therapy will be considered suitable for participation. Participants with known BRAF mutation (determined by standard of care tissue testing) will undergo blood draws every 4 weeks (+/- 1 week) and at the time of disease progression.
62781542|NCT01840527||Stage II/III Melanoma|For patients in the high-risk stage II/III cohort, a blood draw will be performed 4-8 weeks after the completion of surgical management at the time of standard of care blood work. In participants who sign informed consent prior to definite surgical management, a pre-operative blood draw may be obtained at the time that standard of care pre-op blood work is performed. Blood samples will then be obtained every three months following the initiation of either adjuvant therapy or routine, close follow-up for up to two years.
62192861|NCT03151746|EXPERIMENTAL|Gabapentin|Gabapentin pill (1200mg) administered orally 1 hour prior to planned surgical procedure
62192862|NCT02592915|EXPERIMENTAL|Test Group|Patients randomized in the Test Group will receive the clonidine hydrochloride
62781543|NCT05693506|NO_INTERVENTION|Control Group Arm A|Arm A: Usual care in the investigating hospitals + questionnaires on daily eating habits, feeling of self-efficacy, etc.
62781544|NCT05693506|EXPERIMENTAL|Experimental Group Arm B|Arm B: Usual care in the investigating hospitals + Classic cooking workshops (number of 6) + questionnaires on daily eating habits, feeling of self-efficacy, etc.
62781545|NCT05693506|EXPERIMENTAL|Experimental Group C|Arm C: Usual care in the investigating hospitals + Cooking workshops in the form of culinary challenges (number of 6) + questionnaires on daily eating habits, feeling of self-efficacy...
62573159|NCT01168414|ACTIVE_COMPARATOR|Ganfort|Fixed combination of Bimatoprost and Timolol
62007289|NCT06046638|ACTIVE_COMPARATOR|Propofol|For patients in the propofol group, propofol will be given as induction of anesthesia (2 mg/kg) followed by a continuous infusion (5 mg/kg/h) until the end of surgery.
62007290|NCT04614766|EXPERIMENTAL|Combination Therapy|Combined treatment with Lutathera® and Azedra® Administered amounts of each drug are based on imaging and radiation dose constraints to the kidneys and the bone marrow. The drug administration is individualized to each participant.
62573160|NCT01168414|ACTIVE_COMPARATOR|Duotrav|Fixed combination of Travoprost and Timolol
62573161|NCT05434195|NO_INTERVENTION|Normotensive|A sub-cohort of 32 normotensive women will be recruited to establish normal pregnancy values for the measures performed as well as validation of outcome measures.
62573162|NCT05434195|PLACEBO_COMPARATOR|Preeclampsia - Placebo|A sub-cohort of 32 preeclampsia women will be recruited taking the placebo.
62573163|NCT05434195|ACTIVE_COMPARATOR|Preeclampsia - low dosage|A sub-cohort of 32 preeclampsia women will be recruited taking the placebo low dose of 5-MTHF.
62573164|NCT05434195|ACTIVE_COMPARATOR|Preeclampsia - high dosage|A sub-cohort of 32 preeclampsia women will be recruited taking the placebo high dose of 5-MTHF.
62573165|NCT03683225|EXPERIMENTAL|CTC-413|Pramipexole with/with out aprepitant orally once daily
62007291|NCT04614766|ACTIVE_COMPARATOR|Lutathera® only|Single agent Lutathera® administered per standard of care: 200 millicuries of drug every 8 weeks for a total of 4 doses.
62007292|NCT03344185|EXPERIMENTAL|Low GI diet|This diet contained three meals, all with a low GI value. This was the Low Glycaemic Diet intervention.
62007293|NCT03344185|EXPERIMENTAL|High GI diet|This diet contained three meals, all with a high GI value. This was the High Glycaemic Diet intervention.
62007294|NCT02652624|EXPERIMENTAL|B/F/TAF|Participants will switch to B/F/TAF FDC and receive treatment for 48 weeks.
62007295|NCT02652624|ACTIVE_COMPARATOR|Baseline Regimen|Participants will remain on their baseline regimen of E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF for 48 weeks.
62007296|NCT02652624|EXPERIMENTAL|Extension Phase|Following Week 48, participants in countries where B/F/TAF is not available may have the option to receive B/F/TAF for up to 48 additional weeks.
62192863|NCT02592915|PLACEBO_COMPARATOR|Control Group|Patients randomized in the Control Group will receive the Placebo
62192864|NCT02137005||Cerebral Palsy|Patients with cerebral palsy who were seen at the Center for Gait and Movement Analysis (CGMA) at Children's Hospital Colorado as children.
62192865|NCT05104255||Twin neonates|The demographic data and characteristics of the twins were evaluated.
62192866|NCT02444468|EXPERIMENTAL|IPC and bandage|Pneumatic device and bandage
62573166|NCT06565494|EXPERIMENTAL|Participant|midomafetamine (MDMA)-assisted therapy
62573167|NCT03819712|EXPERIMENTAL|No recurrent UTI|Healthy female volunteer aged 18 to 28 years reporting a single cystitis since the age of 14 years
62573168|NCT03819712|EXPERIMENTAL|Recurrent UTI|
62573169|NCT06240936|ACTIVE_COMPARATOR|Active cycle of breathing technique|ACBTs will be applied on the patients. It consist of the following three phases, breathing control,tboracic expension and forced expiration technique.
62573170|NCT06240936|EXPERIMENTAL|Active Cycle of breathing with Acapela|ACBTs will be applied on the patients. It consist of the following three phases, breathing control,tboracic expension and forced expiration technique. The Acapella device is a handheld device used to help loosen mucus in the lungs. Sit up straight and hold the device in the upright position. Take a deep breath in and seal lips around the mouthpiece. Exhaleforcefully through the mouthpiece, using your stomach muscles to push the air out. Repeat this process several times, taking breaks. After using Acapella cough to clear any mucus that has been loosened. Clean the device after each use.
62573171|NCT00719485|EXPERIMENTAL|1|Educational program
62573172|NCT00719485|NO_INTERVENTION|2|Standard care
62573173|NCT05822323|EXPERIMENTAL|Control group (FGG)|The patients in this group only underwent the FGG operation.
62573174|NCT05822323|ACTIVE_COMPARATOR|Study group (FGG+BTX)|The patients in this group received 5 U BTX-A injection into the mental muscle immediately after the FGG operation.
62573175|NCT04557215|ACTIVE_COMPARATOR|Standard dose for IBS-D|Rifaximin 550 mg
62007297|NCT05288205|EXPERIMENTAL|Dose escalation|
62007298|NCT05288205|EXPERIMENTAL|Dose expansion|
62007299|NCT03142503|PLACEBO_COMPARATOR|Placebo|Soybean supplementation
62192867|NCT02444468|ACTIVE_COMPARATOR|Bandage only|Bandage only
62192868|NCT00703183|EXPERIMENTAL|1|ACU-4429
62192869|NCT00703183|PLACEBO_COMPARATOR|2|matching placebo
62192870|NCT04527185|EXPERIMENTAL|Endotoxin|Endotoxin (0.4ng/kg i.v.) will be administered one time during the laboratory session.
62192871|NCT04527185|PLACEBO_COMPARATOR|Placebo|Administered one time during the laboratory session.
62398124|NCT05718921|PLACEBO_COMPARATOR|Part B, Placebo and High body surface area|The intervention is Placebo on high body surface area twice daily, Placebo for multiple topical administration
62573176|NCT04557215|PLACEBO_COMPARATOR|Traveler's diarrhea dose + placebo|Rifaximin 200 mg + placebo
62781546|NCT04886791|EXPERIMENTAL|VANH hysterectomy|Access to the peritoneal cavity will be performed similar to vaginal surgery by a circular incision around the cervix, anterior and posterior colpotomy and transsecting the sacro-uterine ligaments. The vNOTES port will be placed to get access to the abdominal cavity and a pneumoperitoneum will be created. After positioning in 20o degree Trendelenburg laparoscopic instruments will be introduced. The peritoneal cavity and ureters are inspected. The hysterectomy is performed by dissecting from caudally to cranially. The fallopian tubes will be removed elective after counselling in the outpatient clinic and the ovaries will be removed on indication only. Haemostasis is checked and the vNOTES port and the uterus are removed trans-vaginally and the pneumoperitoneum is deflated. The vaginal cuff will be closed using a running Vicryl-1 suture. The urinary bladder catheter will be removed directly postoperative.
62007300|NCT03142503|ACTIVE_COMPARATOR|Diet + placebo|Soybean supplementation and diet intervention
62007301|NCT03142503|EXPERIMENTAL|Diet + Supplementation|Omega 3 and diet intervention
62007302|NCT04409028|ACTIVE_COMPARATOR|indirect restoration|
62192872|NCT03751670|EXPERIMENTAL|PR+conventional treatment|Patients will be treated with daily medication prescribed by the physician. Additionally, patients will receive 6 sessions (2 times a week during 3 weeks) of Pulmonary Rehabilitation (PR). PR will include breathing retraining and airway clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training, education and psychosocial support.
62007303|NCT04409028|ACTIVE_COMPARATOR|direct restoration|
62398125|NCT02662959|EXPERIMENTAL|Irinotecan|In the experimental arm, patients receive single agent of irinotecan as third line treatment in metastatic gastric cancer.
62398126|NCT04057651||Hip osteoarthritis waiting for surgery|
62398127|NCT04057651||Knee osteoarthritis waiting for surgery|
62398128|NCT05142462||EUROSCUP Fixe|120 patients who received EUROSCUP Fixe
62573177|NCT04557215|EXPERIMENTAL|Traveler's diarrhea dose + NAC|Rifaximin 200 mg plus N-acetylcysteine (NAC) 600 mg days
62573178|NCT05540847|ACTIVE_COMPARATOR|Ultrasound guided interfascial obturator nerve block|In supine position, ultrasound probe will be placed on inguinal region, 2-3 cm below to the inguinal crease. Patients in this group will receive interfascial obturator nerve block under ultrasound guidance.
62573179|NCT05540847|EXPERIMENTAL|Ultrasound guided subpectineal obturator nerve block|In supine position, the ultrasound probe will be placed on in inguinal region, 1-2 cm below to the inguinal crease to identiy the subpectineal area. Patients in this group will receive subpectineal obturator nerve block under ultrasound guidance.
62573180|NCT05944497||ISBPB group|Interscalene brachial plexus block involving the C5 to C8 nerve roots
62573181|NCT01130441||self-harming group|
62781547|NCT04886791|ACTIVE_COMPARATOR|Vaginal hysterectomy|A circumferential incision is made around the cervix. Access to the peritoneal cavity will be performed through anterior and posterior colpotomy. The sacro-uterine ligaments, ligamenta cardinalia uterine arteries will be clamped and dissected. Finally, the ovarian ligament, round ligament and fallopian tubes will be dissected and tied. The uterus will be removed and the vagina will be closed. The urinary bladder catheter will be removed directly postoperative.
62573182|NCT01130441||non-self-harming group -control group|
62573183|NCT01519219||Hepatic Irradiation|
62007304|NCT02138851|EXPERIMENTAL|Ficus Carica|Ficus Carica 300g/day
62007305|NCT02138851|PLACEBO_COMPARATOR|Placebo|Placebo 300g/day
62007306|NCT04230642|EXPERIMENTAL|Robotic device|Needle placement to the tumor, one time, the day of the ablation procedure
62007307|NCT02248129||Hypertensive patients|
62007308|NCT04828655|NO_INTERVENTION|CONTROL GROUP|Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity. Specific micronutrient intake focused on improving cardiovascular parameters and body composition.
62781548|NCT00428389|EXPERIMENTAL|Immediate Switch|Patients randomized to the immediate switch group continued treatment with donepezil through the evening prior to Day 8 of the study. On Day 8, all patients began open-label treatment with 5 cm\^2 rivastigmine patch formulation. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm\^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm\^2 patch and continued on their best tolerated dose for the remainder of the study.
62007309|NCT04828655|EXPERIMENTAL|EXPERIMENTAL GROUP|Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity through an application based on machine learning. Intake of specific micronutrients focused on improving cardiovascular parameters and body composition.
62007310|NCT04471584|ACTIVE_COMPARATOR|Abbott Confirm Rx|All patients randomized to this group will be implanted Abbott Confirm RX
62573184|NCT03416426||patients undergone PFO closure|patients with ischemic stroke and PFO documented by bubble contrast TEE with no other identifiable cause of the ischemic event who undergone PFO closure using Amplatzer® PFO occluder or Gore® Septal Occluder
62007311|NCT04471584|ACTIVE_COMPARATOR|Medtronic Reveal LINQ|All patients randomized to this group will be implanted Medtronic Reveal LINQ
62007312|NCT04471584|ACTIVE_COMPARATOR|Biotronik Biomonitor|All patients randomized to this group will be implanted Biotronik Biomonitor
62573185|NCT04631601|EXPERIMENTAL|Acapatamab and Enzalutamide: Dose Exploration|The dose-exploration part of the study will estimate the MTD/recommended phase 2 dose (RP2D) of Acapatamab in combination with enzalutamide.
62573186|NCT04631601|EXPERIMENTAL|Acapatamab and Enzalutamide: Dose Expansion|Following dose exploration, dose expansion will be conducted to confirm the safety and tolerability of the selected dose and to further evaluate the efficacy of Acapatamab in combination with enzalutamide.
62573187|NCT04631601|EXPERIMENTAL|Acapatamab and Abiraterone: Dose Exploration|The dose exploration part of the study will estimate the MTD/recommended phase 2 dose (RP2D) of Acapatamab in combination with abiraterone.
62573188|NCT04631601|EXPERIMENTAL|Acapatamab and Abiraterone: Dose Expansion|Following dose exploration, dose expansion will be conducted to confirm the safety and tolerability of the selected dose and to further evaluate the efficacy of Acapatamab in combination with abiraterone.
62007313|NCT06437405|EXPERIMENTAL|Liquid vinegar|2 tablespoons of liquid apple cider vinegar (5% acidity) diluted in one cup of water twice daily with meals providing 1.5g acetic acid.
62007314|NCT06437405|PLACEBO_COMPARATOR|Vinegar pill|one apple cider vinegar tablet (0.022g acetic acid) daily.
62007315|NCT04926675|EXPERIMENTAL|Combined intervention|Participants accessing one-to-one psychological therapy from the IAPT service will be asked if they have any money worries affecting their mental health. Suitable participants will be offered one-to-one support from a money advisor, who they will access in tandem to their therapy.
62007316|NCT05605067||Cases|Participants will self-select into the study. All enrolled will meet study specific criteria and be considered cases.
62007317|NCT03863366|EXPERIMENTAL|Prucalopride|1mg prucalopride capsule
62398129|NCT06723795|EXPERIMENTAL|Intervention|Patients will be evaluated by a pulmonologist during their admission, in addition to a cardiologist, aiming to identify cardiovascular comorbidities including dyslipidemia, diabetes, hypertension, ischemic heart disease, heart failure, valvular disease, personal or family history of ischemic heart disease, and smoking. Part of the evaluation will include assessing the management of diagnosed cardiovascular conditions. Finally, recommendations for further investigation or initiation of drug treatment will be made.
62398130|NCT06723795|ACTIVE_COMPARATOR|Control|Patients will be evaluated by a pulmonologist during their hospitalization, who will focus on their pulmonary condition, optimize basic treatment, and recommend continued follow-up as needed.
62781549|NCT00428389|EXPERIMENTAL|Delayed Switch|Patients randomized to the delayed switch group were switched to 5 cm\^2 rivastigmine patch formulation on Day 8, following a 7-day withdrawal period from donepezil. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm\^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm\^2 patch and continued on their best tolerated dose for the remainder of the study.
62573189|NCT04631601|EXPERIMENTAL|Acapatamab and AMG 404: Dose Exploration|The dose-exploration part of the study will estimate the MTD/RP2D of Acapatamab in combination with AMG 404.
62573190|NCT04631601|EXPERIMENTAL|Acapatamab and AMG 404: Dose Expansion|Following dose exploration, dose expansion will be conducted to confirm the safety and tolerability of the selected dose and to further evaluate the efficacy of Acapatamab in combination with AMG 404.
62781550|NCT03900273|EXPERIMENTAL|Novel measures of cognition and everyday function|"No Practice Effects (NPE) cognitive battery~Miami Computerized Functional Assessment Scale (CFAS)~Participants will receive three serial assessments of the NPE and CFAS over a one year period. Assessments will take place at baseline, week 12, and week 52."
62781551|NCT03900273|ACTIVE_COMPARATOR|Established measures of cognition and everyday function|"Preclinical Alzheimer's Cognitive Composite (PACC)~Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)~Functional Assessment Questionnaire (FAQ).~Participants will receive three serial assessments of the PACC, ADAS-Cog and FAQ over a one year period.~Assessments will take place at baseline, week 12, and week 52."
62781552|NCT04510103|OTHER|Regression Group|The Regression Group received the two test moisturizers to use split-leg (right vs. left lower leg randomized) for 6 weeks and then entered a 2-week regression period (no moisturizer usage).
62007318|NCT03863366|PLACEBO_COMPARATOR|Placebo|Lactose placebo capsule
62007319|NCT03777189|EXPERIMENTAL|Cognitive-Behavioral Therapy|Cognitive-behavioral therapy will be delivered in line with recommendations (e.g., NICE 2017). Format will be guided self help with added content related to physical activity.
62007320|NCT05829603|EXPERIMENTAL|Sequence A|Six varying doses of a fixed-combination of Dimethyltryptamin (DMT) and harmine
62398131|NCT06260995||Social Prescribing|Participants are those who are referred or self-referred to a social prescribing link worker for any reason and who undergo an intervention delivered by an intermediary i.e., undergo assessment, follow-up, and onward connection to local physical activities.
62398132|NCT06260995||Local Sports Partnership|Participants are those who are referred or self-referred to a local sports partnership community development officer for any reason and who undergo an intervention delivered by an intermediary i.e., undergo assessment, follow-up, and onward connection to local physical activities.
62398133|NCT06111963||Septic patients|
62573191|NCT04631601|ACTIVE_COMPARATOR|AMG 404 Monotherapy|AMG 404 monotherapy is being conducted to evaluate the preliminary anti-tumor activity of PD-1 inhibition in the mCRPC population.
62007321|NCT05829603|EXPERIMENTAL|Sequence B|Six varying doses of a fixed-combination of Dimethyltryptamin (DMT) and harmine
62007322|NCT02359292|EXPERIMENTAL|CHF 5993 HS 200/6/25 pMDI|High Strength fixed combination
62007323|NCT02359292|ACTIVE_COMPARATOR|CHF 5993 MS 100/6/25 pMDI|Medium Strength fixed combination
62398134|NCT06111963||Non Septic patients|
62007324|NCT02359292|EXPERIMENTAL|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|High Strength fixed combination plus Charcoal Block
62573192|NCT04631601|EXPERIMENTAL|Acapatamab and Enzalutamide: Dose Expansion Asia Cohort|Following dose exploration, dose expansion will be conducted in the Asia cohort at the combination MTD/RP2D determined in dose exploration to confirm the safety, tolerability and PK of Acapatamab in combination with enzalutamide for subjects in Asia.
62007325|NCT02359292|ACTIVE_COMPARATOR|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|Medium Strength fixed combination plus Charcoal Block
62007326|NCT02359292|PLACEBO_COMPARATOR|Placebo pMDI|Placebo
62007327|NCT03026673||NSAID use|The purpose of this study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
62007328|NCT02309385|EXPERIMENTAL|8% DSP-Visulex|8% dexamethasone sodium phosphate - Visulex (DSP- Visulex) and placebo eye drops in the affected eye.
62007329|NCT02309385|EXPERIMENTAL|15% DSP-Visulex|15% dexamethasone sodium phosphate - Visulex (DSP- Visulex) and placebo eye drops in the affected eye.
62007330|NCT02309385|ACTIVE_COMPARATOR|Pred Forte|Prednisolone acetate (1%) eye drops and vehicle - Visulex in the affected eye.
62007331|NCT00414050|EXPERIMENTAL|Modified Process Hepatitis B vaccine 5 μg|Infants received a primary series of 3 doses of experimental vaccine (5 μg per dose) at 2, 4 and 6 months of age.
62007332|NCT00414050|ACTIVE_COMPARATOR|RECOMBIVAX HB™ Hepatitis B Vaccine|Infants received a primary series of 3 doses of currently licensed vaccine (5 μg per dose) at 2, 4 and 6 months of age.
62573193|NCT04631601|EXPERIMENTAL|Acapatamab and Abiraterone: Dose Expansion Asia Cohort|Following dose exploration, dose expansion will be conducted in the Asia cohort at the combination MTD/RP2D determined in dose exploration to confirm the safety, tolerability and PK of Acapatamab in combination with abiraterone for subjects in Asia.
62573194|NCT04631601|EXPERIMENTAL|Acapatamab and AMG 404: Dose Expansion Asia Cohort|Following dose exploration, dose expansion will be conducted in the Asia cohort at the combination MTD/RP2D determined in dose exploration to confirm the safety, tolerability and PK of Acapatamab in combination with AMG 404 for subjects in Asia.
62781553|NCT04510103|OTHER|Non-Regression Group|The Non-Regression Group received the two test moisturizers to use split-leg (right vs. left lower leg randomized) for 6 weeks and then underwent a physical insult (tape stripping) on the lower legs and continued using the moisturizer for 4 additional days.
62007333|NCT00414050|EXPERIMENTAL|Modified Process Hepatitis B vaccine 10 μg|Infants received a primary series of 3 doses of experimental vaccine (10 μg per dose) at 2, 4 and 6 months of age.
62007334|NCT00414050|ACTIVE_COMPARATOR|ENGERIX-B®|Infants received a primary series of 3 doses of currently licensed vaccine (10 μg per dose) at 2, 4 and 6 months of age.
62007335|NCT02505243||HCV patients|HCV patients treated with direct acting antivirals and ribavirin
62007336|NCT06203405|EXPERIMENTAL|Titrating sedation targeting both optimal P0.1 and appropriate arousal level|• Sedative drug adjustment to achieve the target of light sedation (RASS 0 to -2) and optimal respiratory drive measured by P0.1 of 1.5 - 3.5 cmH2O
62781554|NCT01246336||Patients with parkinsonism|Patients suffering from Parkinson's disease or parkinsonism
62781555|NCT01246336||Healthy controls|Patients not suffering from Parkinson's disease or any other neurological disorder
62007337|NCT06203405|NO_INTERVENTION|Titrating sedation targeting appropriate arousal level alone|• Sedative drug adjustment to achieve the target of light sedation (RASS 0 to -2) according to the standard clinical practice guidelines for managing pain and agitation for patients receiving mechanical ventilation in the ICU.
62007338|NCT04251533|EXPERIMENTAL|Part A: alpelisib + nab-paclitaxel|Participants received alpelisib 300 mg orally + nab-paclitaxel 100 mg/m\^2 intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle
62007339|NCT04251533|PLACEBO_COMPARATOR|Part A: placebo + nab-paclitaxel|Participants received placebo + nab-paclitaxel 100 mg/m\^2 IV on Days 1, 8, and 15 of each 28-day cycle.
62007340|NCT04251533|EXPERIMENTAL|Part B1: alpelisib + nab-paclitaxel|Participants received alpelisib 300 mg orally + nab-paclitaxel 100 mg/m\^2 IV on Days 1, 8, and 15 of each 28-day cycle.
62007341|NCT04214028||Maviret Participants|Participants receiving glecaprevir plus pibrentasvir (GLE/PIB, other names: Maviret) as routine standard of care for HCV.
62007342|NCT05676034|EXPERIMENTAL|AMX0035|AMX0035 administered by mouth for 96 weeks: Once daily for first 3 weeks and then twice daily for the remainder of the study if tolerated by participant
62007343|NCT05784701|ACTIVE_COMPARATOR|TSCV (Full-strength)|Full-strength GMP formulation of Trivalent Salmonella Conjugate Vaccine (TSCV)
62007344|NCT05784701|ACTIVE_COMPARATOR|TSCV (Half-strength)|Half-strength GMP formulation of TSCV
62007345|NCT05784701|ACTIVE_COMPARATOR|Typbar-TCV|Licensed Monovalent Typbar-TCV
62007346|NCT05784701|PLACEBO_COMPARATOR|Placebo|PBS
62007347|NCT03620851||elderly patients (≥70 yo) vs. younger patients (<70 yo)|elderly patients (≥ 70 yo) and younger patients (\< 70 yo)
62007348|NCT04863976|EXPERIMENTAL|Dynamic stretching|
62007349|NCT04863976|ACTIVE_COMPARATOR|Passive stretching|
62007350|NCT04863976|ACTIVE_COMPARATOR|Self-stretching|
62007351|NCT00983814|EXPERIMENTAL|Droxidopa+Carbidopa Open-Label|3 weeks of open label droxidopa (200, 400, or 600 milligrams \[mg\] three times daily \[TID\]) monotherapy followed by 3 weeks of droxidopa in combination with carbidopa (25 mg or 50 mg TID).
62007352|NCT00983814|PLACEBO_COMPARATOR|Placebo Randomized Period|2 week double-blind period in which participants either continued to receive droxidopa+carbidopa treatment or placebo
62007353|NCT03228810||Men >18 years old with metastatic prostate cancer|
62007354|NCT05848635|EXPERIMENTAL|Experimental: Lung tumor ablation using hydromorphone for pain control and anaesthesia|"Premedication:hydromorphone is started 15min before surgery with a single subcutaneous injection of 2mg.~Intraoperative administration:NRS（Numeric Rating Scale）≥7 during operation, 2mg hydromorphone is injected intravenously and slowly pushed for 2-3 minutes.~Postoperative administration:The drug is administered as needed according to the patient's postoperative pain, 2mg/time."
62192873|NCT03751670|ACTIVE_COMPARATOR|Conventional treatment|Patients will be treated with daily medication prescribed by the physician.
62192874|NCT02701062|OTHER|LAA Exclusion with AtriClip®|LAA Exclusion with AtriClip®: AtriClip® is used per label and is not experimental.
62573195|NCT04631601|EXPERIMENTAL|Acapatamab Monotherapy|Acapatamab monotherapy is being conducted to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and efficacy of Acapatamab in subjects with mCRPC.
62192875|NCT02701062|ACTIVE_COMPARATOR|Medical Management|Medical Management: Standard of Care Oral Anticoagulation Therapy at the discretion of the Investigator.
62192876|NCT02939846|EXPERIMENTAL|Trametinib|Subjects will be administrated with trametinib 2 mg once daily until disease progression.
62781556|NCT01700153|EXPERIMENTAL|Experimental: Robotic-assisted therapy|All patients will receive a similar classical rehabilitation as a basis. the 10 patients of this group will receive a supplement of robotic-assisted therapy.
62781557|NCT01700153|ACTIVE_COMPARATOR|Classical therapy|All patients will receive a similar classical rehabilitation as a basis. the 10 patients of this group will receive a supplement of classical rehabilitation.
62781558|NCT05096949|NO_INTERVENTION|Clinic visit arm|Patient will receive Cabenuva injection at the clinic
62781559|NCT05096949|EXPERIMENTAL|Home visit arm|Patient will receive Cabenuva injection at home
62781560|NCT06583356|EXPERIMENTAL|Motivational interviewing|Will receive motivational interviewing intervention previously, delivered face-to-face at participants' home, 1 session, followed by 2 brief follow-up sessions. Each session is expected to last approximately 30 to 45 minutes.
62781561|NCT01506284||Anesthetized patients ASA I-II|ASA classification I-II, scheduled for elective surgery requiring general anesthesia.
62781562|NCT05485623|EXPERIMENTAL|clinician guided scan comparing the device output to the in clinic scan (ground truth)|"Naïve subjects who haven't use the FC device will be allocated to use the CG-mode~The patient will perform a CG scan, guided by a professional sonographer on a Pulsenmore telehealth platform, who will instruct the patient during the exam. At visit 1: the procedure will be performed in a private room in the clinic, while the clinician will be in a different room than the patient. At visit 2 and all other visits, until the last visit, FC scans will be done from home. The clinician will guide the patient using a standardized language which was practiced and used during the clinician training. By the end of the scan, the patient will transmit the videos to the cloud. Then the clinician will review the video scans for visualization of ovaries and uterus, identifying the number and size of ovarian follicles, endometrial thickness and additional parameters"
62781563|NCT05485623|EXPERIMENTAL|App guided scan comparing the device output to the in clinic scan (ground truth)|"Experienced patients who already used the FC device will be offered to use the AG node for a second cycle.~The patient will perform self - administered vaginal sonography using the study device and assisted by videos on Pulsenmore app. The procedure will be performed at home, in the morning before the patient come to the clinic for the conventional US and tests. All scans are automatically uploaded to the Pulsenmore web-viewer. A qualified reviewer will review the videos for visualization of ovaries and uterus, identify the number and size of ovarian follicles, and measure endometrial thickness. Other parameters might be evaluated as well. The App guided scan is limited to 4 minutes and the session will be deactivated by the end of the scanning time."
62781564|NCT03777319|EXPERIMENTAL|Spironolactone|An anticipated twelve subjects will be prescribed a standard clinical dose of spironolactone of 1 mg/kg/day. The spironolactone will be provided as suspension.
62781565|NCT03777319|ACTIVE_COMPARATOR|Prednisolone|An anticipated twelve subjects will be prescribed a standard clinical dose of prednisolone of 0.75 mg/kg/day or weekend dosing per sites standard of care. The prednisolone will be provided will be provided as suspension.
62781566|NCT05198843|EXPERIMENTAL|Treatment (icosapent ethyl, dasatinib)|Patients receive icosapent ethyl PO BID and dasatinib PO QD in each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62781567|NCT05804032|ACTIVE_COMPARATOR|Arm A - Intravenous isatuximab|Patients in arm A are treated with 3 cycles RVd + i.v. isatuximab, followed by a standard intensification and autologous stem cell transplantation.
62781568|NCT05804032|EXPERIMENTAL|Arm B - Subcutaneous isatuximab|Patients in arm B are treated with 3 cycles RVd + s.c. isatuximab, followed by a standard intensification and autologous stem cell transplantation.
62781569|NCT02812927|OTHER|Standard infusion line|The standard insulin infusion system consisted in regular human insulin administration through a six-stopcock manifold connected to the distal line of a multilumen central venous catheter by 150 cm tubing. Insulin was systematically infused by syringe pump on the patient proximal port of the manifold. Carrier was infused via pump through the manifold. All others medicines were infused through the other five stopcocks.
62781570|NCT02812927|EXPERIMENTAL|Optimised infusion line|The optimised insulin infusion system consisted in regular human insulin administration through a multilumen device (Edelvaiss Multiline-8, Doran International, Toussieu, France). This device had ports for eight infusions which run through separate channels within a 150 cm flexible plastic tube. Since fluids from the individual channels do not meet until they exit the distal tip. Carrier was infused through the high flow (HF) line and insulin was infused by syringe pump systematically next to the HF line port. All others medicines were administered via adjacent ports on the Multiline-8.
62781571|NCT04046978|EXPERIMENTAL|Group F|Mos3.1 100 ug at Month 0 Mos3.2 100 ug at Month 2 Mos3.3 100 ug at Month 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
62781572|NCT04046978|EXPERIMENTAL|Group G|Mos3.2 100 ug at Month 0 Mos3.1 100 ug at Month 2 Mos3.3 100 ug at Month 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
62781573|NCT04046978|EXPERIMENTAL|Group H|Mos3.3 100 ug at Month 0 Mos3.2 100 ug at Month 2 Mos3.1 100 ug at Month 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
62781574|NCT04046978|EXPERIMENTAL|Group I|Mos3.1 33 ug, Mos3.2 33 ug and Mos3.3 33 ug at Months 0, 2 and 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
62781575|NCT04720092|EXPERIMENTAL|Treatment A-B|Subjects received a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A) during intervention period 1; and then a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B) during intervention period 2. A wash-out of at least 7 days was maintained between the treatments.
62192877|NCT06016218|PLACEBO_COMPARATOR|PRF|PRF alone was added to extraction site prior to implant insertion
62192878|NCT06016218|ACTIVE_COMPARATOR|SIM+ PRF|PRF + 1.2mg Statin powder are inserted into the extraction site before implant insertion
62192879|NCT06016218|ACTIVE_COMPARATOR|BO+ PRF|PRF + Bone powder are inserted into the extraction site before implant insertion.
62192880|NCT04978090|EXPERIMENTAL|Enteroatmospheric fistula (EAF) management solution|Participants will receive a custom fitted device designed to isolate EAF effluent independent of negative pressure wound therapy (NPWT) utilizing 3D printing technology to design a participant-matched device that more easily and effectively separates the participant's fistula and any emanated intestinal contents surrounding the wound.
62007355|NCT05848635|ACTIVE_COMPARATOR|Active Comparator:Lung tumor ablation using morphine for pain control and anaesthesia|"Premedication:morphine is started 15min before surgery with a single subcutaneous injection of 10mg.~Intraoperative administration:NRS（Numeric Rating Scale）≥7 during operation, 10mg morphine is injected intravenously and slowly pushed for 2-3 minutes.~Postoperative administration:The drug is administered as needed according to the patient's postoperative pain, 10mg/time."
62007356|NCT04917302|EXPERIMENTAL|NMDAE plus Anti-inflammatory Agent (AIFA)|An NMDA enhancer plus a drug with anti-inflammatory property
62573196|NCT01961739|EXPERIMENTAL|2% lidocaine|topical application, two times per day for 15 consecutive days
62192881|NCT02552017|ACTIVE_COMPARATOR|Endocuff Vision-assisted Colonoscopy|Participants in this arm undergo Endocuff Vision-assisted colonoscopy
62192882|NCT02552017|NO_INTERVENTION|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy
62192883|NCT03908892|EXPERIMENTAL|Combination group|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day, plus local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day, till paronychia relief or progression.
62192884|NCT03908892|ACTIVE_COMPARATOR|Control group|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day, till paronychia relief or progression.
62192885|NCT02294851|EXPERIMENTAL|Single Ascending dose cohorts|Single ascending dose escalation, safety, tolerability, PK, PD and immunogenicity study of BMS-986168 administered by an intravenous infusion in healthy subjects.
62573197|NCT01961739|PLACEBO_COMPARATOR|placebo|vaseline base applied topically, two times per day for 15 consecutive days
62192886|NCT02294851|PLACEBO_COMPARATOR|Placebo|BMS-986168 Placebo
62781576|NCT04720092|EXPERIMENTAL|Treatment B-A|Subjects received a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B) during intervention period 1; and then a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A) during intervention period 2. A wash-out of at least 7 days was maintained between the treatments.
62781577|NCT01870310|NO_INTERVENTION|Standard medical therapy|
62781578|NCT01870310|EXPERIMENTAL|Renal denervation + standard medical therapy|Patients in this arm will undergo catheterised renal denervation in addition to having optimization of medical therapy for heart failure.
62781579|NCT02211456|EXPERIMENTAL|Participants|Having an ablation procedure with access to the left side of the heart
62781580|NCT05407779|EXPERIMENTAL|Cohort 1|"The Cohort 1 include one subject (sentinel volunteer) to receive BCD-180 at a dose 1"
62007357|NCT04917302|PLACEBO_COMPARATOR|NMDAE plus Placebo|An NMDA enhancer plus Placebo
62007358|NCT03101709|EXPERIMENTAL|CART-19|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CART-19 cells. The CART-19 cells are to be administered on day0,day1,day2.
62007359|NCT05244031|ACTIVE_COMPARATOR|Superficial ESP|The investigators performed superficial erector spina plane block to that patient group for postoperative analgesia
62192887|NCT04253847|EXPERIMENTAL|RAMPS group|"Radical antegrade modular pancreatosplenectomy (RAMPS) includes the following aspects. Firstly, the surgical approach is antegrade, which means from the right to the left, the pancreatic neck will be transected at first and the spleen will be seperated at last. Secondly, lymph nodes dissection includes not only the regional lymph nodes(No.10,11,18 lymph nodes), but also N1 station lymph nodes (N1: 6, 8a, 8p, 12a2/b2/p2, 13a/b, 14b/c/d, 14v, 17a/b), No.7, 9 lymph nodes, the lymph nodes anterior and left of superior mesenteric artery, as well as the peripheral nerve of celiac trunk. Thirdly, the transection platform is in the pancreatic neck, which is mandatory. At last, left prerenal fascia will be resected. When the tumor abuts or infiltrates the left adrenal gland, left adrenalectomy will be performed, which is also called posterior approach RAMPS. While in normal cases, left adrenal gland will be preserved."
62192888|NCT04253847|ACTIVE_COMPARATOR|SRPS group|"Standard retrograde pancreatosplenectomy(SRPS) includes several key points. Firstly, the surgical approach is retrograde, which means from the left to the right, spleen will be seperated at first and the pancreas will be transected later on. Secondly, only the regional lymph nodes will be dissected, which include No.10, No.11, No.18 lymph nodes, and No.9 lymph nodes should be dissected only when the lesion is in pancreatic neck. Thirdly, the transection platform is in the left side of the lesion, but transection at pancreatic neck is not mandatory. At last, the surgical plane is anterior to the left renal fascia, prerenal fascia will be preserved."
62398135|NCT06724692|ACTIVE_COMPARATOR|Ultra-processed breakfast|During one study phase, subjects receive an ultra-processed breakfast
62398136|NCT06724692|ACTIVE_COMPARATOR|Low-processed breakfast|During the other study phase, subjects receive a low-processed breakfast
62398137|NCT02148042||Anorexics|
62398138|NCT02148042||Controls|
62398139|NCT05805306|EXPERIMENTAL|PrEP Promotion|
62573198|NCT02644993|EXPERIMENTAL|Proton beam therapy|
62573199|NCT02915705|EXPERIMENTAL|Burosumab|Burosumab 0.8 mg/kg starting dose, administered Q2W by SC injection during the Treatment Period (up to Week 64). During the Treatment Extension Period (Week 64 to Week 140), participants continued to receive a starting dose of SC burosumab 0.8 mg/kg Q2W. Participants in Japan and Korea did not enter the Treatment Extension Period.
62573200|NCT02915705|ACTIVE_COMPARATOR|Active Control|Multiple daily doses of oral phosphate and one or more daily doses of active vitamin D therapy, titrated and individualized by the investigator based on published recommendations during the Treatment Period (up to Week 64). During the Treatment Extension Period (Week 64 to Week 140), participants crossed over to receive a starting dose of SC burosumab 0.8 mg/kg Q2W. Participants in Japan and Korea did not enter the Treatment Extension Period.
62573201|NCT04867122|PLACEBO_COMPARATOR|Attention Control|"Family caregivers in the attention control study arm will receive three sessions of attention-matched control in addition to the services and support provided as part of usual outpatient palliative care. Attention-matched control will consist of three friendly visits with a trained research staff person."
62781581|NCT05407779|EXPERIMENTAL|Cohort 2|The Cohort 2 include 3 subjects to receive BCD-180 at a dose 2
62781582|NCT05407779|EXPERIMENTAL|Cohort 3|The Cohort 3 include 3 subjects to receive BCD-180 at a dose 3
62781583|NCT05407779|EXPERIMENTAL|Cohort 4|The Cohort 4 include 3 subjects to receive BCD-180 at a dose 4
62781584|NCT05407779|EXPERIMENTAL|Cohort 5|The Cohort 5 include 3 subjects to receive BCD-180 at a dose 5
62781585|NCT05407779|EXPERIMENTAL|Cohort 6|The Cohort 6 include 3 subjects to receive BCD-180 at a dose 6
62192889|NCT05331469|ACTIVE_COMPARATOR|Daily basal insulin titration|Participants in this intervention arm will be started with basal insulin of 10 units or 0.2 unit/kg (whichever lower) at pre-bed time. They will then check their morning fasting CBG the following day. If they have no hypoglycemia symptoms or documented hypoglycemic CBG (\<3.9mmol/L), and their fasting CBG is more than 7mmol/L, they will then self-titrate their basal insulin by 1 unit (ie 10+1) the following night. This same process is going to be repeated until their fasting CBG achieve 7mmol/L or lower. Then, they will continue and maintain on the desired basal insulin dosage till their appointment. The maximum basal insulin that is allowed to be titrated by the participants is up to 0.5unit/kg. Participants are required to document down their CBG and any hypoglycemia symptoms in a simple table method provided to them
62192890|NCT05331469|ACTIVE_COMPARATOR|3 daily basal insulin titration|Participants in this intervention arm will be started with basal insulin of 10 units or 0.2 unit/kg (whichever lower) at pre-bed time. They will then check their morning fasting CBG the following 3 days. If they have no hypoglycemia symptoms or documented hypoglycemic CBG (\<3.9mmol/L), and their fasting CBG is more than 7mmol/L (for 2 out of 3 days), they will then self-titrate their basal insulin by 2 units (ie 10+2) on the 3rd night. This same process is going to be repeated until their fasting CBG achieved 7mmol/L or lower. Then, they will continue and maintain on the desired basal insulin dosage till their appointment. The maximum basal insulin that is allowed to be titrated by the participants is up to 0.5unit/kg. Participants are required to document down their CBG and any hypoglycemia symptoms in a simple table method provided to them.
62192891|NCT00098527|EXPERIMENTAL|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62192892|NCT05688553|EXPERIMENTAL|Flexi-bar group|
62192893|NCT05688553|ACTIVE_COMPARATOR|balance and strength group|
62192894|NCT01580904|NO_INTERVENTION|control group|Patients will not be followed by the pharmacist.
62192895|NCT01580904|EXPERIMENTAL|Intervention group|"Patients will be followed by the pharmacist by Pharmacotherapeutic monitoring and dosing parameters such as glucose and glycated hemoglobin.~Intervention: Pharmaceutical Care"
62192896|NCT00405938|EXPERIMENTAL|Bevacizumab/anastrozole|Bevacizumab 10mg/kg IV every 2 weeks \[patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)\] and anastrozole (1 mg orally daily). Treatment will be given in 4-week cycles.
62192897|NCT00405938|EXPERIMENTAL|Bevacizumab/fulvestrant|Bevacizumab/fulvestrant (with trastuzumab in HER2+ patients). Bevacizumab 10mg/kg IV every 2 weeks \[patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)\] fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant). Treatment will be given in 4-week cycles.
62398140|NCT05805306|PLACEBO_COMPARATOR|Vaccine Promotion|
62398141|NCT05003765|NO_INTERVENTION|Saline injection (CTRL)|Arm 1- 50 Patients-Control Group (CTRL): No Block (Saline) Post-operatively patients will receive 20 mL of Saline (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
62398142|NCT05003765|EXPERIMENTAL|SPIP Block|Arm 2-50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
62573202|NCT04867122|EXPERIMENTAL|Problem Solving Therapy Intervention|Family caregivers in the intervention study arm will participate in three problem-solving therapy sessions with a trained interventionist in addition to receiving the services and support provided as part of usual outpatient palliative care.
62192898|NCT01263509|EXPERIMENTAL|Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID|
62192899|NCT01263509|EXPERIMENTAL|Alogliptin 25 mg QD and Voglibose 0.2 mg TID|
62192900|NCT04375553|ACTIVE_COMPARATOR|Exercise group|Intradialytic aerobic exercise, 3 times a week, for 12 weeks.
62192901|NCT04375553|NO_INTERVENTION|Non-exercise group|Without intradialytic aerobic exercise for 12 weeks.
62192902|NCT03132506||paper-based patient-reported-outcomes|
62192903|NCT03132506||on web-based patient-reported-outcomes|
62192904|NCT03585088|OTHER|SPI Group|All patients who received the liver resection surgery will receive surgical pleth index
62192905|NCT02039895|EXPERIMENTAL|HITS for CTCL|Cutaneous T-cell lymphoma treats by helical irradiation of the total skin (HITS) using helical tomotherapy
62192906|NCT02838134|EXPERIMENTAL|Group A: Deep Neuromuscular blockade|An extra bolus of rocuronium after intubation followed by infusion
62192907|NCT02838134|SHAM_COMPARATOR|Group B: Moderate neuromuscular Blockade|Moderate neuromuscular Blockade No additional rocuronium after intubation.
62192908|NCT02301338||Usual Care|"The patient will get instructions on: - Follow-up appointment date/time with your surgeon - Proper diet - Medications - Communicating concerning symptoms with the surgeon~The patient will answer questions on:~* Social support~* Quality of life"
62192909|NCT02301338||Phone Calls|"In addition to what the usual care group gets, the patient will also receive weekly phone calls by a geriatrics RN following hospital discharge.~The patient will answer questions on:~* Social support~* Quality of life"
62192910|NCT01587690||Healthy subjects|Self-explanatory
62192911|NCT01587690||Untreated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are not on any disease-modifying treatment approved for MS
62192912|NCT01587690||Treated Patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who were prescribed Interferon-beta-1a prior to enrollment
62007360|NCT05244031|ACTIVE_COMPARATOR|Control group|The investigators performed intravenous opioid infusion with PCA to that patient group for postoperative analgesia
62007361|NCT05493267|EXPERIMENTAL|Vγ2Vδ2 T lymphocyte-based immunotherapy +Treatment regimens for MDR-TB|Treatment was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis, with the addition of immunotherapy：zoledronic acid and recombinant human interleukin 2
62007362|NCT05493267|ACTIVE_COMPARATOR|Treatment regimens for MDR-TB|Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
62007363|NCT01296958|EXPERIMENTAL|Targeted screening|Screening for intestinal tapeworm carrier followed by treatment with niclosamide as indicated.
62192913|NCT02420249|EXPERIMENTAL|Qigong training group|Participants assigned to the Qigong group will receive Qigong training. The Qigong training programme will be run for 3 months with two supervised 1-hour sessions per week. Participants will learn the 18 Forms of Tai Chi Internal Qigong. The training sessions will be conducted by a qualified Qigong instructor from the Natural Health Qigong Association. Participants in the control group will receive no Qigong training during the study period. They will receive an 18 Forms of Tai Chi Internal Qigong training package after the study.
62192914|NCT02420249|NO_INTERVENTION|Control group|Participants in the control group will receive no Qigong training.
62192915|NCT02016209|EXPERIMENTAL|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of platinum-based nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
62192916|NCT06125158|ACTIVE_COMPARATOR|Control group|Participants in this group will receive conventional ankle interventions including ankle strength training and balance training. All treatments target the affected lower extremity for 40 minutes per session, once per day, 3 days per week for 6 weeks.
62573203|NCT04867122|OTHER|In-Depth Interviews for non-FCG Stakeholders|Each year of the project, the investigators will recruit 6 key stakeholders to participate in individual interviews focused on potential barriers and facilitators to adoption of the PST intervention into clinical practice for a total of 30 unique stakeholders who will be interviewed over the duration of this 5-year study.
62007364|NCT01296958|ACTIVE_COMPARATOR|Education|Community education about Taenia solium prevention.
62007365|NCT05954234|ACTIVE_COMPARATOR|pelvic floor rehabilitation and postural re-education|
62192917|NCT06125158|EXPERIMENTAL|Experimental Group A|Participants in this group will be asked to perform conventional ankle training and hip strength training. The conventional ankle training routine for this group will have the same movements as the control group, but the volume of training will be half that of the control group, and the duration of training will be 20 min/session. Hip strength training will consist of elastic band resistance exercises, forward step-up and lateral step-up for 20 min/session. All treatments target the affected lower extremity for 40 minutes per session, once per day, 3 days per week for 6 weeks.
62192918|NCT06125158|EXPERIMENTAL|Experimental Group B|"Participants in this group will be asked to perform conventional ankle training and neuromuscular electrical stimulation. The conventional ankle training routine for this group will have the same movements as the control group, but the volume of training will be half that of the control group, and the duration of training will be 20 min/session. Neuromuscular electrical stimulation aims to stimulate the gluteus maximus and gluteus mediums muscles of the affected lower limb. The researcher chose the Neuromuscular Electrical Stimulation 1 mode for the treatment prescription (this prescription can output a variety of waveforms with frequencies varying continuously from 1 to 100 Hz to stimulate the target muscles alternately, effectively preventing muscle fatigue caused by a single stimulation) and set the stimulation time to 20 min per session. All treatments target the affected lower extremity for 40 minutes per session, once per day, 3 days per week for 6 weeks."
62192919|NCT00989547|ACTIVE_COMPARATOR|A|
62192920|NCT00989547|NO_INTERVENTION|B|
62573204|NCT02844933|EXPERIMENTAL|Cannabidiol|Cannabidiol oral solution (40 milligram/kilogram/day \[40 mg/kg/day\]) divided into two daily doses with a standard meal
62573205|NCT02844933|PLACEBO_COMPARATOR|Placebo|Matching placebo solution divided into two daily doses with a standard meal
62573206|NCT01757002|EXPERIMENTAL|Tailored asthma management program|Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.
62007366|NCT05954234|ACTIVE_COMPARATOR|pelvic floor rehabilitation and spinal mobilization|
62007367|NCT01324375||THA (total hip arthroplasty)|Patients undergoing THA, preoperatively heat tested
62007368|NCT01632800|EXPERIMENTAL|Single arm study|Each subjects will undergo escalating exposure to magnetic field
62007369|NCT06663527|EXPERIMENTAL|Study Group|Study group (n=30) treated fumigating-washing therapy with the CPD
62007370|NCT06663527|PLACEBO_COMPARATOR|Control Group|Control group (n=30) underwent fumigating-washing therapy with a placebo
62007371|NCT03609294|EXPERIMENTAL|Sequence A|"Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)~There will be a washout of 35 days between the each period."
62007372|NCT03609294|EXPERIMENTAL|Sequence B|"Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)~There will be a washout of 35 days between the each period."
62007373|NCT03609294|EXPERIMENTAL|Sequency C|"Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)~There will be a washout of 35 days between the each period."
62007374|NCT02386202||Patients with hemorrhagic stroke|All patients with hemorrhagic stroke admitted to the neurosciences ICU are eligible for study enrollment.
62573207|NCT01757002|ACTIVE_COMPARATOR|Control|Teens in the control group will receive generic, web-based asthma education.
62781586|NCT05407779|EXPERIMENTAL|Cohort 7|The Cohort 7 include 3 subjects to receive BCD-180 at a dose 7
62007375|NCT05253482|EXPERIMENTAL|Intervention group|The intervention group will undergo 3 successive wet cupping therapy (WCT) sessions once in a month throughout 3 months (On 0, 30, and 60 days
62007376|NCT05253482|NO_INTERVENTION|Control group|Control group will not receive any intervention
62007377|NCT05849402|ACTIVE_COMPARATOR|Active aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
62007378|NCT05849402|SHAM_COMPARATOR|Sham aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
62007379|NCT03135756||Depression and anxiety symptoms|
62007380|NCT03135756||Healthy controls|
62007381|NCT04226079||Normal control|Normal population with low prevalence of gastrointestinal bleeding who underwent EGD and CFS which revealed no abnormal finding.
62007382|NCT04226079||Patients with GI bleeding|Patients who visited emergency room and were highly suspected to have recent or active upper GI bleeding and scheduled for upper GI endoscopy.
62007383|NCT04115358|EXPERIMENTAL|Hyaluronic acid|Gengigel teething (%0,54 hyaluronic acid), 0,1ml to the orifice of the root canals of the primary molar.
62007384|NCT04115358|ACTIVE_COMPARATOR|Formocresol|0,1 ml to the orifice of the root canals of the primary molar.
62007385|NCT04115358|ACTIVE_COMPARATOR|Ferric sulfate|0,1 ml to the orifice of the root canals of the primary molar.
62007386|NCT01512719|EXPERIMENTAL|POEM procedure|Patients with achalasia that undergo POEM
62007387|NCT01867034|ACTIVE_COMPARATOR|Bare Metal stent|Stent that has not been impregnated with an anti-restenotic drug
62573208|NCT02215200|EXPERIMENTAL|Anti-Thymocyte Globulin (ATG) and Placebo|"Anti-Thymocyte Globulin (ATG)/Placebo: Anti-Thymocyte Globulin (ATG) will be administered at a dose of 2.5mg/kg as two divided IV infusions of 0.5mg/kg and 2mg/kg. First dose (0.5mg/kg) will be infused over a minimum of 12 hours, and the second dose (2mg/kg) over a minimum of 8 hours. The second dose should be given no less than 12 and no more than 24 hours after the previous dose.~Placebo(for GCSF) treatment will begin 6 hours after completion of the ATG. Placebo will be given subcutaneously every 2 weeks for a total of 6 doses"
62781587|NCT05407779|EXPERIMENTAL|Cohort 8|The Cohort 8 include 3 subjects to receive BCD-180 at one of two selected for the further development doses
62781588|NCT05407779|EXPERIMENTAL|Cohort 9|The Cohort 9 include 3 subjects to receive BCD-180 at one of two selected for the further development doses
62781589|NCT06548932|EXPERIMENTAL|GZR33 Injection|Participants will receive GZR33 Injection or placebo, s.c. a single dose (Part A)
62781590|NCT06548932|EXPERIMENTAL|GZR101 Injection|Participants will receive GZR101 Injection or placebo, s.c. a single dose (Part B)
62781591|NCT03505528|EXPERIMENTAL|Cohort Group|There are five patient cohort groups. Each will receive a progressively higher starting dose of phenelzine sulfate, consecutively. Cohort A will start at 15mg/day and will be increased to 30mg/d by week 2 and further increased to 45mg/d for week 3, which will be maintained throughout the study. Cohort B will start at 45mg/d and will be held constant throughout the Study. Similarly, Cohort C, D \& E will start at 60, 75 and 90mg/d, respectively, and will also be held on this dose throughout the study. The decision to escalate the dose for the next cohort will be made on the basis of the number of dose limiting toxicity (DLT) events observed during the first 8 weeks in the preceding cohort group. In addition, all cohort groups will receive a constant dose of Abraxane at 100mg/m2.
62007388|NCT01867034|ACTIVE_COMPARATOR|Drug Eluting Stent|Stent that has been impregnated with an anti-restenotic drug
62007389|NCT01511380|EXPERIMENTAL|Risk Reduction Therapy for Adolescents|Youth randomly assigned to RRTA will complete a family focused treatment program that will work with the youth and his or her caregiver to help reduce youth substance use and risky sexual behavior using principals of behavior modification and contingency management.
62007390|NCT01511380|ACTIVE_COMPARATOR|Usual services|For youth randomly assigned to usual treatment services, the youth will receive the treatment services recommended by the drug court.
62007391|NCT03078998|EXPERIMENTAL|Juvenile idiopathic Arthritis|
62007392|NCT03078998|EXPERIMENTAL|Obstetric Brachial Plexus Palsy|
62007393|NCT03078998|EXPERIMENTAL|Cerebral Palsy|
62007394|NCT05524402|EXPERIMENTAL|TOR-C 1|TOR-C 1 is an active intervention adapted from the original Toolkit for Optimal Recovery program, adjusted for patients with mTBI and anxiety. The TOR-C 1 sessions address mind-body skills, including eliciting the relaxation response (eg, body scan, deep breathing, mindfulness), cognitive-behavioral strategies (eg, reframing), acceptance and commitment skills (eg, acceptance), and skills for returning to activity (eg, goal setting, activity pacing). The format is a 4-week program delivered over live video with weekly sessions and home practice.
62007395|NCT05524402|ACTIVE_COMPARATOR|TOR-C 2|TOR-C 2 is an active intervention teaching educational information on key modifiable factors relating to recovery after concussion, such as return to activity, the role of nutrition and sleep, and the relationship between concussion and anxiety. The format is a 4-week program delivered over live video with weekly sessions.
62007396|NCT01830140|EXPERIMENTAL|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
62007397|NCT01830140|ACTIVE_COMPARATOR|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
62007398|NCT03226067|EXPERIMENTAL|GKT137831 400mg twice daily|"GKT137831 400mg twice daily~Patients will self-administer 4 capsules in the morning and 4 capsules in the evening."
62007399|NCT03226067|EXPERIMENTAL|GKT137831 400mg once daily|"GKT137831 400mg once daily~Patients will self-administer 4 capsules in the morning and 4 capsules in the evening. The capsules in the evening will be placebos."
62781592|NCT00208533|OTHER|1 Open Label|Open Label Aripiprazole
62781593|NCT04200144|ACTIVE_COMPARATOR|active endoscopic treatment|Patients that will undergo Endoscopic Sleeve Gastroplasty
62007400|NCT03226067|PLACEBO_COMPARATOR|Placebo Arm|Patients will self-administer 4 capsules in the morning and 4 capsules in the evening. All capsules will be placebos.
62007401|NCT00968110|EXPERIMENTAL|Xolair|All patients will receive Xolair treatment for 16 weeks.
62007402|NCT03794765|EXPERIMENTAL|Antibiotic|Standard of Care (steroids, prophylactic anticoagulation, oral nutrition) And Antibiotics (Inj Ceftriaxone 1 gram intravenous twice daily And Inj Metronidazole 500 mg intravenous thrice daily) for initial 48 hours
62192921|NCT04351269||CanGaroo Envelope|Patients who received a CanGaroo Envelope with their Cardiac Implantable Electronic Device (CIED) implantation.
62781594|NCT04200144|ACTIVE_COMPARATOR|standard medical therapy control diet group|Patients that will undergo diet
62781595|NCT00250276|EXPERIMENTAL|Cervarix Lot1 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 1 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
62007403|NCT03794765|PLACEBO_COMPARATOR|Placebo|Standard of care (steroids, prophylactic anticoagulation, oral nutrition) And Placebo infusions similar to the active drugs
62007404|NCT00810121|EXPERIMENTAL|1|Ketoprofen 100 mg b.i.d. for 5 days
62007405|NCT00810121|EXPERIMENTAL|2|Ketoprofen 150 mg b.i.d. for 5 days
62007406|NCT02881814|EXPERIMENTAL|Lung ultrasound and clinical decision|Clinical assessment and choice of chest physiotherapy treatmetn performed by the clinical physiotherapist, followed by a comprehensive lung and diaphragm ultrasonography. After ultrasonography, the clinical physiotherapist is asked what CPT treatment he was going finally to implement, and explain the reasons for change, if any.
62007407|NCT02881814|EXPERIMENTAL|Mechanically ventilated patients|In case of mechanically ventilated patient at St. Vincent Hospital (Sydney, Australia), LUS scan will be performed immediately following intubation. Additionnal LUS scans will be performed 72h after intubation and Immediately prior to or following extubation.
62007408|NCT05406544||FD qualitative study on quality of life.|FD patients (FD monostotic, FD polyostotic, with or without craniofacial damages) will be invited to attend a focus group on the following themes: symptoms, self-image, psychological and emotional well-being, difficulties in daily life and adaptative strategies. The focus-groups will be conducted in a semi-directive manner by a moderator and will be recorded; after a verbatim transcription of the focus group recordings, the data will be analyzed manually and with the help of a semantic analysis software. It will allow common notions about quality of life in FD to emerge. A demographic questionnaire will also be completed by the participants.
62192922|NCT04351269||TYRX Envelope|Patients who received a TYRX Envelope with their Cardiac Implantable Electronic Device (CIED) implantation.
62398143|NCT05003765|EXPERIMENTAL|SPIP Block + Magnesium|Arm 3-50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine + 200mg of magnesium sulfate (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
62007409|NCT05406544||FD quantitative sudy on quality of life and olfaction.|Participants will receive two questionnaires to complete: the SF36 questionnaire (quality of life) and the SELF-MOQ questionnaire (olfaction impairment evaluation). Other data required for the study will be extracted from the medical record: age, weight, height, affected bone sites, Radiological/ biological activity data, sensorial deficit, medication. A demographic questionnaire will also be completed.
62007410|NCT05406544||FD qualitative and quantitative study on quality of life and olfaction.|Patients will be invited to attend a focus group on quality of life (qualitative study) as described for group 1 and to complete questionnaires on quality of life and olfaction (quantitative study) as described for group 2
62007411|NCT06067594||MTC cases|• Cases: Patients who meet the above inclusion and exclusion criteria and have a diagnosis of medullary carcinoma by histology
62007412|NCT06067594||Controls|Controls: Patients who meet the above inclusion and exclusion criteria and do not have a diagnosis of medullary carcinoma by histology.
62007413|NCT02582840|EXPERIMENTAL|dapagliflozin 5mg|dapagliflozin tablet 5mg
62007414|NCT02582840|EXPERIMENTAL|dapagliflozin 10mg|dapagliflozin tablet 10mg
62007415|NCT02582840|PLACEBO_COMPARATOR|Placebo|dapagliflozin tablet 5mg placebo or 10 mg placebo
62007416|NCT00427804|EXPERIMENTAL|Calcitriol|Calcitriol 0.25 mcg orally twice a day for 7 days or calcitriol 0.50 mcg orally twice a day for 7 days.
62007417|NCT01281488|EXPERIMENTAL|Treatment 1 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.018 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
62007418|NCT01281488|EXPERIMENTAL|Treatment 2 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.036 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
62007419|NCT01281488|EXPERIMENTAL|Treatment 3 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.07 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
62007420|NCT01281488|EXPERIMENTAL|Treatment 4 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.14 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
62192923|NCT04351269||No Envelope|Patients who had their Cardiac Implantable Electronic Device (CIED) implanted with no envelope.
62192924|NCT01851707|EXPERIMENTAL|IPI-145, low dose BID|
62398144|NCT05003765|EXPERIMENTAL|SPIP Block + Magnesium + Buprenorphine|Arm 4-50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine+ 200mg of magnesium sulfate + buprenorphine (300mcg) (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
62398145|NCT05180734|EXPERIMENTAL|JS001 240mg, Q3W with XELOX regimen or SOX regimen|"JS001 240mg, will be intravenously administered once every 3 weeks, until 17 cycles XELOX regimen (oxaliplatin + capecitabine) or SOX regimen (oxaliplatin + S-1), given in one therapeutic cycle of 3 weeks for up to 8 cycles XELOX regimen: Oxaliplatin, 130mg/m2, intravenous drip for over 3 hours, day 1, Q3W; capecitabine, 1000mg/m2, orally, twice per day, from day 1 to day 14, Q3W.~SOX regimen: Oxaliplatin, 130mg/m2, intravenous drip for over 3 hours, day 1, Q3W; S-1 Capsules, 40-60mg, orally, twice per day, from day 1 to day 14, Q3W."
62398146|NCT05180734|PLACEBO_COMPARATOR|Placebo combine with chemotherapy|"XELOX regimen (oxaliplatin + capecitabine) or SOX regimen (oxaliplatin + S-1), given in one therapeutic cycle of 3 weeks for up to 8 cycles XELOX regimen: Oxaliplatin, 130mg/m2, intravenous drip for over 3 hours, day 1, Q3W; capecitabine, 1000mg/m2, orally, twice per day, from day 1 to day 14, Q3W.~SOX regimen: Oxaliplatin, 130mg/m2, intravenous drip for over 3 hours, day 1, Q3W; S-1 Capsules, 40-60mg, orally, twice per day, from day 1 to day 14, Q3W."
62573209|NCT02215200|EXPERIMENTAL|ATG plus Granulocyte colony stimulating factor (GCSF)|"Granulocyte colony stimulating factor (GCSF) is supplied in 0.6 mL prefilled syringes for subcutaneous injection. Each syringe contains 6 mg GCSF (based on protein weight), in a sterile, clear, colorless, preservative-free solution (pH 4.0) containing acetate (0.35 mg), sorbitol (30.0 mg), polysorbate 20 (0.02 mg), and sodium (0.02 mg) in water for injection, U.S. Pharmacopeial Convention (USP). The standard 6mg dose will be given with the exception of subjects who weigh less than 45 kg.~GCSF treatment will begin 6 hours after completion of the ATG / Placebo. GCSF will be given subcutaneously every 2 weeks for a total of 6 doses"
62007421|NCT01281488|EXPERIMENTAL|Treatment 5 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.21 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
62007422|NCT03643523||ALbumin level|Detection of serum albumin levels in postoperatory of colorectal surgery
62781596|NCT00250276|EXPERIMENTAL|Cervarix Lot2 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 2 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
62781597|NCT00250276|EXPERIMENTAL|Cervarix Lot3 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 3 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
62007423|NCT00651482|EXPERIMENTAL|Bevacizumab + RAD001 (everolimus)|"Study treatment, consisting of bevacizumab + everolimus, was administered as 28-day cycles~Bevacizumab 10 mg/kg administered by IV infusion every 14 days (dose suspension permitted, dose reduction not permitted)~Everolimus 10 mg daily was administered orally (dose reduction to 5 mg daily and then 5 mg every other day, was permitted as needed for toxicity or tolerability)"
62007424|NCT04414384|EXPERIMENTAL|Abdominal Binder|During this time they will wear a step counter and track their steps. This step counter will be returned at the time of their two week visit.
62007425|NCT04414384|OTHER|Control|This group of patients will not wear abdominal binders, but during this time they will wear a step counter and track their steps. This step counter will be returned at the time of their two week visit.
62192925|NCT01851707|EXPERIMENTAL|IPI-145, medium dose BID|
62192926|NCT01851707|EXPERIMENTAL|IPI-145, high dose BID|
62398147|NCT06495645|EXPERIMENTAL|AI-HD group|AI-assisted upper gastrointestinal endoscopy follow immediately by high definition (HD) upper gastrointestinal endoscopy
62398148|NCT06495645|ACTIVE_COMPARATOR|HD-AI group|HD upper gastrointestinal endoscopy follow immediately by AI-assisted upper gastrointestinal endoscopy
62398149|NCT06520865||Tinnitus cases/patients|Subjects that have a diagnosis of chronic and constant tinnitus (for at least 6 months based on history)
62398150|NCT06520865||Control group|Subjects that never experienced tinnitus (excluding short-term tinnitus, i.e. not tinnitus that persists over a longer period of time)
62398151|NCT06298721|ACTIVE_COMPARATOR|Standard of Care TKA|Patients scheduled to undergo TKA at Cleveland Clinic will follow the standardized TKA Care Pathway as part of Standard of care. Patients enter the TKA care path after consenting to undergo TKA for symptomatic knee pain that has not relieved with nonoperative measures. They stay in the care path until 90-days after the operation is complete. The TKA care path guides the care delivered through the preoperative, intraoperative and postoperative phases.
62007426|NCT05911620|EXPERIMENTAL|Cushing's Syndrome|Patients with proven autonomic cortisol secretion (Cushing's Syndrome)
62192927|NCT01851707|PLACEBO_COMPARATOR|Placebo BID|
62192928|NCT02619214|EXPERIMENTAL|Oxygen 30%|Patient receives 1 hour of general anesthesia with a 30% oxygen concentration.
62192929|NCT02619214|EXPERIMENTAL|Oxygen 60%|Patient receives 1 hour of general anesthesia with a 60% oxygen concentration.
62192930|NCT02738905|EXPERIMENTAL|Rifaximin|Participants will receive study drug for a period of 7 days.
62007427|NCT05911620|EXPERIMENTAL|Suspected Cushing's Syndrome|Patients with possible autonomic cortisol secretion (Suspected Cushing's Syndrome)
62007428|NCT05911620|ACTIVE_COMPARATOR|Metabolic Syndrome|Patients with metabolic syndrome
62007429|NCT04160299|EXPERIMENTAL|Dance-based exergaming|This will be an intervention-based study with single-group design, where participants will receive VR-based dance training for ten weeks. An anticipated 20 participants with a diagnosis of mild cognitive deficits will be recruited for initial screening
62007430|NCT00749424|EXPERIMENTAL|1|crushing technique
62007431|NCT00749424|ACTIVE_COMPARATOR|2|provisional T stenting technique
62192931|NCT06544850||Experimental Group|Participants Individuals between 18-65 will be included in the study because pain mechanisms and effects are different between adults and children. Inclusion criteria are having low back pain for 3 months or longer, Mini mental test score\>23, Healthy individuals who do not experience chronic low back pain will be evaluated in the control group. Hypertension, congestive heart failure, chronic obstructive pulmonary disease, rheumatological diseases, vertigo, nausea, vomiting, specific diagnosis underlying back pain (e.g. radicular symptoms), significant decrease in vision and hearing, body mass index higher than 30, serious psychiatric condition, inability to communicate, traumatic low back pain, those who have had back surgery, those who refused to participate in the study and did not fill out the consent form will be excluded.
62192932|NCT06544850||Control Group|Consists of healthy volunteer participants who meet the inclusion criteria. The control group will be selected from those who have never felt back pain that would affect their daily life activities and who have not received treatment.
62192933|NCT03600415|EXPERIMENTAL|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
62192934|NCT03600415|EXPERIMENTAL|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
62192935|NCT01938053|OTHER|Reminder card with no number|Patients receive a card to remind them of the time frame for results but no number is listed.
62007432|NCT02421458|ACTIVE_COMPARATOR|arm 1: 6 fractions of radiation|radiation in a 6 fractions scheme and a daily dose of 6 Gy
62007433|NCT02421458|ACTIVE_COMPARATOR|arm 2: 16 fractrions of radiation|radiation in a 16 fractions scheme and a daily dose of 3.125 Gy
62007434|NCT04844229|NO_INTERVENTION|Control group|21 patients will receive conservative management for PDPH in the form of oral paracetamol 1000 mg/8hours, and caffeine 300-500 mg/day, 1000 mL 0.9% normal saline infusion over the initial 4 hours with increasing oral fluids and bed rest to be maintained. After 6 hour of starting treatment if the above measures failed to control pain with the VAS ≥ 4 non-steroidal anti-inflammatory drugs (NSAID) will be added in the form of ketorolac 30 mg IV which can be repeated every 12 hours if needed. Participants will be followed up after 1 hour, 6 hours and 24 hours with assessment of VAS score, modified Lybecker clas¬sification score and TCD parameters. EBP will be considered after 24 hours of treatment if pain still not controlled with VAS ≥ 4 and modified Lybecker clas¬sification score ≥ 2 and after patients' consent.
62192936|NCT01938053|OTHER|Card with number|Patients receive a card to remind them of the time frame for results but and a number to call for results is listed
62573210|NCT02215200|PLACEBO_COMPARATOR|Placebo|Placebo for ATG will be administered by IV infusion in 2 doses. Placebo for GCSF will be administered subcutaneously every 2 weeks for a total of 6 doses
62007435|NCT04844229|ACTIVE_COMPARATOR|Interventional group|"21 patients will receive the same conservative management as in control group together with bilateral transnasal sphenopalatine ganglion block.~After one hour Participants who will show improvement in pain scores will be followed up after 6 hours and 24 hours, while, patients who will show persistent headache will be subjected for bilateral ultrasound guided greater occipital nerve block.~then these patients will be assessed after 1 h, 6 h, and 24 h of the block. If still suffering epidural blood patch will be indicated and performed after gaining patients' consent."
62007436|NCT02268097|EXPERIMENTAL|Freehand|Patellar resurfacing with freehand technique:Using freehand technique for patella preparation during total knee arthroplasty.
62192937|NCT06240429|EXPERIMENTAL|Collagen Supplementation|Participants will receive a daily dose of 10 g each of collagen peptides
62192938|NCT06240429|NO_INTERVENTION|Placebo|Participants will receive a daily dose of 10 g each of placebo
62192939|NCT05271968|NO_INTERVENTION|Control|Standard Care : The classic treatment recommended is the prescription of an oral drug, Ivermectin to be taken two times at one or 2 weeks interval. And recommendations on the need to change the clothes and the linen of the bedding the following day after taking the drug, washing them at more than 50° as well as all the clothes three days before are explained. The first course of oral treatment is swallowed at the BOPC, while the second course is given to be swallowed one week later.
62573211|NCT01209949|OTHER|Adapalene 0.1% and Benzoyl Peroxide 2.5% gel|
62573212|NCT06575387|ACTIVE_COMPARATOR|Group A: Uncomplicated Normal Labour|About 140 prime gravidae females delivered before or at alert line
62573213|NCT06575387|ACTIVE_COMPARATOR|Group B: Complicated Normal Labour|About 40 prime gravidae females delivered between alert and action line
62573214|NCT06575387|ACTIVE_COMPARATOR|Group C: Cesarean Section Labour|About 20 prime gravidae females delivered after action line
62573215|NCT02527733|ACTIVE_COMPARATOR|Ranibizumab|After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
62007437|NCT02268097|ACTIVE_COMPARATOR|Resection guide|Patellar resurfacing with resection guide technique: Using patellar resection guide technique for patella preparation during total knee arthroplasty.
62007438|NCT01500824|EXPERIMENTAL|Crizotinib|
62007439|NCT03168347|ACTIVE_COMPARATOR|Anecdotal Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on anecdotal evidence.
62007440|NCT03168347|ACTIVE_COMPARATOR|Research Study Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence.
62573216|NCT02527733|ACTIVE_COMPARATOR|Ranibizumab and laser|After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers. Macular laser photocoagulation will be performed when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
62573217|NCT06576869|ACTIVE_COMPARATOR|A: Closure without releasing the tourniquet.|Tourniquet is dropped after closure.
62781598|NCT00250276|EXPERIMENTAL|Cervarix Low Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine manufactured lower scale-80L according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
62781599|NCT05050864|ACTIVE_COMPARATOR|internal ventricular shunt (neurosurgery)|The internal ventricular shunt consists of the introduction of a catheter from a lateral ventricle into the atrium or peritoneum. It is associated with a valve whose opening pressure is adjustable. The goal is that cerebrospinal fluid can be absorbed extra-cranial
62007441|NCT03168347|ACTIVE_COMPARATOR|Anecdotal + Research Study Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence and anecdotal evidence.
62007442|NCT03168347|PLACEBO_COMPARATOR|No Evidence|Scenario describes a medication's (biologic's) therapeutic effect with no mention on anecdotal nor research study evidence.
62007443|NCT03081416|EXPERIMENTAL|Intranasal Ketamine arm|Intranasal ketamine administered to participant
62007444|NCT03081416|ACTIVE_COMPARATOR|Standard Therapy|Reglan 10 mg; Benadryl 25 mg administered to all participants Toradol 15-30 mg; dexamethasone 10 mg added at treating providers discretion.
62192940|NCT05271968|EXPERIMENTAL|Intervention|Patients in this interventional arm will come back to BOPC the following day after intake the treatment (D1 and D8) to take a shower and to receive again new clothes
62007445|NCT03778970|EXPERIMENTAL|Pain Neuroscience Education + Exercises|The PNE will follow the principles established by Explain Pain, addressing reconceptualization of pain, emphasizing modern neuroscience concepts. The PNE workshop will last 40 minutes (2 sessions). The movement control exercises will consist of active exercises that address posture and control of movements which are impaired and trigger pain. The session will last approximately 30 minutes, starting with the execution of the coordination exercises in the control of movement with an intensity of 10 to 30 repetitions and then performing exercises for stretching in 3 series of 30 seconds. Finally, strengthening exercises in 3 sets of 15 repetitions will be implemented. The exercises will be administered 1 session/week (volunteers will be oriented to execute the same exercises at home twice a week). The volunteers will receive 8 sessions at the clinic.
62007446|NCT03778970|ACTIVE_COMPARATOR|Self-Management Education + Exercises|"The Self-Management Education (SME) strategy will be aligned with the Back Book concepts, focused on behavior change and encouraging participants to be active despite of the pain. The SME workshop will last 40 minutes (2 sessions). The movement control exercises will consist of active exercises that address posture and control of movements which are impaired and trigger pain. The session will last approximately 30 minutes, starting with the execution of the coordination exercises in the control of movement with an intensity of 10 to 30 repetitions and then performing exercises for stretching in 3 series of 30 seconds. Finally, strengthening exercises in 3 sets of 15 repetitions will be implemented. The exercises will be administered 1 session/week (volunteers will be oriented to execute the same exercises at home twice a week). The volunteers will receive 8 sessions at the clinic."
62007447|NCT05545852|EXPERIMENTAL|Study Group|Gasless Transaxillary Posterial Endoscopic Thyroidectomy and Ipsilateral Central Lymph Node Dissection
62007448|NCT05545852|ACTIVE_COMPARATOR|Control Group|Conventional Open Thyroidectomy and Ipsilateral Central Lymph Node Dissection
62007449|NCT03683134|EXPERIMENTAL|Mediterranean diet group|Participants will receive both nutrition education on patterns of a Mediterranean style diet as well as olive oil and mixed nuts.
62007450|NCT03683134|ACTIVE_COMPARATOR|American Heart Association group|Participants will receive nutrition education on the dietary recommendations for heart health from the American Heart Association.
62007451|NCT01502722|EXPERIMENTAL|Group 1 - Crossover|This group will drink water in the 1st study.
62007452|NCT01502722|EXPERIMENTAL|Group 2 - Crossover|This group will drink Pineapple Soda in the 1st study
62007453|NCT01502722|EXPERIMENTAL|Group 3 - Crossover|This group will drink Pineapple Diet Soda in the 3rd study
62007454|NCT01349283|EXPERIMENTAL|HepavaxGene Stratum 1a|Subjects of mothers with chronic hepatitis B (positive for both HBsAg and hepatitis B envelope antigen - HBeAg)
62192941|NCT02130245|ACTIVE_COMPARATOR|Early cholecystectomy|Laparoscopic cholecystectomy well be done after the immediate admission
62192942|NCT02130245|ACTIVE_COMPARATOR|Delayed cholecystectomy|Laparoscopic cholecystectomy after a period of conservative treatment
62192943|NCT02784743|EXPERIMENTAL|albendazole and ivermectin|Before and after design with all eligible volunteers receiving the study drugs. Administration of a yearly unique dose of albendazole 400mg and ivermectin 150ug/kg weight ( according to the height).
62573218|NCT06576869|ACTIVE_COMPARATOR|B: Releasing the tourniquet and then closing the incision|Tourniquet is dropped prior to closure.
62573219|NCT01723085||Open myomectomy|All patients belong to the same group Description includes the surgical technique
62573220|NCT01747031|EXPERIMENTAL|Single arm study|Single arm study.The investigators will conducte computed tomography,angiography and FFR measurement during angiography in this single arm.
62573221|NCT06575556||Patients who underwent Ross procedure with loose jacket technique|Patients who underwent Ross procedure with loose jacket technique regardless of the timing of surgery, all patients will undergo both CT and MRI scans
62573222|NCT03794648|EXPERIMENTAL|Intervention Group|
62573223|NCT03794648|NO_INTERVENTION|Control Group|
62007455|NCT01349283|ACTIVE_COMPARATOR|Comparator vaccine Stratum 1a|Subjects of mothers with chronic hepatitis B (positive for both HBsAg and HBeAg)
62192944|NCT00502502||Symptom-Related Cytokines Questionnaire|
62192945|NCT04601636|ACTIVE_COMPARATOR|Active Prewarming group (PW group)|Group randomized to receive at least 30 minutes of active prewarming before induction of anesthesia, combined to active warming intraoperatively.
62192946|NCT04601636|PLACEBO_COMPARATOR|Control group (C group)|Group randomized to receive the standard care : passive prewarming before induction of anesthesia combined to active warming intraoperatively.
62192947|NCT01840462||Subjects naïve to botulinum toxin A (BoNT-A) treatment|Patients naïve to botulinum toxin A treatment
62192948|NCT01840462||Subjects pre-treated with botulinum toxin A (BoNT-A) injection|"Patients pre-treated with botulinum toxin A for at least 2 years.~4 injection cycles, each at 3 to 4 months intervals. Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics)."
62573224|NCT00508014|ACTIVE_COMPARATOR|Control|usual care
62192949|NCT05631041|NO_INTERVENTION|Control group|Group I (Control group ; n=32) which will receive FOLFIRI regimen (5-flourouracil, leucovorin, irinotecan) or XELIRI (Capecitabine and irinotecan) with or without target therapy (Bevacizumab).
62192950|NCT05631041|ACTIVE_COMPARATOR|Silymarin group|Group II: (Silymarin group ; n=32) which will receive FOLFIRI regimen (5-flourouracil, leucovorin, irinotecan) or XELIRI (Capecitabine and irinotecan) with or without target therapy (Bevacizumab). plus silymarin 140 mg once daily.
62192951|NCT05440604|EXPERIMENTAL|Fortified milk group|2 daily servings of the investigational fortified milk for 16 weeks
62192952|NCT05440604|NO_INTERVENTION|Observational group|will be asked to consume beverages in accordance with their habitual pattern of intake
62192953|NCT01508338|PLACEBO_COMPARATOR|Placebo|
62192954|NCT01508338|EXPERIMENTAL|HMB|
62781600|NCT05050864|ACTIVE_COMPARATOR|endovacascular stenting (interventional neuroradiology)|The placement of a vascular endoprosthesis (stent) is an interventional neuroradiology procedure aimed, by venous approach (percutaneous puncture), to restore the diameter of a venous sinus. It requires 6 months of antiplatelet aggregation. The aim is to allow better venous drainage from the brain to increase the absorption of cerebrospinal fluid.
62781601|NCT04557709||Observational (chart review)|Patients' medical charts are reviewed.
62781602|NCT06426849|EXPERIMENTAL|GROUP A|"LiuzijueExercise will be performed by delivering 6 distinct sounds,(xū, hē, hū, sī, chuī, and xī) through termination along with comparing body activities."
62192955|NCT01508338|EXPERIMENTAL|ATP and HMB|
62192956|NCT01508338|EXPERIMENTAL|ATP|
62573225|NCT00508014|EXPERIMENTAL|Concurrent Peer Review Visit|See description of interventioin
62573226|NCT06128772|OTHER|Waitlist control|Eight weeks of waitlist control and then 8 weeks of weekly treatment
62573227|NCT06128772|OTHER|Immediate treatment|Eight weeks of weekly treatment and then eight weeks of follow up
62781603|NCT06426849|EXPERIMENTAL|GROUP B|10 FORM OF YANG NG STYLE Tai Chi Chuan Exercise that combines deep diaphragmatic breathing and relaxation with many fundamental postures.
62007456|NCT01349283|EXPERIMENTAL|HepavaxGene Stratum 1b|Subjects of mothers with chronic hepatitis B (positive for HBsAg only)
62007457|NCT01349283|ACTIVE_COMPARATOR|Comparator vaccine Stratum 1b|Subjects of mothers with chronic hepatitis B (positive for HBsAg only)
62007458|NCT01349283|EXPERIMENTAL|HepavaxGene Stratum 2|Subjects of mothers without chronic hepatitis B (negative for both HBsAg and HBeAg)
62007459|NCT01349283|ACTIVE_COMPARATOR|Comparator vaccine Stratum 2|Subjects of mothers without chronic hepatitis B (negative for both HBsAg and HBeAg)
62007460|NCT04139785|EXPERIMENTAL|Intervention|Guided Cognitive Behavioural Therapy based app
62007461|NCT04139785|NO_INTERVENTION|Care as usual|Care as usual
62007462|NCT06620237|NO_INTERVENTION|LBBAP Amvia|All patients with successful implantation of Amvia pacemaker and a lead in a position intended for LBBA pacing.
62192957|NCT03682185|EXPERIMENTAL|Timed Activity Intervention Protocol|The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem solving approaches, and provide education.
62192958|NCT03682185|ACTIVE_COMPARATOR|Attention-Control Condition|This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.
62192959|NCT00935532|EXPERIMENTAL|exenatide once weekly|
62192960|NCT00935532|ACTIVE_COMPARATOR|insulin glargine|
62192961|NCT01044992|EXPERIMENTAL|Drug and radiation|Levodopa and H215O PET
62192962|NCT04448145||COVID-19 Positive|Participants who have been diagnosed with COVID-19 or experienced symptoms of COVID-19.
62192963|NCT04448145||COVID-19 Negative|Participants who have never tested positive for COVID-19.
62192964|NCT01613690|EXPERIMENTAL|Healthy volunteers|control group receiving 100 μg NVA237
62573228|NCT05629780|EXPERIMENTAL|Conservative|Resuscitation fluids were only given under certain pre-defined criteria
62573229|NCT05629780|NO_INTERVENTION|Traditional (liberal)|Patients were treated with standard of care for each site with regards to recuscitation fluids.
62573230|NCT00658723|EXPERIMENTAL|1|
62573231|NCT00658723|ACTIVE_COMPARATOR|2|SURGICEL™ Absorbable Hemostat
62781604|NCT04488016|EXPERIMENTAL|Cohort 1 -Part 1|Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (\>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (\>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)\* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
62192965|NCT01613690|EXPERIMENTAL|Mild renal impairment|(eGFR 50-80 mL/min/1.73m2) receiving 100 μg NVA237
62573232|NCT06128239|EXPERIMENTAL|Two-Way Caring Contacts Texts (CC2)|"In addition to receiving enhanced usual care as described below, a series of 25 standardized outgoing Caring Contacts text messages will be sent to participants randomized to the CC2 intervention arm through our online texting platform. To remind participants that they can respond, the outgoing texts will periodically invite replies in a non-demanding way, e.g., Hope you're doing well this week, Anna. Feel free to text me back if you feel like it, I'm here for you. Responses to CC2 participant replies will be unscripted and individually tailored."
62192966|NCT01613690|EXPERIMENTAL|Moderate renal impairment|(eGFR 30-49 mL/min/1.73m2) receiving 100 μg NVA237
62781605|NCT04488016|EXPERIMENTAL|Cohort 2- Part 1|Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (\>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (\>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)\* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
62007463|NCT06620237|EXPERIMENTAL|LBBAP Solia CSP S|All patients with successful implantation of a Solia CSP S lead in LBB area. Additionally, all patients with a non-successful Solia CSP S implantation attempt in which an ADE (adverse device effect) or SADE (serious adverse device effect) related to the Solia CSP S lead occurred.
62192967|NCT01613690|EXPERIMENTAL|Severe renal impairment|(eGFR \<30 mL/min1.73m2) receiving 100 μg NVA237
62192968|NCT01613690|EXPERIMENTAL|End-stage subjects requiring dialysis (ESRD)|receiving 100 μg NVA237
62192969|NCT04597944||Participants with Hereditary or Acquired Angioedema|Participants older than 18 years that are diagnosed with Hereditary or Acquired Angioedema and treated by lanadelumab.
62192970|NCT05772143||Lumbar disc herniation|Patient over 18 years of age suffering from radiculalgia related to lumbar disc herniation visualized on MRI with radio-clinical concordance, failure of conservative treatment and nerve root infiltrations
62192971|NCT04192864|EXPERIMENTAL|Lingually based triangular flap|
62192972|NCT04192864|ACTIVE_COMPARATOR|Buccally based triangular flap|
62192973|NCT05404555||acute myocardia infarction patients with right coronary artery occlusion|
62192974|NCT05404555||acute myocardia infarction patients with non-right coronary artery occlusion|
62192975|NCT06360211|EXPERIMENTAL|Healthy participants from United States|The healthy volunteers will be confined to the clinic throughout the intervention period of the study. The study includes visits during screening, intervention, and follow-up.
62192976|NCT01546506|EXPERIMENTAL|Midodrine|Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
62192977|NCT01546506|NO_INTERVENTION|No treatment|
62192978|NCT04169191|EXPERIMENTAL|Sildenafil|
62192979|NCT02623660|EXPERIMENTAL|Experimental|This group will receive treatment from the ODIN1 device in conjunction with standard care and diagnostic device testing.
62192980|NCT02623660|ACTIVE_COMPARATOR|Control|This group will receive the standard care and the diagnostic device testing.
62573233|NCT06128239|EXPERIMENTAL|One-Way Caring Contacts Texts (CC1)|"In addition to receiving enhanced usual care as described below, CC1 participants will be sent 25 caring texts, such as Even though know we do not personally know each other, we truly value your wellbeing and are thinking of you. If you'd like to connect with someone, feel free to call or text 988 anytime - their team would be happy to hear from you. CC1 participants will not be able to reply to the texts and the online texting platform will block incoming messages. This will be clearly communicated to CC1 participants during the informed consent process and they will be asked to sign off on understanding this and other key points before enrolling in the study."
62781606|NCT04488016|EXPERIMENTAL|Cohort 3- Part 1|Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (\>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (\>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)\* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
62192981|NCT02640105||Patient with Cluster headache|Prospective follow-up of patient with Cluster headache
62192982|NCT06544681||Coronary Stent Malapposition|Measurement results of deep learning-based OCT system: Coronary Stent Malapposition
62192983|NCT06544681||Coronary Stent Well Apposed|Measurement results of a deep learning-based OCT system: Coronary Stent Well Apposed
62192984|NCT06474065||Treated patiens' Group as Group 1|Patients submitted to hysteroscopic, laparoscopic or laparotomic myomectomy
62192985|NCT06474065||Untreated patiens' Group as Group 2|Control group - unoperated patients
62192986|NCT05321849||Use Fluoroscopy (Control)|PDA closure in 30 patients with fluoroscopy guide
62007464|NCT03318614|EXPERIMENTAL|Probiotics M-63 group|Participants assigned to the M-63 group were given a sachet of B. infantis M63 (Morinaga Milk Industry Co., Ltd., Japan) to consume daily in addition to advice of good hygiene and sanitation practices.
62007465|NCT03318614|PLACEBO_COMPARATOR|Control group|No probiotic intervention was given to the control group over three months other than advice of good hygiene and sanitation practices.
62192987|NCT05321849||No fluoroscopy (test)|PDA closure in 30 patients with echocardiography guide, without fluoroscopy
62192988|NCT06182345||Experiment gourp|Autologous skin cell suspension combined with autologous skin graft was used to treat burn wound
62192989|NCT06182345||Control group|Autologous skin graft was used to treat burn wound
62192990|NCT05570812|EXPERIMENTAL|Placebo|"Participants will be on the following dosage schedule:~50 mg daily for 2 weeks, THEN 100 mg daily for 1 week, THEN 250 mg daily for 1 week, THEN 500 mg daily for 4 weeks"
62192991|NCT05570812|EXPERIMENTAL|Pregnenolone|"Participants will be on the following dosage schedule:~50 mg daily for 2 weeks, THEN 100 mg daily for 1 week, THEN 250 mg daily for 1 week, THEN 500 mg daily for 4 weeks"
62192992|NCT05338697||Ischemic & Hemorrhagic stroke patients|557 ischemic stroke patients and 100 hemorrhagic stroke patients
62781607|NCT04488016|EXPERIMENTAL|Cohort 4 - Part 1|Subjects will be randomized to one of 4 sequences: ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (\>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (\>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)\* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
62781608|NCT04488016|EXPERIMENTAL|Cohort 1- Part 2|Subjects will be randomized to one of 2 sequences in a 2×4 crossover: ABCD or BADC. In Part 2, subjects will be receiving 100 mg acalabrutinib tablet (Variant 1), Variant 2, Variant 3, and 100 mg acalabrutinib solution.
62007466|NCT02709395|EXPERIMENTAL|Navina Smart|Navina Smart will be used, during 4 weeks, for transanal irrigation (TAI).
62781609|NCT04488016|EXPERIMENTAL|Cohort 2 - Part 2|Subjects will be randomized to one of 2 sequences in a 2×4 crossover: ABCD or BADC.In Part 2, subjects will be receiving 100 mg acalabrutinib tablet (Variant 1), Variant 2, Variant 3, and 100 mg acalabrutinib solution.
62781610|NCT03825016|EXPERIMENTAL|Lidocaine|Lidocaine Hydrochloride
62781611|NCT03825016|EXPERIMENTAL|Diclofenac|Oral Diclofenac
62007467|NCT05638555||Lactated Ringer's (LR) solution|
62007468|NCT05638555||Normal Saline (NS)|
62007469|NCT01461096|EXPERIMENTAL|Quadrivalent HPV Vaccine|Participants were prescribed the quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
62007470|NCT01461096|PLACEBO_COMPARATOR|Placebo Vaccine|Participants were prescribed the placebo vaccine at baseline and Weeks 8 and 24.
62007471|NCT04257578|EXPERIMENTAL|Treatment (acalabrutinib, axicabtagene ciloleucel)|Beginning up to 3 weeks and at least 24 hours prior to leukapheresis, patients receive acalabrutinib PO every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also receive axicabtagene ciloleucel IV at 36-96 hours after completion of lymphodepleting chemotherapy.
62007472|NCT04298528|EXPERIMENTAL|dronabinol|Patient will be directed to take 2.5mg of Study Drug 2 times a day for 4 weeks. Patient is blinded as to whether or not this is Dronabinol.
62214831|NCT04869007||Patients with a history of cesarean section without isthmocoele hysterosonographically diagnosed|"For patients who agreed to participate in the study, a specific measurement is made during the hysterosonography examination in order to determine the presence or absence of an isthmocele. Inclusion in the study is validated after a successful hysterosonography examination that confirms the presence or absence of an isthmocele. The patients are then attributed either to the: isthmocele + group or isthmocele - group."
62781612|NCT06543329|ACTIVE_COMPARATOR|polyglactin 910|- Group A: (75) women with subcuticular suture polyglactin 910, braided, (VICRYL RAPIDE®; Ethicon) was used in subcuticular skin closure.
62781613|NCT06543329|ACTIVE_COMPARATOR|poliglecaprone 25|Group A: (75) women with subcuticular suture poliglecaprone 25, (MONOCRYL) was used in subcuticular skin closure.
62007473|NCT04298528|PLACEBO_COMPARATOR|placebo|Patient will be directed to take 2.5mg of Study Drug 2 times a day for 4 weeks. Patient is blinded as to whether or not this is Dronabinol.
62007474|NCT04713384|EXPERIMENTAL|Treatment|Participants will undergo 4 weeks (20 sessions) of experimental rehabilitation in their home. They will play custom therapeutic games that are intensive and adapt to their condition. Before and after the 4-week intervention participants will travel to Kessler Foundation to undergo evaluations. The therapy is designed to improve arm range, strength, endurance, as well as memory, focusing and decision making. Data will be stored on the cloud, protected and monitored by the research team.
62781614|NCT06543329|ACTIVE_COMPARATOR|polypropylene|Group A: (75) women with subcuticular suture polypropylene, (PROLENE) was used in subcuticular skin closure.
62781615|NCT06543329|ACTIVE_COMPARATOR|POLYESTER|Group A: (75) women with subcuticular suture POLYESTER, (ETHIBOND EXCEL Suture) was used in subcuticular skin closure.
62007475|NCT05600569||All the target population|Patients who will undergo any surgical procedure in a Spanish Thoracic Surgery Department
62007476|NCT01992237||ALI patients|Patients with ARDS by Berlin definition and with or without clinical indication for ECMO treatment.
62007477|NCT01403103|EXPERIMENTAL|Treatment (chemoprevention)|Patients receive cholecalciferol orally (PO) 7 days prior to scheduled surgery or endorectal ultrasound. Patients with sigmoid colon cancer or clinical stage I rectal cancer would proceed with surgical resection without preceding chemoradiation and will have a portion of normal colorectal mucosa and tumor tissue obtained for research purposes.
62007478|NCT03040258|EXPERIMENTAL|Intervention group- Health-E-PALS-Pilot|Group of students receiving the school-based intervention: Health-E-PALS (pilot), it consists of in class activities and lessons.
62007479|NCT03040258|NO_INTERVENTION|Control group|Group of students not receiving any intervention
62007480|NCT00008346|OTHER|SFM then FFDM|Screen Film Mammography (SFM) followed by Full Field Digital Mammography (FFDM)
62007481|NCT00008346|OTHER|FFDM then SFM|Full Field Digital Mammography (FFDM) followed by Screen Film Mammography (SFM)
62007482|NCT02317159|EXPERIMENTAL|imatinib，Capsule|400mg imatinib qd
62192993|NCT04003766|ACTIVE_COMPARATOR|Percutaneous Biopsy|"The subject would undergo the standard of care procedure for a percutaneous biopsy of the liver.~All percutaneous biopsies will be performed after administration of local anesthetic. No pre-procedure antibiotics will be administered. Subcostal or subxyphoid area will be cleaned and draped in the standard manner. 2% lidocaine solution will be injected subcutaneously using a 25-gauge needle and then administered into the subcutaneous tissue up to the liver capsule. A 16-gauge biopsy needle is inserted into the liver parenchyma under US or CT-guidance, with the location of needle placement left to the discretion of the performing radiologist. One or two core biopsy samples will be obtained. All procured specimens will be placed in a single specimen container of 10% formalin for tissue processing. When biopsy samples have been obtained, the patient will be taken to the recovery area for post-procedure monitoring."
62192994|NCT04003766|ACTIVE_COMPARATOR|Endoscopic-guided Ultrasound Biopsy|"The subject would undergo the standard of care procedure for an endoscopic-guided biopsy of the liver.~The left lobe of the liver is identified from the gastric lumen, EUS-guided fine needle biopsy (FNB) will be performed using a 19-gauge FNB needle, with the choice of needle type at the discretion of the performing endoscopist. Stylet will only be used to puncture the liver at the time of the first pass and then subsequently removed. No suction will be used. Fanning technique will not be used. A total of 10 to-and-fro needle movements will be performed during each pass. A total of two passes will be performed.All tissue specimens procured will be placed in a single specimen container of 10% formalin for tissue processing. When two passes are complete under EUS-guidance, the echoendoscope will be withdrawn from the patient and the patient will be taken to the recovery area for post-procedure monitoring."
62192995|NCT01963169|EXPERIMENTAL|TO-BoneHealth Group|The group will use the 8-week TO-BoneHealth program, which includes: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.
62192996|NCT01963169|EXPERIMENTAL|TO-BoneHealth Plus Group|The group will use the TO-BoneHealth Plus program intervention, which includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
62192997|NCT01963169|NO_INTERVENTION|Control Group|No specific intervention will be provided to the control group participants. To keep in contact with participants, a monthly e-mail will be sent to inform them of upcoming follow-up surveys. At the end of the study (upon completion of all five surveys), the control group participants will receive a CD version of the TO-BoneHealth program via mail.
62781616|NCT04443309|EXPERIMENTAL|Lenvatinib plus Camrelizumab|"Camrelizumab (Jiangsu HengRui Medicine Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.~Lenvatinib is a novel angiogenesis inhibitor which targets multiple tyrosine kinases， including vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT."
62781617|NCT05673070|EXPERIMENTAL|Ritual Epre|This group will receive 2 Ritual Epre multivitamin-mineral supplement pills daily.
62781618|NCT05673070|ACTIVE_COMPARATOR|Control MVI|For the prenatal arm, this group will receive a control multivitamin-mineral supplement pill and a 200 mg docosahexaenoic acid (DHA) pill that are commercially available.
62781619|NCT05437432|EXPERIMENTAL|Vita ambria onlay restoration|onlays constructed from zirconia-reinforced lithium disilicate glass ceramic press system
62781620|NCT05437432|ACTIVE_COMPARATOR|e.max onlay restoration|onlays constructed from lithium disilicate glass ceramic press system
62781621|NCT02904148|EXPERIMENTAL|Shoulder mobilisation|The shoulder mobilisation is performed daily by a physiotherapist for 45 days.
62781622|NCT03009084|EXPERIMENTAL|Intervention group|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
62781623|NCT03009084|NO_INTERVENTION|Control group|Usual care.
62007483|NCT05877586|EXPERIMENTAL|Caregivers using CLARE app|Caregiver participants in the study
62007484|NCT05190458|OTHER|Non-invasive mechanical ventilation (group A)|Patients will be Randomized into 2 subgroups by (1:1) crossover:- Group A will be put on NIMV Group B will be put on HVNI
62007485|NCT05190458|OTHER|High Velocity Nasal Insufflation (group B)|Patients will be Randomized into 2 subgroups by (1:1) crossover:- Group A will be put on NIMV Group B will be put on HVNI
62007486|NCT02645994|EXPERIMENTAL|Target Controlled Infusion|Propofol is administered through a target controlled infusion pump based on Marsh model to achieve a BIS of 50 and manually adjusted to maintain BIS between 40 and 60
62007487|NCT02645994|ACTIVE_COMPARATOR|Closed Loop Anesthesia Delivery System|Propofol is administered through Closed Loop Anesthesia Delivery System which is titrated automatically to achieve a target BIS of 50 and maintain it between 40 and 60.
62007488|NCT06654726|EXPERIMENTAL|aldafermin|Aldafermin 3mg given subcutaneously, daily, for up to 6 years
62192998|NCT03176004|EXPERIMENTAL|Attention Bias Modification|Participants play a game in which they can move up in levels by reducing their reaction time to targets presented in the location of a threatening word.
62192999|NCT03176004|ACTIVE_COMPARATOR|Active Control Condition|Participants play a game in which they can move up in levels by reducing their reaction time to targets presented in the location of a word with a specific color.
62781624|NCT05248477|NO_INTERVENTION|usual practice|
62007489|NCT06654726|PLACEBO_COMPARATOR|placebo|Placebo given subcutaneously, daily, for up to 6 years
62007490|NCT01061749|EXPERIMENTAL|Treatment (selumetinib, cixutumumab)|Patients receive selumetinib PO BID on days 1-28 and cixutumumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62007491|NCT04835402|EXPERIMENTAL|Intervention|Day 1: Pembrolizumab 400mg Day 10: Irreversible electroporation Day 42/84/126/168: Pembrolizumab 400mg
62007492|NCT04390152|EXPERIMENTAL|Mesenchymal stem cell|WJ MSC 50\*10e6, two doses plus standard treatment with hydroxychloroquine + Lopinavir/Ritonavir or Azithromycin and ventilation support.
62007493|NCT04390152|ACTIVE_COMPARATOR|Control group|Hydroxychloroquine, lopinavir/ritonavir and ventilation support plus placebo
62007494|NCT03390907|EXPERIMENTAL|Hybrid APC|Hybrid APC ( Erbe Hybrid APC) design for ablation of abnormal tissue in GI tract.
62007495|NCT01534468|EXPERIMENTAL|Group 1: Previous H7N7 ca LAIV recipients|Participants in Group 1 will have previously received an H7N7 ca LAIV. In this study, they will receive one intramuscular (IM) injection of the H7N7 vaccine at study entry.
62007496|NCT01534468|EXPERIMENTAL|Group 2: Previous H7N3 ca LAIV recipients|Participants in Group 2 will have previously received an H7N3 ca LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
62007497|NCT01534468|EXPERIMENTAL|Group 3: Previous H2N3 ca LAIV recipients|Participants in Group 3 will have previously received an H2N3 ca LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
62007498|NCT01534468|EXPERIMENTAL|Group 4: Vaccine-naive participants|Participants in Group 4 will have not previously received a LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
62007499|NCT02212730|EXPERIMENTAL|Neoadjuvant Pembrolizumab + RCC Resection|Participants received pembrolizumab, 200 mg intravenously (IV) once every 3-week cycle for up to 2 cycles followed by standard of care (SOC) renal cell carcinoma (RCC) surgical resection; and then received post-resection pembrolizumab 200 mg IV once every 3 week cycle for up to approximately 1 year (17 cycles). Post-resection pembrolizumab was only administered to participants who enrolled after Protocol Amendment 04.
62007500|NCT02212730|EXPERIMENTAL|RCC Resection|Participants received SOC renal cell carcinoma (RCC) surgical resection; and then may have received post-resection pembrolizumab 200 mg IV once every 3 week cycle for up to approximately 1 year (17 cycles). Post-resection pembrolizumab was only administered to participants who enrolled under Protocol Amendment 04.
62007501|NCT03111992|EXPERIMENTAL|Arm A|Dose escalation of single agent CJM112
62007502|NCT03111992|EXPERIMENTAL|Arm B|Dose escalation of CJM112 in combination with a fixed dose of PDR001
62007503|NCT03111992|EXPERIMENTAL|Arm C|Dose escalation of LCL161 in combination with a fixed dose of PDR001
62007504|NCT01752140|ACTIVE_COMPARATOR|10-core prostate biopsy protocol group|Ultrasound guided prostate biopsy with extraction of 10 cores
62007505|NCT01752140|ACTIVE_COMPARATOR|Vienna nomogram prostate biopsy protocol group|Ultrasound guided prostate biopsy performed according to the Vienna nomogram
62007506|NCT01282424|EXPERIMENTAL|Idelalisib|Treatment with idelalisib will be continued until tumor progression or development of unacceptable toxicity.
62007507|NCT01280188|EXPERIMENTAL|Desmopressin|Day 1 - participants continue desmopressin intranasal. Day 2 up to Day 4 - Desmopressin oral melt to optimum dose. Continue optimum dose for the four week treatment and one year follow-up periods.
62193000|NCT03176004|NO_INTERVENTION|Wait List|Participants simply return after 8 weeks.
62193001|NCT01937169|EXPERIMENTAL|Drug + motor task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep.This group will be administered with a quarter of a Dopicar pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a motor task (e.g., walking) for 30 minutes."
62214832|NCT06172751||anti-IL-5/IL-5R therapy|Patients initiated anti-IL-5/IL-5R therapy
62214833|NCT06172751||other therapies|Patients initiated other therapies.
62214834|NCT04929405|EXPERIMENTAL|Intervention group|This group has access to the intervention (website for bereaved parents)
62214835|NCT02549196|EXPERIMENTAL|Cohort 1|Donepezil 20mg/day upward dose titration of 10mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
62781625|NCT05248477|EXPERIMENTAL|Premex protocol|a new organization of care, based on the EXPRIM (EXtrem PRematurity Innovative Management) protocol, involving early, standardized, and multidisciplinary management of women hospitalized for a risk of extremely preterm birth and their children
62781626|NCT06441149|EXPERIMENTAL|standard informed consent|standard informed consent
62781627|NCT06441149|EXPERIMENTAL|AI-based informed consent|Patients receiving personalized data-based informed consent procedure before bronchoscopy
62193002|NCT01937169|PLACEBO_COMPARATOR|Placebo + motor task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep. This group will be administered with a quarter of a Placebo pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a motor task (e.g., walking) for 30 minutes."
62781628|NCT02508428|ACTIVE_COMPARATOR|Crosslinked Marathon polyethylene|The crosslinked Marathon polyethylene liners used for the primary total hip replacements in this study were treated with 5 Mrad (50 kGy) of gamma irradiation to induce crosslinking and then heated above the melting temperature (150 degrees Celsius) to eliminate free radicals. This manufacturing process was designed to improve the polyethylene's resistance to wear through increased crosslinking and eliminate free radicals that render it susceptible to oxidative degradation. These liners were machined and terminally sterilized with gas plasma, a noncrosslinking chemical surface treatment. These liners did not have had free radicals at the time of implantation and did not incorporate antioxidants.
62781629|NCT02508428|ACTIVE_COMPARATOR|Noncrosslinked Enduron polyethylene|The standard, noncrosslinked Enduron polyethylene liners used for the primary total hip replacements in this study were manufactured from the same polyethylene resin as the crosslinked Marathon liners but never irradiated. Like the Marathon components, these liners were machined and terminally sterilized with gas plasma, a noncrosslinking chemical surface treatment. Based on the manufacturing methods, these liners would not have had free radicals at the time of implantation and did not incorporate antioxidants.
62193003|NCT01937169|SHAM_COMPARATOR|Dopicar + Sham task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep. This group will be administered with a quarter of a Dopicar pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a non-motor task (e.g., crossword puzzle) for 30 minutes."
62193004|NCT04455022||Any infant who will have a blood culture collected.|During the study period educational actions will be taken to raise the awareness of importance of collecting adequate volume of blood for culture (posters, leaflets and educational activities). The minimum volume will be defined as at least 1 ml. The paramount role of blood culture in process of ruling out newborn sepsis will be emphasized. The sample volume control by using bedside precision scale will be introduced.
62193005|NCT01617499||University employees|Participants will include employees of Washington University in St. Louis. Recruitment will be directed to staff employees of the Central Fiscal Unit (CFU) on the Danforth campus.
62193006|NCT05144945|EXPERIMENTAL|Group 1: Quadrivalent Recombinant Influenza Vaccine (RIV4)|Participants received a single intramuscular (IM) injection of 0.5 milliliters (mL) RIV4 on Day 1.
62781630|NCT06582368||Cardiac Surgery Patients|Mechanically ventilated postoperative adult patients after cardiac surgery within 6 hours after intensive care unit admission.
62781631|NCT01189643|EXPERIMENTAL|Chemotherapy|This is a pilot study to evaluate the acute toxicities and activity of irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator based therapy in newly diagnosed patients with DSRCT.
62007508|NCT02851238|NO_INTERVENTION|Protective Ventilation|The control arm receives existing conventional protective ventilation with tidal volume of 6mL/kg of ideal body weight and positive end expiratory ventilation of 5cmH2O during one-lung ventilation
62007509|NCT02851238|EXPERIMENTAL|Driving Pressure Limited Ventilation|The intervention arm receives driving pressure limited ventilation during one-lung ventilation
62781632|NCT04072263|EXPERIMENTAL|Cohort 1|"* Carboplatin-paclitaxel day1, q3 weeks, 6x, plus~* Tumor Infiltrating Lymphocytes (TIL) starting 14 days after the 2nd chemotherapy cycle, q3 weeks, 3x."
62781633|NCT04072263|EXPERIMENTAL|Cohort 2|"* Carboplatin-paclitaxel day1, q3 weeks, 6x, plus~* Tumor Infiltrating Lymphocytes (TIL) starting 14 days after the 2nd chemotherapy cycle, q3 weeks, 3x, plus~* Interferon Alpha 2A (3x10e6 U daily) starting one week before the first TIL infusion for 12 weeks in total."
62781634|NCT00417963|EXPERIMENTAL|stent placement in the carotid artery|placement of a bare metal stent for treatment of carotid artery stenosis
62781635|NCT05503225|ACTIVE_COMPARATOR|Colchicine|0.5 mg of Colchicine for 12 months to be orally taken
62193007|NCT05144945|ACTIVE_COMPARATOR|Group 2: Quadrivalent-inactivated Influenza Vaccine (IIV4)|Participants received a single IM injection of 0.5 mL IIV4 on Day 1.
62193008|NCT03314831||Sepsis|Patients with sepsis or septic shock admitted on Intensive Care Unit.
62193009|NCT03314831||Systemic Inflammatory Response Syndrome|Patients with Systemic Inflammatory Response Syndrome non-infectious etiology.
62193010|NCT03314831||No inflammation|Patients without systemic inflammation.
62214836|NCT02549196|EXPERIMENTAL|Cohort 2|Donepezil 20mg/day upward dose titration of 20mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
62007510|NCT01501812||Schizophrenia|Subjects who are suffering from Schizophrenia or Schizoaffective disorder acording to the DSM-IV-R criteria
62007511|NCT01501812||Control|Healthy subjects without any mental ilness in axis I or II.
62007512|NCT01501812||Bipolar|Subjects who are suffering from bipolar I or 2 disorder acording to the DSM-IV-R criteria
62781636|NCT05503225|NO_INTERVENTION|Standard of care|Standard medical therapy
62007513|NCT01501812||MDD|Subjects who are suffering from Major Depressive disorder acording to the DSM-IV-R criteria
62007514|NCT01501812||Anxiety|Subjects who are suffering from Panic disorder or from Generalized Anxiety disorder acording to the DSM-IV-R criteria
62007515|NCT01501812||PTSD|Subjects who are suffering from Post Traumatic Stress Disorder acording to the DSM-IV-R criteria
62193011|NCT03000790|EXPERIMENTAL|Lingual Ring Splint|"A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.~The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior arch will make the Ring around the tongue"
62193012|NCT05671497|EXPERIMENTAL|Cilostazol arm|35 patients receiving conventional synthetic disease modifying antirheumatic drugs in addition to Cilostazol 100 mg twice daily for 6 months.
62193013|NCT05671497|ACTIVE_COMPARATOR|Control|35 patients receiving conventional synthetic disease modifying antirheumatic drugs for 6 months.
62781637|NCT01153360|EXPERIMENTAL|T3|triiodothyronine
62007516|NCT05424471|EXPERIMENTAL|Family Spirit Nurture (FSN)|Intervention group participants receive 1 Family Spirit Nurture lesson taught by Family Health Coaches. Mothers will receive the lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The lesson focuses on age-appropriate parental feeding practices, including snack routines, avoidance of SSBs and promotion of water consumption. The lesson is highly visual and interactive, and incorporates cultural teachings related to child feeding and nutrition that support aims. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
62781638|NCT01153360|ACTIVE_COMPARATOR|cyanocobalamin|vitamin B12
62781639|NCT03502902|EXPERIMENTAL|HEC68498|administered once on first day in each Treatment Period， HEC68498 VS placebo 3:1 ratio
62781640|NCT03502902|PLACEBO_COMPARATOR|placebo|administered once on first day in each Treatment Period
62781641|NCT04552106|ACTIVE_COMPARATOR|Group 1|10 subjects
62781642|NCT04552106|ACTIVE_COMPARATOR|Group 2|10 subjects
62781643|NCT04552106|ACTIVE_COMPARATOR|Group 3|10 subjects
62781644|NCT04552106|ACTIVE_COMPARATOR|Group 4|10 subjects
62781645|NCT04552106|ACTIVE_COMPARATOR|Group 5|10 subjects
62781646|NCT03372863||Cardiac surgery patients|
62781647|NCT06409494|EXPERIMENTAL|HZV-1|Biological: EuHZV Healthy adults received 0.5mL single intramuscular dose on Visit 2(Day 0) and Visit 4(day 56).
62781648|NCT06409494|EXPERIMENTAL|HZV-2|Biological: EuHZV Healthy adults received 0.5mL single intramuscular dose on Visit 2(Day 0) and Visit 4(day 56).
62781649|NCT06409494|ACTIVE_COMPARATOR|Shingrix|Biological: Shingrix Healthy adults received 0.5mL single intramuscular dose on Visit 2(Day 0) and Visit 4(day 56).
62781650|NCT02199561|EXPERIMENTAL|Fecal Microbiota Transplant|Open label single arm delivering fecal transplant to each participant
62781651|NCT06468670|EXPERIMENTAL|short-course radiotherapy+sintilimab|
62781652|NCT01076413|EXPERIMENTAL|skill-based exercise|2 times per week for 12 weeks. warm-up, stretching, strengthening, and skill-based exercises. Pre-gait and gait activities including stepping patterns and walking patterns and treadmill training at various walking speeds
62781653|NCT01076413|ACTIVE_COMPARATOR|aerobic exercise training|warm-up, strengthening and aerobic conditioning (treadmill walking)
62781654|NCT02696759|OTHER|Blood & Fecal Collection|Subjects receiving neoadjuvant chemotherapy for advanced breast cancer will be asked to complete questionnaires, provide two blood samples, and provide 2 fecal samples while receiving standard of care neoadjuvant chemotherapy
62781655|NCT02724527|PLACEBO_COMPARATOR|Placebo|Matching capsule (BID administration Q12H)
62781656|NCT02724527|EXPERIMENTAL|Cavosonstat (N91115) 400 mg|Cavosonstat (N91115) at 400 mg dose (100 mg x 4 capsules) (BID administration Q12H)
62781657|NCT01124461||Brain Tumor|Brain neoplasms, malignant
62781658|NCT03162081||Users|"Elderly patients who use prescription benzodiazepines/Z-hypnotics or opiates~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Cognistat Neurobehavioural cognitive status examination (Cognistat), Neuropsychological profiling, Medication use, Comorbidity"
62781659|NCT03162081||Non-users|"Age and gender matched controls not using the above~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Cognistat Neurobehavioural cognitive status examination (Cognistat), Neuropsychological profiling, Medication use, Comorbidity"
62781660|NCT03162081||Screening group|"Patients over 65 admitted to hospital as in-patients~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Medication use, Comorbidity"
62781661|NCT01068158|EXPERIMENTAL|0.5% Ivermectin Cream|Up to 4 ounces of topical Ivermectin Cream applied to hair and scalp on day 1
62781662|NCT01068158|PLACEBO_COMPARATOR|Vehicle control|Up to 4 ounces of topical control applied to hair and scalp on day 1.
62193014|NCT04258683|EXPERIMENTAL|Pembrolizumab with CyBorD|This will be a single arm study of pembrolizumab with cyclophosphamide, bortezomib and dexamethasone (CyBorD).
62193015|NCT05390177|EXPERIMENTAL|First health video|This video presents health information for one study condition.
62193016|NCT05390177|ACTIVE_COMPARATOR|Second health video|This video presents health information for one study condition.
62193017|NCT02295176|EXPERIMENTAL|Armolipid Plus|Armolipid Plus: 1 tablet daily in the evening after dinner for 24 weeks.
62193018|NCT02295176|PLACEBO_COMPARATOR|Placebo|1 tablet matching Armolipid Plus daily in the evening after dinner for 24 weeks
62193019|NCT04650698|EXPERIMENTAL|Tranexamic acid (TXA) Injection|Participants scheduled for Revision Total Shoulder Arthroplasty (TSA) will receive two injections of TXA.
62193020|NCT04650698|NO_INTERVENTION|Control - No Tranexamic acid (TXA) Injection|Participants scheduled for Revision Total Shoulder Arthroplasty (TSA) won't receive any injections TXA.
62193021|NCT02747888|NO_INTERVENTION|Lower Suspected Familial Predisposition|"Lower Suspected Familial Predisposition~Screening and Enrollment:~Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.~- Sample stored in Biorepository"
62193022|NCT02747888|EXPERIMENTAL|Higher Suspected Familial Predisposition|"Higher Suspected Familial Predisposition~Screening and Enrollment:~Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.~- Specimen Testing and Analysis~•Referral to Genetic Counselor, if indicated"
62193023|NCT05291377||high disbility group|Group scored more than half of the score of the neck disability index
62193024|NCT05291377||low disability group|Group scored less than half of the score of the neck disability index
62193025|NCT05825222|ACTIVE_COMPARATOR|E-PR-01 (Low Dose)|One capsule twice a day
62781663|NCT03207594||Arm 1|Current smokers with cancer who are planning to get radiation therapy at MUSC.
62007517|NCT05424471|OTHER|Control Vehicle Safety|Control group participants receive 1 lesson with vehicle safety information, taught by Family Health Coaches. Mothers will receive the lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
62007518|NCT04541758|EXPERIMENTAL|surgical treatment|Minimally invasive internal fixation under spontaneous respiratory anesthesia and analgesic treatment and chest strap fixation
62007519|NCT04541758|EXPERIMENTAL|Conservative treatment|analgesic treatment and chest strap fixation
62007520|NCT03734848|NO_INTERVENTION|Group 1|patients did not receive Bilateral Ultrasound Guided Pectoralis Nerve Block (control group).
62193026|NCT05825222|ACTIVE_COMPARATOR|E-PR-01 (High Dose)|One capsule twice a day
62193027|NCT05825222|PLACEBO_COMPARATOR|Placebo|One capsule twice a day
62193028|NCT02764099|EXPERIMENTAL|Life Skills Training|"All youth who consent to participate in the proposed study will 1) complete the youth peer court sanction delivered by the jury of peers (e.g., apologies or essays, restitution, curfew and travel restrictions, counseling, etc.), which will constitute treatment as usual; and 2) complete pre, post, and six-month follow-up surveys. Those randomized to the intervention condition (n=280) will participate in the LST program concurrently during the weeks when they serve as peer court jurors."
62193029|NCT01485120|OTHER|Blood Pressure monitoring|Blood Pressure (BP) monitoring using invasive arterial insertion as a standard reference, and an investigational, non-invasive blood pressure (NIBP) monitoring cuff. Data obtained from the cuff used the SuperSTAT NIBP algorithm and the Classic NIBP algorithm for output.
62193030|NCT06171555|ACTIVE_COMPARATOR|Standard of Care Steroid Injection|Group 1 Control Group: standard corticosteroid injection: 1cc of celestone (6mg) diluted with 1 cc of 1% lidocaine and inject at the ECRB origin at area of maximal pain when palpated.
62781664|NCT00038558|EXPERIMENTAL|Filgrastim + ABVD Chemotherapy|
62781665|NCT06385054|EXPERIMENTAL|Probiotic|Participants in this group will be randomized to receive the probiotic B. lactis B94 for 4 weeks.
62781666|NCT06385054|PLACEBO_COMPARATOR|Placebo|Participants in this group will be randomized to receive a placebo for 4 weeks.
62781667|NCT05809492|EXPERIMENTAL|Patients with a diagnosis of cystic fibrosis, FEV1(functional expiratory volume)< 40%|calculation of the maximum exercise capacity using the a-step test
62781668|NCT05809492|EXPERIMENTAL|Patients with a diagnosis of cystic fibrosis, FEV1(functional expiratory volume)< 40-70%|calculation of the maximum exercise capacity using the a-step test
62781669|NCT05809492|EXPERIMENTAL|Patients with a diagnosis of cystic fibrosis, FEV1(functional expiratory volume)> 70%|calculation of the maximum exercise capacity using the a-step test
62781670|NCT03012204|EXPERIMENTAL|combined rTMS at both M1|combined rTMS at both M1: sham 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / real 6 Hz rTMS on affected M1
62781671|NCT03012204|EXPERIMENTAL|real primed LFrTMS at unaffected M1|real primed LFrTMS at unaffected M1: real 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / sham 6 Hz rTMS on affected M1
62007521|NCT03734848|ACTIVE_COMPARATOR|Group 2|patients receive Bilateral Ultrasound Guided Pectoralis Nerve Block (control group).
62193031|NCT06171555|EXPERIMENTAL|Test CTM Injection|Group 2 Test Group: CTM injection: 1cc of CTM Boost will be diluted with 1 cc of 1% lidocaine and injected at the ECRB origin at area of maximal pain when palpated. CTM Boost is a connective tissue matrix suspended in saline. (injection will need to be with a 23 gauge needle and 3 cc syringe)
62193032|NCT01474629|ACTIVE_COMPARATOR|probiotic-based dietary supplement|
62193033|NCT01474629|PLACEBO_COMPARATOR|placebo|
62193034|NCT02641587|EXPERIMENTAL|CHTP 1.2|Ad libitum use of the CHTP 1.2
62781672|NCT03012204|ACTIVE_COMPARATOR|real LFrTMS at unaffected M1|real LFrTMS at unaffected M1: sham 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / sham 6 Hz rTMS on affected M1
62781673|NCT03012204|SHAM_COMPARATOR|all sham stimulation|all sham stimulation： sham 6 hertz(Hz) rTMS on unaffected M1 / sham 1 Hz rTMS on unaffected M1 /sham 6 Hz rTMS on affected M1
62781674|NCT06120439|EXPERIMENTAL|T Group|The T Group received PECS II(PMID: 22939099) combined with intercostal nerve block
62781675|NCT06120439|ACTIVE_COMPARATOR|C Group|C Group underwent laryngeal mask insertion after general anesthesia induction.
62781676|NCT03263338|ACTIVE_COMPARATOR|Group A|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target.
62193035|NCT02641587|ACTIVE_COMPARATOR|CC|Ad libitum use of subject's own preferred non-menthol brand of CC
62193036|NCT06533488|EXPERIMENTAL|Feedback group|This group will receive feedback upon completion of the task.
62781677|NCT03263338|EXPERIMENTAL|Group B|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group B.
62781678|NCT03263338|EXPERIMENTAL|Group C|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group C.
62193037|NCT06533488|PLACEBO_COMPARATOR|Control group|This group will not receive any feedback
62781679|NCT00614484|EXPERIMENTAL|Proton therapy with chemotherapy|"Induction Chemotherapy - Two cycles Taxol 200mg/m2 and Carboplatin AUC6 on day 1 and day 22. Weekly chemotherapy concurrent with radiotherapy Taxol 50mg/m2 and Carboplatin AUC 2 weekly for 5 weeks.~Proton therapy - 76 Gy in 5 weeks to lung tumor."
62781680|NCT00106353|EXPERIMENTAL|1.0|
62007522|NCT02892981|OTHER|Pulmonary hypertension patients|All Pulmonary hypertension patients enrolled in the study underwent a cardiopulmonary exercise test and hypoxia and hypercapnia tests
62193038|NCT00531089|EXPERIMENTAL|Study group|"All patients in the study will be in the study group and will receive rituximab. There is no control arm."
62193039|NCT00759642|EXPERIMENTAL|Lapatinib|lapatinib
62193040|NCT05317442|EXPERIMENTAL|Pressure Injury in Sacrum and Greater Trochanter Wound|"1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day~6. Duration: up to 16 weeks"
62193041|NCT02949245||Groups/Cohorts|"Surgical treatment~This observational study is examining the outcomes of standard surgical treatments for adult spinal deformity."
62781681|NCT04316026|EXPERIMENTAL|interventional group|group receiving shock wave therapy
62007523|NCT04216732||Observational (questionnaire, blood pressure)|"AIM I \& II: Patients complete questionnaires over 10-40 minutes 2-4 times per year about health and how finances and quality of life effect experience with disease.~AIM III: Patients complete a questionnaire over 2 minutes and undergo blood pressure measurements every day for up to 12 weeks."
62007524|NCT03643003|EXPERIMENTAL|Music Therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Order is randomly assigned, and all participants engage in both study arms."
62193042|NCT05654233|EXPERIMENTAL|Taking sulodexide|Sixty patients with varicose veins who received radiofrequency ablation combined with sclerotherapy were given Sulodexide softgels 250LSU twice a day for two months after surgery。
62193043|NCT05654233|NO_INTERVENTION|Not taking drug|Sixty patients with varicose veins of the lower extremities who received radiofrequency ablation combined with sclerotherapy were selected and did not take sulodexide after surgery.
62193044|NCT05730491|EXPERIMENTAL|Social Learning and Cognitive Behavioral Therapy (SLCBT)|
62193045|NCT05730491|PLACEBO_COMPARATOR|Attention Education Control|
62781682|NCT04316026|SHAM_COMPARATOR|control group|sham shock wave therapy
62781683|NCT06229327|EXPERIMENTAL|PEDİATRİC|Children in the intervention group were played a therapeutic game explaining the procedure before indwelling catheter intervention. Children in the control group did not undergo any intervention other than the hospital's normal procedure before indwelling catheter intervention.
62781684|NCT06469528|EXPERIMENTAL|Low dose colchicine 0.5mg OD|Low dose colchicine 0.5mg OD for 6 months
62781685|NCT06469528|NO_INTERVENTION|Guideline directed therapy|Guideline directed therapy; participants will be maintained on maximal tolerated dose of established statin therapy (\>4 weeks)
62193046|NCT00987662|ACTIVE_COMPARATOR|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP\>135/85 mmHg add HCZ 12.5 mg.
62193047|NCT00987662|ACTIVE_COMPARATOR|Amplodipine|Treatment with amlodipine 10 mg for 4 weeks. If BP\>135/85 mmHg add hydrochlorothiazide 12.5 mg
62007525|NCT03643003|PLACEBO_COMPARATOR|Non-Music Verbal Interaction|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Order is randomly assigned, and all participants engage in both study arms."
62007526|NCT04368962||MMF group|Post-transplant patients accept immunosuppression protocol based on MMF for at least 12 months.
62007527|NCT03678012|ACTIVE_COMPARATOR|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio
62007528|NCT03678012|PLACEBO_COMPARATOR|Hydrogen peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio
62007529|NCT03678012|SHAM_COMPARATOR|Water|Sham solution (water; negative control)
62007530|NCT04440293|EXPERIMENTAL|Group BBAT / CT|Group BBAT / CT started treatment with BBAT and received 2 days a week for 6 weeks. After the interval of 5-week, group BBAT / CT was treated with CT twice a week for 6 weeks.
62781686|NCT05322226|OTHER|Adults undergoing pre- liver transplant assessment|All patients included in the study will have blood and urinary test from their registration on the transplant list and during their classic follow-up with their hepatologist for 12 months to quantify the biological markers of alcoholism (every 3 months). Additional tubes and urine will be collected in order to measure these markers (urinary ethylglucuronide and blood phosphatidylethanol).
62007531|NCT04440293|EXPERIMENTAL|Group CT / BBAT|Group CT / BBAT started treatment with CT and received 2 days a week for 6 weeks. After the interval of 5-week, group CT / BBAT was treated with BBAT twice a week for 6 weeks.
62193048|NCT05251675|ACTIVE_COMPARATOR|Coaching Group|This arm will receive physician led coaching during the first 6 months of the study.
62781687|NCT01423266|EXPERIMENTAL|High Protein Group|12-week supervised weight loss program consisting of a HP diet defined as 30% of energy from protein, 40% from carbohydrates and 30% from fat
62781688|NCT01423266|ACTIVE_COMPARATOR|Standard Protein Group|12-week supervised weight loss program consisting of a SP diet defined as 15% of energy from protein, 55% from carbohydrates and 30% from fat
62781689|NCT06294847|EXPERIMENTAL|Experimental arm: 'UDCA'|Experimental arm: 'UDCA': Patients will be treated with ursodeoxycholic acid (UDCA), receiving a single dose of Ursolvan® (10mg/kg) orally within 24 hours before the surgical intervention, followed by a daily dose of 10mg/kg in two divided doses for 30 days.
62781690|NCT06294847|PLACEBO_COMPARATOR|Control arm: 'Placebo'|Control arm: 'Placebo': Patients will receive a single dose of placebo orally within 24 hours before the surgical intervention, followed by two doses per day for 30 days.
62781691|NCT05547308|EXPERIMENTAL|Prosthetic device|All subjects will receive the 3D myoelectric prosthetic device
62781692|NCT00167310|EXPERIMENTAL|1|Eicosapentaenoic acid (omega-3 fatty acid, 2 g in 4x500 mg softgels daily) + Antipsychotic drug (doctor's choice) treatment for baseline, 1 month, 2 months and 4 months duration.
62781693|NCT00167310|PLACEBO_COMPARATOR|2|Placebo (soy bean oil, 2 g in 4x500 mg softgels daily) + Antipsychotic drug (doctor's choice) treatment for baseline, 1 month, 2 months and 4 months duration.
62781694|NCT01705093|EXPERIMENTAL|Flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
62007532|NCT02225964||aMCIp,aMCIs|progressive aMCI,stable aMCI
62007533|NCT00796965|EXPERIMENTAL|1|
62781695|NCT01705093|PLACEBO_COMPARATOR|macronutrient- matched control powder|50g macronutrient-matched control powder that will lack strawberry flavonoids
62781696|NCT03094065|ACTIVE_COMPARATOR|News with Spin|News items reporting results of pre-clinical studies with spin.
62781697|NCT03094065|EXPERIMENTAL|News without spin|News items reporting results of pre-clinical studies without spin.
62007534|NCT00796965|PLACEBO_COMPARATOR|2|
62007535|NCT02516124||NISSC|Autologous HSCT
62007536|NCT01814176|ACTIVE_COMPARATOR|Macintosh Direct Laryngoscope|2 main forces - a 'lifting' force to elevate the structures not in the line of sight and a force exerted by the user's wrist to counterbalance the torque effect of the tongue tissues on the blade
62007537|NCT01814176|ACTIVE_COMPARATOR|GlideScope Video Laryngoscope|The GlideScope has a 60º angulation anteriorly at the distal portion of the blade, allowing an anterior view of the larynx.
62007538|NCT03555526|EXPERIMENTAL|Genotypic resistance guided therapy|The regimen will be chosen according to the genotyping of 23S rRNA and gyrase A of H. pylori. In the absence of gyrase A mutation, esomeprazole (Nexium), amoxicillin (Amoxicillin), levofloxacin (Cravit), metronidazole (Flagyl) for 14 days will be given. In the presence of gyrase A mutation but in the absence of 23S rRNA mutation, esomeprazole (Nexium), amoxicillin (Amoxicillin), clarithromycin (Klaricid), metronidazole (Flagyl) for 14 days will be given. In the presence of both gyrase A and 23S rRNA mutation, bismuth quadruple therapy including esomeprazole (Nexium), bismuth (KCB), tetracycline, and metronidazole (Flagyl) for 10 days will be given.
62781698|NCT06434467|EXPERIMENTAL|Nelarabine injection|"Adults (≥18 years old): 1500 mg/m², administer intravenously for at least 2 hours on days 1, 3, and 5, repeating every 21 days.~Children (1-17 years old): 650 mg/m ², administer intravenously for 1 hour daily for 5 consecutive days, repeating every 21 days."
62021052|NCT01202773|EXPERIMENTAL|120 milligrams (mg) LY2127399|"Given every 4 weeks (Q4W) for 24 weeks. Participants receive a 240-mg loading dose when initiating treatment.~During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks (Q2W).~At Week 16, responders will receive 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period.~At Week 16, non-responders (NR) will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
62193049|NCT05251675|PLACEBO_COMPARATOR|Non-Coached Group|This arm will not receive physician led coaching until after the Coaching Group is finished with their coaching.
62193050|NCT01693835||Patients|Patients with metastatic colorectal cancer
62193051|NCT01693835||Healthy subjects|Age and sec-matched healthy subjects
62193052|NCT04584671||Mild COVID-19 Infection Group|100 participants age ≥ 18 and \<80 years who experienced a documented case (documented by positive COVID-19 test and/or clinical history) of mild COVID-19 infection, all of whom are within 3 months post recovery and non-infectious.
62193053|NCT04584671||Severe COVID-19 Infection Group|100 participants age ≥ 18 and \<80 years who experienced a documented case (documented by positive COVID-19 test and/or clinical history) of severe COVID-19 infection, including at least 50 participants who were hospitalized with COVID-19 infection, all of whom are within 3 months post recovery and non-infectious.
62573234|NCT06128239|NO_INTERVENTION|Enhanced Usual Care (UC)|Participants randomized to the UC arm will receive best available usual care from the health system, such as standardized clinical assessments, the safety planning intervention or other intervention(s), appropriate referrals and/or medication management through a system wide electronic health record system-assisted suicide care clinical workflow. Usual care will vary based on patient clinical needs, availability of providers/staff, and provider clinical judgment. Following study enrollment, all participants will be given a list of resources, offered a warm hand-off to 988, and encouragement to call or text 988 as needed. During the baseline survey, participants will have the opportunity to opt into a call from the follow-up team to develop or revise a safety plan.
62781699|NCT02522130|ACTIVE_COMPARATOR|lidocaine group|Group A will receive 10 ml 1% lidocaine (Xylocaine 1%, Astra Zeneca, Egypt) Para cervical block prior to insertion of IUD (injection sites at cervix-vaginal junction typically at 4 ,8 O'clock), Then 3 minutes waiting period between the administration of the Para cervical block and IUD insertion,
62193054|NCT00979290||Separate anti-TB drugs|
62193055|NCT00979290||Fix-dosed combination anti-TB drugs|
62193056|NCT00778232|EXPERIMENTAL|1|Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited
62193057|NCT00778232|ACTIVE_COMPARATOR|2|Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd
62193058|NCT04830189|EXPERIMENTAL|shoulder slings|Patients were used shoulder sling in addition to conservative treatment.
62781700|NCT02522130|ACTIVE_COMPARATOR|misoprostol group|Group B will receive 400 mcg oral misoprostol (Sigma, Egypt) prior to IUD insertion
62781701|NCT02522130|ACTIVE_COMPARATOR|non steroid group|Group C will receive oral naproxen (Naprosyn, Syntax, Egypt) prior to IUD insertion
62781702|NCT02522130|PLACEBO_COMPARATOR|placebo group|group D will receive placebo tablets.
62193059|NCT04830189|ACTIVE_COMPARATOR|forearm sling|Patients were used forearm sling in addition to conservative treatment.
62007539|NCT03555526|ACTIVE_COMPARATOR|Phenotypic resistance guided therapy|The regimen will be chosen according to the susceptibility testing result. In the absence of levofloxacin resistance, esomeprazole (Nexium), amoxicillin (Amoxicillin), levofloxacin (Cravit), metronidazole (Flagyl) for 14 days will be given. In the presence of levofloxacin resistance but in the absence of clarithromycin resistance, esomeprazole (Nexium), amoxicillin (Amoxicillin), clarithromycin (Klaricid), metronidazole (Flagyl) for 14 days will be given. In the presence of both levofloxacin and clarithromycin resistance, bismuth quadruple therapy including esomeprazole (Nexium), bismuth (KCB), tetracycline, and metronidazole (Flagyl) for 10 days will be given.
62007540|NCT01945385|EXPERIMENTAL|Video intervention|Participants will view a seven - minute theory-based video of patient testimonials about their own postabortal LARC uptake.
62007541|NCT01945385|NO_INTERVENTION|Control|Patients will view a 7 minute video about stress management delivered by local psychologist.
62007542|NCT01878604||Homozygous Familial Hypercholesterolemia|Gene Analysis for Homozygous Familial Hypercholesterolemia cases
62007543|NCT02094859||GlucoClear System|
62007544|NCT01611324|EXPERIMENTAL|Alkalinised anesthetic solution|
62007545|NCT01611324|ACTIVE_COMPARATOR|Non alkalinised anesthetic solution|
62007546|NCT04122248||M6-C|Subjects treated with an M6-C device
62007547|NCT04122248||ACDF|Subjects treated with Anterior Cervical Discectomy and Fusion (ACDF)
62007548|NCT02361567|ACTIVE_COMPARATOR|Tramacet|Tramacet 1-2 tabs PO q4h prn
62007549|NCT02361567|ACTIVE_COMPARATOR|Percocet|Percocet (5/325) 1-2 tab PO q4h PRN
62781703|NCT04107207|ACTIVE_COMPARATOR|Kombucha Intervention|Either ginger kombucha or placebo ginger water will be given to subjects for weeks 1-4 and then the reciprocal beverage for weeks 6-10.
62781704|NCT04107207|PLACEBO_COMPARATOR|Placebo Intervention|Either ginger kombucha or placebo ginger water will be given to subjects for weeks 1-4 and then the reciprocal beverage for weeks 6-10.
62007550|NCT06309875|ACTIVE_COMPARATOR|Conventional|Set of specific activities carried out by the health care team by the health care team at the time of hospital discharge of HF patients: the patients with HF:
62007551|NCT06309875|EXPERIMENTAL|PLAN CUIDARTE|"The PLAN CUIDARTE is an intervention aimed at addressing the hospital discharge of people with HF, based on the nursing theory of transitions of Afaf Meleis(46) and under the guidelines of Robin Whittemore for the systematic development of complex interventions for experimental type research in nursing. The PLAN CUIDARTE addresses the specific educational needs of HF patients, as established by the patients with HF, as established by international accreditation standards."
62007552|NCT04268342|NO_INTERVENTION|Standard care|When clinical services are in the standard case phase of the study, all cases of gonorrhoea infection diagnosed at those services will be managed according to current standard of care management guidelines i.e. all cases of gonorrhoea infection will be treated with ceftriaxone by injection plus oral azithromycin tablets as first line therapy, regardless of whether the treatment is given at the initial clinic or the return clinic visit.
62007553|NCT04268342|ACTIVE_COMPARATOR|Implementation|When clinical services are assigned to the implementation phase, first line treatment for gonorrhoea infection for patients treated at their first clinic visit will remain the same as it is currently: ceftriaxone by injection plus oral azithromycin tablets. However, patients who are not treated presumptively will be treated at their return visit on the basis of the drug resistance test results. Patients with gonorrhoea infection that is shown to be susceptible to ciprofloxacin will be treated with oral ciprofloxacin therapy when they return for review at clinical services in the implementation phase. Patients with gonorrhoea infection that is not susceptible to ciprofloxacin or with an indeterminate ciprofloxacin result will be treated with ceftriaxone by injection.
62781705|NCT03447847|EXPERIMENTAL|Phase 1|A=oligomineral water, B=oligomineral water
62398152|NCT06298721|EXPERIMENTAL|Standard of Care TKA + Personalized Outcome Prediction Tool with targeted interventions|"Patients who are identified to have a TKA PROMs phenotype which includes lower than median scores for VR-12 MCS will be further screened for:~Distress ➔ using the NCCN Distress Thermometer (DT) Depression ➔ using the Patient Health Questionnaire-9 Those patients with a score ≥ 8 on the DT, or a score ≥ 10 on the PHQ-9, or any response other than 0 to question 9 on the PHQ-9 will have a consult with Psychiatry and Behavioral Science to determine a mental health diagnosis.~Patients who are identified to have a TKA PROMS phenotype which includes lower than median scores for KOOS-PS (score of =\<51.5) will be scheduled for a 4 to 8 week intervention of pre-rehabilitation. All patients who undergo the PT intervention will have a an assessment before and after the rehab TKA."
62398153|NCT03953300|EXPERIMENTAL|Benralizumab|Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks
62398154|NCT03953300|PLACEBO_COMPARATOR|Placebo|Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks
62007554|NCT03235024|ACTIVE_COMPARATOR|B244|"B244 suspension in 30ml/bottle~Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day."
62007555|NCT03235024|PLACEBO_COMPARATOR|Vehicle|"Vehicle, 30ml/bottle~Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day."
62007556|NCT00451282|EXPERIMENTAL|Stepped Preventive Care|Receiving Stepped Preventive Care intervention - at least 2 brief assessments with nurse and/or social worker (1) during hospital admission , and (2) approximately 2 weeks post-discharge. Additional interventions provided as needed, based on manual.
62007557|NCT00451282|NO_INTERVENTION|Treatment as usual|Medical and psychosocial care per usual hospital protocols, which may include social work support.
62007558|NCT02658110|SHAM_COMPARATOR|Non Protein Trial|Mixed Macronutrient Breakfast Meal and Mixed Macronutrient Lunch Meal served without additional whey protein
62007559|NCT02658110|EXPERIMENTAL|Preload Trial|Whey protein (20g) administered 15 minutes prior to Mixed Macronutrient Breakfast Meal
62007560|NCT02658110|EXPERIMENTAL|With Meal Trial|Whey protein (20g) administered alongside Mixed Macronutrient Breakfast Meal
62007561|NCT02658110|EXPERIMENTAL|Post Meal Trial|Whey protein (20g) administered 15 minutes after Mixed Macronutrient Breakfast Meal
62007562|NCT05501197|ACTIVE_COMPARATOR|Synchronous Telerehabilitation Group|Synchronous Telerehabilitation Group will receive exercise therapy via video conference.
62007563|NCT05501197|EXPERIMENTAL|Asynchronous Telerehabilitation Group|Asynchronous Telerehabilitation Group will receive exercise therapy via mobile application.
62007564|NCT02978690|EXPERIMENTAL|Spesolimab|
62398155|NCT03050749|OTHER|Princess® VOLUME|
62781706|NCT03447847|EXPERIMENTAL|Phase 2|A=oligomineral water, B=bicarbonate-rich water
62781707|NCT03447847|EXPERIMENTAL|Phase 3|A=bicarbonate-rich water, B=oligomineral water
62398156|NCT05206305|EXPERIMENTAL|AD Patients|Patients with Alzheimer's Disease, as verified by positive A(beta)-PET and/or CSF tau/A(beta) biomarkers, who will receive one hour daily gamma frequency sensory stimulation from the investigational device for an 8 week period.
62398157|NCT00706901|EXPERIMENTAL|Arm 1 GMI|Patients randomized to GMI received four structured 75-minute sessions consistent with the central principles and style of motivational interviewing (Miller \& Rollnick, 2012). The goal of MI is to develop a sense of discrepancy between personal goals and current behavior and enhance change talk among participants, particularly for taking responsibility of one's substance use and being proactive for remaining in treatment.
62007565|NCT01280929|ACTIVE_COMPARATOR|Panretinal Photocoagulation (PRP)|Group 1: Panretinal photocoagulation treatment (PRP) at month-0 that can be repeated after month-3.
62007566|NCT01280929|EXPERIMENTAL|Ranibizumab|Group 2: Intravitreous injections of ranibizumab every 4 weeks at month-0, month-1 and month-2 that can be repeated after month-3.
62007567|NCT01280929|EXPERIMENTAL|Ranibizumab + Panretinal Photocoagulation (PRP)|Group 3: Combination treatment of ranibizumab intravitreous injections plus PRP (2 weeks +/- 1 week after injection), at month-0, month-1 and month-2 that can be repeated after month-3.
62007568|NCT06333938|EXPERIMENTAL|Bridge|Experimental - 30 participants will receive the Bridge device, up to 10 patients per month
62007569|NCT06333938|ACTIVE_COMPARATOR|Battlefield Acupuncture (BFA)|30 participants will receive BFA, up to 10 patients per month
62007570|NCT02442817|ACTIVE_COMPARATOR|Linagliptin patients with schizophrenia|This group will be made up of 8 participants with schizophrenia and minimal thought disorder who have been stable and taking their prescribed antipsychotics; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment.
62007571|NCT02442817|ACTIVE_COMPARATOR|Linagliptin control group|This group will be made up of 10 control participants with no diagnosis of mental disorder; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day.
62193060|NCT02762188|EXPERIMENTAL|wet ARMD patients|Patients with the wet form of ARMD who receive or have received in the past anti VEGF intra vitreal injections. Diagnosis of wet ARMD is made based on clinical data-visual acuity, fundus presence of subretinal fluid and/or haemorrhage and/or hard exudates, fundus photographs -color and red free, optical coherence tomography (SD-OCT), fluorescein angiography and indocyanine green angiography showing the presence and activity of subretinal neovascularisation.
62781708|NCT03447847|EXPERIMENTAL|Phase 4|A=bicarbonate-rich water, B=bicarbonate-rich water
62781709|NCT02750839||proximal humerus fracture|Patients with proximal humerus fracture treated with mini-invasive plate.
62781710|NCT01138501|EXPERIMENTAL|rFVIII|
62007572|NCT03376997|EXPERIMENTAL|Perampanel: 30-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 milligram (mg) dose of perampanel intravenous (IV) infusion (30-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
62007573|NCT03376997|EXPERIMENTAL|Perampanel: 60-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 mg dose of perampanel IV infusion (60-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
62193061|NCT02694042|EXPERIMENTAL|Mission is Remission® Group|Participants in this group will be given access to the Mission is Remission® web-based teaching and support site. They will also be emailed a link to complete online questionnaires at set time points throughout the study.
62573235|NCT02430519|EXPERIMENTAL|11 Patients with Grade II Manibular Molar Furcation|Group A- Furcation Treatment with PRF
62007574|NCT03376997|EXPERIMENTAL|Perampanel: 90-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 mg dose of perampanel IV infusion (90-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
62007575|NCT03365284|EXPERIMENTAL|Smart Kneebrace|Smart Kneebrace with a smart phone app will be used during the rehabilitation after surgery for three months
62007576|NCT03365284|PLACEBO_COMPARATOR|without Smart Kneebrace|regular rehabilitation procedure will be applied after surgery
62573236|NCT02430519|EXPERIMENTAL|11 Patients with Grade II Mandibular Molar Furcation D|Group B- Furcation Treatment with Allograft and GTR
62193062|NCT02694042|NO_INTERVENTION|Control Group|Participants in this group will continue to receive standard care without access to the Mission is Remission® website. They will also be emailed a link to complete online questionnaires. At the end of the 6 month study period, participants in this group will be given access to the study website.
62193063|NCT06417762|NO_INTERVENTION|Control: One year baseline period|Initial baseline period before rollout of the intervention at seven distinct predominantly Hispanic community areas in Chicago.
62214837|NCT02549196|EXPERIMENTAL|Cohort 1b|Donepezil 10mg/day upward dose titration of 10mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
62573237|NCT06578572|EXPERIMENTAL|Experimental Group|Three monthly doses of R21/MM will be administered to all eligible residents in the 27 intervention villages (15 in The Gambia and 12 in Burkina Faso), starting from May 2024, with the aim of having completed the vaccination schedule by end of July 2024, before the malaria transmission season starts. A booster vaccine dose will be administered in June 2025 to all eligible individuals who received at least one vaccine dose the previous year. Residents who are eligible but not vaccinated in the previous year, will be offered a complete vaccination schedule, i.e. 3 monthly doses, starting from April. After each vaccination, the first 100 vaccinated individuals will be visited at home daily, for 3 consecutive days, and then at day 7 after the vaccination to collect local and systemic adverse events (AE). Vaccinated individuals (or their parents) will be asked to report to the nurse based in their study village any illness occurring during the 28 days after vaccination.
62214838|NCT02549196|EXPERIMENTAL|Cohort 3c|Donepezil 10mg/day upward dose titration of 5mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 40mg/day with solifenacin 15mg/day.
62214839|NCT00562055|EXPERIMENTAL|Arm A|
62214840|NCT00562055|ACTIVE_COMPARATOR|Arm B|
62214841|NCT02808078|EXPERIMENTAL|Augmented reality training|Gait training with augmented reality
62214842|NCT02808078|ACTIVE_COMPARATOR|Standard training|Gait training without augmented reality
62214843|NCT03480308|ACTIVE_COMPARATOR|Bupivacaine fentanyl group|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
62214844|NCT03480308|ACTIVE_COMPARATOR|Bupivacaine dexamethasone group|Patients will receive bupivacaine (0.5%) 20 ml , dexamethasone 4 mg in paravertebral block
62007577|NCT05664035||Case group|18 to 65 year old patients with a history of recurrent bacterial infections of upper and/or lower respiratory tract for at least 2 years
62398158|NCT00706901|EXPERIMENTAL|Arm 2 IHMD|Participants randomized to In-Home-Messaging Devices (IHMD) received a 27-day Care Coordination Home Telehealth (CCHT) program targeting their acute recovery from alcohol and other substance use disorder. Participants received their IHMD device through the Charleston VAMC CCHT program, including device accessories and a phone number to reach their CCHT provider. They were provided with specific instructions on how to set up their IHMD in their residence after discharge. The research associate followed-up with the patient one day after receiving the device to ensure that the device was successfully set up and to provide assistance as necessary. Participants received standard VA CCHT services.
62781711|NCT00811174|EXPERIMENTAL|Octagam 10%|
62214845|NCT03480308|ACTIVE_COMPARATOR|Bupivacaine fentanyl dexamethasone group|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg in paravertebral block
62214846|NCT01691768|EXPERIMENTAL|Intervention|1% tenofovir gel provision through a public sector family planning services with 2-3 monthly provision and monitoring and the use of Quality Improvement methodology to promote reliable service delivery
62214847|NCT01691768|ACTIVE_COMPARATOR|Control|monthly 1% tenofovir gel provision and monitoring through CAPRISA research clinics
62214848|NCT05419973||Pregnant Women|Women in third semester of pregnancy who are willing to include their babies as samples for the next study, no history of abortion, and not suffering from hypertension and preeclampsia.
62214849|NCT05419973||Infants|Babies born from mothers who are willing to be included in the study, aterm, with birth weight more than 2500 grams. No congenital abnormalities at birth and no acute infection at birth.
62214850|NCT02797431|EXPERIMENTAL|CYT107 high frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for 4 weeks
62214851|NCT02797431|EXPERIMENTAL|CYT107 low frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for the first week, followed by CYT107 and Placebo once a week for the three following weeks
62214852|NCT02797431|PLACEBO_COMPARATOR|Control|Patients will receive Placebo (NaCl 0.9%) twice a week for 4 weeks
62214853|NCT01205334|EXPERIMENTAL|Autologous CMV-specific CTL|"The patient will receive one of the following doses:~* 1.5x10\^7 cells/m2~* 4.5x10\^7 cells/m2~* 1.5x10\^8 cells/m2"
62214854|NCT02907307|EXPERIMENTAL|LactiSal vaginal gel 1%|5g of 1%LactiSal Gel vaginal gel once daily for 6 days
62193064|NCT06417762|EXPERIMENTAL|Experimental: Cohort 1 participation in science communication curriculum|"Promotores de salud servicing two geographically adjacent community areas out of the seven selected for participation in this study will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. The core of the implementation strategy consists of augmenting training and self-efficacy for natural community champions, promotores de salud from the Hispanic community as trusted messengers to debunk vaccination misinformation."
62193065|NCT06417762|EXPERIMENTAL|Experimental: Cohort 2 participation in science communication curriculum|"Promotores de salud servicing two geographically adjacent community areas out of the seven selected for participation in this study will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. The core of the implementation strategy consists of augmenting training and self-efficacy for natural community champions, promotores de salud from the Hispanic community as trusted messengers to debunk vaccination misinformation."
62214855|NCT02907307|EXPERIMENTAL|LactiSal vaginal tablet 50 mg|50 mg of LactiSal vaginal tablet daily for 6 days
62573238|NCT06578572|NO_INTERVENTION|Control Group|Only standard malaria control measures ( Malaria Chemoprevention (SMC), Intermittent Preventive Treatment during pregnancy (IPTp), Insecticide-Treated bed Nets (ITN), prompt diagnosis and treatment of patients with uncomplicated malaria and Indoor Residual Spraying (IRS)) will be implemented in control villages.
62781712|NCT04015466||Cases|Patients with high diagnostic suspicion of advanced GC diagnosis
62214856|NCT02907307|ACTIVE_COMPARATOR|Clotrimazole vaginal tablet 100mg|100 mg Clotrimazole vaginal tablet daily for 6 days
62214857|NCT01605916|EXPERIMENTAL|Selumetinib (AZD6244) 25 mg|monotherapy
62214858|NCT01605916|EXPERIMENTAL|Selumetinib (AZD6244) 50 mg|monotherapy
62214859|NCT01605916|EXPERIMENTAL|Selumetinib (AZD6244) 75 mg|monotherapy
62214860|NCT01605916|EXPERIMENTAL|Selumetinib (AZD6244) 75 mg + Doce|Combination
62214861|NCT01605916|EXPERIMENTAL|Selumetinib (AZD6244) 25 mg + Doce|combination
62781713|NCT04015466||Control|Patients with confirmed absent of GC
62781714|NCT03036189|EXPERIMENTAL|Intervention arm|There are no devices or drugs used in this trial. The treatment is the same for the intervention arm and the wait-list control arm. The treatment is group trial of 7 meetings designed to improve chronic illness self-management. The name of the treatment is baa nnilah.
62781715|NCT03036189|EXPERIMENTAL|Wait-list control arm|There are no devices or drugs used in this trial. The treatment is the same for the intervention arm and the wait-list control arm. The treatment is group trial of 7 meetings designed to improve chronic illness self-management. The name of the treatment is baa nnilah.
62781716|NCT04986930|EXPERIMENTAL|SBRT+mFOLFIRINOX|"* Stereotactic body radiotherapy: 3500 cGy (5 fractions)~* mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2"
62781717|NCT04986930|ACTIVE_COMPARATOR|mFOLFIRINOX|-mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
62781718|NCT06444802|EXPERIMENTAL|Linezolid Dosing based on TDMx|Linezolid dosing based on a model-informed precision dosing (TDMx)
62781719|NCT06444802|ACTIVE_COMPARATOR|Standard Linezolid dosing|Patient will receive Linezolid at standard dose
62781720|NCT03350906|EXPERIMENTAL|n3-PUFA|Participants will be instructed to swallow 2 Docosahexaenoic acid (DHA)/EPA soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day.
62781721|NCT03350906|PLACEBO_COMPARATOR|Placebo|Participants will be instructed to swallow 2 placebo soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day.
62781722|NCT06343909|ACTIVE_COMPARATOR|Hip abductor strengthening exercise along with conventional exercises|"Hip abductor strengthening Participant was positioned in side lying with bottom leg hip abducting to a 45-degree and knee in flexion. The uppermost leg was actively abducted while it remains in slight extension making sure no rotation occurred. Participant was instructed to hold the leg in that position for 5-10 seconds and then to lower it to resting position.~Participant was instructed to repeat the exercise with weight cuff attached to the proximal part of ankle"
62781723|NCT06343909|ACTIVE_COMPARATOR|intrinsic foot muscle strengthening exercise along with conventional exercises|"Wring towel with feet:~. Patient in sitting position, place a hand towel flat on the floor pull the towel towards your heel.~Grapping object with toes:~Sitting, place the object flat on the floor.~. Hold it for a second and then according to the resistance of the release it.~Toe abduction (hallux and 2nd toe):~Sitting place a small band between the hallux and second toe. Open and separate your toe and then squeeze the toe against the resistance of elastic. Always leave your feet resting on the floor..~Toggle toe support:~Sitting with feet resting on the floor, alternately touch the first and fifth toes on the floor. Be careful not to move your knees."
62781724|NCT02592460|EXPERIMENTAL|poor-polyamines diet|
62781725|NCT02592460|ACTIVE_COMPARATOR|high-polyamines diet|
62781726|NCT03137628||patients undergoing colectomy, GA and MV|venous blood samples collected from colorectal cancer patients undergoing selective colectomy with general anesthesia(GA) and mechanical ventilation(MV) before general anethesia and the third hour after
62781727|NCT03137628||healthy controls|donated venous blood samples from healthy people undergoing physical examination but not general anesthesia or mechanical ventilation.
62781728|NCT01786395|EXPERIMENTAL|- UF-021|UF-021 is experimental code for isopropyl unoprostone
62781729|NCT01786395|PLACEBO_COMPARATOR|- Placebo|
62781730|NCT04667546|OTHER|Patient having urinary tract infection|Patients with a confirmed urinary tract infection in accordance with the GPIP (french Pediatric Infectious Disease Group) definition and inclusion criteria.
62781731|NCT00211887|ACTIVE_COMPARATOR|Interferon beta 1-a|"Active Interferon B1a Weekly vs. Placebo Glatiramer Acetate~Interferon b-1a (IFN) intramuscularly weekly"
62781732|NCT00211887|ACTIVE_COMPARATOR|glatiramer acetate|"Placebo Interferon B1a Weekly vs. Active Glatiramer Acetate~Glatiramer acetate 20mg daily"
62781733|NCT00211887|ACTIVE_COMPARATOR|IFN and GA|Active Interferon B1a Weekly and Active Glatiramer Acetate
62007578|NCT04900103|EXPERIMENTAL|Tech-volunteer|"A complex intervention with two phases is proposed.~* First phase: volunteers new technologies training (tech-volunteering). Volunteers will be trained in the use of NT and their interconnectivity as tools to support their volunteer work. This training will be integrated into the PC volunteer training programme.~* Second phase: using the NT with patients and relatives."
62007579|NCT04900103|NO_INTERVENTION|Usual volunteer|the control group will receive standard volunteer service.
62007580|NCT06142812|EXPERIMENTAL|Intervention Group|Students will be required to log in with a Pin number using a nickname that allows them to remain anonymous. Questions will be displayed on a large screen with four graphic shapes along with a countdown timer, and students will respond using their internet-enabled digital device. Students will choose, from four options, the possible answer by selecting the graphical shape, which they believe is correct, and will receive instant feedback accordingly. After each question, the game will rank players based on their speed and accuracy. The system will award a higher score to the student who enters the correct answer first. At the end of the quiz, the names of the top five players will be displayed on the leaderboard. The results can then be downloaded to highlight problematic questions and identify students who may be struggling.
62007581|NCT01222494|PLACEBO_COMPARATOR|Antipsychotic Treated Educational Cntrl|Antipsychotic treated participants randomized to this arm will receive diet and exercise education at monthly intervals with a study clinician or coordinator.
62007582|NCT01222494|EXPERIMENTAL|Antipsychotic Treated Weekly BWL|Antipsychotic treated participants randomized to this arm will engage in an evidence-based, 16 week manualized behavioral weight loss intervention that includes weekly meetings and phone check-ins with a trained study therapist.
62007583|NCT01222494|ACTIVE_COMPARATOR|Non-antipsychotic Treated Weekly BWL|Participants assigned to this arm will engage in an evidence-based, 16 week manualized behavioral weight loss intervention that includes weekly meetings and phone check-ins with a trained study therapist.
62007584|NCT02690961|EXPERIMENTAL|Kukoamine B Mesilate 0.06mg/kg|Dose Escalation: Kukoamine B Mesilate 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
62007585|NCT02690961|EXPERIMENTAL|Kukoamine B Mesilate 0.12mg/kg|Dose Escalation: Kukoamine B Mesilate 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
62193066|NCT06417762|EXPERIMENTAL|Experimental: Cohort 3 participation in science communication curriculum|"Promotores de salud servicing three geographically distinct community areas out of the seven selected for participation in this study will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. The core of the implementation strategy consists of augmenting training and self-efficacy for natural community champions, promotores de salud from the Hispanic community as trusted messengers to debunk vaccination misinformation."
62193067|NCT01079910|EXPERIMENTAL|Experimental toothpaste|0.1% isopropylmethylphenol and 1150ppm fluoride
62193068|NCT01079910|OTHER|Marketed toothpaste|NaF/Silica toothpaste containing 1150ppm fluoride
62193069|NCT05518695|EXPERIMENTAL|A1/100mg|Drug:BAT2022 for Intravenous fluids 100mg
62193070|NCT05518695|EXPERIMENTAL|A2/300mg|Drug:BAT2022 for Intravenous fluids 300mg
62193071|NCT05518695|EXPERIMENTAL|A3/1000mg|Drug:BAT2022 for Intravenous fluids 1000mg
62193072|NCT05518695|EXPERIMENTAL|A4/1500mg|Drug:BAT2022 for Intravenous fluids 1500mg
62193073|NCT01673789|EXPERIMENTAL|Stem Cell Educator|The collected lymphocytes are transferred into the device for exposure to CB-SCs, and other blood components are automatically returned to the patient. The Stem Cell Educator functions as part of a closed-loop system that circulates a patient's blood through a blood cell separator, briefly co-cultures the patient's lymphocytes with CB-SCs in vitro, and returns the educated lymphocytes to the patient's circulation. CB-SCs tightly attached to interior surfaces in the device, and only the CB-SC-educated autologous lymphocytes are returned to the subjects. The Stem Cell Educator therapy requires only two venipunctures with minimal pain, and does not introduce stem cells or reagents into patients.
62193074|NCT02484586|OTHER|Presbyope group|"40 years and over with a reading add.~Control lens: Etafilcon A, Nelfilcon A, Nesofilcon A, Somofilcon A, 58% Poly-HEMA~Test lens: Etafilcon A~Up to 10 prototype contact lens designs and at least 1 commercially available contact lens designs will be worn by each participant for up to a week on a daily disposable modality. Participants will attend separate fitting and assessment visits for each lens type (Fitting Visit on Day 1, and Assessment Visit as late as Day 7, but may be as early as 6 hours after the Fitting Visit). There will be a minimum 1 night washout period between lens designs, i.e. after an assessment visit but before the next fitting visit."
62781734|NCT05984888|EXPERIMENTAL|MIND-BC Intervention Group|Individual, tailored, behaviorally based nutrition counseling provided by a Registered Dietitian Nutritionist (RDN) and dietetic interns.
62781735|NCT05984888|ACTIVE_COMPARATOR|General Health Curriculum (GHC) Control|Sessions of non-diet related health topic education.
62781736|NCT03133351||PCM|All enrolled subjects will have a blood sample tested using PCM.
62781737|NCT04566432||Immune checkpoint inhibitors|
62781738|NCT04566432||Targeted therapy|Targeting ALK, ROS1, MET ex14 skipping
62781739|NCT02141139|NO_INTERVENTION|Control arm|no medication or acetaminophen
62781740|NCT02141139|EXPERIMENTAL|NSAIDS (ketorolac intravenous, ibuprofen)|ketorolac IV (just before surgery) and ibuprofen for 1 weeks
62781741|NCT06279507|ACTIVE_COMPARATOR|Hyaluronic acid|Hyaluronic acid, Ostenil Plus, 2 mL (40 mg) will be injected once afer 2-4 week of glucocorticoid injection
62781742|NCT06279507|PLACEBO_COMPARATOR|Normal saline|Two-millilitres of normal saline will be injected once after 2-4 weeks of glucocorticoid injection
62193075|NCT02484586|OTHER|Non-Presbyope group|"18-39 years with no reading add.~Control lens: Etafilcon A, Nelfilcon A, Omafilcon A~Test lens: Etafilcon A~Up to 10 prototype contact lens designs and at least 1 commercially available contact lens designs will be worn by participants for up to a week on a daily disposable modality. Participants will attend separate fitting and assessment visits for each lens type (Fitting Visit on Day 1, and Assessment Visit as late as Day 7, but may be as early as 6 hours after the Fitting Visit). There will be a minimum 1 night washout period between lens designs, i.e. after an assessment visit but before the next fitting visit."
62193076|NCT04411186|ACTIVE_COMPARATOR|Standard Enhanced Recovery After Surgery (ERAS) Protocol|Control for this study will be the standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations.
62193077|NCT04411186|EXPERIMENTAL|ERAS and 5 Lung Protective Interventions|"The standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations. The subject will also receive the following lung protective interventions:~1. Pressure control ventilation-volume guaranteed (PCV-VG) ventilation at approximately 7cc/kg of predicted body weight (derived from combination of sex and height)~2. Positive end-expiratory pressure (PEEP) 7cm H2O5~3. Immediately post intubation recruitment breath (30cm water for 30 seconds)~4. Every 1 hour recruitment breath (30cm water for 30 seconds)~5. 40% FIO2 initially - titrate up as necessary to maintain SPO2 \>94%"
62193078|NCT05174533||with schizophrenia|"with schizophrenia group : patients aged 40 and more with schizophrenia"
62193079|NCT00891553||Ronacaleret|Subjects receiving ronacaleret (200mg,300mg or 400mg) in study CR9108963 will be enrolled into this study.
62193080|NCT00891553||Placebo|Subjects receiving placebo in study CR9108963 will be enrolled into this study.
62193081|NCT04250753||Patients with lumbar spinal stenosis|
62007586|NCT02690961|EXPERIMENTAL|Kukoamine B Mesilate 0.24mg/kg|Dose Escalation: Kukoamine B Mesilate 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
62193082|NCT01509261|EXPERIMENTAL|Ilaprazole|Ilaprazole 20mg
62193083|NCT01509261|ACTIVE_COMPARATOR|lansoprazole|lansoprazole 30mg
62193084|NCT01611961|EXPERIMENTAL|DT-LM|Docetaxel Lipid Microsphere (DT-LM)
62193085|NCT01611961|ACTIVE_COMPARATOR|Taxotere|Commerical Product
62193086|NCT03674775|ACTIVE_COMPARATOR|Intervention Group Providers|DART QI Program Participation
62781743|NCT01730586|EXPERIMENTAL|Abraxane|Abraxane 220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
62781744|NCT02406105|EXPERIMENTAL|Radiosurgical thalamotomy|Cyber Knife based functional radiosurgical thalamotomy, photons 6MV, single dose 70-110 Gy
62007587|NCT02690961|EXPERIMENTAL|Placebo 0.06mg/kg|Dose Escalation: placebo 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
62007588|NCT02690961|EXPERIMENTAL|Placebo 0.12mg/kg|Dose Escalation: placebo 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
62007589|NCT02690961|EXPERIMENTAL|Placebo 0.24mg/kg|Dose Escalation: placebo 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
62007590|NCT04374474|SHAM_COMPARATOR|Control Group|The participants, randomly assigned to this arm, will receive a paper hand-out about post-viral anosmia with instructions to smell common household items (current care). Besides, it will be prescribed nasal irrigation twice a day.
62007591|NCT04374474|EXPERIMENTAL|Olfactory Retraining Group|The participants, randomly assigned to this arm, will receive instructions on olfactory retraining and will also be given an essential oil retraining kit, which they will use twice a day. Besides, it will be prescribed nasal irrigation twice a day.
62007592|NCT04374474|EXPERIMENTAL|Olfactory Retraining_Budesonide Group|The participants, randomly assigned to this arm, will receive instructions on olfactory retraining, the olfactory training kit and it will be prescribed nasal irrigation with Budesonise, twice a day.
62193087|NCT03674775|NO_INTERVENTION|Control Group Providers|Usual Care
62007593|NCT04915859|ACTIVE_COMPARATOR|Active Cooling|Participants will be actively cooled during rest breaks
62193088|NCT03135990|EXPERIMENTAL|CBT + VR|Cognitive Behavioral Therapy with Virtual Reality technology.
62193089|NCT01197612|OTHER|Single Arm; nostrils as experimental and comparator|each subject serves as their own control with one nostril being treated with pulmicort and one not
62193090|NCT02430753|EXPERIMENTAL|IRE Group|irreversible electroporation for Lung Neoplasms accompanied by Respiratory Function Insufficiency
62193091|NCT02430753|NO_INTERVENTION|Control|The patients without treatment
62193092|NCT01139359|EXPERIMENTAL|Single Arm, darinaparsin and CHOP|open label, single arm, unblinded
62193093|NCT00121667|EXPERIMENTAL|Saxagliptin + Metformin (A)|Pioglitazone 15-45 mg (as needed for rescue)
62193094|NCT00121667|EXPERIMENTAL|Saxagliptin + Metformin (B)|Pioglitazone 15-45 mg (as needed for rescue)
62193095|NCT00121667|EXPERIMENTAL|Saxagliptin + Metformin (C)|Pioglitazone 15-45 mg (as needed for rescue)
62781745|NCT05826847|SHAM_COMPARATOR|Control Group|ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.
62193096|NCT00121667|PLACEBO_COMPARATOR|Placebo+ Metformin (D)|Pioglitazone 15-45 mg (as needed for rescue)
62193097|NCT04432792||Clinical Records Review|We will receive clinical chart data from the telehealth providers on 3,000 patients (which could include the survey study participants, but we will not know their identities) which will include date of birth, zip code, and dates of service - but will otherwise be de-identified.
62193098|NCT04432792||Study Survey Participants|We aim to enroll at least 3,000 participants to complete the study surveys.
62193099|NCT05506423||CycloPen Cyclodialysis System in conjunction with cataract surgery|Ophthalmic surgical intervention with the CycloPen Cyclodialysis System in conjunction with cataract surgery
62193100|NCT05506423||CycloPen Cyclodialysis System in standalone surgery|Ophthalmic surgical intervention with the CycloPen Cyclodialysis System
62193101|NCT02623998|EXPERIMENTAL|Intervention|Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy
62193102|NCT02623998|NO_INTERVENTION|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
62214862|NCT03223662|OTHER|Neoadjuvant Chemoradiotherapy and esophagectomy|Standard of care neoadjuvant chemoradiotherapy (nCRT) and esophagectomy
62007594|NCT04915859|PLACEBO_COMPARATOR|No Intervention|"Participants will participate in passive cooling where they sit in a chair during rest"
62007595|NCT05698095|EXPERIMENTAL|Cohort 1 - 0.5 mg single-dose|A single 0.5 mg 5-MeO-DMT or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
62193103|NCT03174665||Patients with Pain|"Patients who had upper limb surgery or other trauma with a history of persistent spontaneous and/or evoked pain with duration of at least 3 months.~Patients will be recruited to the study by using a postal follow up questionnaire. Patients who judge their pain at least moderate and/or affecting daily life by will be eligible and asked to participate. Patients will visit the Pain Clinic once. Oral and written information about the study will be provided, informed consent obtained. The affected nerve will be identified and the anatomy verified by ultrasound when needed."
62193104|NCT03174665||Patients with no pain|Patients operated with nerve suture surgery after a lesion of the nerves of upper extremity will be recruited to the study by using a postal follow up questionnaire. Patients with no pain will be asked to participate. Patients will visit the Pain Clinic once. Oral and written information about the study will be provided, informed consent obtained. The affected nerve will be identified and the anatomy verified by ultrasound when needed.
62007596|NCT05698095|EXPERIMENTAL|Cohort 2 - 2.5 mg single-dose|A single 2.5 mg 5-MeO-DMT or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
62193105|NCT01437423|EXPERIMENTAL|TETRAXIM™ vaccine|Participants will receive a primary or booster dose of TETRAXIM™
62193106|NCT00629005|EXPERIMENTAL|Arm 1|Constraint-Induced Movement Therapy (wear a mitt on non-paretic hand for 90% of waking hours + functional task practice for 3 hours) plus 1 hour of strength training for the arms and hands 3x/week
62193107|NCT00629005|ACTIVE_COMPARATOR|Arm 2|Constraint-Induced Movement Therapy (wear a mitt on non-paretic hand for 90% of waking hours + functional task practice for 3 hours) plus non-resisted arm and hand movements for 1 hour 3x/week
62193108|NCT03567044|EXPERIMENTAL|Blood Collection|Patients will be asked to have blood draws at specific time points during their whole breast irradiation.
62007597|NCT05698095|EXPERIMENTAL|Cohort 3 - 4.5 mg single-dose|A single 4.5 mg 5-MeO-DMT or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
62007598|NCT05698095|EXPERIMENTAL|Cohort 4 - 7 mg single-dose|A single 7 mg 5-MeO-DMT or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
62193109|NCT06497803|EXPERIMENTAL|Intervention Group|Nurse-led body protection education was provided to the intervention group in groups of 3-4 in 40 minutes. The education was provided as verbal narration by using a doll and distress whistle. In addition, two weeks after the post-test, a reminder education brochure prepared with the braille alphabet was distributed to the students in the intervention group.
62007599|NCT05698095|EXPERIMENTAL|Cohort 5 - 10 mg single-dose|A single 10 mg 5-MeO-DMT or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
62007600|NCT05698095|EXPERIMENTAL|Cohort 6 - 13 mg single-dose|A single 5-MeO-DMT 13 mg or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
62193110|NCT06497803|NO_INTERVENTION|Control Group|Pretest, posttest and follow-up test were applied simultaneously to the intervention group and the control group. Throughout the research, the control group continued their routine education. After the follow-up test, the control group was also provided with nurse-led body protection education.
62193111|NCT05878912|EXPERIMENTAL|Diet|Diet intervention (in addition to standard clinical care)
62007601|NCT05698095|EXPERIMENTAL|Cohort 7 - multiple-dose, 3 hour interval|Administration of up to two 5-MeO-DMT (2.5 mg followed by 4.5 mg) or placebo doses administered intramuscularly within a single day with a 3 hour dose interval (randomized as 5 active and 1 placebo subject).
62007602|NCT05698095|EXPERIMENTAL|Cohort 8 - multiple-dose, 3 hour interval|Administration of up to two 5-MeO-DMT (2.5 mg followed by 7 mg) or placebo doses administered intramuscularly within a single day with a 3 hour dose interval (randomized as 5 active and 1 placebo subject).
62007603|NCT05698095|EXPERIMENTAL|Cohort 9 - multiple-dose, 3 hour interval|Administration of up to two 5-MeO-DMT (2.5 mg followed by 10.5 mg) or placebo doses administered intramuscularly within a single day with a 3 hour dose interval (randomized as 5 active and 1 placebo subject).
62007604|NCT04630522|EXPERIMENTAL|JMT103- 120 mg SC Q4W|Eligible patients will receive JMT103 120 mg SC Q4W for up to 13 cycles.
62007605|NCT04630522|EXPERIMENTAL|JMT103- 120 mg SC Q8W|Eligible patients will receive JMT103 120 mg SC Q8W for up to 7 cycles.
62007606|NCT04630522|EXPERIMENTAL|JMT103- 180 mg SC Q8W|Eligible patients will receive JMT103 180 mg SC Q8W for up to 7 cycles.
62193112|NCT05878912|NO_INTERVENTION|Control|Standard clinical care only
62193113|NCT03854357|EXPERIMENTAL|Additional Isolated Subscapularis Rehabilitation|Patients will be randomized to receive additional isolated subscapularis specific rehabilitation exercises during their standard post-operative physical therapy sessions after anatomic total shoulder arthroplasty.
62573239|NCT05252325|OTHER|HAL on the right side of the face; HA on the left side of the face|the subjects will receive HAL ( hyaluronic acid +lidocaine)in the right side of the face, HA (hyaluronic acid without lidocaine) in the left side
62007607|NCT03330535|ACTIVE_COMPARATOR|Verbal oral hygiene instructions|Participants will receive verbal oral hygiene instructions during routine orthodontic visits.
62007608|NCT03330535|EXPERIMENTAL|Reminders once a week|Participants will receive active reminders once a week.
62007609|NCT03330535|EXPERIMENTAL|Reminders three times a week|Participants will receive active reminders three times a week.
62007610|NCT03330535|EXPERIMENTAL|Daily reminders|Participants will receive active reminders daily.
62007611|NCT06503588||Before guidelines|Patients treated for ureteral stent associated urinary tract infection in the University Hospital of Nancy from January 1, 2018 to May 31, 2020
62007612|NCT06503588||After guidelines|Patients treated for ureteral stent associated urinary tract infection in the University Hospital of Nancy from August 1, 2020 to December 31, 2022
62007613|NCT01245179|EXPERIMENTAL|Panobinostat|All patients will receive Panobinostat at specified dose levels and dosing schedules.
62007614|NCT04217551|EXPERIMENTAL|6 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 6 hours of hypothermia with a target of 33 degrees followed by 6 hours of controlled rewarming.
62007615|NCT04217551|EXPERIMENTAL|12 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 12 hours of hypothermia with a target of 33 degrees followed by 12 hours of controlled rewarming.
62193114|NCT03854357|ACTIVE_COMPARATOR|Standard Post-Operative TSA Rehabilitation|Patients will be randomized to receive additional isolated subscapularis specific rehabilitation exercises during their standard post-operative physical therapy sessions after anatomic total shoulder arthroplasty.
62007616|NCT04217551|EXPERIMENTAL|18 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 18 hours of hypothermia with a target of 33 degrees followed by 18 hours of controlled rewarming.
62193115|NCT00150618|EXPERIMENTAL|SPD503 (Guanfacine HCl) (1 mg)|
62193116|NCT00150618|EXPERIMENTAL|SPD503 (2 mg)|
62007617|NCT04217551|EXPERIMENTAL|24 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 24 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
62573240|NCT05252325|OTHER|HAL on the left side of the face; HA on the right side|the subjects will receive HA in the right side of the face, HAL in the left side
62573241|NCT02158013|ACTIVE_COMPARATOR|Diltiazem, calcium channel blocker|Diltiazem gel 2% applied twice daily for 8 weeks
62007618|NCT04217551|EXPERIMENTAL|30 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 30 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
62007619|NCT04217551|EXPERIMENTAL|36 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 36 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
62007620|NCT04217551|EXPERIMENTAL|42 Hours - shockable|Participants with shockable initial rhythm will be assigned to receive 42 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
62007621|NCT04217551|EXPERIMENTAL|48 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 48 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
62007622|NCT04217551|EXPERIMENTAL|60 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 60 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
62573242|NCT02158013|EXPERIMENTAL|Levorag, Hibiscus plant extract|Levorag Emulgel applied twice daily for 8 weeks
62007623|NCT04217551|EXPERIMENTAL|72 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 72 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
62007624|NCT04217551|EXPERIMENTAL|6 hours - non shockable|Participants with non-shockable initial rhythm will be assigned to receive 6 hours of hypothermia with a target of 33 degrees followed by 6 hours of controlled rewarming.
62007625|NCT04217551|EXPERIMENTAL|12 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 12 hours of hypothermia with a target of 33 degrees followed by 12 hours of controlled rewarming.
62193117|NCT00150618|EXPERIMENTAL|SPD503 (3 mg)|
62193118|NCT00150618|EXPERIMENTAL|SPD503 (4 mg)|
62193119|NCT00150618|PLACEBO_COMPARATOR|Placebo|
62193120|NCT05250765|EXPERIMENTAL|Bonding with rubberdam|The retainer is bonded under rubber dam isolation
62193121|NCT05250765|ACTIVE_COMPARATOR|Bonding under relative isolation|The retainer is bonded under relative isolation (hygrophormic suction, cotton pads)
62193122|NCT03353597|EXPERIMENTAL|Plasma Transfusion|Plasma Transfusions with 2 units of plasma per dose, for a total of 6 doses
62193123|NCT04470947||Next generation functional drug screening|
62193124|NCT04470947||Comprehensive genomic profiling|
62573243|NCT05270616|EXPERIMENTAL|robotic surgery group|minimally invasive lung surgery using the Davinci robotic system to assist.
62573244|NCT05270616|ACTIVE_COMPARATOR|uniport surgery group|VATS minimally invasive lung surgery under the uniportal status.
62573245|NCT05270616|ACTIVE_COMPARATOR|multiple- port surgery group|VATS minimally invasive lung surgery under the multiple- port status.
62573246|NCT04467567|EXPERIMENTAL|patients treated with lutathera|Patients undergoing treatment with Lutathera® and who accept to participate in the study, regardless of the cycle of treatment, 1, 2, 3 or 4.
62781746|NCT05826847|EXPERIMENTAL|Prone Positioning|ARDS patients at spontaneous breathing onset on pressure support ventilation mode in prone position, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.
62781747|NCT05826847|EXPERIMENTAL|Thoracoabdominal Binding|ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees using thoracoabdominal binding with the binder's upper edge above the costal margin, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.
62193125|NCT04470947||Physician's choice|
62193126|NCT00958711|EXPERIMENTAL|Biologic - Unite Biomatrix|
62193127|NCT00958711|ACTIVE_COMPARATOR|Saline and Gauze|
62193128|NCT05262010|EXPERIMENTAL|experiment group|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
62193129|NCT05262010|PLACEBO_COMPARATOR|placebo|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
62193130|NCT02263040|EXPERIMENTAL|High Dose Fluzone|Fluzone High-Dose® Licensed for use in the USA in persons ≥ 65 years of age as a single dose of 0.5 mL containing 60μg hemagglutinin per virus strain
62193131|NCT02263040|ACTIVE_COMPARATOR|Fluzone (standard dose)|Fluzone ® Licensed for the prevention of influenza as a single dose of 0.5 mL containing 15μg hemagglutinin per virus strain for adults
62193132|NCT02924597|EXPERIMENTAL|Robot-assisted laparoscopic RFA assisted TE|RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.
62193133|NCT02924597|ACTIVE_COMPARATOR|Robot-Assisted laparoscopic partial nephrectomy|The tumor then will be laparoscopic enucleation without hilar clamping.
62193134|NCT04949802|EXPERIMENTAL|Laser|Treated with ViaLase Laser
62193135|NCT00307047|EXPERIMENTAL|XIENCE V®|
62573247|NCT02817295||elderly|patients underwent bariatric surgery and are above 65 years old
62573248|NCT02817295||non-elderly|patients underwent bariatric surgery and are below 65 years old
62007626|NCT04217551|EXPERIMENTAL|18 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 18 hours of hypothermia with a target of 33 degrees followed by 18 hours of controlled rewarming.
62007627|NCT04217551|EXPERIMENTAL|24 hour - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 24 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
62007628|NCT04217551|EXPERIMENTAL|30 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 30 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
62007629|NCT04217551|EXPERIMENTAL|36 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 36 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
62007630|NCT04217551|EXPERIMENTAL|42 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 42 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
62193136|NCT00307047|ACTIVE_COMPARATOR|TAXUS™ EXPRESS2™|
62193137|NCT06430333|EXPERIMENTAL|Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)|PUMAS is a clinician-administered psychotherapy intervention for prenatal insomnia that includes six weekly 60-minute sessions in an individual format. PUMAS combines behavioral sleep strategies with mindfulness exercises and tailors all components to pregnancy to improve sleep quality. PUMAS will be delivered via telemedicine video.
62193138|NCT06430333|ACTIVE_COMPARATOR|Treatment-as-usual (TAU)|TAU reflects real-world care where patients and their providers make their own treatment decisions for treating prenatal insomnia. Common TAU options include over-the-counter sleep aids, sleep hygiene education, melatonin, and cognitive-behavioral therapy for insomnia. The TAU group will be well-characterized (i.e., we will monitor interventions administered by the usual care providers and collect information on dosage, frequency, duration, adherence) to best describe treatment options sought and completed in the real world.
62193139|NCT05730309|EXPERIMENTAL|Feasibility: Disclosure, customized discharge and expedited referral instructions|Participants enrolled in the Aim 1 cohort with LVH on POCUS will receive the study intervention consisting of disclosure, counseling with set discharge instructions and expedited referral (communication to existing primary care physician OR referral to follow-up clinic if no existing primary care)
62193140|NCT01193010|ACTIVE_COMPARATOR|Control|Surgery without computer-assisted planning.
62193141|NCT01193010|EXPERIMENTAL|Computer-Assisted Surgical Planning|
62193142|NCT01782729|EXPERIMENTAL|Tacrolimus ointment (pediatric)|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
62193143|NCT04216888|EXPERIMENTAL|Open label|Open label intranasal ketamine
62193144|NCT03197766|EXPERIMENTAL|Active BMN 111|Daily subcutaneous injection of 15 micrograms per kilogram BMN111
62193145|NCT03197766|PLACEBO_COMPARATOR|Placebo|Daily subcutaneous injection of placebo
62193146|NCT00960362|PLACEBO_COMPARATOR|A|
62007631|NCT04217551|EXPERIMENTAL|48 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 48 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
62007632|NCT04217551|EXPERIMENTAL|60 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 60 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
62007633|NCT04217551|EXPERIMENTAL|72 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 72 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
62193147|NCT00960362|EXPERIMENTAL|B|Intravenous cohort 1; 0.01 mg/kg
62193148|NCT00960362|EXPERIMENTAL|C|Intravenous cohort 2; 0.1 mg/kg
62193149|NCT00960362|EXPERIMENTAL|D|Intravenous cohort 3; 0.6 mg/kg
62193150|NCT00960362|EXPERIMENTAL|E|Intravenous cohort 4; 3.0 mg/kg
62193151|NCT00960362|EXPERIMENTAL|F|Intravenous cohort 5; 10 mg/kg
62193152|NCT00960362|EXPERIMENTAL|G|Intravenous cohort 6; 30 mg/kg
62193153|NCT02313337|EXPERIMENTAL|Oral administration|-Oral administration of a mixture at preoperative 30 minutes : ketamine 3 mg/kg, midazolam 0.5 mg/kg and atropine 0.02 mg/kg, plus 50% glucose solution to 0.5ml /kg.
62193154|NCT02313337|EXPERIMENTAL|Intramuscular injection|-At preoperative 30 minutes intramuscular injection of atropine 0.02 mg/kg, 5 minutes before entering the operation room, intramuscular injection of ketamine 5 mg/kg.
62781748|NCT03376685|EXPERIMENTAL|Endurance Exercise Training (END)|This group is performing END training for 6 weeks in duration. Intervention: Behavioral: Endurance Exercise Training (END)
62007634|NCT02985242|EXPERIMENTAL|Empagliflozin/glimepiride placebo|"Empagliflozin 25 mg film-coated tablet p.o. daily and glimepiride matching placebo p.o. daily~Duration of treatment: 12 months"
62007635|NCT02985242|ACTIVE_COMPARATOR|Glimepiride/empagliflozin placebo|"Glimepiride 2 mg tablet p.o. daily and empagliflozin matching placebo p.o. daily~Duration of treatment: 12 months"
62007636|NCT04612322||Patients undergoing coronary microvascular function assessment|
62007637|NCT01176825|EXPERIMENTAL|CBT|14-week individual cognitive-behavior therapy
62007638|NCT01176825|NO_INTERVENTION|Treatment As Usual|14-week waitlist control
62007639|NCT01252459|EXPERIMENTAL|Arm A: AA-PET based target volume delineation|Experimental intervention (Arm A): High-precision re-irradiation. Target volume delineation based on AA-PET.
62007640|NCT01252459|ACTIVE_COMPARATOR|Arm B: T1Gd-MRI based target volume delineation|Control intervention (Arm B): High-precision re-irradiation. Target volume delineation based on T1Gd-MRI.
62007641|NCT05494255|ACTIVE_COMPARATOR|Group RM|One single recruitment maneuver will be applied in this group at the end of the surgery and before the extubation
62007642|NCT05494255|NO_INTERVENTION|Group NoRM|Usual care will be applied in this group
62193155|NCT02313337|EXPERIMENTAL|Rectal perfusion|-At preoperative 30 minutes rectal infusion of midazolam 0.5mg/kg
62193156|NCT02313337|EXPERIMENTAL|Dripping nose|-At preoperative 30 minutes dripping nose of Imidazole valium 0.2 mg/kg
62193157|NCT05096039||Treatment Group 1 (use of sacubitril/valsartan)|Beneficiaries with one or more prescription claim with an NDC for sacubitril/valsartan during the 90-day episode window (for BPCA) and CY2018 (for MSSP). Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
62007643|NCT03828305|EXPERIMENTAL|Training and creation of the Network-CPR|Training in CPR
62007644|NCT03828305|ACTIVE_COMPARATOR|Control Group|Primary Care Center Emergency Personnel
62007645|NCT00967408|EXPERIMENTAL|Rehabilitation + Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
62007646|NCT00967408|PLACEBO_COMPARATOR|Rehabilitation + Placebo|Rehabilitative treatment + Non active Placebo tablets for 6 months
62007647|NCT03317990|EXPERIMENTAL|NeuroSAFE procedure|These patients will undergo robotic radical prostatectomy with bilateral nerve spare.The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade.The tissue sample will be snap frozen and embedded in OCT.Using a cryostat, 10 micron thick slices will be placed on slides.The entire length of the area of interest will be sampled in this way generating ≈10 frozen sections per side.The slides will be stained with H\&E and will be examined by a consultant pathologist.As soon as examination is complete the pathologist will telephone the operating surgeon to give the result.Presence of cancer cells at the margin of resection constitutes a positive margin and the neurovascular bundle on that side will be resected if the PSM is present in more than one slice on the same side or for a distance of 3 or more mm.
62007648|NCT03317990|ACTIVE_COMPARATOR|Control|These patients will undergo robotic radical prostatectomy with a nerve sparing procedure based on surgical planning performed by a consultant radiologist. The mp-MRI will be reviewed by a consultant radiologist along with the details of the prostate biopsy and DRE a decision to perform unilateral, bilateral or non-nerve sparing will be established and recorded in the clinical record form (CRF) for each patient.
62007649|NCT00779948||Targon FN|
62781749|NCT03376685|EXPERIMENTAL|Sprint Exercise Training (SIT)|This group is performing SIT training for 6 weeks in duration. Intervention: Behavioral: Sprint Exercise Training (SIT)
62781750|NCT05735535|EXPERIMENTAL|3TC/DTG|·To evaluate efficacy of switching to a two-drug one-pill regimen with DTG/3TC
62007650|NCT00779948||DHS|
62007651|NCT04742595|EXPERIMENTAL|Treatment (SARS-COV-2 specific cytotoxic T cells)|Patients receive SARS-COV-2 specific cytotoxic T lymphocytes IV over 30 minutes on day 1. Treatment may repeat every 14 days at investigators' discretion if patient fails to respond, the infection reoccurs, until the viral load becomes negative or until complete resolution of clinical and radiological signs.
62007652|NCT05215821||group1|subjects with evidence of insulin resistance estimated by high HOMA level
62007653|NCT05215821||group 2|subjects without insulin resistance estimated by normal HOMA level
62007654|NCT03208738|NO_INTERVENTION|Assessment only|
62007655|NCT03208738|EXPERIMENTAL|VetChange mobile app|
62007656|NCT03208738|EXPERIMENTAL|AFT + VetChange mobile app + supportive accountability tool|
62007657|NCT00436280|EXPERIMENTAL|Enzastaurin + Gemcitabine Rituximab Oxaliplatin (R-GEMOX)|
62007658|NCT03575832|EXPERIMENTAL|Supportive care (exercise, nutrition counseling)|Participants receive an exercise plan and printed materials at baseline. Participants also receive 10 telephone coaching calls over 45-60 minutes weekly during month 1, every 2 weeks during month 2, and every month during months 3-6. Participants complete 2 nutrition counseling sessions before month 3.
62007659|NCT01581203|EXPERIMENTAL|Arm 1: Null or Partial Responder to P/R (ASV + DCV)|"Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 Weeks"
62007660|NCT01581203|EXPERIMENTAL|Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV)|"Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 Weeks"
62781751|NCT05735535|ACTIVE_COMPARATOR|TDF Regimen|comparision arm to maintaining the three-drugs regimen in women currently receiving any three-drug regimen containing Tenovofir (TAF or TDF) (e.g. TAF/F/E/C; TAF/F/RPV; TDF/F/RPV; TAF/F+PI/C; TAF/F+PI/r; TDF/F/PI/r; TAF/F+DTG; TDF/F/DTG; TAF/F+RTG; TDF/F/RTG; TAF/F/BIC) who are virologically suppressed.
62007661|NCT01581203|EXPERIMENTAL|Arm 3: Treatment naive (ASV + DCV)|"\[Subjects will receive ASV + DCV for 24 weeks\] followed by ASV + DCV for 24 weeks in protocol AI444026\]~Subjects meeting prespecified rescue criteria in the treatment naive cohort may have therapeutic rescue instituted with QUAD regimen (QUAD= ASV + DCV + P/R)~Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 or 48 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 or 48 Weeks~Pegylated-interferon alfa 2a (PegIFN) 180 mcg/0.5 mL injection subcutaneously (SC), once weekly for 24 or 48 weeks~Ribavirin 1000 mg/1200 mg (total daily dose) tablet by mouth for 24 or 48 weeks"
62214863|NCT04192019|EXPERIMENTAL|Micro-dose glucagon|80 µg (micro-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
62214864|NCT04192019|EXPERIMENTAL|Mini-dose glucagon|150 µg mini-dose of subcutaneous Dasiglucagon 5 min before exercise the start of exercise
62007662|NCT01581203|EXPERIMENTAL|Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week|"Subjects meeting prespecified rescue criteria in the null or partial responder cohort or active arm of the treatment naive cohort may have therapeutic rescue instituted with QUAD regimen (QUAD= ASV + DCV + P/R)~Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 or 48 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 or 48 Weeks~Pegylated-interferon alfa 2a (PegIFN) 180 mcg/0.5 mL injection subcutaneously (SC), once weekly for 24 or 48 weeks~Ribavirin 1000 mg / 1200 mg (total daily dose) Tablet by mouth, for 24 or 48 weeks"
62007663|NCT04795414||Vaccination Group|Participants vaccinated with inactivated SARS-CoV-2 vaccine are studied for safety and antibody response.
62007664|NCT01948375|EXPERIMENTAL|real needle- placebo needle|Participants received acupuncture with real needle in the first period, and with pragmatic placebo acupuncture needle in the second period.
62007665|NCT01948375|EXPERIMENTAL|placebo needle - real needle|Participants received acupuncture with pragmatic placebo needle in the first period, and with real acupuncture needle in the second period.
62007666|NCT01038778|EXPERIMENTAL|Treatment (entinostat, aldesleukin)|"Patients receive entinostat PO every 2 weeks beginning on day -14 and high-dose aldesleukin IV every 8 hours on days 1-5 and 15-19. Cycles repeat every 84 days\* in the absence of disease progression or unacceptable toxicity.~NOTE: \*Patients with evidence of tumor shrinkage may receive up to 3 cycles of high-dose aldesleukin therapy. Patients with stable disease by RECIST version 1.0 criteria, but without evidence of tumor shrinkage after two cycles will receive only entinostat until disease progression is documented."
62007667|NCT01788501|EXPERIMENTAL|Tacrolimus/Methotrexate|"Tacrolimus D-1\~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20\~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to therapeutic drug monitoring(TDM) (10-20ng/ml)~Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push"
62007668|NCT01788501|ACTIVE_COMPARATOR|Cyclosporine/Methotrexate|"Cyclosporine D-1\~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20\~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)~Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push"
62007669|NCT05550129|EXPERIMENTAL|AMG 510 + Metformin|
62007670|NCT06054672|EXPERIMENTAL|Group 1|This group will receive subthreshold stimulation
62398159|NCT00706901|ACTIVE_COMPARATOR|Arm 3 TCC|Participants randomized to the Treatment Control Condition (TCC) received a psycho-educational group (e.g., addiction as a chronic disease, relapse prevention, developing a plan to prevent relapse) that was delivered with the aid of sequential standardized PowerPoint presentations. Group members were encouraged to ask questions and make comments. Therapists were encouraged to conduct the sessions using an instructional quality that minimized the use of GMI strategies. TCC consisted of four sessions, lasting 75 minutes, and was conducted on four consecutive days within the course of one week.
62398160|NCT03785782||Women scheduled for biopsy|40 participants with diagnosed BIRADS-4a, 4b, 4c, or -5 masses will be recruited. The investigators aim to have approximately 10 in each of the BIRADS categories (4a, 4b, 4c, 5), resulting in 40 total subjects for Aim #1.
62398161|NCT03785782||Women scheduled for neoadjuvant chemo|40 participants with malignant masses undergoing neoadjuvant chemotherapy (NAC) will be recruited.
62573249|NCT05679947|EXPERIMENTAL|Mobilization Protocol|The study group patients were mobilized according to the developed mobilization protocol.The protocol includes six levels. Protocol levels are applied from the day the patient is operated and ends on the discharged day. The researcher explains the protocol levels to the patient before surgery.The patient is mobilized within the first 24 h after surgery. Implement mobilization protocol 3 times during the day and more as tolerated. Mobilization protocol:Level 1: Repositioning should occur every 2 h. Level 2: ROM should occur at least 3 times a day. Level 3: The head of bed (HOB) \>30 degrees. Duration goal: 5-15 min. HOB 65≥ degrees with patient sit in the bed. Duration goal: 5-15 min. Progress to level 4. Level 4: HOB 65≥ degrees with legs in dependent position (recliner chair). Duration goal: 5-15 min. Progress to level 5. Level 5: Stand/pivot/step to chair. Sitting in chair. Duration goal: 5-15 min. Progress to level 6. Level 6: Patient is able to ambulate at least 3 times a day.
62007671|NCT06054672|NO_INTERVENTION|Group II|This group will receive no stimulation
62007672|NCT02338947|ACTIVE_COMPARATOR|Off-pump coronary-artery bypass grafting - OPCAB|"Pre-frail and frail patients will be randomly assigned to OPCAB after the evaluation of the target vessels by an internet-based, password protected database program. The surgery will be performed as described in the intervention section and the patients will be followed up for two years."
62007673|NCT02338947|ACTIVE_COMPARATOR|On-pump coronary-artery bypass grafting - CABG|"Pre-frail and frail patients will be randomly assigned to CABG after the evaluation of the target vessels by an internet-based, password protected database program. The surgery will be performed as described in the intervention section and the patients will be followed up for two years."
62214865|NCT04192019|NO_INTERVENTION|No treatment|No treatment before the start of exercise
62214866|NCT03149809|ACTIVE_COMPARATOR|Behavioral therapy|Pelvic floor muscle exercise-based behavioral therapy
62398162|NCT03194724||High Vitamin A exposure|There was no intervention
62214867|NCT03149809|ACTIVE_COMPARATOR|Drug Therapy|Daily solifenacin drug therapy
62214868|NCT01145898||Glaucoma patients|Patients with Glaucoma
62214869|NCT05310851|EXPERIMENTAL|PIOMI group|Infants in the PIOMI group will receive a 5-minute PIOMI 30 minutes before feeding time. PIOMI will be applied once daily for 14 days.
62398163|NCT03194724||Low vitamin A exposure|No intervention
62573250|NCT05679947|NO_INTERVENTION|Control|No intervention was made to the control group, only data were collected at the same time as the study group.The patients in the control group was mobilized by the researchers according to the routine clinical mobilization practice.
62007674|NCT01401491|ACTIVE_COMPARATOR|clozapine + fluvoxamine|
62007675|NCT01401491|PLACEBO_COMPARATOR|clozapine + placebo|
62007676|NCT02953834|EXPERIMENTAL|Kisspeptin and Insulin Resistance Test|Intravenous (IV) administration of kisspeptin 112-121; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose
62007677|NCT02953834|PLACEBO_COMPARATOR|Placebo and Insulin Resistance Test|IV administration of fluids that contain no study drug; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose
62007678|NCT00656253|EXPERIMENTAL|A|
62007679|NCT00656253|PLACEBO_COMPARATOR|B|
62007680|NCT04655404|EXPERIMENTAL|Feasibility Cohort|Larotrectinib administered PO, BID @100 mg/m2 on a 28-day cycle schedule.
62007681|NCT04655404|EXPERIMENTAL|Surgical Cohort|Larotrectinib administered PO, BID @100 mg/m2 3-5 days prior to definitive surgery, followed by Larotrectinib administered PO, BID @100 mg/m2 on a 28-day cycle schedule.
62193158|NCT05096039||Treatment Group 2 (use of ACEI or ARB and no use of sacubitril/valsartan)|Beneficiaries with one or more prescription claim with an NDC for any ACEI/ARB and no prescription claims for sacubitril/valsartan during the 90-day episode window (for BPCA) and CY2018 (for MSSP). Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
62398164|NCT06723093|EXPERIMENTAL|University Health Network Standard Care|"The Social Medicine Housing Initiative is part of standard care and is not contingent on participating in any research activities. Patients who participate in the Housing Initiative will have the option to participate in the research study.~The Social Medicine Housing Initiative provides a housing-first approach which offers housing to individuals without prerequisites (e.g., requiring cessation of substance use, adherence to treatment). Through the Initiative, patients will receive access to permanent supportive housing and support services based on the Social Medicine model. Participants will not only have access to housing but will also be provided with customized social and medical support within and beyond the University Health Network, tailored to their specific needs and preferences."
62007682|NCT04408196||Patients|100 patients admitted to an inpatient rehabilitation facility
62007683|NCT04408196||Caregivers|100 caregivers of patients admitted to an inpatient rehabilitation facility
62193159|NCT05096039||Treatment Group 3 (no use of ACEI, ARB, or sacubitril/valsartan)|Beneficiaries who did not qualify for Group 1 or Group 2 were assigned a value of '1'; patients that did not meet this criteria were assigned a value of '0'
62193160|NCT05096039||Cohort Group 1 (Overall cohort)|"The beneficiaries who met the inclusion criteria and were divided into the three treatment groups were considered Cohort Group 1 or the overall cohort."
62193161|NCT05096039||Cohort Group 2 (subgroup 1)|Patients with evidence of systolic HF defined as: having at least 2 medical claims (on different dates) with an ICD-9/-10 diagnosis code for systolic HF in any position during the lookback period and/or during the entire 90-day episode window (for BPCA) and CY2017 and/or CY2018 (for MSSP). Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
62573251|NCT03182504|EXPERIMENTAL|Nacubactam Plus Meropenem|Participants will receive a single dose of nacubactam co-administered with meropenem.
62573252|NCT04858776|EXPERIMENTAL|Treatment|
62007684|NCT03759093|ACTIVE_COMPARATOR|Standard of Care|Dosing of VCD(bortezomib, cyclophosphamide,dexamethasone), VTD (bortezomib,thalidomide, dexamethasone), or VRD (Bortezomib, Lenalidomide, Dexamethasone) combinations according to standard of care
62007685|NCT03759093|EXPERIMENTAL|CURATE.AI-guided dosing|CURATE.AI optimized modulation of bortezomib and cyclophosphamide dosages in the VCD (bortezomib, cyclophosphamide, dexamethasone), bortezomib and thalidomide in the VTD (bortezomib, thalidomide, dexamethasone) or bortezomib and lenalidomide in the VRD (bortezomib, lenalidomide, dexamethasone) combinations
62193162|NCT05096039||Cohort Group 3 (subgroup 2)|Patients with evidence of Heart Failure Reduced Ejection Fraction (HFrEF) identified based on a published algorithm
62573253|NCT04858776|SHAM_COMPARATOR|Control|
62573254|NCT04152070||Community-dwelling older adults|Community-dwelling older adults living in the Valencia region (Spain).
62573255|NCT03124368|EXPERIMENTAL|Group 1: Danicopan 100 mg TID (Sentinel)|All participants received 100 milligrams (mg) of danicopan three times per day (TID) during the Treatment Period.
62781752|NCT06584266||AF or AFl patients|Patients with AF or AFl in whom TEE will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period.
62781753|NCT06066008|EXPERIMENTAL|group 1|IVT administration of a single low dose ZM-01 injection
62781754|NCT06066008|EXPERIMENTAL|group 2|IVT administration of a single high dose ZM-01 injection
62781755|NCT04913662|EXPERIMENTAL|PIPAC Paclitaxel with FOLFOX|PIPAC (Paclitaxel) + Systemic mFOLFOX6(5-FU, Oxaliplatin, Leucovorin)
61978010|NCT04997785|EXPERIMENTAL|Ultrasound-guided Pericapsular Nerve Group (PENG) Block|PENG blocks is performed by Emergency Medicine board-certified emergency physicians (EPs) with standard training program. PENG block is performed using a spinal needle (NIPRO® 21G × 70 mm) at the level of of anterior superior iliac spine, parallel to the inguinal crease, with real-time ultrasound guidance, according to the steps published by Girón-Arango et al in 2018. The investigators use 20 ml of 1% lidocaine for nerve block because this drug has a short onset time, which is adequate to relieve pain before surgical intervention.
62007686|NCT03563768|EXPERIMENTAL|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
62007687|NCT03563768|NO_INTERVENTION|Staging strategy group|PCI will be performed several days after EVAR
62007688|NCT06114576|EXPERIMENTAL|Orange juice enriched with vitamin D3 and encapsulated probiotics|250 ml of orange juice enriched with vitamin D3 and encapsulated probiotics
62007689|NCT06114576|ACTIVE_COMPARATOR|Conventional orange juice|250 ml of conventional orange juice
62007690|NCT01200199||Varicose veins|
62007691|NCT03490084||Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
62007692|NCT03490084||Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
62007693|NCT05740722|EXPERIMENTAL|Placebo|Placebo vs study drug
62007694|NCT05740722|EXPERIMENTAL|Nicotinamid Riboside|Placebo vs study drug
62007695|NCT02842268|EXPERIMENTAL|BAY987517|Subject will self-apply the test sunscreen formula to his/her face with the goal of applying 0.65 to 0.85 grams.Subject should sweat profusely.
62193163|NCT01964846|EXPERIMENTAL|Resveratrol, curcumin|Subjects will take 2 capsules of resveratrol and curcumin. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
62193164|NCT01964846|PLACEBO_COMPARATOR|Placebo|Subjects will take 2 capsules of Placebo. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
62193165|NCT04197076||Neoadjuvant immunotherapy|pd-1 or pd-l1 inhabitors
62573256|NCT03124368|EXPERIMENTAL|Group 2: Danicopan up to 200 mg TID|All participants received not more than 200 mg of danicopan TID depending on the available safety, pharmacokinetic, and pharmacodynamic data from Group 1 (Sentinel) during the Treatment Period.
61978011|NCT04997785|ACTIVE_COMPARATOR|Intravenous Morphine|Dosage of intravenous morphine was determined according to 0.1 mg per kg; EPs were instructed to aim to reduce the pain by 50% or per patient request.
61978012|NCT04304391|EXPERIMENTAL|Group A|Conventional Gingivectomy:Technique is performed with conventional surgical instruments.
62007696|NCT01772498|EXPERIMENTAL|Heart rate variability biofeedback|Heart rate variability biofeedback training administered in eight, individual, weekly, one hour sessions. There will also be 20 minutes a day of resonant frequency breathing to be conducted at home. This intervention involves teaching subjects how to breath at their resonant frequency in a relaxed, diaphramatic manner.
62007697|NCT04296812|EXPERIMENTAL|Injeti Self-Love Model|"Psychoeducational intervention focusing improving self-esteem and increasing self-awareness.~* The session will start with discussion on healthy relationships, self-esteem.~* A white board will be used in group format and regular 8.5 by 11 paper during individual session to illustrate the Self-Love model and the characteristics and traits that are effected by self-love and lack of self-love.~* At the end of illustration and discussion there will be handout of the self-love intervention.~* The session will end by answering questions and emphasizing the importance of having self-awareness of traits that promote low-self-esteem, and finally, strategies to promote and maintain self-esteem."
62007698|NCT05226650|EXPERIMENTAL|Regular meal pattern|Participants will follow a regular meal pattern for a week
62193166|NCT04197076||Neoadjuvant targeted therapy|TKIs
62193167|NCT04197076||Neoadjuvant chemotherapy|chemotherapy
62193168|NCT02884037||1|Rifaxmin group
62007699|NCT05226650|EXPERIMENTAL|Irregular meal pattern|Participants will follow an irregular meal pattern for a week
62007700|NCT05932290||Elranatamab|Patients treated with elranatamab from the MagnetisMM-3 trial
62007701|NCT05932290||Standard of care|Patients treated with standard-of-care therapies from real-world data sources
62193169|NCT02884037||2|placebo group
62193170|NCT04547777|EXPERIMENTAL|D2C7-IT + 2141-V11|Single D2C7-IT intratumoral infusion (4613.2 ng/mL in 36 mL) over 72 hours followed by single 2141-V11 infusion (5 dose levels) over 7 hours
62193171|NCT02432651|OTHER|6 mg xanthohumol per day vs. placebo|All participants take 6 mg xanthohumol daily and placebo in a crossover design with a washout period.
62193172|NCT02432651|OTHER|12 mg xanthohumol per day vs. placebo|All participants take 12 mg xanthohumol daily and placebo in a crossover design with a washout period.
62193173|NCT02432651|OTHER|24 mg xanthohumol per day vs. placebo|All participants take 24 mg xanthohumol daily and placebo in a crossover design with a washout period.
62193174|NCT02272829|ACTIVE_COMPARATOR|Active|Participants in this arm will receive the study intervention (sessions with the BHC and the PCP).
62193175|NCT02272829|PLACEBO_COMPARATOR|Health Education|Participants in this arm will receive study sessions about various health topics.
62193176|NCT02312557|EXPERIMENTAL|Treatment (pembrolizumab)|"INITIAL TREATMENT PHASE: Patients who are progressing on enzalutamide will receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily.~MONITORING PHASE: After completion of the initial treatment phase, patients continue to receive standard of care enzalutamide PO daily for the duration of the trial.~RETREATMENT PHASE: Patients with disease response or stability after the initial treatment phase will receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for an additional 4 courses in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily for the duration of the trial."
61978013|NCT04304391|EXPERIMENTAL|Group B|Diode Laser Assisted Gingivectomy: Technique is performed with using diode laser.
62007702|NCT00727194|EXPERIMENTAL|1|eculizumab
62007703|NCT00727194|PLACEBO_COMPARATOR|2|Placebo
62007704|NCT06572826||Cardiogenic Shock|Study population: All consecutive patients with a clinical diagnosis of Cardiogenic Shock enrolled in the Altshock registry will be included.
61978014|NCT04304391|EXPERIMENTAL|Group C|Er:YAG Laser Assisted Gingivectomy: Technique is performed with using Er:YAG laser.
61978015|NCT04304391|NO_INTERVENTION|Group D|Negative Control Group
62193177|NCT03804606|EXPERIMENTAL|High benefit, MTM|This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.
62193178|NCT03804606|NO_INTERVENTION|High benefit, no MTM|This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will continue to receive clinical standard-of-care: regular follow-ups with Community Medicine (every 3 months) and Cardiology (every six months). Importantly, these individuals are eligible for referral to MTM at the discretion of their physicians.
62398165|NCT06723093|NO_INTERVENTION|Propensity score matched cohort|The Institute of Clinical Evaluative Sciences of Canada database will provide health administrative data on the Housing Initiative individuals and similar individuals. Each individual in the treatment arm will be matched with four individuals (1:4 pair) in the control arm who are observationally similar. The propensity score-matched cohort method will control for demand-side characteristics that reflect the utilization of health care services, focusing on the use of emergency department visits and inpatient hospital days, nursing home use, and inpatient utilization for severe mental illness. To assess whether the propensity score model has adequately specified, the authors will examine whether the distribution of measured baseline covariates is similar between treated and untreated subjects with the same estimated propensity score.
62193179|NCT03804606|ACTIVE_COMPARATOR|Low benefit, MTM|This arm will comprise patients with heart failure who are predicted to receive low benefit (reduction in mortality risk) by addressing open care gaps. They will be selected based on age, sex, and risk-matching to the High benefit, MTM arm. They will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.
62193180|NCT03772769|EXPERIMENTAL|Subjects with advanced deep space odontogenic infection|Subjects will be diagnosed via two methods: 1. Target Enriched Multiplex PCR (TEM- PCR) and 2. Standard microbial culture.
62193181|NCT01949181|EXPERIMENTAL|Pulmonary cancer|
62193182|NCT00770588|EXPERIMENTAL|gefitinib|Gefitinib (Iressa® 250 mg) 1 tablet daily
62193183|NCT00770588|PLACEBO_COMPARATOR|placebo|placebo 1 tablet daily
62193184|NCT01906697|ACTIVE_COMPARATOR|group B|middle turbinate resection
62193185|NCT01906697|ACTIVE_COMPARATOR|group C|middle turbinate medialization
62398166|NCT04565769||Cancer patients with melanoma|Forty seven cancer patients with melanoma included prior to treatment with ICI.
62573257|NCT00291876|EXPERIMENTAL|Havrix Group|Subjects who received during the primary study 2 doses of Havrix™ at Day 0 and at Month 12.
62007705|NCT02864641|EXPERIMENTAL|TX Group: Planet K Treatment|Participants in the TX Group will receive access to Planet K. Families participating in the TX condition will be asked to attend a one-hour orientation session, during which study expectations and tasks will be explained. Families will be asked to watch a short 2-minute study overview video that summarizes study requirements and expectations. Parents and their children will then have the opportunity to provide informed consent/assent prior to their participation in the study. Adolescent and young adult participants will then receive a mobile phone preloaded with the Planet K app and a brief orientation to the app and associated website.
62021053|NCT01202773|EXPERIMENTAL|90 mg LY2127399|"Given Q2W for 24 weeks. Participants receive a 180-mg loading dose when initiating treatment.~At Week 16, both responders and NR will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
62573258|NCT00172172|EXPERIMENTAL|1|PTH 100 mcg and 700 mg calcium
62193186|NCT01906697|ACTIVE_COMPARATOR|group A|middle turbinate Radio Frequency (RF) turbinoplasty
62193187|NCT00851565|ACTIVE_COMPARATOR|1|Patients with Crohn's disease with secondary loss of response to infliximab.
62193188|NCT00851565|ACTIVE_COMPARATOR|2|Patients with Crohn's disease with secondary loss of response to infliximab.
62193189|NCT04969705|ACTIVE_COMPARATOR|Group A (spinal Dexmedetomidine)|. Spinal needles (22 G) will be introduced in sitting position after skin disinfection with povidine iodine, iliac crest will be palpated and thumb extended to meet the midline, feeling the space between L4 and L5. spinal needle penetrates through the dura matter, a pop will be felt and then after the needle puncture into the subarachnoid space and the appearance of clear cerebrospinal fluid, the intrathecal local anesthetic will be injected. All patients will be receiving 2 ml heavy bupivacaine 0.5% plus 5 µg dexmedetomidine to total volume of 2.5 ml.
62398167|NCT04565769||Healthy controls|Fifthy three age- and gender- matched healthy controls.
62398168|NCT01214382|EXPERIMENTAL|Sertraline|
62398169|NCT00887562|EXPERIMENTAL|Idebenone 900 mg/day|Idebenone 900 mg/day
62398170|NCT00887562|EXPERIMENTAL|Idebenone 2250 mg/day|Idebenone 2250 mg/day
62398171|NCT00887562|PLACEBO_COMPARATOR|placebo|Placebo
62398172|NCT05933057|EXPERIMENTAL|Givinostat|Patients will receive concomitant corticosteroid treatment as part of the standard of care.
62398173|NCT05933057|PLACEBO_COMPARATOR|Placebo|Patients will receive concomitant corticosteroid treatment as part of the standard of care.
62398174|NCT06722209|OTHER|Experimental: Intervention group|Intestinal preparation protocol with polyethylene glycol (Protocol I)
62573259|NCT00172172|EXPERIMENTAL|2|PTH 100 mcg and placebo
62573260|NCT00172172|PLACEBO_COMPARATOR|3|Placebo and 700 mg calcium
62007706|NCT02864641|NO_INTERVENTION|CO Group: Treatment-as-usual|A national sample of CKD participants will be recruited. Because of the inability to meet with remotely located participants for orientation and distribution of phones, these participants will be assigned to the treatment-as-usual, online control (CO) condition. For recruitment of the online control group, youth and parents interested in participating will be asked to complete a brief eligibility survey. Participants in the treatment-as-usual CO condition will not receive access to the Planet K app and website but will receive email reminders to complete surveys online at each time point.
62007707|NCT06098950|EXPERIMENTAL|AI model biased for heart failure, no AI explanation|Participants in this arm will be shown standard AI model predictions during 3 patient clinical vignettes within the survey and systematically biased AI model predictions during 3 clinical vignettes. When shown systematically biased AI model predictions, the model will be biased against heart failure, always predicting that heart failure is present with high likelihood in patients with a body mass index (BMI) at or above 30. Standard predictions will be shown for the other 2 diagnoses. Participants in this arm will not be shown an AI explanation when shown AI model predictions.
62007708|NCT06098950|EXPERIMENTAL|AI model biased for pneumonia, no AI explanation|Participants in this arm will be shown standard AI model predictions during 3 patient clinical vignettes within the survey and systematically biased AI model predictions during 3 clinical vignettes. When shown systematically biased AI model predictions, the model will be biased against pneumonia, always predicting that pneumonia is present with high likelihood in patients 80 years or older. Standard predictions will be shown for the other 2 diagnoses. Participants in this arm will not be shown an AI explanation when shown AI model predictions.
62007709|NCT06098950|EXPERIMENTAL|AI model biased for COPD, no AI explanation|Participants in this arm will be shown standard AI model predictions during 3 patient clinical vignettes within the survey and systematically biased AI model predictions during 3 clinical vignettes. When shown systematically biased AI model predictions, the model will be biased against COPD, always predicting that COPD is present with high likelihood when a pre-processing filter was applied to the patient's X-ray. Standard predictions will be shown for the other 2 diagnoses. Participants in this arm will not be shown an AI explanation when shown AI model predictions.
62398175|NCT06722209|OTHER|Control group|Intestinal preparation protocol with with sodium phosphate content (protocol II)
62398176|NCT04022473|EXPERIMENTAL|Bafiertam|oral capsules administered twice daily
62398177|NCT04022473|ACTIVE_COMPARATOR|Tecfidera|oral capsules administered twice daily
62398178|NCT00401310|PLACEBO_COMPARATOR|1|Placebo
62573261|NCT00356603|EXPERIMENTAL|Sumatriptan|Sumatriptan
62573262|NCT03067532|EXPERIMENTAL|A|
62573263|NCT03067532|ACTIVE_COMPARATOR|B|
62573264|NCT01941849|EXPERIMENTAL|Vandetanib + 131I-mIBG|"Vandetanib (100, 200 or 300 mg once daily) in combination with 131I-mIBG radiation therapy (activity to be prescribed to deliver whole body absorbed dose of 0.5 Gy) on day 1 of each 12-weekly cycle.~Patients will receive up to 4 cycles of vandetanib in combination with 131I-mIBG."
62781756|NCT03491111|EXPERIMENTAL|IMT & EMT|Interventions: Respiratory muscle training for EMT+IMT. Respiratory muscle training for IMT (Inspiratory muscle training)+EMT (Expiratory muscle training). Respiratory muscle breathing training for patients with inspiratory muscle weakness and swallowing disturbance (MIP less than 70% of normal range).
62781757|NCT03491111|ACTIVE_COMPARATOR|Control group|Intervention: Non-training group, receive regular rehabilitation. All participants will receive usual rehabilitation care including body positioning instruction, postural correction, breathing control, cough maneuver, respiratory muscle stretch, chest wall mobility exercise and ventilation, fatigue management.
62781758|NCT03491111|EXPERIMENTAL|EMT group|Intervention: Respiratory muscle training for EMT. Respiratory muscle breathing training for swallowing disturbance. EMT for patients with swallowing disturbance will commence from 15% to 75% of threshold load of an individual's MEP.
62781759|NCT00895310|EXPERIMENTAL|Ketoconazole and Hydrocortisone|Ketoconazole 200mg PO TID + Hydrocortisone 20mg PO Qam, 10mg PO Qpm
62781760|NCT01616251|EXPERIMENTAL|Vegetable protein meal|Vegetable protein meal based on legumes (3.6 MJ, 19E% protein, 28 g dietary fibers)
62781761|NCT01616251|EXPERIMENTAL|Egg protein meal + fibers|Protein meal based on eggs and added pea dietary fibers (3.6 MJ, 19E% protein, 28 g dietary fibers)
62781762|NCT01616251|EXPERIMENTAL|Egg protein meal|Protein meal based on egg without added dietary fibers (3.6 MJ, 19E% protein, 6 g dietary fibers)
62781763|NCT01616251|EXPERIMENTAL|Meat protein meal + fibers|Protein meal based on meat and added pea dietary fibers (3.6 MJ, 19E% protein, 29 g dietary fibers)
62781764|NCT01905449|EXPERIMENTAL|Ultrasound plus prosodic cues|One sound in error is treated with ultrasound visual feedback while also cueing prosodic variation (7 one-hour sessions). Another sound in error is treated with the ultrasound visual feedback with no prosodic variation (7 one-hour sessions). Prosodic variations are cues to coordinate production of the target sound with intonation patterns such as questions (rising intonations), commands (loud/emphatic), or statements (neutral)
62573265|NCT00492648|EXPERIMENTAL|GSK1437173A 18-30 Years Old Group|Subjects aged 18 to 30 years old receiving 2 doses GSK1437173A vaccine in the primary study.
62573266|NCT00492648|EXPERIMENTAL|GSK1437173A 50-70 Years Old Group|Subjects aged 50 to 70 years old receiving 2 doses GSK1437173A vaccine in the primary study.
62573267|NCT05533268|EXPERIMENTAL|Mental Training|mindfulness meditation for 6-weeks.
62573268|NCT05533268|EXPERIMENTAL|Physical Training|Continuous moderate-intensity training for 6-weeks.
62573269|NCT05533268|EXPERIMENTAL|Mental and Physical Training|Combination of mindfulness meditation and continuous moderate-intensity training for 6 weeks.
62398179|NCT00401310|EXPERIMENTAL|2|MK0724
62398180|NCT02132065|NO_INTERVENTION|Standard pain keller|
62007710|NCT06098950|EXPERIMENTAL|AI model biased for heart failure, Image-based AI explanation presented|Participants in this arm will be shown standard AI model predictions during 3 patient clinical vignettes within the survey and systematically biased AI model predictions during 3 clinical vignettes. When shown systematically biased AI model predictions, the model will be biased against heart failure, always predicting that heart failure is present with high likelihood in patients with a body mass index (BMI) at or above 30. Standard predictions will be shown for the other 2 diagnoses. Participants in this arm will also be shown AI explanation when shown AI model predictions.
62007711|NCT06098950|EXPERIMENTAL|AI model biased for pneumonia, Image-based AI explanation presented|Participants in this arm will be shown standard AI model predictions during 3 patient clinical vignettes within the survey and systematically biased AI model predictions during 3 clinical vignettes. When shown systematically biased AI model predictions, the model will be biased against pneumonia, always predicting that pneumonia is present with high likelihood in patients 80 years or older. Standard predictions will be shown for the other 2 diagnoses. Participants in this arm will also be shown AI explanation when shown AI model predictions.
62193190|NCT04969705|ACTIVE_COMPARATOR|Group B (spinal with transversus abdominus plane block)|Spinal needles (22 G) introduced in sitting position . patients receiving1.7 to 2.2 ml heavy bupivacaine 0.5%( according to weight and height ) + 1 ml normal saline = total volume of 2.5 ml then at surgery end under sonographic guide transducer placed in transverse plane above iliac crest.A 90 mm 22 G short beveled block needle inserted in-plane with transducer, in anterior-posterior direction. needle connected to syringe contains20 ml of bupivacaine 0.25%+10 µg dexmedetomidine to deposit local anesthetic deep into the fascial layer between internal oblique \& transversus abdominis muscles on each side.
62193191|NCT04969705|ACTIVE_COMPARATOR|Group C ( controlled group ) Spinal Anesthesia only :|Patients will be anesthetized only with spinal anesthesia using Bupivacaine Hcl( 10 mg).
62781765|NCT01905449|EXPERIMENTAL|Ultrasound vs Traditional treatment|One sound in errors is treated with ultrasound visual feedback for approximately half of each session and traditional treatment for half of the session (7 one-hour sessions). Another sound in error is treated with no ultrasound visual feedback, using traditional treatment for the entire session (7 one-hour sessions). These traditional cues include verbal instructions on how to move the tongue to achieve a particular speech sound.
62781766|NCT02280317|EXPERIMENTAL|Cohort 1: 0.5 mg/kg|VAL201-001 Sub-cutaneous injection. 0.5 mg/kg
62781767|NCT02280317|EXPERIMENTAL|Cohort 2: 1 mg/kg|VAL201-001 Sub-cutaneous injection. 1.0 mg/kg
62781768|NCT02280317|EXPERIMENTAL|Cohort 3: 2 mg/kg|VAL201-001 Sub-cutaneous injection. 2.0 mg/kg
62781769|NCT02280317|EXPERIMENTAL|Cohort 4: 4 mg/kg|VAL201-001 Sub-cutaneous injection. 4.0 mg/kg
62781770|NCT02280317|EXPERIMENTAL|Cohort 5: up to 8 mg/kg|VAL201-001 Sub-cutaneous injection. 8.0 mg/kg; potential to escalate to 16 mg/kg after 3 cycles according to clinician decision Flexibility of dosing enabled under protocol.
62781771|NCT01971008|EXPERIMENTAL|Elastic abdominal binder, then placebo binder|"Patients in this arm will be invited to wear an elastic abdominal binder (Abdosyncro Abdominalbandage, Syncro Med GmbH) for 2 hours on day 1 and a placebo binder (Clima Care Body warmer, Bort Medical) for 2 hours on day 3, after wash-out on day 2"
62781772|NCT01971008|EXPERIMENTAL|Placebo binder, then elastic abdominal binder|"Patients in this arm will be invited to wear a placebo binder (Clima Care Body warmer, Bort Medical) for 2 hours on day 1 and an elastic abdominal binder (Abdosyncro Abdominalbandage, Syncro Med GmbH) for 2 hours on day 3, after wash-out on day 2"
62781773|NCT00065845|NO_INTERVENTION|Abdominal Sacral Colpopexy with no Burch colposuspension|Abdominal sacral colpopexy is performed through a laparotomy approach.
62781774|NCT00065845|EXPERIMENTAL|Abdominal Sacral Colpopexy with Burch Colposuspension|The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
61978016|NCT04550247||Nivolumab treatment|Administered according to the market authorization in France
62193192|NCT05201053||Mild acute pancreatitis|Groups are defined by the Revised Atlanta classification. Anticipated 60% mild, 30% moderate and 10% severe patients
62193193|NCT05201053||moderately severe acute pancreatitis|Groups are defined by the Revised Atlanta classification. Anticipated 60% mild, 30% moderate and 10% severe patients
62573270|NCT05533268|ACTIVE_COMPARATOR|DASH Diet Plan|Dietary Approaches to Stop Hypertension for 6-weeks.
62781775|NCT06362720||standard GVHD prophylaxis|calcineurin inhibitor (cyclosporin A ;CSA) and methotrexate (MTX)
62781776|NCT06362720||posttransplant cyclophosphamide (PTCy)|
62781777|NCT03878758|EXPERIMENTAL|BD Nano™ PRO pen needle vs 33G Artsana Insupen Extr3me|Subjects are to perform 2 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G x 2
62781778|NCT03878758|EXPERIMENTAL|BD Nano™ PRO pen needle vs 34G Artsana Insupen Extr3me|Subjects are to perform 2 pairs of injections. Each pair consists of Nano™ PRO pen needle vs Artsana Insupen Extr3me 3.5mm x 34G x 2
62781779|NCT03878758|EXPERIMENTAL|BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™|Subjects are to perform 2 pairs of injections. Each pair consists of BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™ 4mm x 33G x 2
62781780|NCT01587430|ACTIVE_COMPARATOR|high dose ARA-C|High dose ARA-C will be applied after two 7+3 induction courses during the first and the second consolidation courses: ARA-C 1 g/m2 bid 1-3 days with idarubicin (8mg/m2 3-5 days)and mitoxantrone (10 mg/m2 3-5 days)
62781781|NCT01587430|ACTIVE_COMPARATOR|standard dose ARA-C|Standard dose ARA-C will be applied after two 7+3 induction courses the first and the second consolidation courses : ARA-C 100 g/m2 bid 1-7 days with idarubicin (8mg/m2 1-3 days)and mitoxantrone (10 mg/m2 1-3 days)
62007712|NCT06098950|EXPERIMENTAL|AI model biased for COPD, Image-based AI explanation presented|Participants in this arm will be shown standard AI model predictions during 3 patient clinical vignettes within the survey and systematically biased AI model predictions during 3 clinical vignettes. When shown systematically biased AI model predictions, the model will be biased against COPD, always predicting that COPD is present with high likelihood when a pre-processing filter was applied to the patient's X-ray. Standard predictions will be shown for the other 2 diagnoses. Participants in this arm will also be shown AI explanation when shown AI model predictions.
62007713|NCT01697436|EXPERIMENTAL|Crossover Period 1|
62573271|NCT04509193||Group A|Participants with diagnoses of type 2 diabetes and non-valvular atrial fibrillation (NVAF) newly-initiated on rivaroxaban
62007714|NCT01697436|EXPERIMENTAL|Crossover Period 2|
62007715|NCT01697436|EXPERIMENTAL|Crossover Period 3|
62007716|NCT01697436|EXPERIMENTAL|Crossover Period 4|
62007717|NCT00879671|ACTIVE_COMPARATOR|1|Lutamax
62007718|NCT00879671|PLACEBO_COMPARATOR|2|Placebo
62007719|NCT04865835|PLACEBO_COMPARATOR|placebo and metformin|single dose of placebo + single dose of metformin-HCl 850 mg (approximately 663 mg metformin) (placebo will be dosed 1 hour prior to metformin administration)
62007720|NCT04865835|EXPERIMENTAL|SEP-363856 and metformin|single dose of SEP 363856 100 mg + single dose of metformin-HCl 850 mg (SEP 363856 will be dosed 1 hour prior to metformin administration)
62007721|NCT02618330|EXPERIMENTAL|retainer: 0.75-mm-thick film|
62007722|NCT02618330|EXPERIMENTAL|retainer: 1.00-mm-thick film|
62781782|NCT06205082|EXPERIMENTAL|LIT-00814 20mg|Take a fixed dose of LIT-00814 tablets orally once a day in the morning and evening, and take them orally continuously.
62781783|NCT06205082|EXPERIMENTAL|LIT-00814 50mg|Take a fixed dose of LIT-00814 tablets orally once a day in the morning and evening, and take them orally continuously.
61978017|NCT06401616|EXPERIMENTAL|Discontinue OAC|OAC stopped for the duration of the trial
62007723|NCT02995915|EXPERIMENTAL|Tele-health Mobile Contingency Management Intervention|This arm includes a proactive tele-health intervention that combines evidence-based telephone cognitive behavioral treatment for alcohol and smoking cessation, a tele-medicine clinic for access to smoking cessation pharmacotherapy (including nicotine replacement therapy and bupropion), and mobile contingency management treatment administered via a smart-phone based application (mobile CM).
62007724|NCT02995915|ACTIVE_COMPARATOR|Tele-health for Alcohol and Smoking Cessation|This arm includes a proactive tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same evidence-based telephone CBT for alcohol and smoking cessation, and tele-medicine clinic for access to smoking cessation pharmacotherapy as in the mCM intervention, but does not include mCM. Instead, participants will receive monetary compensation for each assessment, regardless of abstinence.
62007725|NCT04884516|OTHER|Intervention arm|Participants take retinol gummy once a day
62007726|NCT04409782|EXPERIMENTAL|Arm 1|Our study will be largely advertised to DCC's patients and caregivers via electronic provider portal BPA. Providers will provide prospective participants with a link to an online survey where they can consent, complete eligibility screening, the pretest, and contact information.
62007727|NCT04409782|EXPERIMENTAL|Arm 2|People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via a geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online follow-up.
62007728|NCT06468644|EXPERIMENTAL|Group A|dose 1 of radiotherapy+sintilimab
62007729|NCT06468644|EXPERIMENTAL|Group B|dose 2 of radiotherapy+sintilimab
62007730|NCT06081218|EXPERIMENTAL|Chronic cannabis users|
62007731|NCT06081218|SHAM_COMPARATOR|Healthy subjects|
62398181|NCT02132065|EXPERIMENTAL|TAP block|Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
62573272|NCT04509193||Group B|Participants with diagnoses of type 2 diabetes and non-valvular atrial fibrillation (NVAF) newly-initiated on warfarin
62781784|NCT06205082|EXPERIMENTAL|LIT-00814 100mg|Take a fixed dose of LIT-00814 tablets orally once a day in the morning and evening, and take them orally continuously.
62781785|NCT06205082|EXPERIMENTAL|LIT-00814 150mg|Take a fixed dose of LIT-00814 tablets orally once a day in the morning and evening, and take them orally continuously.
61978018|NCT06401616|NO_INTERVENTION|Continue OAC|OAC continued for the duration of the trial
62007732|NCT03552159|EXPERIMENTAL|Behavioral Activation|For the first 4 weeks,participants received psychoeducation about the symptoms and associated behavioral changes of dementia and the possible effects on the caregivers, t the physical, social and psychological consequences of stress, event scheduling and communication skills. After psychoeducation, eight bi-weekly behavioral activation sessions were administered, focusing pleasant event scheduling and effective communications.
62007733|NCT03552159|ACTIVE_COMPARATOR|Psychoeducation|For the first 4 weeks, participants were taught about the symptoms and associated behavioral changes of dementia and the possible effects on the caregivers, the physical, social and psychological consequences of stress, event scheduling and communication skills. After psychoeducation, eight biweekly phone sessions of general support but not behavioral activation.
62007734|NCT00402389|EXPERIMENTAL|1|Participants assigned to take omega-3 fatty acids
62007735|NCT00402389|PLACEBO_COMPARATOR|2|Participants assigned to take placebo
62398182|NCT06722859|OTHER|Open surgical decompression|
62398183|NCT06722859|OTHER|Microsurgical decompression|
62398184|NCT02719093|EXPERIMENTAL|recombinant FSH|recombinant FSH 150UI daily
62398185|NCT05934682||Children submitted to surgery|We will follow children submitted to surgery until hospital discharge or until 30 days after surgery.
62781786|NCT05564585|EXPERIMENTAL|Kinesio Tape|Kinesio Tape was applied over the Calf Muscle on Either leg.
62781787|NCT05564585|SHAM_COMPARATOR|Sham Tape|Sham Tape was applied over the Calf Muscle on Either leg.
62398186|NCT02180659|EXPERIMENTAL|buprenorphine implants + placebo tablets|Four 80 mg Probuphine implants + daily SL placebo tablets
62193194|NCT05201053||severe acute pancreatitis|Groups are defined by the Revised Atlanta classification. Anticipated 60% mild, 30% moderate and 10% severe patients
62193195|NCT01202799|EXPERIMENTAL|Treatment A|2% w/w diclofenac sodium topical gel
62193196|NCT01202799|ACTIVE_COMPARATOR|Treatment B|
62193197|NCT01202799|ACTIVE_COMPARATOR|Treatment C|
62193198|NCT01191008||Latan-timolol maleate fixed comb ophthalmic solution|
62193199|NCT02514551|EXPERIMENTAL|12mg/kg Ramucirumab + 80 mg/m² Paclitaxel|12 milligram per kilogram (mg/kg) ramucirumab administered intravenously (IV) on day 1 and day 15 (28 day cycles) in combination with 80 milligram per square meter (mg/m²) paclitaxel administered IV on day 1, day 8 and day 15.
62193200|NCT02514551|ACTIVE_COMPARATOR|8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel|8 mg/kg ramucirumab administered IV on day 1 and day 15 (28 day cycles) in combination with 80 mg/m² paclitaxel administered IV on day 1, day 8 and day 15.
62398187|NCT02180659|ACTIVE_COMPARATOR|buprenorphine tablets + placebo implants|Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
62781788|NCT00151372|EXPERIMENTAL|Treatment Adherence Intervention|In the Treatment Adherence Intervention group, a study therapist regularly meets with subjects in order to identify obstacles to depression and chronic obstructive pulmonary disease treatment adherence and to help the participant overcome those obstacles.
62781789|NCT00151372|ACTIVE_COMPARATOR|Enhanced Care|In the Enhanced Care group, physicians providing aftercare will be informed in writing of the patients' diagnosis but will receive no clinical instructions by the research team.
62781790|NCT01648816||postpartum depression|caucasian mothers with postpartum depression
62781791|NCT01648816||control|caucasian mothers without depression
62007736|NCT02111486|EXPERIMENTAL|breakfast #1|breakfast food containing high viscosity fibre
62007737|NCT02111486|EXPERIMENTAL|breakfast #2|breakfast food containing low viscosity fibre
62007738|NCT02111486|PLACEBO_COMPARATOR|Control|breakfast food without viscous fibre
62007739|NCT01584947|PLACEBO_COMPARATOR|Placebo lozenge|The patients will be randomized to start two weeks treatment with either a bupivacaine lozenge or a placebo lozenge (taken three times a day). The two weeks treatment is followed by a week without treatment. Afterwards they start another two weeks treatment with the opposite type of lozenge from the first treatment period.
62007740|NCT01584947|ACTIVE_COMPARATOR|Bupivacaine lozenge|The patient will be randomized to start two weeks treatment with either a bupivacaine lozenge or a placebo lozenge (taken three times a day). The two weeks treatment is followed by a week without treatment. Afterwards the patient starts another two weeks treatment with the opposite type of lozenge from the first treatment period.
62193201|NCT01173978|EXPERIMENTAL|No intervention|Each participant is examined during a normal, active lifestyle, without any intervention: The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl
62193202|NCT01173978|EXPERIMENTAL|Intervention|Each participant is examined during a 12 days intervention.The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl
62193203|NCT01895036|EXPERIMENTAL|Naltrexone|PO naltrexone titration on a mixed inpatient/outpatient basis, followed by administration of Vivitrol four days following the 1st dose of naltrexone
62193204|NCT03827447|ACTIVE_COMPARATOR|Drug: Vancomycin Group|Subjects will receive oral vancomycin capsules by mouth, 125 mg every 6 hours for 14 days.
62398188|NCT02259777|EXPERIMENTAL|Telmisartan/Amlodipine, fed|
62781792|NCT03422666|EXPERIMENTAL|Teduglutide|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose
62781793|NCT03422666|PLACEBO_COMPARATOR|Placebo|Placebo, subcutaneous, single dose
62781794|NCT00147303|EXPERIMENTAL|group L|25mg sarpogrelate
62781795|NCT00147303|EXPERIMENTAL|group M|50mg sarpogrelate
62781796|NCT00147303|EXPERIMENTAL|group H|100mg sarpogrelate
62007741|NCT05267067|ACTIVE_COMPARATOR|manual respirtory exercises|Using manual traditional respiratory exercises.
62573273|NCT04940793||Group 1|Patients indicated for cataract surgery who are candidates for a trifocal IOL implantation and have corneal astigmatism over 1.00 D will be selected for inclusion by the investigators
62573274|NCT06183385|OTHER|Saliva|"Collection of two saliva samples (approx. 1.5 to 2 mL each) by passive drooling in healthy volunteers~These samples will be centrifuged and the supernatant collected."
62573275|NCT06183385|OTHER|Vaginal secretions|In order to be as close as possible to real life, two vaginal swabs (introduced through the vaginal orifice over a length of 2 to 3 cm) will be taken with a sterile dry swab during the gynecological examination (prior to endovaginal ultrasound or any other endovaginal procedure) of patients included in the Reproductive Medicine Service.
62193205|NCT03827447|PLACEBO_COMPARATOR|Drug: Placebo Group|Subjects will receive a placebo oral capsule by mouth every 6 hours for 14 days. The placebo oral capsule is manufactured by Study Site's pharmacy to be identical in size, shape, color, appearance and taste as the drug comparator
62214870|NCT05310851|EXPERIMENTAL|Non-nutritive sucking group|Infants in the non-nutritive sucking group will receive pacifier 3 minutes before 1 hour any feeding time and, 2 minutes before 10 minutes. Non-nutritive sucking will be applied once daily for 14 days.
62214871|NCT05310851|NO_INTERVENTION|control group|only feeding follow-up will be done in the infants in the control group.
62573276|NCT01184820|EXPERIMENTAL|Arm 1|
62573277|NCT01184820|EXPERIMENTAL|Arm 2|
62573278|NCT02309762|EXPERIMENTAL|FB825|6 cohorts of subjects are planned to be dosed by IV injection, with single- ascending doses ranging from 0.003 - 10 mg/kg
62573279|NCT02309762|PLACEBO_COMPARATOR|Placebo|Placebo
62573280|NCT04033861|EXPERIMENTAL|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
62007742|NCT05267067|ACTIVE_COMPARATOR|Respiratory exercises with respiratory pressure meter|Using pressure respiratory meter in exercises.
62214872|NCT03693326|EXPERIMENTAL|PDR001|PDR001 300 mg (fixed dose) intraveneously every 3 weeks
62573281|NCT04033861|PLACEBO_COMPARATOR|Control|saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour after randomization.
62573282|NCT05022940||TBI rehabilitation|All individuals with mild, moderate or severe TBI registered into rehabilitation.
62573283|NCT03809754|EXPERIMENTAL|OCT-guided PCI|
62573284|NCT03809754|SHAM_COMPARATOR|Angiography-guided PCI|
62007743|NCT02056171|EXPERIMENTAL|Quetiapine|A randomized group will receive quetiapine as treatment for delirium.
62007744|NCT02056171|PLACEBO_COMPARATOR|Placebo|A randomized group will receive placebo, and not quetiapine.
62007745|NCT00393939|EXPERIMENTAL|A|
62007746|NCT00393939|ACTIVE_COMPARATOR|B|
62007747|NCT01101841|EXPERIMENTAL|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate)
62007748|NCT01101841|PLACEBO_COMPARATOR|Placebo capsules|Sugar pill
62007749|NCT06108934|EXPERIMENTAL|Intervention group|Insignia hip stem study group
62007750|NCT03228238|EXPERIMENTAL|Dual subgroup|Standard medication for variant angina plus Vitamin C+E plus Statin Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU Statin : Atorvastatin calcium 10mg
62007751|NCT03228238|EXPERIMENTAL|Statin subgroup|Standard medication for variant angina plus Statin Statin : Atorvastatin calcium 10mg
62007752|NCT03228238|EXPERIMENTAL|Vitamin subgroup|Standard medication for variant angina plus Vitamin C+E Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU
62007753|NCT03228238|ACTIVE_COMPARATOR|Control group|Control subgroup : Standard medication for Variant angina only
62007754|NCT06304337|NO_INTERVENTION|Ordinary oral cushion set|Before anesthesia induction, patients in the experimental group received 5-6L/min of oxygen for about 1min through the endoscopic bite connecting oxygen supply device, and patients in the control group inhaled 5-6L/min of oxygen for about 1min through the nasal catheter.Both groups were anesthetised with propofol 3mg/Kg and sufentanil 7ug.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. After the subjects achieved sufficient sedation (about BIS40), The ordinary endoscopic bite group began to perform endoscopic operation after sufficient sedation was achieved,In both groups, 5mg/Kg/h propofol was continuously pumped to maintain anesthesia until completion of the examination.
62007755|NCT06304337|EXPERIMENTAL|New oropharyngeal airway group|Before anesthesia induction, patients in the experimental group received 5-6L/min of oxygen for about 1min through the endoscopic bite connecting oxygen supply device, and patients in the control group inhaled 5-6L/min of oxygen for about 1min through the nasal catheter.Both groups were anesthetised with propofol 3mg/Kg and sufentanil 7ug.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. After the subjects achieved sufficient sedation (about BIS40), the new oropharyngeal airway group was placed into the oropharyngeal airway through the endoscopic bite and then began gastroscopy,In both groups, 5mg/Kg/h propofol was continuously pumped to maintain anesthesia until completion of the examination
62007756|NCT01422434|ACTIVE_COMPARATOR|LEO 90105 ointment|LEO 90105 ointment applied once daily for 4 weeks.
62214873|NCT04518605|EXPERIMENTAL|Low protein breakfast|Subject will eat a low protein breakfast and maintain their habitual physical activity.
62007757|NCT01422434|ACTIVE_COMPARATOR|Dovonex® ointment|Applied twice daily for 4 weeks.
62007758|NCT01422434|ACTIVE_COMPARATOR|Rinderon® - DP ointment|Applied once daily for 4 weeks
62007759|NCT00853658|EXPERIMENTAL|Combination Aliskiren / Enalapril|Aliskiren / Enalapril combination therapy-150 mg/10 mg titrated to 300 mg/ 10 mg film-coated tablets and administered orally.
62007760|NCT00853658|EXPERIMENTAL|Aliskiren|Aliskiren monotherapy - 150 mg titrated to 300 mg film-coated tablets and administered orally.
62007761|NCT00853658|ACTIVE_COMPARATOR|Enalapril|Enalapril monotherapy -10 mg film-coated tablet and administered orally.
62007762|NCT00794872||1|Patients with stage 3 CKD
62007763|NCT00794872||2|Patients with stage 4 CKD
62007764|NCT00794872||3|Patients without evidence for CDK
62214874|NCT04518605|EXPERIMENTAL|High protein breakfast|Subject will eat a high protein breakfast and maintain their habitual physical activity.
62398189|NCT02259777|ACTIVE_COMPARATOR|Telmisartan/Amlodipine, fasted|
62398190|NCT03907059|ACTIVE_COMPARATOR|Omnivorous|Interventions: Daily protein intake was adjusted to 1.6g/kg/day via supplementation (whey) + 12 weeks of resistance training
62007765|NCT04206163|EXPERIMENTAL|Acute myocarditis|Included patients with clinically suspected acute myocarditis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI and endomyocardial biopsy (if clinically indicated) as part of the clinical routine work-up.
62007766|NCT04206163|EXPERIMENTAL|Cardiac sarcoidosis|Included patients with clinically suspected cardiac sarcoidosis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI, 18F-FDG PET/CT and endomyocardial biopsy as part of the clinical routine work-up.
62398191|NCT03907059|EXPERIMENTAL|Vegan|Interventions: Daily protein intake was adjusted to 1.6g/kg/day via supplementation (soy) + 12 weeks of resistance training
62398192|NCT03247023||Integra Cadence Total Ankle System|
62398193|NCT03380091|EXPERIMENTAL|Metformin|Metformin 1000 mg PO bid
62398194|NCT03380091|EXPERIMENTAL|Vitamin D (Cholecalciferol)|Cholecalciferol 5,000 IU PO daily
62398195|NCT00431106|ACTIVE_COMPARATOR|1|Vinorelbine/Gemcitabine (VG)
62007767|NCT02102139|EXPERIMENTAL|DXM + Propofol|"DXM (1 µg kg -1) was loaded intravenously for 10 min before anaesthesia induction.During DXM loading, the depth of anaesthesia was monitored using a bispectral index (BIS) monitor. Electrocardiogram, heart rate, pulse oximetry, and non-invasive arterial blood pressure were monitored at 2-min intervals.~Anaesthesia was induced with propofol 3.5 μg mL 1 and remifentanil 5 ng mL 1 at an effect site concentration using a target-controlled infusion (TCI) device. Anaesthesia was maintained with propofol and remifentanil continuous infusions.~During surgery except the study period, propofol and remifentanil doses were adjusted to maintain BIS value of 40-60 and systolic blood pressure (SBP) within ±20% from baseline respectively."
62007768|NCT02102139|PLACEBO_COMPARATOR|Saline + Propofol|"Saline (1 µg kg -1) was loaded intravenously for 10 min before anaesthesia induction.During saline loading, the depth of anaesthesia was monitored using a bispectral index (BIS) monitor. Electrocardiogram, heart rate, pulse oximetry, and non-invasive arterial blood pressure were monitored at 2-min intervals.~Anaesthesia was induced with propofol 3.5 μg mL 1 and remifentanil 5 ng mL 1 at an effect site concentration using a target-controlled infusion (TCI) device. Anaesthesia was maintained with propofol and remifentanil continuous infusions.~During surgery except the study period, propofol and remifentanil doses were adjusted to maintain BIS value of 40-60 and systolic blood pressure (SBP) within ±20% from baseline respectively."
62007769|NCT04441450|EXPERIMENTAL|[14C]ICP-022|Subjects will take a single of 150mg 100μCi of \[14C\]ICP-022.
62007770|NCT05492084||active group|The first - active group (100 people) included patients who had type 1 myocardial infarction (MI) (54 people) within 2 years prior to the study or the diagnosis of CAD was established according to selective coronary angiography: the presence lumen stenosis of at least two coronary arteries by 50 % or more (46 people) and an additional two (or more) cardiovascular events from the following: MI or unstable angina, emergency arterial stenting, stroke, peripheral arterial thrombosis, critical ischemia, and lower limb amputation. The combination of two or more of these cardiovascular events that occurred within two years indicated the rapid progression of atherosclerosis in these patients.
62007771|NCT05492084||comparison group|The second (comparison group) included 102 patients with confirmed coronary heart disease in a similar way (55 people had only 1 type 1 MI in the past and 45 had coronary artery disease confirmed by selective coronary angiography, respectively), in whom two years before inclusion in the study there were no cardiovascular events from the above, which indicated the spontaneous course of atherosclerosis.
62007772|NCT02616250|EXPERIMENTAL|Brimonidine 0.33% gel / CD07805/47 (Br) + Ivermectin 1% cream|"Half group will receive once-daily Br 0.33% gel in the morning and once-daily IVM 1% cream in the evening for 12 weeks.~Half group will receive once-daily Br vehicle gel in the morning for the first 4 weeks and once-daily Br 0.33% gel in the morning for the following 8 weeks and once-daily IVM 1% cream in the evening for 12 weeks."
62007773|NCT02616250|PLACEBO_COMPARATOR|CD07805/47 (Br) placebo gel + CD5024 (IVM) placebo cream|Subjects will receive once-daily Br vehicle gel in the morning and once-daily IVM vehicle cream in the evening for 12 weeks.
62007774|NCT04894045|OTHER|Personalized management group|Intraoperative MAP will be maintained at least at the mean nighttime MAP (assessed using preoperative automated blood pressure monitoring). If the mean nighttime MAP is below 65 mmHg, intraoperative MAP will be maintained at least at 65 mmHg.
62007775|NCT04894045|NO_INTERVENTION|Control group|Routine intraoperative blood pressure management with a lower intervention threshold of 65 mmHg. In contrast to the patients in the personalized management group, the individual mean nighttime MAP assessed using preoperative automated blood pressure monitoring is not taken into account and the treating anesthesiologists are blinded to the data of preoperative automated blood pressure monitoring.
62007776|NCT02099721|ACTIVE_COMPARATOR|Group A: Secondary prevention patients- device implant|"Patients who are guideline indicated for an ICD/CRT-D for secondary prevention of sudden cardiac arrest.~These subjects receive an ICD/CRT-D implant."
62007777|NCT02099721|NO_INTERVENTION|Group B: Secondary prevention patients - no device implant|"Patients who are guideline indicated for an ICD/CRT-D for secondary prevention of sudden cardiac arrest.~These subjects choose not to receive an ICD/CRT-D implant."
62398196|NCT00431106|ACTIVE_COMPARATOR|2|Capecitabine (Cap)
62398197|NCT04819022||Musculoskeletal disorder|
62398198|NCT02974738|EXPERIMENTAL|Part 1A|"Drug: PART 1A: Belzutifan for the treatment of advanced solid tumors~Belzutifan inhibits HIF-2α and is a novel approach to treatment of solid tumors."
62398199|NCT02974738|EXPERIMENTAL|Part 1B|"Drug: PART 1B: Belzutifan for the treatment of advanced ccRCC~Belzutifan inhibits HIF-2α and is a novel approach to treatment of ccRCC."
62007778|NCT02099721|ACTIVE_COMPARATOR|Group C: 1.5 Prevention patients - device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF).~These subjects receive an ICD/CRT-D implant."
62007779|NCT02099721|NO_INTERVENTION|Group D: 1.5 prevention patients - no device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF).~These subjects choose not to receive an ICD/CRT-D implant."
62007780|NCT02099721|OTHER|Group E: Primary, non-1.5 patients - device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they do NOT fall into the 1.5 prevention group. These patients do not have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF) which would put them into the 1.5 prevention group.~These subjects receive an ICD/CRT-D implant."
62007781|NCT02099721|NO_INTERVENTION|Group F: Primary, non-1.5 patients - no device|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they do NOT fall into the 1.5 prevention group. These patients do not have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF) which would put them into the 1.5 prevention group.~These subjects choose not to receive an ICD/CRT-D implant."
62007782|NCT06254417|ACTIVE_COMPARATOR|NON VENTILATED GROUP|
62573285|NCT01227590|EXPERIMENTAL|Pharmacokinetics single-arm|The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
62007783|NCT06254417|ACTIVE_COMPARATOR|VENTILATED GROUP|
62781797|NCT02386826|EXPERIMENTAL|INC280 + Bevacizumab|"1. Dose Escalation: 18 GBM patients received bevacizumab 10 mg/kg intravenously (IV) once every 2 weeks in combination with INC280 given by mouth (PO) starting at 100 mg twice daily and escalating on a 3+3 escalation pattern until the maximum tolerated dose (MTD) was determined.~2. Dose Expansion: Up to 45 GBM patients enrolled in 3 Cohorts:~Cohort A: 20 GBM patients - progressed during or after standard 1st-line therapy; Cohort B: 15 GBM patients - progressed during or after 2nd-line bevacizumab therapy; Cohort C: 10 unresectable GBM patients.~INC280: PO twice daily at the MTD. Bevacizumab: 10 mg/kg IV once every 2 weeks for Cohorts A and B; 15 mg/kg IV every 4 weeks for Cohort C Treatment cycles will be repeated every 28 days (4 weeks)."
62781798|NCT04689789||Patients with RAP|Patients with previous diagnosis of retinal angiomatous proliferation
62007784|NCT01890200|EXPERIMENTAL|TCM-700C (low dose)|an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
62007785|NCT01890200|EXPERIMENTAL|TCM-700C (high dose)|an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
62398200|NCT02974738|EXPERIMENTAL|Part 2|"Drug: Part 2: Belzutifan for the treatment of other specified solid tumors~Belzutifan inhibits HIF-2α and is a novel approach to treatment of specified solid tumors."
62573286|NCT03709303||SCD patients|Patients with sickle cell disease who have decided about enrollment in an NIH study of PBSCT or Gene therapy
62781799|NCT04689789||Patients with reticular pseudodrusen|Patients with previous diagnosis of reticular pseudodrusen
62781800|NCT04689789||Control group|Healthy eyes without actual and previous ocular diseases
62781801|NCT00855049|EXPERIMENTAL|1|Intranasal acetaminophen administration
62781802|NCT00855049|ACTIVE_COMPARATOR|2|Oral acetaminophen administration
62781803|NCT00639626|EXPERIMENTAL|Levemir|
62781804|NCT06579690|EXPERIMENTAL|8.4g of 8.4% sodium bicarbonate solution Arm|Each participant will receive 100mls of 8.4g, 8.4% sodium bicarbonate solution, up to two doses, four hours apart.
62007786|NCT01890200|PLACEBO_COMPARATOR|Placebo|placebo add on(t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
62007787|NCT00177424|ACTIVE_COMPARATOR|1|Sertraline
62007788|NCT00177424|PLACEBO_COMPARATOR|2|matching placebo
62007789|NCT00394966|EXPERIMENTAL|SCH 619734 Dose 1|
62007790|NCT00394966|EXPERIMENTAL|SCH 619734 Dose 2|
62007791|NCT00394966|EXPERIMENTAL|SCH 619734 Dose 3|
62398201|NCT02974738|EXPERIMENTAL|Part 2A|"Drug: Part 2A: Belzutifan for the treatment of patients with recurrent GBM who have been previously treated with radiation therapy and temozolomide~Belzutifan inhibits HIF-2α and is a novel approach to treatment of specified solid tumors."
62193206|NCT04168281|EXPERIMENTAL|PCI- free after response to radical chemoradiotherapy|Patients with no metastases will be followed-up with MRI: at the qualifying visit before MRI-1, and then every 6 months +/- 2 weeks), the patients will have a cognitive examination performed using dedicated neuropsychological tests and QoL assessment using the QLQ-C30 questionnaire. The tests will be conducted in the following order: California verbal learning test (CVLT) with a delay of 15 min, Color connection test (CTT), CVLT (after delay), Benton visual memory test (BNRT), Verbal fluency test by the certified psychologist.
62007792|NCT00394966|EXPERIMENTAL|SCH 619734 Dose 4|
62193207|NCT03338439||CSII|CSII: patients with continuous subcutaneous insulin infusion
62193208|NCT03338439||MDI|MDI: patients with multi-daily injections
62193209|NCT05005702|EXPERIMENTAL|study group|Patients were assigned to inspiratory muscle training (IMT) for 6 weeks. During training, patients were instructed to maintain diaphragmatic breathing, and try to maintain 10-15 breaths, and rested 5-10 between breaths. As soon as the patients managed; they were encouraged to maintain 25-30 breaths at each workload. All patients wore nose-clip during training. The inspiratory load was set at 40% of maximal inspiratory pressure. The training session was supervised at the hospital.
62193210|NCT00932971|PLACEBO_COMPARATOR|PEG-IFN alfa-2a plus placebo|Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus placebo once daily, orally
62193211|NCT00932971|ACTIVE_COMPARATOR|PEG-IFN alfa-2a plus Tenofovir|Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus Tenofovir disoproxilfumarat 245mg once daily, orally
62193212|NCT03585777||Group 1|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking metformin
62193213|NCT03585777||Group 2|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking linagliptin
62193214|NCT03585777||Group 3|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking impaglifluzin
62193215|NCT02045290|PLACEBO_COMPARATOR|Oral Placebo|"A central pharmacy will compound a placebo to match the metformin tablets.~The placebo product will contain the following components:~* Micosolle™, silica based excipient~* Silicified Micro Crystalline Cellulose, National Formulary~* Safflower Oil, United States Pharmacopeia~* K-30 Povidone Powder~* Magnesium Stearate, National Formulary (Vegetable source)~* Fumed Silica, National Formulary"
62193216|NCT02045290|EXPERIMENTAL|Metformin|Metformin 2000 mg per day
62193217|NCT02768883|EXPERIMENTAL|Clinic + Home + Community|"Clinic Intervention = 4 clinical visits with provider over 12 months, 4 visits with clinic asthma educator~Home Intervention = 4 home visits with community health worker over 2 months, 4 mailers, and 4 phone calls~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
62193218|NCT02768883|EXPERIMENTAL|Clinic + Community|"Clinic Intervention = 4 clinical visits with provider over 12 months, 4 visits with clinic asthma educator~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
62193219|NCT02768883|EXPERIMENTAL|Home + Community|"Home Intervention = 4 home visits with community health worker over 2 months, 4 mailers, and 4 phone calls~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
62193220|NCT02768883|ACTIVE_COMPARATOR|Community only|Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook.
62193221|NCT02464605|EXPERIMENTAL|SEL-037 (pegsiticase)|Pegylated uricase
62193222|NCT00517049|EXPERIMENTAL|1|
62193223|NCT02134509|EXPERIMENTAL|Experimental App|This is a 3-week smartphone-based training program that trains behavioral strategies for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
62193224|NCT02134509|ACTIVE_COMPARATOR|Active comparator app|This is a 3-week smartphone application for smoking cessation in which smokers self-monitor their smoking habits, mood, and experience, to quit smoking with a target quit date of 3 weeks.
62781805|NCT06579690|EXPERIMENTAL|12.6g of 8.4% sodium bicarbonate solution Arm|Each participant will receive 150mls of 12.6g, 8.4% sodium bicarbonate solution, up to two doses, four hours apart.
62007793|NCT00394966|PLACEBO_COMPARATOR|Placebo|
62007794|NCT05630807|EXPERIMENTAL|Bepirovirsen|
62007795|NCT05630807|PLACEBO_COMPARATOR|Placebo|
62007796|NCT02636972||Group 1|Mild or absent dysmenorrhoea and no other pelvic pain symptoms without contraceptive pill use.
62781806|NCT06579690|EXPERIMENTAL|16.8g of 8.4% sodium bicarbonate solution Arm|Each participant will receive 200mls of 16.8g, 8.4% sodium bicarbonate solution, up to two doses, four hours apart.
62007797|NCT02636972||Group 2A|History of mild or absent dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).
62007798|NCT02636972||Group 2B|History of severe dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).
62007799|NCT02636972||Group 3|Severe dysmenorrhoea but without chronic pelvic pain and without contraceptive pill use.
62007800|NCT02636972||Group 4|Severe dysmenorrhoea but without chronic pelvic pain and with contraceptive pill use (Participants already using contraceptive pills).
62193225|NCT02480699|EXPERIMENTAL|Hemodialysed patients|
62193226|NCT03378037|EXPERIMENTAL|Acupuncture group|Disposable acupuncture needles will be inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.
62193227|NCT03378037|SHAM_COMPARATOR|Control group|Streitberger's non-invasive placebo acupuncture needles will be used in the control group; blunt-tipped needles will touch the skin quickly without being inserted. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.
62193228|NCT01749852|EXPERIMENTAL|Polyphenol-rich Dark chocolate|Dark chocolate with 500 mg of polyphenols
62781807|NCT06579690|ACTIVE_COMPARATOR|Normal Saline 0.9% Arm|Each participant will receive 50mls of Normal Saline 0.9%, up to two doses, four hours apart.
62781808|NCT00794885|EXPERIMENTAL|Enalapril/folic acid|A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
62007801|NCT02636972||Group 5|Chronic pelvic pain and severe dysmenorrhoea without contraceptive pill use
62007802|NCT02636972||Group 6|Chronic pelvic pain and severe dysmenorrhoea with contraceptive pill use (Participants already using contraceptive pills).
62007803|NCT04502771||Antifungal treatment|Patients receiving antifungal treatment during their stay in Intensive Care Unit
62007804|NCT03138668|EXPERIMENTAL|Low dose Ropivacaine|Perineural injection of 8 ml of Ropivacaine 0.75% at the lateral femoral cutaneous nerve
62007805|NCT03138668|EXPERIMENTAL|High dose Ropivacaine|Perineural injection of 16 ml of Ropivacaine 0.75% at the lateral femoral cutaneous nerve.
62007806|NCT01769157|ACTIVE_COMPARATOR|L-carnitine|L-carnitine 330mg, 3 tablet twice daily
62007807|NCT01769157|PLACEBO_COMPARATOR|Placebo|placebo drug, 3 tablet twice daily
62007808|NCT03033797|EXPERIMENTAL|MoviLetrando-MoveHero|Half of the children will play first two different levels of the game MoviLetrando (2 minutes each) and, after the game MoveHero, more 2 minutes
62007809|NCT03033797|EXPERIMENTAL|MoveHero-MoviLetrando|The other half of the children will play first 2 minutes of the game MoveHero and after, two different levels of the Game MoviLetrando, two minutes each.
62007810|NCT01337024||Control group|Healthy volunteers, examined with ECG without any treatment (controls)
62007811|NCT01337024||100 BoNT/A|patients with neurogenic detrusor overactivity, examined with ECG, injection of 100 units BoNT/A
62193229|NCT01749852|PLACEBO_COMPARATOR|Placebo Dark chocolate|This chocolate contains little or no polyphenols
62781809|NCT00794885|ACTIVE_COMPARATOR|Enalapril|Enalapril maleate 10 mg per day is given
62781810|NCT06547255|ACTIVE_COMPARATOR|standard bupivicaine|patient receive mandibular and maxillary infiltrations with 3mL of standard 3mL standard bupivacaine.
62007812|NCT01337024||300 BoNT/A|patients with neurogenic detrusor overactivity, examined with ECG, injection of 300 units BoNT/A
62781811|NCT06547255|EXPERIMENTAL|liposomal bupivacaine|patient receive mandibular and maxillary infiltrations with 3mL of 1.3% liposomal bupivacaine (Exparel)
62007813|NCT04176796|NO_INTERVENTION|Condition 1: Combined only|Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals.
62007814|NCT04176796|EXPERIMENTAL|Condition 3: Stratified only|Participants randomized to Condition 3 will view only stratified transplant survival outcome information when making a choice between the two hospitals.
62007815|NCT05802693|EXPERIMENTAL|The dose increase phase of this study adopts a 3+3 half-step design|"The main research objective of active comparator is to observe the efficacy and safety of Epidermal Growth Factor Receptor Variant III Chimeric antigen receptor T cells(EGFRvIII CAR-T cells) injected by local administration (Omaya capsule administration) in the treatment of Glioblastoma(GBM).~Initial dose 22 × 10\^6 cells will adopt accelerated titration (ATD); 60 × 10\^6 cells，160 × 10\^6 cells and 220 × 10\^6 cells will use the BOIN method to increase the dose. The planned dose increase scheme is divided into accelerated titration stage (ATD) and BOIN stage"
62398202|NCT06272487|EXPERIMENTAL|Zilebesiran|Participants will receive zilebesiran on Day 1 of the 6-month double-blind (DB) treatment period. Participants must be on stable doses of at least 2, but not more than 4, antihypertensive medications for at least 30 days prior to screening and plan to remain on stable doses of these medications during screening and through the DB treatment period.
62781812|NCT05107765|EXPERIMENTAL|Pioglitazone|
62781813|NCT05107765|PLACEBO_COMPARATOR|Placebo|
62781814|NCT06454877|EXPERIMENTAL|active heating|It is the group to be actively heated with the heating method using hot air blowing device.
62781815|NCT06454877|EXPERIMENTAL|pasive heating|Passive heating using reflective blankets is the group to be made.
62781816|NCT06454877|NO_INTERVENTION|control group|The group will receive routine hospital care without any intervention.
62781817|NCT00748319|OTHER|1|Detection of KIR receptor
62781818|NCT03897855|OTHER|Patient (TSPT-R)|Post Traumatic Stress Disorder
62781819|NCT03897855|EXPERIMENTAL|control|No Post Traumatic Stress Disorder
62781820|NCT02020408|EXPERIMENTAL|[11C]raclopride, [11C]DASB, amphetamine|One time administration of oral amphetamine based on subject's weight (0.5 mg/kg). One PET scan using \[11C\]DASB. Two PET scans using \[11C\]raclopride.
62781821|NCT06379269|EXPERIMENTAL|App group|
62781822|NCT06379269|ACTIVE_COMPARATOR|Control group|
62781823|NCT05740332|EXPERIMENTAL|All participants|1 mL of alcohol foam hand sanitizer automatically dispensed into hands, spread over hands and rubbed until dry.
62573287|NCT04245436|ACTIVE_COMPARATOR|Duloxetine|Patients randomized to duloxetine, treatment will be initiated at 30 mg qAM through Week 4 (V5) (consistent with the registration trial for duloxetine in pediatric patients with generalized anxiety disorder). Then, duloxetine will be increased to 60 mg qAM at Week 4 (V5) and will be continued at this dose until Week 6 (V6) or the end of the acute phase of the study. Beginning at Week 6 (V6), duloxetine may be increased to 90 mg daily and at Week 8 (V7), may be increased to 120 mg daily.
62193230|NCT06064747|EXPERIMENTAL|LF-rTMS|"Using 8 coil,1-Hz rTMS to stimulate the M1 region of the ipsilateral hemisphere, the stimulation intensity was RMT 100%, 1200pulses/session, two sessions (2400 pulses)/day (interval ≥ 2 hours), lasting 3 days (total 6 sessions, 7200pulses)"
62573288|NCT04245436|ACTIVE_COMPARATOR|Escitalopram|Patients randomized to escitalopram, will initiate treatment at 5 mg qAM for 1 week and then 10 mg qAM (the recommended starting dose for adolescents 12-17 years and the dose used in the pediatric registration trials). After Week 4 (V5), escitalopram will be increased to 15 mg and this dose will be continued until either Week 6 (V6) or the end of the acute phase of the study; however, at Week 6 (V6), escitalopram may be increased to 20 mg qAM based on efficacy.
62781824|NCT05454124|EXPERIMENTAL|Training visual sensitivity|A standard Perceptual Learning approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold- level contrast. Preliminary data, using this method, in normally seeing and MD participants show both feasibility and preliminary evidence that this training gives rise to improvements in acuity.
62007816|NCT04744727|ACTIVE_COMPARATOR|paracetamol group|Included 48 pregnant women who received 1000 mg of intravenous paracetamol. The treatment was administered at the begining of the active phase of 1st stage of labor \[roughly defined as a cervical dilatation of 3-4 cm and a cervical effacement ≥ 50%\].
62007817|NCT04744727|ACTIVE_COMPARATOR|pethidine group|Included 48 pregnant women who received 50 mg of intravenous pethidine HCL diluted in 10 ml normal saline. The treatment was administered at the beginning of the active phase of 1st stage of labor \[roughly defined as a cervical dilatation of 3-4 cm and a cervical effacement ≥ 50%\].
62007818|NCT04173130|EXPERIMENTAL|Injection of botulinum toxin with investigational device|
62007819|NCT03837795|EXPERIMENTAL|Neurofeedback therapy group|
62007820|NCT01400841|EXPERIMENTAL|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
62007821|NCT02442830|EXPERIMENTAL|Early Video Capsule Endoscopy|The intervention for subjects in this arm will be to have a video capsule deployed as soon as possible after presentation to the emergency department. Information from the video capsule will be obtained and reviewed to determine location of bleeding. Once that information has been obtained a decision will be made on which endoscopic test is most pertinent in finding and treating the source of bleeding.
62007822|NCT02442830|NO_INTERVENTION|Standard of Care Workup Group|"In this arm, patients will receive standard of care workup for non-hematemesis gastrointestinal bleeding. This could include upper endoscopy, colonoscopy, and additional capsule or small bowel enteroscopy depending on the subject's presentation and the results of the workup performed by the gastroenterology team. For patients requiring a video capsule endoscopy as part of standard of care workup the patients will be given the same Olympus video capsule that is used in the Early Capsule group."
62193231|NCT06064747|SHAM_COMPARATOR|Sham coil stimulation|The sham stimulation coil was used to stimulate the same site, duration and sound as the LF-rTMS group, ensuring no effective stimulation, twice a day for 3 days
62193232|NCT02531854|EXPERIMENTAL|ADXS11-001 + Pemetrexed|
62193233|NCT02531854|ACTIVE_COMPARATOR|Pemetrexed Only|
62193234|NCT00880022|ACTIVE_COMPARATOR|arm compression only|Intervention of arm compression only by Flexitouch System
62193235|NCT00880022|EXPERIMENTAL|arm, trunk and chest compression|Intervention of arm, trunk and chest compression by Flexitouch System
62193236|NCT04016116|EXPERIMENTAL|Pembrolizumab (Cohort 1)|Pembrolizumab IV every 3 weeks (Cohort 1: Advanced progressive MPNs)
62193237|NCT04016116|EXPERIMENTAL|Pembrolizumab + Ruxolitinib|Pembrolizumab IV every 3 weeks \& Ruxolitinib po days 1-21 (Cohort 1: Advanced progressive MPNs)
62193238|NCT04016116|EXPERIMENTAL|Pembrolizumab + Ruxolitinib (Cohort 2)|Pembrolizumab IV every 3 weeks \& Ruxolitinib po days 1-21 (Cohort 2, unresponsive to PD-1)
62193239|NCT03452865|EXPERIMENTAL|Esomeprazole|Patients randomized to Esomeprazole Group will receive a bolus of 160 mg of esomeprazole (diluted in 100 ml of 0.9% sodium chloride for intravenous use and administered over 60 minutes) and an intravenous infusion of 12 mg/hr (diluted in 0.9% sodium chloride at a concentration of 8 mg/ml will be injected at a rate of 1.5 ml/hr) for 72 hours .
62193240|NCT03452865|PLACEBO_COMPARATOR|Placebo|Patients randomized to Placebo Group will receive a bolus of 100 ml of 0.9% sodium chloride for intravenous use administered over 60 minutes with no active principle and an intravenous infusion of 0.9% sodium chloride at a rate of 1.5 ml/hr with no active principle for 72 hours .
62193241|NCT03784820|EXPERIMENTAL|UNITE|UNITE is a manualized cognitive-behavioral couple therapy (CBCT) intervention that engages the couple to address the core psychopathology of BED.
62193242|NCT03784820|ACTIVE_COMPARATOR|CBT-E|CBT-E is a trans-diagnostic cognitive behavioral individual therapy treatment for eating disorders. It has been shown to be effective in numerous controlled and open trials.
62007823|NCT04677920|EXPERIMENTAL|Healthy Cookie Group|All participants in the study
62007824|NCT06453993|OTHER|Investigate whether exhaled breath can be used to detect and monitor esophageal cancer.|The procedures will include collecting participant's personal information and samples of participant's exhaled breath, urine, and saliva.
62007825|NCT01046916|EXPERIMENTAL|TAK-700|
62007826|NCT05867394|EXPERIMENTAL|Stress ball|Data were collected by the investigator 25-30 minutes before coronary angiography and the first measurement of vital signs was made. After the stress ball application, State Anxiety Inventory data were collected for the second time and the second measurement of vital signs was made. Vital signs were measured and noted for the third time after coronary angiography.
62007827|NCT05867394|NO_INTERVENTION|Control|25-30 minutes before the coronary angiography procedure, data were collected from the patients by the investigator and the first measurements of their vital signs were recorded. Vital signs were measured a second time just before coronary angiography without any intervention. Vital signs were measured and recorded for the third time after coronary angiography ischemia.
62007828|NCT01040429|ACTIVE_COMPARATOR|Clonidine capsula|
62007829|NCT01040429|PLACEBO_COMPARATOR|Lactose capsula|
62007830|NCT05100875|EXPERIMENTAL|Intervention SSERT|The SSERT intervention will take place over 10 weekly individual intervention sessions of 60 minutes. SSERT for trauma history in psychosis will draw inspiration from the Skills Training in Affective and Interpersonal Regulation intervention as well as other CBT and DBT-based interventions for emotion regulation and social skills functioning. Therapists will be provided with a semi-structured manual that can be implemented flexibly to consider participant needs.
62007831|NCT00732121|ACTIVE_COMPARATOR|1|Sitagliptin
62007832|NCT00732121|PLACEBO_COMPARATOR|2|Placebo arm
62193243|NCT03126110|EXPERIMENTAL|Phase 1 Group A: INCAGN01876 1.0 mg/kg Q2W + nivolumab 240 mg Q2W|Participants received INCAGN01876 1.0 milligrams per kilogram (mg/kg) administered intravenously (IV) every 2 weeks (Q2W) in combination with nivolumab 240 mg administered IV Q2W.
62398203|NCT06272487|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo on Day 1 of the 6-month DB treatment period. Participants must be on stable doses of at least 2, but not more than 4, antihypertensive medications for at least 30 days prior to screening and plan to remain on stable doses of these medications during screening and through the DB treatment period.
62781825|NCT05454124|EXPERIMENTAL|Combination training|In combination training, investigators test the extent to which a combined training gives rise to the joint benefits of each training individually, or integrative benefits potentially surpassing benefits of the individual training alone. The visual sensitivity task will alternate across blocks with the spatial integration task, using the timing of targets and location switches from spatial attention training.
62781826|NCT03515564|EXPERIMENTAL|Alternative therapy|"Dance/Movement Therapy, Art Therapy, Mindful Yoga~60 minutes once weekly for 8 weeks"
62781827|NCT03515564|NO_INTERVENTION|No Intervention|No Intervention
62007833|NCT05421078|PLACEBO_COMPARATOR|Placebo|Once-daily placebo
62007834|NCT05421078|EXPERIMENTAL|2.5 mg Obicetrapib|once-daily Obicetrapib
62007835|NCT05421078|EXPERIMENTAL|5 mg Obicetrapib|once-daily Obicetrapib
62007836|NCT05421078|EXPERIMENTAL|10 mg Obicetrapib|once-daily Obicetrapib
62007837|NCT05168995||Asthmatic patients in treatment with BDP/FF NEXThaler® 100/6 micrograms|Not adequately controlled asthmatic patients in treatment with Beclometasone dipropionate (BDP)/formoterol fumarate (FF) 100/6 micrograms per actuation inhalation powder via NEXThaler®
62781828|NCT05378737|EXPERIMENTAL|A/1.2mg/kg|Drug：BAT8006 for Injection, 1.2mg/kg, Q3W（Dose escalation study）
62781829|NCT05378737|EXPERIMENTAL|B/2.4mg/kg|Drug：BAT8006 for Injection, 2.4mg/kg, Q3W（Dose escalation study）
62781830|NCT05378737|EXPERIMENTAL|C/ 3.0mg/kg|Drug：BAT8006 for Injection, 3.0mg/kg, Q3W（Dose escalation study）
62781831|NCT05378737|EXPERIMENTAL|D/ 3.6mg/kg|Drug：BAT8006 for Injection, 3.6mg/kg, Q3W（Dose escalation study）
62007838|NCT06453590|EXPERIMENTAL|Uncovered SEMS|Allocated to treatment with an uncovered SEMS in the distal bile duct.
62007839|NCT06453590|EXPERIMENTAL|Partially covered SEMS|Allocated to treatment with a partially covered SEMS in the distal bile duct.
62007840|NCT06453590|EXPERIMENTAL|Fully covered SEMS|Allocated to treatment with a fully covered SEMS in the distal bile duct.
62193244|NCT03126110|EXPERIMENTAL|Phase 1 Group A: INCAGN01876 3.0 mg/kg Q2W + nivolumab 240 mg Q2W|Participants received INCAGN01876 3.0 mg/kg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.
62193245|NCT03126110|EXPERIMENTAL|Phase 1 Group A: INCAGN01876 5.0 mg/kg Q2W + nivolumab 240 mg Q2W|Participants received INCAGN01876 5.0 mg/kg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.
62573289|NCT02439541|EXPERIMENTAL|UCMSC group|Patients in this arm received umbilical cord MSCs by intracoronary injection
62007841|NCT05354375|EXPERIMENTAL|CAR-T cell immunotherapy|The registered patients will receive CAR-T cell immunotherapy for the new specific chimeric antigen receptor of PSMA antigen by infusion.
62007842|NCT01698463|OTHER|Identify Patients at Risk/Exercise Prescription|The intervention was delivered in two visits and two follow-up phone calls. Physician identifies that the patient is at risk of falls or fractures Visit one: individualized exercise prescription by a physiotherapist. Visit two: motivational interviewing (behavioural counselling) by kinesiologist Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions.
62007843|NCT03191903|EXPERIMENTAL|Cingal|Cingal is a combination product consisting of 88 milligrams of cross-linked HA (hyaluronic acid) with 18 milligrams of TH (triamcinolone hexacetonide) in a 4 milliliter (mL) intra-articular injection.
62573290|NCT02439541|NO_INTERVENTION|Control group|Patients in this arm did not receive any intervention.
62573291|NCT02499211|EXPERIMENTAL|Intervention stores|Supermarkets will be the unit of randomization, intervention, and analysis. During randomization, stores are paired by size and percent sales of Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) and Supplemental Nutrition Assistance Program (SNAP) funding. The intervention will last for 2 years, and will consist of in-store marketing of healthier (lower calorie) products through placement and promotion strategies in 6 food and beverage categories: milk; frozen meals; beverages in checkout coolers; bread; salty snacks; and cheese.
62007844|NCT03191903|ACTIVE_COMPARATOR|Monovisc|Monovisc is a device that consists of 88 milligrams of cross-linked HA (hyaluronic acid) in a 4 milliliter (mL) intra-articular injection.
62573292|NCT02499211|NO_INTERVENTION|Non-intervention stores|No intervention administered. Supermarkets will be the unit of randomization, intervention, and analysis. During randomization, stores are paired by size and percent sales of WIC and SNAP funding. The non-intervention stores will not receive an intervention.
62573293|NCT02955095|EXPERIMENTAL|Current cigarette smoker|
62573294|NCT03612596|EXPERIMENTAL|Narrative visualization|Wearable activity monitor, app, and enhanced motivational scrapbook materials (instant camera, stickers, markers, enhanced content)
62573295|NCT03612596|ACTIVE_COMPARATOR|Standard self-regulation|Wearable activity monitor, app, and standard workbook materials (markers, a workbook with a calendar log to keep track of steps over time)
62573296|NCT05704998|EXPERIMENTAL|Posterior Edentulous Group|Posture exercises, manual therapy and kinesio taping were applied twice a week for six weeks.
62573297|NCT05704998|EXPERIMENTAL|Fully Toothed Group|Posture exercises, manual therapy and kinesio taping were applied twice a week for six weeks.
62573298|NCT00578019|ACTIVE_COMPARATOR|1, A|
62573299|NCT00578019|EXPERIMENTAL|2, B|Group B patients will have their fracture stabilized with the LISS plates (Synthes \[USA\], Paoli, PA, USA).
62573300|NCT02594033|EXPERIMENTAL|3 mm needle|
62573301|NCT02594033|EXPERIMENTAL|3.5 mm needle|
62573302|NCT02594033|ACTIVE_COMPARATOR|4 mm needle|
62007845|NCT03191903|ACTIVE_COMPARATOR|Triamcinolone Hexacetonide (TH)|Triamcinolone hexacetonide (TH) is a corticosteroid supplied in a 20 milligram per 1 milliliter (20 mg/mL) intra-articular injection.
62007846|NCT04507958||Electronic auscultation|
62398204|NCT02007798|EXPERIMENTAL|low-dose group|S group : dexmedetomidine is infused intravenously at a dose of 0.4 ug/kg
62398205|NCT02007798|EXPERIMENTAL|middle-dose group|M group: dexmedetomidine is infused intravenously at a dose of 0.8 ug/kg
62573303|NCT02404636||Alcoholic hepatitis|Individuals admitted to hospital with acute alcoholic hepatitis, defined as acute onset of jaundice in the context of recent hazardous alcohol use and the absence of other liver disease
62573304|NCT02404636||Hazardous alcohol use|Individuals admitted to hospital for any cause who drink hazardous quantities of alcohol but without evidence of alcoholic hepatitis or advanced liver disease
62573305|NCT05017350|EXPERIMENTAL|Radiofrequency ablation group|hemostasis using radiofrequency ablation for track bleeding
62398206|NCT02007798|EXPERIMENTAL|control group|P group: normal saline is infused intravenously
62398207|NCT02318485|EXPERIMENTAL|Transplant|A limbal epithelial stem cell graft will be transplanted onto the limbal stem cell deficient eye after it has been debrided of fibrovascular pannus
62573306|NCT06576141|ACTIVE_COMPARATOR|Kaleidoscope group|The kaleidoscope will be used 5 minutes before the blood collection procedure, as the child who will be included in the kaleidoscope group sits in the patient chair. The nurse will start preparing the child for the blood collection procedure at that time.
62573307|NCT06576141|ACTIVE_COMPARATOR|virtual reality glasses|The child to be included in the virtual reality group will be seated in the patient chair and the virtual reality will be used 5 minutes before the blood collection procedure. The nurse will start preparing the child for the blood collection procedure at that time.
62781832|NCT05378737|EXPERIMENTAL|93mg/m^2 or 84mg/m^2|Drug：BAT8006 for Injection, 93mg/m\^2 or 84mg/m\^2, Q3W（Dose extension study）
62398208|NCT04148508|EXPERIMENTAL|Tailored Emotional Competence|Self-help Tailored Emotional Competence delivered via mobile app
62398209|NCT04148508|ACTIVE_COMPARATOR|Cognitive-behavioural Approach|Self-help cognitive-behavioural approach delivered via mobile app
62398210|NCT04148508|PLACEBO_COMPARATOR|Self-monitoring|Self-help self-monitoring delivered via mobile app
62398211|NCT06461650|EXPERIMENTAL|Nicotine cessation program|
62781833|NCT02171741|EXPERIMENTAL|Docetaxel + BIBW 2992|
62007847|NCT04507958||Conventional ausculatation|
62007848|NCT03500757||360-degree Display of solid tumors|Evaluate the feed back of using the HoloLens headset to have a 360 degree visualization of patient tumors during percutaneous liver tumor ablation
62007849|NCT03438435|EXPERIMENTAL|QRH-882260 Heptapeptide|Five mL of reconstituted (with sterile 0.9% NaCl) QRH-882260 Cy-5-labeled heptapeptide
62781834|NCT02421588|EXPERIMENTAL|Arm A|lurbinectedin (PM01183)
62781835|NCT02421588|ACTIVE_COMPARATOR|Arm B|"pegylated liposomal doxorubicin~OR~topotecan"
62781836|NCT03244163|EXPERIMENTAL|LASER ARM|Spyglass DS cholangioscope guided laser or electrohydraulic lithotripsy
62781837|NCT03244163|ACTIVE_COMPARATOR|CONVENTIONAL ARM|Stone removal by conventional techniques, for example BML, without laser lithotripsy
62007850|NCT06471933|EXPERIMENTAL|Juläine|
62781838|NCT01368081|EXPERIMENTAL|BI 10773 low dose|BI 10773 low dose tablet once daily
62781839|NCT01368081|EXPERIMENTAL|BI 10773 high dose|BI 10773 high dose tablet once daily
62007851|NCT04201288|EXPERIMENTAL|Acceptance-Based Behavior Therapy (ABBT)|The 2-session ABBT will be delivered in person at session 1 and by telephone at session 2.
62007852|NCT04201288|PLACEBO_COMPARATOR|Enhanced-Treatment-as-Usual (ETAU)|In addition to receiving treatment-as-usual at the clinic, ETAU participants will receive a 2-session program of HIV education.
62007853|NCT05654324|EXPERIMENTAL|Pregnant women|Pregnant women aged 18-40, 20-40 weeks of gestation.
62007854|NCT05654324|ACTIVE_COMPARATOR|Non-Pregnant|Being a non-pregnant woman who is in the same age range as the experimental group.
62007855|NCT01820611||With Bonemaster HA|100 patients using Arcos Revision Stem System with BoneMaster Hydroxyapatite
62007856|NCT01820611||Without BoneMaster HA|100 patients using Arcos Revision Stem System without BoneMaster Hydroxyapatite
62007857|NCT03252821|EXPERIMENTAL|High-intensity aerobic training group|High intensity interval training
62007858|NCT03252821|ACTIVE_COMPARATOR|Resistance training group|Muscle strengthening
62007859|NCT03252821|NO_INTERVENTION|Control group|Usual care
62007860|NCT06315257|EXPERIMENTAL|pBI-11 DNA plus TA-HPV via Skin Scarification|Participants will receive pBI-11 DNA and TA-HPV via Skin Scarification
62007861|NCT06315257|EXPERIMENTAL|pBI-11 DNA plus TA-HPV via IM Injection|Participants will receive pBI-11 DNA and TA-HPV via IM Injection
62007862|NCT04891224|OTHER|Pathway Platform application use|Study participants will download the Pathway app to their mobile device. This app will gather patient health data, present standardized questionnaires and research data collection tools. Subject responses will be visible to their provider via interface with the electronic medical record.
62781840|NCT01368081|ACTIVE_COMPARATOR|Metformin|Metformin tablets 500-2250 mg a day (twice or three times per day)
62781841|NCT01817959|EXPERIMENTAL|Reparixin group|Continuous iv infusion
62781842|NCT01817959|PLACEBO_COMPARATOR|Placebo group|Continuous iv infusion
62781843|NCT00888342|ACTIVE_COMPARATOR|1 supplementary oxygen|participant receives supplementary oxygen one night, polysomnography with capnography will be compared to no treatment another night
62781844|NCT00888342|ACTIVE_COMPARATOR|2 Zopiclone|participant receives 5 mg zopiclone one night, polysomnography with capnography will be compared to no treatment another night
62781845|NCT00888342|ACTIVE_COMPARATOR|3 Alcohol|participant receives 0,5 mg alcohol /kg body weight before sleep one night, polysomnography with capnography will be compared to no intervention another night
62781846|NCT02624427|EXPERIMENTAL|Glaucoma Eyes|Measurement of intraocular pressure (IOP)
62781847|NCT02624427|ACTIVE_COMPARATOR|Healthy Eyes|age-matched healthy eyes as controls will undergo Measurement of intraocular pressure (IOP)
62781848|NCT05374629|EXPERIMENTAL|The Intervention group had Shared Decision Making of smoking cessation.|The intervention group had the shared decision-making of smoking cessation which was guided by the smoking cessation health educator, and it containing the nicotine addiction, the impact of smoking on health, the methods and difficulties about smoking cessation, and the way of decision.
62781849|NCT05374629|NO_INTERVENTION|The control group received routine smoking cessation health education|The control group received routine smoking cessation health education by another smoking cessation health educator, and it containing the harm of smoking, the benefits of quitting smoking, smoking cessation methods, and second-generation smoking cessation .
62781850|NCT03791775|EXPERIMENTAL|Polidocanol 3% Foam|Patients enrolled in the study, according to the inclusion and exclusion criteria, will undergo sclerotherapy performed with polidocanol foam (Atossisclerol® 3%, Chemische Fabrik Kreussler \& Co. GmbH, Wiesbaden, Germany).
62781851|NCT05247281|ACTIVE_COMPARATOR|Culture-based treatment|
62781852|NCT05247281|ACTIVE_COMPARATOR|Next Generation Sequencing (NGS) with Culture-based treatment|
62781853|NCT05487417|EXPERIMENTAL|Minocycline treatment group|Patients were given minocycline 200mg/d orally from the day of admission for 5 days. At the same time, the patient received mechanical thrombectomy and other standard treatments for acute ischemic stroke.
62573308|NCT06576141|OTHER|control group|Children in the control group will not undergo any interventional procedures. Blood collection will be arranged to be taken from the antecubital region by the same nurse via a vacutainer.
62573309|NCT03397498|EXPERIMENTAL|Computerized cognitive training|Received the Computerized cognitive training program, CogniFit™
62573310|NCT03397498|ACTIVE_COMPARATOR|Control-games|Received the Computerized games program
62573311|NCT06457802|EXPERIMENTAL|Sit Less Group - mHealth intervention|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention.
62781854|NCT05487417|NO_INTERVENTION|Routine treatment group|Patients were given mechanical thrombectomy and other standard treatment for acute ischemic stroke, without minocycline treatment.
62781855|NCT05758428|EXPERIMENTAL|Cohort 1|Subjects will receive a 3 mg ensifentrine single dose, followed by 3 mg repeated dose (twice daily, BID).
62007863|NCT02575781|EXPERIMENTAL|SAR428926-Escalating cohort|SAR428926 will be administered intravenously up to disease progression or dose limiting toxicities
62007864|NCT02575781|EXPERIMENTAL|SAR428926 in triple negative breast cancer-Expansion Cohort 1|SAR428926 will be administered intravenously at maximum tolerated dose (MTD) up to disease progression or unacceptable toxicity
62007865|NCT02575781|EXPERIMENTAL|SAR428926 in solid tumors-Expansion Cohort 2|SAR428926 will be administered intravenously at the MTD up to disease progression or unacceptable toxicity
62007866|NCT00061048|EXPERIMENTAL|Campath-1H|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week.
62193246|NCT03126110|EXPERIMENTAL|Phase 1 Group A: INCAGN01876 10.0 mg/kg Q2W + nivolumab 240 mg Q2W|Participants received INCAGN01876 10.0 mg/kg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.
62573312|NCT06457802|NO_INTERVENTION|Control Group - Standard Care|Participants in the control group will receive standard care, including educational materials from the American Heart Association's Healthy Living booklet and a Fitbit. They will not receive the smart water bottle or the tailored text messages aimed at reducing sedentary behavior. The Fitbit move alert setting will be disabled for the control group.
62573313|NCT05708872|EXPERIMENTAL|Study group|
62573314|NCT05708872|ACTIVE_COMPARATOR|Control group|
62781856|NCT05758428|EXPERIMENTAL|Cohort 2|Subjects will receive two single doses of 1.5 mg and 6 mg ensifentrine, separated by at least a 7-day washout period using crossover design.
62781857|NCT04522479|NO_INTERVENTION|prolonged protocol of early follicular phase|Inject a full dose of GnRH-a in 1st-3rd day of menstruation (leuprorelin acetate, injection, 3.75mg), the level of E2, P, LH in peripheral blood and the number of follicles in bilateral internal ovarian sinuses were monitored 32-38 days after the depression. If the pituitary desensitization was achieved, Gn (recombinant human follicle stimulating hormone or urofollicle stimulating hormone, injection, 75-300iu) was used for contralled hyperstimulation, when the diameter of 2 follicles was ≥ 18mm，hCG (human chorionic gonadotropin, injection, 4000-10000IU) was used to trigger and retrieve the oocyte. Selective single blastocyst transplantation was performed on the 4th-6th day after the oocyte retrieved. β-hCG was detected on the 12th day after embryo transplantation, and pregnancy or not was judged. If patients get pregnancy, follow-up was continued until the 42nd day after baby delivery.
62007867|NCT04068181|EXPERIMENTAL|Cohort 1 - Locally Recurrent/Metastatic - Primary Resistance|"Includes participants who received anti-PD1 therapy in the locally recurrent/metastatic setting and experienced a best overall response of disease progression or stable disease prior to confirmed disease progression.~Participants will receive talimogene laherparepvec at an initial dose of up to 4.0 mL of 10\^6 plaque-forming units (PFU)/mL on Day 1. Subsequent doses of up to 4.0 mL of 10\^8 PFU/mL will be administered every 3 weeks for up to 35 cycles in total. Participants will also receive pembrolizumab at a dose of 200 mg every 3 weeks for up to 35 cycles."
62007868|NCT04068181|EXPERIMENTAL|Cohort 2 - Locally Recurrent/Metastatic - Acquired Resistance|"Includes participants who received anti-PD-1 therapy in the locally recurrent/metastatic setting and experienced confirmed disease progression following a complete or partial response on anti-PD-1 therapy.~Participants will receive talimogene laherparepvec at an initial dose of up to 4.0 mL of 10\^6 plaque-forming units (PFU)/mL on Day 1. Subsequent doses of up to 4.0 mL of 10\^8 PFU/mL will be administered every 3 weeks for up to 35 cycles in total. Participants will also receive pembrolizumab at a dose of 200 mg every 3 weeks for up to 35 cycles."
62007869|NCT04068181|EXPERIMENTAL|Cohort 3 - Adjuvant Setting -Disease Free Interval < 6 months|"Includes participants who received anti-PD-1 therapy in the adjuvant setting and experienced confirmed disease progression following a disease-free interval of \< 6 months after starting the adjuvant anti-PD-1 therapy.~Participants will receive talimogene laherparepvec at an initial dose of up to 4.0 mL of 10\^6 plaque-forming units (PFU)/mL on Day 1. Subsequent doses of up to 4.0 mL of 10\^8 PFU/mL will be administered every 3 weeks for up to 35 cycles in total. Participants will also receive pembrolizumab at a dose of 200 mg every 3 weeks for up to 35 cycles."
62007870|NCT04068181|EXPERIMENTAL|Cohort 4 - Adjuvant Setting -Disease Free Interval ≥ 6 months|"Includes participants who received anti PD-1 therapy in the adjuvant setting and experienced confirmed disease progression following a disease-free interval of ≥ 6 months after starting the adjuvant PD-1 inhibitor.~Participants will receive talimogene laherparepvec at an initial dose of up to 4.0 mL of 10\^6 plaque-forming units (PFU)/mL on Day 1. Subsequent doses of up to 4.0 mL of 10\^8 PFU/mL will be administered every 3 weeks for up to 35 cycles in total. Participants will also receive pembrolizumab at a dose of 200 mg every 3 weeks for up to 35 cycles."
62007871|NCT02820194|ACTIVE_COMPARATOR|Stereotactic body radiation therapy|Patients are treated with Stereotactic Body Radiation Therapy, a methodology for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule.
62007872|NCT02820194|ACTIVE_COMPARATOR|Microwave Ablation|Patients are treated with Microwave Ablation,a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis.
62007873|NCT06655935|ACTIVE_COMPARATOR|44 patients with ASD who underwent the ordinary transcatheter closure technique using ASO.|The dilator of the Amplatzer delivery sheath of the Amplatzer™ Septal Occluders ASO is advanced over stiff wire into the pulmonary veins
62007874|NCT06655935|EXPERIMENTAL|36 patients with ASD who underwent the modified transcatheter closure technique using ASO|Amplatzer delivery sheath of the Amplatzer™ Septal Occluders ASO is advanced over the multipurpose catheter to the left atrial cavity
62573315|NCT04947384||Patients with moderate mitral valve disease, undergoing interventions|Patients with established WHO-2 diagnosis of PH undergoing open and interventional mitral valve procedures.
62573316|NCT04947384||Patients undergoing mitral valve interventions without pulmonary hypertension|Patients with no PH undergoing open and interventional mitral valve procedures. This group will serve as a control.
62573317|NCT04947384||Patients with precapillary pulmonary hypertension scheduled for right heart catheterization|Patients with established diagnosis of WHO-1-4 groups of PH undergoing right heart catheterization. This group will serve as a control.
62573318|NCT05866705||Cancer|Individuals living with cancer
62573319|NCT05866705||Care Partner|Care partner for someone who is living with cancer
62007875|NCT02111616|ACTIVE_COMPARATOR|Standard of Care (SCP)|Patient will attend a transition visit at the conclusion of cancer treatment. Patient will receive an individualized cancer survivorship care plan based on their cancer type and treatment.
62007876|NCT02111616|EXPERIMENTAL|Intervention Arm (SCP + PCP visit)|"Patient will attend a transition visit at the conclusion of cancer treatment. Patient will receive an individualized cancer survivorship care plan based on their cancer type and treatment.~SCP plus Coordinated PCP Visit: Care coordinators will schedule patient appointment with PCP within 4 weeks of treatment."
62007877|NCT02081495|EXPERIMENTAL|Sequence AB|Twenty-one participants will receive DOXIL/CAELYX reference product in Cycle 1 and DOXIL/CAELYX test product in Cycle 2. Each cycle will be separated by 28 days.
62007878|NCT02081495|EXPERIMENTAL|Sequence BA|Twenty-one participants will receive DOXIL/CAELYX test product in Cycle 1 and DOXIL/CAELYX reference product in Cycle 2. Each cycle will be separated by 28 days.
62007879|NCT05674487|EXPERIMENTAL|Trans-cervical balloon|Induction of labor by cervical ripening with trans-cervical balloon (Foley catheter).
62007880|NCT05674487|ACTIVE_COMPARATOR|Misoprostol|Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)
62007881|NCT01518075|EXPERIMENTAL|Non invasive mechanical ventilation|Evaluation of breathing swallowing interaction under non invasive mechanical ventilation
62007882|NCT01518075|ACTIVE_COMPARATOR|Spontaneous Breathing|Evaluation of breathing swallowing interaction without non invasive mechanical ventilation
62007883|NCT05666401||group 1|follicles with a diameter of 17 mm and more
62007884|NCT05666401||group 2|follicles with a diameter of 14 mm to 17 mm
62007885|NCT06052904|EXPERIMENTAL|Intervention group|Home-based music breathing therapy comprising eight 1-hour weekly sessions for 2 months delivered through Zoom, an online video conferencing platform, by a qualified music therapist.
62007886|NCT06052904|ACTIVE_COMPARATOR|Control group|Eight weekly online educational modules on medical information and advice about caring for a child who has been newly diagnosed with cancer via email for 2 months.
62007887|NCT03154619|ACTIVE_COMPARATOR|TR987|This group will receive twice-weekly applications of 0.1% TR 987 in a gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.
62193247|NCT03126110|EXPERIMENTAL|Phase 1 Group B: INCAGN01876 1.0 mg/kg Q2W, then nivolumab 240 mg Q2W|Participants received INCAGN01876 1.0 mg/kg administered IV Q2W for a total of 2 doses as run-in, followed by INCAGN01876 1.0 mg/kg Q2W in combination with nivolumab 240 mg administered IV Q2W starting at Cycle 3.
62007888|NCT03154619|PLACEBO_COMPARATOR|Placebo|This group will receive twice-weekly applications of placebo gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.
62007889|NCT06504238||NIMABI Group|"Eligible patients will be recruited on admission to the ICU followed by the Neurointensive care team.~Demographic, invasive ICP monitoring data, clinical, laboratory, diagnostic, treatment (medical and surgical) and outcome data will be collected. Data will be collected from non-invasive devices using either clinical review from the chart, or if not available and/or used for additional measurements, from the device (smartguard for pupillometry, imaging, EEG data, Brain4care data)."
62007890|NCT06050590|EXPERIMENTAL|NeuroGlove Treatment Arm|Study participants undergoing treatment using the NeuroGlove.
62007891|NCT04423042|EXPERIMENTAL|Tocilizumab Arm|Tocilizumab 8 mg/kg IV up to a maximum of 800 mg with possible repetition of the same dosage within 28 hours (the optional second dose after 12 hours but before 28 hours following the first dose), based on the clinical judgement of the attending physician in consultation with the COVID-inflammation team.
62007892|NCT04423042|NO_INTERVENTION|No Intervention Arm|No intervention arm patients will be identified from medical records, as being COVID-19 positive patients with hyperinflammation who did not receive any interleukin antagonist treatment.
62007893|NCT06300554|EXPERIMENTAL|Participants from the 10th Mountain Division|
62193248|NCT03126110|EXPERIMENTAL|Phase 1 Group B: INCAGN01876 3.0 mg/kg Q2W, then nivolumab 240 mg Q2W|Participants received INCAGN01876 1.0 mg/kg administered IV Q2W for a total of 2 doses as run-in, followed by INCAGN01876 1.0 mg/kg Q2W in combination with nivolumab 240 mg administered IV Q2W starting at Cycle 3.
62193249|NCT03126110|EXPERIMENTAL|Phase 1 Group B: INCAGN01876 5.0 mg/kg Q2W, then nivolumab 240 mg Q2W|Participants received INCAGN01876 5.0 mg/kg administered IV Q2W for a total of 2 doses as run-in, followed by INCAGN01876 5.0 mg/kg Q2W in combination with nivolumab 240 mg administered IV Q2W starting at Cycle 3.
62007894|NCT03518320|EXPERIMENTAL|TAR-200 and Nivolumab Combination|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 is placed into the bladder through an Inserter and gradually releases gemcitabine during the 21-day indwelling period before being removed. In combination, subjects are dosed intravenously with a Nivolumab Injection \[Opdivo\] within 3 days of TAR-200 placement. Subjects will receive four consecutive 21-day dosing cycles of the combination of TAR-200 and Nivolumab prior to radical cystectomy.
62193250|NCT03126110|EXPERIMENTAL|Phase 1 Group C: INCAGN01876 1.0 mg/kg Q2W + ipilimumab 1 mg/kg Q6W|Participants received INCAGN01876 1.0 mg/kg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV every 6 weeks (Q6W).
62193251|NCT03126110|EXPERIMENTAL|Phase 1 Group C: INCAGN01876 3.0 mg/kg Q2W + ipilimumab 1 mg/kg Q6W|Participants received INCAGN01876 3.0 mg/kg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV Q6W.
62193252|NCT03126110|EXPERIMENTAL|Phase 1 Group C: INCAGN01876 5.0 mg/kg Q2W + ipilimumab 1 mg/kg Q6W|Participants received INCAGN01876 5.0 mg/kg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV Q6W.
62193253|NCT03126110|EXPERIMENTAL|Phase 1 Group D: INCAGN01876 + Nivolumab + Ipilimumab|Participants received INCAGN01876 1.0 mg/kg administered IV Q2W in combination with nivolumab 3 mg/kg administered IV Q2W and ipilimumab 1 mg/kg administered IV Q6W.
62193254|NCT03126110|EXPERIMENTAL|Phase 2 Group C2 PD-1/PD-L1: INCAGN01876 300 mg + ipilimumab 1 mg/kg|Participants with programmed cell death protein/programmed cell death ligand 1 (PD-1/PD-L1) relapsed melanoma received INCAGN01876 300 mg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV Q6W.
62193255|NCT03126110|EXPERIMENTAL|Phase 2 Group F GC: INCAGN01876 300 mg + nivolumab 240 mg|Participants with gastric cancer (GC) received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.
62193256|NCT03126110|EXPERIMENTAL|Phase 2 Group F SCCHN INCAGN01876 300 mg + nivolumab 240 mg|Participants with squamous cell carcinoma of the head and neck (SCCHN) received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.
62193257|NCT03126110|EXPERIMENTAL|Phase 2 Group F CC: INCAGN01876 300 mg + nivolumab 240 mg|Participants with cervical cancer (CC) received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.
62193258|NCT03126110|EXPERIMENTAL|Phase 2 Group F PD-1/PD-L1: INCAGN01876 300 mg + nivolumab 240 mg|Participants with PD-1/PD-L1 relapsed melanoma received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.
62193259|NCT03126110|EXPERIMENTAL|Phase 2 Group F Biopsy: INCAGN01876 300 mg + nivolumab 240 mg|Participants with gastric cancer, squamous cell carcinoma of the head and neck, cervical cancer, or PD-1/PD-L1 relapsed melanoma who had tumor lesions that were amenable to percutaneous biopsy received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.
62193260|NCT05683145|EXPERIMENTAL|Computerized Cognitive Behavioral Therapy for Insomnia|Self-guided computerized CBT-I program with assistance from a licensed mental health professional.
62193261|NCT05683145|NO_INTERVENTION|Enhanced Treatment as Usual|ETU is defined as treatment per usual which is enhanced by participating in data collection related to study participation.
62193262|NCT01896180|EXPERIMENTAL|ALZ-1101|ALZ-1101 ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular adminstration
62193263|NCT01896180|ACTIVE_COMPARATOR|Latanoprost|Latanoprost 0.005% ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular administration
62193264|NCT02901769|EXPERIMENTAL|Depressed suicide attempters|20 subjects
62193265|NCT02901769|EXPERIMENTAL|Depressed patients with past history of|20 subjects
62193266|NCT02901769|EXPERIMENTAL|Depressed patients with no history of|20 subjects
62193267|NCT02901769|PLACEBO_COMPARATOR|Healthy controls|20 subjects
62193268|NCT02296749|EXPERIMENTAL|Sirolimus tablets 2 mg|Sirolimus tablets 2 mg of Dr. Reddys Laboratories Limited
62193269|NCT02296749|ACTIVE_COMPARATOR|Rapamune|Rapamune® 2 mg tablets of Wyeth Laboratories, Philadelphia
62193270|NCT00950482|ACTIVE_COMPARATOR|TA|Active TA
62193271|NCT00950482|ACTIVE_COMPARATOR|AA|Alternative Acupuncture
62193272|NCT00950482|ACTIVE_COMPARATOR|WC|Waiting Group
62193273|NCT02803281||Lung Cancer - Frialty Assessment|Patients who will undergo surgery for lung cancer
62573320|NCT06575608||direct VO2max test group|Group A (n-26) will perform a direct VO2max test on the treadmill and vo2max will be calculated by the cardiopulmonary exercise testing (CPX) device Spirometry Medisoft Ergocart professional.
62007895|NCT03779841|EXPERIMENTAL|AGN-151607 (250 U)|Injections of 50 U were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
62193274|NCT02803281||Esophageal Cancer - Frailty Assessment|Patients who will undergo esophagectomy for esophageal cancer
62193275|NCT01921647|EXPERIMENTAL|YH4808, amoxicillin, clarithromycin|single administration of YH4808 or amoxicillin or clarithromycin or YH4808 + amoxicillin + clarithromycin
62193276|NCT01921647|EXPERIMENTAL|YH4808, amoxicillin and clarithromycin|7 days repeat administration of YH4808, amoxicillin and clarithromycin for H.pylori eradication
62193277|NCT01921647|EXPERIMENTAL|YH4808 and amoxicillin|7 days repeat administration of YH4808 and amoxicillin for H.pylori eradication
62193278|NCT01921647|ACTIVE_COMPARATOR|nexium, amoxicillin and clarithromycin|BID, 7 days repeat administration of nexium, amoxicillin and clarithromycin for H.pylori eradication
62193279|NCT00731133|OTHER|Disulfiram|Disulfiram at 250 mg daily
62193280|NCT02669615|EXPERIMENTAL|Melphalan HCl for injection (propylene glycol free)|Patients will receive 200 mg/m\^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).
62007896|NCT03779841|EXPERIMENTAL|AGN-151607 (125 U)|Injections of 25 U were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
62193281|NCT01479270|ACTIVE_COMPARATOR|TAP Block|20mL of 0.25% Ropivacaine with Epinephrine 1:200,000 is injected into bilateral transversus abdominal planes under ultrasound guidance.
62193282|NCT01479270|NO_INTERVENTION|No Block|Patients randomized to this arm have band aids applied to sites on lateral abdomen without injection.
62193283|NCT03573869|EXPERIMENTAL|Cryoballoon ablation|A 28-mm cryoballoon (Arctic Front Advance™ Cardiac CryoAblation Catheter, Medtronic, Minneapolis, MN) will be employed. The cryoballoon catheter will be introduced into the left atrium, following a single transeptal puncture, through a 12F FlexCath steerable sheath (Medtronic), constantly flushed with heparinized saline. A circular mapping catheter (Achieve, Medtronic) will be advanced through the cryoballoon to the PV orifice and positioned as proximally as possible inside the vessel to record the PV potentials at baseline and monitor the isolation procedure in real time.
62781858|NCT04522479|EXPERIMENTAL|prolonged protocol of middle luteal phase|Inject a full dose of GnRH-a in 21st-23rd day of menstruation (leuprorelin acetate, injection, 3.75mg), the level of E2, P, LH in peripheral blood and the number of follicles in bilateral internal ovarian sinuses were monitored 32-38 days after the depression. If the pituitary desensitization was achieved, Gn (recombinant human follicle stimulating hormone or urofollicle stimulating hormone, injection, 75-300iu) was used for contralled hyperstimulation, when the diameter of 2 follicles was ≥ 18mm，hCG (human chorionic gonadotropin, injection, 4000-10000IU) was used to trigger and retrieve the oocyte. Selective single blastocyst transplantation was performed on the 4th-6th day after the oocyte retrieved. β-hCG was detected on the 12th day after embryo transplantation, and pregnancy or not was judged. If patients get pregnancy, follow-up was continued until the 42nd day after baby delivery.
62193284|NCT03573869|NO_INTERVENTION|Standard treatment|Standard treatment, including at least one rhythm control medication, on top of optimized rate control and HF treatment
62007897|NCT03779841|PLACEBO_COMPARATOR|Placebo|Injections of placebo were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
62193285|NCT00926081|NO_INTERVENTION|Best medical treatment|Patients with peripheral artery disease receiving best medical treatment only
62193286|NCT00926081|ACTIVE_COMPARATOR|Supervised exercise training|Patients with peripheral artery disease receiving best medical treatment plus supervised exercise training
62193287|NCT04476212|EXPERIMENTAL|Intervention|In the experimental arm, the surgical wound will be irrigated using an antibiotic solution (amoxicillin-clavulanate) for topical prophylaxis
62193288|NCT04476212|NO_INTERVENTION|Control|In the control arm, the surgical wound will be irrigated with saline, which is our routine at present.
62193289|NCT05334043|EXPERIMENTAL|CuminUP30,then Curcumin capsules|Participants first received CuminUP30 3500mg on the first day in a fasting state.After a washout period of 7days,they then received curcumin capsules 2250mg on the eighth day in a fasting state.
62573321|NCT06575608||1-mile walk test group|Group B (n-26) will perform the 1 mile walk test and VO2 max will be calculated by the smartphone application VO2max calculator
62573322|NCT04632069|EXPERIMENTAL|NAC + taVNS|NAC will be given via nasogastric tube (n,g.) 100mg/kg loading dose, then 75mg/kg/dose n.g. q 6h, administered 1h before a feed, for a total of 14 days. taVNS will be administered to left ear during active sucking with 2 daily feedings starting after 4 days of NAC, continuing for 10 days.
62781859|NCT02804035|EXPERIMENTAL|sc2Wear Furosemide Combination Product|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump) for subcutaneous administration of 80 mg dose delivered over 5 hours.
62781860|NCT00478686||Severe Toxicity|Patients who experienced severe toxicity (at least one grade 4 side effect) with capecitabine chemotherapy
62781861|NCT00478686||Dose-Limiting Toxicity|Patients who experienced dose-limiting toxicity (at least one grade 3, or recurrent grade 2, side effect)with capecitabine chemotherapy
62781862|NCT00478686||Low/No Toxicity|Patients who have experienced low/no toxicity (none or only side effects at grade 1 \& 2) with capecitabine chemotherapy.
62781863|NCT02915978|EXPERIMENTAL|Lower Dose Fentanyl|Lower dose Fentanyl delivered via sublingual spray every 4 hours.
62781864|NCT02915978|EXPERIMENTAL|Higher Dose Fentanyl Sublingual Spray|Higher dose Fentanyl delivered via sublingual spray every 4 hours.
62007898|NCT05676671|EXPERIMENTAL|Self-etching adhesive Clearfil SE Bond|Group 1 received treatment with Clearfil SE Bond after selective caries removal
62007899|NCT05676671|EXPERIMENTAL|Self-etching adhesiveClearfil SE Protect containing MDPB|Group 2 received treatment with Clearfil SE Protect containing MDPB after selective caries removal
62007900|NCT01663259|EXPERIMENTAL|Cetuximab|
62007901|NCT01142739||Parkinson's Disease patient|levodopa-treated parkinson's disease (PD) patients
62007902|NCT01142739||Non Parkinson's disease controls|Non Parkinson's disease controls
62193290|NCT05334043|EXPERIMENTAL|Curcumin capsules,then CuminUP30|Participants first received curcumin capsules 2250mg on the first day in a fasting state.After a washout period of 7days,they then received CuminUP30 3500mg on the eighth day in a fasting state.
62007903|NCT03832959|NO_INTERVENTION|Non esophageal protection|Patients in this group will undergo a first atrial fibrillation catheter ablation procedure with pulmonary vein isolation to study esophageal lesions. The esophageal protection probe will not be used.
62007904|NCT03832959|EXPERIMENTAL|Esophageal protection|Patients in this group will undergo a first atrial fibrillation catheter ablation procedure with pulmonary vein isolation, using the esophageal protection probe EnsoETM
62398212|NCT05123482|EXPERIMENTAL|Sub-Study 1 AZD8205 Monotherapy|"Sub-Study 1 has two parts:~Part A : The aim is to determine the safety, tolerability, Recommended Phase 2 Dose(RP2D), and/or the Maximum Tolerated Dose (MTD) of AZD8205.~Part B: The aim of dose expansion is to evaluate anti-tumor activity of AZD8205 as monotherapy in select solid tumors."
62573323|NCT04604613||Ancillary-Correlative (biospecimen collection, node mapping)|Patients undergo hysterectomy and sentinel lymph node mapping. Patients may also undergo bilateral salpingo-oophorectomy at the direction of the treating physician. If peritoneal disease or other contraindications to lymphatic mapping are detected at the time of surgery, mapping and sentinel node biopsy are performed at the surgeon's discretion. At the time of hysterectomy, patients undergo collection of tissue for molecular testing. Before and after surgery, patients also undergo collection of blood samples for tumor marker analysis.
62193291|NCT06423651|EXPERIMENTAL|REHACOP+MCT therapy|The participants will receive a combined therapy: Metacognitive Training (MCT) with Cognitive Remediation (CR).
62573324|NCT05501418|EXPERIMENTAL|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after COVID-19 infection.
62781865|NCT02915978|PLACEBO_COMPARATOR|Placebo|Placebo (matching Fentanyl) delivered via sublingual spray every 4 hours.
62781866|NCT00501865|EXPERIMENTAL|Sequence AB|Subjects will be randomized to sequence AB, where A represents fasted state and B represents fed state. Subjects will be administered a single oral dose of GW273225 50 milligrams (mg) in the fasted state in dosing period 1. The subjects will receive a single oral dose of GW273225 50 mg immediately after a high fat breakfast in dosing period 2. There will be at least 21 days between doses for the fasted and fed treatment phases of the study.
62007905|NCT03428776|SHAM_COMPARATOR|Controls|Self returns
62007906|NCT03428776|ACTIVE_COMPARATOR|Standard Compliance-linked incentives|Standard mobile-phone reminders and compliance-linked incentives
62007907|NCT03428776|ACTIVE_COMPARATOR|Intelligent Compliance-linked incentives|Intelligent mobile-phone reminders and compliance-linked incentives
62193292|NCT06423651|ACTIVE_COMPARATOR|MCT alone|The participants will receive Metacognitive Training (MCT)
62193293|NCT05696132|EXPERIMENTAL|Decolonization|Nasal decolonization with betadin gel
62007908|NCT03329352|EXPERIMENTAL|F&P Full-Face Mask|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial full-face mask during this treatment arm. Participants on the extension will use for a further six months after Visit 3.
62007909|NCT05953077|EXPERIMENTAL|Easy first|Children are treated for an emergent grammatical form that is used correctly at least 60% during three pre-treatment probe sessions. This form is treated until children generalize it's use an average of 90% or more across 3 probe sessions. Their treatment target is then switched to a grammatical form that is used less than 30% correct across 3 pre-treatment probe sessions.
62193294|NCT03374293|EXPERIMENTAL|Experimental Group|Radiation to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody . Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes.
62193295|NCT00388804|ACTIVE_COMPARATOR|RT Group 1|Radiation Therapy (RT) over 8 1/2 weeks: 42 treatments, 5 days per week with 2 days rest in between.
62193296|NCT00388804|ACTIVE_COMPARATOR|RT Group 2 + Hormone Therapy|Radiation Therapy over 8 1/2 weeks; + Hormone Therapy (Bicalutamide 50 mg orally/day or Flutamide 250 mg orally 3 times daily on first 21-30 Days) + Leuprolide (22.5 mg Intramuscularly (IM)/every 3 months or 7.5 mg IM monthly) or Goserelin (10.8 mg subcutaneously every 3 months or 3.6 mg subcutaneously monthly)
62214875|NCT04518605|EXPERIMENTAL|Low protein breakfast and exercise training|Subject will consume a low protein breakfast (bread, jam, juice) and and participate in organized exercise-training three times per week (and maintain habitual physical activity)
62214876|NCT04518605|EXPERIMENTAL|High protein breakfast and exercise training|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr) with oats) and and participate in organized exercise-training three times per week (and maintain habitual physical activity)
62214877|NCT05480579|EXPERIMENTAL|Cohort 1: treated with different doses of single intravenous injection of IBI311|
62214878|NCT05480579|PLACEBO_COMPARATOR|Cohort 1: placebo group|
62214879|NCT00727779|EXPERIMENTAL|metabolic syndrome|intervention is to undergo eight weeks of progressive strength training; metabolic syndrome subjects will have baseline and post-intervention assessments including muscle biopsies and insulin clamps
62214880|NCT00727779|ACTIVE_COMPARATOR|control subjects|intervention is to undergo eight weeks of progressive strength training; non-obese sedentary subjects will have the same assessments as the metabolic syndrome subjects and exercise training simultaneously.
62214881|NCT02480959|OTHER|Medial plication|Patient undergoing surgical treatment for recurrent patellar instability that includes medial retinacular plication
62193297|NCT02735304|OTHER|Innovation treatment 3M ESPE materials|"The Innovation treatment arm will receive the innovation treatment first and then crossover to receive the standard clinical practice treatment during the Impression intervention.~Materials to be used all 3M ESPE - Astringent Retraction Paste, Imprint™ 4 Preliminary, Imprint™4 VPS, Imprint™ 4 Bite, Intra-oral syringes, Impression Tray,"
62193298|NCT02735304|OTHER|standard clinical practice treatment|"The standard clinical practice treatment will receive the standard clinical practice treatment first and then crossover to receive the innovation treatment during the Impression intervention~Materials as per the operating dentist's choice to be recorded on CRF"
62193299|NCT05347017|EXPERIMENTAL|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using HCL acid as demineralized dentin block graft and inserted in the extraction socket
62193300|NCT05347017|ACTIVE_COMPARATOR|Alveolar ridge preservation using autogenous bone block graft|Atraumatic extraction of non-restorable teeth, then autogenous bone block will be harvested from the maxillary tuberosity and reshaped and inserted in the extraction socket
62193301|NCT00967005|EXPERIMENTAL|N Acetyl Cysteine|The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and PG symptoms in nicotine dependent pathological gamblers.
62398213|NCT05123482|EXPERIMENTAL|Sub Study 2: AZD8205 in combination with rilvegostomig|"Sub-Study 2 has two parts:~Part A : Dose escalation to determine the safety, tolerability of AZD8205 + rilvegostomig Part B: Dose expansion to evaluate anti-tumor activity of AZD8205 + rilvegostomig in select solid tumors."
62781867|NCT00501865|EXPERIMENTAL|Sequence BA|Subjects will be randomized to sequence BA, where A represents fasted state and B represents fed state. Subjects will be orally administered a single dose of GW273225 50 mg immediately after a high fat breakfast in dosing period 1. The subjects will receive a single oral dose of GW273225 50 mg in the fasted state in dosing period 2. There will be at least 21 days between doses for the fed and fasted treatment phases of the study.
62007910|NCT05953077|ACTIVE_COMPARATOR|Hard first|Children are treated for a grammatical form that is used accurately less than 30% of the time during 3 pre-treatment probe sessions. This form is treated until children generalize it's use an average of 90% or more across 3 probe sessions. Their treatment target is then switched to a grammatical form that is used less than 30% correct across 3 pre-treatment probe sessions.
62193302|NCT00967005|PLACEBO_COMPARATOR|Sugar Pill|
62193303|NCT00208325|OTHER|PFC Sigma Fixed Bearing PCL Sacrificed|PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
62007911|NCT04311034|EXPERIMENTAL|RC48|
62193304|NCT00208325|ACTIVE_COMPARATOR|PFC Sigma RP PCL Sacrificed|PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
62193305|NCT00208325|OTHER|PFC Sigma Fixed Bearing PCL Retained|PFC Sigma Fixed Bearing Total Knee System with PCL Retained
62193306|NCT00208325|ACTIVE_COMPARATOR|PFC Sigma RP PCL Retained|PFC Sigma Rotating Platform Total Knee System with PCL Retained
62193307|NCT00826332|ACTIVE_COMPARATOR|Abdominal|Transabdominal ultrasound guided embryo transfer
62398214|NCT05609838|EXPERIMENTAL|Experimental group|A 15 minutes hot water foot bath was applied to the experimental group patients 3 hours after the cesarean section.Data collection tools were applied at the 5th minute, 1st hour and 2nd hour after the hot water footbath and the gas output was questioned.
62398215|NCT05609838|NO_INTERVENTION|Control Group|The control group was given routine post-cesarean care without any intervention and data collection tools were applied at the same time as the experimental group.
62398216|NCT04796142|EXPERIMENTAL|Reconciliation|Interventional trial without drugs
62193308|NCT00826332|ACTIVE_COMPARATOR|Vaginal|Transvaginal ultrasound guided embryo transfer
62193309|NCT06531304|EXPERIMENTAL|EXP GROUP|Patients will receive visual FB information about the Lokomat joint torque on the screen in front of him/her in order to adapt on-line hips and knees performances. In the EXP group, the Physical Therapist will receives also visual FB information and will guide the patient along the sessions with continuos verbal instructions, thus optimizing the PhT-Pt interaction with an high level of interaction. Patient will be asked to modify his/her hips or knees performances according to both the FB visualized on the screen and the information provided by the PhT.
62398217|NCT03808415|EXPERIMENTAL|EMG-driven|The hand training system functions as a biofeedback device which surface electromyography (EMG) sensors are used to capture the user's own muscle signals to activate the system for moving his/her paretic hand.
62193310|NCT06531304|ACTIVE_COMPARATOR|CTRL GROUP|Patients will receive visual FB information about the Lokomat joint torque on the screen in front of him/her in order to adapt on-line hips and knees performances, but the level on interaction between Patient and Physical Therapist will be reduced to its minimum because of no verbal instruction provided by the Physical Therapist to the patient. Consequently, patient will be asked to modify his/her hips or knees performances according only to the FB visualized on the screen, without no technical exchange with the Physical Therapist.
62193311|NCT00986596|ACTIVE_COMPARATOR|vitamin D3|vitamin D3 capsule 4000 IU p.o. daily
62193312|NCT00986596|PLACEBO_COMPARATOR|placebo|microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
62193313|NCT02793310|ACTIVE_COMPARATOR|DMEK|The intervention group will receive cornea transplantation by DMEK
62193314|NCT02793310|ACTIVE_COMPARATOR|DSAEK|The usual care / control group will receive cornea transplantation by DSAEK
62398218|NCT02839330|EXPERIMENTAL|Group A|aH5N1c lot #1; receive 2 doses (on Day 1 and Day 22)
62398219|NCT02839330|EXPERIMENTAL|Group B|aH5N1c lot #2; receive 2 doses (on Day 1 and Day 22)
62398220|NCT02839330|EXPERIMENTAL|Group C|aH5N1c lot #3; receive 2 doses (on Day 1 and Day 22)
62398221|NCT02839330|PLACEBO_COMPARATOR|Group D|Placebo; receive 2 doses (on Day 1 and Day 22)
62573325|NCT05501418|PLACEBO_COMPARATOR|Placebo|Normal saline will be administered to patients after COVID-19 infection.
62573326|NCT00540150|ACTIVE_COMPARATOR|1|Standard specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany
62007912|NCT04750122|EXPERIMENTAL|Neoadjuvant therapy base on PTC drug screenning|Patients will receive neoadjuvant therapy including trastuzumab, pertuzumab, and chemotherapy based on PTC drug screening.
62007913|NCT05875038|EXPERIMENTAL|Intelligent Video Monitoring + Tele-alarm|
62007914|NCT05875038|ACTIVE_COMPARATOR|Tele-alarm only|
62193315|NCT05879237|ACTIVE_COMPARATOR|Triple therapy therapy and vitamin D3|Vitamin D3 ,1000 unit ,once daily, oral, for 1 month plus the standard triple therapy of H pylori (double antibiotics and proton pump inhibitor)
62007915|NCT06156215|EXPERIMENTAL|PROBOOSTVAXED Intervention M (Messaging + Vaccine Question)|"* Vaccine messaging~* Vaccine acceptance question All patients will receive an Intake Survey assessing their demographic and vaccination information.~At the end of the Intake Survey, the Clinical Research Coordinator (CRC) will deliver the booster vaccine information flyer and ask the patient if they will watch a short video on booster vaccines. If they agree, the CRC will give them a QR code to view the video on their smartphone or an iPad. After finishing with the video, the CRC will tell the subject that they will be back for the Vaccine Acceptance survey. The CRC will then leave the room and ask the patient's primary provider to deliver the booster vaccine scripted message. This message is short and should not significantly impact provider workflow.~Vaccine Acceptance Survey (Post-Intervention) in the ED: We will administer the Vaccine Acceptance Survey at 30 minutes to 3 hours after the Intake Survey."
62193316|NCT05879237|ACTIVE_COMPARATOR|Triple therapy only|Standard triple therapy of H pylori
62573327|NCT00540150|ACTIVE_COMPARATOR|2|Shortened specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany
62781868|NCT01307462|EXPERIMENTAL|Treatment (BOS therapy)|Patients receive fluticasone propionate inhaled PO BID, azithromycin PO 3 days a week, and montelukast sodium PO QD. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
62007916|NCT06156215|ACTIVE_COMPARATOR|Intervention Q (Vaccine Question, No Messaging)|"* No vaccine messaging~* Vaccine acceptance question asked in the Vaccine Acceptance Survey~Vaccine Acceptance Survey: We will administer the Vaccine Acceptance Survey at some time (generally 30 minutes but up to 3 hours) after the Intake Survey. The surveys in the control group retain the same key primary and secondary outcome questions as in the intervention group Vaccine Acceptance surveys."
62007917|NCT06156215|NO_INTERVENTION|Control (No Messaging, No Vaccine Question)|"* No vaccine messaging~* No vaccine acceptance question~The workflow during this arm is identical to the Intervention Q arm except there will be no Vaccine Acceptance Question survey."
62007918|NCT04354259|EXPERIMENTAL|Ambulatory Cohort - Treatment|to receive a single dose of peginterferon lambda 180µg SC at baseline (day 0).
62007919|NCT04354259|PLACEBO_COMPARATOR|Ambulatory Cohort - placebo|Patients in the arm will be given a single injection of 0.9% sodium chloride (normal saline) solution at baseline (day 0). A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
62007920|NCT04354259|EXPERIMENTAL|Hospitalized Cohort - Treatment|To receive a dose of peginterferon lambda 180µg SC at baseline and a second dose on day 5.
62007921|NCT04354259|PLACEBO_COMPARATOR|Hospitalized Cohort - placebo|Patients in the arm will be given an injection of 0.9% sodium chloride (normal saline) solution at baseline (day 0). A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse. Patients will be administered a second dose of placebo on day 5.
62193317|NCT05987254|ACTIVE_COMPARATOR|FICB group|received ultrasound guided suprainguinal fascia iliaca block
62193318|NCT05987254|ACTIVE_COMPARATOR|PENG group|received ultrasound guided pericapsular nerve group block
62193319|NCT02331199|EXPERIMENTAL|preterm labour|200 women with preterm prelabour ruptured membranes or undergoing preterm CS
62193320|NCT02593123|EXPERIMENTAL|Arm I (MMF-15, sargramostim)|Patients receive mycophenolate mofetil (MMF) PO or IV twice daily (BID) on days 0-15 and sargramostim SC from post-transplant day 4 until neutrophil engraftment.
62193321|NCT02593123|ACTIVE_COMPARATOR|Arm II (MMF-30, filgrastim)|Patients receive mycophenolate mofetil PO or IV (twice daily) BID on days 0-30 and filgrastim G-CSF from post-transplant day 4 until neutrophil engraftment.
62573328|NCT04167033|EXPERIMENTAL|Premature ovarian insufficiency|60 patients with POI followed in the endocrinology department
62573329|NCT04167033|OTHER|healthy volunteers|60 healthy volunteers matched with POI's patients
62781869|NCT02116088|ACTIVE_COMPARATOR|Receiving Teacher Coaching|Teachers who currently take part in teacher coaching
62781870|NCT02116088|NO_INTERVENTION|Waiting for Teacher Coaching|Teachers who are currently waiting for taking part in teacher coaching
62781871|NCT04682535||Cohort 1|Spousal/partner family caregivers to persons living with dementia. Participants will complete 14-days of surveys about their relationships, social interactions, as well as health and health behaviors. A subsample of n=15 may volunteer to provide diurnal saliva samples.
62781872|NCT00667849|ACTIVE_COMPARATOR|Exogen 4000+|Single arm, Exogen 4000+
62193322|NCT00422734|PLACEBO_COMPARATOR|1|Placebo
62193323|NCT00422734|ACTIVE_COMPARATOR|2|5 mg tadalafil
62193324|NCT02839785|EXPERIMENTAL|Ibuprofen|Active ibuprofen
62193325|NCT02839785|PLACEBO_COMPARATOR|Placebo|Placebo of ibuprofen
62781873|NCT00667849|SHAM_COMPARATOR|Sham|Single arm, sham (identical device with the exception of administration of ultrasound).
62781874|NCT06384755|EXPERIMENTAL|Intervention group|Intervention group: receives the HOP program consisting of four 2-hour sessions divided between week 1, week 2, week 3 and week 6, in groups of 4-10 participants, using a Norwegian adaptation of HOP workbook. The intervention group also receives treatment as usual, consisting of weekly or monthly appointments with a mental health care professional at an outpatient unit in the public mental health care service. The appointments can involve medication management, psychoeducation, support therapy or psychotherapy.
62781875|NCT06384755|NO_INTERVENTION|Waiting list control group|"Waiting list control group: receives only treatment as usual, consisting of weekly or monthly appointments with a mental health care professional at an outpatient unit in the public mental health care service. The appointments can involve medication management, psychoeducation, support therapy or psychotherapy.~They are offered the HOP program after the trial."
62781876|NCT03167528|EXPERIMENTAL|Lung transplant|"Patients who must undergo a lung transplant at the FOCH hospital.~Before and after transplantation, patients benefits of learning and realization sessions of complementary techniques:~* Relaxation,~* Hypnosis,~* Holistic gymnastics,~* Transcutaneous electrical nerve stimulation (TENS),~* Sophrology."
62781877|NCT05150522|EXPERIMENTAL|BCMA CAR-T|BCMA CAR-T cells infusion
62781878|NCT01395680||cancer adolescent|
62781879|NCT02642380|EXPERIMENTAL|4 cycles|Oral administration of dexamethasone 40 mg for four consecutive days every 14 days for 4 courses
62781880|NCT02642380|ACTIVE_COMPARATOR|1 cycle|Oral administration of dexamethasone 40 mg for four consecutive days
62781881|NCT03114384|EXPERIMENTAL|Healthy volunteers|
62781882|NCT02391519||High Altitude (3000 m)|Collection of myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
62193326|NCT00872053|EXPERIMENTAL|Arm 1|Focused Ankle Training
62193327|NCT00872053|EXPERIMENTAL|Arm 2|Combination Therapy
62193328|NCT02997046||Pre-transplant assessment|"* CTA abdominal and aortoiliac vasculature before transplantation~* FeMRA abdominal and aortoiliac vasculature \& CMR before transplantation"
62193329|NCT02997046||Mapping & surveillance (for fistula)|"* US vascular mapping before fistula creation~* 6 week US fistula arm~* FeMRA fistula arm/central veins \& CMR before fistula creation and at 6 weeks"
62193330|NCT02997046||Mapping & surveillance (for graft)|"* US vascular mapping before graft creation~* 6 week US graft arm~* FeMRA fistula arm/central veins \& CMR before graft creation and at 6 weeks"
62193331|NCT02820597|EXPERIMENTAL|Intervention|Cryoablation with the ClariFix device
62193332|NCT01766713|EXPERIMENTAL|Ezetimibe|10 mg/day of Ezetimibe
62193333|NCT01766713|PLACEBO_COMPARATOR|Placebo|one tablet per day (identical to ezetimibe)
62781883|NCT02391519||Low Altitude (1600 m)|Collection of myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
62781884|NCT03857542|PLACEBO_COMPARATOR|Vehicle|Participants received one drop of vehicle in each eye, once daily, for up to 30 days.
62781885|NCT03857542|EXPERIMENTAL|Pilocarpine HCl Ophthalmic Solution|Participants received one drop of pilocarpine HCl ophthalmic solution 1.25% in each eye, once daily, for up to 30 days.
62781886|NCT04718493|EXPERIMENTAL|Stent|
62781887|NCT04718493|ACTIVE_COMPARATOR|Dilatation|
62781888|NCT03300063|NO_INTERVENTION|control|Standard Medical care
62781889|NCT03300063|ACTIVE_COMPARATOR|Low Flow Nocturnal Oxygen|This group will receive standard medical care as well as low flow oxygen during sleep.
62781890|NCT00902707|EXPERIMENTAL|Mucinex 1200mg|Pill
62781891|NCT00902707|PLACEBO_COMPARATOR|Placebo|Pill
62781892|NCT04302545|EXPERIMENTAL|Cystoinflation group|Bladder will be recognized by observing its gradual distension during bladder retro-fill with 300cc saline to perform adhesiolysis.
62781893|NCT04302545|NO_INTERVENTION|Control group|Pelvic adhesiolysis will be performed without bladder retrofill.
62781894|NCT00365274|EXPERIMENTAL|SGN-30 + Combination Chemotherapy|"Monoclonal antibody SGN-30 monotherapy: SGN-30 12 mg/kg weekly intravenously(IV) over 2 hours once weekly for 3 weeks.~SGN-30 and CHOP chemotherapy: Beginning 1 week after completion of monoclonal antibody SGN-30 monotherapy, SGN-30 12 mg/kg IV over 2 hours on day 1 and CHOP chemotherapy comprising cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, and vincristine IV over 15 minutes on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 6-8 courses."
62007922|NCT05714527|EXPERIMENTAL|Close-loop FiO2 Controller|Two hours period where the fraction of inspired oxygen (FiO2) delivered will be automatically titrated based on SpO2 values obtained from the patient.
62007923|NCT05714527|ACTIVE_COMPARATOR|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values
62007924|NCT06383039|SHAM_COMPARATOR|sham tDCS|Sham transcranial Direct Current Stimulation
62398222|NCT02118467|ACTIVE_COMPARATOR|Norepinephrine and epinephrine|"Patients will receive norepinephrine infusion per standard protocol. Dose range will be 0.03-0.3 mcg/kg/minute. Norepinephrine concentration will be 16 mg/250 mL. If a second vasopressor is required, epinephrine will be added. Dose range of epinephrine will be 0.03-0.3 mcg/kg/minute. Epinephrine concentration will be 16 mg/250 mL. The drugs norepinephrine and epinephrine will be mixed and blinded by the research pharmacy. The research pharmacist will list the dose ranges in mL/hr; this will allow the bedside nurse to program the medication per standard protocol.~If the patient's shock is not adequately treated with the highest doses of both norepinephrine and epinephrine, additional, open-label norepinephrine will be added, and titrated to achieve target blood pressure. If the patient's shock is not adequately treated with three vasopressors, additional open-label epinephrine will be added, and titrated to achieve target blood pressure."
62573330|NCT04031040|EXPERIMENTAL|Genio(TM) system therapy|Following activation of the Genio™ system at 8 weeks post-surgery, patients will be followed at 12 weeks, 6 months, 9 months, 12 months and then every year for a total period of 5 years after surgery.
62781895|NCT05176834|EXPERIMENTAL|B-Cure laser pro|In case of appearance of mucositis, patients will receive standard treatment as usual (rinses, painkillers, etc.). In addition, study participants will treat themselves with the B-Cure laser pro before each radiation therapy session at the clinic and will continue with daily treatment until the disappearance of the mucositis should it develop.
62781896|NCT04494126|EXPERIMENTAL|Tranexamic acid|Experimental: TXA Group One gram of intravenous tranexamic acid (TXA) in normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 6 hours later in the postoperative period.
62781897|NCT04494126|PLACEBO_COMPARATOR|Placebo|Placebo Comparator: Control Group Intravenous normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 6 hours later in the postoperative period.
62781898|NCT03614299||pSS cohort|Patients with pSS included in the study
62781899|NCT04369625|EXPERIMENTAL|CHIMPS-T|(Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents. CHIMPS-T is based on a theory model, needs analyses and the pioneering studies of Williams Beardslee. The CHIMPS approach was tested, evaluated and manualized in an initial project (2007-2011).
62781900|NCT04369625|EXPERIMENTAL|CHIMPS-P|"CHIMPS-P is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening. These families will receive the 3 family sessions from the modular CHIMPS intervention. The sessions will be carried out by a social worker (based on the Finnish model Let's talk about children (Solantaus), but in a family setting Let's talk WITH children)."
62007925|NCT06383039|ACTIVE_COMPARATOR|sma tDCS|Anodal-supplementary motor area transcranial Direct Current Stimulation
62007926|NCT06383039|ACTIVE_COMPARATOR|cerebellar tDCS|Anodal-cerebellar transcranial Direct Current Stimulation
62007927|NCT05684679|EXPERIMENTAL|IS Group|"• Patients were instructed to utilize an incentive spirometer in the sitting or half lying position as taught preoperatively.~* 3 to 5 consecutive breath with the spirometer were interspersed between period of quite breathing.~* Duration 10-15 minutes/session."
62007928|NCT05684679|EXPERIMENTAL|DBE Group|"• Patients were advised to do diaphragmatic breathing exercise in the sitting or half lying position as taught preoperatively.~* 3 to 5 consecutive deep breath were interspersed between period of quite breathing.~* Duration 10-15 minutes/session."
62007929|NCT02502357|EXPERIMENTAL|Healing Statements|Patients in the healing statements group will be read healing statements during anesthesia induction, prior to undergoing surgery.
62007930|NCT02502357|NO_INTERVENTION|No Healing Statements|Patients in the no healing statements group will not be read healing statements during anesthesia induction prior to undergoing surgery. They will receive standard of care.
62398223|NCT02118467|ACTIVE_COMPARATOR|Phenylephrine and vasopressin|"Patients will receive phenylephrine infusion per standard protocol. Dose range will be 0.3 to 3.0 mcg/kg/minute. Phenylephrine concentration will be 160 mg/250 mL. If a second vasopressor is required, vasopressin will be added. Dose range of vasopressin will be 0.1 to 0.6 milliunits/kg/minute. Vasopressin concentration will be 40 units/250 mL. The drugs phenylephrine and vasopressin will be mixed and blinded by the research pharmacy. The research pharmacist will list the dose ranges in mL/hr; this will allow the bedside nurse to program the medication per standard protocol.~If the patient's shock is not adequately treated with the highest doses of both phenylephrine and vasopressin, additional, open-label norepinephrine will be added, and titrated to achieve target blood pressure. If the patient's shock is not adequately treated with three vasopressors, additional open-label epinephrine will be added, and titrated to achieve target blood pressure."
62007931|NCT04252859|EXPERIMENTAL|All Participants|"One session of \[18F\]FES PET/CT Imaging - COMPLETED~Up to three imaging sessions:~1. \[18F\] FES-PET/CT exam,~2. Optional \[18F\]FDG PET/CT scan and~3. Optional follow-up \[18F\] FES-PET/CT exam."
62007932|NCT00595582|OTHER|single arm|Curcumin + Bioperine
62007933|NCT01669551||Structural or Valvular Heart Disease|
62007934|NCT01707004|EXPERIMENTAL|Treatment (donor bone marrow transplant)|"Beginning between days -29 and -22, patients receive decitabine IV over 1 hour daily for 10 days, fludarabine phosphate IV over 30 minutes on days -5 to -2, and busulfan IV over 3 hours on days -5 to -2.~PREPARATIVE REGIMEN: Patients undergo total-body irradiation BID on day -1.~TRANSPLANT: Patients undergo allogeneic bone marrow transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus PO BID or IV continuously on days 5-180, mycophenolate mofetil PO TID on days 5-35, and filgrastim SC beginning day 5 until ANC \>= 1,000/mm\^3 for 3 consecutive days."
62007935|NCT05691426||Test|Periodontitis patients
62007936|NCT05691426||Control|Periodontally healthy patients
62007937|NCT05555381|EXPERIMENTAL|Intervention group (pilot study)|"* needs detection by means of survey and interviews (mixed-methods)~* 6 week program (1 hour) on a weekly basis including cognitive behavioural therapy, sleep/stress hygiene education, heart coherence exercises, mindfulness and relaxation exercises"
62007938|NCT00556595|EXPERIMENTAL|1|primary electrophysiological approach
62007939|NCT00556595|ACTIVE_COMPARATOR|2|primary anatomical approach
62007940|NCT05834140|ACTIVE_COMPARATOR|Traditional physical therapy|TENS and Heating pads
62007941|NCT05834140|EXPERIMENTAL|Muscle Energy Technique|Muscle Energy Technique protocol in along with TENS and Heating pads
62007942|NCT01332734||severe sepsis and septic shock|
62007943|NCT01850004|EXPERIMENTAL|Dasatinib|Dasatinib 50, 80, 100, 140, 180 mg tablets by mouth, once daily, up to 60 months
62007944|NCT02213276|EXPERIMENTAL|Healthy males|Oral glucose tolerance test (OGTT) and intravenous glucose tolerance test (IVGTT).
62007945|NCT06331052|EXPERIMENTAL|3-D Tractography Vim FUSA|Twenty-four consecutive essential tremor (ET) participants undergoing Vim FUSA using 3-D tractography will be assessed at baseline and Month 3.
62007946|NCT02877550|EXPERIMENTAL|Part A - dose escalation and part B - dose expansion|"Part A: dose escalation:~Combination therapy N= 4-18 pts Cycle 1-6 (1 cycle = 28 days) Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6 Venetoclax: p.o. once daily according to dose level (DL)~Part B - dose expansion:~Combination therapy N= up to 25 pts Cycle 1-6 (1 cycle = 28 days) Obinutuzumab: 1000 mg, i.v. infusion d1, 8, 15 C1 and d1 C2-6 Venetoclax: p.o. once daily according to MTD~Part A and part B are followed (in case of no PD) by an obinutuzumab maintenance therapy for 2 years"
62007947|NCT06664541||Group 1|Patients or parents of pediatric patients diagnosed with beta-thalassemia or sickle cell disease and eligible to receive treatment for their disease with gene therapy.
62007948|NCT04400513||Aortic Stenosis|Subjects with echo-confirmed AS graded moderate-to-severe or worse
62007949|NCT04400513||Mitral Regurgitation|Subjects with echo-confirmed MR graded moderate-to-severe or worse
62007950|NCT04400513||Tricuspid Regurgitation|Subjects with echo-confirmed TR graded moderate-to-severe or worse
62007951|NCT04400513||Innocent Murmur|Subjects with echo-confirmed trace/trivial valve disease severity
62007952|NCT04400513||Diastolic Murmur|Subjects with pathology associated with diastolic murmur (e.g. AR, PR, MS, TS)
62007953|NCT04400513||Continuous Murmur|Subjects with pathology associated with continuous murmur (e.g. congenital shunts, PDA)
62021054|NCT01202773|PLACEBO_COMPARATOR|Placebo|"Given Q2W for 24 weeks. Participants receive 2 injections of placebo when initiating treatment.~At Week 16, responders will receive 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.~At Week 16, NR will receive a 180-mg loading dose of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
62021055|NCT00614029|EXPERIMENTAL|A|IMITREX -abd. to Intraject-abd. to IMITREX -thigh to Intraject-thigh
62781901|NCT04369625|EXPERIMENTAL|The CHIMPS-MFT-group|The CHIMPS-MFT-group is a prevention with a multi-family setting based on the CHIMPS approach. The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families: preliminary talk, one additional session with the family (if needed), multifamily group with three to six other families, concluding session.
62007954|NCT06292143|OTHER|Advance Care Planning toolkit|"Provision of access to the digital ACP (Advance Care Planning) platform to patients and caregivers, baseline assessment with the ACP digital platform on day 0.~Information to guide decision making around care and treatment preferences are accessed by patients and carers on days 1 to 7. Where desired, care and treatment preferences are recorded.~Evaluation of usefulness and burden of the digital platform for ACP on day 7. Content stored on digital platform for ACP shared across care settings to those involved in care of participant on day 8 to 29.~Evaluation of usefulness and burden of the digital platform for ACP, participant and carer experience of completion. Initial exploration of impact on communication between health and social care professionals, access to timely information to inform clinical decision making, and efficiency savings (e.g. reduction in paper forms and duplication, less time chasing information) on day 90."
62007955|NCT05650879|EXPERIMENTAL|Phase 1a Monotherapy Dose Escalation|ELVN-002 will be administered either once or twice daily. Each cohort of patients will receive a higher dose. ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.
62021056|NCT00614029|EXPERIMENTAL|B|Intraject-abd. to IMITREX -abd. to Intraject-thigh to IMITREX -thigh
62193334|NCT03044977|EXPERIMENTAL|Cohort 1|"This is the initial treatment arm. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 150 centiGray (cGy) Radiation exposure to the kidneys is limited to 1900 centiGray (cGy)"
62193335|NCT03044977|EXPERIMENTAL|Cohort 2|"This treatment arm is opened if Cohort 1 is successful. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 200 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)"
62193336|NCT03044977|EXPERIMENTAL|Cohort 3|"This treatment arm is opened if Cohort 2 is successful. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 250 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)"
62193337|NCT03044977|EXPERIMENTAL|Cohort -1 (alternative cohort)|"This treatment arm is opened if Cohort 1 is not tolerated.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 100 centiGray (cGy) Radiation exposure to the kidneys is limited to 1500 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
62193338|NCT03044977|EXPERIMENTAL|Cohort 2.1 (renal alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 200 centiGray (cGy) Radiation exposure to the kidneys is limited to 1500 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
62193339|NCT03044977|EXPERIMENTAL|Cohort 2.2 (bone marrow alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 100 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
62398224|NCT05733208|EXPERIMENTAL|Remote ischemic preconditioning|Transient ischemic ischemia consisting of 5-minute ischemia followed by 5-minute perfusion will occur on the upper arm
62398225|NCT05733208|SHAM_COMPARATOR|Sham-remote ischemic preconditioning|Transient ischemic ischemia will not actually occur on the upper arm
62398226|NCT04246281|ACTIVE_COMPARATOR|Group 1: Peripheral Nerve Stimulation (PNS)|Subjects in Group 1 will have leads placed in their lower back. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
62007956|NCT05650879|EXPERIMENTAL|Phase 1a Monotherapy Dose Exploration|ELVN-002 will be administered either once or twice daily. A maximum of 80 patients will enroll in this arm. A maximum of 10 patients may be enrolled at a single dose or tumor type. ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.
62007957|NCT05650879|EXPERIMENTAL|Phase 1b Monotherapy Dose Expansion|"ELVN-002 will be administered either once or twice daily. A maximum of 40 patients will enroll in this arm. Patients will be randomized 1:1 to one of two dose levels.~ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason."
62007958|NCT05650879|EXPERIMENTAL|Phase 1a Combination Dose Escalation with T-DXd|ELVN-002 will be administered either once or twice daily starting on Day 1. ELVN-002 is an oral capsule. Each cohort will receive a higher dose of ELVN-002. All patients in all cohorts will initiate with 5.4mg/kg of intravenous T-DXd once every 3 weeks starting on day 22 of the study. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.
62007959|NCT05650879|EXPERIMENTAL|Phase 1a Combination Dose Escalation with T-DM1|ELVN-002 will be administered either once or twice daily starting on Day 1. ELVN-002 is an oral capsule. Each cohort will receive a higher dose of ELVN-002. All patients in all cohorts will initiate with 3.6 mg/kg of intravenous T-DM1 once every 3 weeks starting on day 22 of the study. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.
62007960|NCT02607488|PLACEBO_COMPARATOR|Placebo|Patients will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.
62007961|NCT02607488|ACTIVE_COMPARATOR|Lidocaine 1%|"Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
62007962|NCT02607488|ACTIVE_COMPARATOR|Lidocaine 1.5%|Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1,5% solution which will be continued for 24 hours after surgery.
62007963|NCT02607488|ACTIVE_COMPARATOR|Lidocaine 2%|Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.
62007964|NCT03152786|EXPERIMENTAL|Group I (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO 2 hours prior to standard of care prostatectomy.
62398227|NCT04246281|ACTIVE_COMPARATOR|Group 2: Standard Interventional Management (Standard of Care)|Subjects in Group 2 will receive the standard of care. Group 2 subjects may be able to crossover to receive PNS after 12 months from start of treatment (Visit 16).
62398228|NCT01773434|EXPERIMENTAL|MORAb-004|
62398229|NCT03447015|EXPERIMENTAL|Ambulation during labour|"women will be encouraged to ambulate Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking)."
62573331|NCT01385969||Standard Practice|
62193340|NCT03044977|EXPERIMENTAL|Cohort 3.1 (renal alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 3.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 250 centiGray (cGy) Radiation exposure to the kidneys is limited to 1900 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
62193341|NCT03044977|EXPERIMENTAL|Cohort 3.2 (bone marrow alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 150 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
62193342|NCT01850537|EXPERIMENTAL|single arm study|treatment of degenerative disc disease using the PROW LIF
62193343|NCT04554537|PLACEBO_COMPARATOR|Brain Health Workshop|The BHW training has been used in multiple prior studies as a comparison training program in cognitive training trials It consists of sessions of fact-based information about the brain but does not train cognitive strategies. Topics include neuroanatomy, neuroplasticity, and effects of TBI on cognitive functioning. Other sessions focus on diet, exercise, sleep, and social functioning and their relationships to brain health. Participants are encouraged to share how the topics impact their lives. Participants are given take-home reading materials on related topics that were then discussed at the last session. At home, they were instructed to watch assigned videos but had no other homework.
62193344|NCT04554537|EXPERIMENTAL|SMART|"SMART emphasizes top-down processing by targeting focused attention, assimilation of information, and mental flexibility and innovation, all higher-order cognitive functions driven by the frontal lobes. SMART was delivered in small groups (n = 2 to 8) consisting of two 3-hour sessions over two days, followed by one 3-hour session a month later. Overall, sessions focused on strategic attention, integrative reasoning, and cognitive control functions (Chapman, 2014). Training consists of initial sessions of skills training with the one-month follow-up session being a booster session consisting of review. We modified the training such that all sessions included skills training with briefer review. The first two sessions consisted of strategic attention and integrated reasoning and the final session discussed innovation."
62193345|NCT04925869||The hospitals of Besançon|Adult patients with MRI-confirmed CVA admitted to the hospitals of Besançon
62193346|NCT04925869||the hospitals of Cayenne|Adult patients with MRI-confirmed CVA admitted to the hospitals of Cayenne.
62193347|NCT04925869||the hospitals of Tours|Adult patients with MRI-confirmed CVA admitted to the hospitals of Tours.
62193348|NCT01216072|EXPERIMENTAL|Fingolimod|Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period .
62193349|NCT01216072|ACTIVE_COMPARATOR|Multiple Sclerosis Disease Modifying Treatments (MS DMTs)|Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months. An open-label extension of up to 3 months of treatment with fingolimod was to be available for patients in the DMT arm who successfully completed all study visits.
62193350|NCT01719510|OTHER|Positive Group B Streptococcus vaginal sample|"At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.~For all women included will be achieved in the delivery room:~a blood sample to the mother and a sampling of umbilical cord blood. Newborns will have a search for GBS (standard culture) in the stools and the pharynx.~For mothers, the collection of milk when breastfeeding."
62193351|NCT04490785|EXPERIMENTAL|patients under aortic surgery with CPB|Patients under aortic surgery with CPB will have MRI and postoperative dosage of released troponin
62193352|NCT02320526|EXPERIMENTAL|Control|Control intervention: Subjects will continue their life unaltered during the 14 days intervention period
62193353|NCT02320526|EXPERIMENTAL|Continuous walking|Training intervention: Subjects will perform continuous walking for one hour per day at every weekday during the 14 days intervention period
62193354|NCT02320526|EXPERIMENTAL|Interval Walking|Training intervention: Subjects will perform interval walking for one hour per day at every weekday during the 14 days intervention period. Interval walking will be performed as repeated cycles of three minutes of slow and hree minutes of fast walking during the entire training session
62193355|NCT03298269|EXPERIMENTAL|Mindfulness-Oriented Recovery Enhancement|
62007965|NCT03152786|ACTIVE_COMPARATOR|Group II (no treatment)|Patients receive no treatment prior to standard of care prostatectomy.
62007966|NCT05721040||Covid-19 Group|"Motor nerve study was performed in the median and posterior tibial nerve to assess the motor function of the upper and lower limbs.~Sensory nerve study was done for the median and sural nerves to estimate the peripheral neurological function of both upper and lower limbs.~F wave study was performed for the upper limb in the median nerve."
62193356|NCT03298269|ACTIVE_COMPARATOR|Supportive Counseling|
62193357|NCT00676104|EXPERIMENTAL|Treatment|
62193358|NCT00676104|SHAM_COMPARATOR|Control|
62193359|NCT03023722|EXPERIMENTAL|All Subjects|Patients with advanced metastatic pancreatic cancer who have measurable disease
62193360|NCT04232267||Patients prescribed Polysomnology (PSG - sleep study)|Patients that are at least 18 years old but not older than 75 years old, who have been referred to a sleep clinic for sleep disturbance.
62193361|NCT04029805|EXPERIMENTAL|Combination of a Plant Extract and a Probiotic|Volunteers will take twice at day for 12 weeks a capsule containing the combination of a plant extract (BSL_EP044) and Lactobacillus BSL_PS6
62193362|NCT04029805|PLACEBO_COMPARATOR|Placebo|Volunteers will take twice at day for 12 weeks a capsule containing maltodextrin.
62193363|NCT02281123||Patient suspected of being infected by chikungunya|Patient (\>= 45 ans) suspect d'infection par le virus du chikungunya et présentant des symptomes depuis moins de 10 jours
62193364|NCT06243237|EXPERIMENTAL|Intervention group(acupuncture group)|After blind random allocation, investigators applied acupuncture on patient with acute intracranial hemorrhage.
62193365|NCT06243237|PLACEBO_COMPARATOR|Control group(sham acupuncture group (superficial acupuncture))|After blind random allocation, investigators applied superficial acupuncture on patient with acute intracranial hemorrhage.
62193366|NCT01267669|EXPERIMENTAL|EVL plus Somatostatin|Emergency EVL plus Somatostatin (250 mcg/hr) infusion for 5 days
62193367|NCT01267669|PLACEBO_COMPARATOR|EVL plus Placebo|Emergency EVL plus placebo infusion for 5 days
62193368|NCT04883112|NO_INTERVENTION|No Intervention: ankle dorsiflexion|ankle dorsiflexion pre measurement with bipedestation position, will be performed
62193369|NCT04883112|EXPERIMENTAL|Experimental: ankle dorsiflexion|ankle dorsiflexion post measurement with bipedestation position, will be performed
62193370|NCT04883112|PLACEBO_COMPARATOR|Placebo: ankle dorsiflexion|ankle dorsiflexion post measurement with bipedestation position, will be performed
62193371|NCT02339623||threatened preterm labour|"Women who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) :~* Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )~* Cervical dilataion \>1cm, \&/or~* Cervical effacement ≥ 80%"
62193372|NCT05976776|EXPERIMENTAL|Experimental group|The Childbirth and Parenthood Preparation Education program
62193373|NCT05976776|NO_INTERVENTION|Control group|No intervention
62193374|NCT04370015|EXPERIMENTAL|Treatment group|Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.
62398230|NCT03447015|NO_INTERVENTION|Standard Maternity care|women will receive usual maternity care.
62193375|NCT04370015|PLACEBO_COMPARATOR|Control group|Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.
62398231|NCT04525066|EXPERIMENTAL|Treatment Group - Receiving Hyaluronic Acid Injection|Randomized group of patients receiving hyaluronic acid injection into the glottis during transoral laser microsurgery for early glottic cancer.
62021057|NCT00614029|EXPERIMENTAL|C|Intraject-abd to IMITREX -abd to Intraject-arm. to IMITREX -arm.
62193376|NCT03482752|EXPERIMENTAL|Molgramostim nebulizer solution (300 μg)|Open-label treatment with molgramostim nebulizer solution (300 μg) administered intermittently (repetitive cycles of 7 days of treatment followed by 7 days off-treatment).
62193377|NCT04415853|EXPERIMENTAL|Lerotinib Arm|350 mg,qd, orally about half an hour after a meal, continuous administration, every 21 days for a treatment cycle.
62193378|NCT04415853|ACTIVE_COMPARATOR|Active Comparator Arm|"Irinotecan: Intravenously administered at a dose of 180 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.~Tegafur: 40-60mg po bid(d1-d14),every 21 days as a cycle, continuous drug administration from 1 to 14 days of each cycle, and then stopped 7 days."
62193379|NCT05575297|EXPERIMENTAL|Methotrexate|
62193380|NCT05575297|EXPERIMENTAL|Methotrexate + Rifampicin|Methotrexate + Rifampicin
62193381|NCT05575297|EXPERIMENTAL|Methotrexate + Febuxostat|Methotrexate + Febuxostat
62193382|NCT05575297|EXPERIMENTAL|Methotrexate + Rifampicin + Febuxostat|Methotrexate + Rifampicin + Febuxostat
62193383|NCT00597142|EXPERIMENTAL|1|
62398232|NCT04525066|PLACEBO_COMPARATOR|Control Group - Not Receiving Hyaluronic Acid Injection|Randomized group of patients not receiving hyaluronic acid injection into the glottis during transoral laser microsurgery for early glottic cancer.
62398233|NCT05482646|EXPERIMENTAL|Tai Chi|This group will perform 3 months of Tai Chi training
62398234|NCT05482646|ACTIVE_COMPARATOR|Conventional exercise|This group will perform 3 months of conventional exercise training
62398235|NCT05482646|OTHER|Health Education Control|This group will participate in a 3-month health education program
62573332|NCT01385969||Syringe recoil|
62573333|NCT01385969||Pressure Transducer|
62007967|NCT05721040||Control Group|"Motor nerve study was performed in the median and posterior tibial nerve to assess the motor function of the upper and lower limbs.~Sensory nerve study was done for the median and sural nerves to estimate the peripheral neurological function of both upper and lower limbs.~F wave study was performed for the upper limb in the median nerve."
62007968|NCT01037478|EXPERIMENTAL|Resminostat (4SC-201)|oral administration
62193384|NCT05203341|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo orally once a day.
62193385|NCT05203341|EXPERIMENTAL|NBI-1065845 Low Dose|Participants will receive low-dose NBI-1065845 orally once a day.
62193386|NCT05203341|EXPERIMENTAL|NBI-1065845 High Dose|Participants will receive high-dose NBI-1065845 orally once a day.
62193387|NCT05000905|EXPERIMENTAL|Adaptive Attention Training|Participants will complete approximately 15 hours of an at-home training on a novel adaptive attention training program ('Engage'), which will consist of completing thirty, 30-minute sessions over a total of 6-8 weeks.
62193388|NCT05000905|ACTIVE_COMPARATOR|Low-dose Adaptive Attention Training|Participants will complete approximately 1 hour of at-home training on 'Engage' which consists of two, 30-minute sessions at the beginning and middle of a 6-8 week period.
62193389|NCT05000905|OTHER|No Contact Group (Not Randomized)|An additional thirty participants will be enrolled separately (not randomized) into the no-contact group. Participants in the no-contact group will not complete any study activities for 6-8 weeks after completing the baseline assessments. After this period, participants will be prompted to log into Nexus to complete end of study assessments (same set of assessments administered/completed at baseline).
62193390|NCT05671354|EXPERIMENTAL|The auto-wrapping commode chair|The experimental group will use the auto-wrapping commode chair for 7 days.
62193391|NCT06234176|EXPERIMENTAL|Personalised psychomotor therapy group|1 psychomotor therapy session of 45 minutes per week for 12 weeks + Duke Health Scale.
62781902|NCT04369625|EXPERIMENTAL|iCHIMPS|iCHIMPS is an online intervention. In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group. iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included. Overall, 8 consecutive online modules as well as elective modules will be included. These modules (e.g., dealing with difficult situations, emotion regulation, taboos and shame, self-worth) will be provided based on the specific constellation of children and adolescents of mentally ill parents. iCHIMPS will be completed by 2 booster session within a six months follow-up.
62781903|NCT04369625|NO_INTERVENTION|Treatment as usual|The treatment as usual implies that families of the control group receive the treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system.
62007969|NCT01701258|ACTIVE_COMPARATOR|CSA/MDD-amisulpride|Subjects experiencing a current episode of major depression (MDD) with a history of child sexual abuse (CSA) are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
62781904|NCT01223183|ACTIVE_COMPARATOR|isotonic saline then hypertonic saline|Subjects inhaled nebulized isotonic saline on study day 1, and then after a 5-24 day washout period, subjects inhaled nebulized 7% hypertonic saline on study day 2.
62781905|NCT01223183|ACTIVE_COMPARATOR|hypertonic saline then isotonic saline|Subjects inhaled nebulized 7% hypertonic saline on study day 1, and then after a 5-24 day washout period, subjects inhaled nebulized isotonic saline on study day 2.
62781906|NCT05236504|EXPERIMENTAL|Supplement|Melatonin and magnesium-containing pod
62007970|NCT01701258|PLACEBO_COMPARATOR|CSA/MDD-placebo|Subjects experiencing a current episode of major depression (MDD) with a history of child sexual abuse (CSA) are randomized to receive a placebo during the fMRI session.
62781907|NCT05236504|PLACEBO_COMPARATOR|Placebo|Placebo pod
62781908|NCT06141291|OTHER|Old 1|1. Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.
62007971|NCT01701258|ACTIVE_COMPARATOR|CSA/RES-amisulpride|Subjects with a history of child sexual abuse (CSA) without a current or past diagnosis of major depressive disorder (RES) are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
62021058|NCT00614029|EXPERIMENTAL|D|IMITREX-abd to Intraject-abd to IMITREX-arm. to Intraject-arm.
62193392|NCT06234176|ACTIVE_COMPARATOR|Usual treatment group|Standard treatment for depression administered by a doctor + a weekly telephone interview for 12 weeks to administer the Duke Health Scale.
62193393|NCT01809015||Cohort A: Regular medical care|Patients treated with vitamin K antagonists in regular medical care system
62193394|NCT01809015||Cohort B: Coagulation service|Patients with oral anticoagulation therapy in a telemedicine-based coagulation service
62193395|NCT04800939|EXPERIMENTAL|Acupressure Group|The experimental group will be given acupressure on their own, three times a week for four weeks, one hour before going to bed at night.
62193396|NCT04800939|OTHER|Placebo Acupressure Group|The control group will be given plasebo acupressure on their own, three times a week for four weeks, one hour before going to bed at night.
62193397|NCT00073398|EXPERIMENTAL|1|Ph II Arm 1
62193398|NCT05416567|EXPERIMENTAL|Endovascular embolization|
62193399|NCT05144399|EXPERIMENTAL|Accelerated antibiotic treatment|Patients are treated shorter than usual
62193400|NCT05144399|OTHER|Standard length of antibiotic treatment|Patients are receiving the standard length of antibiotic treatment
62193401|NCT03024892|EXPERIMENTAL|ICG gallbladder|patients who received ICG injection via gallbladder and received fluroscence image guided surgery
62193402|NCT03024892|EXPERIMENTAL|ICG IV|patients who received ICG injection via peripheral vein and received fluroscence image guided surgery
62193403|NCT03024892|SHAM_COMPARATOR|LC conventional|Patients received conventional laparoscopic cholecystectomy
62193404|NCT03024892|SHAM_COMPARATOR|LC conventional and IOC|Patients received conventional laparoscopic cholecystectomy + intraoperative cholangiography
62193405|NCT06361862|NO_INTERVENTION|inactive alarms|Patients with continuous monitoring without active alerts from WARD.
62007972|NCT01701258|PLACEBO_COMPARATOR|CSA/RES-placebo|Subjects with a history of child sexual abuse (CSA) without a current or past diagnosis of major depressive disorder (RES) are randomized to receive a placebo during the fMRI session.
62193406|NCT06361862|EXPERIMENTAL|active alarms|Patients with continuous monitoring with active alerts from WARD.
62193407|NCT04600986|EXPERIMENTAL|New oocyte triggering|The final oocyte maturation will be triggered with a single dose of 0.2 mg s.c triptorelin (decapeptyl) and in addition a repeat dose of 0.1 mg s.c triptorelin (decapeptyl) will prescribed 12 h following the first dose.
62193408|NCT04600986|OTHER|Routine oocyte trigering|The final oocyte maturation will be triggered with a single dose of 0.2 mg s.c triptorelin (decapeptyl), 35 h prior to oocyte retrieval.
62193409|NCT06344468|EXPERIMENTAL|Experimental Group|"Early mobilization began after discontinuation of sedation and resolution of its effects within the first 12 hours. During early mobilization, physiological parameters (respiratory rate, SpO2, heart rate, blood pressure, body temperature, pain) were evaluated and recorded in the supine and semi-fowler positions for in-bed mobilization assessment. For out-of-bed mobilization, physiological parameters were determined and recorded while the patient was in a sitting position, with the head elevated at 45° before mobilization.~With the assistance of a nurse, the patient was guided to sit on the edge of the bed, stand up with support, sit on a chair next to the bed, and record respiratory rate, SpO2, heart rate, blood pressure, body temperature, and pain levels at 1, 5, and 10 minutes while sitting on the chair. Similar procedures were repeated during patient mobilization at 24 and 36 hours."
62193410|NCT06344468|NO_INTERVENTION|Control Group|"They underwent routine/standard postoperative mobilization procedures. Accordingly, patients were mobilized within the first 24 hours post-surgery, and during in-bed mobilization, physiological parameters (respiratory rate, SpO2, heart rate, blood pressure, body temperature, pain) were evaluated in the supine and semi-fowler positions.During out-of-bed mobilization, physiological parameters (respiratory rate, SpO2, heart rate, blood pressure, body temperature, pain) were determined.~Respiratory parameters were frequently evaluated at intervals of up to 4 hours using arterial blood gas analysis. The patient was assisted by a nurse to sit on the edge of the bed, stand up with support, sit on a chair next to the bed, and record respiratory rate, SpO2, heart rate, blood pressure, body temperature, and pain levels at 1, 5, and 10 minutes while sitting on the chair. These data were then evaluated internally. Similar procedures were repeated during patient mobilization at 24 and 36 hours."
62193411|NCT03767972|EXPERIMENTAL|Rejuvenation|Adults requiring rejuvenation of either the face, neck/décolletage, hands, upper and lower extremities, trunk and/or vagina will receive energy-based treatment (Fraxel Restore, Helios III, PicoWay, Halo, ThermiVa or DiVa) based on the investigators' assessment and discretion. The treating physician will decide which energy-based device is best-suited to addressing the patients' aging concerns; although patient preference will be taken into account, ultimately the treating physician will be responsible for the correct assessment of patients' rejuvenation needs and use of appropriate energy-based devices for the final treatment.
62193412|NCT02349945|EXPERIMENTAL|Arm 1|FSHR A680G SNP homozygous for allele N treated with follitropin alpha
62193413|NCT02349945|EXPERIMENTAL|Arm 2|FSHR A680G SNP homozygous for allele S treated with follitropin alpha
62193414|NCT01165619||Hypothalamic Amenorrhea|This group is for pre-menopausal women between the aged 18-40 who have been previously diagnosed with Hypothalamic Amenorrhea. They can be currently diagnosed or may have recovered.
62193415|NCT01165619||Healthy Adult Men|This group is men over the age of 18 who do not have any history of reproductive disorders or chronic disease.
62193416|NCT01165619||Healthy Adult Women|This group is pre-menopausal, regularly menstruating women ages 18-40 who do not have a history of reproductive disorders or chronic disease.
62193417|NCT01165619||Idiopathic Hypogonadotropic Hypogonadism|This group is for adult men and women over the age of 18 who have been diagnosed with Idiopathic Hypogonadotropic Hypogonadism with or without anosmia.
62193418|NCT00455845|ACTIVE_COMPARATOR|1 levonorgestrel IUD|
62193419|NCT00455845|NO_INTERVENTION|2 control|
62193420|NCT02392104|EXPERIMENTAL|Intervention Arm|All patients in the study will be in the intervention arm.
62193421|NCT03694977|EXPERIMENTAL|MCS110/PDR001 combination|
62193422|NCT06445400|EXPERIMENTAL|Study treatment|Participants received BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+ Pertuzumab+Docetaxel in the first cycle (3 weeks). Participants who had a clinical benefit could receive additional cycles of additional treatment. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
62193423|NCT00157027|ACTIVE_COMPARATOR|1|"Photopheresis (or extracorporeal photoimmunetherapy \[ECP\]) is a process developed by THERAKOS, Inc., a Johnson and Johnson Company. During the process of ECP, whole blood is drawn from the patient over several cycles, centrifuged and separated into the components of plasma, white cells (or buffy coat), and red blood cells. A portion of the white cells and the plasma are saved in a separate compartment. The remaining plasma and red blood cells are immediately returned to the patient.~The saved buffy coat (white blood cells) and plasma are inoculated with the photosensitizing agent UVADEX. Photoactivation begins when the suspension is exposed to a prescribed amount of ultraviolet-A light. After photoactivation is complete, the treated suspension is returned to the patient."
62007973|NCT01701258|ACTIVE_COMPARATOR|MDD-amisulpride|Subjects without a history of child sexual abuse that are currently experiencing a major depressive episode are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
62007974|NCT01701258|PLACEBO_COMPARATOR|MDD-placebo|Subjects without a history of child sexual abuse that are currently experiencing a major depressive episode are randomized to receive a placebo during the fMRI session.
62021059|NCT00614029|EXPERIMENTAL|E|IMITREX-arm to Intraject-arm to IMITREX-thigh to Intraject-thigh
62193424|NCT01397279|ACTIVE_COMPARATOR|Botnia clamp|hyperinsulinemic euglycemic clamp following intravenous glucose tolerance test
62193425|NCT01397279|ACTIVE_COMPARATOR|hyperinsulinemic euglycemic clamp|hyperinsulinemic euglycemic clamp without previous intravenous glucose tolerance test
62193426|NCT04154800|EXPERIMENTAL|Part A:SAD|Single Ascending Dose
62193427|NCT04154800|EXPERIMENTAL|Part B: MAD|Multiple Ascending Dose
62193428|NCT04154800|EXPERIMENTAL|Part C: DDI|Drug-Drug Interaction
62193429|NCT04154800|EXPERIMENTAL|Part A (SAD) Placebo|
62193430|NCT04154800|EXPERIMENTAL|Part B (MAD) Placebo|
62193431|NCT00979953|EXPERIMENTAL|ADL5859|One 50-milligrams (mg) ADL5859 capsule, one 100-mg ADL5859 capsule, and 2 placebo capsules administered orally twice daily (BID) for 14 days
62007975|NCT01701258|ACTIVE_COMPARATOR|Control-amisulpride|Subjects without a history of child sexual abuse and without a current or past diagnosis of major depressive episode are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
62007976|NCT01701258|PLACEBO_COMPARATOR|Control-placebo|Subjects without a history of child sexual abuse and without a current or past diagnosis of major depressive episode are randomized to receive a placebo during the fMRI session.
62007977|NCT02287597||Cohort|
62007978|NCT03436472|EXPERIMENTAL|dexmedetomidine group|For patients who were not intubated, dexmedetomidine was infused at a rate of 0.1 microgram/kg per hour from study recruitment on the day of surgery until 8:00 am on the first day after surgery. For patients who were intubated and mechanically ventilated, dexmedetomidine infusion was started after the Richmond Agitation Sedation Scale was -2 or higher after intensive care unit admission until 8:00 am on the first day after surgery.
62007979|NCT03436472|PLACEBO_COMPARATOR|placebo group|Normal saline was infused in the same rate for the same duration as that in the placebo group.
62007980|NCT00073905|ACTIVE_COMPARATOR|Arm A|Capecitabine plus Gemcitabine
62007981|NCT06572956|EXPERIMENTAL|recurrent or unresectable solid tumors|One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion.
62007982|NCT05554861|EXPERIMENTAL|Low Frequency rTMS Protocol|It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex foot area in the non-lesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.
62007983|NCT05554861|ACTIVE_COMPARATOR|Intermittent Theta Burst Stimulation (iTBS) Protocol|It was planned to apply 50 Hz high-frequency stimulation protocol to the primary motor cortex foot area in the ipsilesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.
62007984|NCT05554861|PLACEBO_COMPARATOR|Sham rTMS Protocol|It was planned to apply daily sham rTMS to the motor extremity area of the primary motor cortex along a 10 cm thick wood for 10 sessions.
62007985|NCT06661837||School children|"Children were clinically examined by the dentist (examiner 1) and a mobile photo was taken by one volunteer dental assistant. While examiner 2 examined the clinical mobile photos and did not participate in the clinical examination.~Also, examiner 1 examined the clinical mobile photos after 48 hours as a wash-out period. Calibration was performed between both examiners."
62007986|NCT04630405|ACTIVE_COMPARATOR|Wright jet nebulizer|Will employ the Wright jet nebulizer for use in an allergen challenge triad
62193432|NCT00979953|EXPERIMENTAL|ADL5747|One 150-mg ADL5747 capsule and 3 placebo capsules administered orally BID for 14 days
62193433|NCT00979953|ACTIVE_COMPARATOR|Oxycodone CR|"One 10-mg Oxycodone controlled release (CR) capsule and 3 placebo capsules administered orally BID Days 1 through 4~One 20-mg Oxycodone CR capsule and 3 placebo capsules administered orally BID Days 5 through 14"
62193434|NCT00979953|PLACEBO_COMPARATOR|Placebo|Four placebo capsules administered orally BID for 14 days
62193435|NCT00855413|OTHER|Darunavir/Ritonavir and Etravirine|"Darunavir/Ritonavir 800 mg/100 mg orally once daily.~ETR will be given 200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen."
62193436|NCT01389089|SHAM_COMPARATOR|Control group|The Control group received ice gel packs and elevation to reduce edema.
62193437|NCT01389089|EXPERIMENTAL|Multi-layer compression bandage|A multi-layer compression bandage was applied to the lower limb and foot of the patient to reduce edema. Additionally, the limb was constantly elevated.
62007987|NCT04630405|ACTIVE_COMPARATOR|Solo vibrating mesh nebulizer|Will employ the Aerogen Solo vibrating mesh device for use in an allergen challenge triad
62007988|NCT01122199|EXPERIMENTAL|Open Label|RAD001+ AMG479
62007989|NCT02502786|EXPERIMENTAL|humanized anti-GD2 antibody, hu3F8, when combined with GM-CSF|One cycle consists of treatment with hu3F8 at a dose of 2.4mg/kg/dose for 3 days (day 1, 3, and 5) in the presence of subcutaneous (sc) GM-CSF (day -4 through 5). These 3 doses of hu3F8 and 10 days of GM-CSF constitute a treatment cycle. Cycles are repeated at \~2-4 week intervals between first days of hu3F8, through 5 cycles. A maximum of 5 cycles will be administered on protocol. If elevations of amylase and/or lipase (\>Grade 1) or clinical signs suggestive of pancreatitis (e.g. upper abdominal pain) occurs, naxitamab and GM-CSF doses should be held until improvement of toxicity to ≤Grade 1 if laboratory elevations and/or pancreatitis is possibly related to either naxitamab or GM-CSF.
62007990|NCT00393055|EXPERIMENTAL|xylitol lozenge|1g xylitol lozenge. Five/day, dissolved in mouth
62007991|NCT00393055|PLACEBO_COMPARATOR|inactive lozenge|1g placebo lozenge. Five/day, dissolved in mouth
62007992|NCT04865757|EXPERIMENTAL|Space Flap|A space flap is formed out of Palacos®, adjusted to the skull surface with temporal augmentation
62007993|NCT05495412|OTHER|Rebound therapy|Exercise therapy which uses a full sized trampoline to provide opportunities for movement, therapeutic exercise and recreation for children and young people.
62021060|NCT00614029|EXPERIMENTAL|F|Intraject-thigh to IMITREX-thigh to Intraject-arm to IMITREX-arm
62193438|NCT01389089|ACTIVE_COMPARATOR|A-V Impulse compression|An A-V Impulse compression device was used to reduce edema.
62193439|NCT02034162|ACTIVE_COMPARATOR|Mebendazole|Mebendazole will be administered as a single 500-mg chewable tablet in a double-blind manner at the baseline visit (Day 1) and in an open-label manner at Visit 4 (Day 21).
62193440|NCT02034162|PLACEBO_COMPARATOR|Placebo|Matching placebo will be administered as a single-dose chewable tablet in a double-blind manner at the baseline visit (Day 1).
62193441|NCT03158909|EXPERIMENTAL|Interventional|Patients in this group will receive eyemask and earplugs, for use during the night, and orientations about space and time, every night.
62193442|NCT03158909|ACTIVE_COMPARATOR|Orientation about space and time|This group will receive orientations about space and time olny, every night.
62193443|NCT03688776|EXPERIMENTAL|1805AA, 1805AB Use Group|Use of product 1805AA exclusively for approximately 3 days prior to a PK assessment, followed by use of product 1805AB exclusively for approximately 3 days prior to a PK assessment.
62193444|NCT03688776|EXPERIMENTAL|1805AB, 1805AA Use Group|Use of product 1805AB exclusively for approximately 3 days prior to a PK assessment, followed by use of product 1805AA exclusively for approximately 3 days prior to a PK assessment.
62193445|NCT04746885|OTHER|Group A|(interventional group/ DHA): A minimum of 40 preterm infants will be included to receive 100mg DHA daily administered by enteral route for 30 days. This group will be subdivided into breast fed / artificially fed infants.
62193446|NCT04746885|OTHER|Group B|(control group / Placebo): 40 of preterm infant controls will be included to receive placebo (physically matched solution). This group will be subdivided into breast fed / artificially fed infants.
62193447|NCT02012023|EXPERIMENTAL|Controllable tube ileostomy|After LAR, the experimental group accepted controllable tube ileostomy.
62193448|NCT02012023|ACTIVE_COMPARATOR|Loop ileostomy|After LAR, the experimental group accepted loop ileostomy.
62193449|NCT05176366|EXPERIMENTAL|15ml at Day 0, 2, 4, 30 ml at Week 2, Week 6, and every 4 weeks after to week 46|IV administration of 15 mL study agent at Day 0, Day 2, Day 4 and 30 mL at Week 2, Week 6 and every 4 weeks thereafter to week 46 (total # doses = 15).
62398236|NCT00976989|EXPERIMENTAL|T+P Concomitant Anthracycline-based chemotherapy|5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab (T) and pertuzumab (P) every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
62573334|NCT03227744|ACTIVE_COMPARATOR|Enrolled in group therapy|Patients in the group therapy arm will be enrolled in group therapy and be issued surveys.
62573335|NCT03227744|PLACEBO_COMPARATOR|Not enrolled in group therapy|Patients in control arm will be issued surveys
62193450|NCT00894504|EXPERIMENTAL|Panitumumab/Gemcitabine/Carboplatin|Systemic therapy
62573336|NCT01219829||Family History patients|Patients with a strong family history of pancreatic cancer or with a genetic syndrome that puts them at risk for pancreas cancer.
62193451|NCT01543997|EXPERIMENTAL|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP)to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
62193452|NCT01543997|ACTIVE_COMPARATOR|Supportive Education|Supportive Education program will provide educational lectures on disability, sleep hygiene, and current research on depression and non-directive, supportive discussions about these topics.
62193453|NCT01603433|EXPERIMENTAL|Sapheon™ Closure System|Sapheon™ Closure System for the treatment of incompetent saphenous veins.
62193454|NCT05347472|EXPERIMENTAL|Experimental group|In this group, women will receive the smartphone application intervention that will include daily physical therapy exercises program
62398237|NCT00976989|EXPERIMENTAL|T+P Sequential Anthracycline-based chemotherapy|FEC every three weeks for three cycles, followed by docetaxel, trastuzumab (T) and pertuzumab (P) every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.
62398238|NCT00976989|EXPERIMENTAL|T+P Concomitant Non-Anthracycline chemotherapy|Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab (P) every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
62398239|NCT01256866|ACTIVE_COMPARATOR|DEXMEDETOMIDINE, SEDATION|
62398240|NCT01256866|ACTIVE_COMPARATOR|Midazolam, sedation,|
62573337|NCT01219829||Recurrence patients|Patients who underwent surgery for pancreatic cancer and developed tumor recurrence after surgery
62573338|NCT02744729|EXPERIMENTAL|Esophagus Cancer, 99mTc-3PRGD2, SPECT/CT|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis of Esophagus cancer patients.
62573339|NCT02607774|EXPERIMENTAL|Secukinumab|Secukinumab over 24 weeks
62021061|NCT01089140|EXPERIMENTAL|. Tranexamic acid low dose 10 mg/kg|
62021062|NCT01089140|EXPERIMENTAL|Tranexamic acid 100mg/kg|
62021063|NCT01089140|PLACEBO_COMPARATOR|Saline Placebo|
62021064|NCT03346759|EXPERIMENTAL|Tampon A First|Subjects were provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for the first of two consecutive menstrual cycles. Subjects were then provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the second of two consecutive menstrual cycles. For the third menstrual cycle, subject used tampons of their choosing.
62021065|NCT03346759|EXPERIMENTAL|Tampon B First|Subjects were provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the first of two consecutive menstrual cycles. Subjects were then provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for the second of two consecutive menstrual cycles. For the third menstrual cycle, subject used tampons of their choosing.
62193455|NCT05347472|PLACEBO_COMPARATOR|Control group|In this group, women will receive the sham application that includes information and general advice about UI only
62193456|NCT00560144|EXPERIMENTAL|1|
62007994|NCT02746614|ACTIVE_COMPARATOR|Psychomotor Therapy & Adaptive Behavior|After the initial assessment of adaptive behavior, i.e.., set of skills that each individual with intellectual disability should train to cope with environmental demands, a Psychomotor Intervention Program was designed specifically. The program integrated individual and group sessions during 3 months, and the main goals of the program were related to independent functioning, motor development, economic and professional activities, academic and verbal skills.
62007995|NCT02746614|ACTIVE_COMPARATOR|Psychomotor Therapy & Motor Proficiency|Motor Proficiency After the initial assessment, a Psychomotor Intervention Program was designed specifically for participants with IDD. This program integrated individual and group sessions during 3 months, and the main goals of the program were related to motor coordination (balance, manual dexterity and coordination, global and fine praxis).
62007996|NCT03245021|OTHER|Open-Label|Opdivo - Single-arm open label study
62007997|NCT05283096||Patients with chronic inflammatory rheumatic disease|
62007998|NCT02649972|EXPERIMENTAL|Cobimetinib|This is an open-label, multicenter, phase II study exploring the efficacy and safety of single-agent Cobimetinib in patients with histiocytic disorders whose tumors are 1) BRAFV600 wildtype or 2) BRAFV600E mutant and are intolerant to, or unable to access, BRAF inhibitors. Visits during the treatment period are to be completed on Day 1, Day 15 (this visit can be by telephone), Day 29, and every 28 days thereafter. For patients treated on the study for six months, at the discretion of the Principal Investigator, visits can be spaced out to every 56 days (every 2 cycles instead of every cycle). After 24 cycles of treatment, if imaging demonstrates sustained stability in the opinion of the principal investigator, tumor assessments can be performed ever 1 year.
62007999|NCT00813124|EXPERIMENTAL|Azacytidine Maintenance after allotx|Busulfan + Fludarabine + ATG + Azacytidine after allogeneic stem cell transplantation (allotx)
62008000|NCT04475393|EXPERIMENTAL|Carmat TAH|Subjects implanted with Carmat TAH
62008001|NCT04085523|EXPERIMENTAL|TransCon CNP 6 mcg|TransCon CNP 6 mcg CNP/kg delivered once weekly by subcutaneous injection.
62008002|NCT04085523|EXPERIMENTAL|TransCon CNP 20 mcg|TransCon CNP 20 mcg CNP/kg delivered once weekly by subcutaneous injection.
62008003|NCT04085523|EXPERIMENTAL|TransCon CNP 50 mcg|TransCon CNP 50 mcg CNP/kg delivered once weekly by subcutaneous injection.
62008004|NCT04085523|EXPERIMENTAL|TransCon CNP 100 mcg|TransCon CNP 100 mcg CNP/kg delivered once weekly by subcutaneous injection.
62008005|NCT04085523|PLACEBO_COMPARATOR|Placebo|Placebo mimicking 6, 20, 50, or 100 mcg CNP/kg delivered once weekly by subcutaneous injection.
62008006|NCT04085523|EXPERIMENTAL|Open-Label Extension Period|Subjects who complete the 52-week blinded treatment period can continue into the 104-week open-label extension period and will receive treatment with TransCon CNP.
62008007|NCT05459129|ACTIVE_COMPARATOR|Atezo + Tira|Participants in the atezolizumab plus tiragolumab arm will receive treatment for two cycles (6 weeks) until surgery or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
62008008|NCT05459129|EXPERIMENTAL|Atezo + Tira + CP|Participants in the atezolizumab plus tiragolumab plus carboplatin plus paclitaxel arm arm will receive treatment for two cycles (6 weeks) until surgery or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
62008009|NCT04047017|EXPERIMENTAL|Test group|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd
62008010|NCT03559842||Surgery patients|Obese patients undergoing laparoscopic sleeve gastrectomy
62008011|NCT03559842||Non-surgery patients|Obese patients not undergoing laparoscopic sleeve gastrectomy (delayed or refused proposed treatment)
62008012|NCT00428610|EXPERIMENTAL|LY573636|LY573636-sodium (LY573636) is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
62193457|NCT00560144|EXPERIMENTAL|2|
62193458|NCT00560144|EXPERIMENTAL|3|
62193459|NCT04766190|OTHER|Group 1: Usual Care|"The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.~The patient will be video recorded at their appointment. The oncologist has agreed to be video recorded. Immediately after this appointment, the patient will be asked to complete another brief survey that takes about 20 minutes. The questions will ask about how the meeting went. The patient's meeting with the oncologist will not be delayed or changed in any way because of this study."
62008013|NCT02100072|EXPERIMENTAL|Nd:YAG 1440 nm laser|
62008014|NCT04284657|NO_INTERVENTION|ARM I: Control group|Standard therapy alone
62008015|NCT04284657|ACTIVE_COMPARATOR|ARM II: PRAVASTATIN|Standard therapy and PRAVASTATIN 40 mg QD
62008016|NCT04284657|ACTIVE_COMPARATOR|ARM III: PRAV + Sodium Citrate|Standard therapy and PRAVASTATIN 40 mg QD and Sodium Citrate (up to 30 mL TID)
62008017|NCT04699994|EXPERIMENTAL|FLOT therapy|
62021066|NCT05636540|EXPERIMENTAL|Cohort A|After undergoing screening assessments and verifying eligibility for study participation subjects will be scheduled to undergo a baseline experimental \[18F\]FTT PET/CT scan prior to surgery. Patients in Cohort A will undergo surgery with or without additional therapy.
62214882|NCT02480959|OTHER|MPFL reconstruction|Patient undergoing surgical treatment for recurrent patellar instability that includes medial patellofemoral ligament reconstruction using a tendon graft
62214883|NCT04310280|EXPERIMENTAL|Topical insulin glargine|The wound surface is treated locally with glargine insulin injected sub-dermal in a daily matter for 7 days. Allocation is randomized.
62008018|NCT05198492||Patients with hospitalizations or emergency room visits due to acute coronary syndromes|Data on hospitalization for acute coronary syndromes were obtained and extracted from the National Health Fund reports. In the present analysis, we used data from patients registered as residents in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020. The set of variables that were subjected to the analysis included demographic features and ICD-10 codes. The diagnosis was based on reports obtained from to the National Health Fund, and these reports have not been reviewed with patient hospital documentation.
62008019|NCT05198492||Patients with hospitalizations or emergency room visits due to atrial fibrillation|Data on hospitalization for atrial fibrillation were obtained and extracted from the National Health Fund reports. In the present analysis, we used data from patients registered as residents in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020. The set of variables that were subjected to the analysis included demographic features and ICD-10 codes. The diagnosis was based on reports obtained from to the National Health Fund, and these reports have not been reviewed with patient hospital documentation.
62008020|NCT05198492||Patients with hospitalizations or emergency room visits due to kidney diseases|Data on hospitalization for kidney diseases were obtained and extracted from the National Health Fund reports. In the present analysis, we used data from patients registered as residents in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020. The set of variables that were subjected to the analysis included demographic features and ICD-10 codes. The diagnosis was based on reports obtained from to the National Health Fund, and these reports have not been reviewed with patient hospital documentation.
62008021|NCT05198492||Patients who died due to cardiovascular diseases|Data on mortality were collected from the National Statistical Office in Poland. These include information on all the deaths recorded in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020 The records included sex and age of people who had died, and the causes of deaths were classified according to codes in the International Classification of Diseases-10th Revision (ICD-10).
62008022|NCT05198492||Patients who died due to neoplasm diseases|Data on mortality were collected from the National Statistical Office in Poland. These include information on all the deaths recorded in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020 The records included sex and age of people who had died, and the causes of deaths were classified according to codes in the International Classification of Diseases-10th Revision (ICD-10).
62008023|NCT05198492||Patients who died due to kidney diseases|Data on mortality were collected from the National Statistical Office in Poland. These include information on all the deaths recorded in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020 The records included sex and age of people who had died, and the causes of deaths were classified according to codes in the International Classification of Diseases-10th Revision (ICD-10).
62008024|NCT05198492||Patients with hospitalizations or emergency room visits due to ischemic strokes|Data on hospitalization for ischemic strokes were obtained and extracted from the National Health Fund reports. In the present analysis, we used data from patients registered as residents in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020. The set of variables that were subjected to the analysis included demographic features and ICD-10 codes. The diagnosis was based on reports obtained from to the National Health Fund, and these reports have not been reviewed with patient hospital documentation.
62193460|NCT04766190|OTHER|Group 2: The DISCO App|"The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.~The patient will be shown an iPad with an app while waiting to see their oncologist. The app includes a short video and asks questions about the patient's financial concerns. The app will give the patient a list of questions the patient may want to ask their oncologist during their appointment. The patient will then meet with their oncologist. The meeting with the patient's oncologist will be video recorded. The oncologist has agreed to be video recorded. Immediately after meeting the oncologist, the patient will complete another brief survey. The questions will ask about how the meeting went and what the patient thought of the app. The meeting with the oncologist will not be delayed or changed in any way because of this study."
62398241|NCT06056076|EXPERIMENTAL|Group A|Mini Squats at a rate of ten squats at minimum range around 10-15 degrees at start along with Interferential Therapy for 10 minutes.
62398242|NCT06056076|ACTIVE_COMPARATOR|Group B|Endurance training by the use of medium resistance therapeutic band at start along with Interferential Therapy for 10 minutes.
62398243|NCT06375044|EXPERIMENTAL|SIM0500|
62781909|NCT06141291|EXPERIMENTAL|Old 2|"1. Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.~2. Test the ability of high protein diet (1.4 g protein/kg/day) with branched chain amino acid and cysteine supplementation to decrease bed rest induced muscle atrophy, glutathione depletion and insulin resistance in old subjects."
62781910|NCT06141291|OTHER|Young|1. Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.
62781911|NCT05340790|EXPERIMENTAL|Antimicrobial Peptide PL-18 Vaginal Suppositories|Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
62781912|NCT05340790|PLACEBO_COMPARATOR|Placebo dose|Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
62781913|NCT01688193||HCP 1004|
62781914|NCT01688193||Vimovo 500/20mg|
62781915|NCT03534375||Female Early Adolescents|
62781916|NCT03534375||Male Early Adolescents|
62781917|NCT02646813|ACTIVE_COMPARATOR|Intraluminal Placement|These patients will have the Arndt endobronchial blocker placed within the endotracheal tube for lung isolation during their thoracic surgery. The observer will measure time required to place blocker correctly prior to surgery.
62781918|NCT02646813|EXPERIMENTAL|Extraluminal Placement|These patients will have the Arndt endobronchial blocker placed outside of the endotracheal tube for lung isolation during their thoracic surgery. The investigator will measure the time required for placement.
62193461|NCT04766190|OTHER|Group 3: The DISCO App + Booster|"The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.~The patient will be shown an iPad with an app while waiting to see your oncologist. The app includes a short video and asks questions about your financial concerns. The app will give the patient a list of questions they may want to ask their oncologist during their appointment. The patient will then meet with their oncologist. The meeting with their oncologist will be video recorded. The oncologist has agreed to be video recorded. Immediately after meeting their oncologist, they will complete another brief survey. The questions will ask about how the meeting went and what they thought of the app. The patient's meeting with the oncologist will not be delayed or changed in any way because of this study. Two months after that appointment, the patient will be sent a reminder of the information that was presented on the app."
62193462|NCT00284193|EXPERIMENTAL|feiba-VIIa, hemophilia A-inhibitor therapy|COMBINED PATIENT- TAILORED THERAPY WITH CONCOMITANT ADMINISTRATION OF BOTH DRUGS , FOLLOWING EX VIVO THROMBIN GENERATION PREDICTING ASSAYS
62193463|NCT00322569|EXPERIMENTAL|1|Corio™ Pimecrolimus-Eluting Cobalt Chromium Coronary Stent System
62193464|NCT00322569|EXPERIMENTAL|2|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System
62193465|NCT00322569|ACTIVE_COMPARATOR|Control Arm|Costar ™ Paclitaxel-Eluting Coronary Stent System
62193466|NCT02595320|EXPERIMENTAL|Group A|capecitabine, 1500 mg, twice a day for 7 days on then 7 days off
62193467|NCT02595320|ACTIVE_COMPARATOR|Group B|capecitabine, 1250 mg/m2 OR 1000 mg/m2, twice a day for 14 days on then 7 days off
62781919|NCT06317168|ACTIVE_COMPARATOR|Standardized automated office BP measurements|BP measured using a highly standardized procedure using a validated office-grade device on a bare arm supported at heart level.
62781920|NCT06317168|ACTIVE_COMPARATOR|Sleeved arm|BP measured using a highly standardized procedure using a validated office-grade device over a standardized sleeve with the arm supported at heart level.
62781921|NCT06317168|ACTIVE_COMPARATOR|Arm not supported|BP measured using a highly standardized procedure using a validated office-grade device on a bare arm resting vertically.
62781922|NCT06317168|ACTIVE_COMPARATOR|Non-validated device|BP measured using a highly standardized procedure using a non-validated home device on a bare arm supported at heart level.
62781923|NCT02413047|EXPERIMENTAL|Immunomodulator|Azathioprine, 6 mercaptopurine or methotrexate.
62781924|NCT04071704||Patients|Patients who have been or are being treated for sarcoma.
62781925|NCT04071704||Health care professionals|Health care professionals with extensive experience in sarcoma care (medical oncologists, radiation oncologists, surgical oncologists, orthopaedic surgeons, nurse specialists, psychologists, physiotherapists)
62781926|NCT04787354|ACTIVE_COMPARATOR|Control arm|"Standard adjuvant XELOX 8 cycles~Oxaliplatin: 130 mg/m2/day(day 1) Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, total 8 cycles"
62781927|NCT04787354|EXPERIMENTAL|Study arm|"Adjuvant XELOX 4 cycles followed by capecitabine monotherapy 4 cycles~Oxaliplatin: 130 mg/m2/day(day 1) Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, 4 cycles~followed by~Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, 4 cycles"
62781928|NCT05158725|ACTIVE_COMPARATOR|Standard Colonoscopy|Subjects will undergo colonoscopy using a standard colonoscope
62781929|NCT05158725|ACTIVE_COMPARATOR|Discovery aided colonoscopy|Subjects will undergo colonoscopy using a a standard colonoscope and the Discovery aided colonoscopy
62781930|NCT05158725|EXPERIMENTAL|Discovery and G-EYE aided colonoscopy|Subjects will undergo colonoscopy using the G-EYE Endoscope and the Discovery aided colonoscopy
62781931|NCT04599595||Multiple Scerosis (MS) Group|This group will be composed by 150 MS patients who, consecutively, from the start of the study, will refer to the MS clinic of the Neurology Unit of the Ferrara University Hospital, Italy. The first 50 patients with a PACQoL score ≥ 32 will be asked to be willing to enter the next phase of the study that continues at the Coloproctological Outpatient Clinic of Ferrara University Hospital, Italy with an appointment provided by the neurologist with a pre-established schedule (with written consent).
62781932|NCT04691908|ACTIVE_COMPARATOR|Phase III Adult-vaccine (A Sample, blind study)|Group 1 (phase III): 2400 volunteers from 18 years old and elder who will be the QazCovid-in® twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
62781933|NCT04691908|PLACEBO_COMPARATOR|Phase III Adult-Placebo (A Sample, blind study)|Group 1 (phase III): 600 volunteers from 18 years old and elder who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
62781934|NCT01754272||FOLFIRI + Aflibercept|Non-interventional study. No drugs administered. In this arm 612 patients from the VELOUR trial
62781935|NCT01754272||FOLFIRI + Placebo|Non-interventional study. 614 patients from the FOLFIRI + placebo arm in the VELOUR trial.
62781936|NCT05695144|EXPERIMENTAL|tDCS active stimulation combined with rTMS sham stimulation group|1
62781937|NCT05695144|EXPERIMENTAL|rTMS active stimulation combined with tDCS sham stimulation group|2
62193468|NCT00349466|EXPERIMENTAL|CF101 1mg|CF101 1 mg given orally every 12 hours for 12 weeks
62193469|NCT00349466|PLACEBO_COMPARATOR|Placebo|Placebo given orally every 12 hours for 12 weeks
62193470|NCT04463680|EXPERIMENTAL|Intervention|Will receive 2 week regimen of rifampin 600mg per day
62193471|NCT02523547|EXPERIMENTAL|Cavir|entecavir/0.5mg/day
62398244|NCT06566742|EXPERIMENTAL|Olutasidenib|Participants will take capsules of olutasidenib 2 times each day while you are on study. Each dose should be taken about 12 hours apart at least 1 hour before or 2 hours after a meal.
62573340|NCT06575062|ACTIVE_COMPARATOR|Direct Capping|The direct capping technique was applied when the pulp exposure was less than 2 mm. In this application, cavity disinfection was achieved with a 2.5% sodium hypochlorite solution due to the exposed pulp. After controlling the bleeding, the MTA was prepared according to the manufacturer's recommendations and placed on the exposed area. The MTA was then covered with resin-modified glass ionomer cement. To ensure proper bonding of the restorative material and a leak-proof restoration, material residues on the cavity walls were removed with a steel round bur. The cavity walls were roughened with 35% orthophosphoric acid. Following the application of a dentin bonding agent, the upper restoration was completed with composite resin using the layering technique.
62734599|NCT02457689|ACTIVE_COMPARATOR|Group 4 (Electroporation and Active)|Group 4 (Electroporation and Active) Participants will receive 1.0ml intramuscular injections of the GTU®-MultiHIV B Clade Vaccine (2mg/ml) into the upper thigh using the ICHOR TriGridTM delivery system for intramuscular (TDS-IM) delivery with electroporation. Electroporation (EP) improves the delivery of the product into muscle cells, by delivering an electrical pulse with the injection using a hand held device that is pressed against your thigh. This will cause a muscle twitch with a sharp cramp-like feeling in the thigh lasting a few seconds. Once the procedure is carried out, the muscle will feel sore for up to 72 hours. The investigator will ask volunteers not to engage in any strenuous exercise for at least 24 hours after the procedure.
62781938|NCT05695144|EXPERIMENTAL|tDCS active stimulation combined with rTMS active stimulation group|3
62781939|NCT05695144|EXPERIMENTAL|tDCS sham stimulation combined with rTMS sham stimulation group|4
62008025|NCT03533075|EXPERIMENTAL|Teachable Moment Brief Intervention|The TMBI is informed by evidence based strategies to collaboratively identify 1) drivers of suicidal ideation, 2) functional aspects of the recent suicide attempt, 3) the patient's relationship with the concept of suicide, 4) what has been lost and gained as a result of the suicide attempt, 5) short term management suicide prevention management strategies, and 6) documentation of factors to address in a suicide-specific treatment plan.
62008026|NCT03533075|NO_INTERVENTION|Care as Usual|Usual care at Veterans Affairs Medical Centers (VAMC) for Veterans who have attempted suicide involves psychiatric evaluation/treatment and ongoing medical stabilization.
62781940|NCT05494034|EXPERIMENTAL|"implantable cardiac monitoring device (Reveal LINQTM)"|All included patients will have long-term heart rate monitors (Reveal LINQ; Medtronic)
62193472|NCT02523547|ACTIVE_COMPARATOR|Baraclude|entecavir/0.5mg/day
62193473|NCT00711308|EXPERIMENTAL|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
62193474|NCT00711308|ACTIVE_COMPARATOR|acenocoumarol|tinzaparin followed by acenocoumarol for 6 months
62193475|NCT01224470|ACTIVE_COMPARATOR|bupivacaine|0.5% bupivacaine 1.2 mL + normal saline 0.8 mL = total 2 mL
62193476|NCT01224470|PLACEBO_COMPARATOR|saline|
62193477|NCT02245646||Control group|No indication for stapedotomy
62193478|NCT02245646||Distortion positive|Subjects after stapedotomy perceiving sound distortions
62193479|NCT02245646||Distortion negative|Subjects after stapedotomy not perceiving sound distortions.
62193480|NCT06154928|NO_INTERVENTION|Control Groups|Routine treatment and care of patients in the CG was continued. The onset of bowel sounds and flatus requires the initiation of oral fluid and nutrient intake. Patients in the CG were evaluated at T0, T1, T2, and T3, and data were recorded on a data collection form.
62193481|NCT06154928|EXPERIMENTAL|Wather Groups|Patients in the WG were provided warm water at the 2nd postoperative hour on the day of surgery. Patients in the WG were evaluated at T0, T1, T2, and T3 and data were recorded on a data collection form. The onset of bowel sounds and flatus requires the initiation of oral fluid and nutrient intake. No other water or food was provided to patients who had no bowel sounds or flatus other than warm water.
62193482|NCT04082351|ACTIVE_COMPARATOR|Magnalife|the group of patients receiving the nanotechnology structured water
62193483|NCT04082351|PLACEBO_COMPARATOR|Ordinary water|the group of patients receiving ordinary water
62193484|NCT06035081|EXPERIMENTAL|Prednisolone first, then placebo|Prednisolone 12.5 mg twice daily for 5 days. Placebo twice daily for 5 days
62398245|NCT04828330||Observational cohort|This is a case-crossover study nested within a cohort study.
62781941|NCT03465930||Patients with lymphedema|Patients affected by primary or secondary lymphedema. The intervention will consist in supermicrosurgical lymphatico-venous anastomoses (sLVA) to allow drainage of the lymph in the venous stream distal to the obstruction. sLVA is a minimally invasive procedure performed under local anesthesia. It requires an accurate visualization of the lymphatic vessels that are still functional.
62781942|NCT00122369|EXPERIMENTAL|Self-hypnotic Relaxation|A research assistant displayed defined behaviors of empathic attention and read to the patient a self-hypnotic relaxation script. Patients also received lidocaine as local anesthetic which is the standard care approach and not considered a unique intervention in terms of the trial.
62781943|NCT00122369|NO_INTERVENTION|Standard Care|Patients received the routine standard treatment which included application of lidocaine as local anesthetic. This is not considered a unique intervention in terms of the trial. Omitting local anesthetic actually would have been an intervention deviating from routine care.
62781944|NCT00122369|ACTIVE_COMPARATOR|Empathic Attention|A research assistant displayed defined behaviors of empathic attention. Patients also received lidocaine as local anesthetic which is the standard care approach and not considered a unique intervention in terms of the trial.
62193485|NCT06035081|EXPERIMENTAL|Placebo first, then prednisolone|Placebo twice daily for 5 days Prednisolone 12.5 mg twice daily for 5 days.
62193486|NCT04834713||Mild patients|defined as patients who had kidney injury without oliguria and hypotension
62193487|NCT04834713||moderate patients|defined as patients who had uremia, effusion (bulbar conjunctiva), hypotension, hemorrhage (skin and mucous membranes), and AKI with typical oliguria
62193488|NCT04834713||severe patients|defined as patients who had severe uremia, effusion (bulbar conjunctiva and either peritoneum or pleura), hemorrhage (skin and mucous membranes), hypotension and AKI with oliguria (urine output of 50-500 mL/day) for ≤ 5 days or anuria (urine output of \< 100 mL/day) for ≤ 2 days
62193489|NCT04834713||critical patients|defined as patients who usually had one or more of the following complications compared with the severe patients: refractory shock (≥ 2 days), visceral hemorrhage, heart failure, pulmonary edema, brain edema, severe secondary infection, and severe AKI with oliguria (urine output of 50-500 mL/day) for \> 5 days or anuria (urine output of \< 100 mL/day) for \> 2 days
62193490|NCT04834713||healthy control|defined as people without HFRS
62193491|NCT02834299|EXPERIMENTAL|DBT Guided Self-Help|"Participants will be provided with the DBT self-help manual Dialectical Behavior Therapy for Binge Eating: A Self-Help Program by Safer, Adler \& Masson (2016) and receive six brief therapy sessions via video-calling."
62193492|NCT02834299|EXPERIMENTAL|DBT Unguided Self-Help|"Participants will be provided with the DBT self-help manual Dialectical Behavior Therapy for Binge Eating: A Self-Help Program by Safer, Adler \& Masson (2016) and asked to follow the manual on their own."
62193493|NCT02834299|ACTIVE_COMPARATOR|Self-Esteem-Focused Unguided Self-Help|"Participants will be provided with the self-help manual Self-Esteem by McKay \& Fanning (2016) as asked to follow the manual on their own."
62193494|NCT04729205|EXPERIMENTAL|Promitil 1.6 mg/kg|PROMITIL (1.6 mg/kg body weight) will be intravenously (IV) administered on the first day of three 28-day cycles. On days 1 and 15 of each PROMITIL cycle, patients will be treated with the mFOLFOX6 regimen, which includes concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h
62193495|NCT04729205|EXPERIMENTAL|Promitil 2.0 mg/kg|PROMITIL (2.0 mg/kg body weight) will be intravenously (IV) administered on the first day of three 28-day cycles. On days 1 and 15 of each PROMITIL cycle, patients will be treated with the mFOLFOX6 regimen, which includes concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h
62193496|NCT00955890|NO_INTERVENTION|control arm|anthracycline chemotherapy only
62193497|NCT00955890|EXPERIMENTAL|low dose dexrazoxane group|anthracycline chemotherapy plus low dose dexrazoxane(10:1)
62193498|NCT00955890|EXPERIMENTAL|middle dose dexrazoxane group|anthracycline chemotherapy plus middle dose dexrazoxane(15:1)
62193499|NCT00133575|EXPERIMENTAL|Group E: ACAM3000 MVA 10^7 ID|10 subjects to receive ACAM3000 MVA dose 10\^7 TCID50 via intradermal route on days 0 and 28; 2 subjects to receive placebo via intradermal route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.
62193500|NCT00133575|EXPERIMENTAL|Group F: ACAM3000 MVA 10^8 IM|10 subjects to receive ACAM3000 MVA dose 10\^8 TCID50 via intramuscular route on days 0 and 28; 2 subjects to receive placebo via intramuscular route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.
62193501|NCT00133575|EXPERIMENTAL|Group D: ACAM3000 MVA 10^8 SC|10 subjects to receive ACAM3000 MVA dose 10\^8 TCID50 via subcutaneous route on days 0 and 28; 2 subjects to receive placebo via subcutaneous route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.
62193502|NCT00133575|EXPERIMENTAL|Group B: ACAM3000 MVA 10^7 IM|10 subjects to receive ACAM3000 MVA dose 10\^7 TCID50 via intramuscular route on days 0 and 28; 2 subjects to receive placebo via intramuscular route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.
62781945|NCT00863291|ACTIVE_COMPARATOR|1|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
62781946|NCT00863291|PLACEBO_COMPARATOR|2|Placebo given in a manner similar to he active comparator
62781947|NCT00325520||Anorexia nervosa|Individuals with anorexia nervosa receiving inpatient treatment
62781948|NCT00325520||Healthy controls|
62781949|NCT03595527|EXPERIMENTAL|Patients consulting in the emergency room|Patients consulting in the emergency room.
62781950|NCT01108523|EXPERIMENTAL|HP828-101|HP828-101 Experimental Formulation
62781951|NCT04934657||normal steps|patients in this group have normal preoperative step counts
62781952|NCT04934657||low steps|patients in this group have low preoperative step counts
62781953|NCT01345669|EXPERIMENTAL|Afatinib (BIBW 2992)|Once daily
62781954|NCT01345669|PLACEBO_COMPARATOR|Placebo|Once daily
62781955|NCT03663335|EXPERIMENTAL|Arm 1/Cohort 1|CFZ533 dose A+ MMF + Corticosteroids
62781956|NCT03663335|EXPERIMENTAL|Arm 2/Cohort 1|CFZ533 dose B + MMF + Corticosteroids
62781957|NCT03663335|ACTIVE_COMPARATOR|Arm 3/Cohort 1|Control/Standard of Care: TAC + MMF + Corticosteroids
62781958|NCT03663335|EXPERIMENTAL|Arm 1/Cohort 2|CFZ533 dose C + MMF ± Corticosteroids
62781959|NCT03663335|ACTIVE_COMPARATOR|Arm 2/Cohort 2|Tac + MMF ± Corticosteroids
62781960|NCT05700032|EXPERIMENTAL|high MI|patients receiving high MI impulses
62781961|NCT05700032|ACTIVE_COMPARATOR|low MI|patients receiving low MI impulses
62193503|NCT00133575|EXPERIMENTAL|Group A: ACAM3000 MVA 10^6 ID|10 subjects to receive ACAM3000 MVA dose 10\^6 tissue culture infectious dose 50 (TCID50) via intradermal (ID) route on days 0 and 28; 2 subjects to receive placebo via intradermal route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.
62193504|NCT00133575|EXPERIMENTAL|Group C: ACAM3000 MVA 10^7 SC|10 subjects to receive ACAM3000 MVA dose 10\^7 TCID50 via subcutaneous (SC) route on days 0 and 28; 2 subjects to receive placebo via subcutaneous route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.
62193505|NCT03091816||Diagnostic (DPCT)|Patients undergo DPCT at baseline, during SBRT (after 2 of 3 fractions or 3 of 5 fractions), and then at 1 and 3 months post stereotactic body radiation therapy.
62008027|NCT01891734|EXPERIMENTAL|Problem Solving Therapy plus Moving Forward (PST-MF)|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
62193506|NCT01862497||Carvedilol (for Aim 3 only)|"Eligible case subjects from aims 1-2 will participate in a randomized crossover study where each subject will receive carvedilol and prazosin for 8 weeks each(under randomized treatment sequence) with a 1 week washout period included in between treatments.~The first arm will include subjects that are assigned to the randomization sequence: Carvedilol x 8 weeks (titrated up to 50 mg po bid), washout x 1 week, Prazosin x 8 weeks (titrated up to 16 mg daily)"
62193507|NCT01862497||Prazosin (for Aim 3 only)|"Eligible case subjects from aims 1-2 will participate in a randomized crossover study where each subject will receive carvedilol and prazosin for 8 weeks each(under randomized treatment sequence) with a 1 week washout period included in between treatments.~The first arm will include subjects that are assigned to the randomization sequence: Prazosin x 8 weeks, washout x 1 week, Carvedilol x 8 weeks"
62398246|NCT06537414|EXPERIMENTAL|Treatment Arm 1A: DAP/TOM + Bepirovirsen|Participants with high Hepatitis B surface antigen (HBsAg) level will receive dose level 1 of DAP/TOM in Treatment Stage 1. After DAP/TOM Treatment, eligible participants will receive bepirovirsen in Treatment Stage 2. All participants will continue background NA treatment throughout these treatment stages. After bepirovirsen Treatment Stage, participants will be observed during the NA Only Stage, while maintaining background NA treatment. Eligible participants will then discontinue background NA treatment.
62573341|NCT06575062|ACTIVE_COMPARATOR|Pulpotomy|In cases where the pulp exposure was more than 2 mm, the pulpotomy technique was employed. The procedure began with the removal of the pulp roof using steel round burs. The pulp was then amputated up to the pulp canal openings with a sterile sharp spoon excavator. Hemostasis was achieved using a sterile cotton pellet impregnated with physiological saline for 3-5 minutes. If hemostasis could not be achieved and inflammation had progressed to the root pulp, regenerative endodontics was applied. Once hemostasis was secured, the cavity was disinfected again with 2.5% sodium hypochlorite. A 2 mm thick layer of MTA was applied to the pulp base and covered with MTA resin-modified glass ionomer cement. The cavity walls were roughened with 35% orthophosphoric acid after removing material residues with a steel round bur. Following the application of a dentin bonding agent, the upper restoration was completed with composite resin using the layering technique.
62008028|NCT01891734|ACTIVE_COMPARATOR|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
62008029|NCT01634204|EXPERIMENTAL|KiloCoach|Study subjects use the KiloCoach program on at least 4 days per week within the first half of the 6 months intervention period. In the second half, program usage is ad libitum.
62008030|NCT01634204|NO_INTERVENTION|Control|Study subjects try to reduce body weight on their own, without participating in an organized weight loss program, over a period of 6 months.
62008031|NCT06118294|EXPERIMENTAL|Probiotics|daily ingestion of 2 capsules of probiotics (\>30 billion CFU/capsule)
62008032|NCT06118294|PLACEBO_COMPARATOR|Placebo|daily ingestion of 2 capsules which only contained 425 ± 25 mg microcrystalline cellulose
62193508|NCT05693077|EXPERIMENTAL|Group A (phase 1) (N=10)|5 doses of 10E4 NTCD spores on day 0-4.
62193509|NCT05693077|EXPERIMENTAL|Group B (phase 1) (N=10)|5 doses of 10E7 NTCD spores on day 0-4.
62193510|NCT05693077|PLACEBO_COMPARATOR|Group C (phase 1) (N=4)|5 doses of placebo on day 0-4.
62008033|NCT04328493|NO_INTERVENTION|Control arm|Patients randomized to the control arm will receive a standard of care therapy (a supportive care/treatment according to VN MoH's guideline).
62008034|NCT04328493|EXPERIMENTAL|Intervention arm|"In addition to standard of care therapy, patients randomized to the intervention arm receive chloroquine phosphate as below.~For adult ≥ 53kg: 1000mg (4 tablets) at initial dose (T=0), followed by 500mg (2 tablets) at 6 hours later (T=6), and 500mg (2 tablets) once daily for 9 days.~For adult from 45 - 52kg: 875mg (3.5 tablets) at T=0, followed by 500mg (2 tablets) at T=6 and 500mg (2 tablets) once daily thereafter.~For adult weighted 38 -\<45 kg: 750mg (3 tablets) at T=0, followed by 375mg (1.5 tablets) at T = 6 and 375mg (1.5 tablets) once daily thereafter.~For adult weighted \<38 kg: 625mg (2.5 tablets) at T=0, followed by 375mg (1.5 tablets) at T=6 and 375mg (1.5 tablets) once daily thereafter.~The total duration of treatment with chloroquine will be 10 days."
62573342|NCT01483027|EXPERIMENTAL|Treatment group|Standard of care second-line chemotherapy plus TheraSphere
62008035|NCT04089267|EXPERIMENTAL|experimental group 1|rhTPO injection7500 U ;one time a day; 14 times of administration
62573343|NCT01483027|NO_INTERVENTION|Control group|Standard of care second-line chemotherapy with no added therapy
62008036|NCT04089267|EXPERIMENTAL|experimental group 2|rhTPO injection15000 U;one time a day;14 times of administration
62193511|NCT05693077|EXPERIMENTAL|Group D (phase 2) (N=10)|"Based upon the colonisation results of phase 1, there are three dosing options for this group, one of the three options will be chosen, the chosen option number will be congruent for all three groups in phase 2:~* Option 1: 3 doses of 10E4 NTCD spores on day 0-2.~* Option 2: 3 doses of 10E7 NTCD spores on day 0-2.~* Option 3: 1 day of vancomycin on day -7, followed by 5 doses of 10E4 NTCD spores on day 0-4."
62193512|NCT05693077|EXPERIMENTAL|Group E (phase 2) (N=10)|"Based upon the colonisation results of phase 1, there are three dosing options for this group, one of the three options will be chosen, the chosen option number will be congruent for all three groups in phase 2:~* Option 1: 1 dose of 10E4 NTCD spores on day 0, and 2 doses of placebo on day 1-2.~* Option 2: 1 dose of 10E7 NTCD spores on day 0, and 2 doses of placebo on day 1-2.~* Option 3: 1 day vancomycin on day -7 followed by 5 doses of 10E7 NTCD spores on day 0-4."
62193513|NCT05693077|PLACEBO_COMPARATOR|Group F (phase 2) (N=3 or 6)|"Based upon the colonisation results of phase 1, there are three dosing options for this group, one of the three options will be chosen, the chosen option number will be congruent for all of the groups:~* Option 1 (N=6): 3 doses of placebo on day 0-2.~* Option 2 (N=6): 3 doses of placebo on day 0-2.~* Option 3 (N=3): 1 day vancomycin on day -7, followed by 5 doses of placebo on day 0-4."
62193514|NCT05693077|EXPERIMENTAL|Group G (phase 3) (N=10)|"Escalation to the third phase will only be done if option 3 is selected in phase 2. Based upon the colonisation results of phase 2, there are three dosing options for this group, one of the three options will be chosen, the chosen option number will be congruent for all of the groups in phase 3:~* Option 1: 1 day vancomycin on day -7, followed by 3 doses of 10E4 NTCD spores on day 0-2.~* Option 2: 1 day vancomycin on day -7, followed by 3 doses of 10E7 NTCD spores on day 0-2.~* Option 3: 5 days of vancomycin on day -11 until day -7, followed by 5 doses of 10E4 NTCD spores on day 0-4."
62193515|NCT05693077|EXPERIMENTAL|Group H (phase 3) (N=10)|"Escalation to the third phase will only be done if option 3 is selected in phase 2. Based upon the colonisation results of phase 2, there are three dosing options for this group, one of the three options will be chosen, the chosen option number will be congruent for all of the groups in phase 3:~* Option 1: 1 day of vancomycin on day -7, followed by 1 dose of 10E4 NTCD spores on day 0, and 2 doses of placebo on day 1-2.~* Option 2: 1 day of vancomycin on day -7, followed by 1 dose of 10E7 NTCD spores on day 0 and 2 doses of placebo on day 1-2.~* Option 3: 5 days of vancomycin on day -11 until day -7, followed by 5 doses of 10E7 NTCD spores on day 0-4."
62193516|NCT05693077|PLACEBO_COMPARATOR|Group I (phase 3) (N=3)|"Escalation to the third phase will only be done if option 3 is selected in phase 2. Based upon the colonisation results of phase 2, there are three dosing options for this group, one of the three options will be chosen, the chosen option number will be congruent for all of the groups in phase 3:~* Option 1: 1 day of vancomycin on day -7, followed by 3 doses of placebo on day 0-2.~* Option 2: 1 day of vancomycin on day -7, followed by 3 doses of placebo on day 0-2.~* Option 3: 5 days of vancomycin on day -11 until day -7, followed by 5 doses of placebo on day 0-4."
62573344|NCT04074941|EXPERIMENTAL|Low sodium diet|This group will get a low sodium diet (\<0.9 mg per kcal of energy intake).
62573345|NCT04074941|ACTIVE_COMPARATOR|Usual sodium diet|This group will get a usual sodium diet (\~2 mg per kcal of energy intake).
62573346|NCT05457036|EXPERIMENTAL|Active Treatment Group|Active Treatment device device provides gentle energy to the lower spine and hips.
62573347|NCT05457036|SHAM_COMPARATOR|Sham Treatment Group|Sham Treatment device is identical to the Active Treatment device except the sham device does not produce the gentle energy.
62573348|NCT03534518|ACTIVE_COMPARATOR|SCI-patients receiving overground training|
62008037|NCT04089267|EXPERIMENTAL|experimental group 3|rhTPO injection15000 U;1 time every other day, 7 times;
62573349|NCT03534518|ACTIVE_COMPARATOR|SCI-patients receiving treadmill training|
62781962|NCT05818267|EXPERIMENTAL|Treatment group|The drug dose that taken by the subject is gradually increased to the maximum dose tolerated by the patient according to individualization. Specifically, the initial dose of 80 mg/day was gradually increased to 120 mg/day (80 mg/day in the first week, 120 mg/day in the second week, and a maximum tolerated dose of 160 mg/day). The maximum tolerated dose is 160 mg/day. The dose is administered once daily in a 4-week cycle (3 weeks of dosing and 1 week of rest) and the maximum dose achieved in the first treatment cycle is maintained.At the discretion of the investigator, regorafenib may be delayed or discontinued. Dose adjustments and interruptions due to toxicity are made according to the recommendations specified in the protocol.
62781963|NCT00745433||A|Repaglinide add-on to metformin.
62781964|NCT03399474|ACTIVE_COMPARATOR|Lidocaine only|Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline for intravenous regional anesthesia.
62008038|NCT04089267|EXPERIMENTAL|experimental group 4|rhTPO injection30000 U；1 time every other day, 7 times;
62008039|NCT00053430|EXPERIMENTAL|1|Participants will receive low dose thalidomide for 28 days
62008040|NCT00053430|PLACEBO_COMPARATOR|2|Participants will receive low dose thalidomide placebo for 28 days
62008041|NCT02082717|EXPERIMENTAL|Neut (4%sodium bicarbonate additive)|4% sodium bicarbonate additive during intravenous potassium chloride replacement.
62398247|NCT06537414|EXPERIMENTAL|Treatment Arm 1B: DAP/TOM + Bepirovirsen|Participants with high HBsAg level will receive dose level 2 of DAP/TOM in Treatment Stage 1. After DAP/TOM treatment, eligible participants will receive bepirovirsen in Treatment Stage 2. All participants will continue background NA treatment throughout these treatment stages. After bepirovirsen Treatment Stage, participants will be observed during the NA Only Stage, while maintaining background NA treatment. Eligible participants will then discontinue background NA treatment.
62008042|NCT02082717|ACTIVE_COMPARATOR|Control|standard of practice potassium chloride replacement (with no additive)
62008043|NCT01659424|OTHER|Single Arm|This is a single arm study.
62193517|NCT06454045||Isolated coronary involvement (Group 1)|Patients with previous infarction and isolated coronary involvement
62573350|NCT02573181|EXPERIMENTAL|V114|Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of V114 on Day 1.
62781965|NCT03399474|EXPERIMENTAL|0.5 ug/kg dexmedetomidine|Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline (maximum dose200 mg)+ Dexmedetomidine intravenous in a dose of 0.5 ug/kg, with the total volume diluted to 40 ml with normal saline 0.9%. The solution will be injected at a rate of 20 ml/min for intravenous regional anesthesia.
62781966|NCT03399474|EXPERIMENTAL|0.25 ug/kg dexmedetomidine|1 Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline (maximum dose200 mg)+ Dexmedetomidine intravenous in a dose of 0.25 ug/kg, with the total volume diluted to 40 ml with normal saline 0.9%. The solution will be injected at a rate of 20 ml/min. for intravenous regional anesthesia.
62781967|NCT00408434|EXPERIMENTAL|CS-7017|CS-7017 from 0.05 to 3.2 mg bid
62781968|NCT05426941|EXPERIMENTAL|Music Imagery|MI sessions will be delivered by board-certified music therapists with specialized training in MI and the study treatment protocol.The 8-session protocol has two stages. Stage 1 (sessions 1-4) is focused on learning to use music and imagery for self-regulation. Once the Veteran has demonstrated skill in using music for self-regulation, Stage 2 (sessions 5-8) shifts to identify and deepen their inner resources and how they can use those resources for self-care.
62781969|NCT05426941|EXPERIMENTAL|Music Listening|Following a one-time meeting with a music therapist, an electronic playlist will be compiled for the Veteran to listen to during the 12-week treatment period.
62781970|NCT05426941|NO_INTERVENTION|Usual care|Participants in the usual care arm (as is the case for MI and ML groups) may receive analgesics and non-pharmacological treatments (e.g., physical therapy) for their chronic musculoskeletal pain.
62781971|NCT03332446|EXPERIMENTAL|cooling|strength training and cold water immersion
62781972|NCT03332446|NO_INTERVENTION|control|strength training and no cold water immersion
62781973|NCT02948738|EXPERIMENTAL|Interactive Education|Interactive asthma education
62781974|NCT02948738|ACTIVE_COMPARATOR|Standard Education|Standard asthma education
62781975|NCT01089205|EXPERIMENTAL|Torrent's Metformin tablets 750 mg|
62781976|NCT01089205|ACTIVE_COMPARATOR|Glucophage XR® of Bristol- Myers Squibb Company, USA|
62781977|NCT01793883|ACTIVE_COMPARATOR|40 mg Laninamivir Octanoate DPI|40 mg Laninamivir Octanoate and matching placebo
62008044|NCT03481959|EXPERIMENTAL|Methylphenidate|Methylphenidate delay shape, 10 and 30 mg capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).
62193518|NCT06454045||Concomitant presence of Lower Extremity Peripheral Artery Disease (Group 2)|Patients with previous AMI and concomitant presence of Lower Extremity Peripheral Artery Disease
62734600|NCT02919891||Participants with Chronic Pain|Questionnaire results will allow the diagnosis of chronic pain. No intervention will be administered. The results of the IENFD will be compared to the group without chronic pain.
62781978|NCT01793883|ACTIVE_COMPARATOR|80 mg Laninamivir Octanoate DPI|80 mg Laninamivir
62781979|NCT01793883|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62781980|NCT06584435|EXPERIMENTAL|High-risk Renal Cell Carcinoma|Tremelimumab is administered intravenously at a fixed dose of 240 mg every 3 weeks for 1 treatment cycle until tumor recurrence or intolerable toxic effects.
62008045|NCT03481959|PLACEBO_COMPARATOR|Matching Placebo|
62008046|NCT04953923|EXPERIMENTAL|Treatment A|Cedazuridine at a therapeutic dose
62781981|NCT04025229|EXPERIMENTAL|HIIT exercise|Participants will perform HIIT exercises as instructed by the study team in the weeks prior to standard of care surgery
62781982|NCT04364152|EXPERIMENTAL|PD patients with freezing of gait, internal strategies|Participants in this group will include PD patients with freezing of gait. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
62781983|NCT04364152|EXPERIMENTAL|PD patients with freezing of gait, external strategies|Participants in this group will include PD patients with freezing of gait. During dual-task walking training, external attentional strategies will be given, aiming to improve their gait performance.
62193519|NCT00383123|EXPERIMENTAL|Fluarix Group|"Subjects in this group received Fluarix™ and will be further stratified by 3 age groups~* 1:1 in 6 months to \< 36 months~* 1:1 in 3 to \< 5 years~* 3:1 in 5 to \< 18 years"
62193520|NCT00383123|ACTIVE_COMPARATOR|Fluzone Group|"Subjects in this group received Fluzone and will be further stratified by 3 age groups~* 1:1 in 6 months to \< 36 months~* 1:1 in 3 to \< 5 years~* 3:1 in 5 to \< 18 years"
62193521|NCT05225987|EXPERIMENTAL|Experimantal Group|Postpartum Nurse Navigation Program based care
62193522|NCT05225987|NO_INTERVENTION|Control group|This group will take routin care
62781984|NCT04364152|EXPERIMENTAL|PD patients without freezing of gait, internal strategies|Participants in this group will include PD patients without freezing of gait. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
62781985|NCT04364152|EXPERIMENTAL|PD patients without freezing of gait, external strategies|Participants in this group will include PD patients without freezing of gait. During dual-task walking training, external attentional strategies will be given, aiming to improve their gait performance.
62008047|NCT04953923|EXPERIMENTAL|Treatment B|Cedazuridine at a supratherapeutic dose
62008048|NCT04953923|PLACEBO_COMPARATOR|Treatment C|Placebo control
62008049|NCT04953923|ACTIVE_COMPARATOR|Treatment D|Moxifloxacin positive control
62008050|NCT05033964|EXPERIMENTAL|DESyne BDS Plus Arm|DESyne BDS Plus Drug Eluting Coronary Stent System (DESyne BDS Plus DECSS; DESyne BDS Plus) is loaded with Sirolimus, Rivaroxaban and Argatroban
62008051|NCT05033964|ACTIVE_COMPARATOR|DESyne X2 Arm|The DESyne X2 Novolimus Eluting Coronary Stent System (DESyne X2 NECSS; DESyne X2) is loaded with Novolimus
62193523|NCT01526837|EXPERIMENTAL|bevacizumab (Avastin)|Open-label, dose-escalating study conducted in cohorts of 1-3 patients treated at increasing doses of bevacizumab in the dose range of 1-25mg/Ml. A maximum of 24 subjects will be treated in this study (up to 8 cohorts of 3 subjects).
62193524|NCT05317676|ACTIVE_COMPARATOR|Palmitoylethanolamide|300 mg PEA twice a day for a total of 600 mg PEA daily 2-month supply upon discharge
62193525|NCT05317676|PLACEBO_COMPARATOR|Placebo|1 placebo tablet twice a day for a total of 2 tablet placebo daily 2-month supply upon discharge
62193526|NCT03821467|EXPERIMENTAL|Healthy subjects|Dual beam Doppler Fourier-domain OCT (DOCT) Dynamic Vessel Analyzer (DVA) Optical coherence tomography (OCT)
62193527|NCT01913262||IFH Patients on Depression Registry|Patients at the Institute for Family Health who have a diagnosis of depression active on their problem list or have had a diagnosis of depression used as an encounter diagnosis in the past year or patients with a PHQ-9 score greater than or equal to 10.
62193528|NCT01551797|EXPERIMENTAL|Test Sustained Release (SR) Paracetamol (2000 mg)|A single 2000 mg oral dose of SR paracetamol formulation (2 x 1000 mg) administered with 150 mL of water.
62193529|NCT01551797|EXPERIMENTAL|Test SR Paracetamol (1500 mg)|A single 1500 mg oral dose of SR paracetamol formulation (2 x 750 mg) administered with 150 mL of water.
62193530|NCT01551797|ACTIVE_COMPARATOR|Reference Paracetamol (2000 mg)|Two single 1000 mg doses of paracetamol (2 x 500 mg/dose) administered orally 6 hours apart, administered with 150 mL of water.
62008052|NCT02560636|EXPERIMENTAL|Dose level 1a|Radiotherapy: 24Gy in 6f Pembrolizumab: 100mg
62008053|NCT02560636|EXPERIMENTAL|Dose level 1b|Radiotherapy: 24Gy in 6f Pembrolizumab: 200mg
62008054|NCT02560636|EXPERIMENTAL|Dose level 2a|Radiotherapy: 24Gy in 4f Pembrolizumab: 100mg
62008055|NCT02560636|EXPERIMENTAL|Dose level 2b|Radiotherapy: 24Gy in 4f Pembrolizumab: 200mg
62008056|NCT02560636|EXPERIMENTAL|Dose level 3a|Radiotherapy: 30Gy in 5f Pembrolizumab: 200mg
62008057|NCT01902485|ACTIVE_COMPARATOR|Quickstart|Immediate start
62008058|NCT01902485|ACTIVE_COMPARATOR|Afterstart|Delayed start
62193531|NCT03814304|EXPERIMENTAL|Personalized tDCS|Personalized tDCS: This intervention is designed to facilitate the excitability of the left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
62193532|NCT03814304|SHAM_COMPARATOR|Active-Sham|The investigators will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
62193533|NCT06012708|EXPERIMENTAL|Dose Level 1|
62008059|NCT01344109||Breast cancer patients|Newly diagnosed patients with breast cancer presenting with operable breast tumor prior to initiation of of neoadjuvant chemotherapy (choice of chemotherapy will be the the treating physician's discretion)
62193534|NCT06012708|EXPERIMENTAL|Dose Level 2|
62193535|NCT06012708|EXPERIMENTAL|Dose Level 3|
62781986|NCT04364152|EXPERIMENTAL|Healthy elders, internal strategies|Participants in this group will include healthy elders. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
62781987|NCT04364152|EXPERIMENTAL|Healthy elders, external strategies|Participants in this group will include healthy elders. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
62193536|NCT06012708|EXPERIMENTAL|Dose Level 4|
62781988|NCT05226312|EXPERIMENTAL|Local Warm Compress|They are gauze covers brought to a certain temperature (temperature varies between 26-34°C or 79-93°F in warm applications) as a compress material, or wraps and covers that can be reheated.
62008060|NCT01344109||Healthy volunteers|Adult women without a cancer diagnosis.
62008061|NCT03063827||Treatment group|Patients with chronic SCI causing NDO and urinary incontinence
62008062|NCT03063827||Control group|Female patients who underwent anti-incontinence suregery without lower urinary tract symptoms
62008063|NCT01438541|EXPERIMENTAL|Window|WindowTM is a protective layer that may reduce the shear and friction on the skin and may help to prevent skin breakdown. Window TM provides instant tack adhesion that minimizes the requirement of extra pressure in order to fixate well. The product does not leave residues and the adhesion level does not increase over time.
62008064|NCT04817241|EXPERIMENTAL|Arm I (decitabine and cedazuridine, venetoclax)|Patients receive ASTX727 PO QD at the recommended phase II dose and venetoclax PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy and collection of blood samples throughout the trial.
62008065|NCT04817241|ACTIVE_COMPARATOR|Arm II (cytarabine, daunorubicin)|Patients receive cytarabine IV over 24 hours on days 1-7 of each cycle and daunorubicin IV over 10-30 minutes on days 1-3 of each cycle. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy throughout the trial.
62008066|NCT04817241|EXPERIMENTAL|Phase Ib (decitabine and cedazuridine, venetoclax)|Patients receive ASTX727 PO QD on days 1-4 or 1-5 of each cycle and venetoclax PO QD on days 1-28 or days 1-21 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy and collection of blood samples throughout the trial.
62008067|NCT00714246|EXPERIMENTAL|Phase I - Dose Level 1|Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
62193537|NCT01131104||Cohort 1|Participants with NAION who have used PDE5 inhibitors
62193538|NCT02811718|EXPERIMENTAL|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
62193539|NCT02811718|EXPERIMENTAL|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
62193540|NCT01151215|EXPERIMENTAL|1|AZD8931 40mg (bd) plus anastrozole 1mg (od)
62193541|NCT01151215|EXPERIMENTAL|2|AZD8931 20mg (bd) plus anastrozole 1mg (od)
62193542|NCT01151215|PLACEBO_COMPARATOR|3|Placebo (bd) plus anastrozole 1mg (od)
62193543|NCT01436305|ACTIVE_COMPARATOR|Tac maintenance|"Group 1 Study Therapy Regimen:Induction with alemtuzumab and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF).~Campath® (alemtuzumab); long-term Prograf® (tacrolimus), or equivalent ; CellCept® (mycophenolate mofetil- MMF), or equivalent , and 4 day course of MEDROL® (methylprednisolone)"
62573351|NCT02573181|ACTIVE_COMPARATOR|Prevnar 13™|Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.
62781989|NCT05226312|NO_INTERVENTION|Not Local Warm Compress|No warm wet application will be made to this group. It will be tracked for only 3 days.
62781990|NCT04591444|ACTIVE_COMPARATOR|ClinproTM White Varnish|"Application of ClinproTM White Varnish containing sodium fluoride (5%) and Tricalcium phosphate (TCP).~A technology that allows calcium and phosphate ions to coexist with fluoride ions separately, forming a more resistant mineral on the tooth surface (3M ESPE Clinpro White Varnish; 3M ESPE Clinpro 5000)."
62781991|NCT04591444|ACTIVE_COMPARATOR|ClinproTM XT Varnish|"Application of ClinproTM XT Varnish, a resin-modified glass ionomer sealant.~Creates a protective layer on exposed dentin, which is durable and has the ability to release fluoride, calcium and phosphate into the surroundings. (3M ESPE Clinpro XT Varnish)."
62398248|NCT06537414|EXPERIMENTAL|Treatment Arm 2A: DAP/TOM + Bepirovirsen|Participants with low HBsAg level will receive dose level 1 of DAP/TOM in Treatment Stage 1. After DAP/TOM treatment, eligible participants will receive bepirovirsen in Treatment Stage 2. All participants will continue background NA treatment throughout these treatment stages. After bepirovirsen Treatment Stage, participants will be observed during the NA Only Stage, while maintaining background NA treatment. Eligible participants will then discontinue background NA treatment.
62193544|NCT01436305|EXPERIMENTAL|Belatacept maintenance|"Group 2 Study Therapy Regimen: Induction with alemtuzumab and maintenance with Nulojix® (belatacept) and mycophenolate mofetil (MMF).~Campath® (alemtuzumab); Nulojix® (belatacept); CellCept® (mycophenolate mofetil- MMF), or equivalent, and 4 day course of MEDROL®(Methylprednisolone)"
62573352|NCT03555318|EXPERIMENTAL|Geriatrician + Cardiologist|Patients randomized to a combined ambulatory follow up with a cardiologist and a geriatrician.
62781992|NCT04591444|PLACEBO_COMPARATOR|Placebo Group|Participants who were part of the placebo group continuously used only the conventional toothpaste provided in the oral hygiene kit during the initial four weeks of the research and received a simulated treatment.
62781993|NCT01628965|EXPERIMENTAL|SPM 962|SPM 962 transdermal patch
62781994|NCT06553872|EXPERIMENTAL|Arm A|"Participants will recieve pirtobrutinib as bridging therapy from day -27 to day -7. Participants randomized to Arm A (n=30) will continue to receive concurrent pirtobrutinib (con-pirto), starting at day -6 and continued until 1-year post-CD19 CAR T-cell therapy with brexucel."
62781995|NCT06553872|EXPERIMENTAL|Arm B|"Participants will recieve pirtobrutinib as bridging therapy from day -27 to day -7. Participants on Arm B (n=30) will discontinue pirtobrutinib after day -7 and will not receive concurrent pirtobrutinib (con-none) between day -6 and 1-year post-CD19 CAR T-cell therapy."
62781996|NCT02238860|ACTIVE_COMPARATOR|Entacavir|Entacavir 0.5 mg (OD) for 48 weeks
62781997|NCT02238860|ACTIVE_COMPARATOR|Tenofovir|Tenofovir 300 mg ,OD for 48 weeks
62781998|NCT00421135|EXPERIMENTAL|Single Arm|ZIO-201
62781999|NCT01835002|EXPERIMENTAL|OkuStim|Electrostimulation Standard Treatment with OkuStim
62573353|NCT03555318|ACTIVE_COMPARATOR|Cardiologist|Patients randomized to usual care (ambulatory follow up with a cardiologist).
62008068|NCT00714246|EXPERIMENTAL|Phase I - Dose Level 2A|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
62008069|NCT00714246|EXPERIMENTAL|Phase I - Dose Level 2B|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
62193545|NCT01436305|EXPERIMENTAL|Basiliximab induction/Short-term Tac|"Short term = 3 months~Group 3 Study Therapy Regimen: Induction with 2 doses of basiliximab and tacrolimus for 84 days and maintenance with Nulojix® (belatacept) and mycophenolate mofetil (MMF).~Simulect® (basiliximab); Nulojix® (belatacept); short-term course of Prograf® (tacrolimus), or equivalent; CellCept® (mycophenolate mofetil- MMF), or equivalent, and 4 day course of MEDROL® (methylprednisolone)"
62193546|NCT03375736|EXPERIMENTAL|Intervention arm|Whole body vibration will be provided by an equipment, GalileoTM Med L Plus (Novotech Medical GmbH). The study participant will stand still on the vibration platform with both knees slightly flexed.
62193547|NCT02264119|EXPERIMENTAL|Lefradafiban tablet with Pantoprazole|
62193548|NCT02264119|ACTIVE_COMPARATOR|Lefradafiban tablet without Pantoprazole|
62782000|NCT04271033|EXPERIMENTAL|Carotid Artery Stenting|Consecutive male and female patients older than 18 year with symptomatic and increased-stroke-risk asymptomatic carotid lesions that require revascularization by Neurovascular Team decision.
62782001|NCT04769245||Single donor convalescent plasma|Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with single donor plasma
62193549|NCT02264119|EXPERIMENTAL|Lefradafiban double chamber sachet with Pantoprazole|
62193550|NCT02264119|ACTIVE_COMPARATOR|Lefradafiban double chamber sachet without Pantoprazole|
62193551|NCT01508663|EXPERIMENTAL|PCI+OMT group|PCI (Everolimus Eluting Stent or Zotalolimus Eluting Stent) added to OMT after randomization and follow up for 12 months
62193552|NCT01508663|ACTIVE_COMPARATOR|OMT alone group|OMT alone after randomization and follow up for 12 months
62193553|NCT00305344|ACTIVE_COMPARATOR|Cord Blood|Umbilical Cord Blood
62193554|NCT05603364|EXPERIMENTAL|EOF group：early carbohydrate feeding|The EOF group drank 10.5% of 5 ml/kg body weight (100ml containing 12.5g maltodextrin, fructose and glucose) after extubation in the resuscitation room.
62782002|NCT04769245||ACB- IP 1.0|Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with ACB- IP 1.0 pathogen-free concentrated cocktail convalescent plasma
62782003|NCT06006403|EXPERIMENTAL|Acute Myeloid Leukemia|Infusion of CD123-targeted CAR-NK cells by dose of 1-10x10\^6 cells/kg
62782004|NCT06006403|EXPERIMENTAL|Blastic Plasmacytoid Dendritic Cell Neoplasm|Infusion of CD123-targeted CAR-NK cells by dose of 1-10x10\^6 cells/kg
62782005|NCT05179759|EXPERIMENTAL|Tealeaf - Year 1: Clusters (schools) and associated participants assigned to sequence 1|Clusters (schools) and associated participants assigned to sequence 1 will be under the EUC condition in the 1st year of trial participation and under the Tealeaf condition in all subsequent years.
62782006|NCT05179759|ACTIVE_COMPARATOR|Enhanced Usual Care - Year 1: Clusters (schools) and associated participants assigned to sequence 2|Clusters (schools) and associated participants assigned to sequence 2 will be under the EUC condition in the 1st and 2nd year of trial participation and under the Tealeaf condition in all subsequent years.
62782007|NCT05179759|EXPERIMENTAL|Tealeaf - Year 2: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
62782008|NCT05179759|ACTIVE_COMPARATOR|Enhanced Usual Care - Year 2: Clusters (schools) and associated participants assigned to sequence 2|EUC (control arm)
62782009|NCT05179759|EXPERIMENTAL|Tealeaf - Year 3: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
62193555|NCT05603364|EXPERIMENTAL|Control group：conventional feeding|Patients in group C were observed with 60minutes of abnormal vital signs after extubation, and returned to the ward for fasting and fasting for at least 6 hours, and began to eat gradually through the mouth after anal exhaust.
62193556|NCT02165553|EXPERIMENTAL|Hibiscus sabdariffa calyces extract as a cold drink|Subjects are asked to consume 250 ml of Hibiscus calyces drink after a high fat breakfast
62193557|NCT02165553|PLACEBO_COMPARATOR|Water|Subjects are asked to consume 250 ml of water after a high fat breakfast
62193558|NCT01551368|EXPERIMENTAL|Nimodipine|Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hCG will be given immediately and two IUIs will be performed 24 hours apart.
62782010|NCT05179759|ACTIVE_COMPARATOR|Enhanced Usual Care - Year 3: Clusters (schools) and associated participants assigned to sequence 2|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
62782011|NCT05179759|EXPERIMENTAL|Tealeaf - Year 4: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
62008070|NCT00714246|EXPERIMENTAL|Phase I - Dose Level 3|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
62008071|NCT00714246|EXPERIMENTAL|Phase I - Dose Level 4|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
62008072|NCT00714246|EXPERIMENTAL|Phase I - Dose Level 5|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.3 mg/m2 (Day 1,4,8,11)
62008073|NCT00714246|EXPERIMENTAL|Phase II|Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
62008074|NCT06663098|EXPERIMENTAL|Arm 1|re-challenge chemotherapy plus atezolizumab 1200 mg flat dosing
62008075|NCT00654524|EXPERIMENTAL|1|Patients in this arm will be treated with goserelin depot-3.6mg plus add-back therapy.
62008076|NCT00654524|NO_INTERVENTION|2|The patient with advanced endometriosis（stage III-IV）confirmed histologically after conservative laparoscopic surgery will be suggested to prepare for spontaneous pregnancy rather than any medical administration.
62008077|NCT01323569|PLACEBO_COMPARATOR|Placebo|
62008078|NCT01323569|EXPERIMENTAL|Sativex 4 sprays|
62008079|NCT01323569|EXPERIMENTAL|Sativex 8 sprays|
62008080|NCT01323569|EXPERIMENTAL|Sativex 16 sprays|
62008081|NCT01323569|ACTIVE_COMPARATOR|Marinol low dose|
62008082|NCT01323569|ACTIVE_COMPARATOR|Marinol high dose|
62008083|NCT00649116|EXPERIMENTAL|1|Metoprolol Tartrate Tablets 100 mg
62573354|NCT00887575|EXPERIMENTAL|Dose Level I|"Neoadjuvant - Paclitaxel IV (70 mg/m\^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 5) day 1 of every cycle and Sunitinib PO (25mg) daily.~Maintenance - Sunitinib PO (25mg) daily"
62008084|NCT00649116|ACTIVE_COMPARATOR|2|Lopressor® Tablets 100 mg
62008085|NCT02645916|EXPERIMENTAL|DSGOST|admission to Danggui-Sayuk-Ga-Osuyu-Saenggang-tang granule
62008086|NCT02645916|PLACEBO_COMPARATOR|Placebo|admission to placebo
62008087|NCT01418781||Gout|Patients with ICD-9 for gout
62008088|NCT01418781||No Gout|Patients withOUT ICD-9 for gout
62573355|NCT00887575|EXPERIMENTAL|Dose Level II|Paclitaxel IV (80 mg/m\^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 5) day 1 of every cycle and Sunitinib PO (25mg) daily.
62008089|NCT01418781||Tophaceous gout|Patients with ICD-9 for tophaceous gout
62008090|NCT01418781||non-tophaceous gout|those with ICD-9 for gout other than the codes specific for tophaceous gout
62008091|NCT03362840|EXPERIMENTAL|Early Start Denver Model (ESDM) group|The ESDM is a manualized comprehensive treatment model for young children (12-48 months). In the preschool based ESDM, learning objectives are guided by the ESDM curriculum checklist, which includes developmental skills in language, play, motor skills, personal independence, imitation and cognition.
62008092|NCT03362840|ACTIVE_COMPARATOR|Eclectic preschool intervention group|The eclectic approach consists of a combination of methods from several treatment-models. Individualized educational plans are based on multi-disciplinary assessment, and include objectives in several domains - communication, social-skills, play, emotional adjustment, adaptive daily skills, motor skills and cognition. They are presented to parents at the beginning of the year and are reviewed by the staff three times a year.
62008093|NCT01294189||ICU-patients that died on the ICU|ICU-patients (post-operative and non operative patients) will be enrolled in the study. All patients are followed until their death on the ICU.
62008094|NCT06390475||Chronic splanhnic thrombosis|Chronic Splanchnic vein thrombosis is defined by incident SVT with chronic thrombi on 2 serial imaging tests with an at least 3 months interval.
62193559|NCT01551368|PLACEBO_COMPARATOR|Placebo|Same as for nimodipine but an identical placebo will be self-administered.
62193560|NCT02332902|EXPERIMENTAL|Intervention|This is a single arm intervention using Everolimus
62193561|NCT00502268|PLACEBO_COMPARATOR|Group 1|Doxercalciferol administration by DOQI and 2nd Gen PTH assay
62193562|NCT00502268|ACTIVE_COMPARATOR|Group 2|Doxercalciferol administered by 1-84-7-84 ratio between 1.4-1.6
62008095|NCT06390475||Acute splanchnic thrombosis|Acute splanchnic vein thrombosis is defined as acute symptomatic or acute incidental asymptomatic thrombosis in the mesenteric, splenic, portal or hepatic veins. Acute symptomatic thrombosis refers to acute onset (\< 2 week existent) of symptoms characteristic for SVT thrombosis (including but not limited to abdominal pain) with SVT confirmed with DUS, CTA or MRA, dependent on the anatomical location. Acute incidental asymptomatic thrombosis refers to an incidentally detected SVT with DUS, CTA or MRA, absent on previous diagnostic tests performed in the last 2 weeks before the new incidental finding, in patients without symptoms characteristic of SVT.
62008096|NCT04142541|EXPERIMENTAL|Carotid artery stenting with Neuroguard IEP System|To evaluate the safety and feasibility of the Neuroguard IEP System when used in patients with clinically significant carotid artery stenosis requiring revascularization.
62008097|NCT01158924|EXPERIMENTAL|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
62008098|NCT00902356|ACTIVE_COMPARATOR|B|Six female subjects in each of cohorts 1 to 5 will receive AMG 167; six male subjects in each of cohorts 6 and 8; three female subjects in each of cohorts 7 and 9.
62008099|NCT00902356|PLACEBO_COMPARATOR|A|Two female subjects in each of cohorts 1 to 5 will receive placebo; two male subjects in each of cohorts 6 and 8; and 1 female subject in each of cohorts 7 and 9.
62193563|NCT01882764|EXPERIMENTAL|HMPL-004 1800 mg/day|"Subjects qualifying for entry into the Maintenance Phase of the study were randomized to take an oral dose of HMPL-004 (600 mg TID; total dose 1800 mg/day) daily, for 52 weeks.~Those subjects who demonstrated clinical remission or response after completing the HMPL-004-03 Induction Study, or after completing the Open Label Phase of this study, were eligible for enrollment in the Maintenance Phase of this study."
62193564|NCT01882764|PLACEBO_COMPARATOR|Placebo|"Subjects qualifying for entry into the Maintenance Phase of the study were randomized to take an oral dose of Placebo tablets TID, daily, for 52 weeks.~Those subjects who demonstrated clinical remission or response after completing the HMPL-004-03 Induction Study, or after completing the Open Label Phase of this study, were eligible for enrollment in the Maintenance Phase of this study."
62193565|NCT05396508|ACTIVE_COMPARATOR|physical therapy|physical therapy
62193566|NCT05396508|ACTIVE_COMPARATOR|physical therapy + interfacial injection|physical therapy + interfascial injection
62193567|NCT04515407|OTHER|Order 1|All participants will receive PAS in three experimental conditions, randomized to the order of condition. Experimental order will be counterbalanced across participants. Order 1 will be: Seated@Rest, Seated@Active, Walking.
62398249|NCT06537414|EXPERIMENTAL|Treatment Arm 2B: DAP/TOM + Bepirovirsen|Participants with low HBsAg level will receive dose level 2 of DAP/TOM in Treatment Stage 1. After DAP/TOM treatment, eligible participants will receive bepirovirsen in Treatment Stage 2. All participants will continue background NA treatment throughout these treatment stages. After bepirovirsen Treatment Stage, participants will be observed during the NA Only Stage, while maintaining background NA treatment. Eligible participants will then discontinue background NA treatment.
62193568|NCT04515407|OTHER|Order 2|All participants will receive PAS in three experimental conditions, randomized to the order of condition. Experimental order will be counterbalanced across participants. Order 2 will be: Seated@Active, Walking, Seated@Rest.
62214884|NCT04310280|PLACEBO_COMPARATOR|0.9% saline solution|The wound surface is treated with conventional wound care in a daily matter for 7 days. Allocation is randomized.
62782012|NCT05179759|ACTIVE_COMPARATOR|Enhanced Usual Care - Year 4: Clusters (schools) and associated participants assigned to sequence 2|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
62782013|NCT01990612|NO_INTERVENTION|Expectant Management|Expectant management (unless a medical indication arises) until at least 40 weeks 5 days.
62193569|NCT04515407|OTHER|Order 3|All participants will receive PAS in three experimental conditions, randomized to the order of condition. Experimental order will be counterbalanced across participants. Order 3 will be: Walking, Seated@Rest, Seated@Active.
62193570|NCT06450236|EXPERIMENTAL|Perampanel Tablets|Perampanel 10mg Tablets
62193571|NCT06450236|ACTIVE_COMPARATOR|Fycompa film-coated tablets|Fycompa 10mg film-coated tablets (Perampanel 10mg)
62193572|NCT00547534|EXPERIMENTAL|Lymphoma Subjects receiving protocol therapy|Subjects that met all eligibility criteria and were treated with Bendamustine, Rituxan and Bortezomib.
62782014|NCT01990612|OTHER|Elective Induction of Labor|Elective induction of labor between 39 weeks 0 days and 39 weeks 4 days
62573356|NCT00887575|EXPERIMENTAL|Dose Level III|Paclitaxel IV (80 mg/m\^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 6) day 1 of every cycle and Sunitinib PO (25mg) daily.
62782015|NCT02864160|EXPERIMENTAL|Health Coaching|The health coaching intervention group (n=100) will receive written educational materials on diabetes self-management in Spanish and the diabetes self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish). In addition, patients in the intervention group will be assigned a health coach who will provide health coaching over the course of 6 months with 14 phone calls.
62193573|NCT03792490|EXPERIMENTAL|Fasudil 30 mg|Fasudil (Fasudil hydrochloride hydrate IV solution) Dosage form: intravenous, application over 45 minutes Dosage: 30 mg/ day Frequency: 2 x 15 mg Duration of treatment: 20 days
62193574|NCT03792490|EXPERIMENTAL|Fasudil 60 mg|Fasudil (Fasudil hydrochloride hydrate IV solution) Dosage form: intravenous, application over 45 minutes Dosage: 60 mg/ day Frequency: 2 x 30 mg Duration of treatment: 20 days
62193575|NCT03792490|PLACEBO_COMPARATOR|Placebo|Sodium chloride (NaCl) 0.9% Dosage form: intravenous, application over 45 minutes Dosage: 100 ml Frequency: 2 x Duration of treatment: 20 days Do2 x 1 ml, NaCl 0.9%
62193576|NCT01065467|EXPERIMENTAL|Treatment|LBH589
62193577|NCT04588766||constipation group|Constipation symptoms of individuals with cerebral palsy who were randomly evaluated were questioned and recorded according to Rome IV criteria. The group with cerebral palsy constipation was included in this group.
62193578|NCT04588766||control group|Constipation symptoms of individuals with cerebral palsy who were evaluated randomly were questioned and recorded according to Rome IV criteria. The group with cerebral palsy without constipation was included in this group.
62193579|NCT04337671|EXPERIMENTAL|Training group (A)|The training was a moderate intensity aerobic training on a bicycle ergo-meter(corresponding to 60% to 70% of the maximal heart rate they reach during peak oxygen uptake in the initial exercise test) for 30 to 45 min/day, 3 sessions/week for 12 weeks (36 sessions). In addition to their prescribed medications.
62573357|NCT01010412|EXPERIMENTAL|Ultrasound|Ultrasound guided nerve localization through direct visualization of the nerves and surrounding structures.
62193580|NCT04337671|NO_INTERVENTION|control group (B)|Control group not receiving any training . They are taking their prescribed medications only.
62193581|NCT02043743|EXPERIMENTAL|Laboratory and Clinical|"Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.~Stem Cell Dose:~•3-5 Million Autologous MSCs Injected into Ovarian tissue."
62193582|NCT05585645|EXPERIMENTAL|Stimus|"NNG-DEPO (Darbepoetin alfa 10 mcg/0.4 mL, 20 mcg/0.5 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL) is available as a prefilled syringe in a sterile, colorless, glass tube.~Storage: 2-8ºC, not frozen. The process of transporting and storing the drug must ensure the temperature in the range of 2-8ºC.~NNG-DEPO/Aranesp is administered subcutaneously (or intravenously) at a dose of 0.75 g/kg initially, every 2 weeks at the second visit.~Study drug will be prepared according to standard procedure (SOP). Dosage adjustment guideline:~Patients will have hemoglobin levels monitored every 2 weeks. The investigators will evaluate and adjust the dose of Darbepoetin alfa to maintain the Hb levels within the target range (10 - 12 g/dL)"
62573358|NCT01010412|ACTIVE_COMPARATOR|Nerve Stimulation|Standard of Care
62573359|NCT02449031||TOBI® PODHALER® cohort|
62573360|NCT02449031||non-TOBI® PODHALER® cohort|Approximately 250 patients treated with other FDA-approved inhaled antipseudomonal antibacterial drugs at enrollment
62573361|NCT05456178||Adult subjects with chronic obstructive pulmonary disease|In adult patients with chronic obstructive pulmonary disease, an electrostatic wipe will be deposited in the living room and another one in the bedroom for 12 weeks, to be analyzed by the mycology laboratory of the Croix-Rousse hospital, Lyon.
62008100|NCT03380923|EXPERIMENTAL|Moderate Intensity (MOD)|"Endurance Training (ET): 3 d/wk x 30 minutes (min) of steady-state, moderate-intensity exercise on a treadmill or stationary cycle ergometer at target heart rate (HR) = 65-75% of maximum oxygen consumption rate (VO2max). The two modes (treadmill, bicycle) are offered for variety, and each subject is required to use each mode at least 1 d/wk to prevent bias.~Resistance training (RT): 2 d/wk consisting of a prescription engaging all major muscle groups in 10 movements. Excluding abdominal crunches, target intensity is 12 repetitions/set to volitional fatigue. Subjects complete 3 sets of each movement, with \~60 seconds (s) rest between sets. For each movement, resistance increases when 14 repetitions are achieved for 2 of 3 sets.~HR is monitored throughout each session and stored for analysis."
62008101|NCT03380923|EXPERIMENTAL|High Intensity (HI)|"RT: The 2 d/wk RT prescription differs from the MOD arm only in intensity and rest intervals. The same approach to progression applies, but HI RT intensity targets 8-10 repetitions per set; thus, resistance loads increase when 10 repetitions are achieved for 2 of 3 sets. The HI arm performs superset training, pairing movements stressing different muscle groups, with only 30-45 s between.~ET: In lieu of steady-state endurance exercise, the HI arm performs high-intensity interval training (HIIT) 3 d/wk using a mix of challenging, explosive movements at maximal intensity. 10 x 30 s maximal intensity intervals are separated by 30 s rest intervals.~HR is monitored throughout each session and stored for analysis."
62008102|NCT04958733|ACTIVE_COMPARATOR|Autologous Bone Grafting|Excess bone obtained from graft preparation and the coring reamer will be used to fill the patellar and tibial donor sites.
62008103|NCT04958733|PLACEBO_COMPARATOR|Control|The control group will have their patellar and tibial defects remain unfilled.
62008104|NCT03082794|EXPERIMENTAL|Study group I|Study group I (53 participants) received the NCD (details of diet: 15% protein, 75% carbohydrates, 10% fat). Both groups had 15% caloric restriction from their maintenance energy requirements.
62008105|NCT03082794|EXPERIMENTAL|Study group II|Study group II (51 participants) received the LCD or healthy weight maintenance diet (details of diet: 15% protein, 55% carbohydrates, 30% fat).Both groups had 15% caloric restriction from their maintenance energy requirements.
62008106|NCT00947622|PLACEBO_COMPARATOR|Placebo stimulation|Placebo stimulation at the occipital head area for 1800 seconds at 0 mA, three times a week, during one week (with seconds of stimulation to get onset tingling sensation)
62008107|NCT00947622|EXPERIMENTAL|Effective transcranial stimulation|Effective stimulation at the occipital head are for 1800 seconds at 2 mA, 3 times a week for 1 week
62008108|NCT03358576|EXPERIMENTAL|Sulopenem|Sulopenem 1000 mg IV once daily for at least 5 days, followed by Sulopenem-Etzadroxil/Probenecid 500 mg PO twice daily to complete 7-10 days of treatment
62573362|NCT05368818||All patients|Included all patients prescribed an on-label secukinumab dose
62008109|NCT03358576|ACTIVE_COMPARATOR|Ertapenem|Ertapenem 1000 mg IV once daily for at least 5 days, followed by ciprofloxacin 500 mg PO twice daily along with metronidazole 500 mg PO four times daily. If patient is found to have causative pathogens that are resistant to ciprofloxacin they will receive amoxicillin-clavulanate 875 mg PO twice daily instead
62193583|NCT05585645|ACTIVE_COMPARATOR|Aranesp|"Aranesp® (Darbepoetin alfa 10 mcg/ 0.4 mL, 20 mcg/ 0.5 mL, 40 mcg/ 0.4 mL, 60 mcg/ 0.3 mL) is manufactured by Amgen, as a pre-filled syringe in a sterile, glass tube, colourless.~Storage: 2-8ºC, not frozen. The process of transporting and storing the drug must ensure the temperature in the range of 2-8ºC.~NNG-DEPO/Aranesp is administered subcutaneously (or intravenously) at a dose of 0.75 g/kg initially, every 2 weeks at the second visit.~Study drug will be prepared according to standard procedure (SOP). Dosage adjustment guideline:~Patients will have hemoglobin levels monitored every 2 weeks. The investigators will evaluate and adjust the dose of Darbepoetin alfa to maintain the Hb levels within the target range (10 - 12 g/dL)"
62193584|NCT03815370|PLACEBO_COMPARATOR|Usual Care|"The current approach for temporary coverage of abdomen is called vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site."
62193585|NCT03815370|EXPERIMENTAL|Device: ABRO™Binder Arm|Intervention is the usual care (listed above) plus a novel new abdominal binder device called ABRO™
62193586|NCT01731262||RA group|expression of Shh pathway associated factors from peripheral blood mononuclear cells or synovial tissues will be detected
62193587|NCT01731262||control group|expression of Shh pathway associated factors from peripheral blood mononuclear cells or synovial tissues will be detected
62782016|NCT02864160|ACTIVE_COMPARATOR|Comparison group|The comparison group (n=100) will receive the standard diabetes care that is offered at Heart of Ohio clinics including consultations with a primary care provider, a dietician, a pharmacist, and a diabetes educator. The comparison group will receive written educational materials on diabetes self-management in Spanish and diabetes self-management tools including a stretch band, a glucometer, and a diabetes cookbook in Spanish.
62193588|NCT02688530|PLACEBO_COMPARATOR|0mg IV Dexamethasone|0mg IV Dexamethasone
62193589|NCT02688530|EXPERIMENTAL|4mg IV Dexamethasone|4mg IV Dexamethasone
62193590|NCT02688530|EXPERIMENTAL|6mg IV Dexamethasone|6mg IV Dexamethasone
62193591|NCT02688530|EXPERIMENTAL|8mg IV Dexamethasone|8mg IV Dexamethasone
62193592|NCT05775783||Consecutive patients with CIEDs, treated with TLE (infections)|
62193593|NCT05775783||Consecutive patients with CIEDs, treated with TLE (no-infections)|
62193594|NCT05502822|ACTIVE_COMPARATOR|real stimulation|Stimulation electrodes were arranged in a 4 × 1 ring configuration at F1, F2, C1 ,C2 and FCz, with the central one delivering an alternating current 2 mA and the surrounding 4 electrodes delivering one-fourth of the central electrode's current in the opposite polarity. The average peak-to-peak stimulation intensity across participants was 2 mA for the 6-Hz tACS. Participants will receive real tACS once daily for two weeks.
62193595|NCT05502822|SHAM_COMPARATOR|sham stimulation|In the sham condition, 6-Hz tACS was delivered only during the ramp-up and ramp-down periods (30 s); no current was delivered during the 30-minute intervention. Participants will receive sham tDCS once daily for two weeks.
62193596|NCT03985436|EXPERIMENTAL|Trek for Surgical Success|Cognitive behavioral therapy for pain
62193597|NCT03242902|EXPERIMENTAL|Light intensity 1|The light intervention includes exposure to white light (10.000 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
62193598|NCT03242902|EXPERIMENTAL|Light intensity 2|The light intervention includes exposure to white light (10-20 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
62193599|NCT00947947|EXPERIMENTAL|intervention media condition|Received a stage tailored DVD-based intervention
62193600|NCT00947947|PLACEBO_COMPARATOR|standard of care|received only clinical standard of care
62193601|NCT04187859|OTHER|Education Session|The participant will receive an education session in their home, lasting between 15-30 minutes from a District Nurse. The District Nurses will advise the participant on how to drink more fluids, the importance of hydration and the effects of dehydration.
62193602|NCT04187859|OTHER|Prompting Cup|Participants will receive a Droplet Cup with an electronic prompting device and a brief tutorial session from the District Nurse. The Droplet Cup will encourage the participant to stay hydrated during the day, by emitting a voice or light to encourage them to drink more.
62193603|NCT04187859|NO_INTERVENTION|Control Group|There will be no change to the care the participant receives from the District Nurse.
62193604|NCT04187859|OTHER|Prompting Cup and Education|Participants will receive a Droplet Cup with an electronic prompting device and an education session on the importance of hydration and the effects of dehydration.
62193605|NCT02593383|EXPERIMENTAL|Treat group 1|Group 1: 0.1% Adapalene + 1% Clindamycin Hydrochloride
62193606|NCT02593383|EXPERIMENTAL|Treatment group 2|Group 2: 0.1% Adapalene + 2% Clindamycin Hydrochloride
62193607|NCT02593383|EXPERIMENTAL|Treatment group 3|Group 3: 0.05% Adapalene + 0.5% Clindamycin Hydrochloride
62193608|NCT02593383|EXPERIMENTAL|Treatment group 4|Group 4: 0.05% Adapalene + 1% Clindamycin Hydrochloride
62193609|NCT02593383|PLACEBO_COMPARATOR|Placebo group|Placebo Group: Blank Gel
62193610|NCT03755973|EXPERIMENTAL|CFA plus step-down rFSH (1A)|"A single dose of 150 IU of CFA followed by daily rFSH will be administered. The initial rFSH administration will be dosed between 100 IU and 200 IU according to the following criteria:~* 200 or 300 IU: \<3 follicles above 13 mm visible on transvaginal ultrasound;~* 150 IU, \>2 follicles above 13 mm and circulating day-8 follicle-stimulating hormone (FSH) levels ≤20 IU/mL.~* 100 IU, \>2 follicles above 13 mm and circulating day-8 FSH levels \>20 IU/mL;~Subjects will perform a step-down daily rFSH dose (fixed decreases in the dosing of 25 IU/day) until the triggering criteria are met or a minimum of 50 IU/day is reached. Subjects with \<3 follicles above 13 mm visible will maintain 200 IU/day of rFSH until this criterion is met, initiating a fixed 25 IU/day stepdown protocol only from then onwards."
62193611|NCT03755973|EXPERIMENTAL|CFA plus fixed daily dose rFSH (1B)|A single dose of 150 IU of CFA followed by a fixed daily rFSH dosing protocol of 200 or 300 IU will be administered as ovarian stimulation
62782017|NCT05620264||Keratitis Group|Patients with clinically suspected bacterial or fungal keratitis
62193612|NCT03755973|ACTIVE_COMPARATOR|Fixed daily dose rFSH only|A fixed daily rFSH dosing protocol of 200 or 300 IU will be administered as ovarian stimulation
62193613|NCT04936685|EXPERIMENTAL|Group 1|Participants will receive a first booster dose of MenACYW conjugate vaccine at Day 1 and a second booster dose at year 5 of study MEQ00073
62193614|NCT04936685|EXPERIMENTAL|Group 2|Participants will receive a single booster dose of MenACYW conjugate vaccine at year 5 of study MEQ00073
62193615|NCT01744704|EXPERIMENTAL|rhNGF 0.5 µg/mL Sentinel|1 x 35 µL drop 3 subjects
62193616|NCT01744704|EXPERIMENTAL|rhNGF 5 µg/mL Sentinel|1 x 35 µL drop 3 subjects
62193617|NCT01744704|EXPERIMENTAL|rhNGF 60 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
62193618|NCT01744704|EXPERIMENTAL|rhNGF 20 µg/mL Sentinel|1 x 35 µL drop 3 subjects
62193619|NCT01744704|EXPERIMENTAL|rhNGF 20 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
62193620|NCT01744704|EXPERIMENTAL|rhNGF 180 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
62193621|NCT01744704|PLACEBO_COMPARATOR|Placebo Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
62193622|NCT01744704|EXPERIMENTAL|rhNGF 20 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 12 subjects
62193623|NCT01744704|EXPERIMENTAL|rhNGF 60 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
62193624|NCT01744704|EXPERIMENTAL|rhNGF 180 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
62193625|NCT01744704|PLACEBO_COMPARATOR|Placebo Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 10 subjects
62193626|NCT00651898||A|This group will receive the circulating water garment
62193627|NCT00651898||B|This group will receive the circulating water mattress and be covered by a forced air warming device for both the upper body and lower body connected to two warmers.
62193628|NCT03851081|EXPERIMENTAL|Treatment (inotuzumab ozogamicin, liposomal vincristine)|See Detailed Description.
62193629|NCT03078335|EXPERIMENTAL|Glove based care|The intervention is the use of non-sterile gloves, after standard hand hygiene for all routine patient care needs.
62193630|NCT03078335|ACTIVE_COMPARATOR|Standard care|The control group will provide standard care, that is, hand hygiene before all patient, bed, and intravenous catheter contact.
62398250|NCT06537414|EXPERIMENTAL|Treatment Arm 2C: Placebo + Bepirovirsen|Participants with low HBsAg level will receive Placebo in Treatment Stage 1. After Placebo treatment, eligible participants will receive bepirovirsen in Treatment Stage 2. All participants will continue background NA treatment throughout these treatment stages. After bepirovirsen Treatment Stage, participants will be observed during the NA Only Stage, while maintaining background NA treatment. Eligible participants will then discontinue background NA treatment.
62398251|NCT03326323||Patients undergoing ANH during CABG|Patients undergoing Acute Normovolemic Hemodilution during CABG surgery.
62193631|NCT00325598|EXPERIMENTAL|Cohort 1 (36 Gy)|36 Gy in 9 fractions BID x 4 1/2 treatment days
62193632|NCT00325598|EXPERIMENTAL|Cohort 2 (40 Gy)|40 Gy in 10 fractions BID over 5 treatment days
62193633|NCT05020145||Immunocompromised|Vaccinated Subject with 1 or \>1 immunocompromising conditions.
62193634|NCT05020145||Non-Immunocompromised|Vaccinated subjects without evidence of immunocompromising condition.
62193635|NCT05020145||Total Population (immunocompromised and non)|Vaccinated Subjects with or without 1 or \>1 immunocompromising conditions.
62193636|NCT05536206||Observed patients|Adult patients (≥18 years) admitted with an acute medical disease and who are scheduled for discharge to their own homes within five days from inclusion.
62193637|NCT05219838|EXPERIMENTAL|Lu AG06466 Low Dose|Participants will receive Lu AG06466 low dose capsule orally once daily for 6 days approximately 30 minutes following a light meal.
62193638|NCT05219838|EXPERIMENTAL|Lu AG06466 High Dose|Participants will receive Lu AG06466 high dose capsule orally once daily for 6 days approximately 30 minutes following a light meal.
62193639|NCT05864404|EXPERIMENTAL|remimazolam-remifentanil (RR group)|
62193640|NCT05864404|ACTIVE_COMPARATOR|dexmedetomidine-remifentanil (DR group)|
62193641|NCT04036851|NO_INTERVENTION|Local standard of care|Women receive integrated antenatal and HIV services during pregnancy and are referred to general adult HIV services after delivery; no standardized peer support groups exist for this patient population.
62193642|NCT04036851|EXPERIMENTAL|Peer support intervention|Women will be invited to attend monthly peer support groups during pregnancy and postpartum, separate from any routine health services.
62193643|NCT05037747|EXPERIMENTAL|Time-restricted feeding(TRF)|The TRF group was asked to restrict the eating window to 8 hours a day, during waking hours and also continue a low-protein diet.
62193644|NCT05037747|NO_INTERVENTION|Control|The control group was asked to continue their usual low-protein diet eating schedule and pattern.
62193645|NCT05859490|EXPERIMENTAL|Vaccination arm|Participants will receive a standard dose of of the yellow fever vaccine 17D (YFVax(r)), 0.5mL suspension in normal saline administered subcutaneously once.
62398252|NCT04506658|EXPERIMENTAL|Intervention group|
62008110|NCT04425499|PLACEBO_COMPARATOR|Control group|On GEN (Gamified Educational Network), each student will view individually eight videos of an expert performing a running subcuticular suture correctly. The OSATS (Objective Structured Assessment of Technical Skills) Global Rating Scale (GRS) and Subcuticular Suture Checklist will be available beside each video and students will be required to fill them out for each video. For three days, students will have access to a distinct set of videos on GEN to learn running subcuticular sutures. Three days later, students will view the same eight videos of an expert performing a running subcuticular suture, however, the videos will be shuffled in a different order. The order of the videos will be the same for all students.
62573363|NCT05368818||Patients with Psoriatic Arthritis (PsA)|Included patients classified as having a concomitant PsA diagnosis, if it was declared in the Baseline table
62008111|NCT04425499|EXPERIMENTAL|Self-learning|Each student will view eight videos individually and complete the GRS and Subcuticular Suture Checklist for each video. Six videos will contain errors and two videos will not. The errors will be technical mistakes in the execution of a running subcuticular suture. For three days, students will have access to a distinct set of videos on GEN to learn running subcuticular sutures. Three days later, all students will repeat this activity. However, the same videos will be shuffled in a different order. The order of the videos will be the same for all students.
62008112|NCT04425499|EXPERIMENTAL|Peer-learning|Each student will view eight videos and complete the GRS and Subcuticular Suture Checklist for each video. Six videos will contain errors and two videos will not. After this initial test, students will interact with other medical students in their group on the GEN platform anonymously for three days. We will display distinct videos on GEN. Comments will be allowed in an interactive way to encourage exchanges. Students will be required to participate in the discussion of at least two videos. Students will not be able to modify their answers on the initial test. On the third day, students in this group will perform a post-test individually with the same eight initial videos but shuffled. The order of the videos will be the same for all students.
62193646|NCT00592189|EXPERIMENTAL|1|Amnion tissue and blood collection
62193647|NCT05257447|EXPERIMENTAL|Baclofen 20mg tablet|Single oral dose of baclofen, 20 mg
62193648|NCT05257447|EXPERIMENTAL|Chlorzoxazone 500mg tablet|Single oral dose of chlorzoxazone, 500 mg
62193649|NCT05257447|EXPERIMENTAL|Baclofen 20 mg tablet and chlorzoxazone 500 mg tablet|Concurrent doses of baclofen, 20 mg, and chlorzoxazone, 500 mg
62193650|NCT03209869|EXPERIMENTAL|Single arm|All subjects will receive Ex vivo Expanded and Activated Haploidentical Donor NK Cells + hu14.18-IL2
62398253|NCT04506658|SHAM_COMPARATOR|Control group|
62573364|NCT04103892|EXPERIMENTAL|Part A - CLE-100 (oral esketamine)|Part A: 1 oral tablet of CLE-100 once daily for 1 week.
62573365|NCT04103892|PLACEBO_COMPARATOR|Part A - Placebo|Part A: 1 oral tablet of Placebo once daily for 1 week.
62193651|NCT02615509|OTHER|Imaging on experimental tomo device|"Women will have a bilateral two-view mammogram (a total of four images) with the Philips MicroDose Tomosynthesis system and a bilateral two-view mammogram (a total of four images) with an FFDM system. The order of this will be randomised.~After collecting the cases together with ground truth a readers study will be performed."
62193652|NCT01573949|EXPERIMENTAL|Metformin|Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
62214885|NCT05498987|EXPERIMENTAL|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant Achilles Tendon|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant Achilles Tendon
62214886|NCT03688451|EXPERIMENTAL|Intrathecal rituximab|Cohort 1: 10 mg dose, day 1 chemotherapy cycles 2-5 Cohort 2: 20 mg dose, day 1 chemotherapy cycles 2-5
62214887|NCT05485545|OTHER|Fallot group|Patient with Fallot Tetralogy operated
62214888|NCT05485545|OTHER|Control group|Patient benefiting from electrophysiological exploration for a healthy heart arrhythmia
62214889|NCT00350350||elderly people|elderly people over 70 years residents of old's people homes with symptoms of dry mouth
62214890|NCT00751387||1|
62398254|NCT05819775|EXPERIMENTAL|CSL312|Ages 2-5 years and 6-11 years will have specific subcutaneous dosing schedules
62398255|NCT06724939|ACTIVE_COMPARATOR|3M bulk-fill composite resin class I|class I bulk-fill composite
62398256|NCT06724939|ACTIVE_COMPARATOR|3M bulk-fill compsite resin class II|class I bulk-fill
62573366|NCT04103892|EXPERIMENTAL|Part B - CLE-100 (oral esketamine)|Part B: 1 oral tablet of CLE-100 once daily for 4 weeks.
62573367|NCT04103892|PLACEBO_COMPARATOR|Part B - Placebo|Part B: 1 oral tablet of Placebo once daily for 4 weeks.
62573368|NCT03084107|EXPERIMENTAL|Questionnaire|technology acceptance model (TAM) questionnaire
62573369|NCT02183883|EXPERIMENTAL|Afatinib|Afatinib, tablet, 40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision
62193653|NCT01864460|EXPERIMENTAL|Diet, Physical Activity and Balance Enhancement Program (DPAE|Subjects in the DPAEP group will undergo a structured weight loss for approximately 6 months, followed by approximately 6 months of weight maintenance, as well as 12 months of aerobic exercise. This intervention stresses a personalized program emphasizing activities that are meaningful to and are tailored to individual participants; provides consistent contact between the participants and research staff; and allows monitoring of activity levels using questionnaires, actigraphy, monitoring of heart rate, direct and telephone contact. Participants dietary and physical activity goals as assessed by the dietician and trainer will be discussed at face-to face meetings to re-establish these goals. These programs will be tailored to meet the realistic goals of the individual participant. The program stresses aerobic exercise, rather than other types of exercise interventions, as aerobic exercise appears to correlate best with improved autonomic function.
62573370|NCT04668248|EXPERIMENTAL|Simulation intervention|Providers assigned to the intervention arm will participate in a short simulation training at the beginning of their 2-week block (planned for their second day). The training will take place at the Neil and Elise Wallace STRATUS Center for Medical Simulation at Brigham and Women's Hospital and will follow all of their recommended and hospital-recommended practices on social distancing, including the learning limits.
62193654|NCT01864460|ACTIVE_COMPARATOR|Standard Care (SC)|The SC group will be assigned an interventionist assessor. This assessor will meet with the subjects during their orientation meeting and will be provided guidelines and a weight loss and physical activity target to achieve by the end of the program at their orientation meeting. Participants will contacted approximately weekly during the approximate 12 month period.
62193655|NCT01675349|EXPERIMENTAL|Chenopodium album allergen extract|Four concentrations of Chenopodium album allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
62193656|NCT02737813|EXPERIMENTAL|Isobaric Marcaine|Isobaric Marcaine 2.2 mL for spinal block
62193657|NCT02737813|ACTIVE_COMPARATOR|Hyperbaric Marcaine|Hyperbaric Marcaine 2.2 mL for spinal block
62193658|NCT01948076|PLACEBO_COMPARATOR|resident without GE vscan|baseline physical exam use
62193659|NCT01948076|ACTIVE_COMPARATOR|resident with GE vscan|residents with augmentation of physical exam by ultrasound
62193660|NCT06337487|EXPERIMENTAL|Patients|Quality of life and satisfaction assessment
62008113|NCT04425499|EXPERIMENTAL|Peer-learning with expert feedback|"Same as group 3, the only difference is that an expert will actively participate in the discussion by commenting on each video on GEN, enhancing students' educational experience. Although anonymous, students will be able to identify the expert as the name expert will be used. The expert will answer any question and comment on the discussion in order to guide the students."
62008114|NCT05218174|EXPERIMENTAL|Exercise training program|"Participants in this arm will complete an 8-week exercise training program comprised of an initial functional assessment to create an exercise prescription, followed by 7 in-person weekly sessions. Each session consisting of approximately 50 minutes of individualized exercise training and approximately 10 minutes of cognitive training via the Sports Academy CogPT iPad app. All participants will receive exercise and cognitive training delivered weekly in a group-based setting at Sports Academy within the Star in Frisco, Texas during the intervention period. Additionally, they will have access to daily workouts pushed to their phone via the MOVE exercise app developed by our team."
62008115|NCT05218174|SHAM_COMPARATOR|No training program|Participants in this arm will be wearing the WHOOP band for 8-weeks but will not be exposed to any active intervention.
62008116|NCT02685774|OTHER|RT group|R: Reference drug(Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T) T: Test drug(CKD-395 0.25/500mg 2T)
62008117|NCT02685774|OTHER|TR group|T: Test drug(CKD-395 0.25/500mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T)
62008118|NCT01006811|EXPERIMENTAL|modified Atkins diet|
62008119|NCT02583256|EXPERIMENTAL|aQIV/aQIV|Subjects previously vaccinated with aQIV followed one year later by aQIV
62008120|NCT02583256|EXPERIMENTAL|aQIV/QIV|Subjects previously vaccinated with aQIV followed one year later by QIV
62008121|NCT02583256|EXPERIMENTAL|QIV/aQIV|Subjects previously vaccinated with QIV followed one year later by aQIV
62008122|NCT02583256|EXPERIMENTAL|QIV/QIV|Subjects previously vaccinated with QIV followed one year later by QIV
62193661|NCT06337487|OTHER|Nurses|Assess the value of nurses using the Quality of Life (QoL) scores from the EORTC QLQ-C30 questionnaire to help identify SOS needs at the start of care.
62193662|NCT06337487|OTHER|Health professionals and professionals assimilated to the health|ORIC questionnaire
62193663|NCT06251999|EXPERIMENTAL|fospropofol|
62193664|NCT06251999|PLACEBO_COMPARATOR|propofol|
62193665|NCT03752086|EXPERIMENTAL|Greater omentum binding|Bind greater omentum to pancreatic stump after distal pancreatectomy
62193666|NCT03752086|EXPERIMENTAL|Pancreatic stump exposed|pancreatic stump exposed without binding greater omentum after distal pancreatectomy
62573371|NCT04668248|ACTIVE_COMPARATOR|Online education intervention|Providers assigned to the control arm will receive online educational training about other poorly-prescribed medications, including albumin, transfusion, and blood product repletion guidelines.
62573372|NCT06577480||Liver transplant recipients|
62573373|NCT04781283|EXPERIMENTAL|specular microscopy|The density measurement is a painless and very brief examination (less than a minute) during which the patient places his head on a chin rest while maintaining his forehead on a bar provided for this purpose while looking straight ahead. The measurements are then taken without contact with the patient's eye.
62573374|NCT06256952|EXPERIMENTAL|Control (HC) - exclusion first|Healthy participants without SUD Cyberball: Exclusion Day 1; Cyberball: Inclusion Day 2
62782018|NCT04757545|ACTIVE_COMPARATOR|HM-PRO intervention|The intervention group will have a predetermined nurseled consultation planned to assess medical status and symptom control at 0, 6 and 12 months. Seven days prior to the scheduled visit, the patient will receive an electronic invitation via RedCap to complete and send PRO data (HM-PRO). Prior to each appointment PRO data will be evaluated by a nurse from an algorithm deciding one of three tracks for the patients.
62782019|NCT04757545|NO_INTERVENTION|Standard outpatient follow-up care|The control group will receive standard care in the outpatient clinic. The patient has a predetermined consultation appointment at the hospital one time a year with a doctor to evaluate medical status and symptom control.
62193667|NCT05202756|EXPERIMENTAL|Mobile Application to Prevent Suicide (MAPS)|"Participants receiving MAPS will receive the Safety Planning Intervention (SPI) which will be uploaded into the smartphone app. They will be prompted four times per day to complete a brief ecological momentary assessment check-in inquiring about their cognitions, affect, and behavior, including suicidal thoughts and behaviors. Based on these responses, they will be provided with coping strategies from their safety plans and from a database of coping strategies created by study staff. They will also have access to emergency phone numbers, the coping strategies database, and can communicate with their study clinician through a text-like interface in the app. They will receive this intervention for one month."
62398257|NCT06724939|EXPERIMENTAL|surefil one class I|class I surefil one
62398258|NCT06724939|EXPERIMENTAL|surefil one class II|class II surefil one
62398259|NCT05631158||Early Parkinson's disease|All the participants will undergo five clinical examination, four MRI scans and one fasting blood test in total in this serial study.
62398260|NCT05631158||Healthy Controls|This cohort will undergo the same procedure of the patient's group.
62398261|NCT03498963|OTHER|bronchoalveolar lavage|
62398262|NCT06016296|EXPERIMENTAL|Upper middle level experimental groups|The intervention will be implemented by early childhood educators, who will be previously trained in Combined Movement and Storytelling Intervention (CMSI). Each session will take place in the classroom where the preschoolers usually attend, which will depend on the admission policies of each educational community regarding to level classes (upper middle). The intervention will last 12 weeks (36 sessions), distributed in 3 weekly sessions (Monday, Wednesday and Friday) of 40 minutes per session. The CMSI is based on 2 previous studies, and a book related to CMSI. Twelve unpublished motor stories were elaborated, of which one per week will be executed distributed in 3 sessions per week with the corresponding progressions for each session carried out, placing the children in a sequence of stories that begin with the presentation of a motivating character that will accompany children's in the development of the whole story.
62398263|NCT06016296|NO_INTERVENTION|Upper middle level control groups|The upper middle level control groups (n= 2 classes; n= 24 children) will participate in the assessments (initial and final) and will be asked to maintain their regular session of their educational establishments. At the end of the intervention period (according to the results obtained), the control groups children, parents and/or legal guardians, managers and coordinators of each community will be contacted and provided with the material so that they can replicate the experience. In addition, the educators of these establishments (teachers and classroom assistants) will be trained in the CMSI strategy.
62398264|NCT06016296|EXPERIMENTAL|Transition level 1 experimental groups|The intervention will be implemented by early childhood educators, who will be previously trained in Combined Movement and Storytelling Intervention (CMSI). Each session will take place in the classroom where the preschoolers usually attend, which will depend on the admission policies of each educational community regarding to level classes (transition level 1). The intervention will last 12 weeks (36 sessions), distributed in 3 weekly sessions (Monday, Wednesday and Friday) of 40 minutes per session. The CMSI is based on 2 previous studies, and a book related to CMSI. Twelve unpublished motor stories were elaborated, of which one per week will be executed distributed in 3 sessions per week with the corresponding progressions for each session carried out, placing the children in a sequence of stories that begin with the presentation of a motivating character that will accompany children's in the development of the whole story.
62193668|NCT05202756|ACTIVE_COMPARATOR|EMA Monitoring Only (EMO)|Participants in this condition will receive the Safety Planning Intervention (SPI) and will receive ecological momentary assessment prompts on the same schedule as the MAPS condition. However, they will not have access to any other MAPS features.
62193669|NCT06315920|EXPERIMENTAL|Parecoxib|40mg of IV Parecoxib
62398265|NCT06016296|NO_INTERVENTION|Transition level 1 control groups|The transition level 1 control groups (n= 2 classes; n= 24 children) will participate in the assessments (initial and final) and will be asked to maintain their regular session of their educational establishments. At the end of the intervention period (according to the results obtained), the control groups children, parents and/or legal guardians, managers and coordinators of each community will be contacted and provided with the material so that they can replicate the experience. In addition, the educators of these establishments (teachers and classroom assistants) will be trained in the CMSI strategy.
62573375|NCT06256952|EXPERIMENTAL|Control (HC) - inclusion first|Healthy participants without SUD Cyberball: Inclusion Day 1; Cyberball: Exclusion Day 2
62573376|NCT06256952|EXPERIMENTAL|Moderate to sever alcohol users (AUD) - exclusion first|Participants with alcohol use disorder (moderate to severe if no withdrawal symptoms) and no other substance use disorder (SUD) Cyberball: Exclusion Day 1; Cyberball: Inclusion Day 2
62573377|NCT06256952|EXPERIMENTAL|Moderate to sever alcohol users (AUD) - inclusion first|Participants with alcohol use disorder (moderate to severe if no withdrawal symptoms) and no other substance use disorder (SUD) Cyberball: Inclusion Day 1; Cyberball: Exclusion Day 2
62573378|NCT06043505|EXPERIMENTAL|Interventional Strategy: STOPFLUID Algorithm|Fluid management is optimised using the specific echographic hemodynamic algorithm ('STOPFLUID') of this study described during the first 4 days of septic shock. Fluid bolus will not be administered in case of increased left ventricle filling pressures; fluid challenge will be performed based on dynamic indices and fluid depletion will be considered on the basis of Lung UltraSound (LUS) assessment.
62573379|NCT06043505|NO_INTERVENTION|Standard Strategy|Fluid management will be handled according to standard care, without using transthoracic echocardiography (TTE) during the first 4 days of septic shock management. Haemodynamic monitoring including pulmonary artery catheter, transpulmonary thermodilution, or any other device will be left at the physician's discretion. TTE will be allowed in the standard group only for excluding cardiac tamponade in case of clinical suspicion (one or more of the following signs: jugular distension, pulsus paradoxus)
62573380|NCT03568292|EXPERIMENTAL|Arm I: Virtual Reality|Participants receive the VR intervention during bone marrow biopsy or lumbar puncture lasting until completion of the procedure. Participants will be trained to use VR equipment prior to the bone marrow biopsy or lumbar puncture. The headset will cover both eyes with a strap along the back to hold the headset in place. The headset will be attached by a wire to a laptop which will power the headset and provide content. A remote control will be available for assistance in setting up or stopping the content in the case of an event. The VR content will consist of meditation and relaxing techniques through visual and auditory input which can last up to one hour. There will be minimal stimulatory effort to decrease excess movement for the procedure.
62573381|NCT03568292|ACTIVE_COMPARATOR|Arm II: No Virtual Reality|Participants receive standard of care during bone marrow biopsy or lumbar puncture.
62573382|NCT04614025|EXPERIMENTAL|PLX-PAD Treatment|"PLX-PAD 300 million cells (20 million/mL) administered via 15 IM injections (1 mL each).~Single administration in addition to best standard medical care."
62573383|NCT04614025|NO_INTERVENTION|Control Group|Best standard medical care
62573384|NCT00234975|ACTIVE_COMPARATOR|HCV +|
62573385|NCT00234975|ACTIVE_COMPARATOR|HCV -|
62782020|NCT02878837|ACTIVE_COMPARATOR|DEX|Patients undergoing surgical procedures under regional anesthesia sedated with a loading dose of 1 µg/Kg of Dexmedetomidine over 10 minutes followed by continuous infusion at 0.2 to 0.8 µg/Kg/h, along with 0.5µg/Kg bolus breakthrough doses of Fentanyl as necessary to achieve a RASS score between -3 and -1.
62193670|NCT06315920|ACTIVE_COMPARATOR|Morphine|5 mg of IV Morphine
62193671|NCT00203034|EXPERIMENTAL|Experimental 1|0.5 mg rasagiline mesylate oral once daily
62573386|NCT04426721|EXPERIMENTAL|Ozone|Participant will receive an intraarticular injection of oxygen-ozone, once a week for three weeks. During procedure a clear ultrasound image is to be taken to document needle placement in the synovial space. The injector may choose the position of the knee (e.g., extended or bent) and the approach for the injection (e.g., medial or lateral).
62782021|NCT02878837|ACTIVE_COMPARATOR|MDZ|Patients undergoing surgical procedures under regional anesthesia sedated with a 0.05mg/Kg bolus dose of Midazolam, along with 0.02 mg/Kg bolus doses of Midazolam plus 0.5µg/Kg bolus doses of Fentanyl as necessary to achieve a RASS score between -3 and -1
62782022|NCT02870634|EXPERIMENTAL|Cu(II)ATSM|Cu(II)ATSM capsules, administered orally once daily
62782023|NCT01939639|EXPERIMENTAL|Oxytocin|24 IU Oxytocin, intranasal application 30 min prior to the experiment
62782024|NCT01939639|PLACEBO_COMPARATOR|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
62782025|NCT04623814|EXPERIMENTAL|Food effect|HEC113995 20mg will be administered fasted, with regular meal or with high-fat meal for once.
62782026|NCT04623814|EXPERIMENTAL|Multiple Ascending Doses-HEC113995 10mg|HEC113995 10mg will be administered fasted for 10 days
62193672|NCT00203034|EXPERIMENTAL|Experimental 2|1.0 mg rasagiline mesylate oral once daily
62193673|NCT00203034|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62193674|NCT00709397||Observation|antiretroviral-experienced patients requiring raltegravir to construct an adequately potent antiretroviral regimen.
62193675|NCT06232447|EXPERIMENTAL|Cigarette Type Switching|Participants will be switched from smoking menthol cigarettes to non-menthol cigarettes
62193676|NCT01765062||Before Rapid Maxillary Expansion|T0
62193677|NCT01765062||3 months After Rapid Maxillary Expansion|T1
62193678|NCT01765062||One year After Rapid Maxillary Expansion|T2
62193679|NCT01517204|EXPERIMENTAL|Direct laryngoscope|Direct laryngoscope was used to facilitate the intubation of left-sided double lumen endobronchial tube.
62193680|NCT01517204|EXPERIMENTAL|Trachway(R) intubating stylet|Trachway(R) intubating stylet was used to facilitate left-sided double lumen endobronchial tube intubation.
62193681|NCT02078492|EXPERIMENTAL|Group 1 - 10 mg of Ketorolac|Subjects will be administered 10 mg of Ketorolac for pain relief.
62193682|NCT02078492|EXPERIMENTAL|Group 2 - 15mg|Subjects will be administered 15mg of Ketorolac.
62782027|NCT04623814|EXPERIMENTAL|Multiple Ascending Doses-HEC113995 20mg|HEC113995 20mg will be administered with food for 10 days
62782028|NCT04623814|EXPERIMENTAL|Multiple Ascending Doses-HEC113995 40mg|HEC113995 40mg will be administered with food for 10 days
62008123|NCT02805647||Fracture/study group|The study group consisted of 100 children aged 3 to 18 years (78% boys) hospitalized in the Department of Pediatric Orthopedics in 2011-2013 due to low-energy fractures
62782029|NCT04623814|PLACEBO_COMPARATOR|Multiple Ascending Doses-placebo|Placebo arms will be administered fasted or with food for 10 days
62398266|NCT06016296|EXPERIMENTAL|Transition level 2 experimental groups|The intervention will be implemented by early childhood educators, who will be previously trained in Combined Movement and Storytelling Intervention (CMSI). Each session will take place in the classroom where the preschoolers usually attend, which will depend on the admission policies of each educational community regarding to level classes (transition level 2). The intervention will last 12 weeks (36 sessions), distributed in 3 weekly sessions (Monday, Wednesday and Friday) of 40 minutes per session. The CMSI is based on 2 previous studies, and a book related to CMSI. Twelve unpublished motor stories were elaborated, of which one per week will be executed distributed in 3 sessions per week with the corresponding progressions for each session carried out, placing the children in a sequence of stories that begin with the presentation of a motivating character that will accompany children's in the development of the whole story.
62782030|NCT06301932||Epidural analgesia|Group of the patients received epidural analgesia
62782031|NCT06301932||Non epidural analgesia|Group of the patients who did not received epidural analgesia
62782032|NCT01196416|EXPERIMENTAL|Treatment (RO4929097, cisplatin, vinblastine, temozolomide)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21, cisplatin IV over 30 minutes and vinblastine IV over 30 minutes on days 1-3, and temozolomide PO QD on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without progressive disease continue to receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 and temozolomide as above in the absence of disease progression or unacceptable toxicity.
62782033|NCT00745043|PLACEBO_COMPARATOR|R302|Daily placebo capsules
62782034|NCT00745043|ACTIVE_COMPARATOR|R303|Daily metoprolol 95mg capsules
62782035|NCT00745043|ACTIVE_COMPARATOR|R304|Daily propranolol 80mg capsules
62008124|NCT02805647||Control group|The control group (122 children, 68% boys) consisted of children aged 3 to 17 years, hospitalized for other reasons (injuries, diagnosis of knee ligament injuries and others) without fractures
62734601|NCT02919891||Participants without Chronic Pain|Questionnaire results will reveal the absence of chronic pain. No intervention will be administered. The results of the IENFD will be compared to the group with chronic pain.
62734602|NCT01229007|EXPERIMENTAL|Biostate|
62782036|NCT00745043|ACTIVE_COMPARATOR|Open Label|Daily Metoprolol 190mg capsules
62008125|NCT03947060||Nasal & Frontal sensor position|One group of participants with two modes of measurement. First mode is standard frontal placement of the SedLine® sensor. Second mode is alternative nasal placement of the SedLine® sensor.
62782037|NCT04356235||A:Exp-impl-mastopexy|expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction
62782038|NCT04356235||B: exp-impl-mastopexy+mesh|expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling
62782039|NCT04356235||C: exp-impl-mastopexy+implant|expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation
62782040|NCT04356235||D: exp-impl-mastopexy+implant+mesh|expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation
62782041|NCT04356235||E: simple masectomy|unilateral simple mastectomy
62782042|NCT04356235||F: bilateral exp-impl|after bilateral SSM, ASM, NSM, expander-implant exchange
62782043|NCT01540669|ACTIVE_COMPARATOR|Polydextrose, low dose|Polydextrose, low dose
62008126|NCT02036034|ACTIVE_COMPARATOR|drape with forced air warmer|forced air warmer placed under the chin before draping, inflated after draping completed.
62008127|NCT02036034|PLACEBO_COMPARATOR|drape with warming blanket|warming blanket placed on torso of patient under the drape.
62008128|NCT01978431|EXPERIMENTAL|Stimulant|Cocaine and Methylphenidate
62008129|NCT01978431|PLACEBO_COMPARATOR|Placebo|methylphenidate
62734603|NCT04475562|OTHER|COVID-19 suspected|Participants were recruited at the outpatient clinic for MUMC+ employees with COVID-19 symptoms or at the nursing unit where a SARS-CoV-2 patient was admitted.
62782044|NCT01540669|ACTIVE_COMPARATOR|Polydextrose, medium dose|Polydextrose, medium dose
62782045|NCT01540669|ACTIVE_COMPARATOR|Polydextrose, high dose|Polydextrose, high dose
62782046|NCT01540669|PLACEBO_COMPARATOR|Placebo powder|Placebo powder
62782047|NCT04536207|EXPERIMENTAL|the study group|Group (A) the study group received cryotherapy
62782048|NCT04536207|NO_INTERVENTION|the control group|Group (B) the control group not received cryotherapy
62782049|NCT06464016||Pediatric patients with Berlin Heart EXCOR|Patient under 18 years old of age at the time of BH assistance in HCL Lyon France
62782050|NCT02841462|EXPERIMENTAL|Bursitis|Intra-bursal thermal ablation
62008130|NCT02676544|EXPERIMENTAL|Embosphere microspheres|Embospheres are calibrated microspheres which will be percutaneously delivered intra-arterially via a microcatheter under fluoroscopic guidance to occlude the prostatic arteries.
62008131|NCT04483440|EXPERIMENTAL|4D-110 Dose 1|4D-110 IVT injection
62008132|NCT04483440|EXPERIMENTAL|4D-110 Dose 2|4D-110 IVT injection
62008133|NCT04483440|EXPERIMENTAL|4D-110 Dose 3|4D-110 IVT injection
62734604|NCT01671553|EXPERIMENTAL|Counseling group|Study participants in the intervention group were received an intensive smoking cessation telephone counselling with 2-weeks free and 6-weeks discount nicotine replacement therapy (NRT).
62782051|NCT05820984|EXPERIMENTAL|SPIRIT checklist plus usual practice|After accepting to review an article, peer reviewers will receive the automated, journal specific standard email with general information as per each journal's usual practice (e.g. where to access the manuscript, date when the peer review report is due). In addition, peer-reviewers who received a manuscript which was randomised to the experimental arm will receive an additional email including a short version of the SPIRIT checklist together with a short explanation of those items.
62782052|NCT05820984|OTHER|Usual practice|After accepting to review an article, peer reviewers will receive the automated, journal specific standard email with general information as per each journal's usual practice.
62782053|NCT00006400|ACTIVE_COMPARATOR|Hydroxyurea|Participants will receive hydroxyurea.
62782054|NCT00006400|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62008134|NCT05510297|OTHER|In-home feasibility test|In this single-arm trial, participants will use an active seating system for a 3- to 7-day period. The system provides a seating platform and treadles to pedal while in a seated or semi-reclined position. The system will also include a digital user interface to track performance.
62008135|NCT03992326|EXPERIMENTAL|TIL-ACT + LDI|Non-myeloablative lymphodepleting chemotherapy (cyclophosphamide and fludarabine), Low Dose Irradiation (LDI), Tumor Infiltrating Lymphocyte (TIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2).
62008136|NCT01000051|EXPERIMENTAL|Eltrombopag|Starting dose 50 mg/day orally for 8 weeks
62782055|NCT01554800|EXPERIMENTAL|ACP-501|
62782056|NCT06224803|EXPERIMENTAL|Dibifree|Take Dibifree 3 times a day, 10 capsules each time, 5 to 10 minutes before meals
62782057|NCT06224803|PLACEBO_COMPARATOR|Control|Take Placebo 3 times a day, 10 capsules each time, 5 to 10 minutes before meals
62782058|NCT00206713|EXPERIMENTAL|Arm 1|
62782059|NCT00206713|PLACEBO_COMPARATOR|Arm 2|
62782060|NCT04137458|EXPERIMENTAL|Participants|The investigator will withdraw biological samples and a biological and DNA bank will also be realized
62782061|NCT06348628|EXPERIMENTAL|Motivational Interview with Placebo|"Each participant receives a motivational interview session at the recruitment, 1, 3, 6 months.~Simultaneously, They receive dietary, exercise and lifestyle advices."
62782062|NCT06348628|PLACEBO_COMPARATOR|Placebo|Participants receive dietary, exercise and lifestyle advices at the recruitment, 1, 3 and 6 months
62782063|NCT03243448||The general public|people between 20-85 years old, without sympathetic hyperactivity disease
62782064|NCT03243448||Sympathetic hyperactivity diseases|Sympathetic hyperactivity diseases included: hypertension, heart failure atherosclerotic diseases, arrhythmias, cardiomyopathy, pulmonary hypertension, chronic obstructive pulmonary disease, sleep apnea, pulmonary embolism, hepatitis, liver cirrhosis, hepatopulmonary syndrome, hepatorenal syndrome, renal failure, nephritis, irritable bowel syndrome.
62782065|NCT01575314|EXPERIMENTAL|stapling device|stapling device refer to patients who were randomized to use stapler for dividing lung parenchyma.
62782066|NCT01575314|NO_INTERVENTION|hand sewn|hand sewn refer to patients who were randomized to use hand suturing for dividing lung parenchyma.
62782067|NCT03989362|EXPERIMENTAL|LM1|Phase 2 study of vopratelimab by intravenous (IV) infusion administered in combination with ipilimumab by IV infusion in NSCLC
62008137|NCT01000051|PLACEBO_COMPARATOR|Placebo|Once a day orally for 8 weeks
62008138|NCT03752723|EXPERIMENTAL|combination with CPA, GX-I7, and pembrolizumab|"Experimental: combination~Assigned interventions: CPA, GX-I7 and pembrolizumab"
62782068|NCT03989362|EXPERIMENTAL|LT1|Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in NSCLC
62782069|NCT03989362|EXPERIMENTAL|UM1|Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in urothelial cancer
62782070|NCT03989362|EXPERIMENTAL|UT1|Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in urothelial cancer
62008139|NCT03752723|EXPERIMENTAL|combination with GX-I7, and pembrolizumab|"Experimental: combination~Assigned interventions: GX-I7 and pembrolizumab (without CPA)"
62193683|NCT02078492|EXPERIMENTAL|Group 3 - 30mg|Subject will receive 30mg of Ketorolac as a part of standard care.
62782071|NCT03989362|EXPERIMENTAL|LM2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in NSCLC
62782072|NCT03989362|EXPERIMENTAL|LT2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in NSCLC
62782073|NCT03989362|EXPERIMENTAL|UM2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in urothelial cancer
62008140|NCT04090814|EXPERIMENTAL|Movement-Evoked Pain during TENS treatment|Participants performed several physical tasks while using the HeatTens device (HV-F311-E). During these tasks, participants needed to rate their pain.
62008141|NCT04090814|NO_INTERVENTION|Movement-Evoked Pain|Participants performed several physical tasks during with their pain was assessed.
62193684|NCT00667459|EXPERIMENTAL|Investigational|PRESTIGE® LP Cervical Disc
62193685|NCT00667459|ACTIVE_COMPARATOR|Control|Control patients who received a ACDF fusion treatment from a previous IDE trial (NCT00642876)
62782074|NCT03989362|EXPERIMENTAL|UT2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in urothelial cancer
62782075|NCT03401268|EXPERIMENTAL|Patient cohort|The study population will include 24 patients, that are either already on IVIG or are eligible for ScIG as initial Ig replacement, that will undergo Ig replacement with subcutaneous immunoglobulin (ScIG) for a total of 6 months.
62008142|NCT05295173|EXPERIMENTAL|experimental group|Recombinant human tissue plasminogen kinase derivatives(r-PA) for injection: the first intravenous bolus injection of 18mg, after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time. Subjects were closely monitored during the treatment period and within 24 hours after administration.
62008143|NCT05295173|ACTIVE_COMPARATOR|comparative group|Recombinant human tissue plasminogen activator (rt-PA) for injection: 0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h. Subjects should be closely monitored during the treatment period and within 24 hours after administration.
62008144|NCT02751151|EXPERIMENTAL|1|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
62008145|NCT04542629|EXPERIMENTAL|RITUXIMAB|rituximab INTRAVENOUS 750MG/m2 every 2 weeks for 2 doses
62008146|NCT04542629|ACTIVE_COMPARATOR|KETOGENIC DIET|"The common element of these different approaches is variable reduction in the amount of carbohydrate with appropriate increase in fat.~Diets that produce a state of ketosis are referred to as ''ketogenic"
62008147|NCT04542629|ACTIVE_COMPARATOR|TRACE ELEMENTS|. Essential trace elements that include zinc, copper, magnesium, and selenium
62008148|NCT04542629|ACTIVE_COMPARATOR|CORTICOSTEROID|corticosteroid pulse therapy 30 mg /kg /day for 5 days monthly for 6 month
62008149|NCT03178656|ACTIVE_COMPARATOR|PVTT WITH SORAFENIB|"AASLD recommend therapy:~sorafenib tablet, 400mg, bid."
62008150|NCT03178656|EXPERIMENTAL|PVTT WITH OPERATION|patients suitable for surgery
62782076|NCT02227199|EXPERIMENTAL|Phase I: Dose Escalation, Dose Level 1 (brentuximab 1.2mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.2mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
62734605|NCT01671553|NO_INTERVENTION|Control group|Study participants in the control group were not received any quitting assistance other than the self-help materials provided by Hong Kong Council on Smoking and Health (COSH).
62734606|NCT05160012|NO_INTERVENTION|Control|This group will not receive peer comparison messages and will continue with usual care.
62008151|NCT03998124|EXPERIMENTAL|Peer-led intervention|Individuals met twice a week for 8 weeks and participated in a peer-mediated social communication skills group.
62008152|NCT03998124|ACTIVE_COMPARATOR|Staff-led social activity group|Individuals met twice a week for 8 weeks and participated in staff-led social activities.
62008153|NCT04140994|ACTIVE_COMPARATOR|Intermittent theta burst stimulation|"Volunteers will be submitted to non-invasive parietal stimulation before a mirror drawing task.~A transcranial magnetic stimulator (MagPro X100, Medtronic Functional Diagnostics, Skovlunde, Denmark) will deliver interrmittent bursts of bipolar magnetic pulses exerting an excitation on the underlying brain tissue (iTBS). The stimulation coil will be placed over the parietal cortex. Stimulation consisted of a burst of three pulses administered at 50Hz, repeated at a frequency of 5Hz, delivered in 2 s trains followed by an 8 s interval for a total of 600 pulses12. Stimulation intensity was set at 70% of RMT.~Each session will consist of two spaced neuronavigated iTBS applications, separated by 15 minutes."
62008154|NCT04140994|SHAM_COMPARATOR|Sham intermittent theta burst stimulation|For sham iTBS, the protocol is the same, except the sham coil produces no magnetic field.
62008155|NCT04299711||Baseline|This study intends to recruit 3,428 Chinese adolescent students exposed to the novel coronavirus disease 2019 in the baseline survey
62008156|NCT04299711||6-month follow-up|This study will track the mental health status among these recruited 3,428 participants exposed to the novel coronavirus disease 2019 in the 6 follow-up study.
62008157|NCT04299711||12-month follow-up|This study will track the mental health status among these recruited 3,428 participants exposed to the novel coronavirus disease 2019 in the 12 follow-up study.
62193686|NCT02536742|EXPERIMENTAL|Experimental|Palbociclib plus Fulvestrant
62008158|NCT04299711||18-month follow-up|This study will track the mental health status among these recruited 3,428 participants exposed to the novel coronavirus disease 2019 in the 18 follow-up study.
62008159|NCT05035771|EXPERIMENTAL|Pressure wire measurements|
62008160|NCT06467526|EXPERIMENTAL|Hydroxychloroquine group|Hydroxychloroquine with steroid
62782077|NCT02227199|EXPERIMENTAL|Phase I: Dose Escalation, Dose Level 2 (brentuximab 1.5mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.5mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
62782078|NCT02227199|EXPERIMENTAL|Phase II: Dose Expansion (brentuximab 1.5mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.5mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
62782079|NCT01549977|EXPERIMENTAL|Febuxostat 80 mg|Febuxostat 80 mg, tablets, orally, once daily for up to 12 weeks.
62782080|NCT01549977|PLACEBO_COMPARATOR|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 12 weeks.
62782081|NCT01130896||MRI and Cardiac Devices|Clinically indicated MRI (all types) in patients with implanted pacemakers and ICD
62782082|NCT00621140|EXPERIMENTAL|linagliptin 5 mg|linagliptin 5 mg once daily
62782083|NCT00621140|PLACEBO_COMPARATOR|placebo|placebo matching linagliptin 5 mg tablets
62782084|NCT04565951|EXPERIMENTAL|Treatment arm|Participants in this arm will receive the intervention, VA S.A.V.E.
62782085|NCT04565951|SHAM_COMPARATOR|Sham arm|"Participants in this arm will receive a sham training, not the intervention, consisting of information unrelated to suicide prevention but relevant to transitioning veterans and their loved ones."
62782086|NCT01584362|EXPERIMENTAL|oxfendazole 0.3|administration of a single oral 0.3mg/kg dose of oxfendazole
62782087|NCT01584362|PLACEBO_COMPARATOR|placebo comparator|administration of a single oral dose of placebo
62782088|NCT01584362|EXPERIMENTAL|oxfendazole 1.0|administration of a single oral 1.0 mg/kg dose of oxfendazole
62782089|NCT01584362|EXPERIMENTAL|oxfendazole 3.0|administration of a single oral 3 mg/kg dose of oxfendazole
62782090|NCT01584362|EXPERIMENTAL|oxfendazole 10|administration of a single oral 10 mg/kg dose of oxfendazole
62782091|NCT01584362|EXPERIMENTAL|oxfendazole 20|administration of a single oral 20 mg/kg dose of oxfendazole
62782092|NCT01584362|EXPERIMENTAL|oxfendazole 30|administration of a single oral 30 mg/kg dose of oxfendazole
62782093|NCT03458156|EXPERIMENTAL|SLE group|The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.
62782094|NCT03458156|EXPERIMENTAL|LN group|The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.
62782095|NCT03458156|EXPERIMENTAL|the control group|The patients will be assigned to the control group.
62782096|NCT05290116|EXPERIMENTAL|HAIC Combined with Tislelizumab and Apatinib|
62782097|NCT01831674|EXPERIMENTAL|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
62782098|NCT01831674|ACTIVE_COMPARATOR|GLUCOPHAGE®XR|GLUCOPHAGE®XR tablet 750 mg of Bristol-Myers Squibb Company, USA
62214891|NCT01200589|EXPERIMENTAL|Arm A: Ofatumumab|Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.
62734607|NCT05160012|EXPERIMENTAL|Intervention|This group will receive peer comparison messages.
62008161|NCT06467526|OTHER|Control group|Steroid only
62008162|NCT01528358||Early Sepsis Critically Ill Patients|Patients who are admitted to ICU with a diagnosis of early sepsis.
62008163|NCT01528358||Non-septic Critically ill patients|Patients who are critically ill and admitted to ICU without diagnosis of sepsis.
62008164|NCT03538639||1|Adult index cases (affected) and relatives (affected and unaffected)
62008165|NCT03538639||2|Child index cases (affected) and child relatives (affected and unaffected)
62008166|NCT03538639||3|Healthy adult volunteers
62008167|NCT00546715|ACTIVE_COMPARATOR|Dose Panel A|"Daclatasvir - 1 mg~Placebo - 0 mg"
62734608|NCT01555996|EXPERIMENTAL|Early and intensive OT|
62734609|NCT01555996|ACTIVE_COMPARATOR|Standard non-pharmacological prevention|
62734610|NCT02455804|OTHER|Single Arm|This is a prospective, post-marketing, non-randomized, multi-center, single-arm clinical study that will be conducted at up to 15 sites in the United States (US). All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
62734611|NCT02081508|EXPERIMENTAL|Unfilled interference|Interference onset: delayed test at 540000 ms
62734612|NCT02081508|EXPERIMENTAL|Early interference|Interference onset: delayed test at 0 ms
62734613|NCT02081508|EXPERIMENTAL|Mid interference|Interference onset: delayed test at 360000 ms
62734614|NCT02081508|EXPERIMENTAL|Late interference|Interference onset: delayed test at 180000 ms
62734615|NCT04014751||Symptom Monitoring Cohort|This cohort will include up to1,050 cancer patients being seen at regional Northwestern Medicine (NM) cancer centers for their cancer care. Patients who have recently completed an on-line, EHR-integrated patient-reported symptom and needs assessment as part of their regular care will be invited to complete a survey at baseline, 6- and 12-months targeting the assessment of their symptoms, healthcare experiences and utilization. Patients may also be invited to participate in a one-time interview or focus group designed to help study investigators better understand the value of the symptom and needs assessment from the patient perspective.
62734616|NCT02281227|ACTIVE_COMPARATOR|compression group|skin compression with an indicator for determination of needle entry point
62734617|NCT02281227|ACTIVE_COMPARATOR|non-compression group|non skin compression with an indicator for determination of needle entry point
62782099|NCT01468350|PLACEBO_COMPARATOR|(PART A) AB: dalfampridine-ER 10mg then placebo|Each subject randomized to the AB arm will receive a single witnessed dose of (A) dalfampridine-ER 10 mg, and a single witnessed dose of (B) placebo, two days apart
62008168|NCT00546715|ACTIVE_COMPARATOR|Dose Panel B|"Daclatasvir - 10 mg~Placebo - 0 mg"
62782100|NCT01468350|PLACEBO_COMPARATOR|(PART A) BA: placebo then dalfampridine-ER 10mg|Each subject randomized to the BA arm will receive a single witnessed dose of (B) placebo, and a single witnessed dose of (A) dalfampridine-ER 10 mg, two days apart
62782101|NCT01468350|PLACEBO_COMPARATOR|(PART B) AB: dalfampridine-ER 10mg then placebo|Each subject randomized to the AB arm will receive multiple doses of (A) dalfampridine-ER 10mg and multiple doses of (B) placebo
62782102|NCT01468350|PLACEBO_COMPARATOR|(PART B) BA: Placebo then dalfampridine-ER 10mg|Each subject randomized to the BA arm will receive multiple doses of (B) placebo, and multiple doses of (A) dalfampridine-ER 10mg
62782103|NCT01458015|ACTIVE_COMPARATOR|oxycodone|
62782104|NCT01458015|ACTIVE_COMPARATOR|tapentadol|
62782105|NCT00900029||No HP802 Treatment|Treatment received in Study 802-247-09-015 was HP802
62782106|NCT00900029||No HP802 Vehicle Treatment|Treatment received in Study 802-247-09-015 was HP802 Vehicle
62782107|NCT02371408|EXPERIMENTAL|1a: Treatment-naive patients, without ribavirin (RBV)|PPI-668 + sofosbuvir for 12 weeks
62782108|NCT02371408|EXPERIMENTAL|1b: Treatment-naive patients, with RBV|PPI-668 + sofosbuvir + ribavirin (RBV) for 12 weeks
62008169|NCT00546715|ACTIVE_COMPARATOR|Dose Panel C|"Daclatasvir - 100 mg~Placebo - 0 mg"
62008170|NCT00546715|ACTIVE_COMPARATOR|Dose Panel D|"Daclatasvir - 0.5 - 200 mg (to be determined)~Placebo - 0 mg"
62008171|NCT02432365|EXPERIMENTAL|Weekly paclitaxel and cisplatin|7-day cycle schedule of paclitaxel (60 mg/m2) combining with cisplatin (40 mg/m2) NAC regimen followed by radical hysterectomy and bilateral pelvic lymphadenectomy
62008172|NCT05063396|ACTIVE_COMPARATOR|opioid free anesthesia|opioid free anesthesia
62782109|NCT02371408|EXPERIMENTAL|2a: Non-cirrhotic previous non-responders, without RBV|PPI-668 + sofosbuvir for 12 weeks
62008173|NCT05063396|PLACEBO_COMPARATOR|Opioid-sparing anesthesia|Opioid-sparing anesthesia
62782110|NCT02371408|EXPERIMENTAL|2b: Non-cirrhotic previous non-responders, with RBV|PPI-668 + sofosbuvir + ribavirin for 12 weeks
62782111|NCT02371408|EXPERIMENTAL|3a: Cirrhotic previous non-responders 12 weeks|PPI-668 + sofosbuvir + ribavirin for 12 weeks
62782112|NCT02371408|EXPERIMENTAL|3b: Cirrhotic previous non-responders 16 weeks|PPI-668 + sofosbuvir + ribavirin for 16 weeks
62782113|NCT05571020|EXPERIMENTAL|Mat Pilates Group|"Two days a week, approximately one hour a day, for a total of eight weeks, in groups of 5-6 people, they were included in the mat pilates exercise program.~Before starting the exercise program, the study group participants were informed about the principles of the pilates working system (I am not sure if this statement is correct terminologically), the training program and the 5 key elements of the pilates approach, neutral spine (head-neck-shoulder-waist-abdominal placement), lumbopelvic stabilization, Informative training on scapular stabilization, focusing and breathing was given."
62782114|NCT05571020|NO_INTERVENTION|Control Group|Control group participants did not participate in any exercise program.
62782115|NCT01093391|PLACEBO_COMPARATOR|BARE METAL STENT|BARE METAL STENT - STENT CRONUS
62782116|NCT01093391|EXPERIMENTAL|DRUG ELUTING STENT|STENT INSPIRON WITH SIROLIMUS
62782117|NCT04811482|EXPERIMENTAL|Intervention Group|This study consists of one arm, an intervention group.
62782118|NCT03687606|ACTIVE_COMPARATOR|Human Chorionic Gonadotropin alone|Human Chorionic Gonadotropin 2000U\~6000U, intramuscular injection, two times per week for 3 years.
62782119|NCT03687606|EXPERIMENTAL|hCG alone for 6 months then hMG added|Human Chorionic Gonadotropin 2000U\~6000U, intramuscular injection, two times per week for six months, then 75\~150IU human menopausal gonadotropin, intramuscular injection, two times per week, was added and last for the next 30 months.
62008174|NCT04510116|EXPERIMENTAL|AIM preventive intervention|Families were assigned to receive a 6 session, 12 hour prevention program in their community.
62008175|NCT04510116|NO_INTERVENTION|Control|Families were assigned to no intervention control.
62008176|NCT05571501|ACTIVE_COMPARATOR|Typically developing children|"500 children aged 1-18 male and female will be recruited from local schools, after school clubs and playgroups.~Each child will complete a screening form following appropriate information and consent process. Each child will then complete the walking assessment which takes 15 minutes in total"
62193687|NCT00839956|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive bortezomib IV on days 2 and 5 and vorinostat PO QD on days 1-14. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
62573387|NCT04426721|ACTIVE_COMPARATOR|Hyaluronic acid|Participant will receive an intraarticular injection of hyaluronic acid, once a week for three weeks. During procedure a clear ultrasound image is to be taken to document needle placement in the synovial space. The injector may choose the position of the knee (e.g., extended or bent) and the approach for the injection (e.g., medial or lateral).
62782120|NCT03687606|EXPERIMENTAL|hCG and hMG|Human Chorionic Gonadotropin 2000U\~6000U and 75\~150IU human menopausal gonadotropin, intramuscular injection, two times per week for 3 years.
62782121|NCT02144025|EXPERIMENTAL|Topical cyclosporine|This is a single arm study of patients who have received allogeneic bone marrow transplants performed with a reduced intensity conditioning regimen. In this arm, patients who are candidates to this trial, will receive topical cyclosporine twice a day for 12 months to prevent ocular graft versus host disease.
62782122|NCT06560905|EXPERIMENTAL|PSMA PET-CT|"Within the two weeks prior to surgery, the patients will undergo both PSMA PET-CT \& FDG PET-CT scans at least 48 hours apart.~The Investigational Medicinal Product (IMP) under investigation in this trial is 68Ga-PSMA. This is an imaging radionuclide tracer."
62782123|NCT06543030||Transfemoral approach (TFA) group|
62782124|NCT06543030||Transradial approach (TRA) group|
62782125|NCT00761722|EXPERIMENTAL|Arm 1|"subcutaneous and oral azacitidine~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle."
62782126|NCT00761722|EXPERIMENTAL|Arm 2|"Oral Azacitidine~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle."
62008177|NCT05571501|ACTIVE_COMPARATOR|Clinical groups|"Children will be recruited through their patient journey. Families who consent to participation will complete the screening form and the GAITRite walking assessment as part of their pre-planned clinical followup in outpatient clinics.~One group of children will be assessed at one time point, whilst a second group of children with progressive orthopaedic conditions or treatment will be assessed at intervals to give longitudinal data"
62008178|NCT05040711|EXPERIMENTAL|mindfulness coach|"Mindfulness coach is an app that provides a training plan with 14 sequential levels, a practice now area with evidence-based mindfulness audio exercises, assessments using the Five-Factor Mindfulness Questionnaire Short Form (FFMQ-SF)90, and education about mindfulness an iOS- and Android-based app designed to deliver a mindfulness training course centered on Veteran's Affairs (VA) protocols. Developed by the VA's National Center for PTSD, the app provides an engaging introduction to MT, regardless of specific psychiatric illness or patient population. . To progress to the next level, the user must interact with every element. The training plan levels include psychoeducation and exercises (guided meditations and seated practices), which increase in duration as users progress. Levels 1,7 and 14 also include an assessment with the FFMQ-SF. The practice now area has guided meditations to practice new skills."
62193688|NCT03542110|ACTIVE_COMPARATOR|Alirocumab 150 MG/ML subcutaneous injection|Alirocumab 150 mg subcutaneously every 2 weeks
62193689|NCT03542110|PLACEBO_COMPARATOR|Matching Placebo subcutaneous injection|Matching placebo subcutaneously every 2 weeks
62573388|NCT02406027|EXPERIMENTAL|Double-blind Treatment Phase: JNJ-54861911, 10 mg|Participants will continue with their current treatment regimen (10 milligram \[mg\] of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 10 milligram (mg) of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
62734618|NCT06516081|EXPERIMENTAL|Experimental arm|Micronutrient powders (Sprinkles®). One sachet daily containing minerals and vitamins in powder form.
62782127|NCT00558181|EXPERIMENTAL|Rituximab, Methylprednisolone|
62782128|NCT05553392|EXPERIMENTAL|StrataXRT|Studied products will be applied as per the patient information leaflet following manufacturer guidelines to the treatment area. The studied products will be used starting on the first day of radiation therapy. The studied products will be applied twice a day to both the right and left inguinal regions. The studied products will be used daily during the entire course of radiotherapy including on weekends and holidays until at least 4 weeks upon completion of radiation therapy or otherwise until resolution of RD on both sides.
62008179|NCT05040711|ACTIVE_COMPARATOR|control - web MD|A a widely available health and wellness app that provides users with daily content on general health, WebMD, will serve as the attention control. Similar health-based apps have been used as controls in other mHealth psychotherapy intervention trials.100,101 The control group will be instructed to access the app 4x/week (same as intervention group) and will receive an orientation and 2 booster sessions as well. I considered other control group options including treatment as usual, but attention control was selected due to the variability of treatment as usual.
62008180|NCT06358391|EXPERIMENTAL|Radiofrequency energy needle|Radiofrequency energy needle(TS-RF Needle) for transseptal access
62193690|NCT02987647|EXPERIMENTAL|Hidrafemme|"The arm in question will have 14 patients who use the Hidrafemme product, encoded as group A.~Name: hidrafemme Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
62193691|NCT02987647|ACTIVE_COMPARATOR|Vagidrat|"The arm in question will have 14 patients who use the Vagidrat product, encoded as group B.~Name: vagidrat Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
62398267|NCT06016296|NO_INTERVENTION|Transition level 2 control groups|The transition level 2 control groups (n= 2; n= 24 children) will participate in the assessments (initial and final) and will be asked to maintain their regular session of their educational establishments. At the end of the intervention period (according to the results obtained), the control groups children, parents and/or legal guardians, managers and coordinators of each community will be contacted and provided with the material so that they can replicate the experience. In addition, the educators of these establishments (teachers and classroom assistants) will be trained in the CMSI strategy.
62398268|NCT06188351|EXPERIMENTAL|Three-Dimensional Navigation Atrial Septal Puncture|Atrial septal puncture will be performed using a three-dimensional navigation intracardiac guidance kit
62398269|NCT06188351|ACTIVE_COMPARATOR|Conventional Atrial Septal Puncture|Atrial septal puncture will be performed using trational atrial septal puncture kit using traditional method.
62398270|NCT01050998|EXPERIMENTAL|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 milligram (mg) injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
62008181|NCT06358391|ACTIVE_COMPARATOR|Mechanical needle|Mechanical needle(BRK Transseptal Needle) for transseptal access
62008182|NCT00909805|EXPERIMENTAL|Cutaneous suture with glue|Inguinal surgical incision closing using Dermabond® glue instead of cutaneous suture with surjet
62008183|NCT00909805|ACTIVE_COMPARATOR|Conventional suture|Inguinal surgical incision closing with conventional cutaneous suture (surjet)
62008184|NCT01648309||TAVI|patients with significant aortic stenosis that are candidates for transvascular aortic valve implantation
62008185|NCT05731219|EXPERIMENTAL|B7-H3 target, CAR gene modified gdT cell injection|UTAA06 injection After the subjects who signed the informed consent form were screened by the inclusion/exclusion criteria, the qualified subjects will enter 1.0 in order of priority × 10\^8，3.0 × 10\^8 and 6.0 × 10\^8 CAR gdT groups were administered once.
62008186|NCT06493513|EXPERIMENTAL|40Hz stimulation group|At the start of anesthesia, the child received 40Hz transcranial stimulation for 1h.
62008187|NCT06493513|NO_INTERVENTION|Control group|At the start of anesthesia, the child did not receive any additional treatment.
62193692|NCT02987647|ACTIVE_COMPARATOR|Lubrinat|"The arm in question will have 14 patients who use the Lubrinat product, encoded as group C.~Name: lubrinat Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
62193693|NCT02987647|ACTIVE_COMPARATOR|Antrofi|"The arm in question will have 14 patients who use the Antrofi product, encoded as group D.~Name: antrofi Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
62193694|NCT06273618|ACTIVE_COMPARATOR|Immediate|ECP participants who receive access to the Micro-Learning intervention immediately upon completing the Core Training.
62398271|NCT01050998|EXPERIMENTAL|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
62398272|NCT01050998|EXPERIMENTAL|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
62734619|NCT06516081|ACTIVE_COMPARATOR|Comparator arm|IFA tables daily
62734620|NCT03340285|EXPERIMENTAL|AkP06|first two weeks: Placebo + prescribed Diet then 4 weeks AkP06 two tablet/day before meals + Diet
62734621|NCT03340285|PLACEBO_COMPARATOR|Placebo|first two weeks: Placebo + prescribed Diet then 4 weeks Placebo two tablet/day before meals + Diet
62573389|NCT02406027|EXPERIMENTAL|Double-blind Treatment Phase: JNJ-54861911, 25 mg|Participants will continue with their current treatment regimen (25 mg of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 25 mg of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
62193695|NCT06273618|ACTIVE_COMPARATOR|3-month|ECP participants who receive access to the Micro-Learning intervention 3 months after upon completing the Core Training.
62782129|NCT05553392|ACTIVE_COMPARATOR|Aquaphor|Studied products will be applied as per the patient information leaflet following manufacturer guidelines to the treatment area. The studied products will be used starting on the first day of radiation therapy. The studied products will be applied twice a day to the entire treatment field. The studied products will be used during the entire course of radiotherapy and for a further 4 weeks upon completion of radiation therapy.
62193696|NCT06273618|ACTIVE_COMPARATOR|6-month|ECP participants who receive access to the Micro-Learning intervention 6 months after upon completing the Core Training.
62193697|NCT06273618|ACTIVE_COMPARATOR|9-month|ECP participants who receive access to the Micro-Learning intervention 9 months after upon completing the Core Training.
62193698|NCT06273618|ACTIVE_COMPARATOR|Non-ECPs|Non-ECP participants
62193699|NCT02322086|EXPERIMENTAL|PH-10|Active treatment
62193700|NCT03482362|EXPERIMENTAL|Cohort A; KRASmt, BRAFwt, BRAF-like CC|Patients with KRAS mutant and BRAF wildtype colon cancer that met the BRAF-like signature according to the validated test of Agendia will be treated with vinorelbine tartrate.
62193701|NCT03482362|EXPERIMENTAL|Cohort B; KRASwt, BRAFmt, BRAF-like CC|Patients with KRAS wildtype and BRAF mutant colon cancer that met the BRAF-like signature according to the validated test of Agendia will be treated with vinorelbine tartrate.
62193702|NCT04625010|EXPERIMENTAL|Group 2 (Swaddling group)|Swaddling group: Swaddling is a wrapping procedure in which a baby's arms and legs are comfortable, sometimes only the arms are wrapped inside, and two ends of fabric are crossed on the chest of the baby, generally with thin cotton and soft fabric or a blanket. In the swaddling group, neonates were placed in the supine position on a blanket. In compliance with the newborn anatomic posture, the legs were wrapped in the flexion and abduction position. The arms of the neonates were placed close to their torso with both hands, without restraining limb movements. Swaddling was carried out 1 minute before the heel stich procedure and continued 3 minutes after the procedure. The neonate remained on the examination table during the swaddling procedure. Swaddling was applied not too loose or too tight during the procedure.
62193703|NCT04625010|EXPERIMENTAL|Group 3 (Maternal Holding group)|Maternal holding group: Neonates in this group were held in their mothers' lap while their mothers were seated reclining on a comfortable chair. Neonates remained clothed in their mothers' lap during the heel stick procedure, and no breastfeeding was administered during the procedure. Holding was continued for a minimum of 3 minutes during and after the procedure.
62193704|NCT04625010|NO_INTERVENTION|Group 1|In the control group, the heel stick procedures were conducted using the standard method and the neonates received no interventions during the procedures.
62193705|NCT04224168|EXPERIMENTAL|Green Beans|Green beans will be provided in the daily diets of the patients enrolled for 3 months via gtube or oral means. Only up to 6g of fiber total from green beans will be given. This equates to 3x 4 ounce jars of green beans per day.
62214892|NCT01200589|ACTIVE_COMPARATOR|Arm B: Rituximab|Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.
62573390|NCT02406027|PLACEBO_COMPARATOR|Double-blind Treatment Phase: Placebo|Participants will continue with their current treatment regimen established in the parent study of JNJ-54861911. Participants will receive placebo matching to JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
62573391|NCT02406027|ACTIVE_COMPARATOR|Open-label Phase: JNJ-54861911, 5 mg|Participants who were receiving JNJ-54861911, 10 mg and placebo in the DB treatment phase, will receive the 5 mg JNJ-54861911 once daily up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) in Open-label phase.
62734622|NCT00996879|EXPERIMENTAL|Midazolam + BMS-791325|
62782130|NCT04356352|ACTIVE_COMPARATOR|Lidocaine|1 mg/kg lidocaine to a max of 100 mg
62782131|NCT04356352|ACTIVE_COMPARATOR|Esmolol|0.5 mg/kg esmolol to a max of 50 mg
62782132|NCT04356352|PLACEBO_COMPARATOR|Placebo|Saline water
62193706|NCT04224168|EXPERIMENTAL|Liquid Pectin|Liquid pectin will be provided in the daily diets of the patients enrolled for 3 months via gtube or oral means. Only up to 6g of fiber total from liquid pectin will be given. This equates to 6 teaspoons or 30mL of liquid pectin per day.
62573392|NCT02406027|ACTIVE_COMPARATOR|Open-label Phase: JNJ-54861911, 25 mg|Participants who were receiving JNJ-54861911, 25 mg in the DB treatment phase, will continue to receive the same regimen in open-label treatment phase. Participants who were receiving placebo in the DB treatment phase will be randomly assigned to receive 25 mg of JNJ-54861911 once daily up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) in the open-label treatment phase.
62782133|NCT05229029|EXPERIMENTAL|TCM decoction|Compound granules of Traditional Chinese Medicine
62782134|NCT05229029|PLACEBO_COMPARATOR|placebo|Placebo only
62782135|NCT06388603|ACTIVE_COMPARATOR|Standard of Care - Osteomyelitis treatment|Subjects randomized in this group will be treated according to standard of care for the surgical managment of Osteomyelitis in the forefoot in patient suffering from diabetic foot syndrome. All standard of care approaches will be allowed (e.g use of bone sobsitutes, cements, cements loaded with antibiotics etc) with the only exception of Bioactive Glasses.
62782136|NCT06388603|EXPERIMENTAL|Bioactive Glass|"Subjects randomized in this group will be treated using the S53P4 Bioactive Glass of Bonalive Biomaterials Ltd; in the form of:~* Bonalive Granules 2.5 CC (0.5-0.8 MM)~* Bonalive Putty 2.5 CC (SIRINGA 0.5-0.8 MM)~The quantity that will be implanted will vary according to the bone cavity of each patient."
62573393|NCT00382200|EXPERIMENTAL|Decitabine and All-Trans Retonoic Acid (Tretinoin)|Decitabine and All-Trans Retonoic Acid (Tretinoin)
62782137|NCT05457088|EXPERIMENTAL|intervention group|Dietary intervention with protein intake 1.5 gr/kg/day
62782138|NCT05457088|EXPERIMENTAL|control group|Dietary intervention with protein intake 0.8 gr/kg/day
62782139|NCT02982941|EXPERIMENTAL|Dose Escalation & Cohort Expansion|enoblituzumab administered IV weekly
62782140|NCT01215825||HD, LD, NIL|HD: the highest daily dose of steroids receiving more than 60 mg/day LD: the highest daily dose of steroids receiving less or equal to 60 mg/day NIL: no steroid use
62008188|NCT00567788|ACTIVE_COMPARATOR|1|Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
62782141|NCT00524472|EXPERIMENTAL|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
62008189|NCT00567788|ACTIVE_COMPARATOR|2|Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
62782142|NCT00524472|OTHER|Insulin at the standard of care levels|Group B will be administered insulin at the standard of care levels established by the participating institution.
62782143|NCT01580202|ACTIVE_COMPARATOR|Lamivudine|LAM (100 mg/day) will be started within 1 week prior to initiation of the 1st cycle of chemotherapy, and continued until 24 weeks after completion of the last chemotherapy.
62782144|NCT01580202|EXPERIMENTAL|Entecavir|ETV (0.5 mg/day) will be started within 1 week prior to initiation of the 1st cycle of chemotherapy, and continued until 24 weeks after completion of the last chemotherapy.
62782145|NCT03973294|ACTIVE_COMPARATOR|Supraglottic jet ventilation|Ventilation of the patient is performed over a steel laryngoscope or a thin catheter by means of jet ventilation (JV) using the TwinStream jet ventilator (C. Reiner Corp, Vienna, Austria). The driving pressure of the device is 1.5-3 bar and respiratory rates of 10-900 per min can be provided. In superimposed high frequency jet ventilation (SHFJV), jet ventilation of normal frequency and high frequency is conducted simultaneously and enables ventilation at two different pressure levels through the steel jet laryngoscope. It is equipped with two jet nozzles, which are placed at the distal end of the jet laryngoscope.
62573394|NCT03485417|ACTIVE_COMPARATOR|Aripiprazole Arm|Aripiprazole (oral or depot) Oral: 10-30mg daily Depot: 300-400mg every four week; Intramuscularly
62008190|NCT03237234|SHAM_COMPARATOR|Motor Training + Sham tDCS|Individuals will participate in 3 consecutive sessions of lower extremity motor skill training while receiving sham transcranial direct current stimulation (tDCS).
62008191|NCT03237234|EXPERIMENTAL|Motor Training + tDCS|Individuals will participate in 3 consecutive sessions of lower extremity motor skill training combined with transcranial direct current stimulation (tDCS) delivered at 2mA to the motor cortex.
62008192|NCT06482047|EXPERIMENTAL|Moderate-intensity cycling|Moderate-intensity cycling on Ergoline Ergoselect 100
62008193|NCT06482047|EXPERIMENTAL|Vigorous-intensity cycling|Vigorous-intensity cycling on Ergoline Ergoselect 100
62193707|NCT03345745||Periodontally healthy subjects|Salivary samples
62193708|NCT03345745||Chronic periodontitis patients|Salivary samples
62193709|NCT03345745||Gingivitis patients|Salivary samples
62573395|NCT03485417|ACTIVE_COMPARATOR|Paliperidone Arm|Paliperidone (oral or depot) Oral: 3-12mg Depot: Intramuscularly; a) sustenna 50-150mg every four weekly, or b) trinza 273-819mg every 12 weekly
62573396|NCT03485417|OTHER|Treatment as Usual Arm|Treatment as Usual arm
62573397|NCT06537427||Control group/CTRL|Healthy adults undergoing spinal anesthesia for lower limbs orthopaedic surgery.
62573398|NCT06537427||Patients with an acute spinal cord injury/SCI|Patients with an acute, traumatic SCI
62573399|NCT00464958|EXPERIMENTAL|Sublingual tizanidine|Once nightly dosing of 12 mg sublingual tizanidine tablet
62193710|NCT04456244||Group 1:Transtibial Amputation|Photographs will be taken with posturography device during free posture and equal weighting on both extremities. Static postural adaptations will be determined by photo analysis.
62008194|NCT06482047|EXPERIMENTAL|Uninterrupted sitting|Uninterrupted sitting in a quiet room
62008195|NCT04368702|EXPERIMENTAL|Phase I - Gastric Cancer|"The research study procedures include:~* Screening for eligibility~* Study treatment including evaluations~* MR-image guided radiation will be administered per disease site standards.~* Follow up visits~* Questionnaires"
62008196|NCT04368702|EXPERIMENTAL|Phase I - Breast Cancer|"The research study procedures include:~* Screening for eligibility~* Study treatment including evaluations~* MR-image guided radiation will be administered per disease site standards.~* Follow up visits~* Questionnaires"
62008197|NCT04368702|EXPERIMENTAL|Phase I - Mantle Cell Lymphoma|"The research study procedures include:~* Screening for eligibility~* Study treatment including evaluations~* MR-image guided radiation will be administered per disease site standards.~* Follow up visits~* Questionnaires"
62193711|NCT04456244||Group 2:Transfemoral Amputation|Photographs will be taken with posturography device during free posture and equal weighting on both extremities. Static postural adaptations will be determined by photo analysis.
62193712|NCT00334542|EXPERIMENTAL|Simvastatin|Simvastatin 40 mg for 24-28 weeks
62193713|NCT05508269||Control subjects|control cases who were diagonosed as healthy subjects after diagnostic catheterization
62573400|NCT01506037|EXPERIMENTAL|Desloratadine OD tablets 5 mg|Desloratadine OD tablets 5 mg of Dr. Reddy's Laboratories Limited
62573401|NCT01506037|ACTIVE_COMPARATOR|Clarinex|Clarinex 5 mg of Schering Corporation Inc USA
62008198|NCT04368702|EXPERIMENTAL|Phase I - Larynx|"The research study procedures include:~* Screening for eligibility~* Study treatment including evaluations~* MR-image guided radiation will be administered per disease site standards.~* Follow up visits~* Questionnaires"
62008199|NCT04368702|EXPERIMENTAL|Phase I - Bladder|"The research study procedures include:~* Screening for eligibility~* Study treatment including evaluations~* MR-image guided radiation will be administered per disease site standards.~* Follow up visits~* Questionnaires"
62008200|NCT03762603|EXPERIMENTAL|robotic exoskeleton device|Patients who are scheduled to be discharged to a ECF will be asked if they would want to use the exoskeleton device ( for which safety and comfort has been established) instead of going for ECF.
62193714|NCT05508269||Stable coronary artery disease|patients with stable coronary artery disease undergoing elective PCI who were diagnozed with coronary lesion/s and underwent stent implantation without previous history of myocardial infarction
62193715|NCT05508269||Myocardial infarction patients|patients with history of myocardial infarction or with acute myocardial infarction undergoing primary PCI
62214893|NCT05978115|EXPERIMENTAL|short implant supported removable partial overdenture|
62214894|NCT05978115|EXPERIMENTAL|short Implant supported fixed partial denture|
62008201|NCT06414499|EXPERIMENTAL|rhTNK-tPA|"Within 12 hours of symptom onset:~Intervention group (rhTNK-tPA): 0.25mg/kg, the maximum dose does not exceed 25mg: 1 vial is dissolved in 3ml of sterile water for injection to prepare a medicinal solution with a concentration of 5.33mg/ml. Calculate the total amount of the drug according to the weight of participant, and the maximum dose shall not exceed 25 mg. It is administered as a single bolus intravenous injection, and the injection is completed within 5-10 seconds."
62782146|NCT03973294|ACTIVE_COMPARATOR|Subglottic jet ventilation|"Subglottic HFJV is performed through the LaserJet catheter. It is characterized by the delivery of small tidal volumes from a high pressure jet at very high frequencies (100-400) followed by passive expiration for a very short period before delivering the next jet, creating an auto-PEEP."
62008202|NCT06414499|PLACEBO_COMPARATOR|Standard medical care|"Within 12 hours of symptom onset:~Control group: Standard medical care according to the guideline (Stroke. 2019;50(12): e344-e418.). Antiplatelet therapy is chosen by researchers-Single/dual antiplatelet therapy can be chosen."
62008203|NCT06449781|EXPERIMENTAL|Experimental|The intervention will consist of a single administration of 177Lu-PSMA with an activity of 7.4 GBq. Participants will also receive standard hormone therapy
62008204|NCT06449781|NO_INTERVENTION|Control|Participants will receive standard hormone therapy
62782147|NCT05567926|EXPERIMENTAL|Experimental condition, receiving beetroot juice supplement|Participants will receive beetroot juice intervention in the experimental condition.
62782148|NCT05567926|PLACEBO_COMPARATOR|Placebo condition|Participants will receive placebo (blackcurrant juice) in the placebo condition
62782149|NCT01776866|OTHER|Coronary Angiography|"Patient first undergo standard coronary angiography(SA) of either left or right coronary system followed by dual-axis rotational coronary angiography(DARCA). The SA protocol consist of six different projections (right anterior oblique (RAO)-caudal, RAO-cranial (CRA), left anterior oblique (LAO)-CRA, LAO-caudal (CAU), antero-posterior (AP)-CRA and AP-CAU) for left coronary artery (LCA) and two projections (LAO and AP-cranial) for right coronary artery (RCA).~The DARCA protocol consist of two coronary acquisitions specified by the protocol: one for LCA (Swing LCA CRA 35 5.8s), another for RCA (Swing RCA AP 4.0s)."
62193716|NCT05508269||Ischaemic cardiomyopathy patients|patients with ischaemic cardiomyopathy diagnosed by ejection fraction less than 35% with history of coronary artery disease or myocardial infarction or those with acute myocardial infarction with reduced ejection fraction.
62214895|NCT05978115|EXPERIMENTAL|Ridge Augmentation and implant supported fixed partial denture|
62214896|NCT06610591||Achilles Lengthening Surgery|Participants will receive Achilles lengthening surgery, as usual care.
62398273|NCT01050998|EXPERIMENTAL|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
62782150|NCT02267538|EXPERIMENTAL|Dex group|The intervention drug (dexmedetomidine hydrochloride for injection) will be administered during a period from before anesthesia induction until the end of mechanical ventilation after surgery.
62782151|NCT02267538|PLACEBO_COMPARATOR|Placebo group|The placebo drug (normal saline, i.e., 0.9% sodium chloride for injection) will be administered in the same way and rate for a same duration as that in the Dex group.
62782152|NCT01496846|ACTIVE_COMPARATOR|IANB Articaine|IANB Articaine: Inferior alveolar nerve block (IANB) anesthesia with articaine local anesthetic.
62782153|NCT01496846|ACTIVE_COMPARATOR|SUP Articaine|SUP Articaine: Supplemental buccal anesthesia (SUP) with articaine local anesthetic after unsuccessful IANB.
62782154|NCT01496846|ACTIVE_COMPARATOR|SUP Lidocaine|SUP Lidocaine: Supplemental buccal anesthesia (SUP) with lidocaine local anesthetic after unsuccessful IANB.
62782155|NCT01103063|EXPERIMENTAL|AZCQ|Azithromycin/chloroquine
62008205|NCT01262313|SHAM_COMPARATOR|Control Group|"The Control group will have an hour-long meeting of instruction by a registered dietitian on using the provided A Healthier You: Everyday Healthy Eating and Physical Activity for Life book, based on the Dietary Guidelines for Americans 2005."
62193717|NCT03322553|EXPERIMENTAL|Plication group|In patients allocated to endoscopic plication, endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of GE junction around the GERD-X device
62193718|NCT03322553|SHAM_COMPARATOR|Sham Group|In sham procedure, identical technique will be followed by positioning the plicator inside the stomach but sutures will not be applied.
62398274|NCT01050998|PLACEBO_COMPARATOR|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
62008206|NCT01262313|EXPERIMENTAL|lifestyle counseling intervention|"This group will participate in the weekly Healthy Creations classes for 8 weeks presented by a Registered Dietitian and a certified fitness trainer. This is a community based lifestyle intervention program."
62008207|NCT03273036|ACTIVE_COMPARATOR|epidural steroid injection|40 mg triamcinolone acetate 1 cc
62008208|NCT03273036|PLACEBO_COMPARATOR|placebo injection|no injection agent
62008209|NCT01431027||Diastolic Function|Patients scheduled for cardiac catheterization.
62008210|NCT06572215||Healthy Participants|
62008211|NCT06572215||Patients with hyperfiltration|
62008212|NCT01687166|EXPERIMENTAL|Blazer Open-Irrigated Ablation Catheter|Blazer Open-Irrigated Ablation Catheter and Ablation Catheter Cable used in conjunction with a compatible electroanatomic mapping system
62008213|NCT01687166|ACTIVE_COMPARATOR|FDA Approved Open-Irrigated Ablation Catheter|FDA approved Open-Irrigated Radiofrequency Ablation Catheter system and compatible electroanatomic mapping system for the treatment of paroxysmal atrial fibrillation.
62398275|NCT06592794|EXPERIMENTAL|mRNA-1403|Participants will receive a single injection of mRNA-1403 on Day 1.
62398276|NCT06592794|PLACEBO_COMPARATOR|Placebo|Participants will receive a single injection of mRNA-1403 matching placebo (0.9% sodium chloride solution) on Day 1.
62398277|NCT06470334|ACTIVE_COMPARATOR|Ropivacaine|Ultrasound-guided PENG block - 20ml 0,2% ropivacaine
62782156|NCT01103063|ACTIVE_COMPARATOR|SP|sulfadoxine-pyrimethamine (Fansidar)
62782157|NCT05090033||Part I study cohort|Retrospective data analysis of up to 1500 de-identified participants contributing onboarding and adherence data via the MSGo Kesimpta Patient App.
62782158|NCT05090033||Part II study cohort|Up to 100 participants responding to PROs via the MSGo Patient App
62782159|NCT03721497|ACTIVE_COMPARATOR|Testosterone Undecanoate|Inj. Testosterone undecanoat (Nebido®), 1000 mg im preoperative (baseline, weeks 6, 18 and 30 depending on time to surgery) and postoperative (weeks 4, 16, 28, 40)
62782160|NCT03721497|PLACEBO_COMPARATOR|Placebo|Inj. placebo preoperative (baseline, weeks 6, 18 and 30 depending on time to surgery) and postoperative (weeks 4, 16, 28, 40)
62782161|NCT04897880|EXPERIMENTAL|Osteosarcoma [arm closed]|
62193719|NCT05828836|PLACEBO_COMPARATOR|placebo|
62193720|NCT05828836|ACTIVE_COMPARATOR|allopurinol|
62193721|NCT01107899|ACTIVE_COMPARATOR|clopidogrel 600 mg|
62193722|NCT01107899|ACTIVE_COMPARATOR|prasugrel 60 mg|
62573402|NCT03668444|EXPERIMENTAL|TXS- Supportive Text Group|Participants randomized to this arm (TXS) of the study will receive care as usual within the Drug Treatment Court (DTC) system plus supportive daily text messages which will be delivered at specific times each day for 30 days and will be signed by the judge for their specific DTC. (TXS) Group receives text messages for drug treatment compliance.
62782162|NCT04897880|EXPERIMENTAL|Malignant Rhabdoid Tumor/Atypical Teratoid Rhabdoid Tumor|
62193723|NCT01107899|EXPERIMENTAL|prasugrel 30 mg|
62398278|NCT06470334|ACTIVE_COMPARATOR|Ropivacaine + Dexamethasone|Ultrasound-guided PENG block - 10ml 0,2% ropivacaine + 4mg Dexamethasone
62398279|NCT05571969|EXPERIMENTAL|2X-121 Monotherapy and Dovitinib in Combination with 2X-121 in Patients with Advanced Solid Tumors|Determine the maximum tolerated dose (MTD) of 2X-121 monotherapy given twice daily (BID) and determine the MTD of dovitinib given in combination with 2X-121 (MTD) in patients with advanced solid tumors.
62782163|NCT04897880|EXPERIMENTAL|Neuroblastoma [arm closed]|
62782164|NCT04087135|EXPERIMENTAL|participant LD|
62782165|NCT04087135|EXPERIMENTAL|participant VL|
62782166|NCT04087135|EXPERIMENTAL|participant VLS|
62008214|NCT05211622|EXPERIMENTAL|Group I, OZOCLO|"• Group I, OZOCLO~1. alpha acid lipoic - 600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days~2. ozonated oil - mouthwash (1 minute- three times/die after oral hygiene, possibly) from the beginning of chemotherapy and for 2 weeks~3. chlorhexidine 0,2% - mouthwash (1 minute- three times/die after oral hygiene, possibly) from five days after the beginning of chemotherapy and for subsequent 2 weeks"
62008215|NCT05211622|PLACEBO_COMPARATOR|Group II, OBC|• Group II, OBC Sodium bicarbonate 5% solution - mouthwash (1 minute- three times/die after oral hygiene, possibly) from the beginning of chemotherapy and for 3 weeks
62008216|NCT05211622|ACTIVE_COMPARATOR|Group III, CHX|• Group III, CHX Chlorhexidine 0,2% - mouthwash (1 minute- three times/die after oral hygiene, possibly) from five days after the beginning of chemotherapy and for subsequent 2 weeks
62008217|NCT05211622|ACTIVE_COMPARATOR|Group IV, AAL-OZ|"• Group IV, AAL-OZ~1. alpha acid lipoic - 600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days~2. ozonated oil - mouthwash (1 minute- three times/die after oral hygiene, possibly) from the beginning of chemotherapy and for 2 weeks"
62193724|NCT00736411|ACTIVE_COMPARATOR|1|IVF
62193725|NCT00736411|OTHER|II|treatment
62193726|NCT06141720|ACTIVE_COMPARATOR|Standard of care for endometriosis surgery plus education|
62193727|NCT06141720|EXPERIMENTAL|Standard of care for endometriosis surgery plus mindfulness|
62193728|NCT05025462|EXPERIMENTAL|SPF|Salmon peptide fraction supplement: powder mixed in water
62193729|NCT05025462|ACTIVE_COMPARATOR|Comparator|Casein peptide fraction supplement: powder mixed in water
62193730|NCT04669769||shaving|patients with DIE and shaving
62193731|NCT04669769||disc resection|patients with DIE and Disc resection
62193732|NCT04669769||segmental resection|patients with DIE and segmental resection
62193733|NCT04669769||multifocal|patients with multifocal DIE having more than one bowel procedure
62193734|NCT04710199|EXPERIMENTAL|Maraviroc experimental group|Maraviroc tablet combined with standard treatment
62193735|NCT04710199|OTHER|Standard treatment|It is based on the treatment protocol for hospitalized COVID-19 patients and that will depend on the clinical status of the patient.
62193736|NCT02450695|EXPERIMENTAL|Active rTMS|"In rTMS, a device called a stimulator provides energy to a magnetic coil. The coil is a handheld unit that delivers magnetic pulses. The coil is placed against the scalp on the top of your head. Sessions will occur once a day, 5 days/week, for 3 weeks."
62573403|NCT03668444|PLACEBO_COMPARATOR|TAU- Treatment As Usual Group|Participants randomized to the (TAU) arm of the study will continue to participate in court-ordered treatments as usual with no additional intervention. Participants will receive motivational text messages for 30-days.
62398280|NCT05952037|EXPERIMENTAL|Cohort 1|Participants with R/R disease to both Bruton tyrosine kinase (BTK) inhibitor and anti-CD20 antibody-based systemic therapy containing chemotherapy or proteasome inhibitor will receive sonrotoclax at a standard dose, given orally once daily.
62782167|NCT04954157|PLACEBO_COMPARATOR|Healthy Subjects|This arm will consist of health subjects, not infected with COVID-19
62782168|NCT04954157|ACTIVE_COMPARATOR|COVID 19 Subjects|This arm will consist of subjects who are currently diagnosed with COVID-19 and fit all other criteria to be enrolled in this study.
62193737|NCT02450695|SHAM_COMPARATOR|Sham rTMS|The coil in the sham rTMS phase will be positioned 90 degrees off the scalp, with one wind of the coil touching the scalp. This will ensure that the participant will not be affected by the machine during this time. All other factors will be similar to the active rTMS phase.
62193738|NCT04721769|ACTIVE_COMPARATOR|Endoscopic strip craniectomy with the use of lateral osteotomies|Patients will have lateral osteotomies incorporated into their surgical procedure following suturectomy of the fused sagittal suture.
62193739|NCT04721769|EXPERIMENTAL|Endoscopic strip craniectomy without the use of lateral osteotomies|Patients will NOT have lateral osteotomies incorporated into their surgical procedure following suturectomy of the fused sagittal suture.
62193740|NCT02638597|EXPERIMENTAL|Gemfibrozil|Participants in this arm will receive smoking cessation counseling and will be provided gemfibrozil 600 mg twice daily by mouth for 9 weeks, starting one week prior to target quit date and ending with study completion
62193741|NCT02638597|OTHER|Waitlist|Participants in this arm will receive the smoking cessation counseling but will not receive medication. After completing the trial without medication, participants who continue to smoke and have a desire to quit may choose to enter the gemfibrozil arm.
62193742|NCT01833689|PLACEBO_COMPARATOR|food consumption: control|The control product will be 50g glucose powder dissolved in 250ml of water
62193743|NCT01833689|ACTIVE_COMPARATOR|food consumption: product|The test food will provide 50g of available carbohydrate
62214897|NCT03302078|EXPERIMENTAL|Treatment T|Fed state
62214898|NCT03302078|EXPERIMENTAL|Treatment R|Fasted state
62398281|NCT05952037|EXPERIMENTAL|Cohort 2|Participants with R/R disease to anti-CD20 antibody-based systemic therapy containing chemotherapy or proteasome inhibitor and were intolerant to BTK inhibitor will receive sonrotoclax at a standard dose, given orally once daily.
62398282|NCT05952037|EXPERIMENTAL|Cohort 3|Participants with R/R disease to a BTK inhibitor treatment and are unsuitable for chemoimmunotherapy will receive sonrotoclax at a standard dose, given orally once daily.
62573404|NCT04463251|EXPERIMENTAL|RPH-104 80 mg|subjects received subcutaneous single injection of 2 mL (80 mg) of RPH-104 and 2 mL of placebo on different administration sites
62573405|NCT04463251|EXPERIMENTAL|RPH-104 160 mg|subjects received subcutaneous single injection of 2 mL (80 mg) of RPH-104 and 2 mL of (80 mg) of RPH-104 on different administration sites
62782169|NCT00799591||1|Intensive Care
62008218|NCT06122324||lidocaine group|Patients in Group 1 will receive 40 mg of lidocaine HCl solution 5 minutes before endotracheal intubation.
62008219|NCT06122324||control group|The second group will receive standard anesthesia management as the control group.
62008220|NCT04522297|EXPERIMENTAL|Midodrine/Octreotide|oral midodrine plus octreotide as subcutaneous injection
62008221|NCT04522297|ACTIVE_COMPARATOR|Nor-epinephrine|Intravenous infusion norepinephrine
62193744|NCT00929253|ACTIVE_COMPARATOR|Computer delivered CRA + CM + Suboxone|"In this arm, participants are administered Suboxone and therapy is delivered by a computer. Fluency training is provided. The participant then listens through headphones and reads the information on the screen. They progress through various modules that involve education regarding high risk situations for potential use drug and skills to deal with those situations. In addition, skills for dealing with anxiety and anger are also provided. Videos are displayed that have examples of real-left situations. HIV/AIDS education is also provided. The program is interactive with the participant being required to answer short questions at the end of each module and prompts for homework worksheets are provided. These participants receive vouchers for providing drug negative urine samples."
62008222|NCT04428138||Patients with Inguinal hernia|Patients presenting with inguinal hernia will undergo vascular in-office visit and echo duplex of aorta, carotid arteries and lower limb arteries in order to detect any abnormalities related to arterial disease (aneurysm, stenosis, flow alteration).
62008223|NCT05556876|ACTIVE_COMPARATOR|Intervention|the intervention group will be provided with oral nutritional supplements for 12 weeks after discharge
62008224|NCT05556876|NO_INTERVENTION|Control|the control group will receive usual care after discharge
62008225|NCT01685112||Conventional Group|Patients who developed refractory shock, but didn't received ECMO as salvage treatment
62008226|NCT01685112||ECMO group|Patient who have septic shock, and progreseed to have ECMO as salvage therapy
62008227|NCT03025022|EXPERIMENTAL|14C-JNJ-42847922 40 miiligram (mg)|Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 on Day 1.
62008228|NCT00057746|ACTIVE_COMPARATOR|Arm I|Prophylactic cranial irradiation, 2.5 Gy fx
62008229|NCT00057746|EXPERIMENTAL|Arm II|Prophylactic cranial irradiation, 2.0 Gy fx
62008230|NCT00057746|EXPERIMENTAL|Arm III|Prophylactic cranial irradiation, 1.5 Gy fx
62193745|NCT00929253|ACTIVE_COMPARATOR|CM + Suboxone|In this arm of the study, the participants receive vouchers for providing a drug negative urine sample. These participants, however, do not have computer delivered therapy.
62398283|NCT05952037|EXPERIMENTAL|Cohort 4|Participants with previously untreated WM will receive sonrotoclax and zanubrutinib combination therapy with fixed duration.
62398284|NCT03267199||patients with high MPV,PDW,PFT|patients with high MPV,PDW,platelet function test
62008231|NCT01560624|EXPERIMENTAL|UT-15C|Treprostinil diolamine extended-release tablets (oral) 0.125 to 12 mg TID
62008232|NCT01560624|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets (oral)
62008233|NCT03969355||Paediatric patients 2008-2012|Paediatric patients admitted to intensive care in 2008-2012 who died during PICU stay
62398285|NCT03267199||patients with normal or low MPV,PDW, PFT|patients with normal or low MPV,PDW,platelet function test
62398286|NCT01445366|EXPERIMENTAL|Patients with end-stage renal disease|
62008234|NCT03969355||Paediatric patients 2013-2017|Paediatric patients admitted to intensive care in 2013-2017 who died during PICU stay
62008235|NCT01285206|EXPERIMENTAL|Routine practice|
62008236|NCT01985984||H&N cancer patients|"Patients with Head and Neck Cancer, treated with curative intent~* Any tumor site~* Stage I-IV, M0~* Treated with radiotherapy alone or in combination with systemic therapy~* Definitive radiotherapy or postoperative radiotherapy~Interventions:~* Radiation alone~* Radiation in combination with systemic therapy"
62008237|NCT01427205|EXPERIMENTAL|Group A: Cetuximab + OSI-906|Cetuximab loading dose of 400 mg/m2 by vein (IV) then 250 mg/m2 weekly + OSI-906 150 mg orally twice a day. 21-Day Cycle.
62008238|NCT01427205|EXPERIMENTAL|Group B: Cetuximab + Placebo|Cetuximab loading dose of 400 mg/m2 by vein (IV) then 250 mg/m2 weekly + Placebo orally twice a day. 21-Day Cycle.
62008239|NCT05192577|EXPERIMENTAL|Study group|
62193746|NCT00905047|OTHER|XELODA|
62193747|NCT00905047|OTHER|UFT|
62193748|NCT00645580|EXPERIMENTAL|A|
62214899|NCT02839525|PLACEBO_COMPARATOR|Omega 3|"* 3000mg of olive oil~* Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
62193749|NCT02718222|EXPERIMENTAL|3-9 months PPIUD intervention|"Tanzania: Baseline (no intervention) period is 9 months. Post-partum IUD intervention begins after 9 months and continues for 3 months.~Nepal and Sri Lanka: Baseline (no intervention) period is 9 months. Post-partum IUD intervention begins after 9 months and continues for 9 months."
62008240|NCT06329154|EXPERIMENTAL|extracorporeal shock wave therapy group|The experimental group received extracorporeal shock wave therapy combined with conventional rehabilitation therapy. Conventional rehabilitation therapy includes medium frequency electricity, ultrasound, ultrashort wave, laser, wax therapy, etc.
62193750|NCT02718222|EXPERIMENTAL|9-15 months PPIUD intervention|"Tanzania: Baseline (no intervention) period is 3 months. Post-partum IUD intervention begins after 3 months and continues for 9 months.~Nepal and Sri Lanka: Baseline (no intervention) period is 3 months. Post-partum IUD intervention begins after 3 months and continues for 15 months."
62193751|NCT02768597|ACTIVE_COMPARATOR|Large-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset
62398287|NCT05539378|EXPERIMENTAL|Auditory Stimulation|Auditory Stimulation during sleep
62398288|NCT05539378|SHAM_COMPARATOR|No Auditory Stimulation|Playing no tones during sleep but still recording brain activity
62782170|NCT06583811|ACTIVE_COMPARATOR|Group A: Remifentanil Group|About 35 Patients will receive Remifentanil bolus of 1 μg/kg over 30 seconds followed by a continuous infusion of 0.03-0.05 μg/kg/min.
62782171|NCT06583811|ACTIVE_COMPARATOR|Group B: Remimazolam Group|About 35 Patients will receive remimazolam bolus of 0.2mg/kg followed by a continuous infusion of 0.3-0.5 μg/kg/h.
62782172|NCT01589393|ACTIVE_COMPARATOR|Early initiation of thromboprophylaxis|Early initiation of thromboprophylaxis with Enoxaparin between 36-48 hours post injury to day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting day 6 post injury.
62008241|NCT06329154|ACTIVE_COMPARATOR|control group|The control group received conventional rehabilitation therapy. Conventional rehabilitation therapy includes medium frequency electricity, ultrasound, ultrashort wave, laser, wax therapy, etc.
62008242|NCT02821585|ACTIVE_COMPARATOR|Mediterranean Diet|Participants will receive nutritional lessons on the principles of the Mediterranean diet. This type of diet is defined with a carbohydrate intake of 45-55% of total energy intake, 15-20% of proteins, 30-35% of lipids and less than 7% for saturated fat. Nine sessions with a nutritionist are planned to cover various topics of the diet.
62008243|NCT02821585|PLACEBO_COMPARATOR|Low Fat Diet|Participants will receive nutritional lessons on the principles of the low fat diet. This type of diet is defined with a carbohydrate intake greater than 45% of total energy intake, 15-20% of proteins, less than 30% of lipids and less than 7% for saturated fat. Nine sessions with a nutritionist are planned to cover various topics of the diet.
62008244|NCT01588002|ACTIVE_COMPARATOR|A danoprevir+ritonavir|
62008245|NCT01588002|ACTIVE_COMPARATOR|B efavirenz|
62398289|NCT03740152|EXPERIMENTAL|Transcranial Light Therapy|All subjects will be administered 1 week of continuous TLT, 1 week of pulsed TLT, and 1 week of sham TLT.
62398290|NCT02996266|EXPERIMENTAL|Fever Prevention|Fever will be prevented using a surface targeted temperature management system
62782173|NCT01589393|PLACEBO_COMPARATOR|Late initiation of thromboprophylaxis|Initiation of placebo 36-48 hours post traumatic injury until day 5, then standard of care (DVT prophylaxis with Enoxaparin) starting on Day 6.
62782174|NCT05830071|EXPERIMENTAL|Single therapeutic dose of CHF5993 (BDP/FF/GB)|Dose: BDP/FF/GB 100/6/12.5 μg, single dose inhalation via pressurized metered dose inhaler (2 puffs from 1 BDP/FF/GB 100/6/12.5 μg pMDI + 2 puffs from 3 placebo pMDI)
62782175|NCT05830071|EXPERIMENTAL|Single supra-therapeutic dose of CHF5993 (BDP/FF/GB)|Dose: BDP/FF/GB 800/48/100 μg single dose inhalation, via pressurized metered dose inhaler (8 puffs from 4 BDP/FF/GB 100/6/12.5 μg pMDI)
62008246|NCT01588002|EXPERIMENTAL|C combination|
62008247|NCT02510846|EXPERIMENTAL|Intensive educative program|5 hours a week
62008248|NCT02510846|ACTIVE_COMPARATOR|Usual practice of educative program|1 hour a week
62008249|NCT00433693|EXPERIMENTAL|1|
62008250|NCT05346627|OTHER|mitochondrial myopathy|Patient affected by mitochondrial myopathy, with genetic confirmation of mitochondrial DNA mutation
62782176|NCT05830071|EXPERIMENTAL|Single supra-therapeutic dose CHF5259 (GB)|Dose: GB 100 μg single dose inhalation, via pressurized metered dose inhaler (8 puffs from 4 GB 12.5 μg pMDI)
62782177|NCT05830071|PLACEBO_COMPARATOR|Single dose Placebo|Dose: placebo single dose inhalation, via pressurized metered dose inhaler 8 puffs from 4 CHF5993 placebo pMDI
62782178|NCT05830071|ACTIVE_COMPARATOR|Moxifloxacin|Dose: moxifloxacin 400 mg single dose, for oral use - open label treatment (1 tablet of moxifloxacin 400 mg PO)
62782179|NCT03322150|ACTIVE_COMPARATOR|Atropine group|Patients that receive atropine 0.01 mg/kg (max 0.5mg) before spinal anesthesia
62008251|NCT01736566|EXPERIMENTAL|Family History + Whole Genome Sequencing|Doctors and their patients receive a Genome Report and an Annotated Family History Report.
62398291|NCT02996266|ACTIVE_COMPARATOR|Standard Care|Standard care in which fever may spontaneously develop
62573406|NCT04463251|PLACEBO_COMPARATOR|Placebo|subjects received subcutaneous single injection of 2 mL of placebo and 2 mL of placebo on different administration sites
62573407|NCT01624740|EXPERIMENTAL|Low Rate Followed By High Rate|The Precision Plus spinal cord stimulation screening trial leads were temporarily implanted by the investigator. Subjects received low rate stimulation (2 Hz) for 3-4 days, followed by high rate stimulation (1200 Hz) for 3-4 days.
62573408|NCT01624740|EXPERIMENTAL|High Rate Followed By Low Rate|The Precision Plus spinal cord stimulation screening trial leads were temporarily implanted by the investigator. Subjects received high rate stimulation (1200 Hz) for 3-4 days, followed by low rate stimulation (2 Hz) for 3-4 days.
62573409|NCT06194240|EXPERIMENTAL|Slow ACT|This group will follow an intervention online based on Acceptance and Commitment Therapy (ACT).
62008252|NCT01736566|ACTIVE_COMPARATOR|Family History Only|Doctors and their patients receive an Annotated Family History Report only.
62193752|NCT02768597|ACTIVE_COMPARATOR|Small-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset
62398292|NCT03978949|EXPERIMENTAL|Probiotics|Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
62573410|NCT06194240|EXPERIMENTAL|Slow Diabète|This group will follow an online Slow Diabète (Slow Diabetes) program created by the French Federation of Diabetics.
62573411|NCT06194240|NO_INTERVENTION|No program|This group will not follow an online program, in order to do the comparaison.
62398293|NCT03978949|PLACEBO_COMPARATOR|Placebo|Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
62573412|NCT04501497||NSCLC cohort (N=800)|Patients with locally advanced or metastatic non-small cell lung cancer who are planning to provide Atezolizumab combination thearapy as the most ppropriate medical care
62008253|NCT02042976|EXPERIMENTAL|Mindfulness-based cognitive therapy + pulmonary rehabilitation|An 8-week manual-based programme developed by Segal, Williams and Teasdale (2013) adjusted to the COPD population. The programme is delivered as an add-on to an 8-week standardised rehabilitation programme consisting of physical exercise and COPD-specific patient education.
62008254|NCT02042976|ACTIVE_COMPARATOR|Pulmonary rehabilitation only|An 8-week standardised rehabilitation programme consisting of physical exercise and COPD-specific patient education.
62193753|NCT02768597|ACTIVE_COMPARATOR|Large-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset
62398294|NCT00429546|EXPERIMENTAL|Intervention|Participants will receive a cognitive-behavioral intervention designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child
62193754|NCT02768597|ACTIVE_COMPARATOR|Small-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset
62398295|NCT00429546|ACTIVE_COMPARATOR|Control|Participants will receive treatment as usual
62398296|NCT04515979|EXPERIMENTAL|vactosertib+Pembrolizumab|Vactosertib (5days on and 2days off) Pembrolizumab 200mg Q3Weeks
62398297|NCT02566629||IBS patients in episodes phase|collect faeces from IBS patients in episodes remission phase
62193755|NCT02727153|EXPERIMENTAL|"Ultra E.R.A.S."|Discharge patients on Post Operative Day 2
62193756|NCT02727153|ACTIVE_COMPARATOR|Classic E.R.A.S.|Discharge patients on Post Operative Day 4
62573413|NCT04501497||ED-SCLC cohort (N=400)|Patients with extensive disease small cell lung cancer who are planning to provide Atezolizumab combination thearapy as the most ppropriate medical care
62193757|NCT06237777|EXPERIMENTAL|Dose-escalation|SKG0106 one-time deliver
62193758|NCT03334253|EXPERIMENTAL|Atropine Group|0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops
62193759|NCT03334253|PLACEBO_COMPARATOR|Placebo Group|Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops
62214900|NCT02839525|PLACEBO_COMPARATOR|Isolate whey protein|"* 23g of maltodextrin~* Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
62398298|NCT02566629||IBS patients in remission phase|collect faeces from IBS patients in remission phase
62398299|NCT02566629||healthy controls|collect faeces from healthy controls
62398300|NCT04971018|EXPERIMENTAL|Active ta-VNS|
62573414|NCT05360147|PLACEBO_COMPARATOR|Placebo|treated with oral antidiabetic drugs alone or combined with insulin, except for glucagon-like peptide type 1 (GLP-1) analogue
62573415|NCT05360147|ACTIVE_COMPARATOR|Liraglutide|liraglutide started at an initial dose of 0.6 mg/day and a maximum dose of 1.8mg/day, adjusted once a week when hyperglycemia was uncontrolled
62573416|NCT03291431|ACTIVE_COMPARATOR|Active iTBS|Participants will be randomized to active or sham iTBS.
62573417|NCT03291431|SHAM_COMPARATOR|Sham iTBS|Participants will be randomized to active or sham iTBS.
62573418|NCT02281435|EXPERIMENTAL|PrePex with Incision|Adult male circumcision by the PrePex™ device using foreskin incision
62573419|NCT05268224||Dense Breast|Women mammographically categorized as having either heterogeneously dense or extremely dense breast tissue.
62734623|NCT04563403|EXPERIMENTAL|Treatment with Multiple Stimuli|Projection-based augmented reality therapy (P-ARET) with Multiple Stimuli (MS) (P-ARET MS). Intervention group that receives P-ARET treatment varying the stimuli available in the system (different cockroaches in colour, size, etc).
62398301|NCT04971018|PLACEBO_COMPARATOR|Sham ta-VNS|
62008255|NCT06659575||Patients aged 60 and over hospitalized, expected length of stay > 48 hours|"Inclusion criteria~* Patients aged 60 and over hospitalized in a conventional medicine, psychiatry or medical and rehabilitation department of one of the GHT 49 healthcare establishments,~* expected length of stay \> 48 hours.~Non-inclusion criteria~* Patient hospitalized for more than 24 hours,~* Inability to answer a questionnaire (assessment by the investigator or the medical team in charge of the patient (dementia, etc.),~* No command of French,~* Patient hospitalized for sleep pathology (evaluation or treatment),~* Patient hospitalized in an intensive psychiatric care room,~* Patients hospitalized under duress,~* Patient opposition,~* Patient under guardianship or curatorship."
62008256|NCT06489886|EXPERIMENTAL|Conventional Chicken|This arm will be given a meal of 100 grams (\~32g of protein) boneless-skinless conventional chicken breast meat together with 250mL of water
62008257|NCT06489886|EXPERIMENTAL|Regenerative Chicken|This arm will be given a meal of 100 grams (\~32g of protein) boneless-skinless regenerative chicken breast meat together with 250mL of water
62193760|NCT02645123|EXPERIMENTAL|Spinal mobilization|The individuals of the group received 5 treatments in total for 10 minutes that included: posterior to anterior spinal accessory mobilization passive physiological inter vertebral rotation The above was applied to the level that the MRI showed disc degeneration
62398302|NCT05804669|EXPERIMENTAL|Multiple Ascending Doses|Sequential, open-label, 10-day fixed-dose cohorts.
62398303|NCT02960022|EXPERIMENTAL|enzalutamide|Subjects will receive enzalutamide orally once daily at the same time each day
62398304|NCT02960022|EXPERIMENTAL|enzalutamide plus abiraterone acetate and prednisone|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide once daily
62008258|NCT05224947|EXPERIMENTAL|Infant formula A|
62008259|NCT05224947|EXPERIMENTAL|Infant formula B|
62008260|NCT05683600|EXPERIMENTAL|LYB001 Booster Group|Subjects 18 years of age or older who has completed two or three-dose inactivated COVID-19 will receive 30μg LYB001 at day 0 as a booster vaccination.
62008261|NCT05683600|ACTIVE_COMPARATOR|Placebo Booster Group|Subjects 18 years of age or older who has completed two or three-dose inactivated COVID-19 will receive placebo at day 0 as a booster vaccination
62008262|NCT01927250|EXPERIMENTAL|Okada Health and Wellness program|12,166 Japanese volunteers with/without illness, who were interested in practicing Okada Health and Wellness program for 3 consecutive months.
62008263|NCT04768036|NO_INTERVENTION|Usual Medical Care|As per standard of care
62008264|NCT04768036|EXPERIMENTAL|"SMART on FHIR application of the IMPROVE DD VTE CPR"|"This study will be a multicenter clustered randomized trial of patients in hospitals in which a universal SMART on FHIR platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry has been incorporated into required admission and discharge EHR workflow versus hospitals following UMC for VTE risk assessment of medically ill patients.~Health outcomes and health resource utilization will be assessed for the duration of patient hospitalization until 90 days post-discharge by review of health records.~2 hospitals will be randomized to the experimental arm and 2 hospitals will be randomized to the No Intervention arm."
62008265|NCT03097419|EXPERIMENTAL|Intervention|Remote post-ischemic conditioning
62008266|NCT03097419|NO_INTERVENTION|Control|Standard medical care by the primary treatment team.
62008267|NCT01014507|ACTIVE_COMPARATOR|A|
62008268|NCT01014507|EXPERIMENTAL|B|
62398305|NCT06724419|EXPERIMENTAL|Intervention group|The nutrition education-based intervention program will span 6 weeks, providing participants with comprehensive nutrition education based on dietary guidelines and comprising 8 topics , each lasting approximately 120 minutes. Its aim is to comprehensively promote participants' adoption of a healthy lifestyle through various educational formats.intervention and will each be provided with The PMS Management Booklet.
62398306|NCT06724419|NO_INTERVENTION|Control group|"The participants in the passive control group will receive no further intervention and will each be provided with The PMS Management Booklet."
62398307|NCT06722339|OTHER|TUS sham|double-blind, sham-controlled, crossover study in N=30 individuals with OCD
62008269|NCT05951491|EXPERIMENTAL|Chronic Stroke|Individuals more than 6 months post-stroke in stable condition with long-term impairment affecting the arm and hand.
62008270|NCT01190540|ACTIVE_COMPARATOR|OSS Phase 1|Thirty-six sites will receive the On Site Support service (OSS) activities for nine to 15 months; 18 will be randomly assigned to receive the OSS in phase 1
62008271|NCT01190540|ACTIVE_COMPARATOR|OSS Phase 2|Thirty-six sites will receive the OSS activities for nine to 15 months; 18 will be randomly assigned to receive the OSS in phase 2 that will serve as a control group in phase 1 and receive OSS nine months later.
62008272|NCT06113718|EXPERIMENTAL|Exercise Group|Group that performed abdominal exercise for 1 week before operation.
62008273|NCT06113718|NO_INTERVENTION|Control Group|Group without preoperative abdominal exercise.
62008274|NCT06656910|NO_INTERVENTION|Control Group|No intervation will be taken.
62782180|NCT03322150|ACTIVE_COMPARATOR|Glycopyrrolate group|Patients that receive glycopyrrolate 0.004mg/kg (max 0.2 mg) before spinal anesthesia
62782181|NCT02697188|EXPERIMENTAL|Testosterone undecanoate|Period 2 - 200 mg T (as TU) QD Period 3 - 200 mg T (as TU) BID (100 mg/dose) Period 4 - 400 mg T (as TU) BID (200 mg/dose)
62782182|NCT02697188|ACTIVE_COMPARATOR|Testosterone enanthate|Period 1 - 400 mg T (as TE) QD Period 5 - 800 mg T (as TE) BID (400 mg/dose)
62782183|NCT06341933||Acute Kidney Injury (NO)|In the postoperative period, patients with normal renal function.
62782184|NCT06341933||Acute Kidney Injury (YES)|There has been a decrease of more than 25% in the estimated glomerular filtration rate (t-GFH), and/or a 1.5-fold increase in serum creatinine, and/or a 6-hour urine volume of less than 0.5 ml/kg/h.
62782185|NCT00597415|PLACEBO_COMPARATOR|A 1|A 1=placebo
62782186|NCT00597415|ACTIVE_COMPARATOR|A 2|A 2=celecoxib
62782187|NCT03311789|EXPERIMENTAL|PD-1 inhibitor + Gemcitabine+Cisplatin|Patients will be enrolled in the experimental arm and will receive Gemcitabine on day 1 and 5 (1000mg/m2 ) +Cisplatin on day 1(75mg/m2)+ PD-1 inhibitor on day 3 (Nivolumab 3mg/kg, or SHR-1210 200mg) every 3 weeks. If there is continued benefit after 6 months, PD-1 inhibitor will be administered as maintenance treatment until tumor progression or death.
62782188|NCT06245213|ACTIVE_COMPARATOR|ANAVEX3-71 30 mg TID (Part A)|The first active treatment arm of the study during Part A (multiple ascending doses).
62008275|NCT06656910|EXPERIMENTAL|Experimental Group|In this study, a 7-week self-compassion development program will be implemented on middle school students by a researcher who has a certificate of participation in an 8-week self-compassion development training, a pedagogical formation training certificate, and has experience working as a nurse in a child and adolescent mental health clinic. The content of the program was created by participating in the self-compassion development training and literature review, and expert opinion was obtained.
62008276|NCT05293275|ACTIVE_COMPARATOR|Virtual Reality Group|patients will use the virtual reality device over two days
62193761|NCT02645123|SHAM_COMPARATOR|Sham Treatment|The investigator touched the skin overlying the low back statically for 10 minutes
62193762|NCT02645123|ACTIVE_COMPARATOR|Classic Physiotherapy|This group received static hamstring stretch for 5 minutes, TENS (2 channels biphasic pulse, 90Hz, 100μs pulse width) for 20 minutes and 15 minutes of Swedish type massage (effleurage, petrissage, kneading)
62193763|NCT01342432|EXPERIMENTAL|Balance reeducation plus exercise|exercises that challenge postural control are performed in addition to general exercises for stretch and strength of abdominal and paraspinal muscles
62193764|NCT01342432|OTHER|General exercise only|general exercise for stretch and strength of paraspinal and abdominal muscles
62193765|NCT06381167|EXPERIMENTAL|Endoscopic bi-portal decomprssion|patients with lumbar canal stenosis will undergo endoscopic decompression
62782189|NCT06245213|ACTIVE_COMPARATOR|ANAVEX3-71 60 mg TID (Part A)|The second active treatment arm of the study during Part A (multiple ascending doses).
62782190|NCT06245213|PLACEBO_COMPARATOR|ANAVEXX3-71 Placebo TID (Part A)|The placebo arm of Part A (multiple ascending doses).
62782191|NCT06245213|ACTIVE_COMPARATOR|ANAVEX3-71 TBD mg TID (Part B)|The active arm of Part B of the study. The dose will be determined based on data obtained in Part A.
62782192|NCT06245213|PLACEBO_COMPARATOR|ANAVEX3-71 Placebo TID (Part B)|The placebo arm of Part B of the study.
62782193|NCT01963156|EXPERIMENTAL|Prescription synchronization|
62782194|NCT01963156|NO_INTERVENTION|Control|
62782195|NCT03937960|ACTIVE_COMPARATOR|Carbohydrate restricted group|This diet is designed to minimize intake of carbohydrate sources such as added sugars, high glycemic grains, and fructose. It will provide a fixed amount of carbohydrate, and a total calorie goal - with proteins and fats to satiety. During the first two weeks of the intervention, carbohydrate (CHO) sources will be primarily derived from leafy greens and non-starchy vegetables and CHO intake will be equally distributed across meals throughout the day. At week three, additional CHO sources will be added back to the diet prescription including nuts, unsweetened yogurt, and low-glycemic fruits such as apples and berries.
62782196|NCT03937960|ACTIVE_COMPARATOR|Standard/Low fat diet group|The control, low-fat diet will contain 55:25:20 %energy from CHO: protein: fat based on the United States Department of Agriculture (USDA) My Plate Daily Food Plan and our groups previous work. For example, an 1800 kcal/d plan will include 5 ounces lean meats, 3 cups low-fat dairy, 6 ounces of whole grains, 1 ½ cups fruit, 2 ½ cups vegetables (starchy and non-starchy) and limited fats.
62782197|NCT02800083|EXPERIMENTAL|Pitolisant (BF2.649)|Histamine H3 receptor H3R antagonist/ inverse agonist
62782198|NCT02800083|PLACEBO_COMPARATOR|Placebo|placebo
62782199|NCT06584175|EXPERIMENTAL|Personalized ICBT|Before initiation of the program, participants in the personalized ICBT group will collaboratively work with the Guide to determine which modules of the ICBT program best meet the participant's needs/goals. The ICBT program contains a total of 21 modules. Once modules have been selected, the Guide will develop a personalized program for the participant. The participant will then be enrolled into the personalized program. Participants in this group will receive guided support by video chat or phone each week (based on participant's preference) by a trained Guide over the 8-week duration of the program. Weekly contact will include motivating participants to complete the weekly lessons and assistance on the practicing/application of the skills. The Guide will spend approximately 10-15 minutes per week with each participant.
62008277|NCT05293275|NO_INTERVENTION|Standard of care|patients will receive standard of care only
62193766|NCT06381167|EXPERIMENTAL|Microscopic decompression|patients with lumbar canal stenosis will undergo microscopic decompression
62398308|NCT06722339|OTHER|TUS Active|double-blind, sham-controlled, crossover study in N=30 individuals with OCD
62193767|NCT03663907|EXPERIMENTAL|Telemonitoring|Structured follow-up in the basis of using telemedicine. Telemedicine will include daily signs and symptoms telemonitoring and structured follow-up by the means of video or audio-conference.
62193768|NCT03663907|NO_INTERVENTION|Usual Care|Patients with usual care follow-up in a heart failure program.
62398309|NCT06722469|EXPERIMENTAL|WCI|The WCI group will receive automated messages based on the Health Belief Model (HBM) and Protection Motivation Theory (PMT), including personalized risk assessments, educational videos featuring medical professionals and relatable scenarios, and tailored prompts to encourage mammographic screening.
62398310|NCT06722469|NO_INTERVENTION|STR|A standard tet reminder will be sent regarding the breast cancer screening program
62193769|NCT03499561||pregnant women in first Trimester|A urine sample will be taken from pregnant women before 14 weeks of pregnancy
62193770|NCT03499561||pregnant women in second Trimester|A urine sample will be taken from pregnant women from 14 weeks +1 day till 28 weeks
62193771|NCT03499561||pregnant women in third Trimester|A urine sample will be taken from pregnant women from 28 weeks +1 day till 40 weeks
62398311|NCT06724185|EXPERIMENTAL|LP28 capsule|Subjects will take two capsule of the experimental group(LP28 capsule) within 30 minutes before breakfast and dinner each day.
62398312|NCT06724185|PLACEBO_COMPARATOR|Placebo capsule|Subjects will take two placebo capsule within 30 minutes before breakfast and dinner each day.
62008278|NCT03152812||free skin flaps|
62193772|NCT04115189||Patients with Metastatic RCC|Patients diagnosed with metastatic RCC with clear cell histology who switched from a 4/2 schedule to a 2/1 schedule of sunitinib in first-line metastatic treatment between January 1, 2014 and June 30, 2018
62193773|NCT00458276|EXPERIMENTAL|1|Tezosentan
62193774|NCT00458276|PLACEBO_COMPARATOR|2|Placebo
62193775|NCT02876848|EXPERIMENTAL|Intervention Site|"The hospital that will be the intervention site will have access to the OPTIMUM e-health tool. The intervention site cancer care team will receive the following OPTIMUM e-health alerts:~1. An electronic alert of increased Adjuvant Endocrine Therapy discontinuation risk.~2. An adherence to Adjuvant Endocrine Therapy monitor.~3. An electronic discontinuation occurrence alert"
62398313|NCT02708446|ACTIVE_COMPARATOR|Sublingual misoprostol|200mg mifepristone + 400mcg sublingual misoprostol q3h
62398314|NCT02708446|ACTIVE_COMPARATOR|Buccal misoprostol|200mg mifepristone + 400mcg buccal misoprostol q3h
62008279|NCT03152812||free muscle flaps|
62008280|NCT04055636||cancer survivors with heart failure and/or fatal arrhythmias|Patients undergoing cancer therapy for the last 3-4 years with signs of heart failure and/or life-threatening arrhythmias. Administered interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
62008281|NCT04055636||Cancer survivors without complications|Patients undergoing cancer therapy for the last 3-4 years without signs of heart failure and/or life-threatening arrhythmias. Administered interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
62398315|NCT06573034|EXPERIMENTAL|Daoist Zhanzhuang|Individuals in this condition will learn and maintain the Zhanzhuang posture, endorsed by this study's religious practitioner and validated by two independent Daoist experts. The core posture involves: a) Standing with feet shoulder-width apart, knees slightly bent, and toes pointed forward; b) Opening the hips slightly to the side as if holding a ball between the legs; c) Sitting slightly back and tucking in the abdomen and tailbone; d) Keeping the back straight while holding in the chest; e) Raising the arms to a height over the chest but under the shoulders as if embracing a tree trunk; f) Facing palms toward the body with fingers apart as if holding a ball; g) Relaxing the shoulders and lowering the elbows in a stationary stance; h) Pointing the head upward as if balancing an object on top of the head; i) Tucking in the chin; j) Breathing naturally, with a focus on the lower abdominal area.
62008282|NCT04055636||Cancer patients before chemotherapy|Cancer patients before administered chemotherapy. Interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
62398316|NCT06573034|ACTIVE_COMPARATOR|Sham Wall Squat|Individuals in this condition will be directed to perform a sham wall squat, essentially a prescribed way to stand straight leaning against the wall. Key instructions include: a) Standing tall with the head and back resting against the wall; b) Positioning feet shoulder-width apart and a foot away from the wall; c) Slightly bending and engaging leg muscles; d) Relaxing hands on the side of the body; e) Concentrating on the balance of weight.
62008283|NCT04055636||Patients with non-toxic dilated cardiomyopathy (control).|Patients with non-toxic dilated cardiomyopathy. Administered interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
62008284|NCT06664424||Adhesive strips group|Patients in whom adhesive strips were employed for skin closure
62008285|NCT06664424||Suture group|Patients in whom sutures were employed for skin closure
62008286|NCT02479919|EXPERIMENTAL|TBS-MPC|Intervention with Magstim® Active TBS aiming Medial Prefrontal Cortex in 18 patients with schizophrenia
62008287|NCT02479919|ACTIVE_COMPARATOR|TBS-CPDLF|Intervention with Magstim® Active TBS aiming Dorsolateral Prefrontal Cortex in 18 patients with schizophrenia
62008288|NCT02479919|SHAM_COMPARATOR|TBS-Sham|Intervention with Magstim® Sham TBS in 25 patients with schizophrenia
62008289|NCT06094348||Group 1A- Thick skin, endonasal osteotomy|Patients with mean nasal soft tissue envelope thickness \> 4 mm undergoing classical endonasal osteotomy procedure during rhinoplasty operation
62008290|NCT06094348||Group 1B -Thick skin, piezo osteotomy|Patients with mean nasal soft tissue envelope thickness \> 4 mm undergoing piezosurgery assisted osteotomy procedure during rhinoplasty operation
62008291|NCT06094348||Group 2A- Thin skin, endonasal osteotomy|Patients with mean nasal soft tissue envelope thickness \<4 mm undergoing classical endonasal osteotomy procedure during rhinoplasty operation
62193776|NCT02876848|NO_INTERVENTION|Control Site|The hospital that will be the control site will not have access to the OPTIMUM e-health tool. The cancer care team will continue to deliver care according to standard processes.
62398317|NCT00003526|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62398318|NCT06206408|EXPERIMENTAL|Fezolinetant low dose|Participants will receive low dose of fezolinetant and placebo once daily for 12 weeks.
62398319|NCT06206408|EXPERIMENTAL|Fezolinetant high dose|Participants will receive high dose of fezolinetant and placebo once daily for 12 weeks.
62398320|NCT06206408|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo once daily for 12 weeks.
62008292|NCT06094348||Group 2B- Thin skin, piezo osteotomy|Patients with mean nasal soft tissue envelope thickness \< 4 mm undergoing piezosurgery assisted osteotomy procedure during rhinoplasty operation
62008293|NCT06003855|EXPERIMENTAL|Oxygen guided supervised exercise|Modified-SET parameters will be determined from resting StO2 during 10 minutes of sitting. The StO2 threshold will be set at 15% lower than baseline StO2 levels. After warm-up, the subjects will walk until they reach the StO2 threshold. The subjects will be instructed to stop walking once they reach the threshold and to rest until the StO2 level returns to the baseline level. Then, subjects will be instructed to begin walking again and this cycle will be repeated for 50 total minutes. The threshold was selected to be above the 31% drop associated with claudication onset time. If subjects experience pain earlier than the 15% drop, the threshold will be progressively decreased by 5%, as needed. Subjects will repeat this for up to 50 minutes (including walking and rest). Walking speed and treadmill incline will be adjusted to allow for 5-10 minutes of walking before reaching the threshold. Subjects will complete 3 sessions/week for 12 weeks.
62193777|NCT05729776||Overall eating pizza|All the patients that ate pizza
62193778|NCT05729776||Overall eating control meal|All patients that ate control mail (bread)
62193779|NCT05729776||Tandem patients eating pizza|All patients that ate pizza using Tandem Tslim system
62193780|NCT05729776||Medtronic 780 patients eating pizza|All patients that ate pizza using Medtronic 780 System
62193781|NCT02429908|OTHER|Post market study of TM-Ardis Interbody|TM-Ardis TLIF MIS or Open single or multi level implant for lumbar fusion
62193782|NCT06427733|PLACEBO_COMPARATOR|Control Group without green banana peel|SPF 30 and Placebo Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
62782200|NCT06584175|ACTIVE_COMPARATOR|Standard ICBT|Participants in the standard group will receive the ICBT program (containing 21 modules) as is. No personalization will be provided. Similar to the personalized ICBT group, participants will receive guided support by video chat or phone each week (based on participant's preference) by a trained Guide over the 8-week duration of the program. Weekly contact will include motivating participants to complete the weekly lessons and assistance on the practicing/application of the skills. The Guide will spend approximately 10-15 minutes per week with each participant.
62008294|NCT06003855|ACTIVE_COMPARATOR|Standard supervised exercise|After the warmup, subjects will walk until claudication pain becomes severe and needs to stop. Then subjects will rest until claudication pain subsides. Afterwards, subjects will walk again, repeating the cycle for up to 50 minutes (including walking and rest). Walking speed and treadmill incline will be adjusted during the SET session to allow individuals with PAD to walk for 5-10 minutes before claudication symptoms arise. Time at each speed and incline, along with rest times will be recorded during each exercise session. Subjects will complete 3 sessions/week for 12 weeks.
62008295|NCT05679791||Group 1|
62008296|NCT05679791||Group 2|
62008297|NCT02371174||HALAVEN treatment group of primary or secondary chemotherapy|Patients with HER2-negative recurrent breast cancer who have received 0 or 1 chemotherapy regimen for recurrent breast cancer.
62782201|NCT01497249|PLACEBO_COMPARATOR|Placebo|Placebo Beverage
62782202|NCT01497249|ACTIVE_COMPARATOR|A dietary fiber (FCHO)|15g/BID
62782203|NCT05975060|EXPERIMENTAL|Group-A XBB.1.5 Vaccine (Booster)|The Monovalent \[5 μg/50 μg\] NVX-CoV2601 XBB.1.5 Vaccine (Booster)
62782204|NCT05975060|ACTIVE_COMPARATOR|Group-B The monovalent XBB.1.5 Vaccine (Single Dose).|Group-B The monovalent \[5 μg/50 μg\] NVX-CoV2601 XBB.1.5 Vaccine (Single Dose).
62782205|NCT00284310|EXPERIMENTAL|wrist surgery|
62782206|NCT06339970|ACTIVE_COMPARATOR|Slider Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique|Therapist approaches the desired level of spinous process from medial aspect of the thumb of one hand which is reinforced by the index finger of the other hand. Second therapist places his axilla over the patient's shoulder to add shoulder depression component. The second therapist performs components of the nerve to be test one by one (distal to proximal or proximal to distal sequence) depending upon patient's offending movements and painful range.Pure transverse glide is performed from affected to unaffected side. While the glide is sustained, another therapist mobilizes the median nerve by performing desired neurodynamic sliding movement. Apply this protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions.
62008298|NCT02371174||HALAVEN treatment group of tertiary or later chemotherapy|Patients with HER2-negative inoperable or recurrent breast cancer who have received 2 or more chemotherapy regimens for inoperable or recurrent breast cancer.
62193783|NCT06427733|ACTIVE_COMPARATOR|Study Group with green banana peel|SPF 30 and pharmaceutical formulation with green banana peel In Study Group, in addition to the SPF 30 sunscreen, a pharmaceutical formulation containing the extract of the green banana peel will be used.
62193784|NCT00416598|EXPERIMENTAL|Treatment (chemotherapy, PBSC or bone marrow transplantation)|See Detailed Description.
62193785|NCT00263211|EXPERIMENTAL|Plavix and Aspirin|Patients will receive a 300 mg loading dose of Plavix on day 1, followed by 75 mg/day, and aspirin 81 mg per day starting day 1. Treatment will be continued until the treating physician elects to resume systemic therapy for the treatment of breast cancer or until unacceptable toxicity is observed. A pill diary will be collected monthly to monitor patients' compliance with the medication regimen.
62193786|NCT00263211|NO_INTERVENTION|Observation only|Observation by treating physician
62193787|NCT03709108|OTHER|Experimental-Control|Subjects randomized to this Arm would go through the Experimental Admission (SI-informed bolus calculator) first and Control Admission (regular bolus calculator) second
62193788|NCT03709108|OTHER|Control-Experimental|Subjects randomized to this Arm would go through the Control Admission (regular bolus calculator) first and Experimental Admission (SI-informed bolus calculator) second
62193789|NCT03352154|EXPERIMENTAL|patients with unilateral cochlear implants submitted to P300|Patients with unilateral cochlear implants, using the speech processor at least 6 months, submitted to P300 exam before CI surgery, on speech processor activation and after 06 months.
62193790|NCT04857567|EXPERIMENTAL|Three Self-Commitment (TSC) program|
62193791|NCT02691988|EXPERIMENTAL|ICS withdrawal|Guided ICS withdrawal combined with optimization of bronchodilator treatment
62193792|NCT02691988|ACTIVE_COMPARATOR|Usual care|Optimization of bronchodilator treatment
62398321|NCT04766528|EXPERIMENTAL|Mediterannen diet|The MED diet was abundant in fiber, micronutrients and plant-based proteins. The diet was rich in essential FA like monounsaturated fatty acids (MUFA) and n-3.
62782207|NCT06339970|EXPERIMENTAL|Tensioners Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique|Therapist approaches the desired level of spinous process from medial aspect of the thumb of one hand which is reinforced by the index finger of the other hand. Second therapist places his axilla over the patient's shoulder to add shoulder depression component. The second therapist performs components of the nerve to be test one by one (distal to proximal or proximal to distal sequence) depending upon patient's offending movements and painful range.Pure transverse glide is performed from affected to unaffected side. While the glide is sustained, another therapist mobilizes nerve by performing desired neurodynamic gliders movement and progressing to tensioners. Apply this protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions.
62782208|NCT03893162|EXPERIMENTAL|"Multi-strain probiotic BioKult"|4 capsules daily for 8 weeks
62193793|NCT03067545|EXPERIMENTAL|step rate increase|increase in running stride rate by 10%
62193794|NCT01806012|EXPERIMENTAL|Enseal|Tissue sealing with Enseal device
62193795|NCT01806012|ACTIVE_COMPARATOR|Supracervical hysterectomy using conventional instruments|Supracervical hysterectomy using conventional instruments
62193796|NCT01986114|EXPERIMENTAL|SM-13496 20-120mg|once daily orally SM-13496 20-120 mg flexibly dosed
62193797|NCT04262206|EXPERIMENTAL|atorvastatin 40mg|40mg atorvastatin po qd from consent to study end
62193798|NCT04262206|PLACEBO_COMPARATOR|Placebo|matching placebo po qd from consent to study end
62193799|NCT04596995|EXPERIMENTAL|Rozanolixizumab Treatment Arm|All study participants will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.
62193800|NCT00577135|EXPERIMENTAL|Q12 hour bolus|Furosemide-Q12 hour bolus
62193801|NCT00577135|EXPERIMENTAL|Continuous Infusion|Furosemide-Continuous Infusion
62193802|NCT00577135|EXPERIMENTAL|Low Intensification|Furosemide-Low Intensification
62193803|NCT00577135|EXPERIMENTAL|High Intensification|Furosemide-High Intensification
62193804|NCT04865042|EXPERIMENTAL|Gabapentin|"GABAPENTIN per os\*:~* DAY 1:300 mg~* DAY 2: 600 mg~* DAY 3: 900 mg"
62193805|NCT04865042|PLACEBO_COMPARATOR|Placebo|"PLACEBO:~* DAY 1:300 mg~* DAY 2: 600 mg~* DAY 3: 900 mg"
62193806|NCT02145845|EXPERIMENTAL|Treatment|Injectable SIS
62193807|NCT03126890||Linezolid TDM (prospective)|Adult patients received linezolid at NTUH. This prospective cohort study will draw blood from every patient to measure the linezolid blood concentration. After blood concentration analysis by high pressure liquid chromatography (HPLC), the investigator will report the concentration to clinicians and dose adjustment is judged by clinician (not the investigators).
62193808|NCT03126890||Linezolid observation (retrospective)|Adult patients received linezolid at NTUH.
62398322|NCT04766528|EXPERIMENTAL|Canadian diet|The NAM diet had a high content in saturated fatty acids (SFA) and simple sugar and was low in fiber.
62398323|NCT06039449|EXPERIMENTAL|Cohort A VYD222|
62398324|NCT06039449|EXPERIMENTAL|Cohort B VYD222|
62398325|NCT06039449|PLACEBO_COMPARATOR|Cohort B Placebo|
62398326|NCT03950531||COPD exacerbation without Bronchiectasis|COPD patients who have been in exacerbation period and have no bronchiectasis
62398327|NCT03950531||COPD exacerbation with Bronchiectasis|COPD patients who have been in exacerbation period and have bronchiectasis
62398328|NCT01692457||Golimumab|Patients will be taking golimumab as per the dosing regimen given on product insert approved in Philippines.
62193809|NCT03080493|ACTIVE_COMPARATOR|Gabapentin|"Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)~Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight"
62008299|NCT03079258|EXPERIMENTAL|Exercise|Participants randomized to the exercise intervention group will be required to complete a 24-wk partially supervised exercise programme consisting of 3-4 sessions per week of 15 minutes progressing to 30 minutes over time.
62193810|NCT03080493|PLACEBO_COMPARATOR|Placebo oral capsule|"Matched placebo~Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight"
62193811|NCT01124071|ACTIVE_COMPARATOR|Korean Diet|Provision of 2 Korean meals per day, 6 days per week
62193812|NCT01124071|ACTIVE_COMPARATOR|Western Diet|Lifestyle counseling, dietary advice, grocery vouchers
62193813|NCT02926287|EXPERIMENTAL|Ambulatory surgery|All the patients operated for pelvic organ prolapse during the study time will be recruited. All the patient eligible for an Ambulatory surgery will be discharged earlier.
62193814|NCT04583644|EXPERIMENTAL|Device - FETO|Fetoscopic Endoluminal Tracheal Occlusion (FETO) surgery and removal of balloon using the BALT GOLDBAL2 balloon and BALTACCIBDPE100 catheter.
62193815|NCT03832972||Women using birth control|
62398329|NCT06308094|OTHER|Afib with ECV measurement|patients who are referred for catheter ablation will undergo additional CT acquisition for measurement of ECV to determine if there is any association between ECV expansion and Afib burden.
62193816|NCT03832972||Women not using birthcontrol|
62398330|NCT00750061|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62573420|NCT04883242|EXPERIMENTAL|Treatment (isatuximab, carfilzomib, pomalidomide, steroid)|"INDUCTION: Patients receive isatuximab IV on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of subsequent cycles carfilzomib IV over 30 minutes on days 1, 8, and 15, pomalidomide PO QD on days 1-21, and dexamethasone PO or IV on days 1,8, 15, and 22. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive isatuximab IV days 1 and 15, carfilzomib IV over 30 minutes on days 1 and 15, pomalidomide PO QD on days 1-21, and dexamethasone PO or IV on days 1, 8, 15, and 22. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.~All patients undergo bone marrow aspirate and biopsy during screening, skeletal x-ray, CT, PET-CT, or MRI, bone marrow and blood sample collection throughout the study."
62008300|NCT03079258|NO_INTERVENTION|Control|Those randomized to the control group will continue with their standard care.
62008301|NCT04705545|NO_INTERVENTION|molar block|No additional anchorage reinforcements besides the banding first and second molar with and tying them together at the buccal tubes (also known as molar block)
62193817|NCT05269862|EXPERIMENTAL|In-Clinic Cohort|Subjects who are implanted with Abbott Infinity DBS systems with the Neuosphere Virtual Clinic feature, and receive programming for their DBS system in-clinic only.
62193818|NCT05269862|ACTIVE_COMPARATOR|Virtual Clinic Cohort|Subjects who are implanted with Abbott Infinity DBS systems with the Neuosphere Virtual Clinic feature, and receive programming for their DBS system with Virtual Clinic and in-clinic sessions.
62193819|NCT00478205|EXPERIMENTAL|1|
62193820|NCT00478205|EXPERIMENTAL|2|
62398331|NCT00750061|EXPERIMENTAL|Lithium carbonate|Lithium Carbonate tablet, 250mg
62193821|NCT02570997|ACTIVE_COMPARATOR|CT1812|"In cohorts 1-6, 8 subjects will be enrolled. 6 subjects will receive CT1812. Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.~Should an MTD not be identified, additional cohorts at higher doses may be enrolled. The maximum dose administered will not exceed 1350mg."
62193822|NCT02570997|PLACEBO_COMPARATOR|Matching Placebo|In cohorts 1-6, 8 subjects will be enrolled. 6 subjects will receive matching placebo.
62193823|NCT03550079|EXPERIMENTAL|three screws fixation|femoral neck fractures were fixed with three converted screws
62193824|NCT03550079|EXPERIMENTAL|four screws fixation|femoral neck fractures were fixed with four screws
62193825|NCT00924222|EXPERIMENTAL|Sevoflurane|
62193826|NCT00924222|EXPERIMENTAL|Propofol|
62193827|NCT03194997|EXPERIMENTAL|Dance|The group randomized to Dance intervention will receive a 3-week intervention with belly dance classes. The classes will be divided in: Warm up and stretching (10 minutes), Main part with belly dance steps and movements (40 minutes) and relaxation (10 minutes).
62398332|NCT01388699||migraine group|female migraineurs with aura
62398333|NCT01388699||control group|healthy women without headache syndrome
62193828|NCT03194997|EXPERIMENTAL|Pilates|The group randomized to Pilates intervention will receive a 3-week intervention with Pilates Methods. The classes will be divided in: Warm up and stretching (10 minutes), Main part with Pilates exercises (40 minutes) and relaxation (10 minutes).
62193829|NCT03194997|NO_INTERVENTION|Control|The group randomized to Control group will be invited to maintain routine activities and be contacted by phone every two months and will receive an explanatory booklet on the benefits of physical activity after diagnosis of breast cancer as well as instructions on lymphedema prevention. Also, this group will be invited to three meeting during the 16 weeks of intervention, the first meeting will focus on stretching exercise to develop at home, a second meeting will be about self-esteem and the last meeting will be about prevented of lymphedema. The women in this group will not receive a dance or pilates intervention.
62193830|NCT04028817|EXPERIMENTAL|group treatment|This group will receive laser treatment combined with low intensity exercises
62782209|NCT03893162|PLACEBO_COMPARATOR|Placebo|4 capsules daily for 8 weeks
62782210|NCT01418742|ACTIVE_COMPARATOR|Doxycycline 100 mg BID oral use|
62008302|NCT04705545|EXPERIMENTAL|TPA group|Bands are selected and an alginate impression taken over the bands. The impression will be sent to the lab for the construction of a transpalatal archwire on a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a U loop pointing posteriorly, soldered to the palatal side of the molar bands. The appliance will be fitted a week later. Molar bands will be fitted to the permanent second molar on the same appointment, with a ligature wire tying the first molar band together at the buccal tubes. The resulting anchorage reinforcement is a molar block with a transpalatal archwire.
62008303|NCT04705545|EXPERIMENTAL|Nance button group|Bands are selected and an alginate impression taken over the bands. Bands are replaced on the tooth and an alginate impression taken over the bands. The impression will be sent to the lab for the construction of a transpalatal archwire on a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a Nance button incorporated in the middle of the wire, soldered to the palatal side of the molar bands. The appliance will be fitted a week later. Molar bands will be fitted to the permanent second molar on the same appointment, with a ligature wire tying the first molar band together at the buccal tubes. The resulting anchorage reinforcement is a molar block with a Nance button
62008304|NCT03236844|EXPERIMENTAL|Gantenerumab G4|Participants will receive single dose of gantenerumab HCLF manufactured by G4 process on Day 1.
62008305|NCT03236844|EXPERIMENTAL|Gantenerumab G3|Participants will receive single dose of gantenerumab HCLF manufactured by G3 process on Day 1.
62193831|NCT04028817|PLACEBO_COMPARATOR|group control|This group will receive placebo laser treatment combined with low intensity exercises
62193832|NCT03441100|EXPERIMENTAL|Experimental: IMA202 Product|"* Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~* One dose of IMA202 product will be infused intravenously. Four dose levels will be evaluated. At least two patients per cohort will be treated.~* Post-infusion of IMA202 product, administration of low dose recombinant human interleukin-2"
62398334|NCT06715904|EXPERIMENTAL|Women|A Morton extension with a height of 5 mm was insert from the proximal area of the first metatarsal head to the base of the proximal phalanx of the Hallux.
62782211|NCT01418742|PLACEBO_COMPARATOR|Placebo 100 mg BID oral use|
62782212|NCT00901199|EXPERIMENTAL|Deferasirox (Exjade) and Deferoxamine (DFO)|All subjects received Deferasirox (Exjade) and Deferoxamine (DFO) dosing based on the iron overload at baseline.
62782213|NCT04478448|EXPERIMENTAL|T test|Test drug (Flupirava) 1 tablet contains 200 mg Favipiravir
62782214|NCT04478448|ACTIVE_COMPARATOR|B reference|Reference drug (Avigan) 1 tablet contains 200 mg Favipiravir
62008306|NCT03735394|EXPERIMENTAL|Gingival Biotype|A Periodontal probe was used to differentiate between thick and thin biotypes and patients were classified into 3 possible categories of Gingival Biotype (A1, A2 and B) according to Müller \& Eger (https://doi.org/10.1034/j.1600-051x.2000.027009621.x). On each group two measurements were taken on the most protruded lower and upper central incisor: 1/ a tangential radiographic film and 2/ an ultrasonic probe measurement with the PIROP Biometric scanner (G-scan) form Echoson
62008307|NCT03595111|EXPERIMENTAL|Myocardial biopsy|The specimens were classified into three categories: normal, focal hydropic change and diffuse hydropic change.
62008308|NCT05225181|EXPERIMENTAL|sequential training|first perform physical exercise followed by cognitive training
62008309|NCT05225181|EXPERIMENTAL|simultaneous training|perform physical exercise and cognitive tasks simultaneously
62008310|NCT05225181|ACTIVE_COMPARATOR|control group|perform body stretching and health education courses
62782215|NCT05642299|EXPERIMENTAL|MBCI-SR|BCI based robotic rehabilitation works by detecting the motor intent of the user from Electroencephalogram signals to drive rehabilitation assisted by the soft robotics gloves.
62782216|NCT06038734||GLP-1 agonists|Pre-operative gastric ultrasound to evaluate for retained gastric contents in appropriately fasted patients who are using GLP-1 agonist medications.
62782217|NCT06038734||Control|Pre-operative gastric ultrasound to evaluate for retained gastric contents in appropriately fasted patients who are not using GLP-1 agonist medications.
62782218|NCT06086834|EXPERIMENTAL|McKenzie Retraction Exercises|McKenzie Retraction Exercises along with hot pack.
62782219|NCT06086834|EXPERIMENTAL|Bruegger's Exercise|Bruegger's Exercise along with hot pack.
62782220|NCT03940391|EXPERIMENTAL|antihistamine combination|Participants in this group will get combination chlorpheniramine and midazolam injection for sedative endoscopy.
62008311|NCT03018353|OTHER|Navigation services with sof/vel therapy|This a single group demonstration project in which, patients are treated with the FDA-approved drug, Sofosbuvir/Velpatasvir (Epclusa). If a patients is released during their treatment regimen, they will receive patient navigation services to continue their care and treatment in the community.
62008312|NCT03548870|EXPERIMENTAL|Test with TENS|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with low frequency TENS
62008313|NCT03548870|SHAM_COMPARATOR|Test with sham-TENS|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with low frequency sham-TENS
62398335|NCT06715904|EXPERIMENTAL|Men|A Morton extension with a height of 5 mm was insert from the proximal area of the first metatarsal head to the base of the proximal phalanx of the Hallux.
62782221|NCT03940391|PLACEBO_COMPARATOR|midazolam|Participants in this group will get only midazolam injection for sedative endoscopy
62782222|NCT02092025||Azilsartan|Azilsartan 20 mg - 40 mg, tablet, orally, once daily for up to 12 months in participants based upon the disease severity. Participants will receive interventions as part of routine medical care.
62782223|NCT00551603|EXPERIMENTAL|1|Group Epo will receive anaemia treatment according to the Romanian Best Practice Guidelines recommendation, with once-weekly SC epoetinum beta during the first phase, then will be switched to receive SC once-fortnightly darbepoetinum. Anaemia treatment schedule will continue according to the Romanian Best Practice Guidelines recommendations, with the same dose. A conversion factor of 1:200 will be used.
62782224|NCT00551603|ACTIVE_COMPARATOR|2|Subjects in the Darbepo Group will receive anaemia treatment according to the Romanian Best Practice Guidelines recommendation, with once-fortnightly or once-monthly darbepoetin SC administration, continuing their previous schedule and will continue their previous schedule of anaemia treatment during the second phase of the study
62782225|NCT01811186|OTHER|Group A|Start oxycodone/naloxone 10/5mg b.i.d. titration-\>20/10mg b.i.d.-\>30/15mg b.i.d-\>40/20mg b.i.d.
62782226|NCT01811186|OTHER|Group B|Start oxycodone/naloxone 5/2.5mg b.i.d titration-\> 10/5mg b.i.d.-\>20/10mg b.i.d.-\>30/15mg b.i.d-\>40/20mg b.i.d.
62782227|NCT01221493|EXPERIMENTAL|Cryo biospy|
62782228|NCT05275036||Cancer Arm|Participants with new diagnosis of lymphoid malignancies, from whom blood samples will be collected.
62782229|NCT05275036||Benign Arm|Participants with new diagnosis of benign lymphoid diseases, from whom blood samples will be collected.
62782230|NCT04320901|EXPERIMENTAL|Harmonic|Endoscopic procedure will be done by Harmonic ACE7+
62782231|NCT04320901|EXPERIMENTAL|Ligasure|Endoscopic procedure will be done by Ligasure
62782232|NCT01169935|EXPERIMENTAL|Administration of Intra-dermal SPIO|MRI scanning before and after intra-dermal injection of SPIO.
62782233|NCT01169935|EXPERIMENTAL|Mantoux, Venesection, Labelled cells|Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by venesection.
62782234|NCT01169935|EXPERIMENTAL|Mantoux, Apheresis, Labelled cells|Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by apheresis.
62398336|NCT04854928|EXPERIMENTAL|LTX-109 treatment|Single Dose by Nasal application of LTX-109 gel 3%, 250 microliters in each nostril.
62782235|NCT01169935|EXPERIMENTAL|Mantoux, Administration of Endorem|Mantoux test then MRI scanning before and after administration of Endorem.
62782236|NCT01169935|EXPERIMENTAL|Mantoux only|Mantoux test then serial MRI scanning.
62782237|NCT02577016|EXPERIMENTAL|Sitagliptin + Ipragliflozin|Sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.
62782238|NCT02577016|ACTIVE_COMPARATOR|Placebo + Ipragliflozin|Placebo to sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.
62008314|NCT05800288||EleveldTCI|Patients who received Midazolam premedication bolus (0.03 mg/kg) before general anesthesia conducted with Eleveld TCI model (this model was choosen at anesthesiologist's discreption)
62008315|NCT05800288||Schnider TCI|Patients who received Midazolam premedication bolus (0.03 mg/kg) before general anesthesia conducted with SchniderTCI model (this model was choosen at anesthesiologist's discreption)
62008316|NCT03919045|EXPERIMENTAL|Sodium chloride injection|Sodium chloride 9mg/ml by injection
62782239|NCT05949632|EXPERIMENTAL|Part 1: Dose Escalation|Up to 6 doses of INCB099280 administered twice daily (BID) in combination with axitinib BID will be evaluated to identify dose(s) for further evaluation in the dose expansion phase of the study.
62008317|NCT03919045|PLACEBO_COMPARATOR|Needle sting|Brief needle stings without injection
62008318|NCT02821104||Healthy Adolescents|Healthy non Hispanic white adolescents
62193833|NCT03890198|EXPERIMENTAL|chimeric Antigen Receptor T cell|LCAR-C182A Cells
62193834|NCT06087575|EXPERIMENTAL|Supira System|Ventricular support indicated for use during elective or urgent high-risk percutaneous coronary interventions.
62193835|NCT01732549|EXPERIMENTAL|Tasquinimod|1 capsule daily, taken orally with water and food (0.25 mg initially then dose escalated to 0.5 mg or 1 mg per day) until disease progression or toxicity or patient's willingness to stop.
62193836|NCT01732549|PLACEBO_COMPARATOR|Placebo|1 capsule daily, taken orally with water and food until disease progression or toxicity or patient's willingness to stop.
62193837|NCT01561482|EXPERIMENTAL|Metformin, Simvastatin|"Both metformin and simvastatin will be taken every day. Metformin will be taken as 1 pill in the morning and 1 pill before going to bed. Simvastatin will be taken as 1 pill before going to bed.~They will be taken until metastasis from the prostate cancer appears or until the subjects PSA has doubled from what it was before they started the study."
62193838|NCT00513786|EXPERIMENTAL|carboplatin/paclitaxel with bevacizumab|A regimen of Carboplatin and paclitaxel combined with bevacizumab given every 21 days in patients with advanced stage endometrial cancer for a maximum of 6 cycles.
62782240|NCT05949632|EXPERIMENTAL|Part 2: Dose Expansion|On completion of Part 1, participants will be enrolled in 1 of 2 disease-specific cohorts: Cohort 1: Adults with clear-cell gynecological cancers with at least 50% clear-cell histology whose disease progressed on or following at least 1 prior line of systemic chemotherapy and are not candidates for curative surgery or (chemo)radiation. Cohort 2: Adults with rare histological subtype epithelial cancers of the gynecological tract whose disease progressed on or following at least 1 prior line of systemic chemotherapy and are not candidates for curative surgery or (chemo)radiation. One or two doses may be selected from Part 1 for each cohort in the Part 2 Expansion.
62782241|NCT03653988|ACTIVE_COMPARATOR|PEC I/II block - pre-operative|The current standard of care at the University of Iowa is to receive a pectoralis nerve block (PEC I/II) prior to surgery for mastectomy and reconstruction case. The intervention administered to Group I will having the block performed by the anesthesiologist after induction of general anesthesia and prior to surgical incision.
62782242|NCT03653988|EXPERIMENTAL|PEC I/II block - intra-operative|The current standard of care at the University of Iowa is to receive a pectoralis nerve block (PEC I/II) prior to surgery for mastectomy and reconstruction cases. Group II will have the block administered by the surgeon after mastectomy is performed and before reconstruction.
62008319|NCT05116735|EXPERIMENTAL|laparoscopic partial cystectomy with omentoplasty|laparoscopic partial cystectomy with omentoplasty
62008320|NCT03199703|ACTIVE_COMPARATOR|Baylis transseptal system group|Patients randomized to the Baylis transseptal system group (Bayliss Group) will undergo transseptal puncture with a large, preformed curve 71-cm-C1 or 98-cm-C1 18-gauge NRG needle (Baylis Medical) through a TorFlex sheath (Baylis Medical), with the sheath curve selected at the discretion of the operating physician.
62008321|NCT03199703|ACTIVE_COMPARATOR|Conventional transseptal group|Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with either a large, preformed curve 71- or 98-cm 18-gauge BRK needle (BRK, BRK-1, BRK-2 needle, St. Jude Medical) through any non-Baylis sheath (for example Schwartz SL, Biosense-Webster Preface) selected at the discretion of the operating physician.
62193839|NCT04563299|EXPERIMENTAL|Dextenza|Dextenza (Dexamethasone Ophthalmic Insert 0.4 mg)
62193840|NCT04563299|ACTIVE_COMPARATOR|Topical Corticosteroids|Topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
62193841|NCT03127670|EXPERIMENTAL|Solanum melongena peel extract 0.05%|25 Patients Solanum melongena peel extract 0.05% Twice daily applied topically for 12 weeks
62193842|NCT04597970|EXPERIMENTAL|cTACE-HAIC(oxaliplatin and raltitrexed)|Patients receive cTACE+HAIC (oxaliplatin, raltitrexed) treatment, 6-8 weeks as a cycle
62193843|NCT00475228|EXPERIMENTAL|Arm I|Levonorgestrel IUD will be inserted immediately after completion of D\&E
62193844|NCT00475228|ACTIVE_COMPARATOR|Arm 2|Levonorgestrel IUD will be inserted at standard time post-procedure (3-6 weeks post D\&E procedure)
62193845|NCT03481257||Ticagrelor|ACS patients treated with aspirin (100mg/d) and ticagrelor (90mg bid)
62193846|NCT03481257||Clopidogrel + very low dose rivaroxaban|ACS patients treated with aspirin (100mg/d), clopidogrel(75mg/d) and very low dose rivaroxaban (2.5mg bid)
62214901|NCT02839525|PLACEBO_COMPARATOR|Omega 3 and Isolate whey protein|"* 3000mg of olive oil and 23g of maltodextrin~* Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
62398337|NCT04854928|PLACEBO_COMPARATOR|Placebo|Single Dose by Nasal application of placebo gel, 250 microliters in each nostril.
62782243|NCT03764683|EXPERIMENTAL|Drug-Drug|This arm will receive the active drug in the first and second phase of the study.
62782244|NCT03764683|OTHER|Placebo-Drug|This arm will receive placebo in the first phase of the study and the active drug in the second phase.
62008322|NCT00428545|EXPERIMENTAL|Bevacizumab + Bortezomib|Bevacizumab starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days. Bortezomib starting Dose 0.7 mg/m\^2 By Vein On Days 1 and 8 Every 21 Days.
62008323|NCT06661993|PLACEBO_COMPARATOR|Placebo Group|control group: 30 septic patients will receive placebo daily for seven days.
62193847|NCT05958134||Diagnosed with diffuse large B-cell lymphoma, and classified regarding the cell of origin|Retrospective data collection will be carried out from the medical records of the participants included in the study. Will be held description of the epidemiological profile and pathological staging of diffuse large B-cell lymphoma conditions (DLBCL/LDGCB), imaging profiling, together with first-line treatment used in subgroups of germinal center or activated B-cell, in patients followed in Brazilian reference cancer treatment centers, within the last 6 years (between 2017 and 2022).
62193848|NCT05954572||psoriasis patients receiving biologic therapy|A standardized form is going to be used to collect demographic information, and details regarding smoking and alcohol habits. Additional information regarding their treatment regimens will be recorded. Furthermore patients will be evaluated for the presence of acne, rosacea, perioral dermatitis, seborrheic dermatitis, folliculitis, blepharitis, or pityriasis folicullorum, as these conditions have been associated with an increased demodicosis. After that the standardized skin surface biopsy (SSSB) technique will be utilized to assess demodicosis.
62398338|NCT05921734|EXPERIMENTAL|AF-termination Group|
62782245|NCT03764683|PLACEBO_COMPARATOR|Placebo-Placebo|This arm will receive placebo in the first phase and second phase of the study.
62782246|NCT02207491|EXPERIMENTAL|AR-13324 Ophthalmic Solution 0.02% & Placebo|1 drop AR-13324 in the evening (PM) \& 1 drop placebo in the morning (AM) in both eyes (OU)
62782247|NCT02207491|ACTIVE_COMPARATOR|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop Timolol maleate twice daily (BID) in the morning (AM) \& evening (PM) in both eyes (OU)
62782248|NCT00718705|EXPERIMENTAL|1|josamycin
62782249|NCT00718705|PLACEBO_COMPARATOR|2|Placebo
62782250|NCT01887353|ACTIVE_COMPARATOR|Ranolazine|
62782251|NCT01887353|PLACEBO_COMPARATOR|Placebo|
62782252|NCT01266590|EXPERIMENTAL|LY2216684 + digoxin|Two oral 0.5-milligrams (mg) (two 0.25-mg tablets) doses of digoxin separated by 12 hours on Day 1, followed by once daily 0.25-mg (single 0.25-mg tablet) dose of digoxin on Days 2-14. Daily oral 18-mg (two 9-mg tablets) doses of LY2216684 on Days 8-14.
62008324|NCT06661993|ACTIVE_COMPARATOR|ALA group|ALA group: 30 septic patients will be given 1800 mg orally or via a nasogastric tube daily for seven days .
62008325|NCT06615570|EXPERIMENTAL|Part A: Single Ascending Dose|Participants will be randomized to receive a single dose of VX-973 under fasted conditions.
62008326|NCT06615570|EXPERIMENTAL|Part B: Multiple Ascending Dose|Participants will be randomized to receive multiple doses of VX-973 under fasted conditions.
62008327|NCT06615570|PLACEBO_COMPARATOR|Placebo Part A|Participants will be randomized to receive placebo matched to VX-973.
62008328|NCT06615570|PLACEBO_COMPARATOR|Placebo Part B|Participants will be randomized to receive placebo matched to VX-973.
62008329|NCT04512274|EXPERIMENTAL|Test Article|The test article was applied to an open application site and to a second site of induced inflammation
62398339|NCT05921734|ACTIVE_COMPARATOR|Prespecified-ablation Group|
62782253|NCT04715971||Patients admitted ≤72 hours to an acute geriatric hospitalisation unit.|All patients aged ≥75 years, admitted to the acute geriatric hospitalisation units of the University Hospitals Leuven in Belgium, were consecutively screened for inclusion within 72 hours of admission in a 2 month period (between October 26 and December 18, 2015).
62782254|NCT05926830|EXPERIMENTAL|Sonovein Treatment|
62782255|NCT02082730|ACTIVE_COMPARATOR|Mid treatment Group|Patients who have completed 6 sessions at the Manchester CFS/ME Service for Children \& Young People will be recruited. They would have had previous experience of using paper diaries.They will collect activity data using the ASARM system.
62782256|NCT02082730|EXPERIMENTAL|Start of Treatment Group|Newly presented patients, will collect activity data using the ASARM system.
62782257|NCT02082730|NO_INTERVENTION|Audit group|"To provide comparative baseline data for general treatment response, we will audit pre-treatment and post-treatment clinical data on the regular gold standard clinical measures package, as these are the outcome measures routinely used in the clinic."
62782258|NCT05164614|EXPERIMENTAL|RT-102 Group 1|In 15 subjects, a RaniPill capsule containing 20 µg of PTH will be administered and serial blood samples will be collected for PK analysis.
62008330|NCT00933491||Diabetic|Type II Diabetes
62008331|NCT00933491||Control|Non-diabetics
62008332|NCT03862976|EXPERIMENTAL|computerized cardiotocography|computerized cardiotocography
62782259|NCT05164614|EXPERIMENTAL|RT-102 Group 2|In 15 subjects, a RaniPill capsule containing 80 µg of PTH will be administered and serial blood samples will be collected for PK analysis.
62782260|NCT05164614|ACTIVE_COMPARATOR|SC Group|In 10 subjects, 20 µg of Forteo will be administered subcutaneously and serial blood samples will be collected for PK analysis.
62782261|NCT05164614|EXPERIMENTAL|Part 2; Group 1|In up to 7 subjects, once-a-day repeat dosing with RT-102 (20 mcg) for 7 days in healthy post-menopausal or surgically sterile with bilateral oophorectomy women.
62782262|NCT05164614|EXPERIMENTAL|Part 2; Group 2|In up to 12 subjects, once-a-day repeat dosing with RT-102 (20 mcg) for 7 days in healthy women.
62193849|NCT05954572||treatment-naive or topically treated psoriasis patients|A standardized form is going to be used to collect demographic information, and details regarding smoking and alcohol habits. Additional information regarding their treatment regimens will be recorded. Furthermore patients will be evaluated for the presence of acne, rosacea, perioral dermatitis, seborrheic dermatitis, folliculitis, blepharitis, or pityriasis folicullorum, as these conditions have been associated with an increased demodicosis. After that the standardized skin surface biopsy (SSSB) technique will be utilized to assess demodicosis.
62008333|NCT03862976|ACTIVE_COMPARATOR|standard cardiotocography|standard cardiotocography non stresstest
62193850|NCT04996368|ACTIVE_COMPARATOR|low dose (10mg/kg)|The dose of tranexamic acid varies widely ranging from 10mg/kg to 100mg/kg. We are comparing 10mg/kg to conventional 30mg/kg dose. The result of this study will help us to review our current practice.
62193851|NCT04996368|ACTIVE_COMPARATOR|high dose or conventional group (30mg/kg)|dose 30mg/kg regularly use in our center as a prophylaxis for prevention of bleeding before open heart surgery
62193852|NCT04005716|EXPERIMENTAL|tislelizumab plus etoposide and platinum|
62193853|NCT04005716|ACTIVE_COMPARATOR|Placebo plus etoposide and platinum|
62008334|NCT01147419|EXPERIMENTAL|bypass|Patients presenting with long occlusion of the superficial femoral artery enrolled in bypass arm will undergo suprageniculate femoropopliteal bypass surgery to bypass the occluded superficial femoral artery. And the graft will be artificial blood vessel.
62008335|NCT01147419|EXPERIMENTAL|stent|
62008336|NCT03759223|EXPERIMENTAL|E-PST (randomized)|Enhanced Problem-Solving Training (E-PST) arm. E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Randomized participants were assigned 1:1 to E-PST or HLM.
62008337|NCT03759223|ACTIVE_COMPARATOR|Control (randomized)|Healthy Living Messages (Control) arm. Healthy Living Messages (HLM) are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care. Randomized participants were assigned 1:1 to E-PST or HLM.
62008338|NCT03759223|OTHER|E-PST (non-randomized)|Enhanced Problem-Solving Training (E-PST) arm. E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Non-randomized participants were assigned to E-PST only.
62193854|NCT00831077|ACTIVE_COMPARATOR|14C-ORM-14540|
62398340|NCT04477239|PLACEBO_COMPARATOR|Placebo|Oral administration of one capsule of Placebo
62782263|NCT04487925|ACTIVE_COMPARATOR|Up to 3 modified natural cycles|
62193855|NCT00831077|ACTIVE_COMPARATOR|14C-ORM-12741|
62193856|NCT05141227|EXPERIMENTAL|two stage ORIF|Two-stage Open reduction and internal fixation
62193857|NCT05141227|EXPERIMENTAL|single stage Ex. Fix|Single-stage external fixation with minimal internal fixation if needed
62782264|NCT04487925|EXPERIMENTAL|Controlled ovarian stimulation|
62782265|NCT05781464|PLACEBO_COMPARATOR|Traditional chest physiotherapy|This group receives traditional chest physiotherapy that include postural drainage, percussion and vibration ( manually or by a vibrator) in each session which is twice daily from admission to neonatal intensive care unit till discharge
62782266|NCT05781464|ACTIVE_COMPARATOR|Prolonged slow expiration technique and traditional chest physiotherapy|This group receives traditional chest physiotherapy that include postural drainage, percussion and vibration ( manually or by a vibrator) plus prolonged slow expiration technique in each session which is twice daily from admission in neonatal intensive care unit till discharge.
62782267|NCT01846741|OTHER|Model 106 VNS Therapy System|
62398341|NCT04477239|ACTIVE_COMPARATOR|Purified gluten (10 mg)|Oral administration of capsules containing 10 mg of purified gluten.
62398342|NCT04477239|ACTIVE_COMPARATOR|Purified gluten (50 mg)|Oral administration of capsules containing 50 mg of purified gluten.
62398343|NCT04477239|ACTIVE_COMPARATOR|Purified gluten (100 mg)|Oral administration of capsules containing 100 mg of purified gluten.
62398344|NCT04477239|ACTIVE_COMPARATOR|Purified gluten (500 mg)|Oral administration of capsules containing 500 mg of purified gluten.
62398345|NCT04477239|ACTIVE_COMPARATOR|Purified gluten (1000 mg)|Oral administration of capsules containing 1000 mg of purified gluten.
62782268|NCT06431269|EXPERIMENTAL|Screening for neurodevelopmental disorders by an advanced practice nurse|
62782269|NCT06024668|EXPERIMENTAL|Detection of colliding pedestrian|Participants will perform a simulated walking task in which surrounding pedestrians will walk towards and make a collision. Participants will respond by pressing buttons to indicate the direction of the colliding pedestrians. Participants will perform the task with and without the multiplexing prism in random orders.
62008339|NCT04915781||Tobacco users|Never smokers (reference group) will be compared with former smokers, occasional smokers and daily smokers. For FinSote 2018 and 2020, we will also compare never users of (1) smokeless tobacco (snus), (2) electronic cigarettes with and without nicotine or (3) nicotine replacement therapy products with respective former, occasional and daily users.
62008340|NCT03325413|NO_INTERVENTION|Control|Usual care with assessment only (no study-related intervention)
62398346|NCT06066242|EXPERIMENTAL|AZA+VEN|Two courses of azacitidine combined with venetoclax as induction regimen
62782270|NCT04043468|EXPERIMENTAL|Improved A&F intervention|Two feedback sessions and four structured focus groups
62782271|NCT04043468|ACTIVE_COMPARATOR|Standard A&F intervention|Two feedback sessions
62193858|NCT03062696|EXPERIMENTAL|Intervention (CBT-RD)|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-RD. There is no control group.
62193859|NCT00882115|EXPERIMENTAL|DEP challenge in subjects consuming BSE|DEP will be administered in nostrils of participants who received BSE intervention by drinking 1 cup of liquid containing 1.25 g BSE daily for 4 days, or without consuming BSE.
62782272|NCT06303323|EXPERIMENTAL|Qigong Exercise|Baduanjin Exercise will be performed which consists of 8 standing postures. At least 30 minutes per time. 10-13 min for a set of Badaunjin
62782273|NCT06303323|EXPERIMENTAL|Wu Dang Tai Chi|Wu Dang 13 form postures will be performed. Initially, each posture will be performed 3 times then progressively increase to more according to the patient's discomfort.
62782274|NCT01673620|EXPERIMENTAL|Montelukast 10 mg/loratadine 10 mg|Montelukast 10 mg/loratadine 10 mg combination tablet administered orally once daily for 2 weeks
62782275|NCT01673620|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet administered orally once daily for 2 weeks
62008341|NCT03325413|OTHER|Implementation|Implementation of intervention measures
62008342|NCT03325413|OTHER|Full-scale intervention|
62008343|NCT03621267|EXPERIMENTAL|Interactive Stepping Exercise|"Interactive Stepping Exercise (1 hour, 3 times/week, 12 weeks)~The 1-hour training program will start with10 minutes warm-up session, after that 40 minutes of ISE, and ended with 10 minutes of cool down session.~Interactive Stepping Exercise (ISE) will perform on a thin mat that was partitioned into 24 squares. The ISE program included forward, backward, lateral and oblique steps, and step patterns were progressively made more complicated."
62008344|NCT03621267|ACTIVE_COMPARATOR|Home exercise program|60 minutes, 3 times/week, 12 weeks of home exercise
62008345|NCT05304858||TME Analysis|Participants who have been diagnosed with metastatic castration-resistant prostate cancer (mCRPC) will volunteer for a biopsy of a site in the body that contains prostate cancer, such as a bone, a lymph node or an organ such as the liver OR are planned to undergo standard of care surgical procedures such as orthopedic surgery or neurosurgery based on a subjects clinical needs.
62008346|NCT05656378||Single Cohort|Participants aged \>0 years with no upper age limit, both healthy volunteers and those with previously known and unknown disease states
62008347|NCT00931905|EXPERIMENTAL|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used, and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.
62008348|NCT00931905|PLACEBO_COMPARATOR|hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol.
62193860|NCT01947322|EXPERIMENTAL|Allogenic NK cells infusion|
62193861|NCT04386603||shoulder-tip pain group|The patients in this group have postoperative phoulder-tip pain after laparoscopic surgery undergoing general anesthesia.
62193862|NCT04386603||non-shoulder-tip pain group|The patients in this group don't have postoperative phoulder-tip pain after laparoscopic surgery undergoing general anesthesia.
62193863|NCT05995509|ACTIVE_COMPARATOR|3 MOPs group|The subjects under a split mouth intervention on the experimental side will undergo 3 micro-osteo-perforations (creating small holes in the buccal cortical bone) to assess the rate of tooth movement.
62193864|NCT05995509|EXPERIMENTAL|1 MOP group|the subjects under the split mouth intervention on the control side will undergo 1 micro-osteo-perforation in comparison to the experimental side.
62193865|NCT04556409|EXPERIMENTAL|low intensity pulsed ultrasound|20 women were treated by low intensity pulsed ultrasound (5 min, 0.5 w/cm2, 1MHZ with 20% duty cycle, 3 times/ week for 4 weeks plus static abdominal and pelvic floor exercises.
62193866|NCT04556409|EXPERIMENTAL|low level laser therapy|20 women were treated by low level laser therapy (Gallium Aluminum Arsenide Laser), 808nm, 4J/cm2, pulsating signal, 60 seconds for each point, 30 Mw/cm2, 3 times/week for 4 weeks plus static abdominal and pelvic floor exercises.
62398347|NCT06066242|EXPERIMENTAL|DA/IA 3+7|Daunorubicin or Idarubicin ×3 days combined with cytarabine × 7 days as induction regimen
62398348|NCT06066242|EXPERIMENTAL|DA/IA 2+5+VEN|Daunorubicin or Idarubicin ×2 days, cytarabine × 5 days combined with venetoclax as induction regimen
62782276|NCT01954108|OTHER|ESWT (Extracorporal Shock Wave Therapy)|Three applications in weekly interval.
62782277|NCT01954108|ACTIVE_COMPARATOR|hyaluronic acid sodium salt|Two injections of 2% (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
62782278|NCT01742806|NO_INTERVENTION|control|not to use bio-absorbable felt(NEOVEIL®)
62782279|NCT01742806|EXPERIMENTAL|NEOVEIL®|To use bio-absorbable felt
62782280|NCT05471089|EXPERIMENTAL|Experimental|Application of radiofrequency diathermy in addition to the exercises protocol same Exercise protocol than control group. Ten sessions of treatment were applied: daily the first week (Monday to Friday), three the second week (Monday, Wednesday, Friday) and two the last week (Monday and Thursday)
62193867|NCT04556409|PLACEBO_COMPARATOR|static abdominal and pelvic floor exercises|20 women were the control group who received only static abdominal and pelvic floor exercises. , 3 times/week for 4 weeks.
62193868|NCT01862068||GPA patients|GPA patients with an active disease at inclusion
62193869|NCT01862068||MPA patients|
62398349|NCT05970120|EXPERIMENTAL|NUVISION NAV Ultrasound Catheter|Participants with five different subgroups (scar-related atrial tachycardia, persistent atrial fibrillation \[PsAF\], paroxysmal atrial fibrillation \[PVF\], ventricular tachycardia \[VT\], and premature ventricular complex \[PVC\]) will be treated using NUVISION NAV ultrasound catheter per investigator's standard of care and followed until 7 days post-procedure.
62398350|NCT04657627|EXPERIMENTAL|PACE plus calorie information intervention group|PACE plus calorie information intervention group will receive PACE plus calorie information of discretionary foods via social media posts.
62398351|NCT04657627|ACTIVE_COMPARATOR|Calorie-only information comparator group|Calorie-only information comparator group will receive calorie-only information of discretionary foods via social media posts.
62782281|NCT05471089|ACTIVE_COMPARATOR|Control|Exercise protocol consisting of: eccentric and concentric strengthening of quadriceps (three squat series of 20 repetitions), hamstrings (three series of 20 seconds performing the bridge exercise), gluteus medius (three series of 20 seconds performing the clam exercise), gastrocnemius and soleus (three series of stretching exercises for 1 minute each). These exercises will be performed along 20 minutes approximately with a minute of rest between each exercise series, never exceeding 3mm in VAS. Participants have to assist to a local facility center to be supervised at doing the exercises daily (from Monday two Friday) along three weeks.
62782282|NCT02113228||Short Bowel Syndrome|Verify the total energy expenditure in patients with short bowel syndrome using the doubly labeled water method.
62782283|NCT02113228||Control Group|Verify the total energy expenditure in patients without short bowel syndrome using the doubly labeled water method.
62782284|NCT01132742||hospitalised children|
62398352|NCT01779466|EXPERIMENTAL|Experimental A|
62398353|NCT01779466|EXPERIMENTAL|Experimental B|
62398354|NCT01779466|PLACEBO_COMPARATOR|Placebo|
62398355|NCT02596074|EXPERIMENTAL|Omiganan (CLS001)|CLS001 topical gel, 2.5%
62398356|NCT02596074|PLACEBO_COMPARATOR|Vehicle|Vehicle topical gel
62782285|NCT00360724|EXPERIMENTAL|duloxetine (cymbalta)|Duloxetine medication: a medication currently marketed in the USA that is reported to have pharmacological effects including reuptake blockage for serotonin and norepinephrine
62782286|NCT00360724|PLACEBO_COMPARATOR|Placebo treatment|placebo treatment: treatment with placebo capsules that match active medication capsules
62782287|NCT04016077|EXPERIMENTAL|PF-06651600 Moderate Hepatic Impairment|This arm includes participants with moderate hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.
62193870|NCT01862068||Healthy Blood Donors|
62193871|NCT01862068||Atherosclerotic patients|
62193872|NCT01862068||EGPA (Eosinophilic Granulomatosis With Polyangiitis)|
62193873|NCT02927912|EXPERIMENTAL|Treatment (IOERT boost)|Patients undergo standard of care lumpectomy and then undergo 1 fraction of IOERT boost to the lumpectomy cavity. Patients then undergo standard of care oncoplastic reconstruction and whole breast radiation therapy.
62214902|NCT04792918||NEC/LOS preterm infants|Collection of biological samples (stool, stomach fluid, blood) and health-related data over the first few weeks of life, additional stool samples after onset of NEC/LOS
62398357|NCT06722547|ACTIVE_COMPARATOR|Group A (Standard Pulmonary Rehabilitation)|Aerobic exercise, PLB, ACBT, Education
62398358|NCT06722547|EXPERIMENTAL|Group B (Standard PR + RMS)|Standard PR plus Respiratory Muscle Stretching
62398359|NCT03674385|EXPERIMENTAL|vitamin E group|30 patient
62398360|NCT03674385|ACTIVE_COMPARATOR|control group|clomiphene
62573421|NCT04143854|EXPERIMENTAL|MBA-P01 24U|Experimental group; Dose: 24U
62008349|NCT05639088|EXPERIMENTAL|Group A: SHIFT2|"Adolescents and young adults will engage in routine medical visits and attend 6 sessions (1x/month) focused on transition preparation and diabetes management with a transition coach and will receive bi-weekly messages during these 6-months that encourage self-management behaviors.~Parents will attend 2 sessions (month 1 and 6) with a transition coach and will receive materials, complementing their child's lesson, 1x/month for months 2-5 that focus on transition their role and supporting their child's diabetes management."
62008350|NCT05639088|PLACEBO_COMPARATOR|Group B: TAU+/Control|Participants will engage in routine medical visits and will receive education materials monthly (1x/month) regarding healthcare transition and diabetes management.
62008351|NCT03882359|ACTIVE_COMPARATOR|Definity|Each subject receives 100 uL x 2, 200 uL x 3, 300 uL x 2 or 1 vial of DEFINITY® 100 diluted in 50 mL of NS as follows: Two milliliter bolus over 10 seconds prior to each infusion rate;, then infusions will run for 5 minutes at 60 mL per hour, 5 minutes at 90 mL per hour, 5 minutes at 100 mL per hour and 5 minutes at 120 mL per hour.
62573422|NCT04143854|EXPERIMENTAL|MBA-P01 12U|Experimental group; Dose: 12U
62008352|NCT03882359|EXPERIMENTAL|MVT-100|Each subject receives 100 uL x 2, 200 uL x 3, 300 uL x 2 or 1 vial of MVT-100 diluted in 50 mL of NS as follows: Two milliliter bolus over 10 seconds prior to each infusion rate;, then infusions will run for 5 minutes at 60 mL per hour, 5 minutes at 90 mL per hour, 5 minutes at 100 mL per hour and 5 minutes at 120 mL per hour.
62008353|NCT05195320|EXPERIMENTAL|Group Intervention|Participants will attend six weekly two-hour facilitator-led sessions that include didactic presentations of eight core skills and related experiential exercises with extensive group discussion. These skills are presented in sequence over the course of the intervention so that participants can gain mastery of introductory concepts before undertaking those that are both more difficult and complex. The culmination of developing these skills and participation in a peer group will assist individuals in increasing self-efficacy and overall QOL, well-being and participation. Participants will complete follow-up assessment at 18- and 30-weeks post-intervention.
62008354|NCT05195320|PLACEBO_COMPARATOR|Placebo|Participants will receive no intervention throughout the course of the study; however, the participants will be tested at 18- and 30-weeks participation in the study.
62573423|NCT04143854|PLACEBO_COMPARATOR|Placebo|Placebo group; normal saline
62193874|NCT06444490|ACTIVE_COMPARATOR|General Approach (GA)|This approach consisted of a 15-minute session in which the dentist attempted to impart knowledge about oral hygiene in general, highlighting some of the most common situations in this age group, namely the difficulty in achieving correct brushing and flossing, demonstrating the correct technique on a typodont (model), and alerting them to the importance of oral health to general health. Periodontal disease, tooth decay and denture care were also covered in general terms. Participants were given a written explanatory guide to reinforce good oral hygiene habits and an explanation of these diseases or conditions. Appropriate oral hygiene tools were also provided to encourage the expected improvement in oral health. Finally, there was a question-and-answer session to clarify any doubts the participant might have.
62398361|NCT04613752|EXPERIMENTAL|experimental group|A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.
62398362|NCT06724341|EXPERIMENTAL|Control group: inferior alveolar nerve block will be administrated with passive behavior management|
62398363|NCT06724341|EXPERIMENTAL|Movies group: inferior alveolar nerve block will be administrated with displaying animated movies di|
62398364|NCT06724341|EXPERIMENTAL|Video games group: Application of active behavior management by usage video games on the screen of a|
62398365|NCT06724341|EXPERIMENTAL|Movies and Video games group: An active and passive behavior management will be applied by usage vid|
62573424|NCT06524362|EXPERIMENTAL|Pelvic Floor Physiotherapy (PFR) group|"Patients completing three months post-low anterior resection (LAR) for rectal cancer or six weeks post-diversion ileostomy closure following LAR will be recruited to Pelvic Floor Rehabilitation (PFR) group after randomization.~Intervention: Participants will undergo a structured pelvic floor physiotherapy program for three months.~The program includes:~Eight Personal Sessions: Each session lasts 45 minutes.~Frequency:~* Once a week for the first month (four sessions).~* Biweekly for the next two months (four sessions).~Home Exercises: Participants will be guided on pelvic floor exercises to be performed at home throughout the three months.~Usual Care: In addition to the pelvic floor rehabilitation, participants will receive the standard postoperative care for rectal cancer surgery."
62573425|NCT06524362|ACTIVE_COMPARATOR|Conventional group|"Patients completing three months post-low anterior resection (LAR) for rectal cancer or six weeks post-diversion ileostomy closure following LAR will be recruited to Conventional group after randomization.~Recruited subjects in the conventional group recieves usual care following low anterior resection such as fluid intake, fiber intake, diet, toilet posture, life style advice etc"
62573426|NCT06445803|EXPERIMENTAL|Dose escalation|CD19/CD22-CAR-transduced T cells at escalating doses (0.5\~5.0 ×10\^6 cells/kg)
62573427|NCT06445803|EXPERIMENTAL|Dose expansion|CD19/CD22-CAR-transduced T cells at MTD or highest dose administered
62573428|NCT04828018||Key Staff|Key Staff will take part in one interview lasting up to 60 minutes
62573429|NCT04828018||In-Pensioners|Royal Hospital Chelsea In-Pensioners will take part in one interview lasting up to 90 minutes and complete n=2 Quality of Life Questionnaires (ICECAP-A and WHOQOL-BREF) at the start of their qualitative interview.
62573430|NCT04828018||New In-Pensioner|New In-Pensioners wil be asked to complete a total of n=4 Quality of Life Questionnaires (ICECAP-A and WHOQOL-BREF), n=2 on admission to Royal Hospital Chelsea and n=2 six months after admission.
62573431|NCT05296083|EXPERIMENTAL|G3P-01 50mg Dose Treatment Period 1|G3P-01 will be administered orally as a powdered mixed with water. Treatment Period one dose will be 50mg of IP.
62573432|NCT05296083|EXPERIMENTAL|G3P-01 500mg Dose Treatment Period 2|G3P-01 will be administered orally as a powdered mixed with water. Treatment Period two dose will be 500mg of IP.
62573433|NCT05296083|EXPERIMENTAL|G3P-01 1000mg Dose Treatment Period 3|G3P-01 will be administered orally as a powdered mixed with water. Treatment Period three dose will be 1000mg of IP.
62782288|NCT04016077|EXPERIMENTAL|PF-06651600 Healthy participants|This arm includes healthy adult participants who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.
62398366|NCT03274791||Healthy subjects|"Healthy non-smoking subjects were never smokers with normal spirometry and did not have a history of lung disease or chronic respiratory symptoms.~Information about respiratory symptoms and comorbidities were collected. Healthy subjects underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
62008355|NCT05901285|EXPERIMENTAL|VAX014|Dose escalation of VAX014 \[recombinant bacterial minicells (rBMCs)\] intratumoral injections alone for subjects with solid tumors relapsed and/or refractory to standard treatment and appropriate for injection of a nodal, subcutaneous, or cutaneous tumor via palpation or with the assistance of ultrasound. In dose expansion, injection may be in metastatic tumors with or without the need for interventional radiology.
62008356|NCT00981279||HIV seroposite patients|Seroposite HIV patients that take their treatment at the Clinical Hospital of The Federal University of Goias, and have their records in the hospital.
62782289|NCT04016077|EXPERIMENTAL|PF-06651600 Mild Hepatic Impairment|"This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met.~The arm includes participants with mild hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10."
62782290|NCT04300036|EXPERIMENTAL|longan syrup|Take 15 ml of longan syrup once a day for 3 months
62782291|NCT04300036|PLACEBO_COMPARATOR|Placebo syrup|Take 15 ml of placebo syrup once a day for 3 months
62008357|NCT02476396||patient-subject|Patients will be recruited from the population of patients scheduled to undergo carotid endarterectomy or stenting (endovascular) for established clinical indications. These indications include patients scheduled to have a carotid endarterectomy or stenting due to the presence of a high-grade atherosclerotic cervical internal carotid artery stenosis with or without clinical symptoms, following the ACAS or NASCET criteria (carotid artery stenosis of 60% or greater without clinical symptoms; stenosis 70% or greater with clinical symptoms).
62008358|NCT02476396||patient-control|The controls will be recruited by the patient-subjects. The investigators will ask their patient-subjects to speak to a spouse or family member to see if they are interested in participating. If they do have an interest they will contact the research team/study coordinator(s). In case, a spouse or a family member is accompanying the patient-subject, they will be recruited at the same time as the patient-subject.
62008359|NCT03581136|EXPERIMENTAL|Prescription Isodose Surface Coverage|"The dose fractionation to the CTV (1cm expansion on cavity) will be 40Gy/ 5 fractions and the PTV (3 mm expansion of CTV) will be a minimum dose of 30Gy/5 fractions.~If PTV \>100cc or if dose constraints cannot be met on higher dose prescribe CTV (1.0cm) to 35Gy/5 fractions and PTV (3mm) to 30Gy/5 fractions. This is to potentially reduce risk of fat necrosis."
62008360|NCT01174030|EXPERIMENTAL|CD07805/47 Gel 0.5% QD|
62008361|NCT01174030|EXPERIMENTAL|CD07805/47 Gel 0.18% QD|
62008362|NCT01174030|EXPERIMENTAL|CD07805/47 Gel 0.18% BID|
62008363|NCT01174030|PLACEBO_COMPARATOR|Vehicle Gel QD|
62008364|NCT01174030|PLACEBO_COMPARATOR|Vehicle Gel BID|
62573434|NCT05296083|EXPERIMENTAL|G3P-01 2000mg Dose Treatment Period 4|G3P-01 will be administered orally as a powdered mixed with water. Treatment Period four dose will be 2000mg of IP.
62573435|NCT01921868|EXPERIMENTAL|Acetyl-L-Carnitine|Open-label administration of Acetyl-L-Carnitine, up to 2 g/day for 24 months.
62573436|NCT04881864|EXPERIMENTAL|Tele-EF|Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training
62573437|NCT06355076|EXPERIMENTAL|New urethral reconstruction arm|The experimental group received a new reconstruction technique, in which the levator anus and the dorsal median ridge (MDR) of the lateral striated muscle were sutured to the Dirichlet fascia for continuous suture before anastomosis
62573438|NCT06355076|ACTIVE_COMPARATOR|Traditional bladder urethral anastomosis arm|End to end anastomosis of bladder and urethra
62573439|NCT01167933|EXPERIMENTAL|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd.
62782292|NCT02713828|EXPERIMENTAL|Phase I: Glembatumumab Vedotin|Glembatumumab vedotin once every three weeks (q3w) by 90-minute intravenous (IV) infusion, until disease progression or intolerance. The Dose-Limiting Toxicity (DLT) evaluation period for determination of the appropriateness of dose-escalation will be through the end of the second treatment cycle.
62782293|NCT02713828|EXPERIMENTAL|Phase II: Glembatumumab Vedotin|Glembatumumab vedotin once every three weeks (q3w) by 90-minute intravenous (IV) infusion, until disease progression or intolerance. The Maximum Tolerated Dose (MTD) determined in Phase I will be used in Phase II.
62008365|NCT06193434|EXPERIMENTAL|IBI356 for Single ascending dose (SAD)|
62008366|NCT06193434|EXPERIMENTAL|IBI356 for Multiple ascending dose (MAD)|
62008367|NCT06193434|PLACEBO_COMPARATOR|Placebo for MAD|
62008368|NCT06193434|ACTIVE_COMPARATOR|Dupilumab for MAD|
62008369|NCT06193434|PLACEBO_COMPARATOR|Placebo for SAD|
62193875|NCT06444490|ACTIVE_COMPARATOR|Personalised Technique (PT)|This approach began with a self-examination in an extra-oral mirror by the participant to allow the professional to understand participant's perception of oral health, and the use of a plaque-disclosing solution to allow the participant to be more sensitive to the areas where brushing and flossing were not effective. Conditions such as caries lesions, major gingival recessions, areas of greater inflammation, areas where plaque accumulation or even tartar was more visible and further denture care were highlighted. The typodont (model) was then used to demonstrate the correct brushing and flossing technique. The session ended with the participant receiving an explanatory guide, a personalized plan, and more appropriate tools to promote the expected improvement in oral health. A question-and-answer session was used to clarify any doubts. This method took about approximately 20 minutes.
62782294|NCT04294836|EXPERIMENTAL|Curcumin|Chemotherapy (cisplatin) plus concomitant radiation therapy (teletherapy + high or low rate brachytherapy) + Curcugreen (BCM95) 2000mg daily (each 6h)
62573440|NCT01167933|ACTIVE_COMPARATOR|Zocor|Zocor® 80 mg tablets of Merck \& Co. Inc., USA
62573441|NCT01605552|EXPERIMENTAL|Beating the Blues (BtB)|An 8-session, empirically supported, computerized, cognitive-behavioral intervention for depression (www.beatingthebluesus.com)
62573442|NCT01605552|OTHER|Usual Care|Patients and their primary care providers were informed of the positive depression screen, and follow-up was encouraged.
62008370|NCT03175224|EXPERIMENTAL|NSCLC Exon 14 Skip Treatment Naive|Cohort A-1: APL-101 Oral Capsules
62008371|NCT03175224|EXPERIMENTAL|NSCLC Exon 14 Skip Previously Treated|Cohort A-2: APL-101 Oral Capsules
62782295|NCT04294836|PLACEBO_COMPARATOR|Placebo|Chemotherapy (cisplatin) plus concomitant radiation therapy (teletherapy + high or low rate brachytherapy) + Placebo Capsules 500mg 2000mg daily (each 6h)
62008372|NCT03175224|EXPERIMENTAL|NSCLC Exon 14 MET Inhibitor Experienced|Cohort B: APL-101 Oral Capsules
62008373|NCT03175224|EXPERIMENTAL|Basket of tumor types MET amplification except for primary CNS tumors|Cohort C: APL-101 Oral Capsules
62008374|NCT03175224|EXPERIMENTAL|NSCLC MET amplification and EGFR wild-type|Cohort C-1: APL-101 Oral Capsules
62782296|NCT01290744|PLACEBO_COMPARATOR|Placebo group|These patients will receive placebo for 12 months after completion of MDT.
62193876|NCT04264715|EXPERIMENTAL|405nm light room|In this room, surgeries will be performed under ambient light including the wavelength 405nm
62573443|NCT01068678|EXPERIMENTAL|IDeg 3 times weekly (3TW)|
62573444|NCT01068678|ACTIVE_COMPARATOR|IGlar OD|
62573445|NCT02127840|EXPERIMENTAL|Synacthen|Synacthen infusion during adrenal venous sampling
62573446|NCT02127840|NO_INTERVENTION|Without Synacthen|Adrenal venous sampling without Synacthen
62782297|NCT01290744|EXPERIMENTAL|Clofazimine for 12 months after MDT|Patients will be given clofazimine (100mg daily) for 12 months after completion of MDT.
62782298|NCT00410007|OTHER|Patients with ADPKD, HS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
62193877|NCT04264715|NO_INTERVENTION|Control room|In this room, surgeries will be performed under ambient light from regular phosphorescent light does not include 405nm frequencies
62193878|NCT02038712|EXPERIMENTAL|Binge eating disorder (BED)|Blood samples, subjective appetite ratings and fMRI scan will be collected in subjects who meet the current criteria for binge eating disorder (BED) in the fed condition and fasted condition.
62193879|NCT02038712|EXPERIMENTAL|Control|Blood samples, subjective appetite ratings and fMRI scan will be collected in subjects who do not meet the current criteria for BED (Controls) in the fed condition and fasted condition.
62193880|NCT04079205|EXPERIMENTAL|Home rehabilitation using Wearable Device|Home rehabilitation using Wearable Device(exoRehab)
62193881|NCT04079205|ACTIVE_COMPARATOR|Control|Standard home rehabilitation program
62193882|NCT02356627|EXPERIMENTAL|The Cancer Home Life Intervention|"One or more of the following:~* prioritisation of resources and everyday activities~* adaptation of activities~* adaptation of posture and seating positioning~* provision of assistive devices~* modification of the physical home environment And usual care from hospital and municipality"
62193883|NCT02356627|NO_INTERVENTION|Control|Usual care from hospital and municipality
62193884|NCT01653600|EXPERIMENTAL|LifeStent|same to SMART CONTROL Stent
62193885|NCT01653600|ACTIVE_COMPARATOR|SMART CONTROL Stent|study design is 2x2 randomization design. First, before randomization, stratification will be performed according to lesion length 15cm criteria at web-based computerized program. Patients will be randomized in a 1:1 manner according to different two (SMART versus LifeStent) stents. And then, patients received aspirin and clopidogrel during one month. After one month from index procedure, clopidogrel will be stopped and changed into cilostazol. Patients were randomized to receive cilostazol 100mg bid either 11 month duration or 5 month duration in separate groups of SMART stent group and LifeStent group. Randomization procedure will be performed using a web-based program
62193886|NCT05701241|ACTIVE_COMPARATOR|somatostatin analogs continuation|Somatostatin analog (octreotide long-acting release (LAR) 30 mg or lanreotide 120 mg) will be given every four weeks for a duration of 18 months.
62193887|NCT05701241|NO_INTERVENTION|somatostatin analogs withdrawal|Somatostatin analog treatment (octreotide LAR 30 mg or lanreotide 120 mg) will be withdrawn for a duration of 18 months.
62193888|NCT01663038|ACTIVE_COMPARATOR|Clopidogrel and Aspirin|
62193889|NCT01663038|EXPERIMENTAL|Copidogrel|
62193890|NCT05306886|EXPERIMENTAL|Intervention group|ICB Special Insoles
62193891|NCT05306886|ACTIVE_COMPARATOR|Control group|ICB Insoles
62008375|NCT03175224|EXPERIMENTAL|EGFR positive NSCLC MET amplification as an acquired resistance|Cohort C-2: APL-101 Oral Capsules + Standard of Care EGFR Inhibitor
62008376|NCT03175224|EXPERIMENTAL|Basket of solid tumor with MET gene fusions except for primary CNS tumors|Cohort D: APL-101 Oral Capsules
62008377|NCT03175224|EXPERIMENTAL|Primary CNS tumors with MET alterations|Cohort E: APL-101 Oral Capsules
62008378|NCT03175224|EXPERIMENTAL|Basket of tumor types wild-type MET with over-expression of HGF and MET|Cohort F: APL-101 Oral Capsules
62008379|NCT00804427|EXPERIMENTAL|Fish oil (90% triglycerides)|Fish oil (4 grams/day of combined EPA and DHA) as 90% triglyceride formulation, taken in two divided doses with main meals.
62008380|NCT00804427|EXPERIMENTAL|Fish oil (60% triglycerides)|Fish oil (4 grams/day of combined EPA and DHA) as 60% triglyceride formulation, taken in two divided doses with main meals.
62193892|NCT02876952|ACTIVE_COMPARATOR|Attention Control Group (AC)|Moderate to high- intensity physical activity and Mediterranean Diet recommendations
62193893|NCT02876952|EXPERIMENTAL|HV-HIIT|"Supervised high volume and high intensity interval training exercise group with Mediterranean Diet recommendations.~High-intensity \[heart rate (HR) values up to second ventilatory threshold (VT2) to peak intensity\] interval training and high-volume increasing gradually from 20 to 40 min and alternating high and moderate \[HR values between first ventilatory threshold (VT1) and VT2\] intensities at different protocols."
62193894|NCT02876952|EXPERIMENTAL|LV-HIIT|"Supervised low volume and high intensity interval training exercise group with Mediterranean Diet recommendations.~High-intensity (HR values up to VT2 to peak intensity) interval training and low-volume (20 min) alternating high and moderate (HR values between VT1 and VT2) intensities at different protocols."
62193895|NCT00193479|EXPERIMENTAL|Cyclophosphamide/Vincristine/Rituximab +/- Mitoxantrone|All patients receive three courses of combination chemotherapy/rituximab followed by pegfilgrastim, administered at 21-day intervals. Treatment administered is as follows: cyclophosphamide 500mg/m2 IV day 1; mitoxantrone 10mg/m2 IV day 1; vincristine 1.0mg/m2 (maximum 2mg) IV day 1; prednisone 80mg PO days 1 - 5; rituximab 375mg/m2 IV day 1.
62193896|NCT03723226|ACTIVE_COMPARATOR|Low Load Resistance Exercise|Subjects allocated to Low Load Resistance Exercise will undergo 6 weeks of single-legged low load (25%) resistance exercise. Their contralateral leg will serve as within subject control.
62193897|NCT03723226|EXPERIMENTAL|Low Load Resistance Exercise + BFR|Subjects allocated to Low Load Resistance Exercise + BFR will undergo 6 weeks of single-legged low load (25%) resistance exercise plus blood flow restriction. Their contralateral leg will serve as within subject control.
62193898|NCT06398509|EXPERIMENTAL|Intervention|The Futuros Fuertes 2.0 intervention includes brief health education and coaching at well child visits in the first two years of life that addresses optimal feeding, screen time and sleep practices. In addition, caregivers receive 2 text messages per week. Caregivers also receive environmental prompts to help support healthy behaviors at home.
62193899|NCT06398509|ACTIVE_COMPARATOR|Control|The control intervention includes brief health education and coaching at well child visits in the first two years of life that addresses home safety, management of common childhood illnesses, and promotion of language development. In addition, caregivers receive 2 text messages per week. Caregivers also receive environmental prompts to help support healthy behaviors at home.
62008381|NCT00804427|EXPERIMENTAL|Fish oil (ethyl esters)|Fish oil (4 grams/day of combined EPA and DHA) as ethyl esters formulation (0% triglycerides), taken in two divided doses with main meals.
62008382|NCT00804427|PLACEBO_COMPARATOR|Soy oil|Soy oil supplement with identical total fat content, taken in two divided doses with main meals.
62008383|NCT00958880|PLACEBO_COMPARATOR|Sugar Pill|Participants will receive placebo (sugar pill) augmented Group Cognitive Behavioral Therapy
62008384|NCT00958880|EXPERIMENTAL|Yohimbine Hydrochloride|Participants will receive Yohimbine Hydrochloride augmented Group Cognitive Behavioral Therapy
62193900|NCT04210843|EXPERIMENTAL|Ligelizumab 72 mg LIVI -ligelizumab 120 mg PFS|Participants received 72 mg of ligelizumab liquid in vial (LIVI) subcutaneously every 4 weeks for the first 12 weeks. Thereafter, participants received 120 mg of ligelizumab pre-filled syringe (PFS) subcutaneously every 4 weeks for up to 92 additional weeks (continuous or interrupted if the participant entered the observation period 2).
62193901|NCT04210843|EXPERIMENTAL|Ligelizumab 120 mg LIVI -ligelizumab 120 mg PFS|Participants received 120 mg of ligelizumab liquid in vial (LIVI) subcutaneously every 4 weeks for the first 12 weeks. Thereafter, participants received 120 mg of ligelizumab pre-filled syringe (PFS) subcutaneously every 4 weeks for up to 92 additional weeks (continuous or interrupted if the participant entered the observation period 2).
62193902|NCT05155566||Breast Cancer Patients|HR + /HER2- Advanced/Metastatic Breast Cancer patients in Latin America
62193903|NCT02603692||Pediatric group (ages 8-17)|PROMIS pediatric domains for emotional distress (anxiety and depression), physical function (fatigue, pain interference, mobility and upper extremity), and peer relations
62193904|NCT02603692||Adult group (ages 18-35)|PROMIS adult domains. To reduce respondent burden, the multi-form design will be used which includes the short form of physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference and pain intensity.
62193905|NCT02603692||Parent/guardian proxy|Parent/guardian will complete the parental proxy PROMIS instruments based on corresponding child age (ages 5 to 17 years)
62193906|NCT03506659|ACTIVE_COMPARATOR|Test|2000 patients healthy in anesthesiology consultation
62193907|NCT03506659|EXPERIMENTAL|Patients|2000 patients in pain clinic consultation
62193908|NCT00673907|SHAM_COMPARATOR|1|Clean air
62193909|NCT00673907|EXPERIMENTAL|2|Wood smoke particle concentration of 200 ug/m3
62193910|NCT00673907|EXPERIMENTAL|3|Wood smoke particle concentration of 400 ug/m3
62193911|NCT03600025|OTHER|non-randomized|Responses will be compared before and after vaccination
62193912|NCT04501393|NO_INTERVENTION|0 ml/kg|The participants will not be asked to drink anything at 2 hours prior to planned procedure.
62193913|NCT04501393|ACTIVE_COMPARATOR|3 ml/kg|The participants will be asked to drink 3ml/kg of clear liquid at 2 hours prior to planned procedure.
62193914|NCT04501393|ACTIVE_COMPARATOR|7 ml/kg|The participants will be asked to drink 7 ml/kg of clear liquid at 2 hours prior to planned procedure.
62193915|NCT04501393|ACTIVE_COMPARATOR|10 ml/kg|The participants will be asked to drink 10 ml/kg of clear liquid at 2 hours prior to planned procedure.
62573447|NCT01356823|EXPERIMENTAL|30μg HPV|Participants in this arm would receive 30μg HPV vaccines which contains 20μg HPV 16 antigen and 10μg HPV 18 antigen
62782299|NCT00410007|OTHER|Patients with ADPKD, LS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
62008385|NCT02262728|EXPERIMENTAL|Panel 1|Participants with Child-Pugh score \<7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient \[HVPG\] greater than or equal to 10 millimeter of mercury \[mm Hg\]) will receive simeprevir (150 milligram \[mg\] capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.
62193916|NCT03251092|ACTIVE_COMPARATOR|SAD PTI-808 Active|Three cohorts of SAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
62782300|NCT00410007|OTHER|Healthy Control Subjects, HS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
62193917|NCT03251092|PLACEBO_COMPARATOR|SAD PTI-808 Placebo|Three cohorts of SAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
62193918|NCT03251092|ACTIVE_COMPARATOR|MAD PTI-808 Active|Three cohorts of MAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
62193919|NCT03251092|PLACEBO_COMPARATOR|MAD PTI-808 Placebo|Three cohorts of MAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
62193920|NCT03251092|ACTIVE_COMPARATOR|FE PTI-808 Active|Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
62193921|NCT03251092|PLACEBO_COMPARATOR|FE PTI-808 Placebo|Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
62193922|NCT03251092|EXPERIMENTAL|Part 2 PTI-808 + PTI-801 + PTI-428 Active|One cohort is planned where subjects will be randomized to either the triple active arm (dosed with PTI 808+PTI 801+PTI 428) OR placebo arm.
62573448|NCT01356823|EXPERIMENTAL|60μg HPV|Participants in this arm would receive 60μg HPV vaccines which contains 40μg HPV 16 antigen and 20μg HPV 18 antigen
62782301|NCT00410007|OTHER|Healthy Control Subjects, LS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
62008386|NCT02262728|EXPERIMENTAL|Panel 2|Participants with Child-Pugh score 7 to 9 (extremes included) will receive simeprevir (150 mg capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.
62008387|NCT02267655|ACTIVE_COMPARATOR|inhaled Nitric Oxide 30 mcg/kg IBW/hr|30 mcg/kg IBW/hr of inhaled Nitric Oxide Part 1
62008388|NCT02267655|ACTIVE_COMPARATOR|inhaled nitric oxide 75 mcg/kg IBW/hr|Part 2: 75mcg/Kg IBW/hr
62193923|NCT03251092|PLACEBO_COMPARATOR|Part 2 matching Placebos|In all three cohorts in part 2, subjects will be randomized to active drug or placebo. The placebo arm for all cohorts consists of placebo capsules matching PTI-808+PTI-801+PTI-428.
62193924|NCT03251092|EXPERIMENTAL|Part 2 dual active arm PTI-801+PTI-428+ PTI-808 placebo|One cohort is planned where subjects are randomized to either 808 placebo + dual active arm (dosed with placebo matching PTI 808 plus PTI 801 + PTI 428) OR placebo arm.
62193925|NCT03251092|ACTIVE_COMPARATOR|Part 2 dual active arm PTI-801+PTI-808+PTI-428 placebo|One cohort is planned where subjects are randomized to either 428 placebo + dual active arm (dosed with placebo matching PTI 428 plus PTI 808 and PTI 801) OR placebo arm.
62214903|NCT04792918||Preterm infants not developing NEC/LOS|Collection of biological samples (stool, stomach fluid, blood) and health-related data over the first few weeks of life
62193926|NCT03251092|ACTIVE_COMPARATOR|Part 3 CF MAD PTI-808 + PTI-801 + PTI-428|In all cohorts in Part 3, subjects will be will be randomized to receive 7 days of PTI-808 or placebo followed by 14 days of co-administration of PTI-808+PTI-801+PTI-428 or matching placebos. A follow-up will occur on Day 28.
62193927|NCT03251092|PLACEBO_COMPARATOR|Part 3 CF MAD PTI-808 placebo+PTI-801 placebo+PTI-428 placebo|In all cohorts in Part 3, subjects will be randomized to receive 7 days of PTI-808 or placebo followed by 14 days of co-administration of PTI-808+PTI-801+PTI-428 or matching placebos. A follow-up will occur on Day 28.
62193928|NCT03251092|ACTIVE_COMPARATOR|Part 4 CF PTI-808 + PTI-801 + PTI-428|In cohorts 3 \& 4 subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
62193929|NCT03251092|ACTIVE_COMPARATOR|Part 4 CF PTI-808 + PTI-801 + PTI-428 placebo|In cohorts 3 \& 4, subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
62193930|NCT03251092|PLACEBO_COMPARATOR|Part 4 CF PTI-808 placebo + PTI-801 placebo + PTI-428 placebo|In cohorts 3 \& 4, subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
62193931|NCT02007200|EXPERIMENTAL|Treatment (soy isoflavones)|Patients receive soy isoflavones PO for approximately 14 days before undergoing surgery.
62193932|NCT02029963|EXPERIMENTAL|Cluster rTMS|Two weeks of daily repetitive Transcranial Magnetic Stimulation (total of 10 rTMS sessions), six months following completion of regular six-week rTMS treatment.
62193933|NCT02029963|EXPERIMENTAL|Taper rTMS|Immediately following completion of regular six-week repetitive Transcranial Magnetic Stimulation treatment, patients in this group will receive three sessions of rTMS a week for two weeks followed by two sessions of rTMS a week for two weeks (total of 10 rTMS sessions tapered in 4 weeks)
62193934|NCT02029963|EXPERIMENTAL|Treatment as Usual|Following their last session of regular six-week rTMS treatment, patients in this group will follow an individually-tailored maintenance plan as determined by their own psychiatrist or primary care provider
62193935|NCT04781270|EXPERIMENTAL|mFOLFOXIRI+Bev|"Patients will receive mFOLFOXIRI plus bevacizumab once every two weeks as the first-line treatment.~Drug: mFOLFOXIRI plus Bevacizumab Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1). A local MDT will assess the efficiency every 4 cycles of the treatment. The maximum period of conversion therapy is 12 cycles."
62193936|NCT04781270|ACTIVE_COMPARATOR|mFOLFOX6+Bev|"Patients will receive mFOLFOX6 plus bevacizumab once every two weeks as the first-line treatment.~Drug: mFOLFOX6 Plus Bevacizumab mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1). A local MDT will assess the efficiency every 4 cycles of the treatment. The maximum period of conversion therapy is 12 cycles."
62193937|NCT02545829|EXPERIMENTAL|Sequence 1|HGP1406 → HIP1302
62193938|NCT02545829|EXPERIMENTAL|Sequence 2|HIP1302 → HGP1406
62193939|NCT03550469|EXPERIMENTAL|Computer-assisted Oxygen Weaning|A computer with an adaptive model algorithm will guide oxygen weaning.
62193940|NCT03550469|NO_INTERVENTION|Manual Oxygen Weaning|Oxygen weaning will be done by staff manually.
62193941|NCT05826145|ACTIVE_COMPARATOR|Vocal Expression|Supportive care through vocal expression sessions where participants can talk for approximately 20-30 minutes about the person who died.
62193942|NCT05826145|EXPERIMENTAL|Cognitive Behavioral|Cognitive-behavioral techniques with sessions consisting of approximately 20-30 minutes.
62193943|NCT05214547|EXPERIMENTAL|Experimental Group|Focal Vibration Group Training with Focal Vibration on the deltoid, trapezius, and biceps muscles with an amplitude of 1.2 mm. Time of training 20-25 min. The configuration of the vibration program will be in an automatic mode of 10 seconds of vibration and 3 seconds of rest to avoid the coupling of the mechanoreceptors. Patients will be treated with FV for three consecutive days: each session consisted of three sessions of 10 minutes each, interspersed with one minute of rest. A vibration frequency of 40 Hz to 100 Hz has been applied, according to the literature. The group also received the Traditional Training.
62193944|NCT05214547|ACTIVE_COMPARATOR|Control Group|"Traditional Training Warm up, grade 1 and 2 mobilization and stretching exercises, strength training, range of motion exercises, and coordination training.~The home exercises program is programmed."
62193945|NCT02366143|EXPERIMENTAL|Arm A (Atezolizumab+Paclitaxel+Carboplatin)|Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
62214904|NCT04792918||Family members of preterm infants|Collection of biological samples (stool, breastmilk, vaginal swab) and health-related data at one timepoint after the birth of the preterm infant from members of the family (mother, father)
62573449|NCT01356823|EXPERIMENTAL|90μg HPV|Participants in this arm would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
62573450|NCT01356823|PLACEBO_COMPARATOR|hepatitis B vaccine|Participants in this arm would receive hepatitis B vaccine.
62573451|NCT03182244|EXPERIMENTAL|ASP2215|ASP2215 will be administered orally once daily.
62193946|NCT02366143|EXPERIMENTAL|Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)|Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
62573452|NCT03182244|ACTIVE_COMPARATOR|Salvage chemotherapy|Options for salvage chemotherapy are limited to the following: Low-dose Cytarabine (LoDAC) will be administered twice daily by subcutaneous or intravenous injection for 10 days. Mitoxantrone, Etoposide, Cytarabine (MEC Induction Chemotherapy) will each be administered intravenously for 5 days (days 1 through 5). Granulocyte colony-stimulating factor (G-CSF) will be administered intravenously for 5 days (days 1 through 5) and also recommended 7 days after completing chemotherapy, Fludarabine and Cytarabine administered intravenously for 5 days (days 2 through 6) (FLAG Induction Chemotherapy). Based on the outcome of interim analysis, participants will be evaluated for eligibility for crossover extension (COE). In COE participants will be administered ASP2215 orally once daily.
62782302|NCT06041126||Group one|Patients with COPD according to the combined COPD assessment Global Intervention (GOLD) guidelines, participants who are in groups A and B (mild-moderate) will be included in group 1.
62782303|NCT06041126||Group two|"COPD patients according to the combined COPD assessment, according to the Global Intervention (GOLD) guidelines, participants who are in groups C and D (severe-very severe) will be included in group 2."
62573453|NCT03182244|EXPERIMENTAL|ASP2215 PK in Chinese population|PK samples will be collected after single and multiple doses in Chinese subjects.
62573454|NCT04082923|OTHER|Gastric bypass operated patients|Two test days in a randomized, patient-blinded, cross-over design
62573455|NCT04082923|OTHER|Gastric sleeve operated patients|Two test days in a randomized, patient-blinded, cross-over design
62573456|NCT04082923|OTHER|Control arm|Two test days in a randomized, patient-blinded, cross-over design
62734624|NCT04563403|EXPERIMENTAL|Treatment with Single Stimuli|Projection-based augmented reality therapy (P-ARET) with Single Stimuli (SS) (P-ARET SS). Intervention group that receives P-ARET treatment using a single stimulus (one cockroach).
62782304|NCT03709394|ACTIVE_COMPARATOR|Group A: Full utrasound guidance|Full utrasound guidance of cathether insertion. Intervention: Ultrasound portable device used for the identification of the target vein and for the ultrasound control of proper catheter placement during the procedure of peripheral venous cannula insertion.
62782305|NCT03709394|ACTIVE_COMPARATOR|Group B: Partial ultrasound guidance|Catheter insertion under partial ultrasound guidance. Intervention: Ultrasound portable device used only for the identification of the target vein, the catheter placement will be done by conventional approach.
62782306|NCT03709394|ACTIVE_COMPARATOR|Group C: No ultrasound guidance|Catheter insertion by conventional approach, without ultrasound guidance
62782307|NCT03851055|ACTIVE_COMPARATOR|intervention group|will receive zinc supplementation
62782308|NCT03851055|NO_INTERVENTION|Control group|Patients will receive placebo only
62008389|NCT02267655|ACTIVE_COMPARATOR|inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr|Part 3a: Dose tritration 5, 10 and 15 mcg/Kg IBW/hr Part 3b: continuing on dose determined by PI in 3a for 4 weeks
62008390|NCT02267655|PLACEBO_COMPARATOR|Placebo|Placebo for 75 mcg/kg IBW/hr
62008391|NCT05913063|EXPERIMENTAL|Participants with Age-Related Macular Degeneration|Conducting the psychophysical task on the perception of OAM-coupled polarized light
62008392|NCT03354429|EXPERIMENTAL|TICAGRELOR|
62008393|NCT03354429|PLACEBO_COMPARATOR|TICAGRELOR PLACEBO|
62782309|NCT00088894|EXPERIMENTAL|Arm I (gemcitabine hydrochloride, bevacizumab)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15.
62782310|NCT00088894|ACTIVE_COMPARATOR|Arm II (gemcitabine hydrochloride, placebo)|Patients receive gemcitabine IV as in arm I and placebo IV over 30-90 minutes on days 1 and 15.
62782311|NCT05446571|EXPERIMENTAL|Letermovir|Maternal daily administration of letermovir + placebo of valaciclovir
62782312|NCT05446571|ACTIVE_COMPARATOR|Valaciclovir|Maternal daily administration of valaciclovir + placebo of letermovir
62008394|NCT05390502|EXPERIMENTAL|Integrated|Participants will have their home blood pressure readings sent directly to their participating health systems. Participants will also receive a wrap-around intervention.
62008395|NCT05390502|ACTIVE_COMPARATOR|Manual|Participants will record their own blood pressures and report them to their health care system as per usual care.
62008396|NCT03120013|EXPERIMENTAL|Real tDCS|10 days anodal cerebellar and cathodal spinal tDCS
62008397|NCT03120013|SHAM_COMPARATOR|Sham tDCS|10 days sham cerebellar and sham spinal tDCS
62782313|NCT03018977|ACTIVE_COMPARATOR|Sedative weaning protocol|We create the new sedative weaning protocol and then use the sedative weaning protocol.
62782314|NCT03018977|PLACEBO_COMPARATOR|Usual Care|no use sedative weaning protocol. Sedative or/and analgesic medications are adjusted base on physician
62782315|NCT03323801|EXPERIMENTAL|13-cis retinoic acid|20 mg 13-cis retinoic acid twice daily (BID) with means for 32 weeks
62193947|NCT02366143|ACTIVE_COMPARATOR|Arm C (Bevacizumab+Paclitaxel+Carboplatin)|Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
62782316|NCT04672122|SHAM_COMPARATOR|Sham tDCS|Sham transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) and Anode on the supraorbital area of contralateral side. Current intensity will be at 2 mA (sham mode). The scope of intervention is to investigate effect of sham tDCS on muscle strength.
62782317|NCT04672122|EXPERIMENTAL|Cathodal-tDCS 1 mA|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) and Anode on the supraorbital area of contralateral side. Current intensity is fixed at 1 mA and current will flow continuously. The scope of intervention is to investigate effect of cathodal tDCS on muscle strength.
62782318|NCT04672122|EXPERIMENTAL|Cathodal-tDCS 1.5 mA|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) and Anode on the supraorbital area of contralateral side. Current intensity is fixed at 1.5 mA and current will flow continuously. The scope of intervention is to investigate effect of cathodal tDCS on muscle strength.
62782319|NCT04672122|EXPERIMENTAL|Cathodal-tDCS 2 mA|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) and Anode on the supraorbital area of contralateral side. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of cathodal tDCS on muscle strength.
62782320|NCT06291064|EXPERIMENTAL|Treatment Arm|Participants will receive epirubicin and cyclophosphamide every three weeks for a total of 12 weeks followed by 3-weekly docetaxel for 12 weeks and carboplatin every three weeks for a total of 12 weeks. All premenopausal participants will receive luteinizing hormone-releasing hormone (LHRH) agonist goserelin (Zoladex) for contraception and fertility preservation.
62782321|NCT06432504|EXPERIMENTAL|caffeine content 100mg|The participants will drink 180 mls coffee
62193948|NCT00780455|EXPERIMENTAL|Interferon beta-1b, FRP within 15 days after randomization|Interferon beta-1b (Betaseron, BAY86-5046) 250 microgram (8 MUI), sub-cutaneous, administration every other day, Participants starting the 6 weeks functional rehabilitation protocol (FRP) within 15 days after randomization
62782322|NCT06432504|EXPERIMENTAL|caffeine content 200mg|The participants will drink 180 mls coffee.
62782323|NCT06432504|EXPERIMENTAL|caffeine content 300mg|The participants will drink 180 mls coffee
62782324|NCT06432504|EXPERIMENTAL|13C3 caffeine content 100mg|The participants will drink 180 mls coffee (caffeine content 100mg) containing 13C labelled caffeine to trace the pattern of caffeine degradation.
62782325|NCT00317096|ACTIVE_COMPARATOR|FCM|"All patients underwent a central randomization procedure. Randomization was done by a Computer program stratified for histology, Response to the preceding chemotherapy, and the number of previous chemotherapies using the method of permutuated blocks.~The FCM combination comprised:~25 mg/m2 fludarabine per day iv over 30 minutes, days 1 to 3 200 mg/m2 cyclophosphamide per day as a 4-hour-infusion, days 1 to 3 8 mg/m2 mitoxantrone per day iv over 30 minutes, day 1 4 treatment Cycles á 4 weeks per cycle In patients with peripheral lymphocyte Counts more than 20.000/mm3 and/or a large Tumor mass (ie, bulky disease more than 10 cm) a cytoreductive pre-phase could be performed, comprising cyclophosphamide at a dose of 200 mg/m2 as a 1-hour-infusion over 3 to 5 days."
62008398|NCT05882539||endotracheal tube material|One group of patients used a spring-loaded endotracheal tube and the other group used a PVC tube.
62782326|NCT00317096|EXPERIMENTAL|R-FCM|"All patients underwent a central randomization procedure. Randomization was done by a Computer program stratified for histology, Response to the preceding chemotherapy, and the number of previous chemotherapies using the method of permutuated blocks.~The R-FCM combination comprised:~375 mg/m2 rituximab on the day before the respective FCM course. 25 mg/m2 fludarabine per day iv over 30 minutes, days 1 to 3 200 mg/m2 cyclophosphamide per day as a 4-hour-infusion, days 1 to 3 8 mg/m2 mitoxantrone per day iv over 30 minutes, day 1 4 treatment Cycles á 4 weeks per cycle In patients with peripheral lymphocyte Counts more than 20.000/mm3 and/or a large Tumor mass (ie, bulky disease more than 10 cm) a cytoreductive pre-phase could be performed, comprising cyclophosphamide at a dose of 200 mg/m2 as a 1-hour-infusion over 3 to 5 days."
62008399|NCT05882539||Bite block Material|One group of patients used hard bite block and the other group used soft bite block
62782327|NCT00317096|OTHER|Observation only|"Patients achieving a complete or partial remission after FCM or R-FCM underwent a subsequent randomization for 2 courses of rituximab to be given 3 and 6 months after completion of salvage therapy versus observation only.~This second randomization was stratified for the type of salvage therapy with FCM or R-FCM, the Response to this Treatment (CR or PR), and histology."
62782328|NCT00317096|OTHER|rituximab maintenance|"Patients achieving a complete or partial remission after FCM or R-FCM underwent a subsequent randomization for 2 courses of rituximab to be given 3 and 6 months after completion of salvage therapy versus observation only.~Courses of rituximab consisted of 4 doses of 375 mg/m2 per day given at 4 consecutive weeks.~This second randomization was stratified for the type of salvage therapy with FCM or R-FCM, the Response to this Treatment (CR or PR), and histology."
62782329|NCT00274677|PLACEBO_COMPARATOR|Placebo|
62782330|NCT00274677|EXPERIMENTAL|lamotrigine|
62782331|NCT05216341|EXPERIMENTAL|Stage 1: Arm 1 (OLP-1002, 1 μg)|"Participants will receive once single dose of 1 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
62193949|NCT00780455|EXPERIMENTAL|Interferon beta-1b, FRP about 6 weeks after randomization|Interferon beta-1b (Betaseron, BAY86-5046) 250 microgram (8 MUI), sub-cutaneous, administration every other day, Participants starting the 6 weeks functional rehabilitation protocol (FRP) about 6 weeks after randomization
62398367|NCT03274791||COPD Never smokers|"Never smokers referred to subjects who had never smoked Airflow limitation in COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio \<70% and FEV1 reversibility of \<12% and 200 mL from baseline values after inhalation of 400 µg of Salbutamol.~Information about respiratory symptoms and comorbidities were collected. Never smoking subjects with COPD underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
62782332|NCT05216341|EXPERIMENTAL|Stage 1: Arm 2 (OLP-1002, 3 μg)|"Participants will receive once single dose of 3 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
62782333|NCT05216341|EXPERIMENTAL|Stage 1: Arm 3 (OLP-1002, 10 μg)|"Participants will receive once single dose of 10 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
62782334|NCT05216341|EXPERIMENTAL|Stage 1: Arm 4 (OLP-1002, 25 μg)|"Participants will receive once single dose of 25 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
62782335|NCT05216341|EXPERIMENTAL|Stage 1: Arm 5 (OLP-1002, 50 μg)|"Participants will receive once single dose of 50 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
62782336|NCT05216341|EXPERIMENTAL|Stage 1: Arm 6 (OLP-1002, 80 μg)|"Participants will receive once single dose of 80 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
62782337|NCT05216341|EXPERIMENTAL|Stage 2: Arm 1 (OLP-1002, 1μg)|"Participants will be randomised to receive single dose of 1μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
62782338|NCT05216341|EXPERIMENTAL|Stage 2: Arm 2 (OLP-1002, 2μg)|"Participants will be randomised to receive single dose of 2μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
62782339|NCT05216341|PLACEBO_COMPARATOR|Stage 2: Arm 3 (Placebo)|"Participants will be randomised to receive single dose of Placebo on Day 1~Mode of Administration: subcutaneously injection"
62782340|NCT05325840|EXPERIMENTAL|music therapy|"Experimental Group: Pre-test will be applied to pregnant women before the intervention. Since ST will be applied later, Nki will be applied to pregnant women, and their props will then be right lateral or lateral. NST registration form will be filled.~After the pregnancy is given, the type of music (Classical Turkish Music, Turkish Classical Music, Lullaby) is asked according to the preferences of the pregnant women and their music is given for 20 minutes. The NST process will be implemented from start to finish. In the application, music from pregnant women will be played on MP3 players. After the NST procedure is applied, the pregnant women will have a son."
62398368|NCT03274791||COPD Smokers|"Smokers were defined as persons who had smoked \> 20 packs of cigarettes in a lifetime and who continue smoking every day.~Airflow limitation in COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio \<70% and FEV1 reversibility of \<12% and 200 mL from baseline values after inhalation of 400 µg of Salbutamol.~Information about respiratory symptoms and comorbidities were collected. Smoking subjects with COPD underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
62782341|NCT05325840|NO_INTERVENTION|standard of care|"Control group: First of all, Personal Information Form, State Anxiety Scale and blood pressure measurement will be made to the pregnant women in the control group. In order to perform the NST procedure, the pregnant women will be given the left side or right side position to fix the probes. NST registration form will be filled.~20 minutes after positioning the pregnant women. During the routine NST procedure will be applied and no intervention will be made. After the NST procedure is completed, the State Anxiety Scale and blood pressure measurement will be repeated as the last test of the pregnant women."
62573457|NCT05202067|EXPERIMENTAL|pharmaceutical education|The patients assigned to the intervention group will receive from the research pharmacist, a didactic talk (of at least 10 and up to 20 minutes), where they will be provided information about type 2 diabetes mellitus and Systemic Arterial Hypertension, causes of the disease and consequences of poor control, on its pharmacological treatments, changes in lifestyle and diet. In addition, the patient will be given an updated list of their prescribed medications on a wallet card.
62573458|NCT05202067|NO_INTERVENTION|control|Patients assigned to the control group will receive only standard care, represented by regular consultation with their prescribing physician.
62573459|NCT03780881|EXPERIMENTAL|Expectation confirmation|The participants in this group receive manipulated feedback indicating that their performance was very good in the test they had previously worked on. This feedback is intended to confirm the previously induced positive expectations of their own performance.
62573460|NCT03780881|EXPERIMENTAL|Expectation disconfirmation|The participants in this group receive manipulated feedback indicating that their performance was below average in the test they had previously worked on. This feedback is intended to negatively disconfirm the previously induced positive expectations of their own performance.
62573461|NCT05961943|EXPERIMENTAL|RESPONSE-2-PAD|All participants will use the activPAL accelerometer to quantify sedentary time/physical activity. The 6-minute-walk test will be assessed. Participants will receive the 12 week tailored intervention (RESPONSE-2-PAD link, coaching calls and activity tracker). Participants will be followed up at 12-weeks and again at six months.
62573462|NCT01208779||1|Women with estrogen receptor positive breast cancer already receiving treatment with an aromatase inhibitor (AI) will be enrolled in the study
62573463|NCT01619267||device associated infection|patients with proven device associated infection
62573464|NCT01619267||control group|patients without device associated infection
62573465|NCT05121311||Newborns under bilirubin monitoring|Bilirubin monitoring according to standard of care of the participating center
62573466|NCT06363331|NO_INTERVENTION|Patients TRS without social cognition damage|Patients TRS without damage without intervention
62573467|NCT06363331|NO_INTERVENTION|Patients TRS with Social Cognition control|Patients TRS with social cognition damage with regular therapy in the centre
62573468|NCT06363331|EXPERIMENTAL|Patients TRS with social cognition with Emotional Training|Patients TRS with social cognition damage with Emotional Training therapy in the centre
62573469|NCT03208998|EXPERIMENTAL|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
62573470|NCT03208998|NO_INTERVENTION|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
62573471|NCT01448473|EXPERIMENTAL|4 views radiograph serie|The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.
62573472|NCT01448473|ACTIVE_COMPARATOR|2-view radiography serie|The 2-film series will include the following views: anterior-posterior and one lateral.
62573473|NCT05801536|EXPERIMENTAL|Upper limb task practice with or without cervical transcutaneous electrical stimulation|Task specific practice will be combined with cervical transcutaneous electrical stimulation.
62573474|NCT04210063|EXPERIMENTAL|IMT Intervention|During the first month, participants will be in a month-long control wash in period where no intervention will be provided. During the second month, participants will be in a 4-week daily IMT intervention period. During the third month, participants will be in a month-long efficacy period with no intervention provided.
62573475|NCT06575426|EXPERIMENTAL|OPF-310|13 patients will be transplanted OPF-310.
62573476|NCT05600231|EXPERIMENTAL|Treatment Group: Brush Only|Participants will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste for 1 timed minute under virtual supervision once daily during the week. At home, participants will brush a second time unsupervised daily in the evening and twice daily over weekends and holidays for 12 weeks. First product use will occur at the site under supervision.
62573477|NCT05600231|EXPERIMENTAL|Treatment Group: Brush / Rinse (LISTERINE COOL MINT Antiseptic Mouthwash)|Participants will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste once daily for 1 timed minute during the week under supervision and rinse with 20 milliliters (mL) of LISTERINE COOL MINT Antiseptic Mouthwash for 30 seconds. At home, participants will brush and rinse a second time unsupervised daily in the evening and twice daily over weekends and holidays for 12 weeks. First product use will occur at the site under supervision.
62573478|NCT05600231|EXPERIMENTAL|Treatment Group: Brush / Rinse LISTERINE COOL MINT ZERO Alcohol Mouthwash)|Participants will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste once daily for 1 timed minute during the week under supervision and rinse with 20 mL of LISTERINE COOL MINT ZERO Alcohol Mouthwash for 30 seconds. At home, participants will brush and rinse a second time unsupervised daily in the evening and twice daily over weekends and holidays for 12 weeks. First product use will occur at the site under supervision.
62573479|NCT05600231|EXPERIMENTAL|Treatment Group: Brush / Floss|Participants will brush their teeth using marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste for 1 timed minute and floss with Reach Unflavored Waxed Dental Floss under virtual supervision once daily during the week. At home, participants will brush a second time unsupervised daily in the evening. Over weekends and holidays, participants will brush and floss once daily. Only brushing will be performed a second time in the evening for 12 weeks. First product use will occur at the site under supervision.
62782342|NCT03817268|EXPERIMENTAL|Capecitabine monotherapy group|
62782343|NCT03817268|NO_INTERVENTION|Control group|
62782344|NCT05222386|OTHER|Usual Care|Community neurologists provide their usual care to enrolled participants. The clinicians may utilize other community resources to support patients and families as per their usual practice.
62008400|NCT05882539||Moisture of oral mucosa|One group of patients had moist oral mucosa after entering the ward and the other group had dry oral mucosa.
62008401|NCT05882539||serum albumin level|One group of patients had normal serum albumin level at the first blood sample analysis after tracheal intubation and the other group was abnormal.
62782345|NCT05222386|OTHER|Online Community-Supported Palliative Care Intervention|Community neurologists get training in palliative care via teleconferences (ECHO model), in addition to other support from our team. Patients and carepartners will also have access to additional support services when their providers enter the intervention (Online support groups, tailored education)
62782346|NCT03937414|EXPERIMENTAL|SLNs were tested by the OSNA assay Intraoperatively|SLNs were tested by the OSNA assay Intraoperatively
62782347|NCT02369419||CRT|Patients over 70 years age, selected for CRT according to the ESC 2013 guidelines.
62573480|NCT05600231|EXPERIMENTAL|Treatment Group: Brush / Floss / Rinse (LISTERINE COOL MINT ZERO Alcohol Mouthwash)|Participants will brush their teeth using marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste for 1 timed minute, floss with Reach Unflavored Waxed Dental Floss and rinse with LISTERINE COOL MINT ZERO Alcohol Mouthwash for 30 seconds under virtual supervision once daily during the week. At home, participants will brush and rinse a second time unsupervised daily in the evening. Over weekends and holidays, participants will brush, floss and rinse once daily. Only brushing and rinsing will be performed a second time in the evening for 12 weeks. First product use will occur at the site under supervision.
62573481|NCT05600231|NO_INTERVENTION|Healthy Reference Group|Healthy participants will enroll in this reference group and will not receive any study product nor will they receive a prophylaxis as part of their participation in this study. The healthy reference group will be used as a comparator group for microbiome.
62782348|NCT04371666|EXPERIMENTAL|Pamrevlumab|Pamrevlumab 35 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally for up to 52 weeks
62214905|NCT05251194|EXPERIMENTAL|video laryngoscope at thyroid surgical position|"After induction of anesthesia and muscle relaxation, the patient will be positioned with a standard pillow to exposure neck for thyroid surgery (thyroid surgical position). Then, tracheal intubation will be performed with a McGrath video laryngoscope. During laryngoscopy with the McGrath video laryngoscope, the intubation practitioner will record the modified Cormack-Lehane grade and the percentage of glottic opening (POGO) score when it is assumed that a direct laryngoscope is used and when using the video laryngoscope, respectively.~Next, the intubation practitioner will perform tracheal intubation with it."
62573482|NCT00840567|OTHER|Healthy Volunteers|To obtain a one time skin sample (4 ml skin punch biopsy) and one time blood sample (1 teaspoon)
62573483|NCT00840567|OTHER|Patients with benign, inherited hematologic disease|To obtain a one time skin sample (4 ml skin punch biopsy) and one time blood sample (1 teaspoon)
62573484|NCT01754129||Participants with Parkinson's disease|Participants with advanced levodopa-responsive Parkinson's disease and severe motor fluctuations and hyper-/dyskinesia who were prescribed and treated in accordance with the local levodopa/carbidopa intestinal gel product label
62573485|NCT04806243|EXPERIMENTAL|Carelizumab Combined With Regorafenib arm|
62573486|NCT06369168|ACTIVE_COMPARATOR|NADA auricular acupuncture|Patients in one intervention group are treated twice a week for five weeks with balanced ear acupuncture.The data sets of those subjects who received at least eight balanced ear acupuncture treatments will be compared with those who got NADA acupuncture and those who were not treated.
62782349|NCT04371666|PLACEBO_COMPARATOR|Placebo|Matching placebo IV every 2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally for up to 52 weeks
62214906|NCT02769767||Cases|Subjects with Relapsing-Remitting Multiple Sclerosis. Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
62573487|NCT06369168|ACTIVE_COMPARATOR|balanced auricular acupuncture|Patients in the other intervention group are treated twice a week for five weeks with NADA ear acupuncture. The data sets of those subjects who received at least eight NADA ear acupuncture treatments will be compared with those who got balanced ear acupuncture and those who were not treated.
62782350|NCT03145948|EXPERIMENTAL|Arm A|Participants, who are healthy volunteers, receiving ABBV-553 dose A or placebo
62573488|NCT06369168|NO_INTERVENTION|wait list control|Control group: At the end of the 3-month follow-up, the patients in the control group received 10 ear acupuncture treatments in a group setting.
62573489|NCT04277364|ACTIVE_COMPARATOR|High dose phosphatidic acid|750mg of phosphatidic acid per day for 8 weeks
62193950|NCT01258127||Pemetrexed and Carboplatin|For patients in arm pemetrexed/carboplatin, folic acid (350-1000 μg) must be given daily beginning approximately 5-7 days prior to first dose of pemetrexed and continuing daily until 3 weeks after the last dose of study therapy. Vitamin B12 (1000 μg) will be administered as an intramuscular injection approximately 1 to 2 weeks prior to first dose of pemetrexed and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy. Dexamethasone (4 mg of oral or equivalent) given twice daily should be taken on the day before, the day of, and the day after each dose of pemetrexed, for rash prophylaxis unless medically contraindicated. Patients must receive pemetrexed at day 1 at the dose of 500 mg/m2 as an IV infusion over approximately 10 minutes, then carboplatin target area under the concentration curve (AUC) 6 (i.v. infusion over 30 minutes) on day 1 of a 21-day cycle. A total of four cycles is intended.
62193951|NCT01258127||Vinorelbine and Carboplatin|Patients in arm vinorelbine and carboplatin follow the regimen: The scheduled infusion time is 6-10 minutes for IV vinorelbine at the dose of 25 mg/m2 d1,8, then carboplatin target area under the concentration curve (AUC) 6 (i.v. infusion over 30 minutes) on day 1 of a 21-day cycle. A total of four cycles is intended.
62214907|NCT02769767||Controls|Healthy subjects. Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
62573490|NCT04277364|ACTIVE_COMPARATOR|Low dose phosphatidic acid|375mg of phosphatidic acid per day for 8 weeks
62573491|NCT04277364|PLACEBO_COMPARATOR|Placebo|750mg of corn starch per day for 8 weeks
62573492|NCT02802202||Fibromyalgia|Individuals who met the criteria for a diagnosis of FM based upon the ACR diagnostic criteria.
62573493|NCT02802202||Myofascial Pain Syndrome|Individuals with a diagnosis of MPS that does not meet the American College of Rheumatology (ACR) diagnostic criteria for FM.
62573494|NCT02802202||Control|Individuals with no current or prior diagnosis consistent with MPS or FM.
62573495|NCT00347009|OTHER|Adefovir Dipivoxil|10mg once daily in patients with CHB related advanced fibrosis/cirrhosis.
62573496|NCT01245959|EXPERIMENTAL|Induction chemotherapy and concurrent chemoradiotherapy|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
62573497|NCT01245959|ACTIVE_COMPARATOR|Concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
62573498|NCT05244070|EXPERIMENTAL|BMS-986403 + Fludarabine + Cyclophosphamide|
62573499|NCT04563910||less than 2 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
62008402|NCT05882539||mean arterial pressure level|One group of patients had normal mean arterial pressure leve after entering the ward and the other group was abnormal.
62008403|NCT05882539||blood lactate level|One group of patients had normal blood lactate levels at the first blood sample analysis after tracheal intubation and the other group was abnormal.
62008404|NCT05882539||constraint|One group of patients was constrained during follow-up and the other group was not constrained.
62008405|NCT05882539||sedation|One group of patients was sedated during follow-up and the other group was not sedated.
62008406|NCT05882539||prone position|One group of patients had a prone position performed during follow-up and the other group did not.
62008407|NCT05882539||Duration of tracheal intubation|Dichotomous grouping of the duration of tracheal intubation according to the results of the study.
62008408|NCT05630937|EXPERIMENTAL|NMS-01940153E|"Phase I: Patients will be allocated to sequential cohorts of progressively higher dose levels of NMS-01940153E based on the presence of Dose Limiting Toxicities (DLT).~Phase II: Patients will be treated at the recommended Phase II dose (RP2D) defined in the Phase I portion."
62008409|NCT03093805|EXPERIMENTAL|Calcipotriene|Patients will apply Calcipotriene cream 2 times per day for 7 days.
62008410|NCT01873989|EXPERIMENTAL|Testosterone replacement|Testosterone replacement for hypogonadism.
62008411|NCT01873989|OTHER|Waitlist control|This arm involves watchful waiting.
62008412|NCT03724604||high NAR|Neuron-Specific Enolase to Albumin Ratio is higher than 3.2×10-7
62008413|NCT03724604||low NAR|Neuron-Specific Enolase to Albumin Ratio is lower than 3.2×10-7
62008414|NCT00211081|EXPERIMENTAL|Open Label|
62008415|NCT02121340|EXPERIMENTAL|Behavioral Activation|CC-DDR is a novel mental health/ophthalmologic intervention that we are designing to treat depression and lower HbA1C levels in older AAs with mild-to-moderate DR and comorbid depression. Community Health Workers, who match participants in race and cultural background, will work with ophthalmologists in the retina clinic to educate participants on the links between depression, HbA1C, and DR, and will extend care into the home where they will use Behavioral Activation to treat depression and improve diabetes self-management skills.
62573500|NCT04563910||2-5 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
62573501|NCT04563910||more than 5 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
62573502|NCT06578533|NO_INTERVENTION|Control group|Patients assigned to this group will have their iSRAA and/or ARM treatment withdrawn or reduced, according to standard clinical practice.
62573503|NCT06578533|EXPERIMENTAL|Experimental group|Patients assigned to this group will be maintained on treatment with iSRAA and/or ARM and oral treatment with CSZ (Lokelma) will be added. A single dose of CSZ consists of one to three sachets (5 to 10 g of active ingredient per sachet) that the subject must suspend in 45 mL of water.
62008416|NCT02121340|NO_INTERVENTION|Usual Care|Usual Care
62008417|NCT04640311|EXPERIMENTAL|Part A: Daprodustat Dissolution 1/Dissolution 2/Reference|
62008418|NCT04640311|EXPERIMENTAL|Part A: Daprodustat Dissolution 2/Reference/Dissolution 1|
62008419|NCT04640311|EXPERIMENTAL|Part A: Daprodustat Reference/Dissolution 1/Dissolution 2|
62008420|NCT04640311|EXPERIMENTAL|Part B: Daprodustat Process 1/ Process 2|
62008421|NCT04640311|EXPERIMENTAL|Part B: Daprodustat Process 2/ Process 1|
62193952|NCT01894997|EXPERIMENTAL|DVT Prophylaxis|"Neuromuscular electrical stimulation is to be applied using a custom-built, two-channel stimulator (Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 5 minutes.~Intermittent pneumatic compression is to be applied using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 3 second duration over a period of 5 minutes."
62008422|NCT02407106|EXPERIMENTAL|BLIS K12 treatment|Once daily tablet of Streptococcus Salivarius BLIS K 12 to be slowly dissolved orally every evening for six month
62008423|NCT02128841|EXPERIMENTAL|All patients|CATHAR is a prospective, open-label, pilot, phase 2 study with independent evaluation of all outcomes. The trial is based on a Bayesian design by incorporating historical information for the control group for all analyses.
62573504|NCT02529046|ACTIVE_COMPARATOR|Aerobic exercise associated with CLA|CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%).
62573505|NCT02529046|PLACEBO_COMPARATOR|Aerobic exercise|Placebo group received 4 g/day of olive oil.
62573506|NCT05904834|EXPERIMENTAL|Flexibility training|The intervention group will undergo a flexibility training focused on hamstring extensibility. Each will they will take part in four stretching sessions besides the normal dance training.
62573507|NCT05904834|NO_INTERVENTION|No training|The control group will continue with their training routine during the experiment.
62193953|NCT01908751|EXPERIMENTAL|Sliding Hip Screw and Vitamin D supplementation|Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
62193954|NCT01908751|EXPERIMENTAL|Sliding Hip Screw and Vitamin D placebo|Participants in the placebo group will receive an identical bottle of placebo drops with no active ingredient. Similarly, they will be instructed to take two drops daily for six months. The placebo supplement is also manufactured by the Ddrops Company.
62193955|NCT01908751|EXPERIMENTAL|Cancellous Screws and Vitamin D supplementation|Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
62193956|NCT01908751|EXPERIMENTAL|Cancellous Screws and Vitamin D placebo|Participants in the placebo group will receive an identical bottle of placebo drops with no active ingredient. Similarly, they will be instructed to take two drops daily for six months. The placebo supplement is also manufactured by the Ddrops Company.
62193957|NCT01530737|PLACEBO_COMPARATOR|Control Group|
62193958|NCT01530737|EXPERIMENTAL|Active Antithrombin Group|
62193959|NCT05329168|EXPERIMENTAL|Sequential ascending-dose cohort|Sequential ascending-dose cohort
62193960|NCT06322147||Doublet or triplet chemotherapy combined with cetuximab|
62193961|NCT06323967|EXPERIMENTAL|Large unconditional cash transfers plus voluntary peer support|These participants will receive monthly cash transfers of $1,500 via debit card for 24 months and can elect to participate in peer support services plus usual care from shelter staff.
62193962|NCT06323967|ACTIVE_COMPARATOR|Nominal cash transfers|These participants will receive monthly cash transfers of $50 via debit card for 24 months plus usual care from shelter staff.
62193963|NCT06323967|OTHER|Passive comparison|These propensity-matched families will reside in other New York City shelters and will be followed anonymously in administrative records only. The will receive usual care from shelter staff.
62193964|NCT03671577|EXPERIMENTAL|Active Treatment|four week computerized intervention designed to reduce fear of intimacy
62398369|NCT01052220|EXPERIMENTAL|BP Education and Self Regulation of BP|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will received a BP educational session at baseline and were asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI made weekly visits with the intervention participants in the HD unit to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
62573508|NCT06176404|ACTIVE_COMPARATOR|The comparison group|"The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
62782351|NCT03145948|EXPERIMENTAL|Arm B|Participants, who are healthy volunteers, receiving ABBV-553 dose B or placebo
62008424|NCT06419049|EXPERIMENTAL|Standing Program Intervention|A single-subject study ABABA design will be used with dependent variables of passive range of motion, functional movement, functional skills performance, engagement, health related quality of life and gait velocity will be recorded repeatedly for the individual participants across time and with systematic manipulation of the independent variable, which is the standing home program intervention. The study will span 28 weeks for the intervention Stage 2, consisting of three baseline phases (A) of four weeks each and two home program intervention phases (B) of eight weeks each that alternate in an ABABA design.
62008425|NCT06419049|NO_INTERVENTION|Reliability|Children will be assessed by two study investigators in two different sessions on the same day, with a washout period of 3 hours between sessions. Intrarater reliability will be determined by comparing rater's scores for each child. These sessions will include goniometric measurements of lower extremity passive range of motion and the 10-Meter Walk Test. Children will have the opportunity to rest or resume normal activities with a minimum of 3 hours between sessions. Interrater reliability will be determined based on the measurements in the same session by 2 different raters.
62008426|NCT05059457||Controlled setting: single capillary and pooled capillary and venous blood|Single drop capillary blood, pooled capillary blood, and venous blood will be collected and hemoglobin measured among non-pregnant women age 15-49 and children age 6-59 months in a controlled setting.
62008427|NCT05059457||Field setting: single capillary and venous blood|Single drop capillary blood and venous blood will be collected and hemoglobin measured among non-pregnant women age 15-49 and children age 6-59 months in a field setting.
62008428|NCT05059457||Field setting: pooled capillary and venous blood|Pooled capillary blood and venous blood will be collected and hemoglobin measured among non-pregnant women age 15-49 and children age 6-59 months in a field setting.
62193965|NCT03671577|NO_INTERVENTION|Wait List Control|Participants will continue as usual and will be given the option to receive the active treatment after completion of the study
62193966|NCT03188367|ACTIVE_COMPARATOR|1A - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
62214908|NCT02769767||Responders|Subjects with MS treated for at least two years that have less than one relapse per year or who had an increase of \<1.5 points on the Expanded Disability Status Scale (EDSS) (if baseline EDSS was 0) or no increase in EDSS (baseline EDSS ≥1). Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
62782352|NCT03145948|EXPERIMENTAL|Arm C|Participants, who are healthy volunteers, receiving ABBV-553 dose C or placebo
62782353|NCT03145948|EXPERIMENTAL|Arm D|Participants, who are healthy volunteers, receiving ABBV-553 dose D or placebo
62398370|NCT01052220|NO_INTERVENTION|Usual Care|Participants in the usual care group did not receive the intervention but continued to receive their standard care in the hemodialysis unit which involved follow-up by the medical provider and BP medication adjustments as needed. .
62398371|NCT06510257|EXPERIMENTAL|Treatment Group|1 tablet of Reconyl, 3 times daily
62008429|NCT01222585|EXPERIMENTAL|Treatment|Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours
62008430|NCT01302964|EXPERIMENTAL|Mirtazapine|The starting dose for subjects is 7.5 mg daily. The maximum daily dose will be 45 mg.
62008431|NCT01302964|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo arm will receive capsules identical in size and appearance to those subjects receiving study drug. Placebo capsules contain inactive ingredients.
62008432|NCT02201797|EXPERIMENTAL|DCE and DWI MRI|MRI SCAN 1 and MRI SCAN 2 must be completed no less than 2 calendar days (to ensure 24 hours for clearance of gadolinium) and no greater than 14 days apart, and both must be completed prior to new treatment initiation. The same MRI unit and configuration must be used for MRI SCAN 1 and MRI SCAN 2.
62008433|NCT02317302|EXPERIMENTAL|FDG-PET/CT or FDG-PET/MR|"* Standard of care FDG-PET/CT or FDG-PET/MR at baseline~* FDG-PET/CT or FDG-PET/MR after the 2nd but before the 3rd brachytherapy treatment~* Standard of care 3 month post treatment FDG-PET/CT or FDG-PET/MR~* We will perform the research-related FDG-PET on the PET/MR rather than the PET/CT if the patient is safe to undergo MR and agrees to undergo MR.~* The standard of care imaging may be performed on the PET/CT scanner or the PET/MR scanner."
62008434|NCT02176733|EXPERIMENTAL|cyclosporine|
62008435|NCT05887622|EXPERIMENTAL|Moderate potassium/low sodium|Subjects will consume a diet moderation in potassium and low in sodium.
62008436|NCT05887622|EXPERIMENTAL|Moderate potassium/high sodium|Subjects will consume a diet moderation in potassium and high in sodium.
62008437|NCT05887622|EXPERIMENTAL|High potassium/high sodium|Subjects will consume a diet moderation in potassium and high in sodium.
62008438|NCT04219163|EXPERIMENTAL|CLL-1.CAR|Group A
62398372|NCT06510257|PLACEBO_COMPARATOR|Control Group|1 tablet of placebo Reconyl, 3 times daily
62398373|NCT06185140|EXPERIMENTAL|Intervention group|Cardiac rehabilitation program
62734625|NCT02788084||B cell Non-Hodgkin Lymphoma|18 years of age or older with new diagnosis of non-Hodgkin lymphoma with FFPE specimen demonstrating enough tissue for elucidation of lymphoma specific variant and immunoglobulin clonotype, willing to provide baseline and follow up bloodwork to look for presence of variant and clonotype.
62734626|NCT06005428|EXPERIMENTAL|Dose 1|CRD-4730 Dose 1 capsule
62734627|NCT06005428|EXPERIMENTAL|Dose 2|CRD-4730 Dose 2 capsule
62734628|NCT06005428|PLACEBO_COMPARATOR|Dose 3|Placebo capsule to match CRD-4730
62782354|NCT03145948|EXPERIMENTAL|Arm E|Participants with psoriasis receiving ABBV-553 dose B or placebo
62782355|NCT03145948|EXPERIMENTAL|Arm F|Participants with psoriasis receiving ABBV-553 dose C or placebo
62782356|NCT02241343|OTHER|Trial cohort|Measurements taken before and after venous occlusion applied
62782357|NCT00410605|EXPERIMENTAL|Arm I|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62398374|NCT06185140|ACTIVE_COMPARATOR|Control group|These patients will complete the program from their home through the TELEA platform that belongs to SERGAS. They go to the hospital once at the beginning of the program to learn the program with the Physiotherapist and once again after a month. The program will be carried out twice a week for their home. Patients will be monitored during physical exercise with Garmin® heart rate monitors. Patients will download heart rate and Borg scale data after each session and can establish contact through the TELEA platform with the nursing staff of the Cardiac RHB Unit at all times.
62573509|NCT06176404|EXPERIMENTAL|The observation group|"The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided.~Based on the invention above, the patients in the observation group were provided with SGB, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)."
62573510|NCT00183859|EXPERIMENTAL|A|Intraperitoneal Irinotecan
62573511|NCT06022510|EXPERIMENTAL|Fetoscopes for Selective Laser Photocoagulation|Single arm study. All patients will undergo selective laser photocoagulation with the use of the fetoscopes in this study.
62573512|NCT05618678|ACTIVE_COMPARATOR|Infection Control Training|Nursing homes randomized to this arm of the study receive CDC guidelines and evidence based information on infection prevention prevention and control. Nursing home staff implement these standard in everyday resident care. Additionally, nursing home staff are invited to participate in Extension for Community Healthcare Outcomes (ECHO) sessions via real-time interactive videoconferencing software to support the implementation of the CDC guidelines and evidence-based practices.
62573513|NCT05618678|EXPERIMENTAL|DIGNITY Intervention|Nursing homes randomized to this arm of the study receive an evidence based risk assessment and care planning protocol for supporting decision making and aging in dementia for autonomy (DIGNITY). Nursing home staff use this manual to implement risk assessment and care planning for resident preferences that they perceive to carry a risk to the resident's health and/or safety. In addition nursing home staff participate in Extension for Community Healthcare Outcomes (ECHO) sessions via real-time interactive videoconferencing software to support the implementation of the DIGNITY protocol.
62734629|NCT02406573|EXPERIMENTAL|Crest® Sensi-Stop™ Strips|Professionally Applied
62193967|NCT03188367|ACTIVE_COMPARATOR|1B - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 10 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
62193968|NCT03188367|ACTIVE_COMPARATOR|1C - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 7 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
62398375|NCT01138995|ACTIVE_COMPARATOR|Ankle-foot orthosis (AFO) Control Group|"The Control Group will walk with the a usual ankle-foot orthosis (AFO) for 30 weeks."
62398376|NCT01138995|EXPERIMENTAL|Ness L300 Treatment Group|The Original Treatment Group will walk with the Ness L300 for 30 weeks.
62398377|NCT05934422|EXPERIMENTAL|Prior Intervention - enhanced micronutrients, probiotics, myo-inositol in preconception & pregnancy|NiPPeR Study intervention drink containing a mix of micronutrients, probiotics and myo-inositol given to the mother during preconception \& pregnancy
62398378|NCT05934422|ACTIVE_COMPARATOR|Prior Control - standard micronutrients in preconception & pregnancy|NiPPeR Study control nutritional drink containing a mix of micronutrients given to the mother during preconception \& pregnancy
62782358|NCT03691571|EXPERIMENTAL|Esophageal Cooling|Patients randomized to Group A receive the EnsoETM (Attune Medical Esophageal Heat Transfer Device).
62782359|NCT03691571|ACTIVE_COMPARATOR|Control|Patients randomized to Group B receive standard of care treatment (standard temperature probe monitoring).
62008439|NCT05686304|EXPERIMENTAL|Money management group|Participants in the money management condition start the 4-week money management program immediately after randomization and complete the post-intervention assessment right after they finish the treatment. They will be invited to participate in an interview after completing the post-intervention assessment.
62008440|NCT05686304|NO_INTERVENTION|Waitlist control group|Participants in the waitlist control group will wait for 4 weeks without the money management program and then complete the post-intervention assessment. The waitlist control participants will start a money management program (equivalent to that of the money management group) immediately after completing the post-intervention assessment.
62008441|NCT06176027|EXPERIMENTAL|Azacytidine plus CAOLD regimen|Patients were treated by Azacytidine plus CAOLD regimen
62008442|NCT06659445|ACTIVE_COMPARATOR|ONL1204 Opthalmic solution (1 of 6 Treatment Groups) administered by intravitreal injection|ONL1204 100 µg administered by intravitreal (IVT) injection every 12 weeks
62782360|NCT06394245|EXPERIMENTAL|Experimental group|All sampled patients will administer STAI-1 and then VAS before relaxation exercises. Pain levels will be evaluated by applying VAS again. VAS and STAI will applie again to all patients at discharge. 400 mg contramol in 100 cc SF at 5cc/hour continues on the first day after surgery by PCA (Patient control analgezia). The total number of boluse administrations and additional analgesic requirements of the patients will record by PCA after the application during the day. After the implementation of the PMR exercise protocol, no side effects or signs of discomfort will observe in the patients. In the hospital where the study will conduct, if patients can tolerate it, they are routinely mobilized for 8 hours after surgery and are fed there 6 hours later. Patients in the experimental and control groups will evaluate in terms of postoperative mobilization and oral feeding initiation times.
62008443|NCT06659445|ACTIVE_COMPARATOR|ONL1204 Opthalmic solution (2 of 6 Treatment Groups) administered by intravitreal injection|ONL1204 200 µg administered by intravitreal (IVT) injection every 12 weeks
62782361|NCT06394245|NO_INTERVENTION|Control Group|Patients in the control group will not receive any special intervention, only routine care. After data will collect from the patients in the control group, they will be informed that they can do progressive muscle relaxation exercises whenever they want.
62782362|NCT03122782|ACTIVE_COMPARATOR|Tranexamic acid (TXA) Group|Subjects in the Tranexamic acd (TXA) group will receive intrauterine instillation of 500 mg (100mg/ml) Tranexamic acid per 500 ml normal salin (distention medium) during Hysteroscopic Myomectomy.
62008444|NCT06659445|EXPERIMENTAL|ONL1204 Opthalmic solution (3 of 6 Treatment Groups) administered by intravitreal injection|ONL1204 200 µg administered by intravitreal (IVT) injection every 24 weeks
62008445|NCT06659445|SHAM_COMPARATOR|Sham Comparator (4 of 6 Treatment Groups)|Sham injection every 12 weeks
62008446|NCT06659445|SHAM_COMPARATOR|Sham Comparator (5 of 6 Treatment Groups)|Sham injection every 24 weeks
62008447|NCT06659445|ACTIVE_COMPARATOR|Avacincaptad pegol intravitreal solution (6 of 6 Treatment Groups - US ONLY)|Avacincaptad pegol administered by intravitreal (IVT) injection - (2 mg (0.1 mL of 20 mg/mL solution) once monthly
62008448|NCT01649856|EXPERIMENTAL|A: Rituximab SC|
62008449|NCT01649856|ACTIVE_COMPARATOR|B: Rituximab IV|
62008450|NCT04139590|PLACEBO_COMPARATOR|Visual Analogue Scale - Original|"Participants indicated the intensity of their pain by marking a X along the original paper version of the Visual Analogue Scale."
62398379|NCT06394427||chemoimmunotherapy group 1|patients received different cycles of neoadjuvant chemoimmunotherapy
62008451|NCT04139590|ACTIVE_COMPARATOR|Visual Analogue Scale - Panda|"Participants indicated the intensity of their pain by marking a X on the smartphone screen using the Panda of the Visual Analogue Scale."
62008452|NCT04139590|PLACEBO_COMPARATOR|Numeric Rating Scale - Original|"Participants indicated the intensity of their pain by marking a X along the original paper version of the Numeric Rating Scale."
62008453|NCT04139590|ACTIVE_COMPARATOR|Numeric Rating Scale - Panda|"Participants indicated the intensity of their pain by marking a X on the smartphone screen using the Panda of the Numeric Rating Scale."
62008454|NCT05993546|ACTIVE_COMPARATOR|vacuum-assisted sheath|
62008455|NCT05993546|ACTIVE_COMPARATOR|passive suction via conventional sheath|
62008456|NCT05802381|EXPERIMENTAL|protein supplements|This group will receive dietary guidance and protein supplements for 3 months
62008457|NCT05802381|OTHER|dietary guidance|this group will receive dietary guidance for 3 months
62008458|NCT05667298|EXPERIMENTAL|Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)|The primary/preferred adjuvant therapy will be immunoradiotherapy (ARM1); however, if this combination is felt to be too high-risk for specific patients, the next preferred therapy will be immunotherapy without radiation (ARM1B).
62008459|NCT05667298|EXPERIMENTAL|Adjuvant chemoradiotherapy|Some patients have medical conditions, i.e., severe auto-immune disease that prohibits them from receiving immunotherapy. In such patients, adjuvant therapy will be provided in the form of concurrent chemoradiotherapy (ARM2).
62008460|NCT04698161||NSCLC|Patients with non-small-cell lung cancer (NSCLC)
62008461|NCT04698161||metastatic melanoma|patients with metastatic melanoma
62008462|NCT01305031|EXPERIMENTAL|Room air|Initiation of resuscitation with 21% Oxygen, adjustments to the inspired oxygen concentration (increased 10%) will be made every 60 seconds for infants to achieve a target SpO2 range of 85-92%
62008463|NCT01305031|ACTIVE_COMPARATOR|100% Oxygen|Initiation of resuscitation with 100% Oxygen and achieve oxygen saturation in the preset limits 85-92%
62008464|NCT02090179||MPS IIIB|Those with a definitive diagnosis of MPS IIIB (Sanfilippo B Syndrome).
62008465|NCT03417661|EXPERIMENTAL|HEXI-PREP By Clinell Wipes vs Placebo|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
62008466|NCT03417661|EXPERIMENTAL|HEXI-PREP By Clinell Wipes vs Chloraprep|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
62008467|NCT03417661|EXPERIMENTAL|Chloraprep vs Placebo|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
62193969|NCT03188367|PLACEBO_COMPARATOR|2C - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
62214909|NCT02769767||No responders|Subjects with MS that have more than one relapse per year treated for at least two years, and who had ≥1 relapse(s) or an increase of 1.5 points on the EDSS (if baseline EDSS was 0) or an increase of ≥0.5 points (baseline EDSS ≥1). Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
62782363|NCT03122782|PLACEBO_COMPARATOR|Normal Saline (control group)|Subjects in the control group will receive 500 ml intrauterine instillation of normal saline with the distention medium (normal saline) during Hysteroscopic Myomectomy.
62782364|NCT02481817||iSGS patients|Participants will receive standard of care treatment at the respective center and will be followed longitudinally for symptom changes, need for further treatment, complications, and will have Patient-reported outcomes (PROs) administered at a priori determined intervals.
62398380|NCT06394427||chemoimmunotherapy group 2|the duration of before patients received surgery after neoadjuvant chemoimmunotherapy
62782365|NCT02472704|ACTIVE_COMPARATOR|Gluten challenge|Gluten powder (10 g every 12 hours), 24 weeks
62782366|NCT02472704|PLACEBO_COMPARATOR|Placebo challenge|Placebo (maltodextrin; 10 g every 12 hours), 24 weeks
62782367|NCT04530864|EXPERIMENTAL|DEXTENZA Insert|This prospective study will use a self controlled design for 35 eyes. Patients scheduled to undergo routine cataract surgery in at least one of their eyes will have their pre-surgical measurements performed, IOL calculated and surgery planned. Then they will receive insertion of an intracanalicular dexamethasone insert into the inferior punctum. At 2 weeks (+/- 2 days) post-insertion, patients will return for an identical set of measurements. The IOL will be calculated and the surgery planned based on post-insert data. The insert will be removed if present (manually or via saline irrigation). This self controlled design allows for greater control of potential confounders tied to participants' systemic and ocular health.
62782368|NCT03021772|ACTIVE_COMPARATOR|Group N|30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
62782369|NCT03021772|ACTIVE_COMPARATOR|Group D|30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
62782370|NCT03908814|EXPERIMENTAL|Drug: LDP|"This is a dose-escalation trial, all participants will receive treatment with LDP. Participants enrolled in this trial may receive one of the following doses dependent upon time of enrolment into the study.~Cohort 1: 0.1 mg/kg Cohort 2: 0.3 mg/kg Cohort 3: 1 mg/kg Cohort 4: 3 mg/kg Cohort 5: 10 mg/kg Cohort 6: 10 mg/kg"
62782371|NCT04408040|OTHER|Critical Patients|
62782372|NCT04408040|OTHER|Severe Patients|
62782373|NCT04408040|OTHER|High Risk|
62782374|NCT04408040|OTHER|Health Care Providers|
62782375|NCT04416906|EXPERIMENTAL|Biktarvy|This is a fixed dose combination regimen containing 50 mg of Bictegravir + 200 mg of Emtricitabine + 25 mg of Tenofovir alafenamide.
62782376|NCT00151476||Celecoxib - Routine Medical Care|800 mg total daily dosing
62782377|NCT00151476||Control Group - Routine Medical Care|Observation of subjects treated with routine medical care
62782378|NCT04243733|OTHER|calcium enriched mixture material (CEM)|Using CEM as a pulpotomy agent against MTA pulpotomy agent.
62782379|NCT04243733|EXPERIMENTAL|Mineral trioxide aggregate material (MTA)|Using MTA as a pulpotomy agent against CEM pulpotomy agent.
62782380|NCT05521789|EXPERIMENTAL|Standard of Care + ESB Thoracic|Patients randomized to this group will receive an erector spinae block in addition to the standard of care treatment
62782381|NCT05521789|NO_INTERVENTION|Standard of Care|Patients randomized to this group will receive standard of care treatment and NO erector spinae block
62782382|NCT04279665|EXPERIMENTAL|Subjects undergoing electrophysiology procedure|Subjects will wear a virtual reality (VR) headset for a total of 40 minutes separated over 2 sessions during an electrophysiology procedure they are already scheduled to undergo.
62782383|NCT06208111|EXPERIMENTAL|Treatment group|"Experimental Group:~participants in the experimental group would receive 8-10 Cognitive Behaviour Therapy-based therapeutic sessions."
62782384|NCT06208111|NO_INTERVENTION|control group|Participants in the control group did not receive the said Cognative Behaviour Therapy intervention
62782385|NCT03801603|EXPERIMENTAL|HPV Vaccination Training and Education|Participants will be educated on the importance of HPV vaccination.
62782386|NCT03956524|EXPERIMENTAL|Test group|Single dose of EuTCV will be administered intramuscularly
62782387|NCT03956524|ACTIVE_COMPARATOR|Comparator group 1|Single dose of Typbar-TCV™ will be administered intramuscularly
62782388|NCT03956524|ACTIVE_COMPARATOR|Comparator group 2|Single dose of Typhim Vi® will be administered intramuscularly
62782389|NCT06172478|EXPERIMENTAL|HER3-DXd Monotherapy|Participants with locally advanced or metastatic cancer (melanoma, head and neck, gastric cancer, ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, and prostate cancer) will receive an intravenous infusion of HER3-DXd monotherapy 5.6 mg/kg every 3 weeks (Q3W).
62782390|NCT05305963||Case|250 women diagnosed with BC when they were aged 30-39 years
62782391|NCT05305963||Control|750 controls currently aged 30-39 years
62782392|NCT02180841|EXPERIMENTAL|Soy 25g|Soy protein powder (25g/day)
62782393|NCT02180841|EXPERIMENTAL|Soy 50g|Soy protein powder 50 g/day
62782394|NCT02180841|PLACEBO_COMPARATOR|Control|Control powder
62214910|NCT04070560|ACTIVE_COMPARATOR|Early (≤ 60 seconds) cord clamping|If the infant don't breathe, the umbilical cord is clamped (≤ 60 seconds) and cut and resuscitation will be provided at a resuscitation table Other Name: Immediate clamping
62008468|NCT06663735||Diagnosis and management of patients with early stage resectable uroepithelial carcinoma|The study is a multicenter, non-interventional, observational cross-sectional study. It is planned to enroll patients with early stage resectable uroepithelial cancer in each study hospital in Henan Province. This is a cross-sectional study, and all patients will be anonymized for clinical data collection, and detailed information on patient demographic characteristics as well as medical and treatment history, hospitals at different stages of treatment, pathological test results, and medication regimens will be recorded at the beginning of enrollment.
62008469|NCT06663735||Diagnosis and management of patients with advanced unresectable uroepithelial cancer|It is planned to enroll patients with advanced unresectable uroepithelial cancer in each study hospital in Henan Province. This is a cross-sectional study, and all patients will be anonymized for clinical data collection, and detailed information on patient demographic characteristics as well as medical and treatment history, hospitals at different stages of treatment, pathological test results, and medication regimens will be recorded at the beginning of enrollment.
62008470|NCT02505126|EXPERIMENTAL|Active tDCS group|Active tDCS
62008471|NCT02505126|PLACEBO_COMPARATOR|Placebo tDCS group|Placebo tDCS : Inactive tDCS
62008472|NCT05009797||Patients undergoing atrial fibrillation catheter ablation|Patients undergoing scheduled atrial fibrillation catheter ablation.
62008473|NCT06144502|EXPERIMENTAL|Intervention from November 2023|Pupils in this arm receive the teaching material from November 2023
62008474|NCT06144502|OTHER|Wait-list control from November 2023 and intervention from January 2024|Pupils in this arm constitute a control group from November 2023 until they receive the teaching material from January 2024
62008475|NCT06368063|EXPERIMENTAL|Huaier treatment group|The subjects take Huaier granules orally and start taking them within 15-30 days after surgery until the end of the study, intolerable toxicity occurs, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that the subjects no longer benefit.
62008476|NCT06368063|ACTIVE_COMPARATOR|Standard chemotherapy group|"Accept treatment with Class 1A chemotherapy drugs recommended by CSCO (choose any one to receive treatment)~* Gemcitabine combine with capecitabine~* mFOLFIRINOX solution~* Gemcitabine monotherapy~* Tegafur，gimeracil and oteracil potassium capsules monotherapy"
62008477|NCT05239676|EXPERIMENTAL|Treatment of Lymphoma|Refractory and relapsed malignant lymphoma
62008478|NCT01720095|EXPERIMENTAL|Niaspan|these are the first episode psychosis patients that are randomized to receive niaspan
62398381|NCT03857126||Pregnancy volunteer subjects|"Subjects who will agree to participate in the investigator's study will be pregnant healthy subjects with no particular antecedent, followed at the University Hospital of Grenoble for a physiological pregnancy; their child will be not affected by any prenatal pathology.~Subjects will be enrolled in a 30 min monitoring phase to collect signals from ECG-PCG-CTG abdominal and thoracic non invasive sensors."
62398382|NCT01097720||LTG-exposed|Children exposed to LTG during pregnancy.
62008479|NCT01720095|NO_INTERVENTION|healthy control|this is the group of healthy controls for cognitive outcome measures
62008480|NCT01720095|NO_INTERVENTION|first episode control group|first episode psychosis patients who are randomized to no intervention
62008481|NCT04904510||Sample Collection|People routinely testing for COVID-19 would have an extra sample collected to assess the diagnostic device.
62008482|NCT04935697|EXPERIMENTAL|Receiving Non-invasive vagus neurostimulation|nVNS treatment will be applied three times daily. One treatment is defined as 2 consecutive stimulations: one, 2-minute stimulation on the side of the neck followed by a second, 2-minute stimulation on the same side of the neck. The treatment will be done 3 times per day (morning, mid-day and 1 hour before bed at night), every day, until patient is discharged from the hospital or requires mechanical ventilation. Patient will record the time they administered these treatments. If the patient is unable to do this, a research staff member who has been trained on the device can assist. Will also receive SOC for TBI.
62008483|NCT04935697|OTHER|Receiving Standard of Care|Patients will be managed according to the institutional best practices and SOC for TBI.
62008484|NCT02028299|EXPERIMENTAL|2D doppler echo with Definity solution|Study subjects will already be scheduled for right heart catheterization to diagnose pulmonary hypertension. Prior to the catheterization, each subject will have a 2D doppler echocardiogram with Definity solution as well.
62008485|NCT06040346|EXPERIMENTAL|Intervention Groups|Up to 60 participants will be enrolled into 1 of 3 meplazumab dose levels (20 participants/dose level).
62398383|NCT01097720||VPA-exposed|Children exposed to VPA during pregnancy.
62008486|NCT06262360|EXPERIMENTAL|General anesthesia with spontaneous mask ventilation|Patients under general anesthesia with spontaneous mask ventilation
62008487|NCT06262360|EXPERIMENTAL|General anesthesia and spontaneous laryngeal mask ventilation|Patients under general anesthesia and spontaneous laryngeal mask ventilation
62398384|NCT01097720||CBZ-exposed|Children exposed to CBZ during pregnancy.
62008488|NCT06262360|EXPERIMENTAL|General anesthesia with spontaneous laryngeal mask ventilation with pressure support|Patients under general anesthesia with spontaneous laryngeal mask ventilation with pressure support
62008489|NCT00647192|ACTIVE_COMPARATOR|1|Eplerenone treatment
62008490|NCT00647192|PLACEBO_COMPARATOR|2|
62008491|NCT04939623|ACTIVE_COMPARATOR|Probenecid 500 mg PO BID|Probenecid 500 mg X 1 PO BID and Placebo X 1 PO BID
62008492|NCT04939623|ACTIVE_COMPARATOR|Probenecid 1000 mg PO BID|Probenecid 500mg X 2 PO BID
62008493|NCT04939623|PLACEBO_COMPARATOR|Placebo PO BID|Placebo X 2 PO BID
62008494|NCT00559962|PLACEBO_COMPARATOR|1|Placebo
62008495|NCT00559962|ACTIVE_COMPARATOR|2|2.5 mg AEGR-733
62214911|NCT04070560|ACTIVE_COMPARATOR|Intact cord (≥ 180 seconds) resuscitation|"If the infant don't breathe, the umbilical cord is not clamped and cut until after 180 seconds. Initial resuscitation will be provided bedside to the mother~Other Names:~Late cord clamping Deferred cord clamping Optimal cord clamping"
62214912|NCT04360343|EXPERIMENTAL|LC51-0255 film-coated tablet|Drug: LC51-0255
62008496|NCT00559962|ACTIVE_COMPARATOR|3|5 mg AEGR-733
62008497|NCT00559962|ACTIVE_COMPARATOR|4|7.5 mg AEGR-733
62008498|NCT00559962|ACTIVE_COMPARATOR|5|10 mg AEGR-733
62398385|NCT04709640|EXPERIMENTAL|Tailored Medication Management Intervention|This research study involved an initial 1.5 hour visit and 2-3 follow up home visits (each lasting 60 minutes). Participants received 2-3 home visits during which they received recommendations on strategies which will improve medication management. Level II occupational therapy fieldwork students made the recommendations, after approval from their supervising licensed OT. The OT fieldwork students provided assistance to the individual in implementing strategies, obtaining adaptive equipment at little or no cost to the individual.
62398386|NCT04312152|ACTIVE_COMPARATOR|PMS Placebo|"If body weight is up to 20 kg:~* Vitamin E 30 mg b.i.d.~* Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)~If body weight is above 20 kg:~* Vitamin E 30 mg b.i.d.~* Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
62008499|NCT00559962|ACTIVE_COMPARATOR|6|5 mg AEGR-733 + 20 mg atorvastatin
62008500|NCT00559962|ACTIVE_COMPARATOR|7|5 mg AEGR-733 + 145 mg fenofibrate
62008501|NCT00559962|ACTIVE_COMPARATOR|8|5 mg AEGR-733 + 10 mg ezetimibe
62008502|NCT06230367|EXPERIMENTAL|SHAG (Sexual Health Advocacy for Guys)|Young people assigned to the intervention arm will receive \~9 weeks of daily text messages that talk about healthy sexuality and ways to reduce HIV risk. After a 3 month 'quiet' period, they will receive a week of review messages. Messages are based upon the information-motivation-behavioral model of preventive behavior.
62398387|NCT04312152|ACTIVE_COMPARATOR|ASD Placebo|"If body weight is up to 20 kg:~* Vitamin E 30 mg b.i.d.~* Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)~If body weight is above 20 kg:~* Vitamin E 30 mg b.i.d.~* Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
62398388|NCT04312152|EXPERIMENTAL|PMS Active compound|"If body weight is up to 20 kg:~* Q10 ubiquinol, 50 mg b.i.d.~* Vitamin E 30 mg b.i.d.~* Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)~If body weight is above 20 kg:~* Q10 ubiquinol, 100 mg b.i.d.~* Vitamin E 30 mg b.i.d.~* Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
62782395|NCT01359189|EXPERIMENTAL|Suspected Primary Prostate Cancer|Patients with suspected prostate cancer will be evaluated for initial proof of concept and feasibility of a scintigraphic rectal probe (ProxiScanTM) utilizing a PSMA receptor radiopharmaceutical (ProstaScint®). To explore the adjunctive benefit/feasibility of PSMA distribution in the normal prostate versus prostate cancer gland utilizing TRUS and CT/SPECT hybrid imaging, biopsy negative patients will be considered as normal controls. This is an exploratory, open label trial and randomization is not required. Subject blinding is not needed and investigator blinding in not possible.
62782396|NCT01359228|EXPERIMENTAL|Rifaximin|rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
62782397|NCT01359228|PLACEBO_COMPARATOR|sugar pill|Placebo 1 tablet three times a day for 14 days.
62782398|NCT02785068|EXPERIMENTAL|Phase 1b/2a|"Phase 1b: Safety Evaluation - MM-151 (weekly dosing) in combination with fixed doses of nal-IRI 70mg/m2 + Leucovorin 400 mg/m2 + 5-FU 2400mg/m2 every two weeks.~Phase 2a: Expansion - MM-151 (Maximum Tolerated Dose or Recommended Phase 2 Dose) in combination with fixed doses of nal-IRI 70mg/m2 + Leucovorin 400 mg/m2 + 5-FU 2400 mg/m2."
62782399|NCT04903795|EXPERIMENTAL|hEGFRvIII-CD3 (BRiTE) infusion|Four escalating doses of BRiTE are planned: #1: 57.0 ng/kg, #2: 570.0 ng/kg, #3: 5700.0 ng/kg, and #4: 57000.0 ng/kg.
62782400|NCT05501470|EXPERIMENTAL|Probiotic|Participant in the treatment arm will receive a daily dose of the probiotic for 8 weeks.
62008503|NCT06230367|PLACEBO_COMPARATOR|Attention-matched control|Young people assigned to the control arm will receive \~9 weeks of daily text messages that talk about healthy lifestyle, such as self-esteem and physical exercise. After a 3 month 'quiet' period, they will receive a week of review messages.
62008504|NCT02343510||primary tubal cancer group|Paraffin blocks of cases of primary tubal cancer
62008505|NCT02343510||high grade serous ovarian cancer group|Paraffin blocks of cases of high grade serous ovarian cancer
62008506|NCT02343510||Low Grade Serous Ovarian Cancer|Paraffin blocks of cases of low grade serous ovarian cancer
62008507|NCT02343510||normal tubes group|Paraffin blocks of tubes of hysterectomies due to non-oncologic causes
62008508|NCT06664242|PLACEBO_COMPARATOR|Control Group|This group will not actually receive a treatment current, being subjected only to the device connected without current.
62008509|NCT06664242|EXPERIMENTAL|TENS convencional group|In this group, patients will undergo the hospital's usual analgesia and physiotherapy routine, plus TENS with a frequency of 140 Hz and a pulse width of 50 µs.
62008510|NCT06664242|EXPERIMENTAL|TENS low frequence group|Patients in this group will undergo the hospital's usual analgesia and physiotherapy routine, plus conventional TENS with a low frequency of 5 Hz and a pulse width of 250 µs
62008511|NCT01416012|EXPERIMENTAL|Group Kinect|Use of the available Kinect games on the Xbox to train balance and gait
62008512|NCT01416012|ACTIVE_COMPARATOR|Physical Therapy Standard|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
62008513|NCT01416012|EXPERIMENTAL|Group Nintendo|Use of video games available Balance and Gait training in Individualized training sessions.
62008514|NCT01416012|EXPERIMENTAL|Group Xbox Kinect (MK)|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
62008515|NCT05375513|ACTIVE_COMPARATOR|SYNERGIC 2|"Personalized multidomain coached 1-to-1 interventions at home (PMI@Home) including:~1. Physical Exercise~2. Cognitive Training~3. Diet~4. Sleep~5. Vascular Risk Factors Control"
62008516|NCT05375513|PLACEBO_COMPARATOR|Brain Health PRO (BHPro)|"Brain Health PRO (BHPROBHPRO) is an independent, educational program with content also related to:~1. Physical Exercise~2. Cognitive Training~3. Diet~4. Sleep~5. Vascular Risk Factors~6. Social engagement"
62008517|NCT02752412|EXPERIMENTAL|LixiLan|"LixiLan (insulin glargine/lixisenatide fixed ratio combination) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Metformin will be continued."
62008518|NCT02752412|ACTIVE_COMPARATOR|insulin glargine|"Insulin glargine U100 (Lantus) will be injected subcutaneously (under skin) once daily. Dose will be individually adjusted.~Metformin will be continued."
62008519|NCT03328689|EXPERIMENTAL|Physical activity in the community|The physical activity program will include an individualized exercise program delivered in community exercise facility plus education..
62008520|NCT03328689|ACTIVE_COMPARATOR|Control group standard care|Participants from the control group will receive no additional intervention other than being encouraged to continue with their physiotherapists or chiropractor recommendation which will often include recommendation to keep activity, home exercise programs and advice to engage in physical activity.
62008521|NCT01195467|EXPERIMENTAL|All Subjects Truvada/Raltegravir|All Subjects will receive the same intervention, Truvada/Raltegravir
62193970|NCT03188367|PLACEBO_COMPARATOR|2B - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 10 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
62193971|NCT03188367|PLACEBO_COMPARATOR|2A - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
62193972|NCT03188367|ACTIVE_COMPARATOR|1A - HV|Seventy healthy volunteers will be given 14 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
62008522|NCT01110915|EXPERIMENTAL|MRI group|Subjects randomized to the MRI group will undergo a one-hour MRI scan, including 16 individual sequences in the chest and head region, at 9-12 weeks post-implant.
62008523|NCT01110915|ACTIVE_COMPARATOR|Control group|Subjects randomized to the Control group will wait for one hour without having any MRI scan at 9-12 weeks post-implant.
62008524|NCT02550964||HCQ/CQ|Patients who treated with HCQ(Hydroxychloroquine) or CQ(Chloroquine) for autoimmune diseases such as Rheumatoid arthritis(RA), systemic lupus erythematosus(SLE) will be recruited, and get the composite examination for toxic maculopathy.
62008525|NCT04766879|EXPERIMENTAL|Spatial Repellent|Transfluthrin
62008526|NCT04766879|PLACEBO_COMPARATOR|Placebo|Inert ingredients
62214913|NCT04360343|ACTIVE_COMPARATOR|LC51-0255 uncoated tablet|Drug: LC51-0255
62214914|NCT03063125||Bladder Cancer Patients|Patients with bladder cancer scheduled to undergo radical cystectomy (RC).
62782401|NCT05501470|PLACEBO_COMPARATOR|Placebo|Participant in the control arm will receive a daily dose of a placebo for 8 weeks.
62008527|NCT02848118|EXPERIMENTAL|A nasal-oral cannula of capnography|Start bronchoscopy when the nasal-oral capnography shows hypoventilation during bronchoscopic sedation.
62573514|NCT01208974|EXPERIMENTAL|Phase 1 MTD NAC RT|"Participants will undergo a Nipple-Areolar Complex (NAC)-sparing mastectomy with immediate reconstruction and axillary surgery, if indicated, on Week 1. Anytime between Weeks 5-8, participants will undergo a dose-escalation/de-escalation of prophylactic NAC radiation treatment (RT) twice daily (minimum of 4 hours apart) for 5 days. Dose escalation/de-escalation design are as follows:~* Dose Level I - 10 fractions of 2.0 Gy for a total of 20 Gy~* Dose Level II - 10 fractions of 2.5 Gy for a total of 25 Gy~* Dose Level III - 10 fractions of 3.0 Gy for a total of 30 Gy~* Dose Level IV - 10 fractions of 3.5 Gy for a total of 35 Gy~Participants will be treated between cohorts of 2-6 patients per dose level starting at dose level II. Dose escalation stops when 2 out of 2-6 participants encounter Dose Limiting Toxicities (DLT).~Standard of care chemotherapy, at treating physician's discretion, can be initiated 2 weeks after RT."
62008528|NCT02848118|ACTIVE_COMPARATOR|Sedation scale|Start bronchoscopy when Observer Assessment of Alertness and Sedation scale (OAAS)=3\~2 during bronchoscopic sedation.
62008529|NCT01410149|ACTIVE_COMPARATOR|PAV|Proportional Assist Ventilation (PAV+ on PB840 ventilator)
62193973|NCT03188367|ACTIVE_COMPARATOR|1B - HV|Seventy healthy volunteers will be given 10 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
62214915|NCT00944398|EXPERIMENTAL|Zinc fortified group|Daily consumption of zinc-fortified complementary food
62214916|NCT00944398|PLACEBO_COMPARATOR|Non-fortified group|Daily consumption of non-fortified complementary food and placebo supplement.
62214917|NCT00944398|EXPERIMENTAL|Zinc supplement group|Daily consumption of zinc supplement and non-fortified complementary food.
62573515|NCT06486558|EXPERIMENTAL|Active Treatment HU6 450 mg tablet|
62573516|NCT06486558|EXPERIMENTAL|Active Treatment HU6 450 mg Capsules (150 mg x 3)|
62573517|NCT02739789|SHAM_COMPARATOR|Sham tDCS|"tDCS stimulation will be administered over the brain area of interest, but will be shorter in duration than the active treatment"
62008530|NCT01410149|ACTIVE_COMPARATOR|PSV|Pressure Support Ventilation (PSV on PB840 ventilator)
62008531|NCT01410149|ACTIVE_COMPARATOR|ACV|Assist Control/ Pressure limited Ventilation (on PB840 ventilator)
62008532|NCT05610111|ACTIVE_COMPARATOR|CLC, then CLC+BAM, then CLC+ABC|Participants will be using closed loop control (CLC) for 2 weeks. Participants will then use closed loop control (CLC) with behavioral adaption module (BAM) for 4 weeks, followed by closed loop control (CLC) adaptive biobehavioral control (ABC) for 16 weeks.
62008533|NCT05610111|ACTIVE_COMPARATOR|CLC+ABC, then CLC+BAM, then CLC|Participants will be using closed loop control (CLC) with adaptive biobehavioral control (ABC) for 16 weeks. Participants will then use closed loop control (CLC) with behavioral adaptation module (BAM) for 4 weeks, followed by closed loop control (CLC) for 2 weeks.
62008534|NCT03944122|EXPERIMENTAL|continuous ultrasound|continuous ultrasound were applied to the patients
62008535|NCT03944122|EXPERIMENTAL|pulsed ultrasound|pulsed ultrasound were applied to the patients
62008536|NCT03944122|EXPERIMENTAL|placebo|placebo (sham) ultrasound were applied to the patients
62008537|NCT02150122|EXPERIMENTAL|10 micrograms (400 IU) vitamin D3|Participants will be given a daily supplement containing 10 micrograms (400 IU) vitamin D3 to take for 5 months.
62008538|NCT02150122|EXPERIMENTAL|20 micrograms (800 IU) vitamin D3|Participants will be given a daily supplement containing 20 micrograms (800 IU) vitamin D3 to take for 5 months.
62008539|NCT02150122|NO_INTERVENTION|Placebo|Participants will be given a placebo, similar in appearance to the vitamin D3 tablets, to take for 5 months.
62008540|NCT02095184|ACTIVE_COMPARATOR|Cohort 1: Normal Weight Anastrozole|Cohort 1: Patients with BMI \< 25.0 kg/m2 treated with anastrozole
62008541|NCT02095184|ACTIVE_COMPARATOR|Cohort 2: Overweight Anastrozole|Cohort 2: Patients with BMI ≥ 25.0-29.9 kg/m2 treated with anastrozole
62008542|NCT02095184|ACTIVE_COMPARATOR|Cohort 3: Obese|Cohort 3: Patients with BMI ≥ 30 kg/m2 treated with anastrozole
62008543|NCT02095184|ACTIVE_COMPARATOR|Cohort 4: Normal Weight Letrozole|Cohort 4: Patients with BMI \< 25.0 kg/m2 treating with letrozole
62573518|NCT02739789|ACTIVE_COMPARATOR|Active tDCS|tDCS stimulation will be administered over the brain area of interest
62573519|NCT01448772|ACTIVE_COMPARATOR|Marinol|
62573520|NCT01448772|EXPERIMENTAL|oral solution|
62193974|NCT03188367|ACTIVE_COMPARATOR|1C - HV|Seventy healthy volunteers will be given 7 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
62193975|NCT03188367|PLACEBO_COMPARATOR|2C- HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
62193976|NCT03188367|PLACEBO_COMPARATOR|2B - HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
62193977|NCT03188367|PLACEBO_COMPARATOR|2A - HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
62193978|NCT00706654|EXPERIMENTAL|Aripiprazole depot 300 or 400 mg|Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.
62193979|NCT00706654|ACTIVE_COMPARATOR|Aripiprazole 10-30 mg orally|Patients received aripiprazole 10-30 mg orally daily for 38 weeks.
62193980|NCT00706654|EXPERIMENTAL|Aripiprazole depot 25 or 50 mg|Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.
62193981|NCT01997177||novices|novice endoscopists, fellows of gastroenterology
62193982|NCT01997177||experienced endoscopist|consultant doctors of gastroenterology
62214918|NCT05696587|EXPERIMENTAL|CRPS|Participants meeting inclusion and exclusion criteria undergoing 4-week multimodal rehabilitation, undergoing assessment at baseline and at 4 weeks.
62573521|NCT05399940||Group 1|:PSA\<4 ng/mL
62573522|NCT05399940||Group 2|PSA\>4 ng/mL
62573523|NCT02713932||Transcatheter aortic valve implantation|
62573524|NCT06576024|EXPERIMENTAL|Participants aged 1-17 years old|Participants aged 1-17 years old in the immunogenicity and safety study
62573525|NCT06576024|EXPERIMENTAL|HAV susceptible participants aged 18-40 years old|HAV susceptible participants aged 18-40 years old in the immunogenicity and safety study
62008544|NCT02095184|ACTIVE_COMPARATOR|Cohort 5: Overweight Letrozole|Cohort 5: Patients with BMI ≥ 25.0-29.9 kg/m2 treating with letrozole
62008545|NCT02095184|ACTIVE_COMPARATOR|Cohort 6: Obese Letrozole|Cohort 6: Patients with BMI ≥ 30 kg/m2 treating with letrozole
62008546|NCT03976921|EXPERIMENTAL|CCTA Strategy|CCTA will be performed with one of the latest generation scanners. A stenosis \> 50% will be considered as significant from an anatomical point of view. For coronary stents, degree of intrastent restenosis will be evaluated by visual assessment of intraluminal contrast density. ISR \> 50% will be considered as significant from an anatomical point of view. For CABG, each graft will be visually evaluated and scored as patent, non-significant stenosis ≤ 50%, significant stenosis \> 50%, or occluded. For patients with positive CCTA results, additional stress CTP will be performed subsequently. If indicated, vasodilatation will be induced with i.v. adenosine injection or regadenoson. Static or dynamic CTP will be performed according to local practice and scanner technology available. For all patients with previous history of MI the presence of reversible ischemia will be obtained by the comparison between rest and stress perfusion.
62008547|NCT03976921|ACTIVE_COMPARATOR|Standard of care Strategy|Patients randomized to this group will be evaluated according to current clinical guidelines with the following approaches: (a) stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET; (b) direct referral to ICA.
62008548|NCT02782650||Survey and interviews|"\* part one \* (quantitative)~Survey on:~A) prenatal counseling at the limits of viability, both current and preferred, within three domains of interest:~* organization of prenatal counseling~* content of prenatal counseling~* decision-making in prenatal counseling~B) treatment options at the limits of viability against the background of the Dutch guideline~\* part two \* (qualitative)~Focus groups interviews (qualitative) to in-depth explore preferences in prenatal counseling~* insight in the specific preferred content of prenatal counseling.~* study influencing factors on preferences in the domains of organization and decision-making."
62008549|NCT04962568|EXPERIMENTAL|NHF-NIV|Subjects will start with NHF. If all measurements are done, subjects will change to NIV. Same measurements will done.
62008550|NCT04962568|EXPERIMENTAL|NIV-NHF|Subjects will start with NHF. If all measurements are done, subjects will change to NIV. Same measurements will done.
62008551|NCT05488899|EXPERIMENTAL|Half iodine - Spectral CT group|Patients receive half dosage of iodine contrast agent, and Spectral CT acquisition with Virtual Monoenergetic Images at 40 and 50 kiloelectronVolts (keV).
62008552|NCT05488899|ACTIVE_COMPARATOR|Standard iodine - Conventional CT|Patients receive standard dosage of iodine contrast agent, and conventional 120 kiloVolts (kV) polychromatic CT images
62008553|NCT00667342|EXPERIMENTAL|Localized Resectable Disease (Stratum A)|Participants with localized resectable disease receive Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin, and doxorubicin, or methotrexate. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, or methotrexate.
62008554|NCT00667342|EXPERIMENTAL|Metastatic Disease (Stratum B)|Participants with metastatic disease (Stratum B) receive Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin and doxorubicin, methotrexate or ifosfamide, and etoposide. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, methotrexate, or ifosfamide, and etoposide. Radiotherapy will be given post-operatively.
62008555|NCT00667342|EXPERIMENTAL|Unresectable Disease (Stratum C)|Participants with unresectable disease (Stratum C) receive treatment identical to Stratum B: Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin and doxorubicin, methotrexate or ifosfamide, and etoposide. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, methotrexate, or ifosfamide, and etoposide. Radiotherapy will be given post-operatively.
62008556|NCT03844373|EXPERIMENTAL|Experimental|Patients established on an oral nutritional supplement, being prescribed oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of STOCKHOLM for a period of 9 days.
62008557|NCT04904523||Cases|"Cases:~1. Children and young people up to age 18 years, admitted to PCCU with probable or confirmed COVID-19, irrespective of severity of illness. This includes patients transferred from other hospitals as well as those admitted from Accident and Emergency department."
62193983|NCT01594827|EXPERIMENTAL|Inhaled Vanc and Oral Abx|In the experimental arm CF participants are randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.
62214919|NCT05696587|NO_INTERVENTION|Healthy Control|Participants matched according to sex, age and education to experimental arm, undergoing psychological assessment at baseline and at 4 weeks.
62008558|NCT04904523||Controls|"Controls:~1. Children proven to have a non COVID infectious illness on laboratory testing.~2. Children with sepsis or septic shock due to non-COVID infectious illness.~3. Children or young people admitted to PCCU following accidental trauma."
62008559|NCT00535886|ACTIVE_COMPARATOR|Elaidic Acid|
62008560|NCT00535886|EXPERIMENTAL|Vaccenic Acid|
62008561|NCT00535886|PLACEBO_COMPARATOR|Oleic Acid|
62008562|NCT00796861|EXPERIMENTAL|Single Arm|Sunitinib (50mg PO daily x 4 wks + 2 wks rest x 3 cycles if able to tolerate tx
62193984|NCT01594827|ACTIVE_COMPARATOR|Inhaled Placebo and Oral Abx|In the active comparator arm CF participants are randomized to 28 days of inhaled sterile placebo (saline) and are treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.
62193985|NCT04652388|EXPERIMENTAL|Nutritional counseling|Children with autism spectrum disorders to whom administer nutritional counseling
62193986|NCT04652388|NO_INTERVENTION|Controls|No intervention
62193987|NCT03444402|EXPERIMENTAL|Group A|Period 1: Test drug(CKD-381 formulation I), Period 2: Test drug(CKD-381 formulation II), Period 3: Reference drug(D026)
62008563|NCT06572007||Low back pain|Fascia thickness of individuals with chronic low back pain will be measured by ultrasound and the relationship with pain, flexibility, disability and depression will be analysed.
62008564|NCT01663272|EXPERIMENTAL|cabozantinib with gemcitabine|The Study Treatment Period will consist of continued treatment during which time patients will receive cabozantinib and gemcitabine until either disease progression or the occurrence of unacceptable drug-related toxicity
62008565|NCT04715984|EXPERIMENTAL|Neural recordings and stimulation|
62193988|NCT03444402|EXPERIMENTAL|Group B|Period 1: Test drug(CKD-381 formulation II), Period 2: Reference drug(D026), Period 3: Test drug(CKD-381 formulation I)
62193989|NCT03444402|EXPERIMENTAL|Group C|Period 1: Reference drug(D026), Period 2: Test drug(CKD-381 formulation I), Period 3: Test drug(CKD-381 formulation II)
62193990|NCT04155970|EXPERIMENTAL|Manual Therapy Arm|The group will receive manual therapy, as well as an evidence-informed home management booklet.
62008566|NCT04010968|ACTIVE_COMPARATOR|FCR|"FCR :~* rituximab (R): 375 mg/m² IV D1 cycle 1 and 500 mg/m² IV D1 cycles 2 to 6.~* fludarabine (F): 40 mg/m² orally, D2 to D4 - cycles 1 to 6.~* cyclophosphamide (C): 250 mg/m² orally, D2 to D4 - cycles 1 to 6."
62008567|NCT04010968|EXPERIMENTAL|venetoclax and ibrutinib (I+VEN)|"* ibrutinib: 420 mg/d orally, continuously from Month 1 to the end of treatment, either Month 15 or Month 27~* venetoclax: stepwise weekly dose ramp-up beginning at Month 4 from a starting dose of 20 mg/d to the final dose of 400 mg/d (20, 50, 100, 200 and then 400 mg) over a 5 weeks, and then 400 mg/d continuously from Month 5 to the end of treatment, either Month 15 or Month 27."
62008568|NCT01157481|EXPERIMENTAL|Conventional therapy plus nifedipine|
62008569|NCT01157481|ACTIVE_COMPARATOR|Conventional therapy|
62008570|NCT05422248|ACTIVE_COMPARATOR|Series|Standard wound care for 4 weeks followed by intervention device wound care for up to 12 weeks.
62008571|NCT05422248|ACTIVE_COMPARATOR|Paired|Intervention device wound care to a portion of wound and standard wound care to the remaining portion of the wound, for up to 12 weeks.
62008572|NCT01593618|EXPERIMENTAL|Web-Based Intervention|UMFollowUp - web-based internet resource for information about their diagnostic histories, recommendations for follow-up care, and tips to enhance their treatment, psychosocial and physical well-being.
62008573|NCT01593618|ACTIVE_COMPARATOR|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
62193991|NCT04155970|EXPERIMENTAL|Non-Manual Therapy Arm|The group will receive an evidence-informed home management booklet only.
62193992|NCT01774045|EXPERIMENTAL|PDC-1421|Dosage form: 380mg PDC-1421 per Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days.
62193993|NCT01774045|PLACEBO_COMPARATOR|Placebo control|Dosage form: Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days.
62193994|NCT00356005|EXPERIMENTAL|Azithromycin + Artesunate|Azithromycin + Artesunate treatment
62193995|NCT00356005|ACTIVE_COMPARATOR|Artesunate|Artesunate treatment controls
62193996|NCT01035541||P group|Fluid Management according to measurements with PiCCO®
62193997|NCT01035541||C group|Conventional fluid management
62193998|NCT01583504|EXPERIMENTAL|High volume saline injection|Patients randomised to this trial arm will receive an ultrasound guided steroid and local anaesthetic injection around the achilles tendon in the same way as the control arm patients. In addition they will receive an injected bolus of normal saline (through the same needle) of between 14-25ml until the new vessels seen on ultrasound scan disappear. They will be then given a programme of stretching and strengthening exercises in the same way as patients on the control arm.
62214920|NCT05991843|EXPERIMENTAL|Study cohort|"The cohort of healthy volunteers, who will breath at three different respiratory rates, as guided by normal, slowly and rapid."
62008574|NCT02791815|EXPERIMENTAL|Sequence AB|Subjects participate in two study periods: During the first period, they receive a single oral dose of midazolam on Day 1. During the second period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. There is a washout period of 14 to 21 days between the two periods.
62008575|NCT02791815|EXPERIMENTAL|Sequence BA|Subjects participate in two study periods: During the first period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. During the second period, they receive a single oral dose of midazolam on Day 1. There is a washout period of 14 to 21 days between the two periods.
62008576|NCT02302105|ACTIVE_COMPARATOR|Prostate Only|66-68 Gray (Gy) in 25 fractions will be prescribed for the prostate PTV
62008577|NCT02302105|EXPERIMENTAL|Whole Pelvis|66-68 Gray (Gy) in 25 fractions will be prescribed for the prostate PTV and 50 Gy in 25 fractions to nodal region .
62193999|NCT01583504|ACTIVE_COMPARATOR|Control Arm|"Patients on this trial arm will receive an ultrasound guided injection of steroid and local anaesthetic between Kager's fat pad and the achilles tendon. They will then be given a programme of stretching and strengthening exercises.~Patients on this trial arm will be offered the high volume saline injection at their 6 week follow up appointment after outcome measures have been taken by the blinded assessor. The whole cohort of patients will then be followed up at 12 and 40 weeks"
62194000|NCT00535379|EXPERIMENTAL|1|
62194001|NCT05017077|EXPERIMENTAL|Telemonitoring|To evaluate the feasibility and efficacy of a new model of tele monitoring in pediatric population in advanced heart failure, we will enroll 20 patients in advanced NYHA/Ross class in waiting list for Heart Transplant. An home telemonitoring capable to detect vital parameters as heart rate, body temperature, blood pressure, oxygen saturation, breathe frequency, weight, arrhythmias and cardiac index may offers to physician valuable information able to strictly monitoring the clinical status of patients
62194002|NCT02883036||Patients with chronic myeloid leukemia|100 adult patients(age\>18 years),with chronic myeloid leukemia defined by the World Health Organization(WHO) criteria
62194003|NCT02883036||Healthy volunteers|Healthy volunteers
62194004|NCT01441219|EXPERIMENTAL|Colon 2|using Colon 2 capsule in detecting bleeding events in small bowel
62194005|NCT01376492||001|Functioning assessment The functioning will be assessed with 2 scales (Personal and Social Performance Scale (PSP) and Brief Psychiatric Rating Scale)
62194006|NCT01376492||002|Quality of sleep assessment The quality of sleep will be assessed with 2 scales (Pittsburgh Sleep Quality Index (PSQI) and Epworth scale)
62194007|NCT06482411||Surgical group|Bariatric surgery Participants underwent LSG, OAGB, SASI, and RYGB surgical treatment during the period from 2024 to 2028.
62194008|NCT06482411||Non-Surgical group|Participants were treated with anti-obesity medications plus lifestyle intervention therapy Participants were treated with TFDA-approved anti-obesity medications (e.g. Saxenda, Contrave, etc.).
62194009|NCT00919204|EXPERIMENTAL|Cohort 1|
62194010|NCT04902183|EXPERIMENTAL|10^9 dose of exosomes overexpressing CD24|The patients will receive the dose of 10\^9 exosomes overexpressing CD24
62194011|NCT04902183|EXPERIMENTAL|10^10 dose of exosomes overexpressing CD24|The patients will receive the dose of 10\^10 exosomes overexpressing CD24
62194012|NCT01512797|ACTIVE_COMPARATOR|Sitagliptin phosphate|100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
62194013|NCT01512797|PLACEBO_COMPARATOR|Placebo|1 Placebo pill / day PO once a day for 4-5 weeks
62194014|NCT00504075|EXPERIMENTAL|Gammaplex (intravenous immunoglobulin)|
62194015|NCT03099252||Enrolled|"Participating hospitals will offer the video to all parents on their MBU during the 6 month intervention period (using the preferred delivery methods of the hospital and the parents). The video will be available via multiple means to facilitate optimal parental exposure in diverse settings. This will ensure flexibility of the delivery of the intervention, based on preferences of the nominated nurse leaders and their HCP team, families and available resources.~All participating maternal/newborn centres will receive the following tools via the designated nurse unit leader of enrolled sites:~1. Parent-targeted BSweet2Babies video~2. Parent cards- Reminder for parents of video, with Quick Response (QR) code of the video~3. BSweet2Babies Poster-visual reminder for parents and HCP's on the enrolled units~4. Monthly support calls for the nursing leaders of the Mother Baby Units (MBU)~5. Bi-monthly community of practice teleconferences for the nursing leaders of the MBU"
62194016|NCT06177951|NO_INTERVENTION|Control Group|This group will receive neither of the interventions (NICU Discharge Passport, NICU Infant Care Class).
62194017|NCT06177951|EXPERIMENTAL|Received NICU Discharge Passport Only|This group will receive only one intervention: NICU Discharge Passport.
62194018|NCT06177951|EXPERIMENTAL|Received NICU Infant Care Class Only|This group will receive only one intervention: NICU Infant Care Class.
62194019|NCT06177951|EXPERIMENTAL|Received Both NICU Discharge Passport and NICU Infant Care Class|This group will receive both interventions: NICU Discharge Passport, NICU Infant Care Class.
62194020|NCT04970290|EXPERIMENTAL|Definisse threads free floating and Definisse threads double needle|"Definisse™ free floating threads will be used with the Soft Tissue Reshaping-2 (STR-2) Technique, to reposition the tissue of the malar area.~It is to be used for the face and neck. The thread presents a central area, free of barbs, and two distal areas with barbs. The 12 cm thread will be used in this study.~Definisse™ double needle thread (12 cm) that is equipped with barbs in the intermediate section, while the side and the central sections are smooth. The thread ends with two straight cut edge needles 10 cm long Definisse™ double needle threads will be used with the Jawline Reshaping (JR) Technique, to reshape the frame of the jawline, lifting the lower face. This is to be used for the face and the neck. The thread ends with two straight cut edge needles The 12 cm thread will be used in this study."
62573526|NCT06576024|EXPERIMENTAL|HAV unsusceptible participants aged 18-40 years old|HAV unsusceptible participants aged 18-40 years old in the immunogenicity and safety study
62573527|NCT06576024|EXPERIMENTAL|Other participants aged 18-40 years old|Other participants aged 18-40 years old in the safety study
62194021|NCT03396068|EXPERIMENTAL|NRX-101|Subjects will be treated with oral NRX-101 (fixed dose combination of D-Cycloserine/lurasidone) that will be titrated to a combined dose of 950mg/66mg per day.
62194022|NCT03396068|ACTIVE_COMPARATOR|Lurasidone comparator|Subjects will be treated with oral lurasidone in a matched placebo capsule that will be titrated to a dose of 66 mg per day
62194023|NCT03577847||1|Intervention group: Stroke patients investigated with rural CT scanning at HSS, Ål. Patients living in the municipalities of Hol, Ål, Gol, Hemsedal and Nes.
62194024|NCT03577847||2|Control-group: Stroke patients with similar transportation time to hospital, but no access to rural CT scanning. Patients living in the municipalities of Nore- and Uvdal, Vang, Øystre and Vestre Slidre, Lesja, Vågå, Lom, Dovre, Skjåk and Sel.
62194025|NCT06212752|EXPERIMENTAL|Arm 1 (MK-3475A + Platinum Doublet Chemotherapy)|Participants with treatment-naïve metastatic NSCLC will receive MK 3475A SC in combination with platinum doublet chemotherapy.
62194026|NCT06212752|ACTIVE_COMPARATOR|Arm 2 (Pembrolizumab + Platinum Doublet Chemotherapy)|Participants with treatment-naïve metastatic NSCLC will receive Pembrolizumab IV in combination with platinum doublet chemotherapy.
62194027|NCT04603742|EXPERIMENTAL|Anakinra IV|Patients in the intervention arm will receive anakinra IV (N=85) 4 times a day for 7 days. The investigator will follow up with patients for up to 60 days.
62573528|NCT00282113|ACTIVE_COMPARATOR|ProBioPlus|
62194028|NCT04603742|PLACEBO_COMPARATOR|Normal Saline IV|Patients in the placebo arm will receive normal saline IV (N=85) 4 times a day for 7 days. The investigator will follow up with patients for up to 60 days.
62194029|NCT06546917|ACTIVE_COMPARATOR|bWell Cognitive Remediation|Patients with Major Depressive Disorder who will complete cognitive remediation sessions using bWell twice a week for eight weeks.
62194030|NCT06546917|SHAM_COMPARATOR|VR Experience|Patients with Major Depressive Disorder who will experience various VR scenes twice a week for eight weeks.
62573529|NCT00282113|ACTIVE_COMPARATOR|Culturelle|
62573530|NCT00282113|PLACEBO_COMPARATOR|Placebo|
62573531|NCT05458999|EXPERIMENTAL|Virtual reality headset|Virtual reality headset during percutaneous coronary intervention
62573532|NCT05458999|NO_INTERVENTION|Control|Routine clinical practice
62573533|NCT02074423|EXPERIMENTAL|MealShape cinnamon extract|Intake of 2 capsules of 500 mg MealShape 30 minutes before consumption of a standard meal (white bread)
62008578|NCT05281731|EXPERIMENTAL|Sonobiopsy|"* Once enrolled, participants would be prepared for standard of care surgery.~* The sonobiopsy involves the standard procedure for a biopsy, but the biopsy needle is replaced with a customized ultrasound probe, a standard ultrasound contrast agent (microbubbles) is injected intravenously, and the probe is turned on for 3 minutes for the sonobiopsy. Then the planned surgery to remove the tumor will occur.~* An additional brief MRI scan will be obtained using the intraoperative MRI to define imaging changes (if any) that occur as a result of the sonobiopsy procedure. The imaging protocols will include a 3D T2-weighted (T2w) scan, and 3D contrast T1-weighted (T1w) with dynamic contrast enhancement and if time allows T2\* sequence.~* Blood will be collected at several time points.~* A small skin biopsy or another blood draw will be drawn for comparison against the genetic mutations shown in the tumor.~* The blood, tumor, and skin (if applicable) will undergo genetic analysis."
62008579|NCT06621121||TNK group|The enrolled patients received treatment with tenecteplase (rhTNK-tPA) at a dosage of 0.25 mg/kg, up to a maximum of 25 mg.
62008580|NCT06621121||rtPA group|The enrolled patients received treatment with alteplase (rtPA) at a dosage of 0.9 mg/kg, up to a maximum of 90 mg.
62008581|NCT06573840|ACTIVE_COMPARATOR|Control Cohort (Healthy Cohort)|Healthy participants who participate in 1 study visit. The unhealthy participant will undergo one functional MRI before, during and after a NeuroGlove session.
62008582|NCT06573840|ACTIVE_COMPARATOR|Treatment Arm|The treatment cohort which consists of patients who have experienced an acute ischemic stroke will participate in 1 study visit. They will undergo 1 function MRI before, during and after a NeuroGlove session.
62782402|NCT05981183|EXPERIMENTAL|Intervention A|Participants will receive 15 minutes of taVNS after an initial 15 minute rest-period and a 15 minute baseline measurement period. For participants assigned to Intervention A, the pulse width = 250 μs, and frequency = 50 Hz.
62008583|NCT05109585||participants willing to receive a 3-dose vaccination schedule|participants who received a 2-dose vaccination schedule, willing to receive a 3rd dose
62008584|NCT05109585||participants unwilling to receive a 3rd dose of vaccination|participants who received a 2-dose vaccination schedule, unwilling to receive a 3rd dose
62008585|NCT05291390|ACTIVE_COMPARATOR|Standard of care treatment plus pyronaridine|Standard of care treatment plus pyronaridine
62008586|NCT05291390|PLACEBO_COMPARATOR|Standard of care treatment plus placebo|Standard of care treatment plus placebo
62008587|NCT01416194||Bazedoxifene|
62008588|NCT01416194||Primary Comparator|
62194031|NCT01372839|ACTIVE_COMPARATOR|Atorvastatin|80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
62573534|NCT02074423|PLACEBO_COMPARATOR|Placebo|Intake of 2 capsules of 500 mg placebo, composed of 20% microcrystalline cellulose and 80% dicalcium phosphate, 30 minutes before consumption of a standard meal (white bread)
62782403|NCT05981183|EXPERIMENTAL|Intervention B|Participants will receive 15 minutes of taVNS after an initial 15 minute rest-period and a 15 minute baseline measurement period. For participants assigned to Intervention B, the pulse width = 300 μs, frequency = 25 Hz.
62782404|NCT05067738|OTHER|Discharge|Phase 1-Patients will continue to be admitted after their surgery as is the current practice. Phase 2-Patients will have their chest tube removed once they meet chest tube removal criteria and will be discharged home once they meet discharge criteria.
62782405|NCT06583369|EXPERIMENTAL|Liangxue ointment|Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses.
62782406|NCT06583369|ACTIVE_COMPARATOR|urea cream|Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses.
62008589|NCT01416194||Secondary Comparator|
62008590|NCT06316414||Severe asthmatics with history of food anaphylaxis|Omalizumab will be administered i.m. with doses ranging from 150 mg every 28 days to 600 mg every 14 days, according to EMA dosing range table.
62008591|NCT00691210|EXPERIMENTAL|V/N: Level 1|Vorinostat: 400mg Niacinamide: 20 mg/kg rounded to 100mg
62008592|NCT00691210|EXPERIMENTAL|V/N: Level 2|Vorinostat: 400mg Niacinamide: 40 mg/kg rounded to 100mg
62008593|NCT00691210|EXPERIMENTAL|V/N: Level 3|Vorinostat: 400mg Niacinamide: 60 mg/kg rounded to 100mg
62008594|NCT00691210|EXPERIMENTAL|V/N: Level 4|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg
62008595|NCT00691210|EXPERIMENTAL|V/N: Level 5|Vorinostat: 400mg Niacinamide: 100 mg/kg rounded to 100mg
62194032|NCT01372839|OTHER|Usual care|statin dose should not be higher than that described in exclusion criteria.
62008596|NCT00691210|EXPERIMENTAL|V/N/E: Level 1|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 25 mg/m2
62008597|NCT00691210|EXPERIMENTAL|V/N/E: Level 2|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 50 mg/m2
62398389|NCT04312152|EXPERIMENTAL|ASD Active compound|"If body weight is up to 20 kg:~* Q10 ubiquinol, 50 mg b.i.d.~* Vitamin E 30 mg b.i.d.~* Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)~If body weight is above 20 kg:~* Q10 ubiquinol, 100 mg b.i.d.~* Vitamin E 30 mg b.i.d.~* Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
62398390|NCT06360159|EXPERIMENTAL|Intervention Group|INTERVENTION GROUP: For newborn babies in the massage group; Field massage protocol will be used and the massage will be applied by the assistant researcher. Field massage developed by Field et al. (1986); In a standardized 15-minute stimulation session, the stimulation technique is changed every 5 minutes, and it is applied 3 times a day as tactile stimulation in the first 5 minutes, kinesthetic stimulation in the second 5 minutes and tactile stimulation in the third 5 minutes.(tactile stimulation-kinesthetic stimulation-tactile stimulation)
62008598|NCT00691210|EXPERIMENTAL|V/N/E: Level 3|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 100 mg/m2
62008599|NCT04700514|NO_INTERVENTION|Control group|"1. Children diagnosed with retinoblastoma and received exam under anesthesia (EUA) before the age of 30 months, and is not yet 4 years old~2. Children who are undergoing exams and treatment such as EUA, chemoport insertion, or intra-arterial chemotherapy under general anesthesia~3. Sevoflurane is used only for anesthesia"
62008600|NCT04700514|EXPERIMENTAL|Dexmedetomidine group|"1. Children who are diagnosed with retinoblastoma and are scheduled for the first EUA before their age of 30 months.~2. No history of anesthesia"
62008601|NCT03946761|EXPERIMENTAL|Cancer goggle system|"* The surgical procedure will be performed according to standard practice, with the exception of microdosing of ICG \& visualization of biliary/liver anatomy using the cancer goggles system~* The surgeon will start with a peripherally injected microdose of 0.02 mg of ICG \& will inject an additional 0.02mg every 5 minutes until a noticeable fluorescent change in the liver is observed. If a change is not observed after 0.14 mg has been injected then the microdosing regimen will stop. Output video from the cancer goggles will be recorded and saved for post-surgical analysis.~* Following resection of the liver parenchyma, the portal area and the cut surface of the liver will be analyzed for the identification of bile ducts leaks with or without cancer goggles."
62008602|NCT02803710||Case group|patients with decreased susceptibility to carbapenems Enterobacteriaceae isolate
62008603|NCT02803710||Control-group|patients with Enterobacteriaceae isolate without decreased susceptibility to carbapenems
62398391|NCT06360159|NO_INTERVENTION|Control Group|CONTROL GROUP: Apart from clinical routine practices, salivary cortisol samples will be taken from newborn babies in the control group and abdominal circumference of the babies will be measured.
62782407|NCT02211430|EXPERIMENTAL|Cognitive-Behavioral Counseling (CBC)|Cognitive-Behavioral Counseling (CBC) consists of two 45-minute on-site intervention sessions (session 1 and 3), one 15 minute on-site session (session 2), and one 15-minutes phone session (booster session).
62782408|NCT02211430|ACTIVE_COMPARATOR|Best Practice (BP) Control|Best Practice (BP) Control Condition consists of two 10-15 min, on-site intervention sessions (session 1 and 3), one brochure pick-up (session 2), and receipt of a newsletter by mail (booster session).
62782409|NCT05482841||ENT cancer surgery patients|all patients undergoing ENT cancer surgery with tracheotomy or tracheostomy at the Centre Léon Bérard.
62782410|NCT01931163|EXPERIMENTAL|Everolimus|Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles Everolimus 10mg by mouth daily
62782411|NCT03223376|ACTIVE_COMPARATOR|fruquintinib+paclitaxel|treatment arm (fruquintinib+paclitaxel) : Fruquintinib once daily, 3 weeks on/1week off combined with Paclitaxel 80mg/㎡ day1, 8, 15 of 4 weeks cycle.
62782412|NCT03223376|PLACEBO_COMPARATOR|placebo+paclitaxel|control arm (placebo+paclitaxel): Fruquintinib placebo once daily, 3 weeks on/1week off combined with Paclitaxel 80mg/㎡ day1, 8, 15 of 4 weeks cycle.
62782413|NCT05652387|OTHER|Father Inclusive Prenatal Care|Co parenting, parenting education, employment and educational readiness training and support.
62782414|NCT03565614|EXPERIMENTAL|Reablement rehabilitation|Reablement rehabilitation to maintain or increase the participants' physical, psychological and social functional abilities.
62782415|NCT03565614|ACTIVE_COMPARATOR|Traditional home care|The traditional home care and required rehabilitation efforts as by the municipality's current practice.
62782416|NCT02491606|EXPERIMENTAL|Load only|Loading with tafenoquine 400 mg base for three days followed by placebo weekly.
62782417|NCT02491606|EXPERIMENTAL|Low weekly dose|Loading with tafenoquine 200 mg base for 3 days followed by tafenoquine 200 mg weekly.
62782418|NCT02491606|EXPERIMENTAL|High weekly dose|Loading with tafenoquine to 400 mg base for 3 days followed by tafenoquine 400 mg base weekly.
62782419|NCT02491606|EXPERIMENTAL|Placebo|Loading with placebo for 3 days followed by placebo once weekly.
62782420|NCT01481077|EXPERIMENTAL|Treatment A|
62782421|NCT01481077|EXPERIMENTAL|Treatment B|
62782422|NCT01481077|EXPERIMENTAL|Treatment C|
62194033|NCT00513162|EXPERIMENTAL|Valproate + Etoposide|Valproate Starting Dose of 10 mg/kg By Mouth Daily. Etoposide 25 - 50 mg/m\^2 By Mouth Daily.
62194034|NCT05707897|EXPERIMENTAL|Fed condition|Period in which subjects receive a single oral dose of TS-142 tablet in fed condition.
62194035|NCT05707897|EXPERIMENTAL|Fasted condition|Period in which subjects receive a single oral dose of TS-142 tablet in fasted condition.
62194036|NCT02977598||non-diabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
62194037|NCT02977598||prediabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
62194038|NCT02977598||diabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
62194039|NCT00132678|EXPERIMENTAL|001|Risperdal Consta 12.5 25 37.5 or 50mg intramuscular (IM) injection every 2 weeks
62194040|NCT00132678|PLACEBO_COMPARATOR|002|Placebo Matching placebo intramuscular (IM) injection every 2 weeks
62194041|NCT05102058||Conventional group (GC)|Not receive perioperative additional medication.
62194042|NCT05102058||Magnesium-dexmedetomidine therapy group (GMD)|Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively.
62194043|NCT01872481|PLACEBO_COMPARATOR|Sham stimulation|"rTMS with sham coil. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks."
62194044|NCT01872481|EXPERIMENTAL|Active stimulation|rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.
62194045|NCT00786084||1|Phase I patients who had a paraesophageal hernia repair with synthetic mesh.
62194046|NCT00786084||2|Phase I patients who had a paraesophageal hernia repair with small intestine submucosa mesh.
62194047|NCT00751322|ACTIVE_COMPARATOR|1|RBC transfusion of 5 days or less storage age
62194048|NCT00751322|ACTIVE_COMPARATOR|2|RBC transfusion of conventional storage age
62194049|NCT01262547|EXPERIMENTAL|Dermabrasion-Micrografting|Dermabrasion-Micrografting
62398392|NCT02930889|EXPERIMENTAL|Prostate Artery Embolization|Prostate Artery Embolization is a surgical procedure to relieve symptoms of Benign Prostatic Hyperplasia (BPH). Embolizing particles are injected into a target blood vessel to occlude blood flow.
62008604|NCT03135522|ACTIVE_COMPARATOR|Zinc Acetate 50 mg oral capsule|50 mg zinc acetate oral capsules, over-encapsulated, administered starting at 1 capsule/day and escalated to 3 capsules/day by Day 8 post-randomization (if tolerated)
62008605|NCT03135522|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo matched to zinc acetate 50 mg oral capsule active arm, administered starting at 1 capsule/day and escalated to 3 capsules/day by Day 8 post-randomization (if tolerated)
62398393|NCT02319265|EXPERIMENTAL|Melatonin|Melatonin at a dose of either 50mg (50ml) or 100mg (100ml) to be decided after an initial PK study to be given at intervals to be decided after PK data is available, for 72h. Oral liquid via nasogastric tube.
62398394|NCT02319265|PLACEBO_COMPARATOR|Placebo|Placebo at a dose of either 50ml or 100ml (to be decided after an initial PK study) to be given at intervals to be decided after PK data, is available for 72h. Oral liquid via nasogastric tube.
62008606|NCT00954213|EXPERIMENTAL|DIR/Floortime parent intervention|
62008607|NCT02247349|EXPERIMENTAL|Dose Escalation (Monotherapy) Dose -1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
62008608|NCT02247349|EXPERIMENTAL|Dose Escalation (Monotherapy) Dose 1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
62194050|NCT01262547|ACTIVE_COMPARATOR|Dermabrasion alone|Dermabrasion alone
62194051|NCT01262547|NO_INTERVENTION|Control|Control
62194052|NCT06077903|EXPERIMENTAL|GT101 treatment group|Autologous tumor infiltrating lymphocyte injection
62194053|NCT02534727||Sputum and blood participants|These participants will contribute both blood and sputum to the study
62194054|NCT02534727||Sputum only participants|These participants will only contribute sputum to the study
62194055|NCT03405077|EXPERIMENTAL|IPT Online Training|"Therapists in this study will be trained in IPT using an online platform. The program is self-paced but will have a deadline; the suggested pace is at least 12 hours spaced over 2 months. The guided online training program was developed in collaboration with 3C institute, an award-winning research and development company that creates web- and evidence-based programs. Content will be adapted from gold-standard training."
62194056|NCT02238249||paediatric patients with urticaria|
62194057|NCT03903718|EXPERIMENTAL|MEDI8852 (dose 1) - part 1|Participants will receive a single intravenous infusion (IV) of MEDI8852 (dose 1)
62194058|NCT03903718|SHAM_COMPARATOR|Placebo - part 2|Participants will received a single IV infusion of placebo ( matched to MEDI8852) on day 2
62194059|NCT03903718|ACTIVE_COMPARATOR|Oseltamivir (OS) 75 mg - part 2|Participants will receive 75 mg orally twice a day for 5 days starting at day 2
62194060|NCT03903718|EXPERIMENTAL|MEDI8852 (dose 2) - part 2|Participants will receive a single IV dose of MEDI8852 on day 2 (dose 2)
62194061|NCT03903718|EXPERIMENTAL|MEDI8852 (dose 1) - part 2|Participants will receive a single IV infusion of MEDI8852 on day 2 (dose 1)
62194062|NCT03903718|EXPERIMENTAL|MEDI8852 (dose 2) +OS 75 mg part 2|Participants will receive a single IV infusion of MEDI8852 (dose 2) on day 2 and 75mg of Oseltamivir twice a day for 5 days starting at day 2
62194063|NCT02323568|OTHER|Gynecological consulation|
62194064|NCT00942747|EXPERIMENTAL|Temsirolimus|Weekly IV temsirolimus
62194065|NCT03084276|EXPERIMENTAL|High-fat meal|
62194066|NCT03084276|ACTIVE_COMPARATOR|Low-fat meal|
62194067|NCT03573193|ACTIVE_COMPARATOR|study group:|ridge preservation alveolar ridge socket preserved using alloplastic material beta tri calcium phosphate type
62194068|NCT03573193|OTHER|control group|ridge preservation (alveolar ridge socket preserved using xenograft material Bio-oss type
62008609|NCT02247349|EXPERIMENTAL|Dose Escalation (Monotherapy) Dose 2|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
62194069|NCT05143164|EXPERIMENTAL|Hydrocolloid dressing|The intervention group will use the weekly hydrocolloid dressing (Duoderm Extra Thin CGF dressing,10 x 10 cm) for peritoneal dialysis exit-site care
62194070|NCT05143164|ACTIVE_COMPARATOR|Gentamicin cream|The control group will apply topical gentamicin cream to catheter exit site daily and cover with normal dressing
62782423|NCT01271374|ACTIVE_COMPARATOR|Hyzaar-Treatment Arm B|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
62398395|NCT03993314|ACTIVE_COMPARATOR|Bupivacaine|1 ml 0.5% isobaric bupivacaine (5 mg) + 15 mcg fentanyl intrathecal plus epidural volume extension (EVE)
62782424|NCT01271374|ACTIVE_COMPARATOR|Azor-Treatment A|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
62782425|NCT01670435||Group 1|
62782426|NCT01677858|EXPERIMENTAL|Carfilzomib|"In phase 1 participants were assigned to one of four sequential dose-escalating cohorts to receive 45, 56, 70 or 88 mg/m² carfilzomib administered by intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle. Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15.~In phase 2 participants received carfilzomib at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study on days 1, 8 and 15 plus 40 mg dexamethasone IV or orally at the same schedule as used in the Phase 1 portion of the study.~Participants were treated until confirmed progressive disease, unacceptable toxicity, withdrew consent for further treatment, were lost to follow-up, died, or the sponsor closed the study."
62194071|NCT03022955|ACTIVE_COMPARATOR|Dark chocolate: FDG-PET|100 g dark chocolate bar (70% cocoa solids (\~500kcal, \~50% fat)) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using chocolate: fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
62194072|NCT03022955|ACTIVE_COMPARATOR|Dark chocolate: Physiological Measurement|150 g dark chocolate mousse (\~500kcal, \~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.
62194073|NCT03022955|PLACEBO_COMPARATOR|White chocolate: FDG-PET|100 g white chocolate bar (0% cocoa solids (\~500kcal, 50% fat) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using FDG-Positron Emission Tomography.
62008610|NCT02247349|EXPERIMENTAL|Dose Escalation (Monotherapy) Dose 3|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
62008611|NCT02247349|EXPERIMENTAL|Dose Escalation (Monotherapy) Dose 4|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
62008612|NCT02247349|EXPERIMENTAL|Dose Expansion (Monotherapy)- Cohort A (Refractory)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
62008613|NCT02247349|EXPERIMENTAL|Dose Expansion (Monotherapy) Cohort B (Refractory)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
62008614|NCT02247349|EXPERIMENTAL|Dose Expansion (Monotherapy) Cohort C (Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
62194074|NCT03022955|PLACEBO_COMPARATOR|White chocolate: Physiological Measurement|150 g white chocolate mousse (\~500kcal, \~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.
62194075|NCT01067846|EXPERIMENTAL|DCS and Cognitive Behavioral Therapy|Subjects will receive 250 mg of Seromycin or D-cycloserine (DCS) prior to computerized cognitive behavioral therapy.
62194076|NCT01067846|PLACEBO_COMPARATOR|Placebo and Cognitive Behavioral Therapy|Subjects will receive a 250 mg identical looking placebo pill prior to computerized cognitive behavioral therapy.
62398396|NCT03993314|EXPERIMENTAL|Chloroprocaine|5 ml 1% spinal chloroprocaine (50 mg) intrathecal plus epidural volume extension (EVE)
62398397|NCT03115723||Group 1 : Percutaneous coronary intervention|All the patients who underwent percutaneous coronary intervention, in 9 invasive cardiology centers in the Aquitaine Region, France.
62398398|NCT03115723||Group 2 : Coronary angiography|All the patients who underwent coronary angiography, in 9 invasive cardiology centers in the Aquitaine Region, France
62398399|NCT05635162|NO_INTERVENTION|Arm A: Control|Active observation
62398400|NCT05635162|EXPERIMENTAL|Arm B: Experimental|Time limited Zanubrutinib-R 6 x 28 day cycles
62782427|NCT02337192|EXPERIMENTAL|Group 1|Negative control - Moutwash with 1,5mL of dimethyl sulfoxide at 5% (DMSO) in water solution - During 2 minutes.
62782428|NCT02337192|EXPERIMENTAL|Group 2|Mouthwash with Swish with Curcumin
62782429|NCT02337192|EXPERIMENTAL|Group 3|Moutwash with Swish with Curcumin + SDS
62782430|NCT02337192|EXPERIMENTAL|Group 4|Experiment use dental irradiation with blue light (LED) only.
62008615|NCT02247349|EXPERIMENTAL|Dose Expansion (Monotherapy) Cohort D (Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
62782431|NCT02337192|EXPERIMENTAL|Group 5|Antimicrobial Photodynamic Therapy (APDT) with blue light and Curcumin salt.
62782432|NCT02337192|EXPERIMENTAL|Group 6|Antimicrobial Photodynamic Therapy (APDT) with blue light, Curcumin salt and surfactant.
62782433|NCT02337192|EXPERIMENTAL|Group 7|Positive control - Use of mouthwash with Chlorhexidine only
62782434|NCT03269058|EXPERIMENTAL|Patients not treated with statins|
62782435|NCT03269058|EXPERIMENTAL|Patients treated with statins|
62782436|NCT01250041|ACTIVE_COMPARATOR|femoral block|
62782437|NCT01250041|EXPERIMENTAL|saphenous block|
62398401|NCT06717256|EXPERIMENTAL|EDUCATION GROUP|"In addition to routine training provided by physicians to patients in this group, training will be provided within the first 6 weeks, where the effect of the nurse coaching program on self-management and skin care behaviors in diabetic patients will be evaluated and monthly reminders will be provided thereafter. The content of the training booklet prepared for self-management and skin care will be presented to the participants as a face-to-face training in the form of one-week presentations to be completed in 6 weeks, in the form of oral presentations. At the end of the module training, participants will be asked questions and answered. Six weeks after the training is completed, participants will be provided with reminders, and the trainings they want to be repeated will be repeated."
62573535|NCT03635515|ACTIVE_COMPARATOR|Standard Protocol (Control) Group|Patients will be given a VAS scale to record their highest level of pain 6 hrs prior to treatment. The standard endodontic protocol will be followed. The same VAS scale from pretreatment will be used to record pain level at 6, 24, 72, and 168 hours post-treatment.
62573536|NCT03635515|ACTIVE_COMPARATOR|Gentlewave Treatment Group|Patients will be given a VAS scale to record their highest level of pain 6 hrs prior to treatment. The standard endodontic protocol will be followed through working length verification. For the Gentlewave treatment group, each canal will be shaped to a canal size of 20.06 and to 0.5 - 1mm short of the apical terminus. An occlusal platform will be prepared using the Kool-dam material recommended by Sonendo. The Gentlewave system will be held on the tooth by the clinician and will cycle through five minutes of 3% sodium hypochlorite, two minutes of 8% EDTA, and a final rinse of distilled water. Canals will be obturated with root canal sealer and gutta-percha. The same VAS scale from pretreatment to take home and asked to record their level of pain at 6, 24, 72, and 168 hours post-treatment.
62573537|NCT04751955|EXPERIMENTAL|Olinvacimab plus Capecitabine|A single arm study with Olinvacimab plus Capecitabine
62573538|NCT00406367|EXPERIMENTAL|incobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to 50 Units per eye; Open-Label Extension Period: up to 5 injections, up to 50 Units per eye per injection session; Mode of administration: intramuscular injection"
62573539|NCT00406367|PLACEBO_COMPARATOR|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
62782438|NCT06525142|EXPERIMENTAL|The Effectiveness of Audiovisual Intervention|The study is to understand the current status of parent-child bond, parenting role perception and well-being of fathers of preterm infants, and to explore the effect of audio-visual interventions on parent-child bonding, parenting role perception and well-being of fathers of preterm infants
62398402|NCT06717256|NO_INTERVENTION|CONTROL GROUP|Participants assigned to the control group will receive information training as part of their check-ups, as in routine practice; however, the intervention program evaluating the effect of the nurse coaching program on self-management and skin care behaviors in diabetic patients will not be implemented.
62782439|NCT06525142|PLACEBO_COMPARATOR|control|The study is to understand the current status of parent-child bond, parenting role perception and well-being of fathers of preterm infants, and to explore the effect of audio-visual interventions on parent-child bonding, parenting role perception and well-being of fathers of preterm infants
62782440|NCT00068302|EXPERIMENTAL|Sirolimus|This is a dose escalation study including 4-dose levels. Subjects will receive a one-time loading dose of sirolimus on day 0, time 0. Subsequent dosing at the assigned dose level will start 24 hours following the initial loading dose
62782441|NCT06349668|EXPERIMENTAL|spinal analgesia|single shot spinal analgesia with 0.2-0.3 mg morphine and 10-20 mg bupivacaine before surgery
62008616|NCT02247349|EXPERIMENTAL|Dose Escalation (Combination) Dose 1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
62008617|NCT02247349|EXPERIMENTAL|Dose Escalation (Combination) Dose 2|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
62782442|NCT06349668|ACTIVE_COMPARATOR|lidocaine infusion|intraoperative intravenous infusion of lidocaine at a rate of 2 mg/kg/t (Ideal Body Weight)
62782443|NCT06430723||Non-obese|Body mass index \< 30 kg/m2
62782444|NCT06430723||Obese|Body mass index \>= 30 kg/m2
62008618|NCT02247349|EXPERIMENTAL|Dose Expansion (Combination)- (Refractory and Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
62008619|NCT00654628|EXPERIMENTAL|1|Patients with intermediate or high risk dyslipidemia will be enrolled to receive treatment with Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks
62398403|NCT06357442||Daily oral micronized progesterone|On estrogen replacement therapy using 100mg oral daily micronized progesterone
62398404|NCT06357442||Etonogestrel implant (Nexplanon)|On estrogen replacement therapy with etonogestrel implant in place
62398405|NCT05965089|EXPERIMENTAL|AX-202|Single and multiple ascending doses of AX-202
62782445|NCT02721095|EXPERIMENTAL|0.9%NaCl|KCl plus 0.9%NaCl
62194077|NCT05849623|ACTIVE_COMPARATOR|Endoscopic Mucosal Resection (EMR)|Patients will have an electrosurgical grounding pad attached, and an Erbe VIO electrosurgical unit will be adjusted to the endoscopist's preferred EndoCut Q and Coagulation settings. The polyp will be injected submucosally with a saline and methylene blue solution, with or without epinephrine at endoscopist's discretion. Using a 15mm snare connected to the electrosurgical unit, the resection will be performed, with the initial cut including a margin of normal mucosa and subsequent cuts to ensure no residual polyp tissue remains. In case of intraprocedural bleeding, snare tip soft coagulation (STSC) or coagulation forceps may be used. The resection site will be examined and any remaining polypoid tissue will be resected. Endoclips may be used to close the defect if there is significant intraprocedural bleeding. The polyp will be retrieved (en bloc or piecemeal) using suction into a trap or RothNet.
62214921|NCT05184712|EXPERIMENTAL|Ivonescimab (SMT112 or AK112) in combination with Pemetrexed and Carboplatin|Subjects will receive Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, AK112 Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
62398406|NCT05965089|PLACEBO_COMPARATOR|Placebo|Single and multiple doses of placebo
62398407|NCT06526104|EXPERIMENTAL|Stride (Single T Regular Interval D) Arm|Tremelimumab dosed once at the beginning of the first cycle, 300mg IV infusion and Durvalumab 1500mg IV dosed with the first dose of Tremelimumab and then once per cycle (every 4 weeks)
62398408|NCT06456424|EXPERIMENTAL|Open Label Arm|Bacteriophage cocktail
62398409|NCT04189874|ACTIVE_COMPARATOR|Conventional stool testing|"All patients randomly allocated to this arm will have their stools tested for the following:~a) Bacterial culture for Salmonella, Shigella, E.coli O157 and Campylobacter - specimen in Enteric Pathogen Transport medium (EPT) planted to: i) MacConkey agar, Sorbitol-MacConkey agar, Hektoen agar and Selenite broth all incubated overnight at 350C ii) Campylobacter agar incubated for 48 hours at 420C in a microaerophilic atmosphere b) Bacterial culture for Yersinia (≤ 18 years old): EPT specimen sent to Dynacare Laboratories for processing, results back in 10-14 days c) Ova \& Parasites investigation: Sodium acetate-Acetic Acid-Formalin specimen sent to the Public Health Laboratories (PHL) for testing, results back in 7-10 days d) Viral culture: rarely requested, requires a specimen in a sterile container, sent to the PHL for testing, results back in 5-7 days e) Clostridioides difficile: specimen in sterile container, results in 1h (GeneXpert)"
62782446|NCT02721095|ACTIVE_COMPARATOR|0.45%NaCl|KCl plus 0.45%NaCl
62782447|NCT01510743|ACTIVE_COMPARATOR|Group SC|US guided subclavian vein catheterization
62782448|NCT01510743|ACTIVE_COMPARATOR|Group IJ|US-guided internal jugular vein catheterization
62782449|NCT05239767|ACTIVE_COMPARATOR|Ketorolac|Ketorolac 20mg orally x 1
62782450|NCT05239767|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 800mg orally x 1
62194078|NCT05849623|ACTIVE_COMPARATOR|Cold Endoscopic Mucosal Resection (C-EMR)|The polyp will be positioned at the 6 o'clock position and injected submucosally with saline and methylene blue, with or without epinephrine. The size of the ensnared polyp will be limited to 10-15mm to make sure that the snare will cut through the tissue. If the snare encounters difficulty in cutting through, it will be loosened to release deeper tissue before being closed again. The base and margins of the resected polyp will be inspected for residual polyp, which will be resected using the same technique if found. The polyp will be retrieved (en bloc or piecemeal) using suction into a trap or RothNet.
62214922|NCT05184712|PLACEBO_COMPARATOR|Placebo in combination with Pemetrexed and Carboplatin|Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
62214923|NCT05570097|NO_INTERVENTION|"the before group"|Control group as a standard therapy in Poland (regional analgesia: intrapleural or bilateral erector spine plane block added to multimodal analgesia).
62214924|NCT05570097|EXPERIMENTAL|"the after group"|During modyfied Nuss thoracoscopy the intraoperative Cryolesia of at least 5 intercostal nerves added to regional analgesia: bilateral erector spine plane block and multimodal therapy.
62214925|NCT00000167|EXPERIMENTAL|1|Laser treatment
62573540|NCT00365157|EXPERIMENTAL|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 1-2 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62782451|NCT03989401|EXPERIMENTAL|Multimedia video education|The experimental group conducted multimedia video education while admission.
62782452|NCT03989401|NO_INTERVENTION|None multimedia video education|The control group conducted usual nursing of oral face-to-face education on admission.
62782453|NCT04236739|EXPERIMENTAL|IMPACT|Application of a mixture of allogenic MSC's and autologous chondrons with a fibrin cell carrier (Tisseel®) during one surgical procedure.
62782454|NCT04236739|NO_INTERVENTION|Control|Optional physical therapy or pain medication, according to participants' desire for 9 months.
62782455|NCT04360876|EXPERIMENTAL|Dexamethasone|Patients assigned to the dexamethasone arm will receive an intravenous dose of 20 mg once daily from day 1 to day 5 which will be reduced to 10mg once daily from day 6 to day 10. Intravenous infusion bags divided into 10 doses will be provided at randomization by the investigational pharmacy. The time from randomization to time for first medication administration will be 4 hours or less. All infusions - dexamethasone and placebo - will be manufactured by the investigational pharmacy at the University of Colorado.
62008620|NCT06444620|EXPERIMENTAL|Switch to DTG/3TC 2DR|Participants will be switched from B/F/TAF to a fixed-dose combined DTG/3TC pill each containing 50mg of dolutegravir and 300mg of lamivudine taken once daily for the duration of the study
62008621|NCT04612491||Pre-operative Consultation|
62008622|NCT04612491||No consultation|
62008623|NCT06285539|EXPERIMENTAL|Intervention|26 weeks of Filgotinib once daily, 200mg, orally,
62008624|NCT06531564||Opioid group|patients receiving intravenous opioid agents after femur fracture
62008625|NCT06531564||NSAID|patients receiving intravenous NSAID agents after femur fracture
62008626|NCT06531564||acetaminophen|patients receiving intravenous acetaminophen after femur fracture
62008627|NCT06531564||Femoral nerve block|patients receiving femoral nerve blocking treatment after femur fracture
62008628|NCT06531564||PENG block|patients receiving PENG blocking treatment after femur fracture
62008629|NCT02170753|EXPERIMENTAL|Regional manual therapy|The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy
62008630|NCT02170753|ACTIVE_COMPARATOR|Standard physical therapy|The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
62008631|NCT02164396|ACTIVE_COMPARATOR|Spectacles Lens|Participant will discontinue soft contact lens wear and wear spectacles only. Spectacle lens refers to the habitual prescription glasses that the participant arrives to the testing center with; they are NOT prescribed or given to the participant by the investigator as part of the study protocol.
62008632|NCT02164396|ACTIVE_COMPARATOR|Habitual Soft Contact Lens|Participant will continue to wear their habitual soft contact lenses. Habitual lenses are the contact lenses used by the subjects prior to participating in the clinical trial. Various types/brands are used by subjects prior to participation.
62008633|NCT02164396|EXPERIMENTAL|Test Lens|Participants will be dispensed senofilcon A or narafilcon A depending on their habitual modality (reusable or daily disposable)
62008634|NCT00260234|EXPERIMENTAL|PEG Islet Cells|
62008635|NCT01374113|EXPERIMENTAL|Group 1|Subjects with moderate renal impairment
62008636|NCT01374113|EXPERIMENTAL|Group 2|Subjects with severe renal impairment
62008637|NCT01374113|EXPERIMENTAL|Group 3|Matched subjects with normal renal function
62008638|NCT06569069|EXPERIMENTAL|US-guided PE|
62008639|NCT06569069|SHAM_COMPARATOR|Sham acupuncture group|
62008640|NCT01395212||Cardiac stem cell therapy 5 years ago|
62008641|NCT00886093|EXPERIMENTAL|Sequence 1|
62008642|NCT00886093|EXPERIMENTAL|Sequence 2|
62008643|NCT03826420|EXPERIMENTAL|Secure Confinement Group|Parolees assigned to this group will be assigned sanctions that include secure confinement.
62008644|NCT03826420|EXPERIMENTAL|Work Release Group|Parolees assigned to this group will be assigned sanctions that include work-release.
62008645|NCT03826420|EXPERIMENTAL|GPS Supervision Group|Parolees assigned to this group will be assigned sanctions that include GPS supervision.
62008646|NCT03826420|NO_INTERVENTION|Control Group|
62194079|NCT05849623|ACTIVE_COMPARATOR|Underwater Endoscopic Mucosal Resection (U-EMR)|In the Underwater EMR arm, the patient will be connected to an electrosurgical grounding pad, and an Erbe VIO electrosurgical unit with EndoCut Q and Coagulation settings will be adjusted to the endoscopist's preference. Water, instead of carbon dioxide, will be used to fill the colon. Submucosal injection will not be performed.The patient will be positioned for optimal polyp exposure, and a 15mm snare will be used. The snare will be opened and positioned with a margin of normal mucosa and used to cut the polyp, en bloc if possible. Piecemeal resection should ensure no residual polyp tissue remains. Snare tip soft coagulation or coagulation forceps may be used for intraprocedural bleeding. The base and margins of the resected polyp will be inspected for residual polyp and resected if necessary. Closure of the defect with endoclips may be considered if there is significant bleeding. The polyp will be retrieved (en bloc or piecemeal) using suction into a trap or RothNet.
62194080|NCT02361086|EXPERIMENTAL|Regimen 1: 7dayPM+DT|VT-464: given orally once daily in 28 day cycles. Dosing in the evening before bed 7-days a week with a 2-week dose titration.
62194081|NCT02361086|EXPERIMENTAL|Regimen 2: 7dayPM-DT|VT-464: given orally once daily in 28 day cycles. Dosing in the evening before bed 7-days a week without dose titration.
62194082|NCT02361086|EXPERIMENTAL|Regimen 3: 7dayAM+DT|VT-464: given orally once daily in 28 day cycles. Dosing in the morning 7-days a week with a 2-week dose titration.
62194083|NCT02361086|EXPERIMENTAL|Regimen 4: 7dayAM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the morning 7-days a week without dose titration.
62194084|NCT02361086|EXPERIMENTAL|Regimen 5: 5dayPM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the evening before bed 5-days a week without dose titration.
62194085|NCT02361086|EXPERIMENTAL|Regimen 6: 5dayAM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the morning 5-days a week without dose titration.
62008647|NCT06197451||1|Patients who are diagnosed with neurologic disorders The first group consists of 170 diagnosed with neurologic disorders who have at least six months of dysphagia complaints. The participants will given the Turkish version of M.D. Anderson Dysphagia Inventory, consisted of 20 questions, Swallowing Quality-of-Life Questionnaire and Mini Mental Questionnaire. After the two weeks, 50 participants will given the MDADI for sampling.
62008648|NCT06197451||2|Healthy subjects The second group consists of 50 healty participants will given the MDADI consists of 20 questions and Swallowing Quality-of-Life Questionnaire.
62194086|NCT04236687|EXPERIMENTAL|Holmium laser enucleation of the prostate|Holmium laser will be used to enucleate the prostatic hyperplasia trough the urethra
62194087|NCT04236687|ACTIVE_COMPARATOR|Artery embolization of the prostate|A catheter is placed in the prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected through the catheter into these small arteries which nourish the prostate. The injected microspheres will slow the blood flow to the prostate.
62194088|NCT05253859||Cystic fibrosis registry (UK)|People with cystic fibrosis registered in the UK CF registry
62194089|NCT05253859||Cystic fibrosis registry (US)|People with cystic fibrosis registered in the US CF registry
62782456|NCT04360876|PLACEBO_COMPARATOR|Placebo|Participants randomized to the control group will received placebo intravenously for 10 days, one dose per day. Intravenous infusion bags divided into 10 doses will be provided at randomization by the investigational pharmacy. The placebo infusion bags will be as similar as possible to the dexamethasone infusion bags to ensure blinding.
62008649|NCT02616575||Silver link|Patients enrolled in NTUH hospital and its Behui branch
62194090|NCT02431052|PLACEBO_COMPARATOR|Olumacostat Glasaretil Gel, Vehicle QD|Olumacostat Glasaretil Gel, Vehicle, applied once daily to the face for 12 weeks
62194091|NCT02431052|PLACEBO_COMPARATOR|Olumacostat Glasaretil Gel, Vehicle BID|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
62194092|NCT02431052|EXPERIMENTAL|Olumacostat Glasaretil Gel, 4.0% QD|Olumacostat Glasaretil Gel, 4.0%, applied once daily to the face for 12 weeks
62194093|NCT02431052|EXPERIMENTAL|Olumacostat Glasaretil Gel, 7.5% QD|Olumacostat Glasaretil Gel, 7.5%, applied once daily to the face for 12 weeks
62734630|NCT03836872|EXPERIMENTAL|True Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints. Bilateral acupoints will be stimulated including Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
62782457|NCT05693792||Follow-up Group|Participants randomized to {WB001+TAU} and {ED001+TAU} in the parent study (WB001-001) will be assessed for 6 months following treatment completion.
62782458|NCT06210230|PLACEBO_COMPARATOR|Control group|
62782459|NCT06210230|EXPERIMENTAL|Intervention group|
62782460|NCT00285168||1 - Control|Usual Bone Density Report
62782461|NCT00285168||2 - Intervention|Bone Density Report with Absolute 10-year Fracture Risk Decision Aide
62008650|NCT03843684|EXPERIMENTAL|Knee osteoarthritis patients|
62008651|NCT04279834|ACTIVE_COMPARATOR|PAP Treatment|Participants will receive a PAP device and will attend four weekly sessions to receive education about this treatment.
62008652|NCT04279834|ACTIVE_COMPARATOR|Sleep Education I|Participants will attend four weekly sessions to receive education about strategies to improve sleep.
62008653|NCT03194646|EXPERIMENTAL|A1(3/1 regimen)|2.0 mg treatment of 12 weeks, each separated by 1 bleeding break
62008654|NCT03194646|EXPERIMENTAL|A2(6/2 regimen)|2.0 mg treatment period of 24 weeks, each separated by 2 bleeding break
62008655|NCT03194646|EXPERIMENTAL|A3(3/2 regimen)|2.0 mg treatment period of 12 weeks, each separated by 2 bleeding break
62194094|NCT02431052|EXPERIMENTAL|Olumacostat Glasaretil Gel, 7.5% BID|Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks
62194095|NCT03653000|EXPERIMENTAL|Patients undergoing this new block|Descriptive study about the effectiveness and the feasability of this new approach of te ultrasound guided brachial plexus blockade
62194096|NCT04606940||IO-KIN|Patients with a histological or cytological confirmed recurrent, metastatic or advanced HNSCC of the oral cavity, oropharynx, hypopharynx, larynx or unknown origin (but being treated as HNSCC). Patients who are going to receive at least one dose of anti-PD1 antibody (nivolumab or pembrolizumab).
62194097|NCT04610411|EXPERIMENTAL|surgical navigation|standard surgical method except for navigated instrumentation of pedicle screws and rod implants
62194098|NCT04610411|ACTIVE_COMPARATOR|standard surgical method|standard surgical method established at the institution
62194099|NCT01244165|OTHER|Cytrix|Observational Study
62194100|NCT01244165|OTHER|Control Group|Patients with similar indications who were treated at the same centers using other products
62194101|NCT05613049||Observational group|Patients have 2 or more miscarriage or repeated implantation failure (RIF), or infertile women would be invited to do endometrial sampling (ES) procedure. The ES will be conducted randomly or when women undergo hysteroscopy or obtained precisely 7 days after LH surge. It will be obtained using a Pipelle sampler as an outpatient procedure.
62008656|NCT03194646|OTHER|B(Standard of care)|Standard of care as determined by the investigators, this could be watch \& wait or non-hormonal medical treatment
62008657|NCT06504017|OTHER|COG-TB: Cognitive Fusion guided prostate targeted Biopsy|Targeted Biopsy 4 cores under cognitive fusion ultrasound
62194102|NCT02480647|EXPERIMENTAL|levonorgestrel & etonogestrel|"Levonorgestrel releasing intrauterine system~Other names:~Mirena."
62398410|NCT04189874|EXPERIMENTAL|BioFire FilmArray Gastrointestinal Panel|All patients randomly allocated to this arm will have their stools tested using a PCR-based molecular assay that can simultaneously test for 22 different infectious pathogens with a turnaround time of approximately 1 hour. As results become available, they will be available for review by the patient's healthcare providers in the electronic medical record.
62008658|NCT06504017|EXPERIMENTAL|FUS-TB: MRI-TRUS Fusion guided prostate targeted Biopsy|Targeted Biopsy 4 cores under MRI-TRUS Fusion ultrasound
62008659|NCT05962905||Pediatric|Subjects meeting inclusion criteria weighing between 4 and 40 kg
62008660|NCT05962905||Infant|Subjects meeting inclusion criteria weighing under 40 kg
62008661|NCT06199986|EXPERIMENTAL|ADT Order Check Attestation (Or)|"Study staff will place a Living Well ADT health factor in the electronic medical record for patients already receiving ADT, and whose clinic visits the study team have confirmed to be targets for ADT de-implementation. Health factors will be entered as eligible clinic visits are identified. This health factor combined with a low PSA level (most recent PSA \< 2) will trigger the ADT Order Check Attestation Intervention (Or) when the provider participant places an order for ADT (e.g., Lupron, Eligard, Goserelin, and Zoladex). Provider participants may override the order check by entering text indicating the reason and continue with the ordering process."
62194103|NCT02480647|ACTIVE_COMPARATOR|etonogestrel|"Etonogestrel implant:~Other name: Implanon Releasing 20μg/day."
62194104|NCT01998204||PD group|Patients with Parkinson's disease undergoing deep brain stimulator implantation and pulse generator placement
62194105|NCT01998204||non-PD group|Patients without Parkinson's disease undergoing intracranial surgery
62194106|NCT05594329|EXPERIMENTAL|Experimental meal 1|Instant noodle soup containing 2 servings of dried Pleurotus oyster mushroom.
62194107|NCT05594329|EXPERIMENTAL|Experimental meal 2|Instant noodle soup containing 1 serving of dried Pleurotus oyster mushroom.
62194108|NCT05594329|EXPERIMENTAL|Experimental meal 3|Instant noodle soup containing 0.5 serving of dried Pleurotus oyster mushroom.
62194109|NCT05594329|PLACEBO_COMPARATOR|Control meal|Instant noodle soup containing cornflour and maltodextrin in a 2.5:1 ratio.
62194110|NCT03042403||Breath stacking|During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds. During the 20 seconds of applying of technic, in the three series the maximum inspiratory and expiratory pressures reached during the carrying out of technic. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
62398411|NCT06723236|EXPERIMENTAL|Cohort 1|Dose level 1 of MGC028, IV
62398412|NCT06723236|EXPERIMENTAL|Cohort 2|Dose level 2 of MGC028, IV
62398413|NCT06723236|EXPERIMENTAL|Cohort 3|Dose level 3 of MGC028, IV
62398414|NCT06723236|EXPERIMENTAL|Cohort 4|Dose level 4 of MGC028, IV
62398415|NCT06723236|EXPERIMENTAL|Cohort 5|Dose level 5 of MGC028, IV
62008662|NCT06199986|EXPERIMENTAL|Provider Script (Sc)|Study staff will enter an electronic health record progress note approximately one business day prior to a target low-value ADT clinic visit from a patient already receiving ADT. The note will include scripted talking points for the provider participant to help with discussion and recent PSA levels and can be edited, signed, or deleted by the provider, giving a quick and simple way to document the discussion. The progress note will prompt provider participants to indicate whether a patient prefers to continue or discontinue ADT. The progress note will include links to a patient-facing clinic handout which will be posted on an external website. Provider participants may modify, ignore, or delete the progress note.
62008663|NCT06199986|NO_INTERVENTION|Control|The study team will match up to 8 sites (i.e., medical centers) to the 4 randomized sites as contemporary controls where no interventions have been deployed to compare the primary outcome of interruption of low-value ADT injections. Low-value ADT injections, eligible clinic visits, and primary outcomes for a matched 6-month period will be ascertained through chart review and compared to intervention site primary outcomes.
62194111|NCT02567305||Actual Sepsis|"For infants below 44 weeks inclusive of corrected age clinical sepsis is defined, according to the Expert Meeting on Neonatal and Pediatric Sepsis (Report on the Expert Meeting on Neonatal and Pediatric Sepsis - 8 June 2010, EMA London). Confirmed sepsis is defined as positive culture for pathogens in a sample from a normally sterile site and at least one laboratory sign or clinical sign (not shown)~For children above 44 weeks corrected age clinical sepsis is defined according to the Goldstein criteria (Goldstein et al, 2005). Confirmed sepsis: positive culture for pathogens in a sample from a normally sterile site and at least one laboratory sign or clinical sign (not shown)"
62194112|NCT02567305||Suspected Sepsis|None of the above.
62194113|NCT03874923|ACTIVE_COMPARATOR|250 mL of fluid challenge|
62194114|NCT03874923|EXPERIMENTAL|500 mL of fluid challenge|
62194115|NCT01552759|EXPERIMENTAL|Obese subjects with BED|"Subjects who meet the BMI requirement for obesity (\>30 kg/m\^2) and the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
62008664|NCT03921411|EXPERIMENTAL|Nemolizumab|Nemolizumab
62008665|NCT05145920|EXPERIMENTAL|Pilot testing of an education program promoting effective parenting habit|Parents will receive a series of 5 short videos via Whatsapp
62008666|NCT05755373||Cardiologists|Cardiologists treating patients with ASCVD and CKD
62008667|NCT01201252||Acute gastroenteritis Group|Suspected/confirmed cases of rotavirus gastroenteritis in children \< 5 years of age
62008668|NCT06363084||study arm|Nimotuzumab plus adjuvant chemotherapy
62398416|NCT06723236|EXPERIMENTAL|Cohort 6|Dose level 6 of MGC028, IV
62734631|NCT03836872|SHAM_COMPARATOR|Sham Acupuncture|In addition to the routine methods of care, patients allocated to the sham control group will receive sham acupuncture treatment at sham acupoints with superficial needling
62194116|NCT01552759|EXPERIMENTAL|Obese without BED|"Subjects who meet the BMI requirement for obesity (\>30 kg/m\^2) but who do not meet the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
62008669|NCT06363084||control arm|adjuvant chemotherapy alone (without Nimotuzumab)
62194117|NCT01552759|EXPERIMENTAL|Normal-weight without BED|"Subjects with BMI 20-25 kg/m\^2 who do not meet the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
62194118|NCT00847626|EXPERIMENTAL|Azilsartan medoxomil 20 mg/chlorthalidone 12.5 mg QD|
62194119|NCT00847626|EXPERIMENTAL|Azilsartan medoxomil 20 mg/chlorthalidone 25 mg QD|
62194120|NCT00847626|EXPERIMENTAL|Azilsartan medoxomil 40 mg/chlorthalidone 12.5 mg QD|
62194121|NCT00847626|EXPERIMENTAL|Azilsartan medoxomil 40 mg/chlorthalidone 25 mg QD|
62194122|NCT00847626|EXPERIMENTAL|Azilsartan medoxomil 80 mg/chlorthalidone 12.5 mg QD|
62398417|NCT06723236|EXPERIMENTAL|Expansion Cohort 1|MTD or MAD of MGC028, IV
62734632|NCT03836872|NO_INTERVENTION|Standard Control Group|The third arm will be a standard care control arm.
62782462|NCT02339194|EXPERIMENTAL|Simplified protocol|"The application of a simplified denture fabrication technique will be tested for patients presenting severely resorbed mandibular alveolar bones according to the following steps:~1. Obtainment of maxillary and mandibular casts by using irreversible hydrocolloid in stainless steel stock trays for record bases fabrication.~2. Adjustment of record bases according to vertical dimension and centric relation measurements, with no use of facebow transfer. Casts will be mounted in semi-adjustable articulator using standardized measures and artificial teeth will be selected.~3. Trial dentures will be evaluated for esthetics and maxillomandibular relationship.~4. Insertion of finished dentures."
62782463|NCT02339194|NO_INTERVENTION|Traditional protocol|"The importance of a second impression for denture fabrication technique will be tested for patients presenting severely resorbed mandibular alveolar bones according to the following steps:~1. Maxillary and mandibular casts obtained by using irreversible hydrocolloid in stainless steel stock trays for maxillary record base and mandibular custom tray fabrication.~2. Mandibular second impression with border molding using compound and impression rubber in custom tray.~3. Record bases adjustments without facebow transfer. Casts will be mounted in semi-adjustable articulator using standardized measures and artificial teeth will be selected.~4. Trial dentures will be evaluated for esthetics and maxillomandibular relationship.~5. Finished dentures insertion."
62782464|NCT02401984||Screening|A Screening tool will be administered to the participants.
62782465|NCT04188145|ACTIVE_COMPARATOR|Fluoropyrimidine|
62782466|NCT04188145|ACTIVE_COMPARATOR|Fluoropyrimidine + Bevacizumab|
62782467|NCT06341023|EXPERIMENTAL|Lab-based FBI|Participants in the lab-based functional balance intervention (FBI) group will receive 4 months of exercise training in the lab (2 times per week for 16 weeks, total 32 sessions). The exercise training will consist of multiple components including functional agility, functional strength, dual-tasking and vestibular exercises.
62008670|NCT01540370||Patients with OAG and/or OHT|Patients with OAG and/or OHT
62008671|NCT00807092|EXPERIMENTAL|BIAsp 30|BIAsp 30 (biphasic insulin aspart 30) administered subcutaneously (under the skin) twice daily (before breakfast and dinner) + metformin. Initial total daily dose of 0.3 U or IU/kg body weight followed by individual dose adjustment for BIAsp 30 was performed over the first 4 weeks (titration period) to achieve the pre-meal blood glucose target of 4.4-6.1 mmol/l. The achieved dose was maintained for the last 2 weeks of treatment unless hypoglycaemia occurred.
62194123|NCT00847626|EXPERIMENTAL|Azilsartan medoxomil 80 mg/chlorthalidone 25 mg QD|
62194124|NCT00847626|ACTIVE_COMPARATOR|Chlorthalidone 12.5 mg QD|
62194125|NCT00847626|ACTIVE_COMPARATOR|Chlorthalidone 25 mg QD|
62194126|NCT00847626|EXPERIMENTAL|Azilsartan medoxomil 20 mg QD|
62194127|NCT00847626|EXPERIMENTAL|Azilsartan medoxomil 40 mg QD|
62194128|NCT00847626|EXPERIMENTAL|Azilsartan medoxomil 80 mg QD|
62194129|NCT00505310|EXPERIMENTAL|Emotional Expression Writing|20 minutes of writing on different topics at four different times. Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
62194130|NCT00505310|EXPERIMENTAL|Neutral Writing|20 minutes of writing on different topics at four different times. Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
62194131|NCT01266304||community members|Pittsburgh area community members, including people who attend an integrative medicine clinic and people who attend a conventional medicine clinic.
62398418|NCT06723236|EXPERIMENTAL|Expansion Cohort 2|MTD or MAD of MGC028, IV
62008672|NCT00807092|EXPERIMENTAL|BHI 30|BHI 30 (biphasic human insulin 30) administered subcutaneously (under the skin) twice daily (30 minutes before breakfast and dinner) + metformin. Initial total daily dose of 0.3 U or IU/kg body weight followed by individual dose adjustment for BHI 30 was performed over the first 4 weeks (titration period) to achieve the pre-meal blood glucose target of 4.4-6.1 mmol/l. The achieved dose was maintained for the last 2 weeks of treatment unless hypoglycaemia occurred.
62782468|NCT06341023|ACTIVE_COMPARATOR|Lab-based Stretching|Participants in the lab-based stretching group will receive 4 months of stretching in the lab (2 times per week for 16 weeks, total 32 sessions).The stretching program will include progressive stretches for upper and lower-limb muscles, core and back muscles followed by a cool-down of 10 mins including relaxation and breathing exercises. Stretching exercises will include single and multi-joint stretches designed to target improvements in performance of daily living activities.
62008673|NCT00058331|EXPERIMENTAL|epoetin alfa - long term dosing|"Patients receive epoetin alfa (EPO) subcutaneously (SC) once weekly for 3 weeks. Then patients receive EPO SC once weekly for 18 weeks. Quality of life is assessed at randomization at then monthly during study treatment.~Patients are followed every 6 months for 1 year."
62008674|NCT00058331|EXPERIMENTAL|epoetin alfa - short term dosing|"Patients receive epoetin alfa (EPO) subcutaneously (SC) once weekly for 3 weeks. Patients receive EPO SC on day 1 of weeks 4, 7, 10, 13, 16, and 19. Quality of life is assessed at randomization at then monthly during study treatment.~Patients are followed every 6 months for 1 year."
62008675|NCT02835365||patients treated with baclofen|Patients treated with baclofen to diminish their alcohol consumption in the ANGH centers will be enrolled
62008676|NCT01969071|ACTIVE_COMPARATOR|Levosimendan, inotropic agent|In the levosimendan group, levosimendan will be used in addition to standard inotropic therapy (one or more agent including; dopamine, dobutamine, noradrenaline, adrenaline)for 24 hours.Levosimendan dosage; a loading dose of levosimendan (6 μg kg-1) will be administered after removal of the aortic cross-clamp, followed by an infusion of levosimendan at a dose of 0.1 μg kg-1 min-1.
62008677|NCT01969071|ACTIVE_COMPARATOR|Control|In the control group, only standard inotropic therapy (one or more agent including; dopamine, dobutamine, noradrenaline, adrenaline)will be administered
62008678|NCT05116722|EXPERIMENTAL|Shoulder Pacemaker Treatment|The patients will be treated using the pacemaker for 15 - 30 minutes at 3-months, 6-months and 12-months during physical therapy.
62008679|NCT06573411|EXPERIMENTAL|ACEI/ARB+finerenone|The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD.
62008680|NCT06573411|PLACEBO_COMPARATOR|ACEI/ARB+Placebo|Control patients will be administered maximum tolerable dose of ACEI/ARB and a placebo.
62734633|NCT05432830|EXPERIMENTAL|"Experimental E-Liquid Order A"|All participants will be given all e-liquids (i.e. 3 flavor conditions all containing nicotine) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across 3 visits).
62782469|NCT06341023|EXPERIMENTAL|Home-based FBI|Participants in the home-based functional balance intervention (FBI) group will be asked to complete 4 months of exercise training at home (2 times per week for 16 weeks, total 32 sessions). The exercise training will consist of multiple components including functional agility, functional strength, dual-tasking and vestibular exercises.
62782470|NCT06341023|ACTIVE_COMPARATOR|Home-Based Stretching|Participants in the home-based stretching group will be asked to complete 4 months of stretching at home (2 times per week for 16 weeks, total 32 sessions).The stretching program will include progressive stretches for upper and lower-limb muscles, core and back muscles followed by a cool-down of 10 mins including relaxation and breathing exercises. Stretching exercises will include single and multi-joint stretches designed to target improvements in performance of daily living activities.
62782471|NCT01160913|ACTIVE_COMPARATOR|Continuous wound infusion above the fascia|
62782472|NCT01160913|ACTIVE_COMPARATOR|Continuous wound infusion below the fascia|
62782473|NCT03424460|EXPERIMENTAL|population 1-A1 : DM1 with VTE|Myotonic dystrophy type 1 patients with a history of venous thromboembolism (pulmonary embolism and/or deep vein thrombosis)
62782474|NCT03424460|ACTIVE_COMPARATOR|population 1-B1 : DM1 without VTE|Myotonic dystrophy type 1 patients without a history of venous thromboembolism
62194132|NCT05860621|EXPERIMENTAL|Brief Physical Activity Counselling|The brief physical activity counselling (PAC) group will receive a group-based, light-touch, motivational counselling program to promote physical activity.
62008681|NCT05491707|EXPERIMENTAL|Music|Patients in the intervention group will receive music after the ASA monitors are applied. The music will be played at a self-selected volume, on Pro Bass Swagger Series Aux disposable earphones and will be played for the duration of the surgical procedure. The music will be played from an iPhone which will be placed in a plastic bag for infection control purposes. These patients will receive standard anaesthetic care.
62008682|NCT05491707|NO_INTERVENTION|Control|The control group will not receive music. These patients will receive standard anaesthetic care.
62008683|NCT00910715|ACTIVE_COMPARATOR|EM-10 days doxycycline|
62008684|NCT00910715|ACTIVE_COMPARATOR|EM-doxycycline 15 days|
62008685|NCT00910715|PLACEBO_COMPARATOR|controls|
62008686|NCT01440322|EXPERIMENTAL|AIR OPTIX® COLORS|Lotrafilcon B contact lenses with color worn in both eyes on a daily wear, monthly replacement basis for 3 months
62008687|NCT01440322|ACTIVE_COMPARATOR|AIR OPTIX® AQUA|Lotrafilcon B contact lenses worn in both eyes on a daily wear, monthly replacement basis for 3 months
62008688|NCT00436306|EXPERIMENTAL|Individualized Intervention: stage-matched/tailored counseling|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
62008689|NCT00436306|PLACEBO_COMPARATOR|Control: Enhanced usual care counseling|The Enhanced Usual Care arm was the control group. It provided computer-based information regarding contraceptive methods, but was not individualized or tailored to the participant stage of change.
62008690|NCT06531603|EXPERIMENTAL|Bupivacaine group|Patients receiving Bupivacaine plus placebo for wound infiltration after abdominal surgery for pain control.
62573541|NCT06110494|EXPERIMENTAL|Iron oxide nanoparticles treatment Ferumoxytol/H2O2|After access preparation with sterile burs and sterile saline irrigation and working length determination as part of routine root canal treatment, and after obtaining a pre-treatment bacteriological samples, 2 mL of a mixture of Ferumoxytol (6mg/mL)/H2O2(3%) was introduced into the canal. Canals were instrumented with 15/0.04, 20/0.04, and 25/0.04 rotary files using 2 mL of treatment solution after each file with a total of 8 mL of solution used and a total contact time of 10 minutes.
62734634|NCT05432830|EXPERIMENTAL|"Experimental E-Liquid Order B"|All participants will be given all e-liquids (i.e. 3 flavor conditions all containing nicotine) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across 3 visits).
62008691|NCT06531603|EXPERIMENTAL|Bupivacaine plus Dexmedetomidine group|Patients receiving Bupivacaine plus Dexmedetomidine for wound infiltration after abdominal surgery for pain control.
62008692|NCT03428516|EXPERIMENTAL|Fixed CPAP|CPAP always deliver air with the same pressure
62008693|NCT03428516|ACTIVE_COMPARATOR|Auto-adjusting CPAP|Auto-CPAP changes the pressure delivered depending on events detected at any time (apnea, hypopnea ...) and applies the lowest pressure required to eliminate events.
62008694|NCT02616003|OTHER|Super-super Obese Patients|Multimorbid, super-super obese patients that need preoperative conditioning therapy (intervention 1: Liraglutide, intervention 2: aminosteril hepa 8%, intervention 3: Caloric diet with 1000 kcal) for weight loss surgery to achieve technical operability.
62008695|NCT05255289|EXPERIMENTAL|Before TOT|Data obtained before the operation
62008696|NCT05255289|EXPERIMENTAL|After TOT|Data obtained after the operation
62008697|NCT05255289|EXPERIMENTAL|Before TVT-O|Data obtained before the operation.
62008698|NCT05255289|EXPERIMENTAL|After TVT-O|Data obtained after the operation.
62194133|NCT05860621|EXPERIMENTAL|Structured Exercise Program|The structured exercise group will receive a group-based supervised multi-component exercise program, with progressive intensity.
62008699|NCT05255289|EXPERIMENTAL|Aged patient (>50 y/o) before TVT-O|Data obtained before the operation.
62008700|NCT05255289|EXPERIMENTAL|Aged patient (>50 y/o) after TVT-O|Data obtained after the operation.
62008701|NCT05255289|EXPERIMENTAL|Young patients (<50 y/o) before TVT-O|Data obtained before the operation.
62008702|NCT05255289|EXPERIMENTAL|Young patients (<50 y/o) after TVT-O|Data obtained after the operation.
62008703|NCT05255289|EXPERIMENTAL|Menopausal patient before TVT-O|Data obtained before the operation.
62008704|NCT05255289|EXPERIMENTAL|Menopausal patient after TVT-O|Data obtained after the operation.
62008705|NCT05255289|EXPERIMENTAL|Pre-menopausal patient before TVT-O|Data obtained before the operation.
62008706|NCT05255289|EXPERIMENTAL|Pre-menopausal patients after TVT-O|Data obtained after the operation.
62008707|NCT05255289|EXPERIMENTAL|Before i-STOP|Data obtained before the operation.
62008708|NCT05255289|EXPERIMENTAL|After i-STOP|Data obtained after the operation.
62008709|NCT05255289|EXPERIMENTAL|Aged patient before i-STOP|Data obtained before the operation.
62008710|NCT05255289|EXPERIMENTAL|Aged patient after i-STOP|Data obtained after the operation.
62194134|NCT05860621|NO_INTERVENTION|Waitlist control|Patients allocated to the control group (i.e., waiting list) will keep daily routines and standard medical care. At the end of the study, the control group will be offered the structured exercise program.
62194135|NCT05656794|EXPERIMENTAL|Arm 1 - Investigational|Radiation treatment (36 Gy in 6 fractions) to be delivered every other day over 2 weeks (excluding weekends).
62194136|NCT05656794|OTHER|Arm 2 - Standard|Radiation treatment (36 Gy in 6 fractions) to be delivered once a week over 6 weeks.
62194137|NCT02563548|EXPERIMENTAL|GAC: PEGPH20 1.6 µg/kg/2.2 µg/kg + Pembrolizumab|Dose escalation part: Participants with relapsed/refractory locally advanced or metastatic gastric adenocarcinoma (GAC) will receive PEGPH20 1.6 micrograms/kilogram (µg/kg) or 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle (i.e. 3 doses/cycle) and pembrolizumab 2 milligrams/kilogram (mg/kg) every 21 days on Day 1 of each cycle (i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration. Dose expansion part: Participants with relapsed/refractory locally advanced or metastatic GAC will receive PEGPH20 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle and pembrolizumab 200 mg on Day 1 of each cycle, 4-6 hours after the completion of PEGPH20 administration. Treatment in both phases of the study will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity (maximum exposure: 60 weeks).
62782475|NCT03424460|ACTIVE_COMPARATOR|population 1-C1 : Healthy volunteers|Healthy volunteers without any medical history or treatment
62782476|NCT03424460|EXPERIMENTAL|population 2-A2 : DM1 liver samples|Liver samples of patients with myotonic dystrophy type 1
62008711|NCT05255289|EXPERIMENTAL|Young patient before i-STOP|Data obtained before the operation.
62008712|NCT05255289|EXPERIMENTAL|Young patient after i-STOP|Data obtained after the operation.
62008713|NCT05255289|EXPERIMENTAL|Menopausal patient before i-STOP|Data obtained before the operation.
62008714|NCT05255289|EXPERIMENTAL|Menopausal patient after i-STOP|Data obtained after the operation.
62008715|NCT05255289|EXPERIMENTAL|Pre-menopausal patient before i-STOP|Data obtained before the operation.
62573542|NCT06110494|ACTIVE_COMPARATOR|Sodium Hypochlorite (NaOCl)|After access preparation with sterile burs and sterile saline irrigation and working length determination as part of routine root canal treatment, and after obtaining a pre-treatment bacteriological samples, 2 mL of 3% NaOCl was introduced into the canal. Canals were instrumented with 15/0.04, 20/0.04, and 25/0.04 rotary files using 2 mL of solution after each file with a total of 8 mL of treatment solution used and a total contact time of 10 minutes.
62782477|NCT03424460|ACTIVE_COMPARATOR|population 2-B2 : Healthy liver samples|Liver samples from patients without any medical history
62008716|NCT05255289|EXPERIMENTAL|Pre-menopausal patient after i-STOP|Data obtained after the operation.
62008717|NCT05255289|EXPERIMENTAL|Before mini Arc|Data obtained before the operation.
62734635|NCT05432830|EXPERIMENTAL|"Experimental E-Liquid Order C"|All participants will be given all e-liquids (i.e. 3 flavor conditions all containing nicotine) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across 3 visits).
62782478|NCT00387725|EXPERIMENTAL|Group A|20ug Experimental
62782479|NCT00387725|EXPERIMENTAL|Group 2|60ug Experimental
62008718|NCT05255289|EXPERIMENTAL|After mini Arc|Data obtained after the operation.
62008719|NCT05255289|EXPERIMENTAL|Age patient before mini Arc|Data obtained before the operation.
62008720|NCT05255289|EXPERIMENTAL|Age patient after mini Arc|Data obtained after the operation.
62008721|NCT05255289|EXPERIMENTAL|Young before mini Arc|Data obtained before the operation.
62782480|NCT00387725|EXPERIMENTAL|Group 3|200ug Experimental
62782481|NCT00387725|ACTIVE_COMPARATOR|Group 4|Active comparator
62782482|NCT04776863||Smokeless tobacco|Individuals using smokeless tobacco
62782483|NCT04776863||No smokeless tobacco|Individuals who do not use smokeless tobacco
62782484|NCT04807257|EXPERIMENTAL|Patients with Malignant Cutaneous Lesions from Advanced Solid Tumors|"The IUdR, which is manufactured as lyophilized powder for injection, is dissolved by normal saline before use.~There are three cohorts with escalating doses of IUdR starting from an injection dose of 0.1 mL per lesion surface area unit of 1 cm2 and if tolerated, escalate to 0.2 mL/cm2 and to 0.25 mL/cm2 as presented below. Meanwhile, the upper limit of total injection doses of IUdR in the 3 levels are 2.83, 5.65, and 7.07ml , which correspond to 0.059, 0.118, and 0.147 mg/kg for a 60 kg adult, respectively. The dose of AUTRON Therapy System irradiation for all 3 cohorts keeps fixed at 25 Gy over 5 days (5 Gy/day)."
62008722|NCT05255289|EXPERIMENTAL|Young patient after mini Arc|Data obtained after the operation.
62008723|NCT05255289|EXPERIMENTAL|Menopausal patient before mini Arc|Data obtained before the operation.
62008724|NCT05255289|EXPERIMENTAL|Menopausal patient after mini Arc|Data obtained after the operation.
62008725|NCT05255289|EXPERIMENTAL|Pre-menopausal before mini Arc|Data obtained before the operation.
62008726|NCT05255289|EXPERIMENTAL|Pre-menopausal patient after mini Arc|Data obtained after the operation.
62008727|NCT01285739||NIMV COPD|Patients with chronic obstructive pulmonary disease (COPD), who underwent tracheostomy for acute respiratory failure and who were discharged with tracheostomy but in domiciliary non invasive ventilation
62008728|NCT01285739||IMV COPD|Patients with chronic obstructive pulmonary disease (COPD), who underwent tracheostomy for acute respiratory failure and who were discharged in domiciliary invasive mechanical ventilation (IMV)
62008729|NCT03613506|EXPERIMENTAL|Peripheral blood TGF-β content before and after radiotherapy|
62008730|NCT05846009|EXPERIMENTAL|SAR442501|
62008731|NCT05846009|PLACEBO_COMPARATOR|Placebo|
62008732|NCT04096560|PLACEBO_COMPARATOR|Part A: Placebo|TAK-994 placebo-matching tablets, orally, twice daily (BID) for 28 days, in participants with NT1.
62782485|NCT00853138|EXPERIMENTAL|CBT|Cognitive-behavioral therapy delivered via the internet in eight treatment modules for children (education, stress and negative emotions, deep breathing and relaxation, distraction, cognitive skills, sleep hygiene and lifestyle, staying active, relapse prevention) and eight treatment modules for parents (education, stress and negative emotions, operant strategies I, operant strategies II, modeling, sleep hygiene and lifestyle, communication, relapse prevention).
62782486|NCT00853138|NO_INTERVENTION|SMC|The standard medical care wait-list control group continued with the treatment recommendations proscribed by their pain care team.
62782487|NCT04667104|EXPERIMENTAL|Treatment Period (TP) 1 (JNJ-73763989 + Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)|Participants will receive combination treatment with JNJ-73763989+ nucleos(t)ide analog (NA) for 12 weeks during Treatment Period 1 and the participants who meet the eligibility criteria for PegIFN-alpha2a at Week 12 will receive combination treatment with JNJ-73763989 + NA plus PegIFN-α2a for 12 weeks during Treatment Period 2.
62194138|NCT02563548|EXPERIMENTAL|NSCLC: PEGPH20 1.6 µg/kg/2.2 µg/kg + Pembrolizumab|Dose escalation part: Participants with relapsed/refractory Stage IIIB or IV non-small cell lung cancer (NSCLC) will receive PEGPH20 1.6 µg/kg or 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle (i.e. 3 doses/cycle) and pembrolizumab 2 mg/kg every 21 days on Day 1 of each cycle (i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration. Dose expansion part: Participants with relapsed/refractory Stage IIIB or IV NSCLC will receive PEGPH20 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle and pembrolizumab 200 mg on Day 1 of each cycle, 4-6 hours after the completion of PEGPH20 administration. Treatment in both phases of the study will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity (maximum exposure: 46 weeks).
62782488|NCT00917488|EXPERIMENTAL|A|Four concentrations of Glycyphagus domesticus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, was tested in every patient in duplicate on the volar surface of the forearm.
62194139|NCT01867047|EXPERIMENTAL|Continuation Group|Subjects randomized to this group will continue their ACE-I through the day of surgery
62194140|NCT01867047|EXPERIMENTAL|Cessation Group|Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose \>48 hours prior to surgery)
62194141|NCT05335200|EXPERIMENTAL|(S)-[18F]FBFP injection and PET/CT scan|Patients will be intravenously injected with(S)-\[18F\]FBFP and undergo PET/CT scan.
62194142|NCT04657042||Healthy|Healthy volunteers from the local community
62194143|NCT04657042||Liver cancer|Patients undergoing radiotherapy for liver cancer
62194144|NCT04657042||Lung cancer|Patients undergoing radiotherapy for lung cancer
62194145|NCT05475275|EXPERIMENTAL|Experimental group|"The experimental group underwent intraoperative measurements (A: short distance from the center of the pancreatic duct to the edge of the pancreas) and (B: pancreatic thickness). When the ratio of the thickness of the short distance from the center of the pancreatic duct to the edge of the pancreas at the pancreatic section was ≥0.401, it was divided into the N1 group (central pancreatic duct). If the ratio was \<0.401, it was divided into the N2 group (eccentric pancreatic duct). The central pancreatic duct group was given 1+1 mode pancreaticojejunostomy; the eccentric pancreatic duct group was given 1+1² mode pancreaticojejunostomy."
62194146|NCT05475275|ACTIVE_COMPARATOR|Control group|"The patients in the control group were given traditional pancreaticojejunostomy"
62194147|NCT01053481|EXPERIMENTAL|Vitamin D|Vitamin D supplement
62398419|NCT00942669|EXPERIMENTAL|SleepStrip OTC(TM)|Participants will receive the SleepStrip OTC(TM) for a night (or two) test at home, before or after undergoing an independent PSG test at the Sleep lab. The reading of both methods will be analyzed.
62008733|NCT04096560|EXPERIMENTAL|Part A: TAK-994 120 mg|TAK-994 120 mg, orally, BID for 28 days, in participants with NT1.
62194148|NCT01606423|PLACEBO_COMPARATOR|Placebo|Administered once, orally
62734636|NCT03198767|EXPERIMENTAL|Part A: LIK066 + P1: 50% CHO / P2: 25% CHO / P3: 0% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 50% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 25% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 0% carbohydrate
62194149|NCT01606423|EXPERIMENTAL|10 mg LY2409021|10 mg LY2409021 administered once, orally
62194150|NCT01606423|EXPERIMENTAL|22.5 mg LY2409021|22.5 mg LY2409021 administered once, orally
62398420|NCT01451177|EXPERIMENTAL|Treated|
62398421|NCT03920774||Familial Dysautonomia|Patients diagnosed with familial dysautonomia, a genetic disorder that affects the development and survival of nerve cells in the autonomic nervous system. It primarily affects neurons that control involuntary actions like regulation of blood pressure and breathing. It also affects the sensory nervous system and the perception of pain, heat and cold.
62782489|NCT04165499|EXPERIMENTAL|Combination of Plant Extracts (BSL_EP026)|Volunteers will take 1 capsule twice daily with the combination of the plant extracts (BSL_EP026).
62782490|NCT04165499|PLACEBO_COMPARATOR|Control|Volunteers will take 1 capsule twice daily with maltodextrin.
62782491|NCT01982461|EXPERIMENTAL|Rosuvastatin|One Rosuvastatin tablet 10mg taken once daily.
62782492|NCT01982461|ACTIVE_COMPARATOR|Crestor®|One Crestor® tablet 10mg taken once daily.
62782493|NCT00761527||Participants with allergic rhinitis or idiopathic urticaria|Outpatient pediatric participants (ages 6 months-11 years) in the Philippines with a diagnosis of allergic rhinitis or chronic idiopathic urticaria.
62782494|NCT00379067|ACTIVE_COMPARATOR|1|Tamsulosin OCAS tablet
62782495|NCT00379067|PLACEBO_COMPARATOR|2|Placebo tablet
62782496|NCT06293313|EXPERIMENTAL|Mindfulness group|Students who agree to participate in the research will be met with students in a quiet room of the school by making an appointment. Individuals will be pre-tested. Mindfulness will be applied within the first 3 days of the menstrual period. After continuing the training for 8 weeks, an interim test will be applied. After 3 months, the final test will be applied
62782497|NCT06293313|SHAM_COMPARATOR|Control Group|Students in the control group will not be given any application. A pre-test will be administered before starting the study, an interim test will be applied 8 weeks after the pre-test, and a post-test will be applied 3 months after the interim test. After the study is over, mindfulness will be applied to the students in the control group.
62782498|NCT02484482|EXPERIMENTAL|Group 1|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~Fasting→Standard Meal→High Fat Meal"
62194151|NCT01606423|EXPERIMENTAL|60 mg LY2409021|60 mg LY2409021 administered once, orally
62008734|NCT04096560|EXPERIMENTAL|Part A: TAK-994 180 mg|TAK-994 180 mg, orally, BID for 28 days, in participants with NT1.
62398422|NCT05473039|EXPERIMENTAL|Seidivid Ferty4|Patients included in this group will be administered dietary supplement Seidivid Ferty4 (2 capsules per day, as a single dose) for at least 30 days prior to controlled ovarian hyperstimulation and until the day of the agonist trigger (GnRH a).
62398423|NCT05473039|PLACEBO_COMPARATOR|Placebo|Patients included in this group will be administered placebo (2 capsules per day, as a single dose) for at least 30 days prior to controlled ovarian hyperstimulation and until the day of the agonist trigger (GnRH-a).
62398424|NCT05128656|OTHER|Cases|SARS-Cov-2 asymptomatic nursing homes employees
62398425|NCT05128656|OTHER|Controls|cohort of patients with a symptomatic COVID-19, preferably recruited in nursing homes or in case of difficulties in the virology service of COCHIN Hospital.
62398426|NCT05243472|NO_INTERVENTION|Control group|Participants in the control group will not receive any intervention during the study period.
62782499|NCT02484482|EXPERIMENTAL|Group 2|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~Standard Meal→High Fat Meal→Fasting"
62008735|NCT04096560|PLACEBO_COMPARATOR|Part B: Placebo|TAK-994 placebo-matching tablets, orally, BID for 56 days, in participants with NT1.
62008736|NCT04096560|EXPERIMENTAL|Part B: TAK-994 30 mg|TAK-994 30 mg tablets, orally, BID for 56 days, in participants with NT1.
62008737|NCT04096560|EXPERIMENTAL|Part B: TAK-994 90 mg|TAK-994 90 mg tablets, orally, BID for 56 days, in participants with NT1.
62008738|NCT04096560|EXPERIMENTAL|Part B: TAK-994 180 mg|TAK-994 180 mg tablets, orally, BID for 56 days, in participants with NT1.
62398427|NCT05243472|EXPERIMENTAL|Protein nutritional supplement group|Participants in the intervention group will receive protein-enriched soups (24-30g of protein) per day for 12 weeks. Protein may come from either soy, bean or milk products.
62398428|NCT03113773|EXPERIMENTAL|Part A|Proleukin/Placebo in patients with stable ischaemic heart disease
62782500|NCT02484482|EXPERIMENTAL|Group 3|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~High Fat Meal→Fasting→Standard Meal"
62008739|NCT04096560|EXPERIMENTAL|Part C: TAK-994 180 mg|TAK-994 180 mg tablets, orally, BID for 56 days, in Chinese participants with NT1.
62194152|NCT01606423|EXPERIMENTAL|200 mg LY2409021|200 mg LY2409021 administered once, orally
62194153|NCT01606423|EXPERIMENTAL|500 mg LY2409021|500 mg LY2409021 administered once, orally
62194154|NCT03325777|EXPERIMENTAL|Approach Bias Retraining Group|Individuals in this condition will receive seven sessions of ABR training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the training may weaken automatic cigarette-approach and strengthen automatic cigarette-avoidance. Furthermore, they will be told that the opposite effect will be true for the stimuli not related to cigarettes (i.e., the positive stimuli).
62398429|NCT03113773|EXPERIMENTAL|Part B|Proleukin/Placebo in patients with cute coronary syndromes
62398430|NCT06525987|EXPERIMENTAL|Immediate intervention|Participants will be allocated to physical activity intervention during the 24 weeks of follow-up.
62398431|NCT06525987|OTHER|Delayed intervention|Participants will not be randomized to physical activity intervention during the first 24 weeks of follow-up. They will be randomized after the 24 weeks of follow-up.
62398432|NCT05710848|EXPERIMENTAL|STM-416|STM-416
62782501|NCT02484482|EXPERIMENTAL|Group 4|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~Fasting→High Fat Meal→Standard Meal"
62782502|NCT02484482|EXPERIMENTAL|Group 5|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~Standard Meal→Fasting→High Fat Meal"
62782503|NCT02484482|EXPERIMENTAL|Group 6|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~High Fat Meal→Standard Meal→Fasting"
62782504|NCT01674205|EXPERIMENTAL|Group 1 (Inpatient, H2N3 MO 2006/AA ca)|Participants will receive one dose of vaccine on Day 0, with 0.2 mL being delivered by Accuspray device (0.1 mL per nostril).
62782505|NCT01674205|EXPERIMENTAL|Group 2 (Inpatient, H9N2 G9/AA ca)|Participants will receive one dose of vaccine on Day 0, with 0.5 mL being delivered as nose drops (0.25 mL per nostril) using a sterile, needle-less tuberculin syringe.
62782506|NCT01674205|EXPERIMENTAL|Group 3 (Outpatient, seasonal LAIV [FluMist®])|2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)
62782507|NCT01674205|PLACEBO_COMPARATOR|Group 4 (Both inpatient and outpatient, placebo)|Participants will receive either the L-15 placebo delivered by nose drops or the FluMist® placebo delivered as a nasal spray.
62782508|NCT00533624|ACTIVE_COMPARATOR|1: Myfortic|Myfortic Group: Myfortic® 1,440 mg/day in two divided doses (induced with either the IL-2 receptor inhibitors or thymoglobulin). Tacrolimus will be dosed to 12-hour trough levels of 8-10 ng/ml. Methylprednisolone is to be given as per our center protocols, weaning to dose levels of \<0.1 mg/kg by 3-6 months post-operatively.
62782509|NCT00533624|ACTIVE_COMPARATOR|2. Cellcept|Cellcept® 2,000 mg/day, in divided doses (induced with either the IL-2 receptor inhibitors or thymoglobulin). Tacrolimus will be dosed to 12-hour trough levels of 8-10 ng/ml. Methylprednisolone is to be given as per our center protocols, weaning to dose levels of \<0.1 mg/kg by 3-6 months post-operatively.
62782510|NCT04703491|EXPERIMENTAL|Full intervention|This group receives the full-featured intervention, including CCBT, CBM, Mindfulness, chatbot with many interactive elements.
62782511|NCT04703491|ACTIVE_COMPARATOR|Limited CCBT control group|This group receives feature-limited intervention (text-based computerized CBT)
62782512|NCT04703491|OTHER|Waitlist control group|This group receives waitlist control.
62782513|NCT05688332|EXPERIMENTAL|Voglibose + Metformin (Group B)|In the B treatment group, 59 participants will be randomly assigned to initially voglibose 0.2mg TDS immediately before meals + metformin 500mg BD immediately before meals daily. Individual drug doses will be adjusted to the next higher doses after 6 to 12 days, at next clinical visits based on home based recorded blood glucose profiles. The maximum daily recommended dose of metformin of 2g and voglibose 0.9mg will not be exceeded.
62782514|NCT05688332|ACTIVE_COMPARATOR|Glibenclamide + Metformin (Group A)|"In treatment group A, 59 participants will initially be randomly allocated by study team members to the glibenclamide 5mg O.D + metformin 500mg BD regimen.~In this study, 10mg glibenclamide and 2g metformin will not be exceeded daily."
62782515|NCT06576219|EXPERIMENTAL|Intervention Group|
62008740|NCT06029959|EXPERIMENTAL|SCOUTS3 Optimization Arm|In a single-arm study, participants from acute ischemic stroke or intraparenchymal hemorrhage within the past 30 days will be tested for OSA with a single-night portable OSA test during inpatient rehabilitation (IPR). Eligible participants will then be started on continuous positive airway pressure (CPAP) therapy and exposed to a multicomponent CPAP adherence intervention, beginning during IPR and extending for 3 months. Participants' CPAP use will be monitored, and input regarding the intervention will be sought from the participants, CPAP partners, and the research team implementing the intervention. Data from an initial group of study participants will be reviewed in meetings with the study team and a patient advisory board, and adaptations will be devised and then implemented within the next batch of study participants. Through this iterative process that includes input from important stakeholders, the behavioral intervention will be adapted for use among stroke patients.
62573543|NCT06110494|PLACEBO_COMPARATOR|Saline (NaCl)|After access preparation with sterile burs and sterile saline irrigation and working length determination as part of routine root canal treatment, and after obtaining a pre-treatment bacteriological samples, 2 mL of 0.89% NaCl was introduced into the canal. Canals were instrumented with 15/0.04, 20/0.04, and 25/0.04 rotary files using 2 mL of treatment solution after each file with a total of 8 mL of solution used and a total contact time of 10 minutes.
62573544|NCT01203514|EXPERIMENTAL|Trial 1 Experimental|Infants 401-1,000g birthweight
62573545|NCT01203514|SHAM_COMPARATOR|Trial 1: Sham Comparator|Infants 401-1,000g birthweight
62782516|NCT04358965|EXPERIMENTAL|intravenous tranexamic acid|patients were given a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision plus one vaginal placebo tablet 1 hour before skin incision
62782517|NCT04358965|ACTIVE_COMPARATOR|vaginal misoprostol|patients will be given one vaginal misoprostol tablet (200 mcg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
62782518|NCT04358965|PLACEBO_COMPARATOR|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
62782519|NCT02403232|EXPERIMENTAL|ASCs injection|Autologous adipose-derived stem cells (ASCs) injection with LIPOGEMS system.
62782520|NCT02783599|EXPERIMENTAL|Olaratumab + Doxorubicin|"Cycle 1: Olaratumab 20 milligram per kilogram (mg/kg) given intravenously (IV) on Day 1 and Day 8 (21 day cycle).~Cycle 2: Olaratumab 20 mg/kg given IV on Day 1 and Day 8 plus doxorubicin 75 mg/m2 given IV on Day 1 (21 day cycle).~Cycle 3 through Cycle 7: Olaratumab 15 mg/kg given IV on Day 1 and Day 8 plus doxorubicin 75 mg/m2 given IV on Day 1 (21 day cycles)."
62008741|NCT00360776|EXPERIMENTAL|Arm I|"Patients will receive tipifarnib by mouth twice a day for 3 weeks. Treatment may repeat every 4 weeks for up to eight courses.~Patients will undergo blood collection periodically for laboratory studies. After finishing treatment, patients will be evaluated every 6 months for 5 years."
62008742|NCT02566759|EXPERIMENTAL|Part 1, Cohort 1: TAK-831 100 mg|TAK-831 100 milligram (mg), suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
62008743|NCT02566759|EXPERIMENTAL|Part 1, Cohort 2: TAK-831 250 mg|TAK-831 250 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
62008744|NCT02566759|EXPERIMENTAL|Part 1, Cohort 3: TAK-831 500 mg|TAK-831 500 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
62008745|NCT02566759|EXPERIMENTAL|Part 1, Cohort 4: TAK-831 30 mg|TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
62194155|NCT03325777|SHAM_COMPARATOR|Control Group|Individuals in this condition will receive seven sessions of SHAM training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the purpose of the training is to improve control over these automatic tendencies and that following the training sessions, they will easily be able to push or pull the stimuli regardless of content.
62008746|NCT02566759|EXPERIMENTAL|Part 1, Cohort 5: TAK-831 750 mg|TAK-831 750 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
62008747|NCT02566759|EXPERIMENTAL|Part 1, Cohort 6: TAK-831 10 mg|TAK-831 10 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
62194156|NCT02344342|EXPERIMENTAL|Health Buddy Web Management system|Patients randomized to the telemonitoring intervention will be assigned to use the Bosch Health Buddy Web management system.
62398433|NCT06706999|EXPERIMENTAL|Intervention Group|Participants will all receive a recommendation from their rheumatology provider based on their DAPS score. Recommendations will consist of an exercise resource and potentially a referral for a brief PT consultation call.
62398434|NCT02008162||Bronchodilators|"Patients with severe heterogeneous emphysema selected as potential candidtes for lung volume reduction surgery.~Bronchodilators employed for the study include albuterol 200µg and tiotropium bromide 18 µg administered by puffs following a first spirometry and plethysmography performed after a washout period of 48h from all bronchodilators and subsequently repeated within 30 min after bronchodilators administration."
62573546|NCT01203514|EXPERIMENTAL|Trial 2: Experimental|Infants 1,001-1,250g birth weight
62008748|NCT02566759|EXPERIMENTAL|Part 2, Cohort 1: TAK-831 30 mg|TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
62008749|NCT02566759|EXPERIMENTAL|Part 2, Cohort 2: TAK-831 100 mg|TAK-831 100 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
62008750|NCT02566759|EXPERIMENTAL|Part 2, Cohort 3: TAK-831 200 mg|TAK-831 200 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
62008751|NCT02566759|EXPERIMENTAL|Part 2, Cohort 4: TAK-831 400 mg|TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
62008752|NCT02566759|EXPERIMENTAL|Part 3, Cohort 1: TAK-831 400 mg|TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once daily from Days 1 to 14.
62782521|NCT02783599|EXPERIMENTAL|Olaratumab + Radiotherapy Addendum|"Olaratumab given IV on Day 1 and Day 8 (21 day cycle) concurrently with radiotherapy.~Radiotherapy addendum was not implemented."
62008753|NCT02566759|EXPERIMENTAL|Part 4:TAK-831(Tablet Fasted+ Tablet Fed + Suspension Fasted)|TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
62008754|NCT02566759|EXPERIMENTAL|Part 4:TAK-831(Tablet Fed + Tablet Fasted + Suspension Fasted)|TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
62194157|NCT02344342|EXPERIMENTAL|Flexible Diuretic Regimen|Patients randomized into the Flexible Diuretic Regimen intervention will have a diuretic regimen specified by specific weight ranges.
62194158|NCT00798252|EXPERIMENTAL|Arm A (Capecitabine + Brivanib alaninate)|
62194159|NCT00798252|EXPERIMENTAL|Arm B (Doxorubicin + Brivanib alaninate)|
62194160|NCT00798252|EXPERIMENTAL|Arm C (Ixabepilone + Brivanib alaninate)|
62194161|NCT00798252|EXPERIMENTAL|Arm D (Docetaxel + Brivanib alaninate)|
62194162|NCT00798252|EXPERIMENTAL|Arm E (Paclitaxel + Brivanib alaninate)|
62398435|NCT05940584|EXPERIMENTAL|Intervention Group Tele-reha (1)|Tele-reha group
62398436|NCT05940584|ACTIVE_COMPARATOR|Control Group Paper-based exercises (1)|Paper-based exercises with option to do tele-reha afterwards
62008755|NCT02566759|EXPERIMENTAL|Part 4:TAK-831(Suspension Fasted+ Tablet Fed + Tablet Fasted)|TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
62398437|NCT05940584|ACTIVE_COMPARATOR|Control Group Paper-based exercises (2)|Only paper-based exercises
62782522|NCT03287037|EXPERIMENTAL|tDCS over DLPFC|Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours.
62008756|NCT05351008|EXPERIMENTAL|Cognitive Functional Therapy group|The group will receive 4 months 1 times per week of cognitive functional therapy.
62573547|NCT01203514|SHAM_COMPARATOR|Trial 2: Sham Comparator|Infants 1,001-1,250g birth weight
62573548|NCT00775229|ACTIVE_COMPARATOR|1|Naltrexone
62008757|NCT05351008|ACTIVE_COMPARATOR|Core strengthening group|The group will receive 4 months 1 times per week of an exercise program aming core strengthening.
62008758|NCT05928702|EXPERIMENTAL|Armbath|"The armbath group will perform a temperature-elevating armbath developed by Hauffe and Schwenninger. A large bowl and a thermometer will be given to each participant.~Participant start with bathing their forearms up to about one third of the upper arm in a large bowl with water at approximately 37°C. Within 30min, they are advised to add hot water to the bowl for multiple times until a temperature of 42°C. After 30min, the arms can be taken out of the water, dried, and participants are recommended to rest for additional 30 min afterwards.~Prior medication should be continued throughout the whole trial."
62398438|NCT06560723|OTHER|Group 1 Interventional Arm (with PHP)|The patient will have a standardized geriatric assessment carried out by a nurse in both Multiprofessional Health Home. This geriatric assessment will be used to draw up a summary with different objectives and priorities, which will then be discussed at a multi-professional consultation meeting in the month following the geriatric assessment. The first multi-professional consultation meeting (MCM) will present the summary of the geriatric assessment and discuss the care and assistance to be implemented in the Personalized Health Plan (PHP). The Personalized Health Plan will then be prepared and formalized by the nurse, in partnership with the other healthcare professionals involved in the Personalized Health Plan. It will be presented to and validated by the patient and his/her carer. The actions will then be implemented.
62398439|NCT06560723|OTHER|Group 2 Control Arm (without PHP)|In the control group, the attending physician will set up appropriate care for a patient identified as frail in a standard general medical care pathway, having been made aware of the patient's frailty at the time of inclusion. He or she will organize the patient's care, referring him or her to the appropriate specialists according to the difficulties identified at inclusion, and according to the patient's habits and network.
62398440|NCT03027258|EXPERIMENTAL|Intervention|mHealth intervention
62008759|NCT05928702|NO_INTERVENTION|Waitlist|Participants will continue their treatment as usual (e.g. medication). After the end of the trial (6 months) they will be offered to get instructed on performing temperature-elevating armbaths.
62398441|NCT03851536|EXPERIMENTAL|Transvaginal Ultrasound Guided ET|Transvaginal ultrasound is used to guide ET
62398442|NCT03851536|EXPERIMENTAL|Transabdominal Ultrasound Guided ET|Transabdominal ultrasound is used to guide ET
62573549|NCT00775229|PLACEBO_COMPARATOR|2|Placebo
62573550|NCT00740792|EXPERIMENTAL|azelastine HCl/fluticasone propionate|nasal spray
62573551|NCT00740792|ACTIVE_COMPARATOR|azelastine HCL|nasal spray
62573552|NCT00740792|ACTIVE_COMPARATOR|fluticasone propionate|nasal spray
62573553|NCT00740792|PLACEBO_COMPARATOR|placebo|nasal spray
62782523|NCT01707901|EXPERIMENTAL|ONO-8539|ONO-8539
62782524|NCT01707901|PLACEBO_COMPARATOR|Placebo|Placebo
62008760|NCT06573216|EXPERIMENTAL|Blood pressure measured by wrist ambulatory blood pressure monitor and mercury sphygmomanometer|
62008761|NCT05796544|EXPERIMENTAL|Intervention Group|The intervention group will receive a total of four remote educational sessions over 2 months.
62008762|NCT05796544|ACTIVE_COMPARATOR|Control group|The control group will receive the standard care, consisting of in-person standard education.
62008763|NCT00978731|EXPERIMENTAL|Dasatinib|
62008764|NCT02548013|EXPERIMENTAL|Home management|outpatient management patients if stable will be discharged to continue treatment at home
62573554|NCT05829629|EXPERIMENTAL|FluBHPVE6E7|intracervical and intramuscular 0.5 ml per dose 3 doses (12 weeks)
62573555|NCT05829629|PLACEBO_COMPARATOR|Placebo|intracervical and intramuscular 0.5 ml per dose 3 doses (12 weeks)
62573556|NCT03525275|EXPERIMENTAL|BFA with Physical Therapy|BFA + post-surgical protocol, intervention = battlefield acupuncture plus post-surgical protocol
62573557|NCT03525275|ACTIVE_COMPARATOR|Physical Therapy alone|Intervention = Post-surgical protocol
62573558|NCT05573932|EXPERIMENTAL|Leaderboard group|The group that has access to weekly leaderboards and on-demand videos.
62573559|NCT05573932|ACTIVE_COMPARATOR|Take-home packet group|The group that has access to paper take-home packets.
62573560|NCT04299646|EXPERIMENTAL|Steretactic radiotherapy plus systemic treatment|
62573561|NCT04299646|ACTIVE_COMPARATOR|Systemic treatment|
62573562|NCT05917457|EXPERIMENTAL|treatment group|to be in the age of 7-14, Except for visual impairment (neurological and systemic diseases, hearing impairment, etc. ) not having an additional disease Having been diagnosed with low vision, To be able to establish cooperation, Volunteering to participate in the study 12 children with these criteria
62573563|NCT05917457|NO_INTERVENTION|control group|to be in the age of 7-14, Except for visual impairment (neurological and systemic diseases, hearing impairment, etc. ) not having an additional disease, Having been diagnosed with low vision, To be able to establish cooperation, Volunteering to participate in the study 10 children with these criteria
62782525|NCT00888953|EXPERIMENTAL|Intervention|Residents living in nursing homes allocated to intervention group. Assessment of risk factors. Implementation of a multifactorial tailored program to prevent falls.
62194163|NCT03178344|EXPERIMENTAL|Sham Stimulation, then Alpha Stimulation|"Participants receive sham stimulation at the first session, followed by a 5-9 day washout period and alpha stimulation at the second session.~Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.~Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS."
62782526|NCT00888953|OTHER|Control|Residents living in nursing homes allocated to control group. Assessment of risk factors. Receive the usual attention.
62008765|NCT02548013|ACTIVE_COMPARATOR|hospital management|Inpatient management patients will continue there treatment in hospital till delivery
62008766|NCT05917873|EXPERIMENTAL|LaKe arm|Ingestion of a combined lactate and ketone body ester, 25 ml twice daily for 28 days.
62194164|NCT03178344|EXPERIMENTAL|Alpha Stimulation, then Sham Stimulation|"Participants receive alpha stimulation at the first session, followed by a 5-9 day washout period and sham stimulation at the second session.~Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.~Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham."
62194165|NCT01907269|EXPERIMENTAL|Video-based intervention|"Video-based intervention providing personalized feedback regarding patients' risk of subsequent fractures, customized information regarding osteoporosis care, and messaging to activate patients to become more engaged in improving osteoporosis treatment and doctor-patient communication. This novel content will use story-telling delivered via the Internet and DVDs. The content will be uniquely tailored to each person based on their reported barriers to care, age and race/ethnicity. The video-based intervention materials will be augmented by a personal phone call and interactive voice response messaging."
62194166|NCT01907269|NO_INTERVENTION|Usual care|
62194167|NCT05355675||observational group|Patients with hematologic malignancies following allogeneic hematopoietic stem cell transplantation treatment
62782527|NCT05474391||MammaPrint group|Pre-menopausal breast cancer patients received MammaPrint test.
62008767|NCT05917873|PLACEBO_COMPARATOR|Placebo arm|Placebo treatment
62008768|NCT01606085|EXPERIMENTAL|HF-DM Self Care|educational counseling intervention about integrated HF-DM self care outcomes
62008769|NCT01606085|NO_INTERVENTION|Usual Care|Usual Care provided by providers
62008770|NCT01885442|EXPERIMENTAL|In-bed leg cycle ergometry|
62194168|NCT05355675||control group|health control group: healthy volunteers
62194169|NCT02296216|ACTIVE_COMPARATOR|Exposed patients|Exposed patients have been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion
62782528|NCT04240158|EXPERIMENTAL|IW-6463|IW-6463 tablets administered orally
62782529|NCT04240158|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets administered orally
62782530|NCT05799794|ACTIVE_COMPARATOR|Standard/As Usual CBT+/EBP Initiative Implementation|All CMHCs involved in the CBT+/EBP Initiative receive virtual clinician training, CBT-phone consultation options over 6-months, access to a supervisor monthly call, listservs (one supervisor-focused), and a yearly advanced clinical training and supervisor training. The Initiative is a program that has been ongoing since 2009.
62008771|NCT02155595||500 with BP treatment|patients will undergo lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
62008772|NCT02155595||500 without BP treatment|patients will undergo lab tests, X-ray, bone scan or MRI, as needed
62008773|NCT00448058|EXPERIMENTAL|GSK372475|flexible-dose design from GSK372475 1.0 mg/day to GSK372475 2.0 mg/day
62008774|NCT00448058|ACTIVE_COMPARATOR|Venlafaxine|Flexible- dose design from Venlafaxine XR 75 mg/day to Venlafaxine XR 225 mg/day
62008775|NCT00448058|PLACEBO_COMPARATOR|placebo|
62008776|NCT05855863|EXPERIMENTAL|Ginkgo Ketone Ester Tablets Treatment Group|Ginkgo Ketone Ester Tablets (Styron), taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic therapy continuously administered for 6 months
62008777|NCT05855863|PLACEBO_COMPARATOR|control group|placebo combined with conventional hypoglycemic therapy for 6 months
62008778|NCT01270945|EXPERIMENTAL|CV-18C3 and standard of care|CV-18C3 and standard of care
62008779|NCT01270945|ACTIVE_COMPARATOR|standard of care|Percutaneous revascularization
62008780|NCT03640663||Midwife led continuity model of care|Women who received antenatal care from midwives from the hospital reaching out to the rural villages
62194170|NCT02296216|PLACEBO_COMPARATOR|Unexposed patients|Unexposed patients have not been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion
62194171|NCT06211777|EXPERIMENTAL|the observation group|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation therapy. The observation group was provided the support of enteral nutrition by Intermittent Oro-esophageal Tube Feeding.
62194172|NCT06211777|ACTIVE_COMPARATOR|the control group|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation. The observation group was provided the support of enteral nutrition by Nasogastric Tube Feeding.
62194173|NCT01315470|EXPERIMENTAL|neupogen|
62573564|NCT05781711|EXPERIMENTAL|Control Group|Control group ( Levo-dopa group, n =30 ) who will receive levodopa/carbidopa (50/250 mg) three times daily for 3 months
62194174|NCT01315470|NO_INTERVENTION|no intervantion|
62573565|NCT05781711|ACTIVE_COMPARATOR|Metformin group|Patients will receive levodopa/carbidopa (50/250 mg) three times daily plus metformin 500 mg two times daily for 3 months
62573566|NCT01136902||Type 2 DM|This group includes subjects diagnosed with type 2 diabetes mellitus with none or minimal diabetic retinopathy.
62573567|NCT05455814|EXPERIMENTAL|Wellness and Meditation-Based Intervention|Shambhavi Mahamudra Kriya: a multi-component 21-minute meditation that incorporates a combination of different breathing patterns and meditative components.
62573568|NCT05455814|NO_INTERVENTION|Control|Control Group: selected to be age, gender and education level matched with the intervention group and will be asked to continue their daily routine while completing surveys at each timepoint.
62782531|NCT05799794|EXPERIMENTAL|Supervisor-led Implementation Coaching|The structure of this arm will depend on Aim 1. However, we imagine that peer supervisors leading implementation coaching, trained in Aim 1, will have 3-5 virtual meetings with supervisors and email communication. Meetings focus on orientation to the theory and rationale for Coaching and supervisors' role as frontline leaders to support EBP implementation. Meetings are likely over 6 months and focus on different implementation phases. Coaches will support supervisors in developing tailored workplans for implementation in their CMHCs. In each meeting, the coach will review the strategies in the workplan, provide examples of how the strategy could be specified, and then facilitate discussion among supervisors. The coach will support supervisors in building a tailored workplan for their CMHC. Supervisors in the Coaching condition receive Coaching plus standard Initiative Implementation support.
62782532|NCT05669651|EXPERIMENTAL|Low dose of group|"Complete the fecal bacteria transplantation through the upper digestive tract:~1. Intestinal preparation: Amoxicillin 0.5g bid, metronidazole 0.4g bid and levofloxacin 0.5g qd for 3 days.~2. FMT: After 12h of antibiotic discontinuation, the total amount of bacterial liquid was 400ml, 100ml each time, Q12h, 2 days after 12h of antibiotic discontinuation."
62782533|NCT05669651|EXPERIMENTAL|High dose of group|"Complete the fecal bacteria transplantation through the upper digestive tract:~1. Intestinal preparation: Amoxicillin 0.5g bid, metronidazole 0.4g bid and levofloxacin 0.5g qd for 3 days.~2. FMT: After 12h of antibiotic discontinuation, the total amount of bacterial liquid was 800ml, 100ml each time, Q12h, 4 days ."
62782534|NCT05921799||General anesthesia Patients|Subjects experiencing general anesthesia such that viscoelastic testing is performed to assess coagulopathy.
62194175|NCT04338789|EXPERIMENTAL|Group 1|It consisted of 20 subjects with bilateral first molar extraction space where piezocesion was performed immediately before molar protraction on the left or right side of the patient.
62194176|NCT04338789|EXPERIMENTAL|Group 2|It consisted of 20 subjects with bilateral first molar extraction space where piezocesion was performed 3 months after molar protraction with no piezocision on the left or right side of the patient.
62194177|NCT04338789|NO_INTERVENTION|Group 3|It consisted of 20 subjects (40 molars) where molar protraction was performed with no piezocesion.
62573569|NCT02593279|ACTIVE_COMPARATOR|asthma with proximal or diffuse lung damage|
62194178|NCT00506805|EXPERIMENTAL|Single Arm|
62194179|NCT05312281|NO_INTERVENTION|"Control group without lumbar belt"|"Control group without lumbar belt"
62194180|NCT05312281|EXPERIMENTAL|Device : Lombastab immo. wear for 6 weeks post-surgery the Lombastab Immo|Lombastab immo. wear for 6 weeks post-surgery the Lombastab Immo
62194181|NCT02493946|EXPERIMENTAL|BTX-A-HAC NG|Clostridium Botulinum Toxin Type A (BTX A HAC NG), total treatment volume 0.25mL will be divided into 5 injections (0.05mL per injections) injected in 5 pre-defined sites across the glabellar region. A total of 50 Units of BTX-A-HAC NG will be injected/ cycle.
62573570|NCT02593279|EXPERIMENTAL|asthma with small airway prevailing damage|
62573571|NCT03005496|PLACEBO_COMPARATOR|Intervention|"* Nifedipin 4x10 mg oral~* Dexamethasone 2x6 mg iv for 2 days~* Zinc 50 mg/day~* Beta-carotene 25,000 IU~* Vitamin D3 50,000 IU/weekly"
62573572|NCT03005496|ACTIVE_COMPARATOR|Control|"* Nifedipin 4x10 mg~* Dexamethasone 2x6 mg iv for 2 days"
62573573|NCT02967315|EXPERIMENTAL|Study Group|"Procedures include:~Two Cardiac Magnetic Resonance Imaging (CMRIs) A central venous line placement, A chest X-ray Electrocardiogram (ECG) Fluid administration Blood draw Pregnancy test"
62573574|NCT06210035|EXPERIMENTAL|Belly-focus concentration meditation|Participants will engage in concentration meditation for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly.
62573575|NCT06210035|EXPERIMENTAL|Belly-focus concentration meditation with slow breathing|Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly while breathing slowly.
62782535|NCT04949074||RNA extracted from Positive NSP samples|RNA extracted from NSP samples, found positive for the presence of SARS-CoV-2
62782536|NCT04949074||RNA extracted from Positive saliva samples|RNA extracted from saliva samples found positive for the presence of SARS-CoV-2
62008781|NCT03640663||Regular care group|Women who received care from doctors, nurses or midwives employed at primary Health care centres in rural villages
62008782|NCT06224829|EXPERIMENTAL|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one point in their neck followed by 30 seconds of complete pressure release 4 times for a total contact time of 240 seconds. Pressure will be applied such that the participant rates the pain = 5/10 on an 11-point numeric pain rating scale with 0 indicating no pain and 10 indicating the most severe pain imaginable.
62573576|NCT06210035|NO_INTERVENTION|No-intervention control|Participants will rest quietly for 40 minutes every day for a week while recording heart rate.
62008783|NCT06224829|ACTIVE_COMPARATOR|Pain Free Massage|Participants will receive 60 seconds of manual pressure applied to one point in their neck followed by 30 seconds of complete pressure release 4 times for a total contact time of 240 seconds. Pressure will be applied such that the participant rates the pain = 0/10 on an 11-point numeric pain rating scale with 0 indicating no pain and 10 indicating the most severe pain imaginable.
62008784|NCT06224829|ACTIVE_COMPARATOR|Cold Water Bath|Participants will place their non-dominant hand into water cooled by a refrigeration unit (NESLAB RTE 7 Digital One, Thermo Scientific Co., Massachusetts, USA) that circulates water continuously to maintain a constant temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times for a total immersion time of 240 seconds.
62008785|NCT05138380|EXPERIMENTAL|Foot orthoses|
62008786|NCT05138380|SHAM_COMPARATOR|Flat shoe insert|
62008787|NCT06426797|EXPERIMENTAL|locally advanced ESCC|Patients with locally advanced esophageal squamous cell carcinoma
62008788|NCT03212677|ACTIVE_COMPARATOR|Iron-deficient children|Previously iron-deficient children aged 6-24 months on iron therapy. Ferrous sulfate administered at 4 mg Fe/kg/d per standard of care.
62008789|NCT03212677|NO_INTERVENTION|Non-iron-deficient children|Non-iron-deficient children aged 6-24 months used as a reference.
62573577|NCT02748642|EXPERIMENTAL|Part A Cohort A: BITS7201A Dose Level 1 Subcutaneous (SC)|Healthy participants will receive a single SC dose of BITS7201A dose Level 1 on Day 1.
62573578|NCT02748642|EXPERIMENTAL|Part A Cohort B: BITS7201A Dose Level 2 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 2 on Day 1.
62573579|NCT02748642|EXPERIMENTAL|Part A Cohort C: BITS7201A Dose Level 4 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 4 on Day 1.
62573580|NCT02748642|EXPERIMENTAL|Part A Cohort D: BITS7201A Dose Level 4 Intravenous (IV)|Healthy participants will receive a single IV dose of BITS7201A dose Level 4 on Day 1.
62573581|NCT02748642|EXPERIMENTAL|Part A Cohort E: BITS7201A Dose Level 6 IV|Healthy participants will receive a single IV dose of BITS7201A dose Level 6 on Day 1.
62782537|NCT04949074||RNA extracted from negative NSP samples|RNA extracted from NSP samples, found negative for the presence of SARS-CoV-2
62782538|NCT04949074||RNA extracted from negative saliva samples|RNA extracted from saliva samples found negative for the presence of SARS-CoV-2
62008790|NCT03212677|PLACEBO_COMPARATOR|Adult Placebo|Iron-replete postmenopausal women, and men, receiving placebo daily for 4 weeks.
62008791|NCT03212677|EXPERIMENTAL|Adult Ferrous sulfate daily|Iron-replete postmenopausal women, and men, receiving ferrous sulfate daily (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving ferrous sulfate daily (containing 120 mg Fe per day) for 4 weeks.
62008792|NCT03212677|EXPERIMENTAL|Adult ferrous sulfate weekly|Iron-replete postmenopausal women, and men, receiving ferrous sulfate weekly (containing 60 mg Fe per day) for 4 weeks.
62573582|NCT02748642|PLACEBO_COMPARATOR|Part A: Placebo|Healthy participants will receive a single SC or IV dose of placebo matched to BITS7201A on Day 1.
62573583|NCT02748642|EXPERIMENTAL|Part B Cohort F: BITS7201A Dose Level 3 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 3 every 4 weeks (Q4W) on Days 1, 29, and 57.
62573584|NCT02748642|EXPERIMENTAL|Part B Cohort G: BITS7201A Dose Level 4 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 4 Q4W on Days 1, 29, and 57.
62573585|NCT02748642|EXPERIMENTAL|Part B Cohort H: BITS7201A Dose Level 5 SC|Healthy participants will receive SC dose of BITS7201A dose Level 5 Q4W on Days 1, 29, and 57.
62573586|NCT02748642|EXPERIMENTAL|Part B Cohort I:BITS7201A Dose Level 5 SC (Mild Atopic Asthma)|Mild atopic asthma participants will receive SC dose of BITS7201 dose Level 5 Q4W on Days 1, 29, and 57.
62573587|NCT02748642|PLACEBO_COMPARATOR|Part B: Placebo|Healthy participants or mild atopic asthma participants will receive SC doses of placebo matched to BITS7201A Q4W on Days 1, 29, and 57.
62573588|NCT01746186||21-35 years of age|200 Men and 200 women: Ages 21-27 and Ages 28-35, BMI: 20-35,living in the Columbia, SC area.
62782539|NCT06039618||Referred to a Centre of Higher Level|Those are the newborns that were referred at the time of delivery or within one week after birth to centers of higher organizational level.
62782540|NCT06039618||Treated at the Centre of Admission|Those are the newborns that were not referred to other centers and were treated in the health facility were the birth took place, and hospitalized in the same center until discharge.
62782541|NCT04038450||Practicing Physical Therapists|licensed physical therapists currently practicing
62782542|NCT04038450||Student Physical Therapists|students currently enrolled in DPT program
62782543|NCT00546949|ACTIVE_COMPARATOR|decompression|Minimal invasive decompression
62782544|NCT00546949|EXPERIMENTAL|x-stop|X-stop, an interspinous decompression device
62782545|NCT04597073|NO_INTERVENTION|Healthy|included individuals with probing depth (PD) ≤3mm, no sites with attachment loss, and no radiographic evidence of alveolar bone resorption. They exhibited no sign of inflammation (GI=0).
62573589|NCT06575491|EXPERIMENTAL|Supraclavicular group|Patients submitted to Supraclavicular approach for ultrasound-guided Subclavian veinous catheterization.
62782546|NCT04597073|EXPERIMENTAL|Gingivitis|had varying degrees of gingival inflammation (GI≥1), PD≤3mm with no clinical attachment loss or with no alveolar bone destruction.
62573590|NCT06575491|EXPERIMENTAL|Infraclavicular group|Patients submitted to Infraclavicular approach for ultrasound-guided Subclavian veinous catheterization.
62782547|NCT04597073|EXPERIMENTAL|Chronic Periodontitis|was defined as those who were with PD ≥ 4mm, clinical attachment loss (CAL) ≥ 2mm, and who had bone loss affecting \>30% of the existing teeth on clinical and radiographic examination.
62782548|NCT03305978|EXPERIMENTAL|Ultra low dose chest CT|
62782549|NCT03305978|ACTIVE_COMPARATOR|Low dose chest CT|
62782550|NCT03876899|ACTIVE_COMPARATOR|Evening Primrose Oil|
62782551|NCT03876899|PLACEBO_COMPARATOR|Placebo|
62782552|NCT01167660||Healthy newborn babies|Healthy newborn babies immediately after birth.
62782553|NCT01167660||Sick newborn babies|Sick newborn babies whose medical condition indicates performing coagulation tests.
62782554|NCT01683370||Patients|Pediatric patients with cancer, receiving standard chemotherapy, and receiving standard supportive therapy in case of fever in neutropenia (FN) (No intervention for study purposes)
62008793|NCT03212677|EXPERIMENTAL|Adult ferrous sulfate + micronutrient|Iron-replete postmenopausal women, and men, receiving ferrous sulfate + micronutrient supplement (containing 60 mg Fe per day) for 4 weeks.
62008794|NCT03212677|EXPERIMENTAL|Adult IHAT|Iron-replete postmenopausal women, and men, receiving IHAT (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving IHAT (containing 120 mg Fe per day) for 4 weeks
62573591|NCT06407115|EXPERIMENTAL|Care Manager Arm|In this feasibility pilot, all participants will be assigned to work with a care manager for 6 months and receive all components of the intervention. The care manager will meet with participants in virtual appointments every month to create a care plan and monitor progress. The program will also include: 6-10 sessions of Cognitive Behavioral Therapy (CBT) for chronic pain, which focuses on skills and strategies to empower participants to better manage their pain. Finally, the Care Manager will help refer patients to Enhance Fitness, an online community program that allows users to access instructor-led group exercise classes from home.
62782555|NCT02396589|ACTIVE_COMPARATOR|Education Group|Participants in the Education group receive five 90 minute tailored stroke education sessions in the home.
62782556|NCT02396589|EXPERIMENTAL|Home Modifications Group|Participants in the treatment group receive a home assessment and home modifications tailored to functional abilities (pre discharge) and then five 90 minute occupational therapy treatment sessions at home (post discharge) to improve functional abilities and community participation.
62782557|NCT01609998|EXPERIMENTAL|Group 1A (12-17yrs):1 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
62782558|NCT01609998|EXPERIMENTAL|Group 1B (6-11yrs):1 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
62782559|NCT01609998|EXPERIMENTAL|Group 2A (12-17yrs):4 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
62782560|NCT01609998|EXPERIMENTAL|Group 2B (6-11yrs):4 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
62782561|NCT01609998|ACTIVE_COMPARATOR|Group 3A: (12-17yrs): TIV+TIV|Licensed 2012/13 TIV at Day 0 and Week 18±2 wks
62782562|NCT01609998|ACTIVE_COMPARATOR|Group 3B: (6-11yrs): TIV+TIV|Licensed 2012/13 TIV at Day 0 and Week 18±2 wks
62008795|NCT03212677|EXPERIMENTAL|Adult Aspiron|Iron-replete postmenopausal women, and men, receiving Aspiron (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving Aspiron (containing 120 mg Fe per day) for 4 weeks.
62194182|NCT02493946|PLACEBO_COMPARATOR|Placebo|The total placebo volume 0.25mL will be divided into 5 injections (0.05mL per injections) injected in 5 pre-defined sites across the glabellar region. Administered in Cycle 1 of the double blind phase only.
62194183|NCT05961540|OTHER|Conventional care group|The management of infants with CHD and their mothers is based on the current breastfeeding process and care protocols at the Cardiovascular Centre of the Children's Hospital of Fudan University.
62194184|NCT05961540|EXPERIMENTAL|Breastfeeding intervention program|Implement intervention programs to improve breastfeeding behaviour among mothers of infants with CHD and observe ongoing changes.
62194185|NCT04636762|EXPERIMENTAL|Treatment (etoposide, cisplatin, carboplatin, radiation, Atezolizumab)|Participants receive EC/EP chemotherapy combined with Atezolizumab（ PD-L1 inhibitor）for 2 cycles, and the efficacy is evaluated 2 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent chemoradiotherapy with EC/EP(2 cycles) + Atezolizumab） will be initiated. After concurrent chemoradiotherapy+ Atezolizumab, Atezolizumab was maintained until PD or intolerance or for at most 2 years. Participants with brain metastases will receive radiotherapy forbrain metastases during the first 2 cycles of chemotherapy.
62194186|NCT04515498||CloudCath System|Patients with End Stage Renal Disease (ESRD) currently using home peritoneal dialysis
62194187|NCT06254170|EXPERIMENTAL|Euterpe Edulis suplementation|Male, aged between 19 and 30 years and practicing physical exercises regularly for at least 3 months will receive the Euterpe Edulis juice for 10 days.
62194188|NCT06254170|PLACEBO_COMPARATOR|Placebo|Male, aged between 19 and 30 years and practicing physical exercises regularly for at least 3 months will receive the placebo product for 10 days.
62194189|NCT04871399|ACTIVE_COMPARATOR|Conventional Right hemicolectomy (Non-CME)|Patients will undergo conventional non-CME procedure.
62194190|NCT04871399|EXPERIMENTAL|Right hemicolectomy with CME+CVL|Patients will undergo Right hemicolectomy CME+CVL procedure.
62194191|NCT00990951|EXPERIMENTAL|Senna alexandrina and associations|Association of Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub
62194192|NCT06146478|EXPERIMENTAL|Thalidomide Group|In addition to routine β-thalassemia treatment patients in this group also received thalidomide at an average dose of 1.5mg/kg/day
62782563|NCT06485388|ACTIVE_COMPARATOR|Thiopental|Venous blood samples will be taken from the patients included in the study and incubated with thiopental (dose: 100, 250, 500 and 1000µM) after appropriate procedures in the laboratory environment. . After incubation, all resuspensions will be subjected to flow cytometric analysis to evaluate erythrocyte NO synthase activity and erythrocyte-mediated NO release.
62194193|NCT06146478|NO_INTERVENTION|Non-Thalidomide Group|Participants received routine treatment for β-thalassemia such as regular blood transfusion and hydroxyurea at an average dose of 20mg/kg/day
62008796|NCT01804556|OTHER|Myofascial trigger point injection|Myofascial trigger point injection on gastrocnemius muscle
62194194|NCT03299348|EXPERIMENTAL|Active Treatment Group|This group will get the AgingPLUS intervention program which addresses negative views on aging, low internal control beliefs, and deficient goal planning skills.
62194195|NCT03299348|PLACEBO_COMPARATOR|Active Control Group|"This group will get a generic health education program, called the 10 Keys to Healthy Aging. The control program will control for the effect of social contact and will not address the intervention targets of the active treatment group. The health education program will only provide information related to some of the most important health conditions, such as cardiovascular disease, cancer, type 2 diabetes, and clinical depression, and how these conditions can be managed."
62782564|NCT06485388|ACTIVE_COMPARATOR|Propofol|Venous blood samples will be taken from the patients included in the study and incubated with propofol (dose: 100, 250, 500 and 1000µM) after appropriate procedures in the laboratory environment. . After incubation, all resuspensions will be subjected to flow cytometric analysis to evaluate erythrocyte NO synthase activity and erythrocyte-mediated NO release.
62782565|NCT04451993||OSAS PATIENTS|mild, moderate and severe OSAS patients
62194196|NCT01836172|PLACEBO_COMPARATOR|Placebo t.i.d.|Placebo t.i.d.
62194197|NCT01836172|PLACEBO_COMPARATOR|YJP-14 25 mg t.i.d.|YJP-14 25 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
62194198|NCT01836172|PLACEBO_COMPARATOR|YJP-14 50 mg t.i.d.|YJP-14 50 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
62194199|NCT01836172|PLACEBO_COMPARATOR|YJP-14 100 mg t.i.d.|YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems. YJP-14 100 mg t.i.d.
62194200|NCT05989594|ACTIVE_COMPARATOR|The REHAB-TAVR group|For the REHAB-TAVR group, discharge preparation will involve an exercise endurance test, exercise prescription guidance, motivational interviews, instruction on telerehabilitation, and the provision of family and peer support. Following discharge, patients will be required to adhere to their personalized exercise prescription and attend scheduled onsite follow-ups after discharge. The management model employed for this group is called home-based mobile guided exercise-based cardiac rehabilitation.
62194201|NCT05989594|OTHER|The Routine-TAVR group|Preparation for discharge will only involve an exercise endurance test and the guidance of an exercise prescription for the Routine-TAVR group. Following discharge, nurses will conduct monthly telephone follow-ups to check on the patient's progress. Additionally, patients will be scheduled for onsite follow-ups at the Outpatient Department.
62194202|NCT04080713|EXPERIMENTAL|Budesonide|
62194203|NCT00092092|EXPERIMENTAL|Montelukast→Placebo|Participants receive one montelukast 5 mg chewable tablet once daily (QD) for 3 weeks. After a 2-week washout period, participants receive one placebo chewable tablet QD for 3 weeks.
62008797|NCT04688840||study results and satisfaction with telemedicine|the investigators designed a group on WhatsApp for all patients included in the study. The questionnaires were sent on the group to be filled by the patients in addition to a request for routine x ray follow up. Also, the investigators used the group to send any announcement, schedule of routine visits and some instructions about how to answer the questionnaires. To keep the privacy of patients' informations, every patient was asked to resend the file and x- ray pictures to the surgeon private account. the investigators collected data received by all patients and reviewed all x-rays. If there was any serious complain or major radiological finding the investigators asked the patient for immediate clinical visit.
62008798|NCT04688840||study results and satisfaction with routine follow up|the investigators asked the patients to come for routine follow up visit (RV) and reevaluate them clinically and radiologically. the investigators asked patients to calculate total time needed for completion of the questionnaires, time needed for x-ray and the investigators added time needed for reviewing these files. The same was done at the RV including time of transportation
62194204|NCT00092092|EXPERIMENTAL|Placebo→Montelukast|Participants receive one placebo chewable tablet QD for 3 weeks. After a 2-week washout period, participants receive one montelukast 5 mg chewable tablet QD for 3 weeks.
62194205|NCT00092092|ACTIVE_COMPARATOR|Budesonide→Placebo|Participants receive budesonide 200 mcg inhalation powder twice daily (BID) for 3 weeks. After a 2-week washout period, participants receive placebo inhalation powder BID for 3 weeks.
62194206|NCT00092092|ACTIVE_COMPARATOR|Placebo→Budesonide|Participants receive placebo inhalation powder BID for 3 weeks. After a 2-week washout period, participants receive budesonide 200 mcg inhalation powder BID for 3 weeks.
62398443|NCT01698749|EXPERIMENTAL|Ozurdex in diabetic macular edema|Intravitreal ozurdex given in patients with diabetic macular edema and patients followed up for change in central macular thickness and visual acuity over period of 6 months
62398444|NCT01590095|ACTIVE_COMPARATOR|Water quality|90 clusters, approx. 720 newborns
62398445|NCT01590095|ACTIVE_COMPARATOR|Sanitation|90 clusters, approx. 720 newborns
62008799|NCT05875441|EXPERIMENTAL|Moxidectin 8mg|Moxidectin 8 mg (over encapsulated) will be administered as a single dose on Day 0. Each subject will receive the same number of capsules made up of moxidectin 2 mg over encapsulated tablets and placebo capsules to maintain the blind.
62008800|NCT05875441|EXPERIMENTAL|Moxidectin 16mg|Moxidectin 16 mg (over encapsulated) will be administered as a single dose on Day 0. Each subject will receive the same number of capsules made up of moxidectin 2 mg over encapsulated tablets and placebo capsules to maintain the blind.
62008801|NCT05875441|EXPERIMENTAL|Moxidectin 32mg|Moxidectin 32 mg (over encapsulated) will be administered as a single dose on Day 0.
62194207|NCT02469155|EXPERIMENTAL|20 mg ITI-007|20 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
62194208|NCT02469155|EXPERIMENTAL|60 mg ITI-007|60 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
62194209|NCT02469155|PLACEBO_COMPARATOR|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
62008802|NCT05875441|PLACEBO_COMPARATOR|Placebo|16 Placebo capsules will be administered as a single dose on Day 0.
62008803|NCT01441427|EXPERIMENTAL|G-CSF|
62398446|NCT01590095|ACTIVE_COMPARATOR|Hand washing|90 clusters, approx. 720 newborns
62398447|NCT01590095|ACTIVE_COMPARATOR|Combined WASH|90 clusters, approx. 720 newborns
62398448|NCT01590095|ACTIVE_COMPARATOR|Nutrition|90 clusters, approx. 720 newborns
62398449|NCT01590095|ACTIVE_COMPARATOR|Nutrition + Combined WASH|90 clusters, approx. 720 newborns
62398450|NCT01590095|NO_INTERVENTION|Non-intervention|180 clusters, approx. 1,440 newborns
62008804|NCT01441427|EXPERIMENTAL|EPO|
62008805|NCT01441427|EXPERIMENTAL|G-CSF and EPO|
62008806|NCT01441427|PLACEBO_COMPARATOR|Placebo|
62194210|NCT02469155|ACTIVE_COMPARATOR|Risperidone|Risperidone administered orally as visually-matched over-encapsulated tablet once daily for 6 weeks
62194211|NCT05132894||Novice Runners|1-5 miles / week 18+ yo
62194212|NCT05132894||Moderate Runners|6-15 miles / week 18+ yo
62398451|NCT02849873|EXPERIMENTAL|IDp-123 Lotion|Lotion
62398452|NCT02849873|ACTIVE_COMPARATOR|Tazorac Cream|Cream
62398453|NCT02056808|EXPERIMENTAL|SMT C1100|Patients will be studied in 3 groups (Groups A to C), with each group consisting of 4 patients aged between 5 to 11 years. It is planned that doses for Groups A to C will be administered in an escalating manner after safety review for each dose group.
62398454|NCT00504816|OTHER|Brevicon|Oral contraceptive used to determine pharmacokinetics when given with GSK189075 to look for interaction.
62398455|NCT00504816|EXPERIMENTAL|GSK189075|Given in conjunction with Brevicon to see if GSK189075 interfered with Brevicon drug levels.
62782566|NCT04451993||HEALTHY INDIVIDUALS|healthy individuals without chronic disease
62782567|NCT04916379|EXPERIMENTAL|Momordica charantia|Two 500 mg capsules of Momordica charantia twice daily before breakfast and dinner for 12 weeks
62782568|NCT04916379|PLACEBO_COMPARATOR|Placebo|Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 12 weeks
62782569|NCT01337544|EXPERIMENTAL|IL-15 STIMULATED NK CELLS|
62782570|NCT04909957||Absence of invaded lymph node after extensive lymph node dissection|Absence of invaded lymph node after extensive lymph node dissection
62782571|NCT04909957||Presence of invaded lymph node after extensive lymph node dissection|Presence of invaded lymph node after extensive lymph node dissection
62573592|NCT01994941|EXPERIMENTAL|Genotype guided group|"Patients are given standard doses of clopidogrel (either 300mg or 600mg according to clinical protocol). Blood will be drawn for rapid genetic testing (Verigene) and results will be expected in 2-4 hours. If patients are intermediate or poor clopidogrel metabolisers, loading dose of ticagrelor 180mg are given to enhance the antiplatelet response.~Apart from the approach in guiding the use of P2Y12 receptor blocker, all patients will be treated according to usual clinical care including medications and coronary intervention. Blood will also be sent to standard laboratory for CYP2C19 genotyping using conventional polymerase chain reaction (PCR) method so as to confirm the accuracy of rapid genetic test. 24 hours after initial clopidogrel loading, blood will be taken to measure platelet reactivity by verifyNow P2Y12 assay (Accumetrics). In case glycoprotein IIbIIIa inhibitor (Integrilin) is used, verifyNow P2Y12 assay will be performed 48 hours after cessation of Integrilin."
62008807|NCT02327208|PLACEBO_COMPARATOR|Control|3 Combat rations only per day. No additional experimental food items (those assigned to the active comparator groups will consume isoenergetic carbohydrate and protein-based food products).
62008808|NCT02327208|ACTIVE_COMPARATOR|Protein|Consume 4 whey protein-based snack-bars in addition to 3 combat rations each day during training.
62194213|NCT05132894||Advanced Runners|16+ miles / week 18+ yo
62194214|NCT05302440||single-group|All care staff who manage the system will complete a very brief survey (1-minute) after each work shift for 14 days. Detection of abnormal vital signs will be recorded by the system. Hospital admission and further medical assistance due to the use of the system will be documented by the care team. The staff will be interviewed about their perceived benefits and acceptability of the system.
62398456|NCT04916132||Peolpe with T2DM and albuminuria|Prospectively we will collect research kidney biopsies and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. The biopsies will be thoroughly investigated with cutting-edge molecular technologies and associated to the biomarkers, disease course and clinical outcome.
62782572|NCT01258283||The study population|See inclusion and exclusion criteria.
62782573|NCT04678947|EXPERIMENTAL|BARF scale|"* Nursing staff (which may include patient technicians and nursing assistants) will use the scale to assess the patient's nausea for the entire duration of the admission. These assessments will take place in conjunction with vital sign monitoring, every 4 hours. The associated script will be read while the laminated scale is shown to the patient.~* The nurse will then log the patient's response in the patient's electronic medical record"
62782574|NCT04678947|NO_INTERVENTION|No intervention|-Patients in the control group will proceed with their inpatient chemotherapy admissions without any interventions. These admissions will take place prior to the admissions of the experimental group, so as not to bias providers.
62782575|NCT04073485|OTHER|Microwave ablation|The uterine fibroid will be identified and located with ultrasonography. A microwave electrode appropriate for the size of target lesion is placed into the target lesion under ultrasound guidance. Appropriate microwave power and application time are selected to provide sufficient ablation coverage to the target lesion.
62782576|NCT05389033|EXPERIMENTAL|Active probiotic|Lactobacillus acidophilus (CUL60 and CUL21), Bifidobacterium bifidum (CUL20), Bifidobacterium animalis subs p. Lactis (CUL34), 25 billion CFU, (Proven Probiotics, United Kingdom)
62008809|NCT02327208|ACTIVE_COMPARATOR|Carbohydrate|Consume 4 carbohydrate-based snack-bars in addition to 3 combat rations each day during training.
62008810|NCT00236938|EXPERIMENTAL|Group A|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
62008811|NCT00236938|ACTIVE_COMPARATOR|Group B|Stable erythropoietin (EPO) dose and no supplemental iron.
62008812|NCT04777396|EXPERIMENTAL|Oral Semaglutide|Participants are given oral semaglutide once daily
62008813|NCT04777396|PLACEBO_COMPARATOR|Placebo (semagludtide)|Participants are given oral placebo once daily
62008814|NCT05664997||violinists|musicians who play the violin in a conservatory or orchestra
62782577|NCT05389033|PLACEBO_COMPARATOR|Placebo|"Chicory Root Extract (Min 90% Fructo-oligosaccharides) - Providing:~100mg FOS Microcrystalline Cellulose - 137.26 mg"
62194215|NCT02765789|EXPERIMENTAL|Immunoadsorption|Immunoadsoprtion (Immunosorba). All (anticipated) 8 participants will be treated with immunoadsorption
62782578|NCT05597553|EXPERIMENTAL|Premixed MTA|The premixed bioceramics putty are ready to use materials, fast setting, with superior handling properties and hydrophilic in nature that necessitate moisture from the adjacent tissues to set. They have advantage of insensitive to moisture and blood contamination with less technique sensitive.
62194216|NCT00566540|EXPERIMENTAL|Treatment (neoadjuvant, adjuvant chemotherapy and radiation)|"PREOPERATIVE:Patients receive cisplatin IV over 2 hours three times weekly in week 1 once daily(QD),5 days a week, in weeks 1-2.~SURGERY:Patients undergo triple endoscopy and biopsy with submandibular gland transfer in week 3.~INTRAOPERATIVE: Patients also undergo Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation.~POSTOPERATIVE: Patients receive paclitaxel IV over 3 hours in weeks 7-10 and cisplatin IV over 1-2 hours three times weekly in weeks 7 and 10. Patients also undergo Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation QD, 5 days a week, in weeks 7-10."
62194217|NCT06102447|EXPERIMENTAL|Treatment Group|
62194218|NCT00572533|ACTIVE_COMPARATOR|Control|ESA Dose Adjustment per standard Anemia Management Protocol
62194219|NCT00572533|EXPERIMENTAL|Treatment|"ESA Dose Adjustment per Smart Anemia Manager Algorithm"
62194220|NCT01615549|ACTIVE_COMPARATOR|Free training|
62194221|NCT01615549|EXPERIMENTAL|Proficiency-based training|
62194222|NCT01078636||EMCI (only cohort recruiting in this study)|Newly recruited early amnestic Mild Cognitive Impairment patients; estimated enrollment 200
62194223|NCT01078636||LMCI (not recruiting in this study)|Late Mild Cognitive Impairment patients; approximately 400 LMCI participants anticipated to follow from the original ADNI study
62782579|NCT05597553|ACTIVE_COMPARATOR|Powder/liquid MTA|Mineral trioxide aggregate (MTA) is a bioactive, biocompatible, antibacterial material with good stability, and excellent sealing ability that has been used as a dressing material in pulp capping procedures in permanent teeth, although it has good properties, it has many limitations, including long setting time, handling property and tooth discoloration making the use of this material challenging for many clinicians.
62782580|NCT05006027||Percutaneous coronary intervention using a 7-Fr thin-walled sheath via the distal radial approach|patients with coronary artery disease who planned to perform PCI using 7-Fr thin-walled sheath via the distal radial approach
62008815|NCT01485601|EXPERIMENTAL|MT10109|Clostridium botulinum toxin type A
62008816|NCT01485601|ACTIVE_COMPARATOR|Botox (registered trade mark)|Clostridium botulinum toxin type A
62008817|NCT00529386|EXPERIMENTAL|Botox|300 IU botox
62008818|NCT02810834|EXPERIMENTAL|Walking/Running Program|Walking/running/jogging program; school-based.
62008819|NCT02810834|EXPERIMENTAL|Classroom activity break program|Classroom physical activity break program; school-based.
62008820|NCT02810834|NO_INTERVENTION|Control|Control/Delayed Intervention
62008821|NCT02665728|EXPERIMENTAL|BLI400|BLI400 Laxative
62008822|NCT04805983|EXPERIMENTAL|10 mg BMS-984923|
62008823|NCT04805983|EXPERIMENTAL|40 mg BMS-984923|
62008824|NCT04805983|EXPERIMENTAL|70 mg BMS-984923|
62008825|NCT04805983|EXPERIMENTAL|100 mg BMS-984923|
62008826|NCT04805983|EXPERIMENTAL|150 mg BMS-984923|
62008827|NCT04805983|EXPERIMENTAL|200 mg BMS-984923|
62008828|NCT06358079|EXPERIMENTAL|Group 1: Use of circuit|Re-infusion of unwashed shed blood
62008829|NCT06358079|NO_INTERVENTION|Group 2: No circuit|No re-infusion of unwashed shed blood
62008830|NCT05443477|EXPERIMENTAL|Hericium Erinaceus Mycelium|patients with premenstrual syndrome received supplementation of Hericium Erinaceus Mycelium capsules
62782581|NCT04313270||Patients with FH starting a treatment with Evolocumab®|
62782582|NCT02286635|EXPERIMENTAL|Cohort A Deflazacort and Rifampin|Subjects will recieve one 18 mg dose of deflazacort on Day 1, Period 1 and Day 10, Period 2; cohort A. Subjects will receive once daily dosing of rifampin on Day 1, Period 2 through Day 10, Period 2.
62782583|NCT02286635|EXPERIMENTAL|Cohort B Deflazacort and Clarithromycin|Subjects will recieve one 18 mg dose of deflazacort on Day 1, Period 1 and Day 4, period 2; cohort B. Subjects will receive twice daily dosing of clarithromycin on Day 1, Period 2 through Day 4, Period 2.
62782584|NCT03063905||Opioid Taper|Patients tapering off their buprenorphine treatment
62008831|NCT05443477|EXPERIMENTAL|Probiotic|patients with premenstrual syndrome received supplementation of Probiotic capsules
62008832|NCT05443477|PLACEBO_COMPARATOR|control|patients with premenstrual syndrome received supplementation of placebo capsules
62008833|NCT04190745|EXPERIMENTAL|The control group|
62008834|NCT04190745|EXPERIMENTAL|The experimental group|
62008835|NCT03962881|EXPERIMENTAL|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
62008836|NCT03962881|EXPERIMENTAL|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2,and 6
62008837|NCT03962881|EXPERIMENTAL|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2,and 6
62194224|NCT01078636||CN (not recruiting in this study)|Cognitively Normal patients; approximately 200 CN participants anticipated to follow from the original ADNI study
62194225|NCT04607707||Postmenopausal Women|Participants who sign an informed consent will be asked to complete study questionnaires at a single visit that coincides with a normal healthcare visit. No other study procedures will be performed.
62194226|NCT01070576||normal fracture healing|group in which normal fracture healing has occured
62194227|NCT01070576||atrophic|patients in which an atrophic non-union occured
62194228|NCT01070576||hypertrophic|patients in which a hypertrophic non-union occured
62194229|NCT00374751|EXPERIMENTAL|Samarium (153SM)|Injection of Samarium (153SM)
62194230|NCT02867683|EXPERIMENTAL|Vibrotactile Feedback|Balance exercises completed while vibration was applied to the trunk (anterior, posterior, right, and left) if postural sway exceeded a pre-determined threshold during the exercise.
62194231|NCT02867683|NO_INTERVENTION|Without Vibrotactile Feedback|Balance training without feedback
62194232|NCT00327509||1-HTG|high tension glaucoma highest IOP \> 21 mmHg
62194233|NCT00327509||2-NTG|normal tension glaucoma highest measured IOP \< 21 mmHg
62194234|NCT00327509||3-PEX|pseudoexfoliation glaucoma PEX material visible
62194235|NCT00327509||4-Juvenile|juvenile glaucoma
62194236|NCT00327509||5-Control1|healthy subjects (age group 1)
62734637|NCT03198767|EXPERIMENTAL|Part A: LIK066 + P1: 25% CHO / P2: 0% CHO / P3: 50% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 25% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 0% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 50% carbohydrate
62194237|NCT00327509||6-Control2|healthy subjects (age group 2)
62194238|NCT01327612|EXPERIMENTAL|Conatumumab Monotherapy|Participants will continue to receive conatumumab every 2 weeks (Q2W) or every 3 weeks (Q3W) at the same dose and regimen as at the conclusion of the parent study.
62194239|NCT01327612|EXPERIMENTAL|Conatumumab + Ganitumab|Participants will receive conatumumab and ganitumab by intravenous infusion at the same dose and regimen as at the conclusion of the parent study.
62194240|NCT01327612|EXPERIMENTAL|Ganitumab Monotherapy|Participants will continue to receive ganitumab Q3W or every 4 weeks (Q4W) at the same dose and regimen as at the conclusion of the parent study.
62194241|NCT01327612|EXPERIMENTAL|Conatumumab + mFOLFOX6 ± Bevacizumab|Participants will continue to receive conatumumab by intravenous infusion in addition to modified FOLFOX6 chemotherapy with or without bevacizumab.
62734638|NCT03198767|EXPERIMENTAL|Part A: LIK066 + P1: 0% CHO / P2: 50% CHO / P3: 25% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 0% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 50% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 25% carbohydrate
62782585|NCT03063905||Opioid Maintenance|Patients starting their buprenorphine treatment
62782586|NCT02353195|EXPERIMENTAL|Radio-frequency group|The equipment used, (INDIBA® activ 902, (448kHz)). The electricity was administered in the following manner: cream was applied to the site with the severe rest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient. Therapy was conducted for 12 minutes, two times per week over four weeks (eight sessions in total)
62194242|NCT01658111|ACTIVE_COMPARATOR|Traditional physiotherapy|Each subject will receive 4 weeks of traditional upper limb rehabilitation treatment (20 sessions, 5 days a week for 4 weeks).
62194243|NCT01658111|EXPERIMENTAL|Robot Group|Each subject will be asked to perform five sessions per week goal-directed, planar reaching tasks, which emphasizes shoulder and elbow movements, moving from the centre target to each of 8 peripheral targets equally spaced on a 0.14 m radius circumference around a centre target using the InMotion2 (IM2) system (20 sessions- 5 days a week for 4 weeks).
62194244|NCT01199068|EXPERIMENTAL|CS-7017+Erlotinib|Drug: CS-7017 from 0.25 mg to 0.50 mg twice a daily Drug: Erlotinib 150 mg once daily
62194245|NCT06201078|EXPERIMENTAL|Salvage SBRT for locally recurrent prostate cancer after radiotherapy|SBRT: 5 x 6.75 Gy (every other day) to the total dose of 33.75 Gy
62782587|NCT02353195|PLACEBO_COMPARATOR|Placebo group|All patients were treated with the same device in a nonfunctional application (no energy source) and the therapy was conducted for 12 minutes, two times per week over four weeks (eight sessions in total).
62782588|NCT02449590|ACTIVE_COMPARATOR|Onion powder|Initial test meal contained 20g freeze dried onion powder in hot meals (1 potato soup and 1 meatball-meal daily). Subsequent daily meals contained 20g onion powder in the same meal formats.
62194246|NCT00664963|EXPERIMENTAL|1|YUKON Sirolimus-eluting Stent
62194247|NCT00664963|ACTIVE_COMPARATOR|2|YUKON Stent (uncoated)
62194248|NCT06186947||COVID-19 group|Patients infected by SARS CoV2 before reproductive events.
62194249|NCT06186947||Control group|Patients who were not infected by SARS CoV2 before reproductive events.
62194250|NCT05658653|NO_INTERVENTION|Standard Practice|The Control group treats their simulated patients using standard practice and has no introduction to the new CDMT test.
62194251|NCT05658653|EXPERIMENTAL|Chronic Disease Management Test (CDMT)|The intervention will receive information regarding the CDMT test and will be given the test results, whether selected or not, in Round 2 of CPV administration.
62194252|NCT01641653|PLACEBO_COMPARATOR|placebo|half of the patients will receive placebo (normal saline 2cc/) prior to entering the OR
62194253|NCT01641653|ACTIVE_COMPARATOR|Midazolam|half of the patients will receive Midazolam 1-2.5mg prior to entering the OR
62194254|NCT00978562|EXPERIMENTAL|Diagnostic (DSC-MRI with ferumoxytol, DCE-MRI with gadolinium)|Patients receive ferumoxytol and gadolinium IV and then undergo DSC-MRI and DCE-MRI. An optional MRI without injection of a contrast agent may be obtained after 20-24 hours at the discretion of the clinician. Patients may receive up to 3 more scans at least 3 weeks apart over up to 2 years.
62194255|NCT02522728|ACTIVE_COMPARATOR|Triathlon CR|Triathlon Cruciate Retaining (CR) versus Triathlon Posterior Stabilized (PS): During knee prosthesis surgery the surgeon many times need to make a judgement on if to keep a defect anatomical structure or if to replace it with knee prosthesis with a design that allows for adjustment of this defect. This study is aimed to evaluate which prosthetic choice to be made in respect of stability, long-term results and patient outcome.
62194256|NCT02522728|ACTIVE_COMPARATOR|Triathlon PS|Triathlon Cruciate Retaining (CR) versus Triathlon Posterior Stabilized (PS): During knee prosthesis surgery the surgeon many times need to make a judgement on if to keep a defect anatomical structure or if to replace it with knee prosthesis with a design that allows for adjustment of this defect. This study is aimed to evaluate which prosthetic choice to be made in respect of stability, long-term results and patient outcome.
62194257|NCT03965338|OTHER|fMRI brain activity|screening
62194258|NCT00725712|EXPERIMENTAL|5-days on/9-days off|Dosing for first 5 days in every 14-day period.
62194259|NCT00725712|EXPERIMENTAL|daily dosing|dosed every day
62194260|NCT01985815|EXPERIMENTAL|VC/VS stimulation ON followed by OFF|triple blind, randomised, two periods of three months
62194261|NCT01985815|EXPERIMENTAL|VC/VS stimulation OFF followed by ON|triple blind, randomised, two periods of three months
62194262|NCT05547698|ACTIVE_COMPARATOR|Off-Pump Bilateral Lung Transplantation|Subjects will receive 'off-pump' technique for lung transplantation as part of standard of care
62194263|NCT05547698|ACTIVE_COMPARATOR|Venoarterial Extra Corporeal Membrane Oxygenation (VA ECMO) Bilateral Lung Transplantation|Subjects will receive VA ECMO technique for lung transplantation as part of standard of care
62194264|NCT02664597|SHAM_COMPARATOR|Standard strategy|In control group, the complex adnexal mass will be managed according to the standard strategy and treatment plan routinely used by the multidisciplinary team.
62194265|NCT02664597|EXPERIMENTAL|ADNEXMR SCORING|In the intervention group, patients will undergo a pelvic MR imaging as routinely performed, including morphological sequences and functional sequences. Prospectively, the radiologist will classify the mass using ADNEXMR SCORING system and the patient will be managed according to the score.
62194266|NCT03414528||Patients with PID|
62194267|NCT03766958||Registry Patients With Nodify Lung Results|Patients providing consent to have data collected to observe how Nodify Lung results were used in the clinical management of their lung nodules.
62194268|NCT03766958||Contemporaneous Group Without Nodify Lung|Contemporaneous group who did not have Nodify Lung test results for use in the clinical management of their lung nodules.
62194269|NCT00323206|EXPERIMENTAL|Intra-tumoral Electroporation of pIL-12|Participants will receive intra-tumoral injection of pIL-12 followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid DNA into tumor cells. For each lesion selected for therapy, a total of three electroporation treatments will be performed.
62194270|NCT01409005|EXPERIMENTAL|Gemcitabine plus UFTE|Gemcitabine plus UFTE chemotherapy (Single arm)
62194271|NCT05011877||Acute Hypercapnic Respiratory Failure patients with Sleep Disorders|Acute Hypercapnic Respiratory Failure patients with Sleep Disorders
62194272|NCT05011877||Acute Hypercapnic Respiratory Failure patients without Sleep Disorders|Acute Hypercapnic Respiratory Failure patients without Sleep Disorders
62194273|NCT03821233|EXPERIMENTAL|ZW49|
62194274|NCT02812056|EXPERIMENTAL|Alisertib + TAK-228|"Dose Escalation Phase:~Starting dose of Alisertib: 30 mg by mouth 2 times a day on Days 1 - 7 each 21 day cycle.~Starting dose of TAK-228: 1 mg by mouth daily Days 3 - 18, with the exception of 2 mg daily Days 3 - 7 and 10 - 14 schedule in a 21 day cycle.~Dose Expansion Phase:~Alisertib and TAK-228 taken at the maximum tolerated dose from Dose Escalation Phase."
62782589|NCT02449590|PLACEBO_COMPARATOR|Placebo|Hot meals (1 potato soup and 1 meatball-meal daily)containing 8.5 g sucrose and 2 g soy protein instead of onion powder
62782590|NCT04508153|OTHER|Leva PDHS arm|"Upon randomization, subjects randomized to the leva® arm will receive the leva® PDHS, and instructions for how to download the smartphone app to facilitate use of the device. They will be instructed to use leva® based on the in-app training provided.~Within the app, subjects will be instructed to use the leva® device to perform PFMT according to the training program provided through the smartphone app associated with the device. This entails 2 ½ minute training sessions, three times daily, 7 days per week for a total of 8 weeks."
62194275|NCT03721705|EXPERIMENTAL|Treatment Arm|The first four sessions will be the escalation phase using the Renew NCP-5. There will be a 5-minute ramp up period where the pressure is increased 1 psi/min until the desired pressure is reached. The goal for the treatment group will be at least 2.5 psi for the first treatment, and then escalate the pressure gradually through the fourth session with an average goal of 3 psi/session. After the fourth session, the pressure will be slowly increased to reach the maximum level the subject can tolerate with a goal of reaching 3-6 psi.
62194276|NCT03721705|SHAM_COMPARATOR|Sham Arm|The subjects will receive the same initial and maintenance treatment regimen on the Renew NCP-5. The pressure will not exceed an average of 0.5 psi over all treatments.
62194277|NCT05262452|EXPERIMENTAL|CureHIFUPanc|Patients diagnosed with locally advanced/borderline resectable pancreatic cancer through biopsy and CT/MRI imaging and planned to undergo anti-cancer treatment using FOLFIRINOX
62008838|NCT06162741|EXPERIMENTAL|Primary Care Brief Mindfulness Training (PCBMT)|PCBMT is a manualized intervention that is a brief adaptation of MBSR Mindfulness Based Stress Reduction (MBSR). Instruction encompasses sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go.
62008839|NCT06162741|ACTIVE_COMPARATOR|Moving Forward (MF)|"Moving Forward (MF) is a transdiagnostic class that seeks to build resilience and reduce emotional distress by teaching step-by-step problem-solving skills such as stop, slow down, think and act."
62008840|NCT01703949|EXPERIMENTAL|Arm A (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62008841|NCT01703949|EXPERIMENTAL|Arm B (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62194278|NCT00517036|EXPERIMENTAL|A|Participants will take EPA
62194279|NCT00517036|EXPERIMENTAL|B|Participants will take DHA
62194280|NCT00517036|PLACEBO_COMPARATOR|C|Participants will take placebo
62194281|NCT06474923||AR patient|Diagnosis was made by inhalant allergen screening and blood-serology specific IgE test results according to ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines. Clinical symptoms include sneezing, runny nose, itchy nose, and pale edema of bilateral inferior turbinate when exposed to specific allergens.
62194282|NCT06474923||Non-AR patient|The final diagnosis of non-allergic rhinitis was made based on the ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines and exclusion by inhalant allergen screening and blood-serology specific IgE test results.
62194283|NCT04438720|ACTIVE_COMPARATOR|Extended Release Nifedipine Tablets（Adalat® GITS）|Extended Release Nifedipine reference formulation at a single dose of 30 mg
62194284|NCT04438720|EXPERIMENTAL|Extended Release Nifedipine Tablets|Extended Release Nifedipine test formulation at a single dose of 30 mg
62194285|NCT04727138|EXPERIMENTAL|EXS21546 Powder for Oral Suspension|EXS21546 Powder for Oral Suspension
62194286|NCT04727138|PLACEBO_COMPARATOR|Placebo|Placebo Powder for Oral Suspension
62194287|NCT04727138|EXPERIMENTAL|EXS21546 Granule in Capsule|EXS21546 Granule in Capsule
62194288|NCT05353777|EXPERIMENTAL|Levita Robotic Platform|
62194289|NCT01566097|EXPERIMENTAL|Intervention group|This study is cluster randomized trial, and the randomization level is physician. Current smokers seen by physician allocated into intervention group were provided with Smoking Cessation Decision Aids along with study questionnaires. The intervention was Smoking Cessation Decision Aids provided to current smokers.
62008842|NCT00318487|EXPERIMENTAL|Bilateral sinus augmentation|
62008843|NCT03056690|EXPERIMENTAL|ASP0819|Participants received ASP019 15 mg capsules, orally, once daily in the morning, with or without food for 8 weeks.
62782591|NCT04508153|OTHER|Kegel arm|Subjects randomized to the Kegel arm will be provided links to view instructions on how to perform PFMT (written instructions per the handout adapted from Voices for PFD, the patient advocacy arm of the American Urogynecologic Society), as well as an audio/visual didactic instructing them to perform Pelvic Floor Muscle Exercises (PFME) three times daily, seven days per week throughout the 8-week study period.
62008844|NCT03056690|PLACEBO_COMPARATOR|Placebo|Participants received ASP019 matching placebo capsules, orally, once daily in the morning, with or without food for 8 weeks.
62008845|NCT04298710|EXPERIMENTAL|Arm Cycling|Arm cycling on an arm crank ergometer for 20 minutes at light to moderate intensity. 30 minutes before the exercise, participants will consume 60g of carbohydrates mixed with plain water.
62008846|NCT04298710|EXPERIMENTAL|Leg Cycling|Leg cycling on a leg cycling ergometer for 20 minutes at light to moderate intensity. 30 minutes before the exercise, participants will consume 60g of carbohydrates mixed with plain water.
62008847|NCT04298710|PLACEBO_COMPARATOR|Sitting|Participants will remain seated after carbohydrates consumption.
62008848|NCT06534216||Inflammatory bowel disease|Adult patients with active Inflammatory Bowel Disease (IBD) are eligible for enrollment after obtaining informed consent. Active disease will be defined based on endoscopy with a Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score of 2 or greater for ulcerative colitis, and a Simple Endoscopic Score for Crohn's Disease (SES-CD) of 3 or greater for Crohn's disease.
62008849|NCT02621970|EXPERIMENTAL|IC plus CC plus IMRT plus AC|Induction chemotherapy: TP -- Docetaxel 75mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 2 cycles; Concurrent chemotherapy: PX -- Cisplatin 25 mg/m2, D1-3 and Xeloda 2000mg/m2, D1-14, every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy; Adjuvant chemotherapy: Xeloda 2500mg/m2, D1-14, every 3 weeks for 2 cycles
62782592|NCT01558050|EXPERIMENTAL|red rice|commercially available red rice nutritionial supplement
62782593|NCT01558050|PLACEBO_COMPARATOR|placebo|placebo capsules
62782594|NCT02566590|EXPERIMENTAL|Control|Participants will complete bed rest but will receive a non-protein placebo supplement
62194290|NCT01566097|NO_INTERVENTION|Control group|Current smokers seen by physician allocated into control group were provided with only study questionnaires and usual care.
62194291|NCT04921449|EXPERIMENTAL|Embedded ED Physical Therapy (NEED-PT)|An ED physical therapist will be embedded with the primary treatment team to evaluate patients presenting with low back pain at the beginning of the overall treatment course. The physical therapist will utilize a clinical protocol (NEED-PT) that matches the patient's history and exam findings to an appropriate treatment classification consisting of directional preference exercises, manual traction, stabilization exercises, non-thrust manipulation/mobilization, and/or psychologically informed rehabilitation. The NEED-PT intervention will supplement any usual care performed by the treating physician.
62194292|NCT04921449|OTHER|Usual Care|Usual care consists of any ED testing or treatment not involving an ED physical therapist in accordance with the treating physician's usual and customary practice. This could include diagnostic imaging, patient education and reassurance, and administration and/or prescribing of analgesic medications.
62194293|NCT01239784|EXPERIMENTAL|All Subjects|A total of 20 children and their parents will be recruited for this study. Ten children will have had the Glenn procedure and 10 infants will have had the arterial switch operation.
62782595|NCT02566590|EXPERIMENTAL|NMES + PRO|Participants will receive daily treatment with neuromuscular electrical stimulation (NMES) and daily supplements of a protein drink.
62008850|NCT02621970|ACTIVE_COMPARATOR|CC plus IMRT|Concurrent chemotherapy: Cisplatin 100 mg/m2, D1, every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
62008851|NCT00682019|EXPERIMENTAL|Arm 1|
62008852|NCT00682019|PLACEBO_COMPARATOR|Arm 2|
62194294|NCT01702857|EXPERIMENTAL|TDENV-PIV alum4|4 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
62194295|NCT01702857|EXPERIMENTAL|TDENV-PIV AS03B|1 µg TDENV-PIV with AS03B adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
62194296|NCT01702857|PLACEBO_COMPARATOR|Placebo|Phosphate buffered saline; 0.5 mL intramuscular injection at 0 and 28 days
62194297|NCT01702857|EXPERIMENTAL|TDENV-PIV alum1|1 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
62194298|NCT01702857|EXPERIMENTAL|TDENV-PIV AS01E|1 µg TDENV-PIV with AS01E adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
62782596|NCT00759408|EXPERIMENTAL|1|BQ-123
62008853|NCT03685331|EXPERIMENTAL|Phase I Level 0|"(28-day cycle)~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 75 mg by mouth daily, days 1-21, beginning at cycle 1"
62194299|NCT04154969|EXPERIMENTAL|intervention|daily physiotherapy session as part of the rehab plan, which includes 10 minutes of vestibular exercize.
62194300|NCT04154969|ACTIVE_COMPARATOR|control|daily physiotherapy session as part of the rehab plan
62194301|NCT06026930|EXPERIMENTAL|Lipus side: canine retraction|application of LIPUS with translation of maxillary canine that will be performed on intervention sides according to a standardized protocol
62194302|NCT06026930|NO_INTERVENTION|LIPUS side control side|LIPUS side:canine retraction control side
62194303|NCT06026930|EXPERIMENTAL|LLLT side canine retraction|translation of maxillary canine that will be performed with LLLT application according to a standardized protocol
62194304|NCT06026930|NO_INTERVENTION|LLLT side canine retraction control side|LLLT side canine retraction control side wihout intervention
62782597|NCT01791478|EXPERIMENTAL|Treatment (PI3K inhibitor BYL719, letrozole)|Patients receive PI3K inhibitor BYL719 PO QD and letrozole PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62008854|NCT03685331|EXPERIMENTAL|Phase I Level 1|"(28-day cycle)~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 100 mg by mouth daily, days 1-21, beginning at cycle 1~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
62008855|NCT03685331|EXPERIMENTAL|Phase I Level 2|"(28-day cycle)~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 125 mg by mouth daily, days 1-21, beginning at cycle 1~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
62008856|NCT03685331|EXPERIMENTAL|Phase II|"(28-day cycle) Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly once monthly on Day 1 of each cycle + 500 mg intramuscularly on Cycle 1 Day 15; palbociclib dose as per maximum tolerated dose determined during Phase I, by mouth daily, days 1-21~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
62008857|NCT02017691|EXPERIMENTAL|Near Infrared Spectroscopy|crSO2 measurements in addition SpO2 measurements will be visible to guide supplemental oxygen support and respiratory support according predefined interventions depending on the infants breathing efforts and the heart rate during the first 15 minutes after birth
62008858|NCT02017691|OTHER|Pulse-oximetry|Only SpO2 measurements will be visible to guide supplemental oxygen support and respiratory support according predefined interventions depending on the infants breathing efforts and the heart rate during the first 15 minutes after birth
62008859|NCT01343160|OTHER|GORE VIABIL® Biliary Endoprosthesis|Placement of GORE VIABIL® Biliary Endoprosthesis to establish duct patency
62008860|NCT00103792|EXPERIMENTAL|1 MMF induction|mycophenolate and steroids as remission induction, followed by azathioprine as maintenance therapy
62008861|NCT00103792|ACTIVE_COMPARATOR|2 CYC induction|cyclophosphamide and steroids, followed by maintenance therapy (azathioprine)
62008862|NCT00218062|EXPERIMENTAL|D-Amphetamine 60mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. d-Amphetamine sustained release (SR) (Dexedrine Spansules) started at 15 mg (day 1-2), increased to 30mg (day3; 15mg, BID), 45mg (day4; 15mg, TID), and 60mg (day5; 15mg bid plus 30mg qd). A 5-day dose reduction schedule occurred at week 17.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
62008863|NCT00218062|EXPERIMENTAL|Modafinil 400mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. Modafinil started at 200mg (day1) and increased to 400mg (days2-5). A 5-day dose reduction schedule occurred at week 17.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
62008864|NCT00218062|EXPERIMENTAL|Modafinil 200mg + D-Amphetamine 30mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. For the combination condition, dosages of modafinil and d-amphetamine were escalated to one-half of that for the single medication conditions. A 5-day dose reduction schedule occurred at week 17.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
62008865|NCT00218062|PLACEBO_COMPARATOR|Placebo + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
62194305|NCT06026930|EXPERIMENTAL|LIPUS groupMolar distalization group inrervention side|distalization assisted with LIPUS according to a standardized protocol
62194306|NCT06026930|NO_INTERVENTION|LIPUS groupMolar distalization group control side|distalization without LIPUS intervention
62194307|NCT06026930|EXPERIMENTAL|LLLT group: distalization intervntion side|distalization will be commenced with application of LLLT according to a standardized protocol
62194308|NCT06026930|NO_INTERVENTION|LLLT group: distalization control side|distalization will be commenced without application of LLLT according to a standardized protocol
62782598|NCT03075709||Experimental - CPW (Urban)|We are working with Regina Qu'Appelle Health Region (RQHR), a primarily urban health region, to develop and implement a clinical pathway (CPW). The CPW will improve care through the following steps: standardizing diagnostic, coordinating and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices.
62782599|NCT03075709||Experimental - CPW (Rural)|Following implementation in RQHR a rural health region will be chosen as an intervention site for a second CPW. The CPW will improve care through the following steps: standardizing diagnostic, coordinating and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices.
62782600|NCT03075709||Control - Standard Care (Urban)|Saskatoon Health Region (SHR) will act as the urban control site. No attempts will made to alter care in SHR and therefore patients will continue to receive the current standard of care.
62194309|NCT06026930|EXPERIMENTAL|LIPUS group: leveling and alignment|leveling and alignment assisted with LIPUS according to a standardized protocol
62008866|NCT02568410||CABG on CPB|Patients undergoing elective coronary artery bypass grafting using cardiopulmonary bypass. No study interventions beyond the standard clinical practice for these surgeries at Duke University Medical Center. No study drug administration.
62194310|NCT06026930|EXPERIMENTAL|LLLT group: leveling and alignment|leveling and alignment be commenced with application of LLLT according to a standardized protocol
62194311|NCT06026930|NO_INTERVENTION|leveling and alignment without intervention|leveling and alignment without intervention
62194312|NCT06026930|EXPERIMENTAL|LIPUS group: Intrusion|intrusion assisted with LIPUS according to a standardized protocol
62194313|NCT06026930|EXPERIMENTAL|LLLT group: Intrusion|intrusion assisted with application of LLLT according to a standardized protocol
62194314|NCT06026930|NO_INTERVENTION|intrusion control group|intrusion without intervention
62008867|NCT04122443|ACTIVE_COMPARATOR|Acetaminophen|Acetaminophen alone
62194315|NCT01572740|EXPERIMENTAL|Lira+Insulin|
62194316|NCT01572740|PLACEBO_COMPARATOR|Placebo+Insulin|
62194317|NCT06331104||P27 expression groups|12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).
62194318|NCT06331104||ESR1 expression groups|12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).
62194319|NCT04338412|ACTIVE_COMPARATOR|Group U|Performers' umbilicus
62782601|NCT03075709||Control - Standard Care (Rural)|Following implementation in RQHR a rural health region will be chosen to act as the rural control site. No attempts will made to alter care in this health region and therefore patients will continue to receive the current standard of care.
62008868|NCT04122443|ACTIVE_COMPARATOR|Oxycodone/ acetaminophen|Oxycodone + acetaminophen
62008869|NCT06360549|NO_INTERVENTION|Conventional treatment group|• Intrabronchial general anesthesia was used for anesthesia in all patients. Electrocardiogram (ECG), pulse oxygen saturation (SpO2), blood pressure (BP), body temperature (T), end-expiratory carbon dioxide (EtCO2), ventilators related parameters (VT, f, MV, etc.), and EEG monitoring (BIS) were routinely monitored during the operation.
62194320|NCT04338412|ACTIVE_COMPARATOR|Group R|Performers' lowest rib margin
62194321|NCT04338412|ACTIVE_COMPARATOR|Group X|Performers' xiphoid process
62194322|NCT02622399|EXPERIMENTAL|Project NOW|Participants in the intervention arm receive access to free mobile communications and a web-based informational platform supported by txtwire.
62194323|NCT02622399|NO_INTERVENTION|Control|Participants in the control arm do not receive access to the txtwire platform.
62782602|NCT04492111|EXPERIMENTAL|X-space group|Each patient of the experimental group will receive one X-space implant.
62782603|NCT04492111|ACTIVE_COMPARATOR|2P group|Each patient of the control group will receive one 2P implant. Bone System Cylindric implants. Surface Ecotek.
62021067|NCT05636540|EXPERIMENTAL|Cohort B|After undergoing screening assessments and verifying eligibility for study participation subjects will be scheduled to undergo a baseline experimental \[18F\]FTT PET/CT scan prior to systemic therapy with radionuclide or chemotherapy. Up to 10 patients undergoing systemic therapy may undergo a second (optional) scan that will be performed approximately 1-21 days after therapy has started. The second scan is obtained to evaluate whether the initiation of systemic therapy alters \[18F\]FTT uptake. As this is a pilot study, only a limited number of patients are sought for the second scan.
62194324|NCT06198270|OTHER|Close Kinetic Chain Exercise|Control Group (Close Kinetic Chain Exercise)
62194325|NCT06198270|EXPERIMENTAL|Neuromuscular training with K-Tape|Experimental Group (Neuromuscular training with K-Tape
62194326|NCT03674437||Breast Cancer Survivors|Each main cohort has 2 sub-groups: One sub-group in each main cohort will complete the traditional neurocognitive assessments and the Cogsuite Assessment at the MSK Counseling Center, and the other sub-group will complete the Cogsuite Assessment off-site, on their own computers, in a quiet space that is free of distractions.
62734639|NCT03198767|EXPERIMENTAL|Part A: LIK066 + P1: 8% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 8% carbohydrate (CHO) PROTOCOL DEVIATION: subjects received 8% CHO in error and were discontinued after Period 1.
62782604|NCT00517361|EXPERIMENTAL|Carboplatin + Avastin|
62782605|NCT03268291|ACTIVE_COMPARATOR|Standard outpatient observation|Outpatient management according to Ministry of health standards
62008870|NCT06360549|EXPERIMENTAL|Percutaneous acupoint electrical stimulation treatment group|On the basis of the conventional treatment received by the control group, the following additional treatments were implemented: Patients assigned to the treatment group underwent acupuncture with electrode pieces placed on bilateral Sanyin jiao, bilateral Zusanli, bilateral Shenmen, Shenting, Yintang, bilateral Hegu, and bilateral Neiguan 30 minutes before anesthesia. The acupuncture involved electrical stimulation using a dense wave with a frequency of 2/100Hz. The stimulation intensity was adjusted to the maximum current tolerable by the patient, typically ranging from 1-7mA, and continued until the conclusion of the operation.
62008871|NCT05518279|ACTIVE_COMPARATOR|Tranexamic Acid Treatment Group|The intervention for the treatment group is as follows: participants in this treatment arm will given 1950mg of oral tranexamic acid pills (3 tablets, 650mg each) in the emergency department following diagnosis of hip fracture.
62008872|NCT05518279|PLACEBO_COMPARATOR|Oral Placebo Control Group|The intervention for the control group is as follows: participants in this treatment arm will given 3 tablets of oral placebo pills in the emergency department following diagnosis of hip fracture.
62008873|NCT06406205|EXPERIMENTAL|Voclosporin（QL1074）|oral, 23.7 mg twice daily (BID)，52 weeks Drug: Voclosporin calcineurin inhibitor Other Names: QL1074
62008874|NCT06406205|PLACEBO_COMPARATOR|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules twice daily (BID)，52 weeks Drug: Placebo Oral Capsule matching placebo capsule
62194327|NCT03674437||Healthy Controls|Each main cohort has 2 sub-groups: One sub-group in each main cohort will complete the traditional neurocognitive assessments and the Cogsuite Assessment at the MSK Counseling Center, and the other sub-group will complete the Cogsuite Assessment off-site, on their own computers, in a quiet space that is free of distractions.
62194328|NCT03674437||Healthy 21-25 year olds|Healthy participants between the ages of 21 and 25 will be administered the Cogsuite Battery remotely. These participants will not be matched to any other groups and will not be asked for their full medical histories. They will only complete the assessment only once.
62194329|NCT03549091|EXPERIMENTAL|Transthoracic echocardiography and MRI|The TransThoracic Echocardiography imaging data are collected exactly as for a standard examination. However, an additional measurement of the flow at the level of the left subclavian artery is performed, resulting in a 10-minute increase in the examination time. A Cardiovascular Magnetic Resonance Imaging 4D Flow is programmed within a maximum of 10 (no change in treatment that could skew the comparison). The usual procedure for MRI is not modified. The examination allows the acquisition of conventional 2D sequences of flow measurements, regurgitant volume and regurgitation fraction obtained at the level of the descending aorta and the sino-tubular junction of the ascending aorta. An additional 4D sequence is acquired increasing the examination time by 10 minutes.
62194330|NCT01539577||OZURDEX®|OZURDEX® (dexamethasone 700 μg intravitreal implant) administered according to general clinical practice.
62194331|NCT04122547|ACTIVE_COMPARATOR|Roflumilast|Roflumilast 500 microgram one tab oral per day
62194332|NCT04122547|PLACEBO_COMPARATOR|Placebo|One tablet oral per day
62194333|NCT00267098|EXPERIMENTAL|Biventricular pacing|
62194334|NCT00267098|ACTIVE_COMPARATOR|Right ventricular pacing|
62194335|NCT03038035|ACTIVE_COMPARATOR|MLC901|"NeuroAid II MLC901 is a derivative product of NeuroAid MLC601. It is a simplified formula based on the 9 Herbal ingredients that are present in NeuroAid MLC 601. Neuroaid II has been approved for sale as a Chinese Proprietary Medicine in Singapore by the HSA since March 2010. 24 weeks intervention. Dosage: 2 capsules 3 times a a day~Upon completion of 24 weeks, subject will be given an option to continue an open-label extension for another 24 weeks."
62194336|NCT03038035|PLACEBO_COMPARATOR|Placebo|"24 weeks intervention with orally placebo. 2 capsules 3 times a day.~Upon completion of 24 weeks, subject will be given an option to continue an open-label extension for another 24 weeks."
62194337|NCT02160730|EXPERIMENTAL|R-roscovitine|• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.
62194338|NCT06319794|EXPERIMENTAL|Bimiralisib - 2 weeks treatment|Topical bimiralisib for 2 weeks
62194339|NCT06319794|EXPERIMENTAL|Bimiralisib - 4 weeks treatment|Topical bimiralisib for 4 weeks
62573593|NCT01994941|ACTIVE_COMPARATOR|Clinical guided group|"Patients are given standard doses of clopidogrel (either 300mg or 600mg according to clinical protocol).~Apart from the approach in guiding the use of P2Y12 receptor blocker, all patients will be treated according to usual clinical care including medications and coronary intervention. Blood will also be sent to standard laboratory for CYP2C19 genotyping using conventional polymerase chain reaction (PCR) method so as to confirm the accuracy of rapid genetic test. 24 hours after initial clopidogrel loading, blood will be taken to measure platelet reactivity by verifyNow P2Y12 assay (Accumetrics) which is an FDA approved, point-of-care device using light-transmission based optical detection which measures platelet aggregation. In case glycoprotein IIbIIIa inhibitor (Integrilin) is used, verifyNow P2Y12 assay will be performed 48 hours after cessation of Integrilin."
62008875|NCT02828839|EXPERIMENTAL|Treatment Arm|Subjects will receive standard of care prostate biopsies through the use of a trans-rectal ultrasound probe for needle placement and guidance. The intervention for all patients receiving a prostate biopsy will include the use of an investigational single use, disposable stainless steel access needle and a single use, disposable polymeric needle guide.
62573594|NCT03349073|EXPERIMENTAL|T-1101 (Tosylate)|
62573595|NCT00026117|EXPERIMENTAL|BeneFin|"Patients receive oral shark cartilage (BeneFin™) 3-4 times daily. Treatment continues in the absence of unacceptable toxicity. Quality of life is assessed weekly for 1 month and then monthly thereafter during treatment.~Patients are followed every 6 months for 5 years."
62008876|NCT00585806||1|Subjects with Heart Failure and ejection fraction greater than or equal to 45%
62573596|NCT00026117|OTHER|placebo|"Patients receive oral placebo 3-4 times daily. Treatment continues in the absence of unacceptable toxicity. Quality of life is assessed weekly for 1 month and then monthly thereafter during treatment.~Patients are followed every 6 months for 5 years."
62573597|NCT04099992|EXPERIMENTAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.
62194340|NCT03169998||GDFT group|The fluid infusion is to be performed, in accordance with GDFT protocol, on the basis of cardiac index (CI), stroke volume index(SVI) and stroke volume (SV) in addition to invasively measured arterial pressure by Vigilio / FloTrac Monitor.
62194341|NCT03169998||Control group|Patients in whom the surgery was conducted without the use of EV1000/ FloTrac monitoring among those who had undergone laparoscopic hepatobiliary or pancreatic surgery in the past.
62008877|NCT00585806||2|Healthy Volunteers
62008878|NCT05834543|EXPERIMENTAL|TQB2618 injection +Penpulimab injection+Chemotherapy|Experimental group in Cohort 1. TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin, 21 days as a treatment cycle. After 4\~6 cycles, TQB2618 injection combined Penpulimab injection, 21 days as a treatment cycle.
62398457|NCT05905354|EXPERIMENTAL|lose dose,high dose|Four dose groups were set up: dose group 1, a single dose of 2mg, administered at week 0, 4 and 12, three times in total; Dose group 2, a single dose of 6mg, respectively at the 0, 4, 12 weeks, a total of 3 times; Dose group 3, a single dose of 2mg, was given at the 0, 2, 4, 12 weeks, a total of 4 times; Dose group 4, with a single dose of 6mg, was given 4 times at week 0, 2, 4 and 12, respectively. There were 3 subjects in each group. Climb from the low dose group to the high dose group.
62398458|NCT06445972|ACTIVE_COMPARATOR|Ramucirumab + Paclitaxel|Participants will receive ramucirumab at 8mg/kg via intravenous (IV) infusion on days 1 and 15 of each 4-week cycle for up to \~60 weeks plus paclitaxel at 80 mg/M\^2 via IV infusion on Days 1, 8, and 15 of each 4-week cycle (3 weeks on and 1 week off) for up to \~60 weeks.
62398459|NCT06445972|EXPERIMENTAL|MK-2870 + Paclitaxel|Following a 28-day run-in with MK-2870 at 3 mg/kg and 4 mg/kg IV infusion on Days 1 and 15 of a 6-week cycle plus paclitaxel at 80 mg/M\^2 IV infusion on days 1, 8 and 15 of a 4-week cycle, participants will receive paclitaxel at 80 mg/M\^2 IV infusion on days 1, 8, 15 of each 4-week cycle (3 weeks on and 1 week off) up to \~60 weeks plus MK-2870 at selected dose IV infusion on days 1, 15, 29 of every 6-week cycle until discontinuation.
62398460|NCT02270385|EXPERIMENTAL|Experimental group|The experimental group will be implemented a 16-week PU prevention programme. The PU prevention programme includes an intensive training on knowledge and skills ono PU prevention and also a PU prevention protocol. The purpose of the programme is to equip care staff with PU knowledge and skills and to guide especially health workers and personal care workers in PU prevention.
62398461|NCT02270385|OTHER|control group|The control group will be provided with the usual PU prevention care
62398462|NCT05665543|EXPERIMENTAL|GLAm App|Participants will have access to Game based Learning Avatar navigated mobile (GLAm ) app and will receive the receive the quality improvement (QI) intervention plus the GLAm app.
62398463|NCT05665543|NO_INTERVENTION|Usual care|Participants in the control group will not receive the access to the GLAm app. They will receive the quality improvement (QI) intervention only.
62398464|NCT02403115||Lupus Nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies.
62008879|NCT05834543|ACTIVE_COMPARATOR|Penpulimab injection+Chemotherapy|"Active comparator group in Cohort 1. Penpulimab injection, Paclitaxel, Cisplatin, 21 days as a treatment cycle.~After 4\~6 cycles, Penpulimab injection 21 days as a treatment cycle."
62008880|NCT05834543|EXPERIMENTAL|TQB2618 injection +Penpulimab +TQB3617capsules|"Cohort 2. TQB2618 injection, Penpulimab injection, 21 days as a treatment cycle.~TQB3617 capsules are administered on Day 1 and Day 14, 21 days as a treatment cycle."
62008881|NCT05607992|EXPERIMENTAL|Brief exposure-based CBT|"* Patient education: Common reactions following ACS. The role of PTS, cardiac anxiety and avoidance behavior on quality of life and physical health and health behaviors.~* Labeling i.e., describe cardiac-related symptoms, thoughts, and feelings.~* Imaginal exposure to reduce PTSS: Imaginal processing and revisiting of the memory of the ACS~* Interoceptive exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms.~* Gradual exposure in-vivo to avoided situations, activities and physical activity. Continuously use labeling while conducting exposure exercises.~* Relapse prevention: Prevention of relapse into avoidance behaviors by identifying risk situations and encouragement of maintaining a healthy physically active lifestyle."
62008882|NCT05607992|NO_INTERVENTION|Waitlist control|The waitlist control will be offered an opportunity to participate in the intervention after the 2-month intervention evaluation period.
62194342|NCT05434325||TESTING Particpants|All participants who were successfully randomised to the TESTING study who are still alive and have not reached kidney failure requiring dialysis.
62194343|NCT01798979|EXPERIMENTAL|Midazolam and GLPG0634|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8) and multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
62194344|NCT05208359|EXPERIMENTAL|STRONG immediate group|Small mental health support group delivered immediately
62194345|NCT05208359|OTHER|STRONG delayed group|Small mental health support group delivered after a delay of approximately 3 months
62194346|NCT00203268|EXPERIMENTAL|Treatment with dihydroergotamine mesylate (DHE-45)|Subjects who treated a moderate to severe migraine 2 and 4 hours after the onset of throbbing headache pain
62194347|NCT04121780|EXPERIMENTAL|Growth Hormone|Norditropin® (somatropin \[rDNA origin\] injection) via FlexPro® 30 mg / 3ml strength auto-injector pens (Novo Nordisk Inc).
62194348|NCT04121780|PLACEBO_COMPARATOR|Saline|Saline-placebo via auto-injector pens (Haselmeier Inc).
62194349|NCT01568125||Incretin-related drugs|
62194350|NCT06044506|EXPERIMENTAL|Autologous Natural Killer Cell|"Dosage Form: Autologous Natural Killer (NK) Cells. These cells will be harvested from the patient's body and infused back into the patient.~Dosage: The specific dose quantity will be determined based on the patient's medical condition and response to the treatment. Customized dosages will be calculated for each individual.~Frequency: The treatment will be given through an intravenous method.~Duration: The length of the treatment will vary depending on how the patient responds and their medical assessment. It may take several weeks to evaluate its effectiveness and potential impacts thoroughly."
62194351|NCT06264193|EXPERIMENTAL|Hypoxia|live high-train low method was used
62194352|NCT05648487|EXPERIMENTAL|Gastric Cancer With Peritoneal Metastasis, HIPEC, Anti-PD-1 Antibody|"1. Surgical exploration, if PCI≤20, then we perform this study.~2. HIPEC: HIPEC is performed after laparoscopic exploration, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgical exploration;~3. Chemotherapy(SOX) and anti-PD-1 antibody Sintilimab (Tyvyt®) treatment followed (4 cycles): SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40-60 mg/m\^2 bid, po, day 1-14, every 3 weeks for a total of 4 cycles; Sintilimab (Tyvyt®) 200mg fixed dose every 3 weeks, for a total of 4 cycles.~4. Surgery: Imaging and secondary surgical exploration, assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases ). After the surgery, HIPEC for three cycles, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgery; For inoperable patients, continue to use standard chemotherapy.~5. After the surgery, continue to use standard adjuvant chemotherapy."
62398465|NCT02403115||Incident SLE without nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies, in order to evaluate the presence of nephritic manifestations.
62398466|NCT02403115||Prevalent SLE without nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to evaluate the presence of nephritic manifestations.
62398467|NCT02403115||Rheumatoid arthritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to evaluate the presence of nephritic manifestations.
62398468|NCT02403115||Membranous glomerulonephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to exclude secondary forms of the disease.
62398469|NCT04637373|EXPERIMENTAL|the group|Women aged 18-40 years who admit to the gynecology emergency department at our institution with early miscarriage up to 12 weeks and 6 days of gestation, and choose surgical evacuation over medical treatment, are having Hysteroscopy assisted suction curettage as detailed previously. retained products of conception found at the end of the procedure, and intrauterine adhesions found on follow up are compared to the data in the literature.
62398470|NCT05340842|EXPERIMENTAL|Simulation training experiment group|"In this training, the researcher firstly explained breastfeeding by wearing the Lactation Simulation Model on himself and showing it practically on himself.~Afterwards, the model was dressed on the pregnant woman and the pregnant woman was given one-on-one breastfeeding practice.~In this process, all questions of the pregnant woman were answered by the researcher."
62398471|NCT05340842|NO_INTERVENTION|Control group|At this stage, the standard video screening prepared for breastfeeding education within the scope of the hospital protocol was shown to the pregnant woman by the researcher with a tablet.
62398472|NCT00001231||Healthy Women|The purpose of this protocol is to allow for the careful screening of healthy volunteers for participation in research protocols.
62194353|NCT00900692|EXPERIMENTAL|Dynasplint Group|Along with the standard of care Botox and manual therapy, patients will use the Supination Dynasplint every day
62398473|NCT00001231||premenopausal depressed women patients|The purpose of this protocol is to allow for the careful screening of patients for participation in research protocols.
62573598|NCT04099992|ACTIVE_COMPARATOR|Health enhancement program (HEP)|Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions with a day-long retreat.
62194354|NCT00900692|NO_INTERVENTION|Standard of care|Patients in the standard of care group will have the standard Botox treatments and manual therapy with no additional interventions.
62194355|NCT04051918|EXPERIMENTAL|Socially Assistive Robot Intervention|Piano training intervention led by a semi-autonomous socially assistive robot
62398474|NCT03661281|EXPERIMENTAL|Simulated Thumb Arthrodesis|Subjects will have their thumb immobilized in 2 prefabricated wrist splints to simulate 2 different fusion positions tested: one splint to simulate the MCP fusion and one to represent the IP fusion. Patients will complete hand function tests in each of the splints to evaluate hand function.
62194356|NCT04051918|ACTIVE_COMPARATOR|Content Only Intervention|Piano training intervention using the same curriculum displayed on a computer monitor, without the socially assistive robot tutor.
62398475|NCT06033352|EXPERIMENTAL|Laser and cream|
62398476|NCT06033352|ACTIVE_COMPARATOR|Laser alone|
62573599|NCT04099992|EXPERIMENTAL|MBSR+tVNS|"Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.~Transcutaneous vagus nerve stimulation (tVNS) is a simple, noninvasive, self-administered adjunctive therapy, that may enhance the sympatho-inhibitory effects of mindfulness meditation (MM) in chronic kidney disease (CKD) ."
62008883|NCT03684200|EXPERIMENTAL|Copenhagen adductor exercise|20 players allocated to the Copenhagen adductor exercise group complete a progressive strengthening programme comprising of the Copenhagen adductor exercise over a period of 6 weeks. They will complete two exercise sessions a week consisting of one set of the Copenhagen adductor exercise. The exercise will be performed on each side. The training load will increase from 5 repetitions in week 1, to 15 repetitions in week 6. The exercise programme is performed at the end of the warm-up of a regular football training session.
62008884|NCT03684200|NO_INTERVENTION|Control|19 players allocated to the control group will be asked not to perform the Copenhagen adductor exercise or any other specific strength training for the adductor muscles and to continue to play football as usual.
62008885|NCT02720926|EXPERIMENTAL|TKI258 combined with Xeloda/Oxaliplatin|TKI258 200 mg once a day (OD) 5 days on/2 days off Capecitabine (Xeloda) 2000 mg/m2 bid d1-14 Oxaliplatin 130mg/m2 d1 q21days
62008886|NCT04354922|PLACEBO_COMPARATOR|Attention control|Subjects in this group will receive one session of 75 minutes stretching exercise per week throughout the 12 weeks experimental period
62194357|NCT05923645|EXPERIMENTAL|High frequency repetitive Transcranial Magnetic Stimulation|"Children who have given consent for the study and are fulfilling the inclusion and exclusion criteria will be enrolled and given Transcranial magnetic stimulation (TMS) as per protocol as described below over 12 week along with AI based remedial intervention.~TMS protocol - 5 Hz High frequency rTMS, at 100% RMT, 60 pulses per train, total 10 trains , gap between 2 consecutive trains of 30 sec, at left IPL and left STG localised using 10-20 EEG based system at P3 and P5 respectively , using figure of 8 coil~1st cycle of 10 sessions over 10 consecutive days, 2nd cycle of 5 sessions over 5 consecutive days , 3rd cycle for 5 sessions over 5 consecutive days ; gap of 6 weeks between 2 consecutive cycles Total 3 cycles per patient"
62194358|NCT06418009|NO_INTERVENTION|Not cold needle application|Fistül girişimi için kullanılan iğne kendi torbasında durdurulur ve hastalığın takılacağı zaman Resmi tarafından deponun içinden çıkarılarak kullanılacaktır
62194359|NCT06418009|EXPERIMENTAL|Cold needle application|Before use, the needle will be removed from the refrigerator and kept on the nurse's table. When the temperature of the needle reaches 0-2 °C, the patient will be cannulated.
62194360|NCT03049670||latent available chlorine (LAC)|applying LAC on infected wounds
62194361|NCT04529005|EXPERIMENTAL|Angiotensin II (Giapreza)|
62194362|NCT05614310||Development Group 1 (N = 10) (Development Phase)|Development group participants (N = 10) will undergo 1 magnetic resonance imaging (MRI) sessions. Before and after their MRI scan participants will be given a pinprick blood sugar test.
62194363|NCT05614310||Patients (N = 20) (Clinical Phase)|"Patients (N = 20) will attend 2 visits up to 1 week apart. Patients will be asked to have a no-sugar diet and take no exercise for 24 hours before each visit and to avoid eating 6 hours before scan.~Visit 1: Patients will undergo a positron emission tomography (PET) assessment. Before and after their PET assessment patients will be given a pinprick blood sugar test. PET assessment:~Visit 2: Patients will undergo MRI assessment. Before and after their MRI scan patients will be given a pinprick blood sugar test. Healthy controls will complete cognitive assessments."
62194364|NCT05614310||Healthy Controls (N = 20) (Clinical Phase)|"Healthy controls (N = 20) will attend 2 visits up to 1 week apart. Healthy controls will be age matched (+/- 3 years) and sex matched to the patient group. Healthy controls will be asked to have a no-sugar diet and take no exercise for 24 hours before each visit and to avoid eating 6 hours before scan.~Visit 1: Healthy Controls will undergo a positron emission tomography (PET) assessment. Before and after their PET assessment patients will be given a pinprick blood sugar test. PET assessment:~Visit 2: Healthy Controls will undergo MRI assessment. Before and after their MRI scan patients will be given a pinprick blood sugar test. Healthy controls will complete cognitive assessments."
62194365|NCT05614310||Development Group 2 (N = 10) (Development Phase)|To investigate the repeatability of MRI assessment, 10 development phase healthy volunteers will be recruited to undergo two repeated study assessments. The second visit will be between 7 and 14 days after their first visit. The second repeated study assessment will follow the same procedure as the first visit, consisting of blood glucose assessment and MRI assessment. Participants will be advised to fast from mid-night and avoid eating breakfast.
62194366|NCT04594837|EXPERIMENTAL|PTR (Physical Therapy while wearing Robot group) (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
62194367|NCT04594837|ACTIVE_COMPARATOR|PT (Physical Therapy Only) (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks. Subjects perform over-ground mobility tasks of increasing challenge with therapist assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
62008887|NCT04354922|ACTIVE_COMPARATOR|Moderate-intensity walking exercise ×3/wk|Subjects in this group will receive three sessions of 50 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
62008888|NCT04354922|ACTIVE_COMPARATOR|Moderate-intensity walking exercise ×1/wk|Subjects in this group will receive one session of 150 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
62194368|NCT04594837|EXPERIMENTAL|X-PTR, Cross over group for Physical Therapy n Sub-Acute group.|Participants enrolled in the physical therapy only group will be given the option to re-enroll as a cross over participant to receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
62194369|NCT04594837|EXPERIMENTAL|C-PTR, Chronic Stroke Subjects to receive robotic gait training therapy.|Chronic stroke subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
62194370|NCT02397382|EXPERIMENTAL|Guselkumab and Cytochrome P450 Probe Cocktail|Participants will be administered single dose of Guselkumab 200 milligram (mg) by subcutaneous injection (2\*100 mg) on Day 8 and Cytochrome P450 probe cocktail consist of midazolam, warfarin/vitamin K, omeprazole, dextromethorphan and caffeine orally once on Day 1,15 and 36.
62194371|NCT05422183|EXPERIMENTAL|envafolimab，lenvatinib，VP-16|envafolimab：400mg，sc，d1，Q3W； lenvatinib：8 mg(BW\<60 kg) OR 12 mg(BW≥60 kg)，po，qd，d1-21，Q3W； VP-16：50 mg/d, po,d1-14，Q3W
62194372|NCT03287453|EXPERIMENTAL|Screening (educational intervention)|Participants attend educational sessions comprising of an inflatable colon interactive exhibit that allows visitors to walk through a colon while seeing images, a PowerPoint presentation that contains messages that are tailored to meet the cultural and linguistic needs of Black/African Americans, Appalachians, and Hispanics/Latinos, and or flip books/flip charts. Participants also receive a copy of the study information sheet which contains the basic elements of informed consent and a pre-education session knowledge survey.
62194373|NCT01513330|EXPERIMENTAL|First Standard Care, then SenSura Mio|Subjects first test Standard Care (Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima) and after cross-over SenSura Mio
62194374|NCT01513330|EXPERIMENTAL|First SenSura Mio, then Standard Care|Subjects first test SenSura Mio and after cross-over Standard Care(Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima)
62194375|NCT03892005||MOTIVATION HIP Total Hip System|All study subjects have undergone routine preoperative clinical evaluations prior to their THA, and implanted MOTIVATION HIPTM Total Hip System in accordance to indications and intended use, and appropriate surgical technique(s) will be invited to participate in the study at their first year of postoperative follow up visit, and sign ICF.
62194376|NCT05281497|EXPERIMENTAL|Intervention group|Each participant was provided with a wearable device. Each participant downloaded an app (WowGoHealth app) to connect with the health management platform. All participants were taught to record a dietary diary (taking photos of meals) using a smartphone application. All collected information was uploaded to the health management platform. For the intervention group, we encouraged exercise including an 18-minutes calisthenics. We also built a LINE group to inspire the intervention group.
62194377|NCT05281497|PLACEBO_COMPARATOR|Control group|Each participant was provided with a wearable device. Each participant downloaded an app (WowGoHealth app) to connect with the health management platform. All participants were taught to record a dietary diary (taking photos of meals) using a smartphone application. We did not encourage exercise or build a LINE group.
62194378|NCT01304498|EXPERIMENTAL|V503|9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
62194379|NCT01304498|ACTIVE_COMPARATOR|GARDASIL|Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
62194380|NCT04318106|EXPERIMENTAL|'Experimental' coloured spectacle lenses|Precision tinted lenses available from Cerium Technologies (TM) which will be the optimum chromaticity to alleviate visual stress symptoms. To be worn for a minimum of 10 weeks for concentrated tasks.
62008889|NCT04354922|ACTIVE_COMPARATOR|Vigorous-intensity walking exercise ×3/wk|Subjects in this group will receive three sessions of 25 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
62008890|NCT04354922|ACTIVE_COMPARATOR|Vigorous-intensity walking exercise ×1/wk|Subjects in this group will receive one session of 75 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
62008891|NCT03858075|EXPERIMENTAL|Single ascending doses with BLU-782|
62008892|NCT03858075|PLACEBO_COMPARATOR|Single ascending doses with placebo|
62008893|NCT03858075|EXPERIMENTAL|Multiple ascending doses with BLU-782|
62008894|NCT03858075|PLACEBO_COMPARATOR|Multiple ascending doses with placebo|
62008895|NCT03858075|EXPERIMENTAL|Food effect of BLU-782 taken with food|
62008896|NCT03858075|EXPERIMENTAL|Food effect of BLU-782 taken without food|
62008897|NCT02717533||blood volume|dry weight adjusted according to ideal blood volume obtained from absolute blood volume measurement (Daxor)
62008898|NCT04083456|EXPERIMENTAL|Walking Biobehavioral Intervention (EXP)|The EXP group will receive biobehavioral training that is integrated into the conventional outpatient training component and is delivered over 5 months. There will be 10 biobehavioral sessions, 1 of which will be a combined biobehavioral/conventional outpatient session and the other 9 being telehealth sessions.
62398477|NCT03994965|EXPERIMENTAL|Patients|"40 antipsychotic-free, first-episode schizophrenia spectrum patients will receive 6 weeks of treatment with a selective serotonin 2A Receptor (2AR) blockade.~Before initiation of treatment patients will undergo: positron emission tomography (PET) imaging of the serotonin 2AR binding potential using the radioligand \[¹¹C\]Cimbi-36; magnetic resonance spectroscopy (MRS) of cerebral glutamate levels; structural Magnetic Resonance Imaging (MRI), including diffusion tensor imaging (DTI); cognitive and psychopathological examinations; Electrocardiography (ECG), and blood sampling for genetic- and metabolic analyses.~(Full description will be updated on approval)."
62194381|NCT04318106|PLACEBO_COMPARATOR|'Control' coloured spectacle lenses|Precision tinted lenses available from Cerium Technologies (TM) which will be individually determined as being sub-optimal to alleviate visual stress symptoms. This colour will be as similar to the 'experimental' colour as possible and will not be aversive to the participant. To be worn for a minimum of 10 weeks for concentrated tasks.
62398478|NCT00667537|EXPERIMENTAL|Radium-223 chloride|IV administrations of 100 kBq/kg b.w (=110 kBq/kg based on the 2015 National Institute of Standards and Technology standardization). Two administrations took place with an interval of 6 weeks
62194382|NCT00981708|EXPERIMENTAL|Treatment|Lenalidomide, Dexamethasone and cyclophosphamide
62194383|NCT00915824|EXPERIMENTAL|STOPP/START intervention|STOPP/START intervention group
62573600|NCT04099992|ACTIVE_COMPARATOR|MBSR+sham-tVNS|"Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.~Sham stimulation will be delivered using a sham device that is identical in appearance and function to tVNS, but programmed to produce a lower frequency biphasic signal that can be felt by the participant without actually stimulating the vagus nerve."
62194384|NCT06062004|ACTIVE_COMPARATOR|Control|group A, SMILE procedure with lenticule diameter of 6.5 mm
62194385|NCT06062004|ACTIVE_COMPARATOR|Study cases|group B, SMILE procedure with lenticule diameter of 7.0 mm
62194386|NCT03728751|EXPERIMENTAL|study group|Study group receiving dry needling and pupil diameter will be studied up to 23 minutes after needle placement.
62194387|NCT03768336|ACTIVE_COMPARATOR|Waitlist Control|"* The 3RP-AYA will be delivered in weekly sessions over the course of approximately 8 weeks, for a total of 8 sessions~* Mini relaxation practice~* Weekly goal check-ins~* RR-practice"
62194388|NCT03768336|EXPERIMENTAL|3RP Group Sessions|"* The 3RP-AYA will be delivered in weekly sessions over the course of approximately 8 weeks, for a total of 8 sessions~* Mini relaxation practice~* Weekly goal check-ins~* RR-practice"
62398479|NCT02356770|EXPERIMENTAL|Collagen Matrix 10808|Mucosal split-thickness flap in combination with the Collagen Matrix 10808.
62398480|NCT02356770|OTHER|Connective tissue graft (gold standard)|Mucosal split-thickness flap in combination with the connective tissue graft.
62398481|NCT05988866|EXPERIMENTAL|Intervention group|"Participants allocated to the intervention group will receive access to lipodia in addition to treatment as usual (TAU).~lipodia is a digital health application designed for individuals with hypercholesterinemia, accessible through a web browser. The application focuses on treatment methods derived health behavior change and cognitive behavioral therapy (CBT). Topics addressed by lipodia are activity planning and impulse control, dietary habits, physical activity, stress management, mood management, sleep management, weight management, as well as quitting smoking and drinking.~The program operates through interactive dialogues, which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 365 days."
62398482|NCT05988866|NO_INTERVENTION|Control group|Participants allocated to the control group will receive access to treatment as usual (TAU).
62194389|NCT03818126|EXPERIMENTAL|del Nido cardioplegia|
62194390|NCT03818126|ACTIVE_COMPARATOR|cold blood cardioplegia|
62194391|NCT03306173|EXPERIMENTAL|Ventilated cigarettes|Participants in this ARM will be assigned to \~25% filter ventilation commercially available cigarettes.
62194392|NCT03306173|EXPERIMENTAL|Unventilated cigarettes|Participants in this ARM will be assigned to \~0% filter ventilation commercially available cigarettes.
62194393|NCT00830323|EXPERIMENTAL|1|
62194394|NCT00830323|EXPERIMENTAL|Arm 2|
62194395|NCT00830323|ACTIVE_COMPARATOR|Arm 3|
62398483|NCT01611142|EXPERIMENTAL|KW-0761|
62194396|NCT00277095|EXPERIMENTAL|ProACT (Adjustable Continence Therapy)|Implantation with ProACT (Adjustable Continence Therapy), Single Arm
62194397|NCT01544634|EXPERIMENTAL|Propranolol + Low dose Qvar|
62194398|NCT01544634|ACTIVE_COMPARATOR|Placebo + high dose Qvar|
62194399|NCT02638103|EXPERIMENTAL|TEV-48125 225 mg Monthly: New/Placebo Rollover Participants|Participants with CM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive fremanezumab 675 milligrams (mg) SC as loading dose (3 injections of fremanezumab 225 mg/1.5 milliliters \[mL\] on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
62214926|NCT06275139|NO_INTERVENTION|Control group (No-integrated group)|The control group adopt the traditional diagnosis and treatment mode, and only head CT plain scan and carotid artery ultrasound shall be performed. If necessary, relevant disciplines would be consulted but no integrated assessment of cervicocerebral vessels be arranged. The final treatment plan would be decided by the surgeon alone.
62398484|NCT06723704||ACHD cohort|Adult patients with congenital heart disease either untreated, corrected or palliated, evaluated in our ACHD Outpatient Clinic between 2014 and 2026 with at least one-year follow-up.
62573601|NCT04099992|EXPERIMENTAL|HEP+tVNS|"Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator (a registered dietician) in a group setting for 8 weekly 2.5-hour sessions.~Transcutaneous vagus nerve stimulation (tVNS) is a simple, noninvasive, self-administered adjunctive therapy, that may enhance the sympatho-inhibitory effects of mindfulness meditation (MM) in chronic kidney disease (CKD)."
62008899|NCT04083456|ACTIVE_COMPARATOR|Attention Control (CTL)|The CTL group intervention will include the same conventional outpatient training (10 sessions) as the EXP group and receive the same computer tablets with telehealth software as the EXP group (week 3 of prosthetic training).
62008900|NCT03086798|EXPERIMENTAL|Magill forceps|experimental Magill forceps group: Magill forceps technique to facilitate nasotracheal tube advancement into trachea
62194400|NCT02638103|EXPERIMENTAL|TEV-48125 225 mg Monthly: Active Rollover Participants|Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
62573602|NCT04099992|ACTIVE_COMPARATOR|HEP+sham-tVNS|"Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions.~Sham stimulation is be delivered using a sham device that is identical in appearance and function to tVNS, but programmed to produce a lower frequency (0.1 Hz) biphasic signal that can be felt by the participant without actually stimulating the vagus nerve."
62008901|NCT03086798|EXPERIMENTAL|cuff inflation|experimental cuff inflation group: cuff inflation technique to facilitate nasotracheal tube advancement into trachea
62008902|NCT05961215|EXPERIMENTAL|Penguin Cold Cap|Patients will receive Penguin cold cap: 60 minutes prior to melphalan infusion and continue for 5 hours after melphalan infusion start time, for a total of 6 hours, on Days -2 and -1.
62008903|NCT01632579|PLACEBO_COMPARATOR|Placebo|Single dose of placebo administered orally on up to one occasion separated by at least a 3 week wash out period.
62398485|NCT04586127|EXPERIMENTAL|Adolescents and Young Adults Needs Assessment & Service Bridge (AYA NA-SB)|Subjects will complete 2 online surveys over the course of 1 month; each should take about 15 minutes to complete.
62398486|NCT01347827||on pump|Coronary artery bypass grafting (CABG)with with cardiopulmonary bypass
62398487|NCT01347827||off pump|off-pump CABG surgery
62398488|NCT04273594|EXPERIMENTAL|FemBloc|Investigational device and procedure
62398489|NCT01348074|EXPERIMENTAL|Double dose|Re-initiation with warfarin at twice the usual maintenance dose the first 2 days, then maintenance dose.
62398490|NCT01348074|NO_INTERVENTION|Usual maintenance dose|Usual maintenance dose from Day 1, i.e. no postoperative loading dose.
62398491|NCT01718860||Postoperative Residual Paralysis|Patients with train-of-four ratio less than 0.9 measured in the postanesthesia care unit
62398492|NCT01718860||No Postoperative Residual Paralysis|Patients with train-of-four ratio greater than 0.9 measured in the postanesthesia care unit
62008904|NCT01632579|EXPERIMENTAL|LY3023703|Up to 6 single escalating doses of LY3023703 \[0.1 milligram (mg) up to 60 mg\] administered orally on up to two occasions per participant separated by at least a 3 week wash out period.
62398493|NCT06597734|EXPERIMENTAL|Olutasidenib+Azacitidine-IV or SubQ|Participants will take capsules of olutasidenib 2 times each day while you are on study. Each dose should be taken about 12 hours apart at least 1 hour before or 2 hours after a meal.
62398494|NCT06597734|EXPERIMENTAL|Olutasidenib+Decitabine-IV|Participants will take capsules of olutasidenib 2 times each day while you are on study. Each dose should be taken about 12 hours apart at least 1 hour before or 2 hours after a meal.
62398495|NCT06597734|EXPERIMENTAL|Olutasidenib+Decitabine/Cedazuridine-PO|Participants will take capsules of olutasidenib 2 times each day while you are on study. Each dose should be taken about 12 hours apart at least 1 hour before or 2 hours after a meal.
62194401|NCT02638103|EXPERIMENTAL|TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants|Participants with CM or EM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
62194402|NCT02638103|EXPERIMENTAL|TEV-48125 675 mg Quarterly: Active Rollover Participants|Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
62398496|NCT01336647|EXPERIMENTAL|Group A|Group A Low-Dose Ha44 Gel 0.37% w/w topically administered to head and scalp.Single application for 10 minutes.
62008905|NCT01632579|ACTIVE_COMPARATOR|400 mg Celecoxib|Positive control. Single 400 mg dose of celecoxib administered orally, open label, on one occasion separated by at least a 3 week washout period.
62398497|NCT01336647|EXPERIMENTAL|Group B|Group B High-Dose Ha44 Gel 0.74% w/w. Topically administered to hair and scalp. Single application for 10 minutes of duration.
62398498|NCT01336647|PLACEBO_COMPARATOR|Group C|Group C Placebo/ vehicle Ha44 Gel. Topically administered to hair and scalp.Single application for 10 minutes of duration.
62398499|NCT00714831|ACTIVE_COMPARATOR|CG|Control Group
62008906|NCT03792685|EXPERIMENTAL|Normal weight|Normal weight men. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
62008907|NCT03792685|EXPERIMENTAL|Overweight/obesity|Men with overweight or obesity. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
62008908|NCT03792685|EXPERIMENTAL|Diabetes|Men with prediabetes or type 2 diabetes mellitus. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
62008909|NCT02618993|PLACEBO_COMPARATOR|Control group|Control group: Realization of the V3 block with a placebo in maxillofacial surgeries
62008910|NCT02618993|EXPERIMENTAL|Loco-regional anesthesia (LRA) group|Loco-regional anesthesia (LRA) group: Realization of the V3 block with Ropivacaine in maxillofacial surgeries
62194403|NCT05834192|EXPERIMENTAL|Backward treadmill walking group|
62194404|NCT05834192|ACTIVE_COMPARATOR|Lower extremity cross training|
62194405|NCT05733676|ACTIVE_COMPARATOR|Resin Infiltration|Resin infiltration of early intervention of caries lesion as a consequences of orthodontic treatment
62398500|NCT00714831|EXPERIMENTAL|IG|Intervention Group
62398501|NCT06443437|EXPERIMENTAL|study group 1|children who will receive bee-buzzy vibrating cold application
62398502|NCT06443437|ACTIVE_COMPARATOR|study group 2|children who will receive marionette doll
62398503|NCT06443437|OTHER|control group|children who will receive routine care
62398504|NCT06145100||Patients with CVID and autoimmunity and no liver involvement.|Patients with CVID and autoimmune disease, but no liver involvement (normal liver enzymes and normal abdominal ultrasound)
62398505|NCT06145100||Patients with CVID and liver involvement and no clinical significant portal hypertension|Patients with CVID and liver involvement (elevated liver enzymes, abnormal ultrasound and/or abnormal liver biopsy), but no clinically significant portal hypertension
62398506|NCT06145100||Patients with CVID and clinically significant non-cirrhotic portal hypertension|Patients with CVID and clinically significant non-cirrhotic portal hypertension (indicated by the presence of ascites or esophageal varices / portal-hypertensive gastropathy).
62398507|NCT01266967|EXPERIMENTAL|Single Arm|Single arm with 2 cohorts; Cohort A no previous brain therapy and Cohort B previous brain therapy
62398508|NCT06235983|EXPERIMENTAL|LY3537982|LY3537982 administered orally.
62398509|NCT04375033|EXPERIMENTAL|Sublingual Arm|"The sublingual buprenorphine contains naloxone in a ratio of 4:1 and will be prescribed. Consistent with the SAMHSA guidelines, before SL-BUP/NLX is prescribed, participants will be evaluated for recent (within 24 hours) drug use and associated symptoms.~The randomization dose will be determined based on the maintenance dose identified during the induction period, with a target dose of 16-32mg that is standard practice. While the target dose is 16-32mg, doses may go as low as 8mg as occasionally patients prefer lower doses. SL-BUP/NLX will be prescribed at the randomization visit (28-day supply), then every 4 weeks through week 48."
62398510|NCT04375033|EXPERIMENTAL|Injectable Arm|Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously in the abdomen at each 28-day visit. The target dose is 300mg, there is the option to use 100mg dose. The final study dose of injectable buprenorphine will be given at Week 48.
62008911|NCT00012961||Group 1|
62008912|NCT02196597||resection with RCT|rectal resection in the case of rectal carcinoma with preoperative radiochemotherapy
62008913|NCT02196597||resection without RCT|patients with rectal resection without preoperative radiochemotherapy
62398511|NCT06723106|EXPERIMENTAL|RAY121|All enrolled patients will receive RAY121 multiple dose
62573603|NCT03998384|ACTIVE_COMPARATOR|group of autoserum|One of two eyes of one patient which is assessed to have more serious retinal atrophy will receive the retrobulbar injection of autoserum.
62573604|NCT03998384|PLACEBO_COMPARATOR|group of placebo|The other eye which is assessed to have milder retinal atrophy will receive the retrobulbar injection of saline solution.
62008914|NCT00024518|PLACEBO_COMPARATOR|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA). Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
62194406|NCT05733676|ACTIVE_COMPARATOR|Casein Phosphopeptide (CPP) - Amorphous Calcium Phosphate (ACP) - Fluoride|Casein Phosphopeptide (CPP) - Amorphous Calcium Phosphate (ACP) - Fluoride early intervention of caries lesion as a consequences of orthodontic treatment
62398512|NCT05535478|OTHER|STRIDE Intervention|Educational intervention for clinicians
62398513|NCT06464198||Patient|Patients with locally advanced high-grade salivary gland carcinoma after oncological resection
62573605|NCT05436665|ACTIVE_COMPARATOR|UT-DSAEK|"Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (UT-DSAEK) refers to the use of a corneal endothelial/Descemet graft with a thin layer of stroma (\<110um) attached.~The cornea is made up of 5 layers, all of which work to provide a clear image on the retina. The innermost layer of cells, the endothelium, is responsible for pumping fluid out of the cornea and keeping it transparent: a normal endothelium is essential to keeping the cornea clear. The endothelium lies on a membrane called the Descemet membrane. The thickest layer of the cornea is called the stroma and this provides rigidity and strength to the cornea. When the corneal endothelium fails, it cannot regrow and the best treatment is to replace the cells with healthy donor cells. This is called a corneal endothelial transplantation or endothelial keratoplasty.~In the DSAEK technique, a piece of the donor's endothelium is transplanted with a supporting layer of donor stroma."
62398514|NCT01395420|EXPERIMENTAL|1|CAZ104 (2000mg Ceftazidime/500mg Avibactam)
62398515|NCT01395420|EXPERIMENTAL|2|CAZ104 (3000mg Ceftazidime/1000mg Avibactam)
62398516|NCT04568161|EXPERIMENTAL|pre and post chemotherapy assessments|The patients will be assessed before and after chemotherapy treatment.
62782606|NCT03268291|EXPERIMENTAL|"Communicational program Trust"|"The developed program is based on the experience of international research studies and includes the following sections:~* daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials;~* service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators;~* questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services."
62782607|NCT04858295|ACTIVE_COMPARATOR|Texting Arm|"Participants will receive automated text message reminders to check their blood pressure (BP) at least three days per week (participants will choose which days and times to receive reminders). Participants will transmit BP readings with text message to the Way to Health server. If a BP reading is not received within 3 hours, another reminder will be sent. Automated text message feedback will be sent with a tailored message. Participants will asked to set a daily step goal of at least 3,000 steps per day and transmit their step count information from their FitBit. Participants will be reminded once a day to sync their FitBit. Motivating messages will be sent weekly. After 4 weeks, and 8 weeks of the study, a usability survey will be sent. Weekly and daily feedback will be sent. At the conclusion of week 6, individuals will crossover and will continue for an additional 6 weeks using the opposite technology to communicate BP readings."
62194407|NCT04575181|EXPERIMENTAL|NNC0286-0965|NNC0286-0965 administered together with insulin glargine placebo. If previously treated with oral anti-diabetic drugs (OADs), participants will remain on these in the trial
62398517|NCT05648695|EXPERIMENTAL|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
62398518|NCT05648695|PLACEBO_COMPARATOR|Placebo Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7.
62194408|NCT04575181|ACTIVE_COMPARATOR|Insulin glargine|Insulin glargine administered together with NNC0286-0965 placebo. If previously treated with OADs, participants will remain on these in the trial
62194409|NCT05823753|ACTIVE_COMPARATOR|Cannabidiol 900 mg/d|Participants will receive CBD (900 mg/d). Evenly split doses of 450 mg will be taken at morning and evening meals for 3 days, and a 450 mg dose will be taken in the morning of day 4 (before the post-test).
62194410|NCT05823753|ACTIVE_COMPARATOR|Cannabidiol 300 mg/d|Participants will receive CBD (300 mg/d). Evenly split doses of 150 mg will be taken at morning and evening meals for 3 days, and a 150 mg dose will be taken in the morning of day 4 (before the post-test).
62398519|NCT06509048|NO_INTERVENTION|Standard Stimulation|Standard STN-DBS stimulation
62194411|NCT05823753|PLACEBO_COMPARATOR|Placebo|Participants will receive a CBD matching placebo. Evenly split doses will be taken at morning and evening meals for 3 days, and a dose will be taken in the morning of day 4 (before the post-test).
62194412|NCT03384303|OTHER|LBPL-RYGB|
62398520|NCT06509048|EXPERIMENTAL|Theta-Gamma Stimulation|Standard STN-DBS stimulation with addiction of bilateral theta frequency stimulation of ventral contacts
62008915|NCT00024518|EXPERIMENTAL|5,000 Units hrIFN-alpha|hrIFN-alpha = human recombinant interferon-alpha. 5,000 units was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
62008916|NCT00024518|EXPERIMENTAL|30,000 hrIFN-alpha|30,000 units hrIFN-alpha was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
62194413|NCT03384303|OTHER|S-RYGB|
62194414|NCT05062512||Participants living with and without neurodegenerative diseases|No intervention
62398521|NCT01728675|EXPERIMENTAL|Young group|Participants will underwent two isokinetic eccentric exercise sessions
62398522|NCT01728675|EXPERIMENTAL|Elderly group|Participants will underwent two isokinetic eccentric exercise sessions
62398523|NCT01759173||college athletes|
62398524|NCT06580002|EXPERIMENTAL|Riluzole|Study participants randomized to this arm will take 50 mg of riluzole twice daily (every 12 hours) for 8 weeks
62398525|NCT06580002|PLACEBO_COMPARATOR|Placebo|Study participants randomized to this arm will take a placebo, that matches the appearance of 50 mg capsule of riluzole, twice daily (every 12 hours) for 8 weeks
62398526|NCT00509275|EXPERIMENTAL|1|W0027
62398527|NCT00509275|EXPERIMENTAL|2|W0027
62398528|NCT00509275|EXPERIMENTAL|3|W0027
62398529|NCT00509275|PLACEBO_COMPARATOR|4|Placebo
62398530|NCT05525559|EXPERIMENTAL|Dose Escalation|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with ET0038 administered, once daily (QD).
62734640|NCT03198767|EXPERIMENTAL|Part B: LIK066 + 50% CHO + P1: NS / P2: PS / P3: CC|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)
62008917|NCT02465528|EXPERIMENTAL|Inflammatory myofibroblastic tumor (IMT)|Patients diagnosed with IMT with a confirmed translocation involving the ALK gene
62194415|NCT02465736|EXPERIMENTAL|A (DP-RT)|"• Arm A consists of the concurrent chemoradiotherapy prior to surgery. The patient will receive 4 weeks of radiation therapy and 4 weekly cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Chemotherapy is given by intravenous infusion on days 1, 8, 15, and 22.~Interventions:~* Radiation: (44 Gy/20 fractions)~* Drug: Docetaxel~* Drug: Cisplatin"
62008918|NCT02465528|EXPERIMENTAL|Anaplastic large cell lymphoma (ALCL)|Patients with a diagnosis of ALCL histologically or cytologically confirmed to be ALK-positive
62398531|NCT06682494|ACTIVE_COMPARATOR|Traditional Educational Materials|Receiving oral cancer educational materials (handouts from trusted sources such as the Centers for Disease Control (CDC) and American Cancer Association (ACA) and other reliable health education resources.
62398532|NCT06682494|EXPERIMENTAL|Engaging with an AI-powered Chatbot|AI-powered chatbox designed specifically for oral cancer education. The chatbot is programmed to provide accurate information on oral cancer risks, symptoms, preventive measures, and the importance of regular dental check-ups.
62008919|NCT02465528|EXPERIMENTAL|Glioblastoma (GBM)|Patients with GBM with a translocation involving the ALK gene
62008920|NCT02465528|EXPERIMENTAL|Any other ALK-positive tumor|Patients with any other ALK-positive tumor. Patients in this arm included adenocarcinoma (n= 2), sarcoma (1) and other (2).
62008921|NCT06572085|EXPERIMENTAL|Butylphthalide|Butylphthalide and Sodium Chloride Injection 100ml ivgtt bid 14days
62008922|NCT06572085|PLACEBO_COMPARATOR|Saline Solution|Saline Solution 100ml ivgtt bid 14days
62008923|NCT01927770||WES/WGS|Eligible adults (or parents of eligible children) consenting to enroll in an NIH study thatincludes WES/WGS.
62008924|NCT00536367||Patients seen for ADHF at OSUMC|
62008925|NCT05524324|OTHER|CRT ON (biventricular pacing) / CRT OFF (inactive or univentricular pacing)|"Patients with heart failure and SRV and who have a dispositif CRT will be screened for eligibility. If they are eligible and accept to participate (signed informed consent), the order of activation or inactivation of the CRT will be assigned by randomization.Patients randomized into this arm will start the study in CRT ON then CRT OFF mode."
62008926|NCT05524324|OTHER|CRT OFF (inactive or univentricular pacing) / CRT ON (biventricular pacing)|"Patients with heart failure and SRV and who have a dispositif CRT will be screened for eligibility. If they are eligible and accept to participate (signed informed consent), the order of activation or inactivation of the CRT will be assigned by randomization.Patients randomized into this arm will start the study in CRT OFF then CRT ON mode."
62008927|NCT06265220|EXPERIMENTAL|Phase 1: Dose confirmation of AB-101 as Monotherapy|
62008928|NCT06265220|EXPERIMENTAL|Phase 1: Dose confirmation of AB-101 plus Rituximab combination|
62008929|NCT06265220|EXPERIMENTAL|Phase 1: Dose confirmation of AB-101 plus Obinutuzumab combination|
62398533|NCT05644782|ACTIVE_COMPARATOR|Open wheat challenge group|Before starting the elimination diet (time 0, T0), intervention patients will be evaluated by experienced dermatologists, as well as by physicians with expertise in the field of food intolerance about GI and extraintestinal symptoms related to foods intake. Moreover, all these subjects will be subjected to blood, urine, and stools collections, and to a dietary consult, and a food and symptom's diary will be provided to all patients, which must be filled-in daily. After 2 months of elimination diet (time 1, T1), intervention patients will be evaluated again both clinically and by laboratory techniques, identically to T0. At this time-point, intervention patients will go to an open challenge, with reintroduction of wheat. After 2 weeks of open diet or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify (T2int), patients will be valued again both clinically and by laboratory techniques, identically to T0 and T1, and then will end the study.
62008930|NCT03895853|ACTIVE_COMPARATOR|Group I (standard of care)|Patients receive standard of care for septic shock.
62008931|NCT03895853|EXPERIMENTAL|Group II (early metabolic resuscitation)|Patients receive standard of care treatment for septic shock and early metabolic resuscitation (IV) over continuous infusion for up to 7 days.
62008932|NCT03970434|EXPERIMENTAL|Metformin|
62008933|NCT00384137|EXPERIMENTAL|1|
62008934|NCT06259292||HHT patients|Those diagnosed with HHT based on the Curacao diagnostic criteria or genetic testing
62008935|NCT02653677|ACTIVE_COMPARATOR|commercial bread, wheat flour|Intake of the specific kind of bread
62008936|NCT02653677|EXPERIMENTAL|wheat, organic flour|Intake of the specific kind of bread
62008937|NCT02653677|EXPERIMENTAL|wheat, supermarket flour|Intake of the specific kind of bread
62008938|NCT02653677|EXPERIMENTAL|einkorn, organic flour|intake of the specific kind of bread
62008939|NCT04188535|EXPERIMENTAL|Esophageal Cohort|"The research study procedures include:~* Screening for eligibility~* Three MRI scans (prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
62008940|NCT04188535|EXPERIMENTAL|Glioblastoma Cohort|"The research study procedures include:~* Screening for eligibility~* Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
62008941|NCT04188535|EXPERIMENTAL|Glioblastoma Expansion Cohort Serial MR Imaging Registry|"The research study procedures include:~* Screening for eligibility~* Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
62008942|NCT04188535|EXPERIMENTAL|Prostate Cancer Cohort|"The research study procedures include:~* Screening for eligibility~* Three MRI scans prior to start of androgen deprivation therapy, prior to the start of radiation treatment, and after radiation treatment). Imaging with MRI will be performed as per disease site standards.~* Genomic testing of biopsy sample"
62008943|NCT04188535|EXPERIMENTAL|Prostate Cancer Expansion Cohort Serial MR Imaging Registry|"The research study procedures include:~* Screening for eligibility~* Three MRI scans prior to start of androgen deprivation therapy, prior to the start of radiation treatment, and after radiation treatment). Imaging with MRI will be performed as per disease site standards.~* Genomic testing of biopsy sample"
62008944|NCT04188535|EXPERIMENTAL|Vulvar Cancer Cohort|"The research study procedures include:~* Screening for eligibility~* Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
62194416|NCT02465736|EXPERIMENTAL|B (NP-RT)|"• Arm B consists of the concurrent chemoradiotherapy followed by surgery. The patient will receive 4 weeks of radiation therapy and 2 cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Each cycle of chemotherapy lasts 21 days/3 weeks. The drugs include Vinorelbine and Cisplatin.~Interventions:~* Radiation: (44 Gy/20 fractions)~* Drug: Vinorelbine~* Drug: Cisplatin"
62008945|NCT04188535|EXPERIMENTAL|Pediatric Glioma Cohort|"The research study procedures include:~* Screening for eligibility~* Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
62008946|NCT01972360||Diagnosis|Group 3: 99mTCSPECT plus stress echocardiography
62008947|NCT01972360||group 1 : diagnosis|Group 1: 99mTcSPECT plus CMR
62008948|NCT01972360||Group 2: diagnosis|Group 2: 99mTcSPECT plus CT
62008949|NCT01688336|EXPERIMENTAL|FOLFIRINOX|FOLFIRINOX given to all subjects
62194417|NCT01476683|EXPERIMENTAL|FCT|A single 2 x100 mg dose of an experimental Racecadotril Film-coated tablet (FCT) administered orally with 240 ml of water, with a 7- day washout between visits.
62008950|NCT03565185|ACTIVE_COMPARATOR|End-effector|"For stroke rehabilitation 5 days a week in addition to conventional treatment methods robot-assisted gait training(end-effector type-Lokohelp) will be taken with 45 minutes a day for 3 days a week for 4 weeks.~Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level."
62008951|NCT03565185|ACTIVE_COMPARATOR|Exoskeleton|"For stroke rehabilitation 5 days a week in addition to conventional treatment methods robot-assisted gait training (exoskeleton type-Robogait) will be taken with 45 minutes a day for 3 days a week for 4 weeks.~Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level."
62008952|NCT03565185|PLACEBO_COMPARATOR|conventional treatment|conventional treatment methods for stroke rehabilitation 5 days a week Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level.
62008953|NCT06664255||Hypertensive patients|Consecutive hypertensive patients referring to our center, and undergoing systematic diagnostic workup for secondary causes of hypertension
62008954|NCT06572410||Cohort 1|Patient has selected breast conservation therapy
62008955|NCT04793880|EXPERIMENTAL|Medication checklist with cost information|Participants with chronic heart failure with reduced ejection fraction (HFrEF) having a clinic visit at a site randomized to the medication checklist with cost information intervention.
62008956|NCT04793880|ACTIVE_COMPARATOR|Medication checklist|Participants with chronic heart failure with reduced ejection fraction (HFrEF) having a clinic visit at a site randomized to the medication checklist without cost information.
62008957|NCT00797667|EXPERIMENTAL|Telcagepant 140 mg|Participants receive one telcagepant 140 mg tablet and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks
62008958|NCT00797667|EXPERIMENTAL|Telcagepant 280 mg|Participants receive one telcagepant 280 mg tablet and one 140 mg telcagepant placebo, orally, twice daily for 12 weeks
62008959|NCT00797667|PLACEBO_COMPARATOR|Placebo|Participants receive one 140 mg telcagepant placebo and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks
62008960|NCT01980849|EXPERIMENTAL|Long term prophylaxis|Nadroparin, 0.4mL, subcutaneously, qid, given by long-term
62008961|NCT01980849|ACTIVE_COMPARATOR|Short-term prophylaxis|Nadroparin, 0.4mL, subcutaneously, qid, given during hospitalization
62398534|NCT05644782|PLACEBO_COMPARATOR|Placebo group|Before starting the elimination diet (time 0, T0), control patients will be evaluated by experienced dermatologists, as well as by physicians with expertise in food intolerance. Moreover, patients will be subjected to blood, urine, and stools collections, and to a dietary consult, and a food and symptom's diary will be provided. After 2 months of elimination diet (time 1, T1), patients will be evaluated, identically to T0. Then, control patients will be asked to repeat the elimination diet, this time removing wheat and all cow's milk products for further 2 months (T2con). Then, patients will be valued again both clinically and by laboratory techniques, identically to T0 and T1. Then, patients will go to an open challenge, with reintroduction of wheat. After 2 weeks of open diet or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify (T3con), patients will be valued again, identically to T0, T1 and T2con, and then will end the study.
62398535|NCT04920175||NICU Cohort|Participants will undergo a standard polysomnogram
62398536|NCT02505464||Pregnant Women & their fetuses/infants|Information about pregnant women and their fetuses/infants, including the medical history, prenatal, perinatal, and postpartum periods (6 weeks after delivery) and throughout the treatment (e.g.surgery) for the child's medical condition (up to approx. child is @ 6 months of age), will be collected in this repository. The analysis of this information may help in understanding of the causes of fetal anomalies.
62398537|NCT06724679|EXPERIMENTAL|Experimental|
62008962|NCT05446909|EXPERIMENTAL|IBMT mindfulness|An evidence-based preventive intervention - integrative body-mind training (IBMT) has shown positive effects in reducing stress, and improving self-control and brain plasticity related to cognitive performance. It has bodifulness and mindfulness components.
62734641|NCT03198767|EXPERIMENTAL|Part B: LIK066 + 50% CHO + P1: PS / P2: CC / P3: NS|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)
62734642|NCT03198767|EXPERIMENTAL|Part B: LIK066 + 50% CHO + P1: CC / P2: NS / P3: PS|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)
62194418|NCT01476683|EXPERIMENTAL|RPB|A single 2 x100 mg dose of an experimental Racecadotril Powder Blend administered orally with 240 ml of water, with a 7- day washout between visits.
62194419|NCT01476683|ACTIVE_COMPARATOR|TFT|A single 2 x 100 mg dose of a marketed Tiorfast® capsule administered orally with 240 ml of water, with a 7-day washout between visits.
62791825|NCT04383782|EXPERIMENTAL|Expectancy Challenge + Behavioral Activation|In addition to the expectancy challenge intervention (see Expectancy Challenge condition), participants in the Expectancy Challenge + Behavioral Activation group will also receive a novel behavioral activation intervention. Participants will be presented with brief psychoeducation about behavioral activation, several examples of possible functions of cigarette smoking, and several suggestions of behavioral strategies. All participants will receive the same information, but they will be encouraged to apply the information to their personal circumstances and to consider additional examples of rewarding activities they may engage in over the next four weeks. Participants will also be encouraged to engage in at least one behavioral activation activity each week leading up to the follow-up assessment.
62008963|NCT05446909|ACTIVE_COMPARATOR|health education|Health education includes health-related topics - exercise, sleep, stress management, nutrition, lifestyle
62008964|NCT06663397|EXPERIMENTAL|Experimental Group (Laughter Yoga-Supported Childbirth Preparation Training)|Similar to the control group, the training will be conducted by the researcher, covering the same content as the standard childbirth preparation training. However, in addition to this, the experimental group will participate in Laughter Yoga sessions lasting 45 minutes each week for a total of 4 sessions. These sessions will include 30 minutes of laughter and breathing exercises, followed by 15 minutes of laughter meditation and relaxation
62008965|NCT06663397|ACTIVE_COMPARATOR|Control Group (Standard Childbirth Preparation Training)|The sessions will be conducted in groups of 8 participants. Various educational materials, including visual aids, will be used, and the training will involve presentations, direct instruction, video displays, and question-and-answer sessions.
62008966|NCT00349492|ACTIVE_COMPARATOR|EP|etoposide + cisplatin
62008967|NCT06349616|EXPERIMENTAL|Folic acid supplementation|5 mg/day folic acid for 6-7 weeks
62008968|NCT06349616|PLACEBO_COMPARATOR|Control|Cellulose placebo tablet for 6-7 weeks
62008969|NCT05729620|EXPERIMENTAL|STARgraft-3|Participants will be implanted with 6mm diameter STARgraft-3 grafts as an upper arm Brachial Artery to Axillary Vein shunt for hemodialysis access.
62008970|NCT03660046||Depot medroxyprogesterone acetate (DMPA)|This arm includes subjects that choose Depot medroxyprogesterone acetate (DMPA) as contraception.
62008971|NCT03660046||Etonogestrel implant (Eng-Implant)|This arm includes subjects that choose Etonogestrel implant (Eng-Implant) as contraception.
62008972|NCT03660046||Levonorgestrel IUD (Lng-IUD)|This arm includes subjects that choose Levonorgestrel Intrauterine device (Lng-IUD) as contraception.
62008973|NCT03917693|ACTIVE_COMPARATOR|Phytin capsules|2.4 g phytin to be consumed daily for a period of 2 weeks. Participants will consume 2 test capsules containing phytin, 3 times a day with a meal for a period of 2 weeks.
62008974|NCT03917693|PLACEBO_COMPARATOR|Microcrystalline cellulose (MCC) capsules|2.4 g MCC to be consumed daily for a period of 2 weeks. Participants will consume 2 placebo capsules, each containing microcrystalline cellulose, 3 times a day with a meal for a period of 2 weeks.
62008975|NCT01350427|EXPERIMENTAL|Leucine|
62008976|NCT01350427|EXPERIMENTAL|BCAA|
62008977|NCT01350427|PLACEBO_COMPARATOR|Placebo|
62008978|NCT05886764|NO_INTERVENTION|Arm 1 (No Intervention)|"Patient participants in this arm will receive no intervention but will be approached by their providers for participation in treatment clinical trials as per the usual methods.~Provider participants will receive information on available clinical trials for which their patient participant may be eligible from study staff per usual methods. Provider participants will be asked to complete surveys."
62008979|NCT05886764|EXPERIMENTAL|Arm 2 (Digital Intervention)|"Patient participants in this arm will receive digital messages (email, text, etc.) which include general educational information about clinical trials and available resources.~Provider participants will also receive digital messages with educational materials and will receive information on available clinical trials for which their patient participant may be eligible from study staff per usual methods. Provider participants will be asked to complete surveys."
62194420|NCT01476683|ACTIVE_COMPARATOR|TFR|A single 175 mg dose of a marketed Tiorfanor® 175 mg FCT administered orally with 240 ml of water, with a 7-day washout between visits.
62194421|NCT02828397|EXPERIMENTAL|Reference Drug|REGN2222 Reference Formulation
62194422|NCT02828397|EXPERIMENTAL|Test Drug|REGN2222 Test Formulation
62194423|NCT02177253|EXPERIMENTAL|Ipratropium bromide / Salbutamol Inhalation solution|
62194424|NCT02177253|PLACEBO_COMPARATOR|Placebo Inhalation solution|
62194425|NCT02177253|EXPERIMENTAL|Ipratropium bromide Inhalation solution|
62194426|NCT02177253|ACTIVE_COMPARATOR|COMBIVENT Inhalation Aerosol (ipratropium bromide/salbutamol)|
62194427|NCT02177253|PLACEBO_COMPARATOR|Placebo Inhalation Aerosol|
62194428|NCT00600470|EXPERIMENTAL|1|Doctor-office collaborative care management
62194429|NCT00600470|ACTIVE_COMPARATOR|2|"Treatment as usual: psychoeducation and outside referral to treatment (PORT). In papers, this arm is referred to as Enhanced Usual Care (EUC)."
62194430|NCT03923686|EXPERIMENTAL|LAMS plus DPS|Endoscopic ultrasound-guided (EUS) transmural drainage of walled-off pancreatic necrosis (WON) using lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPS).
62194431|NCT03923686|ACTIVE_COMPARATOR|LAMS alone|Endoscopic ultrasound-guided (EUS) transmural drainage of walled-off pancreatic necrosis (WON) using lumen-apposing metal stent (LAMS) alone.
62398538|NCT02726997|EXPERIMENTAL|Treatment (durvalumab, carboplatin, paclitaxel, questionnaire)|"NEOADJUVANT CHEMOTHERAPY: Before debulking surgery, patients receive durvalumab and carboplatin IV over 1 hour on day 1, and paclitaxel IV over 3 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo debulking surgery.~SURGERY: After 3 courses of chemotherapy, patients undergo debulking laparoscopic surgery.~ADJUVANT THERAPY: Beginning after debulking surgery, patients receive carboplatin IV over 1 hour on day 1, paclitaxel IV over 3 hours on days 1, 8, and 15, and durvalumab IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive durvalumab IV over 1 hour on day 1 and 15. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity."
62008980|NCT05886764|EXPERIMENTAL|Arm 3 (Digital Intervention + Community Outreach)|"Patient participants in this arm will receive digital messages (email, text, etc.) which include general educational information about clinical trials and available resources. They will also be invited to contact a Community Ambassador for further information and support in the decision to participate in a clinical trial.~Provider participants will also receive digital messages with educational materials and will receive information on available clinical trials for which their patient participant may be eligible from study staff per usual methods. Provider participants will be asked to complete surveys."
62194432|NCT00844337|ACTIVE_COMPARATOR|1|One study arm will receive injectable gentamicin once daily and oral amoxicillin twice daily for seven days by comparison to other study arms.
62194433|NCT00844337|ACTIVE_COMPARATOR|2|Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days
62194434|NCT00844337|ACTIVE_COMPARATOR|3|Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days (COMPARISON ARM)
62194435|NCT00961506|EXPERIMENTAL|LESS cholecystectomy|LESS cholecystectomy
62194436|NCT00961506|ACTIVE_COMPARATOR|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
62194437|NCT02294747|ACTIVE_COMPARATOR|SHS without TSP|Patients with AO 31 A2 trochanteric fractures operated with sliding hip screw without trochanteric stabilization plate.
62398539|NCT05114031|EXPERIMENTAL|FB101|Active intervention with microbial product FB101
62782608|NCT04858295|ACTIVE_COMPARATOR|mHealth app Arm|"Participants randomized to the mHealth app (Omron Connect) arm will receive reminder messages to check their BP via push notifications from the Omron Connect app at least three times weekly. Upon receipt of the BP reading to the research platform from Omron Connect, participants will receive automatic tailored text message feedback similar to the texting arm. Participants will asked to set a daily step goal of at least 3,000 steps per day and transmit their step count information from their FitBit. Participants will be reminded once a day to sync their FitBit. Motivating messages will be sent weekly. After 4 weeks, and 8 weeks of the study, a usability survey will be sent. Weekly and daily feedback will be sent. At the conclusion of week 6, individuals will crossover and will continue for an additional 6 weeks using the opposite technology to communicate BP readings."
62782609|NCT04596748|PLACEBO_COMPARATOR|Placebo|Participants will be taking a placebo supplement that they will be taking by mouth once per day.
62782610|NCT04596748|EXPERIMENTAL|Probiotic|Participants will be taking a probiotic supplement that they will be taking by mouth once per day.
62782611|NCT05937789|PLACEBO_COMPARATOR|Control1|Participants with serum 25(OH)D levels of 15-19.9 ng/mL, receiving 40 cc. medium-chain triglyceride (MCT) supplement.
62782612|NCT05937789|PLACEBO_COMPARATOR|Control2|Participants with serum 25(OH)D levels of 12-14.9 ng/mL, receiving 50 cc. MCT supplement.
62008981|NCT02417454|EXPERIMENTAL|Probiotic|Participants will undergo the same study procedures as for the comparator; however, the product given will be the active probiotic supplement (ProbioStick).
62194438|NCT02294747|ACTIVE_COMPARATOR|SHS with TSP|Patients with AO 31 A2 trochanteric fractures operated with sliding hip screw with trochanteric stabilization plate.
62194439|NCT01070446|EXPERIMENTAL|1|This study involves children with CF who will take a water soluble vitamin supplement of choline bitartrate, 2 gm per day with meals.
62194440|NCT04205357|OTHER|Sulfasalazine in addition to stereotactic radiosurgery|"3 + 3 dose escalation The first cohort of 3-6 patients will receive 1.5 g Sulfasalazine daily for 3 days before single fraction stereotactic radiosurgery utilizing 12 Gy prescription dose to the tumor margin.~The second, third and fourth cohort will receive 3 days pretreatment with 3 g, 4.5 g and 6 g Sulfasalazine, respectively, before 12 Gy single fraction stereotactic radiosurgery."
62194441|NCT04283708|EXPERIMENTAL|Skeletal chin deficiency|Advancement genioplasty with submental liposuction
62194442|NCT04507633|EXPERIMENTAL|ROMA therapy|ROMA therapy combines four elements including reminiscence, reality orientation, music, and art in the intervention.
62398540|NCT05114031|PLACEBO_COMPARATOR|Placebo|Non-microbial placebo intervention
62008982|NCT02417454|PLACEBO_COMPARATOR|Placebo|Participants will undergo the same study procedures as for the probiotic; however, the product given will be a placebo, identical to the probiotic in taste, smell, colour, and comprised only of the same non-active ingredients in the probiotic supplement
62008983|NCT02640794|ACTIVE_COMPARATOR|Aspirin +clopidogrel|Patients would be randomized within the month prior to the TAVI procedure to receive aspirin/acetylsalicylic acid (80-325 mg/d) + clopidogrel (75 mg/d)
62008984|NCT02640794|ACTIVE_COMPARATOR|Aspirin|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin/acetylsalicylic acid (80-325 mg/d)
62008985|NCT04015661|EXPERIMENTAL|Nab-paclitaxel+Nedaplatin|induction chemotherapy by nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
62008986|NCT04015661|ACTIVE_COMPARATOR|Paclitaxel+Nedaplatin|induction chemotherapy by paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
62008987|NCT02864771||1|Derivation cohort (n=474); may be analyzed separately or combined with cohort #2 to enhance statistical power
62008988|NCT02864771||2|Validation cohort (patient #475 and after); may be combined with cohort #1 to enhance statistical power
62008989|NCT01050595|ACTIVE_COMPARATOR|Methylnaltrexone Bromide|
62008990|NCT01050595|PLACEBO_COMPARATOR|Placebo|
62194443|NCT04507633|NO_INTERVENTION|control group|usual care
62194444|NCT02763215||Total|
62194445|NCT03819634|EXPERIMENTAL|Lantern infusion set|Multi-slitted lantern infusion set
62194446|NCT04621461|PLACEBO_COMPARATOR|Experimental Arm #1|Placebo
62194447|NCT04621461|EXPERIMENTAL|Experimental Arm #2|Zinc sulfate
62008991|NCT01464528|ACTIVE_COMPARATOR|Hyaluronan|Use of hyaluronic acid gel
62008992|NCT01464528|NO_INTERVENTION|control|
62008993|NCT02545907|EXPERIMENTAL|KTD treatment|"Participants in the escalation phase will receive carfilzomib (K), thalidomide (T), and dexamethasone (D) in combination. The dose of thalidomide will be 50mg/day. The dose of dexamethasone will be 20mg on Day 1, 8, and 15. Carfilzomib will be administered on Day 1, 8, and 15, but the level of carfilzomib delivered with depend on the cohort allocation. The dose of carfilzomib may be:~* Level -1 - 27mg/m2~* Level 0 - 36mg/m2~* Level 1 - 45mg/m2~* Level 2 - 56mg/m2~Participants will receive up to six cycles of treatment. Following determination of the maximum tolerated dose and recommended dose, the trial will be opened to an expansion phase where participants will receive the RD of carfilzomib, along with thalidomide and dexamethasone, using the schedule outlined above."
62008994|NCT04065724|OTHER|Physical training resistance and aerobic|Physical training as resistance and aerobic training
62008995|NCT05166434|ACTIVE_COMPARATOR|bone formation around implant at 2mm membrane elevation crestal sinus lifting|
62008996|NCT05166434|ACTIVE_COMPARATOR|bone formation around implant at 4mm membrane elevation crestal sinus lifting|
62008997|NCT05166434|ACTIVE_COMPARATOR|bone formation around implant at 6mm membrane elevation crestal sinus lifting|
62008998|NCT04335344||Control|Healthy patients
62008999|NCT04335344||Periodontitis|Patients with periodontitis
62009000|NCT04335344||Cardiovascular disease|Patients with cardiovascular disease
62009001|NCT04335344||Periodontitis + cardiovascular disease|Patients with Periodontitis + cardiovascular disease
62194448|NCT04211077||Group 1|Occurrence of a SA according to PMSI
62194449|NCT04211077||Group 2|Occurrence of accidental opioid analgesics overdose according to PMSI code
62194450|NCT04211077||Group 3|Controls : Absence of SA and accidental opioid analgesics overdose
62194451|NCT06173011|EXPERIMENTAL|QL2107|QL2107, intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
62009002|NCT03925792|EXPERIMENTAL|Treatment Group|Lifestyle Medicine Group 1
62194452|NCT06173011|ACTIVE_COMPARATOR|Keytruda®(china)|Keytruda® (china), intravenously infusion 35 min (±5min, at least 30min), D1 (Day 1, single dose);
62194453|NCT06173011|ACTIVE_COMPARATOR|Keytruda®(US)|Keytruda® (US), intravenously infusion 35 min (±5min, at least 30min), D1 (Day 1, single dose);
62782613|NCT05937789|PLACEBO_COMPARATOR|Control3|Participants with serum 25(OH)D levels below 12 ng/mL, receiving 60 cc. MCT supplement.
62782614|NCT05937789|EXPERIMENTAL|Vitamin D1|Participants with serum 25(OH)D levels of 15-19.9 ng/mL, receiving vitamin D3 of 576,000 IU supplement
62782615|NCT05937789|EXPERIMENTAL|Vitamin D2|Participants with serum 25(OH)D levels of 12-14.9 ng/mL, receiving vitamin D3 of 720,000 IU supplement
62782616|NCT05937789|EXPERIMENTAL|Vitamin D3|Participants with serum 25(OH)D levels below 12 ng/mL, receiving vitamin D3 of 864,000 IU supplement
62782617|NCT01754571|EXPERIMENTAL|CBT treatment|
62782618|NCT01309971||Questionable occlusal lesions|
62782619|NCT05484869||Early Adolescent Pregnant Women (n:80)|Perinatal and neonatal results of adolescent pregnancies of 16 years and below
62782620|NCT05484869||Very Advanced Maternal Aged Pregnants (n:67)|Perinatal and neonatal results of pregnancies 45 years and older
62782621|NCT05484869||Reproductive period Control Group (n:150)|Reproductive period Pregnant Between 25-35 years
62782622|NCT04775264|EXPERIMENTAL|Pulsed Electric Field Energy Ablation|Ablation of ganglionated plexi (GP) structures on the epicardial surface of the heart delivered as a concomitant procedure during open heart surgery.
62782623|NCT03054779|EXPERIMENTAL|Canola oil|regular canola oil
62782624|NCT03054779|EXPERIMENTAL|High oleic acid canola oil|high stability/high oleic canola oil
62782625|NCT03054779|ACTIVE_COMPARATOR|Western diet oil combination|"a typical Western diet fat intake comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA"
62782626|NCT02843828|EXPERIMENTAL|Samsung Hip Assist v1|gait rehabilitation with Samsung Hip Assist v1 10 sessions (5sessions - treadmill gait training / 5sessions - overground gait training), 30 min per session
62782627|NCT02843828|ACTIVE_COMPARATOR|Conventional gait training|gait rehabilitation without Samsung Hip Assist v1 10 sessions (5sessions - treadmill gait training / 5sessions - overground gait training), 30 min per session
62782628|NCT03725813|EXPERIMENTAL|Person-centred inpatient care|Person-centred inpatient care
62782629|NCT02636023|EXPERIMENTAL|SPhENo-Cardiograph / ECG|SPhENo-Cardiograph and ECG
62782630|NCT02589106|EXPERIMENTAL|Anisotropic Textile Braces|The design of the anisotropic textile braces will provide different mechanisms with rigid, semi-rigid and flexible materials: a) axial elongation through a close fit of the brace supported with textile composites on the lateral sides of the trunk, b) 3-point pressure with push and counter-pushes through semi-rigid pads inserted inside the pocket lining, c) pulling or compression to correct kyphosis or lordosis in the sagittal plane with elastic bands, d) derotation between the pelvis and shoulders with uneven straps, and e) an active mechanism with sensors added to the brace to maintain correct posture.
62009003|NCT03925792|EXPERIMENTAL|Waitlist Control Group|Lifestyle Medicine Group 2
62398541|NCT03090646|NO_INTERVENTION|Standard of Care|Participants in the control arm will be instructed to attend required follow-up as is standard of care, but will not receive a financial incentive.
62782631|NCT01601262|EXPERIMENTAL|Open label|
62782632|NCT03452709|NO_INTERVENTION|Control group: no intervention|Only the normal practise
62782633|NCT03452709|EXPERIMENTAL|therapeutic exercise|In this group the intervention is the prescription of physical activity. The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week.
62782634|NCT03452709|EXPERIMENTAL|ABPM|In this group the arterial pressure is evaluated with ABPM.
62782635|NCT03452709|EXPERIMENTAL|therapeutic exercise + ABPM|
62009004|NCT06364124|EXPERIMENTAL|Treatment arm: standard post-treatment for STEMI and Evolocumab|The intervention group will receive a preoperative subcutaneous injection of Evolocumab (420mg) and standard post-treatment for STEMI
62009005|NCT06364124|ACTIVE_COMPARATOR|Control arm: standard post-treatment for STEMI|Standard post-treatment for STEMI
62782636|NCT03151187|EXPERIMENTAL|Curriculum administered prior to OSCE|Programs randomized to this arm will receive the teaching intervention (two 2 hour lectures) prior to the OSCE.
62782637|NCT03151187|ACTIVE_COMPARATOR|Curriculum administered after OSCE|Programs randomized to this arm will receive the teaching intervention (two 2 hour lectures) after the OSCE.
62782638|NCT02427776|EXPERIMENTAL|IMP|
62782639|NCT06584461|EXPERIMENTAL|Group L: IV Lidocaine Group|Participants in this group will receive a volume of weight\*0.15 ml intravenous (IV) lidocaine at a dose of 1.5 mg/kg diluted to 10 mg/mL, administered at the induction of anesthesia..
62782640|NCT06584461|PLACEBO_COMPARATOR|Group P: Placebo Group|Participants in this group will receive an intravenous placebo (normal saline solution), equivalent in volume (weight\*0.15 ml) to the lidocaine group, administered at the induction of anesthesia.
62782641|NCT06578065|EXPERIMENTAL|ECPS group|Echelon Circular™ Powered Stapler
62009006|NCT04662307|EXPERIMENTAL|Intelligent cardiopulmonary rehabilitation system (ICRS)|The intelligent cardiopulmonary rehabilitation system is designed to improve the user's adherence to pre-determined training intensity. The training intensity is pre-determined using the 60%-80% heart rate reserve which is obtained from the cardiopulmonary exercise test at prestest. The system allows dynamically auto-adjust the paddling resistance in accordance to the patient's current hear rate and paddling rate, with the goal to maintain the patient's heart rate at the pre-determined heart rate zone through the training period.
62194454|NCT06081777||Arms1：For stage III NSCLC patients who underwent complete resection.|"Immunotherapy alone or chemotherapy combined with immunotherapy. Collect patients' baseline puncture tissues, peripheral blood samples from multiple nodes after new adjuvant treatment, surgery (if any), adjuvant treatment, and follow-up, and carry out for 1021-MRD analysis through tumor-informed personalized monitoring MRD test kit.~Assigned Interventions：1021-MRD analysis"
62398542|NCT03090646|EXPERIMENTAL|Financial Incentive|Up to three gift cards to a major online retailer will be mailed to participants assigned to the intervention arm after complete (i.e. all components addressed) and timely (i.e. within the policy-defined follow-up period) submission of follow-up data at each 6-month, 1-year, and 2-year follow-up visit.
62398543|NCT05421689|EXPERIMENTAL|Experimental: 150 x 10⁶ AMDC-GIR dosage|33 subjects will be receiving two doses of 150 x 10⁶ AMDC-GIR spaced 4-6 weeks apart.
62398544|NCT05421689|SHAM_COMPARATOR|Experimental: Identical Placebo composed of the same cryopreservation medium used for AMDC-GIR|33 subjects will be receiving two doses of identical placebo composed of the same cryopreservation medium used for AMDC-GIR. Doses will be spaced 4-6 weeks apart.
62573606|NCT05436665|ACTIVE_COMPARATOR|DMEK|"Descemet membrane endothelial keratoplasty refers to the use of a corneal endothelial/Descemet graft with no layer of associated stroma (15-20um thick).~The cornea is made up of 5 layers, all of which work to provide a clear image on the retina. The innermost layer of cells, the endothelium, is responsible for pumping fluid out of the cornea and keeping it transparent: a normal endothelium is essential to keeping the cornea clear. The endothelium lies on a membrane called the Descemet membrane. The thickest layer of the cornea is called the stroma and this provides rigidity and strength to the cornea. When the corneal endothelium fails, it cannot regrow and the best treatment is to replace the cells with healthy donor cells. This is called a corneal endothelial transplantation or endothelial keratoplasty.~In the DMEK technique only a piece of donor endothelium layer is together with its supporting membrane (the Descemet membrane), is transplanted."
62782642|NCT06578065|ACTIVE_COMPARATOR|MCS Group|2-row circular staplers manual
62573607|NCT03973125|EXPERIMENTAL|Treatment group|The patients in the treatment group receive three monthly intravitreal injection of conbercept followed by PRN rescue treatments such as intravitreal injection of conbercept, laser photocoagulation (when outside the macular) or photodynamic therapy (when in the macular).
62573608|NCT06577506|EXPERIMENTAL|Deaf Diabetes Can Together|
62573609|NCT03788993|EXPERIMENTAL|Blue-depleted evening light condition|
62573610|NCT03788993|ACTIVE_COMPARATOR|Normal light condition|
62734643|NCT00817765|ACTIVE_COMPARATOR|Posaconazole alone|400mg posaconazole BID for 10 days (start on day 1 with 200mg QD, day 2 200mg BID; from day 3 onwards 400mg BID)
62782643|NCT00963794|OTHER|Electromagnetic measurement|Electromagnetic measurement to detect rectal cancer.
62782644|NCT02020317|ACTIVE_COMPARATOR|computer-based reminders and alerts|Behavioral: display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts (decision support in potassium-inc. drug-drug-interactions)
62782645|NCT02020317|NO_INTERVENTION|no computer-based reminders or alerts|Behavioral: no display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
62782646|NCT06201286|EXPERIMENTAL|Mulligan group (MG)|Mulligan group underwent an exercise program planned as 6 sessions. A one-day gap separated each session, and the entire program spanned 11 days. In Mulligan group, they received SNAG and NAGS techniques as part of the Mulligan concept applications, utilizing tools like the Mulligan belt, sponge, and stretcher. Both groups participated in supervised stretching and strengthening exercises.
62782647|NCT06201286|OTHER|Control group|Control group underwent an exercise program planned as 6 sessions. A one-day gap separated each session, and the entire program spanned 11 days. Both groups participated in supervised stretching and strengthening exercises.
62782648|NCT00757822|EXPERIMENTAL|Arm 1|dronabinol
62782649|NCT00757822|ACTIVE_COMPARATOR|Arm 2|ondansetron
62782650|NCT04008251|EXPERIMENTAL|Second generation humanized CAR-T cells|Patients receive humanized CD19 CAR-T cells transduced with a lentiviral vector on days 0/1/2 in the absence of disease progression or unacceptable toxicity.
62009007|NCT04118322|EXPERIMENTAL|intervention group|The patients in the intervention group applied peppermint oil (3%) on lips three times a day, during the five days following chemotherapy administration, in addition to the standard antiemetic treatments. The data were collected using a Patient Information Form, Rhodes Index of Nausea, Vomiting and Retching (INVR), Visual Analog Scale (VAS) Patient Nausea Severity Follow-up Form, Patient Watch Chart, and Oil Application Protocol. Besides, patients in the intervention group were questioned thoughts associated with peppermint oil application using individual in-depth interview method.
62009008|NCT04118322|NO_INTERVENTION|control group|The control group underwent only the routine treatment.
62009009|NCT02012946|ACTIVE_COMPARATOR|dobutamine|patient receiving dobutamine
62009010|NCT02012946|ACTIVE_COMPARATOR|Levosimendan|patient receiving levosimendan
62009011|NCT06664073||Patients will be assessed by supervised cardiology residents in emergency department, within 24 hou|"Patients will be assessed for standardized clinical variables by supervised cardiology residents in emergency department, within 24 hours from ED treatment.~•Routine laboratory values will be collected, cardiac troponins and ECG."
62009012|NCT05919394|ACTIVE_COMPARATOR|Triple treatment with medium doses of CSI/LABA/LA|Medium-dose inhaled triple therapy of inhaled corticosteroid: IC, long-acting beta-agonist: LABA and anticholinergic: LAMA
62009013|NCT05919394|ACTIVE_COMPARATOR|Treatment with high doses of CSI/LABA|High doses of of inhaled corticosteroid: IC and long-acting beta-agonist: LABA
62398545|NCT02651662|EXPERIMENTAL|Dose escalation phase|Safety assessment of odronextamab in combination with cemiplimab and selection of recommended phase 2 dose (RP2D) regimen(s) for the combination of odronextamab and cemiplimab.
62573611|NCT00957320|EXPERIMENTAL|1|"Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL. The dose of sirolimus will be dose escalated following standard phase 1 statistical methods.~For patients with active CNS leukemia, intrathecal methotrexate, hydrocortisone and cytarabine (triple IT) will be administered weekly, with leucovorin rescue at the treating physician's discretion."
62573612|NCT06577974|EXPERIMENTAL|Those treated by COCPs before IVSI|Those with endometrisosis who will undergo ICSI after pretreatment with COCPs
62573613|NCT06577974|EXPERIMENTAL|Those treated by Dionogest before ICSI|Patients diagnosed with endometriosis who will undergo ICSI after oreteatment by dienogest
62009014|NCT03378336||Observational Group|This is an observational study with only one group/cohort with no intervention
62573614|NCT06577974|NO_INTERVENTION|Those undergoing ICSI straighaway|patients diagnosed with endometriosis who will undergo ICSI without any medical pretretament
62573615|NCT01689805||Patients with atopic dermatitis|
62194455|NCT06081777||Arms 2：For stage III NSCLC patients who underwent concurrent radio-chemotherapy.|"Immunotherapy alone or chemotherapy combined with immunotherapy. Collect patients' baseline puncture tissues, peripheral blood samples from multiple nodes after new adjuvant treatment, surgery, adjuvant treatment, and follow-up, and carry out for 1021-MRD analysis through tumor-informed personalized monitoring MRD test kit.~Assigned Interventions：1021-MRD analysis"
62194456|NCT04471545|EXPERIMENTAL|Interventional group|Intervention arm: PECS II block with ropivacaine
62194457|NCT04471545|PLACEBO_COMPARATOR|Control group|Control arm: PECS II block with placebo (saline)
62398546|NCT02651662|EXPERIMENTAL|Dose expansion phase|RP2D administration of the combination treatment.
62398547|NCT05090592||myopic children|Myopic children use overnight orthokeratology or 0.01% atropine eye drop per night for myopia control
62398548|NCT06285890|EXPERIMENTAL|Dose Escalation|If you are found to be eligible to take part in this study, you will be assigned to a dose level of HC-7366 based on when you join this study. Participants enrolled will receive HC-3766 single agent during cycle 1. HC-3766 will be taken once daily while fasting, 1 hour before or 2 hours after a meal, on days 1-28. Cycles 2 and beyond: HC-3766 will be taken once daily while fasting, 1 hour before or 2 hours after a meal, on days 1-28. Azacitidine will be administered either intravenously or subcutaneously on days 1-7 of each cycle. Venetoclax will be taken on daily with water and a meal on days 1-28.
62398549|NCT04159740||Endometriosis - Cases|Premenopausal women with suspected endometriosis, planning to undergo laparoscopic surgery.
62398550|NCT04159740||Controls|Premenopausal women without endometriosis, planning to undergo laparoscopic surgery for non-cancer indications including elective salpingectomy, tubal ligation or surgical procedures for abnormal uterine bleeding
62573616|NCT01689805||Non-atopic controls|
62573617|NCT02684097|ACTIVE_COMPARATOR|Tralokinumab|Tralokinumab subcutaneous injection every two weeks for 24 weeks
62573618|NCT02684097|PLACEBO_COMPARATOR|Placebo|Saline subcutaneous injection every two weeks for 24 weeks.
62573619|NCT06014190|EXPERIMENTAL|Cohort 1 at 4.8 mg/kg of HS-20089 (Phase 2a)|Patients in cohort 1 of phase 2a will be randomly assigned to receive HS-20089 at 4.8 mg/kg or 5.8 mg/kg.
62194458|NCT04157192|ACTIVE_COMPARATOR|Patients receiving real acupuncture treatment|Treatment with needle insertion
62194459|NCT04157192|SHAM_COMPARATOR|Patients receiving sham acupuncture treatment|Treatment without needle insertion
62194460|NCT00307476|ACTIVE_COMPARATOR|rectal trumpet|"Patients meeting all study criteria will be randomized to either the rectal trumpet group or the standard treatment.~For placement of rectal trumpet (Rusch nasopharyngeal airway-32FR):"
62573620|NCT06014190|EXPERIMENTAL|Cohort 1 at 5.8 mg/kg of HS-20089 (Phase 2a)|Patients in cohort 1 of phase 2a will be randomly assigned to receive HS-20089 at 4.8 mg/kg or 5.8 mg/kg.
62573621|NCT06014190|EXPERIMENTAL|Cohort 2 at 5.8 mg/kg of HS-20089 (Phase 2a)|Patients in cohort 2 of phase 2a will receive HS-20089 at 5.8 mg/kg.
62573622|NCT06014190|EXPERIMENTAL|Cohort 3 at 5.8 mg/kg of HS-20089 (Phase 2a)|Patients in cohort 3 of phase 2a will receive HS-20089 at 5.8 mg/kg.
62573623|NCT06014190|EXPERIMENTAL|Cohort 4 at 5.8 mg/kg of HS-20089 (Phase 2a)|Patients in cohort 4 of phase 2a will receive HS-20089 at 5.8 mg/kg.
62573624|NCT06014190|EXPERIMENTAL|Recommended dose of HS-20089 (Phase 2b)|Patients of phase 2b will receive HS-20089 at recommended dose.
62573625|NCT02243722||Larynx pharynx and Esophagus Ca with VCP|The cases of laryngopharyngeal and esophageal cancer with endoscopic characters of vocal fold motion impairment (paralysis or fixation)
62573626|NCT05608915|EXPERIMENTAL|Augmented-Reality Visual Cues|In this single-arm study, all participants will receive all interventions on the same day. They will be wearing an augmented-reality headset that will display a digital obstacle course. Walking performance will be captured with no visual cues, with conventional visual cues, and with augmented-reality visual cues.
62734644|NCT00817765|ACTIVE_COMPARATOR|Fosamprenavir ritonavir|Fosamprenavir 700mg / ritonavir 100mg BID for 10 days
62194461|NCT00307476|OTHER|standard treatment|Patients meeting all study criteria will be randomized to either the rectal trumpet group or the standard treatment. The Numeric Pain Intensity Scale (0-10) or staff observation of physiological indicators (e.g., restlessness, sweating, tachycardia, lacrimation, pupil dilatation, poor ventilator synchrony) for disoriented or unresponsive patients will be used prior to and immediately after placement of either device in order to assess patient comfort. Comfort will be assessed every 8 hours on all oriented patients using the Numeric Pain Intensity Scale.
62194462|NCT02964702|EXPERIMENTAL|Thrombectomy Device(T-01)|Mechanical Thrombectomy with T-01
62194463|NCT04608747|EXPERIMENTAL|Intervention arm|After an overnight fast, participants subjected to baseline measurements and blood and urine collection and then consumed an amount of 50 g of tahini. Blood and urine collection and other measurements were repeated 4 h postprandially.
62573627|NCT02659410|EXPERIMENTAL|Heat stress|4h exposure to heat stress alone or in combination with different solvents. Solvent concentrations are equal to their TLV. Heat conditions are 21, 25 and 30°C (WBGT). Inhalation exposure for all solvents and demal exposure for toluene.
62573628|NCT00409136||Alert|Physicians alerted about their high risk patients who are not receiving any VTE prophylaxis.
62194464|NCT02382562|EXPERIMENTAL|Brief Behavioral Activation Intervention|All eligible participants will undergo the Brief Behavioral Activation Intervention.
62194465|NCT00425607|EXPERIMENTAL|Lonafarnib|All subjects initiated oral Lonafarnib twice daily at a dose of 115mg/m2 and escalated to 150 mg/m2. Two subjects de-escalated to 115mg/m2 following toxicity.
62194466|NCT02127138|EXPERIMENTAL|ATP technique|This arm plan to enroll 158 subjects，Sirolimus-eluting Drug stent implantation via Active transfer of Plaque technique in the treatment of unprotected distal left main bifurcation lesions.In the ATP technique treatment of bifurcation lesions, by the balloon pre-dilation in the target side branch, the plaque will be actively transferred from side branch to main vessel. Subsequently, the plaque will be fixed by the expansive stent in main vessel. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI or stent in SB is recommended if there is at least one of following: residual stenosis\>70%, \>type B dissection and TIMI flow\<3.
62194467|NCT02127138|ACTIVE_COMPARATOR|Provisional T stenting technique|This arm plan to enroll 158 subjects.Sirolimus-eluting Drug stent implantation via Provisional T Stenting technique in the treatment of unprotected distal left main bifurcation lesions.Provisional T stenting technique is the typic step-T stenting. In brief, two wires are advanced to distal MV and SB. Pre dilation is left at operator's discretion, however, pre dilating SB is not encouraged. Kissing balloon inflation before stenting MV is left at operator's discretion. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI is recommended if there is at least one of following: residual stenosis\>70%, \>type B dissection and TIMI flow\<3.
62194468|NCT01377389|EXPERIMENTAL|Ipilimumab + ADT|Ipilimumab 10 mg/kg intravenous (IV) Weeks 5, 9, 13, and 17 plus Androgen Depravation Therapy (ADT) of either Leuprolide 7.5 mg intramuscular (IM) , Goserelin 3.6 mg subcutaneous (SQ) or Degarelix 80 mg SQ once a month for 8 months beginning Week 1.
62194469|NCT03612076||Global cost of management of PJI|
62194470|NCT01077518|EXPERIMENTAL|Ofatumumab and Bendamustine (Arm A)|Up to 8 cycles of bendamustine (90 mg/m2) on Days 1,2 every 21 days with12 doses of ofatumumab (1000 mg, Day 1 q21 days when with bendamustine and q28 days when given as monotherapy)
62194471|NCT01077518|ACTIVE_COMPARATOR|Bendamustine (Arm B)|Up to 8 cycles of bendamustine (120 mg/m2) on Days 1,2 every 21 days
62194472|NCT02385383||Patients with preoperative anemia following treatment protocol|Patients with preoperative anemia according to the WHO definition and treated with a protocol of Iitravenous iron prior to surgery
62194473|NCT02385383||Patients with preoperative anemia - Historical control|Cohort of preoperative anemic patients from the Lundbeckcentre Database. Serving as a historical control
62194474|NCT01721954|ACTIVE_COMPARATOR|Control Arm|Systemic chemotherapy with FOLFOX6m plus or minus bevacizumab repeated every two weeks until evidence of treatment failure.
62194475|NCT01721954|EXPERIMENTAL|Experimental Arm|Systemic chemotherapy with FOLFOX6m plus or minus bevacizumab plus SIR-Spheres microspheres.
62194476|NCT02356705|PLACEBO_COMPARATOR|Saline Placebo|Control patients will receive intranasal saline
62194477|NCT02356705|ACTIVE_COMPARATOR|Nasal Midazolam Only|Patients will receive 0.2 mg/kg of intranasal midazolam
62194478|NCT02356705|ACTIVE_COMPARATOR|Midazolam Plus Xylocaine|Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.
62194479|NCT04183998|EXPERIMENTAL|tsES|trans-spinal Electrical Stimulation (tsES)
62194480|NCT00571441||Primary|All subjects are included in this group, non-randomized observational study.
62194481|NCT03731923|EXPERIMENTAL|High risk group of HCC|High risk group of HCC with chronic hepatitis or liver cirrhosis. Participants undergo biannual ultrasonography and annual abbreviated liver MRI.
62194482|NCT05186311|EXPERIMENTAL|Test product|BD MiniDraw™ Capillary Blood Collection System
62194483|NCT00012064|EXPERIMENTAL|Biological/Vaccine|"Biological/Vaccine: therapeutic autologous dendritic cells.~Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product."
62573629|NCT00409136||No Alert|Physicians not alerted about their high risk patients who are not receiving any VTE prophylaxis.
62573630|NCT04325568|OTHER|Clinician Manual|"Participants in the Clinician Manual arm will be introduced to a trained clinician and will complete one 60-minute session covering equivalent topics addressed in the PsyGist program. The manual will consist of: (1) a section exploring the youth's causal model for their high-risk state; (2) individualization per their causal model; and (3) tutorials that convey the main concepts of genetic malleability.~Clinicians will assess individual causal models via discussion with CHR youth about their at- risk state. Individualization of genetic framing will occur using youths' causal models and will fall into 1 of 3 categories (per PsyGist): 'primarily genetic', 'primarily environmental' or 'combined'."
62573631|NCT04325568|OTHER|AutoTutor (PsyGist)|"AutoTutor is an intelligent system that simulates talking with a human tutor. Our AutoTutor, called PsyGist, has 3 parts: (1) assessment of the youth's causal model for their high-risk state; (2) an individualized 'pre-tutorial' vignette matched to their causal model; (3) a 'tutorial' presenting the 'genetic malleability' framing.~PsyGist will guide participants through its three components."
62194484|NCT06003205|OTHER|Wearable bioimpedance sensor|All subjects will use the investigational device and undergo several interventions: lower body negative pressure (3-40 minutes at 30 mmHg), posture intervention, and pressure intervention.
62194485|NCT01658020|EXPERIMENTAL|DW224|Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days
62194486|NCT01658020|ACTIVE_COMPARATOR|Avelox|Moxifloxacin 400mg tablet P.O. once daily for 7days
62194487|NCT01634269|EXPERIMENTAL|MDT-2111 TAVI 23 mm|Subjects with small annuli and symptomatic severe AS deemed difficult for surgical intervention.
62194488|NCT03131947||Union|Radiological union on RUST score (figure 2) (score of 3 on at least 3 cortices in AP, lateral, medial or posterior cortex - total of 9 or more) within 6 months of surgery
62194489|NCT03131947||Delayed union|Impaired bone healing at six months (RUST score \< 9)
62194490|NCT00984191|EXPERIMENTAL|99mTc positive|99mTechnetium-MIBI SPECT-CT positive compare : Scan - Pathologic report
62782651|NCT05406102|EXPERIMENTAL|Remimazolam group|Patients were slowly injected of 0.08 ug/kg of sufentanil. Patients received remimazolam 0.1mg/kg to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure.
62194491|NCT00984191|EXPERIMENTAL|99mTc Negative_Neck dissection|99mTc Negative but have neck dissection indication compare : 99mTc - Pathologic report
62194492|NCT00984191|EXPERIMENTAL|99mTc Negative_No neck dissection|99mTc Negative and No other indication for neck dissection compare : 99mTc - 7. 131I (post-treatment) whole body scan
62194493|NCT02387151|EXPERIMENTAL|mesenchymal stromal cells|allogeneic mesenchymal stromal cell infusion
62194494|NCT03799419|EXPERIMENTAL|Cognitive bias modification with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of a computerized cognitive training targeting interpretation bias
62194495|NCT03799419|SHAM_COMPARATOR|Psychoeducation with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of psychoeducation
62194496|NCT03799419|EXPERIMENTAL|Approach avoidance training with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of a computerized cognitive training targeting automatic approach tendencies
62194497|NCT03799419|SHAM_COMPARATOR|Inactive sham approach avoidance training|Participants in this group will receive usual treatment in the program and 8 sessions of a sham approach avoidance training
62194498|NCT01417104|ACTIVE_COMPARATOR|Aliskiren|Aliskiren will be administered for 2 weeks at 150mg/day oral pill, followed by 34 weeks oral therapy with 300mg/day
62194499|NCT01417104|PLACEBO_COMPARATOR|Placebo|Placebo (sugar pill) built to mimic both the 150mg Aliskiren tablet ( administered for the first 2 weeks) and the 300mg Aliskiren tablet ( administered for the rest of treatment period)
62194500|NCT04779437|EXPERIMENTAL|Imagery Cognitive Bias Modification First|After completing two weeks of daily QIDS (baseline phase), participants randomly allocated to this arm will complete two weeks of imagery cognitive bias modification followed by two weeks of cognitive control training. Daily QIDS will be completed throughout the intervention phases.
62194501|NCT04779437|EXPERIMENTAL|Cognitive Control Training First|After completing two weeks of daily QIDS (baseline phase), participants randomly allocated to this arm will complete two weeks of cognitive control training followed by two weeks of imagery cognitive bias modification. Daily QIDS will be completed throughout the intervention phases.
62194502|NCT06415604|EXPERIMENTAL|Experimental group|Participants will receive 60-minute weekly online group-based psychoeducation sessions for 12 weeks.
62194503|NCT06415604|ACTIVE_COMPARATOR|Control group|Participants will receive 60-minute weekly online group-based physical health sessions for 12 weeks.
62194504|NCT01651169|EXPERIMENTAL|methylphenidate tablets (10mg), ADHD|Fifteen patients of ADHD
62194505|NCT01651169|EXPERIMENTAL|methylphenidate tablets, Methamphetamine abusers and ADHD|Fifteen patients of ADHD with Methamphetamine abuse for at least 2 years plus
62194506|NCT05941117|ACTIVE_COMPARATOR|weight bearing exercises group|20 patients were assigned to this group with bilateral knees osteoarthritis, they received TENS, stretching exercises and weight bearing strengthening exercises.
62194507|NCT05941117|ACTIVE_COMPARATOR|non-weight bearing exercises group|20 patients were assigned to this group with bilateral knees osteoarthritis, they received TENS, stretching exercises and Non-weight bearing strengthening exercises.
62194508|NCT00379769|EXPERIMENTAL|rosiglitazone in addition to background metformin|Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
62194509|NCT00379769|EXPERIMENTAL|rosiglitazone in addition to background sulfonylurea|Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
62194510|NCT00379769|ACTIVE_COMPARATOR|Sulfonylurea in addition to background metformin|Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.
62194511|NCT00379769|ACTIVE_COMPARATOR|Metformin in addition to background sulfonylurea|Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
62194512|NCT02301377|ACTIVE_COMPARATOR|Intervention Group|Participants will receive a Spiro PD personal spirometer that will allow them to measure their lung function at home and provide medication reminders. Participants will be instructed to use the device to check their lung function once a week. They will also be asked to use the medication reminder feature of their device daily. Participants in this group will receive a telephone call once a week from the research team to review lung function results and answer questions. All participants need to fill out a quality of life questionnaire at the time of enrollment and at the end of the study. Participants will be asked to sign a release form so their pharmacies can be contacted for prescription refill data to monitor adherence over the course of the study. All participants will be asked to come to their quarterly clinic visits with their pediatric pulmonologist where their height, weight, body mass index, lung function and frequency of hospitalizations will be assessed.
62194513|NCT02301377|NO_INTERVENTION|Control|Participants will be asked to fill out a quality of life questionnaire at the time of enrollment and at the end of the study. All participants will be asked to come to their quarterly clinic visits with their pediatric pulmonologist where their height, weight, body mass index, lung function and frequency of hospitalizations will be assessed. All participants will be asked to sign a release form so their pharmacies can be contacted for prescription refill data to monitor adherence over the course of the study.
62194514|NCT03368976||Interscalene|
62194515|NCT03368976||Supraclavicular|
62782652|NCT05406102|ACTIVE_COMPARATOR|Propofol group|Patients were slowly injected of 0.08 ug/kg of sufentanil for 1 min during the examination.Patients received Propofol 1.5mg/kg to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure.
62782653|NCT01386203||Lung Cancer|
62782654|NCT01386203||Lung Cancer after therapy|
62782655|NCT01386203||COPD controls|
62194516|NCT03368976||Infraclavicular|
62194517|NCT03368976||Transversus Abdominus Plane|
62194518|NCT03368976||Paravertebral Space|
62573632|NCT03633123|OTHER|Standard of Care (SoC)|SOC prophylactic treatment pre-operation will be as per Israeli Ministry of Health and international guidelines: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.
62782656|NCT02528786|OTHER|All Participants|Participants who received namilumab previously in M1-1188-002-EM (PRIORA, \[NCT01317797\]) will have blood samples collected on Day 1.
62782657|NCT05348239|EXPERIMENTAL|Oral Chlorophyllin arm|Participants will receive oral Sodium Copper Chlorophyllin at a dose of 750mg once daily (OD) on an empty stomach.
62782658|NCT02487030|EXPERIMENTAL|LDV/SOF 8 wk TN (Cohort 1, Group 1)|LDV/SOF for 8 weeks (treatment-naive (TN))
62782659|NCT02487030|EXPERIMENTAL|LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2)|LDV/SOF+RBV for 8 weeks (treatment-naive)
62782660|NCT02487030|EXPERIMENTAL|LDV/SOF 12 wk TN (Cohort 1, Group 3)|LDV/SOF for 12 weeks (treatment-naive)
62782661|NCT02487030|EXPERIMENTAL|LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4)|LDV/SOF+RBV for 12 weeks (treatment-naive)
62782662|NCT02487030|EXPERIMENTAL|LDV/SOF+RBV 12 wk TE (Cohort 2)|Treatment-experienced (TE) participants who completed treatment in Gilead sponsored study GS-US-334-0138 or in Cohort 1 of this study and did not achieve SVR12 will receive LDV/SOF+RBV for 12 weeks.
62009015|NCT05371587|ACTIVE_COMPARATOR|A - Standard resistance training prescription|"Standard resistance training prescription: participants will perform three sessions per week comprised of six resistance training exercises - horizontal leg press, lat-pulldown, knee extension, chest press, leg curls and shoulder press. They will perform 3 sets of 10 repetitions using 65% percent of the maximal load that can be lifted once according to a one repetition maximum (1RM) test. Their progression model will be as follows:~Weeks 1-3 65%1RM; Weeks 4-6 70%1RM; 1RM reassessment at week 6; Weeks 7-9 70% of the updated 1RM; Weeks 10-12 75%1RM.~Prior to beginning of the program four visits will take place:~1. Laboratory visit for measuring physiological and anthropometric outcomes (see outcomes section)~2. 1RM testing~3. Endurance and maximal voluntary contraction testing + introduction with the exercise program~4. A second introduction session with the exercise program"
62194519|NCT03368976||Fascia Iliaca|
62194520|NCT03368976||Femoral Nerve|
62194521|NCT03368976||Saphenous Nerve via Adductor Canal|
62194522|NCT03368976||Popliteal Sciatic Nerve|
62194523|NCT00953732||1|
62194524|NCT05262751|EXPERIMENTAL|Cohort 1|Each participant received: Nintedanib formulation 1: Monolithic Nintedanib Modified Release Tablet (MR1) as two Prototypes (MR1-1 and MR1-2), compared to the reference (R) treatment: Nintedanib formulation 3: Ofev®.
62194525|NCT05262751|EXPERIMENTAL|Cohort 2|Nintedanib formulation 2: Polyox Nintedanib Modified Release Tablet (MR2) as two Prototypes (MR2-1 and MR2-2) compared to the reference (R) treatment: Nintedanib formulation 3: Ofev®.
62194526|NCT01594645|EXPERIMENTAL|Spermatozoa election using a polscope|AR+ spermatozoa are selected for ICSI using a polscope
62398551|NCT05058677|EXPERIMENTAL|aerosolized lidocaine then Instilled lidocaine solution then instilled saline solution|Treatment will be performed before the endotracheal suctioning
62194527|NCT01594645|ACTIVE_COMPARATOR|Control|Spermatozoa for ICSI are selected based on morphology and motion under conventional light microscopy
62782663|NCT02487030|EXPERIMENTAL|LDV/SOF 12 wk TE (Cohort 3, Group 1)|LDV/SOF for 12 weeks (treatment-experienced)
62194528|NCT02023359||Treatment|Everolimus and exemestane
62782664|NCT02487030|EXPERIMENTAL|LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2)|LDV/SOF+RBV for 12 weeks (treatment-experienced)
62194529|NCT03930329|EXPERIMENTAL|MBRP group|The mindfulness-based relapse prevention program consists of eight weekly 2-hour sessions. It combines mindfulness with evidence-based cognitive behavioural techniques that help participants to recognize internal and external triggers of their substance abuse, including smoking. Each session consists of mindful practices with cognitive exercises. The standardized treatment manual was published
62194530|NCT03930329|NO_INTERVENTION|usual care|All participants in this trial will receive usual care, which consists of 8-12 weeks of counselling and drug treatment to help smokers quit. Data from the centre shows that approximately 50% of smokers are successfully abstinent from smoking at end of the program, as confirmed by the carbon monoxide breath test. This trial will only recruit those who successfully quitted smoking. During this 8-12 week program, written information about relapse prevention is given, including information for maintaining healthy lifestyles (e.g. diet/sleep/exercise/emotional control). Participants will receive follow-up phone interviews by trained smoking cessation counsellors at end of the program (week 8-12)
62194531|NCT03333161|EXPERIMENTAL|Higher TcCO2|"The investigators will evaluate the effects of attempts to increase blood carbon dioxide levels within a narrow range of 5 mm Hg (well within the range of usual clinical practice) in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.~The investigators will attempt to adjust PCO2 by 5 mm Hg higher from baseline (to max of 70 mm Hg), as long as pH is \>7.2. The first 24 hours of the data collection will be the baseline data. Over the next 72 hours, the investigators will evaluate 3 interventions in a cross-over manner, with the initial intervention randomly assigned: Intervention 1 (24-48h of data; Increase TcCO2 by 5 mm Hg), Intervention 2 (48-72h; TcCO2 back to baseline), and Intervention 3 (72-96h; increase TcCO2 again by 5 mm Hg)."
62398552|NCT05058677|EXPERIMENTAL|aerosolized lidocaine then instilled saline solution then Instilled lidocaine solution|Treatment will be performed before the endotracheal suctioning
62398553|NCT05058677|EXPERIMENTAL|Instilled lidocaine solution then aerosolized lidocaine then instilled saline solution|Treatment will be performed before the endotracheal suctioning
62398554|NCT05058677|EXPERIMENTAL|Instilled lidocaine solution then instilled saline solution then aerosolized lidocaine|Treatment will be performed before the endotracheal suctioning
62398555|NCT05058677|EXPERIMENTAL|Instilled saline solution then aerosolized lidocaine then Instilled lidocaine solution|Treatment will be performed before the endotracheal suctioning
62573633|NCT03633123|EXPERIMENTAL|D-PLEX + SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
62782665|NCT04471324|EXPERIMENTAL|EBUS cryo probe|Patients receive a transbronchial cryobiopsy using an eBUS cryo probe
62782666|NCT04792411|EXPERIMENTAL|Prehabilitation group|This arm will be subject to at least 6 weeks of a tailored prehabilitation programme
62791826|NCT04383782|PLACEBO_COMPARATOR|Neutral Reading|The control group will receive neutral reading materials related to the components and structure of a cigarette. The content will be strictly curated so as to avoid inadvertently encouraging or discouraging smoking among participants.
62194532|NCT03333161|ACTIVE_COMPARATOR|Lower TcCO2|"The investigators will evaluate the effects of attempts to decrease blood carbon dioxide levels within a narrow range of 5 mm Hg (well within the range of usual clinical practice) in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.~The investigators will attempt to adjust PCO2 by 5 mm Hg lower than baseline (to minimum of 40 mm Hg), as long as pH is \<7.45."
62782667|NCT01894243|OTHER|Normal hepatic function|"Patients with:~(i) negative result for serum hepatitis B surface antigen and hepatitis C antibody (ii) total bilirubin ≤1.5 x institutional upper limit of normal (ULN), albumin and prothrombin time within normal limits and must not have ascites (unless related to disease under study) or encephalopathy (iii) aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST), alanine aminotransferase or serum glutamic pyruvic transaminase (ALT) ≤2.5 x institutional ULN unless liver metastases are present in which case it must be ≤5 x ULN"
62782668|NCT01894243|OTHER|Mild hepatic impairment|As defined by the Child-Pugh Classification System.
62782669|NCT01894243|OTHER|Moderate hepatic impairment|As defined by the Child-Pugh Classification System.
62782670|NCT01548508|EXPERIMENTAL|Functionnal ElectroStimulation (FES)|
62782671|NCT01548508|SHAM_COMPARATOR|SHAM|
62398556|NCT05058677|EXPERIMENTAL|Instilled saline solution then Instilled lidocaine solution then aerosolized lidocaine|Treatment will be performed before the endotracheal suctioning
62398557|NCT04526639|EXPERIMENTAL|Virtual Reality games for training executive functions|Virtual Reality games for training three core executive functions
62398558|NCT04526639|PLACEBO_COMPARATOR|Control VR Game on Playground|A relaxing virtual reality game for control group to play in VR playground without training their executive functions
62782672|NCT03875352|EXPERIMENTAL|Neutropenia patients|Patients with neutropenia were treated using the CHG and HMG technique.
62782673|NCT03875352|EXPERIMENTAL|No neutropenia patients|Patients with no neutropenia were treated using the CHG and HMG technique.
62782674|NCT03077204|OTHER|BIO4 treatment|Patients undergoing 1 or 2-level Anterior Cervical Discectomy and Fusion (ACDF) spine surgery utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).
62782675|NCT05933668|EXPERIMENTAL|YK0901 cells|"Patients will undergo lymphocytapheresis, then treatment with TCR-T cells (at escalating doses) + IL-2.Accelerated titration and 3 + 3 dose escalation were used in this trial . Five dose levels were set up: the dose level was 1: 1× 108 ± 20%（8×107\~1.2×108）; the dose level was 2: 1 × 109 （±20%：8×108\~1.2×109）; the dose level was 3: 5 × 109 （±20%：4×109\~6×109）; the dose level was 4: 2 × 1010 （±20%：1.6×1010\~2.4×1010）; the dose level was 5: 5 × 1010 （±20%：4×1010\~6×1010）."
62782676|NCT05411939|OTHER|Control|Patients in the control arm of the study will watch a short video and then receive standard of care counseling with an orthopaedic surgeon.
62782677|NCT05411939|EXPERIMENTAL|Shared Decision-Making Tool|Patients in the treatment arm of the study will watch a short video and then receive standard of care counseling with an orthopaedic surgeon that includes discussion of the shared decision-making tool.
62398559|NCT03734874|ACTIVE_COMPARATOR|hesperidin|
62398560|NCT03734874|PLACEBO_COMPARATOR|control|
62398561|NCT06723431||(A)Patient with seizure received rescue interventional (B) Patient with seizure didn't receive it|"We will do 2 groups :~Group A: Patient with recurrent attack of seizure and with prolonged seizure with prescribed treatment at home, Patients aged from 2 years to 18 years, Received rescue intervention.~Group B: Patient with recurrent attack of seizure and with prolonged seizure without prescribed treatment at home, Patients aged from 2 years to 18 years, didn't Received rescue intervention."
62398562|NCT04114227|ACTIVE_COMPARATOR|Acceptance and Commitment Therapy|Participants will learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors.
62398563|NCT04114227|ACTIVE_COMPARATOR|Supportive Psychotherapy|Participants will talk about their experiences to date.
62782678|NCT05704790|EXPERIMENTAL|Intervention|The intervention will include 5 weekly sessions (60-90 minutes each) of cognitive compensatory training (CCT) delivered virtually by a pediatric neuropsychologist.
62782679|NCT04398550|EXPERIMENTAL|Specific Carbohydrate Diet|Exclusive consumption of the specific carbohydrate diet for 6 weeks
62782680|NCT04398550|EXPERIMENTAL|Mediterranean Diet|Exclusive consumption of the Mediterranean diet for 6 weeks
62782681|NCT03100773|EXPERIMENTAL|Group control|Caries-free children submitted to four consecutive sessions of oral health educational strategy (once a week).
62398564|NCT05663749|ACTIVE_COMPARATOR|Metformin arm|1000mg for 8 weeks
62398565|NCT05663749|EXPERIMENTAL|Topiramate arm|50mg for 8 weeks
62398566|NCT06557967||mNSCLC - Overall|Participants with diagnosis of mNSCLC during study period (01/01/2015-06/30/2023)
62398567|NCT06557967||mNSCLC - 1st Line of Therapy|Participants with diagnosis of mNSCLC during study period (01/01/2015-06/30/2023) treated with systemic anti-cancer therapy in first line setting.
62398568|NCT06557967||mNSCLC - 2nd Line of Therapy|Participants with diagnosis of mNSCLC during study period (01/01/2015-06/30/2023) treated with systemic anti-cancer therapy in second line setting.
62398569|NCT06557967||mNSCLC - 3rd Line of Therapy|Participants with diagnosis of mNSCLC during study period (01/01/2015-06/30/2023) treated with systemic anti-cancer therapy in third line setting.
62573634|NCT06282016||Cases|Patients with a neuroendocrine neoplasm of the bronchopulmonary or gastroenteropancreatic system diagnosed in the years 2020 or 2021
62194533|NCT04811144|EXPERIMENTAL|Cavity group|The 35 participants accepted Er:YAG laser treatment for dental cavity. Each participant was collected their data including history records, affected range check, X-ray\&photo, treatment, pain index check, return visit check after two weeks by researchers.
62194534|NCT04811144|EXPERIMENTAL|Sensitive Teeth group|The 35 participants accepted Er:YAG laser treatment for sensitive teeth. Each participant was collected their data including history records, sensitive check, X-ray\&photo, treatment, pain index and effectiveness check, return visit check after two weeks by researchers.
62782682|NCT03100773|EXPERIMENTAL|Group of strategy + ART|Children with at least one decayed primary molar in dentin submitted to four consecutive sessions of oral health educational strategy (once a week) followed by Atraumatic Restorative Treatment (ART)
62782683|NCT03100773|EXPERIMENTAL|Group of ART|Children with at least one decayed primary molar in dentin submitted to Atraumatic Restorative Treatment (ART)
62194535|NCT04811144|EXPERIMENTAL|Abnormal Frenum Attachment group|The 35 participants accepted Er:YAG laser treatment for Abnormal Frenum Attachment. Each participant was collected their data including history records, abnormal position check, photo, cutting, pain index check, return visit check after three, five and seven days. by researchers.
62398570|NCT05375045||prospective|A prospective cohort will be recruited into the study to meet the secondary objective of improving quality of life. In fact, to measure the improvement in quality of life, a questionnaire must be completed by the patient before the implant is placed. Answers to this questionnaire preoperatively cannot be collected for patients recruited retrospectively.
62009016|NCT05371587|EXPERIMENTAL|B- Autonomy and perceptions approach to resistance training (APART)|"Participants will perform 3 sessions/week of the same exercises. They will perform 3 sets of each exercise, self-select the load they lift in each set and perform repetitions aiming to reach a level of effort of 7-8 on a 0-10 rating of perceived effort scale (RPE) at the end of the set. Their progression model will be as follows: Weeks 1-3 RPE 7/10; Weeks 4-12 RPE 8/10. The selected RPE score of 7 and then 8 out of 10 has been shown to lead to increases in maximal strength in previous research. Prior to beginning of the program four visits will take place:~1. Laboratory visit (similar to standard).~2. 1RM testing where the principles of perceived effort will be introduced.~3. Endurance and maximal voluntary contraction testing + introduction with the exercise program. Participants will practice how to self-select the load they prefer and then perform repetitions leading to the target RPE score.~4. A second introduction session with the exercise program and the RPE construct."
62398571|NCT05375045||retrospective|Patients who received one or more EUROTEKNIKA implants before 2017 may be included in the study for the retrospective cohort
62398572|NCT05619263|NO_INTERVENTION|Control|Caregivers who consent to participate, complete a baseline survey, and are assigned to the control arm will receive a four-page handout on Emergency Preparedness published by the Alzheimer's Association that provides tips on preparing for disasters and what to do during and after a disaster. Control participants will complete follow-up surveys at 3 and 6 months, similar to intervention participants.
62573635|NCT06282016||Controls|Patients without a neuroendocrine neoplasm of the bronchopulmonary or gastroenteropancreatic system diagnosed in the years 2020 or 2021 (=no documented diagnosis of neuroendocrine neoplasm of the bronchopulmonary or gastroenteropancreatic system in the Bavarian Cancer Registry)
62398573|NCT05619263|EXPERIMENTAL|Disaster PrepWise-Caregiver Intervention|Caregivers who consent to participate, complete a baseline survey, and are assigned to the intervention arm will receive a Disaster PrepWise-Caregiver program from a trained interventionist and receive a completed household emergency management plan. Control participants will complete follow-up surveys at 3 and 6 months, similar to intervention participants.
62398574|NCT05579600|EXPERIMENTAL|Caring Contact letters|Caring Contact letters will be mailed to a randomly selected group of managed care subscribers over a 6-month period following jail release.
62573636|NCT04228679|EXPERIMENTAL|Erbium laser treatment|Women with vaginal looseness and sexual dysfunction treated with real laser.
62573637|NCT04228679|SHAM_COMPARATOR|Sham laser treatment|Women with vaginal looseness and sexual dysfunction treated with sham laser.
62573638|NCT02810041|EXPERIMENTAL|yoghurts enriched with XXS|
62573639|NCT02810041|PLACEBO_COMPARATOR|yoghurts non enriched with XXS|
62573640|NCT03595514|ACTIVE_COMPARATOR|Single Injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus
62782684|NCT00605345|EXPERIMENTAL|CERA Treatment Once Monthly|
62573641|NCT03595514|EXPERIMENTAL|Double Injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus as well as at the intersection of the subclavian artery and the medial cord.
62782685|NCT00605345|ACTIVE_COMPARATOR|Darbepoetin Alfa Once Biweekly|
62782686|NCT04186338||Patients with myelomeningocele|Patients diagnosed myelomeningocele with the neurological level between L5 and S3
62782687|NCT04186338||Healthy controls|age-, sex-, and body mass index-matched healthy controls
62791827|NCT04355546||COPD patients|Trimbow 87/5/9 pMDI for COPD prescribed according to licensed indication
62009017|NCT06572800|EXPERIMENTAL|Health services research (DiviTum-TKa)|Patients undergo collection of blood samples per SOC on days 1, 15, and 28 of cycle 1, days 15 and 28 of cycle 2, days 15 and 28 of cycle 3, and day 28 of subsequent cycles for up to 12 cycles for analysis by DiviTum-TKa in the absence of disease progression or unacceptable toxicity.
62782688|NCT05485285||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
62573642|NCT04694599|EXPERIMENTAL|Early intervention|The experimental group will receive oxygen supplementation when oxygen saturation decreases according to the monitoring of wearable devices.
62782689|NCT05485285||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
62009018|NCT00575744|NO_INTERVENTION|1|
62009019|NCT00981500||Gastric Bypass|morbidly obese subjects undergoing gastric bypass surgery
62194536|NCT04811144|EXPERIMENTAL|Peri-implantitis intervention group|The 12 participants accepted Er:YAG laser treatment for Peri-implantitis. Each participant was collected their data including History records, measure periodontal pocket depth, anaerobes collect, X-ray, photo, CT, treatment, pain index check, return visit check after one week, two weeks, four weeks and three months, and six month check the effectiveness and collect anaerobes during every return visit. In the last return visit, X-ray and CT would be included
62194537|NCT04811144|NO_INTERVENTION|Peri-implantitis control group|The 12 participants accepted mechanical debridement for Peri-implantitis. Each participant was collected their data including History records, measure periodontal pocket depth, anaerobes collect, X-ray, photo, CT, treatment, pain index check, return visit check after one week, two weeks, four weeks and three months, and six month check the effectiveness and collect anaerobes during every return visit. In the last return visit, X-ray and CT would be included
62398575|NCT05579600|EXPERIMENTAL|Reports, re-engagement, and training|Behavioral health providers (n=120) will be trained in evidence-based suicide prevention screening and intervention practices, in addition to receiving weekly reports with information on clients who have been released from jail to encourage outreach efforts for re-engagement with the healthcare system.
62398576|NCT05398809|EXPERIMENTAL|Ruxolitinib/APECED-AA Patients|All participants receiving IP through this protocol (APECED-AA patients)will receive ruxolitinib.
62782690|NCT02359513|EXPERIMENTAL|boulimic|Analyse of serotoninergic brain activity (determined by positron emission tomography using \[18F\]MPPF) from bulimic patients treated with serotoninergic antidepressants during 3 months. The serotoninergic brain activity is measured before adnd after the serotoninergic antidepressant treatment.
62782691|NCT03799276|EXPERIMENTAL|Opticare study|"Phase I: Identification and Selection of study population The first step will include an active search by OPTICARE team for vulnerable and lost to follow up patients~Phase II: Implementation of the individualized follow-up program The patients who agree to participate to the program will be defined as the OPTICARE population."
62782692|NCT02021903|EXPERIMENTAL|HGPO + Placebo|V1: HGPO 75 mg + meal and V2: Placebo 75 mg + meal
62782693|NCT02021903|PLACEBO_COMPARATOR|Placebo + HGPO|V1: Placebo 75 mg + meal and V2: HGPO 75 mg + meal
62782694|NCT00033553|EXPERIMENTAL|Paclitaxel + Carboplatin|Paclitaxel and carboplatin induction (2 cycles)followed by chemotherapy with the addition of radiotherapy for 7 cycles
62782695|NCT00033553|EXPERIMENTAL|Gemcitabine + Carboplatin|Gemcitabine and carboplatin induction (2cycles) followed by chemotherapy with the addition of radiotherapy for 7 cycles
62782696|NCT00371904|EXPERIMENTAL|1|
62782697|NCT00371904|ACTIVE_COMPARATOR|2|
62009020|NCT00981500||gastric banding|morbidly obese subjects undergoing laparoscopic gastric banding surgery
62194538|NCT05375097||Erenumab responder patients|Patients who met the responder definition of two or more erenumab prescriptions with no evidence of switch to other CGRPi were included in the main analyses
62194539|NCT05375097||Migraine controls|Age and gender matched migraine patients on triptan medication, excluding those on botulinum toxin, erenumab and fremanezumab to benchmark the level of HCRU, sick leaves, and medication patterns
62398577|NCT00206700|EXPERIMENTAL|Arm 1|
62782698|NCT04377555|EXPERIMENTAL|All Participants|Main study participants will be evaluated at baseline, monitored and followed for a 1 year period with the option to participate in a 1 year extension. Participants in the CSF substudy will be followed for two years and will receive two additional doses of 600 mg ocrelizumab at Weeks 48 and 72.
62398578|NCT05191199||Normal erectile response|Peak systolic velocity above 35cm/s, EDV below 5cm/s, Erectile score 4 or 3
62398579|NCT05191199||Abnormal erectile response|Peak systolic velocity below 35cm/s, EDV above 5cm/s, Erectile score 2 or 1
62782699|NCT01279681|ACTIVE_COMPARATOR|Arm A [fluoropyrimidine + bevacizumab (BEV)]|Patients receive either 5FU/LV or Capecitabine, plus BEV. 5FU/LV + BEV is comprised of 5FU IV over 46-48 hours, LV calcium IV over 2 hours, and BEV IV over 10-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Capecitabine + BEV is comprised of capecitabine PO BID on days 1-14 and BEV IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62194540|NCT06390384|OTHER|Intervention group|blinded-care counselling + App STEPS + digital and mental literacy training
62398580|NCT03383276|EXPERIMENTAL|IL-1Ra|
62398581|NCT04516798|EXPERIMENTAL|Experiment|Local and whole body vibration were applied
62398582|NCT03841331|EXPERIMENTAL|5 mg Serlopitant Tablets|Serlopitant Tablets
62398583|NCT03841331|PLACEBO_COMPARATOR|5 mg Placebo Tablets|Placebo Tablets
62009021|NCT00981500||sleeve gastrectomy|morbidly obese subjects undergoing sleeve gastrectomy
62009022|NCT02880371|EXPERIMENTAL|Phase 1b/Part A|Patients in Part A will receive escalating doses of single-agent ARRY-382 in combination with 2 mg/kg pembrolizumab.
62009023|NCT02880371|EXPERIMENTAL|Phase 2|Patients in Phase 2 will receive the MTD/RP2D dose of ARRY-382 determined during Part A in combination with 200mg pembrolizumab.
62009024|NCT04488276||Pregnant women|Non smoking pregnant and post-partum women
62009025|NCT04488276||Smoking fathers|Expectant or new fathers who smoke
62573643|NCT04694599|ACTIVE_COMPARATOR|Typical|The control group will receive oxygen supplementation when oxygen saturation decreases according to typical periodical monitoring.
62573644|NCT05312463|EXPERIMENTAL|Tongjiang granule group|Experiment group: oral administration of Tongjiang granule with warm water after meal for 1 bag each time for three times a day. The medication period was 4 weeks.
62194541|NCT06390384|NO_INTERVENTION|TAU group (Treatment as Usual)|digital and mental literacy training
62194542|NCT04591379|EXPERIMENTAL|Intervention arm|
62194543|NCT03608059|EXPERIMENTAL|ATG/PTCy|The GvHD prophylaxis consisted of ATG 2.5mg/kg administered on day -2 to -1 and cyclophosphamide (Cy) 50 mg/kg on day +3, cyclosporine A (CsA) and mycophenolate mofetil (MMF) initiating on day +4. CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 3 times per day (maximum dose 3g per day) until day +34 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
62194544|NCT03608059|ACTIVE_COMPARATOR|standard ATG|The GvHD prophylaxis consisted of ATG 2.5mg/kg administered on day -4 to -1 , cyclosporine A (CsA) initiating on day -5 and mycophenolate mofetil (MMF) initiating on day +1 . CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 2 times per day (maximum dose 2g per day) until day +30 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
62194545|NCT03608059|ACTIVE_COMPARATOR|standard PTCy|The GvHD prophylaxis consisted of cyclophosphamide (Cy) 50 mg/kg on day +3, +4,cyclosporine A (CsA) and mycophenolate mofetil (MMF) initiating on day +5. CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 3 times per day (maximum dose 3g per day) until day +35 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
62194546|NCT03653767|NO_INTERVENTION|Control Group|The control group will use conventional school furniture.
62398584|NCT03540628|NO_INTERVENTION|Placebo Arm|The control arm of our randomized trial will receive a second pressor agent, hydrocortisone and standard of care to care for septic shock. The IV bags will be blinded by pharmacy. If the patient needs additional pressor support or therapy, the data will be recorded in the results.
62573645|NCT05312463|PLACEBO_COMPARATOR|Tongjiang granule simulant group|Control group:oral administration of Tongjiang granule simulant with warm water after meal for 1 bag each time for three times a day. The medication period was 4 weeks.
62573646|NCT00606385|EXPERIMENTAL|laparoscopic liver resection|Patients who underwent laparoscopic liver resection for HCC
62194547|NCT03653767|EXPERIMENTAL|Adjustable Furniture Group|The experimental group will use adjustable ergonomic school furniture.
62194548|NCT00412607|EXPERIMENTAL|NaviStar ThermoCool Catheter|
62194549|NCT02409095|EXPERIMENTAL|DISPOSABLE-SYRINGE JET INJECTOR (DSJI)|Subjects in this arm will be given three deep intramuscular doses, 0.5 mL each dose 4 weeks apart, of Serum Institute of India Ltd.'s DTP-HB-Hib vaccine (Brand name: Pentavac) via Disposable Syringe Jet Injector (Brand Name:Stratis) of Pharmajet Inc
62194550|NCT02409095|ACTIVE_COMPARATOR|NEEDLE & SYRINGE (N-S)|Subjects in this arm will be given three deep intramuscular doses, 0.5 mL each dose 4 weeks apart, of Serum Institute of India Ltd.'s DTP-HB-Hib vaccine (Brand name: Pentavac) via conventional needle and Syringe
62194551|NCT03460054||IgA Nephropathy (IgAN)|Biopsy-Proven IgAN
62194552|NCT03460054||Focal Segmental Glomerulosclerosis (FSGS)|Biopsy-Proven FSGS
62194553|NCT03460054||Membranous Nephropathy (MGN)|Biopsy-Proven MGN
62194554|NCT03460054||Mesangioproliferative Glomerulonephritis (MPGN)|Biopsy-Proven MPGN
62398585|NCT03540628|EXPERIMENTAL|Thiamine and Vitamin C administration Arm|The experimental arm will receive a second pressor agent and hydrocortisone, plus thiamine and vitamin C along with the standard of care. The IV bags will be blinded by pharmacy. If the patient needs additional pressor support or therapy, the data will be recorded in the results.
62194555|NCT03460054||Minimal Change Disease (MCD)|Biopsy-Proven MCD
62194556|NCT01893489|ACTIVE_COMPARATOR|Atherosclerosis|coronary artery disease patients with carotid plaques confirmed by a ultrasound study
62398586|NCT06722755|EXPERIMENTAL|Intensive Support|The Intensive Support (IS) group will receive the multicomponent intensive behavioral adherence program, which includes a CPAP technical support intervention, Motivational Enhancement Therapy (MET), and a Mobile Health intervention. Participants assigned to the IS group will also receive the 3 basic supportive treatments, including OSA and CPAP education, respiratory therapy and nursing support during inpatient rehabilitation, and referral to a DME company after inpatient rehabilitation discharge if needed.
62398587|NCT06722755|ACTIVE_COMPARATOR|Standard Support|Participants assigned to the control group will receive only the 3 basic supportive treatments, including OSA and CPAP education, respiratory therapy and nursing support during inpatient rehabilitation, and referral to a DME company after study completion if needed. CPAP will be set up by the respiratory therapist (or similar personnel) on the inpatient rehabilitation (IPR) unit with standard mask fitting and troubleshooting, if available. Assistance with mask placement will be provided by IPR nurses and respiratory therapy, as needed. The control interventions mimic usual care, which typically entails a setup by respiratory therapy and support for CPAP placement and device maintenance by IPR nurses.
62194557|NCT01893489|SHAM_COMPARATOR|control|no coronary artery disease patients without carotid plaques confirmed by a ultrasound study
62194558|NCT03321110|EXPERIMENTAL|Placebo|Placebo
62194559|NCT03321110|EXPERIMENTAL|Q10-150|coenzyme Q10 150 mg/d.
62194560|NCT03321110|EXPERIMENTAL|Q10-300|coenzyme Q10 300 mg/d.
62194561|NCT03552523|OTHER|Usual Care|Subject will wear a continuous glucose monitoring device (the Dexcom G5) and use the study provided glucose meter.. Subject will not change their prescribed home insulin therapy regimen during this arm whether that be an insulin pump or multiple daily injections.
62194562|NCT03552523|EXPERIMENTAL|Bionic Pancreas|During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.
62009026|NCT06664463|ACTIVE_COMPARATOR|Study group|"* This study group will undergo an Arousal Enhancement Protocol, designed to increase physiological and psychological arousal in unconscious patients. Participants will be exposed to controlled stimuli, such as visual or auditory tasks, while their responses are monitored using devices to measure heart rate temparature, blood pressure and respiratory rate.~* No drug interventions are involved in this protocol, with a focus on non-invasive sensory stimulation techniques. The goal is to understand how enhanced arousal affects physiological responses and promotes recovery. Participation is conducted with a focus on safety and strict adherence to ethical guidelines"
62194563|NCT00785837|NO_INTERVENTION|Before Hidrotherapy|
62009027|NCT06664463|PLACEBO_COMPARATOR|Control Group|group that will recieve routine hospital care
62194564|NCT00785837|EXPERIMENTAL|Hidrotherapy|
62194565|NCT01735175|ACTIVE_COMPARATOR|Neulasta®|During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.
62194566|NCT01735175|EXPERIMENTAL|LA-EP2006|During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.
62194567|NCT02061878|EXPERIMENTAL|Bexarotene|The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days
62194568|NCT02061878|PLACEBO_COMPARATOR|Placebo|The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
62194569|NCT01003119|EXPERIMENTAL|A CHESS|Those in the ACHESS arm will also be given a smart-phone with access to the ACHESS system (the intervention) for a full 12 months. The ACHESS intervention includes: 1) the Core CHESS system that has been tested in several diseases, 2) a proactive computer-based relapse prevention system, 3) data transfer from the phone to a computer accessible by the patient's counselor/care manager, and 4) systems for the patient to maintain contact with his/her Care Manager
62194570|NCT01003119|NO_INTERVENTION|Usual Care|Those randomized into the Usual Care group will receive usual medical care.
62009028|NCT02066857|ACTIVE_COMPARATOR|Generic plaster or fiberglass cast group|Patients will be randomized to receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture for 6 weeks.
62194571|NCT02833077|EXPERIMENTAL|JUVÉDERM VOLUMA® XC|JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator on Day 0. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 milliliters (mL) for both treatments combined.
62194572|NCT02833077|OTHER|No Treatment then JUVÉDERM VOLUMA® XC|No treatment for 6 months followed by optional treatment with JUVÉDERM VOLUMA® XC injected into the chin at a volume determined by the investigator on Month 6. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 mL for both treatments combined.
62194573|NCT00940875|EXPERIMENTAL|1|
62194574|NCT00940875|ACTIVE_COMPARATOR|2|
62194575|NCT05361564|EXPERIMENTAL|Brigatinib|
62194576|NCT04009031|EXPERIMENTAL|Bootle Blast|"Bootle Blast is a series of 13 mini-games targeting different upper limb motor therapy goals. Bootle Blast is designed with many of the features of mainstream video games known to be appealing to young people. Game rewards are linked to meeting therapeutic objectives, such as daily play targets that are customizable to each child. Bootle Blast is played through movements of the upper limbs tracked via a low-cost camera/sensor (Microsoft Kinect, no hand-held controls needed). The movements required to play are customizable to each child's range of motion. Some of the mini-games are mixed reality, where children interact and manipulate real-life objects (e.g. musical instruments, coloured building blocks) to play the game. The use of skeletal tracking and mixed reality enables both gross and fine motor skills to be practiced in line with each child's therapy goals and motor abilities."
62194577|NCT01896622|EXPERIMENTAL|A|Ritonavir
62194578|NCT01896622|EXPERIMENTAL|B|Cobicistat
62194579|NCT01154140|EXPERIMENTAL|A|
62194580|NCT01154140|ACTIVE_COMPARATOR|B|
62194581|NCT05442268|EXPERIMENTAL|Acetaminophen group|patients will receive intravenous 500 mg acetaminophen(every 6 hours postoperatively.
62194582|NCT05442268|EXPERIMENTAL|Duloxetine group|Patients will receive duloxetine 30 mg every 12 hours for 3 days before surgery, 30 mg 2 hours preoperatively and 30 mg 12 hours postoperatively and intravenous 500 mg acetaminophen (every 6 hours postoperatively)
62194583|NCT02954705||Group AAV|Patients recruited from the Nantes University Hospital. 50 milliliter of blood and 10mL of urine are collected from these patients during levies in clinical visit.
62194584|NCT02954705||Group control|"People recruited from the Etablissement français du sang (French blood establishment ).~10 milliliter of blood are collected from these donors"
62194585|NCT01798875|ACTIVE_COMPARATOR|Metformin|oral metformin at a dose of 850mg twice daily
62194586|NCT01798875|ACTIVE_COMPARATOR|Oral contraceptive|oral contraceptive containing 35ug of ethynylestradiol and 2mg of cyproterone acetate (21 day regimen)
62194587|NCT01049438|EXPERIMENTAL|Nasal, body, and systemic decolonization|
62573647|NCT00606385|ACTIVE_COMPARATOR|open liver resection|Patients who underwent open liver resection for HCC
62573648|NCT05402189|ACTIVE_COMPARATOR|Ketodex group : Group (KD)|
62194588|NCT06059599|EXPERIMENTAL|active informed consent|The experimental group will be prepared for the surgery through the new information tools, a video will be administered with information about the various surgical possibilities, graphics and animations in order to direct the patient toward a more informed choice. Next, an interview with the surgeon will be arranged for the patient and care givers to be listened to and guided through the use of 3D-printed models into the best decision for the individual case (Shared Decision Making - SDM). Having decided on the surgery, patients with similar surgical programs will be guided in educational programs to reinforce information, understanding and long-term retention of the concepts learned. The course will conclude with a second interview with the surgeon and the signing of the standard informed consent.
62194589|NCT06059599|NO_INTERVENTION|Traditional informed consent|The control group of patients will be informed about the surgery according to standard practices. As per standard practice, the patient will meet with the physician before surgery for an explanatory interview and subsequent signing of informed consent.
62194590|NCT00113815|EXPERIMENTAL|003|topiramate 25 mg/kg/day
62573649|NCT05402189|ACTIVE_COMPARATOR|Opioid group: Group (OP)|
62791828|NCT06397105|EXPERIMENTAL|Problem Management Plus|The participants who are assigned to the intervention group will receive five sessions of PM+, a psychological intervention which has been developed by the WHO. PM+ is a short, transdiagnostic (i.e., not specifically aimed at treating a certain mental disorder) program aiming to reduce common mental health symptoms and improve psychosocial functioning. In addition, participants will receive three telephone booster sessions and will have access to a digital support program.
62194591|NCT00113815|EXPERIMENTAL|002|topiramate 15 mg/kg/day
62194592|NCT00113815|EXPERIMENTAL|001|topiramate 5 mg/kg/day
62194593|NCT00113815|EXPERIMENTAL|004|placebo placebo
62194594|NCT01896557|EXPERIMENTAL|omeprazole|Omeprazole 20 mg (oral route) twice a day will be given to the subjects for one week. This intervention will be compared with ranitidin 150 mg (oral route) twice a day.
62194595|NCT01896557|EXPERIMENTAL|ranitidine|Ranitidine 150 mg (oral route) twice a day will be given to the subjects for one week.
62398588|NCT04347174|EXPERIMENTAL|Suspension of Mw + Standard therapy of COVID-19|"0.3 ml (0.1ml x 3 Injection) of intradermal Mw for 3 consecutive days~+ Standard therapy of COVID-19"
62398589|NCT04347174|PLACEBO_COMPARATOR|Standard therapy of COVID-19|0.3 ml (0.1ml x 3 Injection) of Placebo intra-dermal for 3 consecutive days
62398590|NCT06722131||Patients diagnosed with an infectious disease|
62398591|NCT06636123|EXPERIMENTAL|Investigational Agent Administration|GZ17-6.02: 375mg twice daily
62398592|NCT06724471||Fresh ovarian cortex fragments|Pericystic ovarian cortex will be cut into 1mm3 fragments and either directly analyzed on the day of collection (D0) or after organotypic culture (D7 and D14).
62398593|NCT06724471||Fragments of ovarian cortex frozen in thermosoldered cryovials.|Pericystic ovarian cortex will be cut into 1mm3 fragments, frozen using a slow programmable freezing device (Nano Digitcool, Cryo Bio System) in thermosoldered cryovials and stored in liquid nitrogen (-196°C). Then, fragments will be thawed before being analyzed on the day of thawing (D'0) and after 7 and 14 days (D7 and D14) of organotypic culture.
62398594|NCT06724471||Fragments of ovarian cortex frozen in screwed cryovials.|Pericystic ovarian cortex will be cut into 1mm3 fragments, frozen using a slow programmable freezing device (Nano Digitcool, Cryo Bio System) in screwed cryovials and stored in liquid nitrogen (-196°C). Then fragments will be thawed before being analyzed on the day of thawing (D'0) and after 7 and 14 days (D7 and D14) of organotypic culture.
62782700|NCT01279681|EXPERIMENTAL|Arm B [fluoropyrimidine/oxaliplatin (OXAL) + BEV]|Patients receive either mFOLFOX7 plus BEV, or Capecitabine + OXAL (XELOX) plus BEV. mFOLFOX7 + BEV is comprised of OXAL IV over 2 hours, LV calcium IV over 2 hours, and 5FU IV over 46-48 hours on day 1. Patients also receive BEV IV over 10-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. XELOX + BEV is comprised of OXAL IV over 2 hours on day 1 and capecitabine PO BID on days 1-14. Patients also receive BEV IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62782701|NCT03319212|OTHER|Active Comparator|Subjects that are between the ages 18-55 and are current spherical soft contact lens wearers will be assigned to a single study lens type to be worn bilaterally for approximately 4 weeks followed by no contact lens wear for 1 week.
62194596|NCT04309695|EXPERIMENTAL|Treatment Group|Receives intervention with the Zenflow Spring System.
62194597|NCT04347057|EXPERIMENTAL|Arm 1|"Arm 1 (39 patients) included first the control period, followed by one-day wash-out, and then the intervention period.~Procedures for control period included providing daily bed bathing with soap and water over three consecutive days, while intervention period included daily bed bathing with 2% CHG solution over three consecutive days."
62194598|NCT04347057|EXPERIMENTAL|Arm 2|"Arm 2 (39 patients) included first the intervention period, followed by one-day wash-out, and then the control period.~Procedures for control period included providing daily bed bathing with soap and water over three consecutive days, while intervention period included daily bed bathing with 2% CHG solution over three consecutive days."
62194599|NCT02704650|EXPERIMENTAL|Vaginal fluid of healthy patient|vaginal fluid sample from healthy patients
62194600|NCT02704650|EXPERIMENTAL|Vaginal fluid of ovary cancer patients|vaginal fluid sample from patients with ovary cancer
62194601|NCT02388347|PLACEBO_COMPARATOR|Placebo|Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
62194602|NCT02388347|EXPERIMENTAL|MEDI7836 Dose 1|Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
62194603|NCT02388347|EXPERIMENTAL|MEDI7836 Dose 2|Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
62782702|NCT02921711||LVIS®|
62782703|NCT01394913|EXPERIMENTAL|Reumatocept 25mg|50mg each week for 30 weeks
62398595|NCT03702192|EXPERIMENTAL|single-arm novel anticoagulation|Single-arm clinical study to assess the safety, and effectiveness of a novel anticoagulation protocol to be used in conjunction with the Berlin Heart EXCOR Pediatric Ventricular Assist Device as a bridge to heart transplantation in children with severe heart failure who have failed optimal medical therapy.
62573650|NCT02912975|EXPERIMENTAL|Mirror treatment|Five minutes treatment period twice a day for three weeks
62573651|NCT02912975|ACTIVE_COMPARATOR|Tactile treatment|Tactile massage twice a day for three weeks
62782704|NCT01394913|ACTIVE_COMPARATOR|Enbrel 25mg|50mg each week for 30 weeks
62573652|NCT00333983|EXPERIMENTAL|Arm 1|Robot Exercise Group
62782705|NCT05416736|EXPERIMENTAL|Experimental Group|"* Newborns will be fed with formula or breast milk pumped, according to the age and weight of the baby.~* Before the procedure, the newborn's heart rate, saturation and comfort scale score will be recorded.~* Genital area will be cleaned.~* Newborn will be held under the armpit by a nurse, baby boys will be held with their legs hanging down, and baby girls will be held in hip flexion position.~* Newborn with spontaneous voiding during the period from the beginning of the research procedure until the newborn is positioned will be excluded from the study.~* The bladder stimulation technique will be repeated sequentially for 3 minutes until micturition begins.~* After the maneuvers are started, the newborn's heart rate and saturation comfort scale score will be recorded at the 1st and 3rd minutes.~* The success of the procedure and the duration of the procedure will be recorded"
62791829|NCT06397105|OTHER|waitlist control group|The control group will receive the augmented PM+ intervention 12 months after the baseline assessment.
62791830|NCT06397105|NO_INTERVENTION|observational control group|Participants who scored below 20 on the K10 will will only be part of the baseline assessments and receive no intervention.
62194604|NCT02388347|EXPERIMENTAL|MEDI7836 Dose 3|Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
62194605|NCT02388347|EXPERIMENTAL|MEDI7836 Dose 4|Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
62194606|NCT05383339||Patients|Patients with autoimmune diseases, vasculitis and autoinflammatory diseases
62194607|NCT05833841|EXPERIMENTAL|Evaluation of swallowing function|Measurement of swallowing function using Surface Electromyography and video flouroscopy
62573653|NCT00333983|ACTIVE_COMPARATOR|Arm 2|Traditional Upper Extremity Exercise Group
62782706|NCT05416736|ACTIVE_COMPARATOR|Control Group|"* Newborns will be fed with formula or breast milk pumped, according to the age and weight of the baby.~* Before the procedure, the newborn's heart rate, saturation and comfort scale score will be recorded.~* Genital area will be cleaned.~* Newborns will be fitted with a sterile urine bag suitable for their gender.~* Babies who urinate spontaneously during the period until the sterile urine bag is fitted, the next feeding hour will be waited.~* Newborn will be observed for 3 minutes. Newborn's heart rate and saturation comfort pain scale score will be recorded at the 1st and 3rd minutes.~* The success of the procedure and the duration of the procedure will be recorded"
62009029|NCT02066857|ACTIVE_COMPARATOR|"Generic off the shelf removable splint group"|"Subjects will be randomized and receive a generic off the shelf removable splint for treatment of non-displaced distal radius fracture for 6 weeks."
62009030|NCT01115426|OTHER|anti-angiotensin II drugs|Never treated patients with non-nephrotic proteinuria (1-3 g/day), microhematuria, no-evidence of renal failure or other relevant diseases and with diagnosis of I-II stage IgA- or pauciimmune-MsPGN were considered eligible.
62194608|NCT00712647|ACTIVE_COMPARATOR|1|Asbestos-exposed participants and heavy smokers
62782707|NCT04581551|EXPERIMENTAL|Stroke group|"SWE for 6 shoulder muscles will be performed by 2 assessors in randomised order.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor"
62194609|NCT00712647|PLACEBO_COMPARATOR|2|Asbestos-exposed participants and heavy smokers
62194610|NCT05999890|EXPERIMENTAL|Tapentadol|Tapentadol is a novel, centrally acting analgesic with dual mechanism of action, combining mu-opioid receptor agonism with norepinephrine reuptake inhibition.this dual mode of action is responsible for its opioid sparing effect, which contributes to reduction in some of the typical opioid related adverse effects
62194611|NCT05999890|ACTIVE_COMPARATOR|Paracetamol|Paracetamol is one of the most frequently used analgesic and antipyretic agent, interferes neither with platelet nor kidney functions nor does it present the unwanted side effects of NSAIDS.
62194612|NCT00450138|EXPERIMENTAL|1|Radiation + vandetanib
62194613|NCT00450138|EXPERIMENTAL|2|Radiation + cisplatin + vandetanib
62194614|NCT02975076|EXPERIMENTAL|Sanchitongshu & placebo of lopidogrel|sanchitongshu 1 capsule each time ,three times a day and Aspirin 75mg for 90 days ; placebo of clopidogrel 75mg daily for 21 days after randomization
62194615|NCT02975076|PLACEBO_COMPARATOR|placebo of Sanchitongshu & lopidogrel|placebo of sanchitongshu1 capsule each time ,three times a day and Aspirin 75mg for 90 days;clopidogrel 75mg per day for 21 days after randomization
62194616|NCT06328218|EXPERIMENTAL|Simple Gymnastics Training|The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Simple Gymnastics Training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 30 minutes. Each training session will be conducted approximately at 9.00 a.m. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
62194617|NCT00663585|EXPERIMENTAL|1|Structured Intervention Group
62194618|NCT00663585|ACTIVE_COMPARATOR|2.Comparison group|Unstructured comparison group
62194619|NCT03643549|EXPERIMENTAL|Bortezomib and Temozolomide|Botezomib 1.3 mg/m2 administered IV on days 1, 4, 7, during each 4-week chemotherapy cycle with per oral Temozolomide at three dose levels: 150 mg/m2, 175 mg/m2 and 200mg/m2 5 days/week every 4 weeks starting on day 3.
62009031|NCT06128525|EXPERIMENTAL|Treatment (TMA, radical prostatectomy)|Patients undergo MRI/US fusion guided transperineal targeted TMA and then undergo standard of care RP same day or at 30 days post-TMA on study. Patients may undergo planning mpMRI of prostate prior to TMA. Patients also undergo blood sample collection at screening and post RP.
62194620|NCT04905576|EXPERIMENTAL|Relaxation training following daily radiation|All relaxation sessions will be given individually, and will be provided by trained nurses or research assistants. Patients receiving relaxation will learn exercises to release tension through muscle relaxation, breathing, and imagery
62194621|NCT04905576|EXPERIMENTAL|Healing touch therapy following daily radiation|All Healing Touch sessions will be given individually, and will be provided by trained nurses or research assistants. Patients receiving Healing Touch will receive a series of standardized therapeutic techniques designed to promote optimal flow of energy throughout the body.
62194622|NCT04905576|ACTIVE_COMPARATOR|No intervention|The no intervention group will receive no special intervention other than standard medical care, which includes the regular medical care given by the patient's physician and health care professionals.
62194623|NCT02261077|EXPERIMENTAL|Buscopan, single rising doses|
62194624|NCT02261077|EXPERIMENTAL|Buscopan, multiple rising doses|
62194625|NCT02261077|PLACEBO_COMPARATOR|Placebo|
62194626|NCT01736189||Participants treated with adalimumab|40 mg adalimumab via subcutaneous (SC) injection every other week (eow) for 104 weeks
62194627|NCT01133223|ACTIVE_COMPARATOR|Thrombectomy|
62194628|NCT01133223|ACTIVE_COMPARATOR|Usual Care|
62194629|NCT03489876|EXPERIMENTAL|Synthetic Cartilage Implant|Participants receive the synthetic cartilage implant. The synthetic cartilage implant that will be used is the Cartiva implant.
62194630|NCT03489876|ACTIVE_COMPARATOR|Osteochondral Autograft Transfer|Participants receive the current standard osteochondral autograft transfer procedure.
62194631|NCT02358668|EXPERIMENTAL|BTI320 4 grams|three times daily, oral for 16 weeks
62194632|NCT02358668|EXPERIMENTAL|BTI320 8 grams|three times daily, oral for 16 weeks
62782708|NCT04581551|ACTIVE_COMPARATOR|Healthy controls|"SWE for 6 shoulder muscles will be performed by 1 assessors.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor"
62194633|NCT02358668|PLACEBO_COMPARATOR|BTI320 matching placebo|2 tablets three times daily, oral for 16 weeks
62194634|NCT06126588|EXPERIMENTAL|Patient treat with everolimus|The product Everolimus is an oral drug.The dosage is 7.5 mg.
62194635|NCT05893589|EXPERIMENTAL|test|
62398596|NCT04398160|EXPERIMENTAL|HVLA manipulation|"In the intervention of the experimental group, the investigator will be primarily on the right side of the volunteer and identify C3 through the cervical reference of jaw angle, which is at the disc level between C2/C3 and then contact with the phalanges of third metacarpal in the left transverse of this vertebra.~The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally."
62782709|NCT01114828|EXPERIMENTAL|3.75 mg|Once-daily oral administration of OPC-41061
62782710|NCT01114828|EXPERIMENTAL|7.5 mg|Once-daily oral administration of OPC-41061
62782711|NCT03631017|EXPERIMENTAL|Phase I: [18 F]-PARPi and PET/CT Scans|The intervention of this study is the injection of a microdose (\< 10 0 ug) of \[18 F\]- PARPi followed by 3 PET/CT studies to determine the biodistribution of this imaging agent in normal organs as well as the kinetics of uptake in squamous cell carcinomas of the head and neck.
62009032|NCT06572475|EXPERIMENTAL|Trial arm 1|"Group A: Patients with sporadic VS undergoing radiological surveillance (n=12). The sample will include growing tumours (n=6) that are being considered for surgical resection, and non-growing/static tumours (n=6) that are being considered for either further radiological surveillance or surgery.~Group B: Patients with suspected transforming low-grade glioma (n=5). Patients in this cohort will have a proven or suspected diagnosis of low-grade glioma (LGG) but with features on routine clinical imaging suggestive of malignant transformation to either grade III (anaplastic) or grade IV glioma. Patients with suspected transforming LGG who are listed to undergo surgical resection will be enrolled into the study so that acquired imaging can be compared with tissue datasets."
62009033|NCT01620606|EXPERIMENTAL|SLCBT|Social Learning and Cognitive Behavioral Therapy
62009034|NCT01620606|EXPERIMENTAL|SLCBT-R|Phone-based Social Learning and Cognitive Behavioral Therapy
62009035|NCT01620606|ACTIVE_COMPARATOR|ES|Education and Support
62009036|NCT03626129|NO_INTERVENTION|Traditional rapid deflation|"Group A: At time of sheath removal 15 ml. air is inflated in the TR-band. The sheath is removed. Air is deflated until bleeding, and 1-2 ml. air is then re-inflated to achieve hemostasis, and the volume air inflated is registered (Initial inflated air volume). Every 20 minutes 1/3 of the initial inflated air volume is deflated. If bleeding occurs then air is re-inflated until hemostasis and then additional 1-2 ml. air is inflated. This routine is repeated until hemostasis is achieved (TR-band fully deflated without bleeding)."
62009037|NCT03626129|EXPERIMENTAL|Oximetry guided deflation|"Group B: Initial step with sheath removal as in group A. Before departure from the cath.lab. a Patent hemostasis test (see description in Interventions below) is performed. Further action as described in Interventions below."
62009038|NCT05004922||ICSI in upper cavity|Embryo transfer into the upper cavity
62009039|NCT05004922||ICSI in midcavity|Embryo transfer into the midcavity
62194636|NCT05893589|NO_INTERVENTION|control group|
62194637|NCT05933889||Retrospective observational cohort|Retrospective patients undergoing transoral robotic surgery for early stage T1-2 oropharyngeal cancers on or before to 31/12/2021. Data will be collected from medical records.
62194638|NCT05933889||Exploratory molecular analysis|Consenting prospective patients based in the UK identified will be invited to participate in the exploratory molecular analysis by their usual care team. If agreeable, patients will consent to donation of either blood or buccal swab samples, in addition to archival tissue from their primary, and if relevant, recurrent tissue samples.
62194639|NCT05933889||Radiology/ radiomic analysis|Retrospective patients based in the UK and abroad will have their pre-operative imaging transferred to the RMH radiology department which will undergo radiomic and morphological assessment to ascertain features that put patients at high risk of local recurrence and positive margins.
62194640|NCT03007797||vaccination rate- pregnant- influenca|
62194641|NCT04537598|ACTIVE_COMPARATOR|patient controlled analgesia|30 patients will receive only postoperative IV PCA alone for postoperative analgesia.
62194642|NCT04537598|ACTIVE_COMPARATOR|Erector Spinae plane block|30 patients will receive continuous ESPB for postoperative analgesia.
62194643|NCT02357264||pre-eclampsia|Ultrasound of Pregnant Females 18+ with pre-Eclampsia
62573654|NCT00763425|EXPERIMENTAL|1|
62194644|NCT02357264||No pre-eclampsia.|Ultrasound of Pregnant Females 18+ with no pre-eclampsia
62398597|NCT04398160|SHAM_COMPARATOR|Sham technique|"The investigator will be primarily on the right side of the volunteer and identify the C3 vertebra, having as anatomical reference the angle of the jaw, which is at the disc level between C2/C3 and then contact, with the phalanges of the third metacarpal, the left transverse apophysis of this vertebra.~The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally."
62194645|NCT01579643|EXPERIMENTAL|LALAK|
62194646|NCT01579643|ACTIVE_COMPARATOR|Penetrating Keratoplasty (KP)|
62194647|NCT05553197|EXPERIMENTAL|Cognitive Behavior Therapy + Ecological Momentary Assessment (CBT + EMA)|Cognitive Behavior Therapy + Ecological Momentary Assessment
62194648|NCT05553197|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Cognitive Behavioural Therapy (Treatment as Usual)
62194649|NCT00174837|EXPERIMENTAL|Tirapazamine + Cisplatin|
62194650|NCT00174837|ACTIVE_COMPARATOR|Cisplatin|
62194651|NCT03195361|EXPERIMENTAL|Single-arm|Subjects suffering from anterior POP-Q grade 2 (point Aa and Ba≥ -1) and above, who are scheduled for POP surgery, will be transplanted with the SRS device
62194652|NCT05287347||Prospective|Blood specimens will be obtained for the model-assigned high risk cohort at each collaborating HCO, over two years of recruitment period. Data of each participant will be electronically followed for observation of outcome measures for up to 3 years.
62194653|NCT05889689|EXPERIMENTAL|Relationship Smarts Plus & Mind Matters|Relationship Smarts Plus (RSP+) is an adolescent pregnancy prevention curriculum that will be combined with lessons from a trauma-coping skills curriculum, Mind Matters (MM).
62398598|NCT04398160|NO_INTERVENTION|No intervention group|The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally.
62398599|NCT01695681|OTHER|Dietary instruction|Gluten-free diet
62398600|NCT06623422|EXPERIMENTAL|Pembrolizumab + V940|For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via intravenous (IV) infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC\] 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS V940 1 mg via intramuscular (IM) injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks).
62398601|NCT06623422|ACTIVE_COMPARATOR|Pembrolizumab + Placebo|For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via IV infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin AUC 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS matching placebo via IM injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks).
62398602|NCT06018376||Observational Study Group|"* Age greater than or equal to 18 years and less than or equal to 70 years.~* Diagnosis of lung cancer stages IB to IV.~* Having received systemic oncological treatment for at least 3 months~* ECOG ≤ 2"
62573655|NCT00763425|ACTIVE_COMPARATOR|2|
62573656|NCT04007120|EXPERIMENTAL|RVT-1601 Low Dose|Inhaled RVT-1601 administered once daily over two days via eFlow nebulizer
62573657|NCT04007120|EXPERIMENTAL|RVT-1601 Mid Dose|Inhaled RVT-1601 administered once daily over two days via eFlow nebulizer
62573658|NCT05936060|EXPERIMENTAL|IMUNOCEM|Administration of umbilical cord-derived mesenchymal stromal cells suspension
62573659|NCT05936060|PLACEBO_COMPARATOR|PLASMALYTE|Administration of plasmalyte as vehicle for MSC
62573660|NCT00779935|EXPERIMENTAL|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
62782712|NCT03631017|EXPERIMENTAL|Phase II: [18 F]-PARPi and PET/CT Scans|The intervention of this study is the injection of a microdose (\< 10 0 ug) of \[18 F\]- PARPi followed by 3 PET/CT studies to determine the biodistribution of this imaging agent in normal organs as well as the kinetics of uptake in squamous cell carcinomas of the head and neck.
62194654|NCT05889689|EXPERIMENTAL|Relationship Smarts Plus|Relationship Smarts Plus (RSP+) is an adolescent pregnancy prevention curriculum.
62194655|NCT05889689|ACTIVE_COMPARATOR|Control Group|Financial literacy curriculum, Preparing Adolescents for Young Adulthood (PAYA)
62194656|NCT01027052|ACTIVE_COMPARATOR|Hamburger meat patty with Spice Blend|Hamburger meat patty containing spice blend will be consumed on 3 separate occasions
62194657|NCT01027052|PLACEBO_COMPARATOR|Hamburger meat patty with salt|Hamburger meat patty containing salt will be consumed on 3 separate occasions
62194658|NCT04797234|EXPERIMENTAL|Control|There will be no intervention to the control group.
62573661|NCT02861222|EXPERIMENTAL|MYOCET|2 treatments of doxorubicin are administered at 60 mg/m²/day or 75 mg/m²/day in single dose in 1-hour perfusion each 21 days. A maximum of 6 treatments/patient is administered.
62573662|NCT03385993|EXPERIMENTAL|Mediation and Relaxation Intervention|Patients will undergo a technology based guided meditation and relaxation exercise through use of an application on a tablet or virtual reality headset.
62782713|NCT00964561|EXPERIMENTAL|Ciprofloxacin and Valortim|First two subjects to receive treatment arm of Ciprofloxacin and Valortim. Total of sixteen volunteers to be randomized to receive Ciprofloxacin and Valortim.
62782714|NCT00964561|EXPERIMENTAL|Placebo Antibiotic and Valortim|Randomized such that four subjects to receive Placebo Antibiotic and Valortim.
62782715|NCT00964561|EXPERIMENTAL|Placebo Antibiotic and Placebo Valortim|Randomized such that 4 subjects to receive Placebo Antibiotic and Placebo Valortim.
62782716|NCT06006624|ACTIVE_COMPARATOR|Group 1: ACL repair + Exparel + nerve block|30 mL Liposomal bupivacaine (Exparel) + 5 cc's of 0.5% bupivacaine evenly distributed and administered in adductor canal and iPACK block (35 mL total)
62782717|NCT06006624|ACTIVE_COMPARATOR|Group 2: ACL repair + Exparel + Dexamethasone + nerve block|30 mL Liposomal bupivacaine (Exparel) + 10 mg preservative free Dexamethasone + 5 cc's of 0.5% bupivacaine evenly distributed for both adductor canal and iPACK block (35 mL total)
62782718|NCT05725993||TBI Patient|
62782719|NCT05725993||Healthy Control|
62194659|NCT04797234|EXPERIMENTAL|Experiment|The experimental group will be trained for 6 weeks.
62194660|NCT02423603|ACTIVE_COMPARATOR|Paclitaxel + AZD5363|Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Capivasertib 400 mg was administered orally twice per day on an intermittent weekly dosing schedule, with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle.
62194661|NCT02423603|PLACEBO_COMPARATOR|Paclitaxel + Placebo|Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Placebo was administered orally twice per day on an intermittent weekly dosing schedule, with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle.
62194662|NCT00243074|EXPERIMENTAL|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62398603|NCT02033720||Shockable arrest|Initial arrest rhythm shockable. This is either pulseless ventricular tachycardia (pulseless VT) or ventricular fibrillation (VF).
62573663|NCT00478777|EXPERIMENTAL|lenalidomide plus dexamethasone|Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), dexamethasone was to be reduced to 40 mg QD for Days 1-4 of each 28 day-cycle.
62573664|NCT02165917|PLACEBO_COMPARATOR|Excision only|Laparoscopic excision of endometriotic lesions followed by 3 month of GnRH-Analogue administration
62009040|NCT02803697||Patients|All patients who underwent surgery for a NFPA in Reims university hospital between 01/01/1991 and 31/12/2004
62194663|NCT00401258|OTHER|1|12-week, open-label trial of duloxetine in subjects with IBS.
62194664|NCT02627339||Healthy controls|Healthy controls age 10 to 90 years
62573665|NCT02165917|ACTIVE_COMPARATOR|Excision plus hyaluronic acid gel|Standard Laparoscopic excision of endometriotic lesions plus application of 10 cc of a hyaluronic acid gel (Hyalobarrier® ), followed by 3 month of GnRH-analogue administration
62573666|NCT06044415|EXPERIMENTAL|JWH-018 condition|
62194665|NCT02914756||Sepsis|Patients suffering from Severe sepsis or Septic chock at the ICU.
62194666|NCT02914756||Non-Sepsis|Patients being treated at ICU but not suffering from severe sepsis/septic chock
62194667|NCT01217788|EXPERIMENTAL|PH94B intranasal spray|
62398604|NCT02033720||Pulseless electrical activity|Initial arrest rhythm is pulseless electrical activity.
62398605|NCT02033720||Asystole|Initial arrest rhythm is asystole.
62398606|NCT05846659|EXPERIMENTAL|Experimental Arm|PULSAR-ICI + IMSA101
62398607|NCT05846659|ACTIVE_COMPARATOR|Control Arm|PULSAR-ICI
62398608|NCT03557073|EXPERIMENTAL|Phone Call|Subjects in this study arm receive a post-operative phone call by a physician.
62398609|NCT03557073|NO_INTERVENTION|No Phone call|Subjects in this study arm do not receive an additional post-operative phone call by a physician.
62573667|NCT06044415|PLACEBO_COMPARATOR|Placebo condition|
62573668|NCT01541761|EXPERIMENTAL|Family groups|Intervention group members will participate in family groups focused on early childhood obesity prevention in addition to standard care from pediatricians at the primary care clinic.
62573669|NCT01541761|NO_INTERVENTION|Standard care|Mothers enrolled into the control group will continue to receive care from their pediatrician in the primary care clinic.
62573670|NCT02079350||%4 Gelofusine|patients administered %4 Gelofusine during liver transplantation
62782720|NCT04164420|EXPERIMENTAL|Oral neuromuscular training and orofacial sensory-vibration|Intensive training with oral neuromuscular training and orofacial sensory-vibration stimulation for 5 weeks. The oral neuromuscular training is performed three times per session, and three times daily before eating. Regarding the orofacial sensory-vibration stimulation, the instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal by using a toothbrush.
62782721|NCT04164420|ACTIVE_COMPARATOR|Orofacial sensory-vibration stimulation|Orofacial sensory-vibration stimulation by using an electrical toothbrush for five weeks. Instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal.
62791831|NCT05674019|EXPERIMENTAL|Neurodevelopmental Group|The volunteer presents at least 2 of 12 neurodevelopmental crieria
62194668|NCT01217788|PLACEBO_COMPARATOR|Placebo intranasal spray|
62194669|NCT03040609||Group 1|The duration of follow-up of group 1 in the study is 1 day.
62194670|NCT03040609||Group 2|The duration of follow-up of group 2 in the study is 2 weeks.
62194671|NCT03040609||Group 3|The duration of follow-up of group 3 in the study is 6 months.
62782722|NCT02161055|EXPERIMENTAL|Strict control group|"Intensive insulin therapy: Keep Target blood glucose levels between 4.4-7.0 mmol/L;~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours."
62782723|NCT02161055|EXPERIMENTAL|Moderate control group|"Intensive insulin therapy: Keep target blood glucose levels between 7.1 and 10.0 mmol/L.~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours"
62009041|NCT01086579|EXPERIMENTAL|Treatment Arm (IN.PACT Falcon Drug Eluting Balloon)|IN.PACT Falcon™ paclitaxel drug-eluting balloon (DEB) dilatation and provisional spot bare metal stenting (Bare Metal Stent).
62009042|NCT01086579|ACTIVE_COMPARATOR|Control Arm PES|Control Arm: paclitaxel-eluting stent (PES) implantation as per standard practice.
62009043|NCT06602596|NO_INTERVENTION|Control group|The control group in the Hoosier Sport study consists of students who are not enrolled in the PE class and therefore do not participate in the Hoosier Sport program. These students continue with their regular school activities without the added sport, leadership, and health education components provided in the intervention.
62009044|NCT06602596|EXPERIMENTAL|Test group - Hoosier Sport Participants|The intervention group in the Hoosier Sport study consists of students enrolled in the PE class who actively participate in the Hoosier Sport program. These students engage in an 8-week curriculum that includes unique sports activities, leadership exercises, and health education sessions designed to promote physical activity and well-being.
62009045|NCT03698773|ACTIVE_COMPARATOR|Baseline Group|Access to existing educational materials about labor/delivery pain relief options, as well as an opportunity to ask physicians, nurses, and other relevant personnel for more information.
62009046|NCT03698773|EXPERIMENTAL|Website Group|Access to a tablet computer set to display an educational website (thepainlesspush.com) with information about labor/delivery pain relief options, as well as an opportunity to ask physicians, nurses, and other relevant personnel for more information.
62009047|NCT06459557|ACTIVE_COMPARATOR|conservative treatment of displaced pediatric distal radius fractures|children in this group with displaced distal radius fractures would be managed by a cast in the emergency room without anatomically reducing the fracture under general anesthesia in the operating room
62009048|NCT06459557|ACTIVE_COMPARATOR|surgical reduction of displaced distal radius fractures|children in this group with displaced distal radius fractures would be managed by being anatomically reducing the fracture in the operating room under general anesthesia
62009049|NCT01974050|OTHER|Text message monitoring|Use of text messaging to monitor post-vaccination
62194672|NCT04536389||group A|women with normal uterine cavity and normal cervix by office hysteroscopy.
62573671|NCT02079350||%6 HES|patients administered %6 HES during liver transplantation
62782724|NCT02161055|EXPERIMENTAL|Slight control group|"Intensive insulin therapy: Keep target blood glucose levels between 10.1 and 13.0 mmol/L.~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours."
62009050|NCT05690737|EXPERIMENTAL|Tai Chi training|The participants in this arm will receive 24-week Tai Chi training (1 hour per day, 5 days per week) with 24-week follow-up. A modified 33-short form Yang-style Tai Chi Chuan will be adopted.
62009051|NCT05690737|ACTIVE_COMPARATOR|Standard prophylactic medication|Participants in this arm will receive 48-week standard migraine prophylactic medication following neurologist's recommendation.
62009052|NCT01236196|EXPERIMENTAL|Arm 1 - Telephone CBT|telephone cognitive behavior therapy for pain management
62009053|NCT01236196|ACTIVE_COMPARATOR|Arm 2 - telephone education|telephone pain education
62734645|NCT00817765|EXPERIMENTAL|Fosamprenavir posaconazole|Fosamprenavir 700mg / posaconazole 400mg BID for 10 days (start on day 1 with 200mg QD, day 2 200mg BID; from day 3 onwards 400mg BID)
62194673|NCT04536389||group B|women with normal uterine cavity with hysteroscopically detected cervical abnormality.
62194674|NCT04566913|EXPERIMENTAL|Patients recruited from Cairo University|"After Cone beam CT assessment , The patient is assigned for nonsurgical periodontal phase then an impression is taken for stent formation to facilitate tissue thickness measurement .~\> After 2 weeks , the patient is assigned for surgical phase to extract the palatal and apical aspect of the tooth and leave the buccal portion .~Socket preservation is attempted in the socket , using 'genbioss ' bone graft. Modified free gingival graft is done on the pontic site to cover the buccal root shield and the bone graft .~Post operative instructions include :~1. Analgesics (Prufen 400 mg ) three times for three days~2. Antibiotic (Augmentin 1gm ) twice daily for one week The patient will be assured to contact the operator of any unexpected complications occured ."
62194675|NCT02711319|ACTIVE_COMPARATOR|active (real) rTMS (ACTIVE GROUP)|"The patients were randomly distributed in two study groups: real or sham rTMS group.~For real rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes."
62194676|NCT02711319|SHAM_COMPARATOR|sham rTMS (SHAM GROUP)|For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2).
62194677|NCT03940690|EXPERIMENTAL|Anti-VEGF injections (bevacizumab)|5 anti-VEGF injections of bevacizumab at months 0, 1, 2, 4 and 6, combined with laser at months 2, 4 and 6 (laser optional at month 9
62791832|NCT05674019|ACTIVE_COMPARATOR|Non-neurodevelopmental Group|The volunteer does not present any of the 12 neurodevelopmental crieria
62009054|NCT05757375|EXPERIMENTAL|Volleyball players with Chronic Ankle Instability|Before the taping application, the application area of all athletes will be shaved. It will be cleaned with an alcohol wipe before the application so that situations such as sweat or moisture do not reduce the effect of the banding. For taping, while the athlete lies in a supine position on a portable stretcher, the leg weight will be taken by placing the athlete's foot on the abdomen with slight knee and hip flexion. The rigid tape will be measured and cut obliquely starting approximately 2 cm anterior to the fibula and approximately 1 cm anterior to the lateral malleolus and ending in the middle of the anterior tibia region. To increase the strength of the banding, another band will be added to it. In the application, only banding will be preferred and mobilization will not be done.
62009055|NCT05757375|EXPERIMENTAL|Volleybal players without Chronic Ankle Instability|Before the taping application, the application area of all athletes will be shaved. It will be cleaned with an alcohol wipe before the application so that situations such as sweat or moisture do not reduce the effect of the banding. For taping, while the athlete lies in a supine position on a portable stretcher, the leg weight will be taken by placing the athlete's foot on the abdomen with slight knee and hip flexion. The rigid tape will be measured and cut obliquely starting approximately 2 cm anterior to the fibula and approximately 1 cm anterior to the lateral malleolus and ending in the middle of the anterior tibia region. To increase the strength of the banding, another band will be added to it. In the application, only banding will be preferred and mobilization will not be done.
62009056|NCT00622427|EXPERIMENTAL|Ramelteon then placebo|8 mg tablets every night for 2 weeks, then a 2 week washout,then crossover to placebo tablets for 2 weeks.
62009057|NCT00622427|EXPERIMENTAL|Placebo then Ramelteon|placebo tablets for every night for 2 weeks, then a 2 week washout, followed by 8 mg tablets every night for 2 weeks.
62009058|NCT03691220|EXPERIMENTAL|Telemetric Intervention Arm|Adolescent with MLVI\>2 to receive the telemetric intervention.
62194678|NCT03940690|ACTIVE_COMPARATOR|Arm : laser only|3 sessions of laser at months 0, 1 and 2, completed if needed with laser at months 4, 6 et and 9
62194679|NCT02729467|EXPERIMENTAL|Panel 1|Participants will receive a single 250 milligram (mg) dose of JNJ-53718678 on Day 1 and 200 mg itraconazole once a day on Days 4 to 11 along with a single 250-mg dose of JNJ-53718678 on Day 9.
62194680|NCT02729467|EXPERIMENTAL|Panel 2|Participants will receive a single 500-mg dose of JNJ-53718678 on Day 1; a single 600-mg dose of rifampicin along with a single 500-mg dose of JNJ-53718678 on Day 4 and 600 mg rifampicin once daily on Days 5 to 11 along with a single 500-mg dose of JNJ-53718678 on Day 9.
62194681|NCT03651557|EXPERIMENTAL|Neu2000KWL high dose|
62194682|NCT03651557|EXPERIMENTAL|Neu2000KWL low dose|
62573672|NCT04735627|EXPERIMENTAL|Levodopameter|During the single study visit, participants will receive either: 1) one doses of oral carbidopa/ levodopa. The Levodopameter sensor device will serially measure levodopa levels from either capillary blood, sweat, or interstitial fluid and blood will be simultaneously collected from an intravenous line for high-performance liquid chromotography analysis of plasma levodopa levels.
62194683|NCT03651557|PLACEBO_COMPARATOR|saline|
62573673|NCT01406379|EXPERIMENTAL|Prophylactic clip|Prophylactic clip
62009059|NCT03691220|NO_INTERVENTION|Standard of Care Arm|Adolescent with MLVI\>2 to receive standard of care.
62194684|NCT01730378|EXPERIMENTAL|Prepandrix Group|Subjects in this group received 2 doses of Prepandrix™ vaccine at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
62194685|NCT01730378|ACTIVE_COMPARATOR|Fluarix Group|Subjects in this group received 1 dose of Fluarix™ vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid region of non-dominant arm.
62194686|NCT01279837|NO_INTERVENTION|Usual care|Control (Usual care) group in which patients will receive swallowing and prescribed dietary intervention during the radiotherapy period prescribed by the attending physician.
62194687|NCT01279837|EXPERIMENTAL|High Intensity Pharyngocise|Patients receive twice daily swallowing intervention by a speech language pathologist, consisting of the battery of isometric / isotonic exercises.
62194688|NCT01279837|ACTIVE_COMPARATOR|Low Intensity Pharyngocise|Patients will receive a one time only swallowing intervention session by a speech language pathologist, instructing them in the battery of isometric / isotonic exercises plus a home practice instruction digital video tape to support self directed practice of this program at home.
62194689|NCT05431777||Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma|Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma who were treated with avelumab as first-line maintenance therapy
62194690|NCT00240214||1|sirolimus
62009060|NCT02692157|PLACEBO_COMPARATOR|Placebo|Placebo Comparator: Placebo - During this arm, Placebo medication will be administered orally each evening at 8pm.
62009061|NCT02692157|ACTIVE_COMPARATOR|NT-814 50 mg|Active Comparator: NT-814 50 mg - During this arm, 50 mg NT-814 will be administered orally each evening at 8pm.
62009062|NCT02692157|ACTIVE_COMPARATOR|NT-814 100 mg|Active Comparator: NT-814 100 mg - During this arm, 100 mg NT-814 will be administered orally each evening at 8pm.
62009063|NCT02692157|ACTIVE_COMPARATOR|NT-814 200 mg|Active Comparator: NT-814 200 mg - During this arm, 200 mg NT-814 will be administered orally each evening at 8pm.
62194691|NCT03209947|EXPERIMENTAL|Ulnar nerve ultrasound|
62194692|NCT05084339||pregnant group with bariatric surgery|pregnant women with a history of gastric bypass or sleeve gastrectomy
62573674|NCT01406379|ACTIVE_COMPARATOR|Detachable snare|Detachable snare
62194693|NCT05084339||matched pregnant group without history of bariatric surgery|age-and BMI matched pregnant women without history of bariatric surgery
62194694|NCT02880943|EXPERIMENTAL|Group A|"Group A: patients with bone disease mainly will be treated with XOFIGO® alone.~Node and/or adrenal metastases and/or ≤5 lung metastases ≤1cm each are allowed in Group A."
62573675|NCT02739009|EXPERIMENTAL|MOR106|Single intravenous administration of MOR106
62573676|NCT02739009|PLACEBO_COMPARATOR|Placebo|Single intravenous administration of Placebo
62194695|NCT02880943|EXPERIMENTAL|Group B|Group B: patients already treated with an ongoing approved Tyrosine Kinase Inhibitor (TKI) for their visceral metastases will be treated with XOFIGO® for bone disease.
62194696|NCT03699189|EXPERIMENTAL|Immediate ANAIS|Participants that attend the training course immediately.
62573677|NCT02739009|EXPERIMENTAL|MOR106 MAD|Multiple intravenous administration of MOR106
62194697|NCT03699189|NO_INTERVENTION|Delayed ANAIS|Participants that attend the training course a year later.
62194698|NCT00281320|EXPERIMENTAL|Asenapine 2-10 mg BID|Dose titration from 2 mg to 5 mg to 10 mg twice daily (BID)
62194699|NCT00281320|EXPERIMENTAL|Asenapine 5-10mg BID|Dose titration from 5 mg to 10 mg BID
62573678|NCT02739009|PLACEBO_COMPARATOR|Placebo MAD|Multiple intravenous adminstration of Placebo
62009064|NCT01728467|EXPERIMENTAL|RVX000222, 200 mg daily|
62009065|NCT01728467|PLACEBO_COMPARATOR|Placebo|
62009066|NCT02968199|EXPERIMENTAL|Referred women|A brief intervention based on the'5 A' model developed by the Agency for Health Care Policy and Research in the United States.
62009067|NCT00763542|EXPERIMENTAL|I|Combined treatment: CBT for SUD plus structured writing therapy for PTSD
62009068|NCT00763542|ACTIVE_COMPARATOR|II|CBT for SUD only
62009069|NCT05165121|OTHER|Human Factors|The purpose of the human factor study was to verify the feasibility of self-fitting MDHearing Smart hearing aid by listeners with a mild to moderate sensorineural hearing loss.
62009070|NCT05165121|OTHER|Clinical Study|The clinical study included two groups of subjects (self-fit and professional-fit groups) with the main purpose to compare the fitting outcomes between the two fitting groups. The professional-fit group aimed to show whether the MDHearing Smart hearing aids can be fitted by audiology professional on each user reliably and if each user can benefit from using the MDHearing smart hearing aids. The self fit group intended to show whether the MDHearing Smart hearing aids can be fitted by each user reliably and if each user can use the MDHearing app on their smartphone or tablet to make adjustments to achieve a good aided benefit.
62009071|NCT00797615|PLACEBO_COMPARATOR|Alternative Intervention|12-week alternate intervention program focused on building self-esteem and social self-efficacy
62573679|NCT02271646|EXPERIMENTAL|0.5% marcaine 20ml|3 levels ultrasound guided thoracic paravertebral blocks at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
62573680|NCT01367678|EXPERIMENTAL|Laryngeal Mask Airway Supreme|Directly measured mucosal pressures
62573681|NCT01367678|EXPERIMENTAL|i-Gel|Directly measured mucosal pressures
62573682|NCT03569930|EXPERIMENTAL|Standard|standard of care (diet rich in water and vegetable fibers, hygienic)
62573683|NCT03569930|EXPERIMENTAL|ProtFlav|oral supplements (flavonoid-based supplements - ProtFlav) will be added to standard of care
62194700|NCT02567708|EXPERIMENTAL|GSK2269557 and Placebo|Each subject will complete two treatment periods: GSK2269557 1000 mcg in one treatment period, and matching placebo in the other treatment period. Each treatment will be administered once daily for 28 days (+/- 2 days) via the DISKUS DPI. The treatment periods will be separated by a washout of at least 4 weeks.
62009072|NCT00797615|ACTIVE_COMPARATOR|Active Intervention|12-week intervention program focused on dietary intake and physical activity
62194701|NCT02853487||Cluster headache patients|Episodic cluster headache patients in- and outside of bout will wear an actigraph and fill out a diary for 2 weeks.
62194702|NCT02853487||Control group|Healthy, headache-free controls will wear an actigraph and fill out a diary for 2 weeks.
62194703|NCT03681743|EXPERIMENTAL|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during an IV start.
62194704|NCT03681743|NO_INTERVENTION|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors and/or parents.
62194705|NCT06384105|EXPERIMENTAL|FPS 3-5|Frames per second are set at 3-5 at the beginning of the procedure
62194706|NCT06384105|EXPERIMENTAL|FPS >5-8|Frames per second are set at \>5-8 at the beginning of the procedure
62194707|NCT00618579|EXPERIMENTAL|LMWH arm - active LMWH|
62194708|NCT00618579|PLACEBO_COMPARATOR|LMWH arm - placebo|
62194709|NCT00618579|EXPERIMENTAL|Warfarin arm - active warfarin|
62194710|NCT00618579|OTHER|Warfarin arm - control|
62009073|NCT04719910|EXPERIMENTAL|Study group|The study group will watch 15 minute long videos of cooking and preparing the food of the patient's preferred type of food prior to be taken to the operating room.
62009074|NCT04719910|PLACEBO_COMPARATOR|Placebo group|The control group will watch 15 minute long non-food related videos.
62009075|NCT05631080|NO_INTERVENTION|Surveillance with medical treatment for bladder outlet obstruction|Patients with low-risk prostate cancer who were elected for active surveillance protocol will have only medical treatment for control of their lower urinary tract symptoms secondary to bladder outlet obstruction
62009076|NCT05631080|ACTIVE_COMPARATOR|Surveillance with anatomical endoscopic enucleation of the prostate for bladder outlet obstruction|Patients with low-risk prostate cancer who were elected for active surveillance protocol will be offered anatomical endoscopic enucleation of the prostate for control of their lower urinary tract symptoms secondary to bladder outlet obstruction
62573684|NCT03569930|EXPERIMENTAL|ProtCent|anal application of a Centella based cream (Centella asiatica - ProtCent) will be added to standard of care
62782725|NCT02161055|ACTIVE_COMPARATOR|Non-intensive insulin therapy|Rapid blood glucose levels were measured once every 2 hours. When blood glucose levels were ≤ 13.0 mmol/L, no intervention was performed; When blood glucose levels were \> 13.0 mmol/L, regular insulin was subcutaneously injected separately. During fasting, insulin was injected once every 8 hours. During venous or enteral nutrition infusion, insulin was infused at 30 minutes before nutrition infusion. When blood glucose levels were ≤ 13.0 mmol/L, insulin infusion was terminated.
62782726|NCT05014997||Patient|30 male patients with Klinefelter syndrome who were not previously given testosterone replacement.
62194711|NCT03329677|EXPERIMENTAL|Transference-focused Psychotherapy (TFP)|Transference-focused psychotherapy is a psychodynamic talk therapy utilized in treating borderline personality disorder in men and women.
62194712|NCT06432673|EXPERIMENTAL|Arm 1|Participants receive a single dose of ATR-28 in the order Oral capsule - Oral solution with a washout period in between.
62194713|NCT06432673|EXPERIMENTAL|Arm 2|Participants receive a single dose of ATR-28 in the order Oral solution - Oral capsule with a washout period in between.
62194714|NCT06086041||severely to profoundly deaf patients with cochlear implantation indication|"Severely to profoundly deaf patients consulting in Grenoble University Hospital with cochlear implantation indication.~Patients are followed according to current care during 1 year after cochlear implantation."
62194715|NCT01666093|OTHER|revascularization group|patients will revascularized after a conservative treatment failure of at least 4 weeks
62194716|NCT01053767|NO_INTERVENTION|Arm 1|This is a phlebotomy study.
62194717|NCT05408195|EXPERIMENTAL|CHATBOT users|patients downloading and using the CHATBOT
62194718|NCT01754415|NO_INTERVENTION|control|Do exercise at home with video program designed by our team.
62194719|NCT01754415|EXPERIMENTAL|hydraulic resistance circuit training|Intervention:12 weeks resistance training
62573685|NCT03864679|EXPERIMENTAL|Exercise|Subjects will perform a cycling tests
62573686|NCT03145454|EXPERIMENTAL|Pain detection|Electroencephalographical responses will be collected during surgical gesture by different intervention: electroencephalography helmet, dermal electrode, blood pressure sensors, pupillometry glasses and Holter.
62194720|NCT03575949|EXPERIMENTAL|Diagnostic (FDG PET/CT)|Patients receive fludeoxyglucose F-18 IV over 1 minute and undergo PET/CT at 70 and 180 minutes after injection at 12-14 weeks following standard CRT completion.
62573687|NCT00447343||Treatment group|"Patients with cervical myelopathy undergoing decompressive cervical spine surgery will have two scans (pre-operatively and 6 months post-operatively).~A blinded investigator will administer questionnaires at each time point."
62782727|NCT05014997||Control|30 healthy control subject without diagnosis of any chronic disease
62782728|NCT00793130|OTHER|Coltect|Coltect contains natural compounds: curcumin, green tea and selenium which are approved as food supplements by the Ministry of Health in Israel. Curcumin and green tea are widely used in the food industry.
62782729|NCT01743040||CADence plus Standard Angiogram|All patients who were indicated for angiogram due to results of SPECT nuclear stress test
62791833|NCT05154656||patients with early stage of liver fibrosis|
62194721|NCT01407055|NO_INTERVENTION|Standard Medical Care|Patients receive standard treatment protocol for Coronary Artery Bypass Graft Surgery
62194722|NCT01407055|ACTIVE_COMPARATOR|Attention Control Group|In addition to standard medical care patients receive a comparable amount of therapist´s attention (common and unspecific factors = supportive therapy) to the intervention group, without targeting patients' expectations.
62194723|NCT01407055|EXPERIMENTAL|Expectation Manipulation Intervention|In addition to standard medical care patients' expectations prior to surgery are targeted in a brief psycho-educational intervention.
62194724|NCT00398190|ACTIVE_COMPARATOR|Control|Students receive standard anti-tobacco education
62194725|NCT00398190|EXPERIMENTAL|Media Literacy|Students receive media literacy based anti-smoking education
62009077|NCT05483010|EXPERIMENTAL|Atorvastatin|"* Choice of statin is at the discretion of the treating physician and may depend on insurance approval.~* Atorvastatin dosing starts at 80 mg once daily.~* In the absence of disease progression or intolerable side effects, patients may receive up to 12 months of treatment.~* If a patient switches statins due to toxicity, treatment time is still limited to 12 months total (ie, if a patient receives 6 months of atorvastatin and switches to rosuvastatin, the duration of rosuvastatin will be no more than 6 months)."
62009078|NCT05483010|EXPERIMENTAL|Rosuvastatin|"* Choice of statin is at the discretion of the treating physician and may depend on insurance approval.~* Rosuvastatin dosing starts at 40 mg once daily.~* In the absence of disease progression or intolerable side effects, patients may receive up to 12 months of treatment.~* If a patient switches statins due to toxicity, treatment time is still limited to 12 months total (ie, if a patient receives 6 months of atorvastatin and switches to rosuvastatin, the duration of rosuvastatin will be no more than 6 months)."
62009079|NCT06115876||Pre-Diabetes|Fasting Blood glucose ≥ and \<7 5.6mmol/L ≥100 and\<126 mg/dL HbA1C 5.7% to 6.4% 2hr Oral Glucose Tolerance Test (OGTT) ≥7.8 and \<11.1 mmol/L ≥140 and\<200 mg/dL
62009080|NCT06115876||Diabetes|Fasting Blood glucose 7 mmol/L (126mg/dL) or higher HbA1C 6.5% or higher 2hr Oral Glucose Tolerance Test (OGTT) 11.1 mmol/L (200 mg/dL) or higher
62782730|NCT01743040||CADence plus CT Angiogram|All patients who were not indicated for angiogram due to results of SPECT nuclear stress test underwent CT angiogram
62194726|NCT03798873|EXPERIMENTAL|FeelWell™ Compression garment use with increase mobility|"Subjects are randomized to wear custom-fitted FeelWell™ Compression garment daily during regular and exercise activities.~Subjects will work with physical therapist and exercise physiologist to increase strength, mobility and activity."
62573688|NCT00447343||Control group|"Healthy Volunteers will have two scans 6 months apart.~A blinded investigator will administer questionnaires at each time point."
62573689|NCT04862169|PLACEBO_COMPARATOR|Control group|"In the control group, they will only receive electronic version of the modules. They are able to access the module on their own devices.~The observation arm will receive the link of eLOK at the end of data collection and follow-ups (week 14). With this link, then they are able to access modules, videos and case studies provide in SPARK."
62782731|NCT03245775|EXPERIMENTAL|iChoose|12 bi-weekly sessions \& 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only
62194727|NCT03798873|OTHER|Increase mobility|For the control group, subjects will work with physical therapist and exercise physiologist to increase strength, mobility and activity. The control group will not be assigned a compression garment during the trial.
62782732|NCT03245775|EXPERIMENTAL|Family Connections|2 in-person sessions spaced one week apart \& 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
62194728|NCT02909465|PLACEBO_COMPARATOR|placebo|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections of distilled water (one 2 ml and the other 0.05 cc/kg) 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
62194729|NCT02909465|EXPERIMENTAL|midazolam|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. one will be 2 ml of distilled water and the other 0.05 mg/kg midazolam, 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
62782733|NCT04481360||patients with covid 19 pneumonia|clinical presentation \& outcome of covid 19 pneumonia
62782734|NCT05414552||ECP treatment arm|ECP treatment per prtocol
62194730|NCT02909465|EXPERIMENTAL|haloperidol|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. One will be 0.05 cc/kg of distilled water and the other 5 mg of haloperidol (in 2 cc syringes), 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
62194731|NCT02809560|EXPERIMENTAL|Asthmatic children|Induced sputum method using hypertonic serum
62734646|NCT04166773|EXPERIMENTAL|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
62782735|NCT06238804||fracture types|A3.1, A3.2, A3.3
62734647|NCT04166773|EXPERIMENTAL|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
62734648|NCT04166773|EXPERIMENTAL|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
62782736|NCT00637962|EXPERIMENTAL|Active product|CN54gp140 + gel
62782737|NCT00637962|PLACEBO_COMPARATOR|Gel alone|Gel alone
62782738|NCT03416452|EXPERIMENTAL|PD patients no|PD patients without freezing of gait
62782739|NCT03416452|PLACEBO_COMPARATOR|Healthy|HV using Mobile Gait Trainer
62782740|NCT03416452|EXPERIMENTAL|PD patients|pd patients using vibratory cueing device
62782741|NCT03416452|EXPERIMENTAL|PD patients 1|PD patients with freezing of gait
62782742|NCT03416452|EXPERIMENTAL|Healthy Volunteers|Age and gender matched healthy volunteers.
62782743|NCT01797913|EXPERIMENTAL|gemcitabine|
62791834|NCT05154656||subjects with no liver fibrosis|
62009081|NCT02512497|EXPERIMENTAL|Romidepsin + Busulfan + Fludarabine + Stem Cell Transplant|"Part 1:~Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies. Fludarabine 40 mg/m2 by vein on Days -6 to -3. Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the optimal dose. Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1. Stem cell infusion on Day 0.~Romidepsin Maintenance Therapy - Part 2:~Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
62009082|NCT04977843|EXPERIMENTAL|E-BAL|E-BAL carried out within 48 hours
62009083|NCT04977843|NO_INTERVENTION|Conservative/Control|Standard of care management
62782744|NCT01525095||Candida Positive Patients|Symptomatic adult patients, confirmed via concordant diagnostic blood culture and species identification and subsequent second blood culture results and species identification that are Candida positive
62194732|NCT02809560|SHAM_COMPARATOR|Control children|Induced sputum method using hypertonic serum
62194733|NCT02370251|EXPERIMENTAL|Omegaven|Children will receive Omegaven at a maximum of 1 g/kg/day upon enrollment in this arm.
62573690|NCT04862169|EXPERIMENTAL|Intervention group|The intervention on this RCT is an educational training program: SPARK (Strengthening PAlliative caRe in the community by enhancing nurses' Knowledge). This is an educational intervention using an online method with learning method system (LMS) eLOK hosted by Universitas Gadjah Mada Yogyakarta (Affiliation of authors' team). The intervention includes online discussions and access to eLOK for study materials (modules and videos) and some synchronous meetings.
62782745|NCT01525095||Candida Negative Patients|Hospitalized adult patients, confirmed via concordant diagnostic blood culture with subsequent species identification and subsequent second blood culture with subsequent species identification that are Candida negative
62782746|NCT02587819|EXPERIMENTAL|Treatment with BSCT|21 patients with BCC were treated with BSCT (anti-nf-P2X7) 10% Ointment topically applied twice daily for 28 consecutive days.
62194734|NCT03999632|EXPERIMENTAL|Mankai Group|The pre-operative liquid diet will be started two weeks before surgery date for both groups. During the first week patients in group A (Wolffia Globosa) will be allowed to have two meals a day and one protein shake (Wolffia Globosa) of 16 oz. Each meal will consist of 3-5 oz of lean protein (Chicken, turkey or fish) and one cup of vegetables or salad. During the second week, patients will drink one protein shake of 16 oz (Wolffia Globosa) as a meal replacement, three times per day and will not be allowed to eat solid food. Patients will also be allowed to Drink clear liquids in between protein shakes.
62194735|NCT03999632|NO_INTERVENTION|Control Group|The pre-operative liquid diet will be started two weeks before surgery date for both groups. During the first week patients in group B (Control) will be allowed to have two meals a day and one protein shake (Control) of 16 oz. Each meal will consist of 3-5 oz of lean protein (Chicken, turkey or fish) and one cup of vegetables or salad. During the second week, patients will drink one protein shake of 16 oz (Control) as a meal replacement, three times per day and will not be allowed to eat solid food. Patients will also be allowed to Drink clear liquids in between protein shakes.
62194736|NCT02338063|EXPERIMENTAL|1|Virtual Reality
62194737|NCT02338063|EXPERIMENTAL|2|Health Promotion
62194738|NCT05389995|ACTIVE_COMPARATOR|Potassium citrate|
62194739|NCT05389995|ACTIVE_COMPARATOR|Crystal light|
62194740|NCT05389995|ACTIVE_COMPARATOR|Crystal light + potassium citrate|
62782747|NCT04773834|EXPERIMENTAL|Experimental group|Participants will be enrolled virtually into a digital diabetes prevention program through the Noom app and willing to receive text messages based on their engagement levels in Noom from the study team, as well as complete text-based surveys.
62782748|NCT04773834|OTHER|Control group|Participants will be enrolled virtually into the digital diabetes prevention program through the Noom app and willing to receive general text messages from the study team
62782749|NCT03596684|EXPERIMENTAL|citrulline|citrulline 5g/d
62782750|NCT03596684|PLACEBO_COMPARATOR|Placebo|pure mixture of amino acids: alanine, aspartate, glycine, proline, serine, histidine
62782751|NCT00568126|EXPERIMENTAL|Maca Root|Subjects in this arm will be given 3g/day of maca root for 12 weeks
62782752|NCT00568126|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive inactive placebo for 12 weeks.
62782753|NCT04552808|EXPERIMENTAL|Yimitasvir Phosphate Capsules|The mechanism of action of Yimitasvir is the specific inhibition of HCV non-structural protein NS5A
62782754|NCT05860465|EXPERIMENTAL|SPH4336 Tablets|SPH4336 Tablets; Letrozole tablets; Fulvestrant injection
62782755|NCT05860465|PLACEBO_COMPARATOR|SPH4336 Tablets Placebo|SPH4336 Tablets Placebo; Letrozole tablets; Fulvestrant injection
62782756|NCT06141876|EXPERIMENTAL|Active|APEX-002-A02
62782757|NCT06141876|PLACEBO_COMPARATOR|Placebo|matched placebo
62782758|NCT02483117||Eating disorder patients by type of compensating behavior.|Data collection started in 2010; one year follow-ups were conducted through 2011-2012. Psychiatrists collaborating in the study informed personally their patients about the objectives of the study, and recorded the sociodemographic information, including age, gender, marital status, level of education, employment status, and people with whom the patient lived. Those who agreed to take part were also sent the questionnaires and informed consent form by mail. They were asked to return these by mail using an enclosed, pre-stamped envelope. Two reminders also were sent at intervals of 15 days to those who did not respond to the first mailing.
62782759|NCT03404297|EXPERIMENTAL|Immediate Compression Therapy Arm|Patients in this arm will receive a locally sourced version of compression therapy while concurrently receiving chemotherapy
62009084|NCT03274479|EXPERIMENTAL|PBF-1129_40mg|
62009085|NCT03274479|EXPERIMENTAL|PBF-1129_80mg|
62009086|NCT03274479|EXPERIMENTAL|PBF-1129_160mg|
62009087|NCT03274479|EXPERIMENTAL|PBF-1129_320mg|
62009088|NCT03146650|EXPERIMENTAL|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1, 15, 29, 43, 57, and 71 of course 1 and on days 1 and 15 of course 2, over 60 minutes on days 29 and 57 of course 2 and on days 1, 29, and 57 of subsequent courses. Patients also receive ipilimumab over 90 minutes on days 1 and 43. Courses repeat every 84 days in the absence of disease progression or unexpected toxicity.
62009089|NCT05457309|EXPERIMENTAL|malignant fungating wounds care regimen|malignant fungating wounds care regimen based on the evidences, expert consultation, pre-experiment and final determination
62782760|NCT03404297|PLACEBO_COMPARATOR|Delayed Compression Therapy Arm|Patients in this arm will receive a locally sourced version of compression therapy after completing \~ 14 weeks of chemotherapy.
62194741|NCT05665569|ACTIVE_COMPARATOR|Routine Care|Women will undergo routine pelvic physical therapy for birth-related pelvic floor disorders as determined by their physical therapist who is also the Principal Investigator.
62782761|NCT03817112|ACTIVE_COMPARATOR|Dexmedetomidine|Infusion of dexmedetomidine
62009090|NCT04467827||Group A1 male|back shape neutral - a vertical line applied to the back of the body meets at the level of the thoracic segment and buttocks
62009091|NCT04467827||Group A2 female|back shape neutral - a vertical line applied to the back of the body meets at the level of the thoracic segment and buttocks
62194742|NCT05665569|EXPERIMENTAL|Flourish HEC|"In addition to routine physical therapy, women will use a 3-component vaginal hygiene system, Flourish HEC (HEC = hydroxyethylcellulose to differentiate this system from a prior Flourish system based in aloe) plus a personal lubricant called BioNude."
62194743|NCT03656276||Group A: Oncologists (wait list control)|Oncologists will be wait-listed for training on the Tool to improve Participation In Clinical Trials (ToPIC)
62194744|NCT03656276||Group B: Oncologists (training)|Oncologists will receive immediate training on the Tool to improve Participation In Clinical Trials (ToPIC)
62194745|NCT04592094|EXPERIMENTAL|Blueback® Physio|Classic protocole with the use of Blueback® Physio during physiotherapy sessions, , and using the Blueback® Physio in the active mode (patient and physiotherapists see the biofeedback in real time)during the tests required by the protocol of the study.
62194746|NCT04592094|NO_INTERVENTION|Standard Care|Classic protocole without the use of Blueback® Physio during physiotherapy sessions, and using the Blueback® Physio in the blind mode during the tests required by the protocol of the study
62398610|NCT04446468|EXPERIMENTAL|PEACE|The PEACE intervention will be delivered by a trained mental health staff member, such as a study psychologist, mental health nurse, social worker, or psychiatrist. The intervention consists of three synergistic components that work to support the patient after inpatient psychiatric discharge: 1) Brief educational component, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study psychologist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed; and 3) Mobile app, which aims to improve the patient's social connectedness and provide additional educational materials on suicide. Patients in this arm will also continue to receive standard post-discharge psychiatric care.
62194747|NCT04972669|SHAM_COMPARATOR|control group|sham electroaupuncture
62782762|NCT03817112|ACTIVE_COMPARATOR|Propofol|Propofol infusion
62782763|NCT01088399||Somatropin replacement treatment|Adult participants with growth hormone deficiency receiving somatropin replacement treatment.
62782764|NCT01088399||No treatment|Adult participants with growth hormone deficiency receiving no somatropin replacement treatment.
62009092|NCT04467827||Group B1 male|round back shape - a vertical line applied to the back of the body contacts only at the level of the thoracic segment
62009093|NCT04467827||Group B2 female|round back shape - a vertical line applied to the back of the body contacts only at the level of the thoracic segment
62009094|NCT04467827||Group C1 male|round back shape - a vertical line applied to the back of the body only touches the level of the buttock section
62009095|NCT04467827||Group C2 female|round back shape - a vertical line applied to the back of the body only touches the level of the buttock section
62009096|NCT04439240|EXPERIMENTAL|Treatment (AZD4547)|Patients receive AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62009097|NCT00724451||Participants with Chronic Hepatitis C (CHC)|Peginterferon-naïve participants with CHC seen in general clinical practice in Italy and treated with either pegylated interferon alfa-2a or alfa-2b + ribavirin.
62194748|NCT04972669|EXPERIMENTAL|experimental group|Electroaupuncture
62194749|NCT01712061|ACTIVE_COMPARATOR|Arm 1 PF-04634817|
62194750|NCT01712061|PLACEBO_COMPARATOR|Arm 2 Placebo|
62782765|NCT04201613|ACTIVE_COMPARATOR|Early Robotic Rehab Low Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 5-9 after their stroke. They will receive one hour of treatment per day for 20 days.
62782766|NCT04201613|ACTIVE_COMPARATOR|Early Robotic Rehab High Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 5-9 after their stroke. They will receive 2 one-hour treatment sessions per day for 20 days.
62782767|NCT04201613|ACTIVE_COMPARATOR|Late Robotic Rehab Low Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 21-25 after their stroke. They will receive one hour of treatment per day for 20 days.
62782768|NCT04201613|ACTIVE_COMPARATOR|Late Robotic Rehab High Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 21-25 after their stroke. They will receive 2 one-hour treatment sessions per day for 20 days.
62782769|NCT04201613|ACTIVE_COMPARATOR|Control Group|This group will receive usual care with robotic assessment.
62782770|NCT06583408||Women with > 3 months amenorrhea|Women aged 18-40 years old with a diagnosis of functional hypothalamic amenorrhea, or lab results that are within the inclusion criteria.
62782771|NCT06027450||Patients treated with NHIg|"Patients treated for one of the following indications :~* Thrombopenic Idiopathic Purpura (TIP)~* Chronic Demyelinating Inflammatory Polyradiculoneuritis (CDIP)~* Secondary immune deficiency (SID)"
62782772|NCT02653937|EXPERIMENTAL|Kampo medicine|7.5g per day of Tsumura's shigyakusan ( Tsumura \& Co ) was administered to each of 110 cases.
62009098|NCT03145727|PLACEBO_COMPARATOR|Placebo Group|Placebo Group: In this group the participants received TENS with frequency of 75Hz, pulse duration of 200 microseconds. The stimulation time will be for only 10s.
62194751|NCT01053247|EXPERIMENTAL|Test|Test product that contains the active pharmaceutical ingredient
62194752|NCT01053247|ACTIVE_COMPARATOR|Reference|Reference product that contains active pharmaceutical ingredient
62194753|NCT01053247|PLACEBO_COMPARATOR|Vehicle|Placebo that contains no active pharmaceutical ingredient
62194754|NCT05928468|EXPERIMENTAL|LYB002V14|The vaccine LYB002V14 was administered through intramuscular injection.
62398611|NCT04446468|EXPERIMENTAL|Control|Those randomized to the control arm will receive standard psychiatric hospital discharge care alone. Current VA standard discharge care includes five core elements. First, patients and their outpatient providers are required to be involved in discharge planning. Second, patients should be offered evidence-based treatments to address their mental health symptoms. Third, the inpatient team should work with the patient to complete a safety plan prior to discharge. Fourth, the inpatient team should arrange two follow-up care visits within 30 days of discharge. Fifth, the inpatient team in conjunction with the SPC assess whether patients are appropriate to be placed on the High Risk for Suicide List. Patients who are placed on the High Risk for Suicide List receive enhanced oversight as outlined in VA policy.
62782773|NCT03408964||Group 0 (set-up)|Patients with known diagnosis of CSPC (Group 0a) and CRPC (Group 0b) irrespective of the PC treatment (not first diagnosis)
62782774|NCT03408964||Group 1a (control)|Patients who underwent biopsies for suspected Prostate Cancer (PC), with a negative result for invasive cancer
62782775|NCT03408964||Group 1|Patients with a first diagnosis of localized biopsy-proven PC, untreated, planned to undergo radical surgery and / or radical radiotherapy
62782776|NCT03408964||Group 2|Patients with a diagnosis of locally advanced unresectable, recurrent or metastatic PC planned to receive first-line hormono therapy
62782777|NCT03408964||Group 3|Patients with recurrent/progressive/metastatic CRPC planned to receive chemotherapy
62782778|NCT03197051||Q1|Measure the Concentration of Syndecan-1, Heparan sulfate before anesthetic induction and immediately after weaning from cardiopulmonary bypass. Categorize the patients by serum syndecan-1 concentration(off-CPB) quartile. Q1 means a group of lowest 25% of serum syndecan-1 concentration.
62782779|NCT03197051||Q2|Q2 means a group of lower 25\~50% of serum syndecan-1 concentration.
62782780|NCT03197051||Q3|Q3 means a group of higher 50\~75% of serum syndecan-1 concentration.
62782781|NCT03197051||Q4|Q4 means a group of highest 75\~100% of serum syndecan-1 concentration.
62782782|NCT04016844|EXPERIMENTAL|tDCS first then SHAM effects on glucose uptake in leg muscles|"tDCS Block: The subject will walk for 20 min on a treadmill at a self-selected speed during which time tDCS will be applied to the motor cortex (M1) corresponding to the more-affected leg.~Sham Block: The subject will walk for 20 min on a treadmill at a self-selected speed during which time SHAM will be applied to the motor cortex (M1) corresponding to the more-affected leg."
62782783|NCT02166268|ACTIVE_COMPARATOR|Avanz Phleum pratense|Avanz Phleum pratense 15,000 SQ+ (standardised quality), suspension for subcutaneous injection.
62194755|NCT05928468|ACTIVE_COMPARATOR|LYB002V14A|The vaccine LYB002V14A was administered through intramuscular injection.
62194756|NCT05928468|ACTIVE_COMPARATOR|LYB002CA|The vaccine LYB002CA was administered through intramuscular injection.
62782784|NCT02166268|PLACEBO_COMPARATOR|Placebo|Placebo, suspension for subcutaneous injection.
62791835|NCT06079021|ACTIVE_COMPARATOR|CytoSorb hemoadsorption|Patients with acute on chronic liver failure will receive CytoSorb treatment for 72 hours. The aim is to remove the molecules that drive systemic inflammation.
62194757|NCT03617835|EXPERIMENTAL|R - Low dose of BI 655130 Periumbilical|Single low dose of BI 655130 administered as one single subcutaneous injection (given as 1 x 2 milliliter (mL)) in the periumbilical region following an overnight fast of at least 10 hours.
62194758|NCT03617835|EXPERIMENTAL|T1 - Low dose of BI 655130 Periumbilical (left and right)|Single low dose of BI 655130 administered as two single subcutaneous injections (given as 2 x 1 milliliter (mL)) in the periumbilical region (left and right) following an overnight fast of at least 10 hours.
62194759|NCT03617835|EXPERIMENTAL|T2 - Low dose of BI 655130 Thigh|Single low dose of BI 655130 administered as one single subcutaneous injection (given as 1 x 2 milliliter (mL)) in the thigh region following an overnight fast of at least 10 hours.
62194760|NCT03617835|EXPERIMENTAL|T3 - High dose of BI 655130 Periumbilical (left and right)|Single high dose of BI 655130 administered as two single subcutaneous injections (given as 2 x 2 milliliter (mL)) in the periumbilical region (left and right) following an overnight fast of at least 10 hours.
62782785|NCT03960892|EXPERIMENTAL|E-CAU with Group Problem Management Plus (PM+)|"190 participants will be randomly assigned to E-CAU with Group PM+. The PM+ is developed by the World Health Organization (WHO) especially for the communities who are exposed to adversity. PM+ (Dawson et al., 2015) belongs to a set of programs which are low-intensity, shorter, less expensive and trans-diagnostic (i.e., not condition-specific, but targeted at a broader set of symptoms of common mental disorders) programs to reduce common mental health symptoms (including depression, anxiety and stress symptoms) and improve psychosocial functioning.~The participants in the experimental arm will receive Group PM+ by trained, non-specialist peer-refugees in addition to E-CAU."
62194761|NCT06117228||women with Down syndrome aged 18 to 30|women aged 18 to 30 with Down syndrome, whether or not they were receiving medical care, who agreed to take part in the study.
62194762|NCT00701909|ACTIVE_COMPARATOR|Morphine plus Ketamine, then Morphine plus Saline (placebo)|During the first wound care procedure, patients received morphine 0.05 mg/kg (a maximum dose of 4 mg) plus ketamine 0.25 mg/kg (MK). Then, during the second wound care procedure, patients received morphine 0.1 mg/kg (a maximum dose of 8 mg) plus saline (MS).
62782786|NCT03960892|NO_INTERVENTION|Enhanced care as usual (E-CAU) only|190 participants will be randomly assigned to E-CAU group. CAU ranges from the free health services government provides to Refugee and Asylum Seekers Assistance and Solidarity Association's (RASASA) mental health services which are provided by the Psychological Support Unit (MHPSS Support Unit) which includes counselling as well. The enhanced care arm (CAU, with the addition of a leaflet which will include information on the services that they can get from RASASA and other public services. ), is to be used as a benchmark for measuring the effectiveness of STRENGTHS's intervention, which is Problem Management Plus (PM+).
62782787|NCT00856297|EXPERIMENTAL|MenACWY-CRM|Subjects received one primary dose of MenACWY-CRM conjugate vaccine in the parent study and were followed for persistence in the present study.
62194763|NCT00701909|PLACEBO_COMPARATOR|Morphine plus Saline (placebo), then Morphine plus Ketamine|During the first wound care procedure, patients received morphine 0.1 mg/kg (a maximum dose of 8 mg) plus saline (MS). Then, during the second wound care procedure, patients received morphine 0.05 mg/kg (a maximum dose of 4mg) plus ketamine 0.25 mg/kg (MK)
62398612|NCT01583699|EXPERIMENTAL|Endomicroscopy|All patients included into the study will undergo endomicroscopy of the upper GI-tract.
62398613|NCT02316782||Non-blinded IVUS assessment|The non-blinded arm will use the angiogram and IVUS grayscale and VH-IVUS to guide the procedure.
62398614|NCT02316782||Blinded IVUS assessment|After routine coronary angiogram, the physicians in the blinded arm of the study will only use the angiogram to guide the DES stenting procedure;
62398615|NCT00592423|OTHER|1|"A convenience sample of children will be utilized for this study, which will include both genders and all ethnicities. There is no known predilection for any racial or gender inequalities with regard to subject recruitment or outcome variables related to this study."
62398616|NCT05239065|EXPERIMENTAL|Personalized stress management nursing coaching with application of portable device|Arm (Tongji Hospital) All the participants will receive a paper-printed brochure introducing stress and stress management strategies and the instruction of using HUAWEI portable device at the recruitment. During the 3-month intervention phase, multiple formats of stress and stress management knowledge educations will be sent by the health educator on weekly basis. The participants will have personalized stress management nursing coaching and assistance of building up new life habits, they will be also encouraged to submit a weekly questionnaire for self-evaluation. Finally, participants from Tongji hospital will be involved in a social network to share their experience anonymously and gain knowledge from the group chat.
62782788|NCT00856297|ACTIVE_COMPARATOR|Licensed comparator|Subjects received one primary dose of a quadrivalent meningococcal conjugate vaccine with diphtheria toxoid as the protein carrier in the parent study and were followed for persistence in the present study at 5 years postvaccination.
62782789|NCT00856297|OTHER|Naive|Subjects who were age-matched to the other study groups and had not received any previous meningococcal vaccinations.
62782790|NCT00856297|EXPERIMENTAL|MenACWY-CRM/MenACWY-CRM|Subjects received one primary dose of the MenACWY-CRM conjugate vaccine in the parent study and one booster dose of MenACWY-CRM conjugate vaccine at 3 years after primary vaccination.
62782791|NCT00856297|EXPERIMENTAL|Licensed comparator/MenACWY-CRM|Subjects received one primary dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine in the parent study and one booster dose of MenACWY-CRM conjugate vaccine at 3 years after primary vaccination.
62782792|NCT03680300|EXPERIMENTAL|Post Facilitating Stretch|Each patient in group A will be given with hot pack along with Tens for 20 mins then the patient will receive post facilitation stretch only, for about one month on daily basis.
62782793|NCT03680300|EXPERIMENTAL|Post Isometric Relaxation|Each patient in group B will receive hot pack along with Tens for 20 mins then the patients will receive post isometric relaxation alone for about one months on daily basis.
62009099|NCT03145727|EXPERIMENTAL|Low Frequency Group|Low Frequency Group: In this group the TENS will be adjusted with frequency of 10Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
62573691|NCT02020538|PLACEBO_COMPARATOR|Chloride-rich IV fluid|The chloride-rich strategy will include 0.9% saline as the perioperative crystalloid of choice with 4% albumin as the perioperative colloid of choice.
62194764|NCT03933462|EXPERIMENTAL|InnoSpire Go|The InnoSpire Go is a handheld, single patient use, vibrating mesh nebulizer system designed to aerosolize liquid medications for respiratory disease. The device operates continuously once initiated and automatically switches off once the medication has been delivered. The device may be used in pediatric and adult populations, as permitted by the prescribed medication, and is suitable for use in home environments or hospital/clinic settings.
62194765|NCT03933462|ACTIVE_COMPARATOR|Jet Nebulizer|Jet Nebulizers are the standard delivery system for aerosolized medications. A nebulizer breaks up medical solutions into small droplets suspended in air (aerosol) so that they may be delivered to the patient's airways for respiratory therapy.
62194766|NCT03038204||PMA+MVA+CABG|patients with ischemic cardiomyopathy and mitral regurgitation who underwent coronary artery bypass grafting, mitral annuloplasty, and papillary muscles approximation.
62194767|NCT03038204||MVA+CABG|patients with ischemic cardiomyopathy who underwent coronary artery bypass grafting and mitral valve annuloplasty.
62194768|NCT03162445||Typically developing controls|Boys between ages 7 and 14 years old at study onset without medications or diseases impairing bone development
62398617|NCT05239065|SHAM_COMPARATOR|Minimum information transfer and assistance of building up healthy life habits|Arm2 (Wuhan No1 Hospital) - The participants will only receive a paper-printed brochure introducing stress and stress management strategies and the instruction of using HUAWEI portable device at the recruitment. There is no recurrent knowledge education, interpersonal communications, data feedbacks with the participants during the 3-month intervention phase.
62398618|NCT05520359|EXPERIMENTAL|Neurologic Disorders|Evaluation of individual and combined effects of mobility devices and spinal stimulation for individuals with neurologic disorders.
62782794|NCT03680300|EXPERIMENTAL|Frictional Massage|Frictional massage will be given to 3rd group
62194769|NCT03162445||Autism spectrum disorder|Boys between ages 7 and 14 years old at study onset without medications or diseases impairing bone development
62194770|NCT02977390|OTHER|Passive Leg Raise (PLR)|"The patient is placed in a 45 degree recumbent position. Stroke volume is measured in ml.~Intervention:The patient is placed horizontal and the legs are passively raised to 45 degrees.~Measurement:The effect of the PLR on Stroke Volume is measured. Thereafter the patient is repositioned to the initial position and Stroke Volume is measured again."
62194771|NCT03017742|EXPERIMENTAL|Test Group|The subjects enrolled in the test group will receive the pulse oximeter
62194772|NCT00848484|EXPERIMENTAL|1|MK5757
62194773|NCT00848484|PLACEBO_COMPARATOR|2|Placebo
62194774|NCT03758547|EXPERIMENTAL|in-exufflator and percussion technique|"assess the physiological effects, of a common daily practice of secretion removal in intubated patients, that are: in-exufflator technique and percussion technique"
62194775|NCT01435148|EXPERIMENTAL|Stimulation of SGC then VACNAC targets|Stimulation of the subgenual cingulate cortex (SGC) target will take place first, followed by stimulation of the ventral anterior capsule nucleus accumbens target (VACNAC) if no clinical response after a minimum of 4 months.
62194776|NCT01435148|EXPERIMENTAL|Stimulation of VACNAC then SGC targets.|Stimulation of the ventral anterior capsule nucleus accumbens target (VACNAC) will take place first, followed by stimulation of the subgenual cingulate cortex target (SGC) if no clinical response after a minimum of 4 months.
62398619|NCT03389217|EXPERIMENTAL|Real-tDCS + rehabilitation programme|The real transcranial Direct Current Stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 minutes over the the left dorsolateral prefrontal cortex and rehabilitation programme for prevention and management of pain.
62398620|NCT03389217|ACTIVE_COMPARATOR|Sham-tDCS + rehabilitation programme|The sham transcranial Direct Current Stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over left dorsolateral prefrontal cortex and rehabilitation programme for prevention and management of pain.
62398621|NCT06723990||NEOADJUVANT SETTING|Neoadjuvant standard treatment for HER2+: A→Tax +T/P
62782795|NCT05665907||children with vestibular dysfunction with hearing loss|children with vestibular dysfunction with hearing loss
62782796|NCT05665907||children with vestibular dysfunction with normal inner ear function|children with vestibular dysfunction with normal inner ear function
62194777|NCT01783132|OTHER|Budesonide|Asthma treated patient with Budesonide for 1 year, 4 different dosage according to measurement of exhaled NO done with NIOX MINO.
62194778|NCT01783132|NO_INTERVENTION|Standard of care|Asthma treated patient with standard of care during 1 year. Exhaled NO measurement will be done 4 times/year, and compared afterwards with the Budesonide group.
62398622|NCT06723990||ADJUVANT SETTING|Adjuvant standard treatment for HER2+ (N0): Tax + T (+/-ET); Adjuvant standard treatment for HER2+ (N+): A→Tax +T/P (+/- ET)
62398623|NCT06050486|EXPERIMENTAL|Arm 1: Intervention|Participants in Arm 1 receive a psychological intervention (MBT-C).
62398624|NCT04430387|ACTIVE_COMPARATOR|Group 1- The saliva ejector|
62194779|NCT02520583|EXPERIMENTAL|MICROBAC|Bacterial cultures
62194780|NCT02520583|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62398625|NCT04430387|ACTIVE_COMPARATOR|Group 2- The high-volume evacuator|
62398626|NCT04430387|ACTIVE_COMPARATOR|Group 3- The DryShield|
62398627|NCT06082713||Huntington Disease Carriers|
62398628|NCT06082713||Non-Huntington Disease Carriers|
62573692|NCT02020538|ACTIVE_COMPARATOR|Chloride-poor IV fluid|A low-chloride strategy of perioperative IV fluid will include PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice with 20% albumin as the colloid of choice.
62573693|NCT06578494|EXPERIMENTAL|Ultrasound-guided peripheral intravenous access|The patients in the experimental arm will receive ultrasound-guided peripheral intravenous catheter placement, where the dynamic needle tip (DNTP) approach (short-axis) will be used.
62573694|NCT06578494|ACTIVE_COMPARATOR|Traditional palpation intravenous access technique|The comparator group will receive the traditional palpation intravenous access technique.
62573695|NCT05056324|EXPERIMENTAL|Intervention group|
62782797|NCT00364741|ACTIVE_COMPARATOR|A|Fraction of inspired oxygen (FiO2) = 0.30
62782798|NCT00364741|ACTIVE_COMPARATOR|B|FiO2 = 0.80
62782799|NCT04486872|EXPERIMENTAL|anti-CD19 and anti-CD20 dual specific CAR-T Cells|
62194781|NCT05758805|EXPERIMENTAL|Unique Arm|patients with atrial fibrillation and indication for radiofrequency ablation guided by electro-anatomical mapping with high-density mapping catheter and radiofrequency ablation by contact force ablation catheter, according to current guidelines
62194782|NCT04856683||Patients with endocrine and metabolic diseases|Patients with endocrine and metabolic diseases (hypothalamic-pituitary-gonadal and adrenal diseases, type 2 diabetes mellitus and bone diseases)
62194783|NCT00983749|EXPERIMENTAL|Full-pressure ECP|"Patients in the Full-pressure ECP arm receive a 1-hour treatment of ECP at full pressure, which will be applied in a tiered, dose-escalating manner up to 300mmHg, while assessments are made."
62194784|NCT00983749|SHAM_COMPARATOR|Sham-pressure ECP|A 1-hour treatment of ECP at an inactive pressure (75mmHg)
62194785|NCT00965497|EXPERIMENTAL|Escitalopram|All patients will receive escitalopram 20 mg daily.
62194786|NCT03683550|EXPERIMENTAL|SPEC/CT|SLNE with preoperative hybrid SPECT/CT
62194787|NCT03683550|ACTIVE_COMPARATOR|Standard|Standard SLNE (with planar preoperative lymphoscintigraphy)
62194788|NCT01681615|ACTIVE_COMPARATOR|Acetylsalicylate|Acetylsalicylic Acid Eyedrops
62194789|NCT01681615|PLACEBO_COMPARATOR|isotonic NaCl|Saline Eyedrops
62782800|NCT05792917|EXPERIMENTAL|tafolecimab (a modified manufacturing process)|450mg，SC，single dose
62782801|NCT05792917|ACTIVE_COMPARATOR|tafolecimab (a original manufacturing process)|450mg，SC，single dose
62194790|NCT04283890|EXPERIMENTAL|Phase Ib|
62194791|NCT04283890|ACTIVE_COMPARATOR|Phase II - Combination treatment|
62194792|NCT04283890|ACTIVE_COMPARATOR|Phase II - PHP|
62194793|NCT01075477||Cohort|
62194794|NCT02608736|EXPERIMENTAL|Valproic Acid|Valproic acid will be orally administered in a total dose of 1500mg per day (500mg, every 8 hours), for three months.
62194795|NCT02608736|PLACEBO_COMPARATOR|Placebo|Placebo will be orally administered in a total dose of three capsules per day (every 8 hours), for three months.
62194796|NCT01439386|ACTIVE_COMPARATOR|AF ablation with or without AFL ablation|Pulmonary vein antral isolation (PVAI)with or without cavo-tricuspid isthmus (CTI) ablation
62194797|NCT01439386|ACTIVE_COMPARATOR|AFL ablation only|Cavo-tricuspid isthmus ablation only
62194798|NCT04633850||Before implementation|Perineural bupivacaine without adjuvants.
62782802|NCT00774982|EXPERIMENTAL|1 6MP Test Formulation|1 x 40 mg Oral Tablet, 6 MP Delayed Release Test Formulation, for targeted ileal delivery
62194799|NCT04633850||After implementation|Perineural bupivacaine with intravenous dexamethasone.
62194800|NCT01721733|PLACEBO_COMPARATOR|Placebo|Each patient will receive a volume of placebo based on weight
62194801|NCT01721733|ACTIVE_COMPARATOR|EPI-743 15 mg/kg|Each subjects dose will be based on their weight. 15 mg/kg with a maximum dose of 200 mg per dose, t.i.d., will be administered in this treatment arm.
62194802|NCT01721733|ACTIVE_COMPARATOR|EPI-743 5 mg/kg|Each subjects dose will be based on their weight. 5 mg/kg with a maximum dose of 100 mg per dose, t.i.d., will be administered in this treatment arm.
62194803|NCT05429047||SARS-CoV-2 vaccine during pregnancy|Pregnant women who received a vaccine against SARS-CoV-2 during pregnancy and their children
62194804|NCT05429047||SARS-CoV-2 infection during pregnancy|Pregnant women who were diagnosed with a SARS-CoV-2 infection during pregnancy and their children
62194805|NCT05429047||SARS-CoV-2 vaccine or infection before pregnancy|Pregnant women who neither received a COVID-19 vaccine nor were diagnosed with COVID-19 during their pregnancy but had either a COVID-19 vaccine or infection before pregnancy and their children
62782803|NCT00774982|ACTIVE_COMPARATOR|2. 6MP Reference Formulation|2 x 50 mg oral tablet, PURINETHOL
62782804|NCT02899702|EXPERIMENTAL|IVIG|PRIVIGEN (CSL Behring) NORMAL HUMAN IMMUNOGLOBULINS L-PROLINE, Water for injection
62194806|NCT05429047||No exposure|Pregnant women, who were never exposed to a SARS-CoV-2 vaccine or infection until the birth and their children
62194807|NCT01901822|ACTIVE_COMPARATOR|Sutured separately|The soft tissue and the allograft will each be sutured separately using a continuous sling suture.
62194808|NCT01901822|EXPERIMENTAL|Sutured together|The soft tissue and the allograft will be sutured together using a continuous sling suture.
62194809|NCT02592213|EXPERIMENTAL|Treatment|Treatment of lymphedema with cell-assisted lipotransfer using autologous stromal vascular fraction
62194810|NCT06061237|EXPERIMENTAL|Aerobic Thai dance exercise intervention|Aerobic Thai dance exercise 60 minute per times, 3 times per weeks of 12 weeks.
62194811|NCT06061237|NO_INTERVENTION|Control|Give advice on exercise.
62194812|NCT02213731|OTHER|Cryoballoon ablation|Subjects will wear holter monitors at baseline, 6 months and 12 months
62194813|NCT06017739|EXPERIMENTAL|Expiratory Flow Accelerator|Patients for 6 weeks use the Expiratory Flow Accelerator Technology
62194814|NCT06017739|EXPERIMENTAL|Expiratory Flow Accelerator + HIGH FLOW Technology|Patients for 6 weeks use the EFA technology and High Flow Technology
62194815|NCT03514615|PLACEBO_COMPARATOR|Placebo Gel|Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active gel and the other placebo.
62194816|NCT03514615|EXPERIMENTAL|Active Gel|Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active gel and the other placebo.
62398629|NCT05775666|EXPERIMENTAL|UCLM802 Cell Injection|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by UCLM802 cell injection.
62398630|NCT06050928|EXPERIMENTAL|EP262 150 mg|Once daily
62194817|NCT00639327|EXPERIMENTAL|A|CPT-11+ S-1
62782805|NCT02899702|PLACEBO_COMPARATOR|control|"Single administration of Albumin 4% diluted albumin (LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
62782806|NCT05455931||Patients with MF/SS|Adult patients with diagnosed MF/SS receiving Poteligeo treatment.
62194818|NCT00639327|ACTIVE_COMPARATOR|B|CPT-11
62398631|NCT04856566|EXPERIMENTAL|Low Dose THC + 0.05 BAC Alc|Participants will receive low dose of THC along with alcohol leading to a BAC of 0.05.
62782807|NCT03764306|ACTIVE_COMPARATOR|Carotid Artery Stenting|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent with a proximal protection system Mo.Ma
62194819|NCT06072976|EXPERIMENTAL|Exclusive human milk|Mothers will consent to providing DHM if MOM is not available. If the infant reaches 100 ml/kg/day of feeds (one feed advancement prior to full feeds) and MOM remains unavailable, they will transition to formula in preparation for discharge. Infants cannot be discharged on donor milk.
62194820|NCT06072976|EXPERIMENTAL|Standard of care|Mothers will consent to providing DHM (if qualifies per hospital policy) or formula if MOM is not available. Infants are only eligible to receive donor milk only if 1) MOM is not available 2) if infant initiates feeds before day 3 of age. The donor milk feed would be stopped on day 5 of age. After day five of age, the infant will receive formula if MOM is not available. This is congruent with the current donor milk policy (see Policy #12785). It is highly unlikely given these infants would receive any donor milk because these infants require surgery and often are waiting return of bowel function . The median age of initiation of feeds is 12 days of age for infants with gastroschisis (PMID: 33647253) which exceeds the days of what the hospital policy says for eligibility which is initiates feed before day 3 of age. If the infant does not qualify for any donor milk and MOM is not available, the infant will receive formula
62573696|NCT05056324|ACTIVE_COMPARATOR|Control group|
62782808|NCT03764306|ACTIVE_COMPARATOR|Endarterectomy carotid artery|Subjects will undergo carotid endarterectomy
62782809|NCT04975100|EXPERIMENTAL|Test|Patients in the test group will get Sarcosine 500 mg capsules once daily as an add-on to ongoing SSRI treatment.
62782810|NCT04975100|ACTIVE_COMPARATOR|Control|Patients in the control group will get identical-looking capsules containing placebo in addition to SSRI at an once daily dose
62782811|NCT05574088|EXPERIMENTAL|apical patency|30 patients will be in apical patency group
62782812|NCT05574088|NO_INTERVENTION|Control group ( non apical patency)|30 patients will be in control group ( non apical patency)
62194821|NCT03313947|OTHER|Difficult Airway|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
62398632|NCT04856566|EXPERIMENTAL|High Dose THC + 0.05 BAC Alc|Participants will receive high dose of THC along with alcohol leading to a BAC of 0.05.
62398633|NCT04856566|EXPERIMENTAL|Placebo Drug + 0.05 BAC Alc|Participants will receive placebo drug with no THC along with alcohol leading to a BAC of 0.05.
62398634|NCT04856566|EXPERIMENTAL|Placebo Drug + 0.08 BAC Alc|Participants will receive placebo drug with no THC along with alcohol leading to a BAC of 0.08.
62398635|NCT01252914|EXPERIMENTAL|One iStent Supra Stent and medication|The study assesses the efficacy and safety of one iStent Supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma
62398636|NCT05907343|ACTIVE_COMPARATOR|Sham TBS|
62398637|NCT05907343|ACTIVE_COMPARATOR|Closed-Loop TBS|
62398638|NCT05907343|ACTIVE_COMPARATOR|Open-Loop TBS|
62573697|NCT04067167|SHAM_COMPARATOR|WB-EMS (Sham-intervention)|Low-theshold WB-EMS combined with nutritional therapy
62573698|NCT04067167|EXPERIMENTAL|WB-EMS|WB-EMS combined with nutritional therapy
62573699|NCT04067167|EXPERIMENTAL|Free WB-EMS|WB-EMS using a mobile System combined with nutritional therapy
62573700|NCT04067167|EXPERIMENTAL|Flexi Band Resistance Training|Flexi band resistance Training combined with nutritional therapy
62573701|NCT00497523|EXPERIMENTAL|Beclomethasone dipropionate|
62573702|NCT00497523|EXPERIMENTAL|Beclomethasone dipropionate/Salbutamol combination|
62573703|NCT00497523|ACTIVE_COMPARATOR|Salbutamol|
62573704|NCT03668119|EXPERIMENTAL|Nivolumab + Ipilimumab Combination|
62573705|NCT03668119|EXPERIMENTAL|Nivolumab Monotherapy|
62194822|NCT03313947|OTHER|Obstructive Sleep Apnea|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
62194823|NCT03313947|OTHER|Predictive Obstructive Sleep Apnea|"The following 6 questions will be asked during the preoperative visit:~1. While sleeping, does your child snore more than half the time?~2. While sleeping, does your child always snore?~3. Have you ever seen your child stop breathing during the night?~4. Does your child occasionally wet the bed?~5. Did your child stop growing at a normal rate at any time since birth?~6. Is your child overweight"
62194824|NCT05508204|EXPERIMENTAL|Cohort A|A single dose of BION-1301 will be administered subcutaneously on Day 1 at dose level A
62194825|NCT05508204|EXPERIMENTAL|Cohort B|A single dose of BION-1301 will be administered subcutaneously on Day 1 at dose level B
62194826|NCT05508204|EXPERIMENTAL|Cohort C|A single dose of BION-1301 will be administered subcutaneously on Day 1 at dose level C
62194827|NCT05131802||Postcholecystectomy group|which included patients that had undergone cholecystectomy.
62194828|NCT05131802||Biliary intervention group|included patients who had undergone at least one of the following procedures for treatment of benign pathology: endoscopic sphincterotomy (ES) and endoscopic stenting.
62194829|NCT05034068|NO_INTERVENTION|control|the patients will be treated by using oral care only and evaluation will be done before cancer treatment and weekly till the treatment completed. In each weekly visit, oral sites will be examined, and a score was given to each site based on the degree of mucositis.
62194830|NCT05034068|ACTIVE_COMPARATOR|bezaydamine hydrochloride.|All patients were advised to rinse 15 mL of the solution benzydamine for 2 min, four to eight times daily before and during, and for 2 weeks after completion of cancer therapy. In case of any problem (e.g. burning or stinging), patients will be allowed to dilute the solution with water in the ratio 1:1 or 1:2. Study evaluations will be conducted before cancer treatment and weekly thereafter until 2 weeks after completion of the therapy .In each weekly visit, oral sites were examined and a score was given to each site based on the degree of mucositis.
62194831|NCT05034068|ACTIVE_COMPARATOR|low-level laser therapy|the patients will be treated by using a low-level laser therapy, the irradiations will be done three times a week using low power laser with a wavelength of 870 nm. The irradiation mode will be punctual and in contact, perpendicular to the oral mucosa. The power will be 60 mW, energy density of 6 J/cm2. Irradiation time will be 6 seconds per point based on the laser beam spot size of 0.55cm2. The irradiations will be done intra-orally avoiding the tumor site, oral examinations will be recorded at each irradiation session and the degree of mucositis will be recorded.
62194832|NCT06413953|EXPERIMENTAL|TQB3107 tablets|"Dosing regimen 1 (20/28): 28 days per cycle (4 weeks), the medication is administered once daily for 5 consecutive days per week, followed by a 2-day break. The initial dose is a single fasting dose of C0, with a subsequent 7-day observation period.~Dosing regimen 2 (28/28): 28 days per cycle, the medication is administered once daily for the entire 28-day period, all other dosing requirements are consistent with Regimen 1."
62398639|NCT06519578|OTHER|FOLFOX-HAIC Cohort|"Patients in this group received hepatic arterial infusion chemotherapy, with the following protocol:~Oxaliplatin 85 mg/m\^2~Leucovorin calcium 400 mg/m\^2~Fluorouracil 400 mg/m\^2 on Day 1, 2400 mg/m\^2 continuous infusion for 46 hours~Arterial infusion, once every 3 weeks"
62194833|NCT03367598||Normal weight|nondiabetic and nonobese individuals (18.5 kg/m2 ≤ BMI \< 25 kg/m2, n=349)
62398640|NCT06519578|OTHER|RALOX-HAIC Cohort|"Patients in this group received hepatic arterial infusion chemotherapy, with the following protocol:~Oxaliplatin 100 mg/m\^2~Raltitrexed 3 mg/m\^2~Arterial infusion, once every 3 weeks"
62398641|NCT06723652|EXPERIMENTAL|SHR-1918|
62791836|NCT06079021|NO_INTERVENTION|Control group|Historical group that received only standard medical care
62398642|NCT06723652|PLACEBO_COMPARATOR|SHR-1918 placebo|
62194834|NCT03367598||Overweight|nondiabetic and nonobese individuals (25 kg/m2 ≤ BMI \< 30 kg/m2, n=154)
62194835|NCT02634047|ACTIVE_COMPARATOR|conventional technique|transesophageal echocardiography probe was inserted using a traditional blind insertion technique.
62194836|NCT02634047|EXPERIMENTAL|videolaryngoscope technique|transesophageal echocardiography probe was advanced into esophagus under direct vision using videolaryngoscope
62194837|NCT03120429|EXPERIMENTAL|Fish group|subjects will have 3 x 150 g lean fish/ week at main meal
62194838|NCT03120429|EXPERIMENTAL|Control group|subjects will have no seafood.
62194839|NCT02574325|PLACEBO_COMPARATOR|Placebo|Placebo
62398643|NCT03171272|EXPERIMENTAL|Experimental Group|
62398644|NCT03171272|SHAM_COMPARATOR|Control Group|
62398645|NCT00620126|EXPERIMENTAL|Intervention|UC Home Automated Telemanagement
62398646|NCT00620126|ACTIVE_COMPARATOR|Control|Best Available Care
62398647|NCT06019793|EXPERIMENTAL|DBS for Chronic Pain|
62398648|NCT02600559|EXPERIMENTAL|0.1 mL OTO-201|Ciprofloxacin
62398649|NCT05026866|EXPERIMENTAL|Donanemab|Donanemab administered intravenously (IV)
62194840|NCT02574325|EXPERIMENTAL|ARI-3037MO|ARI-3037MO
62194841|NCT01932476|EXPERIMENTAL|Celiac Disease Alone Gluten Challenge|
62194842|NCT01932476|SHAM_COMPARATOR|Celiac Disease Alone Sham Challenge|
62194843|NCT01932476|EXPERIMENTAL|Celiac Disease and T1D Gluten Challenge|
62194844|NCT01932476|SHAM_COMPARATOR|Celiac Disease and T1D Sham Challenge|
62194845|NCT03276390|ACTIVE_COMPARATOR|Intervention study site|"Exposure to the intervention, which is the Northwestern Medicine (TM) Hispanic Kidney Transplant Program, a culturally targeted program for Hispanic potential recipients for transplant evaluation that is implemented into the 2 study sites.~The intervention study site will provide the intervention to its Hispanic patients.~The intervention study will will also provide the routine care (control arm) to all other patients.~For the purposes of this study, Hispanic potential recipients recruited into the study will be exposed to this intervention. Non-Hispanic Whites recruited into the study will not be exposed to this intervention."
62194846|NCT03276390|NO_INTERVENTION|No intervention study site|Exposure to routine transplant evaluation at the two control sites.
62194847|NCT01673022|EXPERIMENTAL|IC Green Arm|One arm only: Receives IC Green for testing of study objective
62194848|NCT05048056|EXPERIMENTAL|AK120 Regimen 1|AK120 Regimen 1- subcutaneous injection every 2 weeks for 30 weeks.
62194849|NCT05048056|EXPERIMENTAL|AK120 Regimen 2|AK120 Regimen 2- subcutaneous injection every 2 weeks for 30 weeks.
62194850|NCT05048056|EXPERIMENTAL|Placebo to AK120|Placebo subcutaneous injection every 2 weeks, then crossover to AK120 Regimen 1, subcutaneous injection at Week16, after primary endpoint evaluation
62194851|NCT05663905|EXPERIMENTAL|Ambroxol Arm|"Amboxol arm will be receiving standard therapy as per control group with the addition of IV ambroxol hydrochloride 30mg TDS as adjunct therapy for 14 days. Each dose of 30mg of ambroxol will be diluted in 50ml of NS/D5% to be given intravenously over an hour. The patients will be considered as drop-outs if ambroxol is discontinued due to its side-effects, or if the patient's duration of ICU stay is less than 24 hours."
62194852|NCT05663905|OTHER|Control Arm|"Control arm will be receiving standard therapy for severe pneumonia as per recommended in the ICU Management Protocols by Malaysian Society of Intensive Care (MSIC).37 This includes antibiotics stewardship and supportive therapy."
62194853|NCT03080818|EXPERIMENTAL|Probiotic|Participants in this arm will receive probiotic supplementation for 12 weeks (Lactobacillus Rhamnosus GG)
62194854|NCT03080818|PLACEBO_COMPARATOR|Control|Participants in this arm will receive placebo that look similar to probiotics
62194855|NCT05306743|EXPERIMENTAL|CONQUEST Intervention Arm|Intervention arm clusters will receive the CONQUEST quality improvement program.
62398650|NCT05026866|PLACEBO_COMPARATOR|Placebo|Placebo is administered intravenously
62194856|NCT05306743|OTHER|Delayed Intervention Arm|The CONQUEST quality improvement program will be rolled-out to the delayed intervention practices at the end of the outcome evaluation period.
62194857|NCT05482191|EXPERIMENTAL|Treatment group|Treatment activity on lifestyle interventions will target the dietary and exercise factors of childhood obesity.
62398651|NCT06443138|EXPERIMENTAL|Personalized pre-habilitation program|
62398652|NCT06619444|EXPERIMENTAL|Aerobic Exercise (AE) only|Aerobic exercise (AE) training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous (50-80% of heart rate reserve). Intensity of the exercise sessions will be built of gradually. Sessions will occur 2 times per week for the duration of the year.
62398653|NCT06619444|EXPERIMENTAL|30 min of resistance exercise (RE)|30 min of resistance exercise (RE) will consist of 30 total minutes of resistance exercise each week (15 min each session) in addition to 60 min of aerobic exercise (AE) each week (30 min each session). Each 15 min session of RE will consist of 2 sets of 8-15 repetitions at 50-80% of 1-rep max of 4 exercises. AE will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 45 min per session. Sessions will occur 2 times per week for the duration of 1 year.
62573706|NCT00116974|EXPERIMENTAL|1|
62009100|NCT03145727|EXPERIMENTAL|High Frequency Group|High Frequency Group: In this group the TENS will be adjusted with frequency of 150Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
62194858|NCT05482191|NO_INTERVENTION|Usual practice group|No intervention
62194859|NCT03243097|EXPERIMENTAL|Study Subjects|All subjects enrolled in the study are required to complete Phase I before entering Phase II, and Phase II before entering Phase III.
62194860|NCT04376502|OTHER|radiation therapy (RT)|RT for all subjects will consist of treating one tumor of the treating physician's preference (40 Gy in 5 fractions), and after a 1-week interval during which Immune checkpoint inhibitor (ICI) is continued alone, RT will be given to a second and separate tumor (30 Gy in 5 fractions).
62194861|NCT02059356||Non-cirrhotic patients with cognitive impairment|
62194862|NCT02044068||children born from HIV-HBV women|Studying retrospectively their status for HBs Ag and HBc Ab
62194863|NCT04541368|EXPERIMENTAL|Administration of CS1 Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
62194864|NCT00636935|EXPERIMENTAL|1|Antibiotic only therapy in patients with PCP and a pO2 of \> 70mmHg.
62194865|NCT00636935|EXPERIMENTAL|2|Antibiotics and Corticosteroid therapy in patients with PCP and pO2 \>70 mmHg.
62194866|NCT00636935|ACTIVE_COMPARATOR|3|Standard of care therapy for patients with PCP and pO2 \< 70mmHg.
62214927|NCT06275139|EXPERIMENTAL|Experimental group (Integrated group)|The experimental group adopt the multidisciplinary collaboration and integrated evaluation mode. In addition to routine diagnosis and treatment as above-mentioned, integrated assessment of cervicocerebral vessels shall be performed, including transcranial color-coded doppler, cerebral perfusion with multislice CT, and cognitive function assessment. Based on the above results, surgical plans will be formulated jointly by multiple disciplines including neurologists, vascular surgeons, ICU physicians and cardiac surgeons.
62194867|NCT04383951|ACTIVE_COMPARATOR|Ketogenic diet|For participants randomized to the ketogenic diet arm, a consultation with the providers of medically supervised weight loss clinic of Indiana University Health will be arranged. Subjects will be educated on the concepts of ketosis, symptoms associated with it, and dietary manipulation to achieve ketosis. Participants in this arm will use the suggested recipes in combination with strict carbohydrate monitoring though checking for urine ketone bodies. These recipes were gathered and vetted by the dietitian at the medically supervised weight loss clinic. We anticipate that this approach will allow for more calorie intake and easier carbohydrate restriction. The follow up visits will be determined by the providers of the medically supervised weight loss clinic based on the symptoms reported and subject's compliance with carbohydrate restriction.
62009101|NCT02909322|ACTIVE_COMPARATOR|Continuous Epidural Analgesia|Analgesic medications will be given via epidural, the standard of care.
62009102|NCT02909322|EXPERIMENTAL|Paravertebral Block Analgesia|Analgesic medications will be given via the paravertebral space.
62009103|NCT04080765|EXPERIMENTAL|HIV-ASSIST + DHHS arm|Decision-making support for ARV selection through DHHS guidelines in conjunction with HIV-ASSIST
62009104|NCT04080765|ACTIVE_COMPARATOR|DHHS-alone arm|Decision-making support for ARV selection through DHHS guidelines alone
62194868|NCT04383951|SHAM_COMPARATOR|Standard of Care|For participants randomized to this arm, a consultation with the providers of medically supervised weight loss clinic will be arranged. The discussion will focus on portion control using a balanced diet. A follow up visit will be at 16 weeks. This is the extent of interventions received for participants in this arm.
62194869|NCT02614612|EXPERIMENTAL|Itacitinib (200 mg)|Itacitinib (200 mg) + prednisone or methylprednisolone (corticosteroids)
62194870|NCT02614612|EXPERIMENTAL|Itacitinib (300 mg)|Itacitinib (300 mg) + prednisone or methylprednisolone (corticosteroids)
62398654|NCT06619444|EXPERIMENTAL|60 min of resistance exercise (RE)|60 min of resistance exercise (RE) will consist of 60 total minutes of resistance exercise each week (30 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 30 min session of resistance exercise will consist of 2 sets of 8-15 repetitions at 50-80% of 1-rep max of 8 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 60 min per session. Sessions will occur 2 times per week for the duration of 1 year.
62194871|NCT02847442|EXPERIMENTAL|Opicapone (BIA 9-1067) 50 mg|Total duration of trial participation and treatment: three months. All subjects will start treatment with 50 mg opicapone (OPC) once daily for a 3-month period in addition to their current treatment with levodopa/dopa decarboxylase inhibitor (L-dopa/DDCI)
62194872|NCT05926869|EXPERIMENTAL|Group A Clindamycin gel|
62194873|NCT05926869|EXPERIMENTAL|Group B Dapsone gel|
62398655|NCT06619444|EXPERIMENTAL|120 min of resistance exercise (RE)|120 min of resistance exercise (RE) will consist of 120 total minutes of resistance exercise each week (60 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 60 min session of resistance exercise will consist of 3 sets of 8-15 repetitions at 50-80% of 1-rep max of 10 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 90 min per session. Sessions will occur 2 times per week for the duration of 1 year.
62573707|NCT00116974|PLACEBO_COMPARATOR|2|
62573708|NCT00839800|EXPERIMENTAL|1|Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + Symbicort Turbuhaler 160/4.5 µg as needed
62573709|NCT00839800|ACTIVE_COMPARATOR|2|Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + terbutaline Turbuhaler 0.4 mg as needed
62009105|NCT02662387|ACTIVE_COMPARATOR|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
62009106|NCT02662387|EXPERIMENTAL|HFNC and external nasal dilator (END)|high flow nasal cannula and external nasal dilator
62573710|NCT01154114|EXPERIMENTAL|moderate hepatic impaired subjects|Male and female subjects with moderate hepatic impairment defined by a Child-Pugh score of 7-9 will be included. The subjects will be administered 40 mg oral doses of darapladib (SB-480848) enteric-coated tablets daily for 10 consecutive days.
62573711|NCT01154114|EXPERIMENTAL|normal healthy volunteers|Healthy male and female subjects will be included and will be matched as closely as possible to the group of moderate hepatic impairment subjects for gender, age and body mass index. Each subject will receive daily 40 mg oral doses of darapladib (SB-480848) enteric-coated tablets for 10 consecutive days.
62734649|NCT04166773|PLACEBO_COMPARATOR|Placebo|Placebo administered SC once a week.
62194874|NCT06186869|ACTIVE_COMPARATOR|Aerobic Exercise and Mediterranean Diet|Subjects randomized and assigned to this intervention group will follow the low glycaemic index Mediterranean diet and simultaneously perform 180 minutes of moderate-intensity aerobic exercise per week for 4 months. Intervention type: aerobic exercise and Mediterranean diet.
62009107|NCT03900533|EXPERIMENTAL|Adjunctive group emotion regulation skills training|Participants will receive a 7 week group emotion regulation skills training together with parents adjacent to treatment as usual provided by the child- and adolescent psychiatric clinic
62009108|NCT03900533|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Participants will receive treatment as usual for 7 weeks as provided by the child- and adolescent psychiatric clinic
62009109|NCT01557075|ACTIVE_COMPARATOR|Atorvastatin group|Atorvastatin 40 mg daily for 12 months after randomization
62009110|NCT01557075|ACTIVE_COMPARATOR|Pravastatin group|Pravastatin 20mg daily for 12 months after randomization
62194875|NCT06186869|ACTIVE_COMPARATOR|HITT and Mediterranean Diet|Subjects randomized and assigned to this intervention group will follow the low glycaemic index Mediterranean diet and simultaneously perform 150 minutes per week of high-intensity interval exercise (HITT) in the gym for 4 months. Intervention type: HIIT and Mediterranean diet.
62009111|NCT00286949|OTHER|Atomoxetine (Strattera)|Open-Label Uncontrolled Active Drug Intervention, No comparator
62009112|NCT00882011||Arm 1|Adult patients with T-lymphoblastic lymphoma treated with intensive chemo/radiotherapy or intensive chemotherapy followed by transplant.
62573712|NCT04604392|EXPERIMENTAL|Tooth tissue-borne (KBME) expander|In this tooth tissue-borne appliance, the occlusal surfaces of the molar and premolar teeth and half of the palatinal and buccal surfaces are covered with heat polymerized acrylic. Hyrax expansion screw is in the midline, as far as possible to the palate positioned close and parallel.
62009113|NCT04083872|EXPERIMENTAL|Group 1|"1. Period 1: Reference drug~2. Period 2: Test drug"
62009114|NCT04083872|EXPERIMENTAL|Group 2|"1. Period 1: Test drug~2. Period 2: Reference drug"
62009115|NCT06469047||the newly diagnosed group|
62194876|NCT06186869|ACTIVE_COMPARATOR|Mediterranean Diet|Subjects randomized and assigned to this intervention group will follow the low-glycaemic index Mediterranean diet for 4 months. Intervention type: Mediterranean Diet.
62194877|NCT05897047|EXPERIMENTAL|"Intervention group Additional telemedical management"|Patients in the interventional arm will receive a predefined additional telemedical management including regular telemedicine visits and automatic data transfer (e.g. vital signs, well-being, medication plan laboratory data and chat) between the patient at home and KTC through a certified smartphone application.
62194878|NCT05897047|NO_INTERVENTION|"Control group Routine posttransplant aftercare"|Patients in the control group will receive routine posttransplant aftercare.
62009116|NCT06469047||the relapsed group|
62194879|NCT03952442|ACTIVE_COMPARATOR|control group|
62194880|NCT03952442|EXPERIMENTAL|experimental group|
62194881|NCT04540237||Case|Patients with idiopathic granulomatous mastitis
62194882|NCT04540237||Control|Healthy volunteers
62194883|NCT03995797|ACTIVE_COMPARATOR|Treatment arm|Treatment with erbium YAG laser
62194884|NCT03995797|PLACEBO_COMPARATOR|Sham arm|Sub therapeutic procedure with erbium YAG laser
62398656|NCT05937295|EXPERIMENTAL|FusionVAC-XS15 and Atecolizumab treatment|
62573713|NCT04604392|EXPERIMENTAL|Tooth-borne (Hyrax) expander|In this tooth-borne expansion appliance, orthodontic bands are placed on the right and left 1st premolar and 1st molar teeth of the patients and the bands are soldered to the Hyrax expansion screw. The expansion screw is in the midline, as far as possible to the palate positioned close and parallel.
62194885|NCT04198571||Zinforo Treated|Only those Adults treated with this treatment for CAP or cSSTi
62194886|NCT05914064|EXPERIMENTAL|Gravitas FT System|
62194887|NCT05914064|ACTIVE_COMPARATOR|Control|
62194888|NCT05109572||Hospitalized group|Hospitalized patient (HP) stayed in hospital during the Covid-19 pandemic period
62194889|NCT05109572||Non-hospitalized with Emergency care|Emergency care plan made but no hospitalization was included to this study during the Covid-19 pandemic period
62194890|NCT05109572||Non-hospitalized and non-emergency care|Patients who neither apply to the emergency department nor are hospitalized was included to this study during the Covid-19 pandemic period
62398657|NCT05746195|EXPERIMENTAL|Text message intervention|Adaptive 12-week text message intervention using reinforcement learning to increase whole grain and reduce refined grain intake. Participants will also complete semi-structured follow-up interviews and study related questionnaires.
62398658|NCT01795846||monosensitized allergic rhinitis, asthma|adult patients with moderate/severe perennial allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites
62398659|NCT01795846||polysensitized allergic rhinitis, asthma|adult patients with moderate/severe perennial allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites or sensitized to at least 2 different allergens including house dust mites.
62573714|NCT04604392|EXPERIMENTAL|Bone-borne (MIDME) expander|This bone-borne expander includes 2 mini-screws with a diameter of 1.6 mm and a length of 10 mm on the right and left sides, coinciding between the roots of the 2nd premolar and 1st molar teeth in addition to the hyrax expansion screw.
62009117|NCT06469047||the complete remission group|
62009118|NCT06469047||the control group|
62009119|NCT03041259|EXPERIMENTAL|Rejuveinix Low Dose|Intravenous dosing of two doses per week of Rejuveinix
62398660|NCT02395757|EXPERIMENTAL|Microperimetry|Microperimetry exam performed in addition to the usual ophthalmological examinations for monitoring AMD.
62009120|NCT03041259|EXPERIMENTAL|Rejuveinix High Dose|Intravenous dosing of two doses per week of Rejuveinix
62009121|NCT01085175|EXPERIMENTAL|Cohort 1|Low risk Heart Failure patients
62009122|NCT01085175|EXPERIMENTAL|Cohort 2|High risk Heart Failure patients with history of Implantable Cardioverter-Defibrillator firing
62009123|NCT03730935|EXPERIMENTAL|Intervention|Respiratory muscle endurance training (30 minutes of volitional hyperpnoea at a target ventilation of 60-70% of the individual maximal voluntary ventilation for 5 days per week for 4 weeks).
62009124|NCT03730935|SHAM_COMPARATOR|Sham|Sham training will be performed 5 times a week for 4 weeks using a mock asthma inhaler filled with 5.5 mg lactose powder. Subjects will be instructed to inhale the powder according to inhaler instructions and to then perform one full inspiration to total lung capacity using custom-made, low resistance tubing, which elicits minimal resistance to breathing.
62194891|NCT06147492|OTHER|laTME|Laparoscopic Total Mesorectal Excision
62194892|NCT06147492|OTHER|taTME|a transanal bottom-up approach was employed for the Total Mesorectal Excision procedure
62194893|NCT06156059|PLACEBO_COMPARATOR|Septic Shock Standard of Care (SOC)|Placebo suspension and capsules
62194894|NCT06156059|ACTIVE_COMPARATOR|Septic shock Oral Bedtime Melatonin (OBM)|100 mg suspension or in capsules OBM
62194895|NCT06156059|PLACEBO_COMPARATOR|Resuscitated Cardiorespiratory Arrest SOC|Placebo suspension and capsules
62194896|NCT06156059|ACTIVE_COMPARATOR|Resuscitated Cardiorespiratory Arrest OBM|100 mg suspension or in capsules OBM
62194897|NCT06156059|PLACEBO_COMPARATOR|Ischemic Stroke (SOC)|Placebo suspension and capsules
62194898|NCT06156059|ACTIVE_COMPARATOR|Ischemic stroke (OBM)|100 mg suspension or in capsules OBM
62194899|NCT06156059|PLACEBO_COMPARATOR|Hemorraghic stroke (SOC)|Placebo suspension and capsules
62194900|NCT06156059|ACTIVE_COMPARATOR|Hemorrhagic stroke (OBM)|100 mg suspension or in capsules OBM
62398661|NCT02874469|NO_INTERVENTION|Control group (first period)|Patients treated as recommended with usual care in a center.
62573715|NCT04423744|EXPERIMENTAL|Intervention ABCD|"Intervention A:~Day 1 and 2: Supra-therapeutic dose of BAY1817080, three times daily (tid) Day 3: Supra-therapeutic dose of BAY1817080 and placebo to moxifloxacin, once~Intervention B:~Day 1 and 2: therapeutic dose of BAY1817080 and placebo to BAY1817080, tid Day 3: therapeutic dose of BAY1817080, placebo to BAY1817080 and placebo to moxifloxacin, once~Intervention C:~Day 1 and 2: Placebo to BAY1817080, tid Day 3: Placebo to BAY1817080 and moxifloxacin, once~Intervention D:~Day 1 and 2: Placebo to BAY1817080, tid Day 3: Placebo to BAY1817080 and placebo to moxifloxacin, once~Subjects will receive intervention A, B, C and D sequentially. The washing-out period between each intervention is at least 14 days"
62573716|NCT04423744|EXPERIMENTAL|Intervention BCDA|Subjects will receive intervention B, C, D and A sequentially. The washing-out period between each intervention is at least 14 days
62573717|NCT04423744|EXPERIMENTAL|Intervention CDAB|Subjects will receive intervention C, D, A and B sequentially. The washing-out period between each intervention is at least 14 days
62782813|NCT02071069|EXPERIMENTAL|maintenance therapy|"Initially, all subjects received 8 cycles of Cetuximab (400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks)plus FOLFIRI (irinotecan 180 mg/m2 IV on day 1 , leucovorin 400mg/m2 on day 1 , fluorouracil 400mg/m2 on day 1 and fluorouracil 2400mg/m2 civ46h every 2 weeks) .~After 8 cycles or severe toxicity, patients received maintenance therapy comprising Cetuximab (250mg/m2 every week or 500mg/m2 every 2 weeks) and either irinotecan( 180 mg/m2 IV every 2 weeks) or fluorouracil arm( leucovorin 400mg/m2 on day 1 , fluorouracil 400mg/m2 on day 1 and fluorouracil 2400mg/m2 civ46h every 2 weeks ). In cases of unacceptable toxicity, only the related medication was stopped"
62573718|NCT04423744|EXPERIMENTAL|Intervention DABC|"Subjects will receive intervention D, A, B and C sequentially. The washing-out period between each intervention is at least 14 days~Note: the intervention sequences in this and above arms are examples, the actual order of intervention may differ from these examples"
62573719|NCT02461069|ACTIVE_COMPARATOR|Dimethyl fumarate treatment arm (A)|All patients will receive dimethyl fumarate (Tecfidera®) according to national recommendations (Krankheitsbezogenes Kompetenznetz Multiple Sklerose, KKNMS) from week 0 to week 24 (EOS-1) in the core study.
62573720|NCT02461069|NO_INTERVENTION|Healthy subject arm (B)|Healthy subjects will not receive any treatment for RRMS during the study.
62194901|NCT01454739|EXPERIMENTAL|On-Demand|The individual dose of rFVIIIFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor VIII (FVIII) levels.
62194902|NCT01454739|EXPERIMENTAL|Prophylaxis|Tailored prophylaxis, Weekly prophylaxis or Personalized prophylaxis available.
62194903|NCT02937649|EXPERIMENTAL|Laparoscopic sleeve gastrectomy using 48-Fr bougie|Patients will undergo laparoscopic sleeve gastrectomy with a 48-Fr (16 mm) bougie
62194904|NCT02937649|ACTIVE_COMPARATOR|Laparoscopic sleeve gastrectomy using standard care bougie|Patients will undergo laparoscopic sleeve gastrectomy with a standard care bougie (34, 36 or 38-Fr)
62194905|NCT06225440|ACTIVE_COMPARATOR|Levagen+® Palmitoylethanolamide (PEA)|Levagen+® Palmitoylethanolamide (PEA) - 700mg/day, containing not less than 600 mg PEA.
62398662|NCT02874469|EXPERIMENTAL|Group with diary (second period)|Intervention group = On top of usual care, an intensive care unit diary will be implemented for patients within the first 8 hours following their admission.
62194906|NCT06225440|PLACEBO_COMPARATOR|Placebo|Placebo - Microcrystalline Cellulose
62398663|NCT04485104|EXPERIMENTAL|GWP42003-P|"The 52-week treatment period includes a fixed 2-week titration schedule followed by flexible dose optimization.~Day 1: 5 mg/kg/day (2.5 mg/kg twice daily (b.i.d.))~Day 8: 10 mg/kg/day (5 mg/kg b.i.d.)~Day 15 to Week 52: Flexible dosing based on the participant's observed efficacy, safety, and tolerability per the investigator's clinical judgement. Up to a maximum of 20 mg/kg/day (10 mg/kg b.i.d.) for LGS and DS or 25 mg/kg/day (12.5 mg/kg b.i.d.) for TSC, in maximum weekly increments of 5 mg/kg/day (≤ 2.5 mg/kg b.i.d.)."
62398664|NCT04227665|EXPERIMENTAL|Sea level|Sea level training camp
62398665|NCT04227665|EXPERIMENTAL|Altitude|Altitude training camp
62398666|NCT04321525|ACTIVE_COMPARATOR|Cognitive-behavioral therapy (CBT)|Individual Cognitive Behavioral Therapy
62398667|NCT04321525|EXPERIMENTAL|Personal construct therapy (PCT)|Individual Personal Construct Therapy
62398668|NCT04321525|EXPERIMENTAL|Personal construct therapy with virtual reality (PCT-VR)|Individual Personal Construct Therapy with an immersive virtual reality app
62398669|NCT03534817|EXPERIMENTAL|Early Access CR|Participants begin cardiac rehabilitation (CR) after 1-week following discharge post-MI.
62398670|NCT03534817|NO_INTERVENTION|Standard Access CR|Participants begin CR after 7-weeks following discharge post-MI, similar to the average Canadian wait time.
62398671|NCT01750034|ACTIVE_COMPARATOR|Closed method|Burn patients randomized to closed method of burn wound care.
62398672|NCT01750034|EXPERIMENTAL|Open method|Burn patients randomized to the open method of burn wound care.
62398673|NCT00439920|EXPERIMENTAL|High-dose anthracycline|
62398674|NCT06400823|EXPERIMENTAL|VR+TENS|"Patients will undergo goal-oriented movements for upper-limb rehabilitation in a VR scenario. While performing the movement, patients will receive synchronous electrical stimulation targeting the medial nerve. The provided sensation will stimulate the interaction with elements in the virtual world.~The intervention phase will last 3 weeks. Patients will undergo a minimum of three sessions per week (of around 60'). During each of these sessions, the first 10' will be employed for the calibration of the Transcutaneous Electrical Nerve Stimulation (TENS). In the remaining part of the session, subjects will perform some of the VR-based task-oriented games targeting different components."
62573721|NCT02131285|EXPERIMENTAL|Sensory training|Experimental group received balance rehabilitation aimed at improving motor strategies and sensory strategies. Subjects in this group were treated to improve recovery of sensory impairment and were given exercises in the impaired sensory conditions, inhibiting the reliable sensory systems and forcing the Central Nervous System to use the impaired ones.
62398675|NCT06400823|ACTIVE_COMPARATOR|Conventional rehabilitation|"Patients in the control group will perform physical conventional rehabilitation provided by the rehabilitation clinic.~The total amount of therapy will be the same as that of the VR+TENS group. The exercises will target the same components of the VR+TENS arm."
62398676|NCT05295810|NO_INTERVENTION|Room Air|All participants will complete an active stand breathing room air with CO2 free to fluctuate
62573722|NCT02131285|NO_INTERVENTION|No sensory strategy|Control group received usual care rehabilitation which did not include training of sensory strategies.
62194907|NCT01589926|EXPERIMENTAL|Bi-level Positive Airway Pressure Device|BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.
62398677|NCT05295810|EXPERIMENTAL|+0mmHg CO2 Clamped at baseline|All participants will complete an active stand with their CO2 held constant at baseline
62398678|NCT05295810|EXPERIMENTAL|+5mmHg CO2|All participants will complete an active stand breathing +5mmHg of CO2 relative to baseline
62398679|NCT05295810|EXPERIMENTAL|+10mmHg|All participants will complete an active stand breathing +10mmHg of CO2 relative to baseline
62398680|NCT05295810|EXPERIMENTAL|+10mmHg CO2 + 50mmHg O2|All participants will complete an active stand breathing +10mmHg of CO2 relative to baseline and 50mmHg of O2
62398681|NCT01273246|EXPERIMENTAL|Children Group 1: 200U EV71 vaccine|12 children received 3 doses of 200U EV71 vaccine 28 days apart
62398682|NCT01273246|PLACEBO_COMPARATOR|Children Group 1: Placebo|6 children received 3 doses of placebo 28 days apart
62194908|NCT01589926|SHAM_COMPARATOR|Sham CPAP|Physiologic continuous positive airway pressure (CPAP) initiated for at least 16 hours per day for a minimum of 48hrs.
62573723|NCT01437254|EXPERIMENTAL|Arm Number 1 CPERT|1 CPERT scan, blood and vital sign collection
62573724|NCT01437254|ACTIVE_COMPARATOR|Arm Number 2 GPERT|1 GPERT Scan
62573725|NCT01710202||Placebo|Control group who will not receive hydrocortisone. Will act as a comparison group to the hydrocortisone group.
62573726|NCT01710202||Experimental: Hydrocortisone|Group will receive 20mg oral hydrocortisone
62009125|NCT03215355|EXPERIMENTAL|Participants receiving Primovist|Because this is a proof of concept study, only one arm will be considered which is the patients that receive the one time contrast injection prior to their first treatment. The intervention is that although this drug is approved, an off label dosing regiment is being used to improve a separate imaging modality than what it was approved for. Based on preliminary phantom experiments and toxicity results in the literature, four times the dose was deemed safe and required to use for CBCT.
62194909|NCT05577325|EXPERIMENTAL|PLANNED EDUCATION BASED ON THE HEALTH IMPROVEMENT MODEL|Educational content based on the health promotion model, including nutrition and physical activity, will be created by the researcher by scanning the literature and considering the needs of the students. For the nutrition and physical activity plans included in the training, a diet specialist and a sports specialist will be consulted on the subject. The created training content and the booklet will be submitted to the opinion of at least three experts who are suitable for the subject area. Educational content deemed appropriate will be shared with students for 1 lesson per week for 10 weeks.
62194910|NCT05577325|EXPERIMENTAL|follow without interference|follow up without any education
62194911|NCT05707910|EXPERIMENTAL|Treatment Cohort|EBV immunological agent administration on day 1,7,14,28 and 60 for Intradermal Injection
62194912|NCT00972322|EXPERIMENTAL|MK-8245 50 mg|MK-8245, 50 mg, twice daily for 28 days
62398683|NCT01273246|EXPERIMENTAL|Children Group 2: 400U EV71 vaccine|12 children received 3 doses of 400U EV71 vaccine 28 days apart
62194913|NCT00972322|PLACEBO_COMPARATOR|Placebo|Placebo to MK-8245, 50 mg, twice daily
62194914|NCT02551211|EXPERIMENTAL|Patients with resectable non-small cell lung cancer|
62194915|NCT02332304|OTHER|Preterm fetus|Patients with pregnancies between 26 and 36 6/7 weeks of pregnancy. Before the birth, a sample of amniotic fluid was taken and analyzed using optical density at 650nm. A value above 0.15 was considered an indication of fetal lung maturity.
62194916|NCT06265519|ACTIVE_COMPARATOR|Patients before surgery|Men between the ages of 50 and 80 diagnosed with BPH before surgery
62398684|NCT01273246|PLACEBO_COMPARATOR|Children Group 2: Placebo|6 children received 3 doses of placebo 28 days apart
62398685|NCT01273246|EXPERIMENTAL|Infants Group 1: 100U EV71 vaccine|24 infants received 3 doses of 100U EV71 vaccine 28 days apart
62398686|NCT01273246|PLACEBO_COMPARATOR|Infants Group 1: Placebo|8 infants received 3 doses of placebo 28 days apart
62398687|NCT01273246|EXPERIMENTAL|Infants Group 2: 200U EV71 vaccine|24 infants received 3 doses of 200U EV71 vaccine 28 days apart
62573727|NCT05598450|EXPERIMENTAL|schizophrenia patients with auditory hallucinations|For schizophrenia patients with auditory hallucinations, rTMS+MEG for implementation intervention
62194917|NCT06265519|ACTIVE_COMPARATOR|Patients after surgery|Men between the ages of 50 and 80 diagnosed with BPH after surgery
62194918|NCT06265519|NO_INTERVENTION|Healthy|Men between the ages of 50-80 years without lower urinary tract disease
62398688|NCT01273246|PLACEBO_COMPARATOR|Infants Group 2: Placebo|8 infants received 3 doses of placebo 28 days apart
62398689|NCT01273246|EXPERIMENTAL|Infants Group 3: 400U EV71 vaccine|24 infants received 3 doses of 400U EV71 vaccine 28 days apart
62398690|NCT01273246|PLACEBO_COMPARATOR|Infants Group 3: Placebo|8 infants received 3 doses of placebo 28 days apart
62398691|NCT06724666|EXPERIMENTAL|Transdiagnostic Internet-delivered intervention|The intervention consists of 8 modules delivered over 8 weeks. It is based on Rational Emotive Behavioral Therapy (REBT).
62573728|NCT00497393|NO_INTERVENTION|Control|regular use of the 2-bed areas in the Emergency department
62573729|NCT05362877|EXPERIMENTAL|Earplug|Earplug group- using earplugs, n=20 Patients will use only earplugs
62782814|NCT02240264|ACTIVE_COMPARATOR|Krill oil capsules|"Capsules containing krill oil rich in omega-3 fatty acid's.~Dietary supplements (krill oil) are provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.~Addendum 25-4-2016: In the Original protocol a dose adjustment after 3 months according to Omega-3 Index was to be executed. As no participant achieved the target Omega-3 Index the dosage was adjusted to 800mg DHA + EPA per day for all participants. The also led to the decision to increase the starting dosage of cohort II to 800mg DHA+ EPA."
62782815|NCT02240264|PLACEBO_COMPARATOR|Placebo|Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
62398692|NCT06724666|NO_INTERVENTION|Control group|Participants in the control group are a delayed intervention group (waiting list control). They will access the intervention after 8 weeks.
62398693|NCT06489041|OTHER|Pharmacogenomic Testing|A pharmacogenomic (PGx) microarray (multi-gene) panel will be performed to test for genetic variations in genes related to drug response.
62398694|NCT02528643|EXPERIMENTAL|Enzalutamide 160 mg|Participants received enzalutamide 160 milligrams (mg) capsules, orally QD during double blind treatment period until disease progression, unacceptable toxicity, or any other discontinuation criterion was met. Eligible participants received enzalutamide 160 mg capsules, orally QD during open label period until disease progression, unacceptable toxicity, or any other discontinuation criterion was met. Median treatment duration was 64 days.
62398695|NCT02528643|PLACEBO_COMPARATOR|Placebo|Participants received enzalutamide matching placebo orally, once daily (QD) during double blind treatment period until disease progression, unacceptable toxicity, or any other discontinuation criterion was met. Median treatment duration was 64 days.
62398696|NCT04051515|EXPERIMENTAL|Intradialysis exercise guided by nursing staff|During 16 weeks subjects will exercise during the hemodialysis session, the exercise will include both aerobic and resistance training. Guidance will be provided by nursing staff
62398697|NCT04051515|ACTIVE_COMPARATOR|Home-based exercise program|During 16 weeks subjects will exercise on their own at home. A booklet will be provided, with a diary. Instructions to do resistance exercise with intervals of walking will be provided. Initial training will be provided by physiotherapy staff from the hospital.
62573730|NCT05362877|EXPERIMENTAL|Splint|Occlusal splint group- using occlusal splints, n=20 Patients will use only occlusal splints
62573731|NCT05362877|EXPERIMENTAL|Physical|Exercise group- using physical therapy, n=20 Patients will do only exercise
62573732|NCT05362877|NO_INTERVENTION|control group|Control group-no intervention, n=20
62573733|NCT05362877|EXPERIMENTAL|Earplug and splint|Earplug group- using earplugs and splints, n=20 Patients will use both interventions
62573734|NCT05362877|EXPERIMENTAL|Earplug and Physical|Earplug group- using earplugs and exercise, n=20 Patients will use both interventions
62398698|NCT06716710|EXPERIMENTAL|Art therapy group|In addition to the medical treatments that the pregnant women in the study group will receive in the clinic for 4 weeks, they will be given 2 mandala painting sessions, 3 days a week, under the supervision of the researcher.
62398699|NCT06716710|OTHER|Control group|Nothing other than routine procedures will be done to the control group.
62573735|NCT02937987||Group 1|non-obese type 2 DM
62573736|NCT02937987||Group 2|obese type 2 DM
62573737|NCT06192862|NO_INTERVENTION|Text reminder group (control)|Randomized subjects to the text reminder group will be asked about their intention to undergo CRC screening in the next 6 months. For those who are at pre-contemplation and contemplation stage, a standard text message will be delivered to invite them to undergo CRC screening by informing them that they are due to CRC screening because they are aged \>50 years and are yet to receive CRC screening. No HBM-based health education video or personalized risk assessment will be provided. The chatbot then asks the subject's intention to undergo CRC screening again. For those who propelled to preparation stage or those who are at preparation stage at the beginning, the website link of the government-subsidized CRC screening program which lists the names of all primary care physicians and their contact and co-payment information will be provided.
62734650|NCT05774015|ACTIVE_COMPARATOR|Interventional group (Mg oxide supplementation):|Interventional group (Mg oxide supplementation): Patients in this group will receive Mg oxide tablet 500 mg (302 mg elemental), with a dosage regimen of 1 table once daily as per the recommended range of the daily dose (from 250 to 500 mg elemental) (29, 31, 41, 45). Tablets should be taken with food and 2 hrs. apart from other medications for 12 consecutive months.
62782816|NCT01359501|EXPERIMENTAL|Chinese medical treatment|
62782817|NCT01359501|PLACEBO_COMPARATOR|Placebo|
62782818|NCT05405101|EXPERIMENTAL|Thermal ablation of adrenal aldosterone producing adenoma (s)|For patients randomized to ablation, thermal ablation (either microwave or radiofrequency ablation) will be deployed to treat the adrenal aldosterone producing adenoma(s)
62782819|NCT05405101|OTHER|Unilateral adrenalectomy for aldosterone producing adenoma (s)|For patients randomized to surgery, unilateral adrenalectomy will be performed to remove aldosterone producing adenoma(s)
62782820|NCT03406897|ACTIVE_COMPARATOR|Omega-3 and Vitamin D Combination|The treatment arm A includes Omega-3 Fatty Acids and Cholecalciferol (Vitamin D) supplement.
62782821|NCT03406897|ACTIVE_COMPARATOR|Vitamin D Only|The treatment arm B (control group) will receive only Cholecalciferol (Vitamin D) supplement.
62782822|NCT02815644|EXPERIMENTAL|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
62782823|NCT00528801||Cases (CLOSED)|These are patients diagnosed with sickle cell disease (confirmed by hemoglobin electrophoresis).
62782824|NCT00528801||Controls (CLOSED)|These are persons that do not have sickle cell disease (confirmed by hemoglobin electrophoresis); matched to cases by age, gender, and education level
62194919|NCT00402051|EXPERIMENTAL|Pemetrexed + Cisplatin|
62194920|NCT00402051|EXPERIMENTAL|Pemetrexed + Carboplatin|
62194921|NCT04455503|EXPERIMENTAL|Cohort A: Nivolumab and EVX-02A|EVX-02A administered IM.
62194922|NCT04455503|EXPERIMENTAL|Cohort B: Nivolumab and EVX-02B|EVX-02B administered IM.
62398700|NCT06520761|EXPERIMENTAL|injectable platelet rich fibrin|blood sample is collected from the patient, centrifuged at 700rpm for 3 minutes then the resulted injectable platelet rich fibrin is injected around the upper right canine while the upper left canine act as a control
62009126|NCT03348761|EXPERIMENTAL|rTMS Group|"Phase I: A Magstim Super-Rapid device with a 70-mm figure-of-eight double air film coil (Magstim Ltd, UK) and Brainsight neuronavigation (Rogue Resolutions Ltd, Canada) are used. Stimulation parameters: 10 Hz, 120% resting motor threshold, 30 trains of 5 seconds with 25 seconds rest, 3000 pulses per day delivered 5 days per week (total: 60000 pulses).~Phase II: MagVita X100 (FDA approved device) will be used to deliver intermittent theta burst stimulation (iTBS) to left DLPFC, comprising of 18 cycles of 10 bursts. Each burst is triplet of pulses discharged at 50 hz and the burst frequency is 5Hz. Between two cycles of bursts is 8-second inter-train rest. The device output is set at 120% above the resting motor threshold"
62009127|NCT05001789|EXPERIMENTAL|Active|Working memory training with task-difficulty increasing across sessions
62009128|NCT05001789|ACTIVE_COMPARATOR|Sham|Working memory training with task-difficulty remaining constant across sessions.
62009129|NCT01275183|EXPERIMENTAL|Raltegravir and cisplatin|
62009130|NCT05572242|EXPERIMENTAL|L-PRF preservation (test)|Using L-PRF membranes inside the socket, covering with L-PRF membranes, (test group).
62009131|NCT05572242|ACTIVE_COMPARATOR|Xenogenic bone plus collagen membrane (control)|Bio-Oss® Collagen at the bone level and application of a collagen matrix (Combi-Kit). Both materials will be used for socket preservation (control).
62009132|NCT03766321|ACTIVE_COMPARATOR|Fecal microbiota transplantation (FMT)|"Fecal microbiota transplantation will be performed during two endoscopic procedures (at baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum. Fecal microbiota will be diluted in saline solution 200 ml and infused at 30 ml/minute speed. Every endoscopic procedure will be performed with sedation of the patient.~Feces for FMT will be obtained by known healthy donors for C. difficile infection according to standard selection procedures."
62194923|NCT04455503|EXPERIMENTAL|Cohort C: Nivolumab and EVX-02A OR Nivolumab and EVX-02B|The selected delivery methodology either EVX02A or EVX-02B.
62194924|NCT00627289||1|patients with chronic postherniotomy pain (\>1 year), affecting everyday activities severely
62194925|NCT04817358||Demirjian method|According to the Demirjian method, the development of the seven left mandibular permanent teeth (except the third molar) were rated on the eight-stage scale from A to H. Each stage of mineralization was given a score, total dental maturity score was evaluated according to standard tables for boys and girls
62398701|NCT06520761|EXPERIMENTAL|Low Level LASER|low level laser from diode laser machine is applied around the upper right canine and the upper left canine acts as a control
62398702|NCT04855682||A|Endoscopic discectomy
62194926|NCT04817358||Willems method|Willems' method was determined using the Demirjian calcification stages but scores were evaluated according to Willems' specific tables
62194927|NCT04817358||Nolla method|In the Nolla method, the development of seven left mandibular and maxillar teeth were defined on 10 stages. If the tooth was between stages an appropriate fraction (0.2, 0.5 or 0.7) was added. The total score was determined according to the tables prepared for girls and boys as recommended by Nolla
62398703|NCT04855682||B|Microdisectomy
62398704|NCT04855682||C|Hemilaminectomy
62009133|NCT03766321|PLACEBO_COMPARATOR|Placebo|"ALS patients will undergo upper GI endoscopy with small-intestine biopsies at baseline and after 6 months. Patients in the placebo arm will not receive any treatment during these procedures, but will undergo intestinal biopsy.~Every endoscopic procedure will be performed with sedation of the patient."
62009134|NCT02112097|EXPERIMENTAL|For Left Upper Arm|"For Left Upper Arm Total Persistent % subdermally, For Left Upper Arm Total Persistent % subcutaneously, and For Left Upper Arm Relative Prolongation Ability Score.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
62009135|NCT02112097|EXPERIMENTAL|For Right Upper Arm|"For Right Upper Arm Total Persistent % subdermally, For Left Upper Arm Total Persistent % subcutaneously, and For Left Upper Arm Relative Prolongation Ability Score.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
62194928|NCT02737423|EXPERIMENTAL|vitamin D|single IM dose 600,000 IU of cholecalciferol
62214928|NCT04680338|ACTIVE_COMPARATOR|Cardiac magnetic resonance imaging|Cardiac magnetic resonance (CMR) stress perfusion imaging with feedback of clinically actionable findings
62214929|NCT04680338|NO_INTERVENTION|Control|No intervention, following the natural course of coronary atherosclerosis
62214930|NCT04241601|ACTIVE_COMPARATOR|low dose interleukin-2|Commercially available aldesleukin with a UK marketing authorisation will be used and will be initially prepared as per SmPC. Active and Placebo doses appearing identical at point of issue and administration.
62398705|NCT05812183|EXPERIMENTAL|Bariatric surgery|Gastric sleeve resection will be performed by experienced surgeons. Postoperative care will follow UCLA's postoperative care pathways for gastric sleeve resection.
62782825|NCT05095350|EXPERIMENTAL|Probiotic powder|The probiotic powder contains 10 strains from Lactobacillus and Bifidobacterium genus. Participants will orally take two sachets daily and last for 8 weeks.
62782826|NCT05095350|PLACEBO_COMPARATOR|Placebo powder|The placebo powder consists of maltodextrin and contains no probiotics. Participants will orally take two sachets daily and last for 8 weeks.
62782827|NCT06529861||Ischemia and no obstructive coronary arteries|patients with angina and reduced myocardial blood flow reserve
62782828|NCT06529861||Control|controls without angina
62782829|NCT01569048|ACTIVE_COMPARATOR|remifentanil|
62782830|NCT01569048|EXPERIMENTAL|dexmedetomidine|
62009136|NCT02112097|EXPERIMENTAL|sPGA 50 n(%)|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, and Efficacy of Enbrel subcutaneously at Week 36 vs. Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, and Efficacy of Enbrel subdermally at Week 36. sPGA 50 n(%) clear or minimal is the % of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and % of patients with a reduction of PASI of at least 50% from baseline."
62009137|NCT02112097|EXPERIMENTAL|PASI 75 n(%)|"PASI 75 n(%)~Response to treatment defined as the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI, as PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, and PASI 75 n(%) subcutaneously at Week 36 vs. PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, and PASI 75 n(%) subdermally at Week 36."
62782831|NCT03100175|EXPERIMENTAL|intervention|"the patient will be scheduled for another appointment and taught a set of exercises including strength training for upper and lower limbs (with elastic bands and weights, rising up from chair and climbing stairs), fitness work out (brisk walking) and balance exercises, as recommended by senior sport programs.~* Patients will be provided with printed instructions explaining the recommended exercises, and with a diary to fill in, with days and number of repetitions of specific training elements to be checked in according to their compliance. Patients will also be equipped with a pedometer and will be asked to record the counts regularly~* Patients will be met again by a physiotherapist for follow up at the start of every chemotherapy course (once in 3-4 weeks) and will be contacted by phone twice weekly to assure they stick to the training recommendations"
62009138|NCT02112097|EXPERIMENTAL|Adverse Injection site reactions|Injection site reactions as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
62009139|NCT02112097|EXPERIMENTAL|Adverse Reactions with Heart failure|Heart failure as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
62194929|NCT01686867|EXPERIMENTAL|Commercially-made followed by locally-made improved cookstove|Following a four month run-in period using their traditional, open-fire cookstoves, the investigators will install a commercially-made improved, ventilated cookstove (Envirofit G-3300/G-3355) in each patient's kitchen. Four months later the investigators will install a locally-made improved, ventilated cookstove in each patient's kitchen. During each of the two periods, the investigators will request that the patient uses the improved, ventilated cookstove installed for that period.
62194930|NCT01686867|EXPERIMENTAL|Locally-made followed by commercially-made improved cookstove|Following a four month run-in period using their traditional, open-fire cookstoves, the investigators will install a locally-made improved, ventilated cookstove in each patient's kitchen. Four months later the investigators will install a commercially-made improved, ventilated cookstove (Envirofit G-3300/G-3355) in each patient's kitchen. During each of the two periods, the investigators will request that the patient uses the improved, ventilated cookstove installed for that period.
62194931|NCT01181492||*1/*1|Grouped by CYP3A4\*1G polymorphism, wild-type homozygote
62194932|NCT01181492||*1/*1G|Grouped by CYP3A4\*1G polymorphism,\*1/\*1G: mutant heterozygote
62194933|NCT01181492||*1G/*1G|Grouped by CYP3A4\*1G polymorphism,\*1G/\*1G: mutant homozygote
62194934|NCT02552147|EXPERIMENTAL|Transdermal nicotine first, placebo last|Subject will receive transdermal nicotine 7 mg daily for 7 days, placebo patch for 7 days, then placebo patch for a final 7 days.
62398706|NCT05812183|EXPERIMENTAL|Medical weight loss|The medical weight loss intervention will follow the University of California at Los Angeles's (UCLA) Research For Obesity (RFO) standard protocol. Over a period of 12 months, patients in the medical weight loss group will follow a very loc caloric diet (VLCD) at the UCLA RFO program. All study patients will be prescribed a VLCD, an exercise regimen and will participate in group classes on behavioral modification. The caloric intake consists of a commercially prepared meal replacement powder supplying 700-800 cal/day. Each formula packet provides 100kcal and 15g of high biological value protein, and the daily allowance of required minerals and vitamins.
62398707|NCT06484387|EXPERIMENTAL|dyad schizophrenia and interacting partner|social interaction between an individual with a diagnosis of schizophrenia and his interacting partner
62398708|NCT06484387|EXPERIMENTAL|dyad healthy subject and interacting partner|social interaction between a healthy subject and his interacting partner
62009140|NCT02112097|EXPERIMENTAL|Adverse Reactions Allergic Reactions|Allergic Reactions as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
62009141|NCT02112097|EXPERIMENTAL|Adverse Reactions Blood/low blood counts|Blood problems/low blood counts as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
62398709|NCT06723496||cases group|children with ALL
62398710|NCT06723496||healthy control group|
62398711|NCT05693233|EXPERIMENTAL|Healthy person|Healthy person
62398712|NCT06006962|EXPERIMENTAL|Intervention|Receiving intervention - AgeWISE-AP
62782832|NCT03100175|NO_INTERVENTION|control|The control group will receive standard treatment and follow-up with no special emphasis on physical activity
62782833|NCT01850407|NO_INTERVENTION|Education Counseling|Education of caregivers to counter lack of Preparedness for Children Undergoing Sexual Abuse Medical Examination
62782834|NCT03372174|EXPERIMENTAL|Mechanical ventilation group|patients with mechanical ventilation during cardiopulmonary bypass for cardiac surgery
62782835|NCT03372174|ACTIVE_COMPARATOR|Control group|patients without mechanical ventilation during cardiopulmonary bypass for cardiac surgery
62782836|NCT03739346|EXPERIMENTAL|Control|Tell, show, do technique
62782837|NCT03739346|EXPERIMENTAL|Intervention|Hypnosis.
62782838|NCT05014685|EXPERIMENTAL|RA group|
62009142|NCT02112097|EXPERIMENTAL|Adverse Reactions with Nervous system|Nervous system problems, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes, as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
62398713|NCT06006962|NO_INTERVENTION|Waitlist Control|No intervention; will be invited to participate in intervention after completion of study.
62782839|NCT05014685|EXPERIMENTAL|RAM group|
62782840|NCT05014685|EXPERIMENTAL|RAB group|
62782841|NCT05014685|ACTIVE_COMPARATOR|RABM group|
62782842|NCT03438136|EXPERIMENTAL|Intervention arm|This arm will be enrolled in the intervention.
62782843|NCT03438136|NO_INTERVENTION|No intervention arm|This arm will be enrolled in a no contact control group.
62573738|NCT06192862|EXPERIMENTAL|Chatbot outreach group|"Subjects in chatbot outreach group will be asked about their intention to undergo CRC screening in the next 6 months and their TTM stage will be determined according to their answers. For subjects who are at preparation stage, the chatbot will further request for the preferred district to have a consultation under the government-subsidized CRC screening.~For subjects who are at pre-contemplation stage, the chatbot will deliver an HBM-based health education video filmed by gastroenterologists and colorectal cancer survivor who has been diagnosed by screening. The subject's intention will be asked again after the video.~For those who upgrade to contemplation stage or remain at pre-contemplation stage and those who are at contemplation stage at the beginning, the chatbot will assess the personalized risk of CRC using the Asia-Pacific Colorectal Screening Score (APCS). Finally, the subject's intention to undergo screening will be asked for the last time."
62782844|NCT04204044|EXPERIMENTAL|GROUP A ( metformin 500 mg TDS)|Life style modifications, Weight reduction and folic acid will be prescribed with metformin 500 mg three times a day
62782845|NCT04204044|EXPERIMENTAL|GROUP B( myoinositol 2000mg x BD )|Life style modifications, Weight reduction and folic acid will be prescribed with myoinositol 2000 mg two times a day
62782846|NCT04204044|EXPERIMENTAL|GROUP C.(both metformin,& myoinositol)|Life style modifications, Weight reduction and folic acid will be prescribed with both metformin,\& myoinositol three and two times a day respectively
62782847|NCT04161261|EXPERIMENTAL|IntraOperative Group|The intra-operative group consists of patients who have met criteria for cochlear implants. We monitor the facial nerve EMG intraoperatively in all patients, and often get some facial nerve activation when we are testing the implant intraoperatively when we are looking to see if we are getting any hearing nerve responses from electrical stimulation of the implant. We will also measure the facial nerve responses for some other charge-balanced pulse shapes, which are asymmetric and in which either the positive or negative charge is expected to stimulate the nerve. We will only measure these for two electrodes, not for all 12-22 electrodes They will be then invited back post operatively for a second testing during a standard of care visit post switch on for other pulse shapes.
62009143|NCT02112097|EXPERIMENTAL|Adverse Reactions with Infections|Infections (upper respiratory infection, pyelonephritis, bronchitis, septic osteomyelitis, wound infection, pneumonia, foot abscess, leg ulcer), as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
62009144|NCT02112097|EXPERIMENTAL|Adverse Reactions with Malignancies|Malignancies (lymphoma, basal \& squamous skin cancer, non-cutaneous solid tumor, \& Wegener's granulomatosis), as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
62009145|NCT02112097|EXPERIMENTAL|Adverse Reactions with Immunogenicity|Immunogenicity as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
62009146|NCT02112097|EXPERIMENTAL|Adverse Reactions with Autoantibodies|Autoantibodies, Lupus-like syndrome, autoimmune hepatitis, as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
62009147|NCT04856176|EXPERIMENTAL|GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed|All patients will receive GM-CSF plus maintenance pembrolizumab with or without pemetrexed, following completion of 4 cycles of chemo-immunotherapy
62009148|NCT00912405|EXPERIMENTAL|Sinexus Intranasal Splint|Patient receives a drug-coated intranasal splint
62009149|NCT03380468|EXPERIMENTAL|Cisplatin plus pemetrexed|Drug: cisplatin 75mg/m2 iv Drug: pemetrexed 500mg/m2 iv
62782848|NCT04161261|EXPERIMENTAL|PostOperative Group|The post-operative group, are patients who are actually having facial nerve stimulation on one or more electrodes, and for whom these electrodes are turned down so much they can't hear very well, or are actually turned off because of the facial nerve stimulation. For these patients, we will slowly increase the current levels on the offending electrodes (maximum of two) until they get some facial nerve twitching, and then turn down the current until they do not have stimulation any more. We will do this for all pulse shapes and determine which shape produces the greatest loudness without stimulating the facial nerve. This will be the only testing session for the second group.
62009150|NCT03380468|NO_INTERVENTION|Observation|Observation and follow up only
62782849|NCT01354119|ACTIVE_COMPARATOR|Early intervention|Early intervention: stent-graft just after acute phase
62009151|NCT05844878|EXPERIMENTAL|Dental anxiety management intervention group|in this arm; the patients will under go combination of 2 anxiety management techniques by using of behavioral therapeutic management including; Cognitive behavioral therapy (CBT) by using Distraction technique, and Mindfulness technique by using of relaxation breathing with muscle relaxation, during dental treatment through 30 minutes. then after 3 months those patients will be followed up for re measurement of anxiety level by using the same modified dental anxiety scale questionnaire.
62194935|NCT02552147|EXPERIMENTAL|Transdermal placebo first, nicotine last|Subject will receive transdermal placebo daily for 7 days, placebo patch for another 7 days, then transdermal nicotine 7 mg daily for a final 7 days.
62194936|NCT02387697|EXPERIMENTAL|Group A|Transfemoral implantation of an Edwards Sapien XT Valve into the vena cava inferior (VCI). For better stability and for downsizing of the VCI diameter the valve will be implanted after preparation of a landing zone. This includes implantation of one or two self expandable stents into the VCI prior to the final deployment of the valve.
62194937|NCT02387697|NO_INTERVENTION|Group B|Control group (no surgery) with optimal medical treatment.
62194938|NCT02523690|EXPERIMENTAL|Intervention|Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
62194939|NCT02523690|PLACEBO_COMPARATOR|Control|Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
62194940|NCT02406248|EXPERIMENTAL|single arm|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
62398714|NCT00444028|EXPERIMENTAL|Cohort A: Inhaled Loxapine 0.625 mg or Placebo|Single 0.625 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
62398715|NCT00444028|EXPERIMENTAL|Cohort B: Inhaled Loxapine 1.25 mg or Placebo|Single 1.25 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
62194941|NCT02034019|ACTIVE_COMPARATOR|OTX-DP (Dexamethasone Punctum Plug)|Resorbable hydrogel drug delivery vehicle containing dexamethasone
62398716|NCT00444028|EXPERIMENTAL|Cohort C: Inhaled Loxapine 2.5 mg or Placebo|Single 2.5 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
62782850|NCT01354119|NO_INTERVENTION|Conservative|Conservative: medial follow-up without early intervention
62782851|NCT02356848|EXPERIMENTAL|Tailored intervention (TI)|Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles. This arm will have biweekly calls for the first two months and then monthly calls for the next four months followed by texts or mailings for months 7-18 with the frequency determine by level of treatment adherence.
62782852|NCT02356848|PLACEBO_COMPARATOR|Current Practice (CP)|This group will receive all the enhancements that the VA has targeted to improve foot risk in diabetes including full EMR functionality, clinical reminders to improve care, and Patient-Centered Medical Home (PCMH) implementation with its benefits for diabetes care. To control for attention and preserve blinding, this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease. This arm will have biweekly calls for the first two months and then monthly calls for the next four months followed by texts or mailings for months 7-18 with the frequency determine by level of treatment adherence to general health recommendations
62009152|NCT05844878|NO_INTERVENTION|control group|in this arm; the patients will under go dental treatment for the same duration as the intervention arm treatment, but without applying the anxiety management techniques. Subsequently, each patient will be followed up after 3 months, similar to the intervention group.
62009153|NCT02841618|EXPERIMENTAL|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (10g grapeseed oil) 1 per day for 2 weeks Phase 1: N=39 adults single arm Phase 2: N=42 adults
62009154|NCT02841618|PLACEBO_COMPARATOR|High Oleic Acid Healthy Cookies|High Oleic Acid Healthy Cookies (10g safflower oil) 1 per day for 2 weeks Matched for Phase 2: N=42 adults
62009155|NCT03842176||Neoadjuvant chemotherapy|CTC of operable breast cancer patients with neoadjuvant chemotherapy before surgery in different periods: before neo-chemotherapy, during neo-chemotherapy, on surgery day, after surgery and follow-up time.
62009156|NCT03842176||Surgery|CTC of operable breast cancer patients with surgery followed by adjuvant chemotherapy in different periods: on surgery day, after surgery, before adjuvant chemotherapy, during adjuvant chemotherapy, and follow-up time.
62009157|NCT01122966|OTHER|trabeculectomy|Subjects who have trabeculectomies with intraocular bevacizumab injection
62194942|NCT02034019|PLACEBO_COMPARATOR|PVPP (Placebo Punctum Plug)|Resorbable hydrogel drug delivery vehicle containing no drug
62398717|NCT00444028|EXPERIMENTAL|Cohort D: Inhaled Loxapine 5 mg or Placebo|Single 5 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
62398718|NCT00444028|EXPERIMENTAL|Cohort E: Inhaled Loxapine 10 mg or Placebo|Single 10 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
62398719|NCT02662140|EXPERIMENTAL|Mobile Health Application Group|"emobile health application will enhance the existing evidence informed curriculum of a Multiple Family Group model (called 4 Rs and 2 Ss for Strengthening Families Model) for families with children who have disruptive behavior disorders. This mobile application consists of two primary components that will support engagement and integration of the model's core concepts in family life. The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the Do process."
62398720|NCT03133208||Sepsis with AMS|Patients presenting to the ED with suspected sepsis who develop altered mental status
62782853|NCT00238238|ACTIVE_COMPARATOR|Arm I - rituximab|Patients receive rituximab IV on days 1, 8, 15, and 22.
62782854|NCT00238238|EXPERIMENTAL|Arm II - lenalidomide|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62782855|NCT00238238|EXPERIMENTAL|Arm III - lenalidomide and rituximab|Patients receive lenalidomide as in arm II. Patients also receive rituximab IV on days 8, 15, 22 and 29.
62009158|NCT05318118|ACTIVE_COMPARATOR|Medial Meniscus Arthroscopic Reconstruction Using the Fast Fix|
62009159|NCT05318118|ACTIVE_COMPARATOR|Medial Meniscus Arthroscopic Reconstruction Using the Fiber Stitch|
62009160|NCT06189092||Performed electrosclerotherapy|All patients who performed electrosclerotherapy in the treatment of vascular malformations
62009161|NCT06363916||Open Loop|Patients using the Insulin Management System device in a manual mode of operation. Patient must use the interface directly to deliver insulin. The algorithm will not be activated.
62009162|NCT06363916||Closed Loop|"Patients using the Insulin Management System device in the Closed Loop mode of operation. The algorithm will be activated. The algorithm is capable of delivery of insulin based on sensor derived glucose levels, glucose level trends and insulin pump delivery history.~Patients in this group can continue to an exploratory phase for the Automatic Meal Management function."
62194943|NCT02866669|ACTIVE_COMPARATOR|Enhanced usual care|Practices in the usual enhanced care arm will receive a blood pressure medication algorithm developed using national guidelines and content experts on our study team. Practices will be provided the Joint National Committee (JNC) recommended protocol to measuring blood pressures. Practices will receive a laptop workstation that has access to the Patient Activated Learning System - an online education video system.
62009163|NCT03269279|EXPERIMENTAL|Medical abortion arm|200mg of Mifepristone and repeat doses of 400mcg of misoprostol every 3 hours administered for medical abortion in 2nd trimester
62009164|NCT06243497||Matched eyes|Patients with glaucoma matched by sex and age.
62009165|NCT06243497||Treated eyes with UCP|The patients were definitely diagnosed as glaucoma, No age or gender limitation, IOP(intraocular pressure) ≥ 21mmHg under the maximum tolerated dose of antiglaucoma medication, or IOP \< 21mmHg and glaucomatous optic nerve damage progressed. UCP treatment is required for the patients.
62009166|NCT02651623|EXPERIMENTAL|Sertraline|Maximum dose of 400 mg/day (200 mg BID given at approximately 12 hours apart) sertraline, dose titrated from a starting single dose (QD) of 50 mg in the morning on Day 1 followed by BID doses administered on Days 2 through 14 (Day 14 morning dose only) will be administered
62009167|NCT02651623|ACTIVE_COMPARATOR|Moxifloxacin|400 mg single dose of moxifloxacin (Avelox®) administered on Day 14
62009168|NCT02651623|PLACEBO_COMPARATOR|Drug - Placebo|placebo - placebo administered on Days 1 through 14
62009169|NCT01915277|EXPERIMENTAL|Neonate dosing cohort 1|Neonate dexmedetomidine dosing cohort 1
62009170|NCT01915277|EXPERIMENTAL|Neonate dosing cohort 2|Neonate dexmedetomidine dosing cohort 2
62194944|NCT02866669|EXPERIMENTAL|Practice facilitation|Practices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. Practice facilitation is a highly customized, staged approach to helping a practice to implement process and structural changes to enhance the quality of care and improve patient and staff satisfaction
62398721|NCT03133208||Sepsis without AMS|Patients presenting to the ED with suspected sepsis without change in mental status
62573739|NCT01659606|EXPERIMENTAL|alemtuzumab/fludarabine conditioning|alemtuzumab/fludarabine conditioning; calcineurin-inhibitor/mycophenolate mofetil GVHD prophylaxis
62573740|NCT05468905||Cognitive normal Aging (CN)|Normal aging subjects with normal cognitive function
62573741|NCT05468905||Subjective cognitive impairment (SCI)|"Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event. Answering yes to both of the following questions: Do you feel like your memory or thinking is becoming worse? and Does this concern you?"
62573742|NCT05468905||Mild cognitive impairment (MCI)|Mild cognitive impairment subjects with memory loss as predominant symptom
62009171|NCT01915277|EXPERIMENTAL|Neonate dosing cohort 3|Neonate dexmedetomidine dosing cohort 3
62009172|NCT01915277|EXPERIMENTAL|Neonate dosing cohort 4|Neonate dexmedetomidine dosing cohort 4
62009173|NCT01915277|EXPERIMENTAL|Neonate dosing cohort 5|Neonate dexmedetomidine dosing cohort 5
62009174|NCT01915277|EXPERIMENTAL|Infant dosing cohort 1|Infant dexmedetomidine dosing cohort 1
62009175|NCT01915277|EXPERIMENTAL|Infant dosing cohort 2|Infant dexmedetomidine dosing cohort 2
62009176|NCT01915277|EXPERIMENTAL|Infant dosing cohort 3|Infant dexmedetomidine dosing cohort 3
62009177|NCT01915277|EXPERIMENTAL|Infant dosing cohort 4|Infant dexmedetomidine dosing cohort 4
62194945|NCT02866669|EXPERIMENTAL|Peer coach|Participants enrolled from practices that are randomized to the peer coach arm will be matched with peer advisors who will work with the participants for 12 months.
62194946|NCT02866669|EXPERIMENTAL|Peer coach and Practice facilitation|Practices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. The patients will also be matched with peer advisors who will work with the participants for 12 months.
62194947|NCT03439358|EXPERIMENTAL|Magnesium sulfate|Magnesium sulfate (MgSO4) infusion will be commenced prior to epidural top-up.
62398722|NCT03133208||Control|Patients presenting to the ED with no suspicion of systemic inflammation that need hospitalization (control category)
62009178|NCT01915277|EXPERIMENTAL|Infant dosing cohort 5|Infant dexmedetomidine dosing cohort 5
62009179|NCT01941953|EXPERIMENTAL|Metformin and Flourouracil|
62009180|NCT01993407|EXPERIMENTAL|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
62009181|NCT01993407|PLACEBO_COMPARATOR|Pure Task Training|Participants will complete four, one-hour training sessions in which they will perform a single task each session, alternating tasks between but not within sessions.
62194948|NCT03439358|PLACEBO_COMPARATOR|Normal saline|Normal saline infusion will be commenced prior to epidural top-up.
62398723|NCT04603339|EXPERIMENTAL|Intervention Arm|Single arm trial, all participants will receive the intervention
62398724|NCT05934409|ACTIVE_COMPARATOR|Control group|without T2D according to Diabetes Canada diagnostics criteria:
62398725|NCT05934409|EXPERIMENTAL|group with Type 2 diabetes|with T2D according to Diabetes Canada diagnostics criteria:
62398726|NCT06526247|EXPERIMENTAL|Strength at Home (SAH)|Participants randomized into this arm with receive a trauma-informed intimate partner violence (IPV) intervention program.
62573743|NCT05468905||Alzheimer's disease (AD)|Mild to moderate sporadic and familial Alzheimer disease subjects
62573744|NCT05468905||Vascular cognitive impairment (VCI)|Cognitive impairment subjects caused by cerebral vessel disease
62573745|NCT01236274||Antipsychotic agents AND MI|In the self-controlled case series study, patients who experienced a myocardial infarction and received an antipsychotic agent during up to standard (UTS) follow-up in the GPRD will be included and will act as their own control.
62573746|NCT01236274||Myocardial Infarction|In the case-control study, all cases with a first recorded occurrence of MI during up to standard (UTS) follow-up in the GPRD will be identified
62194949|NCT05204069|EXPERIMENTAL|Three-dimensional screening for visual disorders using the RetinoMax Device|Instillation of cyclopentolate of 3 drops of cyclopentolate at T0',T5' and t10' with to induce a certain level of cycloplegia and evaluate manifest refraction at t45' using the RetinoMax Device.
62194950|NCT05204069|ACTIVE_COMPARATOR|Non-standardized device for usual vision disorders|Screening device for usual vision disorders, performed by the school doctor during the usual prevention visit, with the tools used in the school doctor's current practice, non-standardized, according to his preference
62194951|NCT05716568|ACTIVE_COMPARATOR|Standard contrast dose|Standard contrast dose administration
62194952|NCT05716568|ACTIVE_COMPARATOR|Calculated contrast dose|Contrast dose by calculation
62194953|NCT05716568|ACTIVE_COMPARATOR|Calculated contrast dose -50%|Contrast dose by calculation, with extra dilution by 50%.
62194954|NCT03354468||fall prevention program time 1|orthopedic department in Kristiansund hospital before implementation of a fall prevention program
62573747|NCT01236274||No Myocardial Infarction|In the case-control study, a control group with subjects who never experienced a myocardial infarction will be matched to cases (5:1) by age, gender, General Practitioner and registration in the GPRD on the date of MI of the case
62194955|NCT03354468||no fall prevention program time 1|orthopedic department in Ålesund hospital without fall prevention program
62194956|NCT03354468||fall prevention program time 2|orthopedic department in Kristiansund hospital after implementation of a fall prevention program
62194957|NCT03354468||no fall prevention program time 2|orthopedic department in Ålesund hospital without fall prevention program
62194958|NCT03266718|OTHER|Physical Activity Intervention|Couples will receive four 60-minute intervention sessions via videoconference with Duke staff. Study staff will provide couples with instructions for use of the iPad computer and videoconference software which will be used to deliver the intervention sessions.The first 3 sessions will be conducted weekly, with a booster session occurring approximately one month later.
62194959|NCT03266718|OTHER|Waitlist control|Couples will have the option to receive the intervention after they complete the follow-up survey. This version of the intervention will not include the booster session, so will last approximately 1 month in total. If they choose to receive the intervention, they will be provided with a tablet computer if they do not have one.
62194960|NCT02353468|EXPERIMENTAL|Enzyme inhibitor, biological therapy, chemotherapy|"CONSOLIDATION: Patients receive VLD therapy comprising bortezomib IV on days 1, 4, 8, and 11, lenalidomide PO QD on days 1-14, and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Courses continue for 28 days and repeat every 3 months in the absence of disease progression or unacceptable toxicity.~In between courses of VLD, patients receive LD therapy comprising lenalidomide PO QD on days 1-21 and dexamethasone PO QD or IV every Monday (x3). Courses continue for 28 days.~MAINTENANCE: Starting in the third year of therapy, patients receive lenalidomide PO QD on days 1-14 and dexamethasone PO QD or IV every Monday (x2). Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
62194961|NCT00460018|EXPERIMENTAL|Intervention|Women receiving the DEBI Intervention
62194962|NCT00460018|NO_INTERVENTION|No intervention|Women receiving standard care
62194963|NCT06241781|EXPERIMENTAL|GT101 injection treatment group|
62194964|NCT06241781|ACTIVE_COMPARATOR|Gemcitabine injection treatment group|
62194965|NCT00762476|PLACEBO_COMPARATOR|Placebo|
62194966|NCT00762476|EXPERIMENTAL|3804-250A|
62194967|NCT04038242|EXPERIMENTAL|Resilience promotion program|Subjects in the intervention group will participate in an eight-session resilience promotion program.
62194968|NCT04038242|NO_INTERVENTION|Treatment as usual|Treatment as usual for subjects in the control group.
62194969|NCT01516749|EXPERIMENTAL|Anakinra|All patients in this arm will receive the investigation drug anakinra once daily subcutaneously.
62194970|NCT00634842|EXPERIMENTAL|FPG 70-90 mg/dL|Aggressive FPG (fasting plasma glucose) titration target range group
62194971|NCT00634842|EXPERIMENTAL|FPG 80-110 mg/dL|Conventional FPG (fasting plasma glucose) titration target range group
62194972|NCT01972932|PLACEBO_COMPARATOR|Placebo|Placebo 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
62194973|NCT01972932|ACTIVE_COMPARATOR|Bio K+®|Bio K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
62194974|NCT03272503|EXPERIMENTAL|Group 1 Pimozide 2 mg (current) or 4 mg/day (study initiation)|Pimozide will be initiated at 2 mg once daily. The maximum dose will then be administered for a target period of 22 weeks.
62194975|NCT03272503|PLACEBO_COMPARATOR|Group 2 Placebo|Placebo tablets will be utilized and administered in an identical manner for subjects in Group 1
62214931|NCT04241601|PLACEBO_COMPARATOR|Placebo|Commercially available dextrose 5% injection with a UK marketing authorisation at equivalent dose volume will be used for the placebo formulation. Placebo and Active doses appearing identical at point of issue and administration.
62214932|NCT04550338|EXPERIMENTAL|Tranexamic Acid Treatment|
62214933|NCT04550338|PLACEBO_COMPARATOR|Placebo Treatment|
62214934|NCT00901706|EXPERIMENTAL|CGA plus APS Usual Care|Comprehensive geriatric assessment coupled with Adult Protective Services (APS) usual care for elders with self-neglect.
62214935|NCT00901706|ACTIVE_COMPARATOR|APS Usual Care|APS usual care consisting of social, medical, and legal interventions.
62214936|NCT06611267|EXPERIMENTAL|Participants assess their experienced pain|
62214937|NCT06611267|ACTIVE_COMPARATOR|Participants assess their expected and experienced pain|
62214938|NCT02135354|EXPERIMENTAL|Azithromycin|"N = 250~* From day 1 up to and including day 3: 500 mg azithromycin PO once a day~* From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days"
62214939|NCT02135354|PLACEBO_COMPARATOR|Placebo|"N = 250~* From day 1 up to and including day 3: 500 mg placebo PO once a day~* From day 4 up to and including day 90: 250 mg placebo PO once every 2 days"
62398727|NCT06526247|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Participants randomized into this arm with receive a standard IPV intervention program in the state of Washington.
62573748|NCT03227081|NO_INTERVENTION|Sleep|Sleep
62573749|NCT03227081|EXPERIMENTAL|Sleep Deprivation|Sleep Deprivation
62194976|NCT05087251|EXPERIMENTAL|Intervention: Five Psycho-educational Sessions|Approximately 6 weeks after the patient's cancer treatment is complete, participants in the intervention arm will proceed to receive up to 5 study sessions (approximately weekly, \~50 minutes each) with a trained interventionist focused on psychoeducational topics. This arm was designed to enhance patient skills to address key concerns during the transition from treatment to surveillance, using a cognitive-behavioral approach. Sessions will be based on an intervention manual.
62573750|NCT04310670|EXPERIMENTAL|Patients with FND|Diagnosis of Functional Neurological Disorder of movement clinically established according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria
62009182|NCT06456021|EXPERIMENTAL|Enhanced|CCLs will be randomized to enhanced leadership coaching implementation support (n=3) or standard implementation support (n=3). All groups will implement the Playbook. The enhanced group will receive 6 months of leadership coaching support. The standard implementation group will receive logistical support, but no alternative to coaching, such as advisement.
62009183|NCT06456021|ACTIVE_COMPARATOR|Standard|The standard implementation group will receive logistical support, but no alternative to coaching, such as advisement.
62194977|NCT05087251|EXPERIMENTAL|Enhanced Usual Care: One Psycho-educational Session|At approximately 6 weeks after treatment completion (as defined by our eligibility criteria), control patients will attend one study session (\~50 minutes) with a study clinician. This session is designed to control for patient access and connection to psychosocial resources as recommended in recent work.
62573751|NCT05622838||Pregnant Pre-eclamptic women with IUGR at 32-36 weeks|
62194978|NCT02270671|PLACEBO_COMPARATOR|Placebo|The placebo protocol consists of 160 trials (120 angry-neutral face pair and 40 neutral-neutral face pair presentations). In this condition, angry-face location, probe location and actor are fully counterbalanced in presentation. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
62194979|NCT02270671|EXPERIMENTAL|Intervention|The attention bias modification training (ABMT) protocol consists of 160 trials (120 angry-neutral face pair presentations and 40 neutral-neutral face pair presentations). In the ABM condition, the target-probe appears at the neutral-face locations in all angry-neutral trials. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
62194980|NCT06151210|EXPERIMENTAL|DA-5219|administered for 2weeks(DA-5219 + Stillen® Tab placebo)
62194981|NCT06151210|ACTIVE_COMPARATOR|Stillen® Tab|administered for 2weeks(Stillen® Tab + DA-5219 placebo)
62194982|NCT02769442|EXPERIMENTAL|Terumo SurFlash Plus catheter|Patients randomized to the Terumo catheter
62194983|NCT02769442|ACTIVE_COMPARATOR|BD Insyte Autoguard catheter|Patients randomized to the BD catheter
62194984|NCT00775411|EXPERIMENTAL|700 µg dexamethasone and ranibizumab|700 µg dexamethasone intravitreal injection at Day 1 in the study eye. Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
62194985|NCT02398253|EXPERIMENTAL|CBT + Hypo-energetic Diet|
62573752|NCT05622838||Pregnant Pre-eclamptic women with healthy fetus at 32-36 weeks|
62009184|NCT04670016||Patient/Caregiver dyad diagnosed with DIPG|"All of these criteria must be met for a patient to be eligible for this study:~1. Patient aged \>2 and \<21 years treated with a repeat course of radiation for DIPG~2. Radiation for the first tumour must be a primary brain neoplasm (i.e. not leukemia).~3. Enrollment within 14 days of starting re-irradiation (RT2).~4. Patients with malignant transformation of the first tumour are eligible.~5. There are no restrictions on histology or RT1/RT2 dose-fractionation or RT2 body site. In other words, RT2 may be directed at a different location to RT1.~6. The patient is treated at a site where the study is approved by the local ethics board~7. Consent, and, if applicable, assent, has been obtained according to institutional standards"
62194986|NCT02398253|EXPERIMENTAL|Hypo-energetic Diet only|
62194987|NCT01179776|EXPERIMENTAL|Ilomedin and standard low dose treatment|
62194988|NCT01179776|PLACEBO_COMPARATOR|Placebo|
62194989|NCT00273286|EXPERIMENTAL|family diabetes management intervention|A trained health advisor will be responsible for interactions with parents and patients prior to each diabetes clinic visit (Preparation Phase), at the time of the diabetes clinic visit (Consolidation Phase) and by phone, e-mail, etc. after the clinic visit (Follow-up Phase). Using educational modules developed for the study, families will be engaged in problem identification and solving activities to improve shared parent-youth responsibility for diabetes management and foster increased adolescent's independent management capabilities.
62573753|NCT05622838||Normal pregnant women with healthy fetus|
62573754|NCT05478161|EXPERIMENTAL|treatment|TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
62573755|NCT06468345|EXPERIMENTAL|Acupressure Group|Acupressure application to CV12, ST25, SP6, LI4 and HT7 areas
62573756|NCT06468345|NO_INTERVENTION|Control Group|No action was taken.
62573757|NCT06468345|SHAM_COMPARATOR|Placebo Group|Massage application to feet, hands and abdomen areas that are not acupressure areas
62573758|NCT04815811|EXPERIMENTAL|Children suffering from acute inflammatory processes.|"The study population will consist of male and female children, aged from 6 months to 7 years old, admitted to the hospital for one of the three following types of acute inflammatory processes:~* Urinary tract infection caused by Escherichia coli~* Pneumonia with pleural effusion caused by Streptococcus pneumoniae~* Sepsis"
62573759|NCT04815811|OTHER|Control group|Male and female children, aged from 6 months to 7 years old, admitted to the hospital for a scheduled operation for a non-inflammatory pathology.
62782856|NCT01504841|EXPERIMENTAL|Cohort I: Treatment experienced, 2 to 6 years of age|Children in this arm were at least 2 but younger than 6 years of age; they received the study drug etravirine (ETR) together with an optimized background regimen (OBR) consisting of one active boosted protease inhibitor (PI) and at least one other active antiretroviral (ARV) drug.
62194990|NCT04193423|EXPERIMENTAL|A-Group: craniocervical and cervicothoracic extension training|
62194991|NCT04193423|EXPERIMENTAL|B-Group: craniocervical flexion training|
62194992|NCT04193423|ACTIVE_COMPARATOR|C-Group: control group|No intervention will be performed due to the fact that they will be still on the waiting list.
62782857|NCT01504841|EXPERIMENTAL|Cohort II: Treatment experienced, 1 to 2 years of age|Children in this arm were at least 1 but younger than 2 years of age; they received ETR together with an OBR consisting of one active boosted PI and at least one other active ARV drug.
62782858|NCT01504841|EXPERIMENTAL|Cohort III: Treatment experienced, 2 months to 1 year of age|Children in this arm were at least 2 months but younger than 1 year of age; they received ETR together with an OBR consisting of one active boosted PI and at least one other active ARV drug.
62782859|NCT01753089|OTHER|WDVAX|Treatment
62782860|NCT04560387|EXPERIMENTAL|Interventional|"Physician-lead complex program of weight-reducing interventions including education, diet counselling and regular physical activity aimed at achieving and maintaining a 10% reduction of baseline body weight.~Bariatric surgery - sleeve gastrectomy in a subgroup of subjects with BMI \> 35 kg/m2, i.e. standard indication of bariatric surgery (patients with BMI \> 35 kg/m2 and a presence of metabolic or other complications)."
62782861|NCT04560387|NO_INTERVENTION|Conservative|Routine treatment of obesity
62782862|NCT04338971|EXPERIMENTAL|IpsiHand Device|All participants will receive treatment with the IpsiHand Device.
62782863|NCT02237755|ACTIVE_COMPARATOR|Clomiphene citrate|Administration of Clomiphene citrate in combination with gonadotropins according to a short stimulation GnRH antagonists protocol.
62782864|NCT02237755|ACTIVE_COMPARATOR|Gonadotropins|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists.
62782865|NCT02929459|EXPERIMENTAL|Riboflavin Dose 1|100 mg Riboflavin (one capsule) per day for 2 weeks
62782866|NCT02929459|EXPERIMENTAL|Riboflavin Dose 2|50 mg Riboflavin (one capsule) per day for 2 weeks
62782867|NCT02929459|PLACEBO_COMPARATOR|Placebo|100 mg starch plus 0,5% silica (one capsule) per day for 2 weeks
62782868|NCT05400304||Training dataset|No interventions
62782869|NCT05400304||External validation1|No interventions
62782870|NCT05400304||External validation2|No interventions
62782871|NCT05862311|EXPERIMENTAL|systemically healthy and periodontitis|
62782872|NCT05862311|EXPERIMENTAL|type 2 diabetes and periodontitis|
62194993|NCT06068140||Study Cohort|Patients taking Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate
62194994|NCT06068140||Control cohort|Patients who do not take Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate
62194995|NCT06215209||ultra-low tidal volume group|ARDS patients with ultra-low tidal volume ventilation
62194996|NCT02373631|EXPERIMENTAL|Dry Needling, Conventional PT|
62194997|NCT02373631|ACTIVE_COMPARATOR|Conventional PT|
62573760|NCT03738670|EXPERIMENTAL|RFA|Single-arm prospective observational study
62573761|NCT04787913|NO_INTERVENTION|controlgeneric|No intervention provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English and French.
62194998|NCT03809039|EXPERIMENTAL|Single Ascending Dose: MT-6345 & Placebo|
62194999|NCT03809039|EXPERIMENTAL|Multiple Ascending Dose: MT-6345 & Placebo|
62195000|NCT01857037|OTHER|Single arm|Single arm
62195001|NCT03740243|ACTIVE_COMPARATOR|buprenorphine|"Buprenorphine 2 mg to 8 mg daily: Light to moderate history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 5-24~Buprenorphine 8 mg to 16 mg daily: Heavy history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 25-36+"
62573762|NCT04787913|NO_INTERVENTION|controlmeasles|No intervention provided. Participant answers outcome questions about measles. English and French.
62573763|NCT04787913|NO_INTERVENTION|controlpertussis|No intervention provided. Participant answers outcome questions about pertussis. English and French.
62573764|NCT04787913|NO_INTERVENTION|controlflu|No intervention provided. Participant answers outcome questions about flu. English and French.
62573765|NCT04787913|EXPERIMENTAL|herdimmgeneric|Web-based application (main intervention) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English and French.
62573766|NCT04787913|EXPERIMENTAL|herdimmmeasles|Web-based application (main intervention) provided. Participant answers outcome questions about measles. English and French.
62782873|NCT05182268||endoscopic ear surgery group(EES)|
62782874|NCT05182268||microscopic ear surgery group(MES)|
62782875|NCT02227394|EXPERIMENTAL|Z7200 - Symbicort® Turbohaler|"The patients randomized to this sequence were to receive a single dose consisting of 2 inhalations of the test product (Z7200) on the first dosing day (Period 1, Visit 2), then, after a wash out period of at least 3 days but no more of 31 days, a single dose consisting of 2 inhalations of the reference treatment (Symbicort® Turbohaler) on the second dosing day (Period 2, Visit 3).~Patients were also to receive 2 inhalations with matching placebo to the alternate treatment as a dummy inhaler to achieve double-blinding.~Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.~Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided."
62573767|NCT04787913|EXPERIMENTAL|herdimmpertussis|Web-based application (main intervention) provided. Participant answers outcome questions about pertussis. English and French.
62573768|NCT04787913|EXPERIMENTAL|herdimmflu|Web-based application (main intervention) provided. Participant answers outcome questions about flu. English and French.
62009185|NCT04670016||Patient/Caregiver dyad with re-RT for a recurrent brain tumour|"All of these criteria must be met for a patient to be eligible for this study:~1. Patient aged \>2 and \<21 years treated with a repeat course of radiation for a recurrent or progressive brain tumour (stratum 2).~2. Radiation for the first tumour must be a primary brain neoplasm (i.e. not leukemia).~3. Enrollment within 14 days of starting re-irradiation (RT2).~4. Patients with malignant transformation of the first tumour are eligible.~5. There are no restrictions on histology or RT1/RT2 dose-fractionation or RT2 body site. In other words, RT2 may be directed at a different location to RT1.~6. The patient is treated at a site where the study is approved by the local ethics board~7. Consent, and, if applicable, assent, has been obtained according to institutional standards"
62009186|NCT01537341|ACTIVE_COMPARATOR|Traditional Treadmill|Participants will follow the same guidelines as the split belt component but will complete the intervention on a traditional, single belt/speed treadmill.
62009187|NCT01537341|EXPERIMENTAL|Split-belt|Participants will walk on a custom-built split-belt treadmill comprised of two separate belts, each with its own motor, that permitted the speed of each belt (i.e. each leg) to be controlled independently.
62009188|NCT03536728|EXPERIMENTAL|Part 1|Dose escalation of AMXT1501 with a fixed low dose of DFMO will follow a 3 + 3 dose escalation design. The AMXT 1501 starting dose administered in the first cohort will be 80 mg (2 capsules); each capsule contains 40 mg of active drug. The dose will be given orally, once daily, fasted state alone for 14 days, and starting on Day 15 AMXT 1501 80 mg given in combination with fixed low-dose oral DFMO at 250mg 2x per day (BID), for an additional 14 days; for a total 28 days of treatment per cycle. Cycle 2 includes AMXT1501 + DFMO that will be administered for 28 days. The patient can be treated for additional 28 day treatment cycles as deemed appropriate by their study investigator. Dose escalation of AMXT1501 alone will increase per Part 1 cohort.
62009189|NCT03536728|EXPERIMENTAL|Part 2|"Dose escalation of DFMO with the Part 1 AMXT1501 RP2D fixed dose will follow a 3 + 3 dose escalation design.~The AMXT 1501 starting dose administered in the first cohort will be one level below the AMXT 1501 Part 1 RP2D with 500 mg DFMO BID. The morning dose will be given orally of both AMXT1501 and DFMO, in a fasted state. The evening dose of DFMO alone will be given prior to bed-time for 28 days per cycle. The patient can be treated for additional 28 day treatment cycles as deemed appropriate by their study investigator. Dose escalation of DFMO alone will increase per Part 2 cohort."
62009190|NCT03536728|EXPERIMENTAL|Expansion|The expansion cohort will include up to 14 evaluable patients at a proposed RP2D level of AMXT1501 and DFMO defined by Part 2 to further characterize safety at proposed RP2D dose level with repeat dosing, and characterize early anti-tumor activity.
62009191|NCT02387021|ACTIVE_COMPARATOR|Continous femoral nerve block|Patients will receive ultrasound-guided (USG) continuous femoral nerve block with 20 ml ropivacaine 0.2% and USG Continuous adductor canal block with 20 ml of saline and USG infragluteal SNB with 20 ml of saline .
62573769|NCT04787913|ACTIVE_COMPARATOR|robertkochgeneric|Web-based application (comparator) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English only.
62009192|NCT02387021|EXPERIMENTAL|Continuous adductor canal block|Patients will receive ultrasound-guided continuous adductor canal block with 20 ml ropivacaine 0.2% and USG infragluteal SNB with 20 ml ropivacaine 0.2% and USG continuous FNB with 20 ml of saline .
62009193|NCT05447988|OTHER|Two-stage reconstruction|136 participants will undergo two-stage reconstruction
62009194|NCT04897542|EXPERIMENTAL|Patients will undergo a Gallium-68 NODAGA-JR11 PET/CT as well as a Gallium-68 DOTATATE PET/CT|"Each patient receive a single intravenous injection of Gallium-68 DOTATATE (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.~All patients have to do a Gallium-68 NODAGA-JR11 PET/CT scan (40ug/150-200MBq, 40-60 min post-injection) for comparison on the next day of DOTATATE scan."
62009195|NCT04003597|PLACEBO_COMPARATOR|Usual-salt diet|Usual-salt diet followed for 5 weeks
62009196|NCT04003597|ACTIVE_COMPARATOR|Reduced-salt diet|Reduced-salt diet followed for 5 weeks
62009197|NCT02992899|EXPERIMENTAL|Vagal Nerve Stimulation|Participants randomized to this arm will receive stimulation of the vagus nerve in conjunction with stress exposure.
62573770|NCT04787913|ACTIVE_COMPARATOR|sbsnewsgeneric|Video (comparator) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English only.
62573771|NCT04787913|ACTIVE_COMPARATOR|guardianmeasles|Video (comparator) provided. Participant answers outcome questions about measles. English only.
62573772|NCT04787913|ACTIVE_COMPARATOR|theotheredmundmeasles|Video (comparator) provided. Participant answers outcome questions about measles. English only.
62573773|NCT04787913|ACTIVE_COMPARATOR|publichealthagencycanadaflu|Video (comparator) provided. Participant answers outcome questions about flu. English and French.
62573774|NCT01883726|EXPERIMENTAL|Grayson NAM|Intervention: Grayson nasoalveolar molding This technique uses an acrylic plate to mold the alveolar segments and uses an extension to mold the alar cartilage of the nasal component. The construction is made by gradual modification of the acrylic plate with periodic acrylic add on and grinding. When the alveolar gap is reduced to 5 mm, nasal component are added to gradually mold the nasal cartilage and other nasal structures.
62573775|NCT01883726|EXPERIMENTAL|Figueroa NAM|Intervention: Figueroa's nasoalveolar molding Figueroa technique uses labial tapes and acrylic relief to the palatal plate to approximate alveolar gap \[3\]. The nasal component is added in the beginning of the treatment to mold the nasal cartilage.
62573776|NCT00644917|EXPERIMENTAL|A|Drug
62195002|NCT03740243|EXPERIMENTAL|buprenorphine/naloxone|"Buprenorphine/naloxone 4 mg/1 mg daily once daily or twice daily (BID): Light to moderate history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 5-24~Buprenorphine/naloxone 8 mg/2 mg daily once daily or twice daily (BID): Heavy history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 25-36+"
62009198|NCT02992899|SHAM_COMPARATOR|Sham Stimulation|Participants randomized to this arm will receive sham stimulation of the vagus nerve in conjunction with stress exposure.
62009199|NCT02114970|OTHER|Focus Group- paper and tablet consent|Participation in a focus group of other older adults, lasting 120 minutes. Participants will answer semi-structured questions in a group format, describing their impressions of both a prototype tablet-delivered and a paper consent.
62009200|NCT02114970|ACTIVE_COMPARATOR|Randomized- paper consent|Participants will review a mock paper consent form with a study clinician, and complete a series of questionnaires assessing their comprehension of material covered and general experience with the paper informed consent form.
62009201|NCT02114970|ACTIVE_COMPARATOR|Randomized- Tablet-delivered consent|Participants will review a mock tablet-delivered consent form with a study clinician, and complete a series of questionnaires assessing their comprehension of material covered and general experience with the tablet-delivered informed consent.
62195003|NCT06487663|EXPERIMENTAL|TACE combined ICI|TACE combined ICI
62195004|NCT05688618|ACTIVE_COMPARATOR|Experimental group|
62573777|NCT00644917|PLACEBO_COMPARATOR|B|Placebo comparator
62009202|NCT01824303|EXPERIMENTAL|LiRIS 400 mg|LiRIS 400 mg: investigational drug-delivery system which contains Lidocaine; the system remains in the bladder for 14 days. If eligible, participants could participate in the Open Label Extension where all participants were treated with LiRIS 400 mg.
62009203|NCT01824303|PLACEBO_COMPARATOR|LiRIS Placebo|LiRIS Placebo: investigational drug-delivery system which contains Lactose and no Lidocaine; the system remains in the bladder for 14 days. If eligible, participants could participate in the Open Label Extension where all participants were treated with LiRIS 400 mg.
62195005|NCT05688618|PLACEBO_COMPARATOR|Control group|
62195006|NCT02768350|EXPERIMENTAL|Control group|All of the participants in control group will be treated with conventional treatment for 3 days, The conventional treatments consist of: (1) Passive chest mobilization, (2) Positioning, (3) Side lying (good lung down), (4) Vibration. The conventional treatment consists of three consecutive periods; (1) baseline period: 10 minutes, (2) intervention period, and (3) recovery period: 10 minutes.
62195007|NCT02768350|EXPERIMENTAL|Experimental group|All of the participants of the experimental group will be treated with ventilator hyperinflation technique (VHI) for 3 days. Tidal volume will increase from baseline (100% VT) to the tidal volume target at 1.5 times (150% VT). At this level, patients will receive six breathes and in each breathe will be sustained for 5 second (6 hyperinflation breathe per set); expiratory VT will return to baseline after each breath. Four sets of hyperinflation breathing will be used. After this, VT will decrease to baseline and patients have a 60 second for rest between hyperinflation set. The ventilator hyperinflation technique (VHI) consists of three consecutive periods; (1) baseline period: 10 minutes, (2) intervention period, and (3) recovery period: 10 minutes.
62195008|NCT00730015|EXPERIMENTAL|145 μg linaclotide|
62573778|NCT00644917|NO_INTERVENTION|C|Subjects serve as own controls.
62573779|NCT02423395|EXPERIMENTAL|Orphenadrine(Norflex)|50 patients will be treated with orphenadrine 100 mg twice daily for 1 month
62573780|NCT02423395|PLACEBO_COMPARATOR|Placebo|50 patients will be given placebo
62573781|NCT06404970|ACTIVE_COMPARATOR|Functional status screening initiative plus standard bundle of implementation strategies|During an initial 3 month run-in period, the investigators will implement the intervention at all sites using the standard implementation strategy bundle (implementation champions, system-level audit and feedback). After run-in, the investigators will identify sites with inadequate Reach, defined as \<80% of eligible Veterans receiving screening and/or assessment. Sites with \>80% Reach at the end of run-in will receive standard implementation for all phases of implementation. For sites with \<80% Reach, the investigators will randomize 1:1 by medical center to 3 additional months of a standard vs. enhanced implementation bundle. The enhanced implementation bundle will include technical assistance plus clinician-level audit and feedback. After 3 months' implementation, the investigators will then perform 3 months of crossover allocation. After crossover allocation, both arms will receive 3 months of standard implementation.
62734651|NCT05774015|PLACEBO_COMPARATOR|Control group (placebo tablets)|Control group (placebo tablets): Patients in this group will receive placebo tablets labeled as 500 mg (302 mg elemental), with a dosage regimen of 1 tablet once daily. Tablets should be taken with food and 2 hrs. apart from other medications for 12 consecutive months.
62195009|NCT00730015|EXPERIMENTAL|290 μg linaclotide|
62195010|NCT00730015|PLACEBO_COMPARATOR|Matching Placebo|
62195011|NCT05355129|EXPERIMENTAL|Dose 1|low dose
62195012|NCT05355129|EXPERIMENTAL|Dose 2|Middle dose
62195013|NCT05355129|EXPERIMENTAL|Dose 3|High dose
62573782|NCT06404970|EXPERIMENTAL|Functional status screening initiative plus enhanced bundle of implementation strategies|During an initial 3 month run-in period, the investigators will implement the intervention at all sites using the standard implementation strategy bundle (implementation champions, system-level audit and feedback). After run-in, the investigators will identify sites with inadequate Reach, defined as \<80% of eligible Veterans receiving screening and/or assessment. Sites with \>80% Reach at the end of run-in will receive standard implementation for all phases of implementation. For sites with \<80% Reach, the investigators will randomize 1:1 by medical center to 3 additional months of a standard vs. enhanced implementation bundle. The enhanced implementation bundle will include technical assistance plus clinician-level audit and feedback. After 3 months' implementation, the investigators will then perform 3 months of crossover allocation. After crossover allocation, both arms will receive 3 months of standard implementation.
62573783|NCT01628198|EXPERIMENTAL|Renal denervation group|Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter
62782876|NCT02227394|EXPERIMENTAL|Symbicort® Turbohaler - Z7200|"The patients randomized to this sequence were to receive a single dose consisting of 2 inhalations of the reference treatment (Symbicort® Turbohaler) on the first dosing day (Period 1, Visit 2), then, after a wash out period of at least 3 days but no more of 31 days, a single dose consisting of 2 inhalations of the test product (Z7200) on the second dosing day (Period 2, Visit 3).~Patients were also to receive 2 inhalations with matching placebo to the alternate treatment as a dummy inhaler to achieve double-blinding.~Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 320 mcg/9 mcg)."
62782877|NCT00878059||Proxies|A family member-caregiver (the medical decision-maker) for someone with Alzheimer's Disease. Must be the person who would be able to make decisions for someone with Alzheimer's disease about being in medical research.
62782878|NCT00917839|EXPERIMENTAL|lamotrigine|7 weeks initial phase with increasing dose beginning with 25 mg oral 12 months treatment phase with fixed dose of 100 mg oral
62782879|NCT00917839|PLACEBO_COMPARATOR|Placebo|300mg Mannitol with 2% Aerosil
62573784|NCT03371862|EXPERIMENTAL|Test group|
62573785|NCT02569125|EXPERIMENTAL|Everolimus (RAD001) 4.5 mg/m² daily over|Everolimus (RAD001) 4.5 mg/m² daily over 12 months. Patients will be on Everolimus (RAD001) therapy for 12 months; discontinuation can be necessary due to intolerable toxicity, withdrawal of consent, death or termination of the trial. After 12 months treatment is stopped. If there is progress of disease (see below) after end of therapy, re-start with Everolimus (RAD001) on a compassionate use is possible.
62195014|NCT05355129|PLACEBO_COMPARATOR|Placebo|
62195015|NCT02529423|PLACEBO_COMPARATOR|Placebo|Placebo
62573786|NCT05258357|ACTIVE_COMPARATOR|Landmark|For a landmark bone marrow biopsy procedure, the patient is first positioned either prone or lateral decubitus. The lateral, superior iliac crest is palpated and an attempt is made to follow the course of the posterior iliac crest until the posterior superior iliac spine (PSIS) is palpated. Additionally, the gluteal cleft is visualized indicating the patient midline. The area over the sacrum at midline is then palpated, proceeding laterally until the PSIS can be felt. The skin is marked with a marker at the estimated PSIS and point of entry.
62195016|NCT02529423|EXPERIMENTAL|Multi-nutrient supplement|Multi-nutrient supplement
62195017|NCT02529423|EXPERIMENTAL|Placebo + Behavioral Activation|Placebo + Behavioral Activation
62782880|NCT01714999|EXPERIMENTAL|Bursectomy: Vienna|At the Department of Trauma Surgery, Medical University of Vienna, bursectomy is considered the gold standard in case of traumatic laceration of the OB or PB bursa.
62782881|NCT01714999|EXPERIMENTAL|Bursal reconstruction: Munich|At the Department of Trauma Surgery, Medical University of Munich, the treatment regime is a primary bursa-preserving therapy.
62782882|NCT01099397||PEAR Participants|All participants eligible for PEAR study. Each participant will be have fasting and oral glucose tolerance test data collected.
62195018|NCT02529423|EXPERIMENTAL|Multi-nutrient + Behavioral Activation|Multi-nutrient + Behavioral Activation
62195019|NCT00808002|EXPERIMENTAL|1|From Baseline to Week48: Raltegravir BID + Tenofovir/Emtricitabine QD + Maraviroc BID From W48 to W72: Raltegravir BID + Tenofovir/Emtricitabine QD
62195020|NCT00808002|ACTIVE_COMPARATOR|2|Start ARV treatment with : Raltegravir BID + Tenofovir/Emtricitabine
62573787|NCT05258357|EXPERIMENTAL|Ultrasound-Assisted|"After the usual landmark technique is performed and the potential site has been marked, procedure team physician will use the ultrasound machine to fine tune the drill site location."
62573788|NCT04988555|EXPERIMENTAL|Phase 1 Arm A without Antifungals|Patients not taking antifungals within 7 days of study entry
62782883|NCT05262296||Laparoscopic Surgeon|This cohort of participants will have their procedure completed by a human surgeon.
62782884|NCT05262296||Robotic Arm|This cohort of participants will have their procedure completed by the Versius Surgical Robotic System
62782885|NCT02103777|ACTIVE_COMPARATOR|High dose caffeine|High dose (loading 40 mg/kg/day equivalent to 20 mg /kg/day of caffeine base and maintenance of 20 mg/kg/day equivalent to 10 mg /kg/day of caffeine base)
62195021|NCT06385184||Parkinson's disease|"This group includes adults who:~* Have been diagnosed with Parkinsons Disease by a healthcare professional~* Are at least 40 years old and~* Do not possess a diagnosis of autism or any other developmental disability (e.g., Down syndrome)"
62195022|NCT06385184||Neurotypical adults|"This group includes adults who:~* Are at least 40 years old~* Do not have a diagnosis of Parkinsons Disease or any form of dementia and~* Do not have a diagnosis of autism or any other developmental disability (e.g., Down syndrome)"
62195023|NCT04149704|EXPERIMENTAL|ACP video decision aid|"The research study procedures include: screening for eligibility and study interventions including questionnaires and follow up visits.~* In-person interview where the patient and caregiver together will randomized to either the video aid intervention or standard care~* 10 minute video decision aid: describing the goals-of-care options .~* Follow telephone interview at 3 months"
62214940|NCT02581631|EXPERIMENTAL|Nivolumab+Brentuximab Vedotin|Nivolumab+Brentuximab Vedotin dose as specified
62195024|NCT04149704|ACTIVE_COMPARATOR|Standard Care|"The research study procedures include: screening for eligibility and study interventions including questionnaires and follow up visits.~* In-person interview where the patient and caregiver together will randomized to either the video aid intervention or standard care~* Receive the verbal description of the three types of care~* Follow telephone interview at 3 months"
62782886|NCT02103777|ACTIVE_COMPARATOR|Low dose caffeine|Low dose (loading 20 mg/kg/day equivalent to 10 mg /kg/day of caffeine base and maintenance of 10 mg/kg/day equivalent to 5 mg /kg/day of caffeine base) caffeine.
62782887|NCT04611802|EXPERIMENTAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial vaccination)|2 doses of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21 in Initial Vaccination Period.
62782888|NCT04611802|PLACEBO_COMPARATOR|Placebo (Initial Vaccination)|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21in Initial Vaccination Period.
62782889|NCT04611802|EXPERIMENTAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination)|One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 0 or Day 21 in Crossover Vaccination Period.
62195025|NCT01535001|ACTIVE_COMPARATOR|MEDIC|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.
62782890|NCT04611802|EXPERIMENTAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)|One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 0 Booster Vaccination Period.
62782891|NCT04611802|EXPERIMENTAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster)|One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 0 Second Booster Vaccination Period.
62782892|NCT04611802|PLACEBO_COMPARATOR|Placebo (Crossover Vaccination)|One dose of Placebo (Saline) on Day 0 or Day 21 in Crossover Vaccination Period.
62782893|NCT01938040|ACTIVE_COMPARATOR|Ibuprofen|800mg administered IV in 100cc of normal saline over 5 minutes
62782894|NCT01938040|PLACEBO_COMPARATOR|Sugar water|100mL of normal saline to be administered over 5 minutes
62782895|NCT00769509|EXPERIMENTAL|preterm formula|Assessment of energy expenditure of preterm infant during fed with preterm formula
62009204|NCT02047617|ACTIVE_COMPARATOR|the standard physiotherapy group|Physiotherapy rehabilitation techniques used in the management of this group include passive range of motion, active range of motion/bed exercises, sitting at edge of bed, sitting in armchair, active transfer from the bed to chair. Mobilization and rehabilitation program is progressively introduced after clinical stabilization with a goal of progressing to ambulation and pulmonary rehabilitation.
62195026|NCT01535001|ACTIVE_COMPARATOR|Standard treatment|Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
62195027|NCT05711277|EXPERIMENTAL|N-ICE CREAM|
62398728|NCT06722768||Responder group|"Patients with iNPH were divided into responder group and non-responder group after CSF tap test.~The responder group consists of patients who underwent the tap test and exhibited improvements in gait and balance, including increased gait speed as measured by the 10-Meter Walk Test (10MWT), reduced time on the Timed Up and Go Test (TUGT), and resolution of shuffling, magnetic, and wide-based gait patterns. Classification were done by a multidisciplinary team including physiatrist, neurologist, and neurosurgeon.~Surgical treatment was carefully considered for the responder group. Patients who declined surgery or were considered at high risk for surgical complications due to advanced age or comorbidities were excluded. Patients who were able to get an operation primarily underwent shunt surgery.~Additional gait and balance analyses were performed on patients who underwent surgery within 24 hours after their last operation."
62009205|NCT02047617|EXPERIMENTAL|standing table group|The same program as standard physiotherapy group is applied, with daily sessions of standing table in supplement. Standing table was performed on a motorized tilt table (ref: table de verticalisation, Franco\&fils). The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform, at 10° intervals from 30° to 80°.
62573789|NCT04988555|EXPERIMENTAL|Phase 1 Arm B with Antifungals|Patients receiving anti-fungals that are moderate to strong cytochrome CYP3A4/5 inhibitors (i.e. Posaconazole, voriconazole, fluconazole, or isavuconazonium (prodrug of isavuconazole).
62782896|NCT00769509|ACTIVE_COMPARATOR|human milk with fortifier|Assessment of energy expenditure by indirect calorimetry during fed with human milk with fortifier
62009206|NCT01182077|EXPERIMENTAL|Group 1|ASP015K low dose and midazolam followed by ASP015K high dose and midazolam
62009207|NCT01182077|EXPERIMENTAL|Group 2|ASP015K high dose and midazolam followed by ASP015K low dose and midazolam
62009208|NCT06192771|ACTIVE_COMPARATOR|Arm 1 - Control|Participants in this Arm will receive the current standard of care, which includes a referral to SLP in response to suspicion of a swallowing problem from either assessment by the medical team and/or patient report.
62195028|NCT05711277|ACTIVE_COMPARATOR|Milkshake ONS|
62195029|NCT06508892||Comparison of acceleration and 3D rotation during balance and movement|Can consumer-grade sensors used in mobile phones provide an accurate and valid measure of balance and gait when compared to gold standard research-grade sensors? A computational model for risk of fall will be developed.
62195030|NCT00524186|EXPERIMENTAL|Oral Sunitinib|Patients receive oral sunitinib malate on day -7 and then once daily on days 2-28 in course 1 and on days 1-28 in all subsequent courses
62195031|NCT05633498|EXPERIMENTAL|Self-help book|A self-help book for coping with shift work
62009209|NCT06192771|EXPERIMENTAL|Arm 2 - Intervention|Participants in this Arm will receive the ESSI-SURG behavioural intervention by a live SLP.
62009210|NCT03339518|EXPERIMENTAL|BRIM3 Educational intervention|Individuals will receive a booklet and counseling about risk.
62009211|NCT03339518|OTHER|Wait list Control|At the completion of the study, individuals in the wait list condition will receive a booklet.
62195032|NCT05633498|ACTIVE_COMPARATOR|Sleep hygiene advice|A sheet of paper with basic and standard sleep hygiene advice
62009212|NCT00864500|EXPERIMENTAL|A|Clobetasol Propionate 0.05% lotion, single exposure
62009213|NCT00864500|ACTIVE_COMPARATOR|B|Clobex TM 0.05% Lotion, single exposure
62009214|NCT04862091|EXPERIMENTAL|Abiraterone Acetate Tablets (I)|
62009215|NCT04862091|ACTIVE_COMPARATOR|ZYTIGA®.|
62009216|NCT04717128|EXPERIMENTAL|Baby doll with user remote controlled jaw|In this arm, standardized patients will use the Newborn Oral Assessment and Latch Simulator (NORALSim) to demonstrate and teach newborn positioning and attachment in the breastfeeding skills workshop.
62009217|NCT04717128|ACTIVE_COMPARATOR|Baby doll with hand controlled jaw|In this arm, standardized patients will use a cloth baby doll with a puppet-style mouth to demonstrate and teach newborn positioning and attachment in the breastfeeding skills workshop.
62195033|NCT04872023|EXPERIMENTAL|Patients|All patients will have a extra blood sampling before first cycle of treatment and after one cycle. They also have an extra bone marrow sampling after the first cycle of treatment
62195034|NCT04395170|EXPERIMENTAL|Convalescent plasma|Plasma from patients recovering from COVID-19.
62009218|NCT01831687|ACTIVE_COMPARATOR|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA
62009219|NCT01831687|EXPERIMENTAL|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India
62009220|NCT01284647|EXPERIMENTAL|Teprenone capsule|
62009221|NCT01284647|ACTIVE_COMPARATOR|sucralfate|
62195035|NCT04395170|EXPERIMENTAL|Anti-COVID-19 human immunoglobulin|Anti-COVID-19 human immunoglobulin to be administered intravenously.
62214941|NCT02081430|EXPERIMENTAL|CT Manipulation|Prone cervicothoracic manipulation
62214942|NCT02081430|ACTIVE_COMPARATOR|Upper trapezius stretch|Passive sustained stretch to upper trapezius muscle
62214943|NCT02081430|NO_INTERVENTION|Control|8 Minute wait
62214944|NCT04023500|ACTIVE_COMPARATOR|Motivational interview|The MI-intervention is used as a part of normal dental hygienist appointment. Dental hygienists are trained to focus on patients view of their oral health, self-care skills and need for oral-health related behaviour change. They are supposed to use open-ended questions, reflective listening and reinforcing with patients. Dental hygienist support patients in decision making although patients were addressed as an active agent.
62214945|NCT04023500|ACTIVE_COMPARATOR|Prevailing education|In control group prevailing, more professional-centered education is used. Dental hygienist define patients educational needs and give direct instructions how to change behaviour and self-care.
62214946|NCT01533480|ACTIVE_COMPARATOR|Zirgan, Adenovirus conjunctivitis,|Zirgan
62214947|NCT01533480|PLACEBO_COMPARATOR|genteal gel|0.3% Hypromellose gel (genteal gel)
62214948|NCT00510237|EXPERIMENTAL|1|5-7 females per group at each of the four sites.
62214949|NCT00510237|EXPERIMENTAL|2|5-7 males per group at each of the four sites.
62214950|NCT06069817|EXPERIMENTAL|High flow nasal cannula group|Treatment with High Flow Nasal Cannula minimum twenty (20) minutes three times a day (one \[1\] hour a day in total) and up to 10 hours a day in total, according to patient's preferences.
62214951|NCT06069817|ACTIVE_COMPARATOR|nebulized saline group|Treatment with nebulization of 4-8 cc of normal saline three times daily
62214952|NCT03386110|EXPERIMENTAL|Couples Health Project (CHP)|The CHP intervention is a three session intervention that occurs once a week for three weeks. The CHP intervention will be delivered by MI-trained mental health counselors. The CHP intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.
62214953|NCT03386110|ACTIVE_COMPARATOR|Education|The Education intervention is a attention-matched control three-session intervention that occurs once a week for three weeks. The education intervention will be delivered by trained health educators. The education intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.
62214954|NCT02586571||Exclusive Breastfeeding A|Mother/infant pairs with exclusive breastfeeding up to 6 months of age. Secondary outcome measure 2 (Metabolisable energy content of breast milk) measured in this group only.
62214955|NCT02586571||Exclusive Breastfeeding B|Mother/infant pairs with exclusive breastfeeding up to 6 months of age.
62214956|NCT02586571||Partial Breastfeeding|Mother/infant pairs with partial breastfeeding along with complementary foods at 6 months of age.
62214957|NCT00924027|EXPERIMENTAL|1/Radiation Therapy|Radiation therapy given as high dose radiation (HDR) Brachytherapy.
62214958|NCT01467882|EXPERIMENTAL|Triptorelin|Triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169
62214959|NCT04683068|ACTIVE_COMPARATOR|First-person gain-framed self-referred messages|"This group receives a message in which the main character is a man who speaks in first-person. The character is a man with a sister with a BRCA germline mutation. After this common introduction, the content of the messages becomes different.~Group 1 receives a self-referred narrative message in which the protagonist explains that he has decided to have a genetic test to discover BRCA germline mutation. He then explains the reasons why this decision is important to himself (e.g., implementing preventive behaviors) and what are the possible benefits for the individual."
62214960|NCT04683068|EXPERIMENTAL|First-person gain-framed family-referred messages|"This group receives a message in which the main character is a man who speaks in first-person. The character is a man with a sister with a BRCA germline mutation. After this common introduction, the content of the messages becomes different.~Group 2 receives a family-referred narrative message in which the frame is similar to the previous message, but the character this time explains what are that the benefits for his family and why his decision to have a genetic test is important to them."
62782897|NCT04198077|EXPERIMENTAL|CONSERVATIVE|Participants in the conservative group will receive the lowest FiO2 to maintain SpO2 between 94 and 98 percentage, or when available a PaO2 between 70 mmHg and 100 mmHg. A SpO2 alarm limit of 99 percent will apply whenever supplemental oxygen is being administered. The FiO2 will be reduced or oxygen supplementation discontinued whenever the SpO2 or PaO2 exceeded 98 percent or 100 mm Hg. An oxygen supplementation will be given only if SpO2 falls below 94 percent. Pre-oxygenation with FiO2 1.0 will not be performed during in-hospital transports or in anticipation of diagnostic and therapeutic manoeuvres.
62782898|NCT04198077|ACTIVE_COMPARATOR|CONVENTIONAL|In the conventional group, participants will receive a FiO2 aiming to maintain a SpO2 equal or major than 98 percentage, accepting an upper limit of PaO2 of 150 mmHg and a lower limit of 70 mmHg. The use of a FiO2 of less than 0.3 whilst ventilated is discouraged. According to standard Intensive Care Unit practice, control patients will receive a FiO2 of 1.0 during endotracheal intubation manoeuvre, airway suction or in-hospital transfers.
62398729|NCT06722768||Non-Responder group|"Patients with iNPH were divided into responder group and non-responder group after CSF tap test.~The non-responder group consists of patients who underwent the tap test but did not exhibit improvements in gait or balance. Classification were done by a multidisciplinary team including physiatrist, neurologist, and neurosurgeon.~Surgical treatment was not considered for the responder group."
62009222|NCT02764749|EXPERIMENTAL|freeze dried powder whole cranberry dissolved in water|Dietary Supplement: freeze dried cranberry powder
62195036|NCT04395170|ACTIVE_COMPARATOR|Standard (specific) therapy|"Standard therapy for COVID-19 according to the recommended pharmacological recommendations of the Colombian Association of Infectious Diseases - ACIN. This therapy is subject to changes that are defined by the Colombian Health Regulatory Authorities.~To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin."
62398730|NCT04950452|EXPERIMENTAL|CLL-EX|Subjects will undergo supervised exercise training 3 x per week for 12 weeks. Three/sessions per week will consist of intervals of high-intensity (\~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes. Following this, on 2 occasions/week subjects will complete muscular endurance resistance training on machine weights.
62398731|NCT04950452|NO_INTERVENTION|CLL-CON|Subjects will not receive supervised exercise training and will be asked to maintain their daily lifestyle behaviors.
62195037|NCT01893476|NO_INTERVENTION|control|In this arm, practitioners will provide usual care for COPD patients.
62195038|NCT01893476|OTHER|adherence to guideline|Implementation educational programme: guideline adherences. The results of this trial will be directly applicable to primary care settings. Should the interventions delivered at the level of the GP practice be found to be effective in improving patients' quality of life then the findings would have a wider application.
62573790|NCT04988555|EXPERIMENTAL|Phase 2 Arm A AML with MLL (KMT2A) gene rearrangements|Patients with R/R AML w/MLL (KMT2A) gene rearrangements
62782899|NCT04560075|EXPERIMENTAL|Text2Connect|Participants receiving Text2Connect (T2C) personalized messages will receive a monthly check-in text prompt. Based on their response, the participants then receive either general psychoeducational videos and prompts to continue to monitor mental health or are then prompted to endorse stressors and symptoms they are experiencing to prompt awareness of treatment targets in daily life.
62782900|NCT04560075|ACTIVE_COMPARATOR|Psychoeducational Videos (PE) Only|Participants will receive a web link to a library of 4 PE videos. These brief 2-minute videos include general information about self-care during college.
62009223|NCT02764749|PLACEBO_COMPARATOR|freeze dried cranberry deprived powder dissolved in water|Placebo comparator: freeze dried cranberry deprived powder
62009224|NCT02944877|EXPERIMENTAL|intervention|experimental
62009225|NCT02944877|OTHER|control|Other
62009226|NCT05695157|EXPERIMENTAL|Single arm|Closure of the abdomen after laparotomy with Suture-TOOL.
62009227|NCT06098820|EXPERIMENTAL|Group 1 (UV-C mushroom+normal bread group)|UV-C mushroom+normal bread group
62009228|NCT06098820|EXPERIMENTAL|Group 2 (UV-C mushroom + UV-C bread group)|UV-C mushroom + UV-C bread group
62195039|NCT03698799||LPV|Patients receive LPV strategy at the initiation of MV support. The LPV strategy is defined as ventilation with tidal volume of \<8 mL/kg of PBW plus applying PEEP of at least 5 cm H2O.
62195040|NCT03698799||Non-LPV|Patients do not receive LPV strategy at the initiation of MV support.
62195041|NCT01353547||Received anti-TNFa therapy|Received anti-TNFa therapy
62195042|NCT01353547||First-degree relative of MS patients|"First-degree relative (child, parent or sibling) of a diagnosed MS patient~A subgroup will be asked to undergo magnetic resonance imaging (MRI). Participants may be asked to donate a stool sample for gut flora analysis and a blood sample for ribonucleic acid (RNA) sequencing."
62195043|NCT01353547||Referred by the Partners MS Center|Referred by the Partners MS Center
62195044|NCT05071313|EXPERIMENTAL|Group 1: Coadministration (CoAd) Group|Participants will receive Ad26.RSV.preF-based vaccine and quadrivalent high dose influenza vaccine concomitantly on Day 1 and placebo on Day 29.
62195045|NCT05071313|EXPERIMENTAL|Group 2: Control Group|Participants will receive placebo and quadrivalent high-dose influenza vaccine on Day 1 and Ad26.RSV.preF-based vaccine on Day 29.
62195046|NCT03358238|PLACEBO_COMPARATOR|No weekly review|Individuals will not review self-report and activity tracker data with an interviewer on a weekly basis over the phone.
62195047|NCT03358238|EXPERIMENTAL|Weekly review|Individuals will review self-report and activity tracker data with an interviewer on a weekly basis over the phone.
62195048|NCT03219177|EXPERIMENTAL|Patient education group|
62195049|NCT03219177|ACTIVE_COMPARATOR|Control- Standard of care counseling|
62398732|NCT02585089|ACTIVE_COMPARATOR|Spanish cured-pork ham|"One group will receive dry-cured pork ham of \>10 months proteolysis (intervention product).~Intervention: Dietary intake Dry-cured pork ham contains high doses of bioactive peptides produced during more than 10 months of proteolysis."
62782901|NCT05118399|ACTIVE_COMPARATOR|To receive supraclavicular BPB using standard ropivacaine only.|20ml of plain bupivacaine will be injected using 2 syringes, so 10ml of 0.5% plain bupivacaine will be injected, and immediately followed by another 10ml of 0.5% plain bupivacaine.
62782902|NCT05118399|EXPERIMENTAL|To receive supraclavicular BPB using liposomal bupivacaine together with ropivacaine.|10ml of 0.5% plain bupivacaine will be injected, and immediately followed by 10ml of 1.33% liposomal bupivacaine.
62195050|NCT02614183|EXPERIMENTAL|Galcanezumab 120mg|Galcanezumab given by subcutaneous (SC) injection at 120mg dose once a month for 6 months. Participants received a loading dose of 240mg (2 injections of 120mg each) was administered at visit 3 only.
62195051|NCT02614183|EXPERIMENTAL|Galcanezumab 240mg|Galcanezumab 240mg given by SC injection once a month for 6 months.
62195052|NCT02614183|PLACEBO_COMPARATOR|Placebo|Placebo given by SC injection once a month for 6 months.
62195053|NCT04537988|EXPERIMENTAL|Feasibility and usability intervention trial|Pre-post evaluation of a 3-month pilot-trial of an electronic health (eHealth) intervention
62195054|NCT01857336|EXPERIMENTAL|infusion group|Patients with PGF were planed to infusion peripheral harvest. The peripheral cell harvest was aphaeresis on the fourth or fifth day after mobilization with recombinant human granulocyte colony stimulating factor.
62195055|NCT02693951|EXPERIMENTAL|the prophylactic use of antibiotics group|Half an hour before endoscopic treatment, cefotiam 2.0g intravenous
62195056|NCT02693951|NO_INTERVENTION|Control|Routine endoscopic examination and treatment. Antibiotics are not used before endoscopic treatment
62195057|NCT02855736|EXPERIMENTAL|Intervention group|Positive Psychology (gratitude journal)
62195058|NCT02855736|PLACEBO_COMPARATOR|Control group|Alimentary list
62195059|NCT01403870||Low Back Pain Subjects|Subjects who have low back pain at the time of the study, and wish to receive physical therapy to reduce their low back pain.
62195060|NCT04879212|EXPERIMENTAL|PCIA +Acupuncture group|Acupuncturing bilateral Zusanli (ST36) and Sanyinjiao (SP6) to connect Huatuo brand electroacupuncture apparatus, but no electricity. Acupuncture was given once a day. PCIA（patient controlled intravenous analgesia）.
62195061|NCT04879212|EXPERIMENTAL|PCIA +2 Hz Electroacupuncture group|Acupuncture bilateral Zusanli (ST36) and Sanyinjiao (SP6) to connect Huatuo brand electroacupuncture apparatus, and the ipsilateral Zusanli, Sanyinjiao were respectively connected as a loop. The parameters of electroacupuncture were set as 2Hz, continuous wave, 25min, and current intensity was 0.1-5.0mA. Acupuncture was given once a day.
62195062|NCT04879212|EXPERIMENTAL|PCIA +20/100 Hz Electroacupuncture group|Acupuncture bilateral Zusanli (ST36) and Sanyinjiao (SP6) to connect Huatuo brand electroacupuncture apparatus, and the ipsilateral Zusanli, Sanyinjiao were respectively connected as a loop. The parameters of electroacupuncture were set as 20 / 100Hz, density wave, 25min, and current intensity was 0.1-5.0mA. Acupuncture was given once a day.
62195063|NCT06442124||Group (A):|o Group (A): will includes subjects with sacroiliac dysfunction and their body mass index \< 25
62195064|NCT06442124||Group (B):|o Group (B): will includes subjects with sacroiliac dysfunction and their body mass index \> 25.
62195065|NCT01663506||Cohort|
62195066|NCT01882153|EXPERIMENTAL|Developmentally Based Intervention|
62195067|NCT01882153|EXPERIMENTAL|Behaviorally Based Intervention|
62195068|NCT04548986|OTHER|single arm|single arm study
62195069|NCT01999972|EXPERIMENTAL|Axitinib in combination with crizotinib, escalation phase|Dose Escalation Advanced solid tumor that is resistant to standard therapy or for which no standard therapy is available
62195070|NCT01999972|EXPERIMENTAL|Expansion Phase Cohort 1|Dose Expansion, Cohort 1: axitinib in combination with crizotinib Advanced renal cell cancer \[RCC\] with no prior systemic therapy
62195071|NCT01999972|EXPERIMENTAL|Expansion Phase Cohort 2|Dose Expansion, Cohort 2: axitinib in combination with crizotinib Advanced renal cell cancer with at least one but no more than two prior systemic treatment regimens directed at advanced RCC
62398733|NCT02585089|PLACEBO_COMPARATOR|Cooked pork ham|The other group will receive cooked, uncured ham (placebo product). Intervention: Dietary intake. Cooked ham does not display bioactive peptides as they are produced during proteolysis of pork ham.
62398734|NCT02654184|ACTIVE_COMPARATOR|Supine group|Anesthesia induction with sevoflurane for the patient while he is in supine position.
62398735|NCT02654184|ACTIVE_COMPARATOR|Right lateral group|Anesthesia induction with sevoflurane for the patient while he is in right lateral position position.
62782903|NCT06226584|EXPERIMENTAL|multiple-strain probiotics|
62195072|NCT00551746|ACTIVE_COMPARATOR|1|Grape Juice
62195073|NCT00551746|PLACEBO_COMPARATOR|2|Grape Juice Placebo
62195074|NCT04696393|EXPERIMENTAL|Treatment Sequence 1: AB|Participants will receive Treatment A (mitapivat 100 milligram \[mg\] tablet formulation, orally, under fasted conditions once on Day 1 of Period 1), followed by Treatment B (mitapivat 2 x 50 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 2). Each treatment period will be separated by a washout period of at least 7 days.
62195075|NCT04696393|EXPERIMENTAL|Treatment Sequence 1: BA|Participants will receive Treatment B (mitapivat 2 x 50 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 1), followed by Treatment A (mitapivat 100 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 2). Each treatment period will be separated by a washout period of at least 7 days.
62195076|NCT00515788|EXPERIMENTAL|DepoCyt + Temozolomide|DepoCyt Starting 50 mg Intrathecal Day 1 every 14 days for 12 weeks (6 treatments), then every 28 days for 40 weeks (10 treatments). Temozolomide 100 mg/m\^2 by mouth daily for 7 days every 14 days.
62782904|NCT01398748|ACTIVE_COMPARATOR|Intranasal GSH 100mg/ml|Study participant will be provided with monthly supply of study medication and will be asked to intake 100mg/ml of intranasal glutathione (n=15) An amount of 1ml with a frequency 3x per days and duration of 12 weeks with a dosage of 2100mg
62782905|NCT01398748|ACTIVE_COMPARATOR|Intranasal glutathione 200mg/ml|Study participant will be provided with monthly supply of study medication and will be asked to intake 200/ml of intranasal glutathione (n=15) An amount of 1ml with a frequency 3x per days and duration of 12 weeks with a dosage of 4200mg
62009229|NCT06098820|EXPERIMENTAL|Group 3 (normal mushroom + normal bread group)|normal mushroom + normal bread group
62009230|NCT06098820|EXPERIMENTAL|Group 4 (normal mushroom+normal bread+supplemente group)|normal mushroom + normal bread + supplement group
62195077|NCT05794477|EXPERIMENTAL|phase Ib：SHR-1802+Adebrelimab|
62195078|NCT05794477|EXPERIMENTAL|phase II cohort 1: SHR-1802+Adebrelimab|
62195079|NCT05794477|EXPERIMENTAL|phase II cohort 2: SHR-1802+Adebrelimab + Platinum Doublet Chemotherapy (PDCT)|
62195080|NCT05794477|EXPERIMENTAL|phase II cohort 3: SHR-1802+Adebrelimab + PDCT|
62398736|NCT05524805|EXPERIMENTAL|BTL-785-7 Treatment|Treatment with the BTL-785-7 applicator to the BTL-785F system.
62398737|NCT02366546|EXPERIMENTAL|Low dose TBI-1301 with pre-treatment 1|TBI-1301(5\*10\^8) single-dose administration with pre-treatment of cyclophosphamide alone.
62398738|NCT02366546|EXPERIMENTAL|High dose TBI-1301 with pre-treatment 1|TBI-1301(5\*10\^9) single-dose administration with pre-treatment of cyclophosphamide alone.
62398739|NCT02366546|EXPERIMENTAL|High dose TBI-1301 with pre-treatment 2|TBI-1301(5\*10\^9) single-dose administration with pre-treatment of cyclophosphamide and fludarabine.
62398740|NCT02366546|EXPERIMENTAL|TBI-1301 with pre-treatment 1 or 2|Arm1, 2 or 3, which is considered as optimal.
62398741|NCT05893160|EXPERIMENTAL|Experimental Intervention|The intervention group will receive sodium nitrite SR (40 mg b.i.d. for 30 days)
62398742|NCT05893160|PLACEBO_COMPARATOR|Placebo|The comparison group will receive an inert placebo on the same schedule as the intervention group
62398743|NCT06235034|EXPERIMENTAL|diagnostic CT|patients will have their palliative radiotherapy designed on their diagnostic CT
62398744|NCT06722898|PLACEBO_COMPARATOR|Placebo|
62398745|NCT06722898|ACTIVE_COMPARATOR|Liquid|
62398746|NCT02146365||PATH-wSP 300 µg + Booster|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.
62398747|NCT02146365||PATH-wSP 300 µg Only|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.
62398748|NCT02146365||PATH-wSP 600 µg + Booster|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.
62009231|NCT04432350||Treated with Repurposed Drugs|This cohort will be for individuals who have tested positive for COVID-19 and were treated with repurposed drugs. This will be tracked via drug claims data in a PrescribeWellness Pharmacy.
62009232|NCT04432350||Not Treated with Repurposed Drugs|This cohort will be for individuals who have tested positive for COVID-19 and were not treated with repurposed drugs. This will be tracked via drug claims data in a PrescribeWellness Pharmacy.
62009233|NCT06664580||Post-Metabolic Bariatric Surgery Patients|A cohort of 249 patients who underwent metabolic bariatric surgery, including various procedures such as Laparoscopic Sleeve Gastrectomy (LSG) and Roux-en-Y Gastric Bypass (RYGB), with follow-up on long-term outcomes related to weight maintenance, nutritional deficiencies, and patient satisfaction
62195081|NCT05794477|EXPERIMENTAL|phase II cohort 4: SHR-1802+Adebrelimab|
62195082|NCT01084226|ACTIVE_COMPARATOR|Sterol|Additional plant sterols incorporated in the rye bread
62195083|NCT01084226|PLACEBO_COMPARATOR|control|No added plant sterol in the identical-looking rye bread
62195084|NCT04923347|EXPERIMENTAL|Participants receiving FF/UMEC/VI via ELLIPTA inhaler|
62398749|NCT02146365||PATH-wSP 600 µg Only|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.
62195085|NCT00292097|EXPERIMENTAL|1|Early conversion from endotracheal intubation to percutaneous tracheostomy for ventilator support of trauma patients with severe brain injury
62195086|NCT00292097|ACTIVE_COMPARATOR|2|Conventional conversion from endotracheal intubation to percutaneous tracheostomy for ventilator support of trauma patients with severe brain injury
62195087|NCT04129047|EXPERIMENTAL|Omnichroma (one shade universal) composite by Tokuyama|class V cavities will be made under isolation. Omnichroma (one shade universal) composite by Tokuyama will be placed according to guidelines.
62398750|NCT02146365||Booster Only (300 µg)|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.
62398751|NCT02146365||Booster Only (600 µg)|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.
62398752|NCT02146365||No Intervention (300 µg)|Toddlers who enrolled during Cohort 1 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).
62195088|NCT04129047|ACTIVE_COMPARATOR|A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA)|class V cavities will be made under isolation. A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA) will be placed according to guidelines.
62195089|NCT02081053|OTHER|RF Ablation and Vertebral Augmentation|
62398753|NCT02146365||No Intervention (600 µg)|Toddlers who enrolled during Cohort 2 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).
62398754|NCT05614544|EXPERIMENTAL|Treatment A: HSK3486 dose 1|Treatment A: HSK3486 dose 1 (IV bolus over 30 seconds \[+5 seconds\] from a syringe; dose to be determined in Part 1)
62398755|NCT05614544|EXPERIMENTAL|Treatment B: HSK3486 dose 2|Treatment B: HSK3486 dose 2 (IV bolus over 30 seconds \[+5 seconds\] from a syringe; dose to be determined in Part 1)
62398756|NCT05614544|ACTIVE_COMPARATOR|Treatment C: Propofol|Treatment C: Propofol (IV bolus over 30 seconds \[+5 seconds\] from a syringe; dose to be determined in Part 1)
62195090|NCT00971997|EXPERIMENTAL|Lispro 50/50|
62195091|NCT01371422|EXPERIMENTAL|A1 (PVB)|PVB technique will be utilized for injection of the anaesthetic under the skin before the procedure.
62398757|NCT05614544|PLACEBO_COMPARATOR|Treatment D: Placebo|Treatment D: Placebo (Treatment A matched) (IV bolus over 30 seconds \[+5 seconds\] from a syringe)
62398758|NCT05818774|EXPERIMENTAL|RFN of CMBNn with end-on lesioning with multitIned trident cannulae|"Intervention type: RF nerve end-on lesioning at 80-850 Celsius for 90 seconds~Intervention name: End-on placement of the multitined trident cannulae~Intervention description:~Patient in lateral position, targeting joint position between the inferior C2 and superior C3 facets, the middle of the facet pillars for the third to fifth cervical levels, and the superior part of the sixth and seventh cervical facets"
62398759|NCT05818774|ACTIVE_COMPARATOR|RFN of CMBNn with parallel lesioning with sharp straight conventional cannulae (SIS's technique)|"Intervention type: RF nerve parallel lesioning at 80-850 Celsius for 90 seconds~Intervention name: Straight sharp conventional (SIS's technique)~Intervention description:~Technique as described in the SIS Practice Guidelines for parallel lesioning cannulae placement"
62398760|NCT04179864|EXPERIMENTAL|Phase 1b: Tazemetostat in Combination with Abiraterone/Prednisone|In Phase 1b, abiraterone/prednisone will be administered in combination with tazemetostat in cycle 1 (28 days) to establish the recommended dose of tazemetostat in this combination; participants may continue treatment in additional 28-day cycles, as tolerated, until progression or unacceptable toxicity
62398761|NCT04179864|EXPERIMENTAL|Phase 1b: Tazemetostat in Combination with Enzalutamide|In Phase 1b, enzalutamide will be administered in combination with tazemetostat in cycle 1 (28 days) to establish the recommended dose of tazemetostat in this combination; participants may continue treatment in additional 28-day cycles, as tolerated, until progression or unacceptable toxicity
62195092|NCT01371422|PLACEBO_COMPARATOR|A2 (Placebo)|The placebo is an inactive substance that looks identical to the test intervention but contains no active ingredients and will be administered the same as the PVB by a local skin injection, but no advancement of the needle to the paravertebral space will be made to avoid unnecessary risks.
62009234|NCT05068440|EXPERIMENTAL|Zanubrutinib|administered orally
62009235|NCT06325774|EXPERIMENTAL|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy over 3 weeks.
62009236|NCT06295549|EXPERIMENTAL|Experimental: LUCAR-G39P cells product|Each subject will be given a single-dose LUCAR-G39P cells infusion at each dose level.
62195093|NCT02646787|EXPERIMENTAL|Active Virtual Reality|The subject is actively engaged in using virtual reality during a painful burn wound care session.
62195094|NCT02646787|EXPERIMENTAL|Passive Virtual Reality|The subject is passively engaged in using virtual reality during a painful burn wound care session.
62195095|NCT02646787|NO_INTERVENTION|Control|No intervention during the subject's standard wound care session
62195096|NCT06376877|ACTIVE_COMPARATOR|Real aiTBS|Participants in this group will receive aiTBS with neuronavigation to the anxiosomatic treatment target.
62398762|NCT04179864|EXPERIMENTAL|Phase 2: Tazemetostat in Combination with Enzalutamide|"Participants will receive the newly established recommended phase 2 dose, orally twice daily when given in combination with enzalutamide) as determined in phase 1b part of the study) or enzalutamide alone.~All participants will receive treatment in 28-day cycles."
62782906|NCT01398748|PLACEBO_COMPARATOR|Saline intranasal delivery|Study participant will be provided with monthly supply of study medication and will be asked to intake Intranasal saline delivery (n=15) An amount of 1ml with a frequency 3x per day with a duration of 12 weeks
62782907|NCT01398748|NO_INTERVENTION|Watchful waiting|No intervention, watchful waiting only (n=4)
62009237|NCT03835442|ACTIVE_COMPARATOR|baclofen arm|baclofen 10mg tid for 4 weeks
62009238|NCT03835442|PLACEBO_COMPARATOR|placebos arm|placebo tid for 4 weeks
62009239|NCT01024400|EXPERIMENTAL|vaccine|
62195097|NCT06376877|SHAM_COMPARATOR|Sham aiTBS|Participants in this group will receive sham aiTBS with neuronavigation to the anxiosomatic treatment target.
62195098|NCT02444780||elective cardiac surgery patients|consecutive patients who undergo elective cardio-thoracic surgery during a 6 to 8 week period
62195099|NCT04229810|ACTIVE_COMPARATOR|STD-02|Conventional standardized lung protective ventilation.
62398763|NCT04179864|ACTIVE_COMPARATOR|Phase 2: Enzalutamide only|In Phase 2, Enzalutamide will be administered on cycle 1 day 1
62782908|NCT01192412|ACTIVE_COMPARATOR|'Less tight' control.|The diastolic blood pressure (dBP) treatment goal is 100 mmHg.
62782909|NCT01192412|ACTIVE_COMPARATOR|'Tight' control.|The diastolic blood pressure (dBP) treatment goal is 85 mmHg.
62782910|NCT01159392||Brain injury plus acute lung injury|Patients with severe brain injury (Glasgow coma score\<13) with acute lung injury (PaO2/FiO2 \<300 mmHg)
62782911|NCT03460561|ACTIVE_COMPARATOR|TEA group|peri operative thoracic epidural block (TEA) via fentanyl-levo bupivacaine infusion.
62782912|NCT03460561|ACTIVE_COMPARATOR|RSB group|peri operative rectus sheath block (RSB) via fentanyl-levo bupivacaine infusion.
62009240|NCT03930004||Type 1 diabetic patients|"Patients diagnosed with type 1 diabetes mellitus with criteria for cardiovascular autonomic neuropathy, asymptomatic, normotensive, with negative medical history of cardiovascular disease.~Transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of heart structure and function."
62009241|NCT03930004||Control - Healthy subjects|"Fifteen age- and sex-matched healthy control subjects, asymptomatic, normotensive, with negative medical history of cardiovascular disease.~Transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of heart structure and function."
62009242|NCT05863754|EXPERIMENTAL|Experimental: Intervention - implant neuroprosthesis|Receives implanted networked neuroprosthetic system for arm and hand function. Undergoes functional training and assessment.
62009243|NCT01298297|ACTIVE_COMPARATOR|Buprenorphine + Placebo|
62009244|NCT01298297|PLACEBO_COMPARATOR|Morphine + Placebo|
62009245|NCT04357405||Experimental arm|This group consists of 100 EHPAD which will benefit from ECG teletransmission. all data will be collected
62009246|NCT04357405||Control arm|This arm consists of 50 EHPAD that have not benefited from ECG teletransmission. Only the global death occurrence data will be analyzed, no individual data will be collected.
62009247|NCT04251559|ACTIVE_COMPARATOR|patients with gestational diabetes mellitus|study group
62009248|NCT04251559|PLACEBO_COMPARATOR|healthy participants|control group
62573791|NCT04988555|EXPERIMENTAL|Phase 2 Arm B: AML with NPM1c mutations|Patients with R/R AML w/ NPM1c mutations
62573792|NCT02976740|EXPERIMENTAL|SBRT+GM-CSF+Tα1|Metastasis lesion will be treated with a SBRT of 50Gy/4-10F from day 1 to day 10 . Subcutaneous injection of Immunological Agent- human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle. Subcutaneous injection of another Immunological Factors Thymosin Alpha 1(1.6mg Biw)will be executed from the fist WEEK to the 12th Weeks.
62009249|NCT06449157|EXPERIMENTAL|Inhalation induction with parosmia|The experimental group will be told about a magical machine that can change the smell of the mask to any flavor the patient desires. The participant will be asked to take a deep breath thinking about that smell and then sevoflurane will be introduced. The patient will be asked if the the chosen flavor is smelled and the response will be noted.
62009250|NCT06449157|NO_INTERVENTION|Standard inhalation induction|Standard inhalation induction.
62009251|NCT06587347|EXPERIMENTAL|Tirofiban Group|Patients will receive tirofiban in the first 24 hours after intravenous thrombolysis, then bridge to oral antiplatelet therapy.
62009252|NCT06587347|ACTIVE_COMPARATOR|Control group|Aspirin, clopidogrel, or other antiplatelet drugs will be used in principle after 24 hours of thrombolytic therapy or until the primary outcome occurs.
62009253|NCT04996992||Parkinson's disease|The cohort includes patients with Parkinson's disease who underwent MRgFUS pallidothalamic tractotomy (PTT).
62398764|NCT06723080|EXPERIMENTAL|VC005 low dose group|
62009254|NCT02872415|EXPERIMENTAL|The forearm as blood puncture site|The child receives a puncture blood on the forearm
62009255|NCT02872415|PLACEBO_COMPARATOR|Fingers like blood puncture site|Premature receiving a puncture blood on the finger
62009256|NCT04492033|EXPERIMENTAL|CTX-009 (ABL001) and Paclitaxel (P1b)|
62009257|NCT04492033|EXPERIMENTAL|CTX-009 (ABL001) and Irinotecan (P1b)|1 cycle = 4weeks
62009258|NCT04492033|EXPERIMENTAL|CTX-009 (ABL001) and Paclitaxel (P2)|1 cycle = 4weeks
62009259|NCT01901380||extensively hydrolysed casein formula + LGG|children receiving extensively hydrolysed casein formula plus Lactobacillus GG
62009260|NCT01901380||other formulas|children receiving formulas without supplementation of Lactobacillus GG
62009261|NCT00306592|EXPERIMENTAL|Natalizumab|All study participants in 101-MS-322 (NCT00306592) and 101-MS-321 (NCT00297232) received open label 300 mg intravenous (IV) natalizumab 60-minute infusion once every 4 weeks (28 days ±7 days) for up to 48 weeks. After 48 weeks, participants from 101-MS-322 (NCT00306592) entering study 101-MS-321 (NCT 00297232; considered the Long-Term Treatment Period of 101-MS-322) were continued on treatment from Week 52 through Week 480.
62009262|NCT04314193|EXPERIMENTAL|methotrexate|
62009263|NCT04314193|ACTIVE_COMPARATOR|prednisolone|
62009264|NCT02084030||Experimental: Patient with POCD|Patients who suffer from POCD after surgery. The mini-mental state examination scale decline more than 1 SD of baseline after surgery.
62195100|NCT04229810|EXPERIMENTAL|iOLA-iHFNC|Individualized ventilatory strategy that mantains an open lung condition.
62398765|NCT06723080|EXPERIMENTAL|VC005 high dose group|
62398766|NCT06723080|PLACEBO_COMPARATOR|VC005 placebo group|
62573793|NCT04228614||Retrospective cohort|Whole exome sequencing of 2500 retrospective tissue sample.
62573794|NCT04228614||Prospective cohort|Whole exome sequencing of 500 prospectively collected tissue samples. Panel sequencing of 451 genes of prospectively collected blood samples.
62195101|NCT02129868|EXPERIMENTAL|Closed-loop on day 1 of CGM sensor life|Glucose level is controlled by the automated closed-loop glucose control system on day 1 after CGM sensor insertion.
62782913|NCT05623657|EXPERIMENTAL|Trunk Stabilization Exercise Training Group|
62782914|NCT05623657|EXPERIMENTAL|Game Based Exercise Program Group|
62782915|NCT00296140|OTHER|self management of PSD symptoms|
62782916|NCT00296140|OTHER|screening and treatment of PSD|
62009265|NCT02084030||Sham Comparator: patient without POCD|Patients who don't suffer from POCD after surgery. There is no obvious difference between pre-operation and post-operation in mini-mental state examination scale
62009266|NCT06435247|EXPERIMENTAL|Accompaniment in the recovery area|The first group will have a family member accompany them in the recovery area
62009267|NCT06435247|NO_INTERVENTION|without accompaniment|The second group will not have accompaniment as is currently standard practice
62398767|NCT02195479|ACTIVE_COMPARATOR|Treatment Arm A (VMP Alone)|Participants will receive velcade (bortezomib) 1.3 milligram per square meter (mg/m\^2) as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m\^2 , orally, once daily (on Days 1-4) and prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
62195102|NCT02129868|ACTIVE_COMPARATOR|Closed-loop on day 3 of CGM sensor life|Glucose level is controlled by the automated closed-loop glucose control system on day 3 or 4 after CGM sensor insertion.
62195103|NCT04144647|EXPERIMENTAL|Healthy adults 18-80 years old|Healthy adults 18-80 years old
62398768|NCT02195479|EXPERIMENTAL|Treatment Arm B (D-VMP)|Participants will receive velcade 1.3 mg/m\^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m\^2, orally, once daily (on Days 1-4) and prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 mg/kg as IV infusion, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. On days when daratumumab is given, dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute, and prednisone 60 mg/m2 once daily will be given on Days 2-4. Following amendment 7, participants will have the option to switch to daratumumab subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.
62398769|NCT05691530|EXPERIMENTAL|Flavivirus Naive|Those with \<=50% neutralization at a 1:10 dilution to all four DENV serotypes, no history of flavivirus vaccination, or travel history that increases the likelihood of other flavivirus infections.
62573795|NCT03647618||Adductor canal|Patients receiving ultrasound-guided regional anaesthesia
62782917|NCT03162237|EXPERIMENTAL|Porcine islets and autologous treg|Porcine islets:10000 islet equivalent（IEQ）/Kg; Treg:2x10\^6/Kg
62782918|NCT03162237|ACTIVE_COMPARATOR|AutologousTreg|Autologous Treg:2x10\^6/Kg
62782919|NCT01771159|EXPERIMENTAL|Population|All subjects will undergo the implantation of the TBC.
62782920|NCT04165603|ACTIVE_COMPARATOR|5mg/kg of ICG, 24h before surgery|5mg/kg of indocyanine green, intravenously injection 24 hours before surgery
62782921|NCT04165603|EXPERIMENTAL|1mg/kg of ICG, 24h before surgery|1mg/kg of indocyanine green, intravenously injection 24 hours before surgery
62782922|NCT04165603|EXPERIMENTAL|5mg/kg of ICG, 48h before surgery|5mg/kg of indocyanine green, intravenously injection 48 hours before surgery
62782923|NCT04165603|EXPERIMENTAL|1mg/kg of ICG, 48h before surgery|1mg/kg of indocyanine green, intravenously injection 48 hours before surgery
62782924|NCT06075121|EXPERIMENTAL|Abdominal massage group|Patients in the massage group will receive an abdominal massage twice a day for 5 days, between 10.00 in the morning and 22.00 in the evening for 15 minutes.
62782925|NCT06075121|NO_INTERVENTION|Control group|Routine treatment and care practices in the hospital will continue for 5 days without any additional intervention and the same data will be evaluated at the same time.
62214961|NCT05847959|ACTIVE_COMPARATOR|intervention group|The intervention group will receive not only Western medicine, but also XK-I. The therapeutic drugs used in the control group will be according to the European Society of Cardiology's 2021 guidelines for the diagnosis and treatment of acute and chronic heart failure.
62214962|NCT05847959|NO_INTERVENTION|The control group|The control group will receive Western medicine.The therapeutic drugs used in the control group will be according to the European Society of Cardiology's 2021 guidelines for the diagnosis and treatment of acute and chronic heart failure.
62398770|NCT05691530|EXPERIMENTAL|Polytypic DENV Antibody Profile|Those considered immune (a \>=70% neutralization or plaques at a 1:40 dilution) to at least two serotypes.
62573796|NCT03647618||Popliteal|Patients receiving ultrasound-guided regional anaesthesia
62009268|NCT02310659||lower calcificant score group|patients with coronary artery calcificant score \<400
62009269|NCT02310659||higher calcificant score group|patients with coronary artery calcificant score ≥400
62009270|NCT05369221|EXPERIMENTAL|ReSpace™|The subjects who meet all the inclusion criteria and do not meet any of the exclusion criteria will be enrolled in this study. Subjects will undergo placement of ReSpace™ hydrogel.
62195104|NCT05238831|EXPERIMENTAL|Treatment (SMMART-ACT)|Administered in monotherapy or in combination with other targeted agents or immunotherapies, chemotherapies, or radiation. Combination treatment plans may include a two-week monotherapy lead-in, followed by a combination treatment regimen. Each ACT study intervention must have an established RP2D determined in a prior clinical trial. Participants undergo a Pre-Treatment Biopsy, plus an On-Treatment Biopsy after two weeks on first dose of study drug(s) and prior to starting Cycle 2, regardless of regimen. Participants continue to receive study agent(s) after the On-Treatment Biopsy, according to the biopsy results and the results of ongoing safety and clinical assessments. Treatment cycles repeat every 21 to 28 days in the absence of disease progression or unacceptable toxicity. Cycles are determined based on the study agent(s). Upon disease progression, participants are given the option to undergo an additional biopsy.
62195105|NCT00570908|EXPERIMENTAL|Study Group|capecitabine administered concurrently with WBRT followed by combination the combination of capecitabine with sunitinib
62195106|NCT04030429|EXPERIMENTAL|Crizotinib arm|Crizotinib 250 mg bid orally
62195107|NCT05815615|PLACEBO_COMPARATOR|Placebo|Simulated plasma donation, same procedure as for plasmapheresis but without drawing blood.
62195108|NCT05815615|EXPERIMENTAL|Low-frequency|Plasma donation 1x/month for 3 months
62195109|NCT05815615|EXPERIMENTAL|High-frequency|Plasma donation 3x/month for 3 months
62195110|NCT05815615|EXPERIMENTAL|US scheme|Plasma donation 2x/week for 3 months
62195111|NCT04128410||T1|At 5 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
62195112|NCT04128410||T2|At 10 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
62398771|NCT05691530|EXPERIMENTAL|Primary Heterotypic DENV Antibody Profile|Those who have a \>=70% neutralization or plaques at a 1:40 dilution for a single serotype, either DENV1, DENV2, or DENV4.
62398772|NCT06722326|EXPERIMENTAL|Hydrogen-rich water|One liter per day of hydrogen rich water
62398773|NCT06722326|PLACEBO_COMPARATOR|Control water|One liter per day of tap water
62009271|NCT00555438|EXPERIMENTAL|1|patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery
62398774|NCT01437982|EXPERIMENTAL|Loteprednol Etabonate|Ophthalmic Gel 0.5%
62009272|NCT01338116|EXPERIMENTAL|Management by TREAT/PCR|The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly.
62398775|NCT01437982|EXPERIMENTAL|Prednisolone Acetate 1% Oph Susp|Ophthalmic suspension 0.5%
62398776|NCT00502866||breastfed children|children, 6-15 months old, predominately breastfed for at least 6 months without supplemental vitamin D
62398777|NCT06717217|NO_INTERVENTION|CONTROL GROUP|
62398778|NCT06717217|EXPERIMENTAL|WORKING GROUP|
62398779|NCT04691570|EXPERIMENTAL|ANX005|Participants will receive two once-weekly doses of ANX005 at specific time points
62398780|NCT06722456||IBD in remission|Patient affected with an inflammatory bowel disease that is considered in remission.
62195113|NCT04128410||T3|At 15 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
62195114|NCT04128410||T4|At 20 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
62195115|NCT04128410||T5|At 25 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
62195116|NCT04128410||T6|At 30 minutes after flurbiprofen axetil injected intravenously, 14 patients' samples were required to be collected,including 7 younger patients
62398781|NCT06722456||IBD active|Patient affected with an inflammatory bowel disease that is considered under an active state.
62573797|NCT03647618||Fascia Iliaca|Patients receiving ultrasound-guided regional anaesthesia
62009273|NCT01338116|NO_INTERVENTION|Usual management|Patients will be managed by physicians as in regular clinical practice.
62009274|NCT04025918|EXPERIMENTAL|vasopressor delivery automated system|vasopressor delivery automated system that administered phenylephrine and ephedrine based on data from continuous non-invasive hemodynamic monitor
62398782|NCT06722456||IBD not classified|Patient affected with an inflammatory bowel disease that is difficult to classify as active or in remission.
62398783|NCT04478591||Patients with multiple sclerosis using ocrelizumab.|Patients with multiple sclerosis using ocrelizumab for a minimum of one year.
62009275|NCT04025918|ACTIVE_COMPARATOR|manual vasopressor delivery|manual bolus that delivered phenylephrine and ephedrine based on data from non-invasive intermitted blood pressure monitor
62009276|NCT05126888|EXPERIMENTAL|SCI-110|Cannabinoid-based medication consisting of Dronabinol and PEA
62009277|NCT05126888|PLACEBO_COMPARATOR|Dronabinol|Placebo matched in taste, odour and appearance to SCI-110
62009278|NCT06003725|EXPERIMENTAL|ADAP-ITT Phase 8|Phase 8 consists of piloting the culturally adapted CYT intervention with 30 Black JIY to examine feasibility and acceptability.
62009279|NCT00779454|OTHER|KRAS wildtype|
62009280|NCT00779454|OTHER|KRAS mutation|Inclusion has been completed in the KRAS mutation arm.
62195117|NCT04128410||T7|At 35 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
62398784|NCT00873496||Sjögren|Pre and post treatment establishment of salivary flow rate, objective and subjective clinical oral complications' severity of the patients using hydroxychloroquine
62573798|NCT03647618||Rectus sheath|Patients receiving ultrasound-guided regional anaesthesia
62573799|NCT03647618||Axillary|Patients receiving ultrasound-guided regional anaesthesia
62573800|NCT02523508|EXPERIMENTAL|Experimental group|Passive manual lumbar mobilization on L2-3 level
62573801|NCT02523508|PLACEBO_COMPARATOR|Control group|Passive limb mobilization which did not involve the spine
62398785|NCT06718348|NO_INTERVENTION|Group CTRL|Participants will undergo 30 sessions of conventional physiotherapy
62573802|NCT02260336|EXPERIMENTAL|Panax Notoginseng Powder 1g|Panax Notoginseng Powder 1g, daily
62782926|NCT01964638|OTHER|Targeted Biopsy|Men being evaluated for prostate cancer based upon standard of care clinical parameters (e.g. elevated PSA levels, abnormal DRE, mpMRI) will be considered for enrollment. Men who have undergone prostate mpMRI that has revealed an area(s) of suspicion for prostate cancer are eligible for enrollment. All men enrolled in the study undergo fusion targeted biopsy, visual estimation biopsy, and systematic biopsy. As a result the study includes a single arm with direct comparison of biopsy techniques.
62195118|NCT04128410||T8|At 40 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
62195119|NCT04128410||T9|At 45 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
62195120|NCT04128410||T10|At 50 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
62195121|NCT05213546|ACTIVE_COMPARATOR|High intensity aerobic training group(HIT)|15 patients who received High Intensity aerobic Training in the form of bicycle ergometer exercise for the lower limbs three times /week for three months.
62195122|NCT05213546|ACTIVE_COMPARATOR|Moderate intensity aerobic training group(MIT)|15 patients who received moderate Intensity aerobic Training in the form of bicycle ergometer exercise for the lower limbs three times /week for three months.
62195123|NCT05213546|ACTIVE_COMPARATOR|Low intensity aerobic training group(LIT)|15 patients who received low Intensity aerobic Training in the form of bicycle ergometer exercise for the lower limbs three times /week for three months
62573803|NCT02260336|EXPERIMENTAL|Panax Notoginseng Powder 5g|Panax Notoginseng Powder 5g,daily
62573804|NCT02260336|EXPERIMENTAL|Panax Notoginseng Powder 10g|Panax Notoginseng Powder 10g,daily
62195124|NCT03570268|EXPERIMENTAL|Experimental group: Education group|Participants in the experimental intervention group (education group) received an educational program and tailored home exercises. This intervention consist of multiple, interacting components supported by a handbook and audio-video material designed to teach people the skills, techniques, and strategies for preventing falls, and increase social participation and engagement in inactivity of daily living. . After the educational session, two one hour sessions were spent to teach safe balance exercises that were developed in preceding studies, the patient was invited to perform at home for 2 months.
62195125|NCT03570268|ACTIVE_COMPARATOR|Control Group: Usual care|Participants allocated to the control group received ongoing usual treatments. In addition, two one hour lessons were spent to teach stretching exercises that the patient was invited to perform at home for 2 months.
62195126|NCT05835271|EXPERIMENTAL|exoskeleton assist|A powered exoskeleton describes a wearable robot designed around the shape and function of the human body with segments and joints externally coupled to those of the user. The exoskeleton includes a belt frame, sensors that detect a user's desired movements, a computerized controller, motors and actuators, and lightweight batteries.
62398786|NCT06718348|EXPERIMENTAL|Group EXP|Participants will undergo 30 sessions of physiotherapy with the use of the Japet.W+ Exoskeleton
62398787|NCT06487806|EXPERIMENTAL|Beta testing group|
62573805|NCT02260336|EXPERIMENTAL|Panax Notoginseng Powder 15g|Panax Notoginseng Powder 15g,daily
62573806|NCT02260336|ACTIVE_COMPARATOR|Celecoxib Capsule 400 mg daily|Celecoxib Capsule 400 mg daily
62573807|NCT03718208|EXPERIMENTAL|Paediatric formula|"Each child will receive for a period of seven days. The formula is a food for special medical purposes for use under medical supervision.~The dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube. One week intake diary, one week tolerance diary, product intake."
62573808|NCT02324504|EXPERIMENTAL|Placement with C3 Wave Tip System|Subjects will have their central catheters placed with the addition of the FDA approved C3 Wave ECG-Based PICC Tip Confirmation System to the standard institution protocol. The system will assist with location of the catheter tip in real-time, during the procedure.
62573809|NCT02706431|NO_INTERVENTION|Normoventilation|The patients will be normoventilated before anesthesia
62573810|NCT02706431|EXPERIMENTAL|Hyperventilation|Prior to anesthesia, the patients will hyperventilate during 2 mins or until symptoms from the central nervous system (e.g. dizziness).
62573811|NCT01708382|EXPERIMENTAL|Ultherapy treatment on the elbows|All enrolled subjects will receive one Ultherapy treatment to the elbows.
62573812|NCT04202120|EXPERIMENTAL|Age-related priming|Participants received a review of the profile of their social participation. They also received psycho-education about memory components. They were give given memory tests with age-related primes.
62782927|NCT01874444|EXPERIMENTAL|Active rTMS1|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex .
62782928|NCT01874444|EXPERIMENTAL|Active rTMS2|Temporal low frequency rTMS of left primary auditory cortex.
62782929|NCT01874444|EXPERIMENTAL|Active rTMS3|Frontal low frequency rTMS of left dorsolateral prefrontal cortex .
62782930|NCT01874444|SHAM_COMPARATOR|Sham rTMS4|sham treatment Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.
62009281|NCT05606068|EXPERIMENTAL|Cancer patients|Cancer patients will undergo limb cryocompression based on the established optimal temperature and pressure from previous studies over multiple cycles of chemotherapy to establish safety and tolerability of repeated therapy.
62009282|NCT02097134|EXPERIMENTAL|Treatment (melphalan)|Patients receive melphalan IA on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62009283|NCT05528991||mesangial hypercellularity, M|the histopathology was graded based on the revised Oxford Classification system as follows: M absent (M0) or M present (M1)
62009284|NCT05528991||endocapillary hypercellularity, E|E absent (E0) or E present (E1)
62195127|NCT04852913|EXPERIMENTAL|Bowen's Technique|Bowen's Technique The session lasted for 20 minutes, 3 sessions/week 6th week
62195128|NCT04852913|ACTIVE_COMPARATOR|Conventional Physical Therapy|Conventional Physical Therapy with myofascial release The session lasted for 20 minutes, 3 sessions/week 6th week
62195129|NCT03272906|EXPERIMENTAL|A-tDCS & speech-language therapy|Anodal transcranial direct current stimulation (2 mA) plus speech-language therapy for 16 sessions (20-minutes per each 60-minute treatment session) over the course of 8 weeks. The electrical current will be administered over ventral inferior frontal gyrus. The stimulation will be delivered at an intensity of 2mA for a maximum of 20 minutes.
62195130|NCT03272906|SHAM_COMPARATOR|Sham-tDCS & speech-language therapy|Sham transcranial direct current stimulation (2 mA) plus speech-language therapy for 16 sessions (20-minutes per each 60-minute treatment session) over the course of 8 weeks. Electrodes will be placed as in A-tDCS. Current will be ramped up for the first 30 seconds following which the intensity will drop to 0 mA.
62195131|NCT06119152|NO_INTERVENTION|Control|Usual Care
62195132|NCT06119152|EXPERIMENTAL|Intervention|The DESA Intervention will use a telehealth device to help the patient take blood pressure daily, and monitor blood pressure management.
62573813|NCT04202120|ACTIVE_COMPARATOR|Non-age related priming|Participants received a review of the profile of their social participation. They also received psycho-education about memory components. They were give given memory tests with NON age-related primes.
62573814|NCT04213885|EXPERIMENTAL|Pulsed Accelerated|30mW, 5 sec, 5 sec off, 10 minutes of illumination. Combination Product: PXL-330 Platinum device for cross linking with Peschke riboflavin solution will be used to load the cornea followed by UV-A cross linking of the cornea
62782931|NCT05363111|EXPERIMENTAL|Treatment (daratumumab, 225Ac/111In-DOTA-daratumumab)|Patients receive daratumumab IV over 45 minutes. Two hours later, patients receive 111In-DOTA-daratumumab and 225Ac-DOTA-daratumumab IV over 20-30 minutes.
62009285|NCT05528991||segmental glomerulosclerosis, S|S absent (S0) or S present (S1)
62009286|NCT05528991||tubular atrophy/interstitial fibrosis, T|T ≤ 25% (T0) or T 26%-50% (T1), or T \> 50% (T2)
62573815|NCT04213885|ACTIVE_COMPARATOR|Conventional|9mW continuous, 10 minutes of illumination. Combination Product: PXL-330 Platinum device for cross linking with Peschke riboflavin solution will be used to load the cornea followed by UV-A cross linking of the cornea
62009287|NCT05528991||crescents, C|C absent (C0) or C present ≥ 1 glomerulus (C1) or C \> 25% glomeruli (C2)
62009288|NCT00963729|EXPERIMENTAL|Arm I|Patients receive fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62573816|NCT05994872|SHAM_COMPARATOR|Traditional extraction drilling|A standard hamstring autograft procedure was performed using traditional extraction drilling to prepare bone tunnel (n = 108).
62782932|NCT04646330|EXPERIMENTAL|AK104 10mg/kg Q2W plus anlotinib|Subjects receive AK104 10mg/kg every 2-week cycle(Q2W) intravenously (IV) plus anlotinib 1-14days of every 3-week cycle (Q3W) until no more benefits from treatment.
62782933|NCT04646330|EXPERIMENTAL|AK104 15mg/kg Q3W plus anlotinib|Subjects receive AK104 15mg/kg intravenously (IV) plus anlotinib 1-14days of every 3-week cycle (Q3W) until no more benefits from treatment.
62009289|NCT00963729|EXPERIMENTAL|Arm II|Patients receive oral letrozole daily for 18-23 weeks until day of surgery.
62195133|NCT00013247|OTHER|Arm 1|
62782934|NCT04646330|EXPERIMENTAL|AK104 10mg/kg Q3W plus anlotinib|Subjects receive AK104 10mg/kg Q3W plus anlotinib 1-14days of every 3-week cycle until no more benefits from treatment.
62782935|NCT02726724|EXPERIMENTAL|Condition B|An audience of 5 people with at least 2 neonatologists will be present with the operator during the intubation of the mannequin.
62573817|NCT05994872|EXPERIMENTAL|Reverse drilling technique|A standard hamstring autograft procedure was performed using reverse drilling technique to prepare bone tunnel (n = 108).
62009290|NCT01412840|EXPERIMENTAL|Standard care and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
62573818|NCT06578689||DM with DFU|
62573819|NCT06578689||DM without DFU|
62782936|NCT02726724|EXPERIMENTAL|Condition A|Only the staff will be present with the operator during the intubation of the mannequin.
62573820|NCT06534619|EXPERIMENTAL|Maitland joint mobilization + Rocabdo exercises|"Therapeutic ultrasound: pulse mode - 1:4, frequency 3 MHz, intensity- 0.8 watt/cm2 for about 3-4 Minutes.~Mobilizations will be performed in Grade 1 initially and then progressed to Grade 2 and 3.~Techniques used are anterior, lateral and inferior glides Frequency: 3-4 times in 1 week . 4 sessions in total."
62009291|NCT01412840|PLACEBO_COMPARATOR|Standard care and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
62195134|NCT06509620||cases|community dwelling elderly patients with fatigue. 70 Participants aged 60 years old and above both males and females with fatigue for at least 4 weeks not due to acute condition
62195135|NCT06509620||control|age and gender matched elderly patients without fatigue
62573821|NCT06534619|EXPERIMENTAL|Rocabado exercises|"Participants of this Group will receive the conventional physical therapy along with 6 Rocabado exercises.6 reps each Therapeutic ultrasound: pulse mode - 1:4, frequency 3 MHz, intensity- 0.8 watt/cm2 for about 3-4 Minutes.~Frequency: 3-4 times in 1 week . 4 sessions in total."
62573822|NCT04073004|EXPERIMENTAL|Rapid Resolution Therapy|"RRT is a talk therapy that uses Neurolinguistic Programming Language and trance states to cause a shift in how the mind is processing incoming data.~The understanding is that the part of the mind that is causing the disturbing emotion, thought or sensation is causing them to cause the person to take an action to ensure the organisms survival. RRT therapists employ psycho-therapeutic techniques taht are designed to cause the mind to process information differently so that the disturbing content and distorted meaning shift."
62573823|NCT04047836|OTHER|Low Nicotine|Using an electronic cigarette, the patient will participate in a standardized vaping session using 3 mg/ml nicotine e-liquid.
62573824|NCT04047836|OTHER|Medium or High Nicotine|The patient will participate in a standardized vaping session using either an electronic cigarette with 18 mg/ml nicotine e-liquid or a JUUL device with a JUUL e-liquid pod.
62573825|NCT05163925||EUROSETS ECMOLIFE SYSTEM|"Thirty consecutive patients that require ECLS and who receive the EUROSETS ECMOLIFE SYSTEM will be included. ECMOLIFE System is a perfusion system enabling operation and monitoring of extracorporeal circulation. ECMOLIFE System operates, powers, controls and regulates ECMOLIFE Centrifugal Pump which represents the disposable blood pump. ECMOLIFE System, when used in combination with ECMOLIFE Centrifugal Pump, is suitable for full or partial cardiac, circulatory and pulmonary support.~ECMOLIFE System is composed by an active programmable console (ECMOLIFE Console), a bearing-less motor driver (ECMOLIFE Motor driver), and sensors for blood parameters detection (flow rate, pressure, temperature, SvO2 and Hb). The console is equipped with an integrated back-up which in case of primary unit failure may be operated in combination with a back-up motor driver and flowmeter (besides, the ECMOLIFE system includes an Heater cooler device)."
62573826|NCT00002875|EXPERIMENTAL|Regimen A|Following surgery, craniospinal irradiation followed by a boost to the primary tumor. Beginning within 1 week after initiation of radiotherapy, patients receive vincristine sulfate weekly for 8 doses. Beginning 6 weeks after the completion of radiotherapy, patients receive adjuvant lomustine/vincristine sulfate/cisplatin every 6 weeks for a total of 8 courses.
62573827|NCT00002875|EXPERIMENTAL|Regimen B|Following surgery, craniospinal irradiation plus vincristine sulfate, followed by adjuvant cyclophosphamide/vincristine sulfate/cisplatin every 6 weeks for a total of 8 courses.
62782937|NCT02425514|EXPERIMENTAL|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs(TM), which is the PEEK cage filled with b-TCP.
62782938|NCT02425514|EXPERIMENTAL|NovoMax™|The ACDF surgery will be carried out with NovoMax™, which is the bioactive glass ceramic intervertebral spacer
62782939|NCT01622387|EXPERIMENTAL|Radial artery|Use of the radial artery as a conduit in CABG surgery
62782940|NCT01622387|ACTIVE_COMPARATOR|Long saphenous vein|Use of long saphenous vein as a conduit in CABG surgery
62782941|NCT01329848||discomfort symptoms|level of discomfort symptoms while performing near work
62782942|NCT04723680||Early dose finding cohort|People with Haemophilia who took part in the early dose finding studies
62782943|NCT04723680||Subsequent studies group cohort|People with haemophilia who took part in subsequent gene therapy studies
62195136|NCT04627454|EXPERIMENTAL|dynamic cervical implant|dynamic cervical implant in treatment of cervical disc disease
62195137|NCT04627454|EXPERIMENTAL|discectomy|insertion of dynamic cervical implant post cervical discectomy single level
62195138|NCT04659122|EXPERIMENTAL|AT-100 75 mg|Once daily AT-100 via intratracheal administration for up to 7 doses.
62195139|NCT04659122|EXPERIMENTAL|AT-100 150 mg|Once daily AT-100 via intratracheal administration for up to 7 doses, if the prior dose level was safe \& tolerated.
62195140|NCT04659122|EXPERIMENTAL|AT-100 75 mg or 150 mg (Optional Cohort)|Once daily AT-100 via intratracheal administration for up to 7 doses, at the highest safe \& tolerated dose as determined by the prior 2 dosing levels.
62195141|NCT03786744|EXPERIMENTAL|ASD CB-MNC injection.|ASD CB-MNC injection from different donors and standard therapy.
62195142|NCT03786744|OTHER|Standard therapy.|Patients with standard therapy as control group.
62195143|NCT01089803||Patients Treated with Laryngectomy|Patients initially treated with laryngectomy and followed for 12 months after receiving this treatment.
62195144|NCT01089803||Patients Treated with Chemoradiation|Patients treated initially with chemoradiation and followed for 12 months after receiving treatment.
62009292|NCT01412840|NO_INTERVENTION|Standard care|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac.
62009293|NCT01233297|ACTIVE_COMPARATOR|Antibiotics|Azithromycin (10 mg/kg once a day for 3 days)
62573828|NCT06578520|EXPERIMENTAL|Group 1|They will receive standard of care plus Dapaglifozin for 8 weeks, after a 4-week wash out, they will receive receive standard of care for another 8 weeks.
62573829|NCT06578520|EXPERIMENTAL|Group 2|They will receive standard of care for 8 weeks, after a 4-week wash out, they will receive receive standard of care for another 8 weeks plus Dapaglifozin.
62573830|NCT04122313||Patients with Dupuytren's Contracture Disease|Patients with Dupuytren's Disease following the current treatment pathway
62573831|NCT01597570|EXPERIMENTAL|FASTSEAL® Bioabsorbable VCD|Fastseal® Bioabsorbable Vascular Access Closure System
62009294|NCT01233297|PLACEBO_COMPARATOR|Placebo|Placebo mixture (once a day for 3 days)
62009295|NCT01516190|ACTIVE_COMPARATOR|Exercise Group|Supervised exercise sessions and independent exercise
62009296|NCT01516190|ACTIVE_COMPARATOR|Mind-Body Group|Surgical preparation program
62573832|NCT01597570|ACTIVE_COMPARATOR|Perclose® ProGlide SMC System|Perclose® ProGlide Suture-Mediated Closure System
62009297|NCT06573164||Mometasone furoate/Budesonide nasal with/without Budesonide/Formoterol group|"Treatment based on patient symptoms includes:~Mometasone furoate 4 sprays daily (qd) or Budesonide nasal spray 2 sprays twice daily ;Budesonide/Formoterol 160/5 µg or 320/5 µg, inhaled twice daily."
62398788|NCT02649673|EXPERIMENTAL|LCL161+topotecan+Pegylated GCSF (PEG-GCSF)|"Dose Escalation: Groups of 3-6 patients per dose level (DL) will initiate treatment in escalating doses until the maximum tolerated dose (MTD) is reached. MTD is defined as the highest combination of doses that results in dose-limiting toxicities for 2 of 6 patients per dosing group.~* LCL161: orally, on Days 1, 8, 15 of each 21-day cycle. Maximum dose not to exceed 1200 mg/week.~* topotecan: orally, for first 5 days of each 21-day cycle. Maximum dose not to exceed 2.3 mg/m2 per day.~* Pegylated GCSF (PEG-GCSF) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.~Dose Expansion: 24 additional patients will be treated at the MTD in 2 cohorts (SCLC-12 patients; ovarian cancer-12 patients)"
62398789|NCT04711031||Usual care + FLUS|At index consultation, patients will receive a FLUS examination in addition to the GP's usual care of adults presenting with symptoms of an acute LRTI.
62573833|NCT06575257|EXPERIMENTAL|Darolutamide Plus ADT|All participants in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus Darolutamide. Goserelin 3.6 mg will be used once per 4 weeks. Darolutamide will be administered orally as 600 mg twice a day. Subjects will continue to take Darolutamide Plus Goserelin for 12 weeks before radical prostatectomy
62009298|NCT06573164||conventional medication combined with Qipian® treatment group.|"Treatment based on patient symptoms includes:~Mometasone furoate 4 sprays daily (qd) or Budesonide nasal spray 2 sprays twice daily； Budesonide/Formoterol 160/5 µg or 320/5 µg, inhaled twice daily; Qipian® 4 tablets, taken orally three times daily."
62009299|NCT05543213|NO_INTERVENTION|Control group|Videos of nature will be shown to them, and exercises similar to those in the intervention group will be practiced with them.
62398790|NCT06377267|EXPERIMENTAL|HRD positive arm|Patient with harboring HRD tumor, that will receive olaparib in combination with bevacizumab
62398791|NCT06377267|OTHER|HRD negative arm|Control group receiving bevacizumab alone as standard of care.Patient with non harboring HRD tumor, that will receive bevacizumab
62573834|NCT06575257|EXPERIMENTAL|ADT alone|All participants in this arm will receive LHRHa alone for 12 weeks before receiving radical prostatectomy. Goserelin 3.6 mg will be administered once per 4 weeks.
62009300|NCT05543213|ACTIVE_COMPARATOR|Action Observation group|In the intervention group, the same exercises related to balance and walking are practiced after watching videos of the exercises
62009301|NCT04988685||Treatment|The project ́s main goal is to collect baseline, clinical and procedural data as well as to assess angiographic and clinical outcomes of CAD patients treated with contemporary DCBs.
62398792|NCT04621604|EXPERIMENTAL|Patients|
62009302|NCT05107310|EXPERIMENTAL|Navigation group 1 ARSN|Augmented reality surgical navigation (ARSN). Pedicle screw placement using the Philips ClarifEye system combined with Philips Allura for imaging.
62009303|NCT05107310|ACTIVE_COMPARATOR|Control group 1 FH|Free hand (FH) surgical technique. Pedicle screw placement using conventional free hand technique.
62195145|NCT03836859|EXPERIMENTAL|rhNGF 20μg/mL|rhNGF 20μg/mL eye drop solution, formulation containing L-methionine as excipient.
62398793|NCT00057642|OTHER|Sertraline, venlafaxine, bupropion|This is an open trial so there is only one arm using standard antidepressant medications.
62398794|NCT06148298||Pancreatic Ductal Adenocarcinoma|
62573835|NCT05319925||Study 1|"Initial examination of the developed questionnaire in the first 100 participants to identify problematic questions and to optimise the instrument.~To evaluate test-retest reliability, collected data of the first 100 patients will be used as baseline value and re-assessed in Study 2."
62573836|NCT05319925||Study 2|"Second examination in 300 additional participants and re-assessment in participants from Study 1 (n=400) to validate modified questionnaire in its final form.~To evaluate test-retest reliability, data of Study 1 is compared against Study 2 of the same participant sample (n=100)."
62573837|NCT01304511||Participants Treated|Women undergoing controlled ovarian COH for ART
62573838|NCT02667704|EXPERIMENTAL|Nintedanib|
62573839|NCT02667704|EXPERIMENTAL|Bosentan|
62573840|NCT05999071|EXPERIMENTAL|Coriandrum sativum group|500 mg of C. sativum (capsules) were administered twice daily
62398795|NCT04816591|EXPERIMENTAL|Experimental: Interventional Cohort: Treatment Arm|Standard of Care Surgery + Embolization
62573841|NCT05999071|PLACEBO_COMPARATOR|control group|500 mg of starch (capsules) were administered twice daily
62398796|NCT04816591|ACTIVE_COMPARATOR|Active Comparator: Interventional Cohort: Control Arm|Standard of Care Surgery Only
62573842|NCT05268081|EXPERIMENTAL|Virtual specialist conferences|The group of general practices who participates in the virtual specialist conferences with endocrinologists.
62573843|NCT05268081|NO_INTERVENTION|Standard of care|Receives the usual, standard practice.
62573844|NCT04044040|EXPERIMENTAL|Symptom screening with Targeted Early Palliative care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
62573845|NCT02180529|EXPERIMENTAL|Methylphenidate|On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention. Two hours after taking the drug participants will be assessed cognitively by means of Mindstreams and MoCA (Montreal Cognitive Assessment).
62573846|NCT02180529|PLACEBO_COMPARATOR|Placebo|Participants in the control group will receive placebo. On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of Placebo every day of intervention. Two hours after taking the placebo participants will be assessed cognitively by means of Mindstreams and MoCA (Montreal Cognitive Assessment).
62573847|NCT06096077||Retrospective Cohort|ED at MCMC for ACEi-AE with TXA
62573848|NCT06096077||Retrospective Chort|ED at MCMC for ACEi-AE without TXA
62782944|NCT04723680||Withdrawn/ineligible Cohort|People with haemophilia who were withdrawn or proved ineligible
62009304|NCT05107310|EXPERIMENTAL|Navigation group 2 IRSN|Infrared surgical navigation (IRSN). Pedicle screw placement using Brainlab Curve 1.2 combined with Medtronic o-arm for imaging.
62009305|NCT05107310|ACTIVE_COMPARATOR|Control group 2 FH|Free hand (FH) surgical technique. Pedicle screw placement using conventional free hand technique.
62009306|NCT06449339|EXPERIMENTAL|non-selective beta-blocker (NSBB)|oral carvedilol 6.25mg-50mg daily
62398797|NCT04816591|EXPERIMENTAL|Experimental: Observational Cohort: Treatment Arm|Standard of Care Medical Management + Embolization
62573849|NCT02719717|EXPERIMENTAL|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
62573850|NCT01056237|EXPERIMENTAL|Multi-target therapy|(Tarcrolimus+mycophenolate mofetil)
62573851|NCT01056237|ACTIVE_COMPARATOR|Azathioprine|Aza
62573852|NCT06111378||Group 1:|control group (n:7)
62573853|NCT06111378||Group 2:|fish oil group (n:7)
62573854|NCT06111378||Group 3:|linseed oil group (n:7)
62573855|NCT06111378||Group 4:|walnut oil group (n:7)
62573856|NCT06111378||Group 5:|sham group (non-lactating rats) (n:4)
62573857|NCT06044636|ACTIVE_COMPARATOR|Digi-physical breastfeeding counceling|"Interventions: Digi-physical breastfeeding counseling~* At discharge from the maternity ward: contact with lactation consultant (breastfeeding support and care) via the support hotline with chat as soon as questions or problems arise. The hotline will be available during the whole project period.~* After discharge from the maternity ward: pediatric nurse from Child Health Care Unit (CHC) will contact families and make a home visit (physical or digital), giving extended lactation advice and support. Additional home visits if needed.~* After discharge until one year after childbirth: the possibility of getting into contact with specialized lactation consultant/nurse at lactation counseling units if needed.~Intervention type: Chatt via Application Alltid Öppet owned by Region Stockholm.~The intervention group will follow current healthcare routines in the Region Stockholm and will get access to an evidence-based information package about breastfeeding from pregnancy week 20."
62573858|NCT06044636|NO_INTERVENTION|Usual care with physical visits|Title: Usual care with physical visits The control group will follow current healthcare routines in the Region Stockholm and will get access to an evidence-based information package about breastfeeding from pregnancy week 20.
62573859|NCT00981812|EXPERIMENTAL|PEM Breast Biopsy|All patients underwent PEM biopsy.
62782945|NCT04723680||Not interested cohort|People with haemophilia who are definitely not interested in gene therapy
62782946|NCT04723680||Not offered cohort|People with haemophilia who are interested in gene therapy but have not been the opportunity to take part
62782947|NCT03762018|ACTIVE_COMPARATOR|Bevacizumab plus chemotherapy|Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks
62782948|NCT03762018|EXPERIMENTAL|Atezolizumab plus bevacizumab plus chemotherapy|Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks
62009307|NCT06449339|NO_INTERVENTION|Conventional|Not on oral carvedilol
62009308|NCT04685135|EXPERIMENTAL|MRTX849|
62009309|NCT04685135|ACTIVE_COMPARATOR|Docetaxel|
62009310|NCT03393221|EXPERIMENTAL|SBWC+ER|Participants randomized to the Standard Behavioral Weight Control and Emotional Regulation (SBWC+ER) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16. They receive the same information as the Standard Behavioral Weight Control group, but weekly sessions also include elements of TRAC, and it is designed to help teach emotion regulation skills to decrease overeating and sedentary behaviors and increase the likelihood of maintaining diet and exercise behaviors that are taught as part of SBWC interventions.
62195146|NCT03836859|PLACEBO_COMPARATOR|Placebo|Vehicle: formulation containing L-methionine as excipient.
62195147|NCT03725111|EXPERIMENTAL|arterio venous leg ulcers|
62195148|NCT00599274||A|This group was treated with Avonex once a week
62195149|NCT00599274||B|This group was treated with Rebif three times a week
62195150|NCT02336425|EXPERIMENTAL|QGE031 240 mg|QGE031 240 mg subcutaneous injection every 4 weeks
62195151|NCT02336425|EXPERIMENTAL|QGE031 72 mg|QGE031 72 mg subcutaneous injection every 4 weeks
62398798|NCT04816591|ACTIVE_COMPARATOR|Active Comparator: Observational Cohort: Control Arm|Medical Management Only
62195152|NCT02336425|EXPERIMENTAL|QGE031 24 mg|QGE031 24 mg subcutaneous injection every 4 weeks
62398799|NCT05659875|EXPERIMENTAL|ARM-program|
62398800|NCT01848769|EXPERIMENTAL|CHF1535 pMDI + AC Plus|Fixed combination of Beclomethasone Dipropionate and Formoterol 50/6 mcg with Aerochamber Plus spacer device
62398801|NCT01848769|ACTIVE_COMPARATOR|BDP and Formoterol + AC Plus|Beclomethasone Dipropionate 50 mcg and Formoterol 6 mcg with Aerochamber Plus spacer device
62398802|NCT06008782|EXPERIMENTAL|Immediate treatment|immediate treatment
62398803|NCT06008782|PLACEBO_COMPARATOR|Delayed treatment|1 month delayed treatment
62573860|NCT02325388|EXPERIMENTAL|Treatment group with ForeSite PT™ system|Inpatients assigned to the treatment group with the ForeSite PT™ system will have its LCD monitor turned on (i.e., real-time images of interface pressure will be displayed on the monitor) during their enrolment in the trial.
62573861|NCT02325388|NO_INTERVENTION|Control group|Inpatients assigned to the control group will have the ForeSite PT™ system's LCD monitor turned off and hidden (i.e., real-time images of interface pressure will not be displayed on the monitor). As the ForeSite PT™ system will continue to record interface pressure with the display turned off, this enables patients enrolled in the control group to undergo silent monitoring.
62573862|NCT02220036|ACTIVE_COMPARATOR|Magnesium Oxide|magnesium tablets, 250 milligram magnesium, 12 weeks, every day 1 tablet
62398804|NCT00516698||Group 1|"Patients undergo blood sample collection at baseline and at 1 year after initiation of aromatase inhibitor therapy (anastrozole or exemestane). Samples are analyzed for estrogen and testosterone levels and additional hormone levels and growth factors that have been previously linked with breast density and that could be altered by aromatase inhibitor use (i.e., sex hormone-binding globulin \[SHBG\], DHEA, DHEA sulfate, progesterone, prolactin, insulin-like growth factor-1 \[IGF-1\], and insulin-like growth factor binding protein 3 \[IGF BP3\]). Samples are also analyzed for anastrozole and exemestane levels by HPLC. Pharmacogenetic studies are also performed. Haplotype-tagged single nucleotide polymorphisms in genes in the aromatase pathway are examined.~Patients also undergo mammogram at baseline (≤ 6 months prior to study registration) and at 1 year after initiation of aromatase inhibitor therapy."
62398805|NCT05832073|EXPERIMENTAL|Experimental group|Natural full human monoclonal antibody CBB 1 injection：Each dose (2.5ml) contained 0.5 mg / natural monoclonal antibody ml CBB 1 Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection Character: colorless to pale green and yellow liquid Specification: 1.25 mg (2.5 ml) / bottle Mode of administration: intramuscular injection of the vastus lateralis muscle. Usage and dosage: The injection dose was calculated according to the group and body weight of the volunteer. On day 0, unilateral or bilateral extrafemoral muscle group injections were selected by dose, with no more than 5 mL at each site, and at least 2.5 cm apart.
62398806|NCT05832073|ACTIVE_COMPARATOR|Positive control group|"Rabies Human Immunoglobulin (HRIG) Active ingredient: Rabid human immunoglobulin Specification: 200 IU / 2 ml / bottle Administration mode: intramuscular injection of the vastus lateral muscle group.~Usage and dosage: the injection dose was calculated according to the body weight of the volunteer. On day 0, unilateral or bilateral extrafemoral muscle group injections were selected by dose, with no more than 5 mL at each site and at least 2.5 cm apart"
62573863|NCT02220036|PLACEBO_COMPARATOR|Placebo|Placebo tablets, the same in color, odor and appearance with magnesium tablets, 12 weeks, one tablet every day
62573864|NCT04167319||Paclitaxel|Patients scheduled to receive paclitaxel as part of their standard treatment
62782949|NCT01428167||Thyroidectomy|All patients undergoing thyroidectomy for a variety of indications.
62782950|NCT04861376|EXPERIMENTAL|Pueraria lobata group|Pueraria lobata will be made into granules.
62398807|NCT05832073|PLACEBO_COMPARATOR|Placebo group|Healthy people in placebo group will receive a dose of placebo
62195153|NCT02336425|PLACEBO_COMPARATOR|Placebo to QGE031|Placebo subcutaneous injection every 4 weeks
62195154|NCT05323019|OTHER|Intranasal (esketamine) Ketamine with Addition of Almond therapy|Intranasal (esketamine) Ketamine - Dose of 56mg for a maximum of 2 weeks, followed by 56 mg or 84mg twice a week for a total of 8 doses during the 28 day study.
62195155|NCT05323019|OTHER|Intranasal (esketamine) Ketamine with Treatment as Usual|Intranasal (esketamine) Ketamine - Dose of 56 mg for a maximum of 2 weeks, followed by 56mg or 84mg twice a week for a total of 8 doses during the 28 day study.
62195156|NCT05640492|EXPERIMENTAL|MCT Group|Older adults (more than 59 years old) with depressive symptoms
62782951|NCT04861376|EXPERIMENTAL|Pueraria thomsoni group|Pueraria thomsoni will be made into granules.
62782952|NCT04861376|PLACEBO_COMPARATOR|Placebo group|The dosage form, specifications and packaging of the placebo will be no different from those of Pueraria lobata and Pueraria thomsoni Granules, and the smell and taste will be basically the same.
62782953|NCT01600937|NO_INTERVENTION|Control|Standard care including physician recommendations for daily PA
62195157|NCT05640492|NO_INTERVENTION|Control Group|
62195158|NCT03859817||Patients with albuminuria|Comparison of eGFR values and ketonemia in diabetic patients
62195159|NCT03859817||patients with normo albuminuria|Comparison of eGFR values and ketonemia in diabetic patients
62195160|NCT00537342|EXPERIMENTAL|A|Biological Vaccine
62195161|NCT00537342|PLACEBO_COMPARATOR|B|
62195162|NCT02475304|EXPERIMENTAL|Experimental FP187|Treatment with a daily dose of 500mg FP187 (twice daily). Other names: Dimethyl fumarate
62782954|NCT01600937|EXPERIMENTAL|Exercise|Theoretical \& practical exercise counseling including 2 sessions/ per wk for 1 month of supervised exercise training
62782955|NCT01488201|EXPERIMENTAL|KHK4827|
62782956|NCT01488201|PLACEBO_COMPARATOR|Placebo|
62009311|NCT03393221|ACTIVE_COMPARATOR|SBWC|Participants randomized to the Standard Behavioral Weight Control (SBWC) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16. The intervention includes a dietary plan, a fitness plan, behavioral weight control management that includes self-monitoring, goal-setting, stimulus control strategies, and planning, as well as parental involvement.
62398808|NCT01077908|EXPERIMENTAL|ACT plus standard therapy|Adoptive Cellular Therapy (ACT) prepared using Multimer or Gamma Catch Selection in combination with standard best available antiviral drug therapy
62782957|NCT06223126||Oral Contraception-Starter|Women who start taking oral contraception
62782958|NCT06223126||Oral Contraception-Stopper|Women who stop taking oral contraception
62782959|NCT06223126||Oral Contraception-Long-Term User|Women who use oral contraception continuously
62782960|NCT00348309|EXPERIMENTAL|Arm 1|Rosiglitazone Extended Release 2mg OD
62782961|NCT00348309|EXPERIMENTAL|Arm 2|Rosiglitazone Extended Release 8mg OD
62782962|NCT00348309|PLACEBO_COMPARATOR|Arm 3|Placebo
62009312|NCT01587326|EXPERIMENTAL|Escitalopram|Escitalopram 10 mg/d to 20 mg/d
62782963|NCT01712425|EXPERIMENTAL|0-24 week prime/boost regimen (ARM A)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly, 0-24 week prime/boost regimen
62782964|NCT01712425|EXPERIMENTAL|0-8 week prime/boost regimen (ARM B)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly, 0-8 week prime/boost regimen
62009313|NCT01449903||Rebilda DC|
62009314|NCT01449903||Clearfil Core DC / Plus|
62009315|NCT01449903||Multicore Flow|
62009316|NCT04545242|ACTIVE_COMPARATOR|Dexamethasone (low dose)|Dexamethasone: 6 mg/iv/day during 10 days.
62009317|NCT04545242|ACTIVE_COMPARATOR|Dexamethasone (moderate dose)|Dexamethasone: 20 mg/iv/ daily from day of randomization (day 1) during 5 days, followed by 10 mg/iv/ daily from Day 6 to Day 10 of randomization.
62009318|NCT00861497|EXPERIMENTAL|Bifeprunox|
62782965|NCT01712425|NO_INTERVENTION|Arm A control (ARM C)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm A.
62782966|NCT01712425|NO_INTERVENTION|Arm B control (ARM D)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm B.
62782967|NCT04724967|EXPERIMENTAL|CeraVe Group|Participants in this group will receive the CeraVe Hydrating Cleanser and Moisturizing Cream for 28 days.
62782968|NCT03006874|EXPERIMENTAL|CJ-12420 50mg QD|CJ-12420 50mg tablet, once daily, oral administration for up to 8 weeks.
62782969|NCT03006874|EXPERIMENTAL|CJ-12420 100mg QD|CJ-12420 100mg tablet, once daily, oral administration for up to 8 weeks.
62782970|NCT03006874|ACTIVE_COMPARATOR|Esomeprazole 40mg|Esomeprazole 40mg, tablet. once daily, oral administration for up to 8 weeks.
62782971|NCT04638114|EXPERIMENTAL|CAM lesion|Mini-Open DAA Hip Arthroscopy
62782972|NCT04638114|OTHER|PINCER impingement|Mini-Open DAA Hip Arthroscopy
62195163|NCT02475304|PLACEBO_COMPARATOR|Placebo Comparator|Patients will receive the same number of tablets as patients randomized to FP187 arm in order to maintain the blind. The colour and shape of the FP187 and placebo tablets will be the same so that no visible difference is detectable
62195164|NCT00955708||Implants|Patients successfully implanted with the ACUITY Spiral Lead
62195165|NCT01425905|EXPERIMENTAL|Depression Prevention|
62782973|NCT03274856|OTHER|Treatment Sequence 1|GLWL-01 (450mg) twice a day/ Placebo
62009319|NCT03556631|EXPERIMENTAL|probiotics group|live combined Bifidobacterium and Lactobacillus tablets were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months
62009320|NCT03556631|PLACEBO_COMPARATOR|placebo group|placebo were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months
62009321|NCT06002763||Vaginal delivery|Patients who have vaginal deliveries with neuraxial labour analgesia.
62009322|NCT06002763||Cesarean delivery|Patients who have a scheduled cesarean delivery with neuraxial anesthesia.
62009323|NCT04483804||disease free survival|Time from randomization to relapse or death due to disease progression
62398809|NCT01077908|ACTIVE_COMPARATOR|Best available antiviral drug therapy|
62398810|NCT06031948|EXPERIMENTAL|DLPFC group|Active iTBS will be delivered to the left DLPFC.
62398811|NCT06031948|EXPERIMENTAL|DMPFC group|Active iTBS will be delivered to the left DMPFC.
62782974|NCT03274856|OTHER|Treatment Sequence 2|Placebo / GLWL-01 (450mg), twice a day
62782975|NCT02415270|EXPERIMENTAL|Reduced Nicotine Cigarettes|Participants will be randomized to receive low nicotine cigarettes to replace their usual high nicotine brand.
62782976|NCT02415270|EXPERIMENTAL|Reduced ROS/RNS|Participants will be randomized to receive Reduced Oxidative/Nitrogen Species (ROS/RNS) cigarettes to replace their usual cigarettes.
62782977|NCT02415270|PLACEBO_COMPARATOR|Control Group|Participants will be assigned to continue smoking their usual brand of cigarettes.
62782978|NCT04934644|EXPERIMENTAL|Hyperbaric oxygen treatment|30 HBO treatments and standard care. If surgery is needed an additional 10 HBO treatments postoperative.
62782979|NCT04934644|NO_INTERVENTION|Control|Standard care. Surgery if needed.
62009324|NCT04483804||non-disease free survival|Time of metastasis or death
62009325|NCT00066196|OTHER|2|Integrin + Dacarbazine
62009326|NCT00066196|ACTIVE_COMPARATOR|1|MEDI-522
62009327|NCT05843877|EXPERIMENTAL|Experimental Therapy|Total pancreatectomy with autologous islet cell transplantation
62009328|NCT05843877|OTHER|Standard Therapy|Pancreaticoduodenectomy (classic Whipple or pylorus-preserving)
62009329|NCT04491630|ACTIVE_COMPARATOR|Self-Hypnosis (SH)|
62195166|NCT01425905|ACTIVE_COMPARATOR|Health Education|
62214963|NCT03851718|EXPERIMENTAL|Acupuncture Procedure|Acupuncture is a type of Traditional Chinese Medicine (TCM) therapeutic approaches involving the insertion and manipulation of fine needles in specific points. Mothers in acupuncture group will be given three standardized sessions of acupuncture within 5 weekdays, preferably on 3 consecutive days.
62398812|NCT06031948|SHAM_COMPARATOR|Sham to DLPFC group|Sham iTBS will be delivered to the left DLPFC.
62398813|NCT06031948|SHAM_COMPARATOR|Sham to DMPFC group|Sham iTBS will be delivered to the left DMPFC.
62398814|NCT04725864|NO_INTERVENTION|No progesterone|Patients will have FET in natural cycles with no extra intervention.
62398815|NCT04725864|EXPERIMENTAL|Progesterone for 3 weeks|At day LH+3 patients will start treatment with vaginal progesterone tablet at 100mg three times daily for three weeks.
62398816|NCT04725864|EXPERIMENTAL|Progesterone for 7 weeks|At day LH+3 patients will start treatment with vaginal progesterone tablet at 100mg three times daily for seven weeks.
62398817|NCT06612645|EXPERIMENTAL|B7H3/IL-7Ra CAR T cell in Solid tumors|B7H3-specific chimeric antigen receptor (CAR) T cell with additional of IL-7Ra signaling domain Dose level: 1x10e6 cells/kg, 3x10e6 cells/kg, 10x10e6 cells/kg
62782980|NCT03129360|EXPERIMENTAL|Levetiracetam 185 mg|A single dose of 185mg of levetiracetam administered orally to participants. Participants undergo a 15-minute MRI scan using arterial spin labeling (ASL) before dosing and two hours post-dosing.
62782981|NCT03129360|EXPERIMENTAL|Levetiracetam 500mg|A single dose of 500mg of levetiracetam administered orally to participants. Participants undergo a 15-minute MRI scan using arterial spin labeling (ASL) before dosing and two hours post-dosing.
62009330|NCT04491630|ACTIVE_COMPARATOR|Mindfulness meditation (MM)|
62009331|NCT04491630|ACTIVE_COMPARATOR|Christian prayer (CP)|
62009332|NCT04491630|NO_INTERVENTION|Control condition (CN)|Participants in the CN condition will not be instructed to use any particular coping strategy to cope with the painful stimulation provided by the Cold Pressor Arm Wrap. Participants in the CN condition will listen to a 20-minute natural history audio recording. The option for this recording is supported by: (a) previous research showing that individuals who were asked to listen to it found it to be a neutral, yet relaxing, passage; (b) the use of this passage as an effective control condition in previous studies.
62009333|NCT02002897|EXPERIMENTAL|Fractional carbon dioxide laser|Single session of fractional laser is done using DEKA machine , for 3 months .
62782982|NCT03129360|PLACEBO_COMPARATOR|Placebo|A single dose of placebo administered orally to participants. Participants undergo a 15-minute MRI scan using arterial spin labeling (ASL) before dosing and two hours post-dosing.
62782983|NCT06407531|EXPERIMENTAL|VR-G|The patient will wear virtual glasses and watch a video 30 minutes before the procedure.
62782984|NCT06407531|NO_INTERVENTION|Control|No intervention will be performed on control group patients and the standard care protocol of the clinic will be applied.
62009334|NCT02002897|ACTIVE_COMPARATOR|Ultraviolet A1 phototherapy (UVA1)|24 sessions of UVA 1 phototherapy are give at a rate of 3 sessions per week , at a dose of 30 joules using a Waldman targeted machine.
62009335|NCT05102994||VRL patients group|Presenting clinical features suggestive for VRL with positive finding in laboratory exam
62009336|NCT05102994||uveitis group|Even if characterized as clinical features of presumed VRL, no positive laboratory investigations for lymphoma and well response to IMT
62009337|NCT04852094||Parents|parents of hospitalized children, speaking and understanding enough French, not presenting psychiatric disorders, voluntary to participate in focus groups
62195167|NCT05518474|EXPERIMENTAL|Self-proning|"Participants assigned to the intervention arm will receive a SMS link to a PDF containing instructions on proning/repositioning and information about its physiological benefits. They'll also receive a PDF with standard recommendations for treating COVID-19 at home. Participants will be encouraged to lie flat on their belly, on their side, or sit upright and rotate between these positions when lying down during the day and night. Participants will be sent a daily SMS proning reminder and asked to complete a secure REDCap survey regarding their proning activity. They'll be advised to prone and reposition for seven days minimum whenever they are lying down. Participants who have failed to reach their functional baseline after this time period will be advised to continue doing so. Follow up assessment by telephone will be conducted in 7 day increments from baseline up to 28 days."
62195168|NCT05518474|NO_INTERVENTION|Standard care|Participants assigned to the comparator arm will receive a SMS link to a PDF with standard recommendations for treating COVID-19 at home. This includes antipyretics and analgesics for fever, myalgias, and headaches; hydration; and rest with advancement of activity as soon as tolerated. Follow up assessment by telephone will be conducted in 7 day increments from baseline up to 28 days.
62195169|NCT06113588||Retrospective cohort|Patients with type 1 diabetes mellitus known to Royal North Shore Hospital, who underwent transition from paediatric to adult health care from 1st January 2020-8th June 2023
62195170|NCT06113588||Prospective cohort|Patients with type 1 diabetes mellitus known to Royal North Shore Hospital, undergoing transition from paediatric to adult health care, from 9th June 2023 onwards
62195171|NCT06432244||Number of central lymph node dissection|By exploring the relationship between the number of lymph nodes in the central region of the thyroid gland and parathyroid function, evaluate the effectiveness of different surgical procedures and intraoperative protective measures on parathyroid function protection.
62195172|NCT00847522|EXPERIMENTAL|All patients|All participants enrolled.
62195173|NCT04266015|NO_INTERVENTION|Control group|Patients assigned to control group will not receive feeding via the nasogastric tube during operation
62398818|NCT04948697|EXPERIMENTAL|Arm A: ociperlimab + tislelizumab + BAT1706|tislelizumab 200 mg intravenously once every 3 weeks followed by BAT1706 15 mg/kg intravenously once every 3 weeks followed by ociperlimab 900 mg intravenously once every 3 weeks
62009338|NCT04852094||Professionals|Nurses, assistant nurses, psychologist, physiotherapist, physicians, residents and fellows
62009339|NCT02565381|ACTIVE_COMPARATOR|Control (N=25)|"* Transdermal nicotine patch~* In-person smoking cessation counseling"
62009340|NCT02565381|EXPERIMENTAL|Financial rewards (N=25)|"* Transdermal nicotine patch~* In-person smoking cessation counseling~* Contingent financial rewards for smoking abstinence"
62009341|NCT02565381|EXPERIMENTAL|Text messaging (N=25)|"* Transdermal nicotine patch~* In-person smoking cessation counseling~* Text messages to support smoking abstinence"
62195174|NCT04266015|EXPERIMENTAL|Intraoperative feeding group|Patients assigned to intraoperative feeding group will receive enteral nutrition formula via the nasogastric tube during operation
62195175|NCT01511263|ACTIVE_COMPARATOR|Arm A|The patients will be divided into 4 strata according to cardiac dysfunction and to the quality of hematologic response. After stratification the patients will be randomized (1:1) within each stratum to receive Standard Therapy alone (Arm A) or Standard Therapy plus Investigational Drug (Arm B).
62195176|NCT01511263|EXPERIMENTAL|Arm B|The patients will be divided into 4 strata according to cardiac dysfunction and to the quality of hematologic response. After stratification the patients will be randomized (1:1) within each stratum to receive Standard Therapy alone (Arm A) or Standard Therapy plus Investigational Drug (Arm B)
62195177|NCT01349452|EXPERIMENTAL|Ganciclovir|
62195178|NCT01349452|SHAM_COMPARATOR|Artificial tear|
62573865|NCT04167319||Oxaliplatin|Patients scheduled to receive oxaliplatin as part of their standard treatment
62195179|NCT05893992|EXPERIMENTAL|Hearing loss|All participants will have hearing loss and be assigned to all three interventions. The interventions consist of aided-omnidirectional, aided-directional, and no hearing aids (no intervention).
62573866|NCT03950830|EXPERIMENTAL|Treatment arm|Cisplatin 50mg/m2 day 1 and 2, every 3 weeks, Disulfiram 400mg daily, continuously
62195180|NCT02981927|NO_INTERVENTION|Control|24 h habitual physical activity fed in energy balance
62195181|NCT02981927|EXPERIMENTAL|Bed rest matched diet|24 hour period of whole body bed-rest with a matched diet
62009342|NCT02181231|EXPERIMENTAL|venlafaxine plus buprenorphine|Drug: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 MRI sessions may occur before and during randomization.
62195182|NCT02981927|EXPERIMENTAL|Bed rest balanced diet|24 hour period of whole body bed-rest fed in energy balance
62009343|NCT02181231|PLACEBO_COMPARATOR|venlafaxine XR plus placebo|Drug: venlafaxine XR plus placebo Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 MRI sessions may occur before and during randomization.
62009344|NCT05226962|ACTIVE_COMPARATOR|Ketone|An acute bout of exercise performed after the ingestion of a commercial ketone monoester supplement.
62009345|NCT05226962|PLACEBO_COMPARATOR|Control|An acute bout of exercise performed after the ingestion of a taste-matched placebo supplement.
62009346|NCT05591677|ACTIVE_COMPARATOR|Active iTBS + active DCS 50mg/day|Active iTBS (600 pulses), 5 days/week x 4 weeks + active DCS 50mg/day x 2 weeks, taken 2-hours prior to scheduled iTBS treatment.
62009347|NCT05591677|ACTIVE_COMPARATOR|Active iTBS + active DCS 100mg/day|Active iTBS (600 pulses), 5 days/week x 4 weeks + active DCS 100mg/day x 2 weeks, taken 2-hours prior to scheduled iTBS treatment.
62195183|NCT04041830|EXPERIMENTAL|NW (Normal Weight)|20 to 55 years old lean adults
62195184|NCT04041830|EXPERIMENTAL|OBESE|20 to 55 years old adults with obesity
62195185|NCT05261841||TYPE 2 DIABETES|Patients affected by type 2 diabetes
62398819|NCT04948697|EXPERIMENTAL|Arm B: tislelizumab + BAT1706|tislelizumab 200 mg intravenously once every 3 weeks followed by BAT1706 15 mg/kg intravenously once every 3 weeks
62398820|NCT06545708||Patients|This group consists of children and adolescents between the ages of 5 and 14, diagnosed with self-limited epilepsy with centrotemporal spikes by a medical professional (epileptologist or neurologist), and in the active phase of the disorder.
62398821|NCT06545708||Controls|This group consists of healthy individuals between 5 and 14 years old, with no history of epilepsy and/or other neurodevelopmental disorders.
62195186|NCT00399841|ACTIVE_COMPARATOR|1|Stimulation will occur at the T7 followed by T8 during the trial implant period
62195187|NCT00399841|ACTIVE_COMPARATOR|2|Stimulation will occur at the T8 followed by T7 during the trial implant period
62195188|NCT03030313|EXPERIMENTAL|Respiration rate monitoring|Reassure Non-Contact Respiration Monitor
62195189|NCT03504345|ACTIVE_COMPARATOR|Control Group|This arm of the study will have their frozen-thawed embryo transfer take place on the sixth day of progesterone supplementation (Prometrium), which is the standard protocol in our clinic.
62195190|NCT03504345|EXPERIMENTAL|Experimental Group|This arm of the study will have their frozen-thawed embryo transfer take place on the seventh day of progesterone supplementation (Prometrium).
62195191|NCT05215691||Group I (n=45, TAPA)|The patients who received TAPA block for postoperative analgesia are named as a Group I ( n=45). The TAPA block is performed at the rib margin where the 9th and 10th ribs meet. A linear transducer is placed at the costochondral angle in the sagittal plane. It is carried out by injecting 20 ml of Bupivacaine %0.200 between the upper and lower surface of the chondrium. All patients receive IV PCA with morphine 0.5 mg/ml.
62398822|NCT00881374|EXPERIMENTAL|Dermacyd Infantile (Lactic Acid)|six weeks treatment
62398823|NCT05140109|EXPERIMENTAL|Cognitive-dissonance based program|Group program of 8 sessions of one hour and a half.
62573867|NCT03870269|EXPERIMENTAL|Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
62573868|NCT03870269|NO_INTERVENTION|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
62734652|NCT01966354|EXPERIMENTAL|Long axis, in-plane needle|"Ultrasound-guided Internal jugular venous approach~Long axis, in-plane needle:~Jugular vein is ultrasonographically visualized in a longitudinal fashion (long axis) and the needle is inserted in the same ultrasound plane, aligned with the longitudinal axis of the transducer."
62782985|NCT00544791|EXPERIMENTAL|A|melatonin 5 mg, daily dose for 6 months
62009348|NCT05591677|PLACEBO_COMPARATOR|Active iTBS + placebo|Active iTBS (600 pulses), 5 days/week x 4 weeks + placebo x 2 weeks, taken 2-hours prior to scheduled iTBS treatment.
62009349|NCT01422070||Patients admitted to the Study Units|Consecutive adult patients consecutively admitted to the Study Units during one month (either from 7th November to 4th December 2010, or from 16th January to 12th February 2012)
62009350|NCT05105503||Adults with AVFs currently in the process of maturing|Adults with ESRD who currently have a maturing AVF that has not yet been cannulated
62398824|NCT05140109|ACTIVE_COMPARATOR|Mindfulness-based program|Group program of 8 sessions of one hour and a half.
62573869|NCT02525120|EXPERIMENTAL|Triojection System for ozone injection|Triojection is a system including a single-use sterile syringe cartridge and an accessory console. The console is interfaced to a supply of medical oxygen and uses this supply to fill the syringe with oxygen. Ozone is produced by applying a high voltage to electrodes physically located within the syringe. When a concentration of 35µg/ml is reached, the cartridge is removed from the console. The sterile syringe, containing the gas, is extracted from the protective housing and the gas is administered directly to the center of the herniated disc through a spinal needle.
62573870|NCT02525120|ACTIVE_COMPARATOR|Surgical discectomy|The surgical group will be receive a standard surgical discectomy to remove the herniated disc material.
62573871|NCT04521179|EXPERIMENTAL|KN026 combined with KN046|KN026 combination therapy
62573872|NCT02608216|EXPERIMENTAL|FLT PET/CT|All subjects will receive an \[18F\]FLT PET/CT scan.
62573873|NCT01226784|ACTIVE_COMPARATOR|Physcial exercise|15 weeks of progressive resistance group exercise, twice/week supervised by physical therapist
62573874|NCT01226784|ACTIVE_COMPARATOR|Relaxation exercise|15 weeks of relaxation exercise, twice/week supervised by physical therapist
62573875|NCT03248999|EXPERIMENTAL|Experimental|realization of a rectal swab or stool sample for all the résidents included in the study.
62573876|NCT05970510|EXPERIMENTAL|Toludesvenlafaxine Hydrochloride Sustained-release Tablets 80 mg group|orally once a day
62573877|NCT05970510|EXPERIMENTAL|Toludesvenlafaxine Hydrochloride Sustained-release Tablets 160 mg group|orally once a day
62573878|NCT05970510|SHAM_COMPARATOR|Placebo|orally once a day
62573879|NCT03358069||deep anesthetic state|technique of Anesthesia at the time of airway device removal
62573880|NCT03358069||awake|technique of Anesthesia at the time of airway device removal
62573881|NCT03358069||emergence time (clinical): min|The duration from the time of anesthestic medications stop and the time that patient spontaneously open their eyes
62573882|NCT03358069||Emergence time (entropy): min|time from Entropy value above 60 to 90
62573883|NCT02211209|PLACEBO_COMPARATOR|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 52 weeks.
62573884|NCT02211209|EXPERIMENTAL|Volanesorsen|Volanesorsen 300 mg administered subcutaneously once-weekly for 52 weeks.
62573885|NCT06409754|EXPERIMENTAL|Experimental Group|The experimental group will receive both the conventional physical and occupational therapy as well as the functional electrical stimulation therapy coupled to the brain-computer interface system.
62573886|NCT06409754|ACTIVE_COMPARATOR|Control Group|The control group will receive double conventional physical and occupational therapy to equalize the time dosages received by the experimental group.
62573887|NCT03146949|ACTIVE_COMPARATOR|Sorin Inspire Oxygenator|Sorin Inspire Oxygenator is used on the cardiopulmonary bypass machine
62573888|NCT03146949|ACTIVE_COMPARATOR|Medtronic Affinity Fusion Oxygenator|Medtronic Affinity Fusion Oxygenator is used on the cardiopulmonary bypass machine
62573889|NCT00389311|ACTIVE_COMPARATOR|Nonoxynol-9|Gynol-II, 2% N-9, 5 mL
62573890|NCT00389311|OTHER|Normosol-R|Normosol-R, 5 mL, single administration, negative control
62573891|NCT00389311|EXPERIMENTAL|Normosol with simulation, endoscopy and biopsy|Normosol-R, 5 mL following simulation, endoscopy and biopsy
62573892|NCT05912647|NO_INTERVENTION|Usual Care|
62782986|NCT00544791|PLACEBO_COMPARATOR|B|
62782987|NCT02147288|EXPERIMENTAL|Breast Recon with acellular dermal matrix (ADM) on NPWT|
62782988|NCT02147288|EXPERIMENTAL|Lipoabdominoplasty on NPWT|The Smith\&Nephew Renasys\*GO device connected to non-compressible drains will be applied to the lipoabdominoplasty patients enrolled in this arm.
62195192|NCT05215691||Group II (n=45, IV opioid)|The patients who did not prefer the block and preferred intravenous patient-controlled analgesia (PCA) are named as Group II (n=45). IV PCA is prepared with morphine 0.5 mg/ml.
62009351|NCT05430516||Families|Patients with confirmed SARS-Cov-2 infection and their household members of all ages can be enrolled in the study, if at least one household member is a child age under 18.
62009352|NCT05822011|ACTIVE_COMPARATOR|Erector spinae block|Under strict aseptic precautions, we will begin the scout scan with a high-frequency (6-12 MHz) linear US probe placed parasagitally in cephalocaudal orientation adjacent to C7 spinous process and the first rib will be identified with ultrasound. Then, we can directly count the ribs and come down to desired level of ribs or corresponding transverse process (the 8th thoracic spinous process). Once located, erector spinae and trapezius muscles will be identified overlying it. The skin will be infiltrated by 2 ml of lidocaine 1% subcutaneously and a 22- gauge, 80 mm needle (Stimuplex D, B-Braun, Germany) will be advanced in plane in the cranio-caudal direction. When the needle contacted the transverse process, 1 ml normal saline will be injected to confirm correct needle placement by visualizing the linear pattern of hydrodissection. After aspiration, 30 ml bupivacaine 0.25% will be injected.
62009353|NCT05822011|ACTIVE_COMPARATOR|Rhomboid intercostal block|While the patient in the sitting position, the 5th thoracic spinous process can be identified, a high-frequency (6-12 MHz) linear US probe will be placed in the sagittal plane medial to the medial border of the scapula and then rotated to be 1 to 2 cm medial to the medial scapular border. The plane between the rhomboid major and the intercostal muscles will be identified. 2 ml of lidocaine 1% subcutaneously and a 22- gauge, 80 mm needle (Stimuplex D, B-Braun, Germany) will be advanced in plane from a superomedial to an inferolateral direction then 15 ml of bupivacaine 0.25% will be administered (at the T5 level). Then the probe will be moved caudally and laterally to identify the tissue plane between the serratus anterior and the external intercostal muscle at the T8 level. The needle will be directed caudally and laterally beyond the inferior angle of the scapula. 15 ml of bupivacaine 0.25% will be administered.
62009354|NCT05822011|ACTIVE_COMPARATOR|Thoracic epidural analgesia|While the patient in the sitting position, the T7-T8 interspace can be identified. Then, skin infiltration with 2 ml of 1% lidocaine will be performed. Then, an 18-G Tuohy needle with a 20-G catheter (Perifix®, B.Braun, Germany) will be inserted through, and the epidural space will be located using the loss of resistance approach, then the patient will be given (5-10 mL) of bupivacaine 0.25% and rested into the supine position.
62009355|NCT06142916|EXPERIMENTAL|MHLS|
62195193|NCT03297502|EXPERIMENTAL|Pimecrolimus cream, 1%|
62195194|NCT03297502|ACTIVE_COMPARATOR|Elidel (pimecrolimus) cream 1%|
62195195|NCT03297502|PLACEBO_COMPARATOR|placebo|
62195196|NCT04855045|EXPERIMENTAL|Group 1 - open label|
62195197|NCT04855045|EXPERIMENTAL|Group 2 - open label|
62195198|NCT04855045|EXPERIMENTAL|Group 3: open label|
62398825|NCT05140109|ACTIVE_COMPARATOR|Person-centered program|Group program of 8 sessions of one hour and a half.
62573893|NCT05912647|EXPERIMENTAL|Medication Therapy Management (MTM)|
62009356|NCT06142916|ACTIVE_COMPARATOR|CONTROL GROUP|
62009357|NCT01208233|EXPERIMENTAL|1 mg PF-03049423|
62009358|NCT01208233|EXPERIMENTAL|3 mg of PF-03049423|
62009359|NCT01208233|EXPERIMENTAL|6 mg of PF-03049423|
62009360|NCT01208233|PLACEBO_COMPARATOR|Placebo|
62009361|NCT04613609|PLACEBO_COMPARATOR|Placebo|E-cigarette containing no nicotine.
62573894|NCT05912647|EXPERIMENTAL|Community Health Worker (CHW)|
62009362|NCT04613609|ACTIVE_COMPARATOR|Nicotine|E-cigarette containing nicotine
62195199|NCT04855045|EXPERIMENTAL|Group 4: double-masked, randomized to one of 2 dose cohorts|
62195200|NCT00837590|EXPERIMENTAL|Acute Salsalate|Nondiabetic lean and obese subjects will be studied in this arm. Subjects will be studied at baseline and after a single dose of oral salsalate.
62195201|NCT00837590|EXPERIMENTAL|Chronic Salsalate - Obese|Obese subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate.
62195202|NCT00837590|EXPERIMENTAL|Chronic Salsalate - Lean|Lean subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate. The effects of an acute fatty acid infusion on vascular function will be measured on both occasions.
62195203|NCT01499563|EXPERIMENTAL|ITI-007 Low Dose|
62195204|NCT01499563|EXPERIMENTAL|ITI-007 High Dose|
62195205|NCT01499563|PLACEBO_COMPARATOR|Placebo|
62195206|NCT01499563|ACTIVE_COMPARATOR|Risperidone|
62195207|NCT01383811|ACTIVE_COMPARATOR|Moderate Intensity Aerobic Exercise|
62195208|NCT01383811|OTHER|Wait List/Usual Care|The subjects in this group will continue to receive the usual treatment that they were on at the time of enrollment through the wait list period of 12 weeks. Subsequently they will receive the 12 weeks of aerobic exercise program intervention
62195209|NCT04586166|EXPERIMENTAL|RP Sling Group|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure
62573895|NCT05912647|EXPERIMENTAL|MTM + CHW|
62573896|NCT02275819|NO_INTERVENTION|control|Will not receive intervention with exercise
62195210|NCT04586166|EXPERIMENTAL|SIS Group|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure
62573897|NCT02275819|ACTIVE_COMPARATOR|Intervention group|2 groups will receive 2 different types of therapy (exercise or Inspiratory Muscle Therapy)
62573898|NCT03850470||Patients with Musculoskeletal Pain|Subjects reporting for care with complaints of musculoskeletal pain will be examined and a diagnosis and plan of care will be established. The accuracy of the clinical examination will be compared to pathology detected by MRI
62573899|NCT06188871|EXPERIMENTAL|Dupilumab|Two injections of 300mg dupilumab, subcutaneous 14 days apart
62573900|NCT06329856||members of the Taiwan Academy of Hospice Palliative Medicine|members of the Taiwan Academy of Hospice Palliative Medicine
62573901|NCT06329856||members of the Taiwan Society of Cancer Palliative Medicine|members of the Taiwan Society of Cancer Palliative Medicine
62009363|NCT04496258|EXPERIMENTAL|Positive VR Scene|Participants will explore a virtual reality (VR) environment of a beach scene. Participants will be randomly assigned (between subjects) to beach or office scene. VR will be presented on an Occulus Rift device.
62009364|NCT04496258|EXPERIMENTAL|Neutral VR Scene|Participants will explore a virtual reality (VR) environment of a neutral office scene. Participants will be randomly assigned (between subjects) to beach or office scene. VR will be presented on an Occulus Rift device.
62009365|NCT03844451|EXPERIMENTAL|Liposomal bupivicaine with nerve block|The treatment group will receive an intraoperative V2 trigeminal nerve block using liposomal bupivacaine in addition to a standard bupivacaine nerve block.
62009366|NCT03844451|PLACEBO_COMPARATOR|Nerve block only|The control group will undergo conventional perioperative management without an ERAS protocol and standard bupivacaine intraoperative nerve block.
62009367|NCT03556046|EXPERIMENTAL|89Zr-girentuximab|A single administration of 37 MBq (+/-10%) 89Zr-girentuximab, containing a mass dose of 5 mg of girentuximab
62195211|NCT06205147|EXPERIMENTAL|Short Falls Efficacy Scale International|The Short Falls Efficacy Scale International (Short FES-I) consists of 7 questions. Scores range from a minimum of 7 points (no fear of falling) to a maximum of 28 points (severe fear of falling). Scores of 7 to 8 points indicate low concern about falling, 9 to 13 points indicate moderate concern about falling, and 14 to 28 points indicate high concern about falling.
62782989|NCT02147288|EXPERIMENTAL|Abdominoplasty on NPWT|The Smith\&Nephew Renasys\*GO device connected to non-compressible drains will be applied to the abdominoplasty patients enrolled in this arm.
62782990|NCT02147288|EXPERIMENTAL|Ventral Hernia Repair (VHR) on NPWT|The Smith\&Nephew Renasys\*GO device connected to non-compressible drains will be applied to the VHR patients enrolled in this arm.
62009368|NCT05696197|EXPERIMENTAL|Experimental group|Practicing the Swipe Slide Pattern task in ST and DT conditions, offered in a random order over a period of 2 weeks, 5 days a week, approximately 10 minutes per training session. Training will be performed independently at home.
62009369|NCT05696197|NO_INTERVENTION|Control group|Participants in the control group will receive no intervention during the study period. They are given the opportunity to perform the SSP-training after the study period to ensure motivation in this group.
62009370|NCT05956314|EXPERIMENTAL|KM-001 cream 1% 12 weeks treatment.|"KM-001 1% cream will be applied to the affected area, twice daily for 12 consecutive weeks.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves."
62195212|NCT06205147|EXPERIMENTAL|Geriatric Depression Scale, GDS 15|"The assessment will be conducted within one week. Depressive symptoms in the elderly will be evaluated using a binary method, with answers of yes or no. Questions 1, 5, 7, 11, and 13 should be answered with no. Questions 2, 3, 4, 6, 8, 9, 10, 12, 14, and 15 should be answered with yes. Each yes response is assigned 1 point, resulting in a total score of 15 points. Scores ranging from 0 to 6 indicate good emotional adjustment, scores from 7 to 10 indicate moderate emotional distress, and scores above 11 indicate severe emotional distress."
62195213|NCT04129476|EXPERIMENTAL|Cooperative Education Program|We explore the effects of a cooperative education program based on precede-proceed model during pregnancy on preventing postpartum depression.
62195214|NCT04129476|NO_INTERVENTION|Control|We provide routine care for these people during pregnancy
62195215|NCT02836288|EXPERIMENTAL|Ketamine|Oral ketamine 1.0 mg/kg mixed with syrup
62195216|NCT02836288|PLACEBO_COMPARATOR|Placebo|Oral placebo (syrup)
62195217|NCT02836288|EXPERIMENTAL|Ketamine after placebo|Optional oral Ketamine 1.0 mg/kg mixed with syrup for patients on placebo arm after 12 week treatment is completed.
62195218|NCT02092532|OTHER|Intravitreal Aflibercept Injection|All patients will receive monthly IAI 2.0 mg intravitreally for 3 months (Baseline, Months 1 and 2), followed by mandatory IAI 2.0 mg every 2 months (Months 4, 6, 8 and 10) for 12 months.
62195219|NCT01560845|EXPERIMENTAL|ABMSCi plus surgery group|Autologous bone marrow stem cells infusion through hepatic artery in open abdominal portal hypertension surgery
62195220|NCT01560845|NO_INTERVENTION|portal hypertension surgery group|only portal hypertension surgery for this group patients
62782991|NCT02147288|EXPERIMENTAL|Panniculectomy on NPWT|The Smith\&Nephew Renasys\*GO device connected to non-compressible drains will be applied to the panniculectomy patients enrolled in this arm.
62195221|NCT00000331|EXPERIMENTAL|Test Drug|Test drug to prevent heroine withdrawal
62398826|NCT03045107|EXPERIMENTAL|Intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected and a side-to-side anastomosis is fashioned with a laparoscopic stapler.
62573902|NCT04059614|ACTIVE_COMPARATOR|"High flow nasal cannula (HFNC)"|"HFNC group: those who receive high-flow nasal cannula therapy"
62782992|NCT02147288|NO_INTERVENTION|Breast Recon with ADM on Jackson-Pratt (JP) Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
62009371|NCT05956314|EXPERIMENTAL|KM-001 cream 1% 16 weeks treatment.|"KM-001 1% cream will be applied to the affected area, twice daily for 16 consecutive weeks.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves."
62009372|NCT04875104|ACTIVE_COMPARATOR|Invisalign|Patients treated with Invisalign aligners
62009373|NCT04875104|EXPERIMENTAL|Spark|Patients treated with Spark aligners
62009374|NCT04875104|EXPERIMENTAL|Quicksmile|Patients treated with Quicksmile aligners
62009375|NCT04875104|EXPERIMENTAL|ClearCorrect|Patients treated with ClearCorrect aligners
62009376|NCT02251665||Acute ischemic stroke, acute ICH, TIA|Consecutive patients with acute ischemic stroke, intracerebral hemorrhage, and transient ischemic attack who are emergently managed in the stroke care unit or stroke units in the National Cerebral and Cardiovascular Center
62195222|NCT00000331|PLACEBO_COMPARATOR|Placebo Pill|Placebo drug
62782993|NCT02147288|NO_INTERVENTION|Abdominoplasty on JP Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
62782994|NCT02147288|NO_INTERVENTION|Lipoabdominoplasty on JP Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
62782995|NCT02147288|NO_INTERVENTION|Ventral Hernia Repair (VHR) on JP Drains|Standard of Care
62009377|NCT02648087|OTHER|With and without SDB|comparison of patients with and without sleep-disordered breathing
62195223|NCT03463499|EXPERIMENTAL|Hyaluronic Acid and Chondroitin Sulfate|Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.
62573903|NCT04059614|EXPERIMENTAL|conventional oxygen therapy (COT)|COT group: those who receive conventional oxygen therapy group
62573904|NCT04699318|EXPERIMENTAL|Single Dartos TIP|Single dartos tubularized incised plate urethroplasty
62573905|NCT04699318|EXPERIMENTAL|Double Dartos TIP|Double dartos tubularized incised plate urethroplasty
62573906|NCT05931042||Group recieving Trastuzumab + Chemotherapy|Two different treatment regimens of Trastuzumab were giving in the 9 studies Dosage of trastuzumab was 4 mg/kg loading dose followed by 2 mg/kg every 3 weeks in four clinical trials included in this systematic review Dosage of trastuzumab was 8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks in five clinical trials included in this systematic review The different chemotherapeutic agents given included Paclitaxel, docetaxel, fluorouracil, epirubicin, carboplatin, cyclophosphamide, methotrexate, and fluorouracil.
62573907|NCT05931042||Group receiving chemotherapy|Different neoadjuvant chemotherapy regimens were given in the nine clinical trials included in this systematic review. The different chemotherapeutic agents given included Paclitaxel, docetaxel, fluorouracil, epirubicin, carboplatin, cyclophosphamide, methotrexate, and fluorouracil.
62573908|NCT06576349|EXPERIMENTAL|CALM Hearts Self-Compassion Intervention for Women at Risk for Heart Disease|"The CALM Hearts intervention will be conducted individually (i.e., one facilitator meeting with one participant) over the phone or via Zoom videoconferencing once per week for three weeks.~Session 1 (90 minutes): Participants will learn about their CVD risk factors. The facilitator will introduce self-compassion as a tool for coping with CVD risk and adopting health behaviours. Participants will set a health behaviour goal to accomplish by intervention end.~Sessions 2 (60 minutes) and 3 (60 minutes each): Lesson, workbook activity, and discussion on applying self-compassion to health behaviours and CVD risk.~Participants will independently complete self-compassionate writing activities in their workbooks after Sessions 1 and 2."
62573909|NCT04758468|EXPERIMENTAL|Telerehabilitation-based pelvic floor muscle training|
62195224|NCT05772169|EXPERIMENTAL|Mifepristone 300 mg|Randomized to receive 300 mg mifepristone, titrated to 600 mg mifepristone after 4 weeks with an opportunity to increase to 900 mg mifepristone at week 8 or 12
62195225|NCT05772169|PLACEBO_COMPARATOR|Placebo|Patients who meet the entry criteria for the Study C-1073-310 will be randomized to receive placebo for 24 weeks
62195226|NCT06106542||stroke group|assessment of effect motor imagery on muscle oxygenation
62195227|NCT03708497|ACTIVE_COMPARATOR|carbetocin|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
62195228|NCT03708497|EXPERIMENTAL|Tranexamic acid plus misoprostol|1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
62573910|NCT04758468|ACTIVE_COMPARATOR|Home-based pelvic floor muscle training|
62573911|NCT04758468|NO_INTERVENTION|Control (no specific intervention)|
62195229|NCT03708497|ACTIVE_COMPARATOR|misoprostol|600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
62195230|NCT02887820|OTHER|Pilot Arm|All subjects enrolled in the trial will be in the pilot group. These subjects will have traditional laboratory coagulation and blood transfusion tests (baseline arterial blood gas (ABG), complete blood count (CBC), fibrinogen, platelet count, aPTT, PT, anti-Xa, ACT), as well as thromboelastograph (TEG). Pertinent TEG results will include: heparinase-kaolin TEG maximum amplitude (MA) in millimeters (mm), heparinase-kaolin TEG r-time in seconds, heparinase-kaolin TEG alpha angle in degrees, and TEG functional fibrinogen (FLEV) MA in mm.
62195231|NCT02932098|EXPERIMENTAL|App Notifications|The web-based app will be used to remind patients of discharge instructions, ask questions related to current prescription pain medication use, new symptoms, or changes in the severity of symptoms. Patients will receive reminders via text or email to use the app. Daily reminders will be sent in Week 1, every other day in Week 2, and once per week for Weeks 3-4. All participants will be followed for a minimum of 30 days and will be asked to complete a baseline survey at enrollment and a follow-up survey scheduled 30 days after hospital discharge.
62195232|NCT02932098|ACTIVE_COMPARATOR|Usual Care|Patients will have access to the web-based app, but will not receive reminders to use it. All participants will be followed for a minimum of 30 days and will be asked to complete a baseline survey at enrollment and a follow-up survey scheduled 30 days after hospital discharge.
62195233|NCT04288349|ACTIVE_COMPARATOR|epinephrine + ropivacaine +saline|1% epinephrine solution + 30 ml of 1% ropivacaine solution diluted with 20 ml of 0.9% saline for achievement a 0.75% anesthetic solution in a ratio of 1: 200 000
62398827|NCT03045107|ACTIVE_COMPARATOR|Extracorporeal ileocolic anastomosis|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. Then, a primary ileocolic side-to-side handsewn or mechanical anastomosis is fashioned extracorporeally.
62398828|NCT06087822|EXPERIMENTAL|IMD SiPore21®|IMD Class IIb Total daily dose: 3 stick packs (1 x 3 main meals) uration 12 weeks
62009378|NCT05819125||Conventional prophylaxis|Hospitalized obese participants with an acute medical condition or undergoing surgery, receiving conventional (i.e., 40 mg once daily for 7 days) enoxaparin VTE prophylaxis
62009379|NCT05819125||High dose prophylaxis|Hospitalized obese participants with an acute medical condition or undergoing surgery, receiving high dose enoxaparin for the conventional VTE prophylaxis duration
62009380|NCT05819125||Extended duration prophylaxis|Hospitalized obese participants with an acute medical condition or undergoing surgery, receiving the conventional enoxaparin dose for an extended VTE prophylaxis duration
62782996|NCT02147288|NO_INTERVENTION|Panniculectomy on JP Drains|Standard of care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
62009381|NCT05819125||High dose and extended duration prophylaxis|Hospitalized obese participants with an acute medical condition or undergoing surgery, receiving high dose enoxaparin for an extended VTE prophylaxis duration
62009382|NCT00550836|ACTIVE_COMPARATOR|Arm A: GE|Patients receive 1000 mg/m\^2 gemcitabine hydrochloride IV on days 1, 8, and 15; and 100 mg oral erlotinib hydrochloride on days 1-28. Treatment repeats every 28 days for 2 courses. Patients achieving a complete response (CR) after 2 courses receive 2 additional courses of treatment; patients achieving a partial response (PR) receive retreatment as above. Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride and erlotinib hydrochloride until second progression.
62782997|NCT05914207|EXPERIMENTAL|Vestibular Migraine group|Written, verbal and pictorial descriptions will be provided for each participant regarding lifestyle modifications and vestibular rehabilitation exercise
62782998|NCT02038075|EXPERIMENTAL|Brief Cognitive Behavioral Therapy (BCBT)|In addition to TAU, participants in BCBT receive 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. BCBT was is delivered in three sequential phases. In phase I (5 sessions), the therapist identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
62782999|NCT02038075|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Participants in TAU receive usual care from military clinicians as well as non-military clinicians from the local community, as determined by participants' primary mental health care provider. All mental health, substance abuse, and medical treatment are provided within the military health care system at no cost to participants.
62783000|NCT03515096|EXPERIMENTAL|Eltrombopag|Thrombopoietin- receptor (TPO-R) agonist
62783001|NCT03515096|PLACEBO_COMPARATOR|rhTPO|Recombinant human thrombopoietin (rhTPO)
62195234|NCT04288349|PLACEBO_COMPARATOR|epinephrine + saline|1% epinephrine solution + 50 ml of 0.9% saline in a ratio of 1: 200 000.
62398829|NCT06087822|PLACEBO_COMPARATOR|Placebo Comparator|Placebo Total daily dose: 3 stick packs (1 x 3 main meals) duration 12 weeks
62398830|NCT04271111|EXPERIMENTAL|Active treatment|Computerized intervention aimed at reducing perceived hostility.
62398831|NCT04271111|ACTIVE_COMPARATOR|Control condition|Computerized intervention aimed at increasing overall physical health.
62783002|NCT03779815|EXPERIMENTAL|[18F]Florbetaben PET/CT imaging|"* Maximally 18 subjects with multiple myeloma (up to 6 subjects in whom amyloidosis in suspected and up to 12 subjects in whom amyloidosis is not suspected)~* Intravenous injection of \[18F\]Florbetaben and PET/CT scanning~* Intervention: Drug (\[18F\]Florbetaben)"
62009383|NCT00550836|EXPERIMENTAL|Arm B: PGE|Patients receive 1000 mg/m\^2 gemcitabine hydrochloride IV on days 1, 8, and 15; 100 mg oral erlotinib hydrochloride on days 1 - 28; and 4.0 mg/kg panitumumab IV on days 1 and 15. Treatment repeats every 28 days for 2 courses. Patients achieving a CR after 2 courses receive 2 additional courses of treatment; patients achieving a PR receive retreatment as above. Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride and panitumumab until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride, erlotinib hydrochloride, and panitumumab until second progression.
62009384|NCT01494233|EXPERIMENTAL|Low dose|500 mg LX1033 two times daily
62009385|NCT01494233|EXPERIMENTAL|Mid dose|500 mg LX1033 three times daily
62009386|NCT01494233|EXPERIMENTAL|High dose|1000 mg LX1033 two times daily
62009387|NCT01494233|PLACEBO_COMPARATOR|Placebo|Matching placebo dosing
62009388|NCT00110266|EXPERIMENTAL|ICL670|Evaluate the safety and tolerability of deferasirox 20 mg/kg/day over one year in patients with MDS
62398832|NCT03773354|EXPERIMENTAL|Intervention|There is no control group for this study, and all participants receive the intervention. Although a few participants will be asked to give additional information during the intake and after the study concludes for quality improvement purposes. Effects of these additional interview questions will be considered during analysis
62783003|NCT02772185|EXPERIMENTAL|active tDCS plus real CT|Participants will receive active transcranial direct current stimulation and real cognitive training.
62783004|NCT02772185|EXPERIMENTAL|sham tDCS plus real CT|Participants will receive sham transcranial direct current stimulation and real cognitive training.
62783005|NCT02772185|EXPERIMENTAL|active tDCS plus placebo CT|Participants will receive active transcranial direct current stimulation and placebo cognitive training.
62783006|NCT02772185|PLACEBO_COMPARATOR|sham tDCS plus placebo CT|Participants will receive sham transcranial direct current stimulation and placebo cognitive training.
62009389|NCT05002946|EXPERIMENTAL|A: SP-104 Fasting|Oral administration of SP-104 under fasting conditions
62009390|NCT05002946|EXPERIMENTAL|B: SP-104 Under Fed Conditions|Oral administration of SP-104 under fed conditions
62009391|NCT05002946|ACTIVE_COMPARATOR|Naltrexone Hydrochloride Tablets Fasting|Oral administration of Naltrexone Hydrochloride Tablets, 50 mg USP under fasting
62573912|NCT01935726||Pulmonary fibrosis patients or their caretaker/supporter|Patients with pulmonary fibrosis of any cause (idiopathic, related to connective tissue disease \[e.g., rheumatoid arthritis, systemic sclerosis/scleroderma, dermato-/polymyositis, sjogren's syndrome\], familial or genetic) or the primary supporter/caregiver of a patient with pulmonary fibrosis
62573913|NCT05770141|OTHER|LHP GROUP|patients received Laser Hemorrhoidoplasty procedure
62009392|NCT00782652|ACTIVE_COMPARATOR|1|inhaled nitric oxide at 40 or 80ppm
62009393|NCT00782652|PLACEBO_COMPARATOR|2|inhaled nitrogen at either 40 or 80ppm
62009394|NCT02905305|EXPERIMENTAL|CA with dexamethasone base|Contour Advance electrode with controlled dose of dexamethasone base
62009395|NCT02905305|ACTIVE_COMPARATOR|Contour Advance|Standard Contour Advance electrode array
62573914|NCT05770141|OTHER|MM GROUP|patients received conventional open surgical hemorrhoidectomy
62573915|NCT02741726|EXPERIMENTAL|dual acupoint stimulation|The acupoints of dual point group are bilateral Neiguan points(PC6) combined with Danzhong point(RN17), electric stimulation was given through electrode attached to the acupoints.
62195235|NCT02902159|EXPERIMENTAL|BWW|Free access to online peer support through BWW for 6 months
62195236|NCT02902159|EXPERIMENTAL|MZ|Access to NHS Moodzone Information Only
62573916|NCT02741726|EXPERIMENTAL|single acupoint stimulation|The acupoints of single point group is bilateral Neiguan points(PC6), Electric stimulation was given through electrode attached to the acupoints.
62573917|NCT02741726|PLACEBO_COMPARATOR|no stimulation|false stimulation group only attach electrodes without electric current.
62783007|NCT03392649|NO_INTERVENTION|Sham Group|At the end of cardiac surgery, the Parasym alligator clip was placed on the subject's tragus, but the Parasym was not turned on and the subject did not receive any stimulation. The clip was switched to the other ear every 4 hours for a total of 48 hours.
62573918|NCT05353257|EXPERIMENTAL|Serplulimab + carboplatin/cisplatin-etoposide + radiotherapy|Participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) plus Serplulimab 300 mg every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy, with maximum 1 year after completion of cCRT or until disease progression, intolerable toxicity or other reasons specified in the protocol, whichever occurs first.
62783008|NCT03392649|EXPERIMENTAL|Stimulation Group|At the end of cardiac surgery, the Parasym alligator clip was placed on the subject's tragus, and the subject received continuous stimulation for 48 hours. The clip was switched to the other ear every 4 hours.
62783009|NCT05191875|EXPERIMENTAL|group 1 of stage I|14-day therapy：Saccharomyces boulardii. 500mg b.i.d
62783010|NCT05191875|NO_INTERVENTION|group 2 of stage I|Observe for one month before treatment
62783011|NCT05191875|OTHER|stage 2|14-day therapy：Ilaprazole. 5mg b.i.d Doxycycline. 0.1g b.i.d Furazolidone. 0.1g b.i.d Colloidal Bismuth Tartrate . 220mg b.i.d
62783012|NCT06584500|EXPERIMENTAL|E Group|Experimental group which receives real dry needling
62783013|NCT06584500|SHAM_COMPARATOR|C Group|Control group which receives sham dry needling
62783014|NCT06145347||Acute kidney injury group|Patients developed acute kidney injury.
62783015|NCT06145347||Non-Acute kidney injury group|Patients didn't develope acute kidney injury.
62783016|NCT03098225|EXPERIMENTAL|Radiotherapy|Patients with moderately severe GO treated with Intravenous glucocorticoids associated with orbital radiotherapy
62783017|NCT03098225|ACTIVE_COMPARATOR|No Radiotherapy|Patients with moderately severe GO treated with Intravenous glucocorticoids alone
62783018|NCT06204081|EXPERIMENTAL|persons with Parkinson's Disease, Hoehn & Yahr stage 4, FOG|This group tests first without the use of cues (CSO evaluates gait pattern, but does not adjust), and then with cues.
62009396|NCT02105077||Xenon|Patients undergoing surgery with xenon-based general anesthesia
62009397|NCT04711304|EXPERIMENTAL|Wharton's Jelly|Intraarticular injection of Wharton's Jelly
62009398|NCT04711304|ACTIVE_COMPARATOR|Hyaluronic Acid|Intraarticular injection of Hyaluronic Acid
62009399|NCT04711304|PLACEBO_COMPARATOR|Saline|Intraarticular injection of Saline
62009400|NCT06165744|EXPERIMENTAL|UNITY VCS|Eye surgery performed with UNITY VCS
62009401|NCT02628275|NO_INTERVENTION|Control|Continued inactivity
62009402|NCT02628275|ACTIVE_COMPARATOR|Moderate to vigorous physical activity|MVPA (55-90% of maximum heart rate) for 150 min/week (current recommendations)
62009403|NCT02628275|ACTIVE_COMPARATOR|Light physical activity|LPA (40-55% of maximum heart rate) for 150 min/week
62009404|NCT05732285|EXPERIMENTAL|CRT plus CBT and Lifestyle modifications|
62009405|NCT05732285|ACTIVE_COMPARATOR|Usual care|
62195237|NCT03924115|EXPERIMENTAL|Group Total|This group of patients was chosen at random. They are patients who receive the full PST as intervention, that is, they receive a Smartphone with the AFAM-Health application with all the contents of the PST and data plan for 1 year.
62195238|NCT03924115|EXPERIMENTAL|Group Partial|This group of patients was chosen at random under the criteria of parity with group A. They are patients who receive partial PST as intervention, that is, they only receive video capsules reproduced in the CESFAM waiting room as educational content.
62195239|NCT03924115|NO_INTERVENTION|Group Control|This group of patients is the control group, that is, they do not receive any type of intervention additional to the one they already receive from their CESFAM.
62398833|NCT06724627|OTHER|Standard of care|Standard of care
62783019|NCT00356343|EXPERIMENTAL|NMES Strengthening Group|Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
62783020|NCT00356343|NO_INTERVENTION|Control Group|No Intervention Control Group
62783021|NCT00356343|ACTIVE_COMPARATOR|Volitional Strengthening|Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
62783022|NCT06169111|EXPERIMENTAL|Autism Spectrum Disorders (ASD) patients with Maternal Immune Activation (MIA)|
62783023|NCT06169111|ACTIVE_COMPARATOR|Autism Spectrum Disorders (ASD) patients without Maternal Immune Activation (MIA)|
62009406|NCT05154903|ACTIVE_COMPARATOR|Citicoline|the Citicoline group will receive citicoline in continuous Iv infusion in a dose of 2000 mg per day for the first week following AIS then by oral route for the next 5 weeks
62009407|NCT05154903|NO_INTERVENTION|control|the control group will not receive citicoline
62009408|NCT02118233||Carotid Endarterectomy (CEA)|Surgical Revascularization- Carotid Endarterectomy (CEA)
62783024|NCT03188510|EXPERIMENTAL|Reference: 250 mg LY3074828|250 mg LY3074828 lyophilized formulation administered subcutaneously (SC) as 3 injections
62783025|NCT03188510|EXPERIMENTAL|Test 1: 250 mg LY3074828|250 mg LY3074828 solution formulation administered as SC injections in two prefilled syringes
62783026|NCT03188510|EXPERIMENTAL|Test 2: 500 mg LY3074828|500 mg LY3074828 solution formulation administered as SC injections in four prefilled syringes
62783027|NCT04138680|EXPERIMENTAL|Active Biofeedback|The patients in the active group will receive one active biofeedback training session.
62783028|NCT04138680|SHAM_COMPARATOR|Sham Biofeedback|The patients in the sham group will receive one sham biofeedback training session.
62783029|NCT00089466|EXPERIMENTAL|A|200 mg AMD11070 every 12 hours
62783030|NCT00089466|EXPERIMENTAL|B|400 mg AMD11070 every 12 hours
62783031|NCT00089466|EXPERIMENTAL|C|600 mg AMD11070 every 12 hours
62009409|NCT02118233||Carotid Angioplasty and Stenting (CAS)|Surgical Revascularization- Carotid Angioplasty and Stenting (CAS)
62009410|NCT02118233||Control Group- Medical Management|Control Group- Medical Management
62573919|NCT05353257|PLACEBO_COMPARATOR|placebo + carboplatin/cisplatin-etoposide + radiotherapy|Participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) plus placebo every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy, with maximum 1 year after completion of cCRT or until disease progression, intolerable toxicity or other reasons specified in the protocol, whichever occurs first.
62573920|NCT06154824|EXPERIMENTAL|1st pruritogen|The study takes place over two sessions over a period of 7 days. The duration of the sessions is approx. 4 hours in total. In the 1st session, a squared area of 4x4 cm will be selected at the center of each middle forearm of the subject. The two areas will be randomly treated with one of the following substances: cowhage, histamine, BAM 8-22 or vehicle. Each substance will be applied for 10 minutes, during which the pain/itch following the substance application will be monitored. Twenty minutes after each application, the measurements with FLPI will be conducted. Then the measurements of alloknesis and mechanically evoked itch, will be conducted. This procedure will be repeated three times for each substance; so in total each substance will be applied three times, each application lasting 10 minutes.
62783032|NCT00089466|EXPERIMENTAL|D|800 mg AMD11070 every 12 hours
62783033|NCT00089466|EXPERIMENTAL|E|1000 mg AMD11070 daily
62783034|NCT00089466|EXPERIMENTAL|F|1500 mg AMD11070 daily
62783035|NCT00089466|EXPERIMENTAL|G|1000 mg AMD11070 every 12 hours
62783036|NCT00089466|EXPERIMENTAL|H|2000 mg AMD11070 daily
62009411|NCT05580718|EXPERIMENTAL|Online CBT targeting cardiac anxiety|CBT for MI primarily targets two processes of MI-related disability: fear of cardiac-related symptoms avoidance behavior and physical inactivity. The CBT is therapist-guided and lasts for 8 weeks.
62195240|NCT05808296|EXPERIMENTAL|Experiment|aromatherapy will be performed by dropping 2 drops of lavender oil on the shoulder with a sponge 20 minutes before bedtime every night for a week
62195241|NCT05808296|SHAM_COMPARATOR|Control|Saline solution will be performed by dropping 2 drops of saline solution on the shoulder with a sponge 20 minutes before bedtime every night for a week
62195242|NCT03530137|OTHER|families living at Families Moving Forward (FMF)|
62783037|NCT06206915|EXPERIMENTAL|XZ120 monotherapy|
62783038|NCT04179253|OTHER|Unexplained infertility|"The patient was placed in the dorsal lithotomy position. Normal saline was used for uterine distension connected to the inflow channel on the sheath with intravenous tubing. The tip of the hysteroscope was positioned in the vaginal introitus, the labia being slightly separated with fingers. The vagina was distended with saline.~The uterine cavity was systematically explored by rotating the fore-oblique scope in order to identify any anomaly in the uterine walls and/or the right and left tubal ostia. At this stage it was crucially important to avoid lateral movements as much as possible to reduce patient discomfort to a minimum. After that, the scope was removed Finally the evaluation and the data that had been found were written in details by the surgeon. Operative intervention was done if needed. Any complication in the form of pain, bleeding, vasovagal attack and perforation, were registered in the patient sheet."
62783039|NCT05573126|EXPERIMENTAL|Module A - EP0062 Dose Finding|Patients are assigned to dose level cohorts to identify MTD and assess safety, tolerability and PK profile.
62195243|NCT03873454|ACTIVE_COMPARATOR|Experimental Group|The experimental group listened to music and wore Sennheiser non-occlusive headphones
62195244|NCT03873454|OTHER|Control 1 with no music|This cohort wore non-occlusive earphones but did not listen to music
62195245|NCT03873454|OTHER|Control 2 with no music|The control 2 patients did not listen to music nor wore earphones.
62195246|NCT01808183||supracondylar humerus fractures|All members of the study will have near Infrared spectroscopy pads placed on their injured and uninjured arms as a part of this study.
62195247|NCT00910897|ACTIVE_COMPARATOR|Velcade-Dexamethasone|
62734653|NCT01966354|EXPERIMENTAL|Short axis, out-of-plane needle|"Ultrasound-guided Internal jugular venous approach~Short axis, out-of-plane needle:~Jugular vein is ultrasonographically visualized in a transverse fashion (short axis) and the needle is inserted perpendicular to the longitudinal axis of the transducer (out-of-plane)."
62783040|NCT05573126|EXPERIMENTAL|Module B - EP0062 Dose level 1|Patients randomised to one of the 2 expansion doses selected from Module A, with up to 30 patients included per dose level, to further characterise the safety and efficacy of EP0062.
62195248|NCT00910897|ACTIVE_COMPARATOR|Velcade-Thalidomide-Dexamethasone|
62783041|NCT05573126|EXPERIMENTAL|Module B - EP0062 Dose level 2|Patients randomised to one of the 2 expansion doses selected from Module A, with up to 30 patients included per dose level, to further characterise the safety and efficacy of EP0062.
62783042|NCT04209595|EXPERIMENTAL|Phase I Arm 1 Level -1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 200 mg|"Phase I - Participants with solid tumors enrolled to PLX038 (PEGylated SN38) and rucaparib escalation dose levels.~PLX038, every 3 weeks, 1.3 g/m\^2, intravenous (IV); Rucaparib, days 5-19 twice a day (BID), total dose, 200 mg by mouth (PO)"
62195249|NCT02760147|OTHER|Pressure Support Over Support|Pressure Support Level upward by 50%, 2 hours
62195250|NCT02760147|OTHER|Pressure Support Under Support|Pressure Support Level downward by 50%, 2 hours
62195251|NCT02760147|OTHER|PEEP Over Level|PEEP Level upward by 50%, 2 hours
62195252|NCT02760147|OTHER|PEEP Under Level|PEEP Level downward by 50%, 2 hours
62195253|NCT06544356||One grups|Mums who've just given birth, Over 18 years of age, literate mothers with at least primary school education
62195254|NCT01165177|EXPERIMENTAL|GSK1437173A group|Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
62195255|NCT01165177|PLACEBO_COMPARATOR|Placebo group|Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
62195256|NCT03400683|ACTIVE_COMPARATOR|misoprostol only group|given 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), in sublingual every four hours for a maximum of five doses
62195257|NCT03400683|ACTIVE_COMPARATOR|misoprostol with letrozole group|group received 15mg( letrozole2.5mg) on three successive day patient take doses of letrozole for daily oral three successive day at home by herself and forth day admitted to our hospital followed by sublingual misoprostol 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), every four hours for a maximum of five doses
62195258|NCT03400683|ACTIVE_COMPARATOR|misoprotol with Foley's catheter group|the transcervical 16F Foley's catheter with 30 ml balloon capacity (Euromed for Medical Industries, Cairo, Egypt, under license of Kanglite, USA), inserted under aseptic conditions withsublingual misoprostol 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), every four hours for a maximum of five doses
62195259|NCT00463853|EXPERIMENTAL|Arm 1|direct intramyocardial injection of cells as adjunct to CABG
62195260|NCT03380195|EXPERIMENTAL|Watermelon juice|
62195261|NCT03380195|ACTIVE_COMPARATOR|Sport drink|
62783043|NCT04209595|EXPERIMENTAL|Phase I Arm 1 Level 1, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 400 mg|"Phase I - Participants with solid tumors enrolled to PLX038 (PEGylated SN38) and rucaparib escalation dose levels.~PLX038, every 3 weeks, 1.3 g/m\^2, intravenous (IV); Rucaparib, days 3-19 twice a day (BID), total dose, 400 mg by mouth (PO)"
62783044|NCT04209595|EXPERIMENTAL|Phase I - Arm 1 Level 1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 300 mg|"Phase I Participants with solid tumors enrolled to PLX038 (PEGylated SN38) and rucaparib escalation dose levels.~PLX038, every 3 weeks, 1.3 g/m\^2, intravenous (IV); Rucaparib, days 5-19 twice a day (BID), total dose, 300 mg by mouth (PO)"
62783045|NCT04209595|EXPERIMENTAL|Phase IIA Arm 2|"Phase IIA Participants with small cell lung cancer (SCLC) enrolled at the maximum tolerated dose (MTD) of PLX038 (PEGylated SN38) and rucaparib after the MTD of PLX038 and rucaparib is established.~Level 2, PLX038, every 3 weeks, 1.3 g/m\^2, intravenous (IV); Rucaparib, days 3-19 twice a day (BID), total dose, 600 mg by mouth (PO); Level 3, PLX038, every 3 weeks, 1.7 g/m\^2, intravenous (IV); Rucaparib, days 3-19 twice a day (BID), total dose, 600 mg by mouth (PO); Level 4, PLX038, every 3 weeks, 2.3 g/m\^2, intravenous (IV); Rucaparib, days 3-19 twice a day (BID), total dose, 600 mg by mouth (PO); Level 2A PLX038, every 3 weeks, 1.3 g/m\^2, intravenous (IV); Rucaparib, days 5-19 twice a day (BID), total dose, 400 mg by mouth (PO); and/or Level 3A. PLX038, every 3 weeks, 1.3 g/m\^2, intravenous (IV); Rucaparib, days 5-19 twice a day (BID), total dose, 600 mg by mouth (PO)."
62195262|NCT03380195|ACTIVE_COMPARATOR|Sugar water|
62195263|NCT03380195|PLACEBO_COMPARATOR|Water|
62195264|NCT03614676|OTHER|Pregnant Women/Mothers Group|Subjects, 18 to 45 years of age enrolled in the study in view of determining pregnancy outcomes and related events of interest, as well as the occurrence of lower respiratory tract illness (LRTI) associated with respiratory syncytial virus (RSV).
62195265|NCT03614676|OTHER|Neonates/Infants Group|Infants born to mothers aged 18-45 years old, enrolled for the collection of infant events of interest, nasal swabs and the incidence of RSV LRTI and RSV hospitalization.
62195266|NCT02579772|ACTIVE_COMPARATOR|N-acetylcysteine|Pharmacological treatment with N-acetylcysteine (NAC) pills
62195267|NCT02579772|PLACEBO_COMPARATOR|Placebo|Treatment with placebo pills
62195268|NCT03540277|EXPERIMENTAL|"Prevention Program young In Favor of Myself, active parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents will also participate by a phone app that will pass the parents activities to do with their children, in parallel to the program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
62195269|NCT03540277|ACTIVE_COMPARATOR|"Prevention Program young In Favor of Myself, passive parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents won't participate in the program, they will get only a brochure about Media literacy, self-esteem, self-image and body image. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
62195270|NCT03540277|NO_INTERVENTION|control group|The control group will not receive the intervention program. The control group will complete the same self-report questionnaire as the intervention group at baseline, after the program ends, and three months after the completion of the program.
62195271|NCT02838979|EXPERIMENTAL|Oral L-Glutamine first, then Maltodextrin|"Subjects will receive 0.4 g/kg/day of L-glutamine (Nutrestore, EMMAUS Life Sciences, Inc Torrance, CA) in three divided daily doses OR identical appearing maltodextrin powder.~Duration 2 weeks"
62195272|NCT02838979|EXPERIMENTAL|Maltodextrin first, then L-glutamine|"Subjects will crossover to receiving the study product which they did not receive in the first period.~Either 0.4 g/kg/day of L-glutamine in three divided daily doses OR identical appearing maltodextrin powder.~Duration 2 weeks"
62195273|NCT06197659|ACTIVE_COMPARATOR|Liberal Fluid Group|Patients in this group will be administered 20 mL/kg/h ringer lactate intravenously peroperatively.
62195274|NCT06197659|SHAM_COMPARATOR|Restrictive Fluid Group|Patients in this group will be administered 4 mL/kg/h ringer lactate intravenously peroperatively.
62195275|NCT05411172|EXPERIMENTAL|Experimental|"The Effect of the Education Based on the Mastery Learning Model on the Practical Skills of Student Nurses in Chemical, Biological, Radiological, and Nuclear Hazards.~The MLM-CBRN Education Program was carried out with the students in the experimental group face-to-face as theoretical and practical education once a week for four weeks."
62195276|NCT05411172|NO_INTERVENTION|Control|No intervention
62398834|NCT06142032|EXPERIMENTAL|Metaverse support group|Online intervention
62398835|NCT06142032|ACTIVE_COMPARATOR|In-Person support group|In-person intervention
62195277|NCT02054676|EXPERIMENTAL|Classification assessment.|Random group of the partially edentulous individuals will be assessed according to prepared classification evaluation protocol during dental implant treatment period. Cone-beam computed tomography preoperative evaluation will be made during preoperative stage. Intraoperative edentulous jaw segment parameters evaluation, endosseous dental implant placement parameters assessment during intraoperative stage will be made. Dental implant position evaluation during early postoperative stage will be made. Medications will be prescribed. Late postoperative soft tissue evaluation of edentulous jaw segment will be made during final crown placement. Cone-beam computed tomography analysis results will be compared with subsequent stages assessment results to evaluate reliability of the classification.
62195278|NCT00641680|EXPERIMENTAL|1|Budesonide
62195279|NCT00641680|ACTIVE_COMPARATOR|2|Fluticasone propionate
62195280|NCT00641680|PLACEBO_COMPARATOR|3|
62398836|NCT06142032|NO_INTERVENTION|Waitlist|Control
62398837|NCT05854719|NO_INTERVENTION|Normally hearing children|No intervention, only initial testing (normal-hearing controls).
62783046|NCT04209595|EXPERIMENTAL|Phase IIB Arm 2|"Phase IIB Participants with extra-pulmonary small cell carcinomas enrolled at the maximum tolerated dose (MTD) of PLX038 (PEGylated SN38) and rucaparib after the MTD of PLX038 and rucaparib is established.~Level 2, PLX038, every 3 weeks, 1.3 g/m\^2, intravenous (IV); Rucaparib, days 3-19 twice a day (BID), total dose, 600 mg by mouth (PO); Level 3, PLX038, every 3 weeks, 1.7 g/m\^2, intravenous (IV); Rucaparib, days 3-19 twice a day (BID), total dose, 600 mg by mouth (PO); Level 4, PLX038, every 3 weeks, 2.3 g/m\^2, intravenous (IV); Rucaparib, days 3-19 twice a day (BID), total dose, 600 mg by mouth (PO); Level 2A PLX038, every 3 weeks, 1.3 g/m\^2, intravenous (IV); Rucaparib, days 5-19 twice a day (BID), total dose, 400 mg by mouth (PO); and/or Level 3A. PLX038, every 3 weeks, 1.3 g/m\^2, intravenous (IV); Rucaparib, days 5-19 twice a day (BID), total dose, 600 mg by mouth (PO)."
62009412|NCT05580718|NO_INTERVENTION|Waitlist control|Participants randomised to waitlist can have no other concurrent psychological treatment but are free to use any medical treatment as usual. Participants on the waitlist also complete pre- and post-treatment, the follow-up measurement as well as weekly instruments (with exception of the treatment process measures Credibility scale and WAI). After the 3-month follow-up assessments, participants will receive internet-CBT for MI over 8 weeks
62009413|NCT00464724|EXPERIMENTAL|3T MRSI Prostate|3T Magnetic Resonance Spectroscopic Imaging
62009414|NCT04011878|EXPERIMENTAL|isolated trabeculodysgensis|etiology of primary congenital glaucoma
62195281|NCT03089996|EXPERIMENTAL|Piezocision|Piezocision-assisted canine retraction x Control (split mouth design)
62195282|NCT03089996|EXPERIMENTAL|Corticotomy|Corticotomy-assisted canine retraction x Control (split mouth design)
62398838|NCT05854719|EXPERIMENTAL|Children with hearing impairment/loss with intervention|These children participate in speechreading training for two months at home.
62398839|NCT05854719|NO_INTERVENTION|Children with hearing impairment/loss with no intervention|These children will serve as controls for two months with no speechreading training.
62398840|NCT02315716|EXPERIMENTAL|Consolidation with 4 cycles of CarCyDex|Patients responding to induction treatment will receive 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone (CarCyDex) treatment followed by 18 months of maintenance carfilzomib
62398841|NCT02315716|ACTIVE_COMPARATOR|Autologous Stem Cell Transplant (ASCT)|Patients responding to induction treatment will receive a melphalan conditioned autologous stem cell transplant followed by 18 months of maintenance carfilzomib
62398842|NCT03486873|EXPERIMENTAL|Pembrolizumab 200 mg|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations or more for First Course participants and up to 17 administrations for Second Course participants.
62398843|NCT03486873|EXPERIMENTAL|Pembrolizumab 400 mg|Participants receive pembrolizumab 400 mg via intravenous (IV) infusion on Day 1 of each 6-week cycle for up to 17 administrations or more for First Course participants and up to 8 administrations for Second Course participants.
62783047|NCT05186506|EXPERIMENTAL|Ensatinib|225 mg administered once daily orally for two years.
62783048|NCT05186506|ACTIVE_COMPARATOR|Platinum-Based Chemotherapy|Patients in the chemotherapy group were allowed to cross into the Ensatinib treatment group after the disease progressed.
62783049|NCT01748721|EXPERIMENTAL|Treatment (MORAb-004)|Patients receive anti-endosialin/TEM1 monoclonal antibody MORAb-004 IV on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
62195283|NCT03089996|EXPERIMENTAL|Piezocision x Corticotomy|Piezocision-assisted retraction x Corticotomy-assisted retraction (split mouth design)
62195284|NCT03089996|EXPERIMENTAL|Micro-osteoperforations|Micro-osteoperforations-assisted upper incisors retraction
62195285|NCT03089996|NO_INTERVENTION|Control|Upper incisors retraction not associated with any clinical intervention to accelerate tooth movement
62195286|NCT01896765|EXPERIMENTAL|Intensive prevention program|"Standard care with respect to medical and interventional therapy plus intensive prevention program with study nurse-coordinated education sessions, regular telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available)."
62734654|NCT01966354|EXPERIMENTAL|Oblique axis, in-plane needle|"Ultrasound-guided Internal jugular venous approach~Oblique axis, in-plane needle:~Jugular vein is ultrasonographically visualized in an oblique axis (intermediate view between long and short axis) and the needle is inserted in the same ultrasound plane, aligned with the longitudinal axis of the transducer."
62195287|NCT01896765|OTHER|Usual care|Standard care with respect to medical and interventional therapy.
62398844|NCT03486873|EXPERIMENTAL|Pembrolizumab 200 mg + SOC: Per Parent Study)|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle PLUS standard of care (SOC) treatment (or per parent study if there is no SOC) for up to 35 administrations or more for First Course participants and up to 17 administrations for Second Course participants. Participants receiving a pembrolizumab-based combination treatment will receive the dose regimen of the combination drug(s) which is recommended per SOC or was used in the parent study protocol if there is no SOC recommendation.
62195288|NCT03690427|EXPERIMENTAL|Traditional Charcoal-Heated Hookah followed by Electronic Hookah|"Participants were invited to smoke a 30-minute traditional charcoal-heated hookah-smoking session, followed by a 30-minute electronic hookah vaping session.~To mitigate the impact of carryover effects, the two sessions were separated by a minimum of 7-days."
62783050|NCT02687100|EXPERIMENTAL|Beclomethasone|Patients will receive beclomethasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning. The solution will be aspirated 15 minutes after the instillation.
62195289|NCT03690427|EXPERIMENTAL|Electronic followed by Traditional Charcoal-Heated Hookah|"Participants were invited to vape a 30-minute electronic hookah session, followed by a 30-minute traditional charcoal-heated hookah smoking session.~To mitigate the impact of carryover effects, the two sessions were separated by a minimum of 7-days."
62195290|NCT04206085|EXPERIMENTAL|Active treatment|Radiofrequency and Cryogen
62195291|NCT04206085|ACTIVE_COMPARATOR|Cryogen-Only|Crygen-Only
62195292|NCT04206085|SHAM_COMPARATOR|Sham|Sham comparator
62195293|NCT00855790|ACTIVE_COMPARATOR|RJ3 Biopsy Forcep|use of RJ3 Biopsy forcep for the polypectomy
62009415|NCT06283420||HF patients initiated with sodium-glucose transport protein 2 (SGLT2) inhibitor|HF patients with medical indication to initiation of SGLT2 inhibitors
62195294|NCT00855790|ACTIVE_COMPARATOR|RJ4 Biopsey Forcep|Use of RJ$ biopsy forcep for polypectomy
62195295|NCT04118413|EXPERIMENTAL|Erector spinae plane block|Erector spinae plane block will be administrated to this group at end of the surgery under spinal anesthesia. An intravenous patient-controlled analgesia device within morphine will be given to the patients postoperatively and sheduled paracetamol will be given.
62398845|NCT03486873|EXPERIMENTAL|Pembrolizumab 400 mg + SOC (Per Parent Study)|Participants receive pembrolizumab 400 mg via IV infusion on Day 1 of each 6-week cycle PLUS SOC treatment (or per parent study if there is no SOC) for up to 17 administrations or more for First Course participants and up to 8 administrations for Second Course participants. Participants receiving a pembrolizumab-based combination treatment will receive the dose regimen of the combination drug(s) which is recommended per SOC or was used in the parent study protocol if there is no SOC recommendation.
62783051|NCT02687100|PLACEBO_COMPARATOR|Placebo|Patients will receive 8 mL of saline without any drug.
62783052|NCT03759691||Stroke patients|Structured interviews of patients with stroke, admitted at the Department of Neurology, Aarhus University hospital and Regional Hospital West Jutland (Holstebro)
62783053|NCT03759691||Bystander|Structured interviews of bystanders of patients with stroke, admitted at the Department of Neurology, Aarhus University hospital and Regional Hospital West Jutland (Holstebro)
62783054|NCT03410303|OTHER|Intraoperative ultrasound|An ultrasound of the position of the prosthesis during surgery, under general anesthesia, is performed. A follow-up visit will be carried out 2 months (± 1 month) after the surgery as part of the usual care. An ultrasound of the position of the prosthesis is performed without anesthesia, either as part of the treatment or as part of the research. This measurement is performed without the intraoperative measurement by an independent sonographer.
62783055|NCT05009290|EXPERIMENTAL|Treatment group：SHR3680 + ADT|
62009416|NCT06283420||HF patients initiated with soluble gluanylate cyclase (sGC) stimulator|HF patients with medical indication to initiation of sGC stimulator
62009417|NCT06283420||HF patients initiated with sacubitril/valsartan (ARNI)|HF patients with medical indication to initiation of ARNI
62009418|NCT06283420||HF patients without change of their chronic medication|these HF patients (without ARNI, sGCs or SGLT2i) will serve as internal controls during observational part of the study (3 mo)
62009419|NCT04391582|EXPERIMENTAL|Test - Tilapia Skin|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, the tilapia skin was applied and covered with gauze and bandage.
62009420|NCT04391582|ACTIVE_COMPARATOR|Control - Silver sulfadiazine|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of silver sulfadiazine cream 1% was applied and covered with gauze and band
62009421|NCT00595569||Type 1 diabetes|
62009422|NCT01651741|EXPERIMENTAL|Seaweed and Duolac7S|Seaweed: Real Seaweed granule, Duolac7S: Real probiotics
62009423|NCT01651741|PLACEBO_COMPARATOR|Seaweed and Duolac7S-P|Seaweed: Real Seaweed granule, Duolac7S-P: Placebo probiotics
62009424|NCT01728155|NO_INTERVENTION|Group1|initial observation (chemotherapy is only given if there is subsequent progression)
62195296|NCT04118413|NO_INTERVENTION|Control Group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with morphine and sheduled paracetamol. No block will be performed.
62195297|NCT05852145|PLACEBO_COMPARATOR|Tea lemon flavor|"355 ml of tea lemon flavor should be drunk~* Salivary pH will be collected at 0,5,10,15,30,45 and 60 minutes later~* Dental biofilm pH will be collected at 0,5,10,15,30,45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be collected at 0 and 120 minutes later~* Operative Taxonomic Units of dental biofilm will be analyzed at 0 minutes and 120 minutes later"
62398846|NCT03486873|ACTIVE_COMPARATOR|SOC (Per Parent Study)|Participants receive the dose matched non-pembrolizumab SOC treatment (e.g. chemotherapy) they were receiving as per parent study protocol.
62009425|NCT01728155|ACTIVE_COMPARATOR|Group 1: chemotherapy|chemotherapy and surgery
62009426|NCT01728155|EXPERIMENTAL|Group 2|chemotherapy and surgery
62009427|NCT01728155|EXPERIMENTAL|Group 3|chemotherapy and surgery
62009428|NCT01728155|NO_INTERVENTION|Group 4|Observation
62009429|NCT01728155|EXPERIMENTAL|Group 5|chemotherapy
62009430|NCT01728155|EXPERIMENTAL|Group 6|chemotherapy and surgery
62009431|NCT01728155|EXPERIMENTAL|Group 7|chemotherapy and surgery
62009432|NCT01728155|EXPERIMENTAL|Group 8|chemotherapy, surgery, radiotherapy and 13 cis-retinoic acid
62009433|NCT01728155|EXPERIMENTAL|Group 9|chemotherapy, surgery, radiotherapy and 13 cis-retinoic acid
62009434|NCT01728155|EXPERIMENTAL|Group 10|chemotherapy, surgery,
62009435|NCT02258282|EXPERIMENTAL|Etanercept|Patients under the treatment of 50 mg Etanercept
62398847|NCT03486873|EXPERIMENTAL|Lenvatinib 20 mg|Participants with body weight (BW)\>60kg receive Lenvatinib 20mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
62009436|NCT02258282|SHAM_COMPARATOR|Control|Patients under the treatment of traditional DMARDs
62195298|NCT05852145|EXPERIMENTAL|Stevioside|"355 ml of tea lemon flavor added with 2.2 grams of stevioside should be drunk~* Salivary pH will be collected at 0,5,10,15,30,45 and 60 minutes later~* Dental biofilm pH will be collected at 0,5,10,15,30,45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be collected at 0 and 120 minutes later~* Operative Taxonomic Units of dental biofilm will be analyzed at 0 minutes and 120 minutes later"
62195299|NCT05852145|ACTIVE_COMPARATOR|Sucrose|"355 ml de tea lemon flavor added 7.5 grams with should be drunk.~* Salivary pH will be collected at 0,5,10,15,30,45 and 60 minutes later~* Dental biofilm pH will be collected at 0,5,10,15,30,45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be collected at 0 and 120 minutes later~* Operative Taxonomic Units of dental biofilm will be analyzed at 0 minutes and 120 minutes later"
62195300|NCT04608838|EXPERIMENTAL|JTR-161|
62195301|NCT04608838|PLACEBO_COMPARATOR|Placebo|
62195302|NCT01592045|EXPERIMENTAL|Sequence 1|UTC ch14.18 for two courses and NCI ch14.18 for three courses
62195303|NCT01592045|EXPERIMENTAL|Sequence 2|NCI ch14.18 for two courses and UTC ch14.18 for three courses
62195304|NCT03936842|EXPERIMENTAL|Single Arm|"Eligible patients who are referred to the one-stop diagnostic clinic with breast pain alone and have completed a clinical assessment will be given a patient information sheet inviting them to participate in the study. They will be met by the interviewing clinician at the same visit."
62195305|NCT04232904|ACTIVE_COMPARATOR|TAP Block Group|this is study group.
62195306|NCT04232904|NO_INTERVENTION|Control Group|This patients are control group. TAP block will be not perform
62009437|NCT05448690|ACTIVE_COMPARATOR|Non-combined approach (Single or Staged)|Patients underwent transnasal approach or craniotomy approach; Patients underwent an initial surgery and a sencond staged surgery several months after the initial surgery
62195307|NCT02502747|EXPERIMENTAL|G-CSF and Myocardial Contrast Echocardiography (MCE)|subcutaneous Granulocyte - Colony Stimulating Factor ( on top of optimal standard of care) and Myocardial Contrast Echocardiography with intravenous infusion of sulphur hexafluoride.
62195308|NCT02502747|ACTIVE_COMPARATOR|Placebo and Myocardial Contrast Echocardiography (MCE)|Patients will be receive optimal standard of care and Myocardial Contrast Echocardiography with intravenous infusion of sulphur hexafluoride.
62195309|NCT02743897|EXPERIMENTAL|Direct-acting antiviral treatment for HCV|
62195310|NCT06545461|EXPERIMENTAL|Fruits and vegetables (F+V)|36 participants with hypertension, eGFR 30-59 ml/min/m2, macroalbuminuria (albumin \[mg\] to creatinine \[g\] ratio \> 200 mg/g) and PTCO2 \>22 but \<24 mM will receive a prescribed amount of F+Vs designed to reduce dietary acid intake by half. The chosen level of metabolic acidosis does not warrant alkali treatment by current guidelines with standard therapy, oral NaHCO3. Because macroalbuminuria places them at increased risk for worsening kidney function and development of CVD, they will receive oral enalapril (minimum 5 mg daily) and oral atorvastatin (minimum 10 mg daily). They will otherwise receive standard medical care and followed annually for 10 years.
62195311|NCT06545461|EXPERIMENTAL|NaHCO3 (HCO3)|36 participants with hypertension, eGFR 30-59 ml/min/m2, macroalbuminuria (albumin \[mg\] to creatinine \[g\] ratio \> 200 mg/g) and PTCO2 \>22 but \<24 mM will receive sodium bicarbonate (NaHCO3) dosed to match the alkali intake of the F+V given to the F+V group. Because macroalbuminuria places them at increased risk for worsening of their kidney function and for development of CVD, they will receive oral enalapril (minimum 5 mg daily) and oral atorvastatin (minimum 10 mg daily). They will otherwise receive standard care and followed annually for 10 years.
62195312|NCT06545461|ACTIVE_COMPARATOR|Usual Care (UC)|36 participants with hypertension, eGFR 30-59 ml/min/m2, macroalbuminuria (albumin \[mg\] to creatinine \[g\] ratio \> 200 mg/g) and PTCO2 \>22 but \<24 mM will receive no additional alkali (neither F+V or NaHCO3). The chosen level of metabolic acidosis does not warrant alkali treatment by current guidelines with standard therapy with oral NaHCO3. Because their macroalbuminuria places them at increased risk for worsening of their kidney function and for subsequent development of CVD, they will receive oral enalapril (minimum 5 mg daily) and oral atorvastatin (minimum 10 mg daily). They will otherwise receive standard care and followed annually for 10 years.
62195313|NCT03138642|EXPERIMENTAL|RT|The patients are prescribed a EQD2of 65-70Gy to CTV1(high-risk regions including tumor bed), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT). The Prophylactic irradiation to upper neck is is decided by radiation physicians and given a EQD2 of 70-77Gy to CTVnd (clinically negative lymph nodes), 50-55Gy to CTVn2（neck nodal regions). If there is residual tumor, a EQD2 of 70-77Gy is prescribed to GTV.
62195314|NCT00850122|EXPERIMENTAL|Cefazolin|"Dosage Number of Infants~≤28 days of age 25 mg/kg IV q12 6 29-120 days of age 25 mg/kg IV q8 6"
62195315|NCT00203047|ACTIVE_COMPARATOR|GA + Placebo|Glatiramer acetate (GA) 10mg as a subcutaneous injection daily, plus a placebo to mimic prednisone given daily.
62195316|NCT00203047|EXPERIMENTAL|GA + Prednisone|Glatiramer acetate (GA) 20mg daily as a subcutaneous injection, plus 1250 mg of prednisone daily.
62783056|NCT05009290|PLACEBO_COMPARATOR|Treatment group : Placebo + ADT|
62009438|NCT05448690|EXPERIMENTAL|Combined approach|Patients underwent a combined approach using transnasal approach and craniotomy approach simultaneously
62009439|NCT06662643|EXPERIMENTAL|Staged Turnbull-Cutait Pull-through anastomosis group|Participants in this group will undergo staged Turnbull-Cutait pull-through anastomosis for the treatment of low rectal cancer after internal sphincter resection.
62009440|NCT06662643|ACTIVE_COMPARATOR|Direct anastomosis plus protective ileostomy group|Participants in this group will receive direct anastomosis combined with a prophylactic ileostomy.
62009441|NCT01947530|ACTIVE_COMPARATOR|Navigational Bronch/Standard Bronch|Patient will have first the Navigational Bronchoscopy then the standard bronchoscopy completed.
62009442|NCT01947530|ACTIVE_COMPARATOR|Standard Bronch/Navigational Bronch|Patient will first have a standard bronchoscopy then a navigational bronchoscopy completed.
62009443|NCT06442527|EXPERIMENTAL|Treatment Group|This single arm will include all participants of the study, who will all receive the intervention
62398848|NCT03486873|EXPERIMENTAL|Lenvatinib 24 mg|Participants with body weight (BW)\>60 kg receive Lenvatinib 24 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
62783057|NCT05633173|EXPERIMENTAL|Group E|Ultrasound-guided erector spina plan block was performed for patients in group E for postoperative analgesia. The patients were placed in the lateral decubitus position and the linear ultrasound probe was placed longitudinally into the sterilized area 1-2 cm lateral to the spinous process of the L1 vertebra. After visualizing the erector spina muscle and the transverse process, the transverse process was reached by pushing forward the 22 gauge, 50 mm needle in the direction from cranial to caudal. Hydrodissection was performed with 1 ml of saline for confirmation. 0.5 mL kg-1 dose of 0.25% bupivacaine was injected under the erector spina muscle at the level of the 1st lumbar vertebra by aspiration every 2 mL.
62783058|NCT05633173|ACTIVE_COMPARATOR|Group C|The patients in group C underwent ultrasound guided caudal block for postoperative analgesia. By placing the patients in the lateral decubitus position, the linear ultrasound probe was placed longitudinally on the sterilized area on the midline of the sacrum, and access was provided with a 2.5 cm 22 gauge needle on the dorsal skin of the sacral hiatus at a 90° position. The sacrococcygeal ligament was crossed, the needle was oriented approximately 25° and advanced approximately 2 to 3 mm to reach the sacral canal. When it was understood that the sacral hiatus had been entered, 0.5 mL kg-1 0.25% bupivacaine was injected by aspirating every 2 mL after the location was confirmed with the negative aspiration method.
62398849|NCT03486873|EXPERIMENTAL|Lenvatinib 12 mg|Participants with body weight (BW)\>60 kg receive Lenvatinib 12 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
62398850|NCT03486873|EXPERIMENTAL|Lenvatinib 8 mg|Participants with body weight (BW)\<60 kg receive Lenvatinib 8 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
62783059|NCT00862056||Cardiac CT|All participants will undergo a coronary artery CT angiogram
62783060|NCT03057275||Threatened PTL|abdominal fetal/maternal monitoring
62783061|NCT03057275||Delivered PTL|abdominal fetal/maternal monitoring
62783062|NCT04901273|EXPERIMENTAL|Homologous PRP|This group of patients will be treated with single intra-articular injection of Homologous PRP. At the 6-month follow-up visit, the patient will be informed about the treatment received.
62783063|NCT04901273|PLACEBO_COMPARATOR|Saline solution|This group of patients will be treated with single intra-articular injection of saline solution (placebo). At the 6-month follow-up visit, patients will be informed about the treatment received. Patients of this group can cross-over to the treatment arm after 6 months.
62195317|NCT04893525|ACTIVE_COMPARATOR|Buprenorphine/naloxone Microdosing|"Participants with Opioid use disorder will receive a Buprenorphine/naloxone microdosing package from the ED. This will consist of a five-day take-home packages with gradually increasing doses of 2mg/0.5mg buprenorphine/naloxone tablet employing a four times daily dosing schedule over five days.~Day 1: Buprenorphine 0.5 mg-naloxone 0.125 mg SL\* QID\*\* (One quarter tablet),~Day 2: Buprenorphine 1 mg-naloxone 0.25 mg SL QID (One half tablet),~Day 3: Buprenorphine 2 mg-naloxone 0.5 mg SL QID (1 tablet),~Day 4: Buprenorphine 3 mg-naloxone 0.75 mg SL QID (1.5 tablets)~Day 5: Buprenorphine 16 mg-naloxone 4 mg SL once daily (8 tablets).~\*SL: Sublingual~\*\* QID: four times daily"
62398851|NCT06723743|ACTIVE_COMPARATOR|taVNS active stimulation|Participants will receive transcutaneous auricular vagus nerve stimulation (taVNS) using electrodes placed on the left ear. A low-level electrical current will be delivered to stimulate the vagus nerve. This stimulation is designed to activate brain areas involved in attention and memory.
62398852|NCT06723743|SHAM_COMPARATOR|Sham (Placebo) taVNS|Participants will undergo sham stimulation, where electrodes are placed on the left ear to mimic the experience of active taVNS. However, no electrical current will be delivered to the vagus nerve. This sham condition enables a direct comparison with active taVNS, ensuring that any observed changes in working memory and attention can be attributed to the taVNS intervention.
62783064|NCT01105156||Gastric Band Patients|
62783065|NCT02578056|EXPERIMENTAL|Mid-urethral sling|Patients randomized to anti-incontinence surgery will undergo TVT sling placement as the standard technique at the same time of genital prolapse surgery.
62783066|NCT02578056|SHAM_COMPARATOR|POP|Patients randomized to the sham group will be submitted to genital prolapse surgery and sham incisions as if they had undergone the TVT procedure (two small incisions of 0.5 cm in the suprapubic region in a similar way to that used for the insertion of the sling). These incisions intended to keep the raters blind to the achievement or otherwise of the sling during the postoperative evaluation.
62734655|NCT05392673|EXPERIMENTAL|comprehensive medical treatment|All the 62 patients enrolled received comprehensive medical treatment after admission to the hospital, including anti-viral treatment, general supportive treatment, supplementation of blood products, such as albumin and plasma, and symptomatic treatment.
62783067|NCT01653990|EXPERIMENTAL|moxifloxacin, pill|Oral dose of 400mg moxifloxacin
62783068|NCT01653990|PLACEBO_COMPARATOR|moxifloxacin-placebo,pill|A pill of moxifloxacin-placebo
62009444|NCT05866094|EXPERIMENTAL|Nutrition Intervention|Intervention Feasibility Testing (11-months, Phase 2)
62783069|NCT02728466|ACTIVE_COMPARATOR|Flavanol and procyanidin supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)
62783070|NCT02728466|ACTIVE_COMPARATOR|Procyanidin-containing supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)
62783071|NCT02728466|PLACEBO_COMPARATOR|Flavanols and procyanidins deprived supplement|Control supplement deprived of flavanols and procyanidins Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement
62783072|NCT01023724|ACTIVE_COMPARATOR|bromfenac 0.09%|bromfenac 0.09% drops to be given pre operatively for one day BID, and then postoperatively for 14 days.
62783073|NCT01023724|ACTIVE_COMPARATOR|Acuvail|Acuvail to be given preoperatively at BID for one day pre op and then post operatively for 14 days.
62214964|NCT03851718|ACTIVE_COMPARATOR|Power pumping|Power pumping is a pumping strategy that mimics normal infant cluster feedings by repeatedly emptying mother's breast very frequently in an effort to increase breast milk supply. As there is no standardized protocol of power pumping, one of the most popular recommendations will be adapted as the study power pumping instruction. It suggests the mom to set at least one hour and two hours preferably for the power pumping at least three days within a 5 weekday period, preferably on 3 consecutive days.
62214965|NCT04611321|EXPERIMENTAL|Phase Ib/II|Patients with advanced CSCC. IBI318 administered intravenously every 2 weeks.
62783074|NCT06372691|ACTIVE_COMPARATOR|Subparaneural Injection (Group S)|The position of the patients will be prone.The skin will be cleaned according to asepsis and antisepsis rules.After preparing the USG a high-frequency linear array transducer under sterile conditions,we will be positioned it transversely in the popliteal fossa.After visualizing the artery,its hyperechoic nerves will be founded superficially.The sciatic nerve will be identified proximally to visualize where the TN and CPN eventually come together to form the sciatic nerve and separate distally where the CPN moves laterally and the TN remains medially.Once the nerves began to separate,they will be scanned until a figure 8 or pant leg image will be obtained.Using the in-plane technique under ultrasonography guidance, injection will be applied to the subparaneural area in Group S.1 ml of LA solution was injected for the purpose of verifying proper needle insertion.A standard dose of 15 mL bupivacaine 0.5% and 5mg/mL local anesthetic was used accompanied by a 20G,12mm block needle.
62783075|NCT06372691|ACTIVE_COMPARATOR|Interneural Injection (Group I)|The position of the patients will be prone.The skin will be cleaned according to asepsis and antisepsis rules.After preparing the USG a high-frequency linear array transducer under sterile conditions, we will be positioned it transversely in the popliteal fossa.After visualizing the artery, its hyperechoic nerves will be founded superficially.The sciatic nerve will be identified proximally to visualize where the TN and CPN eventually come together to form the sciatic nerve and separate distally where the CPN moves laterally and the TN remains medially.Once the nerves began to separate, they will be scanned until a figure 8 or pant leg image will be obtained.Using the in-plane technique under ultrasonography guidance, injection will be applied to the interneural area in Group I.1 ml of LA solution was injected for the purpose of verifying proper needle insertion.A standard dose of 15 mL bupivacaine 0.5% and 5mg/mL local anesthetic was used accompanied by a 20 G, 12mm block needle.
62783076|NCT03382808|EXPERIMENTAL|SEE Training|The training sequence comprises four weekly sessions using a modified dote-probe paradigm (fearful vs. neutral expression).
62783077|NCT03382808|ACTIVE_COMPARATOR|GAZE Training|The GAZE training sequence comprises four weekly sessions using a modified dote-probe paradigm (averted vs. directed gaze).
62783078|NCT02819687|EXPERIMENTAL|RDX5791 10mg QD (SAD phase)|10mg of RDX5791 administered once daily PO fasting
62783079|NCT02819687|EXPERIMENTAL|RDX5791 50mg QD (SAD phase)|50mg of RDX5791 administered once daily PO fasting
62783080|NCT02819687|EXPERIMENTAL|RDX5791 150mg QD (SAD phase)|150mg of RDX5791 administered once daily PO fasting
62783081|NCT02819687|EXPERIMENTAL|RDX5791 450mg QD (SAD phase)|450mg of RDX5791 administered once daily PO fasting
62783082|NCT02819687|EXPERIMENTAL|RDX5791 900mg QD (SAD phase)|900mg of RDX5791 administered once daily PO fasting
62783083|NCT02819687|EXPERIMENTAL|RDX5791 3mg QD (MAD phase)|3mg of RDX5791 administered once daily PO fasting
62783084|NCT02819687|EXPERIMENTAL|RDX5791 10mg QD (MAD phase)|10mg of RDX5791 administered once daily PO fasting
62783085|NCT02819687|EXPERIMENTAL|RDX5791 30 mg QD (MAD phase)|30mg of RDX5791 administered once daily PO fasting
62783086|NCT02819687|EXPERIMENTAL|RDX5791 100 mg QD (MAD phase)|100mg of RDX5791 administered once daily PO fasting
62783087|NCT01523509|EXPERIMENTAL|Contrast|All subjects will be in one group who will have a control radiograph of teeth before applying the Sodium Iodide contrast agent topically between the teeth (the intervention) when another radiograph will be taken to test for the presence of contrast in a cavity.
62783088|NCT06083298|PLACEBO_COMPARATOR|control group|patients will be operated under general anesthesia
62214966|NCT02961803|EXPERIMENTAL|MD1003|MD1003 100mg capsules, 1 capsule tid for 24 months
62783089|NCT06083298|ACTIVE_COMPARATOR|MCP group|patients will receive MCP block followed by general anesthesia
62783090|NCT06083298|ACTIVE_COMPARATOR|ISP group|patients will receive ISP block followed by general anesthesia
62573921|NCT06154824|EXPERIMENTAL|2nd pruritogen|The study takes place over two sessions over a period of 7 days. The duration of the sessions is approx. 4 hours in total. In the 1st session, a squared area of 4x4 cm will be selected at the center of each middle forearm of the subject. The two areas will be randomly treated with one of the following substances: cowhage, histamine, BAM 8-22 or vehicle. Each substance will be applied for 10 minutes, during which the pain/itch following the substance application will be monitored. Twenty minutes after each application, the measurements with FLPI will be conducted. Then the measurements of alloknesis and mechanically evoked itch, will be conducted. This procedure will be repeated three times for each substance; so in total each substance will be applied three times, each application lasting 10 minutes.
62573922|NCT06577038||IVL cohort|Patients with calcific CAD undergoing PCI and treated with IVL, irrespectively of the clinical indication (stable angina, acute coronary syndrome), anatomical scenario (de novo coronary stenosis, in-stent restenosis, etc) and/or concomitant use of other debulking techniques
62573923|NCT05369338|EXPERIMENTAL|Low Level Light Therapy|"The application of LLL is applied for 12 minutes using Repuls 7 (Repuls Lichtmedizintechnik GmbH, Vienna). This is a class IIb medical device. It applies pulsed red light of a frequency of 640nm. The intensity is 175 mWcm-2, which corresponds to a power density of 4,100 mW. The pulse frequency is set to 2.5 hz.~The device is positioned 7cm from the skin using a distance ring."
62573924|NCT05369338|SHAM_COMPARATOR|Sham controll|"The application of LLL is applied for 12 minutes using Repuls 7 (Repuls Lichtmedizintechnik GmbH, Vienna). This is a class IIb medical device. It applies pulsed red light of a frequency of 640nm. The intensity is 175 mWcm-2, which corresponds to a power density of 4,100 mW. The pulse frequency is set to 2.5 hz.~The device is positioned 7cm from the skin using a distance ring. The sham treatment is performed with the same device and the same distance ring without activating it."
62573925|NCT03669926|OTHER|DBT+SM|Digital Breast Tomosynthesis+synthetic mammography (DBT+SM) All women are screened with DBT+SM. All examinations are independently double read. Consensus used to decide whether or not to recall.
62573926|NCT01434160|EXPERIMENTAL|Arm 1|
62573927|NCT05349656|EXPERIMENTAL|trans muscular quadratus lumborum (TQL) block|after induction of general anesthesia (GA), the participant will be placed in the lateral position, and a high-frequency linear ultrasound probe (5-13 MHz) will be placed on the anterior iliac crest. The Petit's triangle (formed of the iliac crest inferiorly and the borders of external abdominal oblique anteriorly and latissimus dorsi (LD) posteriorly) will be identified and then Tracing dorsally from Petit's triangle, the external oblique, and the internal oblique are seen disappearing into an aponeurosis as the quadratus lumborum (QL) appears beneath the LD (anteriorly), and going farther dorsally, the QL, erector spinae, and psoas major (PM) muscles around the transverse process of lumbar vertebra L4 are seen. A 22-gauge needle will be inserted using an in-plane technique along the posterior edge of the probe in the anteromedial direction. The needle tip will be placed between the QL muscle and the PM muscle, then 0.5 ml/kg of 0.25% bupivacaine will be injected.
62573928|NCT05349656|EXPERIMENTAL|Pericapsular nerve group (PENG) block|After induction of GA, the participant will be in the supine position. A linear high-frequency ultrasound probe (5-13MHz) will be initially placed in a transverse plane over the anterior inferior iliac spine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees; In this view, the ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle Will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution of 0.25% bupivacaine will be injected in 5-mL increments while observing for an adequate fluid spread in this plane for a total volume of 0.5 ml/kg.
62573929|NCT05727839|EXPERIMENTAL|Phase Ia:Dose escalation|"JCXH-211 will be delivered by intratumoral injection in 2 stages:~（Part1）Intratumoral injection stage of skin/subcutaneous lesions. According to Part 1 study results,1-2 dose groups were selected for deep lesion injection study, dose escalation will follow the 3 + 3 principle."
62573930|NCT05727839|EXPERIMENTAL|Phase Ib: Dose Extension|JCXH-211 will be delivered by intratumoral injection. The dose to be used will be determined after review of the data from Phase Ia.
62214967|NCT02961803|PLACEBO_COMPARATOR|Placebo|Placebo capsule, 1 capsule tid for 12 months, then switch to MD1003 100mg capsule, 1 capsule tid for 12 months
62783091|NCT06526533|ACTIVE_COMPARATOR|Blood Transfusion Domain: Red Blood Cell Transfusion in ECMO - Restrictive|"This is a domain within the RECOMMEND Platform Trial to test the effectiveness of various blood transfusion strategies for patients with acute cardiorespiratory failure undergoing ECMO treatment in ICU.~Arm details:~The Australian Blood Authority's guidelines recommend a transfusion trigger of haemoglobin (Hb) levels between 70g/L and 90g/L for critically ill patients in ICU. However, this range is broad, and allows great variation in standard care. ROSETTA is a comparative effectiveness trial, assigning patients to two intervention groups that are in the realm of standard care. Participants are patients receiving extracorporeal membrane oxygenation (ECMO) in ICU who are eligible for inclusion in the EXCEL National ECMO Registry.~Trigger:~If a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L."
62783092|NCT06526533|ACTIVE_COMPARATOR|Blood Transfusion Domain: Red Blood Cell Transfusion in ECMO - Liberal|"This is a domain within the RECOMMEND Platform Trial to test the effectiveness of various blood transfusion strategies for patients with acute cardiorespiratory failure undergoing ECMO treatment in ICU.~Arm details:~The Australian Blood Authority's guidelines recommend a transfusion trigger of haemoglobin (Hb) levels between 70g/L and 90g/L for critically ill patients in ICU. However, this range is broad, and allows great variation in standard care. ROSETTA is a comparative effectiveness trial, assigning patients to two intervention groups that are in the realm of standard care. Participants are patients receiving extracorporeal membrane oxygenation (ECMO) in ICU who are eligible for inclusion in the EXCEL National ECMO Registry.~Trigger:~If a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused. Additional units can be prescribed to raise the Hb concentration to greater than 90g/L"
62783093|NCT03605914|EXPERIMENTAL|NSAID|The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
62783094|NCT03605914|ACTIVE_COMPARATOR|opioid|The Opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
62783095|NCT00665548||Normal Subjects|Female subjects scoring Kellgren \& Lawrence grade 0.
62783096|NCT00665548||OA Subjects|Female subjects with Kellgren \& Lawrence score of 2 or 3.
62783097|NCT02566694||Failed implants|All patients undergoing revision of an orthopaedic implant (previously this was limited to metal hips but this has now expanded to other orthopaedic implants)
62783098|NCT02566694||Controls with different failure modes|We will compare findings with different types of orthopaedic implants and categories of failure mode.
62783099|NCT04510896|NO_INTERVENTION|Pre-InheRET|Determine appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the pre-intervention 6-month period. Only referrals to Michigan Medicine (MM) genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
62783100|NCT04510896|EXPERIMENTAL|Post-InheRET|Determine appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the post-intervention period. Only referrals to Michigan Medicine genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
62783101|NCT05964036|EXPERIMENTAL|active TMS|active iTBS coupled with medical therapy
62783102|NCT05964036|SHAM_COMPARATOR|sham TMS|Sham iTBS coupled with medical therapy
62783103|NCT04519697|EXPERIMENTAL|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into rectovaginal fistula at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
62783104|NCT04519697|PLACEBO_COMPARATOR|Placebo|Direct injection of normal saline with a possible repeat injection at 3 months if not completely healed from the first injection. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into rectovaginal fistula.
62783105|NCT01054001|ACTIVE_COMPARATOR|Early|men with on- demand sildenafil 100mg dosing from the early postoperative period
62214968|NCT06251297|EXPERIMENTAL|Reflexology session|Patients included in the study and treated with oxaliplatin based regiment will receive 30-min of a standard reflexology session during each infusion for a maximum of 12 sessions over 6 months).
62214969|NCT03408561|EXPERIMENTAL|Health Services Research (message via Twitter)|Patients who mention specific cancer disease keywords and/or hashtags are identified and receive a message via Twitter. Patients are then contacted for recruitment into a clinical trial.
62783106|NCT01054001|ACTIVE_COMPARATOR|Delayed|men with on- demand sildenafil 100mg dosing from the delayed postoperative period
62783107|NCT04979611|OTHER|Patients will undergo 68Ga-NOTA-exendin-4 PET/CT imaging|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously. PET/CT imaging will be performed at 30-60 min post-injection.Visual and semiquantitative method will be used to assess the PET/CT images.
62783108|NCT01500902|OTHER|vascular testing|We are assessing vascular testing in patients presenting with acute coronary syndrome to determine if this type of testing will help identify which patients are more likely at risk to have another heart attack.
62783109|NCT04115098|EXPERIMENTAL|Celecoxib, Then Meloxicam, Then Naproxen, Then A, Then B|Each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. After these 3 initial treatment sessions, participants are then randomized to the 2 best-performing drugs for 2 additional treatment sessions \[randomized to either alphabetical order (A then B) or reverse alphabetical order (B then A)\] There will be no washout periods. All 3 medications will be over-encapsulated in identical opaque capsules.
62783110|NCT04115098|EXPERIMENTAL|Celecoxib, Then Meloxicam, Then Naproxen, Then B, Then A|Each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. After these 3 initial treatment sessions, participants are then randomized to the 2 best-performing drugs for 2 additional treatment sessions \[randomized to either alphabetical order (A then B) or reverse alphabetical order (B then A)\] There will be no washout periods. All 3 medications will be over-encapsulated in identical opaque capsules.
62783111|NCT04115098|EXPERIMENTAL|Celecoxib, Then Naproxen, Then Meloxicam, Then A, Then B|Each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. After these 3 initial treatment sessions, participants are then randomized to the 2 best-performing drugs for 2 additional treatment sessions \[randomized to either alphabetical order (A then B) or reverse alphabetical order (B then A)\] There will be no washout periods. All 3 medications will be over-encapsulated in identical opaque capsules.
62783112|NCT04115098|EXPERIMENTAL|Celecoxib, Then Naproxen, Then Meloxicam, Then B, Then A|Each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. After these 3 initial treatment sessions, participants are then randomized to the 2 best-performing drugs for 2 additional treatment sessions \[randomized to either alphabetical order (A then B) or reverse alphabetical order (B then A)\] There will be no washout periods. All 3 medications will be over-encapsulated in identical opaque capsules.
62783113|NCT04115098|EXPERIMENTAL|Meloxicam, Then Celecoxib, Then Naproxen, Then A, Then B|Each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. After these 3 initial treatment sessions, participants are then randomized to the 2 best-performing drugs for 2 additional treatment sessions \[randomized to either alphabetical order (A then B) or reverse alphabetical order (B then A)\] There will be no washout periods. All 3 medications will be over-encapsulated in identical opaque capsules.
62783114|NCT04115098|EXPERIMENTAL|Meloxicam, Then Celecoxib, Then Naproxen, Then B, Then A|Each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. After these 3 initial treatment sessions, participants are then randomized to the 2 best-performing drugs for 2 additional treatment sessions \[randomized to either alphabetical order (A then B) or reverse alphabetical order (B then A)\] There will be no washout periods. All 3 medications will be over-encapsulated in identical opaque capsules.
62195318|NCT04893525|ACTIVE_COMPARATOR|Buprenorphine/naloxone Standard Dosing|"The control intervention will be provision of a buprenorphine/naloxone standard dosing package from the ED. This will consist of a five day package with a commonly accepted standard dosing regimen aiming to achieve a therapeutic buprenorphine/naloxone dose within 24 hours of initiation. Standard dosing packages are currently available in EDs in BC and Alberta as standard of care.~Day 1: Buprenorphine 2 mg-naloxone 0.5 mg SL q1h prn to a maximum of 6 tablets in the first 24 hours (1 tablet),~Day 2: Buprenorphine 12 mg-naloxone 3 mg SL once daily (6 tablets),~Day 3: Buprenorphine 16 mg-naloxone 3 mg SL once daily (8 tablets),~Day 4:Buprenorphine 16 mg-naloxone 3 mg SL once daily (8 tablets).~Day 5:Buprenorphine 16 mg-naloxone 3 mg SL once daily (8 tablets)."
62195319|NCT00560157|ACTIVE_COMPARATOR|I|Sondalis HP
62195320|NCT00560157|EXPERIMENTAL|II|Crucial
62195321|NCT00497874|EXPERIMENTAL|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
62195322|NCT00497874|NO_INTERVENTION|Usual care|Usual primary care treatment
62195323|NCT04420039||1- Single biliary LAMS|Unresectable/inoperable biliopancreatic cases with distal biliary obstruction who underwent EUS-BD with a single lumen-apposing stent after failed ERCP cannulation or inaccessible papilla.
62195324|NCT04420039||2- Biliary LAMS plus Doublu-Pigtail plastic Etent|Unresectable/inoperable biliopancreatic cases with distal biliary obstruction who underwent EUS-BD with a single lumen-apposing stent (plus double-pigtail plastic stent) after failed ERCP cannulation or inaccessible papilla.
62195325|NCT02136368|EXPERIMENTAL|Multi-Modal, Mind Motor Exercise (M4)|Attend 60 minute exercise class three times per week for 24 weeks. Exercise class includes 45 minutes of multi-modal exercise and 15 minutes of mind-motor exercise.
62195326|NCT02136368|ACTIVE_COMPARATOR|Multi-Modal Exercise (M2)|Attend 60 minute exercise class three times per week for 24 weeks. Exercise class includes 45 minutes of multi-modal exercise and 15 minutes of balance and range of motion exercises.
62195327|NCT04437498|EXPERIMENTAL|nVNS|non invasive vagal nerve stimulation
62195328|NCT04437498|SHAM_COMPARATOR|sham|sham stimulation
62214970|NCT00898209||Health Volunteers|Blood and exhaled breath condensate will be collected.
62214971|NCT00898209||Patients at risk or already identified as having lung cancer|Blood and exhaled breath condensate will be collected.
62783115|NCT04115098|EXPERIMENTAL|Meloxicam, Then Naproxen, Then Celecoxib, Then A, Then B|Each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. After these 3 initial treatment sessions, participants are then randomized to the 2 best-performing drugs for 2 additional treatment sessions \[randomized to either alphabetical order (A then B) or reverse alphabetical order (B then A)\] There will be no washout periods. All 3 medications will be over-encapsulated in identical opaque capsules.
62783116|NCT04115098|EXPERIMENTAL|Meloxicam, Then Naproxen, Then Celecoxib, Then B, Then A|Each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, Each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. After these 3 initial treatment sessions, participants are then randomized to the 2 best-performing drugs for 2 additional treatment sessions \[randomized to either alphabetical order (A then B) or reverse alphabetical order (B then A)\] There will be no washout periods. All 3 medications will be over-encapsulated in identical opaque capsules.
62195329|NCT05728697||Patients with nonalcoholic fatty liver disease and elevated body mass index|Patients who have BMI \>=25 and suspected nonalcoholic fatty liver disease based on imaging, laboratory workup, or clinical history. Patients are included in the study if they have been selected for routine clinical endoscopic ultrasound (can be for any indication) with liver biopsy either during the same session or within 6 months.
62195330|NCT00658606|ACTIVE_COMPARATOR|Alefacept alone|15 mg alefacept intramuscularly (IM) once weekly for 12 weeks
62195331|NCT00658606|EXPERIMENTAL|Alefacept + nbUVB|15 mg alefacept intramuscularly once weekly and narrow band Ultraviolet B (nbUVB) phototherapy 3 times per week for 12 weeks
62195332|NCT00616083||1|Healthy breast fed infants
62195333|NCT06297720|EXPERIMENTAL|Oral hydration|wet swab-ice cube-small amount of water
62195334|NCT06297720|NO_INTERVENTION|No hydration|According to routine care, no oral fluid supplementation is provided.
62195335|NCT03040934|ACTIVE_COMPARATOR|Firehawk implantation|98 subjects will be enrolled to receive a test device (Firehawk™).
62195336|NCT03040934|ACTIVE_COMPARATOR|XIENCE implantation|98 subjects will be enrolled to receive a control device (XIENCE).
62195337|NCT00749242|OTHER|1|conventional orthopedic brace with antalgic treatment
62195338|NCT00749242|OTHER|2|balloon kyphoplasty introduction of balloon into the vertebral body, inflation of the balloon which creates a cavity, then balloon is deflated and removed , then introduction of the cement into the cavity.
62195339|NCT05713695|EXPERIMENTAL|Full MISSION|Participants assigned to this condition will receive full MISSION services. MISSION services include 6-months of integrated mental health and substance use treatment and treatment planning with the MISSION Case Manager (13 session curriculum) and Peer Support Specialist (11 session curriculum). Content of these sessions will be directed using the MISSION Treatment Manual and Consumer Workbooks. MISSION teams will also provide linkages and supports to treatment services within the participant's community throughout the duration of the study.
62195340|NCT05713695|ACTIVE_COMPARATOR|Linkage Only Delivered by a Peer Specialist|Our Linkage only arm delivered by a Peer Specialist will act as the comparison group to the MISSION arm. Participants randomized to the linkage only arm will receive 6-months of linkage care from a Peer Specialist. The Peer Specialist will provide informal treatment planning as well as linkages and support to community services, but will not provide integrated dual disorders treatment, nor will this arm utilize any MISSION materials or offer Peer led groups.
62195341|NCT00760513|ACTIVE_COMPARATOR|Omega 3 fatty acid (fish oil)|OMACOR (alternative name: Lovaza) 4 grammes daily, oral capsule
62009445|NCT04760275|ACTIVE_COMPARATOR|Medication - Fluoxetine|"Approved medication by the U.S. Food and Drug Administration (FDA) for treating anxiety disorders in children.~The study's starting dose, and minimum permitted, will be 10 mg/day; should that not be tolerated, the patient will be withdrawn from active treatment (but not from study follow-up). After 1 week at 10 mg/day, the dose will increase to 20 mg/day. After completion of week 4, 10 mg/day dose increases will be permitted every other week as tolerated, up to a maximum daily dose of 80 mg/day. If patients are on doses \>20mg/day, the total daily dose can be prescribed either once daily or split into twice daily administrations."
62195342|NCT00760513|PLACEBO_COMPARATOR|dummy pill|4 grammes daily, oral capsule (olive oil)
62195343|NCT03142347|ACTIVE_COMPARATOR|Remote endarterectomy|Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.
62195344|NCT03142347|EXPERIMENTAL|Remote endarterectomy + DCB balloon|Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.
62195345|NCT01251406|PLACEBO_COMPARATOR|Placebo|Subcutaneous administration for daily for 8 hours a day for 10 days
62195346|NCT01251406|EXPERIMENTAL|rhNRG-1 Dose 1|Subcutaneous administration for daily for 8 hours a day for 10 days
62195347|NCT01251406|EXPERIMENTAL|rhNRG-1 Dose 2|Subcutaneous administration for 8 hours a day for 10 days
62573931|NCT01174706|EXPERIMENTAL|Usual care arm|Patients randomized to this group will receive usual care. Usual care at the three study sites varies but will be defined as whatever information is usually given to patients regarding the prescription medication or over the counter medicine they were prescribed at emergency department discharge.
62573932|NCT01174706|EXPERIMENTAL|Information prescription|Patients randomized to this arm will receive written information from Medline Plus regarding the prescription or over the counter medicine they have been prescribed at ED discharge plus information on their health condition.
62009446|NCT04760275|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT)|"Type of talk therapy that aims to identify and replace negative thoughts, using positive behavioral skills to create and maintain positive moods and healthy relationships.~The Coping Cat (CC) program will be used as the behavioral intervention for this study.CC is an established evidence-based CBT treatment for pediatric anxiety. It is delivered in individual therapy sessions with anxious children."
62573933|NCT01174706|EXPERIMENTAL|Informationist|Patients in this arm will receive the same information as patients in group 2 but will also be given contact information for a clinical informationist if they have further questions about their prescription medicine or over the counter medicine prescribed at ED discharge.
62573934|NCT01174706|EXPERIMENTAL|practical assistance|Subjects will be offered practical assistance with obtaining prescription such as location of most convenient pharmacy and hours of operation, programs that offer drugs more cheaply, fax prescription from ED to pharmacy
62573935|NCT02649842|EXPERIMENTAL|Extended Cylinder IOL|Approved toric intraocular lenses, Model ZCT450, ZCT525 or ZCT600
62573936|NCT04234490||Patient|Patients who are receiving Home Parenteral Support (HPN) (artificially fed through a vein) due to intestinal failure
62573937|NCT04234490||Carer|Family member or carer of patient who is receiving Home Parenteral Support
62573938|NCT06577064|ACTIVE_COMPARATOR|Sacral erector spinae plane block Group|30 ml of 0.2% ropivacaine will be injected in the plane between the ESM and sacrum on each side While the patient is in prone position
62009447|NCT02647034||pulmonary hypertension|The two groups were defined by catheterization result. (no intervention)
62398853|NCT01886105|EXPERIMENTAL|SmEDTMP/Autologous Stem Cell Infusion/RT|"DAY 1 Tracer dose 153Sm-EDTMP administration (1 mCi/kg) SPECT/High-resolution CT at 4 hours. SPECT/CT (low resolution) at 24 and 48 hrs~DAY 7 Individualized treatment dose 153Sm-EDTMP administration (max 30 mCi/kg) SPECT scans at 4, 24 and 48 hours~DAY 21 (2 weeks following treatment dose) Auto-Stem cell infusion~DAY 40 (approx. two weeks after stem cell rescue) Initiate EBT upon count recovery~1 MONTH following completion of all therapy Response assessment with repeat imaging (CT/MRI, Tc-99m bone scan) 18F-MISO/FDG PET"
62398854|NCT06347848|EXPERIMENTAL|Experimental|Psyhcoeducation Group (Experimental) Psychoeducation focused on reducing internalized stigma will be applied to the experimental group.
62398855|NCT06347848|NO_INTERVENTION|No Intervention|Controls (Control Group) No intervention will be applied to the control group.
62009448|NCT02647034||non-pulmonary hypertension|The two groups were defined by catheterization result. (no intervention)
62009449|NCT03842787||SLE patients with lupus Nephritis|"14 SLE patients with lupus Nephritis~Biological analysis and biopsy were (routinely) performed~Ethics The protocol will be submitted to a randomly chosen Institutional Review Board (Comité de Protection des Personnes), in compliance to French regulation.~Investigators will include patients followed for routine care. Patients will be informed that samples (serum and kidney biopsy) that are performed for routine patient care will subsequently be used for research purposes, with no additional blood draw/biopsy. They will sign informed consent."
62398856|NCT06723405|EXPERIMENTAL|Intravenous EVO301|
62398857|NCT06723405|PLACEBO_COMPARATOR|Placebo|
62398858|NCT02675660|EXPERIMENTAL|L-Homoarginine|125 mg of L-homoarginine
62573939|NCT06577064|PLACEBO_COMPARATOR|non-intervention group|patients will receive general anesthesia plus scheduled analgesia protocol in the form of morphine sulphate I.V. 1 mg every 5 minutes if NRS more than 5 till maximum dose 10 mg
62398859|NCT02675660|PLACEBO_COMPARATOR|Placebo|placebo capsules
62398860|NCT03037138|OTHER|Washed-out scale after using BFR profiling|Blood flow profiling will be used as intervention for washed-out dialysis patients
62573940|NCT00984893||Zoledronic acid|
62573941|NCT00984893||Oral Bisphosphonates|
62573942|NCT01156623|EXPERIMENTAL|With EBUS-TBNA group|The patients enrolled in present study are those with non-small lung cancer and receive contrast-enhanced computed tomography (CT) and Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) examination. In this group, further EBUS-TBNA will be arranged if patients agreed it.
62573943|NCT01156623|NO_INTERVENTION|Without EBUS-TBNA group|The patients enrolled in present study are those with non-small lung cancer and receive contrast-enhanced computed tomography (CT) and Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) examination. In this group, no EBUS-TBNA will be arranged if patients refused it despite we advised it.
62573944|NCT01779128|EXPERIMENTAL|Experimental Arm|PET/CT Scan MR-PET Scan
62573945|NCT06309160|NO_INTERVENTION|Focus Groups to Inform CAST|For the year 1 development activities, the research team will conduct focus groups with administrators, special education teachers, parents, students, and pre-employment transition specialists about how to integrate plans and services across settings.
62009450|NCT05631639|EXPERIMENTAL|PillSense System|The device is composed of an orally ingested sensor capsule and a wireless handheld receiver for real-time display of sensor data. The capsule contains a measuring slot for blood entry. The sensor capsule is used for diagnosis in patients with suspected acute bleeding in the upper gastrointestinal tract.
62195348|NCT03435042|EXPERIMENTAL|Children with cancer + their siblings|
62195349|NCT03435042|EXPERIMENTAL|Parents of children with cancer|
62214972|NCT04461444|OTHER|Group ALMS et BBS|
62398861|NCT01283061|EXPERIMENTAL|zafirlukast|Zafirlukast Tablets 20 mg of Dr. Reddys Laboratories Limited
62398862|NCT01283061|ACTIVE_COMPARATOR|Accolate|ACCOLATE tablets manufactured by IPR pharmaceuticals and manufactured for Astrazeneca Pharmaceuticals
62398863|NCT05730621|EXPERIMENTAL|Sarpogrelate Sustained Release/Aspirin|Sarpogrelate Sustained Release/Aspirin Combination Therapy for 12 weeks
62398864|NCT05730621|ACTIVE_COMPARATOR|Aspirin|Aspirin Monotherapy qd for 12 weeks
62573946|NCT06309160|EXPERIMENTAL|Pre-Post study of CAST|The research team will then conduct a field test of CAST in year 2, making further revisions.
62573947|NCT06309160|ACTIVE_COMPARATOR|Randomized Controlled Study of CAST|In year 3, they will use a mixed methods design using a small RCT and network analysis, oversampling African American students and students from rural areas, to evaluate CAST for improved postsecondary outcomes in employment, training, and education.
62573948|NCT01735825|EXPERIMENTAL|iopromide paclitaxel-eluting balloon|Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter (iopomide coating)
62573949|NCT01735825|ACTIVE_COMPARATOR|drug eluting stent|Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus
62573950|NCT01735825|OTHER|seal-wing PEB|"Observational, non-randomised arm:~Pts with ISR treated by seal-wing paclitaxel-eluting balloon catheter"
62573951|NCT01809301|ACTIVE_COMPARATOR|Niaspan|Single dose of one NIASPAN® 1000 mg Extended-Release Tablet following dinner
62573952|NCT01809301|EXPERIMENTAL|TRIA-662|Single dose of two TRIA-662, 500 mg Immediate-Release Tablets following dinner
62573953|NCT04452214|EXPERIMENTAL|CAN04 and pembrolizumab (Part 1)|Subjects will receive weekly doses of CAN04 in combination with pembrolizumab given as standard regimen
62573954|NCT04452214|EXPERIMENTAL|CAN04 + pembrolizumab + carboplatin + pemetrexed (Part 2)|Subjects will receive doses of CAN04 on Days 1 and 8 (Cycles 1 thru 4), and on Day 1 (Cycle 5 onwards) in combination with pembrolizumab given as standard regimen and carboplatin and pemetrexed standard of care
62573955|NCT03121846|EXPERIMENTAL|apatinib group|apatinib 500mg po qd, 28 days for a cycle.
62573956|NCT03236961|ACTIVE_COMPARATOR|Intravenous & per oral antibiotics|Ertapenem 1 g x 1 for two days i.v. followed by p.o. levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 5 days, duration of treatment one week.
62573957|NCT03236961|ACTIVE_COMPARATOR|Per oral antibiotics|Moxifloxacin 400 mg x 1 foe seven days, duration of treatment one week.
62573958|NCT04689191|EXPERIMENTAL|Experimental Vaccine|One dose of Experimental Group A and C meningococcal polysaccharide vaccine
62573959|NCT04689191|ACTIVE_COMPARATOR|Active Comparator Vaccine|One dose of Control Group A and C meningococcal polysaccharide vaccine
62573960|NCT00789698|EXPERIMENTAL|Lurasidone HC1|
62573961|NCT00789698|ACTIVE_COMPARATOR|Quetiapine|
62573962|NCT04955314|EXPERIMENTAL|PA mobilizations on their main painfull vertebral segment|Patients who will be treated with PA mobilizations on their main painfull vertebral segment.
62573963|NCT04955314|EXPERIMENTAL|PA mobilizations on an adjacent vertebral segment from the most painful|Patients who will be treated with PA mobilizations on an adjacent vertebral segment from the most painful.
62573964|NCT00921557|EXPERIMENTAL|1A: Alendronate/Alendronate|Participants received alendronate for 96 weeks and calcium carbonate/vitamin D for 144 weeks
62195350|NCT03117764|ACTIVE_COMPARATOR|Acute IV AB for exacerbation at hospital|"The study will compare muscular strength of hospitalised patients who receive specific exercise training, with patients who follow their antibiotherapy at home without specific exercise training.~Interventions: microfet dynamometer, 1 minute sit to stand test, accelerometer."
62573965|NCT00921557|EXPERIMENTAL|1B: Alendronate/Placebo|Participants received alendronate for 48 weeks followed by placebo for 48 weeks and calcium carbonate/vitamin D for 144 weeks
62573966|NCT00921557|EXPERIMENTAL|2: Placebo/Alendronate|Participants received placebo for 48 weeks followed by alendronate for 48 weeks and calcium carbonate/vitamin D for 144 weeks
62573967|NCT04985292|EXPERIMENTAL|Probiotic|10\^10 colony-forming units of a Lactobacillus strain, packaged in a capsule, once daily
62573968|NCT04985292|PLACEBO_COMPARATOR|Placebo|Inactive substance packaged to be identical to active treatment
62573969|NCT04400851|EXPERIMENTAL|Sintilimab in advanced childhood cancer patients|
62573970|NCT04496804|EXPERIMENTAL|Behavioral Intervention for Physical Activity in MS (BIPAMS)|The current behavioral intervention consists of two primary components; an Internet website and one-on-one video chats with a behavioral coach. The Internet website involves content delivered through interactive video courses. The interactive video courses are based on elements of social cognitive theory. Each courses consists of an introduction, the primary content, and a take home message. The interactive courses include embedded, supplementary options such as videos on content and worksheets related to the topic. A pedometer is provided for tracking steps, and these steps will be entered into the website so progress can be monitored. The chats support adherence to the intervention, discussion of website material, supportive accountability, and reporting of adverse events/injuries. The chats are conducted face-to-face through Skype. The chats occur 7 times during the first 2 months, 4 times during the second 2 months, and twice during the final 2 months of the intervention.
62573971|NCT04496804|SHAM_COMPARATOR|Wellness for MS (WellMS)|Provides an Internet website and one-on-one video chats that discuss materials about self-managing multiple sclerosis (MS) consequences and health indicators through methods other than physical activity. The materials are transformations of brochures provided by the National MS Society, including Gait or Walking Problems: The Basic Facts; MS and Your Emotions; Pain: The Basic Facts; Solving Cognitive Problems; Taming Stress in MS; Food for Thought: MS and Nutrition; and Vitamins, Minerals, and Herbs: An Introduction. The delivery of the Internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition, and will have a comparable time commitment. The control condition will not involve tracking steps and a pedometer with not be provided.
62573972|NCT05087511||only preterm birth|Peabody Motor Development Scale-2 was used to evaluate motor development performances and Dunn Sensory Profile was used to evaluate sensory processing
62573973|NCT05087511||riskly preterm birth|Peabody Motor Development Scale-2 was used to evaluate motor development performances and Dunn Sensory Profile was used to evaluate sensory processing
62573974|NCT02741661||Normal coronary arteries|Patients in whom coronary arteriography has demonstrated no significant tortuosity.
62573975|NCT02741661||Tortuous coronary arteries|Patients in whom coronary arteriography has demonstrated tortuous coronary arteries defined as \>1 major bend of \>45 degrees in a major coronary artery
62573976|NCT04337905|EXPERIMENTAL|Children with ADHD|Children with ADHD that running the ADHD-VR diagnostic test and also did the psychiatric examination to determine the ADHD diagnosis and to rule out other mental disorders
62573977|NCT04337905|ACTIVE_COMPARATOR|Children without ADHD|Healthy children that also running the ADHD-VR diagnostic test and also psyhchiatric examination to rule out the ADHD diagnosis and other mental disorders
62573978|NCT03303690|EXPERIMENTAL|Ankle Spacer (AS)|This arm will surgically receive the to be implanted ankle spacer in their ankle.
62195351|NCT03117764|EXPERIMENTAL|Acute IV AB for exacerbation at home|"The study will compare muscular strength of hospitalised patients who receive specific exercise training, with patients who follow their antibiotherapy at home without specific exercise training.~Interventions: microfet dynamometer, 1 minute sit to stand test, accelerometer."
62195352|NCT02977767|EXPERIMENTAL|Conversational hypnosis|Use of conversational hypnosis during the tracheal cannula replacement
62195353|NCT03976154|EXPERIMENTAL|Dermabond|Catheter fixation will be performed after appropriate placement of a thoracic epidural with Dermabond. The investigator performing the thoracic epidural will distribute the Dermabond at the catheter insertion site in a space no greater than a 2 cm circle around the site. Once the Dermabond is allowed to dry, mastisol will be applied to the surrounding skin and a clear Tegaderm dressing will be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia with a goal rate of 6ml/hr.
62195354|NCT03976154|ACTIVE_COMPARATOR|Mastisol|Catheter fixation will be performed after appropriate placement of a thoracic epidural with Mastisol spray. The investigator performing the epidural placement will distribute Mastisol spray both in close proximity to the catheter insertion site as well as around the insertion site. Once the Mastisol is allowed to dry, a clear Tegaderm dressing will be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia team with a goal rate of 6ml/hr.
62195355|NCT03976154|ACTIVE_COMPARATOR|Grip-lock|Catheter fixation will be performed after appropriate placement of a thoracic epidural with a Grip-Lok fixation bandage. The investigator performing the epidural placement will place the fixation bandage one centimeter caudal from the insertion site. Mastisol will be applied to the surrounding skin and a clear Tegaderm will then be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia team in the operating room with a goal rate of 6ml/hr.
62195356|NCT01617122|EXPERIMENTAL|Bacteriophage|Subjects receive bacteriophage vaccinations and blood draws
62195357|NCT00486252||This is N/A due to the above description.|This is N/A due to the above description.
62195358|NCT01210326|EXPERIMENTAL|aspiration|90 patients with non-obstructive azoospermi undergo testicular sperm aspiration
62195359|NCT01210326|EXPERIMENTAL|extraction|90 patients with non-obstructive azoospermi undergo testicular sperm extraction
62195360|NCT05398549|ACTIVE_COMPARATOR|Conventional physical therapy|Subjects in group A was treated with conventional physical therapy i.e. grade 1 and 2 mobilization and stretching exercise.
62195361|NCT05398549|EXPERIMENTAL|Virtual reality group|group B was treated with virtual reality stimulation given for 30 minutes per session through kinetic Xbox with sensory accelerator model no.1414.Two traditional training activities was used to improve shoulder Range of motion i.e. badminton and American baseball activity 12 times of the training Baseline treatment protocol hot pack and ultrasound was applied to both groups. Treatment duration for both groups was 30 minutes. Each subjects were receive a total 4 week protocol with 03 treatment sessions per week.
62573979|NCT00746564|EXPERIMENTAL|Open Label|SJM Confirm Device
62195362|NCT00919451|EXPERIMENTAL|Ciclosporin|ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)
62195363|NCT04627051|EXPERIMENTAL|Dysfunction AV graft|Dysfunctional AV graft stenosis treated with atherectomy and drug coated balloon angioplasty
62195364|NCT03609268|ACTIVE_COMPARATOR|MWA|Patients receive microwave ablation (MWA)
62195365|NCT03609268|EXPERIMENTAL|SBRT|Patients receive stereotactic body radiotherapy (SBRT)
62195366|NCT01181453|EXPERIMENTAL|Dermagraft(R)|Weekly application of Dermagraft(R) with standard care
62195367|NCT01181453|OTHER|Standard care only|Weekly application of standard care
62195368|NCT00653731|EXPERIMENTAL|Snoezelen ©|
62195369|NCT00653731|EXPERIMENTAL|Reminiscence|
62573980|NCT00557544|EXPERIMENTAL|1|metoclopramide 0,15 mg/kg and Ketoprofen 1 mg/Kg per os in single dose
62573981|NCT00557544|ACTIVE_COMPARATOR|2|metoclopramide 0,15 mg/Kg + placebo per os
62573982|NCT00557544|ACTIVE_COMPARATOR|3|ketoprofen 1 mg/Kg and placebo in single dose
62573983|NCT00575172||U|Intensified insulin therapy with ultrarapid insulin-analogue (Insulin-Aspart)
62573984|NCT00575172||R|Intensified insulin therapy with human regular insulin
62573985|NCT05082675|EXPERIMENTAL|auto/RICallo treatment arm|Patients with an HLA-identical sibling donor were allocated to the auto-allo arm (n = 108)
62573986|NCT05082675|ACTIVE_COMPARATOR|auto arm|patients without a matched sibling donor were allocated to the auto arm (n = 249). Single (n = 145) or tandem (n = 104)
62573987|NCT06129916||PWID who opt for LADB|People with opioid dependence who opt to initiate LADB across a range of LMIC settings over a 48-week period
62573988|NCT06129916||PWID who opt for standard of care|People with opioid dependence who refuse to initiate LADB and opt for standard of care
62573989|NCT02729051|EXPERIMENTAL|FF/UMEC/VI closed triple therapy plus Placebo|Subjects will receive FF/UMEC/VI, 100 mcg/62.5 mcg/25 mcg and placebo inhalation powder via the dry powder inhaler (DPI), once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
62398865|NCT05042882|EXPERIMENTAL|Early enteral nutrition|Intervention group: enteral nutrition from the first postoperative night until 50% of caloric requirements are covered by oral nutrition. Enteral nutrition will start at a flow of 250 ml/12h. If tolerated, enteral nutrition will be increased to 500 ml/12h on postoperative day 1, 750 ml/12h on postoperative day 2, and 1000 ml/12h on postoperative day 3. A hypercaloric enteral nutrition will be used (Isosource Energy Fibre or similar).
62573990|NCT02729051|ACTIVE_COMPARATOR|FF/VI plus UMEC open triple therapy|Subjects will receive FF/VI, 100 mcg/25 mcg and UMEC, 62.5 mcg inhalation powder via the DPI, once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
62573991|NCT00216619|EXPERIMENTAL|Open Label Phase|Topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening. Until Week 26
62573992|NCT00216619|EXPERIMENTAL|Double Blind and Roll Out Phase|the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26).
62573993|NCT03563963|ACTIVE_COMPARATOR|Lidocaine 2% in Endotracheal Tube cuff|Lidocaine 2% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
62573994|NCT03563963|EXPERIMENTAL|Ropivacaine 0.5% Endotracheal Tube cuff|Ropivacaine 0.5% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
62573995|NCT03563963|ACTIVE_COMPARATOR|Air in the Endotracheal Tube cuff|Air will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
62009451|NCT05972434|EXPERIMENTAL|Group 1: Sunscreen A|Eligible study participants will receive a standard liquid soap to be used on the face and forearms for 3 full days for an initial washout period in place of their usual soap. On their next visit to site an amount of IP will be topically applied to malar on one side of the participant's face by a qualified technician and other side of face will remain without product application (used for control). Six areas will also be marked on inner side of participant's forearms, approximately 5 centimeter (cm) from cubital region. These areas will be randomized, with 1 area for control (without product application) and other 5 areas for product application, being each of them for 02 IPs (Facial Sunscreen A and Face Sunscreen B) and 3 benchmarks. The products will be applied topically only once in marked areas. Next, participants will use Facial Sunscreen A in normal conditions at home for 28 +/- 2 days and then make the last study visit to complete the final analysis.
62009452|NCT05972434|EXPERIMENTAL|Group 2: Sunscreen B|Eligible study participants will receive a standard liquid soap to be used on the face for 3 full days for an initial washout period in place of their usual soap. On their next visit to the Site an amount of the IP will be topically applied to the malar on one side of the participants' face by a qualified technician and the other side of the face will remain without product application (used for control). On their next visit to the Site an amount of the IP will be topically applied to the malar on one side of the participants' face by a qualified technician and the other side of the face will remain without product application (used for control). From Visit 2 to visit 4 participants will use the IP (Face Sunscreen B) at home until 56 +/-2 days of use.
62573996|NCT05320315|OTHER|ACTIVE and UNTREATED|This was an intraindividual comparison study. Active (DM sunscreen) treated zone and Untreated zone are compared
62573997|NCT04684537|ACTIVE_COMPARATOR|Shockwave group|each subject will receive extracorporeal shockwave therapy
62573998|NCT04684537|ACTIVE_COMPARATOR|Injection group|each subject will receive ultrasound-guided piriformis corticosteroid injection
62573999|NCT00792883||patients ARDS|142 Patients in respiratory failure with a diagnosis of ARDS hospitalized at the ICU.
62574000|NCT00792883||Patients non ARDS|432 patients in respiratory failure from other causes (ARDS being formally excluded), hospitalized at the same ICU.
62574001|NCT00792883||Healthy controls|626 healthy patients undergoing elective surgery at the Pediatric Surgery Department or recruited from the pediatric ambulatory.
62574002|NCT00776438|EXPERIMENTAL|Study Group 1|Adult, age 18 to 40 years
62574003|NCT00776438|EXPERIMENTAL|Study Group 2|Adult, age 18 to 40 years
62195370|NCT00653731|EXPERIMENTAL|10 min activation|
62574004|NCT00776438|EXPERIMENTAL|Study Group 3|Elderly, age 60 to 85 years
62574005|NCT00776438|EXPERIMENTAL|Study Group 4|Elderly, age 60 to 85 years
62574006|NCT02027545|EXPERIMENTAL|Decision Aid|Patients of primary care providers randomly assigned to the Decision Aid intervention (DA) that includes an individualized decision aid, provider education, and modified performance measure/reminder.
62574007|NCT02027545|OTHER|No Decision Aid|Patients of primary care providers will be randomly assigned to the pragmatic control (PC) that includes provider education and modified performance measure/reminder, but no decision aid.
62574008|NCT01228890|EXPERIMENTAL|CATCH-IT 2-R Arm|Primary care/Internet based depression prevention intervention (CATCH-IT 2-R) with a family component.
62574009|NCT01228890|ACTIVE_COMPARATOR|Attention Monitoring Psycho-education (AMPE) Arm|
62574010|NCT02565628|EXPERIMENTAL|PF-06669571|Once daily (QD) for 7 days
62574011|NCT02565628|PLACEBO_COMPARATOR|Placebo|QD for 7 days
62009453|NCT03842475||Surgical cohort|Patients with type 2 diabetes undergoing Roux-en-Y gastric bypass surgery
62574012|NCT02127411|EXPERIMENTAL|Mindfulness-based relapse prevention|Mindfulness-Based Relapse Prevention
62574013|NCT02127411|NO_INTERVENTION|Waitlist|this group will stay in the waitlist until the end of follow-up assessments, when they will receive the intervention
62574014|NCT05752019||ETI treatment group > 12 years|CF patients older than 12, whom are eligible to receive elexacaftor/tezacaftor/ivacaftor treatment.
62574015|NCT05752019||Control group > 12 years|CF patients older than 12, whom are not eligible to receive any CFTR-modulator.
62009454|NCT03842475||Control|Healthy volunteers with normal body mass index
62009455|NCT05210920|EXPERIMENTAL|Regular Nail Polish|Participants will have regular nail polish applied to one fingernail of their dominant hand
62195371|NCT00653731|ACTIVE_COMPARATOR|Talk|
62398866|NCT05042882|NO_INTERVENTION|Oral nutrition|Control group: patients will receive standardized oral nutrition. The night after the operation, patients will be allowed to have free drinks. On postoperative day 1, they will receive bouillons, creams, yogurts, and drinks \>2 l. On postoperative day 2, they will receive a light diet. On postoperative day 3, they will receive half portion of normal diet and on postoperative day 4 normal diet.
62398867|NCT04008459||Degenerative musculoskeletal spinal conditions|Participants are included who are enrolled in a 6-week physiotherapy exercise class aimed at improving function in people with degenerative spinal conditions.
62398868|NCT03625102|EXPERIMENTAL|Antroquinonol 100 mg PO BID|Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol, twice a day.
62398869|NCT03625102|EXPERIMENTAL|Antroquinonol 50 mg PO BID|Antroquinonol (Hocena) 50mg/capsule. 1 capsule antroquinonol and 1 capsule placebo,twice a day.
62574016|NCT05752019||ETI treatment group < 12 years|CF patients younger than 12, whom are eligible to receive elexacaftor/tezacaftor/ivacaftor treatment.
62574017|NCT05752019||Control group < 12 years|CF patients younger than 12, whom are not eligible to receive any CFTR-modulator.
62574018|NCT06310733|EXPERIMENTAL|LGG (ATCC 53103)|A suspension of freeze-dried LGG ATCC53103 in excipients in an aqueous solution supplied in a 10-mL dark bottle with a delivery cap.
62574019|NCT06310733|PLACEBO_COMPARATOR|Placebo|An identical aqueous solution in appearance and taste but without LGG.
62009456|NCT05210920|EXPERIMENTAL|Gel Nail Polish|Participants will have gel nail polish applied to one fingernail of their dominant hand
62009457|NCT05210920|NO_INTERVENTION|Bare Nail|Participants will have one fingernail of their dominant hand left bare for comparison
62009458|NCT04736459|EXPERIMENTAL|Washed Catheter|Washed catheter arm: will be washed with culture medium before insemination
62009459|NCT04736459|SHAM_COMPARATOR|Unwashed Catheter|Unwashed catheter arm: will not be washed with culture medium.
62009460|NCT03331874||Basal Cell Carcinoma|Diagnosis of Basal Cell Carcinoma by Reflectance confocal microscopy
62195372|NCT02847481|EXPERIMENTAL|fecal microbiota transplantation|fecal microbiota transplantation
62195373|NCT02847481|PLACEBO_COMPARATOR|placebo fecal microbiota transplantation|placebo fecal microbiota transplantation
62195374|NCT02847481|EXPERIMENTAL|FMT after antibiotic pretreatment v1|fecal microbiota transplantation after antibiotic pretreatment
62195375|NCT02847481|EXPERIMENTAL|FMT after antibiotic pretreatment v2|fecal microbiota transplantation after antibiotic pretreatment
62195376|NCT02022722|ACTIVE_COMPARATOR|Pelvic Rehabilitation|Pelvic Rehabilitation will be conduction on weekly basis for a total of 6 weeks
62398870|NCT03625102|PLACEBO_COMPARATOR|Placebo|Placebo capsule, 2 capsules placebo, twice a day
62398871|NCT04112108||mitral stenosis post percutaneous mitral commissurotomy(PTMC)|successful PTMC after follow up
62398872|NCT02070718|PLACEBO_COMPARATOR|Placebo|Cornstarch, National Formulary
62398873|NCT02070718|EXPERIMENTAL|Standard Dose Kappa Agonist|Pentazocine/Naloxone 50/0.5 mg
62398874|NCT02070718|EXPERIMENTAL|Half Dose Kappa Agonist|Pentazocine/Naloxone 25/0.25 mg
62398875|NCT05801679|EXPERIMENTAL|Sugammadex|Single intravenous (IV) bolus of sugammadex at 2 mg/kg (Twitch count 2-4 of 4) or 4 mg/kg (twitch count less than 2 of 4).
62398876|NCT05801679|PLACEBO_COMPARATOR|Placebo|Single intravenous (IV) bolus of Placebo at 2 mg/kg (Twitch count 2-4 of 4) or 4 mg/kg (twitch count less than 2 of 4).
62398877|NCT05433584|EXPERIMENTAL|Tirzepatide|Participants will receive tirzepatide at the maximum tolerated dose subcutaneously (SC)
62574020|NCT00589758||Acute Decompensated Heart Failure|"Admitted to Heart Failure ICU for acute decompensated heart failure. 2D and 3D echocardiography will be obtained at baseline, 24 -48 hours and 1-2 weeks post discharge.~Blood and urine will be collected for biomarker evaluation at each timepoint"
62574021|NCT03616873||Adults aged 60 or older|
62574022|NCT02919319|EXPERIMENTAL|Dose group 1|Six subjects received 5 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.
62574023|NCT02919319|EXPERIMENTAL|Dose group 2|Three subjects received a single oral dose (25 mg) of ACT-541468 formulation A during Period 1 and a single oral dose (25 mg) of ACT-541468 formulation B during Period 2. Three other subjects Subjects received ACT-541468 formulation B during Period 1 and ACT-541468 formulation A during Period 2. Two additional subjects received the matching placebos in both treatment periods.
62009461|NCT01127399||Bariatric, nonasthma|Participants that will have had a bariatric surgery but do not have asthma.
62398878|NCT05433584|ACTIVE_COMPARATOR|Intensified Conventional Care Dose|Participants will receive an antihyperglycemic medication
62398879|NCT02962999|EXPERIMENTAL|Ketamine|After induction, patients will be received 1 mg/kg ketamine bolus, then will be administered 0,5 mg/kg/hour ketamine infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,25-0,5 microgram/dk/min remifentanil.
62574024|NCT02919319|EXPERIMENTAL|Dose group 3|Six subjects received 50 mg of ACT-541468 (formulation A) as a single oral dose in combination with a \[14C\]-ACT-541468 oral tracer for the mass balance and metabolism analyses. Two other subjects received the matching placebos.
62574025|NCT02919319|EXPERIMENTAL|Dose group 4|Six subjects received 100 mg of ACT-541468 (formulation A) as a single oral dose in combination with a \[14C\]-ACT-541468 intravenous tracer for the absolute bioavailability assessment. Two other subjects received the matching placebos.
62574026|NCT02919319|EXPERIMENTAL|Dose group 5|Six subjects received 200 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.
62398880|NCT02962999|PLACEBO_COMPARATOR|Saline|After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,25-0,5 microgram/dk/min remifentanil.
62398881|NCT00368069|EXPERIMENTAL|Keppra® XR|Keppra® extended release formulation -XR
62574027|NCT03219814|EXPERIMENTAL|Cognitive Dissonance Intervention|"Participants in the Cognitive Dissonance condition will complete tasks from Becker et al.'s (2005) 2-session adaptation of the Body Project. In the intervention groups, participants will be asked to consider the costs of pursuing the thin ideal in verbal, written, and behavioural exercises. Participants will be asked to assume the role as a body activist, and will be given several opportunities to vocalize opposition to the social forces that drive the thin ideal throughout the sessions.~The first session will involve exercises and discussions about the thin ideal and the costs associated with pursuing it. They will be given a homework assignment to complete at home over the next week. In the following week's session the participants will engage in a role-play exercise, as well as continuing the discussion on the costs of pursuing the thin ideal."
62009462|NCT01127399||Bariatric, asthma|Participants that will have had a bariatric surgery and have been physician diagnosed with asthma prior to the surgery.
62009463|NCT01127399||Control, nonasthma|Healthy participants that who will not be getting a bariatric surgery and who do not have asthma.
62009464|NCT01127399||Control, asthma|Healthy participants that will not be having a bariatric surgery but do have asthma.
62009465|NCT01934153|EXPERIMENTAL|Cohort A|Single dose of topical \[14C\]Umeclidinium was applied to the unoccluded axilla, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
62009466|NCT01934153|EXPERIMENTAL|Cohort B|Single dose of topical \[14C\]Umeclidinium was applied to the occluded axilla, and the drug which will be applied to the test site has remain on the application site for 8 hrs
62398882|NCT00368069|PLACEBO_COMPARATOR|Placebo|placebo
62398883|NCT04089943|EXPERIMENTAL|Revascularization group|Participants will be randomized to either an endovascular or an open bypass procedure.
62398884|NCT04089943|OTHER|Control group|Healthy non-PAD participants will be recruited as control group
62398885|NCT06724614|EXPERIMENTAL|VDHPL01 BID|VDPHL01 will be taken orally twice a day, once in the AM and once in the PM.
62195377|NCT02022722|ACTIVE_COMPARATOR|Trigger Point Injections|Trigger point injections will be administered on weekly basis for a total of 6 weeks
62195378|NCT05055401||Anesthesiology providers|Group will contain anesthesiologists, CRNA and AAs. The type of healthcare professional participating will be recorded along with the years of experience the participant has. Each participants experience will be categorized into three ranges, 0-3 years, 3-10 years, and 10+ years of experience. For further clarification and analysis, the healthcare professional's normal practice setting will also be recorded including inpatient, outpatient, or hybrid (inpatient and outpatient) settings. All providers will be analyzed together.
62195379|NCT05163223|EXPERIMENTAL|AST-301(pNGVL3-hICD)+Chemotherapy|"* AST-301/rhuGM-CSF (q 3 weeks, 3 cycles) + Standard adjuvant therapy\*~* A booster (AST-301/rhuGM-CSF) at 24 weeks post the third vaccination~  * Standard adjuvant therapy will be pembrolizumab or capecitabine (q 3 weeks)"
62195380|NCT05163223|ACTIVE_COMPARATOR|Placebo + Chemotherapy|"* Placebo/rhuGM-CSF (q 3 weeks, 3 cycles) + Standard adjuvant therapy\*~* A booster (Placebo/rhuGM CSF) at 24 weeks post the third vaccination~  * Standard adjuvant therapy will be pembrolizumab or capecitabine (q 3 weeks)"
62195381|NCT05773911|EXPERIMENTAL|Test|Curettes+ Ultrasonic scalers supragingivally and a chitosan brush in oscillating handpiece subgingivally with adjunct 4% chitosan gel (pH 3.48).
62574028|NCT03219814|ACTIVE_COMPARATOR|Mediapsychoeducation Intervention|"Participants in the Mediapsychoeducation condition will complete two sessions of tasks as outlined for Becker et al.'s (2005) media psychoeducation group, which includes no cognitive dissonance tasks. The first session will have the participants discuss the thin ideal and the media's influence on it. They will then watch a 35-minute psychoeducational video on the influence that advertisements have on body image and perpetuating the thin ideal. They will be assigned homework to complete at home during the week between the sessions. The second session will include a discussion surrounding the attainability to the thin ideal, and this discussion will also be expanded to include all forms of media. Participants will then be asked to consider and discuss differences between media images and themselves, as well as whether achieving this ideal is realistic, and the costs in trying to achieve this thin ideal. They will then watch a 20-minute video on eating disorders."
62783117|NCT04115098|EXPERIMENTAL|Naproxen, Then Celecoxib, Then Meloxicam, Then A, Then B|Each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. After these 3 initial treatment sessions, participants are then randomized to the 2 best-performing drugs for 2 additional treatment sessions \[randomized to either alphabetical order (A then B) or reverse alphabetical order (B then A)\] There will be no washout periods. All 3 medications will be over-encapsulated in identical opaque capsules.
62783118|NCT04115098|EXPERIMENTAL|Naproxen, Then Celecoxib, Then Meloxicam, Then B, Then A|Each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. After these 3 initial treatment sessions, participants are then randomized to the 2 best-performing drugs for 2 additional treatment sessions \[randomized to either alphabetical order (A then B) or reverse alphabetical order (B then A)\] There will be no washout periods. All 3 medications will be over-encapsulated in identical opaque capsules.
62009467|NCT01934153|EXPERIMENTAL|Cohort C|Single dose of topical \[14C\]Umeclidinium was applied to the unoccluded palm, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
62009468|NCT01934153|EXPERIMENTAL|Cohort D|Single dose of topical \[14C\]Umeclidinium was applied to the occluded palm, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
62009469|NCT00666367|ACTIVE_COMPARATOR|1|Vitamin D (D-cure) will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
62009470|NCT00666367|PLACEBO_COMPARATOR|2|Placebo will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
62195382|NCT05773911|ACTIVE_COMPARATOR|Control|Curettes+ Ultrasonic scalers supragingivally and a chitosan brush in oscillating handpiece subgingivally
62195383|NCT02667106|EXPERIMENTAL|Single-dose, open label RX0041-2|Active Drug
62195384|NCT03414970|ACTIVE_COMPARATOR|Group I (radiation therapy)|Patients undergo radiation therapy daily on Monday-Friday for 5-6 weeks.
62195385|NCT03414970|EXPERIMENTAL|Group II (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy daily on Monday-Friday for 3-4 weeks.
62195386|NCT01012947|EXPERIMENTAL|Lifestyle Counseling Usual Care|Usual care participants in the group A received no additional services.
62195387|NCT01012947|EXPERIMENTAL|Lifestyle Counseling Telephone, Bimonth|Participants in the group B received bimonthly telephonic care management based on manual.
62009471|NCT04981041|EXPERIMENTAL|Potent P2Y12-Inhibition|Prasugrel 10mg (5 mg in patients ≥ 75 years old or weighing \< 60 kg) q.d. per os or Ticagrelor 90mg bid per os
62009472|NCT04981041|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 75mg q.d. per os
62009473|NCT04403022|OTHER|Single arm|Colorectal procedure will be performed by da Vinci SP® Surgical System
62009474|NCT04424121|NO_INTERVENTION|Standard of care plus ECG Stress Testing|Participants will be approached and randomized to receive standard care plus ECG-stress testing
62195388|NCT01012947|EXPERIMENTAL|Lifestyle Counseling Telephone, Month|Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.
62195389|NCT01012947|EXPERIMENTAL|Lifestyle Counseling Visit, Bimonth|Participants in the group D received health educator-initiated visit counseling bimonthly.
62195390|NCT01012947|EXPERIMENTAL|Lifestyle Counseling Visit, Reward|Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
62195391|NCT06103643|EXPERIMENTAL|High Reality Simulator|Breech birth management training will be given by the responsible investigator, and then one of the groups will be allocated by randomization. Using High Reality Simulator will perform emergency breech birth. These trainings will first be in the form of the instructor responsible for the groups demonstrating the application, and then the students will apply it one by one.
62195392|NCT06103643|SHAM_COMPARATOR|control group|Using model will perform emergency breech birth. These trainings will first be in the form of the instructor responsible for the groups demonstrating the application, and then the students will apply it one by one.
62195393|NCT02155270|ACTIVE_COMPARATOR|Precut|A corneal precut of 600µm will be performed.
62195394|NCT02155270|ACTIVE_COMPARATOR|Stab incision|A stab incision without corneal precut will be performed.
62009475|NCT04424121|NO_INTERVENTION|Standard of care plus ECG Stress Testing and CACS|Participants will be approached and randomized to receive standard care plus ECG-stress testing and coronary artery calcium scoring
62195395|NCT06266897||EM group|Patient diagnosed with endometriosis after confirmation by laparoscopic surgery and pathologic examination.
62195396|NCT06266897||Control group|Patient diagnosed without endometriosis after confirmation by laparoscopic surgery and pathologic examination, usually with benign gynecologic conditions such as uterine fibroids or teratomas.
62214973|NCT03583567|PLACEBO_COMPARATOR|0.9% Normal Saline|Syringe No 1 contain normal saline 1 mL Syringe No 2 contain normal saline 2 mL
62574029|NCT03219814|NO_INTERVENTION|Waitlist Control|The participants in the Waitlist condition will be given the Cognitive Dissonance intervention between 5 and 6 weeks after their second assessment-only session (the cognitive dissonance intervention will be offered and scheduled 1 week after their 1-month online follow-up questionnaire).
62734656|NCT05392673|EXPERIMENTAL|PE(plasma exchange)|In addition to comprehensive medical treatment, the PE groups were treated with PE or PE plus half-dose sequential PE. In the current study, PE was carried out using the KM-8800 plasma exchange device (Kuraray, Tokyo, Japan). The device was pre-flushed with 2000 mL of normal saline and 20 U/mL heparin dilution. And the blood pump speed was 100 to 120 mL/min and the plasma exchange speed was 25 to 30 mL/min. Before PE, calcium gluconate and diphenhydramine were routinely administrated to prevent an allergic reaction. For each time of plasma exchange,2800 mL fresh frozen plasma was administrated.
62009476|NCT04424121|ACTIVE_COMPARATOR|Standard of care plus CCTA|Participants will be approached and randomized to receive standard care plus ≥ 64 multidetector coronary computed tomography angiography
62009477|NCT03495986|EXPERIMENTAL|Home-Based Exercise & Diet Group|16-week home based functional electrical stimulation leg cycle ergometry exercise program and diet intervention
62009478|NCT03495986|PLACEBO_COMPARATOR|Home-Based Diet Alone Group|Diet intervention
62009479|NCT06664229|EXPERIMENTAL|Intervention group|Older adults who participated in a group exercise program using the developed mat and software three times per week for six weeks (18 sessions) for a pilot study and twelve weeks (36 sessions) for a main study took part in the pre-post tests. The frequency and duration can be adjusted to twice per week for nine weeks (18 sessions) for a pilot study or twice per week for sixteen weeks (32 sessions) for a main study to accommodate the availability of participants and the spaces in the community center.
62009480|NCT06664229|NO_INTERVENTION|Control group|Older adults who participated only in the pre-post tests without receiving any intervention.
62009481|NCT04897581|EXPERIMENTAL|Brief Behavioral Therapy for Insomnia, BBTI|Participants in this group will receive 3 sessions of BBTI over telehealth.
62009482|NCT04897581|EXPERIMENTAL|Physical Self-Regulation, PSR|Participants in this group will receive 3 sessions of PSR over telehealth.
62009483|NCT02580526|ACTIVE_COMPARATOR|V-E mask ventilation technique crossover C-E mask ventilation|
62009484|NCT02580526|ACTIVE_COMPARATOR|C-E mask ventilation technique crossover V-E mask ventilation|
62009485|NCT02621164|EXPERIMENTAL|NBP607-QIV|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine
62009486|NCT02621164|ACTIVE_COMPARATOR|Agrippal S1|Trivalent Inactivated Egg-derived Influenza Vaccine
62009487|NCT01298024|EXPERIMENTAL|Early neuromusclar exercise|
62009488|NCT01298024|ACTIVE_COMPARATOR|Treatment as usual (late training)|
62009489|NCT03844191|EXPERIMENTAL|Part 1 Cohort 1|Cohort 1: 0.05 mg/kg RUC-4/placebo 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
62009490|NCT03844191|EXPERIMENTAL|Part 1 Cohort 2|Cohort 2: 0.075 mg/kg RUC-4/placebo 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
62009491|NCT03844191|EXPERIMENTAL|Part 2 Cohort 1|Cohort 1: initial dose to be selected by the Safety Review Committee (SRC) after completion of Part 1 (the same initial dose used in Part 1 or one of the previously studied higher doses that is lower than the overall RUC-4 BED) 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
62009492|NCT03844191|EXPERIMENTAL|Part 2 Cohorts 2-3|7 subjects (6 receiving RUC-4, 1 receiving placebo) will be enrolled in each dose cohort, with a safety evaluation performed after 2 subjects in a dose cohort receive RUC 4 and at the completion of dosing for all subjects in the dose cohort. Dose escalation to be determined by the SRC charter and will continue until identification of the overall RUC-4 BED or MTD
62009493|NCT03844191|EXPERIMENTAL|Part 2 Dose Expansion Cohort 1|"14 subjects will receive a selected dose of RUC-4 based on SRC review of dose escalation data.~In the expansion cohort, 7 subjects weighing 55 to 65 kg and 7 subjects weighing 100 to 120 kg will be enrolled; 12 subjects will receive a single subcutaneous dose of RUC-4 and 2 will receive matched placebo"
62009494|NCT04040972|EXPERIMENTAL|Rebalance - Group Compassion Focussed Therapy|
62195397|NCT01621243|PLACEBO_COMPARATOR|nab-paclitaxel, gemcitabine, placebo|"Part A: Not applicable.~Part B: nab-paclitaxel, gemcitabine, and placebo. Placebo administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle."
62195398|NCT01621243|EXPERIMENTAL|nab-paclitaxel, gemcitabine, necuparanib|"Part A: Following a single-dose of necuparanib and a 7-day follow-up period, necuparanib was administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle. Dose escalation of necuparanib proceeded by cohort in a 3+3 design.~Part B: A fixed dose of necuparanib will be administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle."
62195399|NCT01580553|PLACEBO_COMPARATOR|Levocarnitine|
62195400|NCT01580553|ACTIVE_COMPARATOR|L-carnitine|
62195401|NCT01243788|ACTIVE_COMPARATOR|Ipratropium/Albuterol|Ipratropium/Albuterol 36/206ug QID
62195402|NCT03006640|PLACEBO_COMPARATOR|Control group|
62195403|NCT03006640|ACTIVE_COMPARATOR|NTG group|
62195404|NCT02931370||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
62195405|NCT02425540||patients with unclassified ovarian mass|
62195406|NCT03653923|EXPERIMENTAL|Waiting-List|
62195407|NCT03653923|EXPERIMENTAL|Treatment|
62734657|NCT05392673|EXPERIMENTAL|DPMAS+half-dose sequential PE|DPMAS with half-dose sequential PE was applied using the EC-40W plasma separator (Asahi Kasei Medical, Tokyo, Japan), BS330 bilirubin adsorption column (Jianfan Biotechnology, Zhuhai, China), and the neutral microporous adsorption resin HA330-Ⅱ (Jianfan Biotechnology). After the bilirubin adsorption and hemoperfusion treatment, sequential half-dose PE treatment begins. 1400 mL plasma replacement was conducted each time.
62009495|NCT00079105|ACTIVE_COMPARATOR|Treatment|Treatment with VEPEMB - Vinblastine sulfate, Cyclophosphamide, Procarbazine hydrochloride, Prednisolone, Etoposide, Mitoxantrone hydrochloride, and Bleomycin sulfate
62195408|NCT03653923|NO_INTERVENTION|Healthy Controls|Not randomized healthy control group for comparison to normal functioning
62195409|NCT03090750|EXPERIMENTAL|Lavender|Lavender oil
62195410|NCT03090750|EXPERIMENTAL|Bergamot|Bergamot oil
62195411|NCT03090750|PLACEBO_COMPARATOR|Water|Water
62195412|NCT04207580||Inclusion and follow up of pediatric patients|"Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome, from the beginning of the disease to 18 years old or transfer of the follow-up to a nephrology unit for adults.~130 new patients are expected to be included on an annual basis."
62195413|NCT02388152|EXPERIMENTAL|Lu AF20513, low dose (Cohort 1)|10 Patients with mild Alzheimer's.
62195414|NCT02388152|EXPERIMENTAL|Lu AF20513, medium dose (Cohort 2)|10 Patients with mild Alzheimer's.
62195415|NCT02388152|EXPERIMENTAL|Lu AF20513, high dose (Cohort 3)|15 Patients with mild Alzheimer's.
62195416|NCT02388152|EXPERIMENTAL|Lu AF20513, double high dose (Cohort 4)|15 Patients with mild Alzheimer's.
62195417|NCT05474053|EXPERIMENTAL|Brilique group|volunteers in the Brilique group received a loading dose of 180 mg brand Brilique® (AstraZeneca , Sweden) then 90 mg twice daily regimen for 4 days
62195418|NCT05474053|EXPERIMENTAL|Ticaloguard group|volunteers in the Ticaloguard group received the Egyptian made generic ticalogaurd in a loading dose of 180 mg then 90 mg twice daily regimen for 4 day
62195419|NCT02833805|EXPERIMENTAL|Bone marrow transplant|Non-myeloablative bone marrow transplant with a Thymoglobulin (ATG), fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.
62195420|NCT04577131|EXPERIMENTAL|With check-ins|Daily blood pressure monitoring with weekly check-ins
62195421|NCT04577131|NO_INTERVENTION|Without check-ins|Daily blood pressure monitoring without weekly check-ins
62195422|NCT01377246|PLACEBO_COMPARATOR|Saline solution.|
62195423|NCT01377246|EXPERIMENTAL|Octrotide-LAR|
62195424|NCT05828004|NO_INTERVENTION|standard care group|The standard care group is the routine care group, that is, under the current standard antitumor treatment and follow-up mode, the patients independently decided whether to carry out nutritional and psychological intervention after the advice from the medical care department of oncology
62009496|NCT00079105|NO_INTERVENTION|Registration|Registration, without treatment
62009497|NCT00653107|EXPERIMENTAL|A|Stent followed by 3 brachytherapy fractions
62009498|NCT00653107|ACTIVE_COMPARATOR|B|3 fractions of brachytherapy
62009499|NCT02447991|PLACEBO_COMPARATOR|Placebo|During the Treatment Phase, three placebo capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
62195425|NCT05828004|EXPERIMENTAL|MDT care group|The MDT care group is the whole-course multidisciplinary care intervention group, which is conducted by a multidisciplinary team composed of the oncology department, nutrition department, mental health center and rehabilitation department.
62195426|NCT00813722|ACTIVE_COMPARATOR|phone calls|patients received phone calls
62195427|NCT00813722|PLACEBO_COMPARATOR|no phone calls|patients received no phone calls
62574030|NCT03219814|NO_INTERVENTION|Body-Satisfied Assessment Only Condition|Body-satisfied women will be recruited to engage in the assessment portion of the study only (i.e. they will be given NO intervention but are serving as a control in terms of eye-tracking assessment). Body-satisfied women will be assessed to compare their attention to weight words with body-dissatisfied women's attention to weight words. This comparison will be done with an aim of replicating the findings of Tobin (2015), to ensure that for this particular sample, body-dissatisfied women exhibit stronger attentional biases for weight words than body-satisfied women. Attention to weight words in body-satisfied women will be assessed at two time points, one week apart, to ensure there are no spurious changes in attention in body satisfied women.
62574031|NCT02908165|EXPERIMENTAL|Group A- continuous schedule|Subjects with HCC randomized to group A
62574032|NCT02908165|ACTIVE_COMPARATOR|Group B- sequential schedule|Subjects with HCC randomized to group B
62574033|NCT00708552|EXPERIMENTAL|SB-742457 - 15mg|SB-742457 - 15mg
62574034|NCT00708552|PLACEBO_COMPARATOR|Placebo|
62009500|NCT02447991|EXPERIMENTAL|Rizatriptan|During the Treatment Phase, three Rizatriptan capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
62009501|NCT00762489|OTHER|TAT vs. RT|This arm is comparing the Temporal Artery Thermometer (TAT) temperature to the Rectal Temperature (RT).
62009502|NCT00762489|OTHER|TAT vs. AT|This arm is comparing the Temporal Artery Thermometer (TAT) temperature to the Axillary Temperature (AT).
62009503|NCT05949983|EXPERIMENTAL|APA program Group|patients treated and monitored for breast cancer under the APA programme
62009504|NCT05949983|ACTIVE_COMPARATOR|Physical activity recommendation Group|patients treated and monitored for breast cancer who have received recommendations for physical activity
62009505|NCT01234623||UCB eyedrops, single arm|One-centre pilot study, open, non randomized.
62009506|NCT02889159|OTHER|Candida albicans antigen|useful in measuring the capacity of a person to manifest a delayed-type hypersensitivity response
62009507|NCT02889159|OTHER|histamine phosphate|useful to assess type I IgE-mediated hypersensitivity reactions
62009508|NCT02889159|OTHER|imiquimod 5% cream|direct stimulator of TLR-7, a key component of the innate immune response with downstream signaling effects involving the adaptive immune response
62009509|NCT02889159|OTHER|tape stripping|to create alterations in key inflammatory mediators involved in both the innate and adaptive immune responses
62009510|NCT02889159|NO_INTERVENTION|Control|control sample from both sun exposed and non-sun exposed skin
62195428|NCT00813722|ACTIVE_COMPARATOR|current treatment|calcium chanel blocker and at1 antagonist
62195429|NCT00813722|ACTIVE_COMPARATOR|tradittional treatment|beta blocker and diuretic
62195430|NCT06342336|EXPERIMENTAL|HS-IT101 monotherapy|Adoptive transfer of 5x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
62195431|NCT03520218|EXPERIMENTAL|Performance of R-PEM|"5mCi of F-18 FDG will be injected and patients will wait for uptake of FDG before proceeding with first set of R-PEM scans. Additional optional R-PEM scans may be performed 4 hours after injection, and then possibly 7 hours after injection.~These R-PEM images will be compared to standard diagnostic breast work-up using DBT and MRI"
62195432|NCT01059162|EXPERIMENTAL|IOPtiMate|patients will undergo non-penetrating laser assisted filtering surgery by the IOPtiMate (OT-134) system
62195433|NCT03272737|ACTIVE_COMPARATOR|Traditional strength exercise|"This group will be carried out to knee extension exercise without blood flow restriction.~Interventions:~* Plethysmography;~* Protocols of isometric exercise;~* Pulse wave Velocity (PWV);~* Flow-mediated dilatation (FMD);~* Arterial pressure and blood pressure;~* Quality of life (Euro Qol);~* 1RM test~* Speed gait test~* Anthropometric Assessment"
62195434|NCT03272737|ACTIVE_COMPARATOR|Strength exercise with KAATSU|"This group will be carried out to knee extension exercise with partial blood flow restriction.~Interventions:~* Plethysmography;~* Protocols of isometric exercise;~* Pulse wave Velocity (PWV);~* Flow-mediated dilatation (FMD);~* Arterial pressure and blood pressure;~* Quality of life (Euro Qol);~* 1RM test~* Speed gait test~* Anthropometric Assessment"
62009511|NCT04455893|NO_INTERVENTION|Condition 1: Combined only|Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals.
62009512|NCT04455893|EXPERIMENTAL|Combined 2: Stratified only|Participants randomized to Condition 2 will view only stratified transplant survival outcome information when making a choice between the two hospitals.
62009513|NCT02560246||Preterm Labor|Singleton pregnancy between 20 0/7 36 6/7 weeks gestational age who is admitted with PTL or cervical insufficiency (Equal or greater than 2 cm dilated) or PPROM
62214974|NCT03583567|EXPERIMENTAL|Chlorpheniramine and ranitidine|Syringe No 1 contain chlorpheniramine 10 mg (1 mL) Syringe No 2 contain ranitidine 50 mg (2 mL)
62574035|NCT00708552|EXPERIMENTAL|SB-742457 - 35mg|SB-742457 - 35mg
62574036|NCT00708552|ACTIVE_COMPARATOR|Donepezil|
62574037|NCT02069808|EXPERIMENTAL|Group B: Follistim and Menopur|"Group B: N=25 subjects~1. Cycle day 2 start Follistim 200 U/day up to 11 days duration.~2. Cycle day 2 start Menopur (menotropins) 75 U/day up to 11 days duration.~3. Add GnRH antagonist Ganirelix 250 µg/day starting 5 days before GnRH agonist trigger.~4. GnRH agonist Leuprolide Acetate (Lupron) 1 mg subcutaneous injection 36 hours prior to egg collection.~5. Transvaginal ultrasound guided needle aspiration of oocytes 36 hours after Lupron trigger."
62574038|NCT02069808|ACTIVE_COMPARATOR|Group A: Follistim only|"Group A: N=25 subjects~1. Cycle day 2 start Follistim 250 U/day up to 11 days duration.~2. Add GnRH antagonist Ganirelix 250 µg/day starting 5 days before GnRH agonist trigger.~3. GnRH agonist Leuprolide Acetate (Lupron) 1 mg subcutaneous injection 36 hours prior to egg collection.~4. Transvaginal ultrasound guided needle aspiration of oocytes 36 hours after Lupron trigger."
62574039|NCT06215950|EXPERIMENTAL|Intravenous of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg
62009514|NCT02560246||Term Labor|Admitted to the hospital with spontaneous labor (regular contractions, cervical dilation) or spontaneous rupture of membranes
62574040|NCT06215950|EXPERIMENTAL|intraperitoneal injection of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg
62195435|NCT06026475|ACTIVE_COMPARATOR|Intraoperative Goal Directed Fluid Therapy (GDFT) guided by Stroke Volume Variation (SVV)|When SVV values will increase above 11 colloid bolus 200ml will be administered. postbolus change in values of SVV , SV , SVI and CI shall be noted.
62195436|NCT06026475|ACTIVE_COMPARATOR|Intraoperative Conventional Fluid Therapy (CFT) guided by Central Venous Pressure (CVP) .|When CVP values will decrease below 8 cmsH20 colloid bolus 200ml will be administered .Postbolus change in values shall be noted .
62195437|NCT02417441|EXPERIMENTAL|Early Embryo Viability Assessment + Morphological Grading|Embryos of subjects randomized in this group were assessed using Early Embryo Viability Assessment (Eeva) System and morphological grading to identify optimal embryos for transfer.
62195438|NCT02417441|NO_INTERVENTION|Morphological Grading|Embryos of subjects randomized in this group were assessed only using morphological grading to identify optimal embryos for transfer.
62195439|NCT02539316|ACTIVE_COMPARATOR|Médialipides|parenteral nutrition by Médialipides (dosage form depending child's weight as recommended by the SPC)
62195440|NCT02539316|EXPERIMENTAL|SmofLIPID|parenteral nutrition by Smoflipid (dosage form depending child's weight as recommended by the SPC)
62195441|NCT03181347|EXPERIMENTAL|Roux-en-Y Gastric Bypass (RYGB)|Severely obese patients scheduled for Roux-en-Y Gastric Bypass surgery
62195442|NCT03181347|EXPERIMENTAL|Sleeve Gastrectomy (SG)|Severely obese patients scheduled for Sleeve Gastrectomy surgery
62195443|NCT03181347|ACTIVE_COMPARATOR|Non-surgical|Severely obese controls with dietary and activity modifications and excludes meal replacement or pharmacologic interventions
62195444|NCT01327846|EXPERIMENTAL|Canakinumab Dose 50 mg|"Pivotal Phase:~Blinded Canakinumab 50 mg quarterly subcutaneous + standard of care therapy.~Extension Phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
62195445|NCT01327846|EXPERIMENTAL|Canakinumab Dose 150 mg|"Pivotal Phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
62195446|NCT01327846|EXPERIMENTAL|Canakinumab Dose 300 mg|"Pivotal Phase:~Blinded Canakinumab 300 mg quarterly subcutaneous (with one additional dose at week 2) + standard of care therapy.~Extension phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
62195447|NCT01327846|PLACEBO_COMPARATOR|Placebo|"Pivotal Phase:~Blinded matching placebo quarterly subcutaneous + standard of care therapy.~Extension Phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
62195448|NCT04833348|EXPERIMENTAL|Patients|Infants with spinal muscular atrophy cared by the Neuromuscular Reference Center at Necker Hospital and eligible for innovative therapy (gene therapy or pharmacogenetics)
62195449|NCT04011007|ACTIVE_COMPARATOR|vitrectomy without ILM peeling|vitrectomy without ILM peeling
62398886|NCT06724614|EXPERIMENTAL|VDPHL01 QD and Placebo QD|Placebo will be taken orally once a day in the AM. VDPHL01 will be taken orally once a day in the PM.
62398887|NCT06724614|PLACEBO_COMPARATOR|Placebo BID with treatment extension to VDPHL01 BID|Placebo will be taken orally twice a day, once in the AM and once in the PM for the first 6 months of the study. After month 6, VDPHL01 will be taken orally twice a day, once in the AM and once in the PM.
62398888|NCT06724614|PLACEBO_COMPARATOR|Placebo BID with treatment extension to VDPHL01 QD and Placebo QD|Placebo will be taken orally twice a day, once in the AM and once in the PM for the first 6 months of the study. After month 6, placebo will be taken orally once a day in the AM. VDPHL01 will be taken orally once a day in the PM.
62398889|NCT05908474|ACTIVE_COMPARATOR|iowater fibre Group|This exclusive blend of scientifically substantiated ingredients has been demonstrated to contribute to the reduction of body weight and aid the sustainability of weight loss by providing a healthy, hunger-free weight management system. iofibrewater, makes fibre and gut health simple and refreshing. Each 500 ml bottle of ió fibrewater provides 20%\* of your recommended daily fibre intake and 100%\* of your daily prebiotic fibre intake with minimal calories and carbohydrates, making us suitable for people on a variety of diets. ió fibrewater is a functional water infused with prebiotic fibre (aka prebiotics), which leads to sub-optimal gut health and often the onset of digestive disorders. By adding more prebiotic fibre to our diet, we can quickly change the environment in our gut for the better healthy living.
62398890|NCT05908474|PLACEBO_COMPARATOR|Volvic Placebo control Group|This is the equivalent placebo control water that it is matching the energy values
62574041|NCT00955409|EXPERIMENTAL|ACC-001(3µg) + QS21|ACC-001(3µg) + QS21
62574042|NCT00955409|EXPERIMENTAL|ACC-001(10µg) + QS21|ACC-001(10µg) + QS21
62574043|NCT00955409|EXPERIMENTAL|ACC-001(30µg) + QS21|ACC-001(30µg) + QS21
62574044|NCT00409435|ACTIVE_COMPARATOR|pyridostigmine|Active study drug
62574045|NCT00409435|PLACEBO_COMPARATOR|Placebo|Control
62009515|NCT06573775|ACTIVE_COMPARATOR|control group A|the control group received the traditional physical therapy for treating myofascial trigger points in the form of a myofascial trigger point release, stretching and strengthening of the trapezius muscle
62195450|NCT04011007|ACTIVE_COMPARATOR|vitrectomy with inverted ILM flap technique|vitrectomy with inverted ILM flap technique
62195451|NCT04591171|EXPERIMENTAL|n-of-1 trial guided clinical decision making|
62195452|NCT03620097|EXPERIMENTAL|Experimental Arm|30 subjects will receive 800mg of DHA (Dietary Supplement: EuPoly-3 DHA Infant) per day.
62195453|NCT03620097|PLACEBO_COMPARATOR|Control Arm|30 children will take a placebo with similar lipid characteristics
62195454|NCT06064955|EXPERIMENTAL|Peer Support|Former caregivers will be paired with a current caregivers
62195455|NCT02330770|ACTIVE_COMPARATOR|Dual trigger group|Trigger with concomitant GnRHa and HCG (single low-dose) administration
62398891|NCT03814746|EXPERIMENTAL|Crizanlizumab (SEG101) at 5.0 mg/kg|Participants received Crizanlizumab (SEG101) at 5.0 mg/kg
62398892|NCT03814746|EXPERIMENTAL|Crizanlizumab (SEG101) at 7.5 mg/kg|Participants received Crizanlizumab (SEG101) at 7.5 mg/kg
62398893|NCT03814746|PLACEBO_COMPARATOR|Placebo|Participants received the placebo drug.
62574046|NCT01326104|EXPERIMENTAL|Group A|High dose chemotherapy plus peripheral blood stem cell transplant followed by TTRNA-xALT and TTRNA-DCs.
62574047|NCT01326104|EXPERIMENTAL|Group B|NMA Salvage chemotherapy plus peripheral blood stem cell transplant followed by TTRNA-xALT and TTRNA-DCs.
62574048|NCT06578624|EXPERIMENTAL|Phase 1|Dose escalation phase
62574049|NCT06578624|EXPERIMENTAL|Phase 2|Cohort A: DDLPS (MDM2 amplified and p53 wild-type) Cohort B: other p53 wild-type solid tumors
62195456|NCT02330770|ACTIVE_COMPARATOR|Single low-dose HCG group|Trigger with GnRHa then HCG (single low-dose) administration in luteal phase
62195457|NCT02330770|ACTIVE_COMPARATOR|Multiple low-doses HCG group|Trigger with GnRHa then HCG (multiple low-doses) administration in luteal phase
62195458|NCT03981939||CD Participants with CPAF - The Ottawa Hospital (TOH)|Participants diagnosed with Complex Perianal Fistula (CPAF) from the Ottawa Hospital (TOH) were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
62009516|NCT06573775|EXPERIMENTAL|study group B|received pulsed ultrasound in addition to traditional physical therapy for treating myofascial trigger points in the form of a myofascial trigger point release, range of motion exercises, stretching and strengthening of the trapezius muscle
62195459|NCT03981939||CD Participants without CPAF (ICES database)|Participants diagnosed with CD and without CPAF from Institute for Clinical Evaluative Sciences (ICES) database who did not meet the case definition were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
62195460|NCT03981939||CD Participants with CPAF (ICES database)|Participants with CD and CPAF from ICES database who met the case definition were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
62195461|NCT03809598|EXPERIMENTAL|Mindfulness Based Cognitive Therapy|MBCT adapted for pregnancy includes 8 sequential, weekly 2-hour group sessions co-led by two master's level therapists. Sessions include: 1) introducing new mindfulness skills through in-session practice, 2) reviewing mindfulness practices and troubleshooting barriers to practice, 3) reinforcing mindfulness skills through in-session practice and debriefing, 4) learning about how thoughts influence feelings and behaviors (not all sessions), 5) providing psychoeducational information to support skills, and 6) encouraging the establishment of social support. The intervention is focused on skill development through active engagement in mindfulness practices and exercises to increase awareness of thoughts, feelings and behavior in session, and assignment and review of daily home practices.
62195462|NCT03809598|NO_INTERVENTION|Treatment as Usual|All participants will receive routine prenatal care from an identified medical provider, which they have initiated on their own. They will be able to engage in any services recommended by their primary medical provider or that they voluntarily initiate. For ethical reasons, they are not prohibited from engaging in any type of therapeutic, complementary, or medication treatment (after enrollment). The TAU group will be offered a delayed treatment option, after the 6 month follow-up. This will be a 2 hour mindfulness psychoeducation session, offered between 6 and 9 months postpartum. Several core mindfulness concepts included in the full MBCT curriculum will be taught and participants will complete several brief mindfulness activities.
62195463|NCT00654797|EXPERIMENTAL|eProtocol|
62195464|NCT03326024||A|Patients with Polycystic Ovary Syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and underwent laparoscopic ovarian drilling from more than two years.
62195465|NCT03326024||B|Patients with Polycystic Ovary Syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and didn't undergo laparoscopic ovarian drilling
62195466|NCT03288337||Hidradenitis Suppurativa Cohort|Patients with HS who are eligible to fill out the series of quality of life questionnaires
62574050|NCT05708118||Surgical Aortic Valve Replacement (SAVR)|Patients who undergo surgical aortic valve replacement through median longitudinal sternotomy.
62574051|NCT05708118||Transcatheter Aortic Valve Replacement (TAVR)|Patients who undergo transcatheter aortic valve replacement through a transfemoral access.
62195467|NCT02200744||Dislocation reduction using propofol|
62195468|NCT04740723|EXPERIMENTAL|Renal denervation|Renal denervation with the iRF system
62195469|NCT02465918|ACTIVE_COMPARATOR|Original Setting- MCS 30 min off/0 min off|Patients at baseline with their original MCS settings: on 30 minutes, off 0 minutes in any single half-hour.
62195470|NCT02465918|EXPERIMENTAL|MCS 25 min on/5 min off|Patient MCS settings programmed to: on 25 minutes, off 5 minutes in any single half-hour.
62195471|NCT02465918|EXPERIMENTAL|MCS 20 min on/10 min off|Patient MCS settings programmed to: on 20 minutes, off 10 minutes in any single half-hour.
62195472|NCT02465918|EXPERIMENTAL|MCS 15 min on/15 min off|Patient MCS settings programmed to: on 15 minutes, off 15 minutes in any single hour.
62574052|NCT01039480||dual therapy (ASS/CLO)|patients with a prescription for dual antiplatelet therapy with aspirin AND clopidogrel
62574053|NCT01039480||clopidogrel users (CLO)|patients with a prescription for clopidogrel
62574054|NCT01039480||aspirin users (ASP)|patients with a prescription for aspirin
62574055|NCT01268826||dosage of the urinary osmolality|dosage of the urinary osmolality
62574056|NCT06291038|EXPERIMENTAL|Glutamine|• Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks.
62009517|NCT06573775|EXPERIMENTAL|study group C|received lidocaine hydrochloride gel 5%phonophoresis in addition to traditional physical therapy for treating myofascial trigger points in the form of a myofascial trigger point release,range of motion exercises stretching and strengthening of the trapezius muscle
62009518|NCT03250663|ACTIVE_COMPARATOR|Arm 1 - Standard of Care|Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and follow standard of care
62009519|NCT03250663|EXPERIMENTAL|Arm 2 - Online Treatment Response|Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and electronic treatment response emails
62574057|NCT06291038|PLACEBO_COMPARATOR|Protifar|• Control group: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.
62009520|NCT05882513|EXPERIMENTAL|Lung cancer group|"Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1.~Non-squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1 ; pemetrexed 500mg/m2, day1 ; carboplatin AUC=5, i.v, day1.~Preoperative neoadjuvant therapy for 3 cycles, one cycle every 21 days. Surgical resection of lung cancer will be arranged about 4-8 weeks after the last cycle of neoadjuvant therapy."
62195473|NCT04411134|EXPERIMENTAL|Arm 1|Approximately 3x10\^8 or 1.5x10\^9 E7 TCR T cells will be injected on day 0 and 1.5x10\^9 E7 TCR T cells on day 31 (2 escalating dose levels)
62195474|NCT04411134|EXPERIMENTAL|Arm 2|The MTD from among dose level 1 and dose level 2
62195475|NCT03210519|EXPERIMENTAL|Eleutherococcus senticosus|Acanthopanax senticosus-mono formula (30mg/vial) and Fructus Ziziphi Jujube concentrated juice15ml/vial
62195476|NCT03210519|PLACEBO_COMPARATOR|Placebo|Fructus Ziziphi Jujube concentrated juice15ml/vial
62195477|NCT02082470|ACTIVE_COMPARATOR|Arm I (standard post-treatment)|Participants receive standard post-treatment care consisting of regular cancer surveillance visits with treating oncologists.
62195478|NCT02082470|EXPERIMENTAL|Arm II (survivorship care planning)|Participants complete survivorship care planning in close collaboration with treating oncologists.
62195479|NCT03773913||Four facilities in Kozah District|Baseline estimated population of 33,412 served by four public sector facilities in Kozah District.
62398894|NCT05605366|EXPERIMENTAL|Treatment arm (1)|This arm will receive 200mg of minocycline in a single capsule per day.
62398895|NCT05605366|ACTIVE_COMPARATOR|Treatment arm (2)|This arm will receive 300 mg of minocycline in a single capsule per day. This capsule is identical in size and appearance as the 200 mg capsule
62398896|NCT05605366|PLACEBO_COMPARATOR|Placebo|This arm will receive the placebo which is similar in size and appearance as the 200 mg and 300 mg capsules.
62398897|NCT02471898|EXPERIMENTAL|HTX-011|Evaluate the analgesic efficacy of HTX-011
62398898|NCT02471898|PLACEBO_COMPARATOR|Placebo|Saline
62009521|NCT01823393|EXPERIMENTAL|Heparin|injection of unfractionated heparin (50 IU / kg)
62195480|NCT04200469|EXPERIMENTAL|QFR Intervention|Patients submitted to a coronary angiogram with at least one non-left main stable coronary stenosis between 50 and 90% and PCI indication with paired assessment of QFR, dFR, RFR and FFR, before and after PCI once informed consent is provided.
62398899|NCT03646929|OTHER|healthy individuals and patients with multiple sclerosis|MEP in healthy individuals and patients with multiple sclerosis are measured using standard facilitation technique
62398900|NCT03646929|OTHER|patients with multiple sclerosis|MEP in patients with multiple sclerosis are measured using modified facilitation technique
62398901|NCT05874609|EXPERIMENTAL|VR group|In the VR group, the participants spent 30 minutes with the VR spine simulator after receiving the didactic teaching session.
62398902|NCT05874609|ACTIVE_COMPARATOR|Control group|In the control group, the participants received a 30-min traditional didactic teaching session of spine ultrasonography.
62398903|NCT06230523|EXPERIMENTAL|LY3841136 Dose 1|Participants will receive LY3841136 subcutaneously (SC)
62398904|NCT06230523|EXPERIMENTAL|LY3841136 Dose 2|Participants will receive LY3841136 SC
62574058|NCT02063061|SHAM_COMPARATOR|Sham treatment|Subject will answer standardized questionnaires. Sham treatment arm will receive initially 5 sham series and after they answer standardized questionnaires they will receive 5 series of active treatment. Afterwards patients will answer standardized questionnaires again.
62574059|NCT02063061|ACTIVE_COMPARATOR|ESWT treatment|Subject will answer standardized questionnaires. Subjects will receive 10 treatments with ESWT. Afterwards patients will answer standardized questionnaires again.
62574060|NCT01014364|EXPERIMENTAL|Corticosteroids|Hydrocortisone
62195481|NCT02103114|EXPERIMENTAL|Anti-thrombin III|
62195482|NCT02103114|PLACEBO_COMPARATOR|Placebo|
62195483|NCT00843427|EXPERIMENTAL|Aphasia - CIAT|Patients with aphasia \>1 year after left MCA stroke who will be randomized to receive CIAT
62009522|NCT01823393|PLACEBO_COMPARATOR|NaCl|without heparin
62195484|NCT00843427|NO_INTERVENTION|Aphasia - observation|Patients with aphasia \>1 year after left MCA stroke who will be randomized to no intervention (observation)
62195485|NCT00983853|EXPERIMENTAL|Part A|The dose of ribavirin used (fixed versus weight-based) is region dependent
62009523|NCT00861419|EXPERIMENTAL|D|3 mg/kg AMG 386 IV (QW) / 125 mg AMG 706 PO (QD)
62009524|NCT00861419|EXPERIMENTAL|A|3 mg/kg AMG 386 IV (QW) / 15 mg/kg bevacizumab IV (Q3W)
62195486|NCT00983853|EXPERIMENTAL|Part B|The dose of ribavirin used (fixed versus weight-based) is region dependent
62398905|NCT06230523|EXPERIMENTAL|LY3841136 Dose 3|Participants will receive LY3841136 SC
62398906|NCT06230523|EXPERIMENTAL|LY3841136 Dose 4|Participants will receive LY3841136 SC.
62398907|NCT06230523|EXPERIMENTAL|LY3841136 Dose 5|Participants will receive LY3841136 SC
62398908|NCT06230523|EXPERIMENTAL|LY3841136 Dose 6|Participants will receive LY3841136 SC
62398909|NCT06230523|PLACEBO_COMPARATOR|Placebo|Participants will receive LY3841136 matching placebo
62398910|NCT06721988|EXPERIMENTAL|OP group|Participants in this group will receive oxycodone and parecoxib sodium before surgical incision.
62398911|NCT06721988|PLACEBO_COMPARATOR|PP group|Participants in this group will receive a placebo and parecoxib sodium before surgical incision.
62398912|NCT00643331|EXPERIMENTAL|1|Exercise performed at the gym and at home
62398913|NCT00643331|NO_INTERVENTION|2|Usual care no additional exercise
62398914|NCT05697406|EXPERIMENTAL|Experimental|Participants will receive an injection of 250 mM of hyperpolarized 13-C pyruvate intravenously after standard of care imaging sequences are performed. Then participants will undergo HP-MR imaging.
62398915|NCT01952821||Test Group|This group will receive all listed outcome measures on 2 testing visits.
62398916|NCT06297642|EXPERIMENTAL|TQB2928 injection + Penpulimab|TQB2928 injection combined with Penpulimab, 21 days as a treatment cycle.
62195487|NCT05137743|EXPERIMENTAL|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia (CBT-I).
62195488|NCT05137743|ACTIVE_COMPARATOR|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
62195489|NCT01992367|PLACEBO_COMPARATOR|Placebo|placebo arm
62195490|NCT01992367|OTHER|ASLAN003|Active drug
62195491|NCT05109767|EXPERIMENTAL|Virtual reality glass game application|
62398917|NCT05849649|EXPERIMENTAL|BumptUp Mobile App|The intervention group will have full access to the BumptUp mobile app which includes exercise and dietary progress tracking, social support, evidence-based and safe exercise programming, videos, and symptom tracking.
62574061|NCT01014364|PLACEBO_COMPARATOR|Control|isotonic saline
62574062|NCT06339944|EXPERIMENTAL|sensory motor training along with conventional therapy.|"This group will receive sensory motor training exercises after the conventional therapy.~The participants who will be allocated to the SMT group received the same warm-up and stretching program as the CT group, with the same duration and frequency of treatment, but with replacement of the strengthening program with a program emphasizing agility, coordination and balance."
62574063|NCT06339944|ACTIVE_COMPARATOR|kinesthetic exercises along with conventional therapy.|Group will receive kinesthetic balance exercises after the conventional therapy. All agility-based exercises will be conducted before progressing to balance exercises. For the balance exercises, the participants performed static and dynamic balance exercises with eyes open and then closed by standing on a hard surface and then standing on a soft surface.
62195492|NCT05109767|ACTIVE_COMPARATOR|Smartphone game application|
62398918|NCT05849649|ACTIVE_COMPARATOR|Educational Brochure/ Attention Control|This group will receive evidence-based exercise education the form a one-time brochure.
62195493|NCT05109767|NO_INTERVENTION|Control group|
62195494|NCT03327831|EXPERIMENTAL|Aminolevulinic Acid with daylight photodynamic therapy arm|This study has a single, open label treatment arm. Patients will have topical aminolevulinic acid applied to the actinic keratoses in the treatment area (face/scalp) and will spend 2 hours outdoors in the shade to activate the medication. The patient then follow up in clinic 3 months and 6 months after their treatment to have the number of actinic keratoses counted.
62195495|NCT00966563|ACTIVE_COMPARATOR|Mangafodipir treatment|Treatment will be undertaken with a ready-to use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI. Formulation content: MnDPDP 10 mmol/ml.
62195496|NCT00966563|PLACEBO_COMPARATOR|NaCl 0.9%|
62195497|NCT04351698|ACTIVE_COMPARATOR|Investigation|Montelukast
62195498|NCT04351698|PLACEBO_COMPARATOR|Match Placebo|Matched Placebo
62195499|NCT00725543||Remicade|Subjects with AS with severe axial symptoms and elevated serological markers of inflammatory activity will receive Remicade induction therapy consisting of 3 Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians. Whole observation period cannot exceed 102 weeks per subject if the maximal therapy interval of 16 weeks as defined in Summary of Product Characteristics (SPC) is taken into consideration.
62195500|NCT02274090|PLACEBO_COMPARATOR|Placebo Group|Placebo gel without the active ingredient. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.
62195501|NCT02274090|ACTIVE_COMPARATOR|1% Metformin|1% Metformin gel. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.
62195502|NCT06307002|NO_INTERVENTION|Control Arm|The control group will receive SOC counseling, defined as the current practice at our partner institutions. Patients presenting for contraceptive counseling are given informational pamphlets and have the option to review additional materials posted on the clinic walls and on a rotating slide deck on a digital screen. During their counseling session with a provider, they review eligible methods and can make a decision about whether or not to adopt a method, and to select and initiate the contraception of their choice.
62195503|NCT06307002|EXPERIMENTAL|WMM Arm|The intervention group will be provided with a tablet loaded with the WMM game which will be played in the waiting room prior to their visit. They will then receive SOC counseling, defined as the current practice at our partner institutions. Patients presenting for contraceptive counseling are given informational pamphlets and have the option to review additional materials posted on the clinic walls and on a rotating slide deck on a digital screen. During their counseling session with a provider, they review eligible methods and can make a decision about whether or not to adopt a method, and to select and initiate the contraception of their choice.
62195504|NCT06086288|EXPERIMENTAL|Single Arm|
62195505|NCT01371708|EXPERIMENTAL|Desvenlafaxine Succinate Sustained-Release|
62195506|NCT00912210|ACTIVE_COMPARATOR|Higher protein|
62195507|NCT00912210|PLACEBO_COMPARATOR|Higher carbohydrate|
62195508|NCT05472064||Group 1|Primary care doctor persona with direct messages
62398919|NCT01428882|ACTIVE_COMPARATOR|Midazolam balanced propofol sedation|2 mg midazolam in 2 ml saline midazolam followed by continuous propofol iv infusion
62398920|NCT01428882|PLACEBO_COMPARATOR|Single-agent propofol sedation|2 ml saline followed by continuous propofol iv infusion
62398921|NCT04088227|ACTIVE_COMPARATOR|Control Group|The control group will have a joint aspiration performed at an initial visit (within the first 10 days after injury), and at the time of surgery (within 4 weeks of injury).
62398922|NCT04088227|EXPERIMENTAL|Experimental Group|The experimental group will have a joint aspiration performed at an initial visit (within the first 10 days after injury) and receive an injection of leukocyte poor platelet rich plasma injection in their knee. At a second visit 5-12 days after the initial visit, the patient will receive a joint aspiration and platelet rich plasma injection. A final joint aspiration will be performed at the time of surgery (within 4 weeks of injury).
62195509|NCT05472064||Group 2|Breast cancer survivor persona with direct messages
62195510|NCT05472064||Group 3|Primary care doctor with indirect messages
62195511|NCT05472064||Group 4|Breast cancer survivor persona with indirect messages
62195512|NCT05472064||Group 5|Control
62195513|NCT01554722|EXPERIMENTAL|in plane needle placement|
62195514|NCT01554722|EXPERIMENTAL|out of plane needle placement|
62195515|NCT01607151|ACTIVE_COMPARATOR|Normothermia|Core temperature 36-37 C
62195516|NCT01607151|EXPERIMENTAL|Hypothermia|Core temperature 32-34 C
62195517|NCT04518904||Group of poor prognosis|In this group,the patients had suffered from systemic infection,pulmonary complications or died.
62398923|NCT00830310|EXPERIMENTAL|Customized Adherence Enhancement (CAE)|"Participants will be assigned to receive one or more of the study interventions based upon the participant's responses on the Attitudes toward Mood Stabilizers Questionnaire (AMSQ) and reasons for non-adherence on the Rating of Medication Influences (ROMI).~Individuals will participate in a series of 4 60-minute sessions over a 4-week period, with the study therapist who will implement the module-based intervention. The number of modules may differ depending on the baseline adherence profile of the participant.~An intervention manual developed by the investigators will provide explicit guidelines regarding how modules may be co-administered in single or multiple sessions to minimize redundancy as well as time and effort burden on study participants. The manual for each module will specifically address how any module could be combined with the other modules."
62398924|NCT03606473|EXPERIMENTAL|Prenatal cocaine exposed subjects|\[C-11\]NPA PET at baseline and post d-amphetamine
62398925|NCT03606473|EXPERIMENTAL|Comparison subjects|\[C-11\]NPA PET at baseline and post d-amphetamine
62398926|NCT05337410|EXPERIMENTAL|YES IDEAS|Students participate in the YES IDEAS program.
62009525|NCT00861419|EXPERIMENTAL|B|3 mg/kg AMG 386 IV (QW) / 75 mg AMG 706 PO (QD)
62195518|NCT04518904||Group of good prognosis|In this group,the patients were safely discharged without complications.
62195519|NCT06514976||The test group|Basic therapy + Cytoflavin
62195520|NCT06514976||The control group|Basic therapy (with or without other neuroprotector)
62195521|NCT04467723|EXPERIMENTAL|Treatment|"Atezolizumab (Tecentriq) intravenous (IV) 1200mg flat dose day 1 then every 3 weeks.~Pirfenidone (Esbriet) orally (PO) with food according to this schedule:~Days 1-14: 267 milligrams (mg) orally three times per day (PO TID) Days 15-29: 534 mg PO TID Days 30 onward until progression: 801 mg PO TID"
62195522|NCT02091115|PLACEBO_COMPARATOR|Dairy drink|Patients received dairy drink for 60 days and were instructed to consume a glass of 150 mL daily.
62195523|NCT02091115|ACTIVE_COMPARATOR|Dairy drink with probiotic culture|Patients received dairy drink with probiotic culture for 60 days and were instructed to consume a glass of 150 mL daily.
62195524|NCT05435053|EXPERIMENTAL|IRE + Nivolumab|IRE on Day 1, followed by Nivolumab on Day 2/3 and then every 2 weeks (q2w) for a maximum of 24 weeks.
62195525|NCT02772328|EXPERIMENTAL|Peer Mentor|Individuals in this arm will be trained in communication skills to promote HIV and HCV testing to their social network members, linkage to care and risk reduction behaviors.
62195526|NCT02772328|NO_INTERVENTION|Neighborhood Matters|Participants in this arm will view a 15-20 minute video on issues in neighborhoods such as crime and violence, restoring communities and incarceration and discuss their reactions and thoughts.
62195527|NCT01031498|ACTIVE_COMPARATOR|Ondansetron: Standard of Care|Standard of care, Ondansetron 8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
62195528|NCT01031498|EXPERIMENTAL|Palonosetron Group 1 (5 Days)|Palonosetron once a day 0.25 mg IV injection for 5 days, given over 30 seconds, 30 minutes before chemotherapy treatment.
62195529|NCT01031498|EXPERIMENTAL|Palonosetron Group 2 (3 Days)|Palonosetron once a day 0.25 mg IV injection on Days 1, 3, and 5 of chemotherapy treatment, given over 30 seconds, 30 minutes before chemotherapy treatment.
62195530|NCT03689777|ACTIVE_COMPARATOR|Glomerular Filtration Rate|
62398927|NCT05337410|NO_INTERVENTION|Control|Students participate in the regular after-school programming.
62009526|NCT00861419|EXPERIMENTAL|E|3 mg/kg AMG 386 IV (QW) / 400 mg sorafenib PO (BID)
62009527|NCT00861419|EXPERIMENTAL|H|10 mg/kg AMG 386 IV (QW) / 50 mg sunitinib PO (QD - 4 weeks on/2 weeks off)
62009528|NCT00861419|EXPERIMENTAL|G|3 mg/kg AMG 386 IV (QW) / 50 mg sunitinib PO (QD - 4 weeks on/2 weeks off)
62195531|NCT01980004|EXPERIMENTAL|Dietary Education|Participants in this treatment arm will undergo dietary counseling for the prevention of kidney stone formation.
62195532|NCT01980004|EXPERIMENTAL|Potassium Citrate and Dietary Education|Participants in this treatment arm will undergo potassium citrate supplementation and dietary counseling for the prevention of kidney stone formation.
62195533|NCT04814602|ACTIVE_COMPARATOR|Control|Healthy controls Proglumide 400 mg given once by mouth
62195534|NCT04814602|EXPERIMENTAL|Hepatic Impaired|Cirrhosis Child-Pugh A and B Proglumide 400 mg given once by mouth
62195535|NCT04556812|EXPERIMENTAL|Study group|"underwent four-in-one surgical technique centered on tibial tuberosity osteotomy and proximal displacement"
62195536|NCT04556812|PLACEBO_COMPARATOR|Control group|traditional soft tissue surgery
62195537|NCT02843451|EXPERIMENTAL|Silymarin (Milk Thistle)|Each subject will have a 4 week treatment phase with milk thistle.
62195538|NCT02843451|PLACEBO_COMPARATOR|Placebo|4 week placebo phase before or after milk thistle phase depending on randomization.
62195539|NCT00787306|EXPERIMENTAL|Multi-faceted Cardiovascular Decision Support|Risk factor active surveillance, multi-disciplinary disease management and decision aid intervention
62195540|NCT00787306|OTHER|Control Usual Care|Usual care in a wait-list control arm that receives the experimental intervention after 6 months.
62574064|NCT02772211|EXPERIMENTAL|D-cycloserine|Participants in this group would receive 6 infusions of ketamine. Participants who demonstrate symptoms reduction following ketamine infusions would receive oral D-cycloserine, titrated slowly up to 1000mg/d over the next 8 weeks.
62574065|NCT02772211|PLACEBO_COMPARATOR|Placebo|Participants in this group would receive 6 infusions of ketamine. Participants who demonstrate symptoms reduction following ketamine infusions would receive oral Placebo pills, titrated slowly up to 1000mg/d over the next 8 weeks.
62574066|NCT03136640|EXPERIMENTAL|ModraDoc006/r|Weekly ModraDoc006/r treatment as ModraDoc006 (oral docetaxel) 10mg tablets combined with ritonavir 100mg tablets
62195541|NCT05464407|EXPERIMENTAL|Cubitan|2 x oral nutritional supplement daily
62195542|NCT05464407|NO_INTERVENTION|Usual care|usual care
62195543|NCT00202189|EXPERIMENTAL|1|Budesonide
62195544|NCT00202189|PLACEBO_COMPARATOR|2|Saline Solution (0.9% NaCl)
62195545|NCT03637413|EXPERIMENTAL|Hindmilk|Hindmilk, the milk at the end of a breast pumping session, has higher fat and energy content compared to the composite milk.
62195546|NCT00337753|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Weekly Cognitive Behavior therapy
62195547|NCT00337753|OTHER|Wait-list|Subjects in wait-list for six-weeks
62574067|NCT05069220|EXPERIMENTAL|18F-MFBG PET/CT in neuroendocrine malignancies|Each patient receive a single intravenous injection of 18F-MFBG 2-4 MBq/kg and undergo PET/CT scan after 60 min post-injection. Patients with neuroblastoma should have a routine clinical 123I-MIBG scintigraphy (planar and/or SPECT/CT) performed within 6 months prior to the inclusion visit or scheduled within 3 months after the inclusion visit. According to patients' condition and clinical management, part of patients with PPGL and NB will receive 68Ga-DOTATATE PET/CT, comparing with 18F-MFBG PET/CT.
62574068|NCT01994434|OTHER|Decompression of the ulnar nerve|Surgical decompression of the Guyon's canal and ganglion excision
62574069|NCT02284061|EXPERIMENTAL|experimental|Immediate Program : the child follows the physical activity program for a period of 18 months, as soon as his medical condition permits.
62195548|NCT00794924|EXPERIMENTAL|Probiotics, VSL#3|Acutely hospitalized elderly patients in a geriatric orthopedic rehabilitation department received commercially available probiotics (VSL#3) for 45 days.
62195549|NCT00794924|PLACEBO_COMPARATOR|Placebo|Acutely hospitalized elderly patients in a geriatric orthopedic rehabilitation department received placebo sachets for 45 days.
62574070|NCT02284061|OTHER|Control|Delayed Program: the child does not participate to the program during the first 6 months, and he joins the delayed program late after 6 months.
62574071|NCT00921531|EXPERIMENTAL|Thalidomide and TACE|Thalidomide is used for adjuvant therapy for TACE
62574072|NCT00921531|ACTIVE_COMPARATOR|TACE only|
62195550|NCT02928705||telemedicine group|physician operated telemedical prehospital analgesia
62195551|NCT02928705||historical control group|prehospital analgesia by on-scene EMS physicians
62195552|NCT03937141|EXPERIMENTAL|ADU-S100 and pembrolizumab|All eligible subjects will receive intravenous (IV) infusions of pembrolizumab and intratumoral injections of ADU-S100.
62195553|NCT01174446|EXPERIMENTAL|BAX 326|Recombinant factor IX (rFIX)
62195554|NCT01174446|ACTIVE_COMPARATOR|BeneFIX|Recombinant Factor IX (rFIX)
62195555|NCT02000778|EXPERIMENTAL|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
62195556|NCT05406336|NO_INTERVENTION|No Information from Machine Learning Algorithm|The investigators will create case vignettes to assess clinician hypertension management behavior, specifically antihypertensive medication intensification among individuals with uncontrolled blood pressure (BP). This arm will not include information from a machine learning algorithm designed to predict uncontrolled BP at a follow up visit.
62195557|NCT05406336|EXPERIMENTAL|Information from Machine Learning Algorithm|The investigators will create case vignettes to assess clinician hypertension management behavior, specifically antihypertensive medication intensification among individuals with uncontrolled blood pressure (BP). This arm will include information from a machine learning algorithm designed to predict uncontrolled BP at a follow up visit about whether the algorithm predicts that the patient will have uncontrolled BP at the next visit.
62574073|NCT04306965|EXPERIMENTAL|Apremilast|Apremilast will be administered to patients as 30 mg oral tablets taken twice daily for 24 weeks. An initial 5-day titration will be implemented to improve tolerability.
62195558|NCT01758575||antiangiogenic tyrosine kinase inhibitors|Sunitinib: 50 mg orally once daily Sorafenib: 400 mg orally twice daily Pazopanib: 800 mg orally once daily
62195559|NCT01758575||EGFR inhibitors|Cetuximab 250 mg/m2 intravenously, weekly Panitumumab 6 mg/Kg intravenously, every 2 weeks
62195560|NCT01758575||mTOR inhibitors|Everolimus 10 mg orally once daily
62195561|NCT01758575||BRAF inhibitor|Vemurafenib 960 mg orally twice daily
62195562|NCT01758575||anti-CTL4 antibody|Ipilimumab 3 mg/kg intravenously, every 3 weeks
62195563|NCT03560570||Event group|CDG with antecedent of stroke-like, thrombosis or haemorrhages
62195564|NCT03560570||Non event group|CDG without antecedent of stroke-like, thrombosis or haemorrhages
62195565|NCT03560570||Control|Healthy subject
62195566|NCT04296968|EXPERIMENTAL|Expectation and experimental pain in humans|
62195567|NCT05115292|EXPERIMENTAL|Arm1|BJ-005 dose escalation
62195568|NCT05115292|EXPERIMENTAL|Arm 2|BJ-005 cohort expansion
62195569|NCT04377854||MCS recipients|All recipients of durable MCS will be followed up on a yearly basis with collection of blood sample and clinical data for 25 years.
62195570|NCT04377854||Recipient of cardiac transplant|All recipients of cardiac transplantation(s) will be followed up on a yearly basis with collection of clinical data for 25 years.
62195571|NCT04377854||Watchful waiting at Rigshospitalet|Patients referred for evaluation for treatment with advanced treatment (LVAD/HTX) but -for whatever reason- these pts will be on watchful waiting at the Rigshospitalet.
62398928|NCT01322412||Arm A : physical activity program|Arm A : physical activity program (aerobic and strength training) during the 27 weeks of treatment (chemotherapy and radiotherapy) and conventional follow-up during 27 weeks
62574074|NCT04089904|EXPERIMENTAL|ARM 1|
62195572|NCT03780647||Patients with suspicion of thoracic outlet syndrome|
62398929|NCT01322412||Arm B : conventional management|Arm B : conventional management during and after treatment
62398930|NCT05059444||Cohort 1: Muscle invasive carcinoma of the bladder, ureter, or renal pelvis (stage II-III)|
62398931|NCT05059444||Cohort 2: Non-small cell lung cancer (stage IB-III)|
62574075|NCT01863199|ACTIVE_COMPARATOR|Lucentis every 4 weeks|Lucentis 0.5mg administered intravitreally every four weeks for 12 months
62574076|NCT01863199|ACTIVE_COMPARATOR|Lucentis every 12 weeks|Lucentis 0.5mg administered intravitreally every 12 weeks
62574077|NCT01863199|EXPERIMENTAL|Treat and extend|Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.
62574078|NCT02598661|EXPERIMENTAL|Part 1: Imetelstat|Imetelstat will be administered at a starting dose of 7.5 milligram per kilogram (mg/kg) given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.
62574079|NCT02598661|EXPERIMENTAL|Part 2 (Main Study): Imetelstat|"Imetelstat will be administered at a starting dose of 7.5 mg/kg given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.~Subjects receiving imetelstat who continue into the extension phase will continue to receive imetelstat treatment per this same schedule."
62195573|NCT05436925||Dexcom G6 sensor Continuous Glucose Monitor (CGM)|All participants will be assigned to use the continuous glucose monitor
62195574|NCT00557778||1|Receives treatment with rosuvastatin, according to International and National Guidelines on hypercholesterolemia.
62195575|NCT00557778||Group 2|Receives the same treatment as group 1 and information on health improvement, diet and exercises applied to the disease that is being treated. The positive impact of the information upon treatment will be statistically evaluated.
62195576|NCT01445327||Markers of Tumor Burden and Radiation Toxicity|Serum, plasma, urine, and stool samples will be collected prior to radiotherapy for participants with gastrointestinal malignancies.
62195577|NCT05808803||HIV without leukemia|
62195578|NCT05808803||HIV leukemia|
62195579|NCT03867539|ACTIVE_COMPARATOR|Control Group; Bupivacaine + opioids|"This is the standard of care arm. This group will receive pre-operative opioid education and standard of care, which consists of an injection of 10cc bupivacaine (plus \~1cc epinephrine and bicarbonate) into the carpal tunnel and overlying skin pre-operatively, and a post operative prescription for opioids (oxycodone/acetaminophen 5/325). Pain scores and medication usage will be tracked for three days post operatively to assess the validity and efficacy of differing pain management strategies."
62195580|NCT03867539|EXPERIMENTAL|Experimental Group: Exparel, no opioids|This group will receive pre-operative opioid education, Exparel injection (liposomal bupivacaine, with bupivacaine, epinephrine and bicarbonate), and would not receive a prescription for opioids. This injection will be administered as 10cc injected in the operative field, consisting of \~5cc of Exparel (liposomal bupivacaine), \~5cc of bupivacaine, and \~1cc epinephrine. Pain scores and medication usage will be tracked for three days post operatively to assess the validity and efficacy of differing pain management strategies.
62195581|NCT02154906|ACTIVE_COMPARATOR|DFDBA|DFDBA used to graft intrabony defect
62009529|NCT00861419|EXPERIMENTAL|C|10 mg/kg AMG 386 IV (QW) / 15 mg/kg bevacizumab IV (Q3W)
62195582|NCT02154906|EXPERIMENTAL|autologous platelet rich fibrin|autologous platelet rich fibrin used to graft intrabony defect
62195583|NCT01160627|ACTIVE_COMPARATOR|Standard treatment|Hydration
62195584|NCT01160627|ACTIVE_COMPARATOR|Combined Acetylcystein and Sodium Bicarbonat|
62195585|NCT01160627|ACTIVE_COMPARATOR|Sodium Bicarbonate|
62195586|NCT01160627|ACTIVE_COMPARATOR|Acetylcystein for 2 days|Standard treatment + acetylcystein for 2 days
62195587|NCT03959761|EXPERIMENTAL|Treatment Group|Intraperitoneal (IP) nivolumab treatment, after extensive debulking surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
62195588|NCT00387959|EXPERIMENTAL|Unrelated Donor Umbilical Cord Transplant|Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and the Transplantation of Unrelated Donor Umbilixal Cord Blood
62195589|NCT01986296|EXPERIMENTAL|ExAblate Treatment|
62195590|NCT01181245|EXPERIMENTAL|FG-3019|All subjects are treated with FG-3019
62214975|NCT03186573|NO_INTERVENTION|Control Group|The athletes will not receive any drink and will do the simulations of the fight.
62574080|NCT02598661|PLACEBO_COMPARATOR|Part 2 (Main Study): Placebo|Matching Placebo to Imetelstat will be administered.
62574081|NCT02598661|EXPERIMENTAL|Part 2 (Ventricular Repolarization Substudy): Imetelstat|"Imetelstat will be administered at a starting dose of 7.5 mg/kg given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.~Subjects receiving imetelstat who continue into the extension phase will continue to receive imetelstat treatment per this same schedule."
62195591|NCT01951404|ACTIVE_COMPARATOR|Allopurinol|Participants in this arm will be given allopurinol with the dose gradually increasing weekly as tolerated up to the dose determined in the first phase of the study. The drug dose will be given orally 3 times weekly after dialysis for 1 year.
62195592|NCT01951404|PLACEBO_COMPARATOR|Placebo|Participants in this arm will be given placebo with the dose appearing to gradually increase weekly as tolerated up to the dose determined in the first phase of the study. The drug dose will be given orally 3 times weekly after dialysis for 1 year.
62195593|NCT00940745|EXPERIMENTAL|Stereotactic Aspiration and Thrombolysis|To position haematoma's location, drills several millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
62195594|NCT00940745|ACTIVE_COMPARATOR|conservative treatment|dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
62195595|NCT00998842||healthy subjects|five male, five female, ages 18-64
62195596|NCT04134624|ACTIVE_COMPARATOR|Prehospital intervention|All subjects enrolled in this study will receive a sepsis intervention bundle in the prehospital setting, including blood cultures, IV fluids, and antibiotics. These patients will be compared to historical controls.
62195597|NCT04134624|NO_INTERVENTION|Control arm|Historical controls without prehospital sepsis intervention.
62195598|NCT03898700|OTHER|coaching in context|10, 1 hour sessions of face to face strength based coaching sessions provided face to face or over the phone.
62195599|NCT05439330|EXPERIMENTAL|Application of a dental-dedicated MRI|MRI of conditions related to teeth and surrounding structures
62195600|NCT02986945|EXPERIMENTAL|Immediate|"Resiliency App: Study participants randomized to the Immediate group will receive the text-messaging app, B-RESILIENT-an adaptation of a Resiliency Course for improving mood in individuals with depressive symptoms--for 4 weeks.~Wk 1: BOOST - manage unhealthy thoughts. Wk 2: BREAK - doing pleasant activities. Wk 3: BUDDY - effective communication for social support. Wk 4: Review of first 3 weeks. Each day, users will receive a daily affirmation text message, a series of approximately 5-10 text messages on the topic of the day, and a daily goal corresponding to the day's content (e.g. do a pleasant activity). At the end of the day, users will receive text messages asking them to report whether they completed the daily goal, followed by a daily mood measure."
62195601|NCT02986945|OTHER|Delayed|Resiliency App: The Delayed arm will receive the intervention after the Immediate Arm completes its use of the intervention.
62195602|NCT03063684|EXPERIMENTAL|Vaginal atrophy|"With decreasing estrogen levels occurring following menopause, changes of the vaginal mucosa appear: it becomes thin and pale and loses its elasticity. The blood supply decreases, normal secretion is reduced, the epithelial cells do not undergo the normal differentiation process, the bacterial population changes with loss of lactobacilli and pH increases. These changes are associated with morphological and histological changes, manifested, among other findings, by alterations in the collagen composition, loss of the trabecular organization of collagen and reduced amount of elastic fibers. Women with reduced vaginal estrogen content may report dryness, itching, discomfort, burning sensation during micturition, pain and dyspareunia. These changes are reversible: topical or systemic estrogen change the vaginal mucosa's characteristics and may also alleviate complaints arising from estrogen deficiency.~The intervention is 3 treatments with fractional / Pixel CO2 Laser"
62214976|NCT03186573|ACTIVE_COMPARATOR|Intervention group|(Intervention, grape juice) - athletes will receive 400 ml per day of grape juice (containing 66g of carbohydrates) for 14 days and will do the fight simulations.
62009530|NCT00861419|EXPERIMENTAL|F|10 mg/kg AMG 386 IV (QW) / 400 mg sorafenib PO (BID)
62214977|NCT03186573|PLACEBO_COMPARATOR|Placebo Group|(Placebo, grape-flavored maltodextrin carbohydrate) - athletes will receive400ml of drink daily with 66g of maltodextrin for 14 days and will do the fight simulations; The amount of maltodextrin is equal to the amount of carbohydrate present in grape juice.
62214978|NCT01178697|ACTIVE_COMPARATOR|Intravitreal triamcinolone|
62398932|NCT05059444||Cohort 3: Invasive breast carcinoma with hormone receptor and HER2 status|Cohort 3A: High-risk HER2+ breast cancer (any ER, PR status allowed); defined as having stage II-III or having residual invasive disease (i.e. non-pathologic complete response) following a neoadjuvant chemotherapy-containing regimen OR Cohort 3B: High-risk triple negative breast cancer (TNBC); defined as having stage II-III or having residual invasive disease (i.e. non-pathologic complete response) following a neoadjuvant chemotherapy-containing regimen OR Cohort 3C: HR-positive/HER2-negative invasive breast carcinoma with either \>4 positive axillary lymph nodes or 1-3 positive axillary lymph nodes and at least one of the following: tumor size \>5 cm, histologic grade 3, or validated gene expression assay indicating high recurrence risk (OncotypeDx score \> 26, MammaPrint high, ProSigna high, EndoPredict high)
62398933|NCT05059444||Cohort 4: Stage IIB-III cutaneous melanoma or limited (resectable) stage IV melanoma|
62398934|NCT05059444||Cohort 5: Esophageal or gastroesophageal junction carcinoma (stage II-III)|
62398935|NCT05059444||Cohort 6: Gastric adenocarcinoma (stage II-III)|
62398936|NCT05059444||Cohort 7: Pancreatic adenocarcinoma|That is has been surgically resected or is eligible for surgical resection
62574082|NCT02598661|PLACEBO_COMPARATOR|Part 2 (Ventricular Repolarization Substudy): Placebo|Matching Placebo to Imetelstat will be administered.
62009531|NCT05779566||OST|Patients with osteoporosis or severe osteopenia defined as having a significantly reduced BMD (T-score equal or lower than -1.5)
62195603|NCT03063684|EXPERIMENTAL|Lichen sclerosus|"Lichen sclerosus is a chronic cutaneous disease involving the vulvar and peri-anal skin. The involved skin becomes thin and white, with frequently present bruises or petechiae and anatomic changes.~Lichen sclerosus is thought to be an auto-immune disorder and its most frequent signs are itching, irritation or burning. The discoloration may involve the entire vulvar and peri-anal area (sometimes having the form of an 8 or a keyhole surrounding the vulva and anus) or appear as separated spots of various sizes occupying only part of the skin. At advanced stages of lichen sclerosus, scarring may appear, with loss of the labia minor and adhesions which may entirely cover the clitoris.~The treatment is of topical steroid. Lichen sclerosus is a chronic disorder, and even with good treatment, in a certain proportion of cases the skin does not return to its original appearance.~The intervention is 3 treatments with fractional / Pixel CO2 Laser"
62195604|NCT02214511||MDD patients|emotional facial stimuli cyberball game
62195605|NCT02214511||healthy subjects|emotional facial stimuli cyberball game
62195606|NCT01355640|EXPERIMENTAL|breast-feeding group|Mothers console their babies by breast-feeding during heel lance.
62195607|NCT01355640|EXPERIMENTAL|non-nutritive sucking|"Every mother was given a vacuum pacifier( the brand is Goodbaby) to console her baby during heel lance."
62195608|NCT01355640|NO_INTERVENTION|control group|A research nurse also explained the study to the control group parents. Standard clinic procedure for infant injection was also implemented. Mothers in control group also lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed.
62195609|NCT01159951||Hepatitis Cohort|Subjects suffering with hepatitis
62195610|NCT01483144|EXPERIMENTAL|Eflornithine plus Sulindac|Eflornithine 750 mg and Sulindac 150 mg
62195611|NCT01483144|ACTIVE_COMPARATOR|Eflornithine plus Sulindac Placebo|Eflornithine 750 mg and Placebo
62574083|NCT02590549|EXPERIMENTAL|MyoRing Implantation combined with corneal cross linking|Surgical technique: Implantation of a MyoRing in a corneal pocket was performed by using a PocketMaker microkeratome a guided, vibrating diamond blade to create a stromal pocket 9 mm in diameter at a 300-μm depth via a 4- to 5-mm-wide corneal tunnel followed by Corneal Collagen Crosslinking (standard surface UVA irradiation (370 nm, 3 mW/cm2) using Ufalink device)
62574084|NCT00998647||with modified ultrafiltration|"elective cardiac surgery patients undergoing complex surgical intervention:~coronary artery bypass grafting AND valve surgery double valve surgery aortic surgery Re-Dos"
62783119|NCT04115098|EXPERIMENTAL|Naproxen, Then Meloxicam, Then Celecoxib, Then A, Then B|Each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. After these 3 initial treatment sessions, participants are then randomized to the 2 best-performing drugs for 2 additional treatment sessions \[randomized to either alphabetical order (A then B) or reverse alphabetical order (B then A)\] There will be no washout periods. All 3 medications will be over-encapsulated in identical opaque capsules.
62009532|NCT05779566||Mild OST|Patients with mild-to-no reduction of BMD at the same post-treatment time point (T-score higher than -1.5)
62195612|NCT01483144|ACTIVE_COMPARATOR|Sulindac plus Eflornithine Placebo|Sulindac 150 mg and Placebo
62783120|NCT04115098|EXPERIMENTAL|Naproxen, Then Meloxicam, Then Celecoxib, Then B, Then A|Each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. After these 3 initial treatment sessions, participants are then randomized to the 2 best-performing drugs for 2 additional treatment sessions \[randomized to either alphabetical order (A then B) or reverse alphabetical order (B then A)\] There will be no washout periods. All 3 medications will be over-encapsulated in identical opaque capsules.
62783121|NCT01235234|EXPERIMENTAL|CF101 0.1 mg|Subjects were randomized to receive CF 101 0.1mg, orally, twice daily for 24 weeks
62783122|NCT01235234|EXPERIMENTAL|CF101 1 mg|Subjects were randomized to receive CF 101 1.0mg, orally, twice daily for 24 weeks
62009533|NCT02483247|EXPERIMENTAL|Combo with Capecitabine|
62009534|NCT02483247|EXPERIMENTAL|Combo with Doxorubicin|
62195613|NCT03289559|NO_INTERVENTION|Control|
62195614|NCT03289559|PLACEBO_COMPARATOR|GnRH antagonist + Placebo Gel|
62195615|NCT03289559|ACTIVE_COMPARATOR|GnRH antagonist + Testosterone Gel|
62195616|NCT04116801|EXPERIMENTAL|Fluorescence arm|fluorescence guided microsurgical resection (under 560 nm filter) in addition to the usual techniques, after iv injection of 200 mg (i.e. 3-4 mg/kg) of fluorescein sodium at the time of skin incision.
62195617|NCT04116801|ACTIVE_COMPARATOR|Standard excision|microsurgical resection with usual techniques
62195618|NCT05884814|PLACEBO_COMPARATOR|Control|Habitual physical activity
62009535|NCT02483247|EXPERIMENTAL|Combo with Nivolumab (US only)|
62009536|NCT02483247|EXPERIMENTAL|Combo with Pembrolizumab|
62009537|NCT02483247|EXPERIMENTAL|Combo with Paclitaxel|
62009538|NCT02483247|EXPERIMENTAL|Combo with Sunitinib|
62195619|NCT05884814|ACTIVE_COMPARATOR|Morning exercise|Exercise training between 6-10am
62195620|NCT05884814|ACTIVE_COMPARATOR|Afternoon exercise|Exercise training between 4-8pm
62195621|NCT03995927||Data collection/questionnaire|Data collection for patient medical charts and patient fill out questionnaires first visit and post-treatment visits
62195622|NCT03350399||level of placenta growth factor in IUGR|
62214979|NCT01178697|ACTIVE_COMPARATOR|Intravitreal bevasizumab|
62214980|NCT05468892|ACTIVE_COMPARATOR|Arm A|Trifluridine-Tipiracil
62195623|NCT04399343|EXPERIMENTAL|Dexmedetomidine group|Continuously intravenous infusion of dexmedetomidine hydrochloride at a rate of 0.1 μg/kg/hour (0.025 ml/kg/hour) started immediately after enrollment until 08:00 AM on the postoperative day one.
62195624|NCT04399343|PLACEBO_COMPARATOR|Normal saline group|Continuously intravenous infusion of normal saline at a rate of 0.025 ml/kg/hour started immediately after enrollment until 08:00 AM on the postoperative day one.
62195625|NCT02497495|NO_INTERVENTION|GC|Control group - CG (n = 21), which suffered no recuperative technique
62195626|NCT02497495|EXPERIMENTAL|G1|G1 (n = 21) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 9±1 degrees Celsius
62195627|NCT02497495|EXPERIMENTAL|G2|G2 (n = 21) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 14±1 degrees Celsius
62195628|NCT02497495|EXPERIMENTAL|G3|G3 (n = 21) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 9±1 degrees Celsius
62195629|NCT02497495|EXPERIMENTAL|G4|G4 (n = 21) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 14±1 degrees Celsius
62195630|NCT00873262|ACTIVE_COMPARATOR|Hormones|
62195631|NCT00873262|PLACEBO_COMPARATOR|Solvent|
62783123|NCT01235234|PLACEBO_COMPARATOR|Placebo|Subjects were randomized to receive matching placebo, orally, twice daily for 24 weeks
62009539|NCT02132000|ACTIVE_COMPARATOR|tamoxifen|tamoxifen,20mg/day
62195632|NCT04946578|EXPERIMENTAL|Prebiotic intervention group|Prebiotic supplementation
62195633|NCT04946578|PLACEBO_COMPARATOR|Placebo control group|Maltodextrin
62195634|NCT02119247|EXPERIMENTAL|CHF6001 dry powder for inhalation via NEXThaler®|4 inhalations of CHF 6001 NEXThaler®
62195635|NCT02119247|ACTIVE_COMPARATOR|CHF 6001 DPI capsules for inhalation via Aerolizer|3 inhalations of CHF 6001 capsules via Aerolizer®
62195636|NCT02170545||Multi-Part Proximal Humerus Fracture|All participants that meet the entry criteria will be included in the study cohort.
62783124|NCT06034249|EXPERIMENTAL|Experimental Group: Mindfulness-Based VR group|Participants will be ask to attend the six-week course encompassed various mindfulness practices, including breathing observation, body scanning, mindful yoga, mindful walking, holistic meditation, and non-selective awareness practices.
62195637|NCT01667926|EXPERIMENTAL|Ketamine|Subject will receive 6 infusions of ketamine over three weeks.
62195638|NCT01667926|PLACEBO_COMPARATOR|Placebo|Subjects will receive 6 infusions of normal saline over 3 weeks.
62195639|NCT05761613|ACTIVE_COMPARATOR|Endotracheal Tube with Subglottic Secretion Drainage|All patients in this arm will be intubated with an ETT with subglottic secretion drainage
62783125|NCT06034249|PLACEBO_COMPARATOR|Control Group: Mindfulness-based Audio Files|The control group will only be given the mindfulness-based audio files for six weeks.
62009540|NCT02132000|EXPERIMENTAL|toremifene|toremifene,60mg/day
62009541|NCT01332149|EXPERIMENTAL|300 mg/day pregabalin (Lyrica)|Patient take pregabalin capsule twice a day
62009542|NCT01332149|PLACEBO_COMPARATOR|Placebo|
62009543|NCT03127124|EXPERIMENTAL|NANT-008 in combination with other agents|NANT-008 will be administered in combination with 5-fluorouracil, bevacizumab, leucovorin, and oxaliplatin in patients with metastatic pancreatic adenocarcinoma.
62009544|NCT00881075|EXPERIMENTAL|SeeMore(TM)|intravenous imaging agent for enhanced magnetic resonance imaging.
62009545|NCT06514092||Crohn's patients|
62195640|NCT05761613|ACTIVE_COMPARATOR|CeraShield Endotracheal Tube|All patients in this arm will be intubated with a ceragenin coated ETT
62195641|NCT04601324|ACTIVE_COMPARATOR|Dymista (Azelastine hydrochloride and fluticasone propionate)|Participants will receive standard of care, which includes twice daily MP-AzeFlu nasal spray (formulation of 137 mg of azelastine hydrochloride and 50 mcg of fluticasone propionate per spray) separated by 12 hours.
62214981|NCT05468892|EXPERIMENTAL|Arm B|Panitumumab + Trifluridine-Tipiracil
62214982|NCT05167305||liver disease without COVID-19 infection-April-May 2019|
62783126|NCT01743820|ACTIVE_COMPARATOR|dihydroartemisinin-piperaquine only|dihydroartemisinin -piperaquine (DP) only
62783127|NCT01743820|EXPERIMENTAL|DP and 0.125 mg/kg primaquine|DP and single dose oral 0.125 mg/kg primaquine
62783128|NCT01743820|EXPERIMENTAL|DP and 0.5 mg/kg primaquine|DP and single dose oral 0.5 mg/kg primaquine
62783129|NCT01743820|EXPERIMENTAL|DP and 0.25 mg/kg primaquine|DP and a single dose oral 0.25 mg/kg primaquine
62783130|NCT01743820|EXPERIMENTAL|DP and 0.0625 mg/kg primaquine|DP and a single dose oral 0.0625 mg/kg primaquine
62783131|NCT05777512|EXPERIMENTAL|Group A: Gastric Followed by Jejunal Feeds|Participants randomized into this group will begin with one ten-day block of nasogastric (NG) feeds followed by one ten-day block of nasojejunal (NJ, postpyloric) feeds.
62195642|NCT04601324|EXPERIMENTAL|Fluticasone Propionate and Rupatadine|Participants will administer fluticasone propionate nasal spray once daily (2 sprays in each nostril, 50 mcg fluticasone propionate per spray)and 1 tablet of Rupatadine (10mg) once daily in the morning.
62195643|NCT02185105|EXPERIMENTAL|comfilcon A MTO|Subjects will be randomized to receive either the Test or Control lens as a matched pair at each visit per a predetermined randomization schedule.
62195644|NCT02185105|ACTIVE_COMPARATOR|comfilcon A|Subjects will be randomized to receive either the Test or Control lens as a matched pair at each visit per a predetermined randomization schedule.
62195645|NCT00809367|OTHER|Collection of Leukemia Cells|Other: Collection of Leukemia Cells Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
62574085|NCT00998647||without modified ultrafiltration|"elective cardiac surgery patients undergoing complex surgical intervention:~coronary artery bypass grafting AND valve surgery double valve surgery aortic surgery Re-Dos"
62574086|NCT05645640|ACTIVE_COMPARATOR|Intervention|Subjects in the intervention group will receive village doctor-led tailored health management which includes five main components (marking of individual risk factor profiles, tailored targets for risk factor modification, individualized health education based on Smart Phones, health monitoring and feedback based on Smart Bands, and incentive based on gamification).
62574087|NCT05645640|NO_INTERVENTION|Control|Subjects in the control group will receive usual care (advice on lifestyle change, medication, and rehabilitation).
62574088|NCT04928612|EXPERIMENTAL|Part A -CBP-1018 Dose escalation/Part B- CBP-1018 monotherapy|"Part A: CBP-1018 administrated iv Q 2 W (4 weeks/cycle), utilizing accelerated titration at lower doses (0.03 mg/kg and 0.06 mg/kg) and an i 3+3 design at following doses (0.08 mg/kg,0.10 mg/kg,0.12 mg/kg and 0.14 mg/kg, etc.), respectively.~Part B：Further evaluate the efficacy and safety profile of CBP-1018 in 4 tumor-specific cohorts.Cohort 1 (Metastatic castration resistant prostate cancer, mCRPC)；(Advanced renal cell cancer, RCC); Cohort 3 (Advanced lung cancer, LC); Cohort 4 (Other advanced solid tumors)."
62574089|NCT01024140|EXPERIMENTAL|Escitalopram|Flexible dose (5-20mg/day) of escitalopram monotherapy.
62574090|NCT06577584||The Diabetes Care trajectory|The care trajectory is designed for individuals with T2DM who are treated with Glucagon-like peptide-1 (GLP-1) analogs (injectable or oral) or require 1 to 2 insulin injections per day. It can also be initiated when blood sugar-lowering medication (pills) is no longer sufficient and the use of a GLP-1 analog or insulin is being considered. The follow-up and management is mainly being taken care of by general practioners, with minor follow-up in specialised diabetes centers.
62574091|NCT06577584||The Diabetes Convention|The Diabetes Convention is intended for individuals with T2DM who require specialized care due to the complexity of their insulin treatment (multiple daily insulin injections). Specialised diabetes centers in (university) hospitals are responsible for providing comprehensive follow-up and management of these patients.
62195646|NCT03428906|EXPERIMENTAL|Oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (8 IU or 13.44 mg; Syntocinon-spray; Novartis, Switzerland) .
62195647|NCT03428906|PLACEBO_COMPARATOR|Placebo|Placebo contains all ingredients except for the peptide in three puffs of 1.33 IU per 2.24mg nostril.
62195648|NCT03597984|NO_INTERVENTION|Arm A|Standard Radiotherapy: 4 Gy x 5 fractions (fr) to Whole vertebra
62574092|NCT02088905|EXPERIMENTAL|Parent Child Interaction Therapy|Families will either receive Parent Child Interaction Therapy or be placed on a wait-list control group
61978019|NCT01518777|OTHER|Half-dose isotope for NuclearStressTest|"Intervention is Nuclear stress test of the heart. Single-arm of this study Half-dose of isotope for Nuclear stress test is group of study subjects who will do Research Nuclear stress test with half-dose of isotope that normally used for routine Nuclear stress test. Isotope is the tracer CZT (cadmium zinc telluride) that used for Nuclear stress test routinely to see the function of arteries of the heart. Patients with suspected Coronary Artery Disease who meet entry criteria undergo a research nuclear stress test using a decreased dose of isotope, using a new camera."
62195649|NCT03597984|EXPERIMENTAL|Arm B|"Intervention: Radiotherapy with Simultaneous Integrated Boost-SIB on macroscopic metastases~Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:~- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)"
62195650|NCT01535651|EXPERIMENTAL|TOP Program plus Text messaging|Boys and Girls Club members who participate in TOP over 9 months will receive regular text messages in addition to TOP
62195651|NCT01535651|NO_INTERVENTION|TOP Program alone|Boys and Girls Club participants will participate in TOP for 9 months
62214983|NCT05167305||liver disease without COVID-19 infection -April- May 2021|
62214984|NCT00688870|EXPERIMENTAL|1|13vPnC
62574093|NCT02088905|NO_INTERVENTION|Wait list control|Families will wait 18 weeks for treatment, serving as controls.
62574094|NCT02464163|EXPERIMENTAL|Panblok 30µg in 2% SE|30µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
62574095|NCT02464163|EXPERIMENTAL|Panblok 15µg in 2% SE|15µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
62574096|NCT02464163|EXPERIMENTAL|Panblok 7.5µg in 2% SE|7.5µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
62574097|NCT02464163|EXPERIMENTAL|Panblok 30µg (No Adjuvant)|30µg recombinant hemagglutinin (no adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
62398937|NCT05059444||Cohort 8: Invasive squamous cell carcinoma of the head and neck|Includes stage I-IVB oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, nasal cavity, or paranasal sinus
62574098|NCT04943328|OTHER|TrendHip®|
62574099|NCT00734162|EXPERIMENTAL|Tenofovir disoproxil fumarate (TDF)|
62574100|NCT00734162|PLACEBO_COMPARATOR|Placebo|
62574101|NCT00806273|ACTIVE_COMPARATOR|Group 2|For Group II, the ultrasonic irrigation system involves using an initial irrigation with a conventional syringe followed by ultrasonic irrigation.
62574102|NCT00806273|ACTIVE_COMPARATOR|Group 1|For Group I, needle irrigation will be delivered into the pulp chamber using a syringe tip placed above the access opening and removed with high volume suction.
62574103|NCT01006187|ACTIVE_COMPARATOR|Group 1|1 liposomal lidocaine 4% cream .
62574104|NCT01006187|ACTIVE_COMPARATOR|Group 2|Vapocoolant spray
62195652|NCT01833208|EXPERIMENTAL|Treatment (radiation therapy)|Patients undergo single-fraction radiation therapy to at least 1 bone lesion 2 days after the first sipuleucel-T dose.
62195653|NCT06020599||Children who need general anesthesia for surgery|Children who need general anesthesia for surgery (ENT, dentistry) at Louis Mourier Hospital.
62574105|NCT01006187|ACTIVE_COMPARATOR|Group 3|Rubbing adjacent to the injection site
62574106|NCT01006187|ACTIVE_COMPARATOR|Group 4|Distraction by means of self-selected reading material or internet
62574107|NCT00874627|EXPERIMENTAL|Experimental|Administration of Milk
62574108|NCT00874627|PLACEBO_COMPARATOR|Placebo|meals without milk
62574109|NCT04682717||PI group|A cut-off value of baseline PI below which hypotension at 5 min post induction could be predicted will be the primary outcome, while positive and negative predictive values at 15 minutes will be secondary outcomes.
61978020|NCT00613938|PLACEBO_COMPARATOR|004|placebo 1 capsule q4-6 hrs for 3 days
62195654|NCT00350727|EXPERIMENTAL|Combination|Pazopanib and Lapatinib in combination. Subjects remain on treatment until disease progression or withdrawal from study.
62195655|NCT02489734|EXPERIMENTAL|low concentration (LC)|low concentration group
62574110|NCT01081769|EXPERIMENTAL|Paliperidone Palmitate|paliperidone palmitate injection with 150 mg equivalent on Day 1 100 mg equivalent on Day 8 75 mg equivalent on Day 38 and flexible dosing with 25 50 75 100 or 150 mg equivalent once monthly thereafter
62574111|NCT01081769|ACTIVE_COMPARATOR|Oral Antipsychotics|oral antipsychotics daily treatment according to local label for maximally 24 months
62574112|NCT01180868||patients with cancer|patients with hematological malignancies and solid tumors
62574113|NCT01180868||patients with autoimmune dosorders|patients with Rheumatoid arthritis, Crohns's disease, systemic lupus erythematosus.
62574114|NCT01180868||healthy subjects|
62574115|NCT05445505|ACTIVE_COMPARATOR|Early-start single iTBS group|The intensive period: 2 weeks The maintenance period: 12 weeks
62574116|NCT05445505|ACTIVE_COMPARATOR|Early-start double iTBS group|The intensive period: 2 weeks The maintenance period: 12 weeks
62574117|NCT05445505|SHAM_COMPARATOR|Delayed-start single iTBS group|The intensive period: sham/iTBS, 2 weeks The maintenance period: daily sham/iTBS, 12 weeks
62574118|NCT05445505|SHAM_COMPARATOR|Delayed-start double iTBS group|The intensive period: sham/iTBS, 2 weeks The maintenance period: twice daily sham/iTBS, 12 weeks
62574119|NCT06321406|ACTIVE_COMPARATOR|Control Group|Exercises such as progressively resistant oral-facial, lingual, laryngeal exercises, tongue strengthening exercises, effortful swallowing maneuver, thermal/tactile stimulation to oropharyngeal muscles, Masako maneuver, Mendelson maneuver, Shaker maneuver, which are included in traditional swallowing treatment, will be taught and practiced for 30 minutes will be recommended for one month.
62574120|NCT06321406|ACTIVE_COMPARATOR|NMES(neuromuscular electrical stimulation) Group|One electrode will be connected to the suprahyoid region and the other electrode will be connected between the thyroid and hyoid cartilages. Superficial neuromuscular stimulation will be applied by the physiotherapist at 80 Hz, 0-25 µA current range for 20 minutes, for 5 days for the patient, for a total of 4 weeks. At the same time, each patient will be taught the exercises included in traditional swallowing treatment and will be advised to practice them for 30 minutes every day.
62574121|NCT02724657|EXPERIMENTAL|Buteyko Method|Children will perform 6 sessions (twice a week) of treatment with the Buteyko Method.
62574122|NCT02724657|NO_INTERVENTION|Control|Asthma education.
62574123|NCT02162251||E2020|
62574124|NCT01535521|OTHER|SPT in patients with MAD|
62574125|NCT04516343|EXPERIMENTAL|User testing|Two sessions of user-centric testing.
62574126|NCT04516343|EXPERIMENTAL|Therapist-guided training|Therapist-guided gait training with the RAAD.
62783132|NCT05777512|EXPERIMENTAL|Group B: Jejunal Followed by Gastric Feeds|Participants randomized into this group will begin with one ten-day block of nasojejunal (NJ, postpyloric) feeds followed by one ten-day block of nasogastric (NG) feeds.
61978021|NCT00613938|ACTIVE_COMPARATOR|003|oxycodone 10mg capsule q4-6 hrs for 3 days
62195656|NCT02489734|EXPERIMENTAL|high concentration (HC)|high concentration group
62398938|NCT05059444||Cohort 9: High-risk epithelial ovarian or Fallopian tube carcinoma|Defined as stage IC-III or stage I that has high grade (grade 3-4) or clear cell histology).
62398939|NCT05059444||Cohort 10: High-risk endometrial carcinoma|Defined as having any of the following: serous or clear cell adenocarcinoma histology (any stage), grade 3 or 4 deeply invasive (T1b or greater) endometrioid carcinoma, stage III disease (any histology).
62398940|NCT05059444||Cohort 11: High-risk renal cell carcinoma|Defined as high grade (grade 3-4) stage II, stage III or limited (resectable) stage IV treated with curative intent.
62574127|NCT04516343|EXPERIMENTAL|Assistance training|Assistance training with the RAAD
62574128|NCT04516343|EXPERIMENTAL|Therapist supervised resistance training|Resistance training with the RAAD under therapist supervision.
62574129|NCT04516343|EXPERIMENTAL|Parent supervised resistance training|Resistance training under parent supervision.
62574130|NCT00002772|EXPERIMENTAL|High dose chemo|sequential high dose chemotherapy with doxorubicin, paclitaxel and cyclophosphamide with filgrastim support
62574131|NCT00002772|EXPERIMENTAL|chemo with autologous stem cell support|conventional chemotherapy with doxorubicin and cyclophosphamide followed by autologous stem cell support
62195657|NCT01686139|EXPERIMENTAL|ABDM-MSC|"The patient will receive multiple injections in one session during the study. The injections will take place in the chronic wound bed and in the third distal part of the treated shin (in the form of a ring).~Maximal amount of ABMD-MSC cells injected: 10-20\*10\^6 cells (up to volume of 20mL, depending on the wound size \& patient weight)."
62398941|NCT05059444||Cohort 12: Pathologically confirmed adenocarcinoma of the rectum|Located up to 15 cm from the anal verge that is undergoing or underwent a preoperative chemotherapy- or immunotherapy-containing regimen
62574132|NCT01118195||TBI and Suicidal Behavior|
62398942|NCT05274620|OTHER|IntelliCare|8 weeks of IntelliCare
62574133|NCT01118195||TBI and No Suicidal Behavior|
62574134|NCT02203721|EXPERIMENTAL|TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|Bilaterally implanted with TECNIS Symfony Extended Range of Vision Intraocular Lens, Model ZXR00
62574135|NCT02203721|ACTIVE_COMPARATOR|TECNIS Monofocal IOL, Model ZCB00|Bilaterally implanted with TECNIS Monofocal Intraocular Lens, Model ZCB00
62574136|NCT00751920|EXPERIMENTAL|1|
62574137|NCT05008432||HFpEF Patients Diagnosed with Obstructive Sleep Apnea|Right heart cath patients who are diagnosed with HFpEF will undergo a home sleep apnea test (for patients hospitalized with HFpEF, the initial home sleep test will be performed in hospital overnight)
62574138|NCT05984940|ACTIVE_COMPARATOR|GP and AH Plus sealer|Root canal obturation using gutta percha and AH Plus® bioceramic sealer.
62574139|NCT05984940|EXPERIMENTAL|Ortho MTA|Root canal obturation using Ortho MTA cement.
62574140|NCT02374268|EXPERIMENTAL|Exercise program alone|There will be 2 site sessions and 1 home session per week for 12 weeks. Each site exercise session will begin and end with a 5-10 minute warm-up and cool-down routine. The first part of the exercise program consists of 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body. To target the development of muscle power in both the lower and upper extremities, participants will be instructed to perform each concentric movement 'as rapidly as possible,' and the eccentric movement in a slow and controlled manner. A 5-minute rest period will be given prior to the start of the second part of the exercise program that consists of aerobic exercises such as ball games using fitballs or Taichi. Participants will be asked to spend an hour/week on home exercise. Thera-Bands and a leaflet showing the exercise procedures will be given to them and their caregivers.
62574141|NCT02374268|EXPERIMENTAL|Exercise program plus nutrition supplement|This group will receive both the exercise program as well as the nutrition supplement. The components of the exercise program will be same as those of the exercise program alone group. Participants will also be asked to consume two sachets of Ensure NutriVigor every day during the 12-week intervention period. Ensure NutriVigor (one sachet of 54.1 g powder) contains 231 calories, 8.61 g protein, 1.21 g hydroxyl-methyl-butyrate (HMB), 130 IU vitamin D, and 0.29 g omega 3 fatty acid per serving. Participants will be instructed on how to prepare the supplement.
62574142|NCT02374268|OTHER|Waitlist control group|This group will be asked to maintain their usual physical activities and dietary habits during the first 6 months of study period. After they complete the 24-week measurement, they will receive the same 12-week exercise program as of the exercise program alone group.
62574143|NCT00771342|EXPERIMENTAL|1|1% gasoue nitric oxide, delivered topically for 40 minutes daily for three consecutive days
62574144|NCT00771342|PLACEBO_COMPARATOR|2|Nitrogen gas delivered topically for 40 minutes, daily, for 3 consecutive days
62574145|NCT02888041|EXPERIMENTAL|Dinoprostone|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
62195658|NCT05534724|OTHER|Partial weight-bearing (10 - 15kg)|Immediate post-operative partial weight-bearing (10 - 15kg) with a VACOPASO shoe for 6 weeks, crutches and antithrombotic prophylaxis
62195659|NCT05534724|EXPERIMENTAL|Complete weight-bearing|Immediate post-operative complete weight-bearing with a VACOPASO shoe for 6 weeks and antithrombotic prophylaxis
62574146|NCT02888041|ACTIVE_COMPARATOR|Oxytocine|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
62783133|NCT03841435|EXPERIMENTAL|Hypofractionated Radiotherapy|15 Gy given in 3 fractions over 2 weeks
61978022|NCT00613938|EXPERIMENTAL|001|Tapentadol (CG5503) 50mg capsule q4-6 hrs for 3 days
62195660|NCT06052527||Active Covid-19 Infection|Patients with positive SARS-CoV-2 rapid antigen test results within 60 days before the start of the study will be administered pre-defined TCM prescriptions recommended by the Autonomous Treatment System based on machine learning
62214985|NCT00688870|ACTIVE_COMPARATOR|2|7vPnC
62214986|NCT02662452|EXPERIMENTAL|GLPG2222 single dose|Single dose of GLPG2222 oral suspension
62214987|NCT02662452|PLACEBO_COMPARATOR|Placebo single dose|Single dose of placebo oral suspension
62214988|NCT02662452|EXPERIMENTAL|GLPG2222 multiple doses|Multiple doses of GLPG2222 oral suspension
62214989|NCT02662452|PLACEBO_COMPARATOR|Placebo multiple doses|Multiple doses of placebo oral suspension
62214990|NCT00142181|EXPERIMENTAL|Campath-1H|30 mg IV three times a week, 6-12 weeks.
62214991|NCT05022160|EXPERIMENTAL|Group P|Patients in this group will receive bilateral pudendal nerve block after spinal anesthesia- before starting the surgery
62214992|NCT05022160|PLACEBO_COMPARATOR|Group C|Patients in this group will only receive spinal anesthesia before starting the surgery
62214993|NCT04677179|EXPERIMENTAL|High dose LY3471851|Participants received a subcutaneous injection of high dose LY3471851 every 2 weeks from weeks 0 to 12. Week 12 responders entered the maintenance period and continued with the same treatment. Week 12 non-responders entered the extension period where they received subcutaneous injection of high dose LY3471851 every 2 weeks up to week 50. At week 26, extension period non-responders were discontinued from treatment. Post-treatment, participants entered follow-up period and were observed for 6 weeks for safety.
62214994|NCT04677179|EXPERIMENTAL|Low dose LY3471851|Participants received a subcutaneous injection of low dose LY3471851 every 2 weeks from weeks 0 to 12. Week 12 responders entered the maintenance period and continued with the same treatment. Week 12 non-responders entered the extension period where they received subcutaneous injection of high dose LY3471851 every 2 weeks up to week 50. At week 26, extension period non-responders were discontinued from treatment. Post-treatment, participants entered follow-up period and were observed for 6 weeks for safety.
62195661|NCT06052527||Post-Covid-19 Syndrome|Patients with positive Covid-19 antigen test results obtained more than 60 days before the start of the study will be administered pre-defined TCM prescriptions recommended by the Autonomous Treatment System based on machine learning.
62195662|NCT06052527||Influenza|Patients with negative SARS-CoV-2 rapid antigen test results and who are diagnosed with influenza will be administered pre-defined TCM prescriptions recommended by the Autonomous Treatment System based on machine learning.
62009546|NCT04147013|EXPERIMENTAL|Celecoxib Group|Patients will receive the interventional drug for 7 days post endoscopic sinus surgery. These patients will also receive a prescription for tramadol (50 mg PO Q6H PRN x 10 tablets), to be used as needed for breakthrough pain. Patients will also be permitted to take acetaminophen for breakthrough pain as needed and will be encouraged to use acetaminophen prior to narcotic usage. Finally, they will be prescribed a nasal saline rinse, which is to be started on postoperative day one.
62009547|NCT04147013|PLACEBO_COMPARATOR|Control Group|Patients will receive the placebo for 7 days post endoscopic sinus surgery. These patients will also receive a prescription for tramadol (50 mg PO Q6H PRN x 10 tablets), to be used as needed for breakthrough pain. Patients will also be permitted to take acetaminophen for breakthrough pain as needed and will be encouraged to use acetaminophen prior to narcotic usage. Finally, they will be prescribed a nasal saline rinse, which is to be started on postoperative day one.
62195663|NCT03826524|ACTIVE_COMPARATOR|Low Dose Epinephrine|Epinephrine up to 2mg total
62195664|NCT03826524|ACTIVE_COMPARATOR|Standard Dose Epinephrine|Epinephrine up to 6mg total
62195665|NCT03322839|EXPERIMENTAL|Multifaceted implementation strategies|The school-management will participate in a one-day training. In addition each intervention school will form an implementation team that is responsible for the implementation of the guideline within their school. The implementation teams will participate in 4-5 workshops in order to support the implementation process.
62009548|NCT05484401|EXPERIMENTAL|Test Product|Ibuprofen 200mg Oral Liquid Capsule, Placebo of Ibuprofen 200mg Oral Tablet
62195666|NCT03322839|ACTIVE_COMPARATOR|Single implementation strategy|The control-schools will only receive training to the school-management.
62195667|NCT03909490|ACTIVE_COMPARATOR|Control|
62195668|NCT03909490|EXPERIMENTAL|intervention- tool|
61978023|NCT00613938|EXPERIMENTAL|002|Tapentadol (CG5503) 75mg capsule q4-6 hrs for 3 days
62195669|NCT06418321||Participant group 1: HUS Helsinki University Hospital|Participants are tested with the investigational device and the gold-standard device.
62195670|NCT06418321||Participant group 2: Aalto University|Participants are tested with the investigational device.
62195671|NCT00224744|ACTIVE_COMPARATOR|Classical surgical Inguinal curage|Classical Inguinal curage
62195672|NCT00224744|EXPERIMENTAL|Ultracision surgical Inguinal curage|
62195673|NCT01246999|ACTIVE_COMPARATOR|Live Attenuated Influenza vaccine|LAIV 0.2 ml will be given intranasally followed by LAIV 0.2 mg given intranasally 28 days later
62195674|NCT01246999|ACTIVE_COMPARATOR|Trivalent Influenza Vaccine 2010-2011|TIV will be given in a dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 8 years intramuscularly followed by a second dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 9 years intramuscularly 28 days later
62195675|NCT01246999|ACTIVE_COMPARATOR|TIV followed by LAIV|TIV will be given in a dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 9 years intramuscularly followed by LAIV given in a dose of .2 ml intranasally 28 days later
62195676|NCT01246999|ACTIVE_COMPARATOR|LAIV followed by TIV|LAIV will be given in a dose of .2 ml intranasally followed by a dose of TIV given in a dose of .25 ml 2 years to 36 months or .5 ml 37 months to 9 years intramuscularly 28 days later
62574147|NCT02143973|EXPERIMENTAL|nalbuphine HCl ER|nalbuphine HCl ER titrated from a dose of 30 mg QD to 120 BID for up to 3 weeks based on tolerability and efficacy, then maintained for an additional 21 weeks. Total duration of 24 weeks.
61978024|NCT03542344|EXPERIMENTAL|BI 1015550|
61978025|NCT03542344|PLACEBO_COMPARATOR|Placebo|
62009549|NCT05484401|ACTIVE_COMPARATOR|Reference Product|Ibuprofen 200mg Oral Tablet, Placebo of Ibuprofen 200mg Oral Liquid Capsule
62195677|NCT03715777|EXPERIMENTAL|BoNTA Injection|"Patients diagnosed with chronic pelvic floor pain, without contraindications for the administration of BoNTA.~Name of each active substance (INN or proposed INN if available):~Botulinum toxin type A Clostridium botulinum type A (BoNTA) Pharmaceutical form (use standard terms): Powder and solution for solution for injection Route of administration (relevant to the maximum dose): Intramuscular use Specify total dose : 80 U"
62195678|NCT05845541|EXPERIMENTAL|Technology Supported Meditation|Patient's randomized to the treatment arm will receive technology-based meditation therapy at least three times per week for a minimum of 10 minutes per session. They will participate in sessions throughout the length of their inpatient stay via the iom2 device and the interactive meditation software. Signals from the iom2 are then sent to an App on a phone, tablet or personal computer that generates biofeedback information and allows patients to adjust their breathing based on the feedback. The interactive Meditation programs teach specific breathing, mindfulness and relaxation techniques to increase a person's heart rate variability (HRV). Doing so provides the participant with instantaneous awareness of their nervous system state, which helps them to learn to directly influence their HRV.
62195679|NCT05845541|ACTIVE_COMPARATOR|Standard Treatment|Patients at St. John's Rehab undergoing rehabilitation are supported by an interprofessional team - including physiatrists, nurses, occupational therapists, speech language pathologists, physical therapists, social workers and psychiatrists. During their inpatient stay, patients receive a wide range of rehabilitation services aimed at addressing their physical, emotional and cognitive care needs. Length of stay for inpatient services ranges between 2 to 12 weeks.
62574148|NCT03095144||Spinal anesthesia|Lumbar puncture was performed with a midline approach through either the fourth or fifth lumbar space using a 22 or 25 -gauge 4 cm disposable styletted needle. Spinal isobaric Bupivacaine 0.5%, 0.8-1 mg.kg-1 without epinephrine was injected using a 1ml tuberculin syringe.
62783134|NCT05293236|PLACEBO_COMPARATOR|Placebo|Nine COVID-19 patients (three from each treatment-group) treated with saline intravenous infusion
61978026|NCT02121288|EXPERIMENTAL|Ticagrelor|oral ticagrelor 90 mg (yellow) tablet
61978027|NCT02121288|ACTIVE_COMPARATOR|Clopidogrel|oral clopidogrel 75 mg (pink) tablet
62009550|NCT05484401|PLACEBO_COMPARATOR|Placebo|Placebo of Ibuprofen 200mg Oral Liquid Capsule, Placebo of Ibuprofen 200mg Oral Tablet
62574149|NCT03095144||General anesthesia|The General anesthesia is preformed by intravenous Propofol (2-4 mg.kg-1) and Fentanyl (1-2 µg.kg-1) and Rocuronium bromide (0.5mg.kg-1) administration to facilitate endotracheal intubation, assisted by Sellick manoeuvre. Anaesthesia maintenance with Sevoflurane (2-3%) in an air/oxygen mixture, intravenous Fentanyl as required.
62574150|NCT03962777|EXPERIMENTAL|oil pulling|patients used oil pulling therapy for 4 days
62009551|NCT02358694|EXPERIMENTAL|Active Treatment Group|Patients who weigh less than 40 Kg will receive 5 g daily (2.5 g PO BID) of Serum-derived bovine immunoglobulin/ protein isolate Patients who weigh 40 Kg or more will receive 10 g daily (5 g PO BID) of Serum-derived bovine immunoglobulin/ protein isolate
62195680|NCT06502743|EXPERIMENTAL|Part B - Pembrolizumab monotherapy|"Chemotherapy Treatment Pembrolizumab 200 mg IV Day 1 + Paclitaxel 175mg/m2 IV over 3 hours Day 1 + Carboplatin AUC 5 IV Day 1 x 6 cycles (one cycle = 3 weeks~Maintenance Treatment Pembrolizumab 400 mg IV Day 1 x up to 14 cycles (o ne cycle = 6 weeks )~Maximum number of Pembrolizumab cycles (Chemotherapy Treatment + maintenance Treatment ) = 20"
62195681|NCT06502743|EXPERIMENTAL|Part B - Pembrolizumab and nesuparib combination therapy|"Combination therapy Chemotherapy Treatment Pembrolizumab 200 mg IV Day 1 + Paclitaxel 175mg/m2 IV over 3 hours Day + Carboplatin AUC 5 IV Day 1 x 6 cycles (one cycle = 3 weeks)~Maintenance Treatment Pembrolizumab 400 mg IV Day 1 + Nesuparib 150mg or 100mg QD PO x up to 14 cycles (o ne cycle = 6 weeks )~Maximum number of Pembrolizumab cycles (Chemotherapy Treatment + maintenance Treatment ) = 20"
62195682|NCT06502743|EXPERIMENTAL|Part A - Safety Run-in Phase|"Chemotherapy Treatment:~Pembrolizumab 200 mg IV Day 1 + Paclitaxel 175mg/m2 IV over 3 hours Day 1 + Carboplatin AUC 5 IV Day 1 x 6 cycles (one cycle = 3 weeks)~Maintenance Treatment:~Pembrolizumab 400 mg IV Day 1 + Nesuparib 150mg or 100mg QD PO x up to 14 cycles (one cycle = 6 weeks)~Maximum number of Pembrolizumab cycles (Chemotherapy Treatment + Maintenance Treatment) = 20"
62195683|NCT03532503|ACTIVE_COMPARATOR|Foley catheter filled with 30 ml|The transcervical placement of the foley catheter will be performed and it will be filled with 30 ml saline. A gentle traction will be applied.
62195684|NCT03532503|ACTIVE_COMPARATOR|Foley catheter filled with 50 ml|The transcervical placement of the foley catheter will be performed and it will be filled with 50 ml saline. A gentle traction will be applied.
62398943|NCT03441828|EXPERIMENTAL|Group DNMB|"Deep Neuromuscular Block group Intervention: maintenance of a deep neuromuscular block by infusion of rocuronium at the starting dose of 0.3-0.6 mg / kg / h, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point)"
62574151|NCT03962777|ACTIVE_COMPARATOR|chlorhexidine|patients used chlorhexidine digluconate for 4 days
62574152|NCT01031511|EXPERIMENTAL|Treatment Group - CBT|
62009552|NCT02358694|PLACEBO_COMPARATOR|Placebo Arm|The placebo group will receive a hydrolyzed gelatin protein for next 4 weeks on a daily basis.
62009553|NCT02246504|EXPERIMENTAL|HIFU treatment|use of HIFU treatment in patients with non-malignant thyroid nodules
62009554|NCT02897141|EXPERIMENTAL|mVIP group|This group will receive targeted symptom strategies via a Health Management App developed from the UCSF symptom management manual based on the symptoms that they report. This is the intervention app group.
62009555|NCT02897141|PLACEBO_COMPARATOR|Attention Control Group|This group will received an app without symptom strategies, pre-loaded on their smartphones. This is the control app group.
62195685|NCT02019186|EXPERIMENTAL|Vitamin C and E|6 weeks of daily treatment with Vitamin C and E
62398944|NCT03441828|ACTIVE_COMPARATOR|Group MNMB|"Moderate Neuromuscular Block group Intervention: maintenance of a moderate neuromuscular block. neuromuscular blockade will be maintained with intravenous bolus of rocuronium (0.15-0.25 mg/kg) titrated to obtain a TOF count of 1-3.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point)"
62574153|NCT01031511|NO_INTERVENTION|Control Group|
62574154|NCT06244953|EXPERIMENTAL|Regular screening with needs-guided palliative care treatments|The patient continues to receive clinical care from the cardiologist, as well as palliative care treatments that are based upon his/her reported distress and concerns.
62574155|NCT06244953|OTHER|Usual Care|Patient is referred by cardiologist to palliative care.
62574156|NCT02400996||Pancreatic Endocrine Neoplasms|We did an observational analysis from a prospectively maintained database of patients who underwent pancreatic surgery for neoplasms of the pancreas at Sir Ganga Ram Hospital, New Delhi, India from 1995 to 2013 and using pathological reports and preoperative CT scan as gold standard, we identified 40 patients with PENs.
62734658|NCT04148066|OTHER|Osimertinib and Crizotinib|"Osimertinib will be administered according to label: 80 mg once daily.~Crizotinib will only be prescribed upon detection of MET amplification using ctDNA. Crizotinib will be administered according to label: 250 mg bi-daily."
62734659|NCT01915537|EXPERIMENTAL|Infliximab group|Infliximab with MTX treatment
62009556|NCT04302571|NO_INTERVENTION|Healthy control|Voluntary subjects without peripheral arterial disease
62195686|NCT04676789|EXPERIMENTAL|Intervention/treatment|Patients will receive sintilimab,200mg,ivdrip,day1; pegaspargase,2,500 unit/m2 deep intramuscular injection at three different sites,day 1, every 3 weeks for 4 cycles before radiation.Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent sintilimab of 200mg and pegaspargase,2,500 unit/m2 will be administered every 3 weeks for 2 cycles during IMRT for patients who do not achieve complete remission to previous induction therapy. After radiotherapy or CCRT, patients achieving CR with positive plasma EBV-DNA or partial response will continue with sintilimab maintenance up to 2 years.
62398945|NCT01796899|OTHER|Brivaracetam 10 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 10 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~* Strength: 10 mg~* Form: Oral tablet~* Frequency: Once daily~* Duration: 1 day"
62574157|NCT00072280|EXPERIMENTAL|Chemotherapy plus possible surgery|"Comprised of patients with disease lesions that are initially unresectable, or resected but with resulting grossly positive margins. All patients receive vincristine sulfate, dactinomycin, and cyclophosphamide (VAC), and mercaptoethane sulfonate (MESNA). Depending on response, patients may receive ifosfamide and etoposide (IE). Filgrastim may also be given, as needed. In addition to Chemotherapy, patients may receive Conventional Surgery.~(See Interventions section for drug dosage and administration details.)"
62574158|NCT00072280|EXPERIMENTAL|Surgery only|Comprised of patients with initially resectable disease lesions. All patients undergo Conventional Surgery. Those with a result of clear or microscopically positive margins remain on study in this arm, for observation with no further intervention.
62574159|NCT06577688||Volunteer presumed healthy|People presumed healthy undergoing blood pressure measurement with a standard cuff device and with a Smartphone
62398946|NCT01796899|OTHER|Brivaracetam 50 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 50 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~* Strength: 50 mg~* Form: Oral tablet~* Frequency: Once daily~* Duration: 1 day"
62398947|NCT01796899|OTHER|Brivaracetam 75 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 75 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~* Strength: 75 mg~* Form: Oral tablet~* Frequency: Once daily~* Duration: 1 day"
62398948|NCT01796899|OTHER|Brivaracetam 100 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 100 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~* Strength: 100 mg~* Form: Oral tablet~* Frequency: Once daily~* Duration: 1 day"
62574160|NCT06577688||Volunteer suspected of arterial hypertension|People addressed for a suspected diagnosis of arterial hypertension undergoing a home blood pressure monitoring and measurements with a smartphone
62574161|NCT02336568|EXPERIMENTAL|intervention|intervention: Oxytoine treatments - 20 PTSD patients
62574162|NCT02336568|PLACEBO_COMPARATOR|Placebo treatments|Other: Placebo treatments- 20 PTSD patients
62009557|NCT04302571|SHAM_COMPARATOR|IC patients, no exercise|Patients with peripheral arterial disease stage II (intermittent claudication) on best medical treatment, given advices to perform regular aerobic activity
62398949|NCT01796899|OTHER|10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of 10 mL of BRV intravenous bolus injection (10 mg/mL) will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~* Strength: 100 mg (10 mg/mL)~* Form: Intravenous bolus injection~* Frequency: Once daily~* Duration: 1 day"
62398950|NCT04823494|EXPERIMENTAL|Pro-Fit followed by Self Fit|Hearing aids fit by a professional hearing care provider using best practices followed by patient ...
62398951|NCT04823494|EXPERIMENTAL|Self-Fit followed by ProFit|Hearing aids fit by patient followed by ...
62398952|NCT02860650|EXPERIMENTAL|Group 1: AD26.Filo/MVA-BN-Filo or Placebo|Participants will receive Ad26.Filo or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 57.
62398953|NCT02860650|EXPERIMENTAL|Group 2: MVA-BN-Filo/AD26.Filo or Placebo|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.Filo or placebo on Day 57.
62398954|NCT02860650|EXPERIMENTAL|Group 3: MVA-BN-Filo/AD26.Filo or Placebo|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.Filo or placebo on Day 15.
62574163|NCT00785070||1|Perioperative
62574164|NCT06252571|EXPERIMENTAL|Active therapy|Active therapy combining evening melatonin + morning active light over 6 weeks
62783135|NCT05293236|EXPERIMENTAL|Dose 1|Seven COVID-19 patients treated with ApTOLL (0.05mg/kg) intravenous infusion
62783136|NCT05293236|EXPERIMENTAL|Dose 2|Seven COVID-19 patients treated with ApTOLL (0.1mg/kg) intravenous infusion
62783137|NCT05293236|EXPERIMENTAL|Dose 3|Seven COVID-19 patients treated with ApTOLL (0.2mg/kg) intravenous infusion
62783138|NCT02870608|EXPERIMENTAL|preterm labor group|Pregnant women hospitalized for preterm labor
62783139|NCT02870608|OTHER|control group|Pregnant women with a normal pregnancy
62783140|NCT01832532|EXPERIMENTAL|Treatment group- liraglutide|Treatment group- liraglutide daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose.
62783141|NCT01832532|NO_INTERVENTION|Control group|Control group
62783142|NCT02397148|EXPERIMENTAL|patients with sinonasal pathology|Computed Tomography Cone Beam Computed Tomography
62574165|NCT06252571|PLACEBO_COMPARATOR|Placebo therapy|placebo therapy combining evening melatonin placebo + morning placebo light over 6 weeks.
62574166|NCT06480799|ACTIVE_COMPARATOR|Fibre arm|15g of pectin and 5g Inulin provided to healthy participants for 4 weeks.
62574167|NCT06480799|PLACEBO_COMPARATOR|Maltodextrin|10g of maltodextrin provided as the control to participants for 4 weeks.
62574168|NCT01417156|EXPERIMENTAL|All patients|
62574169|NCT06010004|EXPERIMENTAL|Orforglipron Dose 1|Participants will receive orforglipron administered orally.
62195687|NCT04683003|EXPERIMENTAL|Prophylactic Cohort: TAK-755|"All participants will receive prophylactic treatment with 40 IU/kg TAK-755 intravenous (IV) infusions once every week or once every other week for the duration of the study.~Participants who are naïve will receive an initial IV dose of 40 IU/kg TAK-755 to allow measurement of the pharmacokinetics of TAK-755, followed by prophylactic treatment with 40 IU/kg TAK-755 by IV infusion once every week or once every other week for the duration of the study."
62398955|NCT02860650|EXPERIMENTAL|Subset of Group 3: AD26.Filo or Placebo|The first 8 participants in Group 3 who are willing to enroll in the subset for third vaccination, will receive a third vaccination at Day 92. Participants who previously received placebo will receive placebo a third time and participants who previously received MVA-BN-Filo/Ad26.Filo vaccination will receive Ad26.Filo as third vaccination. After enrollment of the 8 participants, the unblinded monitor and unblinded pharmacist will assess whether 7 participants who previously received MVA-BN-Filo/Ad26.Filo vaccination have been enrolled. If less than 7 participants of the active vaccine regimen have been enrolled, 2 additional participants will be enrolled. If at least 7 participants of the active vaccine regimen have been enrolled, no further will be enrolled. The aim is to enroll 7 or 8 participants who will receive Ad26.Filo as third vaccination.
62398956|NCT02860650|EXPERIMENTAL|Group 4: Ad26.ZEBOV/MVA-BN-Filo or placebo|Participants will receive Ad26.ZEBOV or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 57.
62398957|NCT04098991||Participants with primary hypothyroidism|All participants will receive the same treatment (levothyroxine, a synthetic T4 hormone replacement) at a dose that will be titrated using serum thyrotropin (TSH) levels as a goal, according to the American Thyroid Association Task Force recommendations
62398958|NCT00469339||cohort of Mexican-American households|cohort of Mexican-American households
62398959|NCT03612869|EXPERIMENTAL|AAV SGSH gene therapy (LYS-SAF302)|One-time intracerebral administration of adeno-associated viral vector serotype rh10 containing the human N-sulfoglucosamine sulfohydrolase (SGSH) cDNA.
62574170|NCT06010004|EXPERIMENTAL|Orforglipron Dose 2|Participants will receive orforglipron administered orally.
62574171|NCT06010004|EXPERIMENTAL|Orforglipron Dose 3|Participants will receive orforglipron administered orally.
62574172|NCT06524570|EXPERIMENTAL|Single arm|High-intensity focused ultrasound histotripsy combined with ipilimumab + nivolumab
62574173|NCT02928653|ACTIVE_COMPARATOR|Sucrose Sweetened Beverage|100-140 g sucrose/day
62574174|NCT02928653|EXPERIMENTAL|Aspartame Sweetened Beverage|0.541-0.757 g aspartame Sweetened Beverage/day
62574175|NCT02928653|EXPERIMENTAL|Saccharin Sweetened Beverage|0.300-0.455 g saccharin Sweetened Beverage/day
62574176|NCT02928653|EXPERIMENTAL|Sucralose Sweetened Beverage|0.167-0.233 g sucralose Sweetened Beverage/day
62574177|NCT02928653|EXPERIMENTAL|Rebaudioside A Sweeteened Beverage|0.250-0.350 g rebaudioside A Sweetened Beverage/day
62574178|NCT03417557|EXPERIMENTAL|Comfilcon A lens (test)|Subjects are randomized to wear comfilcon A lens for up to 3 hours, either as first or second lens during this cross over study.
62574179|NCT03417557|ACTIVE_COMPARATOR|Omafilcon B Lens (control)|Subjects are randomized to wear omafilcon B lens for up to 3 hours, either as first or second lens during this cross over study.
62574180|NCT03221816|PLACEBO_COMPARATOR|Placebo Oral Tablet|"Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study.~The women were randomly allocated to control or experimental group (30 in each group) in a double-blind controlled clinical trial.~The control group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months."
62574181|NCT03221816|EXPERIMENTAL|Experimental group (Tenavit®)|"Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study.~The experimental group received one tablet of Tenavit® (pyridoxine hydrochloride 4.00mg + folic acid 0.80mg + cyanocobalamin 0.40 mg) daily and the placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months."
62783143|NCT01380067||Group A|the patients were subjected laparoscopic purse-string knot for closing the internal hernia opening
62783144|NCT01380067||Group B|the lateral umbilicus ligament was used to cover the internal hernia opening after the laparoscopic purse-string knot
62783145|NCT05663671||Crohn's colitis|Correlate patient longitudinal study of clinical data and their biopsy data. Investigators will determine DEFA5 levels from endoscopy biopsies from known authentic CC patients.
62783146|NCT05663671||Ulcerative colitis|Correlate patient longitudinal study of clinical data and their biopsy data. Investigators will determine DEFA5 levels from endoscopy biopsies from known authentic UC patients.
62783147|NCT05663671||Indeterminate colitis|Correlate patient longitudinal study of clinical data and their biopsy data. Investigators will determine DEFA5 levels from endoscopy biopsies from known IC patients (into authentic UC and CC)
62783148|NCT05663671||Diverticulitis|Correlate patient longitudinal study of clinical data and their biopsy data. Investigators will determine DEFA5 levels from endoscopy biopsies from known diverticulitis.
62783149|NCT05663671||Ileum|Positive control
62783150|NCT00869518|ACTIVE_COMPARATOR|Rifabutin|Subjects will be assigned to 7 days of treatment with rifabutin plus trimethoprim-sulfamethoxazole
62783151|NCT00869518|PLACEBO_COMPARATOR|Placebo|Subjects will be assigned to 7 days of treatment with placebo plus trimethoprim-sulfamethoxazole
62783152|NCT00240500|EXPERIMENTAL|HBV-1 Group|neonates born to HBsAg+ and HBeAg+ mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
62398960|NCT06690086||Subjects with skin lesions suggestive of skin cancer|Subjects with primary skin lesion(s) suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma requiring biopsy to assess the DermaSensor device accuracy in determining risk of malignancy.
62398961|NCT02737410|ACTIVE_COMPARATOR|Treatment|Treatment group obtaining Gut-directed Hypnotherapy
62398962|NCT02737410|NO_INTERVENTION|Control|Control group
62574182|NCT00760916|PLACEBO_COMPARATOR|Placebo|placebo
62398963|NCT04319939||Participants receiving mechanical ventilation|
62398964|NCT06722274||Group A|patients with diabetes
62398965|NCT06722274||Group B|healthy control (without diabetes)
62398966|NCT05664672|NO_INTERVENTION|Group 1 (CC)|Subjects will be asked to continue smoking their UBCs ad libitum for 7 days.
62398967|NCT05664672|EXPERIMENTAL|Group 2 (NP2)|Subjects will exclusively use 2 mg NP, using at least 3 pouches per day for 7 days.
62398968|NCT05664672|EXPERIMENTAL|Group 3 (NP4)|Subjects will exclusively use 4 mg NP, using at least 3 pouches per day for 7 days.
62398969|NCT05664672|EXPERIMENTAL|Group 4 (NP8)|Subjects will exclusively use 8 mg NP, using at least 3 pouches per day for 7 days.
62398970|NCT05664672|EXPERIMENTAL|Group 5 (NT)|Subjects will completely stop all tobacco product usage for 7 days.
62574183|NCT00760916|ACTIVE_COMPARATOR|UT-15C 0.25 mg|UT-15C 0.25 mg
62574184|NCT00760916|ACTIVE_COMPARATOR|UT-15C 1 mg|UT-15C 1 mg
62574185|NCT00760916|ACTIVE_COMPARATOR|UT-15C 5 mg|UT-15C 5 mg
62574186|NCT01470404||adjuvant chemotherapy|Patients enrolled on to the adjuvant XP trial + patients who received adjuvant chemotherapy following curative resection of gastric cancer
62195688|NCT04683003|EXPERIMENTAL|On-Demand Cohort: TAK-755|"Participants will receive daily IV infusions of TAK-755 when experiencing an acute thrombotic thrombocytopenic purpura (TTP) event until 2 days after the acute TTP event is resolved.~Participants will receive 40 IU/kg TAK-755 on the first day, followed by 20 IU/kg on Day 2, and then 15 IU/kg daily until 2 days after the acute TTP event has resolved. Upon resolution of the acute TTP event, participants may choose to move to the prophylactic cohort of the study or discontinue entirely from the study."
62195689|NCT04574817|EXPERIMENTAL|HX008|Participants will receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)
62195690|NCT04358432|EXPERIMENTAL|AK102 450 mg|Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
62195691|NCT04358432|EXPERIMENTAL|AK102 300 mg|Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
62195692|NCT04358432|EXPERIMENTAL|AK102 150 mg|Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
62195693|NCT04358432|EXPERIMENTAL|AK102 75 mg|Participants received AK102 75 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
62195694|NCT04358432|PLACEBO_COMPARATOR|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
62195695|NCT04358432|PLACEBO_COMPARATOR|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
62195696|NCT02686619|ACTIVE_COMPARATOR|Mycophenolate Mofetil + Cyclosporine|Participants will receive mycophenoate mofetil, daclizumab, cyclosporine, and corticosteroids (prednisolone) for 3 to 12 months.
62195697|NCT02686619|EXPERIMENTAL|Mycophenolate Mofetil + Sirolimus|Participants will receive mycophenoate mofetil, daclizumab, and corticosteroids (prednisolone) for 3 to 12 months. Participants will also receive cyclosporine which will be replaced with sirolimus at later stage of the study.
62195698|NCT01439867|EXPERIMENTAL|Cinacalcet|"Prior to the partial clinical hold, the starting dose was 0.25 mg/kg (based on dry weight) and was titrated upwards (maximum allowed daily dose of 4.2 mg/kg) based on plasma intact parathyroid hormone (iPTH), corrected serum calcium levels obtained monthly, and adverse signs and symptoms.~After the partial clinical hold the starting dose was 0.20 mg/kg (based on dry weight) and was titrated upwards (maximum allowed daily dose of 2.5 or 60 mg, whichever was lower) based on plasma iPTH, corrected serum calcium levels obtained monthly, weekly monitoring of ionized calcium levels, and adverse signs and symptoms.~All participants also received standard of care, which may have included vitamin D sterols."
62195699|NCT01293942|EXPERIMENTAL|IXO+A|IXO regimen with Avastin
62195700|NCT00501657|EXPERIMENTAL|Sitagliptin (100mg)|Active drug (sitagliptin)
62195701|NCT00501657|PLACEBO_COMPARATOR|Placebo (sugar pill)|Inactive drug (placebo)
62398971|NCT04830813|EXPERIMENTAL|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.
62398972|NCT04830813|PLACEBO_COMPARATOR|Placebo|Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
62398973|NCT04708366|EXPERIMENTAL|1L PEG|Patients will be prepared with 1L-PEG-based bowel preparation.
62574187|NCT03364400|EXPERIMENTAL|VT1021|Escalating doses of VT1021 to determine RP2D
62574188|NCT05396040|EXPERIMENTAL|LOLLI METHODE|regular screening with pooled saliva tests (Lolli-Method)
62574189|NCT05396040|NO_INTERVENTION|STANDARD OF CARE|STANDARD OF CARE
62195702|NCT04478253|EXPERIMENTAL|HypnoVR|Insertion of the drain according to the usual management protocol supplemented by the use of a hypnosis software application (HYPNO-VR).
62398974|NCT04708366|ACTIVE_COMPARATOR|2L PEG|Patients will be prepared with 2L-PEG-based bowel preparation.
62398975|NCT04708366|ACTIVE_COMPARATOR|4L PEG|Patients will be prepared with 4L-PEG-based bowel preparation.
62398976|NCT04308668|EXPERIMENTAL|Treatment|Participants in this arm will receive the study drug.
62398977|NCT04308668|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive a placebo treatment.
62398978|NCT01625559|EXPERIMENTAL|MA09-hRPE administration|Biological: MA09-hRPE Cellular therapy
62574190|NCT02187198|EXPERIMENTAL|Buprenorphine low dose|Participants in this arm will receive a low dose (less than or equal to 8/2mg) of buprenorphine for 12 weeks.
62195703|NCT04478253|NO_INTERVENTION|Usual care|Insertion of the drain according to the usual management protocol
62195704|NCT05986422|ACTIVE_COMPARATOR|Methylprednisolone|"Tested IMP: Methylprednisolone (film-coated tablet). Authorization status: Not authorized in this targeted therapeutic indication; methylprednisolone is authorized for treatment of multiple autoimmune diseases. The tablets being administered in this trial are an official trade product provided by the marketing authorization holder JenaPharm.~Administration: Tablet containing 16 mg/tablet will be administered orally and according to bodyweight groups. Treatment period comprises 6 weeks of blinded daily IMP (investigational medicinal product) intake (verum or placebo) and 6 weeks of unblinded daily intake of Methylprednisolone. The general IMP titration regimen was investigated and proven to be safe in patients with cerebral vasculitis (Schirmer et al., 2020)."
62574191|NCT02187198|EXPERIMENTAL|Buprenorphine high dose|Participants in this arm will receive a high dose (16-24mg) of buprenorphine for 12 weeks.
62574192|NCT04756973|ACTIVE_COMPARATOR|Standard weight loss|A 12 week small group weight loss intervention delivered via video teleconference technology.
62574193|NCT04756973|EXPERIMENTAL|Standard weight loss plus self-compassion skills training|A 12 week small group weight loss intervention delivered via video teleconference technology.
62574194|NCT01777906||Fluticasone|Fluticasone nasal spray will be given 2 sprays twice a day for 6 weeks.
62574195|NCT01777906||Dexamethasone sodium phosphate 0.032%|Dexamethasone 0.032% nasal spray will be given at a dose of 2 sprays twice a day for 6 weeks.
62574196|NCT04676477|EXPERIMENTAL|Dose Escalation: HER3-DXd + osimertinib|Participants in the Dose Escalation phase will receive HER3-DXd IV Q3W + osimertinib PO once daily. The dose of HER3-DXd in the first cohort will be 3.2 mg/kg Q3W. The dose of osimertinib in the first cohort will be 80 mg PO once daily.
62734660|NCT01915537|ACTIVE_COMPARATOR|Classic DMARDs treatment group|Classic DMARDs treatment（MTX 、LEF 、HCQ 、 LEF ）
62574197|NCT04676477|EXPERIMENTAL|Second-line Dose Expansion: HER3-DXd + osimertinib (RCD)|Participants in the Second-line Dose Expansion phase will be randomized to receive HER3-DXd + osimertinib at the RCD
62574198|NCT04676477|EXPERIMENTAL|Second-line Dose Expansion: HER3-DXd|Participants in the Second-line Dose Expansion phase will be randomized to receive HER3-DXd 5.6 mg/kg IV Q3W
62574199|NCT04676477|EXPERIMENTAL|First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 3; RCD)|If the RCD includes an osimertinib dose of 80 mg PO once daily, then participants will receive treatment with HER3-DXd and osimertinib at the RCD
62574200|NCT04676477|EXPERIMENTAL|First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 4a)|Participants in the First-line Dose Expansion phase will be randomized to receive HER3-DXd 5.6 mg/kg IV Q3W and osimertinib dose of 80 mg PO once daily.
62574201|NCT04676477|EXPERIMENTAL|First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 4b)|Participants in the First-line Dose Expansion phase will be randomized to receive HER3-DXd 4.8 mg/kg IV Q3W and osimertinib dose of 80 mg PO once daily.
62195705|NCT05986422|PLACEBO_COMPARATOR|Placebo|"Comparator IMP: Placebo (film-coated tablet). Authorization status: Not authorized. To ensure identical conditions with the verum (Methylprednisolone), we will use placebo tablets of the same color and size in identical tablet packages for both the verum and placebo.~Administration: Tablets (7 mm) will be administered orally and according to bodyweight groups. To achieve consistent conditions with the verum, titration will be conducted in a manner similar to the tested IMP (Methylprednisolone). Treatment period comprises 6 weeks of blinded daily IMP intake (placebo or verum) and 6 weeks of unblinded daily intake of Methylprednisolone."
62195706|NCT02489240|EXPERIMENTAL|Vitamin D supplementation group|drug: vitamin D3 tablets (Vigantoletten; Merck Pharma, Germany); the frequency: 2000 IU vitamin D3 tablets were taken daily; duration: study treatment was commenced 3 days before intervention and maintained for 3 days after the procedure.
62195707|NCT02489240|PLACEBO_COMPARATOR|Control group|drug: placebo tablets; the frequency: 2000 IU placebo tablets were taken daily; duration: study treatment was commenced 3 days before intervention and maintained for 3 days after the procedure.
62195708|NCT06378723||Healthy Children|Healthy children between the ages of 8 and 18 will be included in the study. Children with hearing and vision loss will be excluded from the study in order not to affect balance disorders.
62398979|NCT03997695|ACTIVE_COMPARATOR|Core stabilization exercise group|"Core stabilization exercise (CSE):~The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional."
62398980|NCT03997695|EXPERIMENTAL|Core stabilization exercise plus kinesio taping group|"Core stabilization exercise (CSE):~The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.~Kinesio Taping:~The Kinesio Taping was carried out 2 days a week for 6 weeks (12 sessions) by experienced and certificated physiotherapist. Kinesio taping was applied to spinal region."
62574202|NCT04583774|OTHER|Anorexia Nervosa Group|Participants with anorexia nervosa
62574203|NCT04583774|OTHER|Healthy Control Group|Participants who are considered to be healthy controls
62574204|NCT04382781||COVID-19 infection|Consecutive patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by real-time polymerase chain reaction (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who showed clinical and analytical data suggestive of macrophage activation syndrome during admission until March 30, 2020 .
62574205|NCT05002608|EXPERIMENTAL|Navigation Intervention|The intervention will be delivered via synchronous videoconferencing (real-time delivery and communication between the navigator and the participant) by a trained patient navigator and will consist of 5, 30-minute sessions delivered every week. The navigation intervention group will also receive an online or mailed copy of the health insurance resource guide.
62574206|NCT05002608|NO_INTERVENTION|Enhanced Usual Care|Enhanced usual care will consist of an online or mailed health insurance resource guide.
62574207|NCT01757535|EXPERIMENTAL|Oral Azacitidine|300 mg oral azacitidine on days 1 to 14 of each 28-day treatment cycle.
62574208|NCT01757535|PLACEBO_COMPARATOR|Placebo|Identically matching placebo tablets on days 1 to 14 of each 28-day treatment cycle.
62574209|NCT01871129|PLACEBO_COMPARATOR|Saline group|Difference from the normal protocol actualizes at the point when propofol infusion is cut off. From there on the patient in this group receives saline infusion up to the point where 15 minutes have passed after the extubation procedure.
62195709|NCT06378723||Cerebral Palsy Children|Cerebral Palsy children between the ages of 8 and 18 will be included in the study. Children with hearing and vision loss will be excluded from the study in order not to affect balance disorders. In order to standardize their mobility, those with Gross Motor Function Classification levels 1 and 2 will be included in the study.
62195710|NCT01275781|EXPERIMENTAL|A|\[14C\]-AZD9742 1000 mg intravenous over 2 hours
62195711|NCT05569213||DBS latency/MEP latency|Each patient will serve as control and test. Control will be latency of hand MEP generated by DBS stimulation of the corticospinal tract. The test condition will be the latency of hand MEP generated by conventional MEP acquisition.
62195712|NCT06117553||limited|patients adopted limited flushing strategy
62734661|NCT03141125|EXPERIMENTAL|Physalis angulata ethanol extract|"Physalis angulata ethanol extract was given with dosage 3 x 250 mg/day, orally, for 3 months.~In addition, patients also received standard therapy for scleroderma."
62195713|NCT06117553||thorough|Thorough flushing strategy
62195714|NCT00879775|EXPERIMENTAL|Caffeine|Intravenous injections of 200mg of caffeine with 100ml of normal saline over 1 hour
62195715|NCT00879775|PLACEBO_COMPARATOR|Placebo|Intravenous injections of 100ml of normal saline over 1 hour
62574210|NCT01871129|ACTIVE_COMPARATOR|Dexmedetomidine group|Difference from the normal protocol happens when normally the propofol infusion is cut off. From there on the patient in this group receives dexmedetomidine infusion up to the point where 15 minutes have passed after the extubation procedure.
62195716|NCT04678531|EXPERIMENTAL|Swabs containing tea tree oil and chamomile oil|The swabs will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.
62195717|NCT04678531|ACTIVE_COMPARATOR|Baby shampoo|Baby shampoo will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks
62195718|NCT02002377|EXPERIMENTAL|Aflibercept|Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
62195719|NCT00708318|EXPERIMENTAL|A, B, C|
62195720|NCT04593823|EXPERIMENTAL|Furoscix Infusor|Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor. The Infusor is applied to the abdomen via a medical grade adhesive and delivers a subcutaneous infusion of Furoscix through a pre-programmed, biphasic delivery profile with 30 mg (3.75 mL) administered over the first hour, followed by 12.5 mg (1.56 mL) per hour for the subsequent 4 hours (Total dose is 80 mg (10 mL) over 5 hours).
62195721|NCT04593823|NO_INTERVENTION|Continued Medical Therapy|The subjects enrolled in this arm will receive treatment as usual
62195722|NCT00806481|ACTIVE_COMPARATOR|1|Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
62398981|NCT05664178|EXPERIMENTAL|Tele-Resistance Training (RT)|Participants will be encouraged to perform approximately 30 minutes of resistance training exercises approximately twice per week for 12 weeks. Participants will also be encouraged to perform moderate aerobic exercise at least 3 times per week. Participants will wear a FitBit fitness watch to monitor aerobic exercise.
62574211|NCT01139125|EXPERIMENTAL|Cystagon, Cysteamine Bitartrate|We are examining the safety and efficacy of this medication on the treatment of schizophrenia patients.
62574212|NCT05136885|EXPERIMENTAL|SLS-005|SLS-005 is administered via infusion once weekly for 24 weeks.
62574213|NCT05136885|PLACEBO_COMPARATOR|Matching Placebo|Matching placebo is administered via infusion once weekly for 24 weeks.
62195723|NCT00806481|PLACEBO_COMPARATOR|2|Treatment group: treatment with tablets of placebo three times daily for 36 weeks
62195724|NCT02272504||Standard of care arm|Chronic liver disease patients who are under going standard of care surveillance for the development of HCC as defined by AASLD guidelines.
62195725|NCT02272504||Biomarker Arm|Chronic liver disease patients who are under going standard of care surveillance for the development of HCC as defined by AASLD guidelines plus the addition of biomarker assays (AFP, AFP-L3 and DCP) every 6 months.
62195726|NCT05202054|EXPERIMENTAL|The Effect of mindfulness stress reduction program on slepness and quality of life|Groups of 20 will be formed for the implementation of the mindfulness stress reduction program in the experimental group. The BFSAP day and time will be determined by taking into account the time zones where women are available. 150 minutes of BFSAP will be applied to the women in the experimental group once a week, lasting 8 weeks and consisting of 8 times in total. The women will then be given a midterm test. After the midterm, women will be asked to individually repeat the BFSAP application in their own home for 8 weeks (weeks 8-16).
62195727|NCT05202054|NO_INTERVENTION|control group|THESE PARTICIPANTS HAVE NOT BEEN APPLIED
62195728|NCT01605682|EXPERIMENTAL|Berry extract 125|Fresh berry extract containing 125mg of polyphenols
62195729|NCT01605682|EXPERIMENTAL|Berry extract 250|Fresh berry extract containing 250mg of polyphenols
62195730|NCT01605682|EXPERIMENTAL|Berry extract 500|Fresh berry extract containing 500mg of polyphenols
62195731|NCT01605682|PLACEBO_COMPARATOR|Placebo|Berry flavoured juice containing no polyphenols
62195732|NCT00662597|EXPERIMENTAL|ASA404|
62195733|NCT00662597|PLACEBO_COMPARATOR|ASA40 Placebo|
62574214|NCT03783819|ACTIVE_COMPARATOR|Active treatment|One forearm will be treated with ointment containing Hypericum perforatum oil. Forearm (left or right) will be chosen according to randomization protocol.
62574215|NCT03783819|PLACEBO_COMPARATOR|Placebo treatment|Other forearm will be treated with placebo ointment. Forearm (left or right) will be chosen according to randomization protocol.
62734662|NCT03141125|PLACEBO_COMPARATOR|Placebo|Patients received standard therapy and placebo (amylum powder) for comparator at dosage 3 x 250 mg/day, orally, for 3 months.
62195734|NCT02171299|EXPERIMENTAL|intervetional group (local anaesthetic)|intraoperative wound infiltration with ropivacaine 10%.
62195735|NCT02171299|NO_INTERVENTION|control (no local anesthetic)|no infiltration of the wound with local anaesthetic
62195736|NCT03445533|EXPERIMENTAL|Arm A: ipilimumab|ipilimumab 3 mg/kg intravenous
62195737|NCT03445533|EXPERIMENTAL|Arm B: IMO-2125 plus ipilimumab|IMO-2125 by intratumoral injection plus ipilimumab 3 mg/kg intravenous
62195738|NCT01855711|EXPERIMENTAL|GR68755 (Alosetron hydrochrolide) group|GR68755 1 mg tablets QD in the morning every day for 28 days
62783153|NCT00240500|EXPERIMENTAL|HBV-2 Group|neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
62195739|NCT02772939|EXPERIMENTAL|Renal Denervation|Renal denervation for therapy resistant arterial hypertension
62195740|NCT04490577|EXPERIMENTAL|Pilates training group|"In the Pilates group, the exercises were performed with Reformer® for eight weeks, twice in a week, one hour per day."
62783154|NCT00240500|EXPERIMENTAL|HBV-3 Group|neonates born to HBsAg+ and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
62783155|NCT00240500|EXPERIMENTAL|HBV-4 Group|neonates born to HBsAg+ and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
62574216|NCT01732640|EXPERIMENTAL|Study Arm|Eligible patients will begin with a 14-day lead-in period with afatinib alone. This will be followed immediately by 2 cycles of induction chemotherapy (IC) with carboplatin AUC 6 IV Day 1, paclitaxel 175mg/m2 IV Day 1, and oral afatinib as a continuous daily dosing. Each cycle is repeated every 21 days. After completion of 2 cycles of IC, patients will be assessed for response by CT/MRI and clinical exam. After the induction, all patients will receive Intensity Modulated Radiation Therapy (IMRT) with weekly cisplatin 40mg/m2 IV. Chemoradiotherapy (CRT) will begin 2-3 weeks after the completion of the second cycle of IC. The patients will be evaluated with a MRI or CT, and FDG PET approximately 12 weeks after completion of CRT.
62574217|NCT06578325|EXPERIMENTAL|Diabetes kidney disease patients with Thai dance meditation|Male and female diabetic kidney disease patients were selected based on screening for diabetes and renal function. They were recruited for measurement of all variables in the study to compare with another group.
62574218|NCT06578325|SHAM_COMPARATOR|Diabetes kidney disease patients|Male and female diabetic kidney disease patients were not training Thai dance meditation. They were recruited for measurement of all variables in the study to compare with another group.
62574219|NCT03838289||Individuals with absent filling of CVs|Individuals with absent filling of following CVs: superficial middle cerebral vein, vein of Labbe, vein of Trolard, Sphenoid sinus, thalamostriate vein, Internal cerebral vein, Rosenthal's vein
62574220|NCT03838289||individuals without any absent filling of CVs|Individuals without any absent filling of following CVs: superficial middle cerebral vein, vein of Labbe, vein of Trolard, Sphenoid sinus, thalamostriate vein, Internal cerebral vein, Rosenthal's vein
62009558|NCT04302571|ACTIVE_COMPARATOR|IC patients, exercise|Patients with peripheral arterial disease stage II (intermittent claudication) on best medical treatment, home-based combined physical exercise
62574221|NCT06174766|EXPERIMENTAL|Experimental1|Take HGP2102-1 once daily for 4 weeks orally, and then take HGP2102-2 once daily for 6 weeks orally.
62009559|NCT04186910|PLACEBO_COMPARATOR|Control group|The control group will not receive any feedback on levels of physical activities but will receive any planned usual care rehabilitation activities
62195741|NCT04490577|EXPERIMENTAL|Whole-body vibration (WBV) group|"In the WBV group, the training was given Power Plate® for eight weeks, twice in a week, and 30 minutes in a day."
62574222|NCT06174766|EXPERIMENTAL|Experimental2|Take HGP2102-1 once daily for 10 weeks orally.
62574223|NCT06174766|ACTIVE_COMPARATOR|Active Comparator|Take RLD2209-1 once daily for 4 weeks orally, and then take RLD2209-2 once daily for 6 weeks orally.
62574224|NCT00679211|EXPERIMENTAL|Trastuzumab emtansine|Trastuzumab emtansine (T-DM1) was administered to participants at a dose of 3.6 mg/kg by intravenous (IV) infusion every 3 weeks until documented disease progression, unmanageable toxicity, or study termination.
62574225|NCT02240940|EXPERIMENTAL|Parachute Implant|Appropriate patients meeting inclusion / exclusion will be implanted with the Parachute device after screening with transthoracic echocardiography (TTE) and cardiac CT or MRI.
62574226|NCT02792062|EXPERIMENTAL|TAK-385 40 mg (Group A)|A single oral dose of TAK-385 40 milligram (mg) (one tablet) in fasted condition without breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 3.
62009560|NCT04186910|EXPERIMENTAL|Feedback group|The feedback group will have an active feedback intervention of physical activities, consisted of daily feedback, received through a Fitbit application, and weekly meeting group focused on enhancing behavioral strategies to increase self-efficacy and motivation. The experimental group will receive any planned usual care rehabilitation activities.
62009561|NCT05949476|NO_INTERVENTION|Control Group|extraction of the lower third molar will be performed according to the standard protocols of the structure
62009562|NCT05949476|EXPERIMENTAL|Trial Group|In this group ozone will be used, in two formulations: gaseous, injected into the site of the pre- and post-surgery operation, and topical, in the form of a gel, applied at the end of the operation and for home use according to the therapeutic scheme prescribed at the time of resignation
62195742|NCT04490577|NO_INTERVENTION|Control group|The control group did not receive any training.
62195743|NCT04393311|EXPERIMENTAL|Ulinastatin|Patients will receive ulinastatin via IV infusion every 8 hours for up to 5 days or until hospital discharge (whichever is earlier).
62195744|NCT04393311|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo to match ulinastatin via IV infusion every 8 hours for up to 5 days or until hospital discharge (whichever is earlier).
62195745|NCT00540033|EXPERIMENTAL|2|Study arm was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks; the control arm was fed with breast milk or mixed feeding without probiotics.
62195746|NCT05397847|EXPERIMENTAL|Experiment|Education, rational drug use guide and consultancy services will be provided to elderly individuals through home visits.
62195747|NCT05397847|NO_INTERVENTION|Control|No intervention will be made to the control group, and after the post-test, the rational drug use guide and the medicine box will also be given to the control group.
62398982|NCT05664178|NO_INTERVENTION|Usual Care (UC)|Participants randomized to the Usual Care (UC) arm will be provided with information materials outlining resistance training using body weight or basic equipment. Participants will wear a FitBit fitness watch to monitor aerobic exercise.
62398983|NCT05565950|EXPERIMENTAL|AI-09 Dose 1|Dose 1 of botulinum toxin, Type A, intramuscular injection, administered once at baseline
62398984|NCT05565950|PLACEBO_COMPARATOR|Vehicle Dose 1|Vehicle, intramuscular injection, administered once at baseline
62398985|NCT05565950|EXPERIMENTAL|AI-09 Dose 2|Dose 2 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
62398986|NCT05565950|PLACEBO_COMPARATOR|Vehicle Dose 2|Vehicle, intramuscular injection, administered once at baseline
62574227|NCT02792062|EXPERIMENTAL|TAK-385 40 mg (Group B)|A single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 3.
62574228|NCT02792062|EXPERIMENTAL|TAK-385 40 mg (Group C)|A single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 3.
62574229|NCT02792062|EXPERIMENTAL|TAK-385 40 mg (Group D)|A single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 3.
62574230|NCT02792062|EXPERIMENTAL|TAK-385 40 mg (Group E)|A single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 3.
62574231|NCT02792062|EXPERIMENTAL|TAK-385 40 mg (Group F)|A single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 3.
62574232|NCT03053791|EXPERIMENTAL|Intervention group|Single-armed study. All patients will receive treatment.
62574233|NCT03843489|EXPERIMENTAL|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|Reference sensors from the reprocessed oximeter device will be placed on each subject to evaluate the SpO2 accuracy and performance.
62574234|NCT03843489|SHAM_COMPARATOR|Reference CO-oximetry sensor|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
62195748|NCT04851158|EXPERIMENTAL|ShotBlocker|ShotBlocker will be used on 35 patients. For the patient group that is applied ShotBlocker, after cleansing the skin, the protruding surface of the device is placed facing the skin surface. The injection is applied with the appropriate technique, then ShotBlocker is removed and a light pressure is applied to the area with a cotton pad for 15-20 seconds.
62734663|NCT04047615|EXPERIMENTAL|Exercise effects on Behavior|An exercise intervention programme will be implemented 3 times a week for an 8 week period of time in a school setting. Each exercise class will last 60 minutes. The exercise classes will be fun for the students to participate in and will involve aspects of fundamental movement skills.
62398987|NCT05565950|EXPERIMENTAL|AI-09 Dose 3|Dose 3 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
62398988|NCT05565950|PLACEBO_COMPARATOR|Vehicle Dose 3|Vehicle, intramuscular injection, administered once at baseline
62398989|NCT05565950|EXPERIMENTAL|AI-09 Dose 4|Dose 4 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
62398990|NCT05565950|PLACEBO_COMPARATOR|Vehicle Dose 4|Vehicle, intramuscular injection, administered once at baseline
62398991|NCT05565950|EXPERIMENTAL|AI-09 Dose 5|Dose 5 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
62398992|NCT05565950|PLACEBO_COMPARATOR|Vehicle Dose 5|Vehicle, intramuscular injection, administered once at baseline
62398993|NCT05565950|EXPERIMENTAL|AI-09 Dose 6|Dose 6 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
62398994|NCT05565950|PLACEBO_COMPARATOR|Vehicle Dose 6|Vehicle, intramuscular injection, administered once at baseline
62398995|NCT05565950|EXPERIMENTAL|AI-09 Dose 7|Dose 7 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
62398996|NCT05565950|PLACEBO_COMPARATOR|Vehicle Dose 7|Vehicle, intramuscular injection, administered once at baseline
62398997|NCT03601429|EXPERIMENTAL|Lactogyn|1 capsule of Lactogyn 2 times daily for the first 7 days then 1 time daily for 4 months
62398998|NCT03601429|PLACEBO_COMPARATOR|Placebo|1 capsule of Placebo Comparator 2 times daily for the first 7 days then 1 time daily for 4 months
62574235|NCT05099497|EXPERIMENTAL|Intervention group: Practice facilitation and additional support|Ontario Health will send out letters to physicians in the intervention group that will explain to them that they have a large group of eligible and unvaccinated patients and that an initiative is planned to support them in reaching out to those patients, with an embedded evaluation. It will ask them to reach out to the research team to plan a time to access the supports to gather more information, or to opt-out from the evaluation. Specifically, physicians will receive invitations to receive practice facilitation via mail letter and fax, followed by up to five weekly phone calls from a team member at Ontario Health.
62195749|NCT04851158|EXPERIMENTAL|Local Vibration|Local Vibration will be used on 35 patients. For the patient group that was subject to local vibration, local vibration was applied to the region with a vibrator for five minutes prior to injection, following a previous study on this subject. After that, 70% alcohol was used to cleanse the skin. The injection was applied with the appropriate technique, then a light pressure was applied to the area with a cotton pad for 15-20 seconds.
62195750|NCT04851158|NO_INTERVENTION|Control|For the control group (n=35), IM injection into the ventrogluteal region without using any tools is performed with the appropriate technique.
62195751|NCT02441439|OTHER|Iron sucrose 200 mg|first arm will be treated with iron sucrose 200 mg 2-3 times a week
62195752|NCT02441439|ACTIVE_COMPARATOR|Iron sucrose 500 mg|Second arm will be treated with iron sucrose 500 mg once a week
62195753|NCT04550819|EXPERIMENTAL|IEBSs in malignant extrahepatic biliary stricture|Intraintestinal extended biliary stents(IEBSs) in patients with malignant extrahepatic biliary stricture
62195754|NCT04550819|ACTIVE_COMPARATOR|CPBSs in malignant extrahepatic biliary stricture|Conventional plastic biliary stents(CPBSs) in patients with malignant extrahepatic biliary stricture
62195755|NCT04550819|EXPERIMENTAL|IEBSs in benign extrahepatic biliary stricture|Intraintestinal extended biliary stents(IEBSs) in patients with benign extrahepatic biliary stricture
62195756|NCT04550819|ACTIVE_COMPARATOR|CPBSs in benign extrahepatic biliary stricture|Conventional plastic biliary stents(CPBSs) in patients with benign extrahepatic biliary stricture
62195757|NCT06037837||Robotic surgeons|Participants will be robotic surgeons in urologic, gynecologic, colorectal, hepatobiliary, gastric, and thoracic surgery
62195758|NCT02712463||Participants with Schizophrenia|This is an observational study. Data will be collected from the medical records of participants diagnosed with schizophrenia and who had been on oral antipsychotics for at least one year and thereafter have been switched to Long Acting Injectable atypical antipsychotics for at least one year.
62195759|NCT02336100|EXPERIMENTAL|GERD patient|36 GERD patients without obviously abnormality were examined by FICE and then followed by pCLE to evaluate minimal change esophagitis
62195760|NCT02336100|EXPERIMENTAL|Control|18 control patients were were examined by FICE and then followed by pCLE to evaluate minimal change esophagitis
62195761|NCT00994175|EXPERIMENTAL|Pioglitazone, Then Placebo|Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the first treatment phase, followed by 45 mg daily for an additional 14 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the placebo phase for 16 weeks in the second treatment phase to receive the placebo.
62195762|NCT00994175|EXPERIMENTAL|Placebo, Then Pioglitazone|Placebo was administered for 16 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the Pioglitazone treatment group. Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the treatment phase, followed by 45 mg daily for an additional 14 weeks.
62195763|NCT00922688|ACTIVE_COMPARATOR|Dipeptiven Arm Enteral|
62195764|NCT00922688|PLACEBO_COMPARATOR|Placebo Arm Enteral and Intravenously|
62195765|NCT00922688|ACTIVE_COMPARATOR|Dipeptiven ARM Intravenously|
62195766|NCT05652803|EXPERIMENTAL|bibliotherapy-based psychoeducation program|In the bibliotherapy-based psychoeducation program sessions, techniques such as information and discussion based on the bibliotherapy method were included. Brief information will be given for 5-10 minutes in each session. At the end of the sessions, exercises will be given to reinforce the knowledge and skills acquired by the group members in the sessions and to transfer them to daily life, and the sessions will be concluded.
62195767|NCT05652803|EXPERIMENTAL|Psychoeducation Program|The General Purpose of the Psychoeducation Program for Reducing Depression and Hopelessness: To help the participants gain awareness, skills and attitudes in order to help them reduce their depression and hopelessness levels.
62195768|NCT00004251|EXPERIMENTAL|Letrozole|Letrozole 2.5 mg po daily
62009563|NCT03773757|EXPERIMENTAL|IN-PEACE Dementia Care Coordination|In-PEACE intervention arm will have monthly contact with a dementia care coordinator (DCC) to to identify symptoms the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors.
62009564|NCT03773757|NO_INTERVENTION|Usual Care|The usual care arm will have access to education and informational materials from the local chapter of the Alzheimer's Association and other community resources and will be reminded of these resources throughout the study.
62195769|NCT05677386|ACTIVE_COMPARATOR|Intervention group|Primary preventive treatment guided by CTCA
62195770|NCT05677386|SHAM_COMPARATOR|Control group|Primary preventive treatment guided by Systematic COronary Risk Evaluation (SCORE) 2 model risk assessment according to Danish clinical guidelines.
62195771|NCT01218347|EXPERIMENTAL|Rosuvastatin|rosuvastatin treatment
62195772|NCT01475305|PLACEBO_COMPARATOR|Placebo|Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
62195773|NCT01475305|EXPERIMENTAL|MEDI-557|Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
62195774|NCT03877861||Readiband Sleep Tracking - Patient|This group is comprised of 25 participants with a diagnosis of primary Grade IV glioma. A Readiband™ Sleep Tracker device will be provided to each participant, along with necessary instructions. Participantswill return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits.
62195775|NCT03877861||Readiband Sleep Tracking - Control|Aggregate fatigue data and sleep patterns for a group of 30 healthy controls procured from FatigueScience in a de-identified manner for data analysis purposes.
62195776|NCT01335347|EXPERIMENTAL|Experimental Low Dose|Biological: One dose of a live replication incompetent adenovirus given in a capsule
62195777|NCT01335347|EXPERIMENTAL|Experimental Medium Dose|"Biological: One or two doses of replication incompetent adenovirus given in a capsule~Other: Placebo capsules of the same size and shape"
62195778|NCT01335347|EXPERIMENTAL|Experimental High Dose|Biological: One dose of replication incompetent adenovirus in a capsule
62574236|NCT05099497|NO_INTERVENTION|Control group- No intervention|We choose to include a control group as we do not have the resources to deliver the intervention to the entire physician group. Cluster randomization by primary practice address will limit contamination.
62195779|NCT01335347|PLACEBO_COMPARATOR|Placebo Control|Capsules of the same size and shape as the experimental
62574237|NCT03902873|NO_INTERVENTION|usual compression|A group who get no real-time audiovisual feedback from the R Series® Monitor/Defibrillator (Zoll medical).
62398999|NCT01119118|EXPERIMENTAL|1|ZD4054 + multimodal PET/MRI imaging
62574238|NCT03902873|ACTIVE_COMPARATOR|real-time audiovisual feedback|A group who get the real-time audiovisual feedback from the R Series® Monitor/Defibrillator (Zoll medical).
62009565|NCT05867784||supplementary group|take vitamin D supplementation (400 IU/day) during VDZ treatment
62009566|NCT05867784||non-supplementary group|not take vitamin D supplementation (400 IU/day) during VDZ treatment
62399000|NCT04943601|EXPERIMENTAL|Action observation training group|The experimental group will receive a training program with Action observation by watching videos of complex tasks while imitating them. All the movements will be performed bilaterally so that regardless of the affected side the patient had the correct perspective to perform the exercise.
62574239|NCT05658770|EXPERIMENTAL|Five sessions/week|Perform five exercise sessions per week. The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1 (NCT05612698).
62574240|NCT05658770|EXPERIMENTAL|Three sessions/week|Perform three exercise sessions per week. The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1 (NCT05612698).
62399001|NCT04943601|ACTIVE_COMPARATOR|Conventional therapy group|The control group will receive conventional rehabilitation, with exercises of bimanual activities that will target their shoulder, elbow, wrist and finger joints similar to the experimental group but without Action observation
62574241|NCT05658770|EXPERIMENTAL|Two sessions/week|Perform two exercise sessions per week. The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1 (NCT05612698).
62574242|NCT02274012|EXPERIMENTAL|Afatinib and weekly Paclitaxel|In addition to the standard chemotherapy, afatinib 40 mg orally once daily will be administered starting on the first day of paclitaxel. Translational studies to assess circulating tumor cells at the start of therapy and then at several later time points, including at the time of progression. These studies will assess the correlation of circulating tumor cell numbers with radiographic response and pilot studies will also be conducted to assess HER2 expression, HER2 genomic amplification, HER2 pathway activation and secondary genetic changes in the HER2 coding sequence as well as other pathway components.
62574243|NCT03582163||STN|Patients with Parkinson's disease who have undergone subthalamic nucleus (STN) DBS.
62574244|NCT03582163||GPi|Patients with Parkinson's disease who have undergone GPi (GPi) DBS.
62783156|NCT00240500|EXPERIMENTAL|HBV-5 Group|neonates born to HBsAg- and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
62009567|NCT00087568|EXPERIMENTAL|Non-Responders|Participants will receive Pegasys 180 micro grams (µg or mcg) subcutaneously (SC) once a week and ribavirin 1000 or 1200 milligrams per day \[(mg/day), \< or \>=75 kilogram (Kg) body weight, respectively\], orally in divided doses for 60 weeks.
62009568|NCT00087568|EXPERIMENTAL|Non-Tolerators|Participants will receive Pegasys 180 µg subcutaneously (SC) once a week and ribavirin 1000 or 1200 mg/day (\< or \>=75 kg body weight, respectively) orally in divided doses for 36 weeks.
62009569|NCT02871843|EXPERIMENTAL|Escalation of RRx-001 with TMZ + RT|Dose escalation of RRx-001 with fixed doses of Temozolomide and radiation followed by Temozolomide maintenance therapy
62009570|NCT04263818|EXPERIMENTAL|Motions during colonoscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for
62009571|NCT04902859|EXPERIMENTAL|Clonidine with eye speculum|4 mcg/kg Clonidine given orally in GI-tube.
62009572|NCT04902859|PLACEBO_COMPARATOR|Placebo with eye speculum|Sterile water corresponding to the same volume as 4 mcg/kg of Clonidine given orally in GI-tube.
62009573|NCT04902859|EXPERIMENTAL|Clonidine without eye speculum|4 mcg/kg Clonidine given orally in GI-tube.
62195780|NCT01987492|EXPERIMENTAL|Lebrikizumab High Dose|Participants will receive lebrikizumab at high dose level as subcutaneous (SC) injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.
62195781|NCT01987492|EXPERIMENTAL|Lebrikizumab Low Dose|Participants will receive lebrikizumab at low dose level as SC injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.
62195782|NCT01987492|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to lebrikizumab SC injection every 4 weeks during the 44-week DBPC period. Participants will then be randomized to receive either high- or low-dose lebrikizumab every 4 weeks during the 32-week ATE period and will continue same treatment in the LTE period.
62195783|NCT01515943|ACTIVE_COMPARATOR|Computer-based therapy (CBT)|The CBT group will be assigned active home-based computer vergence/accommodative therapy (15 minutes/day) plus placebo yoked prism flipper therapy (5 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
62195784|NCT01515943|ACTIVE_COMPARATOR|Near target push-up (NTP)|The NTP group will be assigned placebo home-based computer vergence/accommodative therapy (5 minutes/day) plus near target push-ups (15 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
62009574|NCT04902859|PLACEBO_COMPARATOR|Placebo without eye speculum|Sterile water corresponding to the same volume as 4 mcg/kg of Clonidine given orally in GI-tube.
62195785|NCT01515943|PLACEBO_COMPARATOR|Placebo|The placebo group will be assigned placebo home-based computer vergence/accommodative therapy (15 minutes/day) plus placebo yoked prism flipper therapy (5 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
62195786|NCT03539068|NO_INTERVENTION|WEB-ED Only Control Arm|Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the no intervention control group will receive no further intervention but asked to participate in a subsequent study phase that addresses VA and post-deployment care access
62195787|NCT03539068|EXPERIMENTAL|WEB-ED+ Treatment Arm|"Veterans who screen positive on one or more mental health screens in WEB-ED will be RCT-eligible. RCT-consenters randomly assigned to the WEB-ED+ Treatment are will receive:~* eHealth interfaces tailored to Veterans' VA and MHV enrollment needs (links for electronic VA enrollment, MHV and MHV premium status enrollment).~* Shared decision making (SDM) interfaces: Patient Decision aids (PTSD, depression, alcohol abuse); SDM educational video; videos).~* Access to study staff available through a toll-free number to assist both Veterans and providers, including addressing questions, problem-solving about or assisting with stuck points (e.g. getting screening results to the provider)."
62195788|NCT01529489|ACTIVE_COMPARATOR|Interval physical training Control group|
62195789|NCT01529489|EXPERIMENTAL|Resisted/Aerobic physical training group|
62195790|NCT01529489|ACTIVE_COMPARATOR|Aerobic/resisted physical training group|
62574245|NCT02653144|EXPERIMENTAL|dexmedetomidine and ropivacaine group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with Ropivacaine 0.5% 20ml + 75mcg of dexmedetomidine
62195791|NCT01529489|EXPERIMENTAL|Interval physical training group|COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic
62195792|NCT04648592|EXPERIMENTAL|Intervention|Low salt diet, aiming at a daily sodium intake of 50 mmol plus oral salt supplements (9 grams) to achieve an overall daily sodium intake of 200 mmol.
62195793|NCT04648592|PLACEBO_COMPARATOR|Control|Low salt diet, aiming at a daily sodium intake of 50 mmol plus oral placebo supplements to achieve an overall daily sodium intake of 50 mmol.
62195794|NCT05443113||Children (<11 years) with pectus excavatum|All pediatric PE patients aged younger than 11 years upon first visit of our outpatient clinic
62195795|NCT02916550|EXPERIMENTAL|Breathing exercise|Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
62195796|NCT03242512|EXPERIMENTAL|30 mg single dose cohort|Subjects would receive a 30 mg single dose of TK006.
62195797|NCT03242512|EXPERIMENTAL|60 mg single dose cohort|Subjects would receive a 60 mg single dose of TK006.
62195798|NCT03242512|EXPERIMENTAL|120 mg single dose cohort|Subjects would receive a 120 mg single dose of TK006.
62195799|NCT01235000||2010-11 influenza vaccine recipients|Participants of an earlier clinical trial (TITRE II) to evaluate prime-boost response across B lineages in 2009-10
62195800|NCT04785105||patient with isolated SMA stenosis|patient with isolated SMA stenosis on initial scanner
62195801|NCT04785105||patient with both SMA stenosis and CA or/and IMA stenosis|patient with both SMA stenosis and CA or/and IMA stenosis on initial scanner
62574246|NCT02653144|EXPERIMENTAL|dexamethasone and ropivacaine group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with. Ropivacaine 0.5% 20ml + 4mg dexamethasone
62574247|NCT02653144|ACTIVE_COMPARATOR|ropivacaine only group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with Ropivacaine 0.5% 20ml (acting as control)
62009575|NCT06464939|EXPERIMENTAL|Group A|KH001 and placebo
62009576|NCT06464939|EXPERIMENTAL|Group B|KH001 and placebo
62195802|NCT01391637||HuCNS-SC transplanted subjects in the lead-in phase|Subjects who had HuCNS-SC transplant in the lead-in phase study CL-N01-PMD
62574248|NCT03476889|EXPERIMENTAL|Intervention|Cows milk based infant formula containing fermented infant formula and prebiotic oligosaccharides
62009577|NCT06464939|PLACEBO_COMPARATOR|Group C|Placebo
62009578|NCT06072066|EXPERIMENTAL|Skin Barrier Oral Supplement|
62195803|NCT04426435|EXPERIMENTAL|Intervention|Group A: patients receiving HB syrup, 10 cc three times daily
62574249|NCT03476889|ACTIVE_COMPARATOR|Control|Cows milk based infant formula containing prebiotic oligosaccharides (commercially available Aptamil ProNutra)
62574250|NCT03476889|NO_INTERVENTION|Breastfed reference|Exclusively breastfed from birth to study completion
62574251|NCT02420561|EXPERIMENTAL|Motivational Interviewing|"The motivational interviewing (MI) intervention consisted of one 45-minute in-person MI session followed by two 15-minute telephone booster sessions"
62195804|NCT04426435|PLACEBO_COMPARATOR|Placebo|Group B: patients receiving placebo, 10 cc three times daily
62574252|NCT02420561|ACTIVE_COMPARATOR|Control|Participants received a brochure on alcohol and drug use risks.
62574253|NCT01736345||Telephone Disclosure|Telephone Disclosure: Participants randomized to telephone disclosure will be asked to provide a personal identifier that the participant will be asked at the time of their telephone disclosure to ensure their identity.
62574254|NCT01736345||In Person Disclosure|Individuals opting out of randomization but still willing to participate in the research will be placed in the self-select in-person arm.
62574255|NCT00123838|EXPERIMENTAL|Single Group Assignment|Calypso® 4D Localization System
62574256|NCT06352112|EXPERIMENTAL|Pelvic Floor Muscle Training|Participants received pelvic floor muscle training only.
62574257|NCT06352112|EXPERIMENTAL|Pelvic Floor Muscle Training combined with Hypopressive Exercises|Participants received hypopressive exercise in addition to pelvic floor muscle training.
62574258|NCT01178749||Chronic Hepatitis C Infection|patients Receiving 24-week Interferon-α with Ribavirin Treatments
62574259|NCT02000635||Leptospirosis|Patient with a diagnosis of leptospirosis confirmed by PCR in the five first day
62574260|NCT06343467|EXPERIMENTAL|Generic Implant|Patients with an isolated distal radius fracture are treated surgically with a generic volar locking plate. All other surgical protocols remain unchanged.
62574261|NCT06343467|ACTIVE_COMPARATOR|Conventional Implant|Patients with an isolated distal radius fracture are treated surgically with a conventional, brand name volar locking plate of the surgeon's choice. All other surgical protocols remain unchanged.
62574262|NCT04411901|EXPERIMENTAL|vitamin D 3|oral vitamin D3 drops and tablets
62783157|NCT00240500|EXPERIMENTAL|HBV-6 Group|neonates born to HBsAg- and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
62783158|NCT05400772||Healthy subjects|
62783159|NCT00321815|EXPERIMENTAL|A|Standard of Care chemotherapy plus experimental intervention (PF-3512676)
62009579|NCT02206113|EXPERIMENTAL|Standing workstation - 16 weeks|This arm, Standing workstation - 16 weeks, received the intervention of a standing workstation for 16 weeks. For the first 8 weeks, the participants were instructed how long to stand per hour for an 8 hour shift. The second 8 weeks their use was monitored for sustainability.
62009580|NCT02206113|ACTIVE_COMPARATOR|Standing workstation - second 8 weeks|This arm, Standing workstation - second 8 weeks, received the intervention of a standing workstation for 8 weeks of the study. For the first 8 weeks, the worked at their normal desks without an intervention. The second 8 weeks they received a standing workstation and their use was monitored.
62195805|NCT02601209|EXPERIMENTAL|Arm I (sapanisertib)|Patients receive sapanisertib as in Phase I. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62195806|NCT02601209|EXPERIMENTAL|Arm II (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm I.
62195807|NCT02344589|EXPERIMENTAL|ACB 10|ACB in right leg with 10ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
62195808|NCT02344589|EXPERIMENTAL|ACB 20|ACB in right leg with 20ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
62195809|NCT02344589|EXPERIMENTAL|ACB 30|ACB in right leg with 30ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
62195810|NCT02344589|ACTIVE_COMPARATOR|FNB|FNB in left leg with 20ml of lidocaine 10mg/ml on day 1. Unblinded arm, used for model control
62399002|NCT06715397||Patients with upper limb injuries|"Patients with upper extremity injury, who can read and write Turkish and are between the ages of 18-64, and only participants with unchanged health status for retesting will be included in the study.~Patients with mental and neurological disorders (major depression, schizophrenia, psychosis, stroke, cerebral palsy, etc.) and/or rheumatological disease, active local or systemic infection, cancer history, severe visual impairment, need for emergency surgery, injection in the last 3 years, sensory problems that may affect the application of scales and cognitive impairment will be excluded from the study."
62399003|NCT03473691|EXPERIMENTAL|Glembatumumab vedotin (GV)|
62399004|NCT06124859|EXPERIMENTAL|Patients with a diagnosis of COPD (GOLD II- V) or pulmonary fibrosis (>6 months).|
62574263|NCT02695667||OSAS subjects|CPAP Referral OSAS
62574264|NCT02695667||Risk-Free subjects|paired normal control subjects
62574265|NCT02434146|EXPERIMENTAL|Supportive care (topical phenylephrine solution)|Patients undergoing a cyclophosphamide and total body irradiation regimen receive topical phenylephrine solution via spray to the oral mucosa 15-20 minutes prior to each cyclophosphamide infusion, 25-30 minutes after the beginning of each cyclophosphamide infusion, and 15-20 minutes prior to each radiation treatment.
62574266|NCT03632928||Migraine patients|"Migraine patients, who do not have any other diseases except from tension type headache.~No intervention, but daily measurements of muscle hardness (Ultrasound Elastography) and tenderness (Pressure pain threshold)"
62574267|NCT05841680|NO_INTERVENTION|Waitlist Control|Participants complete pre, post, and follow-up questionnaires. They have the option to view the SSI module after completing follow-up questionnaires.
62574268|NCT05841680|ACTIVE_COMPARATOR|Single Session Intervention Receivers|Participants complete pre then receive the SSI module. Then they complete post and follow-up questionnaires.
62574269|NCT03656068|EXPERIMENTAL|Open label NTZ|Open label. All patients will receive study drug
62574270|NCT06362538|OTHER|subject with a negative or positive history of cardiovascular disease|no drugs or devices are included.
62574271|NCT02549859|EXPERIMENTAL|Deep Brain Stimulation (DBS)|All patients were treated and assessed under three conditions (60 Hz DBS, 130 Hz DBS and no DBS) at Visit 1 (V1), were then treated with 60 Hz DBS for at least 6 months (14.5 months on average), and were finally reassessed during a second visit (V2) under the same three conditions as V1. The order of treatment/assessment under the three conditions was randomized at each visit.
62574272|NCT01553422|ACTIVE_COMPARATOR|before fluid Therapy|
62574273|NCT01553422|ACTIVE_COMPARATOR|after fluid Therapy|
62734664|NCT04482972||DCB|DCB group: Patients treated with drug coated balloon (DCB) only angioplasty (all-comers: STEMI, NSTEMI, Stable angina)
62734665|NCT04482972||DES|DES group: Patients treated with drug eluting stent (DES) angioplasty (all-comers:STEMI, NSTEMI, Stable angina)
62195811|NCT02344589|PLACEBO_COMPARATOR|Placebo|ACB in left leg with 30ml of isotonic saline on day 2. Unblinded arm used for model control
62574274|NCT01580670|EXPERIMENTAL|TA-650|"Responder criteria: Case where PCDAI score on the evaluation day was decreased by at least 15 points from that in the screening period and was ≤30.~Criteria for dose-increasing: When either of the following 2 items was satisfied after Week 14, the relevant patient would be considered to satisfy the criteria for dose increasing to 10 mg/kg.~1. PCDAI score on the evaluation day was increased by at least 15 points compared to the lowest PCDAI score observed at Week 2, 6 or 10~2. PCDAI score on the evaluation day exceeds 30"
62574275|NCT02906501||Group I (n=15)|Male children and adolescents diagnosed with ADHD not treated with risperidone or any other antipsychotic treatment.
62574276|NCT02906501||Group II (n=15)|Male children and adolescents diagnosed with ADHD intended to start risperidone or any other antipsychotic treatment due to behavioral problems.
62574277|NCT02906501||Group III (n=15)|Male children and adolescents diagnosed with ADHD treated with risperidone or any other antipsychotic treatment due to behavioral problems.
62574278|NCT00766636|EXPERIMENTAL|Gemcitabine + Erlotinib Without Radiation|"Gemcitabine + Erlotinib without radiation - Arm A: Gemcitabine 1000 mg/M\^2 given intravenously over 100 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day. Erlotinib 100 mg daily by mouth on days 1-42.~Surgical removal of the pancreas and duodenum."
62574279|NCT00766636|EXPERIMENTAL|Gemcitabine + Erlotinib With Radiation|Gemcitabine + Erlotinib with radiation - Arm B: Gemcitabine 400 mg/M\^2 given intravenously over 40 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day. Erlotinib 100 mg daily by mouth on days 1-42. Radiation therapy 1 time each day for 5 days in a row for 5 1/2 weeks starting on Day 1 for a total of 50.4 Gy. Surgical removal of the pancreas and duodenum.
62574280|NCT04014205|EXPERIMENTAL|Part 1 Dose Escalation|Patients with r/r B-cell malignancies including Grades 1-3a FL, MZL, MCL, and CLL/SLL
62574281|NCT04014205|EXPERIMENTAL|Part 2 Dose Expansion|"Arm 1: Patients with r/r MCL~Arm 2: Patients with other types of B-cell malignancies, including:~* CLL/SLL with/without prior treatment~* r/r FL~* r/r MZL"
62574282|NCT03446027|NO_INTERVENTION|Control|There will be no change to the local site standard of care for patients with IC attributed to participation in this trial. Those sites with Supervised Exercise Therapy (SET) will continue to provide this intervention as per their normal standard of care and locally agreed protocol.
62574283|NCT03446027|EXPERIMENTAL|Device|Local therapy + Neuromuscular Electrical Stimulation (NMES)
62783160|NCT00321815|ACTIVE_COMPARATOR|B|Standard of Care chemotherapy
62009581|NCT03205696||Cases|36 youth with new diagnosis of acute/recent HIV as defined by laboratory assays Fiebig1-V with standard care of antiretrovirals (ARV) regimen provided by the clinician
62009582|NCT03205696||Controls|36 youth with newly diagnosed HIV but established HIV infection (Fiebig VI) with standard care of antiretrovirals (ARV) regimen provided by the clinician
62009583|NCT04902105|OTHER|Cohort A|"Ecopipam HCL - 2 doses of 200mg~Mefenamic acid 250mg Q6H for 7 days"
62009584|NCT04902105|OTHER|Cohort B|"Ecopipam HCL - 2 doses of 200mg~Divalproex acid 1250mg QD for 10 days"
62009585|NCT01314924|EXPERIMENTAL|Responders|Patients who present an increase in flow-mediated dilation of brachial artery.
62009586|NCT01314924|EXPERIMENTAL|Non responders|Patients who do not present an increase in flow-mediated dilation of brachial artery.
62399005|NCT04123951|EXPERIMENTAL|Home-based Exercise|Patients in this arm will complete a 12 week home-based aerobic and resistance exercise training programme. There will be a 2 week period prior to this in which patients will complete up to 6 supervised sessions in order to learn about the home-based exercise training. There will be a 4 week return visit and an optional 8 week return visit in order to reassess fitness and aid the patients with any questions or queries they may have and to aid them in progressing their exercise.
62399006|NCT04123951|NO_INTERVENTION|Control|"In this arm patients will continue 'as normal' with daily activities.~Patients in this arm will be offered the exercise intervention once they have completed post 12 week assessments."
62574284|NCT02209051|ACTIVE_COMPARATOR|AMNIOEXCEL|Human Amniotic Membrane Allograft
62574285|NCT02209051|ACTIVE_COMPARATOR|Standard of Care, Diabetic Foot Ulcers|Advanced wound care dressings and offloading of wound.
62574286|NCT03068195|EXPERIMENTAL|laparoscopic microwave ablation|laparoscopic microwave ablation will be performed before the renal cysts are decorticated
62574287|NCT03068195|EXPERIMENTAL|percutaneous microwave ablation|percutaneous microwave ablation will be performed to treat the renal cysts without decorticating.
62574288|NCT03068195|ACTIVE_COMPARATOR|laparoscopic decortication|conventional laparoscopic decortication will be performed to treat the renal cysts.
62574289|NCT05893940|EXPERIMENTAL|LIMS vibration Therapy, DEXA Scan - Cohort 1|Patients undergo LIMS vibration therapy over 10 minutes on study. Patients also undergo DEXA scan at follow up and may optionally undergo blood sample collection and questionnaire at baseline and follow up
62574290|NCT05893940|EXPERIMENTAL|LIMS vibration therapy - Cohort II|Patients undergo LIMS vibration therapy over 10-minutes BID for 14 days on study. Patients also undergo blood sample collection throughout the trial.
62574291|NCT04769518|ACTIVE_COMPARATOR|Advanced Recovery Room Care (ARRC)|Patients are provided with high acuity care from arrival in Recovery (PACU) until the morning after surgery. This includes higher than normal nursing ratios (1:2), regular frequent rounds by specialist anaesthetic staff, and access to monitoring and medicines (eg vasopressor infusions) not available on normal postoperative surgical wards.
62574292|NCT04769518|PLACEBO_COMPARATOR|Usual care|Patients are managed in Recovery (PACU), then normal postoperative surgical wards, as per usual care.
62574293|NCT00833495|EXPERIMENTAL|1|FOV1101-00 concentration 1 and Prednisolone Acetate 0.12% (Pred Mild®)
62574294|NCT00833495|EXPERIMENTAL|2|FOV1101-00 concentration 2 and Prednisolone Acetate 0.12% (Pred Mild®)
62574295|NCT00833495|EXPERIMENTAL|3|Vehicle of FOV1101-00 and Prednisolone Acetate 1% (Pred Forte®)
62009587|NCT00399334||001|
62009588|NCT03073616||Lung ultrasound|Every patient will receive a chest RX and lung US
62195812|NCT01186822|EXPERIMENTAL|Lung Flute for BHT|The Lung Flute arm participants were instructed to blow twice in to the Lung Flute device vigorously enough to make the reed oscillate, followed by 5 normal breaths. This was repeated 10 times, followed by 3 huff coughs to complete 1 cycle. Two such cycles were recommended twice a day. One of these cycles was performed under supervision of the study personnel at the time of enrollment and at each subsequent study visit. Baseline COPD medication regimen was continued in all participants, although the primary physicians of the participants could make medically necessary changes. Chest physical therapy, additional breathing exercises and formal pulmonary rehabilitation programs were not prescribed to any of the participants during the study.
62195813|NCT01186822|NO_INTERVENTION|No intervenstion|No intervention. Same population.
62574296|NCT00833495|PLACEBO_COMPARATOR|4|Vehicle of FOV1101-00 and vehicle of FOV1101-00
62574297|NCT06575127|EXPERIMENTAL|modified FOLFOXIRI plus target therapy|"* Pre-Treatment Medications:~  1. Atropine SC: Administered before irinotecan infusion to prevent side effects.~ 2. High-Risk Anti-Emetics Regimen: Used to prevent acute and delayed vomiting.~* Chemotherapy Regimen: All eligible patients will receive the modified FOLFOXIRI regimen as follows:~  * Oxaliplatin: 85 mg/m² IV over 2 hours (Day 1)~ * Irinotecan: 150 mg/m² IV over 90 minutes (Day 1)~ * 5-FU: 2400 mg/m² IV over 48 hours infusion (Days 1)~* Targeted Therapy: Administered according to NRAS/KRAS status and the location of the primary tumor:~  * KRAS/NRAS/BRAF Wild-Type (Left-Sided Tumor): Anti-EGFR treatment with either Panitumumab (6 mg/kg over 60 minutes, Day 1) or Cetuximab (500 mg/m², Day 1).~ * KRAS/NRAS Mutant or Right-Sided Tumor: Bevacizumab at a dose of 5 mg/kg IV over 30 to 90 minutes (Day 1).~* Treatment Schedule: The treatment will be administered biweekly for a maximum of 12 cycles (6 months)."
62574298|NCT00572936|OTHER|Latanoprost/Dorzolamide/Timolol|The participants received latanoprost at night and vehicle in the morning for two weeks, then 6 week washout, then Dorzolamide BID for two weeks, then 6 week washout, then Timolol BID for two weeks. The order in which the participants received the three different drugs was random.
62574299|NCT05779683||Caretaker device in CVICU patient|device placed on the subject after arrival to the cardiac intensive care unit postoperatively
62009589|NCT06664723|EXPERIMENTAL|Group A: high tone external muscle stimulation|The study group will include 40 patients with diabetic foot ulcer receiving high tone external muscle stimulation three times a week for 8 weeks; in addition to Standard Medical Treatment: The Standard care of diabetic foot ulcers includes good glycemic control, adequate nutrition, off-loading (via bed rest or casts), local care (moist dressings and topical management), lessening of edema, surgical debridement of devitalized wound tissue and antibiotic therapy.
62009590|NCT06664723|SHAM_COMPARATOR|Group B: Control|The control group will include 40 patients with diabetic foot ulcer receiving Standard Medical Treatment only. The Standard care of diabetic foot ulcers includes good glycemic control, adequate nutrition, off-loading (via bed rest or casts), local care (moist dressings and topical management), lessening of edema, surgical debridement of devitalized wound tissue and antibiotic therapy.
62009591|NCT04448860|EXPERIMENTAL|Retinitis Pigmentosa patients|Patients with Retinitis Pigmentosa (RP) at different stages of impairment of the visual field, acuity and sensitivity to contrasts 15 patients will be included in phase 1 versus 36 in phase 2 (15 in step 1 and 21 in step 2).
62009592|NCT04448860|OTHER|healthy volunteers patients|36 patients will be included just in phase 2 (15 in step 1 and 21 in step 2).
62009593|NCT04833166|EXPERIMENTAL|Full glottic view on CMAC- D blade|Deliberately obtaining a full glottis view is deﬁned as negotiation and advancement of CMAC D blade tip positioned at the vallecula. Occasionally, external laryngeal pressure may be needed to assist in obtaining a full glottic view. The full glottic view is defined as a percentage of glottic opening (POGO) approximate 100%.
62195814|NCT02328079|ACTIVE_COMPARATOR|Steroid Group|prednisolone 60 mg /day IM /IV for 6 consecutive days then reduced by 10 mg /day (for a total treatment time for 12 days)
62195815|NCT02328079|ACTIVE_COMPARATOR|Steroid + Antiviral Group|Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days)
62195816|NCT01001390|OTHER|Group One|Group one will take a six minute walk test with AFO device, and after a rest of fifteen minutes, they will take another six minute walk test without AFO, with similar speed to the previous test.
62195817|NCT01001390|OTHER|Group Two|Group two will take a six minute walk test without AFO device, and after a rest of fifteen minutes, they will take another six minute walk test with AFO, with similar speed to the previous test.
62195818|NCT01976273|ACTIVE_COMPARATOR|1064nm Q-switch Laser|The 1064 Q-Switch Laser is a medical device that uses a focused laser to remove dark pigment (color) from the skin.
62195819|NCT01976273|ACTIVE_COMPARATOR|Glycolic Acid Peels|A Glycolic Acid Chemical Peel is a mild skin treatment used to correct uneven texture and color by removing dead cells from the skin's outermost layer.
62195820|NCT02497989|EXPERIMENTAL|Inter-personal Communication (IPC)|Interpersonal communication will entail delivery of intervention massages that are custom-made to address individual participants' specific barriers and facilitators of VMMC. RAs will discuss with uncircumcised men why they have not gone for VMMC using the 'VMMC Demand Creation Toolkit'. The aim will be to fully address their barriers and re-enforce their facilitators. RAS will be trained behavioral counselors, circumcised men, female partners, CHWs, or any other cadre of individuals identified during the formative phase.
62195821|NCT02497989|EXPERIMENTAL|Dedicated Service Outlets (DSO)|RAs shall visit all households with eligible men to inform them about the availability of, and give information on location of DSO sites in the Location. DSOs are sites: where services are offered exclusively to men aged ≥25 years by male service providers in the same age bracket; providing services in the evenings/weekends/designated days of the week, and through special mobile services for older men. DSO sites we will strive to shorten the waiting time to ≤ three hours. They will be informed that all other VMMC sites continue to serve all men regardless of age (i.e., including older men) while DSO sites will only serve men aged ≥25 years. RAs will respond to questions using 'All You Need to Know About VMMC' booklet, the same way current recruiters do.
62195822|NCT02497989|EXPERIMENTAL|Combined IPC & DSO|Both Inter-personal Communication (IPC) and Dedicated Service Outlets (DSO) interventions (as described above) will be implemented concurrently. This will be done to determine the effect of both interventions delivered jointly compared to each delivered singly, and compared to no intervention.
62195823|NCT02497989|NO_INTERVENTION|Control|In these Locations, participants will only be given the 'All You Need to Know About VMMC' booklet at the time of enrollment, which is the standard of care.
62195824|NCT05620615||Intensive Drug Therapy|Dual antiplatelet therapy (DAPT) (aspirin 100 mg per day and clopidogrel 75 mg per day were administered for 90 days, followed by aspirin 100 mg per day for long term) and atorvastatin (40 mg per day for 14 days, followed by 20 mg per day long term) after enrollment.
62195825|NCT03193242|EXPERIMENTAL|Intervention|"Electronic Asthma Management System: eAMS Intervention~eAMS consists of simple questionnaire completed either through an app on a patient's smartphone or tablet computer, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and a printable asthma action plan that is given to patients. eAMS will also provide access to a patient-oriented asthma management tool called Breathe."
62195826|NCT03193242|NO_INTERVENTION|Control|"Electronic Asthma Management System: eAMS - Control~At control sites, eligible clinicians will be offered access to the web-based clinician-oriented asthma action plan (AAP) educational module produced by the Lung Association, copies of the Canadian Asthma Guidelines, and standard fillable paper-based AAPs (the eAMS will be offered after study end)."
62195827|NCT05763303|EXPERIMENTAL|intervention group|"received interventional program which will consist of :~1. -The educational part: the health education intervention will be in the form of brief counselling five sessions (about half an hour for each session at 1-week intervals) which are introduced after data collection and blood analysis by simplified manner, in the study's clinic.~2. Training part: We will invite every participant to join this part of the program which will be performed in the fitness center of the faculty of physical education, Assiut University. The entire duration of the 8-week exercise training program is closely supervised by 2 qualified personnel. The exercise session includes running or walking on treadmill, and cycling on bicycle ergometer, about 30 minutes, 3 times per week,"
62195828|NCT05763303|OTHER|control group|traditional care: the participants will received traditional care in health facility but nothing by researcher
62195829|NCT01333553||Image-guided remove Port Wine Stain|Image-guided surgery remove Port Wine Stain
62195830|NCT06230172|EXPERIMENTAL|Prospective group (>1600 grams)|The prospective group is weaned from incubator to crib at a postnatal weight of \>1600 grams following consent process.
62195831|NCT03387761|EXPERIMENTAL|Cohort 1: Ipi + Nivo|"* Day 1: Ipilimumab 3 mg/kg i.v.~* Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~* Day 43: Nivolumab 3 mg/kg i.v."
62195832|NCT03387761|EXPERIMENTAL|Cohort 2a: high-Ipi + low-Nivo|"* Day 1: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~* Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~* Day 43: Nivolumab 3 mg/kg i.v.~* Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84"
62195833|NCT03387761|EXPERIMENTAL|Cohort 2b: low-Ipi + high-Nivo|"* Day 1: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.~* Days 22: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.~* Day 43: Nivolumab 3 mg/kg i.v.~* Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84"
62195834|NCT03944642|EXPERIMENTAL|Intervention|Participants will receive the standard prenatal care and invited to participate of a breastfeeding workshop during the third trimester of pregnancy, with active and intentional participation of the pregnant woman and her partner/relative; based on adult education methodology. In addition, women participants will have continuous support during their breastfeeding process, up to 6 months of the child's life, through a virtual support group (whats-app), where they will receive messages that promote their self-efficacy in relation to their ability to breastfeed and may ask questions that are related to breastfeeding. Professionals in this group will be train before delivering the intervention.
62009594|NCT04833166|ACTIVE_COMPARATOR|Partial glottic view on CMAC- D blade|The partial glottis view is deﬁned as a percentage of glottic opening \<50%. This is achieved by deliberately position the CMAC D-blade tip proximally away from the vallecular.
62195835|NCT03944642|NO_INTERVENTION|Standard Care|This group will receive the standard pre and postnatal regular care, for mother and child. Professionals who provide direct care will maintain their usual attention.
62195836|NCT02813044|EXPERIMENTAL|TIVA group|Anesthesia is maintained with propofol during surgery
62195837|NCT02813044|ACTIVE_COMPARATOR|inhalation anesthesia group|Anesthesia is maintained with sevoflurane during surgery
62195838|NCT03866590||Patients being at risk for Pyruvate Kinase Deficiency|Patients, older than 5 years and younger than 30 years old, being at risk for Pyruvate Kinase Deficiency, due to chronic anaemia or cholelithiasis or cholecystitis of undetermined aetiology
62574300|NCT01906853|NO_INTERVENTION|No BCG|No BCG
62195839|NCT06026553|EXPERIMENTAL|Standard post-operative pain management + Ketorolac (Toradol)|Subject will undergo an IVF cycle with ovarian hyperstimulation and oocyte retrieval. Standard protocols will be used for both study groups and involve administration of gonadotropins to stimulate ovarian follicle growth and regular monitoring with ultrasound and serum estradiol and progesterone levels until follicles reach a desired size. Human Chorionic Gonadotropin (HCG) or leuprolide acetate will be administered to trigger final oocyte maturation prior to oocyte retrieval under anesthesia. On the day of oocyte retrieval, the anesthesia provider will provide syringes of IV ketorolac (30 mg if ≥50 kg or 15 mg if \<50 kg per manufacturer dosing) or IV placebo (saline). If assigned to the study arm, IV ketorolac will be administered by the anesthesia provider. All enrolled patients will receive standard post-operative pain management. Patients will be contacted post-operatively, to access pain scores and record the amount of the prescribed narcotic medications utilized since discharge.
62195840|NCT06026553|PLACEBO_COMPARATOR|Standard post-operative pain management + Placebo (saline)|Subject will undergo an IVF cycle with ovarian hyperstimulation and oocyte retrieval. Standard protocols will be used for both study groups and involve administration of gonadotropins to stimulate ovarian follicle growth and regular monitoring with ultrasound and serum estradiol and progesterone levels until follicles reach a desired size. HCG or leuprolide acetate will be administered to trigger final oocyte maturation prior to oocyte retrieval under anesthesia. On the day of oocyte retrieval, the anesthesia provider will provide syringes of IV ketorolac (30 mg if ≥50 kg or 15 mg if \<50 kg per manufacturer dosing) or IV placebo (saline). If assigned to the control arm, IV placebo (saline) will be administered by the anesthesia provider. All enrolled patients will receive standard post-operative pain management. Patients will be contacted post-operatively, to access pain scores and record the amount of the prescribed narcotic medications utilized since discharge.
62195841|NCT03721172|EXPERIMENTAL|Placebo-controlled Phase:|Participants received placebo as oral tablets twice daily (BID) for up to 16 weeks (Week 0 to Week 16).
62195842|NCT03721172|EXPERIMENTAL|Placebo-controlled Phase: Apremilast 30 mg|Participants received apremilast 30 mg as oral tablets BID for up to 16 weeks (Week 0 to Week 16).
62195843|NCT03721172|EXPERIMENTAL|Extension Phase: Apremilast 30 mg|Eligible participants who completed the placebocontrolled phase entered the extension phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).
62574301|NCT01906853|EXPERIMENTAL|BCG|Mycobacterium bovis BCG (Bacille Calmette Guérin) vaccine, Danish Strain 1331
62574302|NCT06134284|EXPERIMENTAL|OR regimen|The specific medication regimen for the OR regimen is as follows: Orelabrutinib 150mg orally once daily; Rituximab 375mg/m² intravenous infusion, administered every 21 days.
62009595|NCT05054296|ACTIVE_COMPARATOR|Group I (education exercise packet, FitBit)|Patients receive general education exercise packet with instruction to exercise regularly for up to 150 minutes weekly. Patients also wear a FitBit daily over 16 weeks.
62009596|NCT05054296|EXPERIMENTAL|Group II (exercise program FitBit)|Patients participate in supervised and self-directed exercise sessions over 60 minutes BIW for up to 16 weeks. Patients also wear a FitBit daily over 16 weeks.
62195844|NCT02402322|ACTIVE_COMPARATOR|Non-scheduled support|Participants received an Web-based cognitive behavioral treatment for Panic Disorder with the support of a therapist via phone when they required it.
62195845|NCT02402322|EXPERIMENTAL|Scheduled support|Participants received an Web-based cognitive behavioral treatment for Panic Disorder with the support of a therapist via phone weekly.
62574303|NCT02017431|ACTIVE_COMPARATOR|Filtered air|Exposure for 2 hours to filtered air followed by subject specific inhaled allergen challenge
62574304|NCT02017431|EXPERIMENTAL|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by subject specific inhaled allergen challenge
62574305|NCT02017431|ACTIVE_COMPARATOR|Filtered air control|Exposure for 2 hours to filtered air followed by inhaled saline challenge
62574306|NCT02017431|EXPERIMENTAL|Particle depleted diesel exhaust|Exposure for 2 hours to particle depletion diesel exhaust followed by inhaled allergen challenge
62009597|NCT01818505||Gouty arthritis|Patient with gouty arthritis
62009598|NCT01818505||Asymptomatic hyperuricemia|Patient with asymptomatic hyperuricemia
62009599|NCT01818505||OA without hyperuricemia|Patient of osteoarthritis but without hyperuricemia and gout
62009600|NCT00648297|EXPERIMENTAL|1|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
62009601|NCT00648297|ACTIVE_COMPARATOR|2|Corzide® Tablets 80 mg/5 mg
62009602|NCT05724498|ACTIVE_COMPARATOR|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|Compare two behavioral interventions for insomnia
62574307|NCT04603066|EXPERIMENTAL|Ondansetron + Tariquidar|
62574308|NCT04603066|PLACEBO_COMPARATOR|Ondansetron + Placebo|
62195846|NCT02402322|NO_INTERVENTION|Waiting list|Participants in a waiting list.
62195847|NCT00297804|EXPERIMENTAL|Arm 1|
62009603|NCT05724498|ACTIVE_COMPARATOR|Standard Cognitive-Behavioral Therapy for Insomnia (CBT-I)|Standard VA 6 session version of CBT-I
62574309|NCT05884385|NO_INTERVENTION|No intervention|Surgeons performing procedures under this condition will receive no intervention. They will perform the robotic procedure as they would normally on a day-to-day basis without any change. EMG and EEG monitoring will be performed by collecting data at the various predefined POIs.
62195848|NCT00297804|ACTIVE_COMPARATOR|Arm 2|
62195849|NCT01970254||Screening (hepatitis B screening)|Patients with unknown HBV infection status undergo 3 HBV screening tests (HBsAg, anti-HBc, and anti-HBs) before chemotherapy. Patients with known HBV infection status undergo either HBsAg or anti-HBc screening tests if there is no evidence of HBV testing in the last 3 months. All patients complete HBV risk assessment survey.
62195850|NCT06220305||Pulmonary Nodule Group|patient conform pulmonary nodules on CT images
62195851|NCT05106205|EXPERIMENTAL|Sequence A|
62195852|NCT05106205|EXPERIMENTAL|Sequence B|
62195853|NCT01282515|EXPERIMENTAL|ELP active|one PDT treatment with 2 ml hexaminolevulinate 6 mg/ml gel
62195854|NCT01282515|ACTIVE_COMPARATOR|topical steroids|treatment with clobetasol propionate 0.05% ointment used daily for 6 weeks
62195855|NCT06422442|EXPERIMENTAL|Eye tracking tasks|All participants complete three tasks in which they view threat-related and neutral stimuli (words or faces)
62195856|NCT05572593|EXPERIMENTAL|Guided Group|Subjects treating physician will receive PGx results to facilitate clinical decisions
62195857|NCT05572593|ACTIVE_COMPARATOR|Unguided Group|Subjects treating physician will be blinded to PGx results and will receive standard medical care
62195858|NCT00867698|EXPERIMENTAL|AST-120 (6g)|2 grams TID
62574310|NCT05884385|EXPERIMENTAL|Simulated exercises|When surgeons perform procedures under this condition they perform the initial theatre briefing prior to starting an operating list. They then perform 5 minutes of a preloaded simulated task on the robotic console. These tasks are designed to emulate fundamental skills required to perform robot-assisted laparoscopic surgery. They will then proceed to perform surgery as they normally do whilst undergoing EMG and EEG motoring, collecting data at the predefined POIs.
62783161|NCT05485337||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
62195859|NCT00867698|PLACEBO_COMPARATOR|Placebo A|2 grams TID
62195860|NCT00867698|EXPERIMENTAL|AST-120 (12g)|4 grams TID
62195861|NCT00867698|PLACEBO_COMPARATOR|Placebo B|4 grams TID
62195862|NCT01118559|EXPERIMENTAL|fast-fed sequence group|drug is administered in a fasted condition first, and fed-condition study follows
62195863|NCT01118559|EXPERIMENTAL|fed-fast sequence group|drug is administered in a fed condition first, and fasted-condition study follows
62195864|NCT04742231|EXPERIMENTAL|Cohort 1. Patients with brain lesions in non-motor areas undergoing an awake craniotomy (AC)|5 patient minimum
62195865|NCT04742231|EXPERIMENTAL|Cohort 2. Patients with brain lesions within or proximal to motor areas undergoing an AC|5 patient minimum
62009604|NCT06359405|EXPERIMENTAL|Working group|The intervention will take place by presenting the simulation program to the working group.
62009605|NCT06359405|NO_INTERVENTION|Control group|The control group will receive standard nursing education but not additional intervention.
62009606|NCT05146128|EXPERIMENTAL|Analytic group|The participants had to perform analytic exercices for shoulder rotators and scapular stabilizing muscles
62009607|NCT05146128|EXPERIMENTAL|Functional group|The participants had to perform functional exercices for shoulder rotators and scapular stabilizing muscles
62009608|NCT05146128|EXPERIMENTAL|Mixed group|The participants had to perform both analytic and functional exercices for shoulder rotators and scapular stabilizing muscles
62009609|NCT05641194|EXPERIMENTAL|Single arm - intervention|
62009610|NCT00283725||Galantamine|
62009611|NCT00283725||No Alzheimer's disease (AD) treatment|
62009612|NCT05544968|EXPERIMENTAL|CD30biAb-AATC|Patients will undergo weekly administration of dose escalating CD30 biAb-AATC infusions with twice weekly subcutaneous GM-CSF in 4-week cycles for a maximum of two total cycles.
62009613|NCT06113315||patients with sarcoma|This is an observational prospective cohort study of patients with sarcoma treated with immune checkpoint blockade (ICB; anti-PD-1, PD-L1, and/or CTLA-4) based therapy at Memorial Sloan Kettering Cancer Center (MSK)
62009614|NCT02157324|EXPERIMENTAL|acalabrutinib|Starts with acalabrutinib for 7 days, then combined with ACP-319 afterwards.
62009615|NCT02157324|EXPERIMENTAL|ACP-319|Starts with ACP-319 for 7 days, then combined with acalabrutinib afterwards.
62009616|NCT05061446|EXPERIMENTAL|Etrasimod Dose 1|
62009617|NCT05061446|EXPERIMENTAL|Etrasimod Dose 2|
62009618|NCT05061446|PLACEBO_COMPARATOR|Placebo|
62009619|NCT03300245||patients with nasal septal deviation|Maxillofacial CT scan
62009620|NCT01978184|EXPERIMENTAL|gemcitabine and abraxane|Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
62009621|NCT01978184|EXPERIMENTAL|gemcitabine, abraxane and hydroxychloroquine|"Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.~Hydroxychloroquine is an oral drug (capsule) that subjects will take once or twice a day at home. The dose of hydroxychlorquien will be 1200mg. This is an experimental drug. Subjects will take their first dose of hydroxychloroquine on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and will continue to take it every day until the day before surgery."
62009622|NCT02312310|PLACEBO_COMPARATOR|F 0 mg|daily consumption of capsules containing 0 mg cocoa flavanol for 12 weeks
62195866|NCT03472989|ACTIVE_COMPARATOR|Radial extracorporeal shock wave|Active shock wave treatment. All patients will get standardized information and custom made foot orthosis.
62195867|NCT03472989|SHAM_COMPARATOR|Sham-radial extracorporeal shock wave|Sham- shock wave treatment. All patients will get standardized information and custom made foot orthosis.
62195868|NCT03472989|ACTIVE_COMPARATOR|Standardized high-load exercise program|High-load exercise treatment. All patients will get standardized information and custom made foot orthosis.
62195869|NCT03472989|ACTIVE_COMPARATOR|Usual care|Only standardized information and custom made foot orthosis
62195870|NCT01300442|EXPERIMENTAL|Control|The transcutaneous electrical diaphragmatic stimulation will be applied in healthy and COPD subjects.
62195871|NCT01300442|EXPERIMENTAL|Chronic Obstructive Pulmonary Disease|The intervention will be the TEDS in patients with Chronic Obstructive Pulmonary Disease (COPD)
62399007|NCT04217174|EXPERIMENTAL|Avatar intervention app|The intervention is a mobile phone app that features a realistic talking human avatar who promotes adherence to ART and retention in care, motivates, and provides information and opportunities for HIV care-related behavioral skills.
62783162|NCT05485337||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
62009623|NCT02312310|ACTIVE_COMPARATOR|F 260 mg|"daily consumption of capsules containing 260 mg\* cocoa flavanol for 12 weeks~\*see note in Record Log regarding the change in the method of assessment of cocoa flavanol content of the capsules"
62009624|NCT02312310|ACTIVE_COMPARATOR|F 510 mg|daily consumption of capsules containing 510 mg cocoa flavanol for 12 weeks
62009625|NCT02312310|ACTIVE_COMPARATOR|F 770 mg|daily consumption of capsules containing 770 mg cocoa flavanol for 12 weeks
62009626|NCT05515523|EXPERIMENTAL|a single injection of autologous Adipose Derived (AD) Stromal Vascular Fraction (SVF)|a single injection of autologous Adipose Derived (AD) Stromal Vascular Fraction (SVF) for the treatment of knee Post Traumatic Osteoarthritis (PTOA)
62009627|NCT03837496|EXPERIMENTAL|STRIDE Run-In|"* Stride is delivered as a Five weekly one-hour virtual (videophone) or in-person sessions in small groups with a trained clinician~* Two 15-minute check-in phone calls later in the study~* Participants will store hormonal therapy medication in a bottle provided by the study team.~* Participants will complete questionnaires at enrollment and 3-months post- enrollment"
62195872|NCT06146777|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg on Day 1 of each 3-week cycle for up to 17 cycles.
62195873|NCT06146777|PLACEBO_COMPARATOR|Placebo|Participants receive intravenous placebo on Day 1 of each 3-week cycle for up to 17 cycles.
62783163|NCT05608551|EXPERIMENTAL|AA TF-CBT|Participants receive a 10-week animal-assisted trauma-focused group therapy.
62195874|NCT02920112|EXPERIMENTAL|One year post-op Tele-CBT|This group will receive Telephone based Cognitive Behavioral Therapy (Tele-CBT) one year after bariatric surgery.
62195875|NCT03145922||Sarcoidosis|
62195876|NCT03145922||Healthy Controls|
62195877|NCT04210999|EXPERIMENTAL|Homebased resistance training|Resistance training at home instructed via a smart phone training app and avoidance of pain aggravating activities for 3 months
62195878|NCT04210999|ACTIVE_COMPARATOR|Supervised resistance training|Heavy slow resistance training in the gym instructed by a physiotherapist and avoidance of pain aggravating activities for 3 months
62195879|NCT05657418|EXPERIMENTAL|JS107|
62195880|NCT05657418|EXPERIMENTAL|JS107 combination with Toripalimab|
62783164|NCT05608551|ACTIVE_COMPARATOR|TF-CBT|Participants receive a 10-week standard trauma-focused group therapy.
62783165|NCT02769169|EXPERIMENTAL|double-dose|"double-dose~Lucentis® (Raibizumab), 1mg, 3+prn"
62195881|NCT03019419|EXPERIMENTAL|Perampanel 4mg|Once daily 4mg of perampanel with dose-escalation tolerable from 2mg to 4mg for 48 weeks
62009628|NCT03837496|EXPERIMENTAL|STRIDE|"* Stride is delivered as six weekly one-hour virtual (videophone) sessions in small groups with a trained clinician (or individually, in the rare instance in which scheduling doesn't allow for groups and the participant is approaching the 12-week assessment window)~* Two 15-minute check-in phone calls later in the study~* Participants will store hormonal therapy medication in a bottle provided by the study team.~* Participants will complete questionnaires at enrollment, 12-weeks, and 24-weeks post-enrollment"
62009629|NCT03837496|ACTIVE_COMPARATOR|Medication Monitoring Control|"* Medication monitoring plus standard care~* Participants will store hormonal therapy medication in a bottle provided by the study team.~* Participants will complete questionnaires at enrollment, 12-weeks and 24-weeks post-enrollment"
62195882|NCT03019419|EXPERIMENTAL|Perampanel 8mg|Once daily 8mg of perampanel with dose-escalation tolerable from 2mg to 8mg for 48 weeks
62195883|NCT03019419|PLACEBO_COMPARATOR|Placebo|Once daily placebo for control for 48 weeks
62195884|NCT04829747|EXPERIMENTAL|Atogepant|Participants will receive fixed dose of Atogepant once daily for 12 weeks.
62195885|NCT00845312||Complicated hospitalization|"Patients 60 years old or younger, who were diagnosed with community acquired pneumonia (CAP) between March 1, 2005 and December 31, 2008 were retrospectively analyzed for risk factors for severe morbidity or mortality.~was defined as at least one of the following parameters: hospitalization longer than ten days, admission to intensive care unit and in- hospital mortality. Otherwise, the hospitalization was defined uncomplicated .The Rambam hospital Institutional Review Board approved the study."
62195886|NCT01535027|ACTIVE_COMPARATOR|Teriparatide|18 months of daily 20 ug sc. teriparatide monotherapy (TPTD)
62195887|NCT01535027|ACTIVE_COMPARATOR|Teriparatide and Raloxifene|9 months teriparatide 20 ug/day sc. monotherapy (TPTD) continued by combination therapy of raloxifene 60 mg/day orally(RAL)and TPTD for another 9 months
62195888|NCT01535027|ACTIVE_COMPARATOR|Teriparatide and Alendronate|9 months teriparatide monotherapy 20 ug/day sc.(TPTD) continued by combination therapy of alendronate 70 mg/week orally(ALN)and TPTD for another 9 months
62195889|NCT01432626|EXPERIMENTAL|Stress Induced Cardiomyopathy Patients|Patients presenting with stress induced cardiomyopathy, after meeting the Mayo criteria (normal coronary anatomy, EKG changes/Enzyme abnormalities, wall motion abnormalities consistent with stress induced cardiomyopathy and no evidence of pheochromocytoma) and signing informed consent, will receive an I123-mIBG scan to determine the sympathetic function of the heart during the acute presentation and after functional recovery.
62195890|NCT04540445||Concussed Cohort|The concussed cohort will consist of children ages 5-17 diagnosed with a concussion within 72 hours following injury and recruited from a pediatric emergency department.
62195891|NCT04540445||Healthy Matched Controls|The healthy matched control cohort consists of children 5-17, who are age and gender matched to concussed subjects who will be recruited from affiliated pediatric primary care and adolescent clinics.
62195892|NCT03332784|EXPERIMENTAL|Part 1: TAK-925 (Cohort 1; Dose Level 1)|TAK-925, Intravenous single administration. Healthy adults will be enrolled in double blind manner.
62195893|NCT03332784|EXPERIMENTAL|Part 1: TAK-925 (Cohort 2; Dose Level 2)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 2). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
62399008|NCT04217174|OTHER|Control app|The control app is a mobile phone app that features a realistic talking human avatar who primarily promotes food safety and also offers knowledge of sugar content in food. This app is expected to have no effect on ART adherence and retention in care, however, it has never been tested to determine if it may have any effect so it has been categorized as Other (arm type) rather than as placebo.
62574311|NCT05884385|EXPERIMENTAL|Mental Visualisation|"Mental training scripts based on the different surgical procedures performed by the different specialties were developed using the Mackay nodal model of mental practice(34). This involves breaking down a task into individual steps called nodal points with detailed instructions which also incorporate sensory cues to enhance the mental representation in the eye of participants' minds.~On the day of surgery, surgeons performing the procedure under this condition will consent to patients for their robotic procedure and then proceed to perform the initial theatre briefing prior to starting am operating list.~After this, surgeons will then perform 5 minutes of guided mental visualisation rather than self-produced imagery will be performed using the mental training scripts. They will then proceed to perform surgery as they normally do whilst undergoing EMG and EEG motoring, collecting data at the predefined POIs."
62574312|NCT02708628|ACTIVE_COMPARATOR|Patients using contractubex|Scar excision will be performed in second c-section for 60 patients and these patients will use prophylactic topical scar gel containing extract of allium cepae, allantoin and heparin two times in a day.
62574313|NCT02708628|ACTIVE_COMPARATOR|Patients not using contractubex|Scar excision will be performed in second c-section for 60 patients and these patients will not use prophylactic topical scar gel containing extract of allium cepae, allantoin and heparin.
62195894|NCT03332784|EXPERIMENTAL|Part 1: TAK-925 (Cohort 1; Dose Level 3)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 3). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
62195895|NCT03332784|EXPERIMENTAL|Part 1: TAK-925 (Cohort 2; Dose Level 4)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 4). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
62195896|NCT03332784|EXPERIMENTAL|Part 1: TAK-925 (Cohort 1; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
62195897|NCT03332784|EXPERIMENTAL|Part 1: TAK-925 (Cohort 2; Dose Level 6)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 6). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
62195898|NCT03332784|PLACEBO_COMPARATOR|Part 1: Placebo (Cohort 1-2)|TAK-925 Placebo, Intravenous single administration. Healthy adults will be enrolled in double blind manner.
62195899|NCT03332784|EXPERIMENTAL|Part 1: TAK-925 (Cohort 3; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Healthy elderly participants will be enrolled in double blind manner.
62195900|NCT03332784|PLACEBO_COMPARATOR|Part 1: Placebo (Cohort 3)|TAK-925 Placebo, Intravenous single administration. Healthy elderly participants will be enrolled in double blind manner.
62574314|NCT03066648|EXPERIMENTAL|Decitabine and PDR001|Decitabine in combination with PDR001
62574315|NCT03066648|EXPERIMENTAL|Decitabine and MBG453|Decitabine in combination with MBG453
62574316|NCT03066648|EXPERIMENTAL|Decitabine, PDR001 and MBG453|Decitabine in combination with PDR001 and MBG453
62574317|NCT03066648|EXPERIMENTAL|MBG453|MBG453 alone
62574318|NCT03066648|EXPERIMENTAL|MBG453 and PDR001|MBG453 in combination with PDR001
62574319|NCT03066648|EXPERIMENTAL|Azacitidine and MBG453|Azacitidine in combination with MBG453
62574320|NCT03645395|EXPERIMENTAL|MT-3724 10 mcg/kg-LEN|MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks on Days 1, 3, 5, 8, 10, and 12) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2, then MT-3724 will be administered weekly (Days 1, 3, 5, 8, 10, and 12) of each 28-day cycle
62574321|NCT03645395|EXPERIMENTAL|MT-3724 25 mcg/kg-LEN 3x a week|MT-3724 25 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks on Days 1, 3, 5, 8, 10, and 12) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2, then MT-3724 will be administered weekly Days 1, 3, 5, 8, 10, and 12) of each 28-day cycle
62574322|NCT03645395|EXPERIMENTAL|MT-3724 20 mcg/kg-LEN 3x a week|MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks on Days 1, 3, 5, 8, 10, and 12) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2 , then MT-3724 will be administered weekly (Days 1, 3, 5, 8, 10, and 12) of each 28-day cycle
62574323|NCT03645395|EXPERIMENTAL|MT-3724 25 mcg/kg-LEN 2x a week|MT-3724 25 mcg/kg dose IV for 4 doses (days 1, 5, 8 and 12 during cycles 1 and 2) of each 28 day cycle in combination with LEN and weekly during cycles 3 and beyond (days 1, 8, 15 and 22).
62574324|NCT03645395|EXPERIMENTAL|MT-3724 50 mcg/kg-LEN|MT-3724 50 mcg/kg dose IV for 4 doses (days 1, 5, 8 and 12 during cycles 1 and 2) of each 28 day cycle in combination with LEN and weekly during cycles 3 and beyond (days 1, 8, 15 and 22).
62574325|NCT00546377|EXPERIMENTAL|Mitoxantrone|
62574326|NCT04342611||Observational (Patients under the care of TA Oncologist)|Latino patients with advanced cancer as defined in the inclusion criteria
62574327|NCT06574594|EXPERIMENTAL|MTX discontinuation|methotrexate stop for 2 weeks after each shingrix vaccination
62195901|NCT03332784|EXPERIMENTAL|Part 1: TAK-925 (Cohort 4; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Healthy adults will be enrolled in non-blinded manner.
62195902|NCT03332784|EXPERIMENTAL|Part 2: TAK-925 TBD (Cohort 5)|TAK-925, Intravenous single administration. Dose in Cohort 5 will be based on safety and tolerability in the Part 1. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
62195903|NCT03332784|EXPERIMENTAL|Part 2: TAK-925 TBD (Cohort 6)|TAK-925, Intravenous single administration. Dose in Cohort 6 TBD based on safety, tolerability, PK data, and results of the Maintenance Wakefulness Test (MWT) from previous Cohorts. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
62574328|NCT06574594|ACTIVE_COMPARATOR|MTX continuation|
62574329|NCT04941651|EXPERIMENTAL|OBE-COACH program|The OBE-COACH experimental group: access to the complete OBE-COACH program
62574330|NCT04941651|ACTIVE_COMPARATOR|e-learning program|The control group: access to an e-learning program with free access via the web to advice sheets, a menu generator and a catalog of physical activity (resources made available by the site www.mangerbouger.fr ; Public Health France, Ministry of Health) and provision of connected devices (auto-tensiometer and balance).
62574331|NCT03002948||Low orgasm|Female Sexual Function Index orgasm score below 3.6
62783166|NCT02769169|ACTIVE_COMPARATOR|regular-dose|"regular-dose~Lucentis® (Raibizumab), 0.5mg, 3+prn"
62009630|NCT05673720|EXPERIMENTAL|preoperative active tDCS+MBI|Active tDCS with simultaneous meditation intervention will be applied.
62009631|NCT05673720|SHAM_COMPARATOR|preoperative sham tDCS+MBI|Sham tDCS with simultaneous sham MBM intervention will be delivered.
62195904|NCT03332784|EXPERIMENTAL|Part 2: TAK-925 TBD (Cohort 7)|TAK-925, Intravenous single administration. Dose in Cohort 7 TBD based on safety, tolerability, PK data, and results of the Maintenance of Wakefulness Test (MWT) from previous Cohorts. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
62195905|NCT03332784|PLACEBO_COMPARATOR|Part 2: Placebo (Cohort 5-7)|TAK-925 Placebo, Intravenous single administration. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
62399009|NCT00977600|EXPERIMENTAL|GT4P-F|GT4P-F (80% GT4P) was supplied as an odorless, colorless, tasteless liquid oil in 125 ml bottles. This formulation was designed to be mixed in water and create a self-emulsifying suspension, thus administered in water for the trial. The administered dose was calculated to contain the number of moles of PBA equivalent to 3 g/m2 of PBA. GT4P-F was mixed in 50 ml of water, taken orally, and then the cup rinsed with 50 ml of water and taken orally. GT4P-F was stored at ambient temperature away from light.
62399010|NCT00977600|EXPERIMENTAL|GT4P-API|GT4P-API was supplied as an odorless, colorless, tasteless oil in 125 ml bottles. The administered dose was calculated to contain the number of moles of PBA equivalent to 3 g/m2 of PBA. GT4P-API was taken orally and washed down with 100 ml of water. GT4P-API was stored at ambient temperature, away from light.
62574332|NCT01616238|EXPERIMENTAL|Philadelphia Positive Patients|All patients with Philadelphia positive ALL will be treated in this group and will receive a standard imatinib-containing chemotherapy regimen
62574333|NCT01616238|EXPERIMENTAL|Philadelphia -ve Patients- Intensive|Patients with Philadelphia negative ALL who are fit for intensive treatment will be allocated into this group.
62574334|NCT01616238|EXPERIMENTAL|Philadelphia -ve Patients- Intensive +|Patients with Philadelphia negative disease and who are fit for intensive treatment will be entered into this group
62574335|NCT01616238|EXPERIMENTAL|Philadelphia -ve Patients- Non Intensive|Patients with Philadelphia negative disease who are not fit for intensive chemotherapy will be entered into this group
62574336|NCT01616238|NO_INTERVENTION|Registration only|Patients with either Philadelphia positive or negative ALL who do not wish to enter the study will be allocated to this group for data collection purposes only.
62009632|NCT04402827||Cases|HCW highly exposed (defined as more than 15 days of continued personal attention in ICU, anaesthesia, or Infectious Diseases wards) to patients with a diagnosis of COVID-19 (PCR confirmed), who remained asymptomatic and with a negative serology (IgM and IgG negative). Transient entry or stay in the zone (kitchen personnel, rehab members,...) will be not included.
62783167|NCT03193736|EXPERIMENTAL|implant|
62009633|NCT04402827||Controls|HCW highly exposed to PCR-confirmed patients with a diagnosis of COVID-19, as defined above, matched by age and sex, who had suffered confirmed SARS CoV-2 disease (positive PCR or after, positive IgG)
62009634|NCT00966498|EXPERIMENTAL|1|This study is a single-arm, non-randomized trial. Peripheral blood stem cells will be harvested by mobilization with chemotherapy followed by G-CSF. Following adequate peripheral blood stem cell collection, the patients would be transplanted using the conditioning regimen consisting of thiotepa and cyclophosphamide (tandem one) and busulfan and melphalan (tandem two). They will receive G-CSF post transplant. There will be 6-8 weeks interval between tandem transplants. All patients would be carefully observed for any toxicity, transplant-related complications, relapse and disease-free survival.
62009635|NCT04691466||HIP_R|Patients undergoing hip replacement surgery
62574337|NCT03000998|EXPERIMENTAL|Web App Intervention Group|The BoyVac mobile web app will be evaluated in a pair-matched group-randomized pretest-posttest controlled design. In Year 2, 30 clinics in New Mexico will be pair-matched and one member of each pair will be randomized to the intervention (mobile web app) or a usual and customary (UC) HPV vaccine adoption procedures comparison group. Clinics will be paired based on similarities in patient demographic (ethnicity and % Medicaid patients) and location (urban and rural).
62574338|NCT03000998|ACTIVE_COMPARATOR|Usual Customary Care Group|Currently in pediatric clinics in New Mexico, the HPV vaccines are offered to parents and adolescents as part of annual well-child checkups. Typically for boys aged 11-13, parents initiate this checkup as part of a back-to-school activity. As part of the well-child checkup, clinic staff (physician, physician assistant and/or nurse) talk with parents and adolescents about the recommendation that their sons or daughters receive the HPV vaccination. Well-child pediatric visits to promote good health and development are recommended for all children from infancy through adolescence by the American Academy of Pediatrics.
62195906|NCT02952521||Epithelial ovarian cancer|"* Whole blood sample collection~* Up to 3 fresh tumor tissue core biopsies~* Tumor tissue sample taken from tumor tissue already removed from surgery (if surgery is planned)"
62574339|NCT00795002|EXPERIMENTAL|Arm I|Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 60-120 minutes on day 9.
62574340|NCT00795002|EXPERIMENTAL|Arm II|Patients receive alvocidib IV over 30 minutes followed by alvocidib IV over 4 hours on days 1-3. Patients also receive cytarabine and mitoxantrone hydrochloride as in arm I.
62009636|NCT04691466||KNEE_R|Patients undergoing knee replacement surgery
62009637|NCT01438190|EXPERIMENTAL|Experimental|Metformin plus step-down protocol
62009638|NCT01438190|ACTIVE_COMPARATOR|Control|Placebo and step-up protocol
62195907|NCT00532168|EXPERIMENTAL|1|tenofovir plus emtricitabine plus efavirenz
62195908|NCT00532168|EXPERIMENTAL|2|tenofovir plus emtricitabine plus lopinavir-ritonavir
62195909|NCT00532168|EXPERIMENTAL|3|tenofovir plus emtricitabine plus atazanavir-ritonavir
62195910|NCT02570659|NO_INTERVENTION|Information Folder|A folder with advise and exercises used by physiotherapeutic clinic of Södersjukhuset Hospital (Treatment as usual)
62195911|NCT02570659|EXPERIMENTAL|Information Video|A multiprofessional information video
62574341|NCT02420080||Cohort A|"The primary endpoint for subjects in Cohort A is time to progression of AdV disease through Week 24 post initial AdV diagnosis, with progression of AdV disease defined as time to the following outcomes:~Clinical progression to probable or definitive disseminated AdV disease Death"
62574342|NCT02420080||Cohort B|The primary endpoint for subjects in Cohort B is time to all-cause mortality through Week 36 post diagnosis of disseminated AdV disease
62574343|NCT03773250|EXPERIMENTAL|Behavioral Intervention|Children and families in the intervention group will received the FAMILY program developed according to evidence-based guidelines.The intervention content regarding healthy sleep will emphasize the importance of having a consistent sleep schedule, establishing a regular bedtime routine, and creating an environment only for sleeping. The physical activity content will emphasize at least 60 minutes/day of moderate-to-vigorous intensity physical activity, reduction of sedentary behavior, and screen time limited to 2 hours/day. The nutrition content will emphasis the replacement of sugar-sweetened beverages, increased fruit and vegetable as well as water intake, consumption of regular meals, and reduction of discretionary food groups.
62574344|NCT03773250|OTHER|Control|An active placebo control intervention was designed which did not apply evidence-based lifestyle recommendations effective in weight loss and focused on vegetable education.
62574345|NCT04399135|ACTIVE_COMPARATOR|Normal Patients|All patients admitted to Qassim dental clinics, who need root canal treatment would be screened for possible involvement in this study
62574346|NCT04399135|ACTIVE_COMPARATOR|Periodontitis Patients|All patients who need root canal treatment would be screened to determine the periodontal condition for possible involvement in this study. the periodontitis patients would be categorized according to the new periodontitis classification 2017 world workshop.
62574347|NCT05162417|NO_INTERVENTION|Control group|patient in this arm will receive scaling and root planning treatment only.
62574348|NCT05162417|EXPERIMENTAL|Test group (toluidine Blue O)|patients in this arm will receive Toluidine Blue O as an adjunctive to scaling and root planing.
62574349|NCT05162417|EXPERIMENTAL|Methylene blue|Patients will receive Methylene blue as adjunctive to scaling and root planning.
62574350|NCT03627663|EXPERIMENTAL|Intervention|Receiving treatment with Dialectic Behavior Therapy - Skills System + Treatment As Usual
62574351|NCT00053196|EXPERIMENTAL|Non myeloblative allogeneic transplant|Non myeloblative allogeneic hematopoietic cell transplantation after prior autologous transplantation
62574352|NCT03903991||Thoracotomy|All patients needing pulmonary surgery under thoracotomy
62399011|NCT00977600|ACTIVE_COMPARATOR|Ammonul|Ammonul® was supplied as single-use glass vials of 10% sodium phenylacetate and 10% sodium benzoate for intravenous injection. Ammonul® was diluted before use with sterile dextrose injection 10% to a concentration of 9 mg/ml. Once diluted it was kept at room temperature and used within 24 hours. The dose was 2.75 g/m2 and was administered as an intravenous infusion over a 120-minute period. Ammonul® was stored at 25°C, within a range of 15-30°C.
62399012|NCT00977600|ACTIVE_COMPARATOR|Buphenyl|Sodium phenylbutyrate or Buphenyl® was supplied as a white powder in 250 g bottles. The required amount of powder (equivalent to 3 g/m2 of PBA) was weighed out, mixed in 100 ml of water, and administered orally. Doses were calculated on a weight/volume basis and corrected for sodium content and purity. Buphenyl® was stored at ambient temperature.
62399013|NCT06723054|PLACEBO_COMPARATOR|Control group (CG)|Regular fluoride 220 ppm F mouthwash without erythritol
62574353|NCT02436096|EXPERIMENTAL|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8mg Tablet taken sublingually each day at bedtime for 12 weeks
62574354|NCT02436096|PLACEBO_COMPARATOR|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks
62574355|NCT03324386|EXPERIMENTAL|Individual Orientation|This was a prospective randomized clinical study conducted with the following 4 groups of hypertensive patients: Experimental: individual orientation: receiving individual orientation required by an embracement strategy characterized by 7 nursing visits at 20-day intervals, for 4 months);The ntervention is composed by relational strategies characterized by interpersonal relationships
62574356|NCT03324386|EXPERIMENTAL|VLE for Distance Learning|This was a prospective randomized clinical study conducted with the following 4 groups of hypertensive patients:Experimental: a technological education strategy for distance learning (DL), using a technological education strategy (E-Care of Hypertension) for Distance Learning (DL) characterized by 7 nursing visits at 20-day intervals, for 4 months). The intervention is composed by the use of equipment-oriented techniques or audio-visual aids in educational environments remotely accessed for health education specifically for hypertensive patients
62783168|NCT05091125||Patients over 65 years old who have undergone a mild head trauma.|
62783169|NCT04145986||young ladies|Young ladies≤ 35 years old.
62783170|NCT02868684||mild traumatic brain injury|
62783171|NCT02868684||Healthy controls|
62783172|NCT03078855|EXPERIMENTAL|Vitamin D plus rituximab|Rituximab was administered weekly x 4 (intravenous 375 mg/m\^2 or subcutaneous equivalent) per institutional standards and vitamin D3, 2000 IU orally once daily. Participants took vitamin D3 until lack of response at week 13, disease progression, or initiation of a new treatment.
62195912|NCT02980276|ACTIVE_COMPARATOR|Treatment|Participants randomised to the treatment arm will receive active metformin in addition to standard care. Metformin tablets will be titrated according to a dosing schedule to achieve the pre-specified glucose targets. Tablets will be in 500mg doses and will commence at 1 tablet per day (500mg) increasing to a maximum of 5 tablets per day (2500mg).
62195913|NCT02980276|PLACEBO_COMPARATOR|Control|Participants randomised to the placebo arm will receive placebo in addition to standard care. Placebo will be titrated according to the dosing schedule to achieve the pre-specified glucose targets. Placebo tablets will commence at 1 tablet per day and will be increased to a maximum of 5 tablets per day over 10 days as with the treatment group.
62574357|NCT03324386|EXPERIMENTAL|E-blended Learning|This was a prospective randomized clinical study with the patient received experimental intervention: a technological education strategy with E-blended Learning modality with E-Care of Hypertension, associated with face-to-face consultation with the health professional and making 7 nursing visits at 20-day intervals, for 4 months. The intervention is composed by the use of equipment-oriented techniques or audio-visual aids in presential educational environments intended for health education specifically for hypertensive patients
62574358|NCT03324386|NO_INTERVENTION|No intervention|No type of intervention was performed making 2 nursing visits at baseline and 1 after 120 days (No intervention)
62195914|NCT02039076|EXPERIMENTAL|avatrombopag|Each subject will receive a single administration during each of the 5 treatment periods as follows: 40 and 60 mg in the fed and fasted state, and 20 mg in the fed state. Subjects will be randomized to one of four dosing sequences.
62195915|NCT01762969|EXPERIMENTAL|Modified by molecular response|Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
62195916|NCT03498703|EXPERIMENTAL|Azathioprine|
62574359|NCT04925882|EXPERIMENTAL|Block|"The Block group will be made up of patients who will benefit from an injection of levopubivacaïne for the realization of the erector spinae plane block."
62009639|NCT05581368||Chronic Cannabis Cohort|"For investigations on the effects of cannabis on the cardiovascular system, the investigators would like to recruit 50 participants with the following inclusion criteria:~* age: 19 to 80~* males and females~* all ethnicities~* cannabis use at least 3-4 times per week or more in the past 6 months (50 volunteers, experimental group)~* no history of cardiovascular disease~For investigations on the effects of cannabis on the cardiovascular system, the investigators will exclude cannabis users:~* that ingest cannabis containing cannabidiol (CBD)~* that are unable to provide a receipt for the cannabis product(s) they ingest~* that are unwilling to stop consuming soy products and/or genistein 48 hours prior to appointments."
62009640|NCT05581368||Control Cohort|"For investigations on the effects of cannabis on the cardiovascular system, the investigators would like to recruit 50 participants with the following inclusion criteria:~* age: 19 to 80~* males and females~* all ethnicities~* patients who do not use cannabis~* no history of cardiovascular disease~For investigations on the effects of cannabis on the cardiovascular system, the investigators will exclude participants:~* that ingest cannabis~* that are unwilling to stop consuming soy products and/or genistein 48 hours prior to appointments."
62009641|NCT03508089|OTHER|Control Arm|
62009642|NCT03508089|ACTIVE_COMPARATOR|Multiple Sclerosis Arm|
62009643|NCT03841643|ACTIVE_COMPARATOR|C group|In the C group, the cranial bone defect will be reconstructed with HydrosetTM (Stryker, New Jersey, USA), calcium phosphate cement, according to the current standard practice at the department.
62009644|NCT03841643|EXPERIMENTAL|P group|In the P group, the cranial bone defect will be reconstructed with a patient-specific implant (KLS Martin, Tuttlingen, Germany).
62574360|NCT04925882|PLACEBO_COMPARATOR|Placebo|"The Placebo group corresponds to the reference group, that is to say that it will consist of patients who benefit from an injection of physiological serum for the realization of the erector spinae plane block."
62009645|NCT05060419|EXPERIMENTAL|Meropenem-FL058 (180min infusion)|
62009646|NCT05060419|ACTIVE_COMPARATOR|Piperacillin-Tazobactan (30min infusion)|
62009647|NCT04740606||Treatment Group|The patients whose chest CT images show that the pulmonary nodules are highly suspected of malignant and scheduled to be diagnosed by bronchoscopy under the guidance of the Augmented Reality Navigation System.
62574361|NCT05443880|EXPERIMENTAL|Exercise|The exercise intervention will undergo a exercise program 2 days / week (45 minutes per session) during a period of 8 weeks.
62574362|NCT05443880|EXPERIMENTAL|Exercise + mindfulness|The exercise + mindfulness intervention will carry out a an exercise intervention together with mindfulness intervention 1 day / week (2.5 hour per session).
62009648|NCT04286594|EXPERIMENTAL|CBD|0.5ml of sublingual CBD solution (30mg/ml) administered twice daily for six weeks.
62009649|NCT01744444|EXPERIMENTAL|Memantine first|
62195917|NCT03498703|PLACEBO_COMPARATOR|Control|
62195918|NCT06520150|ACTIVE_COMPARATOR|Group I (PSP+SSAP)|Group I will include patients undergoing PSP(Pectoserratus plane block)+SSAP(Superficial serratus anterior plane block) (20+40ml) The solution is defined as a combination of 0.125% ropivacaine solution with 0.25% lidocaine solution in a total volume of 60ml of liquid administered.
62399014|NCT06723054|ACTIVE_COMPARATOR|Intervention group #1 (IG1)|220 ppm F mouthwash with erythritol
62399015|NCT06723054|ACTIVE_COMPARATOR|Intervention group #2 (IG2)|500 ppm F mouthwash with erythritol
62574363|NCT05443880|OTHER|Control|The control group will be provided with the usual care received in the Physical Medicine and Rehabilitation Service: stretching, breathing and motor control exercises 2 days / week (45 minutes per session) during a period of 8 weeks
62009650|NCT01744444|EXPERIMENTAL|Gabapentin first|
62009651|NCT02692833||AKI Patients|Patients who develop acute kidney injury within the first 5 days following their cardiac surgical operation.
62399016|NCT02185820|EXPERIMENTAL|1|"Treatment schedule for 8 cycles of induction:~Carfilzomib = 20 mg/m2 IV once daily on days 1 of cycle 1 only followed by 27/36/45/56 mg/m2 days 8, 15 in cycle 1, then for all subsequent doses 27/36/45/56 mg/m2 IV once daily on days 1, 8, 15 followed by 13-day rest period (day 16 through 28).~Pomalidomide = 4 mg daily on days 1 - 21 every 28 days. Dexamethasone = 20 mg on days 1, 8, 15, 22 every 28 days.~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib = at the MTD achieved in the phase I of the study on days 1, 8, 15 in 28-days cycles.~Pomalidomide = 4 mg daily on days 1 - 21 every 28 days. Dexamethasone = 20 mg on days 1, 8, 15, 22."
62195919|NCT06520150|ACTIVE_COMPARATOR|Group I (SPIP+SSAP)|Group II will include patients undergoing SPIP(Superficial parastenal intercostal plane block)+SSAP(Superficial serratus anterior plane block) (20+40ml) The solution is defined as a combination of 0.125% ropivacaine solution with 0.25% lidocaine solution in a total volume of 60ml of liquid administered.
62195920|NCT00863759|ACTIVE_COMPARATOR|1|Patients will receive an aspheric intraocular lenses (IOL) Akreos AO in the right eye and an spheric IOL Akreos Fit in the left eye, during cataract surgery.
62195921|NCT00863759|ACTIVE_COMPARATOR|2|Patients will receive an spheric intraocular lens (IOL) Akreos Fit in the right eye and an aspheric IOL Akreos AO in the left eye, during cataract surgery.
62195922|NCT01328353|NO_INTERVENTION|control group|Control group arm follows usual care
62195923|NCT01328353|EXPERIMENTAL|Intervention group arm 1|Intervention group arm 1 receives aprn/telephone care coordination
62195924|NCT01328353|EXPERIMENTAL|Intervention group arm 2|Intervention group arm 2 receives aprn/telephone/video care coordination
62195925|NCT01817920|EXPERIMENTAL|integrated multidisciplinary fall prevention program|
62195926|NCT00953147|EXPERIMENTAL|Ciclesonide HFA 80 mcg once daily|Ciclesonide HFA nasal aerosol will be supplied in a 40 mcg canister, to be administered as 1 puff in each nostril (80 mcg per day).
62195927|NCT00953147|EXPERIMENTAL|Ciclesonide HFA 160 mcg once daily|Ciclesonide HFA nasal aerosol will be supplied in a 80 mcg canister, to be administered as 1 puff in each nostril (160 mcg per day).
62399017|NCT06315335|EXPERIMENTAL|Cohort 1 (Caucasian)|Study participants enrolled in this arm will receive either injections (sc) of the lowest dose level of UCB9741 or Placebo
62009652|NCT02692833||Non-AKI patients|Patients who do not develop acute kidney injury within the first 5 days following their cardiac surgical operation.
62009653|NCT06164873|PLACEBO_COMPARATOR|Placebo|
62009654|NCT06164873|EXPERIMENTAL|IBI362|
62195928|NCT00953147|PLACEBO_COMPARATOR|Placebo once daily|The placebo HFA nasal aerosol is identical to active drug, but does not contain ciclesonide.
62195929|NCT03455205|EXPERIMENTAL|shenqifuzheng injection|"Shenqifuzheng injection of 500 ml,intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment,The programme provides for chemotherapy regimens:~Colorectal cancer: CapeOX scheme - oxaliplatin + capecitabine Esophageal cancer: DP/TP programme - docetaxel/paclitaxel + cisplatin/carboplatin Gastric cancer: SOX scheme - oxaliplatin + tigio All test drugs should be covered with dark bags before infusion, and use a dark infusion to guarantee the implementation of the blind method."
62009655|NCT04313166|EXPERIMENTAL|Cu(II)ATSM|copper-containing synthetic small molecule
62195930|NCT03455205|PLACEBO_COMPARATOR|0.9% sodium chloride injection|0.9% sodium chloride injection of 500 ml,intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment,The programme provides for chemotherapy regimens: Colorectal cancer: CapeOX scheme - oxaliplatin + capecitabine Esophageal cancer: DP/TP programme - docetaxel/paclitaxel + cisplatin/carboplatin Gastric cancer: SOX scheme - oxaliplatin + tigio No interventions have been included in Arm Description for '0.9% sodium chloride injection'
62399018|NCT06315335|EXPERIMENTAL|Cohort 2 (Japanese)|Study participants enrolled in this arm will receive either subcutaneous (sc) injections of the lowest dose level of UCB9741 or Placebo
62195931|NCT01358331|EXPERIMENTAL|MK-8353 100 mg twice daily (BID)|100 mg capsules administered orally twice daily for 28 days for each cycle
62195932|NCT01358331|EXPERIMENTAL|MK-8353 200 mg BID|200 mg capsules administered orally twice daily for 28 days for each cycle
62195933|NCT01358331|EXPERIMENTAL|MK-6353 300 mg BID|300 mg capsules administered orally twice daily for 28 days for each cycle
62195934|NCT01358331|EXPERIMENTAL|MK-8353 350 mg BID|350 mg capsules administered orally twice daily for 28 days for each cycle
62195935|NCT01358331|EXPERIMENTAL|MK-8353 400 mg BID|400 mg capsules administered orally twice daily for 28 days for each cycle
62195936|NCT01358331|EXPERIMENTAL|MK-8353 800 mg BID|800 mg capsules administered orally twice daily for 28 days for each cycle
62195937|NCT00269321|EXPERIMENTAL|1|
62195938|NCT00269321|EXPERIMENTAL|2|
62399019|NCT06315335|EXPERIMENTAL|Cohort 3 (Caucasian)|Study participants enrolled in this arm will receive either subcutaneous (sc) injections of the highest dose level of UCB9741 or Placebo
62399020|NCT06315335|EXPERIMENTAL|Cohort 4 (Japanese)|Study participants enrolled in this arm will receive either subcutaneous (sc) injections of the highest dose level of UCB9741 or Placebo
62783173|NCT03078855|PLACEBO_COMPARATOR|Placebo plus rituximab|Rituximab was administered weekly x 4 (intravenous 375 mg/m\^2 or subcutaneous equivalent) per institutional standards and placebo orally once daily. Participants took placebo until lack of response at week 13, disease progression, or initiation of a new treatment.
62195939|NCT00269321|ACTIVE_COMPARATOR|3|
62009656|NCT05239624|EXPERIMENTAL|enfortumab vedotin in combination with pembrolizumab|Enfortumab vedotin will be administered at 1.25 mg/kg on day 1 and day 8 of each 21-day cycle, for up to 6 cycles. Patients can proceed to surgery prior to completion of cycle 6 at the discretion of the investigator and urologist if toxicities prevent completion of 6 cycles of treatment. Enfortumab vedotin will be capped at a maximum dose of 125 mg for each infusion (for patients who weigh \> 100 kg). Pembrolizumab will be administered on day 1 of each cycle, every 21 days, for 6 cycles. After completion of 3 cycles patients with have imaging assessment, and patients with progression of disease as measured by distant metastases will be removed from the study. At completion of cycle 6, patients will have repeat imaging assessment and proceed to cystectomy within 4-8 weeks. Following cystectomy, patients will resume pembrolizumab monotherapy on day 1 of each 21-day cycle for an additional 11 doses (Cycles 7-17), to complete 1 year of pembrolizumab therapy.
62195940|NCT01878396||Mutated Anti-B-RAF|Fourth stage Melanoma patients with both measurable and not measurable lesions undergoing treatment with selective B-RAF inhibitors.
62009657|NCT03572491|EXPERIMENTAL|Allantoic split inactivated seasonal influenza vaccine|A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NYMC X-275 (A/PR/8/34 (M, PB2, PA, NS, NP genes) и A/Michigan/45/2015 (PB1, HA, NA genes)), NYMC X-263В (A/PR/8/34 (PB1, PB2, PA, NS, NP, М genes) и A/Hong Kong/4801/2014 (HA, NA genes)), NYMC BX-35 (B/Lee/40 (NP gene), B/Panama/45/90 (PB2, М genes) и B/Brisbane/60/2008 (HA, NA PB1, PA, NS genes)).
62009658|NCT02538497|EXPERIMENTAL|NBO plus routine care|The Newborn Behavioral Observation
62195941|NCT04162002|EXPERIMENTAL|Restylane® Lyft Filler Injection|
62195942|NCT02986308||Intestinal Polyps|The patients who were diagnosed with Intestinal Polyps.
62195943|NCT02986308||Normal colonoscopy|People who were diagnosed by colonoscopy without intestinal polyps.
62195944|NCT01425177|EXPERIMENTAL|Normal saline irrigation|
62195945|NCT05974670||Wearing device|The subjects are required to fill in the COPD symptom diary every day, and conducted online or offline follow-up at the 4th, 8th, 12th, 16th, 20th, and 24th weeks after enrollment. The physiological parameters of wearable devices, including pulse rate, blood oxygen saturation, physical activity, electrocardiogram, and sleep, will be continuously collected during the study.
62195946|NCT00171912|EXPERIMENTAL|imatinib mesylate (STI571)|
62195947|NCT03747406|EXPERIMENTAL|ESP group|The patient rolled to his side, the level between T9 and T10 identified using ultrasound. An 8-14 MHz curved array probe (Siemens ACUSON X300 Ultrasound System) will be applied longitudinal orientation 3 cm lateral midline. The erector spinae and the psoas muscle will be identified. A skin wheal will be made using lidocaine 1% at each level and then a 22-gauge, 8 cm Tuohy needle (Perifix Epidural Needle) will be advanced inplane until contact with the transverse process. The needle will be withdrawn slightly and 30cc of bupivacaine 0.25 % (15ml for each side) will be injected slowly after negative aspiration confirmed. The same procedure will be repeated in the contralateral side.
62009659|NCT02538497|OTHER|Routine care|
62009660|NCT02061241||Patients|All included patients, having CRT implant procedure Will have both Pacing in vein at site of latest mechanical activation and Pacing in other suitable vein.
62574364|NCT04974996|EXPERIMENTAL|Part 1: Dose Escalation|Participants will receive escalating doses of loncastuximab tesirine (initial dose of 60 μg/kg and highest dose possibly tested of 150 µg/kg) in combination with R-CHOP (rituximab 375 mg/m\^2, cyclophosphamide 750 mg/m\^2, doxorubicin 50 mg/m\^2, vincristine 1.4 mg/m\^2, and prednisone 100 mg/day) according to a standard 3+3 dose escalation design. The dose escalation part will be completed once the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) has been identified.
62399021|NCT06315335|EXPERIMENTAL|Cohort 5 (Caucasian)|Study participants enrolled in this arm will receive either subcutaneous (sc) injections of the highest dose level of UCB9741 (using a different volume per injection than cohort 3) or Placebo
62574365|NCT04974996|EXPERIMENTAL|Part 2: Dose Expansion|Participants will receive the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of loncastuximab tesirine in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as determined in Part 1.
62574366|NCT02631122|ACTIVE_COMPARATOR|Supraclavicular BPNB|Patients in this group will be randomized to receive an Ultrasound Guided Supraclavicular Brachial Plexus Nerve Block and outcomes will be measured over the perioperative and 1day time period.
62574367|NCT02631122|ACTIVE_COMPARATOR|Retroclavicular BNPB|Patients in this group will be randomized to receive an Ultrasound Guided Retroclavicular Brachial Plexus Nerve Block and outcomes will be measured over the perioperative and 1day time period.
62009661|NCT05479175|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 600 mg will be given to the patient one hour before starting root canal treatment.
62195948|NCT03747406|EXPERIMENTAL|TAP group|The patient in supine position. Under complete aseptic conditions, a linear array transducer 5-12 MHz (Siemens ACUSON X300 Ultrasound System) will be positioned inferior and parallel to the costal margin in a medio-lateral orientation. The external oblique, internal oblique and transverse abdominis muscles will be identified immediately lateral to the linea semilunaris. A a 22-gauge, 8 cm Tuohy needle (Perifix Epidural Needle) will be advanced medially and in-plane to the US beam until the tip lies between the fascia of the internal oblique muscle and the transverse abdominis muscle layers. 30 ml of 0.25 % bupivacaine will be injected in each side and the spread will be observed between the two muscles layers.
62195949|NCT03747406|NO_INTERVENTION|opioid group|will receive intravenous morphine with general anesthesia and total opioid consumption will be calculated
62399022|NCT05869188|ACTIVE_COMPARATOR|Pateints with Moderate Acne|20 patients affected by Acne and More than half of the face is involved. Many papules and pustules, many open or closed comedones. One nodule may be present.
62574368|NCT05143346|OTHER|Group A|Group A will include 33 patients and will be intubated by the use of video stylet.
62574369|NCT05143346|OTHER|Group B|Group B will include 33 patients and will intubated by the use of video laryngoscope
62574370|NCT00730860|EXPERIMENTAL|RFA+TACE|treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
62574371|NCT00730860|ACTIVE_COMPARATOR|RFA only|treatment of hepatocellular carcinoma by radiofrequency ablation only
62783174|NCT00713895|ACTIVE_COMPARATOR|Standard Self-Help|receive a standard self-help manual in Chinese and English of the participants' choice at baseline
62009662|NCT05479175|ACTIVE_COMPARATOR|Diode laser|Low-level laser therapy will be applied with an 810 nm wavelength diode laser device for 30 seconds in the area of mesial root and 30 seconds in the area of distal root , total of 60 seconds.
62009663|NCT05479175|ACTIVE_COMPARATOR|Nonactive Diode laser|Placebo, will be explained to the patients that laser treatment will be applied as in group 2, but laser will not be activated.
62195950|NCT02875197||Healthy Controls|"Males and females 18-50 years old~Up to 20 able-bodied sex, age, height, and weight-matched subjects"
62574372|NCT06577350||Axial Spondyloarthritis (AxSpA)|Participants with Axial Spondyloarthritis (AxSpA)
62009664|NCT05479175|NO_INTERVENTION|Control|Control, routine root canal treatment will be done. No medication or laser will be applied before the treatment procedure.
62574373|NCT02504827|EXPERIMENTAL|IV Ceftazidime/Avibactam|Ceftazidime/avibactam 2.5gm IV q8h for 3 doses
62783175|NCT00713895|EXPERIMENTAL|Expert System|receive an expert system intervention that included the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
62783176|NCT06583889|ACTIVE_COMPARATOR|Standard medical care|
62783177|NCT06583889|EXPERIMENTAL|Endovascular treatment with standard medical care|
62783178|NCT01192568|EXPERIMENTAL|DB: OTG (Pre-Amend 3)|"Double-Blind Oxybutynin Chloride topical gel (OTG) (Pre-Amendment 3) Oxybutynin Chloride topical gel (OTG), 0.5 g, 0.75 g (starting dose), or 1 g sachets, applied transdermally once daily for 6 weeks.~Followed by OL OTG for 8 weeks."
62783179|NCT01192568|EXPERIMENTAL|OL: OTG (Post-Amend 3)|Open-Label Oxybutynin Chloride topical gel (OTG) (Pre \& Post-Amendment 3) Oxybutynin Chloride topical gel (OTG), 0.5 g, 0.75 g (starting dose for Pre- and Post-Amendment 3), or 1 g sachets, applied transdermally once daily for 14 weeks.
62195951|NCT02875197||Lower Extremity Amputees|"Males \& females 18-50 years old~* Must have a unilateral, transtibial amputation \& must have been prescribed a running-specific prosthesis~* Subject with amputations resulting from trauma, congenital reasons, or cancer treatment unless cancer is in remission or treatments do not impact gait function~* Physician approval to run~* 4 months experience using a running-specific prosthesis"
62195952|NCT01898377|EXPERIMENTAL|Imatinib mesylate, Mycophenolate mofetil|"MMF 15-20mg/kg (Max 1 g) bid + Imatinib mesylate qd~* Dose of imatinib : starting dose 260 mg/m2/d (Max. 400 mg)~* Imatinib dose adjustment : Dose is adjusted according to the guidelines if there is serious adverse event, toxicity, or intolerance."
62399023|NCT05869188|ACTIVE_COMPARATOR|Pateints with Severe Acne|20 patients affected by Acne and Entire face is involved, covered with many papules and pustules, open or closed comedones and rare nodules
62574374|NCT06503484|EXPERIMENTAL|BCI training|Patients will be instructed to perform kinesthetic motor imagery of the affected upper extremity in response to a visual cue given by the BCI system. The patients will be instructed to do motor imagery. The level of oxygenated hemoglobin (HbO) will be extracted from the ipsilesional motor cortex as the signal intensity. The signal intensity will be quantified as the percent signal change relative to the baseline. Once the signal intensity reaches the predefined individual threshold, patients will receive neurofeedback in the form of visual feedback, presented in a digital mirror therapy system. The visual feedback guides the patients to perform observational imitation using the affected upper limb. The training will last for around 75-90 minutes per session.
62783180|NCT01192568|PLACEBO_COMPARATOR|DB: Placebo (Pre-Amend 3)|Double-Blind Placebo (Pre-Amendment 3) Placebo Gel sachets applied transdermally once daily for 6 weeks. Followed by OL OTG for 8 weeks.
62783181|NCT06524817|ACTIVE_COMPARATOR|Transcranial Magnetic Stimulation-Real 1|Participants will receive active real 1 TMS once daily for two weeks
62783182|NCT06524817|ACTIVE_COMPARATOR|Transcranial Magnetic Stimulation-Real 2|Participants will receive active real 2 TMS once daily for two weeks
62009665|NCT00315094|EXPERIMENTAL|1|
62195953|NCT05614440|ACTIVE_COMPARATOR|Only local anesthetic group|
62195954|NCT05614440|EXPERIMENTAL|Tramadol group|
62399024|NCT05869188|ACTIVE_COMPARATOR|control|20 Health participants
62009666|NCT00315094|NO_INTERVENTION|2|After a control period, this group crosses over to experimental interventions (Arm 1)
62195955|NCT02723227|EXPERIMENTAL|Financial Coaching & Social Service Referral|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
62195956|NCT02723227|ACTIVE_COMPARATOR|Social Services Referral|Enrollment provides for access to referrals to social services.
62399025|NCT06467877||Retrospective Chart Review|Group includes patient with hypercalcemia ≥2.65 mmol/l, who reported to the emergency room of a tertiary hospital
62574375|NCT06503484|SHAM_COMPARATOR|Sham BCI training|In the sham group, patients will wear identical equipment to the BCI group. However, the visual feedback presented in the digital mirror therapy system will be given based on the brain activity of another participant in the BCI group, i.e., yoked sham neurofeedback. Like the BCI group, patients will be instructed to use kinesthetic motor imagery and imitate the movement when receiving visual feedback. The sham training will also last for around 75-90 minutes per session.
62574376|NCT04988880|EXPERIMENTAL|Relapsing multiple sclerosis group|Multiple sclerosis relapsing groups: each unit will provide a group of participant with relapsing multiple sclerosis
62195957|NCT01523600|EXPERIMENTAL|Whole body vibration training|
62399026|NCT02977052|EXPERIMENTAL|Arm A: 2 courses ipi 3 + nivo 1|Patients receive 2 courses standard combination of ipilimumab 3 mg/kg + nivolumab 1 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
62574377|NCT04988880|EXPERIMENTAL|Progressive multiple sclerosis group|Multiple sclerosis progressive groups: each unit will provide a group of participants with progressive multiple sclerosis
62574378|NCT06198491|EXPERIMENTAL|Training for HPV misbeliefs 1|Participants will receive misbeliefs about HPV; training where misbeliefs are mentioned before the current information.
62574379|NCT06198491|EXPERIMENTAL|Training for HPV misbeliefs 2|Participants will receive misbeliefs about HPV; training where misbeliefs are mentioned after the current information.
62574380|NCT04398589|EXPERIMENTAL|SSNB and ANB c DEX|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml (50 μg) of dexmedetomidine each for SSNB and ANB.
62574381|NCT04398589|PLACEBO_COMPARATOR|SSNB and ANB c saline|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml normal saline each for SSNB and ANB.
62783183|NCT02464410|EXPERIMENTAL|Motivational Intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT) and uses the structure of ME brief interventions. The motivational session is overlaid on the VA long-term opioid therapy informed consent process.
61978028|NCT06494943|EXPERIMENTAL|Dose escalation phase|"The first phase is the dose-escalation stage, where fixed doses of IBI110 and sintilimab will be administered, and the doses of paclitaxel and cisplatin will be escalated to determine the R2PD (Recommended Phase 2 Dose). This phase is divided into three dose groups: paclitaxel 135 mg/m² on day 2 and cisplatin 20 mg/m² on days 2-4; paclitaxel 150 mg/m² on day 2 and cisplatin 20 mg/m² on days 2-4; paclitaxel 175 mg/m² on day 2 and cisplatin 25 mg/m² on days 2-4. The accelerated dose-escalation method will be used.~A total of two cycles of neoadjuvant therapy will be given. All subjects will undergo radical surgery after neoadjuvant therapy. Adjuvant radiotherapy (chemoradiotherapy) will be administered postoperatively based on pathological factors as appropriate."
62009667|NCT02661828|ACTIVE_COMPARATOR|Taper A Regimen|Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a Two-Week Taper Regimen to discontinue their medication.
62009668|NCT02661828|ACTIVE_COMPARATOR|Taper B Regimen|Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a One-Week Taper Regimen to discontinue their medication.
62009669|NCT00951210|EXPERIMENTAL|PLX-PAD low dose|IM injection Single treatment; multiple injections
62195958|NCT01523600|ACTIVE_COMPARATOR|Wellness group|
62195959|NCT00414167|EXPERIMENTAL|1|Bupropion
62195960|NCT00414167|PLACEBO_COMPARATOR|2|Placebo
62195961|NCT03344211|EXPERIMENTAL|Arm I (enzalutamide, radium 223)|Patients receive enzalutamide PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive radium Ra 223 dichloride IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62195962|NCT03344211|EXPERIMENTAL|Arm II (enzalutamide)|Patients receive enzalutamide as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62195963|NCT00967083||family caregivers of lung cancer patients|In this 2-year pilot study, we plan to screen family caregivers of lung cancer patients within 4 to 6 weeks after the a new visit to the thoracic clinic. We will screen spouses, adult children, and other family members using the HAD-18 to determine their level of anxiety and depressive symptoms at enrollment.
62399027|NCT02977052|EXPERIMENTAL|Arm B: 2 courses ipi 1 + nivo 3|Patients receive 2 courses ipilimumab 1 mg/kg + nivolumab 3 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
62399028|NCT02977052|EXPERIMENTAL|Arm C: 2 courses ipi 3 + 2 courses nivo 3|Patients receive 2 courses of ipilimumab 3 mg/kg q3wks, directly followed (\> 2 hours and \< 24 hours) by 2 courses nivolumab 3 mg/kg every 2 weeks prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
62399029|NCT02977052|EXPERIMENTAL|PRADO extension cohort|"Patients will be treated with 2 courses ipilimumab and nivolumab at the dose level defined as the winner dosing scheme from OpACIN-neo, which is the dosing schedule of arm B.~Surgery and adjuvant therapy~* Patients achieving a pCR or pnCR will not undergo CLND and will not receive any adjuvant treatment. Structural follow-up will be perfomed every 12 weeks by CT, ultrasound of regional lymph nodes.~* Patients achieving a pPR will undergo CLND and start structural follow-up (including CT and physical examination) every 12 weeks thereafter without any adjuvant treatment.~* Patients achieving no response (pNR) will undergo CLND and start at week 12 with adjuvant nivolumab 480mg q4wks for 52 weeks + radiotherapy (according to patient's and physicians' decision). In patients that are BRAF V600E/K mutation positive, adjuvant BRAF+MEK"
62574382|NCT06237738|EXPERIMENTAL|Stress Ball Intervention|Participants in this group were provided with stress balls to use during their hemodialysis sessions, specifically before the cannulation process. These stress balls, made from medium-firm, high-quality silicone, were utilized by squeezing with the hand opposite the one receiving cannulation. This activity, performed three minutes before the cannulation, aimed to reduce the levels of pain experienced by the participants. The use of stress balls was integrated into the regular hemodialysis routine, and participants consistently engaged in this practice before each cannulation over the course of the study. This intervention provided valuable insights into the effectiveness of simple, non-pharmacological methods for pain management in a clinical setting.
62574383|NCT06237738|NO_INTERVENTION|Standard Care Control|Participants in the control group did not receive any additional intervention. They continued to receive standard care during their hemodialysis sessions, without the use of any extra tools like stress balls for pain management. This group served as a comparison point to assess the effectiveness of the intervention implemented in the experimental group. By maintaining their routine hemodialysis care, the control group provided essential data for evaluating the impact of the stress ball intervention. The completion of their participation in the study was crucial in establishing a baseline for pain levels during cannulation without any non-pharmacological interventions.
62574384|NCT05646264|NO_INTERVENTION|Monotherapy group|Single use of second-generation antipsychotic drugs (including olanzapine, risperidone, aripiprazole, etc.)
62574385|NCT05646264|EXPERIMENTAL|Joint group|second-generation antipsychotic drugs (including olanzapine, risperidone, aripiprazole, etc.) Add Agomelatine
62574386|NCT04846283||Biomarker-group|We considered for the study all patients aged \>16 y undergoing elective or emergency colorectal surgery for cancer, diverticular disease, inflammatory bowel-disease or reversal of Hartmann's procedure. Both patients undergoing open and minimally invasive surgery were considered eligible.
62574387|NCT02092545|OTHER|Ketogenic diet|Weight management on a male population of retired NFL athletes.
62574388|NCT03315975|EXPERIMENTAL|Influenza vaccination cohort|Subjects will receive one dose of seasonal quadrivalent inactivated influenza vaccine intramuscularly for standard of care for prevention of influenza infection.
62574389|NCT05225610|EXPERIMENTAL|VALSALVA Group|40 Patients will perform the Valsalva manoeuvre before starting propofol injection by blowing into rubber tubing connected to a sphygmomanometer and raising the mercury column to 30 mmHg for at least 20 seconds and 5 ml saline will be administered in 5 seconds.
62574390|NCT05225610|EXPERIMENTAL|DEXMED Group|40 patients will receive the tube between the lips, however, the manoeuvre will not be performed in this group, patients will receive 0.5 µg/kg Dexmedetomidine diluted in 5 ml saline in 5 seconds as a sedating dose prior to injection of propofol.
62574391|NCT05225610|PLACEBO_COMPARATOR|CONTROL Group|40 patients will receive the tube between the lips, however, the manoeuvre will not be performed in this group and only 5 ml saline will be administered over 5 seconds.
62574392|NCT02964520|EXPERIMENTAL|A/T Neurofeedback training|10 sessions of uptraining alpha (8-11 Hz) and theta (5-7.5 Hz) frequency bands, inhibiting beta (15-30 Hz) and delta (2-4 Hz)
62574393|NCT02964520|SHAM_COMPARATOR|Sham neurofeedback training|"5 sessions of (sessions 1,3,5,7,9) up-training lobeta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz).~5 sessions of (sessions 2,4,6,8,10) down-training beta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz)"
62574394|NCT02196441|EXPERIMENTAL|Group 2|0.5% bupivacaine Deep topical fornix nerve block anaesthesia (DTFNB)
62574395|NCT02196441|EXPERIMENTAL|Group 1|2% tetracaine local anaesthetic drops
62195964|NCT03603639|EXPERIMENTAL|Placebo, E2730 40 mg, E2730 120 mg|Participants will receive a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 1 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 2 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
62009670|NCT00951210|EXPERIMENTAL|PLX-PAD high dose|IM injection Double treatment; multiple injections
62009671|NCT01905982|EXPERIMENTAL|Conventional breathing therapy|first: conventional breathing therapy, second: reflectory breathing therapy
62195965|NCT03603639|EXPERIMENTAL|E2730 40 mg, E2730 120 mg, Placebo|Participants will receive a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 1 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 2 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
62009672|NCT01905982|EXPERIMENTAL|Reflectory breathing therapy|first: Reflectory breathing therapy second:Conventional breathing therapy
62009673|NCT04698005|EXPERIMENTAL|Supplementation of exogenous ketones|Exogeneous ketones will be administered orally using monoester 3-OHB concentrate without added salts (25g 3-OHB in 65ml H.V.M.N Ketone Ester, H.V.M.N, USA or equivalent). The drink will be administered over 10 mins every 3 hours, 3 times in a row.
62009674|NCT04698005|PLACEBO_COMPARATOR|Control group|The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)
62574396|NCT04279470||Adverse Events with cellular therapies|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Chimeric Antigen Receptor T-cell and Cellular Therapies, with a chronology compatible with the drug toxicity
62009675|NCT02536859|EXPERIMENTAL|IDeg|
62009676|NCT02536859|ACTIVE_COMPARATOR|IGlar U300|
62009677|NCT00507039||grass allergy, bronchial challenge|subjects with known allergy against grass-pollen undergo bronchial challenges
62009678|NCT03481946|EXPERIMENTAL|BAY1093884 in subjects with Hemophilia|Single dose of BAY1093884 over 30 minutes administered in subjects with severe congenital Hemophilia A or B, with inhibitors or without inhibitors
62009679|NCT05491629||surgical team members|The aim of this study is to determine with a deep understanding the perceptions of the operating room nurses' competence and the surgical team's views on the competence of nurses and the factors affecting them. In the research, parallel data type in convergent parallel mixed design (convergent parallel) was used to obtain rigorous, valid and reliable data with survey questions and individual interviews. In the quantitative dimension of the study, it was aimed to determine the perceptions of the operating room nurses about their competencies, and in the qualitative aspect, the thoughts/opinions of the entire surgical team about the competency of the operating room nurses and the factors affecting them.
62009680|NCT02198547|EXPERIMENTAL|Ropivacaine Magnesium sulfate|"Locoregional anesthesia for valgus allux correction with ropivacaine 7,5 mg/ml and Mg 4 mg/Kg.~Sciatic block at popliteal level."
62574397|NCT02941211|EXPERIMENTAL|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
62574398|NCT03806933|EXPERIMENTAL|NT 201 Dose group 1|Stage 1 and 2. Intramuscular injection into the glabellar area.
62574399|NCT03806933|EXPERIMENTAL|NT 201 Dose group 2|Stage 1. Intramuscular injection into the glabellar area.
62009681|NCT02198547|ACTIVE_COMPARATOR|Ropivacaine|Patients undergoing allux valgus correction with locoregional anesthesia with ropivacaine 7,5 mg/ml, without MG
62009682|NCT01922310|OTHER|Communication intervention|This study uses a single arm design with current 'controls' to explore an intervention, the procedure for providing information and requesting consent for donation, that uses new agreed best practice procedures led by specially trained intensive care health professionals. The study intervention is a staff education and training module intended to provide a framework and preparation for select critical care staff to conduct organ donation discussions in line with best practice.
62009683|NCT05785052||Renal-mass patients|Patients diagnosed with a first episode of renal mass attending the urology department.
62009684|NCT05785052||Control subjects|Patients affected by urological functional diseases or living kidney donor.
62195966|NCT03603639|EXPERIMENTAL|E2730 120 mg, Placebo, E2730 40 mg|Participants will receive a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 1 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 2 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
62574400|NCT03806933|EXPERIMENTAL|NT 201 Dose group 3|Stage 1. Intramuscular injection into the glabellar area.
62574401|NCT03806933|EXPERIMENTAL|NT 201 Dose group 4|Stage 2. Intramuscular injection into the glabellar area.
62574402|NCT03806933|EXPERIMENTAL|NT 201 Dose group 5|Open Label Extension Period. Intramuscular injection into the glabellar area.
62009685|NCT05204953||1|patients diagnosed to have myelodysplastic syndrome
62009686|NCT05204953||2|healthy control subjects
62009687|NCT01260987|ACTIVE_COMPARATOR|AK split-face treatment|Split-face treatment of two symmetrical areas with moderate to severe actinic keratoses. One area is treated with conventional PDT the other with fractional laser assisted PDT.
62009688|NCT01260987|ACTIVE_COMPARATOR|Fractional laser assisted PDT for BCC|Difficult to treat nodular basal cell carcinomas in the face is pretreated with fractional CO2 laser followed by methyl-aminolevulinate PDT.
62009689|NCT01260987|ACTIVE_COMPARATOR|Konventional PDT for BCC|Difficult to treat nodular basal cell carcinomas in the face is treated with methyl-aminolevulinate PDT.
62009690|NCT05060224|EXPERIMENTAL|Low Level Laser|EasyLaser: Low Level Laser 808 nm and 500 mW. The first four treatments where planned as two treatments per week. The remaining six treatments where planned as once a week.
62009691|NCT03056703|EXPERIMENTAL|Acetylsalicylic acid [1000mg]|
62009692|NCT03056703|ACTIVE_COMPARATOR|Acetylsalicylic acid [500mg]|
62574403|NCT00980239|EXPERIMENTAL|Group 1|Group 1 = Irinotecan + Bevacizumab
62574404|NCT00980239|EXPERIMENTAL|Group 2|Group 2 = Irinotecan, Bevacizumab + Oxaliplatin
62574405|NCT00980239|EXPERIMENTAL|Group 3|Group 3 = Irinotecan, Bevacizumab + Cetuximab
62574406|NCT06471205|EXPERIMENTAL|BL-B01D1+PD-1 Monoclonal Antibody|Participants receive BL-B01D1+PD-1 Monoclonal Antibody as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62195967|NCT03603639|EXPERIMENTAL|Placebo, E2730 120 mg, E2730 40 mg|Participants will receive a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 1 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 2 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
62574407|NCT04090879|EXPERIMENTAL|RC 1 only|Research Cigarettes #1
62574408|NCT04090879|EXPERIMENTAL|RC 2 only|Research Cigarettes #2
62574409|NCT04090879|EXPERIMENTAL|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)
62574410|NCT04090879|EXPERIMENTAL|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)
62574411|NCT03422068|EXPERIMENTAL|BI 1015550|
62574412|NCT03422068|PLACEBO_COMPARATOR|Placebo|
62574413|NCT06326554|EXPERIMENTAL|STEP2|Moderate-to-severe symptoms on the Edmonton Symptom Assessment System-revised (ESAS-r+) tool will trigger an email to the study team and the study triage nurse. The study triage nurse will review the scores via electronic medical record and call the patient within 2 business days to offer immediate advice by phone. During the phone call, the study triage nurse will offer to schedule a formal in-person or virtual palliative care clinic (PCC) visit. Participants agreeing to the PCC referral subsequently receive at least monthly in-person and/or virtual PCC follow-up visits until study end, based on patient needs and care provider preference.
62574414|NCT01417741|NO_INTERVENTION|Standard Therapy Only|Patients will not receive acupuncture. Standard anti-emetic therapy will be given.
62574415|NCT01417741|EXPERIMENTAL|Acupuncture Plus Standard Therapy|Bilateral P6 acupuncture applied after anesthesia induction and removed at the termination of the surgery. Patients will also receive standard anti-emetic therapy.
62574416|NCT01156961|EXPERIMENTAL|Single Arm|
62574417|NCT01041157|EXPERIMENTAL|1|resistance training
62574418|NCT06051266|EXPERIMENTAL|Dynamic navigation|
62574419|NCT06051266|ACTIVE_COMPARATOR|Static template|
62574420|NCT03948412|EXPERIMENTAL|Closed Incision Negative Pressure Wound Therapy (Prevena)|Patients are randomised intra-operatively to either Prevena or standard dressings as long as inclusion criteria are met, and no exclusion criteria met. This is left in-situ for 7 days, unless clinically indicated.
62574421|NCT03948412|ACTIVE_COMPARATOR|Standard Dressings|Patients are randomised intra-operatively to either Prevena or standard dressings as long as inclusion criteria are met, and no exclusion criteria met. Standard care wound dressings are applied for patients in this arm. These are changed as clinically appropriate whilst in hospital.
62574422|NCT06575023|ACTIVE_COMPARATOR|tamponade of lower uterine segmentin managment of placenta accreta spectrum cases|usage of tamponade of the lower uterine segment in managment of placnta accreta spectrum cases
62574423|NCT06575023|ACTIVE_COMPARATOR|partial myometrial resection of lower uterine segment in management of placenta accreta spectrum|partial resection of lower uterine segment myometrium
62574424|NCT03465059|EXPERIMENTAL|Normal Hepatic Function|Participants with normal hepatic function will be administered a single oral dose of Zanubrutinib (80 mg).
62574425|NCT03465059|EXPERIMENTAL|Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
62009693|NCT06028022|EXPERIMENTAL|Arm I (Reishi mushroom extract, placebo)|Patients receive Reishi mushroom extract PO TID on days 1-28 for weeks 1-4 and then placebo PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity.
62009694|NCT06028022|EXPERIMENTAL|Arm II (placebo, Reishi mushroom extract)|Patients receive placebo PO TID on days 1-28 for weeks 1-4 and Reishi mushroom extract PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity.
62009695|NCT04027686|EXPERIMENTAL|SRP + Adjunctive Laser Therapy|Laser therapy used as an adjunct to scaling and root planing
62009696|NCT04027686|ACTIVE_COMPARATOR|SRP alone|Scaling and root planing used as conventional non-surgical periodontal therapy
62574426|NCT03465059|EXPERIMENTAL|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
62574427|NCT03465059|EXPERIMENTAL|Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
62009697|NCT01595620|ACTIVE_COMPARATOR|THC 0.01 mg/kg|
62009698|NCT01595620|PLACEBO_COMPARATOR|Placebo|
62009699|NCT01595620|ACTIVE_COMPARATOR|THC 0.03 mg/kg|
62009700|NCT05879146|EXPERIMENTAL|nirogacestat|Participants will take nirogacestat by mouth every day of each 28-day study cycle. Based on when you enroll in this study, you will take nirogacestat either 1 time a day at about the same time each day OR 2 times a day, about 12 hours apart.
62195968|NCT03603639|EXPERIMENTAL|E2730 40 mg, Placebo, E2730 120 mg|Participants will receive a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 1 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 2 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
62574428|NCT04808323|EXPERIMENTAL|Cohort A|Radiation dose: 64 Gy over 32 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to total dose of 64 Gy over 32 total fractions.
62009701|NCT04016324|OTHER|Basic evaluation|Subjects with overactive bladder will go through InterStim basic evaluation with the commercially approved foramen needle and basic evaluation kit.
62195969|NCT03603639|EXPERIMENTAL|E2730 120 mg, E2730 40 mg, Placebo|Participants will receive a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 1 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 2 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
62195970|NCT03910322|PLACEBO_COMPARATOR|Placebo|Placebo arm. Similar trial product, but without Bif195 bacteria
62009702|NCT04376645|EXPERIMENTAL|Group 1|Group 1: - Class III patients with increased vertical relationship These patients were scheduled for bimaxillary surgical procedures (Maxillary advancement and mandibular setback with posterior maxillary impaction) to correct the antero-posterior and vertical skeletal discrepancies.
62195971|NCT03910322|EXPERIMENTAL|Low-dose Bif195|Active trial product with minimum 15 billion CFU daily dose
62399030|NCT02272738|EXPERIMENTAL|Gemcitabine, Nab-Paclitaxel|"A conformal phase I study using 3 plus 3 method.~Chemoradiotherapy while Gemcitabine, Nab-Paclitaxel are administered.~Both Gemcitabine and Nab-Paclitaxel are an interventional agents in this arm.~Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.~Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.~Radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions."
62399031|NCT06648408|EXPERIMENTAL|Ballet training|The children in this arm of the study will receive ballet training.
62574429|NCT04808323|EXPERIMENTAL|Cohort B|Radiation dose: 68 Gy over approximately 34 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 68 Gy over 34 total fractions.
62574430|NCT04808323|EXPERIMENTAL|Cohort C|Radiation dose: 72 Gy over 36 total fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 72 Gy over 36 total fractions
62574431|NCT01579786|NO_INTERVENTION|Acetaminophen|A group All patients will be treated only with drugs used for this type during the operation and post operative pain controlled with usual acetaminophen drug administration (maximum 3 g/day)
62574432|NCT01579786|EXPERIMENTAL|Acetaminophen and acupuncture|B group patients. All patients will receive the standard pharmacological treatment for the operation. Acetaminophen (maximum 3g/day) during all seven days after surgery and patients will be treated with acupuncture the first day after surgery and thirty minutes before the surgical procedure
62009703|NCT04376645|EXPERIMENTAL|Group 2|Group 2: - Class III subjects with normal vertical relationship These patients were scheduled for mandibular setback surgical procedure (with no posterior maxillary impaction) to correct the antero-posterior skeletal discrepancy.
62009704|NCT04801446|ACTIVE_COMPARATOR|Transcranial Direct Current Stimulation|
62009705|NCT04801446|SHAM_COMPARATOR|Sham Stimulation|
62009706|NCT05120544|ACTIVE_COMPARATOR|EXTEND|EXTEND participants receive 4 mobile monitoring devices to facilitate chronic disease self-management (glucometer, BP cuff, scale, accelerometer). Device data are transferred to Duke University Health System (DUHS). Participants can review data and trends within the device apps and modify self-management practices accordingly. The EXTEND group continues chronic disease care with their existing providers during the study, and are instructed at baseline to address management questions via their primary clinics' established avenues (as would be the case for any patient using mobile monitoring in clinical practice).
62195972|NCT03910322|EXPERIMENTAL|High-dose Bif195|Active trial product with minimum 50 billion CFU daily dose
62195973|NCT00790400|EXPERIMENTAL|Everolimus|Study drug was given by continuous oral daily dosing of two 5 mg tablets.
62009707|NCT05120544|EXPERIMENTAL|EXTEND Plus|EXTEND Plus participants receive 4 mobile monitoring devices to facilitate chronic disease self-management (glucometer, BP cuff, scale, accelerometer). Device data are transferred to Duke University Health System (DUHS) for use as part of nurse-delivered intervention combining mobile monitoring, self-management support, and medication management. The intervention is administered by clinical registered nurses (RNs) from Duke Primary Care (DPC) or Duke Endocrinology. For the medication management component, RNs work with a study PharmD affiliated with the participant's clinic. The PharmD determines if medication changes are needed, and prescribes accordingly. The RNs deliver EXTEND Plus via scheduled telephone encounters throughout the 12-month intervention. The initial encounter frequency is every two weeks, but may be extended to every four weeks for patients achieving treatment goals.
62009708|NCT05004727|EXPERIMENTAL|Guselkumab + Topicals (GUS)|
62009709|NCT05004727|PLACEBO_COMPARATOR|Placebo + Topicals (PBO)|
62009710|NCT05004727|NO_INTERVENTION|Standard-of-Care Therapy (SOC)|"In this third, non-randomized arm, patients would continue treatment with topical therapy or UVB, as part of our ongoing natural history of disease registries. This arm will include participants fulfilling RM-PsASon criteria but also those that do not (to serve as negative controls)."
62009711|NCT06333444|EXPERIMENTAL|Psychological intervention|four weekly psychological counselling intervention
62009712|NCT06513819|EXPERIMENTAL|Pharmacist lead intervention|Clinical pharmacists will be trained by a team with expertise in behavioral and HIV clinical care, and participate in a 10-hour training course with coaching sessions offered over the course of the study to ensure effective and consistent performance. Pharmacists will be guided by a manual designed to provide and walk them through the necessary skills to perform the pilot intervention easily and effectively. The manual will provide background information, study goals, and describe the critical components of the IMB-MI model and the HARP pilot interventions. An easy to follow, step-by-step approach to performing the intervention will be included. The study protocol to be followed by the clinical pharmacists will be included in the manual along with additional motivational and troubleshooting strategies. Systematic feedback regarding intervention fidelity will be provided by the Evaluation Team.
62009713|NCT00410696|ACTIVE_COMPARATOR|Filgrastim|Filgrastim administration starting 1 day after autologous stem-cell reinfusion up to hemopoietic reconstitution (defined as more than 500/mm3 for 2 days)
62195974|NCT00790400|PLACEBO_COMPARATOR|Placebo|Placebo was given by continuous oral daily dosing of two 5 mg tablets.
62195975|NCT02821351|EXPERIMENTAL|DiamondTemp|Bilateral pulmonary vein isolation by RF ablation using DiamondTemp temperature controlled catheter and RF generator/pump system
62195976|NCT00161265||1|women with breast cancer
62195977|NCT05792098|ACTIVE_COMPARATOR|Standard procedure group|The standard procedure group will undergo PDTS by the attending physician in the standard manner based on clinical examination and anatomical landmarks using bronchoscopic control.
62195978|NCT05792098|ACTIVE_COMPARATOR|Ultrasound navigated group|Ultrasound navigated group, the attending physician will additionally use ultrasound navigation during the procedure.
62195979|NCT03862014|EXPERIMENTAL|SDF+KI|SDF+KI will be applied on molars with MIH
62195980|NCT03862014|ACTIVE_COMPARATOR|SMART(SDF+KI+GIC)|SDF+KI+GIC will be applied on molars with MIH
62195981|NCT04301570|OTHER|Ultrasound|The intervention measurement is the determination of bone age using the ultrasound device.
62574433|NCT02054403||angle closure|
62574434|NCT04687917|ACTIVE_COMPARATOR|Training, Feedback, Consultation, and Facilitation|A multilevel implementation strategy
62195982|NCT04301570|OTHER|XR|The control measurement is the determination of the bone age by the imaging method using X-rays.
62195983|NCT02671500|EXPERIMENTAL|SOF/VEL|SOF/VEL FDC for 12 weeks
62195984|NCT06404853|OTHER|Supplement dietary manna|Administration of supplement dietary manna
62195985|NCT05629299|OTHER|Monkey Pox infection|Men will give semen, saliva, skin, urine and blood specimens
62195986|NCT03427697|EXPERIMENTAL|Intervention group|Head-mounted video display which shows video with virtual reality and accommodation relax technique in combination,40 minutes per day
62195987|NCT03427697|NO_INTERVENTION|Control group|No intervention will be performed in the control group
62195988|NCT02839005|ACTIVE_COMPARATOR|suture with polyglecaprone 25|
62574435|NCT04687917|EXPERIMENTAL|Training, Feedback, Consultation, Facilitation, and P4P|An enhanced version of the multilevel implementation strategy
62574436|NCT05953259|ACTIVE_COMPARATOR|STERN FIX|Combination of at least one STERN FIX device and surgical wires to close median sternotomy (total of 5 fixation points)
62574437|NCT05953259|ACTIVE_COMPARATOR|Wires|Standard of care median sternotomy closure method with surgical wires
62574438|NCT01232413|PLACEBO_COMPARATOR|Treatment A|Placebo
62574439|NCT01232413|EXPERIMENTAL|Treatment B|ASP1941 low dose
62574440|NCT01232413|EXPERIMENTAL|Treatment C|ASP1941 high dose
62574441|NCT01232413|ACTIVE_COMPARATOR|Treatment D|Moxifloxacin
62574442|NCT02507141||SCC of the oral cavity scheduled for surgery|The patients will be imaged for testing the feasibility of intra-oral imaging. Images will be compared to and evaluated against the corresponding pathology that is routinely prepared during surgery.
62574443|NCT00957684|EXPERIMENTAL|ESL 400 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
62574444|NCT00957684|EXPERIMENTAL|ESL 800 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
62574445|NCT00957684|EXPERIMENTAL|ESL 1200 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
62574446|NCT00957684|PLACEBO_COMPARATOR|placebo|Placebo matching tablets
62574447|NCT00957684|EXPERIMENTAL|ESL - PART II|During Part II of the study all patients received Eslicarbazepine Acetate (ESL), including those who had been treated with placebo during Part I. ESL was supplied as scored 800 mg tablets; once daily administration by oral route.
62574448|NCT04267679|EXPERIMENTAL|Cannabidiol|Participants will take 25 mg full-spectrum CBD soft gel capsules (2 to 4 per day) for 12 weeks.
62574449|NCT03563352||Observational (interview, survey)|Participants attend an interview over 15 minutes and complete surveys.
62574450|NCT06578546|EXPERIMENTAL|Venetoclax, Azacitidine, and Orebatinib Regimen|See Detailed Description.
62574451|NCT03458481|EXPERIMENTAL|SOF+DAG181 100 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 100 mg for 12 weeks.
62009714|NCT00410696|EXPERIMENTAL|Pegfilgrastim|Pegfilgrastim administered the day after autologous stem-cell reinfusion
62009715|NCT01049919|EXPERIMENTAL|Concentrated bone marrow aspirate (cBMA)|Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
62009716|NCT01049919|SHAM_COMPARATOR|Placebo control (sham)|Placebo procedure (sham) consists of simulated bone marrow aspiration followed by simulated intramuscular injections into the affected limb
62009717|NCT04530175||patients with hemodialysis|patient treated with intermittent hemodialysis for chronic renal failure
62009718|NCT01276327|EXPERIMENTAL|1 Linagliptin/Pioglitazone (Test)|Fixed-Dose-Combination-Tablet, oral administration with 240 mL water
62009719|NCT01276327|EXPERIMENTAL|2 Linagliptin + Pioglitazone (Ref)|Tablets, oral administration with 240 mL water for each treatment
62009720|NCT01276327|EXPERIMENTAL|3 Linagliptin/Pioglitazone (Test)|Fixed-Dose-Combination-Tablet, oral administration with 240 mL water
62009721|NCT01276327|EXPERIMENTAL|4 Linagliptin + Pioglitazone (Ref)|Tablets, oral administration with 240 mL water for each treatment
62195989|NCT02839005|ACTIVE_COMPARATOR|suture with polyamide (nylon)|
62195990|NCT04894097|ACTIVE_COMPARATOR|study group|Patients will received 3,000 pulses, 1,500 pulses per site at a frequency of 12 Hz per session with the submaximal pressure between 0.39 and 1.95 mJ/mm2 (1.0 and 5.0 bar), depending on the level which the patient can tolerate without local anesthetics.
62574452|NCT03458481|EXPERIMENTAL|SOF+DAG181 200 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 200 mg for 12 weeks.
62574453|NCT01122758||COPD cohort|"Inclusion criteria:~* Patients ≥ 35 years.~* Diagnosis of COPD (GOLD PBD FEV1/FVC ratio \<0.70).~* Being in a stable phase of disease (8 weeks without exacerbation).~* Cummulative smoking ≥ 10 pack-years.~* Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);~* Absence of malignancy or very serious comorbidities that would prevent study completion.~Exclusion criteria:~* Patients \<35 years.~* Recent exacerbation (\<8 weeks).~* Not giving written informed consent.~* Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,~* Diffuse bronchiectasis not associated with COPD.~* Presence of malignancy or very serious comorbidities that would prevent study completion.~* Difficulty to perform appropriate follow-up."
62574454|NCT01122758||Control cohort|"Inclusion criteria:~* Patients ≥ 35 years.~* Absence of diagnosis of COPD (GOLD PBD FEV1/FVC ratio \>=0.70).~* Cummulative smoking ≥ 10 pack-years.~* Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);~* Absence of malignancy or very serious comorbidities that would prevent study completion.~Exclusion criteria:~* Patients \<35 years.~* Not giving written informed consent.~* Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,~* Diffuse bronchiectasis not associated with COPD.~* Presence of malignancy or very serious comorbidities that would prevent study completion.~* Difficulty to perform appropriate follow-up."
62574455|NCT05601453||redo-TAVI patients|Patients with severe aortic stenosis (sAS) treated with TAVI developing SVD and thus an indication for redo-TAVI procedure
62574456|NCT01601119||Rebif cohort|Subject will receive Rebif as the treatment medication as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.
62009722|NCT06023641|EXPERIMENTAL|Low -risk|"The participant will receive 12 weeks (4 cycles) of VAC chemotherapy (vincristine, dactinomycin and cyclophosphamide) followed by 12 weeks (4 cycles) of VA chemotherapy (vincristine, dactinomycin).~Each cycle of VAC/VA chemotherapy will last for 3 weeks, for a total of 12 weeks (VAC or VA will be given in Week 1 of each cycle and vincristine will be given Weeks 2 and 3). At week 12, the participant will have scans and tests to reevaluate your tumor's response to the treatment. After surgery and radiation, the participant will receive an additional 12 weeks (4 cycles) of the same chemotherapy without cyclophosphamide. Vincristine and dactinomycin, also called VA. After 4 cycles of VA, The investigator will re-evaluate the tumor again at week 24 and the patient will not get any more chemotherapy, but will be closely watched for any signs of tumor recurrence."
62009723|NCT06023641|EXPERIMENTAL|Intermediate-risk|"The purpose of this part of the study is to find out if adding a drug called liposomal irinotecan (also called Onivyde) to standard chemotherapy/radiation/surgery will result in better treatment outcomes for patients with intermediate and high risk rhabdomyosarcoma. The investigators also want to find the best radiation dose to give for intermediate and high risk patients who have large tumors (\> 5 cm).~The patient will receive 42 weeks of VAC chemotherapy (vincristine, actinomycin D/dactinomycin and cyclophosphamide) alternating with VLI chemotherapy (vincristine/liposomal irinotecan). The participant will also have surgery to remove the tumor and radiation therapy during this time. After this therapy is completed you will get an additional 6 months of maintenance chemotherapy with vinorelbine and oral (by mouth) cyclophosphamide."
62195991|NCT04894097|SHAM_COMPARATOR|control group|The patients in this group will be treated by sham radial extracorporeal shock wave therapy
62195992|NCT02251236|OTHER|Stribild Arm|Stribild Arm is for participants taking Stribild at the time of study entry. Participants taking Stribild at the time of study entry will switch to Genvoya before the second PK.
62195993|NCT02251236|OTHER|Genvoya Arm|Genvoya Arm is for participants already taking Genvoya at the time of study entry. Participants taking Genvoya at the time of study entry will continue Genvoya for the second PK.
62195994|NCT02251236|OTHER|Untreated Arm|Untreated Arm is for participants who are not taking ART at the time of study entry. Participants will start Stribild at entry and switch to Genvoya before the second PK.
62195995|NCT04623762|NO_INTERVENTION|Control group|yoga was not done
62195996|NCT04623762|EXPERIMENTAL|Experimental group|yoga was done
62195997|NCT05995496|EXPERIMENTAL|Participants with Bulimia Nervosa|"Participants are randomly assigned (in even numbers across the two groups) to scan order:~A. These participants are first scanned after 16 hours of fasting on one day, and are next scanned after a standardized meal on a second day.~B. These participants are first scanned after a standardized meal on one day, and are next scanned after 16 hours of fasting on a second day."
62195998|NCT05995496|ACTIVE_COMPARATOR|Participants without Bulimia Nervosa|"Participants are randomly assigned (in even numbers across the two groups) to scan order:~A. These participants are first scanned after 16 hours of fasting on one day, and are next scanned after a standardized meal on a second day.~B. These participants are first scanned after a standardized meal on one day, and are next scanned after 16 hours of fasting on a second day."
62195999|NCT05444946|EXPERIMENTAL|Steroid itraconazole|Combination of oral glucocorticoid (prednisolone 0.5 mg/Kg body weight tapered over 4 months) and itraconazole for 12 months
62574457|NCT01601119||Other DMT cohort|Subjects will receive DMT other than Rebif as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.
62196000|NCT05444946|ACTIVE_COMPARATOR|Itraconazole|Oral itraconazole for 12 months
62196001|NCT04538846|EXPERIMENTAL|Culinary Art Therapy Group|Patients with eating disorders that will participate in a weekly session of culinary art therapy group.
62196002|NCT04538846|NO_INTERVENTION|No Culinary Art Therapy Intervention|Patients with eating disorders that are not scheduled to come to the outpatients ward on the day of intervention.
62574458|NCT02533245|EXPERIMENTAL|Tx exercise group|"Convenience sample of solid organ transplant recipients (heart, kidney, lung, liver, pancreas, small bowel) participating in the Transplantoux exercise training intervention.~Intervention:~* Home-based individualized exercise training program~* Supervised group training sessions~* Climb of the Mont Ventoux"
62196003|NCT04640740|EXPERIMENTAL|anterolateral approach (ALA)|anterolateral surgical approach of total hip arthroplasty
62196004|NCT04640740|EXPERIMENTAL|posterior approach (PA)|posterior surgical approach of total hip arthroplasty.
62574459|NCT02533245|NO_INTERVENTION|Tx matched control group|Controls are retrieved from the Leuven University Hospital heart, kidney, lung, liver, pancreas, small bowel transplant database and matched (1:4 matching) based on type of transplant, gender, age and time since transplant.
62574460|NCT02533245|EXPERIMENTAL|Healthy exercise group|"Convenience sample of health care providers (e.g. doctor, paramedic or medical companion involved in care programs for organ Tx) and patient's family members and friends participating in the Transplantoux exercise training intervention.~Intervention:~* Supervised group training sessions~* Climb of the mont ventoux"
62574461|NCT05184504||Patients with pathological diagnosis of renal cell carcinoma|Patients aged 18 years or older, who have been diagnosed with renal cell carcinoma (new case or recurrence) since January 2015 and during the study recruitment period.
62196005|NCT03034850||CRS/HIPEC|Patients with a confirmed histological diagnosis of peritoneal disease treated by cytoreductive surgery (CRS) with hyperthermic intraperitoneal peroperative chemotherapy (HIPEC).
62196006|NCT02672449|EXPERIMENTAL|External beam radiotherapy|A total of 65 consecutive newly diagnosed prostate cancer patients with 2013 NCCN high risk category will be consecutively enrolled in a prospective phase II trial on Carbon Ions Boost Followed by Pelvic Photon Radiotherapy .
62196007|NCT02815020|OTHER|Boot Camp Translation|"Boot Camp Translation is rolled out in a stepped wedge design across participating PBRNs to assist practices with SMS implementation. The Boot Camp Translation intervention initiates practices to review and begin uptake and implementation of tools from the AHRQ Self-Management Support tool library."
62196008|NCT02633436||cancer tissues|SLC1A5 expression of esophageal cancer tissues from patients
62196009|NCT02633436||paired adjacent tissues|SLC1A5 expression of paired adjacent esophageal tissues from patients
62196010|NCT02697396||with text messaging reminder system|Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
62009724|NCT06023641|EXPERIMENTAL|High-risk|"The purpose of this part of the study is to find out if adding a drug called liposomal irinotecan (also called Onivyde) to standard chemotherapy/radiation/surgery will result in better treatment outcomes for patients with high risk rhabdomyosarcoma. The investigator also want to find the best radiation dose to give for high risk patients who have large tumors (\> 5 cm).~The patient will receive 42 weeks of VAC chemotherapy (vincristine, actinomycin D/dactinomycin and cyclophosphamide) alternating with VLIT chemotherapy (vincristine/liposomal irinotecan/temozolomide). Also having surgery to remove the participants tumor and radiation therapy during this time. After this therapy is completed the patient will get an additional 6 months of maintenance chemotherapy with vinorelbine and oral (by mouth) cyclophosphamide."
62009725|NCT04002674|PLACEBO_COMPARATOR|Placebo|"Sixty (60) participants will be recruited and randomized into 2 arms (1:1). Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days)."
62009726|NCT04002674|ACTIVE_COMPARATOR|200 mg Nilotinib|Sixty (60) participants will be recruited and randomized into 2 arms (1:1). Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).
62009727|NCT04206111||Preoxygenation|
62009728|NCT00563797|EXPERIMENTAL|Mecamylamine|Mecamylamine is a noncompetitive, high-affinity nAChR antagonist with low selectivity for the alpha-7 receptor. Those receiving mecamylamine started at 2.5mg once daily (second dose was placebo). The dose was increased to 5.0 mg twice daily over 3 weeks.
62574462|NCT04628390|EXPERIMENTAL|Experimental|The low-power therapeutic diode laser will be applied with a wavelength 810nm ± 15nm, output power 0-2 W CW / 0-4.8 W peak power (pulse mode), for a time of 20 seconds per centimeter at lo along the buccal surface of the root of the upper and lower teeth.
62009729|NCT00563797|PLACEBO_COMPARATOR|Placebo|Placebo capsules were prepared by the pharmacy and were identical in size and color to the medication capsules.
62009730|NCT03689127|ACTIVE_COMPARATOR|Control|Heated breathing circuit will be turned off.
62009731|NCT03689127|EXPERIMENTAL|Heat|Heated breathing circuit will be turned on.
62009732|NCT01313234|EXPERIMENTAL|Education|Educational theory based intervention and systematic daily pain assessment
62009733|NCT01313234|NO_INTERVENTION|Control|Control group with care as usual
62009734|NCT04141462|EXPERIMENTAL|Patients with a a constitutional genetic alteration|one genetic consultation and one blood test
62009735|NCT04903691|EXPERIMENTAL|Exercise training|130 patients who underwent open heart surgery and are cleared for exercise.These will include patients who enter supervised cardiac rehabilitation as well as patients who enter a supervised exercise program focusing strength training, endurance of functional training.
62009736|NCT04903691|NO_INTERVENTION|Additional controls|5 patients who choose not to enter any organized exercise program.
62009737|NCT01049659|OTHER|neuropsychological tests|neuropsychological assessment of children around their second birthday
62196011|NCT02697396||without text messaging reminder system|Participants in this arm will receive no additional vaccination reminders. However, the study staff will ask and record if the participant's pediatrician provides appointment reminder cards, emails and/or calls prior to each scheduled vaccination as captured in the Outcomes Survey.
62009738|NCT04245488|OTHER|taste testing|Participants will first taste 5 sour solution containing acetic acid for sour compounds, sucrose esters, and xanthan gum to help them stay dissolved). Then rate them for their taste intensities. Next, participants will taste 5 butyric acid solutions, 5 hexenoic acid solutions, 5 caprylic acid solutions, 5 lauric acid solutions, 5 palmitic acid solutions, 5 oleic acid solutions, and 5 linoleic acid solutions (all will also contain the sucrose esters and xanthan gums.) and rate them for their taste intensities. This should take no longer than 1 hour. Participants will spit all samples into a cup after tasting them. They will not swallow any samples.
62196012|NCT02847286|ACTIVE_COMPARATOR|Treatment A|Dapivirine Ring-004 for 28 days
62196013|NCT02847286|ACTIVE_COMPARATOR|Treatment B|Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
62196014|NCT02847286|ACTIVE_COMPARATOR|Treatment C|Clotrimazole, 5 g per day for 7 days
62196015|NCT03161613||Cancer patients in Mexico|lung cancer, melanoma cancer, renal cancer, Squamous Cell Carcinoma of the Head and Neck, and chronic Hodgkin Lymphoma patients in Mexico who have failed at least one treatment before being treated with nivolumab
62574463|NCT04628390|PLACEBO_COMPARATOR|Placebo|A simulation of the application of therapeutic laser will be carried out as a placebo effect, for a time of 20 seconds per centimeter along the vestibular surface of the root of the upper and lower teeth.
62574464|NCT06501378|EXPERIMENTAL|active BM|
62574465|NCT03915587|OTHER|Fluid Challenge|After defining fluid responders from non-responders in this single arm prospective trial, we will compare the predictive utility of non-invasive devices such as the CipherOx-CRI and IVC CI to currently employed indices (heart rate, systolic blood pressure, urine output and pulse pressure variability) to gauge the need for additional fluid and ongoing resuscitation.
62574466|NCT06448507|EXPERIMENTAL|INJEX|needle less device
62196016|NCT05354713|EXPERIMENTAL|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4) (NVP-1805 80/10/20.8mg)
62196017|NCT05354713|ACTIVE_COMPARATOR|NVP-1805-R1 and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4) (NVP-1805-R1 80mg, NVP-1805-R2 10/20.8mg)
62574467|NCT06448507|ACTIVE_COMPARATOR|Needle syringe|traditional dental needle
62574468|NCT06340113|EXPERIMENTAL|MCKENZIE AND STABILIZATION EXERCISES|In this group, 11 participants will be included. the interventions will be given for 15 mint. The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week
62574469|NCT06340113|EXPERIMENTAL|MULLIGAN AND STABILIZATION EXERCISES|In this group, 11 participants will be included. the interventions will be given for 15 mint. The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week for 10 weeks
62574470|NCT03020992|EXPERIMENTAL|Certolizumab Pegol|Subjects will receive a loading dose of Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) administered at Baseline, Week 2, and Week 4 followed by CZP 200 mg sc every two Weeks
62574471|NCT05711355|ACTIVE_COMPARATOR|Use of Platelet-Rich Plasma after meningomyelocele sac repair|Paitents treated with platelet-rich plasma injection and treated with according to guidelines
62196018|NCT04533048|EXPERIMENTAL|MW33|
62196019|NCT04533048|EXPERIMENTAL|Placebo|
62574472|NCT05711355|ACTIVE_COMPARATOR|Control group of meningomyelocele sac repair|Paitents treated according to guidelines
62009739|NCT02344368|EXPERIMENTAL|0.2 ml sucrose|on 2 occasions within 1 week 0.2 ml sucrose 25% or 0.5 ml sucrose 25% will be given in randomized order to the same infant during blood sampling
62009740|NCT02344368|EXPERIMENTAL|0.5 ml sucrose|on 2 occasions within 1 week 0.2 ml sucrose 25% or 0.5 ml sucrose 25% will be given in randomized order to the same infant during blood sampling
62009741|NCT03320239|EXPERIMENTAL|the online-RASSL intervention group|HIV risk assessment and tailored suggestions, free HIV testing link
62009742|NCT03320239|EXPERIMENTAL|intervention group 2|HIV risk behavior investigation and routine education
62009743|NCT03320239|PLACEBO_COMPARATOR|the control group|The placebo control: HIV/AIDS knowledge assessment, routine education
62009744|NCT02311049|EXPERIMENTAL|Arm 1|16 fractions à rato of 4 fractions a week over 4 weeks
62009745|NCT02311049|EXPERIMENTAL|Arm 2|25 fractions à rato of 5 fractions a week over 5 weeks
62009746|NCT00368940|EXPERIMENTAL|PATH|Participants will receive PATH for 12 weeks
62009747|NCT00368940|ACTIVE_COMPARATOR|ST-CI|Participants will receive ST-CI for 12 weeks
62009748|NCT03861468|NO_INTERVENTION|Usual care|Patients in the usual care group will be referred to their general practitioner (GP) / primary care practitioner as usual.
62009749|NCT03861468|ACTIVE_COMPARATOR|Early care|A different care pathway will be followed by the patients randomized to this group. They will be referred to a specialist (pneumologist) for OSA diagnosis and treatment if necessary
62574473|NCT03316014||Adverse drug reaction|Children from 0 to 17 years inclusive with ADR notifications recorded in the French pharmaco-vigilance database by the Regional Pharmacovigilance Center of Champagne-Ardenne between 1 January 1985 and 31 December 2014
62574474|NCT05837910|PLACEBO_COMPARATOR|Placebo Control 1|Calm Product Form 1 - control
62574475|NCT05837910|EXPERIMENTAL|Active Product 1.1|Calm Product Form 1 - active product 1
62574476|NCT05837910|EXPERIMENTAL|Active Product 1.2|Calm Product Form 1 - active product 2
62574477|NCT05837910|EXPERIMENTAL|Active Product 1.3|Calm Product Form 1 - active product 3
62574478|NCT05837910|PLACEBO_COMPARATOR|Placebo Control 2|Calm Product Form 2 - control
62574479|NCT05837910|EXPERIMENTAL|Active Product 2.1|Calm Product Form 2 - active product 1
62009750|NCT01532362|EXPERIMENTAL|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
62009751|NCT01532362|OTHER|No drug intervention|
62009752|NCT04011059|PLACEBO_COMPARATOR|Comparison/control group|Revascularization surgery, placement of an extracellular matrix patch without WJ-MSCs and injection of culture medium without WJ-MSCs will be performed.
62009753|NCT04011059|ACTIVE_COMPARATOR|Experimental group|Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSCs around the infarcted zone will be performed.
62009754|NCT01138124||UK GPRD 1993-2008|The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993.
62196020|NCT04259827|EXPERIMENTAL|Online cognitive training|6-week online personalized cognitive training using Neuronation platform 4 training session three times a week. Each session is composed of 5 exercises from one out of 4 cognitive domains: Memory, Attention, Speed and Reasoning
62196021|NCT04259827|ACTIVE_COMPARATOR|Aspecific online games|online application not created with a cognitive training purpose, for the same amount of time and frequence as the experimental group
62196022|NCT04259827|NO_INTERVENTION|No online cognitive training|normal clinical follow-up without cognitive training or gaming
62196023|NCT05987020|EXPERIMENTAL|pre-specified group|"The experimental group received aromatherapy, an intervention using lavender essential oil compound, while the control group received a placebo, sweet almond oil. The research tools include: Basic Demographic Information,  The Chinese version of the Pittsburgh Sleep Quality Index, CPSQI , The World Health Organization Quality of Life Questionnaire -Taiwan Version and The World Health Organization Quality of Life Questionnaire -old."
62574480|NCT05837910|PLACEBO_COMPARATOR|Placebo Control 3|Calm Product Form 3 - control
62574481|NCT05837910|EXPERIMENTAL|Active Product 3.1|Calm Product Form 3 - active product 1
62574482|NCT05837910|PLACEBO_COMPARATOR|Placebo Control 4|Calm Product Form 4 - control
62574483|NCT05837910|EXPERIMENTAL|Active Product 4.1|Calm Product Form 4 - active product 1
62574484|NCT02400554|NO_INTERVENTION|Wait List Control|Participants wait one year before receiving the intervention. Three assessments are taken over this period: Month 3, Month 9, and Month 12.
62574485|NCT02400554|EXPERIMENTAL|Yappalli|Yappalli: Participants attend a 12-month behavioral intervention.
62009755|NCT01410110|EXPERIMENTAL|Cognitive Training + Work Therapy|"Cognitive Training using auditory and visual Positscience software 5 hours/per week for 13 weeks.~Work Therapy for 15 hours per week at half minimum wage doing entry level duties at medical center job sites, supervised by regular medical center staff."
62009756|NCT01410110|ACTIVE_COMPARATOR|Work Therapy Only|Same work therapy but for 20 hours per week.
62009757|NCT02791334|EXPERIMENTAL|LY3300054|LY3300054 given intravenously (IV) on day 1 and day 15 of a 28 day cycle or LY3300054 given IV on day 1 of a 21 (or 28) day cycle.
62009758|NCT02791334|EXPERIMENTAL|LY3300054 + Ramucirumab|LY3300054 and ramucirumab given IV on day 1 and day 15 of a 28 day cycle or ramucirumab given IV on day 1 and day 8 and LY3300054 given IV on day 1 of a 21 day cycle.
62009759|NCT02791334|EXPERIMENTAL|Abemaciclib + LY3300054|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
62009760|NCT02791334|EXPERIMENTAL|LY3300054 + Abemaciclib (Concurrent Dosing)|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
62009761|NCT02791334|EXPERIMENTAL|LY3300054 + Abemaciclib|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. This arm will only be initiated if required.
62009762|NCT02791334|EXPERIMENTAL|LY3300054 + Merestinib|LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle.
62009763|NCT02791334|EXPERIMENTAL|LY3300054 Expansion (Metastatic Cutaneous Melanoma)|LY3300054 given IV on day 1 and day 15 of a 28 day cycle.
62009764|NCT02791334|EXPERIMENTAL|LY3300054 Expansion (MSI-H Solid Tumors)|LY3300054 given IV on day 1 and day 15 of a 28 day cycle.
62009765|NCT02791334|EXPERIMENTAL|: LY3300054 + Abemaciclib (HR+, HER2- Breast Cancer) Expansion|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
62009766|NCT02791334|EXPERIMENTAL|LY3300054 + LY3321367 Expansion (PD-1/PD-L1 Naïve, MSI-H)|LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle.
62574486|NCT03028688|NO_INTERVENTION|Current standard of care|Participants in the current standard of care will receive the usual anesthesia care for upper GI endoscopy. In addition participants will have transcutaneous PCO2 measurements performed.
62574487|NCT03028688|EXPERIMENTAL|High flow nasal cannula group|Participants in the high flow nasal cannula group will receive high flow nasal cannula oxygen and will also have transcutaneous PCO2 measurements performed.
62574488|NCT05214443|EXPERIMENTAL|POEM + F arm|This arm will receive the POEM + F procedure
62574489|NCT05450510|ACTIVE_COMPARATOR|Accelerated (ACCEL) physiotherapy group|They will be referred to Physiotherapy and Rehabilitation clinics for a 8-week-long Phase 2 and Phase 3 trainings. The training program includes the following exercises: cold-pack ; TENS (60-120 Hz); soft tissue massage, joint mobilizations; mobility exercises; stretching, controlled strengthening and endurance exercises.
62196024|NCT05987020|PLACEBO_COMPARATOR|subgroup of participant|"The control group received a placebo, sweet almond oil. The research tools include: Basic Demographic Information,  The Chinese version of the Pittsburgh Sleep Quality Index, CPSQI , The World Health Organization Quality of Life Questionnaire -Taiwan Version and The World Health Organization Quality of Life Questionnaire -old."
62196025|NCT05698251|EXPERIMENTAL|Reducing uncertainty distress: Psychological therapy intervention|"Up to 16 sessions of psychological therapy delivered weekly either face to face or via telehealth . Based on empirically grounded models of anxiety/threat, illness uncertainty and intolerance of uncertainty.~Formulation driven and clinically responsive individualised treatment based on four intervention areas: information management, building safety, reducing overestimation of threat and tolerating uncertainty."
62196026|NCT02989623|EXPERIMENTAL|Diagnostic (copper Cu 64 TP3805, PET/CT, biopsy)|Patients receive copper Cu 64 TP3805 IV over 5 minutes and 30 minutes and 2 hours later, undergo whole body Positron Emission Tomography/Computed Tomography (PET/CT) imaging over 1 hour.
62196027|NCT03618004|EXPERIMENTAL|Experimental group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects of the experimental group made use of the restriction of blood flow, using a pressure cuff coupled in the most proximal region of the arm, 10 cm wide. The pressure was calculated based on the initial systolic pressure of the subjects."
62574490|NCT05450510|ACTIVE_COMPARATOR|Slow (SLOW) physiotherapy group|They will be referred to Physiotherapy and Rehabilitation clinics for a 14-week-long Phase 2 and Phase 3 trainings. The training program includes the following exercises: cold-pack ; TENS (60-120 Hz); soft tissue massage, joint mobilizations; mobility exercises; stretching, controlled strengthening and endurance exercises.
62574491|NCT05300711|EXPERIMENTAL|Opportunistic salpingectomy|The participating surgeons will attempt to perform bilateral salpingectomy in addition to the colorectal surgery.
62574492|NCT05300711|ACTIVE_COMPARATOR|Colorectal surgery only|Participants will receive the standard of care, that is colorectal surgery.
62009767|NCT02791334|EXPERIMENTAL|LY3300054 + LY3321367 Expansion|LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle.
62009768|NCT02791334|EXPERIMENTAL|LY3300054 + Merestinib (Pancreatic Cancer) Expansion|LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle.
62009769|NCT06663943|EXPERIMENTAL|CM313 (SC)、Glucocorticoid (Prednisone)|Patients in the experimental group receive CM313 in combination with steroid therapy, with CM313 600mg (4ml/vial) administered subcutaneously at 0 and 1/2 weeks, followed by administration every 6 months or as determined by clinical assessment; subcutaneous injections are performed by doctors from this hospital, and patients are treated according to the normal outpatient diagnostic and treatment process; participants can have DSG antibody testing for free, and doctors will regularly follow up with patients by phone to monitor changes in their condition; the observation and follow-up period is 56 weeks.
62009770|NCT06663943|ACTIVE_COMPARATOR|Glucocorticoid (prednisone), azathioprine|Patients in the control group receive azathioprine in combination with steroid therapy. The dosage of azathioprine (AZA) is adjusted based on the activity of thiopurine methyltransferase (TPMT), and TPMT activity should be measured before the administration of azathioprine. For individuals with normal TPMT activity, it is recommended to use AZA at a dosage of 2.0-3.0 mg·kg/d; for patients with TPMT enzyme mutations, it is recommended to use AZA at a dosage of 0.5-1.5 mg·kg/d. The initial treatment dose is suggested to be 50 mg AZA per day; the dose can be increased to the optimal dosage based on TPMT activity.
62574493|NCT04203602|EXPERIMENTAL|Telepresence round|Patients will be seen during ward rounds by the multidisciplinary team physically present, but with the surgeon remotely present via a telepresence robot.
62574494|NCT04203602|ACTIVE_COMPARATOR|conventional round|Patients will be seen during ward rounds by the whole multidisciplinary team physically present, including the surgeon.
62574495|NCT02048176||Posterior Fossa Mutism|Patients with Posterior Fossa Mutism
62574496|NCT02048176||Non Posterior Fossa Mutism|Patients that did not develop Mutism
62574497|NCT04768413||Group A|A group of patients who have voluntarily adhered to the clinic's tele-assisted consultation and who receive remote, multidisciplinary team care without requiring physical displacement.
62574498|NCT04768413||Group B|Group of patients who wish to continue with the usual face-to-face consultation, since for these patient's isolation measures allow trips to the care centers and who receive care from a multidisciplinary team on a regular basis.
62574499|NCT05702476||MFS Adult patients|Patients with clinical and/or gentic diagnosis of MFS older than 18 years
62196028|NCT03618004|ACTIVE_COMPARATOR|Control group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects in the control group did not use pressure cuffs."
62196029|NCT00902811|ACTIVE_COMPARATOR|AM(LT)|Artesunate (Arsumax®, Sanofi)
62196030|NCT00902811|EXPERIMENTAL|AM(FDC)|Artesunate-mefloquine fixed dose combination
62196031|NCT00902811|EXPERIMENTAL|AL|artemether 20 mg - lumefantrine 120 mg co-formulated tabs
62196032|NCT00902811|EXPERIMENTAL|DP|40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/Piperaquine 160 mg tablets
62196033|NCT00902811|EXPERIMENTAL|AA (FDC)|Artesunate-amodiaquine fixed dose combination
62196034|NCT02214875|EXPERIMENTAL|CQI/BTS|"Experimental: CQI/BTS~CQI/BTS interventions will be applied through rapid structured cycles of data collection, testing of solutions and review of changes will be done. At each site, Quality Improvement Teams (QIT) will be established among facility staff. Local Government/State QI teams will provide oversight function of facility based QI initiatives. Break Through Collaborative Series (BTS) will hold quarterly in each study state at a central location with participants from intervention sites. Sessions will provide opportunity for teams to learn from each other; adapt and implement changes using the Plan-Do-Study-Act (PDSA) model. Process indicators will be used to measure quality improvement from the intervention sites and collaboratives."
62196035|NCT02214875|OTHER|Control|Facilities in control will continue will routine unstructured, irregular continuous quality improvement. Break Through Collaborative will not be applied to the control facilities.
62574500|NCT05702476||MFS Paediatric patients|Patients with clinical and/or gentic diagnosis of MFS younger than 18 years
62574501|NCT04973267|EXPERIMENTAL|Game Plan for PrEP|Participants will be asked to use Game Plan for PrEP for however long they wish. Game Plan for PrEP is a web-based intervention that provides users with feedback about how much their risk for HIV is reduced on PrEP, their risk for bacterial STIs, and helps them make a plan to take their medication regularly and reduce their risk for STIs. Game Plan for PrEP also providers users with feedback about their alcohol use compared to others in their age group and encourages them to make a plan to reduce it.
62196036|NCT04625686||Inpatient Treatment|Inpatient psychiatric treatment
62196037|NCT04625686||OCIC Treatment|In-person outpatient crisis intervention
62196038|NCT04625686||Telehealth Therapy Treatment|Virtual outpatient therapy
62196039|NCT04625686||No Show Group|Participant who do not attend recommended treatment
62009771|NCT04281277|ACTIVE_COMPARATOR|low target group|"target of mean arterial pressure(MAP) at 65-70 mmHg.~The therapeutic means used to obtain the MAP objectives within each group (increase in catecholamines and / or volume expansion) are left to the discretion of the clinician, in accordance with the recommendations."
62009772|NCT04281277|EXPERIMENTAL|high target group|"target of mean arterial pressure (MAP) at 80-85 mmHg.~The therapeutic means used to obtain the MAP objectives within each group (increase in catecholamines and / or volume expansion) are left to the discretion of the clinician, in accordance with the recommendations."
62009773|NCT02888028|ACTIVE_COMPARATOR|ICD remote monitoring|Active Comparator: ICD remote monitoring additionally to regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement
62009774|NCT02888028|OTHER|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
62009775|NCT02851108|EXPERIMENTAL|AS-AQ-MB|Once daily a fixed dose artesunate-amodiaquine formulation combined with once daily methylene blue (15 mg/kg) over a three days period.
62009776|NCT02851108|ACTIVE_COMPARATOR|AS-AQ-PQ|Once daily a fixed dose artesunate-amodiaquine over three days combined with a single dose of primaquine on day 2 (0.25 mg/kg).
62574502|NCT04973267|SHAM_COMPARATOR|Lifestyle Habits Videos|Participants in this condition will view several videos that encourage them to adopt sleep hygiene and healthy diet behaviors. The videos were selected to last as long as the average time users engage with Game Plan for PrEP in its initial modules.
62574503|NCT04002115|EXPERIMENTAL|Clofarabine 30 mg/m^2|Day -14 through Day -10 Clofarabine 30 mg/m\^2, Day - 9 Day of rest, Day - 8 Day of rest, Day - 7 Day of rest, Day - 6 Fludarabine 40 mg/m\^2 IV and Busulfan 3.2 mg/kg IV (Regimen A, Fludarabine 24 mg/m\^2 IV and Cyclophosphamide 14.5 mg/kg IV for Regimen B), Day - 5 Fludarabine 40 mg/m\^2 IV and Busulfan 3.2 mg/kg IV (Regimen A, Fludarabine 24 mg/m\^2 IV and Cyclophosphamide 14.5 mg/kg IV for Regimen B), Day - 4 Fludarabine 40 mg/m\^2 IV(Regimen A, Fludarabine 24 mg/m\^2 IV for Regimen B), Day - 3 Fludarabine 40 mg/m\^2 IV(Regimen A, Fludarabine 24 mg/m\^2 IV for Regimen B), Day - 2 Day of Rest, Day -1 Total Body Irradiation 200 cGys, Day 0 stem cell transplant infusion, Day +1 Day of rest, Day +2 Day of rest, Day +3 Cyclophosphamide 50 mg/kg IV, Day +4 Cyclophosphamide 50 mg/kg IV, Day +5 Start G-CSF, Tacrolimus, and MMF.
62574504|NCT04620447|ACTIVE_COMPARATOR|Mindfulness Meditation|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.~Number of Participants: 125~Dropouts: 7~Final number of participants: 118~Mindfulness Meditation intervention was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
62734666|NCT03995745|EXPERIMENTAL|adherence based financial incentives|Participants randomized to this arm will receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will be randomly assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence. Participants will also be eligible for a financial bonus if participant's viral load is suppressed at the end of the intervention period. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.
62009777|NCT05070624|EXPERIMENTAL|Intervention|"After informed consent, we will assign participants in a 1:1 ratio to the intervention or control group using Randomize.net.~Participants randomized to intervention group will get access to the Virtual Peer Support Program."
62009778|NCT05070624|NO_INTERVENTION|Control|Control group: Those randomized to the waitlist control will be given access to the peer support intervention on completion of the first 12-week program. A waitlist control group is an ethical alternative to no-treatment control groups when studying psychological and behavioral interventions 21. will have access to informational resources via the aTouchAway™ App and will also receive the intervention at the end of the trial.
62009779|NCT03014752|ACTIVE_COMPARATOR|Classical ketogenic diet|The classical ketogenic diet with 4:1 ketogenic ratio, each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced.
62009780|NCT03014752|ACTIVE_COMPARATOR|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
62009781|NCT04219085|ACTIVE_COMPARATOR|Routine Care|Monitoring of control of gestational diabetes with routine care and use of a glucometer and fingersticks 4 times a day
62196040|NCT04429295|EXPERIMENTAL|Group A - Intervention regimen|SHAN6™ + routine pediatric vaccines pneumococcal 13-valent conjugate vaccine \[PCV\] \[Prevnar 13®\] and oral rotavirus vaccine \[ORV-1\] \[Rotarix™\] at age of 2, 4 months; SHAN6™ + Prevnar 13® at age of 6 months; SHAN6™ administered alone as a booster dose at age of 15-18 months
62009782|NCT04219085|EXPERIMENTAL|Continuous Glucose Monitor|Monitoring of control of gestational diabetes with use of a continuous glucose monitor
62009783|NCT03766763|EXPERIMENTAL|ARM A VENETOCLAX|VENETOCLAX
62009784|NCT03246958|EXPERIMENTAL|DTC - Nivolumab alone for two weeks|Differentiated Thyroid Cancer (DTC) participants received Ipilimumab 1mg/kg q6 weeks via IV infusion, starting two weeks after Nivolumab 3mg/kg q6 weeks.
62009785|NCT03246958|EXPERIMENTAL|DTC - Ipilimumab alone for two weeks|Differentiated Thyroid Cancer (DTC) participants received Nivolumab 3mg/kg q6 weeks via IV infusion, starting two weeks after Ipilimumab 1mg/kg q6 weeks.
62009786|NCT03246958|EXPERIMENTAL|Differentiated Thyroid Cancer (Primary cohort)|"Differentiated Thyroid Cancer (DTC) participants received Ipilimumab (Ipi) 1mg/kg q6 weeks and Nivolumab (Nivo) 3mg/kg q6 weeks sequentially either Ipi or Nivo first with 2 weeks apart prior to start of either Ipi or Nivo second.~Per protocol order in sequential design was not expected to impact efficacy rather was for exploratory correlative analyses. Participants were treated indefinitely until disease progression or withdrawal for other reasons."
62196041|NCT04429295|ACTIVE_COMPARATOR|Group B - Control regimen|SHAN5™ + bivalent oral polio vaccine (bOPV), co-administered with Prevnar 13® and Rotarix™ at 2, 4 months of age and with inactivated polio vaccine \[IPV\] at 4 months of age; SHAN5™ + bOPV, co-administered with Prevnar 13® at 6 months of age SHAN6™ administered alone as a booster dose at 15-18 months of age
62574505|NCT04620447|ACTIVE_COMPARATOR|Cognitive Behavior Therapy|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.~Number of Participants: 125~Dropouts: 19~Final number of participants: 102~Cognitive Behavior Therapy intervention was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
62574506|NCT04620447|ACTIVE_COMPARATOR|Novel 'Intelligent Virtual Reality Therapy System' (IVRTS)|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.~Number of Participants: 125~Dropouts: 10~Final number of participants: 115~Novel 'Intelligent Virtual Reality Therapy System' (IVRTS) was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
62574507|NCT04620447|NO_INTERVENTION|Control Group|"A 7-week intervention course (In this case, no intervention) was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.~Number of Participants: 125~Dropouts: 0~Final number of participants: 125~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
62009787|NCT03246958|EXPERIMENTAL|Medullary Thyroid Cancer (Exploratory Cohort)|"Medullary Thyroid Cancer (MTC) participants received Ipilimumab (Ipi) 1mg/kg q6 weeks and Nivolumab (Nivo) 3mg/kg q6 weeks sequentially either Ipi or Nivo first with 2 weeks apart prior to start of either Ipi or Nivo second, or started Ipi or Nivo together.~Per protocol order in sequential design was not expected to impact efficacy rather was for exploratory correlative analyses. Participants were treated indefinitely until disease progression or withdrawal for other reasons."
62009788|NCT03246958|EXPERIMENTAL|Anaplastic Thyroid Cancer (Exploratory Cohort)|"Anaplastic Thyroid Cancer (ATC) participants received Ipilimumab (Ipi) 1mg/kg q6 weeks and Nivolumab (Nivo) 3mg/kg q6 weeks sequentially either Ipi or Nivo first with 2 weeks apart prior to start of either Ipi or Nivo second prior to study amendment or in combination from the start after study amendment due to aggressive nature of the disease in this cohort.~Per protocol order in sequential design was not expected to impact efficacy rather was for exploratory correlative analyses. Participants were treated indefinitely until disease progression or withdrawal for other reasons."
62196042|NCT02867917|OTHER|Total group|Volcolon sugar free \& Metamucil Orange \& Psyllium Orange in a randomized order.
62196043|NCT02043873||25 composite restorations replaced|25 composite replaced with clinically diagnosed secondary caries (Charlie) or undercontoured anatomical form defects (Bravo)
62574508|NCT06454669|EXPERIMENTAL|Drug: Dronabinol|Dronabinol capsules, over-encapsulated with filler to match the appearance of the placebo capsule, up to 15 mg, twice per day for 8 weeks.
62196044|NCT02043873||25 composite repaired|25 composite repaired with clinically diagnosed secondary caries (Charlie) or undercontoured anatomical form defects (Bravo)
62196045|NCT05011344|EXPERIMENTAL|Exposed hospital staff|"Hospital health care or non-health care staff willing to participate in the study:~* Healthcare personnel (physician, nurse, caregiver) who have worked for a minimum of 2 weeks since March 1, 2020 in a care unit dedicated to the management of patients confirmed or suspected of COVID-19 infection, in the participating centers: intensive care units, emergency rooms, radiology, COVID-19 units;~* Staff (physician, technician) who have worked for a minimum of 2 weeks since March 1, 2020 in the AP-HM laboratories handling samples from patients confirmed or suspected of having COVID-19 infection."
62196046|NCT05011344|OTHER|'Non-exposed' hospital workers|Hospital health care worker (physician, nurse, caregiver) willing to participate in the study who has not worked since March 1, 2020 in an intensive care unit or emergency department or other department dedicated to the management of patients confirmed or suspected of having COVID-19 infection.
62196047|NCT03597451||Multiple sclerosis|Patients with MS between 0-5,5 score according to the Extended Disability Status Scale (EDSS)
62196048|NCT03597451||Control|Healthy individuals of similar age and sex to patients
62399032|NCT06648408|NO_INTERVENTION|Control group|The children in the control group in this study will not receive any intervention, according to the German guidelines for idiopathic coxa antetorta 2002. This is in line with the standard approach, as children in this developmental phase typically do not receive therapy for this condition.
62574509|NCT06454669|PLACEBO_COMPARATOR|Placebo|Capsules with placebo (i.e., cellulose filler), twice per day for 8 weeks.
62574510|NCT03531203|EXPERIMENTAL|With Soursop|Treatment group (with soursop group) was a group which receive soursop supplementation
62574511|NCT03531203|PLACEBO_COMPARATOR|Without Soursop|Control group (without soursop group) was a group which do not receive any intervention (placebo)
61978029|NCT06494943|EXPERIMENTAL|Fixed-dose expansion phase|"The second phase is the fixed-dose expansion stage, aiming to enroll 15 patients. They will receive the R2PD doses of paclitaxel and cisplatin, combined with IBI110 200 mg on day 1 every 3 weeks administered intravenously, and sintilimab 200 mg on day 1 every 3 weeks administered intravenously, for a total of two cycles.~All subjects will undergo radical surgery after neoadjuvant therapy. Adjuvant radiotherapy (chemoradiotherapy) will be administered postoperatively based on pathological factors as appropriate."
62196049|NCT00735280|EXPERIMENTAL|Reduced dose of unfractionated heparin|
62196050|NCT05946694||students|30 students of the third year of Emergency Medicine, full-time first-degree program at the Medical University of Lodz, Poland, were enrolled in the study.
62196051|NCT01418404|EXPERIMENTAL|Noxious TS in study A|Noxious TS in study A
62196052|NCT01418404|ACTIVE_COMPARATOR|Innocuous TS|Innocuous TS in study A
62196053|NCT01418404|EXPERIMENTAL|High Frequency of Noxious TS|High Frequency of Noxious TS in study B
62196054|NCT01418404|ACTIVE_COMPARATOR|Low Frequency of Noxious TS|Low Frequency of Noxious TS in study B
62399033|NCT02303327|OTHER|ADT+EBRT+ HDR brachytherapy boost|Standard fractionation radiotherapy: 46 Gy in 23 fractions (EBRT) and a 15-Gy HDRB boost in conjunction with 28 months of androgen deprivation therapy (ADT).
62399034|NCT02303327|ACTIVE_COMPARATOR|ADT+Hypofractionated Dose Escalation RT|Hypofractionated dose escalation radiotherapy: 68 Gy in 25 fractions in conjunction with 28 months of androgen deprivation therapy (ADT).
62196055|NCT01418404|EXPERIMENTAL|High Intensity of Noxious TS|High Intensity of Noxious TS in study C
62574512|NCT04487015|NO_INTERVENTION|Part I: Non-Digital (Control)|Participants who currently receive performance nutrition support, via a qualified practitioner as indicated by a member of the sports science team at their sporting organisation, will be assigned to the non-digital approach (control). These participants will not receive any intervention from the research team for the duration of this study (6 weeks).
62009789|NCT03246958|EXPERIMENTAL|MTC - Nivolumab alone for two week|Medullary Thyroid Cancer (MTC)participants received Ipilimumab 1mg/kg q6 weeks via IV infusion, starting two weeks after Nivolumab 3mg/kg q6 weeks.
62196056|NCT01418404|ACTIVE_COMPARATOR|Low Intensity of Noxious TS|Low Intensity of Noxious TS in study C
62399035|NCT02061293|EXPERIMENTAL|Psilocybin|Psilocybin 25 mg/70 kg PO administered at week 4, 25-40 mg/70 kg PO administered at week 8.
62399036|NCT02061293|ACTIVE_COMPARATOR|Diphenhydramine|Diphenhydramine 50 mg PO administered at week 4, 50-100 mg PO administered at week 8.
62399037|NCT04416009||mild pneumonia ECW|the covid 19 pneumonia patients who hospitalised to the ward
62399038|NCT04416009||severe pneumonia ECW|the covid 19 pneumonia patients who hospitalised to the intensive care unit
62399039|NCT01194323||Controls|No complaints or history of heartburn or acid regurgitation; no erosion at EGD; and normal pH monitoring
62399040|NCT01194323||GERD Cases|Patients with esophageal erosion at EGD and abnormal pH monitoring.
62574513|NCT04487015|EXPERIMENTAL|Part I: MP+ Call + MesC [6 weeks]|For part one of study, participants who currently do not receive performance nutrition support, will be given access to an app-based menu planner (MP) for 6 weeks with coach support that gives ad-hoc messaging and calls.
62574514|NCT04487015|EXPERIMENTAL|Part II: Stage 1- MP [1week]|For the pilot SMART trial (part two of study), participants (not the same participants as part one) who currently do not receive performance nutrition support, will be given access to a menu planner app (MP) for 4 weeks. In the first 1 week, participants will only receive MP.
62574515|NCT04487015|EXPERIMENTAL|Part II: Stage 2 - R1-MP [1 week]|"For participants in Part II: Stage 1- MP \[1week\], after the first 1week, this group of participants are considered responders (R1) so they continue with MP only for another 1 week.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
62574516|NCT04487015|EXPERIMENTAL|Part II: Stage 2 - NR1-MP [1 week]|"For participants in Part II: Stage 1- MP \[1week\], after the first 1 week, this group of participants are considered non-responders (NR1) and are re-randomised to continue with MP only for another 1 week.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
61978030|NCT05693675|EXPERIMENTAL|Postoperative methadone|
61978031|NCT05693675|PLACEBO_COMPARATOR|Postoperative placebo|
62196057|NCT06240819|OTHER|Sleeper Stretch|Sleeper stretch in a side lying position in 90o abduction, elbow at 90o flexion and then performing shoulder IR for three sets with three repetitions.
61978032|NCT01940679|EXPERIMENTAL|Fresh meat stick|Fresh meat stick w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.
61978033|NCT01940679|EXPERIMENTAL|Stored meat stick|Stored meat stick with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production
62009790|NCT03246958|EXPERIMENTAL|MTC - Ipilimumab alone for two weeks|Medullary Thyroid Cancer (MTC) participants received Nivolumab 3mg/kg q6 weeks via IV infusion, starting two weeks after Ipilimumab 1mg/kg q6 weeks.
62009791|NCT03246958|EXPERIMENTAL|ATC - Nivolumab alone for two week|Anaplastic Thyroid Cancer (ATC) received Ipilimumab 1mg/kg q6 weeks via IV infusion, starting two weeks after Nivolumab 3mg/kg q6 weeks.
62009792|NCT03246958|EXPERIMENTAL|ATC - Ipilimumab alone for two week|Anaplastic Thyroid Cancer (ATC) received Nivolumab 3mg/kg q6 weeks via IV infusion, starting two weeks after Ipilimumab 1mg/kg q6 weeks.
62399041|NCT00935675|ACTIVE_COMPARATOR|Antidepressant treatment|
62399042|NCT00935675|PLACEBO_COMPARATOR|Placebo|
62399043|NCT00197704|PLACEBO_COMPARATOR|Placebo|Placebo
62399044|NCT00197704|EXPERIMENTAL|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium
62399045|NCT06011629|OTHER|Arthroplasty-naïve Aquacel group|All subject's receive the same dressing, this group is comprised of patients consented to the study and will receive the Aquacel dressing but have not had previous joint replacement surgery. Therefore, we consider them the arthroplasty-naïve Aquacel group.
62399046|NCT06011629|OTHER|Prior Aquacel group|All subject's receive the Aquacel dressing, this group is comprised of patients who have undergone previous joint replacement surgery (hip or knee) and have had a Aquacel dressing. This also includes patients who have had prior exposure to glue/mesh dressing either as a patient or healthcare worker.
62399047|NCT00054821|EXPERIMENTAL|Group A|Group A participants will be treated with mechanical distraction with motion
62399048|NCT00054821|ACTIVE_COMPARATOR|Group B|Group B participants will be treated with mechanical distraction without motion
62399049|NCT04928508|EXPERIMENTAL|OK-1 capsule|OK-1 (oral, BID) within a 21-days cycle
62399050|NCT01432743|EXPERIMENTAL|Cartomerge|Use of Cartomerge to guide ablation
62399051|NCT01432743|ACTIVE_COMPARATOR|NavX Fusion|Use of NavX fusion to guide ablation
62399052|NCT01194765|EXPERIMENTAL|Cognitive Behavioural Therapy|
62399053|NCT01194765|NO_INTERVENTION|Waiting List|
62574517|NCT04487015|EXPERIMENTAL|Part II: Stage 2 - NR1-MP + Call + MesC [1 week]|"For participants in Part II: Stage 1- MP \[1 week\], after the first 1 week, this group of participants are considered non-responders (NR1) and are re-randomised to have MP and additional coach support for another 1 week. The coach support consists of up to 3 coach-initiated messaging and ad-hoc calls to participant.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
62574518|NCT04487015|EXPERIMENTAL|Part II: Stage 3 - R2-MP [2 weeks]|"After going through Part II: Stage 2, this group of participants are considered responders (R2) so they continue with MP only for 2 weeks.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
62574519|NCT04487015|EXPERIMENTAL|Part II: Stage 3 - NR2-MP [2 weeks]|"After going through Part II: Stage 2, this group of participants are considered non-responders (NR2) and are re-randomised to use MP only for another 2 week.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
62574520|NCT04487015|EXPERIMENTAL|Part II: Stage 3 - NR2-MP + Call + MesC [2 weeks]|"After going through Part II: Stage 2, this group of participants are considered non-responders (NR2) and are re-randomised to have MP and additional coach support for another 2 weeks. The coach support consists of up to 3 coach-initiated messaging and ad-hoc calls to participant.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
62574521|NCT06383754|EXPERIMENTAL|Clareon IOL from Alcon|Monofocal artificial lens implanted in the eye following cataract surgery
62574522|NCT06383754|ACTIVE_COMPARATOR|Tecnis 1 from from Precision Lens|Monofocal 1 piece IOL implanted in the eye following cataract surgery
62574523|NCT01803750||Primary Care Providers|Conduct and analyze in-depth, semi-structured interviews with community-based primary care providers serving large Latino populations and Form a community-based participatory committee.
62574524|NCT03085966|EXPERIMENTAL|autologous immune cell therapy|Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
62574525|NCT00532389|EXPERIMENTAL|Panobinostat (LBH589)|
62009793|NCT03246958|EXPERIMENTAL|ATC - Ipilimumab + Nivolumab|Anaplastic Thyroid Cancer (ATC) received Nivolumab 3mg/kg q6 weeks and Ipilimumab 1mg/kg q6 weeks via IV infusion.
62009794|NCT04575402||CSMC prostate cancer patients receiving ADT|Prostate cancer patients recruited from oncology clinic at Cedars-Sinai Medical Center.
62009795|NCT04575402||Veterans with prostate cancer|Prostate cancer patients recruited from the Veteran Affairs Oncology Clinic (Durham, NC).
62009796|NCT04453384|EXPERIMENTAL|Treatment arm|"Administrations of XAV-19~* Phase 2a: XAV-19 at 0.5 mg/kg at D1 and D5(Group 1) or at 2 mg/kg at D1 and D5 (Group 2), or at 2 mg/kg at D1 (groupe 3)~* Phase 2b: Selected dose from Phase 2a : one administration at 2 mg/kg on day1"
62009797|NCT04453384|PLACEBO_COMPARATOR|Placebo arm|"same administration as treatment arm~* Phase 2a: two administrations of placebo (day 1 and day 5) for Group 1 and 2, one administration of placebo on day 1 for Group 3~* Phase 2b: one administration of placebo on day 1"
61978034|NCT01940679|EXPERIMENTAL|Fresh pound cake|Fresh pound cake w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.
62009798|NCT03680729|EXPERIMENTAL|aBSB|aBSB is the adaptation of BSB. BSB a two part intervention to improve rates of community-based HIV testing and prevention education in black young MSM (YMSM). BSB was developed on Information Motivation Behavioral Skills (IMB) theory. The first part of BSB uses Motivational Interviewing in a culturally appropriate way to encourage participants to accept testing and return for test results. The second part is conducted after the participant has received his result, assuming it was not reactive and offers prevention education.
62009799|NCT03680729|ACTIVE_COMPARATOR|Street Outreach|Standard street outreach was used as the control in the original BSB trial.
62009800|NCT05369702||CASE(coronary artery disease)|Patients with confirmed coronary artery disease
62009801|NCT05369702||CONTROL|People without coronary artery disease
62009802|NCT03090399|NO_INTERVENTION|control group|patients in which standard fluid administration was applied
62009803|NCT03090399|ACTIVE_COMPARATOR|case group|patients in which fluids were administered according to FloTrac parameters
62574526|NCT06211686|EXPERIMENTAL|Protein supplement and Resistance exercise|
61978035|NCT01940679|EXPERIMENTAL|Stored pound cake|Stored pound cake with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production.
62574527|NCT02316600|NO_INTERVENTION|Control|30 frail volunteers of the control group in the second phase won't be equipped with the smart insole.
62574528|NCT02316600|EXPERIMENTAL|Intervention|30 frail volunteers of the intervention group in the second phase will be equipped with the smart insole for 3 months, to encourage the frail elderly person's physical activity and to monitor key parameters of frailty
62574529|NCT02022280|EXPERIMENTAL|Proton Pump Inhibitor|Lansoprazole (Prevacid)
61978036|NCT01862198|EXPERIMENTAL|hybrid metallic stent|Patients group who were inserted a hybrid metallic stent
61978037|NCT06136754|ACTIVE_COMPARATOR|Group I|A fluoride varnish containing 5.0% NaF w/w A fluoride free toothpaste A commercially available adult soft bristle toothbrush
62009804|NCT04770480|ACTIVE_COMPARATOR|Standard Care (SC)|Standard Post-Surgical Care utilizing opioids.
62009805|NCT04770480|ACTIVE_COMPARATOR|Enriched Surgical Management Pathway (EMP)|Enriched Surgical Management Pathway utilizing Physical Therapy and Mindfulness in addition to Standard Protocol.
62009806|NCT05592886|EXPERIMENTAL|Intervention arm|Receive SMT04 formula
62009807|NCT05592886|PLACEBO_COMPARATOR|Placebo arm|Receive active placebo
62009808|NCT02258152|PLACEBO_COMPARATOR|Placebo|
62009809|NCT02258152|EXPERIMENTAL|SYN120|
62574530|NCT02022280|PLACEBO_COMPARATOR|Vitamin pill|
62574531|NCT04174599|EXPERIMENTAL|F-627|Subjects will receive F-627 (20 mg/dose, s.c.) on day 3 of each cycle, i.e., 48 ±4 h after the start of chemotherapy.
62574532|NCT04174599|ACTIVE_COMPARATOR|GRAN®|Subjects will receive GRAN® \[5 μg/kg/day, s.c., once daily (± 4 h) up to 2 weeks or until neutrophil count returns to 5.0 ×109/L\] on day 3 of each cycle, i.e., 48 ±4 h after the start of chemotherapy.
62574533|NCT02300662|EXPERIMENTAL|Cycle Ergometer|Conventional physiotherapy and cycle ergometer 20 minutes, at 20 cycles per minute, once per day for as long as they remain on invasive mechanical ventilation
62574534|NCT02300662|SHAM_COMPARATOR|Conventional Physiotherapy|Upper and lower extremity functional diagonals from the proprioceptive neuromuscular facilitation method and manual bronchial hygiene exercises.
62574535|NCT04543149||Case|Patients with idiopathic granulomatous mastitis
62574536|NCT04543149||Control|Healthy volunteers
61978038|NCT06136754|EXPERIMENTAL|Group II|A fluoride free varnish A fluoride free toothpaste A commercially available adult soft bristle toothbrush
61978039|NCT04097808|EXPERIMENTAL|collagen peptide bovine high molecular weight-Water|source: bovine; standardized to 10 g provided as single dose. Orally applied in water.
61978040|NCT04097808|EXPERIMENTAL|collagen peptide bovine low molecular weight-Water|source: bovine; standardized to 10 g provided as single dose. Orally applied in water.
62009810|NCT05499676|EXPERIMENTAL|Mobile Coached Intervention|Participants randomized to the mobile intervention condition will receive access to the mobile app for 6 consecutive months. Participants will still be able to access other usual care options and will be encouraged to follow the discharge plan provided to them by the eating disorder program from which they were discharged.
62009811|NCT05499676|EXPERIMENTAL|Mobile Coached Intervention Plus Social Networking|Participants randomized to the mobile intervention plus social networking condition will receive access to the mobile app, as well as Facebook social networking component, for 6 consecutive months. Participants will still be able to access other usual care options and will be encouraged to follow the discharge plan provided to them by the eating disorder program from which they were discharged.
62009812|NCT05499676|NO_INTERVENTION|Treatment as Usual|This group will be encouraged to follow the discharge plan provided to them by the eating disorder program from which they were discharged. Participants will also be encouraged to follow-up with their eating program for additional referral information as needed and/or to reach out to the National Eating Disorders Association (NEDA) and/or Association for Anorexia Nervosa and Associated Disorders (ANAD ) for assistance with finding treatment providers/resources as needed. NEDA and ANAD provide helplines and online treatment provider databases to help individuals find providers.
62009813|NCT02147808|EXPERIMENTAL|All subjects|All subjects will receive a single oral midazolam dose on Day 1 while fasting. Days 2 to 4 will be Washout days. On Day 5, subjects will begin a 5-day regimen of telotristat etiprate. On Day 9, subjects will receive a morning dose of telotristat etiprate with a single dose of midazolam while fasting.
62196058|NCT06240819|OTHER|Cross Body Stretch|cross-body stretch will be done in sitting position. Three sets of the each stretch position would be held for 30 seconds with a 1 minute break between sets.
62196059|NCT05436405|EXPERIMENTAL|transpedal access|Trans-pedal Access for Endovascular Revascularization in patients with failed antegrade access forComplex Infra-popliteal Lesions in Critically Ischemic Limb
62574537|NCT03770754|EXPERIMENTAL|Control group|"Control Group (n= 15): the root canals were prepared manually with K-files (Dentsply-Maillefer, Ballaigues, Switzerland) and step back technique up to size #35."
62574538|NCT03770754|EXPERIMENTAL|Group 1|Group 1 (n= 15): the root canals were instrumented with rotary LightSpeed LSX instruments (Discus Dental, Culver City, CA, USA). They were used to complete the canal preparation to a size #50 for the anteriors and molar teeth to size #40.
62574539|NCT03770754|EXPERIMENTAL|Group 2|Group 2 (n= 15): root canals were instrumented with ProTaper Next (Dentsply Maillefer, Ballaigues, Switzerland) using X1, X2 to X3. 0.5% NaOCl was used for irrigation.
62574540|NCT01594736|ACTIVE_COMPARATOR|ORSIRO|
62574541|NCT01594736|ACTIVE_COMPARATOR|XIENCE PRIME DES|
62574542|NCT04860648|EXPERIMENTAL|LUS group|patients receive lung ultrasound examination, and doctors give the treatment according to the LUS results
62574543|NCT04860648|NO_INTERVENTION|Control group|patients receive no lung ultrasound examination and other intervention
62574544|NCT02268292|EXPERIMENTAL|Bicycle Exercise|Bicycle Exercise for 12 weeks
62574545|NCT03298958|PLACEBO_COMPARATOR|Placebo Oral Tablet|Subject will be randomized to take the Placebo once daily for 2 years or until disease recurrence
62574546|NCT03298958|ACTIVE_COMPARATOR|Sirolimus (Rapamycin) 0.5 mg/day for 2 years|Subject will be randomized to take Sirolimus (Rapamycin) 0.5mg once daily for 2 years or until disease recurrence
62574547|NCT03742362|EXPERIMENTAL|Bone marrow fat fraction by MRI|MRI scans of distal radius will be performed to all participants to monitor the fat fraction in bone marrow
62574548|NCT00179660|EXPERIMENTAL|Lenalidomide|Participants received single-agent lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed, lenalidomide treatment was discontinued for any reason, or the study was terminated.
62574549|NCT04863859||Grandchildren|Granddaughter or Grandson of the person living with dementia who serves as the primary caregiver
62574550|NCT04863859||Siblings|Brother, sister, brother-in-law or sister-in-law of the person living with dementia who serves as the primary caregiver
62574551|NCT04863859||Nieces/Nephews|Niece or nephew of the person living with dementia who serves as the primary caregiver
62574552|NCT04863859||Step-Kin|Step-kin (step-daughter, step-son, step-sister, step-brother or other step-kin) of the person living with dementia who serves as the primary caregiver
62574553|NCT04863859||Adult Child|Adult child (son or daughter) of the person living with dementia who serves as the primary caregiver
62574554|NCT04863859||Spouse|Spouse (husband or wife) of the person living with dementia who serves as the primary caregiver
62574555|NCT03713060|OTHER|Women with RYGB and fetus/ child|20 pregnant women with previous gastric bypass surgery. During pregnancy the women will be tested with mixed meal test and continuous glucose monitoring for the diagnosis of hypoglycemia. Ultrasounds of fetal growth will be performed and after birth anthropometrics of the newborn will be meaured including a DXA-scan to estimate bodycomposition.
62574556|NCT03713060|OTHER|Matched controls and fetus/ child|20 pregnant women matched on age, prepregnancy-BMI and parity (n = 20). During pregnancy the women will be tested with mixed meal test and continuous glucose monitoring for the diagnosis of hypoglycemia. Ultrasounds of fetal growth will be performed and after birth anthropometrics of the newborn will be meaured including a DXA-scan to estimate bodycomposition.
62783184|NCT02464410|ACTIVE_COMPARATOR|Enhanced Usual Care|In addition to covering the VHA's long-term OA informed consent process, the enhanced usual care (EUC) condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic. This EUC condition will include some information related to risks of opioid use as part of the informed consent and will consequently have sufficient face validity as an intervention on opioid safety to effectively blind participant to randomization. However, the EUC therapist will not use the motivational enhancement approach of discussing strategies for avoiding these risks. It is designed to be equal in length to the motivational intervention.
62399054|NCT06724133||Case group|Patients diagnosed with colorectal polyps by enteroscopy in the gastroenterology department of our hospital were collected. For patients with two or more different types of histopathological examination results, all cases containing tubular adenoma, tubular villous adenoma and villous adenoma were classified into the adenoma group.
62399055|NCT06724133||Control group|Age - and sex-matched family members of the patient were selected, and no enteric-related diseases were detected by colonoscopy.
62399056|NCT01021449||Control|Healthy subjects
62574557|NCT05290883|EXPERIMENTAL|Group A: Yoghurt drink (polar lipid) intervention|
62574558|NCT01226966||A|
62574559|NCT05891834|EXPERIMENTAL|Low dose|INV-202, 10 mg
62399057|NCT01021449||Schizophrenia|Schizophrenic patients
62574560|NCT05891834|EXPERIMENTAL|High dose|INV-202, 50 mg
62574561|NCT05891834|PLACEBO_COMPARATOR|Placebo|Placebo Matching size and number of tablets
62574562|NCT05891834|EXPERIMENTAL|Middle Dose|INV-202, 20 mg
62574563|NCT05461001|EXPERIMENTAL|Warm Up Exercises daily for Cardiorespiratory Fitness|Effect of warm up activities daily on cardiorespiratory fitness of Male Football Players
62574564|NCT05461001|EXPERIMENTAL|Endurance based Exercises for Cardiorespiratory Fitness|Effect of sports-specific endurance based exercises on cardiorespiratory fitness of Male Football Players
62574565|NCT03894189|ACTIVE_COMPARATOR|doxapram group (GROUP D)|The patients in this group will receive loading dose of (1 mg/kg) followed by an infusion of (1mg/kg/h)
62574566|NCT03894189|ACTIVE_COMPARATOR|theophylline group (GROUP T)|the therapeutic loading dose (5mg/kg) followed by an infusion of (0.5 mg/kg/h)
62574567|NCT05334953|EXPERIMENTAL|Experimental: ESWT(Extracorporeal Shock Wave Therapy)|Group 1 (n = 17) will be given two times a week, total 5 sessions of ESWT + home exercise program
62574568|NCT05334953|EXPERIMENTAL|Phonophoresis|Group 2 ( n=17) will be given five times a week, total 10 sessions of diclofenac phonophoresis + home exercise program
62574569|NCT05334953|EXPERIMENTAL|Ultrasound therapy|Group 2 (n=17) will be given five times a week, total 10 sessions of ultrasound therapy+ home exercise program
62574570|NCT05334953|OTHER|Control goup|Group 4 ( n=17) will be given home exercise program
62734667|NCT03995745|NO_INTERVENTION|control|Of the 20 participants randomized to the control arm, 10 will be randomly assigned to receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.
62399058|NCT05835310|EXPERIMENTAL|Anifrolumab|Randomized participants will receive a single dose of Anifrolumab via IV infusion every 4 weeks
62399059|NCT05835310|PLACEBO_COMPARATOR|Placebo|Randomized participants will receive matching placebo via IV infusion
62399060|NCT01388322|EXPERIMENTAL|Enoxaparin|Subcutaneous administration of one dose daily of enoxaparin
62399061|NCT01388322|NO_INTERVENTION|expectant management|Usual management
62399062|NCT05179811||Cohort|Patients with functional dysphonia using the Voice Handicap Index score.
62009814|NCT06229574|EXPERIMENTAL|intervention group|The effect of breastfeeding education given with virtual reality glasses on breastfeeding success and breastfeeding self-efficacy will be evaluated. The education given during pregnancy will be evaluated on the first and seventh days after birth.
62009815|NCT06229574|NO_INTERVENTION|control group|Breastfeeding success and breastfeeding self-efficacy of women included in this group during pregnancy will be evaluated on the first and seventh days after birth.
62009816|NCT01256775|PLACEBO_COMPARATOR|NCX4016 placebo|NCX4016 placebo b.i.d for 6 months
62214995|NCT04677179|PLACEBO_COMPARATOR|Placebo|Participants received a subcutaneous injection of placebo every 2 weeks from weeks 0 to 12. Week 12 responders entered the maintenance period and continued with the same treatment. Week 12 non-responders entered the extension period where they received subcutaneous injection of high dose LY3471851 every 2 weeks up to week 50. At week 26, extension period non-responders were discontinued from treatment. Post-treatment, participants entered follow-up period and were observed for 6 weeks for safety.
62399063|NCT04590482|EXPERIMENTAL|letrozole then misoprostol|description:letrozole 2.5 mg each 12hours for 2 days at home followed by misoprostol 800mcg vaginally at hospital repeated after 4 hours if needed
62009817|NCT01256775|ACTIVE_COMPARATOR|NCX4016|ncx4016,800 mg b.i.d., on top of aspirin 100 mg o.d.
62009818|NCT02700230|EXPERIMENTAL|Treatment (MV-NIS)|Patients receive MV-NIS intratumorally on day 1. Patients also undergo SPECT/CT at baseline and at 3 and 8 days after MV-NIS. Patients may also undergo SPECT/CT at 15 and 28 days, and at 6 weeks based on whether there is uptake on prior imaging studies. Patients also undergo MRI, ultrasound imaging, blood sample collection and tissue biopsy throughout the trial.
62009819|NCT05459870|EXPERIMENTAL|4SCAR T Cell Therapy for autoimmune diseases|
62009820|NCT01809626|EXPERIMENTAL|Zolpidem (10 mg)|Oral administration of the drug zolpidem (Ambien)
62009821|NCT01809626|PLACEBO_COMPARATOR|Gelatin capsule|Oral administration of a placebo pill that is packaged identically to the active condition.
62009822|NCT04341181|EXPERIMENTAL|Alectinib|Alectinib for patients with a molecular tumor profile that can potentially be targeted by Alectinib.
62009823|NCT04341181|EXPERIMENTAL|Atezolizumab|Atezolizumab for patients with a molecular tumor profile that can potentially be targeted by Atezolizumab.
62009824|NCT04341181|EXPERIMENTAL|Avelumab|Avelumab for patients with a molecular tumor profile that can potentially be targeted by Avelumab.
62009825|NCT04341181|EXPERIMENTAL|Axitinib|Axitinib for patients with a molecular tumor profile that can potentially be targeted by Axitinib.
62009826|NCT04341181|EXPERIMENTAL|Erlotinib|Erlotinib for patients with a molecular tumor profile that can potentially be targeted by Erlotinib.
62009827|NCT04341181|EXPERIMENTAL|Vemurafenib plus Cobimetinib (combination)|Vemurafenib plus Cobimetinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Vemurafenib plus Cobimetinib.
62009828|NCT04341181|EXPERIMENTAL|Trastuzumab plus Pertuzumab (combination)|Trastuzumab plus Pertuzumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab plus Pertuzumab.
62399064|NCT04590482|PLACEBO_COMPARATOR|placebo then misoprostol|Description:placebo each 12 hours for 2days at home followed by 800mcg misoprostol vaginally at hospital and repeat dose after 4 hours if needed
62009829|NCT04341181|EXPERIMENTAL|Trastuzumab emtansin|Trastuzumab emtansin for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab emtansin.
62399065|NCT05419765||non-cirrhotic NAFLD, carriers of the PNPLA3 I148M variant|Italian Caucasians, aged\> 18 and \<70 years, with non-cirrhotic NAFLD and carriers of the PNPLA3 I148M variant
62734668|NCT04670263|EXPERIMENTAL|Dry Eye Disease|Subjects who will be diagnosed at baseline with Dry Eye Disease according to standard diagnosis
62009830|NCT04341181|EXPERIMENTAL|Vismodegib|Vismodegib for patients with a molecular tumor profile that can potentially be targeted by Vismodegib.
62009831|NCT04341181|EXPERIMENTAL|Niraparib|Niraparib for patients with a molecular tumor profile that can potentially be targeted by Niraparib.
62009832|NCT05337059|EXPERIMENTAL|Transpulmonary based ventilation strategy|PEEP and tidal volume will be set to target expiratory and inspiratory transpulmonary pressures of 0 and 20 cmH2O, respectively.
62009833|NCT04037527|EXPERIMENTAL|Neoadjuvant Chemotherapy Plus Radiation Therapy|Up to 6 cycles (once a week) of chemotherapy with a 3+3 dose escalating plan (from 100 mg to 300 mg for Gemcitabine; 10 mg to 25 mg for Docetaxel) along with radiation (five days a week) for up to 6 weeks.
62009834|NCT03666598|NO_INTERVENTION|No tourniquet|No use of tourniquet during surgery
62009835|NCT03666598|EXPERIMENTAL|Tourniquet|Use of tourniquet during surgery. The cuff will be inflated to 300mmHg
62009836|NCT01570075|EXPERIMENTAL|RFA group|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
62009837|NCT01570075|EXPERIMENTAL|HR group|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
62399066|NCT05419765||non-cirrhotic NAFLD, carriers of the wild type allele|Italian Caucasian subjects, aged\> 18 and \<70 years, with non-cirrhotic NAFLD and carriers of the wild type allele
62734669|NCT04670263|ACTIVE_COMPARATOR|Healthy|Subjects who will be diagnosed at baseline with no Dry Eye Disease according to standard diagnosis
61978041|NCT04097808|EXPERIMENTAL|collagen peptide bovine low molecular weight- food matrix 1|source: bovine; standardized to 10 g provided as single dose. Orally applied in Food matrix 1
62399067|NCT06723548|EXPERIMENTAL|Patients with refractory MG treated with Telitacicept combined with low-dose steroids|This is an open-label, single-arm exploratory study of Telitacicept (240mg weekly, then every two weeks after achieving MMS or QMG reduction of ≥ 6 points) combined with a gradual reduction of steroids and other immunosuppressants. When the steroid dose is reduced to 5mg/day or 10mg/every other day, Telitacicept can be reduced to 160mg, administered subcutaneously every two weeks.
62574571|NCT05082259|EXPERIMENTAL|Part A-Escalation|"Increasing doses of ASTX660 in combination with a fixed dose of pembrolizumab to establish the maximum tolerated dose (MTD) of ASTX660 and Pembrolizumab when given in combination in patients with advanced solid tumours.~escalating doses of ASTX660 will be investigated in combination with a fixed dose of Pembrolizumab (200mg). ASTX660 administration will follow a 7 day on / 14 day off pattern (ie dosing for 7 consecutive days leading up to administration of the immune check-point inhibitors). Therefore in Cycle 1, ASTX660 will be given alone from Day 1 to Day 7, followed by a 14 day break, then taken again in Cycle 2 . Each cycle will run for a period of 21 days, with ASTX660 taken always on Days 1 to 7 and Pembrolizumab given always on Day 8.~Up to 4 dose levels of ASTX660 will be explored."
62574572|NCT05082259|EXPERIMENTAL|Part B-Expansion|"Patients in Part B will be treated at the RP2D as determined by the SRC after the initial dose escalation (Part A) has been completed. The treatment schedule will be the same as that for Part A, i.e. each cycle will be 21 days-long. Pembrolizumab will always be administered on D8 of every cycle. ASTX660 will be taken daily on Days 1-7.~Part B will be split into 3 cohorts; Cohort B1, Cohort B2 and Cohort B3.~Cohort B1: Patients with Immune-checkpoint refractory tumours Cohort B2: Patients with PD-L1 positive Cervical Cancer Cohort B3: Patients with Triple Negative Breast Cancer"
61978042|NCT04097808|EXPERIMENTAL|collagen peptide bovine low molecular weight- food matrix 2|source: bovine; standardized to 10 g provided as single dose. Orally applied in Food matrix 2
62574573|NCT00952068|EXPERIMENTAL|Tramadol Contramid® OAD 200mg|1 Tramadol Contramid® OAD 200mg tablet daily.
62574574|NCT02235064|EXPERIMENTAL|Sertraline|Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper
62574575|NCT02235064|PLACEBO_COMPARATOR|Placebo|Identical appearing capsule daily containing color-matched cellulose only
62574576|NCT04864938||Patients: ICU treated covid-19 patients|Neuropsychologic testing Respiratory function testing, chest x-ray and 6 minute walk test MRI of the brain and heart Laboratory tests Olfactory function tests Neuropsychology questionnaires
62574577|NCT04864938||Control group 1, covid-19 patients treated in the regular wards|As above, without 6 minute walk test or routine chest x-ray
62574578|NCT04864938||Control group 2, persons with covid-19 without hospitalization|As above, but without respiratory testing
62574579|NCT04864938||Control group 3, non-covid controls|As control group 2
62574580|NCT00975611|ACTIVE_COMPARATOR|Amantadine 100mg BID|Subjects take amantadine 100mg tablets twice per day (BID)
62574581|NCT00975611|ACTIVE_COMPARATOR|Amantadine, 200mg BID|Subjects take amantadine 200mg tablets twice per day (BID)
62574582|NCT00975611|PLACEBO_COMPARATOR|Amantadine, placebo BID|Subjects take placebo tablets twice per day (BID)
62574583|NCT06534489||Enrolled patients|After the patients were enrolled in the group, further relevant examinations (chest enhancement CT, PET-CT (optional), cranial MR, bronchoscopy, cardiac ultrasound, pulmonary function, electrocardiogram, blood tests) were completed, contraindications to surgery were ruled out, and the patients were evaluated to receive neo-adjuvant immuno-chemotherapy. After treatment, patients should be re-evaluated and amenable to surgical treatment after multidisciplinary discussion (thoracic surgery, respiratory medicine, radiology), and open or minimally invasive radical lung cancer surgery and systematic lymph node dissection were performed, including pneumonectomy, lobectomy, double lobectomy, extended lobectomy or sleeve lobectomy. The perioperative complications, lymph node dissection, R0 clearance rate, 3-year event-free survival rate, overall and disease-free survival rate, quality of life, and pulmonary function were recorded and evaluated.
62574584|NCT01894841|EXPERIMENTAL|CLASP Intervention|A 6 month adjunctive intervention consisting of 3 individual meetings, one family session, and 11 brief phone contacts with patient and identified significant other.
62574585|NCT01894841|OTHER|Safety Assessment and follow up Evaluation|Treatment as usual plus enhanced monitoring.
62574586|NCT05736016|ACTIVE_COMPARATOR|Active Therapy|Active comparator will undergo a 6-week in-patient rehabilitation aimed at: pharmacologic and non-pharmacologic pain management, improvement of vascular function, cardiopulmonary function, functions of skeletal muscles, range of motion and stability of peripheral joints, gait function, body position, with treadmill walking training being a mandatory part of the program. The rehabilitation program will also address individual needs with psychotherapy and vocational therapy. Follow-up period will be 6 weeks. For the time of the treatment and follow-up period the treatment arm will be provided with individually made corrective medial wedge insoles to be used during all therapeutic and other everyday activities.
62574587|NCT05736016|SHAM_COMPARATOR|Sham Therapy|Sham comparator arm will undergo a 6-week in-patient rehabilitation aimed at: pharmacologic and non-pharmacologic pain management, improvement of vascular function, cardiopulmonary function, functions of skeletal muscles, range of motion and stability of peripheral joints, gait function, body position, with treadmill walking training being a mandatory part of the program . The rehabilitation program will also address individual needs with psychotherapy and vocational therapy. Follow-up period will be 6 weeks. For the treatment and follow-up the control arm will be provided with individually made sham insoles to be used during all therapeutic and other everyday activities.
62574588|NCT05101863||Normal-weight, NON-food addicted|
62574589|NCT05101863||obese food addicted|
61978043|NCT04097808|EXPERIMENTAL|collagen peptide fish low molecular weight-Water|source: fish; standardized to 10 g provided as single dose. Orally applied in water.
62574590|NCT05101863||obese NON-food addicted|
62214996|NCT01181427|PLACEBO_COMPARATOR|Single Ascending Dose (SAD)|Healthy volunteers, receiving single ascending doses of ABT-267 or placebo.
62783185|NCT01050244|EXPERIMENTAL|Soy Protein|30g of soy protein from whole soybean soymilk powder given daily for 3 weeks
62783186|NCT01050244|PLACEBO_COMPARATOR|Milk Protein|30g of milk protein from whole milk powder given daily for 3 weeks
62783187|NCT00512785|EXPERIMENTAL|E1|
62783188|NCT00512785|EXPERIMENTAL|E2|
62574591|NCT02854332|ACTIVE_COMPARATOR|MRI by rTMS|Patients which received an MRI study of cortical plasticity by rTMS.
62399068|NCT04914975|EXPERIMENTAL|NMES Group|Participants will receive neuromuscular electrical stimulation of the abdominal wall before defaecation for 30 minutes over the course of 16 weeks.
62574592|NCT02854332|ACTIVE_COMPARATOR|MRI by tDCS|Patients which received an MRI study of cortical plasticity by tDCS.
62574593|NCT01544387|OTHER|Bed Rest|Subjects will have limited activity. Bed Rest
62574594|NCT01544387|OTHER|Activity|Activity
62574595|NCT02782559|EXPERIMENTAL|Sildenafil|Sildenafil 40mg oral tablet three times a day from randomization until delivery
62574596|NCT02782559|PLACEBO_COMPARATOR|Placebo|Matched to oral capsule of active treatment three times a day from randomization until delivery
62574597|NCT05847465||Case group (exercise heat stroke patients)|Participants enrolled in the case group have been experiencing exercise heat stroke and are participating in the main EXPLO-CCE study.
62574598|NCT05847465||Control group (healthy individuals)|Participants enrolled in the control group are healthy individuals who are participating in the main EXPLO-CCE study.
61978044|NCT04097808|EXPERIMENTAL|collagen peptide porcine low molecular weight-Water|source: porcine; standardized to 10 g provided as single dose. Orally applied in water.
61978045|NCT05248945|EXPERIMENTAL|Evobrutinib plus Carbamazepine|
61978046|NCT05195827|EXPERIMENTAL|PRM125|PRM125
61978047|NCT01397123|EXPERIMENTAL|Lifestyle counseling|
62574599|NCT03462160|PLACEBO_COMPARATOR|Placebo supply for 90 days|Patients will receive placebo (in blinded sachets)
62574600|NCT03462160|EXPERIMENTAL|Probiotic supply for 90 days|Patients will receive probiotics containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 (in blinded sachets).
62574601|NCT03267524|EXPERIMENTAL|Supportive Care (Walking for Recovery from Surgery)|Patients and caregivers receive Walking for Recovery from Surgery prehabilitation intervention in 4 sessions 3-7 days before surgery, before discharge, and at 2 and 7 days post-discharge.
62196060|NCT03468790|EXPERIMENTAL|CMAB007 + Seretide/Symbicort + Ventolin|CMAB007(recombinant humanized anti-IgE monoclonal antibody for injection ) will be at a fixed dose determined by the subjects' total IgE and weight at V0. All the subjects will be treated subcutaneously for 24 weeks. The 4-week total dose is 0.016mg/kg/IgE(IU/ml), administered every 2 or 4 weeks, for the subjects with total IgE level 60-700IU/ml. If the total IgE level is 700-1500IU/ml, they will be administered 375mg every 2 weeks. Symbicort(Budesonide and formoterol fumarate powder for inhalation) or Seretide (salmeterol xinafoate and fluticasone propionate powder for inhalation) will be used 1/2 inhalations bid as asthma-controlled drug during the whole study. Ventolin (Salbutamol sulphate aerosol) will be used as asthma rescue drug.
62574602|NCT02778009|EXPERIMENTAL|Fit Physician Group|"Subjects will receive activity monitor and will be required to attend monthly wellness lectures and weekly exercise intervention.~Every subject will undergo an iDEXA scan to measure body mass composition"
62574603|NCT02778009|ACTIVE_COMPARATOR|Activity Monitor Only Group|"Subjects will receive an activity monitor without any intervention Every subject will undergo an iDEXA scan to measure body mass composition~)"
62196061|NCT03468790|PLACEBO_COMPARATOR|Placebo + Seretide/Symbicort + Ventolin|Placebo is without active components of the study drug and used as same as the study drug.
62196062|NCT04773067|EXPERIMENTAL|UB-612|A proprietary high-precision designer S1-RBD protein based vaccine incorporating Th/CTL peptides to activate T cells.
62196063|NCT04773067|PLACEBO_COMPARATOR|Placebo|Normal saline 0.9%.
62214997|NCT01181427|PLACEBO_COMPARATOR|Multiple Ascending Dose (MAD)|Healthy volunteers, receiving multiple ascending doses of ABT-267 or placebo, OR, multiple doses of ABT-267 + single dose of a Cytochrome P450 inhibitor or placebo + single dose of a Cytochrome P450 inhibitor.
62214998|NCT01181427|ACTIVE_COMPARATOR|Food Effect (FE)|Healthy volunteers, receiving ABT-267, multi-dose, food effect.
62574604|NCT02778009|OTHER|Control Group|Subjects will not an activity monitor nor will they receive any intervention Every subject will undergo an iDEXA scan to measure body mass composition
62574605|NCT05898828|EXPERIMENTAL|1/ Phase I|H1299 cell lysate vaccine with Montanide(R) ISA-51 VG, entinostat, and nivolumab (Phase I component to determine lysate dose)
62574606|NCT05898828|EXPERIMENTAL|2/ Phase II|H1299 cell lysate vaccine with Montanide(R) ISA-51 VG, entinostat, and nivolumab (lysate at dose determined in Phase I)
62574607|NCT03942471|OTHER|Intervention Mindfulness Based Stress Reduction|Six Modules each delivering an important principle of Mindfulness Based Stress Reduction
62574608|NCT03942471|NO_INTERVENTION|Control Group|Wait Group - received no mindfulness teaching
62196064|NCT03993808|EXPERIMENTAL|Educational/behavioral support for hypertension self efficacy|On-site monitoring of pulse, blood pressure, weight, and surveys, at Months 0,1,3,6; Four educational sessions to address: 1) basics about blood pressure (BP); 2) training in home BP monitoring with personal Omron 10 device; 3) information about Dietary Intervention to lower Systemic Blood Pressure (DASH) eating plan, recipes and cooking demonstrations; 4) education about BP medication adherence. Interventions occur on the background of Carter Burden Network's implementation of a DASH-congruent menus for congregant meals for all seniors attending the sites, including those not enrolled in the protocol.
62574609|NCT05051280|EXPERIMENTAL|CBCT guidance group|Left atrial appendage occlusion under cone-beam computed tomography fusion image guidance
62574610|NCT00940823|ACTIVE_COMPARATOR|Ahmed FP7 Valve|Ahmed valve glaucoma drainage device implant for treatment of refractory glaucoma.
62574611|NCT00940823|ACTIVE_COMPARATOR|Baerveldt-350 Tube|Baerveldt tube glaucoma drainage device implant for treatment of refractory glaucoma.
62574612|NCT04144413|EXPERIMENTAL|Period 1 Open-label Ikervis|Period 1 for all patients: IKERVIS® (1mg/ml CsA). Instillation of one drop in each affected eye, once daily at bedtime. From Baseline for the first 12 months of treatment.
62574613|NCT04144413|EXPERIMENTAL|Period 2 Masked Ikervis|"Period 2 for markedly improved patients at Month 12 only, and double-masked fashion.~IKERVIS® (1mg/ml CsA). Instillation of one drop in each affected eye, once daily at bedtime. From Month 12 to Month 36."
62574614|NCT04144413|OTHER|Period 2 Masked Vehicle|"Other: Vehicle Comparator. Period 2 for markedly improved patients at Month 12 only, and double-masked fashion.~Vehicle. Instillation of one drop in each affected eye, once daily at bedtime. From Month 12 to Month 36."
62574615|NCT04614935|NO_INTERVENTION|Standard of Care|Pediatric patients with functional constipation who are treated with medications and/or behavioral therapies as they would be if they were not enrolled in the study. In addition to standard of care treatment, these families will fill out a brief quality of life survey.
62574616|NCT04614935|EXPERIMENTAL|Action Plan|Pediatric patients with functional constipation who are treated with standard of care medications and/or behavioral therapies and are also provided with a medication adherence log along with a constipation action plan. These families will also fill out a brief quality of life survey.
62574617|NCT04875221|EXPERIMENTAL|Experimental neurofeedback arm|The experimental arm will be able to view a feedback display that informs them of the strength of connectivity between the target regions. In both arms, feedback signals will be relayed back to the participant in the scanner through visualization software as a thermometer that increases or decreases as the extent to which the neural target model dominates (in other words, as the strength of directed connectivity between regions increases).
62574618|NCT04875221|SHAM_COMPARATOR|Sham-control neurofeedback arm|Participants in the sham-control arm will receive yoked sham neurofeedback signal (or fake signal), corresponding to a replayed feedback signal from a successful participant in the experimental group in order to ensure similar motivational states and following standard methods.
62196065|NCT03167151|EXPERIMENTAL|Arm A Intravesical|"Intravesical Pembrolizumab (solution for infusion) 50-200 mg, given on D1, D8, D15, D22, D29, D36 \& D64.~Dose to be decided after safety run-in."
62196066|NCT03167151|ACTIVE_COMPARATOR|Arm B Intravenous|Intravenous Pembrolizumab (solution for infusion), 200mg, given on D1, D22, D43, D64
62196067|NCT05769946|PLACEBO_COMPARATOR|placebo|Atopic dermatitis patients treated with placebo for 12 week.
62196068|NCT05769946|EXPERIMENTAL|Hemay005 60mg|Atopic dermatitis patients treated with Hemay005 60mg BID for 12 week.
62196069|NCT05769946|EXPERIMENTAL|Hemay006 75mg|Atopic dermatitis patients treated with Hemay005 75mg BID for 12 week.
62196070|NCT01835405|ACTIVE_COMPARATOR|LiquiBand Flex|LiquiBand® Flex skin adhesive is indicated for topical application only, to hold closed easily approximated skin edges from surgical incisions, including punctures from minimally invasive surgery, and simple, thoroughly cleansed trauma-induced lacerations. It may be used in conjunction with, but not in place of deep dermal sutures.
62196071|NCT01835405|ACTIVE_COMPARATOR|Dermabond Advanced|Dermabond Advanced™ adhesive is intended for topical application only, to hold closed easily approximated skin edges of wounds from surgical incisions, including incisions from minimally invasive surgery, and simple, thoroughly cleansed, trauma-induced lacerations. Dermabond Advanced ™ adhesive may be used in conjunction with, but not in place of, deep dermal stitches.
62196072|NCT01835405|ACTIVE_COMPARATOR|Sutures (Prolene)|Prolene™ Suture is indicated for use in general soft tissue approximation and/or ligation, including use in cardiovascular, ophthalmic and neurological procedures.
61978048|NCT03711045||Suicide Risk Group|patients with affective disorders(eg. bipolar disorder, major depression disorder) also have a history of suicide attempt in the past 6 months.
62009838|NCT01989533|PLACEBO_COMPARATOR|A|Placebo controlled (blinded)
62009839|NCT01989533|ACTIVE_COMPARATOR|B|Intranasal Randomized
62009840|NCT01989533|EXPERIMENTAL|C|Oral Open label
62009841|NCT01989533|EXPERIMENTAL|D|Intranasal Open Label
62009842|NCT03417297|EXPERIMENTAL|high intensity focused ultrasound|Initially, 3 patients will be enrolled and followed for 3 months to assess the safety of study intervention which is unilateral MR guides focused ultrasound thalamotomy (anterior nucleus). These data will be reviewed by the Data and Safety Monitoring Committee (DSMC) and the FDA. If approval is granted by the DSMC and FDA, then up to an additional 7 participants will be enrolled.
62009843|NCT06662721|EXPERIMENTAL|Treated with baricitinib|Ten patients with Takayasu arteritis refractory TNF-α inhibirors were treated with baricitinib.
62009844|NCT04947033|EXPERIMENTAL|TJ210001 Injection|Single Arm Dose expansion
62009845|NCT00906308|PLACEBO_COMPARATOR|Placebo|
62009846|NCT00906308|EXPERIMENTAL|MF101 5 g/day|
62009847|NCT00906308|EXPERIMENTAL|MF101 10 g/day|
62009848|NCT04162847|EXPERIMENTAL|Mobile Coached Intervention|This group will receive access to the mobile intervention for 6 months. They will be assigned to the primary program (i.e., anxiety, depression, or eating disorders) they screen positive for. If a person screens positive for more than one disorder, they will be given the choice of which program they want to start with. They will also be provided preventive interventions for anxiety, depressive, or eating of disorders they may not have but be at risk for. After two weeks in the program, the coach will assign the components presumed to be essential to intervention effects for comorbid disorder(s) and risk factors.
62009849|NCT04162847|NO_INTERVENTION|Referral to Counseling Center|This group will receive information about how to make an appointment at their counseling center and will be encouraged to do so.
62574619|NCT05136105|EXPERIMENTAL|Preventive Narrative Exposure Therapy (PreNET) family intervention|"The intervention group receives treatment as usual in the first aid center for survivors of sexual abuse. This includes medical and judicial assistance if necessary. Furthermore, they receive the psychological family focused intervention.~The intervention consists of a total of three sessions with the aim of reestablishing and validating the relationship between sexually abused children and their parents. The intervention focuses on psychoeducation regarding shame and other trauma related disorders. Further, the acknowledgement of shame and embarrassment as well as parental skills are intended to be improved."
62574620|NCT05136105|NO_INTERVENTION|No Intervention group|The control group will receive only the assessments, and treatment as usual in a first aid center for survivors of sexual abuse. This includes usually a brief assessment of what happened as well as medical and judicial assistance if necessary.
62574621|NCT03581058|EXPERIMENTAL|Cannabis - Jean Guy|A participant will be administered 1g of Jean Guy strain of cannabis.
62196073|NCT04499612||"Group Single-chamber CIED (A1)"|50 patients with permanent atrial fibrillation and indications for cardiac implantable electronic device implantation (single-chamber system).
61978049|NCT03711045||Disorder Control Group|patients with affective disorders(eg. bipolar disorder, major depression disorder) and without suicide ideation or behavior.
61978050|NCT03711045||Healthy Control Group|
62574622|NCT03581058|EXPERIMENTAL|Cannabis - Churchill|A participant will be administered 1g of Churchill strain of cannabis.
62574623|NCT03581058|NO_INTERVENTION|Sober|All participants will complete same tasks sober.
62574624|NCT05807698|EXPERIMENTAL|experimental|Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
62009850|NCT02660736|EXPERIMENTAL|Regimen AB|"Subjects will be receive Regimen A treatment in Session 1 followed by Regimen B treatment in Session 2.~Regimen A: 50 mg Albiglutide Liquid Auto-injector + Placebo lyophilized DCC Pen injector.~Regimen B: 50 mg Albiglutide lyophilized DCC Pen injector + Placebo Liquid Auto-injector.~A minimum of an 8-week washout period between study treatment administration of Session 1 and Session 2."
62196074|NCT04499612||"Group Dual-chamber CIED (A2)"|50 patients with atrioventricular block/sick sinus syndrome and indications for cardiac implantable electronic device implantation (dual-chamber system).
62196075|NCT04499612||"Group Dual-chamber CIED + Atrial fibrillation (A3)"|50 patients with atrioventricular block/sick sinus syndrome, paroxysmal or persistent atrial fibrillation and indications for cardiac implantable electronic device implantation (dual-chamber system).
62196076|NCT04499612||"Group CIED Replace (B)"|50 patients with cardiac implantable electronic device implantation 6-12 years ago (single- or dual-chamber system).
62399069|NCT01955291|EXPERIMENTAL|Reinforced Feedback in Virtual Environment|During the experiment, patients in the RFVE training group (Reinforced Feedback in Virtual Environment) will receive 1 hour of virtual reality-based therapy by means of RFVE and 1 hour of TNR treatment (Traditional Neuromotor Rehabilitation). Both treatments will last 1 hour a day, five days weekly for four weeks. The treatment is focused on motor function impairment of the upper extremity.
62399070|NCT01955291|OTHER|Traditional Neromotor Rehabilitation|The TNR training group (Traditional Neuromotor Rehabilitation) patients will be treated totally for two hours daily by means of a TNR programme. The treatment will last 4 weeks.
62399071|NCT02822118|EXPERIMENTAL|Chang'an I Recipe|Patients in this group were administered the Chang'an I Recipe for 8 weeks.
62399072|NCT02822118|PLACEBO_COMPARATOR|Placebo|Patients in this group were administered the placebo for 8 weeks.
62574625|NCT03018080|EXPERIMENTAL|Arm A (Phased Pembrolizumab Regimen)|Paclitaxel will be given as an IV infusion over 60 minutes, on days 1 and 8 every 21 (+/- 3) days during Cycles 1 and 2. No pembrolizumab will be given during Cycles 1 and 2. Starting with cycle 3 and subsequent cycles, pembrolizumab will be given as an IV infusion over 30 minutes before paclitaxel on day 1 every 21 (+/- 3) days.
62574626|NCT03018080|EXPERIMENTAL|Arm B (Concurrent Pembrolizumab Regimen)|Pembrolizumab will be given as an IV infusion on day 1 before paclitaxel every 21 (+/- 3) days. Paclitaxel will be given as an IV infusion over 60 minutes, on days 1 and 8 every 21 (+/- 3) days.
62196077|NCT04499612||"Group Conservative (C)"|50 patients with atrioventricular block/sick sinus syndrome/atrial fibrillation and without indications for cardiac implantable electronic device implantation (conservative group).
62196078|NCT04454034||Group1|The refractory elbow RA who undergo arthroscopic synovectomy
62196079|NCT02307045|ACTIVE_COMPARATOR|varenicline|Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po
62196080|NCT02307045|ACTIVE_COMPARATOR|nicotine|Nicotine replacement therapy with transdermal patches and/or chewing gums
62196081|NCT02033447|EXPERIMENTAL|Magnetic Nanoparticle Injection|Patients undergoing radical cystoprostatectomy or prostatectomy
62399073|NCT06633965|ACTIVE_COMPARATOR|Usual Care→AIDANET|Participants will complete 7 days/6 nights at home usual care period using their personal equipment. Participants will then use the AIDANET system during a 3 days/2 nights hotel admission. Participants will continue to use the AIDANET system at home for 7 days/6 nights.
62734670|NCT02332993||Supplementation Group|15 Type 2 Diabetics receiving Negative Wound Pressure Therapy will receive the FPP supplementation to take 3 times a day for 12 weeks (3g/dose).
61978051|NCT05168267|EXPERIMENTAL|Cognitive Processing Therapy (CPT) group|Arm = Cognitive Processing Therapy (CPT) Group = 4 groups of 12 (48 total; 24F/24M) receive CPT to treat PTSD
61978052|NCT04319120||questionnaires online|Each month, the nurse will contact the patients included, by mail or telephone, to fill out their questionnaires online or by mail, and to make a photo of the ulcer if it is healed.
62009851|NCT02660736|EXPERIMENTAL|Regimen BA|"Subjects will be receive Regimen B treatment in Session 1 followed by Regimen A treatment in Session 2.~Regimen A: 50 mg Albiglutide Liquid Auto-injector + Placebo lyophilized DCC Pen injector.~Regimen B: 50 mg Albiglutide lyophilized DCC Pen injector + Placebo Liquid Auto-injector.~A minimum of an 8-week washout period between study treatment administration of Session 1 and Session 2."
62009852|NCT01132144|EXPERIMENTAL|Endometrial injury group|Endometrial biopsy was performed once with a pipelle de Cornier® in the month before initiating controlled ovarian stimulation.
62009853|NCT01132144|SHAM_COMPARATOR|Control group|Introduction of the speculum and wiping of the cervix with gaze for 30 seconds.
62009854|NCT02366481|PLACEBO_COMPARATOR|Placebo-Control|The placebo-control group will take two placebo softgel capsules every day for 8 weeks.
62009855|NCT02366481|ACTIVE_COMPARATOR|Low-Dose Vitamin K2 (90-mcg/d)|The low-dose vitamin K group will take one 90-mcg vitamin K2 (menaquinone-7) softgel capsule and one placebo softgel capsule every day for 8 weeks.
62009856|NCT02366481|ACTIVE_COMPARATOR|High-Dose Vitamin K2 (180-mcg/d)|The high-dose vitamin K group will take two 90-mcg vitamin K2 (menaquinone-7) softgel capsules every day for 8 weeks.
62009857|NCT05729022|PLACEBO_COMPARATOR|Fluoroscopy|A local anesthetic (2% lidocaine), a 22G, 90mm needle (Quincke spinal needle) is inserted into the skin. Once the needle tip is in its target position, 0.5-5 cc of contrast (Omnipauqe) is injected. If the contrast spread along the spinal nerve into the epidural space, a mixture of 3 cc of 0.125% Marcaine and 40 mg of Depo-Medrol is injected or Diprofos (1/2 ampoule (2 ml) per level).
62009858|NCT05729022|EXPERIMENTAL|Ultrasound Microendoscopic|A US device with a curvilinear probe and with a microendoscope (EvoTouch+7 Star Scope), inserted into an 18G needle is used. This group will also receive one AP view fluoroscopy (as control) to check for the diffusion of the contrast material in the epidural space.
62009859|NCT04258839|EXPERIMENTAL|Brexpiprazole|"Participants received brexpiprazole based on the body weight for 26 weeks in this study.~Participants with body weight \< 50 kilograms (kg), received brexpiprazole tablets orally, once daily (QD) at dose of 0.25 mg on Days 1 to 3 followed by 0.5 mg on Days 4 to 7 and 1 mg on Days 8 to 14. Based on the investigator's judgment, the dose was increased to 1 or 1.5 mg starting from Day 15 until week 26.~Participants with body weight ≥ 50 kg received brexpiprazole tablet orally, QD at dose of 0.5 mg on Days 1 to 3, followed by 1.5 mg on Days 4 to 7, and 2 mg on Days 8 to 14. Based on the investigator's judgment the dose was increased to 1.5, 2, or 3 mg starting from Day 15 until week 26."
62009860|NCT05502796||Patient|Male and female ages 2-45 years old
62009861|NCT06663917|EXPERIMENTAL|Experienced Users|"All subjects will be fit with a modified cochlear implant program (experimental FAT) that changes which frequencies are presented to the cochlear implant. Subjects will complete a 1 month adaptation to the experimental FAT (438 Hz) and then a one month re-adaptation to the standard FAT (188 Hz). Speech perception tests and questionnaires will be collected before and after each FAT adaptation."
62196082|NCT06370845|ACTIVE_COMPARATOR|Verum (natural odour)|Participants will inhale 50 uL of a natural odour contained in mini-inhaler over a period of 15 min.
62009862|NCT01915563|NO_INTERVENTION|SBT and extubation|After a SBT patients will be extubated as usual
62009863|NCT01915563|EXPERIMENTAL|SBT and rest 60 min before extubation|After SBT patients will be reconnected to mechanical ventilation during 60 min before extubation
62009864|NCT04213794|EXPERIMENTAL|Treatment (cytoreduction, HIPEC)|Patients undergo cytoreduction. Patients also undergo HIPEC over 60 minutes consisting of doxorubicin and cisplatin. Patients then receive sodium thiosulfate IV over 12 hours. Patients also undergo CT scan, MRI or PET/CT scan and blood sample collection throughout study.
62196083|NCT06370845|PLACEBO_COMPARATOR|Placebo Inhalation|Participants will inhale 50 uL of placebo (propylene glycol) contained in mini-inhaler over a period of 15 min.
62196084|NCT03916640|EXPERIMENTAL|Co-formulation of insulin analog and pramlintide (ADO09)|Subcutaneous injection of ADO09 formulation + injection of placebo (0.9% NaCl) to ensure double dummy.
62196085|NCT03916640|ACTIVE_COMPARATOR|Humulin® + Symlin®|Simultaneous, separate subcutaneous injections of human insulin and pramlintide.
62009865|NCT01114841|EXPERIMENTAL|Tazarotene Foam|Subjects will be exposed to patches containing Tazarotene foam 0.1%
62009866|NCT01114841|PLACEBO_COMPARATOR|Vehicle Foam|Subjects will be exposed to patches containing Vehicle Foam
62009867|NCT02726763|EXPERIMENTAL|tDCS with cognitive training|We will collect: 1) self-reported demographic information (\~5 min) 2) cognitive functioning data (PAOFI) at session 1 and session 4 (\~10min) \[60\]; 3) behavioral data and EEG data from the tDCS stimulation task for each session (downloaded by investigators); 4) patient feedback on their experience with tDCS (tDCS Patient Experience Questionnaire (tPEQ)) for each session (\~5 min); 5) tDCS accrual and session completion rates at the completion of treatment and 6) Brunoni Adverse Events Questionnaire (\~5 min)
62009868|NCT05627895||Patient cohort|All patients will undergo both the SMA and the basal ganglia condition
62196086|NCT03916640|ACTIVE_COMPARATOR|Humalog®|Subcutaneous injection of insulin lispro + injection of placebo (0.9% NaCl) to ensure double dummy.
62009869|NCT04420026|EXPERIMENTAL|Experimental Arm|Hepatocellular tumours
62009870|NCT05906017|ACTIVE_COMPARATOR|Open repair|Open ventral hernia repair
62009871|NCT05906017|EXPERIMENTAL|Robotic-assisted repair|Robotic-assisted ventral hernia repair
62009872|NCT06572969|EXPERIMENTAL|Experimental|In the experimental group, participants performed the RHK exercises using incrementally resistive elastic tubing. The RHKs targeted shields (Adidas, Curved Kick Shield) held at chest height. Each athlete started with a 2.4 m elastic tubing, one end attached to the ankle and the other to a stable platform, ensuring the tubing's resistance reached 50 N at full kicked extension (Fig.1). After four weeks (12 sessions), resistance increased to 100 N by adding another tubing. Each session comprised three sets of 6 RHKs per leg, at maximum speed, with 30-second intervals between kicks and 3-minute rests between sets. This 8-week, three times weekly, training regimen involved incremental ER training.
62196087|NCT01035268|EXPERIMENTAL|surgery by fatty tissue transfer|
62196088|NCT01035268|NO_INTERVENTION|simple supervision|
62196089|NCT06100770||Aveir AR Leadless Pacemaker|This study will utilize real-world data from patients implanted with the Aveir AR Leadless Pacemaker. No device intervention is required in this study.
62196090|NCT06100770||Single-Chamber Atrial Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a single-chamber atrial pacemaker as a comparator to the Aveir AR LP study arm. No device intervention is required in this study.
62399074|NCT06633965|ACTIVE_COMPARATOR|AIDANET→Usual Care|Participants will use AIDANET system during a 3 days/2 nights hotel admission. Participants will continue to use the AIDANET system at home for 7 days/6 nights and then will complete 7 days/6 nights at home usual care period using their personal equipment.
62574627|NCT01136057||Influenza A Exposure|Participants will include people who have recovered from influenza, received a seasonal influenza vaccine, or have both recovered from influenza and received a seasonal influenza vaccine.
62009873|NCT06572969|OTHER|Control|The control group undertook a similar RHK training regime in sequence and duration, mirroring the number of kicks performed by the experimental group, but without ER equipment. After each training session, a 5-minute rest allotted before resuming standard Taekwondo training. Post the 8-week training, both groups underwent a 2-week retention period with uniform training program.
62009874|NCT00906646|EXPERIMENTAL|Metabolic therapy|Metabolic therapy with antioxidants and cellular energisers
62009875|NCT00906646|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62009876|NCT01079234|EXPERIMENTAL|Flex + insulin aspart|
62196091|NCT06512844|EXPERIMENTAL|Interventional Group|Participants who were assigned to interventional group were exposed to Urdu adapted and translated mindfulness-based stress reduction training. These participants received 8 weeks of intervention.
62196092|NCT06512844|NO_INTERVENTION|Control/Wait list Group|Participant who were assigned to Control Group did not receive any Intervention although they just received some relaxation breathing exercises.
62196093|NCT06198751|EXPERIMENTAL|6 mg/kg of TQB2102 for injection|6 mg/kg TQB2102, Intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle, for 6 or 8 cycles.
62399075|NCT04667793|EXPERIMENTAL|Thymic Epithelial Tumor|"For thymoma:~Neoadjuvant treatment stage: Toripalimab 240mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Carboplatin AUC 5, Amycin 50mg/m2, Cyclophosphamide 500mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: the patients who did not receive 4 cycle therapy will receive 1-2 cycles therapy up to 4 cycles in total, the following therapy is according to the NCCN guidelines.~For thymic carcinoma:~Neoadjuvant treatment stage: Toripalimab 240mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Cisplatin 50mg/m2, Paclitaxel 200mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation."
62399076|NCT06722443|PLACEBO_COMPARATOR|Placebo|Placebo treated with 500 mg/capsule/day of maltodextrin
62399077|NCT06722443|ACTIVE_COMPARATOR|Probiotic|capsules with 10\^9 CFU/ day of Limosilactobacillus fermentum CECT5716
62399078|NCT06722443|ACTIVE_COMPARATOR|Prebiotic|500 mg/capsule/day of olive leaf extract, containing 35% oleuropein, an amount comparable to what could be consumed through daily intake of extra virgin olive oil.
62399079|NCT06722443|ACTIVE_COMPARATOR|Symbiotic|A combination of prebiotic and probiotic at the same doses.
62574628|NCT01781845|EXPERIMENTAL|ARFI-SVI Ultrasound|Ultrasound scan using acoustic radiation force impulse-shear wave velocity imaging in the characterization of pediatric hydronephrosis. This is a non-invasive scan that uses sound waves to create the images.
62574629|NCT01791673|EXPERIMENTAL|Ultrasound Glaucoma treatment|Cyclocoagulation using High Intensity Focused Ultrasound (HIFU)
62009877|NCT01079234|EXPERIMENTAL|Fixed + insulin aspart|
62196094|NCT06198751|EXPERIMENTAL|7.5 mg/kg of TQB2102 for injection|7.5 mg/kg TQB2102, Intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle, for 6 or 8 cycles.
62009878|NCT01079234|ACTIVE_COMPARATOR|IGlar + insulin aspart|
62009879|NCT03835260|OTHER|Pivot Breath Sensor (user group)|Self-reported daily smokers of 2 or more cigarettes per day
62009880|NCT00826085|EXPERIMENTAL|Thermodox in combination with hyperthermia|Single arm study
62009881|NCT03812718|ACTIVE_COMPARATOR|ETT Group|"Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.~Intraoperative ventilation will be instituted through a polyvinyl chloride (PVC) ETT (Portex, Smiths Medical ASD, Inc, Minneapolis, USA). The size of the tube will be standardized for the male (7.5 mm ID) and the female (6.5 MM ID)."
62196095|NCT01371825|EXPERIMENTAL|Open-Label Sebelipase Alfa|Participants received intravenous (IV) infusions of sebelipase alfa during the open-label treatment. Participants initially received 0.35 milligrams (mg)/kilogram (kg) qw and escalated to 1 mg/kg qw after demonstrating acceptable safety and tolerability during at least 2 infusions. One participant initiated treatment under a Temporary Use Authorization prior to enrollment, wherein the participant's dose was gradually escalated from 0.2 to 1 mg/kg over 4 weeks; the participant started the study at this dose. Participants on treatment for 96 weeks and on stable qw dosing for 24 weeks could be switched to an every other week (qow) dosing schedule. In the event of protocol-defined disease progression at any time during treatment, a participant could receive a dose increase from 1 to 3 mg/kg qw and, if necessary, a dose increase to 5 mg/kg qw with Safety Committee approval. Participants dosed qow who met dose-escalation criteria were reverted to qw dosing or escalated to 1 or 3 mg/kg qow.
62196096|NCT04489277||Patients with Silent Brain Infarction|treated with an aortic endoprosthesis deployed in Ishimaru zone 0 to 3 and brain diffusion-weighted magnetic resonance imaging (DW-MRI) within 7 days after the procedure with silent brain infarction
62574630|NCT03915327|EXPERIMENTAL|Intravenous iron group|Enrolled subjects would receive intravenous iron isomaltose anhydride within 24 hours of the subject's inclusion.
62574631|NCT03915327|NO_INTERVENTION|Control group|Clinical management, including surgical procedures, anesthesia, and perioperative management, are performed in accordance with standard clinical practice.
62574632|NCT03288545|EXPERIMENTAL|EV + Pembrolizumab in cisplatin-ineligible 1L and in 2L|Dose Escalation: Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
62574633|NCT03288545|EXPERIMENTAL|Cohort A: EV + Pembrolizumab in cisplatin-ineligible 1L|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
62574634|NCT03288545|EXPERIMENTAL|Optional Cohort B: Enfortumab Vedotin + Pembrolizumab in 2L|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
62574635|NCT03288545|EXPERIMENTAL|Cohort D: Enfortumab Vedotin + Cisplatin in 1L|Enfortumab vedotin on days 1 and 8 plus cisplatin on day 1 every 21 days
62574636|NCT03288545|EXPERIMENTAL|Cohort E: Enfortumab Vedotin + Carboplatin in 1L|Enfortumab vedotin on days 1 and 8 plus carboplatin on day 1 every 21 days
62574637|NCT03288545|EXPERIMENTAL|Optional Cohort F: Enfortumab Vedotin+Gemcitabine in 1L and 2L|Enfortumab vedotin and gemcitabine on days 1 and 8 every 21 days
62574638|NCT03288545|EXPERIMENTAL|Cohort G: Enfortumab Vedotin + Platinum + Pembrolizumab in 1L|Enfortumab vedotin on days 1 and 8 plus cisplatin or carboplatin on day 1 plus pembrolizumab on day 1 every 21 days
62574639|NCT03288545|EXPERIMENTAL|Cohort H: Enfortumab vedotin in MIBC neoadjuvant setting|Enfortumab vedotin on days 1 and 8 every 21 days
62574640|NCT03288545|EXPERIMENTAL|Optional Cohort J:EV+Pembrolizumab in MIBC neoadjuvant setting|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
62574641|NCT03288545|EXPERIMENTAL|Randomized Cohort K: Enfortumab Vedotin Monotherapy|Enfortumab vedotin on days 1 and 8 every 21 days
62009882|NCT03812718|ACTIVE_COMPARATOR|PLMA Group|Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA. intraoperative ventilation will be maintained with PLMA (Telefex Medical, Westmeath Ireland) whose size would be selected based on body weight. In patients weighing 30-50 kg PLMA # 3.0, 50-70 kg PLMA # 4.0, and 50-100 kg PLMA # 5.0 will be inserted.
62196097|NCT04489277||Patients without Silent Brain Infarction|treated with an aortic endoprosthesis deployed in Ishimaru zone 0 to 3 and brain diffusion-weighted magnetic resonance imaging (DW-MRI) within 7 days after the procedure without silent brain infarction
62574642|NCT03288545|EXPERIMENTAL|Randomized Cohort K: Enfortumab Vedotin + Pembrolizumab|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
62574643|NCT03288545|EXPERIMENTAL|Cohort L: Enfortumab vedotin in MIBC in perioperative setting|Enfortumab vedotin on days 1 and 8 and every 21 days
62196098|NCT04731259|EXPERIMENTAL|ATR-04|The intervention is an ointment that will be applied topically BID for 28 days. It will be supplied in small aluminum foil packets. Packets of study medication will be labeled with Subject Kit numbers to ensure the double-blind treatment.
62196099|NCT04731259|PLACEBO_COMPARATOR|Placebo|Placebo ointment will be applied topically BID for 28 days. It will be supplied in small aluminum foil packets. Packets of study medication will be labeled with Subject Kit numbers to ensure the double-blind treatment.
62196100|NCT00128297|ACTIVE_COMPARATOR|Arm A: continuous administration|Pamidronate 90 mg/m2 iv every 3-4 weeks, during 18 months
62399080|NCT05016570|EXPERIMENTAL|Picture narrative lung screening information|Participants in this arm receive information about lung screening purpose, eligibility, benefits and risks in a format which uses text in combination with sequences of pictures to communicate a coherent message. The designs follow conventions from comics/graphic narratives and key stakeholders were involved during the design process.
62399081|NCT05016570|ACTIVE_COMPARATOR|Text with pictures lung screening information|Participants in this arm receive information about lung screening purpose, eligibility, benefits and risks in a format that uses text with non-narrative pictures for decoration. The pictures have been extracted from the picture narratives being used Arm 1.
62399082|NCT05016570|ACTIVE_COMPARATOR|Text-only lung screening information|Participants in this arm receive information about lung screening purpose, eligibility, benefits and risks in a format that uses text and no pictures.
62399083|NCT05835154|EXPERIMENTAL|Supportive Care (advanced care planning checklist)|FIELD TEST: Participants complete the Advance Care Planning (ACP) Mobility Checklist on study. Participants complete questionnaires at baseline and after completing the checklist intervention and undergo interview on study. Participants medical records are also reviewed.
62399084|NCT04513015|EXPERIMENTAL|Antioxidant diet|Group Antioxidant diet will receive 8 weeks of antioxidant dietary treatment
62574644|NCT02705300|EXPERIMENTAL|Chemotherapy plus tocotrienol|"Every 2 weeks: irinotecan 165 mg/m2 iv, oxaliplatin 85 mg/m2 iv, calcium folinate 200 mg/m2 iv, and 5-fluorouracil 3200 mg/m2 as a 46 hour infusion.~Daily: Tocotrienol 300 mg x 3 daily"
62574645|NCT02705300|PLACEBO_COMPARATOR|Chemotherapy plus placebo|"Every 2 weeks: irinotecan 165 mg/m2 iv, oxaliplatin 85 mg/m2 iv, calcium folinate 200 mg/m2 iv, and 5-fluorouracil 3200 mg/m2 as a 46 hour infusion.~Daily: Placebo x 3 daily"
62574646|NCT04404764||Treated with nusinersen at SUS|Patients with Spinal Muscular Atrophy (SMA) 5q types II and III treated with nusinersen in the Brazilian Unified Public Health System
62574647|NCT04404764||With indication to receive nusinersen at SUS|Patients with Spinal Muscular Atrophy (SMA) 5q types II and III with indication, but not yet receiving nusinersen treatment in the Brazilian Unified Public Health System
62574648|NCT06026735||lung cancer with brain metastasis|
62574649|NCT06026735||lung cancer with leptomeningeal metastasis|
62574650|NCT00454363|EXPERIMENTAL|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
61978053|NCT05258890|EXPERIMENTAL|Social Network Counseling|The index patient and influential social network members will meet via Zoom 3 times over the course of 3 months with a clinical research nurse for teamwork counseling and blood pressure education.
62009883|NCT05702073|EXPERIMENTAL|INS068|
62009884|NCT05702073|ACTIVE_COMPARATOR|IGlar|
62574651|NCT06124950|EXPERIMENTAL|GTI Intervention|Participants in the intervention group will be provided with five GTI sessions (60-minutes/session) by trained nurses and social workers throughout participants' fertility treatment cycle throughout participants' fertility treatment cycle.
62574652|NCT06124950|NO_INTERVENTION|Standard Care|Participants in the intervention group will be provided with standard clinical procedures for assisted reproduction and health education.
62574653|NCT01514539|OTHER|Four weeks Postpartum Lactating|women between 18 and 45 who delivered their first child 4 weeks prior and who were currently lactating and planning to lactate for one year postpartum.
62196101|NCT00128297|EXPERIMENTAL|Arm B: alternate administration|Pamidronate 90 mg/m2 iv every 3-4 weeks, during 6 months, followed by a 6 month rest, and a new 6 months treatment period.
62196102|NCT02229578|EXPERIMENTAL|Lidocaine Treatment Group|Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
62196103|NCT02229578|PLACEBO_COMPARATOR|Placebo Treatment Group|Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
62196104|NCT04387877|EXPERIMENTAL|Graston Group|Graston technique will be applied on the lateral and posterior myofascial chain area tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.
62196105|NCT04387877|SHAM_COMPARATOR|Sham Group|"Sham graston technique will be applied on lateral and posterior myofascial chain area (tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.~(Sham graston technique will be applied to the patient by partially touching the muscle or fascia region via ultrasound gel with the flat part of the Graston tool so as not to provide the activity of the fascia)"
62196106|NCT02595580|EXPERIMENTAL|GlucoPred|
62196107|NCT02593799||Patients with esophageal varices|"Esophageal varices were confirmed by endoscopy. They were divided into any grade and high-risk varices."
62399085|NCT04513015|ACTIVE_COMPARATOR|Normal diet|Group Normal diet will continue a normal dietetic scheme (corresponding to a isocaloric, normolipidic diet for age and sex).
62574654|NCT01514539|OTHER|Control Never Pregnant|women between 18 and 45 who have never been pregnant
62574655|NCT05125848|EXPERIMENTAL|Hemodialysis Single Group Assignment|All enrolled subjects will be connected to the CM-1500 for monitoring during their hemodialysis session
62574656|NCT01838564|ACTIVE_COMPARATOR|Routine data collection|Routine collection of patient-reported symptom and Quality of life data using PediQUEST surveys
62574657|NCT01838564|EXPERIMENTAL|Feedback of patient-reported outcomes|Routine collection of QOL and symptom data + feedback
62196108|NCT02593799||Patients without esophageal varices|"Patients without esophageal varices were divided into patients without any grade or high-risk varices."
62574658|NCT00975117|PLACEBO_COMPARATOR|Placebo|
62574659|NCT00975117|EXPERIMENTAL|Spermotrend|
62574660|NCT02395848|EXPERIMENTAL|Fidaxomicin|30-day Fidaxomicin ( 200mg twice daily x 10 days and 200mg once daily x 20 days.
62574661|NCT04221256|EXPERIMENTAL|Administration of SSRI|Participants will be administered either 5, 10 or 20mg of SSRI escitalopram prior to paired associative stimulation.
62574662|NCT04221256|PLACEBO_COMPARATOR|Administration of Placebo|Participants will be administered a placebo prior to paired associative stimulation
62734671|NCT02332993||Control Group|15 Type 2 Diabetics receiving Negative Wound Pressure Therapy will receive no supplementation for 12 weeks.
62734672|NCT04055272|EXPERIMENTAL|Text messaging|Participants in the text messaging intervention arm receive mobile text messages communicating the risks of indoor tanning and motivating cessation on their mobile phones
62196109|NCT03629470|ACTIVE_COMPARATOR|Group 1|standard conservative treatment
62196110|NCT03629470|EXPERIMENTAL|Group 2|nerve gliding exercises along with the standard conservative treatment.
62214999|NCT01181427|PLACEBO_COMPARATOR|Antiviral Activity|HCV genotype 1-infected treatment naïve subjects receiving multiple ascending doses of ABT-267 or placebo monotherapy for 3 days.
62215000|NCT01181427|NO_INTERVENTION|Resistance Monitoring|"HCV genotype 1-infected treatment naïve subjects, receiving at least one dose of ABT-267 or placebo in the Antiviral Activity arm, follow-up to monitor resistance developed to ABT-267, no treatment and only blood samples will be collected"
62215001|NCT04662905|EXPERIMENTAL|ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
62734673|NCT04055272|NO_INTERVENTION|Control|Participants in the control arm receive no intervention
62734674|NCT02096952|EXPERIMENTAL|Methylphenidate extended-release liquid|Methylphenidate extended-release liquid formulation
62215002|NCT06092476|ACTIVE_COMPARATOR|DMR procedure|Patients receive Revita® DMR Treatment Paradigm 1. After unblinding at 24 weeks, they receive retreatment.
62215003|NCT06092476|SHAM_COMPARATOR|Sham procedure|Patients receive a sham procedure. After unblinding takes place at 24 weeks, patients receive a Revita® DMR Treatment Paradigm 1. 48 weeks after initial sham (= 24 weeks after first DMR) patients may receive retreatment, if they want to.
62574663|NCT03477539|EXPERIMENTAL|Treatment (daratumumab, ASCT, lenalidomide)|"CONSOLIDATION I: Patients receive daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, and on days 1 and 15 of cycles 3-4. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION II: Beginning 8 weeks after completion of daratumumab cycle 2 or 4, patients undergo ASCT.~MAINTENANCE: Within 14 days after completion of day 100 visit post-SCT, patients receive daratumumab IV on day 1 and lenalidomide PO daily on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients who are still maintaining response continue to receive daratumumab IV every 3 months in the absence of disease progression or unacceptable toxicity."
62574664|NCT00992901|EXPERIMENTAL|Exendin-(9-39)|To evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion
62574665|NCT00992901|EXPERIMENTAL|atropine|To evaluate the effect of neural activation on insulin secretion and glucose metabolism
62574666|NCT00992901|EXPERIMENTAL|GLP-1 and GIP|to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones
62574667|NCT02046590|ACTIVE_COMPARATOR|Deep Sedation|"Remifentanil 1ng/ml throughout the procedure. Propofol administration starts at an initial (estimated plasma) target concentration of 1,5 microg/ml.~Propofol administration is adjusted to level 1 or 2 on the modified observer's assessment of alertness/sedation scale. The propofol infusion will be increased stepwise by 0,5 microg/ml every 1 minute until loss of consciousness. Propofol is continued while maintaining spontaneous ventilation without assistance and systolic blood pressure ≥ 60 % of baseline systolic blood pressure."
62574668|NCT02046590|ACTIVE_COMPARATOR|General Anaesthesia|"General anesthesia will be induced with target controlled infusion (TCI) of propofol and remifentanil as in the group deep sedation.~Suxamethonium (succinylcholine) will be used to facilitate intubation. Endotracheal tube balloon pressure will be controlled during the procedure. Ventilation will be assisted using 40% oxygen in air mixture and mechanically controlled using an anaesthetic ventilator."
62574669|NCT03520777|OTHER|Artist Intervention|One of the three artists (visual artist, music therapist, creative writer) will work with subjects for up to 90 minutes.
62574670|NCT00653133|ACTIVE_COMPARATOR|USPNB|Ultrasound imaging guided peripheral nerve block
62574671|NCT00653133|ACTIVE_COMPARATOR|NSPNB|Peripheral nerve stimulator guided peripheral nerve block catheter placement for continuous infusion of local anesthetic
62574672|NCT04411810|EXPERIMENTAL|Participants with skin lesions|Participants who have up to 3 concerning skin lesions will be evaluated by both an in-person dermatologist and a team of three teledermatologists(board-certified dermatologists). The teledermatoogy team will deliver a consensus recommendation. If either the in-person dermatologist or teledermatologists are concerned that the skin spot(s) may be a skin cancer, a biopsy will be recommended and can be performed at no charge. Or if both agree that the spot(s) are not concerning for skin cancer, no biopsy will be needed.
62574673|NCT06574074|OTHER|Factor-1|Participants allocated to this will receive full version of the Gain Life intervention
62574674|NCT06574074|OTHER|Factor-2|Participants allocated to this will receive a few components of the Gain Life intervention that include information on depression, available treatments, and stigma reduction
62574675|NCT06574074|OTHER|Factor-3|Participants allocated to this will receive only a few components of Gain Life intervention including information on depression, available treatments, and life transformation experiences
62574676|NCT06574074|OTHER|Factor-4|Participants allocated to this will receive only information on depression, and available treatments components of the Gain Life intervention
62574677|NCT06574074|OTHER|Factor-5|Participants allocated to this will receive three components of the Gain Life intervention that include information on depression, stigma reduction and life transformation experiences
62574678|NCT06574074|OTHER|Factor-6|Participants allocated to this will receive information on depression and stigma reduction components of the Gain Life intervention
62009885|NCT05458479|EXPERIMENTAL|Fluoxetine|Subjects will receive fluoxetine 5 mg each morning at the start of the trial. The dose will be increased by 5 mg every 2 weeks depending on effectiveness and tolerability. The optimal dose will be reached by week 12 of treatment. The minimum starting dose will be 5 mg and the maximum total daily dose will be 30 mg.
62009886|NCT00544596|EXPERIMENTAL|Treatment (R-(-)-gossypol acetic acid, cisplatin, etoposide)|"Patients receive oral R-(-)-gossypol twice daily on days 1-3, cisplatin IV over 60 minutes on day 1\*, and etoposide IV over 30 minutes on days 1\*-3. Treatment repeats every 21 days for up to 6 courses during the dose escalation and 4 courses in the expanded extensive stage small cell lung cancer cohort, in the absence of disease progression or unacceptable toxicity.~Blood samples are collected on day 1 of courses 1 and 2 for pharmacokinetic analysis, biomarker assays, and correlative studies.~After completion of study treatment, patients are followed for 30 days.~\[Note: \*Cisplatin and etoposide will be started on day 2 during course 1; they will be given on day 1 during all subsequent courses.\]"
62009887|NCT04112433||PURE EP 2 Group|Enrolled and consented patients who are indicated for and receive an elective cardiac ablation procedure using the PURE EP 2 system for monitoring and collection of intracardiac electrogram signals.
62196111|NCT04412083|OTHER|PPA Tele-Savvy Pilot Intervention|The Tele-Savvy program is comprised of weekly, two-hour interactive classes, over seven consecutive weeks, the same duration as the proposed intervention. Tele-Savvy consists of educational instruction, video and in-class exercises that engage participants on a functional level. Course material was designed to provide informal caregivers with the knowledge, skills, and attitude needed to carry out their role as a caregiver for a person living with dementia (PLWD). Course learning objectives include: 1) introduction to dementing disorder; 2) caregiver self-care; 3) the anchors of contented involvement; 4) levels of thinking and performance; 5) strengthening the family as a resource for caregiving; and 6) review and integration of the previous sections.
62196112|NCT04917445|EXPERIMENTAL|SPIKES Protocol Compassionate Call|Nurses trained to contact IVF patients with negative pregnancy test results who were trained on the SPIKES-focused bad news delivery script.
62196113|NCT04917445|NO_INTERVENTION|Control: Standard of Care Call|Nurses who will continue to deliver bad news as they have been in the past without a script.
62196114|NCT01100606|EXPERIMENTAL|EUR-1008 (APT-1008) in Apple Juice|
62196115|NCT01100606|EXPERIMENTAL|EUR-1008 (APT-1008) in Apple Sauce|
62196116|NCT01991327|EXPERIMENTAL|Androxal|Androxal 25 mg capsules once a day for 7 days
62783189|NCT02873338|ACTIVE_COMPARATOR|Control (idarubicin+cytarabine)|"Induction:~* Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, and 3)~* Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1 to 7)~Re-induction:~* Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1 and 2)~* Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1 to 5)~Consolidation:~• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, and 5)"
62196117|NCT01991327|ACTIVE_COMPARATOR|Placebo Androxal|
62196118|NCT05256615|EXPERIMENTAL|Diabetes|Participants recruited to this arm have been clinically diagnosed with either gestational, pre- or type 2 diabetes.
62196119|NCT05256615|EXPERIMENTAL|Non-diabetes|Participants recruited to this arm of the study do not have gestational, pre- or type 2 diabetes.
62009888|NCT06534021|EXPERIMENTAL|Experimental group|Drug:IASO-782 injection Dosage and Administration: single dose of IASO-782, 6 mg/kg or 10 mg/kg , intravenous injection at day 1
62009889|NCT06534021|PLACEBO_COMPARATOR|Control group|Drug:placebo Dosage and Administration: single dose of placebo, intravenous injection at day 1
62009890|NCT02816216|OTHER|End User Iterative Testing - CampAir|To ensure the software and website function as intended, investigators will systematically test each of the seven CampAir modules with target end users. Participants will review one module per week for seven weeks. As part of each module, participants will also complete a daily asthma checklist. Following the review of each module, participants will be prompted to complete measures assessing technology acceptability and usability and product quality. Results will be used to modify and finalize the user interface and navigation to maximize usability.
62009891|NCT00934999|ACTIVE_COMPARATOR|Burch|Patients will receive a Burch urethropexy at the time of an abdominal sacral colpopexy.
62196120|NCT00656045|EXPERIMENTAL|A|Arm A focuses on increasing the participant's physical activity level.
62196121|NCT00656045|EXPERIMENTAL|B|Arm B focuses on decreasing the amount of time the participant spends watching Television.
62196122|NCT00098397|EXPERIMENTAL|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62196123|NCT03204162|NO_INTERVENTION|Teams with no CPR Coach|This will be a standardized Resuscitation team with no CPR Coach
62196124|NCT03204162|EXPERIMENTAL|Teams with CPR Coach|This will be a standardized Resuscitation team where one member will be the CPR Coach and provide CPR Coaching to the team.
62009892|NCT00934999|EXPERIMENTAL|Mid-urethral sling|Patients will receive a mid-urethral sling at the time of an abdominal sacral colpopexy.
62399086|NCT04513210||Changes in the lungs on admission|Patients with Covid-19 infection admitted to the University Hospital with changes in the ultrasound on admission, suggesting pneumonia.
62399087|NCT04513210||No changes in the lungs on admission|Patients with Covid-19 infection admitted to the University Hospital without changes in the ultrasound on admission, suggesting pneumonia.
62574679|NCT06574074|OTHER|Factor-7|Participants allocated to this will receive a selected components of the Gain Life intervention such as information on depression, available treatments and life transformation experiences
62574680|NCT06574074|OTHER|Factor-8|Participants allocated to this will receive only the information on depression component of the Gain Life intervention
62574681|NCT03495479||OMN54 -Treated|Six-month, daily oral dosing in softgel capsules throughout the first 6 months of treat.
62009893|NCT00970463||GH|Patients with GHD
62009894|NCT00970463||Pegvisomant and Somatostatin analogues|Acromegaly
62009895|NCT05737641|ACTIVE_COMPARATOR|water ingestion|Ingestion of 102 mL of fresh water
62009896|NCT05737641|EXPERIMENTAL|jelly ingestion|ingestion of 100 gr strawberry jelly
62574682|NCT06576583|EXPERIMENTAL|Engineered cartilage graft (N-TEC)-Iwano grade 1-2|N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membranes for 2 weeks to allow cells to produce extracellular matrix containing cartilage specific proteins. The IMP is implanted in the knee at the patellofemoral joint.
62574683|NCT06576583|ACTIVE_COMPARATOR|Autologous Matrix Induced Chondrogenesis-Iwano grade 1-2|AMIC® Chondro-Gide® combines microfracturing (MFx) with the use of Chondro-Gide®, which covers and protects both the super clot resulting from MFx and the repair tissue.
62574684|NCT06576583|EXPERIMENTAL|Engineered cartilage graft (N-TEC)-Iwano grade 3-4|N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membranes for 2 weeks to allow cells to produce extracellular matrix containing cartilage specific proteins. The IMP is implanted in the knee at the patellofemoral joint.
62574685|NCT06576583|ACTIVE_COMPARATOR|Patellofemoral Arthroplasty (PFA)-Iwano grade 3-4|Patellofemoral Joint Prosthesis
62009897|NCT03120065|OTHER|MEMS follow up|Approximately 25% of the enrolled study population will have their adherence to medicines monitored by research personnel through the use of electronic dose monitoring caps (MEMS) for a period of 3 months. The participant's ART medication regimen will be dispensed in a bottle with a cap that monitors the time and date in which the cap is opened. Each month, the participant will bring the bottle with them on their clinic day for three months and the research personnel will extract the timing information from the cap.
62009898|NCT06652035||Supplemental Quercetin group|These participants received oral 500 mg Quevir® (Quercetin Phytosome®) tablet, twice a day for 90 days. Each Quevir® tablet contains 200 mg pure Quercetin.
62196125|NCT04121897|EXPERIMENTAL|TEMPO|The Therapist Education and Massage for Parent-Infant Outcomes program (TEMPO) is a structured, therapist-led physical therapy program. TEMPO trains and supports parents to deliver physical therapy interventions including massage and developmental play during hospitalization and in the home setting.
62196126|NCT02472002|EXPERIMENTAL|Mesenchymal cell therapy|
62574686|NCT03217383|EXPERIMENTAL|MATRx plus test|All study participants will receive the same test protocol. All participants will complete the MATRx plus theragnostic test and receive a prediction of oral appliance outcome. All participants will then receive a custom oral appliance set to the predicted protrusive position or a sham position, and outcome home sleep tests will be performed with the custom oral appliance in place to determine if the test prediction was correct.
62574687|NCT02230020||Nasal High Flow|All subjects are in this group
62574688|NCT02541357|NO_INTERVENTION|Usual care|Does not receive a specific study intervention
62574689|NCT02541357|EXPERIMENTAL|preoperative relaxation program|preoperative relaxation program
62399088|NCT02093156||training cohort|the training cohort was used to establish the bowel preparation score (BPS)
62399089|NCT02093156||validation cohort|the validation cohort was used to verify the BPS (bowel preparation score)
62574690|NCT02541357|EXPERIMENTAL|preoperative surgery education|single education unit to understand the complete surgical procedures
62574691|NCT02541357|EXPERIMENTAL|preop relaxation and surgery education|preoperative relaxation program AND single education unit
62734675|NCT03975335|EXPERIMENTAL|Intervention group|Health education on NCDs and behavioral risk factors was delivered through motivation and observational learning session.
62009899|NCT06652035||Supplemental Probiotic Strptococcus salivarius K12 (ATCC BAA-1024) group|These participants received orally dissolving Bactoblis® tablet, once daily before bedtime for 90 days. Each Bactoblis® tablet contains at least 1x10⁹ CFU of probiotic S. salivarius K12 (ATCC BAA-1024).
62009900|NCT06662760|EXPERIMENTAL|TQB3002 Tablets|TQB3002 Tablets, 28 days as a treatment cycle
62009901|NCT00420680|EXPERIMENTAL|Arm 1|Sugammadex 2.0 mg/kg
62009902|NCT00420680|EXPERIMENTAL|Arm 2|Sugammadex 4.0 mg/kg
62009903|NCT00420680|PLACEBO_COMPARATOR|Arm 3|Placebo
62196127|NCT05466123|EXPERIMENTAL|Virtual reality intervention in palliative care patients|Palliative care patients with a limited life expectancy will participate in a virtual reality experience for 10-30 minutes
62196128|NCT04483856|EXPERIMENTAL|DermoRelizema cream|The treatment will be applied since about 7 (±3) days prior to RT start and will continue until 14 days post RT end
62574692|NCT02340403|EXPERIMENTAL|Oxaliplatin and neuropathic pain|The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).
62196129|NCT04483856|ACTIVE_COMPARATOR|Dexeryl|The treatment will be applied since 7 (±3) days prior to RT start and will continue until 14 days post RT end (98-112 applications in total).
62196130|NCT04860440||End-Stage Renal Disease on haemodialysis|Wearing accelerometer (fitness tracker) for 7 days.
62196131|NCT04860440||Low clearance pre-dialysis patients|Wearing accelerometer (fitness tracker) for 7 days.
62196132|NCT03169400||Theranova treated|We will collect pool of human sera from HD patients treated with regular bicarbonate dialysis membrane (baseline). Then, patients will be treated for 3 months with Theranove dialyzer, and sera will be collected at 1, 2, and 3 months. We will create a serum pool.
62196133|NCT03169400||Standard treated|We will collect pool of human sera from HD patients treated with regular bicarbonate dialysis membrane (baseline). Then, patients will be treated for 3 months with Theranove dialyzer, and sera will be collected at 1, 2, and 3 months. We will create a serum pool.
62574693|NCT02340403|OTHER|Oxaliplatin without neuropathic pain|The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).
61978054|NCT05258890|ACTIVE_COMPARATOR|Individual Counseling|The index patient will meet via Zoom 3 times over the course of 3 months with a clinical research nurse for blood pressure education.
62009904|NCT06664671|EXPERIMENTAL|Intervention Group|The product used, with NV-2016 code, contains Nature\&Nurture thyme essential oil (10 µL) macra (Barcode No: 8697742121135, Registration No: 381751) and includes components such as 1,3 y-Terpinene, 2.7% p-Cymene, 5.6% linalool, 1.2% terpinen-4-ol, 1.2% borneol, 1.2% β-Bisabolene, 3.2% tymol, and 75.7% carvacrol. The thyme oil will be applied via an inhaler stick with patients instructed to inhale eight breaths, three times daily for four days.
62009905|NCT06664671|PLACEBO_COMPARATOR|Placebo Group|Patients will receive an empty inhaler stick with usage instructions, completing the same pre- and post-test procedures as the intervention group.
62009906|NCT06664671|OTHER|Control|Patients will complete pre- and post-test forms without any intervention.
62009907|NCT01795508|EXPERIMENTAL|PMTO|Parent Management Training Oregon
62009908|NCT01795508|ACTIVE_COMPARATOR|TAU|Other kinds of family treatment
62009909|NCT01312402|ACTIVE_COMPARATOR|Topical Brinzolamide (Azopt)|ophthalmic drop given three times a day
62009910|NCT01312402|PLACEBO_COMPARATOR|placebo ophthalmic drop in 5 mL solution|masked non-active eye drop (absence of Brinzolamide)
62196134|NCT05656755|EXPERIMENTAL|strengthening running program|The experimental group will undergo a specific running training based on leg strength training and interval running
62734676|NCT03975335|PLACEBO_COMPARATOR|Control group|Control group received session on carrier guidance.
62009911|NCT02707640|PLACEBO_COMPARATOR|Matching Placebo|
62009912|NCT02707640|EXPERIMENTAL|N-Acetylcysteine|
62009913|NCT02707640|OTHER|Pirfenidone|Background therapy
62009914|NCT06251700|EXPERIMENTAL|Intervention arm|CADe system will be used during withdrawal phase of colonscopy
62009915|NCT04377139||Prophylaxis|Those LTR receiving prophylaxis against CMV
62009916|NCT04377139||Preemptive therapy|Those LTR receiving preemptive therapy against CMV
62009917|NCT03697954||overactive bladder patients|Female patients with refractory overactive bladder and urge urinary incontinence undergoing direct full stage implantation
62009918|NCT01242904|EXPERIMENTAL|bimodal solution|200 mls of 30% glucose in sterile water is added by the patient to the usual icodextrin day dwell, to create the bimodal solution intraperitoneally
62009919|NCT01242904|ACTIVE_COMPARATOR|icodextrin|200 mls of icodextrin is added by the patient to the usual icodextrin day dwell
62009920|NCT03062800|EXPERIMENTAL|P+Cisplatin/Carboplatin+T|"Induction therapy (Platinum based chemotherapy combined with antiangiogenic therapy 4-6 cycles):~Pemetrexed + Platinum + Thalidomide \[pemetrexed (500mg/m\^2)+cisplatin(75mg/m\^2)or carboplatin(AUC=5) on day 1 of 21-days cycle, ivgtt +thalidomide 100-200mg/d ,oral, qn \]~Continue maintenance therapy (It is defined when a drug included in the induction treatment is used as maintenance .Patients who had not progressed during induction phase will be in this phase):~Thalidomide 100mg/d ,oral, qn, until either disease progression or unacceptable toxicity."
62009921|NCT03062800|EXPERIMENTAL|P+Cisplatin/Carboplatin|"Induction therapy ( Platinum based chemotherapy 4-6 cycles):~Pemetrexed + Platinum \[pemetrexed (500mg/m\^2)+cisplatin(75mg/m\^2)or carboplatin(AUC=5) on day 1 of 21-days cycle,ivgtt \]~Maintenance therapy (It is defined when a drug included in the induction treatment is used as maintenance .Patients who had not progressed during induction phase will be in this phase):~Pemetrexed (500mg/m\^2) on day 1 of 21-days cycle, ivgtt.until either disease progression or unacceptable toxicity"
62009922|NCT01123538|OTHER|Natural progesterone|Combined menopausal treatment containing natural progesterone
62009923|NCT01123538|ACTIVE_COMPARATOR|Chlormadinone acetate|Combined menopausal treatment containing chlormadinone acetate
62009924|NCT01379092|EXPERIMENTAL|Breast biopsy specimen imaging & comparison of image quality|Each subject's explanted tissue will serve as both the control (standard analysis) and the experimental analysis of the quality of the images.
62009925|NCT05337878|PLACEBO_COMPARATOR|SAD: Placebo|Single dose of Pelacarsen-matching placebo administered by SC injection on Day 1 of single-dose treatment period.
62009926|NCT05337878|EXPERIMENTAL|SAD: Pelacarsen 20 milligrams (mg)|Single dose of Pelacarsen, 20 mg, administered by SC injection on Day 1 of single-dose treatment period.
62009927|NCT05337878|EXPERIMENTAL|SAD: Pelacarsen 40 mg|Single dose of Pelacarsen, 40 mg, administered by SC injection on Day 1 of single-dose treatment period.
62196135|NCT05656755|ACTIVE_COMPARATOR|Running program|This running group will serve as control and will undergo a traditional running program composed of only running
62574694|NCT03777436|EXPERIMENTAL|Arm A- Apremilast with Placebo|Subjects randomized to the apremilast 30 mg BID treatment group will receive apremilast 30 mg tablets orally twice daily for the first 16 weeks Subjects randomized to the placebo treatment group will receive placebo tablets (identical in appearance to apremilast 30 mg tablets) orally twice daily for the first 16 weeks
62574695|NCT03777436|EXPERIMENTAL|Arm B - Apremilast 30 mg|All subjects will receive apremilast 30 mg tablets orally twice daily after the Week 16 Visit through the end of the Apremilast Extension Phase of the study
62009928|NCT05337878|EXPERIMENTAL|SAD: Pelacarsen 80 mg|Single dose of Pelacarsen, 80 mg, administered by SC injection on Day 1 of single-dose treatment period.
62009929|NCT05337878|PLACEBO_COMPARATOR|MD: Placebo|Multiple doses of Pelacarsen-matching placebo administered by SC injection every 4 weeks, on Days 1, 29, 57 and 85 of multiple-dose treatment period.
62009930|NCT05337878|EXPERIMENTAL|MD: Pelacarsen 80 mg|Multiple doses of Pelacarsen, 80 mg, administered by SC injection every 4 weeks, on Days 1, 29, 57 and 85 of multiple-dose treatment period.
62009931|NCT05725603|EXPERIMENTAL|Shoulder MRI|Shoulder MRI will be performed at least 3 years after shoulder surgery
62009932|NCT05305313|ACTIVE_COMPARATOR|Total Body Weight group|Anesthesia will be induced and maintained with Propofol administered by CLADS which will be set to deliver Propofol according to total body weight (TBW). A BIS-value of 50 will be used as the target for induction and maintaenance of anesthesia.
62009933|NCT05305313|ACTIVE_COMPARATOR|Adjusted Body Weight group|Anesthesia will be induced and maintained with Propofol administered by CLADS which will be set to deliver Propofol according to adjusted body weight (ABW). A BIS-value of 50 will be used as the target for induction and maintenance of anesthesia.
62009934|NCT02138318|OTHER|chromoendoscopy|
62574696|NCT06353685|EXPERIMENTAL|Continuous hyperfractionated accelerated radiotherapy(CHART)|
62574697|NCT01562600||Nexium|
62196136|NCT01114347|EXPERIMENTAL|Cranberry|Patients randomized to this arm will recieve one gel capsule containing cranberry PAC (36 mg of type A pro anthocyandines: Urell, Pharmatoka) per day starting at the day of the pelvic surgery (j0) until day 10 postop (j10). The gel capsule in taken orally in the morning with a large glass of water.
62574698|NCT03642964|EXPERIMENTAL|treatment|CTC-501 (pramipexole IR, given with ondansetron) given orally twice daily
62574699|NCT03642964|PLACEBO_COMPARATOR|placebo|generic placebo tablets given orally twice daily
62574700|NCT05145374||Stressful Stimuli|Participation in meal, exercise, sleep activities alone or in combination with stressful stimuli.
62574701|NCT02347774|EXPERIMENTAL|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg Twice Daily (BID) via e-Flow (R) Closed System (CS) nebulizer
62574702|NCT02347774|EXPERIMENTAL|SUN-101 25 mcg BID e-Flow (CS) nebulizer|SUN-101 25 mcg (BID) via e-Flow (R) Closed System (CS) nebulizer
62574703|NCT02347774|PLACEBO_COMPARATOR|Placebo BID Eflow (CS) nebulizer|Placebo (BID) via e-Flow (R) Closed System (CS) nebulizer
62574704|NCT00664508|ACTIVE_COMPARATOR|Lateral approach|Lateral approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
62574705|NCT00664508|ACTIVE_COMPARATOR|Anterior approach|Anterior approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
62574706|NCT00664508|ACTIVE_COMPARATOR|Posterior approach|Posterior approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
62574707|NCT05414331|NO_INTERVENTION|Continuation of beta-blocker regimen|Participants will continue with current standard of care on current beta-blocker regimen
62196137|NCT01114347|PLACEBO_COMPARATOR|Placebo|The patients randomized to this arm will recieve one placebo gel capsule per day starting on the day of the pelvic surgery (j0) until the 10th day post-op (j10). The gel capsule is taken orally in the morning with a large glass of water. The placebo contains lactose and is conditioned in a manner to be identical in caliber and color with the experimental treatment gel capsules.
62574708|NCT05414331|EXPERIMENTAL|Withdrawing of beta-blockers|Discontinuation of all BB, and medication changes will be made at the 1-month clinic visit. A cardiopulmonary exercise test (CPET) will be performed 1 month after the randomization (2 months after CABG).
62574709|NCT04258644|EXPERIMENTAL|Camrelizumab+Apatinib+Paclitaxel-albumin+S-1|Camrelizumab：D1, 200 mg ivgtt Apatinib Mesylate：D1\~21, 250 mg, po qd Paclitaxel-albumin：D1\&D8, 100～120 mg/m2 S-1：D1\~14, 60mg bid
62574710|NCT06574542|EXPERIMENTAL|Patients with Melena, No Hematemesis, and Nondiagnostic EGD|Consecutive patients who presented with melena (defined as black, tarry stools) without hematemesis, in whom EGD did not identify a bleeding source, were included for further investigation
62574711|NCT04276480|EXPERIMENTAL|Intervention|The patients included will receive piperacillin-tazobactam as empirical antimicrobial therapy. The empirical microbial therapy will continue until the bacterial susceptibility profile is known.
62574712|NCT05808426|NO_INTERVENTION|observation with no intervention group|The control group only performed routine data collection; the research assistant asked the subjects about their usual activities by telephone every month to understand their physical activity in this half of the year.
62574713|NCT05808426|EXPERIMENTAL|Mahjong group|The experimental group intervened a Bonus Winner Mahjong developed by Bonus Winner Online Entertainment Co., Ltd. The participants in experimental group played three times a week, each time requiring at least lasting 30 minutes, for half of a year.
62574714|NCT01591057|EXPERIMENTAL|2 Portions|
62574715|NCT01591057|EXPERIMENTAL|5 portions|
62574716|NCT01591057|EXPERIMENTAL|8 portions|
62574717|NCT02499367|ACTIVE_COMPARATOR|Radiation therapy|Radiotherapy on metastatic lesion
62574718|NCT02499367|ACTIVE_COMPARATOR|Low dose doxorubicin|15mg flat dose, once weekly for 2 weeks
62574719|NCT02499367|ACTIVE_COMPARATOR|Cyclophosphamide|metronomic schedule, 50mg daily orally for 2 weeks
62574720|NCT02499367|ACTIVE_COMPARATOR|Cisplatin|40mg/m2, weekly for 2 weeks
62574721|NCT02499367|ACTIVE_COMPARATOR|No induction treatment|
62574722|NCT03673644||Primary Open-Angle Glaucoma|"Two following two questionnaires will be administered:~1. Life Space Questionnaire: This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.~2. Low Luminance Questionnaire: This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions."
62574723|NCT06470542|ACTIVE_COMPARATOR|One-level ESPB|Ultrasound-guided ESPB at the L2 level
62574724|NCT06470542|ACTIVE_COMPARATOR|Two-Level ESPB|Bi-level Ultrasound-guided ESPB et the L1 and L4 level
62574725|NCT04586699|EXPERIMENTAL|Medi1TMS|rTMS theta-burst protocol paired with a consistent attention-to-breath task
62574726|NCT04586699|ACTIVE_COMPARATOR|Medi2TMS|rTMS theta-burst protocol paired with an intermittent deep breathing task
62574727|NCT02426905|NO_INTERVENTION|Retrospective|
62574728|NCT02426905|OTHER|Prospective|
62574729|NCT05688839|EXPERIMENTAL|Jaktinib 100mg BID|Jaktinib hydrochloride tablets, 2 x 50mg dosage, BID
62574730|NCT05688839|PLACEBO_COMPARATOR|Placebo|2 x Placebo tablets, BID
62574731|NCT05799352|EXPERIMENTAL|Endoscopic lung volume reduction|All the patients will have endobronchial valves insertion. We will evaluate before and 3 months after the evolution of the diaphragmatic strength and conformation.
62574732|NCT01155440|EXPERIMENTAL|LIDOCAINE group|Beside general anesthesia, patients will receive intravenous lidocaine bolus 1.5 mg/kg just prior induction and an infusion of lidocaine 2mg/kg/h will be started and maintained during the whole surgical procedure. Entering the recovery room, this infusion will be decreased at the rate of 1mg/kg/hour for the 48 first hours
62574733|NCT01155440|ACTIVE_COMPARATOR|Epidural group|Beside general anesthesia, patient will receive epidural freezing medication for 48 hours.
62399090|NCT06716008|ACTIVE_COMPARATOR|Manual diaphragmatic release group|30 women with rheumatoid arthritis who will receive low to moderate intensity aerobic training plus manual diaphragmatic release
62399091|NCT06716008|ACTIVE_COMPARATOR|Control group|30 women with rheumatoid arthritis who will receive low to moderate intensity aerobic training only.
62399092|NCT03650218|EXPERIMENTAL|THIODERM STRONG|"THIODERM STRONG injected into the upper arm (cohort 1)~THIODERM STRONG injected into nasolabial folds (cohort 2)"
62574734|NCT03193372||Rosacea Concierge Program|Patients diagnosed with rosacea and currently receiving topical monotherapy with Finacea Foam
62009935|NCT02138318|OTHER|High definition (HD) endoscopy|
62399093|NCT06722300|NO_INTERVENTION|No.1|Pg negative
62399094|NCT06722300|EXPERIMENTAL|No.2|Patients with Pg infection
62399095|NCT06722300|NO_INTERVENTION|No.3|
62399096|NCT06202079|EXPERIMENTAL|GZR4 Injection|GZR4 Injection + Oral Antidiabetic Drug
62196138|NCT04848324|ACTIVE_COMPARATOR|Intervention group|14 patients (14 hands) who received US-guided corticosteroid hydrodissection
62196139|NCT04848324|ACTIVE_COMPARATOR|Control group|14 patients (14 hands) who received US-guided corticosteroid injection
62009936|NCT04856696|EXPERIMENTAL|combined non-invasive PGT-A & PGT-A|Infertility women who underwent both non-invasive PGT-A and PGT-A
62009937|NCT04856696|EXPERIMENTAL|non-invasive PGT-A|Infertility women who underwent non-invasive PGT-A only
62009938|NCT04856696|ACTIVE_COMPARATOR|PGT-A|Infertility women who underwent PGT-A only
62196140|NCT05536375|OTHER|Healthy volunteers|
62196141|NCT02560753|EXPERIMENTAL|T3D-959 3mg|Nine subjects will take 3mg by mouth once daily for two weeks, with or without food.
62399097|NCT06202079|ACTIVE_COMPARATOR|Insulin Degludec|Insulin Degludec + Oral Antidiabetic Drug
62399098|NCT06096532|OTHER|Older Adults|
62399099|NCT06096532|ACTIVE_COMPARATOR|Younger Adults|
62574735|NCT06576713|EXPERIMENTAL|Genome and RNA sequencing|
62574736|NCT02313168||1|preoperative FRONT score
62574737|NCT02313168||2|intraoperative FRONT score
62734677|NCT02644252|EXPERIMENTAL|Performance status 0-1, Arm A|Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Tocotrienol 300 mg x 3 daily until progression.
62399100|NCT02390869|EXPERIMENTAL|R2-MANT|A) Rituximab B) Lenalidomide
62009939|NCT02409615|ACTIVE_COMPARATOR|Hypnosis Group|Hypnosis Group: ten participants will receive Hypnosis therapy in addition to the standard postoperative pain management protocol
62009940|NCT02409615|ACTIVE_COMPARATOR|Healing Touch Group|Healing Touch Group: ten participants will receive Healing Touch therapy in addition to the standard postoperative pain management protocol
62009941|NCT02409615|NO_INTERVENTION|Control Group|Control Group: ten participants will receive standard postoperative pain management protocol
62196142|NCT02560753|EXPERIMENTAL|T3D-959 10mg|Nine subjects will take 10mg by mouth once daily for two weeks, with or without food.
62399101|NCT02390869|ACTIVE_COMPARATOR|R-MANT|A) Rituximab
62399102|NCT04499248|EXPERIMENTAL|Cohort 1 -Dose A|Single dose of AGN-193408 SR Dose A administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1.
62399103|NCT04499248|EXPERIMENTAL|Cohort 1 - Dose B|Single dose of AGN-193408 SR Dose B administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1.
62009942|NCT06034821|ACTIVE_COMPARATOR|Subanesthetic dose intravenous ketamine (KET)|This trial will use standard dose of ketamine (0.5mg/kg infusion over 40 min period) in accordance with research studies that have used ketamine as an antidepressant.
62399104|NCT04499248|EXPERIMENTAL|Cohort 2 - Dose A|AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
62399105|NCT04499248|EXPERIMENTAL|Cohort 2 - Dose B|AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
62399106|NCT04499248|EXPERIMENTAL|Cohort 3 - Dose A|AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
62399107|NCT04499248|EXPERIMENTAL|Cohort 3 - Dose B|AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
62399108|NCT01249404|EXPERIMENTAL|Dysport® 1000 U, IM|1000 U, I.M. (in the muscle), on day 1 (single treatment cycle)
62009943|NCT06034821|ACTIVE_COMPARATOR|Electroconvulsive therapy (ECT)|ECT will be given in a standard manner 3 times a week for 4 weeks.
62009944|NCT01465802|EXPERIMENTAL|Cohort I|Arm A: Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Doxycycline placebo orally BID for 4 weeks Arm B: Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Doxycycline 100 mg orally BID for 4 weeks
62399109|NCT01249404|EXPERIMENTAL|Dysport® 1500 U, IM|1500 U, I.M., on day 1 (single treatment cycle)
62399110|NCT01249404|PLACEBO_COMPARATOR|Placebo|I.M., on day 1 (single treatment cycle)
62574738|NCT05454644|NO_INTERVENTION|Usual Pharmaceutical Care|Patients in the control arm receive usual pharmaceutical care in hospital. Reconciliation of the medication at hospital admission and a validation of the treatment modifications during the hospitalisation is carried out.
62574739|NCT05454644|EXPERIMENTAL|Person-Centred Prescription Model|An interdisciplinary medicine-optimisation strategy is implemented in people at the end of life (EOL) based on the person-centred prescription (PCP).
62009945|NCT01465802|EXPERIMENTAL|Cohort II|Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
62009946|NCT01465802|EXPERIMENTAL|Cohort III|Cohort III is an interrupted dosing schedule of dacomitinib in the first cycle only
62009947|NCT01983800|ACTIVE_COMPARATOR|intravenous propofol/midazolam|Sedation using intravenous propofol/midazolam, sedation will be titrated to a Riker Agitation Sedation Score
62009948|NCT01983800|ACTIVE_COMPARATOR|isoflurane|Sedation using inhaled isoflurane, sedation will be titrated to a Riker Agitation Sedation Score
62009949|NCT03154710|EXPERIMENTAL|Web-application follow up|Patients will have a clinical and biological exam every 3 months and a web-mediated follow up. Patients will have to connect to the MOOVCARE application every 14 days to complete a questionnaire about their symptoms. Imaging will be performed in the event of an alert or clinical problem
62009950|NCT03154710|NO_INTERVENTION|Standard|Patients will have the usual follow up (Clinical and biological exam every 3 months and imaging every 6 months)
62009951|NCT01347203|EXPERIMENTAL|Treatment A|DPOC-4088 prolonged release tablet 100 mg (Formulation A= 16 hr release formulation)
62009952|NCT01347203|EXPERIMENTAL|Treatment B|DPOC-4088 prolonged release tablet 200 mg (Formulation A= 16 hr release formulation)
62009953|NCT01347203|EXPERIMENTAL|Treatment C|DPOC-4088 prolonged release tablet 100 mg (Formulation B= 20 hr release formulation)
62574740|NCT01654718|EXPERIMENTAL|Pantoprazole Sodium Delayed release tablets|Pantoprazole Sodium Delayed release tablets USP 40 mg of OHM Laboratories Inc.,USA
62574741|NCT01654718|ACTIVE_COMPARATOR|Protonix® Delayed Release 40 mg tablets|Protonix® Delayed Release 40 mg tablets of Wyeth Pharmaceuticals Inc.USA
62574742|NCT02780089||Prospective Patients|There will be 1,600 prospective patients recruited over a period of two years and followed-up for a planned minimum of three years. For the prospective cohort, patients will be recruited after the course of treatment has been decided by the physician and prior to the start of treatment.Prior advanced melanoma treatment information will be collected from patient charts for pre-treated patients. Patients will be followed for a minimum of 3 years from their study index date until death, withdrawal of consent, lost to follow-up/record, or end of study, whichever comes first. Study index date will be the date when first study therapy is initiated.
62574743|NCT02780089||Treatment Group No. 1|Immune checkpoint inhibitor patients who remain on an immune checkpoint inhibitor therapy. Defined as immune checkpoint inhibitor therapy patients who either remained on their initial (index) immune checkpoint inhibitor therapy or switched to another immune checkpoint inhibitor therapy during the study period. Patients in this group remained on an immune checkpoint inhibitor therapy and did not switch to a non-immune checkpoint inhibitor therapy anytime during the study period.
62574744|NCT02780089||Treatment Group No. 2|Immune checkpoint inhibitor patients who switched to a non-immune checkpoint inhibitor therapy. Defined as patients who switched from their index immune checkpoint inhibitor therapy to a non-immune checkpoint inhibitor therapy anytime during the study period.
62574745|NCT02780089||Treatment Group No. 3|Targeted therapy patients who remain on a targeted therapy. Defined as targeted therapy patients who either remained on their initial (index) targeted therapy or switched to another targeted therapy during the study period. Patients in this group remained on a targeted therapy and did not switch to a non-targeted therapy anytime during the study period.
62734678|NCT02644252|EXPERIMENTAL|Performance status 0-1, Arm B|Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Placebo 1 capsule x 3 daily until progression.
62009954|NCT01347203|EXPERIMENTAL|Treatment D|DPOC-4088 prolonged release tablet 200 mg (Formulation B= 20 hr release formulation)
62196143|NCT02560753|EXPERIMENTAL|T3D-959 30mg|Nine subjects will take 30mg by mouth once daily for two weeks, with or without food.
62009955|NCT06664359||myofascial pain|myofascial pain syndrome
62196144|NCT02560753|EXPERIMENTAL|T3D-959 90mg|Nine subjects will take 90mg by mouth once daily for two weeks, with or without food.
62196145|NCT05780034|EXPERIMENTAL|AC676 Dose Escalation|Participants will receive an assigned dose of AC676 in a 28-days cycle.
62574746|NCT02780089||Treatment Group No. 4|Targeted therapy patients who switched to a non-targeted therapy. Defined as patients who switched from their index targeted therapy to a non-targeted therapy anytime during the study period.
62574747|NCT02780089||Treatment Group No. 5|Chemotherapy/other therapy patients who remain on a chemotherapy/other therapy. Defined as chemotherapy/other therapy patients who either remained on their initial (index) chemotherapy/other therapy or switched to another chemotherapy/other therapy during the study period. Patients in this group remained on a chemotherapy/other therapy and did not switch to an immune checkpoint inhibitor therapy or targeted therapy anytime during the study period.
62574748|NCT02780089||Treatment Group No. 6|Chemotherapy/other patients who switched to an immune checkpoint inhibitor therapy or targeted therapy. Defined as patients who switched from their index chemotherapy/other therapy to an immune checkpoint inhibitor therapy or targeted therapy anytime during the study period.
62196146|NCT04843579|EXPERIMENTAL|Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)|"Selinexor~• Given orally at a dose of 60 mg on days 1, 8, and 15 of a 28-day cycle.~Dexamethasone~* Given orally at a dose of 40 mg on days 1, 8, 15 and 22 of a 28-day cycle.~* Subjects will receive a prescription for dexamethasone 4 mg tablets (generic).~Clarithromycin~* Given orally at a dose of 500 mg twice a day on days 1-28 of a 28-day cycle.~* Subjects will receive a prescription for clarithromycin 250 or 500 mg tablets (generic) for oral administration.~Pomalidomide~* Given orally at a dose of 4 mg daily on days 1-21 of a 28-day cycle.~* Subjects will receive a 21-day supply of pomalidomide 1, 2, 3, or 4 mg capsules for oral administration for each treatment cycle."
62196147|NCT03867162|EXPERIMENTAL|Live Attenuated Tularemia Vaccine|0.06 mL of Tularemia Vaccine, Live, Attenuated, NDBR 101, Lot 4
62574749|NCT02780089||Retrospective Patients|Retrospective cohort of 600 patients with unresectable or metastatic melanoma, receiving therapies other than immune checkpoint inhibitor or targeted therapies during the four year period prior to the release of ipilimumab (March 25, 2007 -March 24, 2011), will be identified. The data for these 600 retrospective patients will be used as a benchmark for treatment patterns and outcomes prior to the marketed availability of immune checkpoint inhibitors or targeted therapies.
62574750|NCT06239493||IVUS GUIDED|Those undergoing an already planned IVUS guided treatment for percutaneous vascular interventions
62196148|NCT06489106|ACTIVE_COMPARATOR|Activity based upper extremity training|Activity-based upper extremity training (AB-UET) will be administered 5d/week and 1 hour 30 minutes/session.
62196149|NCT06489106|EXPERIMENTAL|Activity based upper extremity training with stimulation|Activity-based upper extremity training (AB-UET + scTS) will be administered 5d/week and 1 hour 30 minutes/session. UE tasks will be repeated with and without scTS so that scTS is administered intermittently for the duration of \~ 10 minute/bouts.
62196150|NCT04537533|EXPERIMENTAL|first group|1st group (A) will include 30 patients: each one will receive 15mg/kg of I.V tranexemic acid as a bolus over 10 minutes (loading dose) then 10mg/kg/hour of I.V tranexemic acid as infusion all through the operation.
62196151|NCT04537533|ACTIVE_COMPARATOR|second group|2nd group (B) will include 30 patients: : each one will receive 5mg/kg of I.V tranexemic acid as a bolus over 10 minutes (loading dose) then 1mg/kg/hour of I.V tranexemic acid as infusion all through the operation.
62196152|NCT04537533|PLACEBO_COMPARATOR|Third group|3rd group (C){controlled group} will include 30 patients: each one will receive saline (placebo) injection and infusion all through the operation.
62196153|NCT00833872|EXPERIMENTAL|LEO 22811 solution|
62196154|NCT00833872|PLACEBO_COMPARATOR|placebo solution|
62399111|NCT06724198|EXPERIMENTAL|Intervention group|Participants will recieve Psyllium husk twice daily for 8 weeks
62399112|NCT01138709|EXPERIMENTAL|Convexity/Vitala|For all enrolled Subjects, STAGE 1 (Days 1 - 14 equals Convex Product Wear Period followed by, for those who successfully complete Stage I, weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 15 to 21), followed by 8 hours of daily wear time per week (Day 22 to 28), followed by 12 hours of daily wear time (Days 29 to 43).
62399113|NCT06725030|EXPERIMENTAL|Free Tissue Transfer and Lymphovenous Anastomosis Surgery.|
62574751|NCT00862823|ACTIVE_COMPARATOR|Atripla Tablet|Drug exposure after administration of Atripla Tablet
62574752|NCT00862823|EXPERIMENTAL|Atripla Liquid|Drug exposure after administration of an extemporaneously prepared liquid formulation of Atripla
62574753|NCT05817149||Patients with melanoma|Patients with melanoma undergoing sentinel lymph node biopsy with perioperative blood samples.
62574754|NCT04194463|EXPERIMENTAL|ChemoFit exercise prehabilitation intervention|Exercise intervention consisting of walking and increasing daily step count. This is monitored by wearing a pedometer device. Other part of intervention are 5 simple strengthening exercises.
62574755|NCT04676269|SHAM_COMPARATOR|Amnion only|Amnion bilayer as a scaffold to overlay the endometrium, with minor curettage prior to stick the scaffold.
62574756|NCT04676269|EXPERIMENTAL|Amnion- self endometrium stem cells (EnSC)|Amnion bilayer as a scaffold, seeded with endometrium stem cells to regenerate the thin endometrium.
62399114|NCT06723769|ACTIVE_COMPARATOR|Control group|conventional treatment
62399115|NCT06723769|EXPERIMENTAL|rTMS group|The rTMS group was treated with LF-rTMS based on the conventional treatment.
62399116|NCT01150149|NO_INTERVENTION|1|
62399117|NCT01150149|EXPERIMENTAL|2|No face touch
62574757|NCT04676269|EXPERIMENTAL|Amnion- amnion epithelial stem cells (AESC)|Amnion bilayer as a scaffold, seeded with amnion epithelial stem cells to regenerate the thin endometrium.
62574758|NCT04676269|EXPERIMENTAL|Amnion- co culture self EnSC - AESC|Amnion bilayer as a scaffold, seeded with co-culture of endometrium stem cells and amnion epithelial stem cells to regenerate the thin endometrium.
62574759|NCT06509464|EXPERIMENTAL|low volume High-intensity interval training (HIIT)|group A (n =24) will receive low volume High-intensity interval training (HIIT) three times /week for 3 months,
62574760|NCT06509464|EXPERIMENTAL|caloric restricted diet.|group B (24) will receive caloric restricted diet.
62574761|NCT05008276||Youth with overweight/obesity and/or newly diagnosed T2D and elevated HbA1c|All participants will under go GFR (Iohexol Inj 300 MG/ML), EPRF (Aminohippurate Sodium Inj 20%), Dextran sieving (Dextran 40 Sodium Inj 0.9%), IVGTT for insulin sensitivity, in addition to BOLD and ASL Kidney MRI
62574762|NCT05008276||Healthy normal-weight controls|All participants will under go GFR (Iohexol Inj 300 MG/ML), EPRF (Aminohippurate Sodium Inj 20%), Dextran sieving (Dextran 40 Sodium Inj 0.9%), IVGTT for insulin sensitivity, in addition to BOLD and ASL Kidney MRI
62574763|NCT01294696||All Enrolled Participants|All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
62009956|NCT03149328|EXPERIMENTAL|Northern Alberta Renal Program (NARP)|Provide in NARP (intervention group), 1) an electronic tool (ePRO) that facilitates real time PRO data collection and feedback in clinical practice, and 2) educational support to multidisciplinary home dialysis clinicians about how to use PROs routinely in their practice.
62009957|NCT03149328|NO_INTERVENTION|Southern Alberta Renal Program (SARP)|In SARP (comparator group), clinicians will not receive PRO feedback or education sessions.
62009958|NCT03176732||Group 1: Normotensive|Categorized by 24-hr systolic BP (SBP): normotensive (\< 125 mm Hg) on no BP medications
62009959|NCT03176732||Group 2: Controlled Hypertensive|Categorized by 24-hr systolic BP (SBP): controlled hypertensive (\< 130 mm Hg) on BP medication(s) and/or lifestyle modification
62009960|NCT03176732||Group 3: Uncontrolled Hypertensive|Categorized by 24-hr systolic BP (SBP): uncontrolled hypertensive (≥ 130 mm Hg) on 0-2 BP medications
62009961|NCT03176732||Group 4: Hypertensive|Categorized by 24-hr systolic BP (SBP): hypertensive (≥ 135 mm Hg) resistant to 3 or more BP medications ideally including a diuretic (resistant hypertension)
62399118|NCT01150149|EXPERIMENTAL|3|Surgical face mask
62399119|NCT01150149|EXPERIMENTAL|4|Surgical face mask + no face touch
62399120|NCT02930928||Accuracy of weight estimation|Computer based comparison of the two algorithms based on collected patient data
62399121|NCT06713967|EXPERIMENTAL|Glucophage Treatment Group|In this arm, participants will receive a standard diet and exercise plan along with Glucophage (metformin). Metformin will be administered starting at 500 mg daily and gradually increased to 1500 mg daily for non-obese participants and 2000 mg daily for obese participants, starting from the second week of pregnancy until delivery. The goal is to evaluate the effectiveness of Glucophage in improving pregnancy outcomes for women with PCOS, including reducing early pregnancy loss, preterm delivery, gestational diabetes, and intrauterine growth restriction.
62399122|NCT06713967|ACTIVE_COMPARATOR|Standard Care Group:|Participants in this arm will receive a standard diet and exercise plan but will not receive any pharmacological intervention. This group will serve as a comparison to assess the impact of Glucophage on pregnancy outcomes in women with PCOS. All participants will be closely monitored throughout the pregnancy with regular follow-up visits and ultrasounds.
62399123|NCT04553185||Parkinson's disease patients|Patients with idiopathic or familial Parkinson's disease
62399124|NCT03432130|EXPERIMENTAL|Experimental group|Performing a structural training program twice a week, 30 minutes each.
62399125|NCT03432130|NO_INTERVENTION|Control group|
62399126|NCT06125951|EXPERIMENTAL|10 mg Xanamem|10 mg Xanamem tablet, to be administered orally once every morning with or without food
62399127|NCT06125951|PLACEBO_COMPARATOR|Placebo|Placebo tablet, to be administered orally once every morning with or without food
62399128|NCT03440450|EXPERIMENTAL|Cohort 1: Treatment at 1.2 mg/m2|FF-10832 Gemcitabine Liposome Injection, 1.2 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
62399129|NCT03440450|EXPERIMENTAL|Cohort 2: Treatment at 2.4 mg/m2|FF-10832 Gemcitabine Liposome Injection, 2.4 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
62399130|NCT03440450|EXPERIMENTAL|Cohort 3: Treatment at 4.8 mg/m2|FF-10832 Gemcitabine Liposome Injection, 4.8 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
62399131|NCT03440450|EXPERIMENTAL|Cohort 4: Treatment at 8 mg/m2|FF-10832 Gemcitabine Liposome Injection, 8 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
62399132|NCT03440450|EXPERIMENTAL|Expansion Cohort: Treatment at Recommended Phase 2 Dose (RP2D)|For patients with biliary tract cancer: FF-10832 Gemcitabine Liposome Injection, RP2D administered intravenously (IV) on Day 1 of each 21-day cycle
62399133|NCT01069692|PLACEBO_COMPARATOR|Arm 1|Placebo
62399134|NCT01069692|EXPERIMENTAL|Arm 3|
62399135|NCT01069692|EXPERIMENTAL|Arm 2|
62574764|NCT01262222||pts undergoing major surg procedure referred to cardiology|Patients deemed to be at intermediate to high risk for postoperative cardiovascular events by clinical criteria will be the subject of this study. Cardiac risk will be determined according to the Revised Cardiac Risk Index (RCRI). RH-PAT testing and BNP evaluation will take place within 30 days before surgery and may occur on separate days. The blood may be drawn on the day of the RH-PAT testing or at a time of routine blood drawing within the 30 day period. After surgery the patient will be monitored and examined in the PACU for evidence of cardiac events.
62009962|NCT01304888|EXPERIMENTAL|Food basket w/o nutrition education|
62196155|NCT06325917|EXPERIMENTAL|whatsApp ongoing support|70 patients will receive the usual care by DSN in the diabetes clinic through monthly visits supported by ongoing follow-up via what's App for a 3month.
62399136|NCT01069692|EXPERIMENTAL|arm 4|SBR759A
62399137|NCT01069692|EXPERIMENTAL|arm 5|
62399138|NCT00577382|EXPERIMENTAL|Sunitinib|"Cohort A participants received 50 mg sunitinib orally daily for 4 weeks followed by a two-week break from treatment. These 6-week cycles would be repeated until progression or unacceptable toxicity up to 1 year.~Cohort B participants received 37.5 mg sunitinib daily on a continuous basis until progression or unacceptable toxicity up to 1 year."
62009963|NCT01304888|EXPERIMENTAL|Food basket + nutrition education|
62009964|NCT01304888|EXPERIMENTAL|Control|
62009965|NCT01304888|EXPERIMENTAL|Cash + health and nutrition education|
62196156|NCT06325917|PLACEBO_COMPARATOR|usual care|monthly follow-up at the diabetes education clinic patients receiving individual care and education by diabetes nurse specialist
62399139|NCT04828746|NO_INTERVENTION|Control|Patients who will undergo lumbar puncture without pre-procedural ultrasound-guided skin marking
62399140|NCT04828746|EXPERIMENTAL|Experimental|Patients who will undergo lumbar puncture after pre-procedural ultrasound-guided skin marking
62574765|NCT06023719|EXPERIMENTAL|DISC Care|DISC Care implant
62009966|NCT05035069|EXPERIMENTAL|Ciprofol|
62009967|NCT05035069|ACTIVE_COMPARATOR|Propofol|
62009968|NCT04847050|EXPERIMENTAL|Arm 1 messenger ribonucleic acid (mRNA)|100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection intramuscular (IM) on days 1 and 29; with option for subsequent booster dose(s), 100 mcg (0.5 mL) mRNA-1273 injection (IM) no less than 4 weeks after day 29
62009969|NCT04847050|EXPERIMENTAL|Arm 2 messenger ribonucleic acid (mRNA)|100 micrograms (0.5 mL) messenger ribonucleic acid (mRNA) injection on day (D)1
62196157|NCT05196282||UC, Smoker|
62196158|NCT05196282||UC, Smoking cessation|
62196159|NCT05196282||UC, THS user|
62196160|NCT05196282||CD, Smoker|
62196161|NCT05196282||CD, Smoking cessation|
62196162|NCT05196282||CD, THS user|
62196163|NCT00903760|EXPERIMENTAL|Decitabine + Clofarabine|Drug delivery intravenously (IV) in alternating series of cycles (Decitabine 20 mg/m\^2 for 5 days first 3 cycles, then Clofarabine 10 mg/m\^2 five days for next 3 cycles), pattern repeats for up to 24 cycles.
62196164|NCT00903760|EXPERIMENTAL|Decitabine|Decitabine 20 mg/m\^2 IV daily for 5 days for a total of 24 courses.
62215004|NCT05893706||Dual task|A dual-task paradigm is a procedure in experimental neuropsychology that requires an individual to perform two tasks simultaneously, in order to compare performance with single-task conditions.
62215005|NCT05893706||Single task|Single task
62215006|NCT01769768|EXPERIMENTAL|LDE225+Warfarin|At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the warfarin group.
62215007|NCT01769768|EXPERIMENTAL|LDE225+Bupropion|At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the Bupropion group
62215008|NCT01258842|EXPERIMENTAL|B. lactis HN019|
62215009|NCT01258842|PLACEBO_COMPARATOR|Placebo|
62399141|NCT05879614|EXPERIMENTAL|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
62734679|NCT02644252|EXPERIMENTAL|Performance status 2, Arm A|Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Tocotrienol 300 mg x 3 daily until progression
62734680|NCT02644252|EXPERIMENTAL|Performance status 2, Arm B|Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Placebo 1 capsule x 3 daily until progression
62734681|NCT01831466|EXPERIMENTAL|Treatment Group A|
62574766|NCT02780713|EXPERIMENTAL|AZD9496|"This is a fixed sequence study with 5-sequential treatment periods in healthy volunteers. Each volunteer will receive 5 single doses of AZD9496 in different forms, formulations and doses.~1. Treatment period 1 will assess AZD9496 Variant A: 100mg.~2. Treatment period 2 will assess AZD9496 Reference: 100mg.~3. Treatment period 3 will assess one of AZD9496 Variants, B, C or D: 100mg.~4. Treatment period 4 will assess one of AZD9496 Variants, B, C or D: 100mg.~5. Treatment period 5 will assess one of AZD9496 Variants A, B, C or D: \*300mg. \*Based on a review of PK and safety results from Treatment Periods 1, 3 and 4, a lower dose of 200 mg may be administered in Treatment Period 5"
62574767|NCT06578026|EXPERIMENTAL|Treatment|Received the Resilience Builder Program intervention
62574768|NCT06578026|NO_INTERVENTION|Control|Did not receive the Resilience Builder Program
62574769|NCT05920967|EXPERIMENTAL|DXP group|The participants in DXP group will receive a first dose of a single paravertebral space infusion of 21 ml of analgesic containing 0.5 percentage ropivacaine 20 ml and dexamethasone palmitate 1ml.
62574770|NCT05920967|ACTIVE_COMPARATOR|DXM group|The participants in DXM group will receive a single infusion of a paravertebral space first dose of 21 ml of analgesic containing 0.5 percentage ropivacaine 20 ml and dexamethasone sodium phosphate 1ml.
62574771|NCT04589936|EXPERIMENTAL|COVID-19|Non-ventilated patients with COVID-19
62574772|NCT04589936|ACTIVE_COMPARATOR|Pneumonia control|Patients with pneumonia unrelated to COVID-19 requiring supplemental O2.
62574773|NCT03596593|EXPERIMENTAL|Experimental group|A total of 8-10 mL of blood will be collected from this group of patients and used for blood-MSI testing.
62574774|NCT05007028|EXPERIMENTAL|Nitrous Oxide|Active Drug: EMONO (Equimolar Mixture of Oxygen and Nitrous Oxide)
62574775|NCT05007028|PLACEBO_COMPARATOR|Medical air|Control Drug: Medical air : 78% N2 / 22% O2
62574776|NCT06167837|EXPERIMENTAL|Metoclopramide group|Metoclopramide 10 mg +NSS 10ml IV 30-60 min before EGD
62574777|NCT06167837|PLACEBO_COMPARATOR|Placebo group|NSS 10 ml IV 30-60 min before EGD
62574778|NCT03721263|EXPERIMENTAL|ASLAN004 Single Ascending Dose|"Up to 10 dose levels are planned.~ASLAN004 by IV route: 0.1 mg/kg (Cohort 1), 0.3 mg/kg (Cohort 2), 1 mg/kg (Cohort 3), 3 mg/kg (Cohort 4) and 10 mg/kg (Cohort 5), 20 mg/kg (Cohort 6 \[optional\]).~ASLAN004 SC route: 75 mg (Cohort 7), 150 mg (Cohort 8), 300 mg (Cohort 9), and 600 mg (Cohort 10 \[optional\])."
62574779|NCT00086138|EXPERIMENTAL|1|Participants will receive sertraline at a target dose of 100mg daily.
62009970|NCT00320281|PLACEBO_COMPARATOR|placebo|Normal saline injections were used for placebo injections. Injections were based on treatment plan determined in clinical setting by study PI and physical therapist. 25 cc syringe was used and amount of saline injected was unit based on muscles to be injected according to the treatment plan.
62196165|NCT04516005|EXPERIMENTAL|foot reflexology|Foot reflexology was performed in every participant in the foot reflexology group after resting for 5 minutes in a sitting position by the same researcher who was trained and certified by the Department of Thai Traditional and Alternative Medicine, Ministry of Health.
62574780|NCT00086138|PLACEBO_COMPARATOR|2|Participants will receive placebo matched to sertraline
62196166|NCT04516005|NO_INTERVENTION|control|The control group received conventional treatment including anti-HT medications according to the standard HT guideline's recommendations. In the end of the follow-up visit, every participants were informed to adhere to their medication and were encouraged to have healthy lifestyles including salt restriction, regular exercise, and consuming healthy diets.
62574781|NCT02516514|EXPERIMENTAL|Multi-sampling strategy|2 or 3 blood cultures in 24 hours worked at ½ hour intervals with seeding at least a pair of flasks, aerobic and anaerobic, by blood culture.
62574782|NCT02516514|ACTIVE_COMPARATOR|Single-sampling strategy|1 single dose of venous blood 30ml ± 10ml with seeding 4 blood culture bottles (aerobic and anaerobic 2 2).
62196167|NCT05184322|EXPERIMENTAL|Cohort 1A/1B|Cohort 1A/1B will enroll 14 healthy participants.
62009971|NCT00320281|ACTIVE_COMPARATOR|Botulinum toxin A|Botulism toxin A dosage was based on plan developed in clinical setting with study PI and physical therapist. Drug was dosed in 25 cc syringe,diluted with normal saline and injections occured based on treatment plan.
62196168|NCT05184322|EXPERIMENTAL|Cohort 2|Cohort 2 will enroll 14 healthy participants.
62196169|NCT05184322|EXPERIMENTAL|Cohort 3|Cohort 3 will enroll 14 healthy participants.
62574783|NCT01351792|EXPERIMENTAL|Foster®|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
62574784|NCT01351792|ACTIVE_COMPARATOR|Symbicort® Turbohaler®|Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
62574785|NCT01408316|EXPERIMENTAL|Part 1 (Crystalline vs. Amorphous)|Volunteers in part 1 of the study will initially receive either crystalline PX-866 tablets or amorphous PX-866 capsules, then after seven days, the same volunteers will respectively cross-over to receive the alternate amorphous PX-866 capsules or crystalline PX-866 tablets.
62574786|NCT01408316|EXPERIMENTAL|Part 2 (Crystalline Food Effect)|Volunteers in part 2 of the study will receive two single dose treatments of PX-866 crystalline tablets initially administered in either fed or fasted state, then after at least seven days, the same volunteers will respectively cross-over to receive PX-866 tablets in the alternate fed or fasted state.
62574787|NCT03636802||EXPERIMENTAL GROUP|Patient with respiratory failure and on a lung transplant waiting list
62734682|NCT01831466|EXPERIMENTAL|Treatment Group B|
62574788|NCT05517148|EXPERIMENTAL|Mindfulness-based Stress Reduction by Therapeutic VR|47 participates were randomized and allocated to this treatment group. During the study, seven individuals were lost, and a total of 40 nurses participated in the final statistics. Of the seven individuals lost, two withdrew from the intervention due to personal reasons, while the remaining five terminated the intervention due to COVID-19 infection. The therapeutic intervention consisted of an eight-week group intervention that included the same amount of contact and meditations as MBT.
62574789|NCT05517148|OTHER|Mindfulness-based Stress Reduction|Received the same mindfulness therapy training audio as the other set, but did not watch the 3D scene on the VR device. At the end of the study, we will compensate them and let them use VR for relaxation training according to their wishes.
62574790|NCT02498444|EXPERIMENTAL|Treprostinil|The subcutaneous continuous treprostinil infusion will start at a dose of 2 ng/kg/min. The dose will be increased over the first 24 hours to goal 10 ng/kg/min through day five. On postoperative day six, the dose will be decreased by 2 ng/kg/min every 8 hours with plans for discontinuation on postoperative day seven.
61978055|NCT05745558|EXPERIMENTAL|Prehabilitation|A 3-to-6-week prehabilitation program consisting of training and nutritional, smoking cessation and psychosocial counselling.
62196170|NCT05184322|EXPERIMENTAL|Cohort 4|Cohort 4 will enroll 14 otherwise healthy participants with obesity.
62574791|NCT02498444|PLACEBO_COMPARATOR|Saline|Saline administration via subcutaneous infusion
62574792|NCT01742130|EXPERIMENTAL|Sodium bicarbonate|Sodium Bicarbonate (154 mEq/L in dextrose and H2O) 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
62574793|NCT01742130|ACTIVE_COMPARATOR|Saline|Sodium Saline 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
62574794|NCT01840059|EXPERIMENTAL|Renal sympathetic denervation|Renal denervation using the Medtronic Symplicity catheter.
62574795|NCT01840059|NO_INTERVENTION|Control|HF-PEF patients who will serve as control.
62574796|NCT04542486|EXPERIMENTAL|The conventional approach:|Gingivoplasties and removal of excess gingival tissues through the conventional scalpel technique using a reverse bevel.
62574797|NCT04542486|ACTIVE_COMPARATOR|The intervention approach:|"Gingivoplasties and elimination of excess gingival tissues through the use of Soft tissue trimmer."
62574798|NCT06335407|OTHER|BXCL501 Dose Range 40µg to 160µg|Participants will receive 40µg on days 1-2. On days 3 and 4, participants will receive 40µg twice per day. On days 5 and 6 participants will receive 40µg in the morning and 80µg in the evening. On days 7-28 participants will receive 80µg in the morning and evening. Dose escalation will follow the above schedule based on tolerability assessed by clinician.
62574799|NCT04266834|EXPERIMENTAL|Experimental|Experimental-arm providers will complete two rounds of three simulated patient cases (CPVs) with two additions described in the next column:
62574800|NCT04266834|NO_INTERVENTION|Control|These providers will complete two rounds of three simulated patient cases (CPVs) only.
62574801|NCT04950348|EXPERIMENTAL|3D printed personalized TKA prosthesis|Patients in the experimental group received 3D printed personalized TKA prosthesis treatment
62574802|NCT04950348|ACTIVE_COMPARATOR|Zimmer NexGen TKA prostheses|Patients in the active comparator group received Zimmer NexGen TKA prostheses treatment
62574803|NCT04851990|EXPERIMENTAL|Large Patch|"To Better Days Large Patch~1 patch applied daily by 9am - in situ for 24 hours Dosage: vitamin D 30,000 IU + dextrose 13mg"
62574804|NCT04851990|EXPERIMENTAL|Small patch|"To Better Days Small Patch~1 patch applied daily by 9am - in situ for 24 hours Dosage: vitamin D 30,000 IU + dextrose 13mg"
62574805|NCT05225844|EXPERIMENTAL|Camrelizumab Plus Apatinib mesylate|for advanced gastric cancer with previous standard treatment failure
62574806|NCT05225844|EXPERIMENTAL|Camrelizumab and Apatinib mesylate|for advanced colorectal cancer with previous standard treatment failure
62196171|NCT05184322|EXPERIMENTAL|Cohort 5|Cohort 5 will enroll 14 otherwise healthy participants with obesity.
62574807|NCT06207097|EXPERIMENTAL|Dry needling plus exercise program.|
62574808|NCT06207097|EXPERIMENTAL|Elastic taping plus exercise program.|
62574809|NCT01807572||obesity risk status|Lean adolescents at high-risk for obesity, by virtue of parental obesity, and lean adolescents at low-risk for obesity, by virtue of lean parents.
62574810|NCT06237569||Grup 1 -Ketamine Group|Ketamine Group (GROUP 1) 0.5 mg/kg IV single dose bolus diluted to 5 ml with 0.9% saline
62574811|NCT06237569||Group 2-ketamine + midazolam|Midazolam 0.0125 mg/kg is given followed by a single IV bolus dose of 0.5 mg/kg diluted to 5 ml with 0.9% saline.
62574812|NCT06237569||Group 3-placebo|Group 3-placebo ;A single dose of IV 5 ml physiological saline will be given.
62574813|NCT02218437|EXPERIMENTAL|MSC+ATG|The first agent MSC injection, began two weeks after ATG application; Each patient was injected three times, one time per week; Study on single dose tolerance and efficacy index; Each subjects received three dose groups of treatment.
62574814|NCT02337608|EXPERIMENTAL|GLPG1205 100mg QD|GLPG1205 100mg daily dosing in the morning
62196172|NCT05184322|EXPERIMENTAL|Cohort 6|Cohort 6 will enroll 14 otherwise healthy participants with obesity.
62574815|NCT02337608|PLACEBO_COMPARATOR|Placebo|Placebo daily dosing in the morning
62574816|NCT00548587|ACTIVE_COMPARATOR|1|Participants will receive one 50 mg E5555 tablet and two 100 mg placebo tablets, once daily for 12 weeks.
62574817|NCT00548587|ACTIVE_COMPARATOR|2|Participants will receive one 50 mg placebo tablet, one 100 mg E5555 tablet, and one 100 mg placebo tablet, once daily for 12 weeks.
62574818|NCT00548587|ACTIVE_COMPARATOR|3|Participants will receive one 50 mg placebo tablet and two 100 mg E5555 tablets, once daily for 12 weeks.
62574819|NCT00548587|PLACEBO_COMPARATOR|4|Participants will receive one 50 mg placebo tablet and two 100 mg placebo tablets, once daily for 12 weeks.
62574820|NCT01255345||Adult females with CPP living in Denmark|
62574821|NCT00907491||A|
62734683|NCT01831466|PLACEBO_COMPARATOR|Treatment Group C|
62734684|NCT01831466|EXPERIMENTAL|Treatment Group D|
62196173|NCT03613389|EXPERIMENTAL|oral topical vitamin E|
62574822|NCT00328211|EXPERIMENTAL|Bile Acid|To assess the role of bile acid pool size changes on cholesterol absorption, synthesis and intralumenal cholesterol solubilization.
62574823|NCT00328211|EXPERIMENTAL|Cholesterol Absorption|To determine whether cholesterol absorption, synthesis and solubilization will be significantly altered by changes in phospholipid content, specifically sphingolipids and phosphatidylcholine in the intestinal lumen.
62574824|NCT00328211|EXPERIMENTAL|Intralumenal|To assess intralumenal solubilization and absorption of biliary and dietary cholesterol.
62574825|NCT05401500|EXPERIMENTAL|familial aortopathy|
62574826|NCT02402335||1 Fracture of vertebra|Osteoporotic fracture of the vertebra
62574827|NCT02402335||2 Nerve Compression|Osteochondria, Spinal disc herniation, Nerve compression
62574828|NCT05282992|EXPERIMENTAL|Native type II collagen|Native type II collagen
62574829|NCT05282992|PLACEBO_COMPARATOR|Placebo|Placebo
62574830|NCT00646815|EXPERIMENTAL|a|the aim of the present study is to characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic-intramyocellular lipids in 12 adult patients, recently diagnosed with growth hormone deficiency
62574831|NCT00646815|NO_INTERVENTION|Control|Intramyocellular, intrahepatic and intraabdominal lipid content, lean body mass and body fat percentage, are assessed in ten healthy controls matched on age, gender and BMI.
62574832|NCT06237530|EXPERIMENTAL|Visceral Body Scan (VBS)|The VBS consisted of a mindfulness exercise designed to bring awareness to visceral sensations in the cardiac, respiratory, gastrointestinal, and urinary systems. These physiological systems were chosen because most of the paradigms developed in the literature to assess interoception focus on them (Khalsa et al., and they are widely recognized in the literature as interoceptive senses (Nord \& Garfinkel, 2022)
62574833|NCT06237530|ACTIVE_COMPARATOR|Somatosensory body scan (SBS)|The SBS consisted of a mindfulness exercise designed to bring awareness to tactile (e.g., itching) and musculoskeletal (e.g. g., tension) sensations in different parts of the body, namely, the head and neck, back, arms, and legs. Body scan exercises typically focus on these types of bodily cues (in addition to breathing) (Williams, 2010).
62574834|NCT06237530|SHAM_COMPARATOR|External control meditation (ECM)|The ECM consisted of a mindfulness exercise designed to bring awareness to external stimuli, including sounds and visual properties of the environment
62574835|NCT04024345|EXPERIMENTAL|Psychometric assessment group|Arms to whom the psychometric assessment will be administered
62574836|NCT04747353|EXPERIMENTAL|Catheter ablation procedure with heart 3D model|Experimental: Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
62574837|NCT03546491|EXPERIMENTAL|Preventive Gel|0.4% stannous fluoride
62574838|NCT03546491|ACTIVE_COMPARATOR|Marketed Control|0.243 % Sodium Fluoride
62196174|NCT03613389|NO_INTERVENTION|voriconazole and levofloxacin|
62196175|NCT02975063|EXPERIMENTAL|A&T IYCF intervention|A\&T IYCF intervention is includes comprehensive IYCF counseling which includes intensive activity that aims to deliver one-on-one counseling at home or in a health facility.
62196176|NCT02975063|NO_INTERVENTION|Control|No intervention.
62215010|NCT00532493|ACTIVE_COMPARATOR|Prazosin Group|Subjects randomized to this arm will be on prazosin.
62574839|NCT05517668|ACTIVE_COMPARATOR|N-acetylcysteine (NAC) only (Control)|Patients randomized to Control group will receive placebo (D5W) in addition to N-acetylcysteine. Study participants will receive study drug (fomepizole or placebo) throughout the study.
62574840|NCT05517668|EXPERIMENTAL|N-acetylcysteine (NAC) and Fomepizole (4-MP) (Study)|Patients randomized to Study group will receive fomepizole (diluted in D5W) in addition to N-acetylcysteine. Study participants will receive study drug (fomepizole or placebo) throughout the study. If randomized to Study group, the infusion of the study medication should be initiated as soon as feasible but no later than 24 hours after the commencement of acetylcysteine therapy.
62574841|NCT05560269|EXPERIMENTAL|verbal and physical constraint group|Use of verbal and physical constraint
62009972|NCT06571214|EXPERIMENTAL|Treatment group|"The r-hFSH starting dose will be based on the patient's profile and physician's experience. r-hLH will be added at a ratio of 2:1 starting from day 1 of r-hFSH administration; the dose of r-hFSH during COS will be adjusted by the physician based on clinical experience and the patient's ovarian response, and the r-hFSH: r-hLH dose will be 2:1, continuing to 24\~48 hours prior to trigger drug injection.~For both groups, daily injection of 0.25 mg of cetrorelix (Cetrotide®, Merck Serono S.A.) will be administrated subcutaneously when at least one follicle with diameter ≥ 14 mm or serum LH level exceeds 10 IU/L or LH level is 2 folder than basal LH level or P level exceeds 0.8 ng/ml, continuing until ovulation triggering day. Cetrorelix can be administrated earlier in patients with advanced age or diminished ovarian reserve according to judgment of clinicians."
62009973|NCT06571214|ACTIVE_COMPARATOR|Control group|"r-hFSH alone will be administrated for ovarian stimulation. The r-hFSH starting dose will be based on the patient's profile and physician's experience. The dose of r-hFSH during COS will be adjusted by the physician based on clinical experience and the patient's ovarian response, continuing to 24\~48 hours prior to trigger drug injection.~For both groups, daily injection of 0.25 mg of cetrorelix (Cetrotide®, Merck Serono S.A.) will be administrated subcutaneously when at least one follicle with diameter ≥ 14 mm or serum LH level exceeds 10 IU/L or LH level is 2 folder than basal LH level or P level exceeds 0.8 ng/ml, continuing until ovulation triggering day. Cetrorelix can be administrated earlier in patients with advanced age or diminished ovarian reserve according to judgment of clinicians."
62009974|NCT06618599|EXPERIMENTAL|Group 1:midtransverse to pleura block combined with erector spinae block|Patients received ipsilateral Ultrasound guided midtransverse block with injection of 20 ml bupivacaine 0.25% and ipsilateral Ultrasound guided ESPB block with injection of 20 ml bupivacaine 0.25%
62009975|NCT06618599|EXPERIMENTAL|Group 2: paravertebral block|Patients received ipsilateral Ultrasound guided paravertebral plane block with injection of 30 ml bupivacaine 0.25%.
62009976|NCT05081323|EXPERIMENTAL|Self-applied treatment with THERA|Participants in this group will use the Self-applied treatment with THERA for a maximum period of one month.
62009977|NCT05081323|NO_INTERVENTION|Control without treatment|Participants in this group keep on a waiting list, after one month, they will receive the self-applied treatment
62009978|NCT05272592||Nursing staff|Certified local-and-international inpatient-and-outpatient nurses specialised in urology, perioperative nurses, and urology-specific advanced practice nurses/nurse practitioners will be included.
62009979|NCT05971108|EXPERIMENTAL|Patients with liver cirrhosis eligible for HCC Surveillance|Real-world HCC surveillance cohort will be exposed to Elecsys® GAAD in parallel with standard of care tests.
62196177|NCT06012981|EXPERIMENTAL|Acceptance & Commitment Therapy (ACT)|Psyhotherapy based on principles of functional analysis, behavioral activation, and experiential avoidance.
62196178|NCT02893189|EXPERIMENTAL|4G7-CARD T-cells|All patient will receive modified CAR19 T-cells.
62215011|NCT00532493|PLACEBO_COMPARATOR|Placebo Group|Subjects randomized to this arm will be on placebo.
62574842|NCT05560269|ACTIVE_COMPARATOR|verbal constraint group|Use of verbal constraint only
62574843|NCT05560269|EXPERIMENTAL|physical constraint group|Use of constraint only
62574844|NCT04341805|ACTIVE_COMPARATOR|Group A. Physiological saline.|The surgical procedure in group A consisted of the placement of a 6.4cm diameter circular prosthesis (BARD Hernia Patch) at the intra-abdominal level. Subsequently, the liquid contained in the 10 ml opaque vial was administered (Ecolav Physiological Washing Serum 0.9%, (SSF).
62574845|NCT04341805|EXPERIMENTAL|Group B. Solution hyperoxygenated fatty acids|The surgical procedure in group B consisted of the placement of a 6.4cm diameter circular prosthesis (BARD Hernia Patch) at the intra-abdominal level. Subsequently, the liquid contained in the 10 ml opaque vial (AGHO solution) was administered according to randomization.
62574846|NCT01051297||VTE -PROSPECTIVE|Patients diagnosed with VTE
62574847|NCT01051297||sleep study group -PROSPECTIVE|patients undergoing sleep study
62574848|NCT01051297||VTE-Retrospective|patients with VTE , chart review
62574849|NCT01051297||OSA-retrospective|PATIENT WITH OSA -CHART REVIEW
62574850|NCT01051297||OSA group -PROSPECTIVE|patients diagnosed with OSA
62574851|NCT02428309|EXPERIMENTAL|Low Dose Treg Cohort|3-6 participants will receive a single infusion of 1 x 10\^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
62574852|NCT02428309|EXPERIMENTAL|Medium Dose Treg Cohort|Sequential dose escalation, 3-6 subjects will receive a single infusion of 4 x 10\^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
62574853|NCT02428309|EXPERIMENTAL|High Dose Treg Cohort|Sequential dose escalation, 3-6 participants will receive a single infusion of 16 x 10\^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
62574854|NCT06383897|EXPERIMENTAL|Cohort1：HS-10398|SAD： HS-10398 capsule
62574855|NCT06383897|PLACEBO_COMPARATOR|Cohort2：HS-10398 Placebo|SAD：HS-10398 capsule placebo
62574856|NCT06383897|EXPERIMENTAL|Cohort3：HS-10398|MAD： HS-10398 capsule
62574857|NCT06383897|PLACEBO_COMPARATOR|Cohort4：HS-10398 Placebo|MAD：HS-10398 capsule placebo
62574858|NCT06383897|EXPERIMENTAL|Cohort5：HS-10398|HS-10398 capsule will be administered orally once on Day 1 in Participants With Kidney Dysfunction
62574859|NCT01405482|ACTIVE_COMPARATOR|Botulinum Toxin Type A injection|Double-blind, randomized, placebo-controlled trial evaluating changes in pain, paresthesias, and function in subjects with TOS before, at six weeks, and four months following injection of BTX-A into the scalene muscles and pectoralis minor muscle under EMG guidance.
62734685|NCT01831466|EXPERIMENTAL|Treatment Group E|
62734686|NCT01831466|PLACEBO_COMPARATOR|Treatment Group F|
62009980|NCT04844385|EXPERIMENTAL|Cohort A|Patients in cohort A receive 2 cycles Toripalimab plus Paclitaxel/Nedaplatin, followed by radiotherapy at a total dose of 60Gy combined with Capecitabine.
62196179|NCT05594277||surgical elderly patients|Patients ≥ 70 years old, undergoing a major surgery in general and vascular surgery, urology, orthopedics at Maggiore della Carità University Hospital, Novara, Italy, having a General Practitioner listed in the Local Health Authority of Novara.
62196180|NCT02495766|EXPERIMENTAL|Treatment A: XCEL-MC-ALPHA/Placebo|Single infusion of cryopreserved bone-marrow adult mesenchymal stromal cells followed by placebo infusion at month 6.
62196181|NCT02495766|EXPERIMENTAL|Treatment B: Placebo/XCEL-MC-ALPHA|Single infusion of placebo followed by cryopreserved bone-marrow adult mesenchymal stromal cells infusion at month 6.
62574860|NCT01405482|PLACEBO_COMPARATOR|Normal Saline|Double-blind, randomized, placebo-controlled trial evaluating changes in pain, paresthesias, and function in subjects with TOS before, at six weeks, and four months following injection of placebo into the scalene muscles under EMG guidance.
62196182|NCT01250509|EXPERIMENTAL|CALMM|Participants receiving the 'Craving and Lifestyle Management through Mindfulness' intervention, i.e. program that combines stress reduction with mindful eating practices.
62196183|NCT01250509|NO_INTERVENTION|Waitlist Control|Participants were waitlisted for the intervention during the experimental phase.
62574861|NCT03651154|EXPERIMENTAL|Hypovolemic Phlebotomy|"Hypovolemic Phlebotomy will consist of the withdrawal of 7-10 mL/kg of whole blood from the patient, as tolerated (e.g. for a 70kg patient, 490 to 700 mL of whole blood will be removed) The volume of removed blood will not be replaced by the administration of intravenous fluids.~Removed blood will be transfused back to participant at the end of surgery. The phlebotomized whole blood will be transfused back after liver transection regardless of blood loss."
62574862|NCT03651154|NO_INTERVENTION|Control (Standard of Care)|Standard of care (low CVP surgery). In this arm, standard anesthesia will be maintained.
62009981|NCT04844385|EXPERIMENTAL|Cohort B|Patients in cohort B receive 2 cycles Toripalimab plus Paclitaxel/Nedaplatin, followed by radiotherapy at a total dose of 50Gy combined with Capecitabine.
62196184|NCT04849299|EXPERIMENTAL|AT-527 550 mg + cyclosporine (simultaneous)|n=12
62196185|NCT04849299|EXPERIMENTAL|AT-527 550 mg + cyclosporine (staggered)|n=12
62196186|NCT02597322|EXPERIMENTAL|AXITINIB|
62574863|NCT05732337|OTHER|Poxclin Coolmousse|A cooling mousse for application to the skin supplied in a 100 mL plastic bottle with a pump (a foamer)
62574864|NCT06115720|NO_INTERVENTION|Standard video verbal consent process|The control group will undergo the standard video verbal consent process for both GA and RA for orthopaedic surgery. This will be delivered using a standardised video script that will be generated from existing certified material.
62574865|NCT06115720|EXPERIMENTAL|Video assisted consent process|The intervention group will also be shown the same pre-recorded standard verbal consent, but following this will additionally be shown a specifically recorded video of the anaesthetic process for both GA and RA.
62574866|NCT06577051||Children undergoing tonsillectomy ± adenoidectomy without tubal dysfunction|"* 4-15 years old child patient~* No preoperative tubal dysfunction detected in the patient~* Willingness to participate in the study by the patient and his/her parents~* The patient has no craniofacial anomaly, genetic disorder, cleft palate-lip anomaly~* No bleeding disorder or disease"
62574867|NCT01684943|EXPERIMENTAL|Multiplex pharmacokinetic profiling|Multiplex pharmacokinetic profiling of regular human insulin, insulin aspart, insulin lispro, insulin glulisine, and regular human insulin. All subjects participated in the single study arm and received injections of each type of insulin. Blood samples were drawn at intervals for pharmacokinetic profiling.
62734687|NCT05777668||Head and neck cancer patients undergoing radiotherapy|
61978056|NCT04599920|ACTIVE_COMPARATOR|Red meat supplementation providing 25% of protein intake|A diet supplemented with 760 g of cooked and boneless red meat per week, corresponding the average consumption of red meat in Finnish men.
62009982|NCT01938534|EXPERIMENTAL|Experimental|"Omeprazole 30mg twice Clarithromycin 500mg twice Amoxicillin 1000mg twice~for 10 days"
62196187|NCT03394677|EXPERIMENTAL|RVT-501 0.5% ointment|Subjects will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.
62196188|NCT03394677|PLACEBO_COMPARATOR|RVT-501 vehicle ointment|Subjects will receive RVT-501 vehicle ointment twice daily (BID) for 4 weeks.
62009983|NCT01938534|ACTIVE_COMPARATOR|Control|Tetracycline 500mg four times Omeprazole 30mg twice Bismuth 600mg twice Metronidazole 500mg three times for 10 days
62009984|NCT00422565|EXPERIMENTAL|Endeavor|Zotarolimus-eluting stent
62009985|NCT00422565|ACTIVE_COMPARATOR|Cypher|Sirolimus-eluting stent
62009986|NCT00422565|ACTIVE_COMPARATOR|Taxus|Paclitaxel-eluting stent
62009987|NCT05506020|EXPERIMENTAL|ICG group|indocyanine green (ICG) fluorescence cholangiography
62009988|NCT05506020|NO_INTERVENTION|non ICG group|no intervention
62196189|NCT03647761|NO_INTERVENTION|Control|Standard of care
62196190|NCT03647761|EXPERIMENTAL|Treatment|Tetra-grip applied
62196191|NCT06311370||Children age 4 to 7|Children age 4-7 in therapeutic school, diagnosed with ADHD, Autism monitored with raters and the sensor watch.
62196192|NCT06273813|EXPERIMENTAL|Ketorolac tromethamine|Cohort 1 - All subjects receive one Ketorolac tromethamine injection, followed by Ketorolac tromethamine gel topical Cohort 2 and 3 - Ketorolac tromethamine gel topical
62196193|NCT04855305|ACTIVE_COMPARATOR|Patients with Interstitial Lung Disease|
62196194|NCT04855305|ACTIVE_COMPARATOR|Healthy Volunteers|
62196195|NCT05371106||breastfeeding mothers|pregnant women after week 37 intending to nurse or nursing mothers of infants aged 1-12 months
62196196|NCT01851889||CF-LVAD pump speed.|
61978057|NCT04599920|EXPERIMENTAL|Red meat mostly replaced with legume-based foods|A diet supplemented with legume-based foods providing 20% of protein intake and with 200 g per week of red meat providing 5% of protein intake.
62574868|NCT01684943|EXPERIMENTAL|Continuous insulin monitoring|Continuous insulin monitoring (CIM) of insulin lispro. Some subjects participated in the CIM sub-study, which is distinct from the Multiplex Pharmacokinetic Profiling study. This intervention involved administering insulin lispro and monitoring pharmacokinetic profile of the drug using blood samples and an investigational continuous insulin monitoring system.
62196197|NCT02960503|ACTIVE_COMPARATOR|Treatment arm (azithromycin)|Treatment arm: azithromycin 500 mg three times a week for 6 months
62196198|NCT02960503|PLACEBO_COMPARATOR|Placebo arm|Control arm: placebo three times a week for 6 months
62196199|NCT05517226|EXPERIMENTAL|Cohort 1|Participants in each cohort will receive Dose A cotadutide subcutaneously.
62574869|NCT04836013|EXPERIMENTAL|Probiotic group|Lactobacillus reuteri LMG P-27481 and Lactobacillus rhamnosus GG (ATCC 53103), sucralose and isomalt as an oral stick formulation of 1,6 g with a concentration of probiotic of 2x100bilion colony forming unit (CFU) per stick.
62574870|NCT04836013|PLACEBO_COMPARATOR|Placebo group|The placebo will contain 1.6 g per stick of sucralose and isomalt
62574871|NCT02266797|ACTIVE_COMPARATOR|Dexamethasone|Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
62574872|NCT02266797|PLACEBO_COMPARATOR|Saline|Subject will receive doses of intravenous physiological saline solution.
62574873|NCT01983696|EXPERIMENTAL|5% oxygen|the oocytes and embryos are cultured in 5% oxygen concentration after oocytes retrieval until Day 6 (counting from fertilization)
62574874|NCT01983696|NO_INTERVENTION|20% oxygen|the oocytes and embryos are cultured in 20% oxygen concentration (in atmosphere) after oocytes retrieval until Day 6(counting from fertilization)
62574875|NCT06363370|EXPERIMENTAL|Human interferon α1b Inhalation Solution （4ug/kg）|Participants will receive Human interferon α1b Inhalation Solution 4ug/kg twice daily for no more than 7 days.
62574876|NCT06363370|EXPERIMENTAL|Human interferon α1b Inhalation Solution（6ug/kg）|Participants will receive Human interferon α1b Inhalation Solution 6ug/kg twice daily for no more than 7 days.
62574877|NCT06363370|PLACEBO_COMPARATOR|Inhalation Solution Placebo|Participants will receive Placebo twice daily for no more than 7 days.
62574878|NCT01861899||SI-Joint Dysfunction|Device- SI-LOK
62574879|NCT03030560|ACTIVE_COMPARATOR|Lidocaine group|Patients will receive lidocaine infusion.
62574880|NCT03030560|PLACEBO_COMPARATOR|Control group|Patients will receive 0.9% Sodium-chloride infusion infusion
62574881|NCT02730403||Opioid Use Disorder Patients|
62574882|NCT01480466|EXPERIMENTAL|Obesity tools in electronic health record|This arm will consist of a new set of tools within the electronic health record to help primary care clinicians address overweight and obesity with their patients.
62574883|NCT01480466|NO_INTERVENTION|Standard care|This arm is standard care for overweight/obesity.
62574884|NCT05250570|EXPERIMENTAL|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) and psychoeducation about benzodiazepine use in OAT.
62574885|NCT05250570|ACTIVE_COMPARATOR|Relaxation Therapy|The relaxation therapy control condition involves psychoeducation about benzodiazepine use in OAT and progressive muscle-relaxation training.
61978058|NCT01348347|EXPERIMENTAL|Volasertib|Patient to receive low, middle and high doses of Volasertib IV
61978059|NCT05585528|OTHER|Type of management, surgical or functional, after rupture of the anterior cruciate ligament|Patients will choose the type of management, surgical or functional, after rupture of the anterior cruciate ligament.
61978060|NCT06293170|OTHER|Control|Conventional care alone
62196200|NCT05517226|EXPERIMENTAL|Cohort 2|Participants in each cohort will receive Dose A cotadutide subcutaneously.
62196201|NCT05517226|EXPERIMENTAL|Cohort 3|Participants in each cohort will receive Dose A cotadutide subcutaneously.
62574886|NCT03971136|OTHER|Children with sickle cell disease|Child from 12 months to 18 years old admitted for vaso-occlusive crisis
62574887|NCT04932369|EXPERIMENTAL|ER GROUP|The training sessions were based on the Dialectical Behavior Therapy Skills (Linehan, 2015). Each group received eight 90-min sessions of the emotion regulation training (one session per week) carried out by qualified clinical psychologist. The training includes group gathering, homework and telephone consultation as needed.
62574888|NCT04932369|NO_INTERVENTION|Control group|They completed two assessments, 3-months apart
62574889|NCT02199795|EXPERIMENTAL|CCNMES|Contralaterally Controlled Neuromuscular Electrical Stimulation (CCNMES): CCNMES uses electrical stimulation to move the weaker ankle up and down. The user will control the stimulation using the other (stronger) ankle. A special sock is worn on the stronger ankle. When the stronger ankle is moved, a signal is sent from a sensor on the sock to the electrical stimulator. The stimulator then sends stimulation to the weaker ankle which causes it to move. Sound and light cues coming from the stimulator will tell the user when to move the stronger ankle and when to relax.
62574890|NCT02199795|ACTIVE_COMPARATOR|Cyclic NMES|Cyclic Neuromuscular Electrical Stimulation (NMES) uses automatic, repetitive electrical stimulation to stimulate the muscles in order to move the weaker ankle up and down.
62574891|NCT06575231|EXPERIMENTAL|Type 2 diabetic patients|"1. 20 years or older.~2. Willing to participate in the study, able to read and provide written informed consent form.~3. HCT 25\~65%.~4. Subjects including healthy subjects, outpatients, and inpatients."
62196202|NCT05517226|EXPERIMENTAL|Cohort 4|Participants in each cohort will receive Dose A cotadutide subcutaneously.
62196203|NCT03833791|ACTIVE_COMPARATOR|Control Group (CON)|education and modifying diet
62196204|NCT03833791|EXPERIMENTAL|Moderate physical activity Group (PAM)|education, modifying diet and physical activity prescription
62196205|NCT03833791|EXPERIMENTAL|Intensity physical activity Group (PAI)|education, modifying diet and physical activity prescription
62196206|NCT01948674|EXPERIMENTAL|computerized tasks- adaptive|
62196207|NCT01948674|ACTIVE_COMPARATOR|computerized tasks - nonadaptive|
62196208|NCT04560751||Lenvatinib and TACE|Patients in Lenvatinib + TACE group will take oral lenvatinib within ten days after TACE.
62196209|NCT01156740|ACTIVE_COMPARATOR|Intramuscular benzathine Penicillin G|A single dose of intramuscularly administered intramuscular benzathine penicillin G (IM BPG). The dosing was as follows: IM BPG; 600,000 U \> 27kg or 1,200,000 U \<27 kg
62196210|NCT01156740|ACTIVE_COMPARATOR|Amoxicillin|A 10-day once daily dose of Amoxicillin was given in an oral form. The first dose was given at the time of randomization, and parents were instructed on giving the remaining doses. Dosing was as follows: 750 mg/QD
62196211|NCT02654197||H.pylori positive children|Healthy children, 6-12 years old, will undergo screening for H. pylori infection by measuring anti-H. pylori and CagA IgG antibodies in the serum. The status of H. pylori infection will be confirmed using breath test (UBT). Children will be classified as i) H. pylori negative, if they test negative on UBT ii) H. pylori positive- CagA negative, if they test positive on UBT, but lack serum CagA IgG antibodies iii) H. pylori positive- CagA positive, if they are positive for H. pylori on UBT and CagA IgG antibodies.
62196212|NCT02654197||H.Pylori negative children|Healthy children, 6-12 years old, will undergo screening for H. pylori infection by measuring anti-H. pylori and CagA IgG antibodies in the serum. The status of H. pylori infection will be confirmed using breath test (UBT). Children will be classified as i) H. pylori negative, if they test negative on UBT ii) H. pylori positive- CagA negative, if they test positive on UBT, but lack serum CagA IgG antibodies iii) H. pylori positive- CagA positive, if they are positive for H. pylori on UBT and CagA IgG antibodies.
62196213|NCT03994731|EXPERIMENTAL|Pegloticase + MTX|"Following the MTX Tolerability Assessment Period (Week -6 until the Week -4 visit, in which participants take oral MTX 15 mg weekly), participants tolerating MTX are randomized to receive blinded oral MTX 15 mg weekly during the Run-in Period (from Week -4 to Day 1).~During the Pegloticase + Immunomodulator (IMM) Period, in addition to oral 15 mg MTX, participants receive intravenous (IV) pegloticase 8 mg administered every 2 weeks (Q2W) for a total of 26 infusions from Day 1 through the Week 50 Visit.~Per protocol, participants are also required to take folic acid, at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day), and a regimen of fexofenadine, acetaminophen, and methylprednisolone for infusion reaction (IR) prophylaxis."
62196214|NCT03994731|PLACEBO_COMPARATOR|Pegloticase + Placebo|"Following the MTX Tolerability Assessment Period (Week -6 until the Week -4 visit, in which participants take oral MTX 15 mg weekly), participants tolerating MTX are randomized to receive blinded oral placebo for MTX weekly during the Run-in Period (from Week -4 to Day 1).~During the Pegloticase + IMM Period, in addition to oral placebo for MTX, all participants receive IV pegloticase 8 mg administered Q2W for a total of 26 infusions from Day 1 through the Week 50 Visit.~Per protocol, participants are also required to take folic acid, at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day), and a regimen of fexofenadine, acetaminophen, and methylprednisolone for IR prophylaxis."
62196215|NCT00485953|EXPERIMENTAL|Active Medication Group|risedronate 35 mg weekly
62196216|NCT00485953|NO_INTERVENTION|Placebo Group|Placebo
62196217|NCT05435950|EXPERIMENTAL|Adult participants with Carpal Tunnel syndrome or with Trigger Finger/Thumb|
62196218|NCT03508401|EXPERIMENTAL|ICU intubated patients|"After inclusion, Echo-Doppler measurements are performed with Vivid S6 model (GE Healthcare France, Lyon, France). The left ventricular outflow tract velocity time index (LVOT TVI) will be measured with this device. Then, a passive leg raising (PLR) will be performed and finally LVOT VTI will be measured again after PLR~Patients will be classified in two groups according to the hemodynamic response to PLR :~* Patients are responders if LVOT VTI increases of at least 10% after PLR~* patients are non-responders if LVOT VTI does not increase or increase of less than 10% after PLR."
62196219|NCT03192345|EXPERIMENTAL|Dose Escalation SAR439459 monotherapy|SAR439459 administered intravenously every 2 weeks in a 14-day cycle with escalating doses
62196220|NCT03192345|EXPERIMENTAL|Dose Expansion SAR439459 monotherapy|SAR439459 administered intravenously every 3 weeks in a 21-day cycle with the previously determined recommended doses as the patients will be randomized to 2 different doses
62196221|NCT03192345|EXPERIMENTAL|Dose Escalation SAR439459 + cemiplimab combination|SAR439459 + cemiplimab combination administered intravenously every 2 weeks in a 14-day cycle or every 3 weeks in a 21-day cycle with escalating SAR439459 doses and cemiplimab
62574892|NCT02976558|EXPERIMENTAL|Treatment Group|"Interventions:~Acupuncture, music therapy (TaKeTiNa) and Clown theatrical performance starting before allogenic stem cell transplant until three months after transplantation.~Interventions each twice a week for 4 weeks, then once a week for 4 weeks, then once every two weeks for 4 weeks"
62009989|NCT03380039|EXPERIMENTAL|CAR-BCMA T cells|"In this study, autologous T cells transduced with a BCMA-targeted chimeric antigen receptor (CAR-BCMA T cells) are used to treat patients with refractory or relapsed multiple myeloma.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to CAR-BCMA T cells infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
62009990|NCT06139952|EXPERIMENTAL|High-dose Atorvastatin group|40 patients will receive 80 mg Atorvastatin before coronary angiography and will receive adequate hydration using (1ml/kg/hr)
62009991|NCT06139952|EXPERIMENTAL|N-acetyl cysteine group|40 patients will receive 200mg 3 times daily 2 days before coronary angiography and 2 days after and will receive adequate hydration using (1ml/kg/hr)
62009992|NCT06139952|ACTIVE_COMPARATOR|Control group|40 patients will receive adequate hydration using (1ml/kg/hr)
62009993|NCT02634294|EXPERIMENTAL|Peg interferon alfa-2b|Pegylated Interferon α-2b (PEG INTRON®) , 1\~1.5μg/kg qw, subcutaneous injection, 1 to 12 months, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
62009994|NCT00001621||1|Pulmonary Patients
62009995|NCT05874258|EXPERIMENTAL|Real-PL + Real-tES (tDCS)|Participant will receive 30 training sessions with real PL and real tES (tDCS): 3-4 sessions per week, about 1 hour per session
62009996|NCT05874258|EXPERIMENTAL|Real-PL + Sham-tES (tDCS)|Participant will receive 30 training sessions with real PL and sham tES (tDCS): 3-4 sessions per week, about 1 hour per session
62574893|NCT02976558|NO_INTERVENTION|Control Group|control group. No interventions
62574894|NCT01732458|EXPERIMENTAL|Aprepitant Dose 1: Equivalent to 125 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 125 mg in adults on Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered intravenously (IV) immediately prior to anesthesia.
62574895|NCT01732458|EXPERIMENTAL|Aprepitant Dose 2: Equivalent to 40 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 40 mg in adults on Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered IV immediately prior to anesthesia.
62574896|NCT01732458|EXPERIMENTAL|Aprepitant Dose 3: Equivalent to 10 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 10 mg in adults Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered IV immediately prior to anesthesia.
62196222|NCT03192345|EXPERIMENTAL|Dose Expansion SAR439459 + cemiplimab combination|SAR439459 + cemiplimab combination administered intravenously every 3 weeks in a 21-day cycle with previously determined SAR439459 doses and cemiplimab
62196223|NCT03222505|EXPERIMENTAL|Treadmill|
62196224|NCT03222505|EXPERIMENTAL|Overground Walking|
62196225|NCT01005797|EXPERIMENTAL|Expansion A|Expansion A -RCC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
62196226|NCT01005797|EXPERIMENTAL|Expansion B|Expansion B -NSCLC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
62196227|NCT01005797|EXPERIMENTAL|Expansion C|Expansion C -STS cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
62196228|NCT03845270|EXPERIMENTAL|pertuzumab + trastuzumab + docetaxel|Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
62196229|NCT04440020|EXPERIMENTAL|Beverage of Olive Oil Leaves|50 patients Beverage of Olive Oil Leaves
62196230|NCT04440020|ACTIVE_COMPARATOR|Mediterranean dietary protocol Intervention|50 patients Dietary Supplement: Dietary Supplement:Mediterranean Diet
62196231|NCT04081064|EXPERIMENTAL|Non-obese Qatar residents with type 2 diabetes|Newly diagnosed (e.g \<5 years) Type 2 diabetics Qatar residents with a body mass index (BMI) of \>18.5 and \<30.0 kg/m2
62574897|NCT01732458|ACTIVE_COMPARATOR|Ondansetron|Pediatric participants in the control regimen are administered ondansetron IV on Day 1 immediately prior to induction of anesthesia plus a matching placebo dose to aprepitant as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia.
62009997|NCT05874258|PLACEBO_COMPARATOR|Placebo-PL + Sham-tES (tDCS)|Participant will receive 30 training sessions with placebo PL and sham tES (tDCS): 3-4 sessions per week , about 1 hour per session
62574898|NCT01866111|PLACEBO_COMPARATOR|Placebo|Placebo
62009998|NCT01981434|ACTIVE_COMPARATOR|Video game based obesity education|This is the intervention group. They will be given the opportunity to play an interactive educational video game for teaching health and nutrition.
62196232|NCT04081064|EXPERIMENTAL|Obese Qatar residents with type 2 diabetes|Newly diagnosed (e.g \<5 years) Type 2 diabetics Qatar residents with a body mass index (BMI) of \>30.0 to \<40.0 kg/m2
62196233|NCT03177720|ACTIVE_COMPARATOR|Ciprofloxacin|Half of patients and healthy volunteers are receiving ciprofloxacin, the other half imipenem.
62196234|NCT03177720|ACTIVE_COMPARATOR|Imipenem|Half of patients and healthy volunteers are receiving ciprofloxacin, the other half imipenem.
62196235|NCT02947100|EXPERIMENTAL|SCD-Omegatex™|single arm
62196236|NCT05147870||Irrigation group|
62196237|NCT05147870||Suction only group|
62196238|NCT03674723|EXPERIMENTAL|Arms|Methionine bioavailability in Mung beans Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods). You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or a Mung bean stew with or without rice or wheat, which will be provided by the investigators
62196239|NCT01423110|EXPERIMENTAL|BYM338|
62574899|NCT01866111|EXPERIMENTAL|YKP3089 Low Dose|YKP3089 Low Dose
62196240|NCT01423110|PLACEBO_COMPARATOR|Placebo|
62574900|NCT01866111|EXPERIMENTAL|YKP3089 Medium Dose|YKP3089 Medium Dose
62009999|NCT01981434|NO_INTERVENTION|No intervention|This is the control group that will receive only printed information about health and nutrition and will not be given the opportunity to play the educational video game.
62010000|NCT03952533|EXPERIMENTAL|ALA|"ALA Group will be composed of women allocated to the Treatment Group. These women will receive 2 tablets of Alpha lipoic Acid (ALA) as Dav® food supplement 1,2 g (Dav®, Lo.Li. Pharma, Rome, Italy) daily until delivery."
62196241|NCT01609777|OTHER|Handover with SBAR|Handover with handover tool.
62196242|NCT06520891||Patients has ischemic heart failure|30 patients will take statin.
62196243|NCT06520891||Patients has ischemic heart|30 patients will take both of statin and SGLT2i.
62196244|NCT06520891||Patients has heart disease|30 patients will take SGLT2i.
62196245|NCT00043069|ACTIVE_COMPARATOR|Arm I: calcium + cholecalciferol + placebo + estrogen|"Patients receive oral calcium, oral cholecalciferol, oral risedronate placebo, and oral estrogen placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
62010001|NCT03952533|NO_INTERVENTION|Control|"Control Group will be composed by women allocated in the Control Group and will not receive any supplementation but the standard care."
62010002|NCT01495962|ACTIVE_COMPARATOR|Botulinum Toxin A injection|
62196246|NCT00043069|EXPERIMENTAL|Arm II: calcium + cholecalciferol + risedronate + estrogen|"Patients receive oral calcium, oral cholecalciferol, oral risedronate, and oral estrogen placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
62215012|NCT04699773|EXPERIMENTAL|LITT with Hypofractionated RT|Laser interstitial thermal therapy (LITT) followed by hypo-fractionated radiation therapy, 25Gy/10 fractions.
62574901|NCT01866111|EXPERIMENTAL|YKP3089 High Dose|YKP3089 High Dose
62574902|NCT01342770|EXPERIMENTAL|Treatment (pioglitazone hydrochloride)|Patients receive pioglitazone hydrochloride PO QD for 14-42 days. Patients then undergo surgery.
62574903|NCT03107390|OTHER|Patients with CD or RCH|
62196247|NCT00043069|PLACEBO_COMPARATOR|Arm III: calcium + cholecalciferol + placebo + estrogen|"Patients receive oral calcium, oral cholecalciferol, low-dose oral conjugated estrogens, and oral risedronate placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
62574904|NCT03107390|OTHER|The control population|
62574905|NCT04967924|EXPERIMENTAL|Sports specific training|Treatments will be provided in 30 mins per week for 3 consecutive weeks. Weight programs include closed chain exercises (squats, pushups) and open chain exercises (leg press, chest fly using dumbbell) Stretch shortening cycle (enhances performance through storage of elastic energy during eccentric phase and activation of stretch reflex).
62574906|NCT04967924|ACTIVE_COMPARATOR|neuromuscular training|Treatments will be provided in 30 mins per week for 3 consecutive weeks Proprioceptive Neuromuscular Facilitation (PNF)
62574907|NCT02505750|ACTIVE_COMPARATOR|EBRT 45 Gy/capecitabine + EBRT boost|"3D conformal EBRT 45 Gy (1.8Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days).~A cone down EBRT targeting the GTV will deliver a boost dose of 9 Gy in 5 fractions. On week 14 after the start of treatment, the tumour response evaluation will guide the final strategy: surgery (radical TME or local excision) or watch-and-wait (W-W)."
62574908|NCT02505750|EXPERIMENTAL|EBRT 45 Gy/capecitabine + CXB boost|"Arm B divided in 2 subgroups depending on the tumour diameter:~B1: If the tumour is \< 3 cm, a CXB boost dose (90Gy/3 fractions/4 weeks) will be initially delivered to the tumour. After 2 weeks rest, patients will receive 3D conformal EBRT 45 Gy (1.8 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days). Clinical evaluation will be performed 3 weeks after the end of irradiation (week 14) and will guide the final strategy (surgery or W-W) as in arm A.~B2: If the tumour is ≥ 3 cm, patients will receive EBRT first 45 Gy (1.8 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days).~A CXB boost dose (90 Gy/3 fractions/4 weeks) will be delivered to residual tumour, after a rest of 2 weeks. On week 14 after the start of treatment, the tumour response evaluation will guide the final strategy (surgery or W-W) as in arm A. Adjuvant chemotherapy will be left to institution choice."
62574909|NCT01475708||no symptoms|patients with erythema migrans and no additional newly onset symptoms treated with doxycycline
62574910|NCT01475708||mild symptoms|patients with erythema migrans and mild unspecific newly onset symptoms treated with doxycycline
62574911|NCT01475708||severe symptoms-lumbar puncture|"patients with erythema migrans and newly onset intense neurologic symptoms with lumbar puncture performed, treated with doxycycline"
62574912|NCT04056533|EXPERIMENTAL|CMV CTLs|1x10\^5 CMV-CTLs/kg
62574913|NCT03876743|EXPERIMENTAL|Group 1-Knee Arthroscopy|Will have all of their post-operative prescriptions sent down to the pharmacy on the day of surgery to be collected.
62196248|NCT00043069|EXPERIMENTAL|Arm IV: calcium + cholecalciferol + risedronate + estrogen|"Patients receive oral calcium, oral cholecalciferol, low-dose oral conjugated estrogens, and oral risedronate daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
62196249|NCT04411004||Women who underwent shaving for rectal endometriosis|
62196250|NCT04879342|EXPERIMENTAL|VIP Program Group|Participants in this group will receive a 26 week course on risk reduction strategies.
62574914|NCT03876743|EXPERIMENTAL|Group 2-Knee Arthroscopy|Will have all prescriptions sent to pharmacy with the exception of an opiate prescription. Instead, they will be handed a physical paper prescription. They will be instructed to only fill the prescription if absolutely needed.
62196251|NCT01647945|PLACEBO_COMPARATOR|Placebo|
62574915|NCT03876743|EXPERIMENTAL|Group 1-ACL reconstruction|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
62574916|NCT03876743|EXPERIMENTAL|Group 2-ACL reconstruction|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
62574917|NCT04269057||HFpEF|heart failure patients with preserved ejection fraction who using ARNI
62574918|NCT04269057||HFrEF|heart failure patients with reduced ejection fraction who using ARNI
62196252|NCT01647945|EXPERIMENTAL|FK506 level < 2|
62196253|NCT01647945|EXPERIMENTAL|FK506 level 2-3|
62196254|NCT01647945|EXPERIMENTAL|FK506 level 3-5|
61978061|NCT06293170|EXPERIMENTAL|DETECT|DETECT in addition to conventional care will be initiated according to randomization plan
62010003|NCT01495962|PLACEBO_COMPARATOR|Placebo (Normal Saline) injection|
62196255|NCT04785196|EXPERIMENTAL|APG-115+Toripalimab|
62196256|NCT05752526|EXPERIMENTAL|DARE-PDM1 1% Diclofenac Vaginal Gel|1% Diclofenac in 2.5 mL Hydrogel
62574919|NCT00656292|PLACEBO_COMPARATOR|Simvastatin|Subjects randomized to this arm will receive statin therapy (simvastatin 40 mg) two days before surgery -- allowing three doses of simvastatin before incision -- and these will be continued until patients are either discharged from the hospital or have completed a 3-day postoperative course (6 days of simvastatin therapy), whichever occurs earlier. If patients are unable to take oral medications, the enteral route via nasogastric tube (at our institution, nasogastric tubes are routinely placed for both lumbar and thoracic instrumentation) will be used to deliver either placebo or the statin, as no parenteral form of this drug is currently available.
62574920|NCT00656292|EXPERIMENTAL|Placebo|Subjects randomized to this arm will receive placebo two days before surgery -- allowing three doses of placebo before incision -- and these will be continued until patients are either discharged from the hospital or have completed a 3-day postoperative course (6 days of placebo), whichever occurs earlier. If patients are unable to take oral medications, the enteral route via nasogastric tube (at our institution, nasogastric tubes are routinely placed for both lumbar and thoracic instrumentation) will be used to deliver either placebo or the statin, as no parenteral form of this drug is currently available.
62574921|NCT06035367|EXPERIMENTAL|Wearing the non-invasive continous monitoring device during one week to record photoacoustic signal|Wearing the non-invasive continous monitoring device during one week to record photoacoustic signal
62574922|NCT06423898|EXPERIMENTAL|Continuous intravenous antibiotic infusion|Ampicillin 2g/4h plus ceftriaxone 2g/12h intermittently infused. The duration of treatment will be 42 days.
62574923|NCT06423898|ACTIVE_COMPARATOR|Intermittent intravenous antibiotic infusion|Ampicillin 2g/4h plus ceftriaxone 2g/12h intermittent infusion. The duration of treatment will be 42 days.
62574924|NCT02695550|EXPERIMENTAL|CT-707|ALK-positive non-small cell lung cancer resistant to Crizotinib treatment
62196257|NCT05752526|EXPERIMENTAL|DARE-PDM1 3% Diclofenac Vaginal Gel|3% Diclofenac in 2.5 mL Hydrogel
62196258|NCT05752526|PLACEBO_COMPARATOR|Placebo|2.5 mL Hydrogel
62196259|NCT01648153|ACTIVE_COMPARATOR|GSK1070806 0.25mg/kg|TwoIV administrations of 0.25mg/kg GSK1070806 4weeks apart
62196260|NCT01648153|ACTIVE_COMPARATOR|GSK1070806 5mg/kg|Two IV administrations of 5mg/kg of GSK1070806 4 weeks apart
62196261|NCT01648153|PLACEBO_COMPARATOR|Placebo (Saline)|Two IV administrations of saline 4 weeks apart
62196262|NCT01545947|EXPERIMENTAL|CC-223/erlotinib concurrent|Cohorts will receive escalating continuous daily doses (15 mg and 30 mg) of CC-223 in capsules concurrently with at least two different daily dose levels of erlotinib tablets (100 mg and 150 mg) in 28-day cycles.
62196263|NCT01545947|EXPERIMENTAL|CC-223/oral azacitidine concurrent|Cohorts will receive escalating continuous daily doses of CC-223 (15 mg and 30 mg) with one or more dose levels of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Day 1 to 21 of each 28-day cycle.
62196264|NCT01545947|EXPERIMENTAL|CC-223/oral azacitidine sequential|Cohorts will receive escalating continuous daily dose levels of CC-223 (15 mg and 30 mg) administered on Days 8 through 28 sequentially with one or more dose levels of of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Days 1 to 7 of each 28-day cycle
62574925|NCT04386655|EXPERIMENTAL|Telemedicine Group|BICS-T is the intervention that will take place over telemedicine software on the iPad provided to participants
62574926|NCT04386655|ACTIVE_COMPARATOR|In-Person Group|Participants a part of the in-person BICS group will then come to the NRC for the following BICS sessions. This group is the traditional, in-person, BICS group
62574927|NCT00181285|SHAM_COMPARATOR|Sham high frequency chest wall oscillation|Sham high frequency chest wall oscillation
62574928|NCT00181285|ACTIVE_COMPARATOR|Active high frequency chest wall oscillation|Active high frequency chest wall oscillation
61978062|NCT02349581|EXPERIMENTAL|Block|Patients with persistent pain after breast cancer surgery receive the ultrasound guided PECS block of 20mls 0.25% bupivacaine
61978063|NCT02349581|NO_INTERVENTION|Sonoanatomy|16 patients awaiting surgery for breast cancer were scanned using ultrasound to determine the sonoanatomy of the PECS block
62196265|NCT04315805|EXPERIMENTAL|Integrative Yoga Therapy|Integrative Yoga Therapy will be provided by yoga therapist once a week and participants will be encouraged to practice at home once or twice a day.
62196266|NCT04315805|NO_INTERVENTION|Wait-list Control|Participants in waiting list will serve as control group for the intervention period. After the ftherapy group has received treatment, the same program will be offered to participants in the wait-list control group.
62196267|NCT03430622|EXPERIMENTAL|LTP Plus|LTP Plus group participants will receive intervention over the telephone for 3 months one session per week for 2 months and rest of the sessions fortnightly by trained graduates, expert in delivering LTP plus intervention.
62196268|NCT03430622|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|TAU group will receive routine care and their follow up will be done after completion of the intervention and then at 6-month post randomization.
62196269|NCT05427526|ACTIVE_COMPARATOR|group 1: LARA IOL implanted in combination with vitrectomy.|intraocular lens implantation in combination with vitrectomy
62196270|NCT05427526|ACTIVE_COMPARATOR|group 2: LARA IOL implanted in during surgery for cataract secondary to vitrectomy|intraocular lens implantation during surgery for cataract secondary to vitrectomy
62574929|NCT06270602||Cohort A (Retrospective):|All consecutive patients entered in the ROC platform from the start of platform activation (November 2018) until the date in which the study is approved by the local ethical committee (Investigator is allowed to enroll patients) will be enrolled. The retrospective cohort will be made by more than 40000 patients already included in the platform and entered a GOM path
62196271|NCT02607202|EXPERIMENTAL|Arm A|nab-paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration over 30 minutes without premedication, followed by gemcitabine 1000 mg/m2 on Days 1 and 8 by IV administration over 30 minutes. Treatment to be repeated Q21 days.
62196272|NCT02607202|EXPERIMENTAL|Arm B|nab-paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration over 30 minutes without premedication, followed by carboplatin AUC 2 on Day 1 and 8 by IV administration over 60 minutes. Treatment to be repeated Q21 days.
62196273|NCT00786552|EXPERIMENTAL|chemotherapy|
62196274|NCT04845399|EXPERIMENTAL|Arm 1|Participants will receive prophylaxis treatment with Recombinant Human Coagulation Factor VIII-Fc fusion for 6 months.
62196275|NCT03680339|ACTIVE_COMPARATOR|Routine ecbolic group|100 patients will receive routine ecbolics ( oxytocin) after delivery of baby
62196276|NCT03680339|ACTIVE_COMPARATOR|Misoprostol group|The 100 patients will receive routine ecbolics (oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
62196277|NCT05620797|EXPERIMENTAL|Immediate loading implants|
62196278|NCT05620797|ACTIVE_COMPARATOR|Delayed loading implants|
62196279|NCT02002962|ACTIVE_COMPARATOR|RFA+BT injection|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
62574930|NCT06270602||Cohort B (Prospective):|All consecutive patients who enter in the ROC platform as for clinical practice from the date in which the study is approved by the local ethical committee (Investigator is allowed to enroll patients).
62574931|NCT01602861|EXPERIMENTAL|Spironolactone|
62574932|NCT01602861|PLACEBO_COMPARATOR|Placebo|
62574933|NCT03386994||Idiopathic Pulmonary Fibrosis patients|all IPF patients
62010004|NCT01164046|ACTIVE_COMPARATOR|vitamin K antagonists|
62010005|NCT01164046|ACTIVE_COMPARATOR|Low molecular weight heparin|
62010006|NCT00573963|ACTIVE_COMPARATOR|1|Ropivacaine
62010007|NCT00573963|PLACEBO_COMPARATOR|2|Placebo
62196280|NCT02002962|ACTIVE_COMPARATOR|RFA|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
62196281|NCT00867971||RGH treated|
62196282|NCT00867971||Starting treatment with RGH|
62196283|NCT01705899|EXPERIMENTAL|Subjects with preserved kidney function|Subjects with preserved renal function that have not previously received a kidney transplant will be treated with Human Pancreatic Islets (in the form of islets alone - IA).
62196284|NCT01705899|EXPERIMENTAL|Subjects with prior kidney transplant|Subjects with renal failure secondary to diabetes who have received a prior kidney transplant at least 6 months previously and have stable renal function on a steroid-free immunosuppressive regimen will receive Human Pancreatic Islets (in the form of islets after kidney - IAK).
62196285|NCT02421549|ACTIVE_COMPARATOR|Interrogation with unpaired remote monitoring transmitter|Interrogation with unpaired remote monitoring transmitter Interrogation with an unpaired remote monitoring transmitter for devices that are compatible.
62196286|NCT02421549|NO_INTERVENTION|Interrogation with Programmer|Interrogation with programmer Interrogation with programmer according to usual standard of care
62196287|NCT02646020|EXPERIMENTAL|Aprepitant and placebo|aprepitant 125mg d1, 80mg d3 and d5, along with placebo 5mg d1-d28;
62196288|NCT02646020|ACTIVE_COMPARATOR|desloratadine and placebo|placebo 125mg d1, 80mg d3 and d5, along with desloratadine 5mg d1-d28
62196289|NCT03117491|ACTIVE_COMPARATOR|GGNB injection technique|In GGNB group, every patient received two1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the GGNB technique
62196290|NCT03117491|ACTIVE_COMPARATOR|IANB injection technique|In IANB group, every patient received two 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the IANB technique
62196291|NCT03117491|ACTIVE_COMPARATOR|GGNB + IANB injection technique|In IANB + GGNB group, every patient received one 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the IANB technique and one 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the GGNB technique
62196292|NCT03544294||Group|Consecutive patients treated with very thin stents on ULM and bifurcation
62196293|NCT04385576|ACTIVE_COMPARATOR|Aerosol Box|Intubation using the Taiwan model Aerosol Box to assess the duration of time needed for successful endotracheal intubation of an airway manikin.
62196294|NCT04385576|ACTIVE_COMPARATOR|Intubation Box|Intubation using the UMMC model Intubation Box to assess the duration of time needed for successful endotracheal intubation of an airway manikin.
62574934|NCT02531477|EXPERIMENTAL|experimental group|Intracarotid injection of propofol to detect efficacy and safety as a novel route for drug delivery
62574935|NCT04544657||stroke group|
62574936|NCT04544657||normal group|
62574937|NCT02571101|EXPERIMENTAL|Test 1|Test 1 subjects will take one tablet of CDFR0812-15/25mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks.
62574938|NCT02571101|EXPERIMENTAL|Test 2|Test 2 subjects will take one tablet of CDFR0812-15/50mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks.
62574939|NCT02571101|PLACEBO_COMPARATOR|Comparator|Comparator subjects will take one tablet of Condencia and another tablet of CDFR0812-Placebo before sexual intercourse in on-demand for 8 weeks.
62574940|NCT06171087|ACTIVE_COMPARATOR|Domperidon|Participants recieve 10mg of Domperidon, 45 minutes before the start of the experiment
62574941|NCT06171087|PLACEBO_COMPARATOR|Placebo|Participants recieve a placebo pill, 45 minutes before the start of the experiment
62196295|NCT04227145|NO_INTERVENTION|Usual Care|We will recruit up to 85 women with substance abuse disorder (or opioid abuse disorder) from recovery centers. Eligible women will complete a baseline survey and study staff will provide a referral for participants to seek more information on contraception and services. Study staff will record whether the participant accepted the referral. Follow-up will occur via phone call at 2-weeks, 1-month and 3-months post-enrollment to determine if they accessed contraceptive referral services if they initiated any contraceptive method, and if so: if they continued, changed, or discontinued this contraception method. We will recruit, complete baseline and usual care referral at recovery sites on a timely rotation that mirrors the intervention period (e.g., every fourth Friday morning at Site 1), in order to increase the chance of recruiting a comparable population.
62196296|NCT04227145|EXPERIMENTAL|SexHealth Mobile|We will train Swope providers in contraceptive counseling before intervention. We will recruit up to 85 women with substance abuse disorder (or opioid abuse disorder) from recovery centers. Eligible women will complete a baseline survey. Study staff will provide a referral for participants to seek more information on contraception and services. Women will have direct access to contraceptive counseling and services on-site via the mobile medical unit if they choose to use it. Counseling will focus on presenting the most effective contraceptive methods first (i.e., LARC). If women participate in contraceptive counseling, study staff will record the uptake of contraceptive medication and clinic referral at the time of enrollment and conduct follow-up surveys at 2-weeks, 1-month, and 3-months post-enrollment. If the participant refuses contraceptive counseling on MMU, a referral will be given.
62574942|NCT04091789|EXPERIMENTAL|Test Article|Subjects will take Pure Femme sublingual tablets as directed, one tablet 2 days before, one tablet 1 day before, and then up to 3 tablets per day for 3 days (72 hours) during menstruation.
61978064|NCT00391274|EXPERIMENTAL|Pemetrexed|
61978065|NCT00391274|ACTIVE_COMPARATOR|Docetaxel|
62196297|NCT00384605|EXPERIMENTAL|1|Arm 1: MK0364 2 mg capsule once daily
62196298|NCT00384605|EXPERIMENTAL|2|Arm 2: MK0364 1 mg capsule once daily
62196299|NCT00384605|EXPERIMENTAL|3|Arm 3: MK0364 0.5 mg capsule once daily.
61978066|NCT01718080||Group A|Healthy lean children before puberty
62196300|NCT00384605|PLACEBO_COMPARATOR|4|Arm 4: Pbo capsule once daily.
62196301|NCT04027413|PLACEBO_COMPARATOR|Placebo/ Control|participants in this group will receive carbohydrate product which does not include protein at all
62574943|NCT06576102||Patients with B cell malignancies|"All immunocompromised adults (≥18 years) with a new SARS-CoV-2 infection assessed during the study period, hospitalized or followed as outpatients in the participating centers, will be screened for inclusion.~Inclusion Criteria:~* Diagnosis of B cell malignancies or previous treatment with B cell targeting therapies.~* Diagnosis of proven SARS-CoV-2 infection confirmed by a PCR test (only the first infection during the study period will be considered, re-infection will be counted as a secondary endpoint)."
62574944|NCT06021431|EXPERIMENTAL|MORE-VR|"An 8-session version of Mindfulness-Oriented Recovery Enhancement (MORE) delivered by virtual reality. The treatment involves training in mindfulness, reappraisal, and savoring techniques to address OUD.~Participants in this arm will also receive Treatment as usual (TAU) with medications for opioid use disorder (MOUD) such as buprenorphine, methadone, or naltrexone plus any psychological counseling they are already receiving in their standard care."
62574945|NCT06021431|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Treatment as usual (TAU) with medications for opioid use disorder (MOUD) such as buprenorphine, methadone, or naltrexone plus any psychological counseling they are already receiving in their standard care.
62574946|NCT04630691||Control|Patients with HbA1c around 6,0
62574947|NCT04630691||T2DM|Patients with HbA1c above 6,5
62574948|NCT01997788|EXPERIMENTAL|The ITM group|The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
62574949|NCT01997788|PLACEBO_COMPARATOR|The IV-PCA group|The postoperative pain management includes only the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
62574950|NCT03759587|EXPERIMENTAL|Niraparib 300 mg|Niraparib 300 mg, capsules, orally, once daily on Days 1 to 28 of each 28-day treatment cycle (up to 51 cycles).
62734688|NCT00149799|EXPERIMENTAL|Escitalopram|In Phase I, all participants received open-label escitalopram for 14 weeks (at a dosage of 10 mg/d in weeks 1-3, 20 mg/d weeks 4-6, and 30 mg/d thereafter). Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to continue with escitalopram for Phase II of the study (Weeks 16-40)
62734689|NCT00149799|PLACEBO_COMPARATOR|Placebo|Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to receive a placebo for Phase II of the study (Weeks 16-40)
62734690|NCT02795624||Flight attendants|Flight attendants
62574951|NCT03674112|EXPERIMENTAL|A: P+H IV Followed by PH FDC SC|In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
62574952|NCT03674112|EXPERIMENTAL|B: PH FDC SC Followed by P+H IV|In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
62574953|NCT03424057|EXPERIMENTAL|Group 1|"Group 1 were treated with the new technique (Asymmetric Primary Closure and Additional Skin Excision).~In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method, but an advancement tissue flap was performed using additional skin excision, in order to reduce the dead-space volume."
62574954|NCT03424057|ACTIVE_COMPARATOR|Group 2|Group 2 were treated with the standard Karydakis technique.
62574955|NCT00857090|EXPERIMENTAL|1|Drug
62196302|NCT04027413|EXPERIMENTAL|Intervention group|Participants in this group will receive high protein product
62196303|NCT06479928||Mother-infant cohorts (Cesarean section)|Delivery mode, Cesarean section
62574956|NCT00857090|PLACEBO_COMPARATOR|2|Vehicle
62574957|NCT03494634|EXPERIMENTAL|Chidamide|
61978067|NCT01718080||Group B|Otherwise healthy overweight children before puberty
62399142|NCT01390194||subjects with an underlying liver disease|(1)underlying liver disease; (2) have a lesion on a prior imaging study; (3) must be prior standard MR
62399143|NCT03301792|NO_INTERVENTION|Routine Prenatal Care|Subjects randomized to routine care will receive their care in the usual diabetic clinic attended by residents and faculty. They will receive consultation with the diabetes educator at diagnosis and as needed. Patients are seen every 2 weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits are 10-15 minutes and focus on routine screening tests and review of blood sugar logs/medication titration.
62399144|NCT03301792|EXPERIMENTAL|Group prenatal care|Group visits will be held every 2 weeks in a continuous cycle through a six session curriculum. Women will have weekly visits beginning at 37 weeks with traditional prenatal visits on the weeks when the group does not meet. Groups of 2-12 women will meet for two hour visits and much of that time will be spent on pregnancy, behavioral health, diabetes and nutrition education. Groups will be co-facilitated by a health educator and an obstetric provider. Women may be instructed to have additional visits in the traditional clinic at the discretion of the obstetric provider.
62399145|NCT00891124||1|Type II DM and Hypertension and/or Hyperlipidemia
62574958|NCT05006430|ACTIVE_COMPARATOR|Intervention Arm|"Subjects will receive Standard of Care (SOC), based on AASLD/EASL guidelines and one dose of PRIM-DJ2727 (30 grams of stool/dose \~ 3 capsules) every day for a week followed by once weekly for 3 weeks, amounting to total 10 doses.~PRIM-DJ2727 (microbiota suspension) is an intestinal microbial suspension prepared form stool obtained from carefully and thoroughly screened healthy human donors. It will be provided by University of Texas School of Public Health."
61978068|NCT01718080||Group C|Healthy lean adolescents in mid to late puberty
61978069|NCT01718080||Group D|Otherwise healthy overweight adolescents in mid to late puberty
61978070|NCT02742584|EXPERIMENTAL|Group A|Cough Stress Test with a comfortably full bladder.
61978071|NCT02742584|EXPERIMENTAL|Group B|Cough Stress Test with an empty bladder after straight catheterization.
61978072|NCT02742584|EXPERIMENTAL|Group C|Cough Stress Test with a bladder infused with 200 cc of saline.
62010008|NCT01790750|OTHER|PES first, then FFES|A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
62196304|NCT06479928||Mother-infant cohorts (Natural delivery)|Delivery mode, Natural delivery
62196305|NCT02083289|EXPERIMENTAL|Experimental Arm 1|ONO-9054 eye drop solution, 30 µg/mL (0.003%), once daily in both eyes, for 28 days.
62196306|NCT02083289|ACTIVE_COMPARATOR|Active Comparator Arm 2|Latanoprost eye drop solution, 0.005%, once daily in both eyes for 28 days.
62196307|NCT05261308|EXPERIMENTAL|prosthesis|The polyamide prosthesis
62196308|NCT05708547||Atheromatous coronary patients|patients scheduled for coronary artery bypass surgery with extracorporeal circulation
62196309|NCT05708547||Non-atheratomous patients|Patients scheduled for valve or ascending aorta surgery with extracorporeal circulation without coronary lesion or peripheral arterial disease
62196310|NCT00600613|EXPERIMENTAL|1|Patients going for treatment of liver metastases with radiation therapy.
62196311|NCT02097589|EXPERIMENTAL|Pneumovax-Atorvastatin|10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days. Pneumovax 23 injected once, intramuscularly at Day 7.
62196312|NCT02097589|PLACEBO_COMPARATOR|Pneumovax-Placebo|10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days. Pneumovax 23 injected once, intramuscularly at Day 7.
62196313|NCT03742375|EXPERIMENTAL|HPV genotyping|
62010009|NCT06573125|EXPERIMENTAL|MoodMover|Participants engage with MoodMover regularly as instructed over a period of 9 weeks, along with a 9-week follow-up.
62010010|NCT01863446|EXPERIMENTAL|Lighting1|Ocular light exposure of a red wavelength light for one night
62196314|NCT03148522|EXPERIMENTAL|escitalopram|Eligible patients were assigned to escitalopram treatment based on investigators' clinical practice.
62196315|NCT03148522|EXPERIMENTAL|duloxetine|Eligible patients were assigned to duloxetine treatment based on investigators' clinical practice.
62399146|NCT05443633|EXPERIMENTAL|Active therapy group|Participants will undergo individualized language treatment in which they will learn semantically- or phonologically based strategies to facilitate word finding difficulties, sentence formulation difficulties, or challenges in their narration and discourse. The level at which the treatment will be administered will depend on the participants' level of performance determined by the results of the language and cognitive testing done at baseline. Treatment will be administered twice a week for 10 weeks.
62399147|NCT05443633|ACTIVE_COMPARATOR|control group|control group will undergo standard speech-language intervention
62399148|NCT03471507|EXPERIMENTAL|Bonipar|
62574959|NCT05006430|PLACEBO_COMPARATOR|Placebo Arm|"Subjects will receive Standard of Care (SOC), based on AASLD/EASL guidelines and one dose of Placebo every day for a week followed by once weekly for 3 weeks, amounting to total 10 doses.~Placebo will be identical to the investigational product but will not contain active PRIM-DJ2727."
62574960|NCT06068985|EXPERIMENTAL|PHESGO™-Based Neoadjuvant Therapy for HER2-Positive Early Breast Cancer|This is a single-arm phase II neoadjuvant study using PHESGO™. Participants will receive three cycles of neoadjuvant PHESGO™, with a specific dosage regimen. After three cycles, participants will be reevaluated based on their PET-CT response. PET-CT response is defined as a ≥40% reduction in SUVMax without metabolic progression in non-target lesions. Responders will receive 5 additional cycles of PHESGO™ before surgery. Non-responders will exit the study, following institutional guidelines. Local surgery follows 8 cycles. Adjuvant therapy varies based on pCR status: 1 year of PHESGO™ for pCR; T-DM1 for 14 cycles or investigator's choice chemotherapy plus 10 additional adjuvant cycles of PHESGO™ for non-pCR cases.
62574961|NCT02008695|ACTIVE_COMPARATOR|Youth microfinance only|Youth receive loan
62574962|NCT02008695|ACTIVE_COMPARATOR|youth and adult micro finance|youth and adult receive loan
62574963|NCT02008695|ACTIVE_COMPARATOR|adult microfinance|adults receive loan
62574964|NCT03620305||Description of treatment of septic pseudarthrosis|chirurgical and medical treatment
62574965|NCT02148796|ACTIVE_COMPARATOR|Broncho-Vaxom (BV)|One capsule of Broncho-Vaxom for children contains: 3.5 mg of lyophilized bacterial lysates of Haemophilus influenzae, Streptococcus (pneumonia, pyogenes and sanguinis (viridans)), Klebsiella (pneumoniae and ozaenae), Staphylococcus aureus and Moraxella catarrhalis. The content of the capsule will be mixed with a palatable liquid such as fruit juice.
62574966|NCT02148796|PLACEBO_COMPARATOR|Placebo|A placebo capsule will be used that will be indistinguishable from the active study drug.
62574967|NCT04199169|EXPERIMENTAL|Cohort 1, Group 1|"Ten subjects in the first cohort will receive a 10 mcg dose of HeV-sG-V on Visits 1 and 6.5 (Days 1 and 169\*).~\*Second dose was administered at 6 months due to study pause from local COVID-19 shutdown."
61978073|NCT02742584|EXPERIMENTAL|Group D|Cough Stress Test with the bladder filled to half functional capacity as determined from the largest voided volume recorded in the patient's voiding diary.
62010011|NCT01863446|EXPERIMENTAL|Lighting2|Ocular light exposure of a blue-green wavelength light for one night
62010012|NCT01863446|EXPERIMENTAL|Lighting3|Ocular light exposure to a red wavelength light on night 1 and to a red wavelength light on night 2
62399149|NCT03471507|ACTIVE_COMPARATOR|Diclofenac topical solution 1.5%|
62010013|NCT01863446|EXPERIMENTAL|Lighting4|Ocular light exposure to a red wavelength light on night 1 and to a blue-green wavelength light on night 2
62010014|NCT02534610|EXPERIMENTAL|Group ETORICOXIB PREOP|Preoperative (1 h) per os (PO) 120 mg Etoricoxib (Arcoxia) and 1 placebo pill PO at the end of surgery.
62010015|NCT02534610|EXPERIMENTAL|Group ETORICOXIB POSTOP|Preoperative (1 h) 1 placebo pill PO and 120 mg Etoricoxib PO at the end of surgery (Arcoxia).
62010016|NCT02534610|PLACEBO_COMPARATOR|Group PLACEBO|1 placebo pill PO 1 h preoperative and 1 placebo pill PO postoperative at the end of surgery.
62196316|NCT03148522|EXPERIMENTAL|mirtazapine|Eligible patients were assigned to mirtazapine treatment based on investigators' clinical practice.
62196317|NCT04706936|EXPERIMENTAL|Anti-BCMA CAR-T (CBG-002)|All subjects were intravenous administrated with CBG-002.
62196318|NCT03041792|EXPERIMENTAL|Active|Liraglutide
62196319|NCT03041792|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62196320|NCT00387244|EXPERIMENTAL|Precision for Spinal Cord Stimulation|Single arm Precision for Spinal Cord Stimulation
62196321|NCT01473277|ACTIVE_COMPARATOR|BT-A (Dysport 500U)|
62196322|NCT01473277|ACTIVE_COMPARATOR|Triamcinolone acetonide|
62574968|NCT04199169|PLACEBO_COMPARATOR|Cohort 1, Group 2|"Two subjects in the first cohort will receive a dose of the placebo on Visits 1 and 6.5 (Days 1 and 169\*).~\*Second dose was administered at 6 months due to study pause from local COVID-19 shutdown."
62574969|NCT04199169|EXPERIMENTAL|Cohort 2, Group 3|Thirty subjects in the second cohort will receive a 30 mcg dosage of HeV-sG-V on Visits 1 and 2 (Days 1 and 8) with placebo on Visit 3 (Day 29).
62574970|NCT04199169|EXPERIMENTAL|Cohort 2, Group 4|Thirty subjects in the second cohort will receive a 30 mcg dosage of HeV-sG-V on Visits 1 and 3 (Days 1 and 29) with placebo on Visit 2 (Day 8)
62574971|NCT04199169|PLACEBO_COMPARATOR|Cohort 2, Group 5|Twelve subjects in the second cohort will receive a dose of the placebo on Visits 1, 2, and 3 (Days 1, 8 and 29).
62574972|NCT04199169|EXPERIMENTAL|Cohort 3, Group 6|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visit 1 (Day 1) and placebo on Visits 2 and 3 (Days 8 and 29).
62574973|NCT04199169|EXPERIMENTAL|Cohort 3, Group 7|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visits 1 and 2 (Days 1 and 8) and placebo on Visit 3 (Day 29).
62010017|NCT01175382|ACTIVE_COMPARATOR|Behavioral Treatment alone|Behavioral treatment is implemented in 4 clinic visits over a period of 6 weeks, followed by 6 weeks of combined behavioral + drug therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and daily bladder diaries, supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
62010018|NCT01175382|ACTIVE_COMPARATOR|Drug Therapy (Tolterodine + tamsulosin)|Drug therapy for 6 weeks implemented in a clinic visit with telephone follow-up at 3 weeks, followed by 6 weeks of combined drug + behavioral therapy. Participants in the drug group will receive an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
62196323|NCT03982212|EXPERIMENTAL|Intratumoral Copaxone|Eligible subjects receive at least 1 and up to 3 doses of Copaxone® 40 milligrams (mg) intratumorally prior to standard of care surgery. The doses will be administered at least 48 hours apart. The last dose will be given within 96 hours of standard of care surgery.
62196324|NCT02727569||Feasibility Study|10 subjects. Subjects will performed two different versions of the new visual field algorithm with DLS (differential light sensitivity) strategies. Two repeats of each strategy will be performed.
62574974|NCT04199169|EXPERIMENTAL|Cohort 3, Group 8|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visits 1 and 3 (Days 1 and 29) and placebo on Visit 2 (Day 8).
62574975|NCT04199169|PLACEBO_COMPARATOR|Cohort 3, Group 9|Eighteen subjects in the third cohort will receive a dose of the placebo on Visits 1, 2, and 3 (Days 1, 8 and 29).
62010019|NCT01175382|EXPERIMENTAL|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
62010020|NCT02666235|ACTIVE_COMPARATOR|Remote ischaemic conditioning|Intermittent inflation of a forearm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a curtain.
62010021|NCT02666235|SHAM_COMPARATOR|Control group|Sham intervention: Arm cuff placement but without inflation during a 40 minute period. A curtain will obscure the patient from the clinical team during this time. Arm cuff placement, no inflation.
62010022|NCT04368923|EXPERIMENTAL|Oxygen Therapy Group|
62196325|NCT02727569||Clinical evaluation study|100 subjects. Subjects will performed a visual field assessment with the new visual field algorithm with MMDT (Moorfields Motion Displacement Test) and DLS -like stimuli and a commercial available SITA algorithm (DLS-like strategy). Two repeats of each strategy will be performed.
62196326|NCT00660738||01|Patients with clinical and spirometric diagnosis of COPD, with FEV1\<80%
62574976|NCT00570687|EXPERIMENTAL|1|Technosphere Insulin
62010023|NCT04368923|EXPERIMENTAL|Physical Therapy Group|
62010024|NCT04824534||Healthy subjects|
62010025|NCT04824534||Healthy subjects matching baseline characteristics with patients|
62010026|NCT04824534||Patients with sarociliac joint dysfunction|
62010027|NCT01798446|EXPERIMENTAL|Axitinib|This is a single arm study. Axitinib arm is the only arm who receive axitinib.
62196327|NCT00368875|EXPERIMENTAL|vorinostat, paclitaxel, bevacizumab|Vorinostat BID on days 1-3, 8-10, and 15-17, paclitaxel IV over 1 hour on days 2, 9, and 16, bevacizumab IV over 30-90 minutes on days 2 and 16, repeat every 28 days.
62574977|NCT05508698|NO_INTERVENTION|Passive Control|No change to the standard of care for flu vaccines
62574978|NCT05508698|EXPERIMENTAL|Pre-visit Questionnaire|One-item questionnaire in online patient portal and additional information in the flu shot alert
62574979|NCT01609010|ACTIVE_COMPARATOR|Rituximab Monotherapy|Participants received 375 milligrams per square meter (mg/m2) rituximab intravenously (i.v.) weekly for 4 weeks. Participants achieving minor response (MR), partial response (PR), or completer response (CR) received a second cycle of treatment.
62215013|NCT04612933|EXPERIMENTAL|Intervention group video consultations|"All appointments, scheduled and non-scheduled are by telemedicine using video to commutate with the health care professionals.~Patients will follow their usual treatment."
62574980|NCT01609010|EXPERIMENTAL|Rituximab, Interferon|Participants received 375 mg/m2 rituximab i.v. weekly for 4 weeks; and 3 million international units per day (MIU/day) interferon-a2a subcutaneously (s.c.) during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5. Interferon-a2a was not administered on days of rituximab administration. Participants achieving MR, PR, or CR received a second cycle of treatment.
62574981|NCT00686829|EXPERIMENTAL|VCV 30 mg|Participants take VCV 30 mg once daily.
62196328|NCT03925610||Morbidly obese patients with moderate-to-severe OSA|"Morbidly obese patients recovering from general anesthesia after weight loss surgery (gastric bypass and sleeve placement) surgery.~All patients will undergo preoperative and postoperative continuous transcutaneous and intermittent arterial blood PCO2 monitoring.~Sedation depth and pain assessment will be performed in the post-anesthesia care unit (PACU). Fentanyl only will be administered during surgery and in PACU to provide analgesia (verbal numerical score ≤ 3).~A total of 9, 10-mL blood samples (including a preoperative blank sample) will be obtained throughout the study period (1 preoperatively, 4 intraoperatively and 4 in the PACU) to measure fentanyl concentration in the plasma. Five 1-mL samples will be used to determine arterial PCO2."
62574982|NCT04370171||Group TC: Diabetic patients followed by Teleconsultation|Teleconsultation group will be composed of patients for whom the consultation initially scheduled in the presence of the diabetologist has been replaced by a teleconsultation due to the availability of diabetologists whose activity is focused on the management of Covid-19 negative patients.
62574983|NCT04370171||Group P: Diabetic patients with conventional follow-up|Conventional group will be composed of patients for whom the consultation initially scheduled in the presence of the diabetologist was differed by 6 months due to the activity of some diabetologists entirely redirected towards the management of Covid-19 positive patients and not available
62574984|NCT01373502|EXPERIMENTAL|DES Limus Carbostent Coronary Stent|
62574985|NCT01373502|ACTIVE_COMPARATOR|Taxus Liberté Coronary Stent|
62574986|NCT02508077|EXPERIMENTAL|Treatment (panitumumab and FOLFIRI)|Patients receive panitumumab IV over 30-90 minutes, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium PO, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
62196329|NCT03925610||Morbidly obese patients with no or mild OSA|"Morbidly obese patients recovering from general anesthesia after weight loss surgery (gastric bypass and sleeve placement) surgery.~All patients will undergo preoperative and postoperative continuous transcutaneous and intermittent arterial blood PCO2 monitoring.~Sedation depth and pain assessment will be performed in the post-anesthesia care unit (PACU). Fentanyl only will be administered during surgery and in PACU to provide analgesia (verbal numerical score ≤ 3).~A total of 9, 10-mL blood samples (including a preoperative blank sample) will be obtained throughout the study period (1 preoperatively, 4 intraoperatively and 4 in the PACU) to measure fentanyl concentration in the plasma. Five 1-mL samples will be used to determine arterial PCO2."
62196330|NCT03662269|EXPERIMENTAL|indomethacin treatment group|indomethacin (75mg, bid) + omeprazole (20mg, qd)
62010028|NCT01675713|EXPERIMENTAL|Lifestyle intervention|10-14 weeks intensive lifestyle intervention
62010029|NCT01675713|NO_INTERVENTION|Controls|No treatment, waiting list
62574987|NCT06139783|EXPERIMENTAL|Physycal Exercise|Patients included in the study will follow an online physical exercise program supervised by a physical exercise specialist in which they will perform up to 300 minutes of moderate-intensity aerobic exercise or up to 150 minutes of vigorous aerobic exercise and 2 strength sessions per week for 12 weeks (following WHO recommendations for cancer survivors).
62574988|NCT02948751|EXPERIMENTAL|OncoCEE|Patients with breast cancer who are undergoing lumbar puncture for suspicion of leptomeningeal metastasis. An additional CSF sample will be obtained for evaluation of CSF CTCs by OncoCEETM technology and cell-free DNA (recommended amount: 1 tube, 10 mL) at the time of lumbar puncture.
62574989|NCT03691051|EXPERIMENTAL|Pyrotinib Plus Capecitabine|Pyrotinib + Capecitabine
62574990|NCT05957952|SHAM_COMPARATOR|Exercise group|Motor control exercise
62196331|NCT03662269|PLACEBO_COMPARATOR|placebo treatment group|placebo (75mg, bid) + omeprazole (20mg, qd)
62196332|NCT03394131|EXPERIMENTAL|Hyalase|injection and hydro-dissection of median nerve using hyaluronidase followed by 10 cc normal saline ultrasonic guided
62196333|NCT03394131|PLACEBO_COMPARATOR|Placebo|injection and hydro-dissection of median nerve hydro-dissection using 10 cc saline injection ultrasonic guided
62196334|NCT03394131|ACTIVE_COMPARATOR|Insilin|injection and hydro-dissection of median nerve hydro-dissection using 10 IU insuline followed by 10 cc normal saline ultrasonic guided
62010030|NCT03079336|EXPERIMENTAL|State of the art (SOTA) check-in phase|The therapists will apply the usual SOTA check-in phase lasting between 5 and 10 minutes, as recommended in the preexisting guideline including reviewing progress in self-help and agenda setting (Zinbarg et al., 2006).
62010031|NCT03079336|EXPERIMENTAL|Prolonged focus on subtle changes|Based on the robust findings that over 90% of the patients will experience subtle changes, the therapists will extend the above mentioned check-in phase by systematized focus for 7 to 20 minutes capitalizing on small and subtle changes and exceptions.
62574991|NCT05957952|EXPERIMENTAL|Dynamic taping with exercise group|Motor control exercise combined with dynamic taping
62574992|NCT05126069||Standalone Xen45|consecutive patients from June 2012 - July 2017 who received standalone Xen45®
62574993|NCT05126069||Standalone Trabeculectomy|consecutive patients from June 2012 - July 2017 who received standalone trabeculectomy
62010032|NCT06535906|ACTIVE_COMPARATOR|kinesio taping|Kinesio taping is a widely used physiotherapy application for muscle pain. Kinesio taping will be applied to patients in this group.
62196335|NCT02865551|EXPERIMENTAL|Extended catheterization|Participants in which a foley catheter will be inserted adjacent to epidural anesthesia during labor.
62574994|NCT03690843||DCD Group|Children diagnosed with DCD or at-risk DCD at two or three years of age
62574995|NCT03690843||Control Group|Typically developing children
62574996|NCT01359332|EXPERIMENTAL|hypothermia|
62574997|NCT01359332|NO_INTERVENTION|control|
62574998|NCT02602990||Cerebral AVM treated with SQUID™|
62574999|NCT01142817||HIV Postive Women|Women living with HIV who meet study eligibility criteria
62575000|NCT01142817||Healthy Control Subjects|Women without HIV who meet study eligibility criteria
62575001|NCT01057147|EXPERIMENTAL|rebamipide 2% ophthalmic suspension|
62575002|NCT01057147|PLACEBO_COMPARATOR|placebo eye drops|
62575003|NCT06468800|OTHER|ESD with TRACMOTION|Patients already scheduled for ESD will undergo an ESD procedure with the aid of the TRACMOTION device.
62196336|NCT02865551|EXPERIMENTAL|Intermittent catheterization|Participants in which a short term catheter will be inserted every 4 hours during labor after epidural anesthesia until delivery.
62196337|NCT06049368|EXPERIMENTAL|68Ga-P16-093|Within 1 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-P16-093.
62196338|NCT03670251|OTHER|Blood sampling|blood samples from venepuncture (10mL) and from fingertip (approximatively 0.4mL) on a dried blood spots
62196339|NCT00776906|EXPERIMENTAL|1|PTX-coated balloon
62196340|NCT00776906|ACTIVE_COMPARATOR|2|Bare balloon
62783190|NCT02873338|EXPERIMENTAL|Dociparstat 0.125 mg/kg|"Induction:~* Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/hr continuous 24-hour intravenous (IV) infusion (Days 1 to 7)~* Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, and 3)~* Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1 to 7)~Re-induction:~* Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/hr continuous 24-hour IV infusion (Days 1 to 5)~* Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1 and 2)~* Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1 to 5)~Consolidation:~* Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/hr continuous 24-hour IV infusion on (Days 1 to 5; total 120 hours)~* Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, and 5)"
62196341|NCT00003485|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62196342|NCT04496323||LOW|Golf Skill level high, handicap below 11.5
62399150|NCT05378464|EXPERIMENTAL|T-Cell therapy dose level 1|Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines. After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with IL-15 Expanded HER2 specific CD4+ Th1 cell 0.5.0-2.5 x 10\^8, IL-7 and Expanded HER2 specific CD4+ Th1 cell 0.5.0-2.5 x 10\^8.
62575004|NCT02954133|EXPERIMENTAL|I7: Control|Subjects assigned to this group receive no OrthoPulse™ treatment, and switch Invisalign aligners every 7 days.
62010033|NCT06535906|PLACEBO_COMPARATOR|placebo kinesio taping|Kinesio taping is a widely used physiotherapy application for muscle pain. In this group, placebo kinesio taping will be applied to the patients.
62010034|NCT06535906|ACTIVE_COMPARATOR|manual lymph drainage|Manual lymphatic drainage is a method commonly used in cases where lymph flow is impaired. Manual lymphatic drainage will be applied to patients in this group.
62010035|NCT06535906|PLACEBO_COMPARATOR|placebo manual lymph drainage|Manual lymphatic drainage is a method commonly used in cases where lymph flow is impaired. In this group, patients will receive placebo manual lymphatic drainage.
62010036|NCT03970135|EXPERIMENTAL|Fasting|
62010037|NCT03852329|EXPERIMENTAL|Navigated|Lateral skull base navigation intervention is applied
62010038|NCT05979792|EXPERIMENTAL|CAR-T Therapy|
62010039|NCT03261349|EXPERIMENTAL|Anti-HCV (Ledipasvir and sofosbuvir)|Harvoni® (90 mg ledipasvir and 400 mg sofosbuvir) one tablet daily for 12 weeks
62196343|NCT04496323||HIGH|Golf Skill level low, handicap 18.5 - 26.4
62196344|NCT04240249|EXPERIMENTAL|Constructive self-assertiveness with guidance|10 weeks of internet-based treatment with weekly assignments. The homework is commented on by the guide using electronic communication.
62196345|NCT04240249|EXPERIMENTAL|Constructive self-assertiveness without guidance|10 weeks of internet-based treatment with weekly assignments. The homework is NOT commented on by any guide. Hence, same treatment as group 1 but without guidance.
62196346|NCT04240249|NO_INTERVENTION|Waitlist control|No treatment, no guidance, just waiting for 10 weeks. After the ten weeks the participants will receive the treatment.
62196347|NCT01159470||bacterial infection|children with fever due to bacterial infection
62196348|NCT01159470||viral infection|children with fever due to viral infection
62399151|NCT05378464|EXPERIMENTAL|T-Cell therapy dose level 2|Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines. After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with IL-15 Expanded HER2 specific CD4+ Th1 cell .25-1.2 x 10\^9, IL-7 and Expanded HER2 specific CD4+ Th1 cell .25-1.2 x 10\^9.
62575005|NCT02954133|EXPERIMENTAL|OP7: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 7 days.
62196349|NCT00108745|EXPERIMENTAL|Arm I (paclitaxel poliglumex)|Patients receive polyglutamate paclitaxel IV over 10-20 minutes on day 1.Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62196350|NCT00108745|ACTIVE_COMPARATOR|Arm II (paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62196351|NCT00108745|OTHER|Arm III (observation)|Patients receive no further anticancer treatment until evidence of disease progression.
62196352|NCT03548220|PLACEBO_COMPARATOR|Placebo|Participants received a matching placebo to AG-348 tablets, for a period of 12 weeks as an optimized dose. This was followed by matching placebo further, for a period of 12 weeks as a fixed-dose.
62196353|NCT03548220|EXPERIMENTAL|AG-348, 5 mg|Participants received AG-348 tablets, 5 milligrams (mg) twice daily (BID), administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 5 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.
62196354|NCT03548220|EXPERIMENTAL|AG-348, 20 mg|Participants received AG-348 tablets, 5 mg BID, administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 20 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.
62196355|NCT03548220|EXPERIMENTAL|AG-348, 50 mg|Participants received AG-348 tablets, 5 mg BID, administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 50 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.
62196356|NCT00196352|EXPERIMENTAL|1|
62196357|NCT05440747||Newly diagnosed CML-CP patients|Treat with TKI (Imatinib or Flumatinib or Nilotinb or Dasatinib).
62196358|NCT05440747||Patients with suboptimal response|"1. Treat with original TKI~2. Treat with original TKI combined with interferon/thymosin;~3. Replace other TKI ;~4. Replace other TKI and combined with interferon/thymosin."
62196359|NCT05091957|EXPERIMENTAL|Community Support Worker|structured review of participant income supports with a trained CSW, to identify financial needs and benefits for which the family is eligible, including assessment of income and food security, affordability of medications, housing and energy insecurity, and dental care. The visits will be conducted in person, by telephone or by videoconferencing, according to participant preference and to ensure adherence to COVID-19 pandemic-related criteria.
62215014|NCT04612933|NO_INTERVENTION|No intervention|"All appointments, scheduled and non-scheduled are by face-face communication with the health care professionals.~Patients will receive their usual treatment."
62010040|NCT02960880||Rivaroxaban|NVAF patients who were newly initiated on Rivaroxaban for stroke prevention
62010041|NCT02960880||Phenprocoumon|NVAF patients who were newly initiated on Phenprocoumon for stroke prevention
62010042|NCT02304237|EXPERIMENTAL|Vaginal progesterone|Vaginal progesterone(Utrogestan)200mg/day, during 14\~21 weeks.
62010043|NCT02304237|ACTIVE_COMPARATOR|Intramuscular progesterone|Intramuscular progesterone(Progesterone Depot Jenapharm Injection)250mg/week, during 14\~21 weeks.
62010044|NCT04466514|EXPERIMENTAL|Treatment A - Fasting|Fasting conditions
62010045|NCT04466514|EXPERIMENTAL|Treatment B - Fed|High-fat/high-calorie breakfast
62010046|NCT04466514|EXPERIMENTAL|Treatment C - Fed|Low-fat/low-calorie breakfast
62010047|NCT02466308|EXPERIMENTAL|SAM Ultrasound Diathermy Device|SAM (sam Professional System) 3 MHz ultrasound diathermy device: 4 hours/day, at least 5 days per week, for 6 weeks
62010048|NCT02896127|EXPERIMENTAL|Secukinumab|"Secukinumab 150 mg s.c.~Arm includes all patients who received at least 1 dose of study drug including placebo switchers at Week 16"
62010049|NCT02896127|PLACEBO_COMPARATOR|Placebo|Placebo s.c.
62010050|NCT04283175||Neuromuscular disease (MNM) subjects (Charcot Marie Tooth disease, CMT)|
62010051|NCT04283175||Hemiparetic subjects|
62010052|NCT04283175||Healthy subjects|
62010053|NCT04928222|ACTIVE_COMPARATOR|Doxorubicin-containing MNA - 100 µg|A doxorubicin-containing array of 100 µg will be applied to subjects.
62010054|NCT04928222|EXPERIMENTAL|Placebo MNA for Training|Training phase for application of arrays
62010055|NCT01837316|EXPERIMENTAL|FF/VI|A single dose inhalation of FF/VI 100/25 mcg in the morning
62010056|NCT01837316|PLACEBO_COMPARATOR|Placebo|A single dose inhalation of matching placebo in the morning
62010057|NCT04931654|EXPERIMENTAL|Dose Escalation Part A: NSCLC Immuno-oncology (IO) acquired or primary resistance|AZD7789 monotherapy
62010058|NCT04931654|EXPERIMENTAL|Dose Expansion Part B1: NSCLC IO acquired resistance - RP2D level 1|AZD7789 Monotherapy
62010059|NCT04931654|EXPERIMENTAL|Dose Expansion Part B2: NSCLC IO naive, PD-L1 50% or greater - RP2D level 1|AZD7789 Monotherapy
62010060|NCT04931654|EXPERIMENTAL|Dose Expansion Part B3: NSCLC IO acquired resistance - RP2D level 2|AZD7789 Monotherapy
62010061|NCT04931654|EXPERIMENTAL|Dose Expansion Part B4: advanced or metastatic gastric and GEJC IO acquired resistance- RP2D level 1|AZD7789 monotherapy
62010062|NCT04931654|EXPERIMENTAL|Dose Expansion Part B5: NSCLC IO naive, PD-L1 1-49% - RP2D Level 1|AZD7789 monotherapy
62196360|NCT05091957|ACTIVE_COMPARATOR|Usual Care|There is no clear standard of care and potential for practice variation in clinician responses to identified social need. Based on the ethical imperative to provide some support to families who identify unmet social needs, the comparator group will receive Usual Care, defined as: Participants in both groups will receive a written summary of available resources.
62196361|NCT03422861|ACTIVE_COMPARATOR|Nabilone Treatment|Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and nabilone as per protocol
62196362|NCT03422861|PLACEBO_COMPARATOR|Placebo Treatment|Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and placebo
62196363|NCT03065140|EXPERIMENTAL|Healthy Volunteers|"Healthy volunteers will undergo the following:~* CPEX with/without stable isotope infusion~* Muscle biopsies~* Magnetic Resonance Spectroscopy Followed by a period of detraining.~They will then undergo the following:~* CPEX with/without stable isotope infusion~* Muscle biopsies~* Magnetic Resonance Spectroscopy"
62196364|NCT03065140|EXPERIMENTAL|Diabetic Patients|"Diabetic patients will undergo the following:~* CPEX with/without stable isotope infusion~* Muscle biopsies~* Magnetic Resonance Spectroscopy They will then undergo a supervised training period.~They will then undergo the following:~* CPEX with/without stable isotope infusion~* Muscle biopsies~* Magnetic Resonance Spectroscopy"
62196365|NCT06485206|EXPERIMENTAL|Primary Hybrid Construct|Primary hybrid surgery is when patients undergo CDA and ACDF at the same time.
62196366|NCT02909933|EXPERIMENTAL|liraglutide|liraglutide 3 mg QD for 12 weeks
62196367|NCT02909933|EXPERIMENTAL|metformin and liraglutide|metformin 1000 mg BID and liraglutide 1.2 mg QD for 12 weeks
62196368|NCT01258621|EXPERIMENTAL|Laparoscopic Distal Pancreatectomy|
62399152|NCT05378464|EXPERIMENTAL|T-Cell therapy dose level 3|Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines. After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with IL-15 Expanded HER2 specific CD4+ Th1 cell .5-2.5 x 10\^9, IL-7 and Expanded HER2 specific CD4+ Th1 cell .5-2.5 x 10\^9.
62010063|NCT03738904|EXPERIMENTAL|Arm 1 (multimodal ERAS)|"Arm1 (Multimodal ERAS):~Preoperative:~oral gabapentin 600mg and oral acetaminophen 1,000mg~Postoperative pain control:~1. Gabapentin oral 300 mg TID (#42, refill #1)~2. Acetaminophen oral 1000mg TID (#42, refill #1)~3. Ketorolac oral 10 mg TID (#15, refill #0)~4. Oxycodone oral 5 mg PRN every 6 hours (#30, refill #0)~Postoperative laxative regimen:~1. Daily MiraLAX 1 scoop in 1 glass of water for 15 days~2. Daily milk of magnesia 1 tablespoon if no bowel movement by POD2 until regular bowel movements~3. Daily mineral oil 1 table spoon if no bowel movement by POD2 until regular bowel movements"
62010064|NCT03738904|ACTIVE_COMPARATOR|Arm 2 (control)|"Postoperative pain control:~1. Oxycodone oral 5 mg PRN every 6 hours (#30, refill #0)~2. Patients will be allowed to take oral acetaminophen and ibuprofen over the counter if needed but active narcotic-sparing pain management regimen will not be implemented~Postoperative laxative regimen:~1. Daily MiraLAX 1 scoop in 1 glass of water for 15 days~2. Daily milk of magnesia 1 tablespoon if no bowel movement by POD2 until regular bowel movements Daily mineral oil 1 table spoon if no bowel movement by POD2 until regu-lar bowel movements"
62010065|NCT02072850||Myocardial infarction|Patients presenting with acute-ST elevation myocardial infarction referred for emergency invasive management by primary or rescue percutaneous coronary intervention.
62010066|NCT06294509|NO_INTERVENTION|No stimulation (control)|Participants will wear device but will not receive any stimulation
62010067|NCT06294509|ACTIVE_COMPARATOR|Movement-unrelated stimulation (control)|Participants will wear device and receive randomly timed stimulation
62010068|NCT06294509|EXPERIMENTAL|pre-movement taVNS|Stimulation will start after 500ms of being in the home position, before the onset of the movement cue.
62010069|NCT06294509|EXPERIMENTAL|during-movement taVNS|Stimulation will occur during the movement phase.
62010070|NCT06294509|EXPERIMENTAL|post-movement taVNS|Stimulation will occur immediately after a successful trial (no stimulation if the trial is failed).
62010071|NCT05707858||Subject with suspected food allergy|
62010072|NCT03084016||Acute asthma exacerbation|Recruited in secondary care when presenting with acute asthma exacerbation.
62010073|NCT03084016||At risk of acute asthma exacerbation|Recruited in outpatient clinics. Acute exacerbation within the previous 12 months.
62010074|NCT02994030||Participants with Duchenne Muscular Dystrophy (DMD)|Participants diagnosed with Duchenne Muscular Dystrophy (DMD) aged between 2 months and 50 years
62196369|NCT02214953|EXPERIMENTAL|BI 11634 ER formulation A|
62196370|NCT02214953|EXPERIMENTAL|BI 11634 ER formulation B|
62196371|NCT02214953|EXPERIMENTAL|BI 11634 ER formulation M|
62196372|NCT02214953|EXPERIMENTAL|BI 11634 ER formulation C|
62196373|NCT02214953|ACTIVE_COMPARATOR|BI 11634 IR tablet|
62196374|NCT05780086|EXPERIMENTAL|30% icodextrin and 10% dextrose|Dwell time of 24 hours using a 500 ml sodium-free peritoneal dialysis solution based on 30% icodextrin and 10% dextrose
62196375|NCT01603888||healthy newborns, BNP, NT-proBNP|healthy newborns
62196376|NCT01603888||infants, BNP, NT-proBNP|infants
62196377|NCT01603888||children with heart disease, BNP, NT-proBNP|children with heart disease
62196378|NCT00642525|EXPERIMENTAL|A|A prospective, blinded, intraindividual controlled study is conducted with patients with transthoracic esophagectomy due to esophageal cancer. A radiographic contrast study is performed prior to endoscopy at the 5th to 7th postoperative day.
62196379|NCT02250053|EXPERIMENTAL|exercise|aerobic exercise on soluble intercellular adhesion molecules
62196380|NCT00842244|EXPERIMENTAL|A|
62196381|NCT05399901|EXPERIMENTAL|EMG BFB|An educational program will be implemented, and active exercises of the PFM will be performed using verbal instructions together with electromyographic biofeedback (BFB).
62196382|NCT05399901|EXPERIMENTAL|M-mode US|An educational program will be implemented, and active exercises of the PFM will be performed using verbal instructions together with transabdominal M-mode ultrasound biofeedback (US).
62196383|NCT04444531||Ozone autohemotherapy plus standard treatment|
62196384|NCT04444531||Standard treatment alone|
62399153|NCT05378464|EXPERIMENTAL|T Cell therapy dose expansion|Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines. After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with CD4 treated t-cells at the maximum tolerated dose determined.
62196385|NCT03534895|PLACEBO_COMPARATOR|PC1|5mL normal saline intravenous, single-administration, as pre-medication
62196386|NCT03534895|EXPERIMENTAL|PC2|midazolam 0.02mg/Kg in 5mL normal saline, intravenous, single-administration, as pre-medication
62196387|NCT03534895|EXPERIMENTAL|PC3|midazolam 0.06mg/Kg in 5mL normal saline, intravenous, single-administration, as pre-medication
62196388|NCT00371176|EXPERIMENTAL|D-Cycloserine|Brief imaginal exposure therapy plus DCS pill
62196389|NCT00371176|PLACEBO_COMPARATOR|Placebo|Brief imaginal exposure therapy plus Placebo pill
62196390|NCT03708653||PHN(+)|Patients who have persistent pain more than three months after the onset of herpes zoster.
62196391|NCT03708653||PHN(-)|Patients whose pain disappear within three months.
62196392|NCT03258736|OTHER|Caudal block|Caudal block Marcaine
62399154|NCT06382298|EXPERIMENTAL|COTTONSEED OIL|Participants are given a daily shake enriched with cottonseed oil and instructed on how to substitute provided study shake into usual diet to maintain caloric balance.
62575006|NCT02954133|EXPERIMENTAL|OP5: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 5 days.
62575007|NCT02954133|EXPERIMENTAL|OP3.5: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 3.5 days.
62010075|NCT01162629||Osteon|Patients requiring dental implants with deficient alveolar bone height
62196393|NCT03258736|OTHER|ilionguinal/iliohypogastric block|ilionguinal/iliohypogastric block Marcaine
62196394|NCT01224834|PLACEBO_COMPARATOR|1|
62196395|NCT01224834|EXPERIMENTAL|2|
62196396|NCT01684189||Patient registry|Patients with newly diagnosed malignant hematological diseases will be enrolled into this registry
62196397|NCT02349997||OSA group|"Of the 180 heart failure patients,20 OSA were enrolled. Clinical evaluations including NYHA class, electrocardiographic, echocardiographic, arterial blood gas analysis findings, baseline medication, and 6-minute walk test (6MWT) were recorded.~The fluid index, head and neck CT and pharyngeal resistance were tested at 20:00. Then a full night PSG and percutaneous PaCO2 were performed. The fluid index, head and neck CT and pharyngeal resistance were repeated at 6:00 after PSG.~The volume of fluid shift from legs to head and neck,inside diameter of the upper airway, and water content of neck soft tissue were calculated. The lung-to-finger circulation time and loop gain were measured."
62196398|NCT02349997||CSA group|"Of the 180 heart failure patients,20 CSA were enrolled. Clinical evaluations including NYHA class, electrocardiographic, echocardiographic, arterial blood gas analysis findings, baseline medication, and 6-minute walk test (6MWT) were recorded.~The fluid index, head and neck CT and pharyngeal resistance were tested at 20:00. Then a full night PSG and percutaneous PaCO2 were performed. The fluid index, head and neck CT and pharyngeal resistance were repeated at 6:00 after PSG.~The volume of fluid shift from legs to head and neck,inside diameter of the upper airway, and water content of neck soft tissue were calculated. The lung-to-finger circulation time and loop gain were measured."
62196399|NCT04623606|NO_INTERVENTION|Prospective Control (Untreated) and historical controls|Subjects eligible for the trial but not willing/able to participate in any of the experimental arms Matched historical controls. Subjects will be identified in historical registries and data will be retrieved from OI database
62196400|NCT04623606|EXPERIMENTAL|Treatment|Administration of four doses of BOOST cells with the first dose between 1-4 years of age and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10\^6 MSC/kg body weight.
62196401|NCT04626349|EXPERIMENTAL|FOCUS+|Dyads in the FOCUS+ arm will receive the face-to-face nurse-led FOCUS+ program.
62196402|NCT04626349|EXPERIMENTAL|iFOCUS|Dyads in the iFOCUS arm will receive the web-based iFOCUS program.
62196403|NCT04626349|NO_INTERVENTION|Standard care|Dyads in the control group will receive standard care as usual, as determined by the healthcare system in the participating countries. The dose and frequency of usual care will be as deemed appropriate by the medical practitioner in charge of their treatment.
62196404|NCT03315013|EXPERIMENTAL|SLATE|The SLATE arm will be administered the SLATE II algorithm and initiated on ART immediately if eligible under the algorithm. Patients not eligible under the algorithm will be referred for standard care.
62196405|NCT03315013|NO_INTERVENTION|Standard|The standard arm will be referred to standard care after study enrollment.
62399155|NCT06382298|EXPERIMENTAL|MATCHED PUFA DIET|Participants are given a daily shake enriched with a mixture of oils with a similar fatty acid profile to CSO and instructed on how to substitute provided study shake into usual diet to maintain caloric balance.
62399156|NCT06382298|ACTIVE_COMPARATOR|CONTROL|Participants are given a daily shake enriched with a mixture of oils that match the fatty acid profile of the average American diet, and instructed on how to substitute provided study shake into usual diet to maintain caloric balance.
62575008|NCT04740398|EXPERIMENTAL|Ia stage - CBP-1008 Dose escalation/ Ib stage - CBP-1008 monotherapy|"Ia:Patients will receive CBP-1008 IV infusion every 2 weeks until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.~Ib:Patients will receive CBP-1008 RP2D IV infusion every two weeks until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue."
62399157|NCT05850455|EXPERIMENTAL|Group A|will receive local anesthesia with dexmedetomidine infusion
62575009|NCT05472272|EXPERIMENTAL|Formula Diet|Participants will receive a low-calorie formula diet product.
62575010|NCT05472272|EXPERIMENTAL|Food-Based Diet|Participants will receive a low-calorie food-based diet created by dietitians.
62575011|NCT05362617|EXPERIMENTAL|FOLFIRI|"Irinotecan 180 mg/m2 I.V 30-90 min，D1；~LV 400 mg/m2 I.V.，D1；~5-FU 400 mg/m2 IVP，d1,1200 mg/m2/d×2 days（Total:2400 mg/m2，Continuous intravenous infusion,46\~48 hours,）~Repeat Every 14 days"
62575012|NCT05362617|ACTIVE_COMPARATOR|mFOLFOX6|"Oxaplatin 85 mg/m2 I.V 120 min，D1；~LV 400 mg/m2 I.V.，D1；~5-FU 400 mg/m2 IVP，d1,1200 mg/m2/d×2 days（Total:2400 mg/m2，Continuous intravenous infusion,46\~48 hours,）~Repeat Every 14 days"
62575013|NCT05722288|EXPERIMENTAL|Arm I (time-restricted eating)|Patients undergo time-restricted eating Monday through Friday only of each week on study during standard RT or chemoRT. Patients also undergo collection of blood throughout the trial.
62575014|NCT05722288|ACTIVE_COMPARATOR|Arm II (nutritional counseling)|Patients receive nutritional counseling on study. Patients also undergo collection of blood throughout the trial.
62010076|NCT02908997|EXPERIMENTAL|5 week baseline|5 week baseline data collection followed by 6 week MindMate intervention
62783191|NCT02873338|EXPERIMENTAL|Dociparstat 0.25 mg/kg|"Induction:~* Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/hr continuous 24-hour intravenous (IV) infusion (Days 1 to 7)~* Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, and 3)~* Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1 to 7)~Re-induction:~* Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/hr continuous 24-hour IV infusion (Days 1 to 5)~* Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1 and 2)~* Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1 to 5)~Consolidation:~* Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/hr continuous 24-hour IV infusion (Days 1 to 5; total 120 hours)~* Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, and 5)"
62575015|NCT02893033|EXPERIMENTAL|Real stimulation|Real repetitive transcranial magnetic stimulation + swallowing training
62010077|NCT02908997|EXPERIMENTAL|6 week baseline|6 week baseline data collection followed by 6 week MindMate intervention
62575016|NCT02893033|SHAM_COMPARATOR|Sham stimulation|Sham repetitive transcranial magnetic stimulation + swallowing training
62010078|NCT02908997|EXPERIMENTAL|7 week baseline|7 week baseline data collection followed by 6 week MindMate intervention
62196406|NCT01606371|PLACEBO_COMPARATOR|Healthy-Placebo|Placebo (capsule) administered once, orally
62196407|NCT01606371|EXPERIMENTAL|Healthy-2.5 mg LY2409021|2.5 mg LY2409021 administered once, orally
62196408|NCT01606371|EXPERIMENTAL|Healthy-10 mg LY2409021|10 mg LY2409021 administered once, orally
62196409|NCT01606371|EXPERIMENTAL|Healthy-30 mg LY2409021|30 mg LY2409021 administered once, orally
62196410|NCT01606371|EXPERIMENTAL|Healthy-100 mg LY2409021|100 mg LY2409021 administered once, orally
62196411|NCT01606371|EXPERIMENTAL|Healthy-250 mg LY2409021|250 mg LY2409021 administered once, orally
62196412|NCT01606371|EXPERIMENTAL|Healthy-500 mg LY2409021|500 mg LY2409021 administered once, orally
62196413|NCT01606371|PLACEBO_COMPARATOR|Diabetic-Placebo|Placebo (capsule) administered once, orally
62196414|NCT01606371|EXPERIMENTAL|Diabetic-75 mg LY2409021|75 mg LY2409021 administered once, orally
62196415|NCT01606371|EXPERIMENTAL|Diabetic-200 mg LY2409021|200 mg LY2409021 administered once, orally
62196416|NCT01606371|EXPERIMENTAL|Diabetic-500 mg LY2409021|500 mg LY2409021 administered once, orally
62399158|NCT05850455|EXPERIMENTAL|Group B|will receive epidural analgesia
62399159|NCT05850455|EXPERIMENTAL|Group Con|will receive general anesthesia
62399160|NCT04178330|EXPERIMENTAL|Group A|patients with multiple brain metastases (no less than 3 lesions) ,who have not recived whole brain radiotheray (WBRT).
62575017|NCT02492984|EXPERIMENTAL|Intravenous infusions of Xyntha|Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
62399161|NCT04151615||Patients|Treatment-naïve patients with multiple myeloma who are ineligible for hematopoietic transplantation
62399162|NCT00845598|EXPERIMENTAL|Azelastine Fluticasone|
62575018|NCT03692234|PLACEBO_COMPARATOR|placebo|placebo capsules containing lactose - oral once weekly administration for six month
62575019|NCT03692234|ACTIVE_COMPARATOR|homoarginine|125 mg L-homoarginine supplement - oral once weekly administration for six month
62575020|NCT00680095|EXPERIMENTAL|A|AN2690 Solution, 2.5%
62575021|NCT00680095|EXPERIMENTAL|B|AN2690 Solution, 7.5%
62575022|NCT00680095|EXPERIMENTAL|C|AN2690 Solution, 5.0%
62575023|NCT00680095|ACTIVE_COMPARATOR|D|AN2690 Solution, Vehicle
62399163|NCT00845598|ACTIVE_COMPARATOR|Fluticasone propionate|
62399164|NCT01889342|EXPERIMENTAL|Metacognitive therapy|The treatment is based on the generic manual by Wells (2009).
62575024|NCT00680095|ACTIVE_COMPARATOR|E|Sodium Lauryl Sulfate, 0.5%
62575025|NCT00827905||Hospitalized|Patients admitted to the hospital
62575026|NCT00794248|EXPERIMENTAL|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
62575027|NCT00794248|EXPERIMENTAL|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
62575028|NCT02748356|EXPERIMENTAL|Individuals with Spina Bifida|Lactobacillus rhamnosus GG
62575029|NCT03258294|EXPERIMENTAL|Melatonin(Circadin®)|Melatonin(Circadin®) is taken orally, once daily before going to sleep for a period of 4 weeks.
62575030|NCT03258294|PLACEBO_COMPARATOR|Placebo|Placebo tablet is taken orally, once daily before going to sleep for a period of 4 weeks.
62575031|NCT06576635|OTHER|Single Arm|OncoChoiceTM results will provide ranking of drug effectiveness (e.g., active, inactive, moderately active drug) across a list of pre-selected chemotherapies (FDA-approved NSCLC treatments
62575032|NCT06355895|EXPERIMENTAL|High Carbohydrate Diet|"1. First scan: after an overnight fast of at least 8 hours using standard radiation oncology CT scan with contrast for treatment planning.~2. Standardized high-carb meal such as 8 ounces of Ensure® nutritional protein shake or a similar meal, immediately following first scan and consumed within 15 minutes.~3. Second scan: within 1 hour of ingestion of the high-carb meal using similar settings to those used in the first scan except for contrast use.~4. Third CT scan at least 4 hours (but no more than 5 hours) after ingestion of high-carb diet on the same day utilizing same set up used in first scan with exception for the use of contrast."
62575033|NCT03658161|EXPERIMENTAL|CASCADE|Oncology providers will receive the CASCADE coaching intervention.
62575034|NCT06564298|EXPERIMENTAL|Sintilimab+Ramucirumab+SOX/XELOX|
62575035|NCT01599182||High-Risk Prostate Cancer|
62575036|NCT01599182||Intermediate-Risk Prostate Cancer|
62575037|NCT01421680|ACTIVE_COMPARATOR|Ensure powder|Oral Nutritional Supplements with carbohydrate, lipid, protein, vitamin and minerals
62575038|NCT01421680|NO_INTERVENTION|Standard care|Standard care without oral nutritional supplements
62575039|NCT05342623|EXPERIMENTAL|Difelikefalin 1 mg Oral Tablet|Patients receive oral difelikefalin 1 mg once daily
62575040|NCT05342623|PLACEBO_COMPARATOR|Placebo Oral Tablet|Patients receive oral placebo once daily
62575041|NCT05460013|PLACEBO_COMPARATOR|Placebo Control|
62575042|NCT05460013|EXPERIMENTAL|Oral Nutritional Intervention|
62399165|NCT01889342|ACTIVE_COMPARATOR|Cognitive behavorial therapy|CBT includes the diagnose specific manuals for panic disorder (Clark, 1986), Social Phobia (Clark \& Wells, 1995) and PTSD (Foa, 2007).
62399166|NCT06109714|EXPERIMENTAL|ACUMEN guided resuscitation protocol|Fluid resuscitation and hemodynamic management will be guided by ACUMEN based off a protocol.
62399167|NCT06109714|NO_INTERVENTION|Standard of care resuscitation|Fluid resuscitation will be guided by standard monitors (urine output, blood loss, transesophageal echocardiography).
62399168|NCT04872374|EXPERIMENTAL|Young adults|participants will perform an eccentric exercise bout after 10 days of dietary supplementation
62399169|NCT04872374|ACTIVE_COMPARATOR|Older adults|participants will perform an eccentric exercise bout after 10 days of dietary supplementation
62399170|NCT00762281|OTHER|Treatment of Hyperopic LASIK|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
62399171|NCT05338905|EXPERIMENTAL|Group A (quality of life questionnaire)|Patients complete a quality of life questionnaires over 10-15 minutes BIW during standard of care radiation therapy and QW for the first month after completing standard of care radiation therapy course, and then once monthly for 6 months.
62575043|NCT05258266|EXPERIMENTAL|ZX-101A Dose Level A|ZX-101A administered orally at level A once daily in a 28-day cycle
62575044|NCT05258266|EXPERIMENTAL|ZX-101A Dose Level B|ZX-101A administered orally at level B once daily in a 28-day cycle
62575045|NCT05258266|EXPERIMENTAL|ZX-101A Dose Level C|ZX-101A administered orally at level C once daily in a 28-day cycle
62575046|NCT05258266|EXPERIMENTAL|ZX-101A Dose Level D|ZX-101A administered orally at level D once daily in a 28-day cycle
62575047|NCT05258266|EXPERIMENTAL|ZX-101A Dose Level E|ZX-101A administered orally at level E once daily in a 28-day cycle
62575048|NCT05387369||Paxlovid|Patients with COVID-19 who visit Huashan Hospital,Fudan University from 2022 to 2027 and receive Paxlovid therapy
62575049|NCT05387369||Routine therapy|Patients with COVID-19 who visit Huashan Hospital,Fudan University from 2022 to 2027 and receive routine therapy without paxlovid
62575050|NCT04195633|EXPERIMENTAL|Arm A (high dose treosulfan)|"Patients receive high dose treosulfan IV over 120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo total-body irradiation on day -1 and allogeneic hematopoietic stem cell transplantation on day 0. Patients then receive cyclophosphamide IV over 1-2 hours on days 3-4. Beginning on day 5, patients receive cyclosporine IV BID or TID over 1-2 hours or PO (after 3 months, in the absence of GVHD, cyclosporine tapering will start by 5-10% per week, until drug withdrawal at 6 months post-transplant). Beginning on day 5, patients also receive mycophenolate sodium PO TID or mycophenolate mofetil IV or PO TID until day 35 (may be continued if active GVHD is present). Beginning on day 5, patients also receive filgrastim until the absolute neutrophil count is \> 1,000/uL for 3 consecutive days.~Additionally, patients undergo bone marrow aspiration and biopsy, and echocardiography at baseline and blood sample collection and CT or PET/CT on study."
62575051|NCT04195633|EXPERIMENTAL|Arm B (low dose treosulfan)|"Patients receive low dose treosulfan IV over 120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo total-body irradiation and allogeneic hematopoietic stem cell transplantation, and receive cyclophosphamide, cyclosporine, mycophenolate sodium or mycophenolate mofetil, and filgrastim as in Arm A.~Additionally, patients undergo bone marrow aspiration and biopsy, and echocardiography at baseline and blood sample collection and CT or PET/CT on study."
62575052|NCT02497820|ACTIVE_COMPARATOR|100 mg daily aspirin|They will receive one small tablets each day for two years in a blinded fashion
62575053|NCT02497820|ACTIVE_COMPARATOR|300 mg daily aspirin|They will receive two large enteric coated tablets each day for two years in a blinded fashion
62575054|NCT02497820|ACTIVE_COMPARATOR|600 mg daily aspirin|They will receive two large enteric coated tablets each day for two years in a blinded fashion
62575055|NCT06575101||33℃ group|
62010079|NCT01936259|ACTIVE_COMPARATOR|Comprehensive Mini Humeral Stem|"The Comprehensive® Shoulder System with mini stem component, which will be the control device for this clinical investigation and was 510(k) cleared under K060692 on May 30, 2006.~The humeral stem component is manufactured from Ti6Al4V alloy. The taper has a machine finish and accepts the taper adaptor of the humeral head component. The proximal region of the bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy, while the distal portion is polished. Seventeen stem diameters are available - 4 mm to 20 mm, in 1-mm increments."
62010080|NCT01936259|EXPERIMENTAL|Comprehensive Nano Humeral Component|The stemless humeral component is manufactured from Ti6Al4V alloy. It consists of a central tapered region and six outer wings. The taper has a machine finish and accepts the taper adaptor of the humeral head component. A small groove is included just below the taper to accept an inserter/impactor. The bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy for cementless fixation in the proximal humerus. Six sizes are available - 30 mm, 32 mm, 34 mm, 36 mm, 38 mm, and 40 mm.
62010081|NCT06568939|EXPERIMENTAL|Telisotuzumab Vedotin Dose A|Participants will receive telisotuzumab vedotin dose A, as part of the 3 year study duration.
62575056|NCT06575101||36℃ group|
62575057|NCT06175078||Patient with suspected breast cancer|Patients with suspected breast cancer will be recruited and scanned for this study. The results of ultrasound data analysis will be compared and correlated to the histopathology reports on routine core biopsy specimens, surgery reports, or radiology reports.
62575058|NCT06575010|ACTIVE_COMPARATOR|Group 1: Shoulder Block using Exparel|Participants having rotator cuff repair surgery will receive Liposomal bupivacaine (Exparel) + bupivacaine given in their shoulder block before surgery.
62575059|NCT06575010|ACTIVE_COMPARATOR|Group 2: Shoulder Block using Exparel + Dexamethasone|Participants having rotator cuff repair surgery will receive Liposomal bupivacaine (Exparel) + Dexamethasone + bupivacaine given in their shoulder block before surgery.
62575060|NCT00101166|EXPERIMENTAL|Vaccine Therapy|Treatment consisted of intradermal vaccine injections at 28-day intervals for a total of 3 immunizations. Injections were performed on Days 1, 29, and 57.
62575061|NCT02057133|EXPERIMENTAL|LY2835219 + Letrozole|LY2835219 administered orally. Letrozole administered orally. This arm is closed to enrollment.
62575062|NCT02057133|EXPERIMENTAL|LY2835219 + Anastrozole|LY2835219 administered orally. Anastrozole administered orally. This arm is closed to enrollment.
62575063|NCT02057133|EXPERIMENTAL|LY2835219 + Tamoxifen|LY2835219 administered orally. Tamoxifen administered orally. This arm is closed to enrollment.
62575064|NCT02057133|EXPERIMENTAL|LY2835219 + Exemestane|LY2835219 administered orally. Exemestane administered orally. This arm is closed to enrollment.
62575065|NCT02057133|EXPERIMENTAL|LY2835219 + Exemestane + Everolimus Dose Escalation|LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.
62575066|NCT02057133|EXPERIMENTAL|LY2835219 + Exemestane + Everolimus Dose Expansion|LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.
62575067|NCT02057133|EXPERIMENTAL|LY2835219+ Trastuzumab Dose Escalation|LY2835219 administered orally. Trastuzumab administered intravenously (IV) infusion. This arm is closed to enrollment.
62010082|NCT06568939|EXPERIMENTAL|Telisotuzumab Vedotin Dose B|Participants will receive telisotuzumab vedotin dose B, as part of the 3 year study duration.
62010083|NCT02912286|ACTIVE_COMPARATOR|conventional needle irrigation|side-vented needle used for endodontic irrigation
62575068|NCT02057133|EXPERIMENTAL|LY2835219+ Trastuzumab Dose Expansion|LY2835219 administered orally. Trastuzumab administered IV infusion. This arm is closed to enrollment.
62575069|NCT02057133|EXPERIMENTAL|LY3023414 + LY2835219 + Fulvestrant Dose Escalation|LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered intramuscularly (IM).
62010084|NCT02912286|EXPERIMENTAL|passive ultrasonic irrigation|IrriSafe ultrasonic tip used for irrigation agitation in endodontic treatment
62575070|NCT02057133|EXPERIMENTAL|LY3023414 + LY2835219 + Fulvestrant Dose Expansion|LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered IM.
62575071|NCT02057133|EXPERIMENTAL|LY2835219 +Trastuzumab +Pertuzumab +Loperamide Dose Escalation|LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.
62196417|NCT05772182||Groups/Cohorts|Patients undergoing intervention for arrhythmia (electrophysiologic study and/or intracardiac device implantation) with clinical indication
62196418|NCT03238963|EXPERIMENTAL|BI 1467335|
62575072|NCT02057133|EXPERIMENTAL|LY2835219 +Trastuzumab + Pertuzumab +Loperamide Dose Expansion|"Hormone Receptor Negative (HR-): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.~Hormone Receptor Positive (HR+): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion. Endocrine therapy administered orally."
62575073|NCT02057133|EXPERIMENTAL|LY2835219 + Endocrine Therapy|LY2835219 administered orally. Ongoing endocrine therapy administered orally.
62196419|NCT03238963|PLACEBO_COMPARATOR|Placebo|
62196420|NCT02849470|ACTIVE_COMPARATOR|ARM 1|Control: 1) HD-PRP + Matristem Matrix (ACell) (Current Standard of Care); 2) Intradermal injections of hair loss 3) Platelet Rich Plasma 4) Matristem Matrix (ACell)
62575074|NCT02792543|ACTIVE_COMPARATOR|parenteral nutrition|Parenteral nutrition consists of electrolyte supplementation, hydration, and nutrition through a central venous catheter.
62010085|NCT02912286|EXPERIMENTAL|sonic irrigation|Vibringe is a sonic irrigation system used to irrigate and activate the irrigant at same time
62575075|NCT02792543|EXPERIMENTAL|chyme reinfusion|Chyme reinfusion consists of continuously reinfusing the chyme collected from the proximal small bowel segment via the enterostomy, and into the diverted distal small bowel segment. It implies the use of the Entéromate™ pump.
62575076|NCT01905020|ACTIVE_COMPARATOR|Conventional insulin pump therapry|Subjects will use conventional pump therapy to regulate their glucose levels.
62575077|NCT01905020|ACTIVE_COMPARATOR|Single-hormone closed-loop system|Variable subcutaneous insulin infusion rate will be used to regulate glucose levels. Insulin Aspart (Novorapid) will be infused using a subcutaneous infusion pump. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer-generated recommendations of infusion rates.
62196421|NCT02849470|ACTIVE_COMPARATOR|ARM 2|"1. Experimental: HD-PRP + Emulsified AD-tSVF;~   Intervention:~2. Platelet Rich Plasma~3. Adipose Derived Stem/Stromal Cells~4. Intradermal injections of hair loss"
62196422|NCT02849470|EXPERIMENTAL|ARM 3|"Experimental: HD- PRP + Emulsified AD-tSVF + Emulsified AD-cSVF; Intervention: Intradermal injections of hair loss~1. Platelet Rich Plasma~2. Adipose Derived Stem/Stromal Cells~3. Stem/Stromal Cell Isolation~4. Intradermal injections of hair loss"
62196423|NCT02015988|EXPERIMENTAL|Simvastatin and Fenofibrate|Simvastatin 40 mg once daily and fenofibrate 145 mg once daily orally for 52 weeks (1 year)
62196424|NCT02015988|ACTIVE_COMPARATOR|Simvastatin|Simvastatin 40 mg once daily orally for 52 weeks (1 year)
62196425|NCT00548743|EXPERIMENTAL|1|Intervention arm
62196426|NCT00548743|PLACEBO_COMPARATOR|2|Usual care
62196427|NCT04012619|EXPERIMENTAL|Anlotinib Hydrochloride Combined With AP|Patients receive pemetrexed (500mg/m2) with cisplatin (75mg/m2)/carboplatin (area under the curve 5) once every 3 weeks, and anlotinib (dose escalation) once daily on days 1-14 of a 21-day cycle. Anlotinib with AP will be administrated up to 4 cycles followed by maintenance treatment with anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle until disease progression or treatment intolerance.
62196428|NCT00609947|EXPERIMENTAL|Endeavor Zotarolimus-Eluting Coronary Stent|Zotarolimus-eluting stent (ZES) implanted using standard percutaneous coronary intervention (PCI) technique via the femoral approach
62575078|NCT01905020|ACTIVE_COMPARATOR|Dual-hormone closed-loop system|Insulin Aspart (Novorapid) and glucagon (Paladin) will be infused using two separate subcutaneous infusion pumps. The glucose levels as measured by the real time sensor will be entered manually into the computer every 10 minutes. The pumps' infusion rate will then be changed manually based on the computer generated-recommendation delivery levels.
62575079|NCT02564900|EXPERIMENTAL|Part 1 Dose escalation|Part 1 is a dose escalation to identify the Maximum Tolerated dose (MTD) or the recommended phase 2 dose of DS-8201a guided by the modified continuous reassessment method using a Bayesian logistic regression model following escalation with overdose control principal.
62575080|NCT02564900|EXPERIMENTAL|Part 2 Dose expansion|Part 2 is a dose expansion to examine the safety and efficacy of DS-8201a and it is consist of multiple cohorts: in subjects with trastuzumab emtansine (T-DM1)-treated HER2 overexpressing breast cancer (Part 2a); trastuzumab-treated HER2 overexpressing gastric or gastroesophageal junction adenocarcinoma (Part 2b); HER2 low expressing breast cancer (Part 2c), HER2 expressing other solid malignant tumor (Part 2d); HER2 expressing breast cancer (Japan only; Part 2e)
62575081|NCT05680220|EXPERIMENTAL|Active Neurostimulation System (NSS)|Exposure to the NSS device set to 40 Hz invisible spectral flicker 1 hour a day
62575082|NCT05680220|PLACEBO_COMPARATOR|Sham Neurostimulation System (NSS)|Exposure to the NSS device set to continuous color-matched white light for 1 hour a day
62575083|NCT02110758||Pilot Practices Patient Survey Cohort|Patients with any active drug therapy treatment for cancer receiving care at pilot practice in southeastern Pennsylvania
62575084|NCT02110758||Comparison Practices Patient Survey Cohort|Patients with any active drug therapy treatment for cancer receiving care at comparison practice in southeastern Pennsylvania
62575085|NCT02110758||Pilot Practices Utilization Cohort|Patients with an evaluation \& management claim attributed to a medical oncology pilot practice in southeastern Pennsylvania
62575086|NCT02110758||Comparison Practices Utilization Cohort|Patients with an evaluation \& management claim attributed to a medical oncology comparison practice in southeastern Pennsylvania
62575087|NCT02110758||Pilot Practices Quality Measures Cohort|Patients with a new diagnosis of cancer in the past two years
62575088|NCT02744430|ACTIVE_COMPARATOR|Arm 1 - Active|Mirabegron 50 mg orally once every 24 hours starting immediately
62575089|NCT02744430|PLACEBO_COMPARATOR|Arm 2 - Placebo|Placebo orally once every 24 hours starting immediately
62399172|NCT05338905|ACTIVE_COMPARATOR|Group B (standard symptom management)|Patients receive standard symptom management QW during standard of care radiation therapy and for 6 months after completing radiation therapy course.
62575090|NCT01270984|EXPERIMENTAL|Luckyvec 400mg film coated tablet|400mg/tablet, PO, 1 tablet once daily for Period I \& II D1(crossover)
62575091|NCT01270984|ACTIVE_COMPARATOR|Glivec 100mg film coated tablet|100mg/tablet, PO, 4 tablets once daily for Period I \& II D1(crossover)
62010086|NCT04692246|EXPERIMENTAL|Test Group|Patients that will receive the application of the extract in form of irrigation solutions in the periodontal pockets during regular periodontal treatment. Patients would continue at home during the follow-up period, taking the essential oils in as a rinse twice per day, and as a spray when regular toothbrush could not be performed.
62010087|NCT04692246|PLACEBO_COMPARATOR|Control Group|Patients that will follow the same protocol, but using placebo irrigation and a placebo spray at home.
62010088|NCT00901329|EXPERIMENTAL|1: Gender prosthesis|
62010089|NCT00901329|ACTIVE_COMPARATOR|2: LPS flex prosthesis|
62575092|NCT01820117||Hodgkin lymphoma|"Participants previously treated at St. Jude Children's Research Hospital with thoracic radiation therapy for Hodgkin lymphoma.~Interventions: Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Comprehensive Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, and Ophthalmology Examination."
62010090|NCT00739336|EXPERIMENTAL|A, 1|Intervention: Immediate 3 month program
62010091|NCT00739336|NO_INTERVENTION|A, 2|Wait-List Control
62196429|NCT01183390|EXPERIMENTAL|Investigational Test Product|Anastrozole 1 mg Tablets
62196430|NCT01183390|ACTIVE_COMPARATOR|Reference Listed Drug|Arimidex® 1 mg Tablets
62399173|NCT02285673|EXPERIMENTAL|Umbilical Cord Mesenchymal Stem Cell|
62399174|NCT02258893|EXPERIMENTAL|NO2 Scrubber, then HEPA filter, then Control|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of NO2 Scrubber, then HEPA filter, then Control.
62399175|NCT02258893|EXPERIMENTAL|NO2 Scrubber, then Control, then HEPA filter|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of NO2 Scrubber, then Control, then HEPA filter
62575093|NCT01820117||Normal control|"A group of healthy individuals matched for age, sex and race.~Interventions: Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Comprehensive Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, and Ophthalmology Examination."
62575094|NCT03805035|SHAM_COMPARATOR|sham EA group|Minimal needling at ST36 and GB34 (n=10)
62575095|NCT03805035|EXPERIMENTAL|true EA group|EA at ST36 and GB34 (n=10)
62575096|NCT03805035|ACTIVE_COMPARATOR|EA+antihistamine(low dose) group|EA at ST36 and GB34 plus low-dose chlorpheniramine( Dexchlorpheniramine maleate 2mg/tab, 1 tab; n=10)
62575097|NCT03805035|ACTIVE_COMPARATOR|EA+antihistamine(high dose) group|EA at ST36 and GB34 plus high-dose chlorpheniramine (Dexchlorpheniramine maleate 2mg/tab, 2 tabs; n=10)
62575098|NCT03306628|EXPERIMENTAL|Early Laser Therapy|a group which will receive laser therapy to one breast incision at the first post-operative visit
62575099|NCT03306628|EXPERIMENTAL|Late Laser Therapy|a group which will receive laser therapy to one breast incision 6 weeks after surgery
62575100|NCT00685204|EXPERIMENTAL|A|This is a non-random, multicenter, open label, single agent study. Patients with mailgnanat mesothelioma that has reccured or progressed following chemotherapy, and who qualify for this study, will receive oral milataxel.
62575101|NCT01509560|EXPERIMENTAL|Everolimus|All patients will be given everolimus and the magnitude of the side effects will be measured
62575102|NCT05852275|EXPERIMENTAL|Olive oil arm|Participants will include, in their usual diet, the daily intake of 30 mL of an olive oil rich in polyphenols (intervention group) for 100 days. At the beginning (day 1), in the middle (between days 50 and 60) and at the end of the intervention period (day 100), participants will be evaluated.
62575103|NCT00150488|EXPERIMENTAL|1|Uracyst® single arm open label Treatment Group
62575104|NCT05281718|EXPERIMENTAL|Patient Group|In vitro spiking experiments will be realized in plasmas from patients with severe haemophilia A on emicizumab using increasing concentrations of factor IX (rFIX), Activated prothrombin complex (aPCC) and recombinant VIIa (rFVIIa).
62196431|NCT06456489|EXPERIMENTAL|pulse steroid solumedrol|125 mg of methylprednisolone IV pulse will be administered for two consecutive days followed by oral steroid for 2 weeks with gradual withdrawal.
62399176|NCT02258893|EXPERIMENTAL|HEPA filter, then NO2 scrubber, then Control|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of HEPA filter, then NO2 scrubber, then Control
62575105|NCT01957098|PLACEBO_COMPARATOR|0% pentose|Pure sucrose without pentoses added.
62575106|NCT01957098|ACTIVE_COMPARATOR|4% D-xylose|Sucrose drink supplemented with 4% D-xylose
62575107|NCT01957098|ACTIVE_COMPARATOR|8% D-xylose|Sucrose drink supplemented with 8% D-xylose
62575108|NCT01957098|ACTIVE_COMPARATOR|8% L-arabinose|Sucrose drink supplemented with 8% L-arabinose
62575109|NCT02028260|ACTIVE_COMPARATOR|Modafinil|Modafinil 200 mg qAM enterally for the duration the patient is confirmed to be in a hypoactive delirium to a maximum of 14 days.
62575110|NCT02028260|PLACEBO_COMPARATOR|Placebo|normal saline
62575111|NCT05545163|NO_INTERVENTION|I-gel with standard insertion technique|in this arm, trainees performed the standard I-gel insertion technique
62575112|NCT05545163|EXPERIMENTAL|Modified jaw thrust I-gel insertion technique|in this arm, trainees performed modified jaw thrust insertion technique
62196432|NCT06456489|PLACEBO_COMPARATOR|without pulse|patients will not receive any additional treatment
62196433|NCT00855855||Hib vaccine|Participants has received at least one dose of an Hib vaccine
62399177|NCT02258893|EXPERIMENTAL|HEPA filter, then Control, then NO2 scrubber|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of HEPA filter, then Control, then NO2 scrubber
62399178|NCT02258893|EXPERIMENTAL|Control, then HEPA filter, then NO2 scrubber|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of Control, then HEPA filter, then NO2 scrubber
62399179|NCT02258893|EXPERIMENTAL|Control, then NO2 scrubber, then HEPA filter|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of Control, then NO2 scrubber, then HEPA filter
62399180|NCT03230539|EXPERIMENTAL|UPA IUS 20 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
62575113|NCT04782297||Titan HD Catheter|The Titan HD Catheter is a double lumen catheter that provides 2 dedicated (arterial/venous) access lumens. Each lumen is connected through an extension line with female luer connectors. The arterial and venous catheter lumens connect to a hub to facilitate connection of extension tubes with clamps intended to prevent air/fluid communication and control fluid flow through the catheter. At the proximal end of the extension tubes are female Luer fittings to provide a needleless connection. The clamps and the sleeves are color-coded red for the arterial lumen and blue for the venous lumen. Each catheter has a cuff which is intended to be positioned underneath the skin at the skin exit to aid in securing the catheter and to provide a barrier to minimize the risk of infection. Each lumen is connected through an extension line with female Luer connectors. The transition between lumen and extension is housed within a molded hub.
62399181|NCT03230539|EXPERIMENTAL|UPA IUS 5 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks
62196434|NCT04253938|OTHER|Education|"Visit 1 - Parent/Caregiver will complete a questionnaire about breastfeeding/formula feeding practices and food insecurity. The questionnaire includes a nutrition history, asking how much formula is consumed, number of times they are breastfed per day, what types and amounts of solid foods are consumed, and if vitamins and/or iron drops are given (including frequency and amount). After the questionnaire, the participant will be asked to demonstrate how they typically prepare infant formula. Finally, the PI or designee will provide a brief education about appropriate feeding practices as recommended by the AAP. This will include appropriate formula preparation methods, use of juice, introduction of cow's milk and solids, as well as basic nutrition information.~Visit 2 - If the family returns for a clinic visit again before the child turns 1 year of age, the same procedures as Visit 1 will be performed, including reinforcement of education."
62196435|NCT04489953|ACTIVE_COMPARATOR|Clinical and Immunologic criteria|In the clinical and immunologic monitoring criteria was based on the 2010 WHO guidelines. Whereby children were monitored using clinical presentation and CD4 count to define treatment failure.
62196436|NCT04489953|ACTIVE_COMPARATOR|Clinical, Immunologic and Virologic criteria|In the Clinical, Immunologic and Virologic criteria was based on a confirmed viral load of \> 1000 HIV RNA copies/ml; as well as clinical and immunologic criteria
62399182|NCT03230539|EXPERIMENTAL|UPA IUS 40 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks
62399183|NCT04532749|EXPERIMENTAL|Seltorexant|Participants will receive Seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6).
62399184|NCT04532749|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo tablets orally once daily from Day 1 to Day 42 (until the end of Week 6).
62399185|NCT02190994|NO_INTERVENTION|A. Normal function, non-GC replacement|No glucocorticoid replacement will be given perioperatively.
62399186|NCT02190994|ACTIVE_COMPARATOR|B. Normal function, low-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1. 80mg hydrocortisone at day 2; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet at day 4 and day 5; 2.5mg at day 6;
62575114|NCT04782297||Hemo-Flow Catheter|The Hemo-Flow® Catheter has two lumens (one arterial lumen, one venous lumen) comprised of a biocompatible polymeric material that contains radiopaque filler to allow radiographic imaging of the distal tips to ensure proper placement into the superior vena cava. The arterial lumen is utilized to withdraw blood from the patient and the venous lumen returns the blood to the patient after treatment
62575115|NCT04481269|EXPERIMENTAL|Research Group|Research group uses surface-modified composite coated orthopedic implants
62575116|NCT04481269|ACTIVE_COMPARATOR|Controls Group|Controls group uses conventional orthopedic implants
62575117|NCT04650880|ACTIVE_COMPARATOR|Vitamin D|Vitamin D 50,000 IU/ week for 4 weeks, followed by 50,000 IU once every 2 weeks for 52 weeks Those who remain anovulatory after 6 months will be treated with a 6-month course of letrozole (2.5mg to 7.5mg for 5 days per cycle titrated according to response) for ovulation induction.
62575118|NCT04650880|PLACEBO_COMPARATOR|Placebo|Placebo tablets with same external appearance for 52 weeks Those who remain anovulatory after 6 months will be treated with a 6-month course of letrozole (2.5mg to 7.5mg for 5 days per cycle titrated according to response) for ovulation induction.
62575119|NCT02385838|EXPERIMENTAL|5-Color Nutrition Label (5-CNL)|The 5-CNL front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
62575120|NCT02385838|EXPERIMENTAL|Mutiple Traffic Lights (MTL)|The MTL front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
62575121|NCT02385838|EXPERIMENTAL|Guidelines Daily Amounts (GDA)|The GDA front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
62575122|NCT02385838|EXPERIMENTAL|Green Tick (Tick)|The Tick front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
62399187|NCT02190994|ACTIVE_COMPARATOR|C. Impaired function, low-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1. 80mg hydrocortisone at day 2; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet at day 4 and day 5; 2.5mg at day 6;
62399188|NCT02190994|ACTIVE_COMPARATOR|D. Impaired function, high-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1 and day 2. 60mg hydrocortisone at day 3; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet per day, since postoperative day 3.
62010092|NCT01843959||Emirati Population|"The individuals enrolled in this study will be divided into children (5-16 years of age) and adults (above 18). The groups will be further divided into BMI categories and glucose tolerance groups.~\* Group 1: Underweight (adjusted BMI \<10th percentile) and no diabetes~* Group 2:~Normal weight (adjusted BMI 10th to 84.9th percentile) and no diabetes~* Group 3:~Overweight or obese children (adjusted BMI \>= 85th percentile) and no diabetes~* Group 4:~Normal weight (adjusted BMI 10th to 84.9th percentile) and T1DM~* Group 5:~Overweight or obese children (adjusted BMI ≥ 85th percentile) and T1DM~* Group 6:~Normal weight (adjusted BMI 10th to 84.9th percentile) and T2DM~* Group 7:~Overweight or obese children (adjusted BMI ≥ 85th percentile) and T2DM"
62010093|NCT05294263|EXPERIMENTAL|Varenicline|Varenicline will be provided at the standard recommended dose of 0.5mg daily for three days, then 0.5mg twice daily for four days, and then 1mg twice daily for the remainder of the 12-week treatment period.
62010094|NCT05294263|PLACEBO_COMPARATOR|Placebo|Matching placebo will be administered over the 12-week period.
62010095|NCT00612313|ACTIVE_COMPARATOR|Continued medication alone|Participants will receive antidepressant treatment with fluoxetine for 30 weeks
62399189|NCT05269225|EXPERIMENTAL|Organic diet|Consuming organic food from the start of 2nd trimester and until gestational week 37.
62010096|NCT00612313|EXPERIMENTAL|Continued medication plus CBT|Participants will receive antidepressant treatment with fluoxetine for 30 weeks plus relapse prevention cognitive behavioral therapy for the last 24 weeks of treatment
62196437|NCT01613144||OsseoScrew|Test Product: OsseoScrew Spinal Fixation System
62575123|NCT02385838|NO_INTERVENTION|No label|No front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
62196438|NCT01613144||Fenestrated Screw|Control Product: Any commercially available fenestrated screw system augmented with PMMA
62010097|NCT05167344|EXPERIMENTAL|Healthy Relationships Program-Enhanced (HRP-E)|Youth participating in the HRP-E and facilitators delivering in the program
62196439|NCT02227992|EXPERIMENTAL|EVARREST™ Sealant Matrix|EVARREST™ Sealant Matrix/Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
62196440|NCT02227992|ACTIVE_COMPARATOR|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
62399190|NCT05269225|PLACEBO_COMPARATOR|Conventional diet|Consuming conventional food throughout the whole pregnancy.
62575124|NCT02298777||Scleroderma (SSc) patients (beginners and established forms).|"Patients with the ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001)~Biological samples (skin, urine and blood):~* 1st point at patient's inclusion visit~* 2nd point (optional) at SSc patient's visceral complication (assessed during 3 years)"
62010098|NCT06216951||Patients with symptomatic pulpitis|vital permanent molars with symptomatic pulpitis in patients aged between 7-70
62399191|NCT06509880|ACTIVE_COMPARATOR|Chemotherapy according to the FOLFOX regimen in combination with sodium nucleonate|Рatients with metastatic colorectal cancer (stages T3-4 N1-2 M), receiving four courses of FOLFOX chemotherapy (Day 1-2: Oxaliplatin 100 mg/m2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m2 (or levoleucovorin 200 mg/m2) IV infusion, followed by 5-FU 400 mg/m2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m2 for first two cycles, and may be increased to 3000 mg/m2 if tolerated by patient (no toxicity \> grade 1 during the first two cycles), days 3-14: Rest days) combined with mitochondrial immunotherapy using sodium nucleinate. The medical rehabilitation protocol involved administering sodium nucleinate at 50 mg per day: 25 mg in the morning and 25 mg at lunch before meals, daily for four months.
62196441|NCT05911178|EXPERIMENTAL|Early Onset Alzheimer's Disease (EOAD)|"Patients who have been diagnosed with AD according to clinical and biomarker criteria. Early onset AD is considered as having an age of onset of symptoms younger than 65 years.~Age of onset ≤ 65 years"
62399192|NCT06509880|SHAM_COMPARATOR|Chemotherapy according to the FOLFOX regimen|Рatients with metastatic colorectal cancer (stages T3-4 N1-2 M), who received only four courses of FOLFOX chemotherapy (Day 1-2: Oxaliplatin 100 mg/m2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m2 (or levoleucovorin 200 mg/m2) IV infusion, followed by 5-FU 400 mg/m2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m2 for first two cycles, and may be increased to 3000 mg/m2 if tolerated by patient (no toxicity \> grade 1 during the first two cycles), days 3-14: Rest days). In both groups, general and biochemical blood analyses were conducted monthly
62575125|NCT02298777||Undifferentiated Connective Tissue Disease (UCDT) patients|"Patients with criteria proposed by Mosca et al. (1998)~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
62010099|NCT03064126|EXPERIMENTAL|RANGER™ Paclitaxel Coated Balloon|"RANGER™ Paclitaxel Coated Balloon Catheter angioplasty in the SFA/PPA at the index procedure.~Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon."
62010100|NCT03064126|ACTIVE_COMPARATOR|Standard Balloon Angioplasty|Standard Balloon Catheter angioplasty in the SFA/PPA at the index procedure. Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon.
62010101|NCT04388332|ACTIVE_COMPARATOR|Retrospective|40 patients that received one or two level ACDF structural allograft with plates with autograft and /or allograft comprised of cancellous and/or corticocancellous bone chips.
62010102|NCT04388332|EXPERIMENTAL|Prospective|20 patients who are receiving Tritanium C as standard of care.
62010103|NCT03285477|PLACEBO_COMPARATOR|Placebo|Vehicle Ointment was applied topically once daily for 5 consecutive days on face or scalp
62010104|NCT03285477|EXPERIMENTAL|KX2-391 Ointment 1%|KX2-391 Ointment 1% was applied topically once daily for 5 consecutive days on face or scalp
62010105|NCT01462903|EXPERIMENTAL|Drug, T cell immunoterhapy|
62010106|NCT05389592|EXPERIMENTAL|Double-active|Active transcranial electrical stimulation and cognitive training.
62010107|NCT05389592|SHAM_COMPARATOR|Cognitive training-only|Sham transcranial electrical stimulation and cognitive training.
62010108|NCT01372436||1|children in high-school
62010109|NCT01372436||2|children in primary school
62010110|NCT04035772|EXPERIMENTAL|Wiki101 and WikiTrauma|"Wiki101, a theory-based continuing professional development (CPD) program, will train participants at the selected trauma centers to use WikiTrauma effectively and safely to create and share different types of Knowledge Transfer (KT) tools (e.g., care protocols, order sets, patient decision aids). Participants will receive Wiki101 training and then gain access to WikiTrauma with editing rights to the knowledge implementation tools (e.g. care protocols, order sets, care pathways) found in the wiki.~WikiTrauma is the wiki we created to promote best practices in trauma care and will be implemented in four trauma centers in Quebec during 12 months. During this period, we will continue to measure the impact on the quality of care."
62010111|NCT02653196|EXPERIMENTAL|Allogeneic Hematopoietic Stem Cell Transplant|"Matched Unrelated Donor HSCT (minimum 9/10 human leukocyte antigen \[HLA\] match) OR Matched Related Donor HSCT (10/10 HLA match). Conditioning regimen begins 12 days prior to stem cell infusion and includes the following drugs:~Keratinocyte Growth Factor Alemtuzumab Thiotepa Etoposide Melphalan Fludarabine Tacrolimus (Cyclosporine A may be substituted for Tacrolimus) Mycophenolate mofetil"
62010112|NCT05381792||Known colorectal advanced neoplasia group|Subjects with known colorectal advanced neoplasia and requiring endoscopic resection
62010113|NCT03063359|EXPERIMENTAL|Intranasal fentanyl + Oral placebo|Administration of intranasal fentanyl (1.5µg/kg) and oral placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
62010114|NCT03063359|ACTIVE_COMPARATOR|Oral morphine + Intranasal placebo|Administration of oral morphine (0.4mg/kg) and intranasal placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
62010115|NCT03515460|EXPERIMENTAL|sugar oral load|oral ingestion of a high carbohydrate meal
62010116|NCT03515460|EXPERIMENTAL|fat oral load|oral ingestion of a high fat meal
62010117|NCT03515460|EXPERIMENTAL|sugar and fat oral loads|oral ingestion of a high carbohydrate and fat meal
62010118|NCT01243385|OTHER|Metformin|Metformin at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
62010119|NCT04642703||COVID-19 ventilated patients subjected to tracheostomy|Patients who receive percutaneous or surgical tracheostomy due to prolonged mechanical ventilation. The indication is made by an experts team and based on national guidelines
62010120|NCT04642703||COVID-19 ventilated patients without tracheostomy|Patients supported with mechanical ventilation by 10 days or more in who an experts team of physicians decided do not perform a tracheostomy
62196442|NCT05911178|EXPERIMENTAL|Late Onset Alzheimer's Disease (LOAD)|"Patients who have been diagnosed with AD according to clinical and biomarker criteria. Late onset AD is considered as having an age of onset of symptoms older than 65 years.~Age of onset \> 65 years"
62196443|NCT05911178|EXPERIMENTAL|Controls|Healthy control subjects will be matched to patients for age and education level.
62196444|NCT05371366|EXPERIMENTAL|Experimental group|Patients with ASD assigned to experimental group will receive the novel ASD occluder (ReAces)
62196445|NCT05371366|ACTIVE_COMPARATOR|Control Group|Patients with ASD assigned to control group will receive the normal occluder
62196446|NCT05624671|OTHER|IS THERE ANY ROLE OF OVERACTIVE BLADDER IN POSTSPINAL HYPOTENSION IN ELECTIVE CAESAREAN SECTIONS?|According to our institution protocol, intravenous (iv) hydration will not be given as preload and afterload and vasopressor infusion will not be initiated before spinal anesthesia. After the skin is prepared sterile and local infiltration with 2% lidocaine is done, from L3-L4 OR L4-L5 range on midline with the 16 gauge Tuohy needle and the loss of resistance technique epidural space is identified and then 26 gauge pencil point needle is passed trough the Touhy and the dura will be drilled. After the cerebrospinal fluid (CSF) is seen the fluid containing 5mg isobaric bupivacaine and 15µg fentanyl will be given in 30 seconds to patients. After the spinal needle is removed, the epidural catheter is placed 3-5 cm in the epidural space through Tuohy, and after the catheter is fixated, the patients will be placed in the supine position by placing a height under their right hip with a 15 ° angle.
62196447|NCT01989169|ACTIVE_COMPARATOR|Midazolam|Administered as a single oral 6 mg dose on Day 1.
62575126|NCT02298777||Raynaud disease patients|"Patients with primary and isolated Raynaud disease~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
62575127|NCT02298777||Vascular disease patients|"Patients with vascular disease (type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke)~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
62575128|NCT02298777||Healthy control subjects|"Healthy subjects (no sign of connective tissue disease, no Raynaud, no vascular disease)~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
62575129|NCT02819973|EXPERIMENTAL|Educational Video 1|African American/ Black Video
62575130|NCT02819973|EXPERIMENTAL|Educational Video 2|Caucasian Video
62575131|NCT02819973|EXPERIMENTAL|Usual Care (no video) 3|Standard Care/ No video
62575132|NCT04890197|ACTIVE_COMPARATOR|tahini|48 gr per day
62575133|NCT04890197|PLACEBO_COMPARATOR|control|no intervention
62575134|NCT04132869|EXPERIMENTAL|Experimental Group|In Spring of 2020, all 6th graders in Wave 1 intervention schools (6 schools), which include 561 total 6th graders, will be invited to participate the intervention. Those in the experimental group will complete all measures according to the timeline. Those not in the experimental group will also complete the intervention, but will not participate in measurements. In Fall 2020 all 6th graders who attend the Wave 2 intervention schools (schools that were the control schools in Spring), will be invited to participate the intervention. Those in the experimental group will complete all measures on schedule. \*Note these activities were delay due to schools shutting down in March 2020 because of COVID-19 In Fall 2021 all 6th graders who attend the Wave 3 intervention schools, will be invited to participate the intervention. Those in the experimental group will complete all measures on schedule.
62575135|NCT04132869|NO_INTERVENTION|Control group|Wave 1 comparison schools (2 Schools) have a total of 267 6th graders. Students will be invited to join the comparison group. and will have measurements taken at baseline and 6 months. Wave 2 comparison schools (3 Schools) have a total of 363 6th graders adn will be invited to join the comparison group and will have measurements taken at baseline and 6 months. These students will continue with their normal activities as usual.\*Note these activities were delay due to schools shutting down in March 2020 because of COVID-19
62196448|NCT01989169|EXPERIMENTAL|SSP-004184SS + Midazolam|Midazolam (6 mg) + SSP-004184SS (30 mg/kg) concomitantly administered as a single oral dose on Day 1.
62196449|NCT01234415|EXPERIMENTAL|Patient|
62196450|NCT03317847|EXPERIMENTAL|Bromfenac|Patients randomized to this arm will receive Bromfenac 0.09 % Ophthalmic Solution BID for 2 weeks
62399193|NCT02454621|ACTIVE_COMPARATOR|Control|"Participants read a brief statement designed to encourage them to quit smoking (We want you to plan to quit smoking). Participants are presented with a table with two columns and twenty rows. Twenty critical situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to smoke and identifying ways to overcome those temptations had been shown to promote smoking cessation and are asked to tick critical situations/appropriate responses that might be useful to them."
62575136|NCT01998802|ACTIVE_COMPARATOR|Active Comparator: EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day.
62575137|NCT01998802|PLACEBO_COMPARATOR|Placebo Comparator|One of two study arms: placebo topical administered 3 times per day.
62575138|NCT04527718|EXPERIMENTAL|Cohort 1|611 dose 1 (45mg) plus placebo
62575139|NCT04527718|EXPERIMENTAL|Cohort 2|611 dose 2 (150mg) plus placebo
62575140|NCT04527718|EXPERIMENTAL|Cohort 3|611 dose 3 (300mg) plus placebo
62575141|NCT04527718|EXPERIMENTAL|Cohort 4|611 dose 4 (450mg) plus placebo
62575142|NCT04527718|EXPERIMENTAL|Cohort 5|611 dose 5 (600mg) plus placebo
62575143|NCT06270381|EXPERIMENTAL|Arm 1|Participants that receive EMPOWER intervention
62575144|NCT06270381|ACTIVE_COMPARATOR|Arm 2|Participants that receive treatment as usual (TAU) intervention
62575145|NCT01948440|EXPERIMENTAL|ASI-MV Solutions|The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions. The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
62575146|NCT01948440|NO_INTERVENTION|Treatment as Usual|The Control group participants will complete the ASI-MV and receive their normal course of treatment. The Control group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
62575147|NCT03117660|EXPERIMENTAL|Vitamin A|Subjects will receive 3-4weeks of vitamin A
62575148|NCT03117660|NO_INTERVENTION|Control|Subjects will receive no treatment
62575149|NCT00826683|OTHER|Control group of healthy subjects|Control group of healthy subjects : simple blood analysis of EPCs
62575150|NCT00826683|ACTIVE_COMPARATOR|COPD|COPD: one initial blood sample and simple clinical follow-up
62575151|NCT00826683|ACTIVE_COMPARATOR|NSCLC|NSCLC: one initial blood sample and usual clinical follow-up
62575152|NCT00595855|ACTIVE_COMPARATOR|TE|trabeculectomy
62575153|NCT00595855|EXPERIMENTAL|DS|deep sclerectomy
62399194|NCT02454621|EXPERIMENTAL|Volitional help sheet|"Participants read a brief statement designed to encourage them to quit smoking (We want you to plan to quit smoking). Participants are presented with a table with two columns and twenty rows. Twenty critical situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to smoke and identifying ways to overcome those temptations had been shown to promote smoking cessation. Implementation intentions are formed by linking critical situations with appropriate responses by drawing lines between critical situations and appropriate responses."
62399195|NCT06723639|EXPERIMENTAL|NEWSUR|Participants in this group will receive a new two-layer surgical technique followed by a detailed rehabilitation regime.
62575154|NCT04145050|EXPERIMENTAL|Carbohydrate Dose: 0 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
62575155|NCT04145050|EXPERIMENTAL|Carbohydrate Dose: 30 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
62575156|NCT04145050|EXPERIMENTAL|Carbohydrate Dose: 60 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
62575157|NCT01586923|ACTIVE_COMPARATOR|Short-storage RBC|RBC transfusion using packed RBCs stored for 10 days or less.
62010121|NCT04112693|EXPERIMENTAL|Esophageal biopsies during POEM|"In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies for histopathological analysis will be analyzed in Full Field Optical Coherence Tomographie (FFOCT) before that. The FFOCT analysis take place for patient inclued after than 10 nov 2020.~The biopsies are taken by the gastroenterologist who performs the POEM assisted by an endoscopy-specialized nurse."
62399196|NCT06723639|OTHER|CONSER|Participants in this group will receive standard non-surgical treatment followed by a detailed rehabilitation regime.
62399197|NCT01979640|EXPERIMENTAL|39 Fr double lumen group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
62399198|NCT01979640|EXPERIMENTAL|37 Fr double lumen group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
62575158|NCT01586923|ACTIVE_COMPARATOR|Prolonged-storage RBC|RBC transfusion using packed RBCs stored for 25 days or more.
62399199|NCT01979640|EXPERIMENTAL|35 Fr double lumen tube group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
62399200|NCT05223504||Observed patients|Adult patients (≥18 years) admitted with an acute medical disease and who are scheduled for discharge to their own homes within five days from inclusion.
62399201|NCT05834244|EXPERIMENTAL|Dose Escalation|Dose Escalation to evaluate the combination of azacitidine, venetoclax and allogeneic NK cells in older/unfit participants with AML ineligible for intensive chemotherapy or allogeneic stem-cell transplantation (allo SCT).
62399202|NCT05834244|EXPERIMENTAL|Dose Expansion|Dose Expansion to evaluate the combination of azacitidine, venetoclax and allogeneic NK cells in older/unfit participants with AML ineligible for intensive chemotherapy or allogeneic stem-cell transplantation (allo SCT).
62575159|NCT04894214||"Sequential baseline PCV - FCV - VCV"|Each participant will be subjected to baseline pressure controlled ventilation (PCV) during 5 minutes, followed by 30 minutes of FCV with an evone respirator (Ventinova Medical B.V., Eindhoven, The Netherlands) and eventually 30 minutes of VCV. Respiratory rate (RR), positive end-expiratory pressure (PEEP) and inspiratory fraction of oxygen (FiO2) will be held constant. According to the manufacturers guidelines, an I:E ratio of 1:1 will be pursued during FCV. During FCV, the respirator will be set with the same PIP as during baseline PCV. For VCV, the same tidal volume as during baseline PCV will be set.
62575160|NCT00781040||Neutropenic patients|Adult AML and ASCT patients with neutropenic fever.
62575161|NCT03640390|EXPERIMENTAL|Dexmedetomidine group|This group will receive dexmedetomidine infusion at a rate of 0.5 mcg/kg/hour
62575162|NCT03640390|ACTIVE_COMPARATOR|Magnesium Sulphate group|This group will receive Magnesium Sulphate infusion at a rate of 15 mg/Kg/hour
62575163|NCT03640390|PLACEBO_COMPARATOR|Saline group|This group will receive normal saline infusion
62575164|NCT00516672|EXPERIMENTAL|Arm 1|Pazopanib monotherapy or in combination with lapatinib
62575165|NCT03207048|EXPERIMENTAL|Active rTMS|10 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for 15 mins each time, 5 times per week for up to 6 weeks (interrupt for 1-2 weeks after 10 times).
62575166|NCT03207048|SHAM_COMPARATOR|Sham rTMS|Sham repetitive transcranial magnetic stimulation
62575167|NCT04487379||Group with edentulous ridge|This group had edentulous ridge planning to receive a dental implant and had ultrasound and cone-beam computed tomography images of the ridge.
62575168|NCT02099786|EXPERIMENTAL|COMP-VA|Hearing testing at each treatment and at 1 month following treatment.
62575169|NCT02099786|EXPERIMENTAL|Usual Care|Hearing testing done according to Audiology Clinic protocol
62575170|NCT03443362||Chronic urticaria|50 consecutive chronic urticaria patients receiving medical care within the CHU Brugmann Hospital. Diagnose according to the European Academy of Allergy and Clinical Immunology (EAACI) guidelines.
62196451|NCT03317847|ACTIVE_COMPARATOR|Dexamethasone|Patients randomized to this arm will receive Dexamethasone 0.1 % Ophthalmic Suspension QID for one week and BID for the following week
62196452|NCT02134938|EXPERIMENTAL|Konjac Glucomannan|650g KJM-G
62196453|NCT02134938|EXPERIMENTAL|Half Control/Half Konjac Glucomannan|325g KJM-G
62399203|NCT01938027|EXPERIMENTAL|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
62399204|NCT01558466|PLACEBO_COMPARATOR|Group A - Placebo|iNO combined with placebo will be administered
62399205|NCT01558466|ACTIVE_COMPARATOR|Group B- Sildenafil|iNO combined with Sildenafil
62575171|NCT03443362||Control|20 healthy control patients, without chronic urticaria. Patients coming to the CHU Brugmann hospital for the excision of atypical naevi.
62575172|NCT05650177|EXPERIMENTAL|Receiving intervention.|Patients with persistent depression who are receiving the intervention.
62575173|NCT02586038|EXPERIMENTAL|MLN-DEX-CYCLO arm|"Patients will receive nine 28-days induction cycles.~MLN9708: 4,0 mg orally on days 1, 8, 15 Dexamethasone: 40 mg orally on days 1, 8, 15, 22. Cyclophosphamide: 300 mg/sqm orally on days 1, 8, 15"
62575174|NCT02586038|EXPERIMENTAL|MLN-DEX-THAL arm|"Patients will receive nine 28-days induction cycles.~MLN9708: 4,0 mg orally on days 1, 8, 15 Dexamethasone: 40 mg orally on days 1, 8, 15, 22. Thalidomide: 100 mg/day orally"
62010122|NCT01516268|ACTIVE_COMPARATOR|Sufentanyl group|IN case group we add 1cc sufentanyl to 20 cc bupivacain in TAP block
62010123|NCT01516268|PLACEBO_COMPARATOR|Control group|In control group we add 1cc salin to 20cc bupivacain in TAP block
62010124|NCT02927691|EXPERIMENTAL|Immediate Treatment|Participants will begin treatment immediately following baseline testing.
62010125|NCT02927691|OTHER|Delayed Treatment|Following baseline testing, participants will receive no treatment for five weeks, then begin treatment immediately following a second baseline testing session.
62010126|NCT01645475|EXPERIMENTAL|Desmopressin lyophilisate (Melt)|Patients receiving Desmopressin lyophilisate (Melt).
62010127|NCT06662578|NO_INTERVENTION|Control group|
62010128|NCT06662578|ACTIVE_COMPARATOR|Traditional memory workshop|Neurocognitive stimulation as usual
62010129|NCT06662578|EXPERIMENTAL|Equine assisted therapy memory workshop|Neurocognitive stimulation mediated with a horse based on a defined protocol.
62196454|NCT02134938|NO_INTERVENTION|Control|0g KJM-G
62196455|NCT03002298|EXPERIMENTAL|DMD gesture task|Experimental group that made the task using a gesture in front of a webcam
62575175|NCT05188261|EXPERIMENTAL|Cohort 1: 100 μg IW-3300|Dose 1: within the cohort, 6 participants receive active drug (IW-3300)
62010130|NCT05114356||Study group|Patients being treated for degenerative disc disease
62196456|NCT03002298|EXPERIMENTAL|DMD button-press task|Experimental group that made the task pressing the button
62196457|NCT03002298|ACTIVE_COMPARATOR|Control group gesture task|Control group that made the task using a gesture in front of a webcam
62196458|NCT03002298|ACTIVE_COMPARATOR|Control group button-press task|Control group that made the task pressing the button
62196459|NCT03556787|EXPERIMENTAL|Patients with knee pain|Adults patients suffering from osteoarthritis pain or general knee pain
62196460|NCT05454345|EXPERIMENTAL|The three-month Rifapentine&Isoniazid&Pyrazinamide&Sitafloxacin-containing regimen|Thirteen weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and Sitafloxacin.
62196461|NCT05454345|EXPERIMENTAL|The three-month Rifapentine&Isoniazid&Pyrazinamide&Sitafloxacin&SMZ/TMP-containing regimen|Six weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and Sitafloxacin, followed by seven weeks of daily treatment with rifapentine, isoniazid, ,SMZ/TMP and Sitafloxacin.
62399206|NCT05566795|EXPERIMENTAL|Arm #1|Tovorafenib
62575176|NCT05188261|PLACEBO_COMPARATOR|Cohort 1: Placebo|Within the cohort, 2 participants will receive the matching placebo dose
62575177|NCT05188261|EXPERIMENTAL|Cohort 2: 300 μg IW-3300|Dose 2: within the cohort, 6 participants receive active drug (IW-3300)
62575178|NCT05188261|PLACEBO_COMPARATOR|Cohort 2: Placebo|Within the cohort, 2 participants will receive the matching placebo dose
62575179|NCT05188261|EXPERIMENTAL|Cohort 3: 900 μg IW-3300|Dose 3: within the cohort, 6 participants receive active drug (IW-3300)
62575180|NCT05188261|PLACEBO_COMPARATOR|Cohort 3: Placebo|Within the cohort, 2 participants will receive the matching placebo dose
62575181|NCT05188261|EXPERIMENTAL|Cohort 4: 2500 μg IW-3300|Dose 4: within the cohort, 6 participants receive active drug (IW-3300)
62575182|NCT05188261|PLACEBO_COMPARATOR|Cohort 4: Placebo|Within the cohort, 2 participants will receive the matching placebo dose
62575183|NCT01625663||Barth syndrome|Children (8-17 yrs) and adults (18-35 yrs)
62575184|NCT01625663||Controls|Children (8-15 yrs) and adults (18-35 yrs)
62575185|NCT01721096||XIENCE PRIME - Long Length (LL)|Long Lesion Arm patients (n=323) are treated by at least one Long Size stent (28, 33 and 38 mm length).There are no significant difference between both the groups with respect to patient background, ischemic status, risk factors and medical history, numbers of target lesions and the lesion types, target lesion treatment, number of stents implanted, and target lesion characteristics other than lesion lengths.
62575186|NCT01721096||XIENCE PRIME - Core Size|Core Size Arm patients (n=213) are treated with small size stent (8, 12, 15, 18 and 23 mm length). There are no significant difference between both the groups with respect to patient background, ischemic status, risk factors and medical history, numbers of target lesions and the lesion types, target lesion treatment, number of stents implanted, and target lesion characteristics other than lesion lengths.
62575187|NCT06524934|EXPERIMENTAL|Case group|The patients in this group undergo the procedure using virtual reality.
62575188|NCT06524934|NO_INTERVENTION|Control group|The patients in this group undergo the procedure without the use of virtual reality.
62575189|NCT00694083|EXPERIMENTAL|Ridaforolimus|Ridaforolimus (MK-8669), 20 or 40 mg administered orally on Day 1 followed by a washout of at least 6 days, then QD x5 (five consecutive days) followed by a 2-day holiday through Day 28 (Cycle 1), and QD x5 followed by a 2-day holiday for 21 days (Cycle 2 and subsequent cycles).
62575190|NCT04046887|EXPERIMENTAL|Combination of lonsurf + gemcitabine + nab-paclitaxel|
62575191|NCT00501410|EXPERIMENTAL|FOLFOX + Dasatinib + Cetuximab|5-FU 2400 mg/m\^2 by vein over 46 Hours On Days 1 \& 2. Cetuximab initial dose = 400 mg/m\^2 by vein, then 250 mg/m\^2 Weekly On Days 1 \& 8. Dasatinib 100 mg by mouth daily on days 1-14. Leucovorin 400 mg/m\^2 by vein on day 1. Oxaliplatin 85 mg/m\^2 by vein on day 1.
62575192|NCT01112488|NO_INTERVENTION|Control|usual care
62575193|NCT01112488|EXPERIMENTAL|multidisciplinary intervention|Patient engagement Programme
62575194|NCT03745846|EXPERIMENTAL|Composite Gel Containing Black Raspberry|Drug:Composite Gel Containing Black Raspberry 3,000mg Dosage and duration: 1 preparation every other day for 3 months.
62575195|NCT03745846|PLACEBO_COMPARATOR|Composite Gel Containing Black Raspberry-placebo|Drug:Composite Gel Containing Black Raspberry-placebo 3,000mg Dosage and duration: 1 preparation every other day for 3 months.
62575196|NCT05130541|PLACEBO_COMPARATOR|Control|Usual Care
62575197|NCT05130541|EXPERIMENTAL|Proning|Proning, rotating 90 degrees on long axis every 30 minutes - 2 hours
62575198|NCT01718678|ACTIVE_COMPARATOR|Melatonin|Melatonin, Tablet, 3 mg, once, one month
62575199|NCT01718678|PLACEBO_COMPARATOR|Placebo|Placebo, tablet
62575200|NCT03543202|EXPERIMENTAL|Transversus abdominis plane block|will receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia
62575201|NCT03543202|ACTIVE_COMPARATOR|Local infiltration anesthesia|will receive 20ml bupivacaine for Local infiltration anesthesia and intravenous patient controlled analgesia
62575202|NCT03543202|SHAM_COMPARATOR|Intravenous patient control analgesia|will not receive any regional anethetic intervention will receive intravenous patient controlled analgesia
62575203|NCT05413551|EXPERIMENTAL|Rapid acetylator|Participants will receive 1 standard dose (Day 0), followed by 1 higher dose (Day 7), follow by 2 standard doses (Days 14 and 21).
62575204|NCT05413551|ACTIVE_COMPARATOR|Intermediate acetylator|Participants will receive 4 standard doses (Days 0, 7, 14 and 21).
62575205|NCT05413551|EXPERIMENTAL|Slow acetylator|Participants will receive 2 standard doses (Days 0 and 7), followed by 1 lower dose (Day 21), follow by 1 standard dose (Day 21).
62399207|NCT05566795|ACTIVE_COMPARATOR|Arm #2|"Investigator's choice of one of the following current standard of care for pediatric patients with low-grade gliomas:~1. Children's Oncology Group - Vincristine/Carboplatin (COG-V/C)~2. International Society for Paediatric Oncology - Low-Grade Glioma Vincristine/Carboplatin (SIOPe-LGG-V/C)~3. Vinblastine (VBL)"
62399208|NCT02689713|EXPERIMENTAL|Topical Voriconazole Study Drug Group|Subjects between 18 and 60 years old who have sustained a burn wound of less than 30% total body surface area, or traumatic wounds requiring skin graft will have the Topical Voriconazole study drug placed on graft site.
62399209|NCT02689713|PLACEBO_COMPARATOR|Topical Sterile Water Placebo Group|Subjects between 18 and 60 years old who have sustained a burn wound of less than 30% total body surface area, or traumatic wounds requiring skin graft will have the Topical Sterile Water Placebo placed on graft site.
62196462|NCT05454345|ACTIVE_COMPARATOR|The six-month standard Rifampin&Isoniazid&Pyrazinamide&Ethambutol-containing regimen|Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid.
62196463|NCT05454345|ACTIVE_COMPARATOR|The four-month Rifapentine&Isoniazid&Pyrazinamide&Moxifloxacin -containing regimen|Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin.
62575206|NCT04164732|EXPERIMENTAL|LCZ696 BID|Patients were treated with LCZ696. The target dose level was 200 mg p.o. b.i.d.
62196464|NCT04480606|EXPERIMENTAL|Home exercise group|47 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in home exercise group.
62196465|NCT04480606|NO_INTERVENTION|Control Group|The control group will be asked to remain isolated as they are and the exercise program will not be implemented.
62399210|NCT03701971|EXPERIMENTAL|Music Therapy|"* a medical examination~* Before and after music therapy, patients will have to answer questionnaires :~Before :~Questionnaire 5D itch scale Itchy Quality of Life Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~After :~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A) PGIC~• Patients will then benefit from a balneotherapy session the next morning. Patients will have to answer questionnaires before and after balneotherapy :~Before :~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~After :~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A) PGIC"
62399211|NCT03701971|ACTIVE_COMPARATOR|Emollient cream|"* a medical examination~* Before and after music therapy, patients will have to answer questionnaires :~Before :~* Questionnaire 5D itch scale~* Itchy Quality of Life~* Pruritus assessment on the digital scale~* Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~After :~* Pruritus assessment on the digital scale~* Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~* PGIC~  * Patients will then benefit from a balneotherapy session the next morning. Patients will have to answer questionnaires before and after balneotherapy :~Before :~* Pruritus assessment on the digital scale~* Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~After :~* Pruritus assessment on the digital scale~* Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~* PGIC"
62575207|NCT04164732|PLACEBO_COMPARATOR|Placebo BID|Placebo to LCZ696
62575208|NCT02148978|EXPERIMENTAL|Saxagliptin administration|Saxagliptin Administration- The participants in this study will undergo an OGTT (Oral Glucose Tolerance Test) at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin. After 6 weeks of treatment the participants will return to perform a second OGTT.
62575209|NCT00846248|ACTIVE_COMPARATOR|1|Chromium picolinate
62575210|NCT00846248|PLACEBO_COMPARATOR|2|2 sugar pills taken twice daily
62575211|NCT02425124|ACTIVE_COMPARATOR|Control|PC101 Enhanced usual primary health care where non-physician clinicians have been equipped with the basic skills to identify stress and depression/anxiety but with limited access to doctors authorized to prescribe antidepressant medication, and with no specific psychosocial interventions.
62575212|NCT02425124|EXPERIMENTAL|Intervention|PC101 + Mental Health Facility-based stepped care intervention combining stress and depression case detection and management by non-physician clinicians and referral pathways for anti-depressant medication and/or group/individual counselling delivered by lay-health workers for patients with depression.
62575213|NCT04104542|EXPERIMENTAL|Mindfulness MTHM|online mindfulness based stress reduction training
62196466|NCT01533753|EXPERIMENTAL|Arm A: Gabapentin|Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
62196467|NCT01533753|EXPERIMENTAL|Arm B: Venlafaxine|Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
62196468|NCT02514681|ACTIVE_COMPARATOR|Trastuzumab + chemotherapy|Trastuzumab + chemotherapy Chemotherapy regimen is chosen from the following; Docetaxel, Paclitaxel, nab-paclitaxel ,Vinorelbine, Eribulin, Capecitabine or Gemcitabine
62196469|NCT02514681|EXPERIMENTAL|Trastuzumab+ pertuzumab + chemotherapy|Trastuzumab+ pertuzumab + chemotherapy Chemotherapy regimen is chosen from the following; Docetaxel, Paclitaxel, nab-paclitaxel, Vinorelbine, Eribulin, Capecitabine or Gemcitabine
62196470|NCT01770795|EXPERIMENTAL|Genexol-PM/Gemcitabine|
62575214|NCT04104542|EXPERIMENTAL|Mindfulness JBSA|online mindfulness based stress reduction training
62575215|NCT04104542|SHAM_COMPARATOR|Healthy Lifestyle MTHM|online healthy lifestyle training
62575216|NCT04104542|SHAM_COMPARATOR|Healthy Lifestyle JBSA|online healthy lifestyle training
62196471|NCT03438682||Essure Hysteroscopic Sterilization|Women who have undergone Essure hysteroscopic sterilization
62575217|NCT03693612|EXPERIMENTAL|Part 1: feladilimab +tremelimumab|In Part 1, subjects with advanced selected solid tumors will be enrolled. Subjects will be administered escalating doses of feladilimab and tremelimumab in combination. feladilimab will be administered every 3 weeks and tremelimumab will be administered every 3 weeks for 6 doses and every 12 weeks thereafter.
62575218|NCT03693612|EXPERIMENTAL|Part 2: feladilimab +tremelimumab|In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered feladilimab in combination with tremelimumab at recommended Phase 2 dose as determined from Part 1.
62575219|NCT03693612|ACTIVE_COMPARATOR|Part 2: SOC|In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered a single agent SOC therapy of either paclitaxel, docetaxel or cetuximab as per the investigators choice.
62575220|NCT06575907||Persons treated in Kuopio University Hospital|
62575221|NCT06575907||Persons treated in HUS Helsinki University Hospital|
62575222|NCT06134427|OTHER|basic combat training|Pre experimental design, only one group with intervention basic combat training
62575223|NCT03318861|EXPERIMENTAL|Dose Escalation: 3 x 10^7 KITE-585|Participants with relapsed/refractory multiple myeloma (RRMM), will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day intravenous (IV) infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\^7 autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
62734691|NCT02798224|EXPERIMENTAL|e-assist: Colon Health (treatment arm)|Eligible patients identified will receive a prompt (via email) to log into portal for an important health message. Once eligible patient initiates portal session, continuing past IRB consent screen, patient is enrolled.
62196472|NCT03438682||Laparoscopic Sterilization|Women who have undergone laparoscopic sterilization
62196473|NCT03438682||Intrauterine device (IUD) placement|Women who have undergone IUD placement
62196474|NCT02944812|EXPERIMENTAL|Chidamide|Chidamide is given to the patients, the dosage is 30mg,biw,po.
62196475|NCT04654559|OTHER|Unobtrusive data collection|
62399212|NCT03328572|ACTIVE_COMPARATOR|E-max Endocrowns|all patients in this arm will receive e-max endocrowns
62399213|NCT03328572|EXPERIMENTAL|Cerasmart Endocrowns|all patients in this arm will receive Cerasmart endocrowns
62399214|NCT04930562|EXPERIMENTAL|200mg qd|200mg qd po.
62399215|NCT03451630|ACTIVE_COMPARATOR|High-Touch|Delivered primarily via face-to-face interactions, with telephonic interactions and information sharing that does not require access to mobile devices or the Internet. In-person support and/or telephonic interactions to occur at least four times over at least a four-month period.
62399216|NCT03451630|ACTIVE_COMPARATOR|High-Tech|Delivered via a remote care management platform and digital health tools. Remote care support interactions to occur for at least a four-month period.
62399217|NCT03451630|ACTIVE_COMPARATOR|Optimal Discharge Planning|Delivered via Health Plan support and resources within 14-30 days of an initial home or telephonic visit.
62399218|NCT00610922|NO_INTERVENTION|1|
62399219|NCT00610922|EXPERIMENTAL|2|
62399220|NCT04281095|EXPERIMENTAL|Botulinum toxin type A(ATGC-110)|
62399221|NCT04281095|ACTIVE_COMPARATOR|Botulinum toxin type A|
62399222|NCT06284486|EXPERIMENTAL|Venetoclax + Revumenib|Participants may receive the combination of venetoclax and revumenib for up to 1 year, and then 1 more year of venetoclax alone. You will no longer be able to take the study drug(s) if the disease gets worse or if intolerable side effects occur. Participants will take venetoclax by mouth on 1 time a day at about the same time each day, on Days 1-14 of each cycle. Take each dose with about 1 cup of water within 30 minutes after a meal, preferably breakfast.
62399223|NCT05607342|EXPERIMENTAL|Pilot Trial: Osanetant 28 Days|Pilot Trial: A single dose level (200mg twice daily, oral) will be provided for men with prostate cancer undergoing curative intent surgery. Men will undergo serum testing at baseline, days 2, 3, 7, 14, and 28 as well as 6 weeks post-treatment in order to evaluate efficacy. All men enrolled will be subject to the same study procedures and assessments, regardless of completion of the study protocol, and analysis will occur via intent-to-treat principles.
62399224|NCT02096601|EXPERIMENTAL|ND0612L Low LD Dose|"LD daily dose equals to 115 mg administered over 8 hours SC infusion:~* LD/CD 60/7.5 mg/mL on Study Day 3~* LD/CD 60/14 mg/mL on Study Day 4~* LD/CD 60/14 mg/mL and Entacapone 200 mg every 4 hours on Study Day 5"
62399225|NCT02096601|EXPERIMENTAL|ND0612H High LD Dose|"LD daily dose equals to 307 mg administered over 8 hours SC infusion:~* LD/CD 60/7.5 mg/mL on Study Day 3~* LD/CD 60/14 mg/mL on Study Day 4~* LD/CD 60/14 mg/mL and Entacapone 200 mg every 4 hours on Study Day 5"
62575224|NCT03318861|EXPERIMENTAL|Dose Escalation: 1 x 10^8 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\^8 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
62196476|NCT01411241|EXPERIMENTAL|CYD Dengue Vaccine Group 1|Participants received the first injection of CYD dengue vaccine at Month 0 (9 to 12 months of age), a measles, mumps, rubella (MMR) vaccine and pneumococcal conjugate vaccine at Month 1 (10 to 13 months of age), a booster dose of Pentaxim vaccine was administered concomitantly with the second injection of CYD dengue vaccine at Month 6 (15 to 18 months of age), placebo at Month 7 (16 to 19 months of age) to maintain the blind, and the third injection of CYD dengue vaccine at Month 12 (21 to 24 months).
62196477|NCT01411241|EXPERIMENTAL|CYD Dengue Vaccine Group 2|Participants received the first injection of CYD dengue vaccine at Month 0 (9 to 12 months of age), a MMR vaccine and pneumococcal conjugate vaccine at Month 1 (10 to 13 months of age), the Pentaxim vaccine was administered concomitantly with placebo at Month 6 (15 to 18 months of age) to maintain the blind, a second injection of CYD dengue vaccine at Month 7 (16 to 19 months of age), and the third injection of CYD dengue vaccine at Month 12 (21 to 24 months).
62196478|NCT05316792|ACTIVE_COMPARATOR|knee osteoarthritis|In patients with knee osteoarthritis, the thickness of the femoral articular cartilage will be measured with portable USG before and immediately after walking.
62196479|NCT05316792|ACTIVE_COMPARATOR|healthy volunteers|Femoral articular cartilage thickness will be measured with portable USG before and immediately after walking in healthy volunteers.
62196480|NCT02526498|EXPERIMENTAL|Treatment (APBI using HDR brachytherapy)|Within 1-5 days after balloon placement, patients undergo APBI using HDR brachytherapy over 15-60 minutes for 2-3 days.
62196481|NCT01217437|EXPERIMENTAL|Arm I (temozolomide, irinotecan hydrochloride)|Patients receive temozolomide PO and irinotecan hydrochloride IV over 90 minutes on days 1-5.
62196482|NCT01217437|EXPERIMENTAL|Arm II (temozolomide, irinotecan hydrochloride, bevacizumab)|Patients receive temozolomide PO and irinotecan hydrochloride IV as in arm I and bevacizumab IV over 30-90 minutes on days 1 and 15.
62196483|NCT04841434|EXPERIMENTAL|Dose escalation|Patients will receive up to 6 cycles of HD-MTX Treatment Dose escalation will be performed using three dose levels of MTX: 3.0 g/m2, 3.5 g/m2, 4.0 g/m2
62196484|NCT04131816|EXPERIMENTAL|HeartHome Intervention|Participants will be in the HeartHome program for a total of 12 weeks.
62196485|NCT04131816|NO_INTERVENTION|Control|De-identified data from 150 patients who attend a traditional cardiac rehabilitation program during the same general time of the HeartHome implementation
62575225|NCT03318861|EXPERIMENTAL|Dose Escalation: 3 x 10^8 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\^8 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
62575226|NCT03318861|EXPERIMENTAL|Dose Escalation: 1 x 10^9 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\^9 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
62010131|NCT02432794|EXPERIMENTAL|delay phenomenon by arteriography|"intervention: delay phenomenon by arteriography. Patients who will be subjected a delay phenomenon by arteriographic procedure before esophageal resection surgery minimum 14 days before surgery.~An angiogram of the celiac trunk is performed through a femoral access before and after the embolization. A 4-5 Fr Simmons or Cobra catheter is used for the catheterization and embolization of the left gastric artery, and 0.035-inch platinum coils are proximally placed from the main trunk in the splenic artery. When accessory left gastric arteries are present, they are catheterized and embolized as well. The right gastric artery catheterization is realized by a 4-5 Fr catheter and coils or microcoils are proximally placed in the artery as well."
62399226|NCT03801070||Less than median number necrosectomies|Group one includes patients who underwent less than median number necrosectomies
62399227|NCT03801070||At least the median number of necrosectomies|Group two includes patients who underwent at least the median number of necrosectomies
62399228|NCT05754970|EXPERIMENTAL|laser/machined|on the same customized healing abutment laser-treated/machined surface treatments were repeated with the following order: Laser treated/machined/laser treated/machined. This order was performed to eliminate the bias of the different surface allocation on patients.
62575227|NCT03318861|EXPERIMENTAL|Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585|RRMM participants with moderate renal impairment (creatinine clearance 30 to 59 mL/min \[Grade 2 chronic kidney disease\]) will receive a conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 24 mg/m\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a tolerable dose of 3 x 10\^7 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants then had a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
62575228|NCT00931255|ACTIVE_COMPARATOR|Tacrolimus|Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
62575229|NCT00931255|ACTIVE_COMPARATOR|Sirolimus|5 mg, PO , daily
62575230|NCT06685302|EXPERIMENTAL|US-PNM + US-PE + EE|Patients receive three interventions: ultrasound-guided percutaneous neuromodulation, ultrasound-guided percutaneous electrolysis and eccentric exercises
62575231|NCT06685302|ACTIVE_COMPARATOR|US-PE + EE|Patients receive two interventions: ultrasound-guided percutaneous electrolysis and eccentric exercises
62575232|NCT00994630||BP I patients manic phase|
62575233|NCT04322734||ASD (General)|150 children with ASD and unknown MD status
62575234|NCT04322734||ASD (With MD)|50 children with ASD and confirmed MD
62575235|NCT04322734||ASD (No MD)|50 children with ASD and ruled out MD
62575236|NCT04322734||Epilepsy|50 children with epilepsy (primary) and no ASD
62575237|NCT04322734||Brain Tumor|50 children with brain tumor (primary) and no ASD
62575238|NCT04322734||Psychiatric Disorder|50 children with psychiatric disorder (primary) and no ASD, using lithium treatments
62575239|NCT04322734||MD (No ASD)|50 children with MD (primary) and no ASD
62575240|NCT04322734||TD (With ASD Sibling)|50 TD children with a sibling with ASD/neurodevelopmental delay
62575241|NCT04322734||TD (No ASD Sibling)|50 TD children with no siblings with ASD/neurodevelopmental delay
62575242|NCT01912586|NO_INTERVENTION|Arm A|Patients receive no interventions for ED after laparoscopic surgery
62575243|NCT01912586|EXPERIMENTAL|Arm B|sildenafil 25mg/day nightly without vacuum erection device for 3 months after surgery within one or two weeks.
62575244|NCT01912586|EXPERIMENTAL|Arm C|sildenafil 25mg/day nightly and together with using vacuum erection device to make erections for 10-15 minutes/day for 3 months after surgery within one or two weeks.
62575245|NCT02932488|EXPERIMENTAL|Sumatriptan|"In the pilot study (an MR-only study) subjects will receive up to five doses of sumatriptan in the range of 10 ug/kg to 80 ug/kg. This allows us to establish a dose-response curve for each subject. Administration of sumatriptan in the pilot study will be spaced with approximately one week apart to avoid carry-over effects of the drug.~In the main study (a PET-MR study), the sumatriptan dose with the maximal effect size and minimum side effects will be used for all subjects."
62575246|NCT04938661|ACTIVE_COMPARATOR|Conventional Center-Based Cardiac Rehab (CON)|Participants will be prescribed 36 sessions of center-based CR. This includes supervised exercise sessions, cooking demonstrations, didactic lectures, video presentations, group support, and stress management education. During sessions, participants have direct access to the medical director, case manager, registered nurse, exercise physiologist, and stress management specialists.
62575247|NCT04938661|ACTIVE_COMPARATOR|Conventional Center-Based Cardiac Rehab + mHealth (CON+)|"Participants will be prescribed 36 sessions of center-based CR as noted above. In addition, participants will be provided access to the mHealth platform which provides e-Learning modules with factsheets, videos, quizzes, and questionnaires (coinciding with activities being conducted during the CON program), a Social Network Module will allow patients to communicate via secure network with other patients who are part of their invited network. The Social Network Module also allows for secure two-way interaction with healthcare providers in the event that patients are experiencing signs or symptoms suggestive of worsening condition. This platform also contains a Personal Health Record Module allowing patients to upload, archive, and retrieve personal health data (e.g. fitness tracker data, heart rate monitor data, blood pressure recordings, etc.) and record vital signs, symptoms, treatments, and medical history."
62575248|NCT04938661|ACTIVE_COMPARATOR|Home-Based Cardiac Rehab + mHealth (HOM+)|Participants will be provided paper copies of educational content at the time of event/discharge. In addition, these participants will be provided access to the same mHealth platform as the CON+ group. Participants in this group will be encouraged to exercise three days per week while also completing the additional questionnaires and educational content provided by the mHealth platform in accordance with the CR program. Participation will be tracked using web/internet analytics.
62575249|NCT00983203|EXPERIMENTAL|FID 114657|FID 114657
62575250|NCT00983203|ACTIVE_COMPARATOR|Soothe XP Lubricant Eye Drops|Soothe XP Lubricant Eye Drops
62575251|NCT01308021|EXPERIMENTAL|gpASIT400|gpASIT+TM 400 µg
62575252|NCT01308021|EXPERIMENTAL|gpASIT800|gpASIT+TM 800 µg
62575253|NCT01308021|PLACEBO_COMPARATOR|Placebo|
62196486|NCT03797482||Intra-operative tumour tissue biopsies|Intra-operative tumour tissue biopsies will be collected for all patients
62575254|NCT03667885||Small renal Masses|patients with a renal mass of 4 cm or less. Typically incidentally found. Blood and urine samples will be collected from each patient at baseline before a biopsy of the tumor is collected and 14 days later. In addition, all patients will be offered a Multi planar MRI before the biopsy. Patients elected for curative treatment for malignant tumors will have another set of blood and urine samples collected at 1 month and 6 months after the intervention.
62575255|NCT04042623|EXPERIMENTAL|Treatment with AVB-S6-500|Patients will receive AVB-S6-500 by intravenous infusion every 2 weeks for total of 6 doses.
62575256|NCT01353677||HSCT recipients|"1. Adult (≥ 18 years), or pediatric (≥ 2 years and \< 18 years) allogeneic HCT recipient (related, unrelated, or CBU) at participating pilot study transplant centers.~2. Signed informed consent form from adult patient or parent/guardian of pediatric patient.~3. Patient must have a valid mailing address within the United States to receive QOL surveys.~4. Ability to speak and read English.~5. Patients with access to a telephone."
62575257|NCT01415713|EXPERIMENTAL|Statin dose titration|"SLOG regimen:~S-1 20-40 mg/m2/b.i.d., day 1-7;Leucovorin 20 mg/m2/b.i.d., day 1-7;Oxaliplatin 85 mg/m2 in 250 mL of D5W,given as 2-hour intra-venous infusion, day 1;Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate infusion,day 1;After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin; Every 14 days, as one cycle.Prophylactic G-CSF or GM-CSF will not be allowed in this study. In case of grade 4 or complication neutropenia, patients may receive G-CSF according to the regulation of National Insurance Bureru treated with appropriate antibiotics. Therapeutic G-CSF may be used at the discretion of attending physicians."
62575258|NCT04902638|ACTIVE_COMPARATOR|Diabetic patients with steroid|
62575259|NCT04902638|PLACEBO_COMPARATOR|Diabetic patients without steroid|Injection of normal saline
62575260|NCT04902638|ACTIVE_COMPARATOR|Pre-diabetic patients with steroid|
62575261|NCT04902638|PLACEBO_COMPARATOR|Pre-diabetic patients without steroid|Injection of normal saline
62575262|NCT04902638|ACTIVE_COMPARATOR|Non-diabetic patients with steroid|
62575263|NCT04902638|PLACEBO_COMPARATOR|Non-diabetic patients without steroid|Injection of normal saline
62575264|NCT03674346|EXPERIMENTAL|Hypnoanalgesia group|It is performed by a radiologist technologist who has been trained in Ericksonian hypnoanalgesia in the Hospices Civils de Lyon and has been practicing it regularly for 1 year.
62575265|NCT03674346|OTHER|MEOPA Group|The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA)
62575266|NCT05940168|ACTIVE_COMPARATOR|Navigator ACT group|This is a manualized Acceptance and Commitment Therapy group-intervention for 8-16 parents of children with disabilities. The intervention consists of five group sessions with different themes, as well as a booster-session at three months after the fifth session. The intervention is held by two group leaders.
62575267|NCT05940168|EXPERIMENTAL|I-Navigator ACT|This intervention is an internet-delivered version of the manualized Acceptance and Commitment Therapy group. The internet-delivered version is given as an individual treatment via a secure online treatment platform. It consists of ten separate chapters or modules. The duration of the intervention is 10-12 weeks, with a individual follow up-session by phone or video at three months after completion.
62575268|NCT03637062|EXPERIMENTAL|pessary|the test group is pessary.The pregnant woman is assigned to the pessary group and after having excluded a vaginal infection the pessary will be inserted directly.
62575269|NCT03637062|ACTIVE_COMPARATOR|Progesterone|the control group is progesterone. Pregnant women in the control group were treated by 200 mg QN, it is used for 34 gestational weeks.
62575270|NCT06416891|ACTIVE_COMPARATOR|Bupivacaine|SCPB will be administered using 10 ml of bupivacaine 0.25% (5 ml of bupivacaine 0.5% + 5 ml of normal saline).
62575271|NCT06416891|ACTIVE_COMPARATOR|Bupivacaine plus dexamethasone|SCPB will be administered using dexamethasone 2 mg in 10 ml of bupivacaine 0.25% (5 ml of bupivacaine 0.5% + dexamethasone 0.5 ml + 4.5 ml of normal saline).
62575272|NCT02071745||Navigation|
62575273|NCT04674813|EXPERIMENTAL|Administration of CC-95266|
62010132|NCT02432794|NO_INTERVENTION|control group|Patients who will be operated directly without gastric ischemic conditioning. The investigators don't performed any arteriography before the esophageal surgical resection
62575274|NCT06181084|EXPERIMENTAL|Group 1: Tablet versus Capsule|"Treatment A: LY3410738 capsule on Day 1 as a single oral dose in the morning following a fast of at least 10 hours prior to and 4 hours after dosing.~Treatment B: LY3410738 tablet on Day 4 as a single oral dose in the morning 10 hours prior to and 4 hours after dosing."
62010133|NCT00895219|ACTIVE_COMPARATOR|1|Breathing re-training
62010134|NCT00895219|ACTIVE_COMPARATOR|2|Breathing re-training and musculoskeletal physiotherapy techniques
62010135|NCT05970107|EXPERIMENTAL|ALND + LVB|"The prophylactic LVB cohort will undergo ALND plus ARM and immediate lymphatic reconstruction with lymphaticovenous bypass (LVB). During the ALND, axillary reverse mapping will be used to visualize the lymphatics draining into the axilla, to aid in preserving the draining lymphatic vessels for anastomosis in LVB.~Radiation therapy will be administered as determined by the treating radiation oncologist."
62010136|NCT05970107|ACTIVE_COMPARATOR|ALND without LVB|"Patients in the ALND alone cohort will undergo ALND plus ARM~Radiation therapy will be administered as determined by the treating radiation oncologist."
62010137|NCT05968989|EXPERIMENTAL|Group 1|60 mcg of FluMos-v2 on Day 0 and Week 16
62196487|NCT00895895|PLACEBO_COMPARATOR|1|Placebo
62196488|NCT00895895|EXPERIMENTAL|2|SAM-531 1.5 mg
62196489|NCT00895895|EXPERIMENTAL|3|SAM-531 3.0 mg
62196490|NCT00895895|EXPERIMENTAL|4|SAM-531 5.0 mg
62196491|NCT00895895|ACTIVE_COMPARATOR|5|Donepezil
62196492|NCT02594449|ACTIVE_COMPARATOR|low concentration Benzalkonium Chloride|To use low concentration Benzalkonium Chloride Solution to gargle
62196493|NCT02594449|ACTIVE_COMPARATOR|high concentration Benzalkonium Chloride|To use high concentration Benzalkonium Chloride Solution to gargle
62196494|NCT02594449|PLACEBO_COMPARATOR|Normal Saline|To use Normal Saline to gargle
62196495|NCT00697398|PLACEBO_COMPARATOR|1|Sound placebo
62399229|NCT05298527|EXPERIMENTAL|Intervention Group|In this study, the purpose of the study was explained to the women from intervention group and their partners by visiting them in their home. Personal Information Form (PIF), Pittsburgh Sleep Quality Index (PSQI), Menopause Symptoms Rating Scale (MSRS) and Marital Adjustment Scale (MAS) were filled by the women and MAS was filled by their partners. Firstly, back massage was taught to the partners of women in the intervention group. The massage was made half an hour before the women's sleep time for a total of 15 minutes. Partners were ensured to apply this massage twice a week for four weeks. The intervention group was called by telephone every week to ensure continuity of the study. By visiting those at their homes again at the end of the fourth week, PSQI, MSRS, and MAS were filled by the women and MAS was filled by their husbands for the last time.
62399230|NCT05298527|NO_INTERVENTION|Control Group|In this study, the purpose of the study was explained to the women from control group and their partners by visiting them in their home. Their signatures indicating that they agreed to participate in the study were obtained after having them read the informed consent form. Personal Information Form (PIF), Pittsburgh Sleep Quality Index (PSQI), Menopause Symptoms Rating Scale (MSRS) and Marital Adjustment Scale (MAS) were filled by the women and MAS was filled by their partners. No application was made to the couples in the control group. By visiting those at their homes again at the end of the fourth week, PSQI, MSRS, and MAS were filled by the women and MAS was filled by their husbands for the last time. Back massage training was given to the partners of the women in the control group at the end of the fourth week.
62399231|NCT02295124|ACTIVE_COMPARATOR|Oxycodone|Patients will be prescribed oxycodone 10mg (5mg if \> age 65) every 2 hours as needed for post-operative pain management in addition to tylenol 1000mg every 6 hours and celecoxib 200mg every 12 hours.
62575275|NCT06181084|EXPERIMENTAL|Group 2: Food Effect Comparison Group|"Treatment B: LY3410738 table on Day 1 as a single oral dose in the morning following a fast of at least 10 hours prior to and 4 hours after dosing.~Treatment C: LY3410738 table on Day 4 as a single oral dose in the morning 30 minutes after starting a standard low-fat meal."
62575276|NCT06181084|EXPERIMENTAL|Group 3: Potential of Hydrogen (pH) Effect Fasted Group|"Treatment B: LY3410738 table on Day 1 as a single oral dose in the morning following a fast of at least 10 hours prior to and 4 hours after dosing.~Treatment D: Esomeprazole single oral dose once daily (QD) in the morning on Days 4 through 8 in fasted state followed by a standard low-fat meal. On Day 9, Esomeprazole a single oral dose followed by LY3410738 tablet as a single oral dose in the morning, following a fast of at least 10 hours prior to and 4 hours after esomeprazole and LY3410738 coadministration."
62575277|NCT06181084|EXPERIMENTAL|Group 4: pH Effect Fed Group|"Treatment C: LY3410738 table on Day 1 as a single oral dose in the morning 30 minutes after starting a standard low-fat meal.~Treatment E: Esomeprazole as a single oral dose QD in the morning on Days 4 through 8, in fasted state followed by a standard low-fat meal. On Day 9, Esomeprazole as a single oral dose followed by a LY3410738 tablet in the morning in fed state standard low-fat meal."
62575278|NCT04625270|EXPERIMENTAL|Part A|To determine the optimal regimen, either avutometinib(VS-6766) monotherapy or avutometinib (VS-6766) in combination with defactinib, for subsequent evaluation for efficacy in the Expansion Phase (Part B)
62575279|NCT04625270|EXPERIMENTAL|Part B|To determine the efficacy of the optimal regimen identified from Part A
62575280|NCT04625270|EXPERIMENTAL|Part C:|To evaluate additional efficacy parameters for the optimal regimen identified in Part A.
62575281|NCT04625270|EXPERIMENTAL|Part D|To evaluate additional efficacy parameters for a lower dose of avutometinib in combination with defactinib
62575282|NCT05681962||Standard Oxygen Therapy (SOT)|Patients receiving low oxygen flow administration through nasal prongs, oxygen mask with or without reservoir, and Venturi mask.
62575283|NCT05681962||High Flow oxygen through Nasal Cannula (HFNC)|Administration of high flows (up to 60 L/min) of air/oxygen admixtures, heated (at temperatures ranging from 31 to 37°C) and fully humidified (up to 44 mg H2O/L), providing an inspired oxygen fraction ranging from 21 to 100%
62575284|NCT05681962||Continuous Positive Airway Pressure (CPAP)|application of positive end-expiratory pressure (PEEP) throughout the whole respiratory cycle by means of interfaces such as mask or helmet
62575285|NCT05681962||Non-Invasive Ventilation (NIV)|application of a PEEP by means of a mask or helmet, with an inspiratory pressure support triggered by the patient and delivered by a ventilator and through interfaces such as mask or helmet
62575286|NCT05681962||Invasive Mechanical Ventilation (iMV)|application of a ventilatory assistance in controlled or partial assisted modalities through an endotracheal or tracheostomy tube
62575287|NCT03935425|EXPERIMENTAL|FitMi Plus|"Participants will perform targeted movement exercises by interacting with the FitMi Plus Functional modules at least 50% of the time they spend exercising.~Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks."
62575288|NCT03935425|ACTIVE_COMPARATOR|FitMi Basic|"Participants will perform targeted movement exercises by interacting with the FitMi Basic pucks, as described and monitored on a computer.~Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks."
62575289|NCT06450327||Normotensives - apparently healthy|Group of non-hypertensive participants
62010138|NCT05968989|EXPERIMENTAL|Group 2|180 mcg of FluMos-v2 on Day 0 and Week16
62010139|NCT05968989|EXPERIMENTAL|Group 3|180 mcg of FluMos-v2 on Day 0 and Week16
62010140|NCT02962895|EXPERIMENTAL|VAY736 dose 1 - 5mg|VAY736 low
62010141|NCT02962895|EXPERIMENTAL|VAY736 dose 2 - 50mg|VAY736 medium
62010142|NCT02962895|EXPERIMENTAL|VAY736 dose 3 - 300 mg|VAY736 high
62010143|NCT02962895|PLACEBO_COMPARATOR|Placebo|Placebo control
62196496|NCT00697398|EXPERIMENTAL|2|Sound
62399232|NCT02295124|ACTIVE_COMPARATOR|Hydromorphone|Patients will be prescribed hydromorphone 2mg (1mg if \> age 65) every 2 hours as needed in addition to tylenol 1000mg every 6 hours and celecoxib 200mg every 12 hours.
62575290|NCT06450327||Controlled hypertension|Participants diagnosed with primary arterial hypertension and undergoing outpatient follow-up
62575291|NCT06450327||Resistant Hypertension|Participants diagnosed with primary arterial hypertension using 3 or more antihypertensive medications, one of which is preferably a thiazide diuretic
62010144|NCT06149637|ACTIVE_COMPARATOR|Traditional neck dissection approach|Traditional neck dissection approach
62010145|NCT06149637|EXPERIMENTAL|Anterior neck dissection approach|Anterior neck dissection
62196497|NCT02690844|ACTIVE_COMPARATOR|Clonazepam|Clonazepam (Klonopin®) treatment arm - 1 mg clonazepam (Klonopin® tablet) TID, dissolved in mouth for 3 minutes then expectorated
62196498|NCT02690844|PLACEBO_COMPARATOR|Mucolox® alone|Mucolox® only - 5mL Mucolox® TID, swished around mouth for 3 minutes then expectorated
62196499|NCT02690844|EXPERIMENTAL|Mucolox® and clonazepam|Mucolox® and clonazepam - 1mg Clonazepam/5mL Mucolox® TID, swished around mouth for 3 minutes then expectorated.
62196500|NCT06184035|EXPERIMENTAL|Phase I/IIa Dose escalation and dose expansion|"Participants will initially receive 1 cycle of \[177Lu\]Lu-SN201 via slow intravenous infusion and progress to up to 3 cycles, provided retreatment criteria are met before the start of each cycle, occurring every 6 weeks (with an allowable window to delay each cycle by +3 weeks per retreatment criteria).~Dose escalation: The study will evaluate up to 5 dose levels of \[177Lu\]Lu-SN201 (A1=10 MBq/kg, A2=25 MBq/kg, A=50 MBq/kg, A4= \<33% of A3, A5= \<33% of A4). Additional dose levels may be explored until MTD/RP2D is identified. Up to 9 participants may be enrolled at any pre-specified dose level shown to be tolerated for confirmation of MTD and/or RP2D.~Dose expansion: Once the MTD/RP2D has been defined, an expansion phase consisting of multiple tumor types, each with up to 20 participants, will be enrolled to further characterize the safety, tolerability, and assess preliminary efficacy of \[177Lu\]Lu-SN201 at the RP2D and/or MTD identified in Phase I."
62196501|NCT04053439||Lymphoma patients >=60 receiving cytotoxic chemotherapy|Lymphoma patients \>=60 receiving cytotoxic chemotherapy who have consented to DNA extraction and analysis for CHIP.
62575292|NCT06450327||Refractory Hypertension|Participants diagnosed with primary arterial hypertension using 5 or more antihypertensive medications.
62010146|NCT05505981|EXPERIMENTAL|Immediate Functional Progression Group|Athletes randomized to this group will start Physical Therapy immediately (with 7 days of diagnosis). Once in PT, Athletes will perform phase I (neutral spine) of the program and progress to phase II (functional motion) as able without an increase in pain and without compensations noted in function. The athlete will be assessed at each session to determine if they meet the criteria to begin the next step of functional progression program. Once the athlete has met the criteria of phase II, they will progress into the final phase of the functional progression program for return to sport activity. As these athletes progress through the third phase, and are able to meet the return to sport criteria, they will be released to return to sport. Athletes will not be released to return to sport prior to their first physician follow-up visit at 4 weeks.
62010147|NCT05505981|ACTIVE_COMPARATOR|Rest until pain resolves Group|Athletes with an active spondylolysis randomized into the control group will rest from all activity until their pain has resolved. Physicians will assess pain resolution at each visit which occurs every four weeks. Once the pain has resolved, the patient will be referred to physical therapy (PT) two times per week. The time, frequency, and exercise progression will be the same as the IFPP group. Since the pain has resolved in these participants be-fore initiating PT, the criteria to progress through phases will be time-based, not pain and function-based.
62010148|NCT05941039|EXPERIMENTAL|Vestibular Activation Training|
62010149|NCT05941039|NO_INTERVENTION|No Training|
62010150|NCT01698697|ACTIVE_COMPARATOR|U100|
62010151|NCT01698697|EXPERIMENTAL|U200|
62010152|NCT03772405|EXPERIMENTAL|Nascum Plus and ACC|In a cross-over design, patients are exposed to pollen in the ACC twice for 4 hours each 3 weeks apart. Subjects will receive treatment with Nascum Plus either 5 minutes before the first or the second 4 hour pollen challenge.
62010153|NCT01073488|EXPERIMENTAL|EMONC: Community mobilization, HBLSS and Facility Improvement|The intervention group received training in community mobilization activities, Home Based Life Saving Skills (HBLSS) and facility improvement.
62196502|NCT00639522|EXPERIMENTAL|A|
62196503|NCT03006185|EXPERIMENTAL|Split-Person Design: Ablative Fractional Carbon Dioxide (CO2) Laser vs Microdermabrasion|WIthin each participant, two 50 cm2 adjacent test areas were randomized to laser or microdermabrasion pretreatment prior to daylight photodynamic therapy.
62196504|NCT00927173|SHAM_COMPARATOR|Sham|Sham treatment
62196505|NCT00927173|ACTIVE_COMPARATOR|Active|Active Deep Transcranial Magnetic Stimulation treatment
62196506|NCT00276835|EXPERIMENTAL|Genistein and Interleukin-2|
62196507|NCT01062581||Transplant Recipients and Living Donors|"All transplant recipients receiving transplants at the University of Minnesota (kidney, pancreas, liver, heart, lung, islet, intestine). All ages.~All living donors donating an organ at the University of Minnesota (kidney, pancreas, liver, lung) (by law, living donors are required to be at least 18 years old)"
62196508|NCT01981005|EXPERIMENTAL|RO5424802|
62196509|NCT00078377|EXPERIMENTAL|1|Armodafinil 250 mg
62196510|NCT00078377|EXPERIMENTAL|2|Armodafinil 150 mg
62196511|NCT00078377|PLACEBO_COMPARATOR|3|Placebo
62196512|NCT00980642|OTHER|General anesthesia|Temperature is measured by Draeger double-sensor and esophageal stethoscope temperature sensor every 5-min during the surgery.
62196513|NCT00980642|OTHER|Regional anesthesia|Temperature is measured by Draeger double-sensor and Foley catheter temperature sensor every 5-min during the surgery.
62196514|NCT02750449|EXPERIMENTAL|Arm 1|All subjects are patched.
62575293|NCT01737710|EXPERIMENTAL|92 Non-atopic controls vaccinated with Fluzone® Intradermal|Non-atopic controls who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
62575294|NCT01737710|EXPERIMENTAL|Moderate to severe AD vaccinated with Fluzone® Intradermal|92 moderate to severe atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
62575295|NCT01737710|ACTIVE_COMPARATOR|Moderate to severe AD vaccinated with Fluzone® (Intramuscular)|92 moderate to severe atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® (Intramuscular) influenza vaccine from 0.5 mL single dose vials.
62399233|NCT06221852|ACTIVE_COMPARATOR|Ketogenic diet arm|Eligible participants assigned to the ketogenic diet arm will be asked to follow the ketogenic diet (KD) for 12 weeks in addition to any ongoing medications (e.g., mood stabilizers and/or second-generation antipsychotics). Participants will receive weekly and as needed diet counseling from a registered dietician. Participants will be asked to monitor and report their blood ketone levels each day via a finger-prick device provided by the study team. Participants have the ability to opt into an optional open label phase where they can continue on the ketogenic diet with the daily finger pricks for another 12 weeks after the 12-week main study.
62399234|NCT06221852|ACTIVE_COMPARATOR|Dietary Guidelines for Americans arm|Eligible participants assigned to the Dietary Guidelines for Americans (DGA) arm will adhere to the Dietary Guidelines for Americans in addition to any ongoing medications (e.g., mood stabilizers and/or second-generation antipsychotics). Participants will receive weekly and as needed diet counseling from a registered dietician. Participants will be asked to monitor and report their blood ketone levels each day via a finger-prick device provided by the study team. Participants have the ability to opt into an optional open label phase where they can switch to the ketogenic diet with the daily finger pricks for 12 weeks after the 12-week main study.
62399235|NCT05523427|NO_INTERVENTION|Standard treatment of IBS|"Mebeverine 135 mg Sulpiride 25 mg Simethicone 200 mg~They were administered in a single capsule, three time daily before meals."
62575296|NCT01737710|ACTIVE_COMPARATOR|Non-atopic controls vaccinated with Fluzone® (Intramuscular)|20 non-atopic controls who will receive a single dose of the seasonal 2012-2013 Fluzone® (Intramuscular) influenza vaccine from 0.5 mL single dose vials.
62575297|NCT01737710|EXPERIMENTAL|Mild AD participants vaccinated with Fluzone® Intradermal|20 mild atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
62575298|NCT03804450|EXPERIMENTAL|Test group|The root canals were instrumented using Pro-taper next rotary files till size X3. REPs via blood clot using calcium hydroxide were then applied
62575299|NCT03804450|EXPERIMENTAL|Control group|The root canals were instrumented using Pro-taper next rotary files till size X5. REPs via blood clot using calcium hydroxide were then applied.
62575300|NCT04973423|NO_INTERVENTION|CALM|Tight control of inflammatory activity by calprotectin.
62575301|NCT04973423|OTHER|CALM + IRM|Tight control of inflammatory activity by calprotectin associated with transmural evaluation.
62575302|NCT00613964|PLACEBO_COMPARATOR|Standard Therapy|Standard heart failure therapy excluding carperitide administration
62575303|NCT00613964|ACTIVE_COMPARATOR|Carperitide Therapy|Addition of carperitide administration to standard heart failure therapy
62575304|NCT03200769|NO_INTERVENTION|Group I|AHI/h \< 15
62575305|NCT03200769|EXPERIMENTAL|Group IIa|15 \< AHI/h \< 30. Randomization group. Intervention : CPAP active
62575306|NCT03200769|EXPERIMENTAL|Group IIb|15 \< AHI/h \< 30. Randomization group. Intervention : CPAP placebo during the first 3 months. After this period, the patient will have the possibility to continue with an active CPAP.
62575307|NCT03200769|ACTIVE_COMPARATOR|Group III|AHI/h \> 30. Intervention : CPAP active
62575308|NCT01375972|EXPERIMENTAL|SP treatment|S-1 plus cisplatin combination chemotherapy
62575309|NCT01375972|ACTIVE_COMPARATOR|GP treatment|Gemcitabine plus Cisplatin combination chemotherapy
62575310|NCT03875326|SHAM_COMPARATOR|Sham Stimulation|Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
62575311|NCT03875326|EXPERIMENTAL|1 mA Dosage Stimulation|1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
62010154|NCT01073488|NO_INTERVENTION|Control|The control group did not receive an intervention, but collected outcome data through a baseline maternal/newborn birth registry.
62575312|NCT03875326|EXPERIMENTAL|2 mA Dosage Stimulation|2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
62575313|NCT03875326|EXPERIMENTAL|3 mA Dosage Stimulation|3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
62575314|NCT01521520||Clinical Type 1 Diabetes|This group will be subdivided into individuals with recent onset clinical type 1 diabetes (within 6 months of diagnosis), latent autoimmune diabetes of the adult, and longer standing type 1 diabetes.
62575315|NCT01521520||High Risk Pre-Type 1 Diabetes|High risk pre-type 1 diabetes is defined as first degree family relative with type 1 diabetes and at least one islet autoantibody marker (GAD, IAA, or IA-2).
62010155|NCT06211647|EXPERIMENTAL|[177Lu]Lu-XT117 dose escalation|
62010156|NCT05303805|EXPERIMENTAL|Topical sevoflurane|The active treatment group will have sevoflurane applied at approximately 1 ml/cm2 at the start of wound treatment,
62575316|NCT01521520||Low Risk Pre-Type 1 Diabetes|Low risk pre-type 1 diabetes is defined as first degree family relative with type 1 diabetes but no islet autoantibody markers (GAD, IAA, or IA-2).
62575317|NCT01521520||Normal Control|Normal control is based on history with no known history or family history of type 1 diabetes.
62575318|NCT05717296|EXPERIMENTAL|with multimedia support|
62575319|NCT05717296|SHAM_COMPARATOR|without multimedia support|
62575320|NCT05537818|EXPERIMENTAL|Group 1a Clinic Treatment|Randomized, active or sham in-clinic treatment during a migraine, followed by open-label treatments in the home environment.
62575321|NCT05537818|OTHER|Group 1b Clinic & Home Treatment|Open-label, active treatment for subjects treated in prior clinical trials for this device, followed by open-label treatments in the home environment.
62575322|NCT05537818|EXPERIMENTAL|Group 2 Home Treatment|Randomized active or sham for first home treatment followed by open-label treatments in the home environment.
62575323|NCT06574958|EXPERIMENTAL|refractory or relapsed MM|
62010157|NCT05303805|ACTIVE_COMPARATOR|Cyteal|the control group will only have a standard rinse solution with Cyteal PIERRE FABRE MEDICAMENT, France (100 ml of skin fluid contains hexamidine diisetione 100 mg, chlorohexidine digluconate (solutio 20 %) 100 mg and chlorocresol 300 mg), with sevoflurane used to soak the absorbent material held under the distal pole of the wound.
62010158|NCT03413878|EXPERIMENTAL|Wet snow/Small air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet avalanche snow with a small air pocket
62575324|NCT02348788|ACTIVE_COMPARATOR|Artemether-lumefantrine + Primaquine|"1 tablet = 20mg artemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; \>35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, \>10-15kg = 1 tablet.~Primaquine = 7.5mg tablet. Dosing daily for 14 days from Day 0. Dose according to bodyweight; \>35kg = 30mg, \<35kg = 0.5mg/kg"
62575325|NCT02348788|ACTIVE_COMPARATOR|Chloroquine + Primaquine|"1 tablet contains 155mg chloroquine base. Adult dose (\>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.~Child dose (\>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours. Primaquine = 7.5mg tablet. Dosing daily for 14 days from Day 0. Dose according to bodyweight; \>35kg = 30mg, 10-35kg = 0.5mg/kg"
62575326|NCT04305444|EXPERIMENTAL|Disease-specific cohorts|Participants will be administered the oral triple-combination therapy, DTRM-555 (comprised of 200mg of DTRMWXHS-12, 5mg of everolimus and 2mg of pomalidomide), once-daily for 21 consecutive days every 28 days
62575327|NCT05251337|EXPERIMENTAL|Intervention - nausea/vomiting|Patients indicating that nausea/vomiting is their primary symptom of concern and are randomized to receive intervention will be allocated to the intervention - nausea/vomiting arm. This arm will receive peppermint inhaled aromatherapy patches (or mandarin as an alternative if they have a peppermint sensitivity).
62575328|NCT05251337|EXPERIMENTAL|Intervention - anxiety|Patients indicating that anxiety is their primary symptom of concern and are randomized to receive intervention will be allocated to the intervention - anxiety arm. This arm will receive lavender inhaled aromatherapy patches.
62575329|NCT05251337|PLACEBO_COMPARATOR|Control - nausea/vomiting|Patients indicating that nausea/vomiting is their primary symptom of concern and are randomized to receive control will be allocated to the control - nausea/vomiting arm. This arm will receive blank (no essential oil infusion) aromatherapy patches.
62575330|NCT05251337|PLACEBO_COMPARATOR|Control - anxiety|Patients indicating that anxiety is their primary symptom of concern and are randomized to receive control will be allocated to the control - anxiety arm. This arm will receive blank (no essential oil infusion) aromatherapy patches.
62575331|NCT02282813|EXPERIMENTAL|CTAP101 Capsules alone|CTAP101 Capsules 30 or 60 mcg daily for up to 26 weeks
62575332|NCT02282813|EXPERIMENTAL|CTAP101 Capsules +calcitriol|CTAP101 Capsules 60 mcg +calcitriol daily for 14 weeks
62010159|NCT03413878|EXPERIMENTAL|Dry snow/Small air pocket|Breathing in the simulated avalanche snow. Breathing into model of dry avalanche snow with a small air pocket
62196515|NCT03308175|EXPERIMENTAL|flat fixed anterior bite plane|"Bands selection will be done for upper 6s. Alginate impressions taken and molar bands are fitted in place into the impressions. Impressions for upper and lower arches are poured with stone plaster. Mounting on simple hinge articulator will be done.~Lingual arches (diameter 1 mm) with anterior acrylic bite plates with thickness enough to separate posterior teeth 4mm .~The acrylic bite planes were in occlusion with the lower anterior teeth and extended sagittally 2-3mm beyond edges of lower incisors.~Finishing ,polishing and cementation into patient's mouth with glass ionomer cement."
62399236|NCT05523427|EXPERIMENTAL|Probiotics + Standard treatment of IBS|A capsule containing the L. plantarum and L. acidophilus strains is to be administered twice daily for three months in addition to the standard treatment of IBS.
62575333|NCT02282813|EXPERIMENTAL|CTAP101 Capsules +doxercalciferol|CTAP101 Capsules 60 mcg +doxercalciferol daily for 14 weeks
62575334|NCT02282813|EXPERIMENTAL|CTAP101 Capsules +paricalcitol|CTAP101 Capsules 60 mcg +paricalcitol daily for 14 weeks
62575335|NCT03564340|EXPERIMENTAL|Monotherapy|REGN4018 administration
62575336|NCT03564340|EXPERIMENTAL|Combination Therapy|REGN4018 and cemiplimab administration
62399237|NCT01784172|EXPERIMENTAL|electroacupuncture group|"Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward. Bilateral B L35 are given acupuncture of 50～60mm to outward and upward. The electric stimulator is applied to bilateral BL33 and BL35.~Every session lasts for 30 min per day. The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all."
62399238|NCT01784172|EXPERIMENTAL|sham electroacupuncture group|"Bilateral sham BL33 and sham BL35 are given sham electroacupuncture with no current output.~Every session lasts for 30 min per day. The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all."
62399239|NCT00204711||Outpatient Surgery with Sedation|SNAP II EEG data will be recorded continuously during the sedation and intermittently compared to routinely monitored parameters of sedation adequacy including vital signs, patient movement, grimacing, verbal complaints, and patient responsiveness to verbal and tactile stimuli. Following surgery, patients will be questioned to determine recall or memory of discomfort.
62399240|NCT04273802|EXPERIMENTAL|Cohort A - First line treatment|Untreated patients
62399241|NCT04273802|EXPERIMENTAL|Cohort B - Hypomethylating failure|Patients in absence of response after hypomethylating agents treatment
62399242|NCT00501748|EXPERIMENTAL|Rituximab|
62399243|NCT02567331|EXPERIMENTAL|Capecitabine|Participants will receive oral capecitabine 1250 milligrams per square meter (mg/m\^2) twice daily for 14 days followed by 7 day rest period for 6 cycles.
62399244|NCT03754270|ACTIVE_COMPARATOR|Lifestyle advice|Patients receive instructions and advice on lifestyle according to current clinical practice.
62399245|NCT03754270|EXPERIMENTAL|Lifestyle advice and cervical collar|"Patients receive the same instructions and advice as in Arm lifestyle advice and also get a CC and instructions on how to sleep with it."
62196516|NCT03308175|EXPERIMENTAL|modified inclined fixed anterior bite plane|"In modified inclined fixed anterior bite plane,the modification is that some indentations will be done in the acrylic part where the lower anteriors will fit such that mandible will be held in a more forward position. These indentations will be relieved lingually to overcome it's flaring effect on mandibular incisors .The inclined plane will be 60 degrees to occlusal plane.~Functional bite will be taken to position the mandible in the proper position forward.~Bite taken edge-to-edge for appliance construction. Mounting upper and lower casts on simple hinge articulator for construction of modified flat fixed anterior bite plane"
62575337|NCT03303456|EXPERIMENTAL|Clinical high risk (CHR)|Subjects at clinical high risk (CHR) for psychosis and/or bipolar disorder, aged 13-30 years. CHR participants will have no history of psychosis and will demonstrate attenuated psychotic symptoms consistent with the Structured Interview for Prodromal Syndromes (SIPS), or genetic risk (first-degree relative with psychosis) in conjunction with a substantial drop in functioning over the past year. Assigned Mobile health application - Ginger.io
62575338|NCT03303456|EXPERIMENTAL|First Episode Psychosis (FEP)|First Episode Psychosis (FEP) subjects aged 13-30 meeting criteria for schizophreniform disorder, schizophrenia, schizoaffective disorder or another psychotic, non-schizophrenia diagnosis including those with bipolar disorder. FEP participants will be ascertained three years or less from illness onset and have diagnoses of affective (i.e. bipolar) and non-affective psychosis (i.e. schizophrenia) according to DSM-IV criteria. Assigned Mobile health application - Ginger.io
62196517|NCT01240551|ACTIVE_COMPARATOR|Mets via NaF-18 PET/CT|Patients with known bone metastases (i.e. mets).
62196518|NCT01240551|ACTIVE_COMPARATOR|No-Mets via NaF-18 PET/CT|Patients with no clinical evidence of bone metastases
62196519|NCT00883974|EXPERIMENTAL|1|
62196520|NCT00883974|NO_INTERVENTION|2|Standard Neonatal Intensive Care Unit (NICU) procedures for the care of pre-term infants
62196521|NCT06067607|EXPERIMENTAL|Eye gaze technology intervention|Participants will use eye gaze technology and software activities as an intervention to improve visual abilities.
62575339|NCT03303456|EXPERIMENTAL|Healthy Controls (HC)|Healthy individuals with no current/past axis I disorders according to DSM-IV criteria and no first-degree relative with a psychotic disorder. Assigned Mobile health application - Ginger.io
62575340|NCT04634591||Obesity - undergoing bariatric surgery|Patients with morbid obesity, treated with the bariatric surgery
62575341|NCT04634591||Obesity - without bariatric surgery treatment|Patients with morbid obesity, not treated with the bariatric surgery
62575342|NCT04634591||Non-obese|Non-obese patients - control group (without obesity and without the bariatric surgery treatment)
62575343|NCT06577727||Children aged 6-72 months of age|"Approximately 250 children aged above 6 months old and below 6 years of age across potential study sites.~Subjects will be grouped by haemoglobin (Hb) level ranging from \<6 g/dL to ≥ 14.0 g/dL. There will be a minimum of 10 subjects and a maximum of 25 subjects for each group."
62196522|NCT01487187|ACTIVE_COMPARATOR|immediate umbilical cord clamping|The control group will receive immediate cord clamping at birth which is the standard of care in our institution
62196523|NCT01487187|EXPERIMENTAL|Milking the umbilical cord at birth|Infants in the cord-milked group will be placed at or below the level of the placenta, and about 20 cm of the umbilical cord (or the length of cord that is accessible if less than 20 cm) will be vigorously milked towards the umbilicus three times before clamping the cord.
62196524|NCT04867447||Case-Immigrants psychotic patients|"Individuals who have presented at least one non-affective psychotic episode with an immigrant status, defined as a person who migrates to another country, usually for permanent residence"
62196525|NCT04867447||Control-Non immigrants psychotic patients|Individuals who have presented at least one non-affective psychotic episode who do not have an immigrant status.
62196526|NCT00781495||type 2 diabetes mellitus|
62196527|NCT00540943|EXPERIMENTAL|Single Arm|irinotecan and cetuximab in combination with pazopanib.
62196528|NCT04226989|EXPERIMENTAL|Administration of CT-RD06|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
62196529|NCT02993406|EXPERIMENTAL|Bempedoic Acid 180 mg|Bempedoic acid 180 mg tablet taken orally, once daily.
62196530|NCT02993406|PLACEBO_COMPARATOR|Placebo Comparator|Matching placebo tablet taken orally, once daily
62196531|NCT05372107|EXPERIMENTAL|Group 1|One drop of 0.001% AG-80308, two times daily to both eyes for 3 months
62196532|NCT05372107|EXPERIMENTAL|Group 2|One drop of 0.03% AG-80308, two times daily to both eyes for 3 months
62196533|NCT05372107|EXPERIMENTAL|Group 3|One drop of 0.1% AG-80308, two times daily to both eyes for 3 months
62196534|NCT05372107|EXPERIMENTAL|Group 4|One drop of 0.03% AG-80308, new formulation, two times daily to both eyes for 3 months
62575344|NCT00933621|EXPERIMENTAL|Autologous Bone Marrow infusion|Percutaneous intracoronary autologous bone marrow infusion
62575345|NCT03113942|EXPERIMENTAL|Pomalidomide group|Open label - all participants will receive pomalidomide 2mg orally once a day for 6 cycles (21 days on treatment and a 7 day rest period constitutes a cycle).
62575346|NCT02582892|OTHER|Vit D|Vit D 20 mg/day
62575347|NCT01500382|EXPERIMENTAL|Vibegron 100 mg + tolterodine ER 4 mg → placebo|During Treatment Period 1, participants will receive 7 days of once-daily vibegron 100 mg and tolterodine extended-release (ER) 4 mg. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER.
62734692|NCT02798224|ACTIVE_COMPARATOR|Healthwise Educational Program (active control)|Eligible patients identified will receive a prompt (via email) to log into portal for an important health message. Once eligible patient initiates portal session, continuing past IRB consent screen, patient is enrolled.
62196535|NCT02971566||Gastrointestinal complications|"Development of one ore more of the following gastrointestinal complications:~* necrotizing enterocolitis (stage ≥2)~* spontaneous intestinal perforation~* feeding intolerance, defined as enteral feeding withholding ≥1 day because of suggestive clinical signs"
62196536|NCT02971566||Controls|no evidence of gastrointestinal complications during the hospitalization
62196537|NCT00561106|ACTIVE_COMPARATOR|1|
62196538|NCT00561106|PLACEBO_COMPARATOR|2|
62196539|NCT05403931|EXPERIMENTAL|Particular joint point group|This group will receive laser irradiation on 6-7 particular points including 4-5 on tibiofemoral and 2 on patellofemoral joint.
62196540|NCT05403931|EXPERIMENTAL|Acupuncture points group|This group will receive laser irradiation on 6-7 particular acupuncture points which have been previously used in another study and or identified in literature.
62196541|NCT00822770|EXPERIMENTAL|Phase I|ATG + Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant
62196542|NCT00822770|EXPERIMENTAL|Phase II|ATG + MTD Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant
62196543|NCT05005962||Acute ischemic patients suffering with stroke|Acute ischemic patients treated with commercially available neurothrombectomy devices in India. The device can be either a stent retriever or aspiration catheter to treat the stroke as per the labeling indications of the products.
62196544|NCT00564616|PLACEBO_COMPARATOR|voice group|"the voice group received voice CPR instruction via a voice-only cell phone"
62196545|NCT00564616|EXPERIMENTAL|video group|"the video group received interactive voice and video instruction via a video cell phone"
62196546|NCT03435731|EXPERIMENTAL|Treatment Group|This group will undergo 1 month Dual Therapy.
62196547|NCT01546246|NO_INTERVENTION|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
62399246|NCT04790682|EXPERIMENTAL|NSCLC patient in a metastatic stage eligible for 1st-line TT with immune checkpoint inhibitor.|"Patient with histologically proven Non Small Cell Lung Cancer in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible.~Presence of a mutation after NGS analysis is required for ctDNA follow-up."
62399247|NCT02210559|EXPERIMENTAL|FG-3019 + Gemcitabine + Nab-paclitaxel|Participants will receive FG-3019 35 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion on Days 1 and 15 of each treatment cycle and on Day 8 of the first cycle, gemcitabine 1000 mg/square meter (m\^2) and nab-paclitaxel 125 mg/m\^2 by IV infusion on Days 1, 8, and 15 of each treatment cycle. Treatment will be administered over a 28-day cycle, for up to 6 cycles.
62196548|NCT01546246|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
62734693|NCT02798224|NO_INTERVENTION|Usual care control (observational only)|There will be no participant contact in this arm. We will use existing data sources only (e.g., EHRs) to obtain information on participants in this arm (i.e., an observational data review only).
62196549|NCT03591133|OTHER|Step1:3㎎ QD|Drug: TS-143 3mg Drug: Placebo
62196550|NCT03591133|OTHER|Step2:6㎎ QD|Drug: TS-143 6mg Drug: Placebo
62196551|NCT03591133|OTHER|Step3-1:11㎎ QD|Drug: TS-143 11mg Drug: Placebo
62196552|NCT03591133|OTHER|Step3-2:11㎎ QD（Fed)|Drug: TS-143 11mg Drug: Placebo
62196553|NCT03591133|OTHER|Step4:20㎎ QD|Drug: TS-143 20mg Drug: Placebo
62196554|NCT03591133|OTHER|Step5:36㎎ QD|Drug: TS-143 36mg Drug: Placebo
62196555|NCT01028677|EXPERIMENTAL|intranasal spray with oxytocin|Twice daily intranasal oxytocin spray (24 IU, 6 insufflations/dose) for 6 weeks
62196556|NCT01028677|PLACEBO_COMPARATOR|intranasal spray without oxytocin|Twice daily intranasal spray without oxytocin (six 0.1 ml insufflations/dose) for 6 weeks.
62196557|NCT04831879|EXPERIMENTAL|Group A AMPS - sham|Treatment phase 1: AMPS Treatment phase 2: sham
62196558|NCT04831879|EXPERIMENTAL|Group B sham - AMPS|Treatment phase 1: sham Treatment phase 2: AMPS
62196559|NCT01578213|EXPERIMENTAL|Imatinib|
62399248|NCT02210559|ACTIVE_COMPARATOR|Gemcitabine + Nab-paclitaxel|Participants will receive gemcitabine 1000 mg/ meter squared (m\^2) and nab-paclitaxel 125 mg/m\^2 by IV infusion on Days 1, 8, and 15 of each treatment cycle. Treatment will be administered over a 28-day cycle, for up to 6 cycles.
62399249|NCT03308799|EXPERIMENTAL|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
62196560|NCT05173337|NO_INTERVENTION|control group|Nefopam will not be administered in this group.
62196561|NCT05173337|EXPERIMENTAL|nefopam group|Intravenous nefopam 20 mg will be administered twice, immediately after induction of anesthesia and at the end of surgery.
62196562|NCT01467310|EXPERIMENTAL|GSK1120212|
62196563|NCT05707247|EXPERIMENTAL|prototype software|
62196564|NCT04053062|EXPERIMENTAL|LIGHT-PSMA-CART|Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -6 to -4. Patients receive LIGH-PSMA-CART IV at split doses from day 0 on.
62196565|NCT01250925|ACTIVE_COMPARATOR|OPTI-FREE® RepleniSH®|33 participants will be assigned to use this lens care regimen during the six-week assessment period
62196566|NCT01250925|ACTIVE_COMPARATOR|Clear Care®|33 participants will be assigned to use this lens care regimen during the six-week assessment period
62575348|NCT01500382|EXPERIMENTAL|Placebo → vibegron 100 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily vibegron 100 mg and placebo to match tolterodine ER.
62575349|NCT01500382|ACTIVE_COMPARATOR|Placebo → tolterodine ER 4 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily tolterodine 4 mg and placebo to match vibegron.
62575350|NCT01500382|EXPERIMENTAL|Placebo → vibegron 50 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily vibegron 50 mg and placebo to match tolterodine ER.
62575351|NCT00605631|EXPERIMENTAL|1|
62575352|NCT00605631|ACTIVE_COMPARATOR|2|
62196567|NCT01250925|ACTIVE_COMPARATOR|ReNu MultiPlus® MultiPurpose Solution|33 participants will be assigned to use this lens care regimen during the six-week assessment period
62196568|NCT03453697|EXPERIMENTAL|acute intermittent hypoxia|Adjust the proportion of nitrogen and oxygen, through increasing the suction nitrogen concentration, the subject's blood oxygen saturation could decrease to 80%\~90% within 30 seconds and also lasts 30 seconds; then quickly reduce the concentration of nitrogen gas suction to make the subject's blood oxygen saturation gradually return to normal level (consistent with the air inhalation), and then continue breathing air about 60 seconds to enter the next round of hypoxic state.Through adjusting the inhaled nitrogen concentration in patients, the patients could be simulated as the OSA patients who had intermittent hypoxic state due to upper airway collapse at night. This process is equivalent to acute intermittent hypoxia 25-30 times/h, which is clinically intermediate to severe OSA.
62196569|NCT02738645||pneumonia in RICU|The patients admit in RICU because of pneumonia.
62575353|NCT00605631|OTHER|3|
62575354|NCT05783167||HIV-positive females in Guinea-Bissau|"The study is conducted on female HIV-infected patients in the Nationwide HIV-cohort at the 9 biggest HIV-clinics in Guinea-Bissau.~Participants will be invited to enroll in the project when they present to the HIV-clinics for HIV-treatment and consultations."
62575355|NCT00955955|EXPERIMENTAL|6(S)-5-MTHF(Deplin)|"Participants will receive 15 mg/day of Deplin, a medical food, for 8 weeks.~The SPCD approach, is modified and conducted as follows:~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
62575356|NCT00955955|EXPERIMENTAL|Placebo/Deplin|"Participants will receive placebo for the first 4 weeks, and then 15 mg/day of Deplin (6(S)-5-MTHF) for the next 4 weeks.~The SPCD approach, is modified and conducted as follows:~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
62575357|NCT00955955|EXPERIMENTAL|Placebo/Placebo|"Participants will receive placebo for both phases of the study.~The SPCD approach, is modified and conducted as follows:~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
62734694|NCT02425956|EXPERIMENTAL|MRI imaging of liver|GE Optima/Discovery® MRI imaging data of the liver and surrounding tissues will be acquired using 1.5T and 3.0T GE Healthcare (GEHC) IDEAL IQ scans and commercially available 1.5T MRI scans conducted according to the FerriScan®
62196570|NCT06355804|EXPERIMENTAL|Physical activity condition|Participants in this arm will receive a remote-delivered physical activity program for 16 weeks that includes access to electronic newsletters and regular one-on-one coaching chats (15 - 30 minutes) over Zoom with a behavioral coach after the baseline assessment. Throughout the 16-week period, The investigators will ask participants to wear a Fitbit (provided) for tracking daily physical activity.
62734695|NCT02147197|EXPERIMENTAL|UPA 5 mg|Ulipristal acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.
62734696|NCT02147197|EXPERIMENTAL|UPA 10 mg|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.
62734697|NCT02147197|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks.
62196571|NCT06355804|OTHER|Waitlist condition|Participants will receive access to a remote-delivered physical activity program for 16 weeks that includes access to electronic newsletters and regular one-on-one coaching chats (15-30 minutes) over Zoom with a behavioral coach after the follow-up assessment.
62196572|NCT04155203|EXPERIMENTAL|Perrigo active|
62196573|NCT04155203|ACTIVE_COMPARATOR|Reference Active|
62196574|NCT04155203|PLACEBO_COMPARATOR|Vehicle control|
62399250|NCT03308799|ACTIVE_COMPARATOR|Cal/BDP combination|Calcipotriene/betamethasone (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.
62399251|NCT03308799|PLACEBO_COMPARATOR|Cream vehicle|One application daily for 8 weeks.
62575358|NCT06463470|EXPERIMENTAL|Cognitive Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)|"This therapy involves four stages.~* Stage 1 -Psychoeducation: This is covered in 2-4 sessions and involves explaining what ARFID is, educating patients and carers on food groups, nutrition and how to develop a balanced diet. Work is also done to increase eating volume for those who are underweight.~* Stage 2 -Treatment planning: This is covered in 2 sessions and involves matching the individuals needs to the correct exposure approach (examples provided in stage 3).~* Stage 3 -Graded exposure is covered for between 12 and 22 sessions (depending on the patient's needs) and describes slowly introducing more variety and volume of foods into the patient's diet.~* Stage 4 -Relapse prevention: This is covered in 2 sessions. In these sessions, individuals are taught to recognise triggers and indicators of relapse. They are then able to go back to the materials provided in treatment to guide their management of these relapsing thoughts/behaviours."
62575359|NCT03110406|EXPERIMENTAL|whole-body vibration|The whole-body vibration training will be performed with the patients in the static position, feet apart at 20 cm, semi-squat with knees at 15º flexion and upper limbs slightly flexed and supported on the platform. The exercises will be performed, in the first two weeks, for 10 minutes consisting of 60 seconds of low intensity with 30 seconds of rest standing in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. °
62575360|NCT03110406|SHAM_COMPARATOR|Simulated whole-body vibration|The simulated whole-body vibration training will be performed with the patients in the static position, feet apart at 20 cm, in semi-squat with knees at 15º of flexion and upper limbs slightly flexed and supported on the platform that presents a motor that simulates the noise of the platform But does not produce any therapeutic effect
62575361|NCT01014169|NO_INTERVENTION|Usual care|Mothers in the control group will receive the nursing discharge newborn information from the nurse practitioner \[sometimes via a Spanish interpreter, if required\] according to current standard of care, which includes verbal information and written handouts.
62575362|NCT01014169|EXPERIMENTAL|Note taking|The mothers in the intervention group will be given a pen and encouraged to take written notes in the notes section of the discharge envelope using their language of preference when receiving the standard newborn information.
62399252|NCT02208466|EXPERIMENTAL|Active rTMS/active fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of active low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of active low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.
62399253|NCT02208466|EXPERIMENTAL|Sham rTMS/active fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.
62399254|NCT02208466|EXPERIMENTAL|Sham rTMS/placebo fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of placebo fluoxetine by mouth daily.
62399255|NCT01707667|EXPERIMENTAL|Prucalopride|
62399256|NCT01707667|ACTIVE_COMPARATOR|PEG 3350|
62399257|NCT04942951||Pregnant women with the diagnosis of urinary incontinence (Study group)|The pregnant women who were diagnosed with the urinary incontinence (n=80) with category 0 or category 1 Pelvic Organ Prolapse Quantification (POP-Q) score in physical examination.
62010160|NCT03413878|EXPERIMENTAL|Wet snow/Large air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet avalanche snow with a large air pocket
62010161|NCT03413878|EXPERIMENTAL|Dry snow/Large air pocket|Breathing in the simulated avalanche snow. Breathing into model of dry avalanche snow with a large air pocket
62010162|NCT00661934||1|Dialysis Group
62010163|NCT00661934||2|Cardiac Malfunction Group
62196575|NCT03468062|EXPERIMENTAL|Dexmedetomidine|0.5 mg/kg of dexmedetomidine (Precedex; Hospira, Lake Forest, IL) is mixed in normal saline 100mL and administered for 5 minutes after anesthetic induction.
62196576|NCT03468062|PLACEBO_COMPARATOR|Placebo|Only normal saline 100mL is administered for 5 minutes after anesthetic induction.
62399258|NCT04942951||Healthy pregnant women (Control group)|Control group consisted of healthy women with uncomplicated pregnancies (n=80). They had no complaint of urinary incontinence and their gynecological examination did not reveal any finding of pelvic organ prolapse.
62399259|NCT01733758|EXPERIMENTAL|Albiglutide 30 mg weekly|Subjects will be randomly assigned to double blind albiglutide 30 mg weekly treatment for 52 weeks
62399260|NCT01733758|EXPERIMENTAL|Albiglutide 50 mg weekly|Subjects will be randomly assigned to double blind albiglutide 50 mg weekly until Week 52
62399261|NCT01733758|PLACEBO_COMPARATOR|Placebo|Subjects will be randomly assigned to double blind matching albiglutide placebo administered weekly. Subjects will then cross-over to double-blind treatment with albiglutide 30 mg weekly at Week 24 until Week 52
62399262|NCT01733758|ACTIVE_COMPARATOR|Liraglutide 0.9 mg daily|Subjects will be randomly assigned to open-label liraglutide for 52 weeks
62399263|NCT03588494|ACTIVE_COMPARATOR|concurrent chemoradiotherapy (CCRT)|"Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
62399264|NCT03588494|EXPERIMENTAL|W1-CCRT|"Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first chemoradiotherapy cycle(days -5～-1).~Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
62399265|NCT03588494|EXPERIMENTAL|W2-CCRT|"Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).~Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
62010164|NCT00501891|EXPERIMENTAL|Bevacizumab and Metronomic Temozolomide|Patients will receive up to 12 cycles of bevacizumab (Avastin) and metronomic temozolomide (Temodar), and each cycle is 28 days. Bevacizumab will be administered at 10 mg/kg every other week beginning a minimum of 7 days after a biopsy or 28 days after a craniotomy. Temozolomide will be dosed at 50 mg/m2 daily in a 28-day cycle.
62010165|NCT04464226|EXPERIMENTAL|Darolutamide (BAY1841788)|Participants enrolled in the current study will use the dose they were assigned to in the feeder study they come from.
62399266|NCT01582932|EXPERIMENTAL|Calcipotriene 0.005% Foam|Foam is a vitamin D3 analog (calcipotriene) foam 0.005%. It is applied twice a day for 8 weeks to psoriasis lesions (except the face).
62399267|NCT04850170|EXPERIMENTAL|Experimental group|"The first ten subjects will be enrolled in a pilot study. The following sixty subjects will be separated randomly to experimental group and control group.~The first ten subjects and the experimental group will be arranged manual therapy and rehabilitation for six months."
62010166|NCT03049813|EXPERIMENTAL|Virtual Reality Job Interview Training|Virtual Reality Job Interview Training
62010167|NCT03049813|OTHER|Supported Employment (Services as Usual)|Supported Employment (Services as Usual)
62010168|NCT06573866|EXPERIMENTAL|Participatory workplace intervention (PWI)|Participants in the PWI group will receive the PWI and continue to receive usual care.
62010169|NCT06573866|NO_INTERVENTION|Usual care control group|The usual care control group comprises usual care. There are no restrictions on usual care.
62010170|NCT05266326|OTHER|Test group|conventional Western medical treatment + bloodletting puncture
62010171|NCT05266326|OTHER|Control group|conventional Western medical treatment.
62010172|NCT05548244|EXPERIMENTAL|MDD patients|Participants will be seen for a maximum of 16 sessions over 16 weeks. Two extra sessions will be allowed during treatment.
62010173|NCT04394416|EXPERIMENTAL|Imatinib|Imatinib oral 400 mg daily for 14 days.
62010174|NCT04394416|ACTIVE_COMPARATOR|Placebo|Placebo oral for 14 days
62010175|NCT02753712|ACTIVE_COMPARATOR|fluticasone/vilanterol DPI (Relvar Ellipta DPI)|Inhalation powder. 92/22µg, I inhalation od
62010176|NCT02753712|EXPERIMENTAL|Fluticasone/formoterol BAI|Pressurised suspension for inhalation 125/5µg, 2 inhalations bid
62010177|NCT04114058|ACTIVE_COMPARATOR|Liposomal Bupivicaine|Following hip arthroscopy, local field infiltration with liposomal bupivicaine will be performed for adjunct pain control
62399268|NCT04850170|ACTIVE_COMPARATOR|Control group|The control group will be arranged rehabilitation.
62399269|NCT03081962|EXPERIMENTAL|Bundle application|The patients in this group will undergo an intraperitoneal irrigation with clindamycin and gentamicin solution, fascial closure with triclosan impregnated sutures and application of Mupirocin ointment over the skin staples
62399270|NCT03081962|ACTIVE_COMPARATOR|Standard care|The patients in this group will follow a standard care, including decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
62010178|NCT04114058|ACTIVE_COMPARATOR|fascia iliaca blockade|Preoperatively before hip arthroscopy, a fascia iliaca blockade will be performed for adjunct pain control
62010179|NCT06568146|EXPERIMENTAL|Multivitamin Supplement Group|Participants in this arm will take 2 capsules of the multivitamin supplement daily with the first meal of the day in the morning.
62010180|NCT05864313|ACTIVE_COMPARATOR|Real 10 Hz rTMS|Participants will receive 1 hour of real rTMS followed by 1 hour of gaze and gait training.
62010181|NCT05864313|SHAM_COMPARATOR|sham rTMS|Participants will receive 1 hour of sham rTMS followed by 1 hour of gaze and gait training.
62010182|NCT00996567|EXPERIMENTAL|Cetuximab (Erbitux)|
62010183|NCT01734226|EXPERIMENTAL|Prunus Mume Extract|
62010184|NCT01734226|PLACEBO_COMPARATOR|Placebo|
62196577|NCT04197375|EXPERIMENTAL|Pre-cooling scenario|One hour before a tennis match, the pre-cooling group was wearing a Cooling Cap (WElkins Sideline Cooling System, SCS) for 45 minutes.
62196578|NCT04197375|SHAM_COMPARATOR|Sham evaluation|Participants were monitored during a usual game without any kind of pre-cooling strategy
62575363|NCT04173156|EXPERIMENTAL|Oscillating Chitosan Device|The brush bristles of the test device (Labrida BioClean®, LABRIDA AS, Oslo, Norway) are made of the biopolymer chitosan. Any debris left from the chitosan bristles is completely biocompatible and will dissolve or be resorbed, thus not causing harm to the tissues.surrounding the tooth. Chitosan is made from chitin derived from shell of marine crustaceans such as shrimp and crab, however chemically modified and thus not even considered to be animally derived. Chitosan has been approved for use in e.g., surgical bandages, as a haemostatic agent and as dietary supplement used in a wide range of nutritional and health products. Chitosan has also been documented to be non-allergenic and it has been suggested that chitosan has anti-inflammatory properties.
62575364|NCT04173156|ACTIVE_COMPARATOR|Regular Curettes|Standard non surgical treatment of active periodontal disease includes supra and subgingival scaling and root planing with periodontal medical grade Gracey system steel curettes
62575365|NCT06240273|EXPERIMENTAL|Metabolic Syndrome patients|Cornsilk (Stigma maydis) is used for preventing symptoms of metabolic syndrome patients Dietary Intervention: Cornsilk Extract Dosage: 2g/day
62575366|NCT04345250|EXPERIMENTAL|Participants|"For a period of 6 days between the exercise trials (i.e., following visit 3), each participant will be put on a restricted energy restricted diet consisting of a 25% reduction in their habitual total daily calorie intake. To keep the diet consistent and standardized, participants will record their typical food intake during a control week using the Eat This Much app, which will then provide an overall portion plan and the 25% caloric restriction measure for the intervention week. Thus, the intervention diet will mirror the control diet in terms of types of food consumed, with the difference being in the amount consumed. There will be no restriction regarding water, but drinks will be restricted according to the overall calorie intake plan."
62575367|NCT03314792|ACTIVE_COMPARATOR|Oxycodone|Active comparator drug administrated.
62575368|NCT03314792|EXPERIMENTAL|Tapentadol|Experimental drug administrated.
62575369|NCT02417142|EXPERIMENTAL|Experimental|Exenatide 2mg subcutaneous injection, once weekly
62575370|NCT02417142|PLACEBO_COMPARATOR|Placebo|Placebo
62575371|NCT00351624|ACTIVE_COMPARATOR|DHA|
62575372|NCT00351624|PLACEBO_COMPARATOR|placebo|
62575373|NCT04797702|EXPERIMENTAL|Experimental group|Glumetinib combined with Toripalimab
62575374|NCT01920958||TachoSil®|TachoSil®, sterile absorbable patch, topical application, used during surgery in participants who had lymphadenectomy according to the Summary of Product Characteristics.
62010185|NCT06028061|ACTIVE_COMPARATOR|Adjuvant-free Quadratus lumborum block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
62196579|NCT01122875|EXPERIMENTAL|A|
62196580|NCT01871688|OTHER|pelvic floor exercise|pelvic floor rehabilitation program with neuromodulation
62196581|NCT05444634|EXPERIMENTAL|distraction card|Immediately before the procedure, the child will be asked questions about the distraction cards. Questions about the cards will continue to be asked immediately after the intramuscular injection is finished.
62399271|NCT02425670|EXPERIMENTAL|Bone marrow derived stem cells (BMSCs)|BMSCs 30-500 million plus conventional management
62399272|NCT02425670|NO_INTERVENTION|Control|Control: conventional management
62399273|NCT05947656|EXPERIMENTAL|Cohort 1|Eligible patients in Cohort 1 will receive two (2) FUS treatments per week for two (2) weeks on Day 1, 4, 8 and 11, followed by three (3) safety follow-up visits on Day 36, 64 and 92.
62575375|NCT06548373||Year 2 Residents|Loma Linda University Post-Graduate Year 2 Anesthesiology residents providing anesthetic care.
62575376|NCT04868045|EXPERIMENTAL|Patients with a history of thyroid hormone suppression (TSH<0.5 mU/L) for at least 5 years|Study subjects will be given 200mcg of TRH as a single intravenous (IV) bolus in endocrine clinic on Day 1 and Day 5. LT3 will be administered orally, twice a day (12 hours apart i.e. 8 AM and 8 PM) at a dosage of 10 mcg on Day 2-4. Levothyroxine will be taken after the TRH stimulation tests on Day 1 and day 5. Levothyroxine will be taken on Days 2-4 of the study. \*Patients will take their own LT4 that they are prescribed by their endocrinologist. The dose of Levothyroxine is titrated for each patient.
62196582|NCT05444634|EXPERIMENTAL|Stress Ball|The child will be informed about the stress ball and asked to play continuously
62196583|NCT05444634|NO_INTERVENTION|Control|
62196584|NCT03053453|ACTIVE_COMPARATOR|Standard of Care Spinal Surgery|Patients will be given spinal anesthesia with 2.6 mL of 0.5% isobaric bupivacaine.
62196585|NCT03053453|EXPERIMENTAL|Sensor Guided Spinal Surgery|The Verasense Knee System device (OrthoSensor inc., Dania Beach, Florida) is a sterile sensor system that replaces the tibial insert trials used during surgery. The sensor contains a microprocessor and integrated nanosensor system, which wirelessly transmits real-time data to a portable graphic display unit used for read-out of the data. The sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces. Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
62196586|NCT04589299|ACTIVE_COMPARATOR|Patients treated with immunoglobulin intravenously (IVIG)|Immunoglobulin (PRIVIGEN) intravenously 2 g/kg/4week for 26 weeks. After this 60 weeks of reduction every 12 weeks (90%, 75%, 50%, 25% and 0%).
62399274|NCT05947656|EXPERIMENTAL|Cohort 2|Eligible patients in Cohort 2 will receive two (2) FUS treatments per week for three (3) weeks on Day 1, 4, 8, 11, 15 and 18, followed by three (3) safety follow-up visits on Day 43, 71 and 99.
62399275|NCT06269562|EXPERIMENTAL|Block|consists of 5 patients in whom both techniques were applied
62399276|NCT00727246|EXPERIMENTAL|CDP-Choline|Treatment with CDP-Choline
62399277|NCT00727246|PLACEBO_COMPARATOR|Placebo|Treatment with Placebo
62734698|NCT05738798|EXPERIMENTAL|oral immunotherapy|oral immunotherapy, maintenance phase with daily 300 mg allergenic protein during 1 year
62734699|NCT05738798|NO_INTERVENTION|routine care|strictly avoidance of the specific allergenic food
62734700|NCT04224103||Inhaled nitric oxide|
62734701|NCT05937386|EXPERIMENTAL|1|AGMB-129 and MDZ
62196587|NCT04589299|ACTIVE_COMPARATOR|Patients treated with immunoglobulin subcutaneously (SCIG)|Immunoglobulin (HIZENTRA) subcutaneously 0.54 g/kg/week for 26 weeks. After this 60 weeks of reduction every 12 weeks (90%, 75%, 50%, 25% and 0%).
62196588|NCT05701904|EXPERIMENTAL|Local mechanical vibration applied group|"Before the injection, local mechanical vibration will be applied for 3 minutes with a vibration device to the deltoid muscle where the injection will be made, and then the vaccine will be given. The vibration device to be used is suitable for contact with the skin and provides 6000 rotations per minute with vibration.~Pregnant women who were asked to receive tetanus+diphtheria vaccine by their physician and agreed to participate in the study will be informed about the research by the researcher, and their written and verbal consents will be obtained. Then the vaccine will be administered. Td vaccine will be administered to all pregnant women in the study as IM to the deltoid muscle in the arm they do not use dominantly. Five minutes after the vaccination, the individual descriptor form will be applied to all pregnant women, and the pregnant women will score their satisfaction levels with regard to pain and the method used."
62399278|NCT02335359|EXPERIMENTAL|Tranexamic Acid|A 500 mg loading dose of tranexamic acid diluted in 100 ml of saline solution will be slowly administered intravenously to patients 20 minutes before surgery, followed by a continuos infusion of 250 mg/h of tranexamic acid from surgical incision until skin closure.
62399279|NCT02335359|PLACEBO_COMPARATOR|Placebo|Saline
62399280|NCT03490253|ACTIVE_COMPARATOR|Static Messaging|We will send patients a total of seven messages per week (one per day) at 10.00 am. For the physical health management messages we use messages from established topics in the Diabetes Prevention Program(23) content with the emphasis on physical activity and stress management. The final message, on the seventh day will ask patients to rate their mood on a scale from 1 to 9. Physical activity (step-count/day) will be passively monitored via the app on their smartphone.
62399281|NCT03490253|EXPERIMENTAL|Adaptive Messaging|Patients in the adaptive messaging arm will receive the daily messages of the static arm, and additionally receive daily messages within different categories of feedback and motivational messages that are chosen using a reinforcement learning (RL) algorithm. Physical activity (step-count/day) will be actively monitored via the app on their smartphone.
62575377|NCT04868045|EXPERIMENTAL|Patients with no history of TSH suppression|Study subjects will be given 200mcg of TRH as a single intravenous (IV) bolus in endocrine clinic on Day 1 and Day 5. LT3 will be administered orally, twice a day (12 hours apart i.e. 8 AM and 8 PM) at a dosage of 10 mcg on Day 2-4. Levothyroxine will be taken after the TRH stimulation tests on Day 1 and day 5. Levothyroxine will be taken on Days 2-4 of the study. \*Patients will take their own LT4 that they are prescribed by their endocrinologist. The dose of Levothyroxine is titrated for each patient.
62575378|NCT01163851|EXPERIMENTAL|PF-04950615 (RN316)|
62575379|NCT04813068||Interview arm|Group of patients who have agreed to have a qualitative interview on the topic of recurrence of lung cancer
62575380|NCT05422274|EXPERIMENTAL|Transcranial Pulse Stimulation (TPS group)|Subjects in the TPS group will be given 6 verum TPS sessions (Pulse: 800 / session) across two weeks time, with 3 sessions per week.
62575381|NCT05422274|SHAM_COMPARATOR|Sham TPS Group|Subjects in the Sham TPS group will be given 6 sham TPS sessions across two weeks time, with 3 sessions per week.
62010186|NCT06028061|ACTIVE_COMPARATOR|Quadratus Lumborum Block with adjuvant|The same block was applied to this group, but a different local anesthetic mixture was used. Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 4mg dexamethasone is injected. The same is done to the opposite side.
62010187|NCT05280119|EXPERIMENTAL|Patients benefitting ultrasound examination|This is the only arm of the study. Patients with an indicative clinical picture that leads the clinician to resort to the use of an ultrasound to potentially support the diagnosis will be examined to verify the presence of pleural effusion or intra-abdominal effusion, or to identify basilic vein. The patients will be assessed first with the echOpen device and second witn an ultrasound routinely used in the department. In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating
62010188|NCT01271881|ACTIVE_COMPARATOR|Percutaneous Transluminal Angioplasty (PTA) alone|Intervention: Procedure: PTA alone without use of the GORE VIABAHN
62010189|NCT01271881|EXPERIMENTAL|PTA with covered stent|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
62010190|NCT04359173||Hypothermic machine perfusion (HMP)|patients who underwent kidney transplantation following HMP
62010191|NCT04359173||Static cold storage (SCS)|patients who underwent kidney transplantation following SCS
62010192|NCT04364633||Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
62010193|NCT04364633||Neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
62399282|NCT03490253|NO_INTERVENTION|Control Condition|Control patients will only install the app on their phone and will not receive any feedback messages. They will receive one message a week, on a fixed day, asking them to assess their mood in the previous week on a scale of 1 to 9. The message will be sent daily at 10:00 am. Non-responders will receive reminders to submit their mood self-assessments in two hour intervals.
62399283|NCT05680545|EXPERIMENTAL|Sevoflurane vaporized in ECMO machines|Patients' sedation will be managed with sevoflurane-based anesthesia directly vaporized into the ECMO machine.
62399284|NCT01704482|EXPERIMENTAL|N-acetylcysteine|N-acetylcysteine bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
62734702|NCT05221996|EXPERIMENTAL|Resistance exercise for 10 min|Resistance circuit training of 10 min
62734703|NCT05221996|EXPERIMENTAL|Resistance exercise for 20 min|Resistance circuit training of 20 min
62734704|NCT05221996|EXPERIMENTAL|Resistance exercise for 30 min|Resistance circuit training of 30 min
62575382|NCT02637206|EXPERIMENTAL|Part 1 (Single Application)|All subjects will have two sets (left and right) of 4 semi-occlusive test patches applied to randomized test sites on their upper backs on Day 1. Test patches on left back will be for simple-patch test and those on right back will be for photo-patch test. Each set will consist of approximately 150 micro liter (0.15 mL) of the following study treatments: GSK2894512 0.5% cream, GSK2894512 1% cream, placebo (cream vehicle without the active ingredient) and an empty patch. The test patches will be applied for 24 hrs (photo-patch test) or 48 hrs (simple-patch test).
62575383|NCT02637206|EXPERIMENTAL|Part 2 (Repeat Application)|All subjects will have repeat applications of GSK2894512 0.5%, 1% cream and placebo twice a day for 7 days on both side (left and right, 3 in total) of their upper back (approximately 5 centimeter (cm) in diameter \>10 cm away from another application area) under non-occlusive conditions and covered with gauze using adhesive. GSK2894512 0.5% and 1% cream and placebo will be randomized according to the randomization code in the same manner as Part 1.
62575384|NCT05139771|OTHER|EndoArt® Artificial Endothelial Layer|EndoArt® is intended to be used as an endothelial prosthesis in patients with chronic corneal edema. One arm - all subjects will be implanted with EndoArt®.
62575385|NCT02764424||Preterm or term newborns|Preterm or term newborns, hospitalized in neonatal intensive care units of our university hospital (Saint-Etienne - France), who have to acute painful stimuli related to their care will be included in the study. This painful stress is made in the patient's usual care and is not modified by the protocol. Their stress due to the painful stimuli will be measured with different scales (2 PIPP (Premature Infant Pain Profile) and DAN (Newborn Acute Pain)) and compared with the index obtained with the NIPE (Newborn Infant Parasympathetic Evaluation - MDoloris®).
62575386|NCT02887976|EXPERIMENTAL|SoluMatrix™ Abiraterone Acetate|SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid)
62196589|NCT05701904|EXPERIMENTAL|Shotblocker group|"It is a U-shaped device with skin contact points on the shotblocker and an opening in the middle for injecting. The Shotblocker will be placed on the skin surface just before inserting the needle and gently pressed with the fingertips, and the vaccine will be administered immediately afterwards. After removing the needle, the shotblocker will be removed.~Pregnant women who were asked to receive tetanus+diphtheria vaccine by their physician and agreed to participate in the study will be informed about the research by the researcher, and their written and verbal consents will be obtained. Then the vaccine will be administered. Td vaccine will be administered to all pregnant women in the study as IM to the deltoid muscle in the arm they do not use dominantly. Five minutes after the vaccination, the individual descriptor form will be applied to all pregnant women, and the pregnant women will score their satisfaction levels with regard to pain and the method used."
62196590|NCT05701904|NO_INTERVENTION|Control group|"The vaccine will be administered by following the standard intramuscular injection procedure. Five minutes after vaccination, an individual descriptive form will be applied to all pregnant women, and pregnant women will score their pain and satisfaction levels with scales.~Pregnant women who were asked to receive tetanus+diphtheria vaccine by their physician and agreed to participate in the study will be informed about the research by the researcher, and their written and verbal consents will be obtained. Then the vaccine will be administered. Td vaccine will be administered to all pregnant women in the study as IM to the deltoid muscle in the arm they do not use dominantly. Five minutes after the vaccination, the individual descriptor form will be applied to all pregnant women, and the pregnant women will score their satisfaction levels with regard to pain and the method used."
62399285|NCT01704482|PLACEBO_COMPARATOR|Glucose 5%|equivalent volume over the same period.
62196591|NCT02125279|EXPERIMENTAL|Calcitriol ointment|
62010194|NCT00079352|EXPERIMENTAL|Treatment (gemcitabine, irinotecan, alvocidib)|Patients receive gemcitabine IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1 and 15. Patients also receive flavopiridol IV over 60 minutes on days 2 and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62399286|NCT03237325|EXPERIMENTAL|SGX942|Patients are randomized 1:1 active/placebo.
62399287|NCT03237325|PLACEBO_COMPARATOR|Placebo|Patients are randomized 1:1 active/placebo.
62010195|NCT03351049|EXPERIMENTAL|Reactive, Low air loss support surface|Participants in this arm will use a reactive support surface with a low air loss feature
62010196|NCT03351049|ACTIVE_COMPARATOR|Reactive, non-low air loss|Participants in this arm will use a reactive support surface without a low air loss feature
62010197|NCT06080620|EXPERIMENTAL|Group A|Surgery+systematic treatment
62399288|NCT06304064|EXPERIMENTAL|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|All participants who were randomized to the Usual Care Treatment Group and completed 12 months of follow-up in the HOPE-Duchenne trial (NCT02485938), will receive CAP-1002 intravenous infusion on Day 1 and at Month 3 in the current study.
62010198|NCT06080620|ACTIVE_COMPARATOR|Group B|Neoadjuvant therapy+surgery+systematic treatment
62010199|NCT06047197|EXPERIMENTAL|First dose group|The initial dose is (0.5 ± 0.1) × 10\^6/kg, with 1 participant enrolled
62010200|NCT06047197|EXPERIMENTAL|Second dose group|The second dose is (1.0 ± 0.2) × 10\^6/kg, with 3-6 study participants enrolled
62010201|NCT06047197|EXPERIMENTAL|Third dose group|The third dose is (2.5± 0.5) × 10\^6/kg, with 3-6 study participants enrolled
62010202|NCT06047197|EXPERIMENTAL|Fourth dose group|The fourth dose is (5± 1) × 10\^6/kg, with 3-6 study participants enrolled
62399289|NCT06509425|ACTIVE_COMPARATOR|Participants undergoing caesarean section and salpingectomy.|
62399290|NCT06509425|ACTIVE_COMPARATOR|Participants undergoing caesarean section and tubal ligation|
62399291|NCT03183661||ALLO-ASC-CD injection|Subjects with ALLO-ASC-CD injection in phase 1 clinical trial of ALLOASC-CD-101
62399292|NCT05156775|NO_INTERVENTION|Intravenous analgesia group|35 Patients will receive intravenous morphine (mg) analgesia only.
62399293|NCT05156775|EXPERIMENTAL|Serratus Plane Block (SPB) group|35 Patients will receive ipsilateral serratus plane block using 30 ml bupivacaine 0.25% at the level of the 5th rib.
62399294|NCT05156775|EXPERIMENTAL|Rhomboid intercostal nerve block (RIB) group|35 Patients will receive ipsilateral rhomboid intercostal nerve block using 30 ml bupivacaine 0.25%.
62399295|NCT02883608|EXPERIMENTAL|Initial cap assisted endoscopy|undergo initial cap assisted forward-viewing endoscope then side-viewing duodenoscope
62399296|NCT02883608|ACTIVE_COMPARATOR|Initial standard endoscopy|undergo initial side-viewing duodenoscope then cap assisted forward-viewing endoscope
62196592|NCT02871167|EXPERIMENTAL|Oocyte/embryo cryopreservation|"1. Controlled ovarian hyperstimulation (COH)~2. Oocyte/embryo freezing"
62575387|NCT02948660|EXPERIMENTAL|Patients with prolonged disorders of consciousness|"1. age ≥ 18 years;~2. presence of unresponsive wakefulness syndrome (UWS) or minimally conscious state (MCS) on admission;~3. time since onset \> 4 weeks;~4. no history of neurodegenerative or psychiatric diseases.~All patients were administered 10 mg of zolpidem tartrate tablets via a feeding tube and received EEG-reactivity test."
62575388|NCT02948660|EXPERIMENTAL|Healthy volunteers|Healthy volunteers without any history of autonomic or any other nervous system disorder were included in this study. They were administered 10 mg of zolpidem tartrate tablets orally.
62575389|NCT01827267|EXPERIMENTAL|neratinib monotherapy|240 mg once daily with food, continuously in 21 day cycles
62575390|NCT01827267|EXPERIMENTAL|neratinib plus temsirolimus|240 mg neratinib plus 8 mg temsirolimus IV with optional dose escalation to 15 mg temsirolimus
62575391|NCT03189693|EXPERIMENTAL|PVB group|Patients will receive two PVB injections at levels T12-L1 and L1-L2 using anesthetic mixture
62575392|NCT03189693|PLACEBO_COMPARATOR|Placebo|Patients will receive two PVB injections containing placebo at levels T12-L1 and L1-L2
62575393|NCT02855372||Lung transplanted patients|
62575394|NCT04073706|EXPERIMENTAL|TH BSO with SNB|Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) with Sentinel Node Biopsy (SNB) using Indocyanine Green (ICG)+/- Methylene Blue Dye (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age), have Grade 1 endometrial adenocarcinoma (EAC) with myometrial invasion \<50% (by MRI) and wish to retain their ovaries a BSO may be omitted.
62575395|NCT04073706|ACTIVE_COMPARATOR|TH BSO without retroperitoneal node dissection|Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) without retroperitoneal node dissection (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age), have Grade 1 endometrial adenocarcinoma (EAC) with myometrial invasion \<50% (by MRI) and wish to retain their ovaries a BSO may be omitted.
62575396|NCT05053620||Single arm|All patients.
62575397|NCT01743560|EXPERIMENTAL|Everolimus and Exemestane|Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive RAD001 at a dose of 10mg daily p.o. and exemestane 25mg daily p.o. for 48 weeks.
62575398|NCT05000671|EXPERIMENTAL|Cohort 1|Drug: STC314/Placebo injection Continuous infusion at rate 58.3mg/hr up to 3 days (72 hours) N=8(Randomization-STC314/Placebo injection=3:1)
62575399|NCT05000671|EXPERIMENTAL|Cohort 2|Drug: STC314/Placebo injection Continuous infusion at rate 87.5mg/hr up to 3 days (72 hours) N=8(Randomization-STC314/Placebo injection=3:1)
62575400|NCT06271785|EXPERIMENTAL|HR-EEG recording|
62575401|NCT02406001|EXPERIMENTAL|Tigran PTG|Surgical intervention: open flap debridement and implantation of bone grafting material
62010203|NCT06531460|EXPERIMENTAL|Experimental enteral nutrition|Patients admitted to the hospital at least three days before surgery Use of an enteral feeding tube to administer enriched enteral formula
62010204|NCT06531460|EXPERIMENTAL|Experimental oral nutrition|Patients admitted one day before surgery. Home-self administration of enriched enteral formula three days before surgery
62010205|NCT06531460|OTHER|Standard enteral nutrition|Patients admitted to the hospital at least three days before surgery Use of an enteral feeding tube to administer standard enteral formula
62010206|NCT06531460|OTHER|Standard oral nutrition|Patients admitted one day before surgery. Home-self administration of standard enteral formula three days before surgery
62010207|NCT05727358|EXPERIMENTAL|intervention group|G-ACT
62010208|NCT05727358|NO_INTERVENTION|control group|
62010209|NCT06632028|ACTIVE_COMPARATOR|stimawell|In the treatment programme to be applied to the spinal rehabilitation group supported by artificial intelligence, the patient's treatment card is first created. Artificial intelligence assisted spinal rehabilitation group will be applied 3 times a week, a total of 6 sessions and 30 minutes of treatment. The person is first prepared by lying on his back on the stimulation mat. There are 12 channels and 24 electrodes in artificial intelligence assisted spinal rehabilitation. The stimulation wave travels in all 12 L-sized channels of the stimulation mat. The two sub-channels in the M dimension are not active, the wave travels over only 10 channels. In size S only 8 channels are used, therefore 4 sub-channels of the stimulation mat are not active Artificial intelligence-assisted spinal rehabilitation overcomes skin resistance more easily with mid-frequency currents in the 2000 - 6000 Hz range compared to currents in lower frequency ranges.
62196593|NCT03749304|EXPERIMENTAL|ANI monitor|
62196594|NCT04118881|EXPERIMENTAL|treatment group|The treatment group was given intradermal needling at ear acupoints: cardia (CO3), stomach (CO4), sympathetic (HX4)
62196595|NCT04118881|SHAM_COMPARATOR|control group|The control group was given intradermal needling at ear acupoints: spiral area (HX7 and HX8).
62196596|NCT01649154|ACTIVE_COMPARATOR|Ligasure Small-JAW|
62196597|NCT01649154|ACTIVE_COMPARATOR|Harmonic Focus|
62196598|NCT01649154|ACTIVE_COMPARATOR|Clamp-and-Tie technique|
62575402|NCT02406001|OTHER|Control|Surgical intervention: open flap debridement
62575403|NCT01599533|OTHER|abdominal aortic aneurysms|
62575404|NCT05656248|EXPERIMENTAL|CPX-351|"Participants will receive CPX-351 for remission induction, and then will proceed to allogeneic HSCT or other therapies as per institutional practice.~Intrathecal (IT) chemotherapy will be given on Day 1 of each cycle, for all participants, but may be delayed if clinically indicated. IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) according to age are all acceptable."
62196599|NCT03637647||Upper gastrointestinal cancer|Upper gastrointestinal cancers including oesophagus and stomach
62196600|NCT03321279|NO_INTERVENTION|Control|Participants' daily step counts will be for weeks 2-13 after hospital discharge. Participants will be asked to complete surveys at 5, 9 and 13 weeks post-discharge.
62575405|NCT01848912||Bone Marrow Transplant Patients|
62575406|NCT04754958|EXPERIMENTAL|VR|In addition to standard care during MRI scan, patient receives VR intervention.
62575407|NCT04754958|NO_INTERVENTION|No VR|Standard of care during MRI scan.
62575408|NCT03757728|OTHER|open haemorrhoidectomy|Open haemorrhoidectomy is performed using an anal retractor, exposed haemorrhoids at 3 - 7- 11 hours are excised using cautery. The arteries are ligated or cauterized. Open or closed technique is used (the choice of the surgeon). The Spongostan plug is then introduced
62575409|NCT03757728|OTHER|Haemorrhodal pedicle ligation|Haemorrhodal pedicle ligation is performed using operating proctoscope. The pedicle of symptomatic haemorrhoid is suture ligated with absorbable Vycril 2/0. Mucopexy is performed simultaneously if the prolapse is noticed. No tissue removal is performed
62575410|NCT03757728|OTHER|Intrahaemoroidal laser coagulation|Intrahaemoroidal laser coagulation is performed using disposable THD kit \[Biolitec Co\]. The haemorrhoidal pedicle is sutured. 1mm opening is created at the external haemorrhoid (skin level). Laser is then introduced up to pedicle and coagulation performed. This is repeated to all the piles. The procedure is finished with placing Spongostan plug into anal canal
62575411|NCT02746978|ACTIVE_COMPARATOR|Peer directed education|A revised education approach that focuses on problem solving discussions delivered by peers and grounded clinical information is compared to traditional approach of didactic clinician-driven education lectures
62575412|NCT02746978|OTHER|Patient Engagement Portal|A patient-owned portal to manage injury information is maintained in real-time by patients and families and shared with other care providers after inpatient rehabilitation discharge.
62575413|NCT01932060|EXPERIMENTAL|Oxytocin Infusion 1|Oxytocin Infusion 15 U/hr to begin after the delivery of the fetus and to terminate at the time of patient discharge from the post-anesthesia care unit.
62575414|NCT01932060|ACTIVE_COMPARATOR|Oxytocin Infusion 2|Oxytocin infusion 2.5 U/hr to begin after the delivery of the fetus and to terminate at the time of discharge from the post-anesthesia care unit.
62575415|NCT02295592|EXPERIMENTAL|group A( TSTstarr+ group)|"TSTstarr+ is a kind of modified STARR（stapled transanal rectal resection ） operation, compared to the traditional STARR operation, it does not need two staplers but with a larger diameter stapler,  + means better . Patients in group A with severe prolapsed hemorrhoids will undergo TSTstarr+ operation ."
62575416|NCT02295592|ACTIVE_COMPARATOR|group B ( PPH group)|PPH is short fo procedure for prolapsed hemorrhoids .Patients in group B with severe prolapsed hemorrhoids will undergo PPH operation.
62575417|NCT03333538|EXPERIMENTAL|Stage 1 (component A)|a single administration of component A (VSV) of vaccine
62575418|NCT03333538|EXPERIMENTAL|Stage 1 (component B)|a single administration of component B (Ad5) of vaccine
62575419|NCT03333538|EXPERIMENTAL|Stage 2 (Primary Group)|150 people who will receive the vaccine in the therapeutic scheme: the sequential introduction of components A and B with an interval of 21 days
62575420|NCT03333538|PLACEBO_COMPARATOR|Stage 2 (Controll Group)|50 people who will receive placebo in the therapeutic scheme: the sequential introduction of components A (placebo) and B (placebo) with an interval of 21 days
62575421|NCT02826486|EXPERIMENTAL|Cohort 1: BL-8040 + Pembrolizumab (Keytruda®)|"BL-8040 monotherapy 1.25 mg/kg subcutaneous (SC) injections daily on Days 1-5 of Week 1 of treatment.~Combination therapy period begins following monotherapy treatment and consists of:~* Pembrolizumab 200 mg once every three weeks.~* Beginning on Day 10, BL-8040 three times a week"
62575422|NCT02826486|EXPERIMENTAL|BL-8040 + Pembrolizumab + Chemotherapy|"BL-8040 monotherapy 1.25 mg/kg subcutaneous (SC) injections daily on days 1-5 of week 1 of treatment.~Combination therapy period begins following monotherapy treatment and consists of:~* IV Onivyde® 70 mg/m2 over 90 minutes followed by IV leucovorin (LV) 400 mg/m2 over 30 minutes or according to local standard, followed by IV fluorouracil (5-FU) 2400 mg/m2 over 46 hours, every 2 weeks.~* Pembrolizumab 200mg once every three weeks.~* Beginning on Day 10, BL-8040 twice a week and following the chemotherapy dosing."
62575423|NCT03421210|OTHER|Nicotine Replacement Therapy|Participants will receive nicotine replacement therapy for 10 weeks after quitting smoking.
62575424|NCT02914704|EXPERIMENTAL|Patients treated with MRI-HIFU|
62575425|NCT00789841||Patients with NET and diarrhea.|
62575426|NCT01579084|EXPERIMENTAL|AGN-199201 Formulation A and B|AGN-199201 Formulation A applied to one side of the face and Formulation B applied to the other side of the face twice daily.
62575427|NCT01579084|EXPERIMENTAL|AGN-199201 Formulation B and C|AGN-199201 Formulation B applied to one side of the face and Formulation C applied to the other side of the face twice daily.
62575428|NCT01579084|EXPERIMENTAL|AGN-199201 Formulation C and A|AGN-199201 Formulation C applied to one side of the face and Formulation A applied to the other side of the face twice daily.
62575429|NCT01579084|OTHER|AGN-199201 Formulation A and Vehicle|AGN-199201 Formulation A applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
62575430|NCT01579084|OTHER|AGN-199201 Formulation B and Vehicle|AGN-199201 Formulation B applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
62575431|NCT01579084|OTHER|AGN-199201 Formulation C and Vehicle|AGN-199201 Formulation C applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
62575432|NCT01579084|EXPERIMENTAL|AGN-199201 Formulation A|AGN-199201 Formulation A applied to both sides of the face twice daily.
62196601|NCT03321279|EXPERIMENTAL|Intervention|Participants' daily step counts will be monitored for weeks 2-13 after hospital discharge. Participants will have a weekly step goal that increases from baseline by 10% each week of the intervention (12 weeks). Participants will engage in a social incentive-based gamification based on points and levels that leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. Participants will receive daily feedback for the step counts and weekly feedback for levels. Participants will be asked to identify a support partner, who will receive weekly reports with the the participant's points and levels balance.
62575433|NCT01579084|EXPERIMENTAL|AGN-199201 Formulation B|AGN-199201 Formulation B applied to both sides of the face twice daily.
62575434|NCT01579084|EXPERIMENTAL|AGN-199201 Formulation C|AGN-199201 Formulation C applied to both sides of the face twice daily.
62196602|NCT03554408|EXPERIMENTAL|Group 1A|HIV-uninfected individuals will be administered one 1 mL (approximately 150 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
62010210|NCT06632028|OTHER|convention|In the traditional treatment group, a total of 15 sessions, 5 times a week, and in each session, 20 minutes of TENS application with the conventional method by placing electrodes on the painful points of the person, 20 minutes of hotpack application and 4 minutes each on the right and left sides of the neck area with intermittent ultrasound 1.5 MHz wave will be applied for a total of 8 minutes. Cervical isometric exercises will be given and 2 sets of 10 repetitions will be performed with 5 sec stretching.
62575435|NCT01579084|PLACEBO_COMPARATOR|AGN-199201 Vehicle|AGN-199201 Vehicle (Placebo) applied to both sides of the face twice daily.
62575436|NCT05312151|EXPERIMENTAL|COMP360 Psilocybin|25 mg COMP360 Psilocybin
62575437|NCT03305341|EXPERIMENTAL|Assess for therapeutic biologics activity (proof-of-concept)|"* 0.1mg Spike-GM-CSF Protein~* 0.5 ml Lactated Ringer's Injection, USP"
62575438|NCT06576310||OSA patients with mandibular advancement appliance|Patients with obstructive sleep apnea (OSA) treated with a mandibular advancement device (MAD), monitored for changes in masticatory muscle activity and occlusal modifications over a 6-month period. The study involves routine clinical visits and additional assessments including electromyography (EMG) with and without the appliance, optical impressions, digital occlusion recordings, patient diaries, and questionnaires on quality of life, temporo mandibular dysfunction pain, oral habits, stress and anxiety, and sleep evaluation.
62575439|NCT03491462|EXPERIMENTAL|Arimoclomol|248 mg arimoclomol base (equivalent to 400 mg arimoclomol citrate) 3 times daily
62575440|NCT03491462|PLACEBO_COMPARATOR|Placebo|248 mg matching placebo 3 times daily
62575441|NCT02083432|ACTIVE_COMPARATOR|5-weeks waiting list control|Half of the participants were randomly assigned to 5-weeks waiting list/Control group.The participants in the waiting list/Control Group are enrolled to the treatment Group (INtervention: 5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV).
62575442|NCT02083432|EXPERIMENTAL|5 session of CBT|Half of the participants were direct enrolled to 5 weeks(5 sessions) of cognitive behaviour therapy (CBT) performed by specially trained dentists. (Intervention: CBT)
62575443|NCT01905527||Standard Services of Group A (Group A1)|
62575444|NCT01905527||Customized Services of Group A (Group A2)|
62575445|NCT01905527||Group B|
62575446|NCT03455101||Patients with diabetes mellitus|Patients with type 1 or type 2 diabetes who were under follow-up in the same center for at least a year.
62010211|NCT06350864|ACTIVE_COMPARATOR|Conventional nasal oxygen therapy (COT) group (35 patients)|Who will receive 5 L/min oxygen flow through standard nasal cannula (gives FiO2 of about 0.4). The allocated flow rates will be maintained throughout the procedure unless intervention will be required at the discretion of the anesthesiologist in charge of the case.
62399297|NCT03678909||Hypoplastic Left Heart Disease|Patients with congenital hypoplastic left heart disease who will undergo surgical palliation with Norwood procedure or DKS or Damus-Kaye-Stansel procedure
62399298|NCT01857570||Adult, clinical suspicion fractures wrist or carpus|- Patients (18 years and older) who are referred to our hospital for conventional radiography of the wrist and carpus
62399299|NCT05671731|EXPERIMENTAL|Intervention|"The intervention group received Beneo Synergy 1 - 4gm twice/school day in 4 ounces orange juice with calcium for 12 weeks. We started with 1gm then increased the next day by a gram to reach the 4gm dose.~Intervention group participants completed Project FUN (8 module online nutrition and physical activity program) individually (password protected) in the school computer lab along with a workbook also used to check intervention completion."
62399300|NCT05671731|NO_INTERVENTION|Control|The control group participated in usual school activities only completing pre and post measures.
62399301|NCT02304770|EXPERIMENTAL|cervical persistent high risk HPV infection|Aminolaevulinic acid photodynamic therapy for the treatment of patients with cervical persistent high risk HPV infection
62399302|NCT02304770|EXPERIMENTAL|CIN 1 with high risk HPV infection|Aminolaevulinic acid photodynamic therapy for the treatment of patients with CIN 1 and high risk HPV infection
62399303|NCT02304770|EXPERIMENTAL|CIN 2/3|Aminolaevulinic acid photodynamic therapy for the treatment of patients with CIN 2/3
62399304|NCT03331302|ACTIVE_COMPARATOR|COPD patients - Xe-133|COPD patients who will be assessed with Xenon-133 scintigraphy (Standard diagnostic study)
62575447|NCT04952805|EXPERIMENTAL|Interventional Arm _400 mg|To all the patients enrolled is admistrated with single dose of MAD0004J08 400 mg.
62575448|NCT04952805|EXPERIMENTAL|Interventional Arm _100 mg|To all the patients enrolled is admistrated with single dose of MAD0004J08 100 mg.
62575449|NCT04952805|PLACEBO_COMPARATOR|Placebo Arm|To all the patients enrolled is admistrated with single dose of placebo
62575450|NCT01220466|EXPERIMENTAL|Refractive Error|
62010212|NCT06350864|ACTIVE_COMPARATOR|High-flow nasal cannula (HFNC) group (35 patients)|Who will receive 30 L/min oxygen flow through VapothermR Precision Flow HFNC. The fraction of inspired Oxygen (FiO2) will be adjusted at 0.4, temperature at 37◦C with 100% humidity.
62010213|NCT04296175|ACTIVE_COMPARATOR|conventional group|epirubincin 90mg/m2 d1 and CTX 600mg/m2 d1, every 2 or 3 weeks followed by paclitaxel 80mg/m2 d1,d8,d15, every 3 weeks.
62010214|NCT04296175|EXPERIMENTAL|carboplatin group|epirubincin 90mg/m2 d1 and CTX 600mg/m2 d1, every 2 weeks followed by paclitaxel 80mg/m2 and carboplatin AUC=2 d1,d8,d15, every 4 weeks.
62010215|NCT02675452|EXPERIMENTAL|AMG 176 - Part 1a|Part 1a - Participants with muliple myeloma (MM) administered AMG 176 as an intravenous (IV) infusion for two-consecutive days (QD2) followed by a 5 days break.
62010216|NCT02675452|EXPERIMENTAL|AMG 176 - Part 1b|Part 1b - Participants with multiple myeloma (MM) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
62010217|NCT02675452|EXPERIMENTAL|AMG 176 - Part 3a|Part 3a - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion once a day, for two-consecutive days (QD2) followed by a 5 day break.
62575451|NCT01136278|EXPERIMENTAL|clonidine, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
62196603|NCT03554408|EXPERIMENTAL|Group 1B|HIV-uninfected individuals will be administered one 2 mL (approximately 300 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
62399305|NCT03331302|EXPERIMENTAL|COPD patients - Hyperpolarized Xe-129|COPD patients crossed over from the Active Comparator Arm who will be assessed with hyper polarized Xenon-129 MRI (Experimental diagnostic study)
62399306|NCT04668066|EXPERIMENTAL|Single ascending doses of PF-07242813 or placebo in healthy participants|Participants will receive a single intravenous dose of either PF-07242813 or placebo
62399307|NCT04668066|EXPERIMENTAL|Multiple ascending doses of PF-07242813 or placebo in healthy participants|Participants will receive multiple subcutaneous doses PF-07242813 or placebo
62399308|NCT04668066|EXPERIMENTAL|Single dose of PF-07242813 or placebo in participants with moderate to severe atopic dermatitis|Participants will receive a single intravenous dose of either PF-07242813 or placebo
62399309|NCT04807816|EXPERIMENTAL|Experimental Arm A: treatment by berzosertib combined with gemcitabine|Patients with advanced leiomyosarcomas will be treated with berzosertib combined with gemcitabine
62575452|NCT00109655|EXPERIMENTAL|1|
62575453|NCT02875626|EXPERIMENTAL|Infracyanine|In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).
62575454|NCT02183558|EXPERIMENTAL|OGTT by randomization|Women without risk factors for GDM are offered OGTT in gestational week 28
62575455|NCT02183558|EXPERIMENTAL|OGTT by indication|Women with risk factors for OGTT are offered diagnostic 2 hour OGTT in pregnancy week 28
62575456|NCT04283149|EXPERIMENTAL|Primary Eyes|First implanted eyes of enrolled participants
62575457|NCT04283149|EXPERIMENTAL|Fellow Eyes|Second implanted eyes of enrolled participants
62575458|NCT04350437|OTHER|induction of labor monitoring|meticulous data collection from patients and plotting that data in a machine learning model
62575459|NCT05354856|EXPERIMENTAL|ICG patient|All patients included in the study will be injected with ICG (0.2 mg/kg bodyweight) to assess gastric perfusion.
62399310|NCT04807816|OTHER|Standard Arm B: treatment by gemcitabine alone|Patients with advanced leiomyosarcomas will be treated with with gemcitabine alone (control arm)
62575460|NCT04504214|EXPERIMENTAL|Experimental group (EG)|An Experimental Group (EG) of post-stroke subjects having vibration stimulation sessions in addition to traditional rehabilitation
62399311|NCT03165851||CAMS-2005 trial|The induction course was Daunorubicin(DNR) + Cytarabine(Ara-C) or Homoharringtonine(HHT) + Ara-C or HHT + DNR + Ara-C. There are 5 consolidation course after complete remission (CR).
62575461|NCT04504214|SHAM_COMPARATOR|Control Group (CG)|A Control Group (WG) of post-stroke subjects having placebo/sham vibration sessions (same vibrators used but without the eccentric mass), in addition to traditional rehabilitation
62575462|NCT05094869||APP self-management group|Patients would register on the APP and visit the clinics according to the routine practice and guidelines. During the study, the APP would regularly send messages including the follow-up reminder (manually set up by the patients on the APP), medication reminder, health education knowledge, etc.
62575463|NCT05094869||APP intelligent-management group|Patients would register on the APP and visit the clinics according to the routine practice and guidelines. During the study, the APP would regularly send messages including the follow-up reminder (automatically set up by the APP), medication reminder, health education knowledge, etc. The doctors will evaluate their disease progression every six months through the APP and guide patients' clinical practice accordingly.
62575464|NCT05094869||Control group|History data of another 4000 Patients who have been on the platform of China Registry of Hepatitis B (CR-Hep B) and been diagnosed as compensatory hepatitis B cirrhosis would be extracted and serve as the control group (No APP, no follow-up reminders, no online interaction).
62010218|NCT02675452|EXPERIMENTAL|AMG 176 - Part 3b|Part 3b - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
62010219|NCT02675452|EXPERIMENTAL|AMG 176 - Part 3c|Part 3c - Participants in Japan only with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
62010220|NCT02675452|EXPERIMENTAL|AMG 176 - Part 3d|Part 3d - Participants in the United States with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW), for 3 weeks, in combination with itraconazole.
62010221|NCT02675452|EXPERIMENTAL|AMG 176 - Part 4|Part 4 - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, either once a week (QW) followed by 6 days break, or once a day, for two-consecutive days (QD2), in combination with azacitidine.
62010222|NCT02675452|EXPERIMENTAL|AMG 176 - Part 5|Part 5 - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion at the maximum tolerated combination dose from Part 4, either once a week (QW) followed by 6 days break, or once a day, for two-consecutive days (QD2), in combination with azacitidine.
62010223|NCT04619316|OTHER|BRAF wild type|In BRAF wild type patients trametinib 2mg (1-0-0) is applied daily over a time span of 3 weeks, then the effect is evaluated via 123I whole-body scintigraphy
62010224|NCT04619316|OTHER|BRAF V600E Mutation|In BRAF wild type patients trametinib 2mg (1-0-0) and dabrafenib 75mg (2-0-2) are applied daily over a time span of 3 weeks, then the effect is evaluated via 123I whole-body scintigraphy
62010225|NCT02358824|EXPERIMENTAL|CKD-828(Fixed Dose Combination)|FDC tablet consisting of Telmisartan 80mg/S-Amlodipine 5mg
62010226|NCT02358824|ACTIVE_COMPARATOR|Combination Therapy|Coadministration of Telmisartan 80mg and S-amlodipine 5mg
62010227|NCT04693364||Observational (questionnaire, 3D breast model, discussion)|Patients complete questionnaire over 5 minutes about difficulties in making decision about breast cancer treatment, then participate in a consultation with regular care doctor and study doctor/study staff using the 3D breast model. Patients then complete questionnaires over 5-10 minutes about their opinions on the breast model and different breast surgical treatment options available.
62010228|NCT01294618|EXPERIMENTAL|nilotinib + pegylated interferon alpha 2a (PEG-IFN).|
62010229|NCT01599650|EXPERIMENTAL|1-ranibizumab monotherapy|Ranibizumab 0.5 mg
62010230|NCT01599650|EXPERIMENTAL|2-ranibizumab with laser|Ranibizumab 0.5 mg + laser
62010231|NCT01599650|ACTIVE_COMPARATOR|3-laser monotherapy|Laser monotherapy with Ranibizumab 0.5 mg from Month 6
62010232|NCT05003986|EXPERIMENTAL|Population 1: FSGS and/or MCD|Subjects with selected proteinuric glomerular diseases associated with FSGS and MCD histological patterns
62010233|NCT05003986|EXPERIMENTAL|Population 2: IgAN, IgAV, or AS|Subjects with kidney biopsy-confirmed immunoglobulin A nephropathy (IgAN), immunoglobulin A vasculitis (IgAV), or Alport syndrome (AS)
62010234|NCT05003986|EXPERIMENTAL|Population 3: IgAN|Subjects with kidney biopsy-confirmed IgAN
62575465|NCT02414243|EXPERIMENTAL|New Amino Acid formula|New Amino-Acid based Infant Formula
62575466|NCT02414243|ACTIVE_COMPARATOR|Control formula|Commercially available Amino Acid Formula
62010235|NCT04622254|PLACEBO_COMPARATOR|Main Period: Placebo (Group P)|Subjects will receive placebo injection in all three UFL (GFL, HFL and LCL) on Day 1 of main period.
62010236|NCT04622254|EXPERIMENTAL|Main Period: NT 201 (Group U)|Subjects will receive a total of 64 Units (U) of NT 201: 20 U of NT 201 injection both in the GFL area and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 of main period.
62196604|NCT03554408|EXPERIMENTAL|Group 2A|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 3 mg/kg.
62575467|NCT01726270|EXPERIMENTAL|tamsulosin hydrochloride|patients will take drug for 8 weeks in this exploratory study
62575468|NCT03741738||Non-segmental vitiligo :|"A. Patients aged 19 years or older who were clinically diagnosed with non-segmented leukopenia at Severance Hospital.~B. Patients (36 patients) who experienced worsening symptoms within the last 3 months and 10 patients whose symptoms were stable within 3 months C. Patients with vitiligo lesion at least 3% of the skin"
62575469|NCT03741738||Segmental VT or Focal VT|A. The investigators evaluated patients who were diagnosed as segmental vitiligo clinically on Severance hospital and who were 19 years old or older.
62575470|NCT03741738||Normal control|A. Subjects aged 19 or older who do not have not only vitiligo but also other skin and systemic diseases
62575471|NCT00786760||1. Men ages 18 - 44 years|
62575472|NCT00786760||2. Men ages 45 - 70 years|
62575473|NCT05669417|ACTIVE_COMPARATOR|Magnesium Sulfate|Magnesium sulfate is the active compound and will be administered to achieve plasma serum level of magnesium between 1.5 and 2.0 mmol/L according to the study protocol.
62575474|NCT05669417|PLACEBO_COMPARATOR|Ringers Lactate|Ringers Lactate is the comparator/placebo and will be administered according to the study protocol.
62010237|NCT04622254|EXPERIMENTAL|Main Period: NT 201 and Placebo (Group L)|Subjects will receive a total of 24 U NT 201: placebo injection both in the GFL and HFL area, and 24 U NT 201 injection in the LCL area (12 U per side) on Day 1 of main period.
62010238|NCT04622254|EXPERIMENTAL|OLEX: NT 201 (Main Period: Group P)|Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.
62010239|NCT04622254|EXPERIMENTAL|OLEX: NT 201 (Main Period: Group U)|Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.
62196605|NCT03554408|EXPERIMENTAL|Group 2B|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg.
62196606|NCT03554408|EXPERIMENTAL|Group 2C|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
62575475|NCT05752149|EXPERIMENTAL|0.05 mg/kg cRGD-ZW800-1|n=3. Injection of 0.05 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery
62575476|NCT05752149|EXPERIMENTAL|0.025 mg/kg cRGD-ZW800-1|n=3. Injection of 0.025 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery
62575477|NCT05752149|EXPERIMENTAL|0.01 mg/kg cRGD-ZW800-1|n=3. Injection of 0.01 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery.
62575478|NCT05752149|EXPERIMENTAL|Expansion Cohort|n=18: expansion cohort will be added to the group of patients that had received the selected dose in WP-I.
62196607|NCT03554408|EXPERIMENTAL|Group 3B|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg
62575479|NCT03433196|EXPERIMENTAL|HS-25 and Atorvastatin|HS-25 20mg, Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet
62196608|NCT03554408|EXPERIMENTAL|Group 3C|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
62575480|NCT03433196|ACTIVE_COMPARATOR|Atorvastatin|Atorvastatin 20mg, Placebo of HS-25 2 tablets
62575481|NCT05646901||Premenopausal women with obesity|
62575482|NCT05646901||Postmenopausal women with obesity|
62575483|NCT05646901||Men with obesity|
62575484|NCT05646901||Premenopausal women without obesity|
62575485|NCT05646901||Postmenopausal women without obesity|
62575486|NCT05646901||Men without obesity|
62575487|NCT00360646||Subjects with liver injury|
62575488|NCT00360646||Subjects without liver injury|
62575489|NCT05160623|EXPERIMENTAL|Study eyes|Once-daily eyelid hygiene with povidone-iodine 1%
62575490|NCT05160623|ACTIVE_COMPARATOR|Control eyes|Once-daily eyelid hygiene with available lid wipes
62575491|NCT05198063|EXPERIMENTAL|Investigational vaccine group|Recombinant novel coronavirus vaccine (CHO cells) injection, Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose.
62575492|NCT02918565|EXPERIMENTAL|Drinking Cognition Feedback (DCF)|12 weeks of interactive text messaging focused on providing feedback related only to pre-weekend drinking cognitions (plans, desire to get drunk).
62575493|NCT02918565|EXPERIMENTAL|Alcohol Risk Feedback (ARF)|12 weeks of interactive text messaging focused on providing feedback related only to post-weekend alcohol consumption (max drinks consumed on any occasion over the weekend).
62575494|NCT02918565|EXPERIMENTAL|Adaptive Goal Support (AGS)|10 weeks of interactive text messaging focused on providing adaptive goal support (based on running average of max drinks consumed).
62196609|NCT03554408|EXPERIMENTAL|Group 4A|HIV-uninfected individuals will be administered one 2 mL (approximately 150 mg of each mAb) subcutaneous injection of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
62575495|NCT02918565|EXPERIMENTAL|COMBO|12 weeks of interactive text messaging incorporating features of DCF, ARF and AGS.
62575496|NCT02918565|NO_INTERVENTION|Control|12 weeks of text message assessments without any feedback
62575497|NCT05871047||practical group|
62575498|NCT05871047||non-practical group|
62575499|NCT03882983|EXPERIMENTAL|Antria Cell Preparation Process|Safety will be evaluated by collection of vital signs, EKG, patient surveys, and assessments
62575500|NCT01307904|ACTIVE_COMPARATOR|dates|Each healthy and diabetic subjects received 50 grams equivalent of carbohydrates of the tested dates, On five separate days.
62575501|NCT01307904|ACTIVE_COMPARATOR|sugar|Each healthy and diabetic subjects received 50 grams of glucose
62575502|NCT02951208|EXPERIMENTAL|Active tDCS + Active VR|Active tDCS over the left DLPFC (30 minutes) combined with active VR motivation training (60 minutes), administered 3 times per week for 4 weeks.
62575503|NCT02951208|SHAM_COMPARATOR|Sham tDCS + Sham VR|Sham tDCS over the left DLPFC (30 minutes) combined with sham VR motivation training (60 minutes), administered 3 times per week for 4 weeks.
62575504|NCT06130514|ACTIVE_COMPARATOR|Ultrasound-guided stellate ganglion block (US-guided SGB)|In the case of ultrasound-guided stellate ganglion block, the patient is made to lie down and stellate ganglion block is performed by injecting 5 mL of 1% mepivacaine at the level of the 6th cervical vertebra using ultrasound.
62575505|NCT06130514|ACTIVE_COMPARATOR|Fluoroscopy-guided thoracic sympathetic ganglion block (FS-guided TSGB)|In the case of fluoroscopic device-guided thoracic sympathetic nerve block, place the patient prone and inject 3 mL of 1% mepivacaine at the level of the third thoracic vertebra to perform thoracic sympathetic nerve block.
62575506|NCT02041663|EXPERIMENTAL|Population|Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
62575507|NCT03296644|ACTIVE_COMPARATOR|PowerScope2 group (G1)|Class II correction using PowerScope2
62196610|NCT03554408|EXPERIMENTAL|Group 4B|HIV-uninfected individuals will be administered two 2 mL (approximately 300 mg of each mAb) subcutaneous injections of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
62575508|NCT03296644|ACTIVE_COMPARATOR|Forsus group (G2)|Class II correction using Forsus
62010240|NCT04622254|EXPERIMENTAL|OLEX: NT 201 (Main Period: Group L)|Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.
62196611|NCT03554408|EXPERIMENTAL|Group 5|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
62575509|NCT00034281|EXPERIMENTAL|TAK-165 QD|
62575510|NCT03321851|OTHER|V-Sensor Device User|This diagnostic medical device is designed to detect the user's 5 vital signs. Each user tests two sensors, each sensor is mounted on a smartphone. Each vital sign is compared to an equivalent reference device obtained by the healthcare provider.
62010241|NCT04922801||Neuroendocrine Toumours|"Patients will undergo 177LU-Dotatate Neoruendocrine Tumours MRT in accordance with existing protocols at GSTTFT. In addition, all MRT patients will be asked to undertake the following non-invasive procedures.~* Post-treatment gamma camera (Planar Whole Body \& SPECT/CT) imaging to estimate disease/ target tissue and whole-body dose for Neuroendocrine and thyroid cancer MRT.~* Post-treatment gamma camera planar Whole Body imaging for hyperthyroidism MRT.~* Post-treatment patient-led self-monitoring.~* Complete a feedback questionnaire relating to the use of self radiation monitoring."
62196612|NCT03554408|EXPERIMENTAL|Group 6|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
62575511|NCT01921478||Cohort|
62575512|NCT00593684|EXPERIMENTAL|Algidex patch|Infants in this group received the Algidex patch on top of the line insertion sites of any of the following lines: umbilical arterial line, umbilical venous line, peripheral arterial line, peripheral long line, and central venous line. This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2. Every 7 days, each insertion site was cleansed and then a new patch was placed and covered with a fresh occlusive dressing (Tegaderm, Opsite).
62575513|NCT00593684|NO_INTERVENTION|Control group|Infants in this group served as the control group and received line-dressing changes every 7 days according to standard hospital protocol specific for the type of line inserted. Insertion sites were covered with only an occlusive dressing (Tegaderm, Opsite).
62575514|NCT04443946|ACTIVE_COMPARATOR|Group-P|Group-P: (Propofol group): 5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
62575515|NCT04443946|EXPERIMENTAL|Group-PAS|Group-PAS: (Propofol and after 20 min adding Sevoflurane group): 2.5 mg kg-1 h-1 propofol were pumped continuously and add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation.
62575516|NCT04443946|EXPERIMENTAL|Group-PS|Group-PS: (Propofol and Sevoflurane group): 2.5 mg kg-1 h-1 propofol were continuously pumped after endotracheal intubation, and 1% sevoflurane was inhaled continuously at the same time.
62575517|NCT04443946|EXPERIMENTAL|Group-S|Group-S: (Sevoflurane group): 2% sevoflurane continued to maintain anesthesia after endotracheal intubation.
62575518|NCT04443946|EXPERIMENTAL|Group-PSu|Group-PSu: (Propofol and Sufentanil group): 5 mg kg-1 h-1 propofol, 0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
62196613|NCT03554408|EXPERIMENTAL|Group 7|HIV-uninfected individuals will be administered three subcutaneous injections of 10-1074-LS (100 mg) admixed with 3BNC117-LS (200 mg) (2 mL) at weeks 0, 12, and 24.
62575519|NCT02502682|NO_INTERVENTION|Control|Receive the bathing standard of care.
62575520|NCT02502682|EXPERIMENTAL|Interventional|Receive daily bathing with 2% Chlorhexidine gluconate bathing wipes.
62196614|NCT03554408|EXPERIMENTAL|Group 8|HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (75 mg) admixed with 3BNC117-LS (225 mg) (2 mL) at weeks 0, 12, and 24.
62196615|NCT03554408|EXPERIMENTAL|Group 9|HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (60 mg) admixed with 3BNC117-LS (250 mg) (2 mL) at weeks 0, 12, and 24.
62196616|NCT04380077|EXPERIMENTAL|sulfur hexafluoride gas|vitreous substitution with 20-30% sulfur hexafluoride gas during vitrectomy
62575521|NCT06053333||Observational|Patients complete a questionaire, undergo blood sample collection and have their medical records reviewed on study.
62196617|NCT04380077|ACTIVE_COMPARATOR|balanced salt solution|vitreous substitution with balanced salt solution during vitrectomy
62399312|NCT03165851||CAMS-2009 trial|The induction course was MAE(Mitoxantrone + Cytarabine + Etoposide) or IAE(Idamycin + Cytarabine + Etoposide). Risk-stratified therapy and dose-dense intensive chemotherapy were adopted in the consolidation therapy. After the second course of therapy, patients in remission were stratified into three risk groups: low-risk children were defined as those with t(8;21) and a white blood cell count lower than 50,000/L, inv(16), or an age younger than 2 years without any high-risk factors; high-risk children were those with CR after consolidation course 1 or induction C , or with abnormalities of monosomy 7, 5q-, t(16;21), t(9;22)(Philadelphia chromosome \[Ph1\]); intermediate-risk children were those who were not in either a low-risk or high-risk group. Hematopoietic stem cell transplantation (HSCT) was indicated for only relapsed patients in the second CR.
62399313|NCT04956068|EXPERIMENTAL|Unresectable PM group|Patients who have progressed on conventional systemic therapy and PIPAC is used as a palliative strategy.
62399314|NCT04956068|EXPERIMENTAL|Extensive PM group|Patients who have significant volume of peritoneal disease are treated with the intent for potential conversion to curative surgery. Role of PIPAC is as an adjunct to systemic chemotherapy to downstage peritoneal metastases.
62399315|NCT02583165|EXPERIMENTAL|Monotherapy arm|MEDI1873
62575522|NCT03771560|EXPERIMENTAL|Open-label|In this open-label trial, all subjects will receive the twice daily dose of folinic acid. Folinic acid will be delivered in pill form at a weight-based dose.
62575523|NCT05510193|EXPERIMENTAL|Aktio|Use of the prosthesis for 2 weeks, after a 3-session training
62575524|NCT05510193|NO_INTERVENTION|Control|Non-use of the prosthesis
62575525|NCT05694481||Circadian rhythm disorders|Observational, no intervention administered.
62575526|NCT05694481||Healthy controls|Observational, no intervention administered.
62196618|NCT01509001|ACTIVE_COMPARATOR|metformin|Participants will randomized into Metformin (750 to 2500 mg/day) or Glimepiride (1 to 8 mg/day) therapy. After 4 months, the patients will crossed-over with no washout period to the alternative treatment for an additional 4-month period on similar dosage schedule
62196619|NCT01509001|ACTIVE_COMPARATOR|glimepiride|Participants will randomized into Metformin (750 to 2500 mg/day) or Glimepiride (1 to 8 mg/day) therapy. After 4 months, the patients will crossed-over with no washout period to the alternative treatment for an additional 4-month period on similar dosage schedule
62196620|NCT05656911|EXPERIMENTAL|Zabedosertib|Participants will receive zabedosertib for up to 12 weeks (84 days).
62196621|NCT05656911|PLACEBO_COMPARATOR|Matching placebo to zabedosertib|Participants will receive placebo to zabedosertib for up to 12 weeks (84 days).
62196622|NCT05420545|EXPERIMENTAL|Intravenous of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x106 cells/kg
62196623|NCT05420545|EXPERIMENTAL|intraperitoneal injection of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x106 cells/kg
62196624|NCT00512486|ACTIVE_COMPARATOR|1|MEDI-563
62196625|NCT05253599|EXPERIMENTAL|Isokinetic training|In the IKT group before isokinetic training, the subjects were asked to perform five minutes' warm-up followed by slow stretching of back extensors and flexors. The subject was asked to be in an isokinetic dynamometer (Biodex Corporation, New York, USA) in a vertical standing position.
62196626|NCT05253599|EXPERIMENTAL|Virtual reality training|The VRT group received virtual reality training with (Pro-Kin system PK 252 N Techno body, Pelvic Module balance trunk MF, Italy) focusing on the balance of core stability muscles.
62196627|NCT05253599|ACTIVE_COMPARATOR|Control group|The Control group focused on conventional balance training for core muscles. The training includes active isotonic and isometric exercise for abdominal muscles (Internal oblique, external oblique, transverse abdominus and Rectus abdominus) deep abdominal muscles (Psoas major, Psoas minor, Illiacus and Quadratus Lumborum) and back muscles (Erector spinae, Transverses spinalis, inter spinalis and Inter transverse).
62196628|NCT04964856|EXPERIMENTAL|ERAS exercise in perioperative period.|The patients take ERAS exercise from hospitalization to 30 days after operation.
62196629|NCT04964856|SHAM_COMPARATOR|No ERAS exercise in perioperative period.|The patients do not take ERAS exercise in perioperative period.
62196630|NCT01255956|EXPERIMENTAL|Rapamycin eluting stent|Patients treated with rapamycin eluting stent (n=100)
62196631|NCT01255956|EXPERIMENTAL|Paclitaxel eluting balloon catheter|Patients treated with paclitaxel eluting balloon catheter (n=100)
62196632|NCT03382769|EXPERIMENTAL|Group A (Immediate Cochlear Implantation)|Group A will consist of 30 individuals who are candidates for cochlear implantation. They will be unilaterally implanted immediately after initial study testing has been completed and then be followed for 12 months after device activation.
62575527|NCT02246140|EXPERIMENTAL|Cannabis users|Cerebral MRI and MRA
62575528|NCT02246140|ACTIVE_COMPARATOR|healthy volunteers|Cerebral MRI and MRA
62575529|NCT02698527|ACTIVE_COMPARATOR|Non-Buffered Lidocaine|Vulvar biopsy conducted using non-buffered lidocaine as anesthesia
62575530|NCT02698527|EXPERIMENTAL|Buffered Lidocaine|Vulvar biopsy conducted using buffered lidocaine as anesthesia
62575531|NCT03114163||Cohort 1: Nivolumab|≥2nd line treatment for recurrent/ metastatic (R/M) Squamous cell carcinoma of the head and neck (SCCHN), prior platinum-based therapy was administered for locally advanced, metastatic or recurrent disease
62575532|NCT03114163||Cohort 2: Nivolumab|1st line treatment for R/M SCCHN, prior platinum-based therapy was administered for locally advanced disease in the adjuvant or primary setting
62575533|NCT02483221|ACTIVE_COMPARATOR|TCI-PCA|
62575534|NCT02483221|ACTIVE_COMPARATOR|PCA|
62575535|NCT05335980|EXPERIMENTAL|Nu-V3 Device|Treatment with the Nu-V3 Device.
62575536|NCT01193374|EXPERIMENTAL|Parent/child tailored mailed materials|Family provided newsletters tailored to issues and readiness to change. Family receives educational nutrition DVD, pedometers for family activities and child nutrition/physical activity games
62575537|NCT01193374|ACTIVE_COMPARATOR|Basic information at single time|Family provided with high quality booklet from American Dietetic Association providing the same information that intervention arm received but not tailored.
62575538|NCT06465381|OTHER|Enhanced Usual Care|In school randomized to EUC, youth who determined to be high risk using the C-SSRS and follow-up diagnostic interviews will be transported to the local government emergency psychiatric services that Dr. Cumbe (Co-I) directs in his role as Provincial Director of Mental Health services in Sofala Province. For students with moderate risk, they will receive information and referral to local government mental health and youth friendly services. At follow-up outcome ascertainment time points, those in the EUC arm will be re-assessed for suicide risk and uptake of referral services.
62575539|NCT06465381|EXPERIMENTAL|Safety Planning Intervention|If the student attends a school that has been randomized to SPI alone, youth will be asked to participate in a collaborative approach to create a stepwise safety plan that includes a simple list of individually tailored, concrete coping mechanisms to be enacted during or leading up to a crisis. The seven steps of the safety plan include: 1) recognizing warning signs of a crisis; 2) employing internal coping strategies; 3) using social contacts and settings to distract from suicidal thoughts; 4) seeking help from family members or close friends; 5) contacting healthcare or emergency services; 6) identifying reasons for living; and 7) reducing access to means. Youth will be followed-up at 2- and 4-weeks post intake to assess suicide risk and review their safety plan.
62575540|NCT06465381|EXPERIMENTAL|Transdiagnostic Cognitive Behavioral Therapy for Suicide Prevention|In schools randomized to TCBT-S, youth will receive 1) the safety planning intervention as outlined above 2) psychoeducation focused on suicidal thoughts and behaviors and how TCBT-S is expected to contribute to recovery; 3) cognitive restructuring adapted to focus on the thoughts and feelings that occur during individual's suicidal thoughts or behaviors; 4) linking the getting active module to coping strategies included in the safety plan for acute distress tolerance and crisis avoidance; and 5) problem solving focused on addressing problems believed to be contributing to suicidal thoughts and behaviors. TCBT-S will be implemented in 8-12 sessions each spaced one week apart.
62575541|NCT05959070||Risankizumab|Participants will receive risankizumab as prescribed by their physician according to local label.
62575542|NCT02691949|EXPERIMENTAL|Mycophenolate mofetil standard|mycophenolate mofetil 250mg 2# twice per day (BID)
62575543|NCT02691949|EXPERIMENTAL|Mycophenolate sodium low|mycophenolate mofetil 250mg 1# twice per day (BID)
62010242|NCT04922801||Thyroid Cancer|"Patients will undergo 131I-Thyroid cancer MRT in accordance with existing protocols at GSTTFT. In addition, all MRT patients will be asked to undertake the following non-invasive procedures.~* Post-treatment gamma camera (Planar Whole Body \& SPECT/CT) imaging to estimate disease/ target tissue and whole-body dose for Neuroendocrine and thyroid cancer MRT.~* Post-treatment gamma camera planar Whole Body imaging for hyperthyroidism MRT.~* Post-treatment patient-led self-monitoring.~* Complete a feedback questionnaire relating to the use of self radiation monitoring."
21074622|NCT06438341|ACTIVE_COMPARATOR|SPOT-mRNA01|SPOT-mRNA01 (COL1A1 mRNA-loaded EVs)
21074623|NCT06438341|PLACEBO_COMPARATOR|Placebo|Sterile isotonic solution
62196633|NCT03382769|ACTIVE_COMPARATOR|Group B (Delayed Cochlear Implantation)|Group B will consist of 30 individuals who are candidates for cochlear implantation. They will continue to wear hearing aids after enrolling in the study and then be unilaterally implanted 6 months after enrollment and followed for 6 more months after device activation.
62196634|NCT02342990|EXPERIMENTAL|Cluster B|After the first neuropsychological assessment (T1), children will start CogMed working memory training. Children will be retested (T2) about six or seven weeks later.
62196635|NCT02342990|OTHER|Cluster A|After the first neuropsychological assessment (T1), children will not start any training. Children will be retested (T2) about six or seven weeks later and will start CogMed working memory training. The group will be again retest (T3) after six or seven weeks after ended training.
62196636|NCT03776305|EXPERIMENTAL|Imipenem ECMO|1-h infusion of 0.5 g of imipenem, q6h
62575544|NCT06495476|ACTIVE_COMPARATOR|Ginkgo biloba extract 50 dropping pills treatment group|Ginkgo biloba extract 50 dropping pills, oral administration, 8 dropping pills /time, 3 times/day
62575545|NCT06495476|PLACEBO_COMPARATOR|Ginkgo biloba extract 50 dropping pills Simulant treatment group|Ginkgo biloba extract 50 dropping pills simulant, oral administration, 8 dropping pills /time, 3 times/day
62575546|NCT05074940|EXPERIMENTAL|Amivantamab|Amivantamab weekly for the first cycle and biweekly thereafter.
62575547|NCT02027805|EXPERIMENTAL|T-Guard|Four doses of T-Guard (4 mg/m2), administered at 48-hour intervals as 4 hour infusions.
62575548|NCT02459912|OTHER|Unilateral Nerve-Sparing Cryoablation|Unilateral Nerve-Sparing Cryoablation of the Prostate using Galil Medical Precise Cryoablation System with IceRod Needles.
62575549|NCT01099293||Cirrhosis, w/o hepatic encephalopathy|Patients with liver cirrhosis without hepatic encephalopathy by clinical (West-Haven), neurophysiological tests (PHES) nor Critical Flicker Frequency evidence.
62575550|NCT01099293||Cirrhosis-minimal hepatic encephalopathy|Patients with cirrhosis, without clinical evidence of hepatic encephalopathy (West Haven 0) and with positive tests for both, PHES and CFF.
62575551|NCT01099293||Cirrhosis, Hepatic encephalopathy I|Patients with cirrhosis and clinical evidence of hepatic encephalopathy with a West Haven score of I.
62196637|NCT05454813|OTHER|All|Each participant will be provided with the FitRight ® System for the duration of the study. The study products will be used to collect real-life measurement data in order to assess the FitRight® System.
62399316|NCT04952376|ACTIVE_COMPARATOR|Short message service (SMS)|Subjects will receive vaccine availability and appointment information via SMS.
62399317|NCT04952376|EXPERIMENTAL|Personalized text message|Subjects will receive vaccine availability and appointment information via a personalized message text from the primary care provider (PCP).
62399318|NCT04952376|EXPERIMENTAL|Interactive or 2-way SMS|Subjects will receive vaccine availability and appointment information via interactive 2-way SMS options.
62575552|NCT01099293||Control|Healthy subjects willing to participate in the study
62575553|NCT02768727|EXPERIMENTAL|Xenon|Xenon anesthesia to determine if neural inertia is present in humans as visualized by CT imaging.
62575554|NCT04604171|EXPERIMENTAL|Action Observation Training|Conventional treatment for 60 mins plus Action Observation Training for 30 mins
62575555|NCT04604171|ACTIVE_COMPARATOR|Task Oriented Training|Conventional treatment for 60 mins plus Task Oriented Training for 30 mins
62575556|NCT03542942|OTHER|treatment with EXIT-target volume|The radiotherapeutic treatment plan is based on an EXIT-target volume in which the non-involved uterus is excluded from the target volume. All other delineations are performed conform standard of care.
62196638|NCT01511341|EXPERIMENTAL|Telenursing|
62196639|NCT01511341|NO_INTERVENTION|Standard practice|Group receive the standard practice, without telephone nursing intervention.
62399319|NCT02550418|EXPERIMENTAL|Budesonide|
62399320|NCT04037579||Down Syndrome Cordoba Association|The participant will answer a questionnaire related to social skills and physical activity
62399321|NCT04037579||Down Syndrome Granada Association|The participant will answer a questionnaire related to social skills and physical activity
62399322|NCT04037579||Down Syndrome Malaga Association|The participant will answer a questionnaire related to social skills and physical activity
62399323|NCT04037579||Observers in Cordoba|Observers from Cordoba, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
62399324|NCT04037579||Observers in Granada|Observers from Granada, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
62575557|NCT01408381|NO_INTERVENTION|Control|No cell therapy
62575558|NCT01408381|EXPERIMENTAL|Low dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 108
62575559|NCT01408381|EXPERIMENTAL|Intermediate dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 5 x 108
62575560|NCT01408381|EXPERIMENTAL|High dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 109
62575561|NCT03278613|EXPERIMENTAL|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS treatment entails insertion of a 36 gauge needle electrode at a 60 degree angle 3-4 cm deep towards the tibial nerve, approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. The PTNS grounding electrode, placed near the calcaneus and the needle electrode will be connected to the ES-130 device pulse generator.
62575562|NCT03278613|SHAM_COMPARATOR|Validated Sham|Sham treatment will use the Streitberger acupuncture placebo needle in the same location as the needle electrode for PTNS. The sham uses an active gel surface electrode pad placed on the bottom of the foot just below the fifth (smallest) toe. This location is not part of the acupuncture nerve pathway connected to the bladder, pelvis or any major organs. Electrical current is delivered to this pad via a TENS unit resulting in sensory stimulation.
62575563|NCT01057810|EXPERIMENTAL|Ipilimumab|
62575564|NCT01057810|PLACEBO_COMPARATOR|Placebo|
62575565|NCT05463380||Hospitalized COVID 19 patients|"Hospitalized adult (\>18 years) patients including patients in the emergency ward Positive for SARS-CoV-2 by PCR any time from 14 days before admission date until hospital discharge. Both first and recurrent episodes of COVID-19 will be included.~Having a signed informed consent when required by ethical approval"
62575566|NCT01427647|ACTIVE_COMPARATOR|Control group|Control group: open surgery under general anesthesia
62575567|NCT01427647|ACTIVE_COMPARATOR|Epidural group|Epidural group: Open surgery under thoracic epidural anesthesia
62575568|NCT01427647|ACTIVE_COMPARATOR|Laparoscopic group|Laparoscopic group: Laparoscopic surgery under general anesthesia
62575569|NCT01436370|EXPERIMENTAL|Group 1 Controls|40 (up to 50) adults, healthy gender and age-matched controls, given a single 15 mcg intramuscular dose of Sanofi Pasteur Fluzone®
62196640|NCT03435146|EXPERIMENTAL|Groups 1,2,3 and 4|"Group 1: The first 12 participants (Group 1A) will undergo semi-intensive PK sampling and will be key to determining whether an increased dosing of dolutegravir is required in groups 1B. Group 1B will receive dolutegravir at the new dose (if applicable) and will also undergo semi-intensive PK sampling. All will undergo safety and HIV VL assessments.~3HP plus DTG +2NRTIs~Group 2: The next 30 (Group 2) will receive dolutegravir at the new dose and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.~3HP plus DTG +2NRTIs~Group 3: The next 25 (Group 3) will receive dolutegravir at the same dose as Group 2 and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.~IPT plus DTG +2NRTIs~Group 4: The next 50 (Group 4) will receive dolutegravir at the same dose as Group 2 and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.~3HP plus DTG +2NRTIs"
62196641|NCT02637323|EXPERIMENTAL|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
62196642|NCT02637323|ACTIVE_COMPARATOR|TCA IR 40 mg|Commercially available triamcinolone acetonide, single 1 mL intra-articular (IA) injection Immediate-release formulation
62196643|NCT00504777|EXPERIMENTAL|1|
62196644|NCT00722241||A|Adult subjects (at least 18 years of age) with a diagnosis of type 1 diabetes (\~80%) or insulin-treated type 2 diabetes (\~20%); method of insulin delivery may be multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII)
62399325|NCT04037579||Observers in Malaga|Observers from Malaga, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
62399326|NCT04697342|ACTIVE_COMPARATOR|NIS with pressure injury(PI) education|Clinical nurses use Nursing information system(NIS) to log in nursing records every day, and pressure injury (PI) education pops out of the NIS window for teaching
62399327|NCT04697342|ACTIVE_COMPARATOR|NIS with PI education, and microvideo|In addition to the built-in PI education in the NIS that nurses use every day, it also provides a flipped digital learning plan course unit, which can be self-study courses anytime, anywhere, without being restricted by time and space. And hold a 4-hour physical course for participants.
62399328|NCT04697342|EXPERIMENTAL|NIS with PI education, and workshop|In addition to the built-in PI education in the NIS that nurses use every day, an 8-hour physical course is also provided.
62575570|NCT01436370|EXPERIMENTAL|Group 2|40 (up to 50) adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy, given a single 60 mcg intramuscular dose of Sanofi Pasteur Fluzone® High Dose.
62575571|NCT01436370|EXPERIMENTAL|Group 2 Controls|40 (up to 50) adults, healthy gender and age-matched controls, given a single 60 mcg intramuscular dose of Sanofi Pasteur Fluzone® High Dose.
62196645|NCT01046006|EXPERIMENTAL|Bortezomib, Rituximab, Dexamethasone|BDR will be administered in one 21-day treatment cycle followed by four 35-day treatment cycles to patients with WM. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of Bortezomib, dexamethasone 40mg iv and Rituximab 375 mg/m2 iv will be administered. A total of 8 infusions of rituximab will be administered. Subsequently patients rated as CR, PR, MR or SD will be followed without any treatment until there is evidence of progressive disease.
62196646|NCT06134336||Research Group|Participants with eating disorders according to the SCOFF Eating Disorders Scale will constitute the research group. Both groups will complete the Occupational Balance Questionnaire and their occupational balances will be compared. The study will be terminated when there are at least 105 participants in the research and control groups and 210 participants in total.
62196647|NCT06134336||Control Group|Participants without eating disorders according to the SCOFF Eating Disorders Scale will constitute the control group. Both groups will complete the Occupational Balance Questionnaire and their occupational balances will be compared. The study will be terminated when there are at least 105 participants in the research and control groups and 210 participants in total.
62575572|NCT01436370|EXPERIMENTAL|Group 1|40 (up to 50) adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy, given a single 15 mcg intramuscular dose of Sanofi Pasteur Fluzone®
62196648|NCT01064700|NO_INTERVENTION|Baseline|1 week period, in which subjects followed usual schedule, though they were asked to maintain a fairly stable sleep schedule. The baseline period was used for comparison with the experimental intervention.
62196649|NCT01064700|EXPERIMENTAL|Experimental Intervention|Randomized exposure to the 4-week experimental treatments.
62575573|NCT00893412|ACTIVE_COMPARATOR|Tramadol + Metal cannula|Fast-release Orodispersible Tramadol Tablet + Metal cannula
62575574|NCT00893412|PLACEBO_COMPARATOR|Placebo + Metal cannula|Placebo + Metal cannula
62575575|NCT00893412|ACTIVE_COMPARATOR|Tramadol + Balloon|Fast-release Orodispersible Tramadol Tablet + balloon catheter
62196650|NCT01749098|EXPERIMENTAL|PF-04958242|PF-04958242 and ketamine
62196651|NCT01749098|PLACEBO_COMPARATOR|Placebo|Placebo and ketamine
62196652|NCT00777075|ACTIVE_COMPARATOR|L-arginine|
62575576|NCT00893412|PLACEBO_COMPARATOR|Placebo + Balloon|Placebo + balloon catheter
62196653|NCT00777075|PLACEBO_COMPARATOR|placebo|
62196654|NCT05354882|EXPERIMENTAL|Intervention|Feasibility group. Single group (intervention group) will be given access to the DEFACTO intervention for twelve-weeks.
62575577|NCT02596971|EXPERIMENTAL|Atezo-G-Benda (Safety Run-In and Expansion Phases)|Safety run-in phase: Participants with previously untreated or relapsed or refractory FL will receive obinutuzumab (G) and bendamustine during Cycle 1 (28-day cycle) and atezolizumab, obinutuzumab, and bendamustine during Cycles 2-6, during induction treatment, followed by atezolizumab (once monthly) and obinutuzumab (every other month \[q2m\]) for 24 months, during maintenance treatment. Expansion phase: Participants with previously untreated FL will receive same treatment regimen as described for safety run-in phase.
62196655|NCT02180750|EXPERIMENTAL|Intervention: Memory Work Therapy|Residential week intervention consisting of memory box, memory book, tree of life, Active Citizen book, all activities facilitated.
62196656|NCT02180750|ACTIVE_COMPARATOR|Control: standard care|Usual care services.
62196657|NCT02036138|ACTIVE_COMPARATOR|Advanced Medical Therapy Patients.|Advanced medical therapy is deﬁned as the use of the latest lifestyle guidelines set forth by the American Diabetes Association to optimize weight loss and glycaemic management, frequent home monitoring/titration strategies, use of latest FDA approved drug therapy (incretin analogues, insulin sensitizers, etc.)
62196658|NCT02036138|EXPERIMENTAL|Bariatric Surgery Patients - Roux-en-Y gastric by- pass|
62196659|NCT02036138|EXPERIMENTAL|Bariatric Surgery Patients -Laparoscopic sleeve gastrectomy|
62575578|NCT02596971|EXPERIMENTAL|Atezo-G-CHOP (Safety Run-In Phase)|Safety run-in phase: Participants with previously untreated or relapsed or refractory FL will receive obinutuzumab and CHOP during Cycle 1 (21-day cycle) and atezolizumab, obinutuzumab, and CHOP during Cycles 2-6, during induction treatment, followed by atezolizumab (once monthly) and obinutuzumab (q2m) for 24 months, during maintenance treatment.
62196660|NCT05094180|OTHER|Face-to-face consultation|
62196661|NCT05094180|ACTIVE_COMPARATOR|Remote consultation (telephone or video consultation mode)|
62196662|NCT03640247|OTHER|Narcotic group regimen|"* Tylenol tablet 1000 mg by mouth every 8 hours alternating with~* Ibuprofen tablet 800 mg by mouth every 8 hours~* Oxycodone 5 mg by mouth every 6 hours as needed for pain, #10 tablet or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg."
62734705|NCT02933879|EXPERIMENTAL|NVXT topical|daily dosing for one 8-week treatment period (Treatment Group A) and two 8-week treatment periods separated by a 32-week rest period (Treatment Group B),
62575579|NCT02596971|EXPERIMENTAL|Atezo-R-CHOP (Expansion Phase)|Participants with previously untreated DLBCL will receive rituximab and CHOP during Cycle 1 (21-day cycle) and atezolizumab, rituximab, and CHOP during Cycles 2-8 (atezolizumab and rituximab for 8 cycles and CHOP for either 6 or 8 cycles, as determined by the investigator), during induction treatment, followed by atezolizumab from Cycles 9-25 during consolidation treatment.
62575580|NCT04490512|EXPERIMENTAL|FluBHPVE6E7|Multiple administration of FluBHPVE6E7
62575581|NCT04490512|PLACEBO_COMPARATOR|Placebo|Multiple administration of buffer solution
62575582|NCT06575829|EXPERIMENTAL|Algucosidase alfa 20 mg/kg once every 4 weeks instead of once every 2 weeks|"Alglucosidase alfa will be administered by intravenous infusion at a dose of 20 mg/kg once every 4 weeks instead of once every 2 weeks for a duration of 9 months.~After 9 months of treatment with the extended interval, it will be determined for each patient whether it is considered safe to discontinue enzyme replacement therapy (ERT). Both, patients who stop ERT after 9 months and those who continue with either the new or the previous dosing schedule, will be closely followed for an additional 12 months, leading to a total study duration of 21 months."
62575583|NCT02117284||Coronary artery disease|All patients present to participating nuclear imaging facilities for diagnosis of CAD and/or risk stratification with Rubidium PET. Subjects will be enrolled according to the clinical indications listed in the approved Ruby-Fill product monograph.
62010243|NCT04922801||Hyperthyrodism|"Patients will undergo 131I-Hyperthyroidism MRT in accordance with existing protocols at GSTTFT. Patients will have one whole-body scan at 24 hr post MRT which will not involve any additional radiation. In addition, all MRT patients will be asked to undertake the following non-invasive procedures.~* Post-treatment gamma camera (Planar Whole Body \& SPECT/CT) imaging to estimate disease/ target tissue and whole-body dose for Neuroendocrine and thyroid cancer MRT.~* Post-treatment gamma camera planar Whole Body imaging for hyperthyroidism MRT.~* Post-treatment patient-led self-monitoring.~* Complete a feedback questionnaire relating to the use of self radiation monitoring."
62010244|NCT02984995|EXPERIMENTAL|Initial dose 30 mg/day quizartinib|Participants who received an initial dose of 30 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 60 mg/day at Day 15.
62010245|NCT02984995|EXPERIMENTAL|Initial dose 20 mg/day quizartinib|Participants who received a CYP3A4 strong inhibitor received an initial dose of 20 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 30 mg/day at Day 15.
62010246|NCT01350206|EXPERIMENTAL|HR group|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
62010247|NCT01350206|EXPERIMENTAL|TACE group|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
62010248|NCT00451620|EXPERIMENTAL|2.|GlucoNorm
62010249|NCT00451620|EXPERIMENTAL|1.|Glyburide
62010250|NCT00643955||DS|Individual with Down Syndrome
62010251|NCT02036905|EXPERIMENTAL|Cervical and thoracic mobilization|Cervical and thoracic mobilization: described as a repetitive low-velocity oscillatory movement applied to a joint segment. It is graded 1-4 based on the size of the amplitude and where in range it is being applied. The mobilization technique chosen will be based on the examination and clinical reasoning process of the therapist. The cervical and thoracic mobilization will be applied to the most provocative level.
62010252|NCT02036905|EXPERIMENTAL|Cervical and thoracic manipulation|Cervical and thoracic manipulation: is defined as high-velocity low-amplitude thrust at end range of a particular spinal segment. The therapist performs this technique by taking up all available slack at a particular segment and applying a high-velocity thrust through the end-range restriction. The manipulation technique will be chosen based on the examination and clinical reasoning process of the therapist.
62010253|NCT04432870||MGH Patients|Patients aged 45-75 who had their screening or surveillance colonoscopy postponed or delayed due to the COVID pandemic at Massachusetts General Hospital
62196663|NCT03640247|ACTIVE_COMPARATOR|Non-narcotic group regimen|"* Tylenol tablet 1000 mg by mouth every 8 hours alternating with~* Ibuprofen tablet 800 mg by mouth every 8 hours"
62196664|NCT01731964|EXPERIMENTAL|WA- NG Telescope Prothesis|Implantable Miniature Telescope for end stage AMD
62196665|NCT01267773|ACTIVE_COMPARATOR|Sequential Treatment|
62196666|NCT01267773|EXPERIMENTAL|Integrated Treatment|
62196667|NCT01040169|PLACEBO_COMPARATOR|Nupro C Prophylaxis paste|Fluoride Free
62196668|NCT01040169|EXPERIMENTAL|ProClude Prophylaxis paste|Arginine
62196669|NCT02761798||Automated Mobile Interactive Audiometer, Test Retest|Each participant will act as his/her own control. The iPad audiogram will be compared to the audiogram in sound booth or to a second iPad audiogram.
62196670|NCT02761798||Automated Mobile Interactive Audiometer, Validation.|iPad testing will be compared to conventional audiometry in the sound booth.
62196671|NCT02761798||Automated Mobile Interactive Audiometer, Speech Recognition|Testing with NU-6 word lists will be conducted by the iPad and by an audiologist in the sound booth.
62196672|NCT02761798||Automated Mobile Interactive Audiometer, Cochlear Implant|Participants with cochlear implants will be tested using iPad against conventional audiometry (warble tone) in the sound booth.
62196673|NCT05761340|EXPERIMENTAL|Helfer Skin Tap Group|Pregnant women were vaccinated against tetanus with the Helfer skin tap technique.The pain was evaluated with Number rating scale immediately after the procedure and also hemodynamic parameters were measured before and after the vaccination. A total of 33 pregnant women completed the study in the Helfer skin tap group
62196674|NCT05761340|EXPERIMENTAL|Standard Application Group|Pregnant women were vaccinated against tetanus with thestandard application technique.The pain was evaluated with Number rating scale. The pain was evaluated immediately after vaccination and hemodynamic parameters were examined before and after the vaccination. A total of 32 pregnant women completed the study in the standard application group.
62196675|NCT03359564||micro endoscopic discectomy|the patients with lumbar disc herniation
62196676|NCT01044927|EXPERIMENTAL|Proactive Integrated Care|COPD-specific education, self-management instruction, remote monitoring and enhanced communication with a coordinator
62196677|NCT01044927|ACTIVE_COMPARATOR|Standard Care Control|No intervention other that measurements taken at 0, 3, 6 and 9 months of the study.
62196678|NCT02429479|ACTIVE_COMPARATOR|Standard ACP/Patient Alone|Patients (without their family caregiver) complete a standard living will form online.
62196679|NCT02429479|EXPERIMENTAL|Decision Aid/Patient Alone|Patients (without their family caregiver) complete Making Your Wishes Known, an online decision aid for advance care planning.
62196680|NCT02429479|ACTIVE_COMPARATOR|Standard ACP/Together|Patients and their family caregiver together complete a standard living will form online.
62196681|NCT02429479|EXPERIMENTAL|Decision Aid/Together|Patients and their family caregiver together complete Making Your Wishes Known, an online decision aid for advance care planning.
62196682|NCT04856735|ACTIVE_COMPARATOR|IPLA:intraperitoneal local anesthetic|intraperitoneal local anesthetic:after the birth of the newborn and placenta, the uterus is closed and the blood accumulated in the pelvis is carefully wiped with surgical towels, after hemostasis is fully achieved, a total of 20 ml solution containing 10 cc of 0.5% bupivacaine +10 cc 2% lidocaine and 2 injectors containing 20ml saline and the 20ml solution were given to the surgeon. The 20 ml solution containing bupivacaine and lidocaine was injected into the uterine peritoneal region by spraying 5 mL to each quadrant of the uterus before closing the parietal peritoneum or fascia. The parietal peritoneal layer was sutured or left open at the surgeon's preference. At the end of the operation, 20 ml of saline solution was applied subcutaneously in the form of LWI instead of the incision before the skin was closed.
62196683|NCT04856735|ACTIVE_COMPARATOR|LWI:Surgical wound infiltration|Surgical wound infiltration:a solution containing 20 ml of saline was added to all four quadrants of the uterus in 5 ml volume and 20 ml solution containing lidocaine and bupivacaine were subcutaneously in the form of LWI before the skin was closed.
62196684|NCT04856735|ACTIVE_COMPARATOR|C: CONTROL GROUP|one of the two sterile injectors containing 20 ml of saline was applied to the uterine peritoneal region and the other was applied to the incision area as a local subcutaneous wound infiltration.
62196685|NCT00910286|OTHER|VENTILATOR WEANING|Two ventilators with different flow termination criteria (TC) were compared: Servo 300 (Siemens-Elema, Sweden) with fixed TC (5% of peak inspiratory flow) and Newport E500 (Newport Medical Instruments, CA) with automatic TC (varies between 5% to 55%). Each patient remained three hours in the protocol, one hour in each ventilator, after been randomized to one of two sequences of 3 steps: Fixed 5% / Automatic / Fixed 5% or Automatic / Fixed 5% / Automatic . The PS, the positive end expiratory pressure (PEEP), the inspiratory oxygen fraction (FiO2) and the pressure trigger sensitivity levels were unchanged during the protocol.
62196686|NCT02952196|PLACEBO_COMPARATOR|placebo|
62196687|NCT02952196|EXPERIMENTAL|cannabinoid dose 1|
62196688|NCT02952196|EXPERIMENTAL|cannabinoid dose 2|
62196689|NCT02580747|EXPERIMENTAL|anti-meso CAR T cells|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Patients receive anti-meso-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity."
62196690|NCT00583297||ABCD Subjects|The cohort will consist of original subjects of the ABCD trial who consent to participate in the genetic sub-study
62196691|NCT06530355||Group 1: Pianists|The non-dominant hands of the pianists in this group were evaluated.
62575584|NCT02798380|EXPERIMENTAL|HTS-519 Insert|Active treatment
62575585|NCT05511610|EXPERIMENTAL|MAAS method trial|Accuracy of sevoflurane and desflurane vaporizers to guarantee the ettHA%, based on the MAAS method.
62010254|NCT03603795|EXPERIMENTAL|A|"55 patients will be randomized in the experimental arm A. If platelets counts \< 100 x 10 Giga/L, patients will be treated with Eltrombopag 200 mg/day per os from day 11 of induction chemotherapy to platelets counts \> 100 x 10 Giga/L or maximum to day 45. If platelets counts ≥ 100 x 10 Giga/L on day 11, the start of IP will be delayed until platelets \< 100 x 10 Giga/L.~Chemotherapy administration would be performed among standard practice:~* Daunorubicin: 60 mg/m² D1 to D3~* Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7~* Lomustine (CCNU): 200 mg/m² per os, at D1.~  200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.~Investigational Product (IP) will be taken at the same time daily on an empty stomach 1 hour before or 2 hours after a meal or preferably no calcium or dairy products."
62575586|NCT01685619||AML Cohort|This cohort is comprised of participants who have acute myelogenous leukemia (AML).
62575587|NCT01685619||MDS Cohort|This cohort is comprised of participants who have myelodysplastic syndrome (MDS).
62734706|NCT02933879|PLACEBO_COMPARATOR|Placebo (Vehicle) Topical|two 8-week treatment periods separated by a 32-week rest period (Treatment Group C),
62196692|NCT06530355||Group 2: Individuals Who Do Not Play Instruments|The dominant hands of the individuals who do not play instruments in this group were evaluated.
62010255|NCT03603795|PLACEBO_COMPARATOR|B|"55 patients will be randomized in the comparator arm B and will received: Placebo once daily from day 11 of induction chemotherapy to AML response evaluation or platelets count \> 100 x 10 Giga/L (maximum day 45)~Placebo 200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.~Chemotherapy administration would be performed among standard practice:~* Daunorubicin: 60 mg/m² D1 to D3~* Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7~* Lomustine (CCNU): 200 mg/m² per os, at D1."
62010256|NCT06234371|EXPERIMENTAL|Treatment|The treatment group will be offered a $500 gift card for completing 6, 12, and 18 counseling sessions; up to $1,500 in total. Because RRC's typical practice involves prescribing and scheduling counseling in 6-session blocks, the financial awards are revealed to veterans in the treatment group in stages. After intake, treatment group individuals are told that they will receive a $500 gift card for completing the first 6 sessions; later sessions and awards are not mentioned. If the counselor decides that another 6-session block should be prescribed, then at the completion of the 5th session (i) the next 6 sessions are scheduled (i.e., sessions 7 through 12) and (ii) the counselor reveals that the participant can earn another $500 for completing the 12th session. The same process takes place during session 11. As part of RRC's typical practice, no veterans are offered more than 18 sessions.
62196693|NCT01932762|EXPERIMENTAL|GT2: Grazoprevir + Elbasvir + RBV (Arm A1)|During Part A of the study, GT2 participants will receive 100 mg grazoprevir + 50 mg elbasvir + standard weight-based dosing of RBV for 12 weeks.
62196694|NCT01932762|EXPERIMENTAL|GT2: Grazoprevir + RBV (Arm B1)|During Part B of the study, GT2 participants will receive 100 mg grazoprevir + standard weight-based dosing of RBV for 12 weeks.
62575588|NCT06535152|EXPERIMENTAL|Lifelight and BP measurement|The accuracy of Lifelight's blood pressure measurements was assessed by comparing Lifelight's measurements with measurements made by dual-observer manual auscultation using the same-arm sequential method specified in ISO 81060-2:2018/AMD 1:2020. The accuracy of Lifelight's pulse rate measurements was assessed by comparing Lifelight's measurements with concurrent ECG-derived heart rate values. The participants were resting before their measurements were taken to ensure stable blood pressure. For each Lifelight measurement, two sets of blood pressure measurements were taken using dual-observer manual auscultation. The first measurement was taken before the Lifelight measurement and the second just after. If there was too much variation between the before and after measurement, or between the 2 independent observers, the measurement was discarded and repeated. For this validation procedure, the measurements taken during the original study were re-processed in the new updated algorithm.
62010257|NCT06234371|NO_INTERVENTION|Control|"The control group will have access to the normal counseling services provided by RRC staff. Those in the control group will receive business as usual services offered by the RRC, which includes the same counseling services and evaluation of how many sessions an individual is recommended to receive."
62575589|NCT06384183||Observational Group|"This observational (i.e., non-interventional), post-market, real-world, Registry was designed to collect, analyze, and identify relevant safety and performance outcomes for all comers using Kerecis devices in routine medical practice within a wide variety of United States (US) medical practice settings."
62575590|NCT03674320|PLACEBO_COMPARATOR|Placebo|Placebo (saline) injections will be given via intramuscular injection at study weeks 2,3, 6, 7, 10, and 11.
62010258|NCT06663410||Fifteen patients of both sexes, older than 18 years, ASA I or II, TN of any etiology|Patients will undergo bilateral sphenopalatine ganglion block with Tx360 nasal applicator using 0.3cc lidocaine 2% in each side, once every week, for a 6-week period.
62196695|NCT01932762|EXPERIMENTAL|GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)|During Part B of the study, GT4/GT5/GT6 participants will receive 100 mg grazoprevir + 50 mg elbasvir + standard weight-based dosing of RBV for 12 weeks.
62196696|NCT01932762|EXPERIMENTAL|GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)|During Part B of the study, GT4/GT5/GT6 participants will receive 100 mg grazoprevir + 50 mg elbasvir for 12 weeks.
62196697|NCT03202680|ACTIVE_COMPARATOR|USDA Style Diet|Healthy, low saturated fat, United States Department of Agriculture (USDA) style diet.
62196698|NCT03202680|EXPERIMENTAL|Lean Beef Diet|Healthy, low saturated fat, high in lean beef diet.
62196699|NCT00002838|EXPERIMENTAL|Combination Chemotherapy + PSCT|PSCT = Peripheral Stem Cell Transplantation
62575591|NCT03674320|ACTIVE_COMPARATOR|Testosterone Enanthate|Testosterone Enanthate (100mg men, 25mg women) will be given via intramuscular injection at study weeks 2, 3, 6, 7, 10 and 11.
62575592|NCT02888418|EXPERIMENTAL|One dose of HPV vaccine in women aged 18 to 30|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in women aged 18 to 30.
62196700|NCT01416857|NO_INTERVENTION|MOD|Group evaluated using the currently available ED measure of disability (MOD)
62196701|NCT01416857|EXPERIMENTAL|RDDT|Group will be evaluated using ED Rasch Disability Diagnostic Tool (RDDT)
62196702|NCT04309461|ACTIVE_COMPARATOR|Stress Management Group|The Stress Management Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target stress, relaxation, and sleep. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. The Stress Management Program, including the use of the app and assessments, is identical to the Adapted MBC2 program, with the exception of the content.
62196703|NCT04309461|EXPERIMENTAL|Adapted MBC2 Group|The Adapted MBC2 Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target fruit and vegetable intake, dietary fat intake, physical activity, and high sedentary leisure screen time. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor goal thermometers to meet targets.
62196704|NCT03689842|EXPERIMENTAL|Couple donor - recipient|
62196705|NCT06227221|EXPERIMENTAL|Sorafenib|
62196706|NCT06227221|PLACEBO_COMPARATOR|Placebo|
62196707|NCT02263807|EXPERIMENTAL|MPFL group|Arthroscopy and MPFL reconstruction
62196708|NCT02263807|ACTIVE_COMPARATOR|Control|Arhroscopy and rehabilitation
62196709|NCT04654910|PLACEBO_COMPARATOR|Control|enrolled subjects that do NOT receive explanation of PROMIS measures during visit.
62010259|NCT04199663||categories of Socioeconomic Status (SES)|"by proxy gender- and calendar year-specific quintiles of disposable income per household consumption unit.~In logistic regression models of associations with secondary prevention activities and established treatment goals: highest vs. lowest income quintile.~In multivariable Cox regression analyses with stepwise built models: quintiles of disposable income and models including covariates level of education and marital status."
62575593|NCT02888418|PLACEBO_COMPARATOR|Placebo in women aged 18 to 30|Placebo in women aged 18 to 30.
62196710|NCT04654910|ACTIVE_COMPARATOR|Intervention|enrolled subjects that DO receive explanation of PROMIS measures during visit.
62196711|NCT06282211|EXPERIMENTAL|Ondansetron Oral Soluble Pellicles|nausea and vomiting prophylaxis with Ondansetron Oral Soluble Pellicles, 8 mg tid for 5-7 days after chemotherapy
62196712|NCT06282211|SHAM_COMPARATOR|no antiemetic drugs or drugs with antiemetic active ingredients|no antiemetic drugs or drugs with antiemetic active ingredients for 5-7 days after chemotherapy
62399329|NCT00070070|EXPERIMENTAL|Cohort 1|"HLA-A2 Status Positive, Previous BCG Therapy; All patients underwent skin testing with the purified protein derivative (PPD) test.~NY-ESO-1 protein, 75 mcg, was administered by intradermal injection every week for 6 weeks. TICE®-strain BCG, 1 x 10E6 viable units in Purified Protein Derivative (PPD) negative patients and 1 x 10E5 viable units in PPD positive (induration greater than or equal to 10 mm) patients, were mixed with each protein vaccination for the first 2 weeks only. For the last 4 weeks GM-CSF, 100 mcg, was mixed with NY-ESO-1 protein given once a week for 4 weeks, intradermally. GM-CSF alone was given subcutaneously on the day prior to the administration of the co-mixture (NY-ESO-1 Protein/GM-CSF) and for 3 days after."
62196713|NCT02979106|EXPERIMENTAL|oral fructose load|test meal calculated to provide 25% of basal energy requirement containing 13C-labeled fructose (0.35 g/kg), protein (0.21 g/kg) and lipid (0.22 g/kg).
62196714|NCT04385758|EXPERIMENTAL|Diabetes-REM Program|
62575594|NCT02888418|EXPERIMENTAL|One dose of HPV vaccine in women aged 9 to 17|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in women aged 9 to 17.
62575595|NCT02888418|PLACEBO_COMPARATOR|Placebo in women aged 9 to 17|Placebo in women aged 9 to 17.
62575596|NCT02888418|EXPERIMENTAL|One dose of HPV vaccine in men aged 9 to 17|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in men aged 9 to 17.
62575597|NCT02888418|PLACEBO_COMPARATOR|Placebo in men aged 9 to 17|Placebo in men aged 9 to 17.
62010260|NCT02305303|EXPERIMENTAL|Diary|Use of diary
62010261|NCT02305303|NO_INTERVENTION|Without Diary|
62196715|NCT02223910|ACTIVE_COMPARATOR|Motor Cortex|Feedback training of functional connectivity between motor cortex and the rest of the brain
62196716|NCT02223910|PLACEBO_COMPARATOR|Control region|Feedback training of functional connectivity between medial prefrontal cortex of healthy hemisphere and the rest of the brain
62575598|NCT02104739|EXPERIMENTAL|Exenatide, then Saxagliptin, then Placebo|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
62196717|NCT01983423|EXPERIMENTAL|Endometrial Biopsy|Endometrial biopsy performed within 5-10 days prior to starting controlled ovarian stimulation, as part of in vitro fertilization treatment.
62196718|NCT01983423|NO_INTERVENTION|Without Biopsy|Those proceeding with in vitro fertilization routinely, without an endometrial biopsy.
62575599|NCT02104739|EXPERIMENTAL|Exenatide, then Placebo, then Saxagliptin|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
62575600|NCT02104739|PLACEBO_COMPARATOR|Saxagliptin, then Exenatide, then Placebo|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
62575601|NCT02104739|EXPERIMENTAL|Saxagliptin, then Placebo, then Exenatide|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
62575602|NCT02104739|EXPERIMENTAL|Placebo, then Exenatide, then Saxagliptin|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
62575603|NCT02104739|EXPERIMENTAL|Placebo, then Saxagliptin, then Exenatide|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
62575604|NCT02104739|EXPERIMENTAL|Exenatide, then Saxagliptin, then Placebo, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
62010262|NCT03574025||Cardiac Arrest Questionnaire|Children who will survive 3 months after Cardiac Arrest
62010263|NCT05249725|EXPERIMENTAL|Irsogladine Maleate|
62010264|NCT05249725|PLACEBO_COMPARATOR|Hydrotalcite|
62010265|NCT04412096|EXPERIMENTAL|Timolol 0.5%|To compare the variation in response to timolol between individuals
62010266|NCT04412096|EXPERIMENTAL|Latanoprost 0.005%|To compare the variation in response to latanoprost between individuals
62010267|NCT01400594|EXPERIMENTAL|HTU-520 Patch|Subjects will receive HTU-520 patch in a 1:1 ratio for 48 weeks applied to all toenails.
62010268|NCT01400594|PLACEBO_COMPARATOR|Placebo Patch|Subjects will receive placebo patch in a 1:1 ratio for 48 weeks applied to all toenails.
62010269|NCT06468488|ACTIVE_COMPARATOR|DIEP flap surgery with drains|Patients will undergo a breast reconstruction by a DIEP flap with drains.
62010270|NCT06468488|EXPERIMENTAL|DIEP flap surgery without drains|Patients will undergo a breast reconstruction by a DIEP flap without drains.
62196719|NCT04887506|EXPERIMENTAL|TAVT-45|TAVT-45 administered twice daily as a 1 x sachet containing TAVT-45 (250 mg abiraterone acetate) + Prednisone (5mg once or twice daily, depending on prostate cancer population). TAVT-45 administered approximately every 12 hours without respect to food. Patients treated for 84 days.
62196720|NCT04887506|ACTIVE_COMPARATOR|Reference abiraterone acetate (Zytiga®) - R-AA|Zytiga (reference abiraterone acetate formulation, hereafter referred to as R-AA) administered once daily as (2 x 500mg Zytiga tablets) + Prednisone (5mg once or twice daily, depending on prostate cancer population). R-AA administered once daily either ≥ 1 hour before or ≥ 2 hours after a meal. Patients treated for 84 days.
62196721|NCT02503319|EXPERIMENTAL|arm A|2 vials ( =1 gram) of Tranexamic Acid oral administered within 5 minutes from the delivery (third stage after labor)
62196722|NCT02503319|EXPERIMENTAL|arm B|2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery(third stage after labor)
62196723|NCT02503319|ACTIVE_COMPARATOR|arm C|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
62196724|NCT01791972|EXPERIMENTAL|Albuterol Spiromax / Placebo Spiromax|Albuterol Spiromax, 180 mcg (2 inhalations of 90 mcg/inhalation), single dose on Day 1. Placebo Spiromax (2 inhalations), single dose on approximately Day 7.
62010271|NCT05726656|EXPERIMENTAL|wii console based exercise group|the patient will recieve wii console based exercise in addition to traditional physical therapy session
62196725|NCT01791972|EXPERIMENTAL|Placebo Spiromax / Albuterol Spiromax|Placebo Spiromax, (2 inhalations), single dose on Day 1. Albuterol Spiromax 180 mcg (2 inhalations of 90 mcg/inhalation), single dose on approximately Day 7.
62196726|NCT00966147|EXPERIMENTAL|Lidco group|All patients monitored by the lidco system and treated to optimize oxygen delivery
62196727|NCT03834519|EXPERIMENTAL|Pembrolizumab + Olaparib|Participants will receive olaparib 600 mg as two 150 mg oral tablets twice daily (BID) continuously until progression PLUS on Day 1 of each 21-day cycle, pembrolizumab 200 mg by intravenous (IV) infusion for up to 35 cycles (approximately 2 years).
62196728|NCT03834519|ACTIVE_COMPARATOR|Next-generation Hormonal Agent Monotherapy (NHA)|Participants will receive a single NHA, which will be either abiraterone acetate (participants previously treated with enzalutamide) 1000 mg as two 500 mg or four 250 mg oral tablets once daily (QD) PLUS prednisone or prednisolone 10 mg as one 5 mg tablet BID until progression OR enzalutamide (participants previously treated with abiraterone acetate) 160 mg as four 40 mg oral tablets or capsules OR two 80 mg tablets QD until progression.
62196729|NCT01422473|EXPERIMENTAL|EnSeal Device|EnSeal Trio Tissue Sealing Device
62196730|NCT03032718|EXPERIMENTAL|Intervention|Patients in the intervention group will receive a defined exercise program twice a week in addition to their usual treatment. Training sessions start immediately after randomization and will be supervised by trained sport students. They will take place twice a week, for twelve weeks in specific training rooms designed to meet the needs of oncological patients in the respective centers. The vibration exercises will take place on a side-alternating vibration platform (GalileoTM, Pforzheim, Germany) ®) according to the previously determined optimal (highest neuromuscular response) setting for each individual. Each session will last for about 15 to 30 minutes, leaving sufficient time for regeneration. Training will consist of four vibration exercises, chosen from a standardized pool of exercises with increasing difficulty in order to allow for individual, optimal progression. All sessions will be documented by the supervisor.
62196731|NCT03032718|NO_INTERVENTION|Control|Patients in the control group will receive treatment as usual and will be given the opportunity to participate in the intervention after completion of the study.
62196732|NCT03306420|EXPERIMENTAL|Part IA Dose Escalation: M4112 100 mg|Participants received an oral dose of 100 milligrams (mg) M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
62010272|NCT05726656|OTHER|control group|the patient will recieve only the traditional physical therapy session
62010273|NCT05049356||Children referred to outpatient clinic|Diagnostic interview (Schedule for Affective Disorders and Schizophrenia (K-SADS) cf. Diagnostic and Statistical Manual of Mental Disorders (DSM-5)) with parents. Diagnostic groups/cohorts (e.g., DMDD, ADHD, Oppositional Defiant Disorder) will be based on the diagnoses given cf. K-SADS.
62575605|NCT02104739|EXPERIMENTAL|Exenatide, then Placebo, then Saxagliptin, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
62010274|NCT05049356||Typical developing children and their parent(s)|Norm values on hair cortisol data will be obtained from typical developing children and their parent(s) by the same procedure as described under Outcome measure(s), 21. Stress Response by Cortisol levels.
62196733|NCT03306420|EXPERIMENTAL|Part IA Dose Escalation: M4112 200 mg|Participants received an oral dose of 200 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
62196734|NCT03306420|EXPERIMENTAL|Part IA Dose Escalation: M4112 400 mg|Participants received an oral dose of 400 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
62196735|NCT03306420|EXPERIMENTAL|Part IA Dose Escalation: M4112 600 mg|Participants received an oral dose of 600 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
62196736|NCT03306420|EXPERIMENTAL|Part IA Dose Escalation: M4112 800 mg|Participants received an oral dose of 800 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
62399330|NCT00070070|EXPERIMENTAL|Cohort 2|"HLA-A2 Status Positive, No Previous BCG Therapy; All patients underwent skin testing with the purified protein derivative (PPD) test.~NY-ESO-1 protein, 75 mcg, was administered by intradermal injection every week for 6 weeks. TICE®-strain BCG, 1 x 10E6 viable units in Purified Protein Derivative (PPD) negative patients and 1 x 10E5 viable units in PPD positive (induration greater than or equal to 10 mm) patients, were mixed with each protein vaccination for the first 2 weeks only. For the last 4 weeks GM-CSF, 100 mcg, was mixed with NY-ESO-1 protein given once a week for 4 weeks, intradermally. GM-CSF alone was given subcutaneously on the day prior to the administration of the co-mixture (NY-ESO-1 Protein/GM-CSF) and for 3 days after."
62196737|NCT00186017|EXPERIMENTAL|Olanzapine/Zyprexa|Olanzapine/Zyprexa 2.5 mg up to 8 per day for 1 week
62575606|NCT02104739|EXPERIMENTAL|Saxagliptin, then Exenatide, then Placebo, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
62575607|NCT02104739|EXPERIMENTAL|Saxagliptin, then Placebo, then Exenatide, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
62010275|NCT06572345|EXPERIMENTAL|Low Energy Diet (LED)|"33 participants will undergo a 12 week low energy diet (LED), followed by a 12 week food reintroduction phase and 24 week weight maintenance phase. 10 participant across all sites from this intervention will be asked to complete a qualitative interview at 2 time points throughout the study, alongside their parent/carer, to understand their thoughts around the intervention, their experience taking part in the study and suggestions for improvement.~Additionally, further interviews will be undertaken with participants and their relatives/carers who declined to take part in the LED portion of the study to understand the reasons why/barriers to them taking part in the intervention. Furthermore, 10 health care professionals (HCPs) from different sites involved in the study will be invited to take part in interviews to garner feedback and experience as well as their impression of the experience of the study for the participants and their families."
62196738|NCT00186017|PLACEBO_COMPARATOR|Placebo|Placebo was taken in the same manner as olanzapine with up to 8 per day for 1 week
62196739|NCT03239327|EXPERIMENTAL|study group|For the study group the enrolled women will receive 50 microgram misoprostol vaginally 60 minutes before CS
62196740|NCT03239327|NO_INTERVENTION|control group|For the control group mothers enrolled will receive nothing.
62196741|NCT06507072|EXPERIMENTAL|Adaptive Rock Climbing|
62196742|NCT02108769|EXPERIMENTAL|Yogic Breathing|"1. Chanting Om~   1. Sharp deep inhalation through nostrils~  2. Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.~   Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.~2. Yogic Breathing:~   1. Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.~  2. Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.~  3. Hold breath in this position for about 16 seconds.~  4. Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.~  5. Go to step a)."
62196743|NCT02108769|ACTIVE_COMPARATOR|Attention Control|The participants will read a text of their choice for 20 minutes.
62575608|NCT02104739|EXPERIMENTAL|Placebo, then Exenatide, then Saxagliptin, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
62575609|NCT02104739|EXPERIMENTAL|Placebo, then Saxagliptin, then Exenatide, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
62575610|NCT05207657|EXPERIMENTAL|Lentiviral vector transduced CD34+ cells|The investigational product is patient-specific and corresponds to cryopreserved autologous CD34+ cells transduced ex vivo with the pCHIM-p47 vector containing the human p47phox (NCF1) gene in final formulation and container closure system, ready for intended medical use. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.
62196744|NCT00134355|EXPERIMENTAL|PTK787|"PTK787:~250 mg orally twice daily x 2 wks, then 250 mg orally am, 500 mg orally pm x 1 wk, then 500 mg orally twice daily"
62196745|NCT04511624|EXPERIMENTAL|Cohort 1|IBI112 SC dose1
62196746|NCT04511624|EXPERIMENTAL|Cohort 2|IBI112 SC dose2
62196747|NCT04511624|EXPERIMENTAL|Cohort 3|IBI112 SC dose3
62196748|NCT04511624|EXPERIMENTAL|Cohort 4|IBI112 IV dose4
62196749|NCT04511624|EXPERIMENTAL|Cohort 5|IBI112 IV dose3
62196750|NCT04511624|EXPERIMENTAL|Cohort 6|IBI112 SC dose5
62196751|NCT04511624|EXPERIMENTAL|Cohort 7|IBI112 IV dose5
62196752|NCT02748551|EXPERIMENTAL|Laparoscopic surgery|Traditional open procedure for patient with locally advanced gastric cancer
62575611|NCT02733848|EXPERIMENTAL|DIET|A registered dietician (RD) will meet with and thoroughly review the patients diet. The patient will be counseled on a diet lower in refined carbohydrates and higher in protein.
62196753|NCT02748551|ACTIVE_COMPARATOR|Open surgery|Minimum invasive procedure (laparoscopic) for patient with locally advanced gastric cancer
62196754|NCT06341140|EXPERIMENTAL|control|Pregnant women in the control group were given a booklet containing information about breastfeeding. In the postpartum period, the breastfeeding process was observed with home visits and telephone for the first 6 months.
62575612|NCT02733848|ACTIVE_COMPARATOR|Creon|Subjects will be provided Creon at a dose of 500 units/kg of lipase to be taken with meals and snacks to see if this decreases frequency and severity of hypoglycemia.
62575613|NCT02733848|PLACEBO_COMPARATOR|Placebo|Subjects will be provided placebo and advised to take it with meals and snacks to provide.
62575614|NCT04618198|NO_INTERVENTION|Diagnosis dependent / conventional dose anti-TB therapy|"Standard care per admitting team including ceftriaxone x 7 days~If subsequent TB test positive, then WHO recommended weight-based anti-TB therapy x 28 days"
62575615|NCT04618198|EXPERIMENTAL|Immediate anti-TB therapy/conventional dose anti-TB therapy|Standard care per admitting team including ceftriaxone x 7 days plus immediate empiric WHO recommended weight-based dose anti-TB therapy x 28 days
62575616|NCT04618198|EXPERIMENTAL|Diagnosis dependent/sepsis specific dose anti-TB therapy|"Standard care per admitting team including ceftriaxone x 7 days~If subsequent TB test positive, then sepsis specific dose anti-TB therapy x 28 days"
62010276|NCT05215639||Venetoclax Participants|Participants treated with Venetoclax in accordance with approved local label.
62575617|NCT04618198|EXPERIMENTAL|Immediate anti-TB therapy/sepsis specific dose anti-TB therapy|Standard care per admitting team including ceftriaxone x 7 days plus immediate empiric sepsis specific dose anti-TB therapy x 28 days
62575618|NCT05571475|EXPERIMENTAL|Simulated competition|During the experimental condition, the participants will be competing for a reward, will be given verbal encouragement, and will receive performance feedback.
62010277|NCT04963504|EXPERIMENTAL|Rest-to-exercise|
62010278|NCT04963504|EXPERIMENTAL|Sitting-to-supine|
62010279|NCT04360824|ACTIVE_COMPARATOR|Standard of Care|1) Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI \<30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30kg/m2).
62010280|NCT04360824|OTHER|Interventional|2) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI\<30 kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
62010281|NCT03671681|EXPERIMENTAL|MT group|Education of patients, Pharmacological Prophylaxis prescribed based on patients' profile, and six group sessions of 45 minutes of mindfulness-based treatment.
62010282|NCT03671681|OTHER|MED group|Education of patients followed by Pharmacological Prophylaxis, prescribed based on patients' profile (i.e. clinical features, previous failures and contraindications)
62010283|NCT05845125|ACTIVE_COMPARATOR|Physiotherapy alone|"Physiotherapy alone after diagnosis of hemiplegic shoulder pain with a capsular pattern. The physiotherapy will focus on stretching and range of motion of the shoulder.~(This is a self-controlled study. The participants' clinical evolution with physiotherapy alone will be compared to their evolution after physiotherapy coupled with the injection.)"
62196755|NCT06341140|EXPERIMENTAL|intervention|Pregnant women in the intervention group were given a booklet containing information about breastfeeding. At the same time, individual breastfeeding support was provided with a wearable breastfeeding model. In the postpartum period, the breastfeeding process was observed with home visits and telephone for the first 6 months.
62196756|NCT05692869|EXPERIMENTAL|ABPM + Wearable Novel Devices + Propranolol|Participants will wear all the devices (ABPM, chest patch device, wrist device and smartwatch device) with propranolol administered orally for 5 days in one of three study periods.
62196757|NCT05692869|EXPERIMENTAL|ABPM + Wearable Novel Devices + Pseudoephedrine|Participants will wear all the devices (ABPM, chest patch device, wrist device and smartwatch device) with pseudoephedrine administered orally for 5 days in one of three study periods.
62196758|NCT05692869|EXPERIMENTAL|ABPM + Wearable Novel Devices Only|Participants will wear all the devices (ABPM, chest patch device, wrist device and smartwatch device) during one of three study periods.
62196759|NCT02919553|EXPERIMENTAL|modified wet-suction technique|Patients in this arm will undergo the modified wet-suction technique. Details in the study description section. After sufficient sampling of the lesion, the needle will be removed and the specimen will be collected.
62196760|NCT02919553|ACTIVE_COMPARATOR|"Capillary slow pull technique"|"Patients in this arm will undergo the Capillary slow pull technique which will include moving the needle to-and-fro into the lesion. Subsequently the needle will be removed and the specimen will be collected."
62196761|NCT00605488|EXPERIMENTAL|1|Pet Scan
62196762|NCT04324905|EXPERIMENTAL|Sequence 1|
62196763|NCT04324905|EXPERIMENTAL|Sequence 2|
62196764|NCT01808677||Thoracic Reirradiation Registry|Data collection on patients being treated with thoracic reirradiation with PBT or IMRT for NSCLC, with or without chemotherapy.
62196765|NCT03240016|EXPERIMENTAL|Pembrolizumab and Abraxane|Pembrolizumab 200mg IV D1 Abraxane 100mg/m\^2 IV D1 and D8 21 Day Cycles
62575619|NCT05571475|NO_INTERVENTION|Control|During the control condition, the participants will be asked to sprint without verbal encouragement or any performance feedback.
62575620|NCT06576739|EXPERIMENTAL|Vitamin Administration|Vitamins B6, B12, and folic acid will be administered orally between 8:30 am - 10:30 am on day of chiropractic manipulation Chiropractic intervention will be applied Number of patients in arm anticipated: 30
62575621|NCT06576739|PLACEBO_COMPARATOR|Placebo Administration|Placebo pills equal in number and appearance to the B vitamins will be administered orally between 8:30 am - 10:30 am on day of chiropractic intervention Chiropractic intervention will be applied Number of patients in arm anticipated: 30
62196766|NCT02209493|EXPERIMENTAL|Food supplementation: nopales|Consumption of 2 cups/day of cooked nopales (prickly pear cactus leaves) with each of two main meals for 2 weeks
62196767|NCT02209493|SHAM_COMPARATOR|Food supplementation: cucumber|Consumption of 2 cups/day peeled and chopped cucumber with each of two main meals for 2 weeks
62196768|NCT01436747|ACTIVE_COMPARATOR|Paricalcitol|
62196769|NCT01436747|PLACEBO_COMPARATOR|Matching placebo|
62196770|NCT06266208||Group A (non-operated):|This group will consist of patients with clinical and radiological diagnosis of painful claw nail with wide nail curvature and presence of dorsal osteophyte on radiograph. They will not have received previous surgery for this condition. They will be followed up conservatively for 1 month, with baseline measurements of nail curvature, nail thickness, osteophyte height and nail-phalange distance. This group will allow correlating the osteophyte height with the degree of nail deformity without surgical intervention.
62196771|NCT06266208||Group B (operated):|This group will include patients who meet the same inclusion criteria as Group A. They will receive surgical treatment for claw nail by partial matrixectomy and removal of the osteophyte. They will be followed up postoperatively for 1 month, with baseline and evolutionary measurements. This group will allow to evaluate the effect of surgery on nail anatomy and symptomatology. At the end of the study, baseline and evolutionary measurements will be compared between groups to analyze the effect of surgical treatment.
62196772|NCT00967967|OTHER|Mometasone furoate and desloratadine|Mometasone and desloratadine treatment
62196773|NCT00150878|OTHER|12 Gy/Cyclophosphamide|Standard intensity conditioning
62196774|NCT00150878|EXPERIMENTAL|8 Gy /Fludarabine|Reduced-intensity conditioning
62196775|NCT03812042||Screen population|The study population will comprise of patients of healthcare institutions in the Washington, D.C. metro area including but not limited to hospitals, clinics, and doctor's offices.
62196776|NCT01385046|EXPERIMENTAL|physical activity and nutrition|
62196777|NCT04685746||Typically developing school-aged children|Study group to achieve objective 1 and 2; control group to achieve objective 3 and 4 - Behavioural protocol: balanced growth protocol, consisting of audiovestibular, cognitive and motor assessments
62196778|NCT04685746||Vestibular-impaired school-aged children|Study group to achieve objective 3 - Behavioural protocol: balanced growth protocol, consisting of audiovestibular, cognitive and motor assessments
62196779|NCT04685746||Neurodevelopmental group (ADHD, ASD and/or DCD)|Study group to achieve objective 4 - Behavioural protocol: balanced growth protocol, consisting of audiovestibular, cognitive and motor assessments
62196780|NCT02879383|EXPERIMENTAL|DMR Procedure|Subjects randomized to the DMR procedure are unblinded at 24 weeks and followed for an additional 24 weeks.
62575622|NCT01921322|EXPERIMENTAL|Pump|Paradigm 722 insulin pump used for insulin infusion and continuous glucose monitoring
62575623|NCT01921322|ACTIVE_COMPARATOR|MDI|Multiple daily insulin injections used for treatment
62575624|NCT03425084|EXPERIMENTAL|Morphine|Intravenous morphine (0,15 mg/kg) will be given as a single dosis at the end of the surgery followed by morphine administrated by patient-controlled analgesia (PCA) as single boluses (0,04mg/kg)
62575625|NCT06574477|EXPERIMENTAL|HOLO+|
62196781|NCT02879383|SHAM_COMPARATOR|Sham Procedure|Subjects are unblinded at 24 Weeks. Sham subjects to cross over to receive DMR treatment at 24 Weeks and followed up for additional 24 weeks.
62196782|NCT04249570|EXPERIMENTAL|Iodine|gastrostomy feeding tube is coated with a layer of Betadine by aseptic gauze before PEG technique
62196783|NCT04249570|NO_INTERVENTION|No iodine|gastrostomy feeding tube is not coated with a layer of Betadine by aseptic gauze before PEG technique
62196784|NCT01953445|EXPERIMENTAL|Treatment (PI3K inhibitor BKM120, paclitaxel)|Patients receive PI3K inhibitor BKM120 PO QD on days 1-28 and paclitaxel IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
62196785|NCT04930497|EXPERIMENTAL|vestibular socket technique with bone grafting|
62196786|NCT04930497|ACTIVE_COMPARATOR|vestibular socket technique without bone grafting|
62196787|NCT04081077|EXPERIMENTAL|Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated
62196788|NCT04081077|EXPERIMENTAL|Regimen 2:Bedaquiline, Pretomanid, Linezolid, Clofazimine|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
62575626|NCT06574477|ACTIVE_COMPARATOR|HOLO-|
62575627|NCT00502112|EXPERIMENTAL|1|lintuzumab and lenalidomide
62575628|NCT01109160|EXPERIMENTAL|Azithromycin|Add-on of study-drug (azithromycin) to 'standard of care': 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment).
62575629|NCT00910143||1|patients operated before summer 1995, that is before the introduction of TME
62575630|NCT00910143||2|patients operated after summer 1995, that is after the introduction of TME.
62575631|NCT01944878||Patients with chronic hepatitis|Patients with chronic hepatitis, who experienced HVPG measurement via transjugular approach and EGD within 3 months of HVPG measurement
62575632|NCT01944878||Patients with liver cirrhosis|Patients with liver cirrhosis, who experienced HVPG measurement via transjugular approach and EGD within 3 months of HVPG measurement
62575633|NCT02313207|ACTIVE_COMPARATOR|FODMAP diet|FODMAP diet for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.
62575634|NCT02313207|ACTIVE_COMPARATOR|Specific bread diet|Specific bread diet eliminating wheat and yeast for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.
62575635|NCT01073813|ACTIVE_COMPARATOR|Minocycline 100mg|Patients are in one of three strata (currently on Glatiramer acetate (GA), Interferon beta (IFN), or neither disease modifying therapy (DMT). There will be a minimum of 12 patients per strata. Patients will be randomized within each strata in a 2:1 fashion to receive either Minocycline 100mg twice daily or no treatment.
62196789|NCT04081077|EXPERIMENTAL|Regimen 3: Bedaquiline, Pretomanid, Linezolid|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
62196790|NCT01853501|EXPERIMENTAL|POF,treatment,ADSC|Fat from POF patients undergo Autologous fat grafting operation were separated, from which Adipose Derived Stem Cell were then purified and injected into the both ovaries of patients.
62196791|NCT01495351|EXPERIMENTAL|ABT-888/Bortezomib|Patients will be on a treatment schedule including twice daily oral dosing for 14 days followed by 1 week rest in combination with standard dosing of Bortezomib and Dexamethasone in a 21 days cycle for a total of 14 cycles.
62196792|NCT05953168|EXPERIMENTAL|Trastuzumab Deruxtecan (T-DXd)|
62196793|NCT01146392||1|Primary care patients with COPD diagnosis
62196794|NCT04513639|EXPERIMENTAL|Arm A|Patients will be followed with MRD assessment every 4 month and start 2.L treatment at loss of MRD negative complete response.
62399331|NCT00070070|EXPERIMENTAL|Cohort 3|"HLA-A2 Status Negative, Previous BCG Therapy; All patients underwent skin testing with the purified protein derivative (PPD) test.~NY-ESO-1 protein, 75 mcg, was administered by intradermal injection every week for 6 weeks. TICE®-strain BCG, 1 x 10E6 viable units in Purified Protein Derivative (PPD) negative patients and 1 x 10E5 viable units in PPD positive (induration greater than or equal to 10 mm) patients, were mixed with each protein vaccination for the first 2 weeks only. For the last 4 weeks GM-CSF, 100 mcg, was mixed with NY-ESO-1 protein given once a week for 4 weeks, intradermally. GM-CSF alone was given subcutaneously on the day prior to the administration of the co-mixture (NY-ESO-1 Protein/GM-CSF) and for 3 days after."
62399332|NCT00070070|EXPERIMENTAL|Cohort 4|"HLA-A2 Status Negative, No Previous BCG Therapy; All patients underwent skin testing with the purified protein derivative (PPD) test.~NY-ESO-1 protein, 75 mcg, was administered by intradermal injection every week for 6 weeks. TICE®-strain BCG, 1 x 106 viable units in Purified Protein Derivative (PPD) negative patients and 1 x 105 viable units in PPD positive (induration greater than or equal to 10 mm) patients, were mixed with each protein vaccination for the first 2 weeks only. For the last 4 weeks GM-CSF, 100 mcg, was mixed with NY-ESO-1 protein given once a week for 4 weeks, intradermally. GM-CSF alone was given subcutaneously on the day prior to the administration of the co-mixture (NY-ESO-1 Protein/GM-CSF) and for 3 days after."
62399333|NCT01784094||Low back pain subjects|Subjects with chronic or recurrent low back pain
62399334|NCT01784094||No low back pain subjects|Subjects who are generally healthy with no low back pain
62399335|NCT06011668|EXPERIMENTAL|distraction method|video game playing
62399336|NCT06011668|EXPERIMENTAL|distraction|kaleidoscope
62010284|NCT05845125|EXPERIMENTAL|Physiotherapy with mild arthrographic distension|"Physiotherapy continues after the participant receives a mild arthrographic distension with corticosteroid of the shoulder.~(This is a self-controlled study. The participants' clinical evolution with physiotherapy alone will be compared to their evolution after physiotherapy coupled with the injection.)"
62010285|NCT03068299|EXPERIMENTAL|Dance|n=29 participants randomized. Cognition performance, frailty and burden will be measured at baseline and after of interventions (6 months after baseline). Instruments of measurement described in Time Frame.
62010286|NCT03068299|EXPERIMENTAL|Health care guidance|n=29 participants randomized. Cognition performance, frailty and burden will be measured at baseline and after of interventions (6 months after baseline). Instruments of measurement described in Time Frame.
62010287|NCT04898231|ACTIVE_COMPARATOR|Infliximab|Infliximab will be administered as a single IV dose of 10 mg/kg over 2 hours.
62010288|NCT04898231|ACTIVE_COMPARATOR|Methylprednisilone (steroids)|Methylprednisilone (steroids) will be administered as 2 mg/kg IV or orally divided every 12 hours. At the time of hospital discharge the patient will be given a steroid taper that will take at least 3 weeks to complete.
62010289|NCT04898231|ACTIVE_COMPARATOR|Anakinra|Anakinra will be administered at a dose of 8 mg/kg/day IV or SQ with 100 mg every 6 hours as the max dose. This is discontinued with a taper during the hospitalization over 2-4 days once a patient is stable with significantly improved clinical course and laboratory profile.
62010290|NCT03079804|EXPERIMENTAL|Experimental MWM|"Other names:~4 mobilizations - 10 seconds 20 seconds of rest"
62010291|NCT03079804|ACTIVE_COMPARATOR|Experimental Thrust|"Other names:~1 traction with caudal direction in high speed and low amplitude increasing dorsiflexion."
62010292|NCT03079804|PLACEBO_COMPARATOR|Placebo|"Other names:~It will accurately reproduce the positioning of the hand in the specific treatment condition (Thrust or MWM), however, without applying any movement or force. All interactions, procedures and deadlines will be identical."
62010293|NCT05428969|EXPERIMENTAL|Phase 1 - Intermediate/high risk MDS, CMML 10-19%, MDS/CMML failure to HMA, r/r AML|Standard of care azacitidine as per label; bexmarilimab 4 dose levels at once every week (Q1W) followed by once every 2 weeks (Q2W); 28-day cycle
62010294|NCT05428969|EXPERIMENTAL|Phase 1 - Newly diagnosed AML patients non-fit for induction therapy|Standard of care azacitidine and venetoclax as per label; bexmarilimab 4 dose levels Q1W followed by Q2W; 28-day cycle
62010295|NCT05428969|EXPERIMENTAL|Phase 2 - Intermediate/high risk MDS, CMML, MDS/CMML failure to HMA, r/r AML & newly diagnosed AML|Standard of care venetoclax and/or azacitidine as per label plus bexmarilmab
62010296|NCT02829359|EXPERIMENTAL|Entecavir therapy|Patients who received entecavir (zhengda Tianqing Co., Ltd, Lianyungang, Jiangsu Province, China; 0.5 mg/d) were submitted to antiviral group. Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month. No immunological therapy in perioperative period will be submitted to any included patients.
62010297|NCT02829359|NO_INTERVENTION|No antiviral therapy|Patients who did not receive any antiviral therapies were submitted as non-antiviral group. Patients in the non-antiviral group who underwent HBV reactivation will receive entecavir therapy. No immunological therapy in perioperative period will be submitted to any included patients.
62399337|NCT06011668|EXPERIMENTAL|distraction methods|virtual reality glasses
62399338|NCT02042807|PLACEBO_COMPARATOR|Placebo|placebo arm
62399339|NCT02042807|ACTIVE_COMPARATOR|MCS® 15 mg/day|MCS® soft capsule
62399340|NCT02042807|ACTIVE_COMPARATOR|MCS® 30 mg/day|MCS® soft capsule
62399341|NCT00359684||Cystinosis|Patients with a diagnosis of cystinosis
62399342|NCT00542074|EXPERIMENTAL|1|
62399343|NCT00542074|ACTIVE_COMPARATOR|2|
62196795|NCT04513639|ACTIVE_COMPARATOR|Arm B|Patients will be followed up by standard criteria and start 2.L treatment at progressive disease.
62196796|NCT01178008|EXPERIMENTAL|Active acupuncture group|Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints.
62575636|NCT01073813|NO_INTERVENTION|No treatment|Patients are in one of three strata (currently on Glatiramer acetate (GA), Interferon beta (IFN), or neither disease modifying therapy (DMT). There will be a minimum of 12 patients per strata. Patients will be randomized within each strata in a 2:1 fashion to receive either Minocycline 100mg twice daily or no treatment.
62575637|NCT05330819||Group and Interventions|Participants: Adult patients with stable coronary artery disease and previous history of myocardial infarction currently receiving aspirin monotherapy.
62575638|NCT05330819||Groups and interventions|Interventions: Blood thrombogenicity in patients with previous history of myocardial infarction will be studied using Badimon perfusion chamber, SEM and TEG.
62010298|NCT00699881|EXPERIMENTAL|A|administer cetuximab in combination with modified FOLFIRI
62010299|NCT06573710|EXPERIMENTAL|Sonic activation|
62010300|NCT06573710|EXPERIMENTAL|LASER activation|
62010301|NCT06573710|EXPERIMENTAL|Ultrasonic activation|
62575639|NCT01780090|EXPERIMENTAL|iPad software|Student participants will use specialized, iPad software under the direction of the SLP, 1 time a week over the course of 2 months.
62575640|NCT01284348|EXPERIMENTAL|Sotatercept 15 mg|Participants will receive sotatercept 15 mg by subcutaneous (SC) injection once every 42 days, up to four doses.
62575641|NCT01284348|EXPERIMENTAL|Sotatercept 30 mg|Participants will receive sotatercept 30 mg by SC injection once every 42 days, up to four doses.
62575642|NCT06212414|EXPERIMENTAL|Mind programme|"This group will receive the Mind programme. This intervention comprises 8 weekly group sessions, with the duration of 120 minutes each, to be delivered via Zoom. Integration of Acceptance and Commitment Therapy, mindfulness and Compassion Focused Therapy components, adapted to women with breast cancer.~All participants will continue on receiving the recommended medical treatment for their clinical diagnosis."
62575643|NCT06212414|ACTIVE_COMPARATOR|Support group|"This group will receive a 8-week support group intervention (weekly sessions, with the duration of 120 minutes each), via Zoom.~All participants will continue on receiving the recommended medical treatment for their clinical diagnosis."
62575644|NCT06212414|NO_INTERVENTION|Waiting list (Treatment As Usual / No psychological intervention)|This group will receive the (psychological) treatment as usual in Portugal (no treatment), besides the recommended medical treatment for their clinical diagnosis. At the end of this research project, the intervention that proves to be most efficacious will be offered to participants from the waiting list condition.
62575645|NCT03941054|NO_INTERVENTION|Control arm|No intervention
62575646|NCT03941054|EXPERIMENTAL|Pressure Release|Digitopressure treatment of the Myosfascial Trigger Points
62010302|NCT06573710|ACTIVE_COMPARATOR|passive irrigation with Endodontic needle|
62010303|NCT06449573||Asthma|"Inclusion Criteria:~* Patients receiving step 5 asthma treatment~* 18-65 years~* Asthma under control (asthma control test ≥20)~* No more than 2 exacerbations in the last 1 year~Exclusion Criteria:~* Non-consenting~* Patients with asthma exacerbation requiring systemic steroid use for at least 3 days in the last 1 month~* Being an active smoker"
62196797|NCT01178008|PLACEBO_COMPARATOR|Placebo acupuncture group|Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
62196798|NCT00006462|EXPERIMENTAL|Relapsed acute lymphoblastic and acute Myelogenous leukemia|Gemcitabine hydrochloride will be given as 10 mg/m2/min x 360 minutes weekly for three weeks. After a one-week rest period it may be repeated in patients without progressive disease or limiting toxicity.
62010304|NCT06449573||Healthy Individuals|"Inclusion Criteria:~* No respiratory, cardiovascular and metabolic diseases~* Regular non-smoker~Exclusion Criteria:~* Non-consenting~* Pregnant women"
62010305|NCT05357391|EXPERIMENTAL|The pressure injury prediction and education model group|The experimental group will be provided a pressure injury prediction of the patient and personalized care information of pressure injury by a smart care platform. The participants (primary caregivers) will fill out the questionnaires online at admission (baseline-T0) and before the patient is discharged(T1). The questionnaires will collect the following data, including demographic information(only T0), knowledge, self-efficacy, anxiety, depression of wound care(T0\&T1), and satisfaction of the smart care platform(only T1). The time to fill out the questionnaires will be about 10 minutes.
62010306|NCT05357391|NO_INTERVENTION|The control group|Routine care
62196799|NCT01808131|EXPERIMENTAL|lesinurad 200 mg + allopurinol|
62196800|NCT01808131|EXPERIMENTAL|lesinurad 400 mg + allopurinol|Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after implementation of protocol amendment 4, dated 07 October 2015.
62196801|NCT03656250||Chemo Patients with Nasopharyngeal cancer|The standard chemoradiation treatment (total 7000 cGy in 35 fractions at 200 cGy/fraction) for 7 weeks with 3 cycles of chemo followed by 3-month chemotherapy.
62196802|NCT06085053|EXPERIMENTAL|TQA3038 injection|One dose of TQA3038 injection in Day 1.
62196803|NCT06085053|PLACEBO_COMPARATOR|TQA3038 injection matching placebo|One dose of TQA3038 injection matching placebo in Day 1.
62196804|NCT04486599|EXPERIMENTAL|Electromagnetic Navigation|The patient have to low Flow Vascular Abnormality diagnosed by Duplex Ultrasound and MRI. Decision of Ultrasound Guided Percutaneous Foam Sclerotherapy taken in multidisciplinary staff meeting
62399344|NCT01966029|EXPERIMENTAL|Treatment|All patients receive treatment with BMN 110
62399345|NCT05090111|EXPERIMENTAL|ALG-055009|Oral dose(s) of ALG-055009 in Healthy Volunteer or subjects with mild hyperlipidemia once daily up to 14 days
62399346|NCT05090111|PLACEBO_COMPARATOR|Placebo|Oral dose(s) of placebo in Healthy Volunteer or subjects with mild hyperlipidemia once daily up to 14 days
62399347|NCT00974896|EXPERIMENTAL|AMG 479 + Sorafenib cohorts|The aim is to determine the safety, tolerability and PK of AMG 479 with sorafenib. AMG 479 will be given bi-weekly; sorafenib will be given daily.
62399348|NCT00974896|EXPERIMENTAL|AMG 479 + Erlotinib cohorts|The aim is to determine the safety, tolerability and PK of AMG 479 with erlotinib. AMG 479 will be given bi-weekly; erlotinib will be given daily.
62399349|NCT06724809|EXPERIMENTAL|eculizumab|All participants will receive open-label eculizumab by intravenous infusion during the Treatment Period, starting on Day 1 for a total of up to 52 weeks.
62399350|NCT02479594|EXPERIMENTAL|competence-feedback|Therapists assigned to this group will receive standardized feedback on their psychotherapeutic competency after every fourth treatment session with a patient for a period of 20 therapy sessions. The feedback will be given by two experienced raters who are licensed as psychological psychotherapists.
62399351|NCT02479594|PLACEBO_COMPARATOR|control|Therapists assigned to this group will receive no competence-feedback.
62399352|NCT05762276|EXPERIMENTAL|VXX-401 Cohort A|VXX-401 100mcg administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12
62575647|NCT04806711|EXPERIMENTAL|Menicon Z Night|The experimental arm consist of a group of Menicon Z Night orthokeratology contact lens wearers
62575648|NCT04806711|ACTIVE_COMPARATOR|Control|The active comparator arm consist of a control group of distance, single-vision glasses and contact lens wearers
62010307|NCT05340686|EXPERIMENTAL|Braining high intensity|Moderate to vigorous physical exercise, supervised by psychiatric staff 3 times per week
62196805|NCT03648424||Linagliptin|Patients who initiate Linagliptin with no use in the prior 180 days
62399353|NCT05762276|EXPERIMENTAL|VXX-401 Cohort B|VXX-401 100mcg administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12
62399354|NCT05762276|EXPERIMENTAL|VXX-401 Cohort C|VXX-401 300mcg administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12
62575649|NCT01967966|EXPERIMENTAL|Bioavailability|
62399355|NCT05762276|EXPERIMENTAL|VXX-401 Cohort D|VXX-401 300mcg administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12
62399356|NCT05762276|PLACEBO_COMPARATOR|Placebo Cohort A and C|Placebo administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12
62399357|NCT05762276|PLACEBO_COMPARATOR|Placebo Cohort B and D|Placebo administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12
62575650|NCT01967966|EXPERIMENTAL|Elimination & PK|
62196806|NCT03648424||Glimepiride|Patients who initiate Glimepiride with no use in the prior 180 days
62196807|NCT05246579||Patients with short cervix|Patients with a short cervix identified on transvaginal ultrasound \<30 mm
62196808|NCT05246579||Patients with a history of spontaneous preterm birth|Patients with a history of spontaneous preterm birth (\<34 weeks)
62196809|NCT05246579||Patients with symptoms of preterm birth|Patients with preterm premature rupture of membranes or \</=2 cm dilated before 34 weeks gestation.
62399358|NCT05762276|EXPERIMENTAL|VXX-401 Cohort E|VXX-401 900mcg administered by intramuscular (IM) injection at Week 0. VXX-401 100 mcg administered by intramuscular (IM) injection at Week 4 and Week 12.
62399359|NCT05762276|EXPERIMENTAL|VXX-401 Cohort F|VXX-401 900mcg administered by intramuscular (IM) injection at Week 0. VXX-401 300 mcg administered by intramuscular (IM) injection at Week 4 and Week 12.
62399360|NCT05267652|ACTIVE_COMPARATOR|Preoxygenation with Non-Invasive Positive Pressure Ventilation Group|Patients assigned to preoxygenation with non-invasive positive pressure ventilation will receive non-invasive mechanical ventilation via a tight-fitting mask from the initiation of preoxygenation until the initiation of laryngoscopy. Trial protocol will not dictate the brand or type of mechanical ventilator that will be used to deliver non-invasive ventilation.
62575651|NCT04831411|ACTIVE_COMPARATOR|Whole Body Vibration|The training program will last 2 days a week and 6 weeks in total. Each session includes a warm-up, progressive whole-body vibration training and a cooling exercise. On the remaining days of the week, all patients will apply the standard exercise program, which includes simple home exercises, at home.
62575652|NCT04831411|ACTIVE_COMPARATOR|Progressive Resistance Training|The training program will last 2 days a week and 6 weeks in total. Each session includes a warm-up, progressive resistance training and a cooling exercise. On the remaining days of the week, all patients will apply the standard exercise program, which includes simple home exercises, at home.
62575653|NCT06340841|EXPERIMENTAL|Individual Receives Incentive - No Restorative Incentive|Participant receives incentives directly
62196810|NCT05246579||Control/Nulliparous|Nulliparous patients
62196811|NCT04990232|PLACEBO_COMPARATOR|Standard of care|Patients will receive the standard type of treatment decided by the attending physicians. They will also receive 20ml (10ml for patients with creatinine clearance lower than 30ml/min) intravenous (IV) 0.9% saline (N/S) three times daily (every eight hours) for 15 days and 0.5 ml subcutaneous (sc) 1ml 0.9% N/S every other day for a total of 15 days.
62399361|NCT05267652|ACTIVE_COMPARATOR|Preoxygenation with Facemask Oxygen Group|For patients randomized to preoxygenation with facemask oxygen, supplemental oxygen will be administered via a non-rebreather mask or bag-mask device without manual ventilation from the initiation of preoxygenation until induction. Trial protocol will not dictate the brand or type of facemask. The decision between use of a non-rebreather mask and use of a bag-mask device will be made by treating clinicians. The decision of whether to provide manual ventilation with a bag-mask device between induction and laryngoscopy will be made by treating clinicians.
62399362|NCT06724289|EXPERIMENTAL|Open-label, single arm trial|25 mg psilocybin administered to each participant
62399363|NCT00857701|NO_INTERVENTION|1|Patient will receive post-surgical standard of care treatment with standard Physical therapy and NSAIDs.
62010308|NCT05340686|ACTIVE_COMPARATOR|Braining relaxing exercise|Relaxation, light yoga or stretching exercise, supervised by psychiatric staff 3 times per week
62010309|NCT05340686|ACTIVE_COMPARATOR|Information about physical exercise|Written and oral information about health benefits from physical exercise, provided by researcher on one occasion.
62010310|NCT06207110|EXPERIMENTAL|Regulation of Cues|The ROC program provides psychoeducation, coping skills, self-monitoring and experiential learning targeting increasing satiety responsiveness and decreasing food cue responsiveness.
62010311|NCT06207110|ACTIVE_COMPARATOR|Family-Based Treatment|The FBT program provides nutrition and physical activity education, behavior therapy skills, and parenting skills targeting changes in energy balance.
62010312|NCT06207110|EXPERIMENTAL|Regulation of Cues +|The ROC+ program includes all of the components of ROC as well as nutrition education and reducing energy intake
62010313|NCT06207110|ACTIVE_COMPARATOR|Health Education|The HE program provides information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
62010314|NCT03113591|EXPERIMENTAL|Osteo introducer group|undergo minimal invasive total hip arthroplasty surgery
62010315|NCT03113591|ACTIVE_COMPARATOR|Control group|undergo common total hip arthroplasty surgery
62196812|NCT04990232|EXPERIMENTAL|Immunotherapy|Patients will receive the standard type of treatment decided by the attending physicians. They will also receive IV anakinra 200 mg three times daily (every eight hours) or sc rhIFNγ 100 μg once every other day. More precisely, patients randomized for hyper-inflammation will receive anakinra three times daily (every eight hours) for 15 days and sc 0.5 ml N/S 0.9% every other day for 15 days. Patients having immunoparalysis will receive IV 20 ml N/S 0.9% (10ml for patients with creatinine clearance lower than 30ml/min) three times daily (every eight hours) for 15 days and sc rhIFNγ every other day for 15 days. Especially for patients with creatinine clearance lower than 30 ml/min anakinra will be given half dose (i.e. 100 mg three times daily). Creatinine clearance is calculated by the Cockcroft Gault equation \[(140-age in years)/ (72 x serum creatinine in mg/dl) for men; this is multiplied by 0.85 for women.
62196813|NCT05595577|EXPERIMENTAL|Physical Activity Intervention|Participants will have the ability to attend one to two training sessions per week and 1-2 sessions per week at home (the 4th level of our multi-level intervention) or the location site using the Trainerize application to deliver the exercise prescription.
62196814|NCT05595577|EXPERIMENTAL|Healthy Living Intervention (Control Arm)|Participants randomized to the control arm will participate in organized health workshops. Each session will last 60 minutes and will be offered on location and virtually (e.g., Zoom) over 6 months. Participants will meet once a week for the first 4 weeks, biweekly for 3 months, and once a month for the last 2 months for a total of 12 sessions.
62196815|NCT05423899|EXPERIMENTAL|Humanoid Robot|
62196816|NCT05423899|ACTIVE_COMPARATOR|Treatment as Usual|
62196817|NCT00108251|PLACEBO_COMPARATOR|1|placebo tablet
62196818|NCT00108251|EXPERIMENTAL|2|eplerenone tablets
62196819|NCT01895790|EXPERIMENTAL|Pancreatic Duct|Consecutive adult patients (18-80 years of age) with cytopathologic diagnosis of unresectable pancreatic cancer complaining of pain due to pancreatic duct obstruction will receive a pancreatic duct stent.
62196820|NCT06292442|ACTIVE_COMPARATOR|Traditional physical therapy|This group received conventional physical therapy treatment including Range of Motion (ROM) exercises for the affected hip, knee, and ankle joints, as well as stretching exercises for tight lower limb muscles, administered 3 times per week for 4 weeks, with each session lasting approximately 20-30 minutes.
62196821|NCT06292442|EXPERIMENTAL|High intensity interval training|This group received high-intensity interval training along with conventional treatment for the lower limb muscles
62196822|NCT05146089|EXPERIMENTAL|Hypoxia Exposure|Men and women will be exposed to acute intermittent hypoxic episodes.
62575654|NCT06340841|EXPERIMENTAL|Individual Receives Incentive -Restorative Incentive|The participant receives incentives directly. There is a restorative incentive if they miss an activity.
62010316|NCT04893889|EXPERIMENTAL|Fabry disease patients|Patients diagnosed with Fabry disease. Interventions will be as follows: Shear wave myocardial elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity (EMD) in Fabry disease (DF) and cardiac amyloidosis (AC) in the ATTRh form and correlating with other complementary imaging tests and laboratory tests (electrocardiogram, 2D echocardiogram, troponin and BNP) and with a 6-minute walk test and quality of life questionnaires.
62010317|NCT04893889|ACTIVE_COMPARATOR|Amyloidosis transthyretin with cardiac commitment|Patients diagnosed with amyloidosis who present cardiac commitment. Interventions will be as follows: Shear wave myocardial elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity (EMD) in Fabry disease (DF) and cardiac amyloidosis (AC) in the ATTRh form and correlating with other complementary imaging tests and laboratory tests (electrocardiogram, 2D echocardiogram, troponin and BNP) and with a 6-minute walk test and quality of life questionnaires.
62010318|NCT04893889|PLACEBO_COMPARATOR|Healthy subjects|Healthy patients. Interventions will be as follows: Shear wave myocardial elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity (EMD) in Fabry disease (DF) and cardiac amyloidosis (AC) in the ATTRh form and correlating with other complementary imaging tests and laboratory tests (electrocardiogram, 2D echocardiogram, troponin and BNP) and with a 6-minute walk test.
62010319|NCT04230382||Adults|Adults (above 18 years) with completed National Health and Health System Survey 2019 (without diagnosis of diabetes)
62010320|NCT01985516|EXPERIMENTAL|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
62010321|NCT01985516|ACTIVE_COMPARATOR|Pouring the gel on the tip of the catheter|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally)
62010322|NCT05380661|EXPERIMENTAL|Individuals with motor-complete SCI|Individuals with motor sensory complete injury (AIS A/B)
62196823|NCT00681668|EXPERIMENTAL|Quetiapine Fumarate 150 - 800mg|Quetiapine 150-800mg
62196824|NCT03197168|EXPERIMENTAL|Intervention|Intervention to reduce self-stigma among people with mental illness + Usual care
62196825|NCT03197168|PLACEBO_COMPARATOR|Control|Usual care
62196826|NCT02051374|ACTIVE_COMPARATOR|Decompression alone|Posterior approach with decompression will be performed. The decompression will be done after microsurgical principles, and the midline structures will be preserved. The surgeons will either use microscope or magnifying glasses.
62399364|NCT00857701|EXPERIMENTAL|2|Patients will be treated with the Standard of Care physical therapy and NSAIDs as well as a Knee Extension Dynasplint that includes tension chambers.
62399365|NCT06723288||Cohort A: nAMD/DME Participants|Participants with nAMD/DME will be enrolled in this cohort given, they meet the eligibility criteria. The SD-OCT test will be conducted for all participants in this cohort. Additionally, swept source optical coherence tomography (SS-OCT) will be performed on the first 50 participants.
62575655|NCT06340841|EXPERIMENTAL|Charity Receives Incentive - No Restorative Incentive|Participant earns money for charity
62399366|NCT06723288||Cohort B: Healthy Subjects|Healthy subjects who meet the eligibility criteria will be enrolled in this cohort. The SD-OCT test will be conducted for all subjects in this cohort. Additionally, SS-OCT will be performed on the first 50 healthy subjects.
62575656|NCT06340841|EXPERIMENTAL|Charity Receives Incentive -Restorative Incentive|Participant earns money for charity. There is a restorative incentive if they miss an activity.
62575657|NCT02511938|EXPERIMENTAL|Menu Only intervention|Restaurants will receive a new healthy kids' menu
62010323|NCT05380661|EXPERIMENTAL|Individuals with motor-incomplete SCI|Individuals with motor sensory incomplete injury (AIS C/D)
62010324|NCT06126549|ACTIVE_COMPARATOR|Usual Care|Usual Care (UC) consists of nurse instruction in care routines, case management family support for discharge, referral to family counseling and community services as indicated, and general information resources about brain injury. Usual Care participants also have access to peer support services, including peer mentoring, brain injury education classes, and workshops for caregivers.
62196827|NCT02051374|ACTIVE_COMPARATOR|Decompression followed by fusion with instrumentation|Posterior approach with decompression will be performed, followed by posterolateral pedicle screw fixation with or without an additional cage. The surgeons will either use microscope or magnifying glasses.
62196828|NCT00833378|ACTIVE_COMPARATOR|Period 2|Treatment B
62196829|NCT00833378|ACTIVE_COMPARATOR|Period 1|Treatment A
62399367|NCT02059473|EXPERIMENTAL|Physiotherapy & Surgery|Mini-open rotator cuff repair
62399368|NCT02059473|ACTIVE_COMPARATOR|Physiotherapy|Structured physiotherapy
62196830|NCT00833378|ACTIVE_COMPARATOR|Period 3|Treatment C
62399369|NCT06723132||breast cancer|breast cancer patients with -Radiological documentation of BM by computed tomography (CT) OR magnetic resonance imaging (MRI)
62399370|NCT06514508|EXPERIMENTAL|Motixafortide+G-CSF|
62399371|NCT06514508|PLACEBO_COMPARATOR|Placebo+G-CSF|
62399372|NCT03651375|EXPERIMENTAL|Sequential chemoradiotherapy|1xAI (doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm) + 5x5 Gy radiotherapy + 2xAI + surgery
62399373|NCT04493658||Sjogrens syndrome dry eye|Patients with a previous diagnosis of dry eye made by an eye care specialist and a diagnosis of Sjogren's syndrome made according to the 2016 revised criteria
62399374|NCT04493658||Non-Sjogrens syndrome dry eye|Patients with a previous diagnosis of dry eye made by an eye care specialist and no diagnosis of Sjogren's syndrome based on 2016 revised criteria.
62575658|NCT02511938|EXPERIMENTAL|Menu Plus Intervention|Restaurants will receive a new healthy kids' menu, supporting marketing materials, and brief trainings for customer service staff and kitchen staff to support and promote the new menu items.
62575659|NCT01430754|EXPERIMENTAL|tasimelteon|20 mg tasimelteon capsules
62575660|NCT01430754|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62575661|NCT01090349|EXPERIMENTAL|Direct Alerts ON|Direct Alerts in implantable device were turned on
62575662|NCT01090349|ACTIVE_COMPARATOR|Direct Alerts OFF|Direct Alerts in implantable device were turned off
62575663|NCT00445172|EXPERIMENTAL|1|
62575664|NCT06428123|EXPERIMENTAL|Mirror Therapy|
62196831|NCT06405763|ACTIVE_COMPARATOR|Snodgrass repair group|"A relaxing incision is made in the midline by using scalpel or scissors from Within the meatus to the end of the plate.~A 6 F stent is passed into the bladder. The neourethra is closed using a fine suture, 7-0 or 6-0 vicryl sutures in two-layer."
62196832|NCT06405763|ACTIVE_COMPARATOR|Snodgrass repair with graft group|A relaxing incision is made in the midline by using scalpel or scissors A free graft was measured and harvested from the inner prepuce and was defatted and sutured onto the incised urethral plate after the urethral plate was incised he graft was sutured overlying the incision line A 6 F stent is passed into the bladder. The neourethra is closed
62196833|NCT02112890||Study Group|A random sample of subjects constituting adolescents and young adults (≥10 - ≤25 years of age) that participated in the ENSANUT 2012 in Mexico.
62196834|NCT03095469|EXPERIMENTAL|study group|when the operation begin,dexmedetomidine will be pumped at 0.4μg/kg•h for 15 minutes ,then reduce the dose to 0.2μg/kg•h until 24 h after PCI.
62196835|NCT03095469|PLACEBO_COMPARATOR|control group|0.9%NaCl solution 0.1ml/kg•h when the operation begin and stopped until 24 h after PCI.
62010325|NCT06126549|ACTIVE_COMPARATOR|Building Better Caregivers|Building Better Caregivers (BBC) was developed for caregivers of patients with Alzheimers' Disease and has been adapted for caregivers of patients with ABI. BBC is a peer-led, problem-solving intervention delivered in 6 group workshop sessions. Key components include problem-solving; making an action plan; managing stress and fatigue, difficult care partner behavior, and difficult thoughts/emotions. Each of the workshops last 60 minutes and usually take place once a week over a 6-8 week span of time.
62196836|NCT05681273|EXPERIMENTAL|Group A|D1: Oral single dose of Empagliflozin 10 mg; D5\~9: Oral multiple doses of Chiglitazar 48 mg; D10: Oral single dose of Empagliflozin 10 mg and Chiglitazar 48 mg.
62196837|NCT05681273|EXPERIMENTAL|Group B|D1: Oral single dose of Atorvastatin 20 mg; D5\~9: Oral multiple doses of Chiglitazar 48 mg; D10: Oral single dose of Atorvastatin 20 mg and Chiglitazar 48 mg.
62575665|NCT06428123|OTHER|Mental Imagery|
62010326|NCT06126549|ACTIVE_COMPARATOR|Problem Solving Training|Problem Solving Training (PST) is a clinician-led intervention, administered one-on-one via phone calls, assigned readings, and practice assignments between calls. PST teaches caregivers how to address problems and apply a specific problem-solving technique that calls for brainstorming, consideration, development, and evaluation to address current problems the caregiver may be facing. The training aims to teach the strategy, so caregivers can apply it in the present, as well as the future. Each of the 6 Problem Solving Training Sessions last from 30-60 minutes and usually take place once a week over a 6-week span of time.
62010327|NCT01251796|EXPERIMENTAL|ARQ 197 and Erlotinib|ARQ 197 and erlotinib hydrochloride
62010328|NCT06333626|EXPERIMENTAL|Observation group|
62010329|NCT06333626|NO_INTERVENTION|Control group|
62575666|NCT00589615|ACTIVE_COMPARATOR|1|The multidisciplinary osteoporosis prevention study started with a five-day program at a rehabilitation centre and will be followed by one-day group appointments twice.
62196838|NCT05681273|EXPERIMENTAL|Group C|D1: Oral single dose of Valsartan 160 mg; D5\~9: Oral multiple doses of Chiglitazar 48 mg; D10: Oral single dose of Valsartan 160 mg and Chiglitazar 48 mg.
62196839|NCT02397551|ACTIVE_COMPARATOR|Small doses of HCG|Supplementing the luteal phase with three small doses (500 IU) of HCG after trigger with GnRH agonist in antagonist IVF/ICSI cycles in high responders
62196840|NCT02397551|ACTIVE_COMPARATOR|Booster HCG dose|Booster HCG dose GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
62196841|NCT04190576|EXPERIMENTAL|Minimally invasive ridge augmentation with LLLT|Subperiosteal minimally invasive aesthetic ridge augmentation with G- Bone (Bone Graft) and low-level laser therapy
62196842|NCT04190576|ACTIVE_COMPARATOR|Minimally invasive ridge augmentation|Subperiosteal minimally invasive aesthetic ridge augmentation with G- Bone (Bone Graft) alone
62196843|NCT00544232|EXPERIMENTAL|epirubicin, paclitaxel and CMF +/- darbepoetin|"Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel"
62196844|NCT00544232|EXPERIMENTAL|EC followed by paclitaxel +/- darbepoetin|"Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF"
62196845|NCT04510480||cardiac arrest|"Out of hospital cardiac arrest patients (Historical cohort) from 1st January 2009 and 30th June 2020.~Out of hospital cardiac arrest patients from 1st July 2020 and 31st December 2025."
62575667|NCT00589615|NO_INTERVENTION|2|The control group will get information about osteoporosis through media and health care system.
62575668|NCT02852135|EXPERIMENTAL|LMA Proseal group|The patients were randomly allocated to two groups by using computer-generated numbers.In LMA Prosealgroup,LMA Proseal was inserted into each patient after anesthesia induction.
62399375|NCT04493658||Control|Normal individuals with no previous diagnosis of dry eye or Sjogren's syndrome
62399376|NCT05245266|OTHER|Analysis of blood samples from healthy pregnant women|Analysis of blood samples from healthy pregnant women. A phlebotomist will be sent to any location in the United States to collect the blood sample. Sample identifiers will be removed as the first step so that laboratory personnel will not see or have access to identifiers. No information will go back to patients or their physicians.
62010330|NCT04437394||Study group|Study group was performed on 30 patients who were diagnosed with ankylosing spondylitis using modified New York criterion.
62010331|NCT04437394||Control group|Control group was performed on 30 participants who were healthy.
62196846|NCT03488680|EXPERIMENTAL|Intervention group|Behavior change communication
62196847|NCT03488680|NO_INTERVENTION|Control group|No Behavior change communication
62196848|NCT01777334|EXPERIMENTAL|Umeclidinium/Vilanterol|Long-acting muscarinic antagonist (LAMA)/Long-acting Beta agonist (LABA)
62196849|NCT01777334|ACTIVE_COMPARATOR|Tiotropium|Long-acting muscarinic antagonist (LAMA)
62196850|NCT05090527|ACTIVE_COMPARATOR|Directly delabeled trough risk stratification tool|"Patients who are stratified as  no penicillin allergy undergo a one dose full dose provocation test with 500 mg amoxicillin."
62196851|NCT05090527|ACTIVE_COMPARATOR|Low risk patients|Patients stratified as low risk on penicillin provocation undergo a one dose full dose provocation test with 500mg amoxicillin
62196852|NCT05090527|ACTIVE_COMPARATOR|High risk|Patient stratified as high risk undergo a full allergologic work up, and only some of these will undergo a provocation test.
62399377|NCT05227404||COVID19 Assays|All participants enrolled will receive 2 point of care assays, and 1 central lab assay
62399378|NCT03011931|EXPERIMENTAL|Simvastatin|Simvastatin tablet, 20 mg, one time by mouth
62399379|NCT06235177|EXPERIMENTAL|Intervention Techniques for Psychoneuromentalism Disorder|"The Interventions to be administered will be as follows:~1. Ashwagandha Herb Tincture and Supplement~2. Damiana Herb Tincture~3. Passion Flower Herb Tincture~4. Grapeseed Extract- Capsule~5. Rhodiola- Herb Tincture~6. Sea Moss Supplement Capsule~7. Theocentric Psychological Counseling~8. Clinical Yoga~9. Meditation~10. Mental Imagery~11. Decompartmentalization Framework~12. Dietary Supplements~13. Applied Relaxation (Music Meditation, Breathing Techniques)~14. Pain Relaxation Techniques~15. Meridian Acupuncture"
62399380|NCT05874921||Jelmyto|Patients with UTUC treated with Jelmyto
62399381|NCT01575158|EXPERIMENTAL|citalopram|citalopram
62399382|NCT01575158|ACTIVE_COMPARATOR|clomipramnine|clomipramine
62399383|NCT01575158|PLACEBO_COMPARATOR|placebo|placebo
62399384|NCT02438293||children undergoing cardiac surgery|paediatric patients with a congenital heart disease undergoing elective cardiac surgery
62196853|NCT00607672|PLACEBO_COMPARATOR|1|Patients are randomized to placebo prior to surgery
62399385|NCT06240468||AIS patient|"AIS inclusion criteria~(1) Inclusion criteria~1. Meet the diagnostic criteria for AIS or TIA;~2. Age 18-80 years old;~3. within 7 days of the onset of stroke;~4. Sign informed consent, provide relevant medical history and biological specimens;~5. Have lived in the local city for the last three years.~(2) Exclusion criteria~1. Patients with recurrent stroke within the past year when first enrolled;~2. mRS \> 2 points before stroke onset;~3. malignant tumor;~4. Liver and kidney dysfunction (alanine aminotransferase or aspartate aminotransferase \>2 times the upper limit of normal, creatinine \> 1.5 times the upper limit of normal);~5. History of drug abuse and chemical poisoning (e.g. pesticide poisoning);~6. In the acute stage of stroke (within 7 days from the onset of stroke) stool specimens could not be collected."
62196854|NCT00607672|ACTIVE_COMPARATOR|2|Patients are randomized to Ramipril prior to surgery
62196855|NCT00607672|ACTIVE_COMPARATOR|3|Patients are randomized to Candesartan (ARB) prior to surgery
62196856|NCT03267446|EXPERIMENTAL|Interventional group|Patients confirmed having one or more of the signs of morbidly adherent placenta will be examined by 3D Ultrasound and 3D power Doppler. Patients will then be prepared for the operation.Cesarean hysterectomy will be done with removal of the uterus and the placenta as one mass.Cases with focal invasion of the uterus will be given a trial for conservative management. The whole specimen will be sent for histopathological examination, and the determination of length and depth of invasion.
62196857|NCT05518071|EXPERIMENTAL|Cohort 1 - N=4 (0.05mg/kg, 2-4h before intervention)|
62196858|NCT05518071|EXPERIMENTAL|Cohort 2 - N=4 (0.05mg/kg, 14-24h before intervention)|
62399386|NCT06240468||Cognitive/emotional subcohort|"(I) Inclusion criteria:~1. It has been included in the AIS queue, meeting the inclusion criteria of the main AIS queue;~2. NIHSS≤15; (II) Exclusion criteria:~(1) Patients with aphasia and unable to cooperate in completing the cognitive/emotional assessment during the study; (2) previous severe mental disorder and dementia (AD8 scale score ≥2); (3) A history of severe anxiety and depression; (4) Previous history of seizures."
62399387|NCT06240468||healthy person|health
62399388|NCT01899417||ConforMIS iTotal® Knee Replacement|knee joint replacement
62010332|NCT04502602|EXPERIMENTAL|Dose Level -1|Neratinib 160 mg and Niraparib 100 mg by mouth once daily for 28 day cycles.
62010333|NCT04502602|EXPERIMENTAL|Dose Level 1|Neratinib 160 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
62010334|NCT04502602|EXPERIMENTAL|Dose Level 2|Neratinib 200 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
62010335|NCT04502602|EXPERIMENTAL|Dose Level 3|Neratinib 240 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
62010336|NCT04502602|EXPERIMENTAL|Dose Level 4|Neratinib 240 mg and Niraparib 300 mg by mouth once daily for 28 day cycles.
62010337|NCT04502602|EXPERIMENTAL|Phase 1b: Platinum Resistant Expansion Cohort|This portion of the study provides for cohort expansion to observe for 4 month or greater progression-free survival in patients with platinum resistant ovarian cancer treated at the recommended phase 2 dose (RP2D) determined in Phase I.
62010338|NCT01787513|EXPERIMENTAL|CBM Version A + iCBT|CBM Version A is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
62196859|NCT05518071|EXPERIMENTAL|Cohort 3 - N=4 (0.025mg/kg, 2-4h before intervention)|
62196860|NCT05518071|EXPERIMENTAL|Cohort 4 - N=4 (0.025mg/kg, 14-24h before intervention)|
62196861|NCT05518071|EXPERIMENTAL|Expansion cohort - N=4 (optimal dose, optimal dose-interval)|
62196862|NCT06503081||Crohn's disease|Patients previously diagnosed with Crohn's disease who have a clinical indication for undergoing a standard white light colonoscopy, as determined by their gastroenterologist, will be invited to participate. Patients undergoing colonoscopy for other indications (for example, for the investigation of possible malignancy, polyps, gastrointestinal bleeding or diarrhea, without colonic inflammation), will not be included in this study.
62196863|NCT00208455|OTHER|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
62196864|NCT02565433|EXPERIMENTAL|questionnaire administration|Quality of life questionnaires administration (EORTC QLQ C30 and BN20 / IADL / HADS / MoCa Edmonton Symptom Assessment Scale)
62196865|NCT05037643|EXPERIMENTAL|Pre-emptive TIPS in Cystic Fibrosis Related Liver Disease and non-cirrhotic portal hypertension|"Patients with CFLD without cirrhosis were eligible for a pre-emptive TIPS, when early (asymptomatic) signs of portal hypertension. All procedures were performed under general anaesthesia by an experienced interventional radiologist. Depending on the patient's age and physiognomy, TIPS was created following a conventional transjugular technique as for adults or by a dedicated combined percutaneous transhepatic-transjugular (PIPS) approach for small children. Routinely, an expanded polytetrafluoroethylene-covered endoprosthesis was used for shunt creation. If the sheath could not be negotiated into the main portal vein, a self-expandable, non-covered stent was placed. We did not pursue a minimum gradient reduction.~Percutaneous liver biopsy was performed during TIPS procedure to confirm the diagnosis of fibrosis or cirrhosis."
62196866|NCT04091698|ACTIVE_COMPARATOR|topical Q10 mucoadhesive tablets|will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.
62196867|NCT04091698|PLACEBO_COMPARATOR|topical corticosteroid|will receive topical corticosteroid (kenacort A Orabase: triamcinolone acetonide 0.1%5gram adhesive paste - dermapharm), 4 times daily for 3months.
62196868|NCT04648137|EXPERIMENTAL|Patients with central diabetes insipidus|
62196869|NCT04648137|EXPERIMENTAL|Healthy volunteers|
62399389|NCT01899417||Standard Knee Replacements|knee joint replacement
62575669|NCT02852135|EXPERIMENTAL|LMA Supreme group|The patients were randomly allocated to two groups by using computer-generated numbers.In LMA Supreme group,LMA Supreme was inserted into each patient after anesthesia induction.
62010339|NCT01787513|PLACEBO_COMPARATOR|CBM Version B (Control) + iCBT|CBM Version B (Control) is an Internet-based intervention taking place over 1 week (identical to CBM Version A without the putative active components) followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
62196870|NCT05365399|OTHER|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|In this study we aim to collect data of newborns with wider range of bilirubin levels and high melanin content, and additionally measurements of skin color reflectance with a spectrophotometer, to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors. .
62196871|NCT01635023|EXPERIMENTAL|AZD6244 white capsule|75mg AZD6244 white (current Phase II) capsule
62196872|NCT01635023|EXPERIMENTAL|AZD6244 blue capsule|75mg AZD6244 blue (planned Phase III) capsule
62575670|NCT05992142|OTHER|UC patients|UC patients, treated by 5-ASA for at least 6 months, free of concomitant UC medications for at least 3 months and presenting for a routine follow-up visit
62575671|NCT01427348|EXPERIMENTAL|with assistant|head extension by an assistant during direct laryngoscopy
62575672|NCT01427348|ACTIVE_COMPARATOR|without assistant|without the help of an assistant during direct laryngoscopy
62575673|NCT01262287|EXPERIMENTAL|dutasteride|dutasteride (1 mg oral daily dose) for 8-week treatment period
62575674|NCT01262287|PLACEBO_COMPARATOR|Placebo|placebo daily for 8-week treatment period
62196873|NCT01635023|EXPERIMENTAL|AZD6244 solution|35mg AZD6244 oral solution
62196874|NCT00749229|OTHER|1|Balloon kyphoplasty
62399390|NCT01092312|EXPERIMENTAL|Signature Knee Guide|Vanguard Knee System with Signature Knee Guide
62399391|NCT01092312|ACTIVE_COMPARATOR|Conventional Approach|Vanguard Complete Knee System with Conventional Approach
62399392|NCT05119101|ACTIVE_COMPARATOR|Magnesium sulphate|patients will recieve Mg sulphate as loading dose of 4 g diluted in 200 ml normal saline intravenous over 10 minutes followed by 1 g/h infusion for 24 h.
62575675|NCT06577389||elderly after spine fusion surgery|patients receive Enhanced recovery after spinal fusion surgery
62575676|NCT04453449||No sedation|Patients who will undergo the diagnostic lumbar medial branch blocks without sedation (control group).
62575677|NCT04453449||Sedation|Patients who will undergo the diagnostic lumbar medial branch blocks with midazolam sedation (treatment group).
62575678|NCT01399775|EXPERIMENTAL|immediate implantation|Immediately after tooth extraction, dental implant is inserted.
62575679|NCT01399775|OTHER|Delayed implantation|Four months after extraction, Dental implant is inserted.
62575680|NCT01473433|OTHER|Control|Patients in which the non-revascularizable area will be left untouched and the revascularizable area will be treated normally.
62575681|NCT01473433|EXPERIMENTAL|adiFLAP|Patients in which the non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure.
62010340|NCT05271929|ACTIVE_COMPARATOR|Current standard of care|"Standard of care therapy may include anti-SARS-CoV-2 specific medication such as, but not limited to:~* Casirivimab~* Casirivimab / Imdevimab (REGN-COV2 or Ronapreve)~* Imdevimab~* Sotrovimab (Xevudy)~* Tixagevimab / Cilgavimab (Evusheld)~* Molnupiravir (MK-4482)~* Nirmatrevlir / Ritonavir (Paxlovid)~* Remdesivir~Centres should ensure that medications used as standard of care are used similarly for patients in both treatment arms."
62196875|NCT06160661|EXPERIMENTAL|single arm study|"The purpose of this study was to assess the accuracy of a splint-less approach for mandibular jaw orthognathic surgery. This approach utilized a personalized orthognathic surgical guide (POSG) system, which comprised a set of cutting guides and 3D printed custom titanium fixation plates for bilateral sagittal split osteotomies (BSSOs).~The cutting guides were first used to predrill screw holes and guide osteotomies. The custom plates were then used to reposition and stabilize the bony segments as planned, without the use of surgical splints or any additional tool such as surgical navigation"
62399393|NCT05119101|ACTIVE_COMPARATOR|Dexamedotomidine adjuvant to Magnesium sulphate|Patients will reccieve Mg sulphate as loading dose of 4 g diluted in 200 ml normal saline intravenous over 10 minutes followed by 1 g/h infusion for 24 h. in addition they will receive an intravenous infusion of dexmedetomidine .5 μg/kg diluted in 200 ml normal saline intravenous over 10 minutes followed by .15 μg/kg/hr infusion for 24 h.
62399394|NCT02016638|EXPERIMENTAL|polysomnography and AMBP on pregnant females|"Consecutive patients undergoing antenatal check up at the Antenatal Clinic at AIIMS hospital and obstetrics wards will be recruited and followed.Using Somnomedic systems, GmbH polysomnography machine by trained staff nurses and technicians at:~Obstetrics ward, AIIMS hospital"
62399395|NCT03714139|EXPERIMENTAL|Immediate implant Loading|Immediate loading is defined as the placement of the implant and immediate prosthetic restoration
62399396|NCT03714139|NO_INTERVENTION|non implant loading|there is not immediate prosthetic restoration
62399397|NCT02739711|ACTIVE_COMPARATOR|Glycoprotein IIb/IIIa inhibitor|Glycoprotein IIb/IIIa inhibitor administration
62575682|NCT05633940|EXPERIMENTAL|Implementation|The centers that implement PCBH.
62575683|NCT05633940|NO_INTERVENTION|No implementation|Control centers that do not implement PCBH.
62575684|NCT00832572|EXPERIMENTAL|Placebo-Ranolazine|Participants were randomized to receive placebo to match ranolazine during Weeks 1 to 6, then ranolazine during Weeks 7 to 12.
62575685|NCT00832572|EXPERIMENTAL|Ranolazine-Placebo|Participants were randomized to receive ranolazine during Weeks 1 to 6, then placebo to match ranolazine during Weeks 7 to 12.
62196876|NCT03510455|EXPERIMENTAL|Single Arm (TIO Subjects)|Phase 2, open-label, non-randomized, single-arm, drug treatment trial. 10 subjects will be studied. Treatment duration of 6 months with 3 months off drug follow-up and optional extension phase.
62399398|NCT02739711|NO_INTERVENTION|Standard therapy|No glycoprotein IIb/IIIa inhibitors
62399399|NCT01466309|EXPERIMENTAL|treatment|patients treated with Somnoguard
62399400|NCT00656942||Healthy|"* subjects with no pain and no opioid treatment for at least six months~* subjects receive quantitative sensory testing (QST)"
62399401|NCT00656942||Pain, no opioid|"* subjects have chronic pain but have not taken any opioid medication for at least 3 months~* subjects receive QST"
62399402|NCT00656942||Pain, opioid|"* subjects have chronic pain and have been taking opioid medication for at least 3 months~* subjects receive QST"
62399403|NCT05571982|EXPERIMENTAL|Tidal volume breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Tidal volume breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
62399404|NCT05571982|ACTIVE_COMPARATOR|Vital capacity breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Vital capacity breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
62575686|NCT02690818|EXPERIMENTAL|Behavioral intervention arm|"Regularly scheduled medication reminder text messages~Daily LTBI text messages without the option to text back. The messages will read, This is a reminder to take your medication.~Standard of care: Monthly reminder call and clinic visit"
62575687|NCT02690818|NO_INTERVENTION|Control group receiving standard care|Standard of care: Monthly reminder call and clinic visit
62575688|NCT05537584|EXPERIMENTAL|MDD with SERT+ Response Marker|Participants with MDD who have been classified as high sertraline responders based on behavioral and brain data.
62010341|NCT05271929|EXPERIMENTAL|Current standard of care and convalescent plasma|Current standard of care and the infusion of two plasma units collected from two different COVID-19 convalescent patients.
62399405|NCT02928198|ACTIVE_COMPARATOR|Fenestration|Fenestration of the Absorb Biovascular Scaffold towards the side-branch
62399406|NCT02928198|ACTIVE_COMPARATOR|No Fenestration|No fenestration of the Absorb Biovascular Scaffold towards the side-branch
62196877|NCT02806492|EXPERIMENTAL|Patient for cardiac surgery|All patient undergo the 5 different intervention in a randomised matter.
62196878|NCT03249870|EXPERIMENTAL|Inotuzumab ozogamicin (INO)|
62196879|NCT04237389|ACTIVE_COMPARATOR|Ablation Index guided catheter radiofrequency ablation|30 patients, who undergo Ablation Index (AI) guided catheter RF ablation
62196880|NCT04237389|ACTIVE_COMPARATOR|Thoracoscopic surgical epicardial ablation|"30 patients, who undergo thoracoscopic ablation using Box-lesion set"
62399407|NCT03372304|EXPERIMENTAL|API+PCA|Infusion of ropivacaine 0.2 %, 10 mL, every 8th hour. Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
62399408|NCT03372304|ACTIVE_COMPARATOR|CI+PCA|Continuous infusion of ropivacaine 0.2 %, 6 mL/hour. Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
62399409|NCT03372304|ACTIVE_COMPARATOR|PCA only|Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
62399410|NCT06724653|ACTIVE_COMPARATOR|RAS blocker tapering arm|RAS blocker tapering
62575689|NCT05537584|EXPERIMENTAL|MDD with BUP+ Response Marker|Participants with MDD who have been classified as high bupropion responders based on behavioral and brain data.
62575690|NCT05071482|EXPERIMENTAL|flumatinib arm|600 mg QD oral administration, fasting (2 hours before administration and 1 hour after administration).
62575691|NCT05071482|ACTIVE_COMPARATOR|imatinib arm|600 mg QD oral administration, with a meal
62196881|NCT01736540|OTHER|Magnetic Resonance Imaging (MRI)|All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.
62575692|NCT04554901|OTHER|Cocoa|2-week, once-daily 70%, 50g cocoa bar manufactured by The UWI Cocoa Research Institute (14 bars)
62196882|NCT00661297|EXPERIMENTAL|Arm 1|
62196883|NCT00661297|PLACEBO_COMPARATOR|Arm 2|
62196884|NCT00795223|ACTIVE_COMPARATOR|1|Injection of 0.3 mg morphine with spinal block and perform femoral nerve block with 0.5% bupivacaine
62196885|NCT00795223|ACTIVE_COMPARATOR|2|Injection of 0.3 mg morphine with spinal block and perform femoral nerve block with 0.25% bupivacaine
62196886|NCT00795223|ACTIVE_COMPARATOR|3|Injection of 0.2 mg morphine with spinal block and perform femoral nerve block with 0.5% bupivacaine
62196887|NCT00795223|ACTIVE_COMPARATOR|4|Injection of 0.2 mg morphine with spinal block and perform femoral nerve block with 0.25% bupivacaine
62196888|NCT02567851|EXPERIMENTAL|Brentuximab Vedotin|brentuximab vedotin will be administered at an initial dose of 1.8 mg/kg every 3 weeks as a 30-minute outpatient i.v. infusion. A maximum of 16 cycles
62575693|NCT05912296|EXPERIMENTAL|RBD7022 SAD experimental group|Subjects in SAD experimental groups will receive a single subcutaneous injection of RBD7022 on Day 0.
62196889|NCT04392024|OTHER|Triumf|Subjects who have cataract surgery with Triumf IOL
62196890|NCT05529888|ACTIVE_COMPARATOR|Patient group|Patients were treated with Isotretinoin in a dose (from 20 to 40) for 3 months and serum homocysteine were assessed before and after treatment
62399411|NCT06724653|ACTIVE_COMPARATOR|Beta blocker tapering arm|Beta blocker tapering arm
62399412|NCT06724653|PLACEBO_COMPARATOR|Control|Drug maintain group
62399413|NCT05970042|EXPERIMENTAL|GameDay Ready Program|GameDay Ready is a 12-week, group-based behavioral weight management program.
62399414|NCT05970042|ACTIVE_COMPARATOR|Walking and General Health Education Program|The walking and general health education program is a 12-week, group-based program that addresses common chronic health conditions that affect men.
62399415|NCT03389633|EXPERIMENTAL|Rehabilitation group|this group follows a 3 months rehab program
62399416|NCT03389633|NO_INTERVENTION|No rehabilitation|This group does not follow a rehab program
62575694|NCT05912296|EXPERIMENTAL|RBD7022 MAD experimental group|Subjects in MAD experimental groups will receive one subcutaneous injection of RBD7022 on Day 0 and another subcutaneous injection of RBD7022 on Day 28.
62196891|NCT05529888|NO_INTERVENTION|Control group|Assessment of serum YKL40 in healthy individuals
62196892|NCT04870268||PD group|percutaneous drainage group
62196893|NCT04870268||END group|endoscopic approach group
62399417|NCT05568212|EXPERIMENTAL|ARM A (experimental arm)|Investigator's choice single-agent chemotherapy plus durvalumab 1500 mg every 3 weeks.
62575695|NCT05912296|PLACEBO_COMPARATOR|Placebo SAD group|Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 0.
62575696|NCT05912296|PLACEBO_COMPARATOR|Placebo MAD group|Subjects in MAD placebo groups will receive one subcutaneous injection of placebo on Day 0 and another subcutaneous injection of placebo on Day 28 .
62010342|NCT02086435|EXPERIMENTAL|Extracorporeal morcellation|"Extracorporeal morcellation in which patients are treated with protected removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself"
62196894|NCT04870268||INT group|surgical internal derivation of WON group
62010343|NCT02086435|ACTIVE_COMPARATOR|Intracorporeal morcellation|Intracorporeal morcellation patients treated with standard intracorporeal morcellation, using reusable electronic device
62010344|NCT02449356|EXPERIMENTAL|prone position endotracheal tube(PPT)|the subjects of this arm are given the prone ventilation endotracheal tube which contains fixed device, fixed rope.
62010345|NCT02449356|NO_INTERVENTION|traditional endotracheal tube(TT)|the subjects of this arm are given the routine endotracheal tube.
62196895|NCT04870268||NE group|surgical necrosectomy group
62010346|NCT05872035|EXPERIMENTAL|Self-Fit Settings|Amplification settings established by algorithm and further adjusted by participants per their preference
62010347|NCT05872035|ACTIVE_COMPARATOR|Pro-Fit Settings|Amplification settings established by clinical reference and further adjusted by an audiologist per current best practice
62196896|NCT02903017|ACTIVE_COMPARATOR|Tranexamic acid 5%|Tranexamic acid 5%, 2000 mg (40 mL) in 60 mL normal saline (0.9%) solution (total 100 mL)
62196897|NCT02903017|PLACEBO_COMPARATOR|Placebo|0.9% normal saline solution (total 100 mL)
62196898|NCT01543022|EXPERIMENTAL|Symphony system|
62196899|NCT00335751|EXPERIMENTAL|positron emission tomography computed tomography (PET/CT)|The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
62196900|NCT05089747||Adult with solid cancer. No intervention.|
62196901|NCT04641169|OTHER|Echocardiography|"• Echocardiography performed by the evaluator 1: 2 LVEF visual evaluations 2 LVEF automatic evaluations~• Echocardiography performed by the evaluator 2: 2 LVEF visual evaluations 2 LVEF automatic evaluations"
62196902|NCT03483610|ACTIVE_COMPARATOR|screening and referral|
62196903|NCT03483610|ACTIVE_COMPARATOR|behavioral intervention|
62196904|NCT02224547|EXPERIMENTAL|Radiotherapy|For centrally located T1 and T2 lesions 4 x 12 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 17 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
62196905|NCT05676970|EXPERIMENTAL|Telehealth Arm: Wellness with Vaccine Education|Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. In addition, they will complete education and counseling on vaccination. All educations will be completed one-on-one as well as small group.
62399418|NCT05568212|ACTIVE_COMPARATOR|ARM B (standard arm)|Investigator's choice single-agent chemotherapy.
62399419|NCT05568212|EXPERIMENTAL|ARM C (experimental arm)|Investigator's choice platinum doublet chemotherapy plus durvalumab 1500 mg every 3 weeks for 4 cycles followed by maintenance durvalumab 1500 mg every 3 weeks plus olaparib 300 mg twice daily.
62575697|NCT03143985|EXPERIMENTAL|Vactosertib + Pomalidomide|"Vactosertib tablets, taken once daily for the first and second dose levels and twice a day for third and fourth dose level levels for 5 days followed by 2 days without treatment, repeated for 28-day cycles until evidence of progressive disease, intolerable toxicity, or participant discontinuation.~For dose escalation - dosing initiated at 60 mg once daily by oral administration and will be increased to determine MTD. Provisional subsequent doses are 60, 120, once daily and 100 mg and 200 mg twice daily on days 1-5, 8-12, 15-19 and 22-26. Extension cohorts will enter at 200 mg twice daily (i.e. if MTD not defined) for 12 months until progression or intolerable toxicity.~POM is administered orally (4 mg/day daily on Days 1 - 21 days). Treatment will occur in a suitable outpatient ambulatory care setting that is equipped for monitoring of patients with hematopoietic malignancies undergoing early clinical trial research."
62575698|NCT04168112|EXPERIMENTAL|Group A|Intracanalicular dexamethasone insert is placed on day of crosslinking (CXL); patients will still receive postoperative fluoroquinolone (or other class in case of allergy) antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye QID x 10 days).
62196906|NCT05676970|ACTIVE_COMPARATOR|Telehealth Arm: Wellness Only|Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. All educations will be completed one-on-one as well as small group.
62196907|NCT02364596|EXPERIMENTAL|1|SA4Ag vaccine
62399420|NCT05568212|EXPERIMENTAL|ARM D (experimental arm)|Investigator's choice platinum doublet chemotherapy plus durvalumab 1500 mg every 3 weeks for 4 cycles followed by maintenance durvalumab 1500 mg every 3 weeks
62399421|NCT06089265|EXPERIMENTAL|HFI patients|HFI participants will receive PF-06835919 for 9 days. Dosage; once daily 300 mg PF-06835919 in the form of 3 tablets, oral.
62399422|NCT06089265|NO_INTERVENTION|Healthy controls|Healthy controls will receive no intervention, but a single fructose tolerance test.
62399423|NCT03990012|EXPERIMENTAL|Patients referred for breast biopsy|Patients with Breast Imaging-Reporting and Data System (BI-RADS) 4C or 5 diagnosis who have been referred for breast biopsy based on the results of their standard diagnostic breast exam will undergo IR and 3D imaging of the breasts.
62399424|NCT03975218||Patients with stroke|In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
62399425|NCT02836795|EXPERIMENTAL|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
62010348|NCT03377621|EXPERIMENTAL|Whole Body Vibration|OSA subjects will be asked to use whole body vibration machine for 30 minutes, 3 times a week for 6 weeks in between visits.
62010349|NCT01331148|ACTIVE_COMPARATOR|Vitamin D|10,000 IU per caplet, with vitamin D dose based on weight, ranging from 240,000 IU to 600,000 IU. Patients will receive calcium/vitamin D daily soft chew as well.
62010350|NCT01331148|PLACEBO_COMPARATOR|Placebo|placebo only, all patients will receive calcium/vitamin D chew
62010351|NCT01138748|EXPERIMENTAL|Radiation therapy|
62010352|NCT02275286|EXPERIMENTAL|Trabectedin+Radiotherapy|Trabectedin 1.3 or 1.5mg/m2 and radiotherapy 30Gy or 45Gy.
62575699|NCT04168112|ACTIVE_COMPARATOR|Group B|Patients are placed on standard postoperative regimen of postoperative fluoroquinolone (or other class in case of allergy) antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye QID x 10 days) and Prednisolone acetate 1% ophthalmic solution tapered over 1 month in the following schedule: QID x1 week, TID x 1 week, BID x 1 week, and Qday x 1 week.
62399426|NCT03048175|EXPERIMENTAL|Cases: wisdom tooth pathology|Subjects affected by bilateral wisdom tooth pathology, undergoing surgical removal
62399427|NCT03048175|NO_INTERVENTION|Controls: no wisdom tooth pathology|Subjects showing agenesia/previous extraction/no symptoms of the lower third molars.
62399428|NCT06407843|EXPERIMENTAL|Schroth Method|In addition to regular physical therapy, this group will engage in Schroth exercises therapy (SET). These regular workouts will include breathing exercises, posture training, spinal flexibility exercises, and stretching activities (especially for the muscles on the concave side of the curve). Patients were positioned asymmetrically to optimize trunk rectification. These exercises will include spinal elongation, de-flexion, stretching, de-rotation, and strengthening. To provide passive support and correct posture during the SET, long poles, foam blocks, and rice sacks were employed. Ten sessions total (30 minutes each, five days a week) will be conducted.
62575700|NCT06242548|OTHER|physical activity at altitude while maintaining usual diet|"organisation of physical activity outings in the mountains at a level already practised by the subjects, while maintaining their usual diet (normoglucidic or ketogenic); '.~collection of capillary blood samples (blood sugar, ketone levels), non-invasive biometric data (weight, oxygen saturation by transcutaneous sensor), and questionnaires (BORG scale, food consumption before/during/after exercise)."
62575701|NCT01797887|EXPERIMENTAL|Ayurveda|Ayurveda Diet and Lifestyle Counseling
62575702|NCT01797887|ACTIVE_COMPARATOR|Conventional|Standard Conventional Diet and Lifestyle Counseling
62575703|NCT02612623|EXPERIMENTAL|Gefapixant 15 mg twice daily|Two 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks
62575704|NCT02612623|EXPERIMENTAL|Gefapixant 30 mg twice daily|Four 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks
62575705|NCT02612623|EXPERIMENTAL|Gefapixant 50 mg twice daily|One 50 mg gefapixant tablet administered by mouth twice daily for 8 weeks
62575706|NCT02612623|EXPERIMENTAL|Placebo to match gefapixant|Matching placebo tablets administered by mouth twice daily for 8 weeks
62575707|NCT02609971|EXPERIMENTAL|Vibration group|The vibration group (Vibration at 50 Hz) will hold an exercise protocol on the vibration platform (model Power Plate® pro5 ™), which is to stay on on affected limb, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 50 Hz.
62575708|NCT02609971|NO_INTERVENTION|Control group|The control group (No vibration) will hold an exercise protocol on the vibration platform, which is to stay on affected limb, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. The vibrating platform will remain off throughout intervention.
62575709|NCT05838937||Investigation cohort|Cardiogenic shock patients from any cause receiving veno-arterial extracorporeal membrane oxygenation
62575710|NCT02416609|EXPERIMENTAL|Gem-based doublets with LDR & sequential SBRT|Four Gem-based doublets cycles will be administered concurrent with LDR. If no progression, three fractions of SBRT will be administered.
62575711|NCT01972243||venous thromboembolism|
62575712|NCT02678065|EXPERIMENTAL|InPact Admiral|Patients treated with the InPact Admiral balloon for popliteal lesions
62575713|NCT06499038|EXPERIMENTAL|Ancillary screw group|Patients with ancillary screw fixation acetabular component
62575714|NCT06499038|ACTIVE_COMPARATOR|Without ancillary screws group|No ancillary screws in acetabular component
62575715|NCT02329379|EXPERIMENTAL|Unigoiter, ATA (+), AUS (+) on Tx|The patients who have uninodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
62575716|NCT02329379|ACTIVE_COMPARATOR|Unigoiter, ATA (-), AUS (+) on Tx|The patients who have uninodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
62575717|NCT02329379|NO_INTERVENTION|Unigoiter, ATA (+), AUS (+) without Tx|The patients who have uninodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
62010353|NCT00456092|EXPERIMENTAL|Apremilast 40 mg QD|"Participants received 40 mg apremilast orally once a day (QD) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 40 mg apremilast QD for an additional 12 weeks.~The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 40 mg QD thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication."
62196908|NCT00126659|EXPERIMENTAL|Group I (cytoreductive nephrectomy and sorafenib tosylate)|"Patients undergo cytoreductive nephrectomy on day 1. Patients then receive oral sorafenib twice daily on days 15-84.~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
62196909|NCT00126659|EXPERIMENTAL|Group II (sorafenib tosylate and cytoreductive nephrectomy)|"Patients receive oral sorafenib twice daily on days 1-7. Patients undergo cytoreductive nephrectomy on day 8. Patients then receive oral sorafenib twice daily on days 22-84.~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
62196910|NCT00126659|EXPERIMENTAL|Group III (sorafenib tosylate and cytoreductive nephrectomy)|"Patients receive oral sorafenib twice daily on days 1-28. Patients undergo cytoreductive nephrectomy on day 29. Patients then receive oral sorafenib twice daily on days 43-84.~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
62196911|NCT03687008|EXPERIMENTAL|Adolescents with SVHD|All adolescents will receive the intervention Cogmed. This is an in home, computer based, cognitive intervention to improve working memory, supervised by trained coaches, \[25 sessions, each 30-45 minutes, 5 days a week / 5 week duration\].
62196912|NCT00304382|EXPERIMENTAL|PPV-PCV|Patients receive Pneumovax, and 6 months later Prevnar
62196913|NCT00304382|EXPERIMENTAL|PCV-PPV|Patients receive Prevnar, and 6 months later Pneumovax
62196914|NCT00304382|EXPERIMENTAL|PCV-PCV|Patients receive Prevnar, and 6 months later Prevnar again
62196915|NCT00304382|EXPERIMENTAL|PCV only|Patients receive Prevnar only
62575718|NCT02329379|NO_INTERVENTION|Unigoiter, ATA (-), AUS (+) without Tx|The patients who have uninodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
62575719|NCT02329379|EXPERIMENTAL|Multigoiter, ATA (+), AUS (+) on Tx|The patients who have multinodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
62575720|NCT02329379|ACTIVE_COMPARATOR|Multigoiter, ATA (-), AUS (+) on Tx|The patients who have multinodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
62010354|NCT00456092|EXPERIMENTAL|Apremilast 20 mg BID|Participants received 20 mg apremilast orally twice a day (BID) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 20 mg apremilast BID for an additional 12 weeks. The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 20 mg BID thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication.
62196916|NCT01452568|EXPERIMENTAL|Aspirin|Aspirin 150mg daily, starting day 1 after surgery, for three months.
62196917|NCT01452568|ACTIVE_COMPARATOR|Warfarin|Warfarin daily dosage to International normalized ratio(INR) value between 2,0 to 3,0.
62196918|NCT00106301|EXPERIMENTAL|FK228 (romidepsin)|romidepsin
62196919|NCT00582725|EXPERIMENTAL|R-CHOP + GM-CSF|R-CHOP therapy (6-8 cycles) with GM-CSF
62196920|NCT05584358|EXPERIMENTAL|Dry Blend|A dry blend of mycoprotein and pea protein.
62196921|NCT05584358|EXPERIMENTAL|Extrudate|An extruded blend of mycoprotein and pea protein
62196922|NCT04259359||patients who will be treated with bee venom immunotherapy|
62196923|NCT03028597|EXPERIMENTAL|Intervention Values Affirmation|The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
62196924|NCT03028597|ACTIVE_COMPARATOR|Control Values Affirmation|The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
62575721|NCT02329379|NO_INTERVENTION|Multigoiter, ATA (+), AUS (+) without Tx|The patients who have multinodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
62575722|NCT02329379|NO_INTERVENTION|Multigoiter, ATA (-), AUS (+) without Tx|The patients who have multinodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
62575723|NCT03466463|EXPERIMENTAL|GNT0003|2 doses of the IMP assessed in the dose escalation, open-label, phase 1/2 study
62196925|NCT01398904||Body dysmorphic disorder (BDD) Participants|Participants must be 18 years or older with a primary diagnosis of body dysmorphic disorder (BDD), a BDD Yale-Brown Obsessive Compulsive Scale (BDDY-BOCS) score of \>20, and a primary facial/head concern. Participants must have the ability to provide informed consent and understand study staff.
62196926|NCT01398904||Healthy Controls|Males and females 18 years of age or older with ability to provide informed consent and understand study staff.
62010355|NCT00456092|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo to apremilast orally BID for 12 weeks during the Treatment Phase. Participants who entered the Extension Phase were re-randomized on Day 85 to receive either 40 mg apremilast QD or 20 mg apremilast BID for 12 weeks.
62010356|NCT04849975|EXPERIMENTAL|Pelvimetry group|The participants oh this group will successively perform MRI pelvimetry and EOS imaging.
62010357|NCT03511560|ACTIVE_COMPARATOR|Tacrolimus, Immediate release|Tacrolimus (immediate-release) will be administered twice daily per clinical judgment of supervising physician (dosing and monitoring in accordance with center protocol) to a minimum whole blood tacrolimus concentration of at least 8 ng/mL.
62196927|NCT01081886|EXPERIMENTAL|PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
62196928|NCT01081886|ACTIVE_COMPARATOR|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
62575724|NCT06065917|EXPERIMENTAL|Artificial intelligence training cohort and validation cohort|Three high-volume Italian centers will enroll 195 obese patients who are candidates for metabolic surgery for obesity. Part of them will be established a training cohort (total = 105 patients), used to set up the AI-based method of TSBL measurement. The other 90 patients (30 for each center) will represent the validation cohort.
62575725|NCT03812016|EXPERIMENTAL|Determine device feasibility|"by evaluating efficacy and safety of the device. Test the device one time ( duration: 60-120 mins/each time) and second time within 12 months.~Intervention: using the magnetic device"
62575726|NCT04623099|OTHER|Standard dosing|Patients randomized to standard dosing (std) will initiate escitalopram at 5 mg daily and will then increase to 20 mg/day at week 4.
62575727|NCT04623099|EXPERIMENTAL|Pharmacogenetically-guided escitalopram dosing|Patients randomized to PGx-guided treatment, escitalopram titration will be based on CYP2C19 phenotype and predicted escitalopram exposure. In poor metabolizers (PM), escitalopram will be initiated at 5 mg daily and increased to 10 mg daily at week 4.
62575728|NCT03991923|EXPERIMENTAL|Non-ischemic heart preservation (NIHP)|Continous cold cardioplegic perfusion of hearts
62196929|NCT03046264||coronary angiography|patients undergoing routine coronary angiography, invasive and non-invasive determination of central blood pressure
62196930|NCT03346005|EXPERIMENTAL|Adult patients with positive FIT test|Adult patients with a positive FIT-test will breath into an e-nose device for 5 minutes.
62575729|NCT03991923|ACTIVE_COMPARATOR|Ischemic cold static storage (ICSS)|Standard preservation technique
62575730|NCT05204680|EXPERIMENTAL|Aerobic Exercise|"The participant will work with the physical therapist on an exercise regimen and first session will be supervised with the therapist. Exercise protocols will include a 15-minute warmup and cooldown session as well. To allow for increased participation and accessibility, the means of aerobic exercise will not be restricted and any safe mechanism of exercise will be allowed e.g., treadmill, stationary bike, etc.~Subjects will be provided an activity monitor (Phillips HealthBand Monitor) for the duration of study participation and receive training on how to use it, including marking events with start and stop of exercise sessions and tracking heart rate. The device can track type of activity as well as cardio fitness index and VO2max."
62196931|NCT05580835|EXPERIMENTAL|PET MRI - PSMA|Patients with an imaging diagnosis of HCC and submitted to PET MRI - PSMA
62734707|NCT05919784|EXPERIMENTAL|Cognitive behavioural therapy|The group therapy program (virtual, synchronous) involves elements based in Cognitive Behavioural Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Dialectical Behaviour Therapy (DBT).
62196932|NCT04259697|EXPERIMENTAL|Clinical pilates|Exercises will be performed two times per week for twelve weeks.
62196933|NCT04259697|EXPERIMENTAL|Whole body vibration|Exercises will be performed two times per week for twelve weeks.
62196934|NCT00545649|EXPERIMENTAL|1|Exercise and education
62196935|NCT00545649|ACTIVE_COMPARATOR|2|Education only
62196936|NCT00746304||1|infantile esotropia
62010358|NCT03511560|EXPERIMENTAL|Envarsus XR|Envarsus XR (Tacrolimus Extended Release Oral Tablet) will be administered once daily at initial weight-based dose of 0.12 mg/kg. Dosing and monitoring thereafter predicated on clinical judgment to a minimum whole blood tacrolimus concentration of at least 8 ng/mL. When possible, patients will receive their daily dose of Envarsus using the fewest number of pills possible.
62575731|NCT04657029|EXPERIMENTAL|Treadmill condition|The intervention condition consisted of a single session of moderate-high intensity aerobic exercise (65% of heart rate reserve) for 30 minutes walking on a standard treadmill. The single treadmill session included a progressive increase in intensity to reach the target heart rate (approx. 5 mins) as well as a cooling down period (approx. 5 mins). The warm-up and cool-down were included as part of the total 30 minutes of walking exercise. Target heart rates were calculated using the Karvonen method \[25\] with levels adjusted for those taking heart rate lowering medications (i.e. beta blockers), following methods previously published in post stroke populations \[26, 27\]. Participants were asked to self-rate their intensity of exercise every 10 minutes verbally using BORG's 6-20 scale rating of perceived exertion \[28\]. Participants were instructed to walk at a pace that resulted in a rating between 11 (fairly light) and 14 (somewhat hard) on the scale.
62196937|NCT00746304||2|acquired esotropia
62196938|NCT03655457|EXPERIMENTAL|group 1 Poractant alfa|Poractant alfa generic name: curosurf 120 and 240 mg flk dosage: 200 mg/ kg intratracheal application frequency and duration: in the first two hours
62196939|NCT03655457|ACTIVE_COMPARATOR|group 2 beractant|beractant generic name: survanta 8 cc flk dosage: 4 cc/ kg intratracheal application frequency and duration: in the first two hours
62196940|NCT06058715|EXPERIMENTAL|TAP block|"Bilateral TAP block is administered intraoperatively at laparoscopy, directly after insufflation and insertion of the first trocar and camera. The ultrasound probe is placed longitudinally on the midaxillary line near umbilicus, and the transversus abdominis and internal oblique muscles are scanned and observed. The needle (22-gauge 90 mm disposable spinal needle) is inserted in plane. After placing the needle-tip into the fascia between transversus abdominis and internal oblique muscles, Ropivacaine 0.25% (Naropin) is injected bilaterally at the dose of 0.5 mg/kg. It is all done by one Anesthetist which is expert in that area and is not in charge of collecting the data.~No additional regional anesthesia, including epidural or spinal anesthesia, is given.~The patients are mobilized in the recovery room 2 h after surgery."
62575732|NCT04657029|OTHER|Control condition|The control condition involved an equivalent time period (30 minutes) of seated resting where participants were provided with an education session about the impact and effects of stroke by the same research assistant.
62575733|NCT06011525|ACTIVE_COMPARATOR|standard cold-cap|"Patients will benefit from the prevention of chemo-induced alopecia using the standard cold cap device throughout the course of anthracycline- and taxane-based chemotherapy.~This device will be supplemented by a compression bandage to add to the vasoconstriction action of the cold, the compression of the bandage on the scalp and thus optimise the effectiveness of the device."
62196941|NCT06058715|ACTIVE_COMPARATOR|Conventional analgesia|"No additional regional anesthesia, including epidural or spinal anesthesia, is given.~For postoperative analgesia, all patients receive paracetamol intravenously at the dose of 1 g three times up to 24 hours, starting immediately after surgery. Complementary opioids are given on request when pain numerical rating scale (pain NRS) : NRS \> 3 at rest or for pain NRS \> 5 on exercise. Oxycodone is given intravenously at the dose of 0.05 mg/kg only in the recovery room up to two hours after the surgery. It is administrated intramuscularly at the dose of 0.1 mg/kg up to 24 hours after surgery. Then, it is given orally at the dose of 0.2 mg/kg from 24 to 48 hours after surgery."
62196942|NCT01234883|EXPERIMENTAL|multiple electrolyte solution|Subjects were randomized to receive either multiple electrolyte solution or saline. These solutions were administered IV at 10-20 mL/kg until the subject appeared clinically rehydrated as assessed by the clinician. The selected dose for these solutions is considered standard of care when treating clinical dehydration in children and is consistent with product labeling.
62196943|NCT01234883|ACTIVE_COMPARATOR|saline|Subjects were randomized to receive either multiple electrolyte solution or saline. These solutions were administered IV at 10-20 mL/kg until the subject appeared clinically rehydrated as assessed by the clinician. The selected dose for these solutions is considered standard of care when treating clinical dehydration in children and is consistent with product labeling.
62196944|NCT05811598|EXPERIMENTAL|repeated red light therapy for 3~4 year-old myopia|0.37mW lighting with wavelength of 650nm for the age of 3\~4 years old(including both 3 and 4 years)myopia.
62196945|NCT05811598|EXPERIMENTAL|repeated red light therapy for 5~6 year-old myopia|0.60mW lighting with wavelength of 650nm for the age of 5\~6 years old(including both 5 and 6 years)myopia.
62196946|NCT04558892|EXPERIMENTAL|Nephrotic syndrome - fixed dose (NS-FD)|Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.
62196947|NCT04558892|EXPERIMENTAL|Nephrotic syndrome - adjusted dose (NS-AD)|Drug: Enoxaparin; Dose: 1 mg/kg of ideal body weight; Administration: once daily subcutaneously.
62575734|NCT06011525|EXPERIMENTAL|scalp-cooling technique|Patients will benefit from the prevention of chemo-induced alopecia using the standard cold cap device throughout the course of anthracycline- and taxane-based chemotherapy.
62575735|NCT01419392|EXPERIMENTAL|Sildenafil citrate|
62575736|NCT01419392|PLACEBO_COMPARATOR|placebo|
62010359|NCT06573060||ACS+T2DM|Patients with Type 2 Diabetes Mellitus (T2DM) diagnosed with Acute Coronary Syndrome (ACS) through coronary angiography.
62010360|NCT06662981|EXPERIMENTAL|preoperative education|The intervention will include oral and written education about the operation, nursing and active participation in self-care. The intervention will take place in 3 phases: One week before THA, one day before THA after patient admission and postoperatively, before patient discharge. After a rough description of the operation, the anatomy and functionality of the joint will be presented, underlining the necessity of the operation. Instructions for recognizing and managing potential complications will be given. Patients will be informed about the appropriate post-operative walking aids, walking style, sitting up techniques, standing-up techniques, lying down techniques and getting in and out of the car. There will be a demonstration of muscle strengthening exercises, isometric quadriceps and gluteal exercises, Patients will also be informed about the necessity of prophylactic postoperative antithrombotic and antibiotic treatment.
62010361|NCT06662981|NO_INTERVENTION|no preoparative education (basic information)|Patients will receive the standard preoperative care, which will not include formalized education beyond routine consent.
62010362|NCT05016102|OTHER|Control condition|30 min to watching exercise-related video
62010363|NCT05016102|OTHER|Aerobic exercise condition|20 minutes of moderate-intensity exercise on treadmill
62010364|NCT05016102|OTHER|Resistance exercise condition|One set of 15 repetition 9 muscle exercises dumbbell squat with chair, dumbbell right/left foot lunge, sit-up, push-up, back muscle with superman, dumbbell right/left bicep curl, dumbbell calf raise.
62010365|NCT03724825||obese men|Adult obese men (BMI ≥ 30 kg/m2)
62010366|NCT03724825||normal men|normal weight men (18.5 ≤ BMI \< 25 kg/m2 )
62399429|NCT06407843|EXPERIMENTAL|Regular Physical Therapy|This Group will engage in independent routine physical therapy (RPT). Stretching exercises (especially for the muscles on the concave side of the curve) will be part of these regular workouts. The patient will be actively taught standard upper extremity range-of-motion exercises. Without using any creams or lotions, myofascial release (MFR) procedures will be applied straight to the skin. To assist avoid back discomfort, pressure will be administered to the restricted area for 90-120 seconds in order to release the tissue. Twice day, perform 10 repetitions of a 5-second hold while supine pelvic tilt, twice. The same protocol will be followed for the cat and camel, double-leg abdominal presses, and superwoman exercises. There will be breathing exercises including thoracic expansion and diaphragmatic breathing.
62399430|NCT02694380||Head and Neck|Subjects with head and neck cancer receiving radiation therapy.
62399431|NCT02694380||Prostate|Subjects with prostate cancer receiving radiation therapy.
62399432|NCT02694380||Breast|Subjects with breast cancer receiving radiation therapy.
62010367|NCT04865822|EXPERIMENTAL|Pain Education|Participant will attend a single session pain education course
62010368|NCT04865822|NO_INTERVENTION|wait list control|Participants will be wait listed then receive intervention
62010369|NCT05870176|ACTIVE_COMPARATOR|Standard Referral|Provider education/training on referral process Patient education material on physical activity benefits Paper referral to LIVESTRONG at the YMCA Fitbit Activity Monitor
62010370|NCT05870176|EXPERIMENTAL|Enhanced Referral|Provider education/training on referral process Patient education material on physical activity benefits Patient decision aid on physical activity program choices Electronic referral to program of patient's choice Fitbit Activity Monitor
62010371|NCT01412775|EXPERIMENTAL|Psychological stress and exhaustion|Twenty four male and female nurses from the cardiac intensive-care unit (CCU) of Meir Hospital, who consent to take part in the offered intervention program, will participate in the study. The participants will be randomly assigned to an experiment group of 12 participants and a control group of 12 participants.
62196948|NCT04558892|ACTIVE_COMPARATOR|Control - fixed dose (C-FD)|Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.
62196949|NCT01913145|EXPERIMENTAL|A1c, Self-collection, Blood sample|"Can a lay-persons safely and effectively self-collect a capillary blood sample of sufficient adequacy for A1c (HbA1c) testing in a clinical laboratory"
62196950|NCT01986088|PLACEBO_COMPARATOR|Placebo|
62399433|NCT02694380||Lung|Subjects with lung cancer receiving radiation therapy.
62196951|NCT01986088|EXPERIMENTAL|Eletriptan 40 mg|
62196952|NCT01986088|EXPERIMENTAL|Eletriptan 80 mg|
62196953|NCT01986088|EXPERIMENTAL|Sumatriptan 50 mg|
62196954|NCT01986088|EXPERIMENTAL|Sumatriptan 100 mg|
62196955|NCT05633069||Patients requiring orotracheal intubation or tracheostomy|"Patients hospitalized in the surgical Intensive Care Unit (ICU) of the University Hospital of Saint-Etienne between September 2015 and August 2016 for medical-surgical pathologies, requiring orotracheal intubation or tracheostomy, and presenting on the day of recording a Riker sedation score of 3 or 4 will be included.~Datas analysed by medical records."
62196956|NCT04161651|EXPERIMENTAL|single arm|
62196957|NCT02035696|EXPERIMENTAL|TIVc-High Dose|Subjects (6 to \<48 months old) received two doses of 0.75 mL of TIVc vaccine
62196958|NCT02035696|EXPERIMENTAL|TIVc-Full Dose|Subjects(6 to \<48 months old) received two doses of 0.50 mL of TIVc vaccine
62196959|NCT02035696|EXPERIMENTAL|TIVc- Half Dose|Subjects (6 to \<48 months old)received two doses of 0.25 mL of TIVc vaccine
62196960|NCT02035696|ACTIVE_COMPARATOR|TIVe|Subjects (6 to \<48 months old) received two doses of TIVe vaccine(IM/0.25mL -for ages 6 to \<36 months and IM/ 0.5 mL -for ages 36 to \<48 months)
62196961|NCT04663477||Trained nurse-completed CRS|
62196962|NCT04663477||Patient-completed CRS|
62196963|NCT02534571|EXPERIMENTAL|TC-325|Endoscopic Application of a Hemostatic Powder TC-325, \<=150gm , once
62196964|NCT02534571|ACTIVE_COMPARATOR|standard treatment|standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine \<=20 clip or4 pulse , once only
62196965|NCT02204657|ACTIVE_COMPARATOR|Continuous Glucose Monitoring System|Patients in this arm will receive Continuous Glucose Monitoring System (CGMS) at 28,32 and 36 weeks of gestation and their insulin titrated according to the CGMS results.
62196966|NCT02204657|NO_INTERVENTION|Control|Patients in this arm will not receive any Continuous Glucose Monitoring System( CGMS) and the insulin titration will be made based on their fingerstick sugar readings.
62196967|NCT06395883||RApre|Patients with a new diagnosis of rheumatoid arthritis and indication for initiating DMARD treatment with a bridging of oral glucocorticoid treatment. Women should be premenopausal and men younger than 50 years.
62196968|NCT06395883||RApost|Patients with a new diagnosis of rheumatoid arthritis and indication for initiating DMARD treatment with a bridging of oral glucocorticoid treatment. Women should be postmenopausal and men older than 50 years.
62196969|NCT06395883||SpA|Patients with a new diagnosis of spondyloarthritis and indication of DMARD treatment without glucocorticoid treatment. Women should be premenopausal and men younger than 50 years.
62196970|NCT06395883||PsA|Patients with a new diagnosis of psoriatic arthritis and indication of DMARD treatment without glucocorticoid treatment. Women should be premenopausal and men younger than 50 years.
62196971|NCT06395883||IA|Patients with an inflammatory joint disease on stable DMARD treatment weith indication of intraarticular glucocorticoid injection. Women should be premenopausal and men younger than 50 years.
62196972|NCT06395883||IM|Patients with an inflammatory joint disease on stable DMARD treatment weith indication of intramuscular glucocorticoid injection. Women should be premenopausal and men younger than 50 years.
62196973|NCT00656747|ACTIVE_COMPARATOR|Arm 2|
62196974|NCT00656747|EXPERIMENTAL|Arm 1|
62196975|NCT01647542|EXPERIMENTAL|TAK-875 25 mg|TAK-875 25 mg tablets, orally, once daily for up to 24 weeks.
62196976|NCT01647542|EXPERIMENTAL|TAK-875 50 mg|TAK-875 50 mg tablets, orally, once daily for up to 24 weeks.
62196977|NCT01647542|PLACEBO_COMPARATOR|Placebo|TAK-875 placebo-matching tablets, orally, once daily for up to 24 weeks.
62196978|NCT01967069|ACTIVE_COMPARATOR|DFD01 Spray|DFD01 Spray twice daily
62196979|NCT01967069|PLACEBO_COMPARATOR|Vehicle Spray|Vehicle Spray twice daily
62196980|NCT02418936||WS|WS diagositic kit
62196981|NCT02418936||LVAS|LVAS diagositic kit
62196982|NCT05099432|EXPERIMENTAL|CARMA Technique|All included participants undergo polyp resection using standard of care polypectomy techniques, followed by the CARMA technique
62399434|NCT05195242|EXPERIMENTAL|Dexamethasone 12 mg|Intravenous bolus injection of dexamethasone 12 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 12 mg at sites, where dexamethasone is not available.
62196983|NCT00218270|EXPERIMENTAL|1|Reduction of tobacco use by substituting tobacco free snuff.
62399435|NCT05195242|ACTIVE_COMPARATOR|Dexamethasone 6 mg|Intravenous bolus injection of dexamethasone 6 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 6 mg at sites, where dexamethasone is not available.
62399436|NCT01915953||anemia|Measuring Hb valuse on anemia patients
62399437|NCT01391260|EXPERIMENTAL|Radiotherapy Combined With Gefitinib|
62196984|NCT00218270|PLACEBO_COMPARATOR|2|Reduction of tobacco use by using behavioral techniques.
62196985|NCT05847907|EXPERIMENTAL|BA Surface test group|"Common procedures: Implants placement in subjects with type 2 diabetes who have lost at least one tooth element and need of a prosthetic implant-supported rehabilitation.~Test procedure: use of implant with BA surface in type 2 diabetic patients."
62196986|NCT05847907|ACTIVE_COMPARATOR|SA Surface control group|Common procedures: Implants placement in subjects with type 2 diabetes who have lost at least one tooth element and need of a prosthetic implant-supported rehabilitation. Control procedure: use implant with SA surface in type 2 diabetic patients
62196987|NCT04916951|NO_INTERVENTION|Amoxicillin - standard-of-care dose|Obtain amoxicillin plasma concentrations in patients already receiving amoxicillin
62196988|NCT04916951|NO_INTERVENTION|Cephalexin - standard-of-care dose|Obtain cephalexin plasma concentrations in patients already receiving cephalexin
62196989|NCT04916951|EXPERIMENTAL|Amoxicillin - study dose|Obtain amoxicillin plasma concentrations after a study-administered dose of amoxicillin
62734708|NCT02458131|EXPERIMENTAL|TEEN HEED|Adolescent pre-diabetics will receive 8-12 weekly peer-led diabetes prevention educational workshops in community sites. The in-person group workshops will be supplemented by support through mobile health technologies such as text messaging and social media.
62196990|NCT04916951|EXPERIMENTAL|Cephalexin - study dose|Obtain cephalexin plasma concentrations after a study-administered dose of cephalexin
62196991|NCT01144377|EXPERIMENTAL|180 mg LY2541546 Q4W + Placebo|"LY2541546: 180 milligrams (mg) administered subcutaneously every 4 weeks (Q4W) for 52 weeks.~Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks."
62196992|NCT01144377|EXPERIMENTAL|180 mg LY2541546 Q2W|LY2541546: 180 milligrams (mg) administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
62010372|NCT02383758|EXPERIMENTAL|Treatment Program|Pediatric subjects with autistic spectrum disorder will begin treatment immediately. The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, subjects will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
62010373|NCT02383758|ACTIVE_COMPARATOR|Waitlist Control|Pediatric subjects with autistic spectrum disorder will wait for 8 weeks and then be offered treatment at that time.The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, participants will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
62010374|NCT02633475||CONTROL: women no miscarriage|Group of patients who referred to the Fourth Affiliated Hospital of Guangxi Medical University or Liuzhou Maternity and Child Healthcare Hospital, who have more than one successful pregnancy without miscarriage. Then the blood sample will be collected and the IL-10 Polymorphism will be analyzed.
62010375|NCT02633475||CASE: patients with IRM|Group of patients who referred to the Fourth Affiliated Hospital of Guangxi Medical University or Liuzhou Maternity and Child Healthcare Hospital, who have more than three consecutive miscarriages without clear cause (Idiopathic Recurrent Miscarriage, IRM). Then the blood sample will be collected and the IL-10 Polymorphism will be analyzed.
62010376|NCT02592733||Historical Cohort|Patients who have undergone infrarenal endovascular repair at each centre in the past.
62010377|NCT02592733||Prospective Cohort|Patients undergoing infrarenal endovascular repair in the study using CYDAR in addition to the local angiography equipment.
62399438|NCT06723730|EXPERIMENTAL|Upper Quadrant Strenghtening + MWM Group|"In addition to upper quadrant core strengthening protocol participants will also perform mobilization with movement.~Mobilization with movement protocol will comprise of following forms.~1. Acromioclavicular joint glides~2. Scapular glides~3. Glenohumeral joint glides ( inferior glides, postero-lateral glides, postero-inferior)"
62399439|NCT06723730|EXPERIMENTAL|Upper Quadrant Strenghtening Group|"Participants will perform upper quadrant core strengthening protocol. Upper quadrant core strengthening protocol will comprise of following four week protocol.~1. Week One Scapular postural correction , Shoulder Shrugging exercises~2. Week Two External rotation at 0 degree~3. Week Three Internal rotation at 0 degree~4. Week Four Standing Row at 45 and 90 degree, Anterior shoulder stretch , Thoracic exercises in sitting"
62399440|NCT02046551|PLACEBO_COMPARATOR|Placebo|placebo
62399441|NCT02046551|EXPERIMENTAL|Atomoxetine|atomoxetine (40 mg/day)
62010378|NCT06250738|EXPERIMENTAL|Study population|
62010379|NCT05896358||Bariatric naive|patients with obesity who have not undergone bariatric surgery in the past
62010380|NCT05896358||Post Bariatric|patients with obesity who have undergone bariatric surgery in the past and have experienced weight regain or insufficient weight loss
62010381|NCT03292822|EXPERIMENTAL|Licochalcone A|Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties.
62575737|NCT01337180||Main study group|"Inclusion criteria: Employment at one of the plants (SiC I) and (SiC II) in Porsgrunn. Both administrative/office workers and workers in the production and maintenance departments will be invited to participate. Non-smokers and smokers and male and female workers will be included in the main study group (study A).~Sputum part of study: nonsmokers."
62575738|NCT06578598|SHAM_COMPARATOR|Igel|Control device
62010382|NCT03292822|ACTIVE_COMPARATOR|Paclitaxel|chemotherapeutic drug
62010383|NCT06664736|EXPERIMENTAL|Exercise|The exercise group performed a home-based exercise program consisting of aerobics 3 days a week and strengthening and stretching exercises 2 days a week, with videos and infographics, for 8 weeks.
62010384|NCT06664736|OTHER|Control|control group was advised to increase physical activity.
62196993|NCT01144377|EXPERIMENTAL|270 mg LY2541546 Q2W|LY2541546: 270 milligrams (mg) LY2541546 administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
62399442|NCT03108664|EXPERIMENTAL|11.25 mg/mL SYL1001 ophthalmic solution|1 drop of 11.25 mg/mL SYL1001 ophthalmic solution in the affected eye(s) q.d
62399443|NCT03108664|EXPERIMENTAL|Vehicle ophthalmic solution|1 drop of vehicle ophthalmic solution in the affected eye(s) q.d
62399444|NCT03648021|ACTIVE_COMPARATOR|paracetamol (acetaminophen)|patient will receive1 gramme of paracetamol intravenously
62399445|NCT03648021|PLACEBO_COMPARATOR|Placebo|patient will receive 100 ml of chlorure de sodium 0,9% intravenously
62399446|NCT02007824|EXPERIMENTAL|ULSD-12D|ultrasound surgical device made by Ultech.
62575739|NCT06578598|ACTIVE_COMPARATOR|Igelplus|Study device
62575740|NCT01094158|EXPERIMENTAL|high dose|Aramchol 300 mg daily (high dose)
62575741|NCT01094158|EXPERIMENTAL|low dose|100 mg daily (low dose)
62575742|NCT01094158|PLACEBO_COMPARATOR|Placebo|Placebo and two doses will be compared. The Aramchol: placebo ratio is of 2:1.
62010385|NCT06382857|EXPERIMENTAL|Microbiome directed food (MDF)|The MDF in this study was developed by the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,B). This MDF is the lead icddr,B prototype that has demonstrated the strongest increase in biomarkers critical to growth, including growth hormone receptor and leptin, and re-establishment of the maturity of the microbiome among moderately malnourished children. Ingredients include chickpea flour, soy flour, peanut paste, green banana powder, sugar, oil, and micronutrients. The same MDF is provided for the treatment of SAM and MAM at modified doses.
62575743|NCT00154284|ACTIVE_COMPARATOR|Everolimus (Certican) with Cyclosporine (Neoral) Continuation|Patients were treated with everolimus and cyclosporine for 3 months post-transplantation. Everolimus (Certican) was administered orally, in two divided doses (b.i.d), and at the same time as Cyclosporine (Neoral). Everolimus (Certican) dose was adjusted in order to maintain a trough level between 3 and 8 ng/mL until randomization. After randomization the target trough range remained at 3 - 8 ng/mL in the cyclosporine (Neoral) continuation groups for a period of 9 months. Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
62575744|NCT00154284|EXPERIMENTAL|Everolimus (Certican) with Cyclosporine (Neoral) Withdrawal|Patients were treated with everolimus and cyclosporine for 3 months post-transplantation. Everolimus (Certican) was administered orally, in two divided doses (b.i.d), and at the same time as Cyclosporine (Neoral). Everolimus (Certican) dose was adjusted in order to maintain a trough level between 3 and 8 ng/mL until randomization. Therefore, patients were randomized to cyclosporine withdrawal over a period of 1 month (±1 week) in study A2419 (NCT00154284) and over 3 months (±1 week) in study A2423 (NCT00170807). After randomization, final target trough range for everolimus was 8 - 12 ng/mL. Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
62575745|NCT00747019|EXPERIMENTAL|PBPA|
62575746|NCT00747019|ACTIVE_COMPARATOR|PE|
62196994|NCT01144377|EXPERIMENTAL|270 mg LY2541546 Q12W + Placebo|"LY2541546: 270 milligrams (mg) administered subcutaneously every 12 weeks (Q12W) for 52 weeks.~Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks."
62575747|NCT06346470|EXPERIMENTAL|Web Based Breast Self-Examination Education Group|For the web-based education group, a web page will be created by the researchers on Google classroom for breast self-examination skills. Prepared education materials will be uploaded to the website. Opinions of field experts will be sought for the prepared web page. The website will be rearranged in line with the suggestions of field experts. The education will last 6 hours in total.
62575748|NCT06346470|NO_INTERVENTION|Traditional Breast Self-Examination Education Group|The group receiving education using the traditional method will be given breast self-examination education by the researchers. The education will cover topics such as the importance of breast self-examination, application times, and breast self-examination methods. Then, the breast self-examination skill will be taught using the technique of demonstrating and performing breast self-examination, and each student in the group will be allowed to perform the skill on the simulator. The education will last 4 hours in total.
62575749|NCT05650684||"exclusive breastfeeding group"|Women initiating exclusive breastfeeding after birth
62575750|NCT04519606||One-lung ventilation|During one-lung ventilation, the dependent lung (non-operation lung) will be mechanically ventilated with a fixed positive end-expiratory pressure (PEEP) of 4 cmH2O and the peak pressure below 30 cmH2O. Tidal volumes will be titrated from the initial 4 ml/kg predicted body weight (PBW) to 7 ml/kg PBW. Optimal lung compliance is determined by the levels of upper reflection point of the pressure-volume loop closed to 30 cmH2O. Chest tomography will be undertaken with the optimal tidal volume during OLV phase and when the independent lung is completely recruited using the stepwise PEEP increase method.
62575751|NCT05131373|EXPERIMENTAL|Experimental 1|C. acnes vaccine in adjuvanted formulation will be administered in double-blind fashion in 3 single increasing doses given i.m.
62575752|NCT05131373|PLACEBO_COMPARATOR|Placebo 1|Placebo in adjuvanted formulation will be administered in double-blind fashion in single i.m. injections
62575753|NCT02035449||McGrath MAC|McGrath MAC is a videolaryngscope
62010386|NCT06382857|ACTIVE_COMPARATOR|Standard nutritional treatment (RUTF/RUSF)|The standard RUTF used in this study for the treatment of SAM is Plumpy'Nut (Nutriset France). RUTF is a specialized therapeutic food that can be consumed without preparation and meets the nutritional requirements for the recovery of SAM. Ingredients include oil, peanut, skimmed milk powder, sugar and micronutrients. The standard RUSF used in this study is Plumpy'Sup (Nutriset France). RUSF is a lipid-based nutritional supplement with a high vitamin and mineral content, specifically designed for the treatment of MAM. Ingredients include oil, peanut, skimmed milk powder, sugar and micronutrients.
62196995|NCT01144377|PLACEBO_COMPARATOR|Placebo Comparator Q2W|Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
62575754|NCT00433589|ACTIVE_COMPARATOR|Chemotherapy randomization: Arm I (anthracycline-based)|"* FEC 100~* Canadian CEF~* CAF~* FAC~* E-CMF"
62575755|NCT00433589|EXPERIMENTAL|Chemotherapy randomization: Arm II (docetaxel and capecitabine)|"* Docetaxel~* Capecitabine"
62196996|NCT02471989|EXPERIMENTAL|Low-FODMAP diet|FOS in diet
62196997|NCT02471989|ACTIVE_COMPARATOR|Classical GERD diet|avoid fatty meals, head of bed elevation...
62196998|NCT05725772||Parkinson's disease|People with Parkinson's disease living in medically underserved areas
62196999|NCT01139788|EXPERIMENTAL|LY2624587|
62197000|NCT00529477|ACTIVE_COMPARATOR|1|The Wright Nebulizer will be used to perform the methacholine challenge in arm 1.
62197001|NCT00529477|ACTIVE_COMPARATOR|2|The Pari LC nebulizer will be used to perform the methacholine challenge in arm 2.
62197002|NCT00529477|ACTIVE_COMPARATOR|3|The Pari Sinustar nebulizer will be used to perform the methacholine challenge in arm 3.
62575756|NCT00433589|ACTIVE_COMPARATOR|Endocrine therapy randomization: Arm I|2 years of tamoxifen followed by 5 years of letrozole
62399447|NCT02007824|ACTIVE_COMPARATOR|SONOCA-180|ultrasound surgical device made by Soering
62399448|NCT00334893|EXPERIMENTAL|Treatment (chemotherapy)|Patients receive eribulin mesylate IV over 15 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62010387|NCT05368207|EXPERIMENTAL|Pembrolizumab|Pembrolizumab will be given as an intravenous infusion at 200 mg, every 6 weeks, for 6 cycles.
62399449|NCT01699321|EXPERIMENTAL|Your Move (physical activity)|The Your Move intervention is a multi-level, theory and evidence-based intervention that will include the following components: monthly handbills with community resources, newsletters, contests (shop and customer level), tailored health feedback report, and monthly phone calls from the research team.
62399450|NCT01699321|OTHER|Your Money (financial empowerment)|The Your Money program is an attention control intervention. Owners and barbers will receive 3 workshops that focus on financial health. Customers will receive monthly handbills and newsletters about different financial health topics.
62399451|NCT04393961|OTHER|Past Positive COVID-19 confirmed|Invited participants who Radish Health has completed a positive COVID-19 test who have recovered from all symptoms for more than 14 days.
62010388|NCT03608800|EXPERIMENTAL|Intermittent fasting|two nonconsecutive days of 75% diet energy restriction per week for 8 weeks
62399452|NCT04393961|OTHER|Physician Diagnosed: Not Tested|Individuals who self report that a medical professional has told them they likely have COVID-19 (and have since recovered), but did not get a confirmatory test.
62399453|NCT04393961|OTHER|Self-Diagnosed Not Tested|Participant suspects they contracted (and have since recovered) from COVID-19, but they do not have a medical diagnosis or confirmatory test.
62575757|NCT00433589|EXPERIMENTAL|Endocrine therapy randomization: Arm II|7 years of letrozole
62575758|NCT00433589|ACTIVE_COMPARATOR|Treatment decision randomization: Arm I|chemotherapy-decision-making according to clinical criteria (using Adjuvant! Online)
62575759|NCT00433589|EXPERIMENTAL|Treatment decision randomization: Arm II|chemotherapy-decision-making according to genomic prognosis using the 70-gene signature
62575760|NCT05003310|EXPERIMENTAL|Active Stimulation; Period 1|Active stimulation for 12 weeks
62575761|NCT05003310|SHAM_COMPARATOR|Sham Stimulation; Period 1|Sham stimulation for 12 weeks
62575762|NCT05003310|EXPERIMENTAL|Open label active stimulation, Period 2|Open label active stimulation for 12 additional weeks
62575763|NCT05003310|OTHER|Open label RA Drug, Period 2|Open label drug treatment with baricitinib for 12 weeks
62197003|NCT02598219|EXPERIMENTAL|Pre-operative SN mapping with radionucleide|"1 Pre-operative Sentinel Node (SN) mapping with Nanocis or Nanocoll or Rotop-nanoHSA~2- Intra-operative SN mapping with patent V blue dye, or Intra-operative SN mapping with indocyanin green for patients with known hypersensitivity, allergy to patent V blue dye~3- Full bilateral laparoscopic lymphadenectomy and Hysterectomy: If bilateral SN are detected, all positive SN are removed, then the surgeon proceeds to a total hysterectomy.~If unilateral SN are detected, surgeon will complete intervention with pelvic LN dissection on the opposite side, in accordance with risk group definition (ex: omentectomy for high-risk non endometrioid carcinomas).~If non SN are detected, surgeon will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic LND with more enlarged dissection regardless the pathology"
62575764|NCT05003310|EXPERIMENTAL|RA drug combined with active stimulation, Period 3|Participants on baricitinib during Period 2 will have active stimulation added for 24 weeks
62575765|NCT05003310|EXPERIMENTAL|Active stimulation combined with RA drug, Period 3|Participants on active stimulation during Period 2 will have baricitinib added for 24 weeks
62575766|NCT05003310|OTHER|Long-term Follow-up, Period 4|Standard of care treatments with or without stimulation
62575767|NCT01202578|EXPERIMENTAL|tympanostomy tube|performance and safety of tympanostomy tube delivery system
62575768|NCT04335773||Sars-CoV-2 positive|Children positive for SARS-CoV-2
62575769|NCT04335773||SARS-CoV-2 negative|Children negative SARS-CoV-2
62197004|NCT02598219|OTHER|B : Current initial staging protocols|Current initial staging protocols
62197005|NCT01502046|EXPERIMENTAL|Sativex|
62575770|NCT00405431|ACTIVE_COMPARATOR|1|Patients received restasis eyedrops during 6 month post-operative period
62575771|NCT00405431|PLACEBO_COMPARATOR|2|Patients receive artificial tears (Endura) during 6 month post-operative period
62575772|NCT04088175|EXPERIMENTAL|Group 1 - Virginia Tobacco and Menthol|Subjects randomized to Group 1 will use JUUL ENDS Virginia Tobacco and Menthol flavors
62575773|NCT04088175|EXPERIMENTAL|Group 2 - Mint and Mango|Subjects randomized to Group 2 will use JUUL ENDS Mint and Mango flavors
62575774|NCT04793308|EXPERIMENTAL|Group (1); (ProTaper Next, Rotary system).|Group I teeth were prepared with rotary instrumentation using ProTaper Next (Dentsply, Switzerland)
62575775|NCT04793308|EXPERIMENTAL|Group (2); K- files, Manual instruments.|Group II root canals were prepared by manual instrumentation using K type files Mani, Japan).
62575776|NCT03163498||ACTIVE|Participating in this group will be 30 active hypertension patients who exercise at least 3 times a week for at least 30 minutes
62197006|NCT01502046|PLACEBO_COMPARATOR|Placebo|
62197007|NCT05941247|EXPERIMENTAL|Hemay005 60 mg|The participant will receive single administration of Hemay005 tablets at dose of 60 mg on Day 1. Thereafter, those participants will receive Hemay005 tablets at dose of 60 mg for 7 consecutive days, which will be administrated twice daily.
62575777|NCT03163498||INACTIVE|Participating in this group will be 30 inactive hypertension patients who do not exercise.
62575778|NCT03779217||group A|In this group there are women in that the mammography shows a breast represented by 80% of adipose tissue and less than 20% by fibro-glandular tissue.
62575779|NCT03779217||group B|In this group there are women in that the mammography shows a breast represented by adipose tissue in the range of 50-75% and for the rest by fibro-glandular tissue
62010389|NCT03608800|NO_INTERVENTION|Control diet|maintain the energy intake as usual
62010390|NCT05647512|EXPERIMENTAL|LM-305 Dose Escalation|Administered intravenously
62010391|NCT05647512|EXPERIMENTAL|LM-305 Combination Expansion|LM-305 Administered intravenously Dexamethasone Orally
62197008|NCT02034097|EXPERIMENTAL|Cohort 1|Subjects with EGFRm NSCLC who have received clinical benefit (CR, PR, SD) for at least 4 months and then progressed on an EGFR-TKI within the last 30 days will receive 150 milligram (mg) erlotinib once daily (OD) and 45 mg foretinib OD as a combination therapy until disease progression
62575780|NCT03779217||group C|In this group there are women in that the mammography shows a breast represented by adipose tissue in the range 25-50% and the rest is from fibro-glandular tissue.
62575781|NCT03779217||group D|In this group there are women in that the mammography shows a breast represented by almost entirely fibro-ghiandular tissue.
62734709|NCT02458131|NO_INTERVENTION|Wait List Control|Adolescent pre-diabetics in this group will not receive any intervention until collection of all follow up data and will then be offered the same intervention as the participants in the experimental arm.
62010392|NCT00901134||hypothermia|Patients with therapeutic hypothermia after cardiac arrest in hospitals
62010393|NCT03614793|ACTIVE_COMPARATOR|Cooled Radiofrequency Ablation Procedure|"Cooled Radiofrequency Ablation (C-RFA) Procedure:~This is performed under image (x-ray) guidance for the accuracy of needle placement. A Cooled Radiofrequency electrode will be placed at the surface of the facet joint. After appropriate electrode positioning, a local anesthetic (lidocaine) will be injected through the needle to take away pain during the ablation. Once the procedure is completed, all needles will be removed and additional local anesthetic (bupivacaine) will be injected. No corticosteroids will be injected."
62010394|NCT03614793|ACTIVE_COMPARATOR|Facet Joint Inject Procedure|"Facet joint injection (FJI) Procedure:~This is performed under image guidance (x-ray) for the accuracy of needle placement. A needle will be carefully placed in the facet joint(s) causing pain. Contrast will be injected to confirm the ideal needle placement. The injection will then be completed with triamcinolone (steroid) and lidocaine. This technique will be repeated for each facet joint injected. For bilateral low back pain, a maximum of 4 facet joints (two on each side) will be treated. For unilateral low back pain, up to 3 facet joints will be treated."
62010395|NCT04496921|ACTIVE_COMPARATOR|Vitamin K supplement, dose #1|Vitamin K supplementation with dose #1
62010396|NCT04496921|ACTIVE_COMPARATOR|Vitamin K supplement, dose #2|Vitamin K supplementation with dose #2
62010397|NCT02154815||PPT|Patients with a pre-emptive kidney transplantation from deceased or living donors
62399454|NCT04393961|OTHER|Likely Exposed, No Symptoms. Not Tested|Participant suspects that they've been exposed to COVID-19, but have not shown symptoms and wonder if they have antibodies so they may return to some normalcy.
62399455|NCT06722911|EXPERIMENTAL|Nimotuzumab+ AG|
62399456|NCT02161809|EXPERIMENTAL|Physical Activity Intervention|This arm (10 summer day camps) will receive the Physical Activity intervention the first year and both healthy eating and physical activity the second and thrid years.
62399457|NCT02161809|OTHER|Healthy EAting Intervention|This arm (10 summer day camps) will receive the Healthy Eating intervention the first year and both healthy eating and physical activity the second and thrid years.
62010398|NCT02154815||PDT|Patients who have experienced a pre-transplant dialysis period of less than 36 months
62010399|NCT03460184||G.A Group A|Group A: n= 30 Parturiant patients will receive general anesthesia. General anesthesia will be conducted After pre-oxygenation for 3-5 minutes. 5% thiopental (5 mg/kg) will be administered intravenously over 30s, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium as needed. After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by intravenous infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake, the anesthesia is adequately reversed, and the patient is following commands
62010400|NCT03460184||Spinal A Group B|"Group B: n= 30 Parturiant patients will receive spinal anesthesia. In the sitting position and after complete aseptic precaution are taken, 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, either via midline or paramedian approaches using 22 guage Quinke needle with the bevel directed laterally. 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl (0.5 ml) will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage.~The patient will be put flat in the supine position with left uterine displacement using wedge under the right loin and the surgeon will be allowed to sterilize and wrap the field after confirmation of the solidity of the block its level.~All patiens will be observed for cardiac complications in the form of non-fatal MI, arrhythmias and sudden cardiac death until discharged after at least 72h."
62399458|NCT06037486|EXPERIMENTAL|Subject glucometer measurement|
62399459|NCT01699061|PLACEBO_COMPARATOR|Placebo|Placebo tablet administered with a meal twice a day on Day 1
62010401|NCT04254354||transgender men|no intervention
62010402|NCT04742738|EXPERIMENTAL|Test group 1 - Stage 1 Low dose-level Cohort|2 doses of GBP510 adjuvanted with Alum (Receptor Binding Domain (RBD) 10μg/dose), 1 dose each on Days 0 and 28.
62010403|NCT04742738|PLACEBO_COMPARATOR|Placebo group - Stage 1 Low dose-level Cohort|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
62197009|NCT02034097|EXPERIMENTAL|Cohort 2|Subjects with EGFR/WT NSCLC who have received clinical benefit (CR, PR, SD) for at least 2 months and then progressed on an EGFR-TKI within the last 30 days will receive 150 mg erlotinib OD and 45 mg foretinib OD as a combination therapy until disease progression.
62399460|NCT01699061|EXPERIMENTAL|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
62197010|NCT02034097|EXPERIMENTAL|Cohort 3|Subjects with NSCLC who are predicted to be sensitive to foretinib based on biomarkers identified with preclinical or clinical data will receive 60 mg foretinib OD as a monotherapy until disease progression
62010404|NCT04742738|EXPERIMENTAL|Test group 2 - Stage 1 High dose-level Cohort|2 doses of GBP510 adjuvanted with Alum (RBD 25μg/dose), 1 dose each on Days 0 and 28.
62010405|NCT04742738|PLACEBO_COMPARATOR|Placebo group - Stage 1 High dose-level Cohort|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
62010406|NCT04742738|EXPERIMENTAL|Test group 1 - Stage 2|2 doses of GBP510 adjuvanted with Alum (RBD 10μg/dose), 1 dose each on Days 0 and 28.
62010407|NCT04742738|EXPERIMENTAL|Test group 2 - Stage 2|2 doses of GBP510 adjuvanted with Alum (RBD 25μg/dose), 1 dose each on Days 0 and 28.
62010408|NCT04742738|PLACEBO_COMPARATOR|Placebo group - Stage 2|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
62197011|NCT03408405|EXPERIMENTAL|Acthar Gel treatment group|Participants will be treated with 'Acthar Gel 80 UNT/ML Injectable Solution'. Initial dose for week 1 will be 50% of 80 units, injected twice per week. Week 2 is 75% of 80 units, week 3 and throughout treatment period (6 months in total) will be 80 units/ml twice per week.
62197012|NCT01564277|EXPERIMENTAL|Arm I (1.5mg rasburicase)|Patients receive 1.5mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.
62197013|NCT01564277|EXPERIMENTAL|Arm II (3 mg rasburicase)|Patients receive 3 mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.
62399461|NCT02681549|EXPERIMENTAL|pembrolizumab plus bevacizumab|
62734710|NCT02791035|EXPERIMENTAL|Ipragliflozin|Ipragliflozin 50 mg/tablet, orally, 1 tablet once daily for 12 weeks
62010409|NCT05242965|EXPERIMENTAL|Arm I (STEMVAC, sargramostim)|Patients receive STEMVAC ID and sargramostim ID on day 14 (+3 days) of the 21-day maintenance therapy cycle for a series of 3 vaccine doses and a booster vaccine 9 weeks after the third vaccine dose. Patients also undergo CT and biopsy during screening and on the trial, as well as blood sample collection on trial and during follow-up.
62010410|NCT05242965|ACTIVE_COMPARATOR|Arm II (sargramostim)|Patients receive sargramostim ID on day 14 (+3 days) of the 21-day maintenance therapy cycle for a series of 3 vaccine doses and a booster vaccine 9 weeks after the third vaccine dose. Patients also undergo CT and biopsy during screening and on the trial, as well as blood sample collection on trial and during follow-up.
62010411|NCT00585754|ACTIVE_COMPARATOR|Guanfacine|
62010412|NCT00585754|PLACEBO_COMPARATOR|PLA|
62010413|NCT04054167|EXPERIMENTAL|Treatment (ultra low dose radiation therapy)|Patients undergo ultra low dose radiation for 1-2 days before chemotherapy free-targeted therapy. Patients may receive a second, longer course of radiation if the lesion treated does not respond.
62010414|NCT04292158||Main Group|Hospitalized for at least 1 day clinic stay at the participating hospitals
62197014|NCT02614547|PLACEBO_COMPARATOR|Placebo|Participants received infusion rates of placebo matched to SAGE-547.
62734711|NCT03985462|EXPERIMENTAL|VSEL Max|A total of 300,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a high dose group
62575782|NCT02949440|EXPERIMENTAL|the caudal-to-cranial approach|Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein（SMV）and Superior mesenteric artery（SMA）and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein（SMV）. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called caudal-to-cranial approach.
62575783|NCT02949440|ACTIVE_COMPARATOR|the medial-to-lateral approach|First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein（SMV）to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
62575784|NCT04569435|EXPERIMENTAL|ANX005|Participants will receive induction dosing of ANX005 on Days 1 and 5 or 6, followed by maintenance doses of ANX005 every 2 weeks up to Week 22.
62575785|NCT00917176|EXPERIMENTAL|Effective stimulation|Effective stimulation at sub-threshold level
62575786|NCT00917176|PLACEBO_COMPARATOR|Placebo stimulation|Stimulation at non-effective strength
62575787|NCT03821454|EXPERIMENTAL|Capecitabine|The experimental group received oral capecitabine for eight cycles.
62575788|NCT03821454|PLACEBO_COMPARATOR|Placebo|The placebo group received oral placebo for eight cycles.
62575789|NCT05906615|OTHER|Intravenous lidocaine|Monitored intravenous lidocaine infusion for patients with CP and pancreatic cancer is already current practice in the participating centers. Patients undergo treatment in the recovery unit of the anesthesiology department, for early detection of possible, although highly unlikely adverse events such as anaphylactic reactions, arrhythmias or hypotension. At the recovery unit continuous monitoring is possible and treatment of the above mentioned side effects can be easily provided. Continuous monitoring includes a 3-lead ECG, saturation, and blood pressure control every 15 minutes.
62575790|NCT03172923|ACTIVE_COMPARATOR|sliding hip screw|fixation of fracture with a sliding hip screw
62575791|NCT03172923|EXPERIMENTAL|intramedullary nail|fixation of the fracture with an intramedullary nail
62575792|NCT01493674|NO_INTERVENTION|placebo tablets|two identical tablets, but composed of crystalline cellulose, lactose and colouring
62575793|NCT01493674|EXPERIMENTAL|a suplemented group|two 5-mg tablets of folic acid
62575794|NCT03318497|EXPERIMENTAL|Diagnostic (Interim FLT PET/CT)|"The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.~* Procedure: Computed Tomography~* Drug: 3'-deoxy-3'-\[F-18\] fluorothymidine: \[F-18\]FLT~* Other: Laboratory Biomarker Analysis~* Procedure: Positron Emission Tomography"
62575795|NCT04940754|OTHER|Stabilzation of Fracture|Arthrodesis nail used for stabilzation of a fracture, single patient
62575796|NCT03564223||Parents/Guardians|"Parents/Guardians aged over 18, attending Great Ormond Street Hospital Outpatients.~Intervention: Administer questionnaire to review and decide on significance of each of 30 child health concerns"
62575797|NCT03564223||Paediatricians|"Paediatricians working at Great Ormond Street Hospital NHS Foundation Trust.~Intervention: Administer questionnaire to review and decide on significance of each of 30 child health concerns"
62575798|NCT05378672|EXPERIMENTAL|Dasiglucagon 0.6 mg|Participants will receive a single dose of 0.6 mg dasiglucagon.
62575799|NCT05378672|EXPERIMENTAL|Dasiglucagon 0.3 mg|Participants will receive a single dose of 0.3 mg dasiglucagon.
62197015|NCT02614547|EXPERIMENTAL|SAGE-547|Participants received a 4-hour dose titration of 30 micrograms per kilogram per hour (micrograms/kg/hr) (0 to 4 hours), then 60 micrograms/kg/hr (4 to 24 hours), then 90 micrograms/kg/hr (24 to 52 hours), followed by a taper to 60 micrograms/kg/hr (52 to 56 hours), and 30 micrograms/kg/hr (56 to 60 hours).
62575800|NCT05435729|EXPERIMENTAL|DSP-9632P 27.5 mg in Periods 3 of Part A|Single dose of DSP-9632P 27.5 mg in patients with levodopa-induced dyskinesia in Parkinson's disease
62575801|NCT05435729|EXPERIMENTAL|DSP-9632P 82.5 mg in Periods 4 of Part A|Single dose of DSP-9632P 82.5 mg in patients with levodopa-induced dyskinesia in Parkinson's disease
62575802|NCT05435729|EXPERIMENTAL|DSP-9632P 55.0 mg in Period 1 or 2 of Part B|Multiple dose of DSP-9632P 55.0 mg in patients with levodopa-induced dyskinesia in Parkinson's disease
62575803|NCT06505707|EXPERIMENTAL|Health Seeking Behavior Training Based on Motivational Interviewing Techniques|"The Migrant Elderly Women with Chronic Diseases in the intervention group, who will receive Health Seeking Behavior Training based on Motivational Interviewing Techniques, will be divided into four groups (the researcher conducting the intervention will interview the individuals in the 4 groups individually for 4 days). The interviews will be conducted 4 days a week (Monday, Tuesday, Thursday and Friday) and the Health Seeking Behavior Training based on Motivational Interviewing Techniques, which lasts 4 weeks and each session is approximately 30-35 minutes, will be applied face-to-face."
62197016|NCT05790070|PLACEBO_COMPARATOR|Placebo|3g/ twice daily (separated by \~12 hours) cellulose placebo for 14 days
62197017|NCT05790070|EXPERIMENTAL|Betaine Supplementation|3g/twice daily (separated by \~12 hours) betaine anhydrous for 14 days
62575804|NCT06505707|NO_INTERVENTION|Control group|There will be no intervention for individuals in this group.
62575805|NCT04455412|NO_INTERVENTION|control group|Conventional ICSI procedure was done for first portion of sibling oocytes
62575806|NCT04455412|EXPERIMENTAL|Study group 1|Laser assisted drilling ICSI procedure was done for second portion of sibling oocytes
62575807|NCT04455412|EXPERIMENTAL|Study group 2|Laser assisted thinning ICSI procedure was done for Third portion of sibling oocytes
62399462|NCT05166161|EXPERIMENTAL|PTC923|Participants will receive PTC923 7.5 mg/kg (participants 0 to \<6 months of age), 15 mg/kg (participants 6 to \<12 months of age), 30 mg/kg (participants 12 months to \<2 years of age), or 60 mg/kg (participants ≥2 years of age) orally once daily for a minimum of 12 months or until participant experiences lack of efficacy, adverse events (AEs) that lead to discontinuation, withdraws from treatment, or PTC923 is authorized and commercially available in the specific country.
62010415|NCT03966235|EXPERIMENTAL|Melatonin group|drug: melatonin tablets (Sigma-Aldrich Co. LLC, St. Louis, MO, USA); the frequency:3mg melatonin tablet was taken daily; duration: study treatment was maintained for 6 months.
62575808|NCT05091541|EXPERIMENTAL|CT120 in relapsed/refractory B-cell non-Hodgkin's lymphoma patients|Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection（CT120）will be infused at 1.0 x 10\^6 CAR+ T cells/kg、3.0 x 10\^6 CAR+ T cells/kg、6.0 x 10\^6 CAR+ T cells/kg in relapsed/refractory B-cell non-Hodgkin's lymphoma patients
62010416|NCT03966235|PLACEBO_COMPARATOR|Control group|drug: placebo tablet; the frequency: placebo tablet was taken daily; duration: study treatment was maintained for 6 months.
62575809|NCT01204684|EXPERIMENTAL|Tumor Lysate-pulsed DC vaccination|Cohort #1 will receive autologous tumor lysate-pulsed DC vaccination together with a placebo cream or intramuscular injection of saline.
62575810|NCT01204684|EXPERIMENTAL|Tumor lysate-pulsed DC vaccination+0.2% resiquimod.|Cohort #2 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant 0.2% resiquimod.
62575811|NCT01204684|EXPERIMENTAL|Tumor-lysate pulsed DC vaccination +adjuvant polyICLC.|Cohort #3 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant poly ICLC (TLR3 agonist).
62575812|NCT02147457||ELBW (CASES)|Extremely low birth weights, born in 2000-2005, birth weight below 1000 grams, who were initially admitted (2000-2005) at the Neonatal Intensive Care Unit, UZ Leuven Belgium and have been well characterized and documented in the postnatal period.
62575813|NCT02147457||CONTROLS|Survivors (CASES) (n = 140) will be matched with two healthy controls. One control will be matched to sex, birth year and residential area and will be suggested by the index patient (e.g. school friend, neighbor), the second control will be age and sex matched from the area of the field.
62575814|NCT01438892||tDMARDs Group|traditional DMARDs
62575815|NCT01438892||Biologics group|Biologics used in RA
62575816|NCT04646343||group for cross cultural adaptation of questionnaire|Pre final French version of the CISS and PWES will be administered to French native speaking patients suffering from various hand injuries. 30 patients are sufficient. They will be asked to write commentaries on difficulties of questionnaire's items, especially comprehension of the different items (clear or unclear).If the item is considered unclear, the patient is asked to provide suggestions for making the item clearer .The distribution of the responses will be examined for searching missing responses. An item considered unclear by 20 % or more of the patients must be re-evaluated . The definitive version of French-CISS and French PWES (F-CISS and F- PWES) and the verification of the different stages of the cross-cultural adaptation will be validated during a new consensus meeting.
62575817|NCT04646343||group for validation of questionnaire|For the second part (validation study) we will administered F-CISS, F-PWES, F-DASH, F-HFS, F-SF 36 questionnaires and a pain VAS to a population of in and outpatients with hand injuries. We aim to include patients during one year for a total expected of 100 patients.
62575818|NCT02983188|ACTIVE_COMPARATOR|Berberine|Patients will receive berberine pills in additional to current atypical antipsychotic agents
62575819|NCT02983188|PLACEBO_COMPARATOR|Placebo|Patients will receive placebos pills in additional to current atypical antipsychotic agents
62575820|NCT04520997|EXPERIMENTAL|Down-up|Participants in this group received up to 2 mL Restylane Defyne on chin at baseline and up to 2 mL of Restylane Defyne per NLF at baseline and up to 2 mL per ML of Restylane Defyne at Week 3. An optional touch-up was administered to participants who had not achieved the optimal aesthetic improvement as agreed between participant and investigator.
62575821|NCT04520997|EXPERIMENTAL|Top-down|Participants in this group received up to 2 mL Restylane Defyne per NLF and up to 2 mL per ML of Restylane Defyne at baseline and up to 2mL on chin Week 3. An optional touch-up was administered to participants who had not achieved the optimal aesthetic improvement as agreed between participant and investigator.
62575822|NCT01234870|EXPERIMENTAL|Ischemic heart disease patients|Patients with suspected ischemic heart disease prospectively recruited for first pass myocardial perfusion MRI. All subject to receive Gadolinium infusion of 0.075 mmol/kg at rate of 4 ml/sec. Adenosine administered at a rate of 0.14 mg/kg/min for a duration of 4 minutes to induce stress.
62010417|NCT05575999|OTHER|Bupivacaine Alone|This is the control group of patients receiving 20 cc of 0.5% bupivacaine (Bupivacaine HCL 100 mg \[5mg/ml\] alone. The dose and number of doses of the medicines will be adjusted as per discretion of the operator.
62010418|NCT05575999|EXPERIMENTAL|Bupivacaine-Ketorolac-Ketamine (BKK) Combination|This is the intervention group of patients receiving 20 cc combination of BKK (Bupivacaine HCl 60 mg \[3 mg/mL\], Ketorolac Tromethamine 24 mg \[1.2mg/mL\], Ketamine HCl 24 mg \[1.2 mg/mL\]).The dose and number of doses of the medicines will be adjusted as per discretion of the operator.
62010419|NCT03930316|OTHER|observation|validation of observational arm
62010420|NCT01544712|ACTIVE_COMPARATOR|Control|Core decompression
62575823|NCT04143698|ACTIVE_COMPARATOR|Disposable (single-use) duodenoscope|This group will be using the disposable (single-use) duodenoscope during endoscopic retrograde cholangiopancreatography (ERCP).
62575824|NCT04143698|ACTIVE_COMPARATOR|Reusable duodenoscope|This group will be using the reusable duodenoscope during endoscopic retrograde cholangiopancreatography (ERCP).
62010421|NCT01544712|EXPERIMENTAL|Bone marrow|core decompression plus autologous concentrated bone marrow
62575825|NCT03805568|ACTIVE_COMPARATOR|dexmedetomidine infusion group|dexmedetomidine infusion (loading dose of 1 ㎍/kg over 10 min and continuous infusion of 0.3-0.6 ㎍/kg/h) during the surgery
62197018|NCT05321199|EXPERIMENTAL|Control patients|Closed Envelope for group A (control); patients receiving no tranexamic acid. With Double-Blind Study in which the participants and observers are unaware of who receives tranexamic acid. The total blood loss (TBL), intraoperative blood loss (IBL), postoperative blood loss (PBL), hemoglobin (HGB) levels and Hematocrit value (Hct) on preoperatively (pre-op) and postoperatively, and amount of allogenic blood transfusion were recorded. Furthermore, the general information was also compared between groups.
62399463|NCT04400773|EXPERIMENTAL|Plyometric Group|This group will receive a 6-week upper body plyometric exercise protocol. Sessions will last for 65 minutes, three times per week. Each week the exercises will be progressed and all sessions will be supervised by an exercise professional.
62399464|NCT04400773|EXPERIMENTAL|Strength Group|This group will receive a 6-week upper body strength exercise protocol. Sessions will last for 65 minutes, three times per week. Each week the exercises will be progressed and all sessions will be supervised by an exercise professional.
62197019|NCT05321199|EXPERIMENTAL|Case patients|Closed Envelope for group B (case); patients receiving tranexamic acid intravenously and topically. With Double-Blind Study in which the participants and observers are unaware of who receives tranexamic acid. The total blood loss (TBL), intraoperative blood loss (IBL), postoperative blood loss (PBL), hemoglobin (HGB) levels and Hematocrit value (Hct) on preoperatively (pre-op) and postoperatively, and amount of allogenic blood transfusion were recorded. Furthermore, the general information was also compared between groups.
62399465|NCT00429026|EXPERIMENTAL|Fludarabine + Cyclophosphamide with ASCT|ASCT=Allogeneic Hematopoietic Stem Cell Transplantation
62399466|NCT00429026|EXPERIMENTAL|Fludarabine + Melphalan with ASCT|ASCT=Allogeneic Hematopoietic Stem Cell Transplantation
62399467|NCT02010359|EXPERIMENTAL|Lovaza|Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks
62399468|NCT02010359|PLACEBO_COMPARATOR|Placebo|An inactive Placebo (2 pills twice daily) will be given for 8 weeks
62575826|NCT03805568|ACTIVE_COMPARATOR|remifentanil infusion group|remifentanil of 4 ng/ml during induction, followed by remifentanil infusion (1.5\~2.5 ng/ml) during the surgery
62575827|NCT03515811||Abdominal|"Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri-Staple™ 2.0 Intelligent Reloads.~Abdominal (approximately 53 subjects)."
62575828|NCT03515811||Thoracic|"Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri-Staple™ 2.0 Intelligent Reloads.~Thoracic (approximately 74 subjects)."
62575829|NCT03831113|ACTIVE_COMPARATOR|Magnitude Group|Subjects will receive alternating reductions of 1 mg or 2 mg weekly.
62783192|NCT02429791|ACTIVE_COMPARATOR|Current antiretroviral regimen (CAR)|Participants continued to receive their CAR (two nucleoside reverse transcriptase inhibitors \[NRTIs\] + a third agent). A third agent included either an: integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). CAR was administered according to the approved labeling in an open-label fashion up to Week 52 during the Early Switch Phase. At Week 52, participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) less than (\<) 50 copies (c)/mL, switched to DTG 50 mg + RPV 25 mg once daily and were followed-up through the Late Switch Phase, at Week 148 and through the Continuation Phase, after Week 148.
62575830|NCT03831113|ACTIVE_COMPARATOR|Frequency Group|Subjects will receive dose reductions of 2 mg on alternating intervals of 1 and 2 weeks.
62575831|NCT06575114|OTHER|Control group: traditional health education|In the control group, a conventional intervention will be used, and health education brochures on the COVID-19 vaccine will be distributed for the study participants to read on their own time. The contents of the brochure included basic knowledge concerning the SARS-CoV-2 coronavirus, COVID-19 vaccine, herd immunity, and precautions for vaccination.
62734712|NCT03985462|EXPERIMENTAL|VSEL Medium|A total of 200,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a middle dose group
62783193|NCT02429791|EXPERIMENTAL|DTG + RPV|Participants received DTG 50 mg + RPV 25 mg together, once daily, at approximately the same time, with a meal, in an open-label fashion up to Week 52, during the Early Switch Phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase. Participants who successfully completed 148 weeks of treatment were given the opportunity to continue to receive DTG + RPV once daily in the Continuation Phase (after Week 148).
62575832|NCT06575114|OTHER|Intervention group: Self-determination theory-based health education measures|The intervention group will receive self-determination theory-based interventions, with targete interventions proposed based on the self-determination theory-including health-related talks and sharing sessions. To ensure that older individuals with varying levels of literacy understood the intervention, the process will be conducted in the local native dialect.
62575833|NCT01487122|EXPERIMENTAL|Continuous Microwave|
62575834|NCT01487122|EXPERIMENTAL|Pulsed Microwaves|
62575835|NCT01487122|SHAM_COMPARATOR|sham microwaves|
62575836|NCT05807919|EXPERIMENTAL|Diet low in all FODMAP groups|
62575837|NCT05807919|EXPERIMENTAL|Diet - Mediterranean|
62197020|NCT06269978|EXPERIMENTAL|Treatment (oxaliplatin, 5FU)|Patients undergo placement of indwelling IP port for chemotherapy infusion. Patients receive oxaliplatin and 5FU over 1-2 hours via IP infusion on days 1 and 15 of each cycle. Cycles repeat every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo diagnostic laparoscopy, biopsy, CT/MRI, and collection of blood samples at screening and on study and undergo collection of IP fluid samples on study.
62197021|NCT04985695|ACTIVE_COMPARATOR|Thoracic epidural anesthesia|Epidural analgesia during midline laparotomy
62197022|NCT04985695|EXPERIMENTAL|Bilateral rectus sheath block|Bilateral rectus sheath block during midline laparotomy
62197023|NCT05764135|EXPERIMENTAL|Intervention Group|25 individuals will be randomized into the intervention group and download SCI-Lynx Mobile Application.
62197024|NCT05764135|NO_INTERVENTION|Control Group|25 individuals will be randomized into the control group or usual care. They will then have an opportunity at the end of the 1-month to download the SCI-Lynx Mobile Application.
62197025|NCT02671188|EXPERIMENTAL|GSK3050002 100 mg/mL|Subjects will be administered GSK3050002 intravenously (IV) over the period of approximately 2 hours on Day 1, Day 15 and Day 29 (total of 3 doses) in a clinical facility with regular monitoring of vital signs. Monitoring of vital signs will continue for a minimum of 2 hours after completion of Infusion. On Day 1, loading dose of GSK3050002 10 milligrams per kilogram (mg/kg) will be administered intravenously, followed by maintenance doses of 5mg/kg IV administered at Day 15 and Day 29. Each subject will receive a cumulative dose of 20 mg/kg.
62197026|NCT02671188|PLACEBO_COMPARATOR|Placebo|Subjects will be administered normal saline (0.9% sodium chloride) intravenously over the period of approximately 2 hours on Day 1, Day 15 and Day 29 (total of 3 doses) in a clinical facility with regular monitoring of vital signs. Monitoring of vital signs will continue for a minimum of 2 hours after completion of Infusion.
62197027|NCT05863767|EXPERIMENTAL|Interventional Group|Baduanjin sequential therapy consists of Six different movements including the preparatory phase. The session will account for 30 minutes twice a day for four weeks.
62197028|NCT05863767|PLACEBO_COMPARATOR|Control group|Control intervention: AROM, Breathing exercises, and stretches 5 repetitions three times a day.
62197029|NCT02172001|EXPERIMENTAL|Iron isomaltoside 1000|Iron isomaltoside 1000. Dose: 1000 mg, 1500 mg or 2000 mg
62197030|NCT02172001|PLACEBO_COMPARATOR|Placebo (NaCl 0,9%)|Sodium Chloride. Dose: 100 ml or 5 ml
62197031|NCT03882151|EXPERIMENTAL|Epilog Preop|patients receive Epilog preop analysis
62197032|NCT00663975|EXPERIMENTAL|1|DCI-1020 Capsules contain an enteric-coated buffered microspheres of pancrelipase, encapsulated in clear capsules. Capsules are equivalent to 4,000 USP units of lipase
62197033|NCT01618370|EXPERIMENTAL|Radium-223 dichloride|
62575838|NCT01558557|EXPERIMENTAL|Gluten Free Diet|
62575839|NCT02420730|EXPERIMENTAL|Cohort 1A: AGN-232411 Dose A|One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants.
62575840|NCT02420730|EXPERIMENTAL|Cohort 1B: AGN-232411 Dose B|One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose A in Cohort 1A is acceptable.
62575841|NCT02420730|EXPERIMENTAL|Cohort 1C: AGN-232411 Dose C|One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose B in Cohort 1B is acceptable.
62734713|NCT03985462|EXPERIMENTAL|VSEL Mini|A total of 100,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a low dose group
62575842|NCT02420730|PLACEBO_COMPARATOR|Cohort 1: AGN-232411 Vehicle|One drop of Vehicle for AGN-232411 topical ophthalmic solution administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants.
62575843|NCT02420730|EXPERIMENTAL|Cohort 2A: AGN-232411 Dose A|One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease.
62575844|NCT02420730|EXPERIMENTAL|Cohort 2B: AGN-232411 Dose B|One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose A in Cohort 2A is acceptable.
62575845|NCT02420730|EXPERIMENTAL|Cohort 2C: AGN-232411 Dose C|One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose B in Cohort 2B is acceptable.
62575846|NCT02420730|PLACEBO_COMPARATOR|Cohort 2: AGN-232411 Vehicle|One drop of Vehicle for AGN-232411 topical ophthalmic solution administered to the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease.
62575847|NCT05847868|EXPERIMENTAL|Device Feasibility|Device feasibility will be performed in this single arm study.
62575848|NCT03322761|EXPERIMENTAL|Systematic exercise training|Two weekly supervised aerobic exercise trainings for 48 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
62575849|NCT03322761|ACTIVE_COMPARATOR|Educational program|Educational program on physical activity and health, consisting of four educational sessions in the intervention period.
62575850|NCT03322761|NO_INTERVENTION|Standard treatment alone|Data from The Danish MS Registry will serve as control-data for standard treatment alone.
62010422|NCT04285190|EXPERIMENTAL|The T89 treatment group|Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID(every morning and evening), for 10 days (Depending on clinical need and practicability, the use can be extended for up to 14 days).
62010423|NCT04285190|NO_INTERVENTION|The blank control group|All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days.
62010424|NCT00529841|EXPERIMENTAL|1 (Hydrocortisone sodium acetate)|Subcutaneous administration of Hydrocortisone sodium acetate via insulin pump
62010425|NCT06377579||AML in 1st line at inclusion|
62010426|NCT06377579||AML in R/R at inclusion|
62010427|NCT01343706|EXPERIMENTAL|BI 409306 0.5 mg PiB [EM]|Extensive metaboliser \[EM\] subjects administered one single dose of 0.5 milligram (mg) BI 409306 powder in bottle (PiB) reconstituted for oral solution (0.5 mg /milliliter (mL)) in a volume of 80 mL of the solvent containing aqueous 0.5% tartaric acid solution orally with 240 mL water (160 mL containing the respective diluted volume of reconstituted solution and 80 mL drinking water) after an overnight fast of at least 10 hours.
62197034|NCT06324123||Patients with neuropathic pain|Patients with acute or chronic neuropathic pain
62197035|NCT03998449|EXPERIMENTAL|Cholera vaccination|Two doses of the vaccine against cholera
62197036|NCT06498284|EXPERIMENTAL|HM-002-1005 61.5 mg or matching placebo|Single dose of 61.5 mg HM-002-1005 or matching placebo
62197037|NCT06498284|EXPERIMENTAL|HM-002-1005 123 mg or matching placebo|Single dose of 123 mg HM-002-1005 or matching placebo
62197038|NCT06498284|EXPERIMENTAL|HM-002-1005 184.5 or 246 mg, or matching placebo|Single dose of 184.5 or 246 mg HM-002-1005 or matching placebo
62197039|NCT06498284|EXPERIMENTAL|HM-002-1005 369 mg or matching placebo|Single dose of 369 mg HM-002-1005 or matching placebo
62197040|NCT05170347||Post-Haematopoietic Stem Cell Transplantation (Post-HSCT) patients|"* Patient aged 18 or above~* Underwent allogeneic HSCT in Queen Mary Hospital(QMH) in the two-year recruitment period"
62197041|NCT05170347||Family Control Subjects|The research team will invite an accompanying family member to be the family control. Microbiome and tear samples will be collected for comparison. The sample collection schedule is the same as the corresponding post-HSCT case.
62197042|NCT04398329|EXPERIMENTAL|Phase 1b (Cohort 1)|Fixed dose of HTX-034.
62197043|NCT04398329|EXPERIMENTAL|Phase 1b (Cohort 2)|Individualized dose of HTX-034.
62197044|NCT04398329|EXPERIMENTAL|Phase 2 (Expansion): Low Dose|Fixed dose of HTX-034.
62197045|NCT04398329|EXPERIMENTAL|Phase 2 (Expansion): High Dose|Individualized dose of HTX-034.
62197046|NCT04398329|ACTIVE_COMPARATOR|Phase 1b and Phase 2|Bupivacaine HCl.
62575851|NCT03076034|EXPERIMENTAL|Post-menopausal women|We will use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.
62197047|NCT02579590||DEMPA group|This group are using DMPA (Depot Medroxyprogesterone Acetate 150 mg) injection every 3 month for 6-12 month
62197048|NCT02579590||Implanon group|"This group are using Implanon  (etonogestrel implant) 68 mg implant for 6-12 month"
62197049|NCT02579590||Cerazette group|This group are using Cerazette pills (75 micrograms desogestrel) one pill every day for 28 days without pill-free interval for 6-12 month.
62197050|NCT02579590||Normal healthy group|Those women not using any method of contraception
62197051|NCT03850132|EXPERIMENTAL|FAM-SOTC-PL|Grief responses, levels of vulnerability, measured using the Adult Attitude to Grief scale (AAG), a self-administered questionnaire
62575852|NCT03076034|EXPERIMENTAL|Males over 50 years|We will recruit males to this second study arm, to use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.
62197052|NCT06366412|EXPERIMENTAL|Dexmedetomidine group|Will receive induction of general anesthesia by loading dose of dexmedetomidine (Precedex) 0.6 μg/kg over 10 minutes in a 20 ml micropump, fentanyl in a dose of 1 μg /kg, propofol 1-1.5 mg/kg, and endotracheal intubation will be facilitated by 0.5mg/kg of atracurium and maintenance of anesthesia will be achieved by dexmedetomidine in a dose of 0.3 μg/kg/hr on 50 ml micropump and isoflurane (1-2%) in oxygen-air mixture.
62197053|NCT06366412|PLACEBO_COMPARATOR|Placebo group|Will receive induction of general anesthesia by infusion of normal saline 20 ml micropump over 10 min, fentanyl in a dose of 1 μg/kg, propofol 1-1.5 mg/kg and endotracheal intubation will be facilitated by 0.5mg/kg of atracurium and maintenance of anesthesia will be achieved by isoflurane (1-2%) in oxygen-air mixture and infusion of 50 ml/hr micropump of normal saline.
62575853|NCT02230904|EXPERIMENTAL|Treatment Arm A-B|4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1)
62575854|NCT02230904|EXPERIMENTAL|Treatment Arm B-A|4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1)
62575855|NCT03782012|EXPERIMENTAL|Knowledge Supported|Students will have 30 seconds to view pictures of the knowledge base items and discuss relations among items.
62575856|NCT03782012|EXPERIMENTAL|Knowledge Not Supported|Students will be provided 30 seconds to view pictures of the knowledge base items.
62575857|NCT05345613|EXPERIMENTAL|Tranexamic Acid group|standard solution for injection with TXA and without adrenaline
62575858|NCT05345613|PLACEBO_COMPARATOR|Standard therapy group|standard solution for injection including adrenaline
62197054|NCT01750970|EXPERIMENTAL|Resection under blue light|
62197055|NCT01750970|ACTIVE_COMPARATOR|Resection under white light|
62197056|NCT02912637||CF patients|Hyperpolarized Xenon MRI
62575859|NCT05424510|ACTIVE_COMPARATOR|Fluid Bolus (FB+)|Patients in the FB+ group will receive a single bolus of 500 ml of Ringer's Lactate over 5-10 minutes.
62575860|NCT05424510|PLACEBO_COMPARATOR|Non fluid bolus (FB-)|Patients in the FB- group will not receive a fluid bolus.
62575861|NCT02533050|EXPERIMENTAL|Patients treated|Patients with CAD and SAS. This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an Epworth sleepiness score (ESS) \<10. After randomization, they will be treated with CPAP treatment.
62783194|NCT01709656|EXPERIMENTAL|MSC plus NSAID|"human mesenchymal stem cells:1\*10\^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment, plus non-steroid anti-inflammatory drugs (NSAID: celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os).~Duration of treatment:24 weeks for follow up. collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
62197057|NCT02912637||Healthy volunteers|Hyperpolarized Xenon MRI
62197058|NCT01541852|ACTIVE_COMPARATOR|Losmapimod|7.5mg tablet twice daily
62783195|NCT01709656|EXPERIMENTAL|NSAID|"non-steroid anti-inflammatory drugs (NSAID: celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up;collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
62197059|NCT01541852|PLACEBO_COMPARATOR|Placebo|One tablet twice daily
62197060|NCT01475461|PLACEBO_COMPARATOR|Placebo|
62197061|NCT01475461|EXPERIMENTAL|PF-04937319 - Dose 1|
62197062|NCT01475461|EXPERIMENTAL|PF-04937319 - Dose 2|
62197063|NCT01475461|EXPERIMENTAL|PF-04937319 - Dose 3|
62197064|NCT01475461|EXPERIMENTAL|PF-04937319 - Dose 4|
62197065|NCT01475461|ACTIVE_COMPARATOR|Sitagliptin|
62197066|NCT05627453|ACTIVE_COMPARATOR|Normal gait training|"The gait training session will consist in 30 min walking side-by-side. If any, the session will take place along an indoor circuit to avoid unfavorable weather conditions. The participants will walk side by side without contact and without instructions about gait synchronisation. They will have to agree on a comfortable pace for the older participant.~The gait training session will be repeated three times a week for four weeks. The last session of each week will also include an assessement of gait quality."
62575862|NCT02533050|NO_INTERVENTION|Patients non-treated|Patients with CAD and SAS. This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an ESS \<10. After randomization, they will be not treated.
62575863|NCT02533050|NO_INTERVENTION|Control group|Patients with CAD but without SAS (AHI\<15).
62734714|NCT03985462|NO_INTERVENTION|Control|5 mL plate-rich plasma with no cells inside were injected into the bilateral fallopian tubes as a control group
62734715|NCT01786382|EXPERIMENTAL|midazolam|potential effects of PPI-668 on midazolam pharmacokinetics
62734716|NCT01786382|EXPERIMENTAL|omeprazole|potential effects of PPI-668 on omeprazole pharmacokinetics
62734717|NCT01786382|EXPERIMENTAL|telaprevir|potential effects of PPI-668 on telaprevir pharmacokinetics
62575864|NCT01266291|OTHER|Treatment with Sabril (vigabatrin)|This is a single arm study. All subjects who are eligible for treatment will begin taking vigabatrin (Sabril) during the third month of the study. Treatment will be in accordance with the FDA-approved prescribing information: upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
62010428|NCT01343706|EXPERIMENTAL|BI 409306 2 mg PiB [EM]|EM subjects administered one single dose of 2 mg BI 409306 PiB reconstituted for oral solution (0.5 mg/mL) in a volume of 80 mL of the solvent containing aqueous 0.5% tartaric acid solution orally with 240 mL water (160 mL containing the respective diluted volume of reconstituted solution and 80 milliliter drinking water) after an overnight fast of at least 10 hours.
62010429|NCT01343706|EXPERIMENTAL|BI 409306 5 mg PiB followed by BI 409306 5 mg Tablet [EM]|EM subjects administered one single dose of 5 mg BI 409306 powder in bottle (PiB) reconstituted for oral solution (0.5 mg/ mL) in a volume of 80 mL of the solvent containing aqueous 0.5% tartaric acid solution orally with 240 mL water (160 mL containing the respective diluted volume of reconstituted solution and 80 mL drinking water) after an overnight fast of at least 10 hours in period 1; followed by a washout period of 5 days; followed by one single dose of 5 mg BI 409306 immediate release tablet administered orally with 240 mL water after an overnight fast of at least 10 hours in period 2.
62010430|NCT01343706|EXPERIMENTAL|BI 409306 10 mg Tablet [EM]|EM subjects administered 2 immediate release tablets of 5 mg BI 409306 as a single dose (total dosage: 10 mg) orally with 240 mL water after an overnight fast of at least 10 hours.
62010431|NCT01343706|EXPERIMENTAL|BI 409306 25 mg Tablet [EM]|EM subjects administered 5 immediate release tablets of 5 mg BI 409306 as a single dose (total dosage: 25 mg) orally with 240 mL water after an overnight fast of at least 10 hours.
62010432|NCT01343706|EXPERIMENTAL|BI 409306 50 mg Tablet followed by BI 409306 50mg PiB [EM]|EM subjects administered one single dose of 50 mg BI 409306 immediate release tablet orally with 240 mL water in period 1; followed by a washout period of 5 days; followed by one single dose of 50 mg BI 409306 powder in bottle (PiB) reconstituted for oral solution (0.5 mg/mL) in a volume of 80 mL of the solvent containing aqueous 0.5% tartaric acid solution administered orally with 240 mL water (160 mL containing the respective diluted volume of reconstituted solution and 80 mL drinking water) after an overnight fast of at least 10 hours in period 2.
62010433|NCT01343706|EXPERIMENTAL|BI 409306 100 mg Tablet [EM]|EM subjects administered 2 immediate release tablets of 50 mg BI 409306 as single dose (total dosage: 100 mg) orally with 240 mL water after an overnight fast of at least 10 hours.
62010434|NCT01343706|EXPERIMENTAL|BI 409306 200 mg Tablet [EM]|EM subjects administered 1 immediate release tablet of 150 mg and 1 immediate release tablet of 50 mg of BI 409306 together as single dose (total dosage: 200 mg) orally with 240 mL water after an overnight fast of at least 10 hours.
62010435|NCT01343706|EXPERIMENTAL|BI 409306 350 mg Tablet [EM]|EM subjects administered 2 immediate release tablet of 150 mg and 1 immediate release tablet of 50 mg of BI 409306 together as single dose (total dosage: 350 mg) orally with 240 mL water after an overnight fast of at least 10 hours.
62010436|NCT01343706|EXPERIMENTAL|BI 409306 10 mg Tablet followed by BI 409306 100mg Tablet [PM]|Poor metaboliser \[PM\] subjects administered 2 immediate release tablets of 5 mg BI 409306 as single dose (total dosage: 10 mg) orally with 240 mL water after an overnight fast of at least 10 hours in period 1; followed by washout period of 5 days; followed by 2 immediate release tablets of 50 mg BI 409306 administered as single dose (total dosage: 100 mg) orally with 240 mL water after an overnight fast of at least 10 hours in period 2.
62197067|NCT05627453|EXPERIMENTAL|Arm-in-arm gait training|"The gait training session will consist in 30 min walking side-by-side. If any, the session will take place along an indoor circuit to avoid unfavorable weather conditions. The participants will be asked to walk arm-in-arm while synchronizing their steps. They will have to agree on a comfortable pace for the older participant.~The gait training session will be repeated three times a week for four weeks. The last session of each week will also include an assessement of gait quality."
62575865|NCT05750602|EXPERIMENTAL|LIMICOL|"LIMICOL : red yeast rice (with monacolin K, 2 mg), artichoke leaf extract, policosanols, French maritime Pine bark extract, Garlic extract, vitamins E, B2 and B3.~1 tablet during the 3 principal meals for 12 weeks."
62575866|NCT05750602|PLACEBO_COMPARATOR|PLACEBO|"dicalcium phosphate, calcium citrate, vegetable magnesium stearate, microcrystalline cellulose, Maltodextrin, Tricalcium phosphate, Beet powder, Yellow coloring shellac, Brown coloring shellac.~1 tablet during the 3 principal meals for 12 weeks."
62575867|NCT00604591|PLACEBO_COMPARATOR|Placebo then Tolcapone|"Participants take placebo during study week 1 and then tolcapone during week 3.~On Day 1, 100 mg of tolcapone/placebo will be taken at three specific times: once in the morning, once in the afternoon, once at night. Then, from Days 2-6, 200 mg of tolcapone/placebo will be taken three times a day: once in the morning, once in the afternoon, once at night. On Day 7, 200 mg of tolcapone/placebo will be taken only in the morning and afternoon. On Day 8, 200 mg of tolcapone/placebo will be taken only in the morning. After the last dose on Day 8 is taken, the wash-out period begins and lasts through Day 14."
62734718|NCT02524236|ACTIVE_COMPARATOR|Botox 50 IU|"Intervention: Botox 50 IU vial will be reconstituted with saline 0.9% to a total volume of 5 ml. All patients will receive five injections of 1 mL of the BoNT-A solution, including two injections in each lateral lobe (one proximal and one distal) and one injection in the median lobe. The injection depth will be 7-10 mm.~Botox injection in the prostate"
62010437|NCT01343706|PLACEBO_COMPARATOR|Placebo matching to BI 409306 PiB|Subjects administered one single dose of placebo matching to BI 409306 powder in bottle (PiB) after an overnight fast of at least 10 hours.
62010438|NCT01343706|PLACEBO_COMPARATOR|Placebo matching to BI 409306 film-coated tablet|Subjects administered one single dose of placebo matching to the BI 409306 film-coated tablet (5 milligrams (mg), 50 mg, and 150 mg) orally with 240 mL water after an overnight fast of at least 10 hours.
62010439|NCT01231763||Healthy volunteers|
62010440|NCT06664658|ACTIVE_COMPARATOR|PEEP 5|Patients are in the group undergoing PEEP 5 cm h2o during surgery
62010441|NCT06664658|ACTIVE_COMPARATOR|peep 10|Patients are in the group undergoing PEEP 10 cm h2o during surgery
62197068|NCT05494970||Patients with ORL cancer for which radiotherapy treatment is required.|
62575868|NCT00604591|EXPERIMENTAL|Tolcapone then Placebo|"Participants take tolcapone during study week 1 and then placebo during week 3.~On Day 1, 100 mg of tolcapone/placebo will be taken at three specific times: once in the morning, once in the afternoon, once at night. Then, from Days 2-6, 200 mg of tolcapone/placebo will be taken three times a day: once in the morning, once in the afternoon, once at night. On Day 7, 200 mg of tolcapone/placebo will be taken only in the morning and afternoon. On Day 8, 200 mg of tolcapone/placebo will be taken only in the morning. After the last dose on Day 8 is taken, the wash-out period begins and lasts through Day 14."
62010442|NCT06573112||Cetral venous catheter group|ICU patients with a new central venous catheter.
62010443|NCT06223672|EXPERIMENTAL|Walnuts|consumption of walnuts every day
62010444|NCT06223672|EXPERIMENTAL|White chocolate-style bar|consumption of a white chocolate-style bar every day
62197069|NCT02643225||pregnant women with gestational diabetes|case group
62197070|NCT02643225||non diabetic pregnant women|control group
62197071|NCT02975102|EXPERIMENTAL|CBL-101 Eye Drops|The test article, CBL-101 Eye Drops, is a CE-marked medical device containing 0.15% sodium hyaluronate and polyethylene glycol (PEG) 8000. An oxide (Oxyd®) used as a soft preservative, rapidly turns into oxygen, water and ions on contact with the eye. The formula is presented in 10 mL bottles.
62197072|NCT02975102|ACTIVE_COMPARATOR|Vismed® Multi Eye Drops|The comparator product, Vismed® Multi ophthalmic solution (CE marked), contains 0.18% sodium hyaluronate, is unpreserved and presented in 10 mL bottles.
62197073|NCT01043003|EXPERIMENTAL|Arm I|Patients and caregivers undergo the Bilingual Breast Cancer Educational Intervention (BBCEI) comprising teaching sessions over 50-65 minutes about 4 specific domains (i.e., physical, psychological, social, and spiritual well being) once weekly during month 1 and also undergo evaluation sessions at months 1, 4, and 7. Patients and caregivers receive reinforcement telephone calls every other week.
62197074|NCT01043003|ACTIVE_COMPARATOR|Arm II|Patients and caregivers undergo usual care comprising evaluation sessions at months 1, 4, and 7. Patients and caregivers may undergo the 4 BBCEI teaching sessions during month 7. Patients and caregivers receive reinforcement telephone calls every other week.
62197075|NCT05311254|EXPERIMENTAL|Fosfomycin|Drug: Fosfomycin: oral capsules containing 700 mg of calcium fosfomycin, equivalent to 500 mg of active drug.
62197076|NCT05311254|ACTIVE_COMPARATOR|Ciprofloxacin|Oral ciprofloxacin, tablets containing 500 mg of active drug.
62575869|NCT01934049|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine in dex group is administered as 1ug/kg by intravenous infusion 10 min and then 0.6 ug/kg until 30 minutes before the operation finishes.
62575870|NCT01934049|PLACEBO_COMPARATOR|Saline|Participants in con group receive placebo(saline) as the same dose at the same time as dex group.
62575871|NCT01873404|EXPERIMENTAL|BG00010|Administered as an IV injection at various dose levels 3 times per week for 1 week
62783196|NCT05691205|EXPERIMENTAL|PEEP-LuTX|Within 48h after LuTX we will evaluate the effects of three levels of PEEP (14\>10\>6 cmH2O) upon: - lung and chest wall mechanics, - intrapulmonary shunt fraction; - distribution of ventilation and perfusion; - gas exchange.
62010445|NCT02699905||Sepsis|Patients with the diagnosis of sepsis or septic shock
62010446|NCT02699905||Control|Healthy control with no evidence of active infection, or recent infection in the past 4 weeks.
62010447|NCT05267171|EXPERIMENTAL|Intervention group|
62010448|NCT05267171|NO_INTERVENTION|Control group|
62010449|NCT04111497|EXPERIMENTAL|Treatment (glasdegib)|Patients receive glasdegib PO QD on days 1-28. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
62783197|NCT01819350|EXPERIMENTAL|G4 and G5|Application of antibiotic group of pediatric medicines and control group (sucrose 10 %)on dental biofilm.
62783198|NCT01819350|EXPERIMENTAL|G1, G2 and G3|Application of Nutritional, Respiratory and Endocrine groups medicines pediatric on dental biofilm
62783199|NCT00487071|EXPERIMENTAL|Anal fistula plug|
62010450|NCT04383444||SARS-CoV-2 exposure|NIH staff exposed to SARS-CoV-2 or current or previous SARS-CoV-2 infection, but currently asymptomatic
62783200|NCT04132921||Patients with AKI|Patients with AKI after joint replacement
62783201|NCT04132921||Patients without AKI|Patients without AKI after joint replacement
62010451|NCT03414242|EXPERIMENTAL|Cervical spine musculature|
62197077|NCT03063944|EXPERIMENTAL|Treatment (STAT inhibitor OPB-111077, venetoclax, decitabine)|"INDUCTION CYCLE 1: Patients receive STAT inhibitor OPB-111077 PO QD on days 1-28, and venetoclax PO QD on days 4-28 of cycle 1. Patients also receive decitabine IV over approximately 1 hour on days 4-8 of cycle 1. Patients who achieve complete remission (CR) after 1 cycle move on to Maintenance, and patients who do not achieve a CR move on to Cycle 2.~INDUCTION CYCLE 2: Patients receive STAT inhibitor OPB-111077, venetoclax, and decitabine as in Induction Cycle 1. Patients who achieve CR, CRi, PR, or stable disease (or clinically significant hematologic improvement as determined by the investigator) move on to Maintenance.~MAINTENANCE: Patients receive STAT inhibitor OPB-111077, venetoclax, and decitabine as in Induction Cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62197078|NCT03735589|EXPERIMENTAL|Treatment (nCTLs, alpha-DC1 vaccine)|Patients receive the alpha-type-1 polarized dendritic cell vaccine ID 2 weeks before day 0, on day 0, and on day 28. Patients also receive aDC1 IP over 3-10 seconds on day 0. In the absence of unacceptable side effects, patients may receive the alpha-type-1 polarized dendritic cell vaccine every 1-3 months at the discretion of the physician.
62197079|NCT05831137|EXPERIMENTAL|intervention side|duration of intercostal nerves cryolesia: 1 minute per left nerve
62197080|NCT05831137|NO_INTERVENTION|control side|duration of intercostal nerves cryolesia: 2 minute per right nerve
62197081|NCT01415934|NO_INTERVENTION|Continue Statins|Participant will continue on statins as per usual
62197082|NCT01415934|EXPERIMENTAL|Discontinue statins|Participant will stop taking their statin drugs
62575872|NCT01873404|PLACEBO_COMPARATOR|Placebo|Matched placebo IV injection 3 times per week for 1 week
62197083|NCT03504722|EXPERIMENTAL|RESCUE+PE|RESCUE is designed to adapt to individualized needs based on each veteran's performance. The volunteer training consists of weekly sessions lasting 90 minutes each and occurring at area Society for the Prevention of Cruelty to Animals (SPCA) facilities.All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD.
62197084|NCT03504722|ACTIVE_COMPARATOR|PE+delayed RESCUE|All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD.
62197085|NCT03780777|EXPERIMENTAL|Home Hazard Removal Group|A tailored home-modification (home-hazard removal) intervention for residents with a high fall risk, delivered in the home by occupational therapists over one to two visits and with a booster session at three months.
62197086|NCT02544165|EXPERIMENTAL|Caffeine intake|100mg of Caffeine intake
62197087|NCT02544165|EXPERIMENTAL|Cigarette smoking|smoking of one cigarette
62197088|NCT02544165|EXPERIMENTAL|Caffeine intake and Cigarette smoking|100mg of Caffeine intake and smoking of one cigarette
62197089|NCT02544165|NO_INTERVENTION|Control group|no intervention group
62575873|NCT01996254|EXPERIMENTAL|SPRINT Group 1|Subjects in Group 1 will have a Lead placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
62575874|NCT01996254|SHAM_COMPARATOR|SPRINT Group 2|Subjects in Group 2 will have a Lead placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System for a total of 8 weeks. They will receive 4 weeks of stimulation and 4 weeks with no stimulation.
62575875|NCT01052194|EXPERIMENTAL|25 mg b.i.d. VX-509|
62575876|NCT01052194|EXPERIMENTAL|50 mg b.i.d. VX-509|
62575877|NCT01052194|EXPERIMENTAL|100 mg b.i.d. VX-509|
62010452|NCT06393192||Epidural analgesia (EA) only group|"In this group 20 patients fulfilling the eligibility criteria, the epidural needle was inserted at the level of the intervertebral gap that separates the 2nd \& 3rd spinal bones.~Upon locating the epidural space through the utilization of the loss of resistance to saline approach, the tip of a spinal needle was inserted through the epidural needle. In order to reach a specific level of sensory block up to the sixth thoracic dermatome, each pregnant woman was administered intrathecal anesthetic consisting of 0.75 percent bupivacaine in a volume of 1.3-1.7 milliliter.~Subsequently, we removed the needle \& proceeded to place an epidural catheter through the epidural needle as a precautionary measure in the event of intrathecal anesthetic failure. The EA group received a single dosage of six milliliters of saline solution containing nine milligrams of bupivacaine (0.15%) \& 2 mg of morphine via the epidural catheter for postoperative pain management."
62010453|NCT06393192||Quadratus Lumborum 2 (QL2) group|"In this group 20 patients fulfilling the eligibility criteria, the ultrasound transducer was positioned horizontally at the level of L2-3 on both sides of the body. It was adjusted until the Shamrock sign created by the QL muscle, psoas major, and erector spinae was visible. The imaging depth was set among 0 as well as 9.9 cm. Needles were inserted from the front-lateral to back-medial direction. An injection of local anesthetic was administered behind the QL muscle.0.2% bupivacaine were administered at a volume of thirty milliliters at the specified sites on each side, resulting in a total of Sixty mL"
62010454|NCT06393192||Quadratus Lumborum 3 (QL3) group|"In this group 20 patients fulfilling the eligibility criteria, the ultrasound transducer was positioned horizontally at the level of L2-3 on both sides of the body. It was adjusted until the Shamrock sign created by the QL muscle, psoas major, and erector spinae was visible. The imaging depth was set among 0 as well as 9.9 cm. Needles were inserted from the front-lateral to back-medial direction. An injection of local anesthetic was administered among the QL and the psoas major muscles.0.2% bupivacaine were administered at a volume of thirty milliliters at the specified sites on each side, resulting in a total of Sixty mL"
62010455|NCT06393192||Quadratus Lumborum 2+3 (QL2+3) group|In this group 20 patients fulfilling the eligibility criteria, the QL2+3 block can be performed in a single plane with only one puncture on each side. 0.2 percent bupivacaine solution of fifteen milliliters were administered at each injection site, with the needle being inserted once on each side
62575878|NCT01052194|EXPERIMENTAL|150 mg b.i.d. VX-509|
62575879|NCT01052194|PLACEBO_COMPARATOR|Placebo|
62575880|NCT06283836|ACTIVE_COMPARATOR|Group D|Continuous infusion of dexmedetomidine during intervention ( 1ug/kg over 15 minutes then 0.4 ug/kg/hour)
62010456|NCT02506114|EXPERIMENTAL|Arm A: PROSTVAC-V/F|PROSTVAC-V: 2 x 10\^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10\^9pfu; subcutaneous; Days 15, and 36.
62399469|NCT02641691|EXPERIMENTAL|Arm 1: Radiation/Oxaliplatin/Leucovorin/5-FU|"* Radiotherapy will consist of five fractions, delivered once daily, to a total dose of 25Gy at 5 Gy per fraction.~* An optional concomitant boost may be delivered to the primary tumor of 1-2 Gy per day (30-35 Gy to tumor total). If a boost is given then the maximum allowed dose to small bowel is 25 Gy.~* Chemotherapy should begin two weeks (9-12 working days) after completion of radiotherapy.~* Oxaliplatin will be given intravenous (IV) over 2 hours on Day 1 every 14 days for a maximum of 8 cycles.~* Leucovorin will be given IV over 2 hours on Day 1 every 14 days for a maximum of 8 cycles.~* 5-FU bolus will given IV push on Day 1 every 14 days for a maximum of 8 cycles.~* 5-FU infusion will be given continuous IV on Day 1 over 46 hours every 14 days for a maximum of 8 cycles~* Alternatively, capecitabine/oxaliplatin (CAPE PO 1000 mg/m2 BID days 1-14 Q21 days, oxaliplatin IV 130 mg/m2 IV Q21 days on day 1) x 5 cycles over 15 weeks may be administered instead of FOLFOX"
62399470|NCT03647995|ACTIVE_COMPARATOR|Probiotic-receiving group|The probiotic-receiving group will receive once daily probiotics containing 25Bn CFU of which: 5Bn CFU Lactobacillus rhamnosus GG, 5Bn CFU Sacchromyces boulardii, 5Bn CFU Bifidobacterium breve, 4.5Bn CFU Bifidobacterium lactis, 2.5 Bn CFU Lactobacillus acidophilus, 2.5Bn CFU Lactobacillus plantarum and 500Mn CFU Lactobacillus reuteri.
62399471|NCT03647995|PLACEBO_COMPARATOR|Placebo|The placebo group will receive once daily, identical capsules containing 0 Bn CFU.
62399472|NCT00716365|EXPERIMENTAL|HemCon|"The purpose of this trial is to test HemCon pad after diagnostic percutaneous coronary angiography as an adjunct to manual compression to better control vascular access site bleeding and reduce time-to-hemostasis.~The HemCon bandage (containing a carbohydrate called chitosan, found in the shells of shrimp, lobster and beetles) will be used to shorten the time needed to achieve hemostasis, time to patient's ambulation, and patient's."
62399473|NCT03539666|EXPERIMENTAL|Pork|Standard American Diet with meat source: lean pork. Diet adheres to 2015-2020 Guidelines for Americans.
62399474|NCT03539666|EXPERIMENTAL|Poultry|Standard American Diet with meat source: chicken. Diet adheres to 2015-2020 Guidelines for Americans.
62575881|NCT06283836|ACTIVE_COMPARATOR|Group R|Target-controlled infusion of remifentanil ( 2ng//ml- plasma concentration)
62010457|NCT02506114|EXPERIMENTAL|Arm B: Ipilimumab Monotherapy|Ipilimumab: 3 mg/kg; intravenously; Days 1 and 21.
62575882|NCT05954195|ACTIVE_COMPARATOR|HIIT group|The group who received high intensity interval training
62575883|NCT05954195|PLACEBO_COMPARATOR|control/comparator group|control group that might be placebo group, standard care group or no intervention group
62575884|NCT02496078|ACTIVE_COMPARATOR|Active dual arm|"Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from day 1 to 12 week~Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from 12 to 24 week and follow up to week 48"
62575885|NCT02496078|PLACEBO_COMPARATOR|Placebo arm|"Daclatasvir placebo in tablet form QD and Asunaprevir placebo in soft capsule form BID from day 1 to 12 week~Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from 12 to 36 week and follow up to week 60"
62575886|NCT01413698||Patient with chronic cough|
62010458|NCT02506114|EXPERIMENTAL|Arm C: Combined PROSTVAC-V/F + Ipilimumab|PROSTVAC-V: 2 x 10\^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10\^9pfu; subcutaneous; Days 15, and 36. Ipilimumab: 3 mg/kg; intravenously; Days 15 and 36.
62197090|NCT01727505|ACTIVE_COMPARATOR|Sequence A: Conventional-Volume Guarantee|This is a crossover study. Infants will be assigned to one of two sequences. Sequence A consists of a 24-hour period during which the infant receives conventional mechanical ventilation followed by a second 24 hour period during which the infant receives volume guarantee ventilation.
62197091|NCT01727505|ACTIVE_COMPARATOR|Sequence B: Volume Guarantee-Conventional|This is a crossover study. Infants will be assigned to one of two sequences. Sequence B consists of a 24-hour period during which the infant receives volume guarantee ventilation followed by a second 24 hour period during which the infant receives conventional mechanical ventilation.
62197092|NCT06202976||Patients|
62197093|NCT04507568|EXPERIMENTAL|Person-Centered Model-of-Care|Patients randomized to the person-centered model-of-care will have a 30 minute education session with a radiation therapist in addition to the standard of care, radiation therapy procedures.
62197094|NCT04507568|OTHER|Standard Model-of-Care|Patients randomized to the standard model of care will be treated as per standard of care.
62575887|NCT02464332|EXPERIMENTAL|BLZ-100|"All participants in the study will receive the investigational drug product BLZ-100.~In part 1 of the study, two dose levels of BLZ-100 will be evaluated (3 mg and 12 mg) in 6 subjects, with a 2-3 post-dose imaging window.~In part 2 of the study up to 15 additional subjects will be randomized to one of three imaging interval groups (up to 6 subjects/interval): Early Imaging (within 1 day post-BLZ-100 dose), Intermediate Imaging (2 - 3 days post- BLZ-100 dose), and Late Imaging (4 - 7 days post- BLZ-100 dose)."
62575888|NCT02786875|EXPERIMENTAL|Group A (high intensity program):|"Diet: low glycemic index (GI) Mediterranean diet. All carbohydrate foods will be low GI choices (GI\<70 on bread scale, e.g. legumes, pasta al dente, barley, oat, apples, oranges, berries, nuts) within a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, \<7% SFA).~Moderate physical activity: brisk walk of at least 30min per day (or approximately 5000 steps) more than the habitual physical activity.~Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach blood levels of 60-80 ng/ml of 25(OH)D."
62010459|NCT01328002|EXPERIMENTAL|Milnacipran|oral administration, twice daily dosing
62010460|NCT01328002|PLACEBO_COMPARATOR|Placebo|oral administration, twice daily dosing
62010461|NCT05735080|EXPERIMENTAL|Part A: Dose Escalation|Multiple doses of INX-315 monotherapy, oral administration
62010462|NCT05735080|EXPERIMENTAL|Part B: Ovarian Dose Expansion|INX-315 monotherapy, oral administration
62010463|NCT05735080|EXPERIMENTAL|Part C: ER+/HER2- BC Dose Expansion|INX-315 in combination with CDK4/6i and endocrine therapy, oral administration
62010464|NCT05735080|EXPERIMENTAL|Part A INX-315 + Fulvestrant|INX-315 dose plus Fulvestrant 500mg
62197095|NCT05261373|NO_INTERVENTION|Control (CG+INACT)|Participants who do not receive neither nutritional education nor exercise program. They will be instructed to maintain their normal life habits with respect to physical activity and diet.
62575889|NCT02786875|ACTIVE_COMPARATOR|Group B (lower intensity program)|"Diet: general recommendations for a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, \<7% SFA).~Basic physical activity: general recommendations to avoid sedentary behaviour. Vitamin D supplement (cholecalciferol) will be given only if vitamin D insufficiency is detected to reach blood levels of 30 ng/ml of 25(OH)D."
62197096|NCT05261373|ACTIVE_COMPARATOR|Moderate-intensity continuous training (CG+MICT)|Participants who do not receive nutritional education but are enrolled in a moderate-intensity continuous training exercise program.
62575890|NCT04994691|PLACEBO_COMPARATOR|No message|No message sent
62575891|NCT04994691|ACTIVE_COMPARATOR|Standard message|2 MyChart reminders that child is overdue for well child check visit
62197097|NCT05261373|ACTIVE_COMPARATOR|High-intensity interval training (CG+HIIT)|Participants who do not receive nutritional education but are enrolled in a high-intensity interval training exercise program.
62197098|NCT05261373|ACTIVE_COMPARATOR|Nutritional Education (EDU+INACT)|Participants who receive nutritional education but not an exercise program.
62399475|NCT02301065||Stem Cell Donors|Allogeneic hematopoietic stem cell transplant (HSCT) donors. Blood samples for phenotypes research will be collected once from donors, prior to apheresis for collection of donor stem cells.
62399476|NCT02301065||Stem Cell Recipients|Allogeneic hematopoietic stem cell transplant (HSCT) recipients. Blood samples will be drawn prior to transplantation and every two weeks, up to day 100 post-transplantation.
62399477|NCT04296331||POC only|Participants who enter the DC Department of Corrections within the first 2 months of the study will be offered opt-out Point-of-Care (POC) rapid testing
62575892|NCT04994691|ACTIVE_COMPARATOR|Tailored message|2 MyChart reminders that child is overdue for well child check visit with date of last WCC and age
62575893|NCT01199835|EXPERIMENTAL|high calcium|Dietary intake of calcium \~ 1500 mg/ d, including \~1200 mg/d from dairy products
62575894|NCT01199835|ACTIVE_COMPARATOR|Low calcium|Low dietary intake of calcium, i.e. \~ \<600 mg/d, including 0-1 portion of dairy products
62575895|NCT04804423|ACTIVE_COMPARATOR|Fluoride varnish (Duraphat®)|Fluoride varnish application is recommended by the German National Health System for managing hypersensitivity and dental caries. Sodium fluoride varnish (Duraphat®) will be applied on hypersensitive active carious lesions (ICDAS 5).
62575896|NCT04804423|EXPERIMENTAL|Silver fluoride and potassium iodide (Riva Star®)|Silver fluoride and potassium iodide (Riva Star®) is primarily indicated for relieving hypersensitivity will be applied on hypersensitive active carious lesions (ICDAS 5) following isolation of the affected teeth and according to manufacturer's instructions.
62575897|NCT02882360|EXPERIMENTAL|Elective LSCS--Kerlix AMD|Kerlix-AMD applied to wound site pre-operatively (3 days) and post-operatively for 2 weeks
62197099|NCT05261373|EXPERIMENTAL|Nutritional Education Moderate-intensity continuous training (EDU+MICT)|Participants who receive nutritional education and are enrolled in a moderate-intensity continuous training exercise program.
62197100|NCT05261373|EXPERIMENTAL|Nutritional Education High-intensity interval training (EDU+HIIT)|Participants who receive nutritional education and are enrolled in a high-intensity interval training exercise program.
62197101|NCT00450229|EXPERIMENTAL|Arm I|Patients receive low-dose, nutritional-grade oral diindolylmethane (DIM) twice daily for 21-28 days in the absence of disease progression or unacceptable toxicity. Treatment may continue for up to 60 days, if surgery is delayed.
62197102|NCT00450229|EXPERIMENTAL|Arm II|Patients receive high-dose, nutritional-grade oral DIM twice daily as in arm I.
62197103|NCT00450229|PLACEBO_COMPARATOR|Arm III|Patients receive oral placebo twice daily for 21-28 days in the absence of disease progression or unacceptable toxicity. Treatment may continue for up to 60 days, if surgery is delayed.
62197104|NCT00309647|EXPERIMENTAL|H5N1 Formulation 1 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 1 vaccine at a 21-day interval
62197105|NCT00309647|EXPERIMENTAL|H5N1 Formulation 2 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 2 vaccine at a 21-day interval
62197106|NCT00309647|EXPERIMENTAL|H5N1 Formulation 3 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 3 vaccine at a 21-day interval
62399478|NCT04296331||POC + Ag/Ab|Participants who enter the DC Department of Corrections within the third and fourth months of the study will be offered opt-out POC and 4th generation laboratory-based antigen/antibody testing (Ag/Ab)
62197107|NCT00309647|EXPERIMENTAL|H5N1 Formulation 4 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 4 vaccine at a 21-day interval
62399479|NCT04296331||Ag/Ab only|Participants who enter the DC Department of Corrections within the fifth and sixth months of the study will be offered Ag/Ab testing.
62399480|NCT02190604|EXPERIMENTAL|Part 1 Cohort 1: QBW251|Single dose of QBW251 10 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
62575898|NCT02882360|PLACEBO_COMPARATOR|Elective LSCS--Placebo|Normal gauze applied to wound site pre-operatively for 3 days and post-operatively for 2 weeks
62575899|NCT02882360|EXPERIMENTAL|Labouring LSCS--Kerlix AMD|Kerlix-AMD applied to wound post-operatively for 2 weeks
62575900|NCT02882360|PLACEBO_COMPARATOR|Labouring LSCS--Placebo|Normal gauze applied to wound post-operatively for 2 weeks
62575901|NCT04429100||liver fibrosis stage F0|
62575902|NCT04429100||early-stage liver fibrosis (F1-2)|
62575903|NCT04429100||late-stage liver fibrosis (F3-4)|
62575904|NCT03660111|OTHER|spirometry|single spirometry: only a routine diagnostic test
62575905|NCT02275546|EXPERIMENTAL|Applicator→No Applicator (manual)|Treatment period 1: Participants will use applicator to insert vaginal ring. Treatment period 2: Participants will manually insert vaginal ring using fingers only.
62575906|NCT02275546|EXPERIMENTAL|No applicator (manual)→Applicator|Treatment period 1: Participants will manually insert vaginal ring using fingers only. Treatment period 2: Participants will use applicator to insert vaginal ring.
62010465|NCT04816006|EXPERIMENTAL|Arm I (Aerobic Exercise)|Patients attend 3 weekly exercise sessions in weeks 1-2, 2 sessions each week in weeks 3-4, 1 session each week in weeks 5-8, biweekly sessions across weeks 9-16, and monthly sessions in weeks 17-24 for a total of 20 supervised sessions. Patients undergo a gait assessment and magnetic resonance imaging (MRI), as well as wear an accelerometer throughout the study.
62575907|NCT01760174|ACTIVE_COMPARATOR|Bupivacain-infusion in epidural catheter|Bupivacain-infusion in epidural catheter and intermittent isotonic potassium chloride bolus in transversus abdominis plane catheter.
62399481|NCT02190604|EXPERIMENTAL|Part 1 Cohort 2: QBW251|Single dose of QBW251 25 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
62010466|NCT04816006|ACTIVE_COMPARATOR|Arm II (Health Education)|Patients participate in up to 9 monthly classes/webinars. Patients also receive informational pdfs, videos, and/or podcasts, and a one-year subscription to the Mayo Clinic Health Letter. Patients undergo a gait assessment and MRI, as well as wear an accelerometer throughout the study.
62399482|NCT02190604|EXPERIMENTAL|Part 1 Cohort 3: QBW251|Single dose of QBW251 75 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
62399483|NCT02190604|EXPERIMENTAL|Part 1 Cohort 4: QBW251|Single dose of QBW251 150 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
62399484|NCT02190604|EXPERIMENTAL|Part 1 Cohort 5: QBW251|Single dose of QBW251 300 mg in healthy volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
62575908|NCT01760174|ACTIVE_COMPARATOR|Ropivacaine bolus in transversus abdominis plane catheter|Intermittent ropivacaine bolus in bilateral transversus abdominis plane catheter and isotonic potassium chloride infusion in epidural catheter.
62575909|NCT05783440|EXPERIMENTAL|Intervention group|Applying a system in which patients undergoing surgery can report pain scores and other pain-related outcomes with their own smartphone, both during hospitalization and for three months after discharge. During clinical admission patient reported pain scores \> 3 (NRS 0-10) in the intervention group are immediately passed on to the nurse who will receive a notification on a smartphone. In the control group the patients' pain scores are not sent to the nurse. After discharge, patients will report pain scores every two weeks for three months.
62575910|NCT05783440|NO_INTERVENTION|control group|Participants in the control group report postoperative pain scores and other pain related outcomes with their own smartphone. Their reported pain-scores will not be surpassed to the nurses on the ward. All patient reported pain-scores by smartphone are stored in a database that is not accessible to medical or nursing staff from the nursing ward.
62783202|NCT02021695||Group I: Non-diabetic controls|"Group I: Non-diabetic controls Good overall health without history of Type II diabetes. Normal fasting glucose level (\<100 mg/dL) and HbA1C \< 5.7%~Also:~1. Must provide informed consent~2. Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus~3. In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)~4. Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
62783203|NCT02021695||Group II: Diabetic with HbA1C<7%|"Group II:~HbA1C\<7%~Also:~1. Must provide informed consent~2. Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus~3. In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)~4. Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
62783204|NCT02021695||Group III: Good controlled diabetics with 7 % <HbA1C < 10%|"Group III Good controlled diabetics with 7 % \<HbA1C \< 10%~Also:~1. Must provide informed consent~2. Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus~3. In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)~4. Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
62783205|NCT02021695||Group IV: Poorly controlled diabetics with HbA1C > 10%.|"Group IV:~Poorly controlled diabetics with HbA1C \> 10%.~Also:~1. Must provide informed consent~2. Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus~3. In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)~4. Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
62399485|NCT02190604|EXPERIMENTAL|Part 1 Cohort 6: QBW251|Single dose of QBW251 500 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
62197108|NCT00309647|ACTIVE_COMPARATOR|H5N1 Formulation 5 Group|Subjects in this group received 2 doses of H5N1 formulation 5 vaccine at a 21-day interval
62197109|NCT00309647|ACTIVE_COMPARATOR|H5N1 Formulation 6 Group|Subjects in this group received 2 doses of H5N1 formulation 6 vaccine at a 21-day interval
62197110|NCT00309647|ACTIVE_COMPARATOR|H5N1 Formulation 7 Group|Subjects in this group received 2 doses of H5N1 formulation 7 vaccine at a 21-day interval
62197111|NCT00309647|ACTIVE_COMPARATOR|H5N1 Formulation 8 Group|Subjects in this group received 2 doses of H5N1 formulation 8 vaccine at a 21-day interval
62197112|NCT04292587||Women with hirsutism|Women between the ages of 18-45 with hirsutism
62399486|NCT02190604|EXPERIMENTAL|Part 1 Cohort 6: QBW251(fed)|Single dose of QBW251 500 mg (fed). single dose with food for a preliminary assessment of the effect of food on the absorption of QBW251 in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
62399487|NCT02190604|EXPERIMENTAL|Part 1 Cohort 7: QBW251|Single dose of QBW251 750 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
62010467|NCT05789732|PLACEBO_COMPARATOR|Placebo group|Patients in this group will receive placebo treatment once daily.
62010468|NCT05789732|EXPERIMENTAL|Silodosin group|Patients will receive Silodosin 8 mg once daily.
62197113|NCT04292587||Women without hirsutism|Women between the ages of 18-45 without hirsutism
62197114|NCT06327776||MILD TBI Diagnostic and long term prognostic study|1000 patients suffering mild Traumatic Brain Injury
62197115|NCT02222298|EXPERIMENTAL|VAAPS group|patients undergoing video assisted ablation of pilonidal sinus
62197116|NCT02222298|ACTIVE_COMPARATOR|conventional treatment group|patients undergoing conventional off-midline Bascom cleft lift procedure
62197117|NCT00558792|EXPERIMENTAL|Isovue 370, 70 mL|iopamidol injection 370, 70 mL
62197118|NCT00558792|EXPERIMENTAL|Isovue 370, 80 mL|iopamidol injection 370, 80 mL
62399488|NCT02190604|EXPERIMENTAL|Part 1 Cohort 8: QBW251|Single dose of QBW251 1000 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
62575911|NCT05950919|EXPERIMENTAL|TASKPEN|"The TASKPEN intervention is a package of five evidence-based intervention (EBI) components that enhances WHO's Package of Essential Noncommunicable Disease Intervention for Primary Care (WHO-PEN) and includes a multi-faceted implementation strategy centred on service integration within routine HIV care settings. The EBI components and multi-faceted strategy have been adapted to the Zambian setting during recently completed formative work."
62010469|NCT05789732|EXPERIMENTAL|Tadalafil group|Patients will receive Tadalafil 5 mg once daily.
62010470|NCT05789732|EXPERIMENTAL|Silodosin and Tadalafil|Patients will receive Silodosin 8mg in combination with Tadalafil 5 mg once daily.
62010471|NCT05210036|ACTIVE_COMPARATOR|Ultrasound Therapy|"The patients in group 1 received therapeutic US with BTL-4710 ultrasound device.~The therapeutic US was administered at the frequency of 3 megahertz, intensity of 1.5 w/cm2 and an area of 25 cm2 for 5 minutes in the continue mode.~The procedure of therapeutic US was performed by a physiotherapist experienced in using the device for 15 sessions in total 5 times a week for 3 weeks."
62197119|NCT00558792|EXPERIMENTAL|Isovue 370, 90 mL|iopamidol injection 370, 90 mL
62197120|NCT02872558|OTHER|Acute Otitis Media Choice Decision Aid|"For patients whose clinician is randomized to the decision aid arm:~1. The study coordinator will provide the decision aid for the parent/clinician dyad.~2. The study coordinator will provide a color-printed copy of the decision aid to the clinician prior to the clinician having the antibiotics discussion with the parents.~3. The study coordinator will offer to provide the treating clinician a concise refresher of the content included in the decision aid in the context of the trial.~4. The clinician will then, using the decision aid as a tool to facilitate discussion regarding the natural course of AOM, pain control, antibiotics exposure and deeper infections.~5. The clinician will then engage the parents in a shared decision regarding the use of immediate antibiotics versus a wait and watch prescription that is consistent with both the parent's values and preferences and the clinician's level of comfort."
62197121|NCT02872558|OTHER|Usual Care|the clinician will discuss management options with the parent in the clinician's usual fashion.
62197122|NCT02172911|EXPERIMENTAL|Cohort I: INO-3112: Curative Intent|Cohort I included participants with biopsy-proven, stage IB-IVB inoperable, newly diagnosed invasive cervical carcinoma associated with HPV-16 and/or HPV-18 treated with standard chemoradiation therapy with curative intent. Participants received a 4-dose series of 1.1 mL IM injection of INO-3112 followed immediately by EP with CELLECTRA™-5P.
62197123|NCT02172911|EXPERIMENTAL|Cohort II: INO-3112: Salvage Therapy|Cohort II included participants with persistent and/or recurrent cervical carcinoma associated with HPV-16 and/or HPV-18 who had been treated with salvage therapy (chemotherapy and/or radiation therapy). Participants received a 4-dose series of 1.1 mL IM injection of INO-3112 followed immediately by EP with CELLECTRA™-5P.
62197124|NCT02623751|EXPERIMENTAL|KHK2375 PO and Exemestane PO|KHK2375 and Exemestane
62197125|NCT00470197|EXPERIMENTAL|Arm I|Patients receive flavopiridol IV over 30 minutes on days 1, 2, and 3. Patients receive cytarabine IV continuously over 72 hours beginning on day 6 and mitoxantrone hydrochloride IV over 60-120 minutes on day 9.
62399489|NCT02190604|PLACEBO_COMPARATOR|Part 1 Placebo|Placebo to QBW251 in all cohorts of part 1 in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
62399490|NCT02190604|EXPERIMENTAL|Part 2 Cohort 1: QBW251|Multiple doses of QBW25 150 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
62197126|NCT06375486|EXPERIMENTAL|AK112 arm|The patients will receive AK112（PD-1/VEGF bispecific antibody）plus HAIC
62399491|NCT02190604|EXPERIMENTAL|Part 2 Cohort 2: QBW251|Multiple doses of QBW251 400 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
62399492|NCT02190604|EXPERIMENTAL|Part 2 Cohort 3: QBW251|Multiple doses of QBW251 750 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
62399493|NCT02190604|EXPERIMENTAL|Part 2 Cohort 4: QBW251|Multiple doses of QBW251 450 mg bid in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
62399494|NCT02190604|EXPERIMENTAL|Part 2 Cohort 5: QBW251|Multiple doses of QBW251 750 mg bid in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
62399495|NCT02190604|PLACEBO_COMPARATOR|Part 2 Placebo|Placebo to QBW251 in all cohorts of part 2 in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
62399496|NCT02190604|EXPERIMENTAL|Part 3 Cohort 1: QBW251|150 mg b.i.d. Multiple doses. Patients having a class III, IV, V, or VI mutation on one allele and any other CFTR mutation on the other allele in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
62197127|NCT01795599|EXPERIMENTAL|mifepristone/misoprostol|
62197128|NCT01795599|ACTIVE_COMPARATOR|misoprostol|
62197129|NCT01795599|ACTIVE_COMPARATOR|mifepristone|
62197130|NCT01088542|NO_INTERVENTION|No intervention|Communities in the no intervention arm received no intervention from the project and continued to implement prevention services as usual.
62197131|NCT01088542|EXPERIMENTAL|Communities That Care Intervention|Communities randomly assigned to the experimental condition received 5 years of training and technical assistance (from 2003 to 2008) to implement the Communities That Care (CTC) prevention system in their communities. They also received 5 years of funding to support a full-time community coordinator and 4 years of seed money to implement tested and effective prevention programs selected as a result of their CTC process.
62197132|NCT04371120||Brain Injury Survivors|Traumatic or acquired brain injury survivors, patients of RHI
62197133|NCT00614562|EXPERIMENTAL|NAVA|
62197134|NCT00803192|ACTIVE_COMPARATOR|Test Drug|
62197135|NCT00803192|ACTIVE_COMPARATOR|Reference Drug|
62197136|NCT04974762|ACTIVE_COMPARATOR|Wound infiltration|Standard intervention - surgical infiltration with local anesthetics
62197137|NCT04974762|EXPERIMENTAL|Truncal blocks|Truncal block for anesthetics
62197138|NCT04635098|EXPERIMENTAL|dexmedetomidine|0.5μg/kg bolus injection in 10 minutes followed by 0.1µg/kg/hr pump infusion from 23:30 pm to 6:30 am
62197139|NCT04635098|PLACEBO_COMPARATOR|saline|the same rate as dexmedetomidine
62197140|NCT03656224||Observational (survey)|Participants complete surveys over 15 minutes at 1-2 days before discharge and at 1 month after discharge.
62197141|NCT05052918|ACTIVE_COMPARATOR|Exercise|"Patients with prediabetes undergoing a 12-week exercise program~(1 hour of moderate-intensity aerobic exercise 3 days a week for 12 weeks)"
62197142|NCT05052918|NO_INTERVENTION|Control|Patients with prediabetes with no intervention
62399497|NCT02190604|EXPERIMENTAL|Part 3 Cohort 2: QBW251|450 mg b.i.d. Multiple doses. Patients having a class III, IV, V, or VI mutation on one allele and any other CFTR mutation on the other allele in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
62399498|NCT02190604|EXPERIMENTAL|Part 3 Cohort 3: QBW251|450 mg b.i.d. Multiple doses. Patients who are homozygous for the F508del mutation in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
62783206|NCT03144986|EXPERIMENTAL|Deep insula-coil rTMS|"Active treatment phase consists of deep rTMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase.~Maintaince treatment phase includes two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks."
62197143|NCT05052918|NO_INTERVENTION|Metformin|Patients with prediabetes using metformin
62399499|NCT02190604|PLACEBO_COMPARATOR|Part 3 Placebo|Placebo to QBW251 in all cohorts of part 3 in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
62399500|NCT04214145|EXPERIMENTAL|Phenylephrine|
62575912|NCT05950919|NO_INTERVENTION|Standard of Care|Screening, diagnosis, and treatment of cardio-metabolic NCDs are generally unavailable in the clinical departments where most PLHIV seek and receive health services. When these services are available, they tend to be siloed and offered only for hypertension in general outpatient medical settings that provide urgent care-like services. Healthcare workers do not have protocolized algorithms for NCD management in HIV service delivery settings. NCD equipment is often unavailable in ART and differentiated service delivery (DSD) clinics; most health facilities do not offer haemoglobin A1c or lipid panel testing; and fragmented NCD supply chain management systems mean that essential medications for the management of hypertension, diabetes, and dyslipidemia are often unavailable
62575913|NCT00441129|ACTIVE_COMPARATOR|Conventional insulin pump therapy|Conventional insulin pump therapy or continuous subcutaneous insulin infusion (CSII)
62575914|NCT00441129|EXPERIMENTAL|Minimed paradigm Real Time Sytem|Minimed paradigm Real Time Sytem
62575915|NCT02555150|ACTIVE_COMPARATOR|PRC-063|Titration during which subjects will be titrated from a starting dose of 45 mg/day (dosed once daily) of PRC-063 oral capsules up to his/her final dose (45, 70 or 100 mg/day of PRC-063). This phase will be 10 to 21 days long.
62197144|NCT01833377|EXPERIMENTAL|caraway sample|caraway sample
62197145|NCT01833377|ACTIVE_COMPARATOR|Placebo|
62783207|NCT03041896||Decompression|Standard of care decompression for spinal stenosis, 1 or 2 levels.
62197146|NCT05807906|EXPERIMENTAL|Intervention Group|virtual reality will be applied in the fistula puncture procedure in patients receiving hemodialysis treatment.
62197147|NCT05807906|NO_INTERVENTION|Control Group|Routine nursing care and diet compliance narration
62399501|NCT04214145|EXPERIMENTAL|Norepinephrine|
62399502|NCT04214145|EXPERIMENTAL|Vasopressin|
62399503|NCT05103462|EXPERIMENTAL|Telehealth Physical Therapy|Weekly sessions of education, advice and exercise instruction provided by a licensed physical therapist using real-time, interactive video conferencing platform.
62783208|NCT03041896||Fusion|Standard pedical and rod fixation with standard decompression, 1 or 2 levels.
62197148|NCT02478437|ACTIVE_COMPARATOR|Group 1|Conventional radiofrequency ablation (RFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.
62197149|NCT02478437|ACTIVE_COMPARATOR|Group 2|Cooled radiofrequency ablation (CRFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.
62197150|NCT00758342|EXPERIMENTAL|Travoprost 0.004% + Brinzolamide 1.0%|Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
62399504|NCT00012350|EXPERIMENTAL|Oral FTI (R115777) Treatment|"Patients will be administered oral FTI (R115777) at a dose of 300-mg by mouth (PO) twice a day (BID). Drug will be taken without regard to meals.~The study regimen will consist of 3 weeks of treatment followed by one week off for a total cycle duration of 4 weeks."
62010472|NCT05210036|ACTIVE_COMPARATOR|High-Intensity Laser Therapy|"The patients in group 2 received HILT with BTL-6000 high-intensity laser device.~The therapy consisted of 2 stages in each session.~* The first stage was performed in analgesic mode for analgesic effect at the frequency of 25 Hz, in the wavelength of 1064 nm, the power of 8 watt, the dose of 12 j/cm2, the area of 25 cm2, and 300 j in total for 2 minutes and 30 seconds.~* The second stage was performed in bio-stimulating mode for biostimulation effect in the wavelength of 1064 nm, the power of 7 watt, the dose of 100 j/cm2, the area of 25 cm2, and 2500 j in total for 5 minutes and 57 seconds.~The total length of administration was approximately 8.5 minutes for each stage.~The procedure of the therapy was performed by a physiotherapist experienced in using the device for 9 sessions in total 3 times a week for 3 weeks."
62197151|NCT00758342|ACTIVE_COMPARATOR|Travoprost 0.004% + Tears Natural|Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
62197152|NCT01340001|SHAM_COMPARATOR|Sham Electrical stimulation of the nucleus basalis of Meynert|Deep brain stimulation
62197153|NCT01340001|EXPERIMENTAL|Electrical stimulation of the nucleus basalis of Meynert|Deep brain stimulation
62197154|NCT04518046|EXPERIMENTAL|Phase 1: Dose Escalation|Patients with poor- or intermediate-risk RCC with clear cell component for first-line treatment.
62197155|NCT04518046|EXPERIMENTAL|Phase 1b Dose Escalation Cohort A|Patients with poor- or intermediate-risk RCC with clear cell component for first-line treatment
62197156|NCT04518046|EXPERIMENTAL|Phase 1b Dose Escalation Cohort B|Patients with favorable-risk RCC with clear cell component for first-line treatment.
62399505|NCT06724835|EXPERIMENTAL|Autologous targeted Nectin4 chimeric antigen receptor T cell injection|Autologous targeted Nectin4 chimeric antigen receptor T cell injection
62399506|NCT01246193|EXPERIMENTAL|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 80mg/S-Amlodipine 2.5mg
62575916|NCT02555150|ACTIVE_COMPARATOR|lisdexamfetamine dimesylate|Titration during which subjects will be titrated from a starting dose of 30 mg/day of lisdexamfetamine up to his/her final dose (30, 50 or 70 mg/day of LDX). This phase will be 10 to 21 days long.
62575917|NCT02555150|PLACEBO_COMPARATOR|Placebo|Subjects will be dosed once daily with a placebo oral capsule for 10 to 21 days.
62575918|NCT01910584||Novasure treated group|patients diagnosed menorrhea were treated with novasure endometrial ablation
62575919|NCT04707469|EXPERIMENTAL|Oral semaglutide 50 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12), 25 mg (week 13-16) and 50 mg (week 17-68).
62575920|NCT04707469|EXPERIMENTAL|Oral semaglutide 25 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12) and 25 mg (week 13-68).
62575921|NCT04707469|ACTIVE_COMPARATOR|Oral semaglutide 14 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8) and 14 mg (week 9-68).
62575922|NCT00910533|ACTIVE_COMPARATOR|Early Lyme neuroborreliosis patients|
62575923|NCT00910533|NO_INTERVENTION|control subjects|Control subjects without a history of Lyme borreliosis.
62575924|NCT04606004|EXPERIMENTAL|Experimental (standard of care + stool application)|In addition to standard of care, they will apply stool from the stoma bag 4 weeks prior, twice daily for 10 minutes at a time.
62575925|NCT04606004|ACTIVE_COMPARATOR|Control group (standard of care)|Will follow standard of care for skin care pre-operatively. They will not be applying ostomy stool output to the skin but can apply an OTC skin barrier such as Aquaphor, Desitin, or Vitamin A\&D if the patient is experiencing skin redness from urine incontinence.
62197157|NCT00862836|EXPERIMENTAL|1|Vandetanib added to standard therapy (pegliposomal doxorubicin)
62399507|NCT01246193|ACTIVE_COMPARATOR|Combination Therapy|Co-administration of single oral doses of a 80mg tablet of Telmisatan and a 2.5 mg tablet of S-Amlodipine
62575926|NCT06574490|EXPERIMENTAL|Myofunctional +|A series of myofunctional exercises
62575927|NCT06574490|ACTIVE_COMPARATOR|Myofunctional -|No exercises
62575928|NCT03369886|OTHER|Early glaucoma group|Patients whose visual field mean deviation is \> -6dB OCT angiography will be taken but there are no difference between patients' group. The same OCT angiography protocol will be applied to all patients' group.
62575929|NCT03369886|OTHER|Advanced glaucoma group|Patients whose visual field mean deviation is \< -6dB OCT angiography will be taken but there are no difference between patients' group. The same OCT angiography protocol will be applied to all patients' group.
62575930|NCT06418724|EXPERIMENTAL|Cetuximab and Cemiplimab|"All patients will be administered the same treatment combination.~Cemiplimab will be administered 350mg intravenously every 21 days. A maximum of 4 cycles will be given.~Cetuximab will be administered 400mg/m2 loading dose on day 1 and 250mg/m2 on day 8 and day 15 for a 21 day cycle for first cycle. Cetuximab will be administered 250mg/m2 on day 1, 8 and 15 for a 21 day cycle for subsequent cycles for 4 cycles."
62575931|NCT03423550||Participants who are suspected with TB|
62575932|NCT02760823|ACTIVE_COMPARATOR|Alpha Lipoic Acid|Subjects in this arm will receive ALA IV, as a dose of 600 mg/12 hours.
62010473|NCT00000410|ACTIVE_COMPARATOR|Surgery|Diskectomy
62197158|NCT04785118|ACTIVE_COMPARATOR|buscopan|Patients will receive IV hyoscine butyl-bromide 20 mg in 2 ml, just before spinal anaesthesia.
62197159|NCT04785118|ACTIVE_COMPARATOR|ondansetron|Patients will receive IV ondansetron 4 mg in 2 ml, just before spinal anaesthesia.
62197160|NCT04785118|PLACEBO_COMPARATOR|control|Patients will receive 2 ml of IV normal saline as a placebo just before spinal anaesthesia.
62399508|NCT03401502|EXPERIMENTAL|Treatment groups|Ranolazine 1000 mg
62399509|NCT03401502|PLACEBO_COMPARATOR|Control group|Placebos
62399510|NCT03455842|EXPERIMENTAL|BCD-089 weekly|
62399511|NCT03455842|EXPERIMENTAL|BCD-089 biweekly|
62575933|NCT02760823|PLACEBO_COMPARATOR|Non-Alpha Lipoic Acid|Subjects in this arm will to receive standard treatment only (without Alpha Lipoic Acid, instead they will receive placebo , which is determined by the attending physician who maintains clinical responsibility for all patients. It consists of patient resuscitation, gastric decontamination (with sodium bicarbonate, and activated charcoal \[1 g/Kg, orally\] in the first 6 hours after onset of poisoning), adequate hydration and supportive treatment.
62197161|NCT06425523|ACTIVE_COMPARATOR|EUC|Enhanced Usual Care
62197162|NCT06425523|EXPERIMENTAL|HGI|Home Gardening Intervention
62399512|NCT03455842|PLACEBO_COMPARATOR|Placebo|
62399513|NCT04104620||patients with neurological syndromes and GAD-Ab|This is a non-interventional study involving clinical data already stored in the database of the Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, or collected by the referral physicians the day of ordinary consultations. No biological sample is necessary to perform this study.
62399514|NCT04982393||Patients with PH1|Patients with a diagnosis of PH1 will be eligible for the study and will be managed and treated per routine clinical practice.
62575934|NCT04000425||ctDNA detection|The blood samples for ctDNA and other tumor markers (such as CEA, et al.) will be first collected within 7 days before surgery, and then be tested after radical gastrectomy in scheduled interval.
62010474|NCT00000410|ACTIVE_COMPARATOR|Non-surgical intervention|Non-surgical treatments
62197163|NCT06425523|EXPERIMENTAL|SH+/HGI|Self-Help Plus in combination with Home Gardening Intervention
62197164|NCT06302660||Oesophageal adenocarcinoma survivors|100 disease free survivors who underwent multimodality treatment for oesophageal adenocarcinoma and are \>1 year post oesophagectomy
62197165|NCT02844452|EXPERIMENTAL|Verum Acupuncture 1|The participants with atopic dermatitis in the acupuncture group 1 will attend twelve acupuncture sessions over 4 weeks: 3 days a week. Once the 4-week treatment period was ended, the additional follow-up period will be conducted. The subjects will stand a final visit 4 weeks from the end of treatment period. Any other intervention will not be allowed during this study period.
62197166|NCT02844452|EXPERIMENTAL|Verum Acupuncture 2|The participants with atopic dermatitis in the acupuncture group 2 will attend eight acupuncture sessions over 4 weeks: 2 days a week. Once the 4-week treatment period was ended, the additional follow-up period will be conducted. The subjects will stand a final visit 4 weeks from the end of treatment period. Any other intervention will not be allowed during this study period.
62575935|NCT01055691|EXPERIMENTAL|1|Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
62197167|NCT02844452|SHAM_COMPARATOR|Sham Acupuncture|The participants in the sham acupuncture group will visit eight acupuncture sessions over 4 weeks. The acupuncture treatment will be conducted on six control points. The acupressure will be applied with ring-sham press tack needles on three control points. Unlike the acupuncture group 2, partially-individualized manual acupuncture according to the patient's symptoms will not be given but the questions about symptoms will be questioned to patients.
62197168|NCT02844452|NO_INTERVENTION|Healthy Control|The participants will go through the screening test. The included subjects will complete questionnaires and their blood sample will be obtained.
62197169|NCT03863145|EXPERIMENTAL|1|Part 1 (Dose Escalation): 100 mg daily.
62197170|NCT01685749||Enrolled participants|The targeted study population will include all people at Seal Beach who have been identified by the Seal Beach Lifeguards to have been stung by a jellyfish over the course of one year who are adults or children whose parent or guardian is present at the time of the injury. Children and pregnant women are included in the group.
62197171|NCT06515938|EXPERIMENTAL|20μg Engerix-B with 0-1-6 intervals|Received three intramuscular injections of the 20μg Engerix-B vaccine with 0, 1, 6 month intervals
62197172|NCT06515938|EXPERIMENTAL|20μg Kangtai with 0-1-6 intervals|Received three intramuscular injections of the 20μg Kangtai hepatitis B vaccine with 0, 1, 6 month intervals
62399515|NCT03028324|EXPERIMENTAL|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
62399516|NCT06722092|EXPERIMENTAL|VR-based script training|
62399517|NCT06722092|NO_INTERVENTION|Control|
62399518|NCT06722092|ACTIVE_COMPARATOR|Computerized script training without VR|
62399519|NCT05689801|EXPERIMENTAL|Patient on conventional hemodialysis then on optimized hemodialysis|
62399520|NCT00960869|EXPERIMENTAL|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole dosed once daily (QD)
62575936|NCT01055691|EXPERIMENTAL|2|Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
62575937|NCT01055691|EXPERIMENTAL|3|Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
62010475|NCT02103478|EXPERIMENTAL|Phase 1 Dose Escalation|Starting cohort was administered 40 mg oral cedazuridine and 20 mg oral decitabine. Participants were enrolled into successive cohorts in which either the cedazuridine or decitabine oral dose was varied in Course 1 Day 2 through Course 1 Day 5 for comparison with a single dose of IV decitabine at 20 mg/m\^2 administered on Day 1 by continuous IV infusion over 1 hour (28 days per course).
62197173|NCT06515938|EXPERIMENTAL|60μg Kangtai with 0-2 intervals|Received two intramuscular injections of the 60μg Kangtai hepatitis B vaccine with 0, 2 month intervals
62197174|NCT06515938|PLACEBO_COMPARATOR|20μg CHO with 0-1-6 intervals|Received three intramuscular injections of the 20μg Huabei hepatitis B vaccine made by recombinant DNA techniques in CHO cell with 0, 1, 6 month intervals
62197175|NCT05863468|EXPERIMENTAL|ArchSinus implantation|Subjects will undergo unilateral or bilateral in-office middle turbinate medialization and subsequent ArchSinus implantation
62197176|NCT03664427||Group 1: Patients with VOD|paediatric patients with Veno-Occlusive Disease (VOD) complicating haematological stem cell transplantation
62197177|NCT03664427||Group 2: matched controls|Paediatric patients defined as matched controls without veno-occlusive disease complicating haematological stem cell transplantation
62197178|NCT05840068|EXPERIMENTAL|Metformin and Chemotherapy|Metformin (500 mg twice daily) plus chemotherapy is administered to Group A (n=57)
62197179|NCT05840068|OTHER|Chemotherapy alone|Chemotherapy is administered alone to Group B (n=50).
62197180|NCT00999999|ACTIVE_COMPARATOR|Standard|Standard dural closure
62197181|NCT00999999|EXPERIMENTAL|Experimental|Experimental dural closure, adding of Investigational Medicinal Product (IMP)
62197182|NCT01851551|EXPERIMENTAL|VSLI plus rituximab|VSLI (vincristine sulfate liposome injection) plus rituximab
62197183|NCT01126034|EXPERIMENTAL|intervention|"Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:~1. The name and medical record # of the patients involved~2. Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy~3. A reminder of the adverse effect of long-term metoclopramide therapy~4. A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients~5. A request that the physician document the discontinuation trial in the electronic medical record"
62197184|NCT01126034|NO_INTERVENTION|non-intervention|No intervention letters were sent to subjects in this arm
62399521|NCT00960869|ACTIVE_COMPARATOR|EC-Aspirin 325 mg|EC-Aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole) dosed once daily (QD)
62399522|NCT03186950|ACTIVE_COMPARATOR|Restoration with Stainless Steel Crowns|Restoration of the tooth after endodontic treatment using stainless steel crown.
62399523|NCT03186950|EXPERIMENTAL|Restoration using BulkFill CR|Restoration of the tooth after endodontic treatment using bulkfill composite resin
62399524|NCT03735056|NO_INTERVENTION|Group 1 (Usual care)|Receives usual care only.
62575938|NCT01055691|EXPERIMENTAL|4|Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
62575939|NCT04439448||HIV+ non-obese|HIV+ adults on antiretroviral therapy with a body mass index \<30 kg/m2
62575940|NCT04439448||HIV+ obese|HIV+ adults on antiretroviral therapy with a body mass index \>=30 kg/m2
62575941|NCT04439448||HIV-negative obese|HIV-negative adults on antiretroviral therapy with a body mass index \>=30 kg/m2
62575942|NCT04549792|EXPERIMENTAL|Open Label|
62575943|NCT06577272||post-RFA recurrence|
62575944|NCT06577272||post-RFA did not recurrence|
62575945|NCT01464164|EXPERIMENTAL|Sotatercept|Sotatercept to be given as a subcutaneous injection once a month for 4 consecutive months, using a dose escalation scale among 3 cohorts. \*Protocol Amendment: Two additional cohorts will be given Sotatercept 0.75mg/kg and 1 mg/kg as a subcutaneous injection once every 3 weeks.
62575946|NCT01464164|EXPERIMENTAL|Sotatercept with prednisone boost|Protocol Amendment: Two additional cohorts will be given Sotatercept 0.75mg/kg and 1 mg/kg as a subcutaneous injection once every 3 weeks along with a prednisone boost of 1 mg/kg daily for 3 weeks (max of 60 mg).
62575947|NCT05899517|EXPERIMENTAL|Oral oxytocin then placebo|Subjects will first receive oral lollipop with oxytocin (24IU). After a washout period of 2 weeks, they will then receive oral lollipop with placebo (identical ingredients, except the active agent).
62010476|NCT02103478|EXPERIMENTAL|Phase 2 Dose Confirmation|Participants were randomized in a 1:1 ratio to receive either oral cedazuridine (E7727) (100 mg) + decitabine (35 mg) capsules Dailyx5 in Course 1 followed by IV decitabine (20 mg/m\^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, participants received cedazuridine and decitabine capsules Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.
62197185|NCT02932930|ACTIVE_COMPARATOR|QLB group|"Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.2% ropivacaine bilaterally.~Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Ropivacaine, 0.2 ml/kg of 0.2% ropivacaine"
62399525|NCT03735056|EXPERIMENTAL|Group 2 (Usual care plus Support 1)|Receives usual care plus Support 1 (MS Nurse Support) which includes one one-to-one, face-to-face session with an MS Nurse Specialist in a hospital setting (or via Skype). The session will include answering newly diagnosed patients' questions about MS, providing psychoeducation and teaching Acceptance and Commitment strategies (Hayes, Strosahl \& Wilson, 1999), and referring to other services (based on needs). Participants will also be given a self-help workbook ('Better living with a diagnosis of MS: Patient Workbook') by the nurses. This session will take place within 2 weeks of diagnosis and last up to 90 minutes. It will be supplemented by phone calls (depending on participant needs). MS Nurses will receive training and on-going supervision from experienced clinical psychologists.
62399526|NCT03735056|EXPERIMENTAL|Group 3 (Usual care plus Support 2)|Receives usual care plus Support 2 (i.e. MS Nurse Support plus Peer Support). In addition to receiving the MS Nurse Support (i.e. Support 1, as described in Group 2), this group will also receive peer support which will be provided by Peer Support Workers who are patients/carers with lived experience and who are recruited and trained to deliver peer support under supervision from experienced clinical psychologists. It will be delivered one-to-one, face-to-face (in a community setting or via Skype, based on participants' preferences). Patients in this group will be triaged to a Peer Support Worker by the MS Nurse during the 2-week MS Nurse Support session. The sessions will be scheduled to a convenient time between weeks 2-6 after diagnosis and each session will last up to 60 minutes.
62399527|NCT02431559|EXPERIMENTAL|Phase 1, Dose Level 0a|Subjects received PLD (40 mg/m\^2 IV on Day 1 of every cycle) + durvalumab (3 mg/kg Q2W \[equivalent to 450 mg Q4W\] IV on Days 3 and 17 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m\^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Days 3 and 17 of Cycles 4-12.
62399528|NCT02431559|EXPERIMENTAL|Phase 1, Dose Level 0b|Subjects received PLD (40 mg/m\^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.0 mg/m\^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.
62399529|NCT02431559|EXPERIMENTAL|Phase 1, Dose Level +1|Subjects received PLD (40 mg/m\^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m\^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.
62399530|NCT02431559|EXPERIMENTAL|Phase 2|Subjects received the MTD determined in Phase 1 (Dose Level +1), comprising PLD (40 mg/m\^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment.
62575948|NCT05899517|EXPERIMENTAL|Oral placebo then oxytocin|Subjects will first receive oral lollipop with placebo (identical ingredients, except the active agent). After a washout period of 2 weeks, they will then receive oral lollipop with oxytocin (24 IU).
62575949|NCT06286527||adult PrEP users|
62783209|NCT03041896||coflex®|Decompression surgery with the coflex® Interlaminar Technology, 1 or 2 levels.
62783210|NCT03041896||Hybrid|coflex and fusion at adjacent levels
62783211|NCT04314011|EXPERIMENTAL|HUC-MSCs Group|Human umbilical cord mesenchymal stem cells (1\*10\^6/kg cells): delivered via peripheral intravenous infusion.
62783212|NCT04314011|PLACEBO_COMPARATOR|Control Group|Placebo:normal saline delivered via peripheral intravenous infusion.
62783213|NCT01325805|EXPERIMENTAL|Structured Weight Loss|Women randomized to this arm will meet with a registered dietician regularly for review of calorie recommendations and food diary. As well as regular clinic visits to measure patients weight.
62783214|NCT01325805|ACTIVE_COMPARATOR|Routine Weight Loss Counseling|Patients are counseled by a physicians about the impact of maternal weight on fertility and pregnancy outcomes.
62783215|NCT01764828|EXPERIMENTAL|Refametinib (BAY86-9766)+ Gemcitabine|Single dose of BAY86-9766 on Cycle 1 Day -17; twice daily dosing every day starting on day -14, start dose 50mg bid ( 30mg or 20mg are possible based on adverse events need) in addition with Gemcitabine intravenous on day 1,8 and 15 1000mg/m2
62783216|NCT04371601|ACTIVE_COMPARATOR|Control group|conventional symptomatic treatments such as antiviral (oseltamivir), hormones, oxygen therapy, mechanical ventilation and other supportive therapies
62197186|NCT02932930|PLACEBO_COMPARATOR|Control group|"Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.9% normal saline bilaterally.~Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Normal saline, 0.2 ml/kg of 0.9 % normal saline"
62197187|NCT01078961|EXPERIMENTAL|Dose Escalation|
62197188|NCT05606289|EXPERIMENTAL|CIT officers|Police officers randomized to the experimental group will receive a 40-hour CIT training curriculum.
62197189|NCT05606289|NO_INTERVENTION|Non-CIT officers|Police officers randomized to the no-intervention group will not receive the 40-hour CIT training curriculum.
62575950|NCT01677572|EXPERIMENTAL|Low-dose #1 Aducanumab|Intravenous doses of low-dose level #1 Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
62010477|NCT02103478|EXPERIMENTAL|Phase 2 Fixed-Dose Combination|Participants were randomized in a 1:1 ratio to receive either the fixed-dose combination (FDC) tablet (100 mg cedazuridine (E7727)/35 mg decitabine) Dailyx5 in Course 1 followed by IV decitabine (20 mg/m\^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, all participants received the FDC tablet Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.
62197190|NCT04047173|EXPERIMENTAL|Stereotactic Body Radiotherapy (SBRT)|GTV is defined as the intrahepatic lesion on images. Internal target volume (ITV) is defined as the combined volume of GTVs on 10 respiratory phases. Planning target volume (PTV) is generated by adding a 5-mm margin to the ITV. OARs include liver, kidney, stomach, small intestine, and spinal cord. Normal liver volume is defined as the entire liver minus GTV. Dose constraints to OARs were as follows: mean dose of normal liver \< 10 Gy, V15Gy (percentage of the normal liver volume receiving ≥ 15 Gy) \< 35%; kidneys Dmean \< 6 Gy; esophagus D0.5cc \< 21 Gy; stomach D0.5cc \< 21 Gy; small intestine D0.5cc \< 21 Gy; colon D0.5cc \< 24 Gy; heart D0.5cc \< 30 Gy; ribs D0.5cc \< 39 Gy; and spinal cord Dmax \< 18 Gy. SBRT is planned using volumetric arc therapy techniques with a prescription dose of 36-54 Gy in 3 fractions, irradiated every other day, and completed within one week. Cone-beam CT is performed before each treatment.
62197191|NCT04047173|ACTIVE_COMPARATOR|Radiofrequency Ablation (RFA)|"RFA is performed under intravenous, epidural, or general anesthesia guided by computed tomography (CT) or ultrasound, preferably through a percutaneous or laparoscopic approach. The ablation electrode is precisely inserted into the center of the tumor and ablated at 30-50W power for 5-10 minutes depending on the size and shape of the tumor. Adequate coverage of the tumor lesion with a defined safety margin is ensured during ablation. After the completion of tumor ablation, the instrument will remaine active as the electrode is retracted, facilitating needle tract ablation. Contrast-enhanced CT, MRI, and ultrasonography will be performed one month after RFA to detect residual disease. Patients with confirmed complete ablation will undergo periodic follow-up, whereas those with residual tumors undergo repeat RFA procedures. Persistent tumor residue after two consecutive RFA sessions is deemed a treatment failure, and RFA treatment will be discontinued."
62197192|NCT00297947|EXPERIMENTAL|600 mg/day quetiapine (Group B)|Patients qualifying for the Double Blind Phase will be randomly assigned to 600 mg quetiapine (Group B) daily and treated on the assigned dose in a double-blind fashion for 8 weeks
62197193|NCT00297947|EXPERIMENTAL|1200 mg/day quetiapine (Group A)|Patients qualifying for the Double Blind Phase will be randomly assigned to high dose 1200 mg quetiapine daily (Group A) on the assigned dose in a double-blind fashion for 8 weeks
62197194|NCT03924102|EXPERIMENTAL|patients with acute decompensated systolic and diastolic heart|
62783217|NCT04371601|EXPERIMENTAL|Experimental group|On the basis of the above-mentioned conventional symptomatic treatment and supportive therapy, umbilical cord mesenchymal stem cells were given at 106/Kg body weight / time, once every 4 days for a total of 4 times. Peripheral intravenous infusion was given within 3 days of first admission
62010478|NCT00572650|ACTIVE_COMPARATOR|1|
62010479|NCT00326534||Controls|Patients without sarcoidosis, but requiring a fiberoptic bronchoscopy
62197195|NCT02588872|ACTIVE_COMPARATOR|Hyaluronic Acid (HA)|Hyaluronic acid administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of ultra high molecular weight hyaluronan (16mg) in a 2mL injection.
62197196|NCT02588872|EXPERIMENTAL|Platelet-rich Plasma (PRP)|Platelet-rich plasma administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of leukocyte poor, buffer/additive free, singe spin, platelet-rich plasma averaging 4mL in volume.
62575951|NCT01677572|EXPERIMENTAL|Low-dose #2 Aducanumab|Intravenous doses of low-dose level #2 Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
62197197|NCT01228175|ACTIVE_COMPARATOR|Varenicline|Varenicline
62197198|NCT01228175|PLACEBO_COMPARATOR|Microcrystal Cellulose|Microcrystal cellulose placebo
62197199|NCT04344951|EXPERIMENTAL|UNIKINON (Chloroquine phosphate)|Once a patient is considered eligible for the study, they will receive oral chloroquine phosphate. The total duration of treatment will be 7 days. The dosage will be 500mg every 12 hours. It is clarified that any other treatment at the discretion of the therapist is permitted except for the administration of hydroxychloroquine.
62197200|NCT01518907|EXPERIMENTAL|AA4500 0.0029 mg in 1 mL|
62197201|NCT01518907|EXPERIMENTAL|AA4500 0.0145 mg in 5 mL|
62197202|NCT01518907|EXPERIMENTAL|AA4500 0.0145 mg in 1 mL|
62197203|NCT01518907|EXPERIMENTAL|AA4500 0.0435 mg in 5 mL|
62197204|NCT01518907|EXPERIMENTAL|AA4500 0.0435 mg in 1 mL|
62197205|NCT01518907|EXPERIMENTAL|AA4500 0.116 mg in 5 mL|
62197206|NCT01518907|EXPERIMENTAL|AA4500 0.116 mg in 1 mL|
62197207|NCT01518907|EXPERIMENTAL|AA4500 0.232 mg in 5 mL|
62197208|NCT01518907|EXPERIMENTAL|AA4500 at 0.232 in 1 mL|
62197209|NCT01518907|EXPERIMENTAL|AA4500 0.464 mg in 5 mL|
62197210|NCT01518907|EXPERIMENTAL|AA4500 0.464 mg in 1 mL|
62197211|NCT00167804|OTHER|1|Present Centered Therapy focuses on the veterans problems in the here and now. It uses a problem solving approach and avoids discussion of war related traumatic events.
62197212|NCT01746589|OTHER|myopic LASIK procedure|All subjects will receive bilateral myopic LASIK procedure using the 200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
62197213|NCT02713399||Soft Contact Lenses|healthy subjects wearing soft contact lenses
62197214|NCT02713399||Rigid Contact Lenses|healthy subjects wearing rigid contact lenses
62197215|NCT06241937|EXPERIMENTAL|DGSOM Class of 2027|
62197216|NCT02870972|EXPERIMENTAL|Part 1: BCX7353 350 mg once daily|BCX7353 capsules, 350 mg dose administered once per day for 28 days
62197217|NCT02870972|EXPERIMENTAL|Parts 2 and 3: BCX7353 250 mg once daily|BCX7353 capsules, 250 mg dose administered once per day for 28 days
62197218|NCT02870972|EXPERIMENTAL|Parts 2 and 3: BCX7353 125 mg once daily|BCX7353 capsules, 125 mg dose administered once per day for 28 days
62197219|NCT02870972|PLACEBO_COMPARATOR|Parts 1, 2 and 3: Placebo|Placebo capsules, administered once per day for 28 days
62197220|NCT02870972|EXPERIMENTAL|Part 3: BCX7353 62.5 mg once daily|BCX7353 capsules, 62.5 mg dose administered once per day for 28 days
62783218|NCT02816281||Reasons of case cancellation|"will be recorded and categorized into 6 groups including~1. patient issue such as surgery refusal, no show on the day of surgery, transport problems~2. facility such as equipment needs, improper estimate case time, case bumps~3. Surgeon unavailable, due to administrative schedules and other problems or changed line of management respectively~4. anesthesiologist fail to adequately prepare the patient, lead to some misunderstanding communication such as NPO violation, preoperative drug error~5. medical condition that may impact the patient's ability to endure anesthesia techniques or surgical procedure~6. miscellaneous."
62197221|NCT04866381|EXPERIMENTAL|SHR-6390|SHR-6390
62197222|NCT04866381|EXPERIMENTAL|SHR-6390 combined with Camrelizumab (SHR-1210)|SHR-6390 combined with Camrelizumab (SHR-1210)
62197223|NCT04866381|EXPERIMENTAL|Camrelizumab (SHR-1210) combined with SHR-1020|Camrelizumab (SHR-1210) combined with SHR-1020
62197224|NCT01460225|EXPERIMENTAL|Treatment|24 micrograms of lubiprostone twice daily for one week.
62197225|NCT00208247|EXPERIMENTAL|CBT|The cognitive behavioural treatment developed by Salkovskis, Warwick and co-workers was used, with adaptations for the specific setting.
62197226|NCT00208247|EXPERIMENTAL|STPP|The short-term psychodynamic psychotherapy (STPP).
62197227|NCT00208247|EXPERIMENTAL|Waiting List|Patients in the waiting-list group were asked to keep in touch with their GP, who had been informed of the trial in writing. The patients and their GPs were instructed not to begin any other treatment during the study period. After 6 months, the patients on the waiting list were re-evaluated for inclusion and exclusion criteria and, if they still met the criteria, re-randomized to CBT or STPP.
62197228|NCT06311305|OTHER|early laparoscopic cholecystectomy after ERCP|we assess the risks and complications of early laparoscopic cholecystectomy after ERCP
62197229|NCT03318029|PLACEBO_COMPARATOR|Placebo UK trial|Placebo and living in the UK
62197230|NCT03318029|ACTIVE_COMPARATOR|Vitamin D UK trial|Vitamin D supplementation and living in the UK
62197231|NCT03318029|PLACEBO_COMPARATOR|Placebo Brazil Trial|Placebo and living in the Brazil
62197232|NCT03318029|ACTIVE_COMPARATOR|Vitamin D Brazil Trial|Vitamin D supplementation and living in Brazil
62197233|NCT00376415|EXPERIMENTAL|Lessertia Fructescens|Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
62197234|NCT00376415|PLACEBO_COMPARATOR|Placebo|Participants received an identical placebo capsule twice daily for 3 months.
62197235|NCT05996367|EXPERIMENTAL|Single Arm|Single-dose radiation to involved-site
62197236|NCT00664534|ACTIVE_COMPARATOR|Glargine|Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)
62197237|NCT00664534|EXPERIMENTAL|Premixed Insulin Lispro|Premixed Insulin Lispro (mid-mixture or low-mixture) 1,2 or 3 injections plus OAMs
62197238|NCT02095041||Healthy Term infants|
62197239|NCT03205670|EXPERIMENTAL|Urethroplasty with a tissue-engineered construct|The investigators will take a sample of the buccal mucosa to isolate epithelial cells. Autologous cells will be seeded on a hybrid matrix. Urethroplasty with this tissue-engineered construct will be performed. This is a single arm study with no control. All patients will undergo the surgical operation.
62197240|NCT05471531|EXPERIMENTAL|Combined immunization group|160 subjects received one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
62399531|NCT03068507|EXPERIMENTAL|Prehabilitation group|Trimodal prehabilitation management
62197241|NCT05471531|EXPERIMENTAL|Non combined immunization group|There were two subgroups in non combined immunization group,and 160 subjects in each subgroup.The non combined immunization subgroup 1 received one dose of quadrivalent influenza vaccine on day 0 and one dose of 23-valent pneumococcal polysaccharide vaccine on day 28.The non combined immunization subgroup 2 received one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of quadrivalent influenza vaccine on day 28.
62399532|NCT03068507|NO_INTERVENTION|Control group|The patients will receive the conventional clinical guidance according to Peking Union Medical College Hospital, including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence.
62399533|NCT01801475|ACTIVE_COMPARATOR|Pregnant women|Full term pregnant women scheduled for Cesarean section and will be given Ondansetron as standard-of-care prior to surgery.
62399534|NCT01801475|ACTIVE_COMPARATOR|Non-pregnant women|Non-pregnant women scheduled for surgery at Stanford who will be given Ondansetron prior to their surgery as standard-of-care.
62575952|NCT01677572|PLACEBO_COMPARATOR|Placebo (low dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
62575953|NCT01677572|EXPERIMENTAL|Mid-dose Aducanumab|Intravenous doses of mid-dose Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
62575954|NCT01677572|PLACEBO_COMPARATOR|Placebo (mid dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
62575955|NCT01677572|EXPERIMENTAL|High-dose Aducanumab|Intravenous doses of high-dose Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
62575956|NCT01677572|PLACEBO_COMPARATOR|Placebo (high dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
62575957|NCT01677572|EXPERIMENTAL|Aducanumab Titration|Intravenous doses of Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
62575958|NCT01677572|PLACEBO_COMPARATOR|Placebo (Titration Group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
62575959|NCT03901820|NO_INTERVENTION|DrApp Without SIMDA|There are approximately 100 inpatients in whom the indications were registered through the use of DrApp, before the implementation of the drug interactions detection module.
62575960|NCT03901820|EXPERIMENTAL|DrApp With SIMDA|There are approximately 100 inpatients in whom the indications were registered through the use of DrApp, AFTER the implementation of the drug interactions detection module (SIMDA).
62575961|NCT00573274||1|Elective cesarean section patients
62575962|NCT00300885|EXPERIMENTAL|Sorafenib + C/P|Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), \[400 mg orally, twice daily\] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
62575963|NCT00300885|ACTIVE_COMPARATOR|Placebo + C/P|Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily\] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
62010480|NCT00326534||Sarcoidosis patients|Patients with newly diagnosed sarcoidosis
62010481|NCT04412941|EXPERIMENTAL|Treatment group|Myofunctional exercises + home oropharyngeal exercises + the rules of sleep hygiene
62010482|NCT04412941|ACTIVE_COMPARATOR|Control group|the rules of sleep hygiene
62010483|NCT03541746|EXPERIMENTAL|Study Group|Platelet Rich Plasma
62399535|NCT01801475|NO_INTERVENTION|Neonates|"Babies of the pregnant women enrolled in the study; no ondansetron is given to babies in this Aim 1 of the study."
62399536|NCT04136041|EXPERIMENTAL|Smartphone Application|Participants watch a video using the Smartphone Application displaying positive word stimuli.
62575964|NCT04565665|EXPERIMENTAL|Phase II Arm I (mesenchymal stem cells)|Patients receive MSCs as in the Pilot study.
62783219|NCT04115137||Women with pelvic congestion syndrome|Women older than 18 years At least 1 birth Present symptoms
62010484|NCT03541746|ACTIVE_COMPARATOR|Control Group|Intrauterine Foley's Catheter
62010485|NCT00363987|EXPERIMENTAL|1|
62010486|NCT00363987|OTHER|2|
62010487|NCT02944578|EXPERIMENTAL|Curcumin Arm|Participants in this arm will use 2000 mg of intravaginal curcumin once a week for 12 weeks.
62399537|NCT04136041|NO_INTERVENTION|No Intervention|No Intervention.
62575965|NCT04565665|ACTIVE_COMPARATOR|Phase II Arm II (standard of care)|Patients receive standard of care.
62575966|NCT04565665|EXPERIMENTAL|Pilot study (mesenchymal stem cells)|Patients receive MSCs IV over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion.
62575967|NCT06575764|EXPERIMENTAL|Heart priority Programme|The Heart Priority Programme was developed to supplement standardised cardiac rehabilitation to reduce dropouts among cardiac patients at risk of dropout due to being in a vulnerable situation
62575968|NCT00140244|ACTIVE_COMPARATOR|r-MetHuLeptin|r-MetHuLeptin SubQ once daily
62575969|NCT00140244|PLACEBO_COMPARATOR|Placebo|SubQ once daily
62575970|NCT02575326|OTHER|Standard Control|Teens in the control group will receive standard or usual care as provided by their physician.
62575971|NCT02575326|OTHER|Intervention|Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
62575972|NCT03021083|EXPERIMENTAL|IONSYS Administration|"Patients who have elective multi-level spinal fusions under general anesthesia (who do not receive methadone) will be enrolled. In addition, all patients will receive Pepcid 20 mg, dexamethasone 10 mg, and ondansetron 4 mg.~When patients will arrive in the post anesthesia care unit (PACU), pain will initially be controlled with IV hydromorphone to achieve an NRS score of 3 or less. Once transferred to the step down unit (SDU), the IONSYS patch will be applied. IONSYS should be utilized when they have pain, but rescue analgesia will be available. If severe pain continues, the chronic pain service will be consulted, to potentially change the medications.~Patients will be assessed for pain at rest and with PT in the AM and PM of POD 1 and POD 2. The IONSYS system will be discontinued after 48 hours, and a total dose of fentanyl received per 24 hours will be recorded. PT milestones for discharge will be assessed on the afternoon of POD 1 and POD 2."
62575973|NCT06144164|EXPERIMENTAL|Participants with Breast Cancer|Participants will have a diagnosis of breast cancer and may undergo axillary lymph node dissection.
62010488|NCT02944578|PLACEBO_COMPARATOR|Placebo Arm|Participants in this arm will use 2000 mg of a placebo once a week for 12 weeks.
62575974|NCT05297370|OTHER|Mixed and Match|Participants can choose to receive their own smoking cessation treatment options from our menu.
62197242|NCT05471531|EXPERIMENTAL|Safety group|2520 subjects were enrolled and received one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
62197243|NCT05287997|OTHER|Baseline|Participants in this arm will be evaluated at 3 time periods. Initial pre-season visit, mid-season visit and end-of-season visit. Capillary blood sample collection will occur at each visit.
62197244|NCT05287997|EXPERIMENTAL|Concussion|Participants in this arm will transition from the baseline arm to the concussion arm if they experience a concussion during the course of the sporting season. They will be evaluated with 72 hours of the injury and then at 2-, 4-, and 12-weeks post-injury. Capillary blood sample collection will occur at each visit.
62197245|NCT04788745|EXPERIMENTAL|Experimental|Trimetazidine 35mg
62197246|NCT03455257|NO_INTERVENTION|Control|Families assigned to this arm will be assessment only controls that do not receive the cash transfer.
62197247|NCT03455257|EXPERIMENTAL|Intervention|Families assigned to this arm will recieve a cash transfer following an in-depth conversation with the head of household and the signing of a contract stating they understand the purpose of the study.
62197248|NCT00129935|ACTIVE_COMPARATOR|Arm A: EC-T|Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.
62197249|NCT00129935|EXPERIMENTAL|Arm B: ET-X|Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.
62197250|NCT03166995|EXPERIMENTAL|Experimental group 1|Low impact aerobic exercise group. 1hour, twice a week
62399538|NCT05147311|EXPERIMENTAL|PATH Intervention|"Participants in the PATH Intervention arm will receive psychosocial support phone calls during week 1 through 9 following enrollment.~At approximately 100-days post-HSCT, participants will begin an 9-week positive psychology program involving weekly calls with an interventionist and exercises (i.e., writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).~-Self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
62399539|NCT05147311|NO_INTERVENTION|Usual Care Control|Participants in the Usual Care Control arm will receive regular social work assessments as part of HSCT recovery and work does not focus on PPWB skill building or cognitive strategies.
62399540|NCT01660152|EXPERIMENTAL|Group A (vacuum therapy, holding erection for 2 minutes)|Patients receive daily vacuum therapy over 10 minutes while holding erection for 2 minutes after undergoing RALP. Patients complete erection process 5 times. SHIM questionnaire administration will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
62399541|NCT01660152|EXPERIMENTAL|Group B (vacuum therapy, holding erection for 5 minutes)|Patients receive daily vacuum therapy over 10 minutes while holding erection for 5 minutes after undergoing RALP. Patients complete erection process 2 times.Patients complete erection process 5 times. SHIM questionnaire administration will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
62575975|NCT05297370|OTHER|Control|Participants will receive a self-help quitting leaflet
62197251|NCT03166995|EXPERIMENTAL|Experimental group 2|Postural exercises group. 1hour, twice a week
62197252|NCT03166995|NO_INTERVENTION|Control propriocepcion|No exercise, just proprioceptive control.
62197253|NCT02638883|EXPERIMENTAL|Implanted|Subjects will be implanted with the Hybrid SRW cochlear implant.
62575976|NCT01676610||Infants presenting to the Clinic|Infants presenting to the Bilal and Bhains Colony Health Center. Devices used to measure Pulse Oximetry (PO) include Rad-5v by Masimo, TuffSat by GE, N-65 by Nellcor, PRO2 by Conmed, and Lifebox by Acare.
62575977|NCT06459453|ACTIVE_COMPARATOR|Kaltenborn Technique|Per participant was randomized to receive weekly low grade Kaltenborn manual mobilization(grade I).Any tightening of the connective tissues surrounding the joint gave (grade II) and oscillations followed by additional stretching gave (grade III).For wrist joints, Kaltenborn mobilization was performed to improve wrist flexion, extension ,radial and ulnar deviation.The duration of intervention will be 4 weeks,3 sessions per week, a total of 12 sessions will be given to the study participants.Each session will be last for 30 minutes .Conventional physical therapy will be given to the participants along with the kaltenborn mobilization.
62575978|NCT06459453|EXPERIMENTAL|Mulligan Technique|Per participant gave concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient . Mulligan mobilization was performed for wrist flexion and extension,(in the form of a fist)MCP joint flexion and extension,Thumb IC joint flexion and extension ,abduction and adduction of fingers.. The duration of intervention will be 4 weeks,3 sessions per week, a total of 12 sessions will be given to the study participants . Each session will last for 30 minutes .Conventional physical therapy will be given to the participants along with mulligan mobilization.
62575979|NCT00144521|EXPERIMENTAL|1|
62010489|NCT04040101|NO_INTERVENTION|Healthy Adult|balance assessment
62197254|NCT01907906|EXPERIMENTAL|Arm 1: Mirasol-treated WB then untreated WB|Screening Period (14 days); Treatment Period 1 (49 days): Donation of WB treated with Mirasol System for Whole Blood on Day 0, LR-pRBCs manufactured \& stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49); WB Donation Deferral Period (35-49 days); Treatment Period 2 (49 days): Donation of WB, UNTREATED on Day 0, LR-pRBCs manufactured \& stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49) Study Exit on Treatment Period 2, Day 49
62010490|NCT04040101|NO_INTERVENTION|Stroke|balance assessment
62010491|NCT04040101|EXPERIMENTAL|Stroke smartphone training|smartphone balance training
62010492|NCT04040101|ACTIVE_COMPARATOR|Stroke traditional training|traditional physical therapy training
62010493|NCT01312766|EXPERIMENTAL|hMG-IBSA|New hMG preparation.
62010494|NCT01312766|ACTIVE_COMPARATOR|Menopur|
62197255|NCT01907906|EXPERIMENTAL|Arm 2: Untreated WB then Mirasol-treated WB|Screening Period (14 days); Treatment Period 1 (49 days): Donation of WB, UNTREATED on Day 0, LR-pRBCs manufactured \& stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49); WB Donation Deferral Period (35-49 days); Treatment Period 2 (49 days): Donation of WB treated with Mirasol System for Whole Blood on Day 0, LR-pRBCs manufactured \& stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49) Study Exit on Treatment Period 2, Day 49
62010495|NCT01086553|EXPERIMENTAL|A|9mg budesonide OD
62197256|NCT02920970|ACTIVE_COMPARATOR|narafilcon A|Participants are randomized to wear narafilcon A lens pair for one week during the cross over study.
62197257|NCT02920970|ACTIVE_COMPARATOR|stenfilcon A|Participants are randomized to wear stenfilcon A lens pair for one week during the cross over study.
62197258|NCT04950595|EXPERIMENTAL|Beef mince group|The test meal provided at lunch will be made up of 45% beef mince, with all remaining ingredients the same as the other arm.
62197259|NCT04950595|EXPERIMENTAL|Plant-based mince group|The test meal provided at lunch will be made up of 45% plant-based mince, with all remaining ingredients the same as the other arm.
62197260|NCT02473965|EXPERIMENTAL|IGIV-C|An IGIV-C loading dose of 2 g/kg and maintenance dose of 1 g/kg will be administered in CS dependent subjects with MG.
62197261|NCT02473965|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride injection, USP or equivalent
62197262|NCT06020950|PLACEBO_COMPARATOR|Control|Reduced calorie diet along with placebo (sunflower oil) pearls
62197263|NCT06020950|ACTIVE_COMPARATOR|Omega-3 supplementation|Reduced calorie diet along with omega-3 supplementation
62197264|NCT06020950|EXPERIMENTAL|Chia seed|Reduced calorie diet along with chia seed consumption
62197265|NCT01739257|EXPERIMENTAL|Theater|"1-hour dramatic reading of The Most Massive Woman Wins"
62197266|NCT01739257|ACTIVE_COMPARATOR|Lecture|1-hour lecture on the medical management of obese patients
62197267|NCT00590434||1|Patients older than 80 years presenting for average risk screening or surveillance colonoscopy
62197268|NCT00590434||2|Patients younger than 80 years presenting for average risk screening or surveillance colonoscopy
62197269|NCT01835353|EXPERIMENTAL|Prasugrel 100mg loading dose|Prasugrel 100mg loading dose
62197270|NCT01835353|ACTIVE_COMPARATOR|Prasugrel 60mg loading dose|
62197271|NCT00520624|EXPERIMENTAL|1|Treatment 1, for those with high degree of EIL
62197272|NCT00520624|EXPERIMENTAL|2|Treatment 2, for those with high degree of EIL
62197273|NCT00520624|NO_INTERVENTION|3|Control group of those with high degree of EIL
62197274|NCT00520624|EXPERIMENTAL|4|Treatment 1, for those with low degree of EIL
62197275|NCT00520624|NO_INTERVENTION|5|Control group of those with low degree of EIL
62197276|NCT02656589||Herceptin probable sensitive group|Plasma microRNAs will be collected using microRNA extraction kit according to manufacturer's instructions; and their expression levels are analyzed by quantitative polymerase chain reaction (qPCR).According to microRNAs - herceptin predictive model(reported by our team), the patients will be considered as Herceptin probable sensitive group
62197277|NCT02656589||Herceptin probable resistant group|Plasma microRNAs will be collected using microRNA extraction kit according to manufacturer's instructions; and their expression levels are analyzed by quantitative polymerase chain reaction (qPCR).According to microRNAs - herceptin predictive model(reported by our team), the patients will be considered as Herceptin probable resistant group
62197278|NCT06485245|EXPERIMENTAL|Cohort A1: 0.2mg CS060304|Healthy subjects in a fasting state will receive a single dose of CS060304 0.2 mg or placebo.
62197279|NCT06485245|EXPERIMENTAL|Cohort A2: 1mg CS060304|Healthy subjects in a fasting state will receive a single dose of CS060304 1 mg or placebo.
62197280|NCT06485245|EXPERIMENTAL|Cohort A3: 4mg CS060304|Healthy subject in fasted state receive a single oral dose of CS060304 4 mg or placebo on day 1, followed by a 4 day washout period, subjects in fed state will receive the same single oral dose of CS060304 4mg or placebo on day 5.
62575980|NCT00144521|ACTIVE_COMPARATOR|2|
62575981|NCT02445157||IPF_Reliability|Patients diagnosed with IPF according to NICE guidelines.
62197281|NCT06485245|EXPERIMENTAL|Cohort A4: 10mg CS060304|Healthy subjects in a fasting state will receive a single dose of CS060304 10 mg or placebo.
62010496|NCT01086553|ACTIVE_COMPARATOR|B|3mg budesonide TID
62197282|NCT06485245|EXPERIMENTAL|Cohort A5: 20mg CS060304|Healthy subjects in a fasting state will receive a single dose of CS060304 20 mg or placebo.
62197283|NCT06485245|EXPERIMENTAL|Cohort A6: 40mg CS060304|Healthy subjects in a fasting state will receive a single dose of CS060304 40 mg or placebo.
62197284|NCT06485245|EXPERIMENTAL|Cohort B1: 2mg CS060304|Elevated LDL-C subjects will receive the CS060304 2 mg or placebo once daily for a consecutive 14 days.
62197285|NCT06485245|EXPERIMENTAL|Cohort B2: 5mg CS060304|Elevated LDL-C subjects will receive the CS060304 5 mg or placebo once daily for a consecutive 14 days.
62197286|NCT06485245|EXPERIMENTAL|Cohort B3: 10mg CS060304|Elevated LDL-C subjects will receive the CS060304 10 mg or placebo once daily for a consecutive 14 days.
62197287|NCT06485245|EXPERIMENTAL|Cohort B4: 20mg CS060304|Elevated LDL-C subjects will receive the CS060304 20 mg or placebo once daily for a consecutive 14 days.
62197288|NCT05858255|EXPERIMENTAL|Exergaming|A 12-weeks, twice a week exergaming program, consisting of a combined high-intensity interval training and flash-reflex pods gaming condition, each session lasting 45 minutes, conducted one-on-one with a designated personal trainer (experienced and authorized health personnel with additional competence in exercise/sports and/or physical therapy).
62197289|NCT03805542|NO_INTERVENTION|Control group|I-stage nephrostomy（Double J stent placement under cystoscopy） and II-stage operation
62197290|NCT03805542|EXPERIMENTAL|I-stage operation group|Disinfection of pelvis with 0.5% iodophors
62197291|NCT04199845|EXPERIMENTAL|PS128|PS128 will be given twice daily for 8 weeks Active capsule containing 300 mg of probiotics, equivalent to 3 x10\^10 CFU of Lactobacillus plantarum PS128.
62197292|NCT04199845|PLACEBO_COMPARATOR|placebo|Placebo containing starch will be given twice daily for 8 weeks.
62575982|NCT02059655|PLACEBO_COMPARATOR|Eye drop solution|Patients will receive 1 dose daily over 3 month period followed by 2 months washout period. Subsequently patient will cross over to the opposite treatment and continue further treatment for 3 month period.
62575983|NCT02059655|ACTIVE_COMPARATOR|Bimatoprost|1 drop daily of Bimatoprost 0.03%. Patients will receive 1 dose daily over 3 month period followed by 2 months washout period. Subsequently patient will cross over to the opposite treatment and continue further treatment for 3 month period.
62575984|NCT00616148|PLACEBO_COMPARATOR|Placebo|
62575985|NCT00616148|EXPERIMENTAL|YKP3089|
62575986|NCT02729766|ACTIVE_COMPARATOR|Empagliflozin 25mg Tbl|Induced hypotonic hyponatremia - SIAD model: Hypotonic hyponatremia will be induced in healthy volunteers through oral overhydration and parenteral administration of desmopressin (Minirin)® 4ug. After administration of the study drug, the artificial SIAD will be sustained with infusion of hypotonic sodium-solution (NaCl 0.45%) over two hours.
62575987|NCT02729766|PLACEBO_COMPARATOR|Placebo P-Tablet|Induced hypotonic hyponatremia - SIAD model: Hypotonic hyponatremia will be induced in healthy volunteers through oral overhydration and parenteral administration of desmopressin (Minirin)® 4ug. After administration of the study drug, the artificial SIAD will be sustained with infusion of hypotonic sodium-solution (NaCl 0.45%) over two hours.
62575988|NCT02527746|EXPERIMENTAL|F-627 80 µg/kg|F-627 at the dose of 80 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
62575989|NCT02527746|EXPERIMENTAL|F-627 240 µg/kg|F-627 at the dose of 240 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
62399542|NCT06136650|EXPERIMENTAL|hormone replacement therapy (HRT)+ opevesostat|Participants receive opevesostat 5 mg by oral tablets twice daily (BID) plus dexamethasone 1.5 mg by oral tablets and fludrocortisone acetate 0.1 mg oral tablet once daily (QD) continuously until disease progression. Hydrocortisone 100 mg (oral or intramuscular \[IM\]) will also be provided to participants for use as rescue medication.
62010497|NCT03887091|EXPERIMENTAL|Postwire© Virtual Education Cohort|"* Participants will be administered a brief questionnaire that asks questions about participant internet access, use, and understanding (Appendix B). This questionnaire will be used to determine eligibility.~* In randomized into the Virtual Education Cohort:A video based, personalized web page will be created that has information related to the participants therapeutic clinical trial.~* This web page will have videos of a research nurse explaining how to take study medication(s), how to fill out the study drug diary, and a description of the main side effects associated with the study drugs.~* Clinic Visit Video Recording Cycle 1-4/Day 1~* Participants from both groups will be asked to complete two surveys before each Day 1 clinic visit for Cycles 1-7"
62197293|NCT04517708|EXPERIMENTAL|Intervention group|"Regarding the intervention group, patients were treated with the intervention regimen, which consisted of:~* Nutritional counseling~* Each patient was assigned a specific menu which were prepared by research members during the time of staying at the hospital. Before discharge, patients were instructed on preparing their diets at home with the recommended amount of energy and protein and given formula milk within two months."
62197294|NCT04517708|NO_INTERVENTION|Control group|Patients had diets based on their demands
62399543|NCT06136650|ACTIVE_COMPARATOR|Alternative next generation hormonal agent (NHA)|Participants receive Abiraterone 1000 mg QD by oral tablets plus Prednisone 5 mg BID by oral tablets or Enzalutamide 160 mg QD by oral tablets until disease progression.
62575990|NCT02527746|EXPERIMENTAL|F-627 320 µg/kg|F-627 at the dose of 320 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
62399544|NCT06089681||Hamstring strain injury history group|Sprinters who have ≥ twice hamstring strain injury occurrence in the past year
62575991|NCT03334643|EXPERIMENTAL|Non-Diabetes|Participants without clinical diagnosis of impaired glucose tolerance or type 2 diabetes and with fasting blood glucose less than 100 mg/dL. They will consume white bread or fiber mix for multiple times over a span of 2 weeks. Changes in blood glucose levels will be monitored.
62575992|NCT03334643|EXPERIMENTAL|Prediabetes/Diabetes|Participants who are clinically diagnosed with impaired glucose tolerance or type 2 diabetes, and those without the above diagnosis but with fasting blood glucose equal to or greater than 100 mg/dL. They will consume white bread or fiber mix for multiple times over a span of 2 weeks. Changes in blood glucose levels will be monitored.
62575993|NCT02868489|EXPERIMENTAL|Proprietary Blend - LactoWise®|After being randomized into two groups, the assigned experimental group, prior to surgery and after consenting, will be asked to complete the Gastrointestinal Quality of Life Index. In addition the experimental group will be given their supply of LactoWise®. They will be required to take 1 capsule per day (300 mg of bacillus coagulans and galactomannans at 4.5 billion live cells) at breakfast consistently for 3 months. There will be three follow up visits (Week-2, Week-6 and Month-3) where participants will be asked to complete the gastrointestinal quality of life index.
62734719|NCT02524236|ACTIVE_COMPARATOR|Botox 100 IU|"Intervention: Botox 100 IU vial will be reconstituted with saline 0.9% to a total volume of 5 ml. All patients will receive five injections of 1 mL of the BoNT-A solution, including two injections in each lateral lobe (one proximal and one distal) and one injection in the median lobe. The injection depth will be 7-10 mm.~Botox injection in the prostate"
62399545|NCT06089681||Control group|Sprinters who match gender, age, BMI, dominant side, training experience, training frequency, PB in 100m with HSI history group and without any hamstring strain injury occurrence in the past year
62399546|NCT00325351|EXPERIMENTAL|Arm 1|
62399547|NCT01884675|EXPERIMENTAL|Ambrisentan|Subjects in this arm will receive ambrisentan 5 mg tablet once daily during the treatment period.
62399548|NCT01884675|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive ambrisentan-matching placebo tablet once daily during the treatment period.
62575994|NCT02868489|PLACEBO_COMPARATOR|Control|For the control group, prior to surgery and after consenting to enroll in the study participants will also be asked to complete the Gastrointestinal Quality of Life Index. Participants of the control group will be administered their supply of a matching placebo. They will be required to take 1 capsule per day at breakfast consistently for 3 months. There will be three follow up visits (Week-2, Week-6 and Month-3) where participants will be asked to complete the gastrointestinal quality of life index.
62575995|NCT00597636||1|NEVER SMOKERS WITH LUNG CANCER
62575996|NCT00597636||2|NEVER SMOKERS WITHOUT ANY CANCER
62575997|NCT00953654|EXPERIMENTAL|Strength Training|Lower-body strength training exercise twice weekly for 6 weeks at an intensity progressing from 50% to 75% predicted one-repetition maximum
62575998|NCT00953654|EXPERIMENTAL|Endurance Training|Six-week lower-body dynamic cycling exercise condition completed twice weekly and matched to the strength training arm on total work completed, total time actively engaged in exercise and load progression.
62010498|NCT03887091|NO_INTERVENTION|No Video Intervention|"Participants will be administered a brief questionnaire that asks questions about participant internet access, use, and understanding (Appendix B). This questionnaire will be used to determine eligibility~* Participants randomized to the control cohort will follow standard of care procedures involving clinic visits that do not include the use of video or access to a personalized web page.~* Participants from both groups will be asked to complete two surveys before each Day 1 clinic visit for Cycles 1-7."
62010499|NCT06664346|ACTIVE_COMPARATOR|Active group|Immersive virtual reality mindfulness intervention software including focus and calm along with mindfulness breathing exercises
62399549|NCT03456557|EXPERIMENTAL|Computed tomography.|
62399550|NCT06023472|EXPERIMENTAL|The microfluidic chip group|The Sperm Separation Device - ZyMōt Multi 850µL or 3 mL device (ZyMōt Fertility, Inc) will be used according to the volume of the raw semen samples. The microfluidics chamber will be used based on the manufacturer's instructions. 850 μL (850 μL device) or 3 mL (3mL device) of the semen sample will be added to the inlet port of the device and 750 μL (850 μL device) or 2.4 mL (3 mL device) of fertilization media will be added to the outlet port. The device will then be incubated in 6% CO2 at 37°C. After 30 minutes, 500 μL (850 μL device) or 1 mL (3mL device) of the prepared sample at the outlet port will be removed and pipetted into a labelled test tube.
62399551|NCT06023472|ACTIVE_COMPARATOR|The density gradient centrifugation group|After liquefaction, sperm preparation will be completed by a discontinuous density gradient centrifugation method, using Pureception (CooperSurgical, Denmark) sperm density gradient media. The resulting sperm pellet after centrifugation will be washed once with the sperm washing medium (G-IVF Plus, Vitrolife, Sweden) The washed spermatozoa will be resuspended with the same medium, adjusting the final volume to 0.5 mL.
62399552|NCT03556202|EXPERIMENTAL|125 Milligram (mg) Mirikizumab Q8W|Participants received 125 mg mirikizumab administered subcutaneously (SC) every eight weeks (Q8W).
62399553|NCT03556202|EXPERIMENTAL|250 mg Mirikizumab Q8W Excluding Secukinumab|Participants received 250 mg mirikizumab administered SC Q8W excluding participants who received secukinumab of their originating study (AMAJ)
62399554|NCT03556202|EXPERIMENTAL|Secukinumab/250 mg Mirikizumab Q8W|Participants from previous originating study \[who received secukinumab (AMAJ)\] received 250 mg mirikizumab administered SC Q8W.
62399555|NCT02257970|EXPERIMENTAL|Part 1: Exploratory Group|"Ketoprofen 225-300 mgs daily, taken orally~Ketoprofen-exploratory group: 225-300 mgs daily for four to six months"
62575999|NCT00953654|NO_INTERVENTION|Waiting List Control|Waiting list control condition in which participants will maintain their current lifestyle and will not enter a six-week exercise training intervention, but will complete outcome measures along the same time progression as the intervention arms.
62783220|NCT04383054|EXPERIMENTAL|Long PA intervention group|The long PA intervention will be a MI (motivational interview) exploring the participant's knowledge and concerns about PA. An MI involves a semi-structured discussion between an investigator and the participant. The MI initially explores the participant's knowledge of the benefits of PA and their concerns about PA. The MI will then explore the participant's confidence in increasing their PAL, help the participant come up with a plan to increase their PAL and finally the participant will be signposted to further support and local opportunities for PA. The investigator will use a Moving Medicine 'more minutes' conversation tool of a chronic health condition that the patient has to facilitate every MI. Where possible the investigator will discuss the chronic condition that most relates to the participant's current admission to hospital. For patients with no health conditions the primary prevention section will be used.
62576000|NCT05088174|EXPERIMENTAL|D1：hetrombopag single dose，D11-D15：cyclosporine,D16 combination use of hetrombopag and cyclosporine|
62576001|NCT00842023|EXPERIMENTAL|Nesiritide Infusion|Nesiritide: 2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours.
62783221|NCT04383054|ACTIVE_COMPARATOR|Short PA intervention group|The short PA intervention will involve a short (1 min) discussion between an investigator and a participant. A Moving Medicine 'one minute' intervention appropriate to the participant's health conditions will be used to guide every short intervention. The short intervention will firstly involve the investigator asking whether the participant knew that doing PA was beneficial for their health. The investigator would then explain to be more PA they could try to build more PA into their daily routine and that this was often enough to meet the current PA recommendations. The investigator will also offer the participant a patient information sheet about PA.
62783222|NCT00979771|EXPERIMENTAL|GSK706769|100 mg GSK706769 twice daily orally (BID) for 28 days
62576002|NCT00842023|ACTIVE_COMPARATOR|Nitroglycerin Infusion|Nitroglycerin was initiated at 10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP\<or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment.
62576003|NCT04551131|EXPERIMENTAL|Frontline Arm|"Safety Phase:~Patients with newly diagnosed HLH will receive ruxolitinib PO or NGT and dexamethasone, PO or IV. Etoposide IV will be added based on disease response.~Expansion Phase:~Patients with newly diagnosed HLH treatment will begin with ruxolitinib PO or NGT at the MTD dose. Dexamethasone will be administered PO or IV. Etoposide IV will be added based on disease response."
62576004|NCT04551131|EXPERIMENTAL|Salvage Arm|Patients with relapsed/refractory HLH will receive ruxolitinib PO or NGT and dexamethasone PO or IV. Etoposide IV will be added based on disease response.
62576005|NCT05353842|EXPERIMENTAL|WOWii Intervention|Workout on Wheels Internet Intervention (WOWii) program which includes: 1) WOWii website to guide participants in an exercise program, 2) home exercise starter program; 3) weekly support from a peer facilitator via online (video) meetings.
62576006|NCT01985932|OTHER|Functional MRI|Subjects in this arm receive functional MRI during radiation therapy treatment planning.
62576007|NCT01921712|EXPERIMENTAL|PUR0200 low dose|PUR0200 low dose, single dose inhalation
62576008|NCT01921712|EXPERIMENTAL|PUR0200 mid dose|PUR0200 mid dose, single dose inhalation
62576009|NCT01921712|EXPERIMENTAL|PUR0200 high dose|PUR0200 high dose, single dose inhalation
62010500|NCT06664346|ACTIVE_COMPARATOR|Delayed group|Immersive virtual reality mindfulness intervention software including focus and calm along with mindfulness breathing exercises
62197295|NCT04913467|EXPERIMENTAL|Groningen Anti-Inflammatory Diet (GrAID)|Specially designed diet based on the most recent scientific evidence of the inflammatory characteristics of food and food groups.
62399556|NCT02257970|EXPERIMENTAL|Part 2: Open-label Group|"Ketoprofen 225 mg daily, taken orally~Open-label group: 75 mgs, three times daily, for four months"
62399557|NCT02257970|PLACEBO_COMPARATOR|Part 3: Placebo Group|"Participants randomized to receive placebo: placebo, three times daily, taken orally~Placebo: 1 capsule, three times daily, for four months"
62399558|NCT02257970|ACTIVE_COMPARATOR|Part 3: Ketoprofen Group|"Participants randomized to receive active medication: ketoprofen 75 mgs., three times daily, taken orally~Ketoprofen: 1 capsule, three times daily, for four months"
62399559|NCT00281736|EXPERIMENTAL|Arm I|Patients receive HPPH IV over 1 hour on day 1. Approximately 24 hours later, the lesion is exposed to laser light endoscopically.
62576010|NCT01921712|PLACEBO_COMPARATOR|Placebo|PUR0200 matched placebo, single dose, inhalation
62576011|NCT01921712|ACTIVE_COMPARATOR|Active Comparator|Active Comparator, single dose, inhalation
62399560|NCT00281736|EXPERIMENTAL|Arm II|Patients receive HPPH as in arm I, but at a higher dose, followed by laser light exposure.
62399561|NCT04217941|ACTIVE_COMPARATOR|Health Education with practical demonstration|Participants assigned to the intervention arm received health education with practical demonstration of nasal spray and intranasal ointment .
62399562|NCT04217941|PLACEBO_COMPARATOR|Health education without practical demonstration|Participants assigned to the control arm received only health education regarding nasal spray and intranasal ointment .
62399563|NCT00265382|OTHER|Open|
62399564|NCT00071006|EXPERIMENTAL|Single arm study|
62399565|NCT06190548||cCRKP|Patients with classic CRKP infection
62399566|NCT06190548||hvCRKP|Patients with hypervirulent CRKP infection
62576012|NCT04552314||patients after primary MMC-augmented trabeculectomy|
62576013|NCT03135054|EXPERIMENTAL|Combination|"Quizartinib is a second generation FLT3 inhibitors.The starting dose of quizartinib will be 30 mg/day oral unless the patients are taking a strong CYP3A4 inhibitor in which case the dose will be 20 mg /day. Quizartinib should be taken continuously throughout the treatment period unless there is no evidence of response at first assessment on day 28 or progressive disease at any time during the treatment.~Omacetaxine Mepesuccinate will be given at 1.5 mg/m2/day (maximum dose 3 mg) for 7 days (concurrently with quizartinib) in 28-day cycle."
62576014|NCT05125796|ACTIVE_COMPARATOR|paracetamol|1000 mg intravenous paracetamol
62576015|NCT05125796|EXPERIMENTAL|Dexketoprofen Trometamol|50 mg intravenous Dexketoprofen Trometamol
62576016|NCT05125796|EXPERIMENTAL|topical lidocaine|%5 lidocaine 5 gr topical
62576017|NCT05125796|PLACEBO_COMPARATOR|placebo|100 mL intravenous normal saline+ placebo topical pomade
62576018|NCT00375973|EXPERIMENTAL|Duloxetine|Duloxetine po 60-120 mg/day for 12 weeks
62576019|NCT00375973|PLACEBO_COMPARATOR|Placebo|Placebo comparator to Duloxetine
62576020|NCT02934698|EXPERIMENTAL|Ivacaftor|There is only one arm to this study. The two sisters with Cystic Fibrosis will both receive Ivacaftor for 6 months for their treatment.
62576021|NCT05401253||Adequate physical activity group|At least 600 met-minutes /week for five or more days of walking, moderate and strenuous physical activity per week.
62576022|NCT05401253||Insufficient physical activity group|Less than 600 met-minutes /week for five or more days of walking, moderate and strenuous physical activity per week.
62576023|NCT06570941|EXPERIMENTAL|Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome|Topical of application of cream to effected area 30-45 minutes before bedtime
62010501|NCT05756647|EXPERIMENTAL|Interventional Arm|The Mandibular Advancement Device for this study will be the ProSomnus Sleep Device. It is a sleep device intended to reduce nighttime snoring and mild to moderate Obstructive Sleep Apnea in adults by holding the lower jaw forward during sleep
62197296|NCT04913467|EXPERIMENTAL|ColoVit capsule|2 times daily intake of a supplement containing 37,5 mg vitamin B2, 2,5 mg vitamin B3 and 250 mg vitamin C in a ColoPulse-coated capsule, a pH-sensitive coating allowing ileocolonic-targeted-delivery
62197297|NCT04913467|PLACEBO_COMPARATOR|Placebo capsule|2 times daily intake of a capsule containing microcrystalline cellulose which is coated using the same ColoPulse technology as is used with the ColoVit
62197298|NCT01825577|EXPERIMENTAL|Transdermal Methylphenidate|2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
62399567|NCT02620228|EXPERIMENTAL|BIP Biopsy System|Biopsy system that enables real-time bioimpedance measurement from the tip of the biopsy needle.
62399568|NCT00063076|EXPERIMENTAL|Targretin®|Targretin® (bexarotene) Gel 1%, treat half head
62399569|NCT00063076|NO_INTERVENTION|Control|Half head untreated as control
62399570|NCT02691845|OTHER|BA|Brief advice to exercise. This serves as a control condition.
62399571|NCT02691845|ACTIVE_COMPARATOR|BA + SHE + HE|Brief advice to exercise + supervised \& home-based exercise + health education
62399572|NCT02691845|EXPERIMENTAL|BA + SHE + CBEX|Brief advice to exercise + supervised \& home-based exercise + cognitive-behavioral sessions focused on increasing and maintaining exercise
62399573|NCT01509638|ACTIVE_COMPARATOR|Group 1 Standard of Care|IV Morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump
62576024|NCT06158984|EXPERIMENTAL|IPL group|IPL group will use 2 sessions of IPL therapy, 15 days apart for the management of drug-induced dry eye in glaucoma patients.
62399574|NCT01509638|ACTIVE_COMPARATOR|Group 2 EXPAREL|bupivacaine liposome injectable suspension.
62576025|NCT06158984|NO_INTERVENTION|Control group|The control group received no treatment
62576026|NCT04549090||No QL block group|These patients will not be receiving QL block based on their shared decision with their surgeon and anesthesiologist. Patients' pain scores and amount of pain killers will be followed up for 24 hours postoperatively
62576027|NCT04549090||QL block group|These patients will be receiving QL block based on their shared decision with their surgeon and anesthesiologist. Patients' pain scores and amount of pain killers will be followed up for 24 hours postoperatively
62783223|NCT00979771|PLACEBO_COMPARATOR|Placebo|GSK706769 matched-placebo twice daily orally (BID) for 28 days
62783224|NCT03163901|ACTIVE_COMPARATOR|Treatment groups|To recruit and organize patients with TBI enrolled in a standard rehabilitation program into three groups ((a) treatment group receiving OMT; (b) control group A receiving sham treatment; and (c) control group B receiving neither OMT nor sham treatment) in order to assess the feasibility and adherence to the protocol and determine participation and attrition rates in preparation for a larger study.
62010502|NCT05756647|ACTIVE_COMPARATOR|Conservative treatment Arm|The conservative treatment will consist of four different interventions: Mometasone nasal rinse, External nasal dilatory therapy, Mouth taping and Lateral positional therapy.
62010503|NCT06142279|OTHER|COVID +|participant with a positive SARS-CoV-2 PCR test
62010504|NCT06142279|OTHER|COVID -|participant with a negative SARS-CoV-2 PCR test
62010505|NCT03609177|EXPERIMENTAL|Advance Care Planning|"-Survey:~* A group of older patients with advanced cancer (N=450) will have a survey over the course of the 36 months of recruitment.~* Participants will be provided written copies of the questions to follow along during the interviews"
62197299|NCT04984005|EXPERIMENTAL|Low intensity exercise training group|
62197300|NCT04984005|EXPERIMENTAL|Moderate intensity exercise training group|
62197301|NCT04984005|EXPERIMENTAL|Intermittent high intensity exercise training group|
62197302|NCT01266551|NO_INTERVENTION|lifestyle counseling|The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring. In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.
62197303|NCT02936882|OTHER|Preoperative gastric ultrasonography|
62197304|NCT03869177|OTHER|Intervention arm|Clusters (psychiatric outpatient clinics) in the intervention arm receives a comprehensive implementation support program during the trial period.
62197305|NCT03869177|NO_INTERVENTION|Control arm|Clusters (psychiatric outpatient clinics) in the control arm receives no implementation support during the trial period.
62399575|NCT01871870|EXPERIMENTAL|Artificial Pancreas Control Software|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 28 hours. For the entire study, the adaptive component of Artificial Pancreas Control Software will be used to control the subject's blood glucose.
62399576|NCT01600677|EXPERIMENTAL|Computerized medication delivery unit|Those hospitalized patients that meet all inclusion and exclusion criteria will be provided with an EMMA MDU for use in their homes for the 90-day period immediately following discharge.
62399577|NCT01600677|ACTIVE_COMPARATOR|Usual care|Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
62399578|NCT01572012|EXPERIMENTAL|Subcutaneous Administration|Ondansetron + Hylenex administered subcutaneously
62399579|NCT01572012|EXPERIMENTAL|Oral Administration|Ondansetron administered orally
62399580|NCT01572012|EXPERIMENTAL|Intramuscular Administration|Ondansetron administered intramuscularly
62399581|NCT01572012|EXPERIMENTAL|Intravenous Administration|Ondansetron administered intravenously
62010506|NCT03609177|EXPERIMENTAL|Advance Care Planning-Video Declaration|"Video Declaration:~* From among this group of 450 participants, the video declaration of preferences activity will be conducted with 240 patients.~* For those participants that agree to the video declaration, they will proceed with recording of their video declarations~* The RA will begin by reading a standardized introduction to aid the subject do the video"
62197306|NCT05803681|EXPERIMENTAL|CCEF group|"In the CCEF Group, patients received, as an adjunct to the clinical study protocol, CCEF stimulation (Osteospine®, IGEA SpA, Carpi, Italy) 8 h/die for sixty days.~Clinical study protocol: (1) bed rest for the first twenty-five days and subsequent mobilization with a three-point hyperextension brace; (2) antiresorptive therapy (75 mg risedronate tablet weekly); (3) supplemental calcium carbonate with 1000 mg of elemental calcium daily if needed based on serum calcium concentration; (4) Vitamin D (≤500 IU daily) if the serum 25-hydroxyvitamin D concentration at the time of screening was below 16 ng/ml). Analgesic therapy with paracetamol 1000mg tablets was assumed for seven days and further depending on pain intensity; patients were required to report on a specific sheet paracetamol assumption."
62399582|NCT00189917|EXPERIMENTAL|GP 1: healthy, no AD|Healthy subjects without any history of, or current signs and symptoms of atopic disease, receiving two doses IMVAMUNE (MVA-BN), subcutaneous.
62399583|NCT00189917|EXPERIMENTAL|GP2: prev. allerg. rhinitis|Subjects having documentation of at least one allergic rhinitis event during the previous year, receiving two doses IMVAMUNE (MVA-BN), subcutaneous..
62399584|NCT00189917|EXPERIMENTAL|GP3: history of AD|Subjects having documentation of a history of Atopic Dermatitis, receiving two doses IMVAMUNE (MVA-BN), subcutaneous..
62399585|NCT00189917|EXPERIMENTAL|GP4: active AD|Subjects presenting active Atopic Dermatitis and having an individual SCORAD value between 1 and 15, receiving two doses IMVAMUNE (MVA-BN), subcutaneous.
62399586|NCT01343329|EXPERIMENTAL|Subjects Receiving Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment.
62576028|NCT01904526|EXPERIMENTAL|Guanfacine|Guanfacine 3 mg/day immediate release followed by Guanfacine 4mg/day extended release followed by Guanfacine 6 mg/day extended release
62010507|NCT03609177|OTHER|Comprehensive Record Review of ACP|"* A review of Medical orders for resuscitation preferences in the electronic health record~* A review of Medical orders for Palliative care consultations preferences in the electronic health record~* A review of Medical orders for Hospice use preferences in the electronic health record"
62197307|NCT05803681|OTHER|Control Group|(1) bed rest for the first twenty-five days and subsequent mobilization with a three-point hyperextension brace; (2) antiresorptive therapy (75 mg risedronate tablet weekly); (3) supplemental calcium carbonate with 1000 mg of elemental calcium daily if needed based on serum calcium concentration; (4) Vitamin D (≤500 IU daily) if the serum 25-hydroxyvitamin D concentration at the time of screening was below 16 ng/ml). Analgesic therapy with paracetamol 1000mg tablets was assumed for seven days and further depending on pain intensity; patients were required to report on a specific sheet paracetamol assumption.
62197308|NCT04527484|ACTIVE_COMPARATOR|Group A|SHR-1314 Vial
62197309|NCT04527484|ACTIVE_COMPARATOR|Group B|SHR-1314 PFS
62197310|NCT03605888|EXPERIMENTAL|RCT Intervention|Overweight or obese (BMI ≥ 25 kg/m2) participants randomized to the Koa Family. intervention
62197311|NCT03605888|NO_INTERVENTION|RCT Control|Overweight or obese (BMI ≥ 25 kg/m2) participants randomized to the control group.
62197312|NCT03605888|OTHER|Exploratory|Normal-weight mothers (BMI 18.5-24.9 kg/m2) assigned to the Koa Family intervention.
62399587|NCT01343329|ACTIVE_COMPARATOR|Subjects receiving Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
62399588|NCT00629382|EXPERIMENTAL|1|
62399589|NCT00629382|OTHER|2|
62399590|NCT00288431|EXPERIMENTAL|1|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
62399591|NCT06650982|EXPERIMENTAL|experimental arm|Before medical device related pressure injury (MDRPI) training is given to students, an introductory characteristics form and knowledge and attitude surveys will be applied (pre-test). The survey questions will be administered immediately after the PK training presentation containing MDRPI information is given to the students (Posttest 1), and 4 weeks later (Posttest 2).
62399592|NCT06650982|NO_INTERVENTION|control arm|Before students are given MDRPI training, an introductory characteristics form and knowledge and attitude surveys will be administered (pre-test). The survey questions will be administered immediately after the traditional educational presentation containing MDRPI information is given to the students (Posttest 1), and again 4 weeks later (Posttest 2).
62783225|NCT03163901|OTHER|Effect of OMT on clinical outcome measures|Clinical outcome measures including Neurocom Balance Manager assessments (Modified Clinical Test of Sensory Interaction and Balance; Stability Evaluation Test; Rhythmic Weight Shift; Limits of Stability), Vestibular Oculomotor Screen, Motion Sensitivity Test, as well as questionnaires such as the Headache Impact Test (HIT-6), Dizziness Handicap Inventory, and the more general quality of life measures (dressing; bathing; medication management, etc. as assessed by the SF 36 QOL questionnaire).
62399593|NCT05619185|EXPERIMENTAL|Intervention|Those randomized to the CRAFT intervention will receive a web-based intervention
62576029|NCT01868022|EXPERIMENTAL|Arm A: GSK3052230 + paclitaxel/carboplatin|Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + paclitaxel (constant infusion for 3 hrs) and carboplatin (constant infusion for 30 to 60 minutes) iv on Day 1 of each 21-day cycle. The number of cycles of paclitaxel/carboplatin will be limited to 4 to 6 cycles.
62576030|NCT01868022|EXPERIMENTAL|Arm B: GSK3052230 + docetaxel|Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + docetaxel as 1 hour iv infusion on Day 1 of each 21-day cycle. Subjects may continue to receive docetaxel until disease progression or as long as they are considered to derive benefit from treatment.
62576031|NCT01868022|EXPERIMENTAL|Arm C: GSK3052230 + pemetrexed and cisplatin|Subject will receive GSK3052230 as 30 minute iv infusion once a week (Day 1, Day 8, Day 15) of each 21 day cycle + pemetrexed iv infusion over 10 minutes on Day 1 of each 21 day cycle followed 30 minutes later by iv Cisplatin infused over 2 hours
62197313|NCT04060693|EXPERIMENTAL|Protocol 1|The subjects enrolled in this protocol will dedicate 30 days of home-based measurement, scheduled within a 40 days' time frame. For reference measurements, subjects will be equipped with a BG-meter (Contour Next One, Ascenia). Optical measurements are collected with the IMD. Each day of measurements consists of four sessions each comprising two capillary blood glucose measurement with a BG-meter and two IMD measurements. IMD measurements will be performed within 3 minutes after the BG measurement using the thenar of the right hand of the subject.
62576032|NCT06451536|EXPERIMENTAL|Treatment arm|Patients underwent Ga68 FAPI PET before immunotherapy
62576033|NCT05831189|EXPERIMENTAL|RBX2660|
62576034|NCT04849910|EXPERIMENTAL|Cohort 1|VOR33 infusion followed by Mylotarg Dose Level 1
62576035|NCT04849910|EXPERIMENTAL|Cohort 2|VOR33 infusion followed by Mylotarg Dose Level 2
62576036|NCT04849910|EXPERIMENTAL|Cohort 3|VOR33 infusion followed by Mylotarg Dose Level 3
62576037|NCT03656653|EXPERIMENTAL|Future-based recovery-oriented imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a future without cocaine use
62576038|NCT03656653|EXPERIMENTAL|Future-based cocaine-aversive imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a future where cocaine is causing significant distress
62576039|NCT03656653|EXPERIMENTAL|Past recovery-oriented imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a past event without cocaine use
62010508|NCT03609177|EXPERIMENTAL|Main Study Arm|Patients with cancer being seen at the 30 oncology clinics will be exposed to clinicians who have had communication skills training (Vital Talk) and who are using video decision aids (ACP Decisions). Our main outcome is advance care planning documentation.
62010509|NCT04600960|EXPERIMENTAL|50 subjects with chemotherapy-induced thrombocytopenia|50 enrolled subjects will be picked up to take eltrombopag at the indicated dose.
62576040|NCT03656653|EXPERIMENTAL|Past cocaine-aversive imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a past event where cocaine use has caused significant distress
62576041|NCT05314127|EXPERIMENTAL|Tazarotene|20 patients of verruca plana receiving daily topical Tazarotene 0.1% gel at night
62576042|NCT05314127|ACTIVE_COMPARATOR|Imiquimod|20 patients with verruca plana will be treated with imiquimod cream 5% applied once daily at night
62576043|NCT05314127|EXPERIMENTAL|5- fluorouracil|20 patients with verruca plana will be treated with topical 5- fluorouracil 5% cream applied once daily at night
62576044|NCT05314127|PLACEBO_COMPARATOR|Petrolatum|20 patients with verruca plana will be treated with petroleum jelly once daily at night.
62576045|NCT05178160|ACTIVE_COMPARATOR|Group A|All the patients undergo to helmet-CPAP setting PEEP at 10 cmH2O and performing a blood gas analysis after 2 hours
62576046|NCT05178160|EXPERIMENTAL|Group B|All the patients undergo to helmet-CPAP. PEEP was increased from 5 to 7.5 and 10 cmH20 in 30-minute steps during which lung ultrasound and blood gas analyses were repeated. The best PEEP was setted as the PEEP value before the appearance of lung pulse and with a PaO2/FiO2 levels stable or major than 20% in comparison to the basal value
62576047|NCT02166060|EXPERIMENTAL|Ivabradine|Ivabradine 5 mg twice a day or 7,5 mg twice a day
62576048|NCT04577261||FNS Participants|Participants who will undergo surgery to treat a fractured femoral neck using the FNS (Femoral Neck System)
62576049|NCT02490501|ACTIVE_COMPARATOR|SC0806|Intervention with SC0806 (implantation of device with FGF1 and peripheral nerves) in addition to rehabilitation
62576050|NCT02490501|OTHER|Controls|Rehabilitation only
62576051|NCT06578507|EXPERIMENTAL|Hydroxycarbamide Pediatric dispersible tablet|Hydroxycarbamide Pediatric dispersible tablet will be administered twice daily during 12 months.
62576052|NCT01975142|EXPERIMENTAL|TDM-1|
62576053|NCT02393950|EXPERIMENTAL|Drug: ODM-106|Oral capsules dosage 2-800mg once daily for one day
62576054|NCT02393950|PLACEBO_COMPARATOR|Drug: Placebo|Oral capsules given once daily for one day
62576055|NCT01733667|EXPERIMENTAL|MediENT|Right or left sinus cavity where MediENT will be place after randomization.
62576056|NCT01733667|ACTIVE_COMPARATOR|MeroPack|Right or left sinus cavity where MeroPack will be placed after randomization of MediENT is assigned.
62197314|NCT03804177|EXPERIMENTAL|implant with hyaluronic melatonin vit c|implant placement with topical application of hyaluronic and melatonin and systemic administration of vitamin C
62576057|NCT02225860|ACTIVE_COMPARATOR|Diet and Water adjustment|Reduction in dietary salt and protein intake
62576058|NCT02225860|NO_INTERVENTION|Control|Continue with usual diet
62576059|NCT06574971|EXPERIMENTAL|Primary arm|All participants in the study we receive the intervention
62576060|NCT03820349||Cystic Fibrosis|Subjects with cystic fibrosis
62576061|NCT03820349||controls|matched healthy controls
62010510|NCT06249100|EXPERIMENTAL|flexible mini percutaneous nephrolithotomy|In Group A (flexible mini-PCNL cases), puncture will be done under fluoroscopic guidance medial to the posterior axillary line using an 18-gauge puncture needle. The puncture will be directed horizontally or with slight upward inclination towards lower or middle calyx. After a successful puncture, a 0.035 Fr Super Stiff guidewire will be inserted either to the ureter or to another calyx. Tract dilatation will be done with Storz 15/16 Fr one step metal dilator followed by 16.5 Fr access sheath. Stone disintegration will be done with the flexible mini-nephroscopy (WiScope Digital Endoscope System by OTU Medical, California, USA) which has a shaft length of 38 cm, distal tip diameter is 15.3 F tapering to 10 F, working channel inner diameter is 6.6 F, and the angle of deflection of distal tip is 210 degrees.
62197315|NCT03804177|ACTIVE_COMPARATOR|immediate implant|immediate implant placement alone without melatonin or hyauronic acid nor vitamin c
62197316|NCT02646956||Age Group-Children|Children between ages of 7 and 14
62197317|NCT02646956||Age Group-Adults|Healthy adults who are the parent of the children
62399594|NCT05619185|ACTIVE_COMPARATOR|Control|Those randomized to CONTROL will complete a self-guided intervention
62576062|NCT02514798|EXPERIMENTAL|High-flow humidified nasal oxygen delivery system|We will describe effects of varying settings of high-flow nasal oxygen (10-30-45-60 L/min) on respiratory rate, tidal volume, and diaphragmatic work of breathing in patients with severe COPD. We will also describe changes in gas exchange and effects on the subjects' comfort and dyspnea. This will be measured using, esophageal and gastric balloons, respiratory inductance plethysmography (RIP) system, and Sentec transcutaneous monitoring system.
62576063|NCT02514798|ACTIVE_COMPARATOR|CPAP (Positive Control)|"We want to describe the breathing responses to varying setting of CPAP in the subject population. We plan to use the CPAP response as a positive control, to determine if our population responds as described by CPAP studies in the literature. This will be measured using, esophageal and gastric balloons, respiratory inductance plethysmography (RIP) system, and Sentec transcutaneous monitoring system."
62576064|NCT04281758|ACTIVE_COMPARATOR|Caffeine beverage (control)|Flavored still beverage with caffeine 100 mg
62010511|NCT06249100|ACTIVE_COMPARATOR|retrograde intrarenal surgery|In Group B (retrograde intrarenal surgery cases), a 0.035 Fr guidewire will be inserted into the ureteric orifice under fluoroscopic guidance. Ureteric dilatation will be done with serial semi-rigid dilators 6- 16 Fr (Nidhi Meditech) followed by 14-16 Fr access sheath. Stone disintegration will be done with the LithoVue Flexible URS (Boston Scientific, Massachusetts, U.S.) which has a shaft length of 68 cm, distal tip diameter is 7.7-10 F, working channel inner diameter is 3.6 F, and the angle of deflection of distal tip is 270 degrees.
62010512|NCT05559619|ACTIVE_COMPARATOR|Drug treatment group|34 postmenopausal women who only received oral calcium and vitamin D3 supplement (Calcium D3F® (Arab Company for Pharmaceutical\& medicinal plants (MEPACO-MEDIFOOD, EGPYT). Each tablet contains 1000 mg of natural calcium carbonate, 1000 IU vitamin D3 (0.025 mg) and 0.25 mg Sodium Fluoride. They received 1 tablet once daily for 12 weeks
62010513|NCT05559619|ACTIVE_COMPARATOR|Drug treatment + laser acupuncture group|34 postmenopausal women who received laser acupuncture therapy in addition to the same calcium and vitamin D3 supplement for 12 weeks.
62010514|NCT03586895|EXPERIMENTAL|e-Connect|County receives training and materials and subsequently begins the e-Connect intervention
62010515|NCT03586895|NO_INTERVENTION|Standard of care|Counties use the standard of care and there is no intervention in practices.
62197318|NCT05266703|OTHER|Isotopically labelled iron sulfate 15mg|
62197319|NCT06383650|EXPERIMENTAL|ASA 81mg|Daily study drug (x30 days)
62197320|NCT06383650|EXPERIMENTAL|ASA 325mg|Daily study drug (x30 days)
62197321|NCT06237088|ACTIVE_COMPARATOR|eight-week mindfulness programs|The intervention consists of 2.5-hour classes per week over a period of eight weeks.
62197322|NCT06237088|EXPERIMENTAL|online mindfulness program|The intervention includes an eight-week internet-based mindfulness program. The program introduces participants to a new mindfulness topic every week. These topics are heavily inspired by the eight-week mindfulness programs.
62197323|NCT06237088|NO_INTERVENTION|care as usual|Hospital-based antenatal care involves all aspects of pregnancy, childbirth and postpartum.
62399595|NCT05619185|EXPERIMENTAL|Phone Based CRAFT|If a member of the recruited dyad does not respond, then participants will be randomized to receive phone-based CRAFT
62399596|NCT05619185|ACTIVE_COMPARATOR|CRAFT Workbook|If a member of the recruited dyad does not respond, then participants will be randomized to receive a CRAFT workbook
62399597|NCT02989701|EXPERIMENTAL|Single arm|
62399598|NCT00984386|EXPERIMENTAL|Intradermal Zesteem|
62399599|NCT00984386|PLACEBO_COMPARATOR|Placebo|
62576065|NCT04281758|EXPERIMENTAL|Caffeine beverage plus bioactive 1|Flavored still beverage with caffeine 100 mg + quercetin 250 mg
62576066|NCT04281758|EXPERIMENTAL|Caffeine beverage plus bioactive 2|Flavored still beverage with caffeine 100 mg + curcumin 80 mg
62576067|NCT04281758|EXPERIMENTAL|Caffeine beverage plus bioactive 3|Flavored still beverage with caffeine 100 mg + methylliberine 75 mg
62399600|NCT04833465||JIA|Patients ages 5-21 with a diagnosis of JIA.
62197324|NCT01594970|EXPERIMENTAL|Bimatoprost 0.01% (Naive Monotherapy)|1 drop in the affected eye(s), administered in the evening in previously treatment naive subjects for 12 weeks.
62197325|NCT01594970|EXPERIMENTAL|Bimatoprost 0.01% (Switched Monotherapy)|1 drop in the affected eye(s), administered in the evening in subjects who were previously on another monotherapy treatment for 12 weeks.
62197326|NCT01594970|EXPERIMENTAL|Bimatoprost 0.01% (with Adjunctive Therapy)|1 drop in the affected eye(s), administered in the evening in subjects who are also receiving adjunctive therapy for 12 weeks.
62197327|NCT05465590|EXPERIMENTAL|MB1707 Single Dose Phase 1|Phase 1 MB1707 given as a single intravenous (IV) dose of 0.3 mg/kg
62197328|NCT02595099|EXPERIMENTAL|Mindfulness training|8 week programme of Mindfulness training
62197329|NCT05503199|EXPERIMENTAL|Combined suture- and plug-based VCD strategy|1 ProGlide or ProStyle + 1 Angio-Seal
62197330|NCT05503199|EXPERIMENTAL|Pure suture-based VCD strategy|2 ProGlides or ProStyles
62399601|NCT04833465||SLE|Patients ages 5-21 with a diagnosis of SLE.
62399602|NCT04833465||FM|Patients ages 5-21 with a diagnosis of FM.
62399603|NCT04282551|EXPERIMENTAL|oligosaccharide group 1|
62399604|NCT04282551|EXPERIMENTAL|oligosaccharide group 2|
62399605|NCT04282551|PLACEBO_COMPARATOR|placebo group|
62399606|NCT04707768|EXPERIMENTAL|Vadadustat low dose|Participants previously receiving Mircera® received vadadustat for up to 52 weeks with an initial dose of 600 milligrams (mg).
62399607|NCT04707768|EXPERIMENTAL|Vadadustat high dose|Participants previously receiving Mircera® received vadadustat for up to 52 weeks with an initial dose of 900 mg.
62197331|NCT04211259|EXPERIMENTAL|Cohort I (loratadine)|Beginning 5 days before the first dose of standard of care filgrastim, patients receive loratadine PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.
62399608|NCT04707768|ACTIVE_COMPARATOR|Mircera®|Participants will continue to receive Mircera® for up to 52 weeks.
62010516|NCT04329962|EXPERIMENTAL|Group I (blueberry extract, blueberry powder)|Participants undergo a washout on days -7 to -1 and then consume blueberry extract confection on day 0. Participants undergo a second washout on days 1-7 and then consume blueberry powder confection on day 8.
62197332|NCT04211259|PLACEBO_COMPARATOR|Cohort II (placebo)|Beginning 5 days before the first dose of standard of care filgrastim, patients receive placebo PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.
62197333|NCT05038605|ACTIVE_COMPARATOR|Topical metronidazole|Topical application of metronidazole cream on the anal verge after surgery
62399609|NCT03004898|EXPERIMENTAL|education arm|multidisciplinary education: multidisciplinary CKD education involving case management nurse, dietitian, social worker, pharmacists.
62783226|NCT03163901|NO_INTERVENTION|Anti-inflammatory Biomarkers|to analyze urine and plasma samples collected from the three groups of participants: urine and plasma samples one hour before, plasma samples one hour after and 48 hours after treatment for alterations in the levels of low molecular weight compounds or protein components to identify potential biomarkers that may correlate with the TBI condition and/or the OMT.
62783227|NCT03163901|NO_INTERVENTION|Infrastructure development|to establish the infrastructure for the recording, management, and extraction of clinical data and to estimate effect sizes and variability in key outcome measures so that a larger, longer term study can be planned with sufficient statistical power to identify significant results.
62197334|NCT05038605|ACTIVE_COMPARATOR|Oral metronidazole|oral metronidazole 500 mg tablets after surgery
62197335|NCT05038605|NO_INTERVENTION|Control|No metronidazole was received
62197336|NCT03427424||AUD-E|Early-in-treatment, healthy alcohol use disorder participants currently enrolled in PHP within 2 months of starting treatment (AUD-E)
62197337|NCT03427424||AUD-L|Long-term-in-treatment, healthy alcohol use disorder participants currently enrolled in PHP more than 2 months and less than 5 years (AUD-L)
62197338|NCT03427424||Characterization|substance use disorder participants currently enrolled in PHP, not eligible for main imaging study
62197339|NCT03427424||CON|healthy, non-drug using control participants (CON)
62197340|NCT03427424||POAUD-E|Early-in-treatment, healthy dual prescription opioid and alcohol and use disorder participants currently enrolled in PHP within 2 months of starting treatment (POAUD-E)
62197341|NCT03427424||POAUD-L|Long-term-in-treatment, healthy dual prescription opioid and alcohol use disorder participants currently enrolled in PHP more than 2 months and less than 5 years (POAUD-L)
62399610|NCT05483062|EXPERIMENTAL|toothpaste with active ingredient of galla chinensis|
62399611|NCT05483062|ACTIVE_COMPARATOR|toothpaste with stannous fluoride|
62399612|NCT00346476||Participants|Individuals in the Masiphumelele Township of Cape Town, South Africa, who have been potentially exposed to TB and/or HIV
62399613|NCT05351970||Monofilament closure|Patients with midline emergency laparotomy, which closure was performed with monofilament suture
62399614|NCT05351970||Barbed closure|Patients with midline emergency laparotomy, which closure was performed with barbed suture
62399615|NCT02263976|EXPERIMENTAL|BEA 2180 BR|single rising doses
62399616|NCT02263976|PLACEBO_COMPARATOR|Placebo|
62399617|NCT02263976|EXPERIMENTAL|Sub-Study|
62399618|NCT03478982|EXPERIMENTAL|Staccato Alprazolam 1.0 mg|single dose for inhalation
62399619|NCT03478982|EXPERIMENTAL|Staccato Alprazolam 2.0 mg|single dose for inhalation
62399620|NCT03478982|PLACEBO_COMPARATOR|Placebo|single dose for inhalation
62399621|NCT04830358|EXPERIMENTAL|EuPCV15|Single dose of Pneumococcal Conjugate Vaccine will be administered intramuscularly at Day 0.
62399622|NCT04830358|ACTIVE_COMPARATOR|Prevenar13|Single dose of Pneumococcal Conjugate Vaccine will be administered intramuscularly at Day 0.
62576068|NCT06252558|EXPERIMENTAL|Symbiotic Group|An over-the counter, once daily symbiotic capsule including: 15 billion CFU probiotic blend and 250mg of prebiotic.
62197342|NCT03427424||POUD-E|Early-in-treatment, healthy prescription opioid use disorder participants currently enrolled in physician health program (PHP) within 2 months of starting treatment (POUD-E)
62399623|NCT06400160|EXPERIMENTAL|TB511|"* Product name or code: TB511 Injection (8 mg)~  * Formulation and appearance: White or off-white color of lyophilized powder ③ Main ingredient: TB511 ④ Storage method: Store in a hermetic container in a freezer (-20℃); protect from light"
62399624|NCT06400160|OTHER|Concomitant drug|"* Product name or code: Keytruda~  ② Formulation and appearance: An injection comprised of clear to slightly opalescent, colorless to slightly yellow liquid contained in a colorless and transparent vial.~  ③ Main ingredient: Pembrolizumab~* Storage method: Store in a hermetic container, refrigerated at 2 to 8℃; protect from light; do not freeze"
62399625|NCT03593109|EXPERIMENTAL|LCAR-L10D treatment group|In LCAR-L10D treatment group, patients will be treated with dual specificity CD19 and CD22 CAR-T cells with a escalation approach, 3 CAR-T dosage will be tested in this study: 0.5×10\^6, 1.5×10\^6, 5.0×10\^6 CAR-T cells/kg.
62399626|NCT03728101|EXPERIMENTAL|Single arm|"* Dabigatran etexilate~* Simvastatin + Dabigatran etexilate"
62399627|NCT05910268|EXPERIMENTAL|Group 1|Control (month 7-12) then NIATx+ECHO (month 13-36) then Maintenance (month 37-54)
62399628|NCT05910268|EXPERIMENTAL|Group 2|Control (month 7-18) then NIATx+ECHO (month 19-42) then Maintenance (month 43-54)
62576069|NCT06252558|PLACEBO_COMPARATOR|Fiber Group|Once daily capsule of microcrystalline cellulose.
62576070|NCT05839080|EXPERIMENTAL|Intervention schools|Pupils are exposed to the schoolgarden intervention eight times during two school years
62576071|NCT05839080|EXPERIMENTAL|Control Schools|Pupils are not exposed to the interventions and will complete questionaries
62576072|NCT00968643|ACTIVE_COMPARATOR|Arm I (control)|Patients undergo radiotherapy to the area of spinal cord compression once daily for 5 days (total of 20 Gy).
62010517|NCT04329962|EXPERIMENTAL|Group II (blueberry powder, blueberry extract)|Participants undergo a washout on days -7 to -1 and then consume blueberry powder confection on day 0. Participants undergo a second washout on days 1-7 and then consume blueberry extract confection on day 8.
62010518|NCT05438082|EXPERIMENTAL|Antibiotic Prophylaxis|one dose of either Trimethoprim (if \< 2 months) or Trimethoprim-Sulfamethoxazole (if ≥ 2 months) or placebo in suspension. Dosing regimen for the active treatment (Trimethoprim) will be based on weight (5mg/kg of Trimethoprim component) with a maximum dosage of 320mg.
62010519|NCT05438082|PLACEBO_COMPARATOR|Placebo|The placebo group will receive an equal volume of placebo suspension that has been developed to have the same colour and taste as the antibiotic to preserve blinding.
62010520|NCT04857866|EXPERIMENTAL|Single Ascending Dose - XmAb27564 Subcutaneous injection of Dose A, B, C, D, E or F|
62010521|NCT04857866|PLACEBO_COMPARATOR|Single Ascending Dose - Placebo Subcutaneous injection of placebo|
62010522|NCT02705950|ACTIVE_COMPARATOR|intrathecal baclofen bolus|In ITB bolus group: An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level. A 50 µg.
62010523|NCT02705950|PLACEBO_COMPARATOR|placebo|In the placebo group: 1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
62010524|NCT04293159|EXPERIMENTAL|Lactobacillus casei DG (Enterolactis duo®)|Lactobacillus casei DG (Enterolactis duo®)
62010525|NCT02644967|EXPERIMENTAL|Phase 2, 8 mg Tilso/Ipi|IMO-2125 intratumoral injection plus ipilimumab
62010526|NCT05298852||Study population|This is a prospective multicenter study that included patients aged more than 21 years old with different clinical presentations other than pulmonary manifestation presenting to different healthcare facilities from June to December 2020. HRCT scan of the chest in order to detect COVID-19 patients was offered after signing an informed consent. Demographic data, clinical presentations, laboratory data, oxygen saturation, radiological findings in HRCT scan of the chest, SARS-CoV-2 PCR results and the need for mechanical ventilation were reported. Effects of different baseline characteristics, findings in HRCT scan of the chest on patient outcomes were analyzed.
62010527|NCT05362032|EXPERIMENTAL|Diagnostic (endorectal MRI, MRI-targeted biopsy)|Patients undergo endorectal MRI and transrectal MRI-targeted biopsy using the OmnEcoil device.
62010528|NCT06663904||HCC group|No previous treatments were performed before MRI examination of patients.
62197343|NCT03427424||POUD-L|Long-term-in-treatment, healthy prescription opioid use disorder participants currently enrolled in PHP more than 2 months and less than 5 years (POUD-L)
62197344|NCT02114762|EXPERIMENTAL|Balloon dilation of the Eustachian tube|Insertion and inflation of balloon into Eustachian tube for up to 1 minute
62576073|NCT00968643|EXPERIMENTAL|Arm II|Patients undergo a single fraction of radiotherapy to the area of spinal cord compression (total of 10 Gy).
62576074|NCT00477399|OTHER|Intervention|Receiving active follow up (two yearly 1 week stays, telephone follow up, GP-visits)
62010529|NCT06663904||Non-HCC group|No previous treatments were performed before MRI examination of patients.
62010530|NCT06663800|EXPERIMENTAL|arm:1 Pranayama|Arm:1 Additional effects of Ujjayi Pranayama
62010531|NCT06663800|OTHER|arm: 2 (standard protocol)|Arm:2 (standard protocol)
62010532|NCT00323739|EXPERIMENTAL|Bevacizumab and RAD001|Bevacizumab 10mg/kg, IV infusion, every 2 weeks RAD001 10 mg by mouth daily
62010533|NCT03127228|OTHER|Standard mechanical debridement|Debridement and surface detoxification of the implant surface and removal of the inflamed tissue with dental scalers.
62399629|NCT05910268|EXPERIMENTAL|Group 3|Control (month 7-24 then NIATx+ECHO (month 25-48) then Maintenance (month 49-54)
62399630|NCT05540678|PLACEBO_COMPARATOR|Placebo|Chewing gum containing maltitol powder
62399631|NCT05540678|EXPERIMENTAL|Investigational|chewing gums containing fibers
62399632|NCT05540678|NO_INTERVENTION|No-treatment control|No study chewing gum
62399633|NCT05420402|ACTIVE_COMPARATOR|Bolus group A|42 participants will receive 1 mg/kg intravenous bolus of propofol 3 min before the end of surgery.
62399634|NCT05420402|ACTIVE_COMPARATOR|Continuous infusion group|42 participants will receive 1 mg/kg continuous intravenous pumping of propofol 3 minutes before the end of the operation, and the pumping time was 3 minutes.
62399635|NCT05420402|ACTIVE_COMPARATOR|Bolus group B|42 participants will receive 1 mg/kg intravenous bolus of propofol at the end of surgery.
62399636|NCT05420402|NO_INTERVENTION|Blank Comparator group|42 participants will not receive propofol
62399637|NCT06046989|EXPERIMENTAL|BEAM Program|The BEAM Program is delivered via mobile application, weekly check-ins, and peer coaching. BEAM includes videos with emotion-regulation strategies that come from the Unified Protocol (evidence-based treatment for depression and anxiety disorders) and Dialectical Behavior Therapy (DBT) to help with mental health, as well they focus on developing self-compassion and effective communication. There are also supportive parenting videos which focus on providing parents with emotion-focused parenting strategies, based on Tuning in to Kids® and Parent Management Training - The Oregon Model (PMTO), which aim to help parents better understand and respond to their child. There will be approximately 15-20 minutes of videos to watch weekly.
62399638|NCT06046989|NO_INTERVENTION|Treatment-As-Usual|This is the control arm of the study. It is designed to account for the potential effects of time on symptoms of depression, anxiety, and anger.
62399639|NCT02090920||Nifedipine|Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
62399640|NCT02631434|EXPERIMENTAL|sit-to-stand|To perform a sit-to-stand test
62399641|NCT02631434|ACTIVE_COMPARATOR|six minute walking test|To perform a six minutes walking test
62576075|NCT00477399|NO_INTERVENTION|Control|Control group
62576076|NCT03850496|NO_INTERVENTION|Group A|No device utilised for 6 weeks.
62576077|NCT03850496|EXPERIMENTAL|Group B|Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 30 mins / day for 6 weeks.
62576078|NCT03850496|EXPERIMENTAL|Group C|Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 60 mins / day for 6 weeks.
62576079|NCT01113437|EXPERIMENTAL|Omalizumab|There are 2 arms of the study; patients in one arm receiving omalizumab and in the other arm receiving placebo.
62399642|NCT05392543|EXPERIMENTAL|Group A|Brunnstrom movement therapy
62399643|NCT05392543|EXPERIMENTAL|Group B|Mirror therapy
62576080|NCT01113437|PLACEBO_COMPARATOR|Placebo|There are 2 arms of the study; patients in one arm receiving omalizumab and in the other arm receiving placebo.
62576081|NCT01620190|EXPERIMENTAL|Treatment (paclitaxel albumin-stabilized nanoparticle formula)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62576082|NCT03378674|EXPERIMENTAL|Group A|remifentanil infusion of 0,15 mcg/Kg/min
62576083|NCT03378674|ACTIVE_COMPARATOR|Group B|remifentanil infusion of 0,3 mcg/Kg/min
62576084|NCT04640636|EXPERIMENTAL|Ketamine|Ketamine hydrochloride 0.5 mg/kg IM single injection
62576085|NCT04640636|ACTIVE_COMPARATOR|midazolam|Midazolam 0.06 mg/kg IM single injection
62576086|NCT02147158|EXPERIMENTAL|UPA 5 mg:Placebo|Ulipristal Acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 2.
62576087|NCT02147158|EXPERIMENTAL|UPA 10 mg:Placebo|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 2.
62576088|NCT02147158|EXPERIMENTAL|UPA 5 mg:UPA 5 mg|UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily in both Treatment Course 1 and Treatment Course 2. There was a 2 menses drug-free interval in between courses.
62576089|NCT02147158|EXPERIMENTAL|UPA 10 mg:UPA 10 mg|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily in both Treatment Course 1 and Treatment Course 2. There was a 2 menses drug-free interval in between courses.
62010534|NCT03127228|EXPERIMENTAL|Er:YAG laser-assisted debridement|Debridement and surface detoxification of the implant surface and removal of the inflamed tissue with the aid of the laser treatment.
62576090|NCT02147158|EXPERIMENTAL|Placebo:UPA 5 mg|Matching placebo tablets (5 mg and 10 mg) orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks in Treatment Course 2.
62010535|NCT04154280|EXPERIMENTAL|prostate cancer Patients|patients over the age of 18 with diagnosed prostate cancer at different stages of the disease.
62010536|NCT05597527|EXPERIMENTAL|Fluzopari and Apatinib group|Fluzopari and Apatinib were used in patients with newly diagnosed ovarian cancer before any treatment. The daily dose should be strictly controlled according to the experimental design.
62010537|NCT00079547|ACTIVE_COMPARATOR|1|Low-calorie diet
62010538|NCT00079547|EXPERIMENTAL|2|Low-carbohydrate diet
62010539|NCT02187016|EXPERIMENTAL|AirFloss + BreathRx|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with BreathRx rinse once a day.
62399644|NCT06722495|EXPERIMENTAL|3-Course of Neoadjuvant Immunochemotherapy combined with SBRT in LA-HNSCC with SD after 2-courses|Stereotactic body radiation therapy added between 2-course and 3-course treatment.
62399645|NCT01303159|EXPERIMENTAL|Radiofrequency probe (ENDOHPB)|"Intervention:~The EndoHPB is an endoscopic bipolar catheter designed to ablate tissue in malignant tumors within luminal structures, such as the biliary tree or pancreatic ducts. EndoHPB can be deployed via an ERCP or Percutaneous Transhepatic Cholangiographic (PTC) route. By using radiofrequency (RF) energy to heat the tissue in the duct prior to insertion of the stent, the surrounding tissue becomes coagulated and this may delay tumour growth and the time before the stent lumen becomes blocked. Thereby, allowing increased periods between the need for intervention and further stent deployment"
62399646|NCT05258968|EXPERIMENTAL|Educational Session on the Injeti Self Esteem Model|The participant will participate in a 1 hour educational session on the Injeti Self Esteem model.
62197345|NCT05525507|EXPERIMENTAL|Immune tolerance in HLA-identical kidney transplant recipient|We seek to establish immunological tolerance in patients with a pre-existing, well- functioning kidney transplant from an HLA-identical donor. Patients will undergo conditioning with TLI and ATG, followed by infusion of hematopoietic stem cells from the same donor . We will evaluate whether recipients can be withdrawn from immunosuppressive drugs without compromising allograft function. At serial time points, graft function will be monitored, and chimerism will be measured. Weaning of tacrolimus will begin at 6 months, with a goal of drug discontinuation within 12 months if the following conditions are met: (1) chimerism (defined as ≥1% donor type cells among the T cells, B cells, NK cells, and granulocytes) is detectable for at least 180 days, (2) stable graft function (defined as eGFR \>30 mL/min and no greater than sustained 30% change over 3 months from baseline) without clinical rejection episodes is maintained, and (3) no evidence of graft vs. host disease (GVHD).
62197346|NCT06433297|EXPERIMENTAL|Partial caries removal followed by Indirect pulp capping.|
62399647|NCT03628872|ACTIVE_COMPARATOR|Scaling and Root Planing with Hand Instruments|Patients will undergo scaling and root planing with hand instruments (half of their mouth, following a split-mouth design)
62576091|NCT02147158|EXPERIMENTAL|Placebo:UPA 10 mg|Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks in Treatment Course 2.
62010540|NCT02187016|EXPERIMENTAL|AirFloss + Listerine|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with Listerine Cool Mint rinse once a day.
62010541|NCT02187016|EXPERIMENTAL|Dental Floss|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device once a day.
62010542|NCT02187016|ACTIVE_COMPARATOR|Manual Toothbrush|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute
62010543|NCT02912481|EXPERIMENTAL|Posterior tibial artery|real time ultrasound guided arterial catheterization on the posterior tibial artery
62010544|NCT02912481|ACTIVE_COMPARATOR|Radial artery|real time ultrasound guided arterial catheterization on the radial artery
62010545|NCT02912481|ACTIVE_COMPARATOR|Dorsalis pedis artery|real time ultrasound guided arterial catheterization on the dorsalis pedis artery
62010546|NCT06061770|EXPERIMENTAL|First APA program|"The evaluation of the primary endpoint to meet our main objective will be done at W13 for both groups. The addition of an APA program in autonomy following the structured program for group 1 will make it possible to answer a secondary question focusing on the comparison of the effectiveness of the self-directed program carried out alone or following a structured program.~1st group: D0: Include S1-S12: APA program at IUR Valmante S13: Break S14-S25: APA Autoprogram~In addition, the patients in group 1 are maintained in the follow-up to study the maintenance of any observed effect."
62399648|NCT03628872|EXPERIMENTAL|Er:YAG Laser Scaling|Patients will undergo scaling and root planing with Er:YAG Laser in the untreated half of their mouth.
62399649|NCT03744858||Group A - Participants with CVD|Patients with chronic venous disease (CVD) will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.
62399650|NCT03744858||Group B - Healthy Participants|Voluntary healthy subjects will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.
62576092|NCT03032042|EXPERIMENTAL|albendazole at day 0, azithromycin at day 7|
62576093|NCT03032042|EXPERIMENTAL|azithromycin at day 0, albendazole at day 7|
62010547|NCT06061770|ACTIVE_COMPARATOR|Second APA program|"Our study design provides for compensatory participation in the structured program for patients in group 2, following the self-program. From an ethical point of view, this scheme allows all patients included in the structured APA program to benefit.~2nd group: D0: Include S1-S12: APA Autoprogram S13: End of study S14-S25: APA program at IUR Valmante compensatory"
62010548|NCT01565993|ACTIVE_COMPARATOR|Hemoclip|In group HEMOCLIP, one or more clips were placed (based on the criteria of the endoscopist in accordance with the size of the pedicle), and the polyp was subsequently resected using a diathermy loop
62010549|NCT01565993|ACTIVE_COMPARATOR|Conventional Polipectomy|In group CONVENTIONAL POLYPECTOMY, a conventional polypectomy was performed, which was not aided beforehand by any other hemostatic technique
62576094|NCT03032042|EXPERIMENTAL|albendazole at day 0, azithromycin at day 0|
62576095|NCT03032042|OTHER|Delayed treatment|albendazole at day 7, azithromycin at day 7
62576096|NCT03656692|OTHER|Acthar Gel|Participants received Acthar 1 mL (80 units \[U\]) subcutaneously (SC) 2 times per week for 36 weeks followed by a taper to Acthar 1 mL (80 U) SC once a week for 2 weeks, then 0.5 mL (40 U) SC once a week for 2 weeks.
62734720|NCT04319068||Healthy|Eligible participants from the Biobank cohort at the National Heart Centre, Singapore, will be screened will be recruited for the study over a period of 3 years.
62576097|NCT00820053|NO_INTERVENTION|no adjuvant TACE|controll group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive adjuvant TACE after liver resection
62576098|NCT00820053|EXPERIMENTAL|adjuvant TACE|patients who adjuvant TACE after liver resection
62576099|NCT06004921|EXPERIMENTAL|Cohort 1 - AB801 Dose A|Participants will receive a single dose of AB801 or placebo
62576100|NCT06004921|EXPERIMENTAL|Cohort 2 - AB801 Dose B|Participants will receive a single dose of AB801 or placebo
62576101|NCT06004921|EXPERIMENTAL|Cohort 3 - AB801 Dose C|Participants will receive a single dose of AB801 or placebo
62576102|NCT06004921|EXPERIMENTAL|Cohort 4 - AB801 Dose D|Participants will receive a single dose of AB801 or placebo
62576103|NCT05667857|NO_INTERVENTION|Non-intervention group|These participants will a undergo a neurocognitive and psychosocial assessment at baseline, and in follow-up after 6 months and 1 year thereafter. The aim of this group is to measure the extent of psychosocial and cognitive difficulties and health-related quality of life.
62576104|NCT05667857|EXPERIMENTAL|Integrative neurocognitive remediation therapy|The experimental group will undergo profound neuropsychological and psychological assessment before starting the integrative neurocognitive remediation therapy, in addition to the assessment already done at baseline. This group will repeat the testing after completion of the integrative neurocognitive remediation therapy, and 6 months thereafter.
62576105|NCT02589132|NO_INTERVENTION|Standard of Care|Families receiving Standard of Care
62010550|NCT03879681|NO_INTERVENTION|No Intervention|
62197347|NCT06433297|ACTIVE_COMPARATOR|Complete caries removal followed by Direct Pulp Capping|
62197348|NCT04209569|ACTIVE_COMPARATOR|NIPP|The NIPP group is a standard social behavior change (SBCC) intervention that tackles a set of underlying causes of malnutrition, with the potential to have both a curative and preventative impact on child malnutrition. The approach in this group/arm involves training and pragmatic behavior change education reinforced by practical activities over a 12-week period to both men and women in selected communities. It aims to utilize easy, viable and accessible solutions within the community that can be used to improve and protect household health and nutrition. The 12-week lesson plans for the circles are divided into 3 components, i) hands-on behavior change sessions that focus on the key pre-identified causes of malnutrition to improve awareness and practice ii) micro-gardening for improved household nutrition security and iii) participatory cooking demonstrations to stimulate improvements in nutritional status and care practices.
62576106|NCT02589132|EXPERIMENTAL|Mobile-Thrive application|Standard care plus Mobile-Thrive app
62576107|NCT01214967|EXPERIMENTAL|1|Problem Solving Education, a psycho-educational intervention
62576108|NCT01214967|NO_INTERVENTION|2|Usual care
62576109|NCT02964208||LAA Occluder PAS|Subjects who were treated with AMPLATZER LAA Occluders will be included.
62576110|NCT03813082|EXPERIMENTAL|Sleep deprivation young men|Young study participants will complete four nights in the sleep laboratory, whereas they will stay awake during one night. PET brain imaging will be conducted at the same circadian time on three consecutive afternoons (prior, during and after prolonged wakefulness). Additionally, validated tests of vigilance and cognitive performance will be administered and the brain waves will be recorded in wakefulness and sleep.
62576111|NCT03813082|EXPERIMENTAL|Sleep deprivation older men|Older study participants will complete four nights in the sleep laboratory, whereas they will stay awake during one night. PET brain imaging will be conducted at the same circadian time on three consecutive afternoons (prior, during and after prolonged wakefulness). Additionally, validated tests of vigilance and cognitive performance will be administered and the brain waves will be recorded in wakefulness and sleep.
62734721|NCT04319068||Hypertensive|Eligible participants from the Biobank cohort at the National Heart Centre, Singapore, will be screened will be recruited for the study over a period of 3 years
62734722|NCT02045888|EXPERIMENTAL|Low Dose ADRC|ADRCs prepared by investigational Celution Device
62734723|NCT02045888|EXPERIMENTAL|High Dose ADRC|ADRCs prepared by investigational Celution Device
62734724|NCT02045888|PLACEBO_COMPARATOR|Placebo|Placebo
62734725|NCT05033184|EXPERIMENTAL|Brief Action Planning Exercise|
62734726|NCT05033184|ACTIVE_COMPARATOR|Goal Setting Exercise|
62734727|NCT00574041|EXPERIMENTAL|1|titrated dose of Avonex
62010551|NCT03879681|EXPERIMENTAL|Jelly Snakes|
62010552|NCT02914964|EXPERIMENTAL|Swank Diet|Individuals randomized to this arm will follow a low saturated fat diet starting at week 12.
62734728|NCT00574041|ACTIVE_COMPARATOR|2|full dose Avonex
62734729|NCT06123715|EXPERIMENTAL|Intervention|Preoperative Vitamin C capsules
62734730|NCT06123715|PLACEBO_COMPARATOR|Placebo|Preoperative placebo capsules
62734731|NCT06435988|NO_INTERVENTION|no ıntervention|no ıntervention
62734732|NCT06435988|EXPERIMENTAL|experimental|Training in the pecha kucha technique
62734733|NCT01299467|EXPERIMENTAL|Dose 1 (0.5 hours)|
62734734|NCT01299467|EXPERIMENTAL|Dose 1 (8 hours)|
62734735|NCT01299467|PLACEBO_COMPARATOR|Dose 1 (placebo)|
62734736|NCT01299467|EXPERIMENTAL|Dose 2 (0.5 hr)|
62734737|NCT01299467|EXPERIMENTAL|Dose 2 (8 hours)|
62734738|NCT01299467|PLACEBO_COMPARATOR|Dose 2 (placebo)|
62734739|NCT04666142|ACTIVE_COMPARATOR|Individual Characteristics of the Individuals in the Experimental and Control Groups|The personal characteristics of the individuals included in the study were examined.
62734740|NCT04666142|ACTIVE_COMPARATOR|Disease Characteristics of the Individuals in Experimental and Control Groups|The intensive care experience of the individuals included in the study, their status of receiving respiratory support, and the reason for staying in the intensive care unit were explained.
62576112|NCT01666158|ACTIVE_COMPARATOR|Exercise|Patients in this group will follow standard MUHC protocol of nutritional counseling and supplementation as needed in order to maintain caloric and protein requirements in the preoperative period. Additionally, these patients will be given a specific physical exercise program before and after surgery by kinesiologist.
62576113|NCT01666158|NO_INTERVENTION|Standard nutrition counselling|Patients in this group will follow standard MUHC protocol of nutritional counseling and supplementation as needed in order to maintain caloric and protein requirements in the preoperative period. This group will receive general instructions on exercises (breathing, ankle rotation) to be done during hospital stay by kinesiologist.
62576114|NCT05524168|EXPERIMENTAL|SBRT+PD-1+Chemotherapy|Patients will receive SBRT first, then PD-1 antibody (Camrelizumab 200mg/Q3W) and chemotherapy (cisplatin 80mg/m2 on d1, gemcitabine 1000mg/m2, d1 and d8, Q3W, maximum 6 cycles), followed by Camrelizumab (200mg/Q3W) until progressive disease, intolerable toxicity, withdrawal of consent or a maximum of 1 year treatment.
62399651|NCT05069909|ACTIVE_COMPARATOR|Conventional technique|The group of patients who received dentures fabricated with conventional technique first
62576115|NCT01808781|EXPERIMENTAL|Intervention group|Home exercise program plus walking program during 8-week period
62576116|NCT01808781|ACTIVE_COMPARATOR|Comparison group|Walking only program throughout the 8-week period.
62576117|NCT04073888|OTHER|Single arm|Men with Fabry Disease
62576118|NCT05259774|EXPERIMENTAL|Relizema cream|Relizema cream, topically applied twice a day in all the affected areas for three cycles of 13 (±2) consecutive days.
62576119|NCT05259774|NO_INTERVENTION|Vehicle|Cream, topically applied twice a day in all the affected areas for three cycles of 13 (±2) consecutive days.
62010553|NCT02914964|EXPERIMENTAL|Wahls Elimination Diet|Individuals randomized to this arm will follow a modified paleolithic diet that eliminates all grains, dairy, eggs, legumes, and nightshade vegetables/spices starting at week 12.
62010554|NCT06154434|EXPERIMENTAL|Group A|
62010555|NCT06154434|EXPERIMENTAL|Group B|
62010556|NCT04034589|EXPERIMENTAL|Pyrotinib plus fulvestrant|Pyrotinib(400 mg once daily) + fulvestrant (500 mg, administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days)
62399652|NCT05069909|ACTIVE_COMPARATOR|Simplified technique|The group of patients who received dentures fabricated with simplified technique first
62576120|NCT05117502|EXPERIMENTAL|intermittent Theta Burst Stimulation|Participants will receive 2 treatments of intermittent Theta Burst Stimulation, each two weeks apart. First session will be iTBS alone, the second session will be combined iTBS with APT (Attention processing training).
62576121|NCT05117502|PLACEBO_COMPARATOR|Placebo intermittent Theta Burst Stimulation|Placebo iTBS participants will not receive any stimulation as the coil will be switched to placebo (P) setting. To maintain double-blind in A and P settings, Veterans and researchers wear headphones connected to a sham noise generator. Participants will receive 2 treatments of placebo intermittent Theta Burst Stimulation, each two weeks apart. First session will be iTBS alone, the second session will be combined placebo iTBS with APT (Attention processing training).
62576122|NCT03681548|ACTIVE_COMPARATOR|Reference Product - R|Doxorubicin Hydrochloride Liposome Injection (Sun Pharma); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose). As this is a cross over study, subjects receiving in Cycle 1 the Reference Product (doxorubicin hydrochloride liposome injection SunPharma), will receive in Cycle 2 the Test Product (doxorubicin hydrochloride liposome injection (Ayana); after at least 4 weeks (RT).
62576123|NCT03681548|EXPERIMENTAL|Test Product - T|Doxorubicin Hydrochloride Liposome Injection (Ayana Pharma Ltd); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose). As this is a cross over study, subjects receiving in Cycle 1 the Test Product (doxorubicin hydrochloride liposome injection (Ayana)will receive in Cycle 2 the Reference Product (doxorubicin hydrochloride liposome injection SunPharma); after at least 4 weeks (RT).
62576124|NCT02225639|ACTIVE_COMPARATOR|PRC-063|
62576125|NCT02225639|PLACEBO_COMPARATOR|Placebo|
62010557|NCT04848766||De-escalation treatment group|Patients diagnosed as acute coronary syndrome, and who receive de-escalation antiplatelet therapy after percutaneous coronary intervention
62010558|NCT04848766||Conventional treatment group|Patients diagnosed as acute coronary syndrome, and who receive conventional (non-de-escalation) antiplatelet therapy after percutaneous coronary intervention
62576126|NCT03266315|EXPERIMENTAL|Probiotics|subjects will be randomly assigned to receive FloraBaby
62576127|NCT03266315|PLACEBO_COMPARATOR|Placebo|subjects will be randomly assigned to receive placebo
62576128|NCT00339235||Non-pregnant women|Non-pregnant women aged 18 years and older
62576129|NCT00339235||Pregant women|Pregnant women aged 18 years and older
62576130|NCT00675363|ACTIVE_COMPARATOR|PS|Nurse-directed protocols for administering sedation and/or analgesia by continuous infusion.
62576131|NCT00675363|ACTIVE_COMPARATOR|PS + DI|Nurse-directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
62010559|NCT04327934|ACTIVE_COMPARATOR|Healthy Control|Healthy control participants.
62010560|NCT04327934|EXPERIMENTAL|AE-PCOS|Participants with AE-PCOS.
62010561|NCT01592266||AML|patients with AML prior and after treatment
62010562|NCT01915368|ACTIVE_COMPARATOR|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
62399653|NCT01560676|ACTIVE_COMPARATOR|HEALTH[e]TEEN|8 lessons over 6-8 weeks Education on healthy eating and physical activity Behavioral support for self-monitoring and goal setting
62399654|NCT01560676|ACTIVE_COMPARATOR|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks Education on healthy eating and coping skills training Behavioral support for self-monitoring and goal setting
62399655|NCT05803668||patients who developed gall stones|
62399656|NCT05803668||patients who did not develope gall stones|
62399657|NCT05349539||Healthy Subjects|Cohort of healthy subjects as control.
62399658|NCT05349539||Patients with Parkinson's disease|Cohort of patients with Parkinson's disease
62576132|NCT03426124||Retrospective|Individuals with intermediate-high or high risk pulmonary embolism who were consecutively treated with the Ekosonic Endovascular System (EKOS) and thrombolytic drug between January 2014 and one year prior to site activation.
62576133|NCT03426124||Prospective|Individuals who are experiencing intermediate-high or high risk pulmonary embolism where the treating investigator has selected the EKOS device and thrombolytic drug. The duration of ultrasound and volume of thrombolytic drug are selected per physician discretion.
62197349|NCT04209569|EXPERIMENTAL|NIPP+|In addition to establishing the circles and implementing the three NIPP components also implemented in the NIPP arm, those randomized to the NIPP+ arm will be provided access to innovations to allow and encourage the households and communities to translate the knowledge into positive practices. The innovations and access to vendors who sell innovations will be made available during the training to the NIPP+ volunteers who will provide trainings and access to vendors during the circle meetings. Most of the additions will be made accessible at a subsidized/low cost. The NIPP+ officers from the program will support NIPP+ volunteers in collaboration with agricultural extension officers.
62197350|NCT04209569|NO_INTERVENTION|Control|No Intervention
62197351|NCT03411785|EXPERIMENTAL|CPC+ practices|This is the intervention group, and includes the practices that were selected and agreed to participate in the CPC+ model.
62197352|NCT03411785|NO_INTERVENTION|Comparison practices|Comparison practices are the control group. This group includes practices not participating in the model that were matched to the CPC+ practices and whose outcomes will be compared to those of the CPC+ practices.
62197353|NCT01540942|ACTIVE_COMPARATOR|Nutrition treat|perioperative nutrition support until the patients get the normal nutrition or disease remission
62399659|NCT02643121||children with sepsis, SIRS|Data will be collected and analyzed from childrens with SIRS or septic state who will be admitted to the Department of Anesthesia and Intensive Care of the University Children´s Hospital Brno, Czech Republic. Infections, sepsis, severe sepsis, septic shock and multiple organ dysfunction syndrome (MODS) will be defined according to commonly used criteria - by International pediatric sepsis consensus conference.
62399660|NCT02643121||control group, healthy children|The samples children undergoing elective surgery will be used as a controls, i.e. samples from patients without signs of infection.
62576134|NCT03422601||3 months treatment|FOLFOX or CAPOX
62576135|NCT03422601||6 months treatment|FOLFOX or CAPOX
62576136|NCT01686126|EXPERIMENTAL|Mirena + Metformin|Metformin tablets, 500mg twice daily orally, 6 months Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months
62576137|NCT01686126|EXPERIMENTAL|Mirena|Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months
62576138|NCT01686126|EXPERIMENTAL|Mirena + Weight Loss Intervention|Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months Weight Loss Intervention will be delivered via Weight Watchers
62576139|NCT05019547||Axial Spondyloarthritis|Participants with Axial Spondyloarthritis
62399661|NCT04130204|EXPERIMENTAL|Active|DYV700, 10mL 3 times per day for 7 days Colchicine 1.2mg plus 0.6 mg 1 hour later at onset of flare (SOC)
62576140|NCT01130376|EXPERIMENTAL|Vaccine and cytokines|"Day 0: Patients receive GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injection.~Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC.~Further vaccine boosters are given on day 42 and day 84. GTU-MultiHIV B clade vaccine 1mg/ml being administered as 10 intradermal injections of 100 µl/injection."
62576141|NCT01130376|ACTIVE_COMPARATOR|Vaccine alone|"Day 0: Patients are given GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injections.~Day 42: GTU-MultiHIV B clade vaccine as day 0.~Day 84: GTU-MultiHIV B clade vaccine as day 0."
62576142|NCT01130376|ACTIVE_COMPARATOR|Cytokines alone|"Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC."
62576143|NCT01288196|EXPERIMENTAL|001|CNTO 6785 1 mg/kg IV A single 30-minute IV infusion of CNTO 6785 1 mg/kg
62576144|NCT01288196|EXPERIMENTAL|002|CNTO 6785 3 mg/kg IV A single 30-minute IV infusion of CNTO 6785 3 mg/kg
62576145|NCT01288196|EXPERIMENTAL|003|CNTO 6785 10 mg/kg IV A single 30-minute IV infusion of CNTO 6785 10 mg/kg
62576146|NCT01288196|PLACEBO_COMPARATOR|004|Placebo IV A single 30-minute IV infusion of placebo
62197354|NCT01540942|ACTIVE_COMPARATOR|bowel resection|bowel resection until the patients get the normal nutrition or disease remission after bowel resection
62399662|NCT04130204|PLACEBO_COMPARATOR|Placebo|Placebo, 10mL 3 times per day for 7 days Colchicine 1.2mg plus 0.6 mg 1 hour later at onset of flare (SOC)
62399663|NCT05129358|EXPERIMENTAL|Hydration sensor|The subjects use the wearable hydration sensor for ten days and undergo a dehydration/rehydration intervention on day 2 or 3.
62399664|NCT01472575||Pre- rotavirus vaccination introduction|Children aged 0-less than 6 years of age admitted to hospital in South Australia with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause during the period 01May2005-30Apr2007 (pre vaccine introduction)
62399665|NCT01472575||post rotavirus vaccine introduction|Children aged 0-less than 6 years of age admitted to hospital in South Australia with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause during the period 01May2009-30Apr2011 (post vaccine introduction)
62576147|NCT01288196|EXPERIMENTAL|005|CNTO 6785 SC A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
62399666|NCT05362318|ACTIVE_COMPARATOR|Group 1: Usual Care|Participants will receive brief advice to quit, an offer of enrollment to the Florida Tobacco Quitline, and a 12 week supply of nicotine replacement therapy (nicotine patches and lozenges).
62399667|NCT05362318|EXPERIMENTAL|Group 2: Usual Care + Motivation and Problem Solving + Relapse Prevention|Participants will receive brief advice to quit, an offer of enrollment to the Florida Tobacco Quitline, and a 12 week supply of nicotine replacement therapy (nicotine patches and lozenges), 6 telephone counseling sessions over 6 months, and access to a web based video.
62197355|NCT04014244|EXPERIMENTAL|Corticosteroids vs. Dextrose|In the first part of the study examiner will randomize substance for left hand infiltration using a dice (odd number - corticosteroids; even number - 5% glucose). Right hand will be infiltrated with the remaining substance.
62576148|NCT01288196|PLACEBO_COMPARATOR|006|Placebo SC A single SC dose of placebo administered in up to 3 SC injections
62576149|NCT05800938|ACTIVE_COMPARATOR|Isosorbid mononitrate group|Imdur 30 mg tablet AstraZeneca egypt twice daily for 4 weeks
62576150|NCT05800938|PLACEBO_COMPARATOR|placebo group|Tablets twice daily for 4 weeks
62197356|NCT04014244|EXPERIMENTAL|Corticosteroids or Dextrose vs. Surgery|In the second part of the study examiner will randomize treatment procedure for left hand using a dice (odd number - corticosteroids or 5% glucose; even number - surgery). Substance for injection will be determined according to the results of the first part of the study - more effective one, or in case of non-inferiority 5% glucose will be used. Surgical release will be performed by the same plastic surgeon. Both treatments will be performed maximally 2 months after diagnosis, with maximum period between them of 1 week.
62399668|NCT01439308|PLACEBO_COMPARATOR|Arm 1|3 incremental capsaicin doses
62399669|NCT01439308|ACTIVE_COMPARATOR|Arm 2|3 incremental capsaicin doses
62399670|NCT03804723|EXPERIMENTAL|GC withdrawal|
62399671|NCT03804723|PLACEBO_COMPARATOR|non GC withdrawal|
62399672|NCT02711085||Acute trauma|Those within the first 3 weeks of a non-catastrophic injury affecting the musculoskeletal system, including but not limited to whiplash or other road-traffic collisions, sports injuries, work-related injuries, sprains, strains, slips and falls and non-displaced fractures that don't require surgical correction.
62399673|NCT05338749|EXPERIMENTAL|Cognitive Training|Participants in this condition will received game-based cognitive training.
62576151|NCT03074058|EXPERIMENTAL|Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)|Fosrenol BAY 77-1931 orally disintegrating tablet (ODT) 500 mg in Period 1 (day 1-3) and Fosrenol chewable tablet 500mg in Period 2 (day 4-6). The washout interval between period 1 and 2 will be at least 14 days.
62576152|NCT03074058|ACTIVE_COMPARATOR|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)|Fosrenol BAY77-1931 chewable tablet in Period 1 and Fosrenol BAY 77-1931 ODT 500 mg in Period 2. The washout interval between period 1 and 2 will be at least 14 days.
62010563|NCT01915368|EXPERIMENTAL|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
62197357|NCT03503305|EXPERIMENTAL|Adipose Derived Regenerative Cell group|Subjects in the treated group will receive an Adipose derived regenerative cells (ADRCs) injection into the wrist using a fluoroscopic-guided injection .
62399674|NCT06373380|EXPERIMENTAL|HB-200 arm|HB-202 and HB-201 will be given in an alternating fashion as per above for a full one-year duration unless there is clinical or radiographic evident and/or pathologically confirmed recurrence.
62576153|NCT02763137|ACTIVE_COMPARATOR|Standard LD/CD|Standard LD/CD administered at patient's usual dose and frequency
62576154|NCT02763137|EXPERIMENTAL|Semi continuous intra-oral administration of LD/CD|Semi continuous intra-oral administration of LD/CD at a dose equivalent to the patient's regular dose of standard LD/CD
62734741|NCT04666142|ACTIVE_COMPARATOR|Distribution of Findings Regarding Sleep Activity of the Individuals in Both Groups|The personal characteristics of the individuals in the experimental and control groups regarding sleep were examined.
62197358|NCT03503305|ACTIVE_COMPARATOR|Corticosteroid group|Subjects in the active control group will receive a corticosteroid injection into the wrist using a fluoroscopic-guided injection.
62197359|NCT03689634|EXPERIMENTAL|Move For Surgery Preconditioning Program Intervention Group|
62010564|NCT01915368|EXPERIMENTAL|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
62010565|NCT04865094|ACTIVE_COMPARATOR|cyclic merocyanine|long-UVA absorber
62010566|NCT04865094|PLACEBO_COMPARATOR|placebo|
62010567|NCT02970968|EXPERIMENTAL|Study Drug|VLY-686 (Tradipitant) oral capsule for 4 weeks.
62399675|NCT06373380|PLACEBO_COMPARATOR|Placebo|Placebo will be given via IV administration on Day 1 of each cycle on the same schedule as HB-200 treatment for a full one-year duration unless there is evidence of radiographic recurrence.
62399676|NCT00184418||All patients admitted to a psychiatric acute ward|
62010568|NCT02970968|PLACEBO_COMPARATOR|Placebo|Placebo oral capsule for 4 weeks.
62010569|NCT05332262||High ABCD-GENE score (≥10)|"All patients in this cohort will have an ABCD-GENE score ≥10 and will be receiving clopidogrel following PCI as per standard of care.~The ABCD-GENE score encompasses a total of 5 variables: 4 clinical (age, body mass index, chronic kidney disease status, and diabetes mellitus) and 1 genetic (CYP2C19 LOF)."
62399677|NCT01993290|ACTIVE_COMPARATOR|USG Supraclavicular block|20 ml of ropivacaine 0,75% is administered to brachial plexus at supraclavicular level.
62197360|NCT03689634|NO_INTERVENTION|Standard Preoperative Care Group|
62197361|NCT04966975||Histologically confirmed bladder cancer treated with NAC|
62399678|NCT01993290|ACTIVE_COMPARATOR|Lateral infraclavicular block|20 ml of ropivacaine 0,75 % is administered to brachialis plexus at lateral infraclavicular level
62399679|NCT01993290|ACTIVE_COMPARATOR|USG Axillaris block|20 ml of ropivacaine 0,75% is administered to plexus brachialis at axillaris level
62197362|NCT00554996|OTHER|E. coli 83972 coated urinary catheter|E. coli 83972 coated urinary catheter
62197363|NCT01714167|ACTIVE_COMPARATOR|intracerebral stem cell transplantation|Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient plus conventional treatment include rehabilitation
62197364|NCT01714167|NO_INTERVENTION|conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
62197365|NCT03681535|EXPERIMENTAL|Single arm interventional study|RT to 19.5-20Gy is given after 3 cycles of rituximab containing chemotherapy. RT is administered daily, 5 days per week in 1.5-2Gy fractions (treatments).
62197366|NCT00450697||observation|
62197367|NCT02825342|NO_INTERVENTION|GERD with PPI's therapy|Patients will abnormal distal acid esophageal exposure will receive PPI twice daily for 8 weeks .
62197368|NCT02825342|ACTIVE_COMPARATOR|PPI's and SSRI's therapy|Patients with positive symptom index for chest pain will receive citalopram 20 mg once daily and PPI once daily for 8 weeks.
62197369|NCT02825342|ACTIVE_COMPARATOR|SSRI's therapy|Patients with a negative symptom index for chest pain will receive citalopram 20mg once daily for 8 weeks
62197370|NCT05145543|PLACEBO_COMPARATOR|Group C|0.9 NaCl % (Saline) (5 ml)
62197371|NCT05145543|ACTIVE_COMPARATOR|Group L|0.25 % levobupivacaine (5 ml) will be applied.
62576155|NCT02246179|EXPERIMENTAL|1: AFXL + AHES|This test region will be pretreated with a fractional carbon dioxide laser (ablative fractional laser; AFXL) with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse at t0 in a subject blinded fashion. Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region at t1.Ten minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam.
62197372|NCT05145543|EXPERIMENTAL|Group LF|fentanyl plus 0.25 % levobupivacaine (5 ml) will be applied.
62399680|NCT01362231|EXPERIMENTAL|GS-6624 125mg|
62010570|NCT05332262||Low ABCD-GENE score (<10)|"All patients in this cohort will have an ABCD-GENE score \<10 and will be receiving clopidogrel following PCI as per standard of care.~The ABCD-GENE score encompasses a total of 5 variables: 4 clinical (age, body mass index, chronic kidney disease status, and diabetes mellitus) and 1 genetic (CYP2C19 LOF)."
62197373|NCT05145543|EXPERIMENTAL|Group LD|dexamethasone plus levobupivacaine (5 ml) will be applied.
62197374|NCT02336451|EXPERIMENTAL|Arm 1 (PrALKi=Y, PrBRad=Y)|Participants with metastases in the brain without evidence of leptomeningeal carcinomatosis (LC), previously treated with radiation to the brain and with prior exposure to an Anaplastic lymphoma kinase inhibitor (ALK-I). Previous treatment with ALK-I other than crizotinib was not allowed in this arm as of protocol amendment 3 and had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
62197375|NCT02336451|EXPERIMENTAL|Arm 2 (PrALKi=Y, PrBRad=N)|Participants with metastases in the brain without evidence of LC, previously untreated with radiation to the brain but with prior exposure to an ALK-I. Previous treatment with ALK-I other than crizotinib was not allowed in this arm 2 as of protocol amendment 3 and had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
62197376|NCT02336451|EXPERIMENTAL|Arm 3 (PrALKi=N, PrBRad=Y)|Participants with metastases in the brain without evidence of LC, previously treated with radiation to the brain but with no prior exposure to an ALK-I. Participants in this arm had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
62197377|NCT02336451|EXPERIMENTAL|Arm 4 (PrALKi=N, PrBRad=N)|Participants with metastases in the brain without evidence of LC, previously untreated with radiation to the brain and with no prior exposure to an ALK-I. Participants in this arm had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
62197378|NCT02336451|EXPERIMENTAL|Arm 5 (LepDis)|Participants had LC with or without evidence of active lesion at the baseline Gadolinium-enhanced brain magnetic resonance imaging (MRI). Previous treatment with ALK-I other than crizotinib was not allowed in this arm as of protocol amendment 3.
62197379|NCT00763490|EXPERIMENTAL|Double cord blood transplant|'full intensity, double umbilical cord, stem cell transplant' with 'Flu/Bu4 conditioning regimen'
62399681|NCT01362231|EXPERIMENTAL|Experimental: GS-6624 200mg|
62399682|NCT04654299||standard PD (ST-PD)|Pancreacoduodenectomy with pancreatic-enteric reconstruction and standard hepaticojejunostomy
62576156|NCT02246179|EXPERIMENTAL|2: AFXL + EMLA|This test region will be pretreated with a fractional carbon dioxide laser (ablative fractional laser; AFXL) with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse at t0 in a subject blinded fashion. Eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) will be applied at this test region at t1.Ten minutes after EMLA cream application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam.
62576157|NCT02246179|SHAM_COMPARATOR|3: Sham AFXL + AHES|"A pass with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse will be given at the area right adjacent to this test region (sham AFXL) at t0 in a subject blinded fashion. Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will then be applied at this test region on the intact skin at t1. Ten minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam."
62576158|NCT02246179|SHAM_COMPARATOR|4: Sham AFXL + EMLA|"A pass with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse will be given at the area right adjacent to this test region (sham AFXL) at t0 in a subject blinded fashion. Eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) will then be applied at this test region on the intact skin at t1. Ten minutes after EMLA cream application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam."
62576159|NCT02209519|EXPERIMENTAL|Metronidazole|Male Partner: metronidazole 500 mg PO BID x 7days Female Partner: metronidazole 500 mg PO BID x 7days
62576160|NCT02209519|PLACEBO_COMPARATOR|Placebo|Male Partner: one tablet PO BID for 7 days Female Partner: metronidazole 500 mg PO BID x 7days
62576161|NCT00430573|EXPERIMENTAL|DCS-augmented CBT-IC|D-cycloserine-augmented CBT-IC
62010571|NCT05183685|EXPERIMENTAL|Intervention group|The participants will receive alternative telecare consultation and face to face consultation every 14 weeks.
62197380|NCT05594290|EXPERIMENTAL|Preoperative arm|"Patients will be treated with one cycle of chemo-immunotherapy with retifanlimab (500 mg day 1), cisplatin (25 mg/sqm i.v. day 1, 2 ) or carboplatin (AUC 4 i.v., day 1 - in patients unsuited or unfit for cisplatin) and etoposide (100 mg/sqm iv. day 1, 2, 3).~After receiving the short-course preoperative chemo-immunotherapy study regimen, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant radiation therapy if indicated"
62399683|NCT04654299||PD with external biliary stent(PD-BS)|Pancreacoduodenectomy with pancreatic-enteric reconstruction and hepaticojejunostomy with external biliary stent for externalization of bile fluid
62576162|NCT00430573|PLACEBO_COMPARATOR|Placebo-augmented CBT-IC|Placebo-augmented CBT-IC
62576163|NCT04774367|OTHER|Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps|
62576164|NCT04774367|OTHER|Order of forceps : First large capacity biopsy forceps and second standard biopsy forceps|
62576165|NCT03483233|EXPERIMENTAL|fMRI and EEG study|
62576166|NCT03992027|EXPERIMENTAL|Immediate CF-CBT Intervention|This group will enter immediately into the 8-session cystic fibrosis-specific cognitive-behavioral intervention program (CF-CBT).
62010572|NCT05183685|PLACEBO_COMPARATOR|Control group|The participants will receive usual face to face consultation every 14 weeks.
62010573|NCT06498973|EXPERIMENTAL|Treatment (tagraxofusp, azacitidine)|Patients receive tagraxofusp IV over 15 minutes QD on days 1-3 and azacitidine IV over 10-40 minutes QD on days 1-5 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and bone marrow aspiration and biopsy on study.
62399684|NCT03292770|NO_INTERVENTION|Control Group|Embryo transfer will be performed as per clinic's routine protocol, where cervical mucus is gently removed with a cotton swab. No manipulation of the cervical canal is executed.
62576167|NCT03992027|OTHER|Waitlist control|This group will enter into the same 8-session cystic fibrosis-specific cognitive-behavioral intervention program (CF-CBT) 3 months after enrollment.
62576168|NCT03732937||Control group|Pregnant ladies with no medical disorders from 16 weeks till term
62010574|NCT01175824|EXPERIMENTAL|Insulin lispro low mixture (LM)|Two daily injections (breakfast and dinner) of insulin lispro mix 75/25
62399685|NCT03292770|EXPERIMENTAL|Flushing Group|"A catheter will be used to perform a flushing of the cervical canal with culture media. The Flushing Catheter has a flared proximal end that is designed to affix to a standard Luer slip syringe and a pre-curved distal closed end, with a biseled opening on the side, 2mm from the tip, in which liquid flushes towards the outside of the cervical canal.~Device: Cook Flushing Catheter J-IUIC-352200 (3.5fr 20cm flushing catheter with positioner closed end) (CEE approval)."
62010575|NCT01175824|ACTIVE_COMPARATOR|Insulin glargine+insulin lispro|Once-daily (bedtime) basal insulin glargine and once-daily (before the main meal with the highest average 2-hour postprandial blood glucose concentration) prandial insulin lispro
62399686|NCT00609934|EXPERIMENTAL|Sorafenib and palliative radiotherapy|
62399687|NCT02514642|EXPERIMENTAL|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients withStable Coronary Artery Disease
62399688|NCT02514642|ACTIVE_COMPARATOR|clopidogrel|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose clopidogrel.
62399689|NCT06380374|EXPERIMENTAL|Gamification Group|Program Prepared with Gamification Strategy Based on Multiple Intelligence Theory in Disaster Nursing Education
62399690|NCT06380374|NO_INTERVENTION|Control Group|No intervention will be made to the students in the control group during the educational process of the experimental group, and they will be on the waiting list. After the education process of the students in the experimental group is completed and the post-test data is collected, all interventions and training will be given to the students in the control group.
62576169|NCT03732937||case group|Pregnant ladies with medical disorders from 16 weeks till term
62576170|NCT01162291||movement|healthy subjects, randomised to do flexion and extension movements with their left and right elbow joint after intramuscular application of NaCl 2ml in the right musculus biceps brachii, and 1ml in the left musculus biceps brachii
62576171|NCT01162291||rest|healthy subjects are randomised to rest after intramuscular application of NaCl 1ml in the left and 2ml in the right musculus biceps brachii
62197381|NCT02119897|EXPERIMENTAL|Low Level Light Therapy (LLLT)|"* LLLT: The LLLT device will be positioned next to the face and neck for a total of 6 exposures: Right face, Midline face, Left face, Left neck, Midline neck, Right neck~* Dose per anatomic site 50mW/cm2, 60 sec = 3.0J/cm2~* Route: Extraoral~* Total Treatment Time (all sites): 6 min~* Schedule: Participants will be treated daily (including weekends and holidays) beginning on the first day of HCT conditioning and continuing through day +20 or hospital discharge if prior to day +20.~* Evaluation: Participants will undergo formal mucositis and toxicity assessments at baseline and daily from day -1 through day +20, with a final assessment on the last day of treatment."
62197382|NCT04921618||Index patients|"People aged 18 or more diagnosed with \>= 1 STI in testing centers.~\[STI = bacterial STIs and/or HIV and/or acute hepatitis C virus (HCV)\]"
62197383|NCT04921618||Notified partners|"People aged 18 or more getting STI testing in testing centers after being notified by a sexual partner.~\[STI = bacterial STIs and/or HIV and/or acute HCV\]"
62197384|NCT05435989|EXPERIMENTAL|Normal-hearing listeners|
62197385|NCT01701336|EXPERIMENTAL|Unique Arm|"* Ad6NSmut~* MVA-NSmut~  15 subjects receiving 2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination"
62197386|NCT02980042|EXPERIMENTAL|Switching Group|600 mg of ocrelizumab will be administered as one 600-mg IV infusions at a scheduled interval of every 24 weeks. The first dose of ocrelizumab will be a split dose of 300 mg on day 1 and day 15 followed by 600 mg, six months later. Each ocrelizumab infusion should be given as a slow IV infusion over approximately 150 minutes (2.5 hours) for the 300-mg dose. Ocrelizumab must not be administered as an IV push or bolus. Well-adjusted infusion pumps should be used to control the infusion rate, and ocrelizumab should be infused through a dedicated line.
62197387|NCT02980042|ACTIVE_COMPARATOR|Comparator Group|Standard of care rituximab doses are 1000 mg infusion given as first dose followed by 500mg (or 1000 mg if evidence of early B cell recovery) infusion every 6 months thereafter. Rituximab must not be administered as an IV push or bolus. Well-adjusted infusion pumps should be used to control the infusion rate, and rituximab should be infused through a dedicated line
62197388|NCT01322191|EXPERIMENTAL|1|Random assignment to a single dose of morphine 0.1 mg/kg infused by syringe pump over 10 minutes; urine and blood sample frozen at -80 degrees Celsius
62197389|NCT05101512|EXPERIMENTAL|Patient with critical ischemia of the lower limb|Patient eligible and scheduled for bypass in venous allograft stored at + 4 ° C with distal anastomosis below the knee
62197390|NCT05650970|ACTIVE_COMPARATOR|routinely treated control group|Unlike the study group, radial nerve mobilization will not be included in the treatment program of this group. only massage, ice and activity modification training will be included.
62197391|NCT05650970|EXPERIMENTAL|radial nerve mobilization study group|The treatment program of this group will include massage, radial nerve mobilization, ice and activity modification training.
62399691|NCT04749862||Breast Cancer Participants-Before Phase|Breast cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time.
62399692|NCT04749862||Colorectal (bowel) Cancer Participants-Before Phase|Colorectal cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time.
62399693|NCT04749862||Breast Cancer Participants-After Phase|Breast cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time. In addition they will also complete an online symptom report from home with self-management advice (frequency of completion to be determined in phase 2)
62576172|NCT01488136|ACTIVE_COMPARATOR|Diazoxide|Oral diazoxide 7 mg/kg
62576173|NCT01488136|PLACEBO_COMPARATOR|Placebo|Matched placebo
62010576|NCT02468843||Biphasic DBS stimulations|Subjects in this group with have Biphasic DBS stimulation setting performed, Unified Dystonia Rating Scale (UDRS), and Burke-Fahn- Marsden scale (BFMDRS), tremor accelerometer, kinesia accelerometer, and GaitRite walking assessments performed.
62399694|NCT04749862||Colorectal (bowel) Cancer Participants-After Phase|Colorectal cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time. In addition they will also complete an online symptom report from home with self-management advice (frequency of completion to be determined in phase 2)
62399695|NCT01128699|EXPERIMENTAL|ISA+AVI|injection of intraoperative subconjunctival Avastin as an adjunct to Ahmed valve implant
62576174|NCT00943540|EXPERIMENTAL|Raltegravir BID-QD|"Week 1-4~* 600 mg of atazanavir to be taken once daily~* 400 mg of raltegravir to be taken twice daily~* 300 mg of lamivudine (or 200 mg of emtricitabine) to be taken once daily~Week 5-8~* 600 mg of atazanavir to be taken once daily~* 800 mg of raltegravir to be taken once daily~* 300 mg of lamivudine (or 200 mg of emtricitabine) to be taken once daily"
62197392|NCT01490892|EXPERIMENTAL|3D HI and SHI of UCA|Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
62399696|NCT01128699|ACTIVE_COMPARATOR|AVI|Ahmed valve implant
62399697|NCT03054272||Residents|Anesthesia residents from University of Montreal Anesthesia Department who were watching the video
62399698|NCT03054272||Attending Physicians|Attending physicians from University of Montreal Anesthesia Department who were watching the video
62399699|NCT05156346|EXPERIMENTAL|LEAVES + usual care|The intervention consists of LEAVES online programme + usual care. LEAVES consists of 10 modules of readings and exercises.
62399700|NCT05156346|NO_INTERVENTION|usual care|The control arm consists of the usual care which entails continuation of existing medication, with or without adjustments, continuation of the person's usual medical, psychological and/or nursing appointments whenever previously scheduled or deemed necessary. GRAI will also be given to participants at baseline (t0) and those meeting the criteria will be referred to specialized grief appointments.
62399701|NCT02377258||1|without previous or ongoing exposure to IS or biologics, (5ASA and Steroids are allowed)
62399702|NCT02377258||2|with on-going anti-TNF monotherapy
62399703|NCT02377258||3|with thiopurines monotherapy
62399704|NCT02377258||4|with on-going combination therapy
62399705|NCT02377258||5|patients on vedolizumab (1 on vedolizumab alone and 1 on combination therapy)
62399706|NCT02377258||6|patients on ustekinumab (alone or on combination therapy)
62399707|NCT04669275|EXPERIMENTAL|telephone counseling|People receiving telephone counselling.
62576175|NCT00894439|EXPERIMENTAL|1|
62399708|NCT04669275|EXPERIMENTAL|telephone counselin|People receiving telephone counselling.
62576176|NCT01332760|ACTIVE_COMPARATOR|narrow diameter heavy dental tool|periodontal tools for dental scaling and cleaning provided that have a narrow diameter (8mm) made of heavy material (steel).
62576177|NCT01332760|EXPERIMENTAL|light large diameter dental tool|periodontal tools for scaling and tooth cleaning provided with large diameter (11mm) handle made of light weight material
62197393|NCT01226732|EXPERIMENTAL|Dose Level 1|Hsp90 Inhibitor AUY922: 22mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
62197394|NCT01226732|EXPERIMENTAL|Dose Level 2|Hsp90 Inhibitor AUY922: 28mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
62399709|NCT04501874|ACTIVE_COMPARATOR|EMB-001 Active|EMB-001 Combination product of 720 mg metyrapone/24 mg oxazepam mg by mouth twice per day for 12 weeks followed by a 1 week taper
62576178|NCT04770220|EXPERIMENTAL|ALZ-801|ALZ-801 265 mg BID tablet orally. Subjects will receive placebo in the morning and one table of ALZ-801 265mg tablet in the evening during the first two weeks of the study; thereafter, they will receive a 265mg tablet BID.
62576179|NCT04770220|PLACEBO_COMPARATOR|Placebo|Subjects in the placebo treatment arm will receive placebo tablets BID throughout the study
62576180|NCT05684861|ACTIVE_COMPARATOR|Group I patients|90 patients with acne vulgaris Patients classified according to the global acne grading system(GAGS) into moderate, severe, and very severe cases
62010577|NCT01976416|EXPERIMENTAL|Hydroxyurea|Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
62010578|NCT01976416|PLACEBO_COMPARATOR|Placebo|Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
62399710|NCT04501874|PLACEBO_COMPARATOR|EMB-001 Placebo|EMB-001 Placebo by mouth twice per day for 12 weeks followed by a 1 week taper
62399711|NCT06062810|EXPERIMENTAL|Crizotinib - Usual|"* XALKORI - Crizotinib~* Chemotherapy~* XALKORI - crizotinib capsule~* XALKORI 250 mg taken orally twice daily~* Usual Approach Group (high dose)"
62399712|NCT06062810|EXPERIMENTAL|Crizotinib - Study|"* XALKORI - Crizotinib~* Chemotherapy~* XALKORI - crizotinib capsule~* XALKORI 200 mg taken orally twice daily~* Usual Approach Group (low dose)"
62399713|NCT05901766|EXPERIMENTAL|Iodine Containing Multiple Micronutrient (UNIMAP)|UNIMAP 1 tablet po once daily from birth to 6 months postpartum
62399714|NCT05901766|NO_INTERVENTION|Routine care (IFA)|Routine clinical care includes iron folic acid (IFA) for 1 month post partum
62399715|NCT03156946|EXPERIMENTAL|Breastfeeding support program|
62399716|NCT03156946|OTHER|Usual or routine care|
62399717|NCT03732274|EXPERIMENTAL|Dose Escalation of TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) and Durvalumab administration.
62399718|NCT01527331|NO_INTERVENTION|control group|usual care
62399719|NCT01527331|EXPERIMENTAL|Video decision aid arm|
62399720|NCT01345266|OTHER|Inhalation Profiling|All subjects have Inhaltion profiling, there are no other arms.
62399721|NCT01298817|EXPERIMENTAL|Soy, Prepared Meals|Soy-based meal replacement weight loss group with additional meals provided
62399722|NCT01298817|ACTIVE_COMPARATOR|Non soy prepared meals|Non-soy based meal replacement weight loss group with additional meals provided
62576181|NCT05684861|ACTIVE_COMPARATOR|Control group|60 age-sex-matched healthy subjects as a control group
62576182|NCT02861586|EXPERIMENTAL|Treatment Group A; MV-CHIK low|"60 subjects will receive i.m. vaccinations with MV-CHIK low dose (5xE4 (± 0.5 log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
62010579|NCT00058240|EXPERIMENTAL|Arm I|Patients receive a loading dose of flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression.
62010580|NCT04877197|EXPERIMENTAL|BA-HT|Behavioral Activation for depression delivered via home-based telehealth (BA-HT) will be implemented over 12, weekly 50-minute sessions via VA approved telehealth software.
62010581|NCT04877197|ACTIVE_COMPARATOR|Standard Care|Best practices standard care delivery for post-CVD hospitalization as regularly implemented at the RHJ VAMC. Standard care may include all or some of the following: post-operative follow up, referral to VA primary care clinic at 1 month post-procedure, primary care visit with VA mandated assessments of pain and depression with referral for these conditions, referral to facility-based or home-based cardiac rehabilitation program as appropriate. All participants in this condition will be referred to mental health care. In addition, these participants will receive a weekly telephone call from project staff during which time supportive questioning about patient progress and general mood and recovery.
62197395|NCT01226732|EXPERIMENTAL|Dose Level 3|Hsp90 Inhibitor AUY922: 40mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
62197396|NCT01226732|EXPERIMENTAL|Dose Level 4|Hsp90 Inhibitor AUY922: 55mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
62576183|NCT02861586|ACTIVE_COMPARATOR|Treatment Group A/C; Priorix®|"20 subjects will receive i.m. vaccinations with Priorix® on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
62576184|NCT02861586|EXPERIMENTAL|Treatment Group B; MV-CHIK low|"60 subjects will receive i.m. vaccinations with placebo on study day 0. MV-CHIK low dose (5xE4 (± 0.5 log) TCID50 per 0.3 mL) on day 28 and MV-CHIK boosting dose on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
62576185|NCT02861586|ACTIVE_COMPARATOR|Treatment Group B/D; Priorix®|"20 subjects will receive i.m. vaccinations with placebo on study day 0, Priorix® on day 28 and one boosting dose with Priorix® on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
62576186|NCT02861586|EXPERIMENTAL|Treatment Group C; MV-CHIK high|"60 subjects will receive i.m. vaccinations with MV-CHIK high dose (5xE5 (± 0.5 log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
62576187|NCT02861586|EXPERIMENTAL|Treatment Group D; MV-CHIK high|"60 subjects will receive i.m. vaccinations with placebo on study day 0, MV-CHIK high dose (5xE5 (± 0.5 log) TCID50 per 0.3 mL) on study day 28 and MV-CHIK boosting dose on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
62576188|NCT02861586|EXPERIMENTAL|Measles Booster Group 1|"20 subjects will receive i.m. vaccinations with Priorix® on study day -28, MV-CHIK on day 0 and 28 and placebo on day 168 and 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
62010582|NCT00860652|EXPERIMENTAL|Adjuvant Radiotherapy (RT)|Adjuvant Radiotherapy (64Gy in 32 Fractions to the prostate bed)
62197397|NCT01226732|EXPERIMENTAL|Dose Level 5|Hsp90 Inhibitor AUY922: 70mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
62197398|NCT01226732|EXPERIMENTAL|Dose Level 6|Hsp90 Inhibitor AUY922: 70mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1250mg/m2 PO BID d 1-14 of 21-day cycles
62197399|NCT01643070|ACTIVE_COMPARATOR|XELOX RT|Concurrent XELOX-RT
62197400|NCT01643070|ACTIVE_COMPARATOR|Induction XELOX|Induction XELOX followed by XELOX-RT
62576189|NCT02861586|EXPERIMENTAL|Measles Booster Group 2|"20 subjects will receive i.m. vaccinations with Priorix® on study day -28, placebo on day 0 and 28 and MV-CHIK on day 168 and 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
62734742|NCT04666142|ACTIVE_COMPARATOR|Comparison of the Individuals in the experimental and control groups after 24 hours of sleep|The effect of light after 24 hours in the experimental and control groups of individuals hospitalized in the intensive care unit was examined.
62197401|NCT01241604|ACTIVE_COMPARATOR|Respironics BiPAP S/T|Control Arm using Respironics BiPAP S/T
62399723|NCT03763448|EXPERIMENTAL|Infrapatellar Fat Pad Preservation|The IPFP retention of more than 80% in actual operation shall be regarded as IPFP retention.
62399724|NCT03763448|ACTIVE_COMPARATOR|Infrapatellar Fat Pad Resection|In the clinical practice, more than 80% of IPFP volume is commonly resected by surgeons during total knee arthroplasty. The investigators hereby define resection of more than 80% IPFP volume as IPFP excision.
62399725|NCT05403944|ACTIVE_COMPARATOR|Standard of Care (SOC)|The SOC rehabilitation group will complete three strength sessions a week. All participants will be provided an educational pamphlet and exercises will be divided into four components - hip abductors, hip extensors, core, and quadriceps muscles. The load magnitude for exercises will be between 60-70% of their 1 repetition max (1RM), with 3 sets of 12 repetitions and a 2-3-minute rest between sets. Time under tension will be prescribed as slow to moderate, with a 2-second concentric phase and 2-second eccentric phase for each exercise. Hip abductor, hip extensor, and core exercises will be initiated during week 1 and continued for the 6-week intervention, while quadriceps focused exercises will be introduced in weeks 3-6.
62399726|NCT05403944|EXPERIMENTAL|Strength Training Rehabilitation Incorporating Power Exercises (STRIPE)|Those in the STRIPE group will complete two power and one strength training sessions a week. All participants will be provided an educational pamphlet and exercises will be divided into four components - hip abductors, hip extensors, core, and quadriceps muscles. The load magnitude will be greater than 60% of the 1RM, with the goal of continually loading against heavy resistance. Participants will complete 4 sets of 6 repetitions, with 3-5 minutes of rest between sets. Time under tension will be prescribed as \<1 second for the concentric phase and 1 second for the eccentric phase of the exercise. The strength training sessions will adhere to same parameters as the SOC. Hip abductor, hip extensor, and core exercises will be initiated during week 1 and continued for the 6-week intervention, while quadriceps focused exercises will be introduced in weeks 3-6.
62399727|NCT02244827|EXPERIMENTAL|WCK 2349|Each subject will receive a single oral dose of WCK 2349 1000 mg (i.e., 2 tablets of 400 mg and 1 tablet of 200 mg) with 240 mL water on Day 1 in the morning. Study drug will be administered after a fast of at least 8 hours.
62399728|NCT06365164||Premature newborns|Children born prematurely between 28 and 37 weeks of amenorrhoea, aged at least 3 days.
62399729|NCT00814502|ACTIVE_COMPARATOR|Zolpidem CR|Subjects randomized to Zolpidem CR
62399730|NCT00814502|PLACEBO_COMPARATOR|Placebo|Subjects randomized to Placebo
62197402|NCT01241604|ACTIVE_COMPARATOR|Respironics BiPAP Auto SV3|Treatment arm using Respironics BiPAP Auto SV3
62197403|NCT02931422|EXPERIMENTAL|Low Financial Incentive|Conditional cash transfer upon HIV testing
62399731|NCT01172327|EXPERIMENTAL|Multicomponent exercise|This arm is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks.
62399732|NCT01172327|ACTIVE_COMPARATOR|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks.
62576190|NCT03697512|EXPERIMENTAL|Ibrutinib and Rituximab|"Induction PART A, from Day 1 to Day 56.~Patients will be treated with:~* Ibrutinib 560 mg/day continuously up to Day 56;~* Rituximab 375 mg/m2 intravenously at Day 1, and then subcutaneous (1400 mg, flat dose) at Day 8, 15 and 22 of cycle 1.~Induction PART B, from Day 57 to Day 196.~Patients will be treated with:~* Ibrutinib 560 mg/day continuously up to Day 196;~* Rituximab subcutaneous (1400 mg, flat dose) at Day 1 every 28 days for 4 cycles.~Maintenance PART C, from Day 197 to Day 730.~Patients will be treated with:~- Ibrutinib 560 mg/day continuously up to Day 730."
62197404|NCT02931422|EXPERIMENTAL|Medium Financial Incentive|Conditional cash transfer upon HIV testing
62197405|NCT02931422|EXPERIMENTAL|High Financial Incentive|Conditional cash transfer upon HIV testing
62197406|NCT00245960|ACTIVE_COMPARATOR|A|Period 1 (Double Blind): 50mg bi-weekly (BIW) for weeks 1-12. Period 2 (Open Label): 50 mg weekly (QW).
62197407|NCT00245960|ACTIVE_COMPARATOR|B|Period 1 (Double Blind): 50mg weekly (QW) with matching placebo for weeks 1-12. Period 2 (Open Label): 50 mg weekly (QW) for weeks 13-24.
62010583|NCT00860652|EXPERIMENTAL|Active Surveillance with Early SalvageRT|Active Surveillance with Early Salvage Radiotherapy
62197408|NCT04878549||Febrile Adults|1200 adult participants (15 to 45 years old) with a febrile illness without localising features and reported duration of 3-14 days.
62197409|NCT04878549||Controls|400 afebrile, healthy adult participants (15 to 45 years old).
62576191|NCT01102868|SHAM_COMPARATOR|Needle in acupuncture point Li11|Acupuncture needle in the acupuncture point Li11
62576192|NCT01102868|EXPERIMENTAL|IMS of musculus pronator teres|Acupuncture needle in musculus pronator teres
62197410|NCT04878549||Febrile Children|400 child participants (2 to 14 years old) with a febrile illness without localising features and reported duration of 3-14 days. This is an exploratory arm of the study.
62197411|NCT05770960|ACTIVE_COMPARATOR|Naloxegol - Codeine phosphate|Participants will receive Naloxegol 25 mg and Codeine syrup in 30 mL and an additional 15 mL at a later stage during the day.
62197412|NCT05770960|OTHER|Placebo - Codeine phosphate|Participants will receive Placebo instaid of Naloxegol 25 mg and Codeine syrup in 30 mL and an additional 15 mL at a later stage during the day.
62576193|NCT03530592|EXPERIMENTAL|Seated Ankle Robot Training|
62197413|NCT05770960|OTHER|Naloxegol - Placebo|Participants will receive Naloxegol 25 mg and Sirupus simplex syrup (as a placebo alternative for Codeine syrup) in 30 mL and an additional 15 mL at a later stage during the day.
62197414|NCT03092817|ACTIVE_COMPARATOR|Dexamethasone|standard anti-tuberculosis drugs plus dexamethasone for 6-8 weeks
62197415|NCT03092817|PLACEBO_COMPARATOR|Identical placebo|standard anti-tuberculosis drugs plus placebo for 6-8 weeks
62197416|NCT02487043|EXPERIMENTAL|Dental health coaches|Telephone-based case-management intervention. Contact with families every 2 weeks during one year. Including motivational interviewing, support for dental preventive measures at home, answer questions, care coordination) + conventional protocol (Fluoride prevention program)
62197417|NCT02487043|NO_INTERVENTION|Control group|Conventional protocol (Fluoride prevention program) and follow-up as usual
62197418|NCT00312598||aripiprazole|observational measures of metabolic parameters of subjects who are making clinically determined medication switch to aripiprazole
62576194|NCT02484274|OTHER|infants followed by pediatrician|
62576195|NCT04409236|EXPERIMENTAL|Arm I (Quit2Heal app)|Patients receive the Quit2Heal app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.
62576196|NCT04409236|ACTIVE_COMPARATOR|Arm II (QuitGuide app)|Patients receive the QuitGuide app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.
62576197|NCT02201108|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets
62576198|NCT02201108|EXPERIMENTAL|Teriflunomide|Teriflunomide oral tablet, three dosages (3.5, 7 or 14 mg) to reach 14 mg adult equivalent
62010584|NCT05257265|EXPERIMENTAL|Centanafadine 164.4 mg|Participants received centanafadine hydrochloride 164.4 milligrams (mg) XR capsules, orally, QD up to 6 weeks.
62010585|NCT05257265|EXPERIMENTAL|Centanafadine 328.8 mg|Participants received centanafadine hydrochloride 328.8 mg XR capsules, orally, QD up to 6 weeks.
62010586|NCT05257265|PLACEBO_COMPARATOR|Placebo|Participants received centanafadine matching placebo capsules, orally, QD up to 6 weeks.
62010587|NCT02716844|EXPERIMENTAL|Exercise Group,|Clinical Pilates exercise were given for 6 weeks, 3 days in a week
62197419|NCT01947569|EXPERIMENTAL|iDC recipients|iDC cells modified by in vitro engineering.
62197420|NCT01947569|ACTIVE_COMPARATOR|Control DC recipients|DC cells which have not been modified.
62197421|NCT01947569|PLACEBO_COMPARATOR|Placebo recipients|Saline injections.
62197422|NCT02775006|ACTIVE_COMPARATOR|Docetaxel|Docetaxel 75mg/m2 every 21 days until disease progression or toxicity related
62197423|NCT02775006|ACTIVE_COMPARATOR|Docetaxel plus erlotinib|Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days, until disease progression, or toxicity related.
62197424|NCT02234947||New onset of Type 1 Diabetes|The subjects with new onset of Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
62576199|NCT05074121|EXPERIMENTAL|NAC|Group receiving intervention/study drug NAC
62576200|NCT05074121|PLACEBO_COMPARATOR|Placebo|Group receiving placebo
62576201|NCT04478695|EXPERIMENTAL|Cohort 1|
62576202|NCT04478695|EXPERIMENTAL|Cohort 2|
62576203|NCT02168257|EXPERIMENTAL|RAM Cannula CPAP|CPAP provided by RAM Cannula
62576204|NCT02168257|ACTIVE_COMPARATOR|Binasal Prong CPAP|CPAP provided by binasal prong
62197425|NCT02234947||Antibody Positive Risk for Diabetes|The subjects with single or double antibody positive risk for Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
62197426|NCT02234947||Antibody Negative Risk for Diabetes|The subjects with antibody negative risk for Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
62197427|NCT02234947||Healthy Control|The subjects has no family history for Type 1 Diabetes. They will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
62197428|NCT03497403|ACTIVE_COMPARATOR|Control|Socket preservation control. After tooth extraction, bone graft is applied to socket and a non-cross-linked membrane is used in primary intentional healing.
62197429|NCT03497403|EXPERIMENTAL|Experimental|Socket preservation experimental. After tooth extraction, bone graft is applied to socket and a cross-linked membrane is used in secondary intention healing.
62197430|NCT02766127|EXPERIMENTAL|Xerostomic Patients|"Patients with evident clinical signs of xerostomia who experienced dentinal hypersensitivity after undergoing radiation therapy due to head and neck cancer.~The following dental materials will be used following the manufacturers' instructions: Veritise Flow; Universal Dentin Sealant; Clearfil Protect Bond, and Flor-Opal® Varnish. In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.~the application of the materials will be made only once. The effectiveness will be evaluated: immediately after application and after 1, 4, 12 weeks."
62197431|NCT02360722|EXPERIMENTAL|Oral Nutritional Supplement|ONS + Nutritional education
62197432|NCT02360722|OTHER|Control Group|Nutritional education only
62197433|NCT00371384|EXPERIMENTAL|2|structural massage
62197434|NCT00371384|EXPERIMENTAL|1|relaxation massage
62197435|NCT01351168|PLACEBO_COMPARATOR|Sugar pill|
62197436|NCT01351168|ACTIVE_COMPARATOR|Levodopa|
62197437|NCT01351168|EXPERIMENTAL|Zolpidam second dose|
62197438|NCT01351168|EXPERIMENTAL|Zolpidam first dose|
62197439|NCT01507649|NO_INTERVENTION|Control|
62010588|NCT02716844|NO_INTERVENTION|Control Group|Nothing given to control group, told to continue their normal life for 6 weeks.
62197440|NCT01507649|EXPERIMENTAL|Telephone-based intervention|
62010589|NCT02046434|EXPERIMENTAL|Parkinson's Diesase|Participant will take Glycerol Phenylbutyrate, participant has Parkinson's Disease
62197441|NCT03849703|EXPERIMENTAL|Full Intervention #1|Participants will receive both of our target curricula but in alternate order. This treatment group will receive the coparenting curriculum before the romantic relationships curriculum.
62197442|NCT03849703|EXPERIMENTAL|Full Intervention #2|Participants will receive both of our target curricula but in alternate order. This treatment group will receive the romantic relationships curriculum before the coparenting curriculum.
62399733|NCT04235127||Catalan population|The target population consists of the dynamic cohort of all Catalan residents during the 6-year period 2014-2019. Annual total population of Catalonia is between 7.5-7.6 million, with annual rates for immigration, emigration, birth and death being \~2.5%, \~1.9%, \~0.9%, and \~0.8%, respectively. Based on these figures, we expect a maximum of \~9.1 million individuals with Catalan residency status on at least one point in time over the 2014-2019 period. However, we expect SA in Catalonia to be extremely rare before the age of 10, in line with findings that self-injurious behaviour generally occurs as from the adolescent period. We will therefore exclude cases and controls that have not reached age 10 by the end of the 2014-2019 period (i.e., \~10.9%), lowering the total expected target population to \~8.1 million.
62399734|NCT06515847|EXPERIMENTAL|Kolcaba's nursing care plan|While the patients of experimental group were cared according to the nursing care plan based on Kolcaba's comfort theory,
62399735|NCT06515847|NO_INTERVENTION|standard care plan|the patients of control group received the standard care plan of the institution
62576205|NCT04929392|EXPERIMENTAL|Treatment (chemoradiation, pembrolizumab, lenvatinib)|"CHEMORADIATION PHASE: Patients receive carboplatin IV and paclitaxel IV QW for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo EBRT over 6 weeks and receive pembrolizumab IV over 30 minutes on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity.~WINDOW PERIOD: Patients receive pembrolizumab IV over 30 minutes on day 1 of week 3 and lenvatinib mesylate PO QD at weeks 3-6 in the absence of disease progression or unacceptable toxicity.~SURGERY/SURVEILLANCE: Patients without complete response undergo standard of care surgical resection. Patients with complete response/pursue non-operative management undergo surveillance via periodic endoscopic biopsy."
62010590|NCT02046434|EXPERIMENTAL|Control|Participant does not have Parkinson's Disease, Participant will be taking glycerol phenylbutyrate
62010591|NCT05932199|EXPERIMENTAL|Induction dual immunotherapy with durvalumab / tremelimumab|3 cycles of durvalumab (1500 mg intravenously) + tremelimumab (75 mg intravenously) starting Cycle1 Day (Cohort A).
62010592|NCT05932199|EXPERIMENTAL|Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab|3 cycles of durvalumab (1500 mg intravenously) + tremelimumab (75 mg intravenously) with cisplatin 75mg/ m2 (or carboplatin AUC 5-6) + pemetrexed 500 mg/m2 (Cohort B).
62197443|NCT03849703|OTHER|Partial Intervention #1|Participants will receive the romantic relationships curriculum along with the control curriculum.
62197444|NCT03849703|OTHER|Partial Intervention #2|Participants will receive the coparenting curriculum along with the control curriculum.
62197445|NCT03092128||sensitive group; non-sensitive group|sensitive patients were defined as patients reached CR or PR after first month administration,SD after first three months administration. non-sensitive patients were defined as patients reached PD after first month administration and first three months administration.
62399736|NCT06713954||Female footballers|Female footballers of varying ages, playing positions and countries
62399737|NCT04941833|EXPERIMENTAL|Desogestrel group|Desogestrel group
62399738|NCT04941833|PLACEBO_COMPARATOR|Control group|Placebo
62010593|NCT02180425||Healthy Group|The subjects in this group do not have a history of acne.
62010594|NCT02180425||Acne Group, Topical Retinoid|These subjects have been prescribed a topical retinoid for their acne. They will participate in the study for a period of 1 month.
62576206|NCT02099617|EXPERIMENTAL|Drug Eluting Stent|Synergy II
62010595|NCT02180425||Acne Group, Isotretinoin|These subjects have been prescribed isotretinoin for their acne. They will participate in the study for a period of 5-6 months.
62010596|NCT03587259|ACTIVE_COMPARATOR|2D mammography|45-46 years old women are invited to attend the usual screening examination (2D mammography). The next year they will be invited to make a 2D mammography, according to screening protocol.
62197446|NCT01792531|EXPERIMENTAL|Treatment focus - Parenting vs lifestyle|To determine the effectiveness of two obesity treatment interventions: 1) parent training group (n=90) and 2) standard treatment with focus on lifestyle (n=90). The two treatment conditions will be evaluated with respect to child weight status (BMI SDS; primary outcome), psychosocial and metabolic health, lifestyle choices, and family functioning (secondary outcomes). This design will allow us to assess whether a program targeting only parents and focusing on parenting practices will result in better outcomes than treatment as usual emphasizing lifestyle changes.
62197447|NCT01792531|EXPERIMENTAL|Length of treatment|To understand the influence of treatment duration by comparing the effectiveness of two obesity treatment interventions: the parent training group administered for 12 wks only (n=45) and the parent training group with booster sessions which include additional booster sessions at 8-week intervals for the following year (n=45). Thus we will randomize families to either a group with booster sessions or without. This design will allow us to evaluate if prolonged care is necessary to maintain intervention effects, or if a 12-week program is equally effective.
62197448|NCT01839942||no gap closure|no hernia gap closure
62197449|NCT01839942||extracorporal gap closure|"extracorporal hernia gap closure~extracorporal suturing of gap"
62197450|NCT01839942||intracorporal gap closure|intracorporal hernia gap closure
62010597|NCT03587259|EXPERIMENTAL|Tomosynthesis|45-46 years old women are invited to attend the Digital Breast Tomosynthesis (DBT) in adjunct to synthetic mammograms (sDM). The next year they will be invited to make a 2D mammography, according to screening protocol.
62010598|NCT05204134|EXPERIMENTAL|Control-IQ Technology with Algorithm Derived Initial Profile Settings and Regular Updates|After CGM run-in, participants will begin use of Control-IQ technology with algorithm derived initial insulin delivery settings, then have regular settings updates from the algorithm through 13 weeks of use.
62010599|NCT03996928|EXPERIMENTAL|Eccentric exercise by physiotherapist|"A physiotherapist will apply (in this order) a plan of stretching exercises, warm-up exercises and eccentric exercises of epicondylar muscle,according to a program of 10 sessions of 20 minutes each, during two weeks.~Before exercise, ultrasounds will be applied at intensity of 0.1 wat/cm2, which is considered as a placebo, in order to achieve greater adherence and monitor the treatment."
62010600|NCT03996928|ACTIVE_COMPARATOR|Illustrated booklet|A physiotherapist will train the patient an exercise plan equivalent to the one above explained with the help of illustrations. Now, in order to achieve palmar flexion at the same time the patients will contract their epicondylar muscles (the eccentric effect), and elastic band is used.
62010601|NCT02275897|EXPERIMENTAL|Slow Speed|Slow group patients will receive spinal injection over 60 seconds. Vital signs monitored every minute after injection. Hypotension is treated with IV Phenylephrine or Ephedrine.
62197451|NCT00476242|EXPERIMENTAL|Memantine and Vivitrol|intramuscular injection of Vivitrol 380 mg and 20 mg bid Memantine (PO)
62576207|NCT02099617|ACTIVE_COMPARATOR|Bare Metal Stent|Omega or Rebel
62576208|NCT06059014|EXPERIMENTAL|177Lu-PSMA-1|Radiopharmaceutical - injectable solution
62010602|NCT02275897|EXPERIMENTAL|Fast Speed|Fast group patients will receive spinal injection over 15 seconds. Vital signs monitored every minute after injection. Hypotension is treated with IV Phenylephrine or Ephedrine.
62010603|NCT06032286|EXPERIMENTAL|Microneedling|4 microneedling sessions at baseline and days 30, 60 and 90.
62010604|NCT06433414|NO_INTERVENTION|Usual Care|"Participants receiving usual care will only receive the SDMG patient handout from their community pharmacist. This handout has been adapted from the Diabetes Canada How to Stay Safe When You Are Sick SDMG patient resource as well as the results of a modified Delphi study conducted by the research team to achieve consensus among 25 international clinicians on recommendations for SDMG for people with diabetes, kidney, or cardiovascular disease. This handout will be reviewed and refined with input from people with lived experience with the chronic conditions of interest prior to the study and is intended to provide guidance on how to self-manage medications during a sick day event."
62197452|NCT00476242|PLACEBO_COMPARATOR|Placebo and Vivitrol|intramuscular injection of Vivitrol 380 mg and Placebo
62197453|NCT06178770||Overall cohort|
62197454|NCT06178770||12-month BRO cohort|
62197455|NCT06178770||18-month BRO cohort|
62197456|NCT06178770||12-month ALT cohort|
62197457|NCT06178770||18-month ALT cohort|
62197458|NCT05876390||Patients undergoing oncological breast surgery|"* mastectomy + reconstruction~* simple quadrantectomy~* quadrantectomy + sentinel lymph node biopsy~* quadrantectomy + axillary hollowing~* bilateral interventions will also be considered"
62197459|NCT03949400||Patients diagnosed with knee OA|Patients diagnosed with knee OA and assigned to undergo exercise therapy and education.
62197460|NCT02193490|ACTIVE_COMPARATOR|DNase|DNase 0.1% eye drops four times a day for 8 weeks
62576209|NCT06447246||Children With Obesity|No intervention or treatment will be administered. This group will not return after initial visits.
62197461|NCT02193490|PLACEBO_COMPARATOR|Vehicle|Drug vehicle eye drops four times a day for 8 weeks
62576210|NCT06447246||Children Without Obesity|No intervention or treatment will be administered. This group will not return after initial visits.
62576211|NCT01548911|EXPERIMENTAL|Treatment (monoclonal antibody therapy)|Patients receive gemtuzumab ozogamicin IV over 2 hours on days 1 and 15. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
62197462|NCT02116569|EXPERIMENTAL|Daratumumab 8 milligram per kilogram (mg/kg)|Participants will be administered intravenously with daratumumab at a dose of 8 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation.
62197463|NCT02116569|EXPERIMENTAL|Daratumumab 16 mg/kg|Participants will be administered intravenously with daratumumab at a dose of 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation.
62197464|NCT05827094|EXPERIMENTAL|Mobile Intervnetion|Participants randomized to the intervention arm will receive verbal and written instructions as well as one-on-one demonstration of the app features. Participants will have an option of either receiving the study mobile device or will be able to use their own device with an installed app. Following the training, participants will be asked to use the app at least once a week.
62197465|NCT05827094|ACTIVE_COMPARATOR|Usual Care|Participants randomly allocated to the control group will receive educational materials on healthy eating, as provided on the NIA web page (https://www.nia.nih.gov/health/healthy-eating).
62197466|NCT04451447|EXPERIMENTAL|white test arm|The White test uses fat emulsion (SMOFLIPID), which is a lipid emulsion with a lipid content of 0.2 grams/mL in 100 mL, 250 mL, and 500 Ml that is normally used for parenteral nutrition, for localization of bile leakage.
62197467|NCT04451447|OTHER|Saline test arm|The conventional intra-operative saline test, which involves injecting an isotonic sodium chloride solution through the cystic duct, has been used for detection of leaking points from the transected liver surface.
62399739|NCT01269138||Factor VII Deficient Patients|Patients affected by Inherited Factor VII deficiency undergoing treatment for bleeding episodes, surgery , prophylaxis.Any patient with levels of FVII less than 50% of normal or a mutation known to be associated to a FVII deficiency. Any patient with a FVII deficiency for whom treatment of bleeding episodes, prevention related to surgery and primary/secondary prophylaxis is considered necessary by his/her treating physician can be enrolled.
62576212|NCT00748462|EXPERIMENTAL|1|Fractional CO2 laser resurfacing
62197468|NCT00624247|OTHER|Immediate|Individuals assigned to be approached for routine HIV testing immediately upon admission to the jail.
62197469|NCT00624247|OTHER|Following Day|Individuals assigned to be approached for routine HIV testing the day following admission to the jail.
62197470|NCT00624247|OTHER|Delayed|Individuals assigned to be approached for routine HIV testing several days following admission to the jail.
62197471|NCT06169072|OTHER|Sentinel node detection with 0.1mL SPIO and Technetium99|An intradermal injection of SPIO (MagTrace®), according to the pre-specified dose of 0.1mL, will be performed 7 days, up to the day of surgery. The injection should be in the skin over the tumour, or at the border of the areola. All patients will also receive technetium per routine.
62197472|NCT02630680||Colorectal diseases patients|
62197473|NCT00636740|EXPERIMENTAL|B|MER-101 20mg Tablets Regimen 1
62399740|NCT03479957|EXPERIMENTAL|REMOTE-CR|Remotely monitored and coached exercise training in real time using the REMOTE-CR system. The patients randomized to remotely monitored exercise can either work out with self-selected activities e.g. Nordic-walking, cycling, skiing or participate in supervised exercise session via video link.
62399741|NCT03479957|OTHER|Usual care|The patients randomized to be controls will receive individualized information and instructions regarding current exercise recommendations but will not be monitored or coached during their exercise sessions (usual care).
62399742|NCT04837807|EXPERIMENTAL|Unit Dose First, Then Multi-Dose|Subjects randomized to this group will apply the unit-dose version of Systane Hydration PF to determine if it helps alleviate symptoms associated with digital eye strain.
62399743|NCT04837807|EXPERIMENTAL|Multi Dose, Then Unit Dose|Subjects randomized to this group will apply multi-dose version of Systane Hydration PF to determine if it helps alleviate symptoms associated with digital eye strain.
62399744|NCT01830621|ACTIVE_COMPARATOR|BBI608|BBI608 480 mg two times daily (960 mg total daily dose)+ Best Supportive Care
62399745|NCT01830621|PLACEBO_COMPARATOR|Placebo|Placebo two times daily + Best Supportive Care
62399746|NCT03666494|ACTIVE_COMPARATOR|Control Arm|As part of the patient's anesthetic induction, they will receive propofol and fentanyl.
62399747|NCT03666494|ACTIVE_COMPARATOR|Ketamine Arm|As part of the patient's anesthetic induction, they will receive propofol, fentanyl, as well as ketamine hydrochloride.
62399748|NCT03240042|EXPERIMENTAL|Nasoendo group|Participants received nasotracheal intubation under general anesthesia for the anterior cervical spine surgery.
62399749|NCT03240042|OTHER|Oroendo group|Participants received orotracheal intubation under general anesthesia for the anterior cervical spine surgery.
62399750|NCT02156570|EXPERIMENTAL|Sofosbuvir and ribavirin|"Sofosbuvir tablet 400 mg daily Ribavirin tablet weight based dosing (1000mg \<75 kg, 1200mg \>/= 75kg) daily~Treatment will be for 6 weeks in all participants."
62399751|NCT01085331|EXPERIMENTAL|Part 1 or Safety Run-in Part: Pimasertib+FOLFIRI|
62399752|NCT01085331|EXPERIMENTAL|Part 2 or Phase 2 Randomized part: Pimasertib+FOLFIRI|Planned, not performed
62399753|NCT01085331|EXPERIMENTAL|Part 2 or Phase 2 Randomized part: Placebo+FOLFIRI|Planned, not performed
62399754|NCT06722573|EXPERIMENTAL|MIED group|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge, and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression, and other emotional problems.
62399755|NCT06722573|NO_INTERVENTION|waitlist control group|no intervention
62399756|NCT04084925||Diabetics with NAFLD|Diabetics whose abdominal ultrasound showed that they have NAFLD
62576213|NCT01341171||tamoxifen or aromatase inhibitors|
62576214|NCT01762917||Obstruction|Patients suffering from pulmonary obstruction
62197474|NCT00636740|EXPERIMENTAL|C|MER-101 20mg Tablets Regimen 2
62197475|NCT00636740|ACTIVE_COMPARATOR|A|Zometa Injection
62576215|NCT01762917||Restriction|Patients suffering from pulmonary restriction
62576216|NCT01762917||Controls|Pulmonary healthy controls
62197476|NCT05338385|EXPERIMENTAL|Intervention|Participants will receive mental skills training in addition to receiving standard-of-care ACL reconstruction and follow-up care. The goal of mental skills training is to help athletes maximize performance, reach self-determined goals, and build confidence in their fields of play. Many of the same tools that benefit athletes in sport performance also translate to their injury experience. Mental conditioning helps athletes navigate the many ups and downs that accompany ACL injury and recovery. Athletes are taught techniques to maintain their sport mindset by capitalizing on motivation, consistency, and resilience. One-on-one sessions are athlete-centered, and are designed to encourage exploration and growth through tangible mental skills strategies.
62197477|NCT01317329|OTHER|Clinically prescribed CPAP therapy|Clinically prescribed CPAP therapy
62197478|NCT03486483|EXPERIMENTAL|Supervised Slackline Training|Supervised Slackline training in children and teenagers with spastic cerebral palsy (grade I and II of the Gross Motor Function Classification System). Intervention included 18 slackline rehabilitation sessions for 6 weeks: 3 sessions per week on non-consecutive days, 30 min each one.
62197479|NCT03486483|NO_INTERVENTION|Physical Activity|The control group followed its usual weekly physical activity routine.
62197480|NCT02939339|EXPERIMENTAL|real treatment|continuous theta burst stimulation (real) will be delivered
62197481|NCT02939339|SHAM_COMPARATOR|sham treatment|continuous theta burst stimulation (sham) will be delivered
62197482|NCT03274115|NO_INTERVENTION|White Light (WL)|White light will be used for histology prediction of colonic polyps (hyperplastic versus adenomatous).
62197483|NCT03274115|ACTIVE_COMPARATOR|Blue Light Imaging (BLI)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps.
62197484|NCT04046458|EXPERIMENTAL|EHR Alert|Physician teams will observe the EHR alert as they perform their clinical duties in the EHR.
62197485|NCT04046458|PLACEBO_COMPARATOR|No Alert|Physician teams will perform their clinical duties in the EHR as usual, with no visible alert.
62576217|NCT05379283|EXPERIMENTAL|lidocaine pretreated skin|one arm will be pretreated with lidocaine before exercise in the heat
62576218|NCT05379283|NO_INTERVENTION|control skin|the other arm will act as the control condition
62010605|NCT06433414|EXPERIMENTAL|PAUSE App Intervention|Participants will receive enhanced care through onboarding and accessing the PAUSE App via the PC Health app to provide continuity of care electronically through a personalized eHealth mobile application, as well as the SDMG patient resource handout. The PAUSE App provides the same guidance as the SDMG handout, but uses algorithms tailored to identify and provide guidance specific to users' symptoms and current medications.
62010606|NCT01947803|EXPERIMENTAL|Paliperidone Palmitate|
62197486|NCT01935752|OTHER|Fibromuscular dysplasia|Fibromuscular dysplasia:blood samples \& vascular echotracking
62197487|NCT01935752|OTHER|healthy volunteer|healthy volunteer:blood samples \& vascular echotracking
62197488|NCT01935752|OTHER|hypertensive patients|hypertensive patients:blood samples \& vascular echotracking
62197489|NCT06207305|EXPERIMENTAL|Phase I/Phase II|"Participants will be assigned to a study phase (Phase I or Phase II) based on when participants join this study. Up to 4 groups of at least 3 participants will be enrolled in Phase I of the study, and up to 15 participants will be enrolled in Phase II.~If you are enrolled in Phase I, the dose of paclitaxel you receive will depend on when the participants join this study. The first group of participants will receive the lowest dose level of paclitaxel. Each new group will receive a higher dose of paclitaxel than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of paclitaxel given intraperitoneally is found.~Participants who are enrolled in Phase II, participants will receive paclitaxel at the recommended dose that was found in Phase I."
62399757|NCT04084925||Diabetics without NAFLD|Diabetics whose abdominal ultrasound showed that they do not have NAFLD
62399758|NCT04271423|ACTIVE_COMPARATOR|Control|The flap procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal.
62399759|NCT04271423|EXPERIMENTAL|Test|The test will be a flapless technique, no flap will be reflected.
62399760|NCT05423275|ACTIVE_COMPARATOR|Negative ion therapy|High density negative ions at 3.4 trillion ions per second with no detectable ozone, used for 30 minutes as soon as possible after awakening, preferably between 7:00-8:00 am.
62399761|NCT05423275|ACTIVE_COMPARATOR|Light therapy|4000 Kelvin white fluorescent light rated at 10,000 lux at 14 inches from screen to cornea, with an ultraviolet filter, used for 30 minutes as soon as possible after awakening, preferably between 7:00-8:00 am.
62399762|NCT00700466||1|Patients with hypertension and/or tachycardia prior to induction of anesthesia requiring i.v. beta-blockade for treatment of raised hemodynamic
62399763|NCT00700466||2|Patients with normal hemodynamic values prior to induction of anesthesia not requiring treatment
62399764|NCT01929551|OTHER|Mango puree and pear juice beverage|Participants will drink 450 milliliters of the juice at time 0.
62399765|NCT01929551|OTHER|Commercial mango juice|Participants will drink 450 milliliters of the juice at time 0.
62399766|NCT01929551|OTHER|Fresh natural mango|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
62399767|NCT01929551|OTHER|Frozen natural mango|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
62010607|NCT00283660|EXPERIMENTAL|Active|Dietary Supplement: 10 mg zinc oxide
62010608|NCT00283660|PLACEBO_COMPARATOR|Placebo|Placebo (double blinded)
62399768|NCT01929551|OTHER|Processed natural mango pulp|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
62399769|NCT01929551|OTHER|Mix of natural mango and pear|Participants will eat 400 to 500 grams of a mixture of fresh natural fruit containing mango (73%) and pear (27%), along with 250 milliliters of water at time 0.
62399770|NCT01929551|OTHER|50 grams glucose load|Participants will drink 250 milliliters of the standard glucose load at time 0.
62399771|NCT02368860|EXPERIMENTAL|OXIRI|OXIRI regimen: oxaliplatin, irinotecan, capecitabine
62576219|NCT05938660|EXPERIMENTAL|Acupressure group|The participants received a 5-minutes acupressure on Sanyinjiao point of both legs per day from 5 days ago of one period untill the third day of the period. The participants received the same intervention in the coming period again.
62197490|NCT05988723||Study Group (obese patient)|Leptin, IL-6, OPG, RANKL levels were measured in samples taken from the distal gingival groove of the canine teeth of obese individuals. Roth metal brackets and tubes with 0.022 inch slots were used for the fixed orthodontic treatment of the patients. After leveling the teeth of the patients with arch wires, it was waited for 2 months in 19x25 stainless steel arch wire and then 150 gr distalization force was applied. DOS samples were taken from the distal gingival groove of teeth on day 7 (T2), day 14 (T3) and day 21 (T4), just before distalization force was applied (T0), 24 hours after force was applied (T1). In order to determine the speed of tooth movement, the patient's mouth was scanned on the days when DOS was taken (T0,T1,T2,T3,T4) and in addition to these days, on the 28th day (T5) and at the end of the 3rd month (T6), and the amount of movement of the canine tooth was measured in mm. Leptin, IL-6, OPG, RANKL levels were examined with Elisa kits from the samples obtained.
62197491|NCT05988723||Control Group (normal patient)|Leptin, IL-6, OPG, RANKL levels were measured in samples taken from the distal gingival groove of the canine teeth of normal weight individuals.Roth metal brackets and tubes with 0.022 inch slots were used for the fixed orthodontic treatment of the patients.After leveling the teeth of the patients with arch wires, it was waited for 2 months in 19x25 stainless steel arch wire and then 150 gr distalization force was applied.DOS samples were taken from the distal gingival groove of teeth on day 7 (T2), day 14 (T3) and day 21 (T4), just before distalization force was applied (T0), 24 hours after force was applied (T1). In order to determine the speed of tooth movement, the patient's mouth was scanned on the days when DOS was taken (T0,T1,T2,T3,T4) and in addition to these days, on the 28th day (T5) and at the end of the 3rd month (T6), and the amount of movement of the canine tooth was measured in mm. Leptin, IL-6, OPG, RANKL levels were examined with Elisa kits from the samples obtained.
62197492|NCT03119545|EXPERIMENTAL|Beardslee family centered intervention|This Group will have the family centered program.
62197493|NCT03119545|NO_INTERVENTION|Comparison group|This Group will have standard care
62197494|NCT03126071|EXPERIMENTAL|Raltitrexed and Irinotecan（RALIRI） plus Bevacizumab(AVASTIN)|Irinotecan:250mg/m2 iv,90min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)
62399772|NCT05611944|EXPERIMENTAL|I&S arm|The 150 participants of the experimental arm will be assigned to the I\&S group and they will be inserted bilateral Nelton drains of 24 sizes in the subcutaneous space after the closure of the rectus sheath. Their wound will be irrigated with 500cc Normal saline at running speed followed by suction for a full day. The procedure will be repeated for three consecutive days. The drains will be removed on the fourth postoperative day.
62399773|NCT05611944|NO_INTERVENTION|control|The 150 participants of the non-intervention group will be assigned to the control arm, The wound will be closed by interrupted mattress stitches without the insertion of subcutaneous drains.
62399774|NCT00719706|ACTIVE_COMPARATOR|1|1000-3000mg/day of acetyl-l-carnitine PLUS 600-1800mg/day of alpha-lipoic acid
62576220|NCT01082705|ACTIVE_COMPARATOR|Artemether-lumefantrine|Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
62576221|NCT01082705|EXPERIMENTAL|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine administered once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
62010609|NCT06664008|ACTIVE_COMPARATOR|Group 1: PPI alone|Proton pump inhibitor
62010610|NCT06664008|EXPERIMENTAL|Group 2 (PPI+Probiotic)|Proton pump inhibitor and Probiotic
62010611|NCT06664008|EXPERIMENTAL|Group 3: PPI+Zinc|Proton pump inhibitor and Zinc
62399775|NCT00719706|PLACEBO_COMPARATOR|2|
62399776|NCT05673486|EXPERIMENTAL|PENG block + multimodal IV analgesia|PENG block + multimodal IV analgesia (Nefopam, Paracetamol, Morphine)
62399777|NCT05673486|ACTIVE_COMPARATOR|Multimodal analgesia alone|Multimodal IV analgesia (Nefopam, Paracetamol, Morphine)
62399778|NCT00371748|EXPERIMENTAL|Arm 1|
62399779|NCT00371748|OTHER|Arm 2|Historical Comparator: control data derived from a TAXUS V de novo lesion and stent size-matched cohort randomized to receive a single, planned 2.25 mm DES
62399780|NCT00371748|OTHER|Arm 3|Historical Comparator: control data derived from a TAXUS V de novo lesion size-matched cohort randomized to receive a 2.25 mm or 2.5 mm BMS
62399781|NCT00453076|EXPERIMENTAL|Paclitaxel eluting covered metal stent|Paclitaxel eluting covered metal stent group
62399782|NCT00453076|ACTIVE_COMPARATOR|Control covered metal stent|Control covered metal stent group
62399783|NCT03781050|EXPERIMENTAL|Rapamycin|"For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months~For adults: rapamycin, 2 mg a day, orally, for at least 6 months"
62399784|NCT02859025|ACTIVE_COMPARATOR|A:Iiac|Treated with anterior iliac crest spongy bone to fill defects, followed by coverage with collagen membrane.
62399785|NCT02859025|EXPERIMENTAL|B:MSCs+LRCP|Treated with lateral ramus cortical bone plate (LRCP) to create a protected healing space by fixing it to adjacent walls of the cleft defect. BFPScs were loaded on NBBM and delivered to the defect
62010612|NCT06664008|EXPERIMENTAL|Group 4: PPI+Probiotic and Zinc|Proton pump inhibitor, Zinc and Probiotic
62010613|NCT06116253|EXPERIMENTAL|Renal Mass Patients|"Patients will be enrolled for 2 MRI visits. These visits will include an approximately 1 hour research MRI scan and a total of between 3 and 5 hours Tc-99m DTPA scan.~In each MRI visit, patients will be scanned for approximately one hour including both standard-of-care clinical sequences and research-based Advanced Diffusion Imaging sequences, on a Prisma 3T MRI scanner. Following the MRI exam or on a day not more than a week after the MRI exam, patients will undergo renal function assessment via Tc-99m DTPA scan and patient's kidneys will be scanned using a gamma camera. Proteinuria will be assessed by standard of care urinalysis of specimens collected at each MRI visit for each patient. Blood test will be performed at each visit to estimate GFR (eGFR) from measurement of serum creatinine."
62010614|NCT01299233||control group|age matched healthy controls
62010615|NCT01299233||Glaucoma|patients with diagnosis of primary open angle glaucoma
62576222|NCT00729612|EXPERIMENTAL|Treatment (nab-paclitaxel, carboplatin)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and carboplatin IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62197495|NCT03126071|EXPERIMENTAL|Raltitrexed and Oxaliplatin（RALOX） plus Bevacizumab(AVASTIN)|Oxaliplatin:130mg/m2 iv,120min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)
62197496|NCT03019081|EXPERIMENTAL|Anorexia nervosa-study drug|"Drug: Isoproterenol Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant. The isoproterenol dose will range from 0.1 micrograms to 4.0 micrograms and exposure during each visit will not exceed 25.0 micrograms. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.~Other Names: Isuprel"
62197497|NCT03019081|PLACEBO_COMPARATOR|Anorexia nervosa-placebo|"Drug: Normal Saline Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.~Other Names:~Saline"
62197498|NCT01975298|EXPERIMENTAL|Laquinimod 0.6 mg|
62576223|NCT01888055|EXPERIMENTAL|transcranial direct current stimulation|
62576224|NCT01888055|PLACEBO_COMPARATOR|sham stimulation|
62576225|NCT00003441|EXPERIMENTAL|Irofulven|6-hydroxymethylacylfulvene (MGI-114) IV over 5 minutes daily for 5 consecutive days every 28 day cycle.
62576226|NCT00664573|EXPERIMENTAL|Group 2|Drug: BG9924 - dose administered as per Biogen-Idec protocol
62576227|NCT00664573|EXPERIMENTAL|Group 1|Drug: BG9924 - dose administered as per Biogen-Idec protocol
62576228|NCT00664573|EXPERIMENTAL|Group 3|Drug: BG9924 - dose administered as per Biogen-Idec protocol
62576229|NCT00664573|EXPERIMENTAL|Group 4|Drug: BG9924 - dose administered as per Biogen-Idec protocol
62576230|NCT00003563|EXPERIMENTAL|WBRT|3 Gy of WBRT daily for a total of 10 days
62197499|NCT01975298|EXPERIMENTAL|Laquinimod 1.2 mg|
62399786|NCT02859025|EXPERIMENTAL|C:MSCs+liac|Treated with anterior iliac crest spongy bone as in Group 1, but BFP-derived mesenchymal stem cells (MSCs ) cultured over NBBM were put over the spongy bone and covered with a collagen membrane.
62197500|NCT01975298|ACTIVE_COMPARATOR|Avonex®|
62399787|NCT06111599|EXPERIMENTAL|Group A|Proximal arterial obliteration
62576231|NCT00003563|EXPERIMENTAL|MGd|IV does of 5.0 mg/kg MGd plus WBRT
62576232|NCT04429217|EXPERIMENTAL|Arm-A|experimental post-operative rehabilitation intervention consisting in immediate weight-bearing
62197501|NCT03638076|EXPERIMENTAL|GLS4 120 mg+ RTV 100mg，bid|Patients with chronic HBV infection will receive GLS4 120 mg+ Ritonavir Tablet 100 mg twice daily for 48 weeks.
62399788|NCT06111599|EXPERIMENTAL|Group B|Distal arterial obliteration
62399789|NCT06111599|EXPERIMENTAL|Group C|Complex arterial obliteration
62399790|NCT06724497|OTHER|patient with mandibular prognathism|same patient will be scanned twice using both devices the optical face scanner and the handheld optical scanner
62399791|NCT02110589|EXPERIMENTAL|Patient Group 1|"Testing of Epidetect:~Adult Patients with difficult to control tonic-clonic (convulsant) epilepsy undergoing hospitalised video telemetry monitoring. Patients will be hospitalised as part of their normal investigation of the epilepsy and patients will be consented 1 week before hospitalisation. Epidetect will be used in conjunction with the normal EEG monotoring and video telemetry. The patient will be fitted with the topical sensors at the start of monotoring and then depending on the seizure activity will wear the sensors until enough data is gathered. Hospitalisation under these circumstances typically lasts no more than five days, so monitoring with the topical sensor will be no longer than this."
62576233|NCT04429217|ACTIVE_COMPARATOR|Arm-B|control post-operative rehabilitation intervention consisting in delayed weight-bearing
62576234|NCT01146093|EXPERIMENTAL|Pravastatin Sodium Tablets 80 mg|Dr.Reddy's Laboratories Limited
62197502|NCT03638076|EXPERIMENTAL|GLS4 120 mg+ RTV 100mg，tid|Patients with chronic HBV infection will receive GLS4 120 mg+ Ritonavir Tablet 100 mg three times daily for 48 weeks .
62197503|NCT03052660|EXPERIMENTAL|Midazolam|Midazolam, 3.75 mg , oral, once, 30-45 minutes before surgery
62399792|NCT02110589|EXPERIMENTAL|Patient Group 2|"Testing of Epidetect:~Paediatric patients (over 7 years) where parental consent will enable the epilepsy monitor to be used at home for 1 week and brought back in for analysis along with video evidence. This will not constitute any change in normal care or treatments, and the video evidence provided represents enhanced care through accurate seizure diary reporting. Suitable families and children will be selected and consented through scheduled clinics in paediatric neurology."
62576235|NCT01146093|ACTIVE_COMPARATOR|Pravachol 80 mg Tablets|Bristol Myers Squibb
62783228|NCT03954587||Artificial (HRT) Cycles|"1. Commence estradiol valerate (E2) 4mg from day 2 or 3 of period for 3 days~2. Increase E2 to 6mg on day 4 of E2 treatment, according to clinician discretion based on endometrial thickness.~3. Transvaginal scan throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of a dominant follicle on the ovaries.~4. Serial measurements of serum LH (luteinizing hormone), estradiol and progesterone levels.~5. Initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 7 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance.~6. Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue E2 administration 6mg (3 tablets daily).~7. Embryo transfer is scheduled on the 5th full day of progesterone administration."
62010616|NCT06532201|EXPERIMENTAL|Su-jok Therapy Group /EXPERIMENTAL GROUP|Su Jok will be applied to the reflection points on the hand based on the painful area of the individual. The painful areas will be determined with the applicator and black pepper seeds will be placed on these areas. Circular massage will be applied to the areas where the seeds are located for 30 minutes.
62010617|NCT06532201|NO_INTERVENTION|Control Group|
62010618|NCT06663124|EXPERIMENTAL|EC-DBS group|participants will undergo EC-DBS ON with the individual stimulation parameters determined in the parameter determination period, then continue to receive stimulation for the remainder of the study.
62197504|NCT03052660|PLACEBO_COMPARATOR|Placebo|Placebo, oral, once, 30-45 minutes before surgery
62197505|NCT02230241||Cohort 1|Subjects of either gender and any race, aged ≥ 18 years, at moderate to very high CV risk, on lipid-lowering pharmacotherapy for at least 3 months (90 days), with no dose change for a minimum of 8 weeks (56 days). Before starting any study-related activities, the investigator should obtain written informed consent personally signed and dated by the subject.
62399793|NCT02110589|EXPERIMENTAL|Patient group 3|"Testing of Epidetect:~Patients where the epilepsy is suspected to be psychogenic (pseudo-seizures) rather than organic epilepsy. We will test whether the epilepsy monitor will be able to differentiate between epilepsy and psychogenic seizures in the medical setting when patients are hospitlised for seizure investigation. Suitable patients will be selected and consented through scheduled clinics in paediatric neurology (under 16) and adult neurology."
62576236|NCT04162431||non-hodgkin lymphoma|patients diagnosed with non-hodgkin lymphoma
62576237|NCT04162431||hodgkin lymphoma|patients diagnosed with hodgkin lymphoma
62576238|NCT04162431||squamous cell carcinoma|patients diagnosed with squamous cell carcinoma
62783229|NCT03954587||Spontaneous natural cycles:|"1. Day 2 of menses and throughout patients' natural cycle scans to monitor follicular growth.~2. Measurements of serum LH, estradiol and progesterone levels to determine ovulation.~3. The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter (Irani et al. 2017, Fatemi et al., 2010).~4. Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5ng/mL confirming ovulation (day 0) (Irani et al., 2017; Speroff et al.). This is considered as day 0 with initiation of vaginal progesterone 100mg at 22hrs that night. The following day (day 1) the patient increases progesterone administration to 100mg vaginally 8 hourly and continues until 7 weeks gestation as per clinic protocol. Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
62783230|NCT00477646|EXPERIMENTAL|Prevention Care Management|Telephone support over 18 months from trained Prevention Care Managers, to help women overcome barriers to colon, breast, and cervical cancer screening
62783231|NCT00477646|NO_INTERVENTION|Usual Care|Usual Care. A sample of patients receive a single telephone call to validate claims data and collect basic demographic information.
62783232|NCT01678612|NO_INTERVENTION|Non copper standard surfaced objects|Rooms assigned to standard surfaced objects
62197506|NCT02617953|EXPERIMENTAL|Active rTMS(A)|low frequency frontal and temporal repetitive transcranial magnetic stimulation
62576239|NCT04162431||reactive|patients diagnosed with a reactive (non-cancerous) lymph node
62576240|NCT04162431||other|none of the above. Other cancer and non-cancer conditions
62576241|NCT03158038|EXPERIMENTAL|Monovalent Influenza Vaccine|Participants will receive a single dose of monovalent influenza vaccine \[10\^7.0 +/- 0.5 fluorescent focus unit (FFU) of each of 1 cold adapted (ca), attenuated (att), temperature sensitive (ts) 6:2 reassortant influenza strain\] by intranasal spray on Day 1.
62197507|NCT02617953|EXPERIMENTAL|Active rTMS(B)|Temporal low frequency repetitive transcranial magnetic stimulation
62197508|NCT02617953|SHAM_COMPARATOR|Sham condition(C)|low frequency frontal and temporal repetitive transcranial magnetic stimulation
62576242|NCT03158038|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo matching with monovalent influenza vaccine by intranasal spray on Day 1.
62197509|NCT03240822|EXPERIMENTAL|Penile Allotransplant and Immunosuppression Treatment|Penile transplantation with monoclonal antibody induction therapy of humanized anti CD52 followed by donor bone marrow infusion and tacrolimus monotherapy.
62576243|NCT01657825|EXPERIMENTAL|Isavuconazole and warfarin|Isavuconazole three times daily (TID) for 2 days followed by once daily (QD) dosing for 11 days and warfarin single doses on Days 1 and 20
62783233|NCT01678612|EXPERIMENTAL|Copper-alloy surfaced objects|Rooms furnished with copper surfaced objects, i.e. bed rails, bed rail levers, IV poles, nurse workstation, clipboards, sink handles.
62197510|NCT02369471|EXPERIMENTAL|Group 1a|Subjects on inducer AEDs will administer GWP42006.
62576244|NCT00534781|EXPERIMENTAL|A|plasma microtenotomy
62010619|NCT01771133|NO_INTERVENTION|Lifestyle and nutrition control group|The control arm will receive routine prenatal care in the prenatal clinic. They will receive regular phone calls and mailings, token gifts and some useful information from data collected in the study, such as physical activity, feedback on behavior throughout the study. To additionally promote adherence (since they will have less contact with study staff), we will include 2 pre-partum and 1 post-partum group sessions meant to increase bonding between participants and retention of control participants. These sessions will include general pregnancy information not related to our interventions.
62783234|NCT05889637||Group G: Patients taking GLP-1receptor agonists|
62197511|NCT02369471|ACTIVE_COMPARATOR|Group 2a|Subjects on inhibitor AEDs will administer GWP42006.
62783235|NCT05889637||Group C: Patients not taking GLP-1 receptor agonists (control group)|
62783236|NCT05068219|ACTIVE_COMPARATOR|Usual technique|Standard rehabilitation
62197512|NCT02369471|EXPERIMENTAL|Group 3a|Subjects on AEDs that are neither inducers nor inhibitors will administer GWP42006.
62783237|NCT05068219|EXPERIMENTAL|CR technique|Standard rehabilitation + 3 CR
62197513|NCT02369471|PLACEBO_COMPARATOR|Group 1b|Matching placebo control for Group 1a.
62197514|NCT02369471|PLACEBO_COMPARATOR|Group 2b|Matching placebo control for Group 2a.
62197515|NCT02369471|PLACEBO_COMPARATOR|Group 3b|Matching placebo control for Group 3a.
62197516|NCT03655743||Patients after refractive surgery|Patients have had any type of corneal or lens refractive surgery.
62197517|NCT03655743||Patients before refractive surgery|Patients will have any type of corneal or lens refractive surgery.
62197518|NCT01857375||Group receiving insulin via vial/syringe|This group will receive their insulin via vial/syringe
62197519|NCT01857375||Insulin Pen|Patients receiving insulin via insulin pen
62197520|NCT05963945||Retrospective collection for the period October 18th, 2022, and November 17th, 2022|A total of 1,073 chest X-rays were acquired within the specified period at the department. The data collection remained intact and unaffected throughout the testing phase, ensuring the integrity of the dataset. The collected sample accurately represents the prevalence of findings within the observed population. After excluding ineligible studies such as X-rays from patients under 18 years of age, lateral projection X-rays, and scans of insufficient quality, a total of 956 relevant CXRs were identified for further assessment.
62783238|NCT06584370|EXPERIMENTAL|Pericardial insufflation with CO2|Intentional transatrial introduction of a microcatheter to insufflate the pericardium with carbon dioxide, to separate the walls of the pericardium
62783239|NCT04725500|EXPERIMENTAL|Auto-titrating EPAP|ExpiraFlowTM technology- Non-invasive ventilator that auto titrates EPAP to abolish Expiratory flow limitation.
62783240|NCT01474720|EXPERIMENTAL|SLE patients|Subjects with mild SLE over age 50 years will receive open-label Zostavax vaccine.
62783241|NCT01474720|ACTIVE_COMPARATOR|Healthy subjects|Healthy subjects aged 50 years and older without any history of autoimmune disease will receive zostavax vaccine. Immune responses to varicella zoster virus and adverse events will be compared to those seen in SLE patients
62783242|NCT00327964||study population|601 children enrolled in an on-going longitudinal antimalarial treatment efficacy trial in Kampala, Uganda.
62783243|NCT05502510||MyHealthyPregnancy (MHP)|Use of the MyHealthyPregnancy application in conjunction with usual care.
62783244|NCT05502510||Usual Prenatal Care (usual care)|Usual prenatal care consisting of biweekly visits with the patient care team.
62783245|NCT04474821|EXPERIMENTAL|Prevention (HPV educational program)|Patients receive educational materials on HPV and are asked of their willingness to proceed with the first HPV vaccination. Patients who express interest in receiving the HPV vaccination, then receive the first dose of the HPV vaccine and the next 2 doses approximately 2 months and 6 months following the initial vaccine.
62576245|NCT00534781|ACTIVE_COMPARATOR|B|Standard Surgical Debridement
62576246|NCT04548713|EXPERIMENTAL|4% EDTA CVC Lock|Patients in this group will be given 4% EDTA as their CVC locking solution.
62576247|NCT04548713|ACTIVE_COMPARATOR|Standard of Care Saline CVC Lock|Patients in this group will be given standard of care saline as their CVC locking solution.
62576248|NCT04398108|EXPERIMENTAL|Margetuximab & Chosen Chemotherapy|The dosage and administering of margetuximab is 15 mg/kg IV every 21 days. Investigators need to choose one of the 3 chemotherapies based on patient conditions.
62197521|NCT00691249|EXPERIMENTAL|1|Resistant starch type 4-Raw
62576249|NCT03466606|EXPERIMENTAL|Prehabilitation|Personalized supervised resistance training and program to promote physical activity and healthy lifestyles
62576250|NCT03466606|NO_INTERVENTION|Control|Conventional treatment
62576251|NCT01417247|EXPERIMENTAL|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with metabolic syndrome.
62576252|NCT01417247|NO_INTERVENTION|Absolute medicine therapy|Maintenance of anti-metabolic syndrome medications only
62576253|NCT02623933|EXPERIMENTAL|MRI assisted HDR monotherapy|HDR monotherapy to the whole prostate gland (19Gy/1) with MRI assisted focal boost to intraprostatic nodule up to 22.5Gy
62576254|NCT04808063|EXPERIMENTAL|Algorithm use for prphylactic mesh after emergency laparotomy|Patients with emergency surgery in whom algorithm for prophylactic mesh is use to help decide abdominal wall mesh reinforcement or not.
62576255|NCT04784429|EXPERIMENTAL|MPK|Microprocessor controlled knee
62576256|NCT04784429|ACTIVE_COMPARATOR|NMPK|Non-microprocessor controlled knee
62197522|NCT00691249|EXPERIMENTAL|2|Resistant starch type 4-Raw
62576257|NCT03177460|EXPERIMENTAL|Arm A (daratumumab)|Patients receive daratumumab IV over 4-8 hours once weekly for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy during week 6.
62576258|NCT03177460|EXPERIMENTAL|Arm B (FMS inhibitor JNJ-40346527)|Patients receive FMS inhibitor JNJ-40346527 PO BID for 4-5 weeks in the absence of disease progression or unacceptable toxicity. After a 3 day wash-out period, patients undergo radical prostatectomy.
62576259|NCT03300349||axillary lymphadenectomy sequels|Patients who have suffered from axillary lymphadenectomy due to breast cancer between 2014 and 2016 and who have developed breast cancer-related lymphedema and/or shoulder disability who fulfill or not a preventive programme
62576260|NCT03300349||No axillary lymphadenectomy sequels|Patients who have suffered from axillary lymphadenectomy due to breast cancer between 2014 and 2016 and who have not develped breast cancer-related lymphedema and/or shoulder disability who fulfill or not a preventive programme.
62576261|NCT03300349||Fulfillment of a preventive programme|Patients who fulfil a preventive programme for axillary lymphadenectomy sequels
62576262|NCT03300349||No fulfillment of a preventive programme|Patients who do not fulfil a preventive programme for axillary lymphadenectomy sequels
62576263|NCT00078767|EXPERIMENTAL|TF-CBT + sertraline|Trauma-Focused CBT provided individually to youth and parent for 12 sessions (90 minute sessions; 45 minutes for youth; 45 minutes for parent); plus Sertraline provided in dosage titrated as clinically indicated by child psychiatrist blind to treatment assignment, from 50mg/day to a maximum dosage of 150 mg/day
62576264|NCT00078767|ACTIVE_COMPARATOR|TF-CBT +placebo|Trauma-Focused CBT provided individually to youth and parent for 12 sessions (90 minute sessions; 45 minutes for youth; 45 minutes for parent); plus placebo identical to Sertraline, provided in pill form and titrated as clinically indicated by child psychiatrist blind to treatment assignment, from 1 to 3 pills/day (identical in appearance to 50 to 150mg/day of Sertraline)
62576265|NCT05368220||Patients with non-autoimmune diabetes (type 2 diabetes)|"Any case of non-T1D defined as:~* Debut \>30 years of age OR~* Debut \<30 years of age AND negative autoantibodies~treated at Steno Diabetes Center Copenhagen"
62576266|NCT05368220||Patients with gestational diabetes|"Any case of diabetes diagnosed in pregnancy treated at the following obstetric clinics in the Capital Region in Denmark:~Rigshospitalet, Nordsjællands Hospital, Herlev Hospital, Hvidovre Hospital"
62576267|NCT03415971|ACTIVE_COMPARATOR|ASTRA TECH implants|implant restoration(replace of a missing tooth) - 35 patients
62197523|NCT00691249|EXPERIMENTAL|3|Resistant starch type 4-Cooked
62576268|NCT03415971|ACTIVE_COMPARATOR|CROWN|to fixed denture restorations in own teeth - 32 patients
62576269|NCT03415971|PLACEBO_COMPARATOR|non-edontulos|control group will consist 38 non-edotulos patients
62197524|NCT00691249|EXPERIMENTAL|4|Resistant starch type 4-Cooked
62197525|NCT00691249|PLACEBO_COMPARATOR|5|Shredded wheat
62576270|NCT00865878|ACTIVE_COMPARATOR|1|Topical Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA) will be applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to blue light treatment for 16 minutes and 40 seconds.
62576271|NCT00865878|PLACEBO_COMPARATOR|2|Kerastick containing vehicle ingredients only (VEH) will be applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to blue light treatment for 16 minutes 40 seconds.
62197526|NCT02868840|EXPERIMENTAL|Tai Chi group|Tai Chi exercise, twice a week, one hour per session. participated in Tai Chi either while seated or standing upon their comfort level.
62576272|NCT06576947|EXPERIMENTAL|Virtual reality therapy|It will ve placement of virtual reality glasses that will indicate to the patient when to contract the pelvic floor.
62576273|NCT06576947|EXPERIMENTAL|Neuromodulation of the tibialis posterior|Is placed a external electrode 5 centimeters (cm) above the medial malleolus and 1 cm behind of the tibia and another electrode on the medial aspect of the foot, below the malleolus. The kind of electric current used will be rectangular, biphasic, with a pulse duration of 220 Ps and a frequency of 10 Hz. To avoid habituation to the current, a phase of 20 s stimulation with a 4 s rest phase. The intensity of the current will be inframotor, just below the contraction threshold of the flexor digitorum muscle brevis.
62576274|NCT06576947|EXPERIMENTAL|Pelvic Floor Muscle Training|Patients will perform Pelvic Floor Muscle Training. Before performing this treatment at home, a session will be held with an expert physiotherapist in pelvic floor who will explain its implementation to the participants of this group.
62576275|NCT06186973||No maternal epidural labor analgesia|Term infants monitored with cardiotocography with ST-segment analysis (STAN) during labour: No maternal epidural labor analgesia
62783246|NCT00764673|OTHER|Primary|Post market study
62783247|NCT00781859|EXPERIMENTAL|125µg Ocriplasmin|125µg intravitreal injection of ocriplasmin
62399794|NCT02110589|EXPERIMENTAL|Patient Group 4|"Testing of Epidetect:~Internal negative Controls. Juveniles or adults with other forms of epilepsy that do not have a hypertonic (increased muscle stiffening) phenotype e.g. absence seizures."
62399795|NCT02110589|OTHER|Control Group 1|"Testing of Epidetect:~Volunteers who do not have a history of seizures / epielsy, head trauma, migraine, neurological or muscular-skeletal disorders. This is to produce the baseline data for the Monitor."
62399796|NCT02311075|EXPERIMENTAL|Patient comparative approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples.
62399797|NCT02311075|EXPERIMENTAL|Control subjects comparative approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples.
62399798|NCT02311075|EXPERIMENTAL|Healthy volunteers metabolic approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples during hyperglycemia or hyperinsulinemia.
62399799|NCT02415491|EXPERIMENTAL|ASO group|ASO group:Evaluation of Correlation of Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test for long term assessment after ASO and recommendation of physical activity of young adults after TGA
62399800|NCT05920382|EXPERIMENTAL|Radiofrequency arm|After identifying the nerves to be treated via ultrasound and confirming with neurostimulation, 1 ml of 2% lidocaine will be administered, followed by radiofrequency ablation. The physical parameters used are as follows: 90 seconds, 80 degrees Celsius, with a 22g needle with an active tip of 10 mm.
62399801|NCT05920382|SHAM_COMPARATOR|Control arm|In the same manner as with the RF group, the nerves to be treated are identified via ultrasound and confirmed by neurostimulation. Subsequently, sham radiofrequency is performed for 90 seconds.
62399802|NCT01046175|EXPERIMENTAL|Airstacking with manual resuscitator|Air-stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
62399803|NCT01046175|ACTIVE_COMPARATOR|Air-stacking with ventilator|Air-stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a ventilator.
62399804|NCT03334604|EXPERIMENTAL|Multispecies probiotic group|175 participants.
62399805|NCT03334604|PLACEBO_COMPARATOR|Control group|175 participants.
62399806|NCT01716221|EXPERIMENTAL|Bupropion & Citalopram|100mg Bupropion \& 20mg Citalopram taken orally one time per day or 100mg Bupropion \& 10mg Citalopram taken orally one time per day or 50mg Bupropion \& 20mg Citalopram taken orally one time per day 0r 50mg Bupropion \& 10mg Citalopram taken orally one time per day
62399807|NCT01716221|ACTIVE_COMPARATOR|Bupropion & Placebo|100mg Bupropion \& Placebo taken orally one time per day or 50mg Bupropion \& Placebo taken orally one time per day
62399808|NCT01716221|ACTIVE_COMPARATOR|Placebo & Citalopram|Placebo \& 20mg Citalopram taken orally one time per day or Placebo \& 10mg Citalopram taken orally one time per day
62399809|NCT01716221|PLACEBO_COMPARATOR|Placebo & Placebo|Placebo \& Placebo taken orally one time per day
62399810|NCT05588466|ACTIVE_COMPARATOR|CDS alone|This arm will only receive the CDS.
62399811|NCT05588466|ACTIVE_COMPARATOR|CDS plus practice facilitation|This arm will receive the CDS and practice facilitation.
62399812|NCT00690612|EXPERIMENTAL|1|investigator determines efficacious dose based on child's BP response.
62399813|NCT06722612||Taxanes combined with carboplatin|Paclitaxel drugs (paclitaxel, liposomal paclitaxel, docetaxel, albumin paclitaxel), carboplatin chemotherapy, combined with targeted therapy with trastuzumab, for a total of 6 cycles, followed by targeted therapy with trastuzumab for 1 year.
62399814|NCT06722612||Taxanes|Taxanes (paclitaxel, liposomal paclitaxel, docetaxel, albumin paclitaxel), combined with targeted therapy with trastuzumab and pertuzumab, for a total of 6 cycles, followed by targeted therapy with trastuzumab and pertuzumab for 1 year.
62399815|NCT01447069|ACTIVE_COMPARATOR|Salbutamol|The patients in the study groups will receive the selective β2 agonist, Salbutamol, in addition to their ongoing optimal heart failure therapy.
62399816|NCT01447069|NO_INTERVENTION|control|The patients in the control group will continue with their regular optimal medical therapy without any intervention.
62010620|NCT01771133|ACTIVE_COMPARATOR|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
62010621|NCT02117063|EXPERIMENTAL|Go Girls! Fitness Support Group|
62010622|NCT01068327|EXPERIMENTAL|Treatment (SRT, radiosensitizer, and chemotherapy)|See Detailed Description
62197527|NCT02868840|ACTIVE_COMPARATOR|Symptom management group|manage stroke symptom through phone and text message along with other rehabilitation therapy.
62197528|NCT06098053|EXPERIMENTAL|Group A|Muscle energy technique was given to this group
62197529|NCT06098053|ACTIVE_COMPARATOR|Group B|Muscle energy technique along with interferential therapy was given to this group
62197530|NCT02847429|EXPERIMENTAL|Crenolanib Arm|Investigational product (crenolanib)
62197531|NCT02847429|PLACEBO_COMPARATOR|Placebo Arm|Matching placebo
62197532|NCT00129753|EXPERIMENTAL|Alemtuzumab|
62576276|NCT06186973||With maternal epidural labor analgesia|Term infants monitored with cardiotocography with ST-segment analysis (STAN) during labour: With maternal epidural labor analgesia
62576277|NCT00695942||1|pregnancy women
62576278|NCT04293939||Preterm children|Children born before the 37th week of gestation: clinical sample
62576279|NCT04293939||Full-term children|Children born after the 37th week of gestation: control sample
62576280|NCT05110937||Sepsis|Blood collection: Blood will be collected from patient at day 4, day 7, day 14-21 and at 3 and 6 months.
62576281|NCT05110937||Healthy Controls|"Blood Collection.~The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable."
62576282|NCT05110937||Trauma|Blood collection: Blood will be collected from patient at day 4, day 7, day 14-21 and at 3 and 6 months.
62576283|NCT02960711|EXPERIMENTAL|METFORMIN (1700MG/DAY) + LIFESTYLE|METFORMIN: 2 tablets per day, one at breakfast (or lunch) and one at dinner, of either metformin (two 850 mg tablets/day) + participation in the life-style intervention activities
62576284|NCT02960711|PLACEBO_COMPARATOR|PLACEBO+ LIFESTYLE|Placebo: (two identical tablets) according to the blind assignment + participation in the life-style intervention activities
62576285|NCT02960711|EXPERIMENTAL|METFORMIN (1700 mg/day) alone|METFORMIN: 2 tablets per day, one at breakfast (or lunch) and one at dinner, of either metformin (two 850 mg tablets/day)
62576286|NCT02960711|PLACEBO_COMPARATOR|PLACEBO alone|Placebo: (two identical tablets) according to the blind assignment
62576287|NCT03819972|PLACEBO_COMPARATOR|Control|Participants will ingest a drink containing 25 g whey protein hydrolysate (227 mg of total calcium ingested)
62576288|NCT03819972|ACTIVE_COMPARATOR|Dose 1|Participants will ingest a drink containing 25 g whey protein hydrolysate and 3179 mg Capolac (984 mg of total calcium ingested)
62576289|NCT03819972|ACTIVE_COMPARATOR|Dose 2|Participants will ingest a drink containing 25 g whey protein hydrolysate and 6363 mg Capolac (1742 mg of total calcium ingested)
62576290|NCT03819972|ACTIVE_COMPARATOR|Dose 3|Participants will ingest a drink containing 25 g whey protein hydrolysate and 9547 mg Capolac (2500 mg of total calcium ingested)
62576291|NCT02184338|EXPERIMENTAL|BIRB 1017 BS in single rising doses|
62576292|NCT02184338|PLACEBO_COMPARATOR|Placebo|
62576293|NCT01516008|EXPERIMENTAL|Tapentadol IR 50 mg|
62576294|NCT01516008|EXPERIMENTAL|Tapentadol IR 75 mg|
62576295|NCT01516008|PLACEBO_COMPARATOR|Placebo|
62576296|NCT02581579|ACTIVE_COMPARATOR|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis
62576297|NCT02581579|PLACEBO_COMPARATOR|Placebo|MANITOL CAPSULES
62576298|NCT01200147|NO_INTERVENTION|Study withdrawn no details|
62576299|NCT03320902|ACTIVE_COMPARATOR|Sudden death counselling|The emergency physician of the prehospital EMS who intervenes at the scene will systematically give the family member allocated to the intervention the option to attend a sudden death counselling during the first month after the event.
62576300|NCT03320902|NO_INTERVENTION|Usual practice|The physician will act as usual. The relatives will not systematically benefit from this option.
62576301|NCT00478816|ACTIVE_COMPARATOR|Group 1|Primed subject with pandemic Vaccine
62576302|NCT00478816|ACTIVE_COMPARATOR|Group 2|Non Primed subject with pandemic Vaccine
62576303|NCT03646864|EXPERIMENTAL|Treatment A|ACT-541468 50 mg from Day 1 to Day 5 of Period A
62576304|NCT03646864|PLACEBO_COMPARATOR|Treatment B|Placebo from Day 1 to Day 5 of Period B
62576305|NCT00741130||C|normal volunteers
62576306|NCT00741130||G|glaucoma patients
62576307|NCT01763060||ECMO survivors|CT scan of the chest of all ECMO survivors after 2009/2010 pandemics Tests for cognitive function MRI of the brain Lung function
62576308|NCT02723396||Parkinson|Prospective observation of a cohort of consecutive patients with idiopathic PD in an ecological setting.
62576309|NCT02723396||Healthy|The same assessments will be performed in a subgroup of age- and sex-matched healthy volunteers.
62576310|NCT02212093||pneumonia and mechanical ventilation|The data are collected retrospectively from this one group.
62576311|NCT00568230|EXPERIMENTAL|1|Patient is screened for study, and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
62197533|NCT02826382|EXPERIMENTAL|Dynamic imaging group|Dynamic imaging of suspected bone metastases with the investigation drug \[68Ga\]P15-041
62197534|NCT02826382|EXPERIMENTAL|Whole body dosimetry group|Determination of human dosimetry of the investigation drug \[68Ga\]P15-041
62197535|NCT03503929|OTHER|LaparoGuard System|All patients receiving laparoscopic surgery, candidates for prolonged time under anesthesia, and are admitted for gynecological, urological or general surgery procedures who consent to use of the LaparoGuard System.
62197536|NCT01575873|EXPERIMENTAL|Denosumab|Participants received 60 mg denosumab by subcutaneous injection on day 1 and at months 6, 12, and 18. Participants also received placebo to risedronate orally once a day for 24 months.
62576312|NCT02276989|EXPERIMENTAL|Compliance Intervention|Subjects will receive acetazolamide, quinine and riboflavin as experimental compliance markers and will serve as their own controls.
62576313|NCT06475755|EXPERIMENTAL|Tislelizumab with anlotinib and platinum-based chemotherapy + Adjuvant Tislelizumab|"Intervention/treatment:~Tislelizumab 200mg iv，d1，q3w， Anlotinib 10mg，po，qd1-14，q3w， Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1 Carboplatin AUC of 5 on Day 1 of each 3-week cycle Paclitaxel 175mg/m2 on Day 1 of each 3-week cycle(SQ only) Albumin-bound paclitaxel 260mg/m2，on D1 IV infusion Q3W or 130mg/m2 on D1D8 IV infusion Q3W for each cycle(SQ only) Pemetrexed 500 mg/m2 on Day 1 of each 3-week cycle(NSQ only) Adjuvant: 4 weeks(±7 Days) following surgery, participants receive no more than 16 cycles (cycle length: 3 weeks) of Tislelizumab \[200 mg, IV; given on cycle day 1\]."
62783248|NCT00781859|PLACEBO_COMPARATOR|Placebo|placebo intravitreal injection
62576314|NCT06475755|OTHER|Tislelizumab with platinum-based chemotherapy + Adjuvant Tislelizumab|Tislelizumab 200mg iv，d1，q3w， Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1 Carboplatin AUC of 5 on Day 1 of each 3-week cycle Paclitaxel 175mg/m2 on Day 1 of each 3-week cycle(SQ only) Albumin-bound paclitaxel 260mg/m2，on D1 IV infusion Q3W or 130mg/m2 on D1D8 IV infusion Q3W for each cycle(SQ only) Pemetrexed 500 mg/m2 on Day 1 of each 3-week cycle(NSQ only) Adjuvant: 4 weeks(±7 Days) following surgery, participants receive no more than 16 cycles (cycle length: 3 weeks) of Tislelizumab \[200 mg, IV; given on cycle day 1\].
62010623|NCT06540586|ACTIVE_COMPARATOR|Quadratus lumborum block group|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 25 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
62010624|NCT06540586|ACTIVE_COMPARATOR|m-tapa block|In the M-TAPA block group, with the patient in the supine position, a linear high-frequency linear ultrasound (USG) probe is angled to visualize the inferior surface of the costochondral junction at the level of the 10th costochondral cartilage. Under sterile conditions, using the in-plane technique with a 22G 80 mm peripheral block needle, the needle is advanced posterior to the 10th costal cartilage by taking the lower edge of the cartilage in the sagittal plane as the midline. After hydrodissection with 2-3 ml isotonic saline to confirm the site, 25 ml of 0.25% Bupivacaine is administered under USG guidance. The same procedure is performed on the contralateral side as well.
62399817|NCT04746170|EXPERIMENTAL|Multiparous|Pregnant women in the experimental group will be given a labor dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
62010625|NCT03145272|EXPERIMENTAL|Age group|"An orogastric tube will be placed in the stomach (placement verified by routine accepted clinical guidelines) under anesthesia as is part of standard routine clinical care to remove gastric contents. The same orogastric tube will be used for intragastric liquid oxycodone administration in a dose of 0.1 mg/kg before the surgical incision. This weight-adjusted dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines.~This arm can be divided into 2 subgroups; (1)12 months - 1.9 years age group. (2) 2 - 5.9 years age group."
62010626|NCT04932200||urgent-endoscopy group|the time interval from gastroenterologic consultation to the start of emergency endoscopy \< 6 hours
62197537|NCT01575873|EXPERIMENTAL|Risendronate|Participants received 5 mg risedronate orally once a day for 24 months and placebo to densumab by subcutaneous injection on day 1 and at months 6, 12, and 18.
62399818|NCT04746170|NO_INTERVENTION|Multiparous Control|Only routine practices were performed with the control group, and data were recorded as in the experimental groups.
62399819|NCT04746170|EXPERIMENTAL|Primipar|Pregnant women in the experimental group will be given a labor dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
62783249|NCT04054375|EXPERIMENTAL|Weekly Steroid|Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
62576315|NCT01070212|EXPERIMENTAL|soft gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
62576316|NCT01070212|EXPERIMENTAL|firm gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
62576317|NCT01070212|EXPERIMENTAL|no gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
62197538|NCT04261764|EXPERIMENTAL|TCM-FMD|"Fasting-Mimicking Diet Combined With a Dispelling Dampness Meal Replacement Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
62197539|NCT04261764|PLACEBO_COMPARATOR|Normal diet|Carrying out normal diet under the guidance of a dietitian, for 12 weeks.
62197540|NCT00531336|EXPERIMENTAL|1|Avastin first followed by retreatment of Macugen
62576318|NCT01614717|ACTIVE_COMPARATOR|Treatment Group|CRT-P Implant. Patients randomized in Treatment Group will have the device programmed to optimized DDD pacing
62197541|NCT00531336|ACTIVE_COMPARATOR|2|Avastin intravitreally every 6 weeks
62197542|NCT00531336|ACTIVE_COMPARATOR|3|Macugen intravitreally every 6 weeks
62197543|NCT03428308|EXPERIMENTAL|Individualized treatment of detected somatic disease(s)|
62197544|NCT03115398|NO_INTERVENTION|Activity Monitoring with Routine Care|Subjects randomized to the control arm will wear activity trackers but will have no specific instructions to increase their activity levels.
62197545|NCT03115398|EXPERIMENTAL|Pedometer-based Walking Program|Subjects randomized to the experimental arm will be instructed to meet the customized daily step count goals that are displayed on their fitness trackers. Patients who fail to meet their step count goal for three consecutive days will be contacted by a study coordinator and reminded to try to meet the activity goals. If the patient reports that his or her activity is limited by treatment-related toxicities, the patient's treating physicians will be notified to ensure that supportive care needs are being met.
62197546|NCT03701048|ACTIVE_COMPARATOR|reappoximation of rectus muscle|During Cesarean Section rectus muscle will be reapproximated with interrupted sutures.
62197547|NCT03701048|ACTIVE_COMPARATOR|no reappoximation of rectus muscle|During Cesarean Section rectus muscle will not be closed.
62576319|NCT01614717|PLACEBO_COMPARATOR|Control Group|CRT-P Implant. Patients randomized in the control Group will have the device programmed to back-up pacing AAI
62197548|NCT01790919|EXPERIMENTAL|Cognitive Therapy plus Cognitive Support|Cognitive therapy for depression with cognitive support added
62197549|NCT01790919|ACTIVE_COMPARATOR|Cognitive therapy|Cognitive therapy for depression
62197550|NCT04982770|EXPERIMENTAL|Intervention|The participants have to read ethical guidelines before they are asked to complete the questionnaire of the Oxford Utilitarianism Scale and exposed to medical triage dilemmas.
62197551|NCT04982770|NO_INTERVENTION|No intervention|The participants do not have to read ethical guidelines before they are asked to complete the questionnaire of the Oxford Utilitarianism Scale and exposed to medical triage dilemmas.
62197552|NCT03566745||Study group|Patients with mutation in AhR gene - presumed low Blood for protein activity
62197553|NCT03566745||Control|Patients without mutation in AhR gene - presumed normal Blood for protein activity
62399820|NCT04746170|NO_INTERVENTION|Primiparous control|Only routine practices were performed with the control group, and data were recorded as in the experimental groups.
62197554|NCT02896075|EXPERIMENTAL|Randomized cross-over approach|"The main study was conducted using a randomized controlled cross-over approach. Participants made three visits each for the two video watching interventions. The interventions were separated by a minimum of~1week as a washout. Each intervention included one day of inducing muscle soreness in one leg through eccentric muscle contractions; a second day of testing muscle soreness and pain tolerance and watching a 30-min video (either a comedy or documentary); and a third day of testing muscle soreness and pain tolerance again to see if the effects of the video viewing persisted the next day (i.e., 24 h after the video viewing)."
62576320|NCT04488302||Implant group|Patients with 1 or more implants with CBCT, ultrasound and open-bone images
62576321|NCT02123589|EXPERIMENTAL|Deep sedation|Injection of 0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -5 and -3
62576322|NCT02123589|EXPERIMENTAL|Deep and daily interruption of sedation|Injection of 0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -5 and -3.and from the second day after subject was admitted in ICU, daily interruption of sedation will be taken .
62576323|NCT02123589|EXPERIMENTAL|Light sedation|Injection of 0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -2 and +1.
62576324|NCT02256124|EXPERIMENTAL|Lamotrigine|"Lamotrigine during 28 consecutive weeks:~* 8 weeks dose-increase phase: from 25mg once daily to 100mg twice daily~* 18 weeks target-dose phase: 100mg twice daily~* 2 weeks decline-phase: 100mg once daily."
62576325|NCT02256124|PLACEBO_COMPARATOR|Placebo|Placebo tablets during 28 consecutive weeks, with identical appearance to lamotrigine tablets, mimicking the lamotrigine dosing schedule.
62197555|NCT05789225|EXPERIMENTAL|Fall prevention program + brochure|Fall prevention program and brochure about falls and fall risk factors
62197556|NCT05789225|ACTIVE_COMPARATOR|Brochure|Brochure about falls and fall risk factors
62197557|NCT05157945|EXPERIMENTAL|ALTO-300|ALTO-300 tablet PO; daily dosing 8 weeks
62197558|NCT03485664||Study Group|Severe pain on percussion of the relevant tooth was considered as basic criteria when deciding on acute infection phase. The acutely infected teeth were labelled as the study group
62197559|NCT03485664||Control Group|The asymptomatic teeth were labelled as the control group
62399821|NCT04430140||1|"CT Scan~Number of research exams: 1 Effective Dose (mSv) for 1 exam: 0.6 Total Effective Dose (mSv)\*: 0.6"
62399822|NCT04997200|EXPERIMENTAL|Intervention: One night's sleeplessness|A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
62197560|NCT02770729|ACTIVE_COMPARATOR|Intracameral moxifloxacin|Intracameral injection of 0.5% moxifloxacin at conclusion of cataract surgery (150 micrograms)
62197561|NCT02770729|SHAM_COMPARATOR|No injection of moxifloxacin|No injection of moxifloxacin at conclusion of cataract surgery
62576326|NCT03447223||ADHD-patients|The children and adolescent 6-15 years old with ADHD. Diagnoses of the children with ADHD were made in Xijing Hospital according to criteria described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Children with ADHD had an IQ score above 70.
62576327|NCT03447223||Controls-healthy children|Age- and gender- matched healthy 6-15 years old children and adolescent.
62197562|NCT03689751|NO_INTERVENTION|LSCS Control Arm|Patients undergoing elective LSCS allocated to this arm underwent the normal preoperative educational pathway. This typically included face-to-face consultation and written information leaflets.
62197563|NCT03689751|EXPERIMENTAL|LSCS Intervention ArmIntervention Arm|Patients undergoing elective LSCS allocated to this arm underwent the normal preoperative educational pathway, but prior to the operation were shown the educational RSAV (LSCS Video) as an additional educational resource.
62197564|NCT03689751|NO_INTERVENTION|TVT/TOT Control Arm|Patients undergoing elective TVT/TOT allocated to this arm underwent the normal preoperative educational pathway. This typically included face-to-face consultation and written information leaflets.
62197565|NCT03689751|EXPERIMENTAL|TVT/TOT Interventional Arm|Patients undergoing elective TVT/TOT allocated to this arm underwent the normal preoperative educational pathway, but prior to the operation were shown the educational RSAV (TVT/TOT Video) as an additional educational resource.
62197566|NCT04318457||Brochoscopy|20 ASA Class II-III, aged 20-80 adult patients who require moderate sedation during bronchoscopy will be enrolled into this study. The moderate sedation will be performed only after patients' inform consents and approval of the institutional ethics committee. Patients with conditions such as neurological disorders, hearing impairment, history of habitual sedative medication and alcoholism will be excluded from this study.
62399823|NCT04997200|NO_INTERVENTION|Control: One night's normal sleep|A normal night's sleep (at least six hours) in the patient's home.
62399824|NCT02862743|EXPERIMENTAL|patients with metastatic melanoma|patients with metastatic melanoma (stage III unresectable or stage IV)
62399825|NCT01002573|EXPERIMENTAL|ibuprofen|Ibuprofen, 10 mg/kg
62399826|NCT01002573|ACTIVE_COMPARATOR|Acetaminophen|Acetaminophen, 10mg/kg
62399827|NCT01435876|ACTIVE_COMPARATOR|Surgical arm|UNIOCULAR/BINOCULAR RECESSION/RESECTION PROCEDURES
62399828|NCT01435876|ACTIVE_COMPARATOR|Exercises|ORTHOPTICS/MINUS LENS THERAPY
62783250|NCT01711450|EXPERIMENTAL|Paravertebral block|Paravertebral space will be needled and an anesthetic agent will be injected.
62197567|NCT04318457||ERCP|20 ASA Class II-III, aged 20-80 adult patients who require moderate sedation during ERCP will be enrolled into this study. The moderate sedation will be performed only after patients' inform consents and approval of the institutional ethics committee. Patients with conditions such as neurological disorders, hearing impairment, history of habitual sedative medication and alcoholism will be excluded from this study.
62197568|NCT04531722|EXPERIMENTAL|drug-resistant temporal lobe epilepsy|Our current standard practice is to use a lateral approach through the middle temporal gyrus to place 3 depth electrodes targeting the hippocampus for intraoperative verification of pathological epileptiform activity prior to resection. Our research protocol will add one FDA approved electrode that has a central cannula for insertion of a microdialysis probe. The electro-physiological data that will be gathered is not altered and this methodology will not impact standard clinical care, except and will not to extend the duration in the OR - the measurements will occur during the clinical electrocorticography (ECoG; intracranial electroencephalography (iEEG)) procedure by 15 min.
62197569|NCT06179147|EXPERIMENTAL|cervical traction group (intervention group)|Immediately after the placenta was expelled, clamping with collum overpens and controlled traction visible through the vaginal introitus were applied to the women in the intervention group of the study. Traction was applied for 90 seconds.
62576328|NCT03731819|EXPERIMENTAL|Follow-up participants|Patients who met eligibility criteria. Participants are going to undergo Abbreviated PB MRI.
62197570|NCT06179147|NO_INTERVENTION|control group|No procedure was applied to the women in the control group after the placenta was expelled.
62197571|NCT01882413||Patients with Planned Cataract Removal|Patients with planned cataract removal surgery are evaluated for the presence of inflammatory dry eye disease. No treatment is administered.
62197572|NCT04494204|EXPERIMENTAL|Intervention|2 tablets Immunofree 500 mg tablets thrice a day for 10 days and 1 capsule Reginmune 750 mg twice a day for 10 days
62197573|NCT04494204|ACTIVE_COMPARATOR|Comparator Agent|As per standard National Clinical Management Protocol for COVID-19 by Government of India, Ministry of Health and Family Welfare, Directorate General of Health Services, (EMR Division), Version 3, 13.06.20
62197574|NCT06541626||MS|Diagnosis meets the 2017 McDonald diagnostic criteria, receive the recommended diagnosis and treatment plans from current international and national guidelines or expert consensus.
62197575|NCT06541626||NMOSD|Diagnosis meets the 2015 IPND diagnostic panel standards, receive the recommended diagnosis and treatment plans from current international and national guidelines or expert consensus.
62197576|NCT06541626||MOGAD|Diagnosis meets the 2023 international expert panel recommended standards, receive the recommended diagnosis and treatment plans from current international and national guidelines or expert consensus.
62399829|NCT01435876|ACTIVE_COMPARATOR|Postoperative Exercises|POST SURGICAL ORTHOPTICS/MINUS LENS
62399830|NCT01435876|ACTIVE_COMPARATOR|Surgical|
62399831|NCT04058665||Observational group|No intervention performed. This is the overall group that will be retrospectively assessed for different variables pertaining to blood loss.
62197577|NCT06541626||ADEM|Diagnosis meets the diagnostic criteria for ADEM
62197578|NCT06541626||CIS|Diagnosis meets the 2017 McDonald diagnostic criteria, receive the recommended diagnosis and treatment plans from current international and national guidelines or expert consensus.
62399832|NCT01746082|EXPERIMENTAL|Subjects 18 - 64 years|100 (up to 120) subjects 18 - 64 years old receive two doses of monovalent inactivated influenza H3N2 variant (MIV), delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart.
62399833|NCT01746082|EXPERIMENTAL|Subjects > /= 65 years|100 (up to 120) subjects greater than or equal to 65 years old receive two doses of monovalent inactivated influenza H3N2 variant (MIV), delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart.
62399834|NCT05693519||Children|Patients aged 0-17 years at primary gastrointestinal cancer diagnosis
62576329|NCT06574893|EXPERIMENTAL|physical exercise group|physical exercise
62576330|NCT06574893|NO_INTERVENTION|control group|no intervention
62197579|NCT06541626||undefined CNS IIDD|First occurrence of CNS inflammatory demyelinating event, not yet diagnosable as MS, NMOSD, MOGAD, ADEM, or other definitive types of central nervous system demyelinating diseases, with symptoms and signs lasting more than 24 hours
62197580|NCT03889847|EXPERIMENTAL|silicone DLT|Fibreoptic intubation with silicone double lumen tube
62197581|NCT03889847|EXPERIMENTAL|PVC DLT|Fibreoptic intubation with PVC double lumen tube
62399835|NCT05693519||Young people aged 18-24 years|Patients aged 18-24 years at primary gastrointestinal cancer diagnosis
62399836|NCT00253071|ACTIVE_COMPARATOR|A,2|Standard treatment: treatment as usual at a community psychiatric center, private psychiatrist or general practitioner.
62399837|NCT00253071|EXPERIMENTAL|A, 1|"Behavioral: Prophylactic combined medical and psychological treatment~Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
62399838|NCT00660153|EXPERIMENTAL|single arm; multiple cohort|Single arm; multiple cohort
62399839|NCT06253507|EXPERIMENTAL|Single arm|
62399840|NCT02454387|EXPERIMENTAL|Experimental: ONO-4474 Part A1|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
62399841|NCT02454387|PLACEBO_COMPARATOR|Experimental: ONO-4474 Placebo Part A1|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
62576331|NCT05675904||Yes Textbook Outcome|Patients undergoing scheduled colon cancer surgery with a R0 resection, number of isolated nodes ≥12, no Clavien-Dindo ≥IIIa complications, no prolonged stay, no readmissions, and no mortality in the first 30 days
62399842|NCT02454387|EXPERIMENTAL|Experimental: ONO-4474 Part A2|Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
62399843|NCT02454387|PLACEBO_COMPARATOR|Experimental: ONO-4474 Placebo Part A2|Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
62399844|NCT02454387|EXPERIMENTAL|Experimental: ONO-4474 Part B|Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
62399845|NCT02454387|PLACEBO_COMPARATOR|Experimental: ONO-4474 Placebo Part B|Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
62399846|NCT02454387|EXPERIMENTAL|Experimental: ONO-4474 Part C|NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
62399847|NCT02454387|PLACEBO_COMPARATOR|Experimental: ONO-4474 Placebo Part C|NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
62399848|NCT02454387|EXPERIMENTAL|Experimental: ONO-4474 Part D|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
62576332|NCT05675904||No Textbook outcome|Patients undergoing scheduled colon cancer surgery without any of the following items: R0 resection, number of isolated nodes ≥12, no Clavien-Dindo ≥IIIa complications, no prolonged stay, no readmissions, and no mortality in the first 30 days
62576333|NCT02496468||new-onset wheeze/asthma|children with inhaled or systemic corticosteroid-/leukotriene receptor antagonist-naïve wheeze/asthma, will undergo follow-up after initial recruitment
62576334|NCT02496468||wheeze/asthma under controller therapy|children with wheeze/asthma, already under controller (inhaled or systemic corticosteroids or leukotriene receptor antagonist) therapy, will undergo follow-up after initial recruitment
62197582|NCT02565524|EXPERIMENTAL|genetic and phenotypic profile|blood sample, clinical and neurocognitive assessment
62197583|NCT02225262|EXPERIMENTAL|CyberKnife Radiosurgery|
62197584|NCT04646356|EXPERIMENTAL|Tacrolimus immediate-release capsules|subjects will be treated with a 6 months course of oral low-dose tacrolimus capsules to be taken twice daily starting dose of 0.025 mg/kg/day, adjusted to maintain drug blood levels of 2-5ng/ml
62197585|NCT00256022|ACTIVE_COMPARATOR|Lactobacillus Acidophilus Arm|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
62576335|NCT02496468||healthy controls|healthy age- and sex-matched controls, will not undergo follow-up after initial recruitment
62197586|NCT00256022|ACTIVE_COMPARATOR|Lactobacillus Fermentum Arm|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
62399849|NCT02454387|PLACEBO_COMPARATOR|Experimental: ONO-4474 Placebo Part D|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
62399850|NCT00411892|EXPERIMENTAL|A|
62399851|NCT00411892|ACTIVE_COMPARATOR|B|
62576336|NCT00790634||Parkinson's Disease|Patients with idiopathic Parkinson's disease
62399852|NCT03613974|EXPERIMENTAL|lidocaine concentraion|the popliteal block will be performed (once) in all patients using 20 ml of lidoacine. The response of a patient determined the lidocaine concentration given to the next patient (a biased-coin design up-down sequential method). If a patient had a negative response (failed block), the lidocaine concentration was increased by 0.1% w/v in the next patient. If a patient had a positive response (successful block), the next patient was randomized to receive the same lidocaine concentration (with probability of 0.89), or to receive a concentration 0.1% w/v less (with probability of 0.11).
62399853|NCT03427320|EXPERIMENTAL|[131]I-IAZA whole body and SPECT imaging|Injection of a single dose of 185MBq ( range 150-220MBq) of \[131\]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
62399854|NCT04587362||Psoriatic Arthritis|Subjects newly diagnosed with psoriatic arthritis (\< 5 years), confirmed by a rheumatologist and fulfilling the ClASsification for Psoriatic ARthritis (CASPAR) criteria.
62399855|NCT04587362||Psoriasis without musculoskeletal symptoms|Patients with dermatologist confirmed psoriasis, without any history of Psoriatic Arthritis, and musculoskeletal symptoms.
62576337|NCT00790634||Obsessive-compulsive disorder|Individuals with a diagnosis of obsessive-compulsive disorder
62576338|NCT00790634||OCD controls|Healthy controls, matched in age and number to obsessive-compulsive group
62576339|NCT00790634||PD controls|Healthy controls, matched in age and number to Parkinson's disease group
62576340|NCT02519998||Concussed patients|The clinical focus of this study will be on concussed athletes, both children and adults, and we will also include non-sports patients who have mild traumatic brain injury due to other situations including slip and fall, occupational, motor vehicle accidents, assault, and blast exposure.
62576341|NCT02519998||Non-concussed patients|Cohort control. Primarily athletes who undergo routine pre-season baseline assessment
62576342|NCT05038774|EXPERIMENTAL|Interventional group|GPs of the Interventional group will receive (1 day) face to face education with structured educational material on strategies of hypertension management by a senior cardiologist.
62010627|NCT04932200||early-endoscopy group|the time interval from gastroenterologic consultation to the start of emergency endoscopy between 6 and 24 hours
62010628|NCT01914432|EXPERIMENTAL|YH16410|PO, Once Daily, 8 weeks
62010629|NCT01914432|ACTIVE_COMPARATOR|Rosuvastatin|PO, Once Daily, 8 weeks
62197587|NCT00256022|ACTIVE_COMPARATOR|Lactobacillus Fermentum and Lactobacillus Acidophilus|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
62197588|NCT00256022|PLACEBO_COMPARATOR|Placebo|The placebo will be given to the patient 2 a day for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
62197589|NCT00636415|EXPERIMENTAL|A|G1 patients received morphine intra-articular route G2 patients received bupivacaine without epinephrine.
62010630|NCT01914432|ACTIVE_COMPARATOR|Telmisartan|PO, Once Daily, 8 weeks
62197590|NCT02470689|ACTIVE_COMPARATOR|Diacerin cream 1%|
62197591|NCT02470689|PLACEBO_COMPARATOR|ultraphil cream|
62197592|NCT00500968|ACTIVE_COMPARATOR|Stent|
62197593|NCT00500968|ACTIVE_COMPARATOR|conventional distal pancreatectomy|
62010631|NCT01914432|PLACEBO_COMPARATOR|Placebo|PO, Once Daily, 8 weeks
62197594|NCT06044246|EXPERIMENTAL|experimental group|Placing dental implant with PRF membrane treatment alone or combined with bone substitute.
62197595|NCT06044246|NO_INTERVENTION|control group|Placing dental implant
62197596|NCT01517997|EXPERIMENTAL|Drug Coated Balloon (DCB) Arm|Patients included in this arm will undergo PTA with the use of a paclitaxel coated balloon.
62010632|NCT01075334|EXPERIMENTAL|Porimore arm|Infertile men will receive 'Porimore' tablets for a period of time in which three intrauterine insemination cycles will be performed.
62010633|NCT01075334|ACTIVE_COMPARATOR|Folate and Zinc|
62010634|NCT04926753|EXPERIMENTAL|Experimental|5-Fluorouracil(750 mg/m2/d, CIV d1-5) Cisplatin(75mg/m2,d1)/Carboplatin(AUC5, d1) Toripalimab 240mg d1
62010635|NCT05850871|EXPERIMENTAL|CAZ/AVI plus Aztreonam|CAZ-AVI was administered at the dose of 2.5 g every 8 hours and ATM at the dose of 2 g every 8 hours
62010636|NCT05850871|ACTIVE_COMPARATOR|Conventional treatment|Other active antibiotics were administered, including colistin, tigecycline, fosfomycin, meropenem.
62010637|NCT00625599||1|Salvadorian students at the Evangelical University in non-health track studies over the age of 18. The students must accept the invitation to participate along with signing the informed consent to be eligible.
62010638|NCT00625599||2|Patients over the age of 45 presenting to Hospital Zacamil with an acute fracture. Patients must accept the invitation to the study and sign the informed consent to be eligible.
62010639|NCT03281811|EXPERIMENTAL|Treatment (aminolevulinic acid hydrochloride, PDT, RT)|Patients receive aminolevulinic acid hydrochloride topically and undergo photodynamic therapy on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning at week 24, patients undergo radiation therapy daily for 4 weeks.
62010640|NCT04875806|EXPERIMENTAL|0.5mg/kg NC762|Subjects received NC762 IV at 0.5mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
62010641|NCT04875806|EXPERIMENTAL|1.5mg/kg NC762|Subjects received NC762 IV at 1.5mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
62010642|NCT04875806|EXPERIMENTAL|5mg/kg NC762|Subjects received NC762 IV at 5mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
62010643|NCT04875806|EXPERIMENTAL|10mg/kg NC762|Subjects received NC762 IV at 10mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
62197597|NCT01517997|ACTIVE_COMPARATOR|Drug Eluting Stents (DES) Arm|Patients in this arm will undergo primary infrapopliteal stenting of the target lesion using a drug-eluting stent.
62197598|NCT00992342|EXPERIMENTAL|PF-03893787 5 mg|
62197599|NCT00992342|EXPERIMENTAL|PF-03893787 15 mg|
62197600|NCT00992342|EXPERIMENTAL|PF-03893787 50 mg|
62197601|NCT01250795|EXPERIMENTAL|15 ug HAI-05 plus Alhydrogel|vaccine
62197602|NCT01250795|EXPERIMENTAL|45 ug HAI-05 plus Alhydrogel|vaccine
62197603|NCT01250795|EXPERIMENTAL|90 ug HAI-05 plus Alhydrogel|vaccine
62197604|NCT01250795|EXPERIMENTAL|90 ug HAI-05 in saline|vaccine
62197605|NCT01250795|PLACEBO_COMPARATOR|Saline|placebo
62197606|NCT00895557|ACTIVE_COMPARATOR|chantix|
62197607|NCT00446888|ACTIVE_COMPARATOR|1|"these subjects will get a standard protein supplement milkshake during thei study."
62576343|NCT05038774|ACTIVE_COMPARATOR|Control group|GPs of the Control group will receive print version of education material (Structured educational material) on strategies of structured hypertension management.
62576344|NCT00485732|EXPERIMENTAL|Cervarix Group|
62576345|NCT00485732|PLACEBO_COMPARATOR|Placebo Group|
62576346|NCT05498844|ACTIVE_COMPARATOR|Treatment as usual|Control group participants will receive usual medical, physical activity, and standard in-person nutrition counseling (IPNC) on site.
62576347|NCT05498844|EXPERIMENTAL|Intervention-remote nutrition councelling|Intervention group participants will receive remote, web-based nutrition counseling (WBNC) in addition to the standard medical counseling and on-site physical activity.
62576348|NCT06574945|PLACEBO_COMPARATOR|group P|Intravenous injection of an equivalent dose of normal saline followed by 2 mg/kg of propofol
62576349|NCT06574945|EXPERIMENTAL|group PK1|Intravenous injection of 0.5 mg/kg esketamine followed by 1.5 mg/kg of propofol
62576350|NCT06574945|EXPERIMENTAL|group PK2|Intravenous injection of 0.25 mg/kg esketamine followed by 1.5 mg/kg of propofol
62576351|NCT04235465||Dyslexia Group|30 patients will be included. Dynamic Gait Index and other assessments will be performed twice with a 7-day interval by two evaluators
62010644|NCT04875806|EXPERIMENTAL|20mg/kg NC762|Subjects received NC762 IV at 20mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
62197608|NCT00446888|EXPERIMENTAL|2|"these subjects will receive an enhanced protein supplement milkshake during their study. Product 4808."
62197609|NCT03444896|EXPERIMENTAL|Acupuncture group|
62197610|NCT03444896|PLACEBO_COMPARATOR|Sham acupuncture group|
62576352|NCT04235465||Healthy Control Group|30 healthy children will be included. Dynamic Gait Index will be performed.
62197611|NCT02693197|EXPERIMENTAL|Cohort 1:T-817MA|Mild hepatic impairment subjects
62576353|NCT04685824|ACTIVE_COMPARATOR|Biofeedback Training|"* Biofeedback training (BFT): 1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks. 1 session per week for 4 weeks (4 sessions total).~* 30 min daily reading at home for 4 weeks."
62576354|NCT04685824|EXPERIMENTAL|Biofeedback Training + Immersive VR|"* Biofeedback training (BFT) \[1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks\], 1 session per week for 4 weeks (4 sessions total).~* 30 min daily reading at home for 4 weeks~* Immersive virtual-reality stimulation (IVR) \[1 session of 3 blocks of 15 trials of 20 seconds each. Rest time is 1-2 minute(s) between blocks\], 1 session every 2 days for 4 weeks (14 sessions total)."
62576355|NCT03995173|ACTIVE_COMPARATOR|active|active rTMS
62576356|NCT03995173|PLACEBO_COMPARATOR|placebo|placebo rTMS
62576357|NCT05510570||control|healthy child
62576358|NCT05510570||experimental|patients with language disorder
62576359|NCT06572384|EXPERIMENTAL|Belimumab|Participants will receive belimumab in addition to standard therapy.
62576360|NCT06572384|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo in addition to standard therapy.
62576361|NCT04161404|EXPERIMENTAL|Period 1|Subjects will randomized to either of the intervention drug in a ratio of 1:1:1 following three period, cross-over study design.
62576362|NCT04161404|EXPERIMENTAL|Period 2|Subjects will randomized to either of the intervention drug in a ratio of 1:1:1 following three period, cross-over study design.
62576363|NCT04161404|EXPERIMENTAL|Period 3|Subjects will randomized to either of the intervention drug in a ratio of 1:1:1 following three period, cross-over study design.
62197612|NCT02693197|EXPERIMENTAL|Cohort 2:T-817MA|Healthy subjects matched to subjects in Cohort 1
62576364|NCT04203446||Adults with asthma or COPD|Adults (18-85 years old) with asthma or COPD diagnosed at least 3 months earlier, who are regularly treated with at least one inhlaer daily
62576365|NCT06353984|EXPERIMENTAL|Intervention group|Intervention group receives the study product
62783251|NCT01711450|PLACEBO_COMPARATOR|Control sham procedure|Paravertebral space will be needled, but only normal saline injected.
62783252|NCT00966212|NO_INTERVENTION|health promotion materials|
62010645|NCT06105476|EXPERIMENTAL|Alcohol|
62010646|NCT06105476|EXPERIMENTAL|Alcohol+protein|
62010647|NCT06105476|EXPERIMENTAL|Alcohol+retinol|
62197613|NCT02693197|EXPERIMENTAL|Cohort 3:T-817MA|Moderate hepatic impairment subjects
62197614|NCT02693197|EXPERIMENTAL|Cohort 4:T-817MA|Healthy subjects matched to subjects in Cohort 3
62197615|NCT02693197|EXPERIMENTAL|Cohort 5 :T-817MA|Severe hepatic impairment subjects
62197616|NCT02693197|EXPERIMENTAL|Cohort 6:T-817MA|Healthy subjects matched to subjects in Cohort 5
62576366|NCT06353984|ACTIVE_COMPARATOR|Reference group|Reference group receives a reference product
62576367|NCT06353984|NO_INTERVENTION|Control group|No intervention
62576368|NCT02482480|EXPERIMENTAL|Interventional group|"Participants followed a 8-week intervention program with a total of 24 sessions (12 of those were supervised). The aim of the supervision was to increase the adherence to the treatment and to control the compliance of patients. General physical activity consisted in walking along previously standardized urban parks designed for the urban EPOC training project (Arbillaga-Etxarri et al, 2016). The duration of walking were 30 minutes. The physiotherapist supervised the accomplishment of other activities such as oropharyngeal exercises and diet control.~Oropharyngeal exercises:~1. Expiratory muscle strength training (EMST):~2. Masako Manoeuvre~3. Shaker Head Lift:~4. Facial exercise"
62576369|NCT02482480|SHAM_COMPARATOR|Control Group|Control group participants only received general recommendations regarding general physical activity, diet and sleep hygiene. After 8-weeks of control, they were re-evaluated with the same evaluation test used in the beginning of the study period. Recommendations for general physical activity were walking during 30 minutes at least 3 times a week maintaining the greatest possible pace. Also, control group patients received the same diet control document as intervention group and verbal advice for sleep hygiene. Approximately 1 month after enrolment, a follow-up phone call was completed were we also informed about the new re-evaluation data.
62783253|NCT00966212|ACTIVE_COMPARATOR|print parent education|
62783254|NCT00077649|ACTIVE_COMPARATOR|PEG-IFN Alfa-2a 180 μg +Ribavirin 1200 mg|Participants received 180 μg of PEG-IFN \[peginterferon\] alfa-2a in 1 mL solution administered \[subcutaneously\] sc, once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered \[orally \] po daily in split doses for 48 weeks
62576370|NCT06096675|EXPERIMENTAL|cardiac rehabilitation group|Intervention group will have baseline 6-minute walk test and cardiopulmonary exercise test (CPET) testing followed by supervised cardiac rehabilitation program including planned 3 one hour sessions a week for a total of 12 weeks (planned 36 sessions). A post intervention 6-minute walk test and CPET test will be performed within 2 weeks of completion of the 12 week program.
62576371|NCT06096675|NO_INTERVENTION|control group - no intervention|Control Group will have baseline 6-minute walk test and CPET testing followed by a repeat 6-minute walk test and CPET test in 12-14 weeks
62576372|NCT06128902|EXPERIMENTAL|intervention group|COPD patients
62576373|NCT06128902|NO_INTERVENTION|Control group|COPD patients
62010648|NCT06105476|EXPERIMENTAL|Retinol|
62197617|NCT01762904|EXPERIMENTAL|Whole group of 135 units of measurement|"The arm is composed of 135 units of measurement, it means, 540 determinations to test 2% chlorhexidine gluconate in 70% isopropyl alcohol and 1% triclosan in 70% isopropyl alcohol and two controls.~The principal unit of measurement it will be four determinations of bacterial counts in a subject for antiseptics and controls to test each of the application sites, and determination as to each separately sampling for each area for each antiseptic forearm. The same subject may be assessed up to three separate occasions provided only after a minimum period of two weeks between each determination.~Interventions:~* Biological: Bacterial culture of the prepared skin's areas with two antiseptics and two controls~* Other: Preparing skin's areas to be tested with two antiseptics and two controls"
62197618|NCT05757557|ACTIVE_COMPARATOR|Control group|Oxygen-air mixture without NO after intubation, during CPB, and six hours after surgery.
62197619|NCT05757557|EXPERIMENTAL|80-ppm NO|NO will be supplemented at 80-ppm concentration to cardiac surgery patients perioperative after trachea intubation, during CPB, and six hours after surgery.
62197620|NCT05304455|EXPERIMENTAL|Apixaban group|From postoperative day 3, Patients will receive oral Dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.
62197621|NCT00364377|ACTIVE_COMPARATOR|Sitagliptin|People with impaired fasting glucose randomized to treatment with sitagliptin 100 mg once daily.
62197622|NCT00364377|PLACEBO_COMPARATOR|Placebo|People with impaired fasting glucose randomized to treatment with placebo once daily.
62576374|NCT03240289|OTHER|Texting|Texting group
62576375|NCT06328556|EXPERIMENTAL|Injectable Type A Botulinum Toxin|This group will be given Left cricopharyngeal muscle botulinum toxin injection, Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once.
62576376|NCT00713947|ACTIVE_COMPARATOR|A|Amoxicillin, Clarythromycin or metronidazole,Pantoprazole,Placebo
62576377|NCT00713947|EXPERIMENTAL|B|Pantoprazole
62576378|NCT00713947|PLACEBO_COMPARATOR|C|Placebo
62576379|NCT05330156|ACTIVE_COMPARATOR|Transurethral resection of the prostate group (TURP).|the 1st group of patients will undergone Transurethral resection of the prostate for treatment of BPH
62576380|NCT05330156|ACTIVE_COMPARATOR|transurethral enucleation of prostate group (TUEP)|the 2nd group of patients will undergone Transurethral enucleation of the prostate for treatment of BPH
62576381|NCT02346838|EXPERIMENTAL|Inulin|Participants will receive 10 g of inulin powder each day for 6 weeks.
62010649|NCT06653257||Bethesda IV-VI report|thyroid nodules who underwent FNAC with a Bethesda IV-VI report
62010650|NCT04888000|OTHER|single|Educational intervention.
62010651|NCT02442700|EXPERIMENTAL|Treatment sequence A, B|Treatment visits were seperated by a 2-week washout period. Treatment A = administration pitavastatin for 12 weeks; Treatment B = administration placebo for 12 weeks
62197623|NCT03581604|OTHER|Patients labeled as penicillin allergic|Patients labeled as penicillin allergic will be allergologically investigated to confirm/exclude the diagnosis. Allergy work-up will be performed. Blood samples will be obtained.Questionnaire to evaluate the effectiveness of the intervention.
62197624|NCT05722639||Representative sample of the U.S. population|"Subjects will be fitted with two electrophysiology acquisition systems (one is FDA-approved, and the other is the one evaluated).~Signals from both systems will be acquired simultaneously while the subjects rest and perform no cognitive tasks.~Following, the signals from both devices will be assessed by an electrophysiology expert to determine if they are of equal quality."
62197625|NCT03832218|OTHER|Mitochondrial disease|Psychiatric assessment
62197626|NCT03263247|EXPERIMENTAL|Visual Imaging Training|"Participants will receive visual imaging training to facilitate learning of written information.~Intervention: Visual Imaging Training in individual sessions"
62576382|NCT02346838|PLACEBO_COMPARATOR|Placebo|Participants will receive 10 g of maltodextrin each day for 6 weeks.
62576383|NCT02205658||Autism|Individuals, aged 18-95 years, with a pre-existing diagnosis of Autism Spectrum Disorder with or without a co-morbid diagnosis of Sensory Processing Disorder.
62576384|NCT02205658||Sensory Processing|Individuals, aged 18-95 years, with a pre-existing diagnosis of Sensory Processing Disorder with no co-morbid diagnosis of Autism Spectrum Disorder
62576385|NCT02205658||Typical|Typically functioning individuals aged 13-95 years
62576386|NCT03627026|OTHER|Patients treated with immune checkpoint inhibitor|
62576387|NCT01308827||Children with suspected pneumococcal invasive disease|
62576388|NCT00687271|EXPERIMENTAL|MK-6213 160 mg + Atorvastatin 20 mg|1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks
62576389|NCT00687271|ACTIVE_COMPARATOR|Atorvastatin 20 mg|1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks
62576390|NCT00687271|EXPERIMENTAL|MK-6213 160 mg|1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks
62576391|NCT00687271|PLACEBO_COMPARATOR|Placebo|1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks
62576392|NCT02735681|ACTIVE_COMPARATOR|Probing Treatment Right Eye|Meibomian gland will be performed on the right upper eye lid of each participant.
62576393|NCT02735681|PLACEBO_COMPARATOR|Fellow Eye (Left) Untreated|The fellow eye (left) will be used at the untreated control
62576394|NCT02741544||Patients with newly-diagnosed multiple myeloma (NDMM)|Patients with newly-diagnosed multiple myeloma (NDMM) who are treated with Revlimid Capsules (Revlimid)
62576395|NCT00983060|EXPERIMENTAL|NIM811|
62197627|NCT03263247|ACTIVE_COMPARATOR|Psychoeducation|"Participants will receive information about memory functioning and aging.~Intervention: behavioral: Psychoeducation in individual sessions"
62197628|NCT03263247|EXPERIMENTAL|Alphabet Search|"Participants will receive alphabet search training.~Intervention: Alphabet Search in individual sessions"
62576396|NCT00983060|PLACEBO_COMPARATOR|Placebo|
62197629|NCT02178930|OTHER|Integrated self management support|The intervention involves the introduction of an interactive chronic disease support platform into doctor-patient consultations, in addition to a self-management support program. Specifically, the intervention comprises the following interlinked components: within consultation engagement; at home exploration; phone and web-based health coaching.
62197630|NCT02178930|NO_INTERVENTION|Usual care|The control group will receive usual care from study sites until all study participants have completed 12 months of follow up from their Baseline Visits. At this point access to the study intervention will be expanded to include control sites.
62197631|NCT03255005|ACTIVE_COMPARATOR|Treatment group|Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
62576397|NCT03732482|PLACEBO_COMPARATOR|RT groups|participants was given radiotherapy only,50Gy in 10 fractions over 2 weeks to metastases synchronously with 25Gy WBRT
62576398|NCT03732482|EXPERIMENTAL|Drug plus RT groups|Temozolomide capsules(Jiangsu tasly diyi pharmaceutical Co.,Ltd) Oral Temozolomide capsules 75mg/m2 begins on day 1 and continues until completion of radiotherapy.
62010652|NCT02442700|EXPERIMENTAL|Treatment sequence B, A|Treatment visits were seperated by a 2-week washout period. Treatment B = adminstration placebo for 12 weeks; Treatment A = adminstration pitavastatin for 12 weeks
62010653|NCT04431232|EXPERIMENTAL|Band Ligation|Band ligation of gastric body for weight loss
62010654|NCT02291627|EXPERIMENTAL|intubation with immobilized cervical spine|endotracheal intubation with immobilized cervical spine
62010655|NCT01578434|ACTIVE_COMPARATOR|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
62010656|NCT01578434|ACTIVE_COMPARATOR|Vitamin D|Vitamin D: 6 lakh IU single im dose
62010657|NCT01578434|ACTIVE_COMPARATOR|Vitamin D and Calcium|vitamin D and Calcium: combination of above two
62010658|NCT01738152|EXPERIMENTAL|HLA treatment|This is a single arm prospective longitudinal clinical trial investigating the feasibility of a hyaluronic acid (HLA) vaginal gel (HyaloGYN®; Cebert Pharmaceuticals, Inc.; Birmingham, Alabama) to improve estrogen deprivation vaginal and vulvar health symptoms in post-menopausal women with a history of hormone-receptor positive cancer with estrogen deprivation symptoms of vaginal dryness and discomfort.
62010659|NCT01751464|EXPERIMENTAL|WrapAround Care|
62010660|NCT06464588|EXPERIMENTAL|Adult Cohort|"Adults (18-30 years) will be enrolled into all dose levels (as tolerated) of Phase 1A. Open label nMSCs will be administered intravenously in the following defined dose groups. The rate of infusion will be approximately 30- 60 minutes at 0, 15 and 30 days, with escalating dose levels:~* Dose level 1: 5.0x107 nMSCs at 0, 15 and 30 days~* Dose level 2: 1.0.x108 nMSCs at 0, 15 and 30 days~* Dose level 3: 2.5x108 nMSCs at 0, 15 and 30 days~Dose escalation will follow 3+3 study design parameters. The next dosing group will be initiated at least one month after the last subject in a particular dose level has received the last dose treatment. Once MTD has been determined, 3 additional patients will be enrolled to ensure a total of 6 patients are enrolled in MTD level for confirmation."
62010661|NCT06464588|EXPERIMENTAL|Pediatric Cohort|"Pediatric participants (ages 4 years-18 years) will be enrolled into dose level as determined in Phase 1B (3+3 study design; open label).~nMSCs will be administered intravenously in the following defined dose groups. The rate of infusion will be approximately 30- 60 minutes at 0, 15 and 30 days, with escalating dose levels:~* Dose Level 1: 0.7x106 nMSCs/kg~* Dose Level 2: 1.43x106 nMSCs/kg~* Dose Level 3: 2.85x106 nMSCs/kg~Dose escalation will follow 3+3 study design parameters. The next dosing group will be initiated at least one month after the last subject in a particular dose level has received the last dose treatment. Once MTD has been determined, 3 additional patients will be enrolled to ensure a total of 6 patients are enrolled in MTD level for confirmation.~Following intravenous delivery of nMSCs, patients will be followed at 3 months, 6 months and 1 year from the last infusion to complete all safety and efficacy assessments."
62010662|NCT02571894|NO_INTERVENTION|Observational arm|Participants randomized to observational arm will receive standard oncological followup and care.
62197632|NCT03255005|ACTIVE_COMPARATOR|Controled group|Diet for 6 months then Endoscopic sleeve gastroplasty (Endomina) with multidisciplinary follow-up for 1 year
62197633|NCT04593953|NO_INTERVENTION|CONTROL|Standard general anesthesia
62576399|NCT06094725|EXPERIMENTAL|No Hepatic Impairment|Subjects with no hepatic impairment will receive relacorilant 300 mg once daily on Days 1 through 10.
62576400|NCT06094725|EXPERIMENTAL|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment (Child-Pugh Class B) will receive relacorilant 300 mg once daily on Days 1 through 10.
62576401|NCT06094725|EXPERIMENTAL|Mild Hepatic Impairment|Subjects with mild hepatic impairment (Child-Pugh Class A) will receive relacorilant 300 mg once daily on Days 1 through 10.
62576402|NCT01333046|EXPERIMENTAL|Antigen-Escalation Stage|"The first stage will be an antigen-escalation stage using a fixed total dose of cells (5 x 10\^6 cells/m\^2 x 2) to evaluate the safety of the T cells primed against PRAME pepmix, and then SSX pepmix, and then MAGE A4 pepmix, and then NY-ESO pepmix, and then SURVIVIN pepmix."
62576403|NCT01333046|EXPERIMENTAL|Dose-Escalation Study Stage|"In the dose escalation stage, three dose levels will be studied. Patients in the dose escalation portion of the study will be entered and stratified separately to the following two groups:~Group A: Patients receiving CTLs as therapy for Hodgkin's or non-Hodgkin's lymphoma.~Group B: Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant."
62010663|NCT02571894|EXPERIMENTAL|Intervention arm|Intervention arm receives standard oncological followup and care + subclinical cardiotoxicity surveillance and treatment.
62197634|NCT04593953|EXPERIMENTAL|TLIP|Standard general anesthesia + TLIP block
62197635|NCT05590442||Training cohort|The patients will be divided into the training and validation cohorts with a ratio of 7:3. The training cohort will be used to screen variables and construct the model.
62399856|NCT04587362||Non-Inflammatory Rheumatic conditions|Patients with non-inflammatory rheumatic conditions such as osteoarthritis, non-specific back pain, soft tissue rheumatism, degenerative tendinopathy and fibromyalgia. Patients with present or past history of psoriasis, psoriatic arthritis, known or suspected rheumatic inflammatory conditions (e.g. rheumatoid arthritis, spondyloarthritis and gout), and/or inflammatory bowel disease will be excluded.
62399857|NCT04077060|EXPERIMENTAL|NIPT|Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization \< 9 6/7 weeks of gestation.
62399858|NCT04077060|OTHER|Combined screening|Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is \>3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
62399859|NCT02513680|ACTIVE_COMPARATOR|LASER and LED therapy application|The first group will use the two techniques under study combined: Infrared Laser + Amber LED (830 nm - 150mW + 590 nm - 1.500 mW)
62399860|NCT02513680|ACTIVE_COMPARATOR|LED Therapy application|The second group will use only Amber LED (590 nm - 1.500 mW)
62399861|NCT03853434|EXPERIMENTAL|Embolization|After angiography all metastases with poor/moderate vascularization will be embolized with acrylic glue in the treatment group.
62576404|NCT01333046|EXPERIMENTAL|azacytidine and multiTAA T cells Stage|This phase will administer aza intravenously at a dose of 75 mg/m2 after premedication with an anti-emetic such as ondansetron po or IV (up to a maximum dose of 16 mg ondansetron or equivalent). This phase will determine whether infusion of TAA-specific T cells (at dose level 2 - 1x10\^7) targeting multiple tumor antigens in combination with azacytidine is safe, and whether CTL infusions (with or without azacytidine) increase the spectrum of epitopes/antigens targeted by endogenous T cells (epitope spreading).
62576405|NCT01333046|EXPERIMENTAL|Pediatric multiTAA T cells Stage|This phase will give patients \< 18 years old two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10\^7 cells/m2. This phase will test the safety and efficacy of multiTAA-specific T cells in pediatric patients with active HL/NHL.
62197636|NCT05590442||Validation cohort|The validation cohort will be used to validate the results obtained using the training cohort.
62399862|NCT03853434|NO_INTERVENTION|No embolization|After angiography all metastasis with poor/moderate vascularization will not be embolized with acrylic glue in the control group
62399863|NCT03394053||Affected Patient|Person with a clinical diagnosis of a PID; either known or unknown as defined by lab and/or clinical findings on 2 or more occasions that are consistent with a defect in innate or adaptive immunity
62399864|NCT03394053||Normal Volunteer|Persons (age 18-75 years) who are not related to another study subject, who do not have a PID, weight \>110lbs, no history of viral hepatitis B or C, have a negative HIV screening test
62399865|NCT03394053||Relative of Patient|Biological relatives (age 0-75 years) of a subject who meets affected patient criteria, but who do not have a PID themselves
62197637|NCT01930097|ACTIVE_COMPARATOR|CHO-dependant bolus|"An insulin bolus dependant of carbohydrate content will be given after each meal.~Each subject insulin-to-carbohydrate ratio (U per 10g CHO) will be used to calculate the insulin bolus to be given. The dual-hormone closed-loop strategy will give the remaining insulin needed based on the sensor readings."
62399866|NCT02035891|ACTIVE_COMPARATOR|colchicine|0.5mg/d colchicine
62399867|NCT02035891|PLACEBO_COMPARATOR|placebo|appearance is same as colchicine
62197638|NCT01930097|ACTIVE_COMPARATOR|CHO-independent bolus|An insulin bolus independent of carbohydrate content will be given after each meal. The dual-hormone closed-loop strategy will give the remaining insulin needed based on the sensor readings.
62197639|NCT01930097|ACTIVE_COMPARATOR|Conventional treatment|Patients will use conventional pump therapy to regulate glucose levels
62197640|NCT04830553|EXPERIMENTAL|Music-based couple therapy.|"Each couple will receive five treatment sessions, including established methods from client-centered and family-systems psychotherapy as well as Sentire, a technological approach providing immediate sound feedback for physical distance and touch. Duration of the treatment phase: five weeks."
62197641|NCT04830553|NO_INTERVENTION|Waiting list.|Each couple will go through an initial waiting period before the treatment phase. Duration of the waiting period: five weeks.
62197642|NCT05071586|EXPERIMENTAL|Children diagnosed with stroke/brain bleed|Male and females aged 8 to 21 with established diagnosis of stroke/brain bleed who are US residents.
62197643|NCT05416047||Frail and no frail|Frailty will be assessed using Rockwood Clinical Frailty Score
62197644|NCT05416047||Sarcopenia and no sarcopenia|Sarcopenia will be assessed using psoas muscle mass
62576406|NCT01313975||1|Patients with non-traumatic subarachnoid hemorrhage
62576407|NCT01313975||2|Patients with severe traumatic brain injury
62576408|NCT05342389|EXPERIMENTAL|Experimental group|A fixed dose of Camrelizumab 200mg will be administered intravenously (without preventive medication), and each infusion lasts 45min (no less than 30min, no more than 60min), once every two weeks; During the treatment period, 250 mg of Apatinib mesylate tablets will be taken orally daily continuously, and every 2 weeks is a treatment cycle. The treatment lasts for up to 2 years or until disease progression, death or intolerable toxicity occurred.
62576409|NCT05342389|ACTIVE_COMPARATOR|Control group|Apatinib mesylate tablets 500 mg will be taken orally daily continuously, every 2 weeks as a treatment cycle. Treatment lasts for up to 2 years or until disease progression, death or intolerable toxicity occurs.
62576410|NCT00688662|ACTIVE_COMPARATOR|1.ERCP with sphincterotomy|ERCP with sphincterotomy: cutting the biliary sphincter muscle (sphincterotomy)
62576411|NCT00688662|PLACEBO_COMPARATOR|2.ERCP without sphincterotomy|ERCP without cutting the biliary sphincter muscle (sphincterotomy)
62576412|NCT00389532|EXPERIMENTAL|1|aged 19 to 59 years
62576413|NCT00389532|EXPERIMENTAL|2|aged ≥ 60 years
62576414|NCT04043533|EXPERIMENTAL|Exercises Group|
62576415|NCT04043533|NO_INTERVENTION|Control Group|
62576416|NCT05879250|EXPERIMENTAL|Cohort I (WP1066, radiation)|Patients whose tumor was completely removed at the time of initial surgery receive WP1066 PO for 6 weeks during routine radiation therapy, and then for twelve 28-day cycles on study. Patients also undergo MRI and collection of blood samples throughout the trial.
62576417|NCT05879250|EXPERIMENTAL|Cohort II (WP1066, radiation, surgery)|Patients whose tumor was not fully removed at the time of initial surgery receive WP1066 PO for 6 weeks during routine radiation therapy on study. Patients may then undergo possible surgery or open biopsy if eligible, followed by twelve 28-day cycles of WP1066 PO on study. Patients also undergo MRI and collection of blood samples throughout the trial.
62576418|NCT03622060|ACTIVE_COMPARATOR|Nitroglycerin|500 microgram intraarterial Nitroglycerin
62197645|NCT05133492|EXPERIMENTAL|Interventional|Use of the EAST System for the stabilization treatment of AAA. The device is delivered endovascularly and placed in the AAA sac to deliver the Stabilizer Infusion Solution.
62197646|NCT01614353||Study Cohort|All participants (N=30) will be asked to identify perceptions and behaviors surrounding the medication-taking process using technology-assisted prompts and recordings. Half (n=15) of the participants will participate in two hermeneutic interviews using an interpretive phenomenological approach to generate an interpretation of the meaning of medication taking.
62399868|NCT02274363||Brazilian Participants with Chronic Plaque-type Psoriasis|Brazilian participants with plaque psoriasis followed up at teaching and non-teaching specialized dermatology centers will be included in this study.
62399869|NCT03733665||Heart failure patients|All patients in NICOR's National Heart Failure Audit will be matched to those in NHS Digital's HES database who have a 4-character primary diagnosis of I50.0-I50.9.
62576419|NCT03622060|PLACEBO_COMPARATOR|Nicardipine|200 microgram intraraterial Nicardipine
62576420|NCT02917291|EXPERIMENTAL|FAB117-HC (Ph 1)|Patients with acute traumatic spinal cord injury grading AIS A (8 patients)
62576421|NCT02917291|OTHER|Control group (Ph 2)|Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)
62576422|NCT02917291|EXPERIMENTAL|FAB117-HC (Ph 2)|Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)
62576423|NCT06294639|EXPERIMENTAL|esketamine|esketamine will be given intravenously
62576424|NCT03198312|EXPERIMENTAL|CathiportTM|be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.
62576425|NCT03198312|ACTIVE_COMPARATOR|Implant Port|be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.
62576426|NCT01591850|EXPERIMENTAL|1 Ketoconazole DDI|
62576427|NCT01591850|EXPERIMENTAL|2 Rifampicin DDI|
62197647|NCT03911934|ACTIVE_COMPARATOR|Usual care|Usual care in the geriatric outpatient clinic.
62576428|NCT01591850|EXPERIMENTAL|3 ATZ/r DDI|
62576429|NCT02189343|EXPERIMENTAL|Dose Escalation Cohort|Dose Escalating Cohorts of ACY-1215 in combination with pomalidomide and dexamethasone.
62576430|NCT00461773|ACTIVE_COMPARATOR|bevacizumab|brief exposure bevacizumab
62576431|NCT00461773|ACTIVE_COMPARATOR|bevacizumab and letrozole|brief exposure bevacizumab and letrozole
62576432|NCT02791542||Asthma|Participants with a history of asthma
62576433|NCT02791542||Healthy controls|Participants without a history of asthma
62576434|NCT02791542||Asthma Bronchoscopy sub-group|Participants with a history of asthma who will undergo the same procedures as other healthy controls with the addition of bronchoscopy
62576435|NCT02791542||Healthy Bronchoscopy sub-group|Participants without a history of asthma who will undergo the same procedures as other healthy controls with the addition of bronchoscopy
62399870|NCT05682066|EXPERIMENTAL|Innovalve TMVR System|MV replacement with Innovalve MR system
62399871|NCT00821847||1:experimental|male, caucasian, HIV infected patients with glomerular filtration rate between 60 and 30 ml/min (estimated with cockcroft and Gault formulae)
62399872|NCT00531921||Kidney transplants|patients from 5 specific sites
62399873|NCT00531921||Liver transplants|patients from 5 specific sites
62399874|NCT00531921||Heart transplants|patients from 5 specific sites
62399875|NCT00531921||Lung transplants|patients from 5 specific sites
62576436|NCT05511701|ACTIVE_COMPARATOR|Usual Care|with paper-based guidelines used by community health workers (CHW) and providers
62576437|NCT05511701|EXPERIMENTAL|Intervention|with central data management system linking digital mHealth screening tool for CHWs, electronic appointment scheduling, point of care testing (POCT) for lipids, clinical decision support for medication initiation, and a SMS reminder system for adherence to medications and life-style changes
62576438|NCT03379766|EXPERIMENTAL|Successor of Phonak Audéo B-Direct|The successor of Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
62576439|NCT03379766|ACTIVE_COMPARATOR|Phonak Audéo B-Direct|The Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
62576440|NCT05021016|EXPERIMENTAL|"Group 1: Vaccine"|150 volunteers who will be vaccinated with the EpiVacCorona vaccine with two doses spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
62576441|NCT04593511|EXPERIMENTAL|Formulation 1|a single dose of LY03009 F1
62576442|NCT04593511|EXPERIMENTAL|Formulation 2|a single dose of LY03009 F2
62576443|NCT04593511|EXPERIMENTAL|Formulation 3|a single dose of LY03009 F3
62010664|NCT03945500|EXPERIMENTAL|Standardized Home Spirometry (SHS) Method|"The Standardized Home Spirometry (SHS) Method consists of an Investigational Mobile Medical Application embedded in an Android Tablet \& FDA approved spirometer \& pulse oximeter.~Participants will be trained with the SHS method, perform an initial home spirometry test session \& a lab-based spirometry test (if practicable).~Pre-surveillance Phase:Daily SHS Testing for 4 to 10 weeks to enable the Mobile Medical application to generate volunteer specific normal range.~Surveillance Phase: At least weekly SHS Testing. During approximately two months of the surveillance phase, the volunteer will test one to four times per week to assess the SHS neural pathways as directed by the study team. Test sessions will be documented on a test log. Subjects may be asked to perform additional SHS pathway test logs, continue at least weekly testing, pause testing or end participation following completion of the initial SHS neural pathway test log."
62010665|NCT03586999|EXPERIMENTAL|Nivolumab and EPOCH|Patients will all receive nivolumab in combination with standard dose adjusted EPOCH for a planned 6 cycles, unless treatment is stopped early for disease progression or toxicity. Patients that have already received up to 1 cycle of standard of care chemotherapy will receive 5 cycles of experimental nivolumab + DA-EPOCH (dose adjusted, continuous infusion etoposide, prednisone, vincristine, doxorubicin, and bolus dosing of cyclophosphamide) for a total of 6 cycles of chemotherapy.
62197648|NCT03911934|EXPERIMENTAL|Usual care plus polypharmacy intervention|Usual care in the geriatric outpatient clinic plus polypharmacy intervention. Polypharmacy intervention consists of a medication review by a physician from the Department of Clinical Pharmacology plus additional communication with patients' GPs before and after the visit in the outpatient clinic.
62576444|NCT04593511|EXPERIMENTAL|Formulation 4|a single dose of LY03009 F4
62576445|NCT03064789||Women with candidiases infection|Women that are prescribed treatment with clotrimazole: 500 mg. and probiotics (routine clinical practice)
62576446|NCT03461952|EXPERIMENTAL|Nivolumab|240mg Q2W
62010666|NCT01581593|EXPERIMENTAL|Kedrion IVIG 10%|Kedrion IVIG 10% treatment.
62576447|NCT03461952|EXPERIMENTAL|Nivolumab + Ipilimumab|Nivolumab 240mg Q2Wk + Ipilimumab 1mg/kg Q6W
62576448|NCT04245748|ACTIVE_COMPARATOR|Escitalopram|Adaptively randomized, double-blind treatment with escitalopram for 11 weeks in Phase 1. Non-remitting patients will be randomized in Phase 2 to adjunctive clonazepam or pregabalin for 8 weeks. Additionally, adults who are already treated with escitalopram or citalopram for at least 6 weeks prior to screening, may enter Phase 2 and be randomized to adjunctive clonazepam or pregabalin for 8 weeks.
62734743|NCT04666142|ACTIVE_COMPARATOR|Comparison of physiological parameters of individuals in both groups after 24 hours|Comparison of the physiological parameters of the individuals in the experimental and control groups 24 hours after their admission to the ICU.
62576449|NCT04245748|ACTIVE_COMPARATOR|Duloxetine|Adaptively randomized, double-blind treatment with duloxetine for 11 weeks in Phase 1. Non-remitting patients will be randomized in Phase 2 to adjunctive clonazepam or pregabalin for 8 weeks. Additionally, adults who are already treated with duloxetine for at least 6 weeks prior to screening, may enter Phase 2 and be randomized to adjunctive clonazepam or pregabalin for 8 weeks.
62576450|NCT02383030|EXPERIMENTAL|Fulvestrant|In Arm A maintenance Fulvestrant will be given until disease progression, unacceptable toxicity or refused of patient to the treatment.
62576451|NCT02383030|NO_INTERVENTION|No intervention|Patients will be randomized to receive fulvestrant (experimental arm) or no treatment
62576452|NCT01931475|EXPERIMENTAL|Duloxetine|"Double Blind Treatment Phase:~60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.~Extension Treatment Phase:~60 mg duloxetine administered by mouth QD for 13 weeks.~Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs)."
62010667|NCT02568488|EXPERIMENTAL|metformin|PCOS women receiving metformin 850 mg orally twice daily over a period of 6 months
62010668|NCT05634616|EXPERIMENTAL|BCI|The experimental group was trained with BCI-controlled pedaling rehabilitation training system. Patients wore EEG caps and were instructed to imagine upper limb pedaling movements. The greater the patients' movement intention, the higher the Mscore of movement intention index on the monitor and the faster the pedaling speed. In addition, the movements on the monitor are synchronized with the actual movements, and the system provides audio and text feedback according to the patient's performance.
62010669|NCT05634616|SHAM_COMPARATOR|Sham BCI|In the control group, the training equipment and scenario were the same as in the experimental group, and the patients wore EEG caps and were also instructed to imagine upper limb pedaling movements. However, the system was changed to only record the EEG signal without controlling the pedaling equipment, and the Mscore score and pedaling speed displayed by the equipment in real time were pre-set data of the training performance of the previous pretest patients, i.e., sham neurofeedback.
62010670|NCT02766491|EXPERIMENTAL|Strengthening and stretching|The intervention group will follow a strengthening-stretching program of the calf muscles.
62010671|NCT02766491|ACTIVE_COMPARATOR|conventional stretching|The control group will receive conventional stretching and strengthening exercises to the upper limb to assure that the same systemic physiological stimuli and a similar number of contact hours is received.
62576453|NCT01931475|PLACEBO_COMPARATOR|Placebo|"Double Blind Treatment Phase:~Placebo administered by mouth once a day (QD) for 13 weeks.~Extension Treatment Phase:~60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.~Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs)."
62576454|NCT04921098|EXPERIMENTAL|Refractory glaucoma|
62576455|NCT04296643|EXPERIMENTAL|Medical Mask|Medical Mask worn when providing care to patient with febrile respiratory illness
62576456|NCT04296643|ACTIVE_COMPARATOR|N95 respirator|N95 respirator worn when providing care to patient with febrile respiratory illness
62576457|NCT05618938|EXPERIMENTAL|Group: A Rocabado's approach|"1. Rest position of the tongue: The anterior 1/3 of the tongue is placed at the palate with mild pressure.~2. Control of TMJ rotation: The jaw is repeatedly opened and closed with the anterior 1/3 of the tongue on the palate.~3. Rhythmic stabilization technique: Gentle isometrics in the resting position are performed for jaw opening, closing, and lateral deviation.~4. Axial extension of the neck: Combined upper cervical flexion with lower cervical extension."
62010672|NCT03528330|ACTIVE_COMPARATOR|Internal hexagon connection|"Small flaps will be elevated to reduce any kind of injury on the periosteum and maintain the blood supply during the healing period.~Patients will receive 2 implants. One implant (assigned randomly) will have internal hexagon connection.~The Internal Hex (IH) implant has a 2.5mm internal hexagon and a 90° cone. The platform diameter is Ø3.5mm."
62197649|NCT06224777|EXPERIMENTAL|Albumin Group A|5% Albumin solution will be administered on day 2 @0.5ml/kg/%burn over 8 hours,in addition to required crystalloids.
62197650|NCT06224777|ACTIVE_COMPARATOR|Crystalloid Group B|Routine Crystalloids will be administered according to weight of the patient.
62576458|NCT05618938|EXPERIMENTAL|Group B: Kraus exercises|"Group B will be treated with Kraus exercises. Kraus exercises will be comprised of eight exercise programs.~1. Tongue position at rest: The patient will be instructed to maintain a resting tongue position except during function, which involves the tip of the tongue sitting on the palate with the tip resting just posterior to the upper incisors~2. Teeth apart: the patient will be educated to maintain the teeth apart can be therapeutic, which facilitates the resting tongue position~3. Nasal-diaphragmatic breathing: The patient will be instructed in nasal breathing to facilitate function of the diaphragm, which reinforces positioning of both the tongue and teeth~4. Tongue up and wiggle: Place the tongue to the palate, then move the jaw from side to side.~5. Strengthening: Resisted closing via self-manual resistance using tongue depressor between lower incisors: 5-10-second contractions."
62576459|NCT02693470|OTHER|single-arm study|"50 patients with severe psoriasis who received Stelara(ustekinumab) at 0 and 1 month. The investigators check microparticles level at baseline and 4 months later.~50 patients without psoriasis: the microparticles are checked at baseline."
62576460|NCT00976001|OTHER|Follow-up at an out-patient stroke unit|Information, measurement of handicap, further rehabilitation efforts, drug therapy for secondary prevention of stroke.
62197651|NCT04697134|EXPERIMENTAL|Conscious Discipline Intervention Group|Participants in this group received one-on-one Conscious Discipline classes with a Roving Caregiver. These classes consisted of the dissemination of Conscious Discipline Skills and fun songs, games, and activities to foster connections between the infant and caregiver. Both the infant and caregiver received the intervention simultaneously.
62197652|NCT04697134|NO_INTERVENTION|Control|Participants in this group did not receive the intervention.
62576461|NCT00976001|OTHER|Follow-up with the general practitioner|
62197653|NCT04487470|EXPERIMENTAL|Flavored Filtered Cigars|Half of the group will be randomized to start with flavored filtered cigars (FCs) at the second visit and cross over to unflavored FCs at the third visit. FCs will be Cheyenne filtered cigars.
62197654|NCT04487470|EXPERIMENTAL|Unflavored Filtered Cigars|Half of the group will be randomized to start with unflavored FCs at the second visit and cross over to flavored FCs at the third visit. FCs will be Cheyenne filtered cigars.
62197655|NCT00648999|ACTIVE_COMPARATOR|1|
62197656|NCT00648999|ACTIVE_COMPARATOR|2|
62197657|NCT03143647||Control|"* Female~* Over 18 years of age~* American Society of Anesthesiologists physical fitness scale 1~* Not pregnant"
62197658|NCT03143647||Case|"* Female~* Pregnant with possible pre-eclampsia~* Over 18 years of age~* American Society of Anesthesiologists physical fitness scale 1"
62197659|NCT02273258|EXPERIMENTAL|Test (T)|SAR342434: single dose injection
62197660|NCT02273258|ACTIVE_COMPARATOR|Reference 1 (R1)|US-approved Humalog®: single dose injection
62197661|NCT02273258|ACTIVE_COMPARATOR|Reference 2 (R2)|EU-approved Humalog®: single dose injection
62197662|NCT01655303|EXPERIMENTAL|Metoprolol Per Oral|50 mg Metoprolol
62197663|NCT01655303|EXPERIMENTAL|Verapamil|40 mg Verapamil Per Oral
62399876|NCT05078229|EXPERIMENTAL|FOCUS|Focusing On mindfulness for Caregivers Under Stress (FOCUS)will consist of six one-on-one, 45-60 minute sessions delivered either in-person (sessions 1-3) or via video conference (sessions 4-6). The first few sessions will primarily focus on how to direct attention to the breath or some object of attention (e.g., parts of the body). As the program progresses, participants are asked to apply these skills to thoughts and emotions. Throughout the treatment, caregivers are reminded to utilize existing coping skills, as well as how to integrate the new skills learned throughout this program for managing stress. Formal mindfulness meditations are conducted within each session, lasting from 7-20 minutes; participants will be asked to practice mindfulness exercises daily.
62399877|NCT05078229|ACTIVE_COMPARATOR|Healthy Living|Healthy Living (HL) will consist of six, 45-60 minute sessions delivered one-on-one; sessions 1-3 in-person on HCT unit and sessions 4-6 via video conference. HL will be based on the American Cancer Society's (ACS) Caregiver Resource Guide.
62783255|NCT00077649|EXPERIMENTAL|PEG-IFN Alfa-2a 180 μg + Ribavirin 1600 mg|Participants received 180 μg of PEG-IFN \[peginterferon\] alfa-2a in 1 mL solution administered \[subcutaneously\] sc, once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered \[orally \] po daily in split doses for 48 weeks
62010673|NCT03528330|EXPERIMENTAL|Conical connection|"Small flaps will be elevated to reduce any kind of injury on the periosteum and maintain the blood supply during the healing period.~Patients will receive 2 implants. One implant (assigned randomly) will have internal hexagon connection.~The Conical Standard (CS) implant has a 2.5mm internal hexagon and 22° cone. The platform diameter is Ø3.1mm."
62010674|NCT06663215|NO_INTERVENTION|control group|
62010675|NCT06663215|EXPERIMENTAL|intervention group|
62010676|NCT02939417|EXPERIMENTAL|using grape seed extract|Grape seed extract as collagen cross-linking agent
62010677|NCT02939417|ACTIVE_COMPARATOR|without uing grape seed extract|
62197664|NCT01655303|EXPERIMENTAL|Propranolol|40 mg Propranolol Per Oral
62197665|NCT01655303|EXPERIMENTAL|Diltiazem|60 mg Diltiazem Per Oral
62399878|NCT05078229|NO_INTERVENTION|Standard of Care - Enhanced Care|Participants in Enhanced Care will receive treatment consistent with what is offered to all caregivers of allogeneic HCT patients. This entails the option of attending weekly support groups and meeting with social workers as needed. At the baseline session, participants randomized to Enhanced Care will be provided with a modified version of the ACS Caregiver Resource Guide.
62783256|NCT00077649|EXPERIMENTAL|PEG-IFN Alfa-2a 270 μg + Ribavirin 1200 mg|Participants received 270 μg of PEG-IFN alfa-2a in 1-mL solution administered sc once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered po daily in split doses for 48 weeks
62783257|NCT00077649|EXPERIMENTAL|PEG-IFN Alfa-2a 270 μg + Ribavirin 1600 mg|Participants received 270 μg of PEG-IFN alfa-2a in 1-mL solution administered sc once weekly + 1600 mg of ribavirin (200 mg/tablet) administered po daily in split doses for 48 weeks.
62783258|NCT01276678||Control|300 healthy controls free from any pharmacologic therapy
62783259|NCT01276678||Suspected CAD - Cardiac Cathetrization|subject's ≥18 years undergoing coronary angiography (inpatient cohort)or who have undergone coronary angiography within 5 years
62783260|NCT03157765|EXPERIMENTAL|EMB intervention|These patients receive and endometrial biopsy
62197666|NCT01931098|EXPERIMENTAL|Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure|Topotecan .25 mg and pazopanib 600 mg are administered orally daily until progression, up to one year.
62197667|NCT01931098|EXPERIMENTAL|Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure|Topotecan .25 mg and pazopanib 600 mg are administered orally daily until progression, up to one year.
62197668|NCT06248437||Healthy participants|Healthy participants (n = 10). At that time, they were explained how they should eat the nutraceutical food (HIC1®), starting the next day and for five consecutive days. During those 5 days, a nurse made contact calls to verify that the participant took the corresponding dose for the day. After 5 days of ingesting the nutraceutical compound, a blood sample was taken again to quantify post-ingestion levels of ORAC units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and the lipid profile.
62197669|NCT06248437||Patients with COPD|Patients with COPD (n = 10). At that time, they were explained how they should eat the nutraceutical food (HIC1®), starting the next day and for five consecutive days. During those 5 days, a nurse made contact calls to verify that the participant took the corresponding dose for the day. After 5 days of ingesting the nutraceutical compound, a blood sample was taken again to quantify post-ingestion levels of ORAC units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and the lipid profile.
62197670|NCT06248437||Patients in the Intensive Care Unit (ICU)|"Patients receiving mechanical ventilation in the Intensive Care Unit (ICU) (n=10)~At that time, they were explained how they should eat the nutraceutical food (HIC1®), starting the next day and for five consecutive days. During those 5 days, a nurse made contact calls to verify that the participant took the corresponding dose for the day. After 5 days of ingesting the nutraceutical compound, a blood sample was taken again to quantify post-ingestion levels of ORAC units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and the lipid profile. In the case of the participants in the ICU, control visits were made to the unit to verify that the dose was delivered to the participant"
62197671|NCT01211301|ACTIVE_COMPARATOR|Food-based, Reduced Energy Diet Plan|
62197672|NCT01211301|EXPERIMENTAL|Medifast 5 & 1 Plan|
62197673|NCT05722886|EXPERIMENTAL|Treatment Arm 1: Alectinib|This alectinib treatment arm is for adult, teenage/young adults (TYA) and paediatric participants with ALK-positive cancers.
62197674|NCT05722886|EXPERIMENTAL|Treatment Arm 2: Atezolizumab|This atezolizumab treatment arm is for adult, teenage/young adults (TYA) and paediatric participants with high tumour mutational burden (TMB) or microsatellite instability high (MSI-high) or proven (previously diagnosed) constitutional mismatch repair deficiency (CMMRD) only.
62197675|NCT05722886|EXPERIMENTAL|Treatment Arm 3: Entrectinib|This entrectinib treatment arm is for adult, teenage/young adult (TYA) and paediatric participants with ROS1 gene fusion-positive malignancies only.
62197676|NCT05722886|EXPERIMENTAL|Treatment Arm 4: Trastuzumab in combination with pertuzumab|This trastuzumab and pertuzumab treatment arm is for adult, teenage/young adult (TYA) and paediatric participants with malignancies with HER2 amplification or activating mutations.
62197677|NCT05722886|EXPERIMENTAL|Treatment Arm 5: Vemurafenib in combination with cobimetinib|This vemurafenib and cobimetinib appendix is for BRAF V600 mutation-positive malignancies occurring in adults only.
62197678|NCT02546297|ACTIVE_COMPARATOR|ICS/LABA Group|Symbicort，Inhalation，Individualized medication，12 months.
62197679|NCT02546297|ACTIVE_COMPARATOR|LAMA Group|Tiotropium Bromide，Inhalation,Individualized medication，12 months.
62197680|NCT02546297|ACTIVE_COMPARATOR|LAMA+LABA Group|Tiotropium Bromide, Symbicort, Inhalation, Individualized medication, 12 months.
62197681|NCT00507403|ACTIVE_COMPARATOR|Infliximab|Infliximab
62197682|NCT00507403|EXPERIMENTAL|Infliximab +methotrexate|Infliximab +methotrexate
62197683|NCT03016351|EXPERIMENTAL|Aerobic Training|Participants will undergo a supervised endurance training program in accordance with established guidelines. Each session will be monitored by a physical therapist or exercise physiologist. Sessions will be carried out 3 times per week. During each session, participants will complete a 5 min warm-up followed by 30-45 min of endurance exercise using cycle ergometry. Intensity will be monitored using heart rate monitors during each exercise session, and each participant will receive an exercise prescription with a heart range equivalent to 65-85% of their heart rate max. Participants will be asked to complete 30 min of exercise during each session in week 1, 35 min in week 2 and 40-45 min weeks 3-8 with a 5 min cool down period.
62197684|NCT03016351|EXPERIMENTAL|Resistance Training|Participants will undergo a supervised resistance training program in accordance with established guidelines. Each session will be monitored by a physical therapist or exercise physiologist. Sessions will be carried out 3 times per week, 45 min per session. Muscle strength will be determined once before and once after resistance training by measuring ten repetition maximum (10 RM) for each exercise. Eight exercises (three sets; 8-12 repetitions) will be used on each of the large muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). In addition, workloads will be progressively increased if the patients can lift the weight more than 12 repetitions.
62576462|NCT06248372|EXPERIMENTAL|External Focus Group (EFG)|Receive exercise program that includes strengthening and stretching exercises however this group will focus on environmental cues apart from body movement by using metaphors or analogies.
62783261|NCT03157765|NO_INTERVENTION|Routine care|These patient receive routine care
62010678|NCT02082522|EXPERIMENTAL|Photodynamic therapy-Photofrin plus SMC|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin followed by the illumination of the tumor using a fiber optic device. Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals. Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen.
62197685|NCT01458054|EXPERIMENTAL|Treatment A|GSK2336805 60mg x 1 dose (fasted) \[Reference Treatment\]
62197686|NCT01458054|EXPERIMENTAL|Treatment B|Omeprazole 40 mg q24h x 4 days (fed)
62197687|NCT01458054|EXPERIMENTAL|Treatment C|GSK2336805 60 mg x 1 dose and Omeprazole 40 mg on Day 1 (fasted) \[Test Treatment\]
62197688|NCT01458054|EXPERIMENTAL|Treatment D|GSK2336805 30mg x 1 dose (fasted) \[Reference Treatment\]
62197689|NCT01458054|EXPERIMENTAL|Treatment E|Ritonavir 100mg q12h x 4 days (fed)
62197690|NCT01458054|EXPERIMENTAL|Treatment F|GSK2336805 30 mg x 1 dose (fasted) and ritonavir 100mg q12h on Day 1 (fasted) \[Test Treatment\]
62197691|NCT01458054|EXPERIMENTAL|Treatment G|Ritonavir 100mg q12h x 1 day
62197692|NCT01175304||Workers in a Barcelona tertiary hospital|Workers attending annual medical checkups
62197693|NCT03683537||Delayed Neurocognitive decline|Patients in whom there is Delayed Neurocognitive Recovery (DNR) after surgery, based on neuropsychological tests or clinically. DNR is defined as follow: 1)decrease of scores of neuropsychological test scores for more than 1 standard deviation (SD) of these tests; 2)clinically - inability of patient to perform test after surgery because of neurocognitive impairment.
62197694|NCT03683537||Normal postop neurocognitive function|Patients in whom there is no clinical signs of DNR, defined as in previous group.
62197695|NCT01024153|EXPERIMENTAL|Active video game play|
62197696|NCT01889576|EXPERIMENTAL|Supplementation of Magnesium oxide.|Supplementation of magnesium oxide (450 mg up to 3 times daily maximum), aiming at a serum magnesium concentration of \>= 1,9 mg/dL).
62783262|NCT01022424|EXPERIMENTAL|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
62783263|NCT05749328|EXPERIMENTAL|Carbohydrate group|Fasting at 20:00 on the eve of surgery, give 800ml of carbohydrate drink, the patient drinks freely, no more than 200ml per hour, to 3h before surgery, give carbohydrate drink again, according to 5ml/kg calculated dose, maximum 400ml, drink within 30 minutes.
62197697|NCT01889576|NO_INTERVENTION|No supplementation or minimal dose.|No supplementation (or a minimal dose to keep serum magnesium concentration ≥ 1.2mg/dL depending on the treating physician).
62010679|NCT02082522|ACTIVE_COMPARATOR|Standard Medical Care (SMC)|Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen. The chemotherapy regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
62197698|NCT02215564||No treatment|Young adults tested by PCR for B. pertussis carriage
62197699|NCT00148668|ACTIVE_COMPARATOR|Arm 1|Herceptin/navelbine
62197700|NCT00148668|ACTIVE_COMPARATOR|Arm 2|Taxotere/carboplatin/herceptin
62197701|NCT05292053|EXPERIMENTAL|COPD subjects|COPD with or without asthma
62197702|NCT04276259|EXPERIMENTAL|Buprenorphine Injection + Oral Placebo Pill|Buprenorphine is a μ-opioid partial agonist and kappa-opioid antagonist that is used to treat moderate to severe pain and opioid dependence. The intramuscular administered opioid agonist which will be used to modulate reward learning signals to understand placebo effects in patients with depression. In the buprenorphine condition, participants will receive one IM injection of 0.3mg/1ML buprenorphine hydrochloride (Buprenex®. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; 2006) (onset of action: ≥15 minutes; peak effect: \~1 hour; duration: \~6 hours) and an oral placebo tablet.
62197703|NCT04276259|EXPERIMENTAL|Naltrexone Oral Tablet + Intramuscular Saline Injection|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate reward learning signals to understand placebo effects in participants with depression. In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: \~1 hour; duration: \~24 hours) and a saline IM injection.
62197704|NCT04276259|EXPERIMENTAL|Oral Placebo Pill + Intramuscular Saline Injection|Inert pill and saline injection that have no inherent power to produce an effect. In the inert pill condition, participants will receive one IM arm injection of saline (1ML) and an oral placebo tablet.
62576463|NCT06248372|EXPERIMENTAL|Internal Focused Group (IFG)|Receive exercise program that includes strengthening and stretching exercises however this group will follow internal cues directing attention to the body movement (i.e., joint movement) while doing exercises.
62576464|NCT06248372|OTHER|Control Group (CG)|Receive exercise program that includes strengthening and stretching exercises however, this group will not focus on any attentional cues while doing exercises.
62576465|NCT01474473|EXPERIMENTAL|CACIPLIQ20 and Cast Boot|This arm receives treatment by CACIPLIQ20 application every 3 to 4 days and the wounded leg is held with a nonremovable, windowed, fiberglass Cast Boot.
62576466|NCT01474473|PLACEBO_COMPARATOR|Placebo and Cast Boot|This arm receives a placebo (saline solution) every 3 to 4 days and the wounded leg is held with a nonremovable, windowed, fiberglass Cast Boot.
62576467|NCT04809103|EXPERIMENTAL|Intratumoral Cisplatin Arm|Single arm approach. There is no comparator or placebo group. Cisplatin will be administered directly into a non-small cell lung cancer, following imaging verification and pathologic diagnosis, during a single bronchoscopic procedure.
62197705|NCT04634474|EXPERIMENTAL|Pain on Endotracheal Suction|Before and after endotracheal aspiration, the pain of the patient will be evaluated according to the DAS and VAS scale. VAS scores will be compared with DAÖ scores. Aspiration process will be applied to all patients by the same nurse. According to the DAQ, the pain will be assessed by a volunteer nurse who is not a researcher.
62576468|NCT00280280|EXPERIMENTAL|1|This study will explore the safety and effectiveness of Botox versus baclofen in treatment subjects with upper-limb spasticity due to neurological damage or a stable neurological disorder. Subjects will be randomized to one of two treatment groups: intramuscular Botox plus oral placebo or intramuscular placebo plus oral baclofen.
62576469|NCT03205722||Melanoma patients with 1st-line Nivo treatment|Non-Interventional. Patients with advanced melanoma treated with nivolumab monotherapy prescribed as first-line therapy between June 2015 and June 2016.
62576470|NCT03800108|OTHER|Personalized DBS adjustments|Individualized stimulation adjustments based on pre- and post- DBS implantation MRIs
62576471|NCT01536080||Reflux esophagitis (RE)|
62197706|NCT03525470|EXPERIMENTAL|Water|Subjects consumed water
62197707|NCT03525470|EXPERIMENTAL|No water|Subjects did not consume water
62576472|NCT01536080||Non-erosive reflux disease (NERD)|
62576473|NCT01536080||Functional heartburn (FH)|
62576474|NCT06119308|EXPERIMENTAL|Benzodiazepine Medication Taper with Cognitive Behavioral Therapy|Brief Cognitive Behavioral Therapy to Enhance Benzodiazepine Deprescribing
62576475|NCT04724083||Fabry Disease subjects with cardiomyopathy|Patients (males and females) with confirmed Fabry disease, with clinical cardiac involvement based on results of structural imaging (cardiac echocardiography and MRI).
62576476|NCT04724083||Fabry Disease subjects without cardiomyopathy|Patients (males and females) with confirmed Fabry disease, without clinical cardiac involvement based on results of structural imaging (cardiac echocardiography and MRI).
62576477|NCT04724083||Healthy control|The control group will consist of age-and gender-matched healthy individuals.
62576478|NCT01742988|EXPERIMENTAL|Fimepinostat - Continuous Once Daily|Fimepinostat 30-60 mg/day
62576479|NCT01742988|EXPERIMENTAL|Fimepinostat - 2x/week|Fimepinostat 60-240 mg/day
62576480|NCT01742988|EXPERIMENTAL|Fimepinostat - 3x/week|Fimepinostat 60-180 mg/day
62576481|NCT01742988|EXPERIMENTAL|Fimepinostat - 4x/week|Fimepinosta 60-180 mg/day
62576482|NCT01742988|EXPERIMENTAL|Fimepinostat - 5x/week|Fimepinostat 60-180 mg/day
62197708|NCT05223218||Breast Cancer|"Individuals aged between 18-100 years who are presenting for an evaluation of an abnormal exam or test (Mammogram, ultrasound, MRI, PET, etc.); presenting for the evaluation of a palpable lump or mass; presenting with a mass pre or post-biopsy as long as there is a portion of the mass remaining; or have been diagnosed with breast cancer but have not received treatment.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
62576483|NCT01742988|EXPERIMENTAL|Fimepinostat - Expansion 5x/week|Fimepinostat 60 mg on the 5 days on/2 days off
62576484|NCT01742988|EXPERIMENTAL|Fimepinostat - Expansion 3x/week|Fimepinostat 120 mg 3 days on/4 days off
62576485|NCT01742988|EXPERIMENTAL|Fimepinostat 60 mg - Combination w/ rituximab|Fimepinostat 60 mg 5 days on.2 days off plus rituximab
62576486|NCT01742988|EXPERIMENTAL|Fimepinostat 120 mg - Combination w/ rituximab|Fimepinostat 120 mg 3x/week plus rituximab
62576487|NCT01742988|EXPERIMENTAL|Fimepinostat - Biocomparability Arm|Biocomparability Arm
62576488|NCT01742988|EXPERIMENTAL|Fimepinostat 30 mg - Combination w/ venetoclax|Fimepinostat 30 mg 5 days on/2 days off plus venetoclax. Different combinations of dose levels for venetoclax will be explored
62576489|NCT01742988|EXPERIMENTAL|Fimepinostat 60 mg - Combination w/ venetoclax|Fimepinostat 60 mg 5 days on/2 days off plus venetoclax. Different combinations of dose levels for venetoclax will be explored
62576490|NCT01742988|EXPERIMENTAL|Fimepinostat - Combination w/ venetoclax and rituximab|Fimepinostat and venetoclax dosed at dose levels determined for that combination. Rituximab dosed at 375 mg/m2 IV on Day 1 of each 21 day cycle
62576491|NCT01754350|EXPERIMENTAL|ketogenic diet and transient fasting|Calorie-restricted, ketogenic diet and transient fasting during reirradiation
62576492|NCT01754350|ACTIVE_COMPARATOR|standard nutrition|nutrition according to recommendations of the German society for nutrition during reirradiation
62576493|NCT03892044|EXPERIMENTAL|Treatment (duvelisib, nivolumab)|Patients receive duvelisib PO BID on days 1-28 and nivolumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62576494|NCT01560234|EXPERIMENTAL|AZD8848|
62576495|NCT01560234|PLACEBO_COMPARATOR|Placebo|
62576496|NCT05561270|SHAM_COMPARATOR|White LED light|Exposure to white LED light for 1-2 hours/day x 10 weeks
62576497|NCT05561270|EXPERIMENTAL|Green LED light|Exposure to green LED light for 1-2 hours/day x 10 weeks
62576498|NCT01377350|EXPERIMENTAL|"Pneumedicares monitoring system"|"Single arm study - Pneumedicares monitoring system is used for monitoring heart failure patients"
62576499|NCT03916549|EXPERIMENTAL|Group 1|The patients with bowel dysfunction following low anterior resection performed at least 1 year ago will undergo acupuncture. The acupuncture procedure is performed by one well trained person, 1 time per week in total of 10 weeks on the same day time. Sterile, disposable, stainless steel acupuncture needles (40x0.25 mm diameter) were inserted to corporal acupoints, with initial gentle stimulation by quick rotation of 1080°, after then leaving needle in located place for twenty minutes. Needling deep - 0.5-1 cm. If the intent was to invigorate - the needle was inserted to the flow of energy; if harmonization needed - the needle was placed perpendicular to the point flow of energy; if sedation was needed, needles were placed against to the flow of energy on channel. The selection of acupoints was based according by traditional Chinese medicine, literature findings.
62576500|NCT05162924|EXPERIMENTAL|Spinal manipulation|Group receiving 12 sessions of spinal manipulative therapy in the lumbar area
62576501|NCT05162924|PLACEBO_COMPARATOR|Placebo|Group receiving 12 sessions of placebo spinal manipulative therapy in the lumbar area
62576502|NCT05162924|NO_INTERVENTION|Healthy controls|A healthy control population will receive no treatment during the same time period (4 weeks) to measure the same physiological variables and their evolution.
62576503|NCT04397016|NO_INTERVENTION|Arm 1: Usual Care|"* Each participating urologic surgeon will begin in the usual care arm of the study. Subsequently, they will be randomized to the intervention arm at staggered time points to undergo training and begin using the Option Grid decision aid intervention with patients who are diagnosed with slow-growing prostate cancer.~* Usual Care-Participating clinicians have treatment options discussion with patients with slow-growing prostate cancer. Visits are audio-recorded and/or described by patient self-report measure."
62010680|NCT05382364|EXPERIMENTAL|Tucatinib Treatment|Chinese participants with HER2+ advanced breast cancer, gastric or gastroesophageal junction adenocarcinoma, or colorectal cancer receive tucatinib 300 mg by mouth twice daily during 21-day cycles. Treatment continues until there is evidence of unacceptable toxicity or documented progression.
62576504|NCT04397016|EXPERIMENTAL|Arm 2: Option Grid|"* Each participating urologic surgeon will begin in the usual care arm of the study. Subsequently, they will be randomized to the intervention arm at staggered time points to undergo training and begin using the Option Grid decision aid intervention with patients who are diagnosed with slow-growing prostate cancer.~* Decision Aid-Participating surgeons use an encounter decision aid to discuss treatment options with patients who have slow-growing prostate cancer. Visits are audio-recorded and/or evaluated by patient self-report measure."
62576505|NCT02087488|EXPERIMENTAL|auricular acupuncture(AA) & Eszopiclone|The disposable Seirin Pyonex Needle will be chosen as AA material to attach every 3 days for 4 weeks, meanwhile, oral Eszopiclone 1 piece (3mg) will be applied 15 minutes before going to sleep everyday for 4 weeks. The manufacturer of disposable Seirin Pyonex Needles is Seirin Corporation, a Japanese company.
62576506|NCT02087488|PLACEBO_COMPARATOR|placebo AA & Eszopiclone|The disposable Pyonex Zero Needle, a non-invasive material will be chosen as placebo AA, with auricular acupoints have no certain effect on PI. Additionally, 1 piece (3mg) Eszopiclone will be administrated to participants 15 minutes before going to sleep everyday for 4 weeks.
62576507|NCT06452719|EXPERIMENTAL|Letrozole & Misprostol|Letrozole 10 mg orally daily for three consecutive days followed by misoprostol 800 mcg vaginally within 24 hours of final letrozole dose
62576508|NCT06524947|EXPERIMENTAL|Infant experimental group (6 weeks -23 months)|At least 6 weeks old but less than 2 years old.
62576509|NCT06524947|PLACEBO_COMPARATOR|Infant placebo control group (6 weeks -23 months)|At least 6 weeks old but less than 2 years old.
62576510|NCT06524947|EXPERIMENTAL|Toddler experimental group (2-5 years old)|At least 2 years old but less than 6 years old.
62576511|NCT06524947|PLACEBO_COMPARATOR|Toddler placebo control group (2-5 years old)|At least 2 years old but less than 6 years old.
62010681|NCT02706210||vascular cognitive disorders pre-dementia (VCD-P)|
62010682|NCT02706210||amnestic mild cognitive impairment (aMCI)|
62576512|NCT06524947|EXPERIMENTAL|Children experimental group (6-13 years old)|At least 6 years of age but under 14 years of age.
62576513|NCT06524947|PLACEBO_COMPARATOR|Children placebo control group (6-13 years old)|At least 6 years of age but under 14 years of age.
62576514|NCT04080245|EXPERIMENTAL|Treatment Group|
62576515|NCT05170048|ACTIVE_COMPARATOR|Control Arm: AREDS2 supplements (SOC)|All patients assigned to this Control Group will receive standard of care to include AREDS2 supplements daily throughout the study.
62576516|NCT05170048|EXPERIMENTAL|Experomental Arm: AREDS2 supplements (SOC) plus EG-301|Patients assigned to the Experimental Group will receive a standard of care equivalent to that of the Control Group plus EG-DPMP-01 (150 mg daily, given at bedtime with a light snack).
62197709|NCT05223218||Pancreatic Cancer|"Individuals aged between 18-100 years who are presenting for an evaluation of an abnormal exam or test (Ultrasound, MRI, PET, etc.); presenting for the evaluation of a palpable lump or mass; presenting with a mass pre or post-biopsy as long as there is a portion of the mass remaining; or have been diagnosed with breast cancer but have not received treatment.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
62197710|NCT05223218||Colon Cancer|"Individuals aged between 18-100 years who are presenting for an evaluation of an abnormal exam or test (Ultrasound, MRI, PET, etc.); presenting for the evaluation of a palpable lump or mass; presenting with a mass pre or post-biopsy as long as there is a portion of the mass remaining; or have been diagnosed with breast cancer but have not received treatment.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
62197711|NCT05223218||Prostate Cancer|"Individuals aged between 18-100 years who are presenting for an evaluation of an abnormal exam or test (Ultrasound, MRI, PET, etc.); presenting for the evaluation of a palpable lump or mass; presenting with a mass pre or post-biopsy as long as there is a portion of the mass remaining; or have been diagnosed with breast cancer but have not received treatment.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
62399879|NCT05650255|EXPERIMENTAL|A Digital Twin for Exoskeleton Pilot|This project is expected to use different machine learning models to make accurate predictions of human intent when healthy people drive different actions or action transitions of common human actions. Drivers will wear sensors such as inertial measurement unit (IMU) and electromyography (EMG) in the lower limbs to measure body signals of participants during actions in a non-invasive way, and let the system calculate the joint angle, angular velocity and angular acceleration of each joint of the driving lower limb related human signals.
62399880|NCT00314262|EXPERIMENTAL|Erlotinib & Celecoxib|
62399881|NCT06335225|EXPERIMENTAL|Precise nutrition group|
62576517|NCT05117632|EXPERIMENTAL|ALTO-100|ALTO-100 PO tablet, daily dosing 8 weeks
62576518|NCT04939233|EXPERIMENTAL|Exoskeleton Glove|Perform a feasibility trial of the robotic orthosis device by providing it to a small cohort of adult patients suffering from paralysis due to a brachial plexus injury.
62399882|NCT06335225|ACTIVE_COMPARATOR|Control group|
62576519|NCT05408065|EXPERIMENTAL|Cingal|A single infiltration of Cingal, 4 mL, 88 of mg hyaluronic acid and 18 mg of triamcinolone hexacetonide
62576520|NCT05408065|ACTIVE_COMPARATOR|Cortisone|A single infiltration of cortisone, 40mg of triamcinolone and 4mL of bupivacaine 0.25%
62576521|NCT06574919||cases group|patients with inherited non-Duchenne Myopathies
62576522|NCT05348863|EXPERIMENTAL|SPARK app|Access to the SPARK app which will provide support for a healthier diet and increased physical activity as well as daily monitoring of blood glucose levels.
62197712|NCT05223218||Melanoma|"Individuals aged between 18-100 years who are presenting for an evaluation of an abnormal exam or test (Ultrasound, MRI, PET, etc.); presenting for the evaluation of a palpable lump or mass; presenting with a mass pre or post-biopsy as long as there is a portion of the mass remaining; or have been diagnosed with breast cancer but have not received treatment.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
62197713|NCT05223218||Healthy Control|"Individuals aged between 18-100 years who do not currently have a previous diagnosis of any cancer for which they are currently being treated.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
62576523|NCT05348863|NO_INTERVENTION|Control arm|Standard care i.e., the routine treatment program for GDM delivered by the care provider.
62576524|NCT04149613||Colorectal Cancer Patients|Newly diagnosed stage IV colorectal cancer patients
62576525|NCT04149613||Controls|cancer free
62399883|NCT05070494|OTHER|้healthy subject with standard dose trivalent influenza vaccine|้healthy volunteer that received Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated) ( 0.5 ml : 15 mcg/strain)
62399884|NCT05070494|ACTIVE_COMPARATOR|ESRD patient with standard dose trivalent influenza vaccine|ESRD patient that received Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated) ( 0.5 ml : 15 mcg/strain)
62399885|NCT05070494|EXPERIMENTAL|ESRD patient with double dose trivalent influenza vaccine|ESRD patient that received Egg-derived double dose trivalent influenza vaccine (surface antigen, inactivated) total 1 ml ( 1 ml /(30 mcg/strain)
62576526|NCT04134767|EXPERIMENTAL|Health Linkage|Research staff will: 1) meet with participants in person or virtually to ask questions about drug use and related behaviors, service access, and personal goals; provide overdose education and help develop a plan for reducing risks and accessing services; conduct drug testing, offer HIV and HCV testing and counseling, naloxone, and harm reduction supplies, and connection with needed services; 2) follow up with participants monthly for three months to help overcome challenges; and 3) six months post-enrollment, contact participants to conduct drug testing. Participants will complete surveys at baseline, 3 months, and 6 months
62576527|NCT04134767|OTHER|Overdose Education|"The investigators will initiate the comparison group in Group 2 counties six months before the intervention begins. Research staff will conduct an overdose intervention with the comparison cohort. This will occur pre-release if individual is recruited in jail. The comparison group participants will watch a video on preventing, recognizing, and responding effectively to an opioid OD, accompanied by information about Kentucky's Good Samaritan Law and Naloxone Access Law. Research staff will answer questions after the video. Individuals will receive a Community Resource Guide at this visit.~As in the intervention group, the comparison group participants will complete surveys at the baseline (in jail if recruited in jail, in a community setting if recruited in the community), and at 3 months and 6 months after the baseline. Surveys will be identical to those delivered to the intervention cohort."
62576528|NCT04933552||Siponimod-Exposed|Pregnant women with MS exposed to siponimod during pregnancy
62576529|NCT04933552||Disease-Matched Comparison|Pregnant women with MS not exposed to siponimod during pregnancy
62576530|NCT04933552||Healthy Comparison|Pregnant women who are neither diagnosed with MS nor with any other autoimmune disease, and not exposed to siponimod or any known teratogenic agent during pregnancy
62576531|NCT06409598|EXPERIMENTAL|Non-immersive virtual reality intervention|"The experimental group will receive the NOVEL (NOn-immersive Virtual reality Exercises for for upper Limb function and balance) program. This adapted program consists of 4 different non-immersive home-based virtual reality exercise games tailored for upper limb and static balance training combined with motivational strategies (performance feedback, automated progression, exercise gamification) and previously used with non-stroke populations. A videoconferencing or phone call session will be done with the main researcher once per week (Asynchronous with the sessions) to check for any technical difficulties, monitor the progression of the exercises and the progression of the difficulty levels).~Dose of exercises: the participant will have to use the exercise platforms for a minimum of 1 hour per day for 5 days per week. The total period of the intervention will be 8 weeks."
62576532|NCT06409598|NO_INTERVENTION|Usual care|Stroke survivors assigned to the control group will continue to receive their usual care in accordance with local policies and practices. Usually, there is no available formal rehabilitation protocol for stroke survivors in the chronic stage of their recovery , but they are considered for long-term management and secondary prevention. No attempt will be made to discourage the provision of additional care, to ensure that usual care is provided. As part of the usual care trial, patients' activity records will be monitored by the researcher, in order to record any stroke care that can be provided to the patients during the trial period.
62197714|NCT04955977|EXPERIMENTAL|G1: People with a diagnosis of COPD stratified in GOLD 1-2.|"* Adult person, over 40 years of age, both sexes, resident in medium altitudes or 2,600 meters above sea level in the last 2 years.~* People with a diagnosis of COPD categorized in GOLD 1-2, with no record of respiratory crises in the last 3 months.~* People with a diagnosis of COPD categorized by lung function in GOLD 1,2,3 and 4 and by severity of symptoms in A, B and C, without the need for supplemental oxygen.~* People with a diagnosis of COPD settled and domiciled for a minimum time of 14 months at moderate altitudes or 2600 m.a.s.l.~* People who have read and signed informed consent and who have membership in a mandatory health plan."
62576533|NCT05931172|EXPERIMENTAL|Dual tasking|Dual tasking utilizes a task-specific approach to balance training, applying repeated exposure to unpredictable mechanical perturbations that mimic balance disturbances experienced in daily life.
62197715|NCT04955977|EXPERIMENTAL|G2: People with a diagnosis of COPD stratified in GOLD 3-4.|"* Adult person, over 40 years of age, both sexes, resident in medium altitudes or 2,600 meters above sea level in the last 2 years.~* People with a diagnosis of COPD categorized in GOLD 1,2,3 and 4, with no record of respiratory crises in the last 3 months.~* People with a diagnosis of COPD categorized by lung function in GOLD 3-4 and by severity of symptoms in A, B and C, without the need for supplemental oxygen.~* People with a diagnosis of COPD settled and domiciled for a minimum time of 14 months at moderate altitudes or 2600 m.a.s.l.~* People who have read and signed informed consent and who have membership in a mandatory health plan."
62576534|NCT05931172|EXPERIMENTAL|Proprioceptive neuromuscular facilitation|Proprioceptive neuromuscular facilitation (PNF) is a therapeutic approach that uses cutaneous, proprioceptive and auditory input to produce functional improvement in motor output.
62576535|NCT04159857|ACTIVE_COMPARATOR|One-hand|During LTCS, the fetal head traditionally is delivered by one-hand manual extraction (a surgeon inserts one hand into the uterus via the hysterotomy and lifts the fetal head out of maternal pelvis, subsequently significant abdominal pressure is required to squeeze the fetal head out of hysterotomy) along with application of significant abdominal/fundal pressure.
62576536|NCT04159857|EXPERIMENTAL|Two-hand|An innovative approach to manual head extraction, with surgeon's both hands formed as a pair of forceps, has been used by the PI of this study for years during the LTCS for head extraction in the difficult situations described above without complication, often time it was used after one hand approach failed to deliver the infant, vacuum/forceps and abdominal pressure usually was not needed in these cases.
62576537|NCT02504242|EXPERIMENTAL|Inject BMP|ExcelOS Inject / rhBMP-2
62576538|NCT02504242|ACTIVE_COMPARATOR|Locally Harvested Bone|Locally Harvested Bone
62576539|NCT01221584||1|Subject 18 years of age or older on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks..
62399886|NCT05070494|EXPERIMENTAL|ESRD patient with double dose - booster trivalent influenza vaccine|ESRD patient that received Egg-derived double dose trivalent influenza vaccine (surface antigen, inactivated) ( 1 ml /(30 mcg/strain) and booster with Egg-derived double dose trivalent influenza vaccine (surface antigen, inactivated) ( 1 ml /(30 mcg/strain) at next 6 months after first dose
62576540|NCT06326398|NO_INTERVENTION|Control group|The control group will perform stoma care using the low-reality simulation (stoma model) method.
62576541|NCT06326398|EXPERIMENTAL|Experimental group|Students in the experimental group will perform stoma care using high-reality simulation (3D printing and moulage) method.
62197716|NCT04955977|ACTIVE_COMPARATOR|G3: Control - People without a COPD diagnosis.|Healthy people, over 40 years old. No history of cigarette smoking or exposure to wood smoke. Who do not present diagnoses of musculoskeletal injuries and who are residents at 2600 meters above sea level for more than 14 months. With affiliation to a mandatory health plan and signature of informed consent.
62197717|NCT03423810|EXPERIMENTAL|Group 1: Hydralazine|Participants will take hydralazine twice daily for total of 6 weeks. The dose of hydralazine will be increased every 2 weeks.
62197718|NCT05051969|EXPERIMENTAL|8 Week Remote Mindfulness-Based Stress Reduction Program|8 Week Remote MBSR Course for MNPS Employees.
62399887|NCT00187005|OTHER|1|
62399888|NCT05288491||Participants With Malignant Lymphoma|All participants diagnosed with histopathologically confirmed malignant lymphoma will be enrolled and observed retrospectively. Complete medical information will be collected at the time of enrollment via chart review.
62399889|NCT05065151|EXPERIMENTAL|Stimulation|Patients will be getting standard clinically acceptable stimulation within already safety validated stimulation ranges through their Medtronic Percept PC device.
62399890|NCT05065151|EXPERIMENTAL|No Stimulation|Patients will have stimulation turned off through their Medtronic Percept PC device.
62399891|NCT01866605|PLACEBO_COMPARATOR|1|Single un-warmed cotton blanket over body and limbs, and reassurance, during preoperative period in anaesthetic room
62399892|NCT01866605|ACTIVE_COMPARATOR|2|Single un-warmed cotton blanket over body and limbs, reassurance and intravenous midazolam 30 µg/kg i.v, during preoperative period in anaesthetic room
62399893|NCT01866605|ACTIVE_COMPARATOR|3|Single un-warmed cotton blanket, reassurance and forced-air warming with a Bair Hugger, during preoperative period in anaesthetic room
62576542|NCT01896128|EXPERIMENTAL|Armodafinil|150 mg armodafinil administered 2 hours prior to start of therapeutic regimen for 10 consecutive days
62197719|NCT05051969|NO_INTERVENTION|8 week waitlist control|8 week waitlist control. They will complete the same assessments at baseline, 8 and 12 weeks
62576543|NCT01896128|PLACEBO_COMPARATOR|Placebo|inactive agent administered 2 hours prior to start of therapeutic regimen for 10 consecutive days
62576544|NCT03314532|NO_INTERVENTION|Surgery group|We will completely resection of the visible tumor and made the resection margin negative. We will use regular/irregular resection of the liver tumor tissue, hemihepatectomy or extended hepatectomy.
62576545|NCT03314532|EXPERIMENTAL|TILA-TACE group|After femoral artery catheterization, 5-Fr angiography catheters will be used for complete radiography of the celiac artery, the hepatic artery proper, left and right hepatic arteries and their branches, and 2.8-Fr micro-catheters will be used for complete radiography of the tumor's nutrient arteries. Lipiodol-epirubicin emulsions and 5% sodium bicarbonate injection solutions will be used for perfusion of chemotherapy drugs. Different sizes of embolic microspheres will be used alternatively for chemoembolization.
62576546|NCT01745536|EXPERIMENTAL|Vitrified oocytes using closed Cryotop®|Oocytes are vitrified/stored using a closed device
62576547|NCT01745536|ACTIVE_COMPARATOR|Vitrified oocytes using open Cryotop®|Oocytes are vitrified/stored using an open device
62576548|NCT00806663|EXPERIMENTAL|Sunitinib Arm|Sutent sunitinib 37 mg once daily (4 weeks on/2 weeks off)
62576549|NCT04001296|EXPERIMENTAL|21 day Brush Day and Night intervention|The 21 day Brush Day and Night programme aims to instruct on and encourage twice a day brushing with a fluoridated toothpaste.
62576550|NCT04001296|NO_INTERVENTION|Control schools|Schools / children who receive only toothpaste / toothbrushes, no 21 day Brush Day and Night intervention
62576551|NCT00728468|EXPERIMENTAL|Treatment arm|
62197720|NCT02594787|ACTIVE_COMPARATOR|Phosphorus|Intervention (500 mg of potassium phosphate) will be administered with 75 g glucose solution and diet induced thermogenesis will be measured afterwards
62399894|NCT03096457|EXPERIMENTAL|Group 1 - Paromomycin cream|40 subjects will be included to receive 15% paromomycin in aquafilm base twice a day during 20 consecutive days. The lesion will be cleaned , then, a generous amount of the study drug (an amount sufficient to cover the area of the ulcer and the lesion border) will be applied to the lesion and rubbed into the ulcer using a gloved finger by a member of the clinical study staff. After application of the study drug, the patient will be observed for 15 minutes for signs of adverse events. If there are no signs of local toxicity, the area of the ulcer will be covered with extra study drug. For Days 2-20, the study drug will be applied and the lesion covered with a sterile gauze and tape dressing as on Day 1.
62576552|NCT02080702||Monosyn|Construction of a gastrointestinal anastomoses
62576553|NCT04997668|ACTIVE_COMPARATOR|SOLTIVE Thulium Fiber Laser|SOLTIVE Thulium Fiber Laser group (laser A)
62576554|NCT04997668|ACTIVE_COMPARATOR|Ho:YAG Laser|Ho:YAG Laser group (laser B)
62576555|NCT01257113|EXPERIMENTAL|supervised exercise|The group gets 10 supervised exerciseclasses at the physiotherapy clinic in addition to homebased exercises
62576556|NCT01257113|EXPERIMENTAL|homebased exercises|The group gets 1 supervised exerciseclass before they do all their exercises at home
62576557|NCT01360242|ACTIVE_COMPARATOR|MIMI procedure (two-step strategy)|Thrombus aspiration is performed to achieve TIMI-3 flow. Once TIMI-3 flow is restored and sustained for \> 10 minutes, the initial procedure is stopped regardless of the presence of any residual stenosis. A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
62576558|NCT01360242|SHAM_COMPARATOR|Immediate Stenting (one-step strategy)|The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
62576559|NCT04283799|EXPERIMENTAL|The new HMF group|Very preterm infants tolerating 80mL/kg/day of enteral feeding for \>24 hours are started to receive the new human milk fortifier. Study procedure is from the first day of full-strength fortification feeding to the 21th days of that.
62576560|NCT04283799|NO_INTERVENTION|Other HMF group|This group is a historical control group using the other HMF. Infants with similar gestational age, birth weight, feeding start time and length of hospitalization are enrolled into the control group.
62576561|NCT04633512|EXPERIMENTAL|ActivSight Group|Patients undergoing intestinal anastomoses (colorectal and bariatric) with ActivSight (n=52) Patients undergoing cholecystectomy with ActivSight (n=28)
62783264|NCT05749328|NO_INTERVENTION|Contral group|Fasting at 20:00 on the eve of surgery, fasting at 24:00, until the induction of anesthesia on the day of surgery
62783265|NCT03167021||Students|Students of the Auvergne Rhone Alpes region will be contacted by email thanks to the student associations and scholarity departments. Answer to the survey will be done online.
62783266|NCT06085924||Cohort 1 - Cases of patients registered in the databases of all ages|Patients with a diagnosis of COVID-19 infection between 01 January 2021 and 31 December 2021
62783267|NCT06085924||Cohort 2 - Cases of patients registered in the databases of ≥12 years of age|Have COVID-19 diagnosis with international classification of diseases (ICD) code between 01 January 2022 and 31 December 2022
62197721|NCT02594787|PLACEBO_COMPARATOR|Placebo|Placebo (cellulose) will be administered with 75 g glucose solution and diet induced thermogenesis will be measured afterwards
62197722|NCT03321253|EXPERIMENTAL|Nd: YAG laser posterior capsulotomy|Posterior capsulotomy was performed by using Nd: YAG laser and macular pigment optical density, intra ocular pressure, choroidal thickness, macular thickness and anterior chamber parameters were measured before Nd: YAG laser, at 1 week, 1 month and 2 months
62197723|NCT00852605|NO_INTERVENTION|Oxygen|Conventional Treatment including Oxygen-support
62197724|NCT00852605|EXPERIMENTAL|NIV|Conventional Treatment plus intermittent Non-Invasive-Ventilation
62399895|NCT03096457|ACTIVE_COMPARATOR|Group 2. Local Injectable Pentamidine|"20 subjects will be included to receive IL pentamidine \[Pentacarinat® Sanofi-Aventis: 30 mg/ml\] will administered at a dose of 120 ug (4 ul) per mm2 of lesion area 3 times (on days 1, 3, and 5) as per our previous experience.~A small button of Xylocaine® will be applied by means of a thin needle at the four cardinal points of the lesion and then a small gauge (23g) needle will introduce the drug in each cardinal point. The needle will be moved in all directions to infiltrate of whole lesion and surrounding infiltrated area."
62399896|NCT03096457|PLACEBO_COMPARATOR|Group 3. Vehicle control|10% Urea en parafilm cream will be used in similar ways as paromomycin cream in group 1
62783268|NCT04310566|EXPERIMENTAL|Test/Control|Eligible subjects that are habitual soft contact lenses will be randomized into one of the two possible lens wear sequences: Test/Control or Control/Test
62783269|NCT04310566|EXPERIMENTAL|Control/Test|Eligible subjects that are habitual soft contact lenses will be randomized into one of the two possible lens wear sequences: Test/Control or Control/Test
62399897|NCT03572465||NAFLD, NASH patients|"All patients enrolled will undergo:~* Acoustic Radiation Force Impulse (ARFI)~* Magnetic Resonance Elastography (MRE)"
62783270|NCT06191172|EXPERIMENTAL|EXPERIMENT I|Reminiscence therapy intervention group
62783271|NCT06191172|EXPERIMENTAL|EXPERIMENT II|Montessori application initiative group
62783272|NCT06191172|EXPERIMENTAL|EXPERIMENT III|Environmental initiative group
62010683|NCT04805814|ACTIVE_COMPARATOR|Intervention Group|All randomised participants will receive stratified medicine. The subjects will undergo stress perfusion CMR as an adjunct to invasive coronary angiography. The CMR results will be disclosed to the clinician to clarify endotypes and re-evaluate the clinical diagnosis. Linked guideline-directed medical therapy and lifestyle measures will be recommended based on the endotype. The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan, in the same way as in the Standard Care control group. They will be blinded to the allocated study arm and CMR findings.
62010684|NCT04805814|SHAM_COMPARATOR|Standard Care Group|All randomised participants in this arm will receive standard angiography-guided care. The endotype will be determined based on the angiogram and all of the available clinical information. The participants in this group will also undergo stress perfusion CMR but the results will not be disclosed. Management of the patient is as per standard of care, with therapy linked to the diagnosis (endotype). The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan in the same way as in the Intervention Group. They will be blinded to the allocated study arm and CMR findings.
62010685|NCT02420860|EXPERIMENTAL|Treatment (elotuzumab, lenalidomide)|Patients receive elotuzumab IV over 2-4 hours on days 1, 8, 15, and 21 of courses 1-2 and on day 1 of each subsequent course. Patients also receive lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62010686|NCT02078739|EXPERIMENTAL|Yoga Program|Yoga Program twice per week for 8 weeks
62010687|NCT02078739|ACTIVE_COMPARATOR|Education|Education once per week for 8 weeks
62010688|NCT06014112|EXPERIMENTAL|Freestyle Libre PRO iQ sensor|Eligible patients
62010689|NCT04683055|ACTIVE_COMPARATOR|Phacoemulsification combined with trabeculectomy|Patients will undergo Two site phacoemulsification combined with trabeculectomy with Mitomycin C
62010690|NCT04683055|ACTIVE_COMPARATOR|Phacoemulsificaiton combined with ab-externo trabeculotomy|Patients will undergo two phacoemulsification combined with deep sclerectomy and ab-externo trabeculotomy
62010691|NCT02530229||Periprosthetic joint infection|Patients with suspected periprosthetic joint infection of the hip, knee and shoulder
62010692|NCT02530229||Septic arthritis|Patients with suspected septic arthritis of a native joint of the hip, knee and shoulder
62010693|NCT01152723|EXPERIMENTAL|UNG-GA|New NRT product
62010694|NCT01152723|EXPERIMENTAL|UNG-GB|New NRT product
62399898|NCT03572465||Non-obese volunteers|"All patients enrolled will undergo:~* Acoustic Radiation Force Impulse (ARFI)~* Magnetic Resonance Elastography (MRE)"
62399899|NCT05026060||Patients with arterial disease|Minor patients with acute or chronic arterial disease: diagnosis of Moyamoya, diagnosis of sickle cell disease, acute or chronic arterial infarction.
62783273|NCT06191172|EXPERIMENTAL|EXPERIMENT IV|Application of contrast ergonomic special equipment initiative group
62783274|NCT06191172|NO_INTERVENTION|CONTROL GROUP|ORDINARY CARE
62783275|NCT02564809|EXPERIMENTAL|Fit Brains training|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will be performing a cognitive training program (Fit Brains training) 6 hours a week for 8 weeks.
62783276|NCT02564809|EXPERIMENTAL|Exercise + Fit Brains training|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will be performing a combination of aerobic exercise and a cognitive training program (Fit Brains training) for 6 hours a week over 8 weeks.
62783277|NCT02564809|SHAM_COMPARATOR|Balanced And Tone|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will complete 3 weekly training sessions of 1 hour for 8 weeks.
62783278|NCT06131138|EXPERIMENTAL|Aquatic exercises|Group A will perform aquatic exercises that includes abdominal hollowing, vertical downward press, lateral downard press, straight leg raising, trading water and deep water running. Three sessions per week for 6 weeks.
62010695|NCT01152723|ACTIVE_COMPARATOR|Nicorette® Gum|Nicorette® Gum
62197725|NCT00484029|EXPERIMENTAL|1|Nasal Carbon Dioxide
62783279|NCT06131138|EXPERIMENTAL|Core strengthening|Group B will perform core strengthening exercises that includes abdominal hollowing, side bridge, spine extension bridge, straight leg raise from prone, alternate arm and leg raise from quadruped and prone bridge. Three sessions per week for 6 weeks
62197726|NCT00484029|PLACEBO_COMPARATOR|2|Air
62197727|NCT05916703|EXPERIMENTAL|SOLUS examination arm|At least 40 adult women, 20 with malignant and 20 with benign breast lesions visible at US examination, aged over 18 years, will be included.
62783280|NCT05574842|EXPERIMENTAL|Intervention|The intervention arm will be received the double duty intervention through nutrition behavior change communication approach using a Health Belief Model.
62783281|NCT05574842|NO_INTERVENTION|Control|The control arm will not be received the double duty intervention, rather they receive the standard intervention given by the government.
62783282|NCT00148876|ACTIVE_COMPARATOR|Capecitabine|Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression and discontinuation of Trastuzumab.
62783283|NCT00148876|EXPERIMENTAL|Capecitabine and Trastuzumab|Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression + Trastuzumab 6 mg/kg body weight every 3 weeks i.v. as a 90 min infusion until progression
62783284|NCT06031363|ACTIVE_COMPARATOR|Regular dosage group|Give indomethacin suppository 100mg anal plug immediately after operation.
62783285|NCT06031363|EXPERIMENTAL|Low dosage group|Give indomethacin suppository 50mg anal plug immediately after operation.
62783286|NCT06031363|EXPERIMENTAL|High dosage group|Give indomethacin suppository 150mg anal plug immediately after operation.
62783287|NCT01413321||SHABI|Subacute hemiparetic ABI subjects group
62783288|NCT01413321||CHABI|Chronic hemiparetic ABI subjects group
62010696|NCT06240897|EXPERIMENTAL|Digital games|Each CURATE.DTx session will be 12 minutes long. The game will be played by each participant via a study-provided tablet. During first session prior to commencing data collection, a trained trial team member will explain in detail how to play the game-based multitasking intervention. The session will require 12 minutes of gameplay for a minimum of three days and up to five days for a total duration of hospitalisation. Participants will also be encouraged to play an optional digital game that is designed to help with their emotional and cognitive health.
62197728|NCT06311903|EXPERIMENTAL|Group I|Patients were received resuscitative fluid \[administered at beginning with the arrival of the patient in the emergency department (mean blood pressure \>70 mmHg)\] followed by low dose of norepinephrine (NE) (0.05-0.2 μg/kg/min).
62197729|NCT06311903|EXPERIMENTAL|Group II|patients were received resuscitative fluid. If there were no response to treatment to resuscitative fluid, they received norepinephrine (NE) gradually till reach high dose (≥0.3 μg/kg/min).
62197730|NCT02090023||NHIRD obstructive sleep apnea|Secondary database from community-based National Health Insurance Research Database
62197731|NCT02090023||NTUH obstructive sleep apnea cohort|Primary database from enrollment of retrospective NTUH hospital-based cohort
62197732|NCT05241353|ACTIVE_COMPARATOR|Standard Self-Monitoring Group|Standard behavioral treatment with a standard (full-frequency) self-monitoring prescription.
62197733|NCT05241353|EXPERIMENTAL|Reduced-Frequency Group|Standard behavioral treatment with a reduced-frequency self-monitoring prescription.
62783289|NCT01318148|EXPERIMENTAL|Caspofungin|
62783290|NCT01985425|EXPERIMENTAL|Active Colchicine|On the day of surgery, the intervention group will receive 2 doses of colchicine 0.6 mg orally. The first dose will be administered within 4 hours before surgery. The second dose will be given between 6:00PM and 11:59PM after surgery. All patients will receive colchicine 0.6 mg or placebo twice daily orally for 10 days.
62783291|NCT01985425|PLACEBO_COMPARATOR|Placebo Colchicine|On the day of surgery, the intervention group will receive 2 doses of colchicine placebo 0.6 mg orally. The first dose will be administered within 4 hours before surgery. The second dose will be given between 6:00PM and 11:59PM after surgery. All patients will receive colchicine 0.6 mg or placebo twice daily orally for 10 days.
62010697|NCT06146569|EXPERIMENTAL|Transcutaneous Auricular Vagus Nerve Stimulation|Each patient in the Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) group will receive a treatment protocol consisting of taVNS. The treatment will be administered for five days beginning on the first day of pain experienced between the 1st and 2nd menstrual cycles.
62010698|NCT06146569|SHAM_COMPARATOR|Sham Transcutaneous Auricular Vagus Nerve Stimulation|Each patient in the sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) group will receive a treatment protocol consisting of sham taVNS. The treatment will be administered for five days beginning on the first day of pain experienced between the 1st and 2nd menstrual cycles.
62783292|NCT06043973|EXPERIMENTAL|almonertinib plus anlotinib|The specific treatment regimen is as follows: Non-squamous NSCLC: almonertinib (110 mg/d) plus anlotinib (12mg/d) is started on the first day of each treatment cycle and administered every three weeks until disease progression or intolerable toxicity. Anlotinib was given for two weeks, followed by one week off.
62783293|NCT01445197|EXPERIMENTAL|Biostate|
62783294|NCT05189028|EXPERIMENTAL|Locally advanced bulk cervical cancer neoadjuvant chemotherapy group(NACT)|"Radiation: Radiotherapy with IMRT/VMAT+192Ir-HDR brachytherapy Radiotherapy: 46Gy/23F to external pelvic radiotherapy and 14Gy/7F boost to imaging diagnosis of positive lymph nodes 192Ir-HDR brachytherapy:A Point dose 6Gy\*4-6F~Drug: gemcitabine plus cisplatin,cisplatin Neoadjuvant chemotherapy:gemcitabine and cisplatin (GP) regimen\*2 cycles Concurrent Chemotherapy: Weekly cisplatin chemotherapy ≥5 cycles"
62399900|NCT05514301|EXPERIMENTAL|Sensitivity of Polydeep vs high experienced endoscopists for colorectal polyp detection|Both diagnostic interventions will be performed in all patients: High definition colonoscopy and Polydeep system.
62783295|NCT05189028|ACTIVE_COMPARATOR|Locally advanced bulk cervical cancer chemoradiotherapy group(CCRT)|"Radiation: Radiotherapy with IMRT/VMAT+192Ir-HDR brachytherapy Radiotherapy: 46Gy/23F to external pelvic radiotherapy and 14Gy/7F boost to imaging diagnosis of positive lymph nodes 192Ir-HDR brachytherapy:APoint A dose 6Gy\*4-6F~Drug: cisplatin Concurrent Chemotherapy: Weekly cisplatin chemotherapy ≥5 cycles"
62783296|NCT02302391||Midazolam/fentanyl: PK analysis|Pediatric intensive care patients under analgosedation with midazolam and fentanyl.
62783297|NCT00687674|EXPERIMENTAL|Sorafenib + Lenalidomide + Dexamethasone|
62783298|NCT01012778|EXPERIMENTAL|Climbup ADHD and Dyslexia Program|"Open label - intervention with pre and post parameters collected~Intervention: Yoga, Meditation, Play therapy for children with ADHD and Dyslexia twice a week in classroom with 6 week and 12 month, primary outcomes in terms of Vanderbilt ADHD scores"
62783299|NCT05228483|EXPERIMENTAL|Photodynamic treatment monotherapy or combined with CO2 fractional laser|For patients who receive photodynamic therapy, lesions will be symmetrically randomized into two sides. One side will receive 5-aminolevulinic acid (5-ALA) with a red light illumination(80mW/cm2, and 120J/ cm2); while the other side will receive CO2 fractional laser(parameter: 20mm \*20mm, spot coverage rate 10%, and 18-25mJ/cm2) before photodynamic therapy. Treating area should cover 0.5cm beyond the visible boundary of the lesion. In total 6 therapies will be given for each patient, with 14±3d intervals.
62010699|NCT05114941|EXPERIMENTAL|Immunoadsorption group|Protein A immunoadsorption therapy
62010700|NCT05114941|ACTIVE_COMPARATOR|intravenous immunoglobulin group|Treatment with intravenous immunoglobulin
62399901|NCT05416268|OTHER|Diopsys NOVA and Diopsys Electrodes|Subjects will receive the PhNR test three times using the Diopsys device and Diopsys Electrodes. Next, subjects will receive the FL Flicker test three times using the Diopsys device and Diopsys Electrodes.
62783300|NCT05228483|ACTIVE_COMPARATOR|Mometasone furoate cream|Mometasone furoate cream (0.1%) for topical application, frequency: once daily, 5 days/week, for the first month; once every other day, for the second month; twice a week for the third month; the area of application should cover 0.5cm beyond the visible boundary of the lesion.
62783301|NCT02922426|EXPERIMENTAL|ALKS 3831|Oral, bilayer tablet
62783302|NCT02922426|ACTIVE_COMPARATOR|Olanzapine|Oral, bilayer tablet
62783303|NCT02922426|PLACEBO_COMPARATOR|Placebo|Oral, bilayer tablet
62783304|NCT01462396|EXPERIMENTAL|Single Arm|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
62783305|NCT03029091|EXPERIMENTAL|EoE +/- CTD|Participants with EoE with and without CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
62197734|NCT01162486|ACTIVE_COMPARATOR|Rifampin control|Rifampin + midazolam
62197735|NCT01162486|EXPERIMENTAL|RPT 1|RPT Cohort 1 - 5 mg/kg
62576562|NCT01329874|NO_INTERVENTION|Gow gates ,conventional block injection|Patients will be selected from a group with acute irreversible pulpitis in mandibular molars. Half of the patients randomly selected for receiving gow gates block injection and half will receive traditional inferior block injection by 3.6 ml Lidocaine plus epinephrine.Teeth with no response to anesthetizing will be randomly divided into two group of either buccal or lingual infiltration.
62576563|NCT01329874|NO_INTERVENTION|Buccal infiltration, Lingual infiltration|
62576564|NCT01455597|EXPERIMENTAL|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream 3 times a week for up to 40 weeks.
62576565|NCT05268783|EXPERIMENTAL|NEN patients|EORTC QLQ-C30, EORTC QLQ-GI.NET21 and satisfaction survey
62576566|NCT01633723|EXPERIMENTAL|DA-6886|
62576567|NCT01633723|PLACEBO_COMPARATOR|DA-6886 placebo|
62576568|NCT01587846|EXPERIMENTAL|Probiotic/abdominal pain|Children with functional abdominal pain that will receive probiotic.
62576569|NCT01587846|EXPERIMENTAL|Placebo/abdominal pain|Children with functional abdominal pain that will receive placebo.
62576570|NCT01587846|EXPERIMENTAL|Probiotic/constipation|Children with chronic constipation tha will receive probiotic plus lactulose
62576571|NCT01587846|EXPERIMENTAL|Placebo/chronic constipation|Children with chronic constipation that will receive placebo plus lactulose
62576572|NCT05589688|EXPERIMENTAL|acyclovir|Subjects take a single dose of 5 mg/kg infused over 1 hour.
62576573|NCT02024074|OTHER|Sestamibi(Tc- MBI) scan of the breast|
62783306|NCT03029091|EXPERIMENTAL|EoE + CTD|Participants with EoE with CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
62783307|NCT03029091|EXPERIMENTAL|EoE - CTD|Participants with EoE without CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
62010701|NCT00993213|ACTIVE_COMPARATOR|Liposuction|Standard of Care with Liposuction
62197736|NCT01162486|EXPERIMENTAL|RPT 2|RPT Cohort 2 - 10 mg/kg
62197737|NCT01162486|EXPERIMENTAL|RPT 3|RPT Cohort 3 - 15 mg/kg
62197738|NCT01162486|EXPERIMENTAL|RPT 4|RPT Cohort 4 - 20 mg/kg
62783308|NCT02554578|EXPERIMENTAL|Pharmaceutical care programme supported by mHealth|
62783309|NCT02554578|NO_INTERVENTION|Routine healthcare by the transplant team|
62010702|NCT00993213|SHAM_COMPARATOR|No Liposuction|Standard of Care without Liposuction'
62197739|NCT01162486|EXPERIMENTAL|RPT 5|RPT Cohort 5 - Maximal tolerated dose, if dose limiting toxicities are observed
62197740|NCT04017338|EXPERIMENTAL|Non Randomized Intervention|"Intervention description: recipients on the wait-list for lung, heart, kidney, and/or pancreas transplants will all receive antiviral treatment in the form of 8 total doses of oral tablets. Lung recipients will also receive donor lungs that are treated with normothermic EVLP (details of both described below).~Drug: All recipients will receive glecaprevir (300mg)/pibrentasvir (120mg) supplied as three tablets per dose 6-12 hours prior to transplant, and for 7 days post-transplant. Other Names: Maviret. Patients will also receive ezetimibe (10mg), supplied as one tablet per dose to be taken at the same time as Maviret tablets (6-12 hours prior to transplant in addition to 7 daily doses post-transplant).~Ex Vivo Lung Perfusion (EVLP): Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions. Other names: Normothermic EVLP."
62197741|NCT02764268|EXPERIMENTAL|Apatinib|
62576574|NCT01134107|EXPERIMENTAL|Insulin Lispro 6 Day (6D)|
62576575|NCT01134107|ACTIVE_COMPARATOR|Insulin Aspart 6 Day (6D)|
62576576|NCT05453188|EXPERIMENTAL|LongCOVID|Patients who have had COVID-19 and have been diagnosed with longCOVID or persistent COVID
62576577|NCT05453188|ACTIVE_COMPARATOR|Control|Patients who have had COVID-19, but have not been diagnosed with longCOVID or persistent COVID
62576578|NCT00826397|EXPERIMENTAL|Acupuncture Arm|Patients in the treatment arm will receive acupuncture administered twice weekly for six weeks and will be allowed to take pain medication as necessary.
62576579|NCT00826397|SHAM_COMPARATOR|Control Arm|The control patients will receive a form of sham acupuncture, which will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks.
62576580|NCT00550745|EXPERIMENTAL|1|Arm 1: vaccine
62576581|NCT00550745|PLACEBO_COMPARATOR|2|Arm 2: Placebo Comparator
62576582|NCT04377425||Patients with acute neurological symptoms|Consecutive patients with acute neurological disease admitted at the Neurology departments will be tested with a nasopharyngeal swap for SARS-COVID-19 RNA according to standard operating procedures at the department (if estimated hospital stay is \>24hours). Medical and clinical characteristics will be collected
62576583|NCT04377425||Stroke patients|"COVID-19 positive patients will be asked to participate in the extended study together with matched COVID-19 negative controls.~Extended study: Collection of cerebrospinal fluid and blood-samples, clinical and cognitive assessment at baseline and at 3-month follow-up"
62783310|NCT01973725|EXPERIMENTAL|Icotinib Hydrochloride|Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.
62197742|NCT03242343|EXPERIMENTAL|VasQ device implantation|"Main study cohort: Prospective, multi-center, single-arm, open label, enrolling patients referred to surgical creation of new brachiocephalic fistula (BCF). The VasQ will be applied to the AV fistula in all patients. The primary effectiveness endpoint for this trial will be measured at 6 months and compared to a performance goal (PG). Safety will compare descriptively between AE rates for Steal, Infection, Aneurysm and Seroma. Patients will be followed up for an additional 18 months for a total of 2 years. Additionally, this trial has several secondary endpoints.~Supplementary study cohort: 15 patients will be prospectively enrolled which are referred to surgical creation of a new forearm arteriovenous fistula. VasQ will be applied to the AV fistula in all patients. Patients will be followed in the same manner as in the Main study cohort, however, the data will be reported separately and not be part of the analysis sets for the study primary and secondary endpoints."
62197743|NCT04508855||Cancer patients with atrial fibrillation|"All patients will be assigned to receive subcutaneous LMWH in therapeutic doses~More specifically the regimens will be as follows:~Tinzaparin 175 units/Kg once daily; Enoxaparin 1unit/kg twice daily; Fondaparinux \<50 kg, 5 mg SC once daily, 50-100 kg, 7.5 mg SC once daily, \>100 kg, 10 mg SC once daily; Bemiparin 115 IU/kg once daily; \<50kg, 5000IU, 50-70kg, 7.500 IU, \>70kg, 10000IU Nadroparin: Patients weighing 40 to 100 kg: SC, 171 anti-factor Xa IU per kg of body weight once a day; patients weighing over 100 kg will not receive nadroparin because a treatment dosage has not been established; Dalteparin: 200 units IU/kg SC daily for 30 days, then 150 units IU/Kg SC daily Dose adjustments will occur only in case of renal insufficiency according to the medicine's SPC The treatment with the LMWH will last at least during the period of active antineoplastic therapy of cancer patients"
62197744|NCT01819142|EXPERIMENTAL|AutoloGel|Subjects will be treated with AutoloGel on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All patients will receive Autologel treatment
62197745|NCT01405651|EXPERIMENTAL|E|ONO-6950
62399902|NCT05416268|OTHER|Diopsys device with LKC Electrode Arrays|Subjects will receive the PhNR test three times using the Diopsys device with LKC Electrode Arrays, followed by the FL Flicker test three times using the Diopsys device with the LKC electrode arrays.
62399903|NCT05416268|OTHER|LKC device with the LKC electrode arrays|Subjects will receive the PhNR test three times using the LKC device with the LKC electrode arrays, followed by the FL Flicker test three times using the LKC device with the LKC electrode arrays.
62399904|NCT03781167|EXPERIMENTAL|ABBV-951 Low Dose Subgroup|After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.
62399905|NCT03781167|EXPERIMENTAL|ABBV-951 High Dose Subgroup|After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.
62399906|NCT05973422|EXPERIMENTAL|SIGI Insulin Management System Observed and At-Home Use|Current insulin pump users with type 1 diabetes, age 18+, will use the SIGI insulin management system for 1 day observed in the hospital setting, then for 2 more weeks of outpatient use.
62399907|NCT01321866|EXPERIMENTAL|Experimental arm|Patients in this arm will have angioplasty of a fistula stenosis using a cutting balloon
62399908|NCT01321866|ACTIVE_COMPARATOR|Standard arm|Patients in this arm will have angioplasty of a fistula stenosis using a non-cutting balloon.
62783311|NCT04079075|EXPERIMENTAL|Non-pharmacological intervention|"Non-pharmacological strategy, implemented in groups of 10 participants, over 10 consecutive months, based on five different interventions:~cognitive training, physical activity; nutrition education; adaption to memory loss; detection and correction of hearing impairment."
62783312|NCT04766008|EXPERIMENTAL|Metformin continuation|
62010703|NCT01435668|OTHER|Control|A simple written advice.
62010704|NCT01435668|EXPERIMENTAL|Brief Motivational Intervention (BMI)|Brief Motivational Intervention (BMI)
62197746|NCT01405651|PLACEBO_COMPARATOR|P|Placebo
62197747|NCT05497544|EXPERIMENTAL|Exercise recommendation group|
62197748|NCT05497544|EXPERIMENTAL|Exercise recommendation plus guidebook group|
62399909|NCT04451070||Family Medicine resident physicians|Family Medicine resident physicians at David Grant Medical Center who started their Family Medicine residency at David Grant Medical Center between June 2018 - June 2019 and are scheduled to graduate from Family Medicine residency between June 2021 - June 2022.
62399910|NCT02059265|EXPERIMENTAL|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62399911|NCT01169662|ACTIVE_COMPARATOR|Vegetable/ Fruit juice|450ml active product, 45 ml no added sugar squash (for flavour)
62399912|NCT01169662|PLACEBO_COMPARATOR|Placebo juice|
62399913|NCT02961361|EXPERIMENTAL|Group Control|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
62399914|NCT02961361|EXPERIMENTAL|Group Dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
62399915|NCT02111473|OTHER|testosterone|testosterone 250 mg injection per 3-4 weeks for 6 months
62399916|NCT02079376|EXPERIMENTAL|Low blood TG patients|subjects with baseline blood triglyceride level ≤ 1.7 mmol/l will have intervention device (DIAMOND Implantable Pulse Generator (IPG)) programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period.
62399917|NCT02079376|EXPERIMENTAL|High blood TG patients treated with blood TG lowering therapy|subjects with baseline blood triglyceride level \> 1.7 mmol/l will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period and will receive fenofibrate at the dose of 160mg per day
62783313|NCT03405428|OTHER|All patients|
62197749|NCT05497544|NO_INTERVENTION|Control|
62783314|NCT05784298|EXPERIMENTAL|Real low-intensity rTMS|One 45 minutes session of stimulation. The stimulation coil will be located in the precuneus, located in the Pz area of the 10-20. The coil will emit a pulsed magnetic field at a frequency of 40 Hz with a magnetic field strength of 150 gauss.
62197750|NCT04920266|EXPERIMENTAL|Smart sweat patch for sweat rate and sweat chloride concentration|Epidermal microfluidic patch that is a flexible 27 cm2 platform with an adhesive backing that collects sweat through a skin-facing inlet port. Custom software uses the smartphone camera to capture and analyze the microfluidic patch.
62783315|NCT05784298|SHAM_COMPARATOR|Sham low-intensity rTMS|One 45 minutes session of stimulation. The stimulation coil will be located in the precuneus, located in the Pz area of the 10-20. The coil will not emit any magnetic field.
62783316|NCT03684382|EXPERIMENTAL|NeW-I group|Participants engage in a weekly structured writing task of 15-30 minutes which provides them an opportunity to reflect on the emotional, practical and financial demands of caregiving, and the means to cope with these challenges (week 1), explore avenues where they can seek information and resources for caregiving (week 2), explore the sources of support which they have within their network of family and friends (week 3) and examine how they (and their children) can rise above illness-related challenges and live their lives as fully as possible (week 4). After participants complete their weekly writing task, the written narrative will be reviewed and edited by the therapist within the next 3-4 days. The revised draft will be shared with the participant along with constructive feedback, empathic support and psychoeducation. In week 5, participants will receive a 'legacy' document and engage in a voice call with the therapist to receive psychosocial support and for closure of therapy.
62197751|NCT04920266|PLACEBO_COMPARATOR|Reference sweat patch for sweat rate and sweat electrolytes|Regional absorbent patch technique for sweat rate (gravimetry) and electrolytes (sodium, potassium, chloride) by ion chromatography
62197752|NCT04920266|EXPERIMENTAL|Smart Cap bottle fluid measurement|Fluid level sensor integrated into the squeeze bottle cap measures the amount of fluid remaining in the bottle via light reflection
62197753|NCT04920266|OTHER|Reference method bottle fluid measurement|Scale weight of bottle (gravimetry method) for Smart Cap bottles (running and fitness subjects) and non-Smart Cap bottles (cyclists)
62197754|NCT01451502|EXPERIMENTAL|Unlicensed Umbilical Cord Blood Infusion|"All patients will be registered in OnCore under this protocol as well as the specific treatment protocol.~* Pre-infusion treatment using intravenous hydration, acetaminophen and diphenhydramine hydrochloride~* Unlicensed Umbilical Cord Blood Infusion according to institutional guidelines.~  * Infusion of minimally manipulated unlicensed UCB units:~ * vital signs Monitoring during and after UCB infusion:~ * Management of infusion reactions~* Post-transplant care and follow-up: will be done according to the disease specific treatment protocol and institutional guidelines."
62197755|NCT04004689||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join the rehabilitation program.~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test."
62197756|NCT00581477|EXPERIMENTAL|Droxidopa|Patients with known or suspected Dopamine beta-Hydroxylase Deficiency were administered Droxidopa doses of 25 mg, 50 mg, 100 mg, 200 mg, 250 mg or 300 mg up to three times daily. Supine and upright blood pressures were subsequently measured 60 to 240 minutes post-dose.
62576584|NCT04377425||Seizure/epilepsy|"COVID-19 positive patients will be asked to participate in the extended study together with matched COVID-19 negative controls.~Extended study: Collection of cerebrospinal fluid and blood-samples, clinical and cognitive assessment at baseline and at 3-month follow-up"
62576585|NCT01547442|EXPERIMENTAL|Artisan Aphakia Intraocular Lens|Implantation of an Artisan intraocular lens to correct aphakia in children
62576586|NCT05687396|EXPERIMENTAL|Virtual reality|Virtual reality while cycling with ergometer in addition to conventional pulmonary rehabilitation. virtual reality designed as cylcling in the forest.
62197757|NCT01909297|ACTIVE_COMPARATOR|ProSeal LMA|Supraglottic airway device
62197758|NCT01909297|ACTIVE_COMPARATOR|suprema LMA|Supraglottic airway device
62197759|NCT01909297|ACTIVE_COMPARATOR|I-gel LMA|Supraglottic airway device
62197760|NCT02167919|EXPERIMENTAL|Prostatic artery embolization|Microspheres measuring 100-300 microns will be injected under fluoroscopic guidance into the left and right prostatic arteries for embolization.
62197761|NCT03066882|EXPERIMENTAL|Study group I|Study group I (19 participants) received the NCD (details of diet: 15% protein, 75% carbohydrates, 10% fat). Both groups had 15% caloric restriction from their maintenance energy requirements.
62197762|NCT03066882|EXPERIMENTAL|Study group II|Study group II (18 participants) received the LCD or healthy weight maintenance diet (details of diet: 15% protein, 55% carbohydrates, 30% fat).Both groups had 15% caloric restriction from their maintenance energy requirements.
62399918|NCT02079376|PLACEBO_COMPARATOR|High blood TG patients|subjects with baseline blood triglyceride level \> 1.7 mmol/l will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period and will receive placebo of fenofibrate administered in the same schedule as the drug.
62399919|NCT03792373||frailty|
62576587|NCT05687396|EXPERIMENTAL|Conventional pulmonary rehabilitation|Deep diafragmatic breathing exercise, chest expansion exercies, pursed lip exhalation, coughing and huffing, upper limp exercies with deep breathing exercise, standing up-right position, cycling with ergometer.
62197763|NCT01367847|ACTIVE_COMPARATOR|Helping the Noncompliant Child (HNC)|Standard HNC (see HNC Arm/Title) Program plus Technology-Enhancement (smartphones, which are being used for mid-week video calls to check-in re: skill-building, videotaping of family practice of skills at home, daily surveys re: skills practice \& child behavior, reminders re: practice \& sessions.
62734744|NCT04666142|ACTIVE_COMPARATOR|Comparison of the Sleep Times of the Individuals in Both Groups 48 Hours After Intensive Care|The effect of light after 48 hours in the experimental and control groups of individuals hospitalized in the intensive care unit was examined.
62010705|NCT02090907|EXPERIMENTAL|Levothyroxin|In the treatment group, daily doses of 100 mg of Levothyroxine will be administered every morning, half an hour before breakfast.
62010706|NCT02090907|PLACEBO_COMPARATOR|Placebo|In the placebo group treatment regimen and advices are identical to that of the treatment group, except for using a pharmacologically neutral agent, with complete resemblance to the real treatment.
62010707|NCT03057626||Observational (specimen collection)|Patients undergo collection of blood and urine samples on day 1. Patients also undergo clinical assessments, laboratory, radiographic, and other ancillary studies on day 1.
62010708|NCT02422381|EXPERIMENTAL|MK-3475 + Gemcitabine|200mg MK-3475 200 given by IV infusion every 3 weeks, for 2 years, or until disease progression and Gemcitabine 1250 mg/m2 iv Days 1, 8 every 3 weeks, for maximum 6 cycles.
62010709|NCT01507428|ACTIVE_COMPARATOR|Arm I (standard chemoradiotherapy)|Patients undergo radiotherapy QD 5 days a week for 30 fractions. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once weekly for 6 weeks. Patients undergo FDG-PET/CT imaging between fractions 18 and 19.
62010710|NCT01507428|EXPERIMENTAL|Arm II (experimental chemoradiotherapy)|Patients undergo an individualized dose of image-guided radiotherapy QD 5 days a week for 30 fractions and undergo 18 F FDG-PET/CT between fractions 18 and 19. Based on the scan results, patients undergo individualized adaptive radiotherapy for the final 9 fractions. Patients also receive paclitaxel and carboplatin as in Arm I.
62010711|NCT04208412|EXPERIMENTAL|Part 1|Subjects received a single dose of 600 mg KVD900.
62010712|NCT04208412|EXPERIMENTAL|Part 2 - Sequence 1: 600 mg KVD900, Then Placebo|Subjects received a single dose of 600 mg KVD900 to treat the first eligible HAE attack. Following resolution of this attack, subjects received a second single dose of placebo to treat the second eligible HAE attack.
62010713|NCT04208412|EXPERIMENTAL|Part 2 - Sequence 2: Placebo, Then 600 mg KVD900|Subjects received a single dose of placebo to treat the first eligible HAE attack. Following resolution of this attack, subjects received a second single dose of 600 mg KVD900 to treat the second eligible HAE attack.
62010714|NCT01336738|PLACEBO_COMPARATOR|Placebo|Matching placebo for PF-04991532 and Sitagliptin
62010715|NCT01336738|EXPERIMENTAL|150 mg PF-04991532|
62010716|NCT01336738|EXPERIMENTAL|450 mg PF-04991532|
62010717|NCT01336738|EXPERIMENTAL|750 mg PF-04991532|
62399920|NCT03792373||nonfrailty|
62734745|NCT04666142|ACTIVE_COMPARATOR|Comparison of physiological parameters of individuals in both groups after 48 hours|Comparison of the physiological parameters of the individuals in the experimental and control groups 48 hours after their admission to the ICU.
62734746|NCT04666142|ACTIVE_COMPARATOR|Distribution of Total Sleep Times of the Individuals in the Experimental and Control Groups|The sleep times of the individuals in both groups were compared
62399921|NCT04098003|EXPERIMENTAL|Rosuvastatin|rosuvastatin 20 mg daily for eight weeks
62399922|NCT04098003|PLACEBO_COMPARATOR|Placebo|placebo daily for eight weeks
62399923|NCT00665418|EXPERIMENTAL|1|
62399924|NCT00556972|EXPERIMENTAL|Fecal Incontinence management system|Fecal Incontinence Management System is based on the same principle as fecal pouches. A barrier around anus to ensure adhesion and prevent leakage.
62734747|NCT00090961|EXPERIMENTAL|12-week exercise program + education|A 12-week supervised exercise program consisting of 3 days a week on a stationary bike or treadmill. In addition, at the time of enrollment patients are provided educational materials focusing on breathing and energy conservation.
62734748|NCT00090961|OTHER|Education|At the time of enrollment patients are provided educational materials focusing on breathing and energy conservation.
62010718|NCT01336738|ACTIVE_COMPARATOR|Sitagliptin 100 mg|
62010719|NCT04738708||Patients referred to CGS at NCCS for HBOC or Lynch syndrome pre-test genetic counselling.|Patients attending genetic counselling for Hereditary Breast and Ovarian Cancer (HBOC) and Lynch Syndrome in Clinical Genetic Services (CGS) at National Cancer Centre Singapore (NCCS)
62010720|NCT02683759|ACTIVE_COMPARATOR|Treatment Arm|Patients will receive 5-Aminosalicyclic acid as per their current treatment regimen and will also take Bio-enhanced curcumin twice daily after meals as per the following regimen:
62399925|NCT05054985|EXPERIMENTAL|Intervention arm|Patients with thoracoabdominal aortic aneurysms, and passed the screening and signed the informed consent form.
62399926|NCT01608321|EXPERIMENTAL|rTMS|Those receiving experimental treatment will receive 20 sessions of rTMS. The treatment will be delivered by trained medical personnel.
62399927|NCT01608321|PLACEBO_COMPARATOR|Sham rTMS|Those receiving the sham rTMS will receive 20 sessions of sham rTMS. The treatment will be delivered by trained medical personnel.
62734749|NCT03823586||Children|
62734750|NCT03823586||Adolescents|
62734751|NCT02886507|ACTIVE_COMPARATOR|NSK-SD (nattokinase)|One capsule (100 mg) nattokinase/day for the 8-week study duration.
62734752|NCT02886507|PLACEBO_COMPARATOR|Placebo|One capsule placebo/day for the 8-week study duration.
62734753|NCT03338478|EXPERIMENTAL|Epilepsy Patients|Patients being tapered off of levetiracetam or lamotrigine monotherapy during epilepsy video monitoring. Patients will receive the Wii Balance Board and computerized reaction time testing.
62734754|NCT03338478|EXPERIMENTAL|Healthy Control Group|Patients without a diagnosis of epilepsy. Control participants will receive the Wii Balance Board and computerized reaction time testing.
62734755|NCT03671421|ACTIVE_COMPARATOR|Quads tendon|The graft tissue will be quadriceps tendon
62734756|NCT03671421|ACTIVE_COMPARATOR|Hamstring|Semitendinosus and gracilis will be used for graft
62734757|NCT03671421|ACTIVE_COMPARATOR|BPTB|Bone patellar tendon bone graft to be used.
62783317|NCT03684382|NO_INTERVENTION|Control group|Participants engage in a weekly unstructured writing task of 15-30 minutes with a single open-ended question for each week which allows them to respond in any manner they find acceptable. Simple empathic weekly feedbacks are provided by the therapist to encourage continuous participation. In week 5, a consolidated document that includes all unedited journal writings together with a brief summary statement of appreciation by the therapist will be given to participants to indicate conclusion of participation.
62010721|NCT02683759|PLACEBO_COMPARATOR|Control Arm|Patients will receive 5-Aminosalicyclic acid as per their current treatment regimen and will also take a placebo pill twice daily after meals
62197764|NCT01367847|EXPERIMENTAL|Technology-Enhanced HNC (TE-HNC)|Standard HNC (see HNC Arm/Title) Program plus Technology-Enhancement (smartphones, which are being used for mid-week video calls to check-in re: skill-building, videotaping of family practice of skills at home, daily surveys re: skills practice \& child behavior, reminders re: practice \& sessions.
62399928|NCT04508504|EXPERIMENTAL|Preop PENG Block|Patients will receive a preoperative ultrasound-guided pericapsular nerve group block with 20 mL 0.5% ropivacaine in a manner consistent with Girón-Arango et al 2018 (PMID:30063657). Using appropriate sterile precautions, and procedural sedation with up to 2 mg IV midazolam, an ultrasound (SonoSite S-Nerve or Export) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) is used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After skin localization with 1-2 mL 1% lidocaine, a 22g 80 mm echogenic block needle (Pajunk SonoBlock II Facet) is advanced lateral to medial, in plane with the ultrasound beam, beneath the psoas tendon to the iliopubic eminence. 20 mL 0.5% ropivacaine is injected beneath the psoas tendon and above the iliopubic eminence, in 5 mL increments with periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site wiped clean.
62576588|NCT01931072|EXPERIMENTAL|High-intensity interval training|The High-intensity interval training group was instructed to complete exercise sessions of 4x4-minutes intervals at 85-95% of maximal heart rate, 3 times a week for 8 weeks. This type of exercise include 10 minutes warm-up, followed by four intervals of four minutes high-intensity (85-95% of HRmax), with three minutes active breaks (70% of HRmax) between each interval, and ending with seven minutes cool-down. An exercise session last for 42 minutes, where the participants should breathe heavily and feel exhausted four times.
62576589|NCT01931072|ACTIVE_COMPARATOR|Moderate training|The moderate training group was instructed to complete exercise sessions of 50 minutes at 70% of maximal heart rate, 3 times a week for 8 weeks.
62576590|NCT01931072|NO_INTERVENTION|Control|The control group followed the baseline and follow-up tests, and was asked to live normally and not change their dietary pattern or exercise habits during their participation in this project. Based on the well-known beneficial effects of exercise on general health, it was regarded unethical to demand the control group to desist from any types of physical activity during the project period. They got no further follow-up on exercise.
62576591|NCT06208839|ACTIVE_COMPARATOR|SBIRT/TAU for those with moderate risk drug or alcohol use|This moderate risk group will receive the standard Screening and Brief Intervention Treatment (SBIRT) along with Treatment as Usual (TAU) at the clinic.
62783318|NCT01833572|EXPERIMENTAL|Gefitinib|A total of 42 cases of resectable stage II-IIIA NSCLCs patients with EGFR activating mutations will be enrolled in this arm.Gefitinib 250 mg/day oral daily is given to patients after enrolment for 42 days or until disease progression or unacceptable toxicity.
62783319|NCT03108417|EXPERIMENTAL|cNEP|continuous negative external pressure will be used nightly by all participants
62010722|NCT05305365|EXPERIMENTAL|Patients with Breast Cancer Parenchymal brain metastasis (Cohort 1)|All participants in Cohort 1 will receive QBS72S IV injections once monthly until disease progression.
62010723|NCT05305365|EXPERIMENTAL|Patients with Breast Cancer Leptomeningeal Disease (Cohort 2)|All participants in Cohort 2 will receive QBS72S IV injections once monthly until disease progression.
62010724|NCT05305365|EXPERIMENTAL|Patients with any Primary Cancer Leptomeningeal Disease (Cohort 3)|All participants in Cohort 3 will receive QBS72S IV injections once monthly until disease progression.
62197765|NCT02142153|EXPERIMENTAL|F901318 0.25 mg/kg|Single intravenous infusion over 4 hours
62197766|NCT02142153|PLACEBO_COMPARATOR|0.25 mg/kg placebo|Single intravenous infusion over 4 hours
62197767|NCT02142153|EXPERIMENTAL|F901318 0.75 mg/kg|Single intravenous infusion over 4 hours
62783320|NCT02732431|OTHER|trisomy 21|Parents will complete two sleep symptom questionnaires (PSQ-SRBD and CSHQ) and children will be evaluated by a paediatric pulmonologist and allergist with skin allergy test. An Ear, Nose and Throat specialist will complete two questionnaires (CAS-15 and SCR) carrying a nasopharyngoscopy. Then, children will perform an overnight polysomnography in the Department of Paediatric Functional Investigations of University Hospital in Nice.
62783321|NCT06584474|ACTIVE_COMPARATOR|Group I : Azithromycin group|Patients will receive nebulized azithromycin (Xithrone, Amoun, Egypt) that will be initiated from day 7 of birth in a dose of 20 mg/kg/day in two divided doses for 3 weeks till the time of primary outcome assessment (at 28 days of age).
62783322|NCT06584474|PLACEBO_COMPARATOR|Group II: conventional treatment group|Patients will not receive the medication, instead will receive 3 ml of nebulized normal saline as placebo control.
62783323|NCT05816434|EXPERIMENTAL|Sleep Extension|1 week of \>1 hour increased time in bed
62783324|NCT05816434|NO_INTERVENTION|Control|Sustained sleep behavior
62783325|NCT02493231|ACTIVE_COMPARATOR|Nefopam|The generic name is 'ACUPAN'. It is infused during operation. A induction dose is 0.3mg/Kg. A maintenance dose is 65 mcg/kg/hr
62783326|NCT02493231|ACTIVE_COMPARATOR|Ketamine|It is infused during operation. A induction dose is 0.3 mg/Kg. A maintenance dose is 3 mcg/kg/hr
62783327|NCT02493231|PLACEBO_COMPARATOR|Saline|It is infused during operation. A induction volume is 3mL A maintenance dose is 10mL/hr
62783328|NCT05809063||cardiovascular patients|neonates that have cardiovascular diseases
62783329|NCT05809063||respiratory patients|neonates that have respiratory diseases
62783330|NCT05809063||gastrointestinal diseases|neonates that havegastrointestinal diseases
62783331|NCT05809063||renal patients|neonates that have renal diseases
62783332|NCT05809063||central nervous system diseases|neonates that have central nervous system diseases
62783333|NCT05809063||metabolic patients|neonates that have metabolic diseases
62783334|NCT05809063||endocrinal patients|neonates that have endocrinal diseases
62783335|NCT06123143|EXPERIMENTAL|Standardized NIS Wean|A standardized maintenance/weaning protocol will be implemented for the treatment group (standardized NIS wean). All infants in the treatment group will remain on NIS until either 32 or 34 weeks CGA, depending on their gestational age at birth. Infants born at 27 6/7 weeks or less will continue on NIS until at least 34 weeks if they are in the treatment group, whereas infants born between 28 0/7 and 29 6/7 weeks will stay on NIS until at least 32 weeks if they are in the treatment group. The weaning protocol in the treatment group will incorporate algorithms outlining stability criteria, failure criteria, and algorithms for registered nurses (RNs) and respiratory therapists (RTs), including steps to take in such situations. The control group will be weaned according to the unit's or medical team's practices.
62783336|NCT06123143|NO_INTERVENTION|Control|Babies in the control group (non-standardized wean) will be weaned based on unit specific practices.
62783337|NCT04840225||Endocarditis|100 patients diagnosed with infectious endocarditis according to DUKE criteria. Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at diagnosis and followed undtill 6 months after discharge.
62010725|NCT04400305|NO_INTERVENTION|Control|No Intervention: Control Group This group will complete baseline and final questionnaires (online). At the end of the study this group will have the option to receive access to the other group's materials (online platform) if they wish, for the 6 week period following the study.
62197768|NCT02142153|PLACEBO_COMPARATOR|Placebo 0.75 mg/kg|Single intravenous infusion over 4 hours
62783338|NCT04840225||TAVI/TEVAR patietns|30 patients undergoing elektive TAVI/TEVAR procedures. Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at directly prior to procedure and followed undtill 3 months after discharge.
62197769|NCT02142153|EXPERIMENTAL|F901318 1.5 mg/kg|Single intravenous infusion over 4 hours
62197770|NCT02142153|PLACEBO_COMPARATOR|Placebo 1.5 mg/kg|Single intravenous infusion over 4 hours
62197771|NCT02142153|EXPERIMENTAL|F901318 mg/kg|Single intravenous infusion over 4 hours
62783339|NCT04840225||Patients with bacterial infections without endocarditis|30 patients diagnosed with with bacterial infections, without endocarditis. Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at diagnosis and followed undtill 3 months after discharge.
62783340|NCT04840225||Healthy blood donors|Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at directly prior to blood donation and approximately 1 week after blood donations
62783341|NCT06085014||Prospective cohort|Patients with paroxysmal AF with clinical indication to first transcatheter ablation procedure of AF by pulmonary vein isolation
62783342|NCT06085014||Retrospective cohort|Patients who underwent ablative procedure in the two years prior to the start of the study
62783343|NCT00938444||Patients with moderate to severe RA|Patients with moderate to severe RA treated with Tocilizumab
62783344|NCT03295019|EXPERIMENTAL|Test Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
62783345|NCT03295019|PLACEBO_COMPARATOR|Placebo Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their placebo mouth spray, 2 times daily (morning and evening), for the 4 week duration of the study.
62783346|NCT02225899||Subjects with Cystic Fibrosis|Cross-sectional, observational study
62783347|NCT02225899||healthy volunteers|Cross-sectional, observational study
62783348|NCT02225899||Subjects with CF in a vitamin D study|This is a longitudinal observational study in subjects enrolled in a high-dose vitamin D study. The investigator (Jessica Alvarez) does not assign the intervention to the subjects of the study.
62197772|NCT02142153|PLACEBO_COMPARATOR|Placebo 3 mg/kg|Single intravenous infusion over 4 hours
62197773|NCT02142153|EXPERIMENTAL|F901318 5 mg/kg|Single intravenous infusion over 4 hours
62010726|NCT04400305|OTHER|Intervention|Participants will complete a baseline questionnaire, and receive access to the our online platform for 6 weeks. Completing the online platform is designed to encourage participants to engage in physical activity. At 3 weeks, a check-in session will occur over the phone. At 6 weeks the participant will be contacted to complete the final questionnaire, and do a wrap up interview. The end-of-trial qualitative interview will evaluate participant satisfaction and feasibility of the intervention. For this reason a lab employee unaffiliated with this study will complete these in person interviews.
62010727|NCT04704089||spectrophotometer, and numerical values of tooth color in the populations studied|at the first visit Shooting with Spectrophotometer and at the second visit for all patients except control population: Tooth extraction or restorative treatment Collection of teeth or enamel debris for analysis
62010728|NCT05949086|NO_INTERVENTION|Work Chat Later|This group will not receive Work Chat during the study, but will receive Work Chat access after data collection is complete.
62197774|NCT02142153|PLACEBO_COMPARATOR|Placebo 5 mg/kg|Single intravenous infusion over 4 hours
62197775|NCT04835454||control group|The control group consisted of healthy men with no cancer and no chronic diseases. They will be age-matched with patient group and recruited among men subjected to the routine periodic medical examination.
62197776|NCT04835454||Prostate cancer group|Patients who are confirmed to have prostate cancer based on digital rectal examination (DRE), trasrectal ultrasonography and histopathological examination of biopsy tissue with no other coexisting cancers or prostate cancer treatment
62197777|NCT04835454||benign prostatic hyperplasia group|Patients who are confirmed to have benign prostatic hyperplasia based on digital rectal examination (DRE), trasrectal ultrasonography and histopathological examination of biopsy tissue
62197778|NCT03659162||neutropenic cancer patient recieving azoles .|neutropenic cancer patients that undergoing chemotherapy with prophylaxis with azoles and exhibit recurrent fungal infection so appropriate clinical specimen will taken for isolation \& identification of causative agent \& it's antimicrobial profile then identification of the mechanism of resistance by invitro technique then confirmed by real time pcr.
62197779|NCT05613153|EXPERIMENTAL|Peppermint Oil|Peppermint oil will be provided free of charge to participants under the trademark Pepogest produced by the maker Nature's Way® (dosage 0.2 mL, 181 mg peppermint oil).
62197780|NCT05108753||Group 1|5 patients underwent TaTME under proctoring
62197781|NCT05108753||Group 2|the first 10 patients underwent TaTME without proctoring
62197782|NCT05108753||Group 3|the second 10 patients underwent TaTME without proctoring
62197783|NCT02047162|EXPERIMENTAL|Bismuth subsalicylate|Bismuth subsalicylate, 262 mg/chewable tablet, 2 tablets every hour as needed up to 16 tablets per 24 hours, for up to 48 hours.
62783349|NCT01571011|EXPERIMENTAL|CURB Intervention|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
62197784|NCT02047162|PLACEBO_COMPARATOR|Placebo|Placebo chewable tablets, 2 every hour as needed up to 16 tablets per 24 h, for up to 48 h.
62734758|NCT02016794||Patients|Patients suffering from degenerative cervical condition that requires anterior decompression and fusion in a single or multiple levels
62734759|NCT02482298|EXPERIMENTAL|Dose A|
62783350|NCT01571011|EXPERIMENTAL|CURB Intervention (Wait List)|Same as the CURB Intervention arm, however, individuals assigned to this arm wait 3 months before receiving the intervention.
62010729|NCT05949086|EXPERIMENTAL|Work Chat Now|Behavioral: Work Chat: An Interactive Virtual Workday Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
62734760|NCT02482298|EXPERIMENTAL|Dose B|
62010730|NCT04358484|EXPERIMENTAL|Intervention Group|Participants attend The Incredible Years - ASLD parenting intervention and continue to receive usual care at their healthcare center
62010731|NCT04358484|NO_INTERVENTION|Treatment As Usual (TAU) Group|Participants continue to receive usual care at their Healthcare Center
62010732|NCT04031885|EXPERIMENTAL|Abemaciclib + Fulvestrant|150 milligram (mg) Abemaciclib given orally twice a day (BID) with 500 mg fulvestrant given by intramuscular (IM) injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), then Day 1 of each subsequent cycle.
62010733|NCT04031885|ACTIVE_COMPARATOR|Standard Chemotherapy|Standard chemotherapy of physician's choice (capecitabine, docetaxel, nab paclitaxel, or paclitaxel), administered according to product label.
62010734|NCT06661109|EXPERIMENTAL|Kinesio Taping|Kinesio tape will be applied with 100% tension.
62197785|NCT00514579|OTHER|Myeloablative double unit UCBT|Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation
62197786|NCT04276051|EXPERIMENTAL|Cryoablation of the Vagus Nerve Plus Lifestyle Intervention|Participants randomized to receive cryoablation of the vagus nerve as well as standardized dietary and exercise counseling from a registered dietitian and exercise physiologist.
62197787|NCT04276051|ACTIVE_COMPARATOR|Lifestyle Intervention Only|Participants randomized to receive standardized dietary and exercise counseling from a registered dietitian and exercise physiologist.
62197788|NCT01063998||Group 1|Patients demonstrate normal serum creatinine and no radiological evidence of a renal tumor.
62734761|NCT02482298|PLACEBO_COMPARATOR|Placebo|
62197789|NCT01063998||p 2|Patients diagnosed with renal cancer and normal creatinine.
62197790|NCT00739258||HIDU|intravenous drug user (IDU) with HIV infected
62197791|NCT00739258||IDU|intravenous drug user (IDU) without HIV
62197792|NCT00739258||MH|persons receiving methadone maintenance treatment
62734762|NCT03512808|EXPERIMENTAL|Ursodiol 500mg tablets|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
62734763|NCT03512808|ACTIVE_COMPARATOR|Urso Forte 500mg tablets|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
62783351|NCT03155438||Low responder|"Low responder : women aged 25-49 years old with less than 5 oocytes (1-4 oocytes) retrieved during controlled ovarian hyperstimulation~Oxidative stress-related gene expression and oocyte competence biomarkers will be performed to access the difference between low and normal responders."
62197793|NCT03554720|ACTIVE_COMPARATOR|Standard implants|ATTUNE PS Knee
62197794|NCT03554720|ACTIVE_COMPARATOR|Enhanced-Fixation|ATTUNE S+ PS Knee
62197795|NCT03128580||Natural Cycle|The patient will not undergo hyperstimulation rather a natural cycle
62197796|NCT03128580||Stimulated Cycle|The 80 patients will undergo hyperstimulation cycle as per the clinical practice planned for the patient.
62399929|NCT04508504|PLACEBO_COMPARATOR|Placebo|Patients in the placebo group will receive a subcutaneous injection of 5 mL 0.9% normal saline. Using appropriate sterile precautions, and procedural sedation with up to 2 mg IV midazolam, an ultrasound (SonoSite S-Nerve or Export) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) is used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After skin localization with 1-2 mL 1% lidocaine, a 22g 80 mm echogenic block needle (Pajunk SonoBlock II Facet) is advanced lateral to medial, in plane with the ultrasound beam, 1-2 cm beneath the skin, remaining in the subcutaneous tissue. 5 mL of 0.9% normal saline is injected, with periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site wiped clean.
62399930|NCT02400658|EXPERIMENTAL|IORT with CT-Guided HDR Brachytherapy|Patients will receive IORT with CT-guided HDR brachytherapy at the time of breast surgery.
62783352|NCT03155438||Normal responder|"Normal responder women aged 25-49 years old with 5-15 oocytes retrieved during controlled ovarian hyperstimulation~Oxidative stress-related gene expression and oocyte competence biomarkers will be performed to access the difference between low and normal responders."
62197797|NCT04567381|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as Usual (TAU)/Control. Individuals randomized to TAU will receive a list of resources which provides participants with community agency information that they can engage on their own. The list of resources will include contact information for various services such as housing, employment, mental health and legal services. Patients randomized into this condition receive little to no assistance from program staff and must navigate the vast terrain of social service providers on their own.
62734764|NCT01949571|EXPERIMENTAL|Mirtazapine|During the first and second phase of the study, subjects assigned to the control group received one tablet of placebo under daily basis, whereas the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, placebo group received same tablet under daily basis, whereas the mirtazapine group received 15 mg of mirtazapine.
62734765|NCT01359033||MINAP cohort|The Myocardial Ischaemia National Audit Project (MINAP) was established in 1999, in response to the national service framework (NSF) for coronary heart disease, to examine the quality of management of heart attacks (myocardial infarction) in hospitals in England and Wales.
62734766|NCT01359033||RIKS-HIA cohort|The Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) has been established to record clinical and treatment information for all patients admitted to the coronary care units in Sweden from 1995.
62783353|NCT03135938|ACTIVE_COMPARATOR|Grading Inferior Oblique Anterior Transposition|in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
62783354|NCT03135938|ACTIVE_COMPARATOR|Classic Inferior Oblique Anterior Transposition|in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes
62010735|NCT06661109|PLACEBO_COMPARATOR|Sham Taping|Kinesio tape will be applied without tension.
62197798|NCT04567381|EXPERIMENTAL|Enhanced Services|Enhanced Services/Treatment (ES). Participants randomized to the ES intervention will receive intensive community-based case management.
62197799|NCT02808975|PLACEBO_COMPARATOR|Placebo|"Period A: Day 1- 4 subcutaneous (SC) injections; Week 2- 2 SC injections; Weeks 4-12- 1 SC injection each week~Period B: Weeks 13-14- 1 SC injection each week~Period C: Weeks 15-23- 1 SC injection each week"
62197800|NCT02808975|ACTIVE_COMPARATOR|Adalimumab|"Period A: Day 1- 4 subcutaneous (SC) 40 mg injections; Week 2- 2 SC 40 mg injections; Weeks 4-12- 1 SC 40 mg injection each week~Period B: Weeks 13-14- 1 SC 40 mg injection each week~Period C: Weeks 15-23- 1 SC 40 mg injection each week"
62197801|NCT02400775|EXPERIMENTAL|Azilsartan|Azilsartan orally once daily in the morning, either before or after breakfast
62197802|NCT00463905|NO_INTERVENTION|1|Current management for identifying postmenopausal women with osteoporotic vertebral fractures in primary care i.e. nothing
62197803|NCT00463905|EXPERIMENTAL|2|Intervention arm: simple clinical assessment to identify high risk 30% (approximately) who will then be offered lateral thoraco-lumbar X-rays
62197804|NCT00534170|EXPERIMENTAL|A,F,T,K|Two arms are for intervention and two are for control or placebo
62734767|NCT00659386|EXPERIMENTAL|A|Patients with chronic idiopathic cardiomyopathy and EMB proven high PVB19 virus load.
62010736|NCT03294369||Cohort of the study|A sample from the general population aged 18 years or older, randomly selected from a database of sanitary cards stratified by age and gender.
62010737|NCT05591417|ACTIVE_COMPARATOR|Intravenous morphine|Patients will receive intravenous morphine 0.1 mg/kg
62010738|NCT05591417|EXPERIMENTAL|Bilevel erector spinae plane block|Patients will receive erector spinae plane block at 2 levels
62197805|NCT01943942|EXPERIMENTAL|A (reference)/ B (test)|initial administration of reference and cross-over to test
62197806|NCT01943942|EXPERIMENTAL|B (test)/ A (reference)|initial administration of test and cross-over to reference
62197807|NCT00719329|EXPERIMENTAL|A|Chlorhexidine cleansing of the cord for seven days
62197808|NCT00719329|EXPERIMENTAL|B|Chlorhexidine cleansing of the cord for 1 day
62197809|NCT00719329|PLACEBO_COMPARATOR|C|Dry cord care, as recommended by WHO
62783355|NCT00880191|EXPERIMENTAL|Arm I|Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral gabapentin once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral gabapentin either two or three times daily on days 2-5 of chemotherapy.
62010739|NCT05591417|EXPERIMENTAL|Bilevel erector spinae plane block with dexamethasone|Patients will receive erector spinae plane block at 2 levels with dexamethasone
62783356|NCT00880191|EXPERIMENTAL|Arm II|Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral placebo once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral placebo either two or three times daily on days 2-5 of chemotherapy.
62010740|NCT05591417|EXPERIMENTAL|Bilevel erector spinae plane block with dexmedetomidine|Patients will receive erector spinae plane block at 2 levels with dexmedetomidine
62197810|NCT04267068|EXPERIMENTAL|Intervention|Online growth mindset interactive article followed by equal length interactive article describing the relationship between modifiable risk factors (MRF) and mental health outcomes
62197811|NCT04267068|ACTIVE_COMPARATOR|Control|Online daily activity scheduling interactive article (control)
62197812|NCT04434326|EXPERIMENTAL|[14C]CM082|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (200mg, 100µCi) of \[14C\]CM082 to healthy Chinese male subjects
62197813|NCT01920477|EXPERIMENTAL|Ofatumumab|Subject received subcutaneous administration of ofatumumab 20 mg once every 4 weeks through Week 56, with an additional 20 mg dose (that is 40mg total) at both Week 0 and Week 4.
62576592|NCT06208839|EXPERIMENTAL|SBIRT/eIntervention for those with moderate risk drug or alcohol use|Subjects assigned to this condition will be instructed by the research assistant in how to download and use the eIntervention app, which they will be free to use as they like for the duration of the study. The app will contain a personalized suite of programs and activities. Unlike the TAU condition, the patient's referral to treatment would be managed through eIntervention. For example, the app will show the patient their referral details (if a referral to treatment was made), including details on the provider, referred services, and contact information, and will offer them videos of peers and professionals educating them on addiction, treatment, and sharing personal stories of recovery.
62783357|NCT03063268|EXPERIMENTAL|Trust-Enhanced Messaged with Interactive Features on E-Consent|Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
62197814|NCT01920477|PLACEBO_COMPARATOR|Placebo|Subject received subcutaneous administration of matching placebo of ofatumumab once every 4 weeks through Week 56, with an additional dose at both Week 0 and Week 4.
62197815|NCT01607476|EXPERIMENTAL|Alzheimer's Disease|"Subjects who have the clinical diagnosis of probable AD ages 50 and older who have a study partner who is the participant's power of attorney (POA) or legally authorized representative (LAR).~Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first."
62197816|NCT01607476|ACTIVE_COMPARATOR|Cognitive Normal Elderly|Cognitive Normal subjects who are greater than 60 years of age. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
62197817|NCT01607476|ACTIVE_COMPARATOR|Cognitive Normal Young|Cognitively normal subjects who are between 30-60 years old. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
62197818|NCT04212351||Patients with NF1 and active LGGs|Patients with Neurofibromatosis Type 1 with clinical or radiographic evidence of low grade glioma but no clinical or radiographic evidence of plexiform neurofibroma.
62197819|NCT04212351||Patients with NF1 and active PNs|Patients with Neurofibromatosis Type 1 with clinical or radiographic evidence of plexiform neurofibroma but no clinical or radiographic evidence of low grade glioma.
62197820|NCT04212351||Patients with NF1 with no active LGGs or PNs|Patients with Neurofibromatosis Type 1 with no clinical or radiographic evidence of both active plexiform neurofibroma and active low grade glioma.
62197821|NCT05510050|EXPERIMENTAL|Manapol|1000 mg (Manapol only) Aloe Vera extract daily
62197822|NCT05510050|EXPERIMENTAL|Dalton Max|1000 mg (Dalton Max only) Aloe Vera extract daily
62197823|NCT05510050|PLACEBO_COMPARATOR|Placebo|Placebo (rice dextrin or similar) taken daily
62576593|NCT06208839|ACTIVE_COMPARATOR|SBIRT/TAU for those assessed with high risk.|This high risk group will receive the standard Screening and Brief Intervention Treatment (SBIRT) along with Treatment as Usual (TAU) at the clinic.
62783358|NCT03063268|EXPERIMENTAL|Interactive Features on E-Consent|Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
62783359|NCT03063268|ACTIVE_COMPARATOR|Standard E-Consent|Standardized text currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
62197824|NCT03259477|EXPERIMENTAL|precise segmental clamping|These participants with clinical T1 renal cell carcinoma(RCC) undergo precise segmental renal arterial clamping during laparoscopic partial nephrectomy.
62197825|NCT03259477|ACTIVE_COMPARATOR|complete clamping|These participants with clinical T1 renal cell carcinoma(RCC) undergo complete renal arterial clamping during laparoscopic partial nephrectomy.
62197826|NCT00000416|EXPERIMENTAL|Rehabilitation counseling|"Rehabilitation counseling~Experimental~Rehabilitation counseling was provided by rehabilitation counselors. They administered the Work Experience Survey; provided and discussed disability rights and responsibilities and provided career counseling they as needed."
62197827|NCT00000416|ACTIVE_COMPARATOR|printed information|"Active comparator~Control group participants received relevant printed information in the mail only; no rehabilitation counseling"
62197828|NCT02708407|EXPERIMENTAL|Peritoneal Dialysis Group|These participants will continue to receive standard HF care and Peritoneal Dialysis with a single daily exchange of icodextrin.
62197829|NCT02708407|NO_INTERVENTION|Control Group|These participants will continue to receive standard HF care.
62783360|NCT06354478|EXPERIMENTAL|D group|D group: Patients will receive two oral placebo capsules (starch capsules) 1 hour before surgery, and then will receive a loading dose of 1µg/kg of dexmedetomidine made to 50 ml using normal saline and given intravenously just before induction of anaesthesia over 10 minutes while patient vital signs monitored followed by intravenous infusion of dexmedetomidine diluted in normal saline with a dose of 0.5µg/kg/hour starts with induction of anaesthesia at a rate of 10 ml/hour through identical syringe pump until skin closure.
62783361|NCT06354478|EXPERIMENTAL|G group|G group: Patients will receive two oral gabapentin (300 mg) capsules for a total of 600 mg gabapentin (Neurontin; Pfizer, Cairo, Egypt) 1 hour before surgery, and then will receive 50 ml of normal saline given intravenously just before induction of anaesthesia over 10 minutes while patient vital signs monitored followed by intravenous normal saline infusion intraoperatively starts with induction of anaesthesia at a rate of 10 ml/hour through identical syringe pump until skin closure.
62783362|NCT06354478|EXPERIMENTAL|DG group|DG group: Patients will receive two gabapentin (300 mg) capsules for a total of 600 mg gabapentin 1 hour before surgery, and then will receive a loading dose of 1µg/kg of dexmedetomidine made to 50 ml using normal saline and given intravenously just before induction of anaesthesia over 10 minutes while patient vital signs monitored followed by intravenous infusion of dexmedetomidine diluted in normal saline with a dose of 0.5µg/kg/hour starts with induction of anaesthesia at a rate of 10 ml/hour through identical syringe pump until skin closure.
62783363|NCT04218539|EXPERIMENTAL|Placebo/Placebo|Subjects will receive a dose of placebo, followed by a dose of placebo approximately 7 days later.
62197830|NCT05812742|ACTIVE_COMPARATOR|Enhanced Usual Care|"For more details on the intervention, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).~Enhanced Usual Care (EUC) All patients had a brief clinical psychiatric and neurological assessment in order to determine eligibility, and they were provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication."
62197831|NCT05812742|EXPERIMENTAL|Enhanced Usual Care + Early intervention programme|"For more details on the intervention, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).~Behavioral: EUC + Early intervention programme All patients had a brief clinical psychiatric and neurological assessment in order to determine eligibility, and were provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.~The early intervention programme was interdisciplinary and was provided by an occupational therapist and a physiotherapist under supervision of a neuropsychologist. It was based on psychoeducation and principles from Cognitive Behavioral Therapy and Graded Exercise Therapy and targeted to patients' individual goals.~Patients received 8 weekly treatment sessions (3 group based and 5 individual sessions). The intervention started approximately 4 months after the concussion."
62197832|NCT01276808|EXPERIMENTAL|Magnetic navigation PCI|These patients will be treated with magnetically navigated percutaneous coronary intervention
62197833|NCT01276808|ACTIVE_COMPARATOR|Conventional PCI|These patients will be treated with normal standard percutaneous coronary intervention
62197834|NCT04278170||Case group|Rheumatoid arthritis patients who met the American College of Rheumatology (ACR) 2010 RA classification
62197835|NCT03149042||CCTA|Patients who are scheduled for clinically mandated elective invasive coronary angiography (ICA) at Buffalo General Hospital.
62197836|NCT03564353|EXPERIMENTAL|memory task with tDCS location 1|memory task paired with tDCS targeting C2 nerve (anode left c2; cathode right C2)
62197837|NCT03564353|EXPERIMENTAL|memory task with tDCS location 2|memory task paired with tDCS targeting C2 nerve (anode right c2; cathode left C2)
62197838|NCT03564353|EXPERIMENTAL|memory task with tDCS location 3|memory task paired with tDCS targeting C5/6 nerve
62197839|NCT03564353|EXPERIMENTAL|memory task with tDCS location 4|memory task paired with tDCS targeting trigeminal nerve dermatomes (left and right temple/jaw)
62576594|NCT06208839|EXPERIMENTAL|SBIRT/eIntervention those assessed with high risk.|Subjects assigned to this condition will be instructed by the research assistant in how to download and use the eIntervention app, which they will be free to use as they like for the duration of the study. The app will contain a personalized suite of programs and activities. Unlike the TAU condition, the patient's referral to treatment would be managed through eIntervention. For example, the app will show the patient their referral details (if a referral to treatment was made), including details on the provider, referred services, and contact information, and will offer them videos of peers and professionals educating them on addiction, treatment, and sharing personal stories of recovery.
62783364|NCT04218539|EXPERIMENTAL|Placebo/Psilocybin|Subjects will receive a dose of placebo, followed by a dose of psilocybin approximately 7 days later.
62783365|NCT04218539|EXPERIMENTAL|Psilocybin/Placebo|Subjects will receive a dose of psilocybin, followed by a dose of placebo approximately 7 days later.
62197840|NCT02385058|EXPERIMENTAL|Mebendazole + Quinfamide|Participants will receive mebendazole 600 milligram (mg) and quinfamide 200 mg tablets orally once starting on Day 1 and 21 in both Phase 1 and 2.
62197841|NCT02385058|EXPERIMENTAL|Mebendazole + Quinfamide + Placebo|Participants will receive mebendazole 600 mg and quinfamide 200 mg tablets orally once starting on Day 1 in Phase 1 and placebo tablets orally once starting on Day 21 in Phase 2.
62197842|NCT01195623|ACTIVE_COMPARATOR|varicose vein surgery with preop duplex|The surgeon has planned surgery for varicose veins from a clinical examination and has then the extra information available from a preoperative duplex examination to plan surgery more in detail
62197843|NCT01195623|NO_INTERVENTION|varicose vein surgery no preop duplex|The surgeon has planned surgery for varicose veins from a clinical examination only
62197844|NCT00750295|EXPERIMENTAL|1|
62197845|NCT00750295|EXPERIMENTAL|2|
62197846|NCT00750295|EXPERIMENTAL|3|
62197847|NCT00750295|EXPERIMENTAL|4|
62197848|NCT00750295|EXPERIMENTAL|5|
62197849|NCT00750295|EXPERIMENTAL|6|
62197850|NCT00750295|EXPERIMENTAL|7|
62010741|NCT04943016|EXPERIMENTAL|CD19 Chimeric Antigen Receptor (CAR) T Cells|The dose is escalated in standard 3 +3 design with a starting dose of 1x10\^6 cell/kilogram and maximum treatment dose of 5 x 10\^6 cell/kilogram. The minimum number of 9 subjects would occur if no dose-limiting toxicities are observed in the 3 dose escalation cohorts. The maximum sample size of 18 subjects would be enrolled in 3 dose escalation cohorts (six in each cohort) for meeting dose-limiting toxicities request. In addition, we hypothesize that we will be able to successfully manufacture CAR T cells to meet the established release criteria at a minimum target dose of 1 X 106 +-30% cells/kilogram in this patient population using the Miltenyi CliniMACS Prodigy® closed transduction system.
62010742|NCT04010110||Patients on hydroxychloroquine|A data collection sheet was used to collect patient's information. All patients underwent a complete ophthalmic examination including assessment of visual acuity, anterior segment examination looking for corneal verticillata and a dilated fundus examination looking for retinal pigment epithelium (RPE) depigmentation either in a para-foveal or extra-macular distribution within the retina. Ancillary tests were done which included: visual field testing (10-2), spectral domain ocular coherence tomography (SDOCT). Fundus auto-fluorescence and mf-ERG were done if further ancillary testing was needed in doubtful cases or to confirm findings.
62197851|NCT04186104|EXPERIMENTAL|Patients with routine outpatient service process|After registration, the patient waits in line at the door of the doctor's office. His doctor uses traditional methods to enter medical records by hand and make diagnosis independently. Then the patient waits in line to pay the bill and queues up for examination. Finally, the patient would take the examination report back to the doctor.
62399931|NCT05956782|ACTIVE_COMPARATOR|Attention Control|"1. Education: Each survivor will receive a copy of Facing Forward; Life After Cancer Treatment (No. 18-2424, March 2018). Each family member or friend will receive When Someone You Love is Being Treated for Cancer (No. 14-5726, May 2014). Specific parts of booklets will be reviewed during the 15-minute/per participant telephone chat.~2. Telephone Chats: The primary purpose is study retention. After the first 12-week period ends the weekly chats will be tapered for 12 weeks.~3. One text message delivered weekly by telephone is a reminder of the day and time of the chat(s).~Tobacco Use Reduction: Many survivors of lung cancer struggle with nicotine addiction; smoking cessation and relapse prevention content will be made available to current smokers (The FOREVER FREE program - a free, twelve short booklet evidence-based resource created by the H. Lee Moffitt Cancer Center \& Research Institute at the University of South Florida)."
62399932|NCT05956782|EXPERIMENTAL|BE Intervention Group|"1. The BE Manual is an educational resource for Managing Stress, Increasing Physical Activity (PA) and Stopping Smoking and Staying Smoke free.~2. A timed, weekly telephone counseling session (60 min./dyad max) will be recorded. The purpose is to provide social support with SMART goal setting, adherence monitoring, encouragement..~3. Breathing Exercises and Meditations are incorporated into the BE Manual and sent by a link via text messages.~4. A Texting Library provides additional education, support, and encouragement daily. There are 5 story lines: BE Active, BE Kind to Yourself, BE Supportive and BE Smoke free (offered to current smokers only). Stay Smoke free will be instituted once tobacco use has stopped.~5. Weekly Logs for tracking goals and progress with behavior changes (PA, breathing practices and meditations) and a pedometer are provided. After 12 weeks, the calls and texts will be tapered."
62576595|NCT04893616|EXPERIMENTAL|Intervention Arm|These facilities will be those selected to have the intervention carried out.
62576596|NCT04205331||obese patients|compare between ultrasonography and conventional clinical methods of airway assessment prior to induction of anesthesia correlating it to the Cormack-Lehane scoring system after induction of anesthesia in obese patients
62576597|NCT00937469|EXPERIMENTAL|Social sk. tr., parent tr.,standard tr.|
62576598|NCT00937469|ACTIVE_COMPARATOR|Standard treatment|
62576599|NCT02251457|EXPERIMENTAL|ranolazine|ranolazine 500mg, twice daily for two weeks; 1000mg twice daily for 2 weeks
62576600|NCT06573450||acute exacerbation CARAS|Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.
62783366|NCT04218539|EXPERIMENTAL|Psilocybin/Psilocybin|Subjects will receive a dose of psilocybin, followed by a dose of psilocybin approximately 7 days later.
62010743|NCT01548690|EXPERIMENTAL|Ornithine·Phenylacetate|Ornithine Phenylacetate is administered intravenously, through a peripheral venous catheter. Each infusion should will be administered over a period of 120 hours.
62010744|NCT00687505|EXPERIMENTAL|1|Single ascending doses
62010745|NCT00285935|EXPERIMENTAL|Treatment with SSRI|"Depressed participants will receive 8 weeks of treatment with one of the following serotonin-specific reuptake inhibitors:~fluoxetine (Prozac®), sertraline (Zoloft®), citalopram (Celexa®), escitalopram (Lexapro®)~The specific drug used for treatment will be selected by the study clinician based on clinical interviews and the participants preferences. Participants will be monitored for response and side effects by study clinician and will return after 8 weeks for a follow up study visit."
62010746|NCT01960231||pancreas specific MODY-2|
62010747|NCT06662708|EXPERIMENTAL|Experimental group|This group of patients will receive predictions assisted by artificial intelligence models.
62010748|NCT06662708|NO_INTERVENTION|Control Group|This group of patients will not receive predictions assisted by artificial intelligence models.
62010749|NCT03592472|EXPERIMENTAL|Pazopanib plus abexinostat|Randomized patients will receive a combination of pazopanib plus abexinostat. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat p.o twice daily (BID) on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of abexinostat at the same time each day.
62783367|NCT04551950|EXPERIMENTAL|Cohort 1A:M7824+Cisplatin/Carboplatin+Paclitaxel+Bevacizumab|
62783368|NCT04551950|EXPERIMENTAL|Cohort1B:M7824+Cisplatin or Carboplatin+Paclitaxel|
62783369|NCT04551950|EXPERIMENTAL|Cohort 2: M7824+Cisplatin+ Radiotherapy|
62010750|NCT03592472|PLACEBO_COMPARATOR|Pazopanib plus placebo|Randomized patients will receive a combination of pazopanib plus abexinostat matching placebo. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat matching placebo p.o BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of placebo at the same time each day.
62197852|NCT04186104|EXPERIMENTAL|Patients with AI assisted outpatient service process|After registration, the patient binds his information to the mobile phone application through outpatient' number. First, AI system would ask the patient a series of questions. Then it would make a judgment based on the patient's response. The system transmits the examination items to the doctor's computer and, with the doctor's approval, sends items back to the patient. So, patient could go straight to do the examination. While waiting for his turn, the patient enters the phone program again, and the AI system collects his medical history. The information is sent back to the doctor. When the patient goes to the doctor's office with the examination report, the doctor's computer already has his medical records. The doctor only needs to adjust the history according to the actual situation. After writing the medical history, the AI system could automatically make the diagnosis. Doctor uses the AI' results and his own judgment to make a comprehensive diagnosis.
62197853|NCT03929705||Test Arm 1- T-SPOT.TB assay|T-SPOT.TB test using density gradient isolation (Leucosep) For each subject recruited in the study, cells will be isolated using Leucosep Tubes and T-Cell Xtend reagent according to package insert. For each subject recruited in the study, the T-SPOT.TB assay will be run according to the assay package insert.
62197854|NCT03929705||Test Arm 2 -QuantiFERON-TB Gold Plus assay|QuantiFERON-TB Gold Plus, for each subject recruited in the study, the QuantiFERON-TB Gold Plus (QFT-Plus) assay will be run according to the assay package insert.
62197855|NCT02288169|EXPERIMENTAL|COPE|The experimental group will receive usual care plus the COPE intervention. This group will receive 3 individual intervention sessions. During the first intervention visit at the cancer center, the COPE group will be taught the COPE intervention in a session focusing on the patient's self-identified most bothersome symptom. Role modeling and additional instruction will be provided via video, and patients will receive the Home Care Guide for Cancer and a copy of the video to take home. Three subsequent visits with the patient during regularly scheduled clinic visits will reinforce the principles of COPE and the use of the Home Care Guide, and will help patients apply this approach to managing other symptoms. In addition they will get 2 phone calls encouraging them to apply COPE.
62197856|NCT02288169|SHAM_COMPARATOR|Support|The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls, matched for time with COPE participants.
62399933|NCT01215968|PLACEBO_COMPARATOR|Placebo|"Each participant will receive placebo on Week 1. Participants randomized to placebo will receive once-weekly doses of placebo on Weeks 2 to 5.~Placebo will be administered by single subcutaneous injection into the skin of the abdominal wall.~Participants regularly taking metformin will continue their normal dosing regimen throughout the study."
62197857|NCT02288169|NO_INTERVENTION|Control|The control group will receive usual care and no additional attention from our interventionists.
62197858|NCT04525599|EXPERIMENTAL|Group 1, ASP3772 Low Dose|Participants will receive a single intramuscular injection of ASP3772 administered on Day 1 at a low-dose level.
62197859|NCT04525599|ACTIVE_COMPARATOR|Group 1, PCV13 Comparator|Participants will receive a single intramuscular injection of the approved dose of PCV13 on Day 1.
62010751|NCT00075868|EXPERIMENTAL|Sandostatin LAR® Depot|Sandostatin LAR® Depot Pre-RT (between day -7 and day -4 of RT) and Day 22 (± 3 days)
62197860|NCT04525599|EXPERIMENTAL|Group 2, ASP3772 Medium Dose|Participants will receive a single intramuscular injection of ASP3772 administered on Day 1 at a medium-dose level.
62399934|NCT01215968|EXPERIMENTAL|LY2189265|"Participants randomized to LY2189265 will receive once-weekly doses of LY2189265 on Weeks 2 to 5.~1.5 milligram (mg) LY2189265 will be administered by single subcutaneous injection into the skin of the abdominal wall.~Participants regularly taking metformin will continue their normal dosing regimen throughout the study."
62399935|NCT02293876|SHAM_COMPARATOR|Eye drop|Eye drop LACRIBELL® - two drops each eye, three times a day, after eye cleansing.
62399936|NCT02293876|SHAM_COMPARATOR|Ocular gel|Ocular gel LIPOSIC® applied three times a day at the lower palpebra from medium line to the lateral border.
62010752|NCT00075868|PLACEBO_COMPARATOR|Placebo|Placebo Pre-RT (between day -7 and day -4 of RT) and Day 22 (± 3 days)
62010753|NCT05397379|EXPERIMENTAL|HEC96719 0.25 mg|Oral dose once daily for 12 weeks
62399937|NCT02293876|SHAM_COMPARATOR|Glad wrap|Occlusion of the orbital area with a Glad wrap, turning the area into a moisture chamber.
62399938|NCT02293876|NO_INTERVENTION|Control group|Ocular cleansing three times a day.
62399939|NCT04043949||Normal|healthy subjects
62399940|NCT04043949||Dry eye group|patients with dry eye
62010754|NCT05397379|EXPERIMENTAL|HEC96719 0.35 mg|Oral dose once daily for 12 weeks
62399941|NCT04043949||Dry eye after treatment|patients with dry eye after treatment
62576601|NCT06573450||chronic persistence CARAS|Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.
62010755|NCT05397379|EXPERIMENTAL|HEC96719 0.5 mg|Oral dose once daily for 12 weeks
62010756|NCT05397379|EXPERIMENTAL|HEC96719 0.25 mg bid|Oral dose twice daily for 12 weeks
62010757|NCT05397379|PLACEBO_COMPARATOR|Placebo|Oral dose once or twice daily for 12 weeks
62010758|NCT05691140|EXPERIMENTAL|Cognitive Behavioural Therapy|
62010759|NCT05691140|NO_INTERVENTION|Treatment as Usual|
62010760|NCT01375296|EXPERIMENTAL|SES|including two types of China-made SES, i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
62010761|NCT01375296|OTHER|medicine|
62010762|NCT06361511|EXPERIMENTAL|High Linoleic Safflower Oil|consumption of 12g of high linoleic safflower oil every day
62010763|NCT06361511|PLACEBO_COMPARATOR|High Oleic Safflower Oil|Consumption of 12g of high oleic safflower oil every day
62010764|NCT00568308|PLACEBO_COMPARATOR|1|
62010765|NCT00568308|EXPERIMENTAL|2|
62197861|NCT04525599|ACTIVE_COMPARATOR|Group 2, PCV13 Comparator|Participants will receive a single intramuscular injection of the approved dose of PCV13 on Day 1.
62197862|NCT04525599|EXPERIMENTAL|Group 3, ASP3772 High Dose|Participants will receive a single intramuscular injection of ASP3772 administered on Day 1 at a high-dose level.
62197863|NCT04525599|ACTIVE_COMPARATOR|Group 3, PCV13 Comparator|Participants will receive a single intramuscular injection of the approved dose of PCV13 on Day 1.
62197864|NCT00723619||1|Children and adolescent from German schools in the region Wesel, Hannover and Düsseldorf, selected via special school lists
62197865|NCT05524090||Implementation cohort|"Inclusion criteria:~1. Age ≥18 years;~2. Pathology confirmed LAPC\*;~3. CT-based non-progressive disease in accordance with the RECIST criteria after at least 4 months of systemic chemotherapy (\[m\]FOLFIRINOX or gemcitabine-nab-paclitaxel).~Exclusion criteria:~(1) Metastatic pancreatic cancer prior to induction chemotherapy.~\*According to the Dutch Pancreatic Cancer Group (DPCG) definition: \>90 degrees arterial tumor involvement (i.e. superior mesenteric artery, celiac axis, and/or hepatic artery) and/or portovenous involvement of either \>270 degrees or occlusion."
62197866|NCT05222594|OTHER|Epileptic participants undergoing intracranial monitoring|Patients with pharmaco-resistant epilepsy undergoing intracranial monitoring involving the left cerebral hemisphere.
62197867|NCT03622970|EXPERIMENTAL|VGBT with Nintendo® Wii and LMC games|"VGBT with Nintendo® Wii and LMC games:~In order to improve the elbow and shoulder functions, Tennis and boxing, the games of Nintendo Wii® Fit WiiSports package that includes shoulder and elbow movements will be used for VGBT with Nintendo® Wii and Leap Motion Controller (LMC) games. In both of the games, the activities are carried out by providing feedback in the context of remote control and sound and vibration notifications."
62197868|NCT03622970|ACTIVE_COMPARATOR|NDT-based upper limb rehabilitation|"NDT-based upper limb rehabilitation:~NDT-based upper limb rehabilitation aims to facilitate normal movement for upper extremity activities such as getting dressed and eating etc by using real materials (clothes, spoons, pencils, buttons, rope, etc.). The target activities were practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools."
62197869|NCT03587766|EXPERIMENTAL|Group A|Fexinidazole (FEXI) 600 mg x 10 days in a single daily dose orally (1 fexinidazole 600 mg tablet and 1 fexinidazole matching placebo oral tablet administered in a single daily dose) (total dose: 6.0 g).
62197870|NCT03587766|EXPERIMENTAL|Group B|Fexinidazole (FEXI) 1200 mg x 3 days orally (2 fexinidazole 600 mg tablets administered in a single daily dose for 3 days), to be followed by matching placebo oral tablet for 7 days (2 fexinidazole matching placebo oral tablets administered once daily for 7 days) (total dose: 3.6 g).
62197871|NCT03587766|EXPERIMENTAL|Group C|Fexinidazole (FEXI) 600 mg for 3 days, followed by 1200 mg in a single daily dose orally for 4 days (1 fexinidazole 600 mg tablet AND 1 fexinidazole matching placebo oral tablet administered in a single daily dose for 3 days, to be followed by 2 fexinidazole 600 mg tablets for 4 days), then followed by matching placebo oral tablet for 3 days (2 fexinidazole matching placebo tablets administered once daily for 3 days) (total dose: 6.6 g).
62197872|NCT04071301|EXPERIMENTAL|Investigational Device|TENA SmartCare Change Indicator
62197873|NCT06470477||Phlegm-heat syndrome|"Phlegm-heat syndrome: the score of Phlegm-dampness syndrome ≥10 and the score of Internal fire syndrome ≥10 in Diagnostic Scale for Syndrome Elements of Ischemic Stroke."
62197874|NCT06470477||Non-phlegm-heat syndrome|"Non-phlegm-heat syndrome: the score of Phlegm-dampness syndrome \<10 and the score of Internal fire syndrome \<10 in Diagnostic Scale for Syndrome Elements of Ischemic Stroke."
61978266|NCT04882267|EXPERIMENTAL|Engagement in home self-directed exercise incorporating Team and Technology (Intervention Period)|"Subjects will take part in a live demonstration of three subscription-based AI-learning home exercise apps, and one self-directed exercise website designed by a CF patient partner. Subjects will be surveyed on willingness to use technology, and provide feedback on exercise options. They will be given free full access to the apps and website (Technology), and receive a phone call once a week from their CF specialty team offering encouragement and positive reinforcement (Team). App and website usage, actigraphy, EB/BS and GHQ 12 scores will be measured at the end of four weeks. Anticipated outcomes: Activity will increase significantly during the Team and Technology intervention period, barriers on the EB/BS score will decrease, and GHQ 12 scores will increase."
62010766|NCT01997086|ACTIVE_COMPARATOR|Transforaminal discectomy|patients diagnosed as lumbar disc herniation undergoing percutaneous transforaminal endoscopic discectomy (PTED).
62197875|NCT02539459|EXPERIMENTAL|Treatment (everolimus)|Patients will take 10 mg (1 tablet) of everolimus each day for 4 months
62399942|NCT01476891|ACTIVE_COMPARATOR|Wait-List|Wait-list Control Group. The control group will receive the next available online MBSR program.
62399943|NCT01476891|ACTIVE_COMPARATOR|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
62399944|NCT02331459|EXPERIMENTAL|Intervention group|"Multicomponent training intervention :~3 sessions a week of 45 minutes of resistance activity (24 weeks) 2 sessions a week of 45 minutes of strength training (24 weeks) 5 sessions a week of 15 minutes of proprioceptive training (24 weeks)"
62399945|NCT02331459|PLACEBO_COMPARATOR|Control group|Normal routine during 24 weeks.
62399946|NCT00777504|ACTIVE_COMPARATOR|A|When PD is being determined the patient will continue with the oral angiogenesis inhibitors for 2 more weeks. After 2 weeks, an Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI). After evaluating these scans patients in group A now stop the orale angiogenesis inhibitor.
62010767|NCT01997086|ACTIVE_COMPARATOR|Microendoscopic discectomy|Patients diagnosed as lumbar disc herniation undergoing microendoscopic discectomy (MED).
62010768|NCT05951816|EXPERIMENTAL|Estimation of dosimetry for 99mTc-p5+14 and Biodistribution Of 99mtc-p5+14 In Healthy Subjects|"For dosimetry, patients with a confirmed diagnosis of systemic AL amyloidosis, patients will be administered a single IV dose of up to 1 mg of 99mTc-p5+14 (\~20 mCi) by slow push (\~1 mL/5 sec.). Patients will then undergo serial planar scintigraphic imaging at \~30 minutes, \~1 hour, \~2 hours, \~4 hours, \~6 hours, and \~24 hours post-injection. At the 4-hour time point, the patient will also undergo a single SPECT/CT scan to provide additional data for estimating dosimetry. Before injection of the radiotracer and at each imaging session, \~2 -3 mL of blood will be acquired to determine the whole blood radioactivity.~Healthy volunteers will undergo an echo examination, thereafter, they will be administered a single IV dose of 99mTc-p5+14 (20 mCi) and will undergo a single planar image acquisition followed by SPECT/CT imaging at \~1 hour and \~3 hours post-injection."
62197876|NCT06380452|ACTIVE_COMPARATOR|5% Permethrin Creme|Permethrin Cream 5 % is the already approved standard therapeutic agent InfectoScab 5 % Cream, contains the active ingredient permethrin in a 5 % concentration and is used for the topical treatment of scabies. The cream is also used as a topical cream, e.g. after washing hands.
62197877|NCT06380452|EXPERIMENTAL|10% Permethrin Creme|Permethrin Cream 10 % also contains the active ingredient permethrin, but in double the concentration, and otherwise corresponds to the approved standard therapeutic agent InfectoScab 5 % Cream in terms of the main other ingredients. This is also used for the topical treatment of scabies, as well as for re-creaming, e.g. after washing hands.
62399947|NCT00777504|ACTIVE_COMPARATOR|B|When PD is being determined the patient will continue with the oral angiogenesis inhibitors for 2 more weeks. After 2 weeks, an Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI). After evaluating these scans patients in group B continue with angiogenesis inhibitors for 2 more weeks. After these 2 weeks(so 4 weeks after inclusion) another Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI) and a FDG-PET-scan.
62576602|NCT06573450||clinical control CARAS|Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.
61978267|NCT04882267|ACTIVE_COMPARATOR|Determination of sustainability (Sustainability Period)|Phone calls will cease, but subjects will maintain access to apps, websites, and actigraphy. After four weeks, EB/BS and GHQ 12 scores, physical activity, app and website use will be reassessed. Anticipated outcomes: Activity will decrease during the sustainability period, but will remain significantly greater than the pre-intervention period. Overall GHQ 12 and EB/BS scores will improve.
61978268|NCT04823039|OTHER|Vaccination in patient with sepsis|
61978269|NCT01477606|EXPERIMENTAL|Midostaurin|
62197878|NCT06320132||Retrospective group|Patients treated for spontaneous intracranial hemorrhage before March 13, 2024.
62399948|NCT03796897|EXPERIMENTAL|Leucine-enriched protein + exercise|whey protein- hydrolyzed whey protein-micellar casein blend (50:43:7 whey:hydrolyzed-whey:casein), vitamin D, and free leucine
62399949|NCT03796897|SHAM_COMPARATOR|Habitual diet + exercise|habitual diet only
62399950|NCT05723120|EXPERIMENTAL|Neuromuscular Score|"Patients undergoing spontaneous ventilation, noninvasive mechanical ventilation, or invasive mechanical ventilation were assessed by two physical therapists with a minimum interval of 15 minutes between them. There was no communication between the physical therapists before, during, or after the assessments. Patients were also evaluated by the EuroSCORE16, SAPS 317, and ARISCAT18 scales. They were evaluated three times during hospitalization: at protocol admission, after five and ten days, or at hospital discharge, whichever occurred first. The surgical patients were also evaluated three times: immediately postoperative, at ICU discharge, and seven days later or at hospital discharge, whichever occurred first.~In addition, patients' characteristics at hospital admission were also analyzed, including demographic characteristics, clinical signs and symptoms, imaging, laboratory findings, and medical history"
62576603|NCT06573450||acute exacerbation BA|Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.
62576604|NCT06573450||chronic persistence BA|Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.
62576605|NCT06573450||clinical control BA|Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.
62576606|NCT06573450||intermittent AR|Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.
62197879|NCT06320132||Prospective group|Patients treated for spontaneous intracranial hemorrhage after March 13, 2024.
62197880|NCT05017051||Dysexecutive patients|Patients with dysexecutive syndrome
62197881|NCT05017051||Healthy subjects|Healthy subjects to be used as control group
62197882|NCT05597813|ACTIVE_COMPARATOR|Group A|microneedling group
62197883|NCT05597813|ACTIVE_COMPARATOR|Group B|microneedling plus timolol group
62197884|NCT03153150|EXPERIMENTAL|Start oral anticoagulant (OAC)|"If the patient is randomized in this arm, an oral anticoagulant:~* Factor Xa inhibitors: Apixaban or Rivaroxaban or Edoxaban or~* Direct thrombin inhibitor: Dabigatran or~* Vitamin K antagonists: Acenocoumarol or Phenindione or Warfarin chosen by the patient's physician before the randomisation, will be prescribed long-term (≥1 year) to the patient."
62197885|NCT03153150|NO_INTERVENTION|Do not start oral anticoagulant (OAC)|"If the patient is randomized in this arm, anticoagulant drugs will not be prescribed to the patient during the entire study period. The standard clinical practice without OAC may include:~* antiplatelet drug(s) or~* no antithrombotic drugs."
62576607|NCT06573450||persistent AR|Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.
62197886|NCT04435964||Overall series|Patients treated with immunocheckpoint inhibitors (ICI) irrespective of treatment schedule. No limitations to previous lines of treatment. ICI therapy may be either as single agent or in combination. Concomitant chemotherapy (CT) and radiotherapy (RT) is allowed.
62197887|NCT00335140|EXPERIMENTAL|Rituximab + standard chemotherapy|Rituximab + high dose methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine. Patients with meningeal involvement will receive additional methotrexate and leucovorin.
62197888|NCT00911651|ACTIVE_COMPARATOR|salbutamol|6 patients with moderate (GOLD 2) and severe (GOLD 3) COPD
62576608|NCT06573450||healthy individuals|Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.
62576609|NCT01222520|EXPERIMENTAL|Telmisartan and amlodipine FDC|once a daily
62197889|NCT00911651|ACTIVE_COMPARATOR|ipratropium bromide|COPD patients GOLD stage II and III
62197890|NCT00905905|EXPERIMENTAL|Ezetimibe-Simvastatin 10/40 mg|
62197891|NCT00905905|ACTIVE_COMPARATOR|Simvastatin 40 mg|
62576610|NCT01222520|ACTIVE_COMPARATOR|Telmisartan monotherapy|once a daily
62576611|NCT05607030|EXPERIMENTAL|Experimental|Local antibiotic irrigation via the VT-X7 Treatment System adjuvant to two-stage exchange arthroplasty per SOC.
62734768|NCT06093958|EXPERIMENTAL|Chest wall loading|All patients who are receiving mechanical ventilation and are passive on the ventilator will have chest wall loading performed to identify whether there is a paradoxical decrease in lung compliance.
62010769|NCT05951816|EXPERIMENTAL|Biodistribution in patients with systemic AL or ATTR amlyoidosis|"Patients with a confirmed diagnosis of systemic AL or ATTR (with or without a positive PyP scan) will be administered a single IV dose of up to 1 mg of 99mTc-p5+14 (\~20 mCi) by slow push (\~1 mL/5 sec.). At \~1 hour and \~3 hours post-injection, patients will undergo abdominothoracic planar imaging followed by SPECT/CT imaging covering the same area. Vital signs (blood pressure, respiration rate, temperature, and pulse) will be acquired before injection of the 99mTc-p5+14, and at \~3 hours post injection.~On Day 3, patient will undergo a trans thoracic echo examination. On Day 4, patients will undergo Technescan™ 99mTc-PYP (20 mCi) planar and SPECT/CT imaging at \~1 hour and \~3 hours post-injection. Vital signs (blood pressure, respiration rate, temperature, and pulse) will be acquired before injection of the 99mPYP, and at \~3 hours post injection."
62576612|NCT05607030|ACTIVE_COMPARATOR|Control|SOC for treatment of chronic PJI - two-stage exchange arthroplasty: surgical removal of the infected implant, aggressive debridement, and exchange arthroplasty with administration of adjuvant systemic antibiotics and temporary antibiotic-impregnated cement spacer.
62197892|NCT04038918|EXPERIMENTAL|Progressive Muscle Relaxation Exercise Group|Standard postoperative physiotherapy program plus progressive muscle relaxation (PMR) exercise will be applied.
62197893|NCT04038918|OTHER|Control Group|Standard postoperative physiotherapy program will be applied.
62197894|NCT02221557|EXPERIMENTAL|New alloplastic bone graft material|
62197895|NCT02294526|EXPERIMENTAL|Sardine diet|Subjects follow general dietary recommendations for diabetes including a fixed amount of sardine in daily meals (100g per day, 5 days a week) as part of their usual diet.
62197896|NCT02294526|NO_INTERVENTION|Control diet|Subjects only follow general dietary recommendations for diabetes.
62197897|NCT00527761|EXPERIMENTAL|Temozolomide, Docetaxel + Cisplatin|
62197898|NCT00682032|EXPERIMENTAL|AIM 2: subjects with suspected or definitive NSCLC diagnosis|1 (one) 250mg beta-glucan capsule 3 times a day for 14 days
62197899|NCT00682032|EXPERIMENTAL|AIM 3: subjects with resectable NSCLC|1 (one) 250mg beta-glucan capsule 3 times a day for 10 to 20 days
62197900|NCT02771379||Patients who are treated with Raxone®|
62197901|NCT03591484|EXPERIMENTAL|G1 dentate healthy older|Treatment with Photodynamic therapy (n = 20). The dentate participants will received periodontal treatment. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
62399951|NCT05723120|EXPERIMENTAL|Respiratory Score|"Patients undergoing spontaneous ventilation, noninvasive mechanical ventilation, or invasive mechanical ventilation were assessed by two physical therapists with a minimum interval of 15 minutes between them. There was no communication between the physical therapists before, during, or after the assessments. Patients were also evaluated by the EuroSCORE16, SAPS 317, and ARISCAT18 scales. They were evaluated three times during hospitalization: at protocol admission, after five and ten days, or at hospital discharge, whichever occurred first. The surgical patients were also evaluated three times: immediately postoperative, at ICU discharge, and seven days later or at hospital discharge, whichever occurred first.~In addition, patients' characteristics at hospital admission were also analyzed, including demographic characteristics, clinical signs and symptoms, imaging, laboratory findings, and medical history"
62399952|NCT01775176||Polycystic Ovary Syndrome|Overweight women with polycystic ovary syndrome. 20 - 40 years, inclusiveBody mass index ≥ 25kg/m2History of irregular menstrual cycles (fewer than 8 regular cycles in the past year)Clinical and/or biochemical androgen excess (Free androgen index\>3.85 and/or hirsuitism rating ≥8)Anovulatory menstrual cycles (determined during screening)
62399953|NCT02442427|ACTIVE_COMPARATOR|Palivizumab|A single dose of IV palivizumab
62399954|NCT02442427|PLACEBO_COMPARATOR|Placebo|An equivalent volume of 0.9% normal saline.
62399955|NCT03774069|EXPERIMENTAL|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor pro.
62576613|NCT04090099|NO_INTERVENTION|Group C|PCA (Patient controlled analgesia) and morphine consumption will be monitored in the postoperative period.
62576614|NCT04090099|ACTIVE_COMPARATOR|Group ES (Erector Spina Plane)|A high frequency (10-18 MHz) ultrasound linear probe covered with a sterile sheath will be placed 2 cm to the side of the T5 spinous process, first to the right or left. After demonstrating the T5 transverse process and the erector spinae muscle on top, the 22-gauge, 80 mm insulated Quincke-type needle will be inserted into the skin at an angle of about 30 degrees from the cranial to the caudal, using an in-plane technique. When the transverse process is touched, the needle is withdrawn and after a negative aspiration test with 0.5 mL of normal saline and after a hypo-echogenic display and hydrodissection, a local anesthetic solution will be applied to the fascia under the erector spinae muscle. A dose of 0.25% bupivacaine will be injected which is shown to spread both above and below the T5 level. The same process will be implemented on the other side.
62734769|NCT05143905|EXPERIMENTAL|Cohort 1: AZD7503 dose 1|Randomised healthy participants will receive a single dose 1 of AZD7503.
62783370|NCT01564732|ACTIVE_COMPARATOR|Standard-LAGB|Subjects will be blinded and randomly assigned to the Standard Laparoscopic Gastric Banding(SLAGB)arm of the study. These subjects will receive the standard of care or standard laparoscopic gastric banding surgery.Subjects will be followed for a period of approximately 36 months.
61978270|NCT01904682|EXPERIMENTAL|Oral rigosertib|Patients will take 560 mg oral rigosertib (two 280 mg capsules) in the morning and 280 mg (one 280 mg capsule) in the afternoon, in fasting conditions, for 21 consecutive days of 21-day cycle (continuous regimen).
62197902|NCT03591484|EXPERIMENTAL|G2 healthy older/dentures|Treatment with Photodynamic therapy (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
62197903|NCT03591484|ACTIVE_COMPARATOR|G3 dentate older bronchiectasis|Treatment with tongue scraper (n = 20). The dentate participants with bronchiectasis will received periodontal treatment. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
62197904|NCT03591484|ACTIVE_COMPARATOR|G4 older bronchiectasis /dentures|Treatment with tongue scraper (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
62197905|NCT02985359||Comparison district|Existing routine community health services by government
62197906|NCT02985359||Program district|In addition to existing routine community health services by the government, daily 20g Nutributter (Lipid-based Nutrient Supplement, LNS) will be provided to children 6 to 24 month of age and caregivers will participate in Social and Behavior Change Communications (SBCC) activities including the promotion of infant and young child feeding (IYCF) behaviors and water, sanitation and hygiene (WASH) behaviors will be conducted with caregivers.
62197907|NCT00416364||1|
62783371|NCT01564732|EXPERIMENTAL|Plicated-LAGB|"Subjects will be blinded and randomly assigned to the Plicated Laparoscopic Gastric Banding(PLAGB)arm of the study. These subjects will receive the plicated laparoscopic gastric banding surgery with involves the placement of plication sutures to anchor the redundant stomach around the newly placed device. Subjects will be followed for a period of approximately 36 months."
62197908|NCT00416364||2|
62197909|NCT00416364||3|
62197910|NCT00416364||4|
62197911|NCT02649205||Chronic kidney disease (pre-dialysis)|Observational study: Supplemented protein-restricted diet
62197912|NCT03120468|EXPERIMENTAL|Topiramate and N-Acetyl Cysteine|Drug: Topiramate and N-Acetyl Cysteine Other Name for Topiramate: Topamax
62197913|NCT03120468|EXPERIMENTAL|Topiramate and Placebo|Drug: Topiramate and Placebo Other Name for Topiramate: Topamax Other Name for Placebo: Sugar Pill
62197914|NCT01747551|ACTIVE_COMPARATOR|mFOLFOX6 + Ziv-aflibercept|Patients received mFOLFOX6 and ziv-aflibercept every 2 weeks. Ziv-aflibercept 4mg/kg was given via intravenous (IV) infusion over 1 hour. Immediately following this was administration of mFOLFOX6: oxaliplatin 85 mg/m2 IV and leucovorin 400 mg/m2 IV were given concurrently over 120 minutes, followed by fluorouracil 400 mg/m2 IV bolus injection and then fluorouracil 2,400 mg/m2 IV infusion over 46 hours. Patients continued on treatment until radiological or clinical progression, unacceptable toxicity, or death.
62197915|NCT01747551|ACTIVE_COMPARATOR|mFOLFOX6 + Placebo|Patients received mFOLFOX6 and placebo every 2 weeks. Placebo was given via intravenous (IV) infusion over 1 hour. Immediately following this was administration of mFOLFOX6: oxaliplatin 85 mg/m2 IV and leucovorin 400 mg/m2 IV were given concurrently over 120 minutes, followed by fluorouracil 400 mg/m2 IV bolus injection and then fluorouracil 2,400 mg/m2 IV infusion over 46 hours. Patients continued on treatment until radiological or clinical progression, unacceptable toxicity, or death.
62197916|NCT00916708|EXPERIMENTAL|Intensive follow up|Intensive follow up in low-risk patients Intensive follow up in high-risk patients
62197917|NCT00916708|EXPERIMENTAL|Minimalist follow up|Minimalist follow up in low-risk patients Minimalist follow up in high-risk patients
62197918|NCT00154687|EXPERIMENTAL|A|
62197919|NCT00769600|ACTIVE_COMPARATOR|Itraconazole with Pemetrexed|Pemetrexed IV every 21 days with oral Itraconazole 200mg daily.
62197920|NCT00769600|ACTIVE_COMPARATOR|Single agent pemetrexed|Pemetrexed IV on day 1 of 21-day cycle.
62197921|NCT03984513|EXPERIMENTAL|STRW|Participants will receive the daily living skills intervention, Surviving and Thriving in the Real World (STRW).
62197922|NCT03984513|ACTIVE_COMPARATOR|PEERS|Participants will receive a social skills intervention, Program for the Education and Enrichment of Relational Skills (PEERS).
62783372|NCT04999345|EXPERIMENTAL|Experimental Group|Provide resistance and aerobic exercise
62783373|NCT04999345|PLACEBO_COMPARATOR|Control Group|Health education and gross range of motion exercise for upper and lower extremities
62197923|NCT01475747||Observational - SPRINT trial subjects|Subjects in the Systolic Pressure Intervention Trial (SPRINT) observed to examine factors that affect atherosclerosis in chronic kidney disease
62197924|NCT01287325|EXPERIMENTAL|DNK333|
62197925|NCT01287325|PLACEBO_COMPARATOR|Placebo|
62197926|NCT04446611|EXPERIMENTAL|Test at 1st ANC + Test-of-Cure (Treatment 1)|Single point-in-time diagnostic screening plus test-of-cure three weeks post-treatment
62197927|NCT04446611|EXPERIMENTAL|Test at 1st ANC + 30-34 gestation (Treatment 2)|Repeated diagnostic screening at first antenatal care and 30-34 weeks gestation
62197928|NCT04446611|NO_INTERVENTION|Syndromic Management (Control)|Syndromic management (standard of care) at every antenatal care visit per South African National Guidelines.
62399956|NCT03774069|ACTIVE_COMPARATOR|Control group- medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted by the medical team
62399957|NCT03750058|EXPERIMENTAL|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
62783374|NCT05997212|EXPERIMENTAL|Active rTMS frequency at 10 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive treatment stimulation in the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 10 Hz, that includes 2 sessions per day for 20 consecutive business days for 4 weeks. Each session will consist of the application of rTMS at a frequency of 10 Hz, to 100% of the motor threshold. The lDLPFC target will be determined using their resting state functional connectivity between anterior cingulate cortex and lDLPFC. Our algorithm performs a calculation of the individual localization of the participant's lDLPFC, which will be used for the whole study in that particular participant.
62783375|NCT05997212|SHAM_COMPARATOR|Sham rTMS frequency at 10 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation (Sham). For this patients the coil will be located backwards to the skull. Each patient will receive sham stimulation in the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 10 Hz, that includes 2 sessions per day for 20 consecutive business days for 4 weeks. Each session will consist of the application of rTMS at a frequency of 10 Hz, to 100% of the motor threshold. The lDLPFC target will be determined using their resting state functional connectivity between anterior cingulate cortex and lDLPFC. Our algorithm performs a calculation of the individual localization of the participant's lDLPFC, which will be used for the whole study in that particular participant.
62399958|NCT01723358|EXPERIMENTAL|Neuromuscular electrical stimulation (NMES)|
62399959|NCT03076827|EXPERIMENTAL|Group A|Group to begin surgery(total hip replacement or hip hemi-arthroplasty) in the morning
62399960|NCT03076827|EXPERIMENTAL|Group P|Group to begin surgery(total hip replacement or hip hemi-arthroplasty) in the afternoon
62783376|NCT02123368|ACTIVE_COMPARATOR|Hialuronic acid|Single intraarticular injection of Hyaluronic acid (Hyal One)
62783377|NCT02123368|ACTIVE_COMPARATOR|Hyaluronic acid and MSC 10|Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells
62197929|NCT03882086|EXPERIMENTAL|foot reflexology group|The intervention group was comprised of 30 women in the early postpartum period. Pretest data were collected on the 14th day postpartum. Then a total of four reflexology sessions were applied for 15 minutes in each foot, in the afternoons, every other day between postpartum 14th-20th day, as the women were available. And posttest data were collected on the 20th day postpartum at the end of the four-reflexology sessions.
62783378|NCT02123368|ACTIVE_COMPARATOR|Hyaluronic acid AND MSC 100|Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells
62783379|NCT06525701|EXPERIMENTAL|Exercise Group|Participants randomized to the exercise group will be asked to perform the SCORE workout two times each week for 4 weeks prior to their urogynecology rotation and for 4 weeks during the rotation.
62783380|NCT06525701|ACTIVE_COMPARATOR|Control Group|No additional exercises or tasks are requested of control participants. Control group participants will perform or not perform exercise as they otherwise would outside of the study
62783381|NCT05034250||Women with infertility|The patient suffers from primary or secondary infertility, defined as the inability to conceive despite frequent unprotected sexual intercourse for at least 12 months.
62783382|NCT05034250||Women with recurrent miscarriage|The patient suffers from recurrent miscarriage, defined as three or more consecutive miscarriages before the 20th gestation week with the same partner.
62197930|NCT03882086|NO_INTERVENTION|standard care group no reflexology|The control group of this study was comprised of 30 women in the early postpartum period who had sleep problem and gave vaginal birth. Pretest data were collected on the 14th day postpartum. On the 20th day postpartum, the posttest data were assessed during home visits. These women only received routine postpartum care from public health nurses but did not access the reflexology
62197931|NCT03997175|EXPERIMENTAL|Intervention|The children were in daily contact with biodiversity sand 5 days a week for two weeks.
62197932|NCT03997175|PLACEBO_COMPARATOR|Placebo|Children were in contact with normal but colored sand that looked as it were the biodiversity sand. All the other details were as above.
62197933|NCT04746105|EXPERIMENTAL|TS-142|Period in which subjects received TS-142 10 mg or The night when subjects received TS-142
62783383|NCT05034250||Healthy controls|The woman does neither suffer from infertility/sterility nor from recurrent miscarriage and is also otherwise healthy with regular cycles.
62783384|NCT03981627|EXPERIMENTAL|Co-formulation of insulin analog and pramlintide (ADO09)|Subcutaneous injection of ADO09 formulation
62783385|NCT03981627|ACTIVE_COMPARATOR|NovoRapid®|Subcutaneous injection of insulin aspart
62783386|NCT02188654|EXPERIMENTAL|Metformin|500 mg metformin
62783387|NCT02188654|PLACEBO_COMPARATOR|Placebo|500 mg of placebo tablets
62783388|NCT05483517|EXPERIMENTAL|physiotherapy and high-PEMF|The patient receives physiotherapy under the physiotherapist's guidance and high-PEMF therapy for three weeks, following two sessions a week.
62783389|NCT05483517|SHAM_COMPARATOR|physiotherapy and sham high-PEMF|The patient receives physiotherapy under the physiotherapist's guidance and sham high-PEMF therapy for three weeks, following two sessions a week.
62783390|NCT01076387|ACTIVE_COMPARATOR|open radical cystectomy|This is a prospective, randomized study designed to compare two techniques of radical cystectomy with PLND (open and robotic) for bladder cancer.
62783391|NCT01076387|ACTIVE_COMPARATOR|robotic-assisted radical cystectomy|This is a prospective, randomized study designed to compare two techniques of radical cystectomy with PLND (open and robotic) for bladder cancer.
62783392|NCT00418574|EXPERIMENTAL|Abagovomab|
62783393|NCT00418574|PLACEBO_COMPARATOR|Placebo|
62783394|NCT02108314|NO_INTERVENTION|Control Group|Participants in the control arm were blinded as to the hypothesis of the study, undergoing a series of questions in about general health behaviours before their consultation, allowing the investigators to determine eligibility for the study. The associated participant information sheets for the control arm did not specifically mention breast cancer screening, maintaining blinding throughout. There was no reminder to the physician to promote mammography to participants. The physician continued with his or her usual counseling on health screening and mammography, if any. A 3-minute health promotion video by the Singapore Heart Foundation on healthy eating habits was administered to each participant, followed by a post-consultation questionnaire. The entire process took approximately 10 minutes.
62783395|NCT02108314|ACTIVE_COMPARATOR|Video Screening and Counselling|The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
61978271|NCT03273192|EXPERIMENTAL|CinnaGen adalimumab|CinnoRA® (adalimumab auto-injector devices produced by CinnaGen Company) 40 mg/0.8 ml in auto-injector devices A single 40-mg dose of Adalimumab was subcutaneously administered to healthy subjects.
62197934|NCT04746105|EXPERIMENTAL|Placebo|Period in which subjects received placebo or The night when subjects received matched placebo
62197935|NCT01128270|EXPERIMENTAL|1A: Chloral Hydrate and DCA: Env|Subjects consume Chloral Hydrate 1.5ug/kg by mouth for 5 nights. On the 6th day they consume DCA 2.5ug/kg by mouth and have blood samples drawn. (Period 1)
62197936|NCT01128270|EXPERIMENTAL|1B: Chloral Hydrate Env dose|Drug Study Subjects are admitted to the clinical research unit and receive 1.5 ug/kg (environmental dose) of Chloral Hydrate for 5 nights. Pharmacokinetics are done on days 1 and day 5. (Period 2)
62197937|NCT01128270|EXPERIMENTAL|2A: Chloral Hydrate and DCA therapeutic|Drug Study Subjects are admitted to the clinical research center and receive a clinical dose of Chloral Hydrate for 5 nights (25mg/kg). On day 6 they are given a clinical dose (25mg/kg)of Dichloroacetate. (Period 3)
62197938|NCT01128270|EXPERIMENTAL|2B: Chloral Hydrate Therapeutic|Subjects are given 25 mg/kg of Chloral Hydrate for five nights. Pharmacokinetics are done on days 1 and 5. (Period 4)
62197939|NCT04837339|OTHER|Patients with lung disease requiring transplantation or who have undergone lung transplantation|There is no intervention to be administered.
62197940|NCT03572881|EXPERIMENTAL|Asymptomatic|
62197941|NCT03572881|EXPERIMENTAL|Symptomatic|
62197942|NCT04011488|NO_INTERVENTION|Standard patient information data sheet|
62010770|NCT06662656||1μg/ kg group|Administration method of sufentanil: the dose of the first patient is 1μg / kg, and the ratio between adjacent doses is 1.2. ( IOC2 values of \< 60, which were the target of this study, indicate adequate analgesic efect and analgesic level for regional surgery. IOC2 values of ≥ 60 indicate inadequate use of analgesics. If the analgesic effect of this patient is satisfactory, the next patient will use the lower dose. If the analgesic efect of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
62010771|NCT06662656||0.83μg/ kg group|Administration method of sufentanil: the dose of the first patient is 1μg / kg, and the ratio between adjacent doses is 1.2. 1/1.2=0.833 ( IOC2 values of \< 60, which were the target of this study, indicate adequate analgesic efect and analgesic level for regional surgery. IOC2 values of ≥ 60 indicate inadequate use of analgesics. If the analgesic effect of this patient is satisfactory, the next patient will use the lower dose. If the analgesic efect of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
62010772|NCT06662656||0.69μg/ kg group|Administration method of sufentanil: the dose of the first patient is 1μg / kg, and the ratio between adjacent doses is 1.2. 0.833/1.2=0.694( IOC2 values of \< 60, which were the target of this study, indicate adequate analgesic efect and analgesic level for regional surgery. IOC2 values of ≥ 60 indicate inadequate use of analgesics. If the analgesic effect of this patient is satisfactory, the next patient will use the lower dose. If the analgesic efect of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
62197943|NCT04011488|EXPERIMENTAL|SDM Tool|A simple, one-page tool that provides a framework for the patient discussion, which improves the consistency of the patient-provider communication. This SDM can also be customized to a specific patient based on gender, race/ethnicity, age, and select comorbidities (obesity, hypertension and diabetes).
62197944|NCT02792595|SHAM_COMPARATOR|Negative Control|Untreated area will be irradiated using a sun simulator with UV irradiation increment of 1.25 to detect MED of the unprotected skin.
62197945|NCT02792595|ACTIVE_COMPARATOR|Positive Control|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, positive control will be applied. The dose of positive control will be measured in accordance to the application volume (2 milligram (mg)/centimeter (cm)\^2 (± 0.05 mg/cm\^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Positive control will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 seconds (s). After waiting for 15 to 30 minutes (min), the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the SPF of positive control, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
62197946|NCT02792595|EXPERIMENTAL|Test Product A|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm\^2 (± 0.05 mg/cm\^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
62197947|NCT02792595|EXPERIMENTAL|Test Product B|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm\^2 (± 0.05 mg/cm\^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
62576615|NCT04090099|ACTIVE_COMPARATOR|Group PS (Para Sternal Block)|Before the wire is inserted into the sternum, the sternotomy and mediastinal tube regions will be infiltrated with a mixture of bupivacaine and saline.
62576616|NCT02304861|ACTIVE_COMPARATOR|Viscoat group|Patients operated using Viscoat OVD
62576617|NCT02304861|ACTIVE_COMPARATOR|Visthesia group|Patients operated using Visthesia OVD
62734770|NCT05143905|EXPERIMENTAL|Cohort 2: AZD7503 dose 2|Randomised healthy participants will receive a single dose 2 of AZD7503.
62734771|NCT05143905|EXPERIMENTAL|Cohort 3: AZD7503 dose 3|Randomised healthy participants will receive a single dose 3 of AZD7503.
62783396|NCT03600532|EXPERIMENTAL|Teachable Moment Brief Intervention|The TMBI is informed by evidence based strategies to collaboratively identify 1) drivers of suicidal ideation, 2) functional aspects of the recent suicide attempt, 3) the patient's relationship with the concept of suicide, 4) what has been lost and gained as a result of the suicide attempt, 5) short term management suicide prevention management strategies, and 6) documentation of factors to address in a suicide-specific treatment plan.
61978272|NCT03273192|ACTIVE_COMPARATOR|AbbVie adalimumab|Humira® (adalimumab auto-injector devices produced by AbbVie Company) 40 mg/0.8 ml in auto-injector devices A single 40-mg dose of Adalimumab was subcutaneously administered to healthy subjects.
61978273|NCT06257810|ACTIVE_COMPARATOR|Intervention Site|In the interventional sites, bioMérieux teams provided training to raise awareness of the diagnosis of dengue, chikungunya and malaria. In addition, a VIDAS instrument was installed and dengue and chikungunya diagnostic kits were supplied so that diagnosis could be carried out systematically for each patient included.
61978274|NCT06257810|PLACEBO_COMPARATOR|Control Site|In the control centres, only routine practices were observed.
62010773|NCT06662656||0.58μg/ kg group|Administration method of sufentanil: the dose of the first patient is 1μg / kg, and the ratio between adjacent doses is 1.2. 0.694/1.2=0.578( IOC2 values of \< 60, which were the target of this study, indicate adequate analgesic efect and analgesic level for regional surgery. IOC2 values of ≥ 60 indicate inadequate use of analgesics. If the analgesic effect of this patient is satisfactory, the next patient will use the lower dose. If the analgesic efect of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
62197948|NCT02792595|EXPERIMENTAL|Test Product C|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm\^2 (± 0.05 mg/cm\^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
62399961|NCT00912756|EXPERIMENTAL|1cilostazol|Cilostazol group: Treatment with cilostazol 200 mg/day BID (morning and evening) and aspirin at 100 mg/day will be started 3 to 7 days prior to EVT and continued until the end of the 2-year follow-up period.
62399962|NCT00912756|ACTIVE_COMPARATOR|2aspirin|Non-cilostazol group: Treatment with aspirin 100 mg/day will be started 3 to 7 days prior to EVT and continued until the end of the 2-year follow-up period.
62576618|NCT06122636|EXPERIMENTAL|Experimental group|An envelope with the same packaging, size, shape and color will be given, it will only differ from the placebo in that it will contain the active ingredient of the intervention which is Lactobacillus Rhamnosus GG, Lactobacillus casei, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium infantis and Lactobacillus bulgaricus.Experimental group
62576619|NCT06122636|PLACEBO_COMPARATOR|Placebo group|The placebo will be given in an envelope with the same packaging, size, shape and color of contents as the intervention of interest, except that the placebo will not contain the active ingredient of the intervention
62576620|NCT03714074|EXPERIMENTAL|PEEK abutment|PEEK abutment restored with PEEK superstructure
62576621|NCT03714074|EXPERIMENTAL|Zirconia abutment|zirconia abutment restored with PEEK superstructure
62576622|NCT00435708|NO_INTERVENTION|Low fruit and vegetables|Control - two or less portions fruit and vegetables/day
62576623|NCT00435708|EXPERIMENTAL|High fruit and vegetables|5 portions fruit and vegetables/day
62576624|NCT00937027|ACTIVE_COMPARATOR|Aminopterin one 1.0 mg tablet|
62783397|NCT03600532|NO_INTERVENTION|Treatment as Usual (TAU)|Usual care at Laureate Psychiatric Clinic and Hospital Adult Stabilization Unit who have attempted suicide involves psychiatric evaluation/treatment and ongoing medical stabilization. Patients will engage in usual care or a rest period before completing the post-assessment.
62783398|NCT03600532|NO_INTERVENTION|Community Control Group (CCG)|Patients will engage in a rest period before completing the post-assessment.
61978275|NCT05332340|EXPERIMENTAL|Healthy Patients|Healthy patients receiving topical application of BZ371A
61978276|NCT02853591|ACTIVE_COMPARATOR|Standard High Pressure (15mmHg)|Pneumoinsufflator mode and setting: standard at 15mmHg
62399963|NCT05842668|EXPERIMENTAL|ESWL Group|
62399964|NCT05842668|NO_INTERVENTION|Control Group|
62399965|NCT01321086|ACTIVE_COMPARATOR|Motivational Interviewing|Motivational Interviewing (MI) is an effective counseling method in individuals who are less ready to change their behavior. 9 MI sessions will be conducted over the course of the six month intervention.
62399966|NCT01321086|ACTIVE_COMPARATOR|PACE|Patient-centered Assessment and Counseling for Exercise (PACE) is a protocol that targets known modifiable determinants of behavior change to motivate participants to increase their physical activity (walking).
62399967|NCT01321086|NO_INTERVENTION|Control|
62399968|NCT03924570|EXPERIMENTAL|Intervention|This arm will receive training in the use of the IPASS package to improve communications during hands off.
62399969|NCT03924570|NO_INTERVENTION|Control|Until randomization this arm will continue running hands offs per usual care.
62399970|NCT02222701||Replacement|Composite resins with Alpha values for the marginal adaptation criteria were used as the positive control and were made with resin composite (Filtek Supreme, 3M ESPE), eith rubber dam isolation and the adhesive system L-Pop Prompt (3M-ESPE)
62399971|NCT02222701||No treatment|Composite resin restorations (Z100, 3M ESPE) in general clinically acceptable, did not receive treatment.
62576625|NCT00937027|ACTIVE_COMPARATOR|Aminopterin 1 four 0.25 mg tablets|
62576626|NCT00704600|EXPERIMENTAL|nelfinavir|see intervention
62576627|NCT05993897|ACTIVE_COMPARATOR|Dapagliflozin|patients who will receive SGLT2 inhibitors
62576628|NCT05993897|PLACEBO_COMPARATOR|Placebo|Patients who will receive Rhythm control +/- oral anticoagulation
62576629|NCT05728827|EXPERIMENTAL|Anti-gravity treadmill + Blood Flow Restriction training|
62576630|NCT05728827|ACTIVE_COMPARATOR|Anti-gravity treadmill|
62576631|NCT01980459|EXPERIMENTAL|Magnesium Lactate|Patients will receive 2 tablets twice a day of Magnesium Lactate for 3 months.
62576632|NCT04252625|ACTIVE_COMPARATOR|Arm 1: Q-Urol|"Patients will be randomized in a 1:1 ratio to receive Q-Urol, two capsules, twice daily for 6 weeks after brachytherapy placement.~Questionnaires will be administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups will be compared."
62783399|NCT02110264|EXPERIMENTAL|Vivitrol (XR-NTX)|50 participants will be randomized to the long-acting naltrexone condition (XR-NTX) which will include monthly injections of study drug.
62783400|NCT02110264|EXPERIMENTAL|XR-NTX+PN|50 participants will be randomized to receive long-acting naltrexone (XR-NTX) and will be assigned to a patient navigator (PN).
62783401|NCT02110264|ACTIVE_COMPARATOR|ETAU|50 participants will be randomized to the drug-education/treatment-as-usual group.
62783402|NCT02249039|EXPERIMENTAL|intermittent IV CLON|Mechanically ventilated infants and children receive intravenous intermittentClonidine
62783403|NCT02361008|EXPERIMENTAL|TPDC group|Patients who matched inclusion criteria and randomly divided into TPDC group underwent the TEE-guided perventricular device closure without CBP. But of them,who underwent TPDC failure during the procedure would be dropped out of the trial.
62010774|NCT06662656||0.48μg/ kg group|Administration method of sufentanil: the dose of the first patient is 1μg / kg, and the ratio between adjacent doses is 1.2. 0.578/1.2=0.482( IOC2 values of \< 60, which were the target of this study, indicate adequate analgesic efect and analgesic level for regional surgery. IOC2 values of ≥ 60 indicate inadequate use of analgesics. If the analgesic effect of this patient is satisfactory, the next patient will use the lower dose. If the analgesic efect of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
62010775|NCT06662656||0.4μg/ kg group|Administration method of sufentanil: the dose of the first patient is 1μg / kg, and the ratio between adjacent doses is 1.2. 0.482/1.2=0.402( IOC2 values of \< 60, which were the target of this study, indicate adequate analgesic efect and analgesic level for regional surgery. IOC2 values of ≥ 60 indicate inadequate use of analgesics. If the analgesic effect of this patient is satisfactory, the next patient will use the lower dose. If the analgesic efect of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
62010776|NCT04901455|EXPERIMENTAL|COPD Frequent Exacerbators|Individuals with two or more episodes of worsening in COPD symptoms requiring treatment with antibiotics and/or steroids in the prior 12 months
62783404|NCT02361008|EXPERIMENTAL|SR group|Patients who matched inclusion criteria and randomly assigned into SR group underwent the surgery repair with CBP.
61978277|NCT02853591|EXPERIMENTAL|AirSeal High Pressure (15mmHg)|Pneumoinsufflator mode and setting: pressure-barrier at 15mmHg
62010777|NCT04901455|EXPERIMENTAL|COPD Infrequent Exacerbators|Individuals with less than two episodes of worsening in COPD symptoms requiring treatment with antibiotics and/or steroids in the prior 12 months
62010778|NCT04901455|EXPERIMENTAL|Healthy Control|Individuals with spirometry-confirmed normal lung function and no asthma history
62010779|NCT06222255|NO_INTERVENTION|Loperamide group|The group only takes loperamide in the evening.
62010780|NCT06222255|EXPERIMENTAL|Loperamide + Transanal irirgation group|The group takes Loperamide in the evening and undergoes Transanal irrigation before bedtime.
62010781|NCT00785226|EXPERIMENTAL|RDEA119 with Sorafenib|Total daily doses of RDEA119 from 10 mg/day to 100 mg/day and sorafenib from 400 mg/day to 800 mg/day.
62010782|NCT04136834|EXPERIMENTAL|Pegtomarginase (PT01)|To determine the MTD of PT01 based on the toxicity observed during Cycle 1 of the Dose Escalation Phase and to investigate the safety and tolerability of PT01 when administered intravenously(IV) to subjects with advanced malignancies
62010783|NCT00941733|EXPERIMENTAL|Drug Eluting Balloon|Intervention: IN.PACT Amphirion™
62010784|NCT00941733|ACTIVE_COMPARATOR|Standard PTA|Intervention: Standard PTA
62010785|NCT05832034|EXPERIMENTAL|Add-on IVIg|Patients in the intervention arm will be treated with Nanogam® in a dosage of 2 g/kg over 2-5 days, with a maximum of 80 g/day and a total of 180 gram at baseline and after 4 and 8 weeks. Nanogam® contains 100 mg/mL normal human immunoglobulin with a purity of at least 95% IgG and a maximum of 12 microgram/mL IgA, in a solution of water for injections and glucose. The first 30 grams are administered in hospital.
62010786|NCT05832034|PLACEBO_COMPARATOR|Placebo|Patients in the control arm will be treated with placebo infusions, containing sodium chloride 0.9%, at baseline and after 4 and 8 weeks. The first 30 grams are administered at the neurology ward, after 4 and 8 weeks infusions will be administered at home
62010787|NCT02472665|EXPERIMENTAL|plasma-derived FVIII/VWF concentrate|Pharmacokinetic single dose study with Fanhdi (high-purity Von Willebrand containing FVIII concentrate)
62010788|NCT01792661|ACTIVE_COMPARATOR|MyChart|The control group receives standard Cleveland Clinic care and has access to MyChart which is the standard Cleveland Clinic electronic PHR.
62010789|NCT01792661|ACTIVE_COMPARATOR|Enhanced MyChart|The enhanced PHR functionality adds the ability to securely receive and review CKD-education related messages to the existing features available to all PHR users. The CKD-educational related messages can be automatically delivered at pre-defined intervals and customized for each individual patient at their discretion and convenience.
62010790|NCT01792661|ACTIVE_COMPARATOR|Patient Navigator|A tracking log is kept by the Patient Navigator of each interaction regarding type of encounter, length of encounter, barriers addressed, and actions that occurred, adapting what is in use for the NIH-funded Patient Navigator program.
62010791|NCT01792661|ACTIVE_COMPARATOR|Patient Navigator and Enhanced MyChart|Combines patient self empowerment, regarding their CKD, with the Enhanced MyChart along with the aid and direction of a Patient Navigator.
62010792|NCT02053727|ACTIVE_COMPARATOR|Abatacept Arm|This arm of study subjects will receive 125 mg subcutaneous abatacept during the 24 week double blind period.
62576633|NCT04252625|PLACEBO_COMPARATOR|Arm 2: Placebo|"Patients will be randomized in a 1:1 ratio to receive Placebo, two capsules, twice daily for 6 weeks after brachytherapy placement.~Questionnaires will be administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups will be compared."
62783405|NCT00682955|ACTIVE_COMPARATOR|B|This group has been given Zinc Sulphate in Suspension Form.
62783406|NCT00682955|ACTIVE_COMPARATOR|A|This group has been given Tablets of Zinc Sulphate.
62783407|NCT01549119|EXPERIMENTAL|Low dose VAC-3S|
62010793|NCT02053727|PLACEBO_COMPARATOR|Placebo Arm|This arm of study patients will receive matching placebo injections during the 24 week double blind period.
62197949|NCT02792595|EXPERIMENTAL|Test Product D|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm\^2 (± 0.05 mg/cm\^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
62399972|NCT02222701||Refurbishing|For this group, The dentists finished the occlusal, lingual or facial surfaces of defective RBC restorations with the medium series of aluminum oxide disks (Sof-Lex,3M ESPE) or carbide burs (12 and 30 blades,Brasseler USA, Dental Instrumentation,Savannah, Ga.) and then polished them with afine series of aluminum oxide disks (Sof-Lex, 3M ESPE) and diamond-impregnated composite polisher (ComposiPro Diacomp, Brasseler). For restorations in which proximal surface areas were affected, the clinicians smoothed them with interproximal aluminum oxide finishing strips (Sof-Lex Finishing Strips, 3M ESPE).
62399973|NCT00066573|EXPERIMENTAL|Exemestane|Patients receive oral exemestane (25 mg) once daily for 5 years.
62783408|NCT01549119|EXPERIMENTAL|Medium dose VAC-3S|
62783409|NCT01549119|EXPERIMENTAL|High dose VAC-3S|
62010794|NCT06515470|EXPERIMENTAL|BTX-9341 (Part A)|BTX-9341 capsule(s) administered orally once daily (QD) in 28-day cycles
62010795|NCT06515470|EXPERIMENTAL|BTX-9341 + fulvestrant (Part A)|BTX-9341 capsule(s) administered orally QD in 28-day cycles and fulvestrant intermuscular injections on Day 15 and then once every 28 days
62010796|NCT06515470|EXPERIMENTAL|BTX-9341 + fulvestrant (Part B)|BTX-9341 capsule(s) administered orally QD in 28-day cycles and fulvestrant intermuscular injections on Day 15 and then once every 28 days
62399974|NCT00066573|ACTIVE_COMPARATOR|Anastrozole|Patients receive oral anastrozole (1 mg) once daily for 5 years.
62399975|NCT04001374||Ticagrelor|Ticagrelor 90mg tablet bid for 12 months
61978278|NCT02853591|EXPERIMENTAL|Standard Low Pressure (9mmHg)|Pneumoinsufflator mode and setting: standard at 9mmHg
62010797|NCT05811104|EXPERIMENTAL|Active stimulation|Bilateral real TBS
62010798|NCT05811104|SHAM_COMPARATOR|Sham stimulation|Bilateral Sham stimulation
62399976|NCT04001374||Ticagrelor + ASA|Ticagrelor 90mg tablet bid for 12 months and enteric coated aspirin 81mg-100mg daily p.o. for 12 months
62399977|NCT01584193|EXPERIMENTAL|US-guided subclavian vein puncture|
62399978|NCT01584193|ACTIVE_COMPARATOR|Cephalic vein dissection|
62399979|NCT03294811|EXPERIMENTAL|Telemonitoring group|Recieve a smartphone with an application to coach them, a blood pressure monitor and scale.
62399980|NCT03294811|NO_INTERVENTION|Control group|Control group (usual care, without telemonitoring)
62576634|NCT02315404|PLACEBO_COMPARATOR|No cap|enteroscopy performed without a cap
62783410|NCT01549119|PLACEBO_COMPARATOR|Placebo|
62783411|NCT01549119|EXPERIMENTAL|Double-dose VAC-3S|
62783412|NCT03743701|ACTIVE_COMPARATOR|Transrectal ultrasound in В-mode|
62783413|NCT03743701|EXPERIMENTAL|Transrectal ultrasound examination using three-di|
62783414|NCT05316506|OTHER|Anticipated Discomfort Group|Participants will be prompted using anticipated discomfort language during the standard of care hysteroscopy.
62783415|NCT05316506|OTHER|Objective Description Group|Participants will be prompted using objective description language during the standard of care hysteroscopy.
62783416|NCT02545244|EXPERIMENTAL|Black Tea|0.5% Black Tea as Mouthwash, 5mL to be used twice daily for 30 seconds undiluted.
62783417|NCT02545244|ACTIVE_COMPARATOR|Green Tea|0.5% Green Tea as Mouthwash, 5mL to be used twice daily for 30 seconds undiluted.
62783418|NCT02545244|ACTIVE_COMPARATOR|Chlorhexidine|0.12% Chlorhexidine Mouthwash 5mL to be used twice daily.
62783419|NCT03405818|EXPERIMENTAL|Tavaborole 5% Topical Solution|All study participants apply study drug
62783420|NCT00483938|EXPERIMENTAL|Pegylated-interferon Alfa-2a + Ribavirin (Group A)|Participants with HCV RNA levels greater than (\>) 15 international units per milliliter (IU/mL) at Week 4, HCV RNA greater than or equal to (\>=) 15 IU/mL at Week 8, and either HCV RNA less than (\<) 15 IU/mL or \>=2 times logarithmic (2 log10) drop at Week 12, will receive pegylated-interferon alfa-2a (Pegasys) 180 micrograms (mcg) subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 milligrams (mg) orally daily for 48 weeks.
62783421|NCT00483938|EXPERIMENTAL|Pegylated-interferon Alfa-2a + Ribavirin (Group B)|Participants with HCV RNA levels \>15 IU/mL at Week 4, HCV RNA \>=15 IU/mL at Week 8, and either HCV RNA \<15 IU/mL or \>=2 log10 drop at Week 12, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 72 weeks, and ribavirin 1000 to 1400 mg orally daily for 72 weeks.
62783422|NCT00483938|EXPERIMENTAL|Pegylated-interferon Alfa-2a + Ribavirin (Group C)|Participants with HCV-RNA levels \>15 IU/mL at Week 4, and HCV-RNA \<15 IU/mL at Week 8, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 36 weeks, and ribavirin 1000 to 1400 mg orally daily for 36 weeks.
62783423|NCT00483938|EXPERIMENTAL|Pegylated-interferon Alfa-2a + Ribavirin (Group D)|Participants with HCV-RNA levels \>15 IU/mL at Week 4, and HCV-RNA \<15 IU/mL at Week 8, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
62783424|NCT00483938|EXPERIMENTAL|Pegylated-interferon Alfa-2a + Ribavirin (Group E)|Participants with HCV-RNA levels \<15 IU/mL at Week 4, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 24 weeks, and ribavirin 1000 to 1400 mg orally daily for 24 weeks.
62783425|NCT00483938|EXPERIMENTAL|Pegylated-interferon Alfa-2a + Ribavirin (Group F)|Participants with HCV-RNA levels \<15 IU/mL at Week 4, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
62197950|NCT02792595|EXPERIMENTAL|Test Product E|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm\^2 (± 0.05 mg/cm\^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
62197951|NCT02792595|EXPERIMENTAL|Test Product F|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm\^2 (± 0.05 mg/cm\^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
62197952|NCT02792595|EXPERIMENTAL|Test Product G|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm\^2 (± 0.05 mg/cm\^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
62197953|NCT02792595|EXPERIMENTAL|Test Product H|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm\^2 (± 0.05 mg/cm\^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
62576635|NCT02315404|ACTIVE_COMPARATOR|Enteroscopy with a cap|Enteroscopy performed with a CAP fitted to the end of the scope
62576636|NCT01583309|NO_INTERVENTION|low-flux hemodialysis|
62576637|NCT01583309|EXPERIMENTAL|online pre-dilution hemofiltration|
62576638|NCT01583309|EXPERIMENTAL|online pre-dilution hemodiafiltration|
62576639|NCT05159375|EXPERIMENTAL|Elio (supplement under investigation)|2.4g of Elio administered orally daily with the first meal of the day for a 17 day period
62576640|NCT05159375|PLACEBO_COMPARATOR|Placebo|2.4g of SMCC administered orally daily with the first meal of the day for a 17 day period
62576641|NCT02965729|ACTIVE_COMPARATOR|No Pedometer|Participants only participated in the family-based weight management intervention. Participants were not given a pedometer or step goals.
62576642|NCT02965729|ACTIVE_COMPARATOR|Pedometer Only|In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. No step goals were provided.
62576643|NCT02965729|ACTIVE_COMPARATOR|Pedometer Plus Step Goals|In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. Participants were given individualized step goals to increase their activity by 500 steps each week (above baseline calculated as average daily steps/day during week 1).
62576644|NCT02095691|EXPERIMENTAL|Resistant Hypertension|The Celsius® ThermoCool® Renal Denervation catheter will serve to treat resistant hypertension.
62783426|NCT00483938|EXPERIMENTAL|Pegylated-interferon Alfa-2a + Ribavirin (Group NR)|Participants who do not have any change in HCV-RNA levels at Weeks 4, 8, and 12 will not be randomized (NR) to any of the other groups. Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
62576645|NCT01985529|EXPERIMENTAL|Exercise|Enrollment in pulmonary rehabilitation
62783427|NCT02422849|OTHER|own GP|The patient is cared for by own General Practitioner in the acute stage
62783428|NCT02422849|OTHER|Hospital specialist|The patient is cared for by a hospital specialist in the acute stage
62783429|NCT01397942|EXPERIMENTAL|Diet intervention - Ancient vegatables|A healthy Nordic diet with high content of bitter strong tasting vegetables and cabbages.
62783430|NCT01397942|NO_INTERVENTION|Control Nordic diet|A diet habitually consumed in the Nordic countries
62783431|NCT01397942|EXPERIMENTAL|Diet intervention - Modern Vegetables|A healthy Nordic diet with high content of sweet and mild tasting vegetables and cabbages.
62783432|NCT02567565||cataract patients|cataract patients undergoing phacoemulsification
62576646|NCT01985529|NO_INTERVENTION|Control|
62197954|NCT04530578|EXPERIMENTAL|NEBULIZED HEPARIN|"Nebulized Heparin (UNF)5000 IU in Saline Solution1 ml every 8 hours plus Enoxaparine 40mg /d or 60mg/d, adjusted by BMI and calculated creatinine clearance .~Device to nebulize without producing aerosolization:~To nebulized heparin we have a modified a fullface snorkel mask, in which instead of the discharge valve a connector for the Venturi has been placed, and in the air outlet / inlet of the snorkel it has been adapted a connector made with 3D printing for the insertion of a disposable antiviral filter (filters commonly used in Mechanical Respiratory Assistance devices).~The mask is made of materials that allow its sterilization with the STERRAT Hydrogen Peroxide plasma system, available at the institution."
62197955|NCT04530578|ACTIVE_COMPARATOR|Enoxaparine|Enoxaparin 40mg/d or 60mg/d adjusted by BMI and calculated creatinine clearance
62576647|NCT02132182||Patients newly diagnosed with osteosarcoma|Blood draw
62576648|NCT02483039|EXPERIMENTAL|AKI Follow-up Clinic|Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. The target appointment date is within 30 days of hospital discharge. Routine laboratory investigations will be performed at minimum every three months. Additional in-person visits with a nephrologist at the AKI Follow-up Clinic will be determined at the local sites based upon the participant's clinical status. If in-person visits at 12, 24, and/or 36 weeks are not necessary given the patient's clinical status, they may be replaced with a telephone visit
62576649|NCT02483039|NO_INTERVENTION|Usual Care|Participants randomized to this arm will have a letter outlining their AKI diagnosis mailed to their family physician. Participants may still be referred to a nephrologist by their inpatient or outpatient healthcare provider, but these participants will not have access to the AKI Follow-up Clinic. Rather, they will proceed through the standard local nephrology referral pathway. In addition, all usual care participants will be contacted via telephone by study staff every three months to assess their clinical condition and ensure study engagement. All usual care participants will be offered a nephrologist assessment and/or bloodwork one year after randomization to determine if ongoing nephrology care is indicated based upon the same criteria applied to AKI Follow-up Clinic participants.
62576650|NCT03857217||Post-cardiotomy patients|Patients submitted to cardiac surgery
62783433|NCT04866901|EXPERIMENTAL|Slow-Paced Breathing (SPB)|Participants will first be provided with a brief overview of the science of breathing and benefits for autonomic regulation. Then, participants will receive specific practice instruction and guided breathing at a rhythm of 6 breaths/min (4-6 count) via auditory tones. Each participant will be encouraged to breathe as comfortably and effortlessly as possible, while keeping the lungs moving in accordance with the audio guidance. The accompanying training and daily instruction reminder will emphasize the importance of following the specific rhythm of breathing, without regard to thoughts or inner experience. A soft but firm tone of voice will be employed to minimize likelihood of relaxing effects, while maintaining similarity to the tone of voice used in the other conditions.
62197956|NCT03406078|EXPERIMENTAL|Tezepelumab|Tezepelumab subcutaneous injection
62197957|NCT03406078|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection
62197958|NCT00078338|EXPERIMENTAL|Rebif®|
62197959|NCT00078338|ACTIVE_COMPARATOR|Copaxone®|
62197960|NCT00555529||1|
62197961|NCT00555529||2|
62576651|NCT02641626|EXPERIMENTAL|Urgent Coronary Angiography|Urgent Coronary Angiography: as soon as possible, when the patient is randomized.
62576652|NCT02641626|ACTIVE_COMPARATOR|Deferred coronariography|Deferred coronary angiography: after extubation if the patient has a good neurologic prognosis.
62576653|NCT03892395|ACTIVE_COMPARATOR|Treatment group|"Supplementation for 2 years with one of the following treatments in capsule form:~Treatment group will receive: B vitamins + vitamin D, a daily capsule containing 200 µg/day folic acid, 10 µg/day vitamin B12, 10 mg/day vitamin B6 and 5 mg/day riboflavin, and 10 µg/day vitamin D combined"
62576654|NCT03892395|PLACEBO_COMPARATOR|Control group|"Supplementation for 2 years with one of the following treatments in capsule form:~Control group will receive: Vitamin D, a daily capsule containing 10 µg/day vitamin D"
62576655|NCT04514458|EXPERIMENTAL|EHR-based alert|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
62576656|NCT04514458|NO_INTERVENTION|Usual Care|Providers will not receive an alert and will proceed with usual care.
62734772|NCT05143905|EXPERIMENTAL|Cohort 4: AZD7503 dose 4|Randomised healthy participants will receive a single dose 4 of AZD7503.
61978279|NCT02853591|EXPERIMENTAL|AirSeal Low Pressure (9mmHg)|Pneumoinsufflator mode and setting: pressure-barrier at 9 mmHg
62197962|NCT03430544|PLACEBO_COMPARATOR|Placebo|
62197963|NCT03430544|EXPERIMENTAL|1.5 mg/d cariprazine|
62197964|NCT03430544|EXPERIMENTAL|3.0 mg/d cariprazine|
62399981|NCT05853276|EXPERIMENTAL|Intervention group|This group downloads and uses Brush DJ app. Reminders are sent through this app to brush their teeth and along with this oral hygiene instructions are also given.
62197965|NCT06277505|EXPERIMENTAL|Prebiotics and probiotics，life-style|Take 3.5g prebiotic +2g probiotic twice a day before meals; At the same time, lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise
62197966|NCT06277505|OTHER|life-style|lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise
62576657|NCT02842580|ACTIVE_COMPARATOR|Standard arm (escalation strategy - arm A)|LV5FU2 (5 FLUOROURACYL)+avastin. After progression: FOLFIRI + avastin. after the 2nd progression:FOLFOX4 (eloxatine)+ avastin.
62576658|NCT02842580|EXPERIMENTAL|Experimental arm (de-escalation strategy -arm B)|(4 cycles of FOLFOXIRI (campto) + avastin and 4 cycles of FOLFIRI + avastin) is followed by maintenance with capecitabine
62576659|NCT03937895|EXPERIMENTAL|Experimental: single arm|"* Biological: 'SMT-NK' Inj. (allogeneic Natural Killer cell) weekly administration for 2 weeks. After that, 1 week is a withdrawal period. (Phase 1: up to \*cycle 3, Phase 2a: up to cycle 9)~* Drug: Pembrolizumab administration of Pembrolizumab 200mg/m2 at first week during cycle.~  * Cycle: 1 cycle is 3 weeks in total.'SMT-NK' Inj is administered at first and second week, and Pembrolizumab is administered at first week. The third week is a withdrawal period."
62576660|NCT03273413|PLACEBO_COMPARATOR|Placebo|Participants will receive inactive 40 mg tablets of placebo everyday for 6 weeks. If well tolerated, participants will continue taking inactive 40 mg dose of placebo everyday for 2 years.
62576661|NCT03273413|ACTIVE_COMPARATOR|Pravastatin|Participants will receive 40 mg tablets of pravastatin everyday for 6 weeks. If well tolerated, participants will continue taking 40 mg dose of pravastatin everyday for 2 years.
62576662|NCT00610155|PLACEBO_COMPARATOR|1|
62197967|NCT01031628|ACTIVE_COMPARATOR|Arm A|Patients with blood level less than 1100 will continue imatinib 400 mg daily
62197968|NCT01031628|ACTIVE_COMPARATOR|Arm B|Patients with blood level less than 1100 dose adjust imatinib mesylate to goal blood level ≥1100 ng/mL
62197969|NCT01031628|ACTIVE_COMPARATOR|Arm C|Patients with blood level ≥1100 will continue imatinib 400 mg daily
62197970|NCT01031628|ACTIVE_COMPARATOR|Arm D|Patients with tumors that harbor exon 9 mutations will continue imatinib mesylate at 400 mg or dose escalate up to 800 mg daily
62576663|NCT00610155|EXPERIMENTAL|2|
62576664|NCT00610155|EXPERIMENTAL|3|
62576665|NCT00942890|EXPERIMENTAL|NMES plus Standard Rehab Protocol|"NMES (EMPI 300PV stimulator) plus standard of care intervention. NMES is to the quadriceps muscle of the residual and intact limb plus rehabilitation. Therapy is 12-wks of NMES home training w/ the EMPI 300PV muscle stimulator. Participants perform training at home for 5days/wk; sessions consisted of 15 to 20 min. of NMES to each leg eliciting15 contractions/leg (10 seconds on:50 seconds off), plus a 5-minute patient treatment log, 5x/wk for 12-wks. Each contraction will be elicited by an electrical impulse generated by a battery-operated device. Two 3 X 5 electrodes are placed over the quadriceps muscle group. Participants will train at 30-40% of MVC during weeks 1-6, and 40-50% of MVC during weeks 7-12; incremental increases will be made at the study visits."
62197971|NCT03567629|EXPERIMENTAL|Irinotecan-based chemotherapy|
62734773|NCT05143905|EXPERIMENTAL|Cohort 5 : AZD7503 dose X|Randomised healthy participants will receive a single dose X of AZD7503.
62734774|NCT05143905|EXPERIMENTAL|Cohort 6: AZD7503 dose Y|Randomised healthy participants will receive a single dose Y of AZD7503.
62197972|NCT03567629|ACTIVE_COMPARATOR|Oxaliplatin-based chemotherapy|
62197973|NCT00597090||1|
62197974|NCT01362504||Clinical sepsis|
62197975|NCT01362504||Proven sepsis|
62197976|NCT01362504||Control group|healthy neonates
62197977|NCT06066502|EXPERIMENTAL|Precision ventilation|Ventilator support will be calibrated to maintain the range of lung stress typical of relaxed breathing in healthy adults. The ventilator management protocol takes into account pleural pressure, tidal volume and driving pressure, fraction of inspired oxygen (FiO2) and oxygen saturation (SpO2), and positive end-expiratory pressure (PEEP) titration.
62197978|NCT06066502|ACTIVE_COMPARATOR|Guided usual care|Ventilator support will be managed by the clinical team per usual care with select protocol-based guard rails to avoid practice extremes beyond the current body of evidence. PEEP titration will be performed by the clinical team within the limits set in. The allowable combinations of PEEP and FiO2 in the control arm reflect pre-intervention usual care observed at baseline in the recent large federally-funded multicenter ARDS trials.
62197979|NCT01269151|EXPERIMENTAL|Lucentis (Ranibizumab)|
62197980|NCT03917745|EXPERIMENTAL|eHealth mindfulness intervention group|8 weeks of internet mindfulness training
62734775|NCT05143905|PLACEBO_COMPARATOR|Pooled Placebo for AZD7503 (Cohorts 1 to 6)|Randomised healthy participants will receive placebo.
62576666|NCT00942890|ACTIVE_COMPARATOR|Standard Rehab Protocol|TMARP standard of care intervention: 12 weeks of the Traditional Military Amputee Rehabilitation Program (TMARP). TMARP training starts 1 week after surgical closure of the residual limb. Physical Therapy performs Pre-Prosthetic Training for about 6 weeks, preparing for the prosthetic. After pre-prosthetic training, patients are fitted with their prosthetic leg and began post-prosthetic training with PT. The training focus is lower limb prosthetic proficient in ambulation.
62197981|NCT03917745|NO_INTERVENTION|Control group|Care as usual
62576667|NCT01113385|EXPERIMENTAL|Galactose|Oral galactose will be given at a dose of 0.2gm/kg/dose twice a day (BID) to a maximum of 15 gm BID for a period of 16 weeks.
62576668|NCT03784742|ACTIVE_COMPARATOR|Nitrate-rich Beetroot juice|Nitrate-rich beetroot juice equivalent to 3.7 mg nitrate per kg body weight daily for 8 weeks.
62576669|NCT03784742|PLACEBO_COMPARATOR|Placebo beetroot juice|Placebo beetroot juice (equivalent volume to the amount of nitrate-rich beetroot juice consumed) daily for 8 weeks.
62576670|NCT03809780|EXPERIMENTAL|Lenalidomide,dexamethasone|"* High dose for intermediate risk group: lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly, every 4 weeks~* Low dose for high risk group: lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly, every 4 weeks Schedule"
62576671|NCT00894608|EXPERIMENTAL|letrozole protocol|patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
62576672|NCT00894608|EXPERIMENTAL|long GnRHa protocol|patients in long GnRHa protocol for ovarian stimulation with Gnrha and gonadotropins
62576673|NCT06152146|ACTIVE_COMPARATOR|SWT group|Participants randomized to the treatment group will receive nine (9) shockwave sessions in total: one (1) shockwave session once per week for four (4) weeks, followed by one (1) shockwave session once per month (30±7 days) for the next five (5) months. 1,440 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura) for a total of 12,960 shocks. Participants will be in this group for up to 6 months.
62576674|NCT06152146|PLACEBO_COMPARATOR|SHAM group|Participants randomized to the sham (control) group will have nine (9) sham therapy sessions in total: one (1) sham session once per week for four (4) weeks, followed by one (1) sham session once per month (30±7 days) for the next five (5) months. The shockwave machine will be set to deliver 1,440 shock treatments, but a barrier will be placed around the shockwave probe to ensure that no shockwaves are delivered. Participants will be in this group for up to 6 months.
62576675|NCT02480569|EXPERIMENTAL|Side-Hole Catheter|2 FFR measurements from an engaged side-hole guide catheter and a disengaged side-hole guide catheter
62576676|NCT02480569|EXPERIMENTAL|Non-Side-Hole Catheter|2 FFR measurements from an engaged non-side-hole guide catheter and a disengaged non-side-hole guide catheter
62734776|NCT05143905|EXPERIMENTAL|Japanese Cohort 1: AZD7503 dose 3|Randomised healthy Japanese participants will receive a single dose 3 of AZD7503.
62197982|NCT03193983|EXPERIMENTAL|Flaps Coverage|Surgical group will undergo surgical coverage of the fingertip defect by V-Y flap using the skin on the volar aspect of the same finger designed as V shaped then mobilized dorsally to cover the defect and stitches to be Y shaped. Stitches are removed after 2 weeks.
62197983|NCT03193983|EXPERIMENTAL|Occlusive Dressing|Conservative group will undergo minimal trimming of the bone end and an occlusive dressing that is changed on a weekly basis till complete healing of the defect that occurs after 6 weeks.
62399982|NCT05853276|NO_INTERVENTION|Control group|This group receives standard oral hygiene instructions
62399983|NCT00892710|EXPERIMENTAL|Pemetrexed/Bevacizumab|"* Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days~* Bevacizumab 15 mg/kg IV every 21 days"
62399984|NCT00892710|EXPERIMENTAL|Pemetrexed/Bevacizumab/Carboplatin|"* Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days~* Bevacizumab 15 mg/kg IV every 21 days~* Carboplatin AUC=5 IV every 21 days"
62399985|NCT00892710|EXPERIMENTAL|Pemetrexed|Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days
62399986|NCT03142282|ACTIVE_COMPARATOR|Maintenance chemotherapy|FDA approved drugs for the study population: Bevacizumab, Xeloda
62399987|NCT03142282|EXPERIMENTAL|Radiotherapy|consolidative radiotherapy plus maintenance chemotherapy
62399988|NCT04661917|EXPERIMENTAL|BAY2327949|Participants will receive 60 mg of BAY2327949 (2 tablets of 30 mg) once daily for 28 days.
62399989|NCT04661917|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo once daily for 28 days.
62399990|NCT01194076|EXPERIMENTAL|5day intensive treatment|
62399991|NCT02410057|ACTIVE_COMPARATOR|Standard infant formula|Standard infant formula
62399992|NCT02410057|EXPERIMENTAL|Protein-reduced whey formula|Protein-reduced whey formula with higher level of α-lactalbumin than in standard infant formula
62399993|NCT02410057|EXPERIMENTAL|Protein-reduced α-lactalbumin formula|Protein-reduced formula with level of α-lactalbumin more similar to breast milk and higher than in experimental whey formula and in standard infant formula
62399994|NCT02410057|NO_INTERVENTION|Breast-feeding|Exclusive breast-feeding
62399995|NCT05586789|EXPERIMENTAL|Ranquilon|Study drug Ranquilon, tablets, 1 mg, 2 tablets 3 times a day (daily dose - 6 mg/day), daily, for 28 days
62399996|NCT05586789|PLACEBO_COMPARATOR|Placebo|Placebo, tablets, 2 tablets 3 times a day, daily, for 28 days
62399997|NCT02582216|EXPERIMENTAL|Open label|3D augmented reality
62399998|NCT02695316|OTHER|Migrant Women|Focus Group Discussion in native Language with n=20
62399999|NCT02695316|OTHER|Health Care Professionals|Focus Group Discussion with n=20 Health Care Professionals
62400000|NCT02695316|OTHER|Interpreters|One-to-one Interviews with n=4 intercultural Interpreters
62197984|NCT03214770|EXPERIMENTAL|Light-cured calcium silicate|This biomaterial calcium silicate is manufactured to have an anti-bacterial effect on micro-organisms within the dentin, thus allowing the inhibition of bacterial growth therefore no caries will progress. Material is injected and light-cured within the dentin and sealed with a restoration.
62197985|NCT03214770|ACTIVE_COMPARATOR|Light-cured calcium hydroxide|This biomaterial calcium hydroxide is manufactured to have an anti-bacterial effect on micro-organisms within the dentin, thus allowing the inhibition of bacterial growth therefore no caries will progress. Material is injected and light-cured within the dentin and sealed with a restoration.
62197986|NCT05733182|ACTIVE_COMPARATOR|3000K|Participants will receive a reading lamp of colour temperature 3000K.
62197987|NCT05733182|ACTIVE_COMPARATOR|4500K|Participants will receive a reading lamp of colour temperature 4500K.
62197988|NCT05733182|ACTIVE_COMPARATOR|6500K|Participants will receive a reading lamp of colour temperature 6500K.
62400001|NCT02695316|OTHER|Telephone Interpreting Protocols|Retrospective quantitative analysis of n=50 Telephone Interpreting Protocols (questionnairs)
62197989|NCT05994638|EXPERIMENTAL|Aerosol for use in the oral cavity|Group of 10 patients with head and neck cancer who have undergone radiotherapy
62197990|NCT04962997||Transgender women|Major person identifying as a transgender women consulting at Cayenne Hospital (French Guiana) or Bichat Hospital (Paris) between 06/2021 and 10/2022
62197991|NCT03735472||Aneurysm/Dissection|Thoraflex™ Hybrid
62197992|NCT03907267|EXPERIMENTAL|Taurine|
62400002|NCT02700893|EXPERIMENTAL|Atropine + propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants \< 1000g - Renewable once 2.5 mg/kg for infants \> 1000G - Possible additional dose of 1 mg/kg
62783434|NCT04866901|EXPERIMENTAL|Mindfulness (M)|Procedures are based on Berghoff et al., providing a brief history of mindfulness practices, definitions, instructions for practice, common challenges, and recommendations. An audio recording will then guide the mindfulness practice. Specific to this study, in order to further distinguish the three conditions, the guided audio recording will emphasize the importance of attending to the quality of experience while not changing or attending to breathing patterns.
62783435|NCT04866901|EXPERIMENTAL|Yogic Breathing (SPB+M)|Information from the other two conditions will be synthesized with the aim of eliciting attention to the same breathing instruction used for SPB, while also observing the quality of experience during the practice, as conducted for M.
62783436|NCT02725229|ACTIVE_COMPARATOR|parasternal block group|Patients in this group will be randomized to receive an parasternal block and PCA.
62783437|NCT02725229|ACTIVE_COMPARATOR|TENS group|Patients in this group will be randomized to receive an TENS and PCA.
62783438|NCT02725229|ACTIVE_COMPARATOR|control group|Patients in this group will be randomized to receive an PCA.
62783439|NCT02547584|ACTIVE_COMPARATOR|Group 1: with baseline anxiety+catheter ablation|Baseline anxiety will be defined as; Cardiac Anxiety Questionnaire (CAQ) score \>2.14 Hospital Anxiety and Depression Questionnaire (HAD) \>7 State-Trait Anxiety Inventory (STAI): State-anxiety score \>40
62197993|NCT03907267|PLACEBO_COMPARATOR|Saline|
62197994|NCT04966026||COPD combined with CAP inpatients|(1) CAP meets the diagnostic criteria published in our 2016 CAP diagnosis and treatment guidelines; CPOPD and AECOPD meet the diagnostic criteria published in our 2013 COPD diagnosis and treatment guidelines; (2) age ≧ 18 years. Exclusion criteria: (1) age \<18 years; (2) pregnancy; (3) positive human immunodeficiency virus (HIV) antibody; (4) suspected or confirmed tuberculosis or fungal infection of the lung.
62400003|NCT02700893|ACTIVE_COMPARATOR|Atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
62400004|NCT03346109|EXPERIMENTAL|MRLN sparing group|Patients in medial group retropharyngeal node（MRLN） sparing group will not routinely receive MRLN irradiation to 56Gy/33Fr
62400005|NCT03346109|NO_INTERVENTION|MRLN prophylactic irradiation group|Patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr
62400006|NCT02311764|EXPERIMENTAL|Carboplatin|Carboplatin will be administered weekly
62400007|NCT06715709|OTHER|(1) dexamethasone administered intraoperatively at the time of anesthesia|(1) dexamethasone administered intraoperatively at the time of anesthesia
62400008|NCT06715709|EXPERIMENTAL|(2) dexamethasone administered intraoperatively and on the morning of the first postoperative day,|(2) dexamethasone administered intraoperatively and on the morning of the first postoperative day,
62576677|NCT04801680||Mpact 3d metal|Subjects, among those whose clinical condition makes them eligible for a primary total hip arthroplasty, will be invited to participate to the study during preoperative visit. The
62783440|NCT02547584|ACTIVE_COMPARATOR|Group 2: Without baseline anxiety + catheter ablation|Cardiac Anxiety Questionnaire (CAQ) score \<2.14 Hospital Anxiety and Depression Questionnaire (HAD) \<7 State-Trait Anxiety Inventory (STAI): State-anxiety score \<40
62197995|NCT05860829|EXPERIMENTAL|Caregivers of children with Autism Spectrum Disorder (ASD)|Arm includes only the caregivers of children with ASD. The knowledge of caregivers of children with ASD regarding oral and nutritional health and the burdens they encounter in dealing and caring for these children will be assessed. Then, educating caregivers on diet diversities, and effective oral health education, expecting from it to the eating habits and oral hygiene of children living with autism.
62197996|NCT02423889|EXPERIMENTAL|1|Stereotactic radiotherapy with a total dose of 36.25 Gy in 5 fractions (7.25 Gy per fraction, 2 fractions per week) in low risk prostate cancer patients is delivered to evaluate acute and subacute toxicty
62400009|NCT06715709|EXPERIMENTAL|(3) dexamethasone administered intraoperatively, the morning of the first& second postoperative day|(3) dexamethasone administered intraoperatively, the morning of the first postoperative day, and the morning of the second postoperative day.
62783441|NCT02597387|EXPERIMENTAL|Mitoxantrone HCL Liposome Injection|Each treatment cycle lasts for 28 days with 20mg/m2
62783442|NCT04382742|EXPERIMENTAL|Exercise|
62783443|NCT02822261|EXPERIMENTAL|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62400010|NCT04784676|EXPERIMENTAL|nanohybrid composite blocks|nanohybrid composite CAD/CAM blocks
62783444|NCT04481217|EXPERIMENTAL|Schizophrenia|Patients included will be diagnosed with schizophrenia or schizoaffective disorder, and experience AVH at the time of the inclusion (n= 350). All will be inpatients.
62783445|NCT02376023|EXPERIMENTAL|mHealth|Women in the mHealth group will receive text and voice messages, in addition to their habitual care from the health clinic they attend. The messages will remind them to schedule a PAP smear, and will be sent for 1 year following enrollment in the study.
62197997|NCT02530710|EXPERIMENTAL|Q203|Q203 drug products (10mg and 100mg tablets)
62400011|NCT04784676|ACTIVE_COMPARATOR|ceramic blocks|ceramic CAD/CAM blocks emax
62400012|NCT06069466||ARDS patient|
62400013|NCT03526627||patient with advanced heart failure|we included the patients with advanced heart failure who had the poor cardiac function(LVEF\<=30%) and was admitted to the general ward or emergency room within one year.
62400014|NCT02616341|EXPERIMENTAL|Team ERP (T-ERP) Intervention|The ERP team intervention (T-ERP) consists of 25 sessions over 20 weeks with four components: (a) 3-4 pretherapy individual session with therapist, (b) 12 weekly group sessions (90-mins) led by a therapist and, (c) 10 individual coaching sessions with a case manager during weeks 2-11 of the group, and (d) 2 booster group sessions to reinforce relapse prevention
62400015|NCT02616341|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Treatment as Usual (TAU) includes standard community treatment consisting of a personalized treatment plan and assistance with treatment referrals to available community resources
62576678|NCT04580134|EXPERIMENTAL|Biotype 1 - Clozapine (B1C)|Target doses will be up to clozapine 500mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol \[non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)\]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin \[up to 10mg at bedtime\], hydroxyzine \[up to 100mg at bedtime\]; benztropine \[up to 4mg/day (2mg twice/day)\], propranolol \[up to 40mg/day (20mg twice/day)\].
62734777|NCT05143905|EXPERIMENTAL|Japanese Cohort 2: AZD7503 dose 4|Randomised healthy Japanese participants will receive a single dose 4 of AZD7503.
62783446|NCT02376023|NO_INTERVENTION|No mHealth|Women in the No mHealth group will not receive any text messages, and will only receive their habitual care from the health clinic they attend.
62197998|NCT02530710|PLACEBO_COMPARATOR|Placebo|Placebo tablets (same excipients used in Q203 drug products)
62197999|NCT00945672|EXPERIMENTAL|PF-04360365 10 mg/kg|
62198000|NCT00945672|EXPERIMENTAL|PF-04360365 7.5 mg/kg|
62198001|NCT00945672|PLACEBO_COMPARATOR|placebo|
62198002|NCT04792476|ACTIVE_COMPARATOR|Active Comparator: Experimental group|The experimental group will receive, in addition to the conventional treatment, a physical exercise intervention along 12 weeks, which will consist of complying with the general recommendations for physical activity: 75 minutes weekly of high intensity physical exercise. The therapeutic exercise intervention will be supervised by a physiotherapist and designed in a progressive, structured and personalized way.
62400016|NCT00553670||1|Patients with elective coronary intervention for LAD-diagonal bifurcation lesion with provisional side branch intervention strategy with successful intravascular ultrasound and fractional flow reserve measurement
62576679|NCT04580134|PLACEBO_COMPARATOR|Biotype 1 - Risperidone (B1R)|Target doses will be up to risperidone 6mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol \[non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)\]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin \[up to 10mg at bedtime\], hydroxyzine \[up to 100mg at bedtime\]; benztropine \[up to 4mg/day (2mg twice/day)\], propranolol \[up to 40mg/day (20mg twice/day)\].
62198003|NCT04792476|NO_INTERVENTION|No Intervention: Control group|"The control group will only receive the conventional treatment offered in the clinical program. For 12 weeks, parients will attend 8 visits with mental health specialist nurse, where they will receive information, oral and written, to comply with the recommendations for physical exercise: 150-300 min/week of moderate physical activity or 75-150 min/week of vigorous physical activity.~In both groups (experimental and control), patients will be informed of the risk of weight gain, and they will be advised, regardless of the group assigned, to watch their diet and increase physical exercise until they meet the weekly recommendations."
62576680|NCT04580134|ACTIVE_COMPARATOR|Biotype 2 - Clozapine (B2C)|Target doses will be up to clozapine 500mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol \[non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)\]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin \[up to 10mg at bedtime\], hydroxyzine \[up to 100mg at bedtime\]; benztropine \[up to 4mg/day (2mg twice/day)\], propranolol \[up to 40mg/day (20mg twice/day)\].
62576681|NCT04580134|PLACEBO_COMPARATOR|Biotype 2 - Risperidone (B2R)|Target doses will be up to risperidone 6mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol \[non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)\]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin \[up to 10mg at bedtime\], hydroxyzine \[up to 100mg at bedtime\]; benztropine \[up to 4mg/day (2mg twice/day)\], propranolol \[up to 40mg/day (20mg twice/day
62576682|NCT00887315|ACTIVE_COMPARATOR|Group 1|Chemotherapy only
62576683|NCT00887315|ACTIVE_COMPARATOR|2|Chemotherapy and hypofractionated image guided radiotherapy
62576684|NCT03881189|EXPERIMENTAL|SUNEKOS ® 200|"The 1st intradermal treatment (T1i) with Sunekos ® 200 was carried out during the basal visit (T0), after basal evaluations planned by the study procedure, and then repeated 2 more times with an interval of 15 days (T2i and T3i)"
62576685|NCT01543035|EXPERIMENTAL|Etravirine switch|Patients in need of lipid-lowering drug switched from boosted PI or EFV to Etravirine
62576686|NCT05276375|ACTIVE_COMPARATOR|Bronchipret|Bronchipret syrup (3x 5,4 ml daily, according to summary of product characteristics) until day 14
62576687|NCT05276375|NO_INTERVENTION|standard of care|no study intervention
62576688|NCT06052202|EXPERIMENTAL|CRC mHealth intervention|Experimental group participants will have access to the CRC mHealth intervention.
62198004|NCT05120037|EXPERIMENTAL|Active|
62198005|NCT05120037|SHAM_COMPARATOR|Sham|
62198006|NCT01008553|EXPERIMENTAL|Fentanyl (Titration period)|One-day adhesive transdermal patch (patch containing a drug that is put on the skin so the drug will enter the body through the skin) containing fentanyl (JNS020QD) applied to chest, abdomen, upper arm and thigh and replaced every day, starting at the dose of 12.5 microgram per hour (mcg/hr) for at least first 2 days, which will be increased by 12.5 mcg/hr at one time based on the medical examination of number of rescue treatments and visual analog scale (VAS) score of the participants. The dose will be increased up to maximum of 50 mcg/hr. The treatment will continue for 10-29 days and then the eligible participants from this group will be randomly assigned to either of the two groups in the double-blind period.
62400017|NCT06514638||Study subjects|Helathy, 18-65 year old subjects with pain when fingerr pointed in the vastus medialis, without serious diseases.
62400018|NCT06722534|EXPERIMENTAL|Celecoxib group|Participants in the interventional group receive 200 mg celecoxib twice daily for 6 months
62400019|NCT06722534|ACTIVE_COMPARATOR|Placebo group|Participants in the control group receive identically appearing placebo twice daily for 6 months
62400020|NCT00895817|ACTIVE_COMPARATOR|Swallowed fluticasone|
62400021|NCT00895817|ACTIVE_COMPARATOR|Esomeprazole|
62400022|NCT01258803|EXPERIMENTAL|Sequence 1|Treatment Period 1: Placebo MDI with spacer; Treatment Period 2: MF/F MDI without spacer; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: F DPI
62576689|NCT06052202|ACTIVE_COMPARATOR|Control Education|Control condition participants will receive information about colorectal cancer and screening developed by the Centers for Disease Control.
62576690|NCT02236962|PLACEBO_COMPARATOR|Placebo|lactose powder in equivalent capsule
62198007|NCT01008553|EXPERIMENTAL|Fentanyl (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to fentanyl group, will be administered one-day adhesive transdermal patch containing fentanyl, applied to chest, abdomen, upper arm and thigh and replaced every day, the dose of which will be same as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will be continued for 12 weeks.
62198008|NCT01008553|PLACEBO_COMPARATOR|Placebo (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to placebo group, will be administered one-day adhesive transdermal placebo patch indistinguishable from fentanyl in appearance, applied to chest, abdomen, upper arm and thigh and replaced every day. The dose of fentanyl (from titration period) will be gradually decreased to prevent withdrawal symptoms and the dose of the matching placebo will be gradually increased up to same dose as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will continue for 12 weeks.
62198009|NCT05795803||SSD group|Adolescents with SSD diagnosis made within previously six months or before unless assessed and confirmed by a specialist within the last six months
62198010|NCT05795803||Without SSD group|Control group: adolescents without diagnosis of SSD, matched with the SSD group by age and sex
62198011|NCT01048697|EXPERIMENTAL|Ethambutol|"All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):~40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) \> 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)"
62198012|NCT02780518|EXPERIMENTAL|Airvo|All patients scheduled for elective microlaryngeal surgery under general anaesthesia and subglottic high frequency jet ventilation
62198013|NCT06179745|EXPERIMENTAL|Brain-computer interface (BCI)|"In the BCI arm, FES stimulation and orthosis triggering are only initiated when the BCI infers on line (in real time) the presence of adequate SMRs or ERD/ERS within the epoch. That is, there is precise contingency between the efferent motor command and the afferent feedback induced by BCI-driven actuators (the patient feels he/she can move his upper limb when he wants to do it)."
62198014|NCT06179745|SHAM_COMPARATOR|Sham-Brain-computer interface (Sham-BCI)|"In the Sham-BCI group, any EEG signals encoding motor intention of the patient are ignored. FES/orthosis triggering is decided at random, by playing back the data of a randomly selected run of a previously recruited participant. Hence, in the Sham-BCI arm, there is no guaranteed contingency between the efferent motor command and the afferent feedback induced by the FES and the orthosis, although it can still happen by coincidence."
62198015|NCT01027130||healthy control|240 female subjects without preeclampsia
62198016|NCT01027130||preeclampsia|120 female subjects with preeclampsia
62198017|NCT00264303|EXPERIMENTAL|Levocetirizine|Levocetirizine, once daily, 4 week duration
62198018|NCT00264303|ACTIVE_COMPARATOR|Desloratadine|Desloratadine, once daily, 4 week duration
62198019|NCT02878603|EXPERIMENTAL|caplacizumab|Participants who completed study ALX0681-C301 (NCT02553317) with standard of care (plasma exchange \[PE\], corticosteroid and other immunosuppressive agents) or caplacizumab with PE and immunosuppressive agents were enrolled in study LTS16371. Participants upon each recurrence of aTTP in LTS16371 and not meeting any criteria (namely: pregnancy, history of severe and/or serious hypersensitivity reaction to investigational medicinal product \[IMP\], withdrawal before receiving IMP, received more than 1 PE) were treated with caplacizumab initial 10 milligrams (mg) intravenous dose followed by a daily 10 mg subcutaneous injections during the period of PE and for 30 days after stop of PE (and eventually 28-day extension period, if needed). Participants with or without recurrence were followed up twice yearly up to maximum of 36 months in LTS16371.
62198020|NCT02600312|ACTIVE_COMPARATOR|oXiris|Continuous renal replacement therapy with filter that adsorbs cytokines/toxins.
62198021|NCT02600312|NO_INTERVENTION|ST150|Continuous renal replacement therapy with filter that does not adsorb cytokines/toxins.
62198022|NCT01528319|EXPERIMENTAL|MG-1|Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1
62198023|NCT02579395|EXPERIMENTAL|With spouse/romantic partner|
62198024|NCT02579395|EXPERIMENTAL|Without spouse/romantic partner|
62198025|NCT02579395|OTHER|Control|No Intervention
62198026|NCT06517238||Study group|Children starting a multi-brackets orthodontic treatment in the oral medicine department of University Hospital of Reims from January 2024. These childrens benefit from semi-annual appointment to analyze their oral health and their individual caries-risk by dentist. Moreover, these results will be communicated with a digital tool to orthodontist who can choose to adapt the orthodontic treatment of these childrens.
62198027|NCT06517238||Control group|
62198028|NCT04341129|EXPERIMENTAL|Abbreviated MRI using Dotarem|Standard breast MRI studies often have lengthy protocols that make them inherently expensive and time-consuming. Several studies of the use of abbreviated MRI protocols have shown that the shorter protocols have diagnostic accuracy comparable to that of the conventional full MRI protocol. The shorter imaging times achieved with the abbreviated DCE-MRI protocols have the potential to increase efficiency and lower cost by decreasing time in the MRI suite, which in turn may make breast MRI accessible for population-based mass screening. The focus of the proposed research is the investigation of an abbreviated MRI protocol using Dotarem® (Gadoterate Meglumine) by comparing the diagnostic accuracy of dynamic contrast-enhanced breast MRIs performed with an abbreviated protocol versus a full protocol.
62198029|NCT01745575|EXPERIMENTAL|A(reference)/B(test)|initial administration of reference and cross-over to test
62198030|NCT01745575|EXPERIMENTAL|B(test)/A(reference)|initial administration of test and cross-over to reference
62198031|NCT02657499||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
62198032|NCT02657499||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
62576691|NCT02236962|EXPERIMENTAL|Drug treatment|sympathetic agonist and thiazolidinedione
62734778|NCT05143905|PLACEBO_COMPARATOR|Placebo (Japanese Cohorts)|Randomised healthy Japanese participants will receive placebo.
62198033|NCT01682265|EXPERIMENTAL|Stretta procedure|"Patient randomized in Stretta procedure arm will be hospitalized to have endoscopy and esophagus will receive radiofrequency.~Control visits will then take place until Month 6. At this visit endoscopic control will take place."
62783447|NCT04611828|EXPERIMENTAL|Philips SmartSleep Device|"Participants will be instructed to sleep wearing the SmartSleep device at home for eight weeks, which will include three (3) two-week periods, one each of the following (in randomized order):~* continuous fixed interval (ITI): SmartSleep will provide 1 Hz, inter-tone interval stimulation continuous during deep sleep opportunities~* block: SmartSleep will provide 5s ON versus 5s OFF,1Hz inter-tone interval stimulation~* in-phase adjustable: SmartSleep will provide constant stimulation with tones timed to be delivered during each upstate of the slow wave~Between periods 1 and 2 and between periods 2 and 3, subjects will undergo one week of sham condition during which SmartSleep will record EEG during sleep using a no-volume sham stimulation"
62198034|NCT01682265|SHAM_COMPARATOR|Sham procedure|"Patient randomized in Sham procedure arm will be hospitalized to have endoscopy. Material necessary to perform Stretta procedure will be inserted (like in Stretta procedure arm) BUT esophagus will not receive radiofrequency.~Control visits will then take place until Month 6. At this visit endoscopic control will take place."
62400023|NCT01258803|EXPERIMENTAL|Sequence 2|Treatment Period 1: F DPI; Treatment Period 2: MF/F MDI without spacer; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: Placebo MDI with spacer
62400024|NCT01258803|EXPERIMENTAL|Sequence 3|Treatment Period 1: MF/F MDI without spacer; Treatment Period 2: F DPI; Treatment Period 3: Placebo MDI with spacer; Treatment Period 4: MF/F MDI with spacer
62010799|NCT05552040|EXPERIMENTAL|START NOW Group|START NOW is an evidence-informed psychotherapy composed of a total of 32-skills-based-sessions, originally designed for inmates in correctional systems. A previous study of incarcerated individuals found that for each additional session of START NOW completed, a 5% reduction in the incident rate of disciplinary reports was noted.10 In fact, individuals with a higher overall security risk score also had a greater reduction in the number of disciplinary reports with more sessions attended, suggesting that START NOW is an effective behavioral intervention for those who need it most. A follow-up study on these same participants concluded that START NOW appears to have a beneficial clinical effect with each session completed being associated with a 5% decrease in subsequent psychiatric hospital days.
62198035|NCT02847039||Early repolarization syndrome|Patients with an aspect of early repolarization syndrome or belonging to a family in which the diagnosis of early repolarization was identified.
62400025|NCT01258803|EXPERIMENTAL|Sequence 4|Treatment Period 1: Placebo MDI without spacer; Treatment Period 2: MF/F MDI with spacer; Treatment Period 3: F DPI; Treatment Period 4: MF/F MDI without spacer
62400026|NCT01258803|EXPERIMENTAL|Sequence 5|Treatment Period 1: MF/F MDI without spacer; Treatment Period 2: F DPI; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: Placebo MDI without spacer
62400027|NCT01258803|EXPERIMENTAL|Sequence 6|Treatment Period 1: MF/F MDI with spacer; Treatment Period 2: Placebo MDI without spacer; Treatment Period 3: MF/F MDI without spacer; Treatment Period 4: F DPI
62400028|NCT02706327|EXPERIMENTAL|CAD/CAM|8-week follow-up with CAD/CAM insole and home based exercise program
62400029|NCT02706327|EXPERIMENTAL|Semi-custom|8-week follow-up with semi-custom insole and home based exercise program
62400030|NCT02706327|PLACEBO_COMPARATOR|Control|8-week follow-up with placebo insole and home based exercise program
62400031|NCT04551326|EXPERIMENTAL|hamstring stretching|Participants' lower limb will be positioned in maximal hip flexion and gradually moved to maximal knee extension by physical therapist. The procedure will take one minute for each lower limb.
62400032|NCT06723002|ACTIVE_COMPARATOR|Arm A|Atherolive simple dose
62400033|NCT06723002|ACTIVE_COMPARATOR|Arm B|Atherolive double dose
62576692|NCT01463332|PLACEBO_COMPARATOR|Group NS|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
62198036|NCT00680992|EXPERIMENTAL|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
62010800|NCT05552040|ACTIVE_COMPARATOR|Treatment-as-Usual (TAU) Group|TAU groups are weekly sessions required in an OBOT clinic and focus primarily on supportive therapeutic techniques.
62576693|NCT01463332|ACTIVE_COMPARATOR|Group D25|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
62576694|NCT01463332|ACTIVE_COMPARATOR|Group D50|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D50 were injected intravenously with 0.50mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
62576695|NCT02569970|ACTIVE_COMPARATOR|FLUOXETINE|4 weeks of treatment before video-EEG monitoring
62576696|NCT02569970|PLACEBO_COMPARATOR|PLACEBO|1 month of treatment before EEG video.
62576697|NCT02812069|OTHER|minor to moderate surgical procedure|The ThermaZone® Device will be used for 30 minutes to warm the cervical spine during
62576698|NCT04358185|EXPERIMENTAL|Itacitinib|Itacitinib (INCB039110) - novel and small molecule selective inhibitor of JAK1
62576699|NCT01634737||Patients with shellfish allergy|Patients with symptoms of allergy to shellfish (OAS-Oral allergy syndrome and/or systemic symptoms) and circulating IgE positive for the extract of shrimp (\> 0.10 kU/L)
62576700|NCT01634737||Patients with respiratory allergy|Patients with respiratory allergy and IgE positive to dust mites, asymptomatic for shrimp or other shellfish and circulating IgE positive for shrimp
62010801|NCT01391117|EXPERIMENTAL|010|TMC649128 panel 4 arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128 administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.
62576701|NCT03711565|ACTIVE_COMPARATOR|Regular Nasal CPAP using a conventional ventilator|Regular nasal CPAP for management of respiratory distress Patient will have regular nasal CPAP placed via nasal prongs with level of pressure adjusted and level of oxygen adjusted as needed for acceptable oxygenation and ventilation
62576702|NCT03711565|ACTIVE_COMPARATOR|High Frequency Nasal CPAP|High Frequency Nasal CPAP for management of respiratory distress Patient will be connected to the high frequency device through nasal prongs. The pressure, frequency and amplitude of the pulsations will be adjusted as needed to provide acceptable oxygenation and ventilation
62576703|NCT04793490|OTHER|Group A (Control group)|Patients will receive paracetamol 1 g thrice daily intravenously
62576704|NCT04793490|ACTIVE_COMPARATOR|Group B (Sphenopalatine ganglion block group)|patients will receive sphenopalatine ganglion block via transnasal approache by a cotton tipped applicator soaked in 2%lignocaine with 4 mg dexamethasone
62576705|NCT01481441|OTHER|SonoVue|Ultrasound Contrast Agent
62010802|NCT01391117|EXPERIMENTAL|001|TMC649128. panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
62576706|NCT03661242|NO_INTERVENTION|Standard of care|No intervention
62576707|NCT03661242|ACTIVE_COMPARATOR|Shared care|Clinic visit with Clincal Exercise Physiologist or physical therapist who does assessment and prescripes individulized physical activity plan
62576708|NCT03991299|EXPERIMENTAL|Botox Arm|Botox will be injected into duodenums of subjects via endoscopy.
62576709|NCT05418998|EXPERIMENTAL|Executive function (EF) training|12 weeks of at-home EF training on a computer or iPad
62576710|NCT05418998|NO_INTERVENTION|Wait-list control|This will be a comparator arm with no cognitive training. Participants will be given access to the same training program following the conclusion of the study, but no further assessment is planned.
62010803|NCT01391117|PLACEBO_COMPARATOR|002|placebo. panel 1: 2 participants receive placebo at a q24h regimen.
62010804|NCT01391117|EXPERIMENTAL|003|TMC649128. panel 2 arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
62010805|NCT01391117|PLACEBO_COMPARATOR|004|placebo. panel 2 arm 1: 2 participants receive placebo at a q12h regimen.
62400034|NCT06723002|PLACEBO_COMPARATOR|Arm C|Palcebo
62400035|NCT04447573|EXPERIMENTAL|BCMA CAR-T cells|Patients will be treated with BCMA CAR-T cells
62400036|NCT00807651|ACTIVE_COMPARATOR|insulin therapy|The participants not accepted written informed consent will receive insulin therapy
62400037|NCT00807651|EXPERIMENTAL|AHSCT|The participants accepted written informed consent will receive the therapy of autologous hematopoietic stem cell transplantation(AHSCT)
62400038|NCT06238544|EXPERIMENTAL|HRS-5965 tablets|
62400039|NCT01510704|PLACEBO_COMPARATOR|Placebo|
62400040|NCT01510704|EXPERIMENTAL|Low dose APD421|1mg dose level
62400041|NCT01510704|EXPERIMENTAL|Mid Dose APD421|5mg dose level
62400042|NCT01510704|EXPERIMENTAL|High Dose APD421|20mg dose level
62198037|NCT01701102|ACTIVE_COMPARATOR|Mepivacaine 37.5 mg|
62198038|NCT01701102|ACTIVE_COMPARATOR|Mepivacaine 30 mg plus fentanyl 10 µg|
62198039|NCT01701102|ACTIVE_COMPARATOR|Mepivacaine 27 mg plus fentanyl 10 µg|
62400043|NCT04959266|EXPERIMENTAL|Arm A|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with itraconazole.
62400044|NCT04959266|EXPERIMENTAL|Arm B|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with rifampicin.
62400045|NCT04959266|EXPERIMENTAL|Arm C|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with omeprazole.
62576711|NCT06530511|EXPERIMENTAL|PRO|"The drugs involved in this trial include Polatuzumab, Rituximab, and orelabrutinib in 21-day cycles.~The dose and administration method of the study drug were as follows:~* Polatuzumab: 1.8 mg/kg, IV, D1;~* Rituximab: 375 mg/m2, IV, D1;~* Orelabrutinib: 150 mg/time, qd, po, D1-21;"
62576712|NCT02738099||Arrest from presume Cardiac etiology|Comatose patients following arrest of presumed cardiac etiology arriving to receiving facility within 12 hours of event.
62576713|NCT05746728|EXPERIMENTAL|surufatinib + tislelizumab|"Safety Lead-in Phase: Six patients with metastatic triple-negative breast cancer will be recruited to receive surufatinib in combination with tislelizumab, and DLT will be evaluated over a 28-day DLT observation period.~Dose expansion phase: Surufatinib was administered according to the dose determined in the safety run-in phase and tislelizumab is same as Safety Lead-in Phase."
62576714|NCT04514913||Healthy Controls|Participants with no history of asthma or other lung diseases.
62576715|NCT04514913||Asthmatics without mucus plugs|Participants with asthma and no evidence of mucus plugging.
62783448|NCT03899987|EXPERIMENTAL|Arm I (aspirin, interferon alpha, rintatolimod, surgery)|Patients receive aspirin PO BID on days -7 to 7. Patients also receive recombinant interferon alfa-2b IV over 20 minutes and rintatolimod IV over 2 hours on days 1-3 and 8-10 in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy on or between day 17-24..
62783449|NCT03899987|EXPERIMENTAL|Arm II (aspirin, rintatolimod, surgery)|Patients receive aspirin PO BID on days -7 to 7 and rintatolimod IV over 2 hours on days 1-3,and 8-10 in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy on or between day 17-24.
62783450|NCT03899987|ACTIVE_COMPARATOR|Arm III (radical prostatectomy)|Patients undergo radical prostatectomy about 4 weeks after enrollment.
62010806|NCT01391117|EXPERIMENTAL|005|TMC649128. panel 2 arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
62010807|NCT01391117|PLACEBO_COMPARATOR|006|placebo. panel 2 arm 2: 2 participants receive placebo at a q24h regimen.
62198040|NCT01701102|ACTIVE_COMPARATOR|Mepivacaine 24 mg plus fentanyl 10 µg|
62198041|NCT04684433||Surgical intervention|Patients who had a surgical procedure since the start of the lockdown in Belgium due to the COVID19 pandemic (16 of March 2020 to the 12 of April 2020.
62198042|NCT05508815|EXPERIMENTAL|Modified Zhiwang Decoction Combined with Methotrexate|
62198043|NCT05508815|ACTIVE_COMPARATOR|Methotrexate|
62010808|NCT01391117|EXPERIMENTAL|007|TMC649128 panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
62010809|NCT01391117|PLACEBO_COMPARATOR|008|placebo. panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
62198044|NCT04329572|EXPERIMENTAL|HCQ + AZT|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D5) and AZT (500 mg/ 5 days) on top of standard care.
62198045|NCT04743531|EXPERIMENTAL|Intervention|Families living in rural Colorado will participate in the HEROs intervention in Fall 2019.
62198046|NCT04743531|EXPERIMENTAL|Staggered Intervention|Families in the staggered intervention arm will serve as controls for the first intervention arm during Fall 2019. Families the staggered intervention arm will then participate in the HEROs intervention in Spring 2020.
62198047|NCT01200290|EXPERIMENTAL|LY2127399|
62400046|NCT04371705|EXPERIMENTAL|ESPB group|31 patients Will undergo ultrasound guided ESP block with 40 ml bupivacaine 0.25% (20 ml on each side).
62400047|NCT04371705|PLACEBO_COMPARATOR|control group|31 patients anesthetized with the protocol followed by Minia University Hospital
62400048|NCT05948670|EXPERIMENTAL|DISC-MVP|Participants randomized to the experimental condition, DISC-MVP, will be asked to download and use the BUILD study application. They will have access to the app throughout the 2 week study.
62400049|NCT05948670|ACTIVE_COMPARATOR|DISC-CON|Participants randomized to the digital control condition, DISC-CON, will be asked to download and use the BUILD study application. They will have access to the app throughout the 2 week study.
62400050|NCT06243679||Adjuvant immunotherapy|
62400051|NCT06243679||Observational|
62400052|NCT04885218|EXPERIMENTAL|Cohort 1：SHR-1209 / placebo|
62400053|NCT04885218|EXPERIMENTAL|Cohort 2：SHR-1209 /placebo|
62400054|NCT04885218|EXPERIMENTAL|Cohort 3：SHR-1209 / placebo|
62400055|NCT06137040|EXPERIMENTAL|Magnesium Sulfate in the first hour|These patients will receive 40-50 mg/kg IV magnesium sulfate within the first hour of treatment alongside all first line asthma exacerbation therapies (ie inhaled beta agonists, IV steroids).
62400056|NCT06137040|PLACEBO_COMPARATOR|No Magnesium Sulfate|These patients will not receive IV magnesium sulfate within the first hour of treatment but may receive it later if the provider feels it is clinically necessary.
62400057|NCT01737359|EXPERIMENTAL|amdoxovir 300 mg bid|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
62400058|NCT01737359|EXPERIMENTAL|amdoxovir 500 mg bid|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
62400059|NCT01737359|ACTIVE_COMPARATOR|tenofovir DF 300 mg qd|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
62400060|NCT05718024|EXPERIMENTAL|Dexmedetomidine-esketamine|Dexmedetomidine-esketamine combination will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation, for a duration of up to 5 days.
62400061|NCT05718024|ACTIVE_COMPARATOR|Propofol-remifentanil|Propofol and remifentanil will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation, for a duration of up to 5 days.
62400062|NCT04923399||TN (Trigeminal Neuralgia) group|Trigeminal neuralgia patients undergoing trigeminal nerve microvascular decompression
62198048|NCT03296800|EXPERIMENTAL|Bexagliflozin/probenecid|Sixteen healthy subjects were dosed with bexagliflozin, qd and/or probenecid tablets, 500 mg, bid, in sequential order as follows: on Day 1 subjects took bexagliflozin; on Days 3 and 4 subjects took probenecid, bid; on Day 5 subjects took one bexagliflozin, and probenecid, bid; and on Day 6 subjects took probenecid tablets, 500 mg, bid.
62198049|NCT03296800|EXPERIMENTAL|Bexagliflozin/rifampin|Sixteen healthy subjects were dosed with bexagliflozin, qd and/or 600 mg of rifampin daily in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet; on Days 3 to 5, subjects took rifampin once daily; on Day 6 subjects took one bexagliflozin tablet and rifampin; and on Day 7 subjects took rifampin.
62400063|NCT04923399||Non-TN group|patients without chronic pain or history of chronic pain
62400064|NCT04100759|EXPERIMENTAL|Non-Smokers|Subjects administer one tablet of sildenafil 50 mg
62400065|NCT04100759|EXPERIMENTAL|Cigarette Smokers|Subjects administer one tablet of sildenafil 50mg
62400066|NCT04100759|EXPERIMENTAL|Cannabis Smokers|Subjects administer one tablet of sildenafil 50mg
62400067|NCT02198157|ACTIVE_COMPARATOR|intermittent urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will receive intermittent catheterization
62400068|NCT02198157|ACTIVE_COMPARATOR|continuous urinary catheter|nullipara women with epidural anaesthesia who pose urination difficulty will receive continuous catheterization
62198050|NCT03296800|EXPERIMENTAL|Bexagliflozin/verapamil|Sixteen healthy subjects were dosed with bexagliflozin, and/or verapamil tablets, 120 mg in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet, on Day 4 subjects took one verapamil tablet, 1 hour before taking a bexagliflozin tablet.
62400069|NCT04828993|EXPERIMENTAL|Tafamidis treatment arm|Chinese patients diagnosed with ATTR-PN treated with tafamidis 20mg once daily oral administration for 72 weeks (18 months).
62400070|NCT06044857|EXPERIMENTAL|SAbR Every other day|SAbR given 2-3/week, at least every other day in spacing with long-term ADT (neoadjuvant ADT x 3months required) with experimental Illucix (PSMA-11 68Ga) PET before and during SAbR (between fraction 3 and 4) to assess and adapt to dominant intra-prostatic lesion boost dose.
62576716|NCT04514913||Asthmatics with mucus plugs|Participants with asthma and evidence by MDCT lung scan showing mucus plugging.
62010810|NCT01391117|PLACEBO_COMPARATOR|009|placebo panel 4 arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.
62010811|NCT03387800|EXPERIMENTAL|WeChat interactive peer support group|Participants will be grouped together by the researcher to form closed online peer support groups (with group names they choose). Activities on the WeChat groups serve two functions: i) It enhances social support among peer members toward smoking cessation. ii) The online support group also enhances the participants' positive affect.
62400071|NCT06044857|EXPERIMENTAL|PULSAR every week|SAbR given 1/week, with long-term ADT (neoadjuvant ADT x 3months required) with experimental Illucix (PSMA-11 68Ga) PET before and during SAbR (between fraction 3 and 4) to assess and adapt to dominant intra-prostatic lesion boost dose.
62400072|NCT06044857|EXPERIMENTAL|PULSAR every 2 weeks|SAbR given every 2 weeks, with long-term ADT (neoadjuvant ADT x 3months required) with experimental Illucix (PSMA-11 68Ga) PET before and during SAbR (between fraction 3 and 4) to assess and adapt to dominant intra-prostatic lesion boost dose.
62400073|NCT06044857|EXPERIMENTAL|PULSAR every 3 weeks|SAbR given every 3 weeks, with long-term ADT (neoadjuvant ADT x 3months required) with experimental Illucix (PSMA-11 68Ga) PET before and during SAbR (between fraction 3 and 4) to assess and adapt to dominant intra-prostatic lesion boost dose.
62400074|NCT06724770|EXPERIMENTAL|e-Resilience Intervention|Middle management and healthcare professionals who voluntarily participate in the e-Resilience intervention.
62400075|NCT05361005|EXPERIMENTAL|Cohort 2mg/kg|All participants (fasted) received either 2 mg/kg of BDB-001 as a single dose or dose-matched placebo.
62400076|NCT05361005|EXPERIMENTAL|Cohort 4mg/kg|All participants (fasted) received either 4 mg/kg of BDB-001 as a single dose or dose-matched placebo.
62576717|NCT04173780|EXPERIMENTAL|Atropine 0.01%|
62576718|NCT04173780|PLACEBO_COMPARATOR|Placebo|
62576719|NCT01097590|EXPERIMENTAL|Active TLA Gut™ column|The active column contain an engineered protein with the ability to specifically bind the inflammatory cells.
62576720|NCT01097590|PLACEBO_COMPARATOR|Placebo TLA Gut™column|The placebo column is identical to the active column except it does not contain the engineered protein that specifically bind the inflammatory cells.
62576721|NCT02821338|ACTIVE_COMPARATOR|Sequence 1|The treatments will be administered according to a randomly assigned pre-generated sequence involving the randomized, four-period, two sequence, fully replicate crossover design. Two study drugs involved are: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
62010812|NCT03387800|ACTIVE_COMPARATOR|Basic health education messages|Members of the control group will receive health education messages that will also be sent to the intervention group through WeChat. The messages include topics on physical and psychological aspects of perceived severity of smoking and perceived benefits of smoking cessation, and tips/skills on resisting situational temptations that may lead to relapse.
62010813|NCT06663007|EXPERIMENTAL|Cohort A|During the treatment phase of patients in cohort A (excluding CDK12 alterations from mutation spectrum features in cohort B), subjects received intravenous infusion of Disitamab Vedotin(RC48) (2.0 mg/kg) every 2 weeks, in combination with subcutaneous injection of Envafolimab (400 mg) every 3 weeks, until disease progression or death occurred.
62010814|NCT06663007|EXPERIMENTAL|Cohort B|During the treatment phase, subjects in cohort B (CDK12 alterations combined with 11q13 co-amplification, MDM2/4 amplification, FGFRs amplification and other chromosomal unstable mutation profiles) received intravenous infusion of Disitamab Vedotin(RC48) (2.0 mg/kg) every 2 weeks until disease progression or death occurred.
62576722|NCT02821338|ACTIVE_COMPARATOR|Sequence 2|The treatments will be administered according to a randomly assigned pre-generated sequence involving the four-period, two sequence, fully replicate crossover design. Two study drugs involved are: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
62198051|NCT06089005|EXPERIMENTAL|Intervention Group|daily use of the IASTM on the hip, quad and glute muscles for 60s in duration each session
62198052|NCT01998789|EXPERIMENTAL|Everolimus Conversion Arm|"Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day). Therapeutic Drug Monitoring will be performed throughout the study. Tacrolimus should be eliminated when the everolimus target range has been reached. Complete tacrolimus elimination will not occur earlier than 90 days post transplant and no later than 120 days post transplant. Enteric coated mycopenolic acid will be maintained for the duration of the study. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Everolimus doses will be adjusted based on local lab results of everolimus trough levels."
62198053|NCT01998789|ACTIVE_COMPARATOR|Standard Tacrolimus Immunosuppresion Arm|"Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels."
62198054|NCT01686737|EXPERIMENTAL|Yoga|"Iyengar Yoga~* 12 weeks of Iyengar yoga~* 2 weekly sessions of 60 minutes"
62198055|NCT01686737|ACTIVE_COMPARATOR|Aerobic exercise|"Walking~* 12 weeks of walking~* 2 weekly sessions of 60 minutes"
62198056|NCT01686737|NO_INTERVENTION|Usual Care|
62198057|NCT01225380|EXPERIMENTAL|Arm 1|GS-9190 and GS-9256 in combination with Pegasys® and Copegus® for 16 or 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
62198058|NCT01225380|EXPERIMENTAL|Arm 2|GS-9256 (active) and placebo matching GS-9190 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
62198059|NCT01225380|PLACEBO_COMPARATOR|Arm 3|Placebo matching GS-9190 and placebo matching GS-9256 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® will be continued for up to 48 weeks total duration
62783451|NCT04241406|EXPERIMENTAL|transcutaneous spinal cord stimulation|"Transcutaneous application of electrical (biphasic current, 1ms, 30Hz) stimulation over the back for a 10 minutes session.The intensity of the current will increase until motor reflex threshold. If it will not possible, intensity will be increase until participants report a strong but comfortable sensation.~Transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)."
62783452|NCT04241406|EXPERIMENTAL|sham stimulation|"Electrodes are placed over the back for a 10 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing current intensity during 30 second and decrease intensity subsequently.~Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)."
62010815|NCT05990049|ACTIVE_COMPARATOR|Hyaluronic acid|During the surgery, the hyaluronic acid will be administered on donor site wound and on recipient site before suturing.
62198060|NCT05449405|ACTIVE_COMPARATOR|Chlorpheniramine Malate (1%) Nasal Spray|Chlorpheniramine Malate (1%) Nasal Spray
62198061|NCT05449405|PLACEBO_COMPARATOR|Placebo Nasal Spray|Placebo Nasal Spray
62400077|NCT05361005|EXPERIMENTAL|Cohort 8mg/kg|All participants (fasted) received either 8mg/kg of BDB-001 as a single dose or dose-matched placebo.
62400078|NCT05361005|EXPERIMENTAL|Cohort 4mg/kg multiple doses|All participants (fasted) received either 4 mg/kg of BDB-001 as a multiple doses or doses-matched placebo.
62400079|NCT00927277|PLACEBO_COMPARATOR|placebo laser|inactive light on the laser device.
62576723|NCT03299114|ACTIVE_COMPARATOR|Intervention Group|Treated with warm whirlpool
62576724|NCT03299114|PLACEBO_COMPARATOR|Placebo group|Treated with sham whirlpool
62576725|NCT00885664|OTHER|Truvada/Kaletra CD4<100|All participants were treated but at baseline by design were divided based upon their CD4 count at baseline measurement. Group with CD4\<100 cells/cu mm
62576726|NCT00885664|OTHER|Truvada/Kaletra CD4>/=100|All participants were treated but at baseline by design were divided based upon their CD4 count at baseline measurement. Group with CD4\>/=100 cells/cu mm
62734779|NCT05143905|EXPERIMENTAL|Chinese Cohort: AZD7503 dose 4|Randomised healthy Chinese participants will receive a single dose 4 of AZD7503.
62734780|NCT05143905|PLACEBO_COMPARATOR|Placebo (Chinese Cohort)|Randomised healthy Chinese participants will receive placebo.
62783453|NCT05052567|EXPERIMENTAL|CEND-1|CEND-1+paclitaxel (albumin-bound type)+gemcitabine
62783454|NCT02982057|ACTIVE_COMPARATOR|Bioresorbable vascular scaffold(BVS)+ OMT|"hypothesis: scaffolding a non culprit coronary plaque with BVS could facilitate the stabilization process into the atherosclerotic plaque with modification of plaque morphology.~Intervention:Device"
62010816|NCT05990049|NO_INTERVENTION|Control|"After the harvesting of the graft from the donor site, the wound will be sutured using only saline to clean the wound.~On the recipient site, before positioning the graft, only saline will be used."
62010817|NCT05592210||Questionnaires assessed Parents of preterm infants|"Inclusion criteria for parents~1. Parents of hospitalized preterm infants with a gestational age of less than 37 weeks;~2. Both parents are at least 18 years old;~3. Able to read and communicate in Chinese, able to complete the questionnaire independently or with the help of the investigator;~Inclusion criteria for infant~1. Gestational age less than 37 weeks;~2. admitted to the NU or NICU and discharged after treatment;"
62010818|NCT01752933|EXPERIMENTAL|SGI-110|SGI-110 administered subcutaneously (SC) daily on Days 1 - 5 every 28 days
62010819|NCT02351752|EXPERIMENTAL|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate 0.1 Tid (eGFR 30-59), 0.2 Bid(eGFR \>60)
62010820|NCT03636490|EXPERIMENTAL|Psychological Stress|All participants will undergo stress-inducing tasks (psychological stress intervention) using cognitive research tools.
62400080|NCT00927277|ACTIVE_COMPARATOR|Erchonia (R) LipoLASER PL|The Erchonia(R) LipoLASER PL is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
62400081|NCT04182529|EXPERIMENTAL|Photoneuromodulation Therapy|In this study low-level LED near-infrared (670-810nm) including MedX Health Model 1100 or WiseFori5-3800 will be used. The United States Food and Drug Administration (FDA) has approved this type of device as imposing insignificant risk (FDA-cleared for home treatment, 2005). At each visit, LED clusters will be applied simultaneously for 20 minutes on the Fp1, Fp2 and Pz regions according to the International 10-20 system (Homan, Herman and Purdy, 1987) (energy density, 13 Joules/cm2 \[J/cm2\] per each LED cluster head placement). The total LED treatment time per visit was 20 minutes.
62400082|NCT04182529|SHAM_COMPARATOR|Control Group|Subject will not be given any active stimulation
62400083|NCT02553993|EXPERIMENTAL|Wii Fit|The Wii Fit training was conducted using the Wii Fit bundle from Nintendo, which consists of the Wii console, a Wii Balance Board, and the Wii Fit Plus balance game disc. The Wii balance board has 4 transducers, which could assess the player's force distribution and resultant movements in the center of pressure (COP). The participants stood on the board and used the change of COP to play the games. Five games (Tilt, Soccer Heading, Balance Bubble, Penguin Slide, and Perfect 10) were selected from the Wii Fit Plus package based on the motor demand of these games. The major movement patterns to play the games included right-left weight shifting and front-back weight shifting.
62400084|NCT02553993|EXPERIMENTAL|Tetrax biofeedback|"The Tetrax biofeedback games aimed at postural rehabilitation to help patients or athletes improve their balance abilities. There were 11 games in Tetrax system; 8 games (Speedtrack, Catch, Skyball, Gotcha, Speedball, Tag, Freeze, Immobilizer) were chosen based on the same principle as those used for choosing Wii Fit games. The parameters of games' difficulties included target size and/or speed of target movement, which could be adjusted according to the patients' ability.~For the Wii Fit or Tetrax group, at each session, the supervising therapist chose 3 to 5 games for participants according to their ability, needs, and favorites."
62400085|NCT02553993|PLACEBO_COMPARATOR|Conventional weight-shifting|The conventional weight-shifting exercise group performed balance exercises with the similar movements and time required by the 2 exergame systems but without video games. By using occupational activities, participants did weight shifting in the sagittal and frontal planes. The investigators also used a balance board (Reebok Core board) for multi-directional weight shifting training
62400086|NCT02934126||breast cancer patients|breast cancer patients who have faced a decision on different types of radiotherapy or to leave radiotherapy out of the treatment
62400087|NCT05123703|EXPERIMENTAL|Ocrelizumab|Participants will receive ocrelizumab by intravenous (IV) infusion every 24 weeks (Q24W). The first dose is given as dual infusions of half the dose of ocrelizumab on Days 1 and 15 and subsequent doses are given as single infusions of ocrelizumab Q24W. Participants will also receive a placebo of fingolimod administered as once a day (QD) capsule.
62198062|NCT05543239|ACTIVE_COMPARATOR|TaVNS|Patients will receive TaVNS stimulation for 30 minutes, twice a day (between 9:00 to 10:00 and 15:00 to 16:00), for 7 consecutive days. Stimulation pulses (30 Hz frequency, 300 μs pulse width) were generated by a commercial transcutaneous auricular vagus nerve stimulation unit (tVNS 501，Jiangsu, China), and the amplitude was increased to the maximum amount tolerated by the subject without pain, then stimulate for 30 min. All subjects were told that they may or may not feel any sensation from the stimulation, and the unit is packed in an opaque bag throughout the treatment.
62400088|NCT05123703|ACTIVE_COMPARATOR|Fingolimod|Participants will receive fingolimod orally (PO) QD as per the prescribing information provided with fingolimod. Participants will also receive a placebo of ocrelizumab administered as IV infusion on Days 1 and 15, and Q24W thereafter.
62400089|NCT02608073|EXPERIMENTAL|Capecitabine + Cisplatin|Participants with metastatic nasopharyngeal cancer will receive combination treatment with capecitabine (1000 milligrams per meter square \[mg/m\^2\] tablets twice daily \[BID\] orally) and cisplatin (100 mg/m\^2/day intravenous \[IV\] infusion) for up to 8 cycles.
62400090|NCT00072982|ACTIVE_COMPARATOR|1|Fish Oil
62400091|NCT00072982|ACTIVE_COMPARATOR|2|Borage Oil
62400092|NCT00072982|ACTIVE_COMPARATOR|3|Fish Oil and Borage Oil
62400093|NCT05011669|EXPERIMENTAL|Latuda® 40mg/d|
62400094|NCT05011669|EXPERIMENTAL|Latuda® 80mg/d|
62400095|NCT00638820|EXPERIMENTAL|Intent-To-Treat|Patients enrolled and received study treatment.
62400096|NCT05784467|OTHER|English|Participants in the English arm will receive the eMPrISe intervention materials in English.
62400097|NCT05784467|OTHER|Spanish|Participants in the English arm will receive the eMPrISe intervention materials in Spanish.
62400098|NCT04337827|EXPERIMENTAL|Rituximab and Acalabrutinib|Participants will receive treatment of Rituximab weekly for 4 weeks, and Acalabrutinib twice daily for 4 weeks. Response assessment via diagnostic CT scans will dictate further treatment decisions.
62400099|NCT00603824|EXPERIMENTAL|A|Fondaparinux
62400100|NCT00603824|ACTIVE_COMPARATOR|B|Direct thrombin inhibitor
62400101|NCT00475839|ACTIVE_COMPARATOR|Tension-free Vaginal Tape|
62400102|NCT00475839|ACTIVE_COMPARATOR|Monarc Sub-fascial hammock|
62400103|NCT01487109|PLACEBO_COMPARATOR|Placebo|matching placebo tablets
62400104|NCT01487109|ACTIVE_COMPARATOR|CTP-499|600 mg tablet
62400105|NCT01041027|EXPERIMENTAL|Treatment (paclitaxel, carboplatin, radiation therapy)|"CHEMOTHERAPY (weeks 1-9, 13-21): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 3 courses during weeks 13-21.~RADIATION THERAPY (weeks 8-13 or 8-15): Patients with stage I disease undergo HDR brachytherapy once weekly for a total of 5 fractions during weeks 8-13. All other patients undergo EBRT QD 5 days a week for a total of 25 fractions during weeks 8-12 and HDR brachytherapy once weekly for a total of 3 fractions during weeks 13-15."
62400106|NCT02635906|EXPERIMENTAL|2 hours|after coronary arteriography or coronary angioplasty, will be removal the introducer and the patient will be in bed rest for two hours
62400107|NCT02635906|ACTIVE_COMPARATOR|4 hours|after coronary arteriography or coronary angioplasty, will be removal the introducer and the patient will be in bed rest for four hours
62198063|NCT05543239|SHAM_COMPARATOR|Sham TaVNS|Patients will receive sham TaVNS stimulation for 30 minutes, twice a day (between 9:00 to 10:00 and 15:00 to 16:00), for 7 consecutive days. Stimulation unit was active for the first 30s, stimulation pulses (30 Hz frequency, 300 μs pulse width) were generated by a commercial transcutaneous auricular vagus nerve stimulation unit (tVNS 501，Jiangsu, China).Then dropped to zero stimulation during 15s and shut down. All subjects were told that they may or may not feel any sensation from the stimulation, and the unit is packed in an opaque bag throughout the treatment.
62198064|NCT03402074|EXPERIMENTAL|Group Hypnosis|5 sessions of group hypnosis, each 90 minutes; plus CDs/MP3 recordings to train at home
62576727|NCT01684423|EXPERIMENTAL|Rivaroxaban (BAY59-7939) tablet, OD, Age: 12 - <18|Subjects aged from 12 - \<18 years were administered with age and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR (immediate-release) tablet once daily (OD) under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kilogram (kg) received a dose (equivalent to 20 milligram \[mg\] in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
62576728|NCT01684423|ACTIVE_COMPARATOR|Comparator, Age: 12 - <18 years|Subjects aged from 12 - \<18 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
62576729|NCT01684423|EXPERIMENTAL|Rivaroxaban (BAY59-7939) tablet, OD, Age: 6 - <12 years|Subjects aged from 6 - \<12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kg received a dose (equivalent to 20 mg in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
62576730|NCT01684423|EXPERIMENTAL|Rivaroxaban (BAY59-7939) suspension, BID, Age: 6 - <12 years|Subjects aged from 6 - \<12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily (BID). Subjects with a body weight of 9 to less than 50 kg received a total daily dose (equivalent to 20 mg in adults) ranging from 6.4 to 15 mg and subjects with a body weight of greater than or equal to 50 kg received a total daily dose of 20 mg.
62576731|NCT01684423|ACTIVE_COMPARATOR|Comparator, Age: 6 - <12 years|Subjects aged from 6 - \<12 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or INR-adjusted (vitamin K antagonist).
62576732|NCT01699269|OTHER|brain tumor|
62576733|NCT05081128|ACTIVE_COMPARATOR|Open Shunt Group|FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve setting to active (open shunt group)(setting 4)(110 mm H2O) at time of shunt implantation
62576734|NCT05081128|SHAM_COMPARATOR|Closed Shunt Group|FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve setting to placebo (closed shunt group)(setting 8)(\>400 mm H2O) at time of shunt implantation followed by setting to active (setting 4) (110 mm H2O) three months after the procedure.
62576735|NCT01022320|EXPERIMENTAL|Surgical outcome|20 consecutive cases of patients who underwent the lateral pharyngoplasty
62576736|NCT06310447||Students|Students of the physiotherapy and rehabilitation department in Istanbul constitute the population of the research.
62198065|NCT00566189|EXPERIMENTAL|1|Roux-en-Y bypass gastroplasty
62198066|NCT00953615|EXPERIMENTAL|Thalidomide|Participants will be treated with Thalidomide, starting at a dose of 100 mg per day, increasing the dose by 100 mg every 14 days to a maximum of 400 mg per day.
62400108|NCT06722599||four cycles of Taxanes combined with target therapy|Four cycle neoadjuvant therapy with taxanes combined with trastuzumab and pertuzumab
62400109|NCT04004299|OTHER|HCV self-test intervention|Diagnostic intervention: participant performs capillary blood sampling at home in between outpatient clinic visits (3 months after) and sends the sample to the investigator's laboratory by regular post mail for HCV RNA analysis. This is on top of standard of care ALT measurement at every 6-monthly outpatient clinic visit, followed by HCV RNA testing if ALT is elevated. Follow-up period is 2 years, in which participants will perform and send in 4 self-tests, in combination with filling out 4 questionnaires into sexual risk behavior.
62400110|NCT01774734|EXPERIMENTAL|neck strength exerciser (NSE) group|Traditional physiotherapy 30 minutes per session for three times weekly + home-based NSE training 20 minutes daily
62400111|NCT01774734|PLACEBO_COMPARATOR|Physical therapy group|Traditional physiotherapy 30 minutes per session for three times weekly + home-based general neck exercise 20 minutes daily
62400112|NCT02606721||Challenge Subjects|Male or female subjects aged 5 - 35 with suspected food allergy and an upcoming scheduled clinical food challenge
62400113|NCT01761565|EXPERIMENTAL|Single dose of SUF NT 15 mcg then 40 doses of SUF NT 15 mcg|"Period 1: Single dose of SUF NT 15 mcg~Period 2: 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes"
62576737|NCT02078245||Familial pancreatic cancer patients|Individual with ten fold higher risk to develop pancreatic cancer.
62400114|NCT04510662|EXPERIMENTAL|Telmisartan|Patients in this group will receive telmisartan 40 mg daily plus standard care.
62198067|NCT00346905|EXPERIMENTAL|Single Arm|Those receiving Enteryx treatment
62576738|NCT02619864|EXPERIMENTAL|AZD2014 plus temozolomide|Patients will receive single agent AZD2014 for 2 days immediately prior to surgery at a fixed dose of 125 mg bid po (i.e. on days -2, -1, and on morning of day 0 \[day of surgery\]). After recovery from surgery, patients will start the dose escalation (within 7-21 days after tumour resection).
62576739|NCT02775513||Mutation|Patients with functional mutation in ion channels
62783455|NCT02982057|ACTIVE_COMPARATOR|OMT|"Comparator with ONLY optimal medical treatment (OMT): the aim of the study is to compare the evolution of non culprit lesions after treatment by BVS versus Optimal Medical Therapy at 2 years follow- up.~Intervention: medical treatment"
62198068|NCT05442684|EXPERIMENTAL|Ad5-nCoV/O group|
62198069|NCT05442684|EXPERIMENTAL|Ad5-nCoV/O-IH group|
62400115|NCT04510662|NO_INTERVENTION|Control|Patients in this group will receive standard care.
62400116|NCT02377674|EXPERIMENTAL|Vascular Graft, Model COR-VG-001|A surgically implanted vascular graft for pediatric patients undergoing extracardiac total cavopulmonary connection.
62198070|NCT05442684|ACTIVE_COMPARATOR|mRNA-based COVID-19 vaccine group|
62198071|NCT01931111||Norwegian Elderly Population|
62400117|NCT00990782|EXPERIMENTAL|Single Arm|PillCam ESO Capsule Endoscope - all patients receive capsule endoscopy before and after RFA procedure.
62400118|NCT04352075|EXPERIMENTAL|Microfat + PRP 3M platelets|microfat (5 ml) associated with PRP with a dose of 3 billions of platelets (5 ml)
62400119|NCT04352075|EXPERIMENTAL|Microfat + PRP 1M platelets|microfat (5 ml) associated with PRP with a dose of 1 billion of platelets (5 ml)
62400120|NCT04352075|EXPERIMENTAL|Microfat|microfat (5 ml) and saline solution (5 ml)
62400121|NCT04860531|ACTIVE_COMPARATOR|Group (I) Platelet Rich Plasma|The participants are randomly assigned for intra-articular injection with autologous platelet rich plasma . The treated segments are determined by clinical signs and MRI detected facet joint synovitis .
62576740|NCT02775513||Control|Matched control
62576741|NCT04455035|ACTIVE_COMPARATOR|Retrospective Group(Control)|
62400122|NCT04860531|ACTIVE_COMPARATOR|Group (II) Corticosteroids|The participants are randomly assigned for intra-articular injection with corticosteroids(a mixture of 0.5% lidocaine and 5mg/ml of betamethasone) . The treated segments will be determined by clinical signs and MRI detected facet joint synovitis .
62400123|NCT03580031|EXPERIMENTAL|Study group|HCG IM 10,000 IU Im 48 hours after first triggering dose
62400124|NCT03580031|PLACEBO_COMPARATOR|Control group|Saline 2m Injection im 48 hours after the first triggering dose
62400125|NCT02218034|EXPERIMENTAL|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
62400126|NCT02218034|EXPERIMENTAL|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
62400127|NCT02218034|ACTIVE_COMPARATOR|TAZORAC® Gel 0.1%|TAZORAC® Gel 0.1% (tazarotene gel 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
62400128|NCT02218034|ACTIVE_COMPARATOR|TAZORAC® Cream 0.1%|TAZORAC® Cream 0.1% (tazarotene cream 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
62400129|NCT04523363|EXPERIMENTAL|Metformin|Study subjects will be randomized to the metformin medication arm. They will take a 500 mg tablet orally twice a day starting at 14 weeks of pregnancy until delivery.
62576742|NCT04455035|EXPERIMENTAL|Prospective Group|
62576743|NCT03123445|EXPERIMENTAL|Endostar + Gemcitabine and Cisplatin|Patients in this group will be given endostar combined with gemcitabine and cisplatine.
62783456|NCT05084092|EXPERIMENTAL|Intraoperative Radiotherapy (IORT)|Intraoperative Radiotherapy (IORT) administered during surgery
62400130|NCT04523363|NO_INTERVENTION|Standard of Care|Study subjects will be randomized to standard of care and receive routine prenatal care without further intervention for their prediabetes.
62400131|NCT00663208|ACTIVE_COMPARATOR|Group 1|"Daclatasvir (1 mg), once daily~or~Matching Placebo, once daily"
62400132|NCT00663208|ACTIVE_COMPARATOR|Group 2|"Daclatasvir (10 mg), once daily~or~Matching Placebo, once daily"
62576744|NCT03123445|ACTIVE_COMPARATOR|Gemcitabine and Cisplatin|Patients in this group will be given gemcitabine and cisplatine.
62400133|NCT00663208|ACTIVE_COMPARATOR|Group 3|"Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
62400134|NCT00663208|ACTIVE_COMPARATOR|Group 4|"Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
62576745|NCT06379646|EXPERIMENTAL|YTS109|YTS109 cell injection
62576746|NCT00267969|EXPERIMENTAL|ustekinumab 45 mg|Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.
62576747|NCT00267969|EXPERIMENTAL|ustekinumab 90 mg|Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.
62576748|NCT00267969|PLACEBO_COMPARATOR|Placebo|Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.
62400135|NCT00663208|ACTIVE_COMPARATOR|Group 5|"Group 5: Active Comparator~Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
62400136|NCT00663208|ACTIVE_COMPARATOR|Group 6|"Group 6: Active Comparator~Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
62400137|NCT00451191|ACTIVE_COMPARATOR|1|100 units botulinum toxin type A (BoNT/A)
62400138|NCT00451191|ACTIVE_COMPARATOR|2|300 units botulinum toxin type A (BoNT/A)
62400139|NCT02039869|EXPERIMENTAL|Proton Pump Inhibitor|Patients will receive proton pump inhibitor therapy with omeprazole twice daily while we observe for improvement in reflux symptoms. We will compare the confocal endomicroscopy images in the responders to non-responders at the end of 8 weeks to determine if confocal endomicroscopy can select patient that would benefit most from proton pump inhibitor therapy.
62576749|NCT02035202|EXPERIMENTAL|CBT2go|Participants assigned to this condition will attend one session with a therapist to identify cognitive and behavioral strategies around four areas: 1) mood/psychotic symptoms, 2) medication adherence, 3) socialization, and 4) relapse prevention. Subsequently they will answer questions on a mobile device (smartphone) 3 times per day for 12 weeks, and they will receive personalized cognitive and behavioral strategies linked to their momentary responses with bi-monthly telephone support.
62576750|NCT02035202|ACTIVE_COMPARATOR|EMA-only|Participants assigned to this condition will answer questions on a mobile device (smartphone) 3 times per day for 12 weeks but will not receive personalized cognitive and behavioral strategies.
62576751|NCT02035202|NO_INTERVENTION|Standard Care|Participants assigned to this condition will only participate in the assessments.
62198072|NCT00003704|EXPERIMENTAL|capecitabine + radiation|This is a dose-escalation study of capecitabine. Patients receive oral capecitabine twice a day 7 days a week for 6 weeks with concurrent radiotherapy. Radiotherapy is initiated on the same day as the initiation of capecitabine and is administered 5 days a week for 5.5-6 weeks. Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose-limiting toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 1 year.
62576752|NCT00764036|EXPERIMENTAL|experimental arm only|add-on therapy with 100, 150 or 200 mg oral artesunate once daily
62576753|NCT00713258|ACTIVE_COMPARATOR|PTH (1-84)|PTH (1-84) + placebo alendronate
62198073|NCT05127759|EXPERIMENTAL|HLX208|Participants receive HLX208 450mg bid po
62400140|NCT02039869|EXPERIMENTAL|Sucralfate|Patients will receive sucralfate therapy four times a day while we observe for improvement in reflux symptoms. We will compare the confocal endomicroscopy images in the responders to non-responders at the end of 8 weeks to determine if confocal endomicroscopy can select patient that would benefit most from sucralfate therapy.
62400141|NCT02652676|EXPERIMENTAL|Reversible Pulmonary Artery Banding Procedure|"The addition of afterload Reversible Pulmonary Artery Banding to a normal-functioning right ventricle (in the setting of end-stage dilated cardiomyopathy) shifts the inter-ventricular septum toward the midline, thus significantly improving left ventricular geometry and function. It permits the infant or young child to operate from a much improved position on Starling's curve with gradual resolution of congestive heart failure and the potential for lethal ventricular dysrhythmia. An abundance of progenitor myocytes known to exist within the myocardium of this patient age group may then contribute to permanent left ventricular restoration."
62400142|NCT06354660|EXPERIMENTAL|Retatrutide Dose Level 1|Participants will receive retatrutide administered subcutaneously (SC).
62400143|NCT06354660|EXPERIMENTAL|Retatrutide Dose Level 2|Participants will receive retatrutide administered SC.
62400144|NCT06354660|EXPERIMENTAL|Retatrutide Dose Level 3|Participants will receive retatrutide administered SC.
62576754|NCT00713258|ACTIVE_COMPARATOR|Alendronate|PTH (1-84) placebo + alendronate
62198074|NCT01252355|EXPERIMENTAL|Teriflunomide 7 mg + IFN-beta|Teriflunomide 7 milligram (mg) once a day concomitantly with IFN-beta therapy.
62198075|NCT01252355|EXPERIMENTAL|Teriflunomide 14 mg + IFN-beta|Teriflunomide 14 mg once a day concomitantly with IFN-beta therapy.
62400145|NCT06354660|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo administered SC.
62576755|NCT02405104|ACTIVE_COMPARATOR|THA+Klorz|All patients in this arm are treated surgically with a THA and medically with Chlorzoxazone
62576756|NCT02405104|PLACEBO_COMPARATOR|THA+Placebo|All patients in this arm are treated surgically with a THA and medically with placebo
62576757|NCT02405104|ACTIVE_COMPARATOR|TKA+Klorz|All patients in this arm are treated surgically with a TKA and medically with Chlorzoxazone
62576758|NCT02405104|PLACEBO_COMPARATOR|TKA+Placebo|All patients in this arm are treated surgically with a TKA and medically with placebo
62198076|NCT01252355|PLACEBO_COMPARATOR|Placebo + IFN-beta|Placebo (for teriflunomide) once a day concomitantly with IFN-beta therapy.
62198077|NCT03670004||Unilateral Below Knee Amputation|Individuals who walk with a below knee prosthesis
62198078|NCT03670004||Non-Impaired|Able-bodied controls
62400146|NCT01024270|EXPERIMENTAL|sublingual, oral and vaginal administration of misoprostol|
62400147|NCT06199856||Hospitalized older adults at risk of sarcopenia|
62576759|NCT03887442|ACTIVE_COMPARATOR|Paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
62576760|NCT03887442|EXPERIMENTAL|Cetuximab + Paclitaxel|Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
62783457|NCT03863808|EXPERIMENTAL|Cognitive Behavioural Therapy|"Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks."
62783458|NCT03863808|ACTIVE_COMPARATOR|Strengthening and Core Stability|"Following assessment 12 sessions over 6 weeks will start, focusing on strengthening exercises of the transversus abdominis and lumbar multifidus muscles (Angela Searle, 2015).~Exercises will be graduated according to the patient pain tolerance."
62783459|NCT00588354|EXPERIMENTAL|Clonidine|Transforaminal epidural clonidine injection
62783460|NCT00588354|ACTIVE_COMPARATOR|Steroid|Transforaminal epidural steroid injection
62783461|NCT00989963|EXPERIMENTAL|Maximum Tolerated Dose (MTD)|Patients in the MTD treatment group will dose escalate weekly by 60µg b.i.d. until they reach the maximum dose of 600µg b.i.d. or they reach an intolerable dose which requires them to down-titrate by 60µg b.i.d. In these instances and at the Investigator's discretion, further attempts at dose escalation may be made.
62198079|NCT05759962|EXPERIMENTAL|Part A: Single Ascending Dose (SAD) LQT-1213|In Part A, 4 dosing cohorts will receive a single oral dose of LQT-1213. The highest dose of LQT-1213 to be administered is 1.67 mg/kg.
62198080|NCT05759962|EXPERIMENTAL|Part A: Food Effect LQT-1213|In Part A, food effect will be integrated into one of the SAD cohorts as a single dose, two-period with at least a 7-day washout, crossover cohort.
62198081|NCT05759962|EXPERIMENTAL|Part B: Multiple Ascending Dose (MAD) LQT-1213|In Part B, 3 dosing cohorts will receive LQT-1213 in the morning on Day 1 and Day 7 and twice daily (BID) on Days 2 to 6.
62198082|NCT05759962|PLACEBO_COMPARATOR|Part A: Single Ascending Dose (SAD) Placebo|In Part A, 6 dosing cohorts will receive a single oral dose of placebo.
62198083|NCT05759962|PLACEBO_COMPARATOR|Part A: Food Effect Placebo|In Part A, food effect will be integrated into one of the SAD cohorts as a single dose, two-period with at least a 7-day washout, crossover cohort.
62400148|NCT06199856||Community-dwelling older adults at risk of sarcopenia|
62400149|NCT00715052|EXPERIMENTAL|1|40 consecutive one hour treatments at 1.5 ATA with 100% O2
62400150|NCT00715052|NO_INTERVENTION|2|
62400151|NCT04522128|ACTIVE_COMPARATOR|Feedback Intervention|"All participants will complete an online questionnaire. This will include demographic information, social distancing/isolation history, The Lubben Social Network Scale, The 6-item Loneliness Scale, Ten-Item Personality Scale, Spontaneous Self-affirmation Scale, Brief Illness Perception Questionnaire and the WHOQoL COMBI plus importance of QOL facet questions.~Participants randomly allocated to the feedback intervention will then be provided with graphs showing WHOQOL COMBI facet scores and their perceived importance ratings. The graphs will highlight where quality of life might be poor but important to the participant. Participants will be asked three questions (i.e. how could your QoL in this domain be improved, what resources would you need to make this change, what practical actions are needed to address the discrepancies in your QoL?) to help them plan how they might be able to improve quality of life currently rated as poor but important."
62576761|NCT04527289|EXPERIMENTAL|Amantadine Group|Group, I are patients who will receive amantadine (100mg) as add on therapy to the standard regimen.
62576762|NCT04527289|PLACEBO_COMPARATOR|Placebo Group|Group II are patients who will be managed with the standard regimen.
62783462|NCT00989963|EXPERIMENTAL|Low Fixed Dose|The low dose group will receive 60µg twice a day(b.i.d.)
62783463|NCT00989963|EXPERIMENTAL|High Fixed Dose|Patients in the high dose group will dose escalate weekly by 60µg twice a day (b.i.d.) until they reach the fixed dose of 240µg b.i.d. Once patients in these treatment groups have reached their assigned maximum dose of active drug,
62198084|NCT05759962|PLACEBO_COMPARATOR|Part B: Multiple Ascending Dose (MAD) Placebo|In Part B, 3 dosing cohorts will receive placebo in the morning on Day 1 and Day 7 and twice daily (BID) on Days 2 to 6.
62198085|NCT04843397||Single Arm|Patients referred for clinically indicated EGD, without known precancerous condition. Patients will receive endoscopy with standardised biopsy and photodocumentation protocol
62198086|NCT02798497|OTHER|staphylococcus aureus PVL-|patients with staphylococcus aureus PVL-
62198087|NCT02798497|OTHER|staphylococcus aureus PVL+|patients with staphylococcus aureus PVL+
62198088|NCT04149938|EXPERIMENTAL|Lidocaine Patch (Sequence AB)|Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours.
62198089|NCT04149938|EXPERIMENTAL|Lidocaine Patch (Sequence BA)|Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours.
62198090|NCT05389553||Patients at term of pregnancy|"We included all full-term pregnancies accepted for delivery that received an accurate ultrasound scan before the birth.~Pregnant women with antepartum hemorrhage, fetal growth restriction, stillbirths, multiple gestations, or congenital abnormalities were excluded."
62576763|NCT05080075|EXPERIMENTAL|Participants receiving a platelet rich plasma injection|All patients in the study will be receiving a platelet rich plasma injection, and we will be following their clinical outcomes
62576764|NCT05465473|ACTIVE_COMPARATOR|Group I|will include 10 patients undergo distalization according to a standardized protocol
62576765|NCT05465473|ACTIVE_COMPARATOR|Group II|will include 10 patients undergo distalization assisted with low level laser therapy according to a standardized protocol
62400152|NCT04522128|EXPERIMENTAL|Extended Intervention|"All participants will complete an online questionnaire (as described above).~Participants randomly allocated to the extended intervention will then be provided with graphs to highlight differences between their actual WHOQoL COMBI scores and their perceived importance ratings. The graphs will highlight where quality of life might be poor but important to the participant. Participants will be asked three questions (i.e. how could your QoL in this domain be improved, what resources would you need to make this change, what practical actions are needed to address the discrepancies in your QoL?) to help them plan how they might be able to improve quality of life currently rated as poor but important.~Participants will then receive an online intervention that will provide them with behaviour change techniques to help them address the discrepancies in the relevant quality of life domains."
62400153|NCT04522128|OTHER|Waitlist Control|"All participants will complete an online questionnaire. This will include demographic information, social distancing/isolation history, The Lubben Social Network Scale, The 6-item Loneliness Scale, Ten-Item Personality Scale, Spontaneous Self-affirmation Scale, Brief Illness Perception Questionnaire and the WHOQoL COMBI plus importance of QOL facet questions.~Participants randomly allocated to the waitlist control group will then receive their WHOQoL COMBI scores only, with no information about differences between quality of life and importance or intervention materials."
62400154|NCT03193996|OTHER|SLIL Injury|Surgical interventions for all subjects will be determined based on combined findings of both 4DCT and standard arthroscopy.
62198091|NCT04532567|EXPERIMENTAL|GLPG1205 dose A|Participants will receive a single dose with dose A of GLPG1205 on Day 1 in Period 1, and 14 days q.d. dosing on Days 1 to 14 in Period 2.
62198092|NCT04532567|PLACEBO_COMPARATOR|Placebo dose A|Participants will receive a single dose placebo on Day 1 in Period 1, and 14 days q.d. dosing on Days 1 to 14 in Period 2.
62198093|NCT04532567|EXPERIMENTAL|GLPG1205 dose B|Participants will receive 14 days q.d. dosing with dose B of GLPG1205 on Days 1 to 14.
62198094|NCT04532567|PLACEBO_COMPARATOR|Placebo dose B|Participants will receive 14 days q.d. dosing placebo on Days 1 to 14.
62198095|NCT05917353|EXPERIMENTAL|Hinex Jelly Nutritional Supplement Intervention Group|Week 0th, Week 4th (14 days before and after), Week 8th (14 days before and after), Week 12th (14 days before and after), diet and exercise health education was given, with daily intervention of Hinex Jelly nutritional supplements 1 serving per day during 0th to 8th Week;
62198096|NCT05917353|NO_INTERVENTION|Routine care group|Week 0th, Week 4th (14 days before and after), Week 8th (14 days before and after), Week 12th (14 days before and after), the subjects were given regular dietary and exercise health education.
62198097|NCT02713477|EXPERIMENTAL|Insulin glargine/ lixisenatide dose 1 Test 1|Test 1 will be administered thru subcutaneous (SC) injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
62198098|NCT02713477|EXPERIMENTAL|Insulin glargine/ lixisenatide dose 2 Test 2|Test 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
62198099|NCT02713477|PLACEBO_COMPARATOR|Placebo - Reference 1|Reference 1 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
62198100|NCT02713477|OTHER|Insulin glargine (Lantus) - Reference 2|Reference 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour pior to breakfast under fasted condition
62198101|NCT05355857|OTHER|18F-FDG injection|Health volunteers with 18-F-FDG injection
62400155|NCT05863039|EXPERIMENTAL|Group 1|Strength training associated with blood flow restriction
62400156|NCT05863039|EXPERIMENTAL|Group 2|Conventional strength training using high loads
62400157|NCT05863039|EXPERIMENTAL|Group 3|Conventional strength training using low loads
62400158|NCT01642472|EXPERIMENTAL|Ulipristal Acetate (PGL4001) 10mg|Ulipristal Acetate (PGL4001)10mg daily administration
62576766|NCT04339153|EXPERIMENTAL|Parent Training (PT)|The goal of intervention plan is to teach the basic applied behaviour analysis techniques to find out the antecedent of the problem behaviour, enhance adaptive skills and reduce noncompliance. Sessions will be interactive, and action-oriented through the provision of workbooks, modelling, videos, rehearsal (with child when present), homework tasks, and feedback (Bearss et al., 2015). The parents will be trained on the protocol and delivered 60 to 90 minutes preferably individual sessions over 24 weeks.
62734781|NCT03884387|EXPERIMENTAL|Use of a Patient Decision Aid|A Patient Decision Aid is used in this arm in the clinical encounter. A tool designed to facilitate shared decision making when patients choose between surgical and non-surgical treatment for lumbar disc herniation .
62198102|NCT05372042|EXPERIMENTAL|Loss Framing + Growth Mindset|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that is framed with toward preventing future losses from trauma exposure, and day 3 will have a reminder that aims to instill a growth mindset about using the skill.
62198103|NCT05372042|EXPERIMENTAL|Loss Framing + Simple Reminder|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that is framed with toward prevent future losses from trauma exposure, and day 3 will have a simple reminder to use the skill.
62198104|NCT05372042|EXPERIMENTAL|Gain Framing + Growth Mindset|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that is framed with toward future benefits from doing so, and day 3 will have a reminder that aims to instill a growth mindset about using the skill.
62198105|NCT05372042|EXPERIMENTAL|Gain Framing + Simple Reminder|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that is framed with toward future benefits from doing so, and day 3 will have a simple reminder to use the skill.
62198106|NCT05372042|EXPERIMENTAL|No Framing + Growth Mindset|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that has no framing, and day 3 will have a reminder that aims to instill a growth mindset about using the skill.
62400159|NCT06023589|EXPERIMENTAL|Tezepelumab|Participants will be receiving tezepelumab subcutaneous injection
62400160|NCT06023589|PLACEBO_COMPARATOR|Placebo|Participants will be receiving placebo through a subcutaneous injection
62400161|NCT00694226|EXPERIMENTAL|1|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
62400162|NCT00694226|ACTIVE_COMPARATOR|2|Treatment as usual (TTU): Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol. After completing the assessment individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis
62400163|NCT05241574|EXPERIMENTAL|radiotherapy dose escalation|Additional two fractions of endorectal high dose rate iridium brachytherapy boost, 10 Gy each.
62400164|NCT05241574|EXPERIMENTAL|chemotherapy dose escalation|Additional three cycles of consolidation chemotherapy consisted of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4).
62400165|NCT01220817|ACTIVE_COMPARATOR|1 POMx capsule|1 POMx capsule daily
62400166|NCT01220817|EXPERIMENTAL|3 POMx capsules daily|
62400167|NCT04064190|EXPERIMENTAL|Vactosertib+Durvalumab|Vactosertib will be administered in combination with standard dose of durvalumab every four weeks.
62400168|NCT02528331|EXPERIMENTAL|rTMS and Cognitive Behavior Therapy|
62400169|NCT06390995|EXPERIMENTAL|Phase 1 Part and Phase 2 Part: TAK-853|TAK-853, 6.0 mg/kg, injection, intravenously (IV), once every 3 weeks. Patients will continue to receive study drug until disease progression, unacceptable toxicity, withdrawal of consent, death, or until the sponsor terminates the study (whichever comes first).
62400170|NCT05290636|EXPERIMENTAL|single arm trial|A single-arm trial was designed. (Two-hour sessions per week for 18 weeks). The value of classroom learning and practical experience for the study subjects is emphasized in this intervention course. The case analysis teaching technique will be used extensively in the classroom, and the school's digital action learning platform will support instructional activities relevant to senior nursing and elderly nursing practice. In each section of the course, combine classroom instruction with case analysis (2 hours each, 20-30 minutes for topic teaching, 70-80 minutes for case discussion and feedback)
62400171|NCT02221362||Observational|No interventions
62400172|NCT03977922|EXPERIMENTAL|Diet group|"The diet group will be involved in a 12-week pilot nutrition program based on the anti-inflammatory diet studied by Allison and Ditor (2015). The nutrition program will entail:~1. Once per week (Monday mornings), nutrition program members will come to Power Cord to pick up their box of ingredients for their meals that week (Monday to Friday). Recipe cards will accompany the ingredients, and enough food will be provided for 3 meals and 2 snacks per day. The meals will be based on the anti-inflammatory diet previously studied in Allison and Ditor (2015).~2. 10-12 online videos that cover basic kitchen/cooking skills, how to prepare the meals in the program, how to shop for healthy foods at the grocery store, etc.~3. At the beginning of the program each member will be provided with a few pieces of accessible kitchen equipment that will made food preparation and cooking much easier.~4. Once per month, we will be offering a live cooking class."
62576767|NCT04339153|NO_INTERVENTION|Parent Education (PE)|"The Parent education group will serve as an attention-placebo condition to control for general effects of the intervention.~There will be 12 core sessions and 1 home visit regarding knowledge of autism, learning about the principles of managing behavior, teaching new skills; improving social interaction and communication. Each session will last for 60 to 90 minutes over 24 weeks."
62783464|NCT03042884|EXPERIMENTAL|Wearable Exercise Trackers - Inpatient Group|"Questionnaires completed at baseline and within 24 hours of discharge.~Participant given a wearable exercise tracker to be worn 24 hours a day while in the acute inpatient rehabilitation unit."
62783465|NCT03042884|EXPERIMENTAL|Wearable Exercise Trackers - Outpatient Group|"Questionnaires completed at baseline and again in 14 days.~Participant given a wearable exercise tracker to be worn 24 hours a day for 14 days."
62576768|NCT01091662|EXPERIMENTAL|eslicarbazepine acetate 1600 mg|Subjects randomized to 1600 mg QD of eslicarbazepine acetate will titrate from 600 mg QD(Day 0) to 1200 mg once a day(Week 2) to 1600 mg QD (Weeks 3-18) and may taper down from 1600 mg to 800 mg QD 3 days after the Week 18 visit.
62198107|NCT05372042|ACTIVE_COMPARATOR|No Framing + Simple Reminder|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that has no framing, and day 3 will have a simple reminder to use the skill.
62783466|NCT02399657|EXPERIMENTAL|Intravitreal dexamethasone implant|Intravitreal dexamethasone 0.7mg implant (Ozurdex)
62198108|NCT00689182|EXPERIMENTAL|A|All patients will receive phlebotomy
62576769|NCT01091662|EXPERIMENTAL|eslicarbazepine acetate 1200 mg|"Subjects randomized to 1200 mg QD eslicarbazepine acetate will titrate from 400 mg QD (Day0) to 800 mg QDweek2) to 1200 mg QD(weeks 3-18) and may taper down from 1200 mg to 600 mg QD 3 days after the Week 18 visit.~Subjects may continue in an open-label extension study with a starting dose of 1200 mg QD, or taper off their previous antiepileptic drugs during weeks 2-8."
62576770|NCT04941612|EXPERIMENTAL|Activa IM-Nail|Activa IM-Nail
62576771|NCT02506556|EXPERIMENTAL|experimental|BYL719 350 mg orally daily until progression, undue adverse events or withdrawal of consent.
62734782|NCT03884387|NO_INTERVENTION|Usual counceling|Usual counseling in the clinical encounter, when patients choose between surgical and non-surgical treatment for lumbar disc herniation .
62734783|NCT03860831|EXPERIMENTAL|intranasal (IN)|"Group IN will receive nasal ketamine+midazolam mixture by mucosal atomisation device: midazolam (0.2 mg/kg) +ketamine (5mg/kg).~the calculated dose will be equally divided into the two nostrils by the parents"
62783467|NCT00514371|EXPERIMENTAL|tanespimycin and bortezomib|A patient will receive a standard dose of bortezomib followed by a high dose of tanespimycin.
62576772|NCT03068832|EXPERIMENTAL|Personalized peptide vaccine and poly-ICLC|"* The synthetic long peptide(s) and poly-ICLC will be given on Cycle 1 Day 1 when available.~* Additional peptide vaccine doses will be administered again on Days 4, 8, 15, and 22 of the first cycle as a priming strategy. On all subsequent cycles, the peptide vaccine will be given on Day 1.~* Peptide vaccine administration will continue until supply is exhausted or development of intolerance or disease progression in the case of fatal high grade neoplasms. Otherwise, vaccination will continue until supply is exhausted or intolerance or one year for non-fatal tumors. Additionally, patients with non-fatal tumors who complete one year of vaccinations and have stable disease will be given the option of resuming vaccinations if they develop subsequent progression if remaining vaccine is available."
62400173|NCT03977922|NO_INTERVENTION|Control group|The control group will eat their usual diet for the 12-week period.
62400174|NCT05126966|EXPERIMENTAL|Ranibizumab|Subjects will have the implant (filled intra-operatively prior to implantation with approximately 20 µL of the 100-mg/mL formulation of ranibizumab \[approximately 2-mg dose of ranibizumab\]) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Subjects will have their implant refilled with ranibizumab at weeks 36 and 72.
62400175|NCT05126966|ACTIVE_COMPARATOR|Aflibercept|Subjects will receive intravitreal injections of aflibercept (2mg) administered in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment.
62734784|NCT03860831|ACTIVE_COMPARATOR|intramuscular (IM)|"Group IM will receive intramuscular administration of liquid ketamine +midazolam mixture:midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.~Mild to moderate restraint was done with the help of the parents during drug administration."
62783468|NCT00514371|EXPERIMENTAL|bortezomib and tanespimycin|A patient will receive a standard dose of bortezomib followed by a mid dose of tanespimycin.
62198109|NCT02737826|EXPERIMENTAL|Phase - Buprenorphine Initiation|"In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an up to 8 hour induction window. Buprenorphine tolerability will be defined as pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper."
62198110|NCT02737826|ACTIVE_COMPARATOR|Phase II - Gabapentin + Buprenorphine|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg oral gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
62198111|NCT02737826|PLACEBO_COMPARATOR|Phase II - Placebo + Buprenorphine|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg oral placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
62198112|NCT02737826|EXPERIMENTAL|Phase II - Buprenorphine taper|After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.
62198113|NCT03197753|EXPERIMENTAL|Laryngeal mask airway|Laryngeal mask airway insertion
62198114|NCT03197753|ACTIVE_COMPARATOR|Nasotracheal intubation|Nasotracheal tube insertion
62198115|NCT02525692|EXPERIMENTAL|Arm A|"Patients had histologically confirmed World Health Organization Grade IV glioblastoma with any number of recurrences.~Patients received 625 mg dordaviprone (ONC201) once every 3 weeks."
62198116|NCT02525692|EXPERIMENTAL|Arm B|"Patients had first recurrence histologically confirmed World Health Organization Grade IV glioma.~Patients received 625 mg dordaviprone (ONC201) weekly (Days 1, 8, and 15 of each cycle)."
62400176|NCT05596695|EXPERIMENTAL|Intervention Group|Intraoperative blood pressure management will be performed to maintain a systolic blood pressure of 120 ±5mmHg using a continuous infusion of a vasopressor starting at induction of anesthesia.
62400177|NCT05596695|NO_INTERVENTION|Standard of Care Group|Intraoperative blood pressure management will be performed according to local clinical standard of care.
62400178|NCT03195166|EXPERIMENTAL|hemodynamic profile|FloTrac sensor/Vigileo
62400179|NCT01062607||1|Patients diagnosed with Bipolar Disorder I or II (DSM-IV-TR) at any phase of the disorder with at least one mood event during the 12 months before the study start.
62400180|NCT01062607||2|Patients diagnosed with Bipolar Disorder I or II (DSM-IV-TR) at any phase of the disorder with at least one mood event during the 12 months before the study start receiving Seroquel extended release at some point during the retrospective period .
62400181|NCT03534921||People with severe mental illness (SMI)|In the study period 01/04/2000-31/03/2016, people with records on the Clinical Practice Research Datalink aged \>=18 years with a record of severe mental illness so that at least one event occurs in the study period.
62400182|NCT03534921||People with SMI and type 2 diabetes|Drawn from the first cohort, this group also has a record of type two diabetes mellitus registered during the study period.
62400183|NCT03534921||People with diabetes (matched controls)|This cohort will be matched on a 4:1 ratio by age (+- 2 years), gender and general practitioner practice to the group of people with comorbid SMI and diabetes.
62400184|NCT00953589|EXPERIMENTAL|Locteron ® PANEL A|PANEL A: Locteron™ 480 µg dosed every 2 weeks in two subcutaneous injections (160 µg and 320 µg)
62400185|NCT00953589|EXPERIMENTAL|Locteron ® PANEL B|PANEL B: Locteron™ 480 µg dosed every two weeks in single subcutaneous injections
62400186|NCT00953589|ACTIVE_COMPARATOR|PEG-Intron® PANEL A|PEG-Intron® 1.5 µg/kg body weight weekly subcutaneous injection
62400187|NCT00953589|ACTIVE_COMPARATOR|PEG-Intron® PANEL B|PEG-Intron® 1.5 µg/kg body weight weekly subcutaneous injection
62400188|NCT03836014|EXPERIMENTAL|Fixed duration therapy for 24 months.|Daratumumab, Lenalidomide, Dexamethasone
62198117|NCT02525692|EXPERIMENTAL|Arm C|"Patients had clinical and/or radiographic evidence of first recurrence of histologically confirmed World Health Organization Grade IV glioblastoma and were eligible for salvage surgical resection.~Patients received 625 mg dordaviprone (ONC201) weekly (Days 1, 8, and 15 of each cycle). Surgical resection was performed approximately 24 hours after at least the second dose of ONC201."
62198118|NCT02525692|EXPERIMENTAL|Arm D|"Patients had confirmed World Health Organization Grade IV glioma with H3 K27M mutation (any number of recurrences were allowed).~Patients received 625 mg dordaviprone (ONC201) weekly (Days 1, 8, and 15 of each cycle)."
62198119|NCT02525692|EXPERIMENTAL|Arm E|"Patients had clinical and/or radiographic evidence of midline glioma (recurrent disease was not required) and were eligible for salvage surgical resection.~Patients received 625 mg dordaviprone (ONC201) weekly (Days 1, 8, and 15 of each cycle). Surgical resection was performed approximately 24 hours after at least the second dose of dordaviprone (ONC201)."
62198120|NCT02525692|EXPERIMENTAL|Arm F|"Patients had diffuse midline glioma involving the brainstem, thalamus, or spinal cord, without the H3 K27M mutation or with unknown H3 mutation status.~Patients received 625 mg dordaviprone (ONC201) weekly (Days 1, 8, and 15 of each cycle)."
62198121|NCT05555147|EXPERIMENTAL|Nerve Block Group|Thirty minutes prior to surgery the patients received bilateral infraorbital and infratrochlear nerve block. Infraorbital nerve block was performed while using an extraoral approach. A 25 gauge needle was inserted laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. The index finger of the non-dominant hand was positioned above the infraorbital foramen, and the needle was advanced until it was felt beneath the finger. 2 mL of the 0.5% ropivacaine slowly injected after negative aspiration of blood was confirmed. Inserting the needle 1 cm above the inner canthus, targeting the junction of the orbit and the nasal bone, performed Infratrochlear nerve block. After negative aspiration of blood, 1 mL of the 0.5% ropivacaine was injected. Contralateral nerve block was performed in the same manner.
62198122|NCT05555147|SHAM_COMPARATOR|Control Group|Patients receiving general anesthesia without Infraorbital and Infratrochlear nerve block.
62198123|NCT01294436|EXPERIMENTAL|Open label treatment|
62198124|NCT02965105|EXPERIMENTAL|First Coloplast Test Catheter; then Speedicath|The subjects allocated to this arm first test Coloplast Test Catheter and then after cross over test the comparator Speedicath Catheter
62198125|NCT02965105|EXPERIMENTAL|First Speedicath; then Coloplast Test Catheter|The subjects allocated to this arm first test Speedicath Catheter and then after cross over test Coloplast Test Catheter
62198126|NCT04716751|EXPERIMENTAL|Toripalimab|
62400189|NCT03836014|ACTIVE_COMPARATOR|Continuous therapy|Daratumumab, Lenalidomide, Dexamethasone
62400190|NCT06055452|EXPERIMENTAL|Empagliflozin|
62734785|NCT05345405|ACTIVE_COMPARATOR|Dyadic CARE|Participants will receive dyadic CARE following baseline and will complete self-report assessments at post-session-1, Month 1, Month 2, and Month 3.
62198127|NCT03527797|NO_INTERVENTION|Control|Standard of care
62400191|NCT06055452|PLACEBO_COMPARATOR|Placebo|
62400192|NCT02144142|EXPERIMENTAL|Moisturizer with each subject's own antimicrobial bacteria|Each subject will have a moisturizer containing their own antimicrobial bacteria species spread over their arms in the clinic
62400193|NCT02163759|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
62400194|NCT02163759|ACTIVE_COMPARATOR|Adalimumab|Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.
62400195|NCT02163759|EXPERIMENTAL|Etrolizumab|Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
62400196|NCT02549391|EXPERIMENTAL|KHK7580|
62734786|NCT05345405|ACTIVE_COMPARATOR|Supporter-Only CARE|Participants will receive supporter-only CARE following baseline and will complete self-report assessments at post-session-1, Month 1, Month 2, and Month 3.
62198128|NCT03527797|EXPERIMENTAL|Intervention|Titration of support level
62400197|NCT02549391|ACTIVE_COMPARATOR|KRN1493|
62400198|NCT01136317|EXPERIMENTAL|Omeprazole|
62400199|NCT01136317|EXPERIMENTAL|Rabeprazole|
62734787|NCT05345405|NO_INTERVENTION|Waitlist Control|After completing baseline, participants will be invited to schedule a CARE session in 3 months (i.e., after the completion of all study assessments). The version of CARE received at that point will be selected by the survivor. Participants will complete self-report assessments at post-session-1, Month 1, Month 2, and Month 3.
62783469|NCT00514371|EXPERIMENTAL|bortezomib tanespimycin|A patient will receive a standard dose of bortezomib followed by a low dose of tanespimycin.
62400200|NCT01136317|PLACEBO_COMPARATOR|Placebo|
62400201|NCT04804306||Diagnostic Test: CBC-Diff Monocyte Volume Width Distribution|MDW measurement used to detect sepsis as part of the CBC-Diff ordered by ED Physician as part of the Institution's Standard of Care. Results will not be used to manage patients
62400202|NCT01580696|ACTIVE_COMPARATOR|Non-vaccine clinically matched control group|HLA-A2-negative patients and HLA-A2+ patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression.
62400203|NCT01580696|EXPERIMENTAL|E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 100mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
62400204|NCT01580696|EXPERIMENTAL|E39 peptide (500mcg) /GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 500mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
62400205|NCT01580696|EXPERIMENTAL|E39 peptide (1000mcg) /GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 1000mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
62400206|NCT01580696|EXPERIMENTAL|E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 100mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
62198129|NCT02089555||African Americans|This group consists of African American (AA) individuals aged 65-80 who are part of the Emory Alzheimer's Disease Research Center (ADRC) (a multi-racial cohort of subjects with normal cognition, Mild Cognitive Impairment (MCI) or mild Alzheimer's Disease (AD)) or the Registry for Remembrance (RfR) (a community of AA individuals who are interested in studies of memory and aging). AA and Non-Hispanic White (NHW) participants will be frequency-matched for age, gender, and education within each cognitive category (35 with normal cognition, 30 with MCI, and 10 with mild AD for each race).
62198130|NCT02089555||Non-Hispanic Whites|This group consists of Non-Hispanic White (NHW) individuals aged 65-80 who are part of the Emory Alzheimer's Disease Research Center (ADRC) (a multi-racial cohort of subjects with normal cognition, Mild Cognitive Impairment (MCI) or mild Alzheimer's Disease (AD)). African American (AA) and Non-Hispanic White (NHW) participants will be frequency-matched for age, gender, and education within each cognitive category (35 with normal cognition, 30 with MCI, and 10 with mild AD for each race).
62198131|NCT04833413||Continue intensive treatment group|Patients with type 2 diabetes who continued intensive treatment within 6 months after hospital discharge
62198132|NCT04833413||Premixed insulin treatment group|Patients with type 2 diabetes who changed to premixed insulin within 6 months after hospital discharge
62198133|NCT04833413||Basic insulin treatment group|Patients with type 2 diabetes who changed to basic insulin treatment within 6 months after hospital discharge
62198134|NCT04833413||Oral hypoglycemic drug treatment group|Patients with type 2 diabetes who changed to oral hypoglycemic drug treatment within 6 months after hospital discharge
62198135|NCT03615053|OTHER|Tailored Regimen|Implementation of WAPPS-Hemo personalized dosing regimen.
62198136|NCT04089397|EXPERIMENTAL|Light therapy group|Five weeks of light therapy, with 3 weekly sessions of 30 minutes, to be performed between 8:00 to 10:00, the days of dialysis (at home, for patients dialyzing the afternoon, or during dialysis for patients dialyzing in the morning)
62198137|NCT04089397|NO_INTERVENTION|Control group|Usual care, without light therapy
62198138|NCT06517264|ACTIVE_COMPARATOR|Outpatient treatment with antibiotics (group A)|"If belonging to group A (receiving oral antibiotic therapy), the usual oral antibiotic regimen of each center will be indicated.~According to according to the guidelines of our hospital:~* 3rd generation cephalosporin (e.g., Cefditoren 200 mg, one tablet every 12 hours) + Metronidazole 500 mg, two tablets every 8 hours. Duration of treatment: 7 days.~* Penicillin allergy: Ciprofloxacin 500 mg, one tablet every 12 hours + Metronidazole 500 mg, two tablets every 8 hours. Duration of treatment: 7 days.~Hygienic-dietary measures:~* Low-residue diet for the first 48 hours. An informative leaflet will be provided to clarify these recommendations.~* Adequate oral hydration during the episode.~* Paracetamol 1 gram orally, one tablet every 8 hours. If pain persists, alternate every 4 hours Paracetamol with Metamizole 575 mg, one tablet every 8 hours. If allergic to Metamizole, it can be substituted with Dexketoprofen 25 mg, one tablet every 8 hours."
62198139|NCT06517264|OTHER|Outpatient treatment without antibiotics (group B)|"Hygienic-dietary measures:~* Low-residue diet for the first 48 hours. An informative leaflet will be provided to clarify these recommendations.~* Adequate oral hydration during the episode.~* Paracetamol 1 gram orally, one tablet every 8 hours. If pain persists, alternate every 4 hours Paracetamol with Metamizole 575 mg, one tablet every 8 hours. If allergic to Metamizole, it can be substituted with Dexketoprofen 25 mg, one tablet every 8 hours."
62198140|NCT05609604|ACTIVE_COMPARATOR|active tDCS|This group will receive 30 minutes of active stimulation from tDCS
62198141|NCT05609604|PLACEBO_COMPARATOR|sham tDCS|This group will receive 30 minutes of sham (placebo) stimulation from tDCS
62198142|NCT01976572|PLACEBO_COMPARATOR|Candesartan alone|Single dose of 16 mg candesartan was administered orally on Day 1.
62198143|NCT01976572|ACTIVE_COMPARATOR|T0hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T-0 of 3 dosing time-points means the single dose of candesartan was administered at the same time relative to the first daily dose of colestilan.
62198144|NCT01976572|ACTIVE_COMPARATOR|T-1hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T-1 of 3 dosing time-points means the single dose of candesartan was administered at 1 hour before relative to the first daily dose of colestilan.
62198145|NCT01976572|ACTIVE_COMPARATOR|T+3hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T+3 of 3 dosing time-points means the single dose of candesartan was administered at 3 hour after relative to the first daily dose of colestilan.
62400207|NCT01580696|EXPERIMENTAL|E39 peptide (500mcg) /GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 500mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
62400208|NCT01580696|EXPERIMENTAL|E39 peptide (1000mcg) /GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 1000mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
62400209|NCT03250728|OTHER|CDG with stroke-like history|
62400210|NCT03250728|OTHER|CDG without stroke-like history|
62400211|NCT02467543|PLACEBO_COMPARATOR|20% Ethanol|20% ethanol containing no active ingredients. Ten drops will be taken three times daily when the pain and cramping of dysmenorrhea start, and should be stopped when the pain and cramping have ceased.
62400212|NCT02467543|EXPERIMENTAL|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol. Ten drops will be taken three times daily when the pain and cramping of dysmenorrhea start, and should be stopped when the pain and cramping have ceased.
62783470|NCT02585050||patients alive discharged from hospital|patients alive discharged from hospital following CPR
62783471|NCT05304897|EXPERIMENTAL|PRP group|
62198146|NCT03519204|EXPERIMENTAL|JUVÉDERM® VOLBELLA® XC with Lidocaine|JUVÉDERM® VOLBELLA® XC with lidocaine injected into lips at Day 1. Participants were eligible to receive optional touch-up retreatment one month following initial treatment if applicable.
62198147|NCT03519204|EXPERIMENTAL|No-treatment Control|No-treatment was administered during control period. After 3 months, participants were eligible to receive treatment with JUVÉDERM® VOLBELLA® XC with lidocaine if applicable followed by an optional touch-up retreatment one month following initial treatment.
62400213|NCT06716632|EXPERIMENTAL|Ligasure|Ligasure is a bipolar vascular sealing system utilized to achieve effective control of bleeding and create a bloodless surgical environment. It operates by utilizing an electrical current within the frequency range of 2-4 MHz It induces denaturation of collagen and elastin within the vessels and surrounding tissues. The localized tissue temperatures typically range between 60-100°C, facilitating the fusion of collagen and elastin in the vessel walls. This fusion process creates a durable sealed zone without any carbonization and enables hemostasis in vessels with diameters of up to 7 mm
62400214|NCT06716632|EXPERIMENTAL|Knot tying|Conventional methods of vessel ligation, which involve the use of ties and suture ligatures, have long been employed in most medical centers
62400215|NCT05741242|EXPERIMENTAL|Personalized Synthetic Long Peptide Vaccine|
62400216|NCT04196023|ACTIVE_COMPARATOR|magnesium treatment|Participants will be assigned to magnesium glycinate
62400217|NCT04196023|PLACEBO_COMPARATOR|placebo|Participants will be assigned to placebo group
62400218|NCT03201601|EXPERIMENTAL|550 mg of MYO and 150 mg of DCI|Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 150 mg of D-chiro-inositol.
62400219|NCT03201601|ACTIVE_COMPARATOR|550 mg of MYO and 13.8 mg of DCI|Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 13.8 mg of D-chiro-inositol.
62400220|NCT02497261||Avoiding and possibly allergic to peanut|Challenge Group: Children with positive skin prick testing to peanut who are avoiding peanut will undergo a double-blind placebo-controlled peanut challenge (gold standard for peanut allergy diagnosis) if their allergy evaluation suggests that they have a good chance of not being allergic to peanut. Children who pass the challenge are not allergic to peanut. Children who react during the challenge are allergic to peanut and will continue to avoid peanut.
62400221|NCT02497261||Not allergic to peanut|Comparison Group: Children with positive skin prick testing to peanut who are eating and tolerating peanut are not clinically allergic to peanut and may continue eating peanut.
62400222|NCT03122327||Newly diagnosed MM patients|newly diagnosed MM patients who fulfilled the inclusion criteria for this study
62400223|NCT06427720||Control|free from any medical, psychosocial, emotional conditions, or cancer (age interval was 28-82) were included in the study as well, matched with BC patients' group in sex and race, menopausal status, and randomly chosen from the female Egyptian population.
62400224|NCT06427720||BC patients|"full family disease/cancer history was recorded, as well as patients' previous surgical procedures, other than breast surgery, that do not affect the tumor burden, such as splenectomy, tonsillectomy, cesarean birth, and plastic surgery, offspring numbers, menopausal or not, and taking hormonal contraceptives or not.~Patients' individual current cancer status and the tumor clinical assessment, done at the NCI, using the tumor-node-metastasis (TNM) categorization (43) and the Bloom-Richardson Scale for histological grading (44), were collected from patients' data files, after a biopsy was taken at the time of BC examination"
62584919|NCT04216290|EXPERIMENTAL|Step 1, Arm C (durvalumab, radiation therapy, chemotherapy)|Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; or cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
62198148|NCT01124968|EXPERIMENTAL|eConsulta|Those patients who are offered to use the eConsulta, a web where they can virtually consult with their primary care doctor or nurse.
62400225|NCT03417648|EXPERIMENTAL|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
62198149|NCT02223104|ACTIVE_COMPARATOR|Sensura|Ostomy pouch
62198150|NCT02223104|EXPERIMENTAL|Flexima Active|Ostomy pouch
62198151|NCT01987895|EXPERIMENTAL|Cadazolid|Subjects receive oral cadazolid 250 mg twice daily (bid) and oral vancomycin-matching placebo 4 times per day (qid) for 10 days
62400226|NCT03417648|PLACEBO_COMPARATOR|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
62400227|NCT03364699|ACTIVE_COMPARATOR|dietary supplementation|The volunteers ingested 3 g daily of Soybean lecithin or fish oil rich in docosa-hexanoic acid (DHA) containing 1.5 g DHA and 0.3 g EPA (DHA:EPA = 5:1) or fish oil rich in eicosapentaenoic acid (EPA) containing 1.6 g EPA and 0.3 g DHA (EPA:DHA = 5.4:1) during 60 days.
62400228|NCT03364699|EXPERIMENTAL|Exercise|All volunteers performed two half-marathons. In the first half-marathon, all participants were not supplemented. In the second half-marathon, participants were supplemented. Blood samples were collected before and after both half-marathon race.
62400229|NCT05780749|EXPERIMENTAL|Active arm - DDI-IBS-001|
62400230|NCT05780749|PLACEBO_COMPARATOR|Placebo arm|
62400231|NCT02164058|EXPERIMENTAL|TandemHeart System + PCI|TandemHeart System prior to percutaneous coronary intervention
62400232|NCT02164058|ACTIVE_COMPARATOR|PCI|Percutaneous coronary intervention
62576773|NCT04139616||No ECG changes in patients without pre-existing RBBB|Patients with no new conduction disturbances on the ECG performed immediately post-TAVR (and no episodes of HAVB/CHB during the procedure) have a very low risk of developing HAVB/CHB or any conduction disturbance within the hours-days following the procedure. In these cases, temporary pacing will be discontinued at the end of the procedure. However, continuous ECG monitoring until hospital discharge is recommended. A 12-lead ECG is recommended 24 hours after the procedure. If no arrhythmic episodes and no ECG changes occur within the 24 hours post-procedure, the patient can be safely discharged (the day after TAVR) with no other monitoring measures in case of otherwise uneventful clinical course (absence of other TAVR related adverse events). If the patient has to remain hospitalized because of other reasons or TAVR complications, telemetry would be recommended (but no strictly required) for the detection of post-TAVR tachyarrhythmias or late ECG changes.
62010821|NCT02550652|EXPERIMENTAL|Obinutuzumab|Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 grams per day (g/day) (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.
62010822|NCT02550652|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to obinutuzumab IV infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 g/day (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.
62400233|NCT03709342|EXPERIMENTAL|All Patients|
62010823|NCT06569576|EXPERIMENTAL|in-person wellness program|The program is delivered at the senior center site.
62010824|NCT06569576|EXPERIMENTAL|Online Wellness Program|The program is delivered remotely. Participants join from their home environment.
62010825|NCT04186962|EXPERIMENTAL|Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
62010826|NCT04186962|NO_INTERVENTION|Usual care|Usual care
62010827|NCT02229877|EXPERIMENTAL|Gefapixant + Omeprazole|"Gefapixant oral tablets (25mg, 50 mg, 150 mg) administered twice daily for 18 days~+ Omeprazole oral capsules (40 mg) administered twice daily for 8.5 days"
62198152|NCT01987895|ACTIVE_COMPARATOR|Vancomycin|Subjects receive oral vancomycin 125 mg qid and oral cadazolid-matching placebo bid for 10 days
62400234|NCT00511706|EXPERIMENTAL|dexamethasone and ranibizumab|Intravitreal injection of dexamethasone 700 µg at Day 1; ranibizumab 500 µg at Day -30 and Day 7-14.
62400235|NCT00511706|SHAM_COMPARATOR|sham and ranibizumab|Sham injection at Day 1; ranibizumab 500 µg at day -30 and Day 7-14.
62400236|NCT03892876|EXPERIMENTAL|Schizophrenia TS+ve|Schizophrenia patients who receive auditory high frequency Tetanizing Stimulation
62400237|NCT03892876|SHAM_COMPARATOR|Schizophrenia TS-ve|Schizophrenia patients who receive sham comparator
62400238|NCT03892876|EXPERIMENTAL|Control TS+ve|Healthy controls who receive auditory high frequency Tetanizing Stimulation
62400239|NCT03892876|SHAM_COMPARATOR|Control TS-ve|Healthy controls who receive sham comparator
62400240|NCT03598712|EXPERIMENTAL|Compression by chest bandage urgo K2®|"After the second puncture, the local compression by thoracic bandage will be put in place.~The system being effective 7 days, it will be left in place between each visit. A visit will be made for all patients 7 days after the installation of the device. However, if necessary, an intermediate visit may be carried out.~During these visits, a puncture will be made according to the criteria mentioned above. The bandage will be renewed after each visit.~The device will be removed after 15 days without indication of a new puncture. The patient will be seen again between 10 and 15 days after the bandage is removed for a final evaluation."
62010828|NCT03384446|ACTIVE_COMPARATOR|Tooth-borne treatment|A cleaning aid that resembles tooth cleaning instruments and is empirically used for implant surface cleaning.
62010829|NCT03384446|EXPERIMENTAL|Implant-specific treatment|A cleaning aid that has been specifically designed for implant surface cleaning.
62400241|NCT03598712|ACTIVE_COMPARATOR|punctures|"After the second puncture, the patient will be seen at the same frequency as in the experimental arm.~The decision to perform a puncture will be made according to the same criteria and the follow-up conditions will be identical."
62400242|NCT05609656|EXPERIMENTAL|IRE + CaEP + Pembrolizumab|Irreversible electroporation (IRE) and calcium electroporation (CaEP) on Day 1, followed by Pembrolizumab on Day 2 (+4 days) and then every 3 weeks (q3w) for up to 12 months in total.
62400243|NCT04959682|EXPERIMENTAL|Intervention group|Patients in the intervention group will receive 30 minutes of patient-tailored instrumental music in the beginning of one weekly hemodialysis treatment for a period of six weeks
62400244|NCT04959682|NO_INTERVENTION|Control group|The procedure in the control group is the same as in the intervention group, except that they don't listen to music
62400245|NCT02635503|EXPERIMENTAL|transrectal specimen extraction|Laparoscopic colorectal resection with natural orifice specimen extraction will be performed for patients in this group.
62198153|NCT06508957||hip fracture patients|this is a observational study. There is no intervention.
62198154|NCT06436105||Group Control|Peripheral nerve block will not be performed on Group Control patients.
62198155|NCT06436105||Group FICB|FICB will be performed with 30 ml %0.25 bupivacaine for Group FICB patients.
62198156|NCT06436105||Group 4 IN 1|4 in 1 block will be performed with 30 ml %0.25 bupivacaine for Group 4 IN 1 patients.
62400246|NCT02635503|ACTIVE_COMPARATOR|Conventional laparoscopic surgery|Conventional laparoscopic surgery for colorectal cancer will be performed for patients in this group.
62400247|NCT06447870||primary non-response group|biologic therapy(eg:IFX,ADA,UST,VDZ)
61978280|NCT05756374|EXPERIMENTAL|OUT to IN Group|This group will participate in biweekly sessions of psychomotricity for 10 weeks. Sessions will be implemented in the outdoors of the preschool, by a psychomotor therapist and children's teacher. Sessions will involve physical play, relaxation and expressive activities.
62010830|NCT00265811|EXPERIMENTAL|Folfox+Cetuximab|FOLFOX-4 Cetuximab alone every 2 weeks
62400248|NCT06447870||response group|biologic therapy(eg:IFX,ADA,UST,VDZ)
62400249|NCT02997787||adenomyosis|First group called adenomyosis was consisted of patients who were pathologically diagnosed pure adenomyosis after hysterectomy
62010831|NCT00265811|ACTIVE_COMPARATOR|Folfox|FOLFOX-4 alone every 2 weeks
62010832|NCT02402010|EXPERIMENTAL|Adjunctive Yoga|Participants may be randomized to receive up to 10 weeks of group yoga class, as an adjunct to medication treatment as usual provided by community clinicians.
62010833|NCT02402010|OTHER|Enhanced Treatment as Usual|Those randomized to the Enhanced Treatment as Usual arm will follow their usual treatment plans in the community, with enhanced monitoring of symptoms and functioning through regular study assessments. With a release of information, we will provide community clinicians with a standardized report that summarizes level of symptom severity and risk, designed to aid in continuity of care.
62198157|NCT01294397|EXPERIMENTAL|Etanercept + Denosumab|Participants received etanercept 50 mg subcutaneously once weekly for 25 weeks. On study day 8, participants were administered a single 60 mg subcutaneous injection of denosumab.
62400250|NCT02997787||leiomyoma|Second group called leiomyoma was consisted of patients who were pathologically diagnosed pure leiomyoma after hysterectomy
62400251|NCT02997787||control|Third group called control group was consisted of healthy patients who were pathologically diagnosed no neoplasm after hysterectomy
62400252|NCT03030131|EXPERIMENTAL|Durvalumab|durvalumab 750 mg IV J1, J15, J29
62400253|NCT02334046|EXPERIMENTAL|Elderly|Remifentanil was maintained at predetermined effect-site concentration during the emergence period in elderly patients.
62400254|NCT02334046|ACTIVE_COMPARATOR|Adult|Remifentanil was maintained at predetermined effect-site concentration during the emergence period in adult patients.
61978281|NCT05756374|NO_INTERVENTION|Control group|This will will maintain their usual routine at preschool.
62010834|NCT03979716|EXPERIMENTAL|Anosmic patients|
62010835|NCT03979716|EXPERIMENTAL|Hyposmic patients|
62010836|NCT03979716|EXPERIMENTAL|Normosmic patients|
62010837|NCT03660956|EXPERIMENTAL|Exercise and back counselling group|
62010838|NCT03660956|ACTIVE_COMPARATOR|Back counselling group|
62010839|NCT04662346|OTHER|patients undergoing robotic pancreatoduodenectomy|patients have pancreatic neoplasm and undergoing robotic pancreatoduodenectomy
62400255|NCT01261299|EXPERIMENTAL|Carbon-14-labeled carboplatin|Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
62400256|NCT05965921||Barrett's oesophagus|Patients over 18 with known Barrett's oesophagus having gastroscopy for either surveillance or assessment of known Barrett's neoplasia
62400257|NCT00589823|ACTIVE_COMPARATOR|1|Immediate Release Morphine sulphate capsules taken at start of relevant BTCP episode. Each episode treated with either this medication OR the experimental comparator.
62400258|NCT00589823|EXPERIMENTAL|2|Nasalfent spray taken at start of relevant BTCP episode. Each episode to be treated with either this medication OR the active comparator (IRMS)
62400259|NCT04466657|ACTIVE_COMPARATOR|Standard of Care (SOC)|Participants in this arm will receive SOC alone, which will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
62400260|NCT04466657|EXPERIMENTAL|SOC plus Intervention|Participants in this arm will receive SOC plus daily antioxidant supplement composed of two proprietary formulations that include reduced glutathione, N-acetylcysteine, superoxide dismutase, and bovine lactoferrin and immunoglobulins.
62400261|NCT02282839|ACTIVE_COMPARATOR|Study group|Oral glutamine 10 g TID (total 30 g/day) one week before radiotherapy till the end of radiotherapy
62400262|NCT02282839|PLACEBO_COMPARATOR|Control group|Placebo (Same ingredients without glutamine) one week before radiotherapy till the end of radiotherapy
62400263|NCT01573988|OTHER|non-obese volunteers|Volunteers with a BMI (Body Mass Index) between 20 and 25 kg/m2.
62400264|NCT01573988|OTHER|Obese volunteers|Volunteers with a BMI (Body Mass Index) between 30 and 35 kg/m2.
62215015|NCT01050790|EXPERIMENTAL|Aza Len Lymphapheresis SCT ALI|Azacitidine will be administered to all the patients subcutaneously at a dose of 75 mg/m2 daily for five days(day 1-5). These cycles will be repeated at 28 day intervals depending on hematopoietic recovery. Starting on day 6 patients will receive lenalidomide 15 mg PO daily until day 21. No drug will be administered from day 22 to day 28. Lymphapheresis will occur after cycles 2 and 3.Patients will undergo a stem cell collection approximately two weeks after complete myeloid recovery from the third cycle of therapy. Stem Cell Transplant (SCT) will occur per transplant center protocols. Post-transplant single or tandem autologous lymphocyte infusions (ALI) will be performed no earlier than 30 days post-transplant and no later than 40 days.
62783472|NCT04213716|EXPERIMENTAL|intracanal medication|After instrumentation of the canals and drying , using Lentulo Spiral Filler medicaments will be placed under aseptic conditions into the canals experimental Intracanal medication of 1ml of nanosilver solution 30ppm concentration mixed with 100 mg of calcium hydroxide powder used as intracanal medication
62783473|NCT04213716|ACTIVE_COMPARATOR|intracanal medicament|After instrumentation of the canals and drying , using Lentulo Spiral Filler comparator intracanal medicaments will be placed under aseptic conditions into the canals which is 100 mg Ca (OH) 2 mixed with 1ml sterile water
62783474|NCT05901883|EXPERIMENTAL|CEL383 Arm|Subjects will receive a single intravenous dose of CEL383
62010840|NCT06444789||Development cohort of patients with known RBD|Detection of RBD signs by using the connected smartwach during 4 weeks
62215016|NCT06191822|OTHER|Nutrition|Set personalized nutrition goals
62400265|NCT02159872|EXPERIMENTAL|Omacetaxine|Omacetaxine 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle. Participant may continue taking the study drug for up to 24 cycles of treatment.
62400266|NCT06197776||chemoradiotherapy combined with immunotherapy|Patients treated with chemoradiotherapy combined with immunotherapy
62400267|NCT03859908|EXPERIMENTAL|Iodine-Povacrylex Alcohol|Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of Iodine-povacrylex 7mg/ml plus isopropyl alcohol 0.74 ml/ml (DuraPrep) , fabricated by 3M, as the experimental intervention. Will be applied from the center of the abdomen centrifuge as recommended by the Centers of Disease Control
62400268|NCT03859908|ACTIVE_COMPARATOR|Chlorhexidine Alcohol|Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of chlorhexidine 20 mg/ml plus isopropyl alcohol 0.7 ml/ml (SoluPrep), fabricated by 3M, as the control intervention. Will be applied from the center of the abdomen centrifuge as recommended by the Center of Disease Control
62400269|NCT02906527||Non-exposed group|Non-exposed group / Patients receiving VKA
62400270|NCT02906527||Exposed group|Exposed group / Patients receiving DOAC
62400271|NCT01015170|EXPERIMENTAL|Bupropion HCl|Up to 8 week of bupropion SR (150mg BID) + counseling.
62783475|NCT05901883|PLACEBO_COMPARATOR|Placebo Arm|Subjects will receive a single intravenous dose of placebo
62783476|NCT05131191||patients with coronary metal stents implantation|
62783477|NCT05025878||[U-13C]glucose|All participants consented to the study will receive the \[U-13C\]glucose infusion and collection of ascites for research.
62010841|NCT06444789||Development cohort of matched controls = people who don't have RBD age and sex matched|Detection of RBD signs by using the connected smartwach during 4 weeks
62010842|NCT06444789||Confirmation cohort of parkinson disease patients = people who are supposed to have RBD|Detection of RBD signs by using the connected smartwach during 3 months
62010843|NCT02496884|EXPERIMENTAL|M-CKD DS-5565 7.5 mg BID|Patients with moderate chronic kidney disease (M-CKD) randomized to receive DS-5565 BID during the treatment period.
62010844|NCT02496884|EXPERIMENTAL|S-CKD DS-5565 7.5 mg QD|Fibromyalgia patients with severe chronic kidney disease (S-CKD) randomized to receive a DS-5565 7.5 mg tablet once per day (QD), and a placebo tablet (no drug) QD, for a total of 7.5 mg DS-5565
62215017|NCT06191822|OTHER|Fitness|Set personalized fitness goals
62783478|NCT06148506||Ribociclib Arm|ribociclib (600 mg, 3 weeks on/1 week off)+ IA/FUL + goserilin for premenopausal patients
62783479|NCT06148506||Combination chemotherapy|The choice of which chemotherapy combination used on study is decided by the physician
62783480|NCT03465267|EXPERIMENTAL|Armeo power|Armeo power robot for upper extremity
62783481|NCT03465267|EXPERIMENTAL|Armeo spring|Armeo spring robot for upper extremity
62783482|NCT04938011|EXPERIMENTAL|Progesterone + 7|the transfer of day 6 blastocyst on the 7th day of progesterone supplementation
62783483|NCT04938011|ACTIVE_COMPARATOR|Progesterone + 6|the transfer of day 6 blastocysts on the 6th day of progesterone supplementation
62400272|NCT02319018|EXPERIMENTAL|Treatment (alisertib, mFOLFOX)|Patients receive alisertib PO BID on days 1-3 and mFOLFOX regimen comprising oxaliplatin IV over 2 hours on day 2, leucovorin calcium IV over 2 hours on day 2, and fluorouracil IV continuously over 46 hours on days 2-4. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62783484|NCT02585921|NO_INTERVENTION|Health & Wellness|Following enrollment, participants will learn about health and wellness.
62010845|NCT02496884|PLACEBO_COMPARATOR|M-CKD Placebo|Patients with M-CKD randomized to receive placebo twice daily (BID) during the treatment period.
62010846|NCT02496884|PLACEBO_COMPARATOR|S-CKD Placebo|Patients with S-CKD randomized to receive placebo once daily (QD) during the treatment period.
62010847|NCT02100592|EXPERIMENTAL|Erigo treated|Early rehabilitation treatment on Erigo Hocoma, a tilt table with integrated stepping device within 3 - 30 days from injury
62010848|NCT02287415|EXPERIMENTAL|Group 1|Phase A: Warfarin Phase B: Warfarin + BIA 2-093 (ESL) Phase C: Warfarin
62010849|NCT03750396|EXPERIMENTAL|Endocrine and local treatments|"Endocrine therapy is a standard-of-care for 1st line treatment in the patients with ER+/HER2- metastatic breast cancer.~Endocrine options included aromatase inhibitors, aromatase inhibitors with CDK4/6 inhibitors, fulvestrant, fulvestrant with CDK4/6 inhibitors, everolimus with exemestane, tamoxifen. For premenopausal women, agents for ovarian function suppression using GnRH agonists or surgical ovarian ablation including bilateral salpingo-oophorectomy are allowed.~Local treatments for metastatic lesions will be added in this group.~Local treatments include modalities described below:~i) Surgical resection: the achievement of tumor-free margin is not obligatory. ii) Stereotactic body radiotherapy iii) Radiofrequency ablation"
62010850|NCT05015491|EXPERIMENTAL|Noom Healthy Weight Program|"The Noom platform uses a cognitive behavioral approach to weight loss that integrates set content with interaction with live coaches to support client efforts at behavior change. The Healthy Weight program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. It has 52 weeks of curriculum with 1-3 articles to read per day (Reading level: Grade 6-8)."
62010851|NCT01499823||Patients with high-grade glioma|Patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who receive concurrent chemoradiation (CCRT) with temozolomide
62010852|NCT02023034|EXPERIMENTAL|Virtual exercises|"All patients underwent 12 sessions, twice a week for a period of 06 weeks. The exercises were performed in the on dopaminergic medication, supervised by the researchers, the period instrument used was the video game with the Nintendo ® Wii Balance Board ® platform."
62010853|NCT02023034|SHAM_COMPARATOR|Control|"Traditional exercises. All patients underwent 12 sessions, twice a week for a period of 06 weeks. The exercises were performed in the on dopaminergic medication, supervised by the researchers."
62010854|NCT05451212|EXPERIMENTAL|MuSK-CAART|"Cohort A: Infusion of MuSK-CAART at various dose levels with or without pre-treatment (6 groups planned).~Cohort B: Infusion of MuSK-CAART at the dose regimen selected from Part A."
62010855|NCT05434897|EXPERIMENTAL|2% dose AK3280 cream|After the 4-week screening period, Eligible subjects will be administered daily 2% dose AK3280 cream b.i.d. for 12weeks.
62010856|NCT05434897|EXPERIMENTAL|4% dose AK3280 cream|After the 4-week screening period, Eligible subjects will be administered daily 4% dose AK3280 cream b.i.d. for 12weeks.
62010857|NCT05434897|EXPERIMENTAL|8% dose AK3280 cream|After the 4-week screening period, Eligible subjects will be administered daily 8% dose AK3280 cream b.i.d. for 12weeks.
62010858|NCT05434897|ACTIVE_COMPARATOR|Placebo cream|The same subject will be randomized to receive topical administration of AK3280 cream or placebo cream at S1 and S3, respectively.
62010859|NCT01341184|EXPERIMENTAL|Group 1|16 subjects: TMC207 400mg orally on days 1 and 29, rifabutin 300mg orally, every day on day 20-41
62010860|NCT01341184|EXPERIMENTAL|Group 2|16 subjects: TMC207 400mg orally on days 1 and 29, rifampin 600mg orally, every day on day 20-41
62010861|NCT02422030|EXPERIMENTAL|Group1: TreatmentA+TreatmentB+TreatmentC|TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
62215018|NCT06191822|OTHER|Sleep|Set personalized sleep goals
62215019|NCT03300973|ACTIVE_COMPARATOR|urodynamics study group|65 patients with stress urinary incontinence were randomly chosen to have urodynamic study before surgery
62400273|NCT04277104|EXPERIMENTAL|Healthy intervention|Acoustic stimulation
62400274|NCT04277104|SHAM_COMPARATOR|Healthy sham|No stimulation
62400275|NCT04277104|EXPERIMENTAL|At risk intervention|Acoustic stimulation
62400276|NCT04277104|SHAM_COMPARATOR|At risk sham|No stimulation
62400277|NCT04277104|EXPERIMENTAL|MCI (mild cognitive impairment) intervention|Acoustic stimulation
62010862|NCT02422030|EXPERIMENTAL|Group2: TreatmentC+TreatmentA+TreatmentB|TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
62010863|NCT02422030|EXPERIMENTAL|Group3: TreatmentB+TreatmentC+TreatmentA|TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
62198158|NCT02467439|ACTIVE_COMPARATOR|Notification Cards|Includes two groups of newly diagnosed HIV-infected participants (ppt): Seropositive and Acutely Infected. After consent and a full survey, blood and urine sample are collected for viral genetic testing and future STI testing. Ppts will be given notification cards for their sexual partners, social contacts. Ppts will receive contract partner notification: if the named sexual partners do not present for testing within 7-14 days, community outreach workers will contact and counsel the partners to visit the clinic. Any returning sexual partner or social contact presenting to the clinic with the notification card linking to the original index ppt will be consented (HIV testing, blood and urine specimen collected for viral genetic testing and future STI testing if HIV positive). If HIV-infected, they will be in the active arm, and will receive partner notification and social contact referral cards. If they are HIV-seronegative they will be screened for acute HIV infection.
62010864|NCT02422030|EXPERIMENTAL|Group4: TreatmentC+TreatmentB+TreatmentA|TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
62010865|NCT02422030|EXPERIMENTAL|Group5: TreatmentB+TreatmentA+TreatmentC|TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
62010866|NCT02422030|EXPERIMENTAL|Group6: TreatmentA+TreatmentC+TreatmentB|TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
62010867|NCT01531959|ACTIVE_COMPARATOR|Midodrine|
62783485|NCT02585921|EXPERIMENTAL|Organ Donation Video Education|Following recruitment, participants will watch and discuss videos about organ donation.
62010868|NCT01531959|PLACEBO_COMPARATOR|Placebo|
62010869|NCT04666038|EXPERIMENTAL|Arm A (LOXO-305)|Orally
62010870|NCT04666038|ACTIVE_COMPARATOR|Arm B (Idelalisib plus rituximab [IdelaR] or bendamustine plus rituximab [BR])|Investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR).
62010871|NCT01507415||Exacerbation|Patients with Chronic Obstructive Pulmonary Disease (COPD)
62010872|NCT06488976||Enuresis nocturna|Patients older than 5 years of age and the main compliment should be bedwetting without any history of additional lower urinary tract symptoms.
62010873|NCT06488976||Healthy control|Patients older than 5 years of age, no remarkable past medical history and complaints.
62010874|NCT05813743|OTHER|Pregnant in 3rd trimester with abnormally invasive placenta|
62400278|NCT04277104|SHAM_COMPARATOR|MCI (mild cognitive impairment) sham|No stimulation
62400279|NCT05252507|EXPERIMENTAL|Paint Night|
62400280|NCT04136509|EXPERIMENTAL|allograft|The filler used in sinus floor elevation is albumin impregnated allograft.
62400281|NCT04136509|EXPERIMENTAL|xenograft|The filler used in sinus floor elevation is anorganic bovine bone mineral.
62400282|NCT06724107|EXPERIMENTAL|UVC group|photofunctionalised (study group) implants
62783486|NCT02585921|EXPERIMENTAL|Organ Donation Discussion Education|Following recruitment, participants will learn techniques to introduce and discuss the topic of organ donation with parents or guardians.
62783487|NCT02585921|EXPERIMENTAL|Both Video and Discussion Education|Following recruitment, participants will watch and discuss videos about organ donation and then learn techniques to introduce and discuss the topic of organ donation with parents and guardians.
62400283|NCT06724107|PLACEBO_COMPARATOR|Control group|non-photofunctionalised (control group) implants
62400284|NCT01283282|ACTIVE_COMPARATOR|Clopidogrel/Placebo|Subjects were randomized to clopidogrel 75 mg daily for 6 weeks. Then immediately transitioned to a placebo daily for 6 weeks.
62783488|NCT01239823|EXPERIMENTAL|Whole Body Vibration Training|The subjects will participate in a 12-week whole body vibration exercise program with 2 sessions (1/2 hour) per week.
62783489|NCT01239823|EXPERIMENTAL|Exercise without vibration|The subjects will participate in a 12-week exercise program with 2 sessions (1/2 hour) per week.
62783490|NCT06299644|ACTIVE_COMPARATOR|Belt and Suspenders Configuration|Endoscopic sleeve gastroplasty with the Endomina system creating proximal and distal gastric plications (belt and suspenders configuration).
62783491|NCT06299644|ACTIVE_COMPARATOR|Belt Configuration|Endoscopic sleeve gastroplasty with the Endomina system creating distal gastric plications (belt configuration).
62783492|NCT05466357|EXPERIMENTAL|Intracapsular excision of pituitary tumor|Literature review was conducted to calculate the excision rate, postoperative recurrence rate and postoperative endocrine improvement of previous endoscopic intracapsular excision of pituitary tumor.
62783493|NCT05252663|EXPERIMENTAL|Study group|Quake breathing, patients were advised to take a deep breath and hold it for 3-5 seconds.
62215020|NCT03300973|ACTIVE_COMPARATOR|surgery only group|60 patients with stress urinary incontinence were randomly chosen to have surgery without urodynamics study
62400285|NCT01283282|ACTIVE_COMPARATOR|Placebo/Clopidogrel|Subjects were randomized to a placebo daily for 6 weeks. Then immediately transitioned to clopidogrel 75 mg daily for 6 weeks.
62576774|NCT04139616||Patients with pre-existing RBBB|A temporary pacing wire is recommended to be maintained for 24 hours (or at least overnight) in all patients with prior RBBB, along with telemetry and daily ECG during the entire hospitalization period (minimum of 2 days). If any ECG changes occur during the initial 2-3 days, patients can be managed according to the proposed strategy (see management strategies for groups 3 and 5). If no ECG changes or significant bradyarrythmias occur within the 2-3 days following the procedure, the patient can be discharged. Considering that the increased risk of life threatening bradyarrhythmias in these patients may extend beyond the hospitalization period, the use of continuous ECG monitoring systems (minimum of 48 hours, up to 4 weeks) may be considered.
62576775|NCT04139616||ECG changes in patients with prior conduction disturbances|"Any significant increase in PR or QRS interval will indicate to continuing the temporary pacing for 24 hrs, with daily ECG and telemetry for 1-2 days. If the ECG changes regress in \<24 hrs, an earlier removal of the temporary pacing may be considered. Also, a strategy of multiple ECGs during the first 24 hrs may be considered. If ECG changes regress or no further changes occur the patient can be discharged with no PPM at 2 days post-TAVR.~If 24 hrs post-TAVR, the PR and QRS interval remain stable but \>240 or \>150 ms, respectively, and ≥20 ms longer than baseline, maintaining the temporary pacing wire for another 24 hrs is recommended. If no decrease in the PR or QRS duration occurs at day 2, the patient can be considered at risk for more advanced conduction disturbances requiring PPM. The use of an EP study may be a reasonable option for deciding PPM in those patients with prior conduction disturbances with worsening of ECG changes post-TAVR"
62584920|NCT04216290|ACTIVE_COMPARATOR|Step 1, Arm D (radiation therapy, chemotherapy)|Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; or cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
62215021|NCT01001182||Non interventional|Patients with RA diagnosis receiving any treatment for RA (DMARDS or biologics)
62215022|NCT04976504||Oxygen reserve index|Male and female patients aged 18 to 80 years with ASA physical status I to III scheduled for elective surgery with planned arterial catheter placement before induction of general anesthesia and did not match the exclusion criteria.
62010875|NCT04638608|OTHER|EMBRACE (Relatives)|Feasibility test of a new palliative rehabilitation blended learning program for relatives of people with ALS/cognitive impairments
62215023|NCT05253989|NO_INTERVENTION|Control|Regular assessments as outlined in the outcomes assessment section. No other change from standard of care.
62400286|NCT00830011|ACTIVE_COMPARATOR|standard care|Medical care including medication for neuropathic pain
62576776|NCT04139616||New-onset LBBB|"Temporary pacing for 24 hrs is recommended, in all patients with new-onset LBBB post-TAVR. Earlier removal of the temporary pacing and discharged at day 1 can be considered if LBBB resolves in \<24 hrs.~If LBBB persists but no further progression of the duration of the QRS or PR interval is observed at day 1, temporary pacing can be discontinued. If no further ECG changes are observed up to day 2-3 post-TAVR, the patient can be discharged. These patients are however at increased risk of HAVB/CHB requiring PPM, and continuous ECG monitoring and/or EP studies may be considered.~If further prolongation of the QRS or PR interval is observed at day 1, the temporary pacing is recommended for an additional 24 hrs. If the prolongation of the QRS or PR intervals continues at day 2, evaluation with EP studies or PPM implantation may be considered.~The occurrence of any episode of HAVB/CHB following TAVR in a patient with new-onset LBBB will be considered an indication for PPM"
62584921|NCT04216290|EXPERIMENTAL|Step 2, Arm E (durvalumab)|Patients previously randomized to Arm C (chemoradiation and durvalumab) who achieve clinical CR or clinical benefit receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
62010876|NCT04638608|OTHER|EMBRACE (Health care providers)|Feasibility test of a new palliative rehabilitation blended learning program health care providers helping people with ALS/cognitive impairments
62215024|NCT05253989|ACTIVE_COMPARATOR|VR Intervention Group|Regular assessments as outlined in the outcomes assessment section. Regular VR training sessions.
62400287|NCT00830011|ACTIVE_COMPARATOR|CBT|
62010877|NCT06663644|ACTIVE_COMPARATOR|Muscle energy technique|Post isometric relaxation technique is performed after positioning the patient and was asked to apply 30% force against therapist force and hold that contraction for 7- 10seconds and after that relax for 5seconds and when patient exhale. Therapists take muscle to new restriction barrier; hold this position for 10-60 seconds . Technique is performed 3-5 reps along with conventional treatment for 3 consecutive weeks.
62400288|NCT04408625|EXPERIMENTAL|Initial Cohort - Low dose|
62400289|NCT04408625|EXPERIMENTAL|Initial Cohort - Medium dose|
62400290|NCT04408625|EXPERIMENTAL|Bridging Cohort - Low dose|Participants enrolled in the Bridging Cohort will be assigned to either low or medium dose in an alternating manner
62400291|NCT04408625|EXPERIMENTAL|Bridging Cohort - Medium dose|Participants enrolled in the Bridging Cohort will be assigned to either low or medium dose in an alternating manner
62400292|NCT02213666||Intracardiac and Transesophageal Echocardiography|Imaging of the right atrial appendage and left atrial appendage with ICE and TEE
62400293|NCT03978689|EXPERIMENTAL|CUE-101 dose escalation and expansion|Part A\&B: CUE-101 Monotherapy IV infusion Q3W Dose Escalation (Part A) and Expansion (Part B)
62576777|NCT04139616||HAVB/CHB during the periprocedural period|"Maintaining temporary pacing in patients with procedural persistent HAVB/CHB, and monitoring in intensive care unit are recommended. If HAVB/CHB persists at 24 hrs, PPM is recommended. If HAVB/CHB recovers the day after TAVR, the temporary pacing can be removed and the patient can remain hospitalized for 1 day. If another episode of HAVB/CHB occurs, PPM is recommended. If no other episode of HAVB/CHB occurs, and no other features potentially justifying PPM exist the patient can be discharged.~Temporary pacing is recommended for 24 hrs in patients with transient HAVB during the procedure, with telemetry and daily ECG for 2 days. Discontinuing temporary pacing may be considered in those cases with brief episodes of HAVB/CHB and normal ECG. If no recurrent episodes of HAVB/CHB occur, and the patient has no other potential indications for PPM the patient can be discharged at day 2. PPM would be indicated if any recurrent episode of HAVB/CHB occurs during the hospitalization period."
62576778|NCT05707026|EXPERIMENTAL|cross fiber fascial manipulation|The group A received three sessions of fascial manipulation in two weeks. FM applied to densified Centre of Coordination (CC) points located on the myofascial sequences for 5 to 8 minutes at each CC point
62734788|NCT03719092|EXPERIMENTAL|Prevention (vitamin A compound)|"Participants receive vitamin A compound PO or enterally once prior to stem cell transplant.~once over a given 24 hour period with or without food. We will re-dose at 2000 IU/kg (maximum 120,000 IU) if Week 2 Vitamin A levels remain within 10% of baseline Vitamin A."
62010878|NCT06663644|EXPERIMENTAL|Hamstring and abdominal muscle activation|"Techniques which target hamstring and abdominal muscle activation is 90/90 hip lift with balloon. It is performed in supine lying position such that lie on back with feet on a wall and knees and hips bent at 90 degrees angle. Place a 4-6 ball between knees. Place right arm above head and a balloon in left hand. Now inhale through nose and slowly blow out into the balloon. Pause 3 seconds with tongue on the roof of mouth to prevent airflow out of the balloon. Slowly blow out as stabilize the balloon .it is performed along with conventional therapy of moist pack for 15 mins, pelvic bridging, pelvic rolling."
62010879|NCT01850199|ACTIVE_COMPARATOR|Usual management (presential visits)|Patient will follow the usual care program, which includes in-person appointment (weekly/biweekly)
62010880|NCT01850199|EXPERIMENTAL|Smart telemedicine remote monitoring for gestational diabetes|After receiving an structured education on the matter, patients will be followed remotely by analysing glucose and diet/physical activity/other events data with a periodicity no longer than 48 hours
62010881|NCT05087017||Intervention Group|Patients with COPD or Lung Fibrosis following rehabilitation program will be invited to participate and answer the questionnaires in the beginning and after eight weeks of rehabilitation.
62010882|NCT05087017||Control group|Patients with COPD or Lung Fibrosis who do not do any regular activity will be invited to participated and answer the questionnaires just once.
62010883|NCT05299541|ACTIVE_COMPARATOR|Control|Measurements and questioners
62010884|NCT05299541|ACTIVE_COMPARATOR|Group A|Receiving Food dish every night for 6 months Measurements and questioners
62010885|NCT05299541|ACTIVE_COMPARATOR|Group B|Receiving Food dish every night for 6 months, at this group extra attention have given to the dish plating and appearance by professional (BOCUSE), Measurements and questioners
62010886|NCT05389124||Experimental gingivitis|Group will wear a splint during oral hygiene to cover one quadrant of their dentition. They will develop gingivitis over 3 weeks. They will practise normal oral hygiene in the rest of their mouth (with minor restrictions, e.g. no mouthwash) and one other quadrant will act as an internal control for the gingivitis. After 3 weeks, normal oral hygiene will be restored throughout the mouth and subjects will continue to be monitored for a further 3 weeks.
62010887|NCT05898399|EXPERIMENTAL|Part A1 (ART6043 as monotherapy)|Patients with advanced or metastatic cancer will receive ART6043 administered in 21-day cycles.
62010888|NCT05898399|EXPERIMENTAL|Part A2 (ART6043 in combination with Olaparib)|Patients with advanced or metastatic cancer and with PARPi as an appropriate treatment option will receive ART6043 in combination with Olaparib twice daily (BID) in 21-day cycles.
62010889|NCT05898399|EXPERIMENTAL|Part A3 (ART6043 in combination with Niraparib)|Patients with advanced or metastatic cancer and with PARPi as an appropriate treatment option will be given ART6043 in combination with Niraparib once daily (QD) in 21-day cycles.
62010890|NCT05898399|EXPERIMENTAL|Part B1 (ART6043 in combination with a PARPi)|Patients with g/sBRCA-m, HER2-ve locally advanced or metastatic breast cancer will be assigned to receive ART6043 in combination with a PARPi (Olaparib or Niraparib).
62010891|NCT05898399|EXPERIMENTAL|Part B2 (ART6043 in combination with a PARPi or a PARPi alone)|Patients with g/sBRCA-m, HER2-ve locally advanced or metastatic breast cancer will be randomly assigned to receive ART6043 in combination with a PARPi or a PARPi alone (Olaparib or Niraparib).
62198159|NCT02467439|NO_INTERVENTION|Base Case Arm|consist of HIV seropositive and seronegative STI clinic patrons . After a brief survey to obtain demographics and sexual behavior, seronegative ppts will have blood collected for screening for acute HIV infection. If a person has acute HIV infection, they will be contacted by a community outreach worker and brought back in for counseling, and, if consenting, enrolled in the active arm. STI clinic patrons who are seropositive at screening will be given cards and asked to refer their sexual partners for evaluation using passive referral. Sexual partners presenting to the clinic with the notification card linking to the original index ppt in the base case arm will be consented to be in study (HIV testing, blood and urine specimen collected for viral genetic testing and future STI testing if HIV positive). If they are seropositive, these participants will be in the base case arm, and will receive partner notification cards for passive referral.
62576779|NCT05707026|EXPERIMENTAL|stretching techniques|Group B received three sessions of sleeper and cross body adduction stretches. Group B received three sessions of sleeper stretch in a side lying position in 90o abduction, elbow at 90o flexion and then performing shoulder IR and cross-body adduction stretch was done in sitting position. Three sets of the each stretch position were held for 30 seconds with a 1 minute break between sets
62576780|NCT02236845|EXPERIMENTAL|Lacrima medical active device|
62198160|NCT04481568|EXPERIMENTAL|The PES-4-BPSD Model|The intervention arm consists of PES and nurse assistants who work on the intervention unit which consists of: I. Cohorting of patients with cognitive impairment AND past or present indication of BPSD, acutely admitted to the medicine or telemetry service, are cohorted on a 10-bed medical unit. II. PES staff: mental health assistants with high school level education, who receive training in de-escalation and crisis prevention techniques and provide direct personal care to psychiatric patients. On the intervention unit, these PES purposefully engage patients with BPSD. III. Staff Support: The PI will hold monthly 20 minute group sessions to reinforce training and discuss challenging patient behaviors; meant to improve the attitude and empathy of HCGs towards patients. IV. Staff Training (please refer to NCT# 04179721 for more details on staff support and training).
62198161|NCT04481568|ACTIVE_COMPARATOR|The attention control condition|The attention control condition will consist of a 40-bed medicine unit, staffed with 39 nurses (1:6 ratio) and 26 nursing assistants (1:8 ratio), that primarily cohorts older patients with geriatric syndromes.
62198162|NCT03424070|ACTIVE_COMPARATOR|Laryngoscopy view with a shoulder roll|The primary outcome is the difference in the height of the lateral canthus of the eyelid of the laryngoscopist above the OR table during laryngoscopy with and then without the shoulder roll. These two positions will be compared using photos of the best glottic view taken during laryngoscopy with a shoulder roll in place. Then a photo of the best glottic view will be taken during laryngoscopy without the shoulder roll in place. These two views will be compared by a blinded anesthesiologist using the POGO scale.
62198163|NCT03424070|PLACEBO_COMPARATOR|Laryngoscopy without a shoulder roll|The primary outcome is the difference in the height of the lateral canthus of the eyelid of the laryngoscopist above the OR table during laryngoscopy without and then with the shoulder roll. These two positions will be compared using photos of the best glottic view taken during laryngoscopy with a shoulder roll in place. Then a photo of the best glottic view will be taken during laryngoscopy without the shoulder roll in place. These two views will be compared by a blinded anesthesiologist using the POGO scale.
62198164|NCT02786472|ACTIVE_COMPARATOR|Haven|"Online Bystander Training or Haven provides students with definitions and statistics associated with sexual assault and relationship violence, bystander skills and strategies, and campus policies and resources. The trainings are personalized and reflective and incorporate the student's unique perspectives and experiences. This 45-minute training is mandatory and students are asked to complete a follow-up survey 45-days after the training. Because this training is mandatory for all incoming students, all students are expected to have exposure to this training."
62576781|NCT02236845|SHAM_COMPARATOR|Lacrima medical sham device|
62576782|NCT04867642|EXPERIMENTAL|Part A Sequence 1|Study participants randomized to Part A will receive single ascending doses of UCB0022 or placebo (PBO) at pre-specified time points during the Treatment Period of alternating cohorts in a crossover design.
62576783|NCT04867642|EXPERIMENTAL|Part A Sequence 2|Study participants randomized to Part A will receive single ascending doses of UCB0022 or placebo (PBO) at pre-specified time points during the Treatment Period of alternating cohorts in a crossover design.
62576784|NCT04867642|EXPERIMENTAL|Part B UCB0022|Study participants randomized to Part B will receive multiple ascending doses of UCB0022 at pre-specified time points during the Treatment Period of cohorts in a parallel design.
62010892|NCT04889092|EXPERIMENTAL|blood flow restriction exercise|8 weeks (20 sessions) of blood flow restriction knee extension/flexion exercise
62010893|NCT04889092|ACTIVE_COMPARATOR|traditional resistance exercise|8 weeks (20 sessions) of traditional knee extension/flexion resistance exercise
62010894|NCT01117818|ACTIVE_COMPARATOR|A: AFFITOPE AD02|
62010895|NCT01117818|ACTIVE_COMPARATOR|B: AFFITOPE AD02|
62010896|NCT01117818|ACTIVE_COMPARATOR|C: AFFITOPE AD02|
62010897|NCT01117818|ACTIVE_COMPARATOR|D: Placebo control|
62198165|NCT02786472|ACTIVE_COMPARATOR|AlcoholEdu|Online Substance Abuse Training or AlcoholEdu provides confidential substance abuse education course which uses a science-based approach to educate students about alcohol and its effects. Whether the student drinks or not, the course will help them make informed decisions about alcohol and better deal with drinking behavior that may occur around them. AlcoholEdu is used by more than 500 colleges nationwide through EVERFi.
62198166|NCT02786472|EXPERIMENTAL|ConnectEd|In-person Combination Training provides Green Dot Intensive Bystander Training AND Substance Abuse Prevention cross-programming to develop ConnectED. The intentional coordination between substance abuse and violence prevention programming would include in-depth information related to interpersonal violence and substance use/abuse, activities to help participants explore their connection to these issues; information and activities related to the culture of violence, drinking and drug use and how everyone has a role in impacting that culture; information about bystander behaviors and barriers to taking action when they encounter problem situations; participant self-evaluation of their own attitudes, beliefs and biases around these issues; and, in-depth skill building activities to prepare participants to safely intervene in problem situations.
62198167|NCT02786472|EXPERIMENTAL|GreenDot|"In-person Bystander Training provides Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions. While a Popular Opinion Leader strategy has been used in prior training, for this trial all incoming students randomized to this condition will be offered intensive bystander training.~NOTE: Green Dot Speeches will be supplemental to Intensive Green Dot Bystander training. These speeches will continue to occur as usual. As the aim of this study is to compare bystander intensive training, we will not attempt to limit participation to Green Dot Speeches."
62198168|NCT00382447|EXPERIMENTAL|1|Standard nebulizer versus standard breath actuated nebulizer
62198169|NCT05089045|EXPERIMENTAL|Population Ⅰ|
62198170|NCT00867295|PLACEBO_COMPARATOR|placebo|no antibiotic is used
62576785|NCT04867642|PLACEBO_COMPARATOR|Part B Placebo|Study participants randomized to Part B will receive placebo (PBO) comparator at pre-specified time points during the Treatment Period of cohorts in a parallel design.
62010898|NCT04584567|EXPERIMENTAL|DOXY ZINC|Doxycycline daily dosing (100mg) Zinc daily dosing (15mg)
62198171|NCT00867295|ACTIVE_COMPARATOR|drug|cefazolin Sodium 1g i.v. before the operation
62198172|NCT02860897|EXPERIMENTAL|Vaginal estrogen cream|
62198173|NCT02860897|EXPERIMENTAL|Vaginal estrogen tablet|
62198174|NCT01914081|ACTIVE_COMPARATOR|Resveratrol|500 mg (1 capsule BID) of resveratrol for 12 months
62198175|NCT01914081|PLACEBO_COMPARATOR|Placebo|500 mg (1 capsule BID) of placebo for 12 months.
62198176|NCT00214253|EXPERIMENTAL|1|Thiazolidinedione therapy
62198177|NCT00214253|NO_INTERVENTION|2|
62010899|NCT04584567|PLACEBO_COMPARATOR|DOXY PLACEBO|Doxycycline daily dosing (100mg) placebo of Zinc
62010900|NCT04584567|PLACEBO_COMPARATOR|PLACEBO|placebo of Doxycycline daily dosing placebo of Zinc
62010901|NCT06662500|EXPERIMENTAL|Shockwave Javelin Coronary IVL Catheter|The Shockwave Javelin Coronary IVL Catheter will be used to treat subjects with moderate-to-severely calcified, stenotic de novo coronary artery lesions presenting with stable angina or following stabilization after acute coronary syndrome (ACS) that are suitable for non-emergent percutaneous coronary intervention (PCI).
62010902|NCT04684797|EXPERIMENTAL|Intervention group|Each participant will undergo two sessions, consisting of performing the virtual T-maze task, scalp-EEG recording and/or intracranial video-EEG recording.
62010903|NCT03909776|ACTIVE_COMPARATOR|IA group|Cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion.
62010904|NCT03909776|SHAM_COMPARATOR|IV group|Cisplatin was given at 100-120 mg/m2 as 6-h infusions.
62198178|NCT01782690||Erlotinib plus Gemcitabine|Patients with metastatic pancreatic cancer, who were planned to receive combination therapy of erlotinib and gemcitabine based on the investigator's assessment.
62198179|NCT03863132|ACTIVE_COMPARATOR|TAVR Group|Patients will be treated by transcatheter aortic valve repair (TAVR).
62198180|NCT03863132|NO_INTERVENTION|Medical Treatment Group|Patients will receive optimal medical treatment alone.
62198181|NCT04631731|EXPERIMENTAL|Single agent PD-1/L1 inhibitor|
62198182|NCT04631731|EXPERIMENTAL|PD-1/L1 inhibitor + CTLA-4 inhibitor|
62198183|NCT04631731|EXPERIMENTAL|Platinum-based chemotherapy + PD-1/L1 inhibitor|
62198184|NCT04631731|EXPERIMENTAL|PD-1/L1 inhibitor + tyrosine kinase inhibitor|
62783494|NCT05252663|ACTIVE_COMPARATOR|Control group|Percussion, vibration and shaking were used accompanied with postural drainage.
62010905|NCT06503835||The patients who underwent transforaminal epidural steroid and ozone injection|Patients who received combination therapy were injected 5ml of ozone at a concentration of 28 g/ml and two mL of dexamethasone (8 mg) and 3 mL of saline for each transforaminal epidural injection level under fluoroscopy guidance
62010906|NCT06503835||The patients who underwent transforaminal epidural steroid injection alone|Patients who received transforaminal epidural steroid injection were injected two mL of dexamethasone (8 mg) and 3 mL of saline for each transforaminal epidural injection level.
62198185|NCT04631731|EXPERIMENTAL|PD-1/L1 inhibitor + VEGF inhibitor|
62198186|NCT00532870|ACTIVE_COMPARATOR|1|laparoscopy
62198187|NCT02117986|EXPERIMENTAL|loading dose of colistin|Patients will receive a loading dose of colistin (6 million international units) followed by a maintenance dose of 3 million international units of colistin every 8 hours intravenous
62198188|NCT02117986|ACTIVE_COMPARATOR|without loading dose of colistin|Patients will receive 3 million international units of colistin every 8 hours intravenous
62198189|NCT01590511||The study population|Patients in the emergency room or intensive care in acute circulatory failure without ventilatory support.
62198190|NCT00725270|PLACEBO_COMPARATOR|Placebo|Patients will be randomized to placebo
62198191|NCT00725270|EXPERIMENTAL|Mifepristone|Patients will be randomized to mifepristone
62198192|NCT05620277|OTHER|Group 1|30 patients will be examined for changes in tooth color.
62198193|NCT05015582|EXPERIMENTAL|Treatment|"Preop: Use of full body forced air warming pre-operative at ambient (32˚C) for at least 30 minutes and fluids from warmed cabinet set at 45˚C~Intraop: Use of upper body and lower forced air warming intra-operative at 32 and 42˚C respectively and IV fluids with hotline fluid warmer set at 42˚C"
62198194|NCT05015582|ACTIVE_COMPARATOR|Control Group|"Preop: Use of full body forced air warming pre-operative at ambient (32˚C) for at least 30 minutes and fluids from warmed cabinet set at 45˚C~Intraop: Use of upper body forced air warming intra-operative at ambient (32˚C) and IV fluids at room temperature"
62198195|NCT03189342|EXPERIMENTAL|Single Task Training|Performed balance and gait exercises
62198196|NCT03189342|EXPERIMENTAL|Dual task training|Performed cognitive activity simultaneously with balance and gait exercises
62198197|NCT03189342|EXPERIMENTAL|Exercise-Cognitive Activity Combined Training|Performed cognitive, balance and gait activity training asynchronously at different times during the same day
62198198|NCT05758103|EXPERIMENTAL|Mechanical debridement + probiotic supplement|Patients with peri-implant mucositis treated through non-surgical professional mechanical debridement and probiotic supplement Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains).
62198199|NCT05758103|NO_INTERVENTION|Mechanical debridement|Patients with peri-implant mucositis treated through non-surgical professional mechanical debridement alone
62198200|NCT05368155|EXPERIMENTAL|ACT and Education Group|The Acceptance and Commitment Training (ACT) and education group will receive the Brief ACT for Pelvic Pain treatment, which will include three weekly, 90-minute group sessions.
62198201|NCT05368155|NO_INTERVENTION|Enhanced Treatment As Usual|The Enhanced treatment as usual (TAU) condition will receive a letter with treatment resources and encouraged to consult with their VHA primary care clinicians for additional education and treatment options.
62010907|NCT02337829|EXPERIMENTAL|Arm A|Subjects will be randomized to receive 1 of 2 dosing regimens: 1) acalabrutinib, dose A once daily; or 2) acalabrutinib, dose B twice daily.
62010908|NCT02337829|EXPERIMENTAL|Arm B|Subjects will be randomized to receive 1 of 2 dosing regimens: 1) acalabrutinib, dose A once daily; or 2) acalabrutinib, dose B twice daily.
62198202|NCT05302180|EXPERIMENTAL|Synchronous online group|The synchronous online pain neuroscience education program (EducaDor program) will be held in groups at until 12 participants, at 10 weekly synchronous meetings on the Whereby® platform.The professional will conduct each synchronous meeting with dialogued exhibition class using multimedia material shared on the computer screen
62198203|NCT05302180|EXPERIMENTAL|Asynchronous group|Participants allocated in the asynchronous group will receive the interactive e-book at the beginning of the program and ten videos (one per week) with the same topics of synchronous online EducaDor program sent on their smartphone devices and e-mail, in addition to usual care. Before receiving the materials, users will participate in an individual or group synchronous meeting of up to 12 participants on the Whereby® platform to receive a guidance for the use of interactive e-book and access to videos over the 10 weeks. The videos were previously developed and tested in another clinical trial.
62783495|NCT01023672|OTHER|Armodifinil|150-250 mg armodafinil by mouth daily
62010909|NCT05574348|EXPERIMENTAL|PO2S - Control|"This arm will start with PO2S, followed by Control. The PO2S consists of two sessions of 30 minutes each, one week apart, composed of normalizations of joint, muscular, ligament and visceral dysfunctions .~Control is a treatment in 2 sessions that is like PO2S but is not an active osteopathic treatment. A light touch will be made for fictitious normalizations."
62010910|NCT05574348|EXPERIMENTAL|Control - PO2|"This arm will start with Control, followed by PO2S. The PO2S consists of two sessions of 30 minutes each, one week apart, composed of normalizations of joint, muscular, ligament and visceral dysfunctions .~Control is a treatment in 2 sessions that is like PO2S but is not an active osteopathic treatment. A light touch will be made for fictitious normalizations."
62010911|NCT02057757|EXPERIMENTAL|Nitazoxanide (NTZ)|Participants will receive NTZ for 5 days. Participants younger than 12 years will receive an oral suspension formulation of NTZ; participants 12 years and older will receive NTZ tablets.
62010912|NCT02057757|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo for 5 days. Participants younger than 12 years will receive an oral suspension formulation of placebo; participants 12 years and older will receive placebo tablets.
62010913|NCT01378000||UFH,once a day|
62010914|NCT01378000||heparin Calcium,every 12 hours|
62400294|NCT03978689|OTHER|Pembrolizumab and CUE-101|Part C\&D: CUE-101 Dose Escalation in Combination with KEYTRUDA® (pembrolizumab) for injection, for IV use 200 mg Q3W (Part C). Expansion of pembrolizumab plus CUE-101 at the combination RP2D (Part D)
62576786|NCT04867642|EXPERIMENTAL|Part C UCB0022|Study participants randomized to this cohort in Part C will receive fixed multiple doses of UCB0022 at pre-specified time points during the Treatment Period.
62576787|NCT04867642|PLACEBO_COMPARATOR|Part C Placebo|Study participants randomized to this cohort in Part C will receive placebo (PBO) comparator at pre-specified time points during the Treatment Period.
62576788|NCT05416021|ACTIVE_COMPARATOR|25 mg dapivirine ring|25 mg dapivirine vaginal ring (Ring-004) for 90 days (replaced every 30 days) (Treatment A), followed by the 100 mg dapivirine ring (Ring-008) used continuously for 90 days (Treatment B)
62576789|NCT05416021|ACTIVE_COMPARATOR|100 mg dapivirine ring|100 mg dapivirine vaginal ring (Ring-008) used continuously for 90 days (Treatment B), followed by the 25 mg dapivirine ring (Ring-004) for 90 days (replaced every 30 days) (Treatment A)
62576790|NCT04157296|EXPERIMENTAL|CBT and computerized cognitive training (CCT)|Participants will play CCT games at home 5 times per week for two weeks before beginning CBT and for two weeks after the first CBT session. Then participants will have CCT games immediately prior to CBT for nine more weeks (one time a week).
62576791|NCT04157296|ACTIVE_COMPARATOR|Cognitive behavioral therapy|Participants will receive CBT sessions once a week for 12 weeks.
62576792|NCT00277238|EXPERIMENTAL|CPG10101 (0.2) + pegylated inteferon + ribavirin|
62010915|NCT01378000||dextran,Salviae,once a day|
62010916|NCT01378000||UFH,continuous intravenous infusion,|
62010917|NCT06576765|EXPERIMENTAL|Group 1|Subjects with Moderate Impairment will receive a single oral dose of AZD0780 under fasted conditions.
62010918|NCT06576765|EXPERIMENTAL|Group 2|Healthy participants will receive a single oral dose of AZD0780 under fasted conditions.
62010919|NCT06576765|EXPERIMENTAL|Group 3 (optional)|Subjects with Mild Impairment will receive a single oral dose of AZD0780 under fasted conditions.
62010920|NCT06014255|EXPERIMENTAL|Enoblituzumab|Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV every 2 weeks for 12 weeks, followed by a radical prostatectomy on day 84, with follow-up visits 30 days, 90 days, 6 months, and 9 months post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.
62198204|NCT05302180|ACTIVE_COMPARATOR|E-book group|Participants allocated to this group will receive the interactive e-book of EducaDor program in their smartphone devices and e-mail, in addition to usual care. Before receiving the e-book, the users will also participate in an individual or group synchronous meeting of up to 12 participants on the Whereby® platform to receive a guidance for the use of interactive e-book over the 10 weeks.
62198205|NCT00448201|ACTIVE_COMPARATOR|Methotrexate Only Arm|GVHD Prophylaxis with Methotrexate
62400295|NCT05710809|EXPERIMENTAL|Intervention group|Patients in the intervention groups will receive neoadjuvant, adjuvant or first line palliative chemotherapy (for metastatic disease). In addition, all patients will undergo three months' targeted specialized physical group-based exercise and Comprehensive Geriatric Assessment with corresponding interventions
62010921|NCT06014255|ACTIVE_COMPARATOR|Standard of Care|Patients will undergo standard of care radical prostatectomy within 4-8 weeks of randomization.
62010922|NCT05022355||scapulothoracic arthrodesis|"Individuals diagnosed with FSHD who have undergone unilateral or bilateral surgery who meet the inclusion criteria.~application of determined outcome scales on patients"
62010923|NCT05022355||non-operative|"Participants diagnosed with FSHD who have not undergone any surgery, who meet the inclusion criteria.~application of determined outcome scales on patients"
62400296|NCT05710809|NO_INTERVENTION|Usual care group|Patients in the usual care groups will receive standard treatment with neoadjuvant, adjuvant or first line palliative chemotherapy (for metastatic disease). If the patients have other health complaints, these will, as current standard procedure, be treated by oncologist or by referral to general practitioner
62576793|NCT00277238|EXPERIMENTAL|CPG10101 (0.5) + pegylated inteferon + ribavirin|
62576794|NCT00277238|ACTIVE_COMPARATOR|Pegylated interferon + ribavirin|
62576795|NCT00277238|EXPERIMENTAL|CPG10101 + pegylated interferon + ribavirin (rollover)|
62576796|NCT00905983|EXPERIMENTAL|Gemcitabine and Docetaxel|Patients received biweekly docetaxel 50 mg/m2 iv, Gemcitabine 2000 mg/m2 iv days 1 and 14.
62400297|NCT02231502|EXPERIMENTAL|Vegetable-based convenience food|"One time ingestion of a vegetable-based convenience product. Dietary restrictions will be observed (i.e. avoidance of some vegetables) for 3 days prior to the bioavailability assessment (a list of foods to avoid will be provided).~At least 7 days wash-out between each assessment visit."
62576797|NCT03910036|EXPERIMENTAL|PRP group|15 patients to constitute the PRP-group was injected intra-articularly with about 5 ml of PRP in the operated knee joint
62783496|NCT02736565|EXPERIMENTAL|Cohort -1|0.02mg/kg pbi-shRNA™ EWS/FL/I1 Type 1 Lipoplex
62400298|NCT02231502|ACTIVE_COMPARATOR|Vegetable meal|"One time ingestion of a minimally processed vegetable meal. Dietary restrictions will be observed (i.e. avoidance of some vegetables) for 3 days prior to the bioavailability assessment (a list of foods to avoid will be provided).~At least 7 days wash-out between each assessment visit."
62576798|NCT03910036|NO_INTERVENTION|control group|The other fifteen patients were not injected and constituted control group.
62576799|NCT00665431|EXPERIMENTAL|Arm 1 PN 400 (VIMOVO)|PN400: 500 mg naproxen/20 mg esomeprazole bid
62576800|NCT00665431|ACTIVE_COMPARATOR|Arm 2 (Celebrex)|Celecoxib 200 mg
62576801|NCT00665431|PLACEBO_COMPARATOR|Arm 3 (Placebo)|sugar pill
62010924|NCT00004317|EXPERIMENTAL|1|This group of infants is treated with a loading dose of oral pyrimethamine followed by a higher dose for the first two months then a lower dose for the remainder of the 12 months. Sulfadiazine and leucovorin calcium are also given orally for 12 months. The pyrimethamine loading dose is omitted if prior prenatal therapy was given.
62010925|NCT00004317|EXPERIMENTAL|2|This group of infants is treated with a higher dose of oral pyrimethamine for the first 6 months and then the lower dose for the remainder of the 12 months. Sulfadiazine and leucovorin calcium are administered concurrently.
62010926|NCT02894203|EXPERIMENTAL|Mindfulness|
62010927|NCT02894203|ACTIVE_COMPARATOR|Hatha Yoga|
62400299|NCT00361790|OTHER|1|
62400300|NCT03230760|EXPERIMENTAL|treatment|
62010928|NCT02894203|NO_INTERVENTION|Wait-list|
62010929|NCT05314153|EXPERIMENTAL|Open Label - Active Drug|Brexanolone (zulresso) infusion arm. All patients enrolled will receive active treatment with brexanolone.
62010930|NCT05840965|NO_INTERVENTION|Asymptomatic flexible flatfoot|This group undergoes no intervention.
62010931|NCT05840965|EXPERIMENTAL|Symptomatic flexible flatfoot: foot core strengthening|"The investigators put together a specific training program emphasizing the neuromuscular recruitment of the plantar intrinsic foot muscles. This will be colloquially referred to as the Foot Core Strengthening Program. The most recognized exercise of our program is the short foot exercise. However, as recently other exercises were validated by Gooding et al., we also included following exercises: toe spread out, first-toe extension and second- to fifth-toes extension. Simultaneously, neuromuscular electrical stimulation (NMES) will be provided, as 77% of healthy active people struggle performing contractions of the foot muscles."
62400301|NCT06722391|PLACEBO_COMPARATOR|Control|Participants will receive stimulation only up to sensory level.
62400302|NCT06722391|EXPERIMENTAL|NMES|Participants will receive stimulation up to maximum tolerable level.
62400303|NCT06722391|PLACEBO_COMPARATOR|Resistance Training|Participants will receive exercise training with stimulation up to sensory level.
62400304|NCT06722391|EXPERIMENTAL|Resistance Training + NMES|Participants will receive exercise training with stimulation up to maximum tolerable intensity.
62576802|NCT06105775|EXPERIMENTAL|Nitrate-Enriched Beetroot Extract Capsule|Once daily capsule containing beetroot extract enriched with 400 mg of sodium nitrate, for 154 consecutive days.
62576803|NCT06105775|PLACEBO_COMPARATOR|Placebo Capsule.|Once daily capsule containing beetroot extract, with nitrate replaced by plant-based flour, for 154 consecutive days.
62576804|NCT03910205||Type 1 diabetes with gingivitis|Children with type 1 diabetes mellitus and gingivitis
62576805|NCT03910205||Type 1 diabetes with healthy gingiva|Children with type 1 diabetes mellitus and healthy gingiva
62576806|NCT03910205||Healthy patients with gingivitis|Systemically healthy patients with gingivitis
62576807|NCT03910205||Healthy patients with healthy gingiva|Systemically healthy patients with healthy gingiva
62400305|NCT03961347|ACTIVE_COMPARATOR|Probiotic Group|The probiotic group will receive a daily capsule with Lactobacillus johnsonii N6.2 1x109 CFUs. Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
62400306|NCT03961347|PLACEBO_COMPARATOR|Placebo Group|The placebo group will receive a capsule daily with dried skim milk (vehicle of the probiotic). Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
62783497|NCT02736565|EXPERIMENTAL|Cohort 0|0.03mg/kg pbi-shRNA™ EWS/FL/I1 Type 1 Lipoplex
62783498|NCT02736565|EXPERIMENTAL|Cohort 1|0.04mg/kg pbi-shRNA™ EWS/FL/I1 Type 1 Lipoplex
62783499|NCT02736565|EXPERIMENTAL|Cohort 2|0.06mg/kg pbi-shRNA™ EWS/FL/I1 Type 1 Lipoplex
62783500|NCT02736565|EXPERIMENTAL|Cohort 3|0.08mg/kg pbi-shRNA™ EWS/FL/I1 Type 1 Lipoplex
62783501|NCT02736565|EXPERIMENTAL|Cohort 4|0.10mg/kg pbi-shRNA™ EWS/FL/I1 Type 1 Lipoplex
62198206|NCT00448201|ACTIVE_COMPARATOR|2 Doses ATG + Methotrexate|GVHD prophylaxis with antithymocyte globulin (ATG) + Methotrexate
62576808|NCT00879476|EXPERIMENTAL|1|Ramipril capsules 10 mg (containing Ramipril 10 mg)of of OHM Laboratories Inc., USA (a subsidiary of Ranbaxy Pharmaceuticals Inc), USA
62576809|NCT00879476|ACTIVE_COMPARATOR|2|ALTACE® capsule 10 mg (containing Ramipril 10 mg)of King Pharmaceuticals Inc., Bristol, TN 37620, USA
62576810|NCT02511145|ACTIVE_COMPARATOR|Microneedles pretreatment and Metvixia|minizone with Microneedles pretreatment and Metvixia cream application
62576811|NCT02511145|ACTIVE_COMPARATOR|Microneedles pretreatment and Metvixia under occlusion|minizone with Microneedles pretreatment and Metvixia cream application with occlusion
62576812|NCT02511145|ACTIVE_COMPARATOR|Laser pretreatment and Metvixia|minizone with laser pretreatment and Metvixia cream application
62576813|NCT02511145|ACTIVE_COMPARATOR|Laser pretreatment and Metvixia under occlusion|minizone with Laser pretreatment and Metvixia cream application with occlusion
62576814|NCT02511145|ACTIVE_COMPARATOR|Metvixia|minizone with Metvixia cream application, without pretreatment
62576815|NCT02511145|ACTIVE_COMPARATOR|Metvixia under occlusion|minizone with Metvixia cream application under occlusion, without pretreatment
62576816|NCT02511145|EXPERIMENTAL|Microneedles pretreatment only|minizone with Microneedles pretreatment only
62010932|NCT05840965|ACTIVE_COMPARATOR|Symptomatic flexible flatfoot: foot orthotics|"Custom-made foot orthotics are the current standard of care (SOC) therapy within this population. Patients choose their own health care provider to customize these orthotics. The sole is made of EVA material whose color and hardness is determined by the podiatrist or bandage maker. Digital scans or plaster of Paris cast will be taken of the participant's non-weightbearing foot (placed in a neutral or corrected position) by a certified pedorthist following the prescription of the orthopaedic surgeon.~The geometry of the foot orthotic will encompass a total contact principle with respect to the medial arch. The orthotics will be manufactured using ethyl vinyl acetate (EVA) with a shore ranging between 45 and 60"
62198207|NCT00448201|ACTIVE_COMPARATOR|2 Doses ATG|GVHD prophylaxis with 2 doses ATG
62400307|NCT06724796|EXPERIMENTAL|Y4BI|The yoga classes will be conducted once a week, in groups, with each session lasting 1 hour. They will be led by a qualified instructor with over 10 years of teaching experience in yoga.
62576817|NCT02511145|EXPERIMENTAL|Laser pretreatment only|minizone with Laser pretreatment only
62576818|NCT02511145|NO_INTERVENTION|Normal skin|Normal skin control mini-zone
62576819|NCT00413946|EXPERIMENTAL|Erythropoietin|Three doses of rErythropoietin (3000 U/kg body weight) intravenously at 3, 12-18 and 36-42 hours after birth.
62576820|NCT00413946|PLACEBO_COMPARATOR|saline|Three doses of placebo (0.9% saline 1 ml/kg body weight) intravenously at 3, 12-18 and 36-42 hours after birth
62576821|NCT04244084|EXPERIMENTAL|MMH-407|Tablet for oral use. One tablet per intake. On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily. The drug is administered not during meals (i.e. between the meals or 15-30 minutes before meal). The tablet should be held in mouth until complete dissolution.
62576822|NCT04244084|PLACEBO_COMPARATOR|Placebo|According to the scheme of receiving MMN-407 until the end of the study.
62576823|NCT03390972|EXPERIMENTAL|Dexmedetomidine|Volunteers are given an intravenous infusion with dexmedetomidine, with an effect-site target concentration of 0.6 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests the effect-site target concentration is raised to 1.2 ng/ml and the swallowing series is repeated.
62576824|NCT03390972|PLACEBO_COMPARATOR|Placebo|Volunteers are given an intravenous infusion with saline 0,9% with target controlled infusion pump in corresponding doses as in the dexmedetomidine arm.
62576825|NCT06520020|EXPERIMENTAL|Non-Traumatic Spinal Cord Injury (ntSCI,) DCM - Progressive|Non-traumatic spinal cord injury (ntSCI) with diagnosis of degenerative cervical myelopathy (DCM) and offered surgical intervention. Prospective.
62400308|NCT06724796|ACTIVE_COMPARATOR|ACTIVE|The total body classes will take place once a week, with each session lasting one hour. They will be led by a kinesiology specialist in preventive and adapted physical activities.
62576826|NCT06520020|EXPERIMENTAL|Traumatic Spinal Cord Injury (tSCI) - Early/Acute|Traumatic spinal cord injury (tSCI) screened during the hospital admission when cervical/thoracic spinal injury was diagnosed. 2-6 weeks after injury.
62400309|NCT04318626|OTHER|PMPBB3|"1. Name: \[18F\] PMPBB3，\[18F\]1-Fluoro-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)ben~2. Dosage form: intravenous injection~3. Dose(s): 7mCi~4. Dosing schedule: Visit 2~5. Mechanism of action (if known): high affinity radiotracer for the tau protein~6. Pharmacological category：Radio pharmaceutical"
62010933|NCT02353312|EXPERIMENTAL|Initial Intervention Arm|Kuvan® supplementation in addition to standard care for heart failure for three months. At the end of three months, stop Kuvan®, patients will only receive Standard care for heart failure for another 3 months
62400310|NCT04318626|OTHER|THK|"1. Name: \[18F\]THK5351，(S)-6-\[(3-Fluoro-2-hydroxy)propoxy\]-2-(2-Methylaminopyrid-5-yl)-quinoline~2. Dosage form: intravenous injection~3. Dose(s): 10mCi~4. Dosing schedule: Visit 2~5. Mechanism of action (if known): high affinity radiotracer for the tau protein~6. Pharmacological category：Radio pharmaceutical"
62400311|NCT03933358||Euthyroid|
62400312|NCT03933358||Low T3|low triiodothyronine syndrome
62576827|NCT06520020|ACTIVE_COMPARATOR|Traumatic Spinal Cord Injury (tSCI) - Chronic|Delayed traumatic spinal cord injury (tSCI) screened 6-24 months after acute cervical/thoracic spinal injury. The use of transcutaneous spinal cord stimulation (Tc-SCS) in chronic SCI delivered in the delayed timeframe is relatively well studied, and therefore will serve as the control arm.
62576828|NCT00379080|EXPERIMENTAL|Arm I - Feasibility|"Patients receive oral tandutinib twice daily for 7 days. Patients then undergo biopsy or surgery to remove the tumor. Within 2 weeks after biopsy or surgery, patients receive oral tandutinib twice daily\* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~conventional surgery~oral tandutinib~Pharmacological study~Tissue samples"
62576829|NCT00379080|EXPERIMENTAL|Arm 2 - Dose Escalation (Phase 1)|"Phase I: Patients receive oral tandutinib twice daily\* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.~the starting dose for tandtinib is 500mg BID~oral tandutinib~Pharmacological study~Tissue samples"
62576830|NCT00379080|EXPERIMENTAL|Arm 3 - Phase 2|"Patients receive tandutinib as in phase I at the MTD determined in phase I.~600mg was the determined MTD in Dose Escalation~oral tandutinib~Pharmacological study~Tissue samples"
62010934|NCT02353312|ACTIVE_COMPARATOR|Delayed Intervention Arm|Standard care for heart failure for three months. At the end of three months, Starting Kuvan® supplementation in addition to Standard care for heart failure for another 3 months
62010935|NCT03670589||radiosurgery gammaknife group|Patient treated by radiosurgery gammaknife for a one side vestibular schwannoma
62010936|NCT03670589||microsurgery resection group|Patient treated by microsurgery resection for a one side vestibular schwannoma
62010937|NCT01810978|ACTIVE_COMPARATOR|Bifidobacterium lactis plus inulin|Bifidobacterium lactis plus inulin
62010938|NCT01810978|PLACEBO_COMPARATOR|maltodextrin|maltodextrin
62198208|NCT00448201|ACTIVE_COMPARATOR|3 Doses ATG|GVHD prophylaxis with 3 doses ATG
62198209|NCT03377296|EXPERIMENTAL|Plasmodium Vivax infection|"Both volunteers will be infected with Plasmodium Vivax (as described below in full in Interventions). i.e., there is only one arm to this study."
62198210|NCT05567042||drug-resistant epilepsy|No intervention
62198211|NCT05567042||Medication is effective|No intervention
62215025|NCT05253989|ACTIVE_COMPARATOR|VR Intervention + FES Group|Regular assessments as outlined in the outcomes assessment section. Regular VR training sessions, with FES stimulation.
62215026|NCT05599620|EXPERIMENTAL|AWARE Program|The AWARE program addresses alcohol use, sexual distress and sexual revictimization risk.
62400313|NCT03500302|EXPERIMENTAL|Evolocumab|All enrolled patients will receive evolocumab sq once a month for a total of two doses
62400314|NCT06724523||Deaf children|Deaf children attending deaf education programs
62400315|NCT00635193|OTHER|Cohort 1|Three subjects will be treated with liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab, 7.5 mg/kg qwk
62576831|NCT05795855|EXPERIMENTAL|ADEPT|Individuals receiving prenatal care at a practice that was randomized to deliver the ADEPT intervention.
62783502|NCT02736565|EXPERIMENTAL|Cohort 5|0.125mg/kg pbi-shRNA™ EWS/FL/I1 Type 1 Lipoplex
62400316|NCT00635193|OTHER|Cohort 2|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk
62400317|NCT00635193|OTHER|Group A|liposomal doxorubicin, 40 mg/m2 q4wk
62400318|NCT00635193|OTHER|Group B|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg q2wk (or other dose and schedule)
62198212|NCT06299735|ACTIVE_COMPARATOR|Patient group using a double-lumen tube for single-lung ventilation|Group DLT: For the assessment of postoperative pulmonary complications, arterial blood gas analysis, chest X-ray, respiratory sounds, and the patient's oxygen requirement will be monitored every 6 hours for 24 hours. The parameters to be examined preoperatively are: smoking history, ARISCAT score (Age, Preoperative SpO₂, Respiratory infection in the last month, Preoperative anemia (Hgb ≤10 g/dL), Surgical incision, Duration of surgery, Emergency procedure).
62198213|NCT06299735|ACTIVE_COMPARATOR|Patient group using a endobronchial blocker for single-lung ventilation|Group BB: For the assessment of postoperative pulmonary complications, arterial blood gas analysis, chest X-ray, respiratory sounds, and the patient's oxygen requirement will be monitored every 6 hours for 24 hours. The parameters to be examined preoperatively are: smoking history, ARISCAT score (Age, Preoperative SpO₂, Respiratory infection in the last month, Preoperative anemia (Hgb ≤10 g/dL), Surgical incision, Duration of surgery, Emergency procedure).
62783503|NCT02736565|EXPERIMENTAL|Cohort 6|0.156mg/kg pbi-shRNA™ EWS/FL/I1 Type 1 Lipoplex
62198214|NCT00258752|EXPERIMENTAL|1|Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST)
62198215|NCT00258752|EXPERIMENTAL|2|Enhanced IPT-AST
62400319|NCT00635193|OTHER|Group C|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk (or other dose and schedule)
62400320|NCT02569931|EXPERIMENTAL|study group|"36 participants recruited aged between 18 to 50 years of age~Participants will be considered eligible for the study group if they have had two or more episodes of patellar dislocation or multiple episodes of subluxation with at least one of the following:~i. Positive patellar apprehension test ii. Tenderness along the medial retinaculum iii. Abnormal patellar tracking or position.~The study group will undergo gait analysis and electromyography before surgery and 6 months after surgery.~During surgery the study group will undergo intra-operative tracking and pressure measurements."
62400321|NCT02569931|OTHER|control group|"36 participants recruited aged between 18 to 50 years of age, matched for age and gender with the study group. Control participants should be healthy subjects with no history of knee injury or surgery.~The control group will undergo gait analysis and electromyography."
62400322|NCT01352871||Concentration / meditation|The subject will try to influence the innate immune response by concentration / meditation in advance of and during endotoxemia
62400323|NCT06723600|EXPERIMENTAL|Experimental Group|The experimental group relatives of patients will be informed by the nurse during surgery.
62400324|NCT06723600|NO_INTERVENTION|Control Group|The control group will take rutin informing.
62400325|NCT06369402||Individuals with symptomatic peripheral arterial disease|Individuals with intermittent claudication caused by confirmed peripheral arterial disease defined as a resting ankle-brachial pressure index of \<0.9 and/or a post-exercise reduction in either ankle-brachial pressure index of \>20% or absolute ankle pressure of \>30mmHg.
62400326|NCT06369402||Healthy controls|Age- and sex-matched cohort of individuals without peripheral arterial disease.
62400327|NCT02140268|ACTIVE_COMPARATOR|Midazolam 7.5 mg|Volunteers will receive Midazolam 7.5 mg administered by mouth as a syrup
62400328|NCT02140268|EXPERIMENTAL|AZD1722 15 mg|Volunteers will received AZD1722 15 mg administered by mouth, as a tablet
62198216|NCT00258752|ACTIVE_COMPARATOR|3|Typical school counseling
62400329|NCT02140268|EXPERIMENTAL|AZD1722 15 mg and Midazolam 7.5 mg|Volunteers will receive AZD1722 15 mg tablet and Midazolam 7.5 mg syrup, by mouth
62576832|NCT05795855|NO_INTERVENTION|Standard of Care|Individuals receiving prenatal care at a practice that was randomized to deliver the standard of care.
62576833|NCT06240169|EXPERIMENTAL|DPC in AGE I with MTA|DPC using MTA in Age group I i.e. 18-40years.
62783504|NCT00815893|EXPERIMENTAL|1 dex group|received dexmedetomidine (1.0 mcg/kg) infusion
62198217|NCT03248544|EXPERIMENTAL|vitamin D|Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection
62198218|NCT03248544|OTHER|control|Control patients will not be received any intervention
62198219|NCT04829097|EXPERIMENTAL|SIB-IMRT|1. New auxiliary TMZ period: oral TMZ 75mg/m2, qd, continued until the beginning of radiotherapy. 2. Concurrent radiotherapy and chemotherapy period: 4 weeks in total. Prior to treatment, radiotherapy positioning and planning were established, using SIB-IMRT technology, the irradiation range, the tumor residual area 60Gy/20f/4w, the tumor bed area 40Gy/20f/4w, 1 time/d, 5 times/w. During radiotherapy, TMZ will continue to be administered orally simultaneously, the specific dose: TMZ 75mg/m2 qd, until 42 days. 3. Intermediate rest period: 4 weeks in total. ;4. TMZ adjuvant chemotherapy period: 6 to 12 months in total. Cycle 1: TMZ 150mg/m2, d1-5, q28d; if the patient can tolerate it, cycles 2-12: TMZ 200mg/m2, d1-5, q28d; after cycles 3, 6, 9, and 12 of adjuvant chemotherapy Head functional magnetic resonance examination was performed to assess the size of residual lesions and edema.
62783505|NCT00815893|PLACEBO_COMPARATOR|2 control group|received 0.9% saline
62783506|NCT00815893|ACTIVE_COMPARATOR|3 Propofol group|received 1% propofol using effect-site TCI(Base Primea, Fresenius, France)
62783507|NCT03107494|EXPERIMENTAL|Treatment with GATS|Gala Airway Treatment System (GATS) / RheOx
62783508|NCT02008773|ACTIVE_COMPARATOR|valacyclovir|3000mg daily oral 16 weeks
62783509|NCT02008773|PLACEBO_COMPARATOR|placebo|placebo 6 capsules daily oral 16 weeks
62783510|NCT01371734|EXPERIMENTAL|Experimental Arm 1 - high dose|
62783511|NCT01371734|EXPERIMENTAL|Experimental Arm 2 - low dose|
62198220|NCT04829097|ACTIVE_COMPARATOR|CRT|1. Concurrent radiotherapy and chemotherapy period: 6 weeks in total. Radiotherapy positioning and planning before treatment, using CRT technology, irradiation range, tumor bed area, 60Gy/30f/6w, 1 time/d, 5 times/w, simultaneous TMZ oral administration on the first day of radiotherapy, specific dose: TMZ 75mg/m2 qd for 42 consecutive days; head functional magnetic resonance imaging was performed at the end of radiotherapy to assess the size of residual lesions and edema. 2. Intermediate rest period: 4 weeks in total. The patient will go to the hospital to recheck blood routine every week;3. TMZ adjuvant chemotherapy period: 6 to 12 months in total. Cycle 1: TMZ 150mg/m2, d1-5, q28d; if the patient can tolerate it, cycles 2-12: TMZ 200mg/m2, d1-5, q28d; head functional magnetic resonance imaging was performed after adjuvant chemotherapy in cycles 3, 6, 9, and 12 to assess the size of residual lesions and edema.
62198221|NCT00234598|NO_INTERVENTION|Control group, usual care|Usual care with no study interventions provided; no tooth brushing intervention and no chlorhexidine intervention. Usual care
62198222|NCT00234598|ACTIVE_COMPARATOR|Tooth brushing only|Tooth brushing by study personnel three times per 24 hours (TID) without chlorhexidine application.
62198223|NCT00234598|ACTIVE_COMPARATOR|Chlorhexidine only|Oral application of chlorhexidine 0.12% oral solution twice per 24 hours (BID) without tooth brushing.
62198224|NCT00234598|ACTIVE_COMPARATOR|Toothbrushing and chlorhexidine|Tooth brushing by study personnel three times per 24 hours (TID) and oral application of chlorhexidine 0.12% oral solution twice per 24 hours (BID)
62576834|NCT06240169|EXPERIMENTAL|DPC in AGE I with BD|DPC using BD in Age group I i.e. 18-40years.
62576835|NCT06240169|EXPERIMENTAL|DPC in AGE II with MTA|DPC using MTA in Age group II i.e. 41-60years
62783512|NCT01371734|PLACEBO_COMPARATOR|Placebo Arm|
62783513|NCT02451462|EXPERIMENTAL|Zoledronic acid arm|Zoledronic acid
62783514|NCT02451462|NO_INTERVENTION|placebo arm|placebo
62783515|NCT00996983|EXPERIMENTAL|A|
62783516|NCT05691114|EXPERIMENTAL|hAESCs treatment|"hAESCs will be administration through Ommaya reservoir implanted into the lateral ventricle.~The tolerability, safety, and efficacy will be examined of 4 monthly doses of hAESCs for 3 months followed by 2 doses every 3 months in dose escalation through 3 cohorts.~* Dose A (5×10\^7 cells/dose)~* Dose B (1.0×10\^8 cells/dose)~* Dose C (1.5×10\^8 cells/dose)."
62783517|NCT01195324|EXPERIMENTAL|001|Canagliflozin/Warfarin Treatment A: Tablets oral canagliflozin 300 mg once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg single dose on Day 6 followed 14 days later by Treatment B: Tablets oral warfarin 30 mg single dose on Day 1
62198225|NCT04126252|EXPERIMENTAL|Group A|This arm received pharmacotherapy for erectile dysfunction.
62198226|NCT04126252|EXPERIMENTAL|Group B|This arm received cognitive behavior psychotherapy for erectile dysfunction.
62576836|NCT06240169|EXPERIMENTAL|DPC in AGE II with BD|DPC using BD in Age group II i.e. 41-60years
62576837|NCT04747886|ACTIVE_COMPARATOR|WW Only|Participants will receive 3-month access to the WW digital program.
62576838|NCT04747886|EXPERIMENTAL|WW + PolyRules!|Participants will receive 3-month access to the WW digital program and the PolyRules! app.
62576839|NCT05678374||Graves' patients with mental fatigue|Women diagnosed with Graves 15 moths to 60 months ago with Mental Fatigue Scale score of more than 13 (maximum 42, cut of 10,5 for mental fatigue)
62576840|NCT05678374||Graves' patients without mental fatigue|Women diagnosed with Graves 15 moths to 60 months ago with Mental Fatigue Scale score of less than 8 (maximum 42, cut of 10,5 for mental fatigue)
62783518|NCT01195324|EXPERIMENTAL|002|Canagliflozin/Warfarin Treatment B: Tablets oral warfarin 30 mg single dose on Day 1 followed 14 days later by Treatment A: Tablets oral canagliflozin 300 mg once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg single dose on Day 6
62783519|NCT05938673|SHAM_COMPARATOR|Sham repetitive transpinal magnetic stimulation|In the Sham group a coil will be positioned in the T2-T3 thoracic region disconnected to the stimulation device and the active coil will be positioned about 15 cm behind the patient, away from his field of vision, to provide sound stimulus.
62783520|NCT05938673|ACTIVE_COMPARATOR|Active repetitive transpinal magnetic stimulation|In the Active group, the patient will receive intermittent theta burst stimulation (iTBS) in the T2-T3 region while seated using a circular magnetic coil positioned at 90º, handle facing to the right, connected to a magnetic stimulator.
62783521|NCT05049109|EXPERIMENTAL|Group X|Patients who have had stroke and high blood pressure will participate in 5 telehealth visits, which will take place over 3 months. In addition, remote BP monitoring will be given.
62783522|NCT05049109|ACTIVE_COMPARATOR|Group Y|Patients who have had stroke and high blood pressure will participate in 3 visits with primary care and stroke practitioner.
62783523|NCT02075892|ACTIVE_COMPARATOR|Mushroom Blend|4 grams daily; oral; 7 and 21 days
62783524|NCT02075892|PLACEBO_COMPARATOR|Placebo|4 grams maltodextrin, oral, 7 and 21 days
62198227|NCT04126252|EXPERIMENTAL|Group C|This arm received combined treatment approach.
62400330|NCT02926768|EXPERIMENTAL|Daily dose of CK-101|Daily oral dose of CK-101
62400331|NCT06374576|EXPERIMENTAL|Lecture on eHealth literacy and digital intervention|Participants in the intervention group will receive a health promotion education program for improving eHealth literacy. The education program will include a 1.5-hour lecture and a 1-week digital intervention
62400332|NCT06374576|PLACEBO_COMPARATOR|Lecture on general health and digital intervention|Participants in the control group will receive a health promotion education program about general health. The education program will include a lecture and a 1-week digital intervention
62576841|NCT05678374||Thyroid healthy controls without mental fatigue|Women without current or previous thyroid disease and with Mental Fatigue Scale scores of less than 8
62576842|NCT06576414|EXPERIMENTAL|Older people with online ACT intervention|4 week ACT plus back exercise group
62576843|NCT06576414|ACTIVE_COMPARATOR|Older people without ACT intervention|4-week back exercise control group
62576844|NCT01835873|ACTIVE_COMPARATOR|Lactated Ringer's|Crystalloid solution - 1000 ml preload
62576845|NCT01835873|ACTIVE_COMPARATOR|HES 130/0.42|Hydroxyethyl starch (HES 130/0.42) - 500 ml preload
62576846|NCT00561392|EXPERIMENTAL|Rivastigmine 5 and 10 cm^2 patch|For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm\^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm\^2 patch, with adjustments as necessary for safety and tolerability.
62198228|NCT04126252|PLACEBO_COMPARATOR|Group D|This arm acted as a control group and received placebo or no intervention.
62400333|NCT01090648|EXPERIMENTAL|001|etravirine One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
62400334|NCT03863821|EXPERIMENTAL|HHHFNC group|Practice 6 MWT with HHHFNC
62400335|NCT03863821|NO_INTERVENTION|non-HHHFNC group|Practice 6 MWT without HHHFNC
62198229|NCT02807883|EXPERIMENTAL|Blinatumomab|Blinatumomab as continuous intravenous infusion at dose of 28 µg/24 hours over 4 weeks followed by 2 week treatment-free period for 6-week treatment cycle; 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
62198230|NCT03057847|EXPERIMENTAL|SOF/VEL|Sofosbuvir/Velpatasvir, One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
62198231|NCT02393742|EXPERIMENTAL|Sodium Nitrite Supplementation|80 mg/day (40 mg 2x/day) slow release sodium nitrite (TheraVasc, Inc) for 3 months
62198232|NCT02393742|PLACEBO_COMPARATOR|Placebo|placebo 2x/day for 3 months
62198233|NCT02879786|EXPERIMENTAL|Phonological dyslexia|Children with phonological dyslexia
62198234|NCT02879786|EXPERIMENTAL|Visuo-attentional dyslexia|Children with visuo-attentional dyslexia
62576847|NCT01575834|EXPERIMENTAL|Romosozumab|Participants received 210 mg romosozumab subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
62576848|NCT01575834|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
62584922|NCT04216290|ACTIVE_COMPARATOR|Step 2, Arm F (observation)|Patients previously randomized to Arm D (chemoradiation) who achieve clinical CR or clinical benefit undergo observation undergo observation. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
62584923|NCT01098760|EXPERIMENTAL|Arm 1|
62198235|NCT02879786|OTHER|Control|Control children, age-matched
62400336|NCT00671645|EXPERIMENTAL|1|
62400337|NCT06136624|EXPERIMENTAL|Opevesostat|Participants receive opevesostat 5 mg by oral tablets twice daily (bid) plus dexamethasone 1.5 mg by oral tablets once daily (qd) and 0.1 mg fludrocortisone acetate by oral tablet qd until progression. Hydrocortisone 100 mg (oral or intramuscular \[IM\]) dose will also be provided to participants for use as rescue medication.
62400338|NCT06136624|ACTIVE_COMPARATOR|Abiraterone Acetate or Enzalutamide|Participants receive abiraterone 1000 mg qd by oral tablets plus prednisone 5 mg bid by oral tablets or enzalutamide 160 mg qd by oral tablets.
62400339|NCT03722641|PLACEBO_COMPARATOR|Bread reference|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread.
62010939|NCT05555472|ACTIVE_COMPARATOR|Care-as-usual Halt-condition|Participants in this arm will follow the regular Halt-intervention. Halt professionals, not trained in YIM-approach, will be instructed to follow their regular working procedure. On average, the intervention consists of 3 meetings: an initial meeting, an intervention meeting, and a closing meeting. The aim is to complete the intervention within 100 days (min.-max.: 1-6 meetings, 1-20 hours). During the initial meeting, compulsory activities are screening and risk assessment, reflection on the committed offense/crime, and parental involvement. Based on these activities, the duration and the content of the intervention are determined. Professionals can select activities from 5 different modules: (1) reflection on behaviour, (2) parental involvement, (3) social skills training, (4) victim-offender reconciliation, and (5) future. A form of victim-offender reconciliation, however, is compulsory. Professionals are required to register relevant information regarding the Halt-process.
62198236|NCT00487825|EXPERIMENTAL|Canakinumab + Methotrexate|Canakinumab, human anti-interleukin-1beta monoclonal antibody plus Methotrexate (MTX). Intravenous (IV) Infusion of 600mg canakinumab on Day 1, 15 continuing every 4 weeks up to week 26. MTX was given as variable dosing regimen of 7.5 mg-15 mg weekly.
62576849|NCT03230058|EXPERIMENTAL|group 1|"Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The experimental group (Group 1) will receive 1% voriconazole eye drop (Aurolab, Madurai, India) + 5% Natamycin ophthalmic suspension eye drop hourly (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).~The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.~Patients will be followed up every week after being discharged until complete resolution is noted."
62198237|NCT00487825|ACTIVE_COMPARATOR|Methotrexate + placebo|Methotrexate (MTX) was given as variable dosing regimen of 7.5 mg-15 mg weekly. Intravenous (IV) Placebo Solution, given in the same mode of administration as the canakinumab solution.
62198238|NCT05789576|EXPERIMENTAL|VTAMA (tapinarof) cream, 1%|VTAMA (tapinarof) cream, 1% applied topically once daily
62584924|NCT06667375||Masi|Patients who were diagnosed with Covid-19, with signs of Acute Respiratory Distress Syndrome (ARDS), intubated, and connected to an automated-bag mechanical ventilator in the ICU
62198239|NCT04765878|EXPERIMENTAL|Humidification|
62198240|NCT03273842|EXPERIMENTAL|PF-06881894|PF-06881894 6 mg SC
62198241|NCT03273842|ACTIVE_COMPARATOR|US-approved Neulasta|US-approved Neulasta 6 mg SC
62400340|NCT03722641|EXPERIMENTAL|Product 1: Milk|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on milk.
62400341|NCT03722641|EXPERIMENTAL|Product 2: Full fat milk + oat|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on full fat milk and oat with high fiber content.
62400342|NCT03722641|EXPERIMENTAL|Product 3: Skim milk + oat, high fibre|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on skim milk and oat with high fiber content.
62400343|NCT03722641|EXPERIMENTAL|Product 4: Skim milk + oat, low fibre|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on skim milk and oat with low fiber content.
62400344|NCT05674682|OTHER|Venipuncture or digital puncture for HIV test|MSM and transgender women aged 18 years or older, willing and able to sign informed consent to accept venipuncture or digital puncture for HIV testing
62400345|NCT05760781|EXPERIMENTAL|lowest dose treatment group|Subjects will receive one single lowest dose of STSG-0002 Injection following protocol requirements
62400346|NCT05760781|EXPERIMENTAL|low dose treatment group|Subjects will receive one single low dose of STSG-0002 Injection following protocol requirements
62400347|NCT05760781|EXPERIMENTAL|Intermediate dose treatment group|Subjects will receive one single intermediate dose of STSG-0002 Injection following protocol requirements
62400348|NCT05760781|EXPERIMENTAL|A single high dose of treatment group|Subjects will receive one single high dose of STSG-0002 Injection following protocol requirements
62400349|NCT06259825|PLACEBO_COMPARATOR|Control Chicken-meat and Control Eggs|Consumption of at least 4 portions of standard chicken-meat and at least 4 standard eggs per week, for 4 months.
62198242|NCT06276010|EXPERIMENTAL|nafamostat mesilate group|The initial dosing of the nafamostat mesilate group is 0.5mg/kg/h. We maintain ACT at 180\~220s by adjusting the dosage of nafamostat mesilate.
62576850|NCT03230058|PLACEBO_COMPARATOR|group 2|"Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The placebo group (Group 2) will receive Vehicle eye drops + 5% Natamycin ophthalmic suspension every hour (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).~The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.~Patients will be followed up every week after being discharged until complete resolution is noted."
62576851|NCT00945035|ACTIVE_COMPARATOR|A|Etoricoxib, 20% tablet
62576852|NCT00945035|ACTIVE_COMPARATOR|B|Etoricoxib, 30% tablet
62198243|NCT06276010|OTHER|unfractionated heparin group|The initial dosing of the unfractionated heparin group is 8\~12U/kg/h. We maintain ACT at 180\~220s by adjusting the dosage of unfractionated heparin .
62198244|NCT01722279||Bariatric surgery patients, at least 5 years post-surgery|Survey participants had bariatric surgery at the St. Vincent Bariatric Center of Excellence at least 5 years before completing survey.
62198245|NCT00903500|EXPERIMENTAL|1|Daily physical activity
62198246|NCT00903500|NO_INTERVENTION|2|Usual care
62576853|NCT05542147|EXPERIMENTAL|Fenofibrate|1 tablet per day per 12 weeks
62576854|NCT05542147|PLACEBO_COMPARATOR|Placebo|1 tablet per day per 12 weeks
62198247|NCT02389764|EXPERIMENTAL|BIBF 1120|Initial dose of BIBF 1120 is 200 mg twice daily orally for a 28 day cycle. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit.
62198248|NCT02003677|EXPERIMENTAL|FIAsp followed by NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
62198249|NCT02003677|ACTIVE_COMPARATOR|NovoRapid® followed by Insulin aspart|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
62198250|NCT06198972|ACTIVE_COMPARATOR|Control Group|strength exercise training
62198251|NCT06198972|EXPERIMENTAL|Study Group|pnf exercise training
62198252|NCT05778942||Single Arm|Single arm with commercial study drug: Eyestil SYNFO
62198253|NCT01721889||Radiostereometric analysis - Intact fusion|Clinically fused per classical radiographic assessment (≤ 2 degrees angular motion and evidence of bone bridging)
62198254|NCT01721889||Radiostereometric analysis - Symptomatic pseudoarthrosis|Definitive clinical evidence of pseudarthrosis (not fused, ˃ 2 degrees angular motion or absence of bone bridge) and scheduled for surgical exploration
62198255|NCT01721889||Radiostereometric analysis - Asymptomatic pseudoarthrosis|Definitive clinical evidence of pseudarthrosis without scheduled surgical exploration.
62576855|NCT06279546||AI-based model|AIWorks-EUS Convolutional Neural Network version 2 (CNNv2) (mdconsgroup, Guayaquil, Ecuador) applied on pre-recorded videos for the detection of normal anatomical structures.
62576856|NCT06279546||Expert endoscopists|Endoscopists with \>190 EUS procedures per year, including 75 pancreatobiliary and mucosal cancer staging procedures each, 40 subepithelial cases; and 50 cases of EUS-fine needle aspiration (FNA) (25 of them being pancreatic cases); following the American Society for Gastrointestinal Endoscopy (ASGE) recommendations.
62576857|NCT06279546||Non-expert endoscopists|Endoscopists with \<190 EUS procedures per year, including 75 pancreatobiliary and mucosal cancer staging procedures each, 40 subepithelial cases; and 50 cases of EUS-FNA (25 of them being pancreatic cases); following the American Society for Gastrointestinal Endoscopy (ASGE) recommendations.
62576858|NCT00582608|EXPERIMENTAL|131I-8H9 and 8H9|This is an open-label single arm study of 131 I-8H9. injected intravenously at 10mCi/1.73m\^2 dose \[intended specific activity of '20mCi/mg protein\] preceded by administration of 50mg/1.73m2 of unlabeled -8H9.
62576859|NCT01417091|EXPERIMENTAL|Treatment group|
62576860|NCT01417091|NO_INTERVENTION|Untreated reference group|
62576861|NCT05142969|NO_INTERVENTION|Control arm|Patients were daily bathed with soap and water only.
62576862|NCT05142969|EXPERIMENTAL|Intervention arm|Patients were daily bathed with soap and water and then receive 2% Chlorhexidine bathing (Petel Skin care wipes, Likang LtD, shanghai, China).
62576863|NCT03232879|EXPERIMENTAL|Experimental 1|Motor Imagery
62576864|NCT03232879|EXPERIMENTAL|Experimental 2|Action Observation
62576865|NCT03232879|NO_INTERVENTION|Control Group|No intervention
62576866|NCT01045577|ACTIVE_COMPARATOR|Masitinib (AB1010)|Masitinib (AB1010)
62576867|NCT01045577|PLACEBO_COMPARATOR|Placebo mactching masitinib|Placebo matching masitinib
62576868|NCT04431349||ticagrelor|The patient with acute myocardial infarction received loading dose of ticagrelor for coronary angiography within 2 days prior to OPCAB or CABG.
62576869|NCT04431349||clopidogrel|The patient with acute myocardial infarction received loading dose of clopidogrel for coronary angiography within 2 days prior to OPCAB or CABG.
62576870|NCT04105296|EXPERIMENTAL|EKSO+ES|6 months of exoskeleton training with spinal cord epidural stimulation.
62576871|NCT06450392|EXPERIMENTAL|Group 1: IV TXA|1g intravenous tranexamic acid (Pfizer, New York, NY) 20 minutes prior to surgery
62576872|NCT06450392|EXPERIMENTAL|Group 2: Local TXA|1-2mL of subcutaneous tranexamic acid 100 mg/mL (manufactured concentration, Pfizer, New York, NY) mixed with local anesthetic to the orbit two minutes prior to incision
62576873|NCT06450392|PLACEBO_COMPARATOR|Group 3: Control|Normal saline and subcutaneous local anesthetic to both eyelids (i.e. standard procedure) as control group
62576874|NCT04637711|EXPERIMENTAL|Specific surgical Intervention|Focus clearing + whole breast exploration and washing + one-stage micro plastic surgery
62198256|NCT03402698|EXPERIMENTAL|cholecalciferol|cholecalciferol at a dose 1000 IU /day for 3 months
62400350|NCT06259825|EXPERIMENTAL|Omega-3 Chicken-meat and Omega-3 Eggs|Consumption of at least 4 portions of omega-3-PUFA enriched chicken-meat and at least 4 omega-3-PUFA enriched eggs per week, for 4 months.
62400351|NCT02822027|EXPERIMENTAL|human gamma globulin|human gamma globulin for infants with encephalopathy of prematurities
62400352|NCT02822027|ACTIVE_COMPARATOR|non-human gamma globulin|non-human gamma globulin for infants with encephalopathy of prematurities
62400353|NCT01744405||Lactating Women with Chagas disease|Women with Chagas disease who fulfill clinical criteria for treatment with nifurtimox, and who are also lactating
62400354|NCT04309149|EXPERIMENTAL|MCT fats|Kanso MCT oils and margarine will be consumed daily for 7 days each to assess tolerability and compliance
62400355|NCT05252351||Adults with congenital aortic stenosis|
62576875|NCT04637711|NO_INTERVENTION|Extensive lesion excision|
62576876|NCT04332081|EXPERIMENTAL|Hyperbaric oxygen therapy (HBOT)|
62400356|NCT00517517|EXPERIMENTAL|1|Intramuscular injection of whole virion, Vero cell-derived influenza vaccine containing 7.5 µg of H5N1 HA antigen per 0.5 mL in a non-adjuvanted formulation
62400357|NCT00517517|EXPERIMENTAL|2|Intramuscular injection of whole virion, Vero cell-derived influenza vaccine containing 3.75 µg of H5N1 HA antigen per 0.25 mL in a non-adjuvanted formulation
62400358|NCT04082494|NO_INTERVENTION|Regular Treatment|"No intervention is planned for the first period. Baseline treatment assesment."
62198257|NCT02191306||HIV Positive Patients (Study Group)|
62198258|NCT02191306||Non HIV Positive Patients (Control)|
62400359|NCT04082494|EXPERIMENTAL|Music|Optional music via internet and noise canceling headphones will be offered.
62400360|NCT04082494|EXPERIMENTAL|Music and Beverages|Additionally to the offered optional music via internet and noise canceling headphones, there will be beverages optionally offered (with and without sugar, warm or cold).
62400361|NCT06469333|NO_INTERVENTION|Control Group|The participant is asked to concentrate on the image or, failing that, the sensory representation representing the worst aspect of the targeted intrusive thought for 10 seconds, and to stare at the black computer screen.
62400362|NCT06469333|EXPERIMENTAL|Eye movements (EM)|The participant is asked to focus on the image or, failing that, the sensory representation representing the worst aspect of the targeted intrusive thought for 10 seconds and visually follow the horizontal displacement of a white dot (Ø 1cm) on the black screen at a constant speed of 1.2 Hz. This speed, implying the displacement of 1.2 left-right-left cycles per second, targets the saturation of working memory.
62576877|NCT04332081|NO_INTERVENTION|Standard of Care|
62576878|NCT06029374|ACTIVE_COMPARATOR|Functional Treatment|
62576879|NCT06029374|ACTIVE_COMPARATOR|Forearm Cast and Finger Splint|
62576880|NCT04375605|ACTIVE_COMPARATOR|Arm A (control arm)|Patients randomized in control arm A will receive four cycles of neoadjuvant chemotherapy with FLOT every two weeks (5-FU 2600 mg/m² d1, folinc acid 200 mg/m² d1, oxaliplatin 85 mg/m² d1, docetaxel 50 mg/m² d1) followed by surgical resection 4-6 weeks after day 1 of the last cycle of neoadjuvant therapy. 6-12 weeks after surgery adjuvant chemotherapy starts with 4 cycles of FLOT (total treatment period 25-32 weeks).
62576881|NCT04375605|EXPERIMENTAL|Arm B (experimental arm)|Patients randomized in experimental arm B will receive two cycles of neoadjuvant induction chemotherapy with FLOT (5-FU 2600 mg/m² d1, folinic acid 200 mg/m² d1, oxaliplatin 85 mg/m² d1, docetaxel 50 mg/m² d1) every two weeks (4 weeks of therapy) followed by radiochemo-therapy beginning at day 21 after day one of the last cycle of chemotherapy. Radiochemotherapy consists of oxaliplatin 45 mg/m² weekly (d1, 8, 15, 22, 29) and continuous infusional 5-FU 225 mg/m² plus concurrent radiotherapy given in 5/week fractions with 1.8 Gy to a dose of 45 Gy over 5 weeks. Resection is performed 4-6 weeks after last treatment with chemotherapy / radiation. Adjuvant treatment starts 6-12 weeks after surgery and consists of 4 cycles of FLOT (total treatment period of 26 - 33 weeks).
62576882|NCT02169375|EXPERIMENTAL|Mu Rhythm with adaptation|
62010940|NCT05555472|EXPERIMENTAL|Halt-plus-YIM-condition|Participants in this arm will follow the Halt-plus-YIM-intervention. YIM trained Halt professionals implement the YIM approach in their regular working procedure in 7 steps: (1) during risk assessment, they support youth in identifying a YIM; (2) during the course of the study, professionals will be instructed to motivate and explain the YIM approach in cases with 3 or more meetings; (3) if a YIM is nominated, a meeting between the professional and the YIM takes place; (4) to 'position' the YIM, a joint meeting is arranged to discuss expectations/goals of all involved parties; (5) interim contact between professional and YIM takes place; (6) a joint evaluative meeting takes place; (7) if agreed upon, closure of Halt's engagement takes place. Note, the YIM often remains involved after this completion. Professionals register on the Halt- and YIM-process and whether the approach was deployed: 'NO' (i.e., only step 1), 'PARTLY' (i.e., steps 1 and 2) or 'YES' (i.e., at least step 3 or 4).
62010941|NCT06325462||Group S|27 patients will receive inhalational general anesthesia using sevoflurane.
62010942|NCT06325462||Group P|27 patients will receive intravenous anesthesia using propofol infusion.
62010943|NCT06663228||breast MMS|
62010944|NCT05120219|EXPERIMENTAL|food effect cohort A|
62010945|NCT05120219|EXPERIMENTAL|food effect cohort B|
62010946|NCT05120219|EXPERIMENTAL|multiple dose pharmacokinetics|
62010947|NCT03877393|EXPERIMENTAL|PRO-GFD|Probiotic supplementation + gluten-free diet
62010948|NCT03877393|PLACEBO_COMPARATOR|PLA-GFD|Placebo supplementation + gluten-free diet
62010949|NCT03877393|EXPERIMENTAL|PRO-GD|Probiotic supplementation + gluten-containing diet
62010950|NCT03877393|PLACEBO_COMPARATOR|PLA-GD|Placebo supplementation + gluten-containing diet
62010951|NCT00068055|EXPERIMENTAL|1|60 subjects to receive Omr-IgG-am.
62010952|NCT00068055|ACTIVE_COMPARATOR|2|20 subjects to receive Polygam® S/D (IVIG).
62010953|NCT00068055|PLACEBO_COMPARATOR|3|20 subjects to receive normal saline.
62010954|NCT05910385|ACTIVE_COMPARATOR|laparoscopic|
62576883|NCT02169375|EXPERIMENTAL|Mu Rhythm without adaptation|
62010955|NCT05910385|EXPERIMENTAL|vnotes|
62010956|NCT06244316|EXPERIMENTAL|IMP 1: rhNGF concentration 1|Investigational Medicinal Product (IMP) 1
62010957|NCT06244316|EXPERIMENTAL|IMP 2: rhNGF concentration 2|Investigational Medicinal Product (IMP) 2
62010958|NCT06244316|PLACEBO_COMPARATOR|Vehicle IMP|
62010959|NCT05975541||case (patients having chronic infections)|Individuals aged between 18-65 years, presenting obesity (BMI between 30-40 kg/m2), type 2 diabetes, and chronic infections (i.e. urinary tract infections, periodontitis, herpetic infections) at the basal time.
62198259|NCT03230604|ACTIVE_COMPARATOR|Bulk-Fill composite Class I, II and V cavities|Restorative with Filtek Bulkfill composite in class I, II and V Restorative with Tetric N Ceram composite in class I, II and V
62198260|NCT03230604|ACTIVE_COMPARATOR|Z 350 xt Composite|Restorative with Z 350 xt composite in class I, II and V
62576884|NCT01566266|EXPERIMENTAL|Amoxicillin|
62576885|NCT01566266|PLACEBO_COMPARATOR|Placebo capsules|
62010960|NCT05975541||control (patients without chronic infections)|Individuals aged between 18-65 years, presenting obesity (BMI between 30-40 kg/m2) and type 2 diabetes.
62010961|NCT06556368|EXPERIMENTAL|Tarcocimab tedromer 5 mg (KSI-301)|Intravitreal injection of tarcocimab tedromer once every 4 weeks for 4 monthly doses followed by individualized dosing every 4 to 24 weeks.
62010962|NCT06556368|EXPERIMENTAL|Tabirafusp tedromer 5 mg (KSI-501)|Intravitreal injection of tabirafusp tedromer once every 4 weeks for 4 monthly doses followed by every-8-week dosing with additional individualized dosing (up to monthly dosing)
62010963|NCT06556368|ACTIVE_COMPARATOR|Aflibercept 2 mg|Intravitreal injection of aflibercept once every 4 weeks for 3 monthly doses followed by every-8-week dosing
62010964|NCT04524962|EXPERIMENTAL|Descartes 30|
62010965|NCT00587587|EXPERIMENTAL|A|Apligraf (bilayered living cell therapy)
62010966|NCT00587587|ACTIVE_COMPARATOR|B|Dressing regimen comprised of a primary nonadherent dressing, dry gauze dressing and bolster gauze dressing, if necessary
62010967|NCT06571279|OTHER|Plant-based diet|4 weeks of plant-based meals and snacks.
62010968|NCT01831375|EXPERIMENTAL|Speak Up|Participants will learn how to speak up to their medical doctors for improving their medical care.
62010969|NCT01831375|OTHER|Get Connected|Attention control group
62010970|NCT03968952|ACTIVE_COMPARATOR|SMARThealth Pregnancy|"The components of the SMARThealth Pregnancy intervention include:~1. Educational and Training component on high-risk pregnancy conditions, focusing on; Anaemia, Hypertensive Disorders of Pregnancy (HDPs) and Gestational diabetes mellitus (GDM).~2. An mHealth platform providing clinical decision support, lifestyle advice, recall and reminder system for Community Health Workers (CHWs) and Primary Care Physicians (PCPs).~Pregnant women in the intervention group will receive 3 visits at home by their CHW, in addition to their standard antenatal and postnatal care. One visit during the third trimester of pregnancy; one during Week 1 postpartum and; one visit during Week 6 postpartum."
62198261|NCT02292472|EXPERIMENTAL|Medytoxin®|Botulinum toxin type A
62198262|NCT02292472|PLACEBO_COMPARATOR|Normal Saline|Normal Saline
62198263|NCT02205034|ACTIVE_COMPARATOR|first arm|4IU of oxytocin every other day
62198264|NCT02205034|ACTIVE_COMPARATOR|second arm|4 IU of oxytocin daily
62576886|NCT03239860|EXPERIMENTAL|Dose 1 GNbAC1|Monthly IV
62576887|NCT03239860|EXPERIMENTAL|Dose 2 GNbAC1|Monthly IV
62576888|NCT03239860|EXPERIMENTAL|Dose 3 GNbAC1|Monthly IV
62576889|NCT03702335|EXPERIMENTAL|Dietary Counselling|Each subject will receive a comprehensive dietary counselling for the first 12-weeks of the study, which will be followed by another 12-weeks without dietary counselling.
62576890|NCT03702335|NO_INTERVENTION|No Dietary Counselling|Subjects in the control group will be followed for 24-weeks without any dietary counselling.
62198265|NCT02205034|ACTIVE_COMPARATOR|third arm|4 IU of oxytocin twice daily
62198266|NCT03376750|EXPERIMENTAL|CO - OP via telerehabilitation + standard care|10 CO-OP videoconferencing sessions from an occupational therapist . Each session will be utilized to guide the participants to achieve their self-identified goals, focusing on problem-solving for daily life situations and on the ability to implement the discussed strategies for a variety of activities.
62198267|NCT03376750|EXPERIMENTAL|CO - OP via face to face + standard care|10 CO - OP face to face sessions from an occupational therapist. Each session will be utilized to guide the participants to achieve their self-identified goals, focusing on problem-solving for daily life situations and on the ability to implement the discussed strategies for a variety of activities.
62783525|NCT03137329|OTHER|Weight Loss Surgery (WLS) Arm|Subjects enrolled in the WLS arm will undergo WLS as part of the routine care provided by the respective WLS centers. During routine care patients typically meet with their dietician at least twice prior to WLS and are placed on a higher protein meal replacement supplement and calorie controlled diet. For weeks 1-52, the investigators will ensure that patients are receiving 1500mg of elemental calcium and 3000 IU of vitamin D based on recent best practice guidelines. In addition, participants will complete an individualized pragmatic exercise program for the first 52 weeks after surgery. Patients will begin the program after receiving clearance from their surgeon. Patients will meet with a physical therapist at BIDMC for individual sessions.
62783526|NCT03137329|OTHER|Lifestyle Arm|Subjects enrolled in the lifestyle group will be prescribed a balanced high protein diet (1g high quality protein/kg body weight/day) that provides an energy deficit of 500 to 750 kcal /day from their daily energy requirements\[58\] and prescribed a weight loss goal of 10% over the course of 6 months. Participants will meet with a trained dietician/nutritionist at the BIDMC General Clinical Research Unit. The investigators will incorporate the HMR (Health Management Resources) high protein meal replacement supplements into participants' diet regimen for the first 24 weeks. In addition, participants will complete a comparable 52-week exercise program consisting of an individualized pragmatic exercise program.
62783527|NCT02489669|NO_INTERVENTION|LVEDP-guided group|Patients allocated to the LVEDP-guided group will continue to receive intravenous 0.9% sodium chloride, according to the protocol suggested in the POSEIDON trial (that is, 5 mL/kg/hr for LVEDP ≤12 mmHg; 3 mL/kg/hr for 13-18 mmHg; and 1.5 mL/kg/h for \>18 mmHg). The fluid rate will be eventually modified at the start of the procedure in case of discordance between non-invasive and invasive LVEDP pressure estimate, being the invasive value considered as gold-standard. The fluid rate will continued during the procedure, and for 4 hours post-procedure.
62576891|NCT04234139||Retrospective Cohort|Early Liver Transplantation (ELT) for patients who presented with Severe Alcoholic Hepatitis (SAH)
62198268|NCT03376750|NO_INTERVENTION|control group - standard care|standard care as given from public health service
62198269|NCT00660322|NO_INTERVENTION|Control|Families assigned to the control arm will receive usual asthma care from the child's primary care provider.
62198270|NCT00660322|EXPERIMENTAL|Intervention|The Telephone Asthma Program and usual care.
62198271|NCT02616159|EXPERIMENTAL|Oatmeal 1|40 g cereal
62198272|NCT02616159|EXPERIMENTAL|Oatmeal2|40 g cereal
62010971|NCT03968952|NO_INTERVENTION|Enhanced Standard Care|"The control group will receive enhanced standard antenatal and postnatal care, involving:~1. An awareness programme for pregnant women, Community Health Workers (CHWs) and Primary Care Physicians (PCPs), held at the villages within the control group Primary Health Centre (PHC) cluster (Enhanced Standard Care). The community and health professionals will receive information on the high-risk conditions of anaemia in pregnancy, HDPs and GDM as part of the awareness programme.~2. Standard antenatal and postnatal care (consisting of free monthly antenatal care, and up to 7 postnatal visits), delivered by CHWs in partnership with their PHC doctor."
62010972|NCT06663657|EXPERIMENTAL|cognitive sensorimotor exercise group|Patients in group A will receive cognitive sensorimotor exercises for 30 minutes, sessions for 5 days per week for 8 weeks.
62010973|NCT06663657|ACTIVE_COMPARATOR|Task based training group|Patients in group B will receive task oriented training for 30 minutes, sessions for 5 days per week for 8 weeks.
62198273|NCT02616159|EXPERIMENTAL|Oatmeal 3|40 g cereal
62198274|NCT02616159|PLACEBO_COMPARATOR|Ready to eat cereal|32.2 g cereal
62198275|NCT02616159|PLACEBO_COMPARATOR|Hot cereal|28.8 g cereal
62198276|NCT02710331|EXPERIMENTAL|Active THC and Placebo Ethanol|
62576892|NCT04234139||Prospective Cohort 1|Early Liver Transplantation (ELT) for patients who present with Severe Alcoholic Hepatitis (SAH)
62010974|NCT04007536||Part 1|Participants from 2 through 10 years of age who have MPS II. Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.
62198277|NCT02710331|EXPERIMENTAL|Active THC and Active Ethanol|
62198278|NCT02710331|EXPERIMENTAL|Placebo THC and Active Ethanol|
62198279|NCT02710331|PLACEBO_COMPARATOR|Placebo THC and Placebo Ethanol|
62198280|NCT03414541|PLACEBO_COMPARATOR|Placebo|Participants in this group will receive matching placebo capsules twice daily.
62198281|NCT03414541|EXPERIMENTAL|500mg DS102|Participants in this group will receive 500 mg DS102 capsules twice daily.
62198282|NCT03414541|EXPERIMENTAL|1000mg DS102|Participants in this group will receive 1000 mg DS102 capsules twice daily.
62198283|NCT02946671|EXPERIMENTAL|Cohort 1|KW-0761 (Mogamulizumab): 0.1 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
62198284|NCT02946671|EXPERIMENTAL|Cohort 2|KW-0761 (Mogamulizumab): 0.3 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
62198285|NCT02946671|EXPERIMENTAL|Cohort 3|KW-0761 (Mogamulizumab): 1.0 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
62198286|NCT04051086|OTHER|Williams Beuren|Subjects aged from 3 months to 60 years with a diagnosis confirmed with FISH of Williams Beuren syndrome.
62576893|NCT04234139||Prospective Cohort 2|Orthotopic Liver Transplantation (OLT) in patient who present with Alcoholic Liver Disease (ALD)
62584925|NCT06667375||Conventional|Patients who were diagnosed with Covid-19, with signs of Acute Respiratory Distress Syndrome (ARDS), intubated, and connected to a commercial mechanical ventilator in the ICU
62010975|NCT04007536||Part 2|Participants from 2 through 30 years of age who have MPS II; Part 2 will entail a single collection of cerebrospinal fluid (CSF), urine, and blood. Clinical outcome assessments are optional in Part 2 for participants aged 18 years or younger; no clinical assessments are planned for participants older than 18 years.
62010976|NCT04007536||Part 3|Participants \<8 years of age who have the neuronopathic form of mucopolysaccharidosis type II (nMPS II). Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.
62198287|NCT04051086|OTHER|Micro-duplication 7q11.23|Subjects aged from 3 months to 60 years with a diagnosis confirmed with CGHarray of micro-duplication 7q11.23 syndrome.
62198288|NCT04051086|OTHER|Healthy Group|Subjects without cardiovascular and neurological medical history.
62198289|NCT02539849|OTHER|adalimumab + FOS|Adalimumab will be administered during 12 weeks in combination with daily FOS 6g. (FOS administration will start 2 weeks before Adalimumab)
62198290|NCT01843725|EXPERIMENTAL|Metronomic arm|capecitabine 1100 to 1600 mg/m2/day orally in association with aflibercept 6mg/kg intravenous every 3 weeks
62198291|NCT01843725|EXPERIMENTAL|Intermittent arm|capecitabine 1700 to 2500 mg/m2/day orally 2 weeks out of 3 and aflibercept 6mg/kg intravenous every 3 weeks
62198292|NCT00543023|EXPERIMENTAL|A|teriparatide 20 micrograms/day subcutaneous
62198293|NCT00543023|ACTIVE_COMPARATOR|B|salmon calcitonin 100 IU/day subcutaneous
62198294|NCT02749110|EXPERIMENTAL|Self-sampling for HPV test|Invitation to participate to the screening process by means of the usual care (pap-test) or the provision of a vaginal self-sampling brush (Evalyn Brush°). Self-collected samples are mailed to a central lab for HPV testing.
62783528|NCT02489669|EXPERIMENTAL|Renalguard group|Patients enrolled in this group will be treated by hydration with 0.9% saline controlled by the RenalGuard system. On top of the 1.5-5.0 ml/kg/h that patients would have received over the previous hour (according to the non-invasive estimate LVEDP), an initial bolus of 250 ml will be administered. In case of LV ejection fraction ≤30% and/or LVEDP \>18 mm Hg the bolus will 150 mL. Therefore, furosemide (0.25 mg/kg) will be administered in order to achieve the optimal urine flow rate (≥300 mL/h). The controlled hydration by the RenalGuard system will be continued during the procedure and for 4 hours following the procedure. Urine flow rate is monitored and maintained at the target value through the procedure and during the following 4 hours. Additional furosemide doses are allowed in case of decrease of the urine flow rate below the target value.
62783529|NCT04836884|EXPERIMENTAL|Vascular anomaly/malformation biopsy|Subjects with a vascular anomaly will have a research percutaneous vascular anomaly/malformation biopsy completed at the time of the clinically indicated percutaneous sclerotherapy, embolization and/or ablation.
62783530|NCT00801398|EXPERIMENTAL|Oxymorphone IR|Open-Label, 2 part ascending-dose multicenter study
62010977|NCT04007536||Part 4|Participants 6 to 17 years of age with the non-neuronopathic form of mucopolysaccharidosis type II (nnMPS II). Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.
62010978|NCT04007536||Part 5|Participants ≤3 years of age with an undetermined MPS II phenotype. Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.
62010979|NCT04007536||Part 6|Participants from 1 to 17 years of age with nMPS II. Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted. Part 6 will also include a single collection of CSF.
62198295|NCT02749110|NO_INTERVENTION|Usual care (Pap test)|Intervention: invitation to participate to the screening process by means of the usual care (pap-test).
62198296|NCT04366505|EXPERIMENTAL|NFB + (MBRP)|Neurofeedback (NFB) from target region or control region plus Mindfulness-based relapse prevention (for some)
62010980|NCT03726112|ACTIVE_COMPARATOR|SpotOn Specs|Eyeglasses with Neuro-Balance Active (NBA) Spots
62010981|NCT03726112|SHAM_COMPARATOR|Sham Specs|Eyeglasses with spots placed in peripheral zones previously identified as neutral
62010982|NCT06661980|ACTIVE_COMPARATOR|Dexmedetomidine Group|30 brain injury patients will treated with Dexmedetomidine 200 mcg/ 2 mL (Intravenous infusion).
62198297|NCT04366505|ACTIVE_COMPARATOR|TAU and sham NFB|TAU + Neurofeedback (NFB) from control region
62198298|NCT02555553|NO_INTERVENTION|Treatment as Usual|"The control group for the RCT will be a usual care condition in which participants are free to seek any assistance for their ED during the study period."
62198299|NCT02555553|EXPERIMENTAL|CBT-GSH with Noom Monitor|Participation will include 12 weeks of guided cognitive-behavioral therapy- guided self help (CBT-GSH) with an MA-level health coach or nutritionist from the KPNW health plan. Patients will use a self-help book, Overcoming Binge Eating (2013) by Christopher Fairburn. The first session will last 60 minutes, and each subsequent session lasts 20-25 minutes. The first four sessions are weekly, with the subsequent four twice monthly. Self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session.
62584926|NCT01459029|ACTIVE_COMPARATOR|D-serine|D-serine up to 6000 mg/day subject to tolerability
62783531|NCT05268172|EXPERIMENTAL|IFN- Y combined with T cells|First, IFN-γ was combined with CIK cells. After three failed treatments, the CIK cells were replaced with T cells. After three failed treatments, CART cells were finally replaced.
62198300|NCT05342805|EXPERIMENTAL|Subtotal stomach|The vessels at the anastomosis of right and left gastric arteries were separated, then the proximal haft of lesser curvature and cardia was resected using linear staplers.
62198301|NCT05342805|ACTIVE_COMPARATOR|Narrow gastric tube|At the lesser curvature, the resection began at the point that was 5-cm from the pyloric, toward to the greater curvature, then the stomach was divided along 3 cm from the greater curvature using linear stapler.
62010983|NCT06661980|PLACEBO_COMPARATOR|Placebo Group|30 brain injury patients will treated with Placebo (Intravenous infusion).
62198302|NCT03555253|EXPERIMENTAL|PwMS and their Support Partner|Support Partners will participate in six resilience coaching Program Sessions conducted weekly by a study resilience coach. PwMS will participate in the initial and final coaching Program Sessions with their Support Partners.
62198303|NCT04901923|EXPERIMENTAL|Part 1 Cohort 1|Participants will receive ACP-196 2.5 mg capsule orally BID on Day 1.
62783532|NCT02401451|EXPERIMENTAL|ECG acquisition|"ECG acquisition using the standard ECG machine~Intervention: An ECG will be performed on every participant using the novel device called the 'RhythmPadGP'"
62783533|NCT05670418||Long COVID-19|Patients post-COVID-19 with Long COVID-19 Syndrome
62198304|NCT04901923|EXPERIMENTAL|Part 1 Cohort 2|Participants will receive ACP-196 5 mg (2 x 2.5 mg capsules) orally BID on Day 1.
62198305|NCT04901923|EXPERIMENTAL|Part 1 Cohort 3|Participants will receive ACP-196 25 mg capsule orally BID on Day 1.
62198306|NCT04901923|EXPERIMENTAL|Part 1 Cohort 4|Participants will receive ACP-196 50 mg (2 x 25 mg capsules) orally BID on Day 1.
62198307|NCT04901923|EXPERIMENTAL|Part 1 Cohort 5|Participants will receive ACP-196 100 mg (4 x 25 mg capsules) orally QD on Day 1.
62198308|NCT04901923|EXPERIMENTAL|Part 2 Cohort 6|Participants will receive ACP-196 75 mg (3 x 25 mg capsules) orally QD on Day 1 and Day 8.
62783534|NCT05670418||COVID-19|Patients post-COVID-19 without Long COVID-19 Syndrome
62198309|NCT04901923|EXPERIMENTAL|Part 3 Cohort 7|Participants will receive ACP-196 50 mg (2 x 25 mg capsules) orally QD on Day 1, itraconazole 200 mg capsules BID from Days 4 to 8 with meals and then ACP-196 50 mg (2 x 25 mg capsules) along with itraconazole 200 mg capsule QD on Day 9 under fasting state.
62198310|NCT04513093|EXPERIMENTAL|İntervention Group|"The elderly individuals in the intervention group underwent aromatherapy massage with ginger and lavender oils for a period of five days and 15 minutes on weekdays for four weeks according to the abdominal massage application protocol.~The Bristol Stool Scale and Constipation Severity Scale were re-applied to the individuals in the intervention before, during the second week of practice and at the end of practice (fourth week)."
62198311|NCT04513093|NO_INTERVENTION|Control Group|"No application was applied to the individuals in the control group. Bristol Stool Scale and Constipation Severity Scale were applied to the individuals in the control group at the same time as (at the beginning, second week and fourth week) the intervention group."
62198312|NCT03020953|EXPERIMENTAL|Exercise + Estrogen|Strength training 3 times a week for 12 weeks. Estrogen patches which provide 100 um pr. 24 hours.
62198313|NCT03020953|ACTIVE_COMPARATOR|Exercise + Placebo|Strength training 3 times a week for 12 weeks. Placebo patches.
62198314|NCT03056651|OTHER|DayCare-HF|Comprehensive service in day-care unit, including education, diagnostic tools (i.e. electrocardiography, transthoracic echocardiography, implanted cardioverter defibrillator (ICD) / cardiac resynchronization therapy device (CRT) interrogation and possibility of intravenous drug administration (i.e. loop diuretics, dobutamine).
62783535|NCT04031989|OTHER|Enrolled Subjects (PSR)|Patients who meet the study's entrance criteria and provide written informed consent, will undergo signal acquisition prior to their scheduled right heart catheterization (RHC) on the day of the procedure.
62783536|NCT01743742|EXPERIMENTAL|Oral vitamin E, vitamin C|Single dose of vitamin E drops 200 IU within 6 hours of birth and vitamin C tablet 250 mg in pulverised form (2 doses at 24 hr interval) via infant feeding tube
62783537|NCT04920110||Phase 1: Qualitative Interviews|Approximately 20 parents/caregivers will discuss typical communication abilities of their loved one and complete the ORCA measure for determination of its content validity through a hybrid approach of concept elicitation and cognitive testing.
62198315|NCT03003377|EXPERIMENTAL|Device: laryngeal mask supreme|Determine the Sevoflurane concentration associate with remifentanil for the insertion of the laryngeal mask supreme
62198316|NCT03003377|ACTIVE_COMPARATOR|Device: laryngeal mask proseal|Determine the Sevoflurane concentration associate with remifentanil for insertion of the laryngeal mask ProSeal
62198317|NCT02302170|EXPERIMENTAL|H. pylori vaccine in children|H. pylori vaccine (15mg/dose) in children between 6-15 years of age
62198318|NCT02302170|PLACEBO_COMPARATOR|placebo in children|placebo (0mg/dose) in children between 6-15 years of age
62584927|NCT01459029|PLACEBO_COMPARATOR|Control|Treatment with inert capsules (placebo)
62783538|NCT04920110||Phase 2: Cross-Sectional Assessment of Psychometric Properties|Approximately 250 parents/caregivers will complete the ORCA measure and additional measures to determine its psychometric properties including reliability, floor/ceiling effects and construct validity.
62783539|NCT02366156|PLACEBO_COMPARATOR|Placebo|Inactive capsules
62783540|NCT02366156|ACTIVE_COMPARATOR|Low Dose Grape Blend|Low dose grape blend providing 375 mg whole grape extract + 375 mg grape seed extract/d (750 mg total botanical extracts/d).
62783541|NCT02366156|ACTIVE_COMPARATOR|High Dose Grape Blend|High dose grape blend providing 500 mg whole grape extract + 500 mg grape seed extract/d (1000 mg total botanical extracts/d)
62198319|NCT05843292|EXPERIMENTAL|Short-term Sintilimab in Combination With Taxane and Carboplatin|Prior to surgery: 2 cycles of sintilimab, in combination with 4 cycles of taxane and carboplatin
62198320|NCT03878329|NO_INTERVENTION|standard of care|standard of care treatment
62198321|NCT03878329|EXPERIMENTAL|remote home monitoring|use of telemedicine based remote home monitoring
62198322|NCT06105190|EXPERIMENTAL|IOL implantation experimental|Experimental arm: Premium monofocal intraocular lens LuxSmart
62198323|NCT06105190|ACTIVE_COMPARATOR|IOL implantation active comparator|Comparator arm: Monofocal intraocular lens LuxGood
62198324|NCT00068432|EXPERIMENTAL|Gemcitabine + Celecoxib|Oral celecoxib twice daily on days 1-28. Gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
62198325|NCT06432114|EXPERIMENTAL|Sensory Awareness Program|
62198326|NCT06432114|OTHER|Treatment as usual|
62198327|NCT04465266|EXPERIMENTAL|50 mg Tolperisone|50 mg tablets (2 days SD, 2 days TID)
62198328|NCT04465266|EXPERIMENTAL|100 mg of Tolperisone|100 mg tablets (2 days SD, 2 days TID)
62584928|NCT03033602|EXPERIMENTAL|Written exposure therapy|5 sessions of imaginal exposure therapy.
62198329|NCT04465266|EXPERIMENTAL|200 mg Tolperisone|200 mg tablets (2 days SD, 2 days TID)
62198330|NCT05164380||PWA|Persons with Aphasia
62198331|NCT05164380||CG|Control Group healthy adults without aphasia
62198332|NCT05863572|ACTIVE_COMPARATOR|Treatment as usual|Training primary care workers in diagnosis and treatment; training community health workers in detection and referral.
62198333|NCT05863572|EXPERIMENTAL|Strengthening care in collaboration with people with lived experience of psychosis in Uganda|Trainings done in collaboration with people with lived experience of psychosis; as well as additional home visits conducted by people with lived experience of psychosis.
62198334|NCT04618367|EXPERIMENTAL|HAIC plus Lenvatinib and Sintilimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 6 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 200 mg intravenously every 3 weeks.
62198335|NCT03889145|ACTIVE_COMPARATOR|Telmisartan, Amlodipine|
62198336|NCT03889145|ACTIVE_COMPARATOR|Hydrochlorothiazide|
62198337|NCT03889145|EXPERIMENTAL|Telmisartan, Amlodipine, Hydrochlorothiazide|
62198338|NCT01562223|EXPERIMENTAL|Repeatability Assessment|Gadolinium motexafin gadolinium All participants will undergo two consecutive DCE-MRI and DWI scans per same imaging parameters and subsequent comparison for repeatability.
62198339|NCT01395069|ACTIVE_COMPARATOR|Nepafenac 0.1%|
62783542|NCT05927363|NO_INTERVENTION|Controls|Patients in Phase 3 of cardiac rehabilitation, undergoing the usual care provided.
62198340|NCT01395069|ACTIVE_COMPARATOR|Ketorolac 0.5%|
62198341|NCT01395069|PLACEBO_COMPARATOR|Placebo|
62198342|NCT03437889|EXPERIMENTAL|Epidural analgesia/anesthesia for childbirth|
62198343|NCT06541496||Fitzpatrick 1|Healthy volunteers with skin type 1.
62783543|NCT05927363|EXPERIMENTAL|Experimental Group|"Patients in Phase 3 of cardiovascular rehabilitation, following a therapeutic educational program for consolidation (patient partner and a caregiver) as well as the usual care provided."
62198344|NCT06541496||Fitzpatrick 2|Healthy volunteers with skin type 2.
62584929|NCT03033602|ACTIVE_COMPARATOR|CPT, cognitive only|12 sessions of cognitive therapy.
62783544|NCT05318872||ENT cancers|patients with ENT cancer in the active care line for who a surgical resection is planned.
62783545|NCT06477185|EXPERIMENTAL|Intervention: Doxycycline|Oral doxycycline (100 mg) administered once daily for 12 weeks
62198345|NCT06541496||Fitzpatrick 3|Healthy volunteers with skin type 3.
62198346|NCT06541496||Fitzpatrick 4|Healthy volunteers with skin type 4.
62198347|NCT06541496||Fitzpatrick 5|Healthy volunteers with skin type 5.
62198348|NCT06541496||Fitzpatrick 6|Healthy volunteers with skin type 6.
62198349|NCT06541496||BMI Group 1|Healthy volunteers with BMI \<18.5.
62198350|NCT06541496||BMI Group 2|Healthy volunteers with BMI \>18.5 but \<25.
62198351|NCT06541496||BMI Group 3|Healthy volunteers with BMI \>25.
62198352|NCT05053880|EXPERIMENTAL|1b dose exploration|1b dose exploration for 18 patients - The starting dose of ACT001 will be administered in combination with a single intravenous (IV) infusion of Pembrolizumab. After recovery from surgical resection, dosing will resume on a 3 weekly cycle and will consist of Pembrolizumab (standard dosing) and daily ACT001. Evaluation of a dose level of at least three (3) patients after completing one cycle of treatment post-surgery is required prior to commencing the next dose level.
62198353|NCT05053880|EXPERIMENTAL|2a- Randomized/Two-treatment Arm|30 Patients will be randomized to Arm A or Arm B at a ratio of 1 (Arm A) : 2 (Arm B). 10 patients will be randomized to the Pembrolizumab only arm (Arm A) and 20 patients will be randomized to the ACT001 plus Pembrolizumab arm (Arm B).
62198354|NCT01803581|EXPERIMENTAL|X92001327|the X92001327 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
62198355|NCT01803581|ACTIVE_COMPARATOR|RID shampoo|The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
62198356|NCT02381353|ACTIVE_COMPARATOR|Plain bupivacaine|Intraoperative injection of local anesthetic agent, standard of care
62198357|NCT02381353|EXPERIMENTAL|Exparel (sustained release bupivacaine)|Intraoperative injection of local anesthetic agent, long acting agent
62198358|NCT04560374|EXPERIMENTAL|Experimental Group|Crochet octopus was delivered to the hands of the neonates in the experimental group 10 minutes before heel lance process and they were contacted with the crochet octopus up to 10 minutes after the procedure.
62198359|NCT04560374|NO_INTERVENTION|Control Group|Control group neonates were performed all the process without delivering them any crochet octopus.
62198360|NCT03104010|EXPERIMENTAL|PEG-rhGH-1|Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The first stage, 1-2mg/2-4mg, subcutaneous injection,weekly, 26 weeks.
62198361|NCT03104010|EXPERIMENTAL|PEG-rhGH-2|Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The second stage (extension period study), maximum ≤4mg/w (24IU/w), 52 weeks.
62198362|NCT03853551|EXPERIMENTAL|Single|Single arm
62198363|NCT01261000|EXPERIMENTAL|Pegvisomant|
62198364|NCT03381677|EXPERIMENTAL|Pedicle Lengthening Osteotomy|Lumbar decompressive surgery via Pedicle Lengthening Osteotomy Procedure with the Altum® Device
62198365|NCT03381677|ACTIVE_COMPARATOR|Control group|"Decompressive surgery via open surgical decompression and Transforaminal Lumbar Interbody Fusion (TLIF) using either a midline or paramedian incision with implantation of bilateral pedicle screws (4 screws) and rods (2 rods) and an interbody fusion cage (1 PEEK fusion cage, coated or uncoated):~1. DePuy Synthes Expedium® 5.5 System, Stryker Xia 5.5 System, Medtronic CD Horizon Solera 5.5 Systemor Innovative Surgical Designs True Spinal Fixation System; and~2. DePuy Synthes Concord TLIF cage, Stryker UniLIF TLIF cage, Medtronic Capstone TLIF cage or Meditech Talos TLIF cage."
62198366|NCT06379542|EXPERIMENTAL|XC8, film-coated tablets, 20 mg, 40 mg|"6-12 years old: 20 mg tablet, 2 per day for 7-14 days on top of standard therapy.~13-17 years old: 40 mg tablet, 2 per day for 7-14 days on top of standard therapy."
62198367|NCT06379542|PLACEBO_COMPARATOR|Placebo|2 tablets per day for 7-14 days on top of standard therapy
62198368|NCT05209516|EXPERIMENTAL|Parkinson's disease (PD) patients Group 1|PD patients treated by Dopamine replacement therapy, recruited through Movement Disorders consultations at the Saint-Luc University Hospital, mainly of Prof. Jeanjean, Prof. Ivanoiu, Dr. Wilhelm
62198369|NCT05209516|EXPERIMENTAL|Parkinson's disease (PD) patients Group 2|PD patients treated by Deep Brain Stimulation, recruited through Movement Disorders consultations at the Saint-Luc University Hospital, mainly of Prof. Jeanjean, Prof. Ivanoiu, Dr. Wilhelm
62198370|NCT05209516|ACTIVE_COMPARATOR|Healthy individuals|Healthy participants, aged between 18 and 85, will be recruited as control subjects by means of ads posting.
62198371|NCT06330935|ACTIVE_COMPARATOR|TXA dose A arm|Subjects will receive a 15 mg/kg bolus of Tranexamic acid over 20 minutes followed by 2 mg/kg/hr. infusion over 8 hours. The maximum bolus dose is 1000 mg, the maximum rate of infusion is 50 mg/min, and the maximum total maintenance dose is 1000 mg
62198372|NCT06330935|ACTIVE_COMPARATOR|TXA dose B arm|Subjects will receive a 30 mg/kg bolus of Tranexamic acid over 20 minutes followed by 4 mg/kg/hr. infusion over 8 hours. The maximum bolus dose is 2000 mg, the maximum rate of infusion is 100 mg/min, and the maximum total maintenance dose is 2000 mg
62198373|NCT06330935|PLACEBO_COMPARATOR|Placebo arm C|Subjects in the placebo group will receive a bolus dose of normal saline over 20 minutes followed by a normal saline infusion over 8 hours (in the same weight-based volume as the other study arms)
62198374|NCT04035980|NO_INTERVENTION|Conventional care|Screening HCV with dried blod spot (DBS) testing and referral to tertiary care hospital to evaluate disease stage and treatment of HCV RNA positive patients
62198375|NCT04035980|ACTIVE_COMPARATOR|Telemedicine care|Two-way videoconference to evaluate the need of screening with DBS, disease stage evaluation and treatment of HCV RNA positive patients at drug addiction centers
62400363|NCT06469333|EXPERIMENTAL|Eye movements and auditory stimulations (EM+AS)|"The participant will have to concentrate on the image or, failing that, the sensory representation representing the worst aspect of the targeted intrusive thought for 10 seconds and follow the horizontal displacement of a white dot on the computer screen, while simultaneously perceiving the auditory beep tones in the headphones provided. These tones will be at a rate of 1.2 Hz (i.e. 1.2 left ear-right ear-left ear alternations per second)."
62400364|NCT06469333|EXPERIMENTAL|Eye movements, auditory stimulations and tactile stimulations (EM+AS+TS)|"The participant is asked to concentrate on the image or, failing that, the sensory representation representing the worst aspect of the targeted intrusive thought for 10 seconds, and to follow the horizontal displacement of a white dot on the computer screen and simultaneously perceive the beeps, as well as the tactile self-stimulations applied at a constant speed of 1.2Hz (i.e. 1.2 left-right-left tapping cycles per second)."
62400365|NCT01125449|OTHER|Intravenous IVC Intervention|Intravenous ascorbic acid, 1.5g/kg at an infusion rate not to exceed 250mg/min.
62400366|NCT00781001|PLACEBO_COMPARATOR|1|Placebo cannabis
62400367|NCT00781001|EXPERIMENTAL|2|Active cannabis - 1% THC by weight
62400368|NCT00781001|EXPERIMENTAL|3|Active cannabis - 4% THC by weight
62400369|NCT00781001|EXPERIMENTAL|4|Active cannabis - 7% THC by weight
62400370|NCT05276726|EXPERIMENTAL|Phase 1 ,Dose Exploration ,monotherapy|Dose escalation of JAB21822 will be administered as monotherapy to determine the MTD and RP2D
62783546|NCT06477185|PLACEBO_COMPARATOR|Control arm|Oral placebo (matching with doxycycline) will be administered once daily for 12 weeks
62783547|NCT04481061|OTHER|Decision Making About Genetic Results|Adolescents between 13-21 and parent (if applicable) will make decisions about learning results using an electronic decision tool. Results that match their choices will be returned.
62783548|NCT00933465|EXPERIMENTAL|tablets first followed by syrup|first 6 weeks of study using tablets, then followed by assessment, and then the next 6 weeks using syrup, followed by assessment
62783549|NCT00933465|EXPERIMENTAL|Syrup first followed by tablets|first 6 weeks of study using syrup, then followed by assessment, and then the next 6 weeks using tablets, followed by assessment
62783550|NCT06507488|EXPERIMENTAL|Daphnetin|oral Daphnetin Capsule three capsules/tid for up to six months.
62198376|NCT03142854|ACTIVE_COMPARATOR|Group A: standard group|Participants are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
62198377|NCT03142854|EXPERIMENTAL|Group B: tailored group|"Participants are given personalized regimens for bowel preparation according to the the predictive model( a model which grades patients as low or high risk according to risk factors such as age, body mass index≧ 30 kg/m2, diabetes, constipation, pelvic surgery and tricyclic antidepressants usage).~Low risk patients are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen; High risk patients are given standard regimen: 4 L Polyethylene Glycol (PEG) regimen."
62198378|NCT04985786|EXPERIMENTAL|AUD Intervention|Risk behavior specific intervention, targeting alcohol drinking
62198379|NCT04985786|ACTIVE_COMPARATOR|AUD Control|Non-risk behavior specific intervention, targeting cognitive exercises
62400371|NCT05276726|EXPERIMENTAL|Phase 2, Dose Expansion, Part1 monotherapy|Part 1 dose expansion is to evaluate the safety and clinical activity of JAB-21822 at RP2D in subjects with previously untreated advanced non-small cell lung cancer (NSCLC)
62400372|NCT05276726|EXPERIMENTAL|Phase 2 Dose Expansion, Part 2 monotherapy|Part 2 dose expansion is to evaluate the safety and clinical activity of JAB-21822 at RP2D in subjects who had received at least one previous line of systemic therapy for NSCLC
62783551|NCT06507488|PLACEBO_COMPARATOR|Placebo|oral Placebo (Daphnetin Capsule simulants) three capsules/tid for up to six months.
62783552|NCT00429169|ACTIVE_COMPARATOR|Paroxetine|Participants will receive paroxetine for 8 weeks
62783553|NCT00429169|ACTIVE_COMPARATOR|Bupropion|Participants will receive bupropion for 8 weeks
62198380|NCT04985786|EXPERIMENTAL|AUD & SZ Intervention|Risk behavior specific intervention, targeting alcohol drinking
62400373|NCT01361282||Triple Procedure|All qualifying patients will have received DSAEK with concurrent cataract extraction and intraocular lens placement. Data collection will occur between 6-18 months post-operation.
62783554|NCT03193710||Total intravenous anesthesia group|The anesthesia of patients in the total intravenous anesthesia group will be maintained with propofol and remifentanil.
62198381|NCT04985786|ACTIVE_COMPARATOR|AUD & SZ Control|Non-risk behavior specific intervention, targeting cognitive exercises
62198382|NCT04985786|EXPERIMENTAL|SZ Intervention|Risk behavior specific intervention, targeting medication non-adherence
62198383|NCT04985786|ACTIVE_COMPARATOR|SZ Control|Non-risk behavior specific intervention, targeting cognitive exercises
62198384|NCT04985786|NO_INTERVENTION|HC Control|Healthy control subjects will participate in fMRI assessments only
62400374|NCT01955902||Opioid addicts|Opioid addicts undergoing bup/nal maintenance therapy
62400375|NCT00329706|EXPERIMENTAL|1|Experimental arm will have an immediate release of the PET report
62400376|NCT00329706|ACTIVE_COMPARATOR|2|Active Comparator arm will have a delayed release of 2 years
62783555|NCT03193710||Inhalational anesthesia group|The anesthesia of patients in the inhalational anesthesia group will be maintained with sevoflurane and remifentanil.
62783556|NCT03888729|EXPERIMENTAL|HCV treatment-naïve participants|HCV-infected individuals naïve to DAA therapy regimen; in this group we consider also HCV-infected individuals who have failed interferon-based therapy. Sofosbubir/velpatasvir (SOF/VEL) will be administered once daily for 12 weeks to eligible HCV treatment-naïve participants.
62783557|NCT03888729|EXPERIMENTAL|HCV treatment-experienced participants|HCV treatment-experienced participants, i.e.HCV-infected individuals with a history of virologic failure to SOF/LDV or other DAA-containing regimen. Sofosbubir/velpatasvir /voxilaprevir (SOF/VEL/VOX) will be administered once daily for 12 weeks to eligible HCV treatment-experienced participants
62783558|NCT02522325|PLACEBO_COMPARATOR|Placebo|Subjects will be maintained on oral placebo, administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
62783559|NCT02522325|EXPERIMENTAL|Phendimetrazine|Subjects will be maintained on oral phendimetrazine (up to 210 mg/day) administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
62783560|NCT04720742|EXPERIMENTAL|Experimental group|The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration, and during the first 8 months, a temporary immune intervention including the combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074, which will be infused once per month.
62198385|NCT05768165|EXPERIMENTAL|Intervention group|Cardiorespiratory and strength exercise training 2-3 sessions per week
62198386|NCT05768165|NO_INTERVENTION|Care as usual|Care as usual and information of health enhancing physical activity according to general recommendations
62198387|NCT06350253||18-24 years old|18-24 years old
62198388|NCT06350253||24-29 years old|
62198389|NCT06350253||30-39 years old|
62198390|NCT06350253||40-49 years old|
62198391|NCT06350253||50-60 years old|
62198392|NCT00790387|EXPERIMENTAL|1 High dose tirofiban and enoxaparin|"Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg .~Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours."
62400377|NCT04907201||Patients|A group pf 30 patients with lower limb spasticity who are already candidate for cryoneurotomy will be invited to have an extra electrophysiological test for participation in this study. The test will be done for both limbs for a better comparison.
62783561|NCT04036812|EXPERIMENTAL|Superficial cervical plexus block group|
62783562|NCT04036812|SHAM_COMPARATOR|Control group|
62198393|NCT00790387|ACTIVE_COMPARATOR|2 tirofiban and unfractionated heparin|"Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours.~UFH heparin was administered as a bolus of 70 U/kg and additional heparin was given to maintain the activated clotting time (ACT) at 250"
62783563|NCT01505439|EXPERIMENTAL|Solifenacin group|Once daily
62198394|NCT04076462|EXPERIMENTAL|CAM2029 (octreotide subcutaneous depot)|CAM2029 (octreotide subcutaneous depot) 20mg/1.0 mL for 20 mg dose, subcutaneous injection once monthly, six months treatment. If down-titration is required, 10mg/0.5 mL for 10 mg dose is available.
62198395|NCT04076462|PLACEBO_COMPARATOR|Matching placebo|Placebo (subcutaneous depot) 1.0 mL, subcutaneous injection once monthly, six months treatment. If down-titration is required, 0.5 mL dose is available.
62198396|NCT01098916|EXPERIMENTAL|X-rays at home|Home hospitalized elderly patients undergo X-rays at home
62400378|NCT04907201||Healthy participants|A group of 30 healthy participants will be invited as a control group, and they will have a single session of electrodiagnostic test for their lower limb in dominant side.
62783564|NCT05297513|NO_INTERVENTION|Standard treatment, no intervention|
62198397|NCT01098916|ACTIVE_COMPARATOR|Hospital X-rays|Home hospitalized elderly patients undergo X-rays examinations in hospital
62198398|NCT01305408|PLACEBO_COMPARATOR|Placebo|Participants began taking placebo to match armodafinil and following the same titration procedure. Treatment was administered for a total of 8 weeks.
62783565|NCT05297513|EXPERIMENTAL|Standard treatment, plus ActiveMatrix|
62783566|NCT05884775|EXPERIMENTAL|iMatter2|All the patients within a primary care provider (PCP) randomized to the intervention will receive iMatter2.
62783567|NCT05884775|NO_INTERVENTION|Usual Care (UC)|All patients within PCPs randomized to UC will receive standard Type 2 diabetes (T2D) care by their PCP.
62783568|NCT01730703||Adults ages 65 and older|
62783569|NCT02486783||Baseline controls (no signs of infection)|Neonates admitted for serial blood draws for uncomplicated hyperbilirubinemia
62783570|NCT02486783||Signs of infection A|No infection: antibiotics stopped after 48 hours; negative cultures
62783571|NCT02486783||Signs of infection B|Clinical infection: 7 day antibiotics; negative cultures
62198399|NCT01305408|EXPERIMENTAL|Armodafinil 150 mg/day|Participants began taking armodafinil at a dosage of 50 mg/day; the dosage was increased by 50 mg/day on days 2 and 4, up to a dosage of 150 mg/day. Treatment was administered for a total of 8 weeks.
62783572|NCT02486783||Signs of infection C|Sepsis: positive bacterial blood culture
62783573|NCT02486783||Signs of infection D|Meningitis: positive bacterial CSF culture
62198400|NCT06518447|EXPERIMENTAL|Digital occlusal splints (CAD/CAM)|"Patients in this arm will receive a CAD/CAM occlusal stabilization splint created using a fully digital workflow. The process includes:~1. Digital Impression: digital scan of the mouth will be performed using a 3shape® intraoral scanner.~2. Digital Design: The scanned data will be processed using Dental Wings' DWOS® software to design the occlusal splint virtually. The design will ensure the splint follows the Michigan splint type specifications.~3. Manufacturing: The designed splint will be fabricated using a Straumann® P series rapidshape P30+ 3D printer with a specific acrylic resin, Cosmos Splint. The splint will be polished to ensure comfort and fit, while maintaining the same surface texture as the conventional splint.~4. Fitting and Adjustment: The digitally fabricated splint will be fitted and adjusted as necessary to ensure proper adaptation and occlusal contacts. An Occlusense device will be used to verify and adjust the occlusal contacts during the fitting process."
62198401|NCT06518447|ACTIVE_COMPARATOR|Conventional occlusal splints|"Patients in this arm will receive a conventional occlusal stabilization splint fabricated using traditional analog methods. The process includes:~1. Impression Taking: Impressions of the patient's upper and lower arches will be taken using alginate.~2. Model Preparation: The plaster models will be mounted on a semi-adjustable articulator using a centric relation occlusal record. A wax-up of the occlusal splint will be created following the Michigan splint type specifications.~3. Manufacturing: The wax-up will be processed and flasked with heat-cured acrylic resin to create the final splint. The splint will be polished similarly to the digital splint to ensure a consistent appearance and texture.~4. Fitting and Adjustment: The conventional splint will be fitted and adjusted to ensure proper adaptation and occlusal contacts. An Occlusense device will be used to verify and adjust the occlusal contacts during the fitting process."
62198402|NCT01600560||Social media|
62198403|NCT02344875|EXPERIMENTAL|Male elder subjects|Male 65- Years
62198404|NCT02344875|EXPERIMENTAL|Male non-elder subjects|Male 20-35 Years
62198405|NCT02344875|EXPERIMENTAL|Female elder subjects|Female 65- Years
62198406|NCT02344875|EXPERIMENTAL|Female non-elder subjects|Female 20-35 Years
62198407|NCT04299243|EXPERIMENTAL|Spherical Lens|Randomized to Spherical Lens worn in a daily disposable mode
62783574|NCT06176638|EXPERIMENTAL|RRF4H Combination Intervention Group|This is a combination intervention that builds on the Usual Care and will consist of (1) a MFG-based FS model, which targets issues such as communication, relationship, and social support network development to assist with parenting and stress management, and stigma reduction96 and (2) a peer-mentoring program called TeenAge Health Consultants (Virtual TAHC) adapted for delivery in virtual environment.
62783575|NCT06176638|NO_INTERVENTION|Usual Care Group|Youth in RRF4H study will receive the usual mental health counseling provided through their school counselors. There is no structured curriculum for the group counseling programs but are available to all students as needed. The Lincoln Public School District also provides additional resources on specific topics such as trauma, depression and anxiety in children and adolescents, and alcohol substance use in families and provide appropriate referrals for those in need. Additionally, through organizations such as the International Council for Refugees and Immigrants (ICRI), refugee youth 7 to 18 years of age can receive educational and social support programs, after-school STEM clubs and one-on-one peer mentoring. Through the New Life Family Alliance, in addition to after-school program, boys and girls basketball program, youth are connected to youth-serving agencies that can help them effectively and successfully develop and take advantage of opportunities available to them.
62198408|NCT04299243|ACTIVE_COMPARATOR|SiHy Daily|Randomized to SiHy Daily worn in a daily disposable mode
62198409|NCT01364753||Pilots|No intervention; observational study
62198410|NCT04699942|ACTIVE_COMPARATOR|Conventional|Conventional low-flow Oxygen Delivery
62198411|NCT04699942|EXPERIMENTAL|Revoxa|Oxygen Delivery via Revoxa Oxygen Rebreather Device
62198412|NCT05721547||RC Repair Group|Participants who had undergone the same arthroscopic RM surgical procedure and technique; had undergone acromioplasty and/or tenodesis with RM repair; had undergone arthroscopic RM surgery from the upper extremity of the dominant side; had completed six months following surgery
62198413|NCT05721547||Healthy Group|Participants who had not undergone any shoulder surgery, had no history of shoulder-related pain, discomfort, or trauma in the last year
62198414|NCT02723097|EXPERIMENTAL|Relaxation Response Resiliency Program (3RP)|
62198415|NCT00534495|EXPERIMENTAL|Group 1|Loading dose of rilonacept (4.4mg/kg) at Week 0, followed by rilonacept 2.2 mg/kg/week for the remainder of the study
62198416|NCT00534495|PLACEBO_COMPARATOR|Group 2|Placebo for 4 weeks, followed by rilonacept loading dose (4.4mg/kg), followed by rilonacept 2.2 mg/kg/week for the remainder of the study
62198417|NCT01703728||Highly purified menotropin (HP-hMG) treatment|Cohort of women from 18 to 36 years old treated by HP-hMG for controlled ovarian stimulation (COS) for a first or second cycle of IVF / ICSI.
62198418|NCT05521412|EXPERIMENTAL|Experimental: Treatment Arm|In this single-arm study, patients will receive doses of \[161 Tb\]Tb PSMA I\&T on Day 1 of every 6 week Cycle. The dose of \[161 Tb\]Tb PSMA I\&T will vary in dose-escalation. Up to 6 Cycles will be given.
62198419|NCT04465955|EXPERIMENTAL|NGM621 Treatment Group A (every 4 weeks)|NGM621 single intravitreal (IVT) injection
62198420|NCT04465955|EXPERIMENTAL|NGM621 Treatment Group C (every 8 weeks)|NGM621 single IVT injection
62198421|NCT04465955|SHAM_COMPARATOR|Sham Group B (every 4 weeks)|Sham single IVT injection
62198422|NCT04465955|SHAM_COMPARATOR|Sham Group D (every 8 weeks)|Sham single IVT injection
62198423|NCT04486625|EXPERIMENTAL|Cohort 1|Normal renal function
62198424|NCT04486625|EXPERIMENTAL|Cohort 2|Severe renal impairment (not on dialysis)
62400379|NCT02509429|EXPERIMENTAL|Control-to-Range algorithm and Threshold Low Glucose Suspend|"On this arm, patients will realize two investigational sessions:~* the first with Control-to-Range algorithm (CTR),~* the second with Threshold Low Glucose Suspend (TLGS)."
62400380|NCT02509429|EXPERIMENTAL|Threshold Low Glucose Suspend and Control-to-Range algorithm|"On this arm, patients will realize two investigational sessions:~* the first with Threshold Low Glucose Suspend (TLGS),~* the second with Control-to-Range algorithm (CTR)."
62400381|NCT03971968||Group 1 = Intervention group|Group 1 suffered from third degree full thickness burns in the face/neck and received a surgical procedure with Integra Artificial Skin in the past
62400382|NCT03971968||Group 2 = Control Group|Group 2 is the healthy skin of a comparable and/or contralateral skin-site of the face/neck
62400383|NCT02081352|ACTIVE_COMPARATOR|DermaPure™|DermaPure™ in combination with standard care comprising surgical debridement, covered by a non-adherent silicone wound contact layer, a wound cavity filler (if required), a secondary foam wound dressing and appropriate off-loading footwear.
62400384|NCT02081352|SHAM_COMPARATOR|Standard care|Standard care comprising surgical debridement, covered by a non-adherent silicone wound contact layer, a wound cavity filler (if required), a secondary foam wound dressing and appropriate off-loading footwear.
62400385|NCT04398030|EXPERIMENTAL|coil-reinforced soft polymer indwelling cannula|Participants in this arm are randomized into the coil-reinforced soft polymer indwelling cannula group and then switched to a soft Teflon indwelling cannula group after a 2-week washout/rest (±1 week). The participant will try to wear each infusion set for 7 consecutive days.
62010984|NCT06283628|ACTIVE_COMPARATOR|Subjects with traditional approach on the right side and parasagittal approach on the left side.|Patients will undergo bilateral RFA; the right side will be done following the traditional approach, and the left side will be done following the parasagittal approach. Traditional approach is done by placing the electrode at a 20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process and transverse process of the vertebral body to target the traversing medial branch nerve. The reason for the proposed angle is to avoid the mamillo-accessory ligament that may be ossified in up to 10% of the normal spine and potentially prevent proper coagulation of the medial branch nerve during the RFA procedure. Parasagittal (new) approach: is performed by placing the RF cannula parasagittally and more dorsally. To achieve maximum nerve coagulation, the electrode should be placed as parallel to the nerve as possible, and placing it parasagittally helps achieve this goal. The remainder of the procedure does not differ from the traditional method.
62198425|NCT00416195|EXPERIMENTAL|E2007|2 mg E2007 once daily for 2 weeks (Days 1 to 14), then 4 mg E2007 once daily for 2 weeks (Days 15 to 28), then 6 mg E2007 once daily for 2 weeks (Days 29 to 42), then 8 mg E2007 once daily for 2 weeks (Days 43 to 56), then 10 mg E2007 once daily for 2 weeks (Days 57 to 70), then 12 mg E2007 once daily for 6 weeks (Days 71 to 112).
62198426|NCT00416195|PLACEBO_COMPARATOR|Placebo|Matching placebo once daily for 16 weeks (Days 1 to 112)
62198427|NCT00698503||M2a- 38™ Hip System|
62198428|NCT05688631||Diabetic participants (case group)|Participants diagnosed with type 2 diabetes mellitus
62198429|NCT05688631||Healthy participants (control group)|Participants not diagnosed with type 2 diabetes mellitus or any other chronic diseases
62198430|NCT00598845||Consecutive numbers|Patients with endometrial cancer
62400386|NCT04398030|ACTIVE_COMPARATOR|soft Teflon indwelling cannula|Participants in this arm are randomized into the soft Teflon indwelling cannula group and then switched to the coil-reinforced soft polymer indwelling cannula group after a 2-week washout/rest (±1 week). The participant will try to wear each infusion set for 7 consecutive days.
62400387|NCT01945866|ACTIVE_COMPARATOR|Sham + intravitreal ranibizumab 0.3 mg|Intravitreal ranibizumab will be given on the day of randomization. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first. Follow-up intravitreal injections of ranibizumab will be given up to every 4 weeks using defined treatment criteria.
62400388|NCT01945866|EXPERIMENTAL|Intravitreal dexamethasone+intravitreal ranibizumab 0.3mg|The initial intravitreal ranibizumab injection will be given on the day of randomization. The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
62400389|NCT00802295|ACTIVE_COMPARATOR|standard dosis protocol|Administration of standard dosis of gonadotrophins for ovarian stimulation.
62400390|NCT00802295|EXPERIMENTAL|2|Administration of low dosis of Gonadotrophins for ovarian stimulation
62400391|NCT05196386|EXPERIMENTAL|Patient with targeted pharmaceutical interview|Specific information about treatment delivered by pharmacist
62010985|NCT06283628|ACTIVE_COMPARATOR|Subjects with traditional approach on the left side and parasagittal approach on the right side.|Patients will undergo bilateral RFA; the left side will be done following the traditional approach, and the right side will be done following the parasagittal approach. Traditional approach is done by placing the electrode at a 20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process and transverse process of the vertebral body to target the traversing medial branch nerve. The reason for the proposed angle is to avoid the mamillo-accessory ligament that may be ossified in up to 10% of the normal spine and potentially prevent proper coagulation of the medial branch nerve during the RFA procedure. Parasagittal (new) approach: is performed by placing the RF cannula parasagittally and more dorsally. To achieve maximum nerve coagulation, the electrode should be placed as parallel to the nerve as possible, and placing it parasagittally helps achieve this goal. The remainder of the procedure does not differ from the traditional method.
62010986|NCT02120339|EXPERIMENTAL|Carvedilol|Carvedilol 0-3.125 mg daily Escalating to 6.25 twice a day
62010987|NCT03970109|ACTIVE_COMPARATOR|ANS-6637 - 200mg|200 mg ANS-6637 (given as 2 x 100 mg tablet) once a day
62010988|NCT03970109|ACTIVE_COMPARATOR|ANS-6637 - 600mg|600 mg ANS-6637 (given as 2 x 300 mg tablet) once a day
62010989|NCT03970109|PLACEBO_COMPARATOR|Matched Placebo|2 placebo tablets once a day
62198431|NCT03953131|EXPERIMENTAL|Diagnostic (gallium Ga 68-DOTATATE PET/CT)|Patients receive gallium Ga 68-DOTATATE IV over a few minutes and, after 60 minutes, undergo a PET/CT scan over 5-10 minutes 14 days before starting scheduled radiation therapy and 6 weeks after completion of radiation treatment.
62198432|NCT01355042||Severe Sepsis and Septic Shock|
62783576|NCT05191108|EXPERIMENTAL|The Effect of mİNDFULNESS Stress Reduction Program on Premenstrual Symptoms|In order to prevent bias in the study groups, the Introductory Information Form and PMSS scale will be applied via online Google forms. Participants who meet the criteria will be randomly assigned to the mindfulness stress reduction group (Group 1) and control group (Group 2) in the number determined by power analysis and a simple random number generator program (www.random.org). These experimental and control groups will be recorded by the researchers as a list. Participants participating in the study will be informed about the mindfulness stress reduction application, but they will not be informed about what the mindfulness stress reduction application does (single-blind method). These participants will be asked to sign the consent form by expressing that they can withdraw from the study at any time.
62198433|NCT01355042||Other Critical Ill with or without Shock|Severe Trauma, Neurological Injury, Other Shock (not Septic)
62198434|NCT04709653|EXPERIMENTAL|Intervention Group|Occupation-based nursing program
62198435|NCT04709653|EXPERIMENTAL|Control Group|Routine nursing care
62198436|NCT04351308|EXPERIMENTAL|API+apatinib|"AP = Doxorubicin (Adriamycin) 20 mg/m2/day \* 2 day (total/cycle 40 mg/m²)~+ Cisplatin 100 mg/m2/course (total/cycle 120 mg/m²);~I = Ifosfamide 2000 mg/m2/day \*5 day (total/cycle 10000 mg/m²);~apatinib = 500 mg QD;"
62198437|NCT04351308|EXPERIMENTAL|MAPI+camrelizumab|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day \* 2day (total/cycle 75 mg/m²)~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²);~M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue;~I = Ifosfamide 2400 mg/m2/day \*5day (total/cycle 12000 mg/m²);~camralizumab = 200mg ivgtt. Q2W;"
62198438|NCT04351308|ACTIVE_COMPARATOR|MAPI|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day \* 2day (total/cycle 75 mg/m²)~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²);~M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue;~I = Ifosfamide 2400 mg/m2/day \*5day (total/cycle 12000 mg/m²);"
62198439|NCT06376760||Insomnia group|Patients with insomnia
62783577|NCT05191108|NO_INTERVENTION|Control group|not routinely do anything to reduce premenstrual symptoms
62783578|NCT01867086|EXPERIMENTAL|Vigil™ Vaccine|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
62783579|NCT04501796|EXPERIMENTAL|NT-I7|NT-I7 will be administered once by IM injection within 24 hours of baseline (day 0). The treatment course pursued in all enrolled participants will be a single dose. Dosing will be staggered with at least 72 hours between each study participant.
62783580|NCT04501796|PLACEBO_COMPARATOR|Placebo|Placebo will be administered once by IM injection within 24 hours of baseline (day 0). The treatment course pursued in all enrolled participants will be a single dose. Dosing will be staggered with at least 72 hours between each study participant.
62783581|NCT05160376|EXPERIMENTAL|Guided Intervention Group|The participants in the guided intervention group will receive feedback calls (approximately 15 minutes) on participants' progress from a clinical psychology trainee or an undergraduate trained psychology student under the supervision of a clinical psychology professor, after each online self-help intervention session. The participants in the guided intervention group will also receive an email reminder and text message if the participants have not completed the required session of that week on the 5th, 6th, and 7th of the same week. Technical supports are available.
62198440|NCT06376760||Normal sleep group|Patients with normal sleep
62198441|NCT02649504|ACTIVE_COMPARATOR|R+3D, MMF|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study. Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study. Mycophenolate mofetil (MMF) will be given starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
62400392|NCT05196386|OTHER|Patient without targeted pharmaceutical interview|No Specific information about treatment delivered by pharmacist
62576894|NCT02040051|ACTIVE_COMPARATOR|GROUP A: Sound isolation / Music therapy|"* PREINTERVENTION: First hour. The patient will remain under the usual conditions of intensive care unit~* INTERVENTION: Second hour. Sound isolation~* INTERVENTION: Third hour. Music therapy~* POSTINTERVENTION: Fourth hour. The patient will remain under the usual conditions of intensive care unit"
62783582|NCT05160376|EXPERIMENTAL|Unguided Intervention Group|The participants in the unguided intervention group will not receive the aforementioned feedback calls. The participants in the unguided intervention group will only receive an email reminder and text message if the participants have not completed the required session of that week on the 5th, 6th, and 7th of the same week. Technical supports are available.
62783583|NCT05160376|NO_INTERVENTION|Wait-list Control Group|The waitlist control group will not receive any online self-help intervention. Unguided intervention will be provided to the waitlist control group after both the Post-treatment Assessment Phrase are finished.
62010990|NCT02501889|EXPERIMENTAL|Walnut-rich weight loss diet arm|Participants will have an individualized reduced-calorie diet prescription and weight loss counseling session with the project coordinator, who is a registered dietitian. Composition of prescribed diets will be based on individual preferences. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. All participants will have contact with the project coordinator a minimum of every 1-2 weeks. Walnuts will be provided to participants in the walnut-rich study arm.
62010991|NCT02501889|ACTIVE_COMPARATOR|Standard weight loss diet arm|Participants will have an individualized reduced-calorie diet prescription and weight loss counseling session with the project coordinator, who is a registered dietitian. Composition of prescribed diets will be based on individual preferences. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Participants assigned to this arm will be instructed to abstain from the consumption of nuts during the study. All participants will have contact with the project coordinator a minimum of every 1-2 weeks.
62010992|NCT03747484|EXPERIMENTAL|Treatment (TCR-T cells, avelumab or pembrolizumab)|Approximated 5-7 days prior to receiving FH-MCVA2TCR T-cells, patients receive interferon gamma administered at the FDA-approved dosing of 50mcg/m2, 3 times weekly for a total of 4 weeks. Patients receive FH-MCVA2TCR T-cells IV over 60-120 minutes. Beginning 14 days after receiving FH-MCVA2TCR T-cells, patients also receive standard of care avelumab IV over 1 hour every 2 weeks for 1 year or pembrolizumab IV over 30 minutes every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity. Patients with partial response or stable disease may then receive an additional cycle of FH-MCVA2TCR T-cells.
62010993|NCT03747484|EXPERIMENTAL|Treatment 2 (TCR-T cells, avelumab or pembrolizumab)|Approximated 5-7 days prior to receiving FH-MCVA2TCR T-cells, patients receive interferon gamma administered at the FDA-approved dosing of 50mcg/m2, 3 times weekly for a total of 4 weeks. Patients receive FH-MCVA2TCR T-cells IV over 60-120 minutes. Beginning 14 days after receiving FH-MCVA2TCR T-cells, patients also receive standard of care avelumab IV over 1 hour every 2 weeks for 1 year or pembrolizumab IV over 30 minutes every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity. Patients with partial response or stable disease may then receive an additional cycle of FH-MCVA2TCR T-cells.
62198442|NCT02649504|PLACEBO_COMPARATOR|R+3D, Placebo|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study. Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study. Placebo will be given starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
62198443|NCT06289595||PBM|PBM = Use of PBM Ortho device
62400393|NCT03878368|EXPERIMENTAL|Intervention|32 participants with moderate osteoarthritis will eat soup with the active ingredient once-a-day for 4 days-a-week for 3 months.
62400394|NCT03878368|ACTIVE_COMPARATOR|Control|32 participants with moderate osteoarthritis will eat soup without the active ingredient once-a-day for 4 days-a-week for 3 months.
62400395|NCT00006401|EXPERIMENTAL|Inhaled Nitric Oxide (iNO)|Nitric Oxide study gas will be initiated at 5 ppm using the INOvent delivery system. The delivery system provides for masked delivery of the treatment gas. This dose will be used for a 21-day period or until extubation.
62400396|NCT00006401|PLACEBO_COMPARATOR|Placebo|
62400397|NCT01411761|EXPERIMENTAL|Saccharomyces boulardii|study group
62400398|NCT01411761|PLACEBO_COMPARATOR|placebo|serum physiologic
62576895|NCT02040051|ACTIVE_COMPARATOR|GROUP B: Music therapy / Sound isolation|"* PREINTERVENTION: First hour. The patient will remain under the usual conditions of intensive care unit~* INTERVENTION: Second hour. Music therapy~* INTERVENTION: Third hour. Sound isolation~* POSTINTERVENTION: Fourth hour. The patient will remain under the usual conditions of intensive care unit"
62576896|NCT02342158|EXPERIMENTAL|Locally advanced /metastatic cancer|
62198444|NCT06289595||Control|Did not receive any photobiomodulation treatment.
62198445|NCT02720562||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-IV criteria
62198446|NCT02720562||TD group|Typically development controls without lifetime diagnosis with ADHD
62400399|NCT04553328|ACTIVE_COMPARATOR|Group T|Group (T) received ultrasound guided (US) combined ipsilateral transverse abdominis plane (TAB) and ilioinguinal- iliohypogastric (ILIH) nerve block
62400400|NCT04553328|ACTIVE_COMPARATOR|Group I|Group (I) received US guided ipsilateral illioinguinal- illiohypogastric nerve block only.
62576897|NCT02647723|EXPERIMENTAL|Oral supplement for pregnant women|450 mg/daily of DHA beginning at 10-16 weeks of gestation through the end of pregnancy
62783584|NCT05107622|EXPERIMENTAL|FMUD+Probiotic|FMUD+Probiotic (n=30): full-mouth ultrasonic periodontal debridement associated with administration of probiotic formulation twice a day for 30 days.
62783585|NCT05107622|PLACEBO_COMPARATOR|FMUD+Placebo|FMUD+Placebo (n=30): full-mouth ultrasonic periodontal debridement associated with administration of placebo formulation, twice a day for 30 days.
62783586|NCT04625764|EXPERIMENTAL|patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB|
62783587|NCT03691662|EXPERIMENTAL|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
62783588|NCT03691662|ACTIVE_COMPARATOR|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months
62783589|NCT02085278|EXPERIMENTAL|Apollo Group|Apollo Micro catheter device
62010994|NCT02598349|EXPERIMENTAL|Proton Radiation with capecitabine|The following will be performed in this group: Proton Radiation Therapy with concomitant oral chemotherapy, capecitabine taken on radiation treatment days for 6 weeks. A surgical resection will be performed between 8 and 16 weeks if radiographic studies suggest operability.
62198447|NCT05596162|EXPERIMENTAL|Blood Flow Restriction Group|"1. Patient specific tourniquet settings to achieve 80% occlusion.~2. Weight- 20% of 1 rep max, 4 sets 30-15-15-15 reps with 30 second rests between sets~3. Exercises: The first phase will focus on active and passive range of motion of the ankle as well as non-weighted concentric exercises. Phase two will progress with gastrocnemius and soleus stretches along with body weight and light resistance band concentric and eccentric exercises focusing on posterior, anterior and lateral muscle groups of the lower limb. Phase three will introduce weighted, dynamic and proprioceptive exercises."
62198448|NCT05596162|ACTIVE_COMPARATOR|Non-Blood Flow Restriction Group|This group will perform the same exercises for the same volume without the use of BFR.
62215027|NCT05599620|PLACEBO_COMPARATOR|General Health Promotion|The General Health Promotion program is a attention and dose-matched comparison condition.
62215028|NCT01757444|EXPERIMENTAL|BiPAP - A40|BiPAP with AVAPS AE mode
62215029|NCT01757444|ACTIVE_COMPARATOR|BiPAP- ST|Patients receiving BiPAP- ST at home
62215030|NCT00473265|EXPERIMENTAL|PTH(1-84)|100mcg of PTH1-84 every other day, every day, or every three days
62400401|NCT02924467|NO_INTERVENTION|No intervention: Usual Care|Patients in this group will not receive any influenza vaccine reminder notifications.
62400402|NCT02924467|EXPERIMENTAL|1 Notice|Patients in this group will receive one influenza vaccine reminder notification via autodialer across the 2016 influenza season.
62783590|NCT02794519|EXPERIMENTAL|Sirukumab 50 mg/mL administered subcutaneously every 4 weeks|Subjects will receive sirukumab 50 milligram/milliliter (mg/mL) subcutaneously every 4 weeks. They will receive the treatment for minimum of 20 weeks but up to 44 weeks of dosing. Sirukumab will be administered by the trained site staff at Baseline, Weeks 4 and Week 8. From the Week 12 visit onwards, subjects may start to self-administer study drug at the site under the supervision of the trained site staff if they are able and willing to do so. If not, study drug will continue to be administered by the trained site staff.
62576898|NCT02647723|PLACEBO_COMPARATOR|Sugar pill|450 mg/daily of sugar pill beginning at 10-16 weeks of gestation through the end of pregnancy
62584930|NCT06111885|ACTIVE_COMPARATOR|Indapamide + Hydrochlorothiazide + Chlorthalidone|1 capsule containing 2.5 mg indapamide per day for 28 days, followed by a 28 days wash out phase, followed by a second treatment phase with 1 capsule containing 50 mg hydrochlorothiazide per day for 28 days, followed by a 28 days wash out phase, followed by a third treatment phase with 1 capsule containing 25 mg chlorthalidone per day for 28 days.
62783591|NCT02794519|PLACEBO_COMPARATOR|Placebo administered subcutaneously every 4 weeks|Subjects will receive placebo subcutaneously every 4 weeks. They will receive the treatment for minimum of 20 weeks but up to 44 weeks of dosing. Placebo will be administered by the trained site staff at Baseline, Weeks 4 and Week 8. From the Week 12 visit onwards, subjects may start to self-administer study drug at the site under the supervision of the trained site staff if they are able and willing to do so. If not, study drug will continue to be administered by the trained site staff.
62198449|NCT02675257|EXPERIMENTAL|Cognitive-behavioural group treatment|"Five group sessions of diabetes-Specific cognitive-behavioural group treatment for diabetes patients with depressive symptoms and/or diabetes distress and suboptimal glycaemic control.~Interventions:~* Diabetes-related affective problems analysis~* Goal setting towards improvement of glycaemic control~* Diabetes-specific problem-solving therapy~* Interventions to increase diabetes treatment motivation~* Activation of personal and social resources~* Reduction of barriers to self-care/glycaemic control~* Cognitive restructuring of diabetes-related problems~* Goal definition regarding self-care/glycaemia/well-being"
62198450|NCT02675257|ACTIVE_COMPARATOR|Treatment-as-usual|"Standard diabetes education.~Interventions:~* Health care and specific topics (e. g. blood pressure)~* Healthy foods, cooking recommendations, recipes~* Sports, activities and exercise~* Foot care: exercises, care \& control, injuries, neuropathy~* Diabetes complications~* Social aspects of living with diabetes"
62198451|NCT01375673|EXPERIMENTAL|Exercise|Exercise: Walking Strength Training Bicycling
62783592|NCT03262636|OTHER|Diagnostic value of Second Window ICG|"The primary study objective is to determine the diagnostic value of Second Window ICG (delayed, high dose IV administration of ICG) in the surgical resection of nervous system tumors.~The first objective is to determine safety/efficacy of high dose, delayed indocyanine green (second window ICG) during surgery of nervous system tumors."
62783593|NCT03262636|OTHER|Optimal timing and dose of SWG|"The second study objective is to calculate diagnostic test characteristics (sensitivity/specificity) of delayed, high dose indocyanine green (second window ICG) as a diagnostic aid during surgery of nervous system tumors.~The third study objective is to optimize timing and dose of second window Indocyanine Green during surgery of nervous system tumors, based on sensitivity/specificity."
62783594|NCT04414566|EXPERIMENTAL|IC plus RT|Patients receive GP(gemcitabine+cisplatin) or TPF(docetaxel+cisplatin+fluorouracil) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m\^2) every three weeks for three cycles during radiotherapy.
62783595|NCT04414566|ACTIVE_COMPARATOR|IC plus CCRT|Patients receive GP(gemcitabine+cisplatin) or TPF(docetaxel+cisplatin+fluorouracil) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy.
62010995|NCT05217368|EXPERIMENTAL|experimental group/mandala painting|Mandala painting will be done in addition to routine antenatal education.
62198452|NCT01375673|NO_INTERVENTION|Usual Care|Usual Care
62010996|NCT05217368|NO_INTERVENTION|antenatal education class|Only routine antenatal education will be done.
62198453|NCT04647747|OTHER|Self measurement of peripheral saturation|Participant will be equipped with a pulse oximeter and perform saturation measurements.
62198454|NCT05233475|ACTIVE_COMPARATOR|Control group (EUC)|"Enhanced usual care (EUC):~All participants will by a health professional be shortly informed about the typical recovery process, the given reassurance about the prognosis.as well as advice on adaptive illness behaviours post-concussion."
62198455|NCT05233475|EXPERIMENTAL|Intervention Group (EUC + GAIN Lite)|"GAIN Lite:~GAIN Lite in an add-on to EUC, and contains two major components: 1) self-administrated e-learning videos and 2) up to four hours video- or phone sessions with an allocated therapist (either an occupational- or a physiotherapist) during a period of 8 weeks. Health professionals provide feedback and guidance, addressing the specific aims and context of the individual."
62198456|NCT01780454|EXPERIMENTAL|Combined Bone Marrow and Kidney Transplantation|Conditioning regimen consisting of Rituximab, MEDI-507, Total Body Irradiation, Thymic Irradiation followed by simultaneous bone marrow and kidney transplantation
62198457|NCT02410005|ACTIVE_COMPARATOR|Losartan alone|In the losartan alone group, subjects are prescribed: losartan 50mg twice daily.
62783596|NCT02930304|EXPERIMENTAL|first physiotherapy|cold pack, TENS, exercise
62783597|NCT02930304|EXPERIMENTAL|second physiotherapy|cold pack, TENS, exercise, kinesiotaping
62400403|NCT02924467|EXPERIMENTAL|2 Notices|Patients in this group will receive up to two influenza vaccine reminder notifications via autodialer throughout the 2016 influenza season.
62400404|NCT02924467|EXPERIMENTAL|3 Notices|Patients in this group will receive up to three influenza vaccine reminder notifications via autodialer throughout the 2016 influenza season.
62400405|NCT06424756|EXPERIMENTAL|MitoQ, then Placebo|Participants will be given a single dose of 80mg MitoQ supplement first following an overnight fast. Then they will receive a matched Placebo single dose within a minimum 14 days
62198458|NCT02410005|EXPERIMENTAL|Losartan and Calcitriol|In the losartan plus calcitriol group, subjects are prescribed: losartan 50mg twice daily and calcitriol 0.25mcg daily.
62198459|NCT04113057|EXPERIMENTAL|Remote Coaching|All subjects enrolled in the study will be enrolled in supervised exercise therapy. They will also receive directions for supplemental home-based exercise and a LIVMOR remote health monitoring system. The remote coaching arm will receive regular provider feedback based on LIVMOR data.
62198460|NCT04113057|NO_INTERVENTION|Remote health monitoring without provider feedback|"All subjects enrolled in the study will be enrolled in supervised exercise therapy. They will also receive directions for supplemental home-based exercise and a LIVMOR remote health monitoring system. The no intervention arm will have access to LIVMOR data, but without provider feedback on the LIVMOR data."
62400406|NCT06424756|EXPERIMENTAL|Placebo, then MitoQ|Participants will be given a single dose of Placebo (matched to 80mg MitoQ) first following an overnight fast. Then they will receive 80mg MitoQ supplement single dose within a minimum of 14 days
62400407|NCT06465394|ACTIVE_COMPARATOR|Isometric Exercise|"Isometric test protocol. Participants will be asked to perform the exercise at a moderate exercise level (3/10 on the mRPE scale provided to them). They will complete a 1, 10-second isometric hold to their hand dominant side (if ambidextrous, the side the participant would report as the most dominant side) to allow them to find their moderate intensity level. The participant will then take a 2-minute rest before beginning the exercise routine and will be instructed to keep a consistent resistance level during the exercise bout. During the exercise, the subjects will hold the rotation contraction for 10 seconds, take a 2-second rest, complete this 5 times, and then change to the left side. They will do this for 3 sets of right and left. Researchers will time the exercises and give verbal instructions to make sure they are performing for the appropriate amount of time and rest periods."
62198461|NCT02864277|NO_INTERVENTION|No Intervention Conventional Strategy|Perioperative Anesthetic No Intervention Management: Conventional Strategy Group 4 pages of concise directions on how to take care of the participant.
62198462|NCT02864277|EXPERIMENTAL|ERAS Group|ERAS (enhanced recovery after surgery)
62198463|NCT04014231||Observational (single wave assessment)|Patients undergo placement of a single wave application near the carotid region of the neck.
62198464|NCT05288829|EXPERIMENTAL|ALXN1210 SC|Participants received ALXN1210 SC.
62783598|NCT02930304|EXPERIMENTAL|third physiotherapy|cold pack, TENS, ESWT, exercise
62783599|NCT03415438||Group 1|Assessments will be done for 30 patients diagnosed as subacromial impingement syndrome in physical medicine and rehabilitation department of Baskent University.
62783600|NCT03415438||Group 2|Assessments will be done for 30 healthy volunteers
62783601|NCT03123016|EXPERIMENTAL|Vitiligo with Apremilast and NB-UVB phototherapy|Each participant will be compared with one side of the body to the other side
62783602|NCT06576128|SHAM_COMPARATOR|control group|only local anesthesia will be applied to surgical field as a part of the routine procedure.
62783603|NCT06576128|ACTIVE_COMPARATOR|block group|local anesthesia will be applied to surgical field as a part of the routine procedure and additionally transversus abdominisl plane block will be applied.
62783604|NCT05809362||Atrial Fibrillation|Subjects with known diagnosis of atrial fibrillation (persistent or paroxysmal) documented in the medical record.
62783605|NCT05809362||No atrial fibrillation|Subjects with no known diagnosis of atrial fibrillation as documented in the medical record.
62783606|NCT00707954|EXPERIMENTAL|TA-7284|
62783607|NCT00707954|PLACEBO_COMPARATOR|Placebo of TA-7284|
62783608|NCT05595733|NO_INTERVENTION|conventional group|Using conventional mode to compare mechanical ventilation day with experimental group
62783609|NCT05595733|EXPERIMENTAL|experimental group|Using neurally adjusted ventilatory assist mode to compare mechanical ventilation day with conventional group
62783610|NCT04707300|EXPERIMENTAL|Human T Lymphoid Progenitor (HTLP) injection|HTLP cellular product obtained after 7 days of culture of immune-selected CB
62783611|NCT00959127|EXPERIMENTAL|ARRY-438162 (MEK 162)|
62783612|NCT03485521|ACTIVE_COMPARATOR|Practical Work|15 students who participate in a practical work lasting two hours about the procedures of the tracheobronchial aspiration
62783613|NCT03485521|EXPERIMENTAL|Stimulation Group|Group with competences and reasoning clinic 15 students Simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence after reading the procedures of the tracheobronchial aspiration
62010997|NCT03372408||Program Clients|Parkdale Parents' Primary Prevention Project (5P's) clients
62010998|NCT06664281|ACTIVE_COMPARATOR|sprint interval training group|
62198465|NCT05288829|EXPERIMENTAL|ALXN1210 IV|Participants received ALXN1210 IV.
62198466|NCT05288829|PLACEBO_COMPARATOR|Placebo SC|Participants received placebo SC.
62198467|NCT03997487|EXPERIMENTAL|Children examined|All children examined for clinical signs of trachoma will be invited to participate to have photos of conjunctivae taken with the TOFTEE smartphone app and a DSLR camera.
62783614|NCT01895959|OTHER|Euflexxa|EUFLEXXA® is a hyaluronate hydrogel produced from bacteria, in a phosphate-buffered saline solution. It is given as a three week treatment regimen. It involves injecting of 2cc or 20mg intra-articularly once per week.
62783615|NCT04802187|OTHER|RADx CHCs testing intervention strategy|Six Massachusetts community health center partnerships implementing both a common testing expansion implementation strategy plus tailored strategies designed for community partner needs.
62783616|NCT04802187|OTHER|Usual care control|
62783617|NCT00495625|EXPERIMENTAL|Sunitinib Malate (SUO11248) Treatment|
62783618|NCT03024190|EXPERIMENTAL|with Kinesiotaping|"* stretching exercises combined with Kinesiotaping~* regular OT rehabilitation program for 3 weeks"
62783619|NCT03024190|OTHER|control group|"* the patients will receive 15-min stretching exercises~* regular OT rehabilitation program for 3 weeks"
62783620|NCT01499966|EXPERIMENTAL|group POP|PLASTER OF PARIS
62783621|NCT01499966|EXPERIMENTAL|TG|TUBIGRIP
62010999|NCT06664281|ACTIVE_COMPARATOR|sprint interval training combined with remote ischemic preconditioning group|
62011000|NCT06664281|NO_INTERVENTION|Control group|
62011001|NCT06081166|ACTIVE_COMPARATOR|obicetrapib + atorvastatin|Obicetrapib 10 mg tablets daily from Days 1-17 plus atorvastatin calcium 80 mg tablets on Day -4 and Day 12
62011002|NCT06081166|ACTIVE_COMPARATOR|obicetrapib + rosuvastatin|Obicetrapib 10 mg tablets daily from Days 1-17 plus rosuvastatin calcium 40 mg tablets on Day -4 and Day 12
62783622|NCT01755455|ACTIVE_COMPARATOR|Ferrous sulfate 325mg|Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks
62783623|NCT01755455|PLACEBO_COMPARATOR|Placebo|Identical-appearing tablet taken by mouth daily for 6 weeks
62783624|NCT01555333|EXPERIMENTAL|Arbaclofen|Open Label Study
62783625|NCT02400541|EXPERIMENTAL|Cognitive remediation therapy|10 sessions of the cognitive remediation therapy program conducted during five weeks
62783626|NCT02400541|PLACEBO_COMPARATOR|relaxation therapy|10 relaxation sessions during 5 weeks
62783627|NCT01251835|ACTIVE_COMPARATOR|Sitaxsentan|
62011003|NCT04577092|ACTIVE_COMPARATOR|Motor-Cognitive|"In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips. After warm up period; participants had been asked to count back from the two-digit number while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.~In 10-minute cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed."
62198468|NCT05457751||M|Group M: patients currently using metoprolol and who did not receive lidocaine before the application of rocuronium.
62198469|NCT05457751||ML|Group ML: patients currently using metoprolol and who received lidocaine before rocuronium application.
62198470|NCT05457751||L|Group L: patients currently not using metoprolol and received lidocaine before rocuronium application.
62198471|NCT05457751||C|Group C: patients currently not using metoprolol and who did not receive lidocaine before rocuronium application.
62198472|NCT03748862||Cases|"Patients who were receiving high-dose, long-term opioid therapy at study entry and achieved a sustained taper during the follow-up period.~A Taper Plan is a plan to reduce or discontinue use of opioids discussed with the primary care provider. Evidence of a taper plan is found in the prescription notes or medical encounter notes in the electronic health record."
62198473|NCT03748862||Controls|Patients who were receiving high-dose, long-term opioid therapy at study entry and didn't achieve a sustained taper during the follow-up period.
62198474|NCT04001452||Level of experience in interventional cardiology|"Total cohort will be grouped according to experience in interventional cardiology, as defined by a single choice questionnaire:~Yearly personal PCI volume Less than 75 / Between 75 and 150 / Between 151 and 250 / More than 250"
62783628|NCT01251835|EXPERIMENTAL|Sitaxsentan plus Rifampin|
62783629|NCT01184924|NO_INTERVENTION|Control|Usual Care only. Usual care is defined as the care these subjects would like to seek from any health care practitioner or other program they may seek for healthy living. The subjects in this arm will be offered the AF Tai Chi intervention after an 8 week followup data collection
62783630|NCT01184924|EXPERIMENTAL|Tai Chi|Usual care plus Tai Chi. These subjects will be allowed to seek care from any health practitioner or any other programs and will receive the AF Tai Chi program for 8 weeks.
62198475|NCT04001452||Level of experience with intravascular ultrasound|"Total cohort will be grouped according to experience with intravascular ultrasound, as defined by a single choice questionnaire:~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years~Yearly: None / Less than 15 / Between 15 and 50 / More than 50"
62400408|NCT06465394|ACTIVE_COMPARATOR|Isotonic Exercise|The resistance level will stay at the participant's selected moderate level during the entire testing unless they need to stop due to pain or difficulty completing the exercise. During the exercise, the participants will be rotating to the right first at a pace of 1 second for concentric contraction to full rotation and 1 second for eccentric contraction, returning the head to the neutral position. The participant will continue this pace to complete 5 repetitions and then take a 2-second rest before continuing this sequence 5 times (a total of 25 reps) before switching and doing left rotation in the same fashion. This will be done for a total of 3 sets for both right and left rotation. The use of a metronome will be used along with the researcher's verbal instructions and cueing to maintain the proper sequence and timing of the exercise.
62783631|NCT04336033|EXPERIMENTAL|Counseling + Renal Diet App|Subjects in the intervention group will receive an individualized dietetic counseling from the researcher aided with the newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients
62783632|NCT04336033|PLACEBO_COMPARATOR|Counseling + Printed Nutrition Pamphlet|Individualized dietetic counseling aided with printed nutrition pamphlet prepared by Ministry of Health, Malaysia
62783633|NCT02757118|PLACEBO_COMPARATOR|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
62783634|NCT02757118|ACTIVE_COMPARATOR|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
62783635|NCT01829139||Wait-and-see group|After endoscopic clearance of their bile duct stones, this group of patients will be follow up without additional managements
62783636|NCT01829139||Choleretics group|After endoscopic clearance of their bile duct stones, this group of patients receives choleretic agents during 3 months
62011004|NCT04577092|ACTIVE_COMPARATOR|Motor-Motor|In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips. After warm up period; participants had been asked to hold with both hand half-filled glasses with 90 degree of flexion elbow and near the trunk while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion. In cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed.
62011005|NCT03509948|EXPERIMENTAL|Schedule A: Fed Then Fasted|"Schedule A (6 participants):~* Period 1: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)~* Period 2: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)"
62011006|NCT03509948|EXPERIMENTAL|Schedule B: Fasted Then Fed|"Schedule B (6 participants):~* Period 1: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)~* Period 2: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)"
62011007|NCT02356835|EXPERIMENTAL|APT001|The APT001 is a medical device that generates a plasma flow containing nitric oxide intended to be applied topically to wound sites. The nitric oxide / plasma flow will be directed at the wound site and surrounding skin at a distance of 11.5 to 15 centimeters from the skin surface. Dose will be 10 seconds / cm2 wound surface area. Administration of the therapy will include a 2 cm border around the defined edges of the wound site.
62215031|NCT04662099|EXPERIMENTAL|Conditioning chemotherapy plus CAR T cells infusion|
62215032|NCT04394468|OTHER|patient group|Data is collected from women (18-45y) with endometriosis (superficial and / or deep infiltrating endometriosis) where the preferred treatment is a laparoscopic intervention at UZ Gent.
62783637|NCT04992845|EXPERIMENTAL|Intervention|Vertebral Body Tethering surgery
62783638|NCT00714311|ACTIVE_COMPARATOR|TFP|Transference-Focused Psychotherapy
62783639|NCT00714311|ACTIVE_COMPARATOR|ECP|treatment by experienced community psychotherapists
62783640|NCT04373746|EXPERIMENTAL|10-40 kg|Patients undergoing major surgery that weigh between 10-20 kg.
62783641|NCT04373746|EXPERIMENTAL|40-80 kg|Patients undergoing major surgery that weigh between 40-80 kg.
62783642|NCT05008198||Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation is delivered as part of routine care and is not managed by this observational study.
62783643|NCT01380834|ACTIVE_COMPARATOR|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
62783644|NCT01380834|PLACEBO_COMPARATOR|Placebo group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
62198476|NCT04001452||Level of experience with optical coherence tomography|"Total cohort will be grouped according to experience with optical coherence tomography, as defined by a single choice questionnaire:~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years~Yearly: None / Less than 15 / Between 15 and 50 / More than 50"
62783645|NCT01622465|EXPERIMENTAL|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises.
62783646|NCT01622465|ACTIVE_COMPARATOR|Conventional exercises|Patients will participate only of the conventional exercises program.
62783647|NCT03422965|ACTIVE_COMPARATOR|Type 1 Diabetes Mellitus|Cohort of Type 1 DM patients
62011008|NCT02356835|SHAM_COMPARATOR|SHAM|Treatment with a sham device to deliver non-medicated, heated room air to the wound in the same manner and dose as the active treatment device.
62011009|NCT05078645|OTHER|Group 1: Maya use on 1st, 3th and 5th day|Group 1 uses the Maya on the 1st, 3th and 5th day and not on the 2nd, 4th and 6th day of their admission to either the ICU, MC or CCU.
62011010|NCT05078645|OTHER|Group 2: Maya use on the 2nd, 4th, and 6th day|Group 2 uses the Maya on the 2nd, 4th and 6th day and not on the 1st, 3th, and 5th day of their admission to either the ICU, MC or CCU.
62011011|NCT01318564||Group 1: Unit-dose - Pill Bottle|Unit-dose (blister) packages used first week, followed second week by pill bottles usage.
62783648|NCT03422965|SHAM_COMPARATOR|Healthy controls|Cohort of Healthy controls
62783649|NCT04224961|EXPERIMENTAL|Minimal to No Respiratory Weakness|MIP ≥ 70% predicted Complete home-based RMT program and participate in weekly web-based RMT therapy sessions.
62783650|NCT04224961|EXPERIMENTAL|Mild to Moderate Inspiratory Weakness|MIP 40-70% predicted Complete home-based RMT program and participate in weekly web-based RMT therapy sessions.
62011012|NCT01318564||Group 2: Pill Bottle - Unit Dose|Pill bottle usage the first week followed second week by Unit-dose (blister) packages.
62011013|NCT02109588|NO_INTERVENTION|Control|Sedentary pregnant women
62783651|NCT03576911|EXPERIMENTAL|Coenzyme Q10|100mg CoQ10 capsule taken orally three times per day for 6 months
62783652|NCT03576911|PLACEBO_COMPARATOR|Placebo|Placebo capsule taken orally three times per day for 6 months
62783653|NCT04785924|OTHER|Observation Treatment Group|All patients observed while treated with IMI/REL.
62783654|NCT01192308|EXPERIMENTAL|40mg QD dose intervention|40mg QD dose intervention during 4 weeks in patients with CYP2D6 variant allele or using CYP2D6 inhibitor.
62198477|NCT04001452||Level of experience with fractional flow reserve|"Total cohort will be grouped according to experience with fractional flow reserve, as defined by a single choice questionnaire:~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years~Yearly: None / Less than 50 / Between 50 and 150 / Between 151 and 250 / More than 250"
62198478|NCT04001452||Level of experience with non-hyperaemic pressure ratios|"Total cohort will be grouped according to experience with non-hyperaemic pressure ratios, as defined by a single choice questionnaire:~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years~Yearly: None / Less than 50 / Between 50 and 150 / Between 151 and 250 / More than 250"
62783655|NCT02956798|EXPERIMENTAL|Stereotactic ablative body radiation (SABR)|Stereotactic ablative body radiation (SAbR) to all sites of measurable metastases (≤3) will be treated by SAbR. New sites of metastasis will be evaluated for continued treatment if deemed appropriate by both medical and radiation oncologists with SAbR.
62400409|NCT01225458|PLACEBO_COMPARATOR|exclusive nephrology follow-up|"250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring."
62198479|NCT00500032|EXPERIMENTAL|Arm 1|Active Comparator for all subjects enrolled in 6108A1-500
62011014|NCT02109588|EXPERIMENTAL|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate"
62011015|NCT00497926|EXPERIMENTAL|Living Kidney Allograft|Recipients with the need for a living kidney allograft are treated with an enriched hematopoietic stem cell infusion from the same living donor
62400410|NCT01225458|EXPERIMENTAL|geriatric follow-up|"250 patients will be included and randomized in the geriatric follow-up arm. They will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients.~About geriatric evaluation Patients randomized in this arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status."
62400411|NCT05877508|EXPERIMENTAL|AER002|AER002 1200mg administered once by IV
62400412|NCT05877508|PLACEBO_COMPARATOR|Placebo|Placebo administered once by IV
62783656|NCT02371603|EXPERIMENTAL|Part A: GSK1278863, pioglitazone and rosuvastatin|Subjects will receive single, oral 15 milligram (mg) pioglitazone, 10 mg rosuvastatin and 25 mg dose of GSK1278863 (Treatment A) or 15 mg pioglitazone and 10 mg rosuvastatin (Treatment B) on Day 1 and a 25 mg dose of GSK1278863 alone on Day 2 in two treatment periods as per treatment sequence AB or BA. The 2 treatment periods will be separated by a wash out period of approximately 7 days
62783657|NCT02371603|EXPERIMENTAL|Part B: GSK1278863 and trimethoprim|Subjects will receive a single, oral 25 mg dose of GSK1278863 on Day 1 and Day 6 morning. The subjects will also receive 200 mg dose of trimethoprim twice daily from Day 3 to 6, with Day 6 dosing being concomitant with morning dosing of GSK1278863
62783658|NCT04764318||Remote patient monitoring for hypertension|All intervention practices will receive communication by email explaining RPM procedures, ordering, use, and financial implications. We will also present this information at practice meetings. Primary care clinicians at these sites will receive clinical decision support (Epic Best Practice Alert) for patients meeting primary or secondary eligibility criteria. It will be at the discretion of the primary care clinicians when to offer or refer patients to RPM.
62783659|NCT04764318||Remote patient monitoring with care management|All intervention practices will receive communication by email explaining RPM procedures, ordering, use, and financial implications. We will also present this information at practice meetings. Primary care clinicians at these sites will receive clinical decision support (Epic Best Practice Alert) for patients meeting primary or secondary eligibility criteria. It will be at the discretion of the primary care clinicians when to offer or refer patients to RPM. In addition, PCPs will receive lists of candidate patients. Care managers will assist with the outreach to patients to offer RPM when recommended by the PCP, will monitor and support patient use of the remote monitor, and will promote action on the part of the patient or PCP when uncontrolled hypertension is present.
62783660|NCT04764318||Usual care|Medicare patients from non-intervention primary care practices in Northwestern Medical Group will contribute EHR data but will not have any new procedures put in place.
62783661|NCT01834079|OTHER|STEM CELL|intra thecal injection of MNC stem cell therapy
62011016|NCT03808610|EXPERIMENTAL|Experimental (venetoclax, vincristine, cyclophosphamide)|See Detailed Description.
62011017|NCT02809976|EXPERIMENTAL|Ruxolitinib 1.5% phosphate cream|Ruxolitinib 1.5% phosphate cream twice daily to vitiligo patches.
62011018|NCT03377348|OTHER|subconjunctival injection of triamcinolone acetonide|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
62011019|NCT06664268|ACTIVE_COMPARATOR|Group A|fractional CO2 laser alone
62011020|NCT06664268|ACTIVE_COMPARATOR|Group B|PRF Injection and fractional CO2 laser
62011021|NCT02489981||Spiriva|Patients with severe persistent asthma
62011022|NCT02256046|EXPERIMENTAL|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
62011023|NCT01639079|NO_INTERVENTION|Usual Care for Smoking|Usual care for smoking cessation with access to the web site after 6 months
62011024|NCT01639079|EXPERIMENTAL|Internet Smoking Cessation Web Site|"Internet Stop Smoking site (TC5) offers a menu of several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are:~English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx"
62011025|NCT03285646|EXPERIMENTAL|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
62011026|NCT03285646|EXPERIMENTAL|Placebo|SC every 4 weeks
62198480|NCT01482936|EXPERIMENTAL|Oxycodone (OxyNorm®) Injection|The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg
62198481|NCT05948969|NO_INTERVENTION|Education alone|
62198482|NCT05948969|ACTIVE_COMPARATOR|Education + decision support to provide suggestions for care optimization|
62011027|NCT04205279|EXPERIMENTAL|Treadmill training|Subjects randomly assigned to the treadmill training, would undergo either a stance or walking perturbation training protocol. The stroke subjects and older adults would be assigned to either the stance or walking perturbation training protocol. All the participants would be asked to perform voluntary stepping, backward and forward with both limbs pre and post perturbation training. Also, all the participants would perform walking trials with head mounted virtual reality system under three conditions: ice, beach and crowd.
62011028|NCT04205279|EXPERIMENTAL|Overground training|Subjects randomly assigned to overground slip will be made to walk at their comfortable natural walking speeds either for 5-8 trials on the instrumented walkway (7 m 1.5 m) at their self-selected preferred speed. All the participants would perform walking trials with head mounted virtual reality system under three conditions: ice, beach and crowd. After establishing baseline walking ability, a slip will be introduced without warning which will comprise the baseline slip test followed by a trip in the form of the trip plate. This is followed by a block of 8 trials for slip training, block of 8 trials for trip training and then the mixed block consisting of slip and trip trials interspersed with walking trials. Slips and trips could be induced under either of the limbs.
62011029|NCT04205279|EXPERIMENTAL|Surefooted training|"Subjects randomly assigned to Surefooted (Surefooted LLC) would be donned a safety harness and instructed that when you experience slip-like or trip-like movements, try to keep walking on the platform. Subjects would undergo 4-minute training block on each of the 6 different conditions. The first 3 training blocks would be unidirectional perturbation (either slip or trip) followed by 3 training blocks of mixed directional perturbations while the subjects are walking on the platform. 3 surface conditions- slippery (vinyl surface plate), normal friction with obstacles (surface plate with 6 tall structures embedded), and a foam surface with obstacles embedded would be used."
62011030|NCT05155969|EXPERIMENTAL|Eskatamine group|Low-dose esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused in 40 minutes before anesthesia induction
62011031|NCT05155969|PLACEBO_COMPARATOR|Placebo group|Placebo (40 ml normal saline) is intravenously infused in 40 minutes before anesthesia induction.
62198483|NCT05948969|ACTIVE_COMPARATOR|Education + facilitated referral to cardiometabolic team-based center for care optimization|
62198484|NCT04139382|EXPERIMENTAL|Intervention|Telephone Consultation for women requesting abortion
62011032|NCT04709237|EXPERIMENTAL|Omafilcon A Control Lens first, then Omafilcon A Test Lens 1, then Omafilcon A Test Lens 2|Participants wore three different types of study contact lenses (1 control and 2 test contact lenses), in a randomized order of testing for the three study contact lens types.
62198485|NCT04139382|ACTIVE_COMPARATOR|Control|Face-to-face consultation for women requesting abortion
62198486|NCT03011762|OTHER|Computer Controlled Mandibular Positioner|All study participants will undergo the computer controlled mandibular positioner test.
62783662|NCT05159804||Carotid plaque length|Patients underwent coronary angiography and carotid ultrasonography simultaneously
62198487|NCT05948423|EXPERIMENTAL|(Group A) Tissue Flossing + Conventional Therapy|"1. Tissue Flossing (3reps of 6 different active and passive movements, total 1-2 mints)~2. Hot Pack (10 mints)~3. PNF technique on Bicep, Tricep, pronator, Supinator muscle (3reps\* 26sec, total 6 mints)~4. Joint Mobilization (3 reps of humeroulnar and radial head mobilization, total 6 mints) Total treatment duration was 24 mints."
62783663|NCT05113381|EXPERIMENTAL|Intraventricular Hemorrhage Subjects|Intervention: Cerebrospinal Fluid (CSF) reduction Extra Ventricular Drainage (EVD) catheters will be used for cerebrospinal fluid drainage
62198488|NCT05948423|ACTIVE_COMPARATOR|(Group B) Conventional Therapy|"1. Hot Pack (10 mints)~2. PNF technique on Bicep, Tricep, pronator, supinator muscle (3reps\* 26sec, total 6 mints)~3. Joint Mobilization (3 reps of humeroulnar and radial head mobilization, total 6 mints)~Total treatment duration was 24 mints."
62198489|NCT00250744|EXPERIMENTAL|Arm A|
62198490|NCT00250744|ACTIVE_COMPARATOR|Arm B|
62783664|NCT04736628|EXPERIMENTAL|Avenciguat 1 mg TID|TID=ter in die (3 times a day)
62783665|NCT04736628|EXPERIMENTAL|Avenciguat 2 mg TID|
62783666|NCT04736628|EXPERIMENTAL|Avenciguat 3 mg TID|
62783667|NCT04736628|PLACEBO_COMPARATOR|Placebo|
62783668|NCT00005085|EXPERIMENTAL|Arm I|Patients receive rebeccamycin analogue IV once on day 1. Treatment repeats every 21 days for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
62198491|NCT01251770|EXPERIMENTAL|half saline|Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.
62198492|NCT01251770|ACTIVE_COMPARATOR|third saline|Subjects in this arm will receive 0.3% NaCl/dextrose 5% intravenous (IV) maintenance fluids.
62198493|NCT04956705|EXPERIMENTAL|The Model for Improvement|Together with the health care staff at the nursing homes, the project group will identify which strategies to implement in order to increase the number of residents receiving the recommended daily supplements of 20 µg of vitamin D and 800-1000 mg of calcium. The Model for Improvement will be the methodological framework for defining, implementing, and evaluating strategies.
62198494|NCT00921947|EXPERIMENTAL|VAX102 IM|VAX102 given as 1 µg intramuscular (i.m.)
62198495|NCT00921947|EXPERIMENTAL|VAX102 SC|VAX102 given as a 2 µg subcutaneous (s.c.) dose
62198496|NCT02899351||Infants less than 12 months|intubated infants in ICU
62198497|NCT04446091|EXPERIMENTAL|Two-drug group|Camrelizumab:200mg,iv,Q2W; Fruquintinib:5mg,po.qd,Day1\~21, repeat every 28 days;or Regorafenib: 80mg,po.qd,Day1\~21, repeat every 28 days;or Apatinib:250mg,po.qd,Day1\~21, repeat every 28 days;
62198498|NCT04446091|EXPERIMENTAL|Three-drug group|Camrelizumab:200mg,iv,Q3W; Irinotecan:150mg/m2,iv 30\~90min,d1,Q3W Fruquintinib:5mg,po.qd,Day1\~21, repeat every 28 days;or Regorafenib: 80mg,po.qd,Day1\~21, repeat every 28 days;or Apatinib:250mg,po.qd,Day1\~21, repeat every 28 days;
62198499|NCT06335342||Radiotherapy to head and neck region|Patients treated at European Institute of Oncology with radiotherapy to head and neck region
62198500|NCT04303507|EXPERIMENTAL|Chloroquine or Hydroxychloroquine|"In Asia, the participant will receive chloroquine.~In Europe, the participant will receive hydroxychloroquine~Specific drug allocation will be determined by country prior to activation based upon factors such as inventory availability and importation requirements"
62198501|NCT04303507|PLACEBO_COMPARATOR|Placebo|
62198502|NCT01661205|EXPERIMENTAL|AtriCure Bipolar System combined with a catheter ablation|Minimally invasive procedure using the AtriCure Bipolar System plus a catheter ablation performed approximately 1-10 days apart
62783669|NCT04483336|EXPERIMENTAL|Virtual reality Distraction.|Subjects watched a video cartoon using virtual reality goggles as a distraction technique during the administration of local anesthesia.
62198503|NCT02251249|EXPERIMENTAL|STEMI Group|
62198504|NCT02251249|OTHER|Stable patient Group|Patient referred for angioplasty for angina or non-ST-segment elevation myocardial infarction (NSTEMI)
62783670|NCT04483336|ACTIVE_COMPARATOR|TV screen Distraction|Subjects watched a video cartoon on a regular TV screen as a distraction technique during the administration of local anesthesia.
62783671|NCT02718716|EXPERIMENTAL|UCB7665 4 mg/kg|Participants in this arm received 5 subcutaneous (sc) doses of UCB7665 (rozanolixizumab) 4 milligram per kilograms (mg/kg) at 1-week intervals.
62783672|NCT02718716|EXPERIMENTAL|UCB7665 7 mg/kg|Participants in this arm received 3 sc doses of UCB7665 (rozanolixizumab) 7 mg/kg at 1-week intervals.
62783673|NCT02718716|EXPERIMENTAL|UCB7665 10 mg/kg|Participants in this arm received 2 sc doses of UCB7665 (rozanolixizumab) 10 mg/kg at 1-week intervals.
62783674|NCT02718716|EXPERIMENTAL|UCB7665 15 mg/kg|Participants in this arm received 1 sc dose of UCB7665 (rozanolixizumab) 15 mg/kg.
62783675|NCT02718716|EXPERIMENTAL|UCB7665 20 mg/kg|Participants in this arm received 1 sc dose of UCB7665 (rozanolixizumab) 20 mg/kg.
62215033|NCT02384187|PLACEBO_COMPARATOR|Group C|Patients in this group will receive 0.3 ml/kg of a placebo solution identical in taste, shape and color to the study medication two hours before the induction of anesthesia.
62215034|NCT02384187|EXPERIMENTAL|Group GAB|Patients in this group will receive 0.3 ml/kg (16 mg/kg) oral gabapentin solution (Neurontin 50 mg/ml, Pfizer Pharmaceutical) as premedication two hours before the induction of anesthesia
62215035|NCT00816478|EXPERIMENTAL|1|Galactose
62215036|NCT06533826|EXPERIMENTAL|Arm A (ADC1 T-DXd HR+)|"Enrolled participants will complete:~* Baseline visit with tumor biopsy, imaging, electrocardiogram and echocardiogram.~* Tumor biopsy between Cycle 2 Day 1 and Day 8.~* Imaging every 9 weeks.~* Cycle 1 through Cycle 3:~  --Day 1 of 21 day cycle: Predetermined dose of Trastuzumab deruxtecan 1x daily.~* Cycle 4 through end of treatment:~  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab deruxtecan 1x daily.~ * Imaging on Day 1.~* End of Treatment visit with imaging, tumor biopsy, echocardiogram~* Follow up: imaging every 9 weeks.~* Long-term Follow Up: visits every 6 months."
62198505|NCT04168970||PSGB group|MD will perform PSGB using Lidocaine. The PGSB will be performed after the administration of the 4th shock if the 3rd shock was unsuccessful in restoring a stable perfusing rhythm, considering all the shocks administered both by an AED or by manual defibrillator. PSGB will be performed after all the actions provided in the ACLS algorithm and which are considered useful in the clinical situation (intubation and ventilation, administration of iv/io adrenaline, amiodarone or lidocaine, use of mechanical chest compression, etc.).
62198506|NCT04168970||Control group|Historical cohort of patients with the same OHCA characteristics (first shockable rhythm and who received more than 4 shocks) enrolled in the Cardiac Arrest Registry of the Province of Pavia
62198507|NCT02314689|EXPERIMENTAL|IV citrulline|IV citrulline 20 mg/kg bolus with dose escalation of 10 mg/kg to target citrulline concentration of 100 µmol/L with a maximum dose of 60 mg/kg.
62198508|NCT05667181|EXPERIMENTAL|robotic group|Robot linear cutting stapler
62198509|NCT05667181|ACTIVE_COMPARATOR|laparocaopic group|laparoscopic linear cutting stapler
62198510|NCT04744753|ACTIVE_COMPARATOR|study group|. This group involved 75 patients with history of fertilization failure in which oocytes were activated by calcium ionophores
62198511|NCT04744753|NO_INTERVENTION|control group|This group involved 75 patients with history of fertilization failure in which oocytes were not activated by calcium ionophores
62198512|NCT02604082|ACTIVE_COMPARATOR|Vibocompression (VB)|Grup 1 - Vibrocompression: Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the thoracic compression during expiration
62198513|NCT02604082|ACTIVE_COMPARATOR|Hyperinflation (HMV)|Grup 2 - Hyperinflation with Mechanical ventilator: Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the increase in inspiratory pressure ventilator .
62198514|NCT02604082|EXPERIMENTAL|HMV+VB|Grup 3 - Hyperinflation with mechanical ventilator and vibrocompression:Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the thoracic compression during expiration and the increase in inspiratory pressure ventilator.
62198515|NCT02900950|EXPERIMENTAL|Arm A-Multicolour inking specimen|"After performing the pancreaticoduodenectomies, the surgeon intraoperatively inked the surfaces/margins of the specimen with different colours. The surfaces/margins inked were the following:~1. Anterior surface of the pancreas (yellow);~2. Posterior surface of the pancreas (orange);~3. Superior mesenteric/portal vein groove (blu);~4. Superior mesenteric artery margin (retroperitoneal margin) (red);~5. Transection margin of the bile duct (green) The trans-section pancreatic and gastric margins were not inked."
62198516|NCT02900950|OTHER|Arm B-Monocolour inking specimen|In arm B, only the superior mesenteric artery margin and the pancreatic margin were intraoperatively indicated by the surgeon in the specimen: a single stitch to identify the transection pancreatic margin and a continuous suture to identify the superior mesenteric artery margin. Monochromatic inking of the superior mesenteric artery margin was subsequently carried out by the pathologist.
62198517|NCT02480192|EXPERIMENTAL|Experimental Group (CBT-Meno)|After an initial assessment, the experimental group received 12 weekly sessions (2 hours each) of group-based cognitive-behavioural therapy for menopausal symptoms (CBT-Meno) (up to n=8 per group). Symptoms that were targeted included vasomotor symptoms (hot flashes/night sweats), depressive symptoms, anxiety, poor sleep, and sexual concerns. Participants were re-assessed at 12-weeks post-baseline and at 3 months post-treatment.
62198518|NCT02480192|NO_INTERVENTION|Waitlist|After an initial assessment, the waitlist comparison group did not receive any treatment for 12 weeks. They were then re-assessed at 12-weeks post-baseline and this data was used to compare this group to the experimental group to determine the effectiveness of the CBT-Meno treatment. After this re-assessment participants in the waitlist condition were offered the same CBT-Meno treatment as the experimental group: 12 weekly sessions (2 hours long) of cognitive-behavioural therapy for menopausal symptoms.
62198519|NCT05910970|EXPERIMENTAL|Adjuvant tislelizumab plus lenvatinib|Patients at high-risk of hepatocellular carcinoma recurrence after curative resection or ablation will receive adjuvant tislelizumab plus lenvatinib treatment for six months, HCC recurrence, or unacceptable adverse events.
62198520|NCT05910970|ACTIVE_COMPARATOR|Adjuvant tislelizumab|Patients at high-risk of hepatocellular carcinoma recurrence after curative resection or ablation will receive adjuvant tislelizumab treatment for six months, HCC recurrence, or unacceptable adverse events.
62400413|NCT01013207|EXPERIMENTAL|Nexus (S9) CPAP device|"Fifty subjects with obstructive sleep apnea (OSA), established on CPAP therapy (≥ 6 months) were recruited into this study. These patients use their CPAP device every night while sleeping to treat their OSA.~Nexus (S9) is a new CPAP device with improved humidification system (heated tube and climate control), reduced noise, improved comfort of breathing and new user interface. During the study, patients will use this CPAP every night in place of their own CPAP for a period of 4 weeks. Compliance data from the Nexus will then be compared to the patient's usual CPAP pre trialling Nexus and post trialling Nexus."
62783676|NCT05169606|EXPERIMENTAL|Tissue Flossing|Tissue flossing is a technique that requires wrapping of a thick rubber band around a joint or muscle concomitantly performing ROM tasks for 1-3 minutes. The results include increase in range of motion and a decrease in pain of the effected muscles. The phenomenon behind getting results through this technique is hypothesized to be blood reperfusion to an occluded area via tissue flossing augments exercise performance mechanisms such as growth hormone, catecholamine responses, muscle force contractility and the efficiency of excitation-contraction coupling in the muscles. In addition, tissue flossing may influence fascia tightness via the fascial mechanoreceptors, therefore reducing muscle activity, resulting in a greater ROM. Nevertheless, the underlying mechanism for tissue flossing, these mechanisms remain speculative.
62400414|NCT05275166|OTHER|Patients|Patients hospitalized for rehab. HRE following induction of alcohol craving and questionnaires
62400415|NCT05275166|OTHER|Healthy Volunteers|Healthy Volunteers with non alcohol dependance. HRE following induction of alcohol craving and questionnaires
62400416|NCT01574924||Medical residents|
61978282|NCT05792631|OTHER|Patients scheduled for radiographic dental caries assessment|"BWR-The most common type of dental x-ray taken during a routine dental checkup is called a bitewing radiograph. This type of X-ray shows the upper and lower back teeth in a single view and is taken to see how the upper and lower teeth line up, to check for decay, and discover bone loss due to infection and serious gum disease."
62783677|NCT05169606|EXPERIMENTAL|Active Isolated Stretch|Active Isolated Stretch is a specific stretching program developed by Aaron Mattes over 30 years ago. Active isolated stretch is also found to be effective to increase flexibility and improve ROM.
62011033|NCT04709237|EXPERIMENTAL|Omafilcon A Test Lens 2 first, then Omafilcon A Control Lens , then Omafilcon A Test Lens 1|Participants wore three different types of study contact lenses (1 control and 2 test contact lenses), in a randomized order of testing for the three study contact lens types.
62011034|NCT04709237|EXPERIMENTAL|Omafilcon A Test Lens 1 first, then Omafilcon A Control Lens , then Omafilcon A Test Lens 2|Participants wore three different types of study contact lenses (1 control and 2 test contact lenses), in a randomized order of testing for the three study contact lens types.
62011035|NCT05067140|EXPERIMENTAL|ARV-766|Oral tablets, once daily in 28 day cycles
62011036|NCT05067140|EXPERIMENTAL|ARV-766 + Abiraterone|Oral tablets, once daily in 28 day cycles
62011037|NCT01940705|ACTIVE_COMPARATOR|Standard of care (SoC)|standard of care hearing-aid orientation as provided by clinical audiologist
62011038|NCT01940705|EXPERIMENTAL|SoC plus hearing-aid informational guide|standard of care hearing-aid orientation as provided by clinical audiologist plus a take-home informational guide regarding their hearing aids
62011039|NCT01940705|EXPERIMENTAL|SoC plus hearing aid DVD|SoC hearing-aid orientation as provided by clinical audiologist plus a take-home hearing aid digital video disc
62011040|NCT01940705|EXPERIMENTAL|Soc plus teach-back technique|standard of care hearing-aid orientation as provided by clinical audiologist plus a teach-back technique session reviewing information on the hearing aids
62011041|NCT04221295|EXPERIMENTAL|Exercise Group|The intervention is a home-based, multimodal exercise prehabilitation program. Exercise is prescribed in one-hour sessions, performed a minimum of three times per week for three weeks, consisting of: 1) strength training, 2) aerobic exercise and 3) flexibility. The intervention group will receive weekly phone calls to gauge adherence, suggest modifications, provide support and track any adverse events.
62011042|NCT04221295|NO_INTERVENTION|Control Group|The control group will receive the World Health Organization recommendations for physical activity for people greater or equal to the age of 65 years old pamphlet, as well as a guide to healthy eating for older adults.
62011043|NCT04840758|EXPERIMENTAL|SABR+Sintilimab|Stereotactic ablation radiotherapy (SABR) was performed sequentially on the primary and secondary lesions. Sintilimab was used 2 weeks after the end of SABR. Sintilimab : 200 mg intravenously, Q3W every cycle , given on the D1 of each cycle, and total of 4 cycles.
62011044|NCT00647855|EXPERIMENTAL|1|Levothyroxine Sodium Tablets 300 μg
62011045|NCT00647855|ACTIVE_COMPARATOR|2|Synthroid® Tablets 300 μg
62011046|NCT06040749|EXPERIMENTAL|Virtual group-based handcycling|Virtual group-based handcycling, twice per week for 12 weeks. Each 60-minute session of the intervention will begin with maximum 15 minutes of physiotherapist-led warm-up exercises. Next, a peer-facilitated handcycling session, lasting maximum 45 minutes, will proceed. The handcycling component involves the upper extremities cycling in tandem on a stationary exercise bike. The peer facilitator will be an individual with SCI aged \>50 years, who will co-lead participants alongside the physiotherapist through brief group discussion, maximum 40 minutes of moderate-vigorous handcycling, and maximum 5 minutes of cool-down.
62011047|NCT03520491|EXPERIMENTAL|Cohort 1|Nivolumab 3 mg/kg on day 1 of each cycle for a total of 5 cycles. Each cycle will be two weeks long and treatment will occur during weeks 0, 2, 4, 6, and 8.
62011048|NCT03520491|EXPERIMENTAL|Cohort 2|Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1 of each cycle, followed by Nivolumab 3 mg/kg on day 22 of each cycle for a total of 2 cycles. Each cycle will be six weeks long. Ipilimumab and Nivolumab will occur on weeks 0 and 6 while Nivolumab alone will occur on weeks 3 and 9.
62011049|NCT03520491|EXPERIMENTAL|Cohort 3|Ipilimumab 3 mg/kg on day 1 each cycle and Nivolumab 1 mg/kg on day 1 of each cycle for a total of 3 cycles. Each cycle will be three weeks long and treatment will occur during weeks 0, 3, and 6.
62011050|NCT03520491|EXPERIMENTAL|Cohort U (UTUC patients) is independent from Cohorts 1 - 3. ( who are cisplatin-ineligible)|Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1, of each cycle, followed by Nivolumab 3 mg/kg on day 22 and Ipilimumab 3mg/kg and Nivolumab 1mg/kg on day 45.
62011051|NCT05540392|EXPERIMENTAL|Acupuncture|Acupuncture group will receive 10 treatments of acupuncture over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
62011052|NCT05540392|EXPERIMENTAL|Waitlist Control|The waitlist control group will not receive any acupuncture treatments during the 14-week waiting period. Patients in waitlist control group will have the option to receive up to 10 acupuncture treatments after a 14-week waiting period.
62011053|NCT04809129|EXPERIMENTAL|External mechanical loading|"Following bariatric surgery (RYGB or SG) patients will be asked to wear a weighted vest for a minimum of 8 hours daily and during physical exercise for three months postoperatively.~Weight will be incrementally added on a weekly basis to maintain the baseline weight as patients lose weight following surgery up to a maximum of 15%."
62011054|NCT04809129|NO_INTERVENTION|Standard postoperative care|Patients following bariatric surgery (RYGB or SG) will receive standard postoperative care.
62783678|NCT05169606|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) technique has already been found to have beneficial effects in improving hamstring flexibility and reducing pain in the knee joint of knee OA patients.
62783679|NCT06256341||allogeneic HSCT peripheral blood|3, 6, 9, 12, 18 and 24 months after allogeneic HSCT peripheral blood mononuclear cells were isolated from patient blood, stimulated with HHV-6-specific antigen (U54) and cultured for 10 days.
62783680|NCT06256341||healthy blood|One blood sample from a age and sex matched healthy controls without any inflammatory, immunological or infectious disease was taken. mononuclear cells were isolated from patient blood, stimulated with HHV-6-specific antigen (U54) and cultured for 10 days.
62783681|NCT03796026|EXPERIMENTAL|Seltorexant Followed by Placebo|Participants will receive seltorexant (40 milligram \[mg\] capsules) once daily for 4 consecutive days, and after a washout period of 7 to 10 days, participants will receive matching placebo orally once daily for 4 consecutive days.
62783682|NCT03796026|EXPERIMENTAL|Placebo Followed by Seltorexant|Participants will receive placebo once daily for 4 consecutive days, and after a washout period of 7 to 10 days, participants will receive seltorexant (40 mg capsules) orally once daily for 4 consecutive days.
62783683|NCT00883441|EXPERIMENTAL|VM|implementation of new vector control tools (insecticide treated curtains and jar covers) through the existing routine vector control programme
62198521|NCT04682782|EXPERIMENTAL|Esketamine|Participants randomized to this arm will receive Esketamine (1 mg/ml) infused at 0.1 mg/kg/hour (0.1 ml/kg/h) throughout the operation
62198522|NCT04682782|PLACEBO_COMPARATOR|Saline|Participants randomized to this arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.1 ml/kg/hour throughout the operation
62400417|NCT02078557|EXPERIMENTAL|MK-8892|Starting dose of 1 mg daily (oral); the dose may be titrated up on the 8th, 15th, and 22nd day of treatment to 2 mg, 3 mg, or 4 mg, respectively, for the duration of the study (28 days) as tolerated. For participants who reach one or more of the down-dosing criteria, there is an opportunity to decrease the dose back to a previously well-tolerated dose level, or to ½ of the starting dose.
62400418|NCT03561272|NO_INTERVENTION|Standard Patient Reported Adherence|Adherence assessment via phone call or in person
62400419|NCT03561272|ACTIVE_COMPARATOR|Smart Phone Application|Adherence assessment via phone app
62400420|NCT03561272|EXPERIMENTAL|POD and Smart Phone Application|"Adherence assessment via phone app partnered with an automated dispensing machine, a Pod."
62783684|NCT00883441|EXPERIMENTAL|PM|implementation of new vector control tools (insecticide treated covers and curtains) through partnerships
62011055|NCT06653894|ACTIVE_COMPARATOR|QLB Group|In the QLB (Quadratus Lumborum Block) group, patients will be placed in the lateral decubitus position, and the block will be performed using ultrasound guidance
62011056|NCT06653894|ACTIVE_COMPARATOR|PENG Block Group|In the PENG (Pericapsular Nerve Group) block group, patients will be positioned supine, and the block will be performed under ultrasound guidance.
62011057|NCT05770544|EXPERIMENTAL|Treatment Arm 03|This entrectinib treatment arm is for adult, teenage/young adult (TYA) and paediatric participants with ROS1 gene fusion-positive malignancies.
62011058|NCT03621943|ACTIVE_COMPARATOR|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped.
62011059|NCT03621943|ACTIVE_COMPARATOR|Early Cord Clamping|The umbilical cord is clamped as soon as possible and within 60 seconds of delivery.
62400421|NCT03112720|ACTIVE_COMPARATOR|Epidural blood patch|20ml of sterile blood is obtained from the patients arm and placed in the epidural space using standard sterile epidural access.
62400422|NCT03112720|EXPERIMENTAL|Sphenopalatine Ganglion Block|Cotton tip applicators are used to deliver lidocaine to the posterior nares in the area of skin overlying the Sphenopalatine gangion
62011060|NCT01181895|EXPERIMENTAL|Vilanterol|Vilanterol inhalation powder once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
62011061|NCT01181895|ACTIVE_COMPARATOR|Salmeterol|Placebo inhalation powder via NDPI once daily + Salmeterol inhalation powder twice daily for 12 weeks
62198523|NCT04977570|EXPERIMENTAL|SYHA1805|subjects will be randomized to receive multiple ascending doses of SYHA1805 tablets.
62198524|NCT04977570|PLACEBO_COMPARATOR|Placebo|subjects will be randomized to receive the matching placebo tablets.
62198525|NCT01947699|EXPERIMENTAL|Glyburide once daily|Timing of glyburide dosing will be changed, glucose will be monitored using continuous a glucose monitor.
62198526|NCT01947699|EXPERIMENTAL|Glyburide twice daily|Dose interval and timing of glyburide dose will be changed, glucose will be monitored using continuous a glucose monitor.
62400423|NCT00755560|ACTIVE_COMPARATOR|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
62400424|NCT00755560|PLACEBO_COMPARATOR|Placebo|Placebo BID for 15 days
62400425|NCT02013726|EXPERIMENTAL|MBI Scan & Tomosynthesis Scan|Patients will receive both scans.
62783685|NCT06256263|ACTIVE_COMPARATOR|stapler repair group|pharyngeal repair after total laryngectomy was done by using a linear stapler
62011062|NCT01181895|PLACEBO_COMPARATOR|Placebo|Placebo inhalation powder via NDPI once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
62400426|NCT01610726|ACTIVE_COMPARATOR|enhanced recovery|
62783686|NCT06256263|ACTIVE_COMPARATOR|conventional repair group|pharyngeal repair after total laryngectomy was done by the conventional method (stitching).
62011063|NCT06663579|ACTIVE_COMPARATOR|Study group: Fathers who practicing kangaroo care|The premature babies treated in the neonatal intensive care unit where the study was conducted practice kangaroo care with their mothers. However, in the intervention conducted by the researcher, the babies practiced kangaroo care with both their mothers and fathers.
62198527|NCT01947699|EXPERIMENTAL|Mixed meal tolerance test.|Subjects will be admitted to the Clinical Translational Research Center, receive a Mixed meal tolerance test and have timed blood draws to assess the effect of glyburide on glucose and insulin metabolism.
62198528|NCT04996433|EXPERIMENTAL|Cognitive Behavioral Analysis System of Psychotherapy (CBASP)|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
62011064|NCT06663579|ACTIVE_COMPARATOR|Control group: Fathers who not practicing kangaroo care|The premature babies treated in the neonatal intensive care unit where the study was conducted practice kangaroo care with their mothers. However, in the intervention conducted by the researcher, the babies practiced kangaroo care with both their mothers and fathers.
62011065|NCT06461572|ACTIVE_COMPARATOR|conventional therapy|This group will receive conventional therapy.
62011066|NCT06461572|EXPERIMENTAL|conventional therapy with Standard therapy and stability exercises|This group will receive conventional therapy with standard therapy and stability exercises.
62011067|NCT00445614|EXPERIMENTAL|Marine trout|150 g/day of trout fed on marine based feed
62011068|NCT00445614|EXPERIMENTAL|Vegetable trout|150 g/d of trout fed on vegetable based feed
62198529|NCT04996433|ACTIVE_COMPARATOR|Behavioral Activation (BA)|Behavioral Activation (BA) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
62011069|NCT00445614|OTHER|Poultry|150 g/d of poultry (for comparison)
62011070|NCT04337554||Older healthy|Individuals over 40 years of age
62011071|NCT04337554||Peripheral artery disease|Individuals over 40 years of age with peripheral artery disease.
62198530|NCT02744248|ACTIVE_COMPARATOR|IOP Injection|Participants will receive 1 injection of the IOP at Days 1,once time.
62198531|NCT02744248|PLACEBO_COMPARATOR|0.9% normal saline|Participants will receive 1 injection of 0.9% normal saline at Days 1,once time.
62198532|NCT01370655|EXPERIMENTAL|MK-7145 6 mg (Treatment A)|MK-7145 3 mg (three x 1-mg MK-7145 capsules administered orally) and placebo to HCTZ (two 12.5-mg capsules) then three x 1-mg MK-7145 capsules 4 hours later, daily for 4 weeks.
62400427|NCT01610726|NO_INTERVENTION|conventional recovery|
62400428|NCT05384600||Patients with Incisional Hernia|Patients who have undergone elective or emergency colonic resection between 2017 and 2020 at Cardiff and Vale UHB, who have subsequently received a diagnosis of Incisional Hernia. One-off self-completed patient questionnaire upon enrolment. Sub-set will be invited to participant in qualitative interview.
62011072|NCT03384667|EXPERIMENTAL|MMDT group|
62011073|NCT03384667|PLACEBO_COMPARATOR|Placebo group|
62011074|NCT00827892|EXPERIMENTAL|1|
62011075|NCT00827892|PLACEBO_COMPARATOR|2|
62198533|NCT01370655|EXPERIMENTAL|MK-7145 3 mg (Treatment B)|MK-7145 3 mg (one 2mg MK-7145 and one MK-7145 placebo capsule) then one 1-mg MK-7145 capsule and two MK-7145 placebo capsules 4 hours later and placebo to HCTZ (2 capsules once daily) daily for 4 weeks.
62783687|NCT03938506||intubation using the endotracheal tube size of 6.0 or 8.0|Adult male patients who require endotracheal intubation using the endotracheal tube size of 6.0 or 8.0
62011076|NCT04106791|EXPERIMENTAL|Closed-loop|Pilot study: one single group of 10 ICU patients.
62011077|NCT04173338|EXPERIMENTAL|Cabozantinib + Pemetrexed|Pemetrexed 500mg/m2 IV day 1 of each 21 day cycle + Cabozantinib 20-60mg by mouth once a day.
62011078|NCT01383681||All Participants|This was a retrospective chart review in patients with spasticity in the Spanish population. There was no treatment in this study.
62011079|NCT06131411|EXPERIMENTAL|Intervention|Health promotion intervention
62011080|NCT06131411|PLACEBO_COMPARATOR|Control|Usual care
62011081|NCT05966025|EXPERIMENTAL|control group|• control group Weight reduction and life style modification(modification in diet like decrease lipids intak).pateints will recieve their conventional therapy
62011082|NCT05966025|EXPERIMENTAL|interventions: drug itopride|• itopride group Weight reduction and life style modification and receive (itopride) 100 mg once dialy for 24 weeks plus their conventional therapy
62198534|NCT01370655|ACTIVE_COMPARATOR|Hydrochlorothiazide 25 mg (Treatment C)|HCTZ 25 mg (two 12.5-mg capsules) and placebo to MK-7145 (one 3-mg capsule) then placebo for MK-7145 (one 3-mg capsule) 4 hours later daily for 4 weeks.
62198535|NCT01370655|PLACEBO_COMPARATOR|Placebo (Treatment D)|Placebo to MK-7145 (2 x 3-mg capsules) and placebo to HCTZ 25 mg (2 capsules) then placebo to MK-7145 (2 x 3-mg capsules) 4 hours later daily for 4 weeks
62198536|NCT05614622|NO_INTERVENTION|Control|Control group receives standard post-operative treatment, which includes self-instillation of Ofloxacin and Dexamethasone eye drops with tapering down from q.i.d for the 1st week to once daily in the 4th week
62198537|NCT05614622|EXPERIMENTAL|Study|The study group receives standard post-operative treatment same as the control group. And additional treatment of a short-acting mydriatic agent (Cyclopentolate Hydrochloride 1.0% eye drops) t.i.d for 4 weeks (to operate eye alone)
62783688|NCT03589027|EXPERIMENTAL|Rilpivirine arm|All subjects will be administered oral rilpivirine 25mg once daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
62783689|NCT03589027|EXPERIMENTAL|Darunavir arm|All subjects will be administered oral darunavir/ritonavir 600/100mg twice daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
62783690|NCT03082092|EXPERIMENTAL|Methylprednisolone Group|The intervention group will receive a single dose intravenous 125mg methylprednisolone diluted in 2.1ml of diluent on induction of total knee replacement.
62011083|NCT05762107|EXPERIMENTAL|ZT-01 7 mg|Participants receive placebo and ZT-01 7 mg each by subcutaneous injection daily for 28 days, randomized to order
62011084|NCT05762107|EXPERIMENTAL|ZT-01 15 mg|Participants receive placebo and ZT-01 15 mg by subcutaneous injection daily for 28 days, randomized to order
62198538|NCT03965442||Control|"Patients who underwent mastectomy under standard general anesthesia~Patients in placebo group received general balanced inhaled anesthesia with sevoflurane and remifentanil and a saline 0,9% infusion pump."
62198539|NCT03965442||Esmolol|Patients in esmolol group received general balanced inhaled anesthesia with sevoflurane and a bolus infection of esmolol 500 mgc/kg followed by a continuous infusion of esmolol 100 mcg/kg/min
62198540|NCT06460324||COVID-19 Vaccination Cohort|Patients with multiple sclerosis (MS) who were receiving ofatumumab at the time of full COVID-19 vaccination and/or first booster vaccination.
62400429|NCT05384600||Patients without Incisional Hernia|Patients who have undergone elective or emergency colonic resection between 2017 and 2020 at Cardiff and Vale UHB, who have not subsequently been diagnosed with (or suspected of having) incisional hernia. One-off self-completed patient questionnaire upon enrolment. Sub-set will be invited to participant in qualitative interview.
62400430|NCT05384600||Patients due to undergo surgery|Patients who are due to undergo elective colonic surgery within Cardiff and Vale UHB, who have an unknown risk of- , and may or may not go on to develop-, incisional hernia. One-off self-completed patient questionnaire upon enrolment. Sub-set will be invited to participant in qualitative interview.
62011085|NCT05762107|EXPERIMENTAL|ZT-01 22 mg|Participants receive placebo and ZT-01 22 mg by subcutaneous injection daily for 28 days, randomized to order
62011086|NCT03383588|ACTIVE_COMPARATOR|bupivacaine 0.25%|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25%
62011087|NCT03383588|ACTIVE_COMPARATOR|bupivacaine 0.25% + epinephrine|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25% with Epinephrine
62198541|NCT04080037|EXPERIMENTAL|Study Participants|All eligible and consented participants will be asked complete a multiple-choice opioid assessment based on the latest CDC opioid guidelines, then care for 6 online QualityIQ patient simulations and receive feedback on their care decisions. They will then all complete an other multiple-choice assessment at the conclusion of the study.
62198542|NCT02871505|EXPERIMENTAL|Molecular subtyping (14d/f) of Treponema pallidum|Benzathine Penicillin G treatment
62783691|NCT03082092|PLACEBO_COMPARATOR|Placebo Group|The placebo group will receive a single dose intravenous 2.1ml of 0.9% IV saline, which is transparent and has no difference in appearance to methylprednisolone, on induction of total knee replacement
62783692|NCT06493240|EXPERIMENTAL|nCRT+PD-1|Long-course chemoradiation followed by PD-1 inhibition (Sintilimab 200mg, 3 times, 2-week interval) starting on Day 15 after completion of radiation therapy. TME surgery is scheduled in 6 weeks after completion of radiation.
62011088|NCT03383588|PLACEBO_COMPARATOR|Saline Solution|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous NACL 0.9% (placebo)
62011089|NCT04917575|EXPERIMENTAL|Mobile Game|An enhanced life-simulation prototype of a playable interactive game to increase HIV testing, risk assessment tool, and HIV and pre-exposure prophylaxis (PrEP) locators embedded within the game.
62011090|NCT04917575|ACTIVE_COMPARATOR|Mobile Application|A mobile application that will include basic information on HIV basics (e.g., routes of transmission, data on the epidemiology of HIV among youth), prevention information on HIV testing and PrEP, as well as a link to the HIV risk estimator, and HIV testing and PrEP locators.
62198543|NCT02871505|EXPERIMENTAL|Molecular subtyping (others) of Treponema pallidum|Benzathine Penicillin G treatment
62198544|NCT06336187||RCC (renal cell carcinoma)|Patients with small, incidentally detected, histologically confirmed renal cell carcinoma
62400431|NCT02050646|EXPERIMENTAL|Low salt/ Liberal salt Diet|Cross-over trial of liberal salt and low salt diet.
62400432|NCT02050646|EXPERIMENTAL|Liberal salt/Low salt diet|Cross-over trial of low salt and liberal salt diet
62011091|NCT04952766|OTHER|immunocompromised and healthy subjects|"Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.~Biological samples :~* Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests~* Nasopharyngeal samples (not mandatory)~Associated data :~* Demographic data~* Description of clinical manifestations related to vaccination~* Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning~* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)"
62400433|NCT01526720||Group A: Diabetic|Newly diagnosed type 2 diabetic patients (i.e. diagnosis made no more than 6 months before recruitment)
62400434|NCT01526720||Group B: Relatives|Relatives of patients with potentially monogenic newly diagnosed type 2 diabetes
62400435|NCT03157804|EXPERIMENTAL|Autologous CD34+ cells transducted with PGK-FANCA-Wpre *|CD34 + cells from patients with Fanconi subtype A (FA-A) transduced ex vivo with lentiviral vector carrying the gene FANCA, PGK-FANCA-Wpre\*The product to be infused consist of a suspension of transduced CD34\^+ cells.
62400436|NCT00359580||AGDB|Those individuals who are listed in the Fisher Family History and other genealogy books ordatabases will be included in the AGDB.
62783693|NCT06333366|EXPERIMENTAL|intraabdominal pressure (IAP) monitor|Patient who will take laparoscopic surgery will be checked for intra-abdominal pressure, intra-vesical pressure, and intra-gastrointestinal pressure ri-operative stage. PDT passage time will be checked.
62783694|NCT04831177|ACTIVE_COMPARATOR|Patients planned to undergo Femtosecond laser FS assisted LASIK|In FS group, Allegretto WaveLight FS-200 femtosecond laser was used to create flaps with flap thickness planned to be 100 um.
62198545|NCT05057338|EXPERIMENTAL|CoreDISTparticipation|"a) at the MS-OP clinic, in addition to the regular consultations, the patient will have a structured digital conversation with the MS-nurse addressing work related issues and a session with a physiotherapist exploring possibilities for change in balance and walking; b) in the municipality, a physiotherapist will continue exploration of improvements, followed by four weeks of GroupCoreDIST focusing on balance, walking and physical activity and conducted in groups of 3-5 individuals with MS and led by a physiotherapist.~To promote participation in employment, a structured digital meeting between each patient, the MS-nurse, the patient's employer, and the physiotherapist will take place; followed by c) four weeks of outdoor group based exercises and physical activity led by a physiotherapist, complemented with an evaluation form regarding employment and physical activity."
62783695|NCT04831177|ACTIVE_COMPARATOR|Patients planned to undergo Microkeratome MK assisted LASIK|In MK group, Moria 2 Microkeratome was used to create flaps with flap thickness planned to be 100 um.
62783696|NCT02754258|PLACEBO_COMPARATOR|Placebo|60 day oral administration of sugar placebo twice per day before lunch and supper.
62011092|NCT05343611|ACTIVE_COMPARATOR|Group A (Controls: HPro diet and HIT)|Subjects included in this group will serve as controls and will maintain the HPro Diet + HIT program prescribed to all the participants included in the randomization step of the study. The subjects' diet will be adjusted to receive the same overall intake of calories (+ 180 kcal) and macronutrients (+ 3 g of proteins, 4 g of carbohydrates, +11 g of fat, + 4 g of fibers) that the chocolate products will provide to groups B and C.
62198546|NCT05057338|ACTIVE_COMPARATOR|Standard care|The control group will receive the usual consultations at the MS-OP clinic including exploration of possibilities for change in balance and walking together with physiotherapist at the MS-OP clinic. The control group will furthermore follow standard care (their usual follow-up) in the municipality.
62400437|NCT04469101|EXPERIMENTAL|Left Uterine Displacement|Supine with left tilt for uterine displacement
62400438|NCT04469101|EXPERIMENTAL|Left Lateral|Left lateral decubitus position
62400439|NCT04469101|EXPERIMENTAL|Right Lateral|Right lateral decubitus position
62400440|NCT04469101|EXPERIMENTAL|Upright|Upright seated position
62783697|NCT02754258|EXPERIMENTAL|Methylphenidate (MPH)|60 day oral administration of active study drug (methylphenidate) twice per day before lunch and supper.
62783698|NCT05856019|EXPERIMENTAL|J Stroke Myofascial Release|Patient is in prone lying position with foot supported. Pressure is applied with the heel of the opposite hand, while a stroke in the shape of the letter J is applied in the direction of the restriction, with two or three fingers, which creates some torque at the end. Myofascial Release techniques will be performed for 20 repetitions.
62783699|NCT05856019|ACTIVE_COMPARATOR|Ischemic Release on Gastrocnemius through Dry Cupping|Dry cupping will provided to the subjects thrice a week for 4 weeks in the dry cupping therapy group, a plastic cupping bell will be used. Cups will applied to the painful site for 10 minutes in each session. A manual hand pump was used to create the vacuum for suction. The intensity of the vacuum will based on subject tolerance.
62783700|NCT01092052|EXPERIMENTAL|1|
62783701|NCT02251938|EXPERIMENTAL|DE-109 Sirolimus|DE-109 440 μg
62783702|NCT06114927||Participants|To answer a 15-question survey.
62783703|NCT03442218|EXPERIMENTAL|Clorhexidine|Vaginal wash with clorhexidine solution
62198547|NCT01441635|EXPERIMENTAL|Cohort 4 Elagolix 400 mg QD|Participants received elagolix 400 mg once a day (QD) for 3 months.
62400441|NCT02279602|EXPERIMENTAL|Single Arm|Subjects will receive fosbretabulin at the same dose and frequency as in study OX4218s
62400442|NCT04897126|ACTIVE_COMPARATOR|Experimental group|The experimental group was treated with Shexiang Baoxin pill（MUSKARDIA） (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
62400443|NCT04897126|PLACEBO_COMPARATOR|Placebo group|The control group was given placebo（ 4 capsules / day, 3 times / day）on the basis of conventional treatment until the end of follow-up.
62400444|NCT02032394|EXPERIMENTAL|Chlorhexidine|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Chlorhexidine 0.2%, 3 times a day for 10 days.
62400445|NCT02032394|EXPERIMENTAL|Povidone-Iodine|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Povidone-iodine 10%, 3 times a day for 10 days.
62400446|NCT02032394|ACTIVE_COMPARATOR|Normal saline|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Normal saline 0.9%, 3 times a day for 10 days.
62783704|NCT03442218|PLACEBO_COMPARATOR|Saline solution|Vaginal wash with saline solution
62783705|NCT04920383|EXPERIMENTAL|Dose Escalation and Expansion|ALPN-202 + pembrolizumab KEYTRUDA®
62783706|NCT06551935|ACTIVE_COMPARATOR|Control Group|Without sleep intervention
62783707|NCT06551935|EXPERIMENTAL|Experimental Group|Sleep hygiene and sleep extension
62783708|NCT01800136|EXPERIMENTAL|rTMS; tDCS|
62783709|NCT04629651|EXPERIMENTAL|Captopril|"In phase I, Cohorts of 3 patients each will receive doses of captopril with a goal dose of 150mg total by mouth (PO) daily. Initial dose per patient will start at 12.5 mg daily, which will then be increased on weekly intervals as tolerated. To be administered per the intra-patient dose escalation scheme below~Phase I:~Day 0: 12.5mg/day Day 7: 12.5mg twice daily Day 14: 12.5mg three times daily Day 21: 25mg three times daily Day 28: 50mg three times daily~Phase II: The efficacy of captopril will be assessed in the Phase II portion. Captopril given at Maximum Tolerated Dose - bone marrow evaluation to be done at 6 months"
62783710|NCT02669992|EXPERIMENTAL|Stapled anastomosis|Stapled anastomosis by the use of commercially available linear stapler device
62783711|NCT02669992|ACTIVE_COMPARATOR|Hand-sewn anastomosis|Hand-sewn by the use of a resorbable monofilament suture
62783712|NCT02669992|EXPERIMENTAL|Abdominal wall mesh closure|Closure by the use of a mesh low-weight net device
62783713|NCT02669992|ACTIVE_COMPARATOR|Abdominal wall suture closure|Closure by the use of slowly absorbing monofilament suture
62783714|NCT01813448|EXPERIMENTAL|Cohort 1: Fidaxomicin low dose in Japanese males|
62011093|NCT05343611|SHAM_COMPARATOR|Group B (Case 1: HPP Choko)|Individuals included in this group will undergo the same diet and physical exercise as Group A and additionally they will add to their diet 30g of 85% dark chocolate high in PP (HPP ≥ 500 mg of PP and corresponding to ≥ 60 mg of epicatechin).
62011094|NCT05343611|EXPERIMENTAL|Group C (Case 2: HPP/VE Chocolate)|Individuals included in this group will undergo the same diet and physical exercise as Group A and additionally they will add to their diet 30 grams of 85% dark HPP chocolate functionalized with 100 mg Vitamin E per day.
62783715|NCT01813448|EXPERIMENTAL|Cohort 2: Fidaxomicin high dose in Japanese males|
62783716|NCT01813448|EXPERIMENTAL|Cohort 3: Fidaxomicin high dose in Caucasian males|
62783717|NCT01813448|PLACEBO_COMPARATOR|Matching Placebo in Caucasian males|
62783718|NCT01813448|PLACEBO_COMPARATOR|Matching Placebo in Japanese males|
62783719|NCT02226887|EXPERIMENTAL|MESH|
62783720|NCT02226887|ACTIVE_COMPARATOR|NO MESH|
62783721|NCT02315560|EXPERIMENTAL|Tibial Nerve Stimulation|The subject/parents will be instructed to record a night-time voiding log specifying the number of incontinent episodes per night. This log is included in the Institutional Review Board application. Subjects/parents will fill out the log for a two week period prior to foot stimulation to determine a baseline average of nocturnal enuresis episodes, during the two week foot stimulation period to measure any acute effect on nocturnal enuresis episodes and finally during the two weeks after stimulation to evaluate any post-stimulation residual benefit
62783722|NCT05299008||Infants with diagnosis of tracheobronchomalacia treated with bethanechol|Infants with a diagnosis of tracheobronchomalacia by dynamic computed tomography and showing \> 50% cross-sectional diameter collapse at 40 to 60 post menstrual age
62783723|NCT01445314||1/Patients|Infants, children, adolescents, and adults who have taken neurobehavioral assessments as part of a past, current, or future IRB-approved protocol.
62783724|NCT00859937|EXPERIMENTAL|Arm I|Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62783725|NCT03748719|EXPERIMENTAL|Stereotactic Body Radiation Therapy, followed by Prostatectomy|Patients will receive 6 Gy per day of Stereotactic Body Radiation Therapy (SBRT) per day for 5 days, followed by prostatectomy in 3 weeks.
62783726|NCT05535829||Patients with FH-deficient RCC|Laboratory analysis of samples
62783727|NCT03907150||Pneumothorax|Pneumothorax
62783728|NCT03907150||Normal|Normal lung
62011095|NCT04886141|NO_INTERVENTION|Standard of Care treatment with Scales|Patients will receive the standard of care restorative procedure with the addition of the FLACC pain scale, Wong Baker FACES Pain rating and Houpt scale to create a baseline data of pain to compare with the experimental group.
62011096|NCT04886141|EXPERIMENTAL|Virtual Reality Headset|Instead of receiving the Nitrous that would be used to help calm patients during the standard of care restorative procedure. Patients will be given a the Oculus Quest 2 Virtual realty headset and a video will be played. The FLACC pain scale, Wong Baker FACES Pain rating and Houpt scale data will be collected to compare the patients pain level between the two groups.
62011097|NCT06477796|EXPERIMENTAL|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 120 minutes of waking up.
62783729|NCT01552356|EXPERIMENTAL|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course length can be extended to 56 days at the discretion of the treating physician after 12 courses (1 year) of treatment on study.
62783730|NCT02634502|EXPERIMENTAL|Treatment|Patients will receive radiofrequency ablation for liver metastatic lesions, as well as two weeks of oral S-1 treatment every three weeks, until progression of disease or adverse effects leading to termination of treatment. Each 3-week period is one cycle of treatment.
62783731|NCT00927238|EXPERIMENTAL|XL TDR|The XL TDR is indicated for reconstruction of the disc following discectomy in skeletally mature subjects with symptomatic degenerative disc disease (DDD) of the lumbar spine at one level from L1-L5. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history radiographic studies.
62783732|NCT00927238|OTHER|Outcomes from lumbar fusion study|
62783733|NCT06006117|EXPERIMENTAL|Arm 1: Mosunetuzumab and Lenalidomide|"- Mosunetuzumab and Lenalidomide~* Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles)~  * C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15~ * C2 to C12: 45 mg D1 28-days cycles~* Lenalidomide PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6 (cycles of 28 days)"
62783734|NCT06006117|ACTIVE_COMPARATOR|Arm 2: Rituximab-Lenalidomide (28-days cycles)|"* Lenalidomide PO 20 mg/day, D1-21 from cycle 1 to cycle 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12"
62783735|NCT06006117|ACTIVE_COMPARATOR|Arm 3: Rituximab-Bendamustine (28-days cycles)|"* Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion~* Rituximab\* 375 mg/m2 intravenously at cycle 1 Day 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6\*\* (28-days cycles) and then at D1 of three additional 56-days cycles (C7 to C9). \*\*For patients in complete response (CR) at 3 cycles, if Bendamustine is stopped, then Rituximab should also be omitted for C5 and C6."
62011098|NCT06477796|SHAM_COMPARATOR|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 120 minutes of waking up.
62198548|NCT01441635|EXPERIMENTAL|Cohort 4 Elagolix 100 mg BID|Participants received elagolix 100 mg twice a day (BID) for 3 months.
62783736|NCT06006117|ACTIVE_COMPARATOR|Arm 4: Rituximab-CHOP (21-days cycles|"* CHOP, IV standard dose from cycle 1 to 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6 (21-days cycles), and then at D1 of three additional 56-days cycles (C7 to C9)"
62198549|NCT01441635|PLACEBO_COMPARATOR|Cohort 4 Placebo|Participants received placebo to elagolix BID for 3 months.
62198550|NCT01441635|EXPERIMENTAL|Cohort 1 Elagolix 200 mg BID|Participants received elagolix 200 mg twice a day for 3 months.
62011099|NCT00710502|EXPERIMENTAL|1|Transvaginal NOTES Cholecystectomy (Phase 1)
62011100|NCT00710502|ACTIVE_COMPARATOR|2|Laparoscopic Cholecystectomy (Phase 2)
62783737|NCT01714401|ACTIVE_COMPARATOR|Salbutamol 2,5 mg|25 mechanically ventilated patients to receive 2,5mg of nebulised salbtamol (Ventolin) duration of nebulisation - 20 minutes
62783738|NCT01714401|ACTIVE_COMPARATOR|Salbutamol 5mg|25 mechanically ventilated patients 5 mg of nebulised salbutamol (Ventolin) duration of nebulisation - 20 minutes
62783739|NCT03698123|EXPERIMENTAL|Dietary Modification|On the first night of the study, participants can eat and drink as they normally would (no dietary intervention). On second and third nights participants will be provided meals, snacks and drinks with specific macronutrient composition, encouraged to only eat and drink study meals, snacks and drinks, and to avoid eating after 10:00 hours. The composition of the study foods and drinks on nights 2 and 3 will be different.
62011101|NCT00710502|EXPERIMENTAL|3|Transvaginal NOTES cholecystectomy (Phase 2)
62011102|NCT04048460|EXPERIMENTAL|eAudiology|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
62011103|NCT01105247|EXPERIMENTAL|PCI-32765|
62198551|NCT01441635|PLACEBO_COMPARATOR|Cohort 1 Placebo|Participants received placebo to elagolix twice a day for 3 months.
62198552|NCT01441635|PLACEBO_COMPARATOR|Cohort 3 Elagolix 200 mg BID + LD E2/NETA|Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.
62011104|NCT04512937|EXPERIMENTAL|All patients|All patients will be subjects to the intervention of computer navigation-assisted surgery
62011105|NCT06663891|OTHER|Early Onset Depression (EOD)|Elderly depressed patients (≥ 60 years and \< 90 years) suffering from active or remitted anergic depression and who have at least one history of a depressive episode strictly before the age of 60 years
62198553|NCT01441635|EXPERIMENTAL|Cohort 5 Elagolix 600 mg QD|Participants received elagolix 600 mg once a day for 3 months.
62198554|NCT01441635|EXPERIMENTAL|Cohort 2 Elagolix 300 mg BID|Participants received elagolix 300 mg twice a day for 3 months.
62011106|NCT06663891|OTHER|Late Onset Depression (LOD)|Elderly depressed patients (≥ 60 years and \< 90 years) suffering from active or remitted anergic depression and who do not have a history of a depressive episode strictly before the age of 60 years.
62011107|NCT06369571|ACTIVE_COMPARATOR|Statin|Participants will receive 10mg of atorvastatin daily for 12 weeks
62011108|NCT06369571|EXPERIMENTAL|Modified Atkins diet (MAD) Modification|Participants will be instructed on how to change their modified Atkins diet for 12 weeks. They will replace 10% of daily dietary energy from saturated fat with poly-unsaturated fat.
62011109|NCT04108039|ACTIVE_COMPARATOR|GnRH antagonist|In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles \>14mm or E2 levels \>400 pg/ml and continuing until ovulation triggering.
62198555|NCT01441635|EXPERIMENTAL|Cohort 2 Placebo|Participants received placebo to elagolix BID for 3 months.
62198556|NCT01441635|EXPERIMENTAL|Cohort 6 Elagolix 300 mg BID + CEP|Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.
62198557|NCT02944162|EXPERIMENTAL|CAR-NK Cell immunotherapy|Enrolled patients will receive CAR-NK cells immunotherapy with a novel specific chimeric antigen receptor targeting CD33 antigen by infusion.
62198558|NCT06274398|EXPERIMENTAL|Active|2 TAF/EVG (20/16mg) rectal inserts
62198559|NCT06274398|PLACEBO_COMPARATOR|Placebo|2 Matching placebo inserts
62198560|NCT03805776|EXPERIMENTAL|Interventional|Will observe intermittent fasting
62198561|NCT03805776|NO_INTERVENTION|Control|
62198562|NCT02475512|EXPERIMENTAL|Wash wipes|Washing with water and soap (standard care) will be replaced with two wash wipes during 30 days: (1) daily total body wash (using 3M Cavilon Bathing and Cleansing wipes) and (2) Continence Care (using 3M Cavilon Continence Care Wipes). No other preventive barrier or hydration products will be allowed in the genital-anal region.
62783740|NCT05279950|ACTIVE_COMPARATOR|Piezoelectric|Full-mouth ultrasonic debridement will be performed with a ultrasonic tip (vibration frequence \>18 kHz) powered by a piezoelectric device
62011110|NCT04108039|EXPERIMENTAL|Micronized progesterone|In the progesterone cycle, endogenous LH suppression will be accomplished by oral administration of micronized progesterone (200 mg) once a day at bed time, from stimulation day 1 and continuing until ovulation triggering.
62783741|NCT05279950|EXPERIMENTAL|Magnetostrictive|Full-mouth ultrasonic debridement will be performed with a ultrasonic tip (vibration frequence \>18 kHz) powered by a magnetostrictive device.
62011111|NCT04603430||Physical Therapy Students|Students will be participating in a focus group and completing a survey.
62011112|NCT04603430||Senior STEPS Participants|Seniors will be participating in a focus group, completing a survey, and researchers will be conducting a retrospective chart review on relevant documented health outcomes of the STEPS program.
62011113|NCT00452881|EXPERIMENTAL|study arm|GemOx
62011114|NCT00452881|ACTIVE_COMPARATOR|control arm|GemCis
62011115|NCT04604522||Ancillary-correlative (biospecimen collection, chart review)|Patients undergo collection of blood samples and 6 brushings of the airway during SOC bronchoscopy. Patients' medical records are also reviewed for data collection.
62011116|NCT02359266|EXPERIMENTAL|Vitamin D supplement|20,000 IU cholecalciferol p.o for the first 7 days, and weekly thereafter for 6 months
62011117|NCT02359266|NO_INTERVENTION|Controls|These patients had normal vitamin D levels and did not receive any treatment with vitamin D.
62011118|NCT03112317||Hypothermia|Patients with mild hypothermia at start of the surgery
62011119|NCT03112317||Normothermia|Patients with normal core temperature at start of surgery.
62011120|NCT02139163||patients with pneumonia|
62198563|NCT02475512|PLACEBO_COMPARATOR|Standard care|Washing will be done using water and pH neutral soap. No other preventive barrier or hydration products will be allowed in the genital-anal region.
62783742|NCT02097654|EXPERIMENTAL|SENATOR|Physicians attending multi-morbid older patients i.e. with 3 or more chronic medical conditions receive a SENATOR software-generated report with advice details on potentially inappropriate pharmacotherapy and/or potentially inappropriate prescribing omissions.
62011121|NCT06018636||Group 1|Infants and young children residing in agropastoral communities of District Swat, Pakistan
62011122|NCT06018636||Group 2|Infant and young children residing in urban areas of district Swat, Pakistan
62011123|NCT06662877|EXPERIMENTAL|Experimental|Experimental treatment under study
62011124|NCT06662877|ACTIVE_COMPARATOR|Control|Standard of care second-line treatment for advanced biliary tract cancer
62011125|NCT02283216|EXPERIMENTAL|Acoustic, Body, Cortical|Acoustic corresponds to noise sound stimulation. Body corresponds to body electrical stimulation. Cortical corresponds to transcranial magnetic stimulation. Acoustic is presented together with body and cortical stimulation. Different body locations and timing among acoustic, body, and cortical stimulation are presented across testing sessions.
62011126|NCT04120389|EXPERIMENTAL|BCL group|bandage contact lenses(PureVision; Bausch \& Lomb Inc., Rochester, NY)
62011127|NCT04120389|ACTIVE_COMPARATOR|control group|
62011128|NCT04471181||All patients with ruptured abdominal aortic aneurysms|"All patients will undergo CTA to confirm the diagnosis. The use of balloon for aortic clamp in case of haemodynamic instability can be used.~All patients included in the research study must undergo standard EVAR with a bifurcated graft or an aorto-uni-iliac and a femoral to femoral crossover. In aneurysms with short proximal neck down to 4mm, or in cases where completion angiography indicates type Ia endoleak, the Heli-FX EndoAnchor system is recommended to be used, as indicated. All patients will have plain abdominal x-rays on discharge. Participants will undergo CTA in 3months and annually post-op.. In case of an adverse event before the 3 months follow up CTA, a more urgent imaging might be requested and proceed to appropriate action according to the findings."
62011129|NCT03109275|ACTIVE_COMPARATOR|Single MRI examination|40 subjects will benefit from a full MRI
62783743|NCT02097654|NO_INTERVENTION|Control|Standard pharmaceutical care as per local practice.
62783744|NCT03022682||IDEO Cohort|"Adipose tissue samples are collected from all participants, including aspirational subcutaneous biopsies from nonsurgical participants and excisional biopsies, performed intra-operatively by surgical collaborators as required.~Participants also undergo anthropometric measurements, stool collection, blood sample collection for circulating blood cells, serum, and plasma.~Dual-energy x-ray absorptiometry (DXA) scan for amount and distribution of body fat as well as bone density is performed.~Study participants complete validated questionnaire inventories to measure bio-behavioral issues such as depression, stress, health locus of control, and dietary habits."
62011130|NCT03109275|SHAM_COMPARATOR|Reproducibility study|10 subjects will benefit from the realization of 3 MRI. An MRI examination performed at the time of inclusion and then an examination, at 3 months and at 9 months (ie 3 examinations per subject).
62011131|NCT03175042||Pregnant patients with anemia|Pregnant patients meeting Center for Disease Control (CDC) guidelines for anemia during pregnancy will be screened for participation in the study. In the outpatient setting at our institution it is standard of care that these women have complete blood counts (CBCs) drawn every 4-6 weeks. At the time of the routine blood draw, we will place the non invasive monitor on their finger to record the hemoglobin value. We will be comparing the hemoglobin values obtained from the CBC to that obtained from the non-invasive monitor.
62011132|NCT01064921|EXPERIMENTAL|Arm I|Patients receive oral vorinostat on days 0-2 and cisplatin IV on days 7, 21 and 35. Patients undergo radiation therapy 5 days a week beginning on day 7. Patients also receive concurrent oral vorinostat along with the radiotherapy to be given 3 days per week (Monday, Tuesday, and Wednesday). Optional repeat tumor and normal mucosal biopsies will be performed and blood will be drawn for correlative studies.
62011133|NCT06293417|EXPERIMENTAL|Treatment group|Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin
62011134|NCT06293417|ACTIVE_COMPARATOR|Control group|Dose escalation of moderate-intensity statin
62011135|NCT02233049|EXPERIMENTAL|R1: erlotinib versus dasatinib|EGFR+ only Tarceva® (erlotinib): 25 mg and 100 mg tablets. The prescribed dose is 125 mg/m²/day orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
62011136|NCT02233049|EXPERIMENTAL|R2: everolimus versus dasatinib|PTEN-loss only Votubia® (everolimus): 2.5 mg tablets. The prescribed dose is 5 mg/m²/day, orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
62198564|NCT05387967|EXPERIMENTAL|Treatment group|All the recruited patients were prescribed Sacubitril/Valsartan at a starting dose of 50 (24/26) mg BID which was up-titrated, over the period of initial 6 weeks, to the maximum tolerated dose up to 200 (97/103) mg BID and further followed for a total of 12 weeks.
62198565|NCT02634086||Percutaneous coronary intervention|Patients with triple-vessel coronary artery disease underwent percutaneous coronary intervention.
62198566|NCT02634086||Coronary artery bypass graft|Patients with triple-vessel coronary artery disease underwent coronary artery bypass graft.
62198567|NCT02634086||Optimal medication therapy|Patients with triple-vessel coronary artery disease underwent optimal medication therapy only.
62198568|NCT03872245|EXPERIMENTAL|PENS T6 + Probiotics|The patients will receive Probiotics (Adomelle 1caps/12h) associated to PENS T6 during 10 weeks.
62011137|NCT02233049|EXPERIMENTAL|R3: erlotinib versus everolimus versus dasatinib|EGFR+ and PTEN-loss or inconclusive biopsy Tarceva® (erlotinib): 25 mg and 100 mg tablets. The prescribed dose is 125 mg/m²/day orally, once daily. Votubia® (everolimus): 2.5 mg tablets. The prescribed dose is 5 mg/m²/day, orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
62011138|NCT02233049|EXPERIMENTAL|Cohort Dasatinib|Neither EGFR overexpression nor loss of PTEN expression Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day
62198569|NCT03872245|ACTIVE_COMPARATOR|PENS T6|The patients will undergo PENS T6 during 10 weeks.
62400447|NCT06615245|SHAM_COMPARATOR|n = 16 participants: No VR condition vs. Immersive VR|Participants will perform a simple attention demanding task during No VR for 2 minutes, and again during a Immersive High Tech Virtual Reality game distraction. They will also rate how distracted they were and how hard it was to concentrate on the attention demanding task during each 2 minute task.
62400448|NCT06615245|ACTIVE_COMPARATOR|n = 20 participants: plausible control (see through VR) condition vs. immersive High Tech VR|20 healthy volunteer participants will perform a simple attention demanding task during a plausible control (see through) VR for 2 minutes, and again during an immersive High Tech Virtual Reality distraction (treatment order randomized). They will also rate how distracted they were and how hard it was to concentrate on the attention demanding task during the 2 minute tasks. During Phase 2 they will also rate their pain and anxiety during a brief thermal stimulus Quantitative Sensory Testing) during No VR vs. during immersive High Tech VR.
62400449|NCT02910895|OTHER|single arm|single tumor biopsy
62783745|NCT05325346|EXPERIMENTAL|VLX-1005|Intravenous administration of VLX-1005 with measurements of PK and PD
62400450|NCT02874235|EXPERIMENTAL|Music therapy treatment|35 patients receiving each 16 sessions of Receptive music therapy
62783746|NCT05325346|ACTIVE_COMPARATOR|Argatroban|Intravenous administration of argatroban with measurements of PK and PD
62783747|NCT05325346|OTHER|VLX-1005 and Argatroban|Intravenous co-administration of VLX-1005 and argatroban with measurements of PK and PD
62011139|NCT06341244|EXPERIMENTAL|Air staking technique group|The air staking group
62400451|NCT02874235|ACTIVE_COMPARATOR|Standard treatment|35 patients receiving each 16 sessions of Psychological treatment
62400452|NCT00475657|EXPERIMENTAL|A|
62400453|NCT06367959|EXPERIMENTAL|Control condition|Participants will be asked to write about facts regarding their cancer diagnosis and treatment in writing sessions.
62011140|NCT05435599|OTHER|Chronic Hepatitis B|Measurement of serum regucalcin level
62011141|NCT05435599|OTHER|Healthy Volunteers|Measurement of serum regucalcin level
62400454|NCT06367959|EXPERIMENTAL|Intervention Condition|Participants will be asked to write about different topics regarding their cancer experience. During session 1, participants will be asked to write about the stress of having cancer and their strategies for coping with stressors associated with their cancer (i.e., stress and coping). During session 2, participants will be asked to write about their deepest feelings regarding their cancer experience (i.e., emotional disclosure). During session 3 and the booster session (at 9-month follow-up), participants will be asked to write about positive thoughts and feelings regarding their experience with cancer.
62400455|NCT03585595|EXPERIMENTAL|Intensive treatment group|Systolic BP target \<120 mmHg for the intensive treatment group
62783748|NCT03240770|NO_INTERVENTION|14 Day Tray + Sham|Trays worn at 14 day intervals + Sham
62783749|NCT03240770|EXPERIMENTAL|7 Day Tray + Sham|"Trays worn at 7 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ Sham"
62783750|NCT03240770|EXPERIMENTAL|5 Day Tray + Sham|"Trays worn at 5 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ Sham"
62011142|NCT05345795||SSc-ILD patients|
62011143|NCT03063541|EXPERIMENTAL|Acetylsalicylic acid, BP-target 120|100 mg ASA plus intensified blood pressure management. Recommended systolic blood pressure 120 mm/Hg
62198570|NCT04165044|ACTIVE_COMPARATOR|L-PRF+CAF|Leukocyte and Platelet Rich Fibrin plus Coronally Advanced Flap
62198571|NCT04165044|ACTIVE_COMPARATOR|CTG+CAF|Connective Tissue graft plus Coronally Advanced Flap
62198572|NCT02935803|OTHER|Modified TVM operation|Modified Trans-vaginal Mesh operation (mTVM): polypropylene monofilament meshes produced by Aspide® fixed up to the mid urethra by a resolvable suture. 76 participants will be involved.
62198573|NCT02935803|OTHER|Control group|76 Participants as control group undergo a traditional Trans-vaginal Mesh operation (TVM) with polypropylene monofilament meshes produced by Aspide® . (Sergent et al.)
62198574|NCT06199895|EXPERIMENTAL|Paclitaxel Polymeric Micelles for Injection|Subjects are given paclitaxel polymeric micelles for injection, three weeks constitutes one cycle of treatment.
62783751|NCT03240770|EXPERIMENTAL|7 Day Tray + VPro5|"Trays worn at 7 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ HFV with the VPro5 device at 5 min/day"
62783752|NCT03240770|EXPERIMENTAL|5 Day Tray + VPro5|"Trays worn at 5 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ HFV with the VPro5 device at 5 min/day"
62783753|NCT02075788|PLACEBO_COMPARATOR|Commercial white bread|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
62783754|NCT02075788|EXPERIMENTAL|Millet based products (porridge etc.)|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
62783755|NCT02075788|ACTIVE_COMPARATOR|Corn based products (porridge etc.)|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
62783756|NCT02595294|EXPERIMENTAL|Cervical Lateral Glide|"* 15 minutes Cervical Lateral Glide neural mobilization~* 5 times a week~* During 6 weeks~* Patient's adequate cervical spine linear alignment was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization."
62011144|NCT03063541|NO_INTERVENTION|standard care|blood pressure management according to guidelines
62198575|NCT03863015|ACTIVE_COMPARATOR|Tocilizumab|A one hour infusion of a single 8mg/kg dose (max. 800mg) of tocilizumab to attenuate systemic inflammation after out-of-hospital cardiac arrest, given as early as possible after hospital admission.
62198576|NCT03863015|PLACEBO_COMPARATOR|Isotonic saline|A one hour infusion of isotonic saline
62198577|NCT06477861||mild to moderate ARDS|100 =\< PO2/FiO2 ratio \< 300
62011145|NCT06535204|EXPERIMENTAL|Experimental Group|"The intervention group consumed the test food twice daily (400 mg in the morning and 400 mg in the evening, each time as one hard capsule), 30 minutes after eating, with water. The administration period lasted 12 weeks for each participant.~The test food is named Aqueous extract of A. sylvestris leaves. The ingredients and their contents are as follows: Aqueous extract of A. sylvestris leaves 62.5%, Microcrystalline Cellulose 35.5%, Silicon Dioxide 1.0%, Magnesium Stearate 1.0%. The dosage form is a hard capsule, with a content weight of 400 mg per capsule."
62011146|NCT06535204|PLACEBO_COMPARATOR|Control Group|"The Control group consumed the test food twice daily (400 mg in the morning and 400 mg in the evening, each time as one hard capsule), 30 minutes after eating, with water. The administration period lasted 12 weeks for each participant.~The test food is named Microcrystalline Cellulose. The ingredients and their contents are as follows: Microcrystalline Cellulose 98%, Silicon dioxide 1.0%, Magnesium stearate 1.0%. The dosage form is a hard capsule, with a content weight of 400 mg per capsule."
62011147|NCT04856163|EXPERIMENTAL|Telelactation support|Participants in the experimental group will receive unlimited, free telelactation visits with lactation consultants (IBCLCs) as demanded up to 24 weeks post-partum. Services will be available through mobile phone app.
62198578|NCT06477861||severe ARDS|100 \< PO2/FiO2 ratio
62198579|NCT02510833|EXPERIMENTAL|Continuing Intervention Group|
62198580|NCT02510833|ACTIVE_COMPARATOR|Control Group|
62198581|NCT00269906|EXPERIMENTAL|Abciximab (c7E3 Fab)|Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight abciximab as bolus intravenous injection followed by continuous infusion of abciximab at rate of 10 microgram per minute for at least 18 hours but not longer than 26 hours.
62198582|NCT00269906|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo as bolus IV injection followed by continuous infusion of matching placebo for at least 18 hours but no longer than 26 hours.
62198583|NCT03735043|EXPERIMENTAL|ccNexfin ©|
62198584|NCT00733395|EXPERIMENTAL|1|Tart cherry juice
62400456|NCT03585595|ACTIVE_COMPARATOR|Standard treatment group|Systolic BP \<140 mmHg for the standard treatment group
62400457|NCT01978067||transvaginal resection of Uterine Scar|transvaginal resection of Uterine Scar From Previous Cesarean Delivery
62400458|NCT02767908|NO_INTERVENTION|Usual Care|Participants in the usual care group will be offered and, if accepted, provided with smoking cessation support that meets the recommendations of NICE PH48 guidance including pharmacotherapy and behavioural support before leaving hospital, referral to NHS SSS for continued care after discharge, and ascertainment of smoking status at 4 weeks; participants will also be asked to consent to smoking status ascertainment at three months. Those who report cessation at 4 weeks and/or three months will be requested to agree to a home visit for CO validation. All will be asked at four weeks and 3 months to list the cessation support, in terms of pharmacotherapy and behavioural support from local or other services, delivered since the last contact.
62011148|NCT04856163|NO_INTERVENTION|ebook|Participants in the control arm will receive care as usual. They will also receive a ebook with content on infant care.
62011149|NCT00485108|ACTIVE_COMPARATOR|1|Prednisolone 1% eye drop
62011150|NCT00485108|ACTIVE_COMPARATOR|2|ketorolac 0.5% eye drop
62011151|NCT00485108|PLACEBO_COMPARATOR|3|Artificial Tears (methyl cellulose eye drop)
62011152|NCT00843791|PLACEBO_COMPARATOR|Placebo|Treatment with placebo for 3 months before spectroscopy, hyperinsulinemic-euglycemic clamp, control diet, blood sampling.
62198585|NCT00733395|PLACEBO_COMPARATOR|2|Fruit juice
62198586|NCT05822492||Group QLB3|Patients who applied the QLB3 block before PCNL surgery were included in this group.
62198587|NCT05822492||Group ESPB|Patients who applied ESP block before PCNL surgery were included in this group.
62198588|NCT05822492||Group Control|Patients who did not use any block before PCNL surgery were included in this group.
62198589|NCT05005377|EXPERIMENTAL|Socket Preservation with Platelet-Rich Fibrin|10cc of blood was drawn from each patient and centrifuged at 2700 revolutions per minute (rpm) for 12 minutes to obtain PRF. The extraction socket was filled with PRF and covered using a membrane made of PRF.
62198590|NCT05005377|EXPERIMENTAL|Socket Preservation with Freeze-Dried Bone Allograft|the extraction socket was filled with FDBA (CenoBone®; Tissue Regeneration Corp., Kish Island, Iran) without flap elevation. The socket was covered using a free palatal mucosal graft obtained by the pouch technique.
62198591|NCT02679326|EXPERIMENTAL|study group|will receive stretching guidance and high level active Ultrasound
62198592|NCT02679326|PLACEBO_COMPARATOR|control group|will receive stretching guidance and very low level of Ultrasound
62198593|NCT04281251|EXPERIMENTAL|ERAT arm|This is the treatment arm where endoscopic therapy of acute appendicitis would be performed
62011153|NCT00843791|ACTIVE_COMPARATOR|pioglitizone|Treatment with pioglitazone for 3 months before hyperinsulinemic-euglycemic clamp, control diet with blood sampling and spectroscopy.
62011154|NCT01922596|EXPERIMENTAL|Active FNB, placebo ACB|FNB with 30 ml of ropivacaine 0,2% and ACB with 30 ml of placebo (saline). The ACB will be performed just prior to the FNB. The blockades will be performed just after obtaining the baseline values (outcome measures) at time 0.
62011155|NCT01922596|EXPERIMENTAL|Active ACB, placebo FNB|ACB with 30 ml of ropivacaine 0,2% and FNB with 30 ml of placebo (saline.The ACB will be performed just prior to the FNB. The blockades will be performed just after obtaining the baseline values (outcome measures) at time 0.
62011156|NCT03569644|OTHER|qualitative study|heterogeneous group of patients
62011157|NCT03480555|ACTIVE_COMPARATOR|Replenish Protein group|Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.
62011158|NCT03480555|OTHER|Standard Protein group|Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
62011159|NCT01790412|EXPERIMENTAL|Exercise group|"Three sessions per week:~Supervised exercise program"
62011160|NCT01790412|NO_INTERVENTION|Control|Sedentary pregnant women
62011161|NCT04116229|ACTIVE_COMPARATOR|Normal-weight|Participants who have a body mass index within the normal-weight category.
62011162|NCT04116229|ACTIVE_COMPARATOR|Obese|Participants who have a body mass index within the obese category.
62576899|NCT00863356|EXPERIMENTAL|Epistaxis Group|"Subjects presenting with epistaxis that have not been controlled by traditional nasal packing, or that recurred immediately upon removal of the nasal packing will be included in this study. Subject will be evaluated during the packing period to determine the effect of hemostasis. Chitosan coated packing will be removed after 48 hours. Subjects' nasal cavities will be examined endoscopically to evaluate bleeding control, morphological changes induced by the chitosan coated packing.~One week after the removal of the packing, the patients will be endoscopically examined to assess the healing of the packed area, to monitor control of bleeding, and observe any potential delayed reaction to the packing material."
62011163|NCT03099135|OTHER|Odalasvir and AL-335 With or Without Simeprevir|Participants who completed the LPVPS (Phase 2 or Phase 3 study), in which they received a regimen containing Odalasvir and AL-335 With or Without Simeprevir for the treatment of HCV infection, and who agree to participate in this follow-up study will be assessed for durability of SVR, incidence of late viral relapse, presence and long term-persistence of resistance associated substitutions (RAS) and liver disease status.
62011164|NCT03915548|EXPERIMENTAL|The Behavioral Activation/ Problem Solving Intervention|BA/PS teaches survivors to a) systematically examine the reasons an activity is challenging, b) set achievable short-term goals that have the potential to improve participation, c) brainstorm solutions including activity adaptations and environmental modifications, d) construct and implement a detailed action plan, and e) evaluate the results and level of goal attainment. The structured process gives participants repeated practice in goal reengagement that leads them progressively closer to their long-term functional goals. The BA/PS framework integrates the cognitive-behavioral therapies of Behavioral Activation and Problem-solving Treatment and incorporates concepts from an occupational therapy theory called the Person-Environment-Occupational Performance Model.
62011165|NCT03915548|ACTIVE_COMPARATOR|Attention Control Condition|"Investigators provide education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts. The control condition will match the intervention in terms of the number of sessions, the delivery by telephone, use of an occupational therapist, and the use of homework between sessions (i.e., reading the education materials for the control condition versus executing the action plan for the BA/PS condition)."
62011166|NCT02071576|EXPERIMENTAL|Proscan|Ametropia Lasik treatment of virgin eyes
62011167|NCT06314698|EXPERIMENTAL|Narlumosbart|120 mg SC Q4W, up to 2 years.
62011168|NCT06314698|ACTIVE_COMPARATOR|Denosumab|120 mg SC Q4W, up to 2 years.
62011169|NCT00965900|ACTIVE_COMPARATOR|Endoscopic band ligation|Endoscopic band ligation until eradication of esophageal varices with 4 weeks interval, and then follow-up endoscopy with 3-6 months interval until 36 months after enrollment
62011170|NCT00965900|ACTIVE_COMPARATOR|Propranolol|start with 20 mg b.i.d, and adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min. After reaching target HR, then follow-up according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)
62011171|NCT00965900|ACTIVE_COMPARATOR|EBL+Propranolol|"* EBL until eradication of esophageal varices with 4 weeks interval, and then follow-up endoscopy with 3-6 months interval until 36 months after enrollment~* start with 20 mg of propranolol b.i.d, and adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min. After reaching target HR, then follow-up according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
62011172|NCT02126254|NO_INTERVENTION|Control group|Control group will be treated in the cardiology and internal medicine departments according to the guidelines for the management of Heart Failure
62011173|NCT02126254|ACTIVE_COMPARATOR|Hemodynamic group|Hemodynamic group patients will be examined in the cardiology and internal medicine departments and treated according to the NICaS system in addition to current guidelines. Patients in this group will be tested within 12 hours from hospitalization and thereafter on an everyday basis until discharge
62011174|NCT06423833|EXPERIMENTAL|Trendelenburg maneuver|The investigator will measure changes in velocity time integral (VTI) and stroke volume (SV) during Trendelenburg maneuver (TM) in high-risk surgical patients by trans-thoracic Doppler echo cardiography
62011175|NCT06423833|ACTIVE_COMPARATOR|Passive leg raising test|The investigator will measure changes in velocity time integral (VTI) and stroke volume (SV) during passive leg raising (PLR) test in high-risk surgical patients by trans-thoracic Doppler echo cardiography
62400459|NCT02767908|ACTIVE_COMPARATOR|Intervention|A home visit will be carried out as soon as practicable after discharge and typically within 48 hours, to deliver a multi-component intervention. Intervention components all have an existing evidence base proving or suggesting potential efficacy for smoking cessation and/or relapse prevention, though their feasibility and importance when delivered as a combined package have not been tested.
62400460|NCT03142984|EXPERIMENTAL|Phase 1|"An open use test in a cohort of newborn babies to confirm the tolerability and evaluate the acceptability of a new Baby Wash \& Shampoo product and Baby Lotion.~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
62400461|NCT03142984|EXPERIMENTAL|Phase 2|"An evaluator blind, randomized, controlled trial to determine whether a wash and lotion regimen used for 12 weeks can strengthen the skin barrier in newborns when compared to standard skincare practices without massage.~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
62576900|NCT06575049||MAXIGESIC|Maxigesig group
62576901|NCT06575049||Ketololac|ketololac group
62576902|NCT02935179|PLACEBO_COMPARATOR|Control Group|Normal diet with 1500\~2000 kcal
62783757|NCT02595294|NO_INTERVENTION|Waiting list control group|- Patients assigned to a 6 week waiting list to receive treatment
62783758|NCT05090852|EXPERIMENTAL|Hi-VNI as primary or adjunct oxygenation technique|Hi-VNI used as a primary or adjunct oxygenation technique during upper airway surgery
62783759|NCT06017505||Subject population|Males and females 50 years of age and over who complete the eSAGE as part of their office visit at the Center for Cognitive and Memory Disorders.
62198594|NCT06149325|EXPERIMENTAL|Repetitive somatosensory stimulation (RSS), then SHAM|Adult patients suffering from post-stroke sensory deficits at the hand. Each participant will participate to the study on two different days, at least a week apart from each other. The length of the experimental session on these two days will be the same: 2 hours in the morning, to perform Pre-evaluation of the tactile acuity, absolute detection, overall hand functionality and manual dexterity, and 3 hours in the afternoon, including 45 minutes of stimulation (RSS or Sham) and 2 hours of Post-evaluation of the tactile acuity, absolute detection, overall hand functionality and manual dexterity. In total, the length of the participation of each patient will be of 10 hours, spread on two days.
62198595|NCT06149325|EXPERIMENTAL|Sham Repetitive somatosensory stimulation (RSS), then RSS|Adult patients suffering from post-stroke sensory deficits at the hand. Each participant will participate to the study on two different days, at least a week apart from each other. The length of the experimental session on these two days will be the same: 2 hours in the morning, to perform Pre-evaluation of the tactile acuity, absolute detection, overall hand functionality and manual dexterity, and 3 hours in the afternoon, including 45 minutes of stimulation (RSS or Sham) and 2 hours of Post-evaluation of the tactile acuity, absolute detection, overall hand functionality and manual dexterity. In total, the length of the participation of each patient will be of 10 hours, spread on two days.
62198596|NCT05451667|EXPERIMENTAL|Cohort 1 (6 active, 2 placebo)|148 mg
62198597|NCT05451667|EXPERIMENTAL|Cohort 2 (6 active, 2 placebo)|296 mg
62198598|NCT05451667|EXPERIMENTAL|Cohort 3 (6 active, 2 placebo)|552 mg
62198599|NCT05451667|EXPERIMENTAL|Cohort 4 (6 active, 2 placebo)|828 mg
62198600|NCT04505839|EXPERIMENTAL|STP1002|
62198601|NCT00340704|EXPERIMENTAL|1. Low dose group|
62400462|NCT00584610|EXPERIMENTAL|1|Levonorgestrel-containing intrauterine device insertion
62576903|NCT02935179|EXPERIMENTAL|Treatment Group|White sweet potato diet with 1500\~2000 kcal
62576904|NCT02602275|EXPERIMENTAL|Neurexan®|0.6 mg / tablet, 3 tablets, 40-60 minutes before the second MRI Intervention: Drug: Neurexan®
62576905|NCT02602275|PLACEBO_COMPARATOR|Placebo|3 tablets, 40-60 minutes before the second MRI
62576906|NCT02075216|EXPERIMENTAL|Myoblasts Preparation|"Myoblast Preparation, Myoblast Transplantation \& Neonatal Cystourethroscope Injection~Approximately 8 to 10 gm muscle will be obtained from the rectus abdominis. Patient muscle fibers will be isolated using the fiber explant technique described by Rosenblatt et al, with some modifications. Culture conditions will be mainly adapted from Rando and Blau.~After 22 days of culture myoblasts will be harvested by trypsinization and incubated in serum-free medium during the last 2 hours before injection. Immediately before injection the cell pellet will be resuspended in autologous serum and/ or platelet rich plasma (PRP)."
62576907|NCT05408208|ACTIVE_COMPARATOR|Methotrexate|Intralesional injection of methotrexate
62576908|NCT05408208|ACTIVE_COMPARATOR|Triamcinolone Acetonid|Intralesional injection of trimethinolone acetonide
62576909|NCT01905917|NO_INTERVENTION|Control|Usual care
62576910|NCT01905917|EXPERIMENTAL|Tele-Rehabilitation|A tele-rehabilitation intervention involving weekly video-conferencing with a therapist, training exercise videos and use of wearable sensors to capture patient participation in exercises.
62198602|NCT00340704|EXPERIMENTAL|2. Medium dose group|
62198603|NCT00340704|EXPERIMENTAL|3. High dose group|
62198604|NCT00332462|EXPERIMENTAL|Cyclosporine (Sandimmun®)|Period 1: Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days followed by Period 2: Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
62198605|NCT04027959|EXPERIMENTAL|Epilation|Hair epilated prior to application of Vitamin B12 solution to skin
62198606|NCT04027959|EXPERIMENTAL|Oleic Acid|Oil is allowed to soak the skin prior to application of Vitamin B12 solution to skin
62198607|NCT04027959|EXPERIMENTAL|No Prep|Skin is cleansed with an alcohol wipe prior to application of Vitamin B12 solution to skin
62011176|NCT04155320|ACTIVE_COMPARATOR|Group A|Subjects are encouraged to disclose their HIV status to their partner(s) with or without a counselor present (Options 1 \& 2).
62400463|NCT00584610|ACTIVE_COMPARATOR|2|Copper containing intrauterine device
62400464|NCT06498570|OTHER|grade 3 keratoconic eyes Grade 3 eyes with stable keratoconus|grade 3 keratoconic eyes Grade 3 eyes with stable keratoconus
62400465|NCT01008059|EXPERIMENTAL|Alfentanil|Alfentanil (0.5-1 mg IV bolus) followed 3 hours later or simultaneously by 1-4 mg oral deuterium-labeled (d3) alfentanil on each study visit.
62576911|NCT04908774|EXPERIMENTAL|Fasting Mimicking Diet Group|The intervention group follows a fasting mimicking diet for 5 days every 6-8 weeks (a total of 3 times in 5 months).
62576912|NCT04908774|NO_INTERVENTION|Control Group|This group maintains their individual diet during the whole time of the study. After 6 months they are offered a fasting intervention.
62576913|NCT02580760||Cosmetic silicone injection|People responding to inclusion criteria with a history of cosmetic silicone injection
62576914|NCT03413267|EXPERIMENTAL|Custard|The food matrix ingested (once by each volunteer) is a custard containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
62576915|NCT03413267|EXPERIMENTAL|Flan|The food matrix ingested (once by each volunteer) is a flan containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
62198608|NCT04243265|EXPERIMENTAL|Patients treated with MPFL reconstruction|"Patients underwent MPFL reconstruction using a minimally invasive technique using a fascia lata allograft performed at the Rizzoli Orthopedic Institute between 2011 and 2015 by the team of Prof. Marcacci.~Clinical and radiographic evaluation will be performed during outpatients visits."
62198609|NCT05029453|EXPERIMENTAL|Experimental Group|apatinib combine with chemotherapy. Apatinib: initial dose: 500mg,oral,once a day, after meal ( try to take the medicine at the same time each day) Recommended chemotherapy: docetaxel(60/75 mg/m2, d1, q3w)、albuminbound paclitaxel(125mg/m2, d1, d8, q3w) or (260mg/m2, d1, q3w)。
62783760|NCT06257173|EXPERIMENTAL|Experimental groups|"The experimental group will be selected among the students who do not take the Patient and Employee Safety course and who volunteer to participate in the study.The experimental group will receive 2 hours of patient safety training with a peer educator. Data collection forms will be applied at the end of the training, and data collection forms will be applied again 6 weeks after the training."
62783761|NCT06257173|NO_INTERVENTION|Control groups|"The control group will be selected among the students taking the Patient and Employee Safety course who volunteer to participate in the studyThe control group will be given 2 hours of patient safety training in the curriculum by the researcher. Data collection forms will be applied at the end of the training, and data collection forms will be applied again 6 weeks after the training."
62783762|NCT01865799||FTC/TDF for PrEP|This prospective case series is composed of every subject in a database containing de-identified patient-level data from all healthcare channels in the US, of individuals that are exposed to FTC/TDF or its components for any indication.
62783763|NCT03650140|ACTIVE_COMPARATOR|Tart cherry concentrate 60 mL|Subjects will receive a single oral dose of 60 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 120 mL dose group.
62783764|NCT03650140|ACTIVE_COMPARATOR|Tart cherry concentrate 120 mL|Subjects will receive a single oral dose of 120 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 60 mL dose group.
62783765|NCT02376972|EXPERIMENTAL|RIFAXIMIN VAGINAL TABLET 25 MG|RIFAXIMIN VAGINAL TABLET 25 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
62783766|NCT02376972|EXPERIMENTAL|RIFAXIMIN VAGINAL TABLET 100 MG|RIFAXIMIN VAGINAL TABLET 100 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
62783767|NCT02376972|PLACEBO_COMPARATOR|PLACEBO VAGINAL TABLET|PLACEBO VAGINAL TABLET ADMINISTERED ONCE A DAY FOR 5 DAYS
62783768|NCT02376972|ACTIVE_COMPARATOR|METROGEL VAGINAL|METROGEL VAGINAL ADMINISTERED ONCE A DAY FOR 5 DAYS
62783769|NCT04292314|EXPERIMENTAL|Omega-3 experimental group|"50 patients from each participating hospital that will receive Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months.~in addition to experimental treatment this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods till efficacy of experimental treatment proved."
62783770|NCT04292314|EXPERIMENTAL|Nigella sativa experimental group|"50 patients from each participating hospital that will receive Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months.~in addition to experimental treatment this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods till efficacy of experimental treatment proved."
62198610|NCT05029453|NO_INTERVENTION|Control Gtoup|chemotherapy Recommended chemotherapy: docetaxel(60/75 mg/m2, d1, q3w)、albuminbound paclitaxel(125mg/m2, d1, d8, q3w) or (260mg/m2, d1, q3w)。
62783771|NCT04292314|EXPERIMENTAL|Hydroxyurea experimental group|"50 patients from each participating hospital that will receive hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods until the efficacy of experimental treatment proved."
62783772|NCT04292314|EXPERIMENTAL|Natural honey experimental group|"50 patients from each participating hospital that will receive natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods until the efficacy of experimental treatment proved."
62783773|NCT04292314|ACTIVE_COMPARATOR|Ordinary hospital treatment group|"50 patients from each participating hospital that will receive the ordinary treatment of iron chelator agent of deferoxamine or deferasirox (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.~in addition to iron chelator agent, this group receive regular blood transfusion session."
62783774|NCT00889642|ACTIVE_COMPARATOR|Active|Contains Lidocaine and Epinephrine
62783775|NCT00889642|PLACEBO_COMPARATOR|Placebo|Contains Epinephrine
62198611|NCT03059277|EXPERIMENTAL|Intravitreal Aflibercept|Intravitreal Aflibercept Injection (IAI)
62783776|NCT03736876|EXPERIMENTAL|Treatment group|These students will receive About Us, an innovative, healthy relationship intervention. The program includes 10 lessons that blend group-based activities with online activities implemented in school-based health centers.
62011177|NCT04155320|EXPERIMENTAL|Group B|Subjects may choose to notify their partners themselves, with or without a counselor present (Options 1 \& 2), or choose to have one or more partners notified anonymously by project staff (Option 3).
62198612|NCT03618199|EXPERIMENTAL|Efficacy of vibrating system on healthy volunteers|
62198613|NCT03618199|EXPERIMENTAL|Efficacy of vibrating system on vestibular patients|
62198614|NCT05809505|EXPERIMENTAL|Multiple Sclerosis Patients|Patients with a diagnosis of multiple sclerosis.
62198615|NCT03133832|EXPERIMENTAL|The cure rate between the two treatment|Compare the cure rate between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
62198616|NCT03133832|EXPERIMENTAL|The amount of eggs produced|Compare the amount of eggs produced between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
62198617|NCT03133832|EXPERIMENTAL|The economic benefit|Compare the economic benefit between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
62198618|NCT03843099|ACTIVE_COMPARATOR|Behavioral Weight Loss + Healthy Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
62198619|NCT03843099|EXPERIMENTAL|Behavioral Weight Loss + Future Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
62198620|NCT01426230||Open Label|"Cohort by age-~- Patients \>70 Yrs old"
62198621|NCT01426230||Open label|"Cohort by age-~- Patients \< 70 Yrs old"
62198622|NCT00263367|OTHER|hyperbaric oxygen at 1.3 ATA|Hyperbaric Oxygen at 1.3 ATA for one hour followed by measurement of glutathione in the blood
62198623|NCT03884322|EXPERIMENTAL|Prepod Group|Premature Infants (31 to 32 weeks gestation on entry to program), healthy who wear a prepod or elastic knit fabric pod with snaps essentially 24 hrs a day with brief breaks for bathing, exams, or parent skin to skin time. The intervention lasts 4 weeks
62198624|NCT03884322|ACTIVE_COMPARATOR|Control Group|Premature infants (31 to 32 weeks of age on entry to program), healthy who receive a joint compression exercise program approximately 10 minutes a day 5 days a week. The intervention lasts 4 weeks
62198625|NCT01299051|ACTIVE_COMPARATOR|Steps to Health|Steps to Health worksite weight management program at Duke.
62198626|NCT01299051|EXPERIMENTAL|Steps to Health Plus!|Steps to Health Plus! worksite weight management program at Duke. Also known as Pathways to Change.
62198627|NCT01299051|NO_INTERVENTION|Observational Comparison|Observational comparison group consisting of employees who are eligible for the study but do not take part will also be used in analyses (approximately 1500 subjects).
62198628|NCT03099902||Cases|Children with asthma/wheezing whose mothers were active smokers during pregnancy
62198629|NCT03099902||Controls|Children without asthma/wheezing whose mothers were active smokers during pregnancy
62198630|NCT04531020||Patients at PACU|Patients undergoing elective surgical or diagnostic intervention admitted to PACU after postanaesthesia recovery
62400466|NCT02730312|EXPERIMENTAL|XmAb14045|Biological/Vaccine: XmAb14045 Administered IV weekly up to 8 weeks
62400467|NCT01644968|EXPERIMENTAL|KLH + anti-OX40|Day 1: KLH + anti-OX40; Day 3: anti-OX40; Day 4: anti-OX40; Day 29: Tetanus vaccine
62400468|NCT01644968|EXPERIMENTAL|Tetanus vaccine + anti-OX40|Day 1: Tetanus vaccine + anti-OX40; Day 3: anti-OX40; Day 5: anti-OX40; Day 29: KLH
62400469|NCT03044691|NO_INTERVENTION|Control Clinic|The control group will have to complete the Adaptive Reserve and Change Process Capability Questionnaire and Clinician Survey at baseline and 9 months. Clinicians will provide their usual care related to tobacco and nicotine product use screening and cessation recommendations. Medical record of patients will be reviewed at baseline and at 6 months.
62400470|NCT03044691|EXPERIMENTAL|Intervention Clinic|Participants will be asked to complete the Youth Tobacco and Nicotine Product Questionnaire and Parent Brief Questionnaire (PBQ) using the ResearchACTS software at the point of care. A follow-up survey Youth Tobacco and Nicotine Product Primary Care survey will be administered to participants at least 30 days after their clinic visit.
62400471|NCT01605370|EXPERIMENTAL|Nebivolol|Subjects randomized to this arm will receive Nebivolol 2.5 mg once daily.
62198631|NCT03847649|ACTIVE_COMPARATOR|Cohort 1: High Risk|
62198632|NCT03847649|ACTIVE_COMPARATOR|Cohort 2: Standard Risk - Arm A|
62400472|NCT01605370|OTHER|Metoprolol succinate|Subjects randomized to this arm will receive metoprolol succinate 50 mg once daily.
62400473|NCT04721431|EXPERIMENTAL|Normal|Body mass index must to be in range limits (18.5-24.9 kg/meter square)
62400474|NCT04721431|EXPERIMENTAL|Overweight|Body mass index must to be in range limits (25-29.9 kg/meter square)
62400475|NCT04721431|EXPERIMENTAL|Obese|Body mass index must to be in range limits (30-34.9 kg/meter square)
62576916|NCT03413267|EXPERIMENTAL|Sponge cake|The food matrix ingested (once by each volunteer) is a sponge cake containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
62576917|NCT03413267|EXPERIMENTAL|Biscuit|The food matrix ingested (once by each volunteer) is biscuits containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
62198633|NCT03847649|ACTIVE_COMPARATOR|Cohort 2: Standard Risk - Arm B|
62400476|NCT06722716||bronchiolitis group|Nasopharyngeal swab
62400477|NCT06722716||healthy group|Infants without RSV bronchiolitis
62400478|NCT05495724|EXPERIMENTAL|Disitamab Vedotin and Tislelizumab|Disitamab Vedotin 120mg IV on day 1 in combination with Tislelizumab 200mg IV on day 2 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.
62400479|NCT05495724|OTHER|Disitamab Vedotin|Disitamab Vedotin 120mg IV on day 1 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.
62400480|NCT04310904||ICU cardiac output (CO) assessment patients|all ICU patients intubated/ventilated with a central line and an arterial catheter who need trans esophageal echocardiography examination with a saline contrast test.
62400481|NCT01463059|PLACEBO_COMPARATOR|Placebo every 2 weeks|Injections administered at week 0, 2, 4, 6, 8 and 10
62576918|NCT01413932|EXPERIMENTAL|HT-2157|
62576919|NCT01413932|PLACEBO_COMPARATOR|Placebo|
62011178|NCT01706952|EXPERIMENTAL|Cocaine|"Cocaine 4%. Three cotton neuropatties will be soaked with 4% cocaine. One neuropattie will be placed in the sphenoethmoidal recess, one in the middle meatus, and one in the anterior end of the middle turbinates on the side that the randomization has determined.~This intervention will be done before the beginning of the surgery, and will be left in the nose for 10 minutes, this will be done just once. After the 10 minutes, the neuropatties will be taken out of the nose."
62011179|NCT01706952|ACTIVE_COMPARATOR|Adrenaline|"Adrenaline 1/1.000 Three cotton neuropatties will be soaked with Adrenaline 1/1,000. One neuropattie will be placed in the sphenoethmoidal recess, one in the middle meatus, and one in the anterior end of the middle turbinates on the side that the randomization has determined.~This will be done before the beginning of the surgery, and will be left in the nose for 10 minutes, this will be done just once. After the 10 minutes, the neuropatties will be taken out of the nose."
62198634|NCT03180567|EXPERIMENTAL|Warfarin resistant patients|Genetic Mutations
62576920|NCT05411783|NO_INTERVENTION|High tie of IMV|The IMV will be tie under the pancreas as the usual procedure in left hemicolectomy and ARR
62576921|NCT05411783|EXPERIMENTAL|Low tie of IMV|The IMV will be tie under the left colic vein
62576922|NCT05581784|EXPERIMENTAL|Pain neuroscience education.|This consists of generating elements from neurobiology and neurophysiology for the understanding of pain from the development of metaphors.
62576923|NCT05581784|OTHER|Conventional treatment or Usual Care|Pharmacological treatment and indications estimated by a specialist in palliative care and pain.
62576924|NCT03839862||Responder|Patient responding to TNF-inhibition
62576925|NCT03839862||non-Responder|Patient not responding to TNF-inhibition
62011180|NCT06113042|EXPERIMENTAL|Comprehensive support (Group 1)|Comprehensive health support will be performed both in district community hub and school. Interventional services include heath talks, learning packs, hub-based comprehensive lifestyle modification programme, school healthy environment evaluation.
62011181|NCT06113042|EXPERIMENTAL|School-based support (Group 2)|Interventional services will be performed in school only, including heath talks, learning packs, school-based lifestyle modification programme, school healthy environment evaluation.
62198635|NCT03180567|PLACEBO_COMPARATOR|Control|Genetic Mutations
62198636|NCT00167206|EXPERIMENTAL|HSCT Patients|Patients who received total body irradiation (450 cGy \[centigray\]) with thymic shielding prior to chemotherapy regimen and Hematopoietic Stem Cell Transplant (HSCT)
62198637|NCT02323958|EXPERIMENTAL|Acupoint stimulation|Electrical stimulation is given through electrodes attached to acupoints
62576926|NCT01091857|EXPERIMENTAL|Exercise intervention (STRIDE)|
62576927|NCT01091857|ACTIVE_COMPARATOR|Health and Wellness Control|
62198638|NCT02323958|PLACEBO_COMPARATOR|Non-acupoint stimulation|Electrical stimulation is given through electrodes attached to non-acupoints
62198639|NCT02323958|SHAM_COMPARATOR|Control stimulation|Electrode attached but no stimulation is given
62576928|NCT02155621|EXPERIMENTAL|Genome Sequencing|There is only one arm to this study.
62576929|NCT02183038|EXPERIMENTAL|Meloxicam low & Placebo|
62576930|NCT02183038|EXPERIMENTAL|Meloxicam high & Placebo|
62576931|NCT02183038|ACTIVE_COMPARATOR|Naproxen sodium & Placebo|
62400482|NCT01463059|EXPERIMENTAL|Olokizumab 60 mg every 2 weeks|Olokizumab 60 mg injections administered at week 0, 2, 4, 6, 8 and 10
62576932|NCT06255496||Obstetric Patients|Obstetric patient population at risk of experiencing excessive bleeding around the time of delivery
62576933|NCT00976742|EXPERIMENTAL|Endurance Exercise Training|
62576934|NCT04946435|EXPERIMENTAL|Drug: Antibiotic Irrigation, and Procedure/Surgery: Nasal Packing|Experimental group will receive nasal packing with antibiotic irrigation.
62011182|NCT06113042|EXPERIMENTAL|District-based support (Group 3)|Interventional services will be performed in community hub only, including heath talks, learning packs, hub-based lifestyle modification programme.
62011183|NCT06113042|PLACEBO_COMPARATOR|Control (Group 4)|Limited services will be provided including health talks and learning packs.
62011184|NCT00123981|ACTIVE_COMPARATOR|CCABG|Coronary artery bypass surgery using cardiopulmonary bypass
62011185|NCT00123981|EXPERIMENTAL|OPCAB|Coronary artery bypass surgery NOT using cardiopulmonary bypass
62011186|NCT04419909|EXPERIMENTAL|Retreatment with CTL019/CTL119|All subjects will receive retreatment with CTL019/CTL119 and be followed per the schedule of procedures.
62011187|NCT00716560||A|Metastatic melanoma treatment with Dartmouth regimen
62011188|NCT03003520|EXPERIMENTAL|DUR + R-CHOP|"On Day 1 of each 21-day cycle, participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP (IV rituximab 375 mg/m\^2, doxorubicin 50 mg/m\^2, vincristine 1.4 mg/m\^2 (maximum dose of 2.0 mg total), and cyclophosphamide 750 mg/m\^2); Participants also were administered daily oral or IV prednisone/prednisolone 100 mg from Day 1 to 5. Induction treatment continued for a total of 6-8 cycles.~Participants who achieve a complete response or partial response continue with consolidation therapy treatment consisting of durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months."
62011189|NCT03003520|EXPERIMENTAL|DUR + R2-CHOP|"Participants start the study on durvalumab in combination with R-CHOP (as described in Arm DUR + R-CHOP). Based on their DLBCL Cell-of-Origin subtype (test typically done between cycles 1 and 2), participants with ABC subtype continue the study taking durvalumab in combination with R2-CHOP. On Day 1 of each 21-day cycle, participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP. Participants were also administered daily oral or IV prednisone/prednisolone 100 mg from Day 1 to 5. In addition, a daily oral lenalidomide 15 mg was administered from Day 1 to 14 of each 21-day cycle. Induction treatment continued for a total of 6-8 cycles.~Participants who achieve a complete response or partial response continue with consolidation therapy treatment consisting of durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months.~Enrollment into Arm B was discontinued."
62011190|NCT02209324|EXPERIMENTAL|ASP2151|
62011191|NCT04776148|EXPERIMENTAL|lenvatinib+pembrolizumab|Participants receive pembrolizumab 400 mg via intravenous (IV) infusion on Day 1 of each 6-week (Q6W) Cycle for up to 18 cycles (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily until progressive disease.
62011192|NCT04776148|ACTIVE_COMPARATOR|standard of care treatment (regorafenib OR TAS-102)|Participants receive regorafenib 160 mg via oral tablet once daily on Days 1 through 21 of each 4-week cycle OR TAS-102 (trifluridine and tipiracil hydrochloride) 35 mg/m\^2 via oral tablet twice a day on Days 1 through 5 and Days 8-12 of each 4-week cycle until progressive disease.
62011193|NCT06204393||COVID-19 has a course of less than 6 days|COVID-19 is mild in hyperthyroidism patients with short course of disease.
62011194|NCT06204393||COVID-19 has a course of 6-9 days|The symptoms and immune level of COVD-19 in this group are in the middle level.
62198640|NCT04678739|EXPERIMENTAL|Group A: Remdesivir + Tocilizumab treatment group|"Drug: Remdesivir Injectable solution Tocilizumab Injectable solution A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (\>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (\>40kg) daily following randomization.~Tocilizumab I/V 8mg/Kg up to 800mg highest 12 hours apart."
62198641|NCT04678739|NO_INTERVENTION|Group B: Control group|Treatment as given without Remdesivir and Tocilizumab.
62011195|NCT06204393||COVID-19 has a course of more than 9 days|Theoretically, the symptoms and immune level of COVD-19 in this group are the worst.
62011196|NCT05889559|NO_INTERVENTION|Control Pressure Monitoring Group|Participants in this group will have pressure monitoring of the anterior compartment of their leg using an indwelling IMP catheter (MY01, MY01 Inc., Montreal, CA). The participants will be treated according to the standard-of-care regarding management of their underlying injury and diagnosis of ACS as practiced by their treating surgeon. Participants will be followed for six months post-injury.
62400483|NCT01463059|EXPERIMENTAL|Olokizumab 60 mg every 4 weeks|Olokizumab 60 mg injection administered at week 0, 4, and 8 and Placebo injection administered at week 2, 6, and 10
62400484|NCT01463059|EXPERIMENTAL|Olokizumab 120 mg every 2 weeks|Olokizumab 120 mg injections administered at week 0, 2, 4, 6, 8 and 10
62400485|NCT01463059|EXPERIMENTAL|Olokizumab 120 mg every 4 weeks|Olokizumab 120 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10
62400486|NCT01463059|EXPERIMENTAL|Olokizumab 240 mg very 4 weeks|Olokizumab 240 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10
62198642|NCT03995316|OTHER|Treatment As Usual + MMB 2.0|Women assigned to use MMB 2.0, along with NorthShore HealthSystem's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.
62783777|NCT03736876|NO_INTERVENTION|Delayed intervention (control group)|These students will receive the business-as--usual condition (e.g., the standard health education that is provided by the school during the study period), and will receive the intervention once the study period has concluded.
62783778|NCT06393179|EXPERIMENTAL|P-V curve group|Enrolled patients will receive a PV curve with a low-flow insufflation of 5 L/min starting from 0 cmH2O to a maximal airway pressure corresponding to the plateau pressure.
62783779|NCT03267888|EXPERIMENTAL|Radiation therapy, pembrolizumab|Patients undergo radiation therapy on day 1. Patients also receive pembrolizumab IV over 30 minutes on day 2 or 3. Courses with pembrolizumab repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
62198643|NCT03995316|OTHER|Treatment As Usual Only|NorthShore HealthSystem's treatment as usual, or usual care, has been in place since 2003. Screen positive women randomized to this condition will receive social work assessment by phone, followed by community mental health referral as indicated. Referrals will vary by need and may include psychotherapy, support groups, or psychiatry. Referrals will include consideration of geographic proximity, insurance, and acuity. Consistent with routine practice, NorthShore staff will document time spent during evaluation and in making specific referrals.
62011197|NCT05889559|EXPERIMENTAL|Tissue Ultrafiltration Intervention Group (TUF)|Participants in this group will have pressure monitoring of the anterior compartment of their leg using an indwelling IMP catheter (MY01, MY01 Inc., Montreal, CA). The participants will be treated according to the standard-of-care regarding management of their underlying injury and diagnosis of ACS as practiced by their treating surgeon. In addition, participants in this group will will undergo three TUF of the anterior compartment of the injured limb. Participants will be followed for six months post-injury.
62198644|NCT00246090|EXPERIMENTAL|1|
62400487|NCT02185131|ACTIVE_COMPARATOR|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
62400488|NCT02185131|ACTIVE_COMPARATOR|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
62783780|NCT00516256|EXPERIMENTAL|CHESS System|CHESS System - Internet-based computer program for 6 months.
62783781|NCT00516256|EXPERIMENTAL|Cancer Information Mentor|Cancer Information Mentor - Phone calls to the patient for 6 months.
62783782|NCT00516256|EXPERIMENTAL|CHESS System + Cancer Information Mentor|CHESS System + Cancer Information Mentor
62783783|NCT03795727|EXPERIMENTAL|Sectional matrix|precontoured sectional matrix band
62783784|NCT03795727|ACTIVE_COMPARATOR|Circumferential matrix|Circumferential matrix band applied by tofflemire retainer
62011198|NCT06523270||prospective cohort|"All adult (≥18 y.o) subjects (until 50000 individuals) presenting to the U.O of Radiologia DiMer Advanced Imaging for Personalized Medicine to be submitted to imaging study on advanced scanner"
62011199|NCT03499652||derivation cohort|The data of derivation cohort are used to derive the neonatal bacterial meningitis risk score
62011200|NCT03499652||validation cohort|The data of validation cohort are used to validate the neonatal bacterial meningitis risk score
62576935|NCT04946435|ACTIVE_COMPARATOR|Procedure/Surgery: Nasal Packing|Patients will be assigned to the control group to collect data on common nasal packing colonization and appropriate antibiotic selection for the experimental group.
62576936|NCT03185195|EXPERIMENTAL|AQX-1125 Oral Tablet|AQX-1125 - Oral Tablet
62576937|NCT03185195|EXPERIMENTAL|[14C]-AQX-1125 IV|Radiolabelled AQX-1125 - Intravenous
62783785|NCT06402032|EXPERIMENTAL|Hesperidin|
62783786|NCT06402032|ACTIVE_COMPARATOR|Mineral trioxide aggregate (MTA)|
62783787|NCT03263260||implanted patients|Patients with native coronary artery lesions with diameter between 2.5 and 4.0 and 34 mm of length treated only with the Inspiron Sirolimus eluting Stent
62783788|NCT02846701|OTHER|patient treated by duloxetine|
62783789|NCT05926024||Cohort A|Women who participated in previous studies namely NCT02167932, NCT02328313, and NCT03761706, will be re-contacted and consented to study activities.
62576938|NCT03185195|EXPERIMENTAL|[14C]-AQX-1125 Oral Solution|Radiolabelled AQX-1125 - Oral Solution
62011201|NCT05304559|EXPERIMENTAL|Drug group|S-ketamine 0.1mg/kg was injected intravenously during anesthesia induction and esmolamine 0.1mg/ (kg.h) was injected intravenously during anesthesia maintenance.S-Ketamine was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
62400489|NCT04479696|EXPERIMENTAL|Arm I (NIRS)|Patients receive standard of care verbal and written education materials. Patients also receive a customized video which includes a description of each of their tumor, functional areas of the brain affected, and possible symptoms from the tumor and radiation treatment based on the neuro-imaging features. Patients and their caregivers watch the video together or separately over 1.5-3 minutes before the end of the first week of radiation treatment. Within 2 weeks after watching the NIRS video, patients complete an optional survey over 5-10 minutes.
62400490|NCT04479696|ACTIVE_COMPARATOR|Arm II (standard of care)|Patients receive standard of care verbal and written education materials.
62400491|NCT06130618|ACTIVE_COMPARATOR|Ozone injection|After localizing the piriformis muscle with ultrasound guidance, 5 ml - 20 μg/mL ozone will be injected.
62400492|NCT06130618|ACTIVE_COMPARATOR|Lidocaine injection|After localizing the piriformis muscle with ultrasound guidance, 5 ml - 2% lidocaine will be injected.
62400493|NCT05083975|EXPERIMENTAL|Buzzy System|Maxillary anesthetic infiltration injection using a conventional 2-ml syringe and a short needle after activating the buzzy device extra orally proximal to the site of injection for 30-60 seconds.
62400494|NCT05083975|ACTIVE_COMPARATOR|Control|Maxillary anesthetic infiltration injection using a conventional 2-ml syringe and a short needle after application of 20% Benzocaine topical anesthestic gel.
62400495|NCT01907373|ACTIVE_COMPARATOR|olmesartan medoxomil, PK of olmesartan|drug: olmesartan medoxomil; dosage form: oral tablet; dosage: 20mg/time; frequency: once a day; duration: 4 days
62400496|NCT01907373|EXPERIMENTAL|olmesartan medoxomil+probenecid, PK of olmesartan|drug1: olmesartan medoxomil; dosage form: oral tablet; dosage: 20mg/time; frequency: once a day; duration: 4 days; drug2: probenecid; dosage form: oral tablet; dosage: 500mg/time; frequency: 2 times/day; duration: 1 day
62576939|NCT04003831|OTHER|Optical Coherence Tomographer|
62576940|NCT01095380|ACTIVE_COMPARATOR|Treadmill training - manual assist (TM)|Participants in the TM group received partial body weight support unilateral or bilateral manual assistance from a trainer for stepping
62400497|NCT02038699|EXPERIMENTAL|ONC201|Oral ONC201 will be administered once every three weeks at various doses.
62400498|NCT03501134||Tumor treating fields|Patients diagnosed with WHO Grade IV malignant glioma who are approved and planned to use the NovoTTF device
62400499|NCT04433858|EXPERIMENTAL|Psilocybin|"25mg of Psilocybin~Note: CA site only is re-dosing participants with an exacerbation in depressive symptoms at a minimum of 12 months post-initial dosing."
62400500|NCT06224569|OTHER|Series of n-of-1 trials administering black tea interventions|A series of n-of-1 trials in which participants will receive 'black tea', 'caffeine-only black tea', and 'placebo black tea'.
62400501|NCT06224569|OTHER|Series of n-of-1 trials administering green tea interventions|A series of n-of-1 trials in which participants will receive 'green tea', 'caffeine-only green tea', and 'placebo green tea'.
62400502|NCT03228615|EXPERIMENTAL|Shared Decision Making Intervention|
62400503|NCT03228615|NO_INTERVENTION|Usual Care Group|
62400504|NCT03447431||MSI colon tumours|MSI colon tumours (as compared to MSS CRCs and matching normal colonic mucosa) Identification of exon/intron sites affected by aberrant splicing events due to MSI in CRC
62400505|NCT04948606||Diroximel Fumarate (DRF)|Participants with a confirmed diagnosis of MS who are newly prescribed DRF in routine clinical practice and who satisfy the approved therapeutic indication for DRF will be enrolled.
62400506|NCT00981331|EXPERIMENTAL|Subtalar joint manipulation|Each subject in this group will recieve a subtalar joint manipulation to their symptomatic ankle
62400507|NCT00981331|SHAM_COMPARATOR|Sham Manipulation|Each subject in this group will recieve a sham subtalar joint manipulation to their symptomatic ankle
62400508|NCT02862002|EXPERIMENTAL|"Therapeutic Patient Education (E.T.P)of type caratif"|Patients in arm E.T.P benefit of the nursing consultation E.T.P,
62400509|NCT02862002|ACTIVE_COMPARATOR|standard care|patients receiving standard care of cancer pain.
62400510|NCT00598442|EXPERIMENTAL|Peginesatide 0.025 mg/kg|
62576941|NCT01095380|ACTIVE_COMPARATOR|Treadmill training - electrical stimulation (TS)|Participants in the TS group received partial body weight support and bilateral functional electrical stimulation to assist stepping
62576942|NCT01095380|ACTIVE_COMPARATOR|Overground Training (OG)|Training over ground with body weight support and electrical stimulation for dorsiflex assistance
62576943|NCT01095380|ACTIVE_COMPARATOR|Treadmill training - locomat robot (LR)|Treadmill training with partical body weight support and assistance of a robotic gait orthosis for stepping
62011202|NCT05304559|EXPERIMENTAL|Device group|The hip fracture was diagnosed clinically on admission and ultrasound-guided iliofascial space block was performed after evaluation, and the analgesia lasted until 2 days after operation.
62011203|NCT05304559|PLACEBO_COMPARATOR|Normal saline group|normal saline 0.1ml/kg was injected intravenously during anesthesia induction and normal saline 0.1ml/ (kg.h) was injected intravenously during anesthesia maintenance.normal saline was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
62011204|NCT06663488|ACTIVE_COMPARATOR|Thoracic spinal anesthesia|Thoracic spinal anesthesia: at T5-T6 or T6-T7 level with a 27G with 4 ml of isobaric bupivacaine 0.5% plus 0.5 ml of 250 ug morphine
62011205|NCT06663488|ACTIVE_COMPARATOR|thoracic epidural anesthesia|Thoracic epidural anesthesia: The epidural needle was inserted At T6-8 space, After verification of the epidural space by resistance loss technique, a test dose of 2 ml of 0.5% bupivacaine will be injected. In the Cephalad direction, the epidural catheter was threaded 3 cm into the epidural space. A total dose of 8-12 ml 0.5 percent plain bupivacaine was injected
62011206|NCT00857181||Liver Cirrhosis|Single cohort of patients with liver cirrhosis to be investigated in the study. Two-monthly measurements of serum cytokines.
62011207|NCT03251924|EXPERIMENTAL|BMS-986226|administered intravenously
62011208|NCT03251924|EXPERIMENTAL|BMS-986226 and Nivolumab|administered intravenously
62011209|NCT03251924|EXPERIMENTAL|BMS-986226 and Ipilimumab|administered intravenously
62011210|NCT01455324||Lower Limb Amputees|Those with lower limb amputations
62011211|NCT01164748||Sentinel Node Biopsy|All women who has Sentinel Node Biopsy as their primary treatment of the axilla
62400511|NCT00598442|EXPERIMENTAL|Peginesatide 0.04 mg/kg|
62400512|NCT00598442|ACTIVE_COMPARATOR|Darbepoetin alfa|
62400513|NCT02764229|EXPERIMENTAL|LYC-30937-EC|LYC-30937-EC 25 mg by mouth once daily
62400514|NCT00253747|ACTIVE_COMPARATOR|Osmotic-Release Methylphenidate|
62783790|NCT05926024||Cohort B|Women with breast cancer, who did not receive chemotherapy, will be consented to be included in the study, and their electronic medical data will be used.
62400515|NCT00253747|PLACEBO_COMPARATOR|Placebo|
62400516|NCT01715480|EXPERIMENTAL|Broccoli sprout homogenate ingestion|Subjects will ingest broccoli sprout homogenate in the form of a shake.
62400517|NCT05324839|EXPERIMENTAL|score 1 before injection|We injected 1-5 u of BoNTA into score 1 crow's feet lines before being included
62400518|NCT05324839|EXPERIMENTAL|score 2 before injection|2-6 u of BoNTA into score 2 crow's feet lines
62400519|NCT05324839|EXPERIMENTAL|score 3 before injection|3-10 u of BoNTA into score 3 crow's feet lines
62400520|NCT05324839|EXPERIMENTAL|score 4 before injection|5-15 u of BoNTA into score 4 crow's feet lines.
62400521|NCT02743117|EXPERIMENTAL|Monovalent Influenza Vaccine|A single dose of 10\^(7.0 +/- 0.5) fluorescent focus units (FFU) strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
62400522|NCT02743117|PLACEBO_COMPARATOR|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
62400523|NCT00636857|EXPERIMENTAL|I|Perioperative fluid management based on body weight
62400524|NCT00636857|ACTIVE_COMPARATOR|II|Perioperative fluid management based on Lean Body Mass (LBM)
62400525|NCT05896072|EXPERIMENTAL|ESP Group|"Erector Spinae Plane Block Group~Drug: 0,25% Bupivacaine 0,5ml/kg (max.20ml) will be used for blocks"
62400526|NCT05896072|ACTIVE_COMPARATOR|Caudal Group|"Caudal Block Group~Drug: 0,25% Bupivacaine 0,5ml/kg (max.20ml) will be used for blocks"
62400527|NCT05580601|EXPERIMENTAL|Cytokine-Induced Memory-Like Natural Killer (CIML-NK) Cells|The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived from the recipient's haploidentical donor's apheresis product.
62576944|NCT04262089|EXPERIMENTAL|primary dMMR uterine cancer patients|primary dMMR uterine cancer patients
62576945|NCT04262089|EXPERIMENTAL|primary POLE-EDM uterine cancer patients|primary POLE-EDM uterine cancer patients
62576946|NCT05836350|ACTIVE_COMPARATOR|4.8 g/m^2/day NaPB|12-week oral administration of 4.8 g/m\^2/day Sodium-phenylbutyrate (NaPB) (in the form of Pheburane)
62576947|NCT05836350|PLACEBO_COMPARATOR|4.8 g/m^2/day Placebo|12-week oral administration of 4.8 g/m2/day identical placebo granules.
62576948|NCT03576963|EXPERIMENTAL|Treatment (guadecitabine, nivolumab)|This study consists of an initial dose escalation followed by an expansion cohort. Dose escalation of guadecitabine starts from 30 mg/m\^2 given SC on days 1-5 every 28 days in combination with fixed dose of nivolumab at 240 mg given IV on days 8 and 22 every 28 days. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered.
62576949|NCT01996007||Children|Pneumococcal nasopharyngeal carriage and immunogenicity in children aged 6-48 months who have previously received PCV13
62011212|NCT01164748||Axillary Lymph Node Dissection|All women who had Axillary Lymph Node Dissection as primary axillary treatment
62783791|NCT05463523||Digital camera|A Real-time Augmented Reality Device with Artificial Intelligence Integration, acquisition of patient skin lesion images as data
62783792|NCT02275156|EXPERIMENTAL|Evolocumab|Participants received a single 140 mg dose of evolocumab subcutaneously on Day 1.
62011213|NCT01377974|ACTIVE_COMPARATOR|Standard Treatment|Meglumine antimoniate as recommended by the Brazilian Ministry of Health
62011214|NCT01377974|EXPERIMENTAL|Tested Intervention|Miltefosine as the tested intervention
62011215|NCT06276478|EXPERIMENTAL|Trial group|
62011216|NCT06276478|ACTIVE_COMPARATOR|Control group|
62011217|NCT03948685|EXPERIMENTAL|Carvedilol SR|Carvedilol SR 8mg, 16mg, 32mg
62011218|NCT03948685|PLACEBO_COMPARATOR|Placebo|Placebo
62400528|NCT01700218|OTHER|telemonitoring|patients in the telemonitoring arm will record vital parameters (blood pressure, heart rate, body weight) and transmit these parameters together with wellbeing and daily dose of heart failure medication
62400529|NCT01700218|OTHER|control|patients in the control arm will not record any vital parameter
62400530|NCT01465958|ACTIVE_COMPARATOR|Intravenous GAMUNEX-C|
62400531|NCT01465958|EXPERIMENTAL|Subcutaneous GAMUNEX-C|
62400532|NCT02014428|EXPERIMENTAL|Hyaluronic acid|220 mg hyaluronic acid per tablet (two tablets/day for 10 days, and subsequently one tablet/day for three months)
62400533|NCT02014428|PLACEBO_COMPARATOR|Placebo|two tablets/day for 10 days, and subsequently one tablet/day for three months
62400534|NCT01062529|EXPERIMENTAL|somatostatin|
62400535|NCT05341011|EXPERIMENTAL|Treatment (TX) Group|The TX group received 14 weeks of the PEERS® intervention immediately following a baseline assessment,
62400536|NCT05341011|EXPERIMENTAL|Delayed Treatment Control (DTC) Group|The DTC group received the same intervention after a 14-week waiting period. Parents and teens attended concurrent sessions held in separate rooms.
62400537|NCT02692404||Hospital Birth|Healthy nulliparous participants, planning spontaneous vaginal or induced vaginal delivery, and planning delivery at a hospital woman-care birth center (Magee-Womens Hospital of UPMC) will be consented to participate in the study at their 3rd trimester clinic visit. Participants and their newborns will be followed for a period of 3 months postpartum. They will be planning to utilize labor epidural analgesia for pain control during labor.
62576950|NCT01996007||Parents|Pneumococcal nasopharyngeal carriage and immunogenicity in parents of children also participating in the study
62576951|NCT04725955|PLACEBO_COMPARATOR|Glucose Solution|
62783793|NCT00235716|EXPERIMENTAL|Arm 1|2,000 IU per day of dl-alpha-tocopherol plus placebo for memantine
62783794|NCT00235716|EXPERIMENTAL|Arm 2|20 mg per day of memantine plus placebo for dl-alpha-tocopherol
62576952|NCT04725955|ACTIVE_COMPARATOR|Wheat bread enriched with a-cyclodextrin|
62576953|NCT04725955|EXPERIMENTAL|Wheat bread enriched with hydroxytyrosol encapsulated in a-cyclodextrin|
62576954|NCT04725955|PLACEBO_COMPARATOR|White wheat bread|
62576955|NCT01522378|EXPERIMENTAL|Biv-ICD|Subjects will be imaged with 123 iodine metaiodobenzylguanidine.
62783795|NCT00235716|EXPERIMENTAL|Arm 3|Combination of 2,000 IU per day of dl-alpha-tocopherol and 20 mg per day of memantine
62198645|NCT02961257|EXPERIMENTAL|Arm A|"Cabazitaxel 25 mg/m² intravenously over 1 hour on Day 1of a 3-week cycle, plus prednisone (or prednisolone) 10 mg orally given daily for a maximum of 10 cycles (ie 30 weeks of treatment).~Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel."
62011219|NCT01790906|ACTIVE_COMPARATOR|RSD+Conventional therapy|We will recruit 100 randomised CHF patients who meet the inclusion criteria.First undergo renal artery angiography procedure to confirm anatomy.If renal artery meet the inclusion criteria,give the renal sympathetic denervation.At the same time, we will use conventional therapy to protect cardiac function.then we will conduct a clinic follow-up and a telephone follow-up.
62011220|NCT01790906|PLACEBO_COMPARATOR|Conventional therapy|We also will recruit 100 randomised CHF patients who meet the inclusion criteria.there are no significant differences in age,gender,race,past medical history,personal history and so on between the two groups.In this group we will use therapy just like the RSD+Conventional therapy group.we will conduct a clinic and a telephone follow-up.
62198646|NCT02961257|EXPERIMENTAL|Arm B|Cabazitaxel 16 mg/m2 on Day 1 and Day 15 of a 4-week cycle plus prednisone (or prednisolone) 10 mg per day up to 10 cycles (ie 40 weeks of treatment). Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel.
62198647|NCT00643617|OTHER|Heterogeneous Dose|38 Gy delivered in 4 fractions of 9.5 Gy per fraction
62198648|NCT05872477|EXPERIMENTAL|Group treatment|There will be 2 arms with intra individual comparison. After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
62198649|NCT05872477|PLACEBO_COMPARATOR|group placebo|"Each grafted side of the body will be randomly assigned to receive twice daily application of placebo cream (Group B).~After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months."
62198650|NCT04918004|EXPERIMENTAL|Case group|Patients in the case group were given one-to-one sleep hygiene training by researchers and, a brochure containing 10 lifestyle changes related to sleep hygiene as well as they assessed at the first interview and the last interview, received routine health care, and
62198651|NCT04918004|NO_INTERVENTION|Control group|Patients in the control group were assessed at the first interview and the last interview, received routine health care, and no intervention was performed during the research.
62198652|NCT05627869|ACTIVE_COMPARATOR|Transversus thoracic muscle plane block|TTPB group will receive bilateral ultrasound-guided transversus thoracic muscle plane block using 20 ml of bupivacaine 0.25% for each side.
62198653|NCT05627869|ACTIVE_COMPARATOR|Pecto-intercostal fascial plane block|PIFB group will receive bilateral ultrasound-guided Pecto-intercostal fascial plane block using 20 ml of bupivacaine 0.25% for each side.
62198654|NCT05631704|EXPERIMENTAL|Part 1: Cohort 1: Participants receiving VH4524184 DL1|Eligible participants will receive VH4524184 Dose Level 1 (DL1) during Cohort 1 of Part 1 of the study.
62198655|NCT05631704|PLACEBO_COMPARATOR|Part 1: Cohort 1: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 DL1 during Cohort 1 of Part 1 of the study.
62198656|NCT05631704|EXPERIMENTAL|Part 1: Cohort 2: Participants receiving VH4524184 DL2|Eligible participants will receive VH4524184 DL2 during Cohort 2 of Part 1 of the study.
62400538|NCT02692404||Midwife Center Birth|Healthy nulliparous participants, planning vaginal delivery under the primary care of a nurse midwife (The Midwife Center for Birth and Womens Health, or UPMC-Mercy) will be consented to participate in the study at their 3rd trimester clinic visit. Participants and their newborns will be followed for a period of 3 months postpartum. They will be planning to avoid labor epidural analgesia for pain control during labor.
62198657|NCT05631704|PLACEBO_COMPARATOR|Part 1: Cohort 2: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 DL2 during Cohort 2 of Part 1 of the study.
62198658|NCT05631704|EXPERIMENTAL|Part 1: Cohort 3: Participants receiving VH4524184 DL3|Eligible participants will receive VH4524184 DL3 during Cohort 3 of Part 1 of the study.
62198659|NCT05631704|PLACEBO_COMPARATOR|Part 1: Cohort 3: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 DL3 during Cohort 3 of Part 1 of the study.
62198660|NCT05631704|EXPERIMENTAL|Part 1: Cohort 4: Participants receiving VH4524184 DL4|Eligible participants will receive VH4524184 DL4 during Cohort 4 of Part 1 of the study.
62198661|NCT05631704|PLACEBO_COMPARATOR|Part 1: Cohort 4: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 DL4 during Cohort 4 of Part 1 of the study.
62576956|NCT02844543|EXPERIMENTAL|Athletes|Participants will be evaluated using the EYE-SYNC eye-tracking device, Desktop Eye-Tracker, and Sport Concussion Assessment Tool (SCAT-3) tool.
62576957|NCT03644394|OTHER|Implantation|Surgical Implantation of IMES sensors
62783796|NCT00235716|PLACEBO_COMPARATOR|Arm 4|Matching placebos for dl-alpha-tocopherol and memantine
62011221|NCT05925517|EXPERIMENTAL|Graded Motor Imagery|Each patient in the Graded Motor Imagery group will receive a treatment protocol consisting of Graded Motor Imagery, conventional physiotherapy, and home exercises.
62576958|NCT02496130||minilaparotomy|Subjects in this group will have tissue (uterus) extracted via mini-laparotomy incision with knife morcellation. Morcellation will be performed within a containment system. Method of extraction/group assignment will be determined clinically by the operating surgeon based on patient characteristics and patient preference.
62783797|NCT02416895||Army recruits|Army recruits at the start of basic training will complete an in vivo immunity model
62011222|NCT05925517|ACTIVE_COMPARATOR|Transcutaneous Electrical Nerve Stimulation (TENS)|Each patient in the Transcutaneous Electrical Nerve Stimulation group will receive a treatment protocol consisting of Transcutaneous Electrical Nerve Stimulation, conventional physiotherapy, and home exercises.
62783798|NCT02051322|EXPERIMENTAL|Jet Nebulizer|Nebulization with a jet nebulizer and a classic mask
62576959|NCT02496130||vaginal extraction|Subjects in this group will have tissue (uterus) extracted via vaginal extraction with knife morcellation. Morcellation will be performed within a containment system. Method of extraction/group assignment will be determined clinically by the operating surgeon based on patient characteristics and patient preference.
62576960|NCT00002924||Source of patient samples|The CALGB conducted a phase III study (CALGB 9583) in which 260 men with AiPC were randomly assigned to antiandrogen withdrawal together with simultaneous ketoconazole and hydrocortisone versus antiandrogen withdrawal alone, followed by sequential ketoconazole and hydrocortisone. Metastatic disease with progression despite castrate levels of testosterone, prior antiandrogen therapy for a minimum of 4 weeks, and a minimum PSA level of 5 ng/mL were required; treatment with sequential antiandrogens was allowed. No prior chemotherapy was allowed. Bone marrow biopsies were obtained from 164 patients enrolled on CALGB 9583 and from 20 patients enrolled on CALGB chemotherapy trials (CALGB 9480, 9680, 9780).
62576961|NCT05988177|EXPERIMENTAL|Carrimycin tablets|Carrimycin tablets
62783799|NCT02051322|EXPERIMENTAL|Trunk Mask Nebulizer|Nebulization with a je nebulizer and a trunk mask
62783800|NCT02051322|EXPERIMENTAL|Aerobika Nebulizer|Nebulization with an Aerobika
62011223|NCT04550481|EXPERIMENTAL|Prevention (lisinopril)|Patients receive lisinopril PO QD for 24 weeks in absence of unacceptable toxicity. Patients undergo transient elastography during screening and on study. Patients also undergo blood sample collection on study and may undergo a PDFF MRI and MRE on study.
62011224|NCT02744846||Children from birth to 5 years|"Children from birth to 5 years where:~1. 1 or more encounters with length and weight measured in the following age interval: 0-12 m, 12-30 m, and~2. \> 1 encounter with height and weight measured in either or both of the following age intervals: 4.0 to 5.9 y (age 5 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data"
62011225|NCT02744846||Children from birth to 10 years|"Children from birth to 10 years where:~1. 1 or more encounters with length and weight measured in each of the following age intervals: 0-12 m, 12-30 m, and~2. \> 1 encounter with height and weight measured in the following age interval: 9.0 to 10.9 y (age 10 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data."
62011226|NCT06599632|EXPERIMENTAL|Baseline phase|There are three baseline phases of 1, 2, or 3 weeks to which participants are block-randomized followed by a 10-week intervention phase. Hence, participants are their own case-controls.
62011227|NCT03545126||Progressive Supranuclear Palsy (PSP)|N=12 Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
62011228|NCT03545126||Corticobasal Degeneration (CBD)|N=8 Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
62011229|NCT03545126||Frontotemporal Dementia: MAPT|N=12 Family members with or at-risk of tau mutations (e.g. P301L) Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
62576962|NCT05491824||Stroke|
62576963|NCT05491824||Non-stroke|
62576964|NCT02782117|EXPERIMENTAL|Treatment Regimen A|Treatment Regimen A will use the Luminopia device for an hour per day for 12 weeks.
62783801|NCT03672058|EXPERIMENTAL|Fitbit plus personalised text messaging & Goal Setting|
62011230|NCT02205892|ACTIVE_COMPARATOR|Lupeol|
62783802|NCT03672058|ACTIVE_COMPARATOR|Fitbit Only|
62783803|NCT04752358|EXPERIMENTAL|Autologous genetically modified ADP-A2M4CD8 cells|
62783804|NCT01252030|EXPERIMENTAL|intervention|stimulation of physical activity by messages sent through e mail or SMS; in combination with monitoring of physical activity with physical activity monitors
62198662|NCT05631704|EXPERIMENTAL|Part 1: Cohort 5: Participants receiving VH4524184 DL5|Eligible participants will receive VH4524184 DL5 during Cohort 5 (optional) of Part 1 of the study.
62400539|NCT06409182|EXPERIMENTAL|Hemopill|HemoPill® acute capsule (Ovesco Endoscopy, Tuebingen, Germany) is a swallowable, wireless, sensor capsule designed for in vivo detection of liquid blood or hematin. The capsule has integrated optical microsensor for blood detection, by transmitting red and violet light via LEDs. It allows the detection of blood by photometric measuring method, in small volumes or in unprepared digestive tract. The dimensions of the capsules are 7.0mm x 26.3mm. The maximal examination time is 9 hours. The HemoPill® receiver is a portable receiver for displaying and storing measured values from the HemoPill® acute capsule. It allows a real-time, wireless, telemetric data transmission. Once activated, the HemoPill® acute capsule can be swallowed by patients with real-time measurement of HemoPill® Indicator (HI). An HI value in the red range suggests a positive finding - liquid blood or hematin has been detected.
62011231|NCT02205892|PLACEBO_COMPARATOR|Vehicle|
62011232|NCT04086472|EXPERIMENTAL|Clesrovimab 100 mg|Participants receive a single IV infusion of clesrovimab 100 mg on Day 1.
62011233|NCT04086472|EXPERIMENTAL|Clesrovimab 200 mg|Participants receive a single IV infusion of clesrovimab 200 mg on Day 1.
62011234|NCT04086472|EXPERIMENTAL|Clesrovimab 300 mg|Participants receive a single IV infusion of clesrovimab 300 mg on Day 1.
62011235|NCT04086472|EXPERIMENTAL|Clesrovimab 900 mg|Participants receive a single IV infusion of clesrovimab 900 mg on Day 1.
62011236|NCT04086472|PLACEBO_COMPARATOR|Placebo|Participants receive a single IV infusion of placebo on Day 1.
62011237|NCT06460727|EXPERIMENTAL|task oriented exercise training on dynamic surface|This group will be provided with task specific exercise training on dynamic surface in cerebral palsy. Following exercises will be performed in this group: Make the child bounce on swiss ball, reaching the toy with both hand kept over the head on platform swing, high sitting on swiss ball throwing ball with both hands, reaching the toy with one hand shifting the wait towards reaching side. Exercise will be conducted 3 times per week for 8 weeks, pre and post session functional mobility will be measured by functional mobility scale and balance will be measured by Time up and Go test
62011238|NCT06460727|EXPERIMENTAL|task oriented training on static surface|This group will be provided with task specific exercise training on static surface in cerebral palsy. The children in this group will receive following TOET: Sit to stand from various cjair heights , standing and reaching indifferent directions for an object, Stepping forwards, backwards, and sideways onto blocks of various heights, walking forward , backward and sideways, Walking up and down stairs. Exercise will be conducted 3 times per week for 8 weeks, pre and post session functional mobility will be measured by functional mobility scale and balance will be measured by Time up and Go test
62011239|NCT02602288|EXPERIMENTAL|AAR+Behavioral Intervention (EXP)|Ask Advise Refer (AAR): WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources. Telebased tobacco counseling: Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke. Mobile phone smoking cessation application: Smartphone based application to support smoking cessation efforts. Nicotine polacrilex: Over the counter nicotine replacement therapy in gum or lozenge form.
62011240|NCT02602288|ACTIVE_COMPARATOR|AAR+Attention Control Intervention (CTL)|Ask Advise Refer (AAR): WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources. Telebased nutrition counseling: Telephone counseling to promote nutritious eating practices in the family. Mobile phone nutrition application: Smartphone based application to support healthy eating habits
62198663|NCT05631704|PLACEBO_COMPARATOR|Part 1: Cohort 5: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 DL5 during Cohort 5 (optional) of Part 1 of the study.
62198664|NCT05631704|EXPERIMENTAL|Part 1: Cohort 6: Participants receiving VH4524184 DL6|Eligible participants will receive VH4524184 DL6 during Cohort 6 (optional) of Part 1 of the study.
62011241|NCT05435573|ACTIVE_COMPARATOR|Crystalloid group|The patients will receive 1000 mL of ringer's acetate solution (250 mL over 5 minutes starting immediately after intrathecal injection using a pressurizer then 500 mL over 55 minutes then 250 mL over 60 minutes).
62576965|NCT00944086||Recruitment Manoeuvre ,Laparoscopy|
62576966|NCT01453088|ACTIVE_COMPARATOR|Treatment A|"Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.~Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.~Dosing will be based on body surface area calculated using actual body weight~Stem cell infusion:~Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.~Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least)."
62576967|NCT01453088|EXPERIMENTAL|Treatment Arm B|"Bortezomib:~Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1."
62783805|NCT01252030|PLACEBO_COMPARATOR|control|no stimulation of physical activity
62783806|NCT06060587|EXPERIMENTAL|Triplet Arm|"Abiraterone+Docetaxel+ADT~Abiraterone Abiraterone acetate will be four (250 mg) tablets (total dose/day 1000 mg). Abiraterone administration is per a 12-week cycle.~Abiraterone must be taken with prednisone. Prednisone will be provided as 5 mg tablets.~Docetaxel Docetaxel on day 1 of each 21-day cycle, 75 mg/m2 via IV. Dexamethasone will be self-administered by the patient at 16 mg per day for 3 days starting 1 day prior to docetaxel infusion.~ADT Patients may be started on an LHRH agonist or antagonist , the selection of the agent is left to the treating investigator for ADT."
62783807|NCT06060587|ACTIVE_COMPARATOR|Doublet Arm|"Abiraterone+ADT~Abiraterone Abiraterone acetate will be four (250 mg) tablets (total dose/day 1000 mg). Abiraterone administration is per a 12-week cycle.~Treatment of abiraterone should start ≤14 days after patient randomization.~Abiraterone must be taken with prednisone. Prednisone will be provided as 5 mg tablets.~Docetaxel Docetaxel on day 1 of each 21-day cycle, 75 mg/m2 via IV. Prior to docetaxel, dexamethasone administration is recommended as discussed, but can be adjusted or altered per the treating investigator's discretion. Dexamethasone will be self-administered by the patient at 16 mg per day for 3 days starting 1 day prior to docetaxel infusion."
62011242|NCT05435573|ACTIVE_COMPARATOR|Crystalloid-colloid group|Patients will receive 250 mL 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride starting immediately after intrathecal injection then 500 mL of ringer's acetate solution then 250 mL of hydroxyethyl starch
62576968|NCT04869774|ACTIVE_COMPARATOR|Virtual Monitoring|Patients discharged from hospital after colorectal surgery will have virtual monitoring of their surgical incision and symptoms, using the mobile application How2Trak, post-operatively.
62576969|NCT04869774|NO_INTERVENTION|Standard of Care|Patients discharged from hospital after colorectal surgery will receive standard of care with no virtual monitoring of their surgical incision and symptoms.
62576970|NCT04062201|EXPERIMENTAL|Study Strategy|
62011243|NCT04518735||Patients on previous oral anticoagulant treatment|Patients receiving chronic anticoagulation with vitamin K antagonists (VKA, warfarin or acenocumarol) or with DOACs (dabigatran, rivaroxaban, apixaban or edoxaban) for any indication
62576971|NCT04062201|ACTIVE_COMPARATOR|Control Strategy|
62576972|NCT00996125|EXPERIMENTAL|Cervarix Group|Subjects received 3 doses of Cervarix vaccine. Cervarix vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
62576973|NCT00996125|EXPERIMENTAL|Placebo Group|Subjects received 3 doses of placebo. Placebo vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
62576974|NCT02138799|EXPERIMENTAL|1: single dose of enzalutamide|
62011244|NCT04518735||Patients on previous antiplatelet therapy|Patients receiving chronic antiplatelet therapy (aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, dipyridamol) for any indication
62011245|NCT04518735||Patients without antithrombotic therapy|Patients receiving nor chronic oral anticoagulation neither chronic antiplatelet therapy
62011246|NCT01696630|ACTIVE_COMPARATOR|Desflurane|Desflurane 6.5% (+/-0.5%) in association with a thoracic epidural analgesia in maintenance phase
62783808|NCT05492201|EXPERIMENTAL|LY3873862 (Part A)|LY3873862 administered orally as single dose.
62783809|NCT05492201|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered orally.
62783810|NCT05492201|EXPERIMENTAL|LY3873862 (Part B)|LY3873862 administered orally as multiple doses.
62783811|NCT05492201|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered orally.
62011247|NCT01696630|EXPERIMENTAL|Xenon|Xenon 60% (+/-5%) in association with a thoracic epidural analgesia in maintenance phase
62198665|NCT05631704|PLACEBO_COMPARATOR|Part 1: Cohort 6: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 DL6 during Cohort 6 (optional) of Part 1 of the study.
62400540|NCT02144311|EXPERIMENTAL|MRI with DW-MRI & DCE-MRI & FDG PET/CT|Study participants will have 1 scan within the 7 days immediately preceding surgery (PET/CT as standard of care and MRI as a research exam). MRI and PET/CT scanning procedures will be identical to those used in routine clinical examinations of the abdomen and pelvis.
62400541|NCT01164631|EXPERIMENTAL|Orthodontic treatment|Snoring patients enrolling for tonsil surgery with maxillary constriction, and/or jaw retrognathism
62400542|NCT01164631|NO_INTERVENTION|Control Group|Patients enrolled for tonsils surgery
62400543|NCT04487626|EXPERIMENTAL|Artificial Intelligence assisted Scoring Group|Patients in this group go through colonoscopy under the AI monitoring device.
62400544|NCT04936126|ACTIVE_COMPARATOR|Quetiapine group|Quetiapine XR 100 mg/day augmentation to the ongoing Sertraline treatment.
62576975|NCT02138799|EXPERIMENTAL|2: multiple doses of rifampin and single dose of enzalutamide|
62576976|NCT01437995|ACTIVE_COMPARATOR|Fluticasone/Salmeterol Diskus 250/50 ug|Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
62576977|NCT01437995|ACTIVE_COMPARATOR|Fluticasone/Salmeterol Diskus 100/50 ug|Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
62576978|NCT01437995|ACTIVE_COMPARATOR|Fluticasone Diskus alone 250 ug|Fluticasone Diskus alone 250 ug twice daily without Salmeterol
62576979|NCT05778968|ACTIVE_COMPARATOR|low ETCO2|
62576980|NCT05778968|ACTIVE_COMPARATOR|normal ETCO2|
62576981|NCT05778968|ACTIVE_COMPARATOR|high ETCO2|
62576982|NCT02654977|EXPERIMENTAL|Metreleptin|Metreleptin open-label
62576983|NCT00687843|ACTIVE_COMPARATOR|1|The TS-1 group
62576984|NCT00687843|EXPERIMENTAL|2|The TS-1+PSK Group
62576985|NCT01582360||antiinfectiva: vancomycin|80 patients Completed.
62576986|NCT01582360||antiinfectiva: meropenem|80 patients recruiting
62576987|NCT01582360||antiinfectiva: flukonazol|80 patients
62576988|NCT01582360||antiinfectiva: cefotaxim|80 patients
62576989|NCT01582360||antiinfectiva: benzylpenicilline|80 patients
62576990|NCT01582360||antiinfectiva: tazobactam piperacillin|80 patients recruiting
62576991|NCT01582360||antiinfectiva: cloxacillin|80 patients
62576992|NCT01582360||antiinfectiva: ciprofloxacin|80 patients
62576993|NCT04075682|NO_INTERVENTION|Standard cigarette packs (control)|Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with the only alteration being the small health warning message on the side of the pack, whose textual content will be the same as that used for the pictorial warning label conditions.
62783812|NCT05492201|EXPERIMENTAL|LY3873862 (Part C)|LY3873862 administered orally as multiple doses.
62783813|NCT05492201|PLACEBO_COMPARATOR|Placebo (Part C)|Placebo administered orally.
62198666|NCT05631704|EXPERIMENTAL|Part 2: Cohort 7: Participants receiving VH4524184 RL1|Eligible participants will receive VH4524184 Repeat dose Level 1 (RL1) during Cohort 7 (Part 2) of the study.
62198667|NCT05631704|PLACEBO_COMPARATOR|Part 2: Cohort 7: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 RL1 during Cohort 7 (Part 2) of the study.
62198668|NCT05631704|EXPERIMENTAL|Part 2: Cohort 8: Participants receiving VH4524184 RL2|Eligible participants will receive VH4524184 RL2 during Cohort 8 (Part 2) of the study. If Cohort 8 is the highest Part 2 dose cohort, participants may also receive midazolam probe before and following repeat dose administration of VH4524184
62400545|NCT04936126|EXPERIMENTAL|Amantadine group|Amantadine 200 mg/day (in two divided doses) augmentation to the ongoing Sertraline treatment
62400546|NCT04936126|EXPERIMENTAL|Pramipexole group|Pramipexole 0.375 mg/day (in three divided doses) augmentation to the ongoing Sertraline treatment
62576994|NCT04075682|EXPERIMENTAL|Cigarette packs with inserts only|Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with packs altered to include inserts with four different rotating messages to promote response efficacy beliefs (2 inserts on the benefits of cessation) or self-efficacy to quit (2 inserts with cessation tips).
62576995|NCT04075682|EXPERIMENTAL|Cigarette packs with pictorial warnings only|Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with packs altered to include four different rotating pictorial warnings showing the consequences of smoking and that cover 50% of the front and back of the pack.
62576996|NCT04075682|EXPERIMENTAL|Cigarette packs with inserts and pictorial warnings|Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with packs altered to include inserts with four rotating efficacy messages (see description above) and four rotating pictorial warnings (see above).
62576997|NCT03271190|EXPERIMENTAL|ENGAGE SPANISH/MUSIC|Cognitive strategies to improve attention and memory skills and application in selected leisure activities (music or Spanish lessons, and videogames) over 4 months.
62576998|NCT03271190|ACTIVE_COMPARATOR|ENGAGE DISCOVERY|Educational program about brain and healthy aging complemented by learning of new information with videogames, documentaries and group discussions over 4 months.
62576999|NCT01545037|ACTIVE_COMPARATOR|Probiotic capsules|L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®. Dosage of 2 capsules per day , corresponding to 100 billions bacterias for a period of 12 weeks.
62783814|NCT05894785|EXPERIMENTAL|Study group|
62783815|NCT00461279|OTHER|1|
62783816|NCT00461279|OTHER|2|
62783817|NCT02990572||Amish and Mennonite|"* Agree to allow access to past, current, and future medical records~* Provide a detailed family health history~* Provide contact information that may be used for future approach regarding research studies"
62783818|NCT03771950|EXPERIMENTAL|Intervention group|Early team based neuro-rehabilitation after Traumatic Brain Injury
62011248|NCT04088461|EXPERIMENTAL|Linagliptin + Metformin and lifestyle|Patients with impaired glucose tolerance randomly assigned to linagliptin 2.5 mg + metftormin 850 mg every 12 hours during 6 months.
62011249|NCT04088461|ACTIVE_COMPARATOR|Metformin|Patients with impaired glucose tolerance randomly assigned to metftormin 850 mg every 12 hours during 6 months.
62011250|NCT05910762|EXPERIMENTAL|Learning and consolidation in Associative Inference|The proposed functional magnetic resonance imaging study assesses the neural representations contributing to humans' ability to associate objects in the support of simple inferences and generalization. All participants will undergo the same procedure. Participants will learn about pairs of objects and then be asked to make judgments and inferences about the relationships between the objects. The order of presentation of the objects will be manipulated within subjects, as different learning theories make different predictions about how learning will unfold under different orderings. Participants will be brought back one week later for a second scan, to evaluate how the neural substrates of these processes change with consolidation.
62011251|NCT05910762|EXPERIMENTAL|Learning and consolidation in category learning|The proposed functional magnetic resonance imaging study assesses the neural representations contributing to humans' ability to learn new categories of objects. All participants will undergo the same procedure. Participants will learn about novel objects, each with several colored parts. Some parts are unique to individual objects and others are shared among the members of the category. The investigators will assess how different regions of the brain contribute to learning and remembering these different kinds of parts, and how the resulting representations support category understanding. Participants will be brought back one week later for a second scan, to evaluate how the neural substrates of these processes change with consolidation.
62198669|NCT05631704|PLACEBO_COMPARATOR|Part 2: Cohort 8: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 RL2 during Cohort 8 (Part 2) of the study. If Cohort 8 is the highest Part 2 dose cohort, participants may also receive midazolam probe before and following repeat dose administration of Placebo matching VH4524184.
62198670|NCT05631704|EXPERIMENTAL|Part 2: Cohort 9: Participants receiving VH4524184 RL3|Eligible participants will receive VH4524184 RL3 during Cohort 9 (Part 2) (optional) of the study. If Cohort 9 is the highest Part 2 dose cohort, participants may also receive midazolam probe before and following repeat dose administration of VH4524184.
62198671|NCT05631704|PLACEBO_COMPARATOR|Part 2: Cohort 9: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 RL3 during Cohort 9 (Part 2) (optional) of the study. If Cohort 9 is the highest Part 2 dose cohort, participants may also receive midazolam probe before and following repeat dose administration of Placebo matching VH4524184.
62198672|NCT05631704|EXPERIMENTAL|Part 3: Cohort 10: VH4524184 Fasted/ VH4524184 Fed|Eligible participants will receive VH4524184 under fasted condition in Treatment Period 1 followed by VH4524184 under fed condition in Treatment Period 2 during Cohort 10 (Part 3) of the study. Treatment Periods will be separated by a washout period.
62400547|NCT00535262|EXPERIMENTAL|EmSam|EmSam will be administered in open-label fashion for 8-weeks during phase I of the study during which symptoms of depression will be assessed weekly. Those whose depression responds after 8-weeks will be entered into an 8-month open-label continuation phase during which they will be maintained on EmSam and be assessed on a monthly basis.
62400548|NCT04740762|EXPERIMENTAL|Intervention group|The study group were provided with individual counseling program and followed in this study, in addition to the usual care provided by healthcare professionals.
62783819|NCT03771950|NO_INTERVENTION|Control group|Treatment as usual.
62783820|NCT06124261||MASLD and PCOS hyperandrogenism|Patients with MASLD and PCOS with the phenotype of hyperandrogenism
62783821|NCT06124261||MASLD and PCOS non-hyperandrogenism|Patients with MASLD and PCOS with the phenotype of non-hyperandrogenism
62783822|NCT06124261||MASLD and no-PCOS|Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and no PCOS
62011252|NCT05910762|EXPERIMENTAL|Manipulating replay during sleep using real-time EEG|In the proposed electroencephalography (EEG) study, all participants will undergo the same procedure. Participants will learn the visual features and spoken names associated with three categories of novel objects. Participants' memory for these objects and the objects' parts will be tested before and after a nap. The investigators will monitor brain activity during the nap in real time and, at optimal moments, quietly play the spoken names of the objects to encourage reactivation of particular objects in particular orders. The investigators will assess how this manipulation impacts memory for these objects.
62011253|NCT04065347||Group 1|A total of 150 participants taking tenofovir alafenamide will be enrolled in this cohort.
62400549|NCT04740762|NO_INTERVENTION|Control group|The control group continued to receive the routine care
62400550|NCT06557356|EXPERIMENTAL|LY3532226 (Part A)|LY3532226 administered subcutaneously (SC)
62400551|NCT06557356|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered SC
62783823|NCT05793242|ACTIVE_COMPARATOR|Static stretching|The static stretch group participants will perform a self-facilitated stretch by looping a strap around the heel of their foot and grasping it with both hands followed by pulling the strap to raise the fully extended leg into hip flexion. The participant will then lift the leg until they reach their maximal tolerable point and then alternate between periods of resting and stretching for a total of 5 minutes.
62783824|NCT05793242|EXPERIMENTAL|Hypervolt|The HyperVolt percussive massage group participants will receive a therapist-performed HyperVolt technique to the hamstrings for a period of 5 minutes.
62783825|NCT05793242|EXPERIMENTAL|Body tempering|The body tempering group participants will receive a therapist-performed body tempering technique to the hamstrings for a period of 5 minutes.
62783826|NCT05793242|EXPERIMENTAL|Dry cupping|The dry cupping group participants will receive a therapist-performed dry cupping technique to the hamstrings for a period of 5 minutes.
62011254|NCT04065347||Group 2|A total of 30 participants initiating/re-initiating tenofovir alafenamide will be enrolled in this cohort.
62011255|NCT04380584||I|30 patients with type 2 DM with nephropathy
62011256|NCT04380584||II|30 type 2 DM without nephropathy
62011257|NCT04380584||III|30 non DM as control group
62400552|NCT06557356|EXPERIMENTAL|LY3532226 (Part B)|LY3532226 administered SC
62400553|NCT06557356|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered SC
62400554|NCT05248633|ACTIVE_COMPARATOR|Radiotherapy|
62400555|NCT05248633|EXPERIMENTAL|Chemotherapy combined with radiotherapy|
62400556|NCT04465643|OTHER|Immunotherapy with Nivolumab and Ipilimumab|Nivolumab 4.5 mg/kg every 3 weeks (Q3W) x 2 Ipilimumab 1 mg/kg Q3W x 2 Nivolumab monotherapy 4.5mg/kg Q3W concurrent with standard therapy Nivolumab monotherapy should be held for at least 2 weeks before and 2 weeks after surgery
62577000|NCT01545037|PLACEBO_COMPARATOR|Placebo capsules|The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria. Dosage of 2 capsules per day , corresponding to 100 billions bacterias for a period of 12 weeks
62577001|NCT01037179|EXPERIMENTAL|AL-4943A|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, 2 drops instilled in each eye twice daily for 10 weeks
62783827|NCT04649684|EXPERIMENTAL|Conventional robot-assisted gait training group|they got conventional robot-assisted gait training, guidance force given equally to both limbs
62783828|NCT04649684|EXPERIMENTAL|Lower CIMT robot-assisted gait training group|they got robot-assisted gait training based on CIMT concept
62783829|NCT03533244|PLACEBO_COMPARATOR|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
62783830|NCT03533244|EXPERIMENTAL|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
62783831|NCT03533244|EXPERIMENTAL|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
62011258|NCT06245070|EXPERIMENTAL|Active high definition transcranial direct current stimulation (HD-tDCS)|High-definition anodal transcranial direct current stimulation (2 milliamps \[mA\]) for 5 consecutive days (one session per day for 20 minutes each). The electrical current will be administered over the left Supplementary motor area. The stimulation will be delivered at an intensity of 2 milliamps (mA) for a maximum of 20 minutes.
62011259|NCT06245070|EXPERIMENTAL|Sham high definition transcranial direct current stimulation (HD-tDCS)|High-definition sham transcranial direct current stimulation (2 milliamps \[mA\]) for 5 consecutive days (one session per day for 20 minutes each). The electrical current will be administered over the left Supplementary motor area. The current will be ramped up for the first 30 seconds following which the intensity will drop to 0 milliamps (mA).
62011260|NCT01845155|EXPERIMENTAL|Music Therapy|Neuro-Music-Therapy according to the Heidelberg Model
62198673|NCT03750864|EXPERIMENTAL|ACT-LCS Therapy|Intervention is psychosocial counseling utilizing Acceptance and Commitment Therapy for Lung Cancer Stigma (ACT-LCS) as a patient-focused intervention to reduce the self-blame, guilt and inhibited disclosure associated with lung cancer stigma.
62198674|NCT01871337|EXPERIMENTAL|Paula method|"the Paula method, a circular muscle exercise, invented in Israel by Paula Garbourg.The method is based on the principle that all sphincters in the body are synchronized, with the movement of one affecting the other.One can rehabilitate damaged muscles by contracting and relaxing specific circular muscles in other parts of the body."
62198675|NCT05304234|ACTIVE_COMPARATOR|Ultrasound + AFP|Screening by abdominal ultrasound + serum AFP testing at 0, 6 and 12 months
62198676|NCT05304234|ACTIVE_COMPARATOR|aMRI + AFP|Screening by abbreviated MRI of the abdomen + serum AFP testing at 0, 6 and 12 months
62198677|NCT03058393|EXPERIMENTAL|Teach-Back Group|A teach-back lesson will be provided to physician participants (Teach-Back Group), who are participating in challenging clinical discussions with patients
62198678|NCT03082937|EXPERIMENTAL|3 mg [14C]-A4250 capsule|
62198679|NCT01758679|EXPERIMENTAL|Licartin，Licartin and CIK|Intravenous Licartin 27.75 M Bq(0.75 mCi)/kg Licartin and CIK
62198680|NCT04154852|EXPERIMENTAL|TNF-antagonist|Adalimumab, 40 mg, 2-weekly Methotrexate, rapid escalation to 25mg, weekly Folic Acid 5mg, 6 days a week
62198681|NCT04154852|ACTIVE_COMPARATOR|Placebo + MTX|Placebo, 2 weekly Methotrexate, rapid escalation to 25mg, weekly Folic Acid 5mg, 6 days a week
62577002|NCT01057966|EXPERIMENTAL|ICAPS AREDS Softgel Capsule - Full Strength|ICAPS Eye Vitamin and Mineral Supplement - Softgel
62011261|NCT01845155|ACTIVE_COMPARATOR|Counselling|Counselling
62011262|NCT03756220|EXPERIMENTAL|Treatment|Combination therapy of vitamin C and thiamine for 2 days.
62011263|NCT03756220|PLACEBO_COMPARATOR|Control|Normal Saline Solution
62198682|NCT02334280|EXPERIMENTAL|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
62198683|NCT02334280|NO_INTERVENTION|Usual-Care Control|Usual-care consumers agreed to delay participation in In SHAPE for 12 months.
62198684|NCT05600140|EXPERIMENTAL|Group A) early training group|T0 = baseline measurement T1 = posttest (within two weeks after training) T2 = follow up measurement (6 months after training)
62198685|NCT05600140|EXPERIMENTAL|Group B) late training group|T0 = baseline measurement T1 = test-retest reliability and natural development (over period 1 1/2-2 months after T0) T2 = posttest (within two weeks after training)
62198686|NCT03143738|EXPERIMENTAL|continuous anesthesia of adductor canal|
62198687|NCT03143738|EXPERIMENTAL|continuous anesthesia of femoral nerve|
62198688|NCT04481685|ACTIVE_COMPARATOR|ATI-450|Treated with 50 mg dose of ATI-450, orally, twice daily for 14 days
62198689|NCT04481685|PLACEBO_COMPARATOR|Placebo|Treated with matched placebo, orally, twice daily for 14 days
62577003|NCT01057966|EXPERIMENTAL|ICAPS AREDS Softgel Capsule - Half Strength|ICAPS Eye Vitamin and Mineral Supplement - Softgel (half -strength)
62577004|NCT01057966|EXPERIMENTAL|ICAPS AREDS coated tablets - Full Strength|ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets
62577005|NCT03316391||Pre-eclampsia|Patients in hospital for pre-eclampsia at the Hopital Femme-Mère-Enfant
62577006|NCT04290715||group A|
62577007|NCT04290715||group I|
62577008|NCT00607074|EXPERIMENTAL|1|
62783832|NCT00863005|EXPERIMENTAL|1. K201|
62783833|NCT00863005|ACTIVE_COMPARATOR|2.|
62783834|NCT01211314|EXPERIMENTAL|lercanidipine-enalapril fixed combination|uncontrolled hypertensive patients will receive fixed combination therapy
62783835|NCT05113030||Test group(1st)|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADOLESCENT AGE GROUP WILL BE ASSESSED
62783836|NCT05113030||Test group(2nd)|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADULT AGE GROUP WILL BE ASSESSED
62783837|NCT03688516|EXPERIMENTAL|Atypical development|30 children with Williams-Beuren syndrome will be presented with two tasks of episodic memory, one with visual stimuli and another one with audio-verbal stimuli. Manipulation of valence and modality (negative, positive, neutral) in order to measure influence of emotion on episodic memory:Spatial and recognition memory ans source and content memory. The tasks will be presented one after another with a break of 15 minutes. In both tasks the participants will have to encode the stimuli and then first recall them and second to recognize the encoded stimuli amongst new stimuli. The stimuli will be presented on the computer. The responses will be collected by the experimenter for recall task and by the computer for recognition task. During the recognition task the EEG recording will be done.
62198690|NCT03755011|EXPERIMENTAL|patients exposed to white noise|Six patients in the interventional arm will have white noise (through in-room workstations- on-wheels and publicly-available white noise websites) playing overnight at a standardized volume to be determined; pausing will be at nurse, provider, and patient discretion during routine care and conversations with the patients.
62198691|NCT03755011|PLACEBO_COMPARATOR|usual care|Six patients exposed to normal ICU activity noise.
62400557|NCT06717321|ACTIVE_COMPARATOR|PEG arm: Patients receiving the 20-French pull-type PEG tube|"PEG Arm:~Participants receive a 20-French pull-type percutaneous endoscopic gastrostomy tube placed into the stomach using standard safe track technique with transillumination and 1:1 finger indentation. The tube is positioned midway between the greater and lesser curves of the stomach. Continuous tube feeds begin 24 hours after placement. Follow-up period is 30 days."
62577009|NCT04120649||endomterial cancer|All patients visiting the clinic at Women Health Hospital who having endometrial carcinoma with their diagnosis based on investigations (tumor marker ) , imaging, histopathology will have surgical staging consisted of total hysterectomy, bilateral salpingo-oopherectomy (based on the age of the patient), pelvic and para-aortic lymphadenectomy, and peritoneal washings
62577010|NCT04344028|EXPERIMENTAL|True Cognitive Training Placebo|"Participants will receive a positive expectation message (e.g., Previous research has shown that training with this program improves performance on other tasks.) and will complete approximately 7 hours of a cognitive training program that has previously been shown to improve cognition."
62783838|NCT03688516|SHAM_COMPARATOR|Typical development|30 control children matched for mental age will be presented with two tasks of episodic memory, one with visual stimuli and another one with audio-verbal stimuli. Manipulation of valence and modality (negative, positive, neutral) in order to measure influence of emotion on episodic memory:Spatial and recognition memory ans source and content memory. The tasks will be presented one after another with a break of 15 minutes. In both tasks the participants will have to encode the stimuli and then first recall them and second to recognize the encoded stimuli amongst new stimuli. The stimuli will be presented on the computer. The responses will be collected by the experimenter for recall task and by the computer for recognition task. During the recognition task the EEG recording will be done.
62783839|NCT01625546|EXPERIMENTAL|High intensity whole-body infrared heating|Subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C using the Whole Body Hyperthermia system.
62783840|NCT01625546|SHAM_COMPARATOR|Low intensity whole-body infrared heating|Subjects will be induced to levels of heat that causes only a minor increase in body temperature using Whole Body Hyperthermia system.
62783841|NCT01930721|EXPERIMENTAL|incision angle of 60 degrees|episiotomy incision angle will be defined as 60 degree as measured before cutting.
62783842|NCT01930721|EXPERIMENTAL|incision angle 40 degree episiotomy|incision angle of episiotomy will be defined as 40 degree as measured before cutting.
62577011|NCT04344028|ACTIVE_COMPARATOR|True Cognitive Training Nocebo|"Participants will receive a negative expectation message (e.g., Previous research has shown that training with this program decreases performance on other tasks.) and will complete approximately 7 hours of a cognitive training program that has previously been shown to improve cognition."
62783843|NCT04209933|ACTIVE_COMPARATOR|Bismuth potassium citrate containing quadruple therapy|Bismuth potassium citrate 220 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
62783844|NCT04209933|ACTIVE_COMPARATOR|Colloidal pectin bismuth capsules containing quadruple therapy|Colloidal pectin bismuth capsules 200 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
62011264|NCT00627406|EXPERIMENTAL|A|More than 14 follicles with a diameter of \> 11mm: triggering of ovulation with 0.5 mg GnRHa (Buserelin) (s.c.) + 1500 IU hCG (Pregnyl)
62783845|NCT04209933|ACTIVE_COMPARATOR|Colloidal pectin bismuth particles A quadruple therapy|Colloidal pectin bismuth particles 150 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
62783846|NCT04209933|ACTIVE_COMPARATOR|Colloidal pectin bismuth particles B quadruple therapy|Colloidal pectin bismuth particles 300 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
62783847|NCT06202040|ACTIVE_COMPARATOR|Group 1:OSTAPand RSB|Group 1 will consist of patients who received general anesthesia, and just before the surgery started, bilateral OSTAP and RSB will be performed.
62783848|NCT06202040|NO_INTERVENTION|Group 2: Intravenous analgesia|Group 2 will include patients who received general anesthesia and were administered intravenous analgesia approximately 30 minutes before the end of the operation.
62011265|NCT00627406|ACTIVE_COMPARATOR|B|More than 14 follicles with a diameter of \> 11mm: triggering of ovulation with hCG (Pregnyl) 5.000 IU (s.c.)
62011266|NCT00627406|EXPERIMENTAL|C|14 or less follicles with a diameter of \> 11mm: triggering of ovulation with 0.5 mg GnRHa (Buserelin) (s.c.) + 1500 IU hCG (Pregnyl) (s.c.) at 35 hours and 1500 IU hCG (Pregnyl) (s.c.) 7 days after triggering of ovulation (OPU + 5)
62783849|NCT00583063|EXPERIMENTAL|A|Sunitinib taken by mouth every day. Rapamycin (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.
62783850|NCT00583063|EXPERIMENTAL|B|Rapamycin taken by mouth every day. Sunitinib (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.
62783851|NCT05100576|EXPERIMENTAL|Active group|This group gets the telemedicine system, with the devices, and gets life-style guide by telephone consultation/ visits, during 3 months
62783852|NCT05100576|NO_INTERVENTION|Comparator group|This group gets the normal, evidence based therapy, without extra visits.
62783853|NCT01957410|EXPERIMENTAL|Ketamine Intravenous (IV)|Patients will receive a single IV dose of ketamine given as a continuous infusion.
62783854|NCT01957410|PLACEBO_COMPARATOR|Placebo Intravenous (IV)|Patients will receive a single IV dose of placebo given as a continuous infusion.
62783855|NCT06584123|EXPERIMENTAL|Study cohort|All patient's enrolled in the study will undergo an 18F-FET-PET
62783856|NCT03088943|OTHER|TTE Apical 4 Chamber View|Patients will receive TTE apical 4chamber echo examinations prior to induction and after induction
62783857|NCT03088943|OTHER|TEE dTG View|Patients will receive TEE deep transgastric echo examinations after induction and after cardiopulmonary bypass induction (paced at 80, 100, and 120 bpm)
62011267|NCT00627406|ACTIVE_COMPARATOR|D|14 or less follicles with a diameter of \> 11mm: triggering of ovulation with 5000 IU hCG (Pregnyl) (s.c.)
62011268|NCT05379959|EXPERIMENTAL|Experimental: Placebo Then MDMA Then Methamphetamine|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 5 days later and will receive 125 mg MDMA. Finally, 5 days later will return to the laboratory and will receive 20 mg of MA.
62783858|NCT03088943|OTHER|TEE ME 4C View|Patients will receive TEE midesophageal 4chamber echo examinations after induction and after cardiopulmonary bypass induction (paced at 80, 100, and 120 bpm)
62783859|NCT04908358|SHAM_COMPARATOR|Sham preceded by cross-over Sham-Stimulation|Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Wash-out period of four weeks Ten daily sessions of sham during 2 weeks
62783860|NCT04908358|SHAM_COMPARATOR|Sham preceded by cross-over Stimulation-Sham|Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by Sham Wash-out period of four weeks Ten daily sessions of sham during 2 weeks
62783861|NCT04908358|EXPERIMENTAL|Stimulation preceded by cross-over Sham-Stimulation|Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Wash-out period of four weeks Ten daily sessions of RAVANS during 2 weeks
62783862|NCT04908358|EXPERIMENTAL|Stimulation preceded by cross-over Stimulation-Sham|Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by sham Wash-out period of four weeks Ten daily sessions of RAVANS during 2 weeks
62783863|NCT04908358|OTHER|cross-over Stimulation-Sham|Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by sham One time RAVANS versus one time Sham Two weeks wash-out
62783864|NCT04908358|OTHER|cross-over Sham-Stimulation|Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) One time RAVANS versus one time Sham Two weeks wash-out
62783865|NCT01601665||Toric High Cylinder Power IOL|Toric high cylinder power intraocular lens implanted during cataract surgery in the first operative eye, with the second operative eye implanted within 30 days of the first implantation.
62198692|NCT06231810|EXPERIMENTAL|Stimulus magnitude|Differing levels of tactile stimulus will be applied
62198693|NCT02450812||Radium-223-dichloride (Xofigo, BAY88-8223)|patients with mCRPC with symptomatic bone metastases
62783866|NCT01601665||Monofocal IOL|Monofocal intraocular lens implanted during cataract surgery in the first operative eye, with the second operative eye implanted within 30 days of the first implantation.
62198694|NCT04243512|EXPERIMENTAL|Time-restricted eating|Participants will be asked to follow a TRE meal pattern for 14 consecutive days. Participants will be encouraged to consume food and beverages only within a 10-h time window for the 14-day intervention, with the exception of water, which will be encouraged at any time.
62198695|NCT06105853|EXPERIMENTAL|Experimental|"All participants will be exposed to the Trier Social Stress Test, followed by an alcohol cue-exposure in a barlab environment and functional magnetic resonance imaging assessing neural alcohol cue-reactivity, inhibition performance, emotion processing and resting state functional connectivity twice on two consecutive days.~Interventions:~Behavioral: Trier Social Stress Test~Behavioral: Cue-Exposure to the favorite drink in a barlab setting"
62198696|NCT00542204|EXPERIMENTAL|Online disease management|The PAMFOnline-mediated Personalized Health Care Program, which couples a multidisciplinary diabetes care management team with an EHR-integrated Online Disease Management (ODM) system.
62198697|NCT00542204|NO_INTERVENTION|Usual care|Usual medical care. No access to the PHCP electronic system and self-management tools supporting this care management.
62400558|NCT06717321|ACTIVE_COMPARATOR|PEG-J arm: Patients receiving the 24-French pull-type PEG with 12-French jejunal extension tube|Participants receive a 24-French pull-type percutaneous endoscopic gastrostomy tube with a 12-French jejunal extension. After standard PEG placement, the jejunal extension tube is advanced past the pylorus and secured to the small bowel wall with endoclips as indicated. Continuous tube feeds begin 24 hours after placement. Follow-up period is 30 days.
62198698|NCT02202785|EXPERIMENTAL|MLN0264 1.8 mg/kg|MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
62400559|NCT01314508|OTHER|All patients will be treated with IGF-1 factors|Patients will serve as their own control.
62400560|NCT03710824||Nintedanib for patients with Idiopathic Pulmonary Fibrosis|
62400561|NCT04482894|EXPERIMENTAL|Palliative Care Intervention|Participants on this arm will see a palliative care specialist twice a week while they are in the hospital and about every other week when they are out of the hospital. If participants see their oncologist less often than every other week while they're out of the hospital, then visits with the palliative care specialist would be timed to occur on the same day as the oncologist visit. Participants will complete a questionnaire about once a month.
62400562|NCT04482894|NO_INTERVENTION|Standard Clinical Care|Participants will see a palliative care specialist only if they have a referral from their oncologist according to standard clinical care. Participants on this arm will not be discouraged from requesting a consult.
62400563|NCT04311814|OTHER|v-MUCP value|All patients referred for urodynamics explorations will have a measure of the MUCP during a Valsalva manoeuver
62400564|NCT02337543|EXPERIMENTAL|Active: NEO6860|NEO6860 suspension is the drug under evaluation
62400565|NCT02337543|PLACEBO_COMPARATOR|placebo|Placebo matching NEO6860 suspension formulation
62400566|NCT05075109|EXPERIMENTAL|High Frequency TENS|high frequency TENS (100 Hz, 200 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks combined with task related training.
62783867|NCT05766657|EXPERIMENTAL|Intervention group|Children with obesity or T1D will be randomized into this group. An individualized dietary approach will be used in this group of children.
62198699|NCT01885689|EXPERIMENTAL|Treatment (clofarabine, melphalan, transplant)|"CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4.~TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure."
62198700|NCT06457243|EXPERIMENTAL|Closed-loop cTBS stimulation based on addiction-induced states|In the initial phase of this study, participants will be subjected to individual closed-loop cTBS interventions at varying frequencies for one-week intervals. Concurrently, they will be exposed to MA-related cue paradigms to induce brain addiction states, while scalp EEG signals are collected. Stimulation will be initiated only upon identifying specific neural signals associated with MA cues, aiming to ascertain the optimal frequency for single-session closed-loop cTBS stimulation that could elicit individual neurological responses. Subsequently, we will embark on a longitudinal closed-loop cTBS intervention control study for MA dependents at one-week intervals, which involves addiction-induced closed-loop cTBS stimulation, random time-point stimulation, and traditional continuous stimulation, to rectify potential sequence effects and delineate the disparities in neurological and behavioral impacts between discrete and continuous stimulations based on brain states.
62011269|NCT05379959|EXPERIMENTAL|Experimental: MDMA Then Placebo Then Methampetamine|Participants first receive 125 mg of MDMA at their first session in the laboratory. Then will return to the laboratory 5 days later and will receive placebo. Finally, 5 days later will return to the laboratory and will receive 20 mg of MA.
62011270|NCT05379959|EXPERIMENTAL|Experimental: Methampetamine Then Placebo Then MDMA|Participants first receive 20 mg of MA at their first session in the laboratory. Then will return to the laboratory 5 days later and will receive placebo. Finally, 5 days later will return to the laboratory and will receive 125 mg of MDMA.
62198701|NCT05602753||Smokers|All patients who participate in the study will complete the smoking history questionnaire and the carbon monoxide breath test. All patients with positive carbon monoxide breath test indicative of active nicotine exposure will be provided a structured smoking cessation program that includes information, counseling from their surgeon, or a trained health care professional and referral to a smoking cessation program.
62198702|NCT05602753||Non-Smokers|Subjects who self-declared as non-smokers
62400567|NCT05075109|EXPERIMENTAL|Low Frequency TENS|low frequency TENS (20 Hz, 0.2 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks with task related training.
62198703|NCT05602753||Declared non-smokers with elevated Co2|subjects who self-declared as non-smokers but who tested positive for elevated Co2,
62400568|NCT05075109|ACTIVE_COMPARATOR|Task Related Training|postural control, shoulder mobilization, weight bearing exercises, functional activities that will comprise of simple tasks to more advanced movement patterns
62198704|NCT06249997|EXPERIMENTAL|Leniolisib|"Leniolisib - Film coated tablets~Leniolisib tablets in doses ranging from 40 to 70 mg twice daily (BID) based on body weight.~A Part 1 clinical study report will be generated once the last patient completes the Day 85 Visit for Part 1. Patients who complete the Day 85 Visit will enter the Extension Period of the study (Part 2), in which patients will be administered leniolisib doses ranging from 40 to 70 mg BID (based on body weight) for 1 year or until marketing approval in Japan, whichever is longer. A 4-week Follow-up Period will occur after the last dose of study treatment is received."
62198705|NCT00527787|EXPERIMENTAL|PN400|Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily
62198706|NCT00527787|ACTIVE_COMPARATOR|Naproxen|Naproxen 500 mg dosed twice daily
62198707|NCT03363139||Patients with T790M mutation|Patient who has progressed to Tyrosin Kinase inhibitors and has the mutation of the gen T790M
62198708|NCT04445298||Pregnant women with expected delivery in the fall or winter|We will enroll up to 40 women who are expected to deliver in the fall (September, October, November) and winter (December, January, February). We will then follow their infant offspring.
62198709|NCT04445298||Pregnant women with expected delivery in the spring or summer|We will enroll up to 40 women who are expected to deliver in the spring (March, April, May) and summer (June, July, August). We will then follow their infant offspring.
62198710|NCT04445298||Infants born in the fall or winter|The infants born to the enrolled mothers will be followed. These are infants born in the fall (September, October, November) or winter (December, January, February).
62400569|NCT00594958|ACTIVE_COMPARATOR|IC51 Group A|IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
62198711|NCT04445298||Infants born in the spring or summer|The infants born to the enrolled mothers will be followed. These are infants born in the spring (March, April, May) or summer (June, July, August).
62198712|NCT01395004|EXPERIMENTAL|Active Drug - GSK2110183|This was an open-label study of oral GSK211083 administered at the maximum tolerated dose of 125 mg once daily.
62400570|NCT00594958|ACTIVE_COMPARATOR|IC51 Group B|IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
62400571|NCT00594958|ACTIVE_COMPARATOR|IC51 Group C|IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
62400572|NCT05214911|EXPERIMENTAL|Experimental drug (Desloratadine 0.5 mg/mL/Prednisolone 4 mg/mL)|ADF Group 1 - Eurofarma drug association of Desloratadine 0.5 mg/mL / Prednisolone 4 mg/mL
62400573|NCT05214911|ACTIVE_COMPARATOR|Active Comparator: Desalex® (Desloratadine 0.5 mg/mL)|Desalex® Group 2 - Eurofarma drug Desloratadine 0.5 mg/mL
62400574|NCT03343002|EXPERIMENTAL|fentanyl at 10-15 min before end of surgery|
62400575|NCT03343002|ACTIVE_COMPARATOR|fentanyl at end of surgery|
62400576|NCT02403427|EXPERIMENTAL|VoiceDiab expert system|the VoiceDiab system using before every main meal; three times per day.
62400577|NCT02403427|NO_INTERVENTION|manual calculation|manula insulin calculation before every main meal; three times per day
62400578|NCT04196959|EXPERIMENTAL|Single Arm|All patients will receive TYR sphere, a Food for Special Medical Purposes, as part of thier restricted diet for 28 consecutive days.
62400579|NCT04651660|EXPERIMENTAL|Manual Insertion|The surgeon will follow a classical surgical procedure for the cochlear implantation, i.e. mastoidectomy to access the temporal bone, posterior tympanotomy to access the cochlea and round window (RW) approach for the CI electrode array insertion. Before opening the RW, the eCochG recording electrode is placed on the cochlear promontory, and placed not to obstruct the surgery. The probe is thus maintained during the whole MANUAL insertion (by the surgeon).
62783868|NCT05766657|PLACEBO_COMPARATOR|Control Group|children assigned to the control group will receive generic advice based on European dietary guidelines for obesity or follow their usual diet in the case of children with T1D.
62011271|NCT05080582|EXPERIMENTAL|Mother-Scented Simulated Hand|The neonates received the same standard care of the NICU, while they wrapped with a warm Mother-Scented Simulated Hand as follow; simulated hand was scented with mothers' body odor by placing it on the mothers' bare chest or behind the neck for one hour. Then, the MSSH was placed under a radiant warmer for a couple of minutes to reach the mothers' unique warm touch. Inside the incubator, the mechanically ventilated neonates were placed in a side-lying flexed fetal position, where they encircled with the two warm simulated human hand to contain them. Where the palm of one MSSH cupped the neonates' head, and the palm of the other hand cupped the lower part of body and extremities. The neonates were kept in such a position throughout the mentioned invasive procedures, as shown in Figure 2. Neonates' physiological response, comfort, distress, and pain levels were assessed the same way as the first day.
62198713|NCT04944667|OTHER|TAVR standard|TAVR planning evaluated without VR and TAVR planning after VR analysis
62198714|NCT04689464||mild covid|
62198715|NCT04689464||moderate covid|
62198716|NCT04689464||severe covid|
62577012|NCT04344028|PLACEBO_COMPARATOR|Control Cognitive Training Placebo|"Participants will receive a positive expectation message (e.g., Previous research has shown that training with this program increases performance on other tasks.) and will complete approximately 7 hours of control training program that has not previously been shown to improve cognition."
62198717|NCT00887770|EXPERIMENTAL|A|600mg AZD5672 + Moxifloxacin placebo
62198718|NCT00887770|EXPERIMENTAL|B|100mg AZD5672 + Moxifloxacin placebo
62577013|NCT04344028|SHAM_COMPARATOR|Control Cognitive Training Nocebo|"Participants will receive a negative expectation message (e.g., Previous research has shown that training with this program decreases performance on other tasks.) and will complete approximately 7 hours of control training program that has not previously been shown to improve cognition."
62198719|NCT00887770|ACTIVE_COMPARATOR|C|AZD5672 placebo + Moxifloxacin 400mg
62198720|NCT00887770|PLACEBO_COMPARATOR|D|AZD5672 placebo + Moxifloxacin placebo
62198721|NCT02274155|EXPERIMENTAL|Group 1|Anti-OX40 antibody administration 3 weeks prior to surgical resection
62198722|NCT02274155|EXPERIMENTAL|Group 2|Anti-OX40 antibody administration 2 weeks prior to surgical resection
62198723|NCT02274155|EXPERIMENTAL|Group 3|Anti-OX40 antibody administration 1 week prior to surgical resection
62198724|NCT02754362|EXPERIMENTAL|Block 1|
62198725|NCT02754362|EXPERIMENTAL|Block 2|
62783869|NCT03955991|EXPERIMENTAL|R-CBSM|10 weeks of group intervention convene by a broadband connection for approximately 75-90 minutes. Intervention given prior to Influenza Vaccine.
62783870|NCT03955991|ACTIVE_COMPARATOR|Wait List Condition (WLC)|Persons assigned to this group will receive R-CBSM approximately 28 days after receiving the Influenza Vaccine.
62783871|NCT00306059|EXPERIMENTAL|patients having acute kidney injury|
62783872|NCT03296449|NO_INTERVENTION|One-Lung Ventilation|During one-lung ventilation, when the chest is open, the non-dependent lung is collapsed and manipulated by the surgeon. It is the routine procedure during video-assisted thoracic surgery.
62577014|NCT03734289|ACTIVE_COMPARATOR|Immediate Coaching|Immediately following randomization, online coaching sessions will occur weekly for 6 weeks. Web-based courses containing instructional materials that deal with preventing and reducing care resistant behavior (CRB) within intimate care (dressing, bathing, toileting) and treatment regimens (medication, therapeutic activities) after the initial study visit. The NeuroNS-Care intervention is an innovative distance-learning , internet based, family caregiver coaching program; one for the caregivers of persons with dementia and one for the caregivers of persons recovering from TBI. It will be delivered using Instructure's Canvas™ web-based platform.
62577015|NCT03734289|ACTIVE_COMPARATOR|Delayed Coaching|6 weeks following the initial visit, online coaching sessions will occur weekly for 6 weeks. Web-based courses containing instructional materials that deal with preventing and reducing care resistant behavior (CRB) within intimate care (dressing, bathing, toileting) and treatment regimens (medication, therapeutic activities) after the initial study visit. The NeuroNS-Care intervention is an innovative distance-learning , internet based, family caregiver coaching program; one for the caregivers of persons with dementia and one for the caregivers of persons recovering from TBI. It will be delivered using Instructure's Canvas™ web-based platform.
62577016|NCT01805466|EXPERIMENTAL|EVADO|"The E.V.A.D.O. system is made of the following components:~* The ADMIRAL oxygenator, that requires low priming volumes (, has a limited contact surface and contains an accessory independent cardiotomy reservoir, allowing separation of pericardial suction blood.~* The HARMONY Smart Suction System, which allows automatic regulation of a pumpless extracavity blood sucker, whose rates and pressures depend on whether suction is required for blood/air surfaces (skimming), or for fluids (pooled).~* Paediatric circuits with 3/8 tubing for both arterial and venous lines."
62011272|NCT05080582|ACTIVE_COMPARATOR|NICU Standard Care|The neonates were provided with standard care, which entailed maintaining a quiet environment with minimal stimulation, uninterrupted periods of sleep, containment. Neonates were placed in a side-lying position, while their extremities were flexed close to the body and wrapped with rolled sheets or towels to simulate the intrauterine posture. This position was maintained during the performance of the invasive procedures.
62011273|NCT06664125|EXPERIMENTAL|JMKX003002 once daily|JMKX003002 once daily for 4 weeks
62577017|NCT01805466|ACTIVE_COMPARATOR|Conventional CPB|conventional cardiopulmonary by-pass (CPB) system
62400580|NCT04651660|EXPERIMENTAL|Robotic insertion|The surgeon will follow a classical surgical procedure for the cochlear implantation, i.e. mastoidectomy to access the temporal bone, posterior tympanotomy to access the cochlea and round window (RW) approach for the CI electrode array insertion. Before opening the RW, the eCochG recording electrode is placed on the cochlear promontory, and placed not to obstruct the surgery. The probe is thus maintained during the whole ROBOTIC insertion.
62577018|NCT03833479|EXPERIMENTAL|No further treatment|No further treatment
62577019|NCT03833479|EXPERIMENTAL|TSR-042|TSR-042 treatment administered using a 30 -minute IV infusion (with a -5 minute and +15 minute window permitted).
62011274|NCT06664125|EXPERIMENTAL|JMKX003002 twice daily|JMKX003002 twice daily for 4 weeks
62400581|NCT04937543|NO_INTERVENTION|No intervation|patients receiving standart of care
62400582|NCT04937543|ACTIVE_COMPARATOR|Experimental intervation one|patients receiving standart of care + inhaled beclometasone
62400583|NCT04937543|ACTIVE_COMPARATOR|Experimental intervation two|patients receiving standart of care + inhaled beclometasone/ formoterol / glycopyrronium
62400584|NCT01491152|EXPERIMENTAL|WBV Training|
62577020|NCT05539287|PLACEBO_COMPARATOR|Control group|25 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.
62577021|NCT05539287|EXPERIMENTAL|Probiotic Group|25 patients will receive Lactobacillus species 5 billion colony forming unit (CFU) 2 capsules daily together with their standard antiepileptic drug for 6 months.
62577022|NCT00556933|EXPERIMENTAL|Group 1|Kidney transplant recipients given a single large dose of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression.
62577023|NCT00556933|EXPERIMENTAL|Group 2|Kidney transplant recipients given 4 small doses of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression.
62577024|NCT00556933|EXPERIMENTAL|Group 3|Kidney transplant recipients given a single large dose of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression until tacrolimus is replaced with mycophenolate mofetil after about 6 months.
62577025|NCT00556933|EXPERIMENTAL|Group 4|Kidney transplant recipients given 4 small doses of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression until tacrolimus is replaced with mycophenolate mofetil after about 6 months.
62400585|NCT01491152|NO_INTERVENTION|Control|No WBV Training. Standard of Care.
62400586|NCT03176602||All patients admitted to the ICU|All patients ≥ 18 years old who had ≥ 24 hours length of stay in the ICU
62011275|NCT06664125|ACTIVE_COMPARATOR|Sevelamer carbonate|Sevelamer carbonate three times daily for 4 weeks
62011276|NCT05838729|EXPERIMENTAL|RiMO-301|Intratumoral injection of RiMO-301 followed by pembrolizumab or nivolumab followed by hypofractionated radiation
62011277|NCT05621239||COMIRNATY|COVID-19 mRNA vaccine
62011278|NCT01111656|ACTIVE_COMPARATOR|1|Interferon beta-1b 250ug subcutaneously every other day
62011279|NCT01111656|EXPERIMENTAL|2|Interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
62011280|NCT02321579|PLACEBO_COMPARATOR|Negative control|Dextrins
62011281|NCT02321579|EXPERIMENTAL|Supplement 1|50 mg/d vitamin B-6
62011282|NCT02321579|EXPERIMENTAL|Supplement 2|500 mg/d Glutathione
62011283|NCT02321579|EXPERIMENTAL|Supplement 3|50 mg/d vitamin B-6 plus 500 mg/d Glutathione
62783873|NCT03296449|ACTIVE_COMPARATOR|CPAP to non-dependent lung|"The patient will be randomly assigned to the study arm Continuous Positive Airway Pressure (CPAP). CPAP will be applied for 20 minutes to the non-dependent lung at a pressure of 2-3cmH20 using the disposable Mallinckrodt Bronchocath CPAP system."
62577026|NCT04510623||COVID-19 Patients on ARBs|This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin Receptor Blockers will be included in this cohort.
62198726|NCT02754362|EXPERIMENTAL|Block 3|
62198727|NCT02175953|EXPERIMENTAL|Interventiongroup|Psychotherapy
62198728|NCT02175953|NO_INTERVENTION|Waitling list group|waiting list
62198729|NCT01133080|EXPERIMENTAL|Minocycline|
62198730|NCT01133080|PLACEBO_COMPARATOR|Placebo|
62198731|NCT03916796|EXPERIMENTAL|Pre-Operative Radiotherapy: Dietary Counseling/Exercise/Psychological Counsel|"* Patients must be treated using daily image-guided radiotherapy~* Dietary counseling at baseline~* Exercise intervention throughout cancer rehabilitation protocol~* Psychological screening with counselling services as needed - nurse will administer the NCCN distress thermometer and refer the patient to applicable psychological counselling"
62198732|NCT03916796|EXPERIMENTAL|Post-Operative Radiotherapy: Dietary Counseling/Exercise/Psychological Counsel|"* Patients must be treated using daily image-guided radiotherapy~* Dietary counseling at baseline~* Exercise intervention throughout cancer rehabilitation protocol~* Psychological screening with counselling services as needed - nurse will administer the NCCN distress thermometer and refer the patient to applicable psychological counselling"
62198733|NCT00951470|OTHER|No CDT|CDT=complete decongestive therapy
62198734|NCT00951470|OTHER|Modified CDT Program|CDT=complete decongestive therapy
62198735|NCT00951470|OTHER|Full CDT Program|CDT=complete decongestive therapy
62198736|NCT00863512|EXPERIMENTAL|Arm I|Patients receive cisplatin IV on day 1 and vinorelbine ditartrate IV on days 1 and 8 OR docetaxel IV and cytarabine IV on day 1 OR gemcitabine hydrochloride IV on days 1 and 8 and cytarabine IV on day 1 OR pemetrexed disodium IV and cisplatin IV on day 1.. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62198737|NCT00863512|EXPERIMENTAL|Arm II|Patients receive standard care (observation).
62198738|NCT04697953|EXPERIMENTAL|brolucizumab 6mg|Open label, brolucizumab 6mg, daily dosing, Treat \& Extend regimen by up to 2 week intervals. Dosing intervals as per previous therapy and treatment extension intervals
62198739|NCT05099900||Pre-pregnancy|
62400587|NCT02316704|ACTIVE_COMPARATOR|OsseoTi™ G7 large|OsseoTi™ G7 acetabular cup and an E1™ liner holding largest possible femoral head (36mm-44mm)
62400588|NCT02316704|ACTIVE_COMPARATOR|OsseoTi™ G7 32|OsseoTi™ G7 acetabular cup and an E1™ insert holding a 32mm femoral head
62198740|NCT05099900||During pregnancy|
62198741|NCT05099900||Post-pregnancy|
62198742|NCT00340808||endometrial cancer cases|endometrial cancer cases
62198743|NCT06091059||Subjects|All adult patients with capacity and requiring an ultrasound guided Botox injection in the Radiology Department will be invited to take part in the study.
62198744|NCT02474043|ACTIVE_COMPARATOR|Usual care|Standard health education and prevention counseling by trained staff
62198745|NCT02474043|EXPERIMENTAL|Hep-Net Intervention|Computerized tailored behavioral intervention
62198746|NCT02188680|ACTIVE_COMPARATOR|Low FODMAPS diet and positive breath testing for fructose|Patients with breath testing positive have a low FODMAPS diet. The test will be considered as positive if we observe an increase of more than 20 ppm of H2 and/or CH4 on a sample with regard to the basal concentration
62198747|NCT02188680|SHAM_COMPARATOR|negative breath testing for fructose|patients with negative breath test have a low FODMAPS diet
62198748|NCT03254043|ACTIVE_COMPARATOR|Treatment-as-Usual|Participants will routine methadone clinic care.
62198749|NCT03254043|EXPERIMENTAL|"Take-home Dosing using MedMinder Jon Electronic Pill Box"|Participants will receive 50% of their methadone dose in the morning in the clinic and 50% of their dose will be dispensed in an electronic pill box for participants to take at home later that day.
62198750|NCT03254043|OTHER|Choice Phase|"Participants will be allowed to select one final Treatment-As-Usual or the MedMinder Jon Electronic Pill Box for the final phase of the study."
62400589|NCT02316704|ACTIVE_COMPARATOR|conventional PPS coated G7 large|conventional PPS coated G7 acetabular cup and an E1™ insert holding largest possible femoral head (36mm-44mm)
62400590|NCT02316704|ACTIVE_COMPARATOR|conventional PPS coated G7 32|conventional PPS coated G7 acetabular cup and an E1™ insert holding a 32mm femoral head
62400591|NCT03332225|EXPERIMENTAL|Anakinra|Treatment with iv anakinra 200 mg three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
62400592|NCT03332225|PLACEBO_COMPARATOR|IV Placebo|Treatment with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
62577027|NCT04510623||COVID-19 Patients on ACE inhibitors|This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin-Converting Enzyme inhibitors will be included in this cohort.
62783874|NCT03296449|EXPERIMENTAL|HFJV to non-dependent lung|"The patient is randomly assigned to the study arm High-frequency jet ventilation (HFJV). HFJV will be applied for 20 minutes to the non-dependent lung with a driving pressure of a 0.6 atm, respiratory rate 100 cycles per minute using the Monsoone III Jet Ventilator (Acutronic, Hirzel, Switzerland)."
62400593|NCT03332225|EXPERIMENTAL|Recombinant human interferon-gamma|Treatment with sc recombinant human interferon-gamma every other day for a total of 15 days and with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days
62400594|NCT00395317|PLACEBO_COMPARATOR|Arm 1|placebo (4 tablets)
62400595|NCT00395317|EXPERIMENTAL|Arm 2|SB-683699 150 mg bid (1 x 150mg + 3 placebo tablets)
62577028|NCT04510623||COVID-19 Patients on ARBs or ACE inhibitors|This is an observational cohort study. Those who have COVID-19 in hospital and are on ARBs or ACEi's will be included in this cohort.
62577029|NCT04510623||COVID-19 Patients not on ARBs or ACE inhibitors|This is an observational cohort study. Those who have COVID-19 in hospital and are not on ARBs or ACEi's will be included in this cohort.
62577030|NCT04338841|NO_INTERVENTION|Phase1: Before HOME-CoV rule implementation|"Observational assessment of current practices: no recommendation is performed.~Patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion.~Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants.~A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion."
62577031|NCT04338841|EXPERIMENTAL|Phase 2: After HOME-CoV rule implementation|"Observational assessment of practices after implementation of the rule: physicians are recommended to apply the HOME-CoV rule but still free to use other determinants in their decision.~Patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion. Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants.~A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion."
62011284|NCT06526884|NO_INTERVENTION|ED-initiated hospitalization|Patients with odd birthdays will be routed to standard-of-care ED-initiated hospitalization pathways.
62011285|NCT06526884|EXPERIMENTAL|Next Day Clinic|Patients with even birthdays who meet inclusion criteria will be given the option to receive care in the Next Day Clinic to avoid hospitalization.
62011286|NCT01085110||Persistent Pain patients|Patients with persistent postherniotomy pain after laparoscopic operation and pain related impaired daily function
62198751|NCT05567107|EXPERIMENTAL|experimental group: applied foot massage|Scales were applied preoperative to the patients. After being discharged from the intensive care unit in the postoperative period, the scales were applied without any intervention on the first day of hospitalization (day 0). Pain intensity was evaluated according to the Visual Comparison Pain Scale and classical foot massage was applied to patients who stated that they had 4 or more pain. After leaving the intensive care unit in the postoperative period, the scales were applied on the 2nd day (day 1) when the patient came to the service. After the scales, foot massage was applied again. After leaving the intensive care unit in the postoperative period, the scales were applied on the third day (day 2) when the patient came to the service. After the scales, foot massage was applied again. After the patient was discharged from the intensive care unit in the postoperative period, the scales were applied on the fourth day (3rd day) when they came to the service.
62400596|NCT00395317|EXPERIMENTAL|Arm 3|SB-683699 600 mg bid (2 x 300mg + 2 placebo tablets)
62577032|NCT03821948||Average CRC Risk Group|Stool sample collection and blood draw in men and women aged 40 and older with average CRC risk undergoing a standard of care colonoscopy procedure
62198752|NCT05567107|NO_INTERVENTION|control group: unapplied foot massage|Each data collection tool was collected without applying foot massage, as in the experimental group patients. While the patients in the control group received only analgesic treatment postoperatively, the patients in the experimental group received foot massage in addition to the analgesic treatment. Only routine nursing care was given to the patients in the control group postoperatively.
62577033|NCT03821948||Increased CRC Risk Group|Stool sample collection and blood draw in men and women aged 40 and older with increased CRC risk undergoing a standard of care colonoscopy procedure
62577034|NCT05762211|EXPERIMENTAL|Oral pooled fecal microbiotherapy - MaaT033|3 capsules per day
62577035|NCT05762211|PLACEBO_COMPARATOR|Placebo capsule|3 capsules per day
62577036|NCT06065462|EXPERIMENTAL|Dostarlimab + LB-100|Dostarlimab will be given by vein over about 30 minutes on Day 1 of each cycle. LB-100 will be given by vein on Days 1-3 of each cycle. The first doses will be given over about 2 hours. After that, doses may be given over as little as 30 minutes.
62198753|NCT02610075|EXPERIMENTAL|AZD1775|This is a single-arm study in which all patients will receive AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
62198754|NCT00611975|EXPERIMENTAL|A|Participants will receive treatment with fluoxetine for 2 months
62198755|NCT00611975|EXPERIMENTAL|B|Participants will receive treatment with bupropion for 2 months
62577037|NCT03512210|EXPERIMENTAL|MINMON 24 weeks with SOF/VEL 12 Weeks|Participants received Sofosbuvir/Velpatasvir (SOF/VEL \[Tradename: Epclusa®\]) tablet for 12 weeks with a minimal monitoring (MINMON) strategy for 24 weeks
62198756|NCT04723290|EXPERIMENTAL|Serological tests|All staff at GHdC who want to know their level of antibodies against SARS CoV-2
62198757|NCT05884489|EXPERIMENTAL|Intervention group|
62400597|NCT00395317|EXPERIMENTAL|Arm 4|SB-683699 900 mg bid (3 x 300 mg + 1 placebo tablet)
62400598|NCT00395317|EXPERIMENTAL|Arm 5|SB-683699 1200 mg bid, male subjects only (4 x 300 mg tablets)
62400599|NCT05480852|EXPERIMENTAL|Bis-GMA Free dental resin composite|Restorative Materials
62400600|NCT05480852|ACTIVE_COMPARATOR|Bis-GMA containing dental resin composite|Restorative Materials
62400601|NCT02077868|OTHER|Control Arm A|Patients in Control Arm A receive usual maintenance Treatment according to local investigator's decsision
62400602|NCT02077868|EXPERIMENTAL|Treatment Arm B|MGN1703 treatment as maintenance therapy
62400603|NCT04155606|ACTIVE_COMPARATOR|Interventional Therapy|Neurosurgery or Endovascular procedure
62400604|NCT04155606|NO_INTERVENTION|Conservative Management|Monitoring with pharmacological therapy if need arises.
62577038|NCT04074369||Pulmonary Tuberculosis Suspects|Individuals with suspected TB infection
62783875|NCT03472586|EXPERIMENTAL|Treatment (ipilimumab, nivolumab, immunoembolization)|Patients receive ipilimumab IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Patients also undergo immunoembolization on day 2. Cycles repeat every 3 weeks for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with complete response, partial response, or stable disease may receive nivolumab IV on day 1 and undergo immunoembolization on day 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. The interval between treatments may be extended up to every 6 weeks at the discretion of the treating physician.
62783876|NCT02200887||Advanced Parkinsons Disease|Polysomnogram
62783877|NCT02200887||Parkinsons Disease with Dyskinesia|Polysomnogram
62783878|NCT02200887||De novo Parkinsons Disease|Polysomnogram
62198758|NCT02053610|EXPERIMENTAL|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
62783879|NCT02200887||Healthy Volunteers|Polysomnogram
62783880|NCT00133666|EXPERIMENTAL|1|
62011287|NCT02220010|EXPERIMENTAL|Pancreatic stent|If POPF grade B or C is detected on post operative day 3 or more, a pancreatic stent is endoscopically positioned in the pancreatic duct.
62011288|NCT02220010|NO_INTERVENTION|Drain only|If POPF grade B or C is detected on post operative day 3 or more, only the per-operatively placed drain is used as treatment
62011289|NCT02558608|EXPERIMENTAL|WR AND DIPL|patients undergo wedge resection and dissection the inferior pulmonary ligament by thoracoscopic surgery or video assisted thoracoscopic surgery
62011290|NCT02558608|ACTIVE_COMPARATOR|WR|patients undergo wedge resection by thoracoscopic surgery or video assisted thoracoscopic surgery without dissection the inferior pulmonary ligament
62400605|NCT04408326||Angiotensin II|Patients with COVID-19 and acute respiratory distress syndrome who received angiotensin II as an add-on vasopressor will be collected
62400606|NCT04408326||Anakinra|Patients with COVID-19 and acute respiratory distress syndrome who received Anakinra (interleukin 1 receptor antagonist) will be collected
62584931|NCT06111885|ACTIVE_COMPARATOR|Hydrochlorothiazide + Chlorthalidone + Indapamide|1 capsule containing 50 mg hydrochlorothiazide per day for 28 days, followed by a 28 days wash out phase, followed by a second treatment phase with 1 capsule containing 25 mg chlorthalidone per day for 28 days, followed by a 28 days wash out phase, followed by a third treatment phase with 1 capsule containing 2.5 mg indapamide per day for 28 days.
62783881|NCT00133666|ACTIVE_COMPARATOR|2|
62783882|NCT06549426|OTHER|Intervention group|Standard care completed with stepwise anti-seizure treatment according to protocols for clinically overt status epilepticus. This consists of a stepwise approach consisting of 3 potential steps. Each next step will be taken as soon as possible (within 30 minutes of ESE first diagnosis or recurrence) if the previous step was insufficiently effective to sustainably suppress ESE.
62783883|NCT06549426|NO_INTERVENTION|Control group|Standard care without anti-seizure treatment.
62783884|NCT03301298|EXPERIMENTAL|SXC-2023, 50 mg|Single dose of 50 mg, given orally in capsule form.
62783885|NCT03301298|EXPERIMENTAL|SXC-2023, 100 mg|Single dose of 100 mg, given orally in capsule form.
62011291|NCT04527068|EXPERIMENTAL|Bevacizumab +Tripleitriumab|Participants receive bevacizumab 7.5mg/kg and tripleitriumab 240mg in day 1 intravenously every 3week until disease progression or unacceptable toxicity
62011292|NCT04613297|OTHER|COVID-19 uninfected patients|Patient with negative PCR result
62011293|NCT04613297|OTHER|non-hospitalized COVID-19 infected patients|Patient with positive PCR result who does not require hospitalization for COVID-19
62011294|NCT04613297|OTHER|hospitalized COVID-19 infected patients|Patient with positive PCR who require hospitalization for COVID-19
62011295|NCT06344065|EXPERIMENTAL|DTaP vaccine|Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed), 0.5ml/vial, injection.
62011296|NCT06344065|ACTIVE_COMPARATOR|Active comparator 1: DTaP vaccine|Diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed), 0.5ml/tube; injection.
62783886|NCT03301298|EXPERIMENTAL|SXC-2023, 200 mg|Single dose of 200mg, given orally in capsule form.
62783887|NCT03301298|EXPERIMENTAL|SXC-2023, 400 mg|Single dose of 400mg, given orally in capsule form.
62783888|NCT03301298|EXPERIMENTAL|SXC-2023, 800 mg|Single dose of 800mg, given orally in capsule form.
62783889|NCT03301298|EXPERIMENTAL|SXC-2023, 1600 mg|Single dose of 1600 mg, given orally in capsule form.
62783890|NCT03301298|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo comparator, given once orally in matching capsule form.
62783891|NCT00996255|EXPERIMENTAL|Dose-Escalation|
62783892|NCT01754493|EXPERIMENTAL|Treatment with Duloxetine|Patients will receive open treatment with Duloxetine
62783893|NCT04266054|EXPERIMENTAL|Intervention|The intervention group will view the 12-minute digital storytelling intervention that has been previously pilot-tested, in addition to usual clinical care
62011297|NCT06344065|ACTIVE_COMPARATOR|Active comparator 2: DTaP-IPV//PRP-T vaccine|Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed) and Haemophilus influenzae type b conjugate vaccine, 0.5ml/tube; injection.
62783894|NCT04266054|NO_INTERVENTION|Control|The comparison group will receive usual clinical care.
62011298|NCT05933837||Patients with MINS|Troponin I level equal to or above 59 ng/L
62011299|NCT05933837||Patients without MINS|Troponin I level under 59 ng/L
62011300|NCT04097379|EXPERIMENTAL|LRX712 Arm 1|"Randomized in a 1:1:1 ratio:~LRX712 Arm 1:LRX712 Arm 2:placebo"
62011301|NCT04097379|PLACEBO_COMPARATOR|Placebo|"Randomized in a 1:1:1 ratio:~LRX712 Arm 1:LRX712 Arm 2:placebo"
62011302|NCT04097379|EXPERIMENTAL|LRX712 Arm 2|"Randomized in a 1:1:1 ratio:~LRX712 Arm 1:LRX712 Arm 2:placebo"
62011303|NCT03755024||normal group|fetuses with normal growth
62011304|NCT03755024||Growth retardation group|fetuses with retarded growth
62011305|NCT05392556|EXPERIMENTAL|Probiotic|Bifidobacterium longum R0175; Lactobacillus helveticus R0052 (Cerebiome; Lallemand Health Solutions)
62011306|NCT05392556|EXPERIMENTAL|Prebiotic|Bimuno-galactooligosaccharide (Bimuno-GOS; Clasado Biosciences)
62400607|NCT04408326||Angiotensin II control|Patients with COVID-19 and acute respiratory distress syndrome who also received vasopressor support will be matched to angiotensin II group by date of intensive care unit admission, age, history of hypertension, history of angiotensin converting enzyme inhibitor/angiotensin receptor blocker, respiratory support
62400608|NCT04408326||Anakinra control|Patients with COVID-19 and acute respiratory distress syndrome will be matched to Anakinra group by matching age and date of intensive unit care admission
62400609|NCT04988620|EXPERIMENTAL|Whole Blood stored for 15-21 days|CPD Whole Blood leukoreduced with a platelet-sparing filter and stored cold for 15-21 days
62400610|NCT04988620|ACTIVE_COMPARATOR|Whole Blood stored for less than 7 days|CPD Whole Blood leukoreduced with a platelet-sparing filter and stored cold for less than 7 days. We aim at using as fresh as possible.
62400611|NCT04988620|ACTIVE_COMPARATOR|Whole Blood stored for 8-14 days|CPD Whole Blood leukoreduced with a platelet-sparing filter and stored cold for 8-14 days. This group may be added if deemed of interest after interim analysis.
62400612|NCT04988620|ACTIVE_COMPARATOR|Standard Blood Component|This group may be added for comparison if deemed of interest after interim analysis.
62584932|NCT06111885|ACTIVE_COMPARATOR|Chlorthalidone + Indapamide + Hydrochlorothiazide|1 capsule containing 25 mg chlorthalidone per day for 28 days, followed by a 28 days wash out phase, followed by a second treatment phase with 1 capsule containing 2.5 mg indapamide per day for 28 days, followed by a 28 days wash out phase, followed by a third treatment phase with 1 capsule containing 50 mg hydrochlorothiazide per day for 28 days.
62783895|NCT02052401|EXPERIMENTAL|Occupational Therapy Intervention|Post Discharge Domiciliary Intervention by Occupational Therapy (OT)
62783896|NCT02052401|NO_INTERVENTION|Usual follow-up|Usual follow-up of post discharge elderly patients, including pharmacological, and non-pharmacological care.
62783897|NCT03172572||Indication for surgery|Solid neoplasms
62783898|NCT03915470|EXPERIMENTAL|XF-73|0.3 mL applications in each naris of 0.2% w/w XF-73 nasal gel for a cumulative dose of 6.0 mg of XF-73.
62783899|NCT03915470|PLACEBO_COMPARATOR|Placebo|0.3 mL applications in each naris of placebo to match XF-73 nasal gel.
62783900|NCT05562258|EXPERIMENTAL|Parent Coaching and Patient Education|This group includes 12 weeks of eating disorder therapy provided to the patient. Outside of therapy, parents will have access to a coach and patients will have access to weekly educational material.
62783901|NCT05562258|EXPERIMENTAL|Parent Education and Patient Coaching|This group includes 12 weeks of eating disorder therapy provided to the patient. Outside of therapy, parents will have access to weekly educational material and patients will have access to a coach.
62783902|NCT02115412||medication non-adherence|
62783903|NCT06462781|EXPERIMENTAL|Treatment Cohort|Intra-arterial 80mg lidocaine and 40mg methylprednisolone
62783904|NCT06462781|ACTIVE_COMPARATOR|Observational Cohort|Continuation of standard therapies
62783905|NCT02650830||1) Normal control|metabolically healthy with no obesity
62783906|NCT02650830||2) prediabetes|defined in 'inclusion criteria'
62783907|NCT02650830||3) type 2 diabetes|defined in 'inclusion criteria'
62011307|NCT05392556|PLACEBO_COMPARATOR|Placebo|Maltodextrin placebo
62011308|NCT05663398|EXPERIMENTAL|Darfen 400|A single oral dose of the test product Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
62011309|NCT05663398|ACTIVE_COMPARATOR|Nurofen® Forte Express|A single oral dose of the reference product Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
62011310|NCT03722875|EXPERIMENTAL|SHR-1210+ apatinib|"SHR-1210 (200mg fixed dose every 3 weeks, one cycle is three weeks, total~1 year ) will be administered as an intravenous infusion over 30 minutes.~apatinib 250 mg qd ， one cycle is three weeks, total 1 year"
62011311|NCT03142295|EXPERIMENTAL|Urine transfusion|Intervention: Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
62011312|NCT00417560|EXPERIMENTAL|Influenza A/H5N1 Vaccine|Two 90ug Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine
62011313|NCT05433558|EXPERIMENTAL|Experimental group|enter the experiment directly
62011314|NCT05433558|EXPERIMENTAL|Waiting group|enter the experiment after waiting eight weeks
62783908|NCT03190616|EXPERIMENTAL|drug,apatinib|apatinib 500mg/qd, 28d/cycle
62783909|NCT02003417||Non-metastatic prostate cancer patients|Histologically-confirmed, non-metastatic prostate cancer patients who received external beam radiation treatment with androgen deprivation therapy (total ADT duration \> 3 months) for definitive treatment.
62783910|NCT00398320|EXPERIMENTAL|Bevacizumab (Avastin), Oxaliplatin (Eloxatin)|
62011315|NCT04349852|EXPERIMENTAL|BrainHQ Cognitive Training Arm|Participants will be randomized into the BrainHQ Cognitive Training modules which are 45 minute training sessions. There will be 40 training sessions. Since the intervention is presented both visually and verbally through the computer, and participants will be asked if they have a quiet space and noise cancelling headphones. Participants will complete the training protocols remotely and their performance will be tracked. Participants will complete the 40 training sessions remotely, but will meet with the study team member online prior to beginning the training and right after completing the training.
62011316|NCT04349852|OTHER|BrainHQ People Skills Arm|Participants will be randomized into the BrainHQ People Skills Modules which are 45 minute training sessions. There will be 40 training sessions. Since the intervention is presented both visually and verbally through the computer, and participants will be asked tocomplete the training in a quiet space and time to complete these activities. Participants will complete the 40 training sessions remotely, but will meet with the study team member online prior to beginning the training and right after completing the training.
62011317|NCT04541446|EXPERIMENTAL|Residents to receive Dynamic Haptic Robotic Training|
62011318|NCT04541446|EXPERIMENTAL|Residents to receive Advanced Dynamic Haptic Robotic Training|
62011319|NCT06662773|EXPERIMENTAL|Inhibitor group|Oral TQB3616 capsules 60 mg after a single meal on days 1 and 13; On days 10 to 21, itraconazole capsules 200mg were taken orally once a day for 12 days after meals.
62011320|NCT06662773|EXPERIMENTAL|Inducer group|180mg of TQB3616 capsules orally after a single meal on days 1 and 17; Oral administration of rifampicin capsules 600mg from day 10 to day 25 on the peritoneum once a day for 16 consecutive days, of which rifampicin capsules 600mg and TQB3616 capsules 180mg were taken at the same time after meals on the 17th day.
62400613|NCT00914940|EXPERIMENTAL|Arm 1|"CONDITIONING: Patients undergo total-body irradiation twice daily on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine IV over 30 minutes on days -6 to -2. TRANSPLANTATION: Patients undergo infusion of CD34+ enriched allogeneic peripheral blood stem cells (PBSC) followed by CD45RA+ T-cell-depleted allogeneic PBSC on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Cohort A: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -1 and continuing until day 50 followed by standard taper in the absence of grade II-IV acute GVHD. Cohort B: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -1 and continuing until day 30 followed by rapid taper in the absence of grade II-IV acute GVHD."
62400614|NCT01367366||Mediastinal malignant lymphadenopathy|
62577039|NCT00217373|EXPERIMENTAL|Arm I|"COURSE I: Patients receive recombinant vaccinia-CEA(6D)-TRICOM vaccine SC on day 1. Patients also receive sargramostim (GM-CSF) SC on days 1-4 and IFN-α-2b\* SC on days 9, 11, and 13.~COURSES II-IV: Patients receive recombinant fowlpox-CEA(6D)-TRICOM vaccine SC on day 1. Patients also receive GM-CSF as in course 1 and IFN-α-2b\* SC on days 1, 3, and 5.~NOTE: \*The initial cohort of 6 patients does not receive IFN-α-2b.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients who do not have progressive disease or unacceptable toxicity may receive recombinant fowlpox-CEA (6D)-TRICOM vaccine, GM-CSF, and IFN-α-2b every 28 days for 2 more courses and then every 3 months for up to 2 years."
62577040|NCT04952025||ALS patients|
62577041|NCT04952025||normal controls|
62577042|NCT04339101|EXPERIMENTAL|Treatment (itacitinib adipate, tacrolimus, sirolimus)|"RIC: Patients receive fludarabine via infusion on days -9 to -5 and melphalan on day -4 in the absence of disease progression or unacceptable toxicity.~ALLOGENEIC HSCT: Patients undergo HSCT on day 0.~GVHD PROPHYLAXIS: Patients receive itacitinib PO QD beginning on day -3 and continuing until day 100 in the absence of disease progression or unacceptable toxicity. Patients also receive tacrolimus IV or PO and sirolimus PO beginning day -3 and continuing until day 100 with a taper in the absence of disease progression or unacceptable toxicity."
62577043|NCT03691207|EXPERIMENTAL|SINGLE-ARM|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
62577044|NCT03691987|EXPERIMENTAL|Preprocessed thawed donor FMT|"The active transplants are processed in a 2-3 weeks period before treatment of the first participant. Fifty to eighty grams of freshly delivered feces from donors is mixed with 100 mL isotonic saline and 25 mL 85% glycerol, homogenized and poured through a 0.5 mm mesh steel strainer, and transferred to 60 ml luerlock syringes and stored at -40°C.~Frozen transplants are slowly thawed 2 hours prior to administration by transferring the FMT-syringes to a waterbath (+30°C). The transplant is then mixed with 125 mL 12°C isotonic saline in an enema bag prior to installation."
62577045|NCT03691987|PLACEBO_COMPARATOR|Preprocessed thawed autologous FMT|"The placebo transplant from each participant is prepared during the inclusion process four to six weeks before intervention and stored at -40°C. Fifty to eighty grams of freshly delivered feces from participants is mixed with 100 mL isotonic saline and 25 mL 85% glycerol is homogenized and poured through a 0.5 mm mesh steel strainer, and transferred to 60ml Luerlock syringes.~Frozen transplants are slowly thawed 2 hours prior to administration by transferring the Luerlock syringes to a waterbath (+30°C). The transplant is then mixed with 125 mL 12°C isotonic saline in the enema bag prior to installation."
62577046|NCT02760004|EXPERIMENTAL|Prism Intervention|PRogram In Support of Moms (PRISM)
62577047|NCT02760004|EXPERIMENTAL|MCPAP for Moms Intervention|MCPAP for Moms (Massachusetts Child Psychiatry Access Program for Moms)
62577048|NCT01120015|EXPERIMENTAL|Diacerein|diacerein 50mg oD first month, 50 mg BD next 2 months
62577049|NCT06577545|NO_INTERVENTION|Usual Care (UC)|Participants in Usual Care (UC) study arm will receive WCRF cancer prevention recommendations.
62577050|NCT06577545|ACTIVE_COMPARATOR|Behavioural Lifestyle (BL)|24-week behavioural lifestyle intervention program.
62577051|NCT04993638||EUROSCUP MOBILE cementless|107 who received cementless version of EUROSCUP MOBILE
62577052|NCT04993638||EUROSCUP MOBILE cemented|40 who received cemented version of EUROSCUP MOBILE
62011321|NCT00626977||R|R group:15 mL of 0.125% ropivacaine (18.75 mg)
62577053|NCT06184204||Patients with confirmed diagnosis of Atrial fibrillation|male, female, 19 or more of age with confirmed diagnosis of Atrial fibrillation
62577054|NCT06258499|EXPERIMENTAL|BHA|Subjects treated with BHA + standard of care
62577055|NCT06258499|NO_INTERVENTION|Control|Subjects treated as per standard of care
62783911|NCT04140045|EXPERIMENTAL|Hypohydrated|Participants will be required to restrict their water intake during cycling in the heat (90-120 minutes at 35°C), in order to achieve a body mass loss of approximately 3%.
62783912|NCT04140045|EXPERIMENTAL|Euhydrated|Participants will be provided with water intake that matches their sweat losses during cycling in the heat (90-120 minutes at 35°C)
62783913|NCT01628055|EXPERIMENTAL|Privigen|The IVIG preparation to be used is 10% liquid (Privigen). IVIG will be applied at a dose of 1.0g/kg, which is approximately 1/2 of the optimal dose used for other immuno/inflammatory indications. The infusion will start at 0.5 ml/kg/hr for the first 30 minutes, to watch for the signs of hypersensitivity to immunoglobulins, and then increased to 2.5 ml/kg/hr, two times slower than the recommended rate indicated in the product package insert (5 ml/kg/hr). Such a low, single dose has not been associated with hyperviscosity and together with a slow infusion will safeguard against occurrence of adverse events related to IVIG infusions. They will receive a total of 1g/kg and depending on patient's weight, it will take between 3.5 to 4+ hours to infuse that amount.
62011322|NCT00626977||RC|RC group:0.0625% ropivacaine (9.375 mg) plus 75 ug clonidine
62011323|NCT06311994|EXPERIMENTAL|Intervention with virtual reality|"Factors that may affect patient compliance with the VR-based intervention method to be applied to patients undergoing knee surgery and the factors that may affect the measurements were evaluated through a literature review and inclusion and exclusion criteria were created."
62011324|NCT06311994|NO_INTERVENTION|Control|Among the randomized patients, patients included in the control group will be included in the conventional rehabilitation program.
62011325|NCT06142201||JT001|
62011326|NCT06142201||No anti-SARS-CoV-2 treatment|
62011327|NCT02497768|EXPERIMENTAL|Chewing of nuts|8 samples (4-5 g) of nuts (pistachios or Brazils) on two separate visit days.
62198759|NCT02053610|ACTIVE_COMPARATOR|rituximab + chlorambucil (RClb)|Participants received 375 mg/m\^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
62198760|NCT02053610|ACTIVE_COMPARATOR|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
62198761|NCT02432664|EXPERIMENTAL|ODM-108 Part I|Oral capsules dosage 0.2 - 240 mg once daily for one day
62400615|NCT00752895|EXPERIMENTAL|Arm I - Ginseng|Patients receive oral American ginseng extract twice daily.
62577056|NCT03768154|EXPERIMENTAL|study arm|all patients will receive all four intervention in the same sequential method
62011328|NCT01131481|OTHER|AcrySof MA50BM,AVS Model X-60|AcrySof MA50BM, AVS Model X-60
62011329|NCT03558828|EXPERIMENTAL|Step1: Initial Treatment|Participants will be randomly assigned to one of the two initial treatment components: a) enhanced physical activity monitor only (physical activity monitor with goal setting and a physical activity prescription) treatment, or b) enhanced physical activity monitor+ motivational text messaging treatment for 8 weeks (early adoption phase). All participants will be given a physical activity step goal The initial treatment time period is from Weeks 1-8.
62011330|NCT03558828|EXPERIMENTAL|Step 2: Augmented Treatment|"At Week 8, it will be determined if a women has met her physical activity step goal. If she has, then she will be classified as a responder, and will continue with the same initial treatment component for weeks 9-34 (later adoption).~If a woman has not met her physical activity step goal she will be classified as a non-responder. In addition to the initial treatment component non-responders to initial treatments will be randomly assigned to one of two augmented treatment components: a) personal calls, or b) group meetings for Weeks 9-34 (later adoption phase)."
62198762|NCT02432664|PLACEBO_COMPARATOR|Placebo Part I|Oral capsules given once daily for one day
62198763|NCT02432664|EXPERIMENTAL|ODM-108 Part II|Oral capsules 4 dose levels to be decided after Part 1 of the study. 1 - 4 times a day for 7 days
62198764|NCT02432664|PLACEBO_COMPARATOR|Placebo Part II|Oral capsules 1 - 4 times per day for 7 days
62198765|NCT02432664|EXPERIMENTAL|ODM-108 Part III|Oral capsules 1-4 times daily for 7 to 10 days
62198766|NCT02432664|ACTIVE_COMPARATOR|Midazolam|Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
62400616|NCT00752895|PLACEBO_COMPARATOR|Arm II - Placebo|Patients receive oral placebo twice daily.
62400617|NCT05694923|NO_INTERVENTION|life style modification and diet control|33 patient of non alcoholic fatty liver patients and non diabetic only receive life style modification and diet control
62198767|NCT04047277|EXPERIMENTAL|Treatment Right-Away|Cognitive Behavioral Therapy using exposure, relaxztion, and rescripting - Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
62198768|NCT04047277|NO_INTERVENTION|Waitlist Control|Waitlist control group will complete pre and post assessments at beginning and end of wait period.
62198769|NCT05685225|EXPERIMENTAL|Naltrexone-Acetaminophen|Subjects take a single dose for a Qualifying Migraine
62198770|NCT05685225|ACTIVE_COMPARATOR|Naltrexone|Subjects take a single dose for a Qualifying Migraine
62198771|NCT05685225|ACTIVE_COMPARATOR|Acetaminophen|Subjects take a single dose for a Qualifying Migraine
62198772|NCT05685225|PLACEBO_COMPARATOR|Placebo|Subjects take a single dose for a Qualifying Migraine
62198773|NCT02269423|EXPERIMENTAL|3x10^6 plaque-forming units (pfu) Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 3x10\^6 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
62198774|NCT02269423|EXPERIMENTAL|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 2x10\^7 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
62198775|NCT02269423|EXPERIMENTAL|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 1x10\^8 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
62198776|NCT02269423|PLACEBO_COMPARATOR|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in each deltoid on Day 0.
62198777|NCT04653233|EXPERIMENTAL|Intervention|After the theoretical lesson, the students in the experimental group were taken to the laboratory room where the 3D Systems Touch Haptic Simulator is located. The simulator has a choice of 45 minutes of full instruction, 5 minutes of haptic arm only, or the option. Since the preparation of the material in the full teaching method in the simulator takes a long time, these steps were removed to show similarity with the control group. The skill practice option for an average of 5-10 minutes where all steps of the Checklist for Teaching Urinary Catheterization Skill can be applied was used. Urinary catheterization with 3D Systems Touch Haptic Simulator was explained by 1 researcher who was responsible for the Fundamentals of Nursing course.
62584933|NCT06111885|ACTIVE_COMPARATOR|Hydrochlorothiazide + Indapamide + Chlorthalidone|1 capsule containing 50 mg hydrochlorothiazide per day for 28 days, followed by a 28 days wash out phase, followed by a second treatment phase with 1 capsule containing 2.5 mg indapamide per day for 28 days, followed by a 28 days wash out phase, followed by a third treatment phase with 1 capsule containing 25 mg chlorthalidone per day for 28 days.
62783914|NCT01628055|PLACEBO_COMPARATOR|Normal Saline|The placebo is the normal saline. Since saline solution will be infused at the volume equivalent to that in which the intended dose of immunoglobulin molecules will be delivered, the placebo (comparator) arm will also serve as a control for the volume of fluid infused to the treatment arm participants.
62783915|NCT03873935||Control|Healthy subjects
62011331|NCT03558828|EXPERIMENTAL|Step 3: Maintenance|At Weeks 35-50 (maintenance phase) all participants in the study return to an enhanced physical activity monitor only treatment component.
62011332|NCT05448001|EXPERIMENTAL|Study Group|
62011333|NCT05448001|ACTIVE_COMPARATOR|Control Group|
62011334|NCT02811198||MDD with SI and No Attempt|Subjects will have MDD with current MDE, current suicidal ideation and no lifetime suicide attempts
62011335|NCT02811198||MDD with SI and Recent Attempt|Subjects with have MDD with current MDE, current suicidal ideation and a suicide attempt within the past 6 months
62783916|NCT03873935||Periodontitis|Patients with periodontal disease
62783917|NCT03873935||Cardiovascular|Patients with cardiovascular disease
62783918|NCT03873935||Periodontitis+Cardiovascular|People with both cardiovascular and periodontitis
62011336|NCT02811198||MDD with no SI and Lifetime Attempt|Subjects with MDD and current MDE but no current suicidal ideation and a lifetime suicide attempt.
62011337|NCT02811198||Healthy Controls|Subjects will have no personal or family psychiatric history and no suicide attempts.
62011338|NCT06663696||Patient population with multivessel disease|Supraflex Cruz Sirolimus-eluting Coronary Stent System
62011339|NCT05705102||OMI/NOMI group|In this group, the patients will be managed according to OMI/NOMI paradigm. OMI patients, even without STEMI criteria, will be taken immediately to the cath lab.
62011340|NCT05705102||STEMI/NSTEMI group|Standard care
62011341|NCT03732638|EXPERIMENTAL|DBT Rimegepant/OL Rimegepant|"DBT Phase (Weeks 1 through 12): Participants received a single oral dose of rimegepant 75 mg tablet every other day (EOD) for 12 weeks.~OLE Phase (Weeks 13 through 64): Participants who continued to meet study entry criteria and had acceptable laboratory test results per protocol, entered the OLE phase and received a single oral dose of rimegepant 75 mg tablet EOD for 52 weeks. If participants had a migraine on a day that they were not scheduled to dose with rimegepant, they could take one tablet of rimegepant 75 mg on that calendar day to treat a migraine (as needed \[PRN\] dosing).~After completing the OLE phase, participants had follow-up safety visits 2 and 8 weeks after the End-of-Treatment (EOT) visit. Participants who did not complete the DBT phase and/or did not enter or complete the OLE phase were to complete the EOT visit, the 2-week follow-up safety visit, and the 8-week follow-up safety visit after their early discontinuation."
62215037|NCT06533826|EXPERIMENTAL|Arn B (ADC1 T-DXd HR-)|"Enrolled participants will complete:~* Baseline visit with tumor biopsy, imaging, electrocardiogram and echocardiogram.~* Tumor biopsy between Cycle 2 Day 1 and Day 8.~* Imaging every 9 weeks.~* Cycle 1 through end of treatment:~  --Day 1 of 21 day cycle: Predetermined dose of Trastuzumab deruxtecan 1x daily.~* Cycle 4 through end of treatment:~  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab deruxtecan 1x daily.~ * Imaging on Day 1.~* End of Treatment visit with imaging, tumor biopsy, echocardiogram~* Follow up: imaging every 9 weeks.~* Long-term Follow Up: visits every 6 months."
62783919|NCT05998382|EXPERIMENTAL|intervention group|There is only one group in the study. This group will participate in a 6-week online group-based parent-mediated intervention program.
62783920|NCT04091243|EXPERIMENTAL|Romosozumab|Romosozumab (210mg) subcutaneously every month for 12 doses
62783921|NCT04091243|ACTIVE_COMPARATOR|Denosumab|Denosumab subcutaneously (60mg) every 6 months for 2 doses
62783922|NCT01750723|ACTIVE_COMPARATOR|Acetazolamide|Acetazolamide 1 g in 10 ml saline, i.v. infusion
62783923|NCT01750723|PLACEBO_COMPARATOR|Saline|Saline, 10 ml i.v. infusion
62011342|NCT03732638|PLACEBO_COMPARATOR|DBT Placebo/OL Rimegepant|"DBT Phase (Weeks 1 through 12): Participants received a single oral dose of placebo matching to rimegepant tablet EOD for 12 weeks.~OLE Phase (Weeks 13 through 64): Participants who continued to meet study entry criteria and had acceptable laboratory test results per protocol, entered the OLE phase and received a single oral dose of rimegepant 75 mg tablet EOD for 52 weeks. If participants had a migraine on a day that they were not scheduled to dose with rimegepant, they could take one tablet of rimegepant 75 mg on that calendar day to treat a migraine (PRN dosing).~After completing the OLE phase, participants had follow-up safety visits 2 and 8 weeks after the End-of-Treatment (EOT) visit. Participants who did not complete the DBT phase and/or did not enter or complete the OLE phase were to complete the EOT visit, the 2-week follow-up safety visit, and the 8-week follow-up safety visit after their early discontinuation."
62011343|NCT02381392|EXPERIMENTAL|AV400|The nurse will use the Accuvein AV400 to assist with intravenous access. If the nurse cannot place the catheter after 2 tries (two needle sticks into the skin) then the nurse will attempt to put in the catheter without using the device. While the nurse is putting in the catheter, a member of the study team will record the number of tries, the type of catheter and where the catheter is successfully put in. Afterwards the parent and nurse will be surveyed on their satisfaction and the nurse will be asked specific questions about using the AV400.
62011344|NCT02381392|NO_INTERVENTION|Standard|The nurse will use the standard technique for intravenous access (not using the Accuvein AV400). If the nurse cannot place the catheter after 2 tries (two needle sticks into the skin) then the nurse will attempt to put in the catheter with the help of the Accuvein AV400. While the nurse is putting in the catheter, a member of the study team will record the number of tries, the type of catheter and where the catheter is successfully put in. Afterwards the parent and nurse will be surveyed on their satisfaction and the nurse will be asked specific questions about using the AV400 if they crossed over to the AV400 after two failures.
62011345|NCT03444857|EXPERIMENTAL|CPAP treatment|Continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) plus standard care (according to current STEMI guidelines) for 3 months after pPCI
62011346|NCT03444857|NO_INTERVENTION|Control|Standard care (according to current STEMI guidelines) for 3 months after PPCI with no intervention for OSA
62011347|NCT06102421||Symptomatic patellar tendon (patellar tendinopathy) treated by ESWT|"The included patients show signs of unilateral patellar tendinopathy and were included in the study in accordance with the inclusion and exclusion parameters. Data of clinical symptoms and morphological measures of symptomatic patellar tendons of enrolled participants are allocated to this group. Participants will receive a low-energy focused ESWT in accordance with study protocol.~ESWT will be applied 4 times with an interval of 7 days from the BTL-6000 FSWT device with piezoelectric generator. The energy can vary between 0.12-0.20 mJ/mm2 based on the pain toleration, frequency 5 Hz, total number of shocks 2x2000. The application of the first set of shocks will be semi-static at the location of the largest USG defined pathology in the patellar tendon and the second set of shocks will be performed dynamically to the proximal tendon. These parameters were selected in accordance to ISMST guidelines."
62011348|NCT06102421||Healthy tendon|"The asymptomatic tendons of enrolled patient are allocated to this group and are considered healthy based on clinical and ultrasound examination of the patellar tendon.~In this group, no specific treatment will be performed, only patellar tendon morphology will be monitored through time."
62011349|NCT01542112|EXPERIMENTAL|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
62011350|NCT01542112|EXPERIMENTAL|No treament|Usual routine in the department
62011351|NCT01623219|EXPERIMENTAL|TeleMedicine Prolonged Exposure|Veterans will receive prolonged exposure therapy (PE)delivered via telemedicine instead of in person. For this study 9 weekly 90 minute sessions will be given over a period of up to 3 months. The first 2 sessions of each treatment will involve education, rational and treatment preparation. Sessions 3-9 will consist of recounting the traumatic event out loud and repeatedly. The purpose of this study is to determine if this treatment is effective when given through telehealth.
62011352|NCT06481150|EXPERIMENTAL|Tenapanor|30 mg Tenapanor twice a day
62400618|NCT05694923|EXPERIMENTAL|empaglifizon 10 mg plus life style and diet control|22 patient of non alcoholic fatty liver patients and non diabetic Will receive empaglifizon in minimum dose 10 mg in addition to life style modification and diet control
62400619|NCT04169789|ACTIVE_COMPARATOR|L. reuteri Low Dose|Capsules of freeze-dried L. reuteri 6475 of 5x10E8 colony-forming units (CFU) mixed with maltodextrin powder and 200 IU of cholecalciferol, taken twice daily for 24 months, yielding a total dose of either 1x10E9 L.reuteri CFU and 400 IU of cholecalciferol per day.
62400620|NCT04169789|ACTIVE_COMPARATOR|L. reuteri High Dose|Capsules of freeze-dried L. reuteri 6475 of 5x10E9 colony-forming units (CFU) mixed with maltodextrin powder and 200 IU of cholecalciferol, taken twice daily for 24 months, yielding a total daily dose of 1x10E10 L.reuteri CFU and 400 IU of cholecalciferol per day.
62577057|NCT04574908|ACTIVE_COMPARATOR|Blinded Ward|Continuous ward monitoring with hallway monitor screens covered. When an alarm goes off (limits based on the stratification of that month) the nursing staff will still be notified via their Ascom phone as per standard of care. Nursing staff will log in to WakeOne to verify the vital sign and/or go to the patient room to check on the patient. To ensure patient safety, factory alarm limits at extremes of physiological vital signs will stay on in the blinded arm. Every 4 hourly checks by nursing teams unless otherwise ordered.Continuous monitoring accessible to clinicians with pre-specified alerts at Systolic Blood Pressure alert \<70, no Mean Arterial Pressure alert, heart rate \>150 beats per minute (b/m), and peripheral capillary oxygen saturation (SpO2) \<80%. Every 4 hourly checks by nursing teams unless otherwise ordered. These alarms are consistent with current standard of care.
62577058|NCT04574908|EXPERIMENTAL|Unblinded Ward|Continuous ward monitoring with hallway monitor screens accessible for viewing but with alarm limits more narrow. When an alarm goes off (limits based on the stratification of that month) the nursing staff will still be notified via their Ascom phone as per standard of care. Nursing staff will be able to view the hallway monitors showing the vital signs in all of the rooms and/or log in to WakeOne to verify the vital sign and/or go to the patient room to check on the patient. To ensure patient safety, factory alarm limits at extremes of physiological vital signs will stay on in the blinded arm. Every 4 hourly checks by nursing teams unless otherwise ordered. Continuous monitoring accessible to clinicians with pre-specified alerts at Mean Arterial Pressure (MAP) \<65 mmHg, heart rate \>110 beats per minute (b/m), and peripheral capillary oxygen saturation (SpO2) \<90%. Every 4 hourly checks by nursing teams unless otherwise ordered.
62577059|NCT02186860|EXPERIMENTAL|CAR-T cells|Targeting CD19
62783924|NCT02599233||The study population|"The study population consists of adult surgery patients at the Nîmes University Hospital, with recruitment based on the operating theater program for a predefined six month period and for a predefined list of surgeries. The latter list of surgical acts was established according to the Medicalization of Information Systems Progam (PMSI) database. Patients are recruited either the day before or the day after surgery, in their respective departments.~Interventions:~* In hospital pain evaluation~* In hospital questionnaires~* Telephone conctact at 3 months"
62783925|NCT02503501|EXPERIMENTAL|Insulin Glulisine|Insulin Glulisine 20 IU (0.1ml/10 units in each nostril) per intranasal dose, 2 times per day for 6 months
62783926|NCT02503501|PLACEBO_COMPARATOR|Placebo|Saline 20 IU (0.1 ml in each nostril) per intranasal dose, 2 times per day for 6 months
62577060|NCT02924168|EXPERIMENTAL|Active Radial Shockwave|Every patient will receive 5,000 continuous pulses per treatment session, at 3.5 to 4 bar air pressure (resulting in an energy flux density \[EFD\] of approximately 0.07 mJ/mm2) and at 15Hz frequency. A total of 4 sessions will be performed.
62577061|NCT02924168|SHAM_COMPARATOR|Sham Radial Shockwave|Every patient will receive 5,000 continuous pulses per treatment session, without air pressure (resulting in no EFD) and at 15Hz frequency. A total of 4 sessions will be performed.
62783927|NCT01357252|EXPERIMENTAL|vildagliptin|
62783928|NCT01357252|PLACEBO_COMPARATOR|placebo|
62783929|NCT06245382|EXPERIMENTAL|Goode Health Beverage|Goode Health Beverage that is high in natural ingredients that are high in Polyphenol 3 content and also have anti-inflammatory and antioxidant properties
62011353|NCT06481150|PLACEBO_COMPARATOR|Placebo|30 mg Placebo twice a day
62400621|NCT04169789|PLACEBO_COMPARATOR|Placebo|Placebo product identical to the active product (L. reuteri) in taste and appearance but without the active component, orally twice daily, for 24 months.The placebo product contains 200 IU cholecalciferol per dose, yielding a total dose of cholecalciferol of 400 IU per day.
62577062|NCT01268618|EXPERIMENTAL|Probiotic|
62577063|NCT01268618|PLACEBO_COMPARATOR|Placebo|
62577064|NCT02941536|OTHER|Circulating Tumor Cells and Radiotherapy|Circulating tumor cells evaluation before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose and correlate with the local and distant brain progression free survival in patients with metastatic breast cancer
62011354|NCT03992690|EXPERIMENTAL|WANR protocol|Including training with Brain-machine interfaces, visuo-tactile feedback and assisted locomotion
62011355|NCT03992690|ACTIVE_COMPARATOR|Classical physiotherapy protocol|Training with classical physiotherapy protocol
62400622|NCT06722079||PEG-rhGH injection|The group of Turner syndrome patients treated with a dose of 0.2 mg/kg/ week in GenSci032-02 clinical trial.
62577065|NCT05464966|EXPERIMENTAL|Glucose-insulin-potassium|
62577066|NCT05464966|NO_INTERVENTION|Control|
62011356|NCT06654310||Learners|All general surgery trainees at each institution will have access to the training program as part of their regularly scheduled educational curriculum, regardless of training year or status as a categorical resident.
62011357|NCT00503685|EXPERIMENTAL|IMC-A12|Administered every 2 weeks
62011358|NCT00503685|EXPERIMENTAL|IMC-A12 + cetuximab|Administered every 2 weeks
62783930|NCT06245382|PLACEBO_COMPARATOR|Vanilla Base Blend Beverage|The control beverage is similar but it does not contain the same amount of fiber, anti-inflammatory, and/or antioxidant properties (i.e. mainly smaller or no amounts of flax, ginger, cinnamon, turmeric, berberine bergamot, bilberry, black garlic, and green tea).
62783931|NCT01810718|EXPERIMENTAL|Nilotinib|"3 patients (pts) will receive Nilotinib 200 mg daily dose. If no dose-limiting toxicity, the next 3 pts will be treated with next dose of Nilotinib 300 mg daily dose.~Doses will not be escalated beyond 600 or below 200 mg/die. The dose estimated as the MTD in phase I will be used for phase II."
62400623|NCT06722079||rhGH injection|"Part A control group: a group of Turner syndrome patients treated with rhGH who met the inclusion criteria of the RWS study population from participating research centers in China.~Part B control group: studies of rhGH treatment for Turner syndrome performed abroad that met all MA inclusion criteria and did not meet any MA exclusion criteria."
62400624|NCT03426735|EXPERIMENTAL|Dry heat|Dry heat application with a termal bag
62400625|NCT03426735|ACTIVE_COMPARATOR|Dry cold|Dry cold application with a termal bag
62783932|NCT06389851|EXPERIMENTAL|Case Group - Tomato-free diet|Subjects assigned to this arm will follow a tomato-free diet
62400626|NCT03509766|EXPERIMENTAL|Skin testing|All subject both allergic and non-allergic will be tested. There is only one (1) arm.
62400627|NCT01409382|ACTIVE_COMPARATOR|Lifestyle counseling|Daily brisk walking plus a carbohydrate-restricted diet
62400628|NCT01409382|NO_INTERVENTION|Standard follow-up|Prenatal care will proceed according to the routine.
62400629|NCT01247649|EXPERIMENTAL|Study group|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
62400630|NCT02136446|EXPERIMENTAL|EchoGlo™ Peripheral Nerve Block Catheter|Echogenic nerve block catheter (test)
62400631|NCT02136446|ACTIVE_COMPARATOR|Pajunk® EpiLong Catheter|Non-echogenic nerve block catheter (control)
62400632|NCT06724159||TRIDA Cohort|Patients with hormone-sensitive prostate carcinoma not castrated who have started treatment with darolutamide in combination with androgen deprivation therapy and docetaxel, from January 1, 2024
62400633|NCT06724159||NIADY Cohort|Patients with urothelial carcinoma who have started treatment with adjuvant Nivolumab on or after August 1, 2023
62783933|NCT06389851|EXPERIMENTAL|Case group - Diet enriched with tomatoes|Subjects assigned to this group will follow a diet with pre-established quantities of tomato and sauce
62011359|NCT00503685|EXPERIMENTAL|IMC-A12 + cetuximab [Kirsten rat sarcoma (K-ras) wild-type]|Participants who have experienced confirmed partial response (PR) or stable disease (SD) ≥ 24 weeks on a prior anti-EGFR-containing therapy followed by disease progression are enrolled in this arm.
62198778|NCT04653233|NO_INTERVENTION|Control|"After the theoretical lesson, the control group was taken to Fundamentals of Nursing Skill Laboratory. 1 researcher, who is responsible for the Fundamentals of Nursing, was explained on the Simple Urinary Catheterization Model by applying the steps of Checklist for Teaching Urinary Catheterization Skills. The students were allowed to ask questions and the questions asked were answered. Then all the students in the control group were taken to an empty class. The two researchers prepared the necessary materials for the urinary catheterization skill practice in the same way in separate rooms. The doors were closed to keep the environment calm during the application. One student was taken to each laboratory rooms in order not to be affected by each other. While the student was practicing, both researchers filled in the Checklist for Teaching Urinary Catheterization Skills. Satisfaction Questionnaire was given to the student who completed the application and asked to fill it."
62198779|NCT01616862||Parents of PA positive CF children|parents of children with cystic fibrosis who are positive for Pseudomonas aeruginosa
62577067|NCT05657561|EXPERIMENTAL|early mobilization|"Patients in the intervention group will be given Early Mobilization Training in the preoperative preparation unit in the preoperative period."
62011360|NCT03122912|EXPERIMENTAL|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
62198780|NCT01616862||parents of Pa negative CF children|parents of children with cystic fibrosis who are negative for pseudomonas aeruginosa
62400634|NCT06724159||EV3aL Cohort|Patients with urothelial carcinoma who have started treatment with Enfortumab Vedotin (EV) on or after January 1, 2024
62400635|NCT04882514|EXPERIMENTAL|Vaccine p*17-K4S2 (50 µg/mL) Vaccine|To evaluate the safety and immunogenicity of p\*17-CRM197 (25µg) + K4S2-CRM197 (6.25µg): TOTAL 31.25 µg
62400636|NCT04882514|EXPERIMENTAL|J8-K4S2 (100 µg/mL ) Vaccine|To evaluate the safety and immunogenicity J8-CRM197 (50µg) + K4S2-CRM197 (6.25µg): TOTAL 56.25 µg
62577068|NCT05657561|NO_INTERVENTION|routine clinical care|Patients in the control group will receive routine clinical care .Routine post-operative mobilization procedure will be delivered by clinic doctors and nurses
62783934|NCT02956187|EXPERIMENTAL|Biofeedback for constipation|Constipation will be treated by correcting functional outlet obstruction.
62011361|NCT03122912|ACTIVE_COMPARATOR|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
62011362|NCT00028834|EXPERIMENTAL|Treatment (gemcitabine hydrochloride, bevacizumab)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62011363|NCT01019681|EXPERIMENTAL|UBC injection into one leg of PVD pt|25 participants with severe peripheral vascular disease in leg(s) and they do not qualify for surgical treatment.
62198781|NCT02712489||No treatment|"All patients that participated to the therapeutic phase II trial of the Tat vaccine ISS T-003"
62198782|NCT05634148|EXPERIMENTAL|Dexmedetomidine group|Patients in this group will receive intravenous dexmedetomidine before extubation
62198783|NCT05634148|PLACEBO_COMPARATOR|Control group|Patients in this group will receive intravenous placebo (0.9 % saline) before extubation
62198784|NCT01799980||Cervical mediastinoscopy|This group will undergo cervical mediastinoscopy before surgery to stage their lung cancer (procedure decided by the surgeon).
62198785|NCT01799980||Endo-bronchial ultrasound|This group will undergo endobronchial ultrasound before surgery to stage their lung cancer (procedure decided by the surgeon).
62400637|NCT04882514|SHAM_COMPARATOR|Rabavert Vaccine|Comparator vaccine (RABAVERT)
62400638|NCT02137473|ACTIVE_COMPARATOR|Bovine protein-based fortifier|
62011364|NCT01714700|ACTIVE_COMPARATOR|High protein diet, Resistance exercise|High protein diet, Resistance exercise total calories 2400 Kcal/day, 55% carbohydrate, 30% protein, and 15% fat
62400639|NCT02137473|EXPERIMENTAL|Human milk-based fortifier|
62400640|NCT03664570|EXPERIMENTAL|Condition A|"* Infusion rate = 25 ml/h~* Radiography: confirmation balloon position~* VIPUN Balloon Catheter~* 13C-Octanoate Breath Test o"
62011365|NCT01714700|PLACEBO_COMPARATOR|Standard diet, Resistance exercise|total calories 2400 Kcal/day, 60% carbohydrate, 15% protein, and 25% fat; ST group
62011366|NCT03197220|EXPERIMENTAL|fish|
62198786|NCT00823953|PLACEBO_COMPARATOR|Placebo|placebo powder (wheat flour) The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
62198787|NCT00823953|ACTIVE_COMPARATOR|Momordica charantia|"Thirty patients will be assigned to each arm in a double blind manner. The active arm will be administered capsules containing a total of 500 mg of Momordica charantia freeze dried powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.~The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3."
62400641|NCT03664570|EXPERIMENTAL|Condition B|"* Infusion rate = 75 ml/h~* Magnetic resonance imaging~* VIPUN Balloon Catheter~* 13C-Octanoate Breath Test"
62400642|NCT03664570|EXPERIMENTAL|Condition C|"* Infusion rate = 250 ml/h~* Magnetic resonance imaging~* VIPUN Balloon Catheter~* 13C-Octanoate Breath Testt"
62400643|NCT02264925|EXPERIMENTAL|Deep Brain Stimulation|All of included patients will receive a standard deep brain stimulation of the thalamus in order to reduce their essential tremor
62400644|NCT04197856|ACTIVE_COMPARATOR|Control / Family-mediated disclosure (standard care)|Genetic counseling according to current clinical practice
62400645|NCT04197856|EXPERIMENTAL|Intervention / Health-care assisted disclosure|Genetic counseling according to current clinical practice with the addition of an offer from health care provider to mail letters directly to eligible at-risk relatives.
62400646|NCT03626337||Hospital-based cohort|100 mg thiamine provided via intramuscular and/or intravenous injection (Thiamine 100 MG/ML) daily for 3 days
62400647|NCT03626337||Community-based cohort|Sex-, age- and regionally matched comparison group
62400648|NCT02129439|EXPERIMENTAL|SB012|"SB012 will be available in this clinical trial in a concentration of 7.5 mg/ml hgd40 in 30ml PBS. The maximum daily dose will not exceed 225mg.~The study will be continued until 18 subjects have completed the four-week treatment phase according to te protocol. 12 of the 18 subjects will receive verum SB012 (in a 2:1 randomization SB012:Placebo)"
62011367|NCT03197220|EXPERIMENTAL|walnut|
62400649|NCT02129439|PLACEBO_COMPARATOR|Placebo|"Placebo will be administered with an identical volume of 30ml PBS.~The study will be continued until 18 subjects have completed the four-week treatment phase according to te protocol. 6 of the 18 subjects will receive placebo (in a 2:1 randomization SB012:Placebo)"
62400650|NCT01809847|EXPERIMENTAL|Ofatumumab|First dose of 300 mg Ofatumumab followed by seven weekly infusions of 2000 mg. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.
62577069|NCT06578013|EXPERIMENTAL|acupressure ice massage + pelvic rocking exercises|It will include 25 participants suffering from primary dysmenorrhea who will receive acupressure ice massage on SP6 and L14 acupoints, 10 minutes on each point for 20 minutes each session, 5 sessions per cycle (through the 5 days before menstruation) for 3 consecutive menstrual cycles, in addition to pelvic rocking exercises, 15 minute/session, 3 times /week, for 3 successive menstrual cycles.
62577070|NCT06578013|ACTIVE_COMPARATOR|pelvic rocking exercises|It will include 25 participants suffering from primary dysmenorrhea, who will perform pelvic rocking exercises only, 15 minutes/session, 3 times /week, for 3 successive menstrual cycles.
62783935|NCT02956187|ACTIVE_COMPARATOR|Fiber supplementation|Constipation will be treated by a fiber supplement
62198788|NCT01465763|EXPERIMENTAL|tofacitinib 10 mg BID|
62011368|NCT03197220|EXPERIMENTAL|fish-walnut|
62011369|NCT01352520|EXPERIMENTAL|SGN-35|1.8 mg/kg intravenously Day 1 of 21-day cycle.
62011370|NCT04745416||Leukemia and COVID-19|Patients diagnosed with acute lymphoblastic leukemia according to the criteria of the World Health Organization and confirmed diagnosis of COVID-19 by RT-PCR test
62011371|NCT04745416||Leukemia|Patients diagnosed with acute lymphoblastic leukemia according to the criteria of the World Health Organization without suspicion of COVID-19
62011372|NCT00764075|EXPERIMENTAL|1|guided implantation of the left ventricular lead
62011373|NCT00764075|PLACEBO_COMPARATOR|2|standard implantation of the left ventricular lead
62011374|NCT00764075|EXPERIMENTAL|Pilot Group|feasibility of guided placement of CRT-leads in 20 Patients
62198789|NCT01465763|PLACEBO_COMPARATOR|Placebo|
62011375|NCT01383902|OTHER|dessert / chocolate|
62011376|NCT06167096|EXPERIMENTAL|Lavender|4 drops of lavender essential oil will be added to an electronic diffusion device with 100ml of water. The device will be turned on 15 minutes before surgery for participants who previously agreed to the study. The device will be turned off after completion of the post- layer questionnaires assessing anxiety and participant experience.
62011377|NCT06167096|PLACEBO_COMPARATOR|Water|On the day of surgery, participants who previously completed the electronic consent will be brought to a room with a diffuser. The diffusers will be turned on 15 minutes before scheduled time of surgery with just water for the control group
62011378|NCT04346615|EXPERIMENTAL|Zavegepant|Zavegepant (BHV-3500) 10 mg intranasal (IN) dosed every 8 hours (3 times/day) (Q8h) for 14 days
62577071|NCT06247605|EXPERIMENTAL|active group（AL8326）|Oral AL8326 (28-day cycle, once daily) until confirmation of disease progression, intolerable toxicity or death, voluntary withdrawal from the study, for a total of no more than 12 months (approximately 13 cycles).
62577072|NCT06247605|PLACEBO_COMPARATOR|Control group（Placebo)|Oral placebo (28-day cycle, once daily) until confirmation of disease progression, intolerable toxicity or death, voluntary withdrawal from the study, for a total of no more than 12 months (approximately 13 cycles).
62577073|NCT06529445|EXPERIMENTAL|High Dose VC004 group|
62011379|NCT04346615|PLACEBO_COMPARATOR|Placebo|"Placebo Q8h for 14 days~Subjects dosed every 8 hours; 3 times/day (Q8h)"
62011380|NCT04783129|EXPERIMENTAL|Face-to-face group|Face-to-face group (FFG), in which participants, in groups of 10 persons, followed a multidisciplinary health education program composed of 10 monthly face-to-face lectures
62011381|NCT04783129|ACTIVE_COMPARATOR|Remote group|Remote group (RG), in which individuals followed 10 monthly remote lectures
62400651|NCT05954117|EXPERIMENTAL|Interventional|patients with esophageal or gastroesophageal adenocarcinoma included to evaluate the energy expenditure before and after chemotherapy and evaluate parameters of cachexia
62400652|NCT00953576|EXPERIMENTAL|Phase I Dose Level 1 (DL1): KHAD+L (250 mg)|"For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.~Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day~Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 250 mg orally 1x day~Participants are treated until unacceptable toxicity, disease progression or withdrawal."
62400653|NCT00953576|EXPERIMENTAL|Phase I Dose Level 2 (DL2): KHAD+L (500 mg)|"For the initial four weeks (1 cycle=28 days), participants will receive KHAD treatment.~Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day~Participants will start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 500 mg orally 1x day"
62400654|NCT00953576|EXPERIMENTAL|All Phase I Participants|"For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.~Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day~Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: according to the established dose escalation schedule~Participants are treated until unacceptable toxicity, disease progression or withdrawal."
62400655|NCT06551467|EXPERIMENTAL|Intervention Group|The Online Ayurveda Program for Detox and Lifestyle Intervention Group will be divided into three individual psychophysiological Dosha-specific treatment groups. Participants will be assigned to these groups based on their results from the Ayurveda Dosha Self-Assessment questionnaire.
62400656|NCT01459016|EXPERIMENTAL|Imaging Biomarkers|
62400657|NCT04145531|EXPERIMENTAL|JZP-458|"Part A (IM JZP-458) of the study will have 2 IM cohorts:~* Cohort 1: a JZP-458 repeat dose/confirmatory cohort; a final IM JZP-458 dose level will be selected, and~* Cohort 2: an expansion cohort to confirm the efficacy and safety of the final IM JZP-458 dose level and schedule~Part B (IV JZP-458 Dose Confirmation) will be conducted to define the optimal dose of the IV administration of JZP-458 for further study in ALL/LBL patients as a repeated dose.~Additional courses of JZP-458 (IM or IV depending on patient's allocation at study enrollment) will be administered based on each patient's original treatment plan for as long as the patient derives clinical benefit."
62400658|NCT05677516||Group 1|Patients undergoing cryoablation of pulmonary veins with paroxysmal or persistent AF with ongoing AF during ablation.
62400659|NCT05677516||Group 2|Patients undergoing cryoablation of pulmonary veins with paroxysmal AF, in sinus rhythm during the procedure.
62577074|NCT06529445|EXPERIMENTAL|Median Dose VC004 group|
62577075|NCT06529445|EXPERIMENTAL|Low Dose VC004 group|
62577076|NCT03800810|EXPERIMENTAL|Control|Week 1: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis)
62783936|NCT01088620|EXPERIMENTAL|Panitumumab plus pemetrexed and cisplatin (PemCisP)|
62011382|NCT04783129|SHAM_COMPARATOR|Control group|Control group (CG), in which participants followed no education program (lectures)
62011383|NCT05144152||History of colorectal adenomas group|Subjects with known colorectal adenomas at the index colonoscopy
62011384|NCT05676047|EXPERIMENTAL|Therapy Group|The Therapy Group will receive 6-10 individual sessions of 30-60 minutes each, delivered by a trained Occupational Therapist or Speech-Language Pathologist. The therapy will be delivered over a 4-week timeframe, with the total number of sessions per participant depending on the number of sessions needed to achieve their treatment targets. Each participant in the Therapy Group will identify three cognitive targets for treatment. Progress in reaching those targets will be documented using Goal Attainment Scaling (GAS)
62011385|NCT05676047|ACTIVE_COMPARATOR|Educational Group|The Education group will receive information about self-management of cognitive symptoms at the time of randomization, a common alternative for adults with Long COVID cognitive symptoms who do not receive Individual Therapy.
62011386|NCT01168999|ACTIVE_COMPARATOR|spinal manipulation|a spinal manipulation known to be effective in the treatment of low back pain for some individuals
62584934|NCT06111885|ACTIVE_COMPARATOR|Indapamide + Chlorthalidone + Hydrochlorothiazide|1 capsule containing 2.5 mg indapamide per day for 28 days, followed by a 28 days wash out phase, followed by a second treatment phase with 1 capsule containing 25 mg chlorthalidone per day for 28 days, followed by a 28 days wash out phase, followed by a third treatment phase with 1 capsule containing 50 mg hydrochlorothiazide per day for 28 days.
62011387|NCT01168999|PLACEBO_COMPARATOR|sham spinal manipulation|a sham spinal manipulation intended to mimic the studied spinal manipulation
62011388|NCT01168999|NO_INTERVENTION|natural history|No intervention is provided to participants in this arm of the study
62011389|NCT01168999|PLACEBO_COMPARATOR|Enhanced sham spinal manipulation|"a sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
62011390|NCT06015698|EXPERIMENTAL|Tubal disconnection|"1. The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated~2. The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently~3. The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow~4. Then, the tube is severed in the middle of the burn area with laparoscopic scissors~5. Ensure adequate hemostasis"
62011391|NCT06015698|ACTIVE_COMPARATOR|Salpingectomy|"1. The tube will be removed from its anatomical attachements by progressive bipolar coagulation~2. Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors~3. Removal of the tube through one of the ancillary ports using artery forceps~4. Ensure adequate hemostasis"
62011392|NCT00784446|NO_INTERVENTION|XELOX, Bevacizumab, Imatinib|
62783937|NCT01088620|ACTIVE_COMPARATOR|Pemetrexed and cisplatin (PemCis)|
62011393|NCT02549144|EXPERIMENTAL|High fat/cholesterol diet|High-fat/high-cholesterol (HFHC) normocaloric diet for 14 days.
62011394|NCT02549144|EXPERIMENTAL|Low fat/cholesterol diet|Low-fat/low-cholesterol (LFLC) normocaloric diet for 14 days.
62011395|NCT01696435|ACTIVE_COMPARATOR|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
62011396|NCT01696435|ACTIVE_COMPARATOR|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])"
62011397|NCT01696435|ACTIVE_COMPARATOR|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~Fish oil placebo"
62011398|NCT01696435|ACTIVE_COMPARATOR|Vitamin D + fish oil|"Vitamin D3 (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])"
62783938|NCT05846555||general anesthesia|patients observed under general anesthesia
62011399|NCT01792999|NO_INTERVENTION|Non-contrast KBCT|About 187 subjects, who had diagnostic imaging of the breast including mammography and were categorized as Breast Imaging-Reporting and Data System(BIRADS) scores 1, 2, 3, 4, or 5, received KBCT imaging without contrast injection.
62011400|NCT01792999|EXPERIMENTAL|Contrast-enhanced KBCT|About 231 subjects, who had diagnostic imaging of the breast including mammography and were scheduled for biopsy or surgery, received contrast-enhanced KBCT imaging of the affected breast before biopsy or surgery.
62011401|NCT01956175|EXPERIMENTAL|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation once daily for 10 minutes on three consecutive days.
62400660|NCT05677516||Group 3|Patients undergoing pulmonary veins isolation with PFA with paroxysmal AF, in sinus rhythm during the procedure.
62783939|NCT05846555||spinal anesthesia|patients observed under spinal anesthesia
62783940|NCT02105675|EXPERIMENTAL|DCVAC/PCa add on to Standard of Care|Combination therapy with Dendritic Cells DCVAC/PCa and Standard of Care
62783941|NCT02105675|ACTIVE_COMPARATOR|Standard of Care|Docetaxel as an Active Comparator
62783942|NCT05352425|EXPERIMENTAL|MobiusHD|Each subject enrolled in the study will undergo implantation of the MobiusHD® device
62783943|NCT06576206|EXPERIMENTAL|conventional physical therapy|Control Group
62783944|NCT06576206|EXPERIMENTAL|bin therapy and finger gnosia|Experimental Group
62783945|NCT02140749|EXPERIMENTAL|sc-FOS 2g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 2 g/day (4 weeks)
62783946|NCT02140749|EXPERIMENTAL|sc-FOS 4g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 4 g/day (4 weeks)
62783947|NCT02140749|EXPERIMENTAL|sc-FOS 8g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 8 g/day (4 weeks)
62011402|NCT01956175|SHAM_COMPARATOR|Sham stimulation|Sham stimulation once daily for 10 minutes on three consecutive days. If the subject cannot be decannulated after three days of sham stimulation, another three days of real electrical pharyngeal stimulation will be delivered.
62011403|NCT03654677|EXPERIMENTAL|inactivated hepatitis A vaccine|Inactivated hepatitis A virus antigen 500U(Name of viral strain: TZ84)
62011404|NCT03654677|ACTIVE_COMPARATOR|Havrix Inj|1440 ELISA/mL_Adult Inj.(Name of Viral strain: HM175 Inj)
62011405|NCT06053658|EXPERIMENTAL|Combination Tivozanib and Nivolumab|Nivolumab by vein over about 60 minutes every 4 weeks (Day 1 of each cycle). Tivozanib tablets by mouth 1 time every day for 21 days (Days 1-21 of each cycle), and then no tablets on Days 22-28 of each cycle.
62011406|NCT04768647||Main cohort|Main cohort of all patients
62011407|NCT04768647||Subgroup of patients with imbalance|Subgroup of patients with imbalance
62011408|NCT02787356|EXPERIMENTAL|TDS Lidocaine 5%; generic|TDS Lidocaine 5%; generic with trained skin graders and images of skin
62011409|NCT02787356|EXPERIMENTAL|TDS Lidocaine 5%; RLD|TDS Lidocaine 5%; RLD with trained skin graders and images of skin
62011410|NCT06663150|EXPERIMENTAL|Experimental group|"Education Component: Lectures and workshops aimed at enhancing awareness and personal growth through knowledge and emotional reflection.~Cognitive Component: One-hour sessions divided into introduction (15 min), cognitive stimulation activities (35 min), and closure with reflection and a brief survey.~Physical Activity Component: A 10-minute warm-up, followed by 30 minutes of guided exercises for balance, coordination, and strength, ending with a 10-minute cool-down.~Nutrition Component: Practical workshops focused on healthy eating, including menu planning and food preparation.~Socio-Community and Occupational Component: Encourages community integration and social networking, with gardening activities for growing herbs and vegetables.~Autonomous Activities: Participants implement physical activity recommendations in daily life, with weekly follow-ups by the research team using the RedCap platform for monitoring."
62198790|NCT04520568|ACTIVE_COMPARATOR|HFNC group|For HFNC group, F\&P AIRVOTM 2 will be adjusted to give the patients the oxygen flow at 50L/min and the FiO2 at 1.0.Then after three minutes of preoxygenation, sedation will be conducted by giving 25 µg fentanyl and a bolus of 1 mg/kg propofol followed by continuous infusion of propofol using a target-controlled infusion system (TCI pump TE371; Terumo Corporation, TokyoJapan).
62400661|NCT05677516||Group 4|Patients undergoing RF ablation of the pulmonary veins using an electroanatomical system with paroxysmal AF, in sinus rhythm during the procedure.
62783948|NCT01680744|EXPERIMENTAL|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure \> 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
62783949|NCT01680744|NO_INTERVENTION|Standard Treatment|
62783950|NCT04659525|EXPERIMENTAL|Evolocumab + Ezetimibe|Patients in this arm will receive subcutaneous evolocumab 140 mg every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
62783951|NCT04659525|PLACEBO_COMPARATOR|Placebo + Ezetimibe|Patients in this arm will receive subcutaneous placebo every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
62783952|NCT01456312|SHAM_COMPARATOR|HBsAg quantification>20,000 IU/ml|stop peginterferon alfa 2a if patients reach HBsAg quantification\>20,000 Iu/ml at 12w
62783953|NCT01456312|SHAM_COMPARATOR|HBsAg<=1500IU/ml|extend peginterferon alfa 2a until 48weeks
62783954|NCT01456312|SHAM_COMPARATOR|HBsAg >1500 <=20,000 IU/ML|add Entecavir for 12w with peginterferon alfa 2a then, extend peginterferon alfa 2a until 48w
62783955|NCT02205242|EXPERIMENTAL|Azithromycin|"N = 250 From day 1 up to and including day 3: 500 mg azithromycin PO once a day From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days~N= 30 During 7 days post discharge from hospital (0 months), 3 months and 9 months, the patient will wear the Dynaport® which will register the patient's physical activity"
62783956|NCT02205242|PLACEBO_COMPARATOR|Placebo|"N = 250 From day 1 up to and including day 3: 500 mg placebo PO once a day From day 4 up to and including day 90: 250 mg placebo PO once every 2 days~N= 30 During 7 days post discharge from hospital (0 months), 3 months and 9 months, the patient will wear the Dynaport® which will register the patient's physical activity"
62783957|NCT04085757|EXPERIMENTAL|long interval dinoprostone|A small envelope including two labeled plastic bags (A \& B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
62783958|NCT04085757|ACTIVE_COMPARATOR|short interval dinoprostone|A small envelope including two labeled plastic bags (A\& B) (each bag containing either 1 dinoprostone tablets(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
62783959|NCT04053309||Males undergoing TESE or microTESE|All male patients undergoing surgical sperm extraction (TESE or microTESE) procedures as part of an IVF cycle at our center will be reviewed for inclusion and offered participation in the study. These men have been previously consented to the TESE or microTESE procedure at our center. The study will utilize the otherwise discarded round spermatids found in the TESE and microTESE surgical samples as the study samples being used for the ROSI procedure.
62783960|NCT05432986||Hydrocephalus Patients|Hydrocephalus patients with an existing ventriculoperitoneal shunt and symptoms of a shunt malfunction.
62783961|NCT01506999||Stable phase of ischemic heart disease|patients with history of angina pectoris, or myocardial infarction
62783962|NCT01506999||acute phase of ischemic heart disease|patients with unstable angina or acute myocardial infarction
62783963|NCT01506999||control group|subjects without ischemic heart disease (IHD)
62783964|NCT05043389|EXPERIMENTAL|Obstructive sleep apnea|myofunctional therapy program
62400662|NCT01566747|EXPERIMENTAL|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
62400663|NCT06546995|EXPERIMENTAL|Part A: NMRA-323511|
62783965|NCT05043389|NO_INTERVENTION|control|standard treatment
62783966|NCT00982839|ACTIVE_COMPARATOR|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
62577077|NCT03800810|EXPERIMENTAL|Intervention 1|Week 1: Intraarticular injection of 10x10\^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories)
62400664|NCT06546995|PLACEBO_COMPARATOR|Part A: Placebo|
62400665|NCT06546995|EXPERIMENTAL|Part B: NMRA-323511|
62400666|NCT06546995|PLACEBO_COMPARATOR|Part B: Placebo|
62011411|NCT06663150|NO_INTERVENTION|Control group|The control group will maintain the usual care provided by their healthcare service provider.
62011412|NCT01088516|EXPERIMENTAL|Aluvia-based HAART|Study regimen: ZDV/3TC (combivir) + 2 Aluvia Tabs all PO BID to start at 14-30 weeks gestational age (GA) and continue through labor and as long as the mother breastfeeds
62400667|NCT04009122|EXPERIMENTAL|IGEN-0206|a sachet after each meal, preferably (3 sachets per day)
62400668|NCT04009122|PLACEBO_COMPARATOR|Placebo|a sachet after each meal, preferably (3 sachets per day)
62400669|NCT04009122|NO_INTERVENTION|group C|standard treatment
62400670|NCT00475527|NO_INTERVENTION|iron only|Only iron therapy
62400671|NCT00475527|EXPERIMENTAL|iron + HP therapy|Iron + 'omeprazole,clarithromycin,amoxicillin (or metronidazole)
62400672|NCT04742439|SHAM_COMPARATOR|Sham stimulation|
62400673|NCT04742439|EXPERIMENTAL|Individualized stimulation|
62400674|NCT04742439|EXPERIMENTAL|2mA stimulation|
62783967|NCT00982839|EXPERIMENTAL|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
62783968|NCT05335941|EXPERIMENTAL|Pemetrexed Plus AB928 (Etrumadenant) Plus AB122 (Zimberelimab)|All patients will receive combination therapy of pemetrexed and ZIMBERELIMAB (AB122) intravenously every 3 weeks as well as ETRUMADENANT (AB928) orally daily.
62783969|NCT05431504|EXPERIMENTAL|Treatment group|Dalpiciclib in combination with endocrine therapy by physicians choice
62783970|NCT04120363|PLACEBO_COMPARATOR|Placebo|single intramuscular injection of 750 mg sesame oil solution on Day 8
62783971|NCT04120363|EXPERIMENTAL|Testosterone|single intramuscular injection of 750 mg testosterone undecanoate on Day 8
62783972|NCT01815840|EXPERIMENTAL|Vismodegib Intermittent Schedule|Vismodegib intermittent schedule of 12 weeks vismodegib followed by 8 weeks placebo, repeated 3 times with a final course of vismodegib (total 72 weeks), followed by 52 weeks treatment-free follow up
62783973|NCT01815840|EXPERIMENTAL|Vismodegib Induction Followed by Intermittent Schedule|Vismodegib beginning with 24 weeks induction followed by intermittent schedule 8 weeks placebo, 8 weeks vismodegib (total 72 weeks), followed by 52 weeks treatment-free follow up
62011413|NCT01527916|PLACEBO_COMPARATOR|sugar pill|
62198791|NCT04520568|PLACEBO_COMPARATOR|control group|induction of general anaesthesia will be done using 2 mg/kg propofol and 1 µg/kg fentanyl. Double lumen tube will be facilitated by cisatracurium 0.2 mg/kg. Anaesthesia will be maintained with isoflurane 0.8 %-1% in 100% oxygen and maintenance dose of cisatracurium 0.02 mg/kg when needed. At the end of surgery, residual neuromuscular paralysis will be antagonized with neostigmine 0.05 mg/kg and atropine 0.01 mg/kg.
62198792|NCT03678090|ACTIVE_COMPARATOR|tPA standard dosage|Tissue Plasminogen Activator (tPA) dose of 10 to 25 mg.
62198793|NCT03678090|EXPERIMENTAL|tPA low dosage|tPA dose of 2.5mg
62198794|NCT00538772||Biomarker|
62400675|NCT04742439|EXPERIMENTAL|4mA stimulation|
62783974|NCT03458650|EXPERIMENTAL|LXI-15028 50 mg|For 50 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo
62011414|NCT01527916|ACTIVE_COMPARATOR|donepezil|
62198795|NCT04922177|EXPERIMENTAL|CAD/CAM Group|For the CAD/CAM group, an indirect ceramic restoration will be made using an optical impression.
62198796|NCT04922177|ACTIVE_COMPARATOR|Direct method Group|For the direct method group, a restoration using a Glass Ionomer Cement will be performed.
62400676|NCT06450990|EXPERIMENTAL|BGY-1601-VT #1|Arm 1: BGY-1601#1: one verum tablet at Day 0 (D0) and one placebo tablet at Day 2 (D2)
62011415|NCT01527916|EXPERIMENTAL|ABT-126 Low Dose|low dose
62011416|NCT01527916|EXPERIMENTAL|ABT-126 Middle Dose|middle dose
62011417|NCT01527916|EXPERIMENTAL|ABT-126 high dose|high dose
62011418|NCT05827302|EXPERIMENTAL|Device: Health Gauge AI-Based Wearable Device - Model: Phoenix|
62783975|NCT03458650|EXPERIMENTAL|LXI-15028 100 mg|100 mg dose group plans to enroll 14 healthy subjects (investigational drug:placebo=10:4), half males and half females. Five subjects of each gender will receive LXI-15028, while 2 subjects of each gender will receive placebo. Intra-group randomization will be implemented in each dose group; each subject will receive either LXI-15028 or placebo.
62783976|NCT03458650|EXPERIMENTAL|LXI-15028 200 mg|200 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo
62783977|NCT03637569||Cancer patients|Newly diagnosed pancreatic, bile duct or GB cancer patients at samsung medical center.
62783978|NCT03843983|OTHER|Lipiflow treatment|Lipiflow® application: Treated with Lipiflow. All patients in this study are treated with Lipiflow once.
62783979|NCT04741490|EXPERIMENTAL|treatment group|The adjuvant treatment of radiotherapy combined with carrilizumab lasted for 6 cycles
62783980|NCT02085109|EXPERIMENTAL|High fat meal|A high fat milkshake containing 60.6 grams of fat
62783981|NCT02085109|PLACEBO_COMPARATOR|Low fat meal|A Low fat milkshake containing 10.5 gram of fat
62783982|NCT02085109|EXPERIMENTAL|A Low fat meal containing theobromine|A low fat milkshake containing 10.5 grams of fat supplemented with 850 mg of theobromine
62783983|NCT05002179|EXPERIMENTAL|Treatment group|"Treatment group, 3 x 2 Echinaforce chewable tablets (EC, 3x800mg) daily during prevention and 5 x 2 EC (5x800mg) during acute viral Respiratory tract infection vRTIs"
62783984|NCT05002179|NO_INTERVENTION|Control Group|"No treatment Comparison group. Participants are free to take none or any preventive measure. Participants are requested not to take any Echinacea products"
62011419|NCT06662838|NO_INTERVENTION|control grubu|Children will first be administered the Personal Information Form, Ergonomics Awareness Questionnaire for Children and First Aid Knowledge Level Questionnaire for Children. After one month without any intervention, Ergonomics Awareness Questionnaire for Children and First Aid Knowledge Level Questionnaire for Children will be administered to the children again.
62400677|NCT06450990|EXPERIMENTAL|BGY-1601-VT #2|BGY-1601#2: one verum tablet at D0 and one verum tablet at D2
62577078|NCT03800810|EXPERIMENTAL|Intervention 2|Week 1: Intraarticular injection of 10x10\^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis)
62011420|NCT06662838|EXPERIMENTAL|intervention group|Children will first be administered the Personal Information Form, Ergonomics Awareness Questionnaire for Children and First Aid Knowledge Level Questionnaire for Children. Afterwards, children will be included in the Ergonomics Awareness and First Aid Training Program. One month after the training, Ergonomics Awareness Questionnaire for Children and First Aid Knowledge Level Questionnaire for Children will be administered again.
62011421|NCT03011814|EXPERIMENTAL|Arm I (durvalumab)|Patients receive durvalumab IV over 1 hour on day 1. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
62783985|NCT03308994||Oral first line disease modifying treatments|
62783986|NCT03308994||Injectable first line disease modifying treatments|
62783987|NCT00492336|ACTIVE_COMPARATOR|Rasagiline|Treatment with Rasagiline
62783988|NCT00492336|PLACEBO_COMPARATOR|Inactive pill|Treatment with Placebo
62783989|NCT05389176|EXPERIMENTAL|Group A|Esmolol is used 6 to 24 hours after onset of septic shock in patients with fluid optimization to control heart beats between 70-100bpm.
62783990|NCT05389176|EXPERIMENTAL|Group B|Esmolol is used 24 hours after onset of septic shock in patients to control heart beats between 70-100bpm.
62783991|NCT05389176|NO_INTERVENTION|Group C|patients received conventional therapy in accordance with septic shock guidelines 2021
62783992|NCT02624453|EXPERIMENTAL|IMMY LFA positive patients|HIV positive patients who will be positive for cryptococcal antigen (by the IMMY LFA test) would be consented for lumbar puncture in search of cryptococcal meningitis (CM). If CM is not confirmed, they would be prescribed pre-emptive fluconazole based therapy at 800mg/day for two weeks (placed on antiretroviral therapy two weeks after screening for cryptococcal antigen), then 400mg/day for 8 weeks and thereafter 200mg/day until CD4 counts increases beyond 200cells/ml. (CM confirmed cases will be referred to the ACTA trial ISRCTN45035509)
62783993|NCT02624453|ACTIVE_COMPARATOR|IMMY LFA negative patients|HIV positive patient who will be negative for cryptococcal antigen (by the IMMY LFA test) would not be consented for lumbar puncture, will be placed immediately on antiretroviral therapy immediately after screening for cryptococcal antigen and would not be placed on fluconazole pre-emptive therapy.
62783994|NCT02736916|EXPERIMENTAL|HS-WBRT PCI|LD-SCLC patients with HS-WBRT PCI
62783995|NCT02736916|ACTIVE_COMPARATOR|Conventional PCI|LD-SCLC patients with Conventional PCI
62783996|NCT03105349|EXPERIMENTAL|Single arm|16 weeks treatment with elbasvir/grazoprevir plus sofosbuvir and ribavirina
62011422|NCT03011814|EXPERIMENTAL|Arm II (durvalumab, lenalidomide)|Patients receive durvalumab IV over 1 hour on day 1 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
62011423|NCT03873051|EXPERIMENTAL|Challenge-Focused Program|This group will receive the challenge-focused group program
62011424|NCT03873051|EXPERIMENTAL|Rewards-Focused Program|This group will receive the rewards-focused group program
62011425|NCT04839081||RA patients|RA patients diagnosed according to the 1987 ACR Criteria
62011426|NCT04839081||Control|Age- and sex-matched control subjects with nociceptive/mechanical pain complaint other than in hand, lasting more than three months
62400678|NCT06450990|PLACEBO_COMPARATOR|PLACEBO|Placebo: one placebo tablet at D0 and one placebo tablet at D2
62400679|NCT06704516|EXPERIMENTAL|Hormone Replacement Therapy|Participants starting any brand, composition, route and dose of oestrogen-based systemic hormone replacement therapy, will be included in this group.
62400680|NCT04519827|EXPERIMENTAL|New Rice-based hydrolysate|The TEST formula is a new Rice-based hydrolysate with new ingredient.
62400681|NCT04519827|PLACEBO_COMPARATOR|Amino-acid based formula|The PLACEBO is an Amino-acid based formula.
62400682|NCT06723535|EXPERIMENTAL|Group A and C|
62400683|NCT06723535|EXPERIMENTAL|Group B: Period 1|
62400684|NCT06723535|EXPERIMENTAL|Group B: Period 2|
62400685|NCT04435652|EXPERIMENTAL|Experimental: Cohort A|Participants receive QL1604 and nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle. If not disease progression after 4 cycles, participants receive QL1604 monotherapy until disease progression、unacceptable toxicity or up to 2 years.
62400686|NCT04435652|EXPERIMENTAL|Experimental: Cohort B-arm1|Participants receive QL1604 and nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle. If not disease progression after 4 cycles, participants receive QL1604 monotherapy until disease progression、unacceptable toxicity or up to 2 years.
62011427|NCT04746937|PLACEBO_COMPARATOR|Control Group|They will receive standard therapy plus placebo
62400687|NCT04435652|EXPERIMENTAL|Experimental: Cohort B-arm2|Participants receive paclitaxel on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
62011428|NCT04746937|ACTIVE_COMPARATOR|Nitazoxanide Group|They will receive standard therapy plus nitazoxanide
62198797|NCT05680753|EXPERIMENTAL|Stratified Blended Approach arm|First, physiotherapists will use two stratification tools to decide the most suitable content and intensity as well as mode of care delivery of primary care physiotherapy. The content and intensity of physiotherapy will be matched to the patient's risk of persistent disabling pain as assessed with the Keele STarT MSK tool. The mode of care delivery of physiotherapy will be matched to the patient's suitability for blended care as assessed using the Dutch Blended Physiotherapy Checklist (i.e. yes or no). Second, physiotherapists will receive two practical tools to provide the matched treatment of the mode of care delivery. If considered suitable for blended care, the patient will receive a blended physiotherapy treatment (e-Exercise), in which a smartphone app with personalized information, exercises and physical activity modules is an integral part of physiotherapy treatment. If patients are considered not to be suitable for blended care, a paper-based workbook will be integrated.
62198798|NCT05680753|ACTIVE_COMPARATOR|Usual physiotherapy arm|Patients in the usual physiotherapy arm will be offered usual care (face-to-face or video consults) based upon the recommendations of the guidelines of the Royal Dutch Association for Physiotherapy (KNGF). The clinical guideline for neck pain, recommends categorization in treatment profiles based on: the severity of neck pain, the course of symptoms (normal vs. deviant) and the presence of psychosocial factors that may hinder recovery (yes vs. no). The clinical guideline for complaints of the arm, neck and shoulder recommends categorization in treatment profiles based on the region of complaints indicated as most problematic and the relationship between complaints, disabilities, and limitations in participation. No stratification tools to identify patient subgroups and subsequently match them to a treatment are recommended by the guidelines.
62577079|NCT03800810|EXPERIMENTAL|Intervention 3|Week 1: Intraarticular injection of 10x10\^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories)
62577080|NCT04601519||Patients-type 1 diabetes|Participants are recruited by e-mail, among the users of the libreview platform (Abbott), who are followed up for type 1 diabetes at the CHU Grenoble Alpes (France), to participate in an anonymous online questionnaire and to allow their glycemic data extracted from the libreview platform to be used for the research.
62577081|NCT03224000|EXPERIMENTAL|MRI Guided Intensity Modulated Radiotherapy (IMRT)|"Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Video-strobe procedure performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~IMRT planned with MRI guidance. Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days."
62577082|NCT03224000|ACTIVE_COMPARATOR|Standard-of-Care Intensity Modulated Radiotherapy (IMRT)|"Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Video-strobe procedure performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~IMRT planned by standard-of-care. Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days."
62584935|NCT06111885|ACTIVE_COMPARATOR|Chlorthalidone + Hydrochlorothiazide + Indapamide|1 capsule containing 25 mg chlorthalidone per day for 28 days, followed by a 28 days wash out phase, followed by a second treatment phase with 1 capsule containing 50 mg hydrochlorothiazide per day for 28 days, followed by a 28 days wash out phase, followed by a third treatment phase with 1 capsule containing 2.5 mg indapamide per day for 28 days.
62783997|NCT02484352|OTHER|0 mg/kg of oxycodone|Intervention: patients receive 10 ml of normal saline without oxycodone through intravenous route before intubation.
62783998|NCT02484352|OTHER|0.05 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.05 mg/kg of oxycodone in normal saline through intravenous route before intubation.
62783999|NCT02484352|OTHER|0.1 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.1 mg/kg of oxycodone in normal saline through intravenous route before intubation.
62784000|NCT02484352|OTHER|0.15 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.15 mg/kg of oxycodone in normal saline through intravenous route before intubation.
62011429|NCT02738021|EXPERIMENTAL|STRONG|A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
62198799|NCT00701324|EXPERIMENTAL|Arm A|BI 811283, 24h infusion d1 and d15 every 4 weeks
62198800|NCT00701324|EXPERIMENTAL|Arm B|BI 811283, 24h infusion d1 every 3 weeks
62198801|NCT03714659|EXPERIMENTAL|Intervention|Group will receive a single injection of autologous, micro-fragmented adipose tissue into the torn meniscus and knee joint. The group will then be followed for one year, filling out pain and function questionnaires.
62198802|NCT03546153|EXPERIMENTAL|Aerobic exercise program|Participants will complete 12 week exercise program.
62198803|NCT01821768|NO_INTERVENTION|Arm 1: No sentinal lymph node biopsy|Patients will receive no additional axillary surgery which is experimental.
62011430|NCT04823845|EXPERIMENTAL|Plantar Wart Treatment Using Adapalene Gel 0.1%|patients treated for plantar warts with Adapalene 0.1% gel
62011431|NCT05669092|EXPERIMENTAL|ARM A: dMMR/MSI-H patients|patients will receive 12 cycles of PD-1 antibody
62011432|NCT05669092|EXPERIMENTAL|ARM B: dMMR/MSI-H patients|patients will receive 5\*5Gy short-course radiotherapy, followed by 12 cycles of PD-1 antibody
62784001|NCT02484352|OTHER|0.2 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.2 mg/kg of oxycodone in normal saline through intravenous route before intubation.
62784002|NCT01459744|EXPERIMENTAL|Communication training for cardiologists|The intervention consists of an educational workshop for heart failure physicians, a reminder system, and a system providing aggregated feedback on their conversations with patients about ICD deactivation.
62784003|NCT01459744|PLACEBO_COMPARATOR|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
62784004|NCT01646606|ACTIVE_COMPARATOR|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Vital signs will be measured at a frequency determined by the responsible physician (as is current practice). The reading will be displayed on the bedside monitor in the participants' room.
62011433|NCT05669092|EXPERIMENTAL|ARM C: pMMR/MSS patients|patients will receive CRT followed by 6 cycles of XELIRI
62784005|NCT01646606|EXPERIMENTAL|Intermittent oxygen monitoring|
62784006|NCT01629953|ACTIVE_COMPARATOR|Group Based Vocational Rehabilitation|Group vocational intervention
62784007|NCT01629953|EXPERIMENTAL|Supported Employment Condition|Group vocational intervention + supported employment
62011434|NCT05669092|EXPERIMENTAL|ARM D: pMMR/MSS patients|patients will receive CRT followed by 12 cycles of FOLFRINOX
62784008|NCT01516463|ACTIVE_COMPARATOR|Collagenase Santyl|
62784009|NCT01516463|SHAM_COMPARATOR|Bacitracin|
62784010|NCT01372332||Normal subjects|Age-related (+ 5 years of age) and gender-matched normal subjects.
62011435|NCT04079933|NO_INTERVENTION|Group 1: Continue Smoking|Subjects were asked to continue smoking their own brand of cigarettes ad libitum for 4 weeks
62011436|NCT04079933|EXPERIMENTAL|Group 2: OTDN|Subjects were allowed to continue smoking their own brand of cigarettes ad libitum and provided the option to use an OTDN (specifically, VERVE® Discs Blue Mint \[VBM-FG2\]) also under ad libitum conditions
62011437|NCT06620926||Patients having astrocytoma with IDH mutant-type|
62011438|NCT06620926||Patients having astrocytoma with IDH wild-type|
62198804|NCT01821768|ACTIVE_COMPARATOR|Arm 2: Sentinel lymph node biopsy|Patients will receive standard of care sentinel lymph node biopsy
62784011|NCT01372332||Patients with homonymous hemianopia|Patients with homonymous visual field defects
62784012|NCT03507010|EXPERIMENTAL|Radiotherapy|Patients assigned to the Radiotherapy group are treated with electrons and will receive a total dose of 30 Gy.
62784013|NCT03507010|PLACEBO_COMPARATOR|Sham Radiotherapy|Patients assigned to the sham-radiotherapy group will not actually receive radiation. For these patients the radiation is simulated.
62784014|NCT05150717|EXPERIMENTAL|[14C]-Jaktinib|Subjects will receive single dose of \[14C\]-Jaktinib (Suspension, 100mg/150μCi)
62784015|NCT02186678|EXPERIMENTAL|assesment by 68Ga-DOTATATE PET-CT|
62784016|NCT05604742|EXPERIMENTAL|Low-dose group of Belimumab|Belimumab 1mg/kg com combined with conventional therapy
62784017|NCT05604742|EXPERIMENTAL|High-dose group of Belimumab|Belimumab 4mg/kg com combined with conventional therapy
62784018|NCT05604742|NO_INTERVENTION|Control group|conventional therapy
62784019|NCT01870726|EXPERIMENTAL|Phase Ib|To estimate the safe dose of the combination INC280 and buparlisib
62784020|NCT01870726|EXPERIMENTAL|Phase II|To estimate anti-tumor efficacy of INC280 single agent and in combination with buparlisib
62784021|NCT03388047|EXPERIMENTAL|Barrett's Esophagus patients|Multi-Spectral Endoscopic Imaging
62011439|NCT05892458|EXPERIMENTAL|Abdominal massage group|The researchers demonstrated the key points of abdominal massage to patients through a video and provided a detailed explanation of the technique. Patients were encouraged to repeat and practice the massage technique after the video session. To track patient compliance, patients were required to document the frequency of their daily massages, and a designated individual collected this information via WeChat. Follow-up consultations were conducted at 1 month after enrollment and every 3 months thereafter. Patients were encouraged to contact their doctors at any time if they experienced discomfort during the study period.
62011440|NCT05892458|NO_INTERVENTION|Control group|The control group did not receive any special intervention and were only followed up at 1 month after inclusion and every 3 months thereafter. Patients in this group were advised to contact their doctors if they experienced discomfort during the study period.
62011441|NCT04770805|EXPERIMENTAL|Fetoscopic repair|Sacral Myelomeningocele and Mye-LDM Fetoscopic repair
62011442|NCT05654506|EXPERIMENTAL|Daratumumab treatment in PGNMID|Subjects with native kidney biopsy consistent with membranoproliferative glomerulonephritis with monoclonal immunoglobulin deposits will receive daratumumab.
62011443|NCT02047604|EXPERIMENTAL|Cohort A - SAN-300 0.5 mg/kg QW|SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks
62011444|NCT02047604|EXPERIMENTAL|Cohort B - SAN-300 1.0 mg/kg QW|SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks
62011445|NCT02047604|EXPERIMENTAL|Cohort C - SAN-300 2.0 mg/kg QOW|SAN-300 2.0 mg/kg subcutaneous every other week for six weeks
62011446|NCT02047604|EXPERIMENTAL|Cohort D - SAN-300 4.0 mg/kg QOW|SAN-300 4.0 mg/kg subcutaneous every other week for six weeks
62011447|NCT02047604|EXPERIMENTAL|Cohort E - SAN-300 4.0 mg/kg QW|SAN-300 4.0 mg/kg subcutaneous every other week for six weeks
62011448|NCT02047604|PLACEBO_COMPARATOR|Placebo|Placebo dosing
62011449|NCT06664372|EXPERIMENTAL|Trans fontanelle US Guided VP Shunt|insertion of proximal vp shunt by trans fontanelle US
62011450|NCT06571357|EXPERIMENTAL|Pranic Healing Intervention|"Participants in this group will receive the Pranic Healing intervention, based on Martha Rogers' Science of Unitary Human Beings, specifically focusing on the concept of Nursing as Facilitation of Healing. The Pranic Healing intervention will follow the advanced protocol as conceptualized by Master Choa Kok Sui, including the following seven techniques:~Sensitizing the hands Scanning the Aura Cleansing the Aura Increasing the receptivity Energizing with prana Stabilizing the projected prana Releasing~The intervention will be applied in three stages: 5 minutes before, during, and 5 minutes after venipuncture."
62011451|NCT06571357|NO_INTERVENTION|routine care|Participants in this group will receive routine care without any Pranic Healing intervention.
62011452|NCT03296696|EXPERIMENTAL|Dose exploration|Dose exploration of the intervention, AMG 596 alone or in combination with AMG 404
62011453|NCT03296696|EXPERIMENTAL|Dose expansion|Dose expansion of the intervention, AMG 596 alone or in combination with AMG 404
62198805|NCT02149238|ACTIVE_COMPARATOR|flavanol rich drink intervention|flavanol rich drink
62011454|NCT02950636|EXPERIMENTAL|Restorative Yoga|Subjects will participate in a structured restorative yoga program. Subjects will attend a 60 minute restorative yoga class twice a week for 8 weeks in a yoga studio.
62011455|NCT00459134|EXPERIMENTAL|Arm I: ArginMax|ArginMax® 3 pills twice daily
62011456|NCT00459134|PLACEBO_COMPARATOR|Arm II: Placebo|Patients receive oral placebo 3 pills twice daily
62011457|NCT06317792|EXPERIMENTAL|Online exergaming-based physiotherapy intervention group|The training tasks consist of a set of 10 pieces of training (20 min per session, five sessions every week, for 8 weeks)
62011458|NCT06317792|NO_INTERVENTION|Online exergaming-based physiotherapy observation group|Observation only
62011459|NCT01130740|NO_INTERVENTION|Arm 1|usual care
62198806|NCT02149238|ACTIVE_COMPARATOR|methylxanthine rich drink intervention|methylxanthine rich drink
62011460|NCT01130740|EXPERIMENTAL|Arm 2|Osteoarthritis Intervention - Primary care providers receive patient-specific osteoarthritis information and treatment recommendations approximately one week prior to the patient's first post-enrollment routine appointment with PCP; patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
62011461|NCT02520024|EXPERIMENTAL|Self-directed Care|"Individuals in the experimental condition will work with a specially trained certified peer specialists (CPS) who will serve as recovery coaches to develop an individualized recovery plan that describes their goals and desires. They will then work with the team to select both the behavioral health treatment and rehabilitation services, and the non-behavioral health materials and resources they believe are necessary to achieve their goals."
62011462|NCT02520024|NO_INTERVENTION|Treatment as usual|Participants in the control condition will receive services as usual.
62011463|NCT00374777|EXPERIMENTAL|1|
62011464|NCT00374777|EXPERIMENTAL|2|
62011465|NCT00374777|ACTIVE_COMPARATOR|3|
62198807|NCT02149238|ACTIVE_COMPARATOR|flavanol + methylxanthine rich drink intervention|flavanol + methylxanthine rich drink
62198808|NCT03414021||Thyroid Diseases|SPECT-CT Scan
62198809|NCT03414021||Heart Diseases|SPECT-CT Scan
62198810|NCT03414021||Bone Diseases|SPECT-CT Scan
62198811|NCT03414021||Brain Diseases|SPECT-CT Scan
62011466|NCT00374777|PLACEBO_COMPARATOR|4|
62011467|NCT04979728||Oral Antivirals|Arm 1: People continuing oral (PO) antivirals for HIV treatment or prevention
62011468|NCT04979728||Q8W CAB±RPV Continuation|Arm 2: People continuing Q8W injections of CAB±RPV for HIV treatment or prevention
62011469|NCT04979728||Q8W CAB±RPV Initiation|Arm 3: People initiating Q8W injections of CAB±RPV for HIV treatment or prevention
62011470|NCT04979728||Q4W CAB±RPV Continuation/Initiation|Arm 4: People continuing or initiating Q4W injections of CAB±RPV for HIV treatment or prevention
62011471|NCT04979728||Q26W LEN Continuation/Initiation|Arm 5: People continuing or initiating Q26W injections of LEN for HIV treatment or prevention
62011472|NCT01636141|PLACEBO_COMPARATOR|Placebo gel|Each study group consists of 6 subjects randomized in a 5:1 ratio to receive OLT1177 Gel or placebo gel in both Part A and B of the study. Eighteen subjects will be enrolled in Part A and 18 in Part B. A total of 30 subjects will receive OLT1177 Gel and 6 subjects will receive placebo gel.
62011473|NCT01636141|ACTIVE_COMPARATOR|OLT1177 Gel|Each study group consists of 6 subjects randomized in a 5:1 ratio to receive OLT1177 Gel or placebo gel in both Part A and B of the study. Eighteen subjects will be enrolled in Part A and 18 in Part B. A total of 30 subjects will receive OLT1177 Gel and 6 subjects will receive placebo gel.
62011474|NCT03698682|EXPERIMENTAL|Short treatment group|1 tablet Levofloxacin 500mg / day for two days completed by 1 tablet Placebo Levofloxacin 500mg / day for 5 days.
62198812|NCT03414021||Kidney Diseases|SPECT-CT Scan
62198813|NCT03412851||A Direct Aspiration First Pass Technique|
62198814|NCT03412851||Stentriever Thrombectomy|
62198815|NCT03993210|EXPERIMENTAL|GYN Cancer Cases|"* Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.~* Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years."
62198816|NCT03993210|ACTIVE_COMPARATOR|GYN Benign Controls|"* Benign gynecological (GYN) fibroids.~* Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years."
62011475|NCT03698682|EXPERIMENTAL|Standard treatment group|1 tablet of Levofloxacin 500mg prescribed for 7days
62011476|NCT01590914|EXPERIMENTAL|Roux-En Y Gastric Bypass|40 subjects who plan to undergo Roux-En-Y Gastric Bypass bariatric surgery. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition Pre-Surgery and 3 months post Surgery.
62011477|NCT01590914|EXPERIMENTAL|Gastric Banding|40 Subjects who plan to undergo Gastric Banding bariatric Surgery. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition Pre-Surgery and 3 months post Surgery.
62011478|NCT01590914|EXPERIMENTAL|Formula Diet Weight-Loss|40 subjects will undertake a 12-week liquid formula weight loss plan. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition pre-weight loss and 3 months after a 12-week weight loss plan.
62198817|NCT03377686||Asthma|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years with doctor's diagnosed asthma
62198818|NCT03377686||Cystic fibrosis|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years with CF
62198819|NCT03377686||Healthy|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years old without respiratory diseases
62198820|NCT01396772|EXPERIMENTAL|PREPARE education program|This is a 6-month program that consists of monthly nutrition and physical activity education sessions (2 hours per session) and includes interactive hands-on activities to help you gain knowledge and skills to make positive lifestyle choices. It is a pilot study to test the effectiveness of this type of health-care program in individuals with prediabetes.
62198821|NCT01396772|OTHER|Control arm|Individuals self-selecting the control arm receive the current standard of care for prediabetes, which is a one-time 2-hour group education session. In addition, the individuals are asked to provide some information at baseline and 6 months and 1 year later. The information collected will include a record of dietary and physical activity habits and whether or not they have developed Type 2 diabetes.
62784022|NCT02854020||An asian airline|
62577083|NCT04428697|EXPERIMENTAL|Sungurtekin Technique|Sungurtekin technique was performed through the base of the posterior fissure; thus, no additional incision was necessary in the lithotomy position. The mucosa was dissected along the submucosal plane, starting at the hypertrophic papilla, and extended for 1.5 cm. After identifying both the internal and external sphincters completely, under direct vision, a 0.5-cm section of the bottom part of the internal anal sphincter was measured and marked with a ruler. This section was preserved during the operation in a standard fashion for all patients . Next, the internal sphincter bundle was measured with a sterile scale and a mark was placed at 1 cm towards the proximal end. The internal sphincter bundle was elevated with a right angle clamp, then cut with cautery . The operation was completed with meticulous hemostasis and additional suturing (3/0 absorbable suture) of the proximally dissected mucosal flap underlying the muscularis layer
62011479|NCT01590914|EXPERIMENTAL|No Treatment|40 subjects who do not undergo any treatment for weight loss. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition at baseline and after 3 months.
62011480|NCT03865277|OTHER|standard radiochemotherapy, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to standard radiation dose, 70 Gy standard radiochemotherapy
62011481|NCT03865277|EXPERIMENTAL|dose-escalated radiochemotherapy, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to escalated radiation dose, 77 Gy radiochemotherapy
62011482|NCT03865277|EXPERIMENTAL|escalated radiochemoth., carbon boost, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, non-randomised arm (only possible in the trial center Heidelberg), 77 Gy radiochemotherapy (boost with carbon)
62011483|NCT03865277|OTHER|standard radiochemotherapy, oxic|HPV (-), oxic in 18F-MISO PET after 2 weeks of radiochemotherapy, 70 Gy standard radiochemotherapy
62011484|NCT03865277|OTHER|standard radiochemotherapy (70 Gy)|HPV (+), HPV positive patients will get the same imaging and clinical examinations as HPV negative patients. This measure is necessary to further elucidate the prognostic role of hypoxia and HPV status and their correlation, the information will be important for consecutive clinical trials. 70 Gy standard radiochemotherapy.
62011485|NCT00618215|EXPERIMENTAL|I|"ROE Group~Interventions:behaviorial"
62011486|NCT00618215|EXPERIMENTAL|2|"MIM Group~Interventions:behaviorial"
62011487|NCT06664086||infertile women|women suffering from infertility
62784023|NCT02462018|EXPERIMENTAL|WalkAide|
62011488|NCT06664086||fertile women|women having children not suffering from infertility.
62011489|NCT00818441|EXPERIMENTAL|Cohort A|Dacomitinib (PF-00299804) in patients with EGFR mutated NSCLC or clinical characteristics defined above to enhance for EGFR mutated NSCLC
62011490|NCT00818441|EXPERIMENTAL|Cohort B|Dacomitinib in patients with HER2 mutated or amplified NSCLC
62011491|NCT05457881|EXPERIMENTAL|Protein-calorie restriction|Four day dietary intervention immediately before surgery of Scandi-Shake \[any of 4 flavors - vanilla, strawberry, banana cream, and caramel\] mixed with almond milk (85 grams Scandi-Shake mix to 240 cc almond milk) calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on gender, age, height, weight, and activity level.
62011492|NCT05457881|NO_INTERVENTION|Control|Ad libitum diet for four days immediately before surgery
61978283|NCT05983276|EXPERIMENTAL|Decitabine / Selinexor/ Carboplatin / Paclitaxel|"C1:~Days 1-5: Decitabine 10 mg/m2 IV daily Day 6: carboplatin AUC 5 and paclitaxel 80 mg/ m2 Days 13, 20, and 27: paclitaxel 80 mg/m2 For a single 28 day cycle~Assess Response toxicities and immune effector cell changes~C2-C6:~Days 1-5: Decitabine 10 mg/m2 IV daily Day 6: carboplatin AUC 5 and paclitaxel 80 mg/ m2 Day 7 and weekly thereafter (day 14, 21, 28, 35...) Selinexor 60 mg PO Days 13, 20, and 27: paclitaxel 80 mg/m2 each given x five 28 day cycles~Assess responses by exam, CT scan and blood tests, assess toxicities, and immune effector cell changes as well as progression and overall survival"
62011493|NCT00838305|PLACEBO_COMPARATOR|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
62011494|NCT00838305|EXPERIMENTAL|mdma|drug: mdma subjects also get citalopram and placebo in a 2x2 crossover design
62784024|NCT04557501|ACTIVE_COMPARATOR|Control - SOC Treatment|Participants to receive surgery or radiotherapy (+/- hormone therapy) as planned per SOC.
61978284|NCT01121887|ACTIVE_COMPARATOR|Standard treatment|
62011495|NCT03806452|EXPERIMENTAL|Hydroxycarbamide|"Hydroxycarbamide will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Hydroxycarbamide will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial."
62198822|NCT02429453|ACTIVE_COMPARATOR|Fresh Frozen Plasma|Administration of a single dose of fresh frozen plasma based on INR per the following regimen: 2U for INR of 2-2.5; 3U for INR of 2.5-3; 4U for INR of 3-3.5; 5U for INR of 3.5-4; 6U for INR of 4+
62784025|NCT04557501|EXPERIMENTAL|Experimental - PSMAiTx|Participants undergo PSMA PET/CT prior to treatment, and treated intensified based on image findings.
62011496|NCT03806452|PLACEBO_COMPARATOR|Placebo|"Placebo will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Placebo will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial."
62011497|NCT06394128|EXPERIMENTAL|Cangpo Liujun Prescription|Cangpo Liujun Prescription composition: Rhizoma atractylodis 15g, Magnolia officinalis 12g, Tangerine peel 15g, Pinellia pinellia 12g, Codonopsis ginseng 15g, Rhizoma atractylodis macrocephalae 15g, Poria cocos 15g, Honey-fried licorice root 6g. It was taken during and between the treatments, in the morning and in the evening, 200ml each time, for 3 courses, and 1 course was 28 days.
62011498|NCT06394128|PLACEBO_COMPARATOR|Placebo|Cangpo Liujun Prescription granule mimics was made into a control placebo according to the content of 5% of the treatment group. It was taken during and between the treatments, in the morning and in the evening, 200ml each time, for 3 courses, and 1 course was 28 days.
62011499|NCT06663683|EXPERIMENTAL|Hip thrust|The subjects in Hip thrust group will be instructed to perform low-load gluteus activation exercises, which included single-leg bridges, clamshells and quadruped hip extensions. One set of ten repetitions or steps will perform for each exercise. In this training program three stages which focused on enhancing hypertrophy and strength of the hip extensors in sequence. During the training period, the subjects will be instructed to maintain their usual daily activities and diet. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between the sessions. Hip thrust training 3 sets with 10 repetitions in each set and 2 minutes rest between each set.
62198823|NCT02429453|EXPERIMENTAL|Four Factor Prothrombin Complex Concentrate|Administration of a single dose of four factor prothrombin complex concentrate per the following dosing regimen: 25 U/kg for INR of 2-4; 35 U/kg for INR of 4-6; 50 U/kg for INR of 6+; maximum dosing weight of 100kg, patients may be dispensed +/- 10% of ordered dose
62198824|NCT03899831|EXPERIMENTAL|Function-Based Elopement Treatment (FBET)|Participants in this group will receive Function-Based Elopement Treatment (FBET) for 16 weeks.
62198825|NCT03899831|ACTIVE_COMPARATOR|Parent Education Program (PEP)|Participants in this group will take part in a parent education program (PEP) for 16 weeks.
62577084|NCT04428697|ACTIVE_COMPARATOR|Closed Lateral Internal Sphincterotomy|The sphincterotomy was performed through a new incision, guided by the surgeon's finger, as described by Boulos et al Boulos PB, Araujo JG. Adequate internal sphincterotomy for chronic anal fissure: subcutaneous or open technique? The British journal of surgery 1984;71:360-2.
62734789|NCT05616546|EXPERIMENTAL|Influenza Vaccine|"Healthy male and female individuals aged 18-64 years will be eligible to participate in this study.~Subjects will be offered the opportunity to participate in the study for up to 3 consecutive years, provided eligibility criteria are met each year. Subjects will be re-screened to verify continued eligibility and re-consented prior to subsequent participation and will receive new subject identifiers"
62784026|NCT04440657|EXPERIMENTAL|Immigrant parents|All enrolled parents will be included in the parenting program
62784027|NCT00006249|NO_INTERVENTION|observation|5 years observation + 5 years follow up
62784028|NCT00006249|EXPERIMENTAL|pegylated interferon alfa|5 years pegylated interferon alfa + 5 years follow up
62784029|NCT06017791|EXPERIMENTAL|PEEK shell in the anterior maxilla inserted by tunnel technique|use of a minimally invasive tunnel technique to fill the skeletal subnasal depression with a PEEK shell in patients with an exaggerated subnasal depression associated with lack of lip support and excessive lip translation
62198826|NCT03743779||Intervention|Participants enrolled in Mastering Diabetes.
62198827|NCT00667394|EXPERIMENTAL|Tandutinib & Bevacizumab in GBM Patients|GBM (glioblastoma multiforme) Tandutinib 500 mg by mouth daily dose twice a day. Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
62734790|NCT06552832|EXPERIMENTAL|CAVEAT|Clinician-Assisted Videofeedback Exposure
62198828|NCT00667394|EXPERIMENTAL|Tandutinib & Bevacizumab in AG Patients|AG (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, and malignant astrocytoma NOS (not otherwise specified)) Tandutinib 500 mg by mouth daily dose twice a day. Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
62198829|NCT03336554||observation group|One group of participants are under observation. This trial has two phase. Phase I: 40 participants will be enrolled. Only if epigenetic cfDNA library has been built, investigators would move on to Phase II. Another 60 participants will be enrolled for further analysis.
62198830|NCT03348410|EXPERIMENTAL|Intervention|Motivational interviewing
62198831|NCT03348410|NO_INTERVENTION|Control|Control group
62198832|NCT02902770|ACTIVE_COMPARATOR|Lidocaine and normal saline push|1.5mg/kg IV Lidocaine Drip (given over 10 minutes) and normal saline push
62198833|NCT02902770|ACTIVE_COMPARATOR|Ketorolac and normal saline drip|IV Ketorolac Tromethamine 30mg push and 10 minute normal saline drip
62734791|NCT03528655|EXPERIMENTAL|Decision aid group|Shared decision making using decision aid
61978285|NCT01121887|EXPERIMENTAL|Motivational Interviewing|
62198834|NCT02902770|ACTIVE_COMPARATOR|Lidocaine and Ketorolac|IV Lidocaine Drip and IV Ketorolac Push
62198835|NCT03624153|EXPERIMENTAL|Robotic-assisted intervention|70 minutes Robotic-assisted intervention.
62198836|NCT03624153|ACTIVE_COMPARATOR|Conventional intervention|70 minutes conventional rehabilitation.
62198837|NCT05022862|ACTIVE_COMPARATOR|Usual Care|Participants will receive routine (non-study directed) medical care for latent tuberculosis infection according to published guidelines, including medication, nurse case management, Tuberculosis health education, and toxicity assessments.
62198838|NCT05022862|ACTIVE_COMPARATOR|Video Directly Observed Therapy alone|Participants in this group will receive the same treatments and education provided to Usual Care Control participants, however treatment will be viewed by video directly observed therapy (video-DOT)
62400688|NCT04221373|EXPERIMENTAL|Exoskeletal-assisted walking training group|Participants will receive locomotor training provided with an Ekso™ powered exoskeleton according to the standard of care of AIR at Mount Sinai Hospital with the exception that the EAW training will be incorporated into the designated therapy times (3 hours of physical therapy (PT) and/or occupational therapy (OT)) which will be provided as determined by the clinical team from the earliest time they are identified to be able to safely stand, through discharge. The goal of EAW intervention is to complete three or more sessions of EAW training a week during the AIR period (after enrolling into the study until discharge).
62400689|NCT04221373|ACTIVE_COMPARATOR|Standard of care group|Participants will receive standard of care of acute inpatient rehabilitation which includes three hours of physical therapy and/or occupational therapy per day until they are discharged.
62400690|NCT02477319||Part A|"* Cohort 1: Healthy Controls~* Cohort 2: Partial CFTR function CF (class IV/V)~* Cohort 3: Absent CFTR function CF (Class I/II)"
62400691|NCT02477319||Part B|CF patients who are homozygous for the F508del
62400692|NCT06058572|EXPERIMENTAL|Tab Rifaximin with Allogeneic stem cell transplant|Tab Rifaximin 200 mg will be given orally twice daily from day -8 to day +60 of allogeneic stem cell transplant in acute leukemia patients. This will be in addition to standard of care post transplant treatment
62400693|NCT06058572|ACTIVE_COMPARATOR|Allogeneic stem cell transplant|Allogeneic stem cell transplant: Standard of care treatment including standard anti GVHD measures, antibiotic support and transfusions as needed.
62400694|NCT02139020||No treatment|"Patients with squamous cell carcinoma of the head and neck, targeted therapies, plasma samples:~* Group 1 = patients treated with radiation therapy and cetuximab according to Bonner et al \[11\]~* Group 2 = patients treated with cetuximab in combination with chemotherapy according to Vermorken et al. \[10\]~* Group 3 = patients treated with a molecular targeted agent as a part of a clinical study"
62400695|NCT02806206|EXPERIMENTAL|Drug: Prucalopride|A single 2 mg dose of prucalopride before ingesting the capsule endoscopy pill.
62198839|NCT05022862|EXPERIMENTAL|Video Directly Observed Therapy plus Financial Incentives|Participants in this group will receive the same treatments and education provided to Usual Care Control participants, as well as treatment viewed by video DOT. This arm will also earn financial contingent incentives. Participants will receive incentive payments when a submitted video is monitored by a staff member and deemed valid. If a participant fails to submit a video on a medication day or if a submitted video is deemed invalid (i.e., not the correct person or no appropriate ingestion of medication), the participant will not receive the scheduled incentive amount that day and the daily incentive value will be decreased.The participant will have opportunities the next day to again resume adherence. After taking the medication again for one week, participants will earn a reduced incentive until they adhere to the medication schedule for a week.
62198840|NCT02354651||Patients With Pompe Disease Eligible for Diaphragm Pacing|Patients will receive tests of breathing pattern, phrenic nerve stimulation, maximal inspiratory pressure (MIP), forced expiration, and EMG.
62198841|NCT05444270|ACTIVE_COMPARATOR|Standard salvage therapy|Subjects will continue to receive current salvage treatment suitable for subjects at the discretion of their doctor, considering the location and size of recurrence, and the patient's comorbidities.
62198842|NCT05444270|EXPERIMENTAL|Standard salvage therapy + SABR|Subjects receive SABR for lesions found in imaging studies. Before or After SABR, standard salvage treatment continues as planned at the discretion of the doctor.
62400696|NCT02806206|PLACEBO_COMPARATOR|Drug: Placebo|A placebo pill just before ingesting the capsule endoscopy pill.
62400697|NCT04717310|ACTIVE_COMPARATOR|Active Comparator: SHR0302 Ointment Dose#1|Drug: SHR0302 Ointment Twice a day (BID)
62400698|NCT04717310|ACTIVE_COMPARATOR|Active Comparator: SHR0302 Ointment Dose#2|Drug: SHR0302 Ointment Twice a day (BID)
62400699|NCT04717310|ACTIVE_COMPARATOR|Active Comparator: SHR0302 Ointment Dose#3|Drug: SHR0302 Ointment Twice a day (BID)
62400700|NCT04717310|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Drug: Vehicle Twice a day (BID)
62734792|NCT03528655|NO_INTERVENTION|Controlled group|Standard oral explanation with booklet.
62734793|NCT05363722|EXPERIMENTAL|Arm A（IBI310 0.5mg/kg）|IBI310 0.5mg/kg IV d1 Q6W, sintilimab 200mg IV d1 Q3W, combined with bevacizumab 15mg/kg IV d1，Q3W
62734794|NCT05363722|EXPERIMENTAL|Arm B（IBI310 0.3mg/kg）|IBI310 0.3mg/kg IV d1 Q6W, sintilimab 200mg IV d1 Q3W, combined with bevacizumab 15mg/kg IV d1，Q3W
62198843|NCT00930345|OTHER|SUTENT before nephrectomy|
62198844|NCT04420247|EXPERIMENTAL|Intervention|"Treatment with either Chloroquine or Hydroxychloroquine according to what was available in the hospital:~Chloroquine - 900mg on the first day, followed by 450mg in the next 4 days. Hydroxychloroquine - 800mg on the first day, followed by 450mg in the next 4 days.~+~Standard treatment available and recomended by the Brazilian Guidelines for COVID-19."
62198845|NCT04420247|ACTIVE_COMPARATOR|Control|Standard treatment available and recomended by the Brazilian Guidelines for COVID-19.
62198846|NCT01443403|PLACEBO_COMPARATOR|Placebo|Participants received placebo orally once daily for 28 days.
62198847|NCT01443403|EXPERIMENTAL|Naldemedine 0.1 mg|Participants received 0.1 mg naldemedine orally once daily for 28 days.
62198848|NCT01443403|EXPERIMENTAL|Naldemedine 0.2 mg|Participants received 0.2 mg naldemedine orally once daily for 28 days.
62198849|NCT01443403|EXPERIMENTAL|Naldemedine 0.4 mg|Participants received 0.4 mg naldemedine orally once daily for 28 days.
62198850|NCT01485497|OTHER|3D endoscopic Fourier Domain OCT|3D endoscopic Fourier Domain OCT
62198851|NCT02859740||permanent prosthesis|
62198852|NCT02859740||Temporary prosthesis|
62198853|NCT01167452|EXPERIMENTAL|Sulfamethoxazole/trimethoprim|2 DS tablets of sulfamehtoxazole/trimethoprim (1600 mg/320 mg)
62198854|NCT03660735||Male Factor Subfertility|Participant is undergoing first or second cycle of IVF and ICSI for male factor subfertility
62198855|NCT03660735||Recurrent Implantation Failure|Participant is undergoing an IVF cycle to treat subfertility with a history of Recurrent Implantation Failure (RIF).
62198856|NCT03660735||Female Subfertility|Participant is undergoing an IVF cycle to treat at least 1 year of subfertility
62198857|NCT02708381||Senior Adult Cancer Patients|Cancer patient population 70 years and older, eligible for screening.
62400701|NCT01545375|EXPERIMENTAL|dPly-PhtD Group|"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving GSK2189242A (dPly-PhtD) vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age.~PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months.~At the primary epoch, the dPly-PhtD vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the dPly-PhtD vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate.~At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate."
62734795|NCT05031117|EXPERIMENTAL|Conventional Epidural Technique|
62198858|NCT00532207|EXPERIMENTAL|A|
62198859|NCT04204382|EXPERIMENTAL|test group|"1. CKI was injected intravenously for 7 days, once a day, 20ml each time；~2. Levofloxacin injection were injected intravenously for 7 days, once a day, 0.5g each time,"
62198860|NCT04204382|OTHER|control group|Levofloxacin injection were injected intravenously for 7 days, once a day, 0.5g each time.
62198861|NCT02858570|EXPERIMENTAL|MenCC-BIO Vaccine|Vaccine against meningococcus serogroup C conjugated to tetanus toxoid produced by Bio-Manguinhos / FIOCRUZ (MenCC-Bio). Stratum I - 11-19 years; Stratum II - 1 to 10; Stratum III - less than 1 year old)For the age groups I and II are applied 2 doses ideal interval of 6 months between them. In stratum III, are recommended 3 doses of the vaccine, at ages 3, 5 and 12 months of age, according to calendar of the National Immunization Program.
62198862|NCT02858570|ACTIVE_COMPARATOR|combined - CRM197|Adsorbed vaccine meningococcal C (combined - CRM197) produced by the Foundation Ezequiel Dias (FUNED). Stratum I - 11-19 years; Stratum II - 1 to 10; Stratum III - less than 1 year old). For the age groups I and II are applied 2 doses ideal interval of 6 months between them. In stratum III, are recommended 3 doses of the vaccine, at ages 3, 5 and 12 months of age, according to calendar of the National Immunization Program.
62198863|NCT02100358||acute cholecystitis|acute cholecystitis
62734796|NCT05031117|ACTIVE_COMPARATOR|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|
62734797|NCT04165460|EXPERIMENTAL|"A Intervention"|Psychoeducation, Relaxation, Cognitive Reestructuring and Problem Solving
62734798|NCT04165460|ACTIVE_COMPARATOR|"B Intervention"|Psychoeducation, Relaxation
62198864|NCT05492851|ACTIVE_COMPARATOR|Zilretta|"Generic Name: Triamcinolone acetonide Zilretta is an extended-release synthetic corticosteroid indicated as an intra-articular injection for the management ofosteoarthritis pain of the knee.~5mL suspension of 32 mg of triamsinolone administered as a 1 dose parapatellar intra-articular injection."
62198865|NCT05492851|ACTIVE_COMPARATOR|Synvisc One|"Generic Name: Hylan G-F 20 Synvisc-One combines the three doses of SYNVISC (hylan G-F 20) which consists of hylan A (average molecular weight6,000,000 daltons) and hylan B hydrated gel in a buffered physiological sodium chloride solution, pH 7.2.~Each 10 mL syringe of Synvisc-One combines the three 2-mL doses (16 mg each) of a complete SYNVISC treatment regimen (48 mg). Synvisc-One belongs to a class of drugs called Intra-Articular Agents; Rheumatologics, Other.~10mL of Hylan G-F 20 administered as a 1 dose parapatellar intra-articular injection."
62198866|NCT05492851|ACTIVE_COMPARATOR|Monovisc|"Generic Name: Hyaluronan The Monovisc™ device is a proprietary high molecular weight hyaluronic acid (HA) viscosupplementation intended for the treatment of pain in patients with moderate osteoarthritis (OA) of the knee who have failed conservative non-pharmacological therapy and simple analgesics. The device is administered by a single injection via the para-patellar approach under sterile conditions.~4mL injection of Hyaluronan administered as a 1 dose parapatellar intra-articular injection."
62198867|NCT03468478|EXPERIMENTAL|sirolimus +tacrolimus|Patients will receive initial dose of 0,05 mg/kg BID oftacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of sirolimus of 3mg once a day to reach blood trough concentration between 4-8 ng/mL.
62198868|NCT03468478|EXPERIMENTAL|everolimus +tacrolimus|Patients will receive initial dose of 0,05 mg/kg BID de tacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of 1.5 mg BID of everolimus to reach blood trough concentration between 4-8 ng/mL.
62198869|NCT03468478|ACTIVE_COMPARATOR|mycophenolate +tacrolimus|Patients will receive initial dose of 0,1 mg/kg BID de tacrolimusto reach blood trough concentration between Fixed dose of mycophenolate (mycophenolate mofetil, 1 g BID or sodium mycophenolate, 720 mg BID).
62198870|NCT04492059|EXPERIMENTAL|Blood flow restriction augmented physical therapy|The group will undergo traditional physical therapy with the augment of blood flow restriction therapy under the supervision of trained physical therapists.
62198871|NCT04492059|ACTIVE_COMPARATOR|Traditional physical therapy|The group will undergo traditional physical therapy without the augment of blood flow restriction therapy under the supervision of trained physical therapists.
62198872|NCT02373579|ACTIVE_COMPARATOR|Intervention arm with Omega 3 FA|"included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .~Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day ."
62198873|NCT02373579|ACTIVE_COMPARATOR|control group|control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
62198874|NCT05173389|OTHER|Group 1|TechnoBody
62198875|NCT05173389|OTHER|Group 2|Thera Trainer
62400702|NCT01545375|PLACEBO_COMPARATOR|Control Group|"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving Placebo vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age.~PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months.~At the primary epoch, the Placebo vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the Placebo vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate.~At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate."
62577085|NCT06574841|ACTIVE_COMPARATOR|Blood Flow Restriction Training|Blood flow restriction resistance exercise (BFR-RE) involves partially restricting arterial blood flow and fully restricting venous blood flow in the active limb during exercise, utilizing loads typically set at 20% to 30% of an individual's maximum repetition (1RM). It will conduct 3-5 sets until concentric failure is achieved, each set will contain 15-30 repetitions. Moreover, rest periods will range from 30 to 60 seconds and 3 sessions per week will be performed.
62577086|NCT06574841|EXPERIMENTAL|Conventional Physical therapy|"It consists of the application of a neural custom volar orthotic device to be worn at night and during strenuous daytime activities. Moreover,exercises required patients to assume five different finger postures during tendon-gliding activities: Straight, Hook Fist, Duck Position, Straight Fist, and Full Fist. As well as, six different postures during nerve-gliding activites: Wrist positioned neutrally with flexed thumb and fingers, Wrist maintained neutrally with extended thumb and fingers, Extended wrist and fingers with the thumb in a neutral position, Extended wrist, fingers, and thumb, Extended wrist, fingers, and thumb with forearm supination, and Extended wrist, fingers, and thumb with forearm supination, accompanied by gentle stretching of the thumb by the therapist.~All will be done 10rep x 5 sec hold, 3-5 times daily for 5 weeks."
62577087|NCT05863260||Intervention|Paclitaxel 135mg / m2d1 + cisplatin 60mg / m2d1 (cisplatin resistance or cisplatin intolerance changed to carboplatin AUC = 5d1), q3w × 4 and Standard IMRT and radiotherapyTislelizumab 200mg, IV, q3w, the day before radiotherapy
62577088|NCT05718869|EXPERIMENTAL|Treatment (tafasitamab and zanubrutinib)|Patients receive tafasitamab IV and zanubrutinib PO on study. Patients also undergo collection of blood samples on study and undergo CT scan and bone marrow biopsy throughout the trial.
62577089|NCT03568370|EXPERIMENTAL|olive oil|use one drop olive oil on each nipple after each feeding
62198876|NCT01888874|PLACEBO_COMPARATOR|Placebo|Participants received GLPG0634 matching placebo capsules, orally, twice daily (BID) during Weeks 1 to 12. Participants who were responders (having at least 20 percent \[%\] improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 milligram (mg) once daily (QD) or 50 mg BID during Weeks 13 to 24.
62198877|NCT01888874|EXPERIMENTAL|GLPG0634 50 mg QD|Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.
62198878|NCT01888874|EXPERIMENTAL|GLPG0634 100 mg QD|Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.
62577090|NCT03568370|NO_INTERVENTION|breast milk|use breast milk on each nipple after each feeding
62198879|NCT01888874|EXPERIMENTAL|GLPG0634 200 mg QD|Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.
62198880|NCT01888874|EXPERIMENTAL|GLPG0634 25 mg BID|Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.
62198881|NCT01888874|EXPERIMENTAL|GLPG0634 50 mg BID|Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.
62198882|NCT01888874|EXPERIMENTAL|GLPG0634 100 mg BID|Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.
62577091|NCT03267134|EXPERIMENTAL|Hydrus Microstent|Hydrus Microstent implanted in the eye per the supplied Hydrus Microstent Instructions for Use and associated training. Only one eye (study eye) will be implanted.
62784030|NCT01092910|EXPERIMENTAL|Esteem Implant|Subjects are implanted with the Esteem Totally Implantable Hearing System
62784031|NCT01013857|ACTIVE_COMPARATOR|Health coaching|Phone patients every week to discuss medication adherence
62784032|NCT01013857|EXPERIMENTAL|Health coaching plus home-titration|Health coaches call patients every week to discuss medication adherence and to intensify medications if appropriate according to physician-created algorithm
62784033|NCT04912817|EXPERIMENTAL|Off the Shelf VR (PR-VR program + usual care)|"* One session per week x 4 weeks; total 4 sessions over 1 month~* PR-VR program (30 min) + Usual care (30 min SVPT)~* Total intervention time = 4 hours~* 10 selected for post-study telephone interview"
62784034|NCT04912817|EXPERIMENTAL|Custom VR (Modified PR-VR program + usual care)|"* One session per week x 4 weeks; total 4 sessions over 1 month~* Mod PR-VR program (30 min) + Usual care (30 min SVPT)~* Total intervention time = 4 hours~* 10 selected for post-study telephone interview"
62784035|NCT04912817|NO_INTERVENTION|Standard Virtual Physiotherapy Treatment (control; usual care),|"* One session per week x 4 weeks; total 4 sessions over 1 month~* Usual care (60 min SVPT)~* Total intervention time = 4 hours"
62784036|NCT00669383|ACTIVE_COMPARATOR|A|Betamethasone (Celestone) 12 mg intramuscular q 24 hours x 2 doses
62198883|NCT02817906|EXPERIMENTAL|ITI-007|9 mg ITI-007 administered as a solid oral dose formulation once daily for 4 weeks.
62198884|NCT02817906|PLACEBO_COMPARATOR|Placebo|Placebo administered as a visually-matched solid oral dose formulation once daily for 4 weeks
62577092|NCT05140382|EXPERIMENTAL|AZD4573 (Monotherapy)|Eligible participants with either r/r PTCL, r/r NKTCL or r/r cHL will receive AZD4573 as monotherapy.
62577093|NCT06577792|OTHER|Lobectomy-First group|Patients with operable NSCLC received lobectomy first then received lymphadenectomy for surgical treatment.
62784037|NCT00669383|PLACEBO_COMPARATOR|B|Placebo dose intramuscular q 24 hours x 2 doses
62784038|NCT05171712|EXPERIMENTAL|Analysis Population|The analysis population will include patients considered at high or extreme surgical risk, who have met all inclusion criteria, have not met any exclusion criteria, have signed an Ethics Committee (EC) approved Informed Consent, and, at the minimum, the FlexNav delivery system entered his/her vasculature for an attempted Portico or Navitor Valve implant
62198885|NCT06519084|EXPERIMENTAL|TG - Training group|In this group, patients were instructed to perform home-based physical training. Training was carried out 4 times a week, each exercise session lasting 40 minutes. The session consisted of aerobic exercises and muscular resistance exercises, using body weight and elastic bands.
62198886|NCT06519084|NO_INTERVENTION|CG - Control group|In this group, patients were advised to maintain their usual activities and not engage in physical training programs.
62198887|NCT01303250|EXPERIMENTAL|Group 1|A balanced hydroxyethyl starch 130/0.4 will be used
62198888|NCT01303250|ACTIVE_COMPARATOR|Group 2|A balanced crystalloid will be used
62577094|NCT06577792|OTHER|Lymphadenectomy-First group|Patients with operable NSCLC received lymphadenectomy first then received lobectomy for surgical treatment.
62577095|NCT00624936|EXPERIMENTAL|Vidaza and Velcade|Vidaza 75mg/m2 IV over 30 min daily on days 1-7 This dose is the same for all dose levels. Velcade will be given immediately after Vidaza is completed at one of the following dose levels: 1, 2, 3, 4
62577096|NCT00423332|PLACEBO_COMPARATOR|1|Cediranib placebo
62577097|NCT00423332|EXPERIMENTAL|2|Cediranib
62577098|NCT03492723|EXPERIMENTAL|garlic groupe|Concentrated Aged Garlic Extract Microcrystalline Cellulose 133 mg Carboxymethylcellulose Calcium 6 mg Agar Powder 35 mg Silicon Dioxide 3.5 mg Calcium Stearate 3.5 mg Total Weight 307 mg
62734799|NCT01738815|EXPERIMENTAL|valproic acid|Patients will be administered valproic acid (Depakote ER) for up to 30 days prior to tumor resection
62784039|NCT05240625|EXPERIMENTAL|Computer-aided colonoscopy|The subject will receive the standard colonoscopy procedure simultaneously with a computer-aided detection (CADe) analysis software designed to automatically detect and highlight potential polyps on colonoscopy images in a real-time manner during colonoscopy procedures.
62784040|NCT05240625|ACTIVE_COMPARATOR|Standard colonoscopy|The subject will receive the standard colonoscopy procedure.
62784041|NCT04676035|EXPERIMENTAL|SHR3680+ Midazolam, Warfarin, Omeprazole, VitaminK1|administrate Midazolam, Warfarin, Omeprazole, VitaminK1 on Day1 and Day22, SHR3680 on day 6-27.
62784042|NCT02245594||Gl motility and sleep pattern|
62784043|NCT06172075|EXPERIMENTAL|Brief video intervention (Black Woman)|A brief social contact-based video with a Black woman protagonist
62784044|NCT06172075|EXPERIMENTAL|Brief video intervention (Latinx Woman)|A brief social contact-based video with a Latinx woman protagonist
62577099|NCT03492723|PLACEBO_COMPARATOR|placebo groupe|Microcrystalline Cellulose 258.55 mg Carboxymethylcellulose Calcium 6 mg Agar Powder 35 mg Coloring Agent 0.45 mg Details: Gardenia Extractive 44.5%, Corn Syrup 55% Potassium pyrophosphate 0.5% Silicon Dioxide 3.5 mg Calcium Stearate 3.5 mg Total Weight 307 mg
62784045|NCT06172075|EXPERIMENTAL|Brief video intervention (White Woman)|A brief social contact-based video with a White woman protagonist
62011500|NCT06663683|EXPERIMENTAL|Back squat|In Back Squat (BS) resistance training the subjects starts with the standing position with the feet flat on the floor, the knees and hips in a neutral, extended anatomical position, and the spine in an upright position with preservation of its natural curves. The squat movement will begin with the descent phase as the hips, knee and ankles flex. A common instruction will be given to the subjectsto descend until the top of the thigh is at least parallel with ground and the hip joint is at least level with or slightly below the knee joint. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between sessions. Back squat training 3 sets with 10 repetitions in each set \& 2 minutes rest between each set.
62577100|NCT03525938|ACTIVE_COMPARATOR|TAP group|
62784046|NCT06172075|OTHER|Vignette Control|A brief vignette control condition
62784047|NCT05268952|EXPERIMENTAL|GEP-NET and lung-NET patients|Liquid biopsies and scans
62784048|NCT03617146|EXPERIMENTAL|Intervention Arm|"Participants in the intervention arm will receive the following interventions:~Month 1: Diabetes Distress-specific Education.~Months 1 to 3: Six 30 to 45-minute telephone-based health coaching sessions targeting diabetes distress reduction and self-care improvement.~Month 3: Follow up distress-specific education.~Months 4 and 5: Two 30 to 45 minute telephone-based health coaching sessions targeting diabetes distress reduction and self-care improvement."
62577101|NCT03525938|SHAM_COMPARATOR|SHAM group|
62784049|NCT03617146|ACTIVE_COMPARATOR|Control Arm|"Participants in the control arm will receive the following interventions:~Month 1: Diabetes Distress-specific Education (same as for the intervention arm).~Month 3: Follow up distress-specific education (same as for the intervention arm)."
62784050|NCT02774369|EXPERIMENTAL|Physical exercise|A 6-week individualised, aerobic intervention program elaborated by a kinesiologist following a complete assessment of the individual's physical condition.
62784051|NCT02774369|ACTIVE_COMPARATOR|Cognitive-behavioral therapy|A 6-week self-administered cognitive-behavioral therapy for insomnia composed of a 60-min video (DVD format) and 6 booklets.
62784052|NCT03220386|OTHER|Emergency Department patients|All patients will be tested for nasal MSSA/MRSA-colonization. Patients tested positive for nasal MSSA/MRSA-colonization receive a decolonization treatment. This treatment includes octinidin nasal treatment and skin washings.
62784053|NCT03330795|EXPERIMENTAL|CD3/CD19 neg allogeneic BMT|All participants will receive a double lung transplant followed by a bone marrow (hematopoietic stem cells) transplant. The lungs and allogeneic hematopoietic stem cells will be from the same partially HLA-matched cadaveric donor. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
62784054|NCT05582941||Control|20 individuals with no cognitive alterations or any other pathology which could alter cognitive performance or blood cells
62784055|NCT05582941||Mild Cognitive Impairment Due to Alzheimer's Disease: MCI group|20 individuals diagnosed with Mild Cognitive Impairment Due to Alzheimer's Disease with positive AD markers in cerebrospinal fluid
62784056|NCT05582941||Dementia due to Alzheimer Disease: AD group|20 individuals diagnosed with Dementia Due to Alzheimer Disease with positive AD markers in cerebrospinal fluid
62784057|NCT06095609|EXPERIMENTAL|Early mobilization plus chest physiotherapy|Physiotherapy program comprised two parts early mobilization and CPT. They could be divided into different levels depended on patients' ability. In terms of the levels of early mobilization, first level was defined as patients who could only receive passive patterns of exercise. Second level would be executed to patient who could only take exercise on the bed or with back support. Third level would be implemented when patients could advance to receive physiotherapy beside the bed without support. The eventual level would be conducted when patients was able to leave beds by their own. In line with chest physiotherapy, level I was defined as patients who could only receive passive lung hygiene protocol. Level II would be executed when patient can control their breath and cough by their own. Level III would be implemented when patient can maintain their body steadily and finish the chest physiotherapy protocol.
62198889|NCT02377167|EXPERIMENTAL|Early Tracheostomy|"Patients randomized to early tracheostomy receive (preferably dilatative) tracheostomy within 5 days from intubation.~Intervention: Procedure: Early Tracheostomy"
62198890|NCT02377167|ACTIVE_COMPARATOR|Prolonged Intubation|"Patients randomized to this arm will be tried to wean off the ventilator and get (an) extubation trial(s) if regarded feasible. In case of failure or non-feasibility, they receive tracheostomy after intubation day 10.~Intervention: Procedure: Late Tracheostomy"
62198891|NCT03908567|PLACEBO_COMPARATOR|Placebo|Nasal spray solution without active ingredient
62577102|NCT06408714|EXPERIMENTAL|Nalmefene|"Nalmefene Rescue Study Arm Treatment:~Subjects will receive study drug if they exhibit respiratory depression (defined as respiratory rate less than 8 breaths per minute and/or end-tidal carbon dioxide measurement of greater than 50 mm Hg) lasting for longer than 10 seconds. Respiratory support with bag-valve mask and/or supplemental oxygen will be provided while the study drug is being prepared. Nalmefene will be administered as per intervention description."
62577103|NCT06408714|ACTIVE_COMPARATOR|Naloxone|"Naloxone Rescue Arm Treatment:~Subjects will receive study drug if they exhibit respiratory depression (defined as respiratory rate less than 8 breaths per minute and/or end-tidal carbon dioxide measurement of greater than 50 mm Hg) lasting for longer than 10 seconds. Respiratory support with bag-valve mask and/or supplemental oxygen will be provided while the study drug is being prepared. Naloxone will be administered as per intervention description."
62011501|NCT03588169||patients hospitalized at the Dijon University Hospital|Patients hospitalized in the endocrinology, digestive surgery, pneumology and geriatric units of the Dijon University Hospital with a prescription for ONS
62011502|NCT06663553|ACTIVE_COMPARATOR|TU-LESS for hysterectomy|Patients diagnosed with enlarged uteri following a bimanual examination, with confirmation of the size and nature of the enlargement through imaging techniques such as ultrasound or magnetic resonance imaging (MRI).
62011503|NCT06663553|EXPERIMENTAL|vNOTES for hysterectomy|Patients diagnosed with enlarged uteri following a bimanual examination, with confirmation of the size and nature of the enlargement through imaging techniques such as ultrasound or magnetic resonance imaging (MRI).
62011504|NCT04751916|EXPERIMENTAL|Proprietary Essential Amino Acid Protein Supplement|Essential amino acid protein supplement; 15 grams (one packet) dissolved in 8 ounces of water twice daily for 6 months.
62011505|NCT04751916|ACTIVE_COMPARATOR|Commercially-available whey protein supplement - Beneprotein®|Beneprotein® whey protein supplement; 15 grams (one packet) dissolved in 8 ounces of water twice daily for 6 months.
62011506|NCT04176770|EXPERIMENTAL|ESP group|ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
62011507|NCT04176770|EXPERIMENTAL|TAP Block|TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
62011508|NCT02097992|EXPERIMENTAL|SD placebo and MD roflumilast then MD placebo|Participants will receive placebo (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily.
62011509|NCT02097992|EXPERIMENTAL|SD placebo and MD placebo then MD roflumilast|Participants will receive placebo (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.
62011510|NCT02097992|EXPERIMENTAL|SD roflumilast and MD placebo then MD roflumilast.|Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.
62011511|NCT02097992|EXPERIMENTAL|SD roflumilast and MD roflumilast then MD placebo|Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily
62011512|NCT03083288|EXPERIMENTAL|Single Arm|
62011513|NCT05390866|EXPERIMENTAL|HIIT group|The HIIT session will be conducted on a bicycle ergometer and consist of a 3-minute warm-up, followed by 4x4-minute intervals performed at 85-95% of the individually determined maximum heart rate, interspersed with 3-minute active recovery phases at a light effort). The HIIT session will be followed by a 2-minute cool-down phase.
62011514|NCT05390866|NO_INTERVENTION|Control group|The control group will follow the same procedure except for the HIIT session, which will be replaced by a 30-minute physical rest in a sitting position. The participants will be allowed to read a book or work on their computer/phone.
62011515|NCT05775198|EXPERIMENTAL|Intrauterine administration of PBMC immunomodulated with IFNt|Approximately 9 ml whole blood will be collected from each patient 5 days post LH peak by peripheral venipuncture using a 21G butterfly catheter affixed via vacutainer to negative pressure receiving tubes (BD vacutainer acid-citrate-dextrose (ACD-A), REF:366645). PBMC will be isolated by density gradient centrifugation in room-temperature centrifuge set to 400 g for 25 min. After washing the obtained PBMCs, they will be suspended in RPMI 1640 supplemented with 10% HSA (human serum albumin) and incubated in the presence of 500 IU/ml IFNt for 24 h at 37˚C. On day 6 after LH peak, this cultured cell suspension will be carefully introduced in the uterine cavity by catheter. The following day (LH+7), patients will undergo a standard embryo transfer (ET) procedure.
62011516|NCT05775198|NO_INTERVENTION|Control Group|Participants will undergo standard embryo transfer procedure with no intervention.
62011517|NCT04603859|EXPERIMENTAL|Elective induction of labour|Elective induction of labour at 39 gestational weeks and 0 to 3 days.
62577104|NCT03333668|ACTIVE_COMPARATOR|Lisdexamfetamine - Placebo|
62011518|NCT04603859|NO_INTERVENTION|Expectant management|Awaiting spontaneous labor.
62011519|NCT02051179||Replacement amalgam|Replacement The clinicians totally removed and replaced the defective restorations. After completing the cavity preparations, the tooth was restored with a new AM (Original D). Bonding agents and/or liners underneath the amalgam restorations were not used in this trial. Rubber dam isolation was used for all restorative treatments. .
62011520|NCT02051179||Repair Amalgam|The clinicians (PV and CM) used Carbide burs (330-010 Komet, Brasseler GmbH Co. Postfach 160.32631, Lemgo, Germany) to explore the defective margin, carious lesion or anatomic form of the restorations. Part of the restorative material adjacent to the defect was removed as an exploratory proceedure thus allowing a proper evaluation and subsequent diagnosis of the extent of the defect. Provided that the defect was limited and localized, the clinician then removed any defective tooth tissue. Mechanical retention was employed inside the existing AM restoration. Rubber dam isolation was used for this procedure. Repair of the restorations was carried out with a dispersed-phased amalgam (Original D, Wyckle Research Inc, Carson City, NV, USA).
62198892|NCT03908567|EXPERIMENTAL|1 mg AM-125|Nasal spray solution with 5 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 3 mg betahistine dihydrochloride.
62198893|NCT03908567|EXPERIMENTAL|10 mg AM-125|Nasal spray solution with 50 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 30 mg betahistine dihydrochloride.
62577105|NCT03333668|ACTIVE_COMPARATOR|Guanfacine - Placebo|
62577106|NCT03333668|EXPERIMENTAL|Lisdexamfetamine - Guanfacine|
62577107|NCT02084108|NO_INTERVENTION|Control arm= usual care|Two clusters of patients over 60 years of age followed by a primary care physician and routinely evaluated by the home nursing service with the resident assessment instrument-home care (RAI-HC) and identified as frail by pre-defined clinical criteria.
62784058|NCT06095609|NO_INTERVENTION|Routine care|no physiotherapy involved
62198894|NCT03908567|EXPERIMENTAL|20 mg AM-125|Nasal spray solution with 100 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 60 mg betahistine dihydrochloride.
62198895|NCT03908567|EXPERIMENTAL|Oral 16 mg betahistine|Tablets containing betahistine dihydrochloride. Administered three times daily as 1 tablet per time. Total daily dose is 48 mg oral betahistine dihydrochloride.
62198896|NCT02511262||Specimen Collection|Prospective patients with symptoms of upper respiratory infections which may be attributable to Mycoplasma pneumoniae, or from patients suspected of having Mycoplasma pneumoniae.
62198897|NCT05762562||Telerehabilitation with OS platforms|Patients with Parkinson's Disease were divided into three subgruops based on their residual motor skills.
62198898|NCT01680575||Training cohort|This cohort is a prospective cohort to develop a risk prediction model. This cohort include patients who underwent staging operation or debulking operation for epithelial ovarian cancer and are planned to receive ajuvant chemotherapy with paclitaxel/carboplatin up to 6 cycles.
62198899|NCT01680575||Validation cohort|"This is a retrospective cohort for validation of a risk prediction model developed using training cohort.~This is consisted with 600 patients with epithelial ovarian cancer who received adjuvant chemotherapy with paclitaxel/carboplatin after staging operation or debulking operation."
62198900|NCT01674023||human vitreous, human blood serum, PCR|"human vitreous and blood serum sampling, PCR~1ml of human vitreous and 3ml of human blood serum of patients with various vitreoretinal diseases"
62198901|NCT01115179|ACTIVE_COMPARATOR|Propofol|Propofol anesthesia
62198902|NCT01115179|ACTIVE_COMPARATOR|Control|Anesthesia with isoflurane alone
62198903|NCT01115179|ACTIVE_COMPARATOR|Solvent|Anesthesia with isoflurane together with the solvent of propofol (intralipid)
62198904|NCT02700659||UC monitoring patients|"Patients undergoing investigative cystoscopy for the detection of urothelial carcinoma as part of a standard-of-care schedule of investigations.~All patients will have urine samples taken and analyzed for NMP22 ELISA, NMP22 BladderChek, urine cytology and Cxbladder.~No results for any tests under evaluation in this study are provided to the clinician for diagnostic purposes."
62198905|NCT01853267|ACTIVE_COMPARATOR|Control group (Packing)|The perianal abscess cavity will continue to be packed after discharge until healing is complete
62198906|NCT01853267|EXPERIMENTAL|Intervention Group (Non-Packing)|The cavity will be allowed to heal by secondary intention without packing.
62198907|NCT03236623|EXPERIMENTAL|Menthol Popsicle|The patient will be questioned when the intensity and discomfort of thirst. After randomization, the patient assigned to the experimental group will experience a menthol popsicle. After 20 minutes of the end of the popsicle, will again be questioned as to the intensity and discomfort of thirst. The popsicle will have a support that will assist the patient in the administration of the intervention, giving him autonomy and safety in the application of the intervention.
62198908|NCT03236623|NO_INTERVENTION|Usual care|The patient will be questioned when the intensity and discomfort of thirst. After randomization, the patient assigned to the control group should receive the usual care consisting of absolute fasting the food and drinks.
62198909|NCT04884919|PLACEBO_COMPARATOR|Regular Gauze Treatment|Participants who undergo a cesarean section are first dissected in about 5 cm length and 2 cm width and receive a regular gauze made of traditional cotton yarn. The regular gauze is applied on the half side of the wound.
62198910|NCT04884919|EXPERIMENTAL|Chitosan Dressing Treatment|Participants who undergo a cesarean section are first dissected in about 5 cm length and 2 cm width and receive a chitosan dressing made of chitosan material. The chitosan dressing is applied on another half side of the wound.
62198911|NCT03924700|EXPERIMENTAL|Biportal endoscopic discectomy|Biportal endoscopic discectomy for lumbar herniated intervertebral disc
62198912|NCT03924700|ACTIVE_COMPARATOR|Microdiscectomy|Microdiscectomy for lumbar herniated intervertebral disc
62198913|NCT01378806|EXPERIMENTAL|Intervention|A 12-week intensive intervention on nutrition and exercise education and coping skills training (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
62198914|NCT06519864|EXPERIMENTAL|Elders over 65-year-old|"* Those who are elders (≥65 years)~* The enrolled participants completes the following evaluations during a single session: Tandem Stance Test (TST), Five Times Sit to Stand Test (FTSS), Turn Up and Go Test (TUG), Berg Balance Scale (BBS), Functional Reach Test (FRT), Four Square Step Test (FSST), Grip Strength (GS), and Short Physical Performance Battery (SPPB). The AK-based measurements are TST, FTSS, and TUG which are also the components of the SPPB."
62198915|NCT06519864|ACTIVE_COMPARATOR|Healthy adults under 65-year-old|"* Those who are young adults over 18 and under 65 years old~* The enrolled participants completes the following evaluations during a single session: Tandem Stance Test (TST), Five Times Sit to Stand Test (FTSS), Turn Up and Go Test (TUG), Berg Balance Scale (BBS), Functional Reach Test (FRT), Four Square Step Test (FSST), Grip Strength (GS), and Short Physical Performance Battery (SPPB). The AK-based measurements are TST, FTSS, and TUG which are also the components of the SPPB."
62198916|NCT02834338|NO_INTERVENTION|Laparoscopic surgery, control|The control group is wearing an activity tracker wristband with covered display, so that the step count can't be read out.
62198917|NCT02834338|ACTIVE_COMPARATOR|Laparoscopic surgery, intervention|activity tracking for autofeedback
62198918|NCT02834338|NO_INTERVENTION|Open surgery, control|The control group is wearing an activity tracker wristband with covered display, so that the step count can't be read out.
62198919|NCT02834338|ACTIVE_COMPARATOR|Open surgery, intervention|activity tracking for autofeedback
62198920|NCT00445835|OTHER|BA :Active arm|A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
62198921|NCT00445835|OTHER|BC: Conservative arm|Conservative medical approach
62198922|NCT03274453|ACTIVE_COMPARATOR|Ketamine Naive|"After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.~Infusion will be maintained for 24 hours."
62198923|NCT03274453|PLACEBO_COMPARATOR|Naive Placebo|Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
62198924|NCT03274453|PLACEBO_COMPARATOR|Tolerant Placebo|Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
62400703|NCT06722690|EXPERIMENTAL|eTSF|This arm will receive the eTSF intervention. eTSF is a smartphone app intervention featuring culturally relevant content aimed at supporting Latinx young adults with alcohol use disorder in participating in 12-step groups.
62577108|NCT02084108|OTHER|Intervention arm|The intervention arm will consist of two clusters of patients over 60 years of age followed by a primary care physician and routinely evaluated by the home nursing service with the RAI-HC and identified as frail by predefined clinical criteria that will receive in addition an in-home multidimensional geriatric assessment, access 24 hours a day, 7 days a week to a call service provided by the Community Geriatrics Unit and coordinated long-term follow-up.
62011521|NCT03243734|EXPERIMENTAL|trūFreeze® System spray cryotherapy|trūFreeze® System spray cryotherapy as clinically indicated for symptom relief
62011522|NCT05446311||DS group|Subjects going to receive dinalbuphine sebacate for post-cesarean section pain.
62577109|NCT00831311|EXPERIMENTAL|1|DTaP IPV HB-PRP\~T vaccine group
62577110|NCT00831311|ACTIVE_COMPARATOR|2|PENTAXIM™ and ENGERIX B® vaccines group
62011523|NCT05658302||Parkinson's disease|"* Diagnosis of idiopathic PD~* Surgery at UMN to implant DBS system with directional lead(s) and multiple independent current control IPG is planned as part of routine clinical care~* At least 21 years old~* Existing or planned 7T brain imagery"
62400704|NCT06722690|ACTIVE_COMPARATOR|Educational control|This arm will receive educational materials on drinking problems and a list of local/online AA meetings
62400705|NCT04822701|PLACEBO_COMPARATOR|Phase II, Arm 1: Placebo intravenous (i.v.) + placebo inhaled|Single dose of sterile normal saline (NaCl 0.9%) used as placebo for intravenous (i.v.) was administered as intravenous infusion over a period of 60 minutes plus a single inhaled of solvent for dilution of BI 767551 used as placebo for inhalation administered via inhalation through a mouthpiece (Aerogen® Ultra) using a mesh nebulizer (Aerogen® Solo) on Day 1, followed by a 90-day follow-up period. The inhalation procedure was to start approximately 25 min after the start of infusion.
62400706|NCT04822701|EXPERIMENTAL|Phase II, Arm 2: BI 767551 10 milligrams (mg)/kilogram (kg) intravenous (i.v.) + placebo inhaled|
62577111|NCT04652531|EXPERIMENTAL|Treatment|In the treatment arm, the lesion will be treated with EV for 3 weeks once a week
62577112|NCT04652531|SHAM_COMPARATOR|Internal control|The contralateral ulcer will be treated with a standard dressing and an elastic-compression bandage for 3 weeks.
62011524|NCT04025814|EXPERIMENTAL|dHealth tool and BPT Group|Parents and School Mental Health Providers (SMHPs) will participate in a 2-month trial during which they will use a digital Health (dHealth) tool in daily life contexts while receiving BPT, aimed to improve parent adherence sustained use of evidence-based parenting strategies. They will also participate in focus groups and discussions to facilitate the build, design, and use of the dHealth.
62198925|NCT03274453|EXPERIMENTAL|Tolerant Ketamine|"After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.~Infusion will be maintained for 24 hours."
62011525|NCT04025814|EXPERIMENTAL|BPT Group|Parents and School Mental Health Providers (SMHPs) will participate in a 2-month trial during which they will be receiving BPT without the use of a digital Health (dHealth) tool.
62400707|NCT04822701|EXPERIMENTAL|Phase II, Arm 3: BI 767551 40 mg/kg intravenous (i.v.) + placebo inhaled|
62577113|NCT01071226|EXPERIMENTAL|Stratum 1|Patients receiving an unrelated donor or partially matched related donor.
62577114|NCT01071226|EXPERIMENTAL|Stratum 2|For the patient's whose donors are haploidentical or a 2 antigen mismatched where one of the mismatches includes DRB1
62577115|NCT01172925|EXPERIMENTAL|Tiotropium|Inhaler
62577116|NCT01172925|PLACEBO_COMPARATOR|Placebo|Inhaler
62577117|NCT02308540|EXPERIMENTAL|Adult SIILPCV10|Single dose of SIILPCV10 on day 0
62577118|NCT02308540|ACTIVE_COMPARATOR|Adult Pneumovax 23|Single dose of Pneumovax 23 on day 0
62400708|NCT04822701|EXPERIMENTAL|Phase II, Arm 4: Placebo intravenous (i.v.) + BI 767551 250 mg inhaled|Single dose of sterile normal saline (NaCl 0.9%) used as placebo for intravenous (i.v.) was administered as intravenous infusion over a period of 60 minutes plus a single inhaled of 250 milligrams (mg) of BI 767551 administered via inhalation through a mouthpiece (Aerogen® Ultra) using a mesh nebulizer (Aerogen® Solo) on Day 1, followed by a 90-day follow-up period. The inhalation procedure was to start approximately 25 min after the start of infusion.
62400709|NCT04822701|EXPERIMENTAL|Phase III, Arm 1: BI 767551 (medium or high dose infusion) or low dose inhalation|
62400710|NCT04822701|PLACEBO_COMPARATOR|Phase III, Arm 2: Placebo|
62400711|NCT05570721|EXPERIMENTAL|Women with perimenopausal depression|Participants will undergo a social stress task (TSST)
62400712|NCT05570721|EXPERIMENTAL|Women without perimenopausal depression|Participants will undergo a social stress task (TSST)
62400713|NCT03873662||Pediatric patients after out-of hospital cardiac arrest|Pediatric patients after out-of hospital cardiac arrest admitted to Department of pediatric anesthesia and intensive care University hospital in Brno in selected study period with blood sample analysis for neurologic outcome prognostication
62400714|NCT02721043|EXPERIMENTAL|Personalized Genome Vaccine 001|"PGV-001 (peptides + Poly-ICLC)~Peptides: 100mcg per peptide per dose.~Poly-ICLC (Hiltonol®, Oncovir): 1.4mg (0.7mL, 2mg/mL)"
62400715|NCT03252808|EXPERIMENTAL|TBI-1401(HF10) + Gem/nab-PTX|1x10\^6 or 1x10\^7 TCID50/mL TBI-1401(HF10) administered to the tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and 1000 mg/m\^2 Gemcitabine and 125 mg/m\^2 Nab-paclitaxel injected by intravenous infusions.
62400716|NCT03252808|EXPERIMENTAL|TBI-1401(HF10) + TS-1 (primary)|1x10\^6 or 1x10\^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and TS-1 administered by oral.
62198926|NCT04392492||Patients undergoing transfemoral TAVI with MANTA closure|Patients undergoing transfemoral transcatheter aortic valve replacement with femoral access site closure using the novel plug-based vascular closure device (MANTA, Teleflex/Essential Medical Inc., Malvern, Pennsylvania, USA).
62198927|NCT05447234|EXPERIMENTAL|TCRX-T|"① 1x10\^7/m2 ;~* 3x10\^7/m2；~  * 1x10\^8/m2；~    * 3x10\^8/m2；~      * 1x10\^9/m2。"
62198928|NCT00657462|EXPERIMENTAL|A|Receives the intervention (reminders displayed at the startup of the application) for both periods (period 1 and period 2) of the study.
62198929|NCT00657462|ACTIVE_COMPARATOR|B|Receives the intervention (reminders displayed at the application startup) only during the second period (period 2) of the study.
62198930|NCT04510181|EXPERIMENTAL|Amino acid-based blend|The amino acid-based blend will be administered PO daily for the study duration
62577119|NCT02308540|EXPERIMENTAL|Toddler SIILPCV10|Single dose of SIILPCV10 on day 0
62198931|NCT02988323|EXPERIMENTAL|Cervicovestibular Physio (CV PT)|In addition to the standard protocol of rest followed by exertion, the CV PT group will participate in a combination of cervical spine and vestibular rehabilitation as per a standardized treatment algorithm based on individual assessment findings. This form of therapy combines treatment techniques for both the cervical spine and vestibular system that are commonly used in physiotherapy practice. Cervical spine treatments may include neuromotor retraining, sensorimotor retraining, manual therapy, soft tissue techniques, and range of motion exercises. Vestibular rehabilitation may include gaze stabilization, habituation, standing balance, dynamic balance and canalith repositioning maneouvers.
62198932|NCT02988323|EXPERIMENTAL|Low-Level Aerobic Exercise (LLAE)|Participants will exercise at 60% maximum heart rate for 15 minutes. This heart rate will be calculated by taking 220-age (in years) and multiplying by 0.6 to determine the target heart rate while performing the low level aerobic exercise. Aerobic exercises may include treadmill, walking or stationary cycling. Exercise will be performed 5-6 times per week independently at home and monitored by their parents. Individuals will be taught how to monitor their heart rate. This protocol has previously been found to be feasible and of minimal risk to participants.
62198933|NCT02988323|OTHER|Combination (LLAE and CV PT)|The combination group will complete a protocol that includes both the cervicovestibular physiotherapy and LLAE interventions described above. As described above, the study participants will be seen once weekly by the study physiotherapist for CV PT and also complete a protocol of LLAE at home.
62198934|NCT04419922||Smartphone Contingency Management Arm|100 participants will be voluntarily recruited at BrightView's Colerain outpatient treatment center to participate in the Smartphone Contingency Management Intervention.
62198935|NCT02283476|EXPERIMENTAL|Endostar continuous intravenous infusion|Endostar continuous intravenous infusion in combination with Gemcitabine and Cisplatin
62198936|NCT02283476|ACTIVE_COMPARATOR|Endostar routine intravenous infusion|Endostar routine intravenous infusion in combination with Gemcitabine and Cisplatin
62198937|NCT03142269|ACTIVE_COMPARATOR|polished group|360°anterior capsule polishing was performed with double-ended capsule polisher randomly in one eye
62198938|NCT03142269|PLACEBO_COMPARATOR|unpolished group|the opposite unpolished was used as the control
62198939|NCT04263987|ACTIVE_COMPARATOR|Holmium Laser Enucleation of Prostate|Traditional holmium laser enucleation of the prostate as currently performed
62198940|NCT04263987|EXPERIMENTAL|Moses Holmium Laser Enucleation of Prostate|holmium laser enucleation of the prostate as currently performed but with Moses laser settings activated.
62198941|NCT00912392|EXPERIMENTAL|Etoposide-Carboplatin with Endostar|Endostar® 7.5mg/m2 on day 1 to day 14, etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
62400717|NCT03252808|EXPERIMENTAL|TBI-1401(HF10) + TS-1 (primary and meta)|1x10\^6 or 1x10\^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and hepatic metastasis in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection or percutaneous injection and TS-1 administered by oral.
62400718|NCT03871231|EXPERIMENTAL|Unpinning Termination Therapy Arm|Subjects will have VT/VF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia
62577120|NCT02308540|ACTIVE_COMPARATOR|Toddler Prevenar 13|Single dose of Prevenar 13 on day 0
62198942|NCT00912392|ACTIVE_COMPARATOR|Etoposide-Carboplatin|Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
62198943|NCT00609856|ACTIVE_COMPARATOR|1|Pioglitazone
62198944|NCT00609856|ACTIVE_COMPARATOR|2|Insulin glargine
62198945|NCT01825798|PLACEBO_COMPARATOR|Placebo Hydrochloride Oral Solution|
62198946|NCT01825798|EXPERIMENTAL|Metformin|
62198947|NCT00713505|EXPERIMENTAL|Arm I (parent intervention program and usual care)|Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care). Parents also receive 8 weekly face-to-face training sessions (75-90 minutes each) with a therapist over approximately 2-3 months. Phone support/assistance is provided by the therapist within 2-3 days following each training session and then every 2 weeks for up to 6 months after completion of the training sessions.
62577121|NCT02308540|EXPERIMENTAL|Infants SIIL PCV10|A three-dose series of SIILPCV10 on day 0, day 28, and day 56
62577122|NCT02308540|ACTIVE_COMPARATOR|Infants Prevenar 13|A three-dose series of Prevenar 13 on day 0, day 28, and day 56
62577123|NCT02308540|EXPERIMENTAL|Infant Booster Dose SIILPCV 10|One dose of SIILPCV 10 at 9 months of age
62577124|NCT02308540|ACTIVE_COMPARATOR|Infant Booster Dose Prevenar 13|One dose of SIILPCV 10 at 9 months of age
62577125|NCT03893188||People asking for PrEP|All individuals aged \>18 years asking for PrEP prescription at one of the participating centers will be asked to participate to the SwissPrEPared Study(consecutive ongoing recruitment). Only HIV negative individuals will be deemed eligible.
62784059|NCT04523961|ACTIVE_COMPARATOR|2.5 g of lidocaine 23% / tetracaine 7% ointment|Patients undergoing 1927 nm fractional thulium fiber laser treatment of the face for photodamage as part of normal clinical care will have randomly assigned half of the face applied with 2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion for 60 minutes.
62784060|NCT04523961|ACTIVE_COMPARATOR|7.5 g lidocaine 2.5%/ prilocaine 2.5% cream|Patients undergoing 1927 nm fractional thulium fiber laser treatment of the face for photodamage as part of normal clinical care will have randomly assigned half of the face applied with 7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion for 60 minutes.
62784061|NCT03455816|EXPERIMENTAL|Group that uses the Social Diabetes App (research group)|This group use the App Social diabetes with the glucometer Glucomen Areo to monitoring the glucemia during 6 month
62784062|NCT03455816|ACTIVE_COMPARATOR|Usual clinical monitoring group (control group)|This group does not use the App. This group have an intermediate visit at 3 months with de doctor to see blood glucose self-monitoring and propose adjustments
62784063|NCT04927403||Chronic gastroenterological diseases - inpatient stay and day clinic|Irritable Bowel Syndrome, Crohn's disease, Ulcerative colitis
62784064|NCT04927403||Chronic Pain patients - inpatient stay and day clinic|Chronic pain syndrome, Rheumatism, Fibromyalgia
62784065|NCT04927403||Oncological diseases - day clinic|all kinds of oncological diseases
62400719|NCT04691674|EXPERIMENTAL|Study group|Endoscopic removal of pancreatic duct stent at 4 weeks following ERCP, unless spontaneously dislodged.
62400720|NCT04691674|PLACEBO_COMPARATOR|Control group|Endoscopic removal of pancreatic duct stent at 2 weeks following ERCP, unless spontaneously dislodged.
62400721|NCT05975762|ACTIVE_COMPARATOR|intervention group|surgical fixation group
62400722|NCT05975762|NO_INTERVENTION|control group|conservation group
62400723|NCT02516462|EXPERIMENTAL|IVM|Immature oocytes recovered from each subject will be placed into IVM media for maturation.
62400724|NCT02779842|EXPERIMENTAL|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62400725|NCT05315687|EXPERIMENTAL|Arm I (systemic therapy, Y90 radioembolization)|Patients receive systemic therapy. Beginning 1-6 weeks after starting systemic therapy, patients also undergo Y90 radioembolization.
62577126|NCT00722774|EXPERIMENTAL|1|Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
62577127|NCT06102746||Sintilimab + Surufatinib + EP|Sintilimab: 200mg intravenously administered on day 1; Surufatinib: 200mg/ day orally, taken continuously; Etoposide: 1, 2, 3 days of continuous administration, 100mg/m2, intravenous infusion; Cisplatin: 75mg/m2 on day 1, or 25mg/m2 on day 1, 2, and 3, intravenous infusion;
62577128|NCT03079024|EXPERIMENTAL|Targeted Cognitive Training (TCT)|Neuroadaptive Cognitive Training
62577129|NCT03079024|EXPERIMENTAL|General Cognitive Exercises (GCE)|Neuroadaptive cognitive training
62577130|NCT03079024|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Treatment as Usual
62577131|NCT03514043||Ambulatory care surgical patients|Patients who have attended the surgical assessment unit with an emergency general surgical condition and have their care completed without an inpatient stay.
62784066|NCT04927403||post Covid syndrome - inpatient stay and day clinic|post Covid sydrome
62784067|NCT04927403||other diseases - day clinic|e.g. patients with cardiovascular diseases, chron. Pulmonary diseases, metabolic disorders and skin diseases, etc.
62400726|NCT05315687|ACTIVE_COMPARATOR|Arm II (systemic therapy)|Patients receive systemic therapy.
62400727|NCT00811499|EXPERIMENTAL|ARRY-371797 (Schedule 1)|
62577132|NCT03514043||Surgical assessment unit staff|Staff who are involved in the care of patients on the surgical assessment unit. This includes senior and junior doctors, nurses, healthcare assistants and ward receptionists.
62577133|NCT04150510||Online Survey|Individuals who are willing to participate in this online survey
62577134|NCT06569771||Patients suffering from motor impairment of the upper limbs following a stroke|Voluntary patients suffering from motor impairment of the upper limbs following a stroke
62784068|NCT05805891|EXPERIMENTAL|bortezomib|bortezomib added on previous treatment
62784069|NCT03774784||ALECT2 Disease|
62784070|NCT06514313|EXPERIMENTAL|VIM|Mitoxantrone Hydrochloride Liposome combined with Irinotecan and Vincristine.
62400728|NCT00811499|EXPERIMENTAL|ARRY-371797 (Schedule 2)|
62577135|NCT03773406|ACTIVE_COMPARATOR|Offline tDCS-before therapy|Participants will receive 20 minutes of tDCS prior to the 40 minute speech-language therapy session.
62577136|NCT03773406|ACTIVE_COMPARATOR|Offline tDCS-after therapy|Participants will receive 20 minutes of tDCS after the 40 minute speech-language therapy session.
62577137|NCT03773406|ACTIVE_COMPARATOR|Online tDCS|tDCS will be applied at the beginning of the 40 minute speech-language therapy session and will last for 20 minutes.
62784071|NCT06514313|ACTIVE_COMPARATOR|VIT|Temozolomide combined with Irinotecan and Vincristine.
62784072|NCT01768195|EXPERIMENTAL|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of immunochemotherapy and/or chemotherapy, and will be continued until 12 months after completion of the immunochemotherapy and/or chemotherapy.
62784073|NCT02384018|NO_INTERVENTION|Control|Patients will receive standard islet transplantation.
62784074|NCT02384018|EXPERIMENTAL|autologous mesenchymal stromal cell|Patients will receive MSCs together with standard islet transplantation.
62784075|NCT05872347|EXPERIMENTAL|SPH4336 Tablets|SPH4336 Tablets; Letrozole tablets; Fulvestrant; Exemestane
62784076|NCT04387578|EXPERIMENTAL|Group A singlestrand NiTi arch wires|in which 10 patients (5 males and 5 females) were treated with round singlestrand NiTi arch wires in a sequence of 0.012, 0.014, and 0.016 inch.
62784077|NCT04387578|EXPERIMENTAL|Group B Gummetal arch wires|in which 10patients (6 males and 4 females) were treated with niobium-titanium-tantalum-Zirconium arch wires (Gummetal arch wires) in a sequence of 0.014, 0.016, and 0.018 inch.
62784078|NCT04387578|EXPERIMENTAL|Group C multistrand NiTi arch wires|in which 10 patients (4males and 6females) were treated with multistrand NiTi arch wires in a sequence of 0.016, 0.018, and 0.020 inch.
62784079|NCT00511238|EXPERIMENTAL|carfilzomib (A0)|
62784080|NCT00511238|EXPERIMENTAL|carfilzomib (A1)|
62784081|NCT00727155|EXPERIMENTAL|1|Treatment
62784082|NCT00727155|NO_INTERVENTION|2|Waitlist
62784083|NCT01106508|EXPERIMENTAL|LEQ506|
62784084|NCT04797351|EXPERIMENTAL|Experimental Group|"* Pre-treatment session + 12 Sessions Group Intervention~* TAU - Treatment as usual (Psychiatric support through Public health system)"
62784085|NCT04797351|NO_INTERVENTION|Control Group|"* TAU - Treatment as usual (Psychiatric support through Public health system)~* Waiting list (will have access to the intervention program BI-REAL after the 3 month follow up assessment)"
62784086|NCT03400163|EXPERIMENTAL|Treatment Group D:|Administered as specified on specified days
62784087|NCT03400163|PLACEBO_COMPARATOR|Treatment Group E:|Administered as specified on specified days
62784088|NCT00856544|EXPERIMENTAL|Active 5 mg|
62784089|NCT00856544|EXPERIMENTAL|Active 10 mg|
62784090|NCT00856544|PLACEBO_COMPARATOR|Placebo Sequence 1|Placebo non-responders advance to 5 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 5 mg CP-690,550 at Month 6 visit.
62011526|NCT05002322|EXPERIMENTAL|intervention health facilities|Health facilities implement the optimization of the cascade under research team support and continuous supervision.
62400729|NCT00811499|PLACEBO_COMPARATOR|Placebo|
62400730|NCT02992743|EXPERIMENTAL|letetresgene autoleucel (GSK3377794)|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
62400731|NCT03142230|EXPERIMENTAL|non-nutritive suction with holed baby bottle nipple|A group using the holed baby bottle nipple
62784091|NCT00856544|PLACEBO_COMPARATOR|Placebo Sequence 2|Placebo non-responders advance to 10 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 10 mg CP-690,550 at Month 6 visit.
62784092|NCT00422383|EXPERIMENTAL|1|
62784093|NCT00422383|EXPERIMENTAL|2|
62011527|NCT05002322|NO_INTERVENTION|Control|Health facilities prior to intensive phase receive standard supervision without research team support
62011528|NCT01866787||Study cohort|
62400732|NCT03142230|ACTIVE_COMPARATOR|Simple non-nutritive suction with personal pacifier|A group using personal pacifier
62400733|NCT03997383|EXPERIMENTAL|Patisiran|Participants will be administered multiple doses of patisiran in the double-blind and open-label extension period.
62400734|NCT03997383|PLACEBO_COMPARATOR|Placebo|Participants will be administered multiple doses of placebo in the double-blind period. In the open-label extension period, participants will be administered multiple doses of patisiran.
62400735|NCT01961310||RA patients|"This group is composed of 25 patients with RA. The diagnosis of RA is based upon the American College of Rheumatology criteria.~* Intervention: Plasma analysis for bacterial translocation~* Intervention: Stool analysis"
62784094|NCT00422383|EXPERIMENTAL|3|
62784095|NCT04527146|EXPERIMENTAL|IMAGINE-PD/Virtual|Pre-test genetic counseling through the Interactive Multimedia Approach to Genetic counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) website. Genetic results disclosure via virtual visit with a genetic counselor.
62784096|NCT04527146|EXPERIMENTAL|IMAGINE-PD/Telephone|Pre-test genetic counseling through the Interactive Multimedia Approach to Genetic counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) website. Genetic results disclosure via telephone with a genetic counselor.
62784097|NCT04527146|EXPERIMENTAL|Virtual/Telephone|Pre-test genetic counseling virtual visit with a genetic counselor. Genetic results disclosure via telephone with a genetic counselor.
62784098|NCT04527146|ACTIVE_COMPARATOR|Virtual/Virtual|Pre-test genetic counseling and genetic results disclosure via virtual visit with a genetic counselor.
62784099|NCT03203434||Esophageal anastomotic leakage|
62784100|NCT03203434||Esophageal uncomplicated controls|
62784101|NCT03203434||Pancreatic anastomotic leakage|
62784102|NCT03203434||Pancreatic uncomplicated controls|
62784103|NCT02815423|EXPERIMENTAL|UCMSCs|Transplantation of umbilical cord mesenchymal stem cells (UCMSCs) in patients with fracture and bone nonunion.
62784104|NCT02815423|PLACEBO_COMPARATOR|Placebo|The patients with fracture and bone nonunion who underwent percutaneous injection of placebo.
62784105|NCT02476695||S0/1|S0 = no fibrosis and S1 = portal fibrosis without septa
62784106|NCT02476695||S2|S2 = portal fibrosis with few septa
62784107|NCT02476695||S3|S3 = numerous septa without cirrhosis
62784108|NCT02476695||S4|S4 = liver cirrhosis (compensatory stage)
62577138|NCT03773406|SHAM_COMPARATOR|Sham tDCS|Sham tDCS will be applied at the beginning of the 40 minute speech-language therapy session.
62577139|NCT02547415||patients with questionnaires and psychological testing|children and adolescents with chronic pain without proven medical cause, type painful somatic complaints
62577140|NCT00638716|EXPERIMENTAL|1|12 weekly doses of 1.5 mg CJC-1134-PC
62198948|NCT00713505|ACTIVE_COMPARATOR|Arm II (wait-list/usual care control [UCC])|Child participants and their families undergo usual care as in arm I and are placed on a wait-list.
62577141|NCT00638716|EXPERIMENTAL|2|4 weekly doses of 1.5 mg CJC-1134-PC followed by 8 weekly doses of 2.0 mg CJC-1134-PC
62198949|NCT06164535|PLACEBO_COMPARATOR|Control Group|35 patients will be given placebo (only adjust their drugs to control blood glucose level)
62198950|NCT06164535|EXPERIMENTAL|DPPI Group|35 T2DM patients will be given DPP4Is once or twice daily
62198951|NCT06164535|EXPERIMENTAL|DPPI + metformin group|35 T2DM patients will be given DPP4Is + metformin once or twice daily
62400736|NCT01961310||Healthy voluteers|"This group is composed of 25 healthy volunteers.~* Intervention: Plasma analysis for bacterial translocation~* Intervention: Stool analysis"
62400737|NCT01715493|EXPERIMENTAL|Lysozyme 90 mg|
62577142|NCT00638716|PLACEBO_COMPARATOR|3|12 weekly doses of placebo
62577143|NCT01324986|ACTIVE_COMPARATOR|Nissen fundoplication|
62577144|NCT01324986|ACTIVE_COMPARATOR|Toupet fundoplication|
62577145|NCT01242670|EXPERIMENTAL|Ross River Virus Vaccine|Subjects will be randomized in equal numbers (1:1:1) to receive one of three different lots of the vaccine on Day 1, Day 22 and Day 181. (The study is blinded with regard to which vaccine lot is administered to a subject but all subjects will receive 3 injections with a 2.5 µg aluminum hydroxide adjuvanted dose of RRV vaccine.)
62198952|NCT06297434|EXPERIMENTAL|J2H-1702 A mg|
62198953|NCT06297434|EXPERIMENTAL|J2H-1702 B mg|
62198954|NCT06297434|EXPERIMENTAL|J2H-1702 C mg|
62198955|NCT06297434|PLACEBO_COMPARATOR|Placebo|
62198956|NCT05833646|EXPERIMENTAL|ShotBlocker Group|In control application, subcutaneous (SC) LMWH injection will be applied in patient's left abdomen with standard method on Post-op 0th day by the researcher. Intervention with ShotBlocker will be performed on the right abdomen site on post-op 1st day by the researcher. During subcutaneous LMWH injection with ShotBlocker, suitable injection site in right abdomen will be grasped by applying medium-weight pressure as ShotBlocker's obtuse touching points would touch the skin. In order to avoid ecchymosis and hematoma, it will be applied slowly for 10 seconds by entering from the middle point of ShotBlocker with a 90° angle. When injection is over, ShotBlocker will be removed 10 seconds will be waited. Removing the needle, the entry point will be applied light pressure with dry cotton for 10 seconds without any massage. Patients' level of pain and satisfaction will be assessed by a nurse working in the clinic with visual analog scale (VAS) within 1 minute after injection.
62198957|NCT05833646|EXPERIMENTAL|Virtual Reality Glasses (VRG) Group|"Standard LMWH application will be performed on the left side for control on Post-op 0th day by the researcher.~Intervention with VRG will be performed on the right abdomen site on post-op 1st day. The researcher will show the patient a video 5 minutes before the injection providing them with virtual reality glasses, which will continue till the end of the operation, after which the glasses will be removed. Patients' level of pain and satisfaction will be assessed by a nurse working in the clinic with visual analog scale (VAS) within 1 minute after injection."
62400738|NCT01715493|PLACEBO_COMPARATOR|Placebo|
62400739|NCT00753402|PLACEBO_COMPARATOR|A|IV Endotoxin plus saline vehicle (placebo)
62400740|NCT00753402|ACTIVE_COMPARATOR|B|IV Endotoxin plus IV epinephrine
62400741|NCT01768169||fish oil capsule|10 capsules per day will provide 2130 mg of EPA (1280 mg) and DHA (850 mg)
62400742|NCT02190162|ACTIVE_COMPARATOR|Tantum Verde® mouthwash|solution of Tantum Verde
62400743|NCT02190162|PLACEBO_COMPARATOR|placebo mouthwash|saline with mint flavor
62577146|NCT03346772|EXPERIMENTAL|Influenza vaccination cohort|Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.
62400744|NCT05420610||Patients with major burn.|Adult patients (age \> 18 years) suffered from major burn which defined as total burned surface area (TBSA) \> 20% with at least second degree burn depth were admitted to the intensive care unit (ICU) of the Burn Center at a tertiary medical center were retrospectively reviewed.
62577147|NCT01703676||Patients|Klinefelter Patients
62577148|NCT01703676||Parents|Parents of Klinefelter Patients
62577149|NCT01703676||Controls M|Healthy Male Control with normal karyotype
62577150|NCT01703676||Controls F|Healthy female controls
62577151|NCT03058705|EXPERIMENTAL|Hexaminolevinulate HCL with Near Infrared Fluorescence (NIRF)|During the transurethral resection of the bladder procedure, the bladder will initially be examined in a systematic meridian fashion. Suspicious tumors identified by white light only, NIRF only, and both will be identified. If intense fluorescence is observed in the initial patient(s) at 10 min, dwell duration will be reduced to 5 min for the next patient(s); if abundant fluorescence is detected there as well, dwell duration will be shortened again to 2.5 min. At least three patients will be studied at each duration to document intense fluorescence before proceeding to shorter instillation durations in subsequent patients.
62577152|NCT04520750|EXPERIMENTAL|Open label treatment arm|PTX-022 QTORIN
62577153|NCT01496950|ACTIVE_COMPARATOR|Active Comparator: Active rTMS|10Hz active rTMS delivered to the left dorsolateral prefrontal cortex
62577154|NCT01496950|PLACEBO_COMPARATOR|Placebo|10Hz placebo rTMS delivered to the vertex
62198958|NCT05833646|EXPERIMENTAL|Cold Application Group|Standard heparin application will be performed on left side for control on post-op 0th day by the researcher. Intervention with cold application will be performed on the right abdomen site on post-op 1st day. Prior to the intervention, cold silica gel pack which stayed in the freezer for at least 2 hours will be placed on patient's injection site by wrapping up with towel and will be applied on the site for 5 minutes. After 5 minutes, the cold gel pack will be removed from the site and subcutaneous LMWH injection will be applied by the researcher. Following the removal of the injector, cold application will continue for another 2 minutes. Patients' level of pain and satisfaction will be assessed by a nurse working in the clinic with visual analog scale (VAS) after injection.
62198959|NCT02070770|EXPERIMENTAL|Very low calorie diet|
62198960|NCT02070770|ACTIVE_COMPARATOR|Standard weight loss diet|
62198961|NCT02806362|EXPERIMENTAL|Ombitasvir/paritaprevir/ritonavir (12 weeks)|Ombitasvir/paritaprevir/ritonavir (25/50/100mg once daily) for 12 weeks
62400745|NCT05986708|EXPERIMENTAL|intervention|The intervention group conducted 6 sessions of interviews with the researcher using the worksheets within the scope of the guided self-determination method.
62198962|NCT01691950||Reconstruction|Those who have undergone limb reconstruction following lower limb trauma
62400746|NCT05986708|NO_INTERVENTION|control|No intervention was made to the individuals in the control group.
62400747|NCT02043002|EXPERIMENTAL|18F-FDG-PET scan|An early evaluation 18F-FDG-PET scan after 7-10 days
62400748|NCT05499052||REKOVELLE®|
62400749|NCT06724094||Failed|This group will be made up of patient who had revision TKR due to aseptic loosening within 10 years of primary arthroplasty
62400750|NCT06724094||Well performing|This group will be made up of patients who have an asymptomatic TKR 10 years after primary arthroplasty.
62400751|NCT02583854|ACTIVE_COMPARATOR|Hemostasis achieved by TR Band|After the transradial procedure and randomization TR Band will be applied to achieve hemostasis. Patient experience and complications after the application will be measured.
62400752|NCT02583854|EXPERIMENTAL|Hemostasis achieved by RY Stop|After the transradial procedure and randomization, RY Stop will be applied to achieve hemostasis. Patient experience and complications after the application will be measured.
62400753|NCT05585008|ACTIVE_COMPARATOR|group A|group A will receive a conventional heat-cure acrylic denture
62400754|NCT05585008|ACTIVE_COMPARATOR|group B|group B will receive a 3D printed complete denture
62198963|NCT01691950||Healthy volunteers|Healthy volunteers for control
62198964|NCT01850589|OTHER|Conservative Therapy|"Conservative therapy:~Subjects counseled by vascular attending/fellow during office appointment to stop smoking.~Counseling consists of:~Self-help materials including Smart Move: A Stop Smoking Guide from the American Cancer Society A brief educational discussion on the benefits of smoking cessation.~Patients randomized to Group 1 will be offered adjunctive treatment with nicotine replacement therapy at no cost."
62400755|NCT01343238|EXPERIMENTAL|Diet|12 week diet modification intervention by dietician
62400756|NCT01343238|EXPERIMENTAL|Exercise|12 week physical exercise modification intervention by physical therapist
62400757|NCT01343238|EXPERIMENTAL|Diet and Exercise|12 week diet and exercise behavioral modification by dietician and physical therapist
62400758|NCT01343238|NO_INTERVENTION|Control|Standard procedure
62400759|NCT02155816|PLACEBO_COMPARATOR|Placebo|MCT (medium chain triglyceride)
62400760|NCT02155816|EXPERIMENTAL|Omega 3|Omega-3 fatty acid ethyl esters, 2 soft gels of total 1000mg (660mg EPA +340mg DHA)/day.
62400761|NCT02155816|EXPERIMENTAL|Omega 7 + 3|210mg of Omega-7 fatty acid and 1000mg (660mg EPA +340mg DHA) of Omega-3
62400762|NCT05140902|EXPERIMENTAL|Glioblastoma patients|glioblastoma patients with newly or enlarged enhancing lesion within 3 months after completing 6 weeks of adjuvant chemoradiation therapy
62400763|NCT04021602|ACTIVE_COMPARATOR|Intervention 1 (Tx1) - DPP + Breastfeeding + Usual Care|Patients randomized to Tx1 will receive education in both the Diabetes Prevention Program (DPP) and in Breastfeeding. At baseline, this includes 16 DPP sessions (core curriculum), one 2-hour breastfeeding session, and participation in a professional peer support group. The 2-hour breastfeeding session is pre-recorded into four (4) 30-minute sessions and archived on a secure, private Facebook group. Participants will have access to all four breastfeeding sessions by week 24 of pregnancy and they need to complete all sessions by week 30 of pregnancy. At delivery, the patient will receive usual lactation support in the hospital, additional breastfeeding assessment and support (at day 3, day 10, week 3 and week 6), followed by 6 DPP sessions (post-core curriculum).
62198965|NCT01850589|OTHER|Aggressive Therapy|"8 week comprehensive smoking cessation and pharmacotherapy program consisting of:~* One hour group counseling sessions, focusing on patient education and behavior modification.~* Behavior modifications including recognition; coping skills; stress management; and relapse prevention skills.~* Counseling including information on nutrition, exercise, and chemical dependency.~Counseling sessions will be held 256C Mason Avenue. Pharmacotherapy adjuncts offered at no cost are as follows: Chantix (varenicline) GlaxoSmithKline, Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline."
62400764|NCT04021602|ACTIVE_COMPARATOR|Intervention 2 (Tx2) - DPP Only + Usual Care|Patients randomized to Tx2 will receive education in only the Diabetes Prevention Program. At baseline, this includes 16 DPP sessions (core curriculum). At delivery, the patient will receive usual lactation support in the hospital, followed by 6 DPP sessions (post-core curriculum).
62400765|NCT04021602|PLACEBO_COMPARATOR|Intervention 3 (Tx3) - Usual Care Only|Patients randomized to Tx3 will receive only usual standard of care. At baseline, the patient will receive only regular prenatal care provided by their physician. At delivery, the patient will receive standard of care breastfeeding support provided by the hospital.
62400766|NCT02501642|EXPERIMENTAL|Concussion Coach group|"After informed consent and randomization, participants will complete baseline study measures and will receive an iPod touch® with the Concussion Coach Explorer version"
62400767|NCT02501642|OTHER|Treatment as usual|Treatment as usual
62198966|NCT04977115|EXPERIMENTAL|Intraocular caliper-assisted capsulotomy group|In intraocular caliper-assisted capsulotomy group, a modified intraocular caliper with standard calibration on the rinse needle was used to measure and locate the position of capsulorhexis with 5.3 mm diameter and the principle of pupillary margin in concentric circles. The surgeon could gently use the blunt needle in the front of the intraocular caliper to further make corresponding markers on the lens anterior capsule, and then carry out capsulotomy according to the marks.
62198967|NCT04977115|ACTIVE_COMPARATOR|Verion navigation system-assisted capsulotomy group|In the Verion-assisted capsulotomy group, Verion navigation system was applied to project a 5.3 mm capsulorhexis centered on the corneal vertex. According to the projected capsulorhexis, capsulotomy was performed.
62198968|NCT04358718|ACTIVE_COMPARATOR|general anesthesia|Patients in this group will receive general anesthesia with intraoperative and postoperative intravenous opioid-based analgesia.
62198969|NCT04358718|EXPERIMENTAL|general analgesia combined with epidural analgesia|Patients in this group will receive combined epidural and general anesthesia with intraoperative and postoperative epidural ropivacaine-based analgesia.
62198970|NCT01810523|EXPERIMENTAL|Narrative|This arm will receive information regarding leg injuries and X-ray usage in narrative form in addition to standard of care discharge information.
62198971|NCT01810523|PLACEBO_COMPARATOR|Control|This arm will receive a blank piece of paper in addition to the standard of care discharge information.
62198972|NCT03176147||Pregnant women|Pregnant women are included during the ultrasound of T1. Written consent will be sought after delivery of the information notice.
62198973|NCT03325790|PLACEBO_COMPARATOR|Placebo|Placebo
62198974|NCT03325790|EXPERIMENTAL|200mg SPI-1005 twice daily (BID)|200mg SPI-1005 BID
62198975|NCT03325790|EXPERIMENTAL|400mg SPI-1005 BID|400mg SPI-1005 BID
62198976|NCT03965715|NO_INTERVENTION|Gait analysis with barefoot|Participants walk without assistance under gait detection.
62198977|NCT03965715|EXPERIMENTAL|Gait analysis with AFOs|Participants walk with AFOs under gait detection.
62198978|NCT03965715|EXPERIMENTAL|Satisfaction questionnaire|User feedback from the participants was obtained by questionnaire, the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST) and SF-36, to compare the satisfaction of AFOs
62198979|NCT05250219||patients for tonsils|40 patients for tonsils
62198980|NCT05250219||patients for appendixes|40 patients for appendixes)
62198981|NCT05385380|EXPERIMENTAL|Safe motherhood Promotion(Educational, Counselling & Training) and maternity waiting homes upgrading|"1. Improving the quality of maternal health services in health centers (training for midwives in basic emergency obstetric care and upgrading maternity waiting homes to the level to provide basic accommodation to address access-related barriers~2. Training community health workers with the aim of improving their knowledge about safe motherhood and about how to prepare a birth plan, including stays in maternity waiting homes~3. Training pregnant women"
62198982|NCT05385380|NO_INTERVENTION|Comparison|The current standard service package
62198983|NCT04074057|OTHER|Control arm|the control group will undergo a conventional weekly CR programme lasting 8-12 sessions. Components of each session will include warm up, aerobic training, resistance exercises and cool down. Patients are encouraged to continue their home exercises, exercising another 2 times a week at home and record down using an activity diary. The importance of CR programme and exercise advice will be explained and reinforced by the CR Physiotherapist. The submaximal exercise test and a body composition analysis will be repeated on the final assessment. Every week research coordinator will call the subject to remind them to exercise.
62400768|NCT02184234|EXPERIMENTAL|Antistax film coated tablets|
62198984|NCT04074057|OTHER|Intervention arm|"During the initial assessment, the importance of CR and regular exercise will be explained and reinforced by CR physiotherapist. A research assistant will teach the patient how to use Heart Track. The patient will then bring Heart Track home to continue their CR program. Patient will then undergo the whole CR programme to exercise for 3 times a day for 8-12 weeks using Heart Track. Each Heart Track session will include warm up, aerobic training, resistance exercises and cool down (same as the traditional CR session). After 8-12 weeks, patient will be called back to the clinic by the research assistant to complete the final assessment (sub-maximal exercise test and a body composition analysis) with the blinded assessor. Every week research coordinator will call the subject to remind them to exercise."
62198985|NCT06189859|ACTIVE_COMPARATOR|Spray coag mode|After initial mucosal incision, Endoscopic submucosal dissection will be performed using Spray coag mode using ERBE VIO 3 generator (effect 3-3.5)
62198986|NCT06189859|ACTIVE_COMPARATOR|Precisect mode|After initial mucosal incision, Endoscopic submucosal dissection will be performed using Precisect mode using ERBE VIO 3 generator (effect 4.5-5)
62198987|NCT00200291|EXPERIMENTAL|1|Behavioral: hypocaloric low-fat diet
62198988|NCT00200291|PLACEBO_COMPARATOR|2|Behavioral: hypocaloric, low-fat diet
62198989|NCT00958542|EXPERIMENTAL|Surgical Arm|Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
62400769|NCT06723353|EXPERIMENTAL|Visceral Manipulation|Participants in this arm will receive Visceral Manipulation (VM) therapy administered by a trained physical therapist. VM is a gentle manual therapy aimed at releasing restrictions within the visceral system to improve the mobility and function of the internal organs. The therapy sessions will focus on enhancing abdominal organ mobility and will be performed in a clinical setting. This treatment will be administered over a six-week period with sessions occurring once per week.
62400770|NCT06723353|EXPERIMENTAL|Kinesio Taping|This arm involves the application of Kinesio Tape (KT) to the abdominal area to support and stabilize the muscles affected by Diastasis Recti Abdominis. The KT will be applied in a crisscross manner to potentially facilitate muscle function and reduce the Inter-Recti Distance (IRD). Participants will receive taping once a week for six weeks, and the tape will be maintained throughout the week to ensure continuous support.
62198990|NCT00958542|NO_INTERVENTION|Non-Surgical Arm|Non-Surgical No intervention - Includes patients who have either refused to have surgery or have not been recommended to have surgery at this point. These patients will continue to be monitored closely, however, will not receive any other intervention.
62198991|NCT05923099|EXPERIMENTAL|Dose regimen 1|Dose A every week from Week 0 to Week 3, then every 2 weeks from Week 4 to Week 16
62198992|NCT05923099|EXPERIMENTAL|Dose regimen 2|Dose B every week from Week 0 to Week 3, then every 2 weeks from Week 4 to Week 16
62198993|NCT05923099|EXPERIMENTAL|Dose regimen 3|Dose A every week from Week 0 to Week 3, then dose C every 2 weeks from Week 4 to Week 16
62198994|NCT05923099|EXPERIMENTAL|Dose regimen 4|Dose C every week from Week 0 to Week 3, then dose D every 2 weeks from Week 4 to Week 16
62198995|NCT05923099|PLACEBO_COMPARATOR|Placebo regimen|Placebo every week from Week 0 to Week 3, then every 2 weeks from Week 4 to Week 16
62198996|NCT02908763|EXPERIMENTAL|Pegylated interferon group|Low replicative chronic HBV infection patients with HBsAg \<1000 IU/ mL and HBV DNA\<2000 IU/mL are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for at most 96 weeks.
62198997|NCT02908763|NO_INTERVENTION|Observing Group|Only observing and following up in this group.
62198998|NCT06165757|EXPERIMENTAL|noise on pain|Comparison of pain sensitivity before and after hearing noise among 15 subjects in each group.
62198999|NCT01055704|EXPERIMENTAL|Methylnaltrexone|
62199000|NCT01055704|EXPERIMENTAL|Codeine|
62199001|NCT01055704|EXPERIMENTAL|Methylnaltrexone + codeine|
62199002|NCT01055704|PLACEBO_COMPARATOR|Placebo|
62199003|NCT05214664|EXPERIMENTAL|Guiding device for inferior alveolar nerve block|"The system consists of a reusable angulator with a tube, a reusable plunger, and a single-use syringe body.~These three components are combined with a single-use needle and an anesthetic cartridge to create the ready-to-use EZ-Block® device."
62199004|NCT05214664|ACTIVE_COMPARATOR|Conventional freehand technique for providing anesthesia|"The injection site is located in the middle of the triangle with an upper base formed, during maximum mouth opening, outside by the mandibular ramus, inside by the mesial pterygoid muscle and above by the lateral pterygoid muscle.~The needle is inserted up to the bone contact (about 20mm) while the body of the syringe is directed towards the contralateral premolars or molars.~Use of a disposable carpule syringe with aspiration. Use of a 35mm long needle with a 0.5mm diameter. Use of an articaine anesthesia carpule with adrenaline 1/200000."
62199005|NCT04273139|EXPERIMENTAL|Ibrutinib and Venetoclax|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~* Ibrutinib will be administered at a predetermined dose, once daily for 28 days~* TLS Prophylaxis (Treatment to reduce risk of tumor lysis syndrome) prior to first dose of venetoclax (and for at least the first 2 weeks of treatment)~* Venetoclax Cycle 2-24. PO daily, predetermined dosage ramp up during cycle 2."
62400771|NCT06723353|EXPERIMENTAL|Combined Visceral Manipulation and Kinesio Taping|Participants in this arm will receive a combination of Visceral Manipulation and Kinesio Taping. The combination is intended to maximize the therapeutic effects by enhancing organ function with VM and providing muscular support with KT. The treatments will be administered concurrently during the same six-week period, with weekly sessions for both therapies.
62400772|NCT06723353|ACTIVE_COMPARATOR|Core Strengthening Exercises|This arm involves participants engaging in core strengthening exercises specifically designed for postpartum rehabilitation. The exercises aim to strengthen the transverse abdominis, multifidus, and pelvic floor muscles, which support the abdominal organs and improve core stability. Participants will perform these exercises under the supervision of a physical therapist three times a week for six weeks to ensure proper technique and progression.
62199006|NCT03745677|EXPERIMENTAL|Phase I|Each study site has selected 1-2 units ideally suited for initial implementation of the Advanced and Integrated MicroSystems (AIMS) interventions (Phase I Implementation) and 1-2 units for later implementation of AIMS interventions (Phase II Implementation). During Implementation Phase I, AIMS interventions were implemented on the initial, phase I Implementation units. The phase II units serve as control units during phase I.
62199007|NCT03745677|EXPERIMENTAL|Phase II|During Implementation Phase II, Advanced and Integrated MicroSystems (AIMS) interventions are being implemented on additional, phase II implementation units, leveraging lessons learned during phase I.
62199008|NCT00551850|EXPERIMENTAL|1|
62199009|NCT03003585|ACTIVE_COMPARATOR|Fiberoptic bronchoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
62577155|NCT02411396||Patients With SCD|Patients treated for uncomplicated VOC in ICs and EDs.
62199010|NCT03003585|ACTIVE_COMPARATOR|Direct laryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
62199011|NCT01061099|ACTIVE_COMPARATOR|Stratum A|Subjects with a diagnosis of Type II or Type III osteogenesis imperfecta who have previously undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.
62199012|NCT01061099|ACTIVE_COMPARATOR|Stratum B|Subjects with Type II or III osteogenesis imperfecta who have not undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.
62199013|NCT02334579|EXPERIMENTAL|CyberKnife Stereotactic Radiosurgery|This treatment concentrates large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. CyberKnife Stereotactic Radiosurgery is not investigational and is considered standard of care.
62199014|NCT03371147|EXPERIMENTAL|CancerLife|Arm A will be asked to download a mobile application called CancerLife. CancerLife is a stand-alone application that is NOT integrated into the patient's electronic health record and will NOT trigger symptom alerts to the treatment team. Participants will be instructed to use the after-visit instructions provided to them by their treatment team for any symptoms or conditions that will require an evaluation by a healthcare provider.
62011529|NCT06041477|EXPERIMENTAL|concurrent treatment group|Participants receive two cycles of HAIC (the drugs are oxaliplatin 135mg/m2 over 3hrs, calcium folinic acid 400mg/m2 or levofolinic acid 200mg/ m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs,every 4 weeks) in combination with targeted drug (lenvatinib 8mg/day) and immunotherapy (PD-1 antibody, dosage and frequency according to instructions), then evaluate the response of tumor, those who achieve complete response (CR) will receive surgical resection or follow-up, those with partial response (PR) or stable disease (SD) continue two cycles of combined therapy, and those with progress disease (PD) will be withdrawn and receive other treatments. After four cycles of combined therapy, second evaluation of efficacy will be performed, those who achieve CR will receive surgical resection or follow-up observation, and the other patients will be evaluated for the possibility of surgical resection or the subsequent treatment.
62199015|NCT03371147|NO_INTERVENTION|Usual care|Arm B will receive usual care provided for in the clinics. Usual care may vary between institutions, practices, and providers. Usual care may consist of but is not limited to any combination of the following: history and physical examination, review of systems, distress screening, symptom assessment measures, and/or interval quality of life measures.
62400773|NCT01360411||Pancreatic lesions|"Any patient with a solid pancreatic lesion of unknown histology may be recruited. Cystic lesions are not included.~Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively."
62400774|NCT01360411||Intramural upper GI-lesions|Patients with intramural lesions discovered by endoscopy or other imaging modalities are recruited. Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively.
62400775|NCT01360411||Lymph nodes|Patients with visible mediastinal lymph nodes or retroperitoneal lymph nodes in patients with inflammatory or malignant diseases are recruited. Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively.
62400776|NCT06123598|EXPERIMENTAL|Action observation plus exercise|Therapeutic exercise plus action observation training
62400777|NCT06123598|SHAM_COMPARATOR|Sham observation plus exercise|Therapeutic exercise plus sham action observation training
62400778|NCT03664700||LMA Protector|The LMA Protector will be used
62577156|NCT00356122|EXPERIMENTAL|Docetaxel/Oxaliplatin/Bevacizumab|Participants with advanced, recurrent, or metastatic Non Small Cell Lung Cancer (NSCLC), treated with the combination of docetaxel, followed by oxaliplatin, and then bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.
62011530|NCT06041477|ACTIVE_COMPARATOR|sequential treatment group|Participants receive two cycles of HAIC (drugs of oxaliplatin 135 mg/m2 over 3 hours; calcium folinic acid 400 mg/m2 or levofolinic acid 200 mg/m2 over 1. 5 hours, 5-FU 400 mg/m2 over 2 hours, and 5-FU 2400 mg/m2 over 46 hours,every 4 weeks), then evaluate the response of tumor, and those who achieve complete response (CR ) will receive surgical resection or follow-up, while other patients continue to receive two cycles of combination therapy, i.e. HAIC combined with targeted drug (levatinib 8mg/day) and immunotherapy (PD-1 antibody, dose and frequency according to instructions). After four cycles, a second efficacy assessment will be performed, and patients who achieve CR will undergo surgical resection or follow-up observation, and the other patients will be evaluated for the possibility of surgical resection or the subsequent treatment.
62011531|NCT00451425|NO_INTERVENTION|control|standard maternity care
62011532|NCT02966405||Healthy pregnant women|A descriptive analysis involving 300 healthy pregnant women according NACB to the establish of trimester-specific reference ranges for thyroid tests in pregnant women.
62011533|NCT02966405||Normal pregnant population|According to the selection criteria, 700 cases were selected as the normal pregnant population to establish a self-sequential longitudinal reference range. The aim of this study to monitor the change of thyroid function and antibody during the course of pregnancy in those who suffer from various thyroid disorders and normal control.
62011534|NCT05508633|EXPERIMENTAL|Low dose Alverine|Alverine 60mg (1 capsule), orally
62199016|NCT05312346||responsiveness to erythropoietin stimulating agent|we evolute responsiveness of patients on hemodialysis for erythropoietin stimulating agents or not and factors effecting this response
62400779|NCT02491333|EXPERIMENTAL|true acupuncture + placebo metformin|"True acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.~Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month."
62577157|NCT04754828|ACTIVE_COMPARATOR|Bedside|The bedside rounding team will perform patient presentations at the bedside, with a focus on the patient, and will ensure nursing involvement when rounding on each patient,
62577158|NCT04754828|ACTIVE_COMPARATOR|Hallway|The hallway rounding team will present patients outside of the patient's room, without an emphasis on nurse participation.
62577159|NCT03285867||HCC received TACE|observational study set only one group with HCC received TACE
62199017|NCT04549818|EXPERIMENTAL|sacral neuromodulation|Sacral neuromodulation group, will be treated with Stimulation of the sacral nerve roots by placement of a lead and generator, typically using an implanted InterStim® device that provides constant electrical stimulation to the S 2, 3 and 4 nerve roots, for 2-week trial stimulation
62199018|NCT04549818|NO_INTERVENTION|medical therapy|this group will be treated with sustained release morphine tablets for pain control
62199019|NCT03776708|EXPERIMENTAL|Spinal manipulation|The spinal manipulation is located between the fifth and eighth thoracic vertebrae, on a level and a side pain-free to a light palpation. The maneuver is of high velocity and low amplitude, oriented posterior to anterior, on the transverse process area of the chosen thoracic vertebrae.
62199020|NCT03776708|SHAM_COMPARATOR|Sham procedure|"The sham procedure is a manual contact on both inferior angles of the scapulae by the chiropractor. After a short tensioning, a slight movement with low velocity and low amplitude is done, respecting scapula-thoracic sliding plans laterally, without repercussion on the spine. It is considered by us to be a credible sham procedure, as it resembles an actual act of thoracic manipulation, and it has been validated, with questionnaires."
62199021|NCT00498472|ACTIVE_COMPARATOR|A|Pre-discharge NT-ProBNP based
62199022|NCT00498472|NO_INTERVENTION|B|Discharge date and treatment not based on the knowledge of pre-discharge NT-proBNP levels
62199023|NCT06238635|EXPERIMENTAL|Cohort A: Immunotherapy Naive|"10 Participants will complete study procedures as follows:~* Baseline visit.~* Imaging tests at baseline visit, at week 9, and then every 12 weeks.~* Cycle 1 through End of Treatment (up to 2 years of treatment):~  • Day 1 of 21 Day cycle: Dostarlimab 1x daily and Cobolimab 1x daily.~* End of Treatment visit with blood tests and imaging tests.~* Follow Up Period: Every 3 months for 2 years and then every 6 months for an additional 5 years. Includes imaging tests.~If \>= 2 participants with objective responses, then 19 additional participants will be enrolled."
62199024|NCT06238635|EXPERIMENTAL|Cohort B: Immunotherapy Exposed|"14 Participants will complete study procedures as follows:~* Baseline visit.~* Imaging tests at baseline visit, at week 9, and then every 12 weeks.~* Cycle 1 through End of Treatment (up to 2 years of treatment):~  • Day of 21 Day cycle: Predetermined dose of Dostarlimab 1x daily. Predetermined dose of Cobolimab 1x daily.~* End of Treatment visit with blood tests and imaging tests.~* Follow Up Period: Every 3 months for 2 years and then every 6 months for an additional 5 years. Includes imaging tests.~If \>= 2 participants with objective responses, then 23 additional participants will be enrolled."
62199025|NCT06478511|ACTIVE_COMPARATOR|Classic immediate implant|Include 11 implants (Nucleoss T6®) , maximum two per patient, will be placed immediately after atraumatic extraction.
62199026|NCT06478511|ACTIVE_COMPARATOR|Immediate implant combined with subepithelial connective tissue graft|Include 11 implants, maximum two per patient will be placed immediately after atraumatic extraction and subepithelial connective tissue graft will be harvested and placed.
62199027|NCT06478511|ACTIVE_COMPARATOR|Immediate implant using socket shield technique|include 11 implants, maximum two per patient will be placed immediately using Socket Shield Technique.
62400780|NCT02491333|SHAM_COMPARATOR|sham acupuncture + placebo metformin|"Sham acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month. Placement of needles is unlikely to affect ovulation and IR in women with PCOS.~Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month."
62400781|NCT02491333|ACTIVE_COMPARATOR|sham acupuncture + metformin|"Sham acupuncture and metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.Placement of needles is unlikely to affect ovulation and IR in women with PCOS.~Metformin will be given at 0.5g/times, 3 times one day and for 4 month."
62400782|NCT04624295|ACTIVE_COMPARATOR|Early Antiplatelet Therapy|
62400783|NCT04624295|PLACEBO_COMPARATOR|Non-Early Antiplatelet Therapy|
62400784|NCT05371340|EXPERIMENTAL|Postmenopausal women: Experimental group|Quercetin 500 mg. One capsule once a day.
62400785|NCT05371340|PLACEBO_COMPARATOR|Postmenopausal women: Placebo group|Placebo (methylcellulose E4M) 500 mg, once capsule once a day.
62400786|NCT01585285|EXPERIMENTAL|LIMA to SVG Bridge|Patients will receive composite coronary artery bypass grafting (CABG) with left internal mammary artery (LIMA) and saphenous vein graft (SVG) Bridge for the anterolateral targets
62400787|NCT01585285|ACTIVE_COMPARATOR|Conventional CABG|Patients will receive conventional coronary artery bypass grafting (CABG) with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
62011535|NCT05508633|EXPERIMENTAL|High dose Alverine|Alverine 120mg (2 capsules), orally
62011536|NCT01600040|OTHER|Proton Radiation Therapy|This is a single arm study; all participants will receive proton radiation therapy.
62400788|NCT06722118|EXPERIMENTAL|Intravenous dexamethasone|
62400789|NCT06722118|PLACEBO_COMPARATOR|Placebo|
62400790|NCT04786327|PLACEBO_COMPARATOR|treated by using Minimally invasive flap only.|7 sites treated with Minimally invasive flap only
62400791|NCT04786327|EXPERIMENTAL|Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin .|7 sites treated with Minimally invasive flap plus EDTA root conditioning and application of platelet rich fibrin graft
62199028|NCT06316518|EXPERIMENTAL|Mindfulness group|Primigravidas randomly assigned to the experimental group will be given web-based mindfulness-based stress reduction trainings after pre-tests are applied.
62199029|NCT06316518|ACTIVE_COMPARATOR|control group|After the pre-tests were applied to the control group, routine nursing care will be given and post-test measurements will be made after 8 weeks.
62199030|NCT04478136||Major bleeders (MB)|Additional blood to be drawn from patients on ECMO who have a major bleeding event.
62199031|NCT04478136||Non-major bleeders (NMB)|
62199032|NCT02437942|EXPERIMENTAL|Biomechanics led physical therapy rehabilitation|Physical therapy exercise rehabilitation
62199033|NCT02625064||1: patient at High risk for ARDSp|Severe pneumonia and（PaO2/FIO2）\>300mmHg
62199034|NCT02625064||2: patient at High risk for ARDSexp|Severe sepsis and without ARDS
62199035|NCT02625064||3: mild ARDS|PaO2/FiO2=201～300 mmHg，and PEEP or CPAP≤5 cm
62199036|NCT02625064||4: moderate ARDS|PaO2/FIO2=101～200 mmHg，且PEEP≥5 cm H2O
62199037|NCT02625064||5: severe ARDS|PaO2/FIO2≤100 mmHg，且PEEP≥10 cm H2O
62199038|NCT05977205||Type 1 Diabetes|280 patients with type 1 diabetes
62199039|NCT05977205||Type 2 Diabetes|155 patients with type 2 diabetes
62199040|NCT05977205||Type 1 Diabetes with Islet or Pancreas Transplantation|23 patients with islet transplantation, 7 with pancreas transplantation, 27 with simultaneous pancreas-kidney transplantation
62199041|NCT02318953|EXPERIMENTAL|Mobile app follow-up care|"The mobile app follow-up group will have no planned in-person follow-up at one- and four weeks postoperative. However, these visits will be replaced with surgical site examination via submitted photos, visual analog scale (VAS) to assess pain, and the quality of recovery-9 (QoR9) questionnaire monitoring. All of this information is submitted via the mobile application (QoC Health Inc. Toronto). Patient will use daily monitoring for two weeks and then weekly monitoring for four weeks. The surgeon will use a wireless interface to access that data and monitor the patient's condition (not in real time). Physicians will summarize the clinical findings recorded by the mobile app at one week and four weeks postoperative using the prototypical SOAP note."
62199042|NCT02318953|ACTIVE_COMPARATOR|Conventional, in-person follow-up care|Patients in the conventional, in-person follow-up group will have a planned clinic follow-up at one- and 4-weeks postoperative. This is the follow-up schedule currently used by both surgeons. At these scheduled follow-ups, patients will be asked to complete the VAS to assess pain and the QoR9 questionnaire.
62199043|NCT06263686|EXPERIMENTAL|Pasteurised yoghurt|
62400792|NCT04786327|EXPERIMENTAL|MIST with root conditioning (EDTA) and GEM 21S .|7 sites treated with Minimally invasive flap plus EDTA root conditioning and application of growth factor enhanced matrix GEM21S
62400793|NCT05141422|EXPERIMENTAL|Treatment group|SHR2150+ efavirenz
61978286|NCT04464122||Neuroendocrine toumor group|30 patients (18-80 years, males and females) affected by histologically-proven neuroendocrine neoplasms, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to medical therapy.
62199044|NCT06263686|EXPERIMENTAL|Fresh natural yoghurt|
62199045|NCT06263686|EXPERIMENTAL|Sterilised yoghurt|
62199046|NCT00618176|EXPERIMENTAL|B|
62199047|NCT00618176|EXPERIMENTAL|A|
62199048|NCT00618176|EXPERIMENTAL|C|
62199049|NCT04291053|EXPERIMENTAL|experimental group|Standard therapy+Huaier granule Huaier granule 20g, po, tid for 2 weeks( or until discharge)
62199050|NCT04291053|NO_INTERVENTION|control group|standard therapy
62199051|NCT03733353|OTHER|Cohort 1|12 healthy volunteers; 8 on EDP1815, 4 on placebo. Dose=1/10th of HED, capsule, once daily, 15 days
62199052|NCT03733353|OTHER|Cohort 2|12 healthy volunteers; 8 on EDP1815, 4 on placebo. Dose= 1 x HED, capsule, once daily, 15 days
62199053|NCT03733353|OTHER|Cohort 3|12 subjects with mild to moderate psoriasis; 8 on EDP1815, 4 on placebo. Dose= 1 x HED, capsule, once daily, 29 days
62199054|NCT03733353|OTHER|Cohort 4|24 subjects with mild to moderate psoriasis; 16 on EDP1815, 8 on placebo. Dose= 5 x HED capsule, once daily, 29 days
62199055|NCT03733353|OTHER|Cohort 5|24 subjects with mild to moderate atopic dermatitis; 16 on EDP1815, 8 on placebo. Dose= 5 x HED, mini-tablets in capsule, once daily, 29 days
62199056|NCT03733353|OTHER|Cohort 6|24 subjects with mild to moderate psoriasis; 16 on EDP1815, 8 on placebo. Dose=5 x HED, mini-tablets in capsule, once daily, 29 days.
62199057|NCT03733353|OTHER|Cohort 7|24 subjects with mild to moderate atopic dermatitis; 16 on EDP1815, 8 on placebo. Dose= 5 x HED, capsule, once daily, 56 days
62199058|NCT03733353|OTHER|Cohort 8|24 subjects with mild to moderate psoriasis; 16 on EDP1815, 8 on placebo. Dose= 8 x HED, tablet, once daily, 56 days
62199059|NCT03733353|OTHER|Cohort 9|24 subjects with mild to moderate psoriasis; 16 on EDP1815, 8 on placebo. Dose= 2 x HED, capsule, once daily, 56 days
62199060|NCT03733353|OTHER|Cohort 10|24 subjects with mild to moderate atopic dermatitis; 16 on EDP1815, 8 on placebo. Dose= 4 x HED, capsule, once daily, 56 days
62199061|NCT01384812|PLACEBO_COMPARATOR|Isoton sodium chloride|
62199062|NCT01384812|ACTIVE_COMPARATOR|Prostin E2 (dinoprostone)|
62199063|NCT03064945|SHAM_COMPARATOR|Shame device|
62199064|NCT03064945|EXPERIMENTAL|Livia® Transcutaneous Electrical Nerve Stimulation (TENS)|
62199065|NCT05925257|EXPERIMENTAL|Intervention group|The intervention group will be given access to the ePRO application and proactive clinical care, including study nurses responding to ePROs and weekly health information videos for six months.
62199066|NCT05925257|NO_INTERVENTION|Control group|Participants of the control group will be provided with a list of electronic links to videos on breast cancer-relevant topics on the websites of recognised cancer associations and health institutions.
62400794|NCT01404104|EXPERIMENTAL|Temsirolimus (pre-surgery)|
62577160|NCT05393648|EXPERIMENTAL|Active iTBS|Patients will receive unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions.
62577161|NCT05393648|PLACEBO_COMPARATOR|Sham iTBS|Patients will receive sham unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions.
62577162|NCT01191125|EXPERIMENTAL|medical food with AN777|
62784109|NCT04499287|PLACEBO_COMPARATOR|Control|Test meal \[bagel with butter (20 g) and apple juice (240 ml) with added sugar (24 g)\] The meal was a total of 640 kcal (100 g carbohydrate, 21 g fat, 10 g protein. Participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption. One week later the test meal was consumed with fiber (36 g, Metamucil powder, Procter\&Gamble, Cincinnati, OH) added to the apple juice (active) and participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption . One week later participants were given 5 minutes to transition to the treadmill following consumption of the test meal and began walking on a motorized treadmill at their calculated preferred walking speed for 15 minutes (experimental). Afterwards participants remained seated in the laboratory with minimal activity for the remainder of the four hours following test meal consumption
62011537|NCT05901129|ACTIVE_COMPARATOR|SPSIPB|SPSIP block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle. All patients had 3x400 mg ibuprofen intravenous (i.v.) in postoperative 24 hours. 50 mg tramadol was given as a rescue analgesic drug to the patients who had numerical rating scale (NRS) 4 or higher.
62011538|NCT05901129|NO_INTERVENTION|Control|Control group patients were not subjected to any block or local infiltration anesthesia (local anesthetic administration around the incision). Their postoperative pain was relieved with ibuprofen 3x400mg intravenous (i.v.) in postoperative 24 hours. The patients had NRS score 4 or higher were given 50 mg tramadol as a rescue analgesic.
62011539|NCT02541266||Group 1|Patients currently recruited to studies with imaging at The Marsden
62011540|NCT02541266||Group 2|Patients who have previously participated in studies with imaging at The Marsden
62011541|NCT02541266||Group 3|Patients attending for scans as part of their clinical pathway
62011542|NCT04928352|EXPERIMENTAL|Group B1|Nebulized Bupivacaine 0.50% 0.25 mg.kg-1
62011543|NCT04928352|EXPERIMENTAL|Group B2|Nebulized Bupivacaine 0.50% 0.50 mg.kg-1
62011544|NCT04928352|PLACEBO_COMPARATOR|Group C|Same volume of nebulized saline placebo
62011545|NCT06466395|EXPERIMENTAL|Phase 1a|"Participants enrolled in Phase 1a, the dose of venetoclax the participant receive will depend on when the participant joins this study. The first group of participants will receive the lowest dose level of venetoclax. Each new group will receive a higher dose of venetoclax than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of venetoclax is found.~The study doctor will discuss with you the doses the participants will receive as part of hyper-CVAD based on standard of care."
62011546|NCT06466395|EXPERIMENTAL|Phase 1b|"Participants enrolled in Phase 1b, will receive venetoclax at the recommended dose that was found in Phase 1.~The study doctor will discuss with you the doses the participants will receive as part of hyper-CVAD based on standard of care."
62011547|NCT06662903|ACTIVE_COMPARATOR|Titanium mesh|this group is operated using titanium mesh
62011548|NCT06662903|ACTIVE_COMPARATOR|Bone cement|this group is operated using bone cement
62011549|NCT03891082|ACTIVE_COMPARATOR|B-Lynch|A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border.The absorbable suture is fed posteriorly and vertically to enter the posterior wall of the uterine cavity at the same level as the upper anterior entry point.
62577163|NCT01191125|ACTIVE_COMPARATOR|oral nutritional formula|
62011550|NCT03891082|ACTIVE_COMPARATOR|Bakri balloon|Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium.
62011551|NCT01607034|EXPERIMENTAL|Sequence 1 - tablet-fast|150 mg Dexpramipexole (intact tablet) single dose under fasted condition
62011552|NCT01607034|EXPERIMENTAL|Sequence 2 - tablet-fed|150 mg Dexpramipexole (intact tablet) single dose under fed condition
62199067|NCT02878447|EXPERIMENTAL|External Beam Radiotherapy|Patients will receive radiotherapy (3.5Gy weekly for 5 fractions to a maximum of 17G) prescribed to a central plane using mega-voltage radiation encompassing all the assessed affected lung tissue
62199068|NCT02878447|NO_INTERVENTION|Control|Patients will receive best medical care.
62577164|NCT00693238|EXPERIMENTAL|Low Risk Proton Radiation|70 Gy/CGE in 28 fractions of 2.5 Gy/CGE/fx
62577165|NCT00693238|EXPERIMENTAL|Intermediate Risk Proton Radiation|72.5 GY/CGE in 29 fractions of 2.5 Gy/CGE/fx
62577166|NCT00820248|ACTIVE_COMPARATOR|Arm I|Patients undergo standard fractionation radiotherapy (IMRT or 3D CRT) once daily, 5 days a week, for 7 weeks. Patients receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
62577167|NCT00820248|EXPERIMENTAL|Arm II|Patients undergo accelerated fractionation radiotherapy (IMRT or 3D CRT) once or twice daily, 5 days a week, for 6 weeks. Patients receive panitumumab IV over 30-90 minutes 1 week prior to and on days 15 and 36 of radiotherapy.
62199069|NCT05303389|EXPERIMENTAL|Posterior plating group|Fix the posterior fragment using a buttress plate through a posterolateral approach by an interval between flexor hallucis longus and peroneii.
62199070|NCT05303389|ACTIVE_COMPARATOR|Anterior to posterior group|Fix the posterior fragment using anterior to posterior 4.0 mm cannulated screws under xray guidance.
62199071|NCT05643755|EXPERIMENTAL|Intervention|Intervention group: educational material provided on the day of surgery containing pictographic and written education material on wound appearance following primary closure after Mohs Micrographic Surgery (MMS) or Wide Local Excision (WLE)
62400795|NCT06217601|EXPERIMENTAL|Treatment status|To account for immortal time bias, each subject will be created with two clones at time zero and assigned each of the two clones to either treatment or no-treatment status, respectively. The treatment status in each evaluative endpoint (i.e., 3-month, 6-month, and 12-month) is defined as subjects who have received the digital intervention for the respective length of time since the time zero during which the intervention has just commenced.
62400796|NCT06217601|PLACEBO_COMPARATOR|No-treatment status|To account for immortal time bias, each subject will be created with two clones at time zero and assigned each of the two clones to either treatment or no-treatment status, respectively. The corresponding no-treatment status is defined as subjects who have not received the digital intervention for the corresponding length of time.
62400797|NCT01345227|EXPERIMENTAL|Intra BM islet infusion|single intra BM islet infusion at the level of the iliac crest will be performed in patients having contraindications for intraportal infusion
62400798|NCT06724406|EXPERIMENTAL|Session 5, In-Person, Communication and Cohesion|Participants will receive core behavioral weight loss group sessions and 5 family skills training sessions in-person with content covering communication and cohesion
62400799|NCT06724406|EXPERIMENTAL|Session 5, In-Person, Communication and No Cohesion|Participants will receive core behavioral weight loss group sessions and 5 family skills training sessions in-person with content covering communication but no cohesion
62577168|NCT03216005|EXPERIMENTAL|BlueLeaf System|The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.
62577169|NCT05069116||pre-Covid era|
62199072|NCT05643755|NO_INTERVENTION|Control|Control group: standard clinical care
62199073|NCT01457638|SHAM_COMPARATOR|No inferior turbinate surgery|During rhinoseptoplasty there is no intervention on inferior turbinates
62577170|NCT05069116||Covid-era|
62577171|NCT01485016||ambulatory epilepsy subjects|
62577172|NCT06621537||Representative Sample of the Austrian General Population|Sample of the Austriang General Population aged \>=14 years representative for age, gender, age x gender, region, education
62577173|NCT01055860||Robotic sacral colpopexy|Our study population will be women who underwent Robotic assisted laparoscopic sacral colpopexy at the Morristown Memorial Hospital for correction of pelvic organ prolapse using a synthetic polypropylene mesh.
62577174|NCT04245631||RAA assay for 2019-nCoV|a simple, fast and portable recombinase aided amplification (RAA) assay for 2019-nCoV
62199074|NCT01457638|EXPERIMENTAL|Inferior Turbinate surgery|During rhinoseptoplasty, inferior turbinate submucosal cauterization is performed.
62199075|NCT03790696|EXPERIMENTAL|Active Cognitive Training|Participants will complete 30-45 minute cognitive training program twice a week for four weeks.
62199076|NCT03790696|SHAM_COMPARATOR|Sham Cognitive Training|Participants will complete 30-45 minute cognitive training program twice a week for four weeks.
62199077|NCT01870947|EXPERIMENTAL|'Assisted-Rate' Exercise Intervention|Subjects in the assisted exercise group will cycle on the same stationary exercise bike; however, a motor will provide assistance to the patient in order to maintain a pedaling rate 35% greater than their voluntary rate. Subjects in the exercise groups will complete 45 minute to 1-hour sessions, three times per week for eight weeks.
62199078|NCT01870947|EXPERIMENTAL|'Voluntary-Rate' Exercise Intervention|Subjects in the voluntary group will exercise on a stationary recumbent exercise cycle and pedal at their preferred rate. Subjects in the exercise groups will complete 45 minute to 1-hour sessions, three times per week for eight weeks.
62199079|NCT01644864|PLACEBO_COMPARATOR|Placebo|saline injection
62199080|NCT01644864|EXPERIMENTAL|Experimental|0.375% ROPIVACAINE
62400800|NCT06724406|EXPERIMENTAL|Session 5, In-Person, Cohesion and No Communication|Participants will receive core behavioral weight loss group sessions and 5 family skills training sessions in-person with content covering cohesion but no communication
62577175|NCT05174299|EXPERIMENTAL|double active magnetic stimulation|the multi-target magnetic stimulation on motor cortex combined with spinal cord
62577176|NCT05174299|ACTIVE_COMPARATOR|single active magnetic stimulation|the active magnetic stimulation on motor cortex and sham stimulation on spinal cord
62577177|NCT05174299|SHAM_COMPARATOR|double sham magnetic stimulation|the sham magnetic stimulation on motor cortex and sham stimulation on spinal cord
62577178|NCT01543178|EXPERIMENTAL|Rifaximin open-label|"Subjects will receive open-label rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up. Responders will continue into Maintenance Phase 1 (treatment free). Nonresponders will withdraw from the study.~Subjects who meet criteria for recurrence in Maintenance Phase 1 enter the double-blind period and are randomized 1:1 to receive rifaximin 550 mg or placebo."
62577179|NCT01543178|EXPERIMENTAL|Double-blind rifaximin (retreatment)|Subjects in this arm receive rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks \[treatment free\]) followed by a second retreatment with rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up.
62199081|NCT06541769|EXPERIMENTAL|Hypothermia|limb Hypothermia with special hypothermia-gel-gloves of the dominant hand starting 30min before chemotherapy application and ending 30min after. The glove will be changed every 30min to provide constant cooling
62400801|NCT06724406|EXPERIMENTAL|Session 5, In-Person, No Communication and No Cohesion|Participants will receive core behavioral weight loss group sessions and 5 family skills training sessions in-person with content covering no communication but no cohesion
62199082|NCT06541769|EXPERIMENTAL|Compression|compression of the dominant hand provided by one-way latex-gloves. The necessary size will be determined after measurement for every Patient individually
62199083|NCT00607724|EXPERIMENTAL|Stage 1: GDC-0449 (150 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 milligram (mg) on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 150 mg, orally, continuing until disease progression (deterioration of evaluable lesions and/or tumor-related symptoms defined using Response Evaluation Criteria in Solid Tumors Version 1.0 (RECIST v1.0), maximum benefit, or intolerability.
62199084|NCT00607724|EXPERIMENTAL|Stage 1: GDC-0449 (270 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 270 mg, orally, continuing until disease progression, maximum benefit, or intolerability.
62400802|NCT06724406|EXPERIMENTAL|Session 5, On-Line, Communication and Cohesion|Participants will receive core behavioral weight loss group sessions and 5 family skills training sessions on-line with content covering communication and cohesion
62400803|NCT06724406|EXPERIMENTAL|Session 5, On-Line, Communication and No Cohesion|Participants will receive core behavioral weight loss group sessions and 5 family skills training sessions on-line with content covering communication but no cohesion
62400804|NCT06724406|EXPERIMENTAL|Session 5, On-Line, Cohesion and No Communication|Participants will receive core behavioral weight loss group sessions and 5 family skills training sessions on-line with content covering cohesion but no communication
62784110|NCT04499287|ACTIVE_COMPARATOR|Fiber|Test meal \[bagel with butter (20 g) and apple juice (240 ml) with added sugar (24 g)\] The meal was a total of 640 kcal (100 g carbohydrate, 21 g fat, 10 g protein. 9 grams of soluble viscous fiber from psyllium husk (36 g, Metamucil powder, Procter\&Gamble, Cincinnati, OH) was mixed with the apple juice. Participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption. One week later participants were given 5 minutes to transition to the treadmill following consumption of the test meal and began walking on a motorized treadmill at their calculated preferred walking speed for 15 minutes (experimental). Afterwards participants remained seated in the laboratory with minimal activity for the remainder of the four hours following test meal consumption. One week later the test meal was consumed, and participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption (placebo).
62400805|NCT06724406|EXPERIMENTAL|Session 5, On-Line, No Communication and No Cohesion|Participants will receive core behavioral weight loss group sessions and 5 family skills training sessions on-line with content covering no communication and no cohesion
62400806|NCT06724406|EXPERIMENTAL|Session 10, In-Person, Communication and Cohesion|Participants will receive core behavioral weight loss group sessions and 10 family skills training sessions in-person with content covering communication and cohesion
62011553|NCT01607034|EXPERIMENTAL|Sequence 3 - water-fast|150 mg Dexpramipexole single dose dispersed in water under fasted condition
62199085|NCT00607724|EXPERIMENTAL|Stage 1: GDC-0449 (540 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 540 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 540 mg, orally, continuing until disease progression, maximum benefit, or intolerability.
62199086|NCT00607724|EXPERIMENTAL|Stage 2: BCC [GDC-0449 (150 mg)]|Participants with basal cell carcinoma (BCC) received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
62199087|NCT00607724|EXPERIMENTAL|Stage 2: BCC [GDC-0449 (270 mg)]|Participants with BCC received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
62199088|NCT00607724|EXPERIMENTAL|Stage 2:Safety Expansion Cohort [GDC-0449 (150 mg)]|Participants received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
62400807|NCT06724406|EXPERIMENTAL|Session 10, In-Person, Communication and No Cohesion|Participants will receive core behavioral weight loss group sessions and 10 family skills training sessions in-person with content covering communication but no cohesion
62400808|NCT06724406|EXPERIMENTAL|Session 10, In-Person, Cohesion and No Communication|Participants will receive core behavioral weight loss group sessions and 10 family skills training sessions in-person with content covering cohesion but no no communication
62400809|NCT06724406|EXPERIMENTAL|Session 10, In-Person, No Communication and No Cohesion|Participants will receive core behavioral weight loss group sessions and 10 family skills training sessions in-person with content covering no communication and no cohesion
62400810|NCT06724406|EXPERIMENTAL|Session 10, On-Line, Communication and Cohesion|Participants will receive core behavioral weight loss group sessions and 10 family skills training sessions on-line with content covering communication and cohesion
62400811|NCT06724406|EXPERIMENTAL|Session 10, On-Line, Communication and No Cohesion|Participants will receive core behavioral weight loss group sessions and 10 family skills training sessions on-line with content covering communication but no cohesion
62011554|NCT01607034|EXPERIMENTAL|Sequence 4 - apple-fast|150 mg Dexpramipexole single dose crushed and mixed in applesauce under fasted condition
62011555|NCT00388518|ACTIVE_COMPARATOR|Actos|
62011556|NCT00388518|EXPERIMENTAL|Aleglitazar 1|
62011557|NCT00388518|EXPERIMENTAL|Aleglitazar 2|
62011558|NCT00388518|EXPERIMENTAL|Aleglitazar 3|
62011559|NCT00388518|EXPERIMENTAL|Aleglitazar 4|
62784111|NCT04499287|EXPERIMENTAL|Walk|Test meal \[bagel with butter (20 g) and apple juice (240 ml) with added sugar (24 g)\] The meal was a total of 640 kcal (100 g carbohydrate, 21 g fat, 10 g protein. Participants were given 5 minutes to transition to the treadmill following consumption of the test meal and began walking on a motorized treadmill at their calculated preferred walking speed for 15 minutes. Afterwards participants remained seated in the laboratory with minimal activity for the remainder of the four hours following test meal consumption One week later the test meal was consumed, and participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption (placebo comparator). One week later the test meal was consumed with fiber (36 g, Metamucil powder, Procter\&Gamble, Cincinnati, OH) added to the apple juice and participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption (active comparator).
62784112|NCT02024724|ACTIVE_COMPARATOR|Dexamethasone|4 mg of Dexamethasone and 4 mL of 0.25% bupivacaine
62011560|NCT00388518|PLACEBO_COMPARATOR|Placebo|
62011561|NCT06440707|ACTIVE_COMPARATOR|Transcranial Direct Current Stimulation in patients ineligible for intravenous thrombolytic|"Patients in the active stimulation group receive cathodal transcranial electrical stimulation via 5 small electrodes for 20 to 60 minutes (min) at 1 or 2 milliamperes (mA) intensities. The duration and intensity of the stimulation will determined by the dose Tier the patient is assigned to. There will be 5 dose tiers, reflecting increasing intensity and duration of stimulation: Tier1- 2 mA, single 20 min cycle; Tier 2 - 1 mA, 2 cycles of 20 min/20 min off; Tier 3- 2mA, 2 cycles of 20 min/20 min off; Tier 4 - 1 mA, 3 cycles of 20min/20 min off; Tier 5 - 2 mA, 3 cycles of 20 min/20 min off.~The decision to which dose Tier the patient should be assigned will be determined by the mathematical Bayesian model."
62011562|NCT06440707|SHAM_COMPARATOR|Sham stimulation in patients ineligible for intravenous thrombolytic|Patients in the sham stimulation arm will have the cap and electrodes in place but will not receive electrical stimulation.
62011563|NCT06440707|ACTIVE_COMPARATOR|Transcranial Direct Current Stimulation in patients receiving intravenous thrombolytic|"Patients in the active stimulation group receive cathodal transcranial electrical stimulation via 5 small electrodes for 20 to 60 minutes (min) at 1 or 2 milliamperes (mA) intensities. The duration and intensity of the stimulation will determined by the dose Tier the patient is assigned to. There will be 5 dose tiers, reflecting increasing intensity and duration of stimulation: Tier1- 2 mA, single 20 min cycle; Tier 2 - 1 mA, 2 cycles of 20 min/20 min off; Tier 3- 2mA, 2 cycles of 20 min/20 min off; Tier 4 - 1 mA, 3 cycles of 20min/20 min off; Tier 5 - 2 mA, 3 cycles of 20 min/20 min off.~The decision to which dose Tier the patient should be assigned will be determined by the mathematical Bayesian model."
62011564|NCT06440707|SHAM_COMPARATOR|Sham stimulation in patients receiving intravenous thrombolytic|Patients in the sham stimulation arm will have the cap and electrodes in place but will not receive electrical stimulation.
62011565|NCT02123407|EXPERIMENTAL|Carbon Nanoparticles|Carbon Nanoparticles could be used in this arm.The drug is injected into the subserosa of stomach.Injections of 1.0 ml of Carbon Nanoparticles (0.2 ml in each cardinal point adjacent to the lesion) will be performed about 10 minutes before surgery.Then,gastrectomy with D2 dissection will be performed.
62011566|NCT02123407|ACTIVE_COMPARATOR|Gastrectomy with D2 dissection|Gastrectomy with D2 dissection will be performed in the control arm,no Carbon Nanoparticles or other coloring materials used
62011567|NCT00704145|EXPERIMENTAL|A|Device, paclitaxel drug-eluting stent
62011568|NCT02541721|EXPERIMENTAL|LabiaStick#01|Each participant will have an at least 2-week baseline period followed by a 4-week treatment period with LabiaStick#01.
62011569|NCT01312467|EXPERIMENTAL|Prevention (metformin hydrochloride)|Patients receive metformin hydrochloride PO QD during week 1 and then BID during weeks 2-12. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.
62400812|NCT06724406|EXPERIMENTAL|Session 10, On-Line, Cohesion and No Communication|Participants will receive core behavioral weight loss group sessions and 10 family skills training sessions on-line with content covering cohesion but no communication
62577180|NCT01543178|PLACEBO_COMPARATOR|Double-blind placebo (retreatment)|Subjects in this arm receive placebo TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks \[treatment free\]) followed by a second retreatment with placebo TID for 2 weeks with a 4-week treatment-free follow-up.
62784113|NCT02024724|ACTIVE_COMPARATOR|Triamcinolone|40 mg of Triamcinolone and 4 mL of 0.25% bupivacaine
62784114|NCT00601549|EXPERIMENTAL|1|Patients with low rectal cancer after CCRT undergoing laparoscopic surgery
62011570|NCT06349044|EXPERIMENTAL|ARM A:Her-2 negative adenocarcinoma of the gastroesophageal junction/gastric adenocarcinoma|patients will receive Probio-M9 ,RT followed by Immunotherapy-Based Systemic Therapy
62011571|NCT06349044|PLACEBO_COMPARATOR|ARM A*:Her-2 negative adenocarcinoma of the gastroesophageal junction/gastric adenocarcinoma|patients will receive placebo ,RT followed by Immunotherapy-Based Systemic Therapy
62011572|NCT06349044|EXPERIMENTAL|ARM B: Liver adenocarcinoma|patients will receive Probio-M9 ,RT followed by Immunotherapy-Based Systemic Therapy
62011573|NCT06349044|PLACEBO_COMPARATOR|ARM B*: Liver adenocarcinoma|patients will receive placebo ,RT followed by Immunotherapy-Based Systemic Therapy
62199089|NCT00607724|EXPERIMENTAL|Stage 2: New Formulation [GDC-0449 (150 mg )]|Participants received a daily oral dose of GDC-0449 Phase II drug product hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
62199090|NCT05065047|EXPERIMENTAL|Belantamab mafodotin|belantamab mafodotin by vein over 30 minutes every 8 weeks
62199091|NCT05446753|EXPERIMENTAL|Animal-based meats (ABMD group)|Participants will be instructed to substitute protein-rich foods consumed habitually with animal-based meats (ABMD group).
62199092|NCT05446753|EXPERIMENTAL|Plant-based meat alternatives (PBMD group)|Participants will be instructed to substitute protein-rich foods consumed habitually with Plant-based meat alternatives (PBMD group).
62199093|NCT06170177||Patients underwent radical cystectomy|
62199094|NCT06050642|NO_INTERVENTION|Control arm (Standard Care)|these patients will continue with their current home support provider's standard care
62199095|NCT06050642|EXPERIMENTAL|Interventional arm (Enhanced Care)|these patients will be prescribed the enhanced care model to replace the standard care provided by their current home support provider. Patients are informed that they can return to standard care at the end of the study period (1 year), or at any time if they wish to leave the study.
62199096|NCT00089960|OTHER|Arm|AMG 125 mg daily continuously
62199097|NCT00489801|OTHER|Exercise intervention|Exercise intervention and lifestyle counseling at centre or exercise intervention at home
62199098|NCT05392647|EXPERIMENTAL|Single arm|Hetrombopag
62199099|NCT00890578||1-abdominal|half abdominal surgeries (20 patients out of 40)
62199100|NCT00890578||2-breast|half breast surgeries (20 out of 40)
62199101|NCT04777110|EXPERIMENTAL|Esketamine injection group (0.25mg/kg)|The main anesthesiologist standing on the right side of the patient gave successive injections of esketamine (0.25 mg/kg), and 1 minute later, injected propofol (1.5 mg/kg) for 30 s
62199102|NCT04777110|SHAM_COMPARATOR|Saline injection group(0.05ml/kg)|The main anesthesiologist standing on the right side of the patient sequentially injects normal saline (0.05ml/kg), and 1 minute later injects propofol (1.5 mg/kg), the injection time is 30 seconds
62400813|NCT06724406|EXPERIMENTAL|Session 10, On-Line, No Communication and No Cohesion|Participants will receive core behavioral weight loss group sessions and 10 family skills training sessions on-line with content covering no communication and no cohesion
62011574|NCT06349044|EXPERIMENTAL|ARM C: Malignant tumors of the biliary system|patients will receive Probio-M9 ,RT followed by Immunotherapy-Based Systemic Therapy
62011575|NCT06349044|PLACEBO_COMPARATOR|ARM C*: Malignant tumors of the biliary system|patients will receive placebo ,RT followed by Immunotherapy-Based Systemic Therapy
62199103|NCT03281161|EXPERIMENTAL|Sun Safe Workplaces Program|A follow up to the previous study that promoted the adoption of occupational sun protection policies by the local government organization comprised of personal visits with senior managers to promote policy adoption, promotional materials for sun safety, and in-person training of outdoor workers by research staff over two years. The follow up program consists of an analysis of sun safe practices by employees and an economic evaluation of the SSW intervention completed 2 years after the initial intervention.
62199104|NCT03281161|ACTIVE_COMPARATOR|Attention Control|A follow up to the previous study that promoted occupational sun protection practices by employees in local government organizations through two mailings containing educational materials and presentations at state professional meetings by project staff. The follow up program consists of an analysis of sun safe practices by employees and an economic evaluation of SSW completed 2 years after the initial program contact.
62199105|NCT04848818|ACTIVE_COMPARATOR|K-wire group|Children with closed or grade I. open, severly displaced distal radial and/or complete forearm metaphyseal fractures between the age 3-13.
62199106|NCT04848818|ACTIVE_COMPARATOR|Activa-IM Nail group|Children with closed or grade I. open, severly displaced distal radial and/or complete forearm metaphyseal fractures between the age 3-13.
62400814|NCT03816969|ACTIVE_COMPARATOR|Self-pressurized air-Q with blocker|Self-pressurized air-Q with blocker has a greater seal pressure compared to Air-Q blocker, easier and faster in insertion and has less morbidity and complications while and after insertion
62400815|NCT03816969|ACTIVE_COMPARATOR|Air-Q ILA blocker|It has a drain tube through which a suction tube is passed
62577181|NCT04476589||COVID-19 Disorders of Consciousness|Patients with COVID-19 and disorders of consciousness
62577182|NCT04081610|EXPERIMENTAL|Lagricel® Ofteno Multidose|Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
62577183|NCT04081610|ACTIVE_COMPARATOR|Lagricel® Ofteno Single dose|Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
62011576|NCT06349044|EXPERIMENTAL|ARM D:Colorectal cancer|patients will receive Probio-M9 ,RT followed by Immunotherapy-Based Systemic Therapy
62011577|NCT06349044|PLACEBO_COMPARATOR|ARM D*:Colorectal cancer|patients will receive placebo ,RT followed by Immunotherapy-Based Systemic Therapy
62011578|NCT02451826|ACTIVE_COMPARATOR|1.5 mg tablet LNG after 12 weeks|CVR delivering 2,500 µg of Ulipristal acetate per day and a single dose of levonorgestrel delivered in a 1.5 mg tablet after 12 weeks of CVR use
62011579|NCT02451826|ACTIVE_COMPARATOR|1.5 mg tablet LNG every 4 weeks|CVR delivering 2,500 µg of Ulipristal acetate per day and one 1.5 mg tablet levonorgestrel every 4 weeks of CVR use (three times).
62199107|NCT00681148|EXPERIMENTAL|A|Botox injection
62199108|NCT00681148|PLACEBO_COMPARATOR|B|Saline injection
62199109|NCT01562639||Nexium|
62199110|NCT03516305|EXPERIMENTAL|Staccato Alprazolam 1 mg|a single inhaled dose
62199111|NCT03636529|ACTIVE_COMPARATOR|Tart cherry juice (TCJ)|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
62400816|NCT06085222|EXPERIMENTAL|Emotional Engagement Distress Tolerance Intervention|The experimental intervention (single 2.5 hour session) is comprised of video-delivered psychoeducation, adaptive skill practice, and emotional exposure. During exposure, a sequence of percussive sounds accompanied by a visual depiction of the participant's skin conductance level during exposure will be presented at the moment the participant's skin conductance returns to the relaxation baseline value. These images/sound will be intermittently sent to the participant's smart phone during the smart phone portion of the intervention.
62199112|NCT03636529|PLACEBO_COMPARATOR|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
62199113|NCT00694109|EXPERIMENTAL|Mipomersen|Mipomersen Sodium once a week for up to 4 years (depending on participant's consent). Participants were followed for additional 24 week post-treatment.
62400817|NCT06085222|PLACEBO_COMPARATOR|Health Education Intervention|The health education control intervention is a single 2.5 hour computerized session. It is comprised of audio-narrated videos on healthy habits and self-care in the domains of sleep, nutrition, hygiene, and physical exercise. The same sequence of percussive sounds used in the Emotional Engagement Distress Tolerance Intervention is presented alongside summary slides presenting key points on healthy habits and self-care. These images/sound will be intermittently sent to the participant's smart phone during the smart phone portion of the intervention.
62577184|NCT05730361|EXPERIMENTAL|ScTIL injection|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention: ScTIL210 injection alone or with B lymphocytes adjuvant.
62577185|NCT04471857|EXPERIMENTAL|Hypnosis|A brief session of hypnosis just before child starts with anorectal manometry
62577186|NCT04471857|NO_INTERVENTION|Control|No hypnosis session, standard care
62577187|NCT04673006||anesthesiologists who will perform endotracheal intubation and extubation for general anesthesia|All anesthesiologists in this study will use face shield for facial protection. Face shield swab will be done before and after the procedures (intubation and extubation)
62577188|NCT02674958|ACTIVE_COMPARATOR|Aspirin|Aspirin 325mg orally bolus followed by 162mg orally daily during alcohol septal ablation for hypertrophic obstructive cardiomyopathy until day 7.
62577189|NCT02674958|NO_INTERVENTION|No aspirin|No aspirin allowed during alcohol septal ablation for hypertrophic obstructive cardiomyopathy until day 7.
62577190|NCT05121701|ACTIVE_COMPARATOR|Videolaryngoscopy|The patients were intubated with the C-MAC PM-Karl Storz Video laryngoscope.
62577191|NCT05121701|ACTIVE_COMPARATOR|Laryngoscopy|The patients were intubated with the Macintosh laryngoscope.
62577192|NCT04448444|EXPERIMENTAL|Motor Program Activating Therapy (MPAT)|The MPAT was chosen for our clinical experience - it was developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centred. Then somatosensory (manual and verbal) stimuli are applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when the patient is lying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to use the acquired motor skills automatically in daily life.
62577193|NCT04448444|EXPERIMENTAL|Vojta Reflex Locomotion (VRL)|VRL was developed by prof. Vojta and is standardly used in the Czech Republic. In this therapy, patients should be set up into the precisely given initial position with defined angular setting of extremities. In each position (supine, prone, lying on the side, and low kneeling position), activation points (zones) are stimulated with precise localization and pressure direction. Such stimulation activates one of the global movement patterns (reflex turning and reflex creeping) corresponding to the initial position. In addition to motor involuntarily reaction, also sensory and autonomic response is activated.
62577194|NCT04448444|NO_INTERVENTION|healthy controls|sex and age matched healthy controls
62784115|NCT00601549|ACTIVE_COMPARATOR|2|Patients with low rectal cancer after CCRT undergoing traditional open surgery
62199114|NCT03251053|EXPERIMENTAL|Electronic cigarette use|Subjects who try to switch to electronic cigarettes (EC) and subjects who successfully switch to EC.
62199115|NCT03251053|OTHER|Control regular cigarette smokers|Habitual smokers without EC use
62199116|NCT02833675||bradykinin angioedema|Hereditary angioedema with or without C1Inhibitor Drug induced angiodema
62199117|NCT02833675||Histaminergic angioedema|Allergic and non allergic angioedema
62199118|NCT02833675||Control group|Patients with abdominal pain
62784116|NCT00894946|EXPERIMENTAL|Recurrent IVF implantation failure|
62577195|NCT02774330||Minneapolis, Minnesota Customers|"Minneapolis, Minnesota has a policy in place whereby minimum quantities and varieties of healthy food are required for all licensed food stores. The policy is our intervention condition."
62577196|NCT02774330||St. Paul, Minnesota Customers|No policy exists in St. Paul, Minnesota. This is the control condition.
62577197|NCT03086967|ACTIVE_COMPARATOR|Six Hour|Placement of foley catheter and extrusion after 6 hours followed by induction.
62577198|NCT03086967|ACTIVE_COMPARATOR|Twelve Hour|Placement of foley catheter and extrusion after 12 hours followed by induction.
62577199|NCT03930563|EXPERIMENTAL|Beetroot Juice Low|Subjects will consume beetroot juice containing 250mg inorganic nitrate and 20mg nitrite dissolved in 120ml bottled water. Peripheral chemoreflex sensitivity as well as common carotid artery blood flow will be assessed before and after supplementation.
62199119|NCT04408352|ACTIVE_COMPARATOR|RF Trigone Ablation Treatment Arm|A compatible standard cystoscopy lens (30°) will be inserted into the Hologic trigone RF Device. The bladder will be emptied of urine and saline infused into the bladder to allow adequate visualization and working space. Ablations at the trigone will be created using the Hologic trigone RF ablation device together with the compatible standard commercially available RF cannula and generator. It is expected that a subject would receive between 4-6 ablations to completely treat the appropriate area of the trigone. At the completion of the procedure, 200 ml of saline is instilled into the bladder to allow for assessment of voiding function prior to discharge.
62577200|NCT03930563|EXPERIMENTAL|Beetroot Juice High|Subjects will consume beetroot juice containing 500mg inorganic nitrate and 40mg nitrite dissolved in 120ml bottled water. Peripheral chemoreflex sensitivity as well as common carotid artery blood flow will be assessed before and after supplementation.
62577201|NCT03930563|ACTIVE_COMPARATOR|Beetroot Juice Placebo|Subjects will consume beetroot juice devoid of inorganic nitrate and nitrite dissolved in 120ml bottled water. Peripheral chemoreflex sensitivity as well as common carotid artery blood flow will be assessed before and after supplementation.
62577202|NCT01552707|EXPERIMENTAL|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stem cells fixed in allogenic bone tissue for spinal fusion"
62577203|NCT01552707|SHAM_COMPARATOR|Standard treatment|Instrumented spinal fusion together with patient's bone iliac crest.
62577204|NCT04897061||Participants undergoing major pelvic organ prolapse surgery|
62577205|NCT04009278|EXPERIMENTAL|1. Self-compression arm|Intervention consist in a explanation by the radiographer to the woman how to use the self-compression device, then position the woman's breasts and reach a compression of 5 daN, that this is a minimum but sub-optimal level of compression, and that at that point the woman will have to complete the compression to reach the optimal compression level up to an acceptable pain.
62577206|NCT04009278|NO_INTERVENTION|2. Control arm|The mammography will be performed as normal clinical practice, with compression controlled by the radiographer.
62577207|NCT05724680|EXPERIMENTAL|Treatment group|"cognitive behavior therapy~* one session per week~* six to eight session"
62577208|NCT05724680|OTHER|Wait list control group|"* waitlist control group~* offer CBT after completing data collection."
62577209|NCT06318637|ACTIVE_COMPARATOR|Control Group|Participants in the control group will follow their typical daily activities with their baby throughout the study, including their typical bathing, skincare, and sleep practices.
62577210|NCT06318637|EXPERIMENTAL|Interventional Group (Wash/Shampoo and Lotion)|Participants in the intervention group will use the provided wash/shampoo, and face and body lotion for their baby. At Baseline, participants caregivers in the intervention group will be provided with instructions for institution of a daily bedtime routine for their infant, which includes a massage with a moisturizing lotion.
62577211|NCT05943236||All patients|All patients
62577212|NCT02857257|EXPERIMENTAL|Treatment arm|Only one treatment arm. Patients are allocated under disease condition and later treated with ACHIM. The post-treatment disease progression is monitored.
62577213|NCT01029782|ACTIVE_COMPARATOR|IV cefazolin plus oral probenecid and placebo cephalexin|
62577214|NCT01029782|ACTIVE_COMPARATOR|Oral cephalexin and saline IV plus probenecid placebo|
62577215|NCT02390596|EXPERIMENTAL|Anakinra|
62577216|NCT02173002|ACTIVE_COMPARATOR|Standard care|Standard care
62577217|NCT02173002|EXPERIMENTAL|myIBDcoach|myIBDcoach
62784117|NCT00894946|EXPERIMENTAL|Endometriosis|
62784118|NCT02389400|EXPERIMENTAL|Experimental arm|methotrexate,1g/m2,iv.d1 cytosine arabinoside,0.1g/m2,iv.,d1-5
62784119|NCT05222126|EXPERIMENTAL|Ultrasound-guided Hydrodissection (HD) with 5 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve using 5 cc of 5% dextrose.
62784120|NCT05222126|ACTIVE_COMPARATOR|Ultrasound-guided Hydrodissection (HD) with 5 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve , using 5 cc normal saline.
62784121|NCT05222126|EXPERIMENTAL|Ultrasound-guided Hydrodissection (HD) with 10 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve , using 10 cc 5% dextrose.
62784122|NCT05222126|ACTIVE_COMPARATOR|Ultrasound-guided Hydrodissection (HD) with 10 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve from , using 10 cc normal saline.
62011580|NCT01961830|EXPERIMENTAL|ME1100|ME1100 inhalation solution 0.6 mL for 90 mg, Single Dose ME1100 inhalation solution 3.0 mL for 450 mg, Single Dose
62011581|NCT03198273|EXPERIMENTAL|Clinical pilates exercises|Participants will exercise 3 times a week for 6 weeks (18 sessions in total, 45-60 minutes each session) in accompany with a physiotherapist. Since the chosen model for exercise training is clinical pilates exercises, separate patient training will be needed. First 3 weeks planned as Warming Phase, Exercise Phase (first 3 weeks), Cooling Phase; and Second 3 weeks planned as Warming Phase, Exercise Phase (first 3 weeks), Cooling Phase.
62011582|NCT03198273|EXPERIMENTAL|Physiotherapy Program|Standard physiotherapy program consisting of conservative treatment is applied to both groups. The conservative treatment schedule to be applied to planned as 10 sessions, 3 times a week.
62011583|NCT00127790|ACTIVE_COMPARATOR|CBT for Insomnia (CBT-I)|Cognitive-Behavioral Therapy for Insomnia (CBT-I)consisting of 10 individual sessions and including sleep education, sleep restriction therapy, stimulus control therapy, sleep hygiene, cognitive therapy, relaxation training and relapse prevention.
62011584|NCT00127790|ACTIVE_COMPARATOR|CBT for Pain (CBT-P)|Cognitive-Behavioral Therapy for Pain (CBT-P)consisting of 10 individual sessions and including pain education, pacing strategies, problem solving, goal setting, cognitive therapy, relaxation training and relapse prevention.
62577218|NCT04504188|EXPERIMENTAL|Heart Rate Monitor Enhanced Treatment Optimization|Subjects will wear an FDA-approved WCD with a 3 month follow-up period. Heart rate (HR) will be continuously monitored by the WCD.
62577219|NCT04532931|PLACEBO_COMPARATOR|Arm A|Paracetamol (SOC)
62577220|NCT04532931|EXPERIMENTAL|Arm B|SOC plus Artesunate-Amodiaquine
62784123|NCT04600934|ACTIVE_COMPARATOR|Standard POBA (plain old balloon angioplasty)|The first 50 patients will be pre-treated with standard POBA
62784124|NCT04600934|EXPERIMENTAL|Shockwave|The second 50 patients will be treated primarily with Shockwave
62215038|NCT06533826|EXPERIMENTAL|Arm C (ADC1 Dato-DXd HR+)|"Enrolled participants will complete:~* Baseline visit with tumor biopsy, imaging, electrocardiogram and eye exam.~* Tumor biopsy between Cycle 2 Day 1 and Day 8.~* Imaging every 9 weeks.~* Cycle 1 through end of treatment:~  --Day 1 of 21 day cycle: Predetermined dose of Datopotamab deruxtecan 1x daily.~* Cycle 4 through end of treatment:~  * Day 1 of 21 day cycle: Predetermined dose of Datopotamab deruxtecan 1x daily.~ * Imaging on Day 1.~* End of Treatment visit with imaging, tumor biopsy, eye exam.~* Follow up: imaging every 9 weeks.~* Long-term Follow Up: visits every 6 months."
62577221|NCT04532931|EXPERIMENTAL|Arm C|SOC plus Pyronaridine-Artesunate
62577222|NCT04532931|EXPERIMENTAL|Arm D|SOC plus Favipiravir plus Nitazoxanide
62577223|NCT04532931|EXPERIMENTAL|Arm E|SOC plus Sofosbuvir/daclatasvir
62577224|NCT03689205||Patients that BMI> 30kg / m2 (Group A)|Venous puncture pain on patients that Body mass index \> 30kg / m2
62784125|NCT02229409|NO_INTERVENTION|Control|Observation only, no behavioral intervention
61978287|NCT04464122||Control group|Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (18-80 years, males and females)
61978288|NCT05988047||Patients with AML|Peripheral blood will be taken at the timepoint of primary diagnosis and analyzed for CMTM6 expression and T cell activation
62784126|NCT02229409|EXPERIMENTAL|Intervention|Intervention Walkadoo.
62784127|NCT00696839|NO_INTERVENTION|1|Usual care (adherence education)
62199120|NCT04408352|SHAM_COMPARATOR|RF Trigone Ablation Sham Arm|"The sham procedure will mimic the Hologic trigone RF ablation device procedure to maintain subject blinding and provide the most accurate assessment of control data while minimizing risk to the subject.~The bladder will be emptied of urine and saline infused into the bladder to allow adequate visualization and working space. Suction will be applied to the bladder wall and the cannulas (needles) will be introduced into the bladder wall. Energy will not be delivered to the tissue when each sham ablation is started. In order to maintain blinding of the subject, the typical sounds that Hologic trigone RF ablation device makes during actual ablation/fulguration will be replicated. The simulated ablation procedure will be repeated as many times as necessary to cover the area of the trigone. 4 to 6 sham ablations would be required. At the completion of the procedure, 200ml of saline is instilled into the bladder to allow for assessment of voiding function prior to discharge."
62199121|NCT02855580||PGX Testing Based Treatment|Treatment will be administered based on the results that are obtained from the pharmacogenomics testing. Results from testing will be provided two weeks after specimen collection.
62199122|NCT02855580||Standard of Care Treatment|Treatment will be based off of the standard of care. Results from pharmacogenomics testing will be provided at the end of the study.
62199123|NCT04709458|EXPERIMENTAL|TBX-2400 treatment|Single intravenous infusion of TBX-2400
62199124|NCT03337438|OTHER|Values-PFI|
62199125|NCT03337438|OTHER|Traditional-PFI with values assessment|
62199126|NCT03337438|OTHER|Traditional PFI no values assessment|
62577225|NCT03689205||Patients that BMI< 30kg / m2 (Group B)|Venous puncture pain on patients that Body mass index \< 30kg / m2
62577226|NCT06410677||esophageal squamous cell carcinoma|
62199127|NCT04256863|EXPERIMENTAL|Breakfast / Lunch (BFL)|This group will complete a 16-week standard behavioral weight control intervention in which they will be asked to consume \>50% of their daily energy goal before 3PM. To do so, they will complete weekly experiential learning sessions in conjunction with the SBT lessons.
62199128|NCT04256863|ACTIVE_COMPARATOR|Dinner (DIN)|This group will complete a 16-week standard behavioral weight control intervention. They will not be given any recommendations regarding the timing of their energy consumption, but instead encouraged to follow the same energy goals at the BFL group.
62199129|NCT00012753|OTHER|Arm 1|
62199130|NCT03487198|EXPERIMENTAL|Brexpiprazole|2-3 mg/day, once daily for 6 weeks, oral administration
62400818|NCT05731830||Takotsubo Syndrome|Patients admitted to the Department of Cardiovascular Sciences of Fondazione Policlinico Universitario A. Gemelli IRCCS with a diagnosis of TTS. TTS will be diagnosed based on the most recent InterTAK Diagnostic Criteria. Myocarditis will be excluded based on clinical presentation (e.g.: previous flu-like symptoms, increased inflammatory biomarkers) and confirmed by cardiac magnetic resonance. We will further include all patients with a confirmed TTS diagnosis made between January 2016 and end of October 2022 (hypothetical beginning of prospective phase).
62400819|NCT06175052|EXPERIMENTAL|Personalized Nutrition|This group will receive the nutrition intervention
62400820|NCT03748628|EXPERIMENTAL|Single arm EDP-305|
62577227|NCT05747001||Cohort 1|Cohort of patients suffering from epilepsy with Focal Onset Seizure (FOS) and enrolled into the Early Access Program (EAP) in Germany, France and UK
61978289|NCT05988047||Healthy controls|Peripheral blood will be taken analyzed for CMTM6 expression and T cell activation
62011585|NCT00127790|EXPERIMENTAL|CBT for Insomnia & Pain (CBT-I/P)|Combined Cognitive-Behavioral Therapy for Insomnia \& Cognitive-Behavioral Therapy for Pain (CBT-I/P)over 10 individual sessions.
62400821|NCT04585828|EXPERIMENTAL|Bili Cocoon|The infants will be treated with phototherapy using a double sided fiber optic pad called Bili Cocoon with an irradiance of 30 uW/cm2/nm from both sides.
62400822|NCT04585828|ACTIVE_COMPARATOR|Conventional blue light|The infants will be treated with blue light from above at 30 Uw/cm2/nm which is the standard treatment.
62400823|NCT03093480|EXPERIMENTAL|Recombinant coagulation factor VIII Fc (rFVIIIFc)|Participants were to receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 48 Weeks in ITI Period. Participants who met the criteria for immune tolerance induction (ITI) success entered the tapering period and received rFVIIIFc at a dose adjusted according to Investigator judgment based on the FVIII activity levels and with the aim of tapering the rFVIIIFc dose to reach a prophylactic dosing regimen within 16 weeks (4 months). Follow-Up was for 32 weeks under an adjusted prophylactic regimen according to Investigator judgment.
62400824|NCT01899573|EXPERIMENTAL|Treatment|
62400825|NCT02319642|EXPERIMENTAL|Certolizumab Pegol (CZP)|"1. Those subjects from either treatment group in RA0044 (NCT02151851) who fail to achieve an ACR20 response in RA0044 (NCT02151851) at Week 12, which is confirmed at Week 14. These subjects are withdrawn from RA0044 (NCT02151851) at Week 16 of that study, and that assessment will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 400 mg sc at Weeks 0, 2, and 4 followed by CZP 200 mg sc Q2W.~2. Subjects from either treatment group in RA0044 (NCT02151851) who completed RA0044 (NCT02151851) through Week 24. The Week 24 assessment in RA0044 (NCT02151851) will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 200 mg sc Q2W."
62400826|NCT03131531||Hodgkin lymphoma|
62400827|NCT03131531||Non-Hodgkin lymphoma|
62400828|NCT03131531||Myeloma|
62577228|NCT00521638|EXPERIMENTAL|1|
62577229|NCT03324347|EXPERIMENTAL|Therapydog|A certified therapydog (together with a certified dog-handler) will be present in the dental clinic while the child will undergo a clinical dental examination by licenced pediatric dentist.
62577230|NCT03324347|NO_INTERVENTION|No therapydog|No therapydog will be present in the dental clinic while the child will undergo a clinical dental examination by licenced pediatric dentist.
62199131|NCT03487198|PLACEBO_COMPARATOR|Placebo|2-3 mg/day, once daily for 6 weeks, oral administration
62199132|NCT03837951||Uninjured hands|healthy participants without injuries to hands or wrists
62199133|NCT03837951||Injured hands|participants undergoing medical treatment for recent hand or wrist injury
62199134|NCT02413281|EXPERIMENTAL|ALKS 5461 Dose 1|Sublingual tablets
62199135|NCT02413281|EXPERIMENTAL|ALKS 5461 Dose 2|Sublingual tablets
62199136|NCT02413281|EXPERIMENTAL|ALKS 5461 Dose 3|Sublingual tablets
62400829|NCT01418066|PLACEBO_COMPARATOR|Placebo|Tea decoction made of Graminis Flores abd Maidis stigmata.
62199137|NCT02413281|ACTIVE_COMPARATOR|Buprenorphine Dose 1|Sublingual tablets
62400830|NCT01418066|EXPERIMENTAL|Ayurvedic herbs|Tea decoction made of Murraya koenigii leaves, Punica granatum and Curcuma
62400831|NCT03914456|EXPERIMENTAL|Body Weight Supported Treadmill Training|"The rehabilitation program consisted of five hours per day of the treatment, five times a week for two months (40 sessions). The treatment protocol included kinesiotherapy (passive and active mobilizations, muscle lengthening), BWSTT, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training. The duration of each event was approximately one hour.~The initial time of the treatment on the BWSTT was 20 minutes, and the modification of the time depended on the endurance and capability of each patient. Training charge began at 40% body weight supported and at treadmill speeds of at least 1.5 km per hour. The treadmill speed was increased progressively to 2.5 km per hour, and the level of weight supported was adjusted within sessions to achieve knee extension."
62400832|NCT00926146|EXPERIMENTAL|NCMIT|Nurse Case Management Plus Contingency Management and Tracking and the HBV vaccine
62400833|NCT00926146|ACTIVE_COMPARATOR|SCMIT|Standard with Contingency Management and Tracking (SCMT) and HBV vaccine
62400834|NCT04971486|EXPERIMENTAL|Performance Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block.
62784128|NCT00696839|EXPERIMENTAL|2|Usual care and Cognitive Behavioral Therapy sessions
62199138|NCT02413281|ACTIVE_COMPARATOR|Buprenorphine Dose 2|Sublingual tablets
62199139|NCT02413281|PLACEBO_COMPARATOR|Placebo|Sublingual tablets
62199140|NCT01202149|ACTIVE_COMPARATOR|Elidel Right Side, Hylatopic Plus Left Side|Elidel applied topically on Right Side of body twice a day and Hylatopic plus emollient foam applied topically on Left Side of body three times a day
62199141|NCT01202149|ACTIVE_COMPARATOR|Elidel Left Side Hylatopic Plus Right Side|Elidel applied topically on Left Side of body twice a day and Hylatopic plus emollient foam applied topically on Right Side of body three times a day
62400835|NCT04971486|EXPERIMENTAL|Performance plus Positive Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block plus positive social comparative feedback.
62400836|NCT05780359|EXPERIMENTAL|Drug eluting stent|Device: Drug-eluting peripheral arterial（G-stream） stent system Manufacturer：Alain Medical (Beijing) Co., Ltd.
62400837|NCT05780359|ACTIVE_COMPARATOR|Drug coating balloon|Device: AcoArt-Orchid® Drug Eluting Balloon Catheter Manufacturer: Acotec Scientific Co., Ltd
62400838|NCT04550143||Septic Shock|
62011586|NCT00127790|NO_INTERVENTION|Wait-List Control (WL)|Waitlist Control condition (WL) with no contact during the intervention period.
62011587|NCT00907894|EXPERIMENTAL|Stratum 1|
62011588|NCT00907894|EXPERIMENTAL|Stratum 2|
62199142|NCT01804868|EXPERIMENTAL|case vignette tutorial|The web tutorial composed of 4 case vignettes.
62784129|NCT05854342|EXPERIMENTAL|bicarbonate-calcium water|participants of this group drink bicarbonate-calcium water
62784130|NCT05854342|NO_INTERVENTION|low mineral water|participants of this group drink low mineral water
62011589|NCT00907894|EXPERIMENTAL|Stratum 3|
62199143|NCT01804868|ACTIVE_COMPARATOR|passive web presentation on research regulation|The presentation will be a web-based voice commented video presentation on research regulation.
62199144|NCT03362983|EXPERIMENTAL|Care HND Intervention|Integrated, multidisciplinary, person centered care at HND-centrum.
62199145|NCT03362983|NO_INTERVENTION|Standard care|Standard care at separate specialty clinics and primary care as needed.
62199146|NCT01099917|EXPERIMENTAL|Maitake|This is a phase II trial examining hematopoietic response in MDS patients.
62199147|NCT04962529||Arm 1: Metastatic Breast Cancer Patients With Contemporaneous Tissue Biopsy|"Investigators plan to enroll patients previously diagnosed with a primary breast cancer of any subtype at least six (6) months before presentation with suspected metastases or be presenting with de novo metastasis The suspected metastases in these patients must be outside the ipsilateral breast, axilla infra/supraclavicular areas. In those with suspected metastases in contralateral axilla, infra/supraclavicular areas only a new contralateral breast primary must be excluded by physical exam, mammogram or MRI~If a tissue biopsy is performed, the matched tissue will be sent to the central pathology lab for reanalysis. If a tissue biopsy was performed, but the tissue block is exhausted or unavailable, patients are still eligible to participate in the study."
62199148|NCT04962529||Arm 2: Metastatic Breast Cancer Patients Without Contemporaneous Tissue Biopsy|"Investigators plan to enroll patients previously diagnosed with a primary breast cancer of any subtype at least six (6) months before presentation with suspected metastases or be presenting with de novo metastasis The suspected metastases in these patients must be outside the ipsilateral breast, axilla infra/supraclavicular areas. In those with suspected metastases in contralateral axilla, infra/supraclavicular areas only a new contralateral breast primary must be excluded by physical exam, mammogram or MRI.~A contemporaneous tissue biopsy is optional for this cohort."
62199149|NCT02509949|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine ivpump 0.2ug/kg/h during living donor renal transplantation.
62199150|NCT02509949|PLACEBO_COMPARATOR|Saline|Saline ivpump 0.2ug/kg/h during living donor renal transplantation.
62400839|NCT04298307||Patients with calcified coronary artery disease|Patients with calcified coronary artery disease require an ICL using the Shockwave catheter.
62784131|NCT04959305|EXPERIMENTAL|Experimental 1|HCP1803-3
62784132|NCT04959305|ACTIVE_COMPARATOR|Active Comparator 1|RLD2003
62784133|NCT04959305|ACTIVE_COMPARATOR|Active Comparator 2|RLD2004
62784134|NCT04959305|ACTIVE_COMPARATOR|Active Comparator 3|RLD2005
62784135|NCT05240001|EXPERIMENTAL|Thulium Fibre Laser (TFL)|Patients randomized to this arm will undergo treatment using the TFL.
62784136|NCT05240001|EXPERIMENTAL|MOSES Holmium Laser|Patients randomized to this arm will undergo treatment using the MOSES Holmium laser.
62784137|NCT06366087|EXPERIMENTAL|Sublingual|1 mg (100 µL of a 1% w/v solution), administered SL by pipette with at least a 30 second dwell time without swallowing.
62784138|NCT06366087|ACTIVE_COMPARATOR|Intramuscular|Multidose vial presentation, 1 mg (2.5 ml) administered by IM injection into the mid-anterolateral thigh.
62784139|NCT00995423|ACTIVE_COMPARATOR|CoroflexTM|highly flexible CoroflexTM Please-Stent features
62784140|NCT00995423|ACTIVE_COMPARATOR|TAXUS|Paclitaxel-eluting stent
62784141|NCT00169208|EXPERIMENTAL|Experimental|4 cycles of rituximab + fludarabine + mitoxantrone
62784142|NCT06160492|EXPERIMENTAL|test group|The test group was set to administer a dose of 20 mg/kg body weight, and 3 hours before anesthesia (range 2-4 hours), 5-ALA HCl was dissolved in drinking water and taken orally, after which they underwent fluorescence-guided resection of malignant gliomas
62784143|NCT06160492|NO_INTERVENTION|control group|The control group was operated by traditional white light microscope tumor resection, and all tumor tissues were removed as far as possible within the safety range. Cranial enhancement MRI was performed within 72h after surgery (60h-72h).
62784144|NCT03560167|EXPERIMENTAL|AccuCinch® Ventricular Restoration System|
62784145|NCT03223259|OTHER|Injury Prevention Workshops|Subjects will attend two Injury Prevention Workshops
62784146|NCT03360799||Observational (questionnaire)|Participants complete 5 questionnaires.
62199151|NCT04262167|EXPERIMENTAL|Low Dose LSCs (cohort 1) n = 4 planned|4-8 weeks following transbronchial biopsy, participants in this arm will receive 100 million Lung Spheroid Stem Cell (LSC) infusion.
62400840|NCT06426680|EXPERIMENTAL|ILB-3101|There are eight escalating dose cohorts. Intravenous (IV) administration of ILB-3101 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
62400841|NCT04637087|EXPERIMENTAL|Atrial Fibrillation Risk Estimation Tool|For eligible patients presenting with an acute ischemic stroke, a clinical atrial fibrillation risk estimation tool will be displayed in the patient's electronic health record through a best practice alert (BPA). The alert will display for the stroke neurologist caring for the patient when they first open the patient's chart. The neurologist may accept the automatically generated atrial fibrillation risk score displayed in the BPA, may modify some of the inputs of the score based on the patient's personal medical history and re-calculate, or may choose to dismiss the BPA.
62784147|NCT03554447|EXPERIMENTAL|Pentoxifylline group|Escitalopram 20 mg tablet once daily for 12 week plus Pentoxifylline 400 mg tablet twice daily for 12 weeks
62199152|NCT04262167|NO_INTERVENTION|Usual Care (Cohort 1) n = 2 planned|Patients will receive standard of care with no biopsy and no infusion. Placebo will not be used.
62199153|NCT04262167|EXPERIMENTAL|High Dose LSCs (Cohort 2) n = 12 planned|4-8 weeks following transbronchial biopsy, participants in this arm will receive 200 million LSC infusion.
62400842|NCT06234566|EXPERIMENTAL|Low Speed Drilling Without Irrigation|
62784148|NCT03554447|PLACEBO_COMPARATOR|Control group|Escitalopram 20 mg tablet once daily for 12 week plus placebo tablet twice daily for 12 weeks
62784149|NCT03719911|EXPERIMENTAL|Live diabetes coaching program|Live diabetes coaching program
62784150|NCT05405140|EXPERIMENTAL|Shock wave therapy with multiphasic neuroplasticity based training protocol|Shock wave therapy with multiphasic neuroplasticity based training protocol based on motor relearning program and task oriented approach
62199154|NCT04262167|NO_INTERVENTION|Usual Care (Cohort 2) n = 6 planned|Patients will receive standard of care with no biopsy and no infusion. Placebo will not be used.
62784151|NCT05405140|ACTIVE_COMPARATOR|Conventional physical therapy|Stretching and strengthing and motor sensory motor training of effected side
62784152|NCT04228601|EXPERIMENTAL|Fluzoparib+mFOLFIRINOX|Fluzoparib+mFOLFIRINOX followed by Fluzoparib maintenance monotherapy
62784153|NCT04228601|PLACEBO_COMPARATOR|Placebo+mFOLFIRINOX|Placebo+mFOLFIRINOX followed by placebo maintenance monotherapy
62011590|NCT06216236|EXPERIMENTAL|Kinect intervention system combined with aerobic exercise training|Kinect intervention system combined with aerobic exercise training
62784154|NCT03927144|EXPERIMENTAL|AMG334 70 mg/140 mg|"Participants were randomized to receive 70 mg or 140 mg of AMG334 as a subcutaneous injection once per month for 52 weeks in the Core Phase.~Participants were permitted to switch to an approved oral prophylactic based on treatment failure status and at the investigator's and participant's discretion.~Participants who completed visits through Week 52 of the Core Phase were eligible to participate in the 52-week Extension Phase of the study."
62784155|NCT03927144|ACTIVE_COMPARATOR|Oral Prophylactic|"Participants were randomized to receive a standard of care (SOC) locally approved oral prophylactic migraine medication once per day for 52 weeks in the Core Phase, as prescribed per local country labels.~Participants were permitted to switch to a different approved oral prophylactic based on treatment failure status and at the investigator's and participant's discretion.~Participants who completed visits through Week 52 of the Core Phase were eligible to participate in the 52-week Extension Phase of the study."
62784156|NCT04894890||secukinumab|Patients administered secukinumab by prescription
62784157|NCT02657447|EXPERIMENTAL|Arm 1: Betalutin with lilotomab dose 1|Betalutin 15 MBq/kg b.w. with lilotomab pre-dosing
62199155|NCT02079025|ACTIVE_COMPARATOR|LR-TRUS|Low-resolution transrectal ultrasound guided prostate biopsy (standard of care)
62199156|NCT02079025|EXPERIMENTAL|UHR-TRUS|Ultra-high resolution transrectal ultrasound guided prostate biopsy
62199157|NCT05838963||Study Participants|This group will consist of at least 200 patients with carpal tunnel syndrome who are undergoing nonsurgical management. Participants will complete the CTQ-SSS and other functional measures at baseline, 3 months, 6 months, and 12 months. The primary outcome will be progression to carpal tunnel release (CTR) surgery. Logistic regression models will be used to assess the predictive value of baseline CTQ-SSS scores for progression to CTR surgery, adjusting for potential confounding factors such as age, sex, and baseline symptom severity. The results of this study can help clinicians identify patients who may benefit from early surgical intervention.
62199158|NCT02207686||von Hippel-Lindau disease|Patients with von Hippel-Lindau disease who have had at least one vHL-related tumor removed
62199159|NCT06294067|PLACEBO_COMPARATOR|DHA0 - 0mg of DHA/d|DHA0 participants are in the placebo group and will take 5 soybean oil based capsules per day and will not receive any DHA. Every group takes 5 capsules per day to maintain blinding.
62400843|NCT06234566|ACTIVE_COMPARATOR|Conventional Drilling with Irrigation|
62400844|NCT02722902|EXPERIMENTAL|LIPID + Carnitor|"intravenous Lipid infusion (IntraLipid) combined with carnitor (L-carnitine) infusion~L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.~Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h."
62011591|NCT06216236|NO_INTERVENTION|aerobic dance training|aerobic exercise at home.
62400845|NCT02722902|PLACEBO_COMPARATOR|LIPID + PLAC|"Intravenous Lipid infusion (IntraLipid) combined with placebo infusion (saline)~Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h."
62199160|NCT06294067|ACTIVE_COMPARATOR|DHA1 - 100mg of DHA/d|DHA1 participants will take 100mg/d of DHA. As the DHA supplements are 200mg of DHA per capsule the participants here will take one 200mg capsule every other day and the rest of the capsules will be placebos.
62400846|NCT02722902|PLACEBO_COMPARATOR|PLAC|"Infusion of saline (no IntraLipid and no carnitor)~Saline will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 ml/h."
62199161|NCT06294067|ACTIVE_COMPARATOR|DHA2 - 200mg of DHA/d|DHA2 participants will take one 200mg capsule of DHA and 4 placebos per day.
62400847|NCT00810654|EXPERIMENTAL|ANPEP|Aspergillus niger prolyl endoprotease (AN-PEP), a microbial-derived prolyl endoprotease which cleaves gluten
62400848|NCT00810654|PLACEBO_COMPARATOR|Placebo|
62400849|NCT06518616|EXPERIMENTAL|10-day meditation intervention|prerecorded meditation units, 10 units, one per day, delivered by smartphone app
62400850|NCT06518616|ACTIVE_COMPARATOR|10-day health education intervention|prerecorded health education units, 10 units, one per day, delivered by smartphone app
62400851|NCT05350761||Clinical Center Cohort|includes Proband, Other carriers in family, Family Controls
62400852|NCT05350761||Field Cohort|includes Proband, Other carriers in family, Family Controls
62400853|NCT06713460|EXPERIMENTAL|Intervention group (multicomponent intervention)|A multi-component group intervention, based on Mayer and Salovey's emotional skills model, will target adolescents with emotional distress. Led by the Community Emotional Well-Being Coordinator and supported by a nurse, physiotherapist, and educational psychologist, the intervention will occur from January to June 2025 in Consorci Sanitari de Terrassa institutes. It will consist of nine 55-minute sessions during school hours, supplemented by voluntary home activities. The program will focus on emotional identification and regulation, structured around seven components: goal-setting, positive thinking, self-awareness, self-esteem, willpower, mindfulness, and assertiveness.
62400854|NCT06713460|NO_INTERVENTION|Control group (non intervention)|Participants in the control group will complete the same research questionnaires as the intervention group during the same period (January 2025 - June 2025). Control group participants will undergo the intervention (if effective) in the following academic year (January - June 2026), when they are in 10th Grade.
62400855|NCT04004975|EXPERIMENTAL|anlotinib|12 mg daily from day 1 to 14 of a 21-day cycle
62400856|NCT02115802|EXPERIMENTAL|Activa PC+S|Specific features of LFP recorded from the deep brain nuclei will be examined for possible correlation with different natural behaviors, such as movement, walking, or speech.
62199162|NCT06294067|ACTIVE_COMPARATOR|DHA3 - 400mg of DHA/d|DHA3 participants will take two 200mg capsules of DHA and 3 placebos per day.
62577231|NCT03755557|PLACEBO_COMPARATOR|Placebo|Application of a placebo nasal spray once daily for 8 days Nasal Sprays
62577232|NCT03755557|ACTIVE_COMPARATOR|Rhinocort|"Nasal Sprays Application of Rhinocort Aqua 64 micrograms, nasal spray once daily for 8 days. Daily dosage 256 µg/d"
62011592|NCT01788540|EXPERIMENTAL|Intralipid|"IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.~the intralipid infusion is then repeated within the one week of positive pregnancy test and every 2 weeks till end of first trimester"
62011593|NCT01788540|NO_INTERVENTION|Control|No intervention
62011594|NCT05480605||Experimental Group|Children with autism ages 6-13
62011595|NCT05480605||Control Group|Typically developing children ages 6-13
62011596|NCT01550939|NO_INTERVENTION|Time Comparison between the Lenstar and IOLMaster|
62784158|NCT02657447|EXPERIMENTAL|Arm 2: Betalutin with lilotomab dose 2|Betalutin 15MBq/kg b.w. with lilotomab pre-dosing
62011597|NCT05713422||Operative procedure; standard treatment|Vaginal level I and/or level II repair will be performed as usual (eg anterior and/or posterior colporrhaphy, sacrospinous fixation etc.) without perineoplasty as decided by surgeon and patient. This procedure is considered as the control group.
62011598|NCT05713422||Operative procedure; standard treatment including level III repair|Vaginal level I and/or level II repair will be performed as usual, but now including perineoplasty (level III repair) as decided by surgeon and patient. The decision of a perineoplasty to vaginal level I and/or level II repair is based on a shared decision made by surgeon together with the patient. The considerations upon which this decision has been established in a consensus meeting of Dutch urogynecologists and will be collected by a questionnaire, This group is considered as the 'intervention' group.
62011599|NCT04368598|EXPERIMENTAL|High-dose Dexamethasone plus Acetylcysteine|For all patients in this arm, DXM was administered intravenously at 40 mg daily for 4 consecutive days and then stopped. If platelet count remained below 30×10\^9/L or there were bleeding symptoms by day 10 to 14, an additional 4-day course of DXM (40 mg daily) was given. Besides, all patients received Acetylcysteine orally at 0.4g three times a day for 4 consecutive weeks in the first month.
62011600|NCT01723891|ACTIVE_COMPARATOR|Surfolase capsule & HT-002-01|
62011601|NCT01723891|ACTIVE_COMPARATOR|HT-002-01 & Surfolase capsule|
62011602|NCT02369497||Primary cohort|Primary cohort of subjects who receive the HRA device.
62011603|NCT01697384|EXPERIMENTAL|one histrelin acetate 50 mg implant|The test product was a histrelin acetate 50 mg hydrogel implant surgically placed subdermally into the inner aspect of the upper arm.
62011604|NCT01963624||Breast masses detected with screening US|Those assessed with conventional B-mode US alone and those assessed with combined elastography and color doppler ultrasonography along with B-mode US.
62011605|NCT03623958|EXPERIMENTAL|iVATS resection|Image guided Video-assisted thoracoscopic surgery (VATS) in either one of two hybrid operating rooms and Fine Needle Aspiration (FNA) under fluoroscopy.
62011606|NCT03623958|ACTIVE_COMPARATOR|Standard VATS resection|Standard video-assisted thoracoscopic surgery (VATS) in operating room and Fine Needle Aspiration (FNA) in pathology frozen section room.
62011607|NCT00999349|EXPERIMENTAL|Silymarin (LEGALON)|
62199163|NCT06294067|ACTIVE_COMPARATOR|DHA4 - 800mg of DHA/d|DHA4 participants will take four 200mg capsules of DHA and 1 placebo per day.
62784159|NCT02829580|EXPERIMENTAL|Sickle group|Children with major sickle cell syndrome will have an usual Echocardiography
62011608|NCT00999349|PLACEBO_COMPARATOR|Placebo|
62011609|NCT06360588|EXPERIMENTAL|Subprotocol Z1G (PTEN loss)|Patients receive copanlisib IV over 1 hour on day 18 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy on study and radiologic evaluation and blood sample collection throughout the study.
62011610|NCT00764348||no treatment|
62199164|NCT06294067|ACTIVE_COMPARATOR|DHA5 - 1000mg of DHA/d|DHA5 participants will take five 200mg capsules of DHA and no placebos per day.
62199165|NCT04964349|EXPERIMENTAL|Intralesional cortisosteroid injection|Intralesional corticosteroid injection
62199166|NCT04964349|EXPERIMENTAL|jessener solution|topical jessener solution
62199167|NCT06382402||CCTA Group|CT group will undergo CCTA to evaluate for coronary artery disease to early address underlying CAD and then care will be directed based on the findings of that CT scan.
62199168|NCT06382402||No CCTA Group|Group 2 will not undergo CCTA and will be managed at the discretion of the primary team using the standard of care pathway comprising of either conservative medical management, stress testing, or invasive evaluation with coronary angiography in the catheterization laboratory.
62400857|NCT03955874||INITIAL SBT|Patients who underwent an Spontaneous Breathing Trial prior to extubation. This cohort will be further subdivided into initial patients who initially pass an SBT successes and those who initially fail an SBT.
62400858|NCT03955874||DIRECT EXTUBATION|Patients that were directly extubated without conduct of a prior SBT or tracheostomy
62400859|NCT03955874||DIRECT TRACHEOSTOMY|Patients who underwent a direct tracheostomy without conduct of a prior SBT or extubation
62577233|NCT03755557|EXPERIMENTAL|Budesolv|Application of a Budesolv 10 micrograms, nasal spray once daily for 8 days. Daily dosage 40 µg/d Nasal Sprays
62784160|NCT02829580|ACTIVE_COMPARATOR|Control group|Children recruited in a previous study and who had an usual Echocardiography
62784161|NCT02908750|EXPERIMENTAL|osimertinib and fexofenadine|Sequential treatments of fexofenadine alone followed by osimertinib + fexofenadine, followed by osimertinib alone, followed by osimertinib + fexofenadine
62199169|NCT02159040|ACTIVE_COMPARATOR|Azacitidine|75mg/m2 7days/28 day cycle
62199170|NCT02159040|EXPERIMENTAL|Azacitidine and Deferasirox|azacitidine 75mg/m2 7 days/28 day cycle deferasirox 10 mg/kg/day
62199171|NCT02218723|ACTIVE_COMPARATOR|Sequence ABECD|Subject will be administered treatment in sequence ABECD. Where, A: a single dose of FF \[100 microgram (mcg) per blister from 0.6% blend\] delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
62199172|NCT02218723|ACTIVE_COMPARATOR|Sequence BCADE|Subject will be administered treatment in sequence BCADE. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
62199173|NCT02218723|ACTIVE_COMPARATOR|Sequence CDBEA|Subject will be administered treatment in sequence CDBEA. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
62215039|NCT06533826|EXPERIMENTAL|Arm D (ADC1 Dato-DXd HR-)|"Enrolled participants will complete:~* Baseline visit with tumor biopsy, imaging, electrocardiogram and eye exam.~* Tumor biopsy between Cycle 2 Day 1 and Day 8.~* Imaging every 9 weeks.~* Cycle 1 through Cycle 3:~  --Day 1 of 21 day cycle: Predetermined dose of Datopotamab deruxtecan 1x daily.~* Cycle 4 through end of treatment:~  * Day 1 of 21 day cycle: Predetermined dose of Datopotamab deruxtecan 1x daily.~ * Imaging on Day 1.~* End of Treatment visit with imaging, tumor biopsy, eye exam.~* Follow up: imaging every 9 weeks.~* Long-term Follow Up: visits every 6 months."
62400860|NCT03955874||No attempt at mechanical ventilation discontinuation|Patients who died without conduct of a prior SBT, extubation or tracheostomy
62400861|NCT01999959|EXPERIMENTAL|Pertubation performed|Study group had pertubation and insemination
62400862|NCT01999959|NO_INTERVENTION|Pertubation not performed|Study group had insemination only
62400863|NCT03339999|PLACEBO_COMPARATOR|Placebo|Placebo-matching AGN-242428 capsules, oral administration, once-daily for up to 12 weeks.
62400864|NCT03339999|EXPERIMENTAL|AGN-242428 Higher Dose|AGN-242428 capsules, oral administration, once-daily for up to 12 weeks.
62784162|NCT02820025|EXPERIMENTAL|doxapram group|the doxapram group iv doxapram 1mg/kg,
62400865|NCT03339999|EXPERIMENTAL|AGN-242428 Medium Dose|AGN-242428 capsules, oral administration, once-daily for up to 12 weeks.
62400866|NCT03339999|EXPERIMENTAL|AGN-242428 Lower Dose|AGN-242428 capsule and placebo-matching AGN-242428 capsule, oral administration, once-daily for up to 12 weeks.
62577234|NCT05131685|EXPERIMENTAL|Non-sedated Immobilization|Immobilization in a cast without reduction
62784163|NCT02820025|PLACEBO_COMPARATOR|Controlled group|the controlled group given equal volume of saline with the doxapram group.
62784164|NCT01480310|EXPERIMENTAL|A|
62784165|NCT01480310|EXPERIMENTAL|B|
62577235|NCT05131685|ACTIVE_COMPARATOR|Formal Reduction|closed reduction under conscious sedation followed by casting
62784166|NCT03043391|EXPERIMENTAL|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO is an altered form of the live polio vaccine. It was produced by removing a piece of the virus and replacing it with a piece from a common cold virus. This was done to make sure PVSRIPO cannot cause polio even when injected into the brain.
62784167|NCT06130592|ACTIVE_COMPARATOR|high risk of Arthrogryposis AMC|Patient with a diagnosis during the 1st, 2nd, or 3rd trimester ultrasound, of an abnormality of position / deformation of one or more joints, and / or an abnormality of fetal movements at screening ultrasound or interrogation
62784168|NCT06130592|ACTIVE_COMPARATOR|low risk of Arthrogryposis AMC|Patient coming for screening ultrasound
62784169|NCT00177255|EXPERIMENTAL|Docetaxel + Capecitabine|"Docetaxel 30mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days. Premedication with dexamethasone will be given to all patients receiving weekly docetaxel therapy to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions. Cycle 2 will begin on day 22.~Capecitabine Capecitabine 825mg/m2 bid (total daily dose 1650mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days. Cycle 2 will begin on day 22."
62784170|NCT03305315||Cases|Diseases of the temporomandibular joint
62784171|NCT03305315||Controls|Asymptomatic subjects
62577236|NCT06575920|EXPERIMENTAL|Intervention|
62577237|NCT00754234|EXPERIMENTAL|MyPyramid Menu Days 1-7|Iron absorption measured from one of the 7 different USDA MyPyramid menus for 1 day each, in randomized order for each subject, separated by 2 weeks
62199174|NCT02218723|ACTIVE_COMPARATOR|Sequence DECAB|Subject will be administered treatment in sequence DECAB. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
62199175|NCT02218723|ACTIVE_COMPARATOR|Sequence EADBC|Subject will be administered treatment in sequence EADBC. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
62199176|NCT02218723|ACTIVE_COMPARATOR|Sequence DCEBA|Subject will be administered treatment in sequence DCEBA. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
62199177|NCT02218723|ACTIVE_COMPARATOR|Sequence EDACB|Subject will be administered treatment in sequence EDACB. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
62400867|NCT03899038|EXPERIMENTAL|Deceasing|Spinal anesthesia with decreasing dose. Real-time ultrasound-guided spinal anesthesia Using Taylor's approach.
62400868|NCT03899038|ACTIVE_COMPARATOR|Similar|Spinal anesthesia with similar dose. Real-time ultrasound-guided spinal anesthesia Using Taylor's approach.
62400869|NCT05921851||cardiac arrest|Cardiac arrest group: Patients who experience cardiac arrest during emergency diagnosis and treatment will use the time of cardiac arrest as the event time.
62400870|NCT05921851||control|The patient did not experience sudden cardiac arrest during the emergency diagnosis and treatment period, and was treated at the 24-hour time window in the emergency roomCollect data and use the end of the window as the event time.
62400871|NCT00921141||study population|Patient with cancer requiring a long-term central venous catheter
62577238|NCT06171308|ACTIVE_COMPARATOR|The study group(using the moxibustion)|"The study group was treated with traditional Chinese moxibustion and western medicine. The control group was treated with blank moxibustion and western medicine.~1. The study group: Using the moxibustion, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~2. The control group: Using the moxibustion with blank patch, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~3. The treatment period is 4 weeks, which is a course of treatment, and the observation period is 8 weeks."
62577239|NCT06171308|PLACEBO_COMPARATOR|The control group(using the moxibustion with blank patch)|"The study group was treated with traditional Chinese moxibustion and western medicine. The control group was treated with blank moxibustion and western medicine.~1. The study group: Using the moxibustion, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~2. The control group: Using the moxibustion with blank patch, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~3. The treatment period is 4 weeks, which is a course of treatment, and the observation period is 8 weeks."
62577240|NCT04150744|EXPERIMENTAL|RFA plus carrizumab|
62400872|NCT05632094|NO_INTERVENTION|Conventional Group|"This group will comprise 20 patients who will receive conventional supportive care for the treatment of acute clozapine toxicity that include the following:~* Airway: maintaining clear patent airways.~* Breathing: oxygen inhalation, respiratory support whenever required (mechanical ventilation).~* Circulation: intravenous fluids, and symptomatic treatment according to ECG abnormalities.~* Decontamination: administration of activated charcoal (1 gm/kg)."
62400873|NCT05632094|EXPERIMENTAL|L-Carnitine Group|This group will comprise 20 patients who will receive conventional supportive care (same as group 1), in addition to IV L-carnitine
62400874|NCT04353323||Covid area|
62400875|NCT04353323||Non-Covid area|
62400876|NCT05036876|EXPERIMENTAL|Degludec|"Study participants with type 2 diabetes undergoing elective coronary artery bypass graft (CABG) surgery will receive 100% of the total daily dose (TDD) given as a basal bolus regimen with degludec once daily plus rapid-acting insulin glulisine before meals.~Degludec insulin 100 Units/mL, average dose: 30-40 U/day; Insulin glulisine 100 Units/mL, average dose: 20-40 U/day"
62011611|NCT03174340|EXPERIMENTAL|Exercise + diet|"Exercise intervention:~During the first session a standardized exercise prescription will be discussed with the participant. The exercise program will be of a moderate intensity, at less than 140 heart beats/min (which corresponds to 60% of the calculated maximum heart rate (HRmax) or 50% maximum oxygen volume (VO2max) ). A session of 30 to 60 minutes/week will be organised.~* Participants will be instructed to conduct a nonsedentary lifestyle. They will be encouraged to increase their number of steps on a daily basis and perform not more that 45 minutes of continuous exercise per day. Pedometers will be used to measure the compliance and as a positive feedback for motivation.~* The participants will return to the exercise laboratory once per week for Actiheart data downloading, number of steps recording, exercise support and counselling, and to perform the supervised group exercise intervention.~This is in addition to the diet (see below, control group)"
62011612|NCT03174340|NO_INTERVENTION|Diet only|Participants will receive diet counselling according to their characteristics. The usual recommendation is to have a fractioned normocaloric diet (unless the dietician identify a grossly hypercaloric diet), with low fat and increase in fibers content.
62011613|NCT03475160|ACTIVE_COMPARATOR|Sildenafil Citrate|Sildenafil Citrate vaginal suppositories: 25 mg every 6 hours. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
62400877|NCT05036876|ACTIVE_COMPARATOR|Glargine U300|"Study participants with type 2 diabetes undergoing CABG surgery will receive 100% of the total daily dose (TDD) given as a basal bolus regimen with glargine U300 once daily plus rapid-acting insulin glulisine before meals.~Glargine U300;300 Units/mL, average dose: 30-40 U/day; Insulin glulisine 100 Units/mL, average dose: 20-40 U/day"
62400878|NCT05180123|OTHER|Patients after ACL reconstruction in adolescence|
62400879|NCT05982652||non-OH group|without orthostaric hypotension in spinal cord injuries
62400880|NCT05982652||symptomatic OH group|Symptomatic individuals in a patient population diagnosed with orthostatic hypotension (Symptom : dizziness, visual disturbance, nausea and headache)
62400881|NCT05982652||asymptomatic OH group|Asymptomatic individuals in a patient population diagnosed with orthostatic hypotension
62400882|NCT03541616||Enrolled Patients|
62400883|NCT04231903||EAC|Patients undergoing surgery endo-aortic clamp.
62400884|NCT04231903||TTC|Patients undergoing surgery through trans-thoracic aortic clamp.
62400885|NCT06519396||Control|Patients in the control group had FPG\< 100 mg/dl or 75g oral glucose tolerance test: second hour plasma glucose \<140mg/dl and HbA1c values \<5.7%.
62400886|NCT06519396||Prediabetes|The diagnosis of prediabetes was also confirmed through the patients' medical records. Patients with FPG 100-125 mg/dl or 75g oral glucose tolerance test: second hour plasma glucose 140-199 mg/dl and HbA1c values 5.7-6.4% was included in the prediabetes group.
62400887|NCT06519396||Diabetes|The diagnosis of Type 2 Diabetes was confirmed through the patients' medical records. Patients with FPG≥ 126mg/dl or 75g oral glucose tolerance test: second hour plasma glucose ≥200mg/dl and HbA1c ≥6.5% were included in the diabetes group.
62400888|NCT01864746|EXPERIMENTAL|Palbociclib|Palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
62784172|NCT06446791|OTHER|Single arm interventionnal study|A lateral approach surgical technique for the treatment of the webbed neck.
62011614|NCT03475160|PLACEBO_COMPARATOR|Placebo|Placebo vaginal suppositories: every 6 hours. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
62011615|NCT06664632|EXPERIMENTAL|Exp Group|
62400889|NCT01864746|PLACEBO_COMPARATOR|Placebo|Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a28-day cycle for thirteen cycles
62400890|NCT01682876|PLACEBO_COMPARATOR|2 through 5 years (1 Vac) MenACWY-CRM 1|Subjects 2 through 5 years received one vaccination of MenACWY-CRM
62400891|NCT01682876|ACTIVE_COMPARATOR|2 through 5 years (2 Vac) MenACWY-CRM 2|Subjects 2 through 5 years received two vaccinations of MenACWY-CRM
62400892|NCT01682876|PLACEBO_COMPARATOR|6 through 10 years (1 Vac) MenACWY-CRM 3|Subjects 6 through 10 years received one vaccination of MenACWY-CRM
62400893|NCT01682876|ACTIVE_COMPARATOR|6 through 10 years (2 Vac) MenACWY-CRM 4|Subjects 6 through 10 years received two vaccinations of MenACWY-CRM
62400894|NCT02710825|EXPERIMENTAL|Osteopathic treatment|
62400895|NCT02710825|PLACEBO_COMPARATOR|Simulated osteopathic treatment|
62400896|NCT03142464|NO_INTERVENTION|IV fluids|Regular IV fluids (Glucose 5% and Sodium Chloride 10% or Ringer) at the surgeon description
62199178|NCT02218723|ACTIVE_COMPARATOR|Sequence AEBDC|Subject will be administered treatment in sequence AEBDC. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
62400897|NCT03142464|EXPERIMENTAL|No IV fluids|No IV fluids after the termination of the operation. T
62400898|NCT04911361|ACTIVE_COMPARATOR|Topical loteprednol suspension in both eyes|25 subjects will be randomized to receive treatment loteprednol etabonate 0.5% suspension QID for 2 weeks.
62400899|NCT04911361|EXPERIMENTAL|Lower eyelid canaliculi DEXTENZA insertion (study group)|25 subjects will be randomized to receive treatment of OTX-DED
62400900|NCT03964142|EXPERIMENTAL|Cardiac Rehabilitation|Patients enrolled in the integrated exercise-based cardiac rehabilitation program (centre-based or telematic)
62784173|NCT02082704|EXPERIMENTAL|SE Game on DSME|The intervention cohort will participate in an online team-based game on diabetes self-management education (DSME) and will receive a paper documents on American history,
62784174|NCT02082704|ACTIVE_COMPARATOR|SE Game on American History|The 'attention control' cohort will participate in an online team-based game on American history and will receive a paper documents on DSME.
62011616|NCT06664632|ACTIVE_COMPARATOR|Control Group|
62011617|NCT05660616|EXPERIMENTAL|Gemcitabine + supportive care|Administration of maintenance gemcitabine (1000 mg/m²) on days 1 and day 8, in cycles of 21 days plus supportive care.
62011618|NCT05660616|OTHER|supportive care|best supportive care alone.
62011619|NCT05728892|ACTIVE_COMPARATOR|Group A|patients undergoing abdominal surgery receiving melatonin
62011620|NCT05728892|PLACEBO_COMPARATOR|Group B|control group
62011621|NCT05676697|EXPERIMENTAL|PI3K Delta Inhibitor|
62011622|NCT05632952||A|120 patients affected by Incisional Hernia with size between 3 to 10 cm, undergoing Intraperitoneal Onlay Mesh with the closure of defect
62011623|NCT06297824|OTHER|ERGT-A|12 session emotion regulation treatment in group format. Psychoeducation and homework assignments. Subjects taught are the function of deliberate self-harm (DSH), functionality of emotions, negative consequences of emotional avoidance, non-avoidant emotion regulation.
62011624|NCT01532687|EXPERIMENTAL|Arm I (gemcitabine hydrochloride and pazopanib hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and pazopanib hydrochloride PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62011625|NCT01532687|ACTIVE_COMPARATOR|Arm II (gemcitabine hydrochloride, placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and placebo PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may receive single-agent pazopanib hydrochloride PO daily. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62011626|NCT02960984|EXPERIMENTAL|Neurorehabilitation|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training on an ergometer and 30' of task-oriented training focused on uppper limb rehabilitation.
62011627|NCT02960984|NO_INTERVENTION|Baseline|No intervention is planned
62011628|NCT00851175|NO_INTERVENTION|1|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia
62011629|NCT00851175|ACTIVE_COMPARATOR|2|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia with concommitant administration of caffeine (90 ug/min/100ml forearm volume) into the brachial artery of the experimental (=non dominant) arm
62011630|NCT00851175|EXPERIMENTAL|3|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia after 7 days oral treatment with rosuvastatin 1dd 20mg
62011631|NCT00851175|ACTIVE_COMPARATOR|4|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia after 7 days oral treatment with rosuvastatin 1dd 20mg with concommitant administration of caffeine (90 ug/min/100ml forearm volume) into the brachial artery of the experimental (=non dominant) arm
62400901|NCT03964142|NO_INTERVENTION|Conventional management|Patients with conventional management and physical activity recommendation
62577241|NCT04150744|PLACEBO_COMPARATOR|carrizumab|
62577242|NCT02236871|NO_INTERVENTION|Control|Maintain current milk and milk product intakes.
62577243|NCT02236871|ACTIVE_COMPARATOR|2 servings|Participants will be asked to consume 1 milk (250 ml) plus a yogurt (100-175 g) or cheese (up to 50 g) to reach an average of 2 servings of milk or milk products/d.
62784175|NCT04554771|EXPERIMENTAL|ADAM12 high with tocilizumab and standard of care|Patients have serum ADAM12 higher than 203ng/mL. Patients will receive tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 in addition to paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
62011632|NCT01237145||non-EAA, pigeon|subject with BAL because of diseases not suspected to be EAA
62784176|NCT04554771|ACTIVE_COMPARATOR|ADAM12 high with standard of care|Patients have serum ADAM12 higher than 203ng/mL. Patients will receive paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
62199179|NCT02218723|ACTIVE_COMPARATOR|Sequence BACED|Subject will be administered treatment in sequence BACED. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
62400902|NCT04754009|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Participants assigned to treatment as usual group are required to see a mental health professional for the 12 week treatment period. How often they seek counseling is up to the participant.
62400903|NCT04754009|EXPERIMENTAL|Trauma-Sensitive Yoga + TAU|Participants assigned to the Trauma-Sensitive Yoga group will attend a 1-hour long session of yoga once a week for 12 weeks. Participants will be required to concurrently see a mental health professional for the 12 week treatment period. How often they seek counseling is up to the participant.
62199180|NCT02218723|ACTIVE_COMPARATOR|Sequence CBDAE|Subject will be administered treatment in sequence CBDAE. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
62199181|NCT01815853|EXPERIMENTAL|Neoadjuvant Chemoradiotherapy|Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 D1; 21-days/cycle) following with D2 Gastrectomy and 3 cycles of Adjuvant XELOX Chemotherapy
62199182|NCT01815853|ACTIVE_COMPARATOR|Neoadjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 D1; 21-days/cycle) following with D2 Gastrectomy and 3 cycles of Adjuvant XELOX Chemotherapy
62199183|NCT06045052|EXPERIMENTAL|Eltrombopag|Eltrombopag will be administered orally once daily for 24 weeks (6 months) and the dose will be adjusted according to race, age and weight. Patients who achieve at least partial remission may continue treatment for up to one year.
62400904|NCT04754009|EXPERIMENTAL|Chen Style Tai Chi + TAU|Participants assigned to the Chen Style Tai Chi group will attend a 1-hour long session of tai chi once a week for 12 weeks. Participants will be required to concurrently see a mental health professional for the 12 week treatment period. How often they seek counseling is up to the participant.
62400905|NCT05839912|EXPERIMENTAL|Cohort 1: Excision of cLN before systemic therapy|Excision of the clinically detected metastatic lymph node before systemic therapy.
62400906|NCT05839912|EXPERIMENTAL|Cohort 2: Excision of cLN after neoadjuvant systemic therapy|Excision of the clinically detected metastatic lymph node after systemic neoadjuvant therapy.
62400907|NCT06724861|OTHER|AB - early experimental treatment, later control usual care|AB - early experimental treatment, later control usual care
62400908|NCT06724861|OTHER|BA - early control usual care, later experimental treatment|BA - early control usual care, later experimental treatment
62400909|NCT04301024||nitrous oxide misusers|nitrous oxide misusers among the teenagers consulting in an addictology center dedicated to young drug users in Montpellier
62400910|NCT03960788|EXPERIMENTAL|MRI with Gadoxetate Sodium|Subjects will receive Gadoxetate Sodium during MRI.
62400911|NCT02305199|ACTIVE_COMPARATOR|Hartmanns' solution|"All the participants went on a fast at midnight and 1 L of 5% dextrose fluid containing 10 units of regular insulin (RI) and 40 mEq of potassium was administered intravenously.~On participant's arrival to the operation room, fluid from the ward was immediately removed and replaced it with 1 L of unknown fluid completely sealed in black bag. Neither the participant nor the researcher were aware of the type of the fluid.~After the fluid change, general anesthesia was induced. Intraoperative blood glucose was checked every one hours and 20% dextrose was injected if the number was below 100 and RI was injected if the number was checked over 200."
62400912|NCT02305199|ACTIVE_COMPARATOR|Normal saline|"All the participants went on a fast at midnight and 1 L of 5% dextrose fluid containing 10 units of RI and 40 mEq of potassium was administered intravenously.~On participant's arrival to the operation room, fluid from the ward was immediately removed and replaced it with 1 L of unknown fluid completely sealed in black bag. Neither the participant nor the researcher were aware of the type of the fluid.~After the fluid change, general anesthesia was induced. Intraoperative blood glucose was checked every one hours and 20% dextrose was injected if the number was below 100 and RI was injected if the number was checked over 200"
62400913|NCT02475109|EXPERIMENTAL|PAN-90806 Ophthalmic Solution|PAN-90806 Ophthalmic Solution taken daily for 8 weeks.
62400914|NCT01579682|EXPERIMENTAL|Psychotherapy|Family-Based Therapy (12 sessions)
62400915|NCT01579682|EXPERIMENTAL|Family-Based Therapy with Intensive Family-Focused Treatment|The patient will receive 4 sessions of Family-Based therapy, and if the participant does not make adequate weight gain within this time period, will be assigned to Intensive Family-Focused Therapy (IFT).
62011633|NCT01237145||EAA, pigeon|Bird fanciers with a typical clinical presentation suspected for pigeon induced EAA
62011634|NCT00824317|PLACEBO_COMPARATOR|1|Placebo
62011635|NCT00824317|EXPERIMENTAL|2|methylphenidate
62199184|NCT06106867|EXPERIMENTAL|Experimental Group|Information about applying external pressure to the palm was provided to the pregnant women in the experimental group. The researcher practically explained how, when and for how long to apply external pressure to the palm. The researcher introduced the comb to be used in the application of external pressure to the palm, and the application stage of the study was started.
62199185|NCT06106867|NO_INTERVENTION|Control Group|Routine midwifery care and services applied to all pregnant women in the hospital were provided to the participants in the control group.
62199186|NCT03237442|EXPERIMENTAL|group 1|
62199187|NCT03237442|ACTIVE_COMPARATOR|group 2|
62199188|NCT04436770|ACTIVE_COMPARATOR|Control Group|Standard physiotherapy and OT
62199189|NCT04436770|EXPERIMENTAL|Experimental|Virtual Reality Therapy and OT
62199190|NCT01138618||CHEMPAQ-venous-CHEMPAQ-venous|The two arms only differ in order of kind of blood samples.
62199191|NCT01138618||Venous-CHEMPAQ-Venous-CHEMPAQ|The two arms only differ in order of kind of blood samples.
62199192|NCT01135654|EXPERIMENTAL|Non-Physician Provider|
62199193|NCT01135654|NO_INTERVENTION|Control|
62199194|NCT01135654|ACTIVE_COMPARATOR|Primary Care Provider|In clinics randomized to this arm, we will train (and provide technical assistance to) Primary Care providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment.
62199195|NCT04113070||Overweight and obesity group|"1. Children with BMI cutoff points greater than 25.0 or 30.0 at 18 years old were defined overweight or obesity according to age- and sex-specific cutoff points standard proposed by International Obesity Task Force (IOTF) for 2- to 18-year-old children.~2. Willingness to comply with study requirements"
62199196|NCT04113070||Non-overweight group|"1. Children with BMI smaller than 25.0 at 18 years old were defined non-overweight according to age- and sex-specific cutoff points standard proposed by International Obesity Task Force (IOTF) for 2- to 18-year-old children.~2. Willingness to comply with study requirements"
62199197|NCT00003622|EXPERIMENTAL|paclitaxel + vinorelbine|
62199198|NCT04215445|ACTIVE_COMPARATOR|Proteinuric diabetic CKD|Tab.empagliflozin 25mg once daily for 28 days
62199199|NCT04215445|ACTIVE_COMPARATOR|Non-Proteinuric diabetic CKD|Tab.empagliflozin 25mg once daily for 28 days
62199200|NCT02630875|ACTIVE_COMPARATOR|A4250 1|Dose I
62199201|NCT02630875|ACTIVE_COMPARATOR|A4250 2|Dose 2
62199202|NCT02630875|ACTIVE_COMPARATOR|A4250 3|Dose 3
62199203|NCT02630875|ACTIVE_COMPARATOR|A4250 4|Dose 4
62199204|NCT02630875|ACTIVE_COMPARATOR|A4250 5|Dose 5
62199205|NCT02630875|ACTIVE_COMPARATOR|A4250 6|Dose 6
62199206|NCT02933086|EXPERIMENTAL|G1: exercises for lumbar stabilization|G1, will perform therapy with specific exercises for lumbar stabilization including the Swiss ball as therapeutic resource
62199207|NCT02933086|EXPERIMENTAL|G2: conventional therapy|G2, will perform conventional therapy including stretching of lower limbs and trunk.
62199208|NCT03274973||Zomacton|
62199209|NCT02257476|EXPERIMENTAL|Carfilzomib|Patients will receive single agent carfilzomib on a weekly dosing schedule (days 1, 8, 15) in a 21 day cycle. The initial dose will be 20 mg/m² for cycle 1, day 1. Dose escalation will proceed in a standard 3+3 fashion with the requirement that dose escalation to the next level can only proceed if 0 of 3 or ≤ 1 of 6 patients experience a dose limiting toxicity (DLT). Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses.
62199210|NCT03435302|EXPERIMENTAL|Temozolomide Plus Cisplatin|per os 200 mg/m\^2/d temozolomide on days 1 to 5 plus i.v. 75 mg/m\^2 cisplatin divided into 3 days,which was repeated every 3 weeks for six cycles
62199211|NCT03435302|ACTIVE_COMPARATOR|High-Dose IFN-a2b|Participants will be treated with i.v. 15×10\^6U/m\^2/d IFN-a2b on days 1 to 5 each week for 4 weeks, followed by s.c. 9×10\^6U IFN- a2b three times per week for 48 weeks.
62199212|NCT00328575|EXPERIMENTAL|Intensity-Modulated Radiotherapy (IMRT)|Patients with brain metastases will be enrolled in one of three dose levels based on tumor size. For tumor size of 3 cm or less (maximum diameter in any dimension), doses of 47.5Gy, 52.5Gy, and 54.5Gy will be tested. For tumor size of greater than 3 cm (maximum diameter in any dimension), doses of 42.5Gy, 47.5Gy, and 52.5Gy will be tested.
62199213|NCT00276198|EXPERIMENTAL|1|Supplementation with daily sprinkle package
62199214|NCT00276198|ACTIVE_COMPARATOR|2|Supplementation with Iron tonic 15mg, vitamins A 300 micrograms, vitamin D 10 micrograms. According to Ministry of Health routine recommendations.
62199215|NCT00276198|NO_INTERVENTION|3|No intervention except for checking outcomes at approprite times.
62199216|NCT03247868|EXPERIMENTAL|Botulinum toxin+SPRInt protocol|patients affected by cervical dystonia receive botulinum toxin treatment (EMG-US guided injections in dystonic muscles) for two times at T0 and T2; after T2 patients are treated also with SPRInt rehabilitation protocol based on motor learning techniques.
62199217|NCT04342143||Stroke|Patients who have a diagnosis of stroke by a stroke consultant from UK National Health Service Trust within 3 months to 5 years of study start date.
62199218|NCT04997772||1|Gaucher disease patients \> 18 years old.
62199219|NCT00801463|EXPERIMENTAL|Large pred|Prednisone 60mg/d\*8 wks
62199220|NCT00801463|EXPERIMENTAL|small pred|Pred 30mg/d\*8wks
62784177|NCT04554771|EXPERIMENTAL|ADAM12 low with tocilizumab and standard of care|Patients have serum ADAM12 lower than 203ng/mL. Patients will receive tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 in addition to paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
62784178|NCT04554771|ACTIVE_COMPARATOR|ADAM12 low with standard of care|Patients have serum ADAM12 lower than 203ng/mL. Patients will receive paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
62784179|NCT06100393|OTHER|Investigational pre-processing algorithm/Standard of Care pre-processing algorithm (Sub A)|
62784180|NCT06100393|OTHER|Investigational pre-processing algorithm/Standard of Care pre-processing algorithm (Sub B)|Using Spatial Automation Profile
62400916|NCT02427542|ACTIVE_COMPARATOR|CBT for DP|Six sessions of CBT covering psycho-education, formulation, enhancing coping strategies (including grounding) and cognitive restructuring techniques.
62400917|NCT02427542|PLACEBO_COMPARATOR|Treatment as usual|Participants will continue to receive their normal treatment - in most cases, this will be care coordination/case management delivered through a community mental health team and may include medication.
62400918|NCT03148509|EXPERIMENTAL|bupropion|receive bupropion
62400919|NCT03148509|EXPERIMENTAL|risperidone|receive risperidone
62400920|NCT03148509|EXPERIMENTAL|aripiprazole|receive aripiprazole
62400921|NCT01296581|EXPERIMENTAL|X-82|
62400922|NCT02087020||Periprosthetic joint infection|Patient treated with 'Debridement, antibiotics and implant retention' for early postoperative periprosthetic joint infection at Danderyd Hospital between 2007-01-01 and 2012-12-01
62400923|NCT02196025|EXPERIMENTAL|Transcranial magnetic stimulation|Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
62784181|NCT05248139|EXPERIMENTAL|Single-dose steroid medication delivered during surgery|Subconjunctival injection of Triamcinolone acetonide.
62784182|NCT05248139|ACTIVE_COMPARATOR|Standard of care post-operative steroid drops|Prednisolone acetate ophthalmic solution, 4-week taper.
62400924|NCT02740751|ACTIVE_COMPARATOR|Still-Tee|Generic name: galactogoe herbal tee, still-tee Dosage: Three cups (each 200 ml) of tea of Still-Tee galactogogue tea will be used Frequency: Three times in a day Duration: for 4 weeks after birth
62400925|NCT02740751|PLACEBO_COMPARATOR|Placebo|The mothers of the babies will receive placebo tea which does not contain galactogogue herbs
62400926|NCT02740751|NO_INTERVENTION|Water|The mothers of the babies will receive water
62400927|NCT01963910|ACTIVE_COMPARATOR|Mannitol in vehicle cream|Once the capsaicin has been removed, .2 mL of 30% mannitol in vehicle cream will be applied to one half of the upper lip and kept there for 10 minutes.
62400928|NCT01963910|PLACEBO_COMPARATOR|Vehicle Cream|Once the capsaicin has been removed, .2 mL of vehicle cream will be applied to the other half of the upper lip and kept there for 10 minutes.
62400929|NCT04103593|EXPERIMENTAL|exercise group|High-intensity circuit exercise training will be performed 3 times weekly for 12 weeks in a group setting. Circuit training is an exercise modality consisting of a series of exercises at different stations. Exercise training will be delivered by VTEL broadcast from the Salem VAMC to participants at the Atlanta VAMC and Baltimore VAMC. Rooms will be equipped with steps, hand and ankle weights, dumbbells, chairs and bands. No stationary exercise equipment will be used in either AEX or RT.
62400930|NCT04103593|NO_INTERVENTION|control group|"Sedentary activity (confirmed at eligibility no more than 1 structured physical activity/week) will be continued in participants randomized to the control group. Participants have the option after 12-week intervention phase to enter delayed exercise training to assure that all participants can receive exercise training."
62400931|NCT01308476||SMS group|
62400932|NCT01308476||control group|
62400933|NCT02502916||Preterm infant|Preterm infants born from October 2009 to June 2010 at a gestational age of less than 32 weeks or with birth weight of less than 1,200 g
62400934|NCT05879458|EXPERIMENTAL|Treatment Arm|Open-Label Ritlecitinib
62400935|NCT03493477||Skeletal Class II Group|From the lateral cephalometric radiograph , Steiner analysis (ANB angle should be higher than mean value, mean value 3 ±2), Witt's appraisal should be higher than mean value (mean value zero), and McNamara analysis (A-B diff NV should be higher than mean value, mean value 4±2).At least two of the three mentioned analyses should verify skeletal class II relation
62400936|NCT03493477||Skeletal Class III Group|From the lateral cephalometric radiograph , Steiner analysis (ANB angle should be lower than mean value, mean value 3 ±2), Witt's appraisal should be lower than mean value (mean value zero), and McNamara analysis (A-B diff NV should be lower than mean value, mean value 4±2).At least two of the three mentioned analyses should verify skeletal class III relation
62400937|NCT03846960|EXPERIMENTAL|preterm infants|A prospective study to assess the safety and efficacy of surfactant administration via thin catheter using a specially adapted VNscope, originally used for endotracheal intubation and adapted for the administration of surfactant without the placement of an endotracheal tube. A feasibility study of 10 preterm infants 30-36 gestational age at birth, that requires surfactant administration for the indication of respiratory distress syndrome, and do not require immediate intubation
62400938|NCT01283802||IOCUS|
62400939|NCT03406780|EXPERIMENTAL|CAP-1002|Patients will receive 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for a total of 4 doses.
62400940|NCT03406780|PLACEBO_COMPARATOR|Placebo|Patients will receive a placebo solution via intravenous infusion every 3 months for a total of 4 doses.
62400941|NCT05531916|EXPERIMENTAL|Group A|Participants wear pressurized gloves and foot caps for 15 minutes before their chemotherapy treatment, during the treatment, and for 15 minutes after it ended.
62400942|NCT05531916|NO_INTERVENTION|Group B|No intervention was done before and after chemotherapy with paclitaxels.
62199221|NCT01126645|OTHER|local ablation group|Local ablation group: Potentially curative treatment of early HCC includes surgical resection and local ablation (RFA, PEI, BT). Recurrence rates after such approaches are reported to amount to 50% at 3 years and 70% at 5 years. Tumor recurrence may be either due to de novo development of new primary tumors or due to intrahepatic (unrecognized) metastases. Prevention of recurrence after local ablation is an important strategy to improve overall survival. So far, adjuvant chemoembolization and chemotherapy have not proven to be effective in preventing recurrences. There is, however, a strong rationale to assume that sorafenib will be of value in the adjuvant treatment of HCC as sorafenib has a dual mechanism of action (inhibition of tumor proliferation and antiangiogenesis) and has proven efficacy in HCC.
62400943|NCT06256861|EXPERIMENTAL|The experimental group|Study lasts 21 days for each patient. All patients are given rehabilitation treatment.The experimental group was given the Myofascial Release Therapy, five days a week, once a day, for 30-60 minutes each time.
62400944|NCT06256861|ACTIVE_COMPARATOR|The control group|Study lasts 21 days for each patient. All patients are given rehabilitation treatment, five days a week, once a day, for 30-60 minutes each time.
62400945|NCT01607489|OTHER|pulmonary vascular disease|Dual-energy computed tomography investigation
62400946|NCT01869959|PLACEBO_COMPARATOR|Placebo|Participants received placebo-matching LY2405319 injected subcutaneously (SC) once daily for 28 days.
61978290|NCT03128112|NO_INTERVENTION|Exam room without poster|All parents will be asked to fill out a questionnaire detailing basic demographic information as well as their perception of their child's weight. Parents who are in exam rooms without posters will be ask to fill out a second short questionnaire after seeing their physician that will ask parents whether they discussed their child's weight status with their physician and whether they believe their own child is: very overweight, overweight, healthy weight, underweight, or very underweight.
62011636|NCT06142955|EXPERIMENTAL|ASD with depression, iTBS then Sham|Participants having ASD with depression will undergo EEG and ET with TMS prior to and following a single iTBS session. Participants first received iTBS then sham approximately one week apart.
62400947|NCT01869959|EXPERIMENTAL|3 mg LY2405319|Participants received 3 milligrams (mg) LY2405319 injected SC once daily for 28 days.
62400948|NCT01869959|EXPERIMENTAL|10 mg LY2405319|Participants received 10 mg LY2405319 injected SC once daily for 28 days.
62400949|NCT01869959|EXPERIMENTAL|20 mg LY2405319|Participants received 20 mg LY2405319 injected SC once daily for 28 days.
62400950|NCT01789307|ACTIVE_COMPARATOR|corn syrup solids|corn syrup solids oral ingestion
62400951|NCT01789307|EXPERIMENTAL|sucrose|sucrose oral ingestion
62400952|NCT05455294|EXPERIMENTAL|Dose Level 0: Decitabine + Venetoclax + Navitoclax [AML and Non-AML]|"Dose Level 0 \[AML and Non-AML\]~Decitabine \[intravenously (IV) preferred\]~Venetoclax Cycle 1: ramp-up days 1-2 and days 3-14 absence of strong/moderate CYP3A inhibitor and reduced doses dependent on presence of moderate or strong CYP3A inhibitor Cycle 2+: dosing days 1-14~Navitoclax Cycle 1: dosing days 3-14; Cycle 2+: dosing on days 1-14~Cycle length=28 days Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
62577244|NCT02236871|ACTIVE_COMPARATOR|4 servings|Participants will be asked to consume recommended servings of milk or milk products/d for their age, so they will receive 1 milk (250 ml), a yogurt (175 g) and cheese (50 g) or more. This would provide ≥ 3 servings/d.
62784183|NCT04735991|NO_INTERVENTION|Control group|The patient's family members need to fill in the family member quality of life questionnaire during the screening and follow-up period. They are able to contact the doctor for questions in terms of medical treatment.
62199222|NCT01126645|ACTIVE_COMPARATOR|palliative treatment group|"Radioembolization has been reported to be effective in patients with unresectable HCC with preserved liver function from a number of trials. Successful downstaging of disease rendering patients eligible for potentially curative therapies, and even histologically confirmed complete responses of unresectable HCC, have repeatedly been reported providing the rationale to evaluate SIRT+sorafenib in comparison to sorafenib alone.~The impact of cirrhosis as a concomitant disease in most patients with HCC is that it limits the ability of many patients to tolerate chemotherapy and is an independent cause of death in HCC patients. Thus, the historical difficulty in demonstrating an effect of therapy on survival in patients with advanced-stage, unresectable HCC (the majority). A new therapy that is effective in controlling hepatic disease, is less toxic than traditional chemotherapy, and improves the quality of life for patients in the advanced stages of HCC could represent an alternative."
62199223|NCT01481688|NO_INTERVENTION|Control|Routine haemodialysis sessions as per usual
62199224|NCT01481688|EXPERIMENTAL|Intradialytic exercise|One hour of exercise completed during haemodialysis.
62199225|NCT01481688|ACTIVE_COMPARATOR|Extra time|30 minutes extra dialysis time.
62400953|NCT05455294|EXPERIMENTAL|Dose Level 1: Venetoclax + Decitabine + Navitoclax [AML and Non-AML]|"Dose Level 1 \[AML and Non-AML\]~Decitabine \[intravenously (IV) preferred\] Cycle 1+: dosing on days 1-5~Venetoclax \[orally\] Cycle 1: ramp-up starting on day 1-2 then days 3-14 continued dosing in absence of strong/moderate CYP3A inhibitor and reduced doses dependent on presence of moderate or strong CYP3A inhibitor Cycle 2+: dosing days 1-14~Navitoclax \[orally\] Cycle 1: Dosing days 3-14 Cycle 2+: dosing on days 1-14~Cycle length=28 days Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
62577245|NCT05347576|EXPERIMENTAL|sequence 1|Period 1- A single dose of 4 tablets(CKD-501 1T, D759 1T, D150 1T, D029 1T) under fed condition Period 2- A single dose of 2 tablets(CKD-393(2) 2T) under fed condition
62577246|NCT05347576|EXPERIMENTAL|sequence 2|Period 1- A single dose of 2 tablets(CKD-393(2) 2T) under fed condition Period 2- A single dose of 4 tablets(CKD-501 1T, D759 1T, D150 1T, D029 1T) under fed condition
62199226|NCT01646177|PLACEBO_COMPARATOR|Placebo|Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, participants are assigned to Dosing Regimen 2.
62577247|NCT04568564|EXPERIMENTAL|Telerehabilitation Group (TG)|Patients diagnosed with lung cancer and underwent thoracotomy
62784184|NCT04735991|EXPERIMENTAL|Study group|The family members of the patients need to fill in the family member quality of life questionnaire during the screening period and follow-up period, and are involved in an interactive management program on the mobile terminal, full participation required.
62577248|NCT04568564|ACTIVE_COMPARATOR|Control group (CG)|Patients diagnosed with lung cancer and underwent thoracotomy
62577249|NCT02582684|EXPERIMENTAL|Arm 1: DTG 50 mg + 3TC 300 mg|Dolutegravir 50mg and Lamivudine 300mg, orally daily
62577250|NCT05253573|EXPERIMENTAL|Automated Treatment|AT consists of all SC components plus a fully automated smartphone-based JITAI that involves proactive, interactive, and personalized messages, images, or videos in Lao.
62577251|NCT05253573|ACTIVE_COMPARATOR|Standard Care|"SC consists of brief advice to quit smoking delivered by research staff, self-help written materials (the WHO's A guide for tobacco users to quit that we have translated to and validated in Lao), and a 2-week supply of NRT (transdermal patches)."
62577252|NCT05679102|ACTIVE_COMPARATOR|Amlopdipine only|Newly diagnosed hypertensive patients who will be given only amlodipine.
62784185|NCT05226299|EXPERIMENTAL|Experimental: Supra-threshold capsaicin|Arm: Experimental: Supra-threshold capsaicin Participants will be exposed to progressively increasing concentrations of aerosolized capsaicin (the ingredient in chili peppers that makes them spicy, and a known cough stimulant) to stimulate an urge-to-cough. Participants will be coached to implement cough suppression strategies following each exposure.
62199227|NCT01646177|ACTIVE_COMPARATOR|50 mg etanercept|Administered by SC injections twice weekly starting at Week 0 up to Week 12. At Week 12, arm is assigned to Dosing Regimen 2
62784186|NCT05226299|PLACEBO_COMPARATOR|Arm: Placebo Comparator: Saline|Participants will be exposed repeatedly to aerosolized saline through a nebulizer during treatment.
62784187|NCT03969927|EXPERIMENTAL|Low-Fidelity PDS Training|Individuals with stroke, PD, or MS
62784188|NCT03969927|ACTIVE_COMPARATOR|High Fidelity Fixed-Base Simulator Training|Individuals with stroke, PD, or MS
62577253|NCT05679102|ACTIVE_COMPARATOR|Amlodipine and Atorvastatin|Newly diagnosed hypertensive patients who will be given Amlodipine and Atorvastatin.
62577254|NCT00606554|EXPERIMENTAL|Computer-assisted weaning|Group assigned to the computer-assisted weaning program
62577255|NCT00606554|ACTIVE_COMPARATOR|Standard of care weaning|Group assigned to receive current, evidence-based, standard of care for discontinuation of mechanical ventilation.
62784189|NCT06395532||Respiratory compromise (RC) group|
62577256|NCT01448330|EXPERIMENTAL|HCP0911|clopidogrel/aspirin combination tablet
62577257|NCT01448330|ACTIVE_COMPARATOR|clopidorel and aspirin|coadministration of clopidogrel and aspirin
62577258|NCT06129604|EXPERIMENTAL|pilot window of opportunity trial of TPST-1495|
62577259|NCT01986933|EXPERIMENTAL|Group1|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
62577260|NCT01986933|EXPERIMENTAL|Group2|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
62577261|NCT01986933|EXPERIMENTAL|Group3|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
62577262|NCT01986933|EXPERIMENTAL|Group4|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
62784190|NCT06395532||Non respiratory compromise (RC) group|
62784191|NCT05821218||back pain group|back pain group
62784192|NCT04386694|EXPERIMENTAL|PBMT/sMF|"Active PBMT/sMF will be applied once a day, during the ICU stay, until discharge or death. The patients will receive standard physical therapy care associated with PBMT/sMF.~PBMT/sMF will be applied using MR5™ ACTIV PRO LaserShower, manufactured by Multi Radiance Medical (Solon, OH, USA). This device has 4 diodes of 905 nm (1.25 mW each diode, 0.32 cm2 each), 8 diodes of 633 nm (25 mW each diode, 0.85 cm2 - each), and 8 diodes of 850 nm (40 mW each diode, 0.56 cm2 - each). The static magnetic field is 110 mT."
62784193|NCT04386694|PLACEBO_COMPARATOR|Placebo PBMT/sMF|"Placebo PBMT/sMF will be applied once a day, during the ICU stay, until discharge or death. The patients will receive standard physical therapy care associated with placebo PBMT/sMF.~The placebo PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA). The ACTIV PRO emits 905nm, and 850nm via an electric diode energy source with outputs to 0%. The static magnetic field will be also turned off. The 660nm light via an electric diode energy source with outputs to \>1% to appear like the active comparator."
62199228|NCT01646177|EXPERIMENTAL|80 mg ixekizumab Dosing Regimen 2|Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 264.
62577263|NCT01986933|EXPERIMENTAL|Group5|Part A: Placebo Part B: nemolizumab (CIM331)
62577264|NCT05526196|OTHER|Placebo|A cigarette containing placebo cannabis and placebo tobacco
62577265|NCT05526196|OTHER|Tobacco|A cigarette with placebo cannabis and active tobacco
62577266|NCT05526196|OTHER|Cannabis|A cigarette with active cannabis and placebo tobacco
62577267|NCT05526196|OTHER|Tobacco and cannabis|A cigarette with active cannabis and active tobacco
62577268|NCT01559025|NO_INTERVENTION|Insulin therapy|Patients will receive the conventional treatment with insulin
62577269|NCT01559025|ACTIVE_COMPARATOR|Vildagliptin|Patients will receive vildagliptin besides the conventional treatment with insulin
62577270|NCT02477332|EXPERIMENTAL|QGE031 24 mg s.c. q4w|ligelizumab 24 mg injection subcutaneous every 4 weeks
62577271|NCT02477332|EXPERIMENTAL|QGE031 72 mg s.c. q4w|ligelizumab 72 mg injection subcutaneous every 4 weeks
62577272|NCT02477332|EXPERIMENTAL|QGE031 240 mg s.c. q4w|ligelizumab 240 mg injection subcutaneous every 4 weeks
62577273|NCT02477332|ACTIVE_COMPARATOR|Omalizumab 300 mg s.c. q4w|omalizumab 300 mg injection subcutaneous every 4 weeks
62577274|NCT02477332|PLACEBO_COMPARATOR|Placebo s.c. q4w|placebo injection subcutaneous every 4 weeks
62577275|NCT02477332|EXPERIMENTAL|QGE031 120 mg s.c. s.d.|ligelizumab 120 mg injection subcutaneous single dose
62577276|NCT00831649|EXPERIMENTAL|natalizumab|
62577277|NCT04974060|EXPERIMENTAL|Remifentanil intervention|After the satisfactory analgesia and sedation, remifentanil will continuously infuse an escalating dose in the sequence of 0.02, 0.04, 0.06, and 0.08 μg/kg/min, each dose infusion lasting at least 30 minutes.
62784194|NCT02675530|EXPERIMENTAL|healthy control|Healthy controls will receive electrophysiological assessments before and after NMDA antagonist administration.
62784195|NCT06011369|EXPERIMENTAL|Fluorescence in thyroid surgery|Patients undergoing thyroid surgery with cervical fluorescence.
62784196|NCT06011369|NO_INTERVENTION|No Fluorescence in thyroid surgery|patients undergoing thyroid surgery without cervical fluorescence.
62784197|NCT02225834|EXPERIMENTAL|early Atorvastatin treatment|Ischemic stroke patients treated with with atorvastatin 80 mg at admission until discharge
62784198|NCT02225834|NO_INTERVENTION|no early treatment with atorvastatin|Ischemic stroke patients not treated with with atorvastatin 80 mg until discharge
62199229|NCT01646177|EXPERIMENTAL|80 mg ixekizumab Dosing Regimen 1|Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, arm is assigned to Dosing Regimen 2.
62199230|NCT03470636|EXPERIMENTAL|HeartLight X3|Pulmonary vein isolation using HeartLight X3
62199231|NCT00804505|EXPERIMENTAL|1|Test arm daily wear hybrid contact lens.
62400954|NCT05455294|EXPERIMENTAL|Dose Level 2: Venetoclax + Decitabine + Navitoclax [AML]|"Dose Level 2 \[AML\]~Decitabine \[intravenously (IV) preferred\] Cycle 1+: dosing on days 1-5~Venetoclax \[orally\] Cycle 1: ramp-up on day 1-2, days 3-21 continued dosing in absence of strong/moderate CYP3A inhibitor and reduced doses dependent on presence of moderate or strong CYP3A inhibitor Cycle 2+: dosing on days 1-21~Navitoclax \[orally\] Cycle 1: dosing on days 3-14 Cycle 2+: dosing on days 1-14~Cycle length=28 days Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
62199232|NCT00804505|OTHER|2|Control: SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Hybrid Contact Lens
62199233|NCT04802889|EXPERIMENTAL|cadaver eyes|The Central region of the retina and preretinal structures of cadaver eyes are examined
62199234|NCT00855504||Subjects|All the consecutive primigravidae who register in the antenatal clinic before 20 weeks of gestation
62577278|NCT04947228|EXPERIMENTAL|intervention group|in addition to the usual therapy, the patients were given access to the trackPAD app
62577279|NCT04947228|NO_INTERVENTION|control group|patients in this group were treated as usual in the clinic without additional interventions.
62784199|NCT02161380|EXPERIMENTAL|Low-dose (1.18x10e9 vg)|"Participants with Chronic Bilateral Severe Vision Loss were administered 200 µL of scAAV2-P1ND4v2 containing a dose of 1.18x10e9 vg.~Participants with Acute Bilateral Severe Vision Loss were administered 200 µL of scAAV2-P1ND4v2 containing a dose of 1.18x10e9 vg.~Participants with Acute Unilateral Severe Vision Loss were administered 200 µL of scAAV2-P1ND4v2 containing a dose of 1.18x10e9 vg"
62199235|NCT02784964|EXPERIMENTAL|Elixcyte 8mL|ADSC 6.4\*10\^7 cells, allogeneic injection, one time injection on Day 1
62199236|NCT02784964|ACTIVE_COMPARATOR|Hya Joint Plus|Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc., one time injection on Day 1
62199237|NCT02784964|EXPERIMENTAL|Elixcyte 4mL|ADSC 3.2\*10\^7 cells, allogeneic injection, one time injection on Day 1
62199238|NCT02784964|EXPERIMENTAL|Elixcyte 2mL|ADSC 1.6\*10\^7 cells, allogeneic injection, one time injection on Day 1
62199239|NCT05829798|EXPERIMENTAL|SYNOLIS VA 80/160|SYNOLIS VA 80/160 (hyaluronic acid 80 mg, sorbitol 160 mg) Intra-articular injection
62199240|NCT05829798|EXPERIMENTAL|SYNOLIS VA 40/80|SYNOLIS VA 40/80 (hyaluronic acid 40 mg, sorbitol 80 mg) Intra-articular injection
62199241|NCT05715749|EXPERIMENTAL|In-home body weight support harness system|All participants will be entered into treatment arm and receive an in-home body weight support harness system
62199242|NCT01744470|EXPERIMENTAL|Group A - tacrolimus half-dose|"Immunosuppressive strategy with 50 % reduction of Advagraf® daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.~Drug: Tacrolimus targeted half-dose"
62199243|NCT01744470|EXPERIMENTAL|Group B - tacrolimus unchanged dose|Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf® and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose
62199244|NCT05875649||Group|Acute myeloid leukemia patients with first-induction failure
62199245|NCT04662060|EXPERIMENTAL|Acebilustat|Participants are randomized to receive acebilustat for 28 days.
62784200|NCT02161380|EXPERIMENTAL|Medium dose (5.81x10e9 vg)|"Participants with Chronic Bilateral Severe Vision Loss were administered 200 µL of scAAV2-P1ND4v2 containing a dose of 5.81x10e9 vg.~Participants with Acute Bilateral Severe Vision Loss were administered 200 µL of scAAV2-P1ND4v2 containing a dose of 5.81x10e9 vg.~Participants with Acute Unilateral Severe Vision Loss were administered 200 µL of scAAV2-P1ND4v2 containing a dose of 5.81x10e9 vg."
62784201|NCT02161380|EXPERIMENTAL|High dose (2.40x10e10 vg)|Participants with Chronic Bilateral Severe Vision Loss were administered 100 µL of scAAV2-P1ND4v2 containing a dose of 2.40x10e10 vg.
62784202|NCT02161380|EXPERIMENTAL|Higher dose (1x10e11vg)|"Participants with Chronic Bilateral Severe Vision Loss were administered 100 µL of scAAV2-P1ND4v2 containing a dose of 1x10e11vg.~Participants with Acute Bilateral Severe Vision Loss were administered 100 µL of scAAV2-P1ND4v2 containing a dose of 1x10e11vg.~Participants with Acute Unilateral Severe Vision Loss were administered 100 µL of scAAV2-P1ND4v2 containing a dose of 1x10e11vg."
62784203|NCT03437577|ACTIVE_COMPARATOR|immediate-release tacrolimus|This is standard of care
62784204|NCT03437577|EXPERIMENTAL|extended release tacrolimus|replace standard of care
62784205|NCT03785964|EXPERIMENTAL|Double-Blind Phase - Nirogacestat|Nirogacestat 150 mg by mouth, twice daily
62784206|NCT03785964|PLACEBO_COMPARATOR|Double-Blind Phase - Placebo|Placebo by mouth, twice daily
62784207|NCT03785964|EXPERIMENTAL|Open-Label Phase - Nirogacestat|Nirogacestat 150 mg by mouth, twice daily
62784208|NCT01309776|EXPERIMENTAL|Tianeptine|
62784209|NCT01309776|ACTIVE_COMPARATOR|Escitalopram|
62784210|NCT06208774|EXPERIMENTAL|LV-ISBP block Group (n=40): US-guided low volume interscalene brachial plexus block|Patient in a semi-sitting position with the head tilted to the opposite side of the injection site. A linear US probe (4-12 MHz) will be placed parallel to the clavicle in the supraclavicular fossa, and the subclavian artery will be seen beating above the first rib.Then the probe will be moved cranially to identify the transverse process of the C7 vertebra at the level of the brachial plexus roots between the scalenus anterior and medius muscles.The needle will be inserted in a plane approach from lateral to medial to scalenus medius and C5-C6 brachial plexus roots. After negative aspiration, a total of 5 mL of bupivacaine 0.5% will be injected incrementally.
62784211|NCT06208774|ACTIVE_COMPARATOR|PENG block Group (n=40): US-guided pericapsular nerve group block for shoulder|The patient's arm was placed in external rotation and abducted at 45 degrees. A linear US probe (4-12 MHz) will be placed longitudinally between the coracoid and the humeral head, visualizing the deltoid muscle and subscapularis tendon. 22-gauge needle will be advanced in-plane into the fascial plane between the deltoid muscle and subscapularis tendon. The location of the needle tip will be confirmed by hydrodissection of inter-fascial planes with 3 ml of normal saline. After negative aspiration, a total of 20 mL of bupivacaine 0.5% will be injected in the fascial plane incrementally, aspirating every 5 ml.
62784212|NCT03328351|EXPERIMENTAL|manual group|"1. The Manual therapy (Mobilization):~   1. Cervical postero-anterior vertebral mobilization glides: the mobilization was grade 3 for 2 min 3 set~  2. Cervical lateral vertebral glides: the mobilization was grade 3 for 1 min 3 set.~2. Strengthening Exercises for deep neck flexor muscle"
62784213|NCT03328351|SHAM_COMPARATOR|sham group|"1. Superficial soft tissue massage~2. Strengthening Exercises: for deep neck flexor muscles for 10 seconds and repeating it for 10 times ."
62199246|NCT04662060|PLACEBO_COMPARATOR|Matching Placebo|Participants are randomized to receive placebo to match acebilustat for 28 days.
62199247|NCT01344551|ACTIVE_COMPARATOR|High Flavanol|High Flavanol cocoa drink containing 495mg cocoa
62199248|NCT01344551|PLACEBO_COMPARATOR|Low Flavanol|Low Flavanol cocoa drink (23mg)
62199249|NCT04836169|EXPERIMENTAL|InCaveo EOA System|InCaveo EOA System (including integrated CBT but without tapering) group
62199250|NCT04836169|NO_INTERVENTION|Control Group-usual care with pill bottles|UCPB group-usual care with pill bottles
62199251|NCT05407831||LDM|Lean Diabetes Mellitus
62784214|NCT04000581|ACTIVE_COMPARATOR|Arm I (usual care)|Patients walk one to two laps around the ward twice per day, and have mobility tracked with Xsens over 5-10 minutes, until discharge from hospital. Patients also mobilize (walk out of the bed) on first day post-surgery under supervision and assistant of attending nurse in the floor if the clinical situation allows.
62784215|NCT04000581|EXPERIMENTAL|Arm II (additional mobility)|Patients walk for minimum 30 minutes per day and mobility is tracked with Xsens over 5-10 minutes up to discharge from hospital. Patients also mobilize (walk out of the bed) on first day post-surgery under supervision and assistant of attending nurse in the floor if the clinical situation allows.
62784216|NCT04638426|EXPERIMENTAL|Treatment A|HL237 tab. 200mg/day
62199252|NCT05407831||ODM|Obese Diabetes Mellitus
62199253|NCT01561677|NO_INTERVENTION|apnea/hypopnea index (AHI<5 : no OSAS)|
62199254|NCT01561677|NO_INTERVENTION|apnea/hypopnea index (5≥AHI<15 : mild OSAS)|
62199255|NCT01561677|NO_INTERVENTION|apnea/hypopnea index (15≤AHI<30 :moderate OSAS)|
62400955|NCT05455294|EXPERIMENTAL|Dose Level -1: Venetoclax + Decitabine + Navitoclax [Non-AML]|"Dose Level -1 \[Non-AML\]~Decitabine \[intravenously (IV) preferred\] Cycle 1+:dosing \[intravenously (IV) preferred\] on days 1-3~Venetoclax \[orally\] Cycle 1: ramp-up of starting day 1-2 then days 3-7 continued dosing in absence of strong/moderate CYP3A inhibitor and reduced doses dependent on presence of moderate or strong CYP3A inhibitor Cycle 2+: dosing on days 1-7~Navitoclax \[orally\] Cycle 1: Dosing days 3-14 Cycle 2+: continued dosing on days 1-14~Cycle length=28 days Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
62784217|NCT04638426|EXPERIMENTAL|Treatment B|HL237 tab. 400mg/day
62199256|NCT01561677|ACTIVE_COMPARATOR|apnea/hypopnea index ( AHI≥30 : severe OSAS treated).|Treated with CPAP
62199257|NCT01561677|SHAM_COMPARATOR|apnea/hypopnea index ( AHI≥30:severe OSAS untreated).|Treated with sham CPAP (placebo)
62199258|NCT00763451|EXPERIMENTAL|Lixisenatide (Two-Step Titration)|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
62011637|NCT06142955|EXPERIMENTAL|ASD with depression, Sham then iTBS|Participants having ASD with depression will undergo EEG and ET with TMS prior to and following a single iTBS session.Participants first received sham then iTBS approximately one week apart.
62011638|NCT06142955|EXPERIMENTAL|ASD without depression, iTBS then Sham|Participants having ASD without depression will undergo EEG and ET with TMS prior to and following a single iTBS session. Participants first received iTBS then sham approximately one week apart.
62011639|NCT06142955|EXPERIMENTAL|ASD without depression, Sham then iTBS|Participants having ASD without depression will undergo EEG and ET with TMS prior to and following a single iTBS session.Participants first received sham then iTBS approximately one week apart.
62011640|NCT06142955|EXPERIMENTAL|TD with depression, iTBS then Sham|Participants that are TD with depression will undergo EEG and ET with TMS prior to and following a single iTBS session. Participants first received iTBS then sham approximately one week apart.
62011641|NCT06142955|EXPERIMENTAL|TD with depression, Sham then iTBS|Participants that are TD with depression will undergo EEG and ET with TMS prior to and following a single iTBS session. Participants first received sham then iTBS approximately one week apart.
62011642|NCT06142955|EXPERIMENTAL|TD without depression, iTBS then Sham|Participants that are TD without depression will undergo EEG and ET with TMS prior to and following a single iTBS session. Participants first received iTBS then sham approximately one week apart.
62011643|NCT06142955|EXPERIMENTAL|TD without depression, Sham then iTBS|Participants that are TD without depression will undergo EEG and ET with TMS prior to and following a single iTBS session. Participants first received sham then iTBS approximately one week apart.
62011644|NCT01566136|NO_INTERVENTION|Usual care|Current routine rehab care for persons with a hip fracture and CI lacks a well integrated care system within the local hospital network. The usual approach to care at the two sites differ in one major way: patients presenting with a hip fracture to Site 1 receive surgery locally, while those presenting to Site 2 receive surgery at a different hospital because of the absence of an operating suite at this site. Within 2 to 10 days 95% of patients presenting to either site hospital's emergency room with a hip fracture, receive internal fixation or arthroplasty surgery. Patients, including some with mild and moderate CI, are then transferred to in-patient rehabilitation beds at Site 1 or Site 2. Screening of patients for dementia or delirium is not routinely done.
62199259|NCT00763451|EXPERIMENTAL|Lixisenatide (One-Step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to the end of treatment.
62199260|NCT00763451|PLACEBO_COMPARATOR|Placebo (Two-Step Titration)|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
62577280|NCT05203796|EXPERIMENTAL|Experimental group: Dry eye disease patients (n=12)|"Patient needs to visit site at least 7 times(Screening, Baseline, wk1, wk2, wk3, wk4, wk5). From baseline visit, patients wear our clinical trial device 30mins per day for 5wks(2Hz stimulation). All other procedures during clinical trial the are the same.~Intervention: Device: Transcutaneous pulsed electrical stimulation"
62577281|NCT05203796|SHAM_COMPARATOR|Comparison group: Dry eye disease patients (n=12)|"Patient needs to visit site at least 7 times(Screening, Baseline, wk1, wk2, wk3, wk4, wk5). From baseline visit, patients wear our clinical trial device 30mins per day for 5wks(sham stimulation). All other procedures during clinical trial the are the same.~Intervention: Device: Sham device"
62577282|NCT00183404|EXPERIMENTAL|Olanzapine|Participants will take open olanzapine for up to 20 additional weeks after phase 1.
62784218|NCT04638426|EXPERIMENTAL|Treatment C|HL237 tab. 800mg/day
62784219|NCT04638426|PLACEBO_COMPARATOR|Placebo|Placebo of HL237 tab.
62199261|NCT00763451|PLACEBO_COMPARATOR|Placebo (One-Step Titration)|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, then 20 mcg QD up to the end of treatment.
62199262|NCT01860599|OTHER|Prediabetes with exercise|150 minutes of moderate exercise per week
62199263|NCT01860599|OTHER|Prediabetes without exercise|Pre-study activity level (i.e. no exercise)
62199264|NCT01348334|ACTIVE_COMPARATOR|Vypromesh®(Ethicon,USA)|Vypromesh®(semiabsorbable multiflament mesh;non-absorbable Polypropylene+absorbable Poliglactin)
62784220|NCT03563196||Chest Radiograph|All the patients will undergo routine chest radiogram on day 1 after operation
62784221|NCT03563196||Lung Ultrasound|The same patient will undergo ultrasound evaluation of lungs on day 1 after operation
62784222|NCT01185977|ACTIVE_COMPARATOR|Fluoxetine|1 week single-blinded placebo lead-in and double-blinded FLX treatment for 8 weeks
62784223|NCT01185977|PLACEBO_COMPARATOR|Placebo (PBO)|Placebo treatment for 9 weeks of study
62011645|NCT01566136|EXPERIMENTAL|Rehabilitation Model of Care|Staff will be introduced to five components of the Patient-Centred Rehabilitation Model of Care (PCRM-CI) in a one-day workshop prior to implementing the PCRM-CI model. They will then be provided with eight additional educational sessions throughout the year. A manual detailing all aspects of training, including specifics on how to present the material, ideas for stimulating discussion, and case vignettes to illustrate training concepts was developed for our pilot study and will be used here. We also produced a short video on care of elderly with CI in rehabilitation which will be utilized in the training session. The model will be tested over a one year period with a sustainability plan in place developed by the local hospital network and the two study sites.
62784224|NCT00573014||OBTP|Obtunded blunt trauma patients with normal CT C-spine
62199265|NCT01348334|ACTIVE_COMPARATOR|Ultrapromesh®(Ethicon,USA)|Ultrapromesh®(semiabsorbable monofilament mesh;non-absorbable Polypropylene+absorbable polyglecaprone).
62011646|NCT06662955|ACTIVE_COMPARATOR|Exercise without audible cues|Terminal knee extension exercise without audible cues
62577283|NCT01732094|EXPERIMENTAL|Corifollitropin Alfa + hMG|
62577284|NCT04820699|EXPERIMENTAL|post isometric relaxation|Group A received Post isometric relaxation technique (MET).The participants performed isometric contractions using 20% of their strength, 5 second holds with 5 seconds rest time in between each contraction
62199266|NCT01348334|ACTIVE_COMPARATOR|Prolene light mesh®(Johnson&Johnson,USA)|Prolene light mesh®(cpp-Condensed monofilament non absorbable polypropylene mesh)
62400956|NCT05455294|EXPERIMENTAL|Recommended Phase 2 Dose Level: Venetoclax + Decitabine + Navitoclax [AML and Non-AML]|"RP2D \[AML and Non-AML\]~Decitabine \[intravenously (IV) preferred\] To be determined based on dose escalation design.~Venetoclax \[orally\] To be determined based on dose escalation design.~Navitoclax \[orally\] To be determined based on dose escalation design.~Cycle length=28 days Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
62400957|NCT00766727|EXPERIMENTAL|GLYDe Dressing|Investigational Dressing
62577285|NCT04820699|EXPERIMENTAL|mulligan bent leg raise|Group B: Mulligan bent leg raise technique. Isometric contraction of hamstring muscle for progressively five greater position of hip flexion; three pain-free repetitions with 5 second hold was performed by participants
62577286|NCT00305084|EXPERIMENTAL|A|
62577287|NCT05323162|EXPERIMENTAL|Encapsulated autologous fecal microbiota transplantation|Encapsulated own microbiota to be transplanted from large- to small intestine by oral ingestion
62577288|NCT05028556|EXPERIMENTAL|Y101D|Y101D in subjects with Metastatic or Locally Advanced Solid Tumors
62784225|NCT04359485|EXPERIMENTAL|glycolic acid peel|
62011647|NCT06662955|EXPERIMENTAL|Exercise with audible cues|Terminal knee extension exercise with audible cues
62400958|NCT00766727|NO_INTERVENTION|Standard of Care|Standard of care comparator
62011648|NCT00014534|ACTIVE_COMPARATOR|Gemcitabine + cisplatin|
62011649|NCT00014534|ACTIVE_COMPARATOR|Gemcitabine + Doxorubicin + Pegfilgrastim|
62199267|NCT00672685|EXPERIMENTAL|1|Omega-3 group without any intervention
62199268|NCT00672685|EXPERIMENTAL|2|Omega-3 combined group (Omega-3 + multi-domain intervention)
62199269|NCT00672685|EXPERIMENTAL|3|Placebo combined group (Placebo + multi-domain intervention)
62199270|NCT00672685|PLACEBO_COMPARATOR|4|Placebo group without any intervention
62199271|NCT04578353|EXPERIMENTAL|AquaPass System|Participants will undergo 3 procedures (each procedure up to 3 (±1) hours operation) using the AquaPass System, with 4-10 days between each procedure.
62577289|NCT06575244|EXPERIMENTAL|Intervention group|Eligible participants will take part in the RAWBONE sailing program, which will utilize dinghies with universal design known for their exceptional stability to prioritize safety. The instructor-to-participant ratio will be 1:6, with each participant accompanied by a volunteer on a 1:1 ratio, and a safety boat present. The program will conclude with participants receiving a certificate of participation. Participants will receive a social skills booklet that is identical to the placebo received by the control group.
62577290|NCT06575244|PLACEBO_COMPARATOR|Controlled group|The control group participants will be directed to continue their usual routines while refraining from sailing-related activities and will be provided with a booklet containing social skills content as a placebo, with no additional support during the intervention period.
62577291|NCT04233112|PLACEBO_COMPARATOR|Placebo/Mock|Placebo capsules; mock osteogenic loading
62577292|NCT04233112|EXPERIMENTAL|Melatonin/Mock|Melatonin capsules; mock osteogenic loading
62577293|NCT04233112|EXPERIMENTAL|Placebo/Osteogenic loading|Placebo capsules/osteogenic loading
62784226|NCT04359485|PLACEBO_COMPARATOR|Saline|
62784227|NCT06173908|EXPERIMENTAL|cell treatment|Autologous epidermal basal cells were used to treat postoperative nonhealing wounds
62784228|NCT06173908|SHAM_COMPARATOR|control treatment|Conventional method were used to treat postoperative nonhealing wounds
62784229|NCT00293618|EXPERIMENTAL|Intervention|Arm of anesthesiologists and senior residents who receive a patient's individual predicted PONV risk intraoperatively
62577294|NCT04233112|EXPERIMENTAL|Melatonin/Osteogenic loading|Melatonin capsules/osteogenic loading
62784230|NCT00293618|ACTIVE_COMPARATOR|Usual Care|Anesthesiologists and senior residents who provide usual care: they provide PONV prophylaxis as they always have
62784231|NCT05218525|EXPERIMENTAL|Intervention group|The specialized COPD community nurses, who are responsible for patients in the intervention group, will experience an extra alarm option in the telehealth system. The COPD prediction algorithm has been implemented by the Danish Company, OpenTeleHealth, into their commercially available telehealth system, Telekit, and thus, the COPD prediction algorithm is approved for clinical use as a part of the existing telehealth system´s CE marking (class I and IIa).
62784232|NCT05218525|NO_INTERVENTION|Control group|"The specialized COPD community nurses responsible for patients in the control group will only experience the usual alarms that are activated in the telehealth system, named Telekit, and are based on low or high values of vital signs. The specialized COPD community nurses are not instructed to act differently compared to how they act normally. This involves that the specialized COPD community nurses monitor as usual and respond to divergent data as usual.~The participants in the control group receive the usual practice, which includes the general offer of the telehealth intervention. The participants in the control group are instructed to do exactly the same procedures as the participants in the intervention group.~The specialized COPD community nurses, who are responsible for patients in the control group continue to monitor the participants as usual, but are informed that more oxygen saturation measurements will be present for the included participants."
62784233|NCT02720406|ACTIVE_COMPARATOR|Intravenous ketamine0.5mg/kg|intravenous ketamine 0.5 mg/kg given after induction of anesthesia and before surgery.
62784234|NCT02720406|ACTIVE_COMPARATOR|Nebulized ketamine 1mg/kg|nebulized ketamine group received 1mg/kg ketamine by nebulzation before induction of anesthesia.
62199272|NCT04456387|EXPERIMENTAL|Arm 1-on demand treatment|Part A-Participants will receive on-demand treatment with Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection for 6 months.
62011650|NCT06664216|ACTIVE_COMPARATOR|Control|Participants use a laparoscopic model without any previous marks.
62011651|NCT06664216|EXPERIMENTAL|Intervention|Participants use a laparoscopic model with incorrect trocar placement marks.
62011652|NCT01297842|EXPERIMENTAL|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
62011653|NCT01297842|ACTIVE_COMPARATOR|Meropenem or Imipenem|Meropenem or Imipenem o.5 or 1 gram 3 to 4 times a day for 7 to 14 days
62199273|NCT04456387|EXPERIMENTAL|Arm 2- prophylaxis treatment|"Part B-Participants will receive prophylaxis treatment with Recombinant Human Coagulation Factor VIII-Fc fusion for 6 months.~12 Participants of them will receive PK assessment at ED1 and ED35(Participants will be tested for PK assessment at timepoints throughout the study based on exposure days (ED). One ED is equivalent to a 24 hours period in which drug is dosed.)，measured by one-stage assay, they would not be given prophylaxis treatment until the completion of PK blood collection."
62199274|NCT02086305|EXPERIMENTAL|Usual Care + Transitional Care Model|Transitional Care, Evidence-based symptom management, Protocol-driven home visit and telephone follow-up, Trained nurse case manager and volunteer partnership
62199275|NCT02086305|ACTIVE_COMPARATOR|Usual Care|Usual care
62199276|NCT00421655|EXPERIMENTAL|1|
62784235|NCT02720406|ACTIVE_COMPARATOR|Nebulized ketamine 2mg/kg|nebulized ketamine group received 2mg/kg ketamine by nebulzation before induction of anesthesia.
62784236|NCT02720406|PLACEBO_COMPARATOR|control group|control group received placebo nebulization
62199277|NCT00421655|PLACEBO_COMPARATOR|2|
62199278|NCT02767752|EXPERIMENTAL|T-ChOS + Gemcitabine + Capecitabine|"T-ChOS: 600 mg given p.o. (two capsules, each 300 mg) daily in the morning 30 minutes before food.~Gemcitabine: 1000 mg/m²i.v. on day 1, day 8 and day 15 of every 28 day cycle. Capecitabine: 1660 mg/m²/day p.o. twice daily 21/28 day i. e. 24 weeks."
62199279|NCT02767752|PLACEBO_COMPARATOR|Placebo + Gemcitabine + Capecitabine|"Placebo: 600 mg given p.o. (two capsules, each 300 mg) daily in the morning 30 minutes before food.~Gemcitabine: 1000 mg/m²i.v. on day 1, day 8 and day 15 of every 28 day cycle. Capecitabine: 1660 mg/m²/day p.o. twice daily 21/28 day i. e. 24 weeks."
62199280|NCT02387268|EXPERIMENTAL|CleanC|Standard colonoscopy procedure using the CleanC system
62199281|NCT00867464||Observational (long term follow-up)|Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10.
62577295|NCT04274010|OTHER|Crohn's capsule|Single-arm non-randomised study, all participants will undergo MRE, ileo-colonoscopy and Crohn's capsule.
62577296|NCT00655941|EXPERIMENTAL|1|Dietary instruction (low-energy diet. This is given by instructions in groups of 8
62011654|NCT03798431|EXPERIMENTAL|M-ROCC|Mindful Recovery OUD Care Continuum (M-ROCC) builds on other mindfulness interventions for addictive disorders, but is specifically designed with the clinical needs of OUD patients on buprenorphine and logistic needs of primary care OBOT clinicians in mind. It focuses on integration of mindfulness practice for living well through stress, anxiety, depression, pain and addiction recovery. M-ROCC curriculum has three primary components, including a low-dose mindfulness phase, an intensive mindfulness training phase and then ongoing mindful recovery support.
62011655|NCT04651959|EXPERIMENTAL|AVICOD then AVIGAN|Participants first received AVICOD 200 mg FT manufactured by Pharma Plant in a fasting state. After a washout period of 24 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state.
62199282|NCT06179225|EXPERIMENTAL|HMD AR|Pairs of older adults with their designated family members who geographically apart will perform collaborative activities using HMD AR in 8 sessions over 4 weeks.
62577297|NCT00655941|ACTIVE_COMPARATOR|2|Exercise
62577298|NCT00655941|NO_INTERVENTION|3|Control
62199283|NCT06179225|ACTIVE_COMPARATOR|2-D Audio-Visual|Pairs of older adults with their designated family members who geographically apart will perform collaborative activities using 2-D Audio-Visual in 8 sessions over 4 weeks.
62199284|NCT04976647|ACTIVE_COMPARATOR|A arm: HLX10+chemo|Participants receive 300mg HLX10 IV every 3 weeks (Q3W) in combination with carboplaitin (AUC5 or 6) IV Q3W and nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle.
62577299|NCT01965340|EXPERIMENTAL|Patients with systematic TDM of anti-infective agents|Patients with systematic TDM of anti-infective agents and dosages adapted accordingly
62577300|NCT01965340|NO_INTERVENTION|Patients treated as usual|
62577301|NCT04478721|EXPERIMENTAL|Temocillin|Patients enrolled in this arm, will receive 2g each 8 hours of intravenous temocillin.
62784237|NCT06013384|EXPERIMENTAL|Active/Active Group|This group will receive eight total treatments of LIFUP across two days one week apart (four treatments each day).
62784238|NCT06013384|OTHER|Sham/Active Group|This group will receive sham LIFUP for four treatments over one day, followed by four total treatments of active LIFUP across one day one week after sham.
62784239|NCT05603598|PLACEBO_COMPARATOR|Placebo|IV infusion of saline, approximately 5.5 hours
62784240|NCT05603598|EXPERIMENTAL|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, approximately 5.5 hours
62011656|NCT04651959|EXPERIMENTAL|AVIGAN then AVICOD|Participants first received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 24 hours, they then received AVICOD 200 mg FT manufactured by Pharma Plant in a fasting state.
62011657|NCT06337617||Cohort A (mucosal melanoma patients)|
62011658|NCT06337617||Cohort B (non-mucosal melanoma patients)|
62199285|NCT04976647|EXPERIMENTAL|B arm: HLX10+HLX07+chemo|Participants receive 300mg HLX10 IV Q3W plus 1500mg HLX07 IV Q3W with chemo.
62577302|NCT04478721|ACTIVE_COMPARATOR|Meropenem|Patients enrolled in this arm, will receive 1g each 8 hours of intravenous meropenem.
62011659|NCT05164705|ACTIVE_COMPARATOR|Intermittent Hypoxia|Participant will visit our center 2-4 times per week for three weeks to receive Acute Intermittent Hypoxia.
62011660|NCT05164705|SHAM_COMPARATOR|Sham Intermittent Hypoxia|Participants will visit our center 2-4 times per week for three weeks to receive Sham Intermittent Hypoxia.
62199286|NCT04976647|EXPERIMENTAL|C arm: HLX10+HLX07|Participants receive 300mg HLX10 IV Q3W plus 1500mg HLX07 IV Q3W.
62199287|NCT02931253|EXPERIMENTAL|Metformin Group|"Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.~Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks."
62199288|NCT02931253|NO_INTERVENTION|Control Group|Standard of care - ablation only
62199289|NCT04953962|EXPERIMENTAL|Arm 1: CBP501 (25) + Cisplatin + Nivolumab|CBP501 25mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously. Nivolumab 240mg will be administered following the completion of CBP501 and cisplatin infusions.
62577303|NCT02923453|PLACEBO_COMPARATOR|Placebo|1g/meal of placebo three times per day (3g/day) for 8-weeks.
62577304|NCT02923453|ACTIVE_COMPARATOR|Ginseng Extract|CNT2000 (Chai-Na- Ta Corp., Langley, BC) American ginseng extract 1g/meal of placebo three times per day (3g/day) for 8-weeks.
62577305|NCT04156906|EXPERIMENTAL|D+ RH genotype matched Red Blood Cell Transfusion|Investigators will provide one red cell unit of D+ RH genotype matched RBCs at the first transfusion study visit. The remainder of units will be provided per clinical standard of care, i.e. D-, CEK-matched, and negative for all other antigens the patient is alloimmunized against. If laboratory monitoring shows no reappearance of anti-D and no signs of increased red cell hemolysis, the patient will receive one unit of D+ RH genotype matched RBCs at the 2nd transfusion study visit, and if tolerated, D+ red cell exposures will increase by one unit per study visit until all units required are D+.
62577306|NCT00247221|EXPERIMENTAL|1) MI/Family Check-Up|Brief integrated individual and family intervention -- the experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up
62577307|NCT00247221|ACTIVE_COMPARATOR|2) MI only|
62577308|NCT04088695|EXPERIMENTAL|Intervention|The arm exposed to the intervention video
62577309|NCT04088695|ACTIVE_COMPARATOR|Control|The control group exposed an informative text.
62577310|NCT00641602|EXPERIMENTAL|1|Nexium
62784241|NCT05775731||shift worker|- shift worker: works at least 60 nights per year Each subject will have blood taken twice (before and after the night-shift), and will answer three questionnaires \[Pittsburgh Sleep Quality Index, Generalized Anxiety Disorder-7 (GAD-7) for anxiety disorder and a general health questionnaire\]
62784242|NCT05775731||daily worker|- daily worker: does not work at night (from 8 pm to 6 am) Each subject will have blood taken once, and will answer three questionnaires (Pittsburgh Sleep Quality Index, GAD-7 for anxiety disorder and a general health questionnaire)
62784243|NCT03139344|EXPERIMENTAL|Acute gene regulation: low frequency|Adaptations in gene regulation in response to single-session low-frequency exercise.
62784244|NCT03139344|EXPERIMENTAL|Acute gene regulation: high frequency|Adaptations in gene regulation in response to single-session high-frequency exercise.
62011661|NCT06531707|EXPERIMENTAL|Ibuprofen + Loratadine|Administered orally (suspension), 5 mL twice a day, for 7 days.
62577311|NCT00641602|ACTIVE_COMPARATOR|2|Prevacid
62199290|NCT04953962|EXPERIMENTAL|Arm 2: CBP501 (16) + Cisplatin + Nivolumab|CBP501 16mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously. Nivolumab 240mg will be administered following the completion of CBP501 and cisplatin infusions.
62199291|NCT04953962|EXPERIMENTAL|Arm 3: CBP501 (25) + Cisplatin|CBP501 25mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously.
62199292|NCT04953962|EXPERIMENTAL|Arm 4: Cisplatin + Nivolumab|Cisplatin 60mg/m2 will be administered as infusion and then Nivolumab 240mg will be administered.
62199293|NCT03831542||direct aspiration group|Transvaginal ultrasound-guided oocyte retrieval was performed 36 hours after ovulation trigger. A 17-gauge double lumen needle will be used to aspirate a single follicle without flushing. If an oocyte is obtained, the subject will be assigned to group 1. If not, operator will proceed with follicular flushing.
62199294|NCT03831542||flushing group|If an oocyte is not obtained with direct aspiration, operator will proceed to follicular flushing and the subject will be assigned to group 2 if an oocyte is obtained following follicular flushing.
62577312|NCT05855954|EXPERIMENTAL|intervention group|"First,20min after the end of cardiopulmonary bypass, on the basis of ensuring that the mean arterial pressure (MAP) ≥ 60mmHg, the patients will accept dorsal elevated position.~After that, if the patient's CVP is less than 10mmHg, nitroglycerin will be pumped at 0.2ug/ (kg \* min). If the patient's CVP is still greater than or equal 10mmHg, we increase the dose by 0.2ug/ (kg \* min) and pump again for 5min, and the like. Until the patient's CVP is less than 10mmHg or the dose of nitroglycerin increases to 1ug/ (kg \* min), the current dose is maintained until the end of surgery."
62577313|NCT05855954|NO_INTERVENTION|control group|no intervention measures
62577314|NCT00039871|EXPERIMENTAL|Overall study population|
62784245|NCT03139344|EXPERIMENTAL|Training study: low frequency|Adaptations in gene regulation, systemic metabolic markers, and patient-report metrics in response to training with low-frequency exercise.
62011662|NCT06531707|ACTIVE_COMPARATOR|Ibuprofen|Administered orally (suspension), 20 mL, twice a day for 7 days.
62784246|NCT03139344|EXPERIMENTAL|Training study: high frequency|Adaptations in gene regulation in response to training with high-frequency exercise.
62199295|NCT03388476||Suspicion of pulmonary hypertension|At Patients with suspicion of pulmonary hypertension, which get a right heart catheterization, in the context of the study the exhaled air, precious the endtidal carbon dioxide (CO2), before or after the right heart catheterization will be measured through capnography.
62199296|NCT00867984|EXPERIMENTAL|1|Torsion-guided VV optimization plus AV optimization.
62199297|NCT00867984|ACTIVE_COMPARATOR|2|AV optimization only.
62577315|NCT05918601|EXPERIMENTAL|Intervention group|Each participant will receive the telephone that will be delivered by a trained peer supporter using the Ask, Warn, Advise, Refer and Do-it-Again (AWARD) model. For the advice steps, participants will be asked about the priority they place on engagement in health-related lifestyles. A brief intervention on the selected health-related lifestyle will be given. In addition, they will be informed that they will receive instant messaging via WeChat or WhatsApp to assist them to adhere to their schedule of the desirable health-related lifestyle throughout the study period. For the first 6 months of the study period, peer supporters will send WhatsApp or WeChat messages approximately once per week to the participants to remind them to adhere to their schedule of the desirable health-related lifestyle. In addition, the participants will receive four independent 1-minute videos which focus on the health risks associated with abusing drugs and the benefits of quitting drugs.
62199298|NCT01227291|EXPERIMENTAL|SYL040012|SYL040012 Ophthalmic drop administration
62784247|NCT03139344|NO_INTERVENTION|Comparator cohort|Participants will undergo selected outcome measures to provide comparison values for Experimental arms.
62784248|NCT03212534|EXPERIMENTAL|Prediction Algorithm|
62784249|NCT03212534|NO_INTERVENTION|Control|
62784250|NCT00604695|ACTIVE_COMPARATOR|1|Two (4mg) doses of tenecteplase
62784251|NCT00604695|PLACEBO_COMPARATOR|2|Two (4mL) doses of sterile saline
62784252|NCT02023684|PLACEBO_COMPARATOR|control|Irrigation will be carried out with saline
62784253|NCT02023684|ACTIVE_COMPARATOR|Lidocaine|Irrigation will be carried out with Lidocaine
62784254|NCT02023684|ACTIVE_COMPARATOR|Ropivacaine|Irrigation will be carried out with Ropivacaine
62784255|NCT01007838|EXPERIMENTAL|Chronic kidney disease progressive resistance training group|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
62784256|NCT01007838|SHAM_COMPARATOR|Chronic kidney disease sham exercise group|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
62784257|NCT01007838|EXPERIMENTAL|Healthy controls progressive resistance training group|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
62011663|NCT06531707|ACTIVE_COMPARATOR|Loratadine|Administered orally (suspension), 5 mL, twice a day for 7 days
62199299|NCT03454841||Prasugrel|Patients with myocardial infarction will receive prasugrel as a part of dual antiplatelet therapy with aspirin.
62199300|NCT03454841||Ticagrelor|Patients with myocardial infarction will receive ticagrelor as a part of dual antiplatelet therapy with aspirin.
62199301|NCT05137314|EXPERIMENTAL|3 mg/mL PLG0206|administered intraoperatively by local irrigation
62199302|NCT05137314|EXPERIMENTAL|10 mg/mL PLG0206|administered intraoperatively by local irrigation
62199303|NCT04708951|ACTIVE_COMPARATOR|ECV colonoscopy|EndoCuff Vision® device (ECV)
62784258|NCT01007838|SHAM_COMPARATOR|Healthy controls sham exercise group|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
62577316|NCT05918601|PLACEBO_COMPARATOR|Control Group|Trained peer supporters will answer calls from potential participants and explain the nature and purpose of the project to them. Each participant will then receive a brief intervention over the telephone that will be delivered by a trained peer supporter using the Ask, Warn, Advise, Refer and Do-it-Again (AWARD) model. Participants will be asked to quit drugs immediately or progressively. In addition, they will be informed that they will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of quitting drugs throughout the study period. For the first six months, participants will receive four independent 1-minute videos which focus on the health risks associated with abusing drugs and the benefits of quitting drugs without any schedule of the desirable health-related lifestyle throughout the study period.
62011664|NCT06657274|EXPERIMENTAL|tele@cognitive treatment|The tele@cognitive treatment group will receive a total of 5 weeks (3 sessions/week, 45 minutes/session) of home-based cognitive rehabilitation activities delivered through a digital telerehabilitation platform.
62011665|NCT06657274|ACTIVE_COMPARATOR|Active Control Group (ACG)|The Active Control Group (ACG), will receive at-home unstructured cognitive stimulation for 5 weeks (3 sessions/week, 45 minutes/session).
62199304|NCT04708951|EXPERIMENTAL|G-EYE® colonoscopy|G-EYE® colonoscope (G-EYE)
62199305|NCT03714568|EXPERIMENTAL|TQ-A3326|TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）
62199306|NCT03714568|EXPERIMENTAL|placebo|Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)
62011666|NCT04104139|EXPERIMENTAL|Treatment (TAS-102, IMRT, 3D-CRT)|Patients receive TAS-102 PO BID Monday-Friday on weeks 1, 3, and 5. Patients also undergo IMRT or 3D-CRT 5 days per week on weeks 1-5. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care FOLFOX or CAPOX.
62199307|NCT03078569|EXPERIMENTAL|testosterone gel|testosterone gel treatment group
62199308|NCT03078569|NO_INTERVENTION|Control group|without testosterone treatment
62199309|NCT00005977|EXPERIMENTAL|STAGE III NHL (Trt 1)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABA"
62199310|NCT00005977|EXPERIMENTAL|STAGE IV NHL, -CNS (Trt 2)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABAB"
62199311|NCT00005977|EXPERIMENTAL|STAGE IV, +CNS (Trt 3)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy. C: Etoposide, Ifosfamide, Dexamethasone IT Therapy.~Treatment ABCABAB"
62577317|NCT02693028|ACTIVE_COMPARATOR|probiotic lozenge|Two probiotic lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
62011667|NCT03767959|EXPERIMENTAL|Chen's U-Suture|Patients in this group will treated by Chen's U-suture technique in pancreaticojejunostomy.
62011668|NCT03767959|ACTIVE_COMPARATOR|Classic pancreatic duct to mucosa|Patients in this group will treated by classic pancreatic duct to mucosa technique in pancreaticojejunostomy.
62199312|NCT00005977|EXPERIMENTAL|B-ALL, -CNS (Trt 2)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABAB"
62199313|NCT00005977|EXPERIMENTAL|B-ALL, +CNS (Trt 3)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy. C: Etoposide, Ifosfamide, Dexamethasone IT Therapy.~Treatment ABCABAB"
62199314|NCT05858684|EXPERIMENTAL|GC012F injection (CD19-BCMA CAR-T cells)|"Dose escalation phase:~DL-1：0.5±20%×10\^5/kg, DL1：1±20%×10\^5/kg, DL2：2±20%×10\^5/kg DL3：3±20%×10\^5/kg"
62784259|NCT06077890|EXPERIMENTAL|Digital Intervention Group|This group incorporates the SIMPLI.REHAB digital tool as a complementary strategy for a rehabilitation program, including flexibility exercises and muscle strengthening, manual dexterity and motor coordination training, thermotherapy, and education on joint protection principles.
62011669|NCT01248117|EXPERIMENTAL|Previously Treated|With prior anti-vegf therapy, only, no sooner than 30 days prior to enrollment into trial
62011670|NCT01248117|EXPERIMENTAL|Treatment-Naive|Treatment-Naive: no previous treatment for PCV
62011671|NCT03198611||Normal function|No systolic dysfunction No diastolic dysfunction No right ventricular dysfunction
62199315|NCT05524662|EXPERIMENTAL|BTL-785-7 Treatment|Subjects will be enrolled for an active treatment with BTL-785F device (BTL-785-7 applicator) for non-invasive facial rejuvenation.
62199316|NCT05524662|NO_INTERVENTION|Control|One subject will serve as a control.
62199317|NCT05661318||BHS|Residents of Ballana from the 1,200 randomly selected households
62199318|NCT03289351|NO_INTERVENTION|2-drug Therapy|ceftriaxone/metronidazole
62199319|NCT03289351|EXPERIMENTAL|1-drug Therapy|piperacillin-tazobactam
62199320|NCT04433299||low back pain patients|no intervention
62199321|NCT04433299||controls|no intervention
62577318|NCT02693028|ACTIVE_COMPARATOR|Probiotic capsule|Two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
62199322|NCT03471546|EXPERIMENTAL|Palliative care|Newly diagnosed patients will be referred to a palliative care provider in the clinic for initial consultation and follow-up during their initial treatment for WHO Grade IV malignant glioma. Patients will be asked to complete a number of questionnaires and assessment forms at different time intervals during the course of their initial treatment. In addition, we will ask patients' neuro-oncology providers for feedback regarding their satisfaction with the Palliative Care services provided to the patient.
62011672|NCT03198611||Left ventricular systolic dysfunction|Left ventricular ejection fraction \< 50%
62011673|NCT03198611||Left ventricular diastolic dysfunction|"Classification according to:~* Mitral lateral annulus e' in tissue Doppler \< 10 cm/s~* American society of echocardiography (ASE) criteria 2009~* ASE criteria 2016"
62011674|NCT03198611||Right ventricular dysfunction|Tricuspid annulus plane systolic excursion \< 17 cm
62011675|NCT04382612|OTHER|HARPOON MVRS|Subjects who were treated with the HARPOON MVRS.
62011676|NCT02694991|EXPERIMENTAL|OMT Group|Osteopathic Manipulative Treatment 15 minutes once a day for 8 days
62011677|NCT02694991|NO_INTERVENTION|Control Group|No intervention, only usual care
62011678|NCT03377335|EXPERIMENTAL|Dapagliflozin|"Dapagliflozin (10mg daily) as add-on to metformin (stable doses ranging from 1500 to 3000 mg daily).~The total duration of treatment is 6 months."
62011679|NCT03377335|PLACEBO_COMPARATOR|Metformin alone|"Metformin alone (stable doses ranging from 1500 to 3000 mg daily).~The total duration of treatment is 6 months."
62011680|NCT03894059||Retrospective|Consecutive cases of out-of-hospital cardiac arrest occurring at participating sites, meeting the study eligibility criteria over a 12-month period preceding the implementation of the educational intervention for ambulance telecommunicators.
62011681|NCT03894059||Prospective|Consecutive cases of out-of-hospital cardiac arrest occurring at participating sites, meeting the study eligibility criteria over a 12-month period following the implementation of the educational intervention for ambulance telecommunicators.
62011682|NCT05580913|EXPERIMENTAL|Subjective auto-regulation training|Participants complete their resistance-training sets to termination based on rating of perceived exertion
62011683|NCT05580913|EXPERIMENTAL|Objective auto-regulation training|Participants complete their resistance-training sets to termination based on reaching a critical slow velocity
62011684|NCT05580913|ACTIVE_COMPARATOR|Traditional standardized training|Participants complete their resistance-training sets by lifting a prescribed percentage of their estimated one-repetition maximum (as determined from baseline four-repetition maximum strength testing)
62011685|NCT05750524|EXPERIMENTAL|reflexology|In the reflexology group, reflexology hand massage applied between two suctioning period
62011686|NCT05750524|PLACEBO_COMPARATOR|classical massage|In the classical massage group, classical hand massage applied between two suctioning period
62011687|NCT00881309|EXPERIMENTAL|immunosuppressor|
62011688|NCT04300400||Delphi panel|Urologists of the Belgian Working group of Functional Urology willing to participate on the Delphi project.
62011689|NCT01396616|EXPERIMENTAL|Single Arm|The enrolled subject will be implanted with Toric IOL manufactured by AuroLab
62011690|NCT05520476||20 patients with at least two seizures per week.|The device collects vital signs and EEG data as well as caregiver information associated with seizure episodes.
62011691|NCT00061490|EXPERIMENTAL|1|16 weekly educational meetings
62011692|NCT00061490|NO_INTERVENTION|2|Wait list control
62011693|NCT04375423|EXPERIMENTAL|Intervention|On smartphones, participants in this arm will receive twice daily and weekly prompts to report on behaviors under study and be able to send self-initiated event-contingent reports on behaviors under study. In response to the behaviors they report, they receive messages on their smartphones supporting ongoing healthy behaviors or suggesting alternative behaviors to limit risks. They will complete in-person assessments at enrollment, 30-days and study exit at 90-days.
62011694|NCT04375423|ACTIVE_COMPARATOR|Control|On smartphones, participants in this arm will receive twice daily and weekly prompts to report on behaviors under study and be able to send self-initiated event-contingent reports on behaviors under study. They will complete in-person assessments at enrollment, 30-days and study exit at 90-days.
62199323|NCT05661435||Participants|
62199324|NCT05636553|EXPERIMENTAL|Massage|Women will receive four 60 minute massage consultations within a four-month period at intervals of their choosing.
62577319|NCT02693028|ACTIVE_COMPARATOR|Probiotic chewing gum|The probiotic chewing gum should be chewed on for about 10 minutes. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
62011695|NCT06005259|EXPERIMENTAL|Intervention|Participants will be administered 25 mg of spironolactone daily for 12 months, beginning 5 to 15 days prior to chemotherapy.
62011696|NCT06005259|PLACEBO_COMPARATOR|Control|Participants will be given placebo daily for 12 months, beginning 5 to 15 days prior to chemotherapy.
62199325|NCT02015507|ACTIVE_COMPARATOR|Cohort 1|participants in Cohort 1 will be administered ivacaftor alone followed by ivacaftor with concomitant ciprofloxacin.
62199326|NCT02015507|EXPERIMENTAL|Cohort 2|Participants in Cohort 2 will be administered VX-661 in combination with ivacaftor followed by VX-661 in combination with ivacaftor and concomitant ciprofloxacin
62199327|NCT03264937|EXPERIMENTAL|Social-software management group|We set up a mini-program based on wechat application. We instruct warfarin therapy via social-software including dose adjustment, answer questions, remind monitoring INR et.al.
62199328|NCT03264937|NO_INTERVENTION|Routine management group|This is the control group, Warfarin therapy was managed via traditional style without social software intervention.
62199329|NCT04313257|ACTIVE_COMPARATOR|Passive Occlusion|This arm will include those participants who will follow a daily occlusive treatment of 2 hours.
62199330|NCT04313257|EXPERIMENTAL|Active Occlusion|This arm will include patients who will be treated with monocular therapy with video-games of one hour on a daily regimen.
62199331|NCT04311710|EXPERIMENTAL|Part 1 Arm A: mM, mUC, HCC|metastatic Melanoma (mM), metastatic Urothelial Carcinoma (mUC), and advanced Heptocellular Carcinoma (HCC)
62577320|NCT02693028|PLACEBO_COMPARATOR|Placebo lozenge|Two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
62784260|NCT06077890|ACTIVE_COMPARATOR|Conventional Intervention Group|This group follows a conventional rehabilitation program delivered in a more traditional, non-digital manner to serve as a comparison to assess the superiority of the experimental intervention using SIMPLI.REHAB digital tool.
62784261|NCT02782221|ACTIVE_COMPARATOR|Growth hormone|Subjects are receiving growth hormone
62784262|NCT02782221|PLACEBO_COMPARATOR|Placebo|Subjects are receiving pegvisomant to block the action of growth hormone
62784263|NCT02141360|EXPERIMENTAL|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
62784264|NCT02141360|PLACEBO_COMPARATOR|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
62784265|NCT03854461|ACTIVE_COMPARATOR|Educational material|Participants will be given written educational material to encourage dietary change towards a better quality diet. Educational material will be adapted from resources used in previous dietary intervention studies.
62011697|NCT06209112||Conventional group' (Group C)|The 'conventional' group (Group C): FGF will be set to 6 L/min and the FVS 3% at Tzero. The FGF will be reduced to 0.5 L/min upon reaching FAS 2%. Hereafter, the FVS will be set to 4% and maintained till 15 min (T15) from Tzero.
62011698|NCT06209112||Over-pressure group' (Group OP)|"The 'over-pressure' group (Group OP): FGF will be set to 0.5 L/min and FVS 8% at Tzero.~Subsequently, the FVS will be set to 4% upon reaching FAS 2% and maintained till 15 min (T15) from Tzero."
62011699|NCT03745703|EXPERIMENTAL|MOCHA|Behavioral: 12-week trial with 3 sessions per week with one small group discussion session of critical issues affecting African-American men's health each week combined with two aerobic exercise sessions each week
62011700|NCT03745703|EXPERIMENTAL|"MOCHA+, Stories Matter"|Behavioral: 12-week trial with 3 sessions per week with one small group discussion session of critical issues affecting African-American men's health each week combined with two aerobic exercise sessions each week
62011701|NCT03745703|NO_INTERVENTION|Wait-list control|There is no intervention to be administered during the 12-week wait-list control period
62011702|NCT05696015|ACTIVE_COMPARATOR|Standard education|Standard education group will be carried out at discharge, discharge orientation of the patient with diabetes and application of the Diabetes Self-Care Activity Questionnaire (QAD). For this group, a new contact will be made within 30 days after discharge, where the QAD will be applied again.
62011703|NCT05696015|EXPERIMENTAL|Amplied education|Amplied education group will be performed at the time of discharge, guidance for discharge of patients with diabetes. This group will receive 3 contacts, the first will be carried out within 72 hours after discharge, the second contact within 10 days after the first contact and the third within 30 days after discharge, where diabetes education guidelines will be given to the patient in all contacts. At the time of discharge, and in the third contact, 30 days, the QAD will also be applied.
62011704|NCT03950024|EXPERIMENTAL|with arthrogenic Muscle Inhibition|
62199332|NCT04311710|EXPERIMENTAL|Part 1: Arm B: mM|metastatic Melanoma (mM)
62199333|NCT04311710|EXPERIMENTAL|Part 2: Arm A: NSCLC|metastatic non small cell lung cancer (NSCLC)
62199334|NCT04311710|EXPERIMENTAL|Part 2: Arm B: RCC|advanced or metastatic renal cell carcinoma (RCC)
62577321|NCT02693028|PLACEBO_COMPARATOR|Placebo capsule|Two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
62784266|NCT03854461|EXPERIMENTAL|Personalised dietary advice and educational material|Participants will also be given the educational material, but will be encouraged to make dietary change using individualized recommendations incorporating food markers of specific components of a high quality diet. Food markers of diet quality will be used to develop an algorithm to deliver personalized dietary advice. Based on biomarker data, a system of categorization of biomarker status will be developed, alongside dietary advice related to this biomarker categorization, and decision trees created, as previously described in the Food4Me study, to ensure standardized delivery of advice within this intervention arm.
62784267|NCT05670613|OTHER|Dispense Ready to Use PN Solutions|Dispensed to patient commercial solution.
62784268|NCT05670613|OTHER|Dispense the most effective commercial Solution calculated with the use of the CDSS|Dispensed to patient the most effective commercial solution after the CDSS calculations.
62199335|NCT05109000|EXPERIMENTAL|Normal Saline|This is a randomized, double-blind, single-center clinical trial comparing normal saline and bacteriostatic saline subcutaneous injection within a single subject. In this arm, the subject will receive a 10 mL subcutaneous injection of normal saline into either their left or right anterior thigh. The side will be determined by randomization protocol.
62199336|NCT05109000|EXPERIMENTAL|Bacteriostatic Saline|This is a randomized, double-blind, single-center clinical trial comparing normal saline and bacteriostatic saline subcutaneous injection within a single subject. In this arm, the subject will receive a 10 mL subcutaneous injection of bacteriostatic saline into either their left or right anterior thigh. The side will be determined by randomization protocol.
62011705|NCT03950024|ACTIVE_COMPARATOR|without arthrogenic Muscle Inhibition|
62011706|NCT02340559|EXPERIMENTAL|Meta-cognitive Training|"The metacognitive training program is comprised of eight modules targeting common cognitive errors in schizophrenia. The modules are : attributional distortions (module 1), a jumping to conclusions bias (module 2 and 7), a bias against disconfirmatory evidence (module 3), deficits in theory of mind (module 4 and 6), over-confidence in memory errors (module 5) and depressive cognitive patterns (module 8).~The treatment group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group."
62011707|NCT02340559|ACTIVE_COMPARATOR|Psychoeducational group|In the control group the modules worked were: 1. Healthy Habits, 2. Risk Behaviors, 3. Prevention of relapse, 4 and 5.Videoforum, 6. Resources of work and development of curriculum vitae 7. Leisure activities, and 8. Resources of the community. The psychoeducational group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group.
62011708|NCT06078397|EXPERIMENTAL|the Remote Programming (RP) group|After implantation of DBS and train for RP in hospital, regularly receive RP instead of in-visit SP for parameter adjustment in 1, 3, 6 month after surgery
62011709|NCT06078397|ACTIVE_COMPARATOR|the Standard Programming (SP) group|After implantation of DBS, regularly receive SP for parameter adjustment in 1, 3, 6 month after surgery
62011710|NCT02932397|ACTIVE_COMPARATOR|Propofol|Active drug given to patients as an intravenous dose of 0.5 mg/kg of propofol
62011711|NCT02932397|PLACEBO_COMPARATOR|Saline solution|Placebo drug given to patients as an intravenous dose of 0.05 mL/kg of saline solution (NaCl 0.9%)
62011712|NCT05833984|EXPERIMENTAL|Dose Escalation Part|Mutiple dose level cohorts in the dose escalation part
62011713|NCT05833984|EXPERIMENTAL|Head and neck squamous cell carcinoma, nasopharyngeal carcinoma|Dose expansion cohort with IMM01 plus Tislelizumab
62011714|NCT05833984|EXPERIMENTAL|Ovarian carcinoma|Dose expansion cohort with IMM01 plus Tislelizumab
62011715|NCT05833984|EXPERIMENTAL|Non small cell lung carcinoma, small cell lung carcinoma|Dose expansion cohort with IMM01 plus Tislelizumab
62011716|NCT05833984|EXPERIMENTAL|Hepatocellular carcinoma|Dose expansion cohort with IMM01 plus Tislelizumab
62011717|NCT05833984|EXPERIMENTAL|Other solid tumors|Dose expansion cohort with IMM01 plus Tislelizumab
62011718|NCT05833984|EXPERIMENTAL|Classic hodgkin lymphoma|Dose expansion cohort with IMM01 plus Tislelizumab
62011719|NCT01895894|EXPERIMENTAL|Mycophenolate mofetil|
62011720|NCT01895894|NO_INTERVENTION|Control|
62011721|NCT06573671||Injecting drug induced histiocytosis|No intervention
62011722|NCT01455675|EXPERIMENTAL|IgY, gargling solution|Avian polyclonal anti-pseudomonas antibodies (IgY), 70 ml gargling solution contains 50 mg IgY with an activity against PA, once daily
62011723|NCT01455675|PLACEBO_COMPARATOR|Placebo, gargling solution|70 ml gargling solution without antibodies, once daily
62011724|NCT00834301|EXPERIMENTAL|Treatment Arm|
62011725|NCT05750693|EXPERIMENTAL|Patients who received neoadjuvant chemotherapy|Breast cancer samples of paraffin embedded tissue, obtained from the waste material of the diagnostic core-biopsy, stored at the Pathological Anatomy Service, will be used in order to analyze PIK3CA mutations status.
62011726|NCT01524640|EXPERIMENTAL|Killed oral cholera vaccine|"Killed Bivalent (O1 and O139) Whole cell oral cholera vaccine (Shanchol TM) Vaccine strain Reformulated version~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) of lipopolysaccharide (LPS) V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
62199337|NCT03285555|ACTIVE_COMPARATOR|STRATAFIX GROUP|For the active arm of the study, wound closure will be performed similarly in 3 layers with the use of barbed equivalents at every layer: STRATIFIX symmetric PDS Plus #1 will be used to close the deep fascia and muscles . The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson \& Johnson) followed by the use of steri-strips and glue
62199338|NCT03285555|PLACEBO_COMPARATOR|CONTROL GROUP|For the control arm of the study, wound closure will be performed similarly in 3 layers with the use of vicryl to closure the deep fascia and muscles. The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson \& Johnson) followed by the use of steri-strips and glue
62199339|NCT01271504|ACTIVE_COMPARATOR|Phase Ib: Cohort 1,2, and 3|Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib
62577322|NCT04947774||prophylactic cranial irradiation group|The extensive-stage SCLC patients will receive prophylactic cranial irradiation after standard first-line chemotherapy combined with immunotherapy, until disease progression or death.
62784269|NCT02842749|EXPERIMENTAL|everolimus (single arm)|Everolimus is taken at a starting dose of 10 mg orally once daily.Patients will be provided with adequate supply of study treatment for self-administration at home until at least their next scheduled study visit.All patients will be followed for adverse events and serious adverse events for 30 days following the last dose of study drug. Beyond these 30 days, any serious adverse events that are suspected to be related to the study drug will also be collected
62784270|NCT00866814||Ventrio Group|Patients diagnosed with a ventral hernia requiring an open surgery for repair.
62199340|NCT01271504|ACTIVE_COMPARATOR|Phase II: Arm 1; E7050 + Sorafenib|Phase II: Arm 1; E7050 + 400 mg Sorafenib Arm 2; 400 mg Sorafenib
62199341|NCT02143661||Critically ill patients in the newly designed ICU rooms|Critically ill patients treated in one of the newly designed ICU rooms.
62199342|NCT02143661||Critically ill patients in the conventional ICU rooms|Critically ill patients treated in one of the conventional rooms on the same ICU.
62199343|NCT04828941|EXPERIMENTAL|Electronic Headache Diary|The electronic headache diary registers: total number of days with headache per month, number of days with migraine per month, number of days with tension headache per month, number of days taking SOS medication per month, number of days with incapacity for work per month, number of days in which patient goes to the emergency department.
62784271|NCT04854382|ACTIVE_COMPARATOR|Intervention group|Tailored information about coronavirus using information videos followed by a teach-back procedure
62199344|NCT04828941|ACTIVE_COMPARATOR|Paper Diary|The paper headache diary registers: total number of days with headache per month, number of days with migraine per month, number of days with tension headache per month, number of days taking SOS medication per month, number of days with incapacity for work per month, number of days in which patient goes to the emergency department.
62199345|NCT03730506|EXPERIMENTAL|CBCT|
62199346|NCT03730506|EXPERIMENTAL|IOS|
62577323|NCT04947774||Observation group|Patients with extensive-stage SCLC do not receive preventive craniocerebral irradiation after standard first-line chemotherapy combined with immunotherapy until the disease progresses or death.
62577324|NCT00936143|EXPERIMENTAL|infliximab|200mg infliximab inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
62784272|NCT04854382|NO_INTERVENTION|Control group|Controls have access to information videos, but do not receive the teach-back procedure (the intervention)
62784273|NCT01716780|NO_INTERVENTION|Routine care|"Patients allocated to the control group will undergo their 'usual care'; they will be given pain medication when they specifically request it or when their oncology doctor/ nurse or GP considers it appropriate to prescribe it, either at the oncology clinic visit or at any time during the course of the study."
62784274|NCT01716780|EXPERIMENTAL|Intervention|"Patients allocated to the intervention group will be reviewed by the pain/palliative care team and will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care."
62784275|NCT00384332|EXPERIMENTAL|Arm 1|Orally disintegrating olanzapine
62784276|NCT00384332|EXPERIMENTAL|Arm 2|regular olanzapine
62784277|NCT04072887|EXPERIMENTAL|QBW251 450 mg|QBW251 was orally administered 450 mg b.i.d for 24 weeks
62784278|NCT04072887|EXPERIMENTAL|QBW251 300 mg|QBW251 was orally administered 300 mg b.i.d for 24 weeks
62784279|NCT04072887|EXPERIMENTAL|QBW251 150 mg|QBW251 was orally administered 150 mg b.i.d for 24 weeks
62784280|NCT04072887|EXPERIMENTAL|QBW251 75 mg|QBW251 was orally administered 75 mg b.i.d for 24 weeks
62784281|NCT04072887|EXPERIMENTAL|QBW251 25 mg|QBW251 was orally administered 25 mg b.i.d for 24 weeks
62784282|NCT04072887|PLACEBO_COMPARATOR|Placebo|Placebo was orally administered b.i.d for 24 weeks
62784283|NCT01678625||Acceleromyography group|Train-of-four ratio calculation (TOF-Watch-SX-Bluestar enterprise)
62784284|NCT01678625||Electromyography group|Train-of-four ratio calculation (T4-EMG)
62784285|NCT04692532|EXPERIMENTAL|8-hour Time restricted eating|Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
62199347|NCT03730506|ACTIVE_COMPARATOR|desktop scanner|
62199348|NCT02330094|EXPERIMENTAL|Gabapentin|Gabapentin capsules 100 mg ter in die (TID), 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
62199349|NCT02330094|PLACEBO_COMPARATOR|Control|Placebo capsules 100 mg ter in die (TID), 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
62199350|NCT02963090|ACTIVE_COMPARATOR|Topotecan|Topotecan IV at 1265mg/m\^2 Days 1-5 of every 21 day cycle
62784286|NCT04692532|EXPERIMENTAL|Calorie restriction|25% energy restriction every day
62784287|NCT04692532|NO_INTERVENTION|Control|Usual diet, Ad libitum intake, eating within \>10 hours per day
62784288|NCT06524323|OTHER|Control side|Intralesional injection of triamcinolone acetonide alone
62784289|NCT06524323|EXPERIMENTAL|Experimental side|Intralesional injection of 5-fluorouracil plus triamcinolone acetonide
62784290|NCT05762406|EXPERIMENTAL|Wearing mask|Subjects will perform a cardiopulmonary exercise test (CPET) and a series of standardized daily activities while wearing a protective mask
62784291|NCT05762406|NO_INTERVENTION|Not wearing mask|Subjects will perform a cardiopulmonary exercise test (CPET) and a series of standardized daily activities in basal conditions
62784292|NCT01847976|EXPERIMENTAL|Doxycycline|100 mg of Doxycycline orally twice a day for 12 weeks.
62784293|NCT06247904|ACTIVE_COMPARATOR|Active rTMS|10 daily sessions of High-frequency Transcranial Magnetic Stimulation (HF-rTMS) applied bilaterally over the hand primary motor area informed by e-field modelling and targeting will be aided by neuronavigation system for precise targeting during each intervention session. Active group will receive HF-rTMS intensity calculated using electric field modelling to create electric field intensity of approximately motor threshold, using the cool-B65 A/P rTMS coil.
62199351|NCT02963090|EXPERIMENTAL|Pembrolizumab|Pembrolizumab IV 200mg infusion Day 1 of every 21 day cycle
62199352|NCT03149575|EXPERIMENTAL|VAL-083, Dianhydrogalactitol|Up to 120 eligible patients will be randomized to receive VAL-083.
62199353|NCT03149575|ACTIVE_COMPARATOR|Physician's Choice of Salvage Therapy|"Up to 60 patients will be randomized to receive Investigator's choice of salvage therapy temozolomide, lomustine, or carboplatin"
62199354|NCT02156323|EXPERIMENTAL|Treatment Sequence 1|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, RO7033877; Period 2, CMS; Period 3, RO7033877 + CMS. Each period is separated by a wash-out period of at least 6 days between last dose and start of next treatment.
62199355|NCT02156323|EXPERIMENTAL|Treatment Sequence 2|Participants will be randomized to one of two treatment sequences. Sequence 2 is: Period 1, CMS; Period 2, RO7033877; Period 3, RO7033877 + CMS. Each period is separated by a wash-out period of at least 6 days between last dose and start of next treatment.
62199356|NCT03902366||AUD+/HCV+|"* With current Alcohol Use Disorder and with HCV~* About to initiate DAA therapy for HCV"
62199357|NCT03902366||AUD-/HCV+|"* Without current Alcohol Use Disorder and with HCV~* About to initiate DAA therapy for HCV"
62199358|NCT03902366||AUD+/HCV-|-With Alcohol Use Disorder and without HCV
62199359|NCT03902366||AUD-/HCV-|-Without Alcohol Use Disorder and without HCV
62199360|NCT02472340||Sedentary, Pre-frail|10 sedentary, pre-frail elderly, \>61 year of age
62199361|NCT02472340||Active, Healthy|10 Active, healthy elderly, \>61 years of age
62199362|NCT01707797||Healthy children aged 9-15 months|Healthy children aged 12 months (± 3 months) at baseline stratified by Medicaid status and/or race/ethnicity to ensure a diverse representation. Each child will be paired with the primary caregiver, whom the investigators expect to most likely be the adult parent or legal guardian.
62199363|NCT04194840|EXPERIMENTAL|Transplant Wellness Clinic|"* Physical therapy consult~* Intake vitals~* CARG online survey, mental status exam~* Medication review~* Nutrition survey~* Social work: available on prn basis (as-needed)~* Exit survey~Recommendations made and given to the participant and sent to the referring MD. Participant receives post clinic phone call before transplant. Referring MD receives questionnaires. Data collected depending on if participant moved forward with transplant"
62199364|NCT03807960|EXPERIMENTAL|visual|The video about patient controlled analgesia device (PCA) usage will shown to the patients via notebook.
62199365|NCT03807960|EXPERIMENTAL|written|The written form which include the same knowledge will give to the patient for reading.
62199366|NCT03807960|OTHER|control|The anesthesiologist will describe the PCA usage as in the routine care to the control group patients.
62784294|NCT06247904|SHAM_COMPARATOR|Sham rTMS|10 daily sessions of Sham High-frequency Transcranial Magnetic Stimulation (HF-rTMS) applied bilaterally over the hand primary motor area informed by e-field modelling and targeting will be aided by neuronavigational system for precise targeting during each intervention session Sham group receives no active magnetic stimulation. Cool-B65 A/P rTMS coil will be used to avoid unblinding of administrator and/or study participant.
62784295|NCT01452581|ACTIVE_COMPARATOR|RBC transfusion|"Administration of up to 2 RBC units on the first postoperative day.~(1 unit at a time followed by evaluation of the primary outcome measure)"
62784296|NCT01452581|PLACEBO_COMPARATOR|Restrictive: Colloid infusion|Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
62784297|NCT02513576|EXPERIMENTAL|Physiotherapy exercises|Two strategies of abdominal exercises with and without movement of the upper limbs applied in patients with sternal instability as randomization.
62784298|NCT04651491||Therapy with interferons' inducers|Therapy according to routine practice (including Kagocel)
62784299|NCT06399250||current in-hospital meal service|n=102 patients admitted to the Maastricht University Medical Centre+ (MUMC+) (surgical nursing wards) will be included.
62784300|NCT06399250||old in-hospital meal service|This will be an historic control group (data already collected in the past)
62784301|NCT00648557|EXPERIMENTAL|1|Levothyroxine Sodium Tablets 200 mg
62784302|NCT00648557|ACTIVE_COMPARATOR|2|Synthroid Tablets 200 mg
62784303|NCT01081899|EXPERIMENTAL|The LCP-I Program.|The Italian version of the Liverpool Care Pathways version 11 for hospital) Programme.
62784304|NCT01081899|NO_INTERVENTION|standard healthcare practices|No specific interventions are planned in the control wards.
62199367|NCT00678301|EXPERIMENTAL|SYNFLORIX™ + ZILBRIX™ HIB + POLIO SABIN™|Subjects in this group received 3 doses of Synflorix™ vaccine, according to a 3-dose schedule at 6-10-14 weeks of age co-administered with 3 doses of Expanded Program on Immunization (EPI) vaccines Zilbrix™ Hib and Polio Sabin™ according to the same schedule. The Synflorix™ and Zilbrix™ Hib vaccines were administered by intramuscular injection, in the right and left thigh respectively. The Polio Sabin™ vaccine was administered orally.
62199368|NCT00678301|EXPERIMENTAL|ZILBRIX™ HIB + POLIO SABIN™|Subjects in this group received 3 doses of Expanded Program on Immunization (EPI) vaccines Zilbrix™ Hib and Polio Sabin™ according to a 3-dose schedule at 6-10-14 weeks of age. The Zilbrix™ Hib vaccine was administered by intramuscular injection, in the left thigh. The Polio Sabin™ vaccine was administered orally.
62784305|NCT00650403|EXPERIMENTAL|1|Paroxetine hydrochloride 40 mg tablet
62784306|NCT00650403|ACTIVE_COMPARATOR|2|Paxil® 40 mg Tablet
62784307|NCT01347996|EXPERIMENTAL|histamine dihydrochloride and IL-2|histamine and IL-2 subcutaneous injections
62011727|NCT01524640|PLACEBO_COMPARATOR|Placebo|"Non biologic placebo~Ingredients Per 1.5 ml dose~1. Starch 60mg~2. Red color\[1mg/ml\] 10 µl~3. Yellow color \[1mg/ml\] 5 µl~4. Xanthum Gum (1% solution) 300 µl~5. Water for Injection Upto 1.5 ml~All the above ingredients are of pharmaceutical grade.~Non-biological placebo of above composition has been used in 2010 for Randomized, double-blind, placebo controlled trial to evaluate the safety and immunogenicity of orally administered, killed, bivalent whole-cell , cholera vaccine, Shanchol in Bangladeshi Adults and Children. This study involving 330 subjects was carried out at International Center for Diarrheal Disease Research Bangladesh (ICDDR,B) located in Dhaka, Bangladesh with Dr. Firdausi Qadri as Principal Investigator (NCT01042951). There were no safety concerns associated with this placebo in this study and the report of this study has been submitted to the National Regulators in Bangladesh and the World Health Organization."
62011728|NCT06663982|EXPERIMENTAL|CTG + L-PRF|
62011729|NCT06663982|ACTIVE_COMPARATOR|L-PRF|
62011730|NCT00984841|EXPERIMENTAL|Tailored letter|Patients in the tailored letter group received by mail a tailored letter detailing their diabetes measures, together with enclosed orders for lab tests when due, and reminder of or scheduling for an office appointment.
62011731|NCT00984841|ACTIVE_COMPARATOR|Usual Care|Patients in the usual care group were part of a practice wide quality improvement process.
62011732|NCT05228210||Partners of breast cancer survivors|Convenience sample of partners/significant others/spouses of breast cancer survivors
62011733|NCT05316298||PRESERVE protocol|"Treatment according to the PRESERVE protocol consists of 2 study phases. Phase 1 consists of standard-of-care non-surgical treatment, performed in accordance with current treatment guidelines, during which the research team performs observations.~After failed standard-of care non surgical treatment, subjects will be included in study phase 2 and undergo treatment by surgical debridement of the diabetic foot ulcer and underlying osteomyelitis, followed by bone void filling with gentamicin-loaded calcium sulfate-hydroxyapatite biocomposite and closure of soft tissues and skin, followed by postoperative treatment regimen including woundcare, 10 days of antibiotics and offloading."
62011734|NCT03176810|ACTIVE_COMPARATOR|OCT-guided PCI|PCI is performed by OCT guidance.
62011735|NCT03176810|ACTIVE_COMPARATOR|Angiography-guided PCI|PCI is performed by angiography guidance alone.
62011736|NCT06323304|EXPERIMENTAL|Auricular acupressure + fluticasone propionate nasal spray|Auricular acupressure therapy (AAT) once a week on the left ear for a total of four weeks (4 sessions). Fluticasone propionate nasal spray will be used whenever symptoms occur.
62011737|NCT06323304|SHAM_COMPARATOR|Sham acupressure + fluticasone propionate nasal spray|Sham acupressure therapy (SAT) once a week on the left ear for a total of four weeks (4 sessions). Fluticasone propionate nasal spray will be used whenever symptoms occur.
62011738|NCT04364997|EXPERIMENTAL|Desvenlafaxine Succinate Sustained-Release|
62011739|NCT04364997|ACTIVE_COMPARATOR|Duloxetine Hydrochloride Enteric-coated|
62011740|NCT01205724|EXPERIMENTAL|A|
62011741|NCT01205724|EXPERIMENTAL|B|
62011742|NCT01205724|EXPERIMENTAL|C|
62011743|NCT04071951|EXPERIMENTAL|Pharmacist Arm|Pharmacist-Led Medication Reconciliation, Regimen Review, and Adherence and Literacy Assessment and Counseling
62011744|NCT04071951|NO_INTERVENTION|Usual Care|Patients in this study will receive usual care. Clinically-indicated services, including pharmacist services, may be provided to control group patients.
62011745|NCT00159523|EXPERIMENTAL|probiotic|
62784308|NCT02812719|ACTIVE_COMPARATOR|Glycolic acid peel alone|"One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals"
62784309|NCT02812719|EXPERIMENTAL|Glycolic and salicylic acid peel|"The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals."
62784310|NCT03774030|EXPERIMENTAL|hearing impaired participants|Hearing impaired participants with mild or severe hearing loss
62784311|NCT03521245||Trastuzumab monotherapy|Her2-positive breast cancer patients treated with Trastuzumab (monotherapy)
62784312|NCT03521245||Chemotherapy plus Trastuzumab|Her2-positive breast cancer patients treated with Trastuzumab in combination with other regimens of chemotherapy
62784313|NCT04706728|EXPERIMENTAL|Playlists with Expert-Curated Music - four weeks|Patients can choose from two expert-curated playlists with music, matching the trajectory of the ECT treatment (immediately before-, during and after the procedure). Playlists are available to the patients for four weeks (the first eight ECT procedures).
62011746|NCT00159523|PLACEBO_COMPARATOR|placebo|
62011747|NCT06489301|EXPERIMENTAL|Fractionated Laser Resurfacing|At 14 days prior to scheduled surgery a 5x5cm square on the left abdomen within the region of skin to be excised and treated with fractionated laser resurfacing. Then at 7 days prior to scheduled surgery a 5 cm diameter circle on the right abdomen within the region of skin to be excised, at least 10 cm away from the square, is treated with fractionated laser resurfacing.
62011748|NCT03986944|EXPERIMENTAL|Linzagolix 75 mg|
62011749|NCT03986944|EXPERIMENTAL|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
62011750|NCT03986944|PLACEBO_COMPARATOR|Placebo|
62011751|NCT04973488|EXPERIMENTAL|Treatment arm|In the treatment arm, Therapeutic plasma exchange will be conducted in the first 24 hours after being admitted into the intensive care unit, after which convalescent plasma from donors that have had COVID-19 will be transfused
62011752|NCT04973488|NO_INTERVENTION|Control arm|In the control arm, patients will receive standard COVID-19 treatment
62011753|NCT03353428|EXPERIMENTAL|LC-CTLs|Autologous lung cancer specific cytotoxic lymphocytes
62011754|NCT03261557|EXPERIMENTAL|CBT + SST|The treatment group will receive the intervention according to the CBSST protocol, adapted to adolescents.
62011755|NCT03261557|ACTIVE_COMPARATOR|Psychoeducation, habits and healthy lifestyle|The control group will receive 3 modules intervention: psychoeducation, habits and healthy lifestyle.
62011756|NCT02616224||Participants with unresectable LA/mBC|
62011757|NCT00132769|EXPERIMENTAL|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
62011758|NCT00132769|PLACEBO_COMPARATOR|Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
62011759|NCT05528094|EXPERIMENTAL|GeniusDrops|"Once participants have signed the consent and assent, they will take the baseline survey to gather information about their ability to focus and concentration.~Once in the study, participants will be asked to take two dropperfuls of the test product (Genius Drops) twice daily. The participants can take the dropperful directly or add it to drinks/snacks. Participants will need to be in school during the entirety of the study.~Participants will take a subsequent survey after two weeks in the trial and then another survey at the end of the trial."
62011760|NCT01970202|ACTIVE_COMPARATOR|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
62584936|NCT02713360|EXPERIMENTAL|Cognitive therapy|The intervention consists of 3 steps. 1: Consultation with a nurse that aims of identifying what the anxiety consist of and how the patient experiences his or her life situation with an ICD. A plan is made to structure the treatment. 2: Participation in an individualized intervention based on anxiety type specific protocols. 3. The intervention is considered finalized if the patient has a HADS-A score under 8 two times in a row. The intervention group will receive usual care as well.
62784314|NCT04706728|ACTIVE_COMPARATOR|Playlists with Expert-Curated Music - two weeks|Patients can choose from two expert-curated playlists with music, matching the trajectory of the ECT treatment (immediately before-, during and after the procedure). Playlists are available to the patients for two weeks (the first four ECT procedures).
62011761|NCT01970202|ACTIVE_COMPARATOR|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
62011762|NCT01970202|OTHER|Control|no treatment
62011763|NCT03262272|EXPERIMENTAL|Hemodialysis|patients treated by conventionnal hemodialysis
62784315|NCT04706728|PLACEBO_COMPARATOR|Playlists with Nature Sounds|Patients can choose from two expert-curated playlists with recorded sounds from nature (Rain, Waves) during ECT treatment (immediately before-, during and after the procedure). Playlists are available to the patients for four weeks (the first eight ECT procedures).
62784316|NCT02591485|EXPERIMENTAL|Attention Control Training|Computerized attention modification training, comprised of six sessions that delivered by internet, in purpose of modulate biases in attention for threat stimuli.
62011764|NCT03262272|EXPERIMENTAL|Hemodiafiltration post dilution|patients treated by HDF post-dilution
62011765|NCT04870840|EXPERIMENTAL|Treatment (proton therapy)|Patients undergo radiation therapy QD 5 days a week (Monday through Friday) for the first 18 days and then BID for 15 days in the absence of disease progression or unacceptable toxicity.
62011766|NCT03116165|EXPERIMENTAL|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
62011767|NCT03116165|PLACEBO_COMPARATOR|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
62011768|NCT02738775|EXPERIMENTAL|Cohort 1|Participant received intravenous (IV) infusion of ublituximab 150 milligrams (mg)/4 hour (hr) on Day 1, 450 mg/3 hr on Day 15 and 450 mg/1.5 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /3 hr on Day 15 before receiving ublituximab.
62011769|NCT02738775|EXPERIMENTAL|Cohort 2|Participant received IV infusion of ublituximab 150 mg/4 hr on Day 1, 450 mg/1.5 hr on Day 15 and 450 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /1.5 hr on Day 15 before receiving ublituximab.
62011770|NCT02738775|EXPERIMENTAL|Cohort 3|Participant received IV infusion of ublituximab 150 mg/4 hr on Day 1, 450 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
62011771|NCT02738775|EXPERIMENTAL|Cohort 4|Participant received IV infusion of ublituximab 150 mg/3 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /3 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
62011772|NCT02738775|EXPERIMENTAL|Cohort 5|Participant received IV infusion of ublituximab 150 mg/2 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /2 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
62011773|NCT02738775|EXPERIMENTAL|Cohort 6|Participant received IV infusion of ublituximab 150 mg/1 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /1 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
62784317|NCT02591485|NO_INTERVENTION|Follow-up only|In this condition, a follow-up interviews will be conducted 3 months since the traumatic event had occurred.
62784318|NCT05034601|EXPERIMENTAL|ESPB group|0.25% ropivacaine 0.5 ml/kg is injected at the fascial plane deep to the erector spinae muscle
62784319|NCT05034601|ACTIVE_COMPARATOR|TPVB group|0.25% ropivacaine 0.5 ml/kg is injected into the thoracic paravertebral space (T5) using TPVB approach.
62784320|NCT00003968|EXPERIMENTAL|Arm I|Patients receive bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment continues every 4 weeks in the absence of unacceptable toxicity or disease progresssion.
62784321|NCT01943591|EXPERIMENTAL|15-caliber platinum coils|Endovascular embolization coiling using 15-caliber platinum coils
62784322|NCT01943591|ACTIVE_COMPARATOR|10-caliber coils|Endovascular embolization coiling using standard 10-caliber platinum coils
62784323|NCT04680975|EXPERIMENTAL|Belumosudil|Participants received belumosudil 200 mg tablet orally PO, BID for 52 weeks.
62577325|NCT01799512|EXPERIMENTAL|real-time continuous glucose monitoring|"real-time continuous glucose monitoring: Use will be made of the online real-time (RT) monitoring facility of the GlucoDay® (a continuous glucose monitoring (CGM)system). This will allow immediate adaptation of the insulin dose in order to maintain values within an optimal range.~The same IV insulin infusion protocol will be used in the experimental and the active comparator group (adapted Yale protocol).~When glycaemic changes of \>25 mg/dl per 30 minutes are observed from the RT-CGM - GlucoDay data, this will be checked by measuring arterial blood glucose and the insulin infusion rate will be adapted according to the adapted Yale protocol."
62577326|NCT01799512|ACTIVE_COMPARATOR|blinded continuous glucose monitoring|"In the active comparator group the same continuous glucose monitoring device (GlucoDay) will be used in a blinded fashion. Glucose data will be analysed retrospectively.~IV insulin infusion will be adapted according to arterial blood glucose values, using the adapted Yale protocol."
62577327|NCT04324970|EXPERIMENTAL|Tookie vest|Participant issued with Tookie vest
62577328|NCT03003494||Spiolto® Respimat®|consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC
62577329|NCT05389566||Type 1 diabetes|People with type 1 diabetes above 40 years
62577330|NCT05389566||People with type 2 diabetes|People with type 2 diabetes above 50 years
62011774|NCT03162861|EXPERIMENTAL|the observation group|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
62011775|NCT03162861|EXPERIMENTAL|the control group|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
62577331|NCT05389566||Healthy controls|Healthy controls without diabetes
62577332|NCT05791539|EXPERIMENTAL|Group 1 Erector spinae plane block|Group 1 (ESPB (control group): (n = 15) patients will receive preoperative US-guided ESPB on the operated side by 20 ml bupivacaine 0.25%.
62577333|NCT05791539|EXPERIMENTAL|Group 2: Erector spinae plane block|US-guided ESPB with 10 ml bupivacaine 0.25% (n = 15) on the operated side.
62577334|NCT05791539|EXPERIMENTAL|Retro laminar block|the US-guided retrolaminar block 10 ml bupivacaine 0.25% group: (n = 15) on the operated side.
62011776|NCT01480934||Group:A-cases-Patients with a history of Diabetes Mellitus|(N=75 eyes). The inclusion criteria for group A: Diabetes mellitus was defined as glycosylated haemoglobin (Hb A1c ) levels of 6% or more , use of diabetic medication (oral hypoglycemic agents, insulin injection or diet restriction), or a physician's diagnosis of diabetes.
62011777|NCT01480934||Group - B:controls|Patients with uncomplicated age-related cataract who were otherwise healthy constituted the controls(Group:)B (n=75 eyes).
62011778|NCT03183791|EXPERIMENTAL|RELAX group|
62011779|NCT03183791|ACTIVE_COMPARATOR|Monitored Usual Care (MUC) group|
62011780|NCT05701800|EXPERIMENTAL|Part 1: mRNA-1468: Dose 1|Participants will receive placebo by intramuscular (IM) injection on Day 1 followed with mRNA-1468 by IM injection on Day 57 in Part 1.
62011781|NCT05701800|EXPERIMENTAL|Part 1: mRNA-1468: Dose 2|Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57 in Part 1.
62011782|NCT05701800|EXPERIMENTAL|Part 1: mRNA-1468: Dose 3|Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57 in Part 1.
62011783|NCT05701800|EXPERIMENTAL|Part 1: mRNA-1468: Dose 4|Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57 in Part 1.
62011784|NCT05701800|ACTIVE_COMPARATOR|Part 1: Shingrix|Participants will receive Shingrix by IM injection on Day 1 and Day 57 in Part 1.
62011785|NCT05701800|EXPERIMENTAL|Part 2: mRNA-1468: Dose 5|Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57 in Part 2.
62011786|NCT05701800|EXPERIMENTAL|Part 2: mRNA-1468: Dose 6|Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57 in Part 2.
62577335|NCT06568822||Older Adults|
62784324|NCT01372176|EXPERIMENTAL|Early Goal-Directed Nutrition|
62577336|NCT05515978|ACTIVE_COMPARATOR|Metformin and Lifestyle Modification Arm|For the metformin arm: metformin will be obtained as a standard of care medication from the patient's general pharmacy. This will be given for a clinical indication (e.g. prediabetes or overweight/obese). It will not be supplied by the study, but billed to Medicare, self pay or 3rd party payer. Lifestyle modification and prediabetes information will be provided via MHC or other electronic means on a quarterly basis.
62011787|NCT05701800|ACTIVE_COMPARATOR|Part 2: Shingrix|Participants will receive Shingrix by IM injection on Day 1 and Day 57 in Part 2.
62011788|NCT00578773|EXPERIMENTAL|Moxidex|Moxidex otic solution
62199369|NCT04674189|EXPERIMENTAL|CVnCoV: Group 1, Lot 1|Participants in Group 1 will be vaccinated with CVnCoV 12 µg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
62199370|NCT04674189|EXPERIMENTAL|CVnCoV: Group 2, Lot 2|Participants in Group 2 will be vaccinated with CVnCoV 12 µg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
62011789|NCT00578773|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin otic solution
62011790|NCT00578773|OTHER|TT only|Tympanostomy tubes only
62011791|NCT04512846||CK-SBRT with TACE group|The hepatocellular carcinoma patients (5-10cm）who received SBRT with TACE.
62011792|NCT04512846||CK-SBRT group|The hepatocellular carcinoma patients (5-10cm）who received SBRT alone.
62199371|NCT04674189|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
62577337|NCT05515978|PLACEBO_COMPARATOR|Lifestyle Modification Only Arm|Patients randomized to this arm will receive standard lifestyle modification recommendations. This will include the general recommendation to increase exercise level mildly, after discussing with the medical provider. There is a potential low-level risk in increasing one's exercise levels.
62577338|NCT02249728|EXPERIMENTAL|Absolute Bioavailability|IV PBT2 microtracer and oral PBT2 single dose
62011793|NCT04951310|NO_INTERVENTION|Control|No Intervention: Control participants (residents of Bucks County, Montgomery County, Delaware County, and Allegheny County, PA) are not eligible for the sweepstakes.
62011794|NCT04951310|EXPERIMENTAL|Selected Zip Code Treatment|Selected Zip Code Treatment participants will have a significantly greater chance to win a prize in the sweepstakes than all other Philadelphia residents. Half of all prizes in every drawing will go to Philadelphia residents in the selected zip code.
62011795|NCT04951310|EXPERIMENTAL|All other Philadelphia Residents Treatment|All other Philadelphia Residents Treatment participants will be eligible for the sweepstakes. Half of all prizes in every drawing will go to Philadelphia residents outside of the selected zip code.
62011796|NCT06363097||Low uromodulin group|Patients with urinary uromodulin levels below median.
62011797|NCT06363097||High uromodulin group|Patients with urinary uromodulin levels above median.
62011798|NCT02331446|NO_INTERVENTION|Control|The control group will be oriented to maintain their normal activity and habits and will not receive the intervention.
62011799|NCT02331446|EXPERIMENTAL|90 minutes per week|The group of 90 minutes per week will do three sessions of 30 minutes per week of concurrent training, which consists on 15 minutes of aerobic exercise and 15 minutes of strength training.
62199372|NCT05369949|EXPERIMENTAL|DEX group|Participants will receive an intraoperative and postoperative DEX infusion. In addition a low dose of sevoflurane will be administered.
62199373|NCT05369949|ACTIVE_COMPARATOR|Control group|Participants will receive general anesthesia with sevoflurane according to institutinal's practice.
62199374|NCT00400998|PLACEBO_COMPARATOR|Vienna Challenge Chamber in season (Phase 3)|"Phase 3 will consist of two treatment periods each lasting 8 days, with a 10 day wash-out between each treatment period.~Subjects will administer 200micrograms (μg) fluticasone propionate or fluticasone propionate matched placebo nasal spray, once daily for 8 days. Dosing will be supervised on the first and last days of each treatment period (Day 1 and Day 8).~Immediately following the last dose received on Day 8 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy."
62199375|NCT00400998|PLACEBO_COMPARATOR|Vienna Challenge Chamber out of season (Phase 1)|"Phase 1 will consist of two treatment periods each lasting 8 days, with a 10 day wash-out between each treatment period.~Subjects will administer 200μg fluticasone propionate or fluticasone propionate matched placebo nasal spray, once daily for 8 days. Dosing will be supervised on the first and last days of each treatment period (Day 1 and Day 8).~Immediately following the last dose received on Day 8 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy.~An intermediate study follow-up visit will take place 7-14 days after the last dose is received in treatment period 2."
62577339|NCT02249728|EXPERIMENTAL|Radiolabelled AME|oral 14C PBT2
62011800|NCT02331446|EXPERIMENTAL|150 minutes per week|The group of 150 minutes will do three sessions of 50 minutes per week, which consists on 25 minutes of aerobic exercise and 25 minutes of strength training.
62011801|NCT02331446|EXPERIMENTAL|210 minutes per week|The group pf 210 minutes per week will do three sessions of 70 minutes per week, which consists on 35 minutes of aerobic exercise and 35 minutes of strength training.
62011802|NCT01175694|ACTIVE_COMPARATOR|Brachytherapy|Interstitial multicatheter brachytherapy
62011803|NCT05514834|EXPERIMENTAL|combined HA with PRP|Hyaluronic acid and PRP combination treatment
62011804|NCT05514834|PLACEBO_COMPARATOR|Placebo|saline solution
62011805|NCT05514834|ACTIVE_COMPARATOR|PRP|Platelet rich plasma without hyaluronic acid
62011806|NCT06442267|EXPERIMENTAL|Enoxaparin group|Anticoagulation for the duration of the study will be conducted using subcutaneous Enoxaparin
62011807|NCT06442267|EXPERIMENTAL|Argatroban group|Anticoagulation for the duration of the study will be conducted using intravenous Argatroban.
62011808|NCT06442267|ACTIVE_COMPARATOR|Unfractionated heparin group|Anticoagulation for the duration of the study will be conducted using intravenous unfractionated heparin
62011809|NCT04726410|EXPERIMENTAL|Cold-stored Platelet (CSP)|early infusion of up to 2 units of urgent release cold stored platelets (CSP)
62011810|NCT04726410|ACTIVE_COMPARATOR|Standard care|standard care therapy
62011811|NCT05914584|EXPERIMENTAL|Baricitinib + Standard of care|"Baricitinib injected per os for 10 days (4mg/day). the first administration of this treatment is performed within the 6 hours following the randomization, followed by daily administration for a total of 10 days.~The standard of care : for treating HAP will comply with international guidelines. For all patients, empiri antimicrobial therapy is initiated imedialty after collecting the respiratory sample and can thus be started before the randomization to avoid delayed antimicrobial therapy. Its recommanded to broaden the spectrum in case of resistant bacteria resistant to the empirical antimicrobial therapy but il is not recommanded to prolong the antibiotic tratment for more than 7-8 days"
62011812|NCT05914584|SHAM_COMPARATOR|Standard of care alone|Same as described in arm 1
62011813|NCT05012592|ACTIVE_COMPARATOR|Intervention Group|Health assessment (health checkup) and health awareness program to reduce malnutrition and helminth infestation among primary school children
62011814|NCT05012592|NO_INTERVENTION|Comparison group|Health assessment (health checkup) was provided but no health educational intervention during the intervention period
62011815|NCT03675659|ACTIVE_COMPARATOR|intra-articular injection|intra-articular injection with magnesium sulfate at weekly interval for four weeks
62011816|NCT03675659|PLACEBO_COMPARATOR|control|intra-articular injection with saline
62011817|NCT00111644|EXPERIMENTAL|1|
62011818|NCT00111644|EXPERIMENTAL|2|
62011819|NCT00111644|ACTIVE_COMPARATOR|3|
62011820|NCT00793442||Novel Endothelial Markers Derivation|"Our study participants will come from the Protocolized Care for Early Severe Sepsis (ProCESS) trial will be eligible participants.~From the ProCESS subjects, the researchers will include those who were: 1) recruited by participating centers who participated in other components of this ancillary study or 2) who were sequentially enrolled from periods derived from the beginning, middle, and end of the ProCESS study."
62011821|NCT00793442||Novel Endothelial Marker Validation|Our study participants will come from the Protocolized Care for Early Severe Sepsis (ProCESS) trial will be eligible participants; the researchers will recruit a sequential 300 patient validation set.
62011822|NCT02358889|EXPERIMENTAL|hI-con1|Patients will receive monthly intravitreal hI-con1 as monotherapy (plus sham injection) for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
62011823|NCT02358889|EXPERIMENTAL|hI-con1 + ranibizumab|Patients will receive monthly intravitreal hI-con1 in combination with intravitreal ranibizumab for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
62011824|NCT02358889|ACTIVE_COMPARATOR|ranibizumab|Patients will receive monthly intravitreal ranibizumab as monotherapy (plus sham injection) for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
62011825|NCT04995640||CILCA patients|Subject with a CILCA and a thoracic cardiovascular disease requiring treatment. Both open cardiovascular repair and endovascular treatment (TEVAR) will be included.
62011826|NCT02737566|EXPERIMENTAL|Standard Care + Financial Incentives|Participants randomized to Standard Care + Financial Incentives for Abstinence will be offered smoking cessation counseling and pharmacotherapy (standard care) and they will have the opportunity to earn small gift cards for biochemically-verified abstinence through 12 weeks post-quit. The amount of the gift cards will escalate each week from the quit date through 4 weeks post-quit with continuous abstinence. Participants who are non-abstinent at any visit may earn incentives for abstinence at the next visit, but the amount will reset to the starting level. Participants may additionally earn an additional gift card for abstinence at the 8 and 12 weeks post-quit visits.
62011827|NCT02737566|ACTIVE_COMPARATOR|Standard Care|Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.
62784325|NCT01372176|ACTIVE_COMPARATOR|ASPEN-guidelines|
62784326|NCT02098278|EXPERIMENTAL|CAT-2003 or Placebo|All patients will receive placebo for 1 week, and CAT-2003 for 12 weeks during the 13 week treatment period.
62784327|NCT00307203|EXPERIMENTAL|I|Experiment group received 300 mgs of bupropion, in addition to weekly CBT and nicotine replacement therapy
62784328|NCT00307203|PLACEBO_COMPARATOR|II|Placebo group received placebo, in addition to weekly CBT and nicotine replacement therapy
62784329|NCT06330337|OTHER|TMZ group|Temozolomide（TMZ） was given orally or intravenously 150mg/(m2·d) for 5 days, repeated every 28 days for 6 cycles
62011828|NCT02621983|ACTIVE_COMPARATOR|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
62011829|NCT02621983|ACTIVE_COMPARATOR|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
62011830|NCT06004817||Juvenile dermatomyositis|Dermatomyositis before 18 years-old
62011831|NCT06004817||Adult-onset dermatomyositis|Dermatomyositis from 18 years-old
62011832|NCT04487977||Surveyed professionals|
62011833|NCT01464918|EXPERIMENTAL|ESD using the MASTER device|Endoscopic submucosal dissection of gastric/colon cancer using the device, MASTER
62011834|NCT04140149||Participants|Adults who have made a suicide attempt in the past 3 months who have been referred to, and enrolled in, the Living with Hope class.
62011835|NCT01590823|OTHER|Dabigatran etexilate 110 mg|Single dose of Dabigatran etexilate 110 mg po
62011836|NCT03285373||patients with NVAF|patients with Non Valvular Atrial Fibrillation
62011837|NCT05500976|EXPERIMENTAL|mini-Med|Mediterranean-amplified habitual/Western (mini-MED) diet, containing 500 kcal/day from Mediterranean target foods (such as raspberries, avocado, red bell pepper, basil, walnuts, chickpeas, oats, salmon).
62011838|NCT05500976|ACTIVE_COMPARATOR|Western|Habitual/Western (Western) diet, containing 500 kcal/day from non-Mediterranean target foods (such as potato, beef, sour cream, refined grain bread, chocolate dessert).
62011839|NCT04840095|EXPERIMENTAL|Metabolic Manipulation via Diet fMRI|All subjects are tested three times, each in a different diet-induced metabolic state: glycolytic (glucose burning), fasting (8 hours no food), and ketotic (fat burning). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink up to 75g glucose. Our data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
62011840|NCT04840095|EXPERIMENTAL|Metabolic Manipulation via Ketone Supplement fMRI|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink either of two fuel sources. In the ketotic (ketone burning) session they will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones. Our data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
62011841|NCT04840095|EXPERIMENTAL|Metabolic Manipulation via Ketone Supplement MR/PET|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). For both sessions, we will intravenously administer the FDG radioisotope continuously throughout the scan. Thus, PET will map glucose uptake across the brain, while we simultaneously use MRS to measure production of the neurotransmitters glutamine and GABA. While having their brains scanned with MR/PET, subjects are initially tested at rest, and then perform a task. Subjects will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones.
62011842|NCT06664164|ACTIVE_COMPARATOR|QLB Group|anterior quadratus lumborum block group
62011843|NCT06664164|ACTIVE_COMPARATOR|adjuvant QLB Group|with adjuvant anterior quadratus lumborum block group
62011844|NCT04645381||Participants with RA|
62011845|NCT00377663|EXPERIMENTAL|1|Participants will use the AsthmaNet web site.
62011846|NCT00377663|NO_INTERVENTION|2|Participants will not use the AsthmaNet Web site.
62011847|NCT03576001|EXPERIMENTAL|Multi-modality intervention group|Hybrid exercise (functional electrical stimulation - leg cycling, FES LC plus arm ergometry) plus Testosterone undecanoate
62011848|NCT03576001|PLACEBO_COMPARATOR|Placebo group|Hybrid exercise plus placebo medication
62577340|NCT06461299|EXPERIMENTAL|A Single-ARM Pilot Study to Evaluate Sarecycline for Treating Periorificial Dermatitis|A Single-Center Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis
62011849|NCT06580821|EXPERIMENTAL|Modified free gingival graft|
62011850|NCT06580821|ACTIVE_COMPARATOR|Conventional free gingival graft|
62011851|NCT03830502||Salpingectomy|Women who gave consent for opportunistic prophylactic bilateral salpingectomy during cesarean section as a Surgical sterilization procedure
62011852|NCT03830502||Tubal ligation|Women who refused salpingectomy and gave consent for tubal ligation during cesarean section as a Surgical sterilization procedure
62011853|NCT06440772||Tolerant Fluid Responders|Patients who are both responsive and tolerant to fluid.
62011854|NCT05078736|EXPERIMENTAL|moderate intensity intermittent training|baseline physical therapy treatment along with moderate intensity intermittent training
62011855|NCT05078736|EXPERIMENTAL|moderate intensity continuous training|baseline physical therapy treatment along with moderate intensity continuous training
62577341|NCT01175096|ACTIVE_COMPARATOR|RAD001|2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day Dose level modifications/interruptions must follow guidelines. One treatment cycle consists of 28 days.
62400959|NCT06149494|EXPERIMENTAL|Vapendavir Cohort|"VPV will be dispensed by the study team on Day 0 at the clinical study visit at the study site. Participants will be given enough VPV for the 7-day treatment phase, (eg. Days 2 to 8). Treatment is twice daily, am and pm, 12 h apart ± 2 h. VPV micronized free base tablets (250 mg each) will be given orally beginning with a 1,000 mg loading dose (4 tablets) as soon as symptoms are present or the subject answers yes to do you think you have a cold today followed by 500 mg (2 tablets) either on the same day (eg day 2) or the next day. Treatment will therefore be for a total of 7 days consisting of an initial 1,000 mg dose (4-tablets) followed by thirteen 500mg doses (2-tablets). Treatment may occur within the home, on non-clinical study days."
62577342|NCT00839683|ACTIVE_COMPARATOR|simvastatin|
62011856|NCT02370888|EXPERIMENTAL|Lenalidomide|"Lenalidomide will be administered for a total of 42 days.~The dose levels of lenalidomide will be as follows:~* Dose Level 1: 2.5 mg PO QOD Day 1-21 for 28-day cycle X 2 cycles~* Dose Level 2: 2.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles~* Dose Level 3: 5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles~* Dose Level 4: 7.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles"
62011857|NCT04165291|EXPERIMENTAL|F4C|Participants randomized to the Fathers for Change (F4C) program.
62199376|NCT00400998|PLACEBO_COMPARATOR|Park In Season (Phase 2)|"Phase 2 will consist of 2 treatment periods lasting either 8 to 14 days (D) (depending on out-door conditions). There will be a 10D wash-out between this treatment period in Phase 2 and that in Phase 3.~Subjects will administer 200μg fluticasone propionate (or fluticasone propionate matched placebo nasal spray, once daily up to 14D, with dosing supervised on the first and last days of each treatment period (D1 and either D8 or up to D14).~Immediately following the last dose received on either D8 or up to D14 baseline measures will be taken (time = 0). The subject is then taken by bus to the Park and the first measurement will be taken 15 minutes after the subjects leave the bus and enter the Park.~Immediately following the last dose received on D8 or up to D14 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy"
62199377|NCT04681053|ACTIVE_COMPARATOR|Group (A) received both oral and inhaled ivermectin in addition to the standard of care.|use oral and inhaled ivermectin
62199378|NCT04681053|ACTIVE_COMPARATOR|B) received oral ivermectin in addition to the standard of care|receive oral ivermectin
62199379|NCT04681053|ACTIVE_COMPARATOR|c) received inhaled ivermectin in addition to the standard of care|received inhaled ivermectin
62199380|NCT04681053|NO_INTERVENTION|Group (d) received the current standard of care only|received standard of care only
62199381|NCT03157297|EXPERIMENTAL|Enrolled|Subjects enrolled in the MARVEL study. Enrolled subjects will have the MARVEL algorithm downloaded into their implanted market released Micra device.
62577343|NCT00839683|ACTIVE_COMPARATOR|Dapagliflozin + simvastatin|
62577344|NCT00839683|ACTIVE_COMPARATOR|Dapagliflozin|
62577345|NCT00839683|ACTIVE_COMPARATOR|valsartan|
62577346|NCT00839683|ACTIVE_COMPARATOR|Dapagliflozin + valsartan|
62577347|NCT04861350|EXPERIMENTAL|motor imagery with action observation|The subjects will perform the exercises mentally for 3 sets with video, 10 reps for 1 set.
62577348|NCT04861350|EXPERIMENTAL|physical training|The subjects will perform the exercise physically for 3 sets with supervision of investigator, 10 reps for 1 set.
62011858|NCT04165291|ACTIVE_COMPARATOR|BIP|Participants randomized to the Batterer Intervention Program (BIP).
62011859|NCT04929561|EXPERIMENTAL|Video-conferencing group|The mothers in the video-conferencing group were counseled via video-conferencing a total of six times (three times a week, at equal intervals) during the first 2 weeks after birth. Each interview was approximately 15-20 minutes. In video-conferencing sessions, the breastfeeding position, the mother's grasping the breast, the baby's latch-on, and sucking duration were observed. Mothers' questions were answered and solutions were offered for breastfeeding problems (sore nipple, engorgement, etc.).
62011860|NCT04929561|NO_INTERVENTION|Control group|The mothers in the control group were given usual care before discharge and no intervention was made after discharge.
62011861|NCT03802097|EXPERIMENTAL|A group (treatment group)|No use of antimicrobial prophylaxis
62577349|NCT04861350|EXPERIMENTAL|combine physical training and motor imagery with action observation|The subjects will perform the exercise mentally with video for 1 set and physically with supervision of investigator for 2 sets, 3 sets totally, 10 reps for 1 set.
62011862|NCT03802097|EXPERIMENTAL|B group (control group)|Use of antimicrobial prophylaxis
62011863|NCT00139997|EXPERIMENTAL|LED phototherapy device|Litebook treatment devices: LED phototherapy device, used for 30 min before 8 am
62011864|NCT00139997|PLACEBO_COMPARATOR|Inactivated Negative Ion Generator|Equivalent exposure to inactivated negative ion generator
62011865|NCT03905057|SHAM_COMPARATOR|Sham ESWT + 5mg Tadalafil|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), using a sham applicator which is highly similar to the active applicator except that the sham applicator does not emit shockwaves, twice a week (total of 6 weeks) without treatment interval. Patients will receive Tadalafil 5mg for 24 weeks daily beginning the day of removal of the urinary catheter.
62011866|NCT03905057|ACTIVE_COMPARATOR|Active ESWT + 5mg Tadalafil|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks). Patients will receive Tadalafil 5mg for 24 weeks daily beginning the day of removal of the urinary catheter.
62011867|NCT05921773|EXPERIMENTAL|GAD Patients with Intervention|The feedback group will get real neurofeedback about changes in anxiety-related cerebral hemodynamics. AI-fNIRS neurofeedback will be provided 3 times a week, for a total of 4 weeks.
62011868|NCT05921773|SHAM_COMPARATOR|GAD Patients with Sham Controls|The sham group will be shown playbacks of someone's real feedback sessions. Sham AI-fNIRS neurofeedback will be provided 3 times a week, for a total of 4 weeks.
62011869|NCT04560803|EXPERIMENTAL|Epidermal Grafting|This irradiated area of the skin will be treated with autologous epidermal grafts
62011870|NCT04560803|NO_INTERVENTION|No treatment|This irradiated area will not receive any treatment
62011871|NCT05809895|EXPERIMENTAL|Arm A: ociperlimab+tislelizumab+chemotherapy (PD-L1 CPS ≥ 10)|Participants with a PD-L1 CPS ≥ 10 will receive after randomization ociperlimab + tislelizumab + chemotherapy. The choice of one of three chemotherapy options is at the discretion of the investigator provided that it is either: (1) paclitaxel, (2) nab-paclitaxel, or (3) gemcitabine plus carboplatin.
62577350|NCT05355584|ACTIVE_COMPARATOR|10-minute Cryotherapy Application|A cold application will be made on the shoulder for 10 minutes. Before and after the application, individuals will be evaluated in terms of muscle strength, flexibility, endurance and balance. The values before and after the application will be compared.
62011872|NCT05809895|ACTIVE_COMPARATOR|Arm B: placebo + pembrolizumab + chemotherapy (PD-L1 CPS ≥ 10)|Participants with a PD-L1 CPS ≥ 10 will receive after randomization placebo + pembrolizumab + chemotherapy. The choice of one of three chemotherapy options is at the discretion of the investigator provided that it is either: (1) paclitaxel, (2) nab-paclitaxel, or (3) gemcitabine plus carboplatin.
62011873|NCT05809895|ACTIVE_COMPARATOR|Arm C: placebo + tislelizumab + chemotherapy (PD-L1 CPS ≥ 10)|Participants with a PD-L1 CPS ≥ 10 will receive after randomization placebo + tislelizumab + chemotherapy. The choice of one of three chemotherapy options is at the discretion of the investigator provided that it is either: (1) paclitaxel, (2) nab-paclitaxel, or (3) gemcitabine plus carboplatin.
62011874|NCT05809895|OTHER|Arm D: ociperlimab + tislelizumab + chemotherapy (PD-L1 CPS score ≥ 1 to < 10)|Exploratory arm: Participants with a PD-L1 CPS ≥ 1 to \< 10 will receive ociperlimab + tislelizumab + chemotherapy. The choice of one of three chemotherapy options is at the discretion of the investigator provided that it is either: (1) paclitaxel, (2) nab-paclitaxel, or (3) gemcitabine plus carboplatin.
62011875|NCT04499404|EXPERIMENTAL|Intervention group|Participants receive breastfeeding-related information from WeChat
62011876|NCT04499404|ACTIVE_COMPARATOR|Control group|Participants receive non-breastfeeding information from WeChat
62011877|NCT05124873|EXPERIMENTAL|Experimental Prosthetic Liner|
62011878|NCT01994395|EXPERIMENTAL|Stride Management Assist (SMA) System|Participants will be randomized into either the SMA group or impairment based (IPT) group. The SMA group (task specific training) will be trained to simulate the demands of overground walking using the Stride Management Assist Device in outpatient physical therapy.
62011879|NCT01994395|ACTIVE_COMPARATOR|Impairment based therapy|Impairment based therapy will include traditional functional mobility training physical therapy. It will match the SMA group in intensity but will be focused on balance and other functional goals rather than explicitly on walking in outpatient physical therapy.
62199382|NCT03265353|OTHER|Moderate Potassium/Low Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the moderate potassium/low sodium diet.
62199383|NCT03265353|OTHER|Moderate Potassium/High Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the moderate potassium/high sodium diet.
62199384|NCT03265353|OTHER|High Potassium/High Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the high potassium/high sodium diet.
62577351|NCT05355584|ACTIVE_COMPARATOR|15-minute Cryotherapy Application|A cold application will be made on the shoulder for 15 minutes. Before and after the application, individuals will be evaluated in terms of muscle strength, flexibility, endurance and balance. The values before and after the application will be compared.
62784330|NCT06330337|OTHER|SMES+ABX+TMZ Group|"Drug:~Oral or intravenous infusion of TMZ 150mg/(m2·d) for 5 days, repeated after 23 days of suspension, a total of 6 treatment cycles. During the TMZ treatment cycle, specific mode electroacupuncture stimulation（SMES） combined with Paclitaxel for Injection (Albumin Bound)（ABX） were used on day 1 and day 8.~ABX： ABX was prepared with 0.9% sodium chloride injection and the dosage required by the patient was calculated at 110mg/mm2. Then the intravenous infusion continues for 30 minutes.~SMES：Immediately after the ABX intravenous infusion began, the patient was placed in a supine position, the skin was routinely disinfected with 75% ethanol, and a stainless steel needle was inserted into GV20 and GV26.Then, the needles are stimulated by using an acupuncture point nerve stimulator with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off)."
62784331|NCT02146001|ACTIVE_COMPARATOR|Moderate-to-vigorous activity group|This group will target achieving the current recommendations for physical activity in older adults. This is 150 minutes of moderate-to-vigorous activity per week.
62784332|NCT02146001|EXPERIMENTAL|Reducing sedentary behavior group|This group will target a 60 minute per day reduction in sedentary behavior using an objective activity monitor.
62784333|NCT01932502|EXPERIMENTAL|clonazepam conversion to clobazam (Onfi)|Subject's clonazepam will be converted to clobazam (Onfi). This is an open label study without placebo control.
62784334|NCT05652712||Immunotherapy Regimen|Patients receiving different treatment regimens of Toripalimab in each center were consecutively enrolled from January 1, 2019 to December 31, 2022
62011880|NCT05229224|EXPERIMENTAL|Osteo-Fluidic-Sensitive method|
62011881|NCT05229224|PLACEBO_COMPARATOR|Placebo method|
62011882|NCT05120908||Mexican Women|Mexican, premenopausal women ages 18-50.
62784335|NCT00648700|EXPERIMENTAL|1|Levothyroxine Sodium Tablets 300 μg
62011883|NCT05120908||Filipina Women|Filipina, premenopausal women ages 18-50.
62011884|NCT00678600|ACTIVE_COMPARATOR|Standard (static) Computer Alerts|Participants in this arm will be assigned to standard care. Participants will be monitored for new laboratory toxicity, suboptimal follow up, and virologic failure. Provider computer alerts will be posted on the participant's electronic health record summary page.
62784336|NCT00648700|ACTIVE_COMPARATOR|2|Levothroid® Tablets 300 μg
62011885|NCT00678600|EXPERIMENTAL|Enhanced Computer Alerts|Participants in this arm will be assigned to the enhanced alert arm. Participants will be monitored for new laboratory toxicity, suboptimal follow up, and virologic failure. Providers will receive population and asynchronous computer alerts with improved functionality.
62577352|NCT05355584|ACTIVE_COMPARATOR|20-minute Cryotherapy Application|A cold application will be made on the shoulder for 20 minutes. Before and after the application, individuals will be evaluated in terms of muscle strength, flexibility, endurance and balance. The values before and after the application will be compared.
62784337|NCT06075407||Fluid responder|All patients will undergo a volume expansion test or fluid challenge according to standard protocol. The volume expansion test will be performed with an intravenous infusion of 0.9% sodium chloride (500mL) within 15 minutes. The patient becomes a fluid responder if SV increases by \> 10% after the fluid challenge.
62199385|NCT05418127|PLACEBO_COMPARATOR|30 Participants receiving Placebo product.|Solution of filtered water, Calcium Carbonate powder, and coconut extract.
62199386|NCT05418127|ACTIVE_COMPARATOR|30 Participants receiving Active product.|Traditionally-fermented coconut milk kefir.
62199387|NCT04210440|EXPERIMENTAL|Hip avascular necrosis|patients affected by avascular necrosis of the Hip classified by Japanese Investigation Committee criteria
62577353|NCT02078440|OTHER|Bromocriptine mesylate (Cycloset)|Bromocriptine mesylate (Cycloset)
62199388|NCT00208559|OTHER|1 Open Label|Open Label
62577354|NCT03684239|EXPERIMENTAL|G-CBT group|G-CBT group has 40 patients, maybe will be divided them into 4 groups. Every group has 8-10 patients. Every group receive 10 times CBT group therapy and 1 times a week for 120 minutes each time.
62577355|NCT03684239|ACTIVE_COMPARATOR|Conventional treatment group|Conventional treatment group has 40 patients, received routine outpatient treatment. Once every two weeks for 45 minutes each time, including nutritional advice, encouragement, and routine treatment by a psychiatrist with work experience with eating disorders.
62199389|NCT04297332|EXPERIMENTAL|Arm I (active EFT, active FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.
62199390|NCT04297332|EXPERIMENTAL|Arm II (active EFT, control FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or control future thinking priming task once per week for 12 weeks, alternating every week between tasks.
62199391|NCT04297332|EXPERIMENTAL|Arm III (control EFT, active FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.
62199392|NCT04297332|ACTIVE_COMPARATOR|Arm IV (control EFT, control TFP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or control future thinking priming tasks once per week for 12 weeks, alternating every week between tasks.
62199393|NCT03759782|EXPERIMENTAL|Group 1|Tenofovir (TDF) 300 mg po once a day (OD)
62199394|NCT03759782|ACTIVE_COMPARATOR|Group 2|Tenofovir 300 mg po OD + Ribavirin 400 mg twice a day (BID) if \<70kg / 600 mg every (q) in the morning (AM) and 400 mg q in the evening (PM) if ≥70kg
62199395|NCT03112109||Intervention Group|Patients receiving 'new care'
62199396|NCT03112109||Control group|Patients receiving 'old / usual care'
62199397|NCT02622555||Mirabegron treatment|Women with overactive bladder syndrome eligible for Mirabegron treatment
62199398|NCT03617276||Outcome measurement|Each participant will be asked to complete each standardised outcome measure (SOM) three times and each trial will be videotaped by the researcher. The selected SOM's are the modified nine-hole peg test, the four square step test and the modified clinical test of sensory integration and balance. A doctor will watch the video on 2 separate occasions to evaluate intra-rater reliability. Inter-rater reliability will be assessed through asking three other neurofibromatosis specialist professionals (two NF2 consultants and one NF2 specialist nurse) to review the video and to score each measure completed. Once the filmed sessions have been analysed by the relevant clinician's the data will be destroyed in line with Trust policy. Each participant will also be required to complete the INFI-QOL questionnaire, the dynamic visual acuity test and provide information about the number of falls/near misses they have had over the past 12 months
62199399|NCT00795275|EXPERIMENTAL|Impaired Fasting Glucose|Treatment of people with impaired fasting glucose with Januvia (sitagliptin phosphate)
62199400|NCT00795275|EXPERIMENTAL|Normal glucose tolerance|Treatment of people with normal glucose tolerance with Januvia (sitagliptin phosphate)
62199401|NCT02126852|EXPERIMENTAL|AMG (one-dimensionally) versus EMG|Neuromuscular monitoring in patients scheduled for surgery under general anesthesia
62577356|NCT05910138|ACTIVE_COMPARATOR|case|
62784338|NCT06075407||Fluid non-responder|All patients will undergo a volume expansion test or fluid challenge according to standard protocol. The volume expansion test will be performed with an intravenous infusion of 0.9% sodium chloride (500mL) within 15 minutes. The patient becomes a fluid responder if SV increases by \> 10% after the fluid challenge (21). If the patient becomes a fluid non-responder, vasopressor infusion or inotrope will start.
62784339|NCT01408459|ACTIVE_COMPARATOR|Tomato product|Motivational telephone counseling weekly
62199402|NCT02126852|EXPERIMENTAL|AMG (three-dimensionally) versus EMG|Neuromuscular monitoring in patients scheduled for surgery under general anesthesia
62199403|NCT04012177|NO_INTERVENTION|Control Arm|Arm-A: Standard antenatal care (ANC) counseling, service provision and nutrition counseling (World Health Organization (WHO) standard)
62199404|NCT04012177|EXPERIMENTAL|Nutrition only Arm|Arm-B:Balanced-energy protein (BEP), ready-to-use utrition supplement for at least 6 months + Standard ANC counseling, service provision and nutrition counseling (WHO standard)
62199405|NCT04012177|EXPERIMENTAL|Nutrition plus Azithromycin Arm|Arm-C:Balanced-energy protein (BEP), ready-to-use nutrition supplement for at least 6 months + 2000 mg of Azithromycin at week 20 and 28 of pregnancy + Standard ANC counseling, service provision and nutrition counseling (WHO standard).
62400960|NCT06149494|PLACEBO_COMPARATOR|Placebo Cohort|"Placebo will be dispensed by the study team on Day 0 at the clinical visit at the study site. Participants will be given enough Placebo for the 7-day treatment phase, (eg. Days 2 to 8). Treatment is twice daily, am and pm, 12 h apart ± 2 h. Placebo tablets will be matched to the active treatment and will be administered orally for 7 days as follows: 4 tablets for the initial dose as soon as symptoms are present or the subject answers yes to do you think you have a cold today on the first day of dosing (eg. Day 2), and 2 tablets, either on the same day (eg Day 2) or the next day. Treatment will therefore be for a total of 7 days (consisting of an initial 4-tablet dose followed by thirteen 2-tablet doses). Treatment may occur within the home, on non-clinical study days."
62400961|NCT06181903|EXPERIMENTAL|Emotional freedom technique group|Emotional freedom technique will be applied to risky pregnant women in the emotional freedom technique group.
62784340|NCT01408459|PLACEBO_COMPARATOR|Control|No Motivation telephone Counseling
62784341|NCT01439594|EXPERIMENTAL|MGH OFDI Imaging|OFDI imaging
62199406|NCT04012177|EXPERIMENTAL|Nutrition plus Choline and Nicotinamide Arm|Arm-D: Balanced-energy protein (BEP), ready-to-use nutrition supplement for at least 6 months + Choline 450 and Nicotinamide 100 mg (1 each once daily orally starting from week 20 until birth outcome) + Standard ANC counseling, service provision and nutrition counseling (WHO standard).
62199407|NCT04701723|EXPERIMENTAL|Cardiac Coherence Training|"The cardiac coherence training will consist in the realization during 3 months by the patient, at home :~* of 6 respiratory cycles by minute (inspiration : 4,5 seconds/expiration : 5,5 seconds),~* during 5 minutes,~* 3 times a day (morning, late morning and late afternoon)"
62011886|NCT04537715|EXPERIMENTAL|Part 1: Tazemetostat and Itraconazole Drug Interaction Cycle 1|"Participants in Part 1 of the study will receive a single oral, 400 mg dose of tazemetostat on Day 1, 15, and Day 36.~The study participants will receive tazemetostat (oral 400 mg) tablets to be taken twice daily on Days 3 - 14 and Days 21 - 35. In addition, the participants will receive oral 200 mg itraconazole once daily on Days 18 - 38.~Study participants may continue tazemetostat from Day 40+ at the recommended therapeutic dose (oral 800 mg twice daily) in 28-day cycles."
62011887|NCT04537715|EXPERIMENTAL|Part 2:Tazemetostat and Rifampin Drug Interaction Cycle 1|"Participants in Part 2 of the study will receive a single oral, 800 mg dose of tazemetostat on Days 1, 15, and Day 36.~The study participants will receive tazemetostat (oral 800 mg dose) tablets to be taken twice daily on Days 3 - 14 and Days 17 - 23. In addition, the participants will receive oral 200 mg rifampin once daily on Days 17 - 25.~Study participants may continue tazemetostat from Day 27+ at the recommended therapeutic dose (oral 800 mg twice daily) in 28-day cycles."
62199408|NCT01913457||Adults w/ PH|Subjects above 18y scheduled to undergo RHC for Doppler ultrasound external right chest wall tests
62199409|NCT01913457||Children w/ PH|Children 0-18y old scheduled to RHC
62011888|NCT01542866|EXPERIMENTAL|Home Monitoring Test|Health management tool (HMT) for measuring vision impairment
62011889|NCT01014494|EXPERIMENTAL|Active - Adaprev|Adaprev (Class III medical device)
62011890|NCT01014494|NO_INTERVENTION|Standard Care|No different treatment to normal
62011891|NCT02782897|EXPERIMENTAL|IVIg group|Participants will receive immunoglobulin therapy plus standard management. The first intravenous infusion of immunoglobulin must be given within 72 hours after the onset.
62011892|NCT02782897|OTHER|Control group|Participants will receive standard management according to Chinese guidelines for intracerebral Hemorrhage.
62011893|NCT06663059|EXPERIMENTAL|Adebrelimab combined with Chemotherapy 2 cycle|Adebrelimab combined with albumin-bound paclitaxel and cisplatin for 2 cycles, followed by surgical resection.
62011894|NCT06663059|EXPERIMENTAL|Adebrelimab combined with Chemotherapy 4 cycle|Adebrelimab combined with albumin-bound paclitaxel and cisplatin for 4 cycles, followed by surgical resection.
62011895|NCT00393172|EXPERIMENTAL|exercise|5 days per week exercise for 4 months
62011896|NCT00393172|NO_INTERVENTION|no exercise|
62011897|NCT01862055||SAS cohort|Consecutive patients undergoing planned cesarean section under spinal anesthesia
62011898|NCT05349422|EXPERIMENTAL|Intervention Group|
62011899|NCT05349422|NO_INTERVENTION|Usual Care Group|Usual Care Clinical Decision Support (CDS) Tools
62011900|NCT04456699|EXPERIMENTAL|Olaparib + bevacizumab|Participants will receive olaparib (300 mg twice daily \[BID\] oral) + Bevacizumab (5 mg/kg intravenous \[IV\] once every 2 weeks \[Q2W\]) until progressive disease or end of study.
62011901|NCT04456699|EXPERIMENTAL|Olaparib|Participants will receive olaparib (300 mg BID) oral, until progressive disease or end of study.
62011902|NCT04456699|ACTIVE_COMPARATOR|Bevacizumab + chemotherapy|Participants will receive investigator's choice of either bevacizumab (7.5 mg/kg IV once every three weeks (Q3W)) + capecitabine (1000 mg/m\^2 BID for 14 days, then 7 days off, Q3W) or bevacizumab (5 mg/kg IV Q2W) + 5-FU (2400 mg/m2 IV over 46 to 48 hours Q2W; bolus 5-FU (400 mg/m2) can be added prior to infusional 5-FU, per local standards and at the investigator's discretion). Leucovorin or levoleucovorin 400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) Q2W IV infusion may be added per investigator's discretion. Treatment will continue until progressive disease or end of study.
62199410|NCT01913457||Children control|Children 0-18y old w/o PH for Lung Doppler tests as controls
62400962|NCT06181903|NO_INTERVENTION|Control group|Pregnant women in the control group will not receive any intervention other than routine hospital care.
62577357|NCT05910138|ACTIVE_COMPARATOR|control|
62577358|NCT03537976|OTHER|Static Images and Facial Videos|2D and 3D still and video images obtained from each patient before surgery.
62577359|NCT00327808|EXPERIMENTAL|Inhaler|TPI 1020
62577360|NCT00327808|ACTIVE_COMPARATOR|Inhaler cortico.|Budesonide inhaler
62577361|NCT00538525|ACTIVE_COMPARATOR|Arm 1|Doxorubicin, Docetaxel, Cisplatin
62011903|NCT06040697||Usability Assessment Cohort|No interventions administered. Device usability assessment only.
62011904|NCT06662591||ASD Case Group|Represents individuals diagnosed with Autism Spectrum Disorder (ASD), who will undergo genetic, epigenetic, and transcriptomic analysis.
62011905|NCT06662591||Control Group|Represents unaffected individuals, serving as the comparison group for genetic and molecular analyses.
62199411|NCT05096520|ACTIVE_COMPARATOR|radiofrequency group|the radiofrequency needle will be advanced percutaneously towards the intermedius genicular nerve on the periosteum of the distal femoral shaft region until bone contact is achieved. In addition to imaging the nerve with ultrasound, sensory stimulation at 50 Hz frequency will be applied with a threshold value less than 0.6 V in order to determine its position more accurately. In order to prevent the inactivation of the motor nerves, the relevant nerve will be tested for the absence of fasciculation in the region of the lower extremity compatible with the application with the stimulation with a frequency of 2.0 V and 2 Hz. Before the activation of the radiofrequency generator, an injection of 1 ml of 2% lidocaine will be made, then the radiofrequency electrode will be added to the needle and the temperature level at the tip of the electrode will be increased to 80 degrees for 2 minutes, the procedure will be performed for each genicular nerve.
62199412|NCT05096520|ACTIVE_COMPARATOR|control group|The intermedius genicular nerve will be found under US guidance and the genicular nerve will be blocked by injecting 1 ml of 2% lidocaine.
62577362|NCT06143943||primary angle-closure glaucoma|
62577363|NCT06143943||narrow angle|
62011906|NCT06662591||HOT Cluster Biomarker Group|Represents participants selected after secondary outcome results based on HOT cluster analysis, who will undergo ELISA to study potential biomarkers derived from RNA transcriptome pathway analysis.
62011907|NCT05740839|EXPERIMENTAL|HIIT Exercise Program Group|"Participants will be randomly assigned to the HIIT exercise group and receive:~* 3x weekly for 16 week home-based virtually supervised High-Intensity Interval Training.~* 16-week self-directed exercise follow up period.~* 3 On-site visits at Week 1, 18 and 34 for assement testing and completion of questionnaires"
62011908|NCT05740839|ACTIVE_COMPARATOR|Control Group|"Participants will be randomly assigned to the HIIT waitlist control group and receive:~* Daily usual activities~* 2 On-site visits at Week 1, and 18 for assement testing and completion of questionnaires~* Option to complete 16 week, 3x weekly HIIT exercise program after initial 16 week period."
62011909|NCT04667819|EXPERIMENTAL|sodium hyaluronate|Sodium hyaluronate has become a novel and effective eye drop for the treatment of the dry eye. However, we design a special method of usage of sodium hyaluronate in dry eye patients.
62011910|NCT05976698|EXPERIMENTAL|Intervention order: 10 μg LSD - 20 μg LSD - Placebo|"Each subject will participate in 3 x 5 h study sessions separated by at least 7 days.~Order of drug administration will be 10 μg LSD - 20 μg LSD - Placebo. Vials will contain either 10μg (Active) or 0 μg LSD (Placebo). Thus, participants will be administered two vials on each study visit. 1. visit: active+placebo; 2. visit: active+active, 3. visit: placebo+placebo."
62011911|NCT05976698|EXPERIMENTAL|Intervention order: 10 μg LSD - Placebo - 20 μg LSD|"Each subject will participate in 3 x 5 h study sessions separated by at least 7 days.~Order of drug administration will be 10 μg LSD - Placebo - 20 μg LSD. Vials will contain either 10μg (Active) or 0 μg LSD (Placebo). Thus, participants will be administered two vials on each study visit. 1. visit: active+placebo; 2. visit: placebo+placebo, 3. visit: active+active."
62011912|NCT05976698|EXPERIMENTAL|Intervention order: 20 μg LSD - 10 μg LSD - Placebo|"Each subject will participate in 3 x 5 h study sessions separated by at least 7 days.~Order of drug administration will be 20 μg LSD - 10 μg LSD - Placebo. Vials will contain either 10μg (Active) or 0 μg LSD (Placebo). Thus, participants will be administered two vials on each study visit. 1. visit: active+active; 2. visit: active+placebo, 3. visit: placebo+placebo."
62577364|NCT03574272|EXPERIMENTAL|Patient Transfer Monitoring System|
62577365|NCT03475862|EXPERIMENTAL|PTI-821 Manipulated|oxycodone 40 mg capsule
62577366|NCT03475862|ACTIVE_COMPARATOR|Oxycodone|Oxycodone 40 mg IR tablet crushed
62577367|NCT03475862|ACTIVE_COMPARATOR|OxyContin|Oxycodone ER 40 mg tablet crushed
62577368|NCT03475862|PLACEBO_COMPARATOR|Placebo|Matching placebos for experimental and active comparator arms
62577369|NCT03475862|EXPERIMENTAL|PTI-821 Non-manipulated|Oxycodone 40 mg non-manipulated
62577370|NCT00098137|EXPERIMENTAL|Olmesartan|Olmesartan tablet, 1 in the morning
62011913|NCT05976698|EXPERIMENTAL|Intervention order: 20 μg LSD - placebo - 10 μg LSD|"Each subject will participate in 3 x 5 h study sessions separated by at least 7 days.~Order of drug administration will be 20 μg LSD -placebo - 10 μg LSD. Vials will contain either 10μg (Active) or 0 μg LSD (Placebo). Thus, participants will be administered two vials on each study visit. 1. visit: active+active; 2. visit: placebo+placebo, 3. visit: active+placebo."
62011914|NCT05976698|EXPERIMENTAL|Intervention order: placebo - 10 μg LSD - 20 μg LSD|"Each subject will participate in 3 x 5 h study sessions separated by at least 7 days.~Order of drug administration will be placebo - 10 μg LSD - 20 μg LSD. Vials will contain either 10μg (Active) or 0 μg LSD (Placebo). Thus, participants will be administered two vials on each study visit. 1. visit: placebo+placebo; 2. visit: active+placebo, 3. visit: active+active."
62199413|NCT03076905|EXPERIMENTAL|IV drug|AUC0-t of single intravenous dose of F901318
62199414|NCT05308394||Control group|The control group for this study will consist of individuals with normal BMI (18.5 - 24.9 kg/m2), body fat percent \< 25% (male) or \< 35% (female), and up to 1 other risk factor among the following: blood pressure \> 130/85 mmHg, fasting glucose \>100 mg/dL, fasting triglycerides \>150 mg/dL, and HDL \< 40 (male) or \< 50 (female).
62577371|NCT00098137|PLACEBO_COMPARATOR|Placebo|Placebo tablets, 1 in the morning
62577372|NCT02587390|EXPERIMENTAL|Gemcabene 900 mg|Gemcabene 900 mg
62577373|NCT02587390|ACTIVE_COMPARATOR|Simvastatin 80 mg|Simvastatin 80 mg
62199415|NCT05308394||Normal-weight obesity|Individuals with normal-weight obesity will be defined as having normal BMI (18.5 - 24.9 kg/m2), body fat percent \> 25% (male) or \> 35% (female).
62199416|NCT05308394||Metabolically Healthy Obesity|Metabolically healthy obesity will be defined as having an obese BMI (\> 30 kg/m2), body fat percent \< 25% (male) or \< 35% (female), and up to 1 other risk factor among the following: blood pressure \> 130/85 mmHg, fasting glucose \>100 mg/dL, fasting triglycerides \>150 mg/dL, and HDL \< 40 (male) or \< 50 (female).
62011915|NCT05976698|EXPERIMENTAL|Intervention order: placebo - 20 μg LSD - 10 μg LSD|"Each subject will participate in 3 x 5 h study sessions separated by at least 7 days.~Order of drug administration will be placebo - 20 μg LSD - 10 μg LSD. Vials will contain either 10μg (Active) or 0 μg LSD (Placebo). Thus, participants will be administered two vials on each study visit. 1. visit: placebo+placebo; 2. visit: active+active, 3. visit: active+placebo."
62199417|NCT05308394||Metabolic Syndrome|Metabolic syndrome will be defined using the international Diabetes Federation criteria of an obese BMI ( \> 30 kg/m2) and 2 or more of the following risk factors: blood pressure \> 130/85 mmHg, fasting glucose \>100 mg/dL, fasting triglycerides \>150 mg/dL, and HDL \< 40 (male) or \< 50 (female).
62199418|NCT01863147|EXPERIMENTAL|Sitagliptin|Sitagliptin 0.1 daily for 1 year
62199419|NCT01863147|ACTIVE_COMPARATOR|acarbose|acarbose 150mg daily for 1 year
62199420|NCT03168542|EXPERIMENTAL|Toric Multifocal Contact Lens|JJVC Investigational Toric Multifocal Contact Lens for Presbyopia
62199421|NCT03168542|EXPERIMENTAL|Multifocal Contact Lens|1-Day Acuvue® Moist Brand Multifocal Contact Lens
62199422|NCT01753726|EXPERIMENTAL|Experimental group|43 people are recruited in order to the inclusion criteria for the study. They are healthy people. A diaphragm stretching technique was employed in this experimental group.
62199423|NCT01753726|PLACEBO_COMPARATOR|Placebo group|37 healthy people were recruited in order to the inclusion criteria.
62199424|NCT04741594|EXPERIMENTAL|Versah group|
62584937|NCT02713360|NO_INTERVENTION|Usual care|The control group will receive usual care which consists of control of ICD, disease control and treatment, and at one of the sites an offer of a group information meeting where experiences and events with ICD are discussed. The meeting takes place at Rigshospitalet every other month.
62584938|NCT03406585|EXPERIMENTAL|Allogeneic transplantation with WJMSCs|Single infusion of 200 million cells per patient.
62011916|NCT00950638|ACTIVE_COMPARATOR|dose comparison|
62011917|NCT00950638|ACTIVE_COMPARATOR|Dose comparison|
62011918|NCT04801524|NO_INTERVENTION|Holdout Arm|In the Holdout arm: patients will not receive a second text message about COVID-vaccine.
62199425|NCT01464775|EXPERIMENTAL|Narrow Band Imaging (NBI)|Women will be randomized to white light/NBI versus white light/white light laparoscopy
62199426|NCT01464775|ACTIVE_COMPARATOR|Standard White Light Laparoscopy|Women will be randomized to white light/NBI versus white light/white light laparoscopy
62199427|NCT03487965|EXPERIMENTAL|Low dose Polyphenol|130 mg of Aronia Extract with 120 mg of licorice root combination blend provided to subjects once per day for 16 weeks.
62199428|NCT03487965|EXPERIMENTAL|High dose Polyphenol|200 mg of Aronia extract provided to subjects once per day for 16 weeks
62199429|NCT03487965|PLACEBO_COMPARATOR|Placebo control|Inert tablet provided to subjects once per day for 16 weeks
62199430|NCT02412735|EXPERIMENTAL|Rexlemestrocel-L|Participants received rexlemestrocel-L 2.0 mL injection of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with saline on Day 0 (Visit 2).
62011919|NCT04801524|EXPERIMENTAL|Self-benefit sub-arm|In the Self-benefit sub-arm, participants will be reminded that the vaccine helps protect themselves from COVID.
62011920|NCT04801524|EXPERIMENTAL|Prosocial-benefit sub-arm|In the Prosocial-benefit sub-arm, participants will be reminded that the vaccine helps protect their family, friends, and community from COVID.
62011921|NCT04801524|EXPERIMENTAL|Early-access and self-benefit sub-arm|In the Early access + self-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect themselves from COVID.
62011922|NCT04801524|EXPERIMENTAL|Early-access and prosocial-benefit sub-arm|In the Early access + prosocial-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect their family, friends, community from COVID.
62199431|NCT02412735|EXPERIMENTAL|Rexlemestrocel-L + HA|Participants received rexlemestrocel-L 2.0 mL injection of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with hyaluronic acid (HA) solution on Day 0 (Visit 2).
62199432|NCT02412735|PLACEBO_COMPARATOR|Placebo|Participants received saline solution as matching-placebo on Day 0 (Visit 2).
62199433|NCT00551330|EXPERIMENTAL|1|Vicriviroc 30 mg QD
62577374|NCT02139202|OTHER|Full Program|"The intervention will (1) use the GlowCaps, a remote monitoring and reminder pill bottle; (2) be assigned an engagement advisor from the study team; (3) be asked to provide the study team with names and contact information of up to 3 family members or friends as support partners for medication adherence. The study team will contact these people in order listed until 1 agrees to serve in this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on medication adherence for the first three months; and (5) will determine their preferences for Way to Health platform communication methods during the study.~The group receiving the program intervention will also have their claims data analyzed for the 1 months post-enrollment."
62784342|NCT03009617|EXPERIMENTAL|Intervention Group|The educational program and counseling Pre-test before intervention Monitoring, education, and consultation through the Web At least two reminders via e-mail or phone message a week The last test after three months The website was closed three months later.
62784343|NCT03009617|NO_INTERVENTION|Control Group|Pre-test No intervention The last test after three months Opening the website to the control group
62784344|NCT02065817|EXPERIMENTAL|Tracer|
62784345|NCT00474617|EXPERIMENTAL|Participants 18 to 64 years old|Participants to receive an intravenous (IV) single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of second twitch (T2) with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
62011923|NCT04801524|EXPERIMENTAL|Fresh start and self-benefit sub-arm|In the Fresh start + self-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect themselves from COVID and chart a new path forward.
62011924|NCT04801524|EXPERIMENTAL|Fresh start and prosocial-benefit sub-arm|In the Early access + prosocial-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect their family, friends, community from COVID and help our nation chart a new path forward.
62011925|NCT02077517|ACTIVE_COMPARATOR|hand sewn anastomosis|Patients with hand sewn anastomosis during Roux en Y Gastric bypass performing
62199434|NCT00551330|PLACEBO_COMPARATOR|2|Placebo
62199435|NCT05370729|EXPERIMENTAL|N-acetyl cysteine (NAC)|Conservative management + ILE infusion 10 ml/hr + N-acetyl cysteine (NAC) infusion 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.
62199436|NCT05370729|NO_INTERVENTION|Intra lipid emulsion (ILE)|Conservative management + ILE infusion 10 ml/hr + normal saline infusion
62199437|NCT03850977||Patients and controls|Patients diagnosed with chronic pancreatitis or cirrhosis and healthy controls
62199438|NCT02571088|EXPERIMENTAL|Training Program|The treatment will consist in an endurance training program. Only patients of the trained group will be subjected to this training program which will typically consist in 3 training sessions per week during 8 weeks i.e., 24 training sessions. Each training session will last 45 min. All training sessions will take place at the hospital and will be under medical supervision.
62199439|NCT02571088|NO_INTERVENTION|No Training Program|It will be asked to the control patients to not change their habitual physical activity during the entire period of observation
62577375|NCT05827133||Individuals implanted with Clareon® Vivity® or Vivity® Toric Intraocular Lenses (IOLs)|
62577376|NCT00464490|NO_INTERVENTION|Standard Hospital Ventilation Weaning Protocol|Control. Hospital weaning protocol
62577377|NCT00464490|EXPERIMENTAL|Dexmedetomidine for Extubation|Dexmedomidine infusion to facilitate extubation
62577378|NCT04274036||Fibromyalgia Patients|Fibromyalgia patients diagnosed according to the 2016 American College of Rheumatology criteria.
62577379|NCT04274036||Healthy-Controls|Healthy controls without pain or chronic illness
62577380|NCT01548625||Healthy middle-aged human volunteers|
62577381|NCT01037517|ACTIVE_COMPARATOR|Successful Mobilizers|Successful Mobilizers are defined as having a peripheral blood CD34 \> 10X106/L.
62011926|NCT02077517|ACTIVE_COMPARATOR|stapled anastomosis|Patients with stapled anastomosis during Roux en Y Gastric Bypass performing
62784346|NCT00474617|EXPERIMENTAL|Participants 65 to 74 years old|Participants to receive an IV single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of T2 with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
62011927|NCT02096055|EXPERIMENTAL|Arm I (guadecitabine)|"INDUCTION THERAPY: Patients receive guadecitabine SC on days 1-5. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.~MAINTENANCE THERAPY: Patients receive guadecitabine as in Induction therapy. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
62011928|NCT02096055|EXPERIMENTAL|Arm II (CLOSED) (guadecitabine)|"INDUCTION THERAPY: Patients receive guadecitabine SC on days 1-10. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.~MAINTENANCE THERAPY: Patients receive guadecitabine SC on days 1-5 (days 1-10 of courses 1 and 2). Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
62199440|NCT00996606|EXPERIMENTAL|Tocilizumab in Active RA|Participants with active RA will receive tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions will be given from Baseline to Week 44, and participants will be assessed through Week 48.
62199441|NCT05761470|EXPERIMENTAL|Camrelizumab, Fluzoparib and Nab-paclitaxel|Participants who confirmed pathogenic or likely pathogenic HRR gene mutation received Camrelizumab and Fluzoparib with nab-paclitaxel from the second cycle followed by nab-paclitaxel for one cycle.
62199442|NCT05292872||OCA Treatment Group|PBC patients with a history of inadequate response or intolerance to UDCA who initiated OCA in the study window (01 Jun 2015 to 31 Dec 2021)
62199443|NCT05292872||Control Group|PBC patients with a history of inadequate response or intolerance to UDCA who were eligible but were not treated with OCA (or off-label fibrates) in the study window (01 Jun 2015 to 31 Dec 2021)
62199444|NCT00521157|EXPERIMENTAL|intervention|Experimental group randomised after abstinence oriented treatment
62199445|NCT00521157|NO_INTERVENTION|2|waiting list control
62577382|NCT01037517|EXPERIMENTAL|Poor Mobilizers|Poor Mobilizer are defined as patients who on Day -1 have a peripheral blood \[CD34\] ≤ 10 X106/L
62577383|NCT01492374|EXPERIMENTAL|Arm 1: BMS-241027 (0.003 mg/kg)|
62577384|NCT01492374|EXPERIMENTAL|Arm 2: BMS-241027 (0.01 mg/kg)|
62577385|NCT01492374|EXPERIMENTAL|Arm 3: BMS-241027 (0.03 mg/kg)|
62577386|NCT01492374|EXPERIMENTAL|Arm 4: Placebo matching BMS-241027|
62577387|NCT04614181|EXPERIMENTAL|Carbohydrate and protein loading|Nestle Resource drink
62577388|NCT04614181|ACTIVE_COMPARATOR|Usual care|Usual fracture care as determined by clinical team
62577389|NCT04284098|PLACEBO_COMPARATOR|GA group|Group I (GA group): Standard general anesthesia (GA) .
62577390|NCT04284098|ACTIVE_COMPARATOR|Bupivacaine group|Group II (B group): ultrasound-guided PECS block using bupivacaine 0.25% + standard GA.
62577391|NCT04284098|ACTIVE_COMPARATOR|Dexmedetomidine&bupivacaine group|Group III (D group): ultrasound-guided PECS block using bupivacaine 0.25% and Dexmedetomidine 1µg/kg+standard GA.
62577392|NCT04698330|EXPERIMENTAL|Group A|LADA patients are assigned to receive berberine and inulin for 3-month.
62577393|NCT04698330|EXPERIMENTAL|Group B|LADA patients are assigned to receive berberine and placebo(for inulin) for 3-month.
62199446|NCT03349502|EXPERIMENTAL|MG4101|"MG4101 administration (Not yet commercialized)~1. Dosage Bwt\<50 : 2.0 x109 cells (2 bags) 50≤Bwt\<70 : 3.0 x109 cells (3 bags) 70≤Bwt\<100 : 4.0 x109 cells (4 bags) Bwt≥100 : 5.0 x109 cells (5 bags)~2. Duration and frequency~   * Intravenous over 1 hour~  * Day 4, Day 11, Day 18 of each cycle"
62199447|NCT02655289|EXPERIMENTAL|Modulated TENS|
62199448|NCT02655289|PLACEBO_COMPARATOR|Placebo TENS|
62199449|NCT06542640|EXPERIMENTAL|CHR with mb-rt-fMRI-NFB Group|This CHR group will receive experimental treatment via mb-rt-fMRI-NFB, in a targeted frontal lobe region including the dorsolateral prefrontal cortex (DLPFC).
62199450|NCT06542640|SHAM_COMPARATOR|CHR with sham mb-rt-fMRI-NFB Group|This CHR group will receive treatment via mb-rt-fMRI-NFB, but in a different, uninvolved brain region
62199451|NCT06542640|EXPERIMENTAL|CHR with rTMS Group|This CHR group will receive experimental treatment via rTMS, along a targeted neural pathway extending from the cerebellum to the midbrain to the dorsolateral prefrontal cortex (DLPFC)
62199452|NCT06542640|SHAM_COMPARATOR|CHR with sham rTMS Group|This CHR group will receive treatment via rTMS, but in a different, uninvolved brain region
62199453|NCT06542640|NO_INTERVENTION|Healthy Control Group|The healthy control group will not receive any treatment, but will be used as a comparison for the 2 experimental and 2 sham groups.
62199454|NCT02511444|OTHER|single arm|All patients will have GBS culture and real time PCR performed.
62199455|NCT01264432|EXPERIMENTAL|Treatment (veliparib, LDRWAR)|Patients receive veliparib PO BID on days 1-21 (days 5-21 of course 1). Patients undergo LDFWAR in BID on days 1 and 5 of weeks 1-3. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
62199456|NCT01537692|EXPERIMENTAL|BDP HFA Nasal Aerosol 80 mcg/d|single dose, intranasal aerosol
62199457|NCT01537692|EXPERIMENTAL|BDP HFA Nasal Aerosol 320 mcg/d|single dose, intranasal aerosol
62199458|NCT01537692|ACTIVE_COMPARATOR|BDP HFA Inhalation Aerosol 320 mcg/d|single dose, orally inhaled aerosol
62199459|NCT03557645|SHAM_COMPARATOR|Baseline Mechanical Ventilation|The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow = 60Lpm and tidal volume = 6mL/IBW. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
62199460|NCT03557645|EXPERIMENTAL|VHI With Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow will be set at 20Lpm, the tidal volume will be increased in steps of 200mL until the peak airway pressure of 40cmH2O is achieved, and an inspiratory pause will be applied at the end of inspiration. After achieving the target pressure, this ventilatory regimen will last 15 minutes. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
62199461|NCT03557645|EXPERIMENTAL|VHI Without Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow will be set at 20Lpm and the tidal volume will be increased in steps of 200mL until the peak airway pressure of 40cmH2O is achieved. After achieving the target pressure, this ventilatory regimen will last 15 minutes. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
62199462|NCT04192110|EXPERIMENTAL|Diuretic initiation or augmentation|Participants will either initiate or increase the dose of a loop or thiazide-type diuretic
62199463|NCT02857075||Rhesus positive individuals|Red cell concentrates from RH1 individuals from each ABO group is used for the study. Red cell concentrates derived from blood donation.
62199464|NCT02857075||Rhesus negative individuals|red cell concentrates from RH-1 individuals from each ABO group is used for the study. Red cell concentrates derived from blood donation.
62199465|NCT00223847|OTHER|1|
62199466|NCT00023998|EXPERIMENTAL|Treatment (combination chemotherapy)|See detailed description.
62199467|NCT04643483|EXPERIMENTAL|Certolizumab pegol low dose arm|"Participants randomized to certolizumab pegol (CZP) who weigh ≥17 kg to \<40 kg will receive placebo at Week 0 and a loading dose of 200 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 100 mg CZP subcutaneously (sc) every 2 weeks (Q2W).~Participants randomized to CZP who weigh ≥40 kg will receive placebo at Week 0 and a loading dose of 400 mg at Weeks 0, 2, and 4, followed by placebo and a maintenance dose of 200 mg CZP sc Q2W."
62199468|NCT04643483|EXPERIMENTAL|Certolizumab pegol high dose arm|"Participants randomized to CZP who weigh ≥17 kg to \<40 kg will receive placebo at Week 0 and a loading dose of 200 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 200 mg CZP sc Q2W.~Participants randomized to CZP who weigh ≥40 kg will receive placebo at Week 0 and a loading dose of 400 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 300 mg CZP sc Q2W."
62199469|NCT04643483|ACTIVE_COMPARATOR|Adalimumab reference arm|"Participants randomized to adalimumab who weigh ≥17 kg to \<40 kg will receive a loading dose of 80 mg at Week 0 and 40 mg at Week 2, followed by a maintenance dose of 20 mg sc Q2W.~Participants randomized to Adalimumab who weigh ≥40 kg will receive a loading dose of 160 mg at Week 0 and 80 mg at Week 2, 40 mg and placebo at week 4 followed by a maintenance dose of 40 mg sc and placebo Q2W."
62199470|NCT01306539|EXPERIMENTAL|Deep Brain Stimulation|Parkinson's patients with deep brain stimulation in the subthalamic nucleus.
62199471|NCT03116568||IBD Case|"1. Pregnant women with IBD~2. Newborns of pregnant women with IBD~3. Family member of pregnant women with IBD~4. Siblings of newborns"
62199472|NCT03116568||Control|"1. Pregnant women without IBD~2. Newborns of pregnant women without IBD~3. Family member of pregnant women without IBD~4. Siblings of newborns"
62577394|NCT04698330|EXPERIMENTAL|Group C|LADA patients are assigned to receive placebo(for berberine) and inulin for 3-month.
62199473|NCT05442281||Vegan diet|Children fed vegan diet from 6 months of life
62199474|NCT05442281||Mixed diet|Children fed mixed diet from 6 months of life
62199475|NCT04400110|EXPERIMENTAL|Short treatment group|Amoxicillin and clavulanic acid 50 mg/kg three times daily administered orally for 5 consecutive days
62199476|NCT04400110|ACTIVE_COMPARATOR|Standard treatment group|amoxicillin and clavulanic acid 50 mg/kg three times daily administered orally for 10 consecutive days
62199477|NCT06023251|OTHER|Cohort|oral food, enteral nutrition, parenteral nutrition
62199478|NCT00788970|EXPERIMENTAL|Acupressure|Acupressure adjuvant therapy
62199479|NCT00788970|PLACEBO_COMPARATOR|Placebo acupressure|Sham acupressure adjuvant therapy
62199480|NCT00788970|NO_INTERVENTION|No treatment|Wait list group (no treatment)
62784347|NCT00474617|EXPERIMENTAL|Participants 75 years and older|Participants to receive an IV single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of T2 with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
62784348|NCT02263443|EXPERIMENTAL|Soap sus enema (S.S.E.)|Patients in S.S.E. group will receive bowel preparation by soap suds enema until clear at night before surgery.
62199481|NCT01754753|ACTIVE_COMPARATOR|Telephone friendship groups|"Participants allocated to telephone friendship groups will take part in 12 weekly group telephone discussions. The participant will be called, by a trained Age UK Sheffield volunteer, in their own home. The group discussions will take place for about an hour each week and involve between 6-8 participants. Participants will be introduced to weekly group calls by the volunteer who will call each participant individually for around 20 minutes each week for up to six weeks before the group is established.~The group may have a particular focus or talk about different topics each week. The individual participants are joined together through a teleconferencing system (provided by Community Network)."
62577395|NCT04698330|PLACEBO_COMPARATOR|Group D|LADA patients are assigned to receive placebo(for berberine) and placebo(for inulin) for 3-month.
62577396|NCT06499454||Patients with suspected lung disease undergoing routine bronchoscopic biopsy|
62577397|NCT02975388|EXPERIMENTAL|Label: RO7079901 (Mild) (Part 1)|Participants with mild renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
62784349|NCT02263443|EXPERIMENTAL|sodium chloride enema|Patients in unison enema group will receive Unison enema 100 ml per rectal at night before surgery.
62011929|NCT02096055|EXPERIMENTAL|Arm III (guadecitabine, idarubicin)|"INDUCTION THERAPY: Patients receive guadecitabine SC on days 1-5 and idarubicin IV over up to 1 hour on days 1-2. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.~MAINTENANCE THERAPY: Patients receive guadecitabine SC on days 1-5 and idarubicin IV over up to 1 hour on day 1. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
62784350|NCT02263443|PLACEBO_COMPARATOR|no enema|Patients will receive none of bowel preparation. NPO after midnight
62011930|NCT02096055|EXPERIMENTAL|Arm IV (CLOSED) (guadecitabine, cladribine)|"INDUCTION THERPAY: Patients receive guadecitabine SC and cladribine IV over up to 1 hour on days 1-5. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.~MAINTENANCE THERAPY: Patients receive guadecitabine SC and cladribine IV over up to 1 hour on days 1-5. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
62011931|NCT02788175|EXPERIMENTAL|HIV-infected Adults on cART|HIV-infected Adults (age 18 - 65) on CART with suppressed viremia
62011932|NCT01196728|EXPERIMENTAL|CM3.1-AC100 dose A|Compound CM3.1-AC100 s.c.
62011933|NCT01196728|EXPERIMENTAL|CM3.1-AC100 dose B|Compound CM3.1-AC100 s.c.
62011934|NCT01196728|EXPERIMENTAL|CM3.1-AC100 dose C|Compound CM3.1-AC100 s.c.
62011935|NCT01196728|PLACEBO_COMPARATOR|Placebo|Placebo for compound CM3.1-AC100 s.c.
62011936|NCT04151810|EXPERIMENTAL|anti-EGFR monoclonal antibody|This is a dose-escalation phase, all participants will receive treatment with CDP1. Participants enrolled in this trial may receive one of the following doses dependent upon time of enrolment into the study.
62011937|NCT04151810|EXPERIMENTAL|anti-EGFR monoclonal antibody + chemotherapy|This is a dose-expansion phase, participants with penile squamous cell carcinoma will receive CDP1 in combination with TIP chemotherapy.
62011938|NCT03167294|OTHER|Single Arm|AquaBeam System for resection and removal of prostatic tissue in males suffering from BPH
62011939|NCT00970086|EXPERIMENTAL|transversus abdominal plane block|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures with ultrasound, insertion of the stimuplex needle G22, 50mm, in an in-plane approach and administration of 0.4ml/kg levobupivacaine 0.25%."
62011940|NCT03433456|EXPERIMENTAL|Home visitation + HABITS Program|The HABITS module will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children. Participants will receive the HABITS module in addition to their standard home visitation services.
62199482|NCT01754753|NO_INTERVENTION|Usual health and social care|Participants allocated to the control arm will not receive any research intervention. However, they will participate in the research by completing questionnaires about their health and wellbeing.
62577398|NCT02975388|EXPERIMENTAL|RO7079901 (Moderate) (Part 1)|Participants with moderate renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
62577399|NCT02975388|EXPERIMENTAL|RO7079901 (Severe) (Part 1)|Participants with severe renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
62784351|NCT05641636||childhood cancer survivors - the main group|childhood cancer survivals after complex management of cranial and craniospinal tumors formed the main group
62011941|NCT03433456|ACTIVE_COMPARATOR|Standard home visitation program|Participants will receive the standard of care home visitation regularly delivered through the existing home visitation program without the HABITS module.
62011942|NCT04800185|OTHER|Treatment group|
62011943|NCT01897311|EXPERIMENTAL|grupo TENS com frequência de 100 Hz|TENS application of high frequency (100 Hz, 100 μs)
62011944|NCT01897311|EXPERIMENTAL|grupo TENS com frequência de 4 Hz|Application of low-frequency TENS (4 Hz, 100 μs)
62011945|NCT01897311|PLACEBO_COMPARATOR|Placebo with TENS off|TENS application when off
62784352|NCT05641636||the control group|healthy people formed the control group
62011946|NCT05597020|EXPERIMENTAL|50 mg daridorexant|Daridorexant will be taken orally, once daily in the evening within approximately 30 min before going to bed.
62011947|NCT05597020|PLACEBO_COMPARATOR|Placebo|Matching placebo will be taken orally, once daily in the evening within approximately 30 min before going to bed.
62784353|NCT05510336|ACTIVE_COMPARATOR|Study group|Concentric needle technique TMJ arthrocentesis using lactated ringer solution to help reduce inflammatory mediators and anterior disc discplacement with reduction
62199483|NCT05351320|EXPERIMENTAL|WX-0593 single arm|"Part 1: Participants will receive WX-0593 monotherapy until disease progression or unacceptable toxicity.~Part 2: Participants will receive 1 or 2 cycles of WX-0593 monotherapy and subsequently with concurrent chemoradiation, followed by WX-0593 monotherapy until disease progression or unacceptable toxicity."
62199484|NCT05017428|EXPERIMENTAL|Low Dose|The Low Dose arm provides subjects with supplementation with 5mg of spermidine (in the form of 5g of a 0.1% spermidine wheat germ extract), 500mg of nicotinamide, 400mg of palmitoylethanolamide, and 200mg of oleoylethanolamide.
62577400|NCT02975388|ACTIVE_COMPARATOR|RO7079901 (Normal) (Part 1)|Control group of participants with normal renal function will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
62577401|NCT02975388|EXPERIMENTAL|RO7079901 (End-stage) (Part 2)|Participants with stable end-stage renal disease undergoing hemodialysis will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
62577402|NCT05737381|NO_INTERVENTION|Control group|"The oocytes from a patient, retrieving more than 8 oocytes will be divided into 2 sibling groups. The control group and the study group.~The first part of the collected oocytes, will be included as controls. If an unequal numbers of oocytes are collected, the extra oocyte will be included into the control group.~Control oocytes are, after fertilization, placed in conventional 5% O2 incubators and cultured herein for 5 days."
62577403|NCT05737381|EXPERIMENTAL|Study group|"The second part of the collected oocytes, from a patient retrieving more than 8 oocytes, will be included as study group.~Study oocytes, are after fertilization, placed and cultured in conventional 5% O2 incubators for the first 3 days. At day 3, the embryos are moved to an incubator with 2% O2 tension and cultured until day 5."
62577404|NCT05366348|EXPERIMENTAL|Horse-back riding|The study group received horse-back riding training for eight weeks.
62577405|NCT05366348|NO_INTERVENTION|Control group|Sedentary adolescent individuals who do not ride horses
62784354|NCT05510336|ACTIVE_COMPARATOR|Control group|Double needle technique TMJ arthrocentesis using lactated ringer solution to help reduce inflammatory mediators and anterior disc discplacement with reduction
62784355|NCT05921253|PLACEBO_COMPARATOR|Self administration of Low Level Tragus Stimulation (LLTS; Placebo)|PARASYM neuromodulation device will be placed in a pre-determined position of one ear for 1 hour every day for 14 days.
62784356|NCT05921253|EXPERIMENTAL|Self administration of LLTS|PARASYM neuromodulation device will be placed in a pre-determined position (different from that of the placebo) of one ear for 1 hour every day for 14 days.
62784357|NCT01139177|EXPERIMENTAL|Stent placement|
62784358|NCT00486824|ACTIVE_COMPARATOR|Indomethacin|50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
62784359|NCT00486824|ACTIVE_COMPARATOR|Nifedipine|30 mg Nifedipine initially followed by 20 mg every 6 hrs for 48 hrs.
62784360|NCT04683445||HR+/HER2- advanced breast cancer|Efficacy and Safety of Eribulin in the Treatment of HR+/HER2- Advanced Breast Cancer
62784361|NCT04683445||HER2+ advanced breast cancer|Efficacy and Safety of Eribulin and anti-HER2 Targeted therapy in the Treatment of HER2+ advanced breast cancer
62784362|NCT04683445||triple negative advanced breast cancer|Efficacy and Safety of Eribulin and Immunotherapy in the Treatment of triple negative advanced breast cancer
62784363|NCT01688115|EXPERIMENTAL|Procedure|
62784364|NCT01688115|ACTIVE_COMPARATOR|Standard Care|
62011948|NCT06562036|EXPERIMENTAL|Sildenafil|Patients were given oral sildenafil at 2 mg per kg per day, 6-hourly, with an increment of 0.5 mg per kg per dose and a target maintenance dose of 2 mg per kg per dose every 6 hours by nasogastric tube.
62784365|NCT01958359|EXPERIMENTAL|Short IVR|IVR-based alcohol diary with feedback
62784366|NCT01958359|EXPERIMENTAL|Therapeutic IVR|IVR-based conversation offering a menu of exercises and vignettes.
62784367|NCT01958359|NO_INTERVENTION|Control|Untreated control group
62784368|NCT02805855|EXPERIMENTAL|S50|Subjects in the S50 cohort will receive one injection of 50 million AMSCs.
62784369|NCT02805855|EXPERIMENTAL|S100|Subjects in the S100 cohort will receive one injection of 100 million AMSCs.
62784370|NCT02805855|EXPERIMENTAL|M50|Subjects in the M50 cohort will receive three injections of 50 million AMSCs at one-month intervals.
62784371|NCT02805855|EXPERIMENTAL|M100|Subjects in the M100 cohort will receive three injections of 100 million AMSCs at one-month intervals.
62784372|NCT00822536|ACTIVE_COMPARATOR|1|Bi therapy : aspirin/ clopidogrel
62784373|NCT00822536|ACTIVE_COMPARATOR|2|Monotherapy: aspirin
62784374|NCT00964821||Flu vaccine|Patients and normal volunteers who have received a flu vaccine
62011949|NCT06562036|EXPERIMENTAL|Sildenafil + Milrinone|In this group, Milrinone was initiated at 0.5 ug per kg per minute using intravenous infusion through a syringe pump, and sildenafil was given in the same protocol mentioned for the Sildenafil Group.
62011950|NCT00654849|EXPERIMENTAL|1|compare security and effectiveness of use Electrosurgical Bipolar Plasmakinetic Vessel Sealing
62011951|NCT00654849|ACTIVE_COMPARATOR|2|traditional abdominal hysterectomy technique with the use of sutures
62011952|NCT05349448|ACTIVE_COMPARATOR|solo group|Bupivacaine 5 mg (1 mL) + Triamcinolone 40 mg (1 mL) + Saline solution (2 mL) + Hyaluronidase 1,500 IU reconstituted in 1 mL distilled water (HYL)
62011953|NCT05349448|ACTIVE_COMPARATOR|dex plus hyalase group|Bupivacaine 5 mg (1 mL) + Triamcinolone 40 mg (1 mL) + Dexmedetomidine 0.5mic/kg + Hyaluronidase 1,500 IU reconstituted in 1 mL distilled water (HYL)+ Saline solution (2 mL)
62400963|NCT02687724|ACTIVE_COMPARATOR|Standard treatment as per SmPC|Patients will receive standard loading dose of GLM of 200/100 mgs at WKS 0 \& 2. They will then receive 100mgs/ 50mgs depending on their weight as per SmPC. Patients will report their modified partial mayo score and SHS score every 4 weeks (PRO) and provide it to the investigator site via a web based application.
62011954|NCT06564376|OTHER|Total magnesium|Magnesium dosing based on total Mg blood level
62011955|NCT06564376|ACTIVE_COMPARATOR|ionized Magnesium|Magnesium dosing based upon ionized Mg level
62400964|NCT02687724|EXPERIMENTAL|Intervention Arm|Patients will receive standard loading dose of GLM of 200/100 mgs at WKS 0 \& 2. As with Group 1, Patients will report their modified partial mayo and SHS score every four weeks ( the window for this will be +/- one week) and provide it to the investigator site via a web based application. In addition FCP, GLM DL and ADA shall be measured every four weeks.
62400965|NCT01400659|ACTIVE_COMPARATOR|CARB Counting|For CARB counting, insulin dose will be calculated according to the carbohydrate content of the test meal (1 carb unit = 10 g carbohydrate). The insulin-to-carbohydrate ratio will be applied according to the current individual therapy of the patient.
62784375|NCT00964821||Non-vaccine|Patients and normal volunteers who have not received the flu vaccine
62011956|NCT06664177|ACTIVE_COMPARATOR|anterior quadratus lumborum block|The anterior QLB block will be applied on the operative side
62011957|NCT06664177|ACTIVE_COMPARATOR|transversalis fascia group|the Transversalis Fascia Block will be applied on the operative side
62011958|NCT02953704||Myelofibrosis Cohort|Patients will be categorized as low-risk using Dynamic International Prognostic Scoring System (DIPSS) risk OR intermediate-1 risk by DIPSS by reason of age alone.
62011959|NCT02953704||Essential Thrombocythemia Cohort|Patients will be age ≥ 60 years OR have history of thromboembolic events OR currently receiving ET-directed therapy.
62400966|NCT01400659|ACTIVE_COMPARATOR|CFP counting|For CFP counting, insulin dose will be calculated according the carbohydrate content (1 carb unit = 10 g carbohydrate) as well as fat/protein content (1 FPU = 100 kcal from fat and protein) of the meal. The insulin-to-carbohydrate ratio will be applied according to the current individual therapy of the patient. The insulin-to-FPU ratio is the same as the insulin to carb ratio.
62011960|NCT06302764||Polish Medical Staff|Medical doctors, and emergency staff (paramedics), involved in treating life-threatening conditions
62011961|NCT06302764||Ukrainian Medical Staff|Medical doctors, and emergency staff (paramedics), involved in treating life-threatening conditions
62011962|NCT06302764||Portuguese Medical Staff|Medical doctors, and emergency staff (paramedics), involved in treating life-threatening conditions
62011963|NCT06302764||Spanish Medical Staff|Medical doctors, and emergency staff (paramedics), involved in treating life-threatening conditions
62011964|NCT05405673||Colorectal neoplasia screening/surveillance cohort|Subjects with average risk of colorectal neoplasias requiring screening/surveillance colonoscopy
62011965|NCT03611634||BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|The aim of this study is just to constitute a biological collection from samples from the GUT microbiote in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
62011966|NCT06533605|EXPERIMENTAL|Arm 1|dose level 1 of SSGJ-706
62011967|NCT06533605|EXPERIMENTAL|Arm 2|dose level 2 of SSGJ-706
62011968|NCT06533605|EXPERIMENTAL|Arm 3|dose level 3 of SSGJ-706
62011969|NCT06533605|EXPERIMENTAL|Arm 4|dose level 4 of SSGJ-706
62011970|NCT06533605|EXPERIMENTAL|Arm 5|dose level 5 of SSGJ-706
62011971|NCT06533605|EXPERIMENTAL|Arm 6|dose level 6 of SSGJ-706
62011972|NCT06533605|EXPERIMENTAL|Arm 7|dose level 1 of SSGJ-706
62011973|NCT06533605|EXPERIMENTAL|Arm 8|dose level 2 of SSGJ-706
62011974|NCT06533605|EXPERIMENTAL|Arm 9|dose level 3 of SSGJ-706
62011975|NCT06533605|EXPERIMENTAL|Arm 10|dose level 4 of SSGJ-706
62400967|NCT04601389|EXPERIMENTAL|"GNR-044 (JSC GENERIUM, the Russian Federation)"|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
62400968|NCT04601389|ACTIVE_COMPARATOR|Xolair® (Novartis Pharma AG, Switzerland)|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
62400969|NCT04570033|EXPERIMENTAL|patients with hyperparathyroidism|We prospectively enrolled 65 consecutive patients with primary hyperparathyroidism (PHPT) who underwent neck ultrasound (US) and parathyroid scintigraphy (99mTc/99mTc-MIBI dual phase). Twenty-two patients had unsuccessful parathyroid surgery prior to the study
62577406|NCT00410332|ACTIVE_COMPARATOR|A|TRAUMEEL S
62199485|NCT05017428|EXPERIMENTAL|Medium Dose|The Medium Dose arm provides subjects with supplementation with 10mg of spermidine (in the form of 10g of a 0.1% spermidine wheat germ extract), 750mg of nicotinamide, 800mg of palmitoylethanolamide, and 400mg of oleoylethanolamide.
62199486|NCT05017428|EXPERIMENTAL|High Dose|The Low Dose arm provides subjects with supplementation with 15mg of spermidine (in the form of 15g of a 0.1% spermidine wheat germ extract), 1000mg of nicotinamide, 1200mg of palmitoylethanolamide, and 600mg of oleoylethanolamide.
62199487|NCT05017428|PLACEBO_COMPARATOR|Placebo|In this arm the participants are given supplementation with a placebo control consisting of 15g of wheat flour.
62011976|NCT06533605|EXPERIMENTAL|Arm 11|dose level 5 of SSGJ-706
62011977|NCT06533605|EXPERIMENTAL|Arm 12|dose level 6 of SSGJ-706
62199488|NCT00975468|ACTIVE_COMPARATOR|Pressure-Controlled Ventilation|The patients' lungs ventilation will be initiated with a peak airway pressure that provided a tidal volume of 8 ml.kg-1. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
62400970|NCT01980056|EXPERIMENTAL|Vosaroxin: All Patients|All patients will receive vosaroxin according to the dose cohort in which they are enrolled.
62400971|NCT06649786|EXPERIMENTAL|Endoscopic superior rectal mucosal ligation group|The patient is treated with endoscopic superior rectal mucosal ligation
62011978|NCT04391010|OTHER|Health care providers with beard|
62011979|NCT04391010|OTHER|Health care providers without beard|
62199489|NCT00975468|PLACEBO_COMPARATOR|Volume Controlled Ventilation|The patients' lungs will ventilated with a tidal volume of 8 ml.kg-1. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
62199490|NCT02438553|EXPERIMENTAL|OSTNS Neurostimulator|Combined Occipital \& Supraorbital Transcutaneous Neurostimulator.
62199491|NCT02438553|PLACEBO_COMPARATOR|Placebo OSTNS Neurostimulator|Placebo Combined Occipital \& Supraorbital Transcutaneous Neurostimulator.
62199492|NCT00477503|ACTIVE_COMPARATOR|Group A|Ga-67 citrate injection alone for individuals with cancer cells in cerebral spinal fluid (CSF), no earlier treatment for disease.
62199493|NCT00477503|ACTIVE_COMPARATOR|Group B|Ga-67 + In 111 DTPA injection for individuals who have cancer cells in CSF, no earlier treatment for disease.
62400972|NCT06649786|ACTIVE_COMPARATOR|Endoscopic hemorrhoid ligation group|The patient is treated with endoscopic hemorrhoids ligation
62577407|NCT00410332|PLACEBO_COMPARATOR|B|
62011980|NCT06570772|EXPERIMENTAL|AVT16|Experimental Arm AVT16 300mg iv is the proposed biosimilar for Entyvio (vedolizumab)
62011981|NCT06570772|ACTIVE_COMPARATOR|Entyvio|Entyvio (vedolizumab) 300mg iv is the proposed active comparator for AVT16
62011982|NCT03135223|EXPERIMENTAL|Intervention group|Co-created, school-based intervention to promote physical activity
62011983|NCT03135223|NO_INTERVENTION|Control group|
62011984|NCT05621421||Patients with long coronary artery lesions|Consecutive patients with functionally significant (FFR ≤ 0.8) long lesion requiring a stent length of ≥ 30mm to undergo FFR and IVUS guided PCI.
62011985|NCT03821571|EXPERIMENTAL|Patient with primary aldosteronism|Brain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.
62199494|NCT00477503|ACTIVE_COMPARATOR|Group C|Individuals with tumors in the CSF that have been treated and are now cleared from the CSF, receive standard follow-up care (baseline injection of Ga-67 citrate and In-111 DTPA).
62199495|NCT01060397|EXPERIMENTAL|Extended Brief Intervention|FRAMES motivational interviewing approach
62577408|NCT03031483|EXPERIMENTAL|Experimental: clarithromycin and lenalidomide|CLARITHROMYCIN: daily orally administration in cycles of 28 days; 500mg film-coated tablets LENALIDOMIDE: every cycle of treatment lasts 28 days; daily orally administration is of 21 consecutive days with a week of rest. 20mg capsule hard. The maximum treatment duration is 12 months.
62784376|NCT04471506|OTHER|study group will receive interval training and mindfulness breathing|exercise program in form of a cycling protocol which will be comprised 5 minutes of warming up before exercise initiation and another 5 minutes for cooling down by the end of the exercise session in the form of slow pedaling (50% of PHR). The work interval also will be consisted of 8-12 cycling intervals (60s cycling work interval with 120s of passive rest or low-intensity cycling (70% of PHR) between work intervals that progressively will be reduced until reaching 90s by the end of the exercise program). Mindful breathing is a exercise that involves using breathing as an object of attention. 15-minute mindful breathing intervention will be adapted. It consists of the following three steps: (a) adopt a physical posture, (b) establish a mindfulness anchor, and (c) maintain mindfulness
62784377|NCT04471506|OTHER|diet recommendations|The control group will receive diet recommendations. The volunteers will follow diet recommendations for 12 weeks
62784378|NCT06272500|PLACEBO_COMPARATOR|Group A|receives only oral administration of placebo, with one capsule taken three times a day.
62784379|NCT06272500|EXPERIMENTAL|Group B|receives only oral administration of a compound digestive enzyme capsule, with one capsule taken three times a day.
62784380|NCT06272500|EXPERIMENTAL|Group C|receives only oral administration of Betaine hydrochloride（BHCL), with one capsule before each meal.
62784381|NCT03986333||Control|Children whose drooling was expected to remain relatively stable over 1 month
62784382|NCT03986333||Intervention|Children receiving a treatment to reduce their drooling
62199496|NCT01060397|EXPERIMENTAL|Control|Usual care
62199497|NCT01627535|EXPERIMENTAL|Optical Imaging|Patients undergo i2DOS
62784383|NCT04869306|ACTIVE_COMPARATOR|Hyaluronic acid|hyaluronic acid gel application after lower third molar removal
62784384|NCT04869306|ACTIVE_COMPARATOR|Hyaluronic acid+carrier|hyaluronic acid gel application together with a carrier after lower third molar removal
62199498|NCT01954225|OTHER|Udumbara sutra|The Udumbara Sutra is a standard medicated thread smeared with latex of Udumbara (Ficus Glomerata) which has cutting and healing property.
62199499|NCT04321421|EXPERIMENTAL|treated|treated with hyperimmune plasma
62199500|NCT01800890|OTHER|Treatment sequence 1|"Subjects randomised to Treatment sequence 1 will test three different products:~1. Coloplast A~2. Coloplast B~3. SenSura Click~The subjects test the three test products in a randomized order: ABS; BSA, SAB"
62199501|NCT01800890|EXPERIMENTAL|Treatment sequence 2|"Subjects randomised to Treatment sequence 2 will test three different products:~1. Coloplast C (C)~2. Coloplast B (B)~3. SenSura Click (S)~The subjects test the three test products in a randomized order: CBS; BSC, SCB"
62577409|NCT01521286||Group A|Subjects presenting with HZ episode.
62784385|NCT04869306|NO_INTERVENTION|Standard treatment|standard treatment after lower third molar removal (i.e., blood clot only)
62784386|NCT05654454|EXPERIMENTAL|Bevacizumab with Paclitaxel and Carboplatin|"Patients will begin Period 1 receiving bevacizumab combination therapy (Bevacizumab 15 mg/kg IV + Paclitaxel 175 mg/m2 + IV Carboplatin AUC 6 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (produced by Mabscale, LLC).~In Period 2, eligible patients will continue to receive bevacizumab (produced by Mabscale, LLC) every 3 weeks as monotherapy."
62784387|NCT05654454|ACTIVE_COMPARATOR|Avastin® with Paclitaxel and Carboplatin|"Patients will begin Period 1 receiving bevacizumab combination therapy ( Avastin® 15 mg/kg IV + Paclitaxel 175 mg/m2 IV + Carboplatin AUC 6 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (as Avastin®).~In Period 2, eligible patients will continue to receive bevacizumab (Avastin®) every 3 weeks as monotherapy."
62011986|NCT03821571|ACTIVE_COMPARATOR|Patient with essential hypertension|Brain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.
62577410|NCT03040778|EXPERIMENTAL|Standard of Care + PENTO|The current standard of care for MRONJ as outlined by the American Association of Oral and Maxillofacial Surgeons position paper based on stage of disease (Ruggiero 2014) AND PENTO regimen consisting of 400mg pentoxifylline (PTX) and 400IU tocopherol twice-daily PO for a total of 800mg/day PTX and 800 IU/day tocopherol
62577411|NCT03040778|PLACEBO_COMPARATOR|Standard of Care|The current standard of care for MRONJ as outlined by the American Association of Oral and Maxillofacial Surgeons position paper based on stage of disease (Ruggiero 2014). Placebo drugs to be taken in the control group 2 pills BID.
62784388|NCT06507696|EXPERIMENTAL|Ice Application|"* In ice application, 5 ml of drinking water was filled in a 10 ml syringe and frozen by inserting a plastic piston into it and then these frozen ice cubes were given into the mouths of the patients.~* The ice cubes were prepared before the application and stored in the freezer section of the refrigerator.~* The ice was taken out of the frozen syringe and the nurse moved it around the patient's mouth to melt it.~* By holding the ice cubes from the piston part to the researcher, the patient was allowed to suck and melt them in the mouth."
62011987|NCT04609319||Cohort 1|
62011988|NCT03992105|OTHER|historical cohort|150 homeless patients in crisis, identified from an extraction of the database of psychiatric emergencies of the same territory, and matched for age, sex, and main diagnosis.
62011989|NCT05379829|EXPERIMENTAL|Ziltivekimab 15 mg|Participants will receive ziltivekimab at weeks 0, 4 and 8.
62011990|NCT05379829|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo at weeks 0, 4 and 8.
62011991|NCT05322603|EXPERIMENTAL|the first group: a fixed combination of Orphenadrine and Diclofenac|dynamics of points 100 mm visual-analog scale,minute inspiratory lung volume
62784389|NCT06507696|EXPERIMENTAL|Wetted Gauze Application|"* During wetted gauze application, sterile gauze swabs were wetted with drinking water.~* Sterile gauze swabs (10 cm\*10cm) were wetted with 5 ml and applied for 5 minutes.~* The wetted end part of the gauze swabs was allowed to be sucked in the patient's mouth by the researcher."
62784390|NCT06507696|NO_INTERVENTION|No intervention|Patients in the control group did not receive any application
62784391|NCT05293158|EXPERIMENTAL|HBIG treatment|
62011992|NCT05322603|EXPERIMENTAL|the second group: patient-controlled analgesia (РСА) with Morphine|dynamics of points 100 mm visual-analog scale,minute inspiratory lung volume
62011993|NCT05589545|EXPERIMENTAL|Intervention|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis
62011994|NCT01722851||Cohort 1|All newly diagnosed breast cancer patients who are scheduled to undergo neoadjuvant chemotherapy
62011995|NCT01722851||Cohort 2|All breast cancer patients who present with metastatic disease, disease recurrence or progression, who are commencing up-front chemotherapy ± hormonal therapy
62011996|NCT01722851||Cohort 3|All breast cancer patient who present with metastatic disease who are commencing hormonal therapy only.
62011997|NCT05328362|ACTIVE_COMPARATOR|CanCope mindfulness|"The CanCope intervention was delivered through the MetricWire app which was available to each participant on their personal smartphone. The intervention included a push component which was responsive to a participant's level of craving (based on self-report assessed via EMA) and sent messages to each participant via the MetricWire app according to a decision rule. MetricWire randomized delivery of the push component with a probability of 0.33 for receiving a mindfulness coping strategy, 0.33 for receiving a distraction coping strategy, and 0.33 for receiving a thank-you message (attention control) at each decision point when participants were available for the intervention."
62011998|NCT05328362|ACTIVE_COMPARATOR|CanCope distraction|"The CanCope intervention was delivered through the MetricWire app which was available to each participant on their personal smartphone. The intervention included a push component which was responsive to a participant's level of craving (based on self-report assessed via EMA) and sent messages to each participant via the MetricWire app according to a decision rule. MetricWire randomized delivery of the push component with a probability of 0.33 for receiving a mindfulness coping strategy, 0.33 for receiving a distraction coping strategy, and 0.33 for receiving a thank-you message (attention control) at each decision point when participants were available for the intervention."
62577412|NCT04836962|PLACEBO_COMPARATOR|control|normal saline is administrated to patients.
62577413|NCT04836962|EXPERIMENTAL|dexamethasone|0.5mg/kg dexamethasone is administered to patients.
62584939|NCT03406585|PLACEBO_COMPARATOR|Sham transplantation (placebo)|Single infusion with albumin and dmso in sodium chloride (identical concentrations as active treatment)
62011999|NCT05328362|PLACEBO_COMPARATOR|CanCope attention control|"The CanCope intervention was delivered through the MetricWire app which was available to each participant on their personal smartphone. The intervention included a push component which was responsive to a participant's level of craving (based on self-report assessed via EMA) and sent messages to each participant via the MetricWire app according to a decision rule. MetricWire randomized delivery of the push component with a probability of 0.33 for receiving a mindfulness coping strategy, 0.33 for receiving a distraction coping strategy, and 0.33 for receiving a thank-you message (attention control) at each decision point when participants were available for the intervention."
62012000|NCT03736421||Control Cohort|"This cohort is recruited to help to define what a normal PIVA value should be during a state of presumed euvolemia."
62012001|NCT03736421||Infection Cohort|This cohort are subjects with suspected infection, enriched to contain sepsis patients.
62784392|NCT02888288|EXPERIMENTAL|Mental Health Intervention|This arm was designed based on mental health needs of HIV-infected youth in Tanzania. It incorporates principles of cognitive behavioral therapy, interpersonal psychotherapy, and motivational interviewing built into 10 group sessions, approximately 90 minutes each (2 sessions with caregiver participation) and 2 individual sessions. Groups are age and gender matched and facilitated by lay counselors with a mix of lived experience and prior mental health research experience.
62784393|NCT02888288|ACTIVE_COMPARATOR|Standard of Care|This arm includes standard medical care and adherence counseling with routine education prior to the start of the HIV youth clinic from which participants are recruited.
62784394|NCT05838092|EXPERIMENTAL|Verum|
62784395|NCT05838092|PLACEBO_COMPARATOR|Placebo|
62012002|NCT03736421||Acute Heart Failure|This cohort will have a diagnosis of CFH who are being admitted to the hospital. These patients will be followed during their hospital course.
62012003|NCT06556680|NO_INTERVENTION|Control Arm|In the control arm, patients will only receive their regular scheduled bronchoscopy for biopsy.
62012004|NCT06556680|EXPERIMENTAL|OCT Imaging Arm|In the OCT-imaging arm, OCT images will be obtained and and used for biopsy guidance.
62012005|NCT06155903|ACTIVE_COMPARATOR|Selective Spinal Anesthesia|The participant will receive selective spinal anesthesia.
62012006|NCT06155903|ACTIVE_COMPARATOR|Peripheral nerve blocks|The participant will receive a combination of femoral nerve block, sciatic nerve block with parasacral approach, lateral femoral cutaneous nerve block and obturator nerve block.
62012007|NCT04796610|EXPERIMENTAL|Intervention patients|Unsuppressed HIV patients at the intervention clinic will receive guidance from their health care provider on the selection of a treatment partner. The patient will receive education on HIV treatment and how treatment partners can support patients in treatment adherence.
62012008|NCT04796610|NO_INTERVENTION|Control patients|Patients at the control clinic will receive standard of care at the clinic during the intervention assessment period.
62012009|NCT04796610|EXPERIMENTAL|Intervention treatment partners|Unsuppressed HIV patients at the intervention clinic will receive guidance from their health care provider on the selection of a treatment partner. The treatment partner will receive education on HIV treatment and how treatment partners can support patients in treatment adherence.
62012010|NCT04796610|NO_INTERVENTION|Control treatment partners|Treatment partners will not receive any intervention; treatment partners' patients at the control clinic will receive standard of care at the clinic during the intervention assessment period.
62012011|NCT06236035||Group Control|
62012012|NCT06236035||Group ANI|
62012013|NCT03047161||High-risk pregnancy|abnormal fetal heart rate or rhythm or risk of abnormal fetal heart rate or rhythm
62784396|NCT03776591|EXPERIMENTAL|Open D3|Right colectomy Open surgery Central lymphadenectomy and vascular ligation
62784397|NCT03776591|ACTIVE_COMPARATOR|Laparoscopic CME with CVL|Right colectomy Laparoscopic surgery Central lymphadenectomy and vascular ligation
62784398|NCT01998308||Group 1|50 Knees will have single injection of Crespine gel
62784399|NCT01998308||Group 2|50 Knees will have single injection of 2 ampules of intragel
62012014|NCT03047161||Uncomplicated pregnancy|uncomplicated pregnancy
62012015|NCT03160703|EXPERIMENTAL|Test dentifrice 1 (RDA~58)|Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.
62012016|NCT03160703|EXPERIMENTAL|Test dentifrice 2 (RDA~77)|Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.
62012017|NCT03160703|OTHER|Reference dentifrice 1 (RDA~80)|Participants will apply dentifrice containing 1000 parts per million (ppm) fluoride as Sodium Monofluorophosphate (SMFP).
62784400|NCT01998308||Group 3|50 knees will have single injection of crespine plus gel
62784401|NCT01998308||Group 4|50 knees will have single injection of Monovisc
62784402|NCT00851929|EXPERIMENTAL|sarcoidosis associated pulmonary hypertension|sarcoidosis associated pulmonary hypertension
62784403|NCT02518633||men with obstructive sleep apnoea|Continuous positive airway pressure devices
62199502|NCT01800890|EXPERIMENTAL|Treatment sequence 3|"Subjects randomised to Treatment sequence 3 will test three different products:~1. Coloplast A (A)~2. Coloplast C (C)~3. SenSura Click (S)~The subjects test the three test products in a randomized order: ACS; CSA, SAC"
62199503|NCT01102764|EXPERIMENTAL|Arm 1: PE via telemedicine|PE via telemedicine
62784404|NCT02518633||control subjects|subjects with no obstructive sleep apnoea
62199504|NCT01102764|ACTIVE_COMPARATOR|Arm 2: PE in person|PE in person
62199505|NCT03160612|OTHER|Case|Transfer Training Subjects will be randomized to receive the transfer training either after baseline measures are collected (case) during visit 1.
62199506|NCT03160612|OTHER|Control|Transfer Training Subjects will be randomized to receive the transfer training during the follow-up testing at visit 2.
62199507|NCT05286125|ACTIVE_COMPARATOR|erector spinae plane (ESP) block group ( (E) group)|Under aseptic conditions, a high frequency linear transducer will be placed on the spinous process at T8 level on the parasagittal plane and then slid 2.5-3 cm laterally to visualize the transverse process and erector spinae muscle.
62199508|NCT05286125|ACTIVE_COMPARATOR|oblique subcostal transverse abdominis plane (TAP) block ( (T) group) )|Under aseptic conditions, the probe will be initially placed below the xyphoid process to view the linea alba, then directed obliquely down the costal margin while keeping the rectus abdominis muscle in view. The transverse abdominis muscle come into view below the rectus abdominis muscle. The probe will be advanced further until the semilunaris is viewed.
62215040|NCT06533826|EXPERIMENTAL|Arm E (ADC2 Dato-DXd HR+)|"Participants will complete:~* Baseline visit with imaging, tumor biopsy, electrocardiogram, eye exam.~* Imaging every 9 weeks.~* Cycle 1 through Cycle 3:~  --Day 1 of 21 day cycle: Predetermined dose of Datopotamab deruxtecan 1x daily.~* Cycle 4 through end of treatment:~  * Day 1 of 21 day cycle: Predetermined dose of Datopotamab deruxtecan 1x daily.~ * Imaging on Day 1.~* End of Treatment visit with imaging, tumor biopsy, eye exam.~* Follow up: imaging every 9 weeks.~* Long-term Follow Up: visits every 6 months."
62784405|NCT02762214|ACTIVE_COMPARATOR|With Uterine Manipulator|77 Patients affected by early stage endometrial cancer submitted to elective laparoscopic/robotic hysterectomy for endometrial cancer using uterine manipulator.
62784406|NCT02762214|EXPERIMENTAL|Without Uterine Manipulator|77 Patients affected by early stage endometrial cancer submitted to elective laparoscopic/robotic hysterectomy for endometrial cancer without support of uterine manipulator.
62012018|NCT03160703|ACTIVE_COMPARATOR|Reference dentifrice 2 (RDA~120)|Participants will apply dentifrice containing 0.454% SnF2.
62012019|NCT04682600|EXPERIMENTAL|Open-label|Volunteers who have agreed to participate in the study will have their liver scanned using the FibroScan, VE (Liver Incytes System) and MRE techniques.
62012020|NCT05053386|EXPERIMENTAL|Idarubicin|10mg idarubicin is dissolved in 5ml water for injection, and 5\~20ml lipiodol is used to prepare lipiodol emulsion.
62012021|NCT05053386|ACTIVE_COMPARATOR|Epirubicin|50mg epirubicin is dissolved in 5ml 5% glucose solution, and 5\~20ml lipiodol is used to prepare lipiodol emulsion.
62012022|NCT03127397|NO_INTERVENTION|Standard of Care|
62012023|NCT03127397|EXPERIMENTAL|Praise Message|Receives up to two praise message phone calls after each completed ART appointment.
62784407|NCT01971385|ACTIVE_COMPARATOR|2% Squaric Acid Sensitization|2% Squaric Acid solution will be applied for sensitization to the inner arm.
62012024|NCT03139656|EXPERIMENTAL|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
62012025|NCT03139656|EXPERIMENTAL|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer \& Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
62012026|NCT03139656|EXPERIMENTAL|Combined (Values Clarification & Planning)|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When \[I encounter the specified obstacle\], I will do \[X\] and remember \[values-based statement or image identified during values clarification exercise\]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
62199509|NCT05570604|EXPERIMENTAL|Cognitive Training|As tested in the investigator's pilot, the Brain HQ program is designed to enhance specific areas of cognitive functioning that will be tested in this study. The goals of the Brain HQ program are to improve visual processing speed, learning and memory and attention. The exercises include time-order judgment, discrimination, spatial-match, forward-span, instruction-following, and narrative-memory tasks. This program systematically reduces the stimulus duration during a series of increasingly difficult information-processing tasks presented via computer. The exercises automatically adjust to user performance to maintain an 85% correct rate. The program will include 4 hours per week over a 10-week period for a total of up to 40 hours. The study team has support from the original developer and Posit Science. For the purposes of this trial, any participants who do not complete the total of up to 40 hours will not be counted as deviations.
62400973|NCT02031601|EXPERIMENTAL|Combination therapy|"Interventions:~Drug: Erlotinib \[Tarceva\] or Gefitinib \[Iressa\] or Icotinib \[Conmana\] plus Drug: Docetaxel for patients of lung squamous cell carcinoma; Pemetrexed for patients of lung adenocarcinoma plus Drug: Platinum (cisplatin or carboplatin)"
62400974|NCT02031601|OTHER|TKI alone therapy|"Interventions:~Drug: Erlotinib \[Tarceva\] or Gefitinib \[Iressa\] or Icotinib \[Conmana\]"
62400975|NCT04752007|ACTIVE_COMPARATOR|RSA group|Conventional RSA to measure the movement in th SI joint.
62784408|NCT01971385|PLACEBO_COMPARATOR|Placebo Solution|Patients in placebo group will be given dimethyl sulfoxide.
62400976|NCT04752007|ACTIVE_COMPARATOR|CT group|Low dose CT to measure the movement in th SI joint.
62784409|NCT03676140|ACTIVE_COMPARATOR|Separate Administration|'Albendazole on day 1' 'Ivermectin on day 1' 'Diethylcarbamazine on day 1' 'Azithromycin on day 8'
62784410|NCT03676140|EXPERIMENTAL|Co-Administration|'Albendazole on day 1' 'Ivermectin on day 1' 'Diethylcarbamazine on day 1' 'Azithromycin on day 1'
62784411|NCT00932867||Group 1|
62784412|NCT00495300||1|Related or Unrelated Hematopoietic Stem Cell Transplantation Recipients for the National Marrow Donor Program
62784413|NCT06297382|EXPERIMENTAL|Experimental|In the 2023-2024 academic year, those in the experimental group will be determined by randomization among the students who are senior students at the faculty of nursing, who have not received ChatGPT training before and who agree to participate in the research. Students in the experimental group will have data collection forms filled out. Then, 4 hours of ChatGPT based nursing process training will be given. Measurements will be taken again after the training and 6 weeks after the training.
62784414|NCT06297382|NO_INTERVENTION|Control|In the 2023-2024 academic year, students who are senior students at the faculty of nursing, who have not received ChatGPT training before and who agree to participate in the research, will be determined by randomization and those in the control group will be determined. Students in the control group will fill out data collection forms. Students in the control group will not be given any training. Data collection forms will be applied again 6 weeks after the training.
62784415|NCT02905669|EXPERIMENTAL|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device.
62784416|NCT03363880|EXPERIMENTAL|experimental group|The trauma treatment team will be established in the experimental group
62784417|NCT03363880|ACTIVE_COMPARATOR|control group|The trauma treatment team will not be established in this group，just establish the basic experimental settings
62784418|NCT04677504|EXPERIMENTAL|Arm A: Atezo+Bev+CisGem, followed by Atezo+Bev|Participants will receive atezolizumab intravenously on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status. Participants will receive bevacizumab intravenously on Day 1 of each 21-day cycle. Participants will receive cisplatin intravenously followed by gemcitabine on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
62199510|NCT05570604|PLACEBO_COMPARATOR|Attention Control|Control participants will be asked to complete activities on the computer. The program offers a choice of activities that will consist of crossword puzzles and word jumbles. The program offers a pre-determined set of computerized crossword puzzles. The site has over 100,000 puzzles and can be accessed easily via the web and are free to users. The computerized crossword puzzles do not provide for progressive challenges of increasing speed, visual field size, number of distractors or degree of difficulty of targeted stimulus differentiation. Training: Participants will be instructed to perform this active attention control intervention 4 hours per week over 10 weeks for a total of up to 40 hours, the same as BrainHQ.
62784419|NCT04677504|ACTIVE_COMPARATOR|Arm B: Atezo+PBO+CisGem, followed by Atezo+PBO|Participants will receive atezolizumab intravenously on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status. Participants will receive placebo matching bevacizumab intravenously on Day 1 of each 21-day cycle. Participants will receive cisplatin intravenously followed by gemcitabine on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
62784420|NCT03102060|EXPERIMENTAL|Prevention (gluten free diet)|Patients undergo a gluten free diet for 30 days during initial hospitalization for allo-SCT, from the time of admission to discharge.
62784421|NCT00881816|EXPERIMENTAL|Liposomal paclitaxel plus capecitabine|
62784422|NCT00627341|EXPERIMENTAL|Exposure and Response Prevention|Participants will receive Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa for 6 months.
62784423|NCT00627341|ACTIVE_COMPARATOR|Cognitive Behavior Therapy|Participants will receive cognitive behavioral therapy for anorexia nervosa for 6 months.
62012027|NCT06664684|ACTIVE_COMPARATOR|Energy-restricted diet|The energy-restricted diet group followed an 8-week long dietary treatment involving 22-25 kcal/kg/day based on ideal body weight.
62012028|NCT06664684|EXPERIMENTAL|Energy + time-restricted diet|Patients in the energy + time-restricted diet group followed the same dietary intervention and a 16:8 eating pattern where they were instructed to restrict their energy intake to an 8-h time window and not to consume energy-containing foods or drinks during the remaining 16 h.
62012029|NCT05458349|EXPERIMENTAL|dermis group|Group will receive standard of care treatment and interventions plus the use of the acellular dermal graft during surgery
62012030|NCT05458349|NO_INTERVENTION|control group|Group will receive standard of care treatment and interventions but the acellular dermal graft will not be used during surgery
62012031|NCT04713748|OTHER|Tasso- SST blood collection|About 100 participants will have blood collected by two methods-regular phlebotomy and Tasso-SST, in this pilot study.
62012032|NCT04713748|OTHER|Regular Venipuncture|About 100 participants will have blood collected by two methods-regular phlebotomy and Tasso-SST, in this pilot study.
62012033|NCT00650533|EXPERIMENTAL|1|Glimepiride Tablets 1 mg
62012034|NCT00650533|ACTIVE_COMPARATOR|2|Amaryl® Tablets 1 mg
62012035|NCT05795023|EXPERIMENTAL|PD patients|Men and women with idiopathic PD (Hoehn \& Yahr scale 1-3) aged 18-85 years
62012036|NCT06572488|EXPERIMENTAL|Active therapy with non-ablative Er:YAG laser|Patients underwent four laser sessions with non-ablative SMOOTH Er:YAG laser therapy, with 1 moth interval between sessions
62012037|NCT04406805||Severe aortic stenosis|Patients will be enrolled among those who will be (i) aged from 18 to 99 years, (ii) admitted to the hospital due to severe aortic stenosis, and (iii) qualified for treatment with either surgical aortic valve replacement or transcatheter aortic valve implantation
62012038|NCT02923375|EXPERIMENTAL|Cohort A|Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 1 million cells/kg (up to a maximum of 100 million cells) by IV infusion on two occasions (Day 0 and Day 7)
62012039|NCT02923375|EXPERIMENTAL|Cohort B|Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 2 million cells/kg (up to a maximum of 200 million cells) by IV infusion on two occasions (Day 0 and Day 7)
62012040|NCT06100068|ACTIVE_COMPARATOR|Standard L-DIBH|Starts with 2 sessions of normal L-DIBH followed by 2 sessions of L-DIBH combined with mental exercises.
62012041|NCT06100068|EXPERIMENTAL|Intervention L-DIBH|Starts with 2 sessions of of L-DIBH combined with mental exercises followed by 2 sessions of normal L-DIBH.
62012042|NCT04595838|EXPERIMENTAL|Arm A:Best supportive oral care and Chemo Mouthpiece|Patients will receive best supportive oral care along with using the Chemo Mouthpiece device.
62199511|NCT03109236|EXPERIMENTAL|Treatment|"Patient will undergo CD133+ cells transplantation at stable compensated state.~5 dose GCSF will be administered 5 days consecutively before bone marrow harvesting.~Approximately 250ml of bone marrow will be harvested and subjected to CD133 isolation using clinimacs (Miltenyi Biotec) in a closed system.~Under ultrasound guidance, 50 mls of 50-100 million CD133 cells will be infused directly through transhepatic route into portal venous circulation of the liver over 5 mins."
62199512|NCT03109236|ACTIVE_COMPARATOR|Control|"Non-Transplant Arm:~Patients will receive 5 doses of GCSF"
62199513|NCT03921853|ACTIVE_COMPARATOR|Active comparator|Control group with obesity under Resistant Training
62012043|NCT04595838|OTHER|Arm B Best supportive oral care only|Patients will receive best supportive oral care only.
62199514|NCT03921853|EXPERIMENTAL|Experimental group with morbid obesity|Experimental group with morbid obesity under Resistant Training
62199515|NCT06131151|EXPERIMENTAL|External Oblique Intercostal Block|27 patients will receive External Oblique Intercostal Block. A volume of 20 ml of LA (20 ml of bupivacaine 0.375% plus 5 ug/ml adrenaline ) will be injected.
62199516|NCT06131151|EXPERIMENTAL|Erector Spinae Plane Block|27 patients will receive Erector Spinae Plane Block. A volume of 20 ml of LA (20 ml of bupivacaine 0.375% plus 5 ug/ml adrenaline ) will be injected.
62199517|NCT00517023|ACTIVE_COMPARATOR|ILR + Syncope Clinic|Patients will have ILR implanted and follow-up in Syncope Clinic
62199518|NCT00517023|ACTIVE_COMPARATOR|ILR Only|Patients will have ILR implanted and routine follow up.
62012044|NCT01376011|EXPERIMENTAL|healthy young|
62012045|NCT01376011|EXPERIMENTAL|healthy old|
62199519|NCT00517023|ACTIVE_COMPARATOR|Routine Mx + Syncope Clinic|Patients will receive routine care and management plus follow up in Syncope Clinic
62199520|NCT00517023|ACTIVE_COMPARATOR|Routine Mx|Patients will receive routine care and management
62199521|NCT05986500|EXPERIMENTAL|Galactose|The participants will receive a galactose infusion
62199522|NCT05986500|EXPERIMENTAL|Saline|The participants will receive a saline infusion
62400977|NCT02340117|EXPERIMENTAL|SGT-53 with gemcitabine/nab-paclitaxel|A course of therapy will include 7 weeks of treatment. SGT-53, at 3.6 mg DNA/infusion, will be administered bi-weekly on days 1 and 5 in weeks 1-3, weekly on day 3 in week 4, and weekly on day 1 in weeks 5-7. Patients who are responding to treatment may receive two additional courses (7 weeks) of SGT-53/gemcitabine/nab-paclitaxel therapy at investigator discretion. If still responding to treatment, they may continue on SGT-53/gemcitabine/nab-paclitaxel at investigator discretion with the approval of the sponsor.
62012046|NCT00934271||Fractionated stereotactic radiotherapy|patients with active acromegaly
62012047|NCT00733824|EXPERIMENTAL|Cohort 1|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~160 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
62012048|NCT00733824|EXPERIMENTAL|Cohort 2|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~240 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
62012049|NCT00733824|EXPERIMENTAL|Cohort 3|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~320 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
62012050|NCT00733824|EXPERIMENTAL|Cohort 4|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~400 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
62199523|NCT02817061|EXPERIMENTAL|NIR brain stimulation|"An Omnilux device will be used to put NIR light on the head and forehead of the subject age 18-25 or 65-85. The device is a low risk device as determined by the IRB. Thirty (30) subjects will receive this light at 6 visits over 16 weeks.~An automated interactive software self-test will be used at baseline and at three subsequent visits to quantify subject cognitive functions."
62400978|NCT05128552|EXPERIMENTAL|Study group|Twenty-five patients who received traditional chest physiotherapy and LVR technique for 30-45 minutes for successive 4 Days after extubation
62400979|NCT05128552|ACTIVE_COMPARATOR|Control group|Twenty-five patients who received only traditional chest physiotherapy for 30 minutes at least for successive 4 Days after extubation
62400980|NCT01333501|EXPERIMENTAL|Fingolimod|0.5 mg in capsules for oral administration once daily
62400981|NCT01333501|ACTIVE_COMPARATOR|Interferon beta 1b|250 μg injected s.c. every other day
62400982|NCT01917149|EXPERIMENTAL|Metoprolol|Patients in the metoprolol group were started on 11.875-23.75mg of metoprolol succinct extended-release tablet once daily (11.875mg was recommended for patients with NYHA functional classes III-IV), and then doses were doubled every 2 weeks to achieve asymptomatic bradycardia (50-60 bpm of heart rate) over 4-6 weeks. Investigators were encouraged to up-titrate metoprolol to a maximum dose of 190mg whenever possible.
62784424|NCT05296564|EXPERIMENTAL|HBI 0201-ESO TCRT (Anti-NY-ESO-1 TCR-transduced peripheral blood lymphocytes)|"This is a two-part, non-randomized, open label, single-site Phase I/II study. The first Part A is a dose ranging maximum tolerated dose (MTD) study and Part B is an extension phase to evaluate safety at the selected safe dose. A Data Safety Monitoring Board (DSMB) will determine the safe dose for testing in the expansion phase (Part B).~Part A will be according to a 3+3 dose escalation design. A total of up to 20 patients will participate in this Part.~Part B will be an expansion phase. The objective will be to determine if the treatment regimen is associated with a clinical response rate that can rule out 5% (p0=0.05) in favor of a modest 20% Partial Response (PR) + Complete Response (CR) rate (p1=0.20).~A total of up to 43 patients may be enrolled in Part B (41 +2, allowing for up to 2 non-evaluable patients)."
62784425|NCT05246813||Osteoporotic hip fracture patients|
62012051|NCT00733824|EXPERIMENTAL|Phase II|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~MTD as determined in Phase I IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
62012052|NCT03227380|OTHER|radiological evaluation|to explore by thoracic densitometry with contrast the spared segments after stapling of the intersegmental plan following a thoracoscopic segmentectomy
62012053|NCT04949672||Open TME|Total Mesorectal Excision (TME) is the gold standard surgical treatment of rectal cancer. According to the technique first described by Bill Heald, TME entails the resection of the rectum including the whole mesorectal fat and an intact mesorectal fascia. Open TME is accomplished through a midline xifo-umbilical laparotomy and requires a complete mobilization of the left colon and central ligature of inferior mesenteric artery and vein.
62400983|NCT01917149|EXPERIMENTAL|Low-dose valsartan|Patients randomized to low dose valsartan receive valsartan 80 mg until study completion.
62400984|NCT01917149|EXPERIMENTAL|Low dose Benazepril|Patients randomized to low dose Benazepril receive Benazepril 10 mg until study completion.
62577414|NCT04120077|PLACEBO_COMPARATOR|DSME + placebo supplement (group 1)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects be instructed to consume two capsules (canola oil soft-gels) per day in the morning and two capsules per day in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
62784426|NCT05246813||Hip osteoarthritis patients|
62784427|NCT02617654|ACTIVE_COMPARATOR|Liraglutide treatment|Liraglutide treatment in the dose of 1.8 mg daily for 52 weeks
62784428|NCT02617654|PLACEBO_COMPARATOR|Placebo treatment|Treatment with placebo once daily for 52 weeks
62784429|NCT05814952|EXPERIMENTAL|LX103 Injection|"Potential doses:~5E10 vg, 0.1 mL/eye/dose (low dose)~1E11 vg, 0.05 mL/eye/dose (high dose)"
62784430|NCT03471741||MARA-2: IMRT with concomitant boost|A forward planned IMRT technique was used and the prescribed dose to the whole breast was 50 Gy plus a concomitant boost of 10 Gy to the tumor bed
62784431|NCT03471741||CG: 3D-RT with sequential boost|The whole breast received 50.4 Gy in 28 fractions delivered with 3D-RT, followed by a sequential boost on the tumor bed of 10 Gy in 4 fractions delivered with electrons
62784432|NCT06583681|OTHER|Sagittal curvatures of the spine|The measuring of the sagittal curvatures of the spine.
62784433|NCT00264264|ACTIVE_COMPARATOR|Direct Compression|
62784434|NCT00264264|ACTIVE_COMPARATOR|Closure Device|
62784435|NCT03191045||Healthy participants|A group of 21 healthy adult participants studied twice (test-retest)
62784436|NCT00516165|EXPERIMENTAL|RAD001|Patients will receive RAD001 10 mg/day orally (6 weeks/cycle). Patients will be continued on treatment until disease progression, limiting toxicity, patient withdrawal of consent, or death.
62012054|NCT04949672||Laparoscopic TME|Laparoscopic TME mirrors the procedure performed through laparotomy with the same operative steps and performing rectal resection including the excision of the surrounding mesorectal fat and fascia.
62012055|NCT04949672||Robotic TME|Robotic TME mirrors the procedure described by Bill Heald for open surgery but the operation is performed by the master-slave DaVinci System under 3D laparoscopic guidance. The rectal resection is performed including mesorectal fat and fascia.
62784437|NCT03701919|EXPERIMENTAL|Botulinum toxin pyloroplasty|Intraoperative laparoscopic intramuscular injection of 100units (10cc) of Botulinum toxin into the pylorus
62400985|NCT01917149|EXPERIMENTAL|High dose valsartan|Patients randomized to high-dose valsartan were started on valsartan 80mg twice daily, and uptitrated to target doses within 7 days under in-hospital observation. The target high doses of valsartan is determined by left-ventricular end-diastolic diameter (LVEDD) (the maximal value of anteroposterior and lateral diameters) obtained by ECG at the randomization visit. A target dose of valsartan 320mg, 480mg, 640mg daily were assigned to patients with LVEDD of 50-59, 60-69, ≥70 mm respectively.
62784438|NCT03701919|PLACEBO_COMPARATOR|Normal saline pyloric injection|Intraoperative laparoscopic intramuscular injection of 10cc normal saline into the pylorus
62784439|NCT01526395|NO_INTERVENTION|Unmodified ECT|Data will be collected on patients receiving ECT in its unmodified form prior to the introduction of low dose propofol sedation.
62784440|NCT01526395|ACTIVE_COMPARATOR|Low Dose Propofol|Subjects will be given low dose propofol prior to ECT.
62012056|NCT04949672||TransAnal TME|TaTME has first described by Antonio Lacy in 2012. This procedure has two steps: abdominal and perineal. The abdominal step is performed through a laparoscopic approach as described for laparoscopic TME but the caudal dissection is stopped right below the level of the peritoneal rectal reflection (Douglas pouch). The perineal step is accomplished transanally inserting a specially designed platform into the anal canal and performing the total mesorectal excision under endoscopic guidance.
62012057|NCT04068675|EXPERIMENTAL|Group counseling arm|There is only one(1) arm in this study. All patients that enroll in the study will receive the group counseling intervention and be compared to historical controls.
62199524|NCT02817061|SHAM_COMPARATOR|Sham|"An Omnilux Device will be used at a safe wavelength not associated with photobiomodulation, putting sham light on the head and forehead of the subject age 18-25 or 65-85. The device is a low risk device as determined by the IRB. Thirty (30) subjects will receive this light at 6 visits over 16 weeks.~An automated interactive software self-test will be used at baseline and at three subsequent visits to quantify subject cognitive functions."
62784441|NCT03252002|EXPERIMENTAL|Single/multiple doses of 10 mg BAY1101042 or placebo|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
62012058|NCT05911802||symptomatic WM|WM patients with symptom(s) : cytopenia, bulky disease or when the physicochemical or immunological properties of IgM explain the occurrence of amyloidosis, cryoglobulin, neurological manifestations, or hyperviscosity syndrome (due to the presence of a large amount of IgM)
62199525|NCT05567367|EXPERIMENTAL|RT234 0.2 mg, Single Ascending Dose (SAD)|Part 1, SAD Cohort 1A
62199526|NCT05567367|EXPERIMENTAL|RT234 0.6 mg followed by oral vardenafil 20mg on day 3, SAD|Part 1, SAD Cohort 2A1
62199527|NCT05567367|EXPERIMENTAL|Oral vardenafil 20mg followed by RT234 0.6 mg on day 3, SAD|Part 1, SAD Cohort 2A2
62012059|NCT05911802||asymptomatic WM|WM patients without any symptom
62012060|NCT04101526|NO_INTERVENTION|Pre-Intervention Qualitative Interviews|Qualitative interviews will be conducted with breast cancer survivors, survivors' caregivers, cancer support group leaders and clinicians regarding sleep disturbance in breast cancer survivors and preferences for an intervention for sleep disturbance.
62012061|NCT04101526|EXPERIMENTAL|Videoconference Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I)|Behavioral: New Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference
62012062|NCT04101526|NO_INTERVENTION|Waitlist control group|No intervention until 6 weeks after the baseline assessment, at which point participants complete a follow-up assessment and then are offered the new CBT-I intervention.
62012063|NCT00949780|ACTIVE_COMPARATOR|chloral hydrate , sedative|
62199528|NCT05567367|EXPERIMENTAL|RT234 1.2 mg, SAD|Part 1, SAD Cohort 3A
62199529|NCT05567367|EXPERIMENTAL|RT234 2.4 mg, SAD|Part 1, SAD Cohort 4A
62199530|NCT05567367|EXPERIMENTAL|RT234 2.4 mg, Multiple Ascending Dose (MAD)|Part 2, MAD Cohort 1B
62784442|NCT03252002|EXPERIMENTAL|Single/ multiple doses of 20 mg BAY1101042 or placebo|Single oral dose of 20 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
62012064|NCT02734485|ACTIVE_COMPARATOR|active Deep Tms|Each DTMS session consisted in two consecutive stimulations: a first low-frequency (1 Hz) stimulation in the motor cortex (110% of the motor threshold, for 15 minutes)and a second high-frequency (10Hz) one in the prefrontal cortex (100% motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).The coil contains two symmetric devices, perfectly designed to rouse both hemispheres at the same time.
62199531|NCT03768622||surgery for femoral neck fracture|patients with proximal femoral fracture (type: femoral neck fracture) with surgical procedure: partial hip arthroplasty
62784443|NCT03252002|EXPERIMENTAL|Single/ multiple doses of 30 mg BAY1101042 or placebo|Single oral dose of 30 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
62784444|NCT03252002|EXPERIMENTAL|Single/ multiple doses of 40 mg BAY1101042 or placebo|Single oral dose of 40 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
62012065|NCT02734485|SHAM_COMPARATOR|sham deep tms|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an inactive DTMS coil.
62199532|NCT03768622||surgery for pertrochanteric femoral fractures|patients with proximal femoral fracture (type:pertrochanteric femoral fractures) with surgical procedure: intramedullary nail type Gamma® Nail or similar
62199533|NCT03404895|SHAM_COMPARATOR|Conventional Therapy|Conventional therapy of DFU comprises of four components: local wound care, antibiotic therapy, debridement and amputation, and pressure offloading.
62199534|NCT03404895|ACTIVE_COMPARATOR|Conventional Therapy + venous stent(s)|Patients will receive a venous stent in addition to conventional therapy
62199535|NCT01849640|ACTIVE_COMPARATOR|DHA-piperaquine with Primaquine|3-day treatment course of DHA-piperaquine with 45mg single dose primaquine
62784445|NCT03252002|EXPERIMENTAL|Single/ multiple doses of 50 mg BAY1101042 or placebo|Single oral dose of 50 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
62199536|NCT01849640|ACTIVE_COMPARATOR|DHA-piperaquine without Primaquine|3-day treatment course of DHA-piperaquine
62400986|NCT01917149|EXPERIMENTAL|High dose Benazepril|Patients randomized to high-dose benazepril were started on benazepril 10mg twice daily, and uptitrated to target doses within 7 days under in-hospital observation. The target high doses of benazepril is determined by left-ventricular end-diastolic diameter (LVEDD) (the maximal value of anteroposterior and lateral diameters) obtained by ECG at the randomization visit. A target dose of benazepril 40mg, 60mg, 80mg daily were assigned to patients with LVEDD of 50-59, 60-69, ≥70 mm respectively.
62400987|NCT03699358||Group 1: Myeloid recipients|Patients diagnosed with hematologic malignancy were recipients who undergone allogeneic-HSCT. Recipients were included in the current study and grouped as myeloid and lymphoid according to origin of their diagnosis. Recipients who had myeloid type disorders were included in myeloid group as well as recipients who had lymphoid type disorders were included in lymphoid group.
62199537|NCT01689857|EXPERIMENTAL|Scarclinic™ Thin|Scarclinic™ Thin
62199538|NCT01689857|ACTIVE_COMPARATOR|Scarclinic™ Normal|Scarclinic™ Normal
62199539|NCT03408587|EXPERIMENTAL|CVA21 / Ipilimumab|Subjects will receive up to 8 cycles (Day 155) of intravenous CVA21 and 4 doses of ipilimumab (Days 8, 29, 50 and 71).
62199540|NCT00426127|EXPERIMENTAL|Docetaxel and Liposomal Doxorubicin Combined with Enoxaparin|Docetaxel 75 mg/m\^2 + Doxil 30 mg/m\^2 + Enoxaparin 1.5 mg/kg
62199541|NCT05724238|EXPERIMENTAL|Traditional Herbal Supplements|Traditional Herbal Supplements (Kuan Sin Yin)
62199542|NCT05724238|PLACEBO_COMPARATOR|Placebo|Placebo starch powder with 10% Kuan Sin Yin
62199543|NCT04277884|EXPERIMENTAL|Firibastat|Capsules
62199544|NCT04277884|PLACEBO_COMPARATOR|Placebo|Matching capsules
62199545|NCT01396850||Psychotic Group|
62199546|NCT01396850||Anxiety|
62199547|NCT01396850||Depressed|
62784446|NCT03252002|EXPERIMENTAL|Optional: Single/multiple doses of 5 mg BAY 1101042 or placebo|Single oral dose of 5 mg BAY1101042 MR tablets or corresponding placebo followed by once daily dosing for 7 days
62784447|NCT03874884|EXPERIMENTAL|177Lu-PSMA + olaparib|Patients will receive a fixed 7.4 GBq of 177Lu-PSMA every 6 weeks together with olaparib on days 2-15 of each cycle. A cycle is 42 days long. Patients will receive 6 cycles of treatment.
62784448|NCT04362423||propofol+fNIRS|During data collection, only propofol is used to maintain the anesthesia. Peripheral noxious stimuli produced from the neurophysiological monitoring (SSEP)
62199548|NCT01396850||Control Group|
62199549|NCT02422576|ACTIVE_COMPARATOR|Control + Product 1|Control product (Thicken Up clear: TUC) + natural ingredient 1 (cinnamon extract)
62199550|NCT02422576|ACTIVE_COMPARATOR|Control + Product 2|Control product (Thicken Up clear: TUC) + natural ingredient 2 (lemon extract)
62199551|NCT02422576|ACTIVE_COMPARATOR|Control + Product 3|Control product (Thicken Up clear: TUC) + natural ingredient 3 (lemon extract+eucalyptus extract)
62199552|NCT01068665|EXPERIMENTAL|IDeg 200 U/mL OD|
62784449|NCT04362423||sevoflurane+fNIRS|During data collection, only sevoflurane is used to maintain the anesthesia. Peripheral noxious stimuli produced from the neurophysiological monitoring (SSEP)
62784450|NCT04362423||neuro-stimulator+fNIRS|During data collection, we use neuro-stimulator to give the stimulation.
62784451|NCT04028141||participants undergoing procedural sedation|"The study gathered observational data about participants who underwent procedural sedation according to the new standard protocol with ketofol in a 1 on 4 concentration.~The participant was observed for complications or cardiorespiratory interventions by the sedating physician until he was fully awake. Thirty minutes after the awakening, the participant was questioned for his remembrance and perception of the sedation and procedure. He was observed for complications until discharge"
62784452|NCT01549925|OTHER|standard surgical resection|standard surgical resection using clamps and surgical ligatures
62199553|NCT01068665|ACTIVE_COMPARATOR|IGlar OD|
62199554|NCT03434067||Primary hyperthyroidism|Patients diagnosed with primary hyperparathyroidism are prepared for parathyroid surgery. PTH test paper is used addtional at the time point according to Miami principle
62199555|NCT03434067||Secondary hyperthyroidism|Patients diagnosed with Secondary hyperthyroidism are prepared for parathyroid surgery. PTH test paper is used addtional at the time point according to Miami principle
62199556|NCT03434067||Unilateral thyroidectomy|Patients diagnosed with unilateral thyroid benign tumor were prepared for unilateral thyroidectomy. PTH test paper is used addtional at postoperation
62199557|NCT03434067||thyroidectomy and bilateral CCD|Patients diagnosed with bilateral thyroid carcinoma were prepared to undergo total thyroidectomy and bilateral central clearing.PTH test paper is used addtional at postoperation
62199558|NCT06047574||PCOS|"1. Oligomenorrhea/amenorrhea~2. Clinical androgen excess or biochemical androgen excess~3. Polycystic ovary showed by gynecological ultrasound"
62199559|NCT06047574||NOPCOS|not meet Rotterdam standards
62199560|NCT03628547||soccer players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur soccer players and10 professional soccer players.
62784453|NCT01549925|ACTIVE_COMPARATOR|LIGASURE|Resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
62199561|NCT03628547||basketball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur basketball players and10 professional basketball players.
62199562|NCT03628547||volleyball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur volleyball players and10 professional volleyball players.
62199563|NCT03628547||runners|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur runners and 10 professional runners.
62199564|NCT03628547||table tennis athlete|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur table tennis athlete and 10 professional table tennis athlete.
62199565|NCT03628547||field tennis athlete|10 amateur field tennis athlete 10 professional field tennis athlete
62199566|NCT03628547||kickboxers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur kickboxers and 10 professional kickboxers.
62199567|NCT03628547||archers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur archers and 10 professional archers.
62199568|NCT00930670|EXPERIMENTAL|Rosuvastatin-omeprazole|Rosuvastatin-omeprazole
62199569|NCT00930670|EXPERIMENTAL|Rosuvastatin-pantoprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
62199570|NCT00930670|EXPERIMENTAL|Rosuvastatin-esomeprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
62199571|NCT00930670|ACTIVE_COMPARATOR|Rosuvastatin-ranitidine|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300 mg for 11 months
62199572|NCT00930670|EXPERIMENTAL|Atorvastatin-omeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
62199573|NCT00930670|EXPERIMENTAL|Atorvastatin-pantoprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40mg for 11 months
62199574|NCT00930670|EXPERIMENTAL|Atorvastatin-esomeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
62199575|NCT00930670|ACTIVE_COMPARATOR|Atorvastatin-ranitidine|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
62199576|NCT03026439||Non-dyspneic smokers/ normal spirometry|Male or female current or former smokers. Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) \>0.7. FVC \>lower limit of normal (LLN). Modified Medical Research Council (mMRC) dyspnea score = 0.
62199577|NCT03026439||Dyspneic smokers/ normal spirometry|Male or female current or former smokers. FEV1/FVC \>0.7. FVC \>LLN. mMRC dyspnea score ≥1.
62199578|NCT03026439||Non-dyspneic mild COPD patients|Male or female current or former smokers. FEV1/FVC ≤0.7. FEV1 \>80% of predicted value. mMRC dyspnea score =0.
62199579|NCT03026439||Dyspneic mild COPD patients|Male or female current or former smokers. FEV1/FVC ≤0.7. FEV1 \>80% of predicted value. mMRC dyspnea score ≥1.
62199580|NCT02786095||Code-AF registry|
62199581|NCT02285296|NO_INTERVENTION|control arm|usual care
62199582|NCT02285296|EXPERIMENTAL|personalized support program|"interview of the primary caregivers to identify their needs and expectations, the implementation of a personalized support program, including telephone follow-up"
62199583|NCT06103604||in-patients requiring temperature monitoring|The patient at any age whose core temperature is monitored during hospitalisation
62199584|NCT00734136|OTHER|1|50 surgical subjects undergoing either liver transplantation or hepatic resection
62199585|NCT00734136|OTHER|2|50 Subjects with Liver disease who are are not surgical candidates
62199586|NCT04791098|EXPERIMENTAL|Stronger pre-transplant check-up|routine patient management + specific infectious diseases consultation
62199587|NCT04791098|NO_INTERVENTION|Standard pre-transplant check-up|routine patient management + letter sent to nephrologist
62199588|NCT01139853|ACTIVE_COMPARATOR|Nasogastric Tube|10 French Nasogastric Tube inserted before surgery
62199589|NCT01139853|NO_INTERVENTION|No Nasogastric Tube|
62199590|NCT04005118||preoperative preparation on microbiome composition|Mechanical Bowel Preparation + oral antibiotics group: receiving mechanical bowel preparation only MBP will be prepared with 4 liters of Polyethylene glycol (PEG) solution to be started 24 hours before the planned surgery. 500mg of Metronidazole will be administrated 3 times one day before the surgery at 2 pm, 3 pm and 10 pm.
62199591|NCT04091061|EXPERIMENTAL|PF-06865571 Moderate Hepatic Impairment|This arm includes participants with moderate hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
62199592|NCT04091061|EXPERIMENTAL|PF-06865571 Severe Hepatic Impairment|This arm includes participants with severe hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
62199593|NCT04091061|EXPERIMENTAL|PF-06865571 Mild Hepatic Impairment|This arm includes participants with mild hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
62199594|NCT04091061|EXPERIMENTAL|PF-06865571 Healthy Participants|This arm includes healthy participants who will receive an oral dose of PF-06865571 100 mg on Day 1
62199595|NCT04198155|EXPERIMENTAL|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to bilateral renal arteries determined by CT-guidance.
62199596|NCT01690377|EXPERIMENTAL|1|PDC or myDC
62199597|NCT05383508|ACTIVE_COMPARATOR|Product Sequence 1|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~CA35 on Day 1; Cig on Day 2; CM35 on Day 3"
62784454|NCT06371521|EXPERIMENTAL|VO2max and Lactate Threshold|"Participants will ingest either Sportlegs or placebo.~The Sportlegs (and placebo) will be ingested as dietary capsules taken with water.~30-minutes after ingestion, the VO2max and lactate threshold testing will commence. This will involve a graded exercise test on a cycle ergometer to volitional fatigue. Heart rate and gas exchange will be measured prior to and throughout the exercise test. Blood will be sampled approximately every 60-seconds from a venous catheter placed in a hand or wrist vein, or from a finger using a lancet and cappillary tube. The amount of blood to be sampled is up to \~2-3 ml per sample, totalling less than 40 mL per lab visit. The blood will be immediately analyzed for lactate concentration using an automated analyzer. Ratings of Perceived Exertion will be recorded every \~2 minutes.~VO2max and lactate threshold are considered important predictors of exercise performance."
62199598|NCT05383508|ACTIVE_COMPARATOR|Product Sequence 2|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~CA35 on Day 1; CM35 on Day 2; Cig on Day 3"
62784455|NCT06371521|EXPERIMENTAL|Maximal Mean Power Output|"The Sportlegs (and placebo) will be ingested as dietary capsules taken with water.~30-minutes after ingestion, participants will begin the FTP20 test. Following a brief, standardized warm-up, participants will exercise on a stationary cycle ergometer at the highest intensity they are able to sustain for 20-minutes. This is akin to a time-trial where cyclists cover as greater distance as possible during a pre-determined period of time. During the FTP20 test, work rate will be monitored and recorded, as will heart rate (monitored continuously but only recorded every 5-minutes via short range telemetry or ECG). Rating of perceived exertion will also be assessed and recorded every 5-minutes.~The FTP20 test is considered an important predictor of exercise performance."
62012066|NCT03835858|OTHER|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
62012067|NCT01438632|EXPERIMENTAL|jet injector|Jet injectors deliver insulin at a high velocity (typically \>100m/s) across the skin in the subcutaneous tissue, without the use of a needle
62012068|NCT01438632|ACTIVE_COMPARATOR|conventional insulin pen|
62012069|NCT00718718|EXPERIMENTAL|Part A, Group 1|Participants will receive placebo (Week 0 to Week 10) and later CNTO 136 100 mg (Week 12 to Week 22) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
62012070|NCT00718718|EXPERIMENTAL|Part A, Group 2|Participants will receive CNTO 136 100 mg (Week 0 to Week 10) and later placebo (Week 12 to Week 22) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
62012071|NCT00718718|EXPERIMENTAL|Part B, Group 1|Participants will receive placebo (Week 0 to Week 10) and later CNTO 136 100 mg (Week 12 to Week 24) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
62012072|NCT00718718|EXPERIMENTAL|Part B, Group 2|Participants will receive CNTO 136 100 mg (Week 0 to Week 24) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
62012073|NCT00718718|EXPERIMENTAL|Part B, Group 3|Participants will receive CNTO 136 100 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6, 10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
62012074|NCT00718718|EXPERIMENTAL|Part B, Group 4|Participants will receive CNTO 136 50 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6,10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
62012075|NCT00718718|EXPERIMENTAL|Part B, Group 5|Participants will receive CNTO 136 25 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6,10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
62012076|NCT06663436|EXPERIMENTAL|altSonflex1-2-3 Dose_A Group|Participants randomized to receive altSonflex1-2-3 Dose A and MR-VAC on Day 1 and Day 169.
62784456|NCT05351866|EXPERIMENTAL|SparkRx|5-week CBT-based mobile intervention for adolescents with depressive symptoms
62012077|NCT06663436|EXPERIMENTAL|altSonflex1-2-3 Dose_B Group|Participants randomized to receive altSonflex1-2-3 Dose B and MR-VAC on Day 1 and Day 169.
62012078|NCT06663436|EXPERIMENTAL|altSonflex1-2-3 Dose_C Group|Participants randomized to receive altSonflex1-2-3 Dose C and MR-VAC on Day 1 and Day 169.
62012079|NCT06663436|ACTIVE_COMPARATOR|Control Group|Participants randomized to receive TYPHIBEV on Day 1, Infanrix hexa on Day 169 and MR-VAC on Day 1 and Day 169.
62012080|NCT05075876|EXPERIMENTAL|Group 1 (SP-01-K)|Application of SP-01 manufactured by Site K (SP-01-K) for 6 days followed by washout period for 21 days followed by application of SP-01 manufactured by Site A (SP-01-A) for 6 days
62577415|NCT04120077|EXPERIMENTAL|DSME + DVS supplement (group 2)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects will be instructed to consume two capsules per day (EyePromise DVS nutritional supplement) in the morning and two capsules per day (canola oil placebo) in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
62784457|NCT05351866|ACTIVE_COMPARATOR|Educational Control|5-week mobile control with education about depression
62784458|NCT00653380|EXPERIMENTAL|A|Subjects received the Par product (Doxycycline Monohydrate) under fasting conditions.
62784459|NCT00653380|ACTIVE_COMPARATOR|B|Subjects received Oclassen's product (Monodox) under fasting conditions.
62784460|NCT03604796|ACTIVE_COMPARATOR|Continuous IV Acetaminophen|Intravenous Infusion
62784461|NCT03604796|ACTIVE_COMPARATOR|Rectal Acetaminophen|Rectal Solution
62784462|NCT02673502|EXPERIMENTAL|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
62784463|NCT02673502|EXPERIMENTAL|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery.
62784464|NCT00759421|EXPERIMENTAL|1|
62784465|NCT00759421|ACTIVE_COMPARATOR|2|
62784466|NCT05705427|EXPERIMENTAL|Tenofovir disoproxil fumarate (TDF) arm|140 pregnant women in the experimental arm will receive tenofovir disoproxil fumarate (TDF) 300 milligrams (mg) daily, beginning at 28-32 weeks' gestation and continuing through 4 weeks' postpartum. Infants born to these women will be included in this arm and will receive a birth-dose of hepatitis B vaccine.
62784467|NCT05705427|PLACEBO_COMPARATOR|Placebo arm|140 pregnant women in the placebo arm will receive a placebo pill daily, beginning at 28-32 weeks' gestation and continuing through 4 weeks' postpartum. Infants born to these women will be included in this arm and will receive a birth-dose of hepatitis B vaccine.
62784468|NCT06230939||Parkinson's Disease Group|The study will be conducted in collaboration with Gazi University Faculty of Health Sciences and Nigde Omer Halisdemir University. The study data will be obtained from individuals diagnosed with PD admitted to the Neurology Outpatient Clinic of Nigde Omer Halisdemir University Training and Research Hospital. Necessary permissions were obtained from all institutions. All evaluations will be collected in a single meeting using the face-to-face interview method. It is calculated that 80% power will be reached with a margin of error of 0.05 when 84 individuals diagnosed with PD are included in the study.
62784469|NCT01546688|ACTIVE_COMPARATOR|Zonisamide at targeted daily doses of 100-500 mg/day|
62784470|NCT01546688|PLACEBO_COMPARATOR|Placebo administered to match daily doses of 100-500 mg/day|
62784471|NCT06583707|ACTIVE_COMPARATOR|Real ultrasound-guided dry needling on the infraspinatus muscle + exercise|Patients who undergo ultrasound-guided real dry needling, using the ultrasound to visualize the needle, and who follow an exercise program.
62784472|NCT06583707|SHAM_COMPARATOR|Placebo ultrasound-guided dry needling on the infraspinatus muscle + exercise|Patients who will undergo ultrasound-guided placebo dry needling on the infraspinatus muscle and will follow an established exercise protocol.
62784473|NCT06583707|ACTIVE_COMPARATOR|Non-ultrasound-guided real dry needling on the infraspinatus muscle + exercise|Patients who will undergo non-ultrasound-guided dry needling on the infraspinatus muscle and will follow an established exercise protocol
62784474|NCT06583707|SHAM_COMPARATOR|Non-ultrasound-guided placebo dry needling on the infraspinatus muscle + exercise|Patients who will undergo non-ultrasound-guided placebo dry needling on the infraspinatus muscle and will follow an established exercise protocol
62784475|NCT01497301|NO_INTERVENTION|Standard Individual Medical Appointment|
62784476|NCT01497301|ACTIVE_COMPARATOR|Group Visits|
62784477|NCT04254601|EXPERIMENTAL|Experimental group 1|Patients in group (A) consisted of 15 participants, received a program of NBUB, DIXWELL EMLY 98 -ABRP 64 ,made in France (wavelength 311 to 313nm) , in addition to topical aknemycin medications (topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period after 8 weeks).
62784478|NCT04254601|EXPERIMENTAL|Experimental group 2|Participants in-group (B) consisted of 15 participants, received a program of R-LLLT that was conducted through laser equipment InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia) with fluence 12 J/cm2, two sessions per week for 8 weeks Plus topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period.
62012081|NCT05075876|ACTIVE_COMPARATOR|Group 2 (SP-01-A)|Application of SP-01 manufactured by Site A (SP-01-A) for 6 days followed by washout period for 21 days followed by application of SP-01 manufactured by Site K (SP-01-K) for 6 days
62012082|NCT05979805|ACTIVE_COMPARATOR|Conventional Oral health Education|Conventional oral health education and nutritional guidelines prior to the placement of fixed appliances, by means of a 5-8 minute video and instructive brochure.
62012083|NCT05979805|EXPERIMENTAL|Motivational interviewing + Conventional Oral health Education|Include the conventional oral health education of the control group and a 30 minute motivational interviewing (MI)
62012084|NCT01103531|EXPERIMENTAL|Exercise Group|Participants in this group will be scheduled for 24 exercise training sessions over an 8-week period (three times weekly) and will be supervised by a certified exercise physiologist.
62012085|NCT01103531|ACTIVE_COMPARATOR|Education Group|Participants in this group will meet with a counselor who will present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
62012086|NCT05319418|EXPERIMENTAL|Hypertensive Patients Monitored Daily|Physicians utilize DailyDoctor remote monitoring platform to virtually monitor daily BP of patients. Physicians use their independent medical judgement to recommend any clinical follow up or adjustment in medications/prescriptions for any patients whose daily reporting of BP triggers an alert based on physician-driven alert thresholds.
62012087|NCT04485481|EXPERIMENTAL|Experimental: Cohort 1:1 - 1:6 ADX-914|ADX-914 single SC dose
62012088|NCT04485481|PLACEBO_COMPARATOR|Placebo Comparator: Cohort 1:1 - 1:6 placebo|Placebo single SC dose
62012089|NCT04485481|EXPERIMENTAL|Experimental: Cohort 2:1- 2:3|ADX-914 multiple SC dose once every 2 weeks for 6 weeks
62012090|NCT04485481|PLACEBO_COMPARATOR|Placebo Comparator: Cohort 2:1- 2:3|Placebo multiple SC dose once every 2 weeks for 6 weeks
62012091|NCT06166953|EXPERIMENTAL|mobile application|The mobile application will be downloaded on smart phones of participants. This group will be able to look up information related to surgical period when needed.
62012092|NCT06166953|NO_INTERVENTION|Control|The control group will receive routine care. This group will wear smart band for pulse rate, sleep, blood pressure, and SpO2 record for data collection times.
62012093|NCT05864027|EXPERIMENTAL|Peer-led Oral Health Recovery educational group|
62012094|NCT05864027|ACTIVE_COMPARATOR|Educational Video|
62784479|NCT04254601|ACTIVE_COMPARATOR|Control group|Patients in the group C, consisted of 15 participants, were asked to apply topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period.
62012095|NCT02985736|EXPERIMENTAL|open label|
62012096|NCT06573593||Tofacitinib treated group|In the real-world settings, patients with AA treated with tofacitinib.
62784480|NCT01002274|EXPERIMENTAL|MCS-2|2 soft-gel capsules Qd for 40 weeks
62784481|NCT03902834|EXPERIMENTAL|Intervention|
62784482|NCT03194243||Patients admitted for acute dyspnea|Patients admitted for acute dyspnea in the emergency department
62784483|NCT05952388|NO_INTERVENTION|Behavioral Patient Care|Chart review
62784484|NCT03775746|EXPERIMENTAL|Clopidogrel with Rivaroxaban|Clopidogrel 75mg o.d. and Rivaroxaban 2.5mg b.i.d.
62784485|NCT03775746|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 75mg o.d.
62784486|NCT03775746|ACTIVE_COMPARATOR|Ticagrelor|Ticagrelor 90mg b.i.d.
62784487|NCT02808910|EXPERIMENTAL|Salt nudge|The following changes will be made in the cafeteria: Salt will be placed in a corner of the buffet, rather than on each dining table. Other spices, without sodium, will be provided on the table. A sign will be placed on the table that nudges participants to try the other spices. Food in the buffet that is high in salt will be labeled with a negative-appearing symbol, and food in the buffet that is low in salt will be labeled with a positive symbol.
62012097|NCT06573593||Baritinib treated group|In the real-world settings, patients with AA treated with baritinib.
62012098|NCT06573593||Ruxolitinib treated group|In the real-world settings, patients with AA treated with ruxolitinib
62012099|NCT06573593||Upadacitinib treated group|In the real-world settings, patients with AA treated with upadacitinib.
62012100|NCT06573593||Abrocitinib treated group|In the real-world settings, patients with AA treated with abhicitinib.
62012101|NCT06573593||Ritlecitinib treated group|In the real-world settings, patients with AA treated with ritlecitinib.
62012102|NCT01150838|EXPERIMENTAL|Propofol administration|"For each of the 6 groups, propofol 2 mg/kg will be administered to first subject. The propofol dose will move separately for each of the 6 groups, and be increased by 0.3 mg/kg for the next subject if intubation score is not excellent and decreased by 0.3 mg/kg if intubation score is excellent. This dosing scheme will be continued until there are 6 crossovers as described above."
62012103|NCT06011213|EXPERIMENTAL|Combined intervention|Participants in the combined intervention group will receive real-time health risk warnings for heat waves and cold spells via a WeChat mini-program and will perform daily self-monitoring of BP and ECG using automated home devices.
62012104|NCT06011213|OTHER|Self-monitoring alone|
62199599|NCT05383508|ACTIVE_COMPARATOR|Product Sequence 3|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~Cig on Day 1; CA35 on Day 2; CM35 on Day 3"
62012105|NCT06011213|NO_INTERVENTION|Control|
62199600|NCT05383508|ACTIVE_COMPARATOR|Product Sequence 4|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~Cig on Day 1; CM35 on Day 2; CA35 on Day 3"
62577416|NCT04120077|EXPERIMENTAL|DSME + DVS supplement + omega-3 supplement (group 3)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects will be instructed to consume two capsules per day (EyePromise DVS nutritional supplement) in the morning and two capsules per day (EyePromise EZTears) in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
62584940|NCT05038592|EXPERIMENTAL|Treatment (decitabine, tagraxofusp-erzs)|Patients receive decitabine IV over 60 minutes on days 1-5, and tagraxofusp-erzs IV over 15 minutes on days 1-3. Cycles of decitabine repeat every 28 days in the absence of disease progression or unacceptable toxicity. Treatment with tagraxofusp-erzs repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
62784488|NCT02808910|EXPERIMENTAL|Vegetable nudge|The following changes will be made in the cafeteria: Names of the vegetable dishes in the buffet will be made more attractive. Signs will be placed with reminders to eat more vegetables. Signs will be placed with a visual indication of the percentage of a meal that should consist of vegetables.
62784489|NCT02808910|EXPERIMENTAL|Portion size nudge|The following changes will be made in the cafeteria: Smaller plates will replace the regular plates. Verbal and visual nudges to reduce portion size will be given. Utensils for self-serving calorie-dense foods in the buffet will be smaller than normal.
62784490|NCT02808910|EXPERIMENTAL|Combined nudge|All three nudges are combined in this intervention.
62784491|NCT02808910|NO_INTERVENTION|Control groups|No changes are made to the cafeteria, compared to the pre-study situation. One control group participates after each of the nudges to control for effects of time of the year.
62784492|NCT01270815|EXPERIMENTAL|Pregabalin controlled release, 330 mg, 400 to 500 calories|
62784493|NCT01270815|EXPERIMENTAL|Pregabalin controlled release, 330 mg, 600 to 750 calories|
62784494|NCT01270815|EXPERIMENTAL|Pregabalin controlled release, 330 mg, 800 to 1000 calories|
62784495|NCT01270815|OTHER|Pregabalin immediate release, 300 mg|Reference
62784496|NCT03215199|NO_INTERVENTION|Usual Care Group|The Usual Care Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Supportive care will be offered or provided according to patients' wishes.
62012106|NCT00672438|PLACEBO_COMPARATOR|Saline placebo infusion|Subjects will receive an intravenous infusion of normal saline.
62012107|NCT00672438|EXPERIMENTAL|Alfentanil infusion|Subjects will receive an intravenous infusion of alfentanil.
62012108|NCT05433883|EXPERIMENTAL|treatment group|30 severe OSA patients (apnea/hypopnea \>30)
62012109|NCT05433883|NO_INTERVENTION|control group|15 simple snoring patients (apnea/hypopnea \<5 )
62012110|NCT05433883|NO_INTERVENTION|comparative group|15 mild cognitive impairment patients.
62199601|NCT05383508|ACTIVE_COMPARATOR|Product Sequence 5|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~CM35 on Day 1; Cig on Day 2; CA35 on Day 3"
62199602|NCT05383508|ACTIVE_COMPARATOR|Product Sequence 6|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~CM35 on Day 1; CA35 on Day 2; Cig on Day 3"
62012111|NCT05856292|EXPERIMENTAL|Teach-Back|The intervention group were educated using the standard educational method with the addition of Teach-back enhancement. It consists of 5 steps: Triage, Tools, Take Responsibility, Tell Me, and Try Again. The Triage, Tools, and Try Again focus on effective information delivery, while the Take Responsibility and Tell Me evaluate the patient's ability to receive the information
62012112|NCT05856292|PLACEBO_COMPARATOR|Non-Teach-Back|No educational intervention, just standard educational methods
62012113|NCT00477919||Weekly assessment by E-MOSAIC|Patients complete a weekly assessment comprising visual analogue scales (VAS) of pain, fatigue, drowsiness, nausea, anxiety, depression, shortness of breath, loss of appetite, and overall well-being; up to 3 optional symptoms selected by the patient; and an estimated nutritional intake using an electronic tool for monitoring symptoms and syndromes associated with advanced cancer (E-MOSAIC). Nurses record the patient's weight, KPS score, body mass index, and assessment of current medication for pain (i.e., morphine-equivalent daily dose), fatigue, and anorexia/cachexia syndromes weekly. A Longitudinal Monitoring Sheet (LoMoS) is printed (comprising VAS of pain, pain medication, fatigue, KPS, medication for fatigue \[i.e., methylphenidate hydrochloride or epoetin alfa\], anorexia, weight change, nutritional intake, medication, supplements, counseling for anorexia, VAS of individually selected symptoms) and stored.
62012114|NCT00477919||Palm-based monitoring tool|Patients complete a weekly symptom assessment and nutritional intake using a Palm-based monitoring tool. Nurses record weight and Karnofsky performance status (KPS) scores weekly. A proof of electronic transfer sheet is printed and stored.
62012115|NCT05895006|EXPERIMENTAL|With PTSD for study|80 patients with PTSD in randomized, double-blind, controlled design
62012116|NCT05895006|ACTIVE_COMPARATOR|Health controls for study|80 healthy subjects in randomized, double-blind, controlled design
62012117|NCT02566551|EXPERIMENTAL|Prostate artery embolization|Prostatic artery embolization (PAE) To perform embolization, gelatin microspheres (300-500 microns) will be used in this arm
62012118|NCT02566551|ACTIVE_COMPARATOR|Transurethral resection of the prostate|Transurethral resection of the prostate (TURP) A bipolar electrosurgery generator will be used to perform TURP
62012119|NCT06424301|EXPERIMENTAL|Intravitreal chemotherapy in patients with refractory retinoblastoma|The enrolled patients underwent blood sample collection and clinical evaluation before the first injection of the targeted drug. Intravitreal injection of the targeted drug at a dosage of 100-1000 μg was performed on day 1 of week 1 and week 3, respectively. Collection of aqueous humor was performed on weeks 1, 3, 5 and 7, respectively. Collection of blood samples and sputum specimens was performed on weeks 1, 3, 5, and 7. And clinical assessment was performed weekly with continuous follow-up until 12 weeks.
62012120|NCT00298896|EXPERIMENTAL|SNS-595|SNS-595; 48 mg/m2 administered IV once every 21 days for up to 6 cycles.
62012121|NCT02864797|EXPERIMENTAL|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software.
62012122|NCT05108181|ACTIVE_COMPARATOR|Slow muscle typology group|The participants receive the same exercise training intervention, but they are divided in two groups: a slow typology group and a fast typology group based on their inherent physiological characteristics: their muscle fiber type.
62012123|NCT05108181|ACTIVE_COMPARATOR|Fast muscle typology group|The participants receive the same exercise training intervention, but they are divided in two groups: a slow typology group and a fast typology group based on their inherent physiological characteristics: their muscle fiber type.
62012124|NCT04885517|EXPERIMENTAL|Spontaneous breathing, Venturi Mask FiO2 0.5, seated decubitus|Patient will be evaluated after 20 minutes of spontaneous breathing, with FiO2 0.5 (Venturi Mask), during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
62012125|NCT04885517|EXPERIMENTAL|Spontaneous breathing, Non Rebreathing Mask, seated decubitus|Patient will be evaluated after 20 minutes of spontaneous breathing, with FiO2 1 (Non Rebreathing Mask), during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
62012126|NCT04885517|EXPERIMENTAL|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 0.5, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 0.5, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
62012127|NCT04885517|EXPERIMENTAL|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 0.5, supine decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 0.5, during supine decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
62012128|NCT04885517|EXPERIMENTAL|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 0.5, prone decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 0.5, during prone decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
62012129|NCT04885517|EXPERIMENTAL|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 1, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 1.0, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
62012130|NCT04885517|EXPERIMENTAL|Continuous Positive Airway Pressure (CPAP) 12 cmH2O, FiO2 0.5, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (12 cmH2O), with FiO2 0.5, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
62012131|NCT04885517|EXPERIMENTAL|Continuous Positive Airway Pressure (CPAP) 12 cmH2O, FiO2 1, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 1.0, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
62012132|NCT01070810|PLACEBO_COMPARATOR|1|50 ml D5W
62012133|NCT01070810|EXPERIMENTAL|2|200mg Thiamine in 50ml D5W
62400988|NCT03699358||Group 2: Lymphoid recipients|Patients diagnosed with hematologic malignancy were recipients who undergone allogeneic-HSCT. Recipients were included in the current study and grouped as myeloid and lymphoid according to origin of their diagnosis. Recipients who had myeloid type disorders were included in myeloid group as well as recipients who had lymphoid type disorders were included in lymphoid group.
62400989|NCT01132027|EXPERIMENTAL|Tacrolimus|Tacrolimus Capsules, 5 mg of Dr.Reddy's Laboratories Limited
62400990|NCT01132027|ACTIVE_COMPARATOR|Prograf Capsules|Prograf Capsules of Astellas Pharma US, Inc.,
62012134|NCT04745143|EXPERIMENTAL|NMDAE|An NMDA enhancer
62199603|NCT02391142|EXPERIMENTAL|cardiac sympathetic nerve block|lidocaine or ropivacaine epidural injection
62577417|NCT05711251|EXPERIMENTAL|Physical Activity in Health Promotion Group|"Students who chose the Physical Activity in Health Promotion course were included in the experimental group. The participants in this group took the courses shown in the weekly schedule below during the semester.~1. Historical Development of Physical Activity~2. Physical Activity Definition and Types~3. Physical Activity Measurement~4. Physical Fitness and Inactivity~5. Physical Activity in Healthy Adults~6. Physical Activity in Children~7. Physical Activity in the Elderly~8. Physical Activity for the Disabled~9. Physical Activity at Work-I~10. Physical Activity at Work-II"
62784497|NCT03215199|ACTIVE_COMPARATOR|NAPT Group|The NAPT Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Patients will be given access to a web-based application that monitors depression, distress, and functional outcomes scores at regular intervals for 12 months. Patients will be able to alert the treatment team of decreased mood, increased distress, and functional issues impacting both. Patients will also be able to track their mood and distress levels throughout the 12 months and involve care-givers in monitoring as well.
62784498|NCT02856204||Diagnostic (collection of blood samples)|Patients undergo collection of blood samples before and during the episode of febrile neutropenia for up to 6 weeks.
62784499|NCT01719133|OTHER|All subjects|placebo histamine T1 T2 T3 T4 T5 T1-T2-T3 T4-T5
62784500|NCT06442670||6-7 years children|
62784501|NCT06442670||10-11 years children|
62784502|NCT06442670||20-35 years adults|
62784503|NCT06442670||60-70 older adults|
62012135|NCT04745143|PLACEBO_COMPARATOR|Placebo|Placebo
62784504|NCT06442670||70-80 older adults|
62784505|NCT02819791|ACTIVE_COMPARATOR|Control group|
62012136|NCT06269328|ACTIVE_COMPARATOR|TIVA group|Patients will be anesthetized with total ıntravenous anesthesia by propofol and remifentanyl infusion. End of the procedure all patients will be extubated and awakened in the operating room. İntravenous morphine patient-controlled analgesia will be used in the postoperative period.
62012137|NCT06269328|ACTIVE_COMPARATOR|İnhalation group|Patients will be anesthetized with induction of propofol and sevoflurane (inhalational agent) will be used for maintenance. End of the procedure all patients will be extubated and awakened in the operating room. İntravenous morphine patient-controlled analgesia will be used in the postoperative period.
62012138|NCT03861000|EXPERIMENTAL|Whole body PET Scan with intravenous 11C-T-1650|10 mCi of 11C-T-1650 given intravenously once followed by a Whole Body PET scan. This was done for whole body dosimetry calculations.
62012139|NCT03861000|EXPERIMENTAL|Brain PET scan with 11C-T-1650 and blocking with BPN14770|Baseline brain PET scan (scan 1) with 20 mCi of 11C-T-1650 given intravenously, followed by a second Brain PET scan (scan 2) 90-180 minutes after first dose administration of BPN14770 50mg given orally. A third brain PET scan (scan 3) is performed after the last dose of BPN14770. 20 mCi of 11C-T-1650 is given intravenously with each PET scan. BPN14770 50mg given orally twice a day for a total of seven doses. BPN14770 is a PDE4D-inhibitor.
62012140|NCT01160965|ACTIVE_COMPARATOR|0.5% levobupivacaine|Participants given 15mls of 0.5% levobupivacaine as the solution for their epidural top-up
62012141|NCT01160965|ACTIVE_COMPARATOR|0.75% Rpoivacaine|Participants given 15mls of 0.75% ropivacaine as the solution for their epidural top-up.
62012142|NCT06074016|EXPERIMENTAL|Zolmitriptan intranasal.|
62012143|NCT06074016|EXPERIMENTAL|Zolmitriptan oral.|
62012144|NCT03969342|EXPERIMENTAL|Trainees|Local mid-level providers who undergo five day training on point of care ultrasound for diagnosing pediatric pneumonia
62199604|NCT02391142|NO_INTERVENTION|non-cardiac sympathetic nerve block|
62784506|NCT02819791|EXPERIMENTAL|Intervention group|
62784507|NCT02707328|EXPERIMENTAL|A|"Chemotherapy:~Gemcitabine 1000 mg/m2 and Abraxane 125 mg/m2 weekly x3 of 28 day cycle~Radiation:~20-55 GY over 5 fractions~Dosing schedule: 3 cycles of chemotherapy, followed by CyberKnife, followed by 3 additional cycles of chemotherapy."
62784508|NCT03314311|EXPERIMENTAL|Rehabilitation Programme|12 week multi-disciplinary intervention prescribing exercise, individual dietary counselling and education sessions.
62784509|NCT03314311|NO_INTERVENTION|Control|Usual care control arm
62199605|NCT01685177||SADI|Patients submitted to a second-step operation after a failed sleeve on which a single-anastomosis duodena-ileal bypass at 250 cm from the cecum is performed.
62199606|NCT05039294|EXPERIMENTAL|intervention|provided the educational programs with all contents, and follow up after one month
62199607|NCT05039294|NO_INTERVENTION|control|received no intervention, but assessed pre-post
62199608|NCT04875442|EXPERIMENTAL|Memowave emitting sound|Patients worn Memowave during one night, and the device emits sounds to increase slow brain signals
62199609|NCT04875442|PLACEBO_COMPARATOR|Memowave not emitting sound|Patients worn Memowave during one night, and the device doesn't emit sounds
62400991|NCT03950947|EXPERIMENTAL|Interventional Study Arm|In the presence of a significant right coronary artery stenosis and randomization to the intervention group, catheter-based occlusion of the right IMA distal to the take-off of the pericardio-phrenic branch is performed at baseline using a dedicated occlusion device (Amplatzer vascular plug, CE0086).
62784510|NCT05213520|EXPERIMENTAL|Alternate Day Intermittent Energy Restriction|Participants assigned to this diet will be asked to alternate between full calorie (no restriction) eating days with eating 40% of their daily caloric requirement on the other day. For example, if their requirement is 2000 calories they would eat 800 calories one day and as much as you want on the other day and repeat every two days. There will be occasional exceptions allowed with maximum of two 40% days in a row (followed by two full days) based on personal schedule with prior approval. They will follow this for 4 weeks.
62012145|NCT06028867|EXPERIMENTAL|Chlorhexidine 0,12% + Sodium DNA mouthwash|Patients are treated with a mouthwash containing Chlorhexidine 0,12% + Sodium DNA
62012146|NCT06028867|ACTIVE_COMPARATOR|Chlorhexidine 0,20% mouthwash|Patients are treated with a mouthwash containing Chlorhexidine 0,20%
62012147|NCT06028867|PLACEBO_COMPARATOR|Placebo mouthwash|Patients are treated with a placebo mouthwash
62199610|NCT02777437|NO_INTERVENTION|Laparoscopic surgery|Patients with T4 colon cancer receive laparoscopic surgery only.
62199611|NCT02777437|EXPERIMENTAL|Neoadjuvantive chemotherapy + Laparoscopic surgery|Patients with T4 colon cancer receive neoadjuvantive chemotherapy and laparoscopic surgery.
62199612|NCT03023553|OTHER|TIV Group|Healthy adult males and females, 18-30 years of age. Immunization with standard trivalent, inactivated influenza vaccine (TIV), Fluzone®.
62199613|NCT03023553|OTHER|LAIV Group|Healthy adult males and females, 18-30 years of age. Immunize with intranasal live, attenuated influenza vaccine (LAIV), FluMist®.
62199614|NCT03568643|EXPERIMENTAL|Azithromycin|children in this arm will receive one dose of azithromycin
62012148|NCT00162136|EXPERIMENTAL|A1|
62012149|NCT00917059|ACTIVE_COMPARATOR|1|Participants will receive a 1-week treatment of escitalopram and then an 8-week treatment with escitalopram.
62199615|NCT03568643|ACTIVE_COMPARATOR|Amoxicillin|Children in this arm will receive a 7 day course of amoxicillin (standard of care)
62012150|NCT00917059|ACTIVE_COMPARATOR|2|Participants will receive a 1-week treatment with escitalopram and then an 8-week treatment with bupropion XL.
62199616|NCT03693976||Ectoin Rhinosinusitis Nasal Spray|application of 1-2 sprays of SNS01 into each nostril several times a day
62199617|NCT03693976||Xylometazoline nasal spray|1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day
62199618|NCT03693976||Xylometazoline + Ectoin Nasal Spray|Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Spray (SNS01): 1-2 sprays per nostril several times a day
62199619|NCT04419233||All Participants|Participants with 5q SMA and who were prescribed with nusinersen sodium injection in China according to the local marketing authorization.
62199620|NCT05719740||45 patients in type 1 .DM|TYPE 1 DIABETES MELLITUS
62400992|NCT03950947|SHAM_COMPARATOR|Sham-Control|In the presence of a significant right coronary artery stenosis, and randomization to the sham-procedure: right IMA will be selectively intubated using an appropriate catheter. Angiography of the RIMA and the pericardiacophrenic branch will be performed.
62012151|NCT02436512|EXPERIMENTAL|Inhaled Nitric Oxide|Active Comparator: Nitric Oxide
62012152|NCT01339533|EXPERIMENTAL|APRV ls|APRV low stretch will titrate Plow to maintain release volumes between 4 and 8 cc/kg.
62012153|NCT01339533|ACTIVE_COMPARATOR|AC/VC Conventional Ventilation|Standard volume control ventilation with the ARDS Net protocol.
62012154|NCT01339533|EXPERIMENTAL|APRV h|APRV Habashi protocol which sets Plow equal to 0.
62199621|NCT05719740||and 45 patients in type 2DM|TYPE 2 DIABETES MELLITUS
62784511|NCT05213520|ACTIVE_COMPARATOR|Reduced Calorie Diet|Participants assigned to this diet will be asked to restrict calorie intake by 500-1000 calories below their daily energy requirement every day. They will follow this for 4 weeks.
62784512|NCT05942599|EXPERIMENTAL|Single dose intravenous infusion of a banded dose of CAR33+ T Cells/Kg BECAR33|Patients will undergo careful screening to confirm that this treatment is appropriate for them. Patients will receive BE CAR-33 before their scheduled bone marrow transplant. Chemotherapy will be given prior to BE CAR-33 infusion to improve the ability of CAR T-cells to establish and grow. Patients will then receive a single infusion of the BE CAR-33 cells and will be closely monitored in hospital for the next 4 weeks. Patient will start chemotherapy for their scheduled bone marrow transplant 28 days after BE-CAR33 infusion unless their disease is progressing. Patients will be monitored on the study for 1 year after transplant and then long term in routine clinics.
62784513|NCT04698993|OTHER|Symptomatic|Collection of specimens from symptomatic COVID-19 positive participants
62784514|NCT04698993|OTHER|Asymptomatic|Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2
62784515|NCT05856981|EXPERIMENTAL|Monotherapy dose escalation, IV, Q3W, multiple dose levels|ADU-1805 monotherapy dose escalation
62784516|NCT05856981|EXPERIMENTAL|Combination dose escalation, IV, Q3W, multiple dose levels, pembrolizumab at fixed dose|ADU-1805 plus pembrolizumab dose escalation
62784517|NCT05231460|ACTIVE_COMPARATOR|narcotic regimen with TAP block|Patient will receive Tap Block and will be administered the Narcotic Pain Regimen post-operatively
62784518|NCT05231460|ACTIVE_COMPARATOR|narcotic regimen with no TAP block|Patient will not receive TAP block and will be administered the Narcotic Pain Regimen post-operatively
62012155|NCT04304001|EXPERIMENTAL|Community Health Advisor|Intervention arm participants will be scheduled to receive the Community Health Advisor intervention within 4 to 6 weeks after enrollment, a Fecal Immunochemical Test kit, a mailed targeted colorectal cancer brochure, and a follow-up telephone survey at 3- and 12-months post-intervention
62012156|NCT04304001|ACTIVE_COMPARATOR|Usual care|Control group participants will receive a Fecal Immunochemical Test kit, a mailed targeted colorectal cancer brochure, and complete a follow-up telephone survey at 3- and 12-months after the mailing.
62012157|NCT05247918|EXPERIMENTAL|Digital-physical care group|Combination of digital and physical care.
62012158|NCT05247918|ACTIVE_COMPARATOR|Treatment as usual.|Treatment as usual in accordance with national guidelines.
62012159|NCT03905551|PLACEBO_COMPARATOR|Standard Dialysis|Patients participated in a 7 months exercise trials receiving standard dialysis (at 37oC)
62577418|NCT05711251|NO_INTERVENTION|Control Group|"Students who chose the Posture Disorders and Waist and Neck Health courses given by different instructors at the same time and day were included in the control group. the participants in this group took 2 different courses, shown in the weekly schedule below, at the same time, from different physiotherapists during the semester.~Waist and Neck Health~1. Functional anatomy, biomechanics and pathomechanics of the spine~2. Risk factors for low back and neck pain~3. Back and neck pain related disorders~4. Outcome measures in low back and neck pain~5. Treatment approaches~6. Cervical and Lumbar disc lesions and physiotherapy~7. Exercise principles for low back and neck pain~8. Core stabilization, strengthening and stretching exercises~9. Neck school: Organization, methods and principles~10. Ergonomics"
62012160|NCT03905551|EXPERIMENTAL|Cold Dialysis|Patients participated in a 7 months exercise trials receiving cold dialysis (at 35oC)
62012161|NCT02710526|EXPERIMENTAL|32 mg CAM2038 weekly|Group 1, 32 mg of CAM2038 subcutaneous weekly injection at multiple injection sites
62577419|NCT04042714|EXPERIMENTAL|TAS-102|Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
62012162|NCT02710526|EXPERIMENTAL|128 mg CAM2038 monthly injection|Group 2: 128 mg of CAM2038 subcutaneous monthly injection in the buttocks
62012163|NCT02710526|EXPERIMENTAL|160 mg CAM2038 monthly injection|Group 3: 24mg sublingual BPN for the first 7 days, and then 160 mg of CAM2038 subcutaneous monthly injection in the buttocks starting on Day 8.
62012164|NCT01648777|EXPERIMENTAL|L bupivacaine|Drug (L bupivacaine) and device (catheter) 750 patients undergoing cardiac surgery with sternotomy are treated with L-bupivacain in the multiperforated catheter of analgesia
62012165|NCT01648777|PLACEBO_COMPARATOR|placebo|Isotonic Nacl 9°/00 solution 750 patients undergoing cardiac surgery with sternotomy are treated with isotonic NaCl solution (placebo) in the multiperforated catheter of analgesia
62012166|NCT04955808||Ancillary-correlative (biospecimen collection)|Patients undergo collection of tumor tissue during surgery. Patients also undergo blood samples. Samples collected may undergo genetic analysis including whole exome sequencing.
62012167|NCT00813761|OTHER|02Optix CL and ReNu MPS with SICS|O2Optix contact lens and ReNu MultiPlus Multi-Purpose Solution
62012168|NCT00813761|OTHER|Proclear CL and ReNu MPS with SICS|Proclear contact lens and ReNu MultiPlus Multi-Purpose Solution
62577420|NCT01265745|ACTIVE_COMPARATOR|Valortim|Valortim 1mg,5mg,10mg
62577421|NCT01265745|PLACEBO_COMPARATOR|Placebo|Saline solution will be used as the placebo
62577422|NCT00903708|EXPERIMENTAL|LY2275796|
62012169|NCT00813761|OTHER|02Optix CL and Clear Care LCS with SICS|O2Optix contact lens and Clear Care lens care solution subject
62012170|NCT00813761|OTHER|Proclear CL and Clear Care LCS with SICS|Proclear contact lens and Clear Care lens care solution
62012171|NCT00813761|OTHER|02Optix CL and ReNu MPS without SICS|O2Optix contact lens and ReNu MultiPlus Multi-Purpose Solution
62012172|NCT00813761|OTHER|Proclear CL and ReNu MPS without SICS|Proclear contact lens and ReNu MultiPlus Multi-Purpose Solution
62012173|NCT00813761|OTHER|02Optix CL and Clear Care LCS without SICS|O2Optix contact lens and Clear Care lens care solution
62012174|NCT00813761|OTHER|Proclear CL and Clear Care LCS without SICS|Proclear contact lens and Clear Care lens care solution
62577423|NCT04122703|EXPERIMENTAL|Percutaneous tibial nerve stimulation (PTNS)|The patients in the PTNS group will receive 1 PTNS treatments per week for 12 weeks.
62577424|NCT04122703|SHAM_COMPARATOR|Transcutaneous electrical nerve stimulation (TENS)|The patients in the Sham group will receive one sham (TENS) treatment per week for 12 weeks
62784519|NCT05231460|ACTIVE_COMPARATOR|non-narcotic regimen with TAP block|Patient will receive Tap Block and will be administered Non-narcotic Pain Regimen post-operatively
62784520|NCT05231460|ACTIVE_COMPARATOR|non-narcotic regimen with no TAP block|Patient will not receive TAP block and will be administered Non-narcotic Pain Regimen post-operatively
62784521|NCT02260947|EXPERIMENTAL|1|
62784522|NCT02260947|EXPERIMENTAL|2|
62784523|NCT02260947|ACTIVE_COMPARATOR|3|
62784524|NCT02260947|ACTIVE_COMPARATOR|4|
62784525|NCT02260947|PLACEBO_COMPARATOR|5|
62199622|NCT02343289|EXPERIMENTAL|Esketamine Regimen|All participants will first receive 28 milligram (mg) of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, followed by 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, followed by 84 mg of intranasal esketamine on Day 1 of Period 3 and then 500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4 and 84 mg of intranasal esketamine on Day 1 of Period 4. Each period will be separated by a washout period of up to 21 days in between.
62199623|NCT02805712|ACTIVE_COMPARATOR|Control|Participant will receive usual care for Heart Failure patients, which include standard written material on Advanced Care planning and supportive cardiology/palliative care consult if ordered by attending.
62199624|NCT02805712|EXPERIMENTAL|Verbal Information and Discussion|Participants will participate in a guided goals of care conversation and the support of a Palliative Care Social Worker who is working closely with the patients' primary cardiology team. Social worker has ongoing clinical review of participants with a Palliative Care physician who will provide a full medical consult if appropriate.
62199625|NCT03780738||Control|Chinese Han people to do physical examination in physical examination center of Guangdong Provincial People's Hospital
62199626|NCT03780738||Aortic dissection|Chinese Han people diagnosed with aortic dissection in Guangdong Provincial People's Hospital
62577425|NCT01059422|EXPERIMENTAL|Raltegravir; Abacavir/Lamivudine|Raltegravir: 400 mg twice daily Abacavir/Lamivudine fixed-dose combination: 600mg/300mg once daily
62577426|NCT00452582|EXPERIMENTAL|Sildenafil|Orally administered sildenafil in addition to usual care.
62577427|NCT00452582|ACTIVE_COMPARATOR|Usual post-stroke care|Usual post-stroke treatment including physical, occupational, and speech therapy.
62577428|NCT02097238|EXPERIMENTAL|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
62199627|NCT03042832|EXPERIMENTAL|LOCI|Leadership development with coaching and organizational change support
62199628|NCT03042832|ACTIVE_COMPARATOR|Internet Based Training|Internet based Webinar leadership training
62199629|NCT02702778|ACTIVE_COMPARATOR|4mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 4mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
62400993|NCT06158295|EXPERIMENTAL|Walking apnea at Low Lung Volume|Participants walk at 5,5 km/h on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at low lung volume with a density of 15 seconds, followed by a normal breath of 10 seconds (15 cycles of 15s apnea - 10s normal breathing, until completing the 6 minutes).
62577429|NCT04027725|EXPERIMENTAL|Sensorimotor neurofeedback training group|"Three interventions will be administered :~* An electroencephalography recording (EEG) for 30 minutes with an electrocap of 19 scalp locations according to the international 10-20 EEG placement system.~* The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2hours.~* The third intervention is the neurofeedback training sensorimotor that will be recorded at channel Cz according to the international 10-20 system."
62784526|NCT03856827|EXPERIMENTAL|IW-6463|IW-6463 tablets administered orally as single ascending doses, multiple ascending daily doses, and single doses with or without food
62012175|NCT06664437|EXPERIMENTAL|group A|Group (A): GH Joint mobilization techniques (Posterior, Inferior glide). Patients were in supine lying position during the whole treatment. The techniques were performed in a rhythmic way, with 2 seconds of glide distraction and then a 2-second break. Each technique was done for 2 minutes \[36\]. Posterior gliding was performed by maintaining lateral humeral distraction with the glenohumeral in abduction range and the scapula stabilized. Then the therapist applied posterior glide in an oscillating manner. For inferior gliding, with the scapula stabilized, the therapist maintained lateral humeral distraction while applying inferior glide in the resting position of the glenohumeral joint. Patients had 3 sessions of joint mobilization per week for 6 weeks.
62012176|NCT06664437|EXPERIMENTAL|Group (B)|Median nerve mobilization techniques (ULLT-1) in addition to GH joint mobilization
62199630|NCT02702778|ACTIVE_COMPARATOR|7mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 7mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
62199631|NCT02702778|ACTIVE_COMPARATOR|10mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 10mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
62199632|NCT00990444|PLACEBO_COMPARATOR|Placebo|Treatment with vehicle capsule containing excipients only, taken in conjunction with standard meal.
62199633|NCT00990444|ACTIVE_COMPARATOR|Oral Insulin in Dextran|Treatment with fixed insulin dose taken in conjunction with standard meal.
62199634|NCT01755377||No Chagas Disease|Participants with no Chagas Disease will be evaluated as a Control Group
62400994|NCT06158295|NO_INTERVENTION|Walking at normal breathing|Participants walk at 5,5 km/h on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
62577430|NCT04027725|NO_INTERVENTION|Control Group|"Three interventions will be administered :~* An electroencephalography recording (EEG) for 30 minutes with an electrocap of 19 scalp locations according to the international 10-20 EEG placement system.~* The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2hours~* The psychopedagogical care: each session will be organized using the same video material"
62577431|NCT05704166|EXPERIMENTAL|Pirfenidone|Patients were given placebo or pirfenidone capsules orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.
62784527|NCT03856827|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets administered orally
62784528|NCT02085304|EXPERIMENTAL|GammaKnife(R) stereotactic radiosurgery|Following surgery for Gross total resection and Gliadel(R) wafers implanted , the patient will receive a one-day GammaKnife(R) stereotactic radiosurgery procedure and will also take temozolomide (Temodar(R)) chemotherapy daily for six weeks with a one month break before taking temodar for additional 12 monthly cycles.
62577432|NCT05704166|PLACEBO_COMPARATOR|Placebo|Patients were given placebo or pirfenidone capsules orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.
62577433|NCT03860272|EXPERIMENTAL|3-Week Monotherapy|3+3 Dose escalation: botensilimab, every 3 weeks, starting at dose level 0.1 milligrams/kilogram (mg/kg) up to 4 mg/kg, administered intravenously (IV) for up to 2 years.
62577434|NCT03860272|EXPERIMENTAL|6-Week Monotherapy|3+3 Dose escalation: botensilimab, every 6 weeks, starting at dose level 1 mg/kg up to 4 mg/kg, administered IV for up to 2 years.
62577435|NCT03860272|EXPERIMENTAL|6-Week Combination Therapy|3+3 Dose escalation: balstilimab, every 2 weeks, at dose level 3 mg/kg in combination with botensilimab, every 6 weeks, starting at dose level 0.1 mg/kg up to 4 mg/kg, administered IV for up to 2 years. Participants enrolled at sites in the United Kingdom (UK) may have the option for extended treatment. An additional cohort will investigate balstilimab, every 3 weeks, at 450 mg in combination with botensilimab every 6 weeks, at 150 mg, administered IV for up to 2 years.
62577436|NCT06255756|EXPERIMENTAL|routine treatment+swallowing rehabilitation training+acupuncture therapy|The experimental group was given routine treatment and swallowing rehabilitation training. Moreover, the experimental group was given acupuncture therapy.
62577437|NCT06255756|ACTIVE_COMPARATOR|routine treatment+swallowing rehabilitation training|The control group was given routine treatment and swallowing rehabilitation training.
62012177|NCT04530682||SARS-CoV-2 seropositive patients with chronic inflammatory rheumatisms (CIRs)|200 SARS-CoV-2 seropositive patients with chronic inflammatory rheumatisms (CIRs) from the COVID-RIC-1 cohort.
62400995|NCT02738931|EXPERIMENTAL|Treatment Sequence ABC|Subject will receive reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 1, experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AA, treatment B) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AB, treatment C) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
62400996|NCT02738931|EXPERIMENTAL|Treatment Sequence BCA|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AA, treatment B) in period 1 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AB, treatment C) in period 2 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
62400997|NCT02738931|EXPERIMENTAL|Treatment Sequence CAB|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 1 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
62577438|NCT01327170|ACTIVE_COMPARATOR|Subthreshold diode micropulse laser|Subthreshold diode micropulse laser in patients with chronic central serous chorioretinopathy
62577439|NCT01327170|SHAM_COMPARATOR|Sham|Sham group simulating the laser treatment
62577440|NCT01435304|EXPERIMENTAL|Hemobag®|Hemobag® method of returning residual CPB blood (study group)
62784529|NCT02085304|ACTIVE_COMPARATOR|Standard fractionated radiation therapy|Following surgery for Gross total resection and Gliadel(R) wafers implanted , the patient will receive six weeks of standard fractionated radiation therapy plus daily temozolomide (Temodar(R)) chemotherapy for six weeks. This is followed by a one month break before taking temodar for additional 12 monthly cycles.
62784530|NCT02741765|ACTIVE_COMPARATOR|Group 1: Sham Group|Sham group will receive Sham rTMS+Aerobic Exercise
62784531|NCT02741765|EXPERIMENTAL|Group 2: Real Group|rTMS+Aerobic Exercise
62784532|NCT03346200|ACTIVE_COMPARATOR|20 mg tamoxifen|
62784533|NCT03346200|EXPERIMENTAL|10 mg tamoxifen|
62577441|NCT01435304|NO_INTERVENTION|cell saver|Standard method of returning the residual pump volume to the patient as washed, centrifuged cells (control group)
62577442|NCT02955355|EXPERIMENTAL|HYQVIA/HyQvia|Participants received HYQVIA/HyQvia (recombinant human hyaluronidase \[rHuPH20\] at a dose of 80 units per gram (U/g) immunoglobulin G \[IgG\], followed by subcutaneous \[SC\] immune globulin infusion \[IGI\] 10%) at the same monthly equivalent dose as the individual participant's IgG treatment in Study 161403, every 3 or 4 weeks in this Extension Study for 77.3 months or until relapse.
62577443|NCT04065984|EXPERIMENTAL|Neuro-Muscular electrical stimulation treatment arm|Active muscle stimulation with a view that this will lead to muscle preservation through muscle fibre recruitment
62784534|NCT03346200|EXPERIMENTAL|5 mg tamoxifen|
62784535|NCT03346200|EXPERIMENTAL|2.5 mg tamoxifen|
62784536|NCT03346200|EXPERIMENTAL|1 mg tamoxifen|
62784537|NCT03346200|PLACEBO_COMPARATOR|0 mg tamoxifen|
62784538|NCT04916912||CABG-1|A group of non-obese patients (BMI less than 30 kg / m2) who underwent isolated coronary artery bypass grafting for chronic ischemic heart disease
62784539|NCT04916912||CABG-2|A group of obese patients (BMI over 30 kg / m2) who underwent isolated coronary artery bypass grafting for chronic ischemic heart disease
62784540|NCT01240200|ACTIVE_COMPARATOR|Vial & Syringe (Period 1) / Pen (Period 2)|Crossover phase: patients randomized to the sequence: Insulin glargine vial and syringe in Period 1 and Insulin glargine SoloSTAR pen in Period 2.
62784541|NCT01240200|EXPERIMENTAL|Pen (Period 1) / Vial & Syringe (Period 2)|Crossover phase: patients randomized to the sequence: Insulin glargine SoloSTAR® pen in Period 1 and Insulin glargine vial and syringe in Period 2.
62784542|NCT02356289|EXPERIMENTAL|MYK-461|single-dose, tablet formulation
62784543|NCT02356289|PLACEBO_COMPARATOR|Placebo|single-dose, tablet formulation
62784544|NCT04839549|EXPERIMENTAL|Dextenza (Intracanalicular ) 0.4mg|Dextenza for the treatment of Ocular Rosacea
62784545|NCT04839549|ACTIVE_COMPARATOR|Fluoromethalone .01%|Fluoromethalone .1% BID for 2 weeks then once daily for 2 weeks for the treatment of Ocular Rosacea
62784546|NCT03150420|EXPERIMENTAL|Sodium Thiosulfate|Sodium Thiosulfate Injection (25 grams sodium thiosulfate)
62784547|NCT03150420|PLACEBO_COMPARATOR|Placebo-Normal Saline|0.9% sodium chloride injection, USP (normal saline)
62784548|NCT04260347||Actilyse® (alteplase) pre-approval|
62784549|NCT04260347||Actilyse® (alteplase) post-approval|
62012178|NCT04530682||Control group|100 health professionals participating in the COVID-BIOTOUL cohort will be selected to be matched on age, gender, and the time between the date of infection with Covid-19 and the first serology of CIR patients.
62012179|NCT04678414||Observational (focus group, survey)|"FOCUS GROUP: Patients attend an audiotaped focus group over 90 minutes to provide feedback for survey development.~SURVEY VALIDATION: Patients complete an online survey over 15-30 minutes at baseline and 2 days later.~TELEPHONE SURVEY: Patients complete a telephone survey."
62012180|NCT06663085|NO_INTERVENTION|control group not received enteral feeding|control group not received enteral feeding during blood transfusion
62012181|NCT06663085|ACTIVE_COMPARATOR|intervention group received enteral feeding|intervention group still received enteral feeding during blood transfusion
62577444|NCT04065984|SHAM_COMPARATOR|Neuro-Muscular electrical stimulation Placebo arm|Stimulator set at a sub therapeutic threshold so as to not recruit muscle fibres
62577445|NCT05485168|EXPERIMENTAL|Sequential Variety, Small Portion|3 different foods served in a small portion in 3 successive courses
62577446|NCT05485168|EXPERIMENTAL|Sequential Variety, Large Portion|3 different foods served in a large portion in 3 successive courses
62784550|NCT01122849|EXPERIMENTAL|Prototype Nasal Dilator|Prototype Nasal Dilator
62784551|NCT01122849|ACTIVE_COMPARATOR|Marketed Nasal Strip|Marketed Nasal Strip
62784552|NCT01122849|PLACEBO_COMPARATOR|Placebo Nasal Strip|Placebo
62012182|NCT00220818|EXPERIMENTAL|Lansoprazole 1.0 mg/kg QD|
62012183|NCT00220818|EXPERIMENTAL|Lansoprazole 2.0 mg/kg QD|
62012184|NCT06526507|EXPERIMENTAL|Implementation strategy package|Package includes a Community of Practice, a quality improvement (QI) practice, and a training \& delivery toolkit.
62012185|NCT06526507|NO_INTERVENTION|Comparison|
62784553|NCT02164266|EXPERIMENTAL|Part 1: Healthy Volunteers|
62784554|NCT02164266|EXPERIMENTAL|Part 2: Patients with T2D, Group A|Low dose daily oral administration of RO6799477
62577447|NCT05485168|EXPERIMENTAL|Single-Food, Small Portion|1 food served in a small portion in 3 successive courses
62577448|NCT05485168|EXPERIMENTAL|Single-Food, Large Portion|1 food served in a large portion in 3 successive courses
62577449|NCT03312387|EXPERIMENTAL|Essential Amino Acid and Exercise|Participants will be provided with essential amino acids during exercise training.
62577450|NCT03312387|PLACEBO_COMPARATOR|Placebo and Exercise|Participants will be provided with placebo supplement during exercise training.
62577451|NCT04740827|PLACEBO_COMPARATOR|Placebo|Participants received atogepant-matching placebo tablets, orally, once daily (QD) for up to 12 weeks in a double-blind (DB) treatment period.
62577452|NCT04740827|ACTIVE_COMPARATOR|Atogepant 60 mg|Participants received atogepant 60 mg, orally, QD for up to 12 weeks in a DB treatment period.
62784555|NCT02164266|EXPERIMENTAL|Part 2: Patients with T2D, Group B|High dose daily oral administration of RO6799477
62784556|NCT06396624|EXPERIMENTAL|Intervention Group|The application of FBM will take place immediately after the conventional physical therapy maneuvers as recommended by the institution's physical therapist, following the institution's protocols. The patient may be positioned in bed or on the lap of the person in charge, in the way that is most comfortable for him/her, with the chest bare. The eyes of the patient, the person in charge and the physiotherapist must be properly protected by the use of appropriate glasses to avoid contact with the light beam emitted by the equipment. The application will be punctual, perpendicular to the thorax, using the portable photobiomodulation device Therapy EC - (DMC equipamentos - São Carlos-SP. ANVISA Registration: 80030819013) in continuous mode, with a power of 100mW, 808nm wavelenght, 4J of energy and 40s of irradiation per point.
62012186|NCT00673452|EXPERIMENTAL|Duloxetine|60-120 mg, oral, every day, 12 weeks
62012187|NCT00673452|PLACEBO_COMPARATOR|Placebo|oral, daily, 12 weeks
62577453|NCT01948193|EXPERIMENTAL|Study Group|Participants will receive Sanofi Pasteur's DTaP-IPV-Hep B-PRP\~T combined vaccine (investigational vaccine) at 6, 10 and 14 weeks of age.
62577454|NCT03806855||OAB-wet|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet.
62784557|NCT06396624|PLACEBO_COMPARATOR|Control Group|The control group will be treated in the same way as the intervention group, as recommended by the institution's physiotherapist, following its protocols. The same photobiomodulation device will be used as a placebo, but turned off, with a lock on the tip to ensure that no light beam is emitted. The device will be wrapped in PVC plastic film that allows it to be cleaned and changed when used in different patients, avoiding possible contamination. The same irradiation points will be used as in the control group (Figures 2 and 3). The patient may be positioned in bed or on the lap of the person in charge, in the way that is most comfortable for him/her, with the chest bare. The eyes of the patient, the caregiver and the physiotherapist must be properly protected.
62012188|NCT02749903|OTHER|Enzalutamide|Patients receive 160 mg enzalutamide orally once daily (1 cycle=28 days). Patients will remain on therapy until progression of disease or development of unacceptable toxicities or patient or physician withdrawal. Patients will undergo radiographic imaging every 2 months while on study treatment in order to determine response.
62012189|NCT01007461|EXPERIMENTAL|IK-1001|IK-1001 Sodium Sulfide (Na2S) for Injection
62012190|NCT01007461|PLACEBO_COMPARATOR|Placebo|0.9% Sodium Chloride (NaCl)
62012191|NCT06546800||RSVpreF vaccine|Individuals aged 60 years or older who has been vaccinated with Abrysvo for the first time.
62012192|NCT02665481|EXPERIMENTAL|MBSR|Mindfulness-Based Stress Reduction consists of a brief introductory meeting, eight weekly 2.5-hour classes, and a retreat, followed by monthly booster sessions for approximately 15 months. Content includes instruction in mindfulness meditation practices, gentle mindful movement, and exercises to enhance mindfulness in everyday life.
62012193|NCT02665481|EXPERIMENTAL|Exercise|The exercise protocol is optimal for improving aerobic fitness and insulin sensitivity in older adults, as well as improving strength and balance and reducing indices of frailty.It consists of classes twice weekly for 6 months, building up to 1.5 hr, under the direct supervision of trained exercise instructors, followed by once weekly classes for 12 months.
62012194|NCT02665481|EXPERIMENTAL|MBSR + Exercise|"This condition will receive both MBSR and exercise as described above. Participants in this condition will come in once weekly to receive MBSR and twice weekly to receive exercise classes, with at-home exercise the other two days as well as daily, at-home mindfulness practice. After the initial classes participants will also attend additional weekly or monthly sessions until completion of the study.~Note that at each site a pilot group is undergoing MBSR + Exercise (not randomized, separate from the RCT)."
62012195|NCT02665481|ACTIVE_COMPARATOR|Health Education|Health Education is a group-based intervention that increases health-related knowledge and action. Health Education improves chronic disease management.Health Education consists of ten weekly 2.5-hour classes, followed by monthly classes for approximately 15 months.
62577455|NCT03806855||OAB-dry|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The absence of urgency associated incontinence was defined to be OAB-dry.
62012196|NCT03427372||group 1: patients with headache|the patients who have post spinal puncture headache after spinal anesthesia
62012197|NCT03427372||group 2: patients without headache|the patients who do not have post spinal puncture headache after spinal anesthesia
62012198|NCT03427372||group 3: patients with backache|the patients who have post spinal puncture backache after spinal anesthesia
62012199|NCT03427372||group 4: patients without backache|the patients who do not have post spinal puncture backache after spinal anesthesia
62012200|NCT06222476|EXPERIMENTAL|Patients treat with Dorzagliatin|Dorzagliatin will be initiated and maintained at 75mg twice a day until the completion of the study. Meanwhile, all patients will also continue on regimen of metformin 500mg three times a day throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs.
62199635|NCT01755377||Chagas Disease|Participants diagnosed with Chagas Disease will be followed-up as a Case Group
62199636|NCT02251769|EXPERIMENTAL|Sequential administration|
62199637|NCT01080326|EXPERIMENTAL|Endoscopic Translumenal Omental Patch|Patients with the clinical diagnosis of a perforated viscus who are scheduled to undergo surgical exploration will be recruited. The endoscope will be gently advanced through the ulcer. Irrigation with saline will proceed. Then a viable mobile piece of omentum will be identified and pulled into the ulcer. After the omentum is located in the stomach, clips will be used to fix the Endoscopic Translumenal Omental Patch in place.
62577456|NCT01788527|EXPERIMENTAL|CGM|Continuous Glucose Monitoring
62784558|NCT02014168|EXPERIMENTAL|Viroflu® and MVA-NP+M1|1 dose (0.5ml) of Viroflu® and 1 dose of 1.5 x10\^8 pfu MVA-NP+M1 intramuscularly into the vastus lateralis muscle on day 0. The vaccines will be given side by side, with MVA NP+M1 being given immediately after the seasonal influenza vaccine.
62012201|NCT06222476|ACTIVE_COMPARATOR|Patients treat with Gliclazide|Gliclazide will be initiated and maintained at 30mg once a day until the completion of the study. Meanwhile, all patients will also continue on regimen of metformin 500mg three times a day throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs.
62199638|NCT05962190|EXPERIMENTAL|High fat, high SFA|\~60% of total energy is from fat, of which \~45% is from SFA, \~55% is from PUFA
62199639|NCT05962190|EXPERIMENTAL|High fat, high UFA|\~60% of total energy is from fat, of which \~25% is from SFA, \~75% from UFA
62199640|NCT03798275|ACTIVE_COMPARATOR|the study group|healthy pregnant women with borderline oligohydramnios who accept to drink a cup of coffee
62577457|NCT01788527|NO_INTERVENTION|HGM|Standard of care, Home Glucose Monitoring
62012202|NCT04959084|EXPERIMENTAL|Acupuncture|Acupuncture group A , consisting of 20 women will be received laser acupuncture therapy and pelvic floor training every other day for 30 min , 3 times per week for 12 sessions
62012203|NCT04959084|NO_INTERVENTION|Medical|Medical group B, consisting of 20 women will be maintained their ordinary medical treatment
62012204|NCT04560504|PLACEBO_COMPARATOR|Control Group|Receive 10 sessions of 45-minute (3 sessions per week) in-office leisure activities e.g. simple non-action computer games or board games (e.g. card and chess games) and 10-20 minutes of video watching at home
62012205|NCT04560504|ACTIVE_COMPARATOR|Intervention Group|Receive 10 sessions of 45-minute office training (3 sessions per week) and 10-20 minute home training (3 sessions per week) of eye movement training
62012206|NCT01040871|EXPERIMENTAL|VR-CAP|VR-CAP arm received rituximab 375 mg/m2 IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, VELCADE 1.3 mg/m2 IV on Days 1, 4, 8, and 11, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.
62199641|NCT03798275|NO_INTERVENTION|the control group|healthy pregnant women with normal amniotic volume
62199642|NCT03415243|EXPERIMENTAL|Treatment A Group|Participants will receive a single dose (1 sachet) of the investigational product (Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg).
62199643|NCT03415243|EXPERIMENTAL|Treatment B Group|Participants will receive a single dose (2 caplets) of the investigational product (Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg).
62199644|NCT01330849|EXPERIMENTAL|Toolkit intervention|
62199645|NCT01330849|NO_INTERVENTION|Waiting List Control Group|Children eligible for the study according to the inclusion criteria, but randomly allocated to the waiting list control group are promised to receive the intervention AFTER the study is finished.
62199646|NCT04692701|EXPERIMENTAL|Pulvinar stimulation|Medial pulvinar deep brain stimulation
62577458|NCT00502970|EXPERIMENTAL|1|16 weeks Interferon Tiw with Ribavirin
62577459|NCT00502970|ACTIVE_COMPARATOR|2|24 weeks Interferon Tiw with Ribavirin
62577460|NCT05486091|EXPERIMENTAL|App-Enhanced Brief Cognitive-Behavioral Therapy|Up to 4 in-person sessions
62577461|NCT04346667|ACTIVE_COMPARATOR|Arm 1|Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care
62577462|NCT04346667|EXPERIMENTAL|Arm 2|Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care
62577463|NCT04346667|ACTIVE_COMPARATOR|Arm 3|Chloroquine 500 mg BID for 5 days plus standard of care
62577464|NCT04346667|PLACEBO_COMPARATOR|Arm 4|Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)
62199647|NCT00506246|EXPERIMENTAL|1|Propofol MCT/LCT
62199648|NCT00506246|ACTIVE_COMPARATOR|2|Propofol LCT
62012207|NCT01040871|ACTIVE_COMPARATOR|R-CHOP|R-CHOP received rituximab 375 mg/m2IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, vincristine 1.4 mg/m2 (maximum total of 2 mg) IV on Day 1, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.Prednisone
62199649|NCT03039062||Chemotherapy group|A total of 120 malignant tumor patients who need to receive chemotherapy are involved for miR-122 detection. They are from 3 centers, 40 for each center. For the first cycle of chemotherapy, the investigators will collect 0.5-1ml blood from the remained blood sample after routine blood test during chemotherapy for each patient.Each patient will have a routine blood test before(±3 days) each cycle of chemotherapy and 7(±3)days after chemotherapy. A routine blood test will include the test of ALT,AST,ALP and TBIL. Sample collection will stop after 4 cycles of chemotherapy. All blood samples collected by investigators are the remained sample after routine tests. Patients in routine care will also have blood tests before each cycle and on day 7(+/- 3) of each cycle of chemotherapy. These patients will also have blood test at these time points even if they are not in this trial.
62199650|NCT03039062||Healthy population|Twenty healthy women or men who come to hospitals for annual physical examinations are enrolled in this study for miR-122 detection. Investigators will collect 0.5-1 ml blood from the remained blood samples after routine blood tests during their annual physical examinations.
62199651|NCT03039062||Patients of intensive care unit|Fourty patients are enrolled in this group for miR-122 detection. The investigators will collect 0.5-1ml blood from the remained blood samples of their routine blood tests or when they need blood tests.
62199652|NCT05866042|EXPERIMENTAL|Active tDCS|Administration of active tDCS, not followed by MCT session, but by a usual visit psychiatric follow-up
62199653|NCT05866042|NO_INTERVENTION|sham tDCS and MCT|Administration of sham tDCS, followed by MCT session
62199654|NCT05866042|EXPERIMENTAL|active tDCS and MCT|Administration of active tDCS, followed by MCT session
62199655|NCT05521243|EXPERIMENTAL|Placebo + Dream Powder|Participants take the placebo product for two weeks, followed by the Dream Powder intervention product for four weeks.
62199656|NCT05521243|EXPERIMENTAL|Placebo + Dream Powder Extra Strength|Participants take the placebo product for two weeks, followed by the Dream Powder Extra Strength intervention product for four weeks.
62400998|NCT02738931|EXPERIMENTAL|Treatment Sequence ACB|Subject will receive reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 1, experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
62199657|NCT06196775|EXPERIMENTAL|AK104+AK112|
62199658|NCT04937322||Interventional Endoscopy procedures|All patients who have had Interventional Endoscopy procedures done which involved radio frequency ablations for pancreatico-biliary disorders since June 2011 and extending forward through June 2023.
62199659|NCT01848613|EXPERIMENTAL|Arm A|•Arm A: first cycle of IV vinorelbine (30 mg/m2) and second cycle of PO vinorelbine (60mg/m2)
62199660|NCT01848613|EXPERIMENTAL|Arm B|• Arm B: first cycle with PO vinorelbine (60mg/m2) followed by a second cycle of IV vinorelbine (30mg/m2)
62199661|NCT01836939|ACTIVE_COMPARATOR|TSO 2500|TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
62199662|NCT01836939|ACTIVE_COMPARATOR|TSO 7500|TSO 7500: 7500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
62199663|NCT00478192|EXPERIMENTAL|Regimen 1 Conivaptan QD|20 mg conivaptan once a day
62199664|NCT00478192|EXPERIMENTAL|Regimen 2 Conivaptan BID|20 mg conivaptan two times a day
62199665|NCT00478192|PLACEBO_COMPARATOR|Regimen 3 Placebo|
62199666|NCT05185505|EXPERIMENTAL|Atezolizumab + Bevacizumab|Patients will receive transarterial chemoembolization (TACE) every 3 months, with a maximum of 4 treatments, plus atezolizumab combined with bevacizumab.
62199667|NCT05070364|EXPERIMENTAL|Peginterferon Lambda for 48 weeks|Peginterferon Lambda 180 mcg once weekly for 48 weeks with 24 weeks follow-up
62199668|NCT05070364|NO_INTERVENTION|No treatment for 12 weeks|No treatment for 12 weeks followed by Peginterferon Lambda 180 mcg once weekly for 48 weeks and 24 weeks follow-up
62199669|NCT04763226|EXPERIMENTAL|Part A Furosemide|
62577465|NCT01217164|NO_INTERVENTION|higher protein|
62577466|NCT00546065|OTHER|ablation of Barretts with concomitant esomeprazole therapy|comparison of recurrence-free survival
62577467|NCT00546065|NO_INTERVENTION|non ablation|non ablation only surveillance
62577468|NCT05486533|EXPERIMENTAL|Experimental|The experimental group will be given acupressure.
62577469|NCT05486533|NO_INTERVENTION|Control|It will only take routine treatment and care.
62012208|NCT06662682|EXPERIMENTAL|Whole-Body Vibration|The intervention (IC) will be specified as a five-minute Whole-Body Vibration session.
62199670|NCT04763226|EXPERIMENTAL|Part B (SAD)|Single Ascending Dose (SAD)
62012209|NCT06662682|OTHER|Control Condition|The control condition (CC) will conduct the same protocol as the intervention condition. The only difference will be that the vibration plate will be switched off.
62199671|NCT04484727||ICU-patients in ventilator treatment|"Directly after intubation and start of mechanical ventilation, a two-PEEP-step up and down procedure with steps of 5-7 cmH2O each is performed and data on airway pressure and tidal volume changes collected. The data is transferred into a dedicated software for calculation of ΔEELV by cumulative difference in expiratory tidal volume before and during PEEP inflation. Consequently, the lung P/V curve from baseline clinical PEEP to end-inspiration of the highest PEEP level. The PEEP level where clinically used tidal volume has the lowest transpulmonary driving pressure is calculated.~A one-PEEP-step procedure with a step of 5-7 cmH2O is performed when clinical events such as disconnection of the breathing circuit, posture changes, suctioning, inhalation, CO2 insufflation etc. is performed, and repeated during the whole period of ventilator treatment."
62199672|NCT04484727||Surgery-patients during general anaesthesia|"Directly after intubation and start of mechanical ventilation, a two-PEEP-step up and down procedure with steps of 5-7 cmH2O each, is performed in the same way as described for ICU patients. Data of airway pressure and volumes are transferred into a dedicated software for calculation of ΔEELV by cumulative difference in expiratory tidal volume before and during PEEP inflation. Consequently, the lung P/V curve from baseline clinical PEEP to end-inspiration of the highest PEEP level. The PEEP level where clinically used tidal volume has the lowest transpulmonary driving pressure is calculated.~A one-PEEP-step procedure with a step of 5-7 cmH2O is performed when clinical events such as disconnection of the breathing circuit, posture changes or suctioning is performed, and before and after implementation of pneumoperitoneum."
62199673|NCT06179004|EXPERIMENTAL|Supraclavicular Liposomal Bupivacaine group|This group will receive the liposomal bupivacaine
62199674|NCT06179004|ACTIVE_COMPARATOR|Supraclavicular Plain Bupivacaine group|This group will receive the plain bupivacaine
62199675|NCT04654767||COPD-PH group|Patients with confirmed COPD and pulmonary hypertension
62199676|NCT04654767||IPF-PH|Patients with confirmed pulmonary fibrosis and pulmonary hypertension
62199677|NCT04654767||Control group|Control group without diagnosed COPD, IPF, or pulmonary hypertension
62400999|NCT02738931|EXPERIMENTAL|Treatment Sequence BAC|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 1 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
62577470|NCT04973969|OTHER|study group|The participants will recieve decapeptyl 0.2 mg on day 2/3 of the follicular phase.At that day, and at the day after, hormonsl profile will be documented. The hormonal profile of the day after follicular decapeptyl administration will be compared to the hormonal profile to test the predictive value.
62577471|NCT03002558||control (non-OSA)|Patients without sleep apnoea
62577472|NCT03002558||OSA-treated|Patients with sleep apnoea who are treated (CPAP, surgery or MAD)
62012210|NCT06262087|EXPERIMENTAL|FIFA 11+ program combined with COD training|Participants in an experimental group will perform the FIFA 11+ program combined with COD training.
62012211|NCT06262087|ACTIVE_COMPARATOR|FIFA 11+|Participants in the control group will perform the FIFA 11+ program.
62199678|NCT03399253|ACTIVE_COMPARATOR|Chemotherapy|chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
62199679|NCT03399253|EXPERIMENTAL|Surgery+Chemotherapy|D2 Gastrectomy and Metastasectomy + chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
62577473|NCT03002558||OSA-non treated|Patients with sleep apnoea who are not treated
62577474|NCT05468684||Neck Pain-Associated Disorders|neck pain without an acceleration-deceleration mechanism
62577475|NCT05468684||Whiplash-Associated Disorders|neck pain resulting from a traumatic acceleration-deceleration mechanism and classified as WAD Grade I-III on the modified Quebec Task Force Scale
62012212|NCT03370328|EXPERIMENTAL|Peppermint oil|post-op surgical patients
62012213|NCT03370328|EXPERIMENTAL|Ginger oil|post-op surgical patients
62012214|NCT03370328|EXPERIMENTAL|Peppermint and ginger oil|post-op surgical patients
62012215|NCT05458193|EXPERIMENTAL|Daridorexant|50 mg once daily from Day 1 to Day 5
62012216|NCT05458193|PLACEBO_COMPARATOR|Placebo|Matching placebo once daily from Day 1 to Day 5
62012217|NCT05007483|EXPERIMENTAL|Group 1 (Modified paleolithic elimination diet).|Modified paleolithic elimination diet.
62012218|NCT05007483|EXPERIMENTAL|Group 2 (TROO)|Time Restricted Olive Oil Based (TROO) Ketogenic Diet
62012219|NCT05007483|ACTIVE_COMPARATOR|Group 3 Control|Usual diet with Dietary Guidelines for Americans Diet information
62012220|NCT05814562|EXPERIMENTAL|Remote Intervention|An automatic blood pressure monitor will be given to patients upon enrollment. During the three months after enrollment, patients will be administered remote intervention weekly during the first month, and biweekly during the second and third month. At the onset of those sessions the patients will be asked to measure their blood pressure and this will be recorded by the coordinator.
62401000|NCT02738931|EXPERIMENTAL|Treatment Sequence CBA|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 1 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 2 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
62577476|NCT05648942|EXPERIMENTAL|Experimental - anemia testing|"All patients in the experimental group will undergo a point of care test. Patients who meet the higher point-of-care-testing thresholds as possibly having anemia (female: 130g/L; male: 140g/L) will have a formal complete blood count (CBC) test. Formal CBC will not be ordered for all patients in the experimental group to limit the burden on hospital resources. The study co-ordinator will review CBC levels and contact patients to inform them of their results. Patients identified as having anemia in the formal CBC test will be invited to be reviewed in the PBOC.~Patients in the experimental group who do not meet the threshold for possible anemia on the point-of-care test will continue the current pathway and be reassessed in the preoperative assessment clinic at the time of scheduled surgery. Patients in the experimental group who are determined not to have anemia after formal CBC tests will follow the same pathway."
62577477|NCT05648942|NO_INTERVENTION|Control|Patients in the control group will not be tested at point of care and will continue on the current pathway and be assessed in the preoperative assessment clinic at the time of scheduled surgery.
62012221|NCT04922593|EXPERIMENTAL|LY03010 treatment group|"LY03010 (paliperidone palmitate) is a pharmaceutical equivalent drug product to the listed drug (LD) product INVEGA SUSTENNA. The chemical name is (±)-3-\[2-\[4-(6-fluoro-1,2-benzisoxazol-3yl)piperidinyl\]ethyl\]-6,7,8,9-tetrahydro-2-methyl-4oxo-4Hpyrido\[1,2-a\]pyrimidin-9-yl hexadecanoate. Its molecular formula is C39H57FN4O4 and its molecular weight is 664.89 g/mol.~LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection. In LY03010 treatment group, all subjects will receive the first dose of 351 mg IM injection on Day 1 in the deltoid muscle, followed by five (5) monthly dosing of 156 mg IM injection in the gluteal muscle with the last dose on Day 141."
62199680|NCT02145468|EXPERIMENTAL|Losmapimod|Losmapimod 7.5 mg twice daily oral tablet
62199681|NCT02145468|PLACEBO_COMPARATOR|Placebo|Placebo twice daily oral tablet
62401001|NCT00779857|EXPERIMENTAL|AtriCure LAA Exclusion System|AtriCure LAA Exclusion System
62401002|NCT03704194|EXPERIMENTAL|Adapted LiFE|Participants in the Adapted LiFE group learns to imbed 19 exercise activities (7 balance and 12 lower extremity muscle strength activities) into daily routines. An Occupational Therapy practitioner conducts 7 in-home visits over 12 weeks and a follow phone call a month after the last in-home visit.
62577478|NCT01861652|EXPERIMENTAL|Venous health systems Vasculaire leg compression device|Vasculaire leg compression device
62577479|NCT02962453|EXPERIMENTAL|Morning walk|Rehabilitation using end-effector type gait robot for 5days.
62577480|NCT02962453|ACTIVE_COMPARATOR|Ground Walker|Rehabilitation using walker for 5days.
62199682|NCT04248478||Fibromiyalgia Patients|Patients diagnosed with fibromyalgia according to 2013 American College of Rheumatology criteria are planned to be included in this arm.
62199683|NCT04248478||Healthy Volunteers|Healthy volunteers are planned to be included in this arm.
62401003|NCT03704194|SHAM_COMPARATOR|Attention control|Participants in the attention control group will learn gentle stretch exercise. An Occupational Therapy practitioner conducts 7 in-home visits over 12 weeks and a follow phone call a month after the last in-home visit.
62401004|NCT00188058|ACTIVE_COMPARATOR|Minimal alveolar distension|PEEP is set for a total PEEP (PEEP + intrinsic PEEP) between 5 and 9 cm H2O
62401005|NCT00188058|EXPERIMENTAL|Maximal alveolar distension|PEEP is set for a plateau pressure between 28 and 30 cm H20
62401006|NCT00761462|EXPERIMENTAL|Ciprofloxacin|Subjects receiving Ciprofloxacin (group followed-up for 5 years)
62199684|NCT06246695|EXPERIMENTAL|Inhibitor group|Jaktinib 100mg, once daily on the 1st and 9th days before meal; Itraconazole 200mg, once daily from the 4th day to the 12th day.
62199685|NCT06246695|EXPERIMENTAL|Inducer group|"1. Jaktinib 100mg, once daily on the 1st and 12th days before meal, Rifampicin 600mg, once daily from the 4th day to the 14th day.~2. Rifampicin 600mg, once daily from the 1th day to the 11th day, Jaktinib 100mg, once daily on the 9st and 25th days before meal."
62199686|NCT04621253|ACTIVE_COMPARATOR|Ciprofloxacin|Day 1: 750 mg ciprofloxacin capsule in the morning and evening Day 2: 750 mg ciprofloxacin capsule in the morning and evening Day 3: 750 mg ciprofloxacin capsule in the morning and evening Day 4: Study day, 750 mg ciprofloxacin 1h prior to 1000 mg metamizole.
62401007|NCT00761462|ACTIVE_COMPARATOR|Non-quinolone antibiotic|Subjects receiving non-quinolone antibiotic (group followed-up for 2 years)
62577481|NCT03990883|OTHER|Treatment of device 1 on left side|Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to left NLF, Comparator is assigned to right NLF
62577482|NCT03990883|OTHER|Treatment of device 1 on right side|Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to right NLF, Comparator is assigned to left NLF
62577483|NCT01609855|EXPERIMENTAL|HBB- Hioscine Butyl Bromide|
62199687|NCT04621253|ACTIVE_COMPARATOR|Fluconazole|Day 1: 400 mg fluconazole in the morning, placebo capsule in the evening Day 2: 200 mg fluconazole in the morning, placebo capsule in the evening Day 3: 200 mg fluconazole in the morning, placebo capsule in the evening Day 4: Study day, 200 mg fluconazole 1h prior to 1000 mg metamizole.
62199688|NCT04621253|PLACEBO_COMPARATOR|Placebo|Day 1: placebo capsule in the morning and evening Day 2: placebo capsule in the morning and evening Day 3: placebo capsule in the morning and evening Day 4: Study day, placebo capsule 1h prior to 1000 mg metamizole.
62199689|NCT06118905|EXPERIMENTAL|Denosumab|Denosumab 60mg SQ with placebo zoledronic acid
62012222|NCT04922593|ACTIVE_COMPARATOR|INVEGA SUSTENNA treatment group|"INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available. INVEGA SUSTENNA is provided in a prefilled syringe (cyclic-olefin-copolymer) with a plunger stopper and tip cap (bromobutyl rubber).~In SUSTENNA treatment group, all subjects will receive the first dose of 234 mg IM injection in the deltoid muscle on Day 1, and a second dose of 156 mg of IM injection in the deltoid muscle on Day 8, followed by five (5) monthly dosing of 156 mg IM injection in the gluteal muscle with the last dose on Day 148."
62012223|NCT04516161||Radium-223 dichloride (Xofigo, BAY88-8223)|Patients with mCRPC who received treatment of Ra-223.
62199690|NCT06118905|ACTIVE_COMPARATOR|Zoledronic acid|Zoledronic acid 5mg IV with Denosumab placebo
62199691|NCT01810939|ACTIVE_COMPARATOR|Patiromer|Patiromer was administered twice a day as a powder mixed with water.
62199692|NCT01810939|PLACEBO_COMPARATOR|Placebo|Placebo was administered twice a day as a powder mixed with water.
62199693|NCT05187429|EXPERIMENTAL|Dose escalation phase (Cohort A)|Drug: Nivolumab Dose form: infusion Dose route: intravenous Dosage: 0.1, 0.3 or 1.0 mg/kg Duration: Single dose administered on Study Day 7
62199694|NCT05187429|EXPERIMENTAL|Randomization phase (Cohort B)|Drug: Nivolumab Dose form: infusion Dose route: intravenous Dosage: determined from Cohort 1 Duration: single dose administered on Day 0 (baseline)
62199695|NCT05187429|PLACEBO_COMPARATOR|Randomization phase comparator (Cohort B)|Comparator: saline Dose form: infusion Dose route: intravenous Duration: single dose administered on Day 0 (baseline)
62199696|NCT04991376||Vancomycin|Critically ill patients who suffered from sepsis, treated with vancomycin.
62199697|NCT04991376||Gentamicin|Critically ill patients who suffered from sepsis, treated with gentamicin.
62401008|NCT02857062|EXPERIMENTAL|E45 Eczema Repair Emollient|Open label, single arm study to evaluate the skin tolerance of E45 Eczema Repair Emollient in babies and children
62401009|NCT00229931|ACTIVE_COMPARATOR|Laser therapy|If randomized to laser therapy at time of cataract surgery, laser therapy will be performed one month after cataract surgery. If macular edema does not respond an additional laser therapy will be performed. If macular edema persists after 2 lasers, then IVTA will be administered as per standard of care.
62577484|NCT01609855|PLACEBO_COMPARATOR|Placebo arm|
62577485|NCT02017847||Gen100|150 participants in the Generation 100 study with anticipated 3000 participants aged 70-75
62199698|NCT04991376||Other antibiotic groups|Critically ill patients who suffered from sepsis, treated by other antibiotic groups except for vancomycin or aminoglycoside (gentamicin).
62199699|NCT05050747||Arm 1|Women with unexplained infertility undergoing ovulation induction following intrauterine adminstration of HCG on the day of trigger
62199700|NCT05050747||Arm 2|Women with unexplained infertility undergoing ovulation induction following endometrial injury by pipelle on day 8-9 of the same cycle of ovulation induction
62199701|NCT05050747||Arm 3|Women with unexplained infertility undergoing ovulation induction following intrauterine adminstration of placebo on the day of trigger
62199702|NCT04480775|EXPERIMENTAL|bupivacaine group|28 Patients will receive 18 ml of bupivacaine 0.5 % plus 1ml 0.9% saline in TAP block divided equally on both sides
62199703|NCT04480775|ACTIVE_COMPARATOR|triamicinolone group|28 Patient will receive 18 ml of bupivacaine 0.5 % plus (20 mg of triamcinolone in 1ml 0.9% saline divided equally on both sides in TAP block
62577486|NCT01454310|EXPERIMENTAL|Acellular skin substitute|
62577487|NCT01454310|ACTIVE_COMPARATOR|Autologous skin graft|
62577488|NCT01718535||CYP2C19 Genotyping|
62577489|NCT02926157|EXPERIMENTAL|Life Style and Sleep Group|Participants randomized into this group will undergo a 4 week sleep hygiene course (classes 1x/week for 1.5 hours), followed by a 20 week lifestyle activation program. During the 20 week lifestyle activation program, participants wear a Fit Bit and receive a call from a fitness professional every other week for motivation and recommendations, and receive a bright light therapy program from a sleep expert based on their initial sleep results at the baseline measurement session.
62199704|NCT04480775|ACTIVE_COMPARATOR|methylprednisolone group|28 Patient will receive 18 ml of bupivacaine 0.5 % plus (40 mg of methylprednisolone in 1ml 0.9% saline ) on both sides in TAP block.
62199705|NCT04391543|EXPERIMENTAL|Experimental Arm|"4 experimental session (baseline, after treatment, 6 month post treatment and 12 months post treatment) with :~* comprehensive interview~* cognitive tests~* anthropometric measures~* postural balance test~* critical force test~* Astrand-Ryhming test~* self-questionnaire (QLQ-C30, FA12, Brief Cope et Hospital Anxiety and Depression Scale)~* actimetry~* clinical and biological characteristics~* determination of inflammatory markers~* skeletal muscle index"
62577490|NCT02926157|NO_INTERVENTION|Wait-list Control|Participants randomized into this group will complete all measurement sessions. After completion of the final measurement session (6 months), participants will be offered an abbreviated version of the Life Style and Sleep Group intervention including the sleep hygiene course, consultation with sleep expert to go over individual sleep patterns and be given recommendations, along with physical activity recommendations from a fitness expert.
62577491|NCT05641142|OTHER|Cohort study|a single arm, the anticoagulant and/or antiplatelet treatment is not conditioned by the study
62577492|NCT05550454|EXPERIMENTAL|Automatic Mechanical Ventilation|Automatic Mechanical Ventilation during ACLS
62577493|NCT05550454|ACTIVE_COMPARATOR|Manual Ventilation|Standard care with manual ventilation, Ambu-bagging, during ACLS
62577494|NCT05975333|EXPERIMENTAL|Participants|Adolescents and young adults (AYA) patients aged 15-25 years currently receiving cancer-directed therapy at St. Jude Children's Research Hospital
62577495|NCT04463420|EXPERIMENTAL|Test Group|Intervention group: : Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days / 25 mg prednisolone daily for 5 days / PHR160 spray one hour oral puff with Demyar ten times a day for ten days in a row, for ten days.
62199706|NCT03659357||A-first CTE examination|
62199707|NCT03659357||B-first MRE examination|
62199708|NCT01168947|EXPERIMENTAL|5% dextrose|5% dextrose rinsing fluid
62199709|NCT03813277|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine 100microg/ml
62401010|NCT00229931|ACTIVE_COMPARATOR|Triamcinolone therapy|"At time of cataract surgery, will have IVTA injection. If macular edema does not show improvement at 1 month, then can have repeat IVTA injection. If the macular edema is stil not improved after 2nd injection, participant will be considered treatment failure and will be given the option to have laser therapy."
62401011|NCT00696332|EXPERIMENTAL|Talampanel 50mg|50mg Talampanel 3 times per day
62199710|NCT06122922|OTHER|Patients with Stable Pulmonary Arterial Hypertension|Stable on current treatment regimen and not planning to undergo initiation of new therapy for at least 3 months Intervention: Drug: 129Xe Hyperpolarized
62199711|NCT00132899|ACTIVE_COMPARATOR|Methotrexate|Methotrexate and infliximab combination
62199712|NCT00132899|PLACEBO_COMPARATOR|Placebo|Placebo plus infliximab combination
62401012|NCT00696332|EXPERIMENTAL|Talampanel 25mg|25mg Talampanel 3 times per day
62401013|NCT00696332|PLACEBO_COMPARATOR|Placebo|placebo 3 times per day
62577496|NCT04463420|PLACEBO_COMPARATOR|Control Group|Control group: Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days Daily / 25 mg prednisolone daily for 5 days / placebo spray one hourly oral puff ten times a day for ten days in a row, for ten days
62577497|NCT00248365|EXPERIMENTAL|Low PDT intensity level|Theralux extracorporeal photochemotherapy PDT dose: TH9402 0.33μM
62401014|NCT01460979|EXPERIMENTAL|Temsirolimus|
62577498|NCT00248365|EXPERIMENTAL|High PDT intensity level|Theralux extracorporeal photochemotherapy PDT dose: TH9402 1.32μM
62577499|NCT01859065|PLACEBO_COMPARATOR|Control|Mothers receive routine anticipatory guidance
62577500|NCT01859065|EXPERIMENTAL|Intervention|Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
62577501|NCT03231995|EXPERIMENTAL|Respiratory microbiome biomarkers|
62577502|NCT03620825|EXPERIMENTAL|Dehydration by sauna exposure|Participants dehydrate using sauna exposure until they lose 3% of their body weight.
62577503|NCT03620825|ACTIVE_COMPARATOR|Indomethacin - Positive control|Indomethacin is administered to induce increased intestinal permeability
62577504|NCT03620825|NO_INTERVENTION|Negative control|No intervention is performed
62784559|NCT02014168|PLACEBO_COMPARATOR|Viroflu® and saline placebo|1 dose (0.5ml) of Viroflu® and 1 dose of a 0.9% saline placebo injected intramuscularly into the vastus lateralis muscle on day 0. The placebo will be administered immediately after the seasonal influenza vaccine.
62784560|NCT02523781|NO_INTERVENTION|Control group|The control group does not receive the information pamphlet
62199713|NCT05554211|EXPERIMENTAL|Experimental Breast|Participants will receive 50 ml of TxA and gentamicin to the assigned experimental breast.
62199714|NCT05554211|PLACEBO_COMPARATOR|Control Breast|Participants will receive a standard irrigation of 50 ml of 0.9% NS and gentamicin to the assigned control breast.
62199715|NCT01860326|EXPERIMENTAL|Alisporivir|Single 200 mg oral dose
62401015|NCT03152721|PLACEBO_COMPARATOR|Control|Treating physician will in advance of upcoming visit be provided with the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment
62401016|NCT03152721|EXPERIMENTAL|Intervention|Treating physician will in advance of upcoming visit be provided with a Parkinson KinetiGraph recording report and interpretation in addition to the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment
62401017|NCT01781130|PLACEBO_COMPARATOR|Percutaneous release alone|The patients who perform percutaneous release of trigger finger only
62401018|NCT01781130|EXPERIMENTAL|Percutaneous release + Steroid injection|Steroid local injection after percutaneous release of trigger finger
62577505|NCT05824702|EXPERIMENTAL|Experimental: Peer education and network support|The intervention sessions will consist of 6 group sessions including 1) Introduction to Peer Educator role and peer Communication skills, 2) HIV and drug treatments, 3) using a decision balance tool with network members for drug treatment, 4) Promoting HIV prevention and medical care \& using text messages as peer educators for promoting MAT and HIV prevention and care, 5) Preventing and responding to relapse, and 6) HIV care retention and medication adherence.
62577506|NCT05824702|ACTIVE_COMPARATOR|comparison: Standard of care of health education|The comparison condition will include 5 group sessions focused on: 1) retention in MAT by addressing the myths about MAT; 2) information to MAT clients on finding local MAT and other health services in areas where they migrate; 3) importance of HIV prevention (including PreP) and HIV treatment including adherence to HIV; 4) harm reduction, safe drug use, overdose prevention and first aid in case of overdose; 5) addressing Hepatitis C, chronic conditions and mental health issues by emphasizing the importance of timely addressing these health problems and providing information on available local and national services.
62577507|NCT03356938|NO_INTERVENTION|Baseline recording|
62577508|NCT03356938|EXPERIMENTAL|Sleep restriction|
62577509|NCT03356938|EXPERIMENTAL|Sleep deprivation|
62401019|NCT02772159|EXPERIMENTAL|Study Population|One dose each of treatments A: \[14C\] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: \[14C\] TD-4208 200 μg oral solution administered in a fasted state.
62577510|NCT06089343||Culprit|Plaques which is related with acute coronary syndrome
62577511|NCT06089343||Non-culprit|Plaques which is not related with acute coronary syndrome
62577512|NCT06275789|EXPERIMENTAL|Test Group|This group will receive the grafting material that is a combination of DFDBA + DBBM + collagen matrix seal during the alveolar ridge preservation procedure.
62577513|NCT06275789|ACTIVE_COMPARATOR|Control Group|This group will receive the grafting material that is a Tutoplast® processed mineralized particulate allograft + collagen matrix seal during the alveolar ridge preservation procedure.
62401020|NCT01300715|ACTIVE_COMPARATOR|MBRF|
62577514|NCT05899283|EXPERIMENTAL|Group A(OCI-HF160+FX800HDF)|Group A first used the hemodialysis filter OCI-HF160, then used FX800HDF.
62577515|NCT05899283|EXPERIMENTAL|Group B(FX800HDF+OCI-HF160)|Group B first used the hemodialysis filter FX800HDF, and then used OCI-HF160.
62199716|NCT03145012|EXPERIMENTAL|Treatment Group|"This is a one arm study in which all individuals receive the treatment; therefore there is no allocation or randomization.~Thirty subjects will receive ranitidine to a maximum of 900 mg/day in 2 daily doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets. The ranitidine will be taken orally."
62577516|NCT00208169|EXPERIMENTAL|1|Aripiprazole start dose at 5 mg/day by day 4-6 increase to 10 mg/da and day 7 and subsequent visits flexible dosing from 10 up to 30 mg/day.
62577517|NCT05043025|ACTIVE_COMPARATOR|Neck extension group|The cricothyroid membrane is identified in a neck extended position.
62577518|NCT05043025|EXPERIMENTAL|Modified ramped position group|The cricothyroid membrane is identified in a modified ramped position.
62577519|NCT01401881||Post STEMI|The study population will consist of adult patients with acute STEMI and primary PCI with clear identification of symptoms onset, willing to participate in the research protocol and not having any of the exclusion criteria. Patient screening will take place after the primary PCI in the cardiac catheterization laboratory or in the coronary care unit. Participation will be offered to all those who meet eligibility criteria.
62577520|NCT00288366|ACTIVE_COMPARATOR|1|aripiprazole (Abilify)
62577521|NCT00288366|ACTIVE_COMPARATOR|2|ziprasidone (Geodon)
62577522|NCT04121130|ACTIVE_COMPARATOR|Group A (F-ESWT Group)|3 F-ESWT sessions, 1 per week (0,10 mJ/mm2; 2000 impulses; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
62012224|NCT02282475||Cohort study of pregnant women|"Participants will complete the following at 12-16 weeks gestation and again at 32-36 weeks gestation:~1. Fasting glucose, insulin and insulin sensitivity testing;~2. Blood tests for cholesterol and fatty acids, liver function, inflammation, and markers of metabolism;~3. Measurements of body fat using air displacement technology and MRI;~4. Ultrasound to measure placental blood flow, visceral fat thickness (12-16 weeks only) and to estimate fetal weight (32-36 weeks only);~5. 24 hour diet recalls~6. Questionaires regarding activity level"
62012225|NCT02282475||Case-control study Gestational Diabetes|"Participants diagnosed with gestational diabetes (cases) and without gestational diabetes (controls) will complete the following at 32-36 weeks gestation:~1. Fasting glucose, insulin and insulin sensitivity testing;~2. Blood tests for cholesterol and fatty acids, liver function, inflammation, and markers of metabolism;~3. Measurements of body fat by using air displacement technology and MRI;~4. Ultrasound to measure placental blood flow and to estimate fetal weight;~5. 24 hour diet recalls~6. Questionaires regarding activity level"
62012226|NCT02261116|EXPERIMENTAL|Telmisartan|
62012227|NCT02261116|ACTIVE_COMPARATOR|Candesartan|
62012228|NCT02261116|PLACEBO_COMPARATOR|Placebo|
62012229|NCT01076725|ACTIVE_COMPARATOR|Standard technique group|In the standard technique group(n = 63), the PLMA was inserted by index finger insertion technique.
62199717|NCT06441253|OTHER|Deep Friction massage|
62577523|NCT04121130|PLACEBO_COMPARATOR|Group B (sham F-ESWT):|3 sham F-ESWT sessions, 1 per week (0,01 mJ/mm2; 2000 SW; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
62577524|NCT03649061|ACTIVE_COMPARATOR|standard COBRA-Slim induction|Leflunomide 10mg PO daily added to the COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)
62199718|NCT06441253|EXPERIMENTAL|Therapeutic exercises|
62012230|NCT01076725|EXPERIMENTAL|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
62401021|NCT06405646||Study group|Participants with chronic pain in the masticatory muscles
62401022|NCT06405646||Control group|Participants without chronic pain in the masticatory muscles
62784561|NCT02523781|EXPERIMENTAL|Intervention group|The intervention group receives the information pamphlet
62784562|NCT00397436|EXPERIMENTAL|1|Comparing irradiated skin to non irradiated skin.
62199719|NCT05010876|EXPERIMENTAL|standard care + C1 inhibitor|The C1 inhibitor will be used at a dose of 1000 units per slow infusion (two hours). Two infusions will be given 24 hours apart. These doses correspond to the usual doses used in the treatment of conditions in which the C1-Inhibitor is indicated.
62199720|NCT05010876|EXPERIMENTAL|standard care + Icatibant + C1 inhibitor|"The C1 inhibitor will be used at a dose of 1000 units per slow infusion (two hours). Two infusions will be given 24 hours apart. These doses correspond to the usual doses used in the treatment of conditions in which the C1-Inhibitor is indicated.~The icatibant will be used in a single injection of 30 mg subcutaneously, preferably in the abdominal region. These doses correspond to the doses usually used in the treatment of conditions in which icatibant is indicated."
62199721|NCT05010876|PLACEBO_COMPARATOR|standard care + placebo|
62199722|NCT02226861|EXPERIMENTAL|1|Subjects will receive CD34-selected stem cells followed by fixed dose ULG IL-2 (100,000 IU/m2) given subcutaneously for 12 weeks+Sirolimus until Day +60
62199723|NCT00821262|EXPERIMENTAL|sevoflurane|The study group will receive Sevoflurane for a 4-6 hours period (from anesthesia induction to transfer to ICU).
62199724|NCT00821262|ACTIVE_COMPARATOR|propofol|The control group will receive propofol for the same 4-6 hours period.
62199725|NCT02693704|EXPERIMENTAL|Normal hearing|People showing no hearing loss (\< 20 dB HL). Introduction of speech signal via the DAI of two hearing aids Phonak Naida IX SP.
62401023|NCT03857165|EXPERIMENTAL|Low dose SAP-001|SAP-001 (Experimental drug) low dose versus placebo
62401024|NCT03857165|EXPERIMENTAL|Mid dose SAP-001|SAP-001 (Experimental drug) mid dose versus placebo
62401025|NCT03857165|EXPERIMENTAL|High dose SAP-001|SAP-001 (Experimental drug) high dose versus placebo
62401026|NCT00677066|EXPERIMENTAL|1|Children discharged home with oxygen
62401027|NCT00677066|NO_INTERVENTION|2|Children remain in hospital for oxygen therapy
62401028|NCT03082040|EXPERIMENTAL|intervention group|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks
62401029|NCT03082040|OTHER|waiting-list control group|Participants in the control condition will conduct the same breathing training as the intervention group after a four-week waiting list period
62401030|NCT01911546|EXPERIMENTAL|everolimus + low-dose tacrolimus|Patients receiving everolimus will be on low dose tacrolimus.
62401031|NCT05942742||Cervical cancer|Patient treated with Linac MRI for their locally advanced cervical cancer
62401032|NCT02182726||MOBEC|
62199726|NCT02693704|EXPERIMENTAL|Moderate hearing impaired|"Patients showing moderate hearing loss (40-60 dB HL).~Introduction of speech signal via the DAI of two hearing aids among:~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
62199727|NCT02693704|EXPERIMENTAL|Severe hearing impaired|"Patients showing severe hearing loss (60-80 dB HL).~Introduction of speech signal via the DAI of two hearing aids among:~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
62577525|NCT03649061|EXPERIMENTAL|COBRA-Slim Bio-induction|Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)
62199728|NCT02693704|EXPERIMENTAL|Profound hearing impaired|"Patients showing profound hearing loss (\> 80 dB HL).~Introduction of speech signal via the DAI of two hearing aids among:~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
62577526|NCT00877487|EXPERIMENTAL|SPD489|
62577527|NCT00877487|PLACEBO_COMPARATOR|Placebo|
62012231|NCT04886921|EXPERIMENTAL|TRAM abdominal muscle training group|"Patients were recruited at least 6 months after the muscle-sparing (MS) pedicled Transverse rectus abdominis musculocutaneous (TRAM) flap procedure and at least 1 month after the conclusion of the last chemotherapy course, if any.~All subjects will receive 1-hr training sessions consisting of core stability exercises for 12 weeks for the TRAM group."
62199729|NCT02222870|EXPERIMENTAL|Fluzone Study Group 1|Participants at 6 months to \< 36 months age at enrollment
62012232|NCT04886921|NO_INTERVENTION|TRAM control group|"Patients were recruited at least 6 months after the muscle-sparing (MS) pedicled Transverse rectus abdominis musculocutaneous (TRAM) flap procedure and at least 1 month after the conclusion of the last chemotherapy course, if any.~The control group was not received any exercise program."
62012233|NCT04886921|NO_INTERVENTION|Healthy women group|A control group comprising female volunteers who were apparently healthy and had comparable socioeconomic backgrounds and physical conditions was recruited by convenience sampling from communities.
62199730|NCT02222870|EXPERIMENTAL|Fluzone Study Group 2|Participants at 3 years to \< 9 years of age at enrollment
62199731|NCT02168348||Diabetic patients with a lesion on the foot|
62199732|NCT06399562||the physical examination population|the physical examination population from the health management center of the Third Xiangya Hospital
62199733|NCT06399562||the community residents|the family-based community residents in Changsha
62577528|NCT04637984|EXPERIMENTAL|Implementation Group|Predictions will be provided to the rehabilitation team and discussed with the patient and their family. Patients will receive a multidisciplinary rehabilitation according to their individual needs.
62577529|NCT04637984|NO_INTERVENTION|Control Group|This group will not received any information on the PREP2
62577530|NCT06217666|EXPERIMENTAL|PCX-12|PCX-12 is an experimental immunotherapy drug that is injected into the pancreatic cancer one time in attempt to stimulate the patient's immune system to fight the cancer.
62577531|NCT03425201|EXPERIMENTAL|Niraparib plus Cabozantinib|"Patients will receive niraparib and cabozantinib p.o. once daily in 28-day cycles.~In phase I, patients will be accrued to each dose level in cohorts of 6 patients. Escalation will continue until a dose-limiting toxicity (DLT) is observed or the highest dose-level is reached.~In phase II study patients will receive niraparib p.o. once daily and cabozantinib p.o. once daily in 28-day cycles at doses recommended in the phase I study.~If niraparib or cabozantinib need to be interrupted due to toxicity, patient can continue only with the other drug."
62577532|NCT04429568|OTHER|Smoked Cannabis, Vaped Cannabis, or Tobacco Cigarette|"* Abstinence from any product night before hospital admission~* Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette~* 6-hr abstinence and blood draws (PK)~* 2 hr Free use session w/ video monitoring~* Free use of assigned product~* 12-hr cardiovascular (CV) monitoring~* Circadian blood draws~* 12-hr urine collection"
62577533|NCT04429568|OTHER|Either of the 2 remaining products|"* Abstinence from any product night before hospital admission~* Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette~* 6-hr abstinence and blood draws (PK)~* 2 hr Free use session w/ video monitoring~* Free use of assigned product~* 12-hr CV monitoring~* Circadian blood draws~* 12-hr urine collection"
62577534|NCT04429568|OTHER|Remaining product|"* Abstinence from any product night before hospital admission~* Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette~* 6-hr abstinence and blood draws (PK)~* 2 hr Free use session w/ video monitoring~* Free use of assigned product~* 12-hr CV monitoring~* Circadian blood draws~* 12-hr urine collection"
62577535|NCT01168778|NO_INTERVENTION|Control|
62577536|NCT01168778|EXPERIMENTAL|Intervention|
62577537|NCT06436911|EXPERIMENTAL|Phase 1|In Phase 1 up to 50 participants are planned to be randomized 1:1 into one of two groups: either 100 μg intramuscular (IM) injection or 250 μg IM injection. Participants are to receive a single 0.5 mL IM injection of VAX-002 100 μg or 250 μg on Day 0. Follow-up visits will occur on Days 7, 14, 17 (phone call visit), 21, 28, 42, and 180. An interim analysis is planned once all participants in Phase 1 have completed their
62577538|NCT06436911|EXPERIMENTAL|Phase 2|"In Phase 2 approximately 250 participants will be enrolled and will receive a single 0.5 mL IM~injection of the optimal VAX-002 dose (determined in the Phase 1 interim analysis) on Day 0. Follow- up visits will occur on Days 7, 14, 17 (phone call visit), 21, 28, 42, and 180."
62577539|NCT04416867|ACTIVE_COMPARATOR|group-1 splint and home exercise|Patients in group 1 will be treated with splinting of the affected hand at night and a home exercise program. A wrist orthosis which held the wrist in the neutral position will be used for splinting at night time for a minimum of eight hours. Each patient will be given a home exercise program of wrist range of motion, wrist stretch, wrist isometric strengthening and median nerve glide exercises to be performed daily for the duration of the study
62577540|NCT04416867|ACTIVE_COMPARATOR|group 2 RESWT|Patients in group 2 will be treated with splinting of the affected wrist at night, a home exercise program similar to that of group one and a total of 3 sessions of RESWT at a frequency of one session per week using the Masterpuls ® mp200 radial shock wave therapy system (Elite-Storz Medical AG, Kreuzlingen, Switzerland). RESWT at a pressure of 4 bars, a frequency of 5Hz and 2000 hits in total will be applied 2cm proximal to the median nerve, with the probe directed towards the palm, diffusely over the pisiform.
62577541|NCT04416867|ACTIVE_COMPARATOR|group 3 physical therapy|Patients in group 3 will be treated with splinting of the affected wrist at night, a home exercise program similar to that of group one and two and 20 minutes of liquid paraffin treatment of the hand, 1.5watt/cm2 therapeutic ultrasound applied to the volar surface of the wrist for 5 minutes and 20 minutes of transcutaneous electrical nerve stimulation (TENS) on five consecutive days of the week for a total of fifteen sessions over 3 weeks.
62577542|NCT00611572|ACTIVE_COMPARATOR|1|Active iomazenil and ketamine
62012234|NCT06008925|EXPERIMENTAL|Single Arm|"Part1:~VG161:~1) 1.0 × 10 \^ 8 PFU daily on Day 1 of each cycle (D1); 2)1.0 × 10 \^ 8 PFU daily for 2 consecutive days on Days 1-2 of each cycle (D1-D2); 3)1.0 × 10 \^ 8 PFU daily for 3 consecutive days on days 1-3 (D1-D3) in the first cycle; 1.0 × 10 \^ 8 PFU daily for 2 consecutive days on days 1-2 (D1-D2) in the second and subsequent cycles; Nivolumab Injection: 3 mg/kg every 2 weeks (D8, D22)~Part2:~Depends on the recommended dose in Part1"
62012235|NCT06205290|EXPERIMENTAL|Arm A: Liso-cel Monotherapy|
62199734|NCT03223831|ACTIVE_COMPARATOR|Partially covered duodenal stent (PCDS)|The PCDS used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions. The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh.
62199735|NCT03223831|ACTIVE_COMPARATOR|Uncovered duodenal stent (UDS)|The UCDS used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
62199736|NCT04144712|EXPERIMENTAL|High Dose arm|subjects will receive the high dose of the drug
62199737|NCT04144712|ACTIVE_COMPARATOR|low dose arm|subject will receive low dose of the drug
62199738|NCT00218608|PLACEBO_COMPARATOR|Placebo|Placebo (microcrystalline cellulose) was suspended in the methadone during weeks 3-14.
62401033|NCT02472600|ACTIVE_COMPARATOR|colistin + neomycin followed by FMT|"CAPSULE APPROACH:~Treatment days 1-5~* Colistin sulphate 2 million IU per os 4x/day (for 5 days)~* Neomycin sulphate 500 mg (salt) per os 4x/day (for 5 days) Treatment day 6: no treatment~Treatment days 7 and 8:~-15 capsules of capsulized Fecal microbiota transplantation (FMT) per os per day~NASOGASTRIC TUBE APPROACH:~Treatment days 1-5~* Colistin sulphate 2 million IU per os 4x/day (for 5 days)~* Neomycin sulphate 500 mg (salt) per os 4x/day (for 5 days)~Treatment day 6 and 7:~- Omeprazole 20 mg per os 1 dose on the evening of day 6 and on the morning of day 7~Treatment day 7:~- Infusion of 80 ml of a standardized stool suspension through a nasogastric tube - Fecal microbiota transplantation (FMT)"
62577543|NCT00611572|PLACEBO_COMPARATOR|2|placebo iomazenil and ketamine
62577544|NCT00786981|OTHER|Epidural steroid injection and physical therapy|
62577545|NCT00786981|OTHER|Epidural steroid injection|
62577546|NCT00902395|ACTIVE_COMPARATOR|Midazolam|Oral midazolam
62577547|NCT00902395|EXPERIMENTAL|Midazolam/ketamine|Combined midazolam and ketamine
62577548|NCT00902395|OTHER|Protective stabilization|No drug or placebo administered
62199739|NCT00218608|ACTIVE_COMPARATOR|Disulfiram at 62.5 mg|Disulfiram at 62.5 mg was suspended in the methadone during weeks 3-14.
62199740|NCT00218608|ACTIVE_COMPARATOR|Disulfiram at 125 mg|Disulfiram at 125 mg/day was suspended in methadone during weeks 3-14.
62199741|NCT00218608|ACTIVE_COMPARATOR|Disulfiram at 250 mg|Disulfiram at 250 mg/day was suspended in methadone during weeks 3-14.
62199742|NCT01793844||A (R-CHOP21)|"CHOP combined with Rituximab regimen（R-CHOP21）~Treatment Arm A(R-CHOP21): Rituximab 375mg/m2 for injection on day1; cyclophosphamide(C), 750mg/m2 for injection on day2; doxorubicin(H), 50mg/m2 for injection on day2; and Vincristine(O), 1.4mg/m2 for injection on day2, prednisone(P) 60mg/m2 orally on days 2 to 6. The therapy was repeated every 21 days for a total of 6 cycles."
62199743|NCT01793844||B (CHOP14)|Biweekly CHOP regimen （CHOP14） Treatment Arm B (CHOP14): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50mg/m2 for injection on day1; and Vincristine(O), 1.4 mg/m2 for injection on day1, prednisone(P) 60mg/m2 orally on days 1 to 5. The therapy was repeated every 14 days for a total of 6 cycles.PS: G-CSF 1.0-2ug/kg/ d for subcutaneous injections will be administered on day 6 for a total use of 6-8 days.
62401034|NCT02472600|NO_INTERVENTION|No intervention|Control arm without any intervention
62401035|NCT06509438|EXPERIMENTAL|Embella (Deoxycholic acid, produced by Espad Pharmed Co.)|The intervention included a minimum of one and a maximum of three treatment sessions, of 2 milliliters of Embella (Deoxycholic acid, produced by Espad Pharmed Co.) injectable solution containing 20 milligrams of deoxycholic acid per session, spaced at least 4 weeks apart.
62577549|NCT00799175|ACTIVE_COMPARATOR|1 Group A(Active)|Group A (Active) receives a multimodal injection intra- and postoperatively
62577550|NCT00799175|PLACEBO_COMPARATOR|2 Group P (Placebo)|Group P (Placebo) receives no injection intraoperatively and a saline injection postoperatively
62577551|NCT06558383|ACTIVE_COMPARATOR|control group -|"Control group (A):~Twenty patients will receive selected physical therapy program for 18 sessions, three sessions per week for six weeks in form hot packs, soft tissue techniques, mobilization and manipulation of lumbar spine, and neurodynamics."
62577552|NCT06558383|ACTIVE_COMPARATOR|study group|"Study group (B):~Twenty patients will receive augmented activation of posterior oblique sling in addition to selected physical therapy program, 18 sessions, three sessions per week for six week"
62577553|NCT02171312||Concussion Cohort|Participants with possible concussion related dizziness will complete iDETECT battery testing and routine balance and vestibular testing.
62577554|NCT02171312||Healthy Controls|Participants without possible concussion related dizziness will complete iDETECT battery testing and routine balance and vestibular testing.
62012236|NCT06205290|ACTIVE_COMPARATOR|Arm B: Investigator's Choice|
62012237|NCT02063165|EXPERIMENTAL|Linoleic Acid|
62199744|NCT01793844||C （R-CHOP14)|Biweekly CHOP combined with Rituximab regimen（R-CHOP14） Treatment Arm C (R-CHOP14): Rituximab 375mg/m2 for injection on day1; cyclophosphamide(C), 750mg/m2 for injection on day2; doxorubicin(H), 50mg/m2 for injection on day2; and Vincristine(O), 1.4mg/m2 for injection on day2, prednisone(P),60mg/m2 orally on days 2 to 6. The therapy was repeated every 14 days for a total of 6 cycles.PS: G-CSF 1.0-2ug/kg/ d for subcutaneous injections will be administered on day 7 for a total use of 6-8 days patients with bulky disease or extranodal lesion wil be received radiotherapy after finishing the chemotherapy.
62199745|NCT04654572|EXPERIMENTAL|burned group|burned patients
62199746|NCT04654572|EXPERIMENTAL|control group|sedentary people
62199747|NCT03192462|EXPERIMENTAL|Group A (Closed to New Patient Enrollment)|"Patients with locally advanced or metastatic pancreatic adenocarcinoma who are responding following 3 cycles of first line chemotherapy will receive 6 infusions with a fixed dose of multiTAA specific T cells beginning on the 4th week of the 4th cycle of chemotherapy. MultiTAA T cell infusions will occur on day 21 (a chemotherapy off week) of each chemotherapy cycle starting on chemotherapy cycle 4."
62199748|NCT03192462|EXPERIMENTAL|Group B (Closed to New Patient Enrollment)|Patients with locally advanced or metastatic pancreatic adenocarcinoma who have failed first line chemotherapy or are intolerant or ineligible to receive standard of care chemotherapy will be evaluated in the clinic and receive 6 infusions (administered at monthly intervals) with a fixed dose of multiTAA specific T cells.
62215041|NCT06533826|EXPERIMENTAL|Arm F (ADC2 Dato-DXd HR-)|"Participants will complete:~* Baseline visit with imaging, tumor biopsy, electrocardiogram, eye exam.~* Imaging every 9 weeks.~* Cycle 1 through Cycle 3:~  --Day 1 of 21 day cycle: Predetermined dose of Datopotamab deruxtecan 1x daily.~* Cycle 1 through end of treatment:~  * Day 1 of 21 day cycle: Predetermined dose of Datopotamab deruxtecan 1x daily.~ * Imaging on Day 1.~* End of Treatment visit with imaging, tumor biopsy, eye exam.~* Follow up: imaging every 9 weeks.~* Long-term Follow Up: visits every 6 months."
62577555|NCT01962766|ACTIVE_COMPARATOR|complete myofunctionnal therapy|complete therapy (at least 5 sessions) to correct their swallowing pattern and tongue position
62577556|NCT01962766|EXPERIMENTAL|instructions|instructions to modify their tongue position (1 session)
62577557|NCT05445635|EXPERIMENTAL|Iriscope|
62577558|NCT05445635|ACTIVE_COMPARATOR|EBUS|
62577559|NCT05445635|EXPERIMENTAL|Combined Iriscope + EBUS|
62577560|NCT00402688|ACTIVE_COMPARATOR|001|levofloxacin 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
62577561|NCT00402688|ACTIVE_COMPARATOR|002|levofloxacin 750mg tablet once daily for 3 weeks followed by 1 week of placebo.
62577562|NCT00402688|ACTIVE_COMPARATOR|003|levofloxacin 500mg tablet once daily for 4 weeks.
62577563|NCT04998617|EXPERIMENTAL|Toothpaste Containing Curcumin|After screening, participants will be randomly assigned to receive toothpaste that contains 0.5% curcumin.
62577564|NCT04998617|PLACEBO_COMPARATOR|Toothpaste Without Curcumin|After screening, participants will be randomly assigned to receive toothpaste that does not contain curcumin.
62577565|NCT01600027|PLACEBO_COMPARATOR|Group B|received 1 ml/kg bupivacaine 0.25%.
62577566|NCT01600027|ACTIVE_COMPARATOR|group BD|received 1 ml/kg bupivacaine 0.25% with dexmedetomidine 2 μg/kg
62577567|NCT04681820||flumatinib|flumatinib 600mg QD, fasting administration
62012238|NCT03606161|EXPERIMENTAL|Supportive care (nrTMS)|Between 1-7 days after standard of care surgery, participants undergo 10 nrTMS sessions over 30 minutes each over 3 weeks.
62012239|NCT03645200|EXPERIMENTAL|Fluzoparib combined with Apatinib|"Fluzoparib in the initial dose of 40mg.bid started into the group of participants, group A combined with a fixed dose of Apatinib 250mg.qd for treatment, followed by the 40mg.bid, 60mg.bid, 80mg.bid, 100mg.bid dose increase.~Fluzoparib in the initial dose of 40mg.bid started into the group of participants, Group B was treated with a fixed dose of Apatinib 500mg.qd, followed by an increase in doses of 40mg.bid, 60mg.bid, 80mg.bid, 100mg.bid ."
62199749|NCT03192462|EXPERIMENTAL|Group C (Closed to New Patient Enrollment)|Patients with resectable pancreatic adenocarcinoma following completion of neoadjuvant chemotherapy, radiotherapy or combination. These patients will receive 6 infusions with a fixed dose of multiTAA specific T cells. One infusion will occur 4 weeks prior to surgical resection (with an option to infuse up to one week earlier) and after the completion of all pre-operative chemotherapy and/or radiation. The subsequent 5 infusions will occur at monthly intervals beginning 8 weeks post-surgery. Following surgery all patients will additionally receive 3 months of standard of care (SOC) chemotherapy starting week 9 after surgery. Hence, SOC chemo will occur weeks 9-11, 13-15, and 17-19 post-surgery and multiTAA T cell infusions will occur at weeks 8, 12, 16, 20, and 24 post-surgery.
62199750|NCT04915092|EXPERIMENTAL|Intervention group|The app is explained and installed during the recruitment to the family in the intervention group. Some families in this group will be selected to take part to the qualitative research.
62012240|NCT05802797|EXPERIMENTAL|Algae Oil Fortified Soymilk|Subjects will drink 12 ounces of 0.4% algae oil-fortified soymilk
62012241|NCT05802797|ACTIVE_COMPARATOR|Algae Oil Supplements|Subjects will take 2 commercial algae oil capsules.
62199751|NCT04915092|NO_INTERVENTION|Control group|Every months during the first year of study a newsletter is sent only to the members of the control group.
62012242|NCT02030691|EXPERIMENTAL|nCPAP - nHFPV|Eligible patient received after randomization nCPAP or nHFPV for 15 minutes then after the 15 minutes, they received the seconde non invasive device for 15 minutes. Study end 30 minutes after randomization or before if mechanical ventilation is required.
62012243|NCT02030691|EXPERIMENTAL|nHFPV - nCPAP|Eligible patient received after randomization nCPAP or nHFPV for 15 minutes then after the 15 minutes, they received the seconde non invasive device for 15 minutes. Study end 30 minutes after randomization or before if mechanical ventilation is required.
62199752|NCT05775172||Waitlist control|Waitlist control (C group n=30) did not achieve any significant weight loss and did not follow lifestyle intervention
62199753|NCT05775172||Lifestyle intervention|Lifestyle intervention (LS group, n=22) follows multimodal lifestyle intervention in form of 500-100 kcal deficit , gradual physical activity and some behavioral modifications
62199754|NCT05775172||Bariatric surgery|Bariatric surgery (BS group n=27) undergoes laparoscopic sleeve gastrectomy
62577568|NCT04681820||nilotinib|nilotinib 400mg BID, fasting administration
62577569|NCT02432612|EXPERIMENTAL|Sativex|Sativex will be administered by trained, clinical trial personnel, via a pump action oromucosal spray. Sativex will be administered as 2 actuations (sprays) under the tongue or inside the cheeks every 4 minutes until 6 sprays have been administered. Following the administration of the first and second set of 2 actuations, patients will be offered 50 mL water to drink; and following the final set of 2 actuations, 100 mL of water will be offered (i.e., a total of 200 mL water will be offered during the Sativex dosing). There must be a period of at least 2 minutes and no more than 3 minutes between Sativex administration and consumption of water. Patients will not be permitted their regular medication until 2 hours post dose of investigational medicinal product (IMP) to minimize any possible drug interactions.
62577570|NCT03318978|EXPERIMENTAL|25 ng dose|Capsule containing 25 ng (2.7 nCi) \[14C\]-benzo\[a\]pyrene (BaP)
62577571|NCT03318978|EXPERIMENTAL|50 ng dose|Capsule containing 50 ng (2.7 nCi) \[14C\]-benzo\[a\]pyrene (BaP)
62577572|NCT03318978|EXPERIMENTAL|100 ng dose|Capsule containing 100 ng (2.7 nCi) \[14C\]-benzo\[a\]pyrene (BaP)
62577573|NCT03318978|EXPERIMENTAL|250 ng dose|Capsule containing 100 ng (2.7 nCi) \[14C\]-benzo\[a\]pyrene (BaP)
62012244|NCT06289413||Development of AD/OI after BS.|
62012245|NCT06364566|EXPERIMENTAL|Short interval group|The patient underwent minimally invasive esophagectomy within 50 days after receiving neoadjuvant therapy
62577574|NCT02568293|EXPERIMENTAL|SBCV|SBCV is administered to the site immediately post balloon dilation.
62577575|NCT02568293|PLACEBO_COMPARATOR|Control|Saline is used as a control and is delivered immediately post balloon dilation.
62012246|NCT06364566|EXPERIMENTAL|Long interval group|The patient underwent minimally invasive esophagectomy 50 days after receiving neoadjuvant therapy
62012247|NCT06018740|EXPERIMENTAL|Daily Balance Gummy|One Daily Balance Gummy should be taken with the last meal of the day.
62012248|NCT03837691|EXPERIMENTAL|g-Cath EZ|Placement of Snowshoe suture anchors from g-Cath EZ Delivery Catheters, in a defined pattern in the mid and distal portions of the stomach, along with a moderate intensity diet \& exercise program, to treat primary obesity.
62199755|NCT05656014||Patients with knee osteoarthritis|Adult patients 50 years of age or older diagnosed with knee osteoarthritis according to American College of Rheumatology criteria
62199756|NCT02627118|EXPERIMENTAL|Dialyzer Comparison|2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR followed by 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H
62199757|NCT04692077|EXPERIMENTAL|CAB LA|In Step 1, participants will receive one CAB tablet orally every day for 5 weeks. In Step 2, participants will receive an intramuscular (IM) injection of CAB LA at Weeks 5, 9, 17, 25, and 33. In Step 3, participants will receive a TDF/FTC tablet orally every day for 48 weeks or may be offered the opportunity to join an open label CAB study instead, if such a study is being implemented in their area at the time.
62199758|NCT00508989|EXPERIMENTAL|1|
62199759|NCT00508989|PLACEBO_COMPARATOR|2|
62199760|NCT05727215|EXPERIMENTAL|Primary dose of inactivated (Sinovac®) vaccine|Subject who had received a complete primary dose of inactivated (Sinovac®) vaccine
62199761|NCT02859077|EXPERIMENTAL|EGFR-TKI and Chemotherapy|NSCLC patients
62199762|NCT01112436|PLACEBO_COMPARATOR|control group (group C)|control group will receive no medication preoperatively and during operation
62199763|NCT01112436|ACTIVE_COMPARATOR|periarticular injecion group (group I)|patients in Group I will receive oral oxycodone SR 10 mg and celecoxib 200 mg 1 hour preoperatively with sips of water, and receive periarticular injection of combination of ropivacaine 15 mg, morphine 10 mg, ketorolac 30 mg epinephrine 0.3 mg and cefmetazole 1000mg during operation.
62199764|NCT05486312|EXPERIMENTAL|Single arm|Single arm acceptability and feasibility of CT-155.
62199765|NCT04206423||Healthy Controls|Age and sex matched healthy controls
62199766|NCT04206423||Lateral epicondylitis|"Newly diagnosed lateral epicondylitis patients.~1. Pain in lateral epicondylitis region~2. Pain increase with palpation~3. Positivity in two diagnostic test out of three (Maudley's test, Mill's test or Cozen's test)"
62199767|NCT06156553|EXPERIMENTAL|Students in 9. grade participating in a school-based intervention|Students from 9. grade at 4 schools in a Norwegian municipality. The students will take part in a school and curriculum based intervention delivered by a combination of educators from a science center (1 session) and teachers (5 sessions)
62199768|NCT04706689||Unresponsive wakefulness syndrome patients (UWS)|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
62199769|NCT04706689||Minimally conscious patients MINUS (MCS-)|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
62199770|NCT04706689||Minimally conscious patients PLUS|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
62199771|NCT04706689||Patients emerging from the minimally conscious state (EMCS)|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
62401036|NCT04648943|ACTIVE_COMPARATOR|Patients undergoing Ex-Press mini shunt insertion|Patients in this arm had the Ex-Press mini shunt inserted in the operated eye in order to reduce the Intraocular Pressure. The corneal biomechanical properties were measured before and at 1, 6 and 12 months after surgery with the Ocular Response Analyzer
62401037|NCT04648943|ACTIVE_COMPARATOR|Patients undergoing trabeculectomy|Patients in this arm had standard trabeculectomy in the operated eye in order to reduce the Intraocular Pressure. The corneal biomechanical properties were measured before and at 1, 6 and 12 months after surgery with the Ocular Response Analyzer
62401038|NCT03783026|EXPERIMENTAL|Apremilast|Participants will receive apremilast 30 mg twice a day for 48 weeks.
62199772|NCT06319742||Stroke|
62199773|NCT06319742||TIA|
62199774|NCT06319742||Stroke Mimic|
62199775|NCT05740813|EXPERIMENTAL|ABBV-CLS-7262 Dose 1|
62199776|NCT05740813|EXPERIMENTAL|ABBV-CLS-7262 Dose 2|
62199777|NCT05740813|PLACEBO_COMPARATOR|Matching Placebo|
62199778|NCT04196192||Group 1|All infants aged 0-90 days (inclusive) undergoing routine assessments for fever without source.
62199779|NCT03895047|ACTIVE_COMPARATOR|dACC,I,AC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) \& the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week."
62199780|NCT03895047|ACTIVE_COMPARATOR|dACC,AC,I|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) \& the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week.12 sessions of Neurofeedback Training, 1-2 times per week."
62199781|NCT03895047|ACTIVE_COMPARATOR|I,dACC,AC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) \& the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week."
62199782|NCT03895047|ACTIVE_COMPARATOR|I,AC,dACC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) \& the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week."
62199783|NCT03895047|ACTIVE_COMPARATOR|AC,dACC,I|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) \& the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week."
62199784|NCT03895047|ACTIVE_COMPARATOR|AC,I,dACC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) \& the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week."
62577576|NCT02085629|EXPERIMENTAL|M reg treatment|"Donor M reg (2.5-7.5 million cells/kg) IV infused (6-7d before Tx) into recipients of a LD renal Tx. Recipients also receive prednisolone, mycophenolate mofetil and tacrolimus, as detailed below:~Prednisolone~* D 0: 500 mg IV~* D 1: 125 mg IV~* D 2 - 14: 20.0 mg/d (oral)~* Wk 3 - 4: 15.0 mg/d~* Wk 5 - 8: 10.0 mg/d~* Wk 9 - 12: 5.0 mg/d~* Wk 13 - 14: 2.5 mg/d~* Wk 15 - End: Cessation~MMF (or biologic equiv.)~* D -7 to -2: 500 mg/d (250mg 2x/d)~* D -1 to 14: 2000 mg/d~* Wk 3 - 36: 1000 mg/d~* Wk 37 - 40: 750 mg/d~* Wk 41 - 44: 500 mg/d~* Wk 45 - 48: 250 mg/d~* Wk 49 - End: Cessation NOTE: MMF tapering will only happen if a 36-Wk biopsy shows no signs of subclinical rejection or if there is no evidence of declining renal function or if the clinician has any other concern about dose reduction.~Tacrolimus (or biologic equiv.)~* ≤ 48 h pre-Tx to D 14: 3-12 ng/ml~* Wk 3 - 12: 3-10 ng/ml~* Wk 13 - 36: 3-8 ng/ml~* Wk 37 - End: 3-6 ng/ml"
62577577|NCT06578845||Pregnant people currently experiencing, or at risk of, antenatal depression|All eligible participants will be given access to the 'HappyMums' mobile application, which will be used to collect data pertinent to their mental health status during pregnancy.
62577578|NCT03570411||HCT Recipient|"All participants who meet eligibility criteria and consent to enrollment on study.~Blood specimens will be collected for the T-SPOT.CMV blood test from HCT recipients over the course of 6 months, starting weekly at Day +1, biweekly starting at Day +45, and monthly starting at day +120.~The amount of blood collected at each visit will be based on age."
62577579|NCT03570411||HCT Donor|"Approved allogeneic HCT donor for a HCT recipient enrolled on the SPOTCMV protocol~A blood sample for the T-SPOT.CMV blood test will be collected from the HCT donor prior to transplant"
62577580|NCT02367027|EXPERIMENTAL|Arm 1 - BAY59-7939|10 mg oral suspension (dry powder) in fasted conditions
62577581|NCT02367027|EXPERIMENTAL|Arn 2 - BAY59-7939|20 mg oral suspension (dry powder) in fed conditions.
62577582|NCT02367027|EXPERIMENTAL|Arm 3 - BAY59-7939|10 mg oral suspension in fasted conditions
62012249|NCT03837691|NO_INTERVENTION|Diet and Exercise|A moderate intensity diet \& exercise program to treat primary obesity
62199785|NCT03642847|ACTIVE_COMPARATOR|Prevnar 13|13 valent Pneumococcal Conjugate
62199786|NCT03642847|EXPERIMENTAL|multivalent pneumococcal conjugate formulation 1|multivalent pneumococcal conjugate formulation 1
62199787|NCT03642847|EXPERIMENTAL|multivalent pneumococcal conjugate formulation 2|multivalent pneumococcal conjugate formulation 2
62401039|NCT04853316||Case: Exposed (SARS-CoV-2 positive)|Participants found positive by SARS-CoV-2 testing.
62577583|NCT02367027|EXPERIMENTAL|Arm 4 - BAY59-7939|10 mg tablet in fasted conditions.
62577584|NCT02055989|EXPERIMENTAL|Dose-escalated radiotherapy level 1|
62577585|NCT02055989|EXPERIMENTAL|Sequential dose-escalated radiotherapy level 2|
62012250|NCT06428097|EXPERIMENTAL|Levothyroxine|Patients will be double-blinded and randomized to receive levothyroxine.
62012251|NCT06428097|PLACEBO_COMPARATOR|No Levothyroxine|Patients will be double-blinded and randomized to receive no levothyroxine. The placebo will be normal saline.
62577586|NCT00665262|EXPERIMENTAL|1|comibined use of tramacet and naloxone infusion perioperatively
62199788|NCT02956837|EXPERIMENTAL|GSK3003891A vaccine formulation 1 Group|Subjects in this group received a single 30 micrograms (µg) dose injection of the investigational GSK3003891A vaccine at Day 0.
62199789|NCT02956837|EXPERIMENTAL|GSK3003891A vaccine formulation 2 Group|Subjects in this group received a single 60µg dose injection of the investigational GSK3003891A vaccine at Day 0.
62199790|NCT02956837|EXPERIMENTAL|GSK3003891A vaccine formulation 3 Group|Subjects in this group received a single 120µg dose injection of the investigational GSK3003891A vaccine at Day 0.
62199791|NCT02956837|PLACEBO_COMPARATOR|Control Group|Subjects in this group received a single placebo injection at Day 0.
62199792|NCT01492751||Spanish Multicentric Clinically Localized Prostate Cancer|A consecutive sample of clinically localized prostate cancer patients treated with radical prostatectomy, external beam radiotherapy and prostate brachytherapy in 10 Spanish hospitals.
62199793|NCT06179121||Phase 1 Cohort (Validation of HLA- DQ2/8 typing)|Children (1-18 years old) coming for consultation at the LUMC for (suspicion of) CD
62577587|NCT01762436|EXPERIMENTAL|bisoprolol|initially received 5 mg of bisoprolol (Concor®, Merck Serono, Darmstadt, Germany) once daily. The heart rate was assessed every two weeks. If the RHR was ≤65 bpm, a 2-week maintenance treatment was added during the final visit. If the target RHR was not achieved, the dose was changed as recommended in the study protocol. The maximal dose was 10 mg Qd for bisoprolol. The longest treatment period was 8 weeks. If the patient's RHR did not reach below 65 bpm at week 6, the treatment was ended at week 8.
62577588|NCT01762436|ACTIVE_COMPARATOR|atenolol|initially received 50 mg atenolol (Beijing Double-Crane Pharmaceutical Co., Ltd, Beijing, China) once daily. The heart rate was assessed every two weeks. If the RHR was ≤65 bpm, a 2-week maintenance treatment was added during the final visit. If the target RHR was not achieved, the dose was changed as recommended in the study protocol. The maximal dose was 100 mg Qd for atenolol. The longest treatment period was 8 weeks. If the patient's RHR did not reach below 65 bpm at week 6, the treatment was ended at week 8.
62577589|NCT00627757||Food challenge test|"Patients~51 patients included"
62577590|NCT00627757||C|Controls 93 healthy controls are included
62577591|NCT05986838|ACTIVE_COMPARATOR|laser puncture group|gallium Arsenide infrared (GaAlAs) laser, using a wavelength at 904nm with a Maximum power output is 150 mW and a power density at 0.417 W/cm2 as well as an energy density of 4 J/cm2 will be employed for 2 minutes on specific acupuncture points
62577592|NCT05986838|ACTIVE_COMPARATOR|Ultraviolet treatment group|The therapist will place the UV arc lamp at a height of 60 to 80 cm above the lower abdomen region, perpendicular to the skin. Each woman's lamp will be switched on and given an individual timer by the minimum effective dose
62577593|NCT05986838|ACTIVE_COMPARATOR|Metformin only group|
62577594|NCT04468347|EXPERIMENTAL|Alzheimer's disease (AD)|Alzheimer's disease subjects receiving a flortaucipir PET scan at baseline and 12 months
62577595|NCT04468347|EXPERIMENTAL|Mild cognitive impairment (MCI)|Mild cognitive impairment subjects receiving a flortaucipir PET scan at baseline and 12 months
62577596|NCT04468347|EXPERIMENTAL|Subjective memory complainers (SMC)|Subjective memory complainers receiving a flortaucipir PET scan at baseline and 12 months
62199794|NCT06179121||Phase 2 Cohort (Implementation of HLA-DQ2/8 typing on the Preventive YHCCs)|Children (12 months to 4 years old), at least with one of the 10 CD-related symptoms, not diagnosed with CD, and not on a GFD,
62199795|NCT05413239|EXPERIMENTAL|Intervention Group|The Intervention Group will receive the monthly intervention sessions during the first year of the study.
62577597|NCT04468347|EXPERIMENTAL|Cognitively normal (CN)|Cognitively normal subjects receiving a flortaucipir PET scan at baseline and 12 months
62199796|NCT05413239|NO_INTERVENTION|Control Group|The Control Group will receive the monthly intervention sessions during the second year of the study (after assessment of primary outcomes at 1 year).
62577598|NCT04046510|ACTIVE_COMPARATOR|High doses|the patients of this group recieved conventionnal doses of ocytocin after foetal extraction in C section: 5IU in bolus followed by 15IU in continuous infusion
62199797|NCT05369429|EXPERIMENTAL|Intervention|The intervention includes cognitive behavioral therapy management strategies for health-related stress in the form of animated videos, interactive activities, and written content. The intervention will be delivered via an online application over an 7-week period. Intervention participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.
62199798|NCT05369429|NO_INTERVENTION|Control|The control application will provide links to helpful resources for patients with cancer, such as the contact information for cancer support services at Northwestern University and the University of Miami, and the link to the National Cancer Institute website, and the American Cancer Society website. Control participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.
62199799|NCT06437951|EXPERIMENTAL|Part1_test group|IV injection of test drugs by dose group
62199800|NCT06437951|PLACEBO_COMPARATOR|Part1_placebo group|IV injection of test drugs by dose group
62199801|NCT06437951|EXPERIMENTAL|Part2|All Participants take IV injection of test drugs
62199802|NCT06437951|EXPERIMENTAL|Part3_test group|In the case of test group, take IV injection in the period 1 and take a tablet in the period 2
62199803|NCT06437951|ACTIVE_COMPARATOR|Part3_reference group|In the case of reference group, take a tablet in the period 1 and take IV injection in the period 2
62199804|NCT04518280|EXPERIMENTAL|Group A|The patients will receive short-course radiotherapy (25Gy/5Fx), followed by 6 cycles of CAPOX and PD-1 antibody. TME surgery is scheduled after TNT while a W\&W option can be applied to patients achieving cCR.
62577599|NCT04046510|EXPERIMENTAL|Intermediate doses|the patients of this group recieved after foetal extraction in C section: 2IU in bolus followed by 10IU in continuous infusion
62577600|NCT04046510|EXPERIMENTAL|Low doses|the patients of this group recieved after foetal extraction in C section: 2IU in bolus followed by 5 IU in continuous infusion
62577601|NCT03442686|EXPERIMENTAL|Spring 2018 Compass Course Group|Two groups of up to 15 participants (30 total) will receive the study intervention during Spring 2018. All participants will complete study questionnaires before and after the Spring sessions.
62577602|NCT03442686|NO_INTERVENTION|Spring 2018 Comparison Group|Two groups of up to 15 participants will receive the study intervention in Fall 2018. All participants will complete study questionnaires before and after the Spring sessions. Those who enroll in the study and agree to participate in the Fall sessions will serve as a no-treatment comparison group.
62577603|NCT02764814|ACTIVE_COMPARATOR|Treatment|subjects receiving cryopreserved amniotic membrane
62577604|NCT02764814|NO_INTERVENTION|Control|no intervention
62401040|NCT04853316||Control: Unexposed (SARS-CoV-2 negative)|Participants found negative by SARS-CoV-2 testing.
62577605|NCT00263939|EXPERIMENTAL|1 - In home intervention|In home (face to face) delivery of the study intervention, Homing in on Health
62577606|NCT00263939|EXPERIMENTAL|2 - Telephone intervention|Telephone delivery of the study intervention, Homing in on Health
62577607|NCT00263939|NO_INTERVENTION|3 - Usual care|Patients receiving the care their usual health providers supply, without an study intervention
62577608|NCT05669313||Adult patients planned for treatment with rivaroxaban|
62577609|NCT05624021|EXPERIMENTAL|SFT group|Received Scapular functional training and cervical isometric exercises
62577610|NCT05624021|ACTIVE_COMPARATOR|Conventional group|Received only isometric cervical exercises and heating
62577611|NCT00356135|EXPERIMENTAL|Prasugrel 10/10 mg|Open label (lead-in) dose of clopidogrel 75 milligram (mg) for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 10 mg and placebo, followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.
62577612|NCT00356135|EXPERIMENTAL|Clopidogrel 75/75 mg|Open label (lead-in) dose of clopidogrel 75 mg for 10 to 14 days. Upon completion, assignment to a single loading dose of clopidogrel 75 mg and placebo, followed by maintenance dose of clopidogrel 75 mg taken for 13 to 15 days.
62577613|NCT00356135|EXPERIMENTAL|Prasugrel 60/10 mg|Open label (lead-in) dose of clopidogrel 75 mg for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 60 mg and placebo followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.
62577614|NCT03924726|OTHER|Control and experimental (4 weeks MOP)|This is a split mouth study. At the experimental site in group 1, three Micro-osteoperforation (MOP) were made directly at the buccal cortical bone of extracted first premolars sites, at equidistance from the canine and second premolar under local anaesthesia. This group received four sessions of MOPs at an interval of 4 weeks.
62577615|NCT03924726|OTHER|Control and experimental ( 8 weeks MOP)|This is a split mouth study. This group received 2 sessions of Micro-osteoperforation (MOP) at an interval of 8 weeks.
62577616|NCT03924726|OTHER|Control and experimental (12 weeks MOP)|This is a split mouth study. This group received 2 sessions of Micro-osteoperforation (MOP) at an interval of 12 weeks.
62012252|NCT06532123|ACTIVE_COMPARATOR|fatigability of various striated continence muscles healthy adults|"Device: anorectal manometry/vaginal manometry (female) with and without applying c-RED Participants will do repetitive anal contraction and sustained contraction without device and with device in a random order. For contraction with the device, three different resistance level will be applied as described previously.~For isometric contraction, the annal balloon of the device will be inflated to internal pressure of 500mmHg, which is noncompressible. Participants will repeat the repetitive contraction and sustained contraction."
62401041|NCT01842412||claudication|
62577617|NCT03244930|EXPERIMENTAL|Arm 1|Plerixafor 0.12 mg/kg SC will be administered in the evening, 11 hours prior to initiation of apheresis. G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
62577618|NCT04854512|EXPERIMENTAL|Investigational Arm (Metformin DR plus metformin IR placebo)|Group A will receive 1800 mg Metformin DR qAM + placebo for 1500 mg metformin IR in divided doses (2×placebo for metformin IR 500 mg qAM and 1×placebo for metformin IR 500 mg qPM).
62577619|NCT04854512|PLACEBO_COMPARATOR|Placebo Arm (Metformin DR placebo plus metformin IR placebo)|Group B will receive placebo for 1800 mg Metformin DR qAM + placebo for 1500 mg metformin IR in divided doses (2× placebo for metformin IR 500 mg qAM and 1×placebo for metformin IR 500 mg qPM).
62577620|NCT04854512|ACTIVE_COMPARATOR|Active Control Arm (Metformin DR placebo plus metformin IR)|Group C will receive placebo for 1800 mg Metformin DR qAM + 1500 mg metformin IR in divided doses (2× metformin IR 500 mg qAM and 1× metformin IR 500 mg qPM).
62577621|NCT03451383||Breast Cancer Case|Women age 60+ with a newly diagnosed breast adenocarcinoma staged 0-3.
62577622|NCT03451383||Non-Cancer Controls|Women age 60+ with no diagnosis of breast cancer.
62577623|NCT01138813||1|Male and female patients aged 18-70 years old with newly diagnosed operable glioma of grade II or higher
62577624|NCT05563779|ACTIVE_COMPARATOR|Volume Control mode|During invasive mechanical ventilation in a study location, Volume Control will be used as the mode for continuous mandatory ventilation.
62577625|NCT05563779|ACTIVE_COMPARATOR|Pressure Control mode|During invasive mechanical ventilation in a study location, Pressure Control will be used as the mode for continuous mandatory ventilation.
62401042|NCT01842412||healthy|
62401043|NCT04290871|EXPERIMENTAL|Treatment Group|Nitric Oxide gas will be administered in the ventilatory circuit.
62401044|NCT04290871|SHAM_COMPARATOR|Control Group|The delivery system will be set up anyway without study gas administration
62401045|NCT00802152|EXPERIMENTAL|Home Monitoring|100 eligible subjects identified as (HbA1c \>= 8% OR SBP \> 130 mm Hg)
62401046|NCT00802152|NO_INTERVENTION|Usual Care|100 eligible subjects identified as (HbA1c \>= 8% OR SBP \> 130 mm Hg)
62401047|NCT03344029|EXPERIMENTAL|SP Shz TIV|Participants aged 18 to 59 years will receive a single injection of SP Shz TIV.
62577626|NCT05563779|ACTIVE_COMPARATOR|Adaptive Pressure Control mode|During invasive mechanical ventilation in a study location, Adaptive Pressure Control will be used as the mode for continuous mandatory ventilation.
62577627|NCT05662254|EXPERIMENTAL|Personalized Behavioral Intervention|Behavioral lifestyle intervention assigned according to each participant's mood and lifestyle data patterns.
62577628|NCT00331669|PLACEBO_COMPARATOR|1|device
62577629|NCT04160039|EXPERIMENTAL|Cycle Ergometry + Standard PT/OT|The study intervention will include the same standard PT/OT procedures as the control arm (Standard PT/OT alone) with the addition of the Motomed Letto 2 lower extremity cycle ergometry sessions.
62199805|NCT04518280|EXPERIMENTAL|Group B|The patients will firstly receive 2 cycles of CAPOX and PD-1 antibody, then receive short-course radiotherapy (25Gy/5Fx), followed by 4 cycles of CAPOX and PD-1 antibody. TME surgery is scheduled after TNT while a W\&W option can be applied to patients achieving cCR.
62199806|NCT06033898|EXPERIMENTAL|12-hr trial|Participants will go through a 48-hr physical activity control phase with 10,000 steps taken every 24 hours (9 pm to 9 pm the next day). This phase will be followed with a 12-hour physical inactive phase (9 pm to 9 am the next morning). Less than 1,000 steps during this 12 hours (mostly night time) will be required. The 1-hr cycling session will take place from 8 pm to 9 pm the same day when inactive phase starts. A high fat tolerance test that lasts 5 hours will take place at 9 am the last day.
62199807|NCT06033898|EXPERIMENTAL|24-hr trial|Participants will go through a 48-hr physical activity control phase with 10,000 steps taken every 24 hours (9 am to 9 am the next morning). This phase will be followed with a 24-hour physical inactive phase (9 am to 9 am the next morning). During this 24 hours, from 9 am to 9 pm (mostly daytime), less than 1,500 steps is required, and from 9 pm to 9 am the next morning (mostly night), less than 1,000 steps is required. The 1-hr cycling session will take place from 8 pm to 9 pm on the day when inactive phase starts. A high fat tolerance test that lasts 5 hours will take place at 9 am the last day.
62199808|NCT06033898|EXPERIMENTAL|36-hr trial|Participants will go through a 48-hr physical activity control phase with 10,000 steps taken every 24 hours (9 pm to 9 pm the next day). This phase will be followed with a 36-hour physical inactive phase (9 pm - 9 am on the high fat tolerance day). During the inactive phase, it includes two 12 hours that mostly at night (9 pm - 9 am the next day) and one 12 hours (9 am to 9 pm the same day) that mostly in the day. Less than 1,500 steps is required for 9 pm - 9 am periods, and less than 1,000 steps is needed for 9 am - 9 pm (same day) phase. The 1-hr cycling session will take place from 8 pm to 9 pm the second last day in the trial. A high fat tolerance test that lasts 5 hours will take place at 9 am the last day.
62199809|NCT01636245|EXPERIMENTAL|Lot 1|inactivated vaccine (Lot 1) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
62199810|NCT01636245|EXPERIMENTAL|Lot 2|inactivated vaccine (Lot 2) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
62199811|NCT01636245|EXPERIMENTAL|Lot 3|inactivated vaccine (Lot 3) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
62199812|NCT01636245|PLACEBO_COMPARATOR|Placebo|Placebo in 350 infants aged 6 months to 5 years old on day 0,28
62199813|NCT03432442|EXPERIMENTAL|Group 1 (6 dengue patients)|Volunteers weighed \> 30 kg receiving 400 µg of ivermectin per 1 kg of body weight
62199814|NCT03432442|EXPERIMENTAL|Group 2 (6 dengue patients)|Volunteers weighed 15 to 30 kg receiving 400 µg of ivermectin per 1 kg of body weight
62199815|NCT03432442|EXPERIMENTAL|Group 3 (6 dengue patients)|Volunteers weighed \> 30 kg receiving 600 µg of ivermectin per 1 kg of body weight
62401048|NCT03344029|ACTIVE_COMPARATOR|Hualan TIV|Participants aged 18 to 59 years will receive a single injection of Hualan TIV.
62401049|NCT01048710||Tomofix_small|Surgical treatment using TomoFix TM Small
62199816|NCT03432442|EXPERIMENTAL|Group 4 (6 dengue patients)|Volunteers weighed 15 to 30 kg receiving 600 µg of ivermectin per 1 kg of body weight
62199817|NCT01711853|EXPERIMENTAL|Dabigatran Etexilate|patient to receive a capsule containing 75 mg of dabigatran etexilate
62199818|NCT01038219||fever measurements|"1000 estimates and measurements of children's body temperatures will be carried out by parents and nurses in children's emergency and pediatric units as part of the routine work. The estimates and the measurements will be carried out on children who are referred to an emergency unit and who are hospitalized in the pediatric department-- both boys and girls of all ages. A patient might be measured several times.~The measurements will be gathered in the course of one year. Before the routine taking of temperature, the accompanying parent will be asked to estimate the patient's temperature by feeling his forehead (with the back of the hand, the palm, lips). The parent will record his evaluation (without telling the nurse). Afterwards the nurse will do a similar evaluation (excepting the lip test), record it, and then the routine temperature measurement will be taken."
62199819|NCT03745898|ACTIVE_COMPARATOR|Nocturnal Oxygen Therapy|Active nocturnal oxygen therapy
62784563|NCT02215135|EXPERIMENTAL|Corifollitropin in PCOS|In GnRH antagonist protocol, a single dose corifollitropin alfa was administered for ovarian stimulation following rFSH daily injection to stimulate follicle development. GnRH agonist was given to trigger final oocyte maturation when three follicles reached 17 mm in size. The IVF or ICSI was planned then all embryos were elective cryopreserved.
62199820|NCT03745898|SHAM_COMPARATOR|Sham Nocturnal Oxygen Therapy|Sham nocturnal oxygen therapy (room air)
62199821|NCT01109511|ACTIVE_COMPARATOR|oxycodone+naloxone|
62199822|NCT01109511|ACTIVE_COMPARATOR|Control|Oxycodone alone without naloxone
62199823|NCT03586934|OTHER|Traditional (Standard) Protocol|Preoperative Single shot interscalene block (30 mL 0.5 ropivacaine), postoperative morphine patient controlled analgesia (1 mg/10 min/30 mg) with Hydrocodone-Acetaminophen (oral, 5/325 mg, 1 tab q4h pro re nata (PRN) for pain score of 1-3), Hydrocodone-Acetaminophen (oral, 10/325 mg, 1 tab q4h PRN for pain score of 4-6) Morphine injectable solution (2 mg IV q3h PRN for pain score 7-10), and oxycodone hydrochloride (oral, 10 mg q12h x2 doses) through postoperative day one. Discharged from hospital with hydrocodone bitartrate and acetaminophen (Norco) (5/325 mg or 10/325 mg, 1-2 oral tabs q4-6h PRN pain) script.
62577630|NCT04160039|NO_INTERVENTION|Standard PT/OT alone|"The control arm will involve standard PT/OT procedures that patients in the transplant intensive care unit receive routinely, with frequency to be determined by a physical and/or occupational therapist, and may include but are not limited to the following:~Passive and active upper and lower extremity strength exercises, while in bed, sitting upright, and standing; stretching various muscle groups while supine in bed, sitting upright, and standing; in-bed mobility training including rolling and boosting; transfer training with and without an assistive device; gait training with and without an assistive device; balance exercises while sitting and standing; activities of daily living while sitting and standing; cognitive retraining"
62577631|NCT00853645|EXPERIMENTAL|Subcutaneous implantable cardioverter defibrillator (S-ICD) System|Single-arm with 6 patients implanted with an S-ICD System
62784564|NCT00771771|ACTIVE_COMPARATOR|Day unit rehabilitation|Discharge from the hospital to the patients' homes as soon as possible, supported by an out-patient ambulatory coordinating multidisciplinary team. The patients will be offered rehabilitation in a day unit, and multidisciplinary policlinical follow-ups will be performed 3 and 6 months after inclusion.
62012253|NCT06532123|ACTIVE_COMPARATOR|contribution of continence muscles motor function enhancement in improving fecal incontinence|Device: anorectal manometry/vaginal manometry (female) with c-RED Patients will then be assigned to one of the exercise protocols for 6 weeks. Protocol 1: 20 Kegel like repetitive short contractions against a progressively increased intra-vaginal resistance Protocol 2: 40 Kegel like repetitive short contractions against a progressively increased intra-vaginal resistance Protocol 3: 20 Kegel like repetitive short contractions against a progressively increased intra-anal resistance Protocol 4: 40 Kegel like repetitive short contractions against a progressively increased intra-anal resistance Protocol 5: 20 Kegel like repetitive short contractions without device Protocol 6: 40 Kegel like repetitive short contractions without device Protocol 7: 20 Kegel like repetitive short contractions against the non-compressible balloon as previously mentioned Protocol 8:40 Kegel like repetitive short contractions against the non-compressible balloon as previously mentioned
62012254|NCT01291797||Neonates with congenital heart disease|The case group will consist of newborns born between 32 and 41 weeks gestation diagnosed with a congenital cardiac anomaly requiring surgical repair during their hospitalization and managed in the Mount Sinai Neonatal Intensive Care Unit. The control arm will include newborns born between 32 and 41 weeks without congenital cardiac anomalies. Both groups will undergo a neurological screening assessment and receive an AEEG to look at sleep wake cycles.
62012255|NCT02556710|EXPERIMENTAL|AMPION™ 4 mL dose|4 mL injection of Ampion
62012256|NCT02556710|PLACEBO_COMPARATOR|Placebo 4 mL dose|4 mL Injection of Placebo
62012257|NCT02211755|EXPERIMENTAL|1|Starting doses are clofarabine at 1 mg/m2 IV on days 1 through 5 of a 21-day cycle, and bortezomib at 0.8 mg/m2 subcutaneously on days 1 and 4 of a 21-day cycle.
62012258|NCT04226716|OTHER|Multiparous, pregnant women|
62012259|NCT03488576|ACTIVE_COMPARATOR|Complete Peeling|Patient underwent scheduled vitrectomy for epiretinal membrane or macular hole with complete macular peeling of the internal limiting membrane.
62012260|NCT03488576|EXPERIMENTAL|Foveal Sparing|Patient underwent scheduled vitrectomy for epiretinal membrane or macular hole with partial peeling the internal limiting membrane (foveal sparing).
62012261|NCT01159067|EXPERIMENTAL|Arm I|Patients receive oral deferasirox once daily for up to 6 months in the absence of unacceptable toxicity.
62012262|NCT02747316|EXPERIMENTAL|Isotopically labeled test meal week of pregnancy 20|
62012263|NCT02747316|EXPERIMENTAL|Isotopically labeled test meal week of pregnancy 30|
62012264|NCT00764140||2|Specific tumor growth factors (IGFs, its binding proteins,receptors; transforming growth factor alpha and beta 1 and epidermal growth factor) in the urine and serum will be measured in patients with hepatocellular carcinoma and healthy controls
62012265|NCT00764140||1|Patients with hepatocellular carcinoma and Healthy controls
62012266|NCT06256497||DMR Treated Patients|
62012267|NCT04560712|EXPERIMENTAL|Arm I (acupuncture, usual care)|Beginning the day after surgery, patients undergo acupuncture sessions over 25 minutes QD for up to 7 days. Patients also undergo usual care including preoperative visits to the primary surgical team, anesthesia preoperative evaluation, referrals to other specialties for perioperative evaluation and optimization of comorbid conditions if necessary, surgical operations, postoperative hospitalization, and post-discharge clinic visits.
62012268|NCT04560712|ACTIVE_COMPARATOR|Arm II (usual care)|Patients undergo usual care including preoperative visits to the primary surgical team, anesthesia preoperative evaluation, referrals to other specialties for perioperative evaluation and optimization of comorbid conditions if necessary, surgical operations, postoperative hospitalization, and post-discharge clinic visits.
62577632|NCT02112630|EXPERIMENTAL|Group 1 - Response Guided Therapy|"Treatment naive and documented relapsers : Subjects who have never been previously treated with P-IFN +/- ribavirin therapy and those who have documented relapse after P-IFN +/- ribavirin therapy.~Subjects in group 1 will receive P-IFN alfa 2a or P-IFN alfa 2b and ribavirin for a 4 week lead-in followed by the addition of boceprevir. Based on the patient's HCV-RNA levels at Treatment Week (TW) 8, TW12 and TW24 treatment with be continued for a total duration of 28 to 48 weeks.Subjects will be followed through treatment and up to 24 weeks post treatment."
62577633|NCT02112630|EXPERIMENTAL|Group 2 - Fixed Duration Therapy|"Partial/Null Responders /Undefined Previous Response, Compensated cirrhosis: Subjects who have compensated cirrhosis, and/or were previously treated with P-IFN +/- ribavirin without SVR (including partial responders, null responders, and those previously treated without adequate documentation of response).~Subjects in Group 2 will all be assigned to fixed duration therapy.Patients will be treated with P-IFN alfa 2a or P-IFN alfa 2b and ribavirin for a 4 week lead-in followed by the addition of boceprevir for a total of 48 weeks of therapy. Subjects will be followed through treatment and up to 24 weeks post treatment."
62577634|NCT03382626|ACTIVE_COMPARATOR|tDCS plus Computer-assisted training|Patients will receive 10 sessions of active anodal tDCS on the left prefrontal cortex dorsolateral (F3 area using International 10-20 system for electroencephalogram (EEG) electrode placement) plus Computer-assisted cognitive training (games to improve working memory, attention, and executive function).
62577635|NCT03382626|SHAM_COMPARATOR|tDCS sham plus Computer-assisted training|Patients will receive 10 sessions of sham anodal tDCS on the left prefrontal cortex dorsolateral plus Computer-assisted cognitive training (games to improve working memory, attention and executive function).
62577636|NCT02329171|EXPERIMENTAL|Imiquimod treatment arm|Patients in this group will be treated with imiquimod during 16 weeks. Colposcopy with diagnostic biopsies will be performed after 10 weeks. In case of progressive disease, the treatment will be ended and appropriate surgical excision will be performed. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies.
62577637|NCT02329171|ACTIVE_COMPARATOR|Standard treatment arm|Large loop excision of the transformation zone (LLETZ) will be performed in this group, as standard treatment.
62577638|NCT05703178|EXPERIMENTAL|Education + Online Pain Coping Skill Training|Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects. They will also be given access to an online pain coping skills training program and asked to complete it at home over 8 to 10 weeks. This interactive, web-based program teaches cognitive and behavioral skills that research has shown can reduce pain and pain-related interference with daily activities. The program includes eight sessions that participants will complete at a rate of about 1 per week. Each session takes 35-45 minutes. Participants will be shown how to use the program and can contact the study team if they have any problems with it. Participants who do not have a device capable of accessing the program will be loaned a tablet computer for the study.
62577639|NCT05703178|ACTIVE_COMPARATOR|Education|Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.
62577640|NCT00935402|EXPERIMENTAL|Short Sleep|Subjects are permitted to spend 4 hours in bed per night for 5 consecutive nights. Subjects are inpatients for a period of 6 days.
62012269|NCT02488512|EXPERIMENTAL|90Y-DOTATOC|90Y-DOTATOC
62012270|NCT00773175|ACTIVE_COMPARATOR|Subcutaneous|Isotonic fluid rehydration by SC administration with hylenex (150 Units in 1 mL)
62012271|NCT00773175|ACTIVE_COMPARATOR|Intravenous|Isotonic fluid rehydration by IV
62577641|NCT00935402|ACTIVE_COMPARATOR|Regular Sleep|Subjects are permitted to spend 9 hours in bed per night for 5 nights. Subjects are inpatients for a period of 6 days.
62012272|NCT03866616|ACTIVE_COMPARATOR|Control (usual care)|"Behavioral: This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics."
62012273|NCT03866616|EXPERIMENTAL|Intervention (group sessions)|Behavioral: Brain Builders Parenting Class-intervention (BBPC). Participants who are selected via the lottery to participate in the BBPC program will be asked to attend six, 1-hour classes, every other week over a 12 week period of time.
62012274|NCT05486949|EXPERIMENTAL|AZD4205 and carbamazepine|Subjects in arm 1 will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with carbamazepine after the wash-out period.
62012275|NCT05486949|EXPERIMENTAL|AZD4205 and itraconazole|Subjects in arm 2 will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with itraconazole after the wash-out period.
62215042|NCT06533826|EXPERIMENTAL|Arm G (ADC2 T-DXd HR+)|"Participants will complete:~* Baseline visit with imaging, tumor biopsy, electrocardiogram, echocardiogram.~* Imaging every 9 weeks.~* Cycle 1 through Cycle 3:~  --Day 1 of 21 day cycle: Predetermined dose of Trastuzumab deruxtecan 1x daily.~* Cycle 1 through end of treatment:~  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab deruxtecan 1x daily.~ * Imaging on Day 1.~* End of Treatment visit with imaging, tumor biopsy, echocardiogram~* Follow up: imaging every 9 weeks.~* Long-term Follow Up: visits every 6 months."
62199824|NCT03586934|EXPERIMENTAL|Multimodal Anesthesia and Analgesia|"Under age 75: Preop: acetaminophen 1000 mg oral, celecoxib 400 mg oral. Interscalene block (30 ml 0.5% ropivacaine with 1:200,000 epinephrine). Intraop: ketorolac 15 mg IV, acetaminophen injectable product. Postop: acetaminophen 500 mg oral, oxycontin 10 mg oral. Breakthrough: ketorolac 15 mg IV, oxycodone 10 mg oral. Floor: tramadol 100 mg q6h oral, acetaminophen 1 g q8h oral, celecoxib 200 mg q12h oral, ketorolac 15 mg IV q6h. Breakthrough: Pain scores 4-6: oxycodone 5 mg q4h PRN oral, pain scores 7-10: oxycodone 10 mg q4h PRN oral. Discharge: acetaminophen 1 g q8h oral, tramadol 100 mg q8h oral, celecoxib 200 mg q12h oral or meloxicam 15 mg daily oral, oxycodone 5 mg q4h PRN oral.~75 or older: Same except: Preop: celecoxib 200 mg oral. PACU meds: acetaminophen 500 mg oral. No OxyER."
62199825|NCT03846440||Participants|Middle to older aged (\>50 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco,Mexico).
62199826|NCT03660423|EXPERIMENTAL|Dance Group|Dance group will participate in a 60 minute integrative dance class two times per week
62577642|NCT02257489|EXPERIMENTAL|50 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (50 mg) and 2 subjects to receive placebo, single injection, intramuscularly
62577643|NCT02257489|EXPERIMENTAL|100 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (100 mg) and 2 subjects to receive placebo, single injection, intramuscularly
62577644|NCT02257489|EXPERIMENTAL|200 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (200 mg) and 2 subjects to receive placebo, single injection, intramuscularly
62577645|NCT02257489|EXPERIMENTAL|100 mg multiple dose|8 subjects in total; 6 subjects to received ACE-083 (100 mg) and 2 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
62577646|NCT02257489|EXPERIMENTAL|200 mg multiple dose|8 subjects in total; 6 subjects to received ACE-083 (200 mg) and 2 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
62577647|NCT02257489|EXPERIMENTAL|100 mg (multiple dose)|9 subjects in total; 6 subjects to received ACE-083 (100 mg) and 3 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
62577648|NCT02257489|EXPERIMENTAL|150 mg multiple dose|9 subjects in total; 6 subjects to received ACE-083 (150 mg) and 3 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
62577649|NCT01450215|EXPERIMENTAL|Revlimid|
62577650|NCT01450215|NO_INTERVENTION|Revlimid and dexamethasone|
62577651|NCT02126579|EXPERIMENTAL|Arm A (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA administered in one skin location rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
62577652|NCT02126579|EXPERIMENTAL|Arm B (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
62577653|NCT02126579|EXPERIMENTAL|Arm C (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Resiquimod will be applied to the vaccine site immediately after the vaccine administration.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
62577654|NCT02126579|EXPERIMENTAL|Arm D (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Resiquimod will be applied to the vaccine site immediately after vaccine administration.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
62577655|NCT02126579|EXPERIMENTAL|Arm E (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
62577656|NCT02126579|EXPERIMENTAL|Arm F (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Resiquimod will be applied to the vaccine site immediately after vaccine administration.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
62199827|NCT03660423|NO_INTERVENTION|Control Group|The Control group will continue with normal activities, not participating in the dance intervention.
62577657|NCT02126579|EXPERIMENTAL|Arm G(Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Resiquimod will be applied to the vaccine site immediately after vaccine administration.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
62577658|NCT02126579|EXPERIMENTAL|Arm E2|"Peptide Vaccine (LPV7) + IFA + PolyICLC vaccines administered in one skin location. Each vaccine will be administered in the same skin site for all 6 vaccines.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
62577659|NCT03547011|ACTIVE_COMPARATOR|US guided Quadratus Lumborum block|Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.
62577660|NCT03547011|ACTIVE_COMPARATOR|US guided Paravertebral block.|Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
62577661|NCT06352008|EXPERIMENTAL|experiment|
62577662|NCT06063070|EXPERIMENTAL|Fluzoparib + Bevacizumab|"Fluzoparib capsule: oral administration, 3 capsules/dose (150 mg/ dose), twice a day, in the morning and evening, before/after meals can be taken orally, it is recommended to take orally within 0.5h after breakfast and dinner, continuous administration. Every 3 weeks is a treatment cycle.~Bevacizumab injection: intravenous, 15 mg/kg, every 3 weeks for a treatment cycle until disease progression or intolerable toxicity, up to a total of 15 months."
62199828|NCT01336049|EXPERIMENTAL|Nimotuzumab|
62577663|NCT04150796|EXPERIMENTAL|Enhanced-view Totally Extraperitoneal (eTEP) Hernia Repair|Initial access into the retromuscular space is achieved using an optical trocar. Insufflation of CO2 is performed under direct visualization. Multiple assistant ports will be placed medial to the semilunar line to continue developing the retromuscular space. The medial insertion of the posterior rectus sheath will be incised to enter the preperitoneal plane and facilitate reduction of hernia contents. The contralateral posterior rectus sheath will be incised and the contralateral retrorectus space will be matured. Suture will be used to close any defect in the hernia sac. The defect will be measured, as will be the retrorectus space. The fascial defect will be closed with suture. Non-barrier coated mesh will be placed in the retrorectus space and flat positioning will be confirmed. Ports will be removed under direct visualization, and the abdomen desufflated. Anterior fascia of any larger ports (8mm or greater) will be closed.
62577664|NCT04150796|ACTIVE_COMPARATOR|Intraperitoneal Onlay Mesh (IPOM) Hernia Repair|Access is achieved using an optical trocar. Insufflation of CO2 is performed. Two additional trocars are placed on the left side along the anterior axillary line. If necessary, auxiliary ports may be placed on the right side. When present, hernia contents are reduced using graspers. Adhesions between abdominal contents and the abdominal wall are lysed. The hernia defect is identified and measured internally with a sterile plastic ruler with the abdomen insufflated. Defect closure is performed using nonabsorbable suture. Mesh repair is performed using polypropylene mesh with an absorbable hydrogel barrier. Mesh is chosen to achieve a minimum 3 to 5-centimeter overlap from the edges of the closed defect. Inside the abdomen, the mesh is unrolled and positioning against the anterior abdominal wall is confirmed. Mesh edges are fixed circumferentially with permanent fixation. Ports are removed and the abdomen is desufflated. The anterior fascia of the 12mm port is closed.
62577665|NCT06149611|EXPERIMENTAL|[14C] TQB3616|100 µCi \[14C\] TQB3616, 180mg, once in total.
62199829|NCT00901953||1|migrainous vertigo
62577666|NCT04594772|EXPERIMENTAL|Neoadjuvant therapy|All patients will receive Neoadjuvant therapy.
62577667|NCT05333601|EXPERIMENTAL|eSCCIP|The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention that combines cognitive behavioral and family systems therapy to provide parents and caregivers of children with cancer (PCCC) with evidence-based coping skills and psychosocial support focused on the family unit. eSCCIP has three 30-minute, self-directed, online modules which feature a unique mix of original video content and interactive activities, supplemented by three telehealth follow-up sessions. eSCCIP aims to reduce acute distress and symptoms of post-traumatic stress while increasing positive coping self-appraisal and use of cognitive coping skills.
62577668|NCT01902745|ACTIVE_COMPARATOR|Fatigue Reduction Diet|"The FRD maintains a participant on a diet with their typical caloric intake and replaces some of their calories with the following foods on a daily basis; whole grains, vegetables (one leafy green, one tomato, and on yellow/orange), fruit (one high in vitamin C), fatty fish and nuts and/or seeds.~A social cognitive theory intervention method will take place that motivates the participant to change their behavior and lifestyle for overall well being."
62577669|NCT01902745|ACTIVE_COMPARATOR|General Health Curriculum|"Counseling sessions on oral health, healthy eyesight, over-the-counter drug disposal, skin and hair health, cell phone and health, hearing loss, colorectal cancer screening, and preventing colds and flu.~A social cognitive theory intervention method will take place that motivates the participant to change their behavior and lifestyle for overall well being."
62577670|NCT04506463|EXPERIMENTAL|Arm A|MM-II 1 ml
62577671|NCT04506463|EXPERIMENTAL|Arm B|MM-II 3 ml
62577672|NCT04506463|EXPERIMENTAL|Arm C|MM-II 6 ml
62577673|NCT04506463|PLACEBO_COMPARATOR|Arm 4|Placebo 1ml
62577674|NCT04506463|PLACEBO_COMPARATOR|Arm 5|Placebo 3ml
62199830|NCT00901953||2|migraine without vertigo
62199831|NCT01696955|EXPERIMENTAL|Arm I (cetuximab and tivantinib)|Patients receive cetuximab IV over 60-120 minutes on days 1 and 15 and tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62199832|NCT01696955|EXPERIMENTAL|Arm II (cetuximab)|Patients receive cetuximab IV over 60-120 minutes on days 1 and 15. Patients who fail cetuximab as a single agent may receive single agent tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62199833|NCT05056597||AN-R|Participants that meet Diagnostic And Statistical Manual Of Mental Disorders (DSM-V) criteria for Anorexia Nervosa restricting subtype.
62577675|NCT04506463|PLACEBO_COMPARATOR|Arm 6|Placebo 6ml
62577676|NCT06032195|EXPERIMENTAL|Custodiol-N|organ will be perfused with Custodiol-N solution
62199834|NCT05056597||AN-BP|Participants that meet DSM-V criteria for Anorexia Nervosa binging/purging subtype
62199835|NCT05056597||BN|Participants that meet DSM-V criteria for Bulimia Nervosa.
62199836|NCT05056597||Healthy Controls|Participants that do not meet DSM-V criteria for any disorder.
62577677|NCT06032195|ACTIVE_COMPARATOR|Custodiol|organ will be perfused with Custodiol solution
62199837|NCT02416453|EXPERIMENTAL|Group 1|Participants will receive intramuscular (IM) injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 29.
62199838|NCT02416453|EXPERIMENTAL|Group 2|Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 57.
62199839|NCT02416453|EXPERIMENTAL|Group 3|Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 85.
62199840|NCT02885584|EXPERIMENTAL|Transpulmonary pressure controlled mechanical ventilation|transpulmonary pressure will be used for ventilation settings
62199841|NCT02885584|NO_INTERVENTION|Conventional pressure-controlled mechanical ventilation|transpulmonary pressure will not be used for ventilation settings
62199842|NCT03744013|ACTIVE_COMPARATOR|Perforated|Fortiva® 1mm perforated ADM
62199843|NCT03744013|ACTIVE_COMPARATOR|Non-perforated|Fortiva® 1mm non-perforated ADM
62199844|NCT02694367||Recurrent miscarriage group|Women with previous history of RM, defined as two or more consecutive miscarriages
62577678|NCT01902641|ACTIVE_COMPARATOR|Succinylcholine|Patient received succinylcholine as a muscle relaxant(0.5 mg /kg)for induction of anaesthesia for rigid bronchoscopy.
62577679|NCT01902641|ACTIVE_COMPARATOR|Rocuronium/Sugammadex|Patient received rocuronium (0.25 mg/ kg) as muscle relaxant for induction of anaesthesia for rigid bronchoscopy, at the end of procedure rocuronium was reversed with sugammadex (0.5mg/kg.)
62577680|NCT01902641|ACTIVE_COMPARATOR|Rocuronium|Patients received rocuronium (0.25 mg /kg)as muscle relaxant for induction of anaesthesia for rigid bronchoscopy.
62577681|NCT01811641||maternal methyl-donors, infant epigenetics|women of reproductive age in rural Gambia, infants born to these women
62577682|NCT03024957|ACTIVE_COMPARATOR|Dexmedetomidine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 5 μg of dexmedetomidine in 1 mL volume intrathecally.
62577683|NCT03024957|ACTIVE_COMPARATOR|Morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 0.5 mg morphine sulphate in 1 mL volume intrathecally.
62199845|NCT02694367||Control group|Women with no history of RM
62199846|NCT01046929|EXPERIMENTAL|limonene|
62199847|NCT01823705|EXPERIMENTAL|Gastric Electrical Stimulation (GES)|Gastric Electrical Stimulation (GES) therapy for the treatment of obesity.
62577684|NCT03024957|ACTIVE_COMPARATOR|Dexmedetomidine + morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 5 μg of dexmedetomidine plus 0.5 mg of morphine sulphate in 1 mL volume intrathecally.
62577685|NCT00044629|EXPERIMENTAL|Cognitive Behavioral Therapy and Ambien|Cognitive Behavioral Therapy and Ambien
62577686|NCT00044629|PLACEBO_COMPARATOR|Cognitive Behavioral Therapy and Placebo|Cognitive Behavioral Therapy and Placebo
62784565|NCT00771771|ACTIVE_COMPARATOR|Home rehabilitation|Discharge from the hospital to the patients' homes as soon as possible, supported by an out-patient ambulatory coordinating multidisciplinary team. The patients will be offered rehabilitation treatment in their homes, and multidisciplinary policlinical follow-ups will be performed 3 and 6 months after inclusion.
62784566|NCT00771771|NO_INTERVENTION|Treatment as usual|Patients will receive rehabilitation treatment after today's principles and routines.
62784567|NCT00067379|ACTIVE_COMPARATOR|1|Medicaid patients with medically necessary malocclusions treated during the mixed dentition with limited goals followed by observation
62784568|NCT00627133|EXPERIMENTAL|1|
62784569|NCT04926311||Developmental Language Disorder patients|
62784570|NCT04702425|EXPERIMENTAL|VOB560-MIK665 - Part 1a|Part 1a - Patients with relapsed/refractory non-Hodgkin lymphoma and relapsed/refractory multiple myeloma administered VOB560 and MIK665 as an intravenous (IV) infusion.
62784571|NCT04702425|EXPERIMENTAL|VOB560-MIK665 - Part 1b|Part 1b - Patients with relapsed/refractory acute myeloid leukemia administered VOB560 and MIK665 as an intravenous (IV) infusion.
62784572|NCT04702425|EXPERIMENTAL|VOB560-MIK665 - Part 2a|Part 2a - Patients with relapsed/refractory multiple myeloma with at least 10 patients with 1q gain cytogenetic abnormality and 10 patients with high risk R/R MM as defined in (Sonneveld et al 2016) administered VOB560 and MIK665 as an intravenous (IV) infusion.
62784573|NCT04702425|EXPERIMENTAL|VOB560-MIK665 - Part 2b|Part 2b - Patients with relapsed/refractory non-Hodgkin lymphoma with at least 10 patients with double-hit (DH) lymphoma, based on the overall bad prognosis and limited therapeutic options for patients with DH NHL administered VOB560 and MIK665 as an intravenous (IV) infusion.
62784574|NCT04702425|EXPERIMENTAL|VOB560-MIK665 - Part 2c|Part 2c - Patients with relapsed/refractory acute myeloid leukemia venetoclax refractory or insensitive with at least 6 patients M5 as proposed by French-American-British (FAB) group, based on the observation that venetoclax resistance in AML M5 can be caused by up-regulation of MCL1 administered VOB560 and MIK665 as an intravenous (IV) infusion.
62784575|NCT04702425|EXPERIMENTAL|VOB560-MIK665 - Part 2d|Part 2d - Patients with relapsed/refractory acute myeloid leukemia venetoclax naive patients administered VOB560 and MIK665 as an intravenous (IV) infusion.
62199848|NCT04592159|EXPERIMENTAL|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Each spray delivers 100 microliters (μL) of nabiximols.
62199849|NCT04592159|PLACEBO_COMPARATOR|Placebo|Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 μL containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 8 weeks.
62577687|NCT00044629|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy alone (no drug)|Cognitive Behavioral Therapy alone (no drug)
62577688|NCT06587399|ACTIVE_COMPARATOR|Manual therapy treatment|Joint mobilization techniques in the shoulder together with the treatment of muscle trigger points using pressure release techniques
62784576|NCT06040853|EXPERIMENTAL|tranexamic group|After intubation, intravenous 15mg/kg tranexamic acid will be given to the study group 10 minutes before the incision and 100 mg/h infusion will be administered until the skin is closed.
62784577|NCT06040853|PLACEBO_COMPARATOR|placebo group|The control group will be given intravenous 100 ml of saline
62784578|NCT03522220|EXPERIMENTAL|3D Super Mario Game Condition|3D navigation video game intervention
62784579|NCT03522220|ACTIVE_COMPARATOR|2D Super Mario Game Condition|Video game intervention without 3D navigation
62784580|NCT03522220|ACTIVE_COMPARATOR|Kindle Device|No 3D navigation
62784581|NCT03540199|EXPERIMENTAL|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
62577689|NCT06587399|EXPERIMENTAL|Radial shock wave treatment|Low-medium energy radial shock waves will be used to treat muscle trigger points and the insertion of the supraspinatus muscle
62199850|NCT01093469|EXPERIMENTAL|Aquaphor Healing Ointment|Aquaphor Healing Ointment three times daily to atopic dermatitis
62577690|NCT01927315|EXPERIMENTAL|Fenofibrate|Fenofibrate 145 mg (Fulcrosupra) oral tablets daily for 12 weeks
62577691|NCT01927315|PLACEBO_COMPARATOR|Placebo|Placebo oral tablets daily for 12 weeks
62577692|NCT01152879||Home Parenteral Nutrition|Patients receiving home parenteral nutrition
62577693|NCT06363773|EXPERIMENTAL|Stereotactic radiotherapy|Patients will perform stereotactic radiotherapy with 3 sessions (8 Gy) during 20 minutes each and with 72 hours in-between, alongside anti-PD1 immunotherapy.
62577694|NCT02973503|EXPERIMENTAL|Elbasvir/Grazoprevir|evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
62577695|NCT05410275|EXPERIMENTAL|Rivaroxaban|"Rivaroxaban 5 mg daily, administered orally, during 3 consecutive days. After a wash-out period of 4 days, Rivaroxaban 10 mg daily, administered orally, during 3 consecutive days.~After a wash-out period of 4 days, Rivaroxaban 15 mg daily, administered orally, during 3 consecutive days."
62577696|NCT05068414||Patients with atrial fibrillation|
62577697|NCT01726907|EXPERIMENTAL|Robotic SMG resection|Robot-assisted SMG resection
62577698|NCT01726907|ACTIVE_COMPARATOR|Endoscopic SMG resection|Endoscope-assisted SMG resection
62577699|NCT05883657|EXPERIMENTAL|Condition 1 : Prototypes (816-v1) every weeks|Application on the brown spots of the face and the hands for the prototypes (816-v1) at D0, D7, D14, D21, D28, D35, D42, D49, D56, D63, D70 and D77.
62577700|NCT05883657|EXPERIMENTAL|Condition 2 : Prototypes (816-v1) every two weeks|Application on the brown spots of the face and the hands for the prototypes (816-v1) at D0, D14, D28, D42, D56 and D70.
62577701|NCT04128046|EXPERIMENTAL|PRFM|Hemi-face injected with PRFM. PRFM was produced from 9 mL of blood (Healeon Medical, Inc).
62577702|NCT04128046|PLACEBO_COMPARATOR|Saline|Hemi-face injected with saline.
62784582|NCT03540199|ACTIVE_COMPARATOR|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length\<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
62784583|NCT03540199|NO_INTERVENTION|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62784584|NCT05758350|EXPERIMENTAL|Iowa Oral Performance Instrument (IOPI) training group|Including conventional speech therapy (tongue range of motion and strength, oral diet suggestion, masseter muscle strengthening) and home- IOPI based resistance training
62577703|NCT02854956|OTHER|X-linked Mental retardation|This is an observational study which will allow to precisely describe the phenotype associated to each X-linked mental retardation gene.
62577704|NCT02854956|OTHER|Control Group|This group will be compared to X-linked mental retardation group in order to obtain a baseline on some cognitive tests.
62784585|NCT05758350|NO_INTERVENTION|controlled group|Including conventional speech therapy (tongue range of motion and strength, oral diet suggestion, masseter muscle strengthening) only
62199851|NCT01093469|ACTIVE_COMPARATOR|Atopiclair Nonsteroidal Cream|Atopiclair Nonsteroidal Cream three times daily to atopic dermatitis
62577705|NCT06278415|EXPERIMENTAL|Physiological based cord clamping (PBCC)|In the intervention group, newborns will receive PBCC. The resuscitation table will place in the operating room as close as possible to the mother's pelvis. After the infant is born, the obstetrician holds the infant. Stabilization will start as soon as the infant is placed on the platform. The nurse places the oximeter sensor on the right wrist and ECG electrodes on the chest of the newborn. Local resuscitation guidelines will be in respect of the NLS-ERC 2021 guidelines. Stabilization of the newborn will be performed while the cord is intact and the cord will be clamped after respiratory stabilization will be achieved, deﬁned as the establishment of regular spontaneous breathing, a HR above 100 bpm SpO 2 above 85% while using supplemental oxygen less than 0,3.
62577706|NCT06278415|ACTIVE_COMPARATOR|Differed cord clamping (DCC)|In the control group, newborns will receive standard DCC defined as time based and performed at 60 seconds after birth. Then infants will be transferred to a standard resuscitation table located in a stabilization room next to the operating room. Further treatment and intervention required for cardiopulmonary stabilization will be provided on the standard resuscitation table. Stabilization will start as soon as the infant is placed on the resuscitation table. The nurse will place the oximeter sensor on the right wrist and ECG electrodes on the chest of the newborn. Local resuscitation guidelines will be in respect of the NLS-ERC 2021 guidelines. The time to reach the stabilisation described above (a HR above 100 bpm and SpO 2 above 85% while using supplemental oxygen less than 0,3) is recorded. Then, the infant will be placed on the mother's chest or partner's chest, or alternatively, be prepared and transferred to the transport incubator if further neonatal care is needed.
62577707|NCT05849298|EXPERIMENTAL|Arm A|Participants will receive 7.4 GBq (+/- 10%) of AAA617 (Lutetium \[177Lu\] vipivotide tetraxetan) once every 6 weeks for 6 cycles. ADT must be ongoing; Best supportive care is allowed.
62577708|NCT05849298|EXPERIMENTAL|Arm B|Participants will receive 7.4 GBq (+/- 10%) of AAA617 (Lutetium \[177Lu\] vipivotide tetraxetan) once every 6 weeks for 6 cycles. In addition of SOC (ADT plus choice of ARPI as per physician's decision), Best supportive care is allowed.
62577709|NCT04870385|EXPERIMENTAL|Treatment|5-week online prevention program
62577710|NCT04870385|OTHER|Control|Waitlist control
62199852|NCT01093469|ACTIVE_COMPARATOR|EpiCream Skin Barrier Emulsion|EpiCream Skin Barrier Emulsion three times daily to atopic dermatitis
62577711|NCT03109314|ACTIVE_COMPARATOR|Single-letter training group|Subjects will be trained on a low-contrast single-letter task. The task is to identify a faint letter (low-contrast). Performance will be measured as correct or incorrect. Training will consist of identifying these low-contrast letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
62577712|NCT03109314|ACTIVE_COMPARATOR|Uncrowd training group|Subjects will be trained on an uncrowd task (identifying the middle letter of groups of three letters presented). Performance will be measured as correct or incorrect. Training will consist of identifying these letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
62577713|NCT00680602|EXPERIMENTAL|1|Group Cognitive Behavior Therapy
62577714|NCT00680602|ACTIVE_COMPARATOR|2|Selective Serotonin Reuptake Inhibitor
62577715|NCT05755204||Apretude group|High-risk women who choose to initiate intramuscular q8week LA-CAB (Apretude) with or without oral lead in for HIV PrEP
62577716|NCT05755204||Truvada group|High-risk women who choose to initiate daily oral TDF/FTC (Truvada) for HIV PrEP
62577717|NCT02737930|EXPERIMENTAL|Fluoxetine|20 mg fluoxetine capsule by mouth once daily for 90 days
62577718|NCT02737930|PLACEBO_COMPARATOR|Placebo|Matching placebo
62199853|NCT01225653|EXPERIMENTAL|Latanoprost|Topical treatment with latanoprost
62199854|NCT01225653|PLACEBO_COMPARATOR|Placebo|Placebo arm
62199855|NCT04832659|ACTIVE_COMPARATOR|CEASE|Those assigned to the Active Comparator arm will receive the CEASE intervention.
62199856|NCT04832659|EXPERIMENTAL|CEASE + BIO|Those assigned to the Experimental CEASE + BIO arm will receive the CEASE intervention plus Biomarker Informed Outreach (BIO).
62199857|NCT01706705|EXPERIMENTAL|Brachytherapy Treatment Planning|"MRI-compatible intracavitary applicator inserted using ultrasound guidance to verify tandem placement in the uterus. Tandem and ovoids, tandem and cylinders, or tandem and ring chosen to accommodate patient's tumor and vaginal anatomy.~Computed tomography (CT) scan and a magnetic resonance imaging (MRI) scan performed after the implant is placed in the operating room. The CT scan should take about 20 minutes and the MRI about 45 minutes."
62577719|NCT02972684|NO_INTERVENTION|Conventional coagulation management|management of perioperative haemorrhage following cardiac surgery using conventional blood coagulation tests.
62577720|NCT02972684|EXPERIMENTAL|Thrombo-elastometry POC testing|management of perioperative haemorrhage following cardiac surgery using the thrombo-elastometry point of care test.
62577721|NCT00596817|PLACEBO_COMPARATOR|Placebo|
62577722|NCT00596817|EXPERIMENTAL|Vortioxetine: 5 or 10 mg|
62577723|NCT00205556|OTHER|1: low flux hemodialysis|standard treatment
62577724|NCT00205556|ACTIVE_COMPARATOR|2 on-line hemodiafiltration|
62577725|NCT00513045|EXPERIMENTAL|IRT|Intervention based on Imagery Rehearsal Therapy
62577726|NCT00513045|ACTIVE_COMPARATOR|Exposure|Treatment based on exposure
62577727|NCT00513045|NO_INTERVENTION|Nightmare diary|Recording nightmares in a diary
62577728|NCT00513045|NO_INTERVENTION|Waiting list|Waiting list
62577729|NCT02522065||Healthy controls|A sample of 30 healthy volunteers will be recruited to compare the typing signal with that of the cases.
62577730|NCT02522065||Early Parkinson's disease cases|A sample of 30 early PD cases (i.e. less than five years of disease and no axial signs or fluctuations) that are going to be prescribed de novo dopaminergic therapy will be recruited.
62577731|NCT01901601|EXPERIMENTAL|LALAK|laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.
62577732|NCT01901601|ACTIVE_COMPARATOR|IEK|Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.
62577733|NCT04111120||Cirrhosis with variceal bleeding|Coagulation factor assays and heparinase treated SONOCLOT at Days 0,3, and 7
62577734|NCT04111120||Cirrhosis without Bleeding|Control group of 25 subjects
62577735|NCT05305417|EXPERIMENTAL|Regenerative Endodontic Treatment|This treatment consists of obturated the root canal preparations under an biological-based protocol using autologous biological elements and bioactive materials that allows restore the connective pulp-like tissue within the canals.
62577736|NCT05305417|ACTIVE_COMPARATOR|Conventional root canal treatment|This treatment consist on obturated the root canal preparations under the conventional protocol with an inert biomaterials like guttapercha and endodontics cements to seal the root canals.
62199858|NCT00567840|EXPERIMENTAL|1|PA-824 200 mg/qd
62199859|NCT00567840|EXPERIMENTAL|2|PA-824 600 mg/qd
62199860|NCT00567840|EXPERIMENTAL|3|PA-824 1000 mg/qd
62577737|NCT01152749|EXPERIMENTAL|UNG-GC-2|2 mg experimental NRT product
62577738|NCT01152749|EXPERIMENTAL|UNG-GC-4|4 mg experimental NRT product
62577739|NCT01152749|ACTIVE_COMPARATOR|Nicorette® Gum-2|2 mg Nicorette® Gum
62577740|NCT01152749|ACTIVE_COMPARATOR|Nicorette® Gum-4|4 mg Nicorette® Gum
62577741|NCT01947543||Ventricular tachycardia|Patients with ventricular tachycardia of unknown origin treated with an ICD.
62577742|NCT01947543||Family members|Family members (parents, siblings and children) for patients with results showing mutations in the calmodulin genes.
62577743|NCT05210556||No Antibiotic Bowel Prep|Patients who did not receive a preoperative antibiotic bowel preparation
62577744|NCT05210556||Antibiotic Bowel Prep|Patients who did receive a preoperative antibiotic bowel preparation
62784586|NCT06436703|EXPERIMENTAL|SSA: Influenza ModRNA Vaccine 2A|- Single Dose on Day 1
62577745|NCT03366480|EXPERIMENTAL|Endometrial cancer|ABTL0812 (starting 1,300 mg tid orally) in combination with paclitaxel and carboplatin will be given to patients with advanced endometrial cancer, up to 12 months from initiation.
62199861|NCT00567840|EXPERIMENTAL|4|PA-824 1200 mg/qd
62199862|NCT00567840|ACTIVE_COMPARATOR|5|Rifafour e-275 mg
62199863|NCT04707664|EXPERIMENTAL|Sargramostim Arm|Day 1 - 5: Sargramostim treatment in addition to standard of care for COVID-19
62199864|NCT04707664|PLACEBO_COMPARATOR|Placebo Arm|Day 1 - 5: Placebo treatment in addition to standard of care for COVID-19
62199865|NCT01597843|EXPERIMENTAL|First educational intervention group|Group that receives intervention first. The intervention is a series of training sessions, in person and on line, to educate post superusers who will in turn educate post members on the utility and mechanics of use of MHV.
62012276|NCT05351203|ACTIVE_COMPARATOR|caudal epidural group|"the patient will be positioned in prone position, sterilized from the iliac crest margin to the lower buttock by betadine three times and will be covered by sterile drapes exposing the sacral area. Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound linear transducer probe that is covered in sterile plastic bag . Short axis (transverse) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.125% bupivacaine will expand the epidural space."
62401050|NCT01048710||Conservative treatment|"In the control group, patients who refused to have surgery will be allowed to be treated using different options of conservative treatment. The frequency of applications depends on the hospital and will therefore be documented in the study. An arthroscopy is not obligatory under this treatment group, but is permitted.~The following conservative treatment methods are allowed:~1. Physical therapy~2. Specific exercises for the muscles~3. Injections into the knee joint~4. Brace~5. Medication~6. No therapy"
62577746|NCT03366480|EXPERIMENTAL|Squamous non-small cell lung cancer|ABTL0812 (starting 1,300 mg tid orally) in combination with paclitaxel and carboplatin will be given to patients with squamous NSCLC, up to 12 months from initiation.
62577747|NCT05572957|ACTIVE_COMPARATOR|GDMT group|"With the current guidelines of recommended therapies for HF, each patient who meets the inclusion criteria should begin being on all 4 drug classes after enrollment, including a beta-blocker (BB), a RAS inhibitor (ACEI, ARB) or ARNI (preferred), an MRA, and an SGLT2i.~The appeal drugs should be gradually uptitrated to the maximum tolerated dose within the first 3-6 months.~Ivabradine will be added to the patients whose resting heart rates remain above 70 beats per minute (bpm) after adequate medical treatment, including a BB at maximum tolerated dose."
62577748|NCT05572957|EXPERIMENTAL|LBBP+GDMT group|"In this arm, medications are the same as the GDMT group. The LBBP lead is introduced into the right ventricle (RV) and is placed on the right side of the interventricular septum (IVS). The lead is advanced deeply into the IVS until reaching the LV septal subendocardium and right bundle branch block (RBBB) morphology of the paced QRS complex is observed in electrocardiogram (ECG) lead V1.~If LBBP fails, his bundle pacing (HBP) should be considered when HBP could correct LBBB.~If both of LBBP and HBP fail, conventional BiVP-CRT could be the last option."
62577749|NCT01348620|EXPERIMENTAL|Single port laparoscopic device|
62577750|NCT01348620|ACTIVE_COMPARATOR|Four-port laparoscopic device|
62577751|NCT01139593||morning dose|women undergoing IVF/ICSi taking their gonadotropin dose in the am
62199866|NCT01597843|EXPERIMENTAL|Second intervention group|This arm receives a series of training sessions over study months 6-9. The training sessions are in person and on line and are directed at post superusers who will in turn educate post members on the utility and mechanics of use of MHV. They complete survey rounds 1 and 2 before the training and survey round 3 after the training.
62199867|NCT01597843|NO_INTERVENTION|Education after data collection complete|This group received a similar intervention, but after all quantitative data collection complete.
62199868|NCT03752177|EXPERIMENTAL|LY3415244 Dose Escalation|Participants received 3 milligrams (mg) LY3415244 (Cohort A1), 10 mg LY3415244 (Cohort A2), 30 mg LY3415244 (Cohort A3) and 70 mg LY3415244 (Cohort A4) as an intravenous (IV) infusion on day (D)1 and D15 of each 28-day cycle every 2 weeks (Q2W).
62199869|NCT03752177|EXPERIMENTAL|LY3415244 Dose Expansion|Phase 1b dose expansion was planned but not initiated as dose escalation ended at cohort A4. Study did not achieve its primary objective of establishing a recommended phase 2 dose (RP2D) due to early termination of the study by Cohort A4.
62199870|NCT03423927|EXPERIMENTAL|Intervention group : hypnosis + self-care|Groupal intervention combining self-care techniques and self-hypnosis exercises
62577752|NCT01139593||evening dose|Women undergoing IVF/ICSI taking their gonadotropin in the evening
62577753|NCT06373601|EXPERIMENTAL|sirolimus-eluting balloon (Selution)|DCB angioplasty with a sirolimus-eluting balloon
62577754|NCT06373601|ACTIVE_COMPARATOR|paclitaxel-eluting balloon (SeQuent Please Neo)|DCB angioplasty with a paclitaxel-eluting balloon
62577755|NCT04493515|EXPERIMENTAL|Oral Oxytocin|Oxytocin orally (24 IU)
62199871|NCT03423927|NO_INTERVENTION|Control group : no intervention|Control group receiving usual care but not the intervention
62199872|NCT00911768|EXPERIMENTAL|Korean Red Ginseng group|The brand name of experimental drug is 'Capsule of Korean Red Ginseng Powder'. It consists of the powder of steamed root of Panax ginseng made by Korean Ginseng Corp.
62199873|NCT00911768|PLACEBO_COMPARATOR|Corn-starch powder with ginseng flavor|The placebo of this study is corn-starch powder with Korean Red Ginseng flavor. It has the same shape, color and flavor like experimental drug.
62577756|NCT04493515|PLACEBO_COMPARATOR|Oral Placebo|Placebo orally (24 IU, identical ingredients, except the active agent)
62577757|NCT03059745||Cholecystitis|Patients consented for robotic assisted cholecystectomy evaluated in study.
62577758|NCT04237064||Patients with carotid artery stenosis|In this study, patients in the age of \> 18 year will be included that are scheduled for an endarterectomy procedure at CZE.
62784587|NCT06436703|EXPERIMENTAL|SSA: Influenza ModRNA Vaccine 3A|- Single Dose on Day 1
62577759|NCT04632082|EXPERIMENTAL|Intervention: Telepsychoeducation with personalized videos|One psychoeducation session administered by a therapist by video call, with interventions focused on promoting protective factors and reducing common risk factors for psychopathology. The intervention is complemented by the sending of 4 videos of 2 to 3 minutes, with psychoeducational content, sent each week by the therapist.
62577760|NCT04632082|ACTIVE_COMPARATOR|Comparator: Telepsychoeducation without personalized videos|One psychoeducation session administered by a therapist by video call, with interventions focused on promoting protective factors and reducing common risk factors for psychopathology.
62199874|NCT05548972|OTHER|G7 Dual Mobility with Vivacit-E polyethylene bearing in primary THA|Subjects in need of a total hip arthroplasty who meet inclusion/exclusion criteria (anticipated enrollment: 60)
62199875|NCT05548972|OTHER|G7 Dual Mobility with Vivacit-E polyethylene bearing in revision (total) hip arthroplasty|Subjects in need of a revision (total) hip arthroplasty who meet inclusion/exclusion criteria (anticipated enrollment: 119)
62577761|NCT00977080|ACTIVE_COMPARATOR|IV Paricalcitol|Participants in the IV stratum received intravenous (IV) paricalcitol and, if hypercalcemia (calcium \>= 10.5 mg/dL), received 30 mg of oral cinacalcet. Paricalcitol was dosed at 0.07 mcg/kg with titration every 2 weeks.
62577762|NCT00977080|ACTIVE_COMPARATOR|Cinacalcet (at sites with IV paricalcitol)|Participants in the IV stratum received 30 mg of oral cinacalcet daily with a low-dose vitamin D receptor activator (VDRA) (doxercalciferol IV 1 mcg 3 times weekly (TIW) at sites in the US and alfacalcidol capsules 0.25 mcg daily at sites in Russia).
62199876|NCT05548972|OTHER|G7 Dual Mobility with Longevity polyethylene bearing in primary THA|Subjects in need of a total hip arthroplasty who meet inclusion/exclusion criteria(anticipated enrollment: 60)
62577763|NCT00977080|ACTIVE_COMPARATOR|Oral paricalcitol|Participants in the oral stratum received oral paricalcitol and, if hypercalcemia (calcium \>= 10.5 mg/dL), received 30 mg of oral cinacalcet. Paricalcitol was dosed at mcg = IPTH/60 3 times weekly (TIW) with titration every 2 weeks.
62577764|NCT00977080|ACTIVE_COMPARATOR|Cinacalcet (at sites with oral paricalcitol)|Participants in the oral stratum received 30 mg of oral cinacalcet daily with a low-dose vitamin D receptor activator (VDRA) (alfacalcidol capsules 0.25 mcg daily).
62784588|NCT06436703|EXPERIMENTAL|SSA: Influenza ModRNA Vaccine 4A|- Single Dose on Day 1
62199877|NCT05548972|OTHER|G7 Dual Mobility with Vivacit-E Longevity bearing in revision (total) hip arthroplasty|Subjects in need of a revision (total) hip arthroplasty who meet inclusion/exclusion criteria (anticipated enrollment: 119)
62199878|NCT02380053|EXPERIMENTAL|Bisoprolol|2.5mg once daily for 2 weeks then 5mg once daily for 2 weeks.
62401051|NCT01258010|EXPERIMENTAL|Tranexamic acid|Study subjects will be randomized to receive a bolus dose of 30 mg/kg of tranexamic acid administered over 30 minutes starting after the induction of anesthesia followed by a continuous intravenous infusion of tranexamic acid of 16 mg/kg/h administered up to 6 hours after surgery.
62401052|NCT01258010|PLACEBO_COMPARATOR|Normal saline (NaCl 0.9%)|Study subjects will be randomized to receive a bolus dose of normal saline (NaCl 0.9%) of equivalent volume administered over 30 minutes starting after the induction of anesthesia followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
62577765|NCT02530125|EXPERIMENTAL|Treatment (pidilizumab)|Patients receive pidilizumab IV over approximately 5 hours on day 1. Treatment repeats every 42 days for 3 courses in the absence of disease progression or unacceptable toxicity.
62784589|NCT06436703|EXPERIMENTAL|SSA: Influenza ModRNA Vaccine 5A|- Single dose on Day 1
62784590|NCT06436703|ACTIVE_COMPARATOR|SSA: QIV1|- Single dose on Day 1
62784591|NCT06436703|EXPERIMENTAL|SSB: Influenza ModRNA Vaccine 3B|- Single Dose on Day 1
62199879|NCT02380053|EXPERIMENTAL|Celiprolol|200mg once daily for 2 weeks then 400mg once daily for 2 weeks.
62199880|NCT01425619|PLACEBO_COMPARATOR|Placebo cream, Skin test, Anxiety, Pain|After placing a placebo cream on both arms, pain and anxiety resulting from performing allergy skin test on one of the arms will be evaluated
62199881|NCT01425619|ACTIVE_COMPARATOR|Anesthetic cream, pain and anxiety, skin test|After placing a placebo cream on one arm and anesthetic cream on the second arm, pain and anxiety resulting from performing allergy skin test on the second arm will be evaluated
62199882|NCT01425619|ACTIVE_COMPARATOR|Medical clown, placebo cream, skin test|After placing a placebo cream on both arms and after receiving care and treatment from a medical clown, pain and anxiety resulting from performing allergy skin test on one of the arms will be evaluated
62199883|NCT01425619|ACTIVE_COMPARATOR|Medical clown, Anesthetic cream, Skin test|After placing a placebo cream on one arm and anesthetic cream on the second arm and after receiving care and treatment from a medical clown, pain and anxiety resulting from performing allergy skin test on the second arm will be evaluated
62784592|NCT06436703|EXPERIMENTAL|SSB: Influenza ModRNA Vaccine 4B|- Single Dose on Day 1
62784593|NCT06436703|EXPERIMENTAL|SSB: Influenza ModRNA Vaccine 5B|- Single dose on Day 1
62784594|NCT06436703|ACTIVE_COMPARATOR|SSB: QIV2|- Single Dose on Day 1
62784595|NCT06436703|ACTIVE_COMPARATOR|SSB: QIV3|- Single Dose on Day 1
62784596|NCT06436703|EXPERIMENTAL|SSC: Influenza ModRNA Vaccine 3C|- Single Dose on Day 1
62784597|NCT06436703|EXPERIMENTAL|SSC: Influenza ModRNA Vaccine 4C|- Single Dose on Day 1
62401053|NCT02110966|EXPERIMENTAL|Mepivacaine plus Tramadol|1.3 ml of Mepivacaine 2% epinephrine 1:100000 mixed with 0.5 ml of Tramadol (50mg/ml) will be used for the anesthetic blockade in the experimental group
62401054|NCT02110966|ACTIVE_COMPARATOR|Mepivacaine|The control group will receive the inferior alveolar nerve block using 1.8 ml of Mepivacaine 2% epinephrine 1: 100000.
62401055|NCT05079711||Symptomatic for vaginal yeast|Women presenting to the clinic with symptoms of vulvovaginal candidiasis.
62401056|NCT05079711||Asymptomatic for vaginal yeast|Women presenting to the clinic with no symptoms of vulvovaginal candidiasis.
62401057|NCT04035707|EXPERIMENTAL|anaesthesia with rocuronium|rocuronium is used during anaesthesia
62401058|NCT04035707|EXPERIMENTAL|anaesthesia without rocuronium|during anaesthesia rocuronium is not used
62784598|NCT06436703|EXPERIMENTAL|SSC: Influenza ModRNA Vaccine 5C|- Single Dose on Day 1
62401059|NCT04745624||manual compression cohort|Manual compression cohort: Patients who underwent coronary or peripheral angiograms via CFA access with moderate to severe stenosis were hemostasis was achieved via manual compression
62401060|NCT04745624||VASCADE cohort|VASCADE cohort: Patients who underwent coronary or peripheral angiograms via CFA access with moderate to severe stenosis were hemostasis was achieved via VASCADE device closure
62199884|NCT05845203|EXPERIMENTAL|transcranial doppler and pulsatility measurements|"PATIENT and HEALTHY VOLUNTEERS:~The intervention consists of:~- perform a simultaneous bilateral DTC acquisition of 20 seconds per hemisphere, and The ultrasound system used will be: ArtUS ultrasound system (Telemed, Vilnius, Lithuania), with transcranial probe P5-1S15-A6.~Two identical devices (ultrasound + probe) will be used, each scanning a cerebral hemisphere. They each carry the CE mark and will be used in accordance with the CE mark. https://www.pcultrasound.com/products/products_artus/"
62199885|NCT02071277|EXPERIMENTAL|Pressure targeted modes|
62199886|NCT03718377|EXPERIMENTAL|Serratus plane block|The subjects were received serratus plane block in the regional-anesthesia unit out of operation room before induction of general anesthesia. And, video-assisted thoracic surgery was performed under balanced general anesthesia.
62199887|NCT03718377|ACTIVE_COMPARATOR|General anesthesia only|Video-assisted thoracic surgery was performed under balanced general anesthesia without serratus plane block
62199888|NCT03944655|ACTIVE_COMPARATOR|Strepsils|
62199889|NCT03944655|PLACEBO_COMPARATOR|Placebo|
62199890|NCT05168462|EXPERIMENTAL|Reduced noradrenaline (MAP ≥ 55 mmHg)|
62199891|NCT05168462|NO_INTERVENTION|Usual care (MAP ≥ 65 mmHg)|
62401061|NCT03461393||Intervention Group|Repetitive Training with Medical-Eye-Trainer (MET)
62401062|NCT05382026|EXPERIMENTAL|1% chocolate milk|250 ml of 1% chocolate milk consumed immediately after resistance training sessions + 250 ml of chocolate milk consumed 1 hour after resistance training sessions
62577766|NCT06063642|EXPERIMENTAL|Experimental neurofeedback intervention|In an approximately 30-minute training session, participants receive activity feedback from a midbrain region involved in reward processing and gaming addiction. Feedback will be presented in the form of a thermometer/bar in the middle of the screen and updated every two seconds. They will be trained to down-regulate the activity in this region with the help of this feedback using cognitive strategies. This down-regulation training is believed to be beneficial to addictive behaviors by the investigators.
62784599|NCT06436703|EXPERIMENTAL|SSC: Influenza ModRNA Vaccine 6C|- Single Dose on Day 1
62784600|NCT06436703|EXPERIMENTAL|SSC: Influenza ModRNA Vaccine 7C|- Single Dose on Day 1
62199892|NCT03455998||post surgery|Patienst consultation Questionnaires
62199893|NCT03455998||pre and post surgery|Patient consultation Questionnaires
62199894|NCT04954326|EXPERIMENTAL|S95014 lyophilizate|Lyophilized S95014 reconstituted will provide 5 mL of extractable volume with the concentration of 750 U/mL. The vial of lyophilized powder (3.750 U/vial) is reconstituted with 5.2 mL of Sterile Water for Injection to obtain a 750 U/mL solution for single use.
62199895|NCT04954326|ACTIVE_COMPARATOR|S95014 liquid|Liquid S95014 is provided as 3.750 U per 5 mL solution in a single use vial to obtain a 750 U/mL solution for single use.
62199896|NCT06181253|EXPERIMENTAL|Prehabilitation group|Watch a video created by the investigators, discussing exercise prior to surgery, receive text message reminders to begin exercise before surgery, and take walking tests before and after surgery.
62199897|NCT06181253|NO_INTERVENTION|Control group|Receive the usual preoperative and post operative care and they will be provided a pedometer.
62199898|NCT04444934||Patients with not-surely pathologic diaphragmatic peritoneum|The definition of not-surely pathologic diaphragmatic peritoneum was given in association with the presence of flat dyschromic areas.
62401063|NCT05382026|ACTIVE_COMPARATOR|Pea-based beverage|250 ml of pea beverage consumed immediately after resistance training sessions + 250 ml of pea beverage consumed 1 hour after resistance training sessions
62784601|NCT06436703|EXPERIMENTAL|SSC: Influenza ModRNA Vaccine 8C|- Single Dose on Day 1
62199899|NCT04444934||Patients with certainly pathologic diaphragmatic peritoneum|The definition of certainly pathological diaphragmatic peritoneum was given when isolated or confluent thick nodules were visualized at the intra-operative inspection.
62199900|NCT04625959|ACTIVE_COMPARATOR|Base BT|16 weekly sessions of behavioral therapy.
62199901|NCT04625959|EXPERIMENTAL|Base BT + Distress Tolerance|16 weekly sessions of behavioral therapy with distress tolerance components of MABTs.
62199902|NCT04625959|EXPERIMENTAL|Base BT + Emotion Regulation|16 weekly sessions of behavioral therapy with emotion regulation components of MABTs.
62199903|NCT04625959|EXPERIMENTAL|Base BT + Mindful Awareness|16 weekly sessions of behavioral therapy with mindful awareness components of MABTs.
62199904|NCT04625959|EXPERIMENTAL|Base BT + Values|16 weekly sessions of behavioral therapy with values components of MABTs.
62199905|NCT04625959|EXPERIMENTAL|Base BT + Distress Tolerance and Emotion Modulation|16 weekly sessions of behavioral therapy with emotion regulation and distress tolerance components of MABTs.
62199906|NCT04625959|EXPERIMENTAL|Base BT + Distress Tolerance and Mindful Awareness|16 weekly sessions of behavioral therapy with distress tolerance and mindful awareness components of MABTs.
62199907|NCT04625959|EXPERIMENTAL|Base BT + Distress Tolerance and Values|16 weekly sessions of behavioral therapy with distress tolerance and values components of MABTs.
62199908|NCT04625959|EXPERIMENTAL|Base BT + Emotion Modulation and Mindful Awareness|16 weekly sessions of behavioral therapy with emotion regulation and mindful awareness components of MABTs.
62199909|NCT04625959|EXPERIMENTAL|Base BT + Mindful Awareness and Values|16 weekly sessions of behavioral therapy with values and mindful awareness components of MABTs.
62199910|NCT04625959|EXPERIMENTAL|Base BT + Emotion Modulation and Values|16 weekly sessions of behavioral therapy with emotion regulation and values components of MABTs.
62199911|NCT04625959|EXPERIMENTAL|Base BT + EM, DT, MA|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, and distress tolerance components of MABTs.
62199912|NCT04625959|EXPERIMENTAL|Base BT + DT, ER, and V|16 weekly sessions of behavioral therapy with emotion regulation, distress tolerance, and values components of MABTs.
62199913|NCT04625959|EXPERIMENTAL|Base BT + DT, MA, and V|16 weekly sessions of behavioral therapy with distress tolerance, mindful awareness, and values components of MABTs.
62401064|NCT05382026|PLACEBO_COMPARATOR|Placebo: Low protein plant-based beverage|250 ml of placebo beverage consumed immediately after resistance training sessions + 250 ml of placebo beverage consumed 1 hour after resistance training sessions
62401065|NCT04675502|EXPERIMENTAL|Supervised Exercise Group|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In this loading program; respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes is taken. Stretching exercises are done during the cooling period. This group was included in an exercise program 2 days a week, 45-90 minutes, for 12 weeks, accompanied by a specialist physiotherapist to the pulmonary rehabilitation unit in the chest diseases ward.
62784602|NCT06436703|EXPERIMENTAL|SSC: Influenza ModRNA Vaccine 9C|- Single dose on Day 1
62784603|NCT06436703|ACTIVE_COMPARATOR|SSC: QIV2|- Single Dose on Day 1
62784604|NCT06436703|ACTIVE_COMPARATOR|SSC: QIV3|- Single Dose on Day 1
62199914|NCT04625959|EXPERIMENTAL|Base BT + ER, MA, and V|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, and values components of MABTs.
62199915|NCT04625959|EXPERIMENTAL|Base BT + ER, MA, V, DT|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, distress tolerance, and values components of MABTs.
62199916|NCT05723757|EXPERIMENTAL|HS Patients|50 adult subjects suffering from moderate to severe HS, aged 18 to 65, diagnosed for at least 1 year
62199917|NCT02049853|NO_INTERVENTION|default group|"Patients with the randomization result default group receive standard diagnostics"
62199918|NCT02049853|ACTIVE_COMPARATOR|POCT group|"patients with the randomization result POCT group receive a NTproBNP measurement with point of care device Cobash232 in the ambulance vehicle"
62199919|NCT03559062|OTHER|Placebo|Participants with genotype F/F received placebo matched to TEZ/IVA fixed dose combination (FDC) in the morning and placebo matched to IVA in the evening for 8 weeks.
62199920|NCT03559062|EXPERIMENTAL|TEZ/IVA|Participants with genotype F/F received TEZ/IVA FDC in the morning and IVA in the evening for 8 weeks. Participants with genotype F/RF received TEZ/IVA FDC and placebo matched to IVA in the morning and IVA in the evening for 8 weeks.
62199921|NCT03559062|EXPERIMENTAL|Ivacaftor|Participants with genotype F/RF received placebo matched to TEZ/IVA FDC in the morning and IVA in morning and evening for 8 weeks.
62199922|NCT06358248||Patients treated|All patients treated with 4-fen PMEG endograft
62199923|NCT00767390||ACL Patch|
62199924|NCT01637077|EXPERIMENTAL|Arm I (pain therapy)|Patients receive pregabalin PO BID, beginning on the first night of chemotherapy, for 12 weeks and then QD for 1 week.
62199925|NCT01637077|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID, beginning on the first night of chemotherapy, for 12 weeks and then QD for 1 week.
62199926|NCT01480063||Fampyra|Fampyra administered as prescribed in routine clinical practice.
62199927|NCT03258320|EXPERIMENTAL|CDMS, Surgery|"Preoperative chemotherapy using Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.~Procedure: radical prostatectomy surgery."
62199928|NCT03258320|NO_INTERVENTION|Control|No neoadjuvant chemotherapy using CDMS will be done for patients who are diagnosed with localized prostate cancer but subject to direct surgery to radically remove the primary tumor.
62199929|NCT05674162|EXPERIMENTAL|Gait measurement|Use of four accellerometers/sensors (1 on each foot, one on the lumbar area and one on the sternum) that measure gait parameters during walking.
62199930|NCT03912662|OTHER|Hernia prevention cohort|single arm safety study, no control arm
62199931|NCT04148781|EXPERIMENTAL|Fampridine-SR|Fampridine-SR 10 mg Orally Twice Daily for 8 weeks.
62401066|NCT04675502|EXPERIMENTAL|Home Exercise Group|For patients to do at home (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), sitting and standing exhaustion, and brisk walking to reach 60-85% of the person's maximum heart rate.)), exercises is taught. Patients were asked to do the exercises at home for 45-90 minutes, 2 days a week, for 12 weeks. Participants of the control group are contacted every two weeks via communication methods such as e-mail, message and telephone conversation.Exercise diary is given to all patients and is taken from them at the end of the study.
62401067|NCT00981695|EXPERIMENTAL|Vaccinees|18 breast-fed and 18 formula-fed infants at the age of 20 weeks
62401068|NCT00981695|NO_INTERVENTION|Controls|18 breast-fed and 18 formula-fed infants at the age of 20 weeks
62401069|NCT00830726||1|Healthy volunteers
62199932|NCT01193413||Non-infected necrosis group|There is no necrosis infection in severe acute pancreatitis.
62401070|NCT00830726||2|Patients with symptomatic heart failure and EF \< 40%
62401071|NCT00830726||3|Patients with symptomatic aortic valve stenosis
62401072|NCT00830726||4|Patients with Acute Coronary syndromes prior to surgical intervention
62401073|NCT00830726||5|Patients with refractory stable angina requiring surgical intervention.
62199933|NCT01193413||Single drainage group|The patients with necrosis infection in severe acue pancreatitis were cured by single drainage.
62199934|NCT01193413||Combined surgery group|If there was no clinical improvement after single drainage about 7 days, an open necrosectomy was performed in the patients with necrosis infection.
62401074|NCT00830726||6|Patients with pulmonary hypertension and preserved systolic left ventricular function.
62401075|NCT01241591|EXPERIMENTAL|CP 690,550 5 mg BID+Placebo BIW|
62401076|NCT01241591|EXPERIMENTAL|CP 690,550 10 mg BID+Placebo BIW|
62401077|NCT01241591|ACTIVE_COMPARATOR|Placebo BID+Etanercept 50 mg BIW|
62401078|NCT01241591|PLACEBO_COMPARATOR|Placebo BID+Placebo BIW|
62401079|NCT02430064|EXPERIMENTAL|Low PAMP diet then high PAMP diet|All subjects on study proceed from 7 days low PAMP diet to 4 days high PAMP diet
62401080|NCT01813162|ACTIVE_COMPARATOR|Tenofovir 1% gel|Participants will vaginally insert 1 applicator of TFV gel twice a day for 7 days, with each dose inserted approximately 12 hours after the previous dose (for a total of 13 doses). Each applicator contains 4.4 gm of TFV 1% gel.
62401081|NCT01813162|ACTIVE_COMPARATOR|Vaginal product alone|"Participants will use their assigned vaginal product for 5 to 21 days depending on the dosing instructions for the particular product:~1. Terconazole 0.4% vaginal cream: once a day for seven days. 1 applicator (5 gm) of terconazole cream contains 20 mg terconazole.~2. Metronidazole gel: once a day for 5 days. 1 applicator (5 gm)of metronidazole gel contains 37.5 mg metronidazole.~3. Contraceptive IVR: insert ring and leave in place for 21 days; return to clinic for removal on day 21. The IVR contains two active components, etonogestrel (progestin) and ethinyl estradiol (estrogen)."
62401082|NCT01813162|EXPERIMENTAL|Vaginal product and Tenofovir 1% gel|"Tenofovir gel: Participants will vaginally insert 1 applicator of TFV gel twice a day for 7 days, with each dose inserted approximately 12 hours after the previous dose (for a total of 13 doses). Each applicator contains 4.4 gm of TFV 1% gel.~In addition, Participants will use their assigned vaginal product for 5 to 21 days depending on the dosing instructions for the particular product:~1. Terconazole 0.4% vaginal cream: once a day for seven days. 1 applicator (5 gm) of terconazole cream contains 20 mg terconazole.~2. Metronidazole gel: once a day for 5 days. 1 applicator (5 gm)of metronidazole gel contains 37.5 mg metronidazole.~3. Contraceptive IVR: insert ring and leave in place for 21 days; return to clinic for removal on day 21. The IVR contains two active components, etonogestrel (progestin) and ethinyl estradiol (estrogen). Use of TFV gel will begin on day 15 of IVR use."
62401083|NCT03465215|EXPERIMENTAL|Assessment of inflammation grade|Tissue obtained by CD patients will be analyzed using digital holographic microscopy and comparing histological analysis.
62401084|NCT04326309||Cohort 1|Individual Application Downloaders
62401085|NCT04326309||Cohort 2|Public Space and Vehicle Data Capture
62401086|NCT04326309||Cohort 3|Individuals dialing a voice-recording study phone number
62401087|NCT04326309||Cohort 4|Individuals utilizing study website's audio recording functionality
62401088|NCT04326309||Cohort 5|Individuals participating in Return-to-Work Project
62401089|NCT01098266|EXPERIMENTAL|A: NGR-hTNF + BIC|NGR-hTNF plus Best Investigator's Choice
62401090|NCT01098266|PLACEBO_COMPARATOR|B: Placebo+BIC|Placebo plus Best Investigator's Choice
62401091|NCT03416023|EXPERIMENTAL|Single|
62199935|NCT02402153|OTHER|Sydvestjysk Hospital|Investigation of EEG recording with the Hyposafe device
62199936|NCT04749680|EXPERIMENTAL|Peritoneal dialysis PD|Treatment for 2 weeks either with the comparators PD-Night or Homechoice PD cycler depending on the previous treatment (clinical phase I). At the end of these 2 treatment weeks and a subsequent training phase which up to 3 weeks, treatment with the Silencia PD cycler for 2 further weeks (clinical phase II).
62199937|NCT01549834|EXPERIMENTAL|ABT-126 Low Dose|low dose
62199938|NCT01549834|EXPERIMENTAL|ABT-126 High Dose|high dose
62199939|NCT01549834|PLACEBO_COMPARATOR|sugar pill|Placebo
62199940|NCT03422575|EXPERIMENTAL|Test|Etoricoxib 120Mg film-coated Tablet at single dose was given to subjects in this arm.
62199941|NCT03422575|ACTIVE_COMPARATOR|Reference|Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp \& Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk) was given to subjects in this arm.
62199942|NCT02927353|EXPERIMENTAL|DMB-3113|adalimumab biosimilar
62199943|NCT02927353|ACTIVE_COMPARATOR|adalimumab|adalimumab
62199944|NCT04779762|EXPERIMENTAL|Group 1|Standard induction regimen of Ustekinumab with the Crohn's disease exclusion diet (CDED)
62199945|NCT04779762|ACTIVE_COMPARATOR|Group 2|Standard induction regimen of Ustekinumab as above without diet
62401092|NCT02101957|EXPERIMENTAL|RP103|RP103 capsule, 16 capsules per day
62401093|NCT02101957|PLACEBO_COMPARATOR|placebo|placebo capsule, 16 capsules per day
62199946|NCT02690753|EXPERIMENTAL|Tailored repositioning + Standardised incontinence care + TAP|A protocol tailored to individual risk factors will be applied to patients at risk.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
62199947|NCT02690753|EXPERIMENTAL|Standard repositioning + Standardised incontinence care + TAP|Instead of developing and using a tailored pressure ulcer prevention protocol, patients will receive standard care.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
62199948|NCT02690753|NO_INTERVENTION|Usual care|Instead of developing and using a tailored pressure ulcer prevention protocol, patients will receive standard care. Instead of using comfort Shield® barrier cream cloths, incontinence care will be given to patients using the standard procedure on the ward. Instead of using the turn and position system, patients will be turned according to the standard procedure on the ward.
62199949|NCT00391703|EXPERIMENTAL|1|Quadriceps electrostimulation program, performed prior to an endurance retraining program using a cycloergometer
62199950|NCT00391703|ACTIVE_COMPARATOR|2|Usual sport activity, performed prior to an endurance retraining program using a cycloergometer
62199951|NCT05702385|NO_INTERVENTION|Standard Practice|The control group treats their simulated patients using standard practice and has no introduction to the new diagnostic test.
62199952|NCT05702385|EXPERIMENTAL|Intervention Group 1 - Test Results Given|Intervention Group 1 will receive information regarding the test and will be given the test results, whether selected or not, in Round 2 of CPV administration.
62199953|NCT05702385|EXPERIMENTAL|Intervention Group 2 - Test Results Optional|Intervention Group 2 will receive information regarding the test and will be given the test results if selected in Round 2 of CPV administration.
62784605|NCT00003512|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62199954|NCT01777165|EXPERIMENTAL|Arm 1 ABT-719 lower dose|
62199955|NCT01777165|EXPERIMENTAL|Arm 2 ABT-719 intermediate dose|
62199956|NCT01777165|EXPERIMENTAL|Arm 3 ABT-719 higher dose|
62199957|NCT01777165|PLACEBO_COMPARATOR|Arm 4 placebo|
62199958|NCT05427227||Gastrointestinal cancer (GI) patients receiving immunotherapy|
62199959|NCT05427227||GI patients receiving anti-HER2 therapy|
62401094|NCT06003283|EXPERIMENTAL|Tapering of rituximab based on disease activity guided dose reduction|"Treatment with rituximab every 6 months (24 weeks) with dosing based on disease activity, measured by the DAS28-CRP.~DAS28-CRP ≤ 3.2: dose reduction according to the following sequence: 1 x 1000 mg IV (maximum), 1 x 500 mg IV, 1 x 200 mg IV (minimum).~DAS28-CRP \> 3.2: administration of previously effective dose."
62199960|NCT05427227||GI patients receiving anti-CLDN18.2 therapy|
62199961|NCT01133418|EXPERIMENTAL|Cognitive Training|Computerized Progressive Attention Training
62199962|NCT01133418|SHAM_COMPARATOR|Non-progressive cognitive training|Children in the control condition will participate in the same tasks as children in the Intervention arm. They will experience the same number of blocks and trials of training as the intervention group. Further, their training will be conducted by the same set of trainers and for the same amount of time as the intervention group. However, children in the control group will remain at the lowest level for each CT task throughout training irrespective of performance.
62199963|NCT03799913|EXPERIMENTAL|anti-MESO CAR-T cells|Administration with anti-MESO CAR-T cells in the MESO-positive ovarian cancer patients
62199964|NCT05424146|PLACEBO_COMPARATOR|Placebo Non-Prebiotic Bar Group|This group of participants will be consuming non-prebiotic bars for the duration of the trial.
62199965|NCT05424146|ACTIVE_COMPARATOR|Prebiotic Bar Group|Participants will be asked to consume prebiotic bars for the duration of the trial.
62199966|NCT04190836|EXPERIMENTAL|Self-Managed Exercise Strategy|
62199967|NCT03381339|EXPERIMENTAL|Powered toothbrush intervention|Subjects will be provided an oscillating rotating powered toothbrush as the experimental intervention, and given written instructions on its proper use. Efficacy of overnight plaque reduction will be assessed at baseline and both gingivitis and plaque reduction will be assessed as change from baseline at 2, 4 and 12 weeks. Subjects will be given a standard fluoride toothpaste and asked to refrain from daily interproximal plaque control for the duration of the study.
62199968|NCT03381339|NO_INTERVENTION|Manual toothbrush|Subjects will be provided a manual toothbrush as the control group and given written instructions on its proper use. Efficacy of overnight plaque reduction will be assessed at baseline and both gingivitis and plaque reduction will be assessed as change from baseline at 2, 4 and 12 weeks. Subjects will be given a standard fluoride toothpaste and asked to refrain from daily interproximal plaque control for the duration of the study.
62199969|NCT04615195||children between 8 and 15 years old|answer to the CRIES 13 questionnaire
62199970|NCT06349447|EXPERIMENTAL|Experimental: LED irradiation|For therapeutic irradiation, the PIH model was induced on D1, and 830 nm (60 J/cm2, 50 mW/cm2) and 590 nm LED (20 J/cm2, 20 mW/cm2) were irradiated on D0, D1, D3, D6 and D8, respectively. For preventive irradiation, 830 nm and 590 nm LED were irradiated on D0, D1, D3, D6 and D8, respectively, and the PIE/PIH model was induced on D9.
62199971|NCT06349447|ACTIVE_COMPARATOR|Control|the PIH model was induced on D1 and without any LED exposition.
62199972|NCT03201510||Observational|Observational study
62199973|NCT02357602|EXPERIMENTAL|1. GS-7340 25mg|The first 8 women on study will be assigned to take a single dose of 25mg TAF (1 tablet) orally.
62401095|NCT06003283|ACTIVE_COMPARATOR|Tapering of rituximab based on interval prolongation|Treatment with fixed dose of rituximab (1 x 1000 mg IV) if DAS28-CRP ≥ 3.2 AND interval of at least 6 months (24 weeks) since previous administration of rituximab.
62401096|NCT02264340|ACTIVE_COMPARATOR|Control|Relaxation technique
62784606|NCT00535119|EXPERIMENTAL|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 3 and veliparib PO twice daily on days 1-7 until the recommended phase II dose is determined. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression or unacceptable toxicity.
62577767|NCT06063642|SHAM_COMPARATOR|Sham feedback intervention|In an approximately 30-minute training session, participants receive activity feedback from a brain region irrelevant to reward processing or gaming addictive behavior. The feedback presentation form and task instructions will be the same as for the experimental group. Based on the functional role of the feedback region, the investigators do not believe this feedback training will change the addictive behaviors of the participants who receive this intervention.
62577768|NCT04454983|EXPERIMENTAL|Lipiflow - All Subjects|Both Lipiflow and iLux procedures were performed bilaterally on all subjects on the same day. Subjects were randomized to which procedure they received first. There was a 1-hour wait between procedures.
62577769|NCT04454983|EXPERIMENTAL|iLux - All Subjects|Both Lipiflow and iLux procedures were performed bilaterally on all subjects on the same day. Subjects were randomized to which procedure they received first. There was a 1-hour wait between procedures.
62199974|NCT02357602|EXPERIMENTAL|2. GS-7340 10mg|The 2nd group of 8 women will be sequentially assigned to take a single dose of 10mg TAF (1 tablet) orally.
62199975|NCT02357602|EXPERIMENTAL|3. GS-7340 5mg|The final 8 women on study will be sequentially assigned to take a single dose of 5mg TAF (1/2 tablet) orally.
62199976|NCT01618747||Cohort|
62199977|NCT01385748|ACTIVE_COMPARATOR|Clonidine Lauriad® 50µg|50µg muco-adhesive buccal tablets, once de day, every day up to 8 weeks
62577770|NCT02166398|ACTIVE_COMPARATOR|Amosartan 5/50 tab|Amosartan 5/50 tab given by oral administration
62577771|NCT02166398|EXPERIMENTAL|UI15AML055MT tab|UI15AML055MT tab given by oral administration
62577772|NCT03668418||Colorectal cancer|Patients operated for colorectal cancer with or without liver metastasis undergoing a chemotherapy treatment after surgery
62199978|NCT01385748|ACTIVE_COMPARATOR|Clonidine Lauriad® 100µg|100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
62199979|NCT01385748|PLACEBO_COMPARATOR|Placebo Lauriad®|Placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
62577773|NCT03668418||Esophagus/gastric cancer|Patients operated for esophagus/gastric cancer undergoing a chemotherapy treatment after surgery
62577774|NCT03668418||Biliary duct cancer|Patients operated for biliary duct cancer undergoing a chemotherapy treatment after surgery
62577775|NCT03668418||Pancreatic cancer|Patients operated for pancreatic cancer undergoing a chemotherapy treatment after surgery
62577776|NCT03269630||Clinic patients (Comprehensive Pulmonary Hypertension Center)|"* Pulmonary hypertension patients (WHO group 1-5)~* Systemic sclerosis patients without pulmonary hypertension~* Mixed connective tissue disease patients without pulmonary hypertension"
62577777|NCT03269630||Outpatient right heart catheterization patients|-Outpatients undergoing right heart catheterization for any indication
62199980|NCT02930395||professional rugby players|
62199981|NCT04033965||women <35 with early breast cancer|
62199982|NCT04033965||women>65 years old with early breast cancer|
62199983|NCT04617314|EXPERIMENTAL|RC108|Participants will be allocated to one of the following dose groups: 0.1, 0.3, 0.9, 1.5, 2.0, 2.5, and 3.0mg/kg, and receive a treatment of RC108-ADC followed by 21 days of dose limited toxicity (DLT) observation period.
62199984|NCT05785923|EXPERIMENTAL|Echo Arm|Chest pain patients identified by their treating physician as being low-risk chest pain will undergo a point-of-care echocardiogram performed by a trained emergency medicine attending or resident prior to discharge from the emergency department. The physician of record will review this ultrasound and it will be documented whether the findings on the ultrasound changed the physician of record's disposition decision for the patient or the follow up instructions or medications.
62199985|NCT05785923|NO_INTERVENTION|Usual Care|Chest pain patients identified by their treating physician as being low-risk chest pain will receive the usual care for their condition.
62577778|NCT03269630||Healthy controls|"* Age\>18~* Not actively smoking~* No chronic medical conditions"
62577779|NCT03818633|EXPERIMENTAL|Elastic abdominal binder|
62577780|NCT03818633|NO_INTERVENTION|No binder|
62577781|NCT01864551|ACTIVE_COMPARATOR|lamotrigine|maintenance treatment of the patients with bipolar disorder with olanzapine or lamotrigine
62577782|NCT01864551|ACTIVE_COMPARATOR|olanzapine|maintenance treatment of the patients with bipolar disorder with olanzapine or lamotrigine
62577783|NCT03439761|EXPERIMENTAL|PT-112 Injection|PT-112 Injection alone
62577784|NCT04017507||Oscillating-rotating electric toothbrush|Twice daily brushing
62199986|NCT04151589|EXPERIMENTAL|Interventional Site|"The process below will be allocated in Interventional Sites:~1. At each interventional sites, implementing full assessment of current emergency work flow of acute ischemic stroke patients who eligible for endovascular treatment. All interventional sites would undergo assessment in order to form a baseline.~2. Drafting intervention approaches based on the assessment results of all interventional sites. These approaches are executable, reproducible, and measurable.~3. Emergency work flow management APP would be installed on smartphones of designated personnel at each interventional sites.~4. Both intervention approaches and APP would be incorporated with original work flow at each interventional site.~5. Training sessions would be held in interventional sites or online every 3 month once the patient enrolment begin.~6. Outcome data would be analysed and dispatched every 3 month for each interventional sites."
62199987|NCT04151589|NO_INTERVENTION|Control Site|The control site would not undergo any emergency work flow modification for acute ischemic stroke patients who eligible for endovascular treatment.
62199988|NCT01183039|ACTIVE_COMPARATOR|Ventilatory threshold|Training at the ventilatory threshold
62577785|NCT04017507||Side-to-side electric toothbrush|Twice daily brushing
62577786|NCT04017507||Manual toothbrush|Twice daily brushing
62577787|NCT05010252|EXPERIMENTAL|Cycled Light|It is planned to be in the Neonatal Intermediate Care Nursery, National Taiwan University Children's Hospital, and the subjects are premature babies over 32 weeks old. Divided into two groups of light intervention group and control group, longitudinal tracking intervention effect and six-weeks and three-months delay effect.
62577788|NCT05010252|NO_INTERVENTION|Dim light|no intervention
62577789|NCT03424902||group1|patients with no or mild paravalular leakage
62577790|NCT03424902||group 2|patients with moderate or or severe paravalvular leakage
62577791|NCT05767021|EXPERIMENTAL|Mirikizumab|Participants will receive mirikizumab intravenously (IV) and mirikizumab subcutaneously (SC).
62577792|NCT01343680|ACTIVE_COMPARATOR|10U/l heparin|
62577793|NCT01343680|EXPERIMENTAL|normal saline|
62577794|NCT06406907|EXPERIMENTAL|High Frequency Blood Flow Restriction Training Group|Subjects allocated to this group will perform squat exercise 6 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM.
62199989|NCT01183039|ACTIVE_COMPARATOR|Metabolic threshold|Training at the metabolic threshold
62577795|NCT06406907|EXPERIMENTAL|Low Frequency Blood Flow Restriction Training Group|Subjects allocated to this group will perform squat exercise 3 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM.
62577796|NCT06406907|EXPERIMENTAL|High Frequency Blood Flow Restriction Training Instability Group|Subjects allocated to this group will perform squat exercise 6 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM while standing on an unstable surface.
62577797|NCT06406907|EXPERIMENTAL|Low Frequency Blood Flow Restriction Training Instability Group|Subjects allocated to this group will perform squat exercise 3 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM while standing on an unstable surface.
62199990|NCT01260818|EXPERIMENTAL|Tranexamic Acid|
62401097|NCT02264340|EXPERIMENTAL|Experimental|Combined treatment
62401098|NCT05160766|ACTIVE_COMPARATOR|Comirnaty-Comirnaty-Comirnaty|Participants are already fully vaccinated with 3x Comirnaty (BNT162b2) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
62401099|NCT05160766|ACTIVE_COMPARATOR|Spikevax-Spikevax-Spikevax|Participants are already fully vaccinated with 3x Spikevax (mRNA-1273) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
62401100|NCT05160766|ACTIVE_COMPARATOR|Vaxzevria-Vaxzevria-Spikevax|Participants are already fully vaccinated with 2x Vaxzevria (ChAdOx-1-S) and 1x Spikevax (mRNA-1273) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
62401101|NCT05160766|ACTIVE_COMPARATOR|Vaxzevria-Vaxzevria-Comirnaty|Participants are already fully vaccinated with 2x Vaxzevria (ChAdOx-1-S) and 1x Comirnaty (BNT162b2) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
62577798|NCT06406907|SHAM_COMPARATOR|Control Group|The subjects of this group will perform squat exercise 6 days a week but without BFR. Pneumatic cuff will be wrapped around the thigh of the subjects but it would not be inflated.
62577799|NCT02128373|ACTIVE_COMPARATOR|Arm I (usual care)|Participants receive usual care (care from physician, physician nurse, and social worker) for 5 weeks. During the week 5 office visit, distance caregivers are not present. In the pre-physician interview patients will verbally complete the FACT, POMS-B, Tension-Anxiety subscale, Distress Thermometer. Distance caregivers will verbally complete the POMS-B, Tension-Anxiety subscale, and Distress Thermometer
62577800|NCT02128373|EXPERIMENTAL|Arm II (usual care with CLOSER intervention)|Participants receive usual care (care from physician, physician nurse, and social worker) for 5 weeks. During the week 5 office visit, distance caregivers will use a computer-assisted intervention to be present electronically with video and audio feed to provide psychosocial support. In the pre-physician interview patients will verbally complete the FACT, POMS-B, Tension-Anxiety subscale, Distress Thermometer. Distance caregivers will verbally complete the POMS-B, Tension-Anxiety subscale, and Distress Thermometer. Up to 96 hours after the week 5 visit, patients and caregivers will be interviewed about their experience during the intervention
62577801|NCT06095297|EXPERIMENTAL|CICT|Constraint-Induced Cognitive Therapy uses in-lab training on everyday activities with important cognitive components and procedures designed to transfer improvements from the treatment setting to every day life. This will be combined with computer-based processing speed training and non-invasive vagus nerve stimulation.
62199991|NCT01260818|PLACEBO_COMPARATOR|control group|
62199992|NCT02749097|EXPERIMENTAL|Cohort 1|Single oral dose of 10 mg SHR0534 or matching placebo
62199993|NCT02749097|EXPERIMENTAL|Cohort 2|Single oral dose of 25 mg SHR0534 or matching placebo
62199994|NCT02749097|EXPERIMENTAL|Cohort 3|Single oral dose of 50 mg SHR0534 or matching placebo
62199995|NCT02749097|EXPERIMENTAL|Cohort 4|Single oral dose of 100 mg SHR0534 or matching placebo
62199996|NCT02749097|EXPERIMENTAL|Cohort 5|Single oral dose of 200 mg SHR0534 or matching placebo
62199997|NCT02687035|EXPERIMENTAL|TAVR|Intermediate risk patients receiving transcatheter aortic valve replacement (TAVR)
62401102|NCT05160766|ACTIVE_COMPARATOR|Spikevax-Spikevax-Comirnaty|Participants are already fully vaccinated with 2x Spikevax (mRNA-1273) and 1x Comirnaty (BNT162b2) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
62577802|NCT06095297|EXPERIMENTAL|CICT + VR|Constraint-Induced Cognitive Therapy plus Vocational Rehabilitation uses in-lab training on everyday activities with important cognitive components and procedures designed to transfer improvements from the treatment setting to every day life. This will be combined with computer-based processing speed training and non-invasive vagus nerve stimulation. This group will also receive vocational rehabilitation from the Alabama Department of Rehabilitation Services, such as career counseling and building important career skills.
62199998|NCT01205022|EXPERIMENTAL|Arm I|Patients receive irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes once every 2 weeks. Patients also receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV over 25 minutes once in weeks 3 and 9.Treatment continues in the absence of disease progression or unacceptable toxicity.
62199999|NCT00022737|EXPERIMENTAL|Arm I|See Design Details.
62200000|NCT05970705|EXPERIMENTAL|A: Regorafenib+TAS-102 combination therapy|Regorafenib 80mg ,orally, once a day, d1-28, every 28 days, TAS-102，35mg/m2, orally，twice a day, d1-5 \& d15-19，every 28 days
62200001|NCT05970705|ACTIVE_COMPARATOR|B：Regorafenib monotherapy|Regorafenib, 120mg orally, once a day, d1-21, every 28 days (If the patient's body surface area is less than 1.5m2, the starting dose of regorafenib is 80mg)
62200002|NCT03749135|ACTIVE_COMPARATOR|Dupilumab|Dupilumab (anti-IL4Ra), s.c. administration
62200003|NCT03749135|PLACEBO_COMPARATOR|Placebo Comparator|matching Placebo, s.c. administration
62200004|NCT04513067|EXPERIMENTAL|Stage 1: Single agent|Intravenous weekly dose of YQ23 for 6 weeks with an ascending dose levels of 20, 30, 60, 90 and 120 mg/kg will be evaluated.
62200005|NCT04513067|EXPERIMENTAL|Stage 2: Combination Therapy|Intravenous weekly dose of YQ23 for 6 weeks with an ascending dose levels from 20 mg/kg to the MTD obtained from Stage 1 in combination of a fixed dose of 200 mg intravenous pembrolizumab given on the same day following YQ23 administration and every 3 weeks thereafter.
62401103|NCT05160766|ACTIVE_COMPARATOR|Comirnaty-Comirnaty-Spikevax|Participants are already fully vaccinated with 2x Comirnaty (BNT162b2) and 1x Spikevax (mRNA-1273) entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
62401104|NCT02751658|OTHER|patients in the Otorhinolaryngology|patients in the Otorhinolaryngology department realization of a levy into the mouth swab on the day of admission to hospital and the day of release
62401105|NCT04447963|EXPERIMENTAL|Non-invasive treatment of wrinkles and rhytids|"The subjects will be enrolled and assigned into one experimental study arm. The subjects will be required to complete three (3) treatment visits and two follow-up visits.~At the baseline visit health status will be assessed and, if needed, additional tests will be performed. Inclusion and exclusion criteria will be verified and informed consent will be signed.~The treatment administration phase consists of three (3) treatment visits, delivered 1 week apart.~At every treatment visit after the first, prior to the procedure, the participants will be assessed for adverse effects resulting from the previous treatment(s) with the BTL-785F device."
62401106|NCT04155567|EXPERIMENTAL|TAK-123|TAK-123 as 3.75 gram per square meter (g/m\^2) of sodium phenylacetate and 3.75 g/m\^2 of sodium benzoate, intravenous administration over 90 minutes, followed by TAK-123 as 3.75 g/m\^2 of sodium phenylacetate and 3.75 g/m\^2 of sodium benzoate, intravenous administration over 24 hours.
62577803|NCT06095297|ACTIVE_COMPARATOR|BFT|Brain Fitness Training involves in-lab training on relaxation, healthy nutrition, and healthy sleep with procedures designed to promote integration of these lifestyles into everyday life. This will be combined with computer-based reaction time training and non-invasive vagus nerve stimulation.
62577804|NCT06095297|ACTIVE_COMPARATOR|BFT + VR|Brain Fitness Training plus Vocational Rehabilitation involves in-lab training on relaxation, healthy nutrition, and healthy sleep with procedures designed to promote integration of these lifestyles into everyday life. This will be combined with computer-based reaction time training and non-invasive vagus nerve stimulation. This group will also receive vocational rehabilitation from the Alabama Department of Rehabilitation Services, such as career counseling and building important career skills.
62577805|NCT03825029|EXPERIMENTAL|Pillow Group|There will be a pillow placed between the patients legs during their operation.
62577806|NCT03825029|NO_INTERVENTION|Control Group|They will receive a normal total hip arthroplasty.
62577807|NCT04418596||Elite Soccer Players|Adolescent male aged 12-16 years old elite athletes that are recruited from special sport school in Leuven-Belgium and play football at a high level.
62200006|NCT01125033|EXPERIMENTAL|Vitamin C & Vitamin E.|The patients in this arm received one tablet of vitamin C (200 mg) and one capsule of vitamin E (400 mg) daily for 8 weeks
62200007|NCT01125033|EXPERIMENTAL|Vitamin C & Placebo|The patients in this arm received one tablet of vitamin C (200 mg) and one placebo capsule daily for 8 weeks.
62200008|NCT01125033|EXPERIMENTAL|Vitamin E & Placebo|The patients in this arm received one capsule of vitamin E (400 mg) and one placebo tablet daily for 8 weeks.
62200009|NCT01125033|PLACEBO_COMPARATOR|Double Placebo|The patients in this arm received one placebo capsule and one placebo tablet daily for 8 weeks.
62200010|NCT06118580|EXPERIMENTAL|Oral alcohol drink|
62200011|NCT06118580|PLACEBO_COMPARATOR|Placebo (non-alcohol drink)|
62200012|NCT05022433||Shukla|Shukla is a birth weight based formula to determine the insertional depth of the UVC
62200013|NCT05022433||UN-1|UN-1 is a body surface based formula to determine the insertional depth of the UVC
62200014|NCT01976247|ACTIVE_COMPARATOR|Noninvasive Cryolipolysis Device|The Zeltiq System is a noninvasive (not breaking the skin) device that reduces fat by freezing fat cells until they break apart.
62200015|NCT01976247|ACTIVE_COMPARATOR|High Intensity Focused Ultrasound Device|The LipoSonix System is a noninvasive ultrasound device, which can be used to selectively target and destroy fat tissue located deep under the skin.
62200016|NCT04396249|EXPERIMENTAL|Active tVNS group|The active tVNS group will be stimulated with 10 sessions of active transcutaneous vagal nerve stimulation (tVNS)
62200017|NCT04396249|SHAM_COMPARATOR|Sham tVNS group|The sham tVNS group will be stimulated with 10 sessions of sham transcutaneous vagal nerve stimulation (tVNS)
62200018|NCT02895932|EXPERIMENTAL|Case|Patients with diagnosed Parkinson's disease
62200019|NCT02895932|EXPERIMENTAL|Control|Healthy adults
62200020|NCT01682551|EXPERIMENTAL|Chinese Medicine|"The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day."
62200021|NCT01682551|PLACEBO_COMPARATOR|Acetazolamide|"If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang."
62200022|NCT05408247|EXPERIMENTAL|N-acetyl Cysteine|"Generic name: N-acetyl cysteine. Brand: ACC-600 (Acetylcysteine). Strength: 600mg per capsule. Form: capsule Route: oral Frequency: 2x capsules twice per day = total 4 capsules/day Duration: 12 weeks~+ Standard of Care: Medical Management."
62200023|NCT05408247|PLACEBO_COMPARATOR|Placebo|"Matched placebo~Generic name: dicalcium phosphate Strength: 600mg per capsule Form: capsule Route: oral Frequency: 2x capsules twice per day = total 4 capsules/day Duration: 12 weeks.~+ Standard of Care: Medical Management."
62200024|NCT00798291|PLACEBO_COMPARATOR|Ad lib diet/placebo|Ad lib diet and control product placebo
62200025|NCT00798291|EXPERIMENTAL|Ad lib diet/AN 777|Ad lib diet and AN 777
62200026|NCT00798291|ACTIVE_COMPARATOR|Ad lib diet/placebo/exercise|Diet ad lib; exercise; and placebo
62200027|NCT00798291|EXPERIMENTAL|Ad lib diet/ AN 777/ exercise|Diet ad lib; AN 777; exercise
62012277|NCT05351203|EXPERIMENTAL|Erector spinae group|● The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear high-frequency ultrasound transducer (Siemens acuson x300 3-5 MHz ultrasound) will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side.
62200028|NCT04340661|EXPERIMENTAL|Bionocol arm|
62200029|NCT04340661|PLACEBO_COMPARATOR|Placebo arm|
62200030|NCT03941600|ACTIVE_COMPARATOR|Community-based Exercise Intervention group (CBEI)|A group performing a 12-week guided exercise program at an accessible community health and wellness center
62200031|NCT03941600|PLACEBO_COMPARATOR|Exercise Education Control group (EEG)|A group receiving educational information about physical activity and exercise at home and then self-direction a 12-week exercise program on their own.
62200032|NCT03838731|EXPERIMENTAL|REGN1908-1909|
62200033|NCT03838731|PLACEBO_COMPARATOR|Placebo|
62200034|NCT02345109|EXPERIMENTAL|Transtek DUT|Which measured by DUT: GBF-835-N2, GBF-835-N2 Plus, LS202-B1, Ls202-B1 Plus, LS206-E1, LS206-E1 Plus, GBF-1251-B1, and GBF-1251-B1 Plus.
62200035|NCT02345109|EXPERIMENTAL|Reference|Measured by Reference: TRANSTEK® Glass Body Fat Analyzer GBF-1251-B, Tanita® Body Composition Monitor BC-533.
62200036|NCT04339712|EXPERIMENTAL|anakinra|In case of diagnosis of MAS, IV anakinra 200mg three times daily (every eight hours) for 7 days. Patients who will receive anakinra treatment and who suffer from kidney dysfunction will receive 50% of the dose i.e. 100mg anakinra three times daily for 15 days
62577808|NCT04418596||Recreational Soccer players (control)|Adolescent male aged 12-16 years old recruited from ordinary school in Flanders Belgium that play soccer or any other sport recreationally with no high intensity training
62577809|NCT02022384||study patients|Blood sample and life quality questionnaires
62577810|NCT01063426|EXPERIMENTAL|Atorvastatin + enoxaparine arm|High dose atorvastatin arm before index surgery+ conventional enoxaparin
62200037|NCT04339712|EXPERIMENTAL|tocilizumab|"In case of diagnosis of immune dysregulation IV tocilizumab 8mg/kg body weight once up to a maximum of 800mg. These patients will receive anakinra at the above dose in case they meet one of the following contra-indications for tocilizumab:~1. absolute neutrophil count less than 2,500/mm3;~2. absolute platelet count less than 100,000/mm3; and~3. AST or ALT more than 1.5 x the upper normal limit"
62200038|NCT01830647||Cohort|
62200039|NCT01436253||Croatian participants with hyperlipidemia|Participants being treated in a physician's office for hyperlipidemia who have not achieved target lipid levels on their current hypolipemic therapy.
62200040|NCT01400360|ACTIVE_COMPARATOR|invasive|After proof of perfusion relevant CVS in interventional therapy should be performed as best possible combination from TBA and intraarterial vasodilators additional to the conventional treatment.
62200041|NCT01400360|NO_INTERVENTION|conventional|After proof of perfusion relevant CVS only conventional treatment should be performed (no intraarterial therapy).
62200042|NCT06507280|EXPERIMENTAL|Gingivitis Group|In the first session, gingival crevicular fluid samples will be taken from teeth numbered 11,21, periodontal measurements will be made, plaques on the teeth will be cleaned and oral hygiene training will be performed. On the 7th and 30th days, gingival crevicular fluid will be taken again and periodontal measurements will be made.
62200043|NCT06507280|NO_INTERVENTION|Healthy Group|Gingival crevicular fluid samples will be taken from teeth numbered 11,21, periodontal measurements will be made
62200044|NCT02180373||vein graft bypass|patients who have had peripheral bypass
62200045|NCT02180373||SFA stent|Patients who have had SFA stenting
62200046|NCT06018662|NO_INTERVENTION|Control|Routine department therapy
62200047|NCT06018662|EXPERIMENTAL|Interventional|Anesthetics, antimicrobials and analgesics are selected and age/weight doses are calculated using the medication management mobile application
62200048|NCT05857254||Chronic intestinal failure patient|Patient with chronic intestinal failure and with home parenteral nutrition treatment stable for at least 3 months and with home parenteral nutrition treatment for at least 6 months.
62012278|NCT01256905|EXPERIMENTAL|Armodafinil|
62012279|NCT06663267||High Temperature Group|Participants experiencing temperatures above the 90th percentile for the region, as recorded during the summer months. Temperature data are sourced from local meteorological statio
62200049|NCT04686149||Neo CCRT+Neo CTx +/- cystectomy|Patients receive neoadjuvant CCRT and neoadjuvant CTx. Radical cystectomy is performed depending on pathologic response. The patients showing clinical complete response after neoadjuvant CCRT and initially stage T2N0M0 are not treated with neoadjuvant chemotherapy.
62200050|NCT00868153||Group 1|
62200051|NCT00561145|EXPERIMENTAL|Young men|Energy restriction period
62200052|NCT00561145|EXPERIMENTAL|Elderly men|Energy restriction period
62200053|NCT00910377|EXPERIMENTAL|visit with grandmother|Teenagers mothers and their grandmothers receive counseling sessions about breastfeeding and complementary feeding.
62200054|NCT00910377|EXPERIMENTAL|visit without grandmother|Teenagers mothers don´t live with their grandmothers and receive counseling sessions about breastfeeding and complementary feeding.
62200055|NCT00910377|NO_INTERVENTION|no visit with grandmother|Teenagers mothers live with their grandmothers and don´t receive counseling sessions about breastfeeding and complementary feeding.
62200056|NCT00910377|NO_INTERVENTION|no visit without grandmother|Teenagers mothers don´t live with their grandmothers and don´t receive counseling sessions about breastfeeding and complementary feeding.
62200057|NCT02489968|EXPERIMENTAL|empagliflozin 10 mg + linagliptin 5 mg|patient to receive a tablet containing low dose empagliflozin and linagliptin once daily
62200058|NCT02489968|EXPERIMENTAL|empagliflozin 10 mg|patient to receive a tablet containing low dose empagliflozin once daily
62200059|NCT02489968|EXPERIMENTAL|empagliflozin 25 mg + linagliptin 5 mg|patient to receive a tablet containing high dose empagliflozin and linagliptin once daily
62200060|NCT02489968|EXPERIMENTAL|empagliflozin 25 mg|patients to receive a tablet containing high dose empagliflozin once daily
62200061|NCT05880108|EXPERIMENTAL|Weight Loss|Participants will be asked to participate in a 1x/week center-based nutrition diet class, 2x/week center-based exercise classes, and 1x/week exercise session conducted on their own for 12 weeks.
62200062|NCT05880108|ACTIVE_COMPARATOR|Weight Stability|Participants will be asked to participate in a 1x/week center-based health education class, 2x/week center-based stretching/balance classes, and 1x/week stretching/balance session conducted on their own for 12 weeks.
62200063|NCT01622062|EXPERIMENTAL|Group 1|"Patients with WHO Category II exposure receive PEP with PVRV using one-week, 4-site (4-4-4-0-0) ID vaccination regimen, and a single-visit, 4-site booster vaccination with PVRV 5 years later"
62200064|NCT01622062|EXPERIMENTAL|Group 2|"Patients with WHO Category III exposure receive PEP with PVRV using one-week, 4-site (4-4-4-0-0) ID vaccination regimen and pERIG Favirab®, and a single-visit, 4-site booster vaccination with PVRV 5 years later"
62200065|NCT01622062|ACTIVE_COMPARATOR|Group 3|"Patients with WHO Category III exposure receive PEP with PVRV using the updated 2-site TRC (2-2-2-0-2) ID vaccination regimen and pERIG Favirab®, and a single-visit, 4-site booster vaccination with PVRV 5 years later"
62200066|NCT02668276|PLACEBO_COMPARATOR|Standard NCCN counseling|National Comprehensive Cancer Network (NCCN) counseling uses recommendations based on currently-accepted approaches to cancer treatment.
62200067|NCT02668276|EXPERIMENTAL|Standard NCCN counseling and Oncotype DX results|National Comprehensive Cancer Network (NCCN) counseling uses recommendations based on currently-accepted approaches to cancer treatment. The result provided by the Oncotype DX prostate test is called a Genomic Prostate Score (GPS). The GPS provides important information about how aggressive a man's cancer is based on the biology of the man's individual tumor.
62401107|NCT02549612|EXPERIMENTAL|Moniri Otovent|A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to ambu bag balloon. A safety valve is used to prevent too high air pressure. The ambu bag balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. On the first day, a low pressure balloon is used, then it is changed with a higher pressure balloon. If no effect is noticed, (the child should experience clicking sound in one or both ears) after day 3, the balloon is replaced with a new balloon with additionally higher pressure. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one week.
62401108|NCT02549612|NO_INTERVENTION|Control|No intervention is used in this group.
62012280|NCT06663267||Low Temperature Group|Includes participants from areas where winter temperatures are below the 10th percentile, based on historical weather data from local meteorological observations
62012281|NCT06663267||High Pollution Group|Participants in this group are those exposed to high levels of air pollutants
62012282|NCT06663267||Low Pollution Group|This cohort consists of individuals living in areas with air pollutant levels consistently below the national air quality standards
62012283|NCT00491790|SHAM_COMPARATOR|1|Sterile Water
62012284|NCT00491790|ACTIVE_COMPARATOR|Montelukast|Dissolved granules in sterile water
62200068|NCT03570723|ACTIVE_COMPARATOR|stepwise uterine devascularization|"Uterine hemostatic sutures, through examination of the placental bed, may use some hemostasis at the placental bed,overswing was commenced using endo-uterine sutures. If there is still significant bleeding, bilateral uterine artery ligation, and internal iliac artery ligation when needed.BUAL started immediately through blunt dissection downwards and laterally of the peritoneum covering the uterine isthmus and cervix. The peritoneum is mobilized freely at the uterine angles to expose both uterine arteries and avoid inclusion of the ureters in the ligation. The uterine artery pulsations were palpated digitally at the level of the internal os."
62200069|NCT03570723|EXPERIMENTAL|A glove-loaded Foley's catheter|A glove-loaded Foley's catheter tamponade, the internal os of the cervix was identified and a double-way 20 Fr Foley's catheter with a 30-50-ml balloon was inserted through the cervix to be handled by an assistant through the vagina and fixed to the patient's lower limb after inflation of the catheter balloon by 300 ml warm saline and pulling it against the lower uterine segment between the two transverse sutures. Only one glove-loaded Foley's catheter was used for tamponade.
62012285|NCT05540223|EXPERIMENTAL|DREAMS 3G RMS|Intervention with a DREAMS 3G Sirolimus Eluting Resorbable Coronary Magnesium Scaffold System
62012286|NCT05540223|ACTIVE_COMPARATOR|Xience DES|Intervention with a Xience Everolimus Eluting Stent System
62577811|NCT01063426|ACTIVE_COMPARATOR|Conventional Enoxaprin|Conventional Enoxaparin before 12hr and on 1-7th day after index surgery
62577812|NCT02008474|ACTIVE_COMPARATOR|Online weight loss + Incentives for behavior 3 months|
62577813|NCT02008474|ACTIVE_COMPARATOR|Online weight loss + Incentives for weight loss 3 months|
62577814|NCT02008474|ACTIVE_COMPARATOR|Online weight loss + Incentives for behavior 12 months|
62577815|NCT02008474|ACTIVE_COMPARATOR|Online weight loss + Incentives for weight loss 12 months|
62200070|NCT04627922|EXPERIMENTAL|N-acetyl cysteine (NAC) & cognitive behavioral therapy|N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
62200071|NCT04627922|PLACEBO_COMPARATOR|Placebo Comparator: Placebo & cognitive behavioral therapy|Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
62200072|NCT00081822|OTHER|Clofarabine + Ara-C|An initial dose escalation of clofarabine with a fixed standard dose of Ara-C in phase I will be used to determine an optimal phase II dose.
62401109|NCT03304886||Migraineurs|with a migraine
62577816|NCT02880878|EXPERIMENTAL|Early Surgical Hematoma Evacuation|Subjects will receive early surgical hematoma evacuation using Minimally Invasive Parafascicular Surgery (MIPS).
62012287|NCT01062685||Shock Cohort|"The SHOCK cohort will meet the American College of Chest physicians/Society of Critical Care Medicine criteria for septic shock, specifically:~* 1) Suspected infection~* 2) Any two of four criteria of systemic inflammatory response:~  * a. Temperature \> 100.4° or \< 96.8° F~ * b. Heart rate \> 90 beats/minute~ * c. Respiratory rate \> 20 breaths/min. or PaCO2 \< 32 mm Hg~ * d. WBC \>12,000 or \< 4000 cells/µL or \> 10% bands~* 3) Hypotension despite adequate fluid resuscitation:~  * a. SBP \< 90 mm Hg after 20cc/kg crystalloid"
62401110|NCT03304886||Control|Participants without migraine
62401111|NCT03730623|NO_INTERVENTION|Control group|Usual care. Conservative management of IC
62401112|NCT03730623|EXPERIMENTAL|Intervention|Supervised exercise
62401113|NCT05891795|EXPERIMENTAL|Clascoterone|
62401114|NCT05891795|PLACEBO_COMPARATOR|Vehicle|
62401115|NCT01631591||eosinophilic esophagitis|PATIENTS WITH A CURRENT DIAGNOSIS OF eosinophilic esophagitis.
62401116|NCT01631591||GERD|PATIENTS WITH A DIAGNOSIS WITH GERD.
62401117|NCT04198974|EXPERIMENTAL|PreVenture Training (PTtT)|Schools randomized to this arm will identify 4 staff members to participate in a 2-day training workshop + 3 hours of supervised practice and will be provided with access to screening and PreVenture intervention materials through the local trainer. Local trainers will deliver 2-day workshops and then supervise school staff in the delivery of two 90-minute group sessions (for at least one personality profile).
62401118|NCT04198974|EXPERIMENTAL|PreVenture Training + Implementation Facilitation (PTtT+IF)|Schools randomized this arm will receive the standard PreVenture TtT protocol plus an additional Implementation Facilitation package that will contain 3 new components designed to increase the likelihood that schools will continue to implement the program with high quality and satisfaction: 1) Youth Engagement, 2) ongoing coaching and supervision for Facilitators, and 3) access to easy-to-use performance metrics.
62577817|NCT02880878|NO_INTERVENTION|Medical Management|Subjects will receive standard of care medical management for ICH.
62577818|NCT03887676|ACTIVE_COMPARATOR|Arbaclofen|
62577819|NCT03887676|PLACEBO_COMPARATOR|Placebo|
62577820|NCT06540638|EXPERIMENTAL|web-based education program|Older surgical participants will receive a web-based educational program in promoting brain health (intervention). Participants will complete pre- and post-education questionnaires and a post-education satisfaction survey.
62577821|NCT02882217|ACTIVE_COMPARATOR|XC8 10mg|Cohort 1: 8 subjects will be randomized in a 3:1 ratio to be treated either with 10mg XC8 (6 subjects) or placebo (2 subjects, see placebo arm)
62577822|NCT02882217|ACTIVE_COMPARATOR|XC8 50mg|Cohort 2: 8 subjects will be randomized in a 3:1 ratio to be treated either with 50mg XC8 (6 subjects) or placebo (2 subjects, see placebo arm)
62577823|NCT02882217|ACTIVE_COMPARATOR|XC8 200mg|Cohort 3: 16 subjects will be randomized in a 3:1 ratio to be treated either with 200mg XC8 (12 subjects) or placebo (4 subjects, see placebo arm)
62577824|NCT02882217|PLACEBO_COMPARATOR|Placebo|Placebo comparator arm consists of 2 subjects in the cohorts 1 and 2 each and 4 subjects in the cohort 3.
62577825|NCT06491875|EXPERIMENTAL|Autism Spectrum Disorder|"1. Sensory integration training for children with ASD was conducted twice a week for two months (before Digital storytelling).~2. The digital storytelling study was conducted for 16 hours over two months."
62577826|NCT06491875|EXPERIMENTAL|Typically Developing Children|The digital storytelling study was conducted for 16 hours over two months.
62577827|NCT01839214|EXPERIMENTAL|VB-201 160mg|Subjects will received 80mg twice daily for 24 weeks.
62577828|NCT01839214|PLACEBO_COMPARATOR|Placebo with crossover to VB-201 160mg|Subjects on placebo will crossover to VB-201 160 at week 12.
62577829|NCT05497310|EXPERIMENTAL|Induction with attenuated ATO plus low-dose ATRA|Remission induction therapy will be administrated as ATRA 25/mg/m2/day for 28 continuous days without interruption if APL is suspected. ATO 0.3mg/kg/day for days 1-5 (5 doses) and then 0.25 mg/kg/day every other day twice a week for the next 3 weeks (6 doses).
62577830|NCT03883230||Patients with chronic wound|All patients will have a Glycologic infection detection test (GLYWD) taken. For this, a standard CE-marked sterile swab is used to take a wound exudate sample. This is then inserted in the GLYWD detection tube device. The device will contain two separate reagents, one in the clear plastic vial end and the other in the foil-sealed compartment. The sterile swab with the wound exudate sample will be pushed into the device, breaking the foil-sealed compartment and allowing the reagents to mix with the sample. the result of the test - to see if there is a bacterial infection present in the wound - is observed up to ten minutes later.
62577831|NCT03474731|EXPERIMENTAL|Diabetes Self-Management Program (DSMP) only|group education classes of the Diabetes Self-Management Program, (DSMP)
62577832|NCT03474731|EXPERIMENTAL|Tailored Patient Navigation (PN) only|assisting patients in navigation to physician offices, allowing for standard of care to follow.
62577833|NCT03474731|EXPERIMENTAL|DSMP AND Tailored Patient Navigation|Both group education classes and patient navigation
62577834|NCT03474731|ACTIVE_COMPARATOR|Diabetes Self-Management Program (DSMP) Delayed|group education classes of the Diabetes Self-Management Program, (DSMP)
62200073|NCT00846807||Patients 75 years or younger|
62401119|NCT04198974|NO_INTERVENTION|Control (TAU)|For schools randomized to this arm, students will have usual access to drug and alcohol prevention through the standard curriculum and mental health care provided through student counseling at the participating schools. The schools will be incentivized to participate in the study with the promise of free PreVenture training and materials in subsequent years of the trial. Information on other drug prevention efforts implemented at the school will be collected, but the randomized design should control for any potential differences between intervention conditions on this random factor.
62401120|NCT02120456|EXPERIMENTAL|LEO 43204|Open-label, dose-escalation, 2-day treatment
62401121|NCT02120456|EXPERIMENTAL|LEO 43204 Dose 0.1%|LEO 43204 dose 0.1% once daily for two consecutive days
62200074|NCT04356534|ACTIVE_COMPARATOR|Control group|local standard of care which include antivirals and supportive care
62401122|NCT02120456|EXPERIMENTAL|LEO 43204 Dose 0.075%|LEO 43204 dose 0.075% once daily for two days
62401123|NCT02120456|PLACEBO_COMPARATOR|Placebo|Placebo once daily for two days
62200075|NCT04356534|EXPERIMENTAL|Intervention group|convalescent patient plasma 400ml given as 200ml over 2 hours in 2 consecutive days, plus routine local standard of care
62200076|NCT01249846|EXPERIMENTAL|Arm 1|Each one of the two selected periodontal pockets (target pockets) will be randomized to the Frequent PerioChip® treatment or to the Routine PerioChip®.
62401124|NCT02291705|EXPERIMENTAL|rectus sheath block|rectus sheath block
62401125|NCT02291705|ACTIVE_COMPARATOR|tramadol|tramadol control group
62401126|NCT03023358|EXPERIMENTAL|chidamide regimen|patients receive chidamide (30mg twice every week) po, cyclophosphamide (750mg/m2) iv on day 1, liposomal doxorubicin (30mg/m2) iv on day 1, vincristine (1.4mg/m2, max to 2mg) iv on day 1 and prednisone (100mg/d) po on day 1-5.
62401127|NCT03023358|ACTIVE_COMPARATOR|CDOP regimen|patients receive cyclophosphamide (750mg/m2) iv on day 1, liposomal doxorubicin (30mg/m2) iv on day 1, vincristine (1.4mg/m2, max to 2mg) iv on day 1 and prednisone (100mg/d) po on day 1-5.
62401128|NCT02563574|EXPERIMENTAL|Motivational Interviewing Group|This group of participants will receive the motivational interviewing. In addition to blood specimen collection, a questionnaire assessment and neurocognitive assessments will also be performed.
62401129|NCT02563574|ACTIVE_COMPARATOR|Control Group|This group of participants will not receive motivational interviewing. They will have blood specimen collection, questionnaire assessment, and neurocognitive assessments performed.
62401130|NCT03957291|ACTIVE_COMPARATOR|Povidine-Iodine|patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye before operation
62401131|NCT03957291|ACTIVE_COMPARATOR|chlorhexidine|patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye before operation
62401132|NCT05428358|EXPERIMENTAL|Preoperative MRI|MRI before surgery.
62200077|NCT01249846|PLACEBO_COMPARATOR|Arm 2|Each one of the two selected target pockets will be randomized to the Frequent PerioChip® treatment or to the Frequent Placebo Chip treatment.
62200078|NCT05440253|EXPERIMENTAL|dry needling group|
62200079|NCT05440253|ACTIVE_COMPARATOR|ischaemic compression group|
62200080|NCT03842540|EXPERIMENTAL|SpeakOut Intervention|"Primary participants will be randomized to this arm or the Alcohol Control Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the SpeakOut intervention and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will not receive intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
62200081|NCT03842540|ACTIVE_COMPARATOR|PartyWise Intervention|"Primary participants will be randomized to this arm or the SpeakOut Intervention Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the Alcohol Control Intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will receive an intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
62200082|NCT00959686|EXPERIMENTAL|Bendamustine|Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
62200083|NCT04033302|EXPERIMENTAL|Single arm|Multiple CAR T cells to treat CD7-positive hematological malignancies
62200084|NCT01229605|EXPERIMENTAL|Single Arm|Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
62200085|NCT05573633|EXPERIMENTAL|smartwatches group|
62200086|NCT05573633|ACTIVE_COMPARATOR|no smartwatche group|
62200087|NCT01973153|ACTIVE_COMPARATOR|Brief Motivational Counseling (BMC)|3-5 minute BMC delivered by clinicians and nurses at well, sick, and WIC visits with the goal of reducing obesogenic behaviors. During BMC, the medical team facilitates the selection of a specific goal (i.e., reduce sugar sweetened beverage consumption) that is meaningful to the mother and teaches the mother simple behavioral strategies.
62200088|NCT01973153|ACTIVE_COMPARATOR|Brief Motivational Counseling Plus Phone Calls (BMC+Phone)|BMC as described above that is supplemented by monthly telephone contacts with community health workers designed to identify and overcome barriers to goal progress.
62200089|NCT01973153|ACTIVE_COMPARATOR|Brief Motivational Counseling Plus Home Visits (BMC+Home)|BMC as described above that is supplemented by monthly home visits with community health workers designed to identify and overcome barriers to goal progress.
62200090|NCT00897793||patients with epithelial cancers|Patients with head and neck cancer, and lung, breast, colorectal, and prostate cancers who are to undergo radiation therapy
62200091|NCT05084053|EXPERIMENTAL|Cohort 1: TAK-771 for CIDP Participants|TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 2, 3, or 4 weeks.
62200092|NCT05084053|EXPERIMENTAL|Cohort 2: TAK-771 for MMN Participants|TAK-771 includes IGI 10% and rHuPH20. Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 2, 3, or 4 weeks.
62200093|NCT03771105|EXPERIMENTAL|Patients with hereditary hypophosphatemic rickets with HHRH|Hereditary hypophosphatemic rickets with hypercalciuria (HHRH)
62200094|NCT03771105|ACTIVE_COMPARATOR|Patients with X-linked Hypophosphatemia|Patients with X-linked hypophosphatemia
62200095|NCT03771105|ACTIVE_COMPARATOR|15 Patients with X-linked Hypophosphatemia|15 Patients with X-linked Hypophosphatemia that will receive phosphate treatment for 30 days.
62200096|NCT03771105|ACTIVE_COMPARATOR|15 Patients Hereditary hypophosphatemic rickets with HHRH|15 patients withHereditary hypophosphatemic rickets with hypercalciuria (HHRH) that will receive phosphate treatment for 30 days.
62401133|NCT01347931|EXPERIMENTAL|NIOV System|Noninvasive ventilation and oxygen delivered via NIOV System oxygen using an open nasal interface. Connected to standard portable oxygen cylinder
62784607|NCT05502445|NO_INTERVENTION|Control Group|"This group will follow the hospital's standard nutritional assessment and monitoring flow:~* 24-hour recall: patients will be interviewed to report about one day of their usual diet.~* Application of a questionnaire: to assess the knowledge about the importance of protein intake in the prevention of sarcopenia and functionality, and whether the participant regularly performs physical activity.~* Energy and protein needs: estimated according to the clinical status and patient associated pathologies. The protocol of the Clinical Nutrition Service will be followed.~* Calculation of the Body Mass Index (BMI)~* Nutritional risk was determined using the Mini Nutritional Assessment-Short Form~* Screening for sarcopenia: SARC-F ,Calf Circumference and Hand Grip Strength"
62200097|NCT02609672|EXPERIMENTAL|Exercise|The participants in this arm were asked to attend 3 group classes per week for 12 weeks taught by a certified exercise instructor. Four class times were offered per week. These classes included a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements were obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
62401134|NCT01347931|ACTIVE_COMPARATOR|Standard Oxygen Therapy|Supplemental oxygen using standard oxygen cannula connected to a portable oxygen cylinder.
62401135|NCT05778682|EXPERIMENTAL|Suction based protocol|Weaning protocol based on suctioning frequency. Once the weaning of mechanical ventilation, the patients in this arm will be on high-flow nasal canula. The canula will be remove if the decannulation conditions are met (if the patient require less than 2 aspirations in 8 hours for 24 consecutive hours)
62401136|NCT05778682|OTHER|Usual care|Usual care will mainly base on the capping trial.
62200098|NCT02609672|OTHER|No Exercise|The participants in this arm were asked to refrain from changing their physical activity over the 12 weeks and maintain any strategies typically used to manage knee and/or hip pain. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the no exercise group were offered a free exercise pass following completion of the study. Measurements were obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
62577835|NCT05601115|EXPERIMENTAL|Robot Assisted Therapy Group|In addition to the conventional treatment for 60 minutes in the Robot asisted therapy (RAT) group, it was planned to perform robotic rehabilitation with a hand-finger robot \[Amadeo (Tyromotion, Graz, Austria)\] for 30 minutes, accompanied by a physiotherapist who is trained in the field of robotic rehabilitation and has at least 5 years of experience. For the purpose of conventional therapy, an exercise program consisting of 45 minutes of range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) accompanied by a physiotherapist experienced in stroke rehabilitation for at least 5 years, and neuromuscular therapy for the upper and lower extremities for 15 minutes.Electrical stimulation (NMES) application was planned. It was planned to apply a total of 60 sessions of treatment 5 days a week to both groups. They will be advised to continue the medical treatment they have been using during the treatment program.
62577836|NCT05601115|ACTIVE_COMPARATOR|Conventional Therapy Group|45 minutes of range of motion exercises, strengthening exercises, balance exercises and neurophysiological studies were performed in the presence of a physiotherapist experienced in stroke rehabilitation for at least 5 years.An exercise program consisting of exercises (Brunstroom exercises) and 15 minutes of NMES were planned. It was planned to apply a total of 60 sessions of treatment 5 days a week to both groups. They will be advised to continue the medical treatment they have been using during the treatment program.
62200099|NCT06092567|EXPERIMENTAL|Group A (Oblique Incremental Placement Techniique)|In this interventional group, a Nanohybrid composite resin Nexcomp (Meta Biomed, Korea) was placed using an oblique incremental technique with increments not exceeding 2 mm in thickness.
62200100|NCT06092567|EXPERIMENTAL|Group B (Bulk-fill Placement Technique)|In this group, a composite Beautifil-Bulk Restorative (SHOFU dental) was utilized for restorative purposes using a bulk-fill technique with a thickness of 4 mm.
62200101|NCT01318798||Patients with post-operative ARF|"Patients developing acute renal failure (ARF) following liver surgery~ARF was defined according to the RIFLE criteria as an absolute increase in serum-creatinine of more than 0.3 mg/dl above baseline, or an increase of more than 1.5 times the pre-operative baseline value within 48 hours after surgery, or a reduction of urinary output less than 0.5 ml/kg/h for at least 6 hrs."
62200102|NCT01318798||Patients without post-operative ARF|Patients with normal kidney function (without acute renal failure (ARF)) following liver surgery
62200103|NCT01244750||First line TKI treatment: Imatinib|Diagnosed CML patients who receive first line TKI treatment: Imatinib
62200104|NCT01244750||First line TKI treatment: Nilotinib|Diagnosed CML patients who receive first line TKI treatment: Nilotinib
62200105|NCT01244750||First line TKI treatment: Dasatinib|Diagnosed CML patients who receive first line TKI treatment: Dasatinib
62200106|NCT01244750||Imatinib treated patients|Imatinib treated patients if their study index date is between January 2, 2008 and September 30, 2010
62200107|NCT00447564|ACTIVE_COMPARATOR|Group A|
62577837|NCT03055312|ACTIVE_COMPARATOR|TPC chemotherapy|"Conventional chemotherapy(choose a):~TX (Taxotere and Xeloda),GT (Gemcitabine and Paclitaxel),GC (Gemcitabine and Carboplatin)"
62577838|NCT03055312|EXPERIMENTAL|Bicalutamide|Bicalutamide 150mg/day every 28 days
62577839|NCT03106766|EXPERIMENTAL|Acne cream 1x|Twice-daily facial applications of the 1X product (avoiding contact with eyes and all mucous membranes) to the entire face for 6 months.
62577840|NCT03106766|EXPERIMENTAL|Acne cream 2x|Twice-daily facial applications of the 2X product (avoiding contact with eyes and all mucous membranes) to the entire face for 6 months.
62577841|NCT03711682|EXPERIMENTAL|Cinnamon (Intervented)|
62577842|NCT03711682|PLACEBO_COMPARATOR|Wheat Flour (Placebo)|
62577843|NCT00691912|EXPERIMENTAL|Myocet/Paclitaxel|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
62200108|NCT00447564|PLACEBO_COMPARATOR|Group B|
62200109|NCT05422053|EXPERIMENTAL|t:slim X2 insulin pump with Control-IQ technology|Adults with type 1 diabetes will use the t:slim X2 insulin pump with Control-IQ technology 1.5 for 3-months of outpatient use. Meal and exercise challenges will be performed.
62200110|NCT01174069|EXPERIMENTAL|NOTES cholecystectomy|
62200111|NCT02993523|PLACEBO_COMPARATOR|Group 1 and Group 2: Placebo + Azacitidine 75 mg/m^2|Participants enrolled under original protocol and enrolled during or after protocol amendment 1 received venetoclax-matching placebo, orally, every day (QD), from Day 1 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m\^2, subcutaneously (SC) or intravenously (IV), QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).
62200112|NCT02993523|ACTIVE_COMPARATOR|Group 1 and Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2|Participants enrolled under original protocol and enrolled during or after protocol amendment 1 received venetoclax 100 mg, once orally, on Day 1 of Cycle 1 followed by venetoclax 200 mg, once orally, on Day 2 of Cycle 1 and venetoclax 400 mg, orally, QD, on Day 3 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m\^2, SC or IV, QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).
62577844|NCT04911023||Patients operated by fissurectomy|
62577845|NCT04911023||Patients operated by fissurectomy with anoplasty|
62577846|NCT02165280|ACTIVE_COMPARATOR|Guided IMagery (GIM)|If randomized to GIM, they will then be given an audio Compact Disc. Patients will be instructed to listen to the recording least once per day in a calm location during the week leading up to surgery. They will then be seen prior to surgery in the surgical waiting area where they will evaluated for anxiety, preparedness and study compliance.
62577847|NCT02165280|NO_INTERVENTION|Standard of Care (SOC)|"Each participant will complete a baseline set of questionnaires. The Pelvic Floor Distress Inventory (PFDI) is a 20 question self-administered questionnaire on the presence and both of pelvic floor symptoms .~The Pelvic Organ Prolapse Quantification System (POPQ) measures the topography of the vagina and is considered to be gold standard for quantifying prolapse .~The State-Trait Anxiety Inventory (STAI) has been used extensively in research and clinical practice since its introduction in 1966 and is the most widely cited measure of anxiety.~New measurements at the 6-week follow-up appointment will include the Patient Global Impression of Improvement (PGII), and a postoperative questionnaire eliciting overall satisfaction and development of new pelvic symptoms."
62012288|NCT01062685||Sepsis cohort|"The SEPSIS cohort will to meet:~* 1) Suspected infection~* 2) Any two of four criteria of systemic inflammatory response:~  * a. Temperature \> 100.4° or \< 96.8° F~ * b. Heart rate \> 90 beats/minute~ * c. Respiratory rate \> 20 breaths/min. or PaCO2 \< 32 mm Hg~ * d. WBC \>12,000 or \< 4000 cells/µL or \> 10% bands~* 3) Absence of refractory hypotension"
62012289|NCT01062685||Non-Infected controls|The third cohort will be comprised of uninfected ED control patients who met the criteria of no suspected infection, no SIRS criteria met and no evidence of hypoperfusion that are age and sex matched on a 1:1 basis with the shock cohort.
62200113|NCT02993523|ACTIVE_COMPARATOR|Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2|Participants received venetoclax 400 mg, orally, QD, from Day 1 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m\^2, SC, QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).
62200114|NCT04588129|EXPERIMENTAL|LB-102 50 mg, single dose Cohort 1|LB-102 (N-Methyl amisulpride) formulated capsule will be administered orally once daily for one day in 4 subjects.
62200115|NCT04588129|EXPERIMENTAL|LB-102 100 mg, single dose Cohort 2|LB-102 (N-Methyl amisulpride) formulated capsule will be administered orally once daily for one day in 4 subjects.
62200116|NCT04588129|EXPERIMENTAL|LB-102 75 mg, single dose Cohort 3|LB-102 (N-Methyl amisulpride) formulated capsule will be administered orally once daily for one day in 4 subjects.
62200117|NCT04588129|EXPERIMENTAL|LB-102 100 & 50 mg, multiple dose Cohort 4|LB-102 (N-Methyl amisulpride) formulated capsule will be administered orally once daily for four days in 4 subjects: 2 subjects @ 100 mg and 2 subjects @ 50 mg.
62200118|NCT03774615|EXPERIMENTAL|Ferric maltol 30 mg (Feraccru®)|Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks
62200119|NCT06242769|ACTIVE_COMPARATOR|Group I|Stannous Fluoride Toothpaste (SnF) Colgate Adult Extra Clean soft-bristle toothbrush brushing 2 X day for 2 min
62401137|NCT01973673|ACTIVE_COMPARATOR|Bone health educational materials|Bone health written educational materials, Bone health prescription,verbal counselling
62577848|NCT05258279|EXPERIMENTAL|Pemetrexed+Carboplatin+Pembrolizumab+Lenvatinib|Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years.
62577849|NCT04724538|EXPERIMENTAL|Healthy volunteers|CT-scans for exclusion of pneumonia. Accumulated absorbed dose calculation of volunteers' lungs after inhalation of 99mTc-pertechnetate aerosol from commercial gas generator which was loaded by 833 MBq of 99mTc-pertechnetate.
62577850|NCT04724538|EXPERIMENTAL|Patient with COVID-19 pneumonia|Inhalation of 99mTc-pertechnetate aerosol from commercial gas generator which was loaded by 4165 MBq of 99mTc-pertechnetate. CT scans a day before, 7 and 14 days after inhalation procedure. Blood tests a day before, 1, 3 and 7 days after inhalation procedure.
62577851|NCT04724538|NO_INTERVENTION|Patient with COVID-19 pneumonia without intervention|Blood tests at 1, 3 and 7 days.
62577852|NCT06047678|EXPERIMENTAL|Normotension group|Participants with normotension Adult: 40 - 63 years old Physically active - no professional sportsman
62577853|NCT06047678|EXPERIMENTAL|Hypertension Stage 1 group|Participants with Hypertension Stage 1 Adult: 40 - 63 years old Physically active - no professional sportsman.
62012290|NCT06377839|ACTIVE_COMPARATOR|With advanced platelet-rich fibrin in the ekstraction socket|Right or left side of the mandible
62012291|NCT06377839|PLACEBO_COMPARATOR|Without advanced platelet-rich fibrin in the ekstraction socket|Right or left side of the mandible
62012292|NCT04016168||Patients with DILD|Patients will be recruited at the consultations of the Rennes Rare Lung Disease Competence Centre. These will be patients in stable condition or in acute exacerbation of IPF.
62200120|NCT06242769|PLACEBO_COMPARATOR|Group II|Fluoride Toothpaste (CDC) Colgate Adult Extra Clean soft-bristle toothbrush brushing 2 X day for 2 min
62401138|NCT01973673|NO_INTERVENTION|Usual care|Usual clinical care to be provided by oncologists.
62401139|NCT02570945|EXPERIMENTAL|Intervention|Pharmacist-physician medication review
62012293|NCT06133582|EXPERIMENTAL|Internet-Based Psychodynamic Psychotherapy|Participants received the internet-based intervention for 10 weeks, supported by messages from their Therapeutic Support Worker.
62012294|NCT04891679|ACTIVE_COMPARATOR|Group A (Titrated OMS)|Titrated oral misoprostol solution
62012295|NCT04891679|ACTIVE_COMPARATOR|Group B (Static OMS)|Static oral misoprostol solution
62401140|NCT02570945|NO_INTERVENTION|Control|
62401141|NCT05110118|EXPERIMENTAL|LY01008|Single intravenous injection of LY01008 3 mg/kg for 90 min(±1 min).
62401142|NCT05110118|ACTIVE_COMPARATOR|Avastin|Single intravenous injection of Avastin 3 mg/kg for 90 min(±1 min).
62401143|NCT05697276|ACTIVE_COMPARATOR|Lidocaine|Patients will receive lidocaine
62401144|NCT05697276|EXPERIMENTAL|Bupivacaine|Patients will receive bupivacaine
62401145|NCT00386191|EXPERIMENTAL|1|50 mg
62401146|NCT00386191|EXPERIMENTAL|2|75 mg
62012296|NCT01548456||Intramedullary nailing|Subjects with a femur fracture who undergo operative fixation with an intramedullary nail
62401147|NCT02516449|EXPERIMENTAL|Patient decision aids|Participants read and fill a patient decision aid before being provided education on asthma.
62577854|NCT03243669|ACTIVE_COMPARATOR|Fujinon standard|
62012297|NCT01548456||Open Reduction Internal Fixation|Subjects with a femur fracture who undergo open reduction internal fixation with a dynamic compression plate
62401148|NCT02516449|NO_INTERVENTION|Usual care|Participants do not read and fill a patient decision aid before being provided education on asthma.
62577855|NCT03243669|ACTIVE_COMPARATOR|Fujinon HD|Fujinon high-definition
62577856|NCT03243669|ACTIVE_COMPARATOR|Fujinon HD + VC|Fujinon high-definition + virtual chromoendoscopy
62577857|NCT03243669|ACTIVE_COMPARATOR|Olympus standard|
62577858|NCT03243669|ACTIVE_COMPARATOR|Olympus HD|Olympus high-definition
62577859|NCT03243669|ACTIVE_COMPARATOR|Olympus VC|Olympus virtual chromoendoscopy
62577860|NCT03243669|ACTIVE_COMPARATOR|Olympus HD + VC|Olympus high-definition + virtual chromoendoscopy
62577861|NCT03243669|ACTIVE_COMPARATOR|Pentax standard|
62577862|NCT03243669|ACTIVE_COMPARATOR|Pentax HD|Pentax high-definition
62577863|NCT03243669|ACTIVE_COMPARATOR|Pentax VC|Pentax virtual chromoendoscopy
62012298|NCT04839497|EXPERIMENTAL|Volar Fibroblast Treatment|Volar fibroblasts are injected into the residual limb of transtibial amputees
62012299|NCT04839497|NO_INTERVENTION|Cryoprotectant|Vehicle Control. Interdermal injection of cryoprotectant
62401149|NCT01700894|EXPERIMENTAL|Walking Program + motivational interviewing calls|"The Women's Walking Program (WWP) core included a lifestyle PA prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every week for 5 weeks in the 1st 24 weeks and 1 3 months later) targeted to increase lifestyle PA in AA women.~Participant in the WWP plus motivational interviewing telephone call arm receives 11 motivational interviewing telephone calls from an interventionist, with two calls in between each of the group-visits. Motivational interviewing calls are tailored to the individual and intended to sustain intervention effects between group-visits"
62401150|NCT01700894|EXPERIMENTAL|Walking Program + automated calls|"The Women's Walking Program (WWP) core, including a lifestyle physical activity prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every 5 weeks during the first 24 weeks and 1 3 months later) targeted to increase lifestyle physical activity in African American women.~Participants in the WWP plus automated telephone call arm receive 11 automated calls with two calls sent between each group-visit. The automated calls are intended to supplement and sustain the intervention effects of the group-visits."
62401151|NCT01700894|EXPERIMENTAL|Walking Program|"The Women's Walking Program (WWP) core, including a lifestyle physical activity prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every 5 weeks during the first 24 weeks and 1 3 months later) targeted to increase lifestyle physical activity in African American women.~Participants in the WWP receive no telephone calls."
62401152|NCT02708576|EXPERIMENTAL|NGM313|Administration of active NGM313
62401153|NCT02708576|PLACEBO_COMPARATOR|Placebo|Administration of placebo comparator
62401154|NCT06014515|EXPERIMENTAL|Experimental: PET/CT scans|Each subject will undergo a dynamic 18F-FDG PET/CT scan and a dynamic 11C-butanol PET/CT scan on the EXPLORER total-body PET/CT system
62577864|NCT03243669|ACTIVE_COMPARATOR|Pentax HD + VC|Pentax high-definition + virtual chromoendoscopy
62577865|NCT00026494|EXPERIMENTAL|Temozolomide and Vinorelbine|Patients will be treated with vinorelbine on days 1 and 8 of each cycle; temozolomide will be administered on days 1 to 7 and 15 to 21 of each cycle. The dose level of temozolomide will be given at a dose of 150 mg/m2/day. A cycle will be defined as 28 days of treatment.
62577866|NCT05416580|EXPERIMENTAL|UDCA + metformin|"UDCA in addition to Metformin Treatment~All subjects will be treated with UDCA 1500 mg/day, and Metformin, up to 2000 mg/day, by oral administration, respectively, for 8 weeks."
62577867|NCT05416580|PLACEBO_COMPARATOR|Placebo + metformin|"Placebo of UDCA in addition to Metformin Treatment~All subjects will be treated with a Placebo of UDCA, and Metformin, up to 2000 mg/day, by oral administration, respectively, for 8 weeks."
62577868|NCT01704118|EXPERIMENTAL|I-gel|I-gel (Intersurgical Ltd, Wokingham, Berkshire, UK) is a disposable supraglottic airway device with a non-inflatable cuff in which part of that is fixed on glottis is made of thermoplastic elastomer, unlike other laryngeal masks
62401155|NCT03642002|EXPERIMENTAL|Toning|Vocal Tonal Holding
62577869|NCT01704118|ACTIVE_COMPARATOR|ProSeal Laryngeal mask|ProSeal laryngeal mask (PLMA) (LMA North America, Inc., San Diego, USA) is a modified type of LMA (larger and deeper bowl and enlarged and softer cuff) with gastric drainage tube.
62577870|NCT00616343|ACTIVE_COMPARATOR|Zonisamide|
62012300|NCT05785091||1|forward head posture with hamstring muscles tightness
62012301|NCT05785091||2|forward head posture with calf muscles tightness
62012302|NCT05785091||3|forward head posture and hamstring- calf muscles tightness
62012303|NCT05785091||4|forward head posture and lumber inflexibility
62012304|NCT05785091||5|forward head posture and hamstring- calf muscles tightness, lumber inflexibility
62012305|NCT04754581|OTHER|All Participants|
62012306|NCT00337649|EXPERIMENTAL|Phase I - Epothilone D Dose Escalation|
62401156|NCT03642002|OTHER|Ocean drum & SOK melody|Ocean drum followed by melody of song of kin
62401157|NCT03642002|EXPERIMENTAL|SOK|Song of kin with lyric content
62401158|NCT03642002|EXPERIMENTAL|Process|Processing of experience
62401159|NCT03642002|EXPERIMENTAL|Holding Harmonic Container|
62577871|NCT05087316|ACTIVE_COMPARATOR|Standard treatment|
62577872|NCT05087316|EXPERIMENTAL|Oral Appliance|
62577873|NCT00603902|EXPERIMENTAL|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening
62577874|NCT00603902|EXPERIMENTAL|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
62577875|NCT00603902|PLACEBO_COMPARATOR|Matching Placebo|Matching placebo tablet each morning and evening
62577876|NCT02185118|EXPERIMENTAL|oxygen plus isoflurane/sevoflurane|"All human peripheral blood mononuclear cells (PBMCs) were from patients with non sepsis/non SIRS/non infection.~The above cells were treated with oxygen or oxygen plus isoflurane/sevoflurane after stimulation of lipopolysaccharide/plasma from septic patients."
62577877|NCT03766867|EXPERIMENTAL|Vortioxetine|
62577878|NCT03766867|PLACEBO_COMPARATOR|Placebo|
62577879|NCT04316104|EXPERIMENTAL|CuidaTXT|This intervention, CuidaTXT \[Spanish for self-care and texting\], will be available in English and Spanish, incorporate two-way messaging and will tailor text messages to the preferences of Latino caregivers. CuidaTXT will be multicomponent and based on the Stress Process Framework as supported by evidence. The intervention will incorporate social support and coping components including dementia education, problem-solving skills training, social network support, care management and referral to community resources.
62200121|NCT05675813|EXPERIMENTAL|T1: CHOP+selinexor+5-Azacitidine (CHOPX2) vs CHOP|"Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T1 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and selinexor 40mg or 60mg qw (d-7, 1, 8) by traditional 3+3 dose escalation methods and decide RP2D of selinexor.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle."
62200122|NCT05675813|EXPERIMENTAL|T2: CHOP+duvelisib+5-Azacitidine vs CHOP|"Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T2 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and duvelisib 25mg or 50mg bid (d1-14) by traditional 3+3 dose escalation methods and decide RP2D of duvelisib.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle."
62577880|NCT04304599|EXPERIMENTAL|LoFric Elle|New hydrophilic female urinary catheter for single use. Ready-to-Use.
62012307|NCT00337649|EXPERIMENTAL|Phase II - Epothilone D Maximum Tolerated Dose|
62577881|NCT05901935|EXPERIMENTAL|DP303c|Eligible patients will be treated with DP303c at 3.0 mg/kg every 3 weeks.
62577882|NCT05901935|ACTIVE_COMPARATOR|Trastuzumab combined with vinorelbine/capecitabine|Eligible patients will be treated with trastuzumab IV on day 1 and oral capecitabine twice daily on days 1-14 every 3 weeks, or patients will be treated with trastuzumab IV on day 1 and vinorelbine IV over on days 1 and 8 every 3 weeks.
62012308|NCT05953584|EXPERIMENTAL|Etavopivat|Participants will receive Etavopivat 400 mg once daily (QD) orally.
62012309|NCT05953584|EXPERIMENTAL|Etavopivat with HU|Participants will receive Etavopivat 400 mg QD orally in combination with HU. The dose of HU (mg/kg) will be stable (no more than a 20% change in dosing except for weight-based changes) during the study, in the opinion of the Investigator.
62012310|NCT01786408|EXPERIMENTAL|TAP20-C|Single Use Integrated Capillary Blood Collection System
62012311|NCT01786408|ACTIVE_COMPARATOR|SAFE-T-FILL CAPILLARY SYSTEM|Single Use Capillary Blood Collection System
62012312|NCT04360200||Normal Aging|Normal Aging with normal cognitive function
62012313|NCT04360200||Mild cognitive impairment (MCI)|Mild cognitive impairment subjects with memory loss as predominant symptom
62012314|NCT04453852|EXPERIMENTAL|Group A|Spike antigen (25ug) + 15 mg Advax-2 adjuvant
62012315|NCT04453852|PLACEBO_COMPARATOR|Group B|Saline
62012316|NCT04543422|EXPERIMENTAL|Green tea extracts|Patients in this arm received green tea extract capsules
62200123|NCT05675813|EXPERIMENTAL|T3: CHOP+chidamide+tislelizumab （CHOPX2）vs CHOP|"Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T3 genetic subtype, for the remaining 5 cycles, they will receive tislelizumab 200mg d0 ivgtt and chidamide 20mg or 30mg biw (d1,4,8,11) by traditional 3+3 dose escalation methods and decide RP2D of chidamide.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T3 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle."
62577883|NCT01766193||vaginal birth|women whose first child was born by spontaneous vaginal delivery
62577884|NCT01766193||cesarean section|women whose first child was born by cesarean section
62577885|NCT01766193||forceps|women whose first child was born by forceps extraction
62577886|NCT01766193||vacuum|women whose first child was born by vacuum extraction
62577887|NCT03097276|OTHER|Patients who underwent open decompression surgery|
62012317|NCT04543422|PLACEBO_COMPARATOR|Placebo|Patients in this arm received placebo treatment
62012318|NCT04558476|EXPERIMENTAL|Convalescent Plasma|2 units of plasma ( 400-500ml) from 2 different donnors duration of treatment =2 h
62012319|NCT04558476|OTHER|Standard of care|Standard of care according the last gold standards
62200124|NCT01606410||young, sedentary|
62200125|NCT01606410||young, active|
62200126|NCT01606410||old, sedentary|
62200127|NCT01606410||old, active|
62200128|NCT04471831|EXPERIMENTAL|Stroke survivors with COVID19|The active intervention group
62401160|NCT03123627|EXPERIMENTAL|New profilaxis|Prophylaxis is discontinued when the patient developed CMV-specific cellular immunity.
62401161|NCT03123627|ACTIVE_COMPARATOR|Profilaxis recommended by TTS|Valganciclovir prophylaxis until day +90 as recommended by the International Consensus document of the TTS.
62200129|NCT04471831|PLACEBO_COMPARATOR|Non-stroke individuals with COVID19|Matching for age, sex and co-morbid status with the stroke survivors
62200130|NCT04553055||community pharmacists|
62200131|NCT04563039|EXPERIMENTAL|Ureteroscopic Laser Lithotripsy with Acoustic Enhancer|Ureteroscopic Laser Lithotripsy with Acoustic Enhancer
62200132|NCT04563039|ACTIVE_COMPARATOR|Standard Ureteroscopic Laser Lithotripsy|Standard Ureteroscopic Laser Lithotripsy
62401162|NCT01881867|NO_INTERVENTION|Cohort I (no therapy)|Patients receive no treatment (observation) after completion of standard sipuleucel-T therapy.
62401163|NCT01881867|EXPERIMENTAL|Cohort II (glycosylated recombinant human interleukin-7)|Patients receive glycosylated recombinant human interleukin-7 SC every week for 4 weeks (on days 0, 7, 14, and 21) beginning 3-7 days after completion of standard sipuleucel-T therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
62401164|NCT01619709|OTHER|lobar hemorrhage group|PET AV-45 in patients with cortical or corticosubcortical hemorrhage (involving predominantly the cortex and underlying white matter)
62401165|NCT01619709|OTHER|deep hemorrhage group|PET AV-45patients with subcortical hemorrhage (involving predominately the basal ganglia, periventricular white matter, or internal capsule).
62401166|NCT02463500||DFU with/without osteomyelitis|Patients of the investigators. Male and female, age 18 and older (up to age 89), of any race or ethnicities, who have diabetes (Type I or II) and a foot ulceration.
62401167|NCT01061398|EXPERIMENTAL|Cardiac CT Arm|Patients referred for stress imaging due to complaints consistent with possible angina, randomized to receive an additional cardiac CT scan.
62577888|NCT02122887|NO_INTERVENTION|control group|no intervention for 3 months
62577889|NCT02122887|EXPERIMENTAL|experimental group|Peace-Building Intervention Process- The intervention process consists of eight sessions and adheres to a manualized protocol that we developed. Each session lasts 120 minutes.
62577890|NCT03091543|EXPERIMENTAL|Sequence A (25 mg - 50 mg - 100 mg - 200 mg - Placebo)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
62577891|NCT03091543|EXPERIMENTAL|Sequence B (Placebo - 25 mg - 50 mg - 100 mg - 200 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
62577892|NCT03091543|EXPERIMENTAL|Sequence C (200 mg - Placebo - 25 mg - 50 mg - 100 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
62784608|NCT05502445|ACTIVE_COMPARATOR|Intervention Group|"In this group, the steps below are added:~* On the first day, the delivery of the leaflet on the importance of nutrition in the hospital environment will be added in addition to verbal guidance.~* On the second day, an educational institutional video with duration of two minutes, will be shown with the title Food Intake and Oral Supplement in Nutritional Rehabilitation via tablet or mobile phone.~* When the 24-hour recall will be collected, an assessment of food intake will be performed, mainly of foods that are sources of protein and, when they were less than 75%, strategies must be designed to increase the acceptance or indication of oral nutritional supplements (ONS)."
62784609|NCT04771637|PLACEBO_COMPARATOR|control with normal saline|
62784610|NCT04771637|EXPERIMENTAL|dexmedetomidine loading dose 1 µg/kg + maintenance dose 0.25 µg/kg/h|
62784611|NCT04771637|EXPERIMENTAL|dexmedetomidine loading dose 0.5 µg/kg + maintenance dose 0.5 µg/kg/h|
62784612|NCT04771637|EXPERIMENTAL|dexmedetomidine loading dose 1 µg/kg + maintenance dose 0.5 µg/kg/h|
62784613|NCT01122615|EXPERIMENTAL|Sunitinib + Temsirolimus|Sunitinib 12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle. Temsirolimus 6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.
62200133|NCT03880253|EXPERIMENTAL|CTP-692 Low Dose or Matching Placebo|Once daily dosing
62577893|NCT03091543|EXPERIMENTAL|Sequence D (100 mg - 200 mg - Placebo - 25 mg - 50 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
62577894|NCT03091543|EXPERIMENTAL|Sequence E (50 mg - 100 mg - 200 mg - Placebo - 25 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
62577895|NCT05326529|ACTIVE_COMPARATOR|Traditional Cardiac Rehabilitation (Hospital based programme)|Traditional Cardiac Rehabilitation will involve 8 hospital-based exercise sessions, and one virtual education day over 8 weeks, supervised by CR health care professionals.
62577896|NCT05326529|EXPERIMENTAL|Traditional combined with Web-based Cardiac Rehabilitation|Traditional combined with Web-based Cardiac Rehabilitation. Patients will attend 8 hospital-based exercise sessions and one virtual education day over 8-weeks with access to additional web-based (MyHeart app) exercise and educational information.
62200134|NCT03880253|EXPERIMENTAL|CTP-692 Mid Dose or Matching Placebo|Once daily dosing
62577897|NCT05326529|EXPERIMENTAL|Web-based Cardiac Rehabilitation|Web-based Cardiac Rehabilitation, using MyHeart app introduced during a pre-CR assessment, will follow an 8-week individualised self-managed platform, allowing contact with the CR health professionals via app messages only (no direct contact for web-based CR).
62577898|NCT04181528|EXPERIMENTAL|Anatomically aligned total knee arthroplasty|Use anatomically aligned TKA implant (Journey II Bi-cruciate substituting total knee system, JII-BCS, Smith \& Nephew) in patients undergoing unilateral TKA
62577899|NCT04181528|ACTIVE_COMPARATOR|Conventaional total knee arthroplasty|Use conventional TKA implant (Legion total knee system, JII-BCS, Smith \& Nephew) in patients undergoing unilateral TKA
62577900|NCT06510543|EXPERIMENTAL|Goal-directed enteral nutritional therapy|The participants will be administered a supervised goal-directed nutritional therapy. The enteral nutrition (EN) regimens include homemade meals with or without ORAL IMPACT® according to the daily goal.
62200135|NCT03880253|EXPERIMENTAL|CTP-692 High Dose or Matching Placebo|Once daily dosing
62200136|NCT00725335|EXPERIMENTAL|group A,non-pringle group|Intervention of curative resection of HCC Without pringle manoeuvre in this arm
62200137|NCT00725335|ACTIVE_COMPARATOR|pringle group(B)|when the curative resection of HCC performed, the pringle manoeuvre will be routinely applied.
62200138|NCT03004053||Volunteers will be identified by the Head and Neck Service|25 volunteers (Part I - 8 volunteers. Part II - 17 volunteers). during the course of 12 months. The volunteers will be imaged with the endoscope, and the images will be evaluated visually and with qualitative (descriptive) statistics.
62200139|NCT01435772|EXPERIMENTAL|BMN 701 20mg/kg|BMN 701 20mg/kg IV every other week
62200140|NCT01435772|EXPERIMENTAL|BMN 701 10mg/kg|BMN 701 10mg/kg IV every other week
62200141|NCT01435772|EXPERIMENTAL|BMN 701 5mg/kg|BMN 701 5mg/kg IV every other week
62200142|NCT03442946||INS|Patients in need of a cardiovascular surgery will be included in this observational study. The focus is on the nutrition therapies provided to these critically ill patients according to institutional or international nutrition guidelines, what ever applies for the participating sites.
62401168|NCT01061398|ACTIVE_COMPARATOR|No CT Arm|Patients with symptoms consistent with possible angina, randomized to receive the type of stress imaging test ordered by their physician.
62401169|NCT02042573|OTHER|Depressive patients treated with rTMS|
62401170|NCT02042573|OTHER|Depressive patients treated with SSRI|
62401171|NCT02042573|OTHER|Controls|
62577901|NCT06510543|ACTIVE_COMPARATOR|Conventional enteral nutritional therapy|The participants will be administered with an unsupervised and liberal nutritional support. The EN regimens will not include ORAL IMPACT®.
62784614|NCT05419934|EXPERIMENTAL|EMDR|"Patient receiving  EMDR therapy  over 6 to 10 sessions."
62784615|NCT05419934|SHAM_COMPARATOR|Routine Care|"Patient receiving the  routine care  over 6 to 10 sessions"
62577902|NCT00022698|EXPERIMENTAL|Cohort 1,Initial Regimen:(Capecitabine + Irinotecan )|Participants will receive capecitabine (Xeloda) 1000 mg/m\^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 125 mg/m\^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks. A total of 12 cycles of treatment will be administered. At the discretion of the investigator, participants who are responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase. Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).
62200143|NCT02405598|EXPERIMENTAL|Salbutamol|"1. age 2-6 year: 0.1mg/kg tid x 2 weeks, then gradually increase to 0.2mg/kg tid (daily total maximal12mg)~2. age 6-12 year: 2mg tid x 2 weeks, then gradually increase to 4mg tid (daily total maximal 24mg)~3. age 12 year and above: 4mg tidx 2 weeks, then gradually increase to 8mg tid (daily total maximal 32mg)"
62200144|NCT03462862|EXPERIMENTAL|Group 1|patients will receive partial denture constructed from PEEK material
62200145|NCT03462862|ACTIVE_COMPARATOR|Group 2|patients will receive partial denture constructed from breflex material
62200146|NCT06533319|OTHER|Patients infected with chronic hepatitis C who are also incarcerated in an Idaho county jail|Patients infected with chronic hepatitis C who are also incarcerated will be enrolled into the study and provided FDA approved Epclusa (sofosbuvir/velpatasvir) for treatment of chronic hepatitis C. Epclusa (sofosbuvir/velpatasvir) is currently used as a first line treatment for chronic hepatitis C. This study will focus on effectiveness of treatment in the county jai setting.
62200147|NCT01285700|ACTIVE_COMPARATOR|Lamazym 25|25 U/kg
62200148|NCT01285700|ACTIVE_COMPARATOR|Lamazym 50|50 U/kg
62401172|NCT01302366|EXPERIMENTAL|Sea cucumber extract|TBL12 is administered orally at a dose of 2 units (of 20 mL each) twice a day, in 4-week cycles, until disease progression or there is sign of disease progression.
62401173|NCT03741530|EXPERIMENTAL|Glibenclamide group|Giving standard management for ICH plus glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
62401174|NCT03741530|PLACEBO_COMPARATOR|Control group|Giving standard management for ICH
62401175|NCT00993941|ACTIVE_COMPARATOR|Group A(conserved therapy )|Thirty of the enrolled patients were randomly assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
62401176|NCT00993941|EXPERIMENTAL|Group B (BMSC Transplantion)|Thirty of the enrolled patients were randomly assigned to Group B were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as Bone Mesenchymal Stem Cells(BMSC) transplantation via portal vein.
62401177|NCT01206296|EXPERIMENTAL|Intraperitoneal Gemcitabine|Intraperitoneal Gemcitabine
62401178|NCT04284046||High CT score|
62200149|NCT04343976|EXPERIMENTAL|Lambda Treatment|Treatment with subcutaneous injection (180 mcg) of pegylated interferon lambda
62200150|NCT04343976|PLACEBO_COMPARATOR|Saline Placebo|Subcutaneous injection of saline placebo
62200151|NCT03019640|EXPERIMENTAL|Treatment (chemotherapy, NK infusion, stem cell transplant)|See Detailed Description.
62200152|NCT04385706|EXPERIMENTAL|Applied Coaching Model|One-group pre/post test
62200153|NCT02944929|EXPERIMENTAL|Self-rehabilitation program|Self-rehabilitation program + standard medical care (BTI + conventional physiotherapy)
62200154|NCT02944929|NO_INTERVENTION|Control arm|Arm with standard medical care ( BTI + conventional physiotherapy) without self-rehabilitation program
62200155|NCT04265326||Head and Neck Cancer patients|Turkish patients diagnosed with Head and Neck Cancer
62200156|NCT01640639|ACTIVE_COMPARATOR|Thalidomide|Thalidomide
62200157|NCT01640639|PLACEBO_COMPARATOR|Placebo|Placebo
62200158|NCT04142268||Preeclampsia group|PE was defined as diastolic BP of at least 110 mmHg on one occasion or diastolic BP of at least 90 mmHg on two consecutive occasions more than 4 hours apart, in combination with proteinuria (≥300 mg total protein in a 24-hour urine collection and, if this was not available, ≥+2 proteinuria by dipstick analysis on two consecutive occasions at least 4 hours apart) that develops after 20 weeks of gestation in previously normotensive women
62200159|NCT04142268||Control group|Normal pregnancy group
62200160|NCT04589728||Study group|All patients being observed during the study duration.
62401179|NCT04284046||Low CTscore|
62401180|NCT02791906|EXPERIMENTAL|ISMN Only|Patients receive only ISMN
62401181|NCT02791906|EXPERIMENTAL|ISMN AND Vitamin C|Patients receive both ISMN and Vitamin C
62401182|NCT04817319|EXPERIMENTAL|Major patients diagnosed with Covid + requiring oral care.|
62401183|NCT02477072|ACTIVE_COMPARATOR|Fixed heparin dose (general anesthesia)|Study subjects will be randomized to receive a fixed dose of 5000 units of heparin administered intravenously 2 minutes prior to vascular clamping and blood flow interruption. A subsequent dose of heparin will be administered if requested by the surgeon following a visual assessment of the anticoagulation in the surgical field. Anticoagulation will be monitored at different time points during surgery using ACT and TEG. Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial index and toe-brachial index.
62200161|NCT04115072|ACTIVE_COMPARATOR|A - Single dose og PZQ|Single dose of Praziquantel 40 mg/kg Standard treatment of schistosomiasis as recommended by WHO
62200162|NCT04115072|EXPERIMENTAL|B - Five doses of PZQ|"Five doses of Praziquantel~1 x 40 mg/kg Praziquantel after enrollment in the study plus two single doses (40 mg/kg) after 12 and 24 hours after the first treatment~1 x 40 mg/kg Praziquantel five weeks following the 1st dose~1 x 40 mg/kg Praziquantel ten weeks following the 1st dose"
62577903|NCT00022698|EXPERIMENTAL|Cohort 2,Amended Regimen:(Capecitabine + Irinotecan)|Participants will receive capecitabine 900 mg/m\^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 100 mg/m\^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks. A total of 12 cycles of treatment will be administered. At the discretion of the investigator, participants who will be responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase. Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).
62577904|NCT00006178|EXPERIMENTAL|Sirolimus and Thymoglobulin|Thymoglobulin (Sangstat), a FDA-approved polyclonal rabbit-IgG antithymocyte preparation, will be given for ten days at the time of transplantation to achieve profound lymphocyte depletion. This will be paired with chronic therapy with Sirolimus (rapamycin, Wyeth-Ayerst), an oral immunosuppressant agent recently approved by the FDA.
62577905|NCT02992236|PLACEBO_COMPARATOR|Placebo|Infusion (6 hours) of Saline
62200163|NCT02084199|EXPERIMENTAL|Part 1 - Severe renal impairment|Part 1 - Group 1: subjects with severe renal impairment or end-stage renal disease (ESRD), not on dialysis: Estimated glomerular filtration rate (eGFR) between 15-29 mL/min/1.73 m2 or \<15 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days
62200164|NCT02084199|EXPERIMENTAL|Part 1: Normal renal function|Part 1 - Group 2: subjects with normal renal function: eGFR ≥90 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days
62577906|NCT02992236|ACTIVE_COMPARATOR|VAS203|Infusion (6 hours) of VAS203 (10 mg/kg)
62577907|NCT03097341|EXPERIMENTAL|xisomab 3G3- Dose 1|Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
62577908|NCT03097341|EXPERIMENTAL|xisomab 3G3- Dose 2|Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
62200165|NCT02084199|EXPERIMENTAL|Part 2 - Mild renal impairment|Part 2 - Group 3: subjects with mild renal impairment: eGFR between 60-89 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
62200166|NCT02084199|EXPERIMENTAL|Part 2 - Moderate renal impairment|Part 2 - Group 4:subjects with moderate renal impairment: eGFR between 30-59 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
62200167|NCT02084199|EXPERIMENTAL|Part 2 - Normal renal function|Part 2 - Group 5: subjects with normal renal function: eGFR ≥90 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
62401184|NCT02477072|EXPERIMENTAL|Weight-adjusted doses of heparin|Study subjects will be randomized to receive 100 units of heparin per kilogram administered intravenously 2 minutes before vascular clamping and blood flow interruption. Subsequent doses of heparin will be administered to maintain the ACT between 300 and 350 seconds at all times during vascular clamping. Anticoagulation will be monitored at different time points during surgery using ACT and TEG. Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial index and toe-brachial index.
62577909|NCT03097341|EXPERIMENTAL|xisomab 3G3- Dose 3|Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
62577910|NCT03097341|EXPERIMENTAL|xisomab 3G3- Dose 4|Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
62577911|NCT03097341|PLACEBO_COMPARATOR|Placebo|Participants will receive a single intravenous dose of placebo.
62577912|NCT00945724|EXPERIMENTAL|R-CHOP, Depocyte, Methotrexate|
62577913|NCT05321238|EXPERIMENTAL|High agency and immediate threat|Participants were asked to make decisions within the interactive digital narrative and were presented with acute alcohol poisoning of the main character in the story.
62200168|NCT02493062|EXPERIMENTAL|single-arm study|This single-arm study is described by women who have undergone prenatal fetal open (uterus was opened to perform a fetal intervention/surgery) surgery and cesarean section delivery. These women will undergo sonohysterogram.
62401185|NCT02477072|ACTIVE_COMPARATOR|Fixed heparin dose (regional anesthesia)|For safety reasons, study subjects under regional anesthesia will automatically be assigned to this group and will receive a fixed dose of 5000 units of heparin administered intravenously 2 minutes prior to vascular clamping and blood flow interruption. A subsequent dose of heparin will be administered if requested by the surgeon following a visual assessment of the anticoagulation in the surgical field. Anticoagulation will be monitored at different time points during surgery using ACT and TEG.
62577914|NCT05321238|EXPERIMENTAL|High agency and distant threat|Participants were asked to make decisions within the interactive digital narrative and were presented with multiple organ failure after years of alcohol consumption of the main character in the story.
62577915|NCT05321238|EXPERIMENTAL|Low agency and immediate threat|Participants were presented with a fixed (passive) narrative without decisions and were presented with acute alcohol poisoning of the main character in the story.
62577916|NCT05321238|EXPERIMENTAL|Low agency and distant threat|Participants were presented with a fixed (passive) narrative without decisions and were presented with multiple organ failure after years of alcohol consumption of the main character in the story.
62577917|NCT06575855|ACTIVE_COMPARATOR|Group A|Group A received IASTM as treatment protocol
62577918|NCT06575855|ACTIVE_COMPARATOR|Group B|Group B received METs as a treatment protocol
62784616|NCT05169424||Stiolto initiators|"Chronic obstructive pulmonary disease (COPD) patients who initiated with Stiolto Respimat (Tiotropium + Olodaterol (5/5 micrograms (mcg)) in the existing real-world data from the Commercial Insurance and Medicare beneficiaries data using administrative claims between 15 September 2016 and 31st March 2020.~All participants had enrolled 1 year before the index date (starting from 15 September 2017)."
62784617|NCT05169424||Trelegy initiators|"COPD patients who initiated with Trelegy Ellipta (Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg) in the existing real-world data from the Commercial Insurance and Medicare beneficiaries data using administrative claims between 15 September 2016 and 31st March 2020.~All participants had enrolled 1 year before the index date (starting from 15 September 2017)."
62784618|NCT02736435|EXPERIMENTAL|Fibroid dimension < 8 cm|"Women with a maximum fibroid dimension less than 8 cm and a total uterine volume less than 900 cc.~Intervention: Treatment of fibroids with Magnetic Resonance Guided High Intensity Focused Ultrasound."
62784619|NCT02736435|EXPERIMENTAL|Fibroid dimension > 8 cm|"Women with a maximum fibroid dimension greater than 8 cm or a total uterine volume greater than 900 cc.~Intervention A: Pre-treated with 11.25mg leuprolide acetate for depot suspension for 3 months to reduce size of fibroids.~Intervention B: Treatment with Magnetic Resonance Guided High Intensity Focused Ultrasound if fibroids decrease to treatable size of less than 8cm and uterine volume less than 900cc."
62401186|NCT04085562|EXPERIMENTAL|Amlodipine|Hypertensive patients on dialysis receiving Amlodipine 5-10 mg tablet daily alone or as part of antihypertensive regimen.
62401187|NCT04085562|EXPERIMENTAL|Bisoprolol|Hypertensive patients on dialysis receiving Bisoprolol 5-10 mg tablet daily alone or as part of antihypertensive regimen.
62401188|NCT01821391|EXPERIMENTAL|NDL-PDT/c-PDT|Metvix natural daylight photodynamic therapy and Metvix conventional photodynamic therapy
62401189|NCT01821391|EXPERIMENTAL|NDL-PDT/placebo c-PDT|Metvix natural daylight photodynamic therapy and Metvix-placebo conventional photodynamic therapy
62401190|NCT02734290|EXPERIMENTAL|Arm A|pembrolizumab + weekly paclitaxel
62401191|NCT02734290|EXPERIMENTAL|Arm B|pembrolizumab + capecitabine
62401192|NCT01196754|OTHER|sevoflurane|
62401193|NCT06119789|EXPERIMENTAL|treatment according to genetic alterations|treatment according to genetic alterations
62401194|NCT01250691||hospital acquired pneumonia|
62401195|NCT01250691||isolated rooms|
62401196|NCT01250691||ward-type ICU|
62401197|NCT01243762|EXPERIMENTAL|Dalotuzumab 7.5 mg/kg + MK-0752 1800 mg|Participants in Part 1 of the study receive dalotuzumab 7.5 mg/kg intravenously (IV) weekly + MK-0752 1800 mg orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy.
62401198|NCT01243762|EXPERIMENTAL|Dalotuzumab 10 mg/kg + MK-0752 1800 mg|Participants in Parts 1 and 2 of the study receive dalotuzumab 10 mg/kg IV weekly + MK-0752 1800 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
62401199|NCT01243762|EXPERIMENTAL|Dalotuzumab 10 mg/kg + MK-2206 90 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK-2206 90 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
62401200|NCT01243762|EXPERIMENTAL|Dalotuzumab 10 mg/kg + MK-2206 135 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 135 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
62401201|NCT01243762|EXPERIMENTAL|Dalotuzumab 10 mg/kg + MK-2206 150 mg|Participants in Parts 1 and 2 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 150 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
62401202|NCT01243762|EXPERIMENTAL|Dalotuzumab 10 mg/kg + MK-2206 200 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 200 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
62401203|NCT01243762|EXPERIMENTAL|Dalotuzumab + Ridaforolimus|Participants in Part 2 of the study receive dalotuzumab 10 mg/kg IV weekly + ridaforolimus 20 mg PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy.
62401204|NCT01156129|ACTIVE_COMPARATOR|Arm A: Standard therapy (use of medications)|stool softener
62401205|NCT01156129|EXPERIMENTAL|Arm B: Acupressure bracelets|device - Biobands
62401206|NCT01156129|EXPERIMENTAL|Arm C|Sugar free gum
62401207|NCT01661426|ACTIVE_COMPARATOR|Low-Carbohydrate Diet first, then Low-Fat Diet (IR)|Participants who were more insulin resistant based on the median AUC for insulin concentrations measured from OGTT prior to randomization.
62401208|NCT01661426|ACTIVE_COMPARATOR|Low-Fat Diet first, then Low-Carbohydrate Diet (IS)|Participants who were more insulin sensitive based on the median AUC for insulin concentrations measured from OGTT prior to randomization.
62784620|NCT03186417|EXPERIMENTAL|Cohort 1|2 million human MSC (hMSC)/kg infusion versus placebo infusion
62784621|NCT03186417|EXPERIMENTAL|Cohort 2|4 million hMSC/kg infusion versus placebo infusion
62784622|NCT03186417|EXPERIMENTAL|Cohort 3|6 million hMSC/kg infusion versus placebo infusion
62784623|NCT06525584|EXPERIMENTAL|Ketamine 1|
62401209|NCT00722618|ACTIVE_COMPARATOR|Intervention|Written materials, telephone based education
62401210|NCT00722618|OTHER|Comparison|Written materials
62401211|NCT02112565|EXPERIMENTAL|Treatment (RNR inhibitor COH29)|Patients receive RNR inhibitor COH29 PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62401212|NCT01220921|EXPERIMENTAL|Lumbar Microdiscectomy|Patients aged 18-80 with symptomatic lumbar disc herniation resulting in single nerve root compression recalcitrant to non-invasive therapies for at least 6 weeks
62401213|NCT01220921|EXPERIMENTAL|Single-Level Lumbar Fusion|Patients aged 18-80 with symptomatic grade I degenerative or isthmic spondylolisthesis with mechanical back pain with or without radiculopathy recalcitrant to non-invasive therapies for at least 3 months
62401214|NCT04037540|EXPERIMENTAL|Operational approach|The patients enrolled in this arm underwent surgical treatment of the Jones fracture.
62401215|NCT04037540|EXPERIMENTAL|Conservative approach|The patients enrolled in this arm were treated conservatively, using fixation of the injured extremity.
62401216|NCT03061916|EXPERIMENTAL|Cinnamon|20% cinnamon will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving cinnamon 20%
62401217|NCT03061916|EXPERIMENTAL|Ginger|20% ginger will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving ginger 20%
62401218|NCT03061916|ACTIVE_COMPARATOR|Chlorhexidine|Chlorhexidine gluconate 0.2%,will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving chlorhexidine.
62784624|NCT06525584|EXPERIMENTAL|Ketamine 3|
62784625|NCT06525584|PLACEBO_COMPARATOR|Control|
62200169|NCT02395731|EXPERIMENTAL|MIND at Home- Plus Intervention|MIND at Home-Plus is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND-Plus systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, occupational therapist, and physician.
62200170|NCT03729427|EXPERIMENTAL|Treatment Arm|ESP Block
62200171|NCT03729427|NO_INTERVENTION|Control Arm|Standard of Care
62200172|NCT05212753|ACTIVE_COMPARATOR|Conventional Physical Therapy Group|The conventional physical therapy group will receive Transcutaneous Electrical Nerve Stimulation (TENS) and hot pack application.
62577919|NCT06287151|ACTIVE_COMPARATOR|General Anesthesia with Penile Block|Penile block: prior to the start of surgery 0.5mg/kg of 0.25% bupivacaine w/o epinephrine will be administered GA : Inhalation induction with sevoflurane followed by peripheral IV access, and placement of an endotracheal tube or laryngeal mask airway. No intravenous neuromuscular blockade will be given. Sevoflurane is FDA approved for the induction and maintenance of general anesthesia in adults and pediatric patients.
62577920|NCT06287151|ACTIVE_COMPARATOR|Spinal Anesthesia with Clonidine|Spinal block: 0.5% isobaric bupivacaine with 1:200,000 epinephrine (0.2mL/kg up to 1mL), with or without 1mcg/kg clonidine Clonidine is an FDA approved medication that is commonly administered as an adjunct to SA and CA in this population.
62577921|NCT06287151|ACTIVE_COMPARATOR|Spinal Anesthesia without Clonidine|Spinal block: 0.5% isobaric bupivacaine with 1:200,000 epinephrine (0.2mL/kg up to 1mL), with or without 1mcg/kg clonidine
62577922|NCT06287151|ACTIVE_COMPARATOR|General Anesthesia with Caudal Anesthesia with Clonidine|Caudal block: single-shot caudal injection following induction of GA with 1mL/kg of 0.25% bupivacaine with 1:200,000 epinephrine, with or without clonidine 1mcg/kg Clonidine is an FDA approved medication that is commonly administered as an adjunct to SA and CA in this population.
62577923|NCT06287151|ACTIVE_COMPARATOR|General Anesthesia with Caudal Anesthesia without Clonidine|Caudal block: single-shot caudal injection following induction of GA with 1mL/kg of 0.25% bupivacaine with 1:200,000 epinephrine, with or without clonidine 1mcg/kg
62577924|NCT06287151|ACTIVE_COMPARATOR|General Anesthesia only|GA alone: Inhalation induction with sevoflurane followed by peripheral IV access, and placement of an endotracheal tube or laryngeal mask airway. No intravenous neuromuscular blockade will be given. Sevoflurane is FDA approved for the induction and maintenance of general anesthesia in adults and pediatric patients.
62577925|NCT05312762|EXPERIMENTAL|MaxioCel|Microfiber wound dressing
62577926|NCT05312762|ACTIVE_COMPARATOR|AquaCel Extra|Hydrofiber dressing
62577927|NCT01340872|EXPERIMENTAL|ST10|ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day
62577928|NCT01340872|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day
62577929|NCT06383910|NO_INTERVENTION|Control Group|The group which doesn't get any intervention.
62577930|NCT06383910|ACTIVE_COMPARATOR|Exercise Group|The group received square stepping exercise training three times a week for six weeks.
62577931|NCT03327727|EXPERIMENTAL|VL-2397|Investigational agent VL-2397 600 mg IV infusion administered every day for 28 days (4 weeks) followed by 2 weeks of standard treatment
62577932|NCT03327727|ACTIVE_COMPARATOR|Standard (First-Line) Treatment|Investigator selected standard treatments of voriconazole, isavuconazole, or liposomal amphotericin B administered every day for 42 days (6 weeks) per product package insert
62577933|NCT00795470|NO_INTERVENTION|No catheter change no antimicrobial|Urinary catheter will not be changed and no antimicrobials will be prescribed
62200173|NCT05212753|ACTIVE_COMPARATOR|Stabilization Group|The stabilization group will receive lumbar stabilization exercises and the conventional physical therapy program. That program includes lumbar stabilization exercises including activation of the transverses abdominals (TA) and multifidi muscles.
62200174|NCT05212753|ACTIVE_COMPARATOR|Breathing Exercise Group|The breathing exercise group will receive breathing exercises including sleep hygiene, and the stabilization group program. Breathing exercises include diaphragmatic breathing and pursed-lip.
62200175|NCT04043897|EXPERIMENTAL|Drug|Patients will receive open-label rifaximin 550mg tid x 4 weeks.
62200176|NCT04238013|ACTIVE_COMPARATOR|Corticospinal Tract Excitability|During the Corticospinal Tract Excitability arm, corticospinal excitability will be assessed by measuring motor evoked potentials after transcranial magnetic stimulation pre-post each intervention in conjunction with other outcome measures.
62784626|NCT05552352|EXPERIMENTAL|Intervention Arm|Patients in the intervention arm receive on the day before the implantation of the artificial aortic valve, a virtual reality assisted information. On the day of the implantation the patients are informed about the process via virtual reality assisted information.
62784627|NCT05552352|NO_INTERVENTION|Control Arm|Patients in the control arm receive no virtual reality assisted information.
62200177|NCT04238013|ACTIVE_COMPARATOR|Spinal Reflex Circuit Excitability|During the Spinal Reflex Circuit Excitability arm, spinal reflex circuit excitability will be assessed by measuring low frequency depression after Hoffmann-Reflex testing pre-post each intervention in conjunction with other outcome measures.
62200178|NCT06203353||weaning success|Patients extubated with no need to non invasive ventilatry support during 48 hours
62577934|NCT00795470|ACTIVE_COMPARATOR|Antimicrobial and catheter change|
62784628|NCT05260762|ACTIVE_COMPARATOR|Arabinoxylan|Arabinoxylan (15 g AX/d) wheat buns
62577935|NCT00795470|ACTIVE_COMPARATOR|Catheter change and NO antimicrobial|
62577936|NCT00795470|ACTIVE_COMPARATOR|Antimicrobial and NO catheter change|
62577937|NCT04152811|ACTIVE_COMPARATOR|Waitlist 1|usual diabetes care
62577938|NCT04152811|EXPERIMENTAL|Intervention 1|6-weeks of cooking matters for diabetes classes
62577939|NCT04152811|ACTIVE_COMPARATOR|Waitlist 2|usual diabetes care
62577940|NCT04152811|EXPERIMENTAL|Intervention 2|6-weeks of cooking matters for diabetes classes
62401219|NCT05115760|EXPERIMENTAL|Supportive care (pea protein oral nutrition supplement)|Patients receive Kate Farms pea protein oral nutrition supplement PO during their mealtimes as directed by their clinical dietitian during and up to 1 month following chemoradiation in the absence of unacceptable toxicity.
62577941|NCT03039530|EXPERIMENTAL|Treatment Group|Group CBT for PPD. Women in the treatment group will attend a 9-week group CBT intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week.
62577942|NCT03039530|ACTIVE_COMPARATOR|Control Group|Standard Care. The usual care group will receive standard care from their family physician and midwife or obstetrician. They will also be made aware of the perinatal programming available to them through Niagara Region Public Health. Women and family physicians will also receive a copy of the Canadian Practice Guidelines for the Treatment of Perinatal Depression.
62401220|NCT00779142|OTHER|Methotrexate 25mg/ml|Methotrexate intravenous 25mg/ml: Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose to subjects with diabetic macular edema resistant to conventional therapies.
62401221|NCT03528265||Patients with melioidosis-like symptoms admitted to Kapit Hosp|
62401222|NCT00766129|EXPERIMENTAL|T|Implantation of Taxus stent into saphenous vein graft
62577943|NCT03973879|EXPERIMENTAL|PVSRIPO + Atezolizumab|Single PVSRIPO infusion at a dose of 5x10\^7 tissue culture infected dose (TCID50). Atezolizumab infusions at a dose of 1200 mg every three weeks for up to two years.
62577944|NCT03279757|EXPERIMENTAL|AHES 5 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 5 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
62401223|NCT00766129|EXPERIMENTAL|C|Implantation of Luc-Chopin stent into saphenous vein graft
62577945|NCT03279757|EXPERIMENTAL|AHES 15 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 15 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
62577946|NCT03279757|EXPERIMENTAL|AHES 25 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 25 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
62577947|NCT03279757|EXPERIMENTAL|LTC 5 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 5 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
62784629|NCT05260762|PLACEBO_COMPARATOR|Control|Non-fiber, carbohydrate control (15 g /d) wheat buns
62401224|NCT05284162|EXPERIMENTAL|Health coaching|Health coaching
62401225|NCT05284162|NO_INTERVENTION|Usual care|Usual care
62401226|NCT00851695||Asthma|All 1024 participants of the Childhood Asthma Management Program, who provided blood samples.
62401227|NCT00851695||Asthma in Hispanics|All 616 subjects in the Genetic Epidemiology of Asthma in Costa Rica who have serum.
62401228|NCT00851695||Lung function and lung function decline|626 subjects from the Normative Aging Study who have serum and lung function.
62784630|NCT05386693||Ilioinguinal Nerve Block|
62784631|NCT02395614|EXPERIMENTAL|Chlorhexidine irrigation|0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles for irrigation. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
62401229|NCT00938366|EXPERIMENTAL|Cladribine followed by Cladribine + Pantoprazole|Subjects will receive a single dose of cladribine10 milligram (mg) orally on Day 1. After a wash out period of 10-25 days, subjects will receive pantoprazole 40 mg orally for 2 consecutive days. On Day 2 of the pantoprazole administration, a single dose of cladribine 10 mg will be administered orally 3 hours after the second pantoprazole dose.
62401230|NCT00938366|EXPERIMENTAL|Cladribine + pantoprazole followed by Cladribine|Subjects will receive pantoprazole 40 mg orally for 2 consecutive days. On Day 2 of the pantoprazole administration, a single dose of cladribine 10 mg will be administered orally 3 hours after the second pantoprazole dose. After a wash out period of 10-25 days, subjects will receive a single dose of cladribine 10 mg orally.
62401231|NCT01294280||Ancillary-Correlative (IHC)|Previously collected tissue samples are analyzed by IHC.
62577948|NCT03279757|EXPERIMENTAL|LTC 15 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 15 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
62577949|NCT03279757|EXPERIMENTAL|LTC 25 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 25 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
62577950|NCT03279757|OTHER|Unanesthetized skin|A pain stimulus will be given at unanesthetized skin with the fractional CO2 laser, 50 mJ, 5% density
62577951|NCT03997240|OTHER|Wait-list control|Six-week wait list control
62577952|NCT03997240|EXPERIMENTAL|Immediate intervention|Immediate treatment group
62577953|NCT04824027|EXPERIMENTAL|HMI Group|Women undergoing standard neoadjuvant chemotherapy for breast cancer
62577954|NCT04192071|ACTIVE_COMPARATOR|high interactive virtual human administered nutrition module|The virtual health assistant will interactively collect nutrition information (alcohol, red meat, and processed meat intake) and report risk information back to users in visual and audio format
62577955|NCT04192071|ACTIVE_COMPARATOR|low interactive virtual human module|Complete the current intervention module that includes items assessing alcohol and meat intake.
62577956|NCT04192071|SHAM_COMPARATOR|attention control module|The attention control group, will complete a related module not related to colorectal cancer or nutrition
62577957|NCT00774514|EXPERIMENTAL|Air exposure|1 hour exposure to filtered air during intermittent exercise
62577958|NCT00774514|EXPERIMENTAL|NO2 exposure|1 hour exposure to nitrogen dioxide at 4ppm during intermittent exercise
62577959|NCT03992924|ACTIVE_COMPARATOR|angiography-guided PCI|
62577960|NCT03992924|EXPERIMENTAL|FFR-guided PCI|
62577961|NCT03992924|EXPERIMENTAL|OCT-guided PCI|
62577962|NCT00491556|EXPERIMENTAL|Experimental Arm|Subjects in the experimental group will begin HAART consisting of TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r upon entry or to begin treatment under current DHHS guidelines. Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
62577963|NCT00491556|OTHER|Standard Care Arm|Subjects randomized to the standard care arm will begin HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care and will be followed for a total of three years. Under these guidelines and under current clinical standards, subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur.
62577964|NCT00758485|EXPERIMENTAL|sugammadex|Participants receiving 4.0 mg.kg-1 Sugammadex at a target depth of NMB of 1-2 PTC after the last dose of rocuronium
62577965|NCT00758485|PLACEBO_COMPARATOR|Placebo|Participants receiving Placebo (0.9% NaCl) at a target depth of NMB of 1-2 PTC after the last dose of rocuronium
62577966|NCT01413126|EXPERIMENTAL|Peanut butter|42.5 g of Peanuts butter were added to a 75g available carbohydrate-matched breakfast meal
62577967|NCT01413126|EXPERIMENTAL|Whole peanut|42.5 g of whole peanuts were added to a 75g available carbohydrate-matched breakfast meal
62577968|NCT01413126|NO_INTERVENTION|No peanuts (control)|
62577969|NCT05536232|EXPERIMENTAL|LCD|
62784632|NCT02395614|ACTIVE_COMPARATOR|triple antibiotic irrigation|triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and 80 mg of gentamicin in 500 mL of normal saline (NS). If the patient is allergic to either component - the allergen will not be used in the solution - for irrigation. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
62200179|NCT06203353||weaning failure|patients requiring reintubation or non invasive ventilation within 48 hours after extubation
62577970|NCT06241170|EXPERIMENTAL|mesentery-guided resection margin group|The research team positions the proximal margin of the anastomosis in a way that the mesentery reaches the point of being palpable and where the fat appears entirely normal under direct visual observation, in contrast to the mesentery near the proximal and distal ends of the anastomosis.
62577971|NCT06241170|NO_INTERVENTION|traditional resection margin group|The proximal margin is defined as being 2 cm from the point where visible mucosal lesions are present. Macroscopic lesions are defined as visible pathologies such as intestinal narrowing, thickening of the intestinal wall, or mucosal ulcers. In both groups, the distal margin is located at the hepatic flexure of the ascending colon, where both the mesentery and the intestinal wall are macroscopically normal.
62784633|NCT05972746|EXPERIMENTAL|Telemonitoring program with electronic alerts + Standard of care|
62577972|NCT04895657|OTHER|Piperacillin/Tazobactam Intermittent infusion|4.5 gm Piperacillin/Tazobactam I.V intermittent over 30 min. every 8 hours.
62577973|NCT04895657|OTHER|Piperacillin/Tazobactam Continuous infusion|4.5 gm Piperacillin/Tazobactam I.V extended infusion over 4 hours every 8 hours.
62577974|NCT05576272|EXPERIMENTAL|QL1706 Combined with Gemcitabine and Cisplatin|
62577975|NCT05576272|ACTIVE_COMPARATOR|Carrilizumab Combined with Gemcitabine and Cisplatin|
62577976|NCT05354388||surgery after ripretinib treatment|For subjects who achieved PR or SD, perform resection of gastrointestinal stromal tumor
62577977|NCT03938844||TLH with BURCH Colposuspension|the patients who underwent simultaneous burch copying with TLH was evaluated. In addition to demographic data and preoperative examination findings, operative times, postoperative hemogram values, postvoiding residual amounts and complications were examined. In addition, FSI test results of women with sexual activity were compared with ICIQ-UI and UDI-6 interrogations related to urinary incontinence.
62577978|NCT03938844||TLH with Transobturatuar Tape (TOT)|In cases of simultaneous toting with TLH; In addition to demographic data and preoperative examination findings, operative times, postoperative hemogram values, postvoiding residual amounts and complications were examined. In addition, FSI test results of women with sexual activity were compared with ICIQ-UI and UDI-6 interrogations related to urinary incontinence.
62577979|NCT01656135|OTHER|Reference Group|"Basiliximab (Simulect®):~* Day 0: 20mg IV ≤2h prior to surgery~* Day 4: 20mg IV~Prednisolone:~* Day 0: 500mg IV (250mg pre-op, 250mg intra-op)~* Day 1: 125mg IV~* Day 2 - 14: 20mg/day oral~* Week 3 - 4: 15mg/day oral~* Week 5 - 8: 10mg/day oral~* Week 9 - 12: 5mg/day oral~* Week 13 - 14: 2.5mg/day oral~* Week 15 - Study End: Cessation~Steroid tapering should not proceed if graft rejection has occurred or if renal dysfunction is observed.~Mycophenolate Mofetil (MMF, or biologic equivalent):~Treatment with MMF should commence one day prior to transplantation (on Day -1) and should continue indefinitely, with a dose reduction after two weeks:~* Day -1 - 14: 2g/day oral~* Day 15 - Study End 1.5g/day oral (750mg twice daily)~Tacrolimus (or biologic equivalent):~* Day -4 - 14: 3-12ng/ml~* Week 3 - 12: 3-10ng/ml~* Week 13 - 36: 3-8ng/ml~* Week 37 - Study End: 3-6ng/ml"
62577980|NCT01631149|EXPERIMENTAL|Deep surgical block|Continuous rocuronium infusion will be used to induce a deep surgical block with post tetanic twitch count of max 2. Rocuronium loading dose = 1.0 mg/kg, followed by 0.6-1.0 mg/kg per hour.
62401232|NCT02096406|OTHER|ACE/ARB Continuation|ACE/ARB will be continued up to and including the morning of surgery.
62577981|NCT01631149|ACTIVE_COMPARATOR|Moderate/normal surgical block|A normal block will be induced by an atracurium bolus dose followed by a mivacurium infusion to induce a train of four count of 1-2.
62577982|NCT01558440|ACTIVE_COMPARATOR|Infant Formula|A diet that is being fed to the young infants
62200180|NCT02028325|EXPERIMENTAL|Fluorescein Sodium|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
62200181|NCT04792177|EXPERIMENTAL|Intervention group|Emotion regulation skills training group
62012320|NCT06136520|EXPERIMENTAL|experimental group|"After the first measurements are made and the groups are determined; Personal Information Form, Perinatal Attachment Inventory and Beck Depression Inventory will be applied to the experimental and control groups. Pregnant women in the experimental group were 32-40 weeks of pregnancy.~After baby massage training is given, 30-42 weeks after birth. between days and 60-72. Maternal Attachment Scale and Edinburgh Postpartum Depression Scale will be applied to the experimental and control groups on the following days. The control group will receive standard care while the experimental group receives training. After the second postpartum data of the pregnant women in the control group are collected, a 30-minute baby massage training will be given by the researcher."
62200182|NCT04792177|NO_INTERVENTION|waitlist control group|The control group will not receive any intervention during the trial but will be offered the same treatment at the end of the six-months follow-up assessment.
62577983|NCT01558440|EXPERIMENTAL|F-100|• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
62577984|NCT01558440|EXPERIMENTAL|Diluted F-100|300 ml of water is added to 1000 ml of F-100
62200183|NCT05230953|EXPERIMENTAL|4th dose mRNA1273 vaccine|The investigators will recruit 150-200 volunteers, who received the 3rd dose at least 4 months previously, and have a known serology history (showing an immune response (even if just a low response) to the three previous doses, but with a recent relatively low IgG (below 700 BAU). These volunteers will recieve a 4th dose (50microgram) of the mRNA1273 vaccine
62200184|NCT05230953|NO_INTERVENTION|Control|As controls, a sub-cohort of similar HCW, who are recruited to the Sheba COVID Cohort study (IRB 8008-20) and are followed monthly with serology tests, and are not receiving the 4th dose. The control group, all of whom signed an informed consent and allowed blood samples to be used for further immunologic studies, will be matched by age, gender, time from 3rd vaccine dose and IgG titers, and will be followed similarly
62577985|NCT00537576|EXPERIMENTAL|Low dose LACTIN-V applicator|Low dose LACTIN-V applicator (150 mg LACTIN-V, 5.0 x 10\^8 CFU), administered vaginally once a day for 5 consecutive days
62577986|NCT00537576|EXPERIMENTAL|Medium dose LACTIN-V applicator|Medium dose LACTIN-V applicator (300 mg LACTIN-V, 1.0 x 10\^9 CFU), administered vaginally once a day for 5 consecutive days
62577987|NCT00537576|EXPERIMENTAL|High dose LACTIN-V applicator|High dose LACTIN-V applicator (600 mg LACTIN-V, 2.0 x 10\^9 CFU), administered vaginally once a day for 5 consecutive days
62012321|NCT06136520|NO_INTERVENTION|Control group|The control group will receive standard care while the experimental group receives training. After the second postpartum data of the pregnant women in the control group are collected, a 30-minute baby massage training will be given by the researcher.
62200185|NCT05230953|EXPERIMENTAL|4th dose BNT162b2 vaccine|The outcomes will be compared to those participating in study IRB-8980-21, with a similar protocol, initiated 1 week earlier.
62200186|NCT04043143|PLACEBO_COMPARATOR|Arm 1 Prescription As Usual|At the time of writing the discharge prescription for a patient the provider will receive a best practice alert (BPA) to consider prescribing the usual medications for pain management after discharge.
62401233|NCT02096406|OTHER|ACE/ARB withdrawal|ACE/ARB will be discontinued medication 48 hours prior to surgery
62577988|NCT00537576|PLACEBO_COMPARATOR|Low dose Placebo applicator|Low dose Placebo applicator (150 mg Placebo), administered vaginally once a day for 5 consecutive days
62577989|NCT00537576|PLACEBO_COMPARATOR|Medium dose Placebo applicator|Medium dose Placebo applicator (300 mg Placebo), administered vaginally once a day for 5 consecutive days
62401234|NCT02526368|EXPERIMENTAL|Pre-surgical Prostate Cancer patients|Participants will receive an infusion of hyperpolarized 13C-pyruvate alone or co-hyperpolarized 13C pyruvate with hyperpolarized 13C, 15N urea injection prior to metabolic/perfusion high spatial resolution MRI/1H MRSI staging exam (PROSE) with endorectal coil using both a phased-array abdominal coil and an endorectal coil will be performed within 12 weeks of subsequent non-interventional radical prostatectomy.
62401235|NCT02995239|ACTIVE_COMPARATOR|CJ-12420 formulation 1|CJ-12420 formulation 1
62784634|NCT05972746|PLACEBO_COMPARATOR|Standard of care|
62012322|NCT06573918|EXPERIMENTAL|EMG-assessed paratonia group|The study evaluated EMG-assessed paratonia to measure motor response efficiency across three groups of healthy young adults with varying physical activity levels: professional athletes (in both open and closed skills sports), amateurs, and sedentary individuals. Surface electrodes were placed on the biceps and triceps brachii muscles during passive elbow movements while participants remained relaxed. EMG activity detected during these movements was used to quantify the level of paratonia, indicating the participants' ability to relax their muscles.
62012323|NCT02528292||Active Rheumatoid Arthritis|Patients with active Rheumatoid Arthritis with a DAS 28 score of greater than 5.1 and eligible for anti-TNF alpha therapy according to National Institute for Clinical Excellence guidelines will be recruited in this study
62012324|NCT03899116||G50|The tourniquet cuff pressure will be deflated gradually by 50 mm Hg every 2 minutes till complete deflation.
62012325|NCT03899116||G100|The tourniquet cuff pressure will be deflated gradually by 100 mm Hg every 2 minutes till complete deflation.
62012326|NCT03899116||G0|The tourniquet cuff will be released till complete deflation.
62012327|NCT05494125|EXPERIMENTAL|ESP Catheters with Ropivacaine 0.2%|
62012328|NCT05494125|PLACEBO_COMPARATOR|ESP Catheters with Saline Solution|
62012329|NCT05915026|EXPERIMENTAL|Gadoquatrane|Participants will receive one intravenous injection of gadoquatrane during MRI.
62012330|NCT05443984|EXPERIMENTAL|Experimental Group|JP-1366 20mg + Esomeprazole 40mg(placebo)
62012331|NCT05443984|ACTIVE_COMPARATOR|Active Comparative Group|JP-1366 20mg(placebo) + Esomeprazole 40mg
62012332|NCT05728112|EXPERIMENTAL|Hydrogen Inhalation|The manufacturer installs the hydrogen inhalation machine at the subject's home and explains the relevant operation methods. The research executor will take care of it in the LINE group on the first day of installation, and after obtaining the pre-test baseline data (baseline data) through the google form, carry out each test. Continuous inhalation of hydrogen was carried out every day, and four post-test assessments were performed before inhalation and on the 1st, 3rd, 7th, and 14th days after inhalation.
62012333|NCT05728112|PLACEBO_COMPARATOR|Ordinary Air Inhalation|This group used the same model to inhale, but the gas released was only ordinary air, as a placebo control.
62012334|NCT02357316||All participants|All individuals visiting the museum who want to participate and sign a consent form.
62577990|NCT00537576|PLACEBO_COMPARATOR|High dose Placebo applicator|High dose Placebo applicator (600 mg Placebo), administered vaginally once a day for 5 consecutive days
62577991|NCT00025675|ACTIVE_COMPARATOR|p450|p450 inhibitor
62012335|NCT03997903|EXPERIMENTAL|Imatinib Intervention|
62012336|NCT04634227|EXPERIMENTAL|Gemcitabine + High-Dose Ascorbate|Ascorabte is administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator. Treatment will be terminated with progression of disease. Disease will be assessed by CT of the chest, abdomen and pelvis or MRI of the lesion every 2 cycles for progression.
62401236|NCT02995239|ACTIVE_COMPARATOR|CJ-12420 formulation 2|CJ-12420 formulation 2
62401237|NCT02087865|ACTIVE_COMPARATOR|Donepezil HCL|Participants will receive 5mg of donepezil HCL for 4 weeks and then 10mg of donepezil HCL for 20 weeks.
62012337|NCT03065881|ACTIVE_COMPARATOR|Dilated versus Natural pupil|
62012338|NCT03065881|ACTIVE_COMPARATOR|Normal retina versus abnormal retina|
62012339|NCT01646034|EXPERIMENTAL|intensified alkylating chemotherapy|a course chemotherapy with high dose cyclophosphamide, G-CSF and peripheral blood progenitor cell (PBPC) harvest followed by tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
62401238|NCT02087865|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo for 24 weeks.
62401239|NCT02087865|NO_INTERVENTION|Control Group|Participants without a family history of AD will undergo the study evaluations but will not receive any study drug
62577992|NCT00025675|ACTIVE_COMPARATOR|nonp450|not on p450 inhibitor
62784635|NCT02076126||Gastric aspirate|L/S ratio on the gastric aspirates are retrospectively compared with the possible development of RDS
62784636|NCT02076126||Hypopharyngeal secretion|L/S ratio on the hypopharyngeal secretions are retrospectively compared with the possible development of RDS
62200187|NCT04043143|EXPERIMENTAL|Arm 2 Prescription Tool Intervention|At the time of writing the discharge prescription for a patient the provider will be informed by the best practice alert (BPA) Prescription Tool that a patient may be considered for a lower post-discharge opioid dose (no opioids for patients who did not take any opioids in the last 24 hours, and 10 oxycodone 5mg tablets, for patients having taken less than 22.5 MME, e.g. 1-3 oxycodone 5mg tablets in the last 24 hours). Final dosing decisions and drug choices will remain at the discretion of the treating provider and decisions will be tracked.
62401240|NCT04487782||High SES / African-American Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of higher socioeconomic status (SES) and will be African-American/Black.
62401241|NCT04487782||High SES / Caucasian Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of higher socioeconomic status (SES) and will be Caucasian/White.
62577993|NCT05468476||Women with PCOS (PCOS group)|PCOS women with obesity previously diagnosed with PCOS（meet the 2003 Rotterdam diagnostic criteria） not using hormonal therapy and without other significant health or endocrine issues.
62577994|NCT05468476||Women without PCOS (Non-PCOS group)|This study enrolled age- and body mass index (BMI)-matched subjects with normal menstrual cycles, not using hormonal therapy, and without any significant health or endocrine issues.
62012340|NCT01646034|ACTIVE_COMPARATOR|three cycles of chemotherapy|"three cycles of chemotherapy depending on previously received agents~chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclophosphamide previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine"
62012341|NCT04846127||CanGaroo Envelope|Participants who receive a CanGaroo envelope during their CIED implant.
62012342|NCT04846127||No Envelope|Participants who do not receive an envelope of any kind during their CIED implant.
62012343|NCT02863354|EXPERIMENTAL|Q4WKS|"Aflibercept 2 mg every 4 weeks (defined as every 28 days (+ 7 days) and at least 21 days between injections) through week 48. Following week 48, aflibercept 2 mg every 12 weeks through week 96.~If NV or PDR are worse per pre-specified criteria at week 60, or at any study visit thereafter, the subject will be treated every 4 weeks through the end of the study."
62401242|NCT04487782||Low SES / African-American Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of lower socioeconomic status (SES) and will be African-American/Black.
62012344|NCT02863354|EXPERIMENTAL|Q12WKS|"Aflibercept 2 mg every 12-weeks. Subjects will be followed every 4 weeks through week 12, and can be treated if the pre-specified criteria are met. Starting at week 12 if NV or PDR are stable or improved (as assessed by investigator) the subject will be monitored and treated at a 12-week interval through week 48. If NV or PDR are worse per the pre-specified criteria at week 12, or at any study visit thereafter, the subject will be treated monthly through the end of the study.~At week 52, aflibercept 2 mg every 4 weeks (defined as 28 days (+ 7 days) and at least 21 days between injections) for subjects with visible retinal non-perfusion. If retinal non-perfusion has completely resolved at week 72, aflibercept every 12 weeks through end of study. For subjects without retinal non-perfusion at week 52, aflibercept 2 mg every 12 weeks through the end of study."
62012345|NCT06592313||Patients undergoing bariatric surgery|Adults with an indication for bariatric surgery who have been schedule for a bariatric surgery procedure.
62577995|NCT00468481|EXPERIMENTAL|Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)|1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks
62577996|NCT00468481|ACTIVE_COMPARATOR|Drospirenone (DRSP)/Ethinylestradiol (EE)|1 tablet 0.020 mg EE/3.0 mg DRSP \[YAZ\] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks
62200188|NCT05083845|ACTIVE_COMPARATOR|Erector Spinae Plane Block with 20 ml %0.25 Bupivacaine|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine was injected into the area.
62200189|NCT05083845|ACTIVE_COMPARATOR|Erector Spinae Plane Block with 30 ml %0.25 Bupivacaine|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 30 ml 0.25% bupivacaine was injected into the area.
62200190|NCT04196634||People on sick leave|People on sick leave due to musculoskeletal conditions for at least 4 weeks.
62200191|NCT01598077|EXPERIMENTAL|Dose escalation and dose expansion|
62200192|NCT04127097|EXPERIMENTAL|cartoon group|
62200193|NCT04127097|NO_INTERVENTION|control group|
62577997|NCT06572306||Continuous glucose monitoring cohort (intervention)|Freestyle libre 2 sensor devices will be used to monitor glucose. The sensors are worn on the upper arm and changed every 14 days. Each subject will have 5 visits with a pharmacist over 12 weeks. Subjects meeting inclusion criteria will include adults ≥18 years of age with type 2 diabetes and a hemoglobin A1c ≥ 8%. Subjects must have a compatible smartphone with the freestyle libre 2 sensor system. Subjects must have access to a glucometer to check blood glucose. Subjects must not have worn a continuous glucose monitor in the last 6 months to be eligible.
62200194|NCT04239599|EXPERIMENTAL|Hypofractionation|Hypofractionation: Using a one phase IMRT plan, the pelvic lymph nodes will be treated to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68 Gy in 25 fractions concomitantly (simulataneous integrated boost) + 18-36 months of Eligard Hormone injection.
62200195|NCT04239599|ACTIVE_COMPARATOR|Standard Fractination|Using 2 sequential IMRT plans, the pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent boost to the prostate to a total dose of 78 Gy + 18-36 months of Eligard Hormone injection.
62200196|NCT03695484||Manual guided RF ablation|Patients with paroxysmal atrial fibrillation treated with Manual guided RF ablation using Contact Force catheters
62200197|NCT03695484||Cryoballoon ablation|Patients with paroxysmal atrial fibrillation treated with Cryoballoon ablation. Cryoballoon: Arctic Front Advance, Medtronic - 28 mm
62200198|NCT03695484||RMN guided RF ablation - High power|"Patients with paroxysmal atrial fibrillation treated with Remote Magnetic Navigation guided RF ablation with e-Contact and high power settings.~High power ablation settings: a minimum of 40 Watt, 43grC, flow 17ml/min. Higher voltages (e.g. anterior wall) are allowed with respect to the operators' preference."
62200199|NCT03695484||RMN guided RF ablation - Low power|"Patients with paroxysmal atrial fibrillation treated with Remote Magnetic Navigation guided RF ablation with e-Contact and low power settings.~Low power ablation settings: a maximum of 39 Watt, 43grC, flow 17ml/min. Lower voltages are allowed with respect to the operators' preference."
62200200|NCT01110408|EXPERIMENTAL|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose) will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
62401243|NCT04487782||Low SES / Caucasian Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of lower socioeconomic status (SES) and will be Caucasian/White.
62401244|NCT04901520|EXPERIMENTAL|High Intensity Training (HIT)|Participants trained at 80-90% of 1RM for 12 weeks, twice per week.
62401245|NCT04901520|EXPERIMENTAL|Moderate Intensity Training (MIT)|Participants trained at 65-75% of 1RM for 12 weeks, twice per week.
62401246|NCT04901520|EXPERIMENTAL|Low Intensity Training (LIT)|Participants trained at 50-60% of 1RM for 12 weeks, twice per week.
62401247|NCT04901520|NO_INTERVENTION|Control Group (CG)|Participants did not participate in any training and they advised to do their daily activity
62012346|NCT02629406||Diabetes typ 1|Patients with typ 1diabetes with a duration of the disease between 10-20 years (HbA1C \>65 mmol/l) and age 20-50 will be exposed to intermittent hypoxia.
62012347|NCT02629406||Healthy controls|Healthy controls, age 20-50 will be exposed to intermittent hypoxia.
62012348|NCT00273364|EXPERIMENTAL|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with Cyclophosphamide and rATG
62012349|NCT00273364|ACTIVE_COMPARATOR|Standard therapy for MS|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), Gilenya (fingolimod) or Dimethyl fumarate (Tecfidera or BG-12)
62012350|NCT01903447|ACTIVE_COMPARATOR|SSRI|sertraline: 100-200mg, citalopram 20-40mg, escitalopram 10-20mg, paroxetine 20-60mg; fluoxetine 20-80mg
62012351|NCT01903447|ACTIVE_COMPARATOR|CBT|12 weeks of individual cognitive behavioral therapy
62012352|NCT01986829|EXPERIMENTAL|Treatment (ablation)|"* Patients undergo cryoablation, radiofrequency ablation, or microwave ablation of each lesion.~* Patients complete pain survey (BPI-Short form) and quality of life questionnaires (FACT-G7)"
62012353|NCT02879097|EXPERIMENTAL|CBT124 arm|CBT124 plus carboplatin and paclitaxel
62012354|NCT02879097|ACTIVE_COMPARATOR|EU Sourced Avastin® arm|EU-sourced Avastin® plus carboplatin and paclitaxel
62012355|NCT02116322|EXPERIMENTAL|Pancreatic mass|Patients with pancreatic mass presenting for EUS-FNA
62012356|NCT04475445|EXPERIMENTAL|Ultrasound guided transforaminal epidural steroid injection|
62012357|NCT04475445|EXPERIMENTAL|Interlaminar epidural steroid injection|
62012358|NCT01668316|EXPERIMENTAL|Weight loss|12 week weight loss program with biweekly meetings with a Registered Dietitian. Participants will be given a nutrition prescription and asked to record dietary intake online. Participants will be given a pedometer and record daily physical activity.
62012359|NCT01668316|NO_INTERVENTION|Control|Participants asked to not change dietary and physical activity habits.
62401248|NCT01004822|EXPERIMENTAL|Active Drug|Weekly infusions of CVX-241 at specified doses
62401249|NCT03243552|ACTIVE_COMPARATOR|L-DOPA versus Placebo|L-DOPA or placebo (1:1 randomization). Dosing will begin at 25mg carbidopa/100mg L-DOPA in 3 divided doses, with a fixed-flexible titration schedule, allowing dose increases once per week of 100mg L-DOPA. Maximum dose is 600mg/d.
62577998|NCT06572306||Self-monitoring of blood glucose cohort (historical cohort)|A retrospective chart review will be performed on patients seen by a clinic pharmacist between 1/1/2020-7/1/2024. Subjects in this group will include adults ≥18 years of age with type 2 diabetes and a hemoglobin A1c ≥ 8% and using a glucometer to monitor blood sugar. Exclusion criteria will be use of any continuous glucose monitoring device within the prior 6 months of the index date (defined as first visit with a pharmacist during study time frame).
62784637|NCT05755672||Synchronous mCRC patients|Patients diagnosed with synchronous metastatic colorectal cancer with planned treatment with curative intent at Skåne University Hospital (Malmö and Lund), who have accepted the study invitation (agreeing to participation - informed consent)
62012360|NCT00546143|EXPERIMENTAL|1|Omalizumab 900 mg
62012361|NCT00546143|EXPERIMENTAL|2|Omalizumab 1050 mg
62012362|NCT00546143|EXPERIMENTAL|3|Omalizumab 1200 mg
62012363|NCT04899063|OTHER|ELIOS Procedure|ELIOS Procedure
62012364|NCT02352324|EXPERIMENTAL|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
62012365|NCT06339034|ACTIVE_COMPARATOR|Lithium|Lithium: 10mg, 2x/day
62012366|NCT06339034|PLACEBO_COMPARATOR|Placebo|Identical capsules filled with cellulose: 10mg, 2x/day
62012367|NCT06663761|EXPERIMENTAL|Experimental group|Participants will be exposed to unpleasant stimuli, and their response will be determined.
62012368|NCT01018264|EXPERIMENTAL|solifenacin succinate (VESIcare)|
62012369|NCT01018264|PLACEBO_COMPARATOR|placebo|
62012370|NCT05259449|NO_INTERVENTION|Control (CG+INACT)|Participants who do not receive neither nutritional education nor exercise program. They will be instructed to maintain their normal life habits with respect to physical activity and diet.
62012371|NCT05259449|ACTIVE_COMPARATOR|Moderate-intensity continuous training (CG+MICT)|Participants who do not receive nutritional education but are enrolled in a moderate-intensity continuous training exercise program.
62012372|NCT05259449|ACTIVE_COMPARATOR|High-intensity interval training (CG+HIIT)|Participants who do not receive nutritional education but are enrolled in a high-intensity interval training exercise program.
62012373|NCT05259449|ACTIVE_COMPARATOR|Nutritional Education (EDU+INACT)|Participants who receive nutritional education but not an exercise program.
62012374|NCT05259449|EXPERIMENTAL|Nutritional Education Moderate-intensity continuous training (EDU+MICT)|Participants who receive nutritional education and are enrolled in a moderate-intensity continuous training exercise program.
62012375|NCT05259449|EXPERIMENTAL|Nutritional Education High-intensity interval training (EDU+HIIT)|Participants who receive nutritional education and are enrolled in a high-intensity interval training exercise program.
62012376|NCT04650828||Experimental:person with TDF+LDT|TDF combined with LDT for 12 months
62012377|NCT04650828||Active comparator:person with TDF|TDF monotherapy was continued for 12 months
62012378|NCT01449916|EXPERIMENTAL|Simplified Severe Sepsis Protocol|This protocol consists of an early aggressive fluid strategy, early blood cultures and antibiotics, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
62012379|NCT01449916|ACTIVE_COMPARATOR|Usual care|Early blood cultures and antibiotics. Monitoring by study nurses as in experimental arm. Other interventions are according to admitting (non-study) doctors' orders.
62012380|NCT02264834|ACTIVE_COMPARATOR|Control group|Lumbar epidural analgesia during the labour and end up after delivery Levobupivacaine 0.1% + Sufentanil 0.2 µg/mL
62012381|NCT02264834|EXPERIMENTAL|Ambulatory group|Lumbar epidural analgesia during the labour and end up after delivery Levobupivacaine 0.07% + Sufentanil 0.3 µg/mL
62012382|NCT05612516|ACTIVE_COMPARATOR|Hydrogen peroxide 9.5% bleaching using a tray with reservoir.|". Alginate impressions of maxillary dental arches of patients will be taken to obtain casts and produce the customized trays.~Reservoirs 1.5 mm thick will be created on the facial surfaces of anterior teeth, including the first premolars in the arches, applying a light-cured resin on the casts. The resin layer thickness will be standardized using a thickness gauge (1.5 mm thickness). Then, customized trays will be fabricated with 1.5 mm-thick vinyl acetate sheets using the thermoforming process. Trays will be precisely trimmed completely involving tooth surface (1.5 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the patients' mouth."
62200201|NCT01110408|EXPERIMENTAL|Cefepime|Cefepime 50 mg/kg per dose (up to 2 g/dose) will be dministered every 8 hours as 30-minutes IV (at least 3 days of IV cefepime only or IV cefepime followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
62200202|NCT04850664|EXPERIMENTAL|CBOT + TAU|CBOT consists of 40 cycles of olfactory stimulation and OFC training tasks, lasting \~45 minutes, once daily over 3 months. Treatment-as-usual (TAU) is standard dosing of buprenorphine (BUP) to a median dose of 24 mg (range 16-32 mg).
62577999|NCT02291666|EXPERIMENTAL|T2D patients with A1C ≤7.0|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
62578000|NCT02291666|EXPERIMENTAL|T2D patients with A1C>7.0|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
62012383|NCT05612516|ACTIVE_COMPARATOR|Hydrogen peroxide 9.5% bleaching using a tray without reservoir.|Alginate impressions of maxillary dental arches of patients will be taken to obtain casts to produce the customized trays. Then, customized trays will be fabricated with no space for reservoir, with 0.9 mm-thick vinyl acetate sheets using the thermoforming process applying a light-cured resin on the casts. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the participants' mouths.
62012384|NCT04307758||Healthy Adults|Healthy subjects aged 18-35 years were enrolled in this study. The muscle strength assessment of the foot intrinsic muscles was assessed with the make test and the break test. The tests were performed with the hip and knee semiflexed in prone position with a hand-held dynamometer. The experimental protocols and methods were explained in detail to all subjects. All participants provided written informed consent in keeping with the ethical principles of the Declaration of Helsinki.
62012385|NCT02784314|EXPERIMENTAL|Robotic-Assisted Radical Prostatectomy|Robotic-Assisted Radical Prostatectomy using da Vinci Surgical System
62012386|NCT02784314|ACTIVE_COMPARATOR|Laparoscopic Radical Prostatectomy|Standard laparoscopic Radical Prostatectomy
62012387|NCT02276495|EXPERIMENTAL|ACB Control + Local Infiltration|ACB Control - 20 ml saline injection for ACB + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
62012388|NCT02276495|EXPERIMENTAL|ACB Study + Local infiltration|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
62578001|NCT02291666|ACTIVE_COMPARATOR|Non T2D subjects|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
62578002|NCT04789148|EXPERIMENTAL|4 IU oxytocin - 24 IU oxytocin - placebo|Main visit 1: 4 IU intranasal oxytocin; Main visit 2: 24 IU intranasal oxytocin; Main visit 3: intranasal placebo
62578003|NCT04789148|EXPERIMENTAL|4 IU oxytocin - placebo - 24 IU oxytocin|Main visit 1: 4 IU intranasal oxytocin; Main visit 2: intranasal placebo; Main visit 3: 24 IU intranasal oxytocin
62200203|NCT04850664|SHAM_COMPARATOR|Sham + TAU|Sham is a CBOT device that uses artificially-scented compressed room air instead of olfactory stimulants and has no OFC cognitive tasks. Similar to the CBOT, sham will be used daily for 45 minutes. TAU is standard dosing of buprenorphine (BUP) to a median dose of 24 mg (range 16-32 mg).
62578004|NCT04789148|EXPERIMENTAL|24 IU oxytocin - 4 IU oxytocin - placebo|Main visit 1: 24 IU intranasal oxytocin; Main visit 2: 4 IU intranasal oxytocin; Main visit 3: intranasal placebo
62578005|NCT04789148|EXPERIMENTAL|24 IU oxytocin - placebo - 4 IU oxytocin|Main visit 1: 24 IU intranasal oxytocin; Main visit 2: intranasal placebo; Main visit 3: 4 IU intranasal oxytocin
62012389|NCT02276495|EXPERIMENTAL|ACB Study Only|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block
62012390|NCT01827904|EXPERIMENTAL|Transcranial ExAblate|Transcranial ExAblate
62012391|NCT01827904|SHAM_COMPARATOR|Sham Transcranial ExAblate|Sham Treatment with Transcranial ExAblate
62578006|NCT04789148|EXPERIMENTAL|Placebo - 4 IU oxytocin - 24 IU oxytocin|Main visit 1: intranasal placebo; Main visit 2: 4 IU intranasal oxytocin; Main visit 3: 24 IU intranasal oxytocin
62578007|NCT04789148|EXPERIMENTAL|Placebo - 24 IU oxytocin - 4 IU oxytocin|Main visit 1: intranasal placebo; Main visit 2: 24 IU intranasal oxytocin; Main visit 3: 4 IU intranasal oxytocin
62578008|NCT02451774|EXPERIMENTAL|Pentoxifylline Plus Chemotherapy|"Pentoxifylline: 10-20 milligrams per kilogram, doses daily by oral, for 30 days.~Chemotherapy: Prednisone, Vincristine, Daunorubicin, L-asparaginase, Cyclophosphamide, Cytarabine, 6-Mercaptopurine, Methotrexate, Hydrocortisone and Cytarabine"
62012392|NCT02285751|EXPERIMENTAL|200mg acetylsalicylic acid per os|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 200mg acetylsalicylic acid per os"
62012393|NCT02285751|EXPERIMENTAL|100mg acetylsalicylic acid intravenous|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 100mg acetylsalicylic acid intravenously."
62200204|NCT06007196||Continuous non-invasive Hemodynamic Monitoring|Continuous non-invasive Hemodynamic Monitoring (Task Force CORE(R) and Task Force CARDIO(R)) will be compared to invasive thermodilution cardiac output measurements in all patients.
62578009|NCT02451774|PLACEBO_COMPARATOR|Placebo Plus Chemotherapy|Placebo: double blind period, one doses daily for 30 days. Chemotherapy: Prednisone, Vincristine, Daunorubicin, L-asparaginase, Cyclophosphamide, Cytarabine, 6-Mercaptopurine, Methotrexate, Hydrocortisone and Cytarabine
62200205|NCT02756533|EXPERIMENTAL|Telemonitoring|Telemonitoring of daily parameters recorded by NIV, transmitted to a remote monitoring platform. When an alert is received the patient is contacted by phone by a nurse to evaluate the worsening of symptoms. Information are transferred to a referent physician for further medical care if needed.
62200206|NCT02756533|PLACEBO_COMPARATOR|control|"Telemonitoring of daily parameters by NIV, transmitted to a remote monitoring platform with no generation of alerts.~Phone calls to patient during the follow-up like false alerts for the blind procedure."
62200207|NCT03330145|EXPERIMENTAL|children who lost a parent to cancer|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
62200208|NCT03330145|ACTIVE_COMPARATOR|children who lost a parent not to cancer|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
62200209|NCT05610124|EXPERIMENTAL|Ad libitum full-fat French fries with beef meatballs|Ad libitum carbohydrate side with fixed amount of protein: Ad libitum full-fat French fries with beef meatballs (25 g protein)
62200210|NCT05610124|EXPERIMENTAL|Ad libitum instant mashed potatoes with beef meatballs|Ad libitum carbohydrate side with fixed amount of protein: Ad libitum instant mashed potatoes with beef meatballs (25 g protein)
62200211|NCT05610124|EXPERIMENTAL|Ad libitum macaroni pasta with beef meatballs|Ad libitum carbohydrate side with fixed amount of protein: Ad libitum macaroni pasta with beef meatballs (25 g protein)
62200212|NCT05610124|EXPERIMENTAL|Ad libitum full-fat French fries with vegetarian substitute meatballs|Ad libitum carbohydrate side with fixed amount of protein: Ad libitum full-fat French fries with vegetarian substitute meatballs (25 g protein)
62200213|NCT05610124|EXPERIMENTAL|Ad libitum instant mashed potatoes with vegetarian substitute meatballs|Ad libitum carbohydrate side with fixed amount of protein: Ad libitum instant mashed potatoes with vegetarian substitute meatballs (25 g protein)
62200214|NCT05610124|EXPERIMENTAL|Ad libitum macaroni pasta with vegetarian substitute meatballs|Ad libitum carbohydrate side with fixed amount of protein: Ad libitum macaroni pasta with vegetarian substitute meatballs (25 g protein)
62200215|NCT04732351||Active sentry|Cataract procedures conducted with the active Sentry handpiece
62200216|NCT04732351||Non-active sentry|Cataract procedures conducted with an handpiece different from the Active Sentry Handpiece
62200217|NCT04689945||Morphine|30 patients who received intravenous morphine intraoperatively, without regional block application
62200218|NCT04689945||Erector Spinae Block|30 patients who had preoperative esp block but did not use morphine during or after surgery
62200219|NCT04689945||Control|30 patients who received multimodal analgesia methods other than ESP block or IV morphine
62200220|NCT05564000|EXPERIMENTAL|Experimental group|"Experimental group: accept three weeks Dating Violence Prevention Program online; every week 20-30 minutes.~The measurements of dating violence myths, bystander attitude, subjective norm, self-efficacy, intention, and behavior were implemented with a pre-, post-test, and 2-month follow-up design to analyze the immediate and continued educational effects."
62401250|NCT03243552|EXPERIMENTAL|Social Skills|All participants will receive 16-week manualized social skills training.
62578010|NCT00912977||Group 1|Groups are defined by another study
62578011|NCT00912977||Group 2|Groups are defined by another study
62578012|NCT00912977||Group 3|Groups are defined by another study
62578013|NCT00812383|EXPERIMENTAL|Bivalirudin|
62200221|NCT05564000|NO_INTERVENTION|Control group|Control group: no intervention. The measurements of dating violence myths, bystander attitude, subjective norm, self-efficacy, intention, and behavior were implemented with a pre-, post-test, and 2-month follow-up.
62200222|NCT01368471|EXPERIMENTAL|MGuard|MGuard stent will be deployed
62200223|NCT01368471|ACTIVE_COMPARATOR|BMS or DES|A regular bare metal stent or drug-eluting stent will be deployed
62200224|NCT02209753|EXPERIMENTAL|BIRB 796 BS, low dose|
62200225|NCT02209753|EXPERIMENTAL|BIRB 796 BS, medium dose 1|
62200226|NCT02209753|EXPERIMENTAL|BIRB 796 BS, medium dose 2|
62200227|NCT02209753|EXPERIMENTAL|BIRB 796 BS, high dose|
62200228|NCT02209753|PLACEBO_COMPARATOR|Placebo|
62200229|NCT03462004|EXPERIMENTAL|Cohort 1: HPIV3/ΔHNF/EbovZ GP vaccine|Participants will receive two doses of 10\^6.0 PFU/mL of HPIV3/ΔHNF/EbovZ GP vaccine on Days 0 and 28 (+28).
62200230|NCT03462004|PLACEBO_COMPARATOR|Cohort 1: Placebo|Participants will receive two doses of placebo on Days 0 and 28 (+28).
62200231|NCT03462004|EXPERIMENTAL|Cohort 2: HPIV3/ΔHNF/EbovZ GP vaccine|Participants will receive two doses of 10\^7.0 PFU/mL of HPIV3/ΔHNF/EbovZ GP vaccine on Days 0 and 28 (+28).
62200232|NCT03462004|PLACEBO_COMPARATOR|Cohort 2: Placebo|Participants will receive two doses of placebo on Days 0 and 28 (+28).
62200233|NCT05842642|PLACEBO_COMPARATOR|Cervical treatment|A treatment of the cervical region will be done for 6 weeks, once a week, and they will be taught exercises to do at home.
62200234|NCT05842642|EXPERIMENTAL|Oculomotor treatment|An oculomotor treatment will be added to the treatment of the cervical group with specific exercises in the area. Once a week during 6 weeks
62200235|NCT05914051|EXPERIMENTAL|Volume preload optimization.|Volume overload with 250 cc saline solution will be performed in the intervention arm, verifying the response of the cardiac output and stroke volume with non invasive continue monitoring.
62200236|NCT05914051|NO_INTERVENTION|Control group|Standard care without volume preload.
62401251|NCT01488695|EXPERIMENTAL|GlideScope Groove|Patient will be intubated using the GlideScope Groove device.
62401252|NCT01488695|ACTIVE_COMPARATOR|Control|Control Group: Macintosh Blade
62401253|NCT05469711|EXPERIMENTAL|Arm 1:|Gamification
62401254|NCT05469711|NO_INTERVENTION|Arm 2|Monitoring
62401255|NCT05477849|EXPERIMENTAL|3+3 design|This is an open label, single-arm trial using standard 3+3 design, in up to 30 HSV seropositive subjects. This rule-based design proceeds with cohorts of three patients
62578014|NCT00812383|ACTIVE_COMPARATOR|Heparin|
62784638|NCT05599243|EXPERIMENTAL|experimental drug|0.15% w/w dutasteride topical O/W emulsion.
62784639|NCT05599243|PLACEBO_COMPARATOR|Placebo|vehicle (excipients)
62578015|NCT03197038|EXPERIMENTAL|Home-based walking exercise|Home-based exercise program: The exercise training group will participate in an educational session on exercise for CKD. Participants will receive a packet of information with an exercise prescription and a heart rate monitor that monitors the exercise. Participants will be asked to exercise (a brisk walk) at home, 3 times per week, for 30-60 minutes for 24 weeks. Participants will be contacted via phone biweekly or more frequently if they are behind the exercise routine, and the investigators will meet with them monthly to provide encouragement and progression of exercise, and to download the heart rate monitor.
62578016|NCT03197038|ACTIVE_COMPARATOR|Control|The control group will receive standard instructions on exercise for patients with kidney disease similar to what is commonly done in clinical practice. The control group will not receive an exercise prescription or heart rate monitor. Participants will be contacted via phone biweekly to answer any questions and ensure continued study participation. The control group will not meet with the investigators monthly.
62578017|NCT01334242|EXPERIMENTAL|LX4211|400 mg of LX4211 administered orally
62578018|NCT01334242|PLACEBO_COMPARATOR|Placebo|Nonidentical placebo administered orally
62578019|NCT00256269|EXPERIMENTAL|Oxaliplatin plus Irinotecan|Drug: Oxaliplatin-40 mg/m2 IV over 60 minutes Every 21 days. Drug: Irinotecan-60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days.
62578020|NCT02173925||Functional dyspepsia group|Patients who had epigastric pain or discomfort with normal upper endoscopy and no organic evidence for explaining these symptoms
62012394|NCT02285751|EXPERIMENTAL|81 mg chewable acetylsalicylic acid|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 81mg chewable acetylsalicylic acid"
62012395|NCT02285751|ACTIVE_COMPARATOR|75mg clopidogrel|"control group for patients with high on treatment platelet reactivity to clopidogrel patients continue with standard treatment 75mg clopidogrel/day"
62012396|NCT02285751|EXPERIMENTAL|60mg prasugrel|"Loading dose of prasugrel for patients who remain tested with high on treatment platelet reactivity in spite of having received an additional loading dose of 600mg clopidogrel"
62012397|NCT02285751|EXPERIMENTAL|600mg clopidogrel|"additional loading dose for 24 patients tested with high on treatment platelet reactivity to clopidogrel"
62012398|NCT02285751|EXPERIMENTAL|180mg ticagrelor|"Loading dose of ticagrelor for patients who remain tested with high on treatment platelet reactivity in spite of having received an additional loading dose of 600mg clopidogrel Loading dose of ticagrelor for patients who remain tested with high on treatment platelet reactivity after being treated with 10mg prasugrel daily"
62012399|NCT02285751|ACTIVE_COMPARATOR|prasugrel 10mg|patients treated with 10mg prasugrel daily
62012400|NCT03394391|EXPERIMENTAL|Intervention group|Daily ART-adherence SMS reminder
62012401|NCT03394391|ACTIVE_COMPARATOR|Control group|Standard adherence counselling/Patient experience group chat
62012402|NCT06404996|EXPERIMENTAL|Smart-phone diary|smart-phone voiding diary application
62012403|NCT06404996|ACTIVE_COMPARATOR|Paper diary|Conventional paper based voiding diary
62012404|NCT01805297|ACTIVE_COMPARATOR|Vitrectomy with Aflibercept Injection|Preoperative 2.0mg intravitreal aflibercept and vitrectomy with intraoperative 2.0mg intravitreal aflibercept injection.
62012405|NCT01805297|ACTIVE_COMPARATOR|Standard Vitrectomy|Preoperative 2.0mg intravitreal aflibercept and standard of care vitrectomy.
62012406|NCT02010424|EXPERIMENTAL|Individual culture|standard IVF protocol: half of the fertilized oocytes of the patient will be cultured individually in drops of 25 µl Cook cleavage medium till day 3 after fertilization and subsequently in drops of 25 µl Cook blastocyst medium till day 5 after fertilization
62012407|NCT02010424|EXPERIMENTAL|WOW|Half of the fertilized oocytes of the patient will be cultured in group in a WOW dish, each in a separate microwell but covered with one drop of 30 µl of Cook cleavage medium till day 3 after fertilization and subsequently all the embryos will be transferred to a new WOW dish (in the exactly the same position) covered with 30 µl of Cook blastocyst medium till day 5 after fertilization
62401256|NCT03874507|EXPERIMENTAL|Technology-based therapy|Patients who require acute rehabilitation due to deconditioning and surgery will receive either virtual reality (VR) or augmented reality (AR) to improve clinical outcomes such as range of motion, gait progression, strength progression, time to first out of bed, time to first step.
62578021|NCT02173925||Control group|Subjects with normal endoscopic finding who do not have any gastrointestinal symptoms
62012408|NCT04003727|ACTIVE_COMPARATOR|Neutral Position|Head and neck will be on neutral position.
62012409|NCT04003727|ACTIVE_COMPARATOR|Sniffing Position|Head and neck will be on sniffing position
62012410|NCT04003727|ACTIVE_COMPARATOR|Head Extension position|Head will be on simple extension position
62012411|NCT04933435|ACTIVE_COMPARATOR|Interventional Radiology Liver Directed Therapies (ILDT)|ILDT includes ablations such as microwave ablation and percutaneous local ablation and embolotherapies including bland embolization, chemoembolization and radioembolization.
62012412|NCT04933435|ACTIVE_COMPARATOR|Hypofractionated Image-Guided Radiation Therapy (HIGRT)|HIGRT is a non-invasive, outpatient procedure typically delivered in 3-10 fractions of radiation.
62012413|NCT05686330|EXPERIMENTAL|Interventional group (Apple watch)|These participants will wear a smartwatch (Apple Watch) for 6 months during 12 hours a day. The smartwatch will alarm the participant if an irregular heart rhythm is detected. When a participant receives an irregular heartbeat notification, they can record an ECG with the smartwatch. The ECG will automatically be sent to the Telecure team for evaluation.
62012414|NCT05686330|NO_INTERVENTION|Control group|These participants will be following standard care alone. These participants are instructed to notify the investigators when atrial fibrillation is detected or when they have visited the emergency department during these six months. At the end of the study period the investigator will either call the participant, or their treating physician to check for these outcome measures.
62012415|NCT04145791|NO_INTERVENTION|No Ice|Patients will receive standard postoperative pain control methods as defined by the participating institution
62012416|NCT04145791|EXPERIMENTAL|Ice|Patients will receive ice packs to the abdomen, in addition to standard postoperative pain control methods as defined by the participating institution
62200237|NCT03863977|ACTIVE_COMPARATOR|Dex4 group|After the surgery, the patients in this group will receive 4 mg dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
62578022|NCT05026112||DCM with MSF (MSF+)|Patients with dilated cardiomyopathy and midwall septal fibrosis identified in a previous cardiac MRI scan
62578023|NCT05026112||DCM without MSF (MSF-)|Patients with dilated cardiomyopathy but without midwall septal fibrosis on previous cardiac MRI scan
62578024|NCT05026112||Control - MSF+|Control healthy volunteers (HV) to the MSF+ cohort
62578025|NCT05026112||Control - MSF-|Control healthy volunteers (HV) to the MSF- cohort
62578026|NCT01136356|EXPERIMENTAL|Morphine, then Buprenorphine|Healthy, out of treatment opioid-dependent residential volunteers (N=7) were randomized to receive morphine (120 mg/day i.m.) administered in four divided doses each day for 9 days (30 mg of morphine four times per day). Participants then underwent an 18-day period of spontaneous opioid withdrawal, during which four double blind i.m. placebo injections were administered daily. After the period of spontaneous withdrawal, participants received buprenorphine (32 mg/day i.m.) administered in four divided doses each day for 9 days (8 mg of buprenorphine four times per day) followed by a second 18-day period of spontaneous withdrawal identical to the withdrawal period described above.
62578027|NCT01136356|EXPERIMENTAL|Buprenorphine, then Morphine|Healthy, out of treatment opioid-dependent residential volunteers (N=7) were randomized to receive buprenorphine (32 mg/day i.m.) administered in four divided doses each day for 9 days (8 mg of buprenorphine four times per day). Participants then underwent an 18-day period of spontaneous withdrawal, during which four double blind i.m. placebo injections were administered daily. After the period of spontaneous withdrawal, participants received morphine (120 mg/day i.m.) administered in four divided doses each day for 9 days (30 mg of morphine four times per day) followed by a second 18-day period of spontaneous withdrawal identical to the withdrawal period described above.
62784640|NCT05593627|EXPERIMENTAL|lithium carbonate|Patients undergoing heart valve surgery with cardiopulmonary bypass will take 250mg lithium carbonate .
62784641|NCT05593627|PLACEBO_COMPARATOR|calcium carbonate|Patients undergoing heart valve surgery with cardiopulmonary bypass will take 500mg calcium carbonate.
62784642|NCT01129661|PLACEBO_COMPARATOR|normal saline (0.9%)|
62784643|NCT01129661|EXPERIMENTAL|CSL112|
62012417|NCT03709550|EXPERIMENTAL|Treatment (decitabine, enzalutamide)|Participants receive decitabine IV over 1 hour on days 1-5 and enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62784644|NCT04228367|EXPERIMENTAL|Meniscal repair|Patients in need of meniscal repair
62784645|NCT01344083|EXPERIMENTAL|T1210|
62012418|NCT06392555||Prenatal ultrasound examinations|
62012419|NCT01221441|EXPERIMENTAL|TissueGene-C|TissueGene-C at 3 x 10e7 cells per injection (intraarticular)
62012420|NCT01221441|PLACEBO_COMPARATOR|Placebo Control|Normal Saline injection
62012421|NCT01340339|EXPERIMENTAL|BILITRON BED®|Super-LED reverse phototherapy
62784646|NCT01344083|ACTIVE_COMPARATOR|Olopatadine hydrochloride|
62784647|NCT03955627|NO_INTERVENTION|Enhanced Standard Care|Participants will receive standard care, plus a brochure about hormonal therapy use.
62012422|NCT01340339|ACTIVE_COMPARATOR|BILIBERÇO®|Fluorescent Reverse Phototherapy
62012423|NCT01563250|NO_INTERVENTION|Core Laboratory|Patients receiving serial routinely available cardiac biomarker testing in a core laboratory setting using Troponin T. (Roche Centaur)
62200238|NCT03863977|ACTIVE_COMPARATOR|Dex8 group|After the surgery, the patients in this group will receive 8 mg dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
62200239|NCT03863977|ACTIVE_COMPARATOR|control group|After the surgery, the patients in this group will 1mg/kg of 0.5% bupivacaine in the TAP block.
62200240|NCT03033940||ATTUNE TM subjects|
62200241|NCT03033940||PFC Sigma subjects|
62200242|NCT00249964|EXPERIMENTAL|Combination Treatment|"Paclitaxel at 175 mg/m2 + Carboplatin at area under the curve (AUC) 5 on day 1. Then, Temozolomide at the doses described under Interventions from day 2 to day 6 (a total of 5 days).~Cycle length is 21 days."
62200243|NCT04747223|EXPERIMENTAL|Retraining (RT) Group|The retraining group will receive a watch accelerometer to use for monitoring their step rate with instructions to increase their preferred step rate by 7.5% over the ten in-field training sessions.
62200244|NCT04747223|NO_INTERVENTION|Control (CON) Group|The control group will receive the same device to monitor their pace but receive no instruction to change their preferred step rate over the ten in-field training sessions.
62200245|NCT01638390|OTHER|Treatment of Myopia|The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
62200246|NCT04448626||Healthy subject|Healthy subject
62200247|NCT04448626||Stable COPD patients|Stable COPD patients
62200248|NCT04448626||Exacerbation COPD patients|Exacerbation COPD patients
62200249|NCT01918592|EXPERIMENTAL|MRI/PET|
62200250|NCT04288505|EXPERIMENTAL|single arm|
62200251|NCT01922388||Early Motor Complication|This group is composed of PD patients with motor complications of 3 years or less. All subjects receive bilateral deep brain stimulation of the subthalamic nucleus and best medical treatment.
62200252|NCT01922388||Late Motor Complication|This group is composed of PD patients with motor complications of more than 3 years. All subjects receive bilateral deep brain stimulation of the subthalamic nucleus and best medical treatment.
62784648|NCT03955627|EXPERIMENTAL|Treatment (Education plus Exercise)|Participants will receive the same materials as the standard care group, plus participate in group exercise and group discussion sessions.
62784649|NCT01632436|EXPERIMENTAL|Stage 1 -Moderate Hepatic Impairment|Pixantrone
62784650|NCT01632436|EXPERIMENTAL|Stage 2 - Severe Hepatic Impairment|Pixantrone
62200253|NCT06160687|ACTIVE_COMPARATOR|PSV arm|Delivery of NIV using PSV mode
62200254|NCT06160687|EXPERIMENTAL|ASV intellisync arm|Delivery of NIV using Intelllisync ASV
62200255|NCT02895919||Control group - blood culture bottles|Standard of care group for control - will inoculate all samples in blood culture bottles for ascitic fluid culture
62200256|NCT02895919||Study group - sample to lab for culture|Study group - will send a sample of ascitic fluid to lab for inoculation in addition to control sample
62200257|NCT03811990|NO_INTERVENTION|Control|
62200258|NCT03811990|ACTIVE_COMPARATOR|Intervention|
62200259|NCT02445651|OTHER|Oral and IV N acetyl Cysteine Cohort|Administration of Intravenous (IV) and Oral N-acetyl Cysteine (NAC) Intervention: IV NAC infusion: Dose: 50mg in 200ml of D5W, frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 600 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
62200260|NCT02445651|NO_INTERVENTION|Control Cohort|Standard of Care Treatment
62200261|NCT01653938|NO_INTERVENTION|control group|
62200262|NCT01653938|EXPERIMENTAL|Video Arm|Use of video decision aid in the experimental arm.
62200263|NCT04149431|ACTIVE_COMPARATOR|Derinat|nasal drops
62200264|NCT04149431|PLACEBO_COMPARATOR|Placebo|nasal drops
62200265|NCT06331390|EXPERIMENTAL|intervenition|immortela cosmetic product
62200266|NCT06331390|PLACEBO_COMPARATOR|placebo|nothing
62200267|NCT02498782|ACTIVE_COMPARATOR|Fexinidazole, 1800 mg, 2 weeks|1800mg (High Dose) 2 weeks (HD - 2 weeks) Group: Fexinidazole, 1800 mg QD for 2 weeks, followed by placebo to complete 8 weeks (total dose: 25,2 g)
62200268|NCT02498782|ACTIVE_COMPARATOR|Fexinidazole, 1800 mg, 4 weeks|1800mg (High Dose) 4 weeks (HD - 4 weeks) Group: Fexinidazole, 1800 mg QD for 4 weeks, followed by placebo to complete 8 weeks (total dose: 50,4 g)
62200269|NCT02498782|ACTIVE_COMPARATOR|Fexinidazole, 1800 mg, 8 weeks|1800mg (High Dose) 8 weeks (HD - 8 weeks) Group: Fexinidazole, 1800 mg QD, for 8 weeks (total dose: 100,8 g)
62200270|NCT02498782|ACTIVE_COMPARATOR|Fexinidazole, 1200 mg, 2 weeks|1200mg (Dose 2 weeks) 2 weeks (LD - 2 weeks) Group: Fexinidazole, 1200 mg QD for 2 weeks, followed by placebo to complete 8 weeks (total dose: 16,8 g)
62200271|NCT02498782|ACTIVE_COMPARATOR|Fexinidazole, 1200 mg, 4 weeks|1200mg (Low Dose) 4 weeks (LD - 4 weeks) Group: Fexinidazole, 1200 mg QD for 4 weeks, followed by placebo to complete 8 weeks (total dose: 33,6 g)
62200272|NCT02498782|ACTIVE_COMPARATOR|Fexinidazole, 1200 mg, 8 weeks|1200mg (Low Dose) 8 weeks (LD - 8 weeks) Group: Fexinidazole, 1200 mg QD for 8 weeks (total dose: 67,2 g)
62200273|NCT02498782|PLACEBO_COMPARATOR|Placebo|Placebo (8 weeks) Group: Fexinidazole matched placebo tablets QD for 8 weeks.
62200274|NCT01132820|EXPERIMENTAL|Treatment (cediranib maleate)|Patients receive cediranib maleate PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62784651|NCT02229929|PLACEBO_COMPARATOR|Part A: Placebo|Intravenous matched placebo
62784652|NCT02229929|EXPERIMENTAL|Part A: CR845 0.5 mcg/kg|Intravenous CR845, 0.5 mcg/kg
62200275|NCT02974400|EXPERIMENTAL|Internet-based guided self-help|Internet-based, guided, CBT-oriented self-help treatment for persecutory ideation and auditory verbal hallucinations with access to a self-help website including regular written electronic contact with a guide and access to smartphone-based interactive worksheets (8 weeks)
62200276|NCT02974400|NO_INTERVENTION|Wait-List|Wait-list control group (8 weeks)
62200277|NCT02282553|EXPERIMENTAL|Magnetically steerable pill camera|Capsule endoscopy uses a swallowable pill camera which passes through the GI tract by the action of peristalsis. The procedure utilizes a battery powered wireless capsule to transmit images of the gastrointestinal tract as it passes through the small intestine. The images are later downloaded to a computer and reviewed by a trained physician. Magnetically steerable gastric capsule endoscopy uses a pill camera containing a small amount of magnetic material, that can be manoeuvred in the gut and intestine by the physician using a handheld magnet. This technique will be compared to conventional gastroscopy which uses a flexible endoscope. Both techniques will be used to diagnose upper gastrointestinal pathology in patients with recurrent/refractory iron deficient anemia.
62401257|NCT03874507|NO_INTERVENTION|Standard of Care therapy|Patients who require acute rehabilitation due to deconditioning and surgery will receive physical therapy based on his/her providers recommendations to improve outcomes such as range of motion, gait progression, strength progression, time to first out of bed, time to first step
62401258|NCT00525499|PLACEBO_COMPARATOR|1|Vehicle control cream applied topically to the face twice daily for 12 weeks
62401259|NCT00525499|EXPERIMENTAL|2|0.001% ASC-J9 cream applied topically to the face twice daily for 12 weeks
62401260|NCT00525499|EXPERIMENTAL|3|0.005% ASC-J9 cream applied topically to the face twice daily for 12 weeks
62401261|NCT00525499|EXPERIMENTAL|4|0.025% ASC-J9 cream applied topically to the face twice daily for 12 weeks
62401262|NCT02147574|EXPERIMENTAL|antiperistaltic ileosigmoid anastomosis|To assess the operative results after laparoscope subtotal colectomy with antiperistaltic ileosigmoid anastomosis for the slow-transit constipation.
62401263|NCT04935528|OTHER|vaccined salaried staff (group 1)|"vaccined salaried staff group (Distinction between~* Employees vaccinated with two doses of vaccine (2 Pfizer doses or 2 Astra doses or 1 Pfizer dose + 1 Astra dose) and never infected with SARS-CoV-2~* And employees vaccinated with one dose of Pfizer or Astra vaccine and previously infected with SARS-CoV-2"
62401264|NCT04935528|OTHER|non vaccined salaried staff (group 2 - witnesses)|non vaccined salaried staff group wtih positive SARS-CoV-2
62401265|NCT04935528|OTHER|vaccined patients (group 3)|vaccined patient group
62401266|NCT02701907|OTHER|breast cancer|In this study, we aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. We will focus our analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
62578028|NCT06143241|EXPERIMENTAL|Experimental Group|It consists of 20 children diagnosed with epilepsy who will receive inspiratory muscle training following routine medication use. The experimental group will receive inspiratory muscle training with the Thershold device for 30 minutes every day for 8 weeks.
62578029|NCT06143241|ACTIVE_COMPARATOR|Control Group|The control group consists of 20 children diagnosed with epilepsy who will only be followed up with routine medication.
62578030|NCT00823069|OTHER|Perlane and Perlane-L|This is a split-face design injecting both Perlane and Perlane-L injectable gels, administered once. Each subject received Perlane-L on one side of the face, and Perlane on the other. Subjects were blinded to which side of their face receive Perlane or Perlane-L. The study was randomized and treatments successive.
62578031|NCT06001788|EXPERIMENTAL|Phase 1a|"Oral ziftomenib; sequential cohorts of escalating dose levels of ziftomenib to identify the safety and tolerability of the combination regimens. Participants will be enrolled in 1 of 5 dose escalation cohorts:~A-1: Participants with a NPM1 mutation: ziftomenib plus FLAG-IDA~A-2: Participants with a NPM1 mutation: ziftomenib plus low-dose cytarabine (LDAC)~A-3: Participants with a NPM1 mutation: ziftomenib plus gilteritinib~B-1: Participants with a KMT2A rearrangement: ziftomenib plus FLAG-IDA~B-2: Participants with a KMT2A rearrangement: ziftomenib plus low-dose cytarabine (LDAC)"
62401267|NCT02701907|OTHER|non-small cell lung cancer|"In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies.~The investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed"
62401268|NCT02701907|OTHER|kidney cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
62401269|NCT02701907|OTHER|colorectal cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
62401270|NCT02701907|OTHER|ovarian cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
62784653|NCT02229929|EXPERIMENTAL|Part A: CR845 1.0 mcg/kg|Intravenous CR845, 1.0 mcg/kg
62784654|NCT02229929|EXPERIMENTAL|Part A: CR845 2.5 mcg/kg|Intravenous CR845, 2.5 mcg/kg
62784655|NCT02229929|PLACEBO_COMPARATOR|Part B: Placebo|Intravenous matched placebo
62784656|NCT02229929|EXPERIMENTAL|Part B: CR845 1.0 mcg/kg|Intravenous CR845, 1.0 mcg/kg
62784657|NCT03100058|EXPERIMENTAL|LIK066 2.5mg qd (Epoch 3)|LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks.
62784658|NCT03100058|PLACEBO_COMPARATOR|Placebo (Epoch 3)|Matching placebo tablets for 24 weeks
62784659|NCT03100058|EXPERIMENTAL|LIK066 10mg qd (Epoch 3)|LIK066 10mg qd (once daily) dosing frequency for 24 weeks
62784660|NCT03100058|EXPERIMENTAL|LIK066 50mg qd (Epoch 3)|LIK066 50mg qd (once daily) dosing frequency for 24 weeks
62401271|NCT02701907|OTHER|skin cutaneous melanoma|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
62578032|NCT06001788|EXPERIMENTAL|Phase 1b|"Oral ziftomenib; Following the determination of the maximum tolerated dose in Phase 1a, participants will be enrolled in 1 of 5 dose validation/expansion cohorts:~A-1: Participants with a NPM1 mutation: ziftomenib plus FLAG-IDA~A-2: Participants with a NPM1 mutation: ziftomenib plus low-dose cytarabine (LDAC)~A-3: Participants with a NPM1 mutation: ziftomenib plus gilteritinib~B-1: Participants with a KMT2A rearrangement: ziftomenib plus FLAG-IDA~B-2: Participants with a KMT2A rearrangement: ziftomenib plus low-dose cytarabine (LDAC)"
62578033|NCT06257472|EXPERIMENTAL|IBS/VR Program (SynerGI)|
62578034|NCT06257472|SHAM_COMPARATOR|Sham VR Program|
62578035|NCT02384746|EXPERIMENTAL|Combination Treatment|Fulvestrant (500mg) + MLN9708 (2.3, 3, and 4mg)
62578036|NCT00237458|EXPERIMENTAL|Lacosamide|Open-label active treatment
62578037|NCT02657122|EXPERIMENTAL|TD-1473 for SAD|6 of out 8 subjects per cohort will be randomized to receive TD-1473
62578038|NCT02657122|PLACEBO_COMPARATOR|Placebo for SAD|2 of out 8 subjects per cohort will be randomized to receive placebo
62578039|NCT02657122|EXPERIMENTAL|TD-1473 for MAD|6 of out 8 subjects per cohort will be randomized to receive TD-1473
62401272|NCT04831255|EXPERIMENTAL|ZILRETTA|Single injection of triamcinolone acetonide extended-release injectable suspension, injected in the glenohumeral joint under ultrasound guidance.
62401273|NCT03134001|EXPERIMENTAL|Test Group|Patients receiving oral analgesics via the PCoA™ Acute device
62401274|NCT03134001|NO_INTERVENTION|Control Group|Patients receiving oral analgesics by nurse, upon request
62578040|NCT02657122|PLACEBO_COMPARATOR|Placebo for MAD|2 of out 8 subjects per cohort will be randomized to receive placebo
62578041|NCT03223415|EXPERIMENTAL|Experimental arm|Detection and isolation of C. difficile carriers
62578042|NCT03223415|NO_INTERVENTION|Control arm|No detection of C. difficile carriers upon admission and no implementation of contact isolation precautions for C. difficile carriers
62578043|NCT05533008|EXPERIMENTAL|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
62578044|NCT05533008|PLACEBO_COMPARATOR|Placebo|IV Placebo administered after each dialysis session (3 times/week)
62401275|NCT01040806|EXPERIMENTAL|Health coaching|Patients with poorly controlled diabetes will receive counseling from a peer health coach -- a patient with diabetes trained in health coaching
62578045|NCT05513274|EXPERIMENTAL|Pain Psychology Neuroscience+ Written Emotional Disclosure|Pain Neuroscience Education exercise followed by Written Emotional Disclosure
62578046|NCT05513274|ACTIVE_COMPARATOR|Pain Psychology Neuroscience + Healthy Habits Disclosure|Pain Neuroscience Education followed by Healthy Habits writing
62578047|NCT05513274|ACTIVE_COMPARATOR|Health Behavior + Written Emotional Disclosure|Health behavior education followed by written emotional disclosure
62578048|NCT05513274|PLACEBO_COMPARATOR|Health Behavior + Healthy Habits Disclosure|Health behavior intervention followed by healthy habits writing
62578049|NCT05099185||Maintenance online post-dilution hemodiafiltration patients|Maintenance hemodialysis patients who undergo hemodialysis 3 times per week with online post-dilution hemodiafiltration process
62578050|NCT03373084||hamstring muscle lesions|Patients with hamstring muscle lesions in sport will be included. As usual practice they will have Magnetic Resonance Imaging (MRI) or ultrasound, and will answer to self-questionnaire
62578051|NCT05017519||Nuclear family type|The husband and wife with baby (aged less than 5 months) and with or without children (2-5)
62578052|NCT05017519||Extended family type (three-generation family)|The husband and wife with baby (aged less than 5 months), children (2-5), and grandparents aged \> 65 years old
62578053|NCT03316651|EXPERIMENTAL|GM-CSF|"After the patients were randomly divided into two groups, they will receive whole lung lavage (WLL), and then one of the two groups with continue the next step as follows:~Induction period: The time of beginning is 1 week after whole lung lavage, aerosolized GM-CSF was given for 7 days (150ug bid), and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle, a total of 6 cycles (3 months) were known as the induction period.~Maintenance period: maintenance period came up after the induction period. The dose of aerosolized GM-CSF was reduced to 150ug/d for three times a week, and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle and maintenance period lasted for 9 months."
62578054|NCT05236439|EXPERIMENTAL|Interposition supraciliary implant|Any patients corresponding to inclusion / exclusion criteria
62578055|NCT04768998||Intersectoral Platform (SÜP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensus data set GECOO), with other NAPKON study platforms (HAP, POP).
62401276|NCT01040806|ACTIVE_COMPARATOR|Usual care|Patients will receive usual care
62401277|NCT04802421|ACTIVE_COMPARATOR|CPAP30|a 30 secondes 30 cmH2O continuous positive airway pressure applied after the orotracheal intubation will be checked and secured following induction of general anesthesia
62401278|NCT04802421|ACTIVE_COMPARATOR|STEP30|a stepwise increase (+5 cmH2O) in postivie airway pressure from +5 cmH2O to +30 cmH2O and decrease (-5 cmH2O) from +30 cmH2O to +5 cmH2O applied after the orotracheal intubation will be checked and secured following induction of general anesthesia
62401279|NCT02456272|EXPERIMENTAL|External hearing aid & Otosclerosis surgery|Trying an hearing aid for at least two months and then undergo otosclerosis surgery
62578056|NCT04768998||Populationbased Platform (POP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensus data set GECOO), with other NAPKON study platforms (HAP, SUEP).
62578057|NCT04768998||High-Resolution Platform (HAP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensus data set GECOO), with other NAPKON study platforms (POP, SUEP).
62578058|NCT03428503|EXPERIMENTAL|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solution Bristol-Myers Squibb_UK) intravenous (IV) was given 100 patients
62578059|NCT03428503|EXPERIMENTAL|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
62578060|NCT01231724|ACTIVE_COMPARATOR|Allstate Nasal Spray|
62012424|NCT01563250|ACTIVE_COMPARATOR|Point of Care|Patients will receive the Point of Care testing intervention using serial cardiac biomarker testing at the bedside including myoglobin, Troponin I and CK-MB. (Triage Cardiac Panel, Alere)
62012425|NCT06288867|ACTIVE_COMPARATOR|Labral Repair|Labral tears will be repaired with suture anchors.
62012426|NCT06288867|ACTIVE_COMPARATOR|Labral Debridement|Labral Debridement will be done by electrocautery
62012427|NCT02039427|PLACEBO_COMPARATOR|Placebo|Normal saline(Placebo) 2 ml 5 min before induction Normal saline 2 ml 10 min before end of surgery
62012428|NCT02039427|ACTIVE_COMPARATOR|Preketorolac|Ketorolac 30 mg 5 min before induction Normal saline 2 ml 10 min before end of surgery
62012429|NCT02039427|ACTIVE_COMPARATOR|Postketorolac|Normal saline 2 ml 5 min before induction Ketorolac 30 mg 10 min before end of surgery
62401280|NCT01795534|EXPERIMENTAL|Beetroot shot then placebo shot|"Intervention: Participants will first consume a Beetroot shot: 1x70ml concentrated NO-3 shot of rich Beetroot juice (\~7mmol nitrate) (Beet It, James White Drinks Ltd, Ipswich, UK).~Following a four day wash out, participants will then consume a Nitrate-depleted beetroot shot: 1x70ml nitrate-depleted beetroot Placebo shot (\~0.003mmol of nitrate)(Beet It, James White Drinks Ltd, Ipswich, UK)"
62012430|NCT02039427|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone 10 mg (total volume 2 ml) 5 min before induction Normal saline 2 ml 10 min before end of surgery
62012431|NCT04747938|EXPERIMENTAL|Energy accumulator|Energy Accumulator was a portable handheld device invented for local heat therapy for healthcare purpose. All subjects treated with thermal therapy using the Energy Accumulator by acupoint concepts.
62012432|NCT04747938|EXPERIMENTAL|Home exercise program|Home exercises aimed at providing gentle mobilization at the shoulder and were capable of carrying out at home. Patients were requested to perform the movements on a daily basis within the first 4 weeks of treatment. Four movements were involved: Movement 1 - Pendular Exercise, Movement 2 - Circle Exercise, Movement 3 - Wall Climbing Exercise, and Movement 4 - Lie on bed and move both arms up and down.
62012433|NCT01484470|NO_INTERVENTION|Unmanipulated arm|Participants that do not meet criteria for StemEx®, will be registered into the unmanipulated UCB arm and receive the standard conditioning regimen.
62012434|NCT01484470|EXPERIMENTAL|Stemx Arm|StemEx is a stem/progenitor cell-based product of ex-vivo expanded allogeneic UCB, which is administered to the subject in combination with the non-manipulated portion of the same cord blood unit (CBU). The CBU must be cryopreserved in two portions of which the larger (or equal) CBU portion contains at least 1.5 x 107 total nucleated cells (TNC)/Kg. This portion remains unmanipulated and is transplanted on Day 0. StemEx is derived from the smaller (or equal) CBU portion, which is expanded ex vivo for 21 days starting pre-transplant in the presence of cytokines TPO, IL-6, Flt-3L and SCF at a concentration of 50ng/ml and 5μM tetraethylenepentamine (TEPA)
62578061|NCT01231724|PLACEBO_COMPARATOR|Placebo Nasal Spray|
62578062|NCT03464331|EXPERIMENTAL|EXP group|Participants in EXP group (EXP) will be asked to practise Zero-time exercises (ZTE) at least 20-30 minutes per day, and on most and preferably all days of the week.
62578063|NCT03464331|PLACEBO_COMPARATOR|CON group|Participants in CON group (CON) will be asked to practise relaxation exercises (RE) and deep-breathing exercises (DBE) at least 30 mins every day.
62578064|NCT06522698|EXPERIMENTAL|Smart Pill Bottle Data Collection Group|Group of patients in which data on postoperative opioid medication consumption will be collected through the use of smart pill bottles.
62578065|NCT00890370|OTHER|1|Active cycle of breathing techniques
62012435|NCT04657159||2010-2016|Patients treated 2010-2016
62012436|NCT04657159||2017-2019|Patients treated 2017-2019
62200278|NCT05284630|ACTIVE_COMPARATOR|Experimental Group|Exercise follow up with mobile application in patients with chronic neck pain five sessions a week for 4 weeks
62012437|NCT05897216|EXPERIMENTAL|Sequence A|Period 1: CKD-383 (A single oral dose of 1 tablets under fed condition) Period 2: CKD-501, D745, D150, D029 (A single oral dose of 4 tablets under fed condition)
62578066|NCT00890370|OTHER|2|Autogenic drainage
62578067|NCT00890370|OTHER|3|R-C Cornet
62578068|NCT00890370|OTHER|4|Flutter
62578069|NCT00890370|OTHER|5|PEP
62784661|NCT03100058|EXPERIMENTAL|LIK066 150mg qd (Epoch 3)|LIK066 150mg qd (once daily) dosing frequency for 24 weeks
62784662|NCT03100058|EXPERIMENTAL|LIK066 2.5mg bid (Epoch 3)|LIK066 2.5mg bid (once daily) dosing frequency for 24 weeks
62784663|NCT03100058|EXPERIMENTAL|LIK066 5mg bid (Epoch 3)|LIK066 5mg bid (once daily) dosing frequency for 24 weeks
62200279|NCT05284630|ACTIVE_COMPARATOR|Control Group|Home based exercise follow up him/herself in patients with chronic neck pain five sessions a week for 4 weeks
62200280|NCT02690116|EXPERIMENTAL|Qigong/Tai Chi Easy|The Qigong/Tai Chi Easy (QG/TCE) intervention has been standardized, manualized, and has a formal training program for instructors from the Institute of Integral Qigong and Tai Chi (IIQTC).
62578070|NCT03317730|EXPERIMENTAL|RT + Xtampza ER|This study will enroll patients scheduled to receive radiation therapy (RT), but RT details are not specified by this protocol. Patients taking long acting opioid analgesics prior to enrollment will be converted to an equivalent dose of Xtampza ER at the time of enrollment. For the remaining patients not previously prescribed opioid analgesics, Xtampza ER will be initiated when 2 or more daily doses of short acting opioids are required, resulting in a total daily dose of at least 30mg morphine sulfate equivalent. During RT, pain will be assessed on a weekly basis using the PI-NRS and the dose of Xtampza ER will be adjusted at the discretion of the treating physician, with recommendation to maintain an equivalent of 100% daily opioid requirement. Assessment for tapering of Xtampza ER will begin 1 month following the completion of RT at the time of first follow-up.The study period will end 3 months following the final fraction of RT.
62200281|NCT02690116|SHAM_COMPARATOR|Sham Qigong|This active control group uses a gentle movement intervention, with similar types of movements with the same energy expenditure, but without the meditative states and breath focus as QG/TCE (validated in the pilot study using the Meditative Movement Inventory).
62200282|NCT02690116|ACTIVE_COMPARATOR|Educational Support|The Recovery Support Group will consist of a classroom-style intervention, designed to educate, engage interaction, and maintain participation and attention over 8 weeks. This group will include readings/discussions specific to breast cancer, and social interaction facilitation.
62200283|NCT03176264|EXPERIMENTAL|PDR001|
62200284|NCT01016847|ACTIVE_COMPARATOR|leukotriene receptor antagonist (LTRA) montelukast|Montelukast (LTRA) administered with moderate dose of inhaled steroid
62200285|NCT01016847|PLACEBO_COMPARATOR|Sugar Pill|High dose of inhaled steroid administered with sugar pill
62200286|NCT05269953|EXPERIMENTAL|Active stimulation|
62200287|NCT05269953|SHAM_COMPARATOR|Sham stimulation|
62200288|NCT05269953|NO_INTERVENTION|Waitlist (no stimulation)|Treatment as usual
62200289|NCT00515723|ACTIVE_COMPARATOR|Olanzapine|Participants in this group were randomized to flexibly-dosed treatment with olanzapine.
62200290|NCT00515723|ACTIVE_COMPARATOR|Risperidone|Participants in this group were randomized to flexibly-dosed treatment with risperidone.
62200291|NCT00515723|ACTIVE_COMPARATOR|Quetiapine|Participants in this group were randomized to flexibly-dosed treatment with quetiapine.
62200292|NCT00515723|ACTIVE_COMPARATOR|Ziprasidone|Participants in this group were randomized to flexibly-dosed treatment with ziprasidone.
62401281|NCT01795534|PLACEBO_COMPARATOR|Placebo shot then beetroot shot|"Intervention: Participants will first consume a Nitrate-depleted beetroot shot: 1x70ml nitrate-depleted beetroot Placebo shot (\~0.003mmol of nitrate)(Beet It, James White Drinks Ltd, Ipswich, UK).~Following a four day wash out, participants will then consume a Beetroot shot: 1x70ml concentrated NO-3 shot of rich Beetroot juice (\~7mmol nitrate) (Beet It, James White Drinks Ltd, Ipswich, UK)."
62401282|NCT05467995|EXPERIMENTAL|AK111 75mg|AK111 75mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.
62401283|NCT05467995|EXPERIMENTAL|AK111 150mg|AK111 150mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.
62578071|NCT04219124|ACTIVE_COMPARATOR|Dapagliflozin|Investigational product: Dapagliflozin 10 mg Dosage form and strength: Green, plain, diamond shaped, film coated 10 mg tablet with frequency of 1 tablet per day for 4 weeks
62401284|NCT05467995|EXPERIMENTAL|AK111 300mg|AK111 300mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.
62578072|NCT04219124|PLACEBO_COMPARATOR|Placebo|Investigational product: Matching placebo for Dapagliflozin 10 mg. Dosage form and strength: Green, plain, diamond shaped, and film coated tablet with frequency of 1 tablet per day for 4 weeks
62200293|NCT05235282|EXPERIMENTAL|Usual care + IQoro|The intervention group receives usual training of swallowing function along with training 3 times each day with an IQoro oral screen
62200294|NCT05235282|ACTIVE_COMPARATOR|Usual care|The comparison group receives usual training of swallowing function
62200295|NCT05988944|ACTIVE_COMPARATOR|Traditional techniques|TT was planned according to the child's hand that was needed. Neurodevelopmental facilitation techniques (Bobath therapy), stretching, and grasping types (cylindrical, spherical, hook, key, fingertip, lateral) were used in hands therapy for 45 minutes two days in a week for all children who were accepted to participate in this study.
62578073|NCT01126814|EXPERIMENTAL|one|
62578074|NCT00585936||1|Normal controls without evidence of diabetes or islet specific autoimmunity
62578075|NCT00585936||2|Individuals within 6 months of diagnosis with type 1 diabetes
62578076|NCT00585936||3|Individuals at high risk for the development of type 1 diabetes
62578077|NCT00585936||4|Individuals with longstanding autoimmune diabetes
62200296|NCT05988944|EXPERIMENTAL|traditional therapy with constraint induced movement therapy|The sling was put on the child's non-paretic arm to apply CIMT. The around of the sling was sewn except the elbow and secured snugly to the trunk with a waist strap to prevent assisting the affected hand during the application of CIMT. However, children with CP who were in the this group used the sling for three hours in daily activity, playing, etc. at home. The CIMT was given as a home program and monitorization was done by the follow-up form every week with no therapy during the weekend.
62200297|NCT05988944|EXPERIMENTAL|traditional therapy with constraint induced movement therapy and virtual reality|After the TT session, a child with CP used the sling for 45 minutes at the rehabilitation center with VR therapy. VR therapy with CIMT was used in hands therapy for 45 minutes at two days a week after TT. During the VR therapy, the child was encouraged verbally to play X-box.The X-box Kinect 360 (by the Microsoft corporation) was used for VR therapy. It has a kinetic sensor that perceives the movement of the child with CP. The child's movement can be seen through the monitor in real time. VR does not need special buttons to play. Therefore, a child with CP who had impaired fine motor skills and dexterity can play easily.
62200298|NCT02434757|EXPERIMENTAL|Acthar 40 U|Acthar 40 U (0.5mL)
62200299|NCT02639455|NO_INTERVENTION|Athlete group|Participants wo regularly exercise and are student athletes.
62578078|NCT02580409|OTHER|Single-arm studies|Behavioral Intervention
62200300|NCT02639455|NO_INTERVENTION|Non-exercise group|Participants who are not student athletes.
62578079|NCT03226769|ACTIVE_COMPARATOR|Thermalon|Participants received application of Thermalon dry eye compress on Days 0 and 7 followed by daily use as per label instructions.
62578080|NCT03226769|EXPERIMENTAL|TrueTear™|Participants received TrueTear™ device intranasally for approximately 8 minutes on Day 0, for approximately 3 minutes on Day 7 followed by daily use of TrueTear™ per participant guide.
62578081|NCT03157271|NO_INTERVENTION|PFPS Treatment|This arm (group of patients) will receive typical/pragmatically designed treatment for patellofemoral pain syndrome.
62578082|NCT03157271|EXPERIMENTAL|PFPS Plus Dry Needling Treatment|This group will receive the same typical/pragmatically designed treatment for patellofemoral pain syndrome but with the addition of a dry needling intervention.
62578083|NCT03945955|EXPERIMENTAL|Melatonin|
62578084|NCT03945955|PLACEBO_COMPARATOR|Placebo|
62578085|NCT05235893|EXPERIMENTAL|Reflexology Group|The newborns who have applied Reflexology to soles three minutes before and during 5-7 minutes of painful procedure by a physiotherapist, certificated in reflexology.
62578086|NCT05235893|ACTIVE_COMPARATOR|Sucrose Group|The newborns who were given one ml of a single-use 24% concentration of sucrose solution in the form of ready to use preparations
62578087|NCT05235893|ACTIVE_COMPARATOR|Kangaroo Care Group|The newborns who were placed on the mother's lap for 3-5 minutes before the painful intervention and kangaroo care was applied
62578088|NCT05235893|ACTIVE_COMPARATOR|Music Group|"Newborns who were exposed to the recorded Deep Sleep track from Bedtime Mozart: Classical Lullabies for Babies music"
62578089|NCT05235893|NO_INTERVENTION|Control Group|Control arm
62200301|NCT02639455|EXPERIMENTAL|Exercise group|Participants are not student athletes but commit to modest exercise for 5 weeks as part of this study.
62200302|NCT00140010|EXPERIMENTAL|A|30,000 units of erythropoietin beta in one vial; 3 vials as one set per patient
62200303|NCT04223544||GPs Healthcare Workers|
62200304|NCT04223544||Hospital Healthcare Workers|
62200305|NCT00271206|ACTIVE_COMPARATOR|Progesterone|200 mg to 400mg of progesterone
62578090|NCT01852149|EXPERIMENTAL|MPAS Implant|MPAS Implant
62578091|NCT05840211|EXPERIMENTAL|Sacituzumab Govitecan-hziy (SG)|Participants will receive SG at a dose of 10 mg/kg infusion on Days 1 and 8 of a 21-day cycle.
62200306|NCT00271206|PLACEBO_COMPARATOR|Sugar Pill|Will mirror active medication
62578092|NCT05840211|ACTIVE_COMPARATOR|Treatment of Physician's Choice (TPC)|"Participants will receive TPC determined prior to randomization to 1 of the 3 allowed regimens:~* paclitaxel 80 mg/m\^2 over 1 hour (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle.~* nab-Paclitaxel 100 mg/m\^2 over 30 minutes (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle.~* capecitabine at 1000-1250 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period of a 21-day cycle."
62200307|NCT04646863|EXPERIMENTAL|group A|consists of 20 patients received a multiwave locked system laser
62200308|NCT04646863|EXPERIMENTAL|group B|consists of 20 patients received Pilates exercises
62200309|NCT04646863|EXPERIMENTAL|group C|consists of 20 patients received a multiwave locked system laser and Pilates exercises
62200310|NCT01968889||Critical illness neuromyopthy|Non invasive phrenic nerve stimulation allowing to measure the twitch airway pressure during airway occlusion
62578093|NCT03220204|EXPERIMENTAL|PP-based health behavior intervention|Participants will undergo a 12-week, Positive Psychology (PP)-based health behavior intervention. Each weekly session will include (a) a review of the week's PP exercise, (b) a discussion of the rationale of the next week's PP exercise through a guided review of the PP manual, and (c) assignment of the next week's PP exercise. Additionally for the goal-setting portion, participants will (a) review their goals and behaviors from the prior week, (b) discuss techniques for improving health behavior adherence (e.g., monitoring physical activity, reading nutrition labels), and (c) set goals for the next week.
62578094|NCT03220204|EXPERIMENTAL|MI-based educational control condition|Participants will undergo 12 weekly phone sessions to learn about a different health behavior topic related to cardiac health. This Motivational Interviewing (MI)-based educational control condition will introduce these participants to motivational interviewing topics in concert with the health behavior education topics.
62578095|NCT03220204|NO_INTERVENTION|Treatment as Usual (TAU)|Participants in the Treatment as Usual (TAU) group will not receive any interventions between the baseline visit and follow-up visits.
62200311|NCT01504776|EXPERIMENTAL|Open Label Drug Therapy|Single arm
62012438|NCT05897216|EXPERIMENTAL|Sequence B|Period 1: CKD-501, D745, D150, D029 (A single oral dose of 3 tablets under fed condition) Period 2: CKD-383 (A single oral dose of 2 tablets under fed condition)
62200312|NCT01495572|EXPERIMENTAL|High Dose (HD) Aldesleukin|Pts receiving high dose aldesleukin: Cyclophosphamide 60 mg/kg intravenous (IV) for days -7 and -6, Fludarabine 25 mg/m\^2 IV for days -5 to -1, plus melanoma antigen recognized by T cells (MART)-127-35 reactive CD8+ peripheral blood lymphocytes (PBL) up to 3x10\^11 IV over 20-30 minutes on day 0, plus aldesleukin 720,000 IU/kg IV over 15 minutes, every 8 hrs for up to 5 days.
62200313|NCT01495572|EXPERIMENTAL|Peripheral Blood Lymphocytes (PBL)|Cyclophosphamide 60 mg/kg intravenous (IV ) for days -7 and -6, Fludarabine 25 mg/m\^2 IV for days -5 to -1, plus MART-127-35 reactive CD8+ PBL up to 3x10\^11 IV over 20-30 minutes on day 0
62200314|NCT05003492|ACTIVE_COMPARATOR|Combination Therapy plus Standard therapy|"Methylene Blue 1 mg/kg water solution. Participants will orally receive Methylene Blue solution of 1 mg/kg concentration one time if any. After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm\^2 energy dose will be performed.~Patients will be administered study medication (Inhaled 100-150 mg phenformin per day; or, if broken into 3 doses/day, 30-50 mg/dose. this dose well be once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.~Patients will receive an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)~Patients received will receive Zinc gluconate capsule 15 mg x 2 per day during 14 days"
62012439|NCT03797027|OTHER|No cushion|Patients in no cushion group undergo prone percutaneous nephrolithotomy without an abdominal cushion
62200315|NCT05003492|SHAM_COMPARATOR|Standard Therapy|Infected patients will receive the standard therapy for COVID-19 for 14 days
62578096|NCT04664738|EXPERIMENTAL|10 % PEP only|Cohort 1: Subjects will receive 10% PEP to the skin graft donor wound.
62200316|NCT03132675|EXPERIMENTAL|tavo-EP plus IV pembrolizumab|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab
62200317|NCT00587691|EXPERIMENTAL|Dose Level 1|6-9 million MRTC
62200318|NCT00587691|EXPERIMENTAL|Dose Level 2|30-45 million MRTC
62012440|NCT03797027|OTHER|5 cm cushion|Patients in 5 cm cushion group undergo prone percutaneous nephrolithotomy with an 5 cm abdominal cushion
62012441|NCT03797027|OTHER|10 cm cushion|Patients in 10 cm cushion group undergo prone percutaneous nephrolithotomy with an 10 cm abdominal cushion
62012442|NCT00927927|EXPERIMENTAL|SD 0.0002 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.0002 mg/kg
62012443|NCT00927927|EXPERIMENTAL|SD 0.0012 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.0012 mg/kg
62012444|NCT00927927|EXPERIMENTAL|SD 0.007 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.007 mg/kg
62012445|NCT00927927|EXPERIMENTAL|SD 0.035 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.035 mg/kg
62012446|NCT00927927|EXPERIMENTAL|SD 0.175 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.175 mg/kg
62200319|NCT00587691|EXPERIMENTAL|Dose Level 3|60-90 million MRTC
62200320|NCT01028872|SHAM_COMPARATOR|Sensar IOL|
62200321|NCT01028872|ACTIVE_COMPARATOR|Tecnis IOL|
62401285|NCT05467995|PLACEBO_COMPARATOR|Placebo|Placebo will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.
62401286|NCT05856357||Active cohort control|Children (aged 10 weeks to 6 months) in the control arm will receive the standard of care: 0 doses of SP.
62012447|NCT00927927|EXPERIMENTAL|SD 0.7 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.7 mg/kg
62200322|NCT01028872|ACTIVE_COMPARATOR|AcrySof IQ|
62200323|NCT03177239|EXPERIMENTAL|Nivolumab and Ipilimumab|"Part 1: nivolumab 240mg IV q2w for a maximum of 12 months.~Part 2; nivolumab 240mg IV q3w in addition to ipilimumab 1mg/kg q3w x 4 cycles Then nivolumab 240mg q2w for a maximum of 12 months."
62200324|NCT06114849|ACTIVE_COMPARATOR|Control|Participants will be identified using a machine learning risk algorithm developed by the investigators that will automatically identify concerning posts (e.g., those mentioning suicidal thoughts or behaviors). RallyPoint members whose posts are flagged will randomly be assigned to the intervention group or the control group.
62200325|NCT06114849|EXPERIMENTAL|Intervention|Participants will be identified using a machine learning risk algorithm developed by the investigators that will automatically identify concerning posts (e.g., those mentioning suicidal thoughts or behaviors). RallyPoint members whose posts are flagged will randomly be assigned to the intervention group or the control group.
62401287|NCT05856357||Active cohort intervention|Children (aged 10 weeks to 6 months) in the intervention arm with receive PMC: five doses of SP at EPI visits (10 weeks, 14 weeks, 9 months, 15 months, 18 months)
62401288|NCT03132610|ACTIVE_COMPARATOR|Experimental group|Conventional Therapy + Xiyanping injection(andrographolide sulfonate)
62401289|NCT03132610|PLACEBO_COMPARATOR|control group|Conventional Therapy + Xiyanping injection simulation/andrographolide sulfonate simulation(0.9% normal saline)
62401290|NCT00008216||alloSCT group|Patients undergoing allogeneic blood or marrow stem cell transplantation (alloSCT).
62578097|NCT04664738|EXPERIMENTAL|20% PEP only|Cohort 2: Subjects will receive 20% PEP to the skin graft donor wound
62578098|NCT04664738|EXPERIMENTAL|20% PEP and TISSEEL|Cohort 3: Subjects will receive 20% PEP and TISSEEL to the skin graft donor wound.
62578099|NCT00056589|EXPERIMENTAL|rFXIII|
62578100|NCT00356148|ACTIVE_COMPARATOR|Prophylaxis Group|patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis
62578101|NCT00356148|NO_INTERVENTION|No Prophylaxis Group|Patients who are BMI over 25 and do not receive antibiotic prophylaxis
62578102|NCT01392924|EXPERIMENTAL|SAR245408|single cohort: SAR245408 administered once daily
62012448|NCT00927927|EXPERIMENTAL|SD 2.5 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 2.5 mg/kg
62012449|NCT00927927|EXPERIMENTAL|SD 7.5 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 7.5 mg/kg
62012450|NCT00927927|EXPERIMENTAL|SD Placebo|Subjects were injected once with placebo
62012451|NCT00927927|EXPERIMENTAL|MD 0.02 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg
62012452|NCT00927927|EXPERIMENTAL|MD 0.3 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg
62012453|NCT00927927|EXPERIMENTAL|MD 1.0 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg
62578103|NCT06192329|SHAM_COMPARATOR|Warm water immersion|On days 2-6 and 8-12 of the therapy sessions, the participants will immerse themselves up to the shoulder in 97°F water for \~30 min, followed by immersion to the hip level for \~60 min (total immersion time of 90 min).
62578104|NCT06192329|EXPERIMENTAL|Hot water immersion|On days 2-6 and 8-12 of the therapy sessions, the participants will immerse themselves up to the shoulder in 105°F water for \~30 min, followed by immersion to the hip level for \~60 min (total immersion time of 90 min).
62578105|NCT00966524|EXPERIMENTAL|Video|Teaching tracheal intubation to medical students using video-guided feedback during the procedure.
62200326|NCT02892643|EXPERIMENTAL|Laparoscopic proximal gastrectomy|Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
62012454|NCT00927927|EXPERIMENTAL|MD 1.6 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg
62200327|NCT02892643|ACTIVE_COMPARATOR|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
62784664|NCT03100058|EXPERIMENTAL|LIK066 25mg bid (Epoch 3)|LIK066 25mg bid (once daily) dosing frequency for 24 weeks
62012455|NCT00927927|EXPERIMENTAL|MD 4.0 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg
62200328|NCT00458952|EXPERIMENTAL|Dose Escalation|Dosing of Ultratrace iobenguane I 131 began at 6.0 mCi/kg and escalated in 1.0 mCi/kg increments in order to establish the MTD. The MTD is the dose immediately below the level at which escalation stops due to dose-limiting toxicity (DLT). An additional 3 patients are to be treated at the MTD, for a total of 6.
62200329|NCT02517177|OTHER|Cardiovascular parameters measurements|
62200330|NCT03750929|NO_INTERVENTION|Non physical exercises|Patients will not be submmitted to combined acute physical exercises (strength and aerobic)
62200331|NCT03750929|EXPERIMENTAL|Physical exercises|Patients will be submmitted to combined acute physical exercises (strength and aerobic) that consist on: supine, paddling, leg press 45º, knee extensor, flexor knee (two sets of 15 to 20 repetitions, with loads between 30% and 40% of a maximum repetition, with 30 seconds of interval). We will perform in the first exercise for upper and lower limbs, for heating, after starting the training where 4 series of 8 to 12 maximum repetitions will be performed, using the load between 70% and 80% of 1 maximum repetitions, already evaluated. The recovery between sets will be 90 seconds and between exercises will be 120 seconds.
62401291|NCT03426995|EXPERIMENTAL|GSK3358699, Part A, Cohort 1|Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose, during TP (1 to 3) with planned escalated doses as 1 mg, 10 mg and 35 mg. Dose of 1 mg will be given as solution and doses of 10 mg and 35 mg, will be given as a capsule. Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654 (NCT03306589).
62578106|NCT00966524|ACTIVE_COMPARATOR|Standard|Teaching tracheal intubation to medical students using direct visualization feedback during the procedure.
62784665|NCT03100058|EXPERIMENTAL|LIK066 50mg bid (Epoch 3)|LIK066 50mg bid dosing frequency for 24 weeks
62012456|NCT00927927|EXPERIMENTAL|MD Placebo|Subjects were injected biweekly four times with placebo
62012457|NCT06191679|NO_INTERVENTION|Usual Care|Subjects will have access to their oncology health care providers and other members of the health care team for questions related to cancer and cancer treatment (as per usual).
62012458|NCT06191679|EXPERIMENTAL|DECIDES|Subjects will receive access to DECIDES with an informational handout that includes goals of the decision support intervention and instructions for accessing the application independently.
62200332|NCT05613777|EXPERIMENTAL|Microgynon®(Run-in)/Microgynon® (treatment reference, R)/ Microgynon®+BI 425809 (treatment test, T)|
62578107|NCT00471081|EXPERIMENTAL|Group A|Single dose GSK134612.
62578108|NCT00471081|EXPERIMENTAL|Group B|Two doses of GSK134612.
62578109|NCT01023477|EXPERIMENTAL|Chloroquine Standard Dose (500mg/week)|Patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month standard dose chloroquine (500 mg/week).
62784666|NCT03100058|EXPERIMENTAL|LIK066 qd/LIK066 25mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
62012459|NCT06191679|EXPERIMENTAL|DECIDES + coach|Subjects will receive access to DECIDES with live, coach-assisted support.
62012460|NCT03181516|EXPERIMENTAL|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt
62012461|NCT03181516|PLACEBO_COMPARATOR|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12
62784667|NCT03100058|EXPERIMENTAL|LIK066 bid/LIK066 35mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
62784668|NCT03100058|EXPERIMENTAL|Placebo/LIK066 25mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
62012462|NCT03927157|EXPERIMENTAL|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
62200333|NCT00513708|NO_INTERVENTION|Treatment As Usual (TAU)|"Treatment as Usual (TAU): Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during medically managed inpatient detoxification."
62578110|NCT01023477|EXPERIMENTAL|Chloroquine Low Dose (250mg/week)|Patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month low dose chloroquine (250mg/week).
62012463|NCT03927157|PLACEBO_COMPARATOR|Placebo|Placebo: Placebo subcutaneous injection
62012464|NCT06664333||Siblings of pediatric intensive care hospitalized children|Siblings of children hospitalized in pediatric intensive care at Necker-Enfants Malades Hospital and Robert Debré Hospital, aged of 10 to 18 years old.
62012465|NCT06664710|ACTIVE_COMPARATOR|Control|Use of the iotaSOFT Insertion System and AIM based on Standard of Care
62200334|NCT00513708|EXPERIMENTAL|Motivational Enhancement Therapy (MET)|"Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during inpatient detoxification plus a 60-minute Motivational Enhancement Therapy (MET) session delivered by a trained professional."
62200335|NCT00513708|EXPERIMENTAL|Peer-delivered Twelve Step Facilitation|"Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during inpatient detoxification plus a 60-minute Peer-delivered Twelve Step Facilitation (P-TSF)session delivered by individuals from a common self-help program."
62200336|NCT05576376|EXPERIMENTAL|plantar fascia release|"plantar fascia open release Longitudinal incision at the medial heel, Exposure of the plantar fascia at its origin on the medial plantar calcaneus. Medial incision of the plantar fascia preserving the lateral portion.. Exposure of the abductor hallucis muscle. Incision of the superficial fascia of the muscle. Retraction of the muscle belly und incision of the deep portion of the fascia, decompression of the first calcaneal branch of the lateral plantar nerve (Baxter's nerve) in cases of its being compressed.~Postoperative management: Two weeks partial weight bearing. Progressively weight bearing using a shoe with a stiff sole for another 4 weeks."
62200337|NCT05576376|EXPERIMENTAL|Plantar fascia endoscopic release|We will draw a line distally from the posterior aspect of the medial malleolus to the intersection of the medial origin of the plantar fascia at the calcaneal tuberosity. A skin incision will be made, and medial portal will be performed at this location. Blunt dissection will be performed to clear the subcutaneous tissue from the plantar fascia with caution to avoid lesion of the calcaneal nerve medial branch.
62200338|NCT05576376|EXPERIMENTAL|Clacaneal osteotomy|calcaneal osteotomy skin incision will be oblique and directed from the inferoposterior edge of the lateral malleolus to the inferior edge of the calcaneal body, and subperiosteal exposure of the lateral calcaneal wall will be performed. Osteotomy will be performed from 1 cm anterior of the calcaneal attachment of the plantar fascia to 1 cm anterior of the calcaneal attachment of the Achilles tendon. After the osteotomy, approximately 5 mm plantar displacement of the proximal fragment, which include attachment of the plantar fascia, will be performed. Fixation after the osteotomy will be performed under an image intensifier using one cannulated cancellous screws 4.5 mm in diameter, which will be inserted from the infero-medial of the calcaneal tuberosity to the distal fragment
62200339|NCT04425590|EXPERIMENTAL|Experimental Group|standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily and DLBS1033 3 times daily (experimental group).
62401292|NCT03426995|EXPERIMENTAL|GSK3358699, Part A, Cohort 2|Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose during TP (1 to 3) with planned escalated doses as 3 mg, 20 mg and 45 mg. Dose of 3 mg will be given as solution and that of 20 and 45 mg, as capsule. Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive 60 microgram per meter\^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654 (NCT03306589).
62578111|NCT02754271|EXPERIMENTAL|Intervention|A research-based film (Fit for Dialysis) and a 16-week exercise program involving activities during dialysis, at home, and in the community.
62578112|NCT02754271|NO_INTERVENTION|Control|The 16-week exercise program involving activities during dialysis, at home, and in the community.
62578113|NCT06389903|EXPERIMENTAL|Behavorial Assessment|post-surgery behavioral assessment using scales
62012466|NCT06664710|EXPERIMENTAL|Experimental|Use of iotaSOFT Insertion System with AIM experimental device
62012467|NCT03610490|EXPERIMENTAL|Treatment (autologous tumor infiltrating lymphocytes MDA-TIL)|"LYMPHODEPLETION REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, and fludarabine IV over 15-30 minutes on days -5 to -1 in the absence of disease progression or unacceptable toxicity.~T-CELL INFUSION: Patients receive autologous tumor infiltrating lymphocytes MDA-TIL IV over 45 minutes on day 0. Patients then receive IL-2 IV over 30 minutes on days 1-4 for up to 6 doses in the absence of disease progression or unacceptable toxicity."
62200340|NCT04425590|ACTIVE_COMPARATOR|Control Group|standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily
62200341|NCT06430229|ACTIVE_COMPARATOR|Patients ventilated with volume controlled ventilation (VCV) mode|Patients to be ventilated with VCV mode were placed on respiratory support (Dräger Primus) with a breathing rate that would provide 8 ml/kg tidal volume, 5 cmH2O positive end expiratory pressure (PEEP), and 30-35 mmHg end-tidal carbon dioxide concentration (etCO2) level.
62200342|NCT06430229|ACTIVE_COMPARATOR|Patients ventilated with pressure controlled ventilation (PCV) mode|Appropriate peak inspiratory pressure was set to create a tidal volume of 8 ml/kg in patients who would be ventilated with PCV mode. The number of breaths (Dräger Primus) was adjusted to provide an end-tidal carbon dioxide concentration (etCO2) level of 30-35 mmHg. PEEP was set to 5 cmH2O.
62200343|NCT03045705|ACTIVE_COMPARATOR|Labor+routine pain management|Women that will be treated by the medical team in the delivery room as if not part of a study regarding pain management.
62200344|NCT03045705|ACTIVE_COMPARATOR|Labor+experimental pain management|Women that will not be asked at all by the medical team in the delivery room regarding analgesia during labor but will be able to receive analgesia at wish at the time of choice.
62401293|NCT03426995|PLACEBO_COMPARATOR|Placebo, Part A, Cohort 1|Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 1 mg and a matching placebo capsule to the study drug GSK3358699, 10 mg and 35 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive Placebo at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654 (NCT03306589).
62578114|NCT04109274|EXPERIMENTAL|Institution-Based Exercise and Self-Management (EXSM)|Eight session of supervised exercise within the cancer institution plus 8 self-management modules focusing on goal setting and action planning for safe and effective exercise strategies (this is based on our team's successful pilot intervention). Four booster sessions will be provided to this group.
62200345|NCT00675532|EXPERIMENTAL|1|Primary Care Counseling
62200346|NCT00675532|EXPERIMENTAL|2|Cognitive-behavioral psychotherapy (CBT)
62200347|NCT04914598|ACTIVE_COMPARATOR|ENDOSTAR combined with cisplatin|
62200348|NCT04914598|PLACEBO_COMPARATOR|Placebo combined with cisplatin|
62200349|NCT02757677||Longitudinal arm|Evaluate optic nerve head blood flow using the new OCT-A software in surgically and medically treated glaucoma patients and in different types of glaucoma
62200350|NCT02757677||24-h Intraocular pressure (IOP) arm|Evaluate the correlation between circadian IOP changes and optic nerve head blood flow using the new OCT-A software
62200351|NCT02757677||Surgery arm|Evaluate blood flow using the new OCT-A software in surgically treated glaucoma patients
62200352|NCT03185884|ACTIVE_COMPARATOR|Control|- 237 ml beverage; consumed once per test visit
62200353|NCT03185884|EXPERIMENTAL|Experimental|- 237 ml beverage; consumed once per test visit
62200354|NCT01373580|EXPERIMENTAL|Raindrop|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near vision.
62200355|NCT02532127|EXPERIMENTAL|Saliva sampling|Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
62784669|NCT03100058|PLACEBO_COMPARATOR|Placebo/Placebo (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
62012468|NCT06570018|EXPERIMENTAL|Enhanced recovery group|who received postoperative enhanced recovery after open surgical repair for perforated peptic ulcer
62012469|NCT06570018|NO_INTERVENTION|Control group|who exposed to standard care
62012470|NCT00216294|EXPERIMENTAL|Currently treated with SSRI|
62012471|NCT00216294|EXPERIMENTAL|Not currently treated with SSRI|
62200356|NCT00645177|ACTIVE_COMPARATOR|A|"In study, this arm is a randomized (blinded) to ABT-869 arm plus paclitaxel.~Note: Prior to randomization, approximately 6-12 subjects will be enrolled in open-label lead-in to assess the tolerability of the combination. The initial open-label, lead-in cohort of six subjects will be monitored for 2 cycles (8 weeks) to assess the PK interactions and the safety of the combination of 0.20 mg/kg QD ABT-869 and paclitaxel (90 mg/m2). Enrollment into the randomized portion will begin after a cohort has completed two cycles (8 weeks) of therapy and no toxicities prohibit the cohort from continuing on to Cycle 3.~Alternative doses may be explored based on the tolerability of the combination"
62578115|NCT04109274|EXPERIMENTAL|Institution-Based Self-management only (SM)|Eight SM sessions for safe and effective exercise strategies will be provided to this group (described above). Four booster sessions will be provided to this group.
62578116|NCT04109274|NO_INTERVENTION|Usual care|Participants in this group will receive care as normally provided by their treating oncologist. This can be heterogeneous between different physicians and centres, but usually includes oncologists encouraging their patients to 'stay active'
62578117|NCT03491046|EXPERIMENTAL|Patient population with ACL injury or reconstruction|
62578118|NCT03491046|EXPERIMENTAL|Patient population without ACL injury or reconstruction|
62578119|NCT03092778|EXPERIMENTAL|Cryoablation Group|Participants with mild to moderate obesity will undergo a cryoablation procedure to the vagal nerve.
62578120|NCT03571282|EXPERIMENTAL|treatment group|The patients in the treatment group receive three monthly intravitreal injection of conbercept followed by PRN rescue treatments such as intravitreal injection of conbercept, laser photocoagulation (when outside the macular) or photodynamic therapy (when in the macular).
61978291|NCT03128112|ACTIVE_COMPARATOR|Exam room with poster|All parents will be asked to fill out a questionnaire detailing basic demographic information as well as their perception of their child's weight. Parents who are in exam rooms with posters will be directed to read the poster on the exam room wall. After viewing the poster and after seeing their physician, parents will be ask to fill out a second short questionnaire that will ask parents whether they discussed their child's weight status with their physician, whether this conversation was prompted by the poster, and whether they believe their own child is very overweight, overweight, healthy weight, underweight, or very underweight.
62200357|NCT00645177|PLACEBO_COMPARATOR|B|"In study, this arm is a randomized (blinded) to placebo for ABT-869 plus paclitaxel arm.~Note: Prior to randomization, approximately 6-12 subjects will be enrolled in open-label lead-in to assess the tolerability of the combination. The initial open-label, lead-in cohort of six subjects will be monitored for 2 cycles (8 weeks) to assess the PK interactions and the safety of the combination of 0.20 mg/kg QD ABT-869 and paclitaxel (90 mg/m2). Enrollment into the randomized portion will begin after a cohort has completed two cycles (8 weeks) of therapy and no toxicities prohibit the cohort from continuing on to Cycle 3.~Alternative doses may be explored based on the tolerability of the combination"
62200358|NCT05864651|EXPERIMENTAL|Tele-exercise program group|"Provide the following programs:~1. tele-exercise program: 5 times per week, 30 minute/session~2. conventional fencing exercise: 5 times per week, 30 minute/session"
62200359|NCT05864651|ACTIVE_COMPARATOR|Control group|"Provide the following programs:~1) conventional fencing exercise: 5 times per week, 30 minute/session"
62200360|NCT02963948||Clinic A1|
62200361|NCT02963948||Clinic A2|
62200362|NCT02963948||Clinic B1|
62578121|NCT05896033|EXPERIMENTAL|Menthol Spectrum Cigarettes and Menthol E-cigarettes|Ppts will be randomly assigned to receive the menthol spectrum cigarettes and Njoy Ace menthol e-cigarettes. Will be used for the duration of the study (8 weeks) starting at the second visit.
62578122|NCT05896033|EXPERIMENTAL|Menthol Spectrum Cigarettes and Tobacco E-cigarettes|Ppts will be randomly assigned to receive the menthol spectrum cigarettes and Njoy Ace tobacco e-cigarettes. Will be used for the duration of the study (8 weeks) starting at the second visit.
62578123|NCT05896033|EXPERIMENTAL|Non-menthol Spectrum Cigarettes and Menthol E-cigarettes|Ppts will be randomly assigned to receive the non-menthol spectrum cigarettes and Njoy Ace menthol e-cigarettes. Will be used for the duration of the study (8 weeks) starting at the second visit.
62578124|NCT05896033|EXPERIMENTAL|Non-menthol Spectrum Cigarettes and Tobacco E-cigarettes|Ppts will be randomly assigned to receive the non-menthol spectrum cigarettes and Njoy Ace tobacco e-cigarettes. Will be used for the duration of the study (8 weeks) starting at the second visit.
62578125|NCT05350371|EXPERIMENTAL|Placebo|
62578126|NCT05350371|EXPERIMENTAL|Pirfenidone Treatment|
62578127|NCT00842920|PLACEBO_COMPARATOR|Placebo|Placebo or 20 mg Simvastatin (stratified by prior use of statins)
62578128|NCT00842920|EXPERIMENTAL|Simvastatin 60 mg|Simvastatin 60 mg once daily
62578129|NCT00842920|EXPERIMENTAL|Simvastatin 20 mg|Simvastatin 20 mg once daily
62578130|NCT03710863|EXPERIMENTAL|CM082 Tablet|Code Name: CM082 Tablet Other Name: X-82 Dosage and Administration: 25/50mg BID, P.O., two-week on/two-week off in four-week cycles until disease progression or unacceptable toxicity
62578131|NCT01237418||Myocardial Infarction|Any patient over 18 years admitted for myocardial infarction (MI) of less than 48 hours, characterized by the typical rise and fall of troponin or CPKMb
62784670|NCT05127239|EXPERIMENTAL|smartphone application with education|participants were provides 3 times lifestyle modification education and using smartphone app program
62784671|NCT05127239|EXPERIMENTAL|smartphone application|participants were only provided smartphone app program
62784672|NCT05127239|NO_INTERVENTION|waiting list|No intervention was provided, but researchers explained the results of OSA screening for participants after every examination
62200363|NCT02963948||Clinic B2|
62200364|NCT02963948||Clinic B3|
62401294|NCT03426995|PLACEBO_COMPARATOR|Placebo, Part A, Cohort 2|Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 3 mg and a matching placebo capsule to the study drug GSK3358699, for 20 and 45 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive Placebo at a dose level already given in TP 1-3, and will then receive 60 microgram per meter\^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654 (NCT03306589).
62401295|NCT03426995|EXPERIMENTAL|Part B, GSK3358699 under Fasted followed by Fed conditions|The subjects in this arm will receive single oral dose of GSK3358699, at a dose level evaluated in Part A, under fasted condition in TP1 followed by fed condition in TP2. This cohort intended to evaluate the effect of food.
62401296|NCT03426995|EXPERIMENTAL|Part B, GSK3358699 under Fed followed by Fasted conditions|The subjects in this arm will receive single oral dose of GSK3358699, at a dose level evaluated in Part A, under fed condition in TP1 followed by fasted condition in TP2. This cohort intended to evaluate the effect of food.
62401297|NCT03426995|EXPERIMENTAL|GSK3358699, Part C|The dose level for the first cohort in Part C will be decided following completion of Part A of the study for GSK3358699. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive GSK3358699, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter\^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
62401298|NCT03426995|PLACEBO_COMPARATOR|Placebo, Part C|The subjects in this cohort will receive a matching placebo to GSK3358699, Part C, as a single oral dose once daily for 14 consecutive days. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive placebo, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter\^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
62401299|NCT03445936|ACTIVE_COMPARATOR|Parietene Macro|Parietene Macro is a macroporous synthetic mesh used in retro muscular sublay position to prevent incisional hernia after loop-ileostomy closure.
62401300|NCT03445936|ACTIVE_COMPARATOR|Permacol|Permacol is a acellular porcine dermal implant used in retro muscular sublay position to prevent incisional hernia after loop-ileostomy closure.
62012472|NCT05568394|EXPERIMENTAL|Intervention group|Manual therapy and therapeutic exercise
62012473|NCT05568394|EXPERIMENTAL|Control group|Routine physical therapy
62200365|NCT02963948||Clinic B4|
62200366|NCT00770900|EXPERIMENTAL|Montelukast|Asthmatic children and teenagers took montelukast daily.
62200367|NCT00770900|PLACEBO_COMPARATOR|Placebo|Placebo to montelukast tablet daily.
62200368|NCT01007110|ACTIVE_COMPARATOR|Docosahexaenoic Acid (DHA)|Docosahexaenoic Acid (DHA)
62401301|NCT02054507|NO_INTERVENTION|Former premature infants|Cognitive and executive evaluation by Wechsler IV tests
62401302|NCT05386199||Healthy controls|Healthy volunteers without conditions altering serotonin content in blood.
62401303|NCT05386199||Sepsis group|Patients with sepsis or septic shock admitted to ICU and receiving mechanical ventilation.
62200369|NCT01007110|PLACEBO_COMPARATOR|Placebo|soy/corn oil placebo
62200370|NCT01030393|EXPERIMENTAL|intrauterine hCG|"Experimental arm : intrauterine injection of 100 iu(group1)or 200 iu (group2) of hCG before embryo transfer.~Intrauterine injection of 500 iu hCG before embryo transfer"
62200371|NCT03270800|EXPERIMENTAL|IMX101 vaccine as intradermal and sublingual application|IMX101 vaccine will be administered intradermally and sublingually
62200372|NCT03270800|EXPERIMENTAL|CTA control as intradermal and sublingual application|CTA mucosal adjuvans will be administered intradermally and sublingually
62200373|NCT05006118|EXPERIMENTAL|Radio-labeled rodatristat ethyl 600 mg|Single dose of rodatristat ethyl 600 mg as an oral suspension containing a mixture of \[12C\]-rodatristat ethyl and \[14C\]-rodatristat ethyl to contain approximately 600 microcuries (uCi) of radioactivity
62200374|NCT01413503|EXPERIMENTAL|131I-MIBG|Patients received 131I-MIBG 8-12 mCi/kg (maximum 500 mCi ± 10% at investigator's discretion) diluted in 25 ml of normal saline. Patients were infused intravenously through a patient's peripheral or central line over 120 minutes
62200375|NCT01788293|ACTIVE_COMPARATOR|Intervention group|Intervention group will receive hydroxyethylstarch 6% bolus in order to minimize and maintain PVI below 14 %.
62200376|NCT01788293|NO_INTERVENTION|Control group|Control group will receive fluid at the discretion of the anesthetist
62200377|NCT03431753|EXPERIMENTAL|PSA, STHLM3 and mpMRI for PC detection|mpMRI, and if suspect MR-targeted prostate biopsy, in men with increased PC risk as judged from the STHLM3 test and/or an elevated prostate specific antigen test.
62200378|NCT01589159|EXPERIMENTAL|Experimental|
62200379|NCT06046417|EXPERIMENTAL|Fully automated Lyumjev-and-pramlintide delivery system (8 μg/u)|Lyumjev and pramlintide fully automated delivery system with no meal announcement. Ratio of 1 unit of insulin for 8 μg of pramlintide.
62200380|NCT06046417|EXPERIMENTAL|Fully automated Lyumjev-and-pramlintide delivery system (10 μg/u)|Lyumjev and pramlintide fully automated delivery system with no meal announcement. Ratio of 1 unit of insulin for 10 μg of pramlintide.
62578132|NCT05750329|EXPERIMENTAL|Surgical group|All patients underwent left hepatectomy combined with orthotopic S2-3 liver segment transplantation, and then underwent autologous right hepatectomy after the graft had grown sufficiently large.
62784673|NCT02065505|EXPERIMENTAL|Pilates Group Solo|participate in this group 30 individuals who will be treated with the Pilates Method performing the exercises on the ground, using the Swiss ball and elastic bands. The exercises will aim to lengthen the musculature that are shortened due to the characteristic postural pattern of pathology (major and minor pectoral, shoulder adductors, biceps, wrist flexors, trunk side chain); strengthen the musculature that provide postural support (abdominal, middle trapezius, rhomboids, gluteus maximus, erector spinae and latissimus dorsi) and the upper limb musculature important for activities of daily living (triceps, biceps, internal rotators, external rotators and abductors of the shoulder).
62784674|NCT02065505|EXPERIMENTAL|Water Pilates Group|participate in this group 30 individuals who will be treated with the Pilates method, but doing the exercises in the therapy pool, with the aid of floats and weights. The protocol of stretches and exercises will work the same muscle groups than the G1, keeping the same decubitus whenever possible. The adaptations to the exercises are justified by the physical principles of water, which at one point may act for or against the activity being performed.
62784675|NCT06464263|EXPERIMENTAL|Dexmedetomidine Group|This Group about 30 patients will receive a loading dose of 1 μg/kg dexmedetomidine (Precedex 4 mcg/ml, Pfizer. Inc, New York, USA) diluted in 100 ml 0.9% saline infused over 10 min immediately postoperative, followed by continuous infusion of 0.2-0.7 μg/kg/h.
62784676|NCT06464263|EXPERIMENTAL|Fentanyl Group|This Group about 30 patients will receive an initial bolus dose of fentanyl (fentanyl 50 mcg/ml, hameln; Netherlands) of 1-2 μg/kg, followed by an infusion at an initial rate of 1 to 2 μg/kg/h.
62401304|NCT05386199||Cardiac arrest group|Patients with cardiac arrest and ROSC admitted to ICU and receiving mechanical ventilation.
62578133|NCT04042688|EXPERIMENTAL|Treatment group|Patients were randomly allocated to one of two groups during preoperative preparation by computer-generated randomization. Treatment group; IA administration of TXA, control group; no TXA administration
62578134|NCT04042688|NO_INTERVENTION|Control gorup|
62784677|NCT02743676||Avian influenza A|Natural history of Avian influenza A, particularly H5N1 strain which has a high potential of causing a global human pandemic, and real-world treatment practices will be observed in this study. This registry program will not require, recommend, or provide any specific treatment or medications.
62200381|NCT06046417|ACTIVE_COMPARATOR|Hybrid automated Lyumjev-and-placebo delivery system with carbohydrate-matched boluses|Lyumjev and saline placebo hybrid automated delivery system with meal announcement. Participants must input the carbohydrate content of their meals to inform the insulin bolus doses based on their pre-programmed insulin-to-carbohydrate ratios.
62200382|NCT05905107|EXPERIMENTAL|Interventional Group A|These patients will be treated by nerve sequencing proximal to distal in 3 sets of 15 repetitions in one session on alternate days for 4 weeks. For this, participants will be given a comfortable supine lying position. ULTT method will be implemented to the ipsilateral upper limb given in the table below
62200383|NCT05905107|ACTIVE_COMPARATOR|Interventional Group B|These patients will be treated by nerve sequencing distal to proximal in 3 sets of 10 repetitions in one session for 4 weeks. For this, participants will be given a comfortable supine lying position. ULTT method will be implemented to the ipsilateral upper limb
62200384|NCT03101462|ACTIVE_COMPARATOR|Group 1|One dose of 0.5 mL Licensed Inactivated Influenza Vaccine (IIV) on Day 0
62200385|NCT03101462|ACTIVE_COMPARATOR|Group 2|One dose of 0.5 mL Licensed Live Attenuated Influenza Vaccine (LAIV) on Day 0
62200386|NCT02121964|OTHER|Capsulectomy|Capsulectomy in Direct Anterior Total Hip Arthroplasty
62200387|NCT02121964|OTHER|Capsulotomy|Capsulotomy in Direct Anterior Total Hip Arthroplasty
62200388|NCT03848039|EXPERIMENTAL|Gardasil-9|Intramuscular Gardasil-9 vaccination at 0, 2 and 6 months.
62200389|NCT03848039|PLACEBO_COMPARATOR|Placebo|Placebo injection at 0, 2 and 6 months
62401305|NCT05386199||Multiple trauma group|Patients with severe multiple trauma admitted to ICU and receiving mechanical ventilation.
62784678|NCT04734301|ACTIVE_COMPARATOR|Group 1: IVES (2 times in a week)|This group included the IVES in addition to all components of the BT. IVES was performed in lithotomy position via electrical stimulation device with a vaginal probe.
62200390|NCT02152943|EXPERIMENTAL|Treatment (everolimus, letrozole, trastuzumab)|Patients receive everolimus PO QD and letrozole PO QD. Patients also receive trastuzumab IV over 30-90 minutes once every 3 weeks. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62200391|NCT02929277|OTHER|single arm study|
62200392|NCT03511690|EXPERIMENTAL|Immediate BRCA-Gist Intervention|Participants randomized to immediate BRCA-gist will complete the adapted intervention and immediately complete a baseline survey. They will be asked to complete a second survey two weeks after completion of the first one. BRCA-gist is a web-based tutoring system that emulates one-to-one human tutoring via avatars to communicate risk of BRCA1/2. We estimate a completion time of 90 minutes.
62200393|NCT03511690|EXPERIMENTAL|Delayed BRCA-Gist Intervention|Participants randomized to delayed BRCA-gist will initially complete a baseline survey. Two weeks after completion of that survey, they will complete the adapted intervention and immediately complete a second survey.
62784679|NCT04734301|EXPERIMENTAL|Group 2: IVES (5 times in a week)|This group also included the IVES in addition to all components of the BT as in Group 1. IVES performed in the same way as Group 1, except for frequency of treatment.
62200394|NCT01888549|EXPERIMENTAL|arm1-High dose PPI|
62784680|NCT04431492||coronary artery bypass|
62784681|NCT04431492||thoracic surgery|
62200395|NCT01888549|ACTIVE_COMPARATOR|arm2-standard dose PPI|
62200396|NCT01888549|PLACEBO_COMPARATOR|arm3-placebo|Esomeprazole placebo
62200397|NCT04760262||Group Propofol|anesthesia was maintained with TIVA (intravenous 125-250 µg/kg/min propofol + 0.1-0.25 µg/kg/min remifentanil infusion)
62200398|NCT04760262||Group Sevoflurane|anesthesia was maintained with inhalation (sevoflurane concentration of 1-2% in 50-50% O2-air mixture).
62200399|NCT04584476|EXPERIMENTAL|SCR group|underwent superior capsular reconstruction
62200400|NCT04584476|OTHER|Partial group|underwent partial rotator cuff repair
62200401|NCT01543542|OTHER|Radiation Therapy Treatment|Whole Brain XRT 30Gy/10 fractions with Simultaneous Infield Boost of Brain Lesions to 60Gy
62200402|NCT03648359|OTHER|Enrolled AS patients|Patients with prostate cancer enrolled i active surveillance protocol using PSA, digital rectal examination and conventional TRUS-biopsies
62200403|NCT04339660|EXPERIMENTAL|UC-MSCs treatment group|Participants will receive conventional and treatment with MSCs, MSCs were suspended in 100 mL of normal saline, and the total number of transplanted cells was calculated by 1\*10E6 cells per kilogram of weight. This product is generally a course of treatment, a total of 1 time, depending on the condition of the need to be given again at an interval of 1 week.
62200404|NCT04339660|PLACEBO_COMPARATOR|Control group|Participants will receive conventional treatment and Placebo intravenously.
62401306|NCT05386199||ICU control group|Patients with isolated neurological disease admitted to ICU and receiving mechanical ventilation.
62784682|NCT02630303|EXPERIMENTAL|LED-RL Phototherapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to LED-RL phototherapy and two subjects randomized to mock therapy).~After either a maximally tolerated dose (MTD) has been established, or the study endpoint of 640 J/cm2 has been achieved, an additional 27 LED-RL phototherapy subjects (for a total of 30) and 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
62401307|NCT06158906||Study group|Dry eye patients were recruited to fill in the questionnaire
62401308|NCT02909127||Cerebral palsied children|The inclusion criteria are age above 18 months, fed orally, referred due to parent complaints about their child's swallowing function and not admitted a swallowing center before. Swallowing evaluation will be performed. The Functional Independence Measure and PEDI-EAT-10 will be filled.
62401309|NCT02909127||Healthy children|Healthy children above the age of 18 months with no medical history of voice, swallowing, reflux, airway, neurologic, rheumatologic, or neoplastic disorders will be included for normative data generation. The PEDI-EAT-10 will be filled.
62401310|NCT01872832|EXPERIMENTAL|5 mg RDEA3170|RDEA3170 5 mg or placebo fasted and fed
62200405|NCT02807610|EXPERIMENTAL|IV Propofol and IV Etomidate lipuro|After premedication with IV midazolam 0.2mg kg-1, IV Fentanyl 2ug kg-1, Group P Patients received IV Propofol 2mg kg-1 slowly over 60 seconds till Entropy of 40 as a comparator agent in patients undergoing Medical termination of pregnancy(MTP) and Group ' E' Patients received IV Etomidate Lipuro 0.3mg kg-1 slowly over 60 seconds till Entropy of 40 as intervention agent in patients undergoing MTP
62200406|NCT02807610|ACTIVE_COMPARATOR|IV Etomidate Lipuro and Placebo|After premedication with IV midazolam 0.2mg kg-1, IV Fentanyl 2ug kg-1, Group ' E' Patients received IV Etomidate Lipuro 0.3mg kg-1 slowly over 60 seconds till Entropy of 40 as intervention agent in patients undergoing MTP and placebo group received normal saline
62200407|NCT04571190|EXPERIMENTAL|Prenatal MBSR|The prenatal MBSR program consists of nine two-hour sessions including teachings in mindfulness meditation and yoga. The program is taught by an experienced MBSR instructor with relevant clinical expertise.
62200408|NCT04571190|NO_INTERVENTION|Usual care|Standard clinical practice, usual care (TAU), imply routine pregnancy visits to the outpatient antenatal clinic at Copenhagen University Hospital, Hvidovre and to a General Practitioner. Usual care include a multidisciplinary approach involving preventive counselling by midwifes, physicians and social workers throughout the pregnancy and follow-up until the early post-partum period.
62200409|NCT05167890|ACTIVE_COMPARATOR|Coffee Arm|Patients in coffee arm receive 1 cup of coffee 3 times per day (150 mL at 8:00 AM, 12:00 PM, and5:00 PM), in addition to the regular infusion therapy and/or alimentation starting the first day postoperatively till the end of the 3 postoperative day.
62200410|NCT05167890|ACTIVE_COMPARATOR|Orange Arm|Patients in orange arm receive 1 cup of orange juice 3 times per day (150 mL at 8:00 AM, 12:00 PM, and5:00 PM), in addition to the regular infusion therapy and/or alimentation starting the first day postoperatively till the end of the 3 postoperative day.
62401311|NCT01872832|EXPERIMENTAL|10 mg RDEA3170|RDEA3170 10 mg or placebo fasted and fed
62401312|NCT01872832|EXPERIMENTAL|15 mg RDEA3170|RDEA3170 15 mg or placebo fasted and fed
62200411|NCT02294357|EXPERIMENTAL|Carfilzomib + Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration.
62200412|NCT02294357|EXPERIMENTAL|Carfilzomib + Prednisone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Prednisone (IV or PO) will be given prior to each carfilzomib administration.
62200413|NCT02294357|EXPERIMENTAL|Carfilzomib + Methylprednisolone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Methylprednisolone(IV or PO) will be given prior to each carfilzomib administration.
62401313|NCT01872832|EXPERIMENTAL|2.5 mg RDEA3170|RDEA3170 2.5 mg or placebo fasted and fed
62401314|NCT02267421|EXPERIMENTAL|Home based aerobic exercise|Home based aerobic exercise on cycle ergometer. Three times per week, 30-60 minutes per session.
62401315|NCT02267421|NO_INTERVENTION|Usual Care group|These patients will continue with their normal activities of daily living and will not be provided with equipment or coaching for home based exercise during the study period .
62401316|NCT01070849|ACTIVE_COMPARATOR|a) educational booklet|
62401317|NCT01070849|ACTIVE_COMPARATOR|b) IRENA|
62784683|NCT02630303|SHAM_COMPARATOR|Mock Therapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to LED-RL phototherapy and two subjects randomized to mock therapy).~After either a maximally tolerated dose (MTD) has been established, or the study endpoint of 640 J/cm2 has been achieved, an additional 27 LED-RL phototherapy subjects (for a total of 30) and 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
62401318|NCT01070849|EXPERIMENTAL|c) RÜCKGEWINN|
62401319|NCT06418789|EXPERIMENTAL|Group 1|In arm patients receive a TI-CE regime based on paclitaxel and ifosfamide in cycles 1-2 and carboplatin and etoposide in cycles 3-5.
62401320|NCT05297162|EXPERIMENTAL|PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy|"Single-arm case-control imaging trial designed to compare in parallel PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy (experimental test) with mpMRI/TRUS fusion prostate biopsy (standard test) in men suspected for PCa after at least one negative biopsy."
62401321|NCT02875743|EXPERIMENTAL|Posaconazole|
62784684|NCT03801226|EXPERIMENTAL|10% dextrose in sterile water|Patients randomized to this arm will undergo a two-hour dwell with 10% dextrose in sterile water at their first visit and Dianeal Low-Calcium with 4.25% Dextrose at their second visit.
62401322|NCT05059561||Patients group|All patients who applied to the orthopedics and traumatology department between July 2017 and June 2018 for a medical board examination were evaluated by physical and radiological examination. According to the Cobb method, individuals with a Cobb angle greater than 10° were diagnosed with Idiopathic Scoliosis. All participants were evaluated by a senior psychiatrist. Before the interview, all subjects fully informed about the purpose and scope of the study. After their permission was obtained the study and control groups completed a socio-demographic data form consisting of questions about detailed personal and medical history and, the participants were asked to fill in the TCI.
62578135|NCT05387096|SHAM_COMPARATOR|Control: standard pharmaceutical care|Patients in the control arm (standard pharmaceutical care) will receive a sham intervention in the form of the modified Medication Adherence Rating Scale (MARS) questionnaire
62578136|NCT05387096|ACTIVE_COMPARATOR|trained physician-implemented intervention|The definitive multi-faceted intervention delivered by a trained physician.
62012474|NCT03465696|NO_INTERVENTION|Group #1 (Control)|"Group #1 (Control)~Oral survey 1 will be administered and patients will be asked:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
62012475|NCT03465696|EXPERIMENTAL|Group #2 (Intervention)|"Group #2 (Intervention)~Survey 2 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
62012476|NCT03465696|EXPERIMENTAL|Group #3 (Intervention)|"Group #3 (Intervention)~Survey 3 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~What do you think would be the best way to describe this to a patient?~1. Stelara® acts in an almost all-natural way to help control psoriasis.~2. Stelara® blocks one of the genetic causes of psoriasis.~3. Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance~4. Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
62200414|NCT02294357|EXPERIMENTAL|Carfilzomib+Lenalidomide+Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration. Lenalidomide will be given at the same dose and schedule as patient was receiving previously.
62200415|NCT02294357|EXPERIMENTAL|Carfilzomib+Pomalidomide+Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration. Pomalidomide will be given PO at 4mg daily on days 1-21 of a 28-day cycle
62200416|NCT06128096||SGLT-2 inhibitor group|"Patients will be given a recommended dose of SGLT-2 inhibitor by cardiologist in a form of tablets based on clinical indication. The SGLT-2 inhibitor includes :~1. Tab Empagliflozin 10mg OD~2. Tab Dapagliflozin 10mg OD~After administration of SGLT-2 inhibitor, the cardiac function and epicardial adipose tissue thickness will be measured (baseline and 6 month) post intervention"
62200417|NCT06128096||Control group|Patient will not be given SGLT-2 inhibitor and continue SOC up to 6 months. The cardiac function and epicardial adipose tissue thickness will be measured (baseline and 6 month) post intervention
62012477|NCT03980847|ACTIVE_COMPARATOR|Alendronate 20 mg with bone graft|after tooth extraction, put teh Alendronate 20mg with bone graft within teh tooth socket
62200418|NCT01083953|EXPERIMENTAL|Sevoflurane|1 arm will receive sevoflurane at varying concentrations at which extubation is attempted according to the Dixon up and down method
62200419|NCT01083953|EXPERIMENTAL|Desflurane|1 arm will receive desflurane at varying end tidal concentration at which extubation will be attempted according to Dixon up and down method
62200420|NCT04993469|EXPERIMENTAL|Genital sensation and sexual functioning assessment|"Genital sensation testing with clinical assessment and self-examination questionnaire.~Sexual functioning testing with questionnaires."
62200421|NCT01601522|EXPERIMENTAL|Oral Immunotherapy with placebo antihistamines|500 mg Peanut Protein with placebo antihistamines
62012478|NCT03980847|ACTIVE_COMPARATOR|bone graft alone|after tooth extraction, put the bone graft within the tooth socket
62200422|NCT01601522|PLACEBO_COMPARATOR|Double Placebo|Placebo (Oat flour) and placebo antihistamines
62012479|NCT04132349|EXPERIMENTAL|Ullipristal Acetate|Women with symptomatic uterine fibroids will be treated with 5 mg UPA / day in 3 months
62012480|NCT01529645|EXPERIMENTAL|Group 1: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: low dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
62012481|NCT01529645|EXPERIMENTAL|Group 2: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: medium dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
62012482|NCT01529645|EXPERIMENTAL|Group 3: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: high dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
62012483|NCT01529645|EXPERIMENTAL|Group 4: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, low dose of D (diphteria) toxoid, fixed dose of T (tetanus) toxoid, followed by one administration of saline solution one month apart.
62200423|NCT01601522|ACTIVE_COMPARATOR|Oral Immunotherapy with H1 and H2 antihistamines|500 mg Peanut Protein with Dosage of desloratidine 5 ml po od (0.5mg/ml = 2.5 mg) and ranitidine be 5ml (15mg/ml=75 mg) po bid.
62200424|NCT00757224|NO_INTERVENTION|non-smoking|
62200425|NCT00757224|NO_INTERVENTION|smoking parents A|
62200426|NCT00757224|EXPERIMENTAL|smoking parents B|Parents will be educated on the hazards of passive smoke exposure and ways to reduce it
62200427|NCT06051110|OTHER|Usual care|Patients who receive usual care by EMS protocols
62200428|NCT06051110|OTHER|point-of-care troponin|Patients in who risk-stratification was performed by the use of a point-of-care troponin in the EMS setting
62200429|NCT06051110|OTHER|Combined risk scores|Patients in who risk-stratification was performed by the use of a combined risk score in the EMS setting
62200430|NCT02963675||Group 1|Prostate cancer patients with bone metastases (mPC)
62200431|NCT02963675||Group 2|Castration-resistant prostate cancer patients with bone metastases (mCRPC)
62200432|NCT02658877|EXPERIMENTAL|Omalizumab|
62578137|NCT05387096|ACTIVE_COMPARATOR|clinical pharmacist-implemented intervention|The definitive multi-faceted intervention delivered by a trained pharmacist.
62578138|NCT06501391|ACTIVE_COMPARATOR|stable BM, PD-1/PD-L1 inhibitors plus chemotherapy|
62012484|NCT01529645|EXPERIMENTAL|Group 5: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
62012485|NCT01529645|EXPERIMENTAL|Group 6: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
62012486|NCT01529645|EXPERIMENTAL|Group 7: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
62012487|NCT01529645|EXPERIMENTAL|Group 8: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
62012488|NCT01529645|EXPERIMENTAL|Group 9: TDaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
62012489|NCT01529645|ACTIVE_COMPARATOR|Group 10: Licensed TdaP booster|Subject received one dose of a licensed TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) followed by one administration of saline solution one month apart.
62012490|NCT02336984|EXPERIMENTAL|Combination Therapy|Combination Therapy: HER-2 pulsed DC1 vaccine with trastuzumab and pertuzumab.
62578139|NCT06501391|EXPERIMENTAL|stable BM, PD-1/PD-L1 inhibitors, chemotherapy plus radiotherapy|
62578140|NCT02965287||19-21 weeks' gestation|"The test validation will be performed on the 1943 serum samples of pregnant women at 19-21 weeks' gestation recruited in New Zealand for the SCOPE Study.~All the samples will be analyzed to extract and purify the whole metabolome. Metabolites will be characterized through mass spectrometric techniques. These data will be interpreted by means of a bioinformatic algorithm specifically designed for this purpose."
62578141|NCT02965287||14-16 weeks' gestation|Five hundred subjects at 14-16 weeks gestation were randomly selected from the whole cohort of patients. The serum samples collected at 14-16 weeks gestation will be used to test the diagnostic performance at this earlier gestational phase.
62578142|NCT03811093|EXPERIMENTAL|Care as Usual Group|A randomly selected group of 20 participants who received treatment per the prescribed trial protocol using a fully functional invisa-RED Technology Elite device. Treatment protocol was as follows: Participants will undergo nine (9) therapy sessions of 20 minutes each over a three week period; using a singular LLLT protocol setting for pulse (3.5s) and delay (0.2s), however power settings will be based on the participants Fitzpatrick Scale skin type. For skin types i and ii a power setting of 7 will be used, for skin types iii and iv a power setting of 6, for skin types v and vi a power setting of 4 will be employed.
62012491|NCT03993418|EXPERIMENTAL|Stevia arm|stevia drops
62012492|NCT03993418|NO_INTERVENTION|Control arm|No change in diet
62012493|NCT04379011|EXPERIMENTAL|Brivaracetam Group|Participants in this arm will receive the investigational drug, Brivaracetam.
62012494|NCT04379011|PLACEBO_COMPARATOR|Control Group|Participants in this arm will receive a placebo.
62012495|NCT04989257|EXPERIMENTAL|Ticagrelor-based dual-antiplatelet therapy|Aspirin with ticagrelor
62012496|NCT04989257|ACTIVE_COMPARATOR|Clopidogrel-based dual-antiplatelet therapy|Aspirin with clopidogrel
62200433|NCT02658877|PLACEBO_COMPARATOR|Placebo|
62200434|NCT00757627|EXPERIMENTAL|1|Etoricoxib
62578143|NCT03811093|PLACEBO_COMPARATOR|Sham Group|A randomly selected group of 20 participants who will receive treatment per the prescribed trial protocol using a non functional invisa-RED Technology Elite device. (The sham device will be disabled and will deliver no low laser light energy during therapy.) Treatment protocol is as follows: Participants will undergo nine (9) therapy sessions of 20 minutes each over a three week period; using a singular protocol setting for pulse (3.5s) and delay (0.2s), however power settings will be based on the participants Fitzpatrick Scale skin type. For skin types i and ii a power setting of 7 will be used, for skin types iii and iv a power setting of 6, for skin types v and vi a power setting of 4 will be employed.
62578144|NCT02635425|EXPERIMENTAL|7 eggs collection|Aspiration of 7 eggs only
62578145|NCT02635425|ACTIVE_COMPARATOR|Full eggs collection|Aspiration of all eggs
62784685|NCT03801226|ACTIVE_COMPARATOR|Dianeal Low-Calcium with 4.25% Dextrose|Patients randomized to this arm will undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first visit and 10% dextrose in sterile water at their second visit.
62784686|NCT02716181|ACTIVE_COMPARATOR|"Атопик phase 1"|"For the first phase of the study, subjects will be randomized to receive treatment with Атопик Soothing Cream."
62200435|NCT01120873|EXPERIMENTAL|Metamin 3D|A randomized, double-blinded and placebo-controlled study
62200436|NCT01757951|EXPERIMENTAL|Unimalleolar Fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to unimalleolar fixation group and no fixation of the lateral side is performed.
62012497|NCT03120624|EXPERIMENTAL|Arm A (VSV-hIFNbeta-NIS, TFB-PET, biopsy)|Patients receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, receive fluorine F18 tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo CT throughout the study. Patients also undergo mouth rinse, buccal swab and urine on study and blood sample collection throughout the study. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29.
62784687|NCT02716181|PLACEBO_COMPARATOR|Placebo - phase 1|For the first phase of the study, subjects will be randomized to receive treatment with Placebo Cream.
62200437|NCT01757951|ACTIVE_COMPARATOR|Bimalleolar Fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to bimalleolar fixation group i.e. additional fixation of the lateral malleolus fracture is performed.
62200438|NCT05410093|EXPERIMENTAL|Patients who taking Resveratrol|Take RES (250mg, NuMedica, FDA approved) at a dose of 250mg per day for three months
62784688|NCT02716181|ACTIVE_COMPARATOR|"Атопик phase 2"|"The second phase of the study is an open-label extension with all subjects receiving Атопик Soothing Cream."
62401323|NCT05059561||Control group|All patients who applied to the orthopedics and traumatology department between July 2017 and June 2018 for a medical board examination were evaluated by physical and radiological examination. Healthy individuals who applied for the same examination and met the inclusion criteria were determined as the control group by random sampling method. All participants were evaluated by a senior psychiatrist. Before the interview, all subjects fully informed about the purpose and scope of the study. After their permission was obtained the control group completed a socio-demographic data form consisting of questions about detailed personal and medical history and, the participants were asked to fill in the TCI.
62401324|NCT04213001|OTHER|measure|circumference measure, ultrasonographic measure
62200439|NCT05410093|ACTIVE_COMPARATOR|Patients who taking VitE|Take vitamin E at a dose of 100 mg per day for three months
62200440|NCT01908153||Overweight/Obese|Children with BMI percentile of 85 or above.
62200441|NCT01908153||Healthy Weight|Children with BMI percentile between 15 and 85.
62200442|NCT01763593||Aurosleek blades|Patients having cataract will undergo surgery by using Aurosleek blades
62401325|NCT04165850|EXPERIMENTAL|Fixed dose Ciprofloxacin and Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day
62401326|NCT03377803|ACTIVE_COMPARATOR|VP-102|VP-102 is contained within a single-use applicator. The VP-102 applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450 μL of VP-102 (0.7% \[w/v\] cantharidin) solution.
62200443|NCT03969134|ACTIVE_COMPARATOR|Vaccine arm|ChAd63 KH 7.5x1010 vp, single dose, by IM injection
62200444|NCT03969134|PLACEBO_COMPARATOR|Placebo|Normal Saline, single dose, by IM injection
62200445|NCT02924090|ACTIVE_COMPARATOR|ECT with Etomidate|Immediately prior to ECT study patients will be administered intravenous etomidate for anesthesia at a dose of 0.3 mg/kg given as a bolus dose.
62200446|NCT02924090|ACTIVE_COMPARATOR|ECT with Ketamine|Immediately prior to ECT study patients will be administered intravenous ketamine for anesthesia at a dose of 0.5 -1.0 mg/kg given as a bolus dose.
62200447|NCT02924090|ACTIVE_COMPARATOR|ECT with Etomidate and Hyperventilation|Immediately prior to ECT study patients will be administered intravenous etomidate for anesthesia at a dose of 0.3 mg/kg given as a bolus dose. Hyperventilation will be administered (20 breaths in 30 seconds) by face mask immediately prior to ECT.
62200448|NCT02924090|ACTIVE_COMPARATOR|ECT with Ketamine and Hyperventilation|Immediately prior to ECT study patients will be administered intravenous ketamine for anesthesia at a dose of 0.5 -1.0 mg/kg given as a bolus dose. Hyperventilation will be administered (20 breaths in 30 seconds) by face mask immediately prior to ECT.
62200449|NCT00936572|EXPERIMENTAL|high dose|high dose of probiotics (109 cfu)
62200450|NCT00936572|EXPERIMENTAL|low dose|low dose of probiotics (107 cfu)
62200451|NCT00936572|PLACEBO_COMPARATOR|probiotics|Maltodoxtrin
62200452|NCT01731223|EXPERIMENTAL|Group treatment for insomnia|Group treatment for insomnia.
62200453|NCT01731223|NO_INTERVENTION|No intervention|Treatment as usual
62200454|NCT04371523|EXPERIMENTAL|Intervention - Hydroxychloroquine|
62200455|NCT04371523|PLACEBO_COMPARATOR|Control|
62401327|NCT03377803|PLACEBO_COMPARATOR|Placebo|Placebo is contained within a single-use applicator. The placebo applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450μl of placebo solution with the same color and consistency as VP-102.
62784689|NCT02716181|PLACEBO_COMPARATOR|Placebo - phase 2|"The second phase of the study is an open-label extension with all subjects receiving Атопик Soothing Cream."
62784690|NCT06239103|EXPERIMENTAL|PEMF treatment arm|Participants receive PEMF therapy. During this, the participant is seated with their right leg extended and with the bore of the PEMF machine between their knee and hip joints, with their left leg at rest. PEMF was applied at 1 mT, 15 Hz for 10 minutes.
62578146|NCT00081224|EXPERIMENTAL|celecoxib + capecitabine + radiation + surgery|"Neoadjuvant chemoradiotherapy: Patients receive oral celecoxib twice daily on days 1-7 and oral capecitabine twice daily on days 1-5. Patients undergo pelvic radiotherapy once daily on days 1-5. Courses repeat weekly for 5.5 weeks.~Surgery: Patients undergo surgery 4-6 weeks after completion of neoadjuvant chemoradiotherapy.~Adjuvant chemotherapy: Patients with a curative resection receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 4 courses.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
62012498|NCT03120624|EXPERIMENTAL|Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)|Patients receive ruxolitinib phosphate PO BID on days -3 to 9. Patients also receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, receive fluorine F18 tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and undergo fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Patients also undergo CT throughout the study. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29. Patients also undergo mouth rinse, buccal swab and urine on study and blood sample collection throughout the study.
62012499|NCT03074734|OTHER|Exposure to secondhand tobacco smoke|Exposure to secondhand tobacco smoke in outside smoking areas
62012500|NCT01222481||Newly-diagnosed Head and Neck Cancer|
62012501|NCT04077034|EXPERIMENTAL|Experimental group|Probiotic DE111®
62200456|NCT05034406|EXPERIMENTAL|Lidocaine group|A total amount of 6 mL of 2% lidocaine was injected at the three trocar insertion sites (2 mL at each insertion site) prior to incision and 10 mL of 2% lidocaine was injected at the end of procedure, under the direct visualization of laparoscope, below and around the defect of the peritoneum at the site of varicocele.
62200457|NCT05034406|EXPERIMENTAL|Levobupivacaine|Total amount of 6 mL of 0.5% levobupivacaine was injected at the three trocar insertion sites (2 mL at each) prior to incision and 10 mL of 2% lidocaine was injected at the end of procedure, under the direct visualization of laparoscope, below and around the defect of the peritoneum at the site of varicocele.
62200458|NCT05034406|NO_INTERVENTION|Control group|No local or peritoneal administration of any local anesthetic prior, during and after the surgical procedure
62200459|NCT00737503|EXPERIMENTAL|1|All eligible children in the experimental arm will be vaccinated with the Rotavirus vaccine
62200460|NCT00737503|NO_INTERVENTION|2|Children will not be vaccinated with rotavirus vaccine.
62200461|NCT05459155|EXPERIMENTAL|Pharmacist team post-intervention|The direct subjects will be the inpatient pharmacists who round with general medicine teams and approve inpatient medication orders. They will be given full access to the Synapse Medicine medication decision support platform.
62401328|NCT02807025||Idiopathic Pulmonary Fibrosis(IPF)|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
62200462|NCT05459155|NO_INTERVENTION|Pharmacist team pre-intervention|Pre-intervention, the inpatient pharmacists will round with general medicine teams and approve inpatient medication orders under conditions of usual care. They will base their recommendations on their knowledge and training and any tools (electronic or otherwise) that they choose to use.
62200463|NCT03614260|EXPERIMENTAL|Renal Denervation|Renal Angiogram and Renal Denervation (Paradise Renal Denervation System)
62200464|NCT03614260|SHAM_COMPARATOR|Sham Control|Renal Angiogram
62200465|NCT05959798||High power short duration ablation|
62200466|NCT05959798||Moderate power long duration ablation|
62200467|NCT05549492|EXPERIMENTAL|Group B|Candidates received 20 ml of 0.25% ropivacaine for TAP block
62200468|NCT05549492|EXPERIMENTAL|Group RB|Candidates received 20 ml of 0.25% ropivacaine and 300 μg of buprenorphine, respectively, for the TAP block.
62401329|NCT02807025||Sarcoidosis|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
62784691|NCT06239103|SHAM_COMPARATOR|Control arm|Participants receive sham therapy, where the PEMF machine does not apply the pulsed electromagnetic waves. However, during this, the participant is kept in the same position as those in the treatment arm.
62012502|NCT04077034|PLACEBO_COMPARATOR|Control group|Placebo
62012503|NCT01590641|EXPERIMENTAL|0.3mg GS-9620|
62012504|NCT01590641|EXPERIMENTAL|1mg GS-9620|
62012505|NCT01590641|EXPERIMENTAL|2mg GS-9620|
62012506|NCT01590641|EXPERIMENTAL|4mg GS-9620|
62012507|NCT01590641|EXPERIMENTAL|0.3mg GS-9620 QW x 2 doses|
62012508|NCT01590641|EXPERIMENTAL|1mg GS-9620 QW x 2 doses|
62012509|NCT01590641|EXPERIMENTAL|2mg GS-9620 QW x 2 doses|
62012510|NCT01590641|EXPERIMENTAL|4mg GS-9620 QW x 2 doses|
62012511|NCT02453451|EXPERIMENTAL|2D-/3D-TTE; 3D-TEE, Walking Test|6 months after the MitraClip procedure
62012512|NCT01623440||Placebo/Naltrexone and fMRI|A placebo or Naltrexone will be given before fMRI. All participants will undergo both procedures. Naltrexone/placebo are not used as an intervention.
62200469|NCT01907867|EXPERIMENTAL|Cohort 1|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 3 hours after the oral dose.~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 6 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
62200470|NCT01907867|EXPERIMENTAL|Cohort 2|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 8 hours after the oral dose.~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose.~Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
62200471|NCT01907867|EXPERIMENTAL|Cohort 3|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose.~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose.~Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 24 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
62200472|NCT06092320|EXPERIMENTAL|Simulation - Didactic Lecture Group|This group will start with a Simulation and debrief followed by a didactic lecture afterwards. They will then complete a simulation 2 months later.
62401330|NCT02807025||Tuberculosis(TB)|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
62401331|NCT02807025||Chronic Obstructive Pulmonary Disease|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
62401332|NCT02807025||Asthma|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
62401333|NCT02807025||Healthy|Nasal, tracheal and bronchial sampling of MLF in patients from healthy controls for comparative data.
62401334|NCT03730064|EXPERIMENTAL|Bipolar depressed|
62578147|NCT02027987|EXPERIMENTAL|valproate acid|The patients began receiving treatment at a dose of 400 mg VPA twice daily on the day after randomization by intravenous drip, with this dose continued for 14 days.The dose was increased to 500 mg twice daily at week 3 and to 400 mg three times daily at week 4 if the DRS score had not improved by at least 2 points from baseline. After the week 4 assessment, the study drug was tapered over a period of 2 to 3 days, with assessment of the patients continued through week 6. Additional procedural details are provided in the study protocol.
62401335|NCT04490551|EXPERIMENTAL|Intervention group|This group will be screened with the risk-based model. The input of the model will be gathered with the FIT, a validated questionnaire, and from data of the Dutch general population registry. The threshold of the model will be set at a calculated risk of 0.10. To comply with ethical guidelines, all participants in this group with a FIT result of \>=15 mcg Hb/g faeces and a calculated risk of \<0.10 will also be offered a colonoscopy.
62401336|NCT04490551|ACTIVE_COMPARATOR|Control group|This group will be screened with the FIT. The threshold of the FIT will be set at \>= 15 mcg Hb/g faeces.
62578148|NCT02027987|PLACEBO_COMPARATOR|placebo|
62578149|NCT05580536|OTHER|Project Dulce + Dulce Digital|Participants will participate in a peer-led group diabetes self-management education and support program and receive ongoing support via text messages designed to improve knowledge, health beliefs, self-management behaviors and clinical outcomes.
62578150|NCT06156072||Patient requiring blood culture|After the request of treating physician of blood culture, each patient deemed eligible, will undergo the prescirbed couple of peripheral blood samples. The first one will be done with the classical blind technique, while the second one with ultrasound guidance.
62012513|NCT02586701|ACTIVE_COMPARATOR|Prehabilitation Plus|Patients in this group will be enrolled in a multimodal program before surgery involving supervised exercise, nutrition counseling and relaxation strategies. Supervised exercise is provided once a week for four weeks before surgery as well as during the hospital stay post surgery. Patients are to continue with a home-based exercise program for 8 weeks after discharge.
62012514|NCT02586701|NO_INTERVENTION|Rehabilitation|Patients in this group are provided with in-hospital supervised exercises with a kinesiologist post surgery until discharge. Patients, upon discharge are provided with a home-based exercise program, nutritional counseling and relaxation strategies for 8 weeks.
62012515|NCT04891549|ACTIVE_COMPARATOR|Tension band fixation|Surgical fixation of the patella fracture utilizing the AO principles using K-wires, screws, cerclage and sutures by surgeons choice.
62012516|NCT04891549|EXPERIMENTAL|Plate fixation|Surgical fixation of the patella fracture utilizing the AO principles and a locking plate with the number of screws by surgeons choice. Additional fixation by surgeons choice.
62200473|NCT06092320|EXPERIMENTAL|Didactic Lecture - Simulation Group|This group will start with a didactic lecture and then complete a simulation and debrief. They will then complete a simulation 2 months later.
62200474|NCT03008798|EXPERIMENTAL|Herbal Medicine C-117|Herbal Medicine C-117 6g granules by mouth,every 12 hours for 1 year
62200475|NCT03008798|PLACEBO_COMPARATOR|The Placebo of Herbal Medicine C-117|The Placebo of Herbal Medicine C-117 6g granules by mouth,every 12 hours for 1 year
62200476|NCT00499967|EXPERIMENTAL|Cohort 1|GS-9191 0.01% ointment
62200477|NCT00499967|EXPERIMENTAL|Cohort 2|GS-9191 0.03% ointment
62200478|NCT00499967|EXPERIMENTAL|Cohort 3|GS-9191 0.1% ointment
62784692|NCT03064971|EXPERIMENTAL|Standard care + PTF DVD|The intervention will include the standard care, with the addition of the PTF DVD. Participants randomized to this condition will receive Pathways to Freedom: Leading the Way to a Smoke-Free Community© (PTF). The content of the intervention parallels the types of education, advice, and cessation/relapse prevention strategies that are delivered in clinic and quitline contexts, except for the focus on the specific needs of the Black community. The 60- minute DVD consists of 7 sections. The cultural adaptations (e.g., focus on menthol, focus on religion/spirituality, Black images and music) were infused throughout the DVD. The PTF DVD is useable at varying levels along the readiness to quit smoking continuum, as viewers are empowered to view sections that match their interests and goals. Quit Coaches will be trained to refer participants to appropriate sections for additional help.
62012517|NCT01812044|OTHER|subtenons anesthetic and topical control|Group 1 (subtenons anesthetic and topical control): 0.5 cc of local anesthetic (preservative-free bupivacaine 0.75%) administered via a cannula subtenons through each surgical wound with 0.5 cc of Hypromellose 0.3% gel applied topically to each surgical wound at end of surgery
62200479|NCT00499967|ACTIVE_COMPARATOR|Cohort 4|GS-9191 0.3%
62200480|NCT00499967|ACTIVE_COMPARATOR|Cohort 5|GS-9191 1.0%
62200481|NCT00499967|PLACEBO_COMPARATOR|Cohorts 1, 2, 3, 4 & 5|Placebo in all cohorts
62200482|NCT05594602|EXPERIMENTAL|EDP-235 and Itraconazole interaction (Part 1)|Subjects will receive EDP-235 and Itraconazole on respective dosing days
62200483|NCT05594602|EXPERIMENTAL|EDP-235 and Carbamazepine interaction (Part 2)|Subjects will receive EDP-235 and Carbamazepine on respective dosing days
62200484|NCT05594602|EXPERIMENTAL|EDP and Quinidine interaction (Part 3)|Subjects will receive EDP-235 and Quinidine on respective dosing days
62200485|NCT06035302|EXPERIMENTAL|Madany closure|the novel port site closure technique is to be done for this group
62200486|NCT06035302|ACTIVE_COMPARATOR|Control|external closure of the port site
62784693|NCT03064971|ACTIVE_COMPARATOR|Standard care + standard smoking cessation DVD|"This arm includes standard care, plus a standard smoking cessation DVD. The evidence-based How to Quit DVD contains 60 minutes of smoking cessation information and strategies. Narrated by a physician, it describes the process of quitting and strategies for increasing physical activity and healthy nutrition. It includes testimonials from former smokers and dialogue among smokers in a group counseling setting. The information is presented in a standard format, intended for the general population of smokers."
62200487|NCT03495973||Participants with Crohn's Disease (CD)|Participants with CD will be assessed for the effectiveness of ustekinumab in accordance with national guidelines and routine standard of care. Data will be prospectively collected with the aid of the Swedish inflammatory bowel disease (IBD) registry, SWIBREG and medical records of each participant. Data will also be collected retrospectively from SWIBREG and other databases including national databases such as the participant registry in which cases the national databases will be considered source data.
62401337|NCT05255939|EXPERIMENTAL|dTRA group|Investigators perform percutaneous coronary intervention by dTRA
62401338|NCT05255939|OTHER|TRA group|Investigators perform percutaneous coronary intervention by conventional TRA
62200488|NCT01715883|EXPERIMENTAL|Sodium Nitrite|"Sodium Nitrite will be administered at three time points:~At the time of organ procurement, a pre-prepared syringe of sodium nitrite will be added to each of the 2.8 liter bags of Perfadex solution to flush the donor lungs.~At the time of transplant just prior to reperfusion of lungs, the donor lungs are flushed with a cold pneumoplegia solution after the bronchial (1st) anastomosis and with warm pneumoplegia solution after the portal vein (3rd, last) anastomosis. The drug will be added to pneumoplegia solution just prior to both the flushes.~Sodium Nitrite will be delivered intravenously to the recipient immediately prior to lung reperfusion as a single infusion at rate of 4 mL/min for the first 30 min, followed by 2.2 mL/min for the next 60 min."
62200489|NCT04688177||smokers|cigarette smokers male 20 ≤ age ≤ 45 years old female 20 ≤ age ≤ 55 years old
62200490|NCT04688177||never smokers|age and gender-matched non-smokers
62200491|NCT01277692|EXPERIMENTAL|Part 1: Single Dose Escalation in Healthy Subjects|The doses currently planned are 10, 30mg, 100mg, 200mg
62200492|NCT01277692|EXPERIMENTAL|Part 2: Repeat Dose Escalation in Healthy Subjects|The first planned dose is currently 10mg QD and the planned maximum dose is 100mg QD
62200493|NCT01277692|EXPERIMENTAL|Part 3: Single Dose Escalation in HCV Infected Subjects|The planned doses for Part 3 are 5mg, 30mg, and 100 mg.
62200494|NCT00615875|ACTIVE_COMPARATOR|A|
62200495|NCT00615875|PLACEBO_COMPARATOR|P|
62401339|NCT01511367|ACTIVE_COMPARATOR|Flutiform|
62401340|NCT01511367|ACTIVE_COMPARATOR|Seretide|
62401341|NCT01511367|ACTIVE_COMPARATOR|Flixotide|
62401342|NCT06378112|EXPERIMENTAL|Group 1 (test group)|Guided bone regeneration procedure with GTO® as bone graft and soft collagenated cortical membrane (OsteoBiol® Lamina; Tecnoss srl) as graft stabilizer.
62401343|NCT06378112|ACTIVE_COMPARATOR|Group 2 (control)|Guided bone regeneration procedure with Apatos Mix® cortico-cancellous heterologous bone mix (OsteoBiol®; Tecnoss srl) as bone graft and soft collagenated cortical membrane (OsteoBiol® Lamina; Tecnoss srl) as graft stabilizer.
62401344|NCT03494452||Low back pain - no intervention|Patients who perform sitting occupational activities for at least 4 hours/day and have had low back pain for at least the previous 6 months
62401345|NCT03494452||Healthy - no intervention|Healthy persons who perform sitting occupational activities for at least 4 hours/day
62401346|NCT04631432||Study participation|All participants will complete the same protocol
62401347|NCT00912431|EXPERIMENTAL|1|
62401348|NCT00912431|PLACEBO_COMPARATOR|2|
62401349|NCT04180956|EXPERIMENTAL|Intervention|The bias-reduction intervention opened with a didactic on health disparities, stereotypes, microaggressions, interracial provider-patient interactions and racism. Then, a guided, interracial eye-contact mindfulness exercise was performed to increase providers' awareness and acceptance of subtle bias that occurs in interracial interactions. Then, in small, mixed-race groups, participants practiced the above mindfulness skills while reciprocally sharing and responding with empathy to each other's personal life histories and personal narratives of loss and/or betrayal. The intervention ended with explicit practice component, involving practice and feedback.
62200496|NCT02472145|EXPERIMENTAL|Decitabine plus Talacotuzumab|"Part A: For Cycle 1 of Part A, participants will receive talacotuzumab on Day 1. Starting from Cycle 2 of Part A, participants may receive decitabine on Day 1, 2, 3, 4, and 5, and talacotuzumab on Day 8 and 22 of a 28-day cycle.~Part B Arm 1: Participants will receive decitabine on Day 1, 2, 3, 4, and 5, and talacotuzumab on Day 8 and 22 of a 28-day cycle."
62401350|NCT04180956|NO_INTERVENTION|Control|The control condition was a waitlist condition. Doctors were given workshop materials after the study ended.
62578151|NCT01830868||Zonisamide tablets|
62200497|NCT02472145|ACTIVE_COMPARATOR|Decitabine|Participants in Part B Arm 2 will receive decitabine on Day 1,2, 3, 4 and 5 of a 28-day cycle.
62200498|NCT03392168|EXPERIMENTAL|Cohort 1 - ARQ-151 cream 0.5%|Single-dose application of ARQ-151 cream 0.5% to 25 cm\^2 of psoriatic plaque(s)
62200499|NCT03392168|EXPERIMENTAL|Cohort 2 - ARQ-151 cream 0.5%|ARQ-151 cream 0.5% applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
62200500|NCT03392168|EXPERIMENTAL|Cohort 2 - ARQ-151 cream 0.15%|ARQ-151 cream 0.15% applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
62200501|NCT03392168|PLACEBO_COMPARATOR|Cohort 2 - ARQ-151 vehicle cream|Vehicle cream applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
62401351|NCT06341582||Neonates with hemolytic hyperbilirubinemia|"Neonates who are diagnosed as neonatal hyperbilirubinemia and hemolytic diseases of newborns.~Neonatal hyperbilirubinemia is defined as the total serum bilirubin (TSB) reaching or exceeding the thresholds in aligned with the 2004 American Academy of Pediatrics (AAP) guidelines.~Hemolytic diseases of newborns is defined as a diagnosis of ABO hemolytic diseases of newborns and/or glucose-6-phosphate dehydrogenase (G6PD) deficiency."
62401352|NCT06341582||Neonates without hemolytic hyperbilirubinemia|Neonates who have no neonatal hyperbilirubinemia.
62401353|NCT00538434|EXPERIMENTAL|Reslizumab 1 mg/kg|reslizumab 1 mg/kg intravenous (IV) on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
62401354|NCT00538434|EXPERIMENTAL|Reslizumab 2 mg/kg|reslizumab 2 mg/kg IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
62401355|NCT00538434|EXPERIMENTAL|Reslizumab 3 mg/kg|reslizumab 3 mg/kg IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
62401356|NCT00538434|PLACEBO_COMPARATOR|Placebo|saline placebo IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
62401357|NCT03514823|EXPERIMENTAL|IMT Group|
62401358|NCT03514823|SHAM_COMPARATOR|No IMT Group|
62401359|NCT03233191|EXPERIMENTAL|Arm A (digital mammography)|Patients undergo bilateral screening DM with standard CC and MLO views at baseline, 12, 24, 36, and 48 months if pre-menopausal or at baseline, 24, and 48 months if post-menopausal.
62578152|NCT01127451|EXPERIMENTAL|Denileukin Diftitox on Days 1 to 4|Participants received Denileukin Diftitox 12 mcg/kg/day (microgram per kilogram) on Days 1 through 4 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks).
62012518|NCT01812044|OTHER|topical anesthetic and subtenons control|Group 2 (topical anesthetic and subtenons control): 0.5 cc of lidocaine 3.5% ophthalmic gel applied topically to each surgical wound and 0.5 cc of normal saline (NS) administered via a cannula subtenons through each surgical wound at end of surgery
62401360|NCT03233191|EXPERIMENTAL|Arm B (digital tomosynthesis mammography)|Patients undergo manufacturer-defined screening TM at baseline, 12, 24, 36, and 48 months if pre-menopausal or at baseline, 24, and 48 months if post-menopausal.
62401361|NCT01001091|EXPERIMENTAL|AL-38583 0.01%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
62401362|NCT01001091|EXPERIMENTAL|AL-38583 0.05%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
62200502|NCT02796768||Participants|"Study participants will be 0 to 4 months of age and undergoing DDH screening. They will have the following scans:~BASELINE - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2, 1 2D US scanning session of right and left hip by Specialist 1, 1 2D US scanning session of right and left hip by Specialist 2.~FOLLOW-UP (OPTIONAL) - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2,~1 2D US scanning session of right and left hip by Specialist 1,~1 2D US scanning session of right and left hip by Specialist 2."
62200503|NCT06224790|EXPERIMENTAL|Group A (Pirfenidone)|Capsule Pirfenidone 200mg, 2 X 8hrly for 3 months
62401363|NCT01001091|EXPERIMENTAL|AL-38583 0.2%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
62578153|NCT01127451|EXPERIMENTAL|Denileukin Diftitox on Days 1, 8, and 15|"Participants received Denileukin Diftitox 12 mcg/kg/day on Days 1, 8, and 15 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks).~ARM 2 was closed. Participants experiencing clinical benefit (irSD, irPR, or irCR per irRC) after 4 cycles of treatment, may continue their denileukin diftitox treatment for up to 8 cycles."
62012519|NCT01812044|OTHER|topical control and subtenons control|Group 3 (topical control and subtenons control): 0.5 cc of topical Hypromellose 0.3% gel applied topically to each surgical wound and 0.5 cc of NS administered via a cannula subtenons through each surgical wound at end of surgery
62200504|NCT06224790|PLACEBO_COMPARATOR|Group B|Placebo capsules - 2 X 8hrly for 3 months
62200505|NCT03523026|EXPERIMENTAL|NMES and Peripheral Muscle Training|"Neuromuscular Electrical Stimulation (NMES) and Peripheral Muscle Training~NMES frequency will be 30 Hertz and the application time will be 30 minutes.Treatment will be programmed for 3 days per week.~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks."
62200506|NCT03523026|EXPERIMENTAL|IMT and Peripheral Muscle Training|"Inspirator Muscle Training (IMT) and Peripheral Muscle Training~IMT will be applied 7 days per week, twice a day for 15 minutes.~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week. The program will continue for 6 weeks."
62401364|NCT01001091|PLACEBO_COMPARATOR|AL-38583 Vehicle|AL-38583 ophthalmic solution vehicle, 1 drop instilled in each eye 3 times per day for 2 weeks
62401365|NCT01001091|ACTIVE_COMPARATOR|MAXIDEX|Dexamethasone ophthalmic suspension, 0.1%, 1 drop instilled in each eye 3 times per day for 2 weeks
62401366|NCT05448469|ACTIVE_COMPARATOR|general anesthesia+ bilateral US guided erector spinae plane block|General anesthesia plus ultrasound guided erector spinae plane block with 20 ml bupivacaine 0.2% at T9
62578154|NCT03873857||Venetoclax|"Participants in this observational study will receive treatment with venetoclax for up to 24 months for treatment of relapsed or refractory CLL.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
62578155|NCT02096874|OTHER|Bevacizumab|Each study subject will recieve Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month.
62012520|NCT01766375|EXPERIMENTAL|IDBUCY|"Idarubicin: 20mg/m2 a day, d-12 \~d-10, intravenous infusion for 1 hour. Busulfan: 4mg/Kg a day, oral administration, d-7 \~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7\~d-4.~cyclophosphamide: 60mg/Kg a day, intravenous infusion, d-3\~d-2."
62200507|NCT03523026|EXPERIMENTAL|Peripheral Muscle Training|"Peripheral Muscle Training~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks."
62200508|NCT04351035||Children with CNS tumours|Patients newly diagnosed with CNS tumours in children younger than 18 y/o, who were under in-patient treatment, were labeled as candidate cases in the CNOG-MC001 cohort for reviewing.
62200509|NCT01424813|PLACEBO_COMPARATOR|Placebo MDPI|Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
62200510|NCT01424813|EXPERIMENTAL|Albuterol MDPI|Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.
62200511|NCT00949377|EXPERIMENTAL|Methylnaltrexone Bromide|
62200512|NCT00949377|PLACEBO_COMPARATOR|Normal Saline|
62401367|NCT05448469|ACTIVE_COMPARATOR|general anesthesia+ bilateral US guided paravertebral block|General anesthesia plus bilateral US guided paravertebral block with 7 ml bupivacaine 0.2% at T8 and T10
62401368|NCT05448469|ACTIVE_COMPARATOR|general anesthesia|general anesthesia plus conventional analgesia
62401369|NCT00717665|EXPERIMENTAL|A, 1, I|
62401370|NCT00717665|ACTIVE_COMPARATOR|A, 2, I|
62401371|NCT03948321|EXPERIMENTAL|Painless Photodynamic Therapy（P-PDT）|The painless photodynamic therapy（P-PDT）group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 400 J/cm2) after applying 20% 5-aminolevulinic acid（ALA）cream for 30min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
62200513|NCT02086318||OvAge assessment|Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle
62200514|NCT02050880||Normal eyes|Eyes without pathology.
62200515|NCT02050880||Glaucoma|Eyes with Glaucoma.
62401372|NCT03948321|ACTIVE_COMPARATOR|Conventional Photodynamic Therapy（C-PDT）|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 100 J/cm2) after applying 20% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once weekly for a maximum of 3 weeks.
62401373|NCT03699722|EXPERIMENTAL|Education + Activities|12 modules which include the following topics: introduction to the CN and intervention, video about PrEP, PrEP use in combination with other HIV, STI, and pregnancy prevention, identification and strategizing about beliefs regarding PrEP initiation, addressing perceived risk, strategizing about vulnerability factors that may interfere with PrEP uptake, skills building for PrEP uptake, and enhanced referral to a PrEP provider. Up to 4 follow-up phone calls to reinforce strategies. Text messaging for support PrEP adherence.
62401374|NCT03699722|ACTIVE_COMPARATOR|Information|PrEP information brochures, frequently asked questions and questions to ask provider. Listing of local PrEP providers.
62401375|NCT03110367|ACTIVE_COMPARATOR|Pain Reframing Intervention|"Participants will be randomized into this group:~- Memory reframe with parent facilitated by researcher:~Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways."
62401376|NCT03110367|SHAM_COMPARATOR|Attention Control Group|"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.~Participants will be randomized into this group:~- Attention control (watch video \[Planet Earth\] for same amount of time): Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience."
62401377|NCT03110367|NO_INTERVENTION|Normal Reminiscing|"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.~Participants will be randomized into this group:~- Normal Reminiscing: Parents and youth in the normal reminiscing group will be instructed to reminisce with their children about the in-hospital and post-surgery periods as they normally would."
62401378|NCT03557775|EXPERIMENTAL|Inspiratory Muscle Strength Training|"The participants in the IMST arm will receive, in addition to standard of care voice therapy, inspiratory muscle strength training (IMST).~The IMST intervention will consist of 5 sets of 5 breaths in the inspiratory threshold device every day during four weeks, with a loading dose set at 75% of the participants' maximal inspiratory pressure (MIP). MIP will be measured once a week during the weekly supervised session to adjust the inspiratory trainer."
62401379|NCT03557775|EXPERIMENTAL|Expiratory Muscle Strength Training|"The participants in the EMST arm will receive, in addition to standard of care voice therapy, expiratory muscle strength training (EMST).~The EMST intervention will consist of 5 sets of 5 breaths in the expiratory threshold device every day during four weeks, with a loading dose set at 75% of the participants' maximal expiratory pressure (MEP). MEP will be measured once a week during the weekly supervised session to adjust the inspiratory trainer."
62401380|NCT03557775|ACTIVE_COMPARATOR|Voice Exercises|The participants in the voice exercises group will receive standard of care voice therapy with a speech language pathologist, once a week during four weeks, plus daily practices.
62401381|NCT02137031|EXPERIMENTAL|Mini Link REAL-Time Transmitter|
62401382|NCT01780948|PLACEBO_COMPARATOR|everolimus|Everolimus administration with adjusted dose to target C trough (C0) level between 3-12 ng/mL
62012521|NCT01766375|ACTIVE_COMPARATOR|BUCY|"Busulfan: 4mg/Kg a day, oral administration, d-7 \~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7\~d-4.~Cyclophosphamide: 60mg/Kg a day, intravenous infusion, d-3\~d-2."
62012522|NCT03487367||Early stage subjects|This cohort is defined by individuals with a total SARA score of less than or equal to 9.5
62012523|NCT03487367||Premanifest mutation carriers|This cohort is defined by the presence of positive genetic diagnosis but no signs of ataxia and total SARA score of less than or equal to 2.5
62012524|NCT03487367||50%-at-risk subjects|This cohort is defined by individuals who are at risk for SCA1 or SCA3 because they have a family member who tested positive for SCA1 or SCA3. Total SARA score is less than or equal to 2.5
62200516|NCT02050880||Retinal|Eyes with Retinal Disease.
62200517|NCT02050880||Corneal|Eyes with corneal disease including a kerato-refractive group.
62200518|NCT04941053||group 1 chronic haemodialysis patients|seroprevalnce of COVID 19
62200519|NCT04941053||healthy control|seroprevalnce of COVID 19
62401383|NCT01780948|EXPERIMENTAL|everolimus with atorvastatin 20 mg|"Co-administration of everolimus and atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.~Atorvastatin 20 mg/day (fixed dose)"
62215043|NCT06533826|EXPERIMENTAL|Arm H (ADC2 T-DXd HR-)|"Participants will complete:~* Baseline visit with imaging, tumor biopsy, electrocardiogram, echocardiogram.~* Imaging every 9 weeks.~* Cycle 1 through Cycle 3:~  --Day 1 of 21 day cycle: Predetermined dose of Trastuzumab deruxtecan 1x daily.~* Cycle 1 through end of treatment:~  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab deruxtecan 1x daily.~ * Imaging on Day 1.~* End of Treatment visit with imaging, tumor biopsy, echocardiogram~* Follow up: imaging every 9 weeks.~* Long-term Follow Up: visits every 6 months."
62012525|NCT03487367||Previously diagnosed early stage|This cohort is defined by individuals who were included in prior CRC-SCA, EUROSCA, ESMI or SPATAX studies who had a total SARA score of less than or equal to 10 in 2009-2012
62012526|NCT06434207||Neonates with Congenital Heart Disease|Neonates born with severe Congenital Heart Disease undergoing corrective heart surgery within the first week of life under cardiopulmonary bypass at Boston Children's Hospital will be eligible for participation. As part of standard clinical care, neonates having cardiac surgery at Boston Children's Hospital have clinical labs drawn during and after surgery. All blood collected from neonates as part of this study will be discarded blood from those routine clinical samples. One sample will be taken before surgery and one sample will be taken after surgery.
62401384|NCT04057586|EXPERIMENTAL|Nonintubated|Nonintubated thoracoscopic surgery
62401385|NCT04057586|ACTIVE_COMPARATOR|Intubated|Intubated thoracoscopic surgery
62401386|NCT02358707|EXPERIMENTAL|phonophoresis in knee osteoarthritis|Ibuprofen phonophoresis in patients with knee osteoarthritis
62401387|NCT02945566|ACTIVE_COMPARATOR|Standard TME surgery|Radical total mesorectal excision
62401388|NCT02945566|EXPERIMENTAL|Long course concurrent chemoradiation|Capecitabine: 825 mg/m² orally, b.i.d., on radiotherapy days Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
62401389|NCT02945566|EXPERIMENTAL|Short course radiotherapy|A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
62401390|NCT00509223|EXPERIMENTAL|Group 1|Lifestyle counseling with Positive Airway Pressure (PAP) therapy
62401391|NCT00509223|ACTIVE_COMPARATOR|Group 2|Lifestyle counseling without Positive Airway Pressure (PAP) therapy
62401392|NCT03033641|EXPERIMENTAL|Ablation procedure|
62401393|NCT05376540|OTHER|Direct gallbladder injection|2.5 mg of ICG will be injected directly into gallbladder intraoperatively.
62401394|NCT05376540|OTHER|2.5 mg intravenously|2.5 mg will ICG will be injected intravenously 1 hour prior to surgery.
62401395|NCT05376540|OTHER|2.5 mg intravenously + direct gallbladder injection|2.5 mg ICG will be injected intravenously 1 hour prior to surgery and another 2.5 mg ICG will be injected directly into the gallbladder intraoperatively.
62401396|NCT05376540|OTHER|5 mg intravenously|5 mg ICG will be injected intravenously 0-8 hours prior to surgery.
62012527|NCT02415816|EXPERIMENTAL|Participants|All patients who consent to participate in this protocol. They will have diffusion weighted magnetic resonance imaging performed at several time points.
62012528|NCT03569722||Older adults|Older adults, ages 65+
62012529|NCT06301165|EXPERIMENTAL|TPC induction chemotherapy + CCRT|TPC induction chemotherapy regimen followed by concurrent chemoraditherapy (cisplatin 100 mg/m2, every 3 weeks for 3 cycles) and IMRT (PTVnx 70Gy/33f; PTVnd 70Gy/33f; PTV1 60Gy/33f; PTV2 54Gy/33f)
62215044|NCT03789604|EXPERIMENTAL|CS1001 monoclonal antibody|
62215045|NCT03789604|PLACEBO_COMPARATOR|CS1001 placebo|
62401397|NCT02331680|EXPERIMENTAL|OPC-41061 15mg/day|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 24 week.
62401398|NCT02331680|EXPERIMENTAL|OPC-41061 30mg/day|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 1 week and then OPC-41061 30 mg/day for 23 weeks
62401399|NCT02331680|PLACEBO_COMPARATOR|Placebo|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. Placebo will be administered for 24 week.
62401400|NCT05360212|PLACEBO_COMPARATOR|Standard fitting|The first group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9
62401401|NCT05360212|EXPERIMENTAL|Anatomy-based fitting|In the second group of users, an anatomy-based frequency distribution is used as per anatomy-based fitting in MAESTRO 9
62401402|NCT05360212|EXPERIMENTAL|Within-subject design: Standard fitting + ABF|The third group constitutes the within-subject design. These subjects are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting.
62401403|NCT03568968|EXPERIMENTAL|Nicotinamide Riboside|nicotinamide riboside, 1000mg daily for the duration of the trial (52 weeks). Dosage form is capsules.
62401404|NCT03568968|PLACEBO_COMPARATOR|Placebo Comparator|Placebo capsules, no active ingredients.
62401405|NCT04805632||Dialysis|Patients on hemodialysis or peritoneal dialysis who received 2 administrations of Gam-COVID-Vac (Sputnik V) vaccine against SARS-CoV-2 infection
62401406|NCT04805632||Healthy|Medical staff who received 2 administrations of Gam-COVID-Vac (Sputnik V) vaccine against SARS-CoV-2 infection
62401407|NCT04303741|EXPERIMENTAL|Camrelizumab +Apatinib+Eribulin|Camrelizumab 200mg(3mg/kg for patient whose weight is below 50kg) iv Q3W combination with Apatinib 250mg, po, daily (d1-d21)and Eribulin1.4mg/m2 iv d1, d8 Q3W
62401408|NCT05673954||Case group|Patients with primary open angle glaucoma
62401409|NCT05673954||Control group|Healthy people
62401410|NCT06463132|EXPERIMENTAL|1A PEP Low Dose|1A PEP Low Dose in Saline
62401411|NCT06463132|EXPERIMENTAL|1B PEP High Dose|1B PEP High Dose in Saline
62401412|NCT06463132|EXPERIMENTAL|2a PEP-EUFLEXXA Low Dose|2A PEP-EUFLEXXA Low Dose
62401413|NCT06463132|EXPERIMENTAL|2b PEP-EUFLEXXA High Dose|2B PEP-EUFLEXXA High Dose
62578156|NCT03763929|EXPERIMENTAL|Trans Sodium Crocetinate|Trans sodium crocetinate (TSC) will be administered intravenously as a bolus to subjects randomized to experimental drug. The bolus dose will consist of 0.25 mg/kg of TSC based on the estimated subject weight.
62578157|NCT03763929|PLACEBO_COMPARATOR|Placebo|The placebo consists of commercially available sterile saline. Placebo will be administered intravenously as a bolus to subjects randomized to placebo. The volume of sterile saline will be based on the estimated subject weight.
62578158|NCT02758938|EXPERIMENTAL|Patient Subjects|Patients that are part of the UW LUTD Program (n=30) will undergo 3 weekly biofeedback sessions each lasting 1 hour. All interactive biofeedback sessions will be conducted by American Family Children's Hospital nurses that are experienced in standard biofeedback techniques. After the patient has completed all of the biofeedback sessions, he/she will complete a feedback form about their satisfaction with the device.
62578159|NCT02758938|EXPERIMENTAL|Biofeedback Nurse Subjects|"The nurses (n=3) involved in the biofeedback portion of the UW LUTD Program will undergo a Nurse Training Session where they will be asked to think aloud while completing an outlined scenario. Their feedback will be used to update the software to make it more user friendly. After the session, they will be asked to complete the System Usability Scale (SUS). Additionally, after guiding patients through biofeedback sessions using the new software, they will be asked to complete the Nurse Feedback Form."
62578160|NCT02758938|EXPERIMENTAL|Biofeedback Physician Subject|The physician (n=1) that oversees the UW LUTD Program will assess data from each patients session. Based on the information he gathers from the session, he will complete a feedback form. Each patient's EMG activity will be stored by the video game which will allow the physician to review the patient's performance. Specifically, the physician will look for the minimum relaxation and the maximum contraction levels of the patient throughout play as well as muscular isolation.
62012530|NCT06301165|ACTIVE_COMPARATOR|GP induction chemotherapy + CCRT|GP induction chemotherapy regimen followed by concurrent chemoraditherapy (cisplatin 100 mg/m2, every 3 weeks for 3 cycles) and IMRT (PTVnx 70Gy/33f; PTVnd 70Gy/33f; PTV1 60Gy/33f; PTV2 54Gy/33f)
62215046|NCT04713891|EXPERIMENTAL|Phase 1a: Cohort 1|KF-0210 tablet will be administered at 120 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
62578161|NCT02758938|EXPERIMENTAL|Focus Group Subjects|A Focus Group session will involve the physician involved in this study, an advisor on the project and staff involved in the project as well as three random individuals outside of the project (n=7). These individuals will provide feedback on the software that will be used to improve the software.
62578162|NCT05400109|EXPERIMENTAL|UF-KURE19 CAR-T cell infusion|"The safety and manufacturing feasability of UF-KURE19 will be determined with up to 10 patients being enrolled. Lymphodepleting therapy will begin on Days -4 to -2 with each weight category of participants receiving 30mg/m2/IV of Fludarabine and 500mg/m2/IV of Cyclophosphamide regardless of the level of UF-KURE19 CAR-T cell dosing.~Dosing:~Participants greater than or equal to 50 kg:~* Level -1: 8.5 x 10\^6 UF-KURE19 CAR-T Cell Dose (CAR positive cells)~* Level 1 : 17.5 x 10\^6 UF-KURE19 CAR-T Cell Dose~Participants less than 50 kg:~* Level -1: 5.5 x 10\^6 UF-KURE19 CAR-T Cell Dose~* Level 1: 11.5 x 10\^6 UF-KURE19 CAR-T Cell Dose"
62012531|NCT04816357||Endometriosis & Migraine|"* Premenopausal women aged 18-55 years, at time of operation~* Endometriosis confirmed with surgery and histologic staging (Report of the surgery available)~* For the cases migraine needs to be confirmed during the interview according to the IHS criteria."
61978292|NCT00478569||Parathyroid Hormone (PTH) (1-84)|PTH(1-84) was prescribed in accordance with the terms of the marketing authorization. Participants were observed for 24 months.
61978293|NCT04311424|EXPERIMENTAL|14C Tirzepatide|A single dose of \[14C\]-tirzepatide administered subcutaneously (SC).
62012532|NCT04816357||Endometriosis|"* Premenopausal women aged 18-55 years, at time of operation~* Endometriosis confirmed with surgery and histologic staging (Report of the surgery available)"
62012533|NCT02460198|EXPERIMENTAL|Cohort A - Pembrolizumab 200 mg|Participants were previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan. Cohort A participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to approximately 52 cycles (up to approximately 3 years).
62012534|NCT02460198|EXPERIMENTAL|Cohort B - Pembrolizumab 200 mg|Participants were previously treated with at least one line of systemic standard of care therapy: fluoropyrimidine + oxaliplatin or fluoropyrimidine + irinotecan +/ - anti vascular endothelial growth factor (VEGF)/ epidermal growth factor regulator (EGFR) monoclonal antibody. Cohort B participants receive pembrolizumab 200 mg IV on Day 1 Q3W for up to approximately 52 cycles (up to approximately 3 years).
62012535|NCT01612546|EXPERIMENTAL|Treatment (cyclodextrin-based polymer-camptothecin CRLX101)|Patients receive cyclodextrin-based polymer-camptothecin CRLX101 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the completion of 6 courses, patients achieving stable disease or better may receive treatment for an additional 6 months.
62012536|NCT00885872|EXPERIMENTAL|Treat|At visit 2 each eligible subject will be allocated to rosuvastatin. Subjects who reach the criteria at visit 3, dosage of rosuvastatin will be titrated. The subjects will be encouraged to take the study drug at the same time each day for 104 weeks.
62012537|NCT05089539|EXPERIMENTAL|HFpEF with ARNI treatment|Sacubitril/valsartan (ARNI, 100mg bid)
62012538|NCT05089539|PLACEBO_COMPARATOR|Control group|placebo (100mg bid)
62012539|NCT05115994||Hypertensive OSA patients, high PAP compliance|Hypertensive OSA patients using their PAP device for at least 4 hrs/night
62012540|NCT05115994||Hypertensive OSA patients, low PAP compliance|Hypertensive OSA patients using their PAP device for less than 4 hrs/night
62012541|NCT05115994||Intra oral device treatment|Hypertensive OSA patients treated with IOD
62012542|NCT05115994||Untreated OSA hypertensive patients|Hypertensive OSA patients not using PAP or IOD
62012543|NCT05115994||Hypertensive patients without OSA|Control population from QregPV without OSA
62578163|NCT05928013|EXPERIMENTAL|Person With Diabetes|A health care professional will conduct the vibration perception threshold testing using both the Neurothesiometer and NERVE diagnostic testing on the person with diabetes. The person with diabetes will conduct the vibration perception threshold testing using the NERVE device. There is an option for a carer/buddy to conduct the vibration perception threshold testing with the NERVE device on the person with diabetes.
62012544|NCT05174767|EXPERIMENTAL|Acute DeBakey Type I Dissection|In eligible patients, the ascending aorta is transected and removed in a routine standard of care manner utilizing hypothermic circulatory arrest; the operator will leave at least 10 mm (1.0 cm) aortic tissue proximal to the innominate artery. AMDS is pre-loaded onto the delivery system and is delivered into the true lumen through the open distal aorta and implanted according to the instructions for use.
62200520|NCT06126679|EXPERIMENTAL|intervention group|"The 1-year lifestyle intervention includes intensive, family-based diet and physical activity counselling. The multidisciplinary team consists of one pediatrician, one specialist nurse and a clinical nutritionist. Children with their parents meet the pediatrician two times, the specialist nurse five times and the clinical nutritionist three times during the 1-year intervention. One of the meetings with the clinical nutritionist is only for parents and the child is with the nurse at the same time.~The treatment is based on educational and behavioural counselling and motivating the participants to change their lifestyle and to support the parents in managing their children´s behaviour. The aim of counselling is to increase awareness of healthy dietary and physical activity habits; to achieve a suitable energy balance, to create a positive attitude to physical activity, to promote optimal sleep duration and to improve the children´s body image and body control."
62200521|NCT06126679|NO_INTERVENTION|control group|Participants in the control group continue with the standard care in primary care and do not receive any special lifestyle intervention during the study.
62578164|NCT01039727|NO_INTERVENTION|care as usual|care as usual
62200522|NCT00863681|EXPERIMENTAL|Arm 1|
62200523|NCT00737477|EXPERIMENTAL|Mircera in Renal Anemia|Participants will receive SC methoxy polyethylene glycol-epoetin beta (Mircera) every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 micrograms (mcg) will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
62215047|NCT04713891|EXPERIMENTAL|Phase 1a: Cohort 2|KF-0210 tablet will be administered at 240 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
62401414|NCT02679300|EXPERIMENTAL|Virtual reality group|During a single intervention session, participants will perform 2 sets of 2 minutes of pelvic tilt exercises using serious games. These serious games have to be controlled by pelvic tilts. Patients will perform the exercises in a standing position in front a TV-screen, on which the games will be displayed. Wireless motion sensors will be mounted to the patient's spine and pelvis to track the movements of the pelvis.
62401415|NCT02679300|ACTIVE_COMPARATOR|Control group|During a single session intervention, participants will perform 2 sets of 2 minutes of pelvic tilt exercises without a serious game. Patients will perform the exercises in a standing position. The number of repetitions and the tempo of the pelvic tilts will be indicated using a metronome.
62578165|NCT01039727|EXPERIMENTAL|autosuggestive support|care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')
62578166|NCT01039727|EXPERIMENTAL|autosuggestive support ++|care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
62578167|NCT06114901|EXPERIMENTAL|Intervention - SleepFix|"Participants will get access to a webpage and video which will show participants information about the dBTi SleepFix mobile application. This information will explain application download, usage concepts and frequently asked questions (FAQ). The intervention webpage will continue to be available for the participants throughout the intervention period for reference if necessary and be only accessible by this group. Participants will also be sent an email and/or text message with a direct link to iOS or Google play app stores to download the SleepFix mobile application. They will be provided a unique alphanumeric access code and instructed to enter this code to access the app program. Participants will be able to commence therapy immediately upon app onboarding."
62578168|NCT06114901|ACTIVE_COMPARATOR|Control - Sleep Health Education modules|The participant will receive a link to three Sleep Health Education modules bi-weekly. All participants in the control group will gain access to the SleepFix mobile application upon completing their control period.
62578169|NCT00800995|SHAM_COMPARATOR|Control|
62401416|NCT02936466|EXPERIMENTAL|Interventional group|Bipolife group
62578170|NCT00800995|EXPERIMENTAL|SOD|
62578171|NCT05925088||Focus group 1|
62578172|NCT05925088||Focus group 2|
62578173|NCT06067555|ACTIVE_COMPARATOR|Intramuscular (IM) Control|An intramuscular control group, from which no skin biopsies will be taken after vaccination. Only the intramuscular cohort will receive the flu vaccine via standard IM route in the deltoid region of the upper arm.
62578174|NCT06067555|EXPERIMENTAL|ID-2hour|Participants receive intradermal flu vaccination in the upper arm and will have skin biopsy of vaccination site 2 hours after vaccine administration.
62578175|NCT06067555|EXPERIMENTAL|ID-6hour|Participants receive intradermal flu vaccination in the upper arm and will have skin biopsy of vaccination site 6 hours after vaccine administration.
61978294|NCT03520231|EXPERIMENTAL|Denosumab and Standard Chemotherapy|"Denosumab, given subcutaneously at a dose of 120 mg, every 4 weeks.~Gemcitabine, given intravenously at standard doses, on Days 1 and 8 of every 21 day cycle, for 3-4 cycles.~Carboplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~OR Cisplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~Calcium, orally at a dose of 1000 mg, once daily.~Vitamin D, orally at a dose of 400 IU, once daily."
62012545|NCT02124291|NO_INTERVENTION|No Assisted Hatching|No Assisted Hatching
62012546|NCT02124291|ACTIVE_COMPARATOR|Assisted Hatching|Mechanical Assisted Hatching - artificial rupture of the embryo external glycoprotein layer (Zona Pellucida) before embryo transfer.
62012547|NCT01048138|EXPERIMENTAL|Biperiden Lactate|5mg IV(in the vein)every 6 hours for 10 days
62012548|NCT01048138|PLACEBO_COMPARATOR|Placebo|5mg IV(in the vein)every 6 hours for 10 days
62200524|NCT02912546|ACTIVE_COMPARATOR|Control group|Eighteen healthy subjects and eighteen hypertensive patients (men and women) will be enrolled. A 1.5 Tesla MRI device with a large magnet bore (70 cm) will be used, allowing positions change. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and Cerebral Blood Flow (CBF) maps will be reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers). Differences in CBF values (in mL/100g/min) will be analyzed using SAS 9.3 software for Windows (SAS Institute, Cary North Carolina, USA).
62200525|NCT02912546|ACTIVE_COMPARATOR|Stroke patients|Eighteen stroke patients (men and women) will be enrolled. A 1.5 Tesla MRI device with a large magnet bore (70 cm) will be used, allowing positions change. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and Cerebral Blood Flow (CBF) maps will be reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers). Differences in CBF values (in mL/100g/min) will be analyzed using SAS 9.3 software for Windows (SAS Institute, Cary North Carolina, USA).
62401417|NCT02936466|NO_INTERVENTION|Control group|No specific intervention, treatment as usual
62200526|NCT00258739|EXPERIMENTAL|1|Concomitant radiotherapy and carboplatin-docetaxel followed by docetaxel-gemcitabine
62200527|NCT00258739|EXPERIMENTAL|2|docetaxel-gemcitabine followed by concomitant radiotherapy with carboplatin-docetaxel
62200528|NCT03695653|ACTIVE_COMPARATOR|Drink Tracking (MA) Condition|Ps will receive weekly mobile assessment trick tracking described above for six months in addition to the guidelines on safe drinking.
62200529|NCT03695653|EXPERIMENTAL|TA Intervention|The TA intervention is tailored but will adapt over time too
62200530|NCT03695653|EXPERIMENTAL|Tailored Content Only (TO)|The TO treatment arm includes tailored text messages sent at 6pm daily based on the baseline assessment.
62200531|NCT03283475|NO_INTERVENTION|control group|"- Control group will include 60 adult individuals between 18 and 35 years old who have body mass index (BMI) between 19 and 25, not complaining of any thigh contour deformities or skin redundancy with no history of body weight fluctuations. This group will be divided into two subgroups, 30 males and 30 females.~The following measurements will be recorded :- Weight, height, thigh length, hip circumference, maximum buttocks circumference, upper thigh, middle thigh and lower thigh circumferences."
62200532|NCT03283475|ACTIVE_COMPARATOR|patient group|"- Patient group will include 30 patients suffering from thigh lipodystrophy and contour deformities who will undergo surgical intervention after their assessment.~After assessment, one of the following techniques will be selected:-~* Liposuction only.~* thigh lift.~* Liposuction assisted thigh lift."
62200533|NCT05963477||Age Group|Neonates Infants Children
62200534|NCT05963477||Gender|Male Female
62200535|NCT05963477||Selective/Emergency|Selective Emergency
62200536|NCT05963477||Wound Class|Clean Clean-contaminated Contaminated Infected
62200537|NCT05963477||Risk Factors|Yes No
62200538|NCT05963477||Type of Incisions|Midline Trransverse Oblique
62200539|NCT03121820|EXPERIMENTAL|Memantinol tablets, 20 mg|"Treatment A: a single oral dose of memantin 20 mg film-coated tablet (JSC GEROPHARM, Russia - test)"
62200540|NCT03121820|ACTIVE_COMPARATOR|Akatinol Memantine® tablets, 20 mg|Treatment B: a single oral dose of memantin 20 mg film-coated tablet (Merz Pharma GmbH \& Co. KGaA, Germany - reference)
62200541|NCT02353364|EXPERIMENTAL|Group A|Transfer of 1 or 2 biopsied euploid embryo of high morphological grade based on NGS testing using CNV-Seq (PGS)
62200542|NCT02353364|NO_INTERVENTION|Group B|Transfer of 1 or 2 non-biopsied embryo of high morphological grade (no PGS)
62200543|NCT04332159|EXPERIMENTAL|Intervention group|Inhalation of Methoxyflurane through a Penthrox inhaler
62200544|NCT04332159|PLACEBO_COMPARATOR|Control group|Inhalation of placebo (0.9% salin solution) through a Penthrox inhaler
62200545|NCT00558844|ACTIVE_COMPARATOR|A|Arikayce™ at 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
62200546|NCT00558844|PLACEBO_COMPARATOR|B|Matching placebo for 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
62200547|NCT00558844|ACTIVE_COMPARATOR|C|Arikayce™ at 70 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
62401418|NCT00968565|EXPERIMENTAL|Citrate|Sodium citrate will be infused as the blood enters the ECMO circuit and calcium chloride will be infused as the blood leaves the ECMO circuit and enters the patient
62200548|NCT00558844|ACTIVE_COMPARATOR|D|Arikayce™ at 140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
62401419|NCT04753931|EXPERIMENTAL|Sensory Training in addition to Bobath Training|Exercises will be applied to the individuals participating in the study 3 days a week, 8 weeks, and 24 sessions in total. Exercises will be applied after the conventional therapy sessions.
62401420|NCT04753931|EXPERIMENTAL|Bobath Training|Exercises will be applied to the individuals participating in the study 3 days a week, 8 weeks, and 24 sessions in total. Exercises will be applied after the conventional therapy sessions.
62401421|NCT01855607|EXPERIMENTAL|topical menthol|Patients with neuropathic pain will receive topical menthol following or during chemotherapy for the treatment of either breast, gastrointestinal, or gynecologic cancer.
62200549|NCT00558844|PLACEBO_COMPARATOR|E|Matching placebo for 70 mg/140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
62200550|NCT00558077|EXPERIMENTAL|A|Metformin plus clomiphene citrate
62578176|NCT06067555|EXPERIMENTAL|ID-1day|Participants receive intradermal flu vaccination in the upper arm and will have skin biopsy of vaccination site 1 day after vaccine administration.
62578177|NCT06067555|EXPERIMENTAL|ID-3day|Participants receive intradermal flu vaccination in the upper arm and will have skin biopsy of vaccination site 3 days after vaccine administration.
62578178|NCT06067555|EXPERIMENTAL|ID-28day|Participants receive intradermal flu vaccination in the upper arm and will have skin biopsy of vaccination site 3 days after vaccine administration.
62578179|NCT06067555|PLACEBO_COMPARATOR|Sal-2hour|"A control group in which bacteriostatic saline is injected intradermally in lieu of influenza vaccine. A skin biopsy will be taken from the vaccination site 2 hours after administration."
62578180|NCT06067555|PLACEBO_COMPARATOR|Sal-6hour|"A control group in which bacteriostatic saline is injected intradermally in lieu of influenza vaccine. A skin biopsy will be taken from the vaccination site 6 hours after administration."
62578181|NCT06067555|PLACEBO_COMPARATOR|Sal-1hour|"A control group in which bacteriostatic saline is injected intradermally in lieu of influenza vaccine. A skin biopsy will be taken from the vaccination site 1 day after administration."
62578182|NCT02403479|EXPERIMENTAL|Saline then Silver Colloid|Each participant uses 6 weeks of Saline first (Frequency= 2 sprays twice daily; Route= topical intra-nasal spray; Duration= 6 weeks) followed by 6 weeks of silver colloid (Dose= 6.7mcg silver daily; Frequency= 2 sprays twice daily; Route= Topical intra-nasal spray; Duration= 6 weeks)
62578183|NCT02403479|EXPERIMENTAL|Silver Colloid then Saline|Each participant uses 6 weeks of Silver Colloid first (Dose= 6.7mcg silver daily; Frequency= 2 sprays twice daily; Route= Topical intra-nasal spray; Duration= 6 weeks) followed by 6 weeks of saline (Frequency= 2 sprays twice daily; Route= topical intra-nasal spray; Duration= 6 weeks).
62200551|NCT00558077|ACTIVE_COMPARATOR|B|Laparoscopic ovarian drilling
62401422|NCT01855607|ACTIVE_COMPARATOR|placebo lotion|Patients with neuropathic pain will receive placebo lotion following or during chemotherapy for the treatment of either breast, gastrointestinal, or gynecologic cancer.
62401423|NCT00650806|EXPERIMENTAL|Canagliflozin 50 mg|Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
62401424|NCT00650806|EXPERIMENTAL|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
62578184|NCT06507046|ACTIVE_COMPARATOR|Mechanical alignment|Patients are operated with ROSA robot and mechanical alignment
62578185|NCT06507046|EXPERIMENTAL|Personalized alignment|Patients are operated with ROSA robot and kinematic alignment
62578186|NCT06196255|EXPERIMENTAL|anti FcRL5 CAR-T|anti-FcRL5 autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy.
62578187|NCT05373979||Narcolepsy|Narcolepsy type 1 (NT1 or narcolepsy with cataplexy) and Narcolepsy type 2 (NT2 or narcolepsy without cataplexy)
62200552|NCT02866513|OTHER|Patient mechanically ventilated with APRV mode|
62578188|NCT05373979||Obstructive Sleep Apnea|mild to moderate obstructive sleep apnea (OSA; obstructive AHI of 1-15/hour)
62578189|NCT01834742|EXPERIMENTAL|Part A, arm 1|Evening dose 1 plus fixed morning dose
62578190|NCT01834742|EXPERIMENTAL|Part A, arm 2|Evening dose 2 plus fixed morninf does
62578191|NCT01834742|EXPERIMENTAL|Part A, arm 3|Evening dose 3 plus fixed morning dose
62578192|NCT01834742|ACTIVE_COMPARATOR|Part A, arm 4|Moviprep
62578193|NCT01834742|EXPERIMENTAL|Part B, arm 1|Fixed evening dose plus morning dose 1
62200553|NCT02237677||Post-traumatic stress disorder (PTSD)|Post-traumatic stress disorder (PTSD)
62200554|NCT02237677||Healthy Controls (HC)|Healthy Controls (HC)
62200555|NCT00896597|EXPERIMENTAL|NRL972|A single dose of 2 mg NRL972 will be administered on four occasions over a period of up to 6 weeks.
62200556|NCT05515354|EXPERIMENTAL|Mid-Follicular Phase Target Quit Date|Participants will start their quit attempts during the mid-follicular phase of their MC (6-8 days post-onset of menses). Each participant will be provided with a range of appropriate dates based on the information about their menstrual cycle, and they will select a target quit date from the range. Participants will be receiving NRT and will have access to behavioral support for the following 6 weeks.
62200557|NCT05515354|EXPERIMENTAL|Mid-Luteal Phase Target Quit Date|Participants will start their quit attempts during the mid-luteal phase of their MC (6-8 days pre-onset of menses). Each participant will be provided with a range of appropriate dates based on the information about their menstrual cycle, and they will select a target quit date from the range. Participants will be receiving NRT and will have access to behavioral support for the following 6 weeks.
62401425|NCT00650806|EXPERIMENTAL|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
62401426|NCT00650806|PLACEBO_COMPARATOR|Placebo|Each patient will receive matching placebo once daily for 12 weeks.
62401427|NCT05011357|EXPERIMENTAL|Phenylephrine|Phenylephrine infusion (0.3 mcg/kg/hr)
62578194|NCT01834742|EXPERIMENTAL|Part B, arm 2|Fixed evening dose plus morning dose 2
62578195|NCT01834742|EXPERIMENTAL|Part B, arm 3|Fixed evening dose plus morning dose 3
62578196|NCT01834742|EXPERIMENTAL|Part B, arm 4|Fixed evening dose plus alternative morning dose
62578197|NCT00530127|PLACEBO_COMPARATOR|A|Placebo solution
62578198|NCT00530127|EXPERIMENTAL|B|Deferiprone oral solution 20 mg/kg/day
62578199|NCT00530127|EXPERIMENTAL|C|Deferiprone oral solution 40 mg/kg/day
62578200|NCT00530127|PLACEBO_COMPARATOR|D|Placebo solution
62578201|NCT00530127|EXPERIMENTAL|E|deferiprone oral solution 60 mg/kg/day
62200558|NCT05515354|ACTIVE_COMPARATOR|Randomly Selected Target Quit Date (Usual Care)|Participants will start their quit attempts within 30 days of their enrollment into the study. They will select their target quit dates without regard for their MC. Participants will be receiving NRT and will have access to behavioral support for the following 6 weeks.
62200559|NCT01076244|OTHER|Minimally invasive lumbar decompression|
62401428|NCT05011357|PLACEBO_COMPARATOR|Control|Saline infusion
62578202|NCT05000008|EXPERIMENTAL|Aerobic Exercise Group|Moderate Intensity Aerobic Exercises
62578203|NCT05000008|EXPERIMENTAL|Resistance Exercise Group|Moderate Intensity Resistance Exercises
62012549|NCT01344057|OTHER|Sub unit, Inactivated, MF59C.1 Adjuvanted Influenza Vaccine|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
62401429|NCT06073106||Stroke|Both acutely admitted stroke patients undergoing rehabilitation and chronic recovered stroke outpatients will be recruited.
62401430|NCT06073106||Traumatic Brain Injury|Both acutely admitted TBI patients undergoing rehabilitation and chronic recovered TBI outpatients will be recruited.
62401431|NCT06073106||Breast Cancer|Only recovered breast cancer patients.
62401432|NCT06073106||Knee Osteoarthritis|For patients with chronic knee osteoarthritis.
62578204|NCT03265951|ACTIVE_COMPARATOR|Ramelteon|Ramelteon 8 mg po at bedtime
62578205|NCT03265951|PLACEBO_COMPARATOR|Usual care|education brochure about sleep hygiene
62578206|NCT03815877|ACTIVE_COMPARATOR|The intervention group (C group receiving caffeinated coffee)|100cc coffee at 3, 6 and 9 hours after the Cesarean section
62578207|NCT03815877|PLACEBO_COMPARATOR|The control group (N group receiving decaffeinated coffee)|100cc decaf coffee at 3, 6, 9 hours after the Cesarean section
62578208|NCT06064994|EXPERIMENTAL|Experimental Group|Patients with ESRD receiving mindfulness meditation
62784694|NCT03064971|ACTIVE_COMPARATOR|Standard care only|Following the first counseling session, participants may receive up to 3 additional proactive counseling calls. Follow-up calls focus on challenges that may have occurred on the quit date or with the use of medication. Quit Coaches® review and modify the person's quit plan, and provide support as appropriate. Participants also receive standard self-help materials by mail, which is often referred to by Quit Coaches. For individuals who have successfully quit, the Coach will focus on relapse prevention strategies. Quit Coaches provide medication education to all participants eligible and interested in using cessation medications. This study will provide starter NRT kits (2 weeks supply) to all participants. Coaches provide decision support using a database-supported algorithm based on current scientific evidence and the product manufacturer use instructions for each drug.
62784695|NCT00932412|EXPERIMENTAL|CLARA|Clofarabine / Intermediate-Dose Cytarabine (CLARA) with G-CSF given during each sequence of chemotherapy in order to increase the blast priming.
62784696|NCT00932412|ACTIVE_COMPARATOR|HDAC|High-Dose Cytarabine (HDAC) with G-CSF given during each sequence of chemotherapy in order to increase the blast priming.
62784697|NCT00448747|EXPERIMENTAL|AEZS-130 ( formerly ARD-07)|A single oral administration of AEZS-130 (0.5 mg/kg po) as Growth Hormone Stimulation Test
62784698|NCT00448747|ACTIVE_COMPARATOR|L-ARG+GHRH|This trial was set up as a multi-center, randomized, cross-over study investigating AEZS-130 as a Growth Hormone Stimulation Tests in terms of safety and efficacy compared to L-ARG+GHRH. When GHRH became unavailable on the US market, this comparator arm was no longer available, which was addressed by Amendment No. 3 (version 27-March-2010). Control subject enrolled under Amendment No. 3 were not randomized as there was no cross-over due to unavailability of L-ARG+GHRH. These control subjects received only AEZS-130
62012550|NCT02279641|EXPERIMENTAL|Sequence A|RDEA3170 qd (once daily), RDEA3170 + allopurinol qd, allopurinol qd
62012551|NCT02279641|EXPERIMENTAL|Sequence B|allopurinol qd, RDEA3170 + allopurinol qd, RDEA3170 qd
62200560|NCT02506751|EXPERIMENTAL|Liothyronine|"Subjects will take oral liothyronine for a total of 24 weeks following the below titration schedule:~0-6 weeks: liothyronine 10mcg po daily (5mcg po BID)~6-12 weeks: liothyronine 20mcg po daily (10mcg po BID)~12-18 weeks: liothyronine 50mcg po daily (25mcg po BID)~18-24 weeks: liothyronine 1mcg/kg/day (0.5mcg/kg po BID), not to exceed 75mcg po daily"
62200561|NCT05063695||Epidural|Patients who underwent Nuss procedure under epidural protocol (between January and December of 2019)
62200562|NCT05063695||ESP|Patients who underwent Nuss procedure using ESP catheter protocol (June 2020 to April 2021)
62401433|NCT05431673|ACTIVE_COMPARATOR|Doxycycline|• Subjects in this group will be treated with Doxycycline (100mg/day for 8 weeks).\[1\]
62578209|NCT06064994|NO_INTERVENTION|Control group|Patients with ESRD receiving traditional care.
62578210|NCT01262157|SHAM_COMPARATOR|placebo|We use the same probe that induces the same sensation on the penis and the same noise yet no energy
62578211|NCT01262157|ACTIVE_COMPARATOR|Shock wave therapy|12 treatment sessions twice a week during 9 weeks with an interim of 3 weeks no treatment
62578212|NCT02619084|EXPERIMENTAL|STN DBS ON First|"The study will be performed according a randomized, double-blind, crossover design with two 3-month phases, during which the stimulation could be switched on or off, separated by a 1-month washout period, At the end of the second double-blind phase, a further open period of 6 months with stimulation switched on will follow."
62578213|NCT02619084|EXPERIMENTAL|STN DBS OFF First|"The study will be performed according a randomized, double-blind, crossover design with two 3-month phases, during which the stimulation could be switched on or off, separated by a 1-month washout period, At the end of the second double-blind phase, a further open period of 6 months with stimulation switched on will follow."
62200563|NCT03901716|EXPERIMENTAL|Sufentanil|Group S received sufentanil 0.1 mcg/kg and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
62200564|NCT03901716|EXPERIMENTAL|Fentanyl|Group F received fentanyl 1 mcg/kg and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
62200565|NCT03901716|EXPERIMENTAL|Remifentanil|Group R received remifentanil target-controlled infusion with effect-site target concentration of 1ng/ml and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
62200566|NCT04866953||<30 units PRBC|Patients who underwent surgery within 24 hours of admission and received less than 30 units of pRBC within 24 hours.
62200567|NCT04866953||>/=30 units PRBC|Patients who underwent surgery within 24 hours of admission and received \>/=30 units of pRBC within 24 hours.
62200568|NCT03128281|EXPERIMENTAL|Conventional Insufflation System (CIS)|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~Conventional Insufflation System (CIS) used for pneumoperitoneum during laparoscopic/robotic surgery."
62200569|NCT03128281|EXPERIMENTAL|ConMed AirSeal Insufflation System (AIS) at Low Pressure|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~ConMed AirSeal Insufflation System (AIS) at Low Pressure used for pneumoperitoneum during laparoscopic/robotic surgery."
62200570|NCT03128281|ACTIVE_COMPARATOR|ConMed AirSeal Insufflation System (AIS) at Higher Pressure|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~ConMed AirSeal Insufflation System (AIS) at Higher Pressure used for pneumoperitoneum during laparoscopic/robotic surgery."
62200571|NCT05511064|EXPERIMENTAL|blood circulation treatment|Blood circulation treatment for the risk group for Deep Vein Thrombosis (DVT)
62200572|NCT05152303|EXPERIMENTAL|A：Remimazolam Tosilate|
62401434|NCT05431673|ACTIVE_COMPARATOR|Doxycycline & Ciprofloxacin|• Subjects in this group will be treated with combination of Doxycycline (100mg/day for 8 weeks) \& Ciprofloxacin (250mg twice daily for 4 weeks).\[1\]
62401435|NCT05431673|ACTIVE_COMPARATOR|Rifampicin|• Subjects in this group will be treated with Rifampicin (600mg/day for 6 weeks)
62012552|NCT01313572|EXPERIMENTAL|Apadenoson|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson
62012553|NCT01313572|ACTIVE_COMPARATOR|Adenosine|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with the active comparator: adenosine.
62200573|NCT05152303|EXPERIMENTAL|B：Remimazolam Tosilate|
62200574|NCT03471858|ACTIVE_COMPARATOR|Cervical Balloon|Transcervical 2-way 18 French (18F) single balloon Foley catheter, applied using a sponge-holding forceps into the cervical canal with the balloon inflated to a minimum of 30ml and maximum of 60ml with sterile water or saline \[1\]. This will be administered once during the study and will be retained for a maximum of 12 hours within the 24 hour study period.
62200575|NCT03471858|ACTIVE_COMPARATOR|Prostaglandin|Prostaglandin E2 (Prostin®) 3mg tablet, placed high in the vaginal fornix. This will be administered per vaginum once in the first 6 hours; a second dose is administered at the discretion of the clinician / clinical team 6 hours after the first pessary, for a cumulative total of 6mg within the 24 hour study period.
62200576|NCT01428427|EXPERIMENTAL|Cohort|Dose escalation to maximum tolerated dose of GSK1120212 and Gemcitabine.
62200577|NCT01462006|EXPERIMENTAL|Sirolimus|
62200578|NCT01462006|PLACEBO_COMPARATOR|Placebo|
62401436|NCT05390294||Patients free of the disease|Patients treated due to SGC without local recurrence or metastases
62401437|NCT05390294||Patients with the disease|Patient with relapse of SGC, metastases or died due to SGC
62401438|NCT05023499||With glutamine supplementation|perioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
62578214|NCT06526468||Acute pulmonary embolism cohort|"1. Patients objectively confirmed acute symptomatic PE or PE with deep vein thrombosis (DVT)~2. PE was confirmed by CTPA, lung V/Q scan or pulmonary angiography."
62012554|NCT03977324|SHAM_COMPARATOR|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
62200579|NCT05216822|EXPERIMENTAL|children received ORS and racecadotril as treatment|25 children received ORS and racecadotril as treatment (at a dose of 1.5 mg/kg/day, an oral single daily dose for three days)
62200580|NCT05216822|ACTIVE_COMPARATOR|children received ORS alone as treatment|25 children received ORS alone for treatment as a control group
62200581|NCT03613025|OTHER|Case : confirmed PCP diagnosis|Sampling of non-invasive and/or non-targeted respiratory tract specimens
62200582|NCT03613025|OTHER|Control : non confirmed PCP diagnosis|Sampling of non-invasive and/or non-targeted respiratory tract specimens
62200583|NCT05909553|EXPERIMENTAL|Venetoclax Sequence 1|Participants will receive whole venetoclax, followed by crushed venetoclax, and completed with ground venetoclax for a 15 day period.
62200584|NCT05909553|EXPERIMENTAL|Venetoclax Sequence 2|Participants will receive crushed venetoclax, followed by ground venetoclax, and completed with whole venetoclax for a 15 day period.
62200585|NCT05909553|EXPERIMENTAL|Venetoclax Sequence 3|Participants will receive ground venetoclax, followed by whole venetoclax, and completed with crushed venetoclax for a 15 day period.
62401439|NCT05023499||Without glutamine supplementation|no glutamine use
62401440|NCT00267826|EXPERIMENTAL|1|Patients with atopic dermatitis.
62401441|NCT03620669|EXPERIMENTAL|Durvalumab|Durvalumab until progression or unacceptable toxicity
62401442|NCT04624282||Patients with chronic superficial gastritis|Patients with chronic superficial gastritis
62401443|NCT04624282||Patients with chronic atrophic gastritis|Patients with chronic atrophic gastritis
62012555|NCT03977324|OTHER|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
62200586|NCT03063151|EXPERIMENTAL|Study Group|The Maximum isometric Voluntary Contraction (MVC) was measured by standard muscle testing. Then the subject sat in front of a table with his forearm resting in a comfortable position. The Hand Reaching Spatial Device (HRSD) was located at the maximal hand-reaching range of motion. Participants were requested to point on each target 5 times according to voice prompting that was activated by the EMG software every 10 seconds, for 45 pointing movements. The order of pointing targets was constant for all the participants.
62200587|NCT03063151|EXPERIMENTAL|Control Group|The Maximum isometric Voluntary Contraction (MVC) was measured by standard muscle testing. Then the subject sat in front of a table with his forearm resting in a comfortable position. The Hand Reaching Spatial Device (HRSD) was located at the maximal hand-reaching range of motion. Participants were requested to point on each target 5 times according to voice prompting that was activated by the EMG software every 10 seconds, for 45 pointing movements. The order of pointing targets was constant for all the participants.
62200588|NCT02789644|EXPERIMENTAL|Ursodeoxycholic acid 400mg|Day 1: Ursodeoxycholic acid 400mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
62200589|NCT02789644|EXPERIMENTAL|Ursodeoxycholic acid 800mg|Day 1: Ursodeoxycholic acid 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
62200590|NCT00555243|EXPERIMENTAL|1|Laparoscopic Simulation Education
62200591|NCT00555243|PLACEBO_COMPARATOR|2|
62200592|NCT02856516|EXPERIMENTAL|Boost Glucose Control (A)|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption in people with Diabetes.
62200593|NCT02856516|EXPERIMENTAL|Boost Glucose Control (B)|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption in people with Diabetes.
62200594|NCT02856516|ACTIVE_COMPARATOR|Boost Original|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption.
62200595|NCT01399918|EXPERIMENTAL|everolimus and bevacizumab|This is a single-institution, single-arm phase II trial of everolimus in combination with bevacizumab in patients with advanced non-clear cell RCC, who have not received prior VEGF-.or mTOR-targeted therapy. A separate cohort of patients with non-clear cell RCC with papillary features will be enrolled in order to gather information regarding the efficacy given the rarity of these entities.
62401444|NCT04624282||Patients with gastric carcinoma|Patients with gastric carcinoma
62401445|NCT03117556|EXPERIMENTAL|BTS Intervention|Bilateral thoracoscopic splanchnicectomy and infusaport placement will be performed on patients randomly selected for treatment with BTS and narcotic analgesia. Narcotics will still be prescribed for pain as needed.
62401446|NCT03117556|NO_INTERVENTION|No BTS Intervention|Patients chosen to be treated with narcotic analgesia alone will undergo infusaport placement only.
62401447|NCT02067728|ACTIVE_COMPARATOR|Usual Care|Usual care is provided to patients in practice groups not undergoing intervention of FNPA tool
62200596|NCT04441047|EXPERIMENTAL|Vaccination|ID injection AlloStim Days 0, 3/4, 7, 10/11 and 14
62200597|NCT00820170|EXPERIMENTAL|dasatinib and paclitaxel|"The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel.~The phase II portion of this trial has a Simon two-stage design to determine the efficacy of dasatinib when administered in combination with paclitaxel."
62200598|NCT05249608|OTHER|Single arm|A single arm study, only investigational product-the Gastric Bypass Stent System is intended to be used in weight loss treatment for obesity in patients with a BMI ≥ 30 kg/m2. to evaluate the safety and performance of the investigational device for the intended use.
62401448|NCT02067728|EXPERIMENTAL|FNPA tool intervention|FNPA tool practice intervention comprising of two components: 1) FNPA assessment which screens for obesigenic behaviors; 2) Brief Action Planning conversation designed to assist the family develop a health behavior change goal based on obesigenic risks on the assessment tool.
62401449|NCT00096031|EXPERIMENTAL|Cetuximab|250 mg/m\^2 on days 1, 8, 15, and 22 of every 28-day cycle.
62012556|NCT03275727|EXPERIMENTAL|A - iACT-BC experimental group|
62012557|NCT03275727|OTHER|B - Waiting list control group|
62012558|NCT04928742|EXPERIMENTAL|Treatment (9-week online CBT group)|Participants assigned to the treatment group will participate in a 9-week group CBT intervention for PPD delivered via Zoom by two public health nurses. This intervention was developed by Dr. Van Lieshout (PI) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. All participants in the treatment group will be mailed a hardcopy of the program manual.
62401450|NCT03013972||Colorectal cancer patients|Colorectal cancer patients during adjuvant chemotherapy
62401451|NCT01640600||Children exposed to SSRIs in utero|This group are comprised of children whose mothers used antidepressants during pregnancy and who were therefore exposed to antidepressants in utero.
62401452|NCT01640600||Children exposed to nicotine in utero|This group is comprised of children whose mothers smoked cigarettes during pregnancy and who were therefore exposed to nicotine in utero.
62401453|NCT01640600||Children exposed to neither nicotine nor SSRIs|This group is comprised of children who were exposed to neither nicotine nor SSRIs in utero.
62401454|NCT05092217|EXPERIMENTAL|Tirelizumab plus salvage surgery|Tirelizumab: Tirelizumab treatment after salvage surgery. Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma
62401455|NCT05092217|ACTIVE_COMPARATOR|salvage surgery alone|Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma
62401456|NCT04054531|EXPERIMENTAL|KN046 + carboplatin/paclitaxel|KN046 5 mg/kg IV every three weeks (Q3W) +Carboplatin AUC5 IV Q3W x 4 cycles + Paclitaxel 500 mg/m2 IV Q3W x 4 cycles
62401457|NCT04054531|EXPERIMENTAL|KN046 + carboplatin/pemetrexed|KN046 5 mg/kg IV Q3W +Carboplatin AUC5 IV Q3W x 4 cycles + Pemetrexed 500 mg/m2 IV Q3W x 4 cycles
62401458|NCT01429194|EXPERIMENTAL|ACE procedure|ACE procedure for the treatment of obesity
62401459|NCT00458133|EXPERIMENTAL|1|We randomly assigned 72 individuals to an aerobic exercise training only group.
62401460|NCT00458133|EXPERIMENTAL|2|We randomly assigned 73 individuals to an resistance exercise training only group.
62401461|NCT00458133|EXPERIMENTAL|3|We randomly assigned 76 individuals to a combination of aerobic plus resistance training group.
62012559|NCT04928742|NO_INTERVENTION|Control (treatment as usual)|The control group will receive standard postnatal care from Niagara Region Public Health, their obstetrician, midwife, and/or family physician.
62012560|NCT04317612|ACTIVE_COMPARATOR|Active berry product|Once daily consumption over the period of the study
62012561|NCT04317612|PLACEBO_COMPARATOR|Reference product|Once daily consumption over the period of the study
62012562|NCT03952039|EXPERIMENTAL|Fedratinib 400mg/day|Will include up to 128 subjects receiving fedratinib 400 mg self-administered Investigational Product (IP) on an outpatient basis, once daily preferably together with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles.
62012563|NCT03952039|ACTIVE_COMPARATOR|Best Available Therapy (BAT)|Best-available Investigator-selected therapy included a number of available compounds to treat MF and/or its symptoms and was chosen by the investigator for each subject. Therapy changed at different times during the treatment period. No investigational agents (e.g. not approved for the treatment of any indication) were allowed. BAT also included the choice of no treatment.
62012564|NCT04619693||The study population|The study population corresponds to patients hospitalized for proven SARS-COV-2 pneumonia with an indication (hypoxemia) for dexamethasone (see eligibility criteria)
62012565|NCT03646344|ACTIVE_COMPARATOR|Active Group|Will receive Heme Arginate (IMP) at a dose of 3mg/kg over 30mins. Participants will receive infusions of the IMP at 2 time-points, the first prior to surgery (transplantation), and the second 20-28 hours later. At each infusion, the IMP will be followed by a 100ml infusion of 0.9% Sodium Chloride over 15mins.
62012566|NCT03646344|PLACEBO_COMPARATOR|Placebo Group|Will receive a 100ml infusion of 0.9% Sodium Chloride (placebo) over 30mins. Participants will receive infusions at 2 time-points, the first prior to surgery, and the second 20-28 hours later. At each infusion, the placebo will be followed by a further 100ml infusion of 0.9% Sodium Chloride over 15mins.
62012567|NCT06663748|EXPERIMENTAL|ARX788|
62012568|NCT03447327|OTHER|operated group|patients undergoing surgery for chronic subdural hematoma by single burr hole under local anaesthesia
62012569|NCT05771519|EXPERIMENTAL|HIV disclosure intervention|"Participants assigned to the intervention group will likely participate in the following:~* Sexual health education~* Cognitive behavioral therapy strategies~* Problem-solving skills building~* Motivational interviewing~* Developing a personalized HIV disclosure plan~* Communication skills building~* Role-playing disclosure strategies Procedures in both arms will encompass 3-5 individual sessions lasting 30-60 minutes over 2-3 months. There may also be a booster session at approximately the six-month timepoint."
62200599|NCT04703998|EXPERIMENTAL|Arthroscopic rotator cuff repair and platelet rich plasma|A standard double-row arthroscopic rotator cuff repair will be performed and at the end of the procedure 10 ml of autologous platelet-rich plasma will be placed under direct vision at the tendon-bone interface.
62200600|NCT04703998|ACTIVE_COMPARATOR|Arthroscopic rotator cuff repair|A standard double-row arthroscopic rotator cuff repair will be performed.
62401462|NCT00458133|PLACEBO_COMPARATOR|4|We randomly assigned 41 individuals to a stretching and relaxation group.
62401463|NCT01162109|PLACEBO_COMPARATOR|Severe sepsis without zinc|Mechanically ventilated patients with severe sepsis will be randomized to receive IV zinc or placebo
62401464|NCT01162109|EXPERIMENTAL|Zinc in severe sepsis|Mechanically ventilated patients with severe sepsis will be randomized to receive IV zinc or placebo
62200601|NCT04175314||Case -|Patient presenting one or more periodontal recession more than 1mm of height
62784699|NCT04448769|OTHER|Anti-SARS-CoV-2 IgT seropositivity|Analysis of the serology result: The ELISA method allows semi-quantitative detection of total IgT antibodies. A positive sample will be defined by a ratio ≥ 1.0.
62578215|NCT06526468||Chronic thromboembolic pulmonary disease without pulmonary hypertension cohort|"1. Patients with functional impairment despite 3 months of adequate anticoagulation therapy after APE.~2. CTPA/ pulmonary angiography or V/Q scan showed unresolved thrombi in the pulmonary vessels.~3. Without pulmonary hypertension at rest(mean pulmonary arterial pressure (mPAP) \<20 mmHg), as measured by right heart catheterization."
62200602|NCT04175314||Control-|Patient presenting no periodontal recession or recession of less than 1 mm of height
62401465|NCT01162109|EXPERIMENTAL|Healthy Volunteers receiving zinc|Cohort of healthy volunteers will receive a single dose of 500 mcg/kg IBW IV zinc and pharmacokinetics will be measured for 8 hours. PK in sepsis patients and healthy volunteers will be compared.
62401466|NCT04576676||Essential Tremor|"1. Subjects must be 50 years of age or older.~2. Subjects must have been diagnosed with Essential Tremor~3. Subjects must live within 3 hours of UTSW~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
62401467|NCT04576676||Parkinson's Disease|"1. Subjects must be 50 years of age or older.~2. Subjects must have been diagnosed with Parkinson's Disease~3. Subjects must live within 3 hours of UTSW~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
62401468|NCT04576676||Healthy Individuals|"1. Healthy individuals living within 3 hours of UTSW~2. Subjects must be 50 years of age or older~3. You are healthy and have not being diagnosed with any neurological disease~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
62401469|NCT04576676||Essential Tremor and Parkinson's Disease|"1. Subjects must be 50 years of age or older.~2. Subjects must have been diagnosed with Essential Tremor~3. Subjects must have been diagnosed with Parkinson's Disease preceded by at least 3 years of enrollment in study~4. Subjects must live within 3 hours of UTSW~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
62401470|NCT00396357|EXPERIMENTAL|vildagliptin + metformin|
62401471|NCT00396357|ACTIVE_COMPARATOR|Metformin|
62401472|NCT03981523|EXPERIMENTAL|BZN-60|150 mg twice a day for 60 days.
62578216|NCT06526468||Chronic thromboembolic pulmonary hypertension cohort|"1. Patients with functional impairment despite 3 months of adequate anticoagulation therapy~2. CTPA/ pulmonary angiography or V/Q scan showed unresolved thrombi in the pulmonary vessels.~3. With pulmonary hypertension at rest (mean pulmonary arterial pressure (mPAP) \>20 mmHg), as measured by right heart catheterization."
62578217|NCT06526468||Other pulmonary vascular disease cohort|Patients diagnosed with other pulmonary vascular disease including Takayasu arteritis, pulmonary artery sarcoma, and fibrosing mediastinitis.
62734800|NCT05739396|EXPERIMENTAL|core stabalization|The core stability exercises will be used for core stabilization training of group (A) in addition to traditional physical therapy. The core stability program included 3 levels. Each exercise lasted 5 min, and the children shifted from one exercise to the next after the complete performance of the preceding exercise. The first (simple) level included supine abdominal draw-in (20 repetitions), abdominal draw-in with both knees to the chest (10-20 repetitions), and supine twist (10-20 repetitions). The second (medium) level included pelvic bridging (3e5 repetitions) and twist with a medicine ball (10e20 repetitions). Finally, the third (difficult) level included bridging with the head on a physio ball (the position was held for 3-5 s, followed by a slow relaxation phase, with 10-20 repetitions)
62012570|NCT05771519|NO_INTERVENTION|Control|Participants assigned to the control group will likely participate in educational topics related to healthy living for men living with HIV. Procedures in both arms will encompass 3-5 individual sessions lasting 30-60 minutes over 2-3 months. There may also be a booster session at approximately the six-month timepoint.
62012571|NCT01126541|EXPERIMENTAL|A|1000 mg IV rituximab
62012572|NCT01126541|EXPERIMENTAL|B|2 x 1000 mg IV rituximab
62012573|NCT03603964|EXPERIMENTAL|Guadecitabine|Participants received guadecitabine, subcutaneous (SC) injection on Days 1-5 of each 28-day cycle at the same dose that they were receiving in the last cycle of their prior study or at a different dose as guided by the dose adjustment guidelines in the prior study protocol.
62012574|NCT02505516|PLACEBO_COMPARATOR|metformin|metformin 500mg
62200603|NCT03957369||Adult naive HIV positive individuals|HIV-diagnosed subjects, older than 18 years, with no prior exposure to antiretroviral drugs.
62012575|NCT02505516|NO_INTERVENTION|not on metformin|
62012576|NCT04174677|EXPERIMENTAL|Inebilzumab Treatment|Infusion of Inebilizumab
62401473|NCT03981523|EXPERIMENTAL|BZN-30|150 mg once a day for 30 days.
62401474|NCT03981523|EXPERIMENTAL|BZN-90|150 mg once a day for 90 days.
62401475|NCT03981523|EXPERIMENTAL|NFX-60|240 mg twice a day for 60 days.
62401476|NCT03981523|EXPERIMENTAL|NFX-30|240 mg twice a day for 30 days.
62401477|NCT03981523|EXPERIMENTAL|NFX-90|240 mg once a day for 90 days.
62401478|NCT02183948|EXPERIMENTAL|oxytocin|nasal spray
62401479|NCT02183948|PLACEBO_COMPARATOR|Placebo|nasal spray
62012577|NCT04174677|EXPERIMENTAL|VIB4920 Treatment|Infusion of VIB4920
62012578|NCT04174677|EXPERIMENTAL|Inebilzumab+VIB4920 Treatment|Infusion of Inebilizumab and VIB4920
62200604|NCT02922504|EXPERIMENTAL|Music intervention group|For the patients in the Music intervention group, a adjuvant treament by a music intervention will be use before the procedure
62200605|NCT02922504|ACTIVE_COMPARATOR|Controlled group|"For the patients in the  controlled  group, the use of analgesic will be use if needed during the procedure"
62200606|NCT01093443|PLACEBO_COMPARATOR|A|Patients undergo a standard treatment with a classical GnRH antagonist protocol.
62578218|NCT06212700|EXPERIMENTAL|Virtual Multimodal Hub and usual care (Intervention Group)|The main aim of the virtual multimodal hub is to prepare participants for surgery (including the role of Enhanced Recovery after Surgery (ERAS) pathway) and support declines in physiological and psychological function associated with preoperative treatments (e.g., chemo-radiotherapy) and major surgery. The post-hospital discharge interventions will focus on the recovery of activities of daily living, occupational tasks, and recreational activities. Aided by standardised assessment tools, a comprehensive holistic baseline (first preoperative multimodal session) and post-discharge (first postoperative multimodal session) assessment of patients' physical, nutritional, psychological and overall health status, presence of co-morbidities and medical history will determine the frequency, intensity, time, type, volume, and progression of the multimodal interventions.
62578219|NCT06212700|ACTIVE_COMPARATOR|Usual care alone (Control Group)|Participants allocated to the control group will receive usual care according to their health care team, which may consist of advice on smoking cessation, reduction of alcohol intake, nutritional counselling, and medical optimisation in the preoperative anaesthetic clinic visits. Participants will be asked to maintain their normal daily activities.
62578220|NCT01209000||FSGS/MCD Cohort (Cohort A)|"Focal Segmental Glomerulosclerosis/Minimal Change Disease (FSGS/MCD) Cohort~Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for FSGS or MCD.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
62200607|NCT01093443|ACTIVE_COMPARATOR|B|Before undergoing a standard protocol for ovarian stimulation, patients in this group receive a pretreatment with GnRH antagonists during 3 consecutive days
62401480|NCT04809415|SHAM_COMPARATOR|Sham Group (G-S)|The LED blanket will be positioned across the quadriceps and hamstring bilaterally, however, there will be no light emission. However, the volunteer will perform the strength training protocol.
62401481|NCT04809415|EXPERIMENTAL|300J Infrared Blanket LED Group (Blanket-300J)|The LED blanket with a wavelength of 940nm, energy of 300J, will be applied across the quadriceps and hamstrings bilaterally, just before the strength training protocol.
62401482|NCT04809415|EXPERIMENTAL|300J Infrared Cluster LED Group (Cluster-300J)|The LED Cluster with a wavelength of 850 nm, energy of 300 J, will be applied to the quadriceps (5 points) and hamstrings (5 points), bilaterally, just before the strength training protocol.
62578221|NCT01209000||MN Cohort (Cohort A)|"Membranous Nephropathy (MN) Cohort~Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for MN.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
62012579|NCT04408443|ACTIVE_COMPARATOR|Reuterin D3|Patients should take 10 drops once a day during meals for 4 months followed by 2 months of follow up.
62012580|NCT04408443|PLACEBO_COMPARATOR|Placebo|Patients should take 10 drops once a day during meals for 4 months followed by 2 months of follow up.
62012581|NCT01886794|EXPERIMENTAL|Postmenopausal, topical vaginal cream|Postmenopausal participants randomized to topical vaginal cream containing estrogen or placebo for about one month's use prior to scheduled surgery. These will include those women randomized to estrogen cream.
62012582|NCT01886794|NO_INTERVENTION|Pre-menopausal, no topical vaginal cream|Pre-menopausal, no topical vaginal cream. These women will be examined at different stages in their menstrual cycle in order to compare characteristics of the cycle at high and lower estrogen timepoints.
62200608|NCT00600327|EXPERIMENTAL|1|
62401483|NCT06372158|OTHER|Stage 1|Day 14
62401484|NCT06372158|OTHER|Stage 2|Day 28
62401485|NCT04163419|EXPERIMENTAL|Arm A (treatment)|Tanezumab 10 mg SC administered on day 1 and Day 57 (± 4 days)
62578222|NCT01209000||Other glomerulopathies cohort|"Participants enrolled in NEPTUNE and determined to not have FSGS/MCD or MN will be followed in a third group.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
62578223|NCT01209000||cNEPTUNE (Cohort B)|Participants \< 19 years of age, with \< 30 days exposure to immunosuppression therapy who are not scheduled for renal biopsy.
62578224|NCT06673212|ACTIVE_COMPARATOR|Control Wheat Bread|Control Wheat Bread will be prepared to the same formulation as white wheat bread.
62578225|NCT06673212|EXPERIMENTAL|Berneray Bere barley bread|Berneray Bere barley bread will be prepared to a formulation as for the white wheat bread, but the wheat flour will be replaced with Berneray Bere barley flour.
62401486|NCT04163419|PLACEBO_COMPARATOR|Arm B (placebo then treatment)|Placebo SC (to match tanezumab SC) administered on Day 1 and tanezumab 10 mg SC on Day 57 (± 4 days)
62401487|NCT01449474|EXPERIMENTAL|Group 1|Patient matched instruments
62401488|NCT01449474|EXPERIMENTAL|Group 2|Jig based instruments
62200609|NCT02110004|OTHER|Ablation procedure|Collect intra-cardiac signals
62200610|NCT04372862|ACTIVE_COMPARATOR|Serratus anterior plane block|Serratus anterior plane block was performed in the supine position placing the ipsilateral upper limb in abduction 90 degrees position. Aiming to find the serratus anterior muscle the investigator identified the fifth rib in the mid-axillary line by the linear probe in the sagittal plane. The latissimus dorsi muscle (superficial and posterior), teres major muscle (superior) and serratus muscles (deep and inferior) were detected using ultrasound. The investigator penetrated the serratus anterior muscle by a 25 GA, 90 mm spinal needle in-plane concerning the ultrasound probe from superoanterior to posteroinferior to inject deep to it.
62401489|NCT02525575|EXPERIMENTAL|Project Life Force Group Treatment|"Project Life Force Clinical Intervention: is a manualized, weekly 90-minute group treatment lasting 3 months coinciding with the time frame for enhanced monitoring of Veterans identified as high-risk. The use of Dialectical Behavior Therapy skills in PLF differs from other DBT interventions in that it focuses primarily on emotion regulation (ER), distress tolerance and interpersonal effectiveness in the specific context of implementing a safety plan. Mindfulness is not covered. PLF is augmented with additional skill modules on strengthening friendships and education pertaining to suicide risk, suicide means restriction and suicide prevention mobile Apps."
62401490|NCT02009072|EXPERIMENTAL|Sutured limbal conjunctival autograft|Sutured limbal conjunctival autograft was done for patients of group 2 after pterygium excision
62401491|NCT02009072|EXPERIMENTAL|Suturless and glue free Limbal conjuctival autograft|Sutureless and glue free Limbal conjunctival autograft was done for patients of group 1 after pterygium excision
62401492|NCT01734499|EXPERIMENTAL|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. Quality of Life survey completed at 5 time points after informed consent."
62401493|NCT01734499|ACTIVE_COMPARATOR|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program, (2)Local support groups centered at community cancer centers, (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation.Quality of Life surveys completed at 5 time points after informed consent.
62401494|NCT03530267|ACTIVE_COMPARATOR|Arm A (mFOLFOX7)|"Patients in the 5-FU / oxaliplatin arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).~This regimen represents the 80% dosage reduced mFOLFOX 7. The 80% dose reduction was shown to be a tolerable regimen in frail elderly patients in the FOCUS 2 study."
62578226|NCT06673212|EXPERIMENTAL|Black Barley bread|Black Barley bread will be prepared to a formulation as for the white wheat bread, but the wheat flour will be replaced with Black Barley flour.
62578227|NCT04679350|EXPERIMENTAL|Standard of care + 3 doses of hzVSF-v13 50 mg/dose IV|Standard of care + 3 doses of hzVSF-v13 50 mg/dose IV
62578228|NCT04679350|EXPERIMENTAL|Standard of care + 3 doses of hzVSF-v13 200 mg/dose IV|Standard of care + 3 doses of hzVSF-v13 200 mg/dose IV
62012583|NCT01886794|PLACEBO_COMPARATOR|Postmenopausal, topical placebo cream|Postmenopausal participants randomized to topical vaginal cream containing estrogen or placebo for about one month's use prior to scheduled surgery. These will include those women randomized to placebo.
62200611|NCT04372862|ACTIVE_COMPARATOR|Erector spinae plane block|Erector spinae plane block was performed at lateral decubitus with the operation site up, the vertebrae were counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe was placed vertically 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle was introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle.
62200612|NCT03799744|EXPERIMENTAL|VCN-01 and Durvalumab; concomitant.|Combination VCN-01 (single iv dose) with Durvalumab, Concomitant schedule; Dose Escalation of VCN-01
62578229|NCT04679350|EXPERIMENTAL|Standard of care + 1 dose of hzVSF-v13 200 mg/dose IV + 2 doses of the placebo|Standard of care + 1 dose of hzVSF-v13 200 mg/dose IV + 2 doses of the placebo
62578230|NCT04679350|PLACEBO_COMPARATOR|Standard of care + 3 doses of the placebo to match hzVSF-v13 (normal saline)|Standard of care + 3 doses of the placebo to match hzVSF-v13 (normal saline)
62578231|NCT05037045|EXPERIMENTAL|GLP-1 RA therapy|GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months.
62578232|NCT01491347||alcohol dependent|
62578233|NCT05584735||Participants with Inflammatory Bowel Disease (IBD)|Participants with IBD who are receiving a flu or COVID-19 vaccine
62578234|NCT05943106|EXPERIMENTAL|Durvalumab + BCG|Participants will receive Durvalumab for 13 cycles every 4 weeks (q4w) for a maximum 12 months. All participants will receive BCG (supplied by the site) intravesically, as induction weekly for 6 weeks. Patients will subsequently receive BCG for maintenance for 3 weekly doses at 3,6,12,18, and up to 24 months, at the physician's discretion.
62578235|NCT01528982|NO_INTERVENTION|Control|Psychoeducation
62784700|NCT01344330||Screening colonoscopy patients|Men and women age 50 to 75 scheduled for screening colonoscopy
62784701|NCT03700489|EXPERIMENTAL|patients take titanium dioxide denture|patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial then in the later phase after one month they will receive( rapid heat cured acrylic resin)denture
62784702|NCT03700489|PLACEBO_COMPARATOR|patients take rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles )
62578236|NCT01528982|ACTIVE_COMPARATOR|Mindfulness|Mindfulness activity and psychoeducation
62012584|NCT00788866|EXPERIMENTAL|Pomegranate juice|This arm with receive 8oz of pomegranate juice per day.
62012585|NCT00788866|PLACEBO_COMPARATOR|Placebo|This group will take 8oz of placebo juice that lacks pomegranate daily
62012586|NCT01177501|EXPERIMENTAL|Topotecan|
62012587|NCT04626674|EXPERIMENTAL|Delandistrogene Moxeparvovec|Participants will receive a single intravenous (IV) infusion of delandistrogene moxeparvovec on Day 1.
62012588|NCT06569342||Main group|Children with OAB, who underwent intradetrusor BoNT-A-injections
62012589|NCT02334748|EXPERIMENTAL|canakinumab|Patients will continue the same dose as their last dose administered in the study CACZ885G2301E1, CACZ885N2301 or CACZ885G2306. For all indications, the maximum canakinumab dose is 4 mg/kg or 300 mg for patients ≥ 40 kg. Ilaris® dosage may be adjusted (or interrupted) according to the clinical response and to investigators judgment.
62012590|NCT04355416|EXPERIMENTAL|curcumin oral gel|
62012591|NCT04355416|OTHER|subgingival scaling and root planing|
62012592|NCT02048462||Cyclists|
62578237|NCT01528982|ACTIVE_COMPARATOR|Cognition|Cognitive training and psychoeducation
62012593|NCT05081661|EXPERIMENTAL|Motor Imagery Group A|This group will follow a program of motor imagery.
62012594|NCT05081661|PLACEBO_COMPARATOR|Motor Imagery Group B|This group will follow a placebo program inspired from Bodyscan
62012595|NCT02752048|EXPERIMENTAL|TAS-205（Low dose group）|Low dose group：Oral administration of tablets for 24 weeks, bis in die (BID) after meal The number of tablets of the study drug corresponding to the dosage (6.67-13.33 mg/kg/dose) by body weight within 14 days before enrollment was to be administered within 30 minutes after breakfast and dinner.
62012596|NCT02752048|EXPERIMENTAL|TAS-205（High dose group）|High dose group: Oral administration of tablets for 24 weeks, bis in die (BID) after meal The number of tablets of the study drug corresponding to the dosage (13.33-26.67 mg/kg/dose) by body weight within 14 days before enrollment was to be administered within 30 minutes after breakfast and dinner.
62012597|NCT02752048|PLACEBO_COMPARATOR|Placebo|Placebo group: Oral administration of tablets for 24 weeks, BID after meal
62578238|NCT03468686|ACTIVE_COMPARATOR|bilateral rTMS|sequential bilateral repetitive Transcranial Magnetic Stimulation (rTMS)
62012598|NCT04992949|EXPERIMENTAL|CPX351|Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of CONSOLIDATION therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course.
62012599|NCT06458049|EXPERIMENTAL|SHAREonline|"Participants will receive:~* One online group session structured around three 60-minute modules and creation of a personal action plan~* Single Coaching phone call at one month~* Questionnaires to complete at baseline, 2 and 4 Months"
62012600|NCT06458049|ACTIVE_COMPARATOR|Individual Self Management|"Brief individualized session with online and written materials and guidance.~All Participants will complete study questionnaires at baseline, 2 months and 4 months post intervention"
62012601|NCT00961259|EXPERIMENTAL|Fenofibric Acid 35 mg (1 x 35 mg tab)|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
62578239|NCT03468686|SHAM_COMPARATOR|Sham rTMS|Sham Transcranial Magnetic Stimulation (rTMS)
62012602|NCT00961259|EXPERIMENTAL|Fenofibric Acid 105 mg (3 x 35 mg tab)|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
62012603|NCT00961259|EXPERIMENTAL|Fenofibric Acid 105 mg (1 x 105 mg tab)|1 x 105 mg tablet administered after an overnight fast of at least 10 hours
62012604|NCT04243824|EXPERIMENTAL|All participants|All enrolled study participants will receive Ga-68MAA and PET/MRI scan.
62012605|NCT05673694|EXPERIMENTAL|EG017|"70 subjects: Part Ia 10 subjects: A total of 3 dose groups of 6 mg/day, 18 mg/day, 24 mg/day are planned. Once a day, each treatment cycle was administered for 28 days.~Part Ib 60 subjects: A total of 2 dose groups of 18 mg/day, 24 or 12mg/day are planned. Once a day, each treatment cycle was administered for 28 days."
62012606|NCT04332172|PLACEBO_COMPARATOR|General information|Control
62578240|NCT03468686|ACTIVE_COMPARATOR|Unilateral rTMS|Unilateral (High frequency) repetitive Transcranial Magnetic Stimulation (rTMS)
62784703|NCT05913024|EXPERIMENTAL|Enterovirus Type 71 Vaccine,Inactivated(Vero Cells),high dose|Participants received two doses of the vaccine, 28 days apart
62784704|NCT05913024|EXPERIMENTAL|Enterovirus Type 71 Vaccine,Inactivated(Vero Cells),low dose|Participants received two doses of the vaccine, 28 days apart
62784705|NCT05913024|ACTIVE_COMPARATOR|Enterovirus Type 71 Vaccine,Inactivated(Human Diploid Cell)|Participants received two doses of the vaccine, 28 days apart
62784706|NCT05888753||Yes Textbook Outcome|Patients undergoing scheduled adrenal neoplasm surgery with a R0 resection, no Clavien-Dindo ≥IIIa complications, no prolonged stay, no readmissions, and no mortality in the first 30 days
62784707|NCT05888753||No Textbook outcome|Patients undergoing scheduled colon cancer surgery without any of the following items: R0 resection, no Clavien-Dindo ≥IIIa complications, no prolonged stay, no readmissions, and no mortality in the first 30 days
62401495|NCT03530267|EXPERIMENTAL|Arm B (Aflibercept + mLV5FU2)|"Patients in the 5-FU / aflibercept arm receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).~The decision to use reduced doses of 5-FU and folinic acid was made to have comparable doses to the reduced FOLFOX 7."
62401496|NCT03917966|EXPERIMENTAL|SHR-1210+Docetaxel+nedaplatin|SHR-1210+Docetaxel+nedaplatin
62401497|NCT03917966|EXPERIMENTAL|SHR-1210+Apatinib|SHR-1210+Apatinib
62401498|NCT05874882|PLACEBO_COMPARATOR|control|patients with periodontitis will receive scaling and rootplaning and a placebo mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
62401499|NCT05874882|ACTIVE_COMPARATOR|chlorohexidine mouthwash|patients with periodontitis will receive scaling and rootplaning and a chlorhexidine mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
62401500|NCT05874882|EXPERIMENTAL|resveratrol mouthwash|patients with periodontitis will receive scaling and rootplaning and a resveratrol mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
62401501|NCT00752063|EXPERIMENTAL|A|All subjects will receive Sorafenib with Capecitabine and Oxaliplatin
62401502|NCT04427241|EXPERIMENTAL|Cerebrolysin|30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously
62401503|NCT04427241|PLACEBO_COMPARATOR|Control|100 ml normal saline, days 4-17, once/day, IV
62401504|NCT03214016|EXPERIMENTAL|Pilates method group|The participants will do Mat Pilates.
62401505|NCT03214016|ACTIVE_COMPARATOR|Aerobic training group|The participants will do aerobic exercise on treadmill.
62578241|NCT05751317||samples containing Enterococci|"Isolates of Enterococci will be identified by Gram staining, colony morphology, catalase test, and growth on Bile Esculin agar. All isolates will be identified to species level using Vitek2 automated system Strains confirmed as Enterococci will be examined for their antibiotic susceptibility by modified Kirby Bauer's disc diffusion method on MuellerHinton Agar.~The biofilm formation activity of Enterococci isolates will be tested using the microtiter plate technique Detection of the effect of nanoparticles on the antibiotic susceptibility profile of Enterococci. Detection of the effect of nanoparticles on the biofilm producing Enterococci. Molecular identification of some virulence factors genes and antibiotic resistance genes of Enterococci using PCR"
62401506|NCT00936468|EXPERIMENTAL|Fluzone® vaccine with JVRS-100 (3.75ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 3.75ug given by IM injection to the upper deltoid.
62578242|NCT05751317||samples with bacteria other than enterococci|
62012607|NCT04332172|EXPERIMENTAL|General information + SMS|SMS refers to tailored text messaging.
62200613|NCT03799744|EXPERIMENTAL|VCN-01 and Durvalumab; sequential|Combination VCN-01 (single iv dose) with Durvalumab, Delayed schedule (14 days); Dose Escalation of VCN-01
62401507|NCT00936468|EXPERIMENTAL|Fluzone® vaccine with JVRS-100 (7.5ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 7.5ug given by IM injection to the upper deltoid.
62578243|NCT00690001||1|HIV-1 infected patients in Taiwan
62401508|NCT00936468|EXPERIMENTAL|Fluzone® vaccine with JVRS-100 (25ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 25ug given by IM injection to the upper deltoid.
62401509|NCT00936468|EXPERIMENTAL|Fluzone® vaccine alone|One vaccination on Day 0 with Fluzone vaccine at 45 ug given by IM injection in the upper deltoid.
62578244|NCT04840056||Intestinal Metaplasia|patient with history of histologically proven gastric intestinal metaplasia
62578245|NCT04840056||Atrophic gastritis|patient with history of histologically proven atrophic gastritis
62578246|NCT05319821|ACTIVE_COMPARATOR|Active Intervention|PCP participants in the practice cohort or the intervention group will receive the ECHO46 intervention via real-time, interactive videoconferencing through Zoom sessions held once weekly for 4 weeks (4 sessions total) at regularly scheduled times convenient to providers. Session topics will focus on training PCP participants to assess, advise, and refer patients to be more physically active, as well as provide evidence-based strategies they can use to supplement and sustain their communication efforts.
62578247|NCT05319821|ACTIVE_COMPARATOR|Delayed Intervention|PCP participants will be offered the intervention in year 5.
62784708|NCT02997059|EXPERIMENTAL|Fluconazole|200mg per day for 6 months
62784709|NCT02997059|PLACEBO_COMPARATOR|Placebo|One capsule per day for 6 months
62784710|NCT01894932|EXPERIMENTAL|MBCT Group for stress patient|Mindfulness-based cognitive Group therapy will be administered on stress patient.
62784711|NCT01894932|EXPERIMENTAL|MBCT Group for depression patient|Mindfulness-based cognitive Group therapy will be administered on depression patient.
62784712|NCT01894932|EXPERIMENTAL|SR group for stress patient|psycho-physiological stress regulation group will be administered on stress patient.
62012608|NCT04332172|EXPERIMENTAL|Baseline brief intervention|Brief technology-delivered intervention for alcohol use during pregnancy
62012609|NCT04332172|EXPERIMENTAL|Baseline brief intervention + SMS|Brief technology-delivered intervention for alcohol use during pregnancy, plus tailored text messaging
62012610|NCT04332172|EXPERIMENTAL|Baseline brief intervention + 2 booster sessions|Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (\<5 minutes) online boosters using the participants' own mobile device.
62012611|NCT04332172|EXPERIMENTAL|Baseline brief intervention + 2 booster sessions + SMS|Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (\<5 minutes) online boosters using the participants' own mobile device, plus tailored SMS.
62784713|NCT01894932|EXPERIMENTAL|SR group for depression patient|psycho-physiological stress regulation group will be administered on depression patients.
62012612|NCT06332794|EXPERIMENTAL|KOKU user|SIngle arm study - all participants will use the KOKU app for 4 weeks.
62012613|NCT04734353|EXPERIMENTAL|E5 group|Escalation in CHIP
62401510|NCT06189482|EXPERIMENTAL|The observation group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition. The observation group receives IOE for enteral nutrition support
62401511|NCT06189482|ACTIVE_COMPARATOR|The control group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The control group receives NGT for enteral nutrition support
62578248|NCT01017133|OTHER|Arm I|With 6 weeks prior to surgery, patients undergo fluorine F18 (18F)-EF5 PET at 10 minutes and 90 minutes after injection of 18F-EF5. Patients also undergo fludeoxyglucose F18 (18F-FDG) PET at 1 hour and 3 hours after injection of 18F-FDG.
62578249|NCT06060951||Incident cohort|Including all patients from the time of PD catheter insertion until 8 weeks after starting PD
62578250|NCT06060951||Prevalent cohort|Including all patients treated with PD who are greater than 8 weeks from the start of dialysis.
62578251|NCT05502237|EXPERIMENTAL|Zimberelimab (ZIM) +Domvanalimab (DOM) + Chemotherapy|"Participants will receive ZIM 360 mg + DOM 1200 mg (up to 35 doses) with chemotherapy every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~Choice of chemotherapy is dependent on histology.~* Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin area under the concentration versus time curve (AUC)5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities.~* Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles."
62578252|NCT05502237|ACTIVE_COMPARATOR|Pembrolizumab (PEMBRO) + Chemotherapy|"Participants will receive PEMBRO 200 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle.~Choice of chemotherapy is dependent on histology.~* Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin AUC 5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities.~* Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles."
62578253|NCT05502237|EXPERIMENTAL|Zimberelimab (ZIM) + Chemotherapy|"Participants will receive ZIM 360 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle.~Choice of chemotherapy is dependent on histology.~* Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin AUC 5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities.~* Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles."
62578254|NCT01451528|EXPERIMENTAL|Allogeneic Umbilical Cord Blood|Allogeneic Umbilical Cord Blood Transplantation
62578255|NCT01219426||students from the University of Nantes|To be more than 18 years old (the legal age to gamble in France)
62578256|NCT01219426||pathological gamblers seeking treatment|To be more than 18 years old (the legal age to gamble in France)and pathological gambler
62578257|NCT04364438|NO_INTERVENTION|Control Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises
62578258|NCT04364438|EXPERIMENTAL|EMS Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises along with Electric Muscle Stimulation (EMS)
62578259|NCT04364438|EXPERIMENTAL|TENS Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises along with Transcutaneous Electric Nerve Stimulation (TENS)
62578260|NCT03813901|EXPERIMENTAL|Samalochana Counselling group|Arsha Vidya advaita vedanta based counselling were given to the women
62578261|NCT03813901|OTHER|Wait-list control group|Wait list group were not given any supportive care during the period. After that, they were offered the similar program as Counselling group.
62578262|NCT01108770||HED affected males|
62012614|NCT04734353|ACTIVE_COMPARATOR|T60 group|Escalation in CHIP
62578263|NCT01108770||Unaffected male controls|
62578264|NCT04614051|EXPERIMENTAL|Cellgram-DC|Cellgram-DC is injected Subcutaneous injection near the upper arm lymph nodes
62784714|NCT01894932|NO_INTERVENTION|normal|normal, no intervention.
62784715|NCT01894932|NO_INTERVENTION|Drug treatment remission patient|Drug treatment remission patient
62784716|NCT04374045||Patients with SARS-CoV-2|patients having a continuous recording of the heart rhythm during their hospitalization
62200614|NCT03553511|EXPERIMENTAL|Uterosacral ligaments suspension|Women affected by stage II-III pelvic organ prolapse undergoing total laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments.
62401512|NCT03831282|EXPERIMENTAL|RD SET Neo SpO2|All subjects enrolled in the study will receive the investigational sensor (RD SET Neo SpO2) for evaluation of SpO2.
62401513|NCT04772339||Healthy Adults|Healthy adults aged between 18-30
62401514|NCT04895423|EXPERIMENTAL|Group №1: Methotrexate therapy|
62401515|NCT04895423|EXPERIMENTAL|Group №2: Mycophenolate mofetil therapy|
62401516|NCT04895423|EXPERIMENTAL|Group №3: Cyclosporine therapy|
62578265|NCT02543905||Family History Cohort|"Men of any ethnicity with a family history of prostate cancer defined as:~* Men with a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at \<70 years~* Men with two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at \<70 years~* Men with three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age"
62578266|NCT02543905||Black African / Black African-Caribbean Cohort|"Men of black African or black African-Caribbean ancestry defined as:~Both parents and all 4 grandparents being of black African or black African-Caribbean ancestry."
62578267|NCT02543905||High-risk gene mutation cohort|Men of any ethnicity with a genetic predisposition to having prostate cancer e.g., being known to have inherited a gene mutation that increases risk of prostate cancer (gene mutation including BRCA1, BRCA2, ATM, PALB2, MLH1, MSH2, MSH6, CHEK2 and other DNA repair gene mutations as listed in the study protocol); and/or being known to have a high polygenic risk score (PRS) (defined as being in the top tenth percentile prior to enrolment).
62578268|NCT02293135|EXPERIMENTAL|Group 1|Verum Stendo session on V1 and Phantom Stendo session on V2
62578269|NCT02293135|EXPERIMENTAL|Group 2|Phantom Stendo session on V1 and Verum Stendo session on V2
62578270|NCT02731352|EXPERIMENTAL|iodine-131 Refractory/Resistant Differentiated Thyroid Cancer|iodine-131 (131I) -Refractory/Resistant Differentiated Thyroid Cancer
62578271|NCT02958735|NO_INTERVENTION|Rest|Participants randomly assigned to this arm rest quietly for thirty minutes instead of participating in the exercise challenge.
62578272|NCT02958735|EXPERIMENTAL|Mild Exercise|Participants randomly assigned to this arm are made to maintain a heart rate equivalent to 60% of the heart rate observed when VO2 max was achieved in the maximal stress test from the first visit.
62401517|NCT04895423|EXPERIMENTAL|Group №4: Dupilumab therapy|
62401518|NCT05151887|EXPERIMENTAL|Meat meal|Minced beef, potato, string beans, apple sauce, and herb butter
62401519|NCT05151887|EXPERIMENTAL|Plant meal|Quinoa, soy beans, chickpeas, broad beans, and soy sauce
62401520|NCT03868059|EXPERIMENTAL|LPCN 1021|LPCN 1021 at a 225 mg dose taken twice daily (total daily dose of 450 mg taken as 225 mg in the morning and 225 mg in the evening),
62012615|NCT04384536|EXPERIMENTAL|Neural therapy group|Neural therapy group underwent local anesthetics injections by the same physician. Local injections, segmental injections and injection of trigger points of the forearm are done. The patients are evaluated at the beginning of the study and after 4 weeks of follow-up. Pre and post-treatment visual analog scale and Duruöz Hand Index scores are obtained.
62012616|NCT04384536|NO_INTERVENTION|Control group|Control group used thumb spica splint and had rest
62012617|NCT04594512|OTHER|LENTICULE IMPLANTATION|The present study may suggest that this procedure safely, reliably, and effectively increases corneal thickness and improves visual acuity with no adverse effects. It may even provide new avenues in the treatment of corneal ectasia. Stem cells and live keratocytes are well organized based on cornea transparency and in anterior segment OCT.
62578273|NCT02958735|EXPERIMENTAL|Hard Exercise|Participants randomly assigned to this arm are made to maintain a heart rate equivalent to 80% of the heart rate observed when VO2 max was achieved in the maximal stress test from the first visit.
62012618|NCT06364826|EXPERIMENTAL|Sintilimab, bevacizumab, gemcitabine|Patients will receive induction therapy (sintilimab + bevacizumab + gemcitabine, Q3W, 3 cycles) followed by IMRT+ Sintilimab. Consolidation therapy with sintilimab continued after radiotherapy until disease progression, intolerable toxicity, death, or the subject's decision to withdraw from the study, with a total treatment period of no more than 12 cycles.
62012619|NCT05750641||diet group|those who removed milk and dairy products under the advice of a dietician without medical treatment.
62012620|NCT05750641||free-diet group|According to current standard algorithms and guidelines, appropriate treatment for FD types was arranged for the patient group who preferred to receive a free diet.
62578274|NCT04713631|ACTIVE_COMPARATOR|Artesunate and Curcumin|Artesunate 200 mg PO once a day x 2 weeks. Curcumin 2 gm PO once a day x 13 weeks.
62578275|NCT04713631|ACTIVE_COMPARATOR|Artesunate and Placebo C|Artesunate 200 mg PO once a day x 2 weeks. Placebo C x 13 weeks.
62578276|NCT04713631|ACTIVE_COMPARATOR|Curcumin and Placebo A|Placebo A x 2 weeks. Curcumin 2 gm PO once a day x 13 weeks.
62578277|NCT04713631|PLACEBO_COMPARATOR|Placebo A and Placebo C|Placebo A x 2 weeks. Placebo C x 13 weeks.
62578278|NCT04230564||AML|Patients diagnosed with AML
62012621|NCT05914467|NO_INTERVENTION|Standard of care|Participants receive teicoplanin on discretion of the doctor
62012622|NCT05914467|EXPERIMENTAL|Model Informed Precision Dosing (MIPD) guided Therapeutic Drug Monitoring(TDM)|Participants start on standard of care dosing. After 2 days blood samples will be analysed and exposure will be determined using MIPD. Wherever necessary dose adjustments will be made.
62012623|NCT06250686|NO_INTERVENTION|Control group|usual care
62012624|NCT06250686|EXPERIMENTAL|Intervention|6 month exercise and nutrition intervention
62012625|NCT01235455||Group 1|
62012626|NCT05251792||Primary Angle Clousure Diseases Eyes|Over 40 years old, regardless of gender. Patients diagnosed with PACD (PACG or PAC or PACS) with phakic eyes. Peripheral iridectomy or trabeculectomy, more than 3 months after operation.
62012627|NCT05251792||Matched Eyes|Healthy population matched by sex and age.
62012628|NCT01231425||With usual concomitant treatment|Two observational cohorts of patients will be evaluated: with and without concomitant analgesic/ antiinflammatory drugs. The objective is evaluate that both therapies (drugs and acupuncture) could be used as adjunctive therapy in order to maximize the analgesia that could be reached
62012629|NCT01231425||Without usual concomitant treatment|This group include patients that are not been treated with analgesic drugs at the beginning of the study. As an observational and naturalistic study any indicated treatment is allowed in any time
62012630|NCT00777452||1|active surveillance
62200615|NCT03553511|ACTIVE_COMPARATOR|McCall culdoplasty|Women affected by stage II-III pelvic organ prolapse undergoing vaginal hysterectomy with McCall culdoplasty.
62578279|NCT04866758||Cancer Survivors|Ambulatory cancer population already seeking psychosocial support.
62578280|NCT01989325|EXPERIMENTAL|Carfilzomib + Filanesib|"Single agent + Carfilzomib arm.~Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information.~Filgrastim to be administered per the approved product prescribing information and institutional guidelines."
62578281|NCT01989325|EXPERIMENTAL|Carfilzomib|"Single agent arm.~Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information."
62012631|NCT00777452||2|radical prostatectomy
62012632|NCT00777452||3|external beam radiotherapy
62012633|NCT00777452||4|high intensity focused ultrasound
62012634|NCT02523833|OTHER|Chronic HP patients|Chronic hypersensitivity pneumonitis patients - use of salbutamol
62012635|NCT03762135|EXPERIMENTAL|Full version of the LIITah App.|Participants will be given the LIITAH app. which consists of 1) enhanced location identification (ELI), 2) self reported nutrients by annotated photos (SNAP), 3) delivery of individually and culturally tailored point of purchase (POP) prompts along with tailored messages sent at other times of the day, 4) use of app. in connection with parents, 5) goal setting, 6) a point system
62012636|NCT03762135|ACTIVE_COMPARATOR|Partial App. (ELI and SNAP only)|Participants will be given only the ELI and SNAP components. It will detect their presence in a restaurant and allow users to document their purchases by submitting annotated photos, but it will not deliver any POP prompts encouraging them to make healthy choices, or messages at other times of the day.
62578282|NCT03860402||Pre-warmed drug|Pre-warmed (38°C) ropivacaine (7.5mg/ml) 19ml and fentanyl 50ug are injected via the epidural route at the L3-4 interspace.
62578283|NCT03860402||Room temperature drug|Room temperature (20°C) ropivacaine (7.5mg/ml) 19ml and fentanyl 50ug are injected via the epidural route at the L3-4 interspace.
62578284|NCT00861393|OTHER|CBT|
62578285|NCT00861393|OTHER|Waitlist|
62578286|NCT03055338|EXPERIMENTAL|MK-8189|Participants receive MK-8189 (4 mg controlled release \[CR\] oral tablet\[s\]) in combination with placebo matching risperidone (oral capsule\[s\]) once daily (QD) for 4 weeks. Over the initial 7 treatment days, MK-8189 is titrated from 4 mg to 12 mg as follows: 4 mg (1 tablet; Day 1); 8 mg (2 tablets; Day 4); and 12 mg (3 tablets; Day 7). Placebo matching risperidone is also titrated as follows: 1 capsule (Day 1), 2 capsules (Day 4), and 3 capsules (Day 7). After Day 7, MK-8189 is maintained at 12 mg (3 tablets) in combination with placebo matching risperidone (3 capsules), QD for 3 weeks.
62200616|NCT06117423|OTHER|No administration of adalimumab-680LT|Patients did not receive adalimumab-680LT, but underwent a Fluorescence Molecular Imaging procedure to serve as a control group and compare results with patients receiving the tracer
62578287|NCT03055338|ACTIVE_COMPARATOR|Risperidone|Participants receive risperidone (2 mg oral capsule\[s\]) in combination with placebo matching MK-8189 (oral tablet\[s\]), QD for 4 weeks. Over the initial 7 treatment days, risperidone is titrated from 2 mg to 6 mg as follows: 2 mg (1 capsule; Day 1); 4 mg (2 capsules; Day 4); and 6 mg (3 capsules; Day 7). Placebo matching MK-8189 is also titrated as follows: 1 tablet (Day 1), 2 tablets (Day 4), and 3 tablets (Day 7). After Day 7, risperidone is maintained at 6 mg (3 capsules) in combination with placebo matching MK-8189 (3 tablets), QD for 3 weeks.
62012637|NCT03840785|EXPERIMENTAL|interventional group A|2 tango session per week during 6 month (M0 to M6)
62200617|NCT06117423|EXPERIMENTAL|4.5 mg adalimumab-680LT|Patients received 4.5 mg adalimumab-680LT and underwent a Fluorescence Molecular Imaging procedure
62200618|NCT06117423|EXPERIMENTAL|15 mg adalimumab-680LT|Patients received 15 mg adalimumab-680LT and underwent a Fluorescence Molecular Imaging procedure
62200619|NCT06117423|EXPERIMENTAL|25 mg adalimumab-680LT|Patients received 25 mg adalimumab-680LT and underwent a Fluorescence Molecular Imaging procedure
62401521|NCT00518609||Indian Neonates|All hospitalized neonates (all live born infants \<60 days of age, independent of birth weight and gestational age) brought to hospital, with the diagnosis of suspected sepsis.
62401522|NCT01065662|EXPERIMENTAL|Cediranib and Temsirolimus|Please see interventions section.
62401523|NCT02525367|EXPERIMENTAL|PD-Experimental|PD patients using the online cognitive training for 8 weeks, 3 times a week
62401524|NCT02525367|ACTIVE_COMPARATOR|PD-Control|PD patients using the active control condition for 8 weeks, 3 times a week
62401525|NCT02525367|EXPERIMENTAL|MS-Experimental|MS patients using the online cognitive training for 8 weeks, 3 times a week
62012638|NCT03840785|PLACEBO_COMPARATOR|Control group B|2 tango session per week during 3 month (M3 to M6)
62200620|NCT06117423|EXPERIMENTAL|>14 weeks of adalimumab therapy + optimal dose adalimumab-680LT|Patients who received the optimal dose during the first Fluorescence Molecular Imaging procedure are invited for a second procedure after at least 14 weeks of adalimumab therapy. They will receive the optimal dose adalimumab-680LT and will undergo another Fluorescence Molecular Imaging procedure
62200621|NCT05299255|EXPERIMENTAL|Utidelone vs placebo|Drug: Utidelone vs placebo in Third-line and above Treatment Extensive Small-cell Lung Cancer
62200622|NCT04806438|ACTIVE_COMPARATOR|Group A (nebulized lignocaine group)|Patients will receive 5 ml of 10% lignocaine by air driven jet nebulizer for 20 min
62200623|NCT04806438|ACTIVE_COMPARATOR|Group B (nerve block group)|Patients will receive bilateral superior laryngeal nerve block and transtracheal instillation of 4 ml of 2% lignocaine, along with viscous xylocaine gargles twice.
62200624|NCT06263075||Infants undergoing craniosynostosis corrective surgery|Infants aged 3 to 8 months with craniosynostosis admitted to the operating room of Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria (AOU) of Bologna Polyclinic Sant'Orsola to undergo corrective surgery.
62200625|NCT03808701|EXPERIMENTAL|low dose group|Initially, 9.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 12.0mg/kg of SCT200 will be administered every two weeks until disease progression.
62200626|NCT03808701|EXPERIMENTAL|HIGH dose group|Initially,12.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 15.0mg/kg of SCT200 will be administered every two weeks until disease progression.
62200627|NCT03366532||Nurses' Health Study|The NHS began in 1976 when 121,700 female nurses aged 33-55 years and residing in the United States responded to a baseline questionnaire.
62200628|NCT03366532||Nurses' Health Study II|The NHSII was initiated in 1989 with the recruitment of 116,671 younger female registered nurses, 24 to 44 years of age, from 14 states
62401526|NCT02525367|ACTIVE_COMPARATOR|MS-Control|MS patients using the active control condition for 8 weeks, 3 times a week
62401527|NCT02525367|EXPERIMENTAL|postECT-Experimental|Depressed elderly treated with ECT patients using the online cognitive training for 8 weeks, 3 times a week
62401528|NCT02525367|ACTIVE_COMPARATOR|postECT-Control|Depressed elderly treated with ECT patients using the active control condition for 8 weeks, 3 times a week
62401529|NCT02032433|ACTIVE_COMPARATOR|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol)
62401530|NCT02032433|ACTIVE_COMPARATOR|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone)
62012639|NCT05686408|EXPERIMENTAL|TNX-601 ER, 39.4 mg|1x TNX-601 ER, 39.4 mg, pill taken orally once daily for 6 weeks.
62012640|NCT05686408|PLACEBO_COMPARATOR|Placebo|Placebo pill taken orally once daily for 6 weeks.
62012641|NCT06664060|EXPERIMENTAL|osteoimplant|
62012642|NCT06664060|PLACEBO_COMPARATOR|placebo|
62012643|NCT06601270||Retrospective|There are no interventions as the study is purely observational.
62012644|NCT06601270||Prospective|There are no interventions as the study is purely observational.
62401531|NCT02345499|EXPERIMENTAL|Laparoscopic radical cystectomy|Surgery: Laparoscopic radical cystectomy with open urinary diversion
62401532|NCT02345499|ACTIVE_COMPARATOR|Open radical cystectomy|Surgery: Open radical cystectomy with open urinary diversion
62401533|NCT00816062|EXPERIMENTAL|Treatment|Patients diagnosed with an abdominal aortic or aorto-iliac aneurysm that are considered candidates for endovascular repair, per the FDA approved IFU.
62401534|NCT01061346|EXPERIMENTAL|High Fat Diet with Fructose|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
62401535|NCT01061346|EXPERIMENTAL|High Fat Diet with Glucose|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
62401536|NCT01061346|EXPERIMENTAL|Low Fat Diet with Glucose|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein.
62401537|NCT00984646|EXPERIMENTAL|Intradermal Prevascar|
62401538|NCT00984646|PLACEBO_COMPARATOR|Placebo (vehicle)|
62200629|NCT03366532||Health Professionals Follow-Up Study|The Health Professionals Follow-up Study (HPFS) was established in 1986 and was comprised of 51,529 US male health professionals ranging in age from 40 to 75 years at enrollment from 50 states
62200630|NCT00566891|ACTIVE_COMPARATOR|A|Tirofiban
62200631|NCT00566891|PLACEBO_COMPARATOR|B|Clopidogrel
62200632|NCT04014647||Event-free|Patients who have had no negative events (as described in group 2)
62200633|NCT04014647||Negative event|"Group 2 - patients with one or more of the following negative events post-operatively:~* Whether the patient has been prescribed inotropic support~* Wound infection by assessing use of antibiotics.~* Length of stay in hospital \>1 week~* Reduced renal function assessed by having any AKI alert during hospital stay~* Cardiac event within 31 days following surgery~* Death within 31 days following surgery"
62200634|NCT04389034||Adults|Patients with IgE-induced Rhinitis, Conjunctivitis and/or asthma due to tree- and/or grass pollen induced allergy
62200635|NCT00858689|EXPERIMENTAL|minocyline 50 mg or 100 mg PO BID|open label treatment with minocycline low or high dose, 50 mg or 100 mg PO (by mouth) BID (twice a day), added to existing medication regimen for 8 weeks
62200636|NCT06307717||volatile anaesthetic (sevoflurane, isoflurane, desflurane）|Patients receiving volatile anaesthetics received at least one volatile anaesthetic (sevoflurane, isoflurane, desflurane), and those who received non-volatile anaesthetics did not receive any volatile anaesthetic.
62200637|NCT06307717||control|Patients receiving volatile anaesthetics received at least one volatile anaesthetic (sevoflurane, isoflurane, desflurane), and those who received non-volatile anaesthetics did not receive any volatile anaesthetic.
62200638|NCT02199158|EXPERIMENTAL|Argon Laser Peripheral Iridoplasty|ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
62200639|NCT01038427|EXPERIMENTAL|Test|Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals) administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
62578288|NCT03055338|PLACEBO_COMPARATOR|Placebo|Participants receive both placebo matching MK-8189 (oral tablet\[s\]) as well as placebo matching Risperidone (oral capsule\[s\]), QD for 4 weeks. Over the initial 7 treatment days, placebo matching both MK-8189 and risperidone are respectively titrated as follows: 1 tablet/1 capsule (Day 1); 2 tablets/2 capsules (Day 4); and 3 tablets/3 capsules (Day 7). After Day 7, placebo matching both MK-8189 and risperidone are respectively maintained at 3 tablets/3 capsules, QD for 3 weeks.
62012645|NCT03717532|EXPERIMENTAL|Patients with Patellopain syndrome with Cuff|Patient will be prescribed to 6 weeks of physical therapy with a cuff around the affected leg during exercises
62012646|NCT03717532|PLACEBO_COMPARATOR|Patients with Patellopain syndrome with Placebo Cuff|
62012647|NCT06268821|OTHER|Intervention|FreeStyle Libre 2 Flash Glucose Monitoring System
62200640|NCT01038427|ACTIVE_COMPARATOR|Reference|Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
62012648|NCT05501509|ACTIVE_COMPARATOR|Restoring Vertical and horizontal stability of the acromioclavicular joint|
62012649|NCT05501509|EXPERIMENTAL|Restoring Vertical stability of the acromioclavicular joint|
62012650|NCT03903107|PLACEBO_COMPARATOR|Conventional Conduction System Pacing(CSP) using fluoroscopy|Subjects in this arm will receive Conduction System Pacing(CSP) using conventional fluoroscopy technique.
62012651|NCT03903107|EXPERIMENTAL|Fluoroless Conduction System Pacing(CSP) utilizing EAM with the CARTO 3 mapping system|Subjects in this arm will receive Conduction System Pacing(CSP) utilizing electroanatomic mapping system to eliminate or minimize fluoroscopic exposure.
62012652|NCT00003545|EXPERIMENTAL|Arm I|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. If residual leukemia/lymphoma is present on day 22, then patients receive a second course of 506U78. If day 22 marrow is hypocellular, then a repeat bone marrow biopsy should be obtained on day 29 to assess response. For day 22 or 29 marrow that is in complete response, patients receive 506U78 for two more courses on days 1, 3, and 5, administered every 21 days. Patients are followed every 3 month for 1 year, then every 6 months for a maximum of 10 years.
62200641|NCT01038427|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray administered once daily for 14 days.
62200642|NCT03923517|EXPERIMENTAL|YOD caregiver|The participants will be encouraged to use RHAPSODY for four weeks. After that they will have two individual MEET sessions with experts (social worker and psychologist).
62200643|NCT02661191|OTHER|asthma severity and disease exacerbation|intramuscular cholecalciferol 100,000 IU, followed by oral cholecalciferol 5000 IU weekly plus 400 IU daily for one year
62200644|NCT02812095|EXPERIMENTAL|The refeeding group|Refeeding is initiated when 120mL/kg/day of enteral feed reaches or stoma loss exceeds more than 40ml/kg/day after operation.
62200645|NCT02812095|NO_INTERVENTION|The control group|
62200646|NCT03037203|EXPERIMENTAL|Arm A|JZP-110 and Placebo
62200647|NCT03037203|EXPERIMENTAL|Arm B|JZP-110 and Placebo
62200648|NCT03037203|PLACEBO_COMPARATOR|Arm C|Placebo
62200649|NCT05817240|EXPERIMENTAL|Experimental|
62200650|NCT04467918|EXPERIMENTAL|Cannabidiol (CBD)|50 cases in the CBD group plus pharmacological and clinical measures. Patients in the investigational treatment group will receive CBD within 24 hours after randomization, with a daily dose of 300mg / day (two 150mg doses; 1mL of the formulation) for 14 days.
62012653|NCT05584501|PLACEBO_COMPARATOR|Dental Team|ETE activity implementation with existing Dental Team only (i.e. practitioners, dental assistants, hygienists)
62012654|NCT05584501|ACTIVE_COMPARATOR|Care Navigator|ETE activity implementation with additional Care Navigator resource
62012655|NCT05596669|ACTIVE_COMPARATOR|Effect of Ketamine on Postoperative Morphine Consumption|cases in Group I received infusion of 0.15 mg/kg/h for the duration. Following a parenteral bolus dose of magnesium and ketamine (0.3mg/kg),
62012656|NCT05596669|ACTIVE_COMPARATOR|Effect of Ketamine Magnesium on Postoperative Morphine Consumption|cases in Group II received Ketamine Magnesium group were given a continuous infusion of (0.15mg/kg/h) of ketamine and (10mg/kg/h) of magnesium
62012657|NCT02526381|EXPERIMENTAL|Danlou Tablets|Danlou prescription is a tablet, each piece weighs 0.3 g, taken orally, three times a day, five at a time, from jilin Cornell's pharmaceutical corporation, Limited Liability Company .
62401539|NCT01710839|EXPERIMENTAL|Targeted Pan Retinal laser combined with 0.5mg ranibizumab|Cohort 1 (n=24), previously treated with at least 2 consecutive or more intravitreal injections of any anti-VEGF agent with persistent or recurrent macular edema will receive 6 loading doses of 0.5 mg ranibizumab followed by PRN treatment with ranibizumab 0.5 mg; after receiving the first loading dose of ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) based on 200° wide field angiography with possibility of a second session of TRP at M4/M7, if non-perfusion persists based on angiogram.The 200°wide field angiography will indicate areas of peripheral ischemia which will be selectively treated, preserving areas of more perfused retina.
62012658|NCT02526381|EXPERIMENTAL|Tongmai Yangxin Pills|Tongmai Yangxin prescription is a pill,each pill weighs 0.1 g,taken orally, 2 times a day,40 pills at a time,produced by tianjin new pharmaceutical group corporation, Limited Liability Company . LeRenTang pharmaceutical.
62012659|NCT02526381|NO_INTERVENTION|no drugs|
62012660|NCT03979365|ACTIVE_COMPARATOR|Tacrolimus twice-daily|Subjects assigned to this arm will take tacrolimus two times daily by mouth, at the clinically prescribed dose.
62012661|NCT03979365|ACTIVE_COMPARATOR|Envarsus XR|Subjects assigned to this arm will take Envarsus XR one time daily by mouth, at the clinically prescribed dose.
62012662|NCT05351606|EXPERIMENTAL|Brief Intervention|Participants will receive one time tobacco use cessation counseling and quitline number.
62012663|NCT05351606|EXPERIMENTAL|Intensive Intervention|Participants will receive intensive behavioral counseling spread over 12 sessions, Nicotine Replacement Therapy and Bupropion, and the quitline number.
62012664|NCT05059015|ACTIVE_COMPARATOR|CERVICAL HPV|Routine screening procedure based on HPV tests with cervical sampling by a health personnel
62012665|NCT05059015|EXPERIMENTAL|SELF SAMPLING HPV ARM 2|Screening based on HPV self-testing and colposcopic evaluation
62012666|NCT05059015|EXPERIMENTAL|SELF SAMPLING HPV ARM 3|Arm 3: screening based only on HPV self-testing
62200651|NCT04467918|PLACEBO_COMPARATOR|Placebo (PLB)|50 in the placebo group plus pharmacological and clinical measures. Patients in the placebo group will also receive, within 24 hours after randomization, 1mL of the same investigational medication vehicle (medium / coconut chain triglyceride oil - MCT) for 14 days
62401540|NCT01710839|ACTIVE_COMPARATOR|Ranibizumab 0.5mg|Cohort 2 (n=6), previously treated with at least 2 consecutive or more intravitreal injections of any anti-VEGF agent with persistent or recurrent macular edema will receive 6 loading doses followed by PRN monthly treatment with ranibizumab 0.5 mg.
62401541|NCT01797458|EXPERIMENTAL|Hall Technique|This technique uses preformed Stainless Steel Crowns (SSCs) to restore carious primary molars. Local anaesthesia, caries removal or tooth preparation are not required.
62012667|NCT02233231|ACTIVE_COMPARATOR|Varenicline|Varenicline 0,5 mg x 1 day 1-3 Varenicline 0,5 mg x 2 day 4-6 Varenicline 2 mg x 1 day 7 to week 12
62012668|NCT02233231|PLACEBO_COMPARATOR|Placebo|Placebo tablets equivalent to IMP.
62012669|NCT02718105||Receiver patients in donor oocyte -ART|Maternal and fetal compatibility KIR HLA-C determinations in ART -oocyte donor
62200652|NCT04383353||Cancer arm|Participants with new diagnosis of cancer, from whom a blood sample and contemporaneous tissue samples will be collected.
62200653|NCT04383353||Benign disease arm|Participants with benign diseases corresponding to the tumor types in the cancer arm, from whom a blood sample and contemporaneous tissue samples will be collected.
62200654|NCT04383353||Non-tumor arm (Healthy)|Participants with no known presence of malignancies or benign diseases, from whom a blood sample will be collected.
62401542|NCT01797458|EXPERIMENTAL|Non-Restorative Caries Treatment|This is a less operative approach, here carious lesions are opened removing the overhanging enamel and making the cavity accessible for biofilm removal. No carious dentine will be removed from the pulpal wall and no local anaesthesia will be placed. Fluoride varnish (Duraphat ®) will be applied to the cavity. Parents/children will be trained to clean the cavity by brushing using a buccolingual technique.
62401543|NCT01797458|ACTIVE_COMPARATOR|Conventional Restoration|This technique corresponds to the conventional way of treating cavitated carious lesions involving complete caries removal, use of local anaesthesia (when needed), and a compomer (Dyract ®) restoration. Cotton wool roll isolation and continuous aspiration will be used.
62401544|NCT01326312|EXPERIMENTAL|GTx- 758 1000mg|GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
62401545|NCT01326312|EXPERIMENTAL|GTx-758 2000mg|GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
62401546|NCT01326312|ACTIVE_COMPARATOR|Lupron Depot|Luteinizing Hormone Releasing Hormone Agonist
62578289|NCT05316961|EXPERIMENTAL|PEMF group|"Participants will receive active pulsed electromagnetic field therapy two times a week for eight weeks. The options of the appliance will be adjusted to 1.5 mT, 10Hz on one leg for 10 minutes. A total of 16 sessions will be given to each participant. Each session will last for 10 minutes. Participants will be positioned in sitting on a chair comfortably. They will receive intervention at Prince of Wales hospital.~3 sets of 10 repetitions of the eccentric exercises are carried out once daily for 6 weeks and after 6 weeks, the patients are instructed to carry out 3 sets of 10 repetitions, 3 times per week for 6 more weeks. The intensity of the exercise should be such that pain, or discomfort, is experienced in the last set of 10 repetitions."
62401547|NCT05158075|EXPERIMENTAL|Neurocognitive training|The experimental group will: i) receive three pre-treatment group sessions (Motivational Interviewing, nutrition and physical exercise); ii) receive an individualized diet and physical exercise planning for 6 weeks; iii) participate in 4 weekly group neurocognitive intervention sessions, that will last about 60-90 minutes each. Two neurocognitive sessions are intended to train impulsivity, and the other two neurocognitive sessions will focus on reflexive training. Participants will practice the content of each session daily at home.
62578290|NCT05316961|SHAM_COMPARATOR|Sham group|"Participants will receive sham pulsed electromagnetic field therapy two times a week for eight weeks. The options of the appliance will be adjusted to 0 mT, 0Hz on one leg for 10 minutes. A total of 16 sessions will be given to each participant. Each session will last for 10 minutes. Participants will be positioned in sitting on a chair comfortably. They will receive intervention at Prince of Wales hospital.~3 sets of 10 repetitions of the eccentric exercises are carried out once daily for 6 weeks and after 6 weeks, the patients are instructed to carry out 3 sets of 10 repetitions, 3 times per week for 6 more weeks. The intensity of the exercise should be such that pain, or discomfort, is experienced in the last set of 10 repetitions."
62200655|NCT04219995|EXPERIMENTAL|Interventional start|Patients who randomize to the interventional start arm will receive the study drug, methylprednisolone sodium succinate, in the first month of the study, followed by placebo in the cross-over phase of the study.
62200656|NCT04219995|PLACEBO_COMPARATOR|Placebo start|Patients who randomize to the placebo start arm will receive placebo in the first month of the study, followed by the study drug, methylprednisolone sodium succinate, in the cross-over phase of the study.
62578291|NCT05560308|EXPERIMENTAL|Trastuzumab Emtansine for Injection；Pyrotinib Maleate Tablets|Trastuzumab Emtansine for Injection: 3.6 mg/kg body weight (IV), administered on day 1, 21 days as a treatment cycle; Pyrotinib Maleate Tablets: The initial dose is 320 mg (PO), administered orally within 30 minutes after meals, at the same time every day, 21 days as a treatment cycle; Efficacy was assessed every two cycles and treatment was continued until disease progression or intolerable toxicity or death.
62578292|NCT00003571||Samples of tumor and normal tissue|Samples of tumor and normal tissue are obtained from CALGB 8896 patients. The samples are tested for somatic mutations and tumor replication error (RER) tumor status. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
62200657|NCT01466218||WTC Volunteers and Workers|Any current participant of the World Trade Center Health Program-Clinical Center of Excellence, formerly known as World Trade Center Medical Monitoring and Treatment Program
62200658|NCT05337553|EXPERIMENTAL|taldefgrobep alfa|"taldefgrobep alfa - Double-blind (DB) Phase: Participants receive weight based 35 mg/50 mg weekly subcutaneous injection for 48-week DB phase.~taldefgrobep alfa/taldefgrobep alfa - Extension Phase: Participants receive weight based 35 mg/50 mg weekly subcutaneous injection for 48-week Open label Extension (OLE) phase."
62012670|NCT06574373|NO_INTERVENTION|240 patients enrolled from 4 centers, 60 selected for clinical-pathological IPMN analysis.|"Characterization of the Tumor Microenvironment (TME): We will investigate the role of the TME in IPMN progression by analyzing archival samples from 240 patients across four centers. Molecular analyses will be performed on 60 selected patients based on the clinical-pathological features of their IPMN cysts, including cyst type (pancreatobiliary, intestinal, and gastric) and dysplasia grade (high and low), in accordance with current guidelines (International evidence-based Kyoto guidelines for the management of IPMN of the pancreas, Pancreatology, 2023).~The goal is to explore the dynamics of tumor progression, focusing on the cellular heterogeneity and phenotypic transitions occurring throughout the process. To achieve this, cutting-edge technologies such as ATAC-seq and spatial transcriptomics (ST) will be used to investigate both intrinsic and extrinsic cellular factors influencing the progression of IPMN."
62012671|NCT06574373|OTHER|Developing tools for IPMN diagnosis and pancreatic cancer risk, analyzing data from 3,600 patients w|"We will develop knowledge-based tools for diagnosing and treating IPMN patients and those at risk of pancreatic cancer. Specifically, we will:~1. \*\*Data Collection and Characterization\*\*: Clinical data from all involved centers will be collected and anonymized according to established practices;~2. \*\*Artificial Intelligence and Machine Learning\*\*;~3. \*\*Tumor Risk Prediction and Decision Support Systems (CDSS)\*\*; Our multicentric initiative will collect clinical data for 3,600 patients including baseline medical conditions, comorbidities, family history, CT scan results (location and size), cancer development timelines, and treatments."
62012672|NCT05268796|ACTIVE_COMPARATOR|In-person treatment|
62012673|NCT05268796|ACTIVE_COMPARATOR|Telehealth-enabled treatment|
62012674|NCT05268796|PLACEBO_COMPARATOR|Psychoeducation|
62012675|NCT05497908|EXPERIMENTAL|Transversus abdominis plane (TAP) block via lateral approach|This group receives a Transversus abdominis plane (TAP) block via lateral approach
62012676|NCT05497908|EXPERIMENTAL|Transversus abdominis plane (TAP) block via posterior approach|This group receives a Transversus abdominis plane (TAP) block via posterior approach
62578293|NCT06223399|EXPERIMENTAL|Imaging-based|66 patients with Parkinson's disease will receive imaging-based DBS programming
62012677|NCT05497908|NO_INTERVENTION|Control group|The control group receives no TAP block.
62012678|NCT03003676|EXPERIMENTAL|Experimental: ONCOS-102+cyclophosphamide+pembrolizumab|"Part I: Patients will receive 3 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, and 8) at 3x10\^11 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. They will then receive pembrolizumab i.v., 2mg/kg or 200mg flat dose, on day 22 (Week 3) and every 3 weeks thereafter until the end of treatment visit on day 169 (Week 24).~Part II: Patients will receive 4 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, 8 and 15) at 3x10\^11 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. ONCOS-102 will be given in combination with Pembrolizumab starting on Day 22/Week 3 and every three weeks thereafter until Day 169/Week 24 or until unacceptable toxicity or clinically relevant disease progression, whichever occurs first. Pembrolizumab will be given according to institutional practice (2mg/kg or 200mg flat dose)."
62200659|NCT05337553|PLACEBO_COMPARATOR|Placebo|"Placebo - Double-blind (DB) Phase: Participants receive weight based 35 mg/50 mg weekly subcutaneous injection for 48-week DB phase.~Placebo/taldefgrobep alfa - Extension Phase: Participants who receive placebo during DB phase, receive weight based 35 mg/50 mg weekly subcutaneous taldefgrobep alfa injection for 48-week OLE phase."
62200660|NCT05231525|EXPERIMENTAL|WiTOF|
62200661|NCT05231525|ACTIVE_COMPARATOR|TOFscan|
62200662|NCT05619497|ACTIVE_COMPARATOR|Care Post Clinic-Wide Trainings|Participants in this arm will receive care in a clinic where providers and staff have been trained in shared decision making and trauma-informed care. Participants in this arm will not view the decision support tool in this phase.
62578294|NCT06223399|ACTIVE_COMPARATOR|Threshold assessment-based|66 patients with Parkinson's disease will receive DBS programming based on the threshold assessment
62578295|NCT00347139|EXPERIMENTAL|GW642444|
62578296|NCT00347139|ACTIVE_COMPARATOR|Salmeterol|
62012679|NCT03037151|EXPERIMENTAL|HCV mono-infection Treatment naives|HCV treatment-naïve patients will be treated with the combination of grazoprevir plus elbasvir for 12 weeks.
62200663|NCT05619497|EXPERIMENTAL|Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)|Participants in this arm will receive care in a clinic where providers and staff have been trained in shared decision making and trauma informed care, and receive the HIV prevention DST intervention immediately before their provider visit.
62200664|NCT05619497|NO_INTERVENTION|Standard Care without the HIV Prevention Decision Support Tool (DST)|Participants in this arm will receive usual care at a clinic that has not received training in shared decision making and trauma-informed care. These participants also will not have viewed the HIV prevention DST. These participants were recruited in Aim 1 of this study.
62578297|NCT05084651|EXPERIMENTAL|Group 1|Each participant will receive a single oral dose of ganaplacide and lumefantrine combination on Day 1 of Period 1. In Period 2, participants will receive itraconazole q.d. on Days 1 to 18 and a single dose of ganaplacide and lumefantrine combination on Day 5, approximately 2 hours after the itraconazole dose
62578298|NCT04559100||Severe and critical COVID-19 survivors|"Radiological alterations assessed by chest radiography and/or thoracic computed tomography Lung function alterations assessed by spirometry, diffusing capacity for carbon monoxide, 6 minute walk.~Quality of life alterations: saint george respiratory questionnaire"
62012680|NCT03037151|EXPERIMENTAL|HCV mono-infection Treatment experienced|HCV treatment-experienced patients, including null responders, partial responders or post-treatment relapsers, will be assigned to treat with the combination plus weight-based RBV for 16 weeks.
62012681|NCT03037151|EXPERIMENTAL|HCV/HIV co-infection Treatment naives|HCV/HIV coinfected, treatment-naïve patients will be treated with the combination of grazoprevir plus elbasvir for 12 weeks.
62012682|NCT03037151|EXPERIMENTAL|HCV/HIV co-infection Treatment experienced|HCV/HIV co-infected treatment-experienced patients, including null responders, partial responders or post-treatment relapsers, will be assigned to treat with the combination plus weight-based RBV for 16 weeks.
62012683|NCT03049163|OTHER|vitrectomy under retrobulbar anesthesia|27-gauge vitrectomy for vitreous floaters under traditional retrobulbar anesthesia
62784717|NCT00098579|EXPERIMENTAL|Treatment (chemotherapy)|Patients receive doxorubicin hydrochloride IV over 5-10 minutes and alvocidib IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients reaching a cumulative doxorubicin dose of 600 mg/m\^2 or experiencing cardiotoxicity may receive alvocidib alone at the discretion of the investigator. Cohorts of 3-6 patients receive escalating doses of alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Ten additional patients receive treatment at the MTD. Patients are followed every 3 months for 1 year.
62012684|NCT03049163|EXPERIMENTAL|vitrectomy under topical anesthesia|27-gauge vitrectomy for vitreous floaters under topical anesthesia
62012685|NCT03361410|EXPERIMENTAL|Grape Powder|
62012686|NCT03361410|PLACEBO_COMPARATOR|Placebo Powder|
62012687|NCT06302387|EXPERIMENTAL|Acellular Dermal Matrix|This group received vertical soft tissue thickness augmentation using an acellular dermal matrix.
62012688|NCT06302387|EXPERIMENTAL|Soft Tissue Expansion using Tenting Technique|This group underwent soft tissue expansion using a tenting technique with a submerged healing abutment.
62200665|NCT05619497|ACTIVE_COMPARATOR|Standard care with the HIV Prevention Decision Support Tool (DST)|Participants in this arm will receive usual care at a clinic that has not received training in shared decision making and trauma-informed care. These participants will view the HIV prevention DST. These participants were recruited in Aim 1 of this study.
62012689|NCT05166291|EXPERIMENTAL|traditional anesthesia (TA)|traditional anesthesia
62012690|NCT05166291|EXPERIMENTAL|comfort-in injection system (CIS)|comfort-in injection system (CIS)
62012691|NCT06381986|EXPERIMENTAL|SHJ002|SHJ002 Ophthalmic Solution will be topically administered to each eye twice daily for 12 weeks
62012692|NCT06381986|PLACEBO_COMPARATOR|Vehicle|Vehicle will be topically administered to each eye twice daily for 12 weeks
62012693|NCT04618081||Participants with FL or MZL|Patients who have been diagnosed with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who receive R2 combination therapy with revlimid and rituximab for the first time.
62012694|NCT05265949|EXPERIMENTAL|diet+physical activity|diet+physical activity
62012695|NCT05265949|EXPERIMENTAL|diet|diet
62012696|NCT05265949|EXPERIMENTAL|physical activity|physical activity
62012697|NCT05265949|NO_INTERVENTION|control|control
62012698|NCT03898817||Taking of cutaneous cells by biopsy|Taking of cutaneous cells by biopsy and a sample of blood
62012699|NCT04436094|EXPERIMENTAL|Orthodontic extrusion|"An orthodontic attachment will be bonded to the core of the experimental tooth. Orthodontic brackets American Orthodontics Roth prescription. 0.022 slot will be bonded to the adjacent teeth. A passive rectangular stainless steel wire (0.016X0.022) will be inserted in the adjacent teeth with a step down and a coil at the site of the experimental tooth.~Orthodontic extrusion will start using a light overlay wire of 0.012 NiTi and then continued by elastic chains/ threads extending between the attachment on the tooth and the stabilizing wire. The patient is followed up for appliance activation every 3-4 weeks and extrusion is performed until an adequate ferrule effect of 2 mm is present all around the tooth circumference (in addition to the biologic width). So the extrusion is completed when the tooth is 4-4.5 mm from the alveolar bone crest as judged by periapical radiographs."
62578299|NCT05051930|EXPERIMENTAL|TQC3721 suspension for inhalation|Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation on Day 1.
62401548|NCT05158075|SHAM_COMPARATOR|Sham cognitive training|The active control group will: i) receive three pre-treatment group sessions (Motivational Interviewing, nutrition and physical exercise); ii) receive an individualized diet and physical exercise planning for 6 weeks; iii) participate in 4 weekly group sessions of sham intervention that mimic the neurocognitive sessions of the experimental group. Two neurocognitive sessions are intended to train impulsivity, and the other two neurocognitive sessions will focus on reflexive training. Participants will practice the content of each session daily at home.
62578300|NCT05051930|PLACEBO_COMPARATOR|TQC3721 suspension placebo for inhalation|Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation on Day 1.
62578301|NCT04468308||Senile Cataract|Patient with senile cataract, whose cataract surgery was postponed in the COVID-19 pandemic
62578302|NCT04095195||Familial pancreatic cancer relatives|
62578303|NCT04095195||Peutz-Jeghers syndrome|
62578304|NCT04095195||BRCA 1/2, PALB2, p16 mutations with familiarity for PC|Known genetic mutation and at least 1 1st- or 2nd-degree relative suffering from PC
62578305|NCT04095195||Lynch syndrome with familiarity for pancreatic cancer|
62578306|NCT04095195||FAMMM syndrome|
62578307|NCT04095195||Hereditary and genetic pancreatitis|
62012700|NCT04436094|ACTIVE_COMPARATOR|Immediate implant placement|The patient is anaesthetized. Atraumatic extraction of the badly broken down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed.
62401549|NCT05158075|OTHER|Control|Participants in the control group will receive three pre-treatment group sessions (Motivational Interviewing, nutrition and physical exercise) and will receive an individualized diet and physical exercise planning for 6 weeks.
62401550|NCT03175809|ACTIVE_COMPARATOR|PFM training|4 sessions (40 minutes approximately), Twice a week for 2 weeks of pelvic floor training with electromyographic biofeedback.
62578308|NCT06246240|NO_INTERVENTION|Control group|The Personal Information Form will be applied to the control group without any intervention and they will be asked to score the VAS Scale at the time the nausea begins and the retests at 60 and 120 minutes. After the interview with the pregnant women, all pregnant women will be called 24-48 hours later and data will be collected by questioning the 60th and 120th minute VAS scores of nausea severity.
62012701|NCT01177098|EXPERIMENTAL|bimatoprost/timolol formulation A|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
62200666|NCT03112915|ACTIVE_COMPARATOR|QLB: Quadratus lumborum block|"QLB: Quadratus lumborum block :Quadratus Lumborum block group (QL)~patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.25 %"
62401551|NCT03175809|EXPERIMENTAL|PFM training plus dry needling|PFM training associated with the use of dry needling over abdominal, gluteal and lombar miofascial trigger points.
62401552|NCT04980599|ACTIVE_COMPARATOR|K56 very high dose -E1|Probiotic drink (lactobacillus paracasei K56 10\^11CFU) 350ml/d , for 60days
62401553|NCT04980599|PLACEBO_COMPARATOR|control -E2|maltodextrin , for 60days
62401554|NCT04980599|ACTIVE_COMPARATOR|K56 high dose-E3|Probiotic powder 1.5g/sachet , 3.0g/d (lactobacillus paracasei K56 10\^10cfu) , for 60days
62578309|NCT06246240|EXPERIMENTAL|Intervention group|After obtaining the consent of the pregnant women, the Personal Information Form and VAS scale were applied. The experimental group was asked to score the VAS scale as soon as nausea started and was practiced chewing vitamin C gum for 30-60 minutes. Pregnant women in the experimental group were asked to score the VAS scale at 60 and 120 minutes after chewing gum.
62784718|NCT04440813|ACTIVE_COMPARATOR|Clinician Training|Traditional healers randomized to the control arm will receive PPE education and training, general HIV prevention education and skill building (including condom use, positive prevention, and pre-/post-exposure prophylaxis services), and three educational outreach and coaching visits at the healer's place of practice to provide on-the-ground advice and support for PPE use. All training will be provided by trained medical personnel.
62784719|NCT04440813|EXPERIMENTAL|Healer + Clinician Training|Traditional healers randomized to the intervention arm will receive PPE education and training, general HIV prevention education and skill building (including condom use, positive prevention, and pre-/post-exposure prophylaxis services), and three educational outreach and coaching visits at the healer's place of practice to provide on-the-ground advice and support for PPE use. All training will be provided by both healers who already use PPE regularly and trained medical personnel.
62784720|NCT03834831|ACTIVE_COMPARATOR|Coenzyme Q10|Coenzyme Q10 200mg/day for 3 months
62012702|NCT01177098|ACTIVE_COMPARATOR|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
62012703|NCT06194903|EXPERIMENTAL|Cellphones treated with isopropyl alcohol wipes|
62012704|NCT06194903|EXPERIMENTAL|Cellphones treated with UVC box|
62012705|NCT03098446|EXPERIMENTAL|Prolonged sitting with exercise|Subjects will be asked to undergo prolonged sitting (\~14-hours/day) for 4 days. On the evening of day 4, they will be asked to run at 65% of VO2max for 1-hour.
62012706|NCT03098446|EXPERIMENTAL|Prolonged sitting without exercise|Subjects will be asked to undergo prolonged sitting (\~14-hours/day) for 4 days. Subjects will not be asked to complete the acute bout of exercise to serve as a control.
62012707|NCT03096782|EXPERIMENTAL|Chemotherapy and Cord blood transfusion|"All patients received Busulfan as per standard of care. Busulfan test dose can be administered either as an outpatient prior to admission or as an inpatient on Day -10.~Busulfan pharmacokinetics will be performed with the test dose and the first dose on Day -7 per standard of care. The doses of Days -6, -5, and -4 will be subsequently adjusted to target an AUC of 4,000 microMol.min-1. In the event that PK adjusting were not possible a dose of busulfan of 130 mg/m2 will be administered.~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
62012708|NCT03158558|EXPERIMENTAL|AM-CBCT for PTSD|Accelerated, Multi-Couple Group Cognitive-Behavioral Conjoint Therapy delivered in a single weekend retreat
62012709|NCT01713777|EXPERIMENTAL|"Lamotrigine Generic A/Generic B"|"Crossover trial. Each arm will receive generic A for two periods and generic B for two periods."
62012710|NCT01713777|EXPERIMENTAL|"Lamotrigine Generic B/Generic A"|"Crossover trial. Each participant will have two periods of generic A and two periods of generic B"
62012711|NCT02772016|EXPERIMENTAL|Intervention group|Patients in the treatment group received daily 15 g oral Colla corii asini(Shandong Dong-E E-Jiao Co., Ltd) in powder form for 4 consecutive weeks. The dosage was adjusted to 10 g per day for 6 consecutive weeks if patients encounter any of the following side effects: swollen gums, dry or sore throat, ulcers in oral cavity.
62012712|NCT02772016|NO_INTERVENTION|Control group|Patients in control groups do not receive any intervention.
62012713|NCT02993601||20 outpatients with peripheral oedema|20 outpatients with clinically detectable peripheral oedema for 1 set of measurements.
62012714|NCT02993601||20 cardiology controls|20 outpatients with heart failure without clinically detectable peripheral oedema (control group) for 1 set of measurements.
62012715|NCT02993601||10 in-patients peripheral oedema|10 in patients hospitalised as a result of heart failure and fluid congestion with peripheral oedema, those patients will have several sets of measurements taken over time to measure the reduction of peripheral oedema which is likely to show common features with the formation of peripheral oedema.
62012716|NCT02993601||30 control without cardiac conditions|less than 30 normal controls (healthy volunteers and patients without heart failure) in the age group 55 and above who agree to have images taken using the Heartfelt-1 device (not the whole set of measurements).
62012717|NCT06454981|EXPERIMENTAL|EXCLEAR 800|"Hemodiafilter (Model \& spec.: EXCLEAR 800) produced by Shinva Medical Instrument Co.,Ltd."
62200667|NCT03112915|ACTIVE_COMPARATOR|TAP: transversus abdominis plan block|"TAP: Transversus abdominis plane block (TAP)~patients will receive a bilateral TAP block using Bupivicaine 0.25%"
62784721|NCT03834831|ACTIVE_COMPARATOR|Selenium|Selenium mcg/day for 3 months
62784722|NCT01745796||Intubated ICU patients|
62784723|NCT02211612|EXPERIMENTAL|Saturated fatty acids (SFA)-group|Weight gain created by addition of muffins baked on saturated fat
62784724|NCT02211612|EXPERIMENTAL|Polyunsaturated fatty acids (PUFA)-group|Weight gain created by addition of muffins baked on polyunsaturated fat
62784725|NCT01918956|ACTIVE_COMPARATOR|conventional regimen of PURETHAL Birch|"Initial treatment:~6 incremental weekly subcutaneous doses of 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 ml PURETHAL Birch, 20.000 AUM/ml (week 1, 2, 3, 4, 5, 6).~Maintenance treatment:~0.5 ml PURETHAL Birch, 20.000 AUM/ml, in intervals according to registered scheme (week 8, 10, 12)."
62784726|NCT01918956|EXPERIMENTAL|rush regimen of PURETHAL Birch|"Initial treatment:~3 incremental weekly subcutaneous doses of 0.1, 0.3, and 0.5 ml PURETHAL Birch, 20.000 AUM/ml (week 1, 2, 3)~Maintenance treatment:~0.5 ml PURETHAL Birch, 20.000 AUM/ml, in 2-weekly intervals (week 5, 7, 9)."
62784727|NCT04202887|ACTIVE_COMPARATOR|Low Fentanyl (LF)|fentanyl cumulative dose below 100mcg
62784728|NCT04202887|ACTIVE_COMPARATOR|High Fentanyl (HF)|fentanyl cumulative dose above 100mcg
62784729|NCT01586221|OTHER|Music & Physical Therapy|Subjects will received Music and Physical Therapy in a group setting.
62784730|NCT06124391||HA-PCOS|Patients were classified into each PCOS subtype based on our machine-learning classification model. The feature of the HA-PCOS group is hyperandrogenism.
62784731|NCT06124391||OB-PCOS|Patients were classified into each PCOS subtype based on our machine-learning classification model. The feature of the OB-PCOS group is overweight/obesity.
62784732|NCT06124391||SHBG-PCOS|Patients were classified into each PCOS subtype based on our machine-learning classification model. The feature of the SHBG-PCOS group is the high level of serum SHBG.
62784733|NCT06124391||LH-PCOS|Patients were classified into each PCOS subtype based on our machine-learning classification model. The feature of the LH-PCOS group is the high level of LH and AMH.
62784734|NCT04991129|EXPERIMENTAL|WJ01024 5mg QD repeat dose every 28 days|
62784735|NCT04991129|EXPERIMENTAL|WJ01024 5mg BID repeat dose every 28 days|
62784736|NCT04991129|EXPERIMENTAL|WJ01024 10mg BID repeat dose every 28 days|
62784737|NCT04991129|EXPERIMENTAL|WJ01024 40mg BIW repeat dose every 28 days|
62784738|NCT04991129|EXPERIMENTAL|WJ01024 60mg BIW repeat dose every 28 days|
62784739|NCT04991129|EXPERIMENTAL|WJ01024 80mg BIW repeat dose every 28 days|
62784740|NCT04991129|EXPERIMENTAL|WJ01024 60mg QW repeat dose every 28 days|
62200668|NCT03496077|EXPERIMENTAL|Flavored LCCs|Half of the group will start with a flavored little cigar/cigarillo (LCC) and cross over to unflavored LCC. The LCCs will be a popular brand already available for sale on the market.
62200669|NCT03496077|EXPERIMENTAL|Unflavored LCCs|Half of the group will start with an unflavored little cigar/cigarillo (LCC) and cross over to flavored LCC. The LCCs will be a popular brand already available for sale on the market.
62578310|NCT02359487|EXPERIMENTAL|Intervention|The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
62578311|NCT02359487|PLACEBO_COMPARATOR|Control|Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
62578312|NCT06576557|EXPERIMENTAL|KNEE-DEeP Intervention arm|The KNEE-DEeP study delivers an intervention at both the level of the healthcare professional and the patient. Healthcare professionals (GPs and physiotherapists) will receive a educational workshop and resources to use with patient participants. Patients in the intervention arm will receive an 'enhanced consultation' with their GP and early access to a 'best practice' one-hour physiotherapy session in University Hospital Kerry, along with educational resources.
62578313|NCT02405546|EXPERIMENTAL|Pre-Rotated Technique (Group R)|90° counterclockwise rotation of bevel of ETT
62578314|NCT02405546|ACTIVE_COMPARATOR|No rotation|No rotation of bevel of ETT
62578315|NCT06173037|EXPERIMENTAL|RC88 for Injection|Participants will receive RC88 2.0 mg/kg every 3 weeks (Q3W)
62578316|NCT00723762||1|Resident of Hattie Larlham long-term care facility receiving VPA
62578317|NCT00723762||2|Control AED patients will be recruited based on similar AED regimens excluding VPA, length of time on AED (number of months to \>1 year), age, and gender; one control patient per VPA patient.
62578318|NCT00723762||3|Control non-AED patients will be recruited based on age and gender; one control patient per VPA patient.
62578319|NCT05174832|ACTIVE_COMPARATOR|Cisplatin+ Nab-paclitaxel + Pembrolizumab followed by Pembrolizumab monotherapy|4\~6 cycles combination therapy of Cisplatin, Nab-paclitaxel and Pembrolizumab as induction therapy; Pembrolizumab monotherapy as maintenance therapy
62578320|NCT05174832|EXPERIMENTAL|Cisplatin+Nab-paclitaxel+Pembrolizumab followed by Pembrolizumab+Olaparib|4\~6 cycles combination therapy of Cisplatin, Nab-paclitaxel and Pembrolizumab as induction therapy; Pembrolizumab plus Olaparib as maintenance therapy
62578321|NCT05938764|ACTIVE_COMPARATOR|Motivational Interviewing and Community Reinforcement Approach|A psychosocial intervention culturally tailoring the combination of motivational interviewing (approximately 1-3 individual therapy sessions) and the community reinforcement approach (could include maximum range of 15-19 individual therapy sessions). Two tribal members were hired and trained to deliver this intervention and were located separately from the other arm.
62784741|NCT04991129|EXPERIMENTAL|WJ01024 80mg QW repeat dose every 28 days|
62784742|NCT04991129|EXPERIMENTAL|WJ01024 50mg QW repeat dose every 28 days|
62784743|NCT04991129|EXPERIMENTAL|WJ01024 40mg QW repeat dose every 28 days|
62784744|NCT05545839|NO_INTERVENTION|Standard care - control|Standard of care, appointments with adult rheumatology
62784745|NCT05545839|EXPERIMENTAL|Transition coaching - experimental|Participants will receive 8 transition coaching sessions (1/month) in addition to standard care
62200670|NCT04715438|EXPERIMENTAL|Cohort A: Individuals without cancer|A cohort of individuals without a cancer diagnosis is included for comparison. Because age is an important predictor of the ability to mount an effective immune response to vaccination, partners of patients in cohort B, C, and D.
62200671|NCT04715438|EXPERIMENTAL|Cohort B: patients receiving immunotherapy|Cancer patients receiving immunotherapy
62200672|NCT04715438|EXPERIMENTAL|Cohort C: patients receiving chemotherapy|Cancer patients receiving chemotherapy
62200673|NCT04715438|EXPERIMENTAL|Cohort D: patients receiving chemo-immunotherapy|Cancer patients receiving chemo-immunotherapy
62200674|NCT05028972|EXPERIMENTAL|Intervention: Personal Amplifier|Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department
62200675|NCT05028972|OTHER|Control: No Personal Amplifier|Consenting participants will be randomly assigned to the control group while receiving care in the emergency department
62200676|NCT02720120|EXPERIMENTAL|Part 1: Ocrelizumab 1000 mg|Participants will receive single IV infusion of ocrelizumab 1000 mg.
62200677|NCT02720120|EXPERIMENTAL|Part 1: Ocrelizumab 1500 mg|Participants will receive single IV infusion of ocrelizumab 1500 mg.
62200678|NCT02720120|EXPERIMENTAL|Part 1: Ocrelizumab 2000 mg|Participants will receive single IV infusion of ocrelizumab 2000 mg.
62200679|NCT02720120|EXPERIMENTAL|Part 1: Ocrelizumab 400 mg|Participants will receive single IV infusion of ocrelizumab 400 milligrams (mg)
62578322|NCT05938764|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as usual (TAU) included an intake session and could include individual counseling, group counseling, or cultural education. Treatment as usual was provided by staff at the reservation based outpatient treatment center. There was no limit on number of sessions provided.
62578323|NCT05582408|ACTIVE_COMPARATOR|Hearing Aid Standard NR1|Hearing Aid with standard Noise Reduction (NR1) serves as reference condition.
62578324|NCT05582408|EXPERIMENTAL|Novel Noise reduction principles|Noise Reduction Principle NR2 and NR3.
62578325|NCT03429933|EXPERIMENTAL|Single Ascending Dose|BMS-986278 or placebo
62578326|NCT03429933|EXPERIMENTAL|Multiple Ascending Dose|BMS-986278 or placebo
62578327|NCT05386017||Young adults who were included in the PRALIMAPINES trial as adolescents|The population is all young adults who were included in the PRALIMAPINES trial as adolescents (n=1419); we estimated 852 young adults participated in the follow-up visit (T3). This visit was proposed to investigate long-term social, economic, educational/professional and health (in particular weight) trajectories in adolescents in the PRALIMAP-INÈS intervention
62012718|NCT06454981|ACTIVE_COMPARATOR|FX 800HDF|Hollow fibre hemodialysis/filter FX 800HDF (registration certificate no.: GuoMeZhiJin 20193101929) manufactured by Fresenius Medical Care AG \& Co.KGaA (Registered agent: Fresenius Medical Care (shanghai) Company Limted)
62012719|NCT06129292|EXPERIMENTAL|İntervention (EFT) group|"Personal Information Form, Motherhood Blues Scale and Breastfeeding Self-Efficacy Scale will be applied for pre-test to women who meet our study criteria.~To EFT Group; After the first tests are done, the 1st EFT session will be held, the 2nd EFT session will be held 10 days later, and the final tests will be done 10 days later. During this period, affirmations will be given depending on the need. Each session is planned to last an average of 45 minutes - 1 hour, and duration and affirmations will be arranged according to the woman's individual difficulties, perspective, support systems, past traumas and emotional blockages.~Procedure 1: Preliminary tests will be carried out and then the 1st EFT session will be held.~2nd Procedure: After 10 days, the first final tests will be performed and then the second EFT session will be held."
62012720|NCT06129292|NO_INTERVENTION|Control group|Personal information form, Motherhood Blues Scale and Breastfeeding Self-Efficacy Scale will be applied for pre-test to women who meet our study criteria. After 10 days, the motherhood blues scale and breastfeeding self-efficacy scale will be administered again for the final test.
62578328|NCT01109953||Breath-Hold PET/CT image|In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both.
62200680|NCT02720120|PLACEBO_COMPARATOR|Part 1: Placebo|Participants will receive single IV infusion of placebo matched to ocrelizumab.
62200681|NCT02720120|EXPERIMENTAL|Part 2: Ocrelizumab 1000 mg|Participants will receive single IV infusion of ocrelizumab 1000 mg.
62200682|NCT02720120|EXPERIMENTAL|Part 2: Ocrelizumab 1500 mg|Participants will receive single IV infusion of ocrelizumab 1500 mg.
62200683|NCT02720120|EXPERIMENTAL|Part 2: Ocrelizumab 400 mg|Participants will receive single IV infusion of ocrelizumab 400 mg.
62200684|NCT01612273|EXPERIMENTAL|Disgren|Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
62200685|NCT01612273|EXPERIMENTAL|Aspirin|Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
62200686|NCT03597373||reintubation|Reestablish of invasive mechanical ventilation
62200687|NCT03597373||not reintubation|Favourable respiratory function
62200688|NCT03429777|EXPERIMENTAL|Hearing Loss Group|The investigators will characterize hearing-in-noise thresholds (also referred to as a speech-reception threshold) as measured by the HearMe app in patients with hearing loss.
62401555|NCT04980599|ACTIVE_COMPARATOR|K56 middle dose-E5|Probiotic powder 8.0g/sachet , 8g/d ( Lactobacillus paracasei K56 10\^9cfu) , for 60days
62401556|NCT04980599|ACTIVE_COMPARATOR|K56 low dose -E7|probiotic k56 capsule, 2capsules/d ( Lactobacillus paracasei K56 10\^7cfu) , for 60days
62401557|NCT04980599|ACTIVE_COMPARATOR|K56 middle dose-E9|probiotic K56 capsule, 2capsules/d (Lactobacillus paracasei K56 10\^9cfu) ,for 60days
62401558|NCT04980599|ACTIVE_COMPARATOR|K56 high dose-E1K|probiotic K56 capsule, 2capsules/d (Lactobacillus paracasei K56 10\^10cfu), for 60days
62200689|NCT03429777|ACTIVE_COMPARATOR|Control Group|The investigators will characterize hearing-in-noise thresholds (also referred to as a speech-reception threshold) as measured by the HearMe app in control subjects without any prior or current hearing loss.
62578329|NCT05345002|EXPERIMENTAL|Arm A (failed prior TMZ + one other alkylating chemotherapy)|Subjects in Arm A are alkylator-refractory and at high risk for progression of disease, have failed temozolmide and another alkylating agent. Subjects in Arm A will receive 28-day cycles of treatment, with ATRA 45mg/m2/day given orally in two equally divided doses on days 1 through 14 and retifanlimab 500mg IV on day 1.
62401559|NCT04980599|ACTIVE_COMPARATOR|K56 very high dose-E11|probiotic K56 capsule, 4capsules/d (Lactobacillus paracasei K56 10\^11cfu) ,for 60days
62578330|NCT05345002|EXPERIMENTAL|Arm B (failed only one prior alkylating chemotherapy)|Subject in Arm B are patients who have failed only one prior alkylating chemotherapy regimen and have gone at least 12 months since the last treatment. Subjects in Arm B will receive 28-day cycles of treatment, with ATRA 45mg/m2/day given orally in two equally divided doses on days 1 through 14 and retifanlimab 500mg IV on day 1.
62200690|NCT01367470|ACTIVE_COMPARATOR|VSL#3 probiotic preparation|30 mothers in the last 4 weeks of gestation and in the first month of breastfeeding will be given (after obtaining their informed consent) 1 sachet per day of probiotics (VSL#3) during the last four weeks of pregnancy and the first month of breastfeeding for four weeks under the usual fasting dosage scheme (1 sachet before meal).
62200691|NCT01367470|PLACEBO_COMPARATOR|Placebo VSL#3|30 mothers in the last 4 weeks of gestation and in the first month of breastfeeding will be given (after obtaining their informed consent) a placebo comparable to VSL#3 during the last four weeks of pregnancy and the first month of breastfeeding for four weeks under the usual fasting dosage scheme (1 sachet/day, before meal)
62200692|NCT04198389|EXPERIMENTAL|partial knee replacement|medial UNI, lateral UNI, patellofemoral replacement, combined UNI+ patellofemoral replacement, combined medial and lateral UNI
62578331|NCT05345002|EXPERIMENTAL|Arm C (surgical arm, ATRA alone pre-operatively)|Subject in Arm C will receive ATRA 45mg/m2/day orally in two equally divided doses for 14 days pre-surgery, then undergo surgery. Following surgery all patients will receive 28-day cycles of treatment, with ATRA 45mg/m2/day given orally in two equally divided doses on days 1-14 and retifanlimab 500mg IV on day 1.
62578332|NCT05345002|EXPERIMENTAL|Arm D (surgical arm, ATRA + retifanlimab pre-operatively)|Subject in Arm D will receive the combination of ATRA 45mg/m2/day orally in two equally divided doses for 14 days pre-surgery plus a 500mg IV dose of retifanlimab 14 days prior to the date of surgery. Following surgery all patients will receive 28-day cycles of treatment, with ATRA 45mg/m2/day given orally in two equally divided doses on days 1-14 and retifanlimab 500mg IV on day 1.
62578333|NCT06517056|EXPERIMENTAL|Intervention: Knee KG informed physical therapy|Participants in this group will receive care guided by the impairments identified with the KneeKG. The KneeKG exam results in recommended exercises that target the specific biomechanical impairments identified. The exercises and dose given to the participant will be based on what the KneeKG device recommends after the exam. The participant will be seen twice a week for 4 weeks.
62578334|NCT06517056|NO_INTERVENTION|Control: Standard of care physical therapy|Participants in this arm will have their KneeKG data captured, but this information will not be provided to the physical therapist to inform their care. Instead, physical therapists will deliver care as they normally do in routine clinical practice. The participant will be seen twice a week for 4 weeks.
62401560|NCT04619043|EXPERIMENTAL|Ankle Orthotic|The participant will wear two different ankle orthotics, their currently prescribed orthotic and the experimental orthotic.
62401561|NCT03045926|EXPERIMENTAL|Diosmectite (Smecta®)|5 weeks of diosmectite 3g, 3 times daily.
62401562|NCT01901029||men of floating population|males who live in Dongguan more than 6 months and without residence cards
62401563|NCT01901029||men of non-floating population|males who live in Dongguan more than 6 months and with residence cards
62578335|NCT02861378|EXPERIMENTAL|Phentolamine mesylate|Once anesthesia is confirmed, subjects in the Phentolamine mesylate group will receive 1 injection of 1ml of a solution containing 0.24 mg of phentolamine mesylate in the same site that was previously anaesthetized (not as a part of the study).
62578336|NCT02861378|PLACEBO_COMPARATOR|Water|Once anaesthesia is confined, the subjects in the water group will receive 1 injection of 1 ml of sterile physiological water in the same site that was previously anaesthetized (not as a part of the study).
62578337|NCT00200876|ACTIVE_COMPARATOR|pain challenge|
62012721|NCT03097068|EXPERIMENTAL|0.3 mg Lucentis|Aqueous Humor sample post injection of 0.3 mg Lucentis
62200693|NCT02963662|EXPERIMENTAL|Roux-en-Y gastric bypass group|The patients undergo Roux-en-Y gastric bypass (RYGB group) following a comprehensive evaluation for the surgical indication
62578338|NCT00200876|SHAM_COMPARATOR|non-painful control|
62578339|NCT04160546|EXPERIMENTAL|Ponatinib plus ASA treatment|Patients will be treated with ponatinib 15 mg/day plus 100 mg/day ASA for 104 weeks. After that, ponatinib and ASA will be stopped.
62401564|NCT03603626|EXPERIMENTAL|Preemptive pregabalin|
62401565|NCT03603626|PLACEBO_COMPARATOR|Placebo|
62401566|NCT00593385|OTHER|iCAST covered stent|This is a one arm trial. All subjects received the iCAST covered stent.
62401567|NCT05809219|NO_INTERVENTION|Control group|Participants maintain usual diet and physical activity without any intervention
62200694|NCT02963662|EXPERIMENTAL|sleeve gastrectomy group|The patients undergo sleeve gastrectomy (SG group) following a comprehensive evaluation for the surgical indication
62012722|NCT05928338|EXPERIMENTAL|Peer-supported, WhatsApp assisted lifestyle modification intervention|Study participants with BMI 23 kg/m2 and above was provided with a lifestyle modification intervention supported by peers for modifying their diet and increase physical activity to reduce weight
62012723|NCT04084145||CKD|Chronic Kidney Disease stage 1 - 4 followed up in secondary care
62012724|NCT03001895|EXPERIMENTAL|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT Scan
62012725|NCT06347354|EXPERIMENTAL|Subdermal injection of 2,5 mg (1 cc) of ICG|Subdermal injection of 2,5 mg (1 cc) of ICG will be performed 3 weeks before surgery
62012726|NCT02440880|PLACEBO_COMPARATOR|CONTROL|TAP block without Dexamethasone neither intravenous nor in combination with the block
62012727|NCT02440880|EXPERIMENTAL|Group 2 (TD8IS)|Dexamethasone in combination with TAP block in dose of 8 mg
62012728|NCT02440880|EXPERIMENTAL|Group 3(TD4IS)|Dexamethasone in addition to TAP block in dose of 4 mg
62012729|NCT02440880|EXPERIMENTAL|Group 4 (TSID8):|Dexamethasone intravenous in addition to TAP block in dose of 8 mg
62012730|NCT02440880|EXPERIMENTAL|Group5(TSID4)|Dexamethasone intravenous 4mg+ TAP block
62012731|NCT06207682|EXPERIMENTAL|Arm 1: Avacopan and Simvastatin|A single dose of 40 mg simvastatin will be given orally in the morning on Day 1 and Day 10. The Day 10 dose of simvastatin will be co-administered with the morning dose of avacopan. On Days 3 through 11, avacopan will be given orally at 30 mg BID.
62012732|NCT06207682|EXPERIMENTAL|Arm 2: Avacopan and Simvastatin|A single dose of 40 mg simvastatin will be given orally in the morning on Day 1 and Day 10. The Day 10 dose of simvastatin will be co-administered with the morning dose of avacopan. On Days 3 through 11, avacopan will be given orally at 60 mg BID.
62012733|NCT02067403|EXPERIMENTAL|Eadi optimized pressure-support|
62012734|NCT02453594|EXPERIMENTAL|Cohort 1|Participants with RRcHL who failed to achieve a response or progressed after auto-SCT and have relapsed after treatment with or failed to respond to BV post auto-SCT received pembrolizumab, 200 mg, intravenously (IV) every 3 weeks (Q3W) on Day 1 of each 21-day cycle for up to 24 months.
62012735|NCT02453594|EXPERIMENTAL|Cohort 2|Participants with RRcHL who were unable to achieve CR or PR to salvage chemotherapy and did not receive auto-SCT, but have relapsed after treatment with or failed to respond to BV received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months.
62012736|NCT02453594|EXPERIMENTAL|Cohort 3|Participants with RRcHL who failed to achieve a response to or progressed after auto-SCT and have not received BV post auto-SCT received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months. These participants may or may not have received BV as part of primary treatment or salvage treatment.
62012737|NCT06072612|EXPERIMENTAL|Bria-IMT Regimen + CPI|"The Bria-IMT regimen:~Day -2 or -3 Cyclophosphamide 300mg/m2 Day 0 SV-BR-1-GM given intradermally divided into 4 inoculations Day 1-3 CPI infusion plus interferon administered intra-dermally within each SV-BR-1-GM inoculation site"
62012738|NCT06072612|ACTIVE_COMPARATOR|Treatment of Physician's Choice|TPC consists of eribulin, carboplatin, capecitabine, gemcitabine, vinorelbine or taxanes in accordance with the investigators' and institutional standard of care. The specific details of the selected regimen must include every detail of administration including frequency, sequencing (for multi-agent regimens), duration of infusion or oral administration, planned dose, dose prescribed, dose administered, dose adjustments after initial prescription or start of TPC treatment, and any other change in TPC from its initial election prior to randomization.
62200695|NCT02963662|NO_INTERVENTION|Normal BMI group|no intervention
62012739|NCT06072612|EXPERIMENTAL|Bria-IMT Regimen Alone|"The Bria-IMT regimen:~Day -2 or -3 Cyclophosphamide 300mg/m2 Day 0 SV-BR-1-GM given intradermally divided into 4 inoculations Day 1-3 CPI infusion plus interferon administered intra-dermally within each SV-BR-1-GM inoculation site"
62012740|NCT05526352||IA Patients|Patients with one or more identified intracranial aneurysm, none of which are believed to have ruptured.
62012741|NCT05526352||IA + SAH Patients|Patients with one or more identified intracranial aneurysm, at least one of which has been radiologically or surgically determined to have ruptured.
62200696|NCT00589303|ACTIVE_COMPARATOR|Drug Therapy|FDA approved rate and rhythm control drugs
62200697|NCT00589303|ACTIVE_COMPARATOR|Atrioventricular Node (AVN) Ablation / Pacing|AV Node ablation and device implant
62200698|NCT03399851|ACTIVE_COMPARATOR|Amplatzer Amulet|Left atrial appendage closure (LAAC) with Amplatzer Amulet implantation will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
62578340|NCT04545567|EXPERIMENTAL|RocketAP|Adolescents will be assessed for a 48-70 hour period on the Rocket AP. This time will include two dinner times, one with and one without announcement of carbohydrate content. This is a cross-over study, so all participants will also be tested on the USS Virginia system under the same conditions.
62578341|NCT04545567|ACTIVE_COMPARATOR|USS Virginia|Adolescents will be assessed for a 48-70 hour period on the USS Virginia system. This time will include two dinner times, one with and one without announcement of carbohydrate content. This is a cross-over study, so all participants will also be tested on the Rocket AP system under the same conditions.
62578342|NCT04830371|EXPERIMENTAL|Arm A (Vi-CRM197, Batch #1)|Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #1 will be intramuscularly administered at Day 0.
62578343|NCT04830371|EXPERIMENTAL|Arm A (Vi-CRM197, Batch #2)|Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #2 will be intramuscularly administered at Day 0.
62578344|NCT04830371|EXPERIMENTAL|Arm A (Vi-CRM197, Batch #3)|Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #3 will be intramuscularly administered at Day 0.
62012742|NCT05526352||Familiy members|Individuals selected on review of a patient's family tree and contacted by said patient, who agree to be approached for recruitment. In affected families each member will be identified as: proband, affected, unaffected, unknown, or not genetically linked.
62012743|NCT05526352||Healthy Volunteers|Individuals, accompanying or contacted by a patient, or responding to open advertisement, or randomly selected in a defined population who agree to be approached for recruitment.
62012744|NCT05024695|EXPERIMENTAL|Implant Group|
62012745|NCT05066841|EXPERIMENTAL|CM group|
62401568|NCT05809219|EXPERIMENTAL|1 hour combined intervention ( Exercise and nutrition)|During intervention period, participants have 3 times exercise program per week. Each program is 30 minutes of resistance exercise and aerobic exercise. Participants take oral supplement (103 kcal and 8.4 g of protein) in 1 to 2 hours after exercise program.
62578345|NCT04830371|ACTIVE_COMPARATOR|Arm D (Typbar-TCV)|Single dose of Typhoid Conjugate Vaccine (Typbar-TCV) will be intramuscularly administered at Day 0.
62012746|NCT05066841|PLACEBO_COMPARATOR|placebo group|
62012747|NCT00870311|EXPERIMENTAL|Blinded Lithium|Bipolar Disorder patients
62012748|NCT04610086||False positive FIT|Participants in the colorectal cancer screening program, with a positive FIT and with a normal colonoscopy
62578346|NCT01964144|EXPERIMENTAL|Dovitinib arm|
62578347|NCT01151527||Sporadic (idiopathic) or familial interstitial pneumonia|We are recruiting patients with Idiopathic Pulmonary Fibrosis and other types of Idiopathic Interstitial Pneumonias that occur sporadically or familial (2 or more affected individuals in a family). Participation can be done by mail or visiting Duke University Medical Center (Durham, NC)or National Jewish Health (Denver, CO).
62578348|NCT05862350|EXPERIMENTAL|Aromatherapy inhalation with lavender essential oil|Patients in this group will receive aromatherapy inhalation with lavender essential oil for 28 days , and their sleep quality, anxiety and fatigue will be evaluated at baseline, the 7th day, and 28th day.
62578349|NCT05862350|PLACEBO_COMPARATOR|Aromatherapy inhalation with coconut essential oil|Patients in this group will receive aromatherapy inhalation with coconut essential oil for 28 days , and their sleep quality, anxiety and fatigue will be evaluated at baseline, the 7th day, and 28th day.
62012749|NCT04610086||Polyps|Participants in the colorectal cancer screening program, with a positive FIT and diagnosed of colorectal polyps in the colonoscopy
62012750|NCT04610086||Colorectal cancer|Participants in the colorectal cancer screening program, with a positive FIT diagnosed by colorectal cancer
62012751|NCT01856972|EXPERIMENTAL|Instrument Assisted Soft Tissue Mobilization|Subjects randomized into this treatment arm will receive Instrument Assisted Soft Tissue Mobilization to the Gastrocnemius/Soleus complex, as well as a standard stretching/ROM protocol
62012752|NCT01856972|EXPERIMENTAL|Rearfoot joint mobilization|Subjects randomized into this treatment arm will receive a rear-foot joint mobilization as well as a standard stretching/ROM protocol
62012753|NCT01856972|ACTIVE_COMPARATOR|Static stretching/ROM exercises|This is the control group consisting of Static stretching/ROM exercises. No manual intervention is performed with the group. The subjects will perform the standard stretching and ROM protocol
62012754|NCT03149640|EXPERIMENTAL|Inhaled amikacin|Inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
62012755|NCT03149640|PLACEBO_COMPARATOR|Placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
62012756|NCT01961869|EXPERIMENTAL|Arm I (Fast release BRB confection 4g)|Participants receive one fast release BRB confection (4g) PO 4-6 hours apart thrice daily (TID) for 2 weeks.
62012757|NCT01961869|EXPERIMENTAL|Arm II (Fast release BRB confection 8g)|Participants receive two fast release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
62401569|NCT05809219|EXPERIMENTAL|3 hours combined intervention ( Exercise and nutrition)|"The only one different between 1 hour combined intervention and this intervention is the time interval between exercise and nutrition. The time interval of 1 hour combined intervention is 1 to 2 hour, and this intervention is 2.5-4 hours. Other procedure is totally the same."
62401570|NCT05809219|EXPERIMENTAL|Nutrition intervention|"Participants only take oral supplement. The oral supplement is the same as the 1 hour combined intervention and 3 hours combined intervention."
62401571|NCT04116307|EXPERIMENTAL|Polymethylsiloxane|Polymethylsiloxane (Enterosgel) is given 3 x 10 g for the initial two days, and 3 x 5 g for the next three days.
62401572|NCT04116307|ACTIVE_COMPARATOR|Lactobacillus reuteri|Probiotic Lactobacillus reuteri (BioGaia) is given 3 x 20 drops (which means 3 x 400,000.000 CFU) per day for five days.
62401573|NCT01173666|PLACEBO_COMPARATOR|Drug therapy|Patients will be treated by standard medical therapy.
62401574|NCT01173666|EXPERIMENTAL|Drug therapy + stenting angioplasty|Patients will be treated by standard medical therapy + stenting angioplasty of renal artery.
62401575|NCT02360904|EXPERIMENTAL|start yoga classes immediately|12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training that will commence concurrently with the start of chemotherapy.
62401576|NCT02360904|ACTIVE_COMPARATOR|Start yoga classes after 3 months|12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training that will commence 3 months after start of chemotherapy
62012758|NCT01961869|EXPERIMENTAL|Arm III (Intermed release BRBconfection 4g)|Participants receive one intermediate release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
62012759|NCT01961869|EXPERIMENTAL|Arm IV (Intermed release BRBconfection 8g)|Participants receive two intermediate release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
62012760|NCT01961869|EXPERIMENTAL|Arm V (Prolong release BRB confection 4g)|Participants receive one prolonged release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
62012761|NCT01961869|EXPERIMENTAL|Arm VI (Prolong release BRB confection 8g)|Participants receive two prolonged release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
62401577|NCT05234281|OTHER|Low back pain|Adults with chronic low back pain and at least 4 months of decreased work participation. Intervention as for all groups but with the use of GLADRyg back rehabilitation principles.
62401578|NCT05234281|OTHER|Chronic Obstructive Pulmonary Disease (COPD)|Adults with COPD (FEV1\<80%). Intervention as for all groups but with added pulmonary rehabilitation focus.
62401579|NCT05234281|OTHER|Diabetes type 2|Adults with type 2 diabetes and diabetes-related challenges including dysglycaemia, diabetic complications and/or weight issues. Intervention as for all groups but with added focus on how to make useful microchoices in terms of lifestyle.
62401580|NCT05234281|OTHER|Mixed anxiety/depression|"Young adults (18-35 years) with mixed anxiety/depression. Intervention as for all groups but with added focus on acceptance and commitment therapy, behavioral analysis, metacognitive therapy and physical activity."
62012762|NCT05855200|EXPERIMENTAL|Dostarlimab|Participants will receive Dostarlimab pre and post surgery
62401581|NCT05234281|OTHER|Post COVID-19|Adults who have persistant fatigue and/or dyspnea following infection with COVID-19.
62401582|NCT00313716|ACTIVE_COMPARATOR|Epo1 and TT10|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, at 24 and 48 hrs after injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger of 10gm/dl
62401583|NCT00313716|ACTIVE_COMPARATOR|Epo1 and TT7|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, at 24 and 48 hrs after injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 7gm/dl
62401584|NCT00313716|ACTIVE_COMPARATOR|Epo2 and TT10|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 10gm/dl
62401585|NCT00313716|ACTIVE_COMPARATOR|Epo2 and TT7|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 7gm/dl
62012763|NCT05855200|ACTIVE_COMPARATOR|Standard of Care (SOC)|Participants will receive SOC (FOLFOX/CAPEOX) or undergo expectant observation post surgery.
62012764|NCT00530023|ACTIVE_COMPARATOR|1. 722|722 arm: MiniMed Paradigm REAL-Time System
62012765|NCT00530023|NO_INTERVENTION|2. Multiple Daily Injections (MDI)|MDI arm: Continue with currently prescribed Multiple Daily Injection therapy. No change in treatment or regime for study.
62401586|NCT00313716|PLACEBO_COMPARATOR|Placebo and TT10|Placebo administration and transfusion threshold 10 gm/dl
62401587|NCT00313716|PLACEBO_COMPARATOR|Placebo and TT7|Placebo administration and transfusion threshold 7 gm/dl
62401588|NCT05748145|EXPERIMENTAL|Metronidazole treated arm|Administration of Metronidazole for 10 days prior to surgery in CRC patients
62401589|NCT02442739|EXPERIMENTAL|Ketamine|oral ketamine 0.5 mg/kg mixed with syrup
62401590|NCT02442739|PLACEBO_COMPARATOR|Placebo|oral placebo (syrup)
62401591|NCT00713882||Observational|
62578350|NCT05420350|ACTIVE_COMPARATOR|Lamotrigine and Bupropion|"Lamotrigine will be taken orally for a duration of 28 weeks, consisting of a six-week titration, 20-week study period, and two-week taper. Possible doses are 25mg one a day, 50mg once a day, 50mg twice a day, 75mg twice a day during titration; 125mg twice a day for the study period; and 125mg once a day during the two-week taper. Patients who discontinue at any point of the study will have a two-week taper of lamotrigine.~Bupropion will be taken orally for the duration of 20 week at the dosage of 100mg twice a day."
62578351|NCT05420350|PLACEBO_COMPARATOR|Placebo|The placebo will match the lamotrigine and bupropion dosage, frequency, and duration.
62578352|NCT06221241|EXPERIMENTAL|JMKX000623|JMKX000623 for 12 weeks
62578353|NCT06221241|ACTIVE_COMPARATOR|Pregabalin|Pregabalin for 12 weeks
62578354|NCT06221241|PLACEBO_COMPARATOR|Placebo|placebo for 12 weeks
62012766|NCT05572905|EXPERIMENTAL|Young lean men and women|25 to 40 y.o. participants with body mass index in range of 18.5 to 25
62012767|NCT05572905|EXPERIMENTAL|Young obese men and women|25 to 40 y.o. participants with body mass index in range of 30 to 45.
62012768|NCT05572905|EXPERIMENTAL|Elderly men and women|65 to 80 y.o. participants with body mass index in range of 18.5 to 30.
62012769|NCT00004577||Healthy Volunteer|Any healthy, male or female volunteer 18 years of age and older.
62012770|NCT00633984|ACTIVE_COMPARATOR|Cognitive Behavioral Group Therapy + D-Cycloserine|Participants received Cognitive Behavioral Group Therapy and 50mg D-Cycloserine.
62012771|NCT00633984|PLACEBO_COMPARATOR|Cognitive Behavioral Group Therapy + Placebo|Participants received Cognitive Behavioral Group Therapy and 50mg Placebo.
62012772|NCT02442921|EXPERIMENTAL|Colchicine|20 patients will receive up to 2 mg of colchicine for 18 months
62012773|NCT02442921|PLACEBO_COMPARATOR|Placebo|20 patients will receive placebo for 18 months
62578355|NCT02921932|ACTIVE_COMPARATOR|Intervention|"In the interventional arm, patients will be given:~1. A 'Threshold' Inspiratory Muscle Trainer~2. A nutritional assessment: if needed, dietary supplements prescribed (i.e Ensure, Glucerna).~3. Cognitive exercise in the form of the 'Memory' card game will be taught to the patients and the caregiver (if available), to be done twice a day.~Patients will be provided with a protocol activities log and a study assistant will be conducting a telephone conversation on day 1, 4 and 7 to encourage compliance to the protocol and answer any queries with regards to the research study."
62578356|NCT02921932|NO_INTERVENTION|Control|In the control arm, patients will be given the standard education materials regarding surgery and carry out daily activities as usual until the admission of the surgery.
62012774|NCT02178943||Heart Transplant Recipients|Heart allograft recipients undergoing scheduled surveillance visits that are part of a long-term management plan.
62012775|NCT05434312|EXPERIMENTAL|TGRX-678|Subjects to be treated with the investigational drug TGRX-678
62012776|NCT01736280|OTHER|1|Standard of Care. Participants will be evaluated and treated for their particular digestive disorder or presenting symptoms.
62200699|NCT03399851|ACTIVE_COMPARATOR|Watchman/FLX|Left atrial appendage closure (LAAC) with Watchman/FLX implantation will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
62200700|NCT02271984|EXPERIMENTAL|Treatment A: MSC2499550A|MSC2499550A: 20 milligram per kilogram (mg/kg) under fed condition
62200701|NCT02271984|EXPERIMENTAL|Treatment B: Cysticide|Cysticide® 40 mg/kg under fed condition
62578357|NCT06074224|EXPERIMENTAL|Clinician with Scores|The patients in the intervention group will include those for whom their clinician was given their sleep questionnaire result before the visit.
62578358|NCT06074224|ACTIVE_COMPARATOR|Clinician without Scores|The control group will include patients whose clinicians do not view the results, simulating usual care.
62401592|NCT05390060|EXPERIMENTAL|Neuromonitoring arm|Neuromonitoring placed after cardiac arrest
62401593|NCT05670470|EXPERIMENTAL|CTP0303|
62401594|NCT05670470|ACTIVE_COMPARATOR|Orafang Tab|
62401595|NCT01342809|EXPERIMENTAL|Follow up|Close follow up from written guidelines, supervision provided.
62401596|NCT01342809|NO_INTERVENTION|Usual Treatment|
62401597|NCT03058861|EXPERIMENTAL|Discipline education - Play Nicely program|Parents in the intervention group will receive 1) a copy of the Play Nicely Healthy Discipline Handbook (see www.playnicely.org), 2) information about how to view the Play Nicely multimedia program online and 3) the TN ACEs Handout.
62578359|NCT02621684|EXPERIMENTAL|Arm 1: Aerobics|"* Complete baseline questionnaires either online or on paper~* Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline~* Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.~* Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations.~* Require physical evaluation and orientation to the WellAware gym~* 12 week walking program at the WellAware Center~  * required to check in with gym staff to check attendance~ * advised to walk at own pace for 3 days per week~ * 15 minutes per day for the first 2 weeks~ * 30 minutes per day for the next 2 weeks~ * 50 minutes or more for remaining weeks"
62784746|NCT04588116|EXPERIMENTAL|The web- based occupational therapy intervention SEE|The web-based intervention starts with eight educational modules focusing on engagement in activities and strategies to support an active life. The modules, that is delivered on a secure national health platform, include short education videos followed by self-reflections and digital assignments supporting the change process. The occupational therapist provides feedback after each assignment and, also, meet the patients for face- to- face online guiding sessions at three times during these first two- three weeks of the intervention. Thereafter, an individually tailored activity plan with goals and activity-based strategies are established. During the change process, the patients receive continued support from the occupational therapist until the goals are achieved.
62012777|NCT06391996||the ustekinumab group|Before treatment, participants underwent routine blood and urine tests, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), liver and kidney function tests, tuberculous infection of T cells spot tests, hepatitis B virus marker tests, chest CT scans, etc. After exclusion of relevant contraindications, participants received subcutaneous ustekinumab therapy. During the treatment period, participants received ustekinumab at weeks 0, 4, 16, and every 12 weeks thereafter until week 48. The single dose of ustekinumab was 45 mg for adult subjects weighing ≤ 100 kg, and 90 mg for subjects weighing \> 100 kg. The ustekinumab dosage for pediatric participants was 0.75 mg/kg for participants weighing \< 60 kg; 45 mg for pediatric participants weighing 60 kg to 100 kg; and 90 mg for pediatric participants weighing \> 100 kg.
62012778|NCT06391996||the secukinumab group|Before treatment, participants underwent routine blood and urine tests, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), liver and kidney function tests, tuberculous infection of T cells spot tests, hepatitis B virus marker tests, chest CT scans, etc. After exclusion of relevant contraindications, participants received subcutaneous secukinumab therapy. During the treatment period, participants received secukinumab at weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter until week 48. The secukinumab dosage was 300mg for adult humans. Pediatric participants received a dose based on their weight category (\< 50 kg, ≥ 50 kg): participants weighing \< 50 kg received 75 mg, those weighing ≥ 50 kg received 150 mg.
62012779|NCT01732835|EXPERIMENTAL|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
62401598|NCT03058861|NO_INTERVENTION|Control Group|Routine primary care will be provided.
62401599|NCT04284176|EXPERIMENTAL|Mirrow therapy and action-observation therapy|The intervention include 20 hours, applied during a four-week period (1 hour per day from Monday to Friday) at home. The first 15 minutes will include myrror therapy 6 activities and the remaing 45 minutes both unimanual and bimanual action-observation therapy activities.
62401600|NCT04284176|EXPERIMENTAL|Action-observation therapy|The intervention include 20 hours, applied during a four-week period (1 hour per day from Monday to Friday) at home. There protocol includes both unimanual and bimanual action-observation therapy activities.
62200702|NCT02271984|EXPERIMENTAL|Treatment C: MSC2499550A|C1:MSC2499550A :10 mg/kg under fed condition C2:MSC2499550A : 30 mg/kg under fed condition
62401601|NCT02208427|EXPERIMENTAL|3M_RH|Rifapentine and Isoniazid for 3 months: weekly oral rifapentine 15 mg/kg plus isoniazid 15 mg/kg for 12 doses
62401602|NCT02208427|ACTIVE_COMPARATOR|9M_INH|Isoniazid for 9 months: daily oral isoniazid 5 mg/kg for 9 months
62401603|NCT03454191|EXPERIMENTAL|Erector spinae plane block|
62401604|NCT03454191|PLACEBO_COMPARATOR|Placebo|
62784747|NCT03985371|EXPERIMENTAL|Drops Used|
62784748|NCT01618825|ACTIVE_COMPARATOR|LAMICTAL®|Lamictal® (Lamotrigine) Tablets 25 mg of GlaxoSmithkline, USA
62401605|NCT04632134|EXPERIMENTAL|Transcutaneous vagal nerve stimulation (tVNS)|"After positioning the tVNS electrodes in the right ear but without delivering tVNS (Sham tVNS), above mentioned signals will be recorded for 10 minutes while supine, for 15 minutes during 75° head-up tilt.~The same protocol will be performed during active tVNS.~The tVNS will be performed while 15 minutes in supine position and during 75°head-up Tilt.~Thereafter, every patient will be provided with a Nemos© device and electrodes for home daily stimulation. Daily stimulation will consist of 4 hours of stimulation organized as 4 sessions each lasting 1 hour, to be applied at the patient's convenience."
62401606|NCT01756651|EXPERIMENTAL|Intranasal Fentanyl 100mcg|fentanyl pectin nasal spray 100mcg
62200703|NCT02271984|EXPERIMENTAL|Treatment D: MSC2499550A|MSC2499550A 20 mg/kg under fasting condition
62200704|NCT02271984|EXPERIMENTAL|Treatment E: MSC2499550A|MSC2499550A: 20 mg/kg directly disintegrated in mouth under fed condition
62200705|NCT04577001|EXPERIMENTAL|Letrozole Group|Subjects with hepatopulmonary syndrome will get the study drug letrozole
62401607|NCT01756651|EXPERIMENTAL|Intranasal Fentanyl 200mcg|fentanyl pectin nasal spray 200mcg
62401608|NCT03374774||Participants with Type 2 Diabetes Mellitus|Participants will be prescribed and treated with commercially available BIAsp 30 according to routine clinical practice at the discretion of the treating physician, independent of this study. The study will gather data over the course of routine treatment on willingness to pay for BIAsp 30 in FlexPen® or Penfill®.
62401609|NCT01904266|SHAM_COMPARATOR|GA + sham block|Patients will receive general anesthetic plus a sham paravertebral block
62401610|NCT01904266|EXPERIMENTAL|GA + paravertebral block|Patients will receive general anesthetic plus a paravertebral block
62401611|NCT04208061|EXPERIMENTAL|Panel 1: Dabigatran etexilate +DRV/COBI|Participants will receive Treatment A (single dose of Dabigatran etexilate orally) on Day 1 followed by Treatment B (single dose of Darunavir/ cobicistat \[DRV/COBI\] as fixed dose combination tablet orally and single dose of dabigatran etexilate) on Day 4 followed by Treatment C (\[DRV/COBI\] as fixed dose combination tablet orally once daily from Day 5 to Day 20 and single dose of dabigatran etexilate on Day 18).
62578360|NCT02621684|EXPERIMENTAL|Arm 2: Resistance training|"* Complete baseline questionnaires either online or on paper~* Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline~* Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.~* Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations.~* Require physical evaluation and orientation to the WellAware gym~* 12 week weight lifting program at WellAware Center~  * exercise physiologists will work with each patient to develop a custom routine~ * exercise load will start at 60% of one-repetition maximum and progress from 8 to 12 repetitions~ * 2-4 sets of repetition exercises will be performed to target upper \& lower muscle groups~ * resistance load will be added by 5 pounds when patients can complete more than 12 repetitions"
62578361|NCT02621684|ACTIVE_COMPARATOR|Arm 3: Usual care|"* Complete baseline questionnaires either online or on paper~* Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline~* Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.~* Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations."
62578362|NCT00952159||Not Poor metabolizer|
62578363|NCT00952159||Poor metabolizer|
62012780|NCT05768503|EXPERIMENTAL|Chidamide + Sintilimab + Bevacizumab Group|The treatment option for the chidamide + sintilimab + bevacizumab is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
62200706|NCT04577001|PLACEBO_COMPARATOR|Placebo Group|Subjects with hepatopulmonary syndrome will get the study placebo
62401612|NCT04208061|EXPERIMENTAL|Panel 2: Dabigatran etexilate +DRV+rtv|Participants will receive Treatment D (single dose of dabigatran etexilate orally) on Day 1 followed by Treatment E (single doses of Darunavir, and ritonavir \[rtv\], and single dose of dabigatran etexilate on Day 4), followed by Treatment F (DRV and rtv orally once daily from Day 5 to Day 20 and single dose of dabigatran etexilate on Day 18).
62401613|NCT05392465|EXPERIMENTAL|Group A|baseline physical therapy treatment along with facial mobilization
62401614|NCT05392465|OTHER|Group B|baseline (Conventional) physical therapy treatment
62401615|NCT03562676|EXPERIMENTAL|weightlessness|
62200707|NCT05559151|EXPERIMENTAL|experimental group (group R)|The experimental group (group R) received target controlled infusion of remimazolam benzenesulfonate, and the BIS value was controlled at 50±5.
62200708|NCT05559151|PLACEBO_COMPARATOR|the control group (group P)|the control group (group P) received target controlled infusion of propofol, and the BIS value was controlled at 50±5.
62200709|NCT00623805|ACTIVE_COMPARATOR|Bevacizumab+capecitabine+oxaliplatin|Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m\^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m\^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.
62200710|NCT00623805|EXPERIMENTAL|Bevacizumab(B)+capecitabine(C)+oxaliplatin followed by B+C|Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m\^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m\^2 orally twice a day on Days 1-14 of each 3-week cycle for 6 cycles followed by bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + capecitabine 1000 mg/m\^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.
62200711|NCT00540462|NO_INTERVENTION|1|Medical Group
62200712|NCT00540462|ACTIVE_COMPARATOR|2|Surgical Group with gastric bypass
62200713|NCT00540462|ACTIVE_COMPARATOR|3|Sugical Group with Sleeve gastrectomy
62200714|NCT02521714|EXPERIMENTAL|Treatment A: 25mg capsule -under fasted condition|Single oral dose of 25mg lenalidomide (reference formulation, 1 x 25mg capsule) under fasted condition.
62401616|NCT05723406|EXPERIMENTAL|Sugammadex|Sugammadex administration at the end of surgery
62401617|NCT05723406|PLACEBO_COMPARATOR|Placebo|Placebo administration at the end of surgery
62578364|NCT06572982|EXPERIMENTAL|Azacitidine 300 mg Film coated tablets|Azacitidine 300 mg Film coated tablets
62784749|NCT01618825|EXPERIMENTAL|Lamotrigine Tablets 25 mg|Lamotrigine Tablets 25 mg of M/s Ipca Laboratories Limited, India
62401618|NCT03401827|EXPERIMENTAL|Gemcitabine + nab-paclitaxel|Case with chemotherapy (Gemcitabine + nab-paclitaxel)
62578365|NCT06685029|EXPERIMENTAL|Dİrect In-House Aligner Group|Patients in this group are treated with clear aligners produced directly by the clinician. The physical model production step is eliminated with direct production technique.Intraoral scan images were obtained from these patients with the 3Shape TRIOS (3Shape, Copenhagen, Denmark) scanning device. Then, the 3D scan images were transferred to the Maestro 3D Dental Studio (New Age, Pisa, Italy) computer software. Using these scan images, the teeth were gradually moved according to the planned final treatment result. The number of transparent plates required is calculated by the program according to the total amount of planned tooth movement. Then, Tera Harz TC-85DAC (Graphy, Seoul, Korea) resin and Asiga MAX UV (Asiga, Sydney, Australia) 3D printer were used for the direct production of the plates designed in the program. The aligners produced were then delivered to the patients.
62578366|NCT06685029|EXPERIMENTAL|Invisalign Group|Intraoral scan images were obtained with the 3Shape TRIOS (3Shape, Copenhagen, Denmark) scanning device from patients who would receive Invisalign (Align Technology, Santa Clara, CA) clear aligners. These 3D intraoral scan images, together with the intraoral and extraoral photographs, radiographic records, and clinical examination findings obtained from the patients, were uploaded to the cloud software 'ClinCheck' for Invisalign . Necessary instructions were written regarding the patients' treatment plans. Afterwards, patient specific 3D treatment simulations sent to the clinician by the companies were reviewed and the necessary revisions were made. The final accepted treatment plan was approved and the aligners were produced by the relevant companies and sent to our clinic.The clear aligners produced are delivered to the patients and treatment started.
62578367|NCT06685029|EXPERIMENTAL|ClearCorrect Group|Intraoral scan images were obtained with the 3Shape TRIOS (3Shape, Copenhagen, Denmark) scanning device from patients who would receive Invisalign (Align Technology, Santa Clara, CA) and ClearCorrect (ClearCorrect®, Round Rock, TX, USA) clear aligners. These 3D intraoral scan images, together with the intraoral and extraoral photographs, radiographic records, and clinical examination findings obtained from the patients, were uploaded to the cloud software 'ClinCheck' for Invisalign . Necessary instructions were written regarding the patients' treatment plans. Afterwards, patient specific 3D treatment simulations sent to the clinician by the companies were reviewed and the necessary revisions were made. The final accepted treatment plan was approved and the aligners were produced by the relevant companies and sent to our clinic.The clear aligners produced are delivered to the patients and treatment started.
62578368|NCT06685029|EXPERIMENTAL|Fixed Orthodontic Treatment Group|In the fixed orthodontic treatment group, all tooth surfaces to which brackets would be bonded were etched with 37% phosphoric acid (dline Phosphoric Acid Etching Gel UAB, Medicinos linij Karaliauciaus str. 29 LT-78348 Siauliai Lithuania) for 30 seconds, then bond (3M Unitek Transbond XT, Minnesota, U.S.A.) was applied and light was applied to all teeth separately for 5 seconds with a light device (Valo Cordless curing light Ultradent Products, Inc. 505 W. Ultradent Drive (10200 South) South Jordan, UT 84095) \[165, 166\]. Afterwards, composite (3M Unitek Transbond XT, Minnesota, U.S.A.) was applied to the base of the metal brackets (AO Mini Master Roth 018, Altenhofstrasse 80, 66386 St. Ingbert, Germany) and after it was placed on the tooth surface and the composite residues around the bracket were cleaned, light was applied for 5 seconds for each bracket. Then, arch wires were applied and the fixed orthodontic treatment of the patients was started.
62578369|NCT00077142|EXPERIMENTAL|TAC-101|Oral TAC-101 daily Days 1-14, repeats every 21 days for 2 courses.
62578370|NCT02639650|ACTIVE_COMPARATOR|control group|etoposide, methotrexate ,actinomycin D,vincristine, cyclophosphamide(EMA-CO), two weeks a cycle
62578371|NCT02639650|EXPERIMENTAL|study group|paclitaxel + cisplatin or carboplatin，two weeks a cycle
62578372|NCT04096482|EXPERIMENTAL|Standard 30° 4mm Endoscope Followed by Peregrine Endoscope|Participants will receive an endoscopy with the standard 30° 4mm endoscope followed by an endoscopy with the Peregrine Drivable ENT Scope.
62578373|NCT06116071||GD subjects with normal growth rate and no bone involvement|No drug interventions.
62578374|NCT06116071||GD type 1 subjects with evidence of bone involvement|No drug interventions.
62578375|NCT06116071||GD type 3 subjects|No drug interventions.
62578376|NCT06116071||Non-GD age and gender-matched controls with normal growth rate and no known bone complications|No drug interventions.
62578377|NCT02277613|EXPERIMENTAL|AMI MultiStem cells|AMI MultiStem cells is a cell therapy medicinal product originating from adherent stem cells taken from the bone marrow of a non-related donor and expanded ex vivo.
62200715|NCT02521714|EXPERIMENTAL|Treatment B: 25mg oral suspension - under fasted condition|Single oral dose of 25mg lenalidomide (test formulation, 2.5mL oral suspension) under fasted condition.
62200716|NCT02521714|EXPERIMENTAL|Treatment C: 25mg oral suspension -under fed condition|Single oral dose of 25mg lenalidomide (test formulation, 2.5mL oral suspension) under fed condition.
62401619|NCT01455168||No treatment|Capsular tension ring is not used in the group.
62578378|NCT02277613|SHAM_COMPARATOR|Sham|Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
62401620|NCT01455168||CTR simply implanted|Capsular tension ring is simply implanted in the group.
62401621|NCT01455168||CTR with the eyelets closed|Capsular tension ring is implanted and closed by tying both eyelets in the group.
62401622|NCT04167449|ACTIVE_COMPARATOR|Hydroponic Red Ginseng|
62401623|NCT04167449|ACTIVE_COMPARATOR|Conventional White Ginseng|
62401624|NCT04167449|PLACEBO_COMPARATOR|Placebo|
62200717|NCT01299480|EXPERIMENTAL|Group 1|rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
62200718|NCT01299480|EXPERIMENTAL|Group 2|rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
62200719|NCT01299480|EXPERIMENTAL|Group 3|rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
62200720|NCT01299480|EXPERIMENTAL|Group 4|rLP2086 at visits 1 and 3, saline at visits 2 and 5
62200721|NCT01299480|EXPERIMENTAL|Group 5|rLP2086 at visits 3 and 5, saline at visits 1 and 2
62200722|NCT03051399|PLACEBO_COMPARATOR|Placebo|Maltodextrin, 500 mg/day, single serving
62200723|NCT03051399|ACTIVE_COMPARATOR|EpiCor|EpiCor, 500 mg/day, single serving
62200724|NCT01424605|EXPERIMENTAL|DLT intubation|
62401625|NCT04017065||Patients treated with the MAXFRAMETM system|Any patient undergoing surgical treatment (primary or revision) for deformity correction using the MAXFRAME™ system
62578379|NCT01513720|EXPERIMENTAL|Lamotrigine Tablets 200 mg|Lamotrigine Tablets 200 mg of Dr. Reddy's Laboratories Limited
62401626|NCT00060320|EXPERIMENTAL|black cohost|"Patients receive oral black cohosh twice daily for 4 weeks. All patients then cross over to the other arm and receive treatment for 4 weeks.~After completion of the crossover treatment, all patients may opt to receive open-label black cohosh for an additional 8 weeks.~Patients complete a hot flash diary daily at baseline and during the 8-week double-blind study, and then daily for 8 weeks during optional open-label treatment.~Patients who opt to receive open-label black cohosh are followed at 6 months, 1 year, and 2 years."
62401627|NCT00060320|PLACEBO_COMPARATOR|placebo|"Patients receive oral placebo twice daily for 4 weeks. All patients then cross over to the other arm and receive treatment for 4 weeks.~After completion of the crossover treatment, all patients may opt to receive open-label black cohosh for an additional 8 weeks.~Patients complete a hot flash diary daily at baseline and during the 8-week double-blind study, and then daily for 8 weeks during optional open-label treatment.~Patients who opt to receive open-label black cohosh are followed at 6 months, 1 year, and 2 years."
62401628|NCT06448611||Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma|Entire cohort
62401629|NCT02103608|EXPERIMENTAL|Percentage of hair reduction|This is an open label, prospective study to evaluate safety and efficiency of Silk'n Glide on the face. During the study, the subjects will perform up to 6 face treatments, two weeks apart. The treatment's safety and efficiency will be evaluated at 4 weeks of after last treatment and at 12 weeks after last treatment .
62578380|NCT01513720|ACTIVE_COMPARATOR|Lamictal® 200 mg Tablets|Lamictal® 200 mg Tablets of GlaxoSmithKline Inc
62200725|NCT03414385|EXPERIMENTAL|Exercise group|Research volunteers will be asked to undergo an acute bout of aerobic exercise at moderate intensity for \~120 minutes. Before and after the exercise the volunteer will undergo leg biopsy.
62200726|NCT06305052|EXPERIMENTAL|Milk group|Olfactory and gustatory stimuli with milk in premature infants before tube feeding.
62578381|NCT00419861||Group 1|Adults \>/= 50 years of age, hospitalized for respiratory illness in Davidson County, TN.
62578382|NCT06110702|EXPERIMENTAL|8-week EMDR Intervention|"Phase 1: The therapist and client develop a secure working relationship. The client's history is discussed and a treatment plan is developed.~Phase 2: The therapist explains the EMDR therapy process. Phase 3: The target event is identified. Baseline measures are set using the Subjective Units of Disturbance (SUD) and the Validity of Cognition (VOC) scale.~Phase 4: Desensitization, sounds, or taps are begun while focusing on the traumatic event until the client's SUD reduces to zero.~Phase 5: The client associates and strengthens a positive belief with the target event until it feels true.~Phase 6: The client is asked to hold in mind the target event and the positive belief while scanning the body.~Phase 7: Reprocessing is complete when the client feels neutral about it (SUD=0, VOC=7), and the body is clear of disturbance.~Phase 8: The client and therapist discuss processed memories to ensure that distress is low and that the positive cognition is strong."
62012781|NCT05768503|ACTIVE_COMPARATOR|FOLFIRI + Bevacizumab Group|The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400 mg/m2 IV Q2W or calcium levofolinate 200 mg/m2 IV Drip Q2W, 5-fluorouracil 400 mg/m2 IV +2400 mg/m2 CIV (infusion 46-48 hr) Q2W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
62401630|NCT00845351|EXPERIMENTAL|Bexarotene|Bexarotene 300 mg/m2/day times 5 days
62401631|NCT02352831|EXPERIMENTAL|Phase I (tosedostat + capecitabine)|"* The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion.~* Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat.~* Capecitabine 1000 mg/m\^2 by mouth BID Days 1-14 of each 21-day cycle~* Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain."
62401632|NCT02352831|EXPERIMENTAL|Phase II (tosedostat + capecitabine)|"* Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle~* Capecitabine by mouth BID Days 1-14 of each 21-day cycle"
62401633|NCT05681221|ACTIVE_COMPARATOR|LSTR in necrotic primary second molar using TAP|Triple antibiotic paste (TAP) is considered the gold standard in LSTR. It is a combination of ciprofloxacin, metronidazole and minocycline. Many anaerobic bacteria are resistant to ciprofloxacin. Hence, it is often used with metronidazole in treating mixed infections to compensate for its limited scope. Therefore, TAP can affect gram-negative, gram-positive, and anaerobic bacteria, and this combination can be effective against odontogenic microorganisms.
62401634|NCT05681221|EXPERIMENTAL|LSTR in necrotic primary second molar using nano silver particles and calcium hydroxide|Nano silver particles have a strong anti-bacterial properties due to its ability to target the bacteria on different cellular levels. Calcium hydroxide has been used for so long as an intra canal medication in odontogenic infections due to its strong alkalinity that gives it its anti bacterial properties. This combination might be a future alternative to antibiotics, in an attempt to decrease the bacterial antibiotic resistance and antibiotics use.
62578383|NCT06110702|NO_INTERVENTION|Control condition - No intervention|The control group will follow routine daily activities
62578384|NCT02285166||Ever User of Omega-3 fatty acid ethyl esters 2 g|The usual adult dosage for oral use was 2 g of omega-3 fatty acid ethyl esters administered once daily or twice daily immediately after meals for treatment of hyperlipidemia. Participants received both interventions and standard antihyperlipidemic therapy as part of routine medical care.
62200727|NCT06305052|PLACEBO_COMPARATOR|Placebo group|Olfactory and taste stimuli with double-distilled water in premature infants before tube feeding
62200728|NCT04367285|EXPERIMENTAL|Sensor-based Training|
62200729|NCT04367285|ACTIVE_COMPARATOR|Upper limb motor training|
62578385|NCT02285166||Never User of Omega-3 fatty acid ethyl esters 2 g|Participants received standard antihyperlipidemic therapy without omega-3 fatty acid ethyl esters 2 g as part of routine medical care.
62578386|NCT02894944|EXPERIMENTAL|Theragene arm|Patients who were treated with Theragene®,Ad5-yCD/mutTKSR39rep-ADP and chemotherapy
62578387|NCT05973305|EXPERIMENTAL|Patients with primary open-angle glaucoma receiving Dorzol 20 mg/ml|Dorzol 20 mg/ml eye drops, dosing schedule t.i.d, 12 weeks
62578388|NCT05973305|ACTIVE_COMPARATOR|Patients with primary open-angle glaucoma receiving Trusopt 20 mg/ml|Trusopt 20 mg/ml eye drops, dosing schedule t.i.d, 12 weeks
62012782|NCT01268644|EXPERIMENTAL|active open label Leptin|Active open label Leptin for type 1 Diabetes
62401635|NCT06406959|EXPERIMENTAL|TAP-block|TAPP inguinal hernia repair under general anesthesia with endotracheal intubation. Patients receive unilateral US-guided TAP-block with 20 ml 0,375% Levobupivacaine before incision
62401636|NCT06406959|NO_INTERVENTION|Standard care|TAPP inguinal hernia repair under general anesthesia with endotracheal intubation (without preemptive regional anesthesia) in accordance with actual standard of care.
62401637|NCT06231849||normal subjects without opioid intoxications.|1. Individuals of male gender aged between 20 to 35 years old
62012783|NCT05322317|OTHER|Pilot participants|"Participants will participate in ADVANCE-PC training via ECHO and will receive practice facilitation support, if needed.~To assess the feasibility of the ADVANCE-PC training and implementation support, research data will be collected from participating clinicians at three time points. Two data collection points will be pre and post ECHO program training questionnaires about attitudes, experience, and intentions related to ACP and dementia. The third will be an interview at the end of the follow-up period, focusing on barriers to and facilitators of ACP in the context of dementia and the impact of the training and implementation support. Feasibility and acceptability of this intervention will be evaluated using descriptive and qualitative analyses of these data."
62012784|NCT05195996|ACTIVE_COMPARATOR|beta blocker|Will be given Propranolol 1mg in 10 ml distilled water intravenous every 6 hours for 48 hours
62012785|NCT05195996|PLACEBO_COMPARATOR|placebo|Will be given normal saline 10 ml every 6 hours for 48 hours
62401638|NCT06231849||individuals with opioid use disorders.|Individuals of male gender aged between 20 to 35 years old with opioid use disorders.
62401639|NCT02179580|EXPERIMENTAL|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days
62401640|NCT02179580|PLACEBO_COMPARATOR|Placebo|Placebo at a rate of 3.0 g three times per day for 28 days
62401641|NCT00148174|EXPERIMENTAL|Phone calling|Phone calling to encourage improved adherence
62401642|NCT02181075|EXPERIMENTAL|Part I|"All participants in Part I received:~Pre-LTLD Biopsy of Target Liver Tumour ThermoDox® (LTLD) Post-LTLD Biopsy of Target Liver Tumour Focused Ultrasound of Target Liver Tumour Thermometry of Target Tumour Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour~Part I of the study was designed to identify optimal focused ultrasound (FUS) exposure parameters for a range of tumour locations within the liver, using real-time thermometry data from an implanted thermometry device (a thermistor or thermocouple). Plasma and biopsy samples of the target liver tumour were taken pre-LTLD, post-LTLD and post-LTLD+FUS."
62401643|NCT02181075|EXPERIMENTAL|Part II|"All participants in Part II received:~ThermoDox® (LTLD) Focused Ultrasound of Target Liver Tumour Post-LTLD Biopsy of Target Liver Tumour~Following a minimum of 5 Part I cases, and subject to Trial Management Group approval, Part II of the study was opened to run in parallel to Part I. Part II did not require implantation of a thermometry device, and instead used predictions from Part I data to set the FUS parameters. Targeted drug delivery in Part II thus proceeded completely non-invasively, and this part of the study was designed to more closely reflect how the therapy might be implemented in routine clinical practice. Plasma samples were taken pre-LTLD, post-LTLD and post-LTLD+FUS. Biopsy samples of the target liver tumour were taken only post-LTLD+FUS."
62578389|NCT05146518|EXPERIMENTAL|Single-arm, pre-post|Maternity staff of health public health facilities will exposed to the intervention package (capacity building and systemic changes in the health facilities).
62578390|NCT03486301|EXPERIMENTAL|Single Agent BDB001|"A single subject will be enrolled at each dose level in the single agent arm until any ≥ Grade 2 treatment-emergent adverse event (TEAE) is observed in the first cycle.~Then dosage escalation will follow a traditional 3+3 dose escalation design.~Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of single agent BDB001 is reached."
62578391|NCT03486301|EXPERIMENTAL|BDB001 in Combination with Pembrolizumab|"In the combination arm of the study, a standard 3+3 dose escalation design will be utilized for all dose levels.~When the MTD or RP2D of single agent BDB001 is reached, the first dose level cohort of the combination arm will begin. Once the MTD or RP2D in combination has been determined, twenty additional subjects will be enrolled in the expansion phase of the study."
62578392|NCT06093516|EXPERIMENTAL|Optimal Precision Tinted Lenses (PTL)|"1. The participant is asked to describe any perceptual distortion and discomfort of the text in the colorimeter.~2. At each of the 12 hues in turn the saturation of colour is increased from white to modest saturation (30) and after 5s returned to white. The participant is asked to compare the coloured text with the white and report any differences in the distortion/discomfort.~3. At the best of the 12 hues, the participant adjusts the saturation to optimise the clarity and comfort of the text (comfort is more important than clarity).~4. At this saturation, the hue is adjusted by small amounts and re-optimised. The saturation is then minimised.~5. At the re-optimised hue/saturation, the brightness is reduced to assess its effects on comfort. If the lower brightness is preferred the saturation is increased slightly to see if the high brightness is better tolerated."
62200730|NCT04477395|EXPERIMENTAL|SRP plus fish oil|Patients will receive scaling and root planing (SRP) supplemented with the dietary fish oil rich in omega-3 PUFAs: 2.6 g of EPA and 1.8 g DHA daily for 6 months.
62578393|NCT06093516|EXPERIMENTAL|Sub-Optimal Precision Tinted Lenses (PTL)|"The sub-optimal colour will be chosen as a colour of similar saturation to the optimal colour but differing in u'v' colour space by 0.07. Two colours of equal radial distance from the optimal colour will be considered. The colour that shares the name of the optimal colour or appears most similar will be chosen.~After colorimetry, participants will choose a spectacle frame. Two pairs of PTLs will be made up by the manufacturing opticians, one to the optimal colour and the other to a slightly sub-optimal colour."
62578394|NCT02692183||Parkinson Disease (PD) tremor patients|Patients with PD before and after MRI guided Focused ultrasound thalamotomy
62578395|NCT02692183||Essential tremor (ET) patients|Patients with ET before and after MRIFocused ultrasound guided thalamotomy
62578396|NCT06215573|EXPERIMENTAL|Melatonin supplementation|5mg melatonin supplement from Ritual Inc's BioSeries
62578397|NCT06215573|PLACEBO_COMPARATOR|Placebo supplementation|Placebo supplement from Ritual Inc.
62012786|NCT03376204||Adult subjets|Adult subjets diagnosed with bronchiectasis by high-resolution computed tomography with symptomatology in stable phase, matched by by sex and age with healthy subjects.
62578398|NCT03752411|EXPERIMENTAL|Research Bottle|This group will have medication dispensed in a research bottle.
62200731|NCT04477395|ACTIVE_COMPARATOR|SRP alone|Patients will receive scaling and root planing (SRP) only.
62578399|NCT03752411|PLACEBO_COMPARATOR|Regular prescription Bottle|This group will have medication dispensed in a regular prescription bottle
62578400|NCT05454748||Healthy controls|
62578401|NCT05454748||Stroke patients|
62578402|NCT05294237|EXPERIMENTAL|Supported Implementation (Intervention)|"The Happy-program will be available online on a webpage and consists of 7 warm-up components and 4 resistance training components that can be completed after handball practice.~The warm-up program has three exercise variations for each of the seven components. The coaches may deliver the four resistance training components in the field or in the gym. The resistance training components in the field and the gym targets the same four body areas but differs in that the components in the gym are performed with equipment, while the components in the field can be performed without equipment. Each resistance training component has three levels.~Happy ambassadors (Health professionals with a handball player or coach background) will conduct a 3-hour train-the trainer workshop in the beginning of the season and provide coaches with the opportunity for support throughout the season. At mid-season, the ambassadors will re-visit the clubs for 1,5-hour supervision and support."
62578403|NCT05294237|ACTIVE_COMPARATOR|Unsupported implementation (control)|Access to the Happy program will be available online to the coaches. No additional education or support will be provided.
62578404|NCT04822688||Basic Science (Biospecimen collection)|Patients undergo collection of tissue sample during surgery. Patients also undergo collection of blood sample.
62578405|NCT03193320|ACTIVE_COMPARATOR|Liberal group protocol|Fluid loading with 500 ml at induction. Baseline fluid infusion - 8 ml/kg/h. Fluid challenge - if mean arterial pressure (MAP) falls to \< 65 mmHg, a fluid challenge will be administered.
62578406|NCT03193320|ACTIVE_COMPARATOR|Restrictive group protocol|No fluid loading at induction. Baseline fluid infusion - 4 ml/kg/h. Fluid challenges - if mean arterial pressure (MAP) falls to \< 65 mmHg, a fluid challenge will be administered.
62578407|NCT03193320|EXPERIMENTAL|PVI-guided group protocol|No fluid loading at induction. Baseline fluid infusion - 2 ml/kg/h. PVI will be monitored continuously since anesthesia induction. Fluid challenges - if PVI rises \>=13 (or MAP falls \< 65 mmHg), a fluid challenge will be administered.
62578408|NCT04600817|EXPERIMENTAL|TJ107|
62578409|NCT04600817|PLACEBO_COMPARATOR|TJ107Placebo|
62012787|NCT00854087|ACTIVE_COMPARATOR|Fuzheng Huayu|Pill with Fuzheng Huayu
62200732|NCT03879174|EXPERIMENTAL|Pembrolizumab + Tamoxifen|Pembrolizumab (200mg IV every three weeks) + Tamoxifen (20 mg OD)
62012788|NCT00854087|PLACEBO_COMPARATOR|Placebo|Pill without Fuzheng Huayu (sugar pill)
62012789|NCT03412643|EXPERIMENTAL|Arm 1|"Celcuity CELx HSF Test on tumor material obtained from research core biopsy to select patients with abnormal HER2 signaling tumors~Doxorubicin + cyclophosphamide followed by Weekly Paclitaxel +Trastuzumab+Pertuzumab"
62012790|NCT02755675|EXPERIMENTAL|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before treatment start to evaluate the prognostic value of uPAR PET/CT.
62200733|NCT02205775|PLACEBO_COMPARATOR|twice placebo before PCI|
62200734|NCT02205775|EXPERIMENTAL|atorvastatin 80 + 40 mg pre PCI|
62200735|NCT02205775|EXPERIMENTAL|rosuvastatin 40 + 40 mg before PCI|
62200736|NCT02205775|EXPERIMENTAL|rosuvastatin 5 + ezetimibe 10 mg twice before PCI|
62200737|NCT05251142|EXPERIMENTAL|Plyometric training|Jumps in place. Standing jumps. Multiple hops and jumps. Box drills. Depth jumps.
62401644|NCT04993547|EXPERIMENTAL|Parents present, peers present|The children are accompanied by their parents during the COVID-19 testing, and a visible covid-19 swab test waiting line is set-up enabling the children to observe their peers being tested.
62401645|NCT04993547|ACTIVE_COMPARATOR|Parent present, peers absent|The children are also accompanied by their parents, but a covered COVID-19 swab test waiting line is set-up whereby the children are unable to observe their peers being tested.
62200738|NCT05251142|ACTIVE_COMPARATOR|General exercises|Dumbbell Squat, Dumbbell Alternating Bench Press, Straight Arm Pulldowns, Dumbbell Front Raises, Reverse Flyes, Overhead Tricep Extensions, Dumbbell Bicep Curls, Jackknife Crunches, Oblique Crunches, External Rotation
62401646|NCT04993547|ACTIVE_COMPARATOR|Parents absent, peers present|Parents are absent during the COVID-19 testing, and a visible COVID-19 swab test waiting line is set-up enabling the children to observe their peers being tested.
62401647|NCT04993547|ACTIVE_COMPARATOR|Parents absent, peers absent|Parents are absent, and a covered COVID-19 swab test waiting line is set-up whereby the children are not able to observe their peers being tested.
62401648|NCT00777920|EXPERIMENTAL|Ambrisentan|Participants will receive ambrisentan 2.5 mg, 5 mg or 10 mg tablet orally once daily until such time as the investigator or participant chooses to stop ambrisentan treatment, ambrisentan becomes commercially available, or the sponsor stops the study.
62401649|NCT04924465||Anti-Jo1|Patients with anti-Jo1 antibodies
62401650|NCT04924465||Anti-PL7|Patients with anti-PL7 antibodies
62401651|NCT04924465||Anti-PL12|Patients with anti-PL12 antibodies
62401652|NCT04924465||Anti-EJ|Patients with anti-EJ antibodies
62401653|NCT04924465||Anti-OJ|Patients with anti-OJ antibodies
62401654|NCT04738799|EXPERIMENTAL|Carbohydrate-Last Meal Sequence, Then Carbohydrate-First Meal Sequence|Participants will consume the carbohydrate portion of their prepared meals last during mealtimes for 6 days. They will then consume the carbohydrate portion of their prepared meals first during mealtimes for the following 6 days.
62784750|NCT02395523|EXPERIMENTAL|Proton Beam Therapy|"Definition of target volume:~* Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan~* Clinical target volume (CTV) = GTV + internal target volume~* Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~* Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week~* Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
62784751|NCT02329899||Possible MBD|"Defined by:~* a bleeding score \>= 4 in adults;~* a bleeding score \>= 2 in children (for girls, up to menses);~* a past medical history that include menorrhagia, haemorrhage from the umbilical stump, bleeding at circumcision, cephalhematoma at birth, hematuria, whatever the bleeding score is;~* a past medical history suggestive of a MBD with no haemostatic challenge and a low bleeding score.~In this group, the second step of investigations will be performed."
62784752|NCT02329899||MBD unlikely|"Patients without criteria for possible MBD as listed above.~In this group, no further investigation will be performed if the first step is normal. The second step of investigations will be performed only in case of significant abnormalities in the first step of investigation."
62784753|NCT02096627||conventional|Patients who undergo routine cataract surgery using conventional phacoemulsification technique
62784754|NCT02096627||FLACS|Patients who undergo femtosecond laser assisted cataract surgery
62784755|NCT05463016|EXPERIMENTAL|Color Vision Deficient with Color Correcting Lenses|10 subjects confirmed to have hereditary color vision deficiency randomly assigned to experimental group 1 which includes baseline testing with and without color correcting lenses, followed by 7 days of wear, minimum 3 hours/day, followed by retesting with and without color correcting lenses.
62784756|NCT05463016|PLACEBO_COMPARATOR|Color Vision Deficient with Placebo Lenses|10 subjects confirmed to have hereditary color vision deficiency randomly assigned to Placebo Group 1 which includes baseline testing with and without placebo lenses, followed by 7 days of wear, minimum 3 hours/day, followed by retesting with and without placebo lenses.
62200739|NCT05616299|EXPERIMENTAL|BrightPoint Epidural|Subjects will receive an epidural using the BrightPoint device concurrent with usual LOR technique using the same epidural needle, sterile saline, syringe, etc.
62401655|NCT04738799|EXPERIMENTAL|Carbohydrate-First Meal Sequence, Then Carbohydrate-Last Meal Sequence|Participants will consume the carbohydrate portion of their prepared meals first during mealtimes for 6 days. They will then consume the carbohydrate portion of their prepared meals last during mealtimes for the following 6 days.
62410058|NCT05254015|EXPERIMENTAL|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)|"Compensatory Cognitive Training (CCT) Modules (7 sessions). Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illnesses. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive impairments and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Exposure to Discarding and Acquiring Modules (19 sessions). Symptoms of acquiring and saving are themselves avoidance behaviors to avoid internal distress related to negative thoughts and emotions. ET utilizes in vivo exposure exercises taking place in the home to enhance generalization of their new skills. Fear hierarchies typically start with a space that has low clutter volume or there is less of an urge to save a particular type of item in that environment."
62578410|NCT00733850|EXPERIMENTAL|1|Kanglaite Injection plus Gemcitabine
62578411|NCT00733850|ACTIVE_COMPARATOR|2|Gemcitabine
62401656|NCT06506617||PCR multiplex (BIOFIRE® FILMARRAY® Pneumonia plus Panel)|"The study seeks to assess the utility of molecular diagnostic tests in the emergency department for the microbiological etiological diagnosis of healthcare-associated pneumonia (HCAP).~In clinical practice, patients with respiratory and infectious symptoms undergo blood sample collection for blood gas, chemical-physical, and culture analyses, urine samples for urinary antigen testing, and imaging diagnostics (X-ray, CT, ultrasound). Due to local infection control and surveillance measures, all patients with respiratory symptoms undergo a nasopharyngeal antigen test for SARS-CoV-2 as part of standard clinical practice.~After completing the diagnostic work-up and diagnosing HCAP pneumonia, endobronchial samples are typically collected for multiplex PCR testing (BIOFIRE® FILMARRAY® Pneumonia plus Panel). Patients from whom these samples are collected are those needing high-flow oxygen therapy (VM35 or FiO2 higher, Reservoir, HFNC, NIV, CPAP), undergoing IOT, SOFA ≥2, PaO2/FiO2 \< 200, o"
62578412|NCT06683950|EXPERIMENTAL|Aflibercept 8mg|In cases where patients previously treated with faricimab or aflibercept 2mg were switched to aflibercept 8mg
62578413|NCT01476878|EXPERIMENTAL|Open Arm|Each study patient will receive high dose, single treatment radiation using a plastic mask instead of a head frame that pins into a patient's skull.
62578414|NCT06461936||Active Surveillance Group（AC）|Patients in AC group received no adjuvant therapy after liver resection.
62578415|NCT06461936||Adjuvant sintilimab group（AS）|Patients in AS group received adjuvant sintilimab after liver resection.
62578416|NCT06461936||Adjuvant sintilimab plus Lenvatinib group （ASL）|Patients in ASL group received adjuvant sintilimab plus lenvatinib therapy after liver resection.
62578417|NCT01006876|ACTIVE_COMPARATOR|Study Arm|Patients receive continuous Coumadin therapy throughout the study.
62578418|NCT01006876|ACTIVE_COMPARATOR|Control Arm|Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
62578419|NCT02119455|EXPERIMENTAL|Vibration Device+Fixed Appliance Tx|Male and female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment in conjunction with vibration therapy (daily use of OrthoAccel Aura device for 20 minutes/day) during the study period.
62578420|NCT02119455|NO_INTERVENTION|No Vibration Device+Fixed Appliance Tx|Male and female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment only and no vibration treatment.
62578421|NCT01109667||oral anticoagulant|Patients receiving and not receiving oral anticoagulant therapy.
62578422|NCT01109667||INR Level|Group I: Patients not receiving OAT, Group II: Patients under OAT and INR values in good therapeutic range and Group III: Patients under OAT and INR values over the therapeutic range.
62200740|NCT05616299|NO_INTERVENTION|Normal Epidural|Subjects will have an epidural placed in usual manner with LOR technique using the same epidural needle, sterile saline, syringe etc. but without use of the BrightPoint device.
62401657|NCT03532048|EXPERIMENTAL|Intervention Group|The Papás Saludables, Niños Saludables Program
62401658|NCT03532048|OTHER|Wait-list Control|The Papás Saludables, Niños Saludables Wait-list Control
62578423|NCT03133065|ACTIVE_COMPARATOR|Group 1: treatment after 6 months post transplantation|53 patients received Sofosbuvir+ribavirin standard of care for treatment of HCV post liver transplantation for 6 months
62401659|NCT05112224|EXPERIMENTAL|Educational Intervention|An educational program based on HBM that was conducted using five one-hour sessions.
62401660|NCT05112224|NO_INTERVENTION|Control|Control group only received the education program provided by the dental clinic.
62578424|NCT03133065|ACTIVE_COMPARATOR|Group 2: early treatment afer 3 months post transplantation|36 patients received other DAAs regiment for treatment of HCV post liver transplantation for 3- 6 months
62578425|NCT01909193|EXPERIMENTAL|Attention Bias Modification (ABM)|Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
62578426|NCT01909193|EXPERIMENTAL|Cognitive Behavior Therapy|CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
62578427|NCT01542489||IDet + IAsp users|
62578428|NCT01542489||IDet + HI users|
62578429|NCT01786135|EXPERIMENTAL|SGN-CD19A|SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
62578430|NCT01046903||1|
62578431|NCT04712448||Healthy subjects|Donors of the Transfusion Center of Venice Healthy volunteers afferent to BioBIM
62784757|NCT05463016|EXPERIMENTAL|Crossover: Placebo to Experimental|Placebo Group 1 crosses over to become Experimental Group 2 which includes baseline testing with and without color correcting lenses, followed by 7 days of wear, minimum 3 hours/day, followed by retesting with and without color correcting lenses.
62784758|NCT05463016|PLACEBO_COMPARATOR|Crossover: Experimental to Placebo|Experimental Group 1 crosses over to become Placebo Group 2 which includes baseline testing with and without placebo lenses, followed by 7 days of wear, minimum 3 hours/day, followed by retesting with and without placebo lenses.
62578432|NCT04712448||Patients|Patients with chronic diseases afferent to BioBIM
62578433|NCT06194110||Endurance Trained Athletes|
62578434|NCT02924285|ACTIVE_COMPARATOR|Procedure|Radiofrequency catheter ablation
62578435|NCT02924285|ACTIVE_COMPARATOR|Antiarrhythmic Drug|Amiodarone
62578436|NCT01659593|EXPERIMENTAL|procog|cognitive remedial program 13 sessions over a 6-month period
62578437|NCT01659593|PLACEBO_COMPARATOR|DISINT|Interactive discussion program of 13 group sessions in a 6-month period
62578438|NCT00701467||Observation|
62578439|NCT03050775|EXPERIMENTAL|Heated Ventilator Circuit|Heated and humidified inspired gases using the ANAPOD™ Heat and Humidification System (Westmed; Tucson, Arizona, USA) circuit prior to induction of general anesthesia in addition to standard ventilation and temperature management.
62200741|NCT01110278||Urge Incontinent Women|Women with documented urge/urgency incontinence with established care at the Oregon Health and Science University.
62200742|NCT01110278||Control Women|Women with no urge/urgency incontinence with established care at the Oregon Health and Science University.
62200743|NCT01627262|PLACEBO_COMPARATOR|Placebo|
62401661|NCT03143933|ACTIVE_COMPARATOR|propofol|this arm will receive propofol in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins
62578440|NCT03050775|ACTIVE_COMPARATOR|Standard Ventilator Circuit|Standard ventilation and temperature management.
62578441|NCT04664036||NAFLD + type 1 diabetes|type 1 diabetes patient with NAFLD on screening
62578442|NCT04664036||noNAFLD + type 1 diabetes|type 1 diabetes patient without NAFLD on screening
62578443|NCT01811810|OTHER|xrt and long term ADT|Radiation therapy (XRT) and long term androgen deprivation therapy
62578444|NCT01811810|OTHER|xrt, chemotherapy and short term ADT|radiation therapy (XRT), chemotherapy and short term ADT
62578445|NCT05896904|EXPERIMENTAL|Echocardiography|
62578446|NCT03687333|EXPERIMENTAL|Alglucosidase Alfa therapy|Alglucosidase Alfa dose is calculated per kg body weight and administered once every 2 weeks for up to 52 weeks.
62401662|NCT03143933|ACTIVE_COMPARATOR|propofol and fentanyl|this arm will receive propofol and fentanyl in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins
62401663|NCT04014556|ACTIVE_COMPARATOR|Aflibercept plus micropulse laser (group A)|Overall 40 patients were included in the study; they were randomized into either group A (Aflibercept + Micropulse; 20 patients) or group B (Aflibercept monotherapy; 20 patients).
62578447|NCT06575816|ACTIVE_COMPARATOR|Control group, intervention group|"This group will receive the standard blood collection procedure without any augmented reality video intervention. Pain, anxiety, and fear levels will be assessed using standardized scales after the procedure.~This group will receive the augmented reality video intervention during the blood collection procedure. The intervention consists of children watching AR videos designed to distract and comfort them during the blood draw. Pain, anxiety, and fear levels will be measured using standardized scales immediately after the procedure."
62401664|NCT04014556|ACTIVE_COMPARATOR|Aflibercept monotherapy (group B)|Overall 40 patients were included in the study; they were randomized into either group A (Aflibercept + Micropulse; 20 patients) or group B (Aflibercept monotherapy; 20 patients).
62578448|NCT06575816|NO_INTERVENTION|Control group|This group will receive the standard blood collection procedure without any augmented reality video intervention. Pain, anxiety, and fear levels will be assessed using standardized scales after the procedure.
62578449|NCT06575816|EXPERIMENTAL|intervention group|This group will receive the augmented reality video intervention during the blood collection procedure. The intervention consists of children watching AR videos designed to distract and comfort them during the blood draw. Pain, anxiety, and fear levels will be measured using standardized scales immediately after the procedure.
62578450|NCT00054431|EXPERIMENTAL|Treatment (imatinib mesylate, decitabine)|Patients receive oral imatinib mesylate daily and decitabine IV over 1 hour daily, 5 days per week, for 2 consecutive weeks. Courses repeat every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
62578451|NCT03612661|EXPERIMENTAL|Intuitive Eating Group Intervention|Intuitive eating intervention delivered in a group format with 8-10 women, led by 2 facilitators.
62578452|NCT03612661|EXPERIMENTAL|Intuitive Eating Guided Self-Help|Participants in this condition engage in 8 weeks of self-study of the intuitive eating intervention have \~20 minute weekly phone call with a study interventionist.
62578453|NCT04671498||Ancillary-correlative (biospecimen collection) (Breast Cancer patients)|Participants undergo collection of blood sample for the Droplet-BC test. All participants' medical records are also reviewed.
62200744|NCT01627262|EXPERIMENTAL|Mesalamine|
62200745|NCT05040347||PVTT group|The diagnosis of portal vein tumor thrombosis was confirmed by clinical correlation using histologic features taken from liver biopsy as determined by a pathologist,and findings from image studies including ultrasound, computed tomography, and MRI, verified by a radiologist.
62200746|NCT05040347||HCC group|The diagnosis of HCC was confirmed by clinical correlation using histologic features taken from liver biopsy as determined by a pathologist,and findings from image studies including ultrasound, computed tomography, and MRI, verified by a radiologist.
62200747|NCT05040347||control group|The presence of PVTT or HCC was confirmed by medical record review and all the recorded events were confirmed by a radiologist using imaging studies, ultrasound, contrast-enhanced, or MR.
62200748|NCT01081847|ACTIVE_COMPARATOR|Group A|Montanide ISA 720 Dose by peptide 50ug
62401665|NCT02235207|EXPERIMENTAL|Neuromuscular exercise|The exercise group will participate in Fustra20 Neck \& Back neuromuscular exercise program.
62401666|NCT02235207|NO_INTERVENTION|Control group|Participants are encouraged to continue there usual physical activity and exercise
62401667|NCT02067923||Anti-CD3 mAb Plus Diabetes Standard of Care Group|This group of individuals received treatment in the original AbATE study.
62401668|NCT02067923||Diabetes Standard of Care Group|During the original AbATE study these individuals received standard care.
62401669|NCT02068001||RYGB|Food preference assessment in 100 patients at different timepoints, in a subset of 30 participants, also brain reward response to food cues will be assessed.
62578454|NCT04671498||Ancillary-correlative (biospecimen collection) (Volunteer)|Participants undergo collection of blood sample for the Droplet-BC test. All participants' medical records are also reviewed.
62578455|NCT06524830|EXPERIMENTAL|VLS-01-BU|
62578456|NCT06524830|PLACEBO_COMPARATOR|VLS-01-BU Placebo|
62578457|NCT03970889|NO_INTERVENTION|Standard Care|Participants will be in their usual care, wearing a continuous glucose sensor and taking insulin by pump or by pens with memory
62578458|NCT03970889|EXPERIMENTAL|Klue|Subjects will wear an Apple watch on their dominant hand and receive alerts when eating behavior is detected by the Klue software.
62578459|NCT06303557|ACTIVE_COMPARATOR|Preoperative Erector Spinae Plane Block|In the preoperative period, under general anesthesia, after the linear ultrasound (US) probe will be placed 2-3 cm lateral to the L3 spinous process, 15 ml of 0.25% bupivacaine will be injected into the interfacial space below the erector spinae muscle, above the transverse process. The same ESPB procedure was performed on the other side. In total, 40 ml of 0.25% bupivacaine was administered.
62578460|NCT06303557|ACTIVE_COMPARATOR|Postoperative Erector Spinae Plane Block|In the postoperative period, under general anesthesia, after the linear ultrasound (US) probe will be placed 2-3 cm lateral to the L3 spinous process, 15 ml of 0.25% bupivacaine will be injected into the interfacial space below the erector spinae muscle, above the transverse process. The same ESPB procedure was performed on the other side. In total, 40 ml of 0.25% bupivacaine was administered.
62578461|NCT06524414|EXPERIMENTAL|Group 1 PG4|Multivalent Pneumococcal Vaccine
62200749|NCT01081847|ACTIVE_COMPARATOR|Group B|Montanide ISA 51 Dose by peptide 50ug
62401670|NCT06102473|EXPERIMENTAL|Intervention group|The dyads (children and caregivers), will receive general nutritional education and also receive guidance on the use of front-of-package warning labels and awareness about the impact of the consumption of processed and ultra-processed foods on health.
62401671|NCT06102473|NO_INTERVENTION|Control Group|The dyads (children and caregivers), will receive general nutritional education.
62578462|NCT06524414|ACTIVE_COMPARATOR|Group 1 20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
62578463|NCT06524414|EXPERIMENTAL|Group 2 PG4|Multivalent Pneumococcal Vaccine
62578464|NCT06524414|ACTIVE_COMPARATOR|Group 2 20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
62578465|NCT06524414|EXPERIMENTAL|Group 3 PG4|Multivalent Pneumococcal Vaccine
62578466|NCT06524414|ACTIVE_COMPARATOR|Group 3 20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
62578467|NCT04571645|EXPERIMENTAL|Dociparstat|Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and dociparstat 4 mg/kg intravenous (IV) bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by dociparstat 0.25 mg/kg/hr via continuous IV infusion 24 hours daily for 5 or 7 days.
62578468|NCT04571645|PLACEBO_COMPARATOR|Control|Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and placebo intravenous (IV) bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by placebo via continuous IV infusion 24 hours daily for 5 or 7 days.
62578469|NCT03283410|EXPERIMENTAL|Single Study Arm|All patients will be sequentially allocated in the single study arm. All patients will receive some propofol dose.
62401672|NCT04973527|EXPERIMENTAL|LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor|An open label, multi center, single arm Phase I study to evaluate the safety, tolerability, and efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor.
62401673|NCT05059366|EXPERIMENTAL|Expert participants randomized to MVG followed by 2VE|Expert participants (Anesthesiology residents and attendings with at least 2 or more years of clinical experience) randomized to perform the ventilation on a manikin using the Manual ventilation grip device (MVG) first followed by the standard 2VE technique alone.
62578470|NCT02586532||1|Residents of towns participating in China Demonstration Project.
62200750|NCT01081847|ACTIVE_COMPARATOR|Group C|Montanide ISA 720 Dose by peptide 100ug
62200751|NCT01081847|ACTIVE_COMPARATOR|Group D|Montanide ISA 51 Dose by peptide 100ug
62200752|NCT01081847|PLACEBO_COMPARATOR|Group E|Control Group. no peptide. Isotonic saline solution
62200753|NCT04184453|EXPERIMENTAL|Deferiprone treated|Deferiprone (25 mg/kg/day) was given to the enrolled patient.
62401674|NCT05059366|EXPERIMENTAL|Expert participants randomized to 2VE followed by MVG|Expert participants (Anesthesiology residents and attendings with at least 2 or more years of clinical experience) randomized to perform the ventilation on a manikin using the standard technique (2VE) alone first followed by Manual ventilation grip device (MVG).
62401675|NCT05059366|EXPERIMENTAL|Novice participants randomized to MVG followed by 2VE|Novice participants (Current medical students or residents with no prior experience in hand mask ventilation techniques) first followed by the standard technique (2VE) alone
62578471|NCT00284492|ACTIVE_COMPARATOR|Lifestyle advice|
62578472|NCT00284492|EXPERIMENTAL|Lifestyle advice and acupuncture therapy|
62578473|NCT01094561|EXPERIMENTAL|Synthetic Human Secretin|Single arm (open label).
62578474|NCT03046667|EXPERIMENTAL|Test drink|Test drink: Barley β-glucan
62578475|NCT03046667|PLACEBO_COMPARATOR|Control drink|Control drink: barley beverage
62578476|NCT03981484|EXPERIMENTAL|PCC|single dose of 4-Factor PCC in addition to standard resuscitation methods
62578477|NCT03981484|ACTIVE_COMPARATOR|Standard of Care|standard resuscitation methods only
62578478|NCT01653678|ACTIVE_COMPARATOR|Vitamin D + fish oil|
62578479|NCT01653678|ACTIVE_COMPARATOR|Vitamin D + fish oil placebo|
62401676|NCT05059366|EXPERIMENTAL|Novice participants randomized to 2VE followed by MVG|Novice participants (Current medical students or residents with no prior experience in hand mask ventilation techniques) randomized to perform the ventilation on a manikin using the standard technique (2VE) alone first followed by Manual ventilation grip device (MVG)
62401677|NCT02384590|EXPERIMENTAL|CCBT + Care Manager Arm|Patients will be given a tablet device with unlimited data. The device will be pre-installed with a pain and mood diary app that will prompt them to enter their pain severity (0-10), pain location, and mood (0-10), once a day. They will also be registered on to the Beating the Blues website and asked to use the tablet device to complete eight 1-hour Beating the Blues CBT sessions, over the next 3-months. They will also be introduced to a care manager who will contact them on a weekly basis by telephone and throughout the week by email or text, for one-month and then as needed for two additional months. At the conclusion of 3 months participants will only have care manager support upon request but are free to continue using the Beating the Blues program for as long as they like.
62401678|NCT02384590|NO_INTERVENTION|Treatment As Usual|Similar to the treatment arm, patients will be given a tablet device with unlimited data that comes pre-loaded with a pain and mood diary app. The app will prompt the usual care patients to complete diary data daily. No other activities are required as part of the study but the patients are free to use the tablet as much as they like for their own leisure. At the end of 3-months, patients who continue to report depressive or anxiety symptoms are invited to cross-over to the treatment arm where they will be registered for the Beating the Blues program and given care manger support.
62401679|NCT04141566||PCPC|pseudocontinent perineal colostomy using shmidt technique for perineal reconstruction after abdominoperineal resection
62401680|NCT04141566||PLIC|Permanenet left iliac colostomy , the standard technique after abdominoperineal resection and primary closure of the perineal wound
62410059|NCT05254015|ACTIVE_COMPARATOR|Case Management (CM)|Case Management (CM). CM consists of a set of well-established strategies commonly used in community service settings to address serious and complex problems in particularly vulnerable and often marginalized populations such as those with HD.
62578480|NCT01653678|ACTIVE_COMPARATOR|Vitamin D placebo + fish oil|
62578481|NCT01653678|PLACEBO_COMPARATOR|Vitamin D placebo + fish oil placebo|
62578482|NCT00576420|EXPERIMENTAL|FS VH S/D 500 s-apr - 60-Seconds|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) will be applied to the study suture line, 60-second polymerization time
62578483|NCT00576420|EXPERIMENTAL|FS VH S/D 500 s-apr - 120-Seconds|FS VH S/D 500 s-apr will be applied to the study suture line, 120-second polymerization time
62578484|NCT00576420|ACTIVE_COMPARATOR|Control Group- Manual compression with surgical gauze pads|Treatment of the study-suture line will be manual compression with surgical gauze pads.
62578485|NCT06315829||Confirmed Epileptic Spasms (Positive Class)|Participants diagnosed with infantile spasms based upon historical data and supportive electroencephalography data (i.e. hypsarrhythmia or modified hypsarrhythmia background).
62578486|NCT06315829||Epileptic Spasm Mimics (Negative Class)|Participants diagnosed with non-epileptic movements (e.g. Sandifer syndrome, shuddering attacks, stretching, stereotypy, startle reflex, writhing movements, jitteriness, sleep myoclonus) based upon historical data and supportive electroencephalography data (when available).
62578487|NCT06315829||Awake and Alert (Negative Class)|Participants exhibiting spontaneous, subtle movements in the awake and alert state.
62578488|NCT02210598|ACTIVE_COMPARATOR|inpatient Foley balloon induction|"Inpatient Foley induction participants will be placed in the dorsal lithotomy position, a Foley catheter will be placed transcervically and its balloon filled with 60mL of sterile saline. One of two methods will be used to place the transcervical foley based on provider preference and determination of which method will offer the greatest chance for successful placement. Method A is placement of the foley blindly by palpation of the cervix. Method B utilizes direct visualization with sterile speculum placement. Method will be documented in the data collection forms. The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded."
62578489|NCT02210598|EXPERIMENTAL|outpatient Foley balloon induction|Patients randomized to the experimental group will undergo outpatient Foley induction of labor. Either of the above two described methods will be used to place an 18 French Foley catheter transcervically and its balloon filled with 60mL of sterile saline. The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours. When the patient returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L\&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.
62578490|NCT06685406|EXPERIMENTAL|Ventilated patients group|
62578491|NCT03493802||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
62578492|NCT03493802||Healthy individuals as controls|Age and gender-matched healthy controls
62578493|NCT04215679|EXPERIMENTAL|Three-dimensional immersive virtual reality application|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose mini Mental State Examination (MMSE) scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
62578494|NCT04215679|ACTIVE_COMPARATOR|Motor imagery|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
62578495|NCT04215679|ACTIVE_COMPARATOR|Conventional physiotherapy|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
62578496|NCT06684717|EXPERIMENTAL|Educational video intervention group|The participants who were randomized into the video group watched a 3-minute video that educated patients about OSA, treatment, and its benefits. We also added the scenario of the real patients who were currently using CPAP, in order to motivated participants to use CPAP more. The participants in the video group also received routine care.
62578497|NCT06684717|NO_INTERVENTION|Usual care group|In the usual care group, they were routinely advised about the disease and CPAP machine use by sleep medicine doctors and sleep technicians.
62578498|NCT01731184|EXPERIMENTAL|Midazolam|Midazolam (Hypnovel) at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
62578499|NCT01731184|PLACEBO_COMPARATOR|Placebo|Placebo at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
62200754|NCT06329323||Cases- Malignant Ovarian Germ Cell Tumour - Arm 1|Patients with a diagnosis of stage 1a MOGCT. Bloods taken at the following time points: Day 0, then 4 weeks; 6 months; 12 months; 24 months post-operatively
62200755|NCT06329323||Cases - Malignant Ovarian Germ Cell Tumour - Arm 2|Patients with a diagnosis of stage 1b/1c MOGCT. Bloods taken at the following time points: Day 0, then 4 weeks; 6 months; 12 months; 24 months post-operatively OR post-final dose of adjuvant chemotherapy
62578500|NCT04280744|EXPERIMENTAL|Music therapy|Music listening intervention provided by a board certified music therapist.
62578501|NCT01958814|EXPERIMENTAL|Salbutamol - Placebo|salbutamol at M0 and M60 placebo administration
62578502|NCT01958814|EXPERIMENTAL|Placebo - Salbutamol|placebo at M0 and M60 salbutamol administration
62578503|NCT00860535|EXPERIMENTAL|Ph+ CML or Ph+ ALL|GFS biomarker evaluation
62578504|NCT02375308|EXPERIMENTAL|Hypnotherapeutic Treatment|HDT (Hypnotherapeutic Treatment of Depression) focuses on the hypnotic activation and strengthening of individual resources, the use of regression techniques to rebuild positive and negative experiences and the development of positive imaginations for the future.
62200756|NCT06329323||Cases - Malignant Ovarian Germ Cell Tumour - Arm 3|Patients with a diagnosis of stage 2 or higher MOGCT. Bloods taken at the following time points: Day 0, then 4 weeks post-neoadjuvant chemotherapy, then 4 weeks; 6 months; 12 months; 24 months post-operatively
62200757|NCT06329323||Controls - Benign Ovarian Germ Cell Tumour|Bloods taken at the time of diagnosis of BOGCT (single blood test)
62401681|NCT01331525|EXPERIMENTAL|Single stage non-randomised|"Patients will receive Carboplatin and Etoposide. Both Chemotherapy drugs will be delivered as a 21 day cycle (q21) with up to a maximum of 6 cycles delivered according to response unless progressive disease (RECIST Version 1.0) and or excessive toxicity.~Ipilimumab will be administered at a dose of 10mg/kg IV on day 1 of cycles 3-6 of Chemotherapy.~In the absence of immune related progression of disease or unacceptable toxicity, subsequent maintenance doses of Ipilimumab will be delivered every 12 weeks starting at week 30 at a dose of 10 mg/kg until unacceptable toxicity or immune related disease progression"
62401682|NCT01240109|ACTIVE_COMPARATOR|propofol|
62401683|NCT01240109|ACTIVE_COMPARATOR|sevoflurane|
62401684|NCT06642441|EXPERIMENTAL|Chemotherapy + vitamin D2|Before the start of treatment and every 3 weeks thereafter, participants will receive a 10-milligram dose of vitamin D2 injection until adjuvant chemotherapy is completed. They will receive a standard adjuvant chemotherapy regimen, which includes 10 mg of vitamin D2 injections per cycle during treatment. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
62578505|NCT02375308|EXPERIMENTAL|Cognitive Behavioral Treatment|ACDT (Activation-focussed Cognitive Treatment of Depression) focuses on psychoeducation, behavior activation, the use of cognitive techniques, and the improvement of social skills.
62578506|NCT01210846|EXPERIMENTAL|tivozanib|
62578507|NCT02830308||Adults with known or suspected endocrine or metabolic dissorde|Adults with known or suspected endocrine or metabolic dissorders
62578508|NCT05622474|EXPERIMENTAL|IC plus CC plus IMRT|Induction chemotherapy followed by Intensity-modulated radiotherapy plus concurrent chemotherapy
62578509|NCT05622474|ACTIVE_COMPARATOR|CC plus IMRT|Intensity-modulated radiotherapy plus concurrent chemotherapy alone
62578510|NCT05404477|OTHER|Treatment|Treatment with TransAeris stimulation upon completion of procedure
62578511|NCT05404477|OTHER|Control|Control subject will cross-over to treatment with the TransAeris System if still on mechanical ventilation at 120 hours post-op
62578512|NCT00305825|EXPERIMENTAL|Study intervention|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral letrozole once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62012791|NCT00585065||Pediatric and adolescent patients receiving CRT with BVP for treating chronic heart failure|"Pediatric and adolescent patients who are receiving cardiac resynchronization therapy with biventricular pacing as a method of treating chronic heart failure. Children of both genders, who are followed in the Division of Pediatric Cardiology at Primary Children's Medical Center, who meet all inclusion and no exclusion criteria are eligible for participation in this clinical study.~No intervention is administered as part of this study. Prospective longitudinal case series study to describe and evaluate clinical and hemodynamic effects of CRT and to identify echocardiographic predictors of positive response to CRT in Group described."
62012792|NCT00580905|ACTIVE_COMPARATOR|1|To compare the effects of adenosine at a dose of 80 mcg/kg/min for 30 minutes, Sodium nitroprusside will be used at a dose that produce similar systemic effects (5 mcg/kg/.min)
62200758|NCT06329323||Controls - No Known Gynaecological Pathology|Single blood test
62401685|NCT06642441|OTHER|chemotherapy|Participants will receive a standard adjuvant chemotherapy regimen for each adjuvant chemotherapy cycle. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
62401686|NCT05821166|EXPERIMENTAL|mWBH|patients receiving moderate Whole Body Hyperthermia
62200759|NCT04565275|EXPERIMENTAL|ICP-192|"1. Dose Escalation Phase ICP-192~2. Dose Expansion Phase ICP-192"
62401687|NCT05821166|NO_INTERVENTION|Control group|Patients do not receive moderate Whole Body Hyperthermia
62401688|NCT04250506|EXPERIMENTAL|Treatment A: Daridorexant 50 mg|Daridorexant (ACT-541468) administered as film-coated tablets for oral use.
62401689|NCT04250506|EXPERIMENTAL|Treatment B: Daridorexant 200 mg|Daridorexant (ACT-541468) administered as film-coated tablets (4 x 50 mg) for oral use.
62401690|NCT04250506|PLACEBO_COMPARATOR|Treatment C: Placebo|Placebo administered as tablets (4 x 50 mg) for oral use.
62401691|NCT04250506|ACTIVE_COMPARATOR|Treatment D: Moxifloxacin 400 mg|Moxifloxacin administered as film-coated tablets for oral use.
62410060|NCT06565923||Adult bladder cancer patients with MRI, pathology, and laboratory data provided|
62578513|NCT05157919|NO_INTERVENTION|Control|Usual care continues. The caregiver will not get to use the app. The caregiver will be asked daily measures and the patient will be asked about thirst and anxiety daily when the patient is awake enough to answer these questions. The caregiver will be asked questions at 3 different times: Day 1, 24-48 hours after enrollment, and 2-4 weeks after the patient is discharged from the ICU.
62578514|NCT05157919|EXPERIMENTAL|Intervention with App|The caregiver gets access to use the app. Each day, investigators will ask the patient to rate their thirst and anxiety and the caregiver to answer daily measures through the application. The caregiver will be asked questions at 3 different times: Day 1, 24-48 hours after enrollment, and 2-4 weeks after the patient is discharged from the ICU. The caregiver will be taught how to use the app. The caregiver will be given the supplies that the caregiver needs to perform the symptom management intervention. Investigators will ask the caregiver to use the app at least once a day, but the caregiver can use it as much as desired while the patient is in the ICU.
62578515|NCT03753464||Peri-implantitis|Patients undergoing surgical treatment for peri-implantitis. Gingival and blood samples will be collected during the treatment for peri-implantitis.
62578516|NCT03753464||Healthy|Healthy patients undergoing treatment for either wisdom tooth extraction or gingivectomy. Gingival and blood samples will be collected during either wisdom tooth extraction or gingivectomy.
62578517|NCT03469674|EXPERIMENTAL|Molecular profile based treatment|Determination of the integrated clinicopathological and molecular profile to determine adjuvant treatment: observation for favourable profile; vaginal brachytherapy for intermediate profile; external beam radiotherapy for unfavourable profile
62200760|NCT05862428|EXPERIMENTAL|Rectal misoprostol|This group received misoprostol transrectally before surgery 1 hour
62200761|NCT05862428|NO_INTERVENTION|Control group|This group not received any drugs before surgery
62200762|NCT05781412|ACTIVE_COMPARATOR|ASD_anodalstimulation|ASD participant, anodal stimulation on the first session, sham stimulation on the second sesion
62200763|NCT05781412|SHAM_COMPARATOR|ASD_shamstimulation|ASD participant, sham stimulation on the first session, anodal stimulation on the second sesion
62200764|NCT05781412|ACTIVE_COMPARATOR|NT_anodalstimulation|Neurotypical participant, anodal stimulation on the first session, sham stimulation on the second sesion
62200765|NCT05781412|SHAM_COMPARATOR|NT_shamstimulation|Neurotypical participant, sham stimulation on the first session, anodal stimulation on the second sesion
62200766|NCT05781412|ACTIVE_COMPARATOR|H-AQ_anodalstimulation|non diagnosed autistic participant,anodal stimulation on the first session, sham stimulation on the second sesion
62200767|NCT05781412|SHAM_COMPARATOR|H-AQ_shamstimulation|non diagnosed autistic participant, sham stimulation on the first session, anodal stimulation on the second sesion
62200768|NCT04329377||platelet count in iiron overload|
62200769|NCT01469520|ACTIVE_COMPARATOR|Reference|Co-administered liquid mixture of Epivir® (lamivudine) solution, Retrovir® (zidovudine)and Viramune® (nevirapine)
62200770|NCT01469520|ACTIVE_COMPARATOR|Test product|Fixed dose combination of lamivudine, zidovudine and nevirapine reconstitutable suspension
62200771|NCT01469520|ACTIVE_COMPARATOR|Test Product|Fixed dose combination combination (Lamivudine, Zidovudine and Nevirapine)tablet
62200772|NCT02834767|EXPERIMENTAL|Group 1 Primary Snoring Treatment|Intervention: Eight weeks of supervised use of the genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
62200773|NCT02834767|PLACEBO_COMPARATOR|Group 2 Primary Snoring Placebo|Intervention: Eight weeks of supervised use of the placebo genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
62200774|NCT02834767|EXPERIMENTAL|Group 3 Primary OSA Treatment|Intervention: Eight weeks of supervised use of the genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
62200775|NCT02834767|PLACEBO_COMPARATOR|Group 4 Primary OSA Placebo|Intervention: Eight weeks of supervised use of the placebo genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
62200776|NCT05814588|EXPERIMENTAL|Group A|
62200777|NCT05814588|SHAM_COMPARATOR|Group B|
62200778|NCT05433649|EXPERIMENTAL|Experimental group|Participants performing 16 sessions of therapeutic exercise for 8 weeks with a frequency of two sessions per week. All sessions had a practical focus (strength and stretching exercises) with the help of elastic bands.
62200779|NCT05433649|NO_INTERVENTION|Control group|They do not change their lifestyle and do not receive the therapeutic exercise sessions.
62200780|NCT00142090|EXPERIMENTAL|2|3% Hypertonic saline
62401692|NCT04938869|EXPERIMENTAL|Supportive care (CGM)|Prior to hospital discharge, patients receive CGM application and education on how to apply the CGM, and how to use the sensor and its associated smart phone app. Patients also receive basic diabetes mellitus education. After hospital discharge, patients use CGM for up to 28 days.
62401693|NCT03641235||exacerbating COPD patients needing ICU admission|sputum collection
62401694|NCT04429607|ACTIVE_COMPARATOR|Erbium:YAG Laser|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
62200781|NCT00142090|PLACEBO_COMPARATOR|1|Normal saline
62200782|NCT02909218|NO_INTERVENTION|National HIV Treatment Guidelines|HIV-positive individuals are offered ART per Swaziland's national treatment guidelines
62200783|NCT02909218|EXPERIMENTAL|Early Access to ART for All|HIV-positive individuals are initiated on ART regardless of client's immunological and clinical staging
62200784|NCT03342833|ACTIVE_COMPARATOR|Blood flow restriction|
62200785|NCT03342833|SHAM_COMPARATOR|Usual training|
62200786|NCT05461287|EXPERIMENTAL|QLS31904|Qls31904 is a bi-specific recombinant protein construct containing 2 humanized antibody derived binding domains.
62200787|NCT06034691|EXPERIMENTAL|PCSK9i group|treatment group
62200788|NCT06034691|NO_INTERVENTION|control group|control group
62200789|NCT05156151|OTHER|Stromal lenticule implantation for management of herpetic stromal keratitis|"The thickness of the herpetic stromal scar in the cornea is calculated in microns in OCT. Based on that extraction is performed using SMILE, a new lenticular stromal pocket is placed in the same volume. AS-OCT evaluated the corneal topography, glass-corrected best visual acuity (BSCVA) measurements and electron microscopy. Postoperative complications were monitored during the follow-up period.~During the three year follow-up period, no signs of recurrence or infections were detected in this patient."
62200790|NCT02246153|EXPERIMENTAL|Laparoscopic gastrectomy|Laparoscopy-assisted distal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
62200791|NCT02246153|ACTIVE_COMPARATOR|Open gastrectomy|Open distal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
62401695|NCT04429607|ACTIVE_COMPARATOR|PDL plus Nd:YAG|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
62578518|NCT03469674|ACTIVE_COMPARATOR|Vaginal brachytherapy|Adjuvant vaginal brachytherapy (standard treatment)
62012793|NCT00580905|ACTIVE_COMPARATOR|2|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
62200792|NCT06331455|EXPERIMENTAL|Neoadjuvant NORT-Durvalumab|administration of non-ablative oligofractionated radiation therapy using 12 Gy in 3 fractions in combination with two doses of durvalumab (1500 mg IV) prior to surgery.
62401696|NCT04429607|ACTIVE_COMPARATOR|ED&C treatment|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
62401697|NCT03851562|EXPERIMENTAL|Alprostadil 20 micrograms|1 μg / kg patient weight up to a maximum of 60 μg
62401698|NCT03851562|PLACEBO_COMPARATOR|Placebo (physiological saline solution)|Placebo (physiological saline solution)
62401699|NCT03780920|ACTIVE_COMPARATOR|Osteopathic treatment|
62401700|NCT03780920|NO_INTERVENTION|Control group|
62401701|NCT01535872|EXPERIMENTAL|DHEA treatment|
62401702|NCT01535872|NO_INTERVENTION|No treatment|
62401703|NCT02503215|EXPERIMENTAL|Compression Stockings|Patients will wear graduated lower limb compression stockings for a week. The investigators will evaluate if such procedure will cause better sleep performance
62401704|NCT03959306|EXPERIMENTAL|Group I|this group of patients will receive their standard anti-diabetic treatment in addition to 1800 mg of black seed oil soft gelatin capsule (900 mg twice daily) for three months
62578519|NCT05271149|OTHER|Control group|conventional physical therapy based on neurodevelopmental techniques, This program will be given for 1 hour, 3 days a week for 12 weeks
62012794|NCT00142909|EXPERIMENTAL|Drug: Lofexidine|"Lofexidine: Study medication~Participants will receive daily lofexidine and the dosing will be initiated at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject."
62784759|NCT05463016|ACTIVE_COMPARATOR|Control Group: Subjects with Normal Color Vision|Fifteen subjects confirmed to have normal color vision will be tested in a single session to determine whether color correcting lenses affect color vision in color vision normal subjects and to provided normative data for several unique measures of color vision performance
62012795|NCT00142909|PLACEBO_COMPARATOR|Drug: Placebo|"Placebo pill.~Participants will receive daily placebo and will follow the same scheduled delivery as those in the intervention for 12 weeks."
62200793|NCT05454605||group 1, ex vivo|"1. Assessment of the degree of cartilage damage according to the International Cartilage Regeneration \& Joint Preservation Society (ICRS) classification.~2. Optical spectroscopy of patient tissue samples.~3. Study of the mechanical properties of intra-articular tissues and cartilage thickness with an indenter.~4. Histological assessment of tissues according to the Osteoarthritis Research Society International (OARSI) classification."
62401705|NCT03959306|ACTIVE_COMPARATOR|Group II|this group of patients will receive their standard anti-diabetic treatment only
62401706|NCT02290704||controls|People without eye disease
62401707|NCT02290704||GO patients|patients with Graves' ophthalmopathy
62401708|NCT05868707|EXPERIMENTAL|OH2|OH2: 10\^7 CCID50/mL intratumoral injection, once every 2 weeks;
62401709|NCT05868707|ACTIVE_COMPARATOR|Salvage chemotherapy or best supportive care|Salvage chemotherapy (single or combined, including but not limited to dacarbazine, temozolomide, taxoid, or platinum) or best supportive care selected by the investigator
62401710|NCT03661112||All of Us Research Program (AoURP) consortium members|
62401711|NCT04985877|EXPERIMENTAL|Sarcopenia group|Yakult light 300 supplementation with sarcopenia patient
62200794|NCT05454605||group 2, in vivo|"1. Assessment of the degree of cartilage damage according to the ICRS classification.~2. Optical spectroscopy during arthroscopy/arthroplasty.~3. Magnetic resonance imaging (MRI)."
62401712|NCT04985877|NO_INTERVENTION|Non sarcopenia group|no intervention to sarcopenia patient
62401713|NCT04985877|NO_INTERVENTION|Control group|no intervention to non-sarcopenia people
62401714|NCT03592082|ACTIVE_COMPARATOR|Standard care alone|Participants will receive standard antibiotic therapy for Clostridium Difficile (CDiff) infection without additional adjuvant therapy.
62401715|NCT03592082|EXPERIMENTAL|Standard care with Bismuth subsalicylate (BSS)|Participants will receive BSS524 mg ((2) 262 mg tablets) four times per day for 14 days in addition to standard antibiotic therapy.
62401716|NCT05783011|EXPERIMENTAL|EA (electroacupuncture)|Individuals who underwent electroacupuncture before and after flap surgery
62401717|NCT05783011|ACTIVE_COMPARATOR|Control|Individuals who have undergone flap surgery only
62401718|NCT00994266|EXPERIMENTAL|A|Diamel
62012796|NCT03563040|EXPERIMENTAL|Methoxsalen with the THERAKOS CELLEX Photopheresis System|Treatment will be performed according to a predefined protocol based on the consensus guidelines in patients with MF/SS. Treatment should be administered for one year unless confirmed disease progression or unless other criteria for treatment discontinuation are met as specified in the protocol.
62012797|NCT04701268|EXPERIMENTAL|Intervention/treatment|Implantation of the Hemiverse Shoulder Prothesis
62200795|NCT02157389|EXPERIMENTAL|placebo|Administration of a pharmacological placebo (sodium chloride) via transdermal application to investigate the influence on pain perception in chronic back pain patients and to investigate the influence of attitude and experience with medication on the placebo effect
62401719|NCT00994266|PLACEBO_COMPARATOR|B|Placebo
62401720|NCT01445015|EXPERIMENTAL|Stress management program|
62401721|NCT01445015|ACTIVE_COMPARATOR|peer viewed movies|
62401722|NCT04988035|EXPERIMENTAL|Remdesivir + Danicopan (< 70 years)|For participants \< 70 years, 200 mg intravenous (IV) loading dose of Remdesivir on Day 1, followed by a 100 mg once-daily IV maintenance dose up to a 10-day total course while hospitalized, and 400 mg oral (PO) (or via nasogastric \[NG\] or gastrostomy \[G\] tube) loading dose danicopan, followed by 250 mg 4 times daily (QID) for the duration of the hospitalization up to a 14-day total course. End of danicopan treatment tapered as 250 mg 3 times daily (TID) for 2 days, followed by 250 mg twice daily (BID) for 2 days, until complete cessation (total treatment duration up to 18 days or 4 days after discharge). Total danicopan participants, N=100.
62578520|NCT05271149|EXPERIMENTAL|study group|conventional physical therapy and orthosis (Thera togs) : the child will wear the orthosis for twelve weeks, from 8 to 10 hours a day, during daily-life activities. The child's guardian (mother) will be trained and will receive a DVD recording, with a step-by-step demonstration on the fitting of TheraTogs® in the child. Markings were made in TheraTogs® to facilitate and improve fitting. All necessary support will be offered, with weekly monitoring in person to control the fitting of the orthosis, as well as for possible questions or clarifications.in addition to conventional physical therapy as the control group
62578521|NCT02402959||Cohort 1|Based on the first TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
62578522|NCT02402959||Cohort 2|Based on the second TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
62578523|NCT02402959||Cohort 3|Based on the third TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
62578524|NCT02402959||Cohort 4|Based on the fourth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
62784760|NCT02396355||All subjects|This is a single arm study. Samples from each subject will be tested with the Investigational BD FACSPresto System, the BD FACSCalibur flow cytometer, and the Sysmex hematology analyzer KX-21.
62784761|NCT03781778|EXPERIMENTAL|Group I (resistant starch foods)|Patients eat a diet consisting of resistant starch foods daily for 8 weeks.
62200796|NCT00338962|ACTIVE_COMPARATOR|Paroxetine and naltrexone|Paroxetine was started at 10 mg per day and the dose was gradually increased over 2 weeks to 40 mg per day. Naltrexone was started at 25 mg the first day and 50 mg per day for the rest of the treatment.
62410061|NCT01153685|EXPERIMENTAL|Fluviral A Group|Subjects aged between 18 and 60 years who received one dose of Fluviral vaccine at Day 0, administered intramuscularly in the deltoid region of the non-dominant arm.
62012798|NCT04634916|EXPERIMENTAL|EndoAVF|
62200797|NCT00338962|ACTIVE_COMPARATOR|paroxetine and placebo|Paroxetine was started at 10 mg per day and the dose was gradually increased over 2 weeks to 40 mg per day.
62200798|NCT00338962|ACTIVE_COMPARATOR|Desipramine and naltrexone|Desipramine was started at a dose of 25 mg per day. The dose was gradually increased over 2 weeks to 200 mg per day. Naltrexone was started at 25 mg the first day and 50 mg per day for the rest of the treatment.
62410062|NCT01153685|EXPERIMENTAL|Fluviral B Group|Subjects over 60 years of age who received one dose of Fluviral vaccine at Day 0, administered intramuscularly in the deltoid region of the non-dominant arm.
62200799|NCT00338962|ACTIVE_COMPARATOR|Desipramine and placebo|Desipramine was started at a dose of 25 mg per day. The dose was gradually increased over 2 weeks to 200 mg per day.
62012799|NCT06574347|EXPERIMENTAL|Vebreltinib 150mg BID+PLB1004 80mg QD|Subjects will receive Vebreltinib 150mg orally twice per day (BID) + PLB1004 80mg orally once per day (QD),21day cycles until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
62012800|NCT06574347|ACTIVE_COMPARATOR|Osimertinib 80mg QD|Subjects will receive Osimertinib 80mg orally once per day (QD),21day cycles until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
62012801|NCT02037503|PLACEBO_COMPARATOR|Placebo for drug resistant depression|Patients will be treated for 21 days with daily oral placebo
62012802|NCT02037503|EXPERIMENTAL|Ketamine for suicidal ideation|Patients will be treated for 21 days with daily oral Ketamine
62012803|NCT02037503|EXPERIMENTAL|Ketamine for drug resistant depression|Patients will be treated for 21 days with daily oral Ketamine
62200800|NCT04247477|EXPERIMENTAL|A-B-A-C|Four consecutive steps (45 min per step) are tested in the following order: Peep titration strategy according to Express method (A) - Peep titration strategy according to overdistension and collapse estimation (B) - Peep titration strategy according to Express method (A) - Peep titration strategy according to estimation of lung inhomogeneity (C)
62200801|NCT04247477|EXPERIMENTAL|A-C-A-B|Four consecutive steps (45 min per step) are tested in the following order: Peep titration strategy according to Express method (A) - Peep titration strategy according to estimation of lung inhomogeneity (C) - Peep titration strategy according to Express method (A) - Peep titration strategy according to overdistension and collapse estimation (B)
62200802|NCT01236638|EXPERIMENTAL|Momelotinib|
62200803|NCT04143711|EXPERIMENTAL|Monotherapy DF1001 Dose Escalation|Dose escalation cohorts of DF1001 in sequential ascending order.
62200804|NCT04143711|EXPERIMENTAL|Monotherapy DF1001 Safety/PK/PD Expansion|Expansion cohorts of monotherapy DF1001 in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
62410063|NCT00794222|EXPERIMENTAL|Mood monitoring|The mobiletype monitoring intervention group will monitor their current activities, current mood, responses to negative mood, any recent stressors and coping strategies. Other activities monitored include eating patterns, exercise patterns, quantity and quality of sleep and alcohol and cannabis use.
62784762|NCT03781778|ACTIVE_COMPARATOR|Group II (foods with regular corn starch)|Patients eat a diet consisting of regular corn starch foods daily for 8 weeks.
62784763|NCT03676907|NO_INTERVENTION|single layer suturation technique|in this arm we use single layer suturation technique to suture uterine incision
62012804|NCT02037503|PLACEBO_COMPARATOR|Placebo in suicidal ideation|Patients will be treated for 21 days with daily oral placebo
62784764|NCT03676907|EXPERIMENTAL|double layer suturation technique|in this arm we use double layer suturation technique to suture uterine incision
62012805|NCT02037503|EXPERIMENTAL|Healthy Participants|Healthy participants that underwent a romantic relationship breakup will attend in tow experimental sessions, one with placebo and one with ketamine. Sessions will be separated within the range of 1 to 6 weeks
62012806|NCT01379326|EXPERIMENTAL|Mebendazole|
62012807|NCT06664645|EXPERIMENTAL|complete repair with LHB tendon reinforcement|complete repair with LHB tendon reinforcement
62012808|NCT06664645|ACTIVE_COMPARATOR|complete repair without reinforcement|complete repair without reinforcement.
62012809|NCT00585949||Angiography|Patients undergoing coronary angiography without percutaneous coronary angioplasty
62012810|NCT00585949||Percutaneous Coronary Angioplasty|Patients with stable coronary artery disease undergoing angioplasty
62012811|NCT05199948|EXPERIMENTAL|Soybean Oil|Consumption of study foods each day made with soybean oil
62012812|NCT05199948|PLACEBO_COMPARATOR|Palm Oil|Consumption of study foods each day made with palm oil
62012813|NCT03603886|EXPERIMENTAL|Telemedicine Pain Management|
62012814|NCT03603886|OTHER|Waitlist Control|Treatment as usual comparator
62012815|NCT04116554|ACTIVE_COMPARATOR|intervention group (A)|which will have an ultrasound-guided bilateral transversus thoracic muscle plane (TTP) block by injection of 20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side.
62012816|NCT04116554|SHAM_COMPARATOR|control group (B)|which will have sham block bilaterally by injection of 20 ml of 0.9%saline will be injected on each side.
62200805|NCT04143711|EXPERIMENTAL|Monotherapy DF1001 Expansion in Urothelial Bladder Cancer|Monotherapy expansion cohort enrolling up to 20 patients with urothelial bladder cancer using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
62215048|NCT04713891|EXPERIMENTAL|Phase 1a: Cohort 3|KF-0210 tablet will be administered at 450 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
62215049|NCT04713891|EXPERIMENTAL|Phase 1a: Cohort 4|KF-0210 tablet will be administered at 600 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
62784765|NCT06294340||Participants with normal body weight|The effects of noise exposure on blood pressure, cardiovascular and hemodynamic parameters, stress hormones, and markers of oxidative stress and inflammation in individuals with normal body weight.
62784766|NCT06294340||Overweight / obese participants|The effects of noise exposure on blood pressure, cardiovascular and hemodynamic parameters, stress hormones, and markers of oxidative stress and inflammation in individuals with overweight/obesity.
62784767|NCT02435927|EXPERIMENTAL|ASLAN001 + CAPOX|ASLAN001 + CAPOX: ASLAN001 twice daily in combination with oxaliplatin 130 mg/m2 intravenously on day 1 and capecitabine 850 mg/m2 orally twice daily on days 1 to 14 every 3 weeks
62784768|NCT02435927|EXPERIMENTAL|ASLAN001 + mFolfox6|ASLAN001 + mFolfox6: ASLAN001 twice daily in combination with mFolfox6 (oxaliplatin 85 mg/m2 intravenously on day 1 and 5-FU bolus 400mg/m2 i.v on day 1 and as a continuous infusion 2400mg/ m2 over 46h and leucovorin 400mg/2 i.v on day 1) every 2 weeks
62784769|NCT06160427|EXPERIMENTAL|CTM Treatment|2.0 cc (cubic centimeter) dose injection of CTM Boost will be administered by injection directly into the rotator cuff using a 20 gauge needle.
62784770|NCT06160427|ACTIVE_COMPARATOR|PRP Treatment|Each participant randomized to this arm will receive a single injection of Platelet Rich Plasma (PRP).
62784771|NCT03421912|EXPERIMENTAL|Arm A : Cicaplast balm B5|Use of Cicaplast balm B5, 2 to 3 applications per day, since the first day of iEGFR treatment initiation for 30 days to avoid or limit appearance of cutaneous toxicities related to iEGFR treatment.
62012817|NCT02381535|EXPERIMENTAL|Treatment (onalespib, cisplatin, IMRT)|Patient receive onalespib IV over 1 hour on days -7, 3, 10, 24, 31, and 38 and cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, 36 and 43. Patients also undergo IMRT QD, 5 days a week over 7 weeks for a total of 35 fractions. Treatment continues in the absence of disease progression or unacceptable toxicity.
62012818|NCT00128258|EXPERIMENTAL|open|open treatment
62012819|NCT05037396||Brolucizumab|Participants received brolucizumab injection during the index period
62012820|NCT03333005|EXPERIMENTAL|APX001 with Standard of Care Anti-fungal agent|
62012821|NCT05628740|EXPERIMENTAL|Part 1-Period 1-Treatment A|3 mg NOC-100 (via nebulizer)
62012822|NCT05628740|PLACEBO_COMPARATOR|Part 1-Periods 2 through 4 -Treatment B|1 mg NOC-110 DPI (1 capsule)
62012823|NCT05628740|PLACEBO_COMPARATOR|Part 1-Periods 2 through 4 - Treatment C|3mg NOC-110 DPI (1 capsule)
62012824|NCT05628740|PLACEBO_COMPARATOR|Part 1-Periods 2 through 4- Placebo|Placebo (1 capsule)
62012825|NCT05628740|PLACEBO_COMPARATOR|Part 1-Period 5- Treatment D|6mg NOC-110 DPI (2 capsules)
62401723|NCT04988035|EXPERIMENTAL|Remdesivir + Danicopan (>/= 70 years)|For participants \>/= 70 years, 200 mg intravenous (IV) loading dose of Remdesivir on Day 1, followed by a 100 mg once-daily IV maintenance dose up to a 10-day total course while hospitalized, and 300 mg oral (PO) (or via nasogastric \[NG\] or gastrostomy \[G\] tube) loading dose danicopan, followed by 200 mg 4 times daily (QID) for the duration of the hospitalization up to a 14-day total course. End of danicopan treatment tapered as 200 mg 3 times daily (TID) for 2 days, followed by 200 mg twice daily (BID) for 2 days, until complete cessation (total treatment duration up to 18 days or 4 days after discharge). Total danicopan participants, N=100.
62401724|NCT04988035|ACTIVE_COMPARATOR|Remdesivir + Placebo (< 70 years)|For participants \< 70 years, 200 mg intravenous (IV) loading dose of Remdesivir on Day 1, followed by a 100 mg once-daily IV maintenance dose up to a 10-day total course while hospitalized, and 400 mg oral (PO) (or via nasogastric \[NG\] or gastrostomy \[G\] tube) loading dose danicopan matching placebo, followed by 250 mg 4 times daily (QID) for the duration of the hospitalization up to a 14-day total course. End of danicopan matching placebo treatment tapered as 250 mg 3 times daily (TID) for 2 days, followed by 250 mg twice daily (BID) for 2 days, until complete cessation (total treatment duration up to 18 days or 4 days after discharge). Total danicopan matching placebo participants, N=100.
62401725|NCT04988035|ACTIVE_COMPARATOR|Remdesivir + Placebo (>/= 70 years)|For participants \>/= 70 years, 200 mg intravenous (IV) loading dose of Remdesivir on Day 1, followed by a 100 mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 300 mg oral (PO) (or via nasogastric \[NG\] or gastrostomy \[G\] tube) of loading dose danicopan matching placebo followed by 200 mg 4 times daily (QID) for the duration of the hospitalization up to a 14-day total course. End of danicopan matching placebo treatment tapered as 200 mg 3 times daily (TID) for 2 days, followed by 200 mg twice daily (BID) for 2 days, until complete cessation (total treatment duration up to 18 days or 4 days after discharge). Total danicopan matching placebo participants, N=100.
62401726|NCT04001478||Control group|Patients who are attending hospital for a gastroscopy as part of their routine clinical care as a 2 week wait rule referral and those on Barrett's surveillance , will be asked to give a sample of their breath prior to the procedure.
62401727|NCT04001478||Early oesophageal cancer (T1)/ Barrett's high grade dysplasia|Patients who have known pre-diagnosed T1 oesophageal adenocarcinoma or HGD attending hospital as part of their clinical care will be asked to give a breath sample prior to their endoscopy resection/ cancer operation. Patients will be sampled upon return for follow up endoscopy to assess breath profile changes and correlation with endoscopy findings.
62401728|NCT04001478||Advanced Oesophageal cancer (T2/3/4)|Patients who have been diagnosed with oesophageal adenocarcinoma attending hospital as part of their clinical care will be asked to give a breath sample prior to their endoscopy resection/ cancer operation.
62012826|NCT05628740|PLACEBO_COMPARATOR|Part 1-Period 5- Placebo|Placebo (2 capsules)
62401729|NCT05235633||Comparison cohort|Children and adolescents at the end of acute treatment for leukemia and non-Hodgkin lymphoma without any exercise intervention
62012827|NCT05628740|PLACEBO_COMPARATOR|Part 2- Active|6mg NOC-110 DPI (2 capsules)
62012828|NCT05628740|PLACEBO_COMPARATOR|Part 2- Placebo|Placebo DPI (2 capsules)
62012829|NCT06529328|EXPERIMENTAL|Group A|For eight weeks, the experimental group in this study will engage in three sessions of thirty to forty-five minutes each, dedicated to core stability exercises that will challenge the muscles of the trunk and abdomen.
62012830|NCT06529328|EXPERIMENTAL|Group B|"In addition to receiving 25 minutes of conventional therapy, the subjects participated in a 30-minute trunk stabilization exercise program three days a week on non-consecutive days.~All tense muscles, including the hamstrings and calf muscles in the lower limb, can benefit from passive stretching exercises. First, it is done five times, then you work your way up to ten repetitions, stretch five times, and finally take five minutes to relax. Extensor muscle strengthening exercises for the back, hips, and knees (for 10 minutes)."
62578525|NCT02402959||Cohort 5|Based on the fifth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
62200806|NCT04143711|EXPERIMENTAL|Monotherapy DF1001 Expansion in Metastatic Breast Cancer (HER2 Low)|Monotherapy expansion cohort enrolling up to 20 patients with metastatic breast cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
62401730|NCT06516783|EXPERIMENTAL|patients with psoriasis, atopic dermatitis, eczema and chronic pruritus|"The study is scheduled for a maximum of 60 irradiations of blue light (maximum 3 cycles of 20 irradiations each). Phototherapeutic light will be administered for 15 minutes to each side of the body of the patient (30 minutes in total), 3-5 times per week.~• Device Full Body Blue GEN 1.0 device (built by PHLECS B.V.) with European Community (EC) Certificate (number 2238613CE01) is used in the study. The device provides phototherapeutic light through light panel with treatment Light Emitting Diodes - LEDs (wavelength 453 nm, irradiance 40mW/cm2; dose 36J for 15min treatment) to one side of the body of the patient who is lying flat on an examination bed"
62578526|NCT02402959||Cohort 6|Based on the sixth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
62578527|NCT02402959||Cohort 7|Based on the seven TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
62578528|NCT02402959||Cohort 8|Based on the eighth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
62578529|NCT02402959||Cohort 9|Based on the nineth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
62784772|NCT03421912|ACTIVE_COMPARATOR|Arm B : Dexeryl|Use of Dexeryl, 2 to 3 applications per day, since de first day of iEGFR treatment initiation for 30 days to avoid or limit appearence of cutaneous toxicities related to iEGFR treatment.
62401731|NCT04516291|PLACEBO_COMPARATOR|Placebo|No drug
62401732|NCT04516291|EXPERIMENTAL|Vupanorsen 80 mg every 4 weeks|80 milligrams (mg) given subcutaneously every 4 weeks.
62784773|NCT00461084||1|lymphoma follicular
62401733|NCT04516291|EXPERIMENTAL|Vupanorsen 60 mg every 2 weeks|60 mg given subcutaneously every 2 weeks.
62784774|NCT00461084||2|lymphoma non-follicular
62784775|NCT00066027|EXPERIMENTAL|low-dose doxycycline|low-dose doxycycline (20 mg doxycycline hyclate)
62784776|NCT00066027|PLACEBO_COMPARATOR|Placebo|Placebo
62784777|NCT06447402|PLACEBO_COMPARATOR|Saline arm|5 ml normal saline will be given as nebulization
62784778|NCT06447402|EXPERIMENTAL|NAB arm|Amphotericin B dexoycholate will be nebulised twice daily
62200807|NCT04143711|EXPERIMENTAL|Monotherapy DF1001 Expansion in Cancers with Erbb2 Amplification|Monotherapy expansion cohort enrolling up to 40 patients with solid tumors showing documented erbb2 amplification using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
62200808|NCT04143711|EXPERIMENTAL|Combination Therapy with DF1001 and Nivolumab|Combination dose escalation of DF1001 in combination with nivolumab in patients with select solid tumors.
62401734|NCT04516291|EXPERIMENTAL|Vupanorsen 120 mg every 4 weeks|120 mg given subcutaneously every 4 weeks.
62401735|NCT04516291|EXPERIMENTAL|Vupanorsen 80 mg every 2 weeks|80 mg given subcutaneously every 2 weeks.
62401736|NCT04516291|EXPERIMENTAL|Vupanorsen 160 mg every 4 weeks|160 mg given subcutaneously every 4 weeks.
62200809|NCT04143711|EXPERIMENTAL|Combination Therapy with DF1001 and Nab-paclitaxel|Combination dose escalation of DF1001 in combination with nab-paclitaxel in patients with select solid tumors.
62012831|NCT04587323||Group 1:|Group 1: COVID-19 + inpatients who did not require mechanical ventilation (25 patients);
62012832|NCT04587323||Group 2:|Group 2: COVID-19 + inpatients who required mechanical ventilation (25 patients).
62012833|NCT04587323||Group 3:|Group 3: COVID-19 + inpatients with no preexisting cardiovascular disease (25 patients)
62012834|NCT04587323||Group 4:|Group 4: COVID-19 + inpatients with preexisting cardiovascular disease (25 patients).
62012835|NCT06034158|OTHER|madopar-propranolol-placebo|In a within-subjects design, participants will take madopar, propranolol, and placebo each once in three separate sessions.
62012836|NCT06034158|OTHER|madopar-placebo-propranolol|In a within-subjects design, participants will take madopar, placebo, and propranolol each once in three separate sessions.
62401737|NCT04516291|EXPERIMENTAL|Vupanorsen 120 mg every 2 weeks|120 mg given subcutaneously every 2 weeks.
62012837|NCT06034158|OTHER|propranolol-madopar-placebo|In a within-subjects design, participants will take propranolol, madopar, and placebo each once in three separate sessions.
62012838|NCT06034158|OTHER|propranolol-placebo-madopar|In a within-subjects design, participants will take propranolol, placebo, and madopar each once in three separate sessions.
62012839|NCT06034158|OTHER|placebo-propranolol-madopar|In a within-subjects design, participants will take placebo, propranolol, and madopar each once in three separate sessions.
62012840|NCT06034158|OTHER|placebo-madopar-propranolol|In a within-subjects design, participants will take placebo, madopar, and propranolol each once in three separate sessions.
62012841|NCT01312116|EXPERIMENTAL|Internet-delivered CBT|Active treatment: Internet-delivered Cognitive Behavior Therapy, 8 weeks treatment, guided self-help
62012842|NCT01312116|EXPERIMENTAL|Internet-delivered PDT|Active treatment: Internet-delivered Psychodynamic Therapy Active treatment: Internet-delivered Psychodynamic Therapy, 8 weeks treatment, guided self-help
62012843|NCT01312116|NO_INTERVENTION|Control condition|Wait-list condition, received treatment 3 months after initial treatment period
62012844|NCT01401530|EXPERIMENTAL|E7777|
62012845|NCT02572271|ACTIVE_COMPARATOR|Rubins Mastopexy|Patients are allocated to a mastopexy using Rubins technique
62012846|NCT02572271|ACTIVE_COMPARATOR|LOPOSAM|Patients are allocated to a mastopexy using the LOPOSAM technique
62012847|NCT05889624|EXPERIMENTAL|CBT while taking a clinically-prescribed, pill-based prevention therapy (amitriptyline)|This intervention consists of Cognitive Behavioral (CBT), a mind and body based intervention using education on gate control theory of pain, behavioral strategies such as muscle relaxation, activity pacing, and cognitive strategies including distraction, problem solving, and using calming self-statements. This arm will also take a daily oral dose of Amitriptyline, which will be clinically prescribed and managed by the patient's headache provider.
62012848|NCT05889624|EXPERIMENTAL|CBT alone|This intervention arm consists of 6 Cognitive Behavioral Therapy (CBT), a mind and body based intervention using education on gate control theory of pain, behavioral strategies such as muscle relaxation, activity pacing, and cognitive strategies including distraction, problem solving, and using calming self-statements.
62012849|NCT01162005|EXPERIMENTAL|Tacrolimus|Tacrobell
62012850|NCT03176394|EXPERIMENTAL|BLASTX Lubricated Catheter|Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with BLASTX. This gel lubricates with the same viscosity as McKesson Jelly and has a biofilm disruptive active ingredient.
62200810|NCT04143711|EXPERIMENTAL|Combination Therapy with DF1001 and Nivolumab Safety/PK/PD Expansion|Expansion cohort of DF1001 in combination with nivolumab after evaluation for safety in the Combination Therapy with DF1001 and nivolumab Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
62401738|NCT04516291|EXPERIMENTAL|Vupanorsen 160 mg every 2 weeks|160 mg given subcutaneously every 2 weeks.
62410064|NCT00794222|NO_INTERVENTION|Comparison monitoring program|"The mobiletype monitoring comparison group will monitor their current activities, eating patterns, exercise patterns, quantity and quality of sleep and alcohol and cannabis use.~This program excludes questions about mood, stress and coping strategies."
62012851|NCT03176394|PLACEBO_COMPARATOR|McKesson Jelly Lubricated Catheter|Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with McKesson Jelly. This jelly lubricates with the same viscosity as BLASTX but has no biofilm disruptive active ingredient.
62012852|NCT06573320|EXPERIMENTAL|physical exercise group|physical exercise
62012853|NCT06573320|NO_INTERVENTION|control group|no intervention
62012854|NCT01611259|EXPERIMENTAL|Rituximab and Lenalidomide|Single arm: 6 cycles for patients with complete response, 8 cycles for subjects with stable disease or partial remission; cycles duration: 28 days Rituximab (Mabthera®): 375 mg/m² i.v. day 1 Lenalidomide (Revlimid®): 20 mg p.o. daily for 21 days
62012855|NCT06034080|ACTIVE_COMPARATOR|Health System Level (HSL) Intervention|"The HSL Intervention is based on the CDC Core Elements of Stewardship and the HSL intervention is recommended by national guidelines. Sites randomized to this arm will require:~1. A change in their Electronic Health Record to their prescription fields to align with national guidelines~2. Individualized feedback report to their clinicians and clinic overall~3. And virtual learning sessions and continuing medical education credits for clinicians."
62012856|NCT06034080|EXPERIMENTAL|Hybrid Intervention|"The Hybrid Intervention will be comprised of Shared Decision-Making (SDM) and the HSL Intervention. A previously validated SDM aid for ear infection care will be implemented. The aid was developed using the International Patient Decision Aid Standards and is freely available. Sites randomized to this arm will require all of the HSL components as well as:~1. Use of the Shared-Decision Aide~2. Clinician Education on SDM"
62012857|NCT06100614|EXPERIMENTAL|Presepsin-guided therapy|The decision to start empirical antibiotics in this group will be based on presepsin measurement within four hours after birth. When the presepsin value is above the cut-off value of 645 pg/ml, antibiotics will be ordered and administered within 4 hours of life and discontinued following the criteria of the Dutch EOS guideline. When the presepsin level is below the cut-off value of 645 pg/ml, the treating physician will not start antibiotic treatment. These infants will be closely observed for at least 72 hours. In case of deterioration of the clinical condition within this observation period, the clinician can decide to perform a sepsis evaluation and start with antibiotic treatment.
62012858|NCT06100614|ACTIVE_COMPARATOR|Standard care|Standard care according to the Dutch EOS guideline. Presepsin will be determined with the treating physician blinded for the test result. In the Dutch EOS guideline maternal and neonatal risk factors for EOS are categorized as red flags or minor criteria. In the presence of 1 red flag or ≥ 2 minor criteria it is advised to perform a blood culture (= sepsis evaluation) and start empirical antibiotics for EOS suspicion. Antibiotic treatment will be advised to discontinue when blood culture turns back negative, reassuring the infants clinical condition with no other indicators of possible infection (e.g. CRP).
62012859|NCT06282484||chronic gastritis|patients with chronic non-atrophic gastritis and chronic atrophic gastritis according to histopathological results
62012860|NCT06282484||precancerous lesion|patients with gastric intestinal metaplasia and intraepithelial neoplasia according to histopathological results
62012861|NCT06282484||gastric cancer|patients with gastric cancer according to histopathological results
62012862|NCT03717337|EXPERIMENTAL|Single visit pulp regeneration|Regenerative endodontic procedure not involving placement of intracanal medicament will be done in single visit
62012863|NCT03717337|ACTIVE_COMPARATOR|Two visit pulp regeneration|Regenerative endodontic procedure involving placing intracanal medicament will be done in two visit
62012864|NCT01235910|OTHER|1|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
62012865|NCT05315388|NO_INTERVENTION|Group 1. Regular therapy group|Group without intervention during the study period no changes will be made in their daily routine. They will receive a weekly intervention operationalized for psychosocial risk.
62012866|NCT05315388|EXPERIMENTAL|Group 2A: Vitamin N therapy group - metropolitan park environment|Group with periodic outings to a neighborhood or metropolitan natural park (once a week) for approximately 2 hours for a minimum period of six months.
62012867|NCT05315388|EXPERIMENTAL|Group 2B: Vitamin N therapy group - forest forest environment|Group with periodic outings to a forest environment (once a week) for a time of approximately 2 hours for a minimum period of six months
62012868|NCT00991302|EXPERIMENTAL|CAP-IT|"Participants received the modified CAP-IT adherence intervention in addition to standard care.~Modified client adherence profiling and intervention tailoring (CAP-IT): Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)"
62012869|NCT00991302|NO_INTERVENTION|Standard care|Participants received standard care.
62012870|NCT02322697|EXPERIMENTAL|Carnitine group|Intravenous administration of L-carnitine 1000mg after each hemodialysis session (three times a week) for one year.
62401739|NCT01092130|EXPERIMENTAL|Vitamin D|Patients were randomized by an automated computer system to 2000 IU oral cholecalciferol once daily or control (i.e. no extra medication), in a 1:1 ratio for a period of six weeks. Blood was collected in a sitting position on visits 2-4 and patients were asked to collect 24h urine samples prior to visits 2 and 4. Heart failure medication was maintained unchanged throughout the trial. Changes in diuretic dose were permitted if necessary to treat decompensation or renal dysfunction.
62012871|NCT02322697|NO_INTERVENTION|control group|No intervention
62012872|NCT01662869|EXPERIMENTAL|Onartuzumab+mFOLFOX6|Participants will receive onartuzumab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion + mFOLFOX6 (oxaliplatin, folinic acid, and 5-fluoruracil) regimen. Participants will receive a maximum of 12 cycles (each cycle is 14 days) of mFOLFOX6 with onartuzumab. Participants whose disease has not progressed after 12 cycles of mFOLFOX6 with onartuzumab will continue treatment with onartuzumab until disease progression, unacceptable toxicity, or death.
62200811|NCT04143711|EXPERIMENTAL|Combination Therapy with DF1001 and Nab-paclitaxel Safety/PK/PD Expansion|Expansion cohort of DF1001 in combination with nab-paclitaxel after evaluation for safety in the Combination Therapy with DF1001 and nab-paclitaxel Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
62012873|NCT01662869|PLACEBO_COMPARATOR|Placebo+mFOLFOX6|Participants will receive onartuzumab matching placebo + mFOLFOX6. Participants will receive a maximum of 12 cycles (each cycle is 14 days) of mFOLFOX6 with placebo. Participants whose disease has not progressed after 12 cycles of mFOLFOX6 with placebo will continue treatment with placebo until disease progression, unacceptable toxicity, or death.
62012874|NCT04950335||AOPT|patients underwent AOPT to treat large cystic OLTs (\>10mm)
62012875|NCT04950335||AOCT|patients underwent AOCT to treat large cystic OLTs (\>10mm)
62012876|NCT06532656|EXPERIMENTAL|Cohort 1: Participants Aged ≥ 12 to < 18 years with Weight ≥ 35 kg: BIC/LEN 75/50 mg FDC|"Participants will receive a 2-day oral loading dose of LEN (600 mg) on Days 1 and 2 and daily oral BIC/LEN 75/50 mg starting on Day 1 through Week 48.~Following Week 48, participants will have an option to continue BIC/LEN in the extension period."
62012877|NCT06532656|EXPERIMENTAL|Cohort 2: Participants Aged ≥ 6 to < 12 years with Weight ≥ 25 kg to < 35 kg|"All participants will receive a 2-day oral loading dose of LEN, and daily oral BIC and LEN dose starting on Day 1 through Week 48. Dose in cohort 2 to be defined.~Following Week 48, participants will have an option to continue BIC/LEN in the extension period."
62578530|NCT02402959||Cohort 10|Based on the tenth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
62578531|NCT01914614||Working Poor Survivors|Low Wage workers
62012878|NCT06532656|EXPERIMENTAL|Cohort 3: Participants Aged ≥ 2 to < 6 years with Weight ≥ 10 kg to < 25 kg|"All participants will receive a 2-day oral loading dose of LEN, and daily oral BIC and LEN dose starting on Day 1 through Week 48. Dose in cohort 3 to be defined.~Following Week 48, participants will have an option to continue BIC/LEN in the extension period."
62012879|NCT03652103|NO_INTERVENTION|GCont|Only dressing will be applied to patients without actually nerve catheter performed
62012880|NCT03652103|EXPERIMENTAL|GBlock|"Ultrasound Guided Erector Spinae Plane Block Catheter will be applied: 20ml Bupivacaine 0.25% Injectable Solution\* will be administered initially.~20 ml Bupivacaine %0.25 Injectable Solution\*\* will be administered 30 minutes before ambulation at postoperative day(POD) 0 and before removal of nephrostomy at POD 2~\*10ml %0,5 Bupivacaine will be diluted with 10ml Saline solution."
62012881|NCT02630771||PDAP only|Persistent dentoalveolar pain disorder patients who do not fit criteria for TMD. Pressure pain threshold before/during conditioned pain modulation.
62012882|NCT02630771||PDAP + TMD|Persistent dentoalveolar pain disorder patients who also fit criteria for TMD. Pressure pain threshold before/during conditioned pain modulation.
62012883|NCT02630771||Painfree controls|Painfree subjects. Pressure pain threshold before/during conditioned pain modulation.
62012884|NCT01108744|ACTIVE_COMPARATOR|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
62012885|NCT01108744|ACTIVE_COMPARATOR|Mannitol|20% mannitol, dosed by patient's ideal body weight
62012886|NCT03193294|ACTIVE_COMPARATOR|Intervention group (coronary function test results disclosed)|In the intervention group, coronary function tests are measured and disclosed to the attending clinician permitting re-evaluation of the initial diagnosis and treatment as compared with initial angiography-guided decisions. The intervention involves measurement of CFR, IMR and RRR in a target, major coronary artery followed by coronary reactivity testing using incremental doses of acetylcholine (10-4M, 10-5M, 10-6M) to assess endothelial function, bolus infusion of ACh (10-4M) for vasospasm provocation testing, followed by administration of a bolus dose (300 micrograms) of glyceryl trinitrate. Endotypes are identified based on established criteria for abnormalities in coronary vasodilator function, vasospasm and microvascular resistance. The endotypes (diagnostic strata) are: obstructive CAD, coronary artery spasm, microvascular angina, endothelial dysfunction (no angina), normal (non-cardiac). A diagnosis may be ruled-in or ruled-out based on the test results.
62012887|NCT03193294|SHAM_COMPARATOR|Usual care group (coronary function results not disclosed)|Coronary function tests are measured but not disclosed to the attending clinician or the participant. The same coronary function tests are undertaken as in the intervention group. Masking is achieved by obscuring the catheter laboratory monitors from the attending clinician and participant. The effectiveness of masking is prospectively monitored.
62012888|NCT04331327|ACTIVE_COMPARATOR|Allogenic lyophilized growth factors|Two doses of intra-articular knee injections of lyophilized growth factors were received one dose at the baseline and the other was after 2 months.
62012889|NCT04331327|NO_INTERVENTION|Standard of care|The patients were kept on their traditional medications without any intervention
62012890|NCT03882619|EXPERIMENTAL|Calligraphy group|
62012891|NCT03882619|NO_INTERVENTION|Treatment-as-usual group|
62578532|NCT01914614||Non-Working Poor Survivors|Higher-Wage Salary Workers
62012892|NCT00129415|EXPERIMENTAL|UVA1 Irradiation|UVA 1 Irradiation (Sellemed UVA1 light source) up to 130 J/cm2
62012893|NCT00129415|EXPERIMENTAL|UVB Irridiation|UVB Irradiation maximum dose of 4000 mJ/cm2
62012894|NCT01049880|EXPERIMENTAL|Ascorbate|
62012895|NCT06183229|EXPERIMENTAL|Cycloferon|Intake of Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.
62012896|NCT06183229|PLACEBO_COMPARATOR|Placebo|Intake of Placebo, 4 tablets per day, on days 1, 2, 4, 6 and 8.
62012897|NCT02197546|OTHER|acupuncture plus local anesthesia|Bilateral acupuncture with 1.5 mm long indwelling fixed needles
62012898|NCT02197546|NO_INTERVENTION|Local anesthesia alone|Standard therapy - local anesthesia alone without acupuncture
62012899|NCT04849949|ACTIVE_COMPARATOR|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
62012900|NCT04849949|EXPERIMENTAL|Black walnut|Participants in this group received a muffin in which part of the butter was substituted out for black walnuts.
62012901|NCT04849949|EXPERIMENTAL|English Walnut|Participants in this group received a muffin in which part of the butter was substituted out for English walnuts.
62410065|NCT03949764|EXPERIMENTAL|HCV Positive Study Participants|Study participants will be administered a standard 12-week course of sofosbuvir/velpatasvir (Epclusa®).
62578533|NCT04736277||Noncardiac surgery|Documentation of HbA1c in patients undergoing noncardiac surgery under general anesthesia
62200812|NCT04143711|EXPERIMENTAL|Combination Therapy with DF1001 and Nivolumab Expansion in Urothelial Bladder Cancer|Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with urothelial bladder cancer using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.
62215050|NCT04713891|EXPERIMENTAL|Phase Ib, Cohort 1|KF-0210 (dose RP2D-2, orally once daily)+ Atezolizumab (1200 mg every 3 weeks) continuously until disease progression/recurrence or death from any cause, or serious adverse events (SAE) observed (whichever occurs earlier) for up to 2 years.
62578534|NCT02439814|EXPERIMENTAL|Pregnenolone|
62578535|NCT02439814|PLACEBO_COMPARATOR|Placebo|
62578536|NCT03861988|EXPERIMENTAL|Open label ketamine|Patients will receive an intravenous ketamine infusion during surgery.
62578537|NCT03861988|EXPERIMENTAL|Double blind ketamine|Patients will receive an intravenous ketamine infusion during surgery.
62578538|NCT03861988|PLACEBO_COMPARATOR|Double blind placebo|Participants will receive placebo (normal saline infusion) during surgery.
62578539|NCT01692379|EXPERIMENTAL|Endovascular treatment|Mechanical embolectomy with Solitaire FR device
62578540|NCT01692379|ACTIVE_COMPARATOR|Medical treatment|Medical treatment (standard of care in acute ischemic stroke)including intravenous thrombolysis
62578541|NCT05356013|PLACEBO_COMPARATOR|Placebo|All subjects who are randomized to Placebo will receive an identical placebo pill to the experimental drug starting the first week of the study. Subjects will be seen every two weeks for 8 weeks. After study conclusion (week 8), the dose will be discontinued.
62578542|NCT05356013|EXPERIMENTAL|Caplyta|All subjects who are randomized to Caplyta will receive 42mg/day starting the first week of the study. Subjects will be seen every two weeks for 8 weeks. Dosage changes and reductions will not be permitted. After study conclusion (week 8), the dose will be discontinued.
62578543|NCT04112043|ACTIVE_COMPARATOR|NR plus Walking Exercise|1,000 mg/day of NR combined with three days/week of supervised, center-based walking exercise (n=18)
62578544|NCT04112043|ACTIVE_COMPARATOR|Walking Exercise plus Placebo|1,000 mg/day of Placebo combined with three days/week of supervised, center-based walking exercise (n=18)
62578545|NCT04112043|ACTIVE_COMPARATOR|NR Alone|1,000 mg/day of NR
62578546|NCT05921643||patient with cholesteatoma who has never been operated on|All patients will benefit from surgical management for a first stage cholesteatoma in the operating room under general anesthesia. The surgical technique (closed technique) is the reference technique for the management of cholesteatoma in adults. It involves a cartilaginous removal to reconstruct the attical region. Then a filling material is used to fill the mastoid (GlassBONE™ or Bonalive™), and above all to stabilize the cartilaginous fragment to prevent a recurrence. The mastoid filler used is left to the discretion and habits of the surgeon.
62578547|NCT02598531||Test Arm|Test Arm participants will be enrolled in the standard of care bariatric surgery program and will undergo surgical weight loss through Laparoscopic Sleeve Gastrectomy or Laparoscopic Gastric Bypass. Approximately 9-13 months post surgery, each participant will be evaluated to determine if he/she is still eligible for a total knee replacement or if their need has been removed. If still eligible, participants will be enrolled in the standard of care TKA program and will undergo a TKA procedure. Participants will complete nine (9) research visits over 3.5-4 years.
62200813|NCT04143711|EXPERIMENTAL|Monotherapy DF1001 Expansion in Metastatic Breast Cancer (HER2 High)|Monotherapy expansion cohort enrolling up to 20 patients with metastatic breast cancer with documented high expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
62200814|NCT04143711|EXPERIMENTAL|Monotherapy DF1001 Expansion in NSCLC|Monotherapy expansion cohort enrolling up to 20 patients with non-small cell lung cancer with documented erbb2 amplification using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
62200815|NCT04143711|EXPERIMENTAL|Combination Therapy with DF1001 and Nivolumab Expansion in NSCLC|Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with non-small cell lung cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.
62200816|NCT04143711|EXPERIMENTAL|Monotherapy DF1001 Expansion in Gastric Cancer|Monotherapy expansion cohort enrolling up to 20 patients with gastric cancer with documented high expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
62200817|NCT04143711|EXPERIMENTAL|Combination Therapy with DF1001 and Nivolumab Expansion in Gastric Cancer|Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with gastric cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.
62200818|NCT04143711|EXPERIMENTAL|Monotherapy DF1001 Expansion in Esophageal Cancer|Monotherapy expansion cohort enrolling up to 20 patients with esophageal cancer with documented high expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
62200819|NCT04143711|EXPERIMENTAL|Combination Therapy with DF1001 and Nivolumab Expansion in Esophageal Cancer|Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with esophageal cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.
62200820|NCT04143711|EXPERIMENTAL|Monotherapy DF1001 Exploratory Efficacy Expansion in NSCLC|Monotherapy expansion cohort enrolling up to 20 patients with non-small cell lung cancer with documentation of HER2 activation.
62200821|NCT04143711|EXPERIMENTAL|Combo Therapy with DF1001 and Sacituzumab Govitecan-hziy Exploratory Efficacy Expansion in NSCLC|Combination therapy with DF1001 and sacituzumab govitecan-hziy cohort enrolling up to 20 patients, including safety lead-in, with non-small cell lung cancer with documentation of HER2 activation.
62200822|NCT04143711|EXPERIMENTAL|Monotherapy DF1001 Exploratory Efficacy Expansion in Metastatic Breast Cancer (HR+/HER2-)|Monotherapy expansion cohort enrolling up to 20 patients with metastatic breast cancer with documentation of HR positive and HER2 negative expression.
62200823|NCT04143711|EXPERIMENTAL|DF1001 with Sacituzumab Govitecan-hziy Exploratory Efficacy Expansion in Breast Cancer (HER2+)|Combination therapy with DF1001 and sacituzumab govitecan-hziy cohort enrolling up to 40 patients, including safety lead-in, with metastatic breast cancer with documentation of HER2 positive expression.
62200824|NCT04143711|EXPERIMENTAL|DF1001 with Sacituzumab Govitecan-hziy Exploratory Efficacy Expansion in Breast Cancer (HR+/HER2-)|Combination therapy with DF1001 and sacituzumab govitecan-hziy cohort enrolling up to 40 patients, including safety lead-in, with metastatic breast cancer with documentation of HR positive and HER2 negative expression.
62410066|NCT03949764|NO_INTERVENTION|Control (Pike County)|After completion of the study, we will compare HCV incidence and prevalence rates in Perry County (intervention) and Pike County (control). This will be measured through data provided by the local health departments of each county. Confidential Hepatitis C screening will be conducted in some cases, and resources will be provided to those testing positive but they will not receive treatment as part of this study.
62784779|NCT00416455|EXPERIMENTAL|Treatment (diagnostic scans, surgery, chemotherapy, radiation)|Patients receive fludeoxyglucose F 18 (FDG) IV followed 60 minutes later by positron emission tomography (PET)/CT scanning on day 1. Patients also receive ferumoxtran-10 IV over 30-45 minutes on day 1 (or 24-36 hours before MRI) and undergo MRI on day 2. Patients undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy with pelvic and abdominal lymph node biopsy within 2 weeks after PET/CT scan. Patients diagnosed with metastatic disease prior to lymph node biopsy proceed directly to primary treatment. Patients with cervical cancer undergo chemoradiotherapy within 4 weeks of PET/CT scan.
62784780|NCT02699710|EXPERIMENTAL|Part 1: GDC-0853, Rabeprazole (Fasting State)|Participants will receive single dose of GDC-0853 (200 milligrams \[mg\]) in a crossover design as either the capsule or tablet formulation in the fasted state with the final fixed treatment consisting of the tablet formulation administered in the fasted state after prior administration of rabeprazole (20 mg twice daily \[BID\]) for 3 days.
62200825|NCT03507907|EXPERIMENTAL|Study Group|Mulligan mobilization techniques were applied to the older adults.
62200826|NCT03507907|OTHER|Control Group|Conventional physiotherapy programs were applied to the older adults who included in control group.
62200827|NCT05223075|EXPERIMENTAL|articaine group|
62200828|NCT05223075|EXPERIMENTAL|lidocaine group|
62200829|NCT01076777|EXPERIMENTAL|Physical exercise|Manualised Exercise performed in groups (5-8 participants per group). 3 sessions (á 60 minutes) per week for 12 consecutive weeks
62200830|NCT01076777|ACTIVE_COMPARATOR|Cognitive-behavioral therapy|Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
62200831|NCT01445041|EXPERIMENTAL|Single infusion of UCB|(autologous red blood cell and volume reduced cord blood cells)
62200832|NCT01445041|EXPERIMENTAL|Three infusions of UCB|(autologous red blood cell and volume reduced cord blood cells)
62410067|NCT02493023|EXPERIMENTAL|navigated bronchoscopy|
62578548|NCT02598531||Control Arm|Control Arm participants will be enrolled in the standard of care TKA program and complete six (6) research visits over 2.5-3 years. This group of participants will undergo a TKA procedure without any surgical weight loss intervention.
62578549|NCT01984632|EXPERIMENTAL|Single-port laparoscopic myomectomy|We will use barbed suture (V-Loc) under intervention of single-port laparoscopic myomectomy
62578550|NCT01984632|ACTIVE_COMPARATOR|Multi-port laparoscopic myomectomy|We will use barbed suture(V-Loc) under intervention of multi-port laparoscopic myomectomy.
62578551|NCT03857386||PECS group|Preoperative bilateral PECS I + PECS II Pecs block performed by anaesthetist using ultrasound guidance in plane approach
62578552|NCT03857386||Control group|Bilateral local anesthesia infiltration Local infiltration anesthesia performed by surgeon during the operation
62012902|NCT06259565|EXPERIMENTAL|Dexmedetomidine Intervention|"Dexmedetomidine (Dex) is an α2-adrenergic agonist sedative commonly used in IMV that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and reduces delirium.~Patients randomized to the experimental arm will receive dexmedetomidine. At initiation, a bolus will NOT be administered. In keeping with Health Canada Guidelines, we will start the infusion at a mid-range dose of 0.5mcg/kg/h with titration either up or down by 0.1mcg/kg/h every 20-30 minutes to a maximum rate of 1.2mcg/kg/h to maintain light sedation (RASS = -2 to +1 or SAS 3-4). Each bag will be composed of composed of dexmedetomidine 4mcg/mL(in 0.9% sodium chloride) prepared as a volume of 100mL and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans."
62012903|NCT06259565|PLACEBO_COMPARATOR|Placebo Control|Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 100mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans
62012904|NCT06662669|EXPERIMENTAL|GroupA (YL-13027+AG )|YL-13027: 180mg BID PO Nab-paclitaxel: 125mg/m2, ivgtt, D1、D8、D15 Q4W Gemcitabine: 1000mg/m2, ivgtt, D1、D8、D15 Q4W
62200833|NCT05899803|EXPERIMENTAL|Using Walker Group|Children who used baby walkers during childhood were included in this group. All assessment procedures were then performed.
62401740|NCT04479774|EXPERIMENTAL|Experimental Group (Group A)|"Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment and on the basis of functional ambulation scale 3,4 and 5 subjects were included, along with this the subjects of age group between 40-60 having ability to understand and follow instructions were included in study.~Results were obtained by using gait parameters including walk speed, cadence, step rate, stride length The tinetti POMA scale was utilized to record changes post treatment in gait , the weight bearing was recorded using Camry ZT-160 analog weight scale At the end of every week results were obtained."
62410068|NCT01035229|EXPERIMENTAL|Everolimus + Best Supportice Care (BSC)|Patients were assigned to the Everolimus + BSC arm in a ratio of 2:1 over the Placebo arm. Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the investigational drug. In addition to taking Everolimus, all patients also received BSC as per normal local practice.
62578553|NCT03484663|EXPERIMENTAL|Small catheter with chest tube after uniport vats|Insertion of small catheter drainage in the same opening with chest tube after uniport vats
62578554|NCT03484663|NO_INTERVENTION|Chest tube only after uniport vats|After uniport vats we put chest tube only
62578555|NCT02173665|EXPERIMENTAL|BI 1356 BS - Powder in bottle (PIB)|
62578556|NCT02173665|EXPERIMENTAL|BI 1356 BS - Tablet|
62578557|NCT02173665|ACTIVE_COMPARATOR|Placebo|
62578558|NCT00401024|EXPERIMENTAL|Treatment|Imatinib mesylate 600mg orally once a day for seven consecutive days prior to surgery with last dose taken one day prior to surgery
62578559|NCT05464056|EXPERIMENTAL|BUILT Study|One group receives the intervention.
62578560|NCT05393856|EXPERIMENTAL|fed state in PART B|
62578561|NCT05393856|EXPERIMENTAL|fasted state in PART B|
62578562|NCT02528539|EXPERIMENTAL|ITP (Integrative Thearpy Program)|"This ITP intervention consists of two distinct phases, Phase I, the active treatment phase and Phase II, the follow-up phase.~Phase I (Intervention phase) begins post-operatively in 4-6 weeks with a baseline visit that includes 30-minute acupuncture treatment, followed by the 30-minute self-management educational session, and the participants will return weekly for 10 weeks.~Phase II (Follow up phase) begins at month 6 and ends at month 18 from the surgery. The phase II consists of 1-hour quarterly ITP therapy at months 6, 9, 12, 15, and 18 and monthly telephone visits between ITP therapies at months 7, 8, 10, 11, 13, 14, 16, and 17. Self-management reinforcement and support will be implemented during telephone follow up visits"
62578563|NCT02915900|EXPERIMENTAL|Intervention|Hormone dosage is calculated by using the new method Gonadotropin removal test.
62200834|NCT05899803|ACTIVE_COMPARATOR|Walker-Free Group|Children who did not use a baby walker during childhood were included in this group. All assessment procedures were then performed.
62200835|NCT02894970||Healthy adults|Healthy adults for checking feasibility of Pulmonary PPG
62578564|NCT02915900|ACTIVE_COMPARATOR|Routine IVF method|Hormone dosage is chosen by the clinician according to standard clinical routine.
62578565|NCT04550689|ACTIVE_COMPARATOR|Xenograft|
62578566|NCT04550689|ACTIVE_COMPARATOR|Allograft|
62200836|NCT02894970||Healthy children|Healthy children for checking feasibility of Pulmonary PPG
62200837|NCT02894970||Healthy neonates|Healthy neonates for checking feasibility of Pulmonary PPG and in order to be a control group for neonates with pulmonary hypertension.
62578567|NCT03824795|ACTIVE_COMPARATOR|Group 1: 125mg b.i.d. for 10 days|Patients will be administered an oral dose of 125mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
62578568|NCT03824795|ACTIVE_COMPARATOR|Group 2: 250mg b.i.d. for 10 days|Patients will be administered an oral dose of 250mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
62784781|NCT02699710|EXPERIMENTAL|Part 2: GDC-0853, Rabeprazole (Fasting or Fed State)|Participants will receive single dose of GDC-0853 (200 mg) tablet formulation in the fasted or fed state in a crossover design with the final fixed treatment consisting of the tablet formulation administered in the fed state after prior administration of rabeprazole (20 mg BID) for 3 days.
62200838|NCT02894970||Healthy preterm neonates|Healthy preterm neonates for checking feasibility of Pulmonary PPG and in order to be a control group for premature neonates with patent ductus arteriosus (PDA).
62200839|NCT02894970||Preterm neonates with PDA|Preterm neonates with hemodynamic significant PDA. Intervention: evaluate Pulmonary PPG and oxygen saturation as compared to normal newborns.
62200840|NCT02894970||Neonates with pulmonary hypertension|Neonates with pulmonary hypertension. Intervention: evaluate Pulmonary PPG and oxygen saturation as compared to normal newborns.
62200841|NCT02229851|EXPERIMENTAL|NNC0195-0092 (somapacitan)|
62200842|NCT02229851|ACTIVE_COMPARATOR|Daily hGH|
62200843|NCT02229851|PLACEBO_COMPARATOR|Placebo|Switch to NNC0195-0092 (somapacitan) treatment in the extension period.
62200844|NCT05986045||Cohort 1|Newborn infants diagnosed with Cystic Fibrosis at newborn screening
62200845|NCT05986045||Cohort 2|Children with previous diagnosis of Cystic Fibrosis up to 5 years of age
62200846|NCT05986045||Control|Newborn infants without cystic fibrosis
62200847|NCT02102438|EXPERIMENTAL|Trastuzumab and weekly chemotherapy|"Treatment schedule Weekly paclitaxel and Carboplatin at 80mg/m2 and Area under the curve (AUC) of 2, respectively. Weekly trastuzumab will be combined with chemotherapy (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg). Chemotherapy will be given at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.~After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles."
62200848|NCT00477490|PLACEBO_COMPARATOR|Placebo|Participants took a placebo 'melt' for 28 days to complete part 1 of the study. In part 2, placebo patients were randomized to one of the other 4 treatment arms based on assignments predetermined at the initial randomization, to receive active desmopressin melt for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
62200849|NCT00477490|EXPERIMENTAL|desmopressin melt 10 μg|Participants took desmopressin melt 10 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
62200850|NCT00477490|EXPERIMENTAL|desmopressin melt 25 μg|Participants took desmopressin melt 25 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
62200851|NCT00477490|EXPERIMENTAL|desmopressin melt 50 μg|Participants took desmopressin melt 50 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
62200852|NCT00477490|EXPERIMENTAL|desmopressin melt 100 μg|Participants will take desmopressin melt 100 μg for 28 days to complete part 1 of the study. Participants will continue on this dose in part 2 of the study for between 1-6 months (until the database for part 1 is locked and treatment is unblinded).
62200853|NCT02448329|EXPERIMENTAL|AZD1775 in Combination With Paclitaxel|AZD1775 225 mg BID q 12 hours (x 5 doses, 2.5 days) administered days 1\~3 Weekly paclitaxel 80 mg/m2 IV on 1, 8 and 15 of a four week l cycle is an widely used dose of paclitaxel given on this schedule in gastric adenocarcinoma patients as second-line therapy.
62200854|NCT06306469|EXPERIMENTAL|single Arm1|All practitioners had undertaken formal training on Pranic Healing, Meditation on Twin Hearts, and higher meditation practices at least six months prior to the retreat. Daily retreat practices, which lasted typically for 16-18 hours with occasional short breaks. These practices included combinations of specifically designed physical and breathing exercises to improve the energetic states and stillness. Exercises were followed by Pranic Healing and self-awareness practices. Meditations included Meditation on Twin Hearts, Arhatic Yoga meditations of Kundalini meditation, Arhatic Dhyan and Meditation on the Higher Soul .
62200855|NCT03935256|EXPERIMENTAL|Full Dose Chemo, Reduced Dose Chemo + RT, Full Dose Chemo|Week 1 : Cycle 1: Full Dose Carboplatin and Paclitaxel Week 4: Pelvic Radiotherapy Begins Cycle 2: Dose reduced Carboplatin and Paclitaxel Week 7 : Cycle 3: Dose reduced Carboplatin and Paclitaxel Weeks 10,13,16: Cycle 4-6: Full Dose Carboplatin and Paclitaxel
62200856|NCT01734733|EXPERIMENTAL|NTCELL|"NTCELL 40 microcapsules (+/- 20%)~The NTCELL microcapsules are drawn up into a catheter system and introduced intracranially by stereotactic insertion into the brain under guidance by neuroimaging."
62200857|NCT01626144||Breast cancer, exemestane treatment|Breast cancer patients receiving standard of care exemestane
62200858|NCT00981877|ACTIVE_COMPARATOR|1|This group will receive S. Boulardii Probiotic and Oral rehydration as needed
62200859|NCT00981877|ACTIVE_COMPARATOR|2|This group will receive a mixed Probiotic preparation and oral rehydration as needed
62200860|NCT00981877|PLACEBO_COMPARATOR|3|This group will receive a placebo, and oral rehydration as needed
62200861|NCT01254747|EXPERIMENTAL|Delefilcon A|Delefilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
62200862|NCT01254747|ACTIVE_COMPARATOR|Lotrafilcon B|Lotrafilcon B contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
62200863|NCT01254747|ACTIVE_COMPARATOR|Nelfilcon A|Nelfilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
62200864|NCT01254747|ACTIVE_COMPARATOR|Narafilcon A|Narafilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
62200865|NCT01883102|EXPERIMENTAL|Capsaicin 0.1%|Capsaicin cream 0.1% will be applied to site A or B on the subject's abdomen daily for 7 days.
62200866|NCT01883102|PLACEBO_COMPARATOR|Placebo/cream without 0.1% capsaicin|The placebo cream will be applied to site A or B on the subject's abdomen daily for 7 days.
62200867|NCT05889767|ACTIVE_COMPARATOR|Normal weight and low body fat percent|The low risk comparator group for this study will consist of individuals with normal BMI (18.5 - 24.9 kg/m2) and body fat percent \< 25% (male) or \< 35% (female).
62200868|NCT05889767|EXPERIMENTAL|Normal-weight obesity|Individuals with normal-weight obesity will be defined as having normal BMI (18.5 - 24.9 kg/m2), body fat percent \> 25% (male) or \> 35% (female).
62578569|NCT03824795|ACTIVE_COMPARATOR|Group 3: 500mg b.i.d. for 10 days|Patients will be administered an oral dose of 500mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
62012905|NCT06662669|EXPERIMENTAL|Group B (HY-0102+AG )|HY-0102: 10mg , ivgtt, D1、D15 Q4W Nab-paclitaxel: 125mg/m2, ivgtt, D1、D8、D15 Q4W Gemcitabine: 1000mg/m2, ivgtt, D1、D8、D15 Q4W
62012906|NCT06662669|EXPERIMENTAL|Group C (YL-13027+HY-0102+AG)|YL-13027: 180mg BID PO HY-0102: 10mg , ivgtt, D1、D15 Q4W Nab-paclitaxel: 125mg/m2, ivgtt, D1、D8、D15 Q4W Gemcitabine: 1000mg/m2, ivgtt, D1、D8、D15 Q4W
62012907|NCT06662669|ACTIVE_COMPARATOR|Group D (AG)|Nab-paclitaxel: 125mg/m2, ivgtt, D1、D8、D15 Q4W Gemcitabine: 1000mg/m2, ivgtt, D1、D8、D15 Q4W
62200869|NCT05889767|ACTIVE_COMPARATOR|Overt obesity and high body fat percent|Overt obesity (BMI \> 30 kg/m2) with high body fat percent (\> 25% \[male\] or \> 35% \[female\]) will be used as a high-risk comparator group.
62200870|NCT01236378|EXPERIMENTAL|sirolimus|Subjects must be taking sirolimus (1 mg tablet formulation) with or without concomitant medications, unless specifically excluded below, for prophylaxis of renal rejection.
62578570|NCT01393028|EXPERIMENTAL|Cardiac CT|Cardiac CT (CT calcium and/or CT angiography), followed by stress testing, invasive angiography or neither depending on the CT scan result
62578571|NCT01393028|OTHER|Standard care|Standard diagnostic management, including stress testing and/or invasive angiography
62578572|NCT05518240||Acute ischemic stroke (AIS)|Patients who experienced acute ischemic stroke (AIS), eligible for restoration of blood flow using a Solitaire or Embotrap device to remove thrombus from the neurovasculature
62578573|NCT01593267|ACTIVE_COMPARATOR|Endovascular|Subjects randomized to endovascular coil embolization will be treated by one of two neurosurgeons expert in such treatment. All endovascular coil embolization treatments will be accomplished using accepted techniques.
62578574|NCT01593267|ACTIVE_COMPARATOR|Surgical|Subjects randomized to surgical clip occlusion repair will receive treatment from one of two neurosurgeons expert in clip occlusion surgery for ruptured aneurysms.
62578575|NCT03554278||Anemia|Stool samples from infants with anemia. Severe anemia defined as hematocrit less than 25%. Anemia defined as hematocrit greater than or equal to 25% and less than 30%.
62578576|NCT03554278||No Anemia|Stool samples from infants without anemia. No anemia defined as hematocrit equal to or greater than 30%.
62578577|NCT03442608|EXPERIMENTAL|mild hypothermia|Device: Zoll 2000 and/or CureWrap 3500 cooling system,lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
62200871|NCT05215964||TAE arm|Patients will receive TAE
62578578|NCT03442608|PLACEBO_COMPARATOR|northermia|normal physical cooling methods,like ice bag, conditionally required.
62012908|NCT02839434||Treated with oral anticoagulants|Ex vivo study using blood samples from patients treated with oral anticoagulant (direct oral anticoagulants or AVK) at curative dose, taken in the usual cardiac monitoring.
62012909|NCT02367313|PLACEBO_COMPARATOR|Placebo|Placebo
62012910|NCT02367313|ACTIVE_COMPARATOR|Vapendavir 264 mg|Vapendavir 264 mg and matching placebo
62012911|NCT02367313|ACTIVE_COMPARATOR|Vapendavir 528 mg|Vapendavir 528 mg and matching placebo
62012912|NCT03311074|EXPERIMENTAL|Strimvelis treatment receivers|Approximately 15 subjects with ADA-SCID who were previously received Strimvelis will be included in the analysis and a total of 5 blood samples will be collected from each subject at approximately annual interval.
62012913|NCT04158401||Control group|Pregnant patients between 12w0d and 22w0d who present for prenatal care.
62200872|NCT01724034|EXPERIMENTAL|Daily Lung Ultrasound|"If there is no lung sliding - evaluation for pneumothorax or mainstream intubation.~If lung ultrasound shows normal pattern - search for reversible airway obstruction or venous embolism. If the patient has COPD, non invasive ventilation must be used as mode of discontinuing mechanical ventilation.~If lung ultrasound shows intersticial syndrome - evaluate the need to negativate hydric balance before the next spontaneous breathing trial.~If findings are asymmetrical - search for new or uncontrolled infection. If there is simple pleural effusion - researchers should determine a negativation of hydric balance or perform thoracocentesis.~If there are signs of complicated pleural effusion - a new image technique should be performed as evaluated by the surgical team."
62578579|NCT00570141|ACTIVE_COMPARATOR|OASIS Wound Matrix (Oasis)|This is a single arm study with only the test article Oasis used on all subjects
62578580|NCT00322231|EXPERIMENTAL|ZOSTAVAX™ / Placebo|Zoster vaccine live on Day 1 (Period 1), placebo on Week 4 (Period 2)
62200873|NCT01724034|NO_INTERVENTION|Control Group|
62578581|NCT00322231|EXPERIMENTAL|Placebo / ZOSTAVAX™|Placebo on Day 1 (Period 1), zoster vaccine live on Week 4 (Period 2)
62578582|NCT02667613|EXPERIMENTAL|HABIT-ILE|HABIT-ILE (Hand and arm bimanual intensive therapy including lower extremities) will be applied over 2 weeks.
62578583|NCT02667613|ACTIVE_COMPARATOR|Control|A two weeks period of usual customary care.
62401741|NCT04479774|OTHER|Control group: (Group B)|"Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment and on the basis of functional ambulation scale 3,4 and 5 subjects were included, along with this the subjects of age group between 40-60 having ability to understand and follow instructions were included in study.~Results were obtained by using gait parameters including walk speed, cadence, step rate, stride length The tinetti POMA scale was utilized to record changes post treatment in gait , the weight bearing was recorded using Camry ZT-160 analog weight scale At the end of every week results were obtained."
62578584|NCT06685250|EXPERIMENTAL|Pressure 8 mmHg|
62012914|NCT04158401||Cerclage group A|Patients who present for a history-indicated cerclage placement.
62200874|NCT00518895|EXPERIMENTAL|A|Dacarbazine with Genasense
62578585|NCT06685250|ACTIVE_COMPARATOR|Pressure 14 mmHg|
62578586|NCT02664129|EXPERIMENTAL|Experimental group with video|30 patients will watch the video of them in acute decompensation phase
62578587|NCT02664129|SHAM_COMPARATOR|Control group without video|30 patients will not watch the video of them in acute decompensation phase, they pass a standard interview with psychometric scales
62578588|NCT06244511|ACTIVE_COMPARATOR|Early Bipedal Exercise|Individuals with a diagnosis of chronic ankle instability who underwent supervised exercise under the guidance of a physiotherapist for 8 weeks, 2 days a week.
62578589|NCT06244511|ACTIVE_COMPARATOR|Late Bipedal Exercise|Individuals with a diagnosis of chronic ankle instability who underwent supervised exercise under the guidance of a physiotherapist for 8 weeks, 2 days a week.
62401742|NCT05181501|EXPERIMENTAL|CT103A in Newly Diagnosed Subjects With High-risk Multiple Myeloma|Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection（CT103A）will be infused at 1.0 x 10\^6 CAR+ T cells/kg in newly diagnosed subjects with high-risk multiple myeloma
62401743|NCT01945034|EXPERIMENTAL|Topical IBU twice daily|
62012915|NCT04158401||Cerclage group B|Patients who present for an ultrasound-indicated cerclage placement.
62012916|NCT04158401||Cerclage group C|Patients who present for an exam-indicated cerclage placement.
62012917|NCT04528563|EXPERIMENTAL|Ketorolac Tromethamine|IV ketorolac tromethamine, 0.5 mg/kg to a maximum of 30 mg plus IV morphine placebo;
62578590|NCT05676463|EXPERIMENTAL|Treatment (MRI-guided IMRT, ADT)|Patients undergo MRI-guided IMRT on study and receive SOC ADT throughout the trial. Patients may also undergo PSMA PET, CT, MRI, and bone scans at screening and undergo collection of blood samples throughout the trial.
62578591|NCT03134573||Multiple Sclerosis|Women and men in Germany with the diagnosis of MS that are treated with Betaferon and use the myBETAapp
62200875|NCT00518895|ACTIVE_COMPARATOR|B|Dacarbazine with placebo
62578592|NCT00627965|EXPERIMENTAL|1|Sildenafil citrate
62578593|NCT00627965|PLACEBO_COMPARATOR|2|Placebo
62578594|NCT05423496|ACTIVE_COMPARATOR|Steroid Control Arm|133 patient undergoing KidneyCare Surveillance with Immune optimization at clinician discretion
62578595|NCT05423496|EXPERIMENTAL|Steroid Immuno-optimization Arm|267 patient undergoing KidneyCare Surveillance with protocolized AlloSure-guided immuno-optimization of steroids/CNI
62200876|NCT02460575|EXPERIMENTAL|Lactobacillus|Active Product: Description Lactobacillus reuteri 17938 suspended in sunflower oil, medium chain triglyceride oil, silicone dioxide. Total viable count of L. reuteri 17938 1 x 108 CFU/5 drops.
62200877|NCT02460575|PLACEBO_COMPARATOR|Placebo|Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
62200878|NCT02076295||Parkinson's disease subjects|
62200879|NCT02076295||Normal control subjects|
62200880|NCT00785304||Traumatic Brain Injury|Active Duty military blast-related TBI patients
62401744|NCT01945034|PLACEBO_COMPARATOR|Placebo twice daily|
62401745|NCT01945034|EXPERIMENTAL|Topical IBU three times daily|
62401746|NCT01945034|PLACEBO_COMPARATOR|Placebo three times daily|
62401747|NCT00379821|EXPERIMENTAL|CQ Monotherapy|N=160: treat with Chloroquine (CQ) alone.
62401748|NCT00379821|EXPERIMENTAL|CQ plus atovaquone proguanil|N=160: treat with CQ plus atovaquone proguanil.
62401749|NCT00379821|EXPERIMENTAL|CQ plus artesunate|N=160: treat with CQ plus artesunate.
62401750|NCT00379821|EXPERIMENTAL|CQ plus azithromycin|N=160: treat with CQ plus azithromycin.
62578596|NCT05423496|ACTIVE_COMPARATOR|Tacrolimus and mycophenolate mofetil (MMF) Control Arm|133 patient undergoing KidneyCare Surveillance with Immune optimization at clinician discretion
62578597|NCT05423496|EXPERIMENTAL|MMF Immuno-optimization Arm|267 patient undergoing KidneyCare Surveillance with protocolized AlloSure-guided immuno-optimization of MMF/CNI
62578598|NCT03777592|ACTIVE_COMPARATOR|ESPB with local agent|ESPB will be performed using 20ml of 0.5% ropivacaine.
62578599|NCT03777592|SHAM_COMPARATOR|ESPB with saline|ESPB will be performed using 20ml of saline.
62578600|NCT03652220|EXPERIMENTAL|Intervention|"8 weeks Minimal treatment + MBLM 16 weeks Multimodal specific treatment + MBLM Consolidation~Definitions Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
62401751|NCT01727804|EXPERIMENTAL|Laser|
62401752|NCT01592526|EXPERIMENTAL|Untrained, healthy volunteers A|(Endotoxin) before (Endotoxin + Nicotine)
62401753|NCT01592526|EXPERIMENTAL|Well-trained healthy volunteers A|(Endotoxin) before (Endotoxin + Nicotine)
62200881|NCT00785304||Other Injury Control|Active duty military patients with other injuries but no TBI
62200882|NCT02628028|EXPERIMENTAL|Part A 5 mg LY3337641|Given once a day for 4 weeks.
62200883|NCT02628028|EXPERIMENTAL|Part A 10 mg LY3337641|Given once a day for 4 weeks.
62200884|NCT02628028|EXPERIMENTAL|Part A 30 mg LY3337641|Given once a day for 4 weeks.
62200885|NCT02628028|PLACEBO_COMPARATOR|Part A Placebo|Given once a day for 4 weeks.
62200886|NCT02628028|EXPERIMENTAL|Part B 5 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
62200887|NCT02628028|EXPERIMENTAL|Part B 10 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
62578601|NCT03652220|ACTIVE_COMPARATOR|Control I|"8 weeks Minimal treatment 16 weeks Multimodal specific treatment~Definitions Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
62578602|NCT03652220|ACTIVE_COMPARATOR|Control 2|"Definitions 24 weeks Multimodal specific treatment~Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
62200888|NCT02628028|EXPERIMENTAL|Part B 30 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
62200889|NCT02628028|PLACEBO_COMPARATOR|Part B Placebo|Given once a day for 12 weeks.
62200890|NCT03931759|ACTIVE_COMPARATOR|Diabetes mellitus|patients with diabetes mellitus
62200891|NCT03931759|NO_INTERVENTION|non-Diabetes mellitus|patients without diabetes mellitus
62578603|NCT02937220|EXPERIMENTAL|Monolithic zirconia crowns|New crown material to restore dental implants
62578604|NCT02937220|ACTIVE_COMPARATOR|metal ceramic crowns|conventional crown material for restoring dental implants
62578605|NCT06203041|EXPERIMENTAL|Lactating women|Subjects identified as having delivered an infant and lactating will receive Vitamin D3 for 28 days.
62578606|NCT06203041|NO_INTERVENTION|Breastfeeding Infants|No intervention will be administered.
62578607|NCT02312089|ACTIVE_COMPARATOR|GnRHa group|Luteal phase SC administration of a single dose (0.2 mg) of GnRHa (Triptorelin)
62578608|NCT02312089|NO_INTERVENTION|Control group|No GnRHa administration in luteal phase
62200892|NCT05951270|EXPERIMENTAL|Intervention|Twelve weeks of 1100 mg of apple polyphenol supplementation. At the start, middle and end of the study, several measurements will take place.
62200893|NCT05951270|PLACEBO_COMPARATOR|Control|Twelve weeks of 1100 mg of maltodextrin. This product is an enzymatically converted potato starch. The flavor and color will have a similar/identical appearance and taste as all mentioned antioxidants.
62200894|NCT03862677||Patients with (suspicion of) primary EOC|
62200895|NCT03862677||Patients with recurrent EOC|
62200896|NCT00561431|ACTIVE_COMPARATOR|1|Standard dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 20 ml/kg/hr
62200897|NCT00561431|EXPERIMENTAL|2|High dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 35 ml/kg/hr
62200898|NCT01538966|ACTIVE_COMPARATOR|High dose SRL + weekly Pegvisomant|"High dose of SRL monthly~* Octreotide LAR 30mg~* Lanreotide 120mg~Weekly Pegvisomant (40-120mg/week)"
62200899|NCT01538966|ACTIVE_COMPARATOR|Low dose SRL + daily Pegvisomant|"Low dose of SRL monthly~* Octreotide LAR 10mg~* Lanreotide 60mg~Daily Pegvisomant (15-60mg/day)"
62200900|NCT01538966|ACTIVE_COMPARATOR|Low dose SRL + weekly Pegvisomant|"Low dose of SRL monthly~* Octreotide LAR 10mg~* Lanreotide 60mg~Weekly Pegvisomant (40-120mg/week)"
62401754|NCT01592526|EXPERIMENTAL|Untrained, healthy volunteers B|(Endotoxin + Nicotine) before (Endotoxin)
62401755|NCT01592526|EXPERIMENTAL|Well-trained healthy volunteers B|(Endotoxin + Nicotine) before (Endotoxin)
62578609|NCT04511520|EXPERIMENTAL|Physical training|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of 6 months)
62200901|NCT02568397|EXPERIMENTAL|Dabigatran Etexilate|Single dose of dabigatran etexilate administered orally.
62578610|NCT04511520|EXPERIMENTAL|Trimetazidine|Treatment of trimetazidine in addition to standart therapy
62578611|NCT04511520|NO_INTERVENTION|Control|Standard follow-up at the participating heart center
62578612|NCT06409338|ACTIVE_COMPARATOR|Active Transcutaneous auricular vagus nerve stimulation|For Experimental Arm, active transcutaneous auricular vagus nerve stimulation, Patients underwent 14 consecutive daily sessions of taVNS.
62578613|NCT06409338|SHAM_COMPARATOR|Sham Transcutaneous auricular vagus nerve stimulation|For sham transcutaneous auricular vagus nerve stimulation arm, Sham Comparator, patients underwent 14 consecutive daily sessions of sham-taVNS (the electrodes were fixed at the the left earlobe).
62578614|NCT05234736|EXPERIMENTAL|CBL-514|All 10 participants enrolled in the study will receive a single course of treatment with CBL-514 800 mg (unit dose: 2.0 mg/cm\^2) on the abdomen (administered as multiple subcutaneous injections) on Day 1 only.
62012918|NCT04528563|ACTIVE_COMPARATOR|Morphine Sulfate|IV morphine 0.1 mg/kg to a maximum of 5 mg plus IV ketorolac placebo
62012919|NCT06155045|EXPERIMENTAL|Modified Carbo-dissection technique|The carbo-dissection technique is performed using an improvised instrument that combines an electrocautery pencil (ValleylabTM Force FX electrocautery Pencil, Covidien, USA) with a CO2 mister blower (PerfX® Heart Lung pack Blower/Mister Kit, B L Lifesciences, Noida, India) and the instruments are fixed together using silk ties.The electrocautery is used in the coagulation mode at a setting of 10 to 15. The C02 flow is set at 2 to 3 litres/minute. Saline flow is adjusted to a level that does not hinder the effective coagulation but still prevents drying and desiccation of the tissues. Following the dissection of LIMA by the techniques mentioned above, blood flow from the harvested LIMA for one whole minute was noted(1 min post division of LIMA). The operative time required for LIMA dissection was also noted and entered. Patient's s demographic data were also collected and entered.
62578615|NCT04489160|EXPERIMENTAL|C1-inhibitor|One dose 6000 IU C1-inhibitor intravenously
62578616|NCT04489160|PLACEBO_COMPARATOR|Placebo|0.9% saline
62200902|NCT02568397|EXPERIMENTAL|Lanabecestat and Dabigatran Etexilate|Single dose of lanabecestat administered orally once daily on Days 3 to 21. Single doses of dabigatran etexilate administered orally on Days 16 and 20 during the lanabecestat dosing.
62401756|NCT02717910|EXPERIMENTAL|Health game group|Participants in this arm will receive the health game intervention including both 20 minutes guided training session at school and 2 weeks free usage of the health game during free time.
62578617|NCT01644708||Overweight, obese adult patients|Patients following a self empowerment group will be included in the study
62578618|NCT06575075|EXPERIMENTAL|0.25 mg/kg RR-HNK|OCD patients in this arm will receive 0.25mg/kg of RR-HNK - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.
62578619|NCT06575075|EXPERIMENTAL|0.5 mg/kg RR-HNK|OCD patients in this arm will receive 0.5mg/kg of RR-HNK - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.
62578620|NCT06575075|PLACEBO_COMPARATOR|Placebo (Sterile Saline)|OCD patients in this arm will receive sterile saline - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.
62578621|NCT05393869|EXPERIMENTAL|AR-Quit|Participants view messages with absolute risk and quit statements
62012920|NCT06155045|ACTIVE_COMPARATOR|Conventional Arm|The conventional technique is performed using an electrocautery pencil (ValleylabTM Force FX electrocautery Pencil, Covidien, USA). The electrocautery is used in the coagulation mode at a setting of 10 to 15. Following the dissection of LIMA, blood flow from the harvested LIMA for one whole minute was noted(1 min post division of LIMA). The operative time required for LIMA dissection was also noted and entered. Patient's s demographic data were also collected and entered.
62012921|NCT00452335|EXPERIMENTAL|Lubiprostone 12 mcg QD|Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (\<6 years of age and able to swallow capsules) who are at least 12 kg body weight
62012922|NCT00452335|EXPERIMENTAL|Lubiprostone 12 mcg BID|Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight
62012923|NCT00452335|EXPERIMENTAL|Lubiprostone 24 mcg BID|Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight
62578622|NCT05393869|EXPERIMENTAL|AR-Switch|Participants view messages with absolute risk and switch statements
62578623|NCT05393869|EXPERIMENTAL|AR-Combination|Participants view messages with absolute risk and combination quit+switch statements
62578624|NCT05393869|EXPERIMENTAL|RR-Quit|Participants view messages with comparative risk and quit statements
62578625|NCT05393869|EXPERIMENTAL|RR-Switch|Participants view messages with comparative risk and switch statements
62578626|NCT05393869|EXPERIMENTAL|RR-Combination|Participants view messages with comparative risk and combination quit+switch statements
62578627|NCT05393869|OTHER|Control|Participants view FDA regulatory messages
62578628|NCT05248373|EXPERIMENTAL|rAd26 single administration|
62578629|NCT05248373|EXPERIMENTAL|rAd5 single administration|
62578630|NCT05248373|EXPERIMENTAL|prime-boost regimen with rAd26 followed rAd5 administration|
62578631|NCT05248373|PLACEBO_COMPARATOR|placebo|
62012924|NCT05551364|NO_INTERVENTION|Conventional Treatment|The children will continue with their current rehabilitation program
62200903|NCT02573389|NO_INTERVENTION|"Retrospective and prospective non-stented"|Non-stented patients undergoing distal pancreatectomy retrospectively (2008-2015) and prospectively from 2015 to 2017.
62578632|NCT04819516|EXPERIMENTAL|HIFU with REGOTORI|
62200904|NCT02573389|EXPERIMENTAL|"Prospective stented"|Patients who undergo prophylactic pancreatic duct stenting prior to a distal pancreatectomy starting approximately September 2015.
62578633|NCT04612738|ACTIVE_COMPARATOR|Group 1:Advance care planning conversation game, 'Hello'|"The 'Hello' game is a commercially available serious game that consists of 32 questions prompting players to share their values, goals, and beliefs about end-of-life issues. The game is played with 4 - 5 players, with each receiving a game booklet and chips. A play reads the first question in the book. Then each player writes down their answers individually and takes turns sharing their answers with the group. Players control what they share, how long they share and when to move to the next questions. During the conversation, plays can acknowledge others for a thoughtful, poignant or even funny comments by giving them a chip. A pre-game coin flip determines whether the player with the most chips wins the game (heads) or player with the least chips win (tails) the game.~Other names; previously name My Gift of Grace"
62578634|NCT04612738|ACTIVE_COMPARATOR|Group 2: The Conversation Project (CP) Starter Kit|The 'CP Starter Kit' (available for free online) is an 11-page workbook with open- ended prompts to consider one's values and preferences for end-of-life care, who to talk with about one's wishes, and suggestions on how to do so.
62012925|NCT05551364|EXPERIMENTAL|Treatment with the ATLAS 2030 Exoskeleton|The children will receive 2 hours of exoskeleton ATLAS 2030 gait training a week for 3 months
62578635|NCT04612738|PLACEBO_COMPARATOR|Group 3: Control Arm (Placebo control game, 'Table Topics')|A placebo/attention control l conversation game called 'Table Topics' will be used. Table Topics is a general conversation starter game that is unrelated to advance care planning. It involves answering open-ended questions in a group setting about a variety of topics.
62200905|NCT01408420|NO_INTERVENTION|Standard blood pressure|Extracorporeal circulation during the surgery are conducted using standard blood pressure
62578636|NCT03836183|OTHER|ultrasound|"* ultrasound is the only study group for all the patients~* pleuropulmonary ultrasound~* clinical examination~* fibroscopy."
62578637|NCT02275455|EXPERIMENTAL|Participants with autism|
62012926|NCT02681874|EXPERIMENTAL|Group A (Treatment Arm)|The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Sessions are 90 minutes. Groups consist of a maximum of five parents. Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions. Parent Leaders receive a week-long leadership training to deliver the program and will be supervised by the PI who is a licensed clinical psychologist.
62012927|NCT02681874|ACTIVE_COMPARATOR|Group B (Control Arm)|Parents in the control condition will receive the Smart and Secure Children (SSC) program's written handouts. Handouts include didactic curriculum content and instruct parents to write goals and document goal progress.
62200906|NCT01408420|ACTIVE_COMPARATOR|MAP > 60 mmHg|A blood pressure of MAP \> 60 mmHg is used during extracorporeal circulation. The higher MAP is maintained by using continuous intravenous administration of norepinephrine titrated to the appropriate dose for each patient.
62200907|NCT03260478|EXPERIMENTAL|Liberal Transfusion Strategy|Patients will receive red blood cells transfusion if Hb ≤ 100 g/L.
62578638|NCT02275455|EXPERIMENTAL|Aged-matched controls|
62578639|NCT05953688|EXPERIMENTAL|ESK-001 Dose Level 1|ESK-001 administered as an oral tablet
62578640|NCT05953688|EXPERIMENTAL|ESK-001 Dose Level 2|ESK-001 administered as an oral tablet
62578641|NCT02875132|EXPERIMENTAL|pembrolizumab|
62578642|NCT05991232|EXPERIMENTAL|Intravenous Ketamine|Open-label ketamine infusion
62578643|NCT02724046|NO_INTERVENTION|Standard care|No chemoprevention for contacts of cases of meningitis (current standard of care) with a health promotion visit by a study nurse after the first notification of cases during the epidemic
62578644|NCT02724046|ACTIVE_COMPARATOR|Household prophylaxis|Chemoprophylaxis with a single dose of oral ciprofloxacin for household members of reported cases of meningitis. For participants age \>12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age \<3 months: 75 mg (1.5 ml oral suspension).
62578645|NCT02724046|ACTIVE_COMPARATOR|Village prophylaxis|Chemoprophylaxis with ciprofloxacin in the setting of a village-wide distribution after the notification of the first case of meningitis in a village. For participants age \>12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age \<3 months: 75 mg (1.5 ml oral suspension).
62784782|NCT02699710|EXPERIMENTAL|Part 3: GDC-0853, Methotrexate|Participants will receive single dose of methotrexate (7.5 mg) under fasting conditions on Day 1 (5 mg folic acid will be administered the following day \[Day 2\]) and then GDC-0853 (200 mg) tablet formulation twice daily (BID) under fasting conditions (an overnight fast for the morning dose and a 2 hour fast for the evening dose) from Days 15 to 20 after washout period from Days 2 to 14. On Day 21, participants will receive single dose of methotrexate (7.5 mg) with single dose of GDC-0853 (200 mg) tablet formulation under fasting conditions, and folic acid (5 mg) will be administered on Day 22.
62784783|NCT01412788|EXPERIMENTAL|peri-areolar incision|Peri-areolar incision was used to carry out lumpectomy
62784784|NCT01412788|ACTIVE_COMPARATOR|traditional incision|traditional incision above tumor was used to carry out lumpectomy
62784785|NCT05670158|EXPERIMENTAL|"Cochlear Implantation group"|50 patients with sensorineural hearing loss eligible for cochlear implantation surgery. The blood and perilymph sampling will be performed during surgery (visit V1). The blood sampling will be additionally done during the visits V2, V3 and V4. After the visit V4, this arm will be subdivided into 2 groups: group 1, 15 patients with the delayed residual hearing loss, and group 2,15 patients with preserved residual hearing. For these 30 patients, blood sampling will be also performed during the visit V5.
62784786|NCT05670158|OTHER|Control group|30 normally hearing patients who will undergo through an otological surgery other than cochlear implantation. A blood sampling will be performed during surgery (visit V1) as well as during the visits V2 and V3.
62200908|NCT03260478|EXPERIMENTAL|Restrictive Transfusion Strategy|Patients will receive red blood cells transfusion if Hb ≤ 70 g/L.
62200909|NCT04371237|EXPERIMENTAL|Intermittent pneumatic compression|IPC sleeve device on leg
62200910|NCT04371237|EXPERIMENTAL|Heat therapy|Custom water-circulating garment on leg
62200911|NCT04794153|EXPERIMENTAL|Pork|Locally sourced
62200912|NCT04794153|EXPERIMENTAL|Salmon|Locally sourced
62200913|NCT04794153|EXPERIMENTAL|Mycoprotein|Provided by Marlow Foods
62200914|NCT04794153|EXPERIMENTAL|Lentils|Red
62200915|NCT04794153|EXPERIMENTAL|Egg|Local supplier
62200916|NCT04794153|ACTIVE_COMPARATOR|Egg whites|Local Supplier
62784787|NCT01890564||Bariatric surgery|Patients undergoing bariatric surgery.
62401757|NCT02717910|SHAM_COMPARATOR|Web page group|Participants in this arm will receive the web page intervention including both 20 minutes guided training session at school and 2 weeks free usage of the web page during free time.
62401758|NCT02717910|NO_INTERVENTION|Group with no intervention|The participants in this arm will receive no intervention.
62578646|NCT01680861|EXPERIMENTAL|Tacrolimus and Everolimus|"Patients in both arms will receive reduced tacrolimus dosing (rTd), 0.1 mg/kg PO divided in two daily doses - beginning when serum Cr decreases to a level of \<4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.~Everolimus initiated within 24 hours post-transplant (i.e., immediately following randomization) at 0.75mg PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml."
62578647|NCT01680861|ACTIVE_COMPARATOR|Tacrolimus and Enteric-Coated Mycophenolate Sodium (EC-MPS)|"Patients in both arms will receive reduced tacrolimus dosing (rTd), 0.1 mg/kg PO divided in two daily doses - beginning when serum Cr decreases to a level of \<4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.~EC-MPS will be initiated at 720 mg PO BID starting on the first post-operative day."
62578648|NCT00886197||GERD|"1. Symptomatic reflux subjects who receive esophagogastroscopy, aged from 20 to 70 years old.~2. Patients with typical reflux symptoms (heartburn and/or acid regurgitation) at least 3 times per week in recent 4 months."
62012928|NCT01625052|EXPERIMENTAL|Baska|
62012929|NCT02652780|EXPERIMENTAL|GS010-treated Eyes|Each participant will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
62012930|NCT02652780|SHAM_COMPARATOR|Sham-treated Eyes|Each participant will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
62200917|NCT06026241||Patients over 75 who died in geriatrics|Patients over 75 years old who died in the geriatric short-stay departments of Saint-Etienne University Hospital
62200918|NCT02958605|EXPERIMENTAL|Smartphone|Smartphone application
62200919|NCT02958605|EXPERIMENTAL|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
62200920|NCT01186705|EXPERIMENTAL|MK-2206|This will be a single-arm, phase II study of the AKT inhibitor MK-2206 in patients with KRAS-wild-type, PIK3CA-mutated, colorectal cancer whose tumors have progressed through standard chemotherapy regimens.
62200921|NCT05422690|EXPERIMENTAL|gemcitabine, cisplatin and Durvalumab chemotherapy with Yittrium-90|single arm - Induction Gemcitabine, Cisplatin and Durvalumab Triplet Chemotherapy followed by Gemcitabine, Cisplatin in combination with yttrium-90 (Y-90) Radioembolization
62200922|NCT04332055|EXPERIMENTAL|ERVIN PLUS|The doctor and the patient will have access to the ERVIN generated data
62200923|NCT04332055|NO_INTERVENTION|ERVIN MINUS|The doctor and the patient will not have access to the ERVIN generated data
62200924|NCT01365936|ACTIVE_COMPARATOR|menotrophin|In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
62401759|NCT02787655|EXPERIMENTAL|Aerobic Exercise + Cognitive Training Group|Exercise 3 times a week on a stationary ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes per session; plus 20 minutes of cognitive training using Mindfit program
62401760|NCT02787655|ACTIVE_COMPARATOR|Cognitive Training Only Group|Cognitive Training Only Group. For this arm of the intervention, randomized participants followed the same guidelines as the cognitive component of the AE+CT group but did not partake in aerobic exercise. To equalize contact/monitoring of the groups this group met for the same total duration time as the AE+CT group; however, instead of aerobic exercise, progressive whole body stretching and toning exercises
62578649|NCT05137444|EXPERIMENTAL|low-dose LYB001 in participants aged 18-59 years|25μg/0.5ml/Vial. Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
62578650|NCT05137444|EXPERIMENTAL|high-dose LYB001 in participants aged 18-59 years|50μg/0.5ml/Vial. Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
62578651|NCT05137444|PLACEBO_COMPARATOR|placebo in participants aged 18-59 years|intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
62578652|NCT05137444|EXPERIMENTAL|low-dose LYB001 in participants aged over 60 years|25μg/0.5ml/Vial. Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
62578653|NCT05137444|EXPERIMENTAL|high-dose LYB001 in participants aged over 60 years|50μg/0.5ml/Vial. Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
62200925|NCT01365936|ACTIVE_COMPARATOR|recombinant FSH|Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
62200926|NCT01708343|SHAM_COMPARATOR|Placebo-sham|Placebo-sham twice a week during four weeks
62200927|NCT01708343|ACTIVE_COMPARATOR|Lidocaine injection|Lidocaine 0.2-0.5 mL of 1% injected each time into the trigger point. Twice a week during four weeks
62200928|NCT01708343|EXPERIMENTAL|DIMMST|"DIMMST include the combination of trigger point deep dry needling (TrP-DDN) is combined with paraspinal deep intramuscular stimulation (PDIMS) and needle rotation (NR).~Twice a week during four weeks"
62200929|NCT04968431||Mitral Stenosis patient|
62200930|NCT02793271|ACTIVE_COMPARATOR|PRIME|The behavioral intervention will be the PRIME/mhGAP training. This is standard mental health training for prescribers (primary care workers who can prescribe psychotropic medication, e.g., health assistants) and non-prescribers (primary care workers who cannot prescribe medications, e.g., auxilliary nurse midwives). For prescribers, training includes introduction to psychosocial techniques and mhGAP. For non-prescribers, training includes psychosocial techniques.
62401761|NCT01627769||second degree blisters patients|blister fluids of second degree burns
62578654|NCT05137444|PLACEBO_COMPARATOR|placebo in participants aged over 60 years|intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
62578655|NCT05137444|EXPERIMENTAL|LYB001 in participants aged over 18 years|intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
62200931|NCT02793271|EXPERIMENTAL|PRIME+RESHAPE|The behavioral intervention will be the PRIME/mhGAP training plus the RESHAPE training adjunct. This is the PRIME training plus social contact component in which mental health service users participate as training co-facilitators. The intended goal of the additional component is to reduce stigma against persons with mental illness.
62200932|NCT01157286||level of apnea|patients will be separated depending on the iah(apnea hypopnea index) in mild, moderate and severe
62200933|NCT06337604|EXPERIMENTAL|Study Group|Rabeprazole sodium enteric-coated tablets + TNP-2092 capsules (n = 10)
62200934|NCT06337604|PLACEBO_COMPARATOR|Control Group|Rabeprazole sodium enteric-coated tablets + TNP-2092 capsules placebo (n = 10)
62200935|NCT00633880|EXPERIMENTAL|Droxidopa|Double-blind
62200936|NCT00633880|PLACEBO_COMPARATOR|Placebo|Double-blind
62200937|NCT01680081|EXPERIMENTAL|CT perfusion group|
62578656|NCT04920201|EXPERIMENTAL|Over-ground walking without GEMS-H|
62578657|NCT04920201|EXPERIMENTAL|Over-ground walking with GEMS-H with resist mode|
62578658|NCT04920201|EXPERIMENTAL|Stair ascent with GEMS-H with assist mode|
62200938|NCT03186001|EXPERIMENTAL|v shape|Technique 1Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a V pattern will be placed in the frontalis. The first injection between the medial brows, 2 injection 1cm below the hairline at the level of the lateral canthus and one injection equidistant to medial and lateral injection.
62401762|NCT01627769||cryotherapy blisters|blister fluids of cryosurgery wounds
62401763|NCT01726556|ACTIVE_COMPARATOR|Rigid thoracoscopy|Rigid thoracoscopy would be done using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany.
62578659|NCT04920201|EXPERIMENTAL|Incline walking with GEMS-H with assist mode|
61978295|NCT03520231|PLACEBO_COMPARATOR|Denosumab Placebo and Standard Chemotherapy|"Denosumab placebo, given subcutaneously, every 4 weeks.~Gemcitabine, given intravenously at standard doses, on Days 1 and 8 of every 21 day cycle, for 3-4 cycles.~Carboplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~OR Cisplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~Calcium, orally at a dose of 1000 mg, once daily.~Vitamin D, orally at a dose of 400 IU, once daily."
62200939|NCT03186001|EXPERIMENTAL|middle frontalis|: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a straight pattern will be placed in the frontalis. One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
62578660|NCT01295671|ACTIVE_COMPARATOR|Sugar-Sweetened Beverages|Provision of beverages: Sugar-sweetened beverages
62578661|NCT01295671|EXPERIMENTAL|Artificially-sweetened Beverages|Provision of beverages: Artificially-sweetened beverages
61978296|NCT02093286||Pentabio Vaccine|1 dose of Pentabio vaccine, 0.5 ml Will be given intramuscularly
61978297|NCT03344432||With intraocular pressure high|Intracranial pressure equal or more than 20 mmHg
62200940|NCT03186001|EXPERIMENTAL|high frontalis|: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally.Then 5 equally spaced injections, in a straight pattern 1 cm below the hairline will be placed in the frontalis. One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
62200941|NCT03684564|EXPERIMENTAL|Rivaroxaban (Treatment Arm)|
62200942|NCT03684564|ACTIVE_COMPARATOR|Warfarin (Control Arm)|
62200943|NCT01364337|ACTIVE_COMPARATOR|DASH diet|
62200944|NCT01364337|ACTIVE_COMPARATOR|lower carbohydrate DASH diet|
62401764|NCT01726556|ACTIVE_COMPARATOR|Semirigid thoracoscopy|The semirigid thoracoscope employed is a model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan.
62401765|NCT04366011|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy is a twelve-week therapeutic intervention based on the theory that maladaptive thoughts contribute to symptom development and maintenance of PD/A.
62401766|NCT04366011|EXPERIMENTAL|Capnometry Assisted Respiratory Training (CART)|Capnometry-assisted respiratory therapy is a five-week treatment based on the theory that hyperventilation causes or maintains panic disorder.
62401767|NCT02504099|EXPERIMENTAL|OBV/PTV/r ± DSV ± RBV for 12 or 24 weeks|OBV/PTV/r (ombitasvir/paritaprevir/ritonavir \[25 mg/150 mg/100 mg once daily\]) with or without dasabuvir (250 mg twice daily) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on HCV genotype/subtype and presence of cirrhosis.
62401768|NCT04121091|EXPERIMENTAL|Pramipexole|
62578662|NCT01295671|EXPERIMENTAL|Unsweetened Beverages|Provision of beverages: Unsweetened beverages
62578663|NCT01483274|EXPERIMENTAL|Safety|Decitabine and donor lymphocyte infused dendritic cell (DC).
62578664|NCT01483274|ACTIVE_COMPARATOR|Vaccine|Decitabine and Dendritic cell (DC) pulsed with MAGE-A1, MAGE-A3, NY-ESO-1 Peptides
62578665|NCT05329623|EXPERIMENTAL|Normal hepatic function|Matched healthy participants with normal hepatic function
62578666|NCT05329623|EXPERIMENTAL|Mild hepatic impairment|Mild hepatic impaired participants with Child-Pugh A (score of 5 to 6)
62012931|NCT04616144|OTHER|FRESH CORNEAL LENTICULE IMPLANTATION|The aim of this study is to investigate the effect of fresh corneal lenticule implantation as allogenic implant that will be taken from myopic patients to implant in hyperopic patients with high astigmatism using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity (far, intermediate, near vision) and secondary objective to stabilize(decrease) high astigmatism by reducing K values. Fresh corneal lenticule implantation as allogenic implant that we took from myopic patients (-5.0D) to implant in hyperopic patients (+4.0 D +3.0cyl) according to high K2 values. The stromal pocket diameter was 8 mm, 4mm super incision and 130-µm cap thickness.
62012932|NCT02527720|EXPERIMENTAL|Mindfulness Therapy|For the current study the investigators have developed a breathing-based, adapted for feasible application among SUD populations, and easy to carry out in clinical or non-clinical settings referred to as breathing-based mindfulness training (BBMT). BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention (more details below).
62200945|NCT02443753|EXPERIMENTAL|Device|Subjects who receive the device
62200946|NCT01971151|EXPERIMENTAL|Exposure with safety-seeking behavior|Patients receive exposure therapy. In the current condition, exposure is offered while patients are allowed to use their own safety-seeking behaviors (i.e., behavior believed to be necessary to prevent a feared catastrophe).
62200947|NCT01971151|EXPERIMENTAL|Exposure without safety-seeking behavior|Patients receive exposure therapy.In the current condition, exposure is offered while patients are instructed to omit their safety-seeking behavior.
62578667|NCT05329623|EXPERIMENTAL|Moderate hepatic impairment|Moderate hepatic impairment with Child Pugh B (score from 7 to 9)
62200948|NCT01971151|ACTIVE_COMPARATOR|Exposure therapy only|Patients receive exposure therapy. In the current condition, exposure is offered while patients do not receive any specific instructions about what to do with their safety-seeking behavior.
62200949|NCT01530581|EXPERIMENTAL|G-BM Transplant|
61978298|NCT03344432||Without intraocular pressure high|Intracranial pressure smaller than 20 mmHg
62200950|NCT01530581|OTHER|G-PB Transplant|G-PB Transplant
62200951|NCT02118649|EXPERIMENTAL|Game|Participants will play a video game directing their gaze to on-screen targets.
62200952|NCT04150159|EXPERIMENTAL|Fasting Mimicking Diet (FMD) Arm|The ProLon® FMD diet is made up of nut bars, dehydrated soups, tea, olives, kale crackers, electrolyte beverages, and a chocolate crisp bar consumed for 5 days every 30 days for 4 months.
62215051|NCT04713891|EXPERIMENTAL|Phase Ib, Cohort 2|KF-0210 (dose RP2D-1, orally once daily)+ Atezolizumab (1200 mg every 3 weeks) continuously until disease progression/recurrence or death from any cause, or serious adverse events (SAE) observed (whichever occurs earlier) for up to 2 years.
62401769|NCT05991401|EXPERIMENTAL|Period 1 or 2 or 3|\[Period 1\] DA-8010 5mg \[Period 2\] DA-8010 5mg, Clarithromycin 500mg \[Period 3\] DA-8010 5mg, Rifampicin 600mg
62578668|NCT05329623|EXPERIMENTAL|Severe hepatic impairment|Severe hepatic impairment with Child Pugh C (score from 10 to 15)
62578669|NCT04669873|ACTIVE_COMPARATOR|Active Comparator: Standard|Whole breast Radiotherapy, 40 Gray (40Gy) fractions
62578670|NCT04669873|EXPERIMENTAL|Experimental 1: Hypofractionated radiotherapy|Whole breast Radiotherapy, 26 Gray (26Gy) in 5 fractions
62578671|NCT04669873|EXPERIMENTAL|Experimental 2: Accelerated Partial Breast Irradiation|Partial Breast Irradiation 26 Gray (26Gy) to the tumor bed in 5 fractions.
62578672|NCT00782795|ACTIVE_COMPARATOR|Pioglitazone|30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
62578673|NCT00782795|PLACEBO_COMPARATOR|sugar pill (placebo)|1 sugar pill (placebo) taken once daily for 48 weeks.
62784788|NCT03401671|EXPERIMENTAL|Japanese|Healthy subjects of Japanese descent will receive a single dose of 300 milligrams (mg) lanadelumab subcutaneous (SC) injection in the abdomen.
62784789|NCT03401671|EXPERIMENTAL|Non-Hispanic Caucasians|Healthy Non-Hispanic Caucasian subjects will receive a single dose of 300 mg lanadelumab SC injection in the abdomen
62784790|NCT00681928||Breast Cancer patients receiving aromatase treatment|
61978299|NCT02178631|EXPERIMENTAL|Deprexis|Online self-help
61978300|NCT02178631|ACTIVE_COMPARATOR|CAU|Care as usual
61978301|NCT03813979|EXPERIMENTAL|Hepatic impairment group|Dolutegravir in HIV-seronegative subjects with severe hepatic impairment (child-Pugh score 10 or greater)
61978302|NCT03813979|ACTIVE_COMPARATOR|Matched controls|Dolutegravir in control group matched for gender, age and BMI with subjects in hepatic impairment group
61978303|NCT04730830|EXPERIMENTAL|Only experimental arm|Only experimental arm. Patients filling out questionnaires.
61978304|NCT01743131|PLACEBO_COMPARATOR|Standard GVHD Prophylxis + Placebo|"Standard GVHD prophylaxis and placebo.~Standard GVHD prophylaxis is calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate."
61978305|NCT01743131|EXPERIMENTAL|Standard GVHD Prophylxis + Abatacept|"Standard GVHD prophylaxis and abatacept (investigational product).~Standard GVHD prophylaxis is calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate."
61978306|NCT02539277|EXPERIMENTAL|Treatment group|Jinyebaidu granule, blunt, 10g / time, three times a day; Fufangshuanghua granule placebo, blunt, 6g / time, 4 times a day.
61978307|NCT02539277|ACTIVE_COMPARATOR|Control group|Fufangshuanghua granule, blunt, 6g / time, 4 times a day; Jinyebaidu granule placebo, blunt, 10g / times, three times a day.
61978308|NCT06526637|ACTIVE_COMPARATOR|Version 1 of Palliate|Participants will be randomised to receive this version of Palliate training and materials.
61978309|NCT06526637|EXPERIMENTAL|Version 2 of Palliate|Participants will be randomised to receive this version of Palliate training and materials.
61978310|NCT06526637|EXPERIMENTAL|Version 3 of Palliate|Participants will be randomised to receive this version of Palliate training and materials.
61978311|NCT00998660|EXPERIMENTAL|Patients receiving an Activa RC implant|
61978312|NCT02982850|EXPERIMENTAL|Dabigatran|Previous treatment of aspirin or warfarin will be changed to dabigatran treatment in patients allocated to dabigatran group.
61978313|NCT02982850|ACTIVE_COMPARATOR|Conventional Treatment|Acetylsalicylic acid or warfarin treatment will be continued in patients allocated to conventional treatment group.
61978314|NCT03124914|ACTIVE_COMPARATOR|Patients considered physically active|Measures of strength and determination of neuromuscular fatigue
61978315|NCT03124914|ACTIVE_COMPARATOR|Patients considered physically inactive|Measures of strength and determination of neuromuscular fatigue
62200953|NCT04150159|ACTIVE_COMPARATOR|Mediterranean Diet Arm|"The Mediterranean diet is based on the traditional foods that people used to eat in countries like Italy and Greece in the 1960s.~* Eat every day: vegetables, fruits, nuts, seeds, legumes, potatoes, whole grains, breads, yogurt, dairy, fish/seafood, herbs, spices and extra virgin olive oil.~* Eat three or fewer servings each week: poultry, eggs, cheese.~* Eat two or fewer servings each week: red meat, potatoes.~* Eat two or fewer servings each week: sweets, sodas, processed meat, refined grains, refined oils and other highly processed foods."
62200954|NCT00769262|ACTIVE_COMPARATOR|Aggressive Weaning|Infants will be weaned from the isolette using our current NICU standard of care.
62401770|NCT03127267|EXPERIMENTAL|Masitinib (4.5) & Riluzole|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control. Masitinib will be administered as an add-on to riluzole at 50 mg b.i.d
62401771|NCT03127267|EXPERIMENTAL|Masitinib (6.0) & Riluzole|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control. Masitinib will be administered as an add-on to riluzole at 50 mg b.i.d.
62401772|NCT03127267|PLACEBO_COMPARATOR|Placebo & Riluzole|Participants receive a matched dose placebo, given orally twice daily, in combination with riluzole at 50 mg b.i.d.
62401773|NCT02605135||Continued Pessary Use|All participants will undergo clinical testing prior to placement of the pessary and the investigator will test their vaginal environment prior to pessary placement. Testing will consists of a vaginal swab and 10 mL of vaginal lavage at each study visit. The participant will then be followed, and repeat testing obtained at the standard clinical interval for pessary follow-up, every three months
62578674|NCT02860975|EXPERIMENTAL|Inhaled Nitrogen|A humidified mixture of gas will be delivered by mask, nasal cannulae, and small room-sized tent. Inspiratory oxygen fraction (FiO2) will be gradually decreased to 11% over a period or five days to obtain a peripheral capillary O2 saturation (SpO2) between 80%-85% (corresponding to 40-55 mmHg of arterial partial oxygen pressure (PaO2)). Healthy volunteers will be monitored and blood and urine will be obtained at 24h and 48 hours after returning to normoxia.
62784791|NCT00681928||Healthy female controls age 60 and older|
62784792|NCT04487652|PLACEBO_COMPARATOR|Placebo spray|Spray consists of matrix out of water, phospholipids and glycerine, plus coloration Colour Sunset Yello E 110 to mimic the test spray
62012933|NCT02563158|NO_INTERVENTION|Hx with hepatic inflow occlusion|Hepatectomy is carried out using Pringle maneuver in cycles of 15 minutes clamping + 5 minutes unclamping of the hepatoduodenal ligament.
62012934|NCT02563158|EXPERIMENTAL|Hx with non-occlusion technique|Hepatectomy without hepatic inflow occlusion (non-occlusion technique)
62012935|NCT05638360|EXPERIMENTAL|Ru-Yi-Jin-Huang-Saan|Participants received Ru-Yi-Jin-Huang-Saan patch topically twice daily for 6 days.
62012936|NCT05638360|PLACEBO_COMPARATOR|Placebo|Participants received a starch patch topically twice daily for 6 days.
62012937|NCT01709058|EXPERIMENTAL|Intramuscular/paravertebral injections of Oxygen-Ozone|"This group will be treated with Intramuscular/paravertebral injections of Oxygen-Ozone twice a week for six weeks"
62401774|NCT02605135||Discontinued Pessary Use|All participants will undergo clinical testing prior to placement of the pessary and the investigator will test their vaginal environment prior to pessary placement. Testing will consists of a vaginal swab (AIM 1) and 10 mL of vaginal lavage (Aim 2) at each study visit. The participant will then be followed, and repeat testing obtained at the standard clinical interval for pessary follow-up, every three months. Should the participant discontinue pessary use, we will additionally culture the microbes that are present on the pessary and compare those to the vaginal microbiota.
62401775|NCT06010199||Myocarditis group|All enrolled patients are administered antiviral drugs, glucocorticoids, immunoglobulins, and other standard treatments. Additionally, the decision to provide ECMO support therapy is based on the severity of the patient's condition.
62401776|NCT04100902|ACTIVE_COMPARATOR|Odactra 12-sq HDM sublingual tablet|House Dust Mite, sublingual tablet
62401777|NCT04100902|PLACEBO_COMPARATOR|Placebo sublingual tablet|Placebo, sublingual tablet
62401778|NCT02366026|EXPERIMENTAL|IR103 REMUNE + AMPLIVAX 1.0|IR103 Vaccine contain the same active component as REMUNE® (Inactivated HIV-1 Antigen Drug Substance at 10 μg/mL p24 dose), and have one dose of Amplivax™ (HYB2055) Adjuvant (1.0 mg) added before emulsification in Incomplete Freund's Adjuvant (the same adjuvant and in the same ratio that is used in REMUNE).
62401779|NCT02366026|PLACEBO_COMPARATOR|AMPLIVAX 1.0 + IFA|AMPLIVAX 1.0 mg Amplivax™ (HYB2055) Adjuvant (1.0 mg) + IFA Incomplete Freund's Adjuvant (the same adjuvant and in the same ratio that is used in REMUNE).
62401780|NCT05364164|EXPERIMENTAL|CT-L01 12.5/1,000 mg FDC Tablet, dosing under fasting condition|Alogliptin Benzoate 12.5 mg/Metformin HCl XR 1,000 mg, FDC Tablet, dosing under fasting condition
62200955|NCT00769262|EXPERIMENTAL|Conservative Weaning|Infants will be weaned from the isolette using a modified conservative weaning schedule.
62401781|NCT05364164|EXPERIMENTAL|CT-L01 12.5/1,000 mg FDC Tablet, dosing under fed condition|Alogliptin Benzoate 12.5 mg/Metformin HCl XR 1,000 mg, FDC Tablet, dosing after high-fat meal
62401782|NCT05913921|EXPERIMENTAL|Sequence TR|16 healthy subjects assigned to the sequence TR were administrated intravenously for 120 mins with the test product of amphotericin B liposome for injection in period 1 and the reference product of AmBisome® in period 2
62401783|NCT05913921|EXPERIMENTAL|Sequence RT|16 healthy subjects assigned to the sequence RT were administrated intravenously for 120 mins with the reference product of AmBisome® in period 1 and the test product of amphotericin B liposome for injection in period 2
62200956|NCT04647838|EXPERIMENTAL|NSCLC|Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
62578675|NCT04948749|EXPERIMENTAL|Drug-eluting stent implantation with aggressive medical treatment group|DES implantation (The Maurora ® Sirolimus Eluting Stent System) combined with aggressive medical treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 mg per day, or ticagrelor 90 mg twice per day for 6 months); management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)
62578676|NCT04948749|ACTIVE_COMPARATOR|Standard medical treatment group|Standard medical treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 mg per day, or ticagrelor 90 mg twice per day for 3 months after enrolment), management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)
62578677|NCT04421287|EXPERIMENTAL|Zhenyuan capsule|
62578678|NCT04421287|PLACEBO_COMPARATOR|Zhenyuan capsule placebo|
62578679|NCT04463147|OTHER|new residents|new residents in ultrasound-guided central vascular catheterization.
62200957|NCT04647838|EXPERIMENTAL|Other cancers|Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
62200958|NCT01623193|ACTIVE_COMPARATOR|Control|Patients receive standard 4:1 cardioplegia for myocardial protection during cardiac surgery
62200959|NCT01623193|EXPERIMENTAL|Treatment|Patients receive all-blood cardiolpegia for myocardial protection during surgery
62200960|NCT01852461|ACTIVE_COMPARATOR|Beractant|Beractant;bovine lung extract; both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
62200961|NCT01852461|ACTIVE_COMPARATOR|Poractant alfa|Poractant alfa; porcine lung extract; initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
62200962|NCT03064152|NO_INTERVENTION|Control|Patients who experience postpartum hemorrhage will receive standard of care for labor and delivery, cesarean delivery, and postpartum care. Transfusion will be based on standard of care utilizing clinical criteria of hemodynamics (noninvasive blood pressure, heart rate, arterial line if deemed clinically useful) and coagulation labs (PT, activated partial thromboplastin time (aPTT), fibrinogen, complete blood count). In addition to standard of care, additional ROTEM blood assays will be performed at any time routine coagulation labs are sent. Providers in the control group will be blinded to ROTEM results.
62401784|NCT02777866|EXPERIMENTAL|1: Bupivacaine 0.5%|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
62401785|NCT02777866|PLACEBO_COMPARATOR|2: 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs, who will be infiltrated in the total thickness of the abdominal wall with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound.
62401786|NCT00636402|EXPERIMENTAL|1|Vessel Sealing System Tonsillectomy (VSST)
62401787|NCT00636402|ACTIVE_COMPARATOR|2|Cold Knife Tonsillectomy (CKT)
62401788|NCT06172374||PCD Individuals confirmed positive for DNAI1|
62401789|NCT06172374||PCD Individuals confirmed positive for other genotypes of interest|
62401790|NCT06172374||Individuals negative for a gene causing PCD|
62401791|NCT02071472|EXPERIMENTAL|DP medication reconciliation|medication reconciliation by a pharmacist using an electronic pharmaceutical record associated to the anesthesiologist consultation for planned surgery patients.
62401792|NCT02071472|NO_INTERVENTION|control|conventional anesthesiologist consultation for planned surgery patients
62401793|NCT01387061|EXPERIMENTAL|hepatic resection|
62401794|NCT02730975|EXPERIMENTAL|AA Reduced dose-normal diet (A)|Abiraterone acetate at reduced dose of 250 mg po daily in cycles of 28 days administered with a standard breakfast
62401795|NCT02730975|EXPERIMENTAL|AA reduced dose-fat diet (B)|Abiraterone acetate at reduced dose of 250 mg po daily in cycles of 28 days administered with a fat breakfast
62401796|NCT02730975|ACTIVE_COMPARATOR|AA normal dose-fasting conditions (C)|Abiraterone acetate at approved dose of 1000 mg po daily in cycles of 28 days administered in fasting conditions
62401797|NCT04567849|NO_INTERVENTION|Control|No intervention control group
62578680|NCT04463147|OTHER|experienced residents or ICU practitioners|experienced residents or ICU practitioners in ultrasound-guided central vascular catheterization.
62578681|NCT02235844|EXPERIMENTAL|Mesenchymal Stem Cells|Umbilical Cord Mesenchymal Stem Cells
62578682|NCT02739425|OTHER|Standard Procedure plus use of sentimag|Detection of the nodes carried out using the gamma probe and also the sentimag - all patients receive both diagnostic interventions
62578683|NCT01030783|EXPERIMENTAL|tivozanib (AV-951)|
62578684|NCT01030783|ACTIVE_COMPARATOR|sorafenib|
62578685|NCT03660332|ACTIVE_COMPARATOR|IL-6 infusion|Healthy young men will receive IL-6 infusion
62200963|NCT03064152|EXPERIMENTAL|ROTEM|Patients will receive standard of care for labor and delivery, cesarean delivery, and postpartum care. Transfusion will be based on standard of care utilizing clinical criteria of hemodynamics (noninvasive blood pressure, heart rate, arterial line if deemed clinically useful) and coagulation labs (PT, aPTT, fibrinogen, complete blood count). In addition to standard of care, additional ROTEM blood assays will be performed at any time routine coagulation labs are sent. Providers in the ROTEM group will receive real-time ROTEM results and a previously validated ROTEM-based transfusion algorithm for PPH.
62200964|NCT04920643|EXPERIMENTAL|High-Exchange Ultrafiltration|Subzero-Balance Simple Modified Ultrafiltration (60ml/kg/hour)
62200965|NCT04920643|ACTIVE_COMPARATOR|Low-Exchange Ultrafiltration|Subzero-Balance Simple Modified Ultrafiltration (6ml/kg/hour)
62200966|NCT03405090|ACTIVE_COMPARATOR|Fentanyl Citrate|Single dose, nebulized 100 mcg fentanyl citrate. This is a randomized, double-blind, two-treatment crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate with a constant fraction of 30% inhaled oxygen to that of a nebulized bronchodilator (Combivent). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and combivent at the second treatment visit, patients in the other arm will receive Combivent first and fentanyl second.
62578686|NCT03660332|PLACEBO_COMPARATOR|Placebo infusion|Healthy young men will receive saline infusion
62578687|NCT04863378|EXPERIMENTAL|Walkers|Walkers continuously wear an actigraph watch to assess activity level. Daily sleep behavior is captured on an under-the-mattress sleep sensor. Participants walk 1-mile routes in triads, three times a week for 16 weeks while engaging in prompted conversational reminiscence recorded for a digital archive.
62012938|NCT01709058|OTHER|Simulated treatment|"The Simulated intramuscular/paravertebral injections will mimic the Oxygen-Ozone injections in the area to be treated by pricking the skin with the needle without drilling. These simulated injections will be performed twice a week for six weeks."
62200967|NCT03405090|ACTIVE_COMPARATOR|Combivent Bronchodilator|Single dose, nebulized Combivent bronchodilator (0.5 mg ipratropium bromide + 2.5 mg salbutamol). This is a randomized, double-blind, two-treatment crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate with a constant fraction of 30% inhaled oxygen to that of a nebulized bronchodilator (Combivent). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and combivent at the second treatment visit, patients in the other arm will receive Combivent first and fentanyl second.
62578688|NCT03487627|EXPERIMENTAL|Electronic and Care Support Manager Contact|Participants receive electronic content and contact with a Care Support Manager
62578689|NCT03487627|ACTIVE_COMPARATOR|Enhanced treatment-as-usual (TAU)|Participants receive enhanced treatment-as-usual
62578690|NCT03250858|PLACEBO_COMPARATOR|Non-personalised advice|"Control group. Online (web-based) delivery of non-personalised dietary, weight and physical activity advice based on the UK general health guidelines.~This is an online trial and this arm will be using the e-Nutri web application. Participants in this group will receive online general recommendations (non-personalised)."
62578691|NCT03250858|EXPERIMENTAL|Personalised advice|Online (web-based) delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive online personalised reports.
62578692|NCT02741830||Uterosacral ligament suspension (USLS)|This group of patients underwent the procedure of native tissue vaginal reconstructive surgery using uterosacral ligament suspension for pelvic organ prolapse.
62784793|NCT04487652|EXPERIMENTAL|CoQ10 spray|The CoQ10 spray contains a high quality Kaneka A10 containing CoQ10 trans-isomers which is embedded in a matrix out of water, phospholipids and glycerine. Adana Pharma GmbH is processing the CoQ10 substance into the matrix. One application contains 7 mg CoQ10.
62200968|NCT02370264|EXPERIMENTAL|Supportive care (musculoskeletal screening, quality of life)|Patients complete the DASH and FACT-B questionnaires over 30-45 minutes.
62200969|NCT01145989|EXPERIMENTAL|AT9283|Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
62401798|NCT04567849|EXPERIMENTAL|Nudge: call provider|This group will receive a patient portal message the morning after completing their procedure. The message will encourage patients to call their recent Women's Health provider (with appropriate phone number listed) if any questions or concerns arise about their healthcare.
62401799|NCT04567849|EXPERIMENTAL|Nudge: call tele-nurse|This group will receive a patient portal message the morning after completing their procedure. The message will encourage patients to call Geisinger's nurse triage hotline (with appropriate phone number listed) if any questions or concerns arise about their healthcare.
61978316|NCT05417165|ACTIVE_COMPARATOR|Arm A (Standard ARM- No Booster)|Patients receive PCV 20 IM at week 0. Titers will be checked 4 weeks after this dose. Booster Vaccine: None. Titers will be checked at 12 weeks and then yearly for 5 years.
62578693|NCT02741830||Robotic sacrocolpopexy (RSC)|This group of patients underwent the reconstructive pelvic surgery of robotic sacrocolpopexy using synthetic mesh.
62784794|NCT02233023|EXPERIMENTAL|Pramixpexole|
62784795|NCT02233023|ACTIVE_COMPARATOR|Bromocriptine and other dopamine agonists|
62784796|NCT00112125|EXPERIMENTAL|Optimizer System + Optimal medical treatment|Optimizer System implanted and cardiac contractility modulation therapy activated.
62784797|NCT00112125|NO_INTERVENTION|Optimal medical treatment|Treatment with optimal medical therapy only.
62012939|NCT05795387|EXPERIMENTAL|Experimental Add-on Intervention - Video-based self-regulated training|"The intervention consist of access to the video e-library on their e-learning platform.~The video e-library consists of 23 videos of brief patient interviews, mostly with inpatients, with adjoining MSE written by three faculty psychiatrists. Selected videos are used for demonstration of phenomena, and five videos will have audio explanation of the resulting MSE.~As well as the authentic patient videos on the e-library there are some pages with written theoretical instructions on the MSE, a brief animated movie and some simulated videos by an actor all regarding the MSE."
62200970|NCT00969683|ACTIVE_COMPARATOR|Double lumen tube without a hook|Broncho-Cath™, Mallinckrodt France, Parc d'Affaires Technopolis, 3 avenue du Canada, Bât Sigma, Les Ulis, 91975 Courtaboeuf Cedex
62578694|NCT04657198|EXPERIMENTAL|Group High Dose_Adjuvanted|Participants in one of the high dose adjuvanted groups in part B of the parent study RSV OA=ADJ-002: Group High Dose Adjuvanted will receive one revaccination dose of the RSVPreF3 OA investigational vaccine in the current study by intramuscular (IM) injection in the non-dominant arm.
62578695|NCT04657198|EXPERIMENTAL|Group Medium Dose_Adjuvanted|Participants in one of the medium dose adjuvanted groups in part B of the parent study RSV OA=ADJ-002: Group Medium Dose Adjuvanted will receive one revaccination dose of the RSVPreF3 OA investigational vaccine in the current study by IM injection in the non-dominant arm.
62578696|NCT04657198|EXPERIMENTAL|Group Low Dose_Adjuvanted|Participants in one of the low dose adjuvanted groups in part B of the parent study RSV OA=ADJ-002: Group Low Dose Adjuvanted will receive one revaccination dose of the RSVPreF3 OA investigational vaccine in the current study by IM injection in the non-dominant arm.
62578697|NCT03926364||Patients|Referred pain
62578698|NCT05628428|EXPERIMENTAL|Exercise|Exercising through educational videos for eight weeks. In addition, they will receive educational information about neck pain and the importance of exercise in this case, at the beginning of the study.
62012940|NCT05795387|ACTIVE_COMPARATOR|Non-video group|For the present trial, also the NV students will receive the same non-authentic patient material I.E written theoretical instructions on the MSE, a brief animated movie and some simulated videos by an actor all regarding the MSE. Ensuring it is the authentic patient video e-library and not the theoretical information responsible for the expected difference in scores.
62012941|NCT05622591|EXPERIMENTAL|ELU001|Dose Escalation: Escalating doses of ELU001
62200971|NCT00969683|EXPERIMENTAL|Double lumen tube with a hook|Broncho-Cath™, Mallinckrodt France, Parc d'Affaires Technopolis, 3 avenue du Canada, Bât Sigma, Les Ulis, 91975 Courtaboeuf Cedex
62200972|NCT00339664||1/ patients|Patients on approved clinical trials
62012942|NCT04720534|EXPERIMENTAL|ARO-APOC3 10 mg, Day 1 and Week 12|2 doses of ARO-APOC3 by subcutaneous (sc) injection
62012943|NCT04720534|EXPERIMENTAL|ARO-APOC3 25 mg, Day 1 and Week 12|2 doses of ARO-APOC3 by sc injection
62012944|NCT04720534|EXPERIMENTAL|ARO-APOC3 50 mg, Day 1 and Week 12|2 doses of ARO-APOC3 by sc injection
62012945|NCT04720534|PLACEBO_COMPARATOR|Placebo, Day 1 and Week 12|calculated volume to match active treatment by sc injection
62012946|NCT03616756|EXPERIMENTAL|Intervention group|
62012947|NCT03616756|ACTIVE_COMPARATOR|Control group|
62200973|NCT04220398|EXPERIMENTAL|NCHT Group|Neoadjuvant chemotherapy combined with hormone therapy, Radical Prostatectomy (RP)+ extended lymph node dissection
62200974|NCT04220398|ACTIVE_COMPARATOR|NHT Group|Neoadjuvant hormonal therapy, radical Prostatectomy (RP)+ extended lymph node dissection.
62200975|NCT04220398|OTHER|RP Group|Radical Prostatectomy (RP)+ extended lymph node dissection alone.
62200976|NCT05727189|EXPERIMENTAL|Part 1 Single Dose|Parallel group comparison, single dose level of 5 forms of the investigational study drug.
62200977|NCT05727189|EXPERIMENTAL|Part 2: Single escalating doses|Parallel group comparison, single p.o. dose escalation (3 dose levels) of 4 forms investigational study drug and placebo administered to two sequential cohorts. Dose Level 1 will be administered to the first cohort. Dose Levels 2 and 3 will be administered to a subsequent cohort. Dose levels in this cohort are separated by a 7-day washout period. Doses to be determined by review of data from Part 1.
62578699|NCT05628428|ACTIVE_COMPARATOR|Control|Educational information about neck pain and the importance of exercise in this case, at the beginning of the study.
62578700|NCT04443075||exposed group|The exposed group consists of the frontline medical workers who take part in the medical team to support Wuhan.
62578701|NCT04443075||non-exposed group|This group includs medical workers who didn't join in the medical team to support Wuhan.
62578702|NCT02252393|EXPERIMENTAL|Arm I (RARC with IUD)|Patients undergo RARC with IUD.
62578703|NCT02252393|EXPERIMENTAL|Arm II (RARC with EUD)|Patients undergo RARC with EUD.
62200978|NCT05727189|EXPERIMENTAL|Part 3: Multiple Dose|Parallel group comparison of 4 active treatments dosed p.o. x 4 days. Each active is dosed in a 2-period placebo-controlled crossover separated by a 5-day washout. Doses to be determined by review of data from Part 2.
62200979|NCT05727189|EXPERIMENTAL|Part 4: Food Effects|Two-period single p.o. dose fasted/fed crossover separated by 5-day washout period. Dose to be determined by review of data from Part 2.
62200980|NCT03551691|ACTIVE_COMPARATOR|Omeprazole|Subjects will take omeprazole 20mg daily for 28 days, then undergo assessments of fat absorption.
62200981|NCT03551691|PLACEBO_COMPARATOR|Placebo|Subjects will take a placebo daily for 28 days, then undergo assessments of fat absorption.
62200982|NCT02734498|ACTIVE_COMPARATOR|Right unilateral (RUL) ECT|Right Unilateral placement of treatment electrodes in electroconvulsive treatment.
62200983|NCT02734498|ACTIVE_COMPARATOR|Bilateral (BL) ECT|Bilateral placement of treatment electrodes in electroconvulsive treatment.
62200984|NCT02734498|NO_INTERVENTION|Control group|No ECT treatment for control group.
62200985|NCT05821556|ACTIVE_COMPARATOR|Standard|Nab-paclitaxel 125 mg/m2 followed by gemcitabine 1000 mg/m2 on days 1, 8, and 15 (AG); or nab-paclitaxel 150 mg/m2, followed by gemcitabine 800 mg/m2, followed by cisplatin 30 mg/m2 on days 1 and 15, and oral capecitabine 1250 mg/m2 on days 1-28 (PAXG).
62200986|NCT05821556|EXPERIMENTAL|Experimental|Chemotherapy (AG or PAXG) + simvastatin oral daily at a fixed dosage of 20 mg in combination with increasing doses of valproic acid administered oral daily from day -7 with an intra-patient titration for a final target serum level of 50-100µg/ml.
62578704|NCT05042661|EXPERIMENTAL|acupuncture-like transcutaneous electrical nerve stimulation|"1. The experimental group received acupuncture-like transcutaneous electrical nerve stimulation three times a week for 4 weeks.~2. Invention and control groups are 4 weeks and 3 weeks respectively. Each time will be for 20 minutes acupuncture-like transcutaneous electrical nerve stimulation treatment"
62578705|NCT05042661|NO_INTERVENTION|Control group:conventional therapy|The control group will receive routine care.
62578706|NCT05579470|OTHER|NIATx Model|Receiving NIATx Coaching
62578707|NCT01158846|ACTIVE_COMPARATOR|prasugrel/bivalirudin|60 mg loading dose of prasugrel will be followed by maintenance dose of 10mg (or 5mg according to body weight and age). During primary PCI, Bivalirudin will be used as anticoagulant (bolus plus infusion), on a weight-adjusted dose.
62578708|NCT01158846|ACTIVE_COMPARATOR|clopidogrel/abciximab|600mg loading dose of clopidogrel will be followed by 75mg maintenance dose. During primary PCI abciximab (bolus plus infusion) will be used as anticoagulant.
62200987|NCT04158804|EXPERIMENTAL|Procalcitonin algorithm+stewardship team|antibiotic prescription guided by PCT values
62578709|NCT03527589||Treated with Embosphere Microspheres|Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres (size of embolic determined at Investigator discretion).
62578710|NCT05866848|PLACEBO_COMPARATOR|No caffeine|The control group took flour capsules.
62784798|NCT06584201||ESP Group|Patients in this group will receive the Erector Spinae Plane Block (ESP) as a method of postoperative pain management.
62784799|NCT06584201||Paravertebral Group|Patients in this group will receive the Paravertebral Block (PVB) for postoperative pain relief.
62200988|NCT04158804|NO_INTERVENTION|standard group|standard of care guided by current guidelines
62200989|NCT06068764|EXPERIMENTAL|Etomidate|Etomidate as the principal hypnotic agent in a single bolus dose of 0.2-0.3 mg/kg along with 250mcg of fentanyl, 50mg ketamine, 0.7 mg/kg rocuronium, and 5ml of 2% lidocaine.
62200990|NCT06068764|ACTIVE_COMPARATOR|Propofol|Propofol as the principal hypnotic agent in a single bolus dose of 50mg of propofol along with 250 mcg of fentanyl, 50mg ketamine, 0.7 mg/kg rocuronium, and 5ml of 2% lidocaine.
62200991|NCT02271360|ACTIVE_COMPARATOR|group A|In group A, (Calcium Dobesilate group), 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given from at day of HCG injection and for 21 days.
62578711|NCT05866848|EXPERIMENTAL|Low caffeine|Group with relatively small amount of caffeine (45 mg) administered.
62578712|NCT05866848|EXPERIMENTAL|High caffeine|Group with greater amount of caffeine (120 mg) administered.
62578713|NCT06113640|ACTIVE_COMPARATOR|control group|Control group (Levo-dopa group, n =30) who received levodopa/carbidopa (250/25 mg) three times daily for 12 months
62578714|NCT06113640|ACTIVE_COMPARATOR|Montelukast group|who received levodopa/carbidopa (250/25 mg) three times daily plus Montelukast 10 mg once daily for 12 months
62578715|NCT01225081|EXPERIMENTAL|ASP group|ASP1941 and pioglitazone
62578716|NCT01225081|PLACEBO_COMPARATOR|Placebo group|placebo and pioglitazone
62784800|NCT02087111|EXPERIMENTAL|Treatment|All patients who are fulfil the entry criteria are treated for 24 weeks with 40 Kd Pegylated interferon alfa 2a, Ribavirin and 12 weeks with telaprevir.
62784801|NCT03314272|NO_INTERVENTION|Sliding scale protocol|"Consists of giving insulin every 30 minutes based on the blood glucose readings as follows:~* \<150 mg/dl: 0 units of insulin~* 150-220 mg/dl: 2 units of insulin~* 201-250 mg/dl: 4 units~* 251-300 mg/dl: 6 units~* 301-350 mg/dl: 8 units~* 351-400 mg/dl: 10 units~* \> 400 mg/dl: inform the MD on call"
62012948|NCT01727531|EXPERIMENTAL|CQ Arm|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks.
62012949|NCT02477020|EXPERIMENTAL|TAK-063 20 mg|TAK-063 20 mg, tablets, orally, once daily for up to 6 weeks. Dose may be titrated down to 10 mg/day, if intolerable.
62578717|NCT06029413|EXPERIMENTAL|Research arm|After the myofascial trigger points are determined by ultrasonography (HI VISION Preirus; Hitachi Aloka Medical, Ltd., Tokyo, Japan), injections will be given to the myofascial layers from the deep to the superficial. First, the local anesthetic solution will be injected to create a separation in the intermuscle (epimysial) fascia. The injectable will then be infiltrated into the intermuscular hypoechoic nodule. Then, the deep fascia will be infiltrated layer by layer. Finally, the procedure will be completed by infiltrating the superficial fascia.
62401800|NCT06325072|EXPERIMENTAL|Pathogenic variants|Variants fitting bioinformatic prioritization criteria for pathogenicity according to ACMG guidelines and the clinical phenotype, and variants already reported in the literature will be defined as pathogenic variants
62401801|NCT06325072|EXPERIMENTAL|Potentially Pathogenic Variants|Variants fitting bioinformatic prioritization criteria but apparently do not correlate with the clinical phenotype and have not been previously reported in the literature will be defined as potentially pathogenic variants
62401802|NCT06325072|EXPERIMENTAL|Variants of Unknown Significance (VUS)|Variants fitting the phenotype but not fitting bioinformatic prioritization criteria will be defined as variants of uncertain clinical significance (VUS)
62401803|NCT00455039|EXPERIMENTAL|GW572016 1500mg|patients received GW572016 1500mg daily
62578718|NCT06029413|ACTIVE_COMPARATOR|Control arm|Patients in the control group will be injected with the same amount of local anesthetic solution under ultrasound guidance to intramuscular hypoechoic nodules detected by ultrasonography (HI VISION Preirus; Hitachi Aloka Medical, Ltd., Tokyo, Japan).
62578719|NCT04215809|EXPERIMENTAL|APG2575 200mg|APG2575 200mg ramp up
62578720|NCT04215809|EXPERIMENTAL|APG2575 400mg|APG2575 400mg ramp up
62578721|NCT04215809|EXPERIMENTAL|APG 2575 600mg|APG2575 600mg ramp up
62578722|NCT04215809|EXPERIMENTAL|APG2575 800mg|APG2575 800mg ramp up
62578723|NCT04215809|EXPERIMENTAL|APG2575 1000 mg|APG2575 1000 mg ramp up
62012950|NCT02477020|PLACEBO_COMPARATOR|Placebo|TAK-063 matching-placebo tablets, orally, once daily for up to 6 weeks.
62578724|NCT04215809|EXPERIMENTAL|APG2575 1200mg|APG2575 1200mg ramp up
62012951|NCT03731299||Stroke|Individuals suffered from a haemorrhagic or ischaemic stroke. Diagnosis has to be confirmed on the basis of CT or MRI imaging.
62012952|NCT03731299||Healthy adults|Healthy individuals without any neurological or orthopaedic disorder that could influence motor performance and balance
62012953|NCT03755765|PLACEBO_COMPARATOR|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
62012954|NCT03755765|EXPERIMENTAL|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
62012955|NCT00274716|EXPERIMENTAL|High BMI:MK-0736 2mg→Placebo|Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
62012956|NCT00274716|EXPERIMENTAL|High BMI:MK-0736 7mg→Placebo|Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
62012957|NCT00274716|EXPERIMENTAL|High BMI:MK-0916 6mg→MK-0916 6mg|Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
62012958|NCT00274716|PLACEBO_COMPARATOR|High BMI:Placebo→Placebo|Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
62401804|NCT01424657|EXPERIMENTAL|ERCP|ERCP is an endoscopic examination that allows opacification of the biliary tree by direct injection into the common bile duct through its distal opening in the duodenum at the ampulla of Vater
62401805|NCT01424657|EXPERIMENTAL|MRCP|The magnetic resonance cholangiopancreatography (MRCP)allows direct visualization of the biliary tree and pancreatic duct, similar to contrast cholangiography, but without the need for administration of contrast medium
62401806|NCT05754359|EXPERIMENTAL|I'm an Active Hero (IAAH) Intervention program (intervention group)|Preschool where the intervention implement will be run.
62401807|NCT05754359|NO_INTERVENTION|Usual physical activities (control group)|No intervention will be delivered in the control group, and children were requested to continue their usual physical activities.
62401808|NCT03573466|EXPERIMENTAL|Amyotrophic Lateral Sclerosis|
62401809|NCT06505330|NO_INTERVENTION|Control group|
62401810|NCT06505330|EXPERIMENTAL|Probiotic group|Dietary Supplement: Probactiol Mini 6 droplets of Probactiol Baby contain 1 billion bacteria (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12)
62401811|NCT00452127|EXPERIMENTAL|1|
62401812|NCT04165174|EXPERIMENTAL|PAS|PD-1:240mg,ivdrip,Q3W,begin with SBRT Apatinib:250mg,po,QD,begin with SBRT SBRT:6-10Gy/F,5-8F
62401813|NCT01143129|EXPERIMENTAL|dexamethasone|Single dose of dexamethasone (1 mg/kg) at the start of the cardiac surgical procedure
62401814|NCT01143129|PLACEBO_COMPARATOR|Placebo|
62401815|NCT02538432|EXPERIMENTAL|RQ-00000007 Alone|RQ-0000007 250 mg will be self-administered orally, with or without food, each morning and evening, approximately 12 hours apart.
62401816|NCT02538432|ACTIVE_COMPARATOR|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be given as an IV.
62578725|NCT06224816|EXPERIMENTAL|3D Mask (3DM)|Custom 3D mask (3DM) application in neonate during 4 hours. Each patient included will be their own control at the same time, receiving each of the different mask models every 4 hours alternately. The study period will be a maximum of 7 days.
62578726|NCT06224816|ACTIVE_COMPARATOR|Traditional Mask (TM)|Traditional Mask (TM) application in neonate during 4 hours. Each patient included will be their own control at the same time, receiving each of the different mask models every 4 hours alternately. The study period will be a maximum of 7 days.
62578727|NCT00813254||Questionnaire|Longitudinal measure of QOL, sexual functioning and symptoms in women with recurrent, platinum-resistant ovarian cancer receiving multiple second-line treatment regimens
62012959|NCT00274716|EXPERIMENTAL|Low BMI:MK-0916 6mg→MK-0916 6mg|Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
62012960|NCT00274716|PLACEBO_COMPARATOR|Low BMI:Placebo→Placebo|Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
62012961|NCT03105050||Countries in Europe|All 51 countries will fill out their unique data on access to bariatric surgery in Europe
62200992|NCT02271360|ACTIVE_COMPARATOR|group B|while in group B (Cabergoline group), 1 tab/day Cabergoline(Dostinex)( 0.5 mg) will be givenat day of HCG injection and for 8 days .
62200993|NCT03512964|OTHER|Rapid HIV Treatment Initiation|Initiation and reinitiation of antiretroviral therapy with dolutegravir 50 mg by mouth once daily and descovy 1 tablet by mouth once daily the same-day as HIV diagnosis and/or first clinic visit for people newly diagnosed with HIV and patients previously diagnosed with HIV but not on medications and not in care for over six months.
62200994|NCT04562740|EXPERIMENTAL|ABLUMINUS DES|"ABLUMINUS DES drug eluting stent will be deployed after successful conventional balloon angioplasty.~Sirolimus drug dosage on the ABLUMINUS DES drug eluting stent system is determined by Concept Medical to deliver the optimal dose of sirolimus to the abluminal surface of the BTK lesions."
62200995|NCT00652769|ACTIVE_COMPARATOR|B|Control arm: Current practice for diagnosing and staging lung cancer. Most patients with intra-thoracic disease suspected of lung cancer will undergo bronchoscopy (or CT guided biopsy), PET scan and possibly mediastinoscopy.
62401817|NCT04582968|EXPERIMENTAL|Pyrotinib Plus Capecitabine combined with brain radiotherapy|Fractionated stereotactic radiotherapy(FSRT) or whole brain radiation therapy (WBRT) Drug: Pyrotinib combined with capecitabine pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
62784802|NCT03314272|EXPERIMENTAL|Space Glucose Control|"Automated protocol consisting of an insulin infusion pump named The Space Glucose Control System.~Intervention:~For glucose measurement, a sample of blood gas will be taken every 30 minutes. Actrapid HM will be used in a 4IU/ ml concentration for infusion in a 50 ml syringe.~The range of glucose will be recorded throughout the intra-operative period. The number of hypoglycemic (\<70mg/dl) and hyperglycemic (\> 200mg/dl) events will be recorded."
62200996|NCT00652769|EXPERIMENTAL|A|Active arm: A new pathway for the diagnosis and staging of lung cancer with endobronchial (EBUS) or endoscopic ultrasound (EUS) as a first test. If EBUS or EUS is negative the patient will have PET scan +/- mediastinoscopy.
62012962|NCT01519518|ACTIVE_COMPARATOR|Unfractionated heparin|70 units/kg body weight intravenous
62012963|NCT01519518|ACTIVE_COMPARATOR|bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
62012964|NCT04452344|ACTIVE_COMPARATOR|Opioid|Combination analgesic of hydrocodone 5mg/acetaminophen 300 mg and a placebo pill.
62012965|NCT04452344|ACTIVE_COMPARATOR|Non-Opioid|Combination of ibuprofen 400 mg/acetaminophen 500 mg
62012966|NCT00040404|EXPERIMENTAL|CEP-1347 10mg|CEP-1347 was administered at a dosage of 10mg twice daily (bid); capsule strengths were 5, 12.5, and 25 mg. Each patient took 2 capsules at each dosing time, approximately 12 hours apart, within 30 minutes after the morning and evening meals) for a total of 4 capsules per day.Patients were randomly assigned to CEP-1347 or placebo treatment in a 1:1:1:1 ratio. A blocked randomization scheme was used to ensure approximately equal numbers of patients in each of the 4 treatment groups at each center.
62012967|NCT00040404|EXPERIMENTAL|CEP-1347 25mg|CEP-1347 was administered at a dosage of 25mg twice daily (bid); capsule strengths were 5, 12.5, and 25 mg. Each patient took 2 capsules at each dosing time, approximately 12 hours apart, within 30 minutes after the morning and evening meals) for a total of 4 capsules per day.Patients were randomly assigned to CEP-1347 or placebo treatment in a 1:1:1:1 ratio. A blocked randomization scheme was used to ensure approximately equal numbers of patients in each of the 4 treatment groups at each center.
62200997|NCT03655886|EXPERIMENTAL|Radical prostatectomy|
62200998|NCT03655886|EXPERIMENTAL|Radiotherapy|
62200999|NCT04329637|ACTIVE_COMPARATOR|IHC (intergrative health care) arm|Meditation and care coordination in addition to usual care
62201000|NCT04329637|NO_INTERVENTION|usual care|usual care
62401818|NCT01493154|EXPERIMENTAL|Cohort 1 - DNA Vaccine (Dose 0.5 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 0.5 mg/dose) + Cyclophosphamide (200 mg/m2)
62401819|NCT01493154|EXPERIMENTAL|Cohort 2 - DNA Vaccine (Dose 1.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 1.0 mg/dose) + Cyclophosphamide (200 mg/m2)
62401820|NCT01493154|EXPERIMENTAL|Cohort 3 - DNA Vaccine (Dose 2.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 2.0 mg/dose) + Cyclophosphamide (200 mg/m2)
62401821|NCT01493154|EXPERIMENTAL|Cohort 4 - DNA Vaccine (Dose 4.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 4.0 mg/dose) + Cyclophosphamide (200 mg/m2)
62401822|NCT01851824|EXPERIMENTAL|Acenocoumarol + Vemurafenib|
62578728|NCT02339532|EXPERIMENTAL|TOP2A amplified|"If TOP2A amplified: FEC x 3 then THP x 3 3 cycles of FEC 100 administered IV q3w~* 5-Fluorouracil (5-FU) 500 mg/m²~* Epirubicin 100 mg/m²~* Cyclophosphamide 500 mg/m²~Followed by 3 cycles of Trastuzumab-Pertuzumab-Docetaxel:~* Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.~* Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.~* DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w"
62578729|NCT02339532|EXPERIMENTAL|TOP2A not amplified|"If TOP2A not amplified: TCHP x 6 TCHP administered IV q3w for 6 cycles~* Trastuzumab 8 mg/kg loading dose administered IV followed by 6 mg/kg IV q3w in subsequent cycles.~* Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.~* DOCETAXEL 75 mg/m² IV q3w~* CARBOPLATIN AUC 6 IV q3w~The Calvert formula will be used to calculate the dose of carboplatin:~Dose (mg) = target AUC (mg/mL x min) x \[GFR mL/min + 25\] Dose (mg) = 6 x \[GFR mL/min + 25\] NOTE: the Calvert formula gives the dose in mg, not mg/m². GFR, glomerular filtration rate The maximum dose of CARBOPLATIN must not exceed 900 mg."
62012968|NCT00040404|EXPERIMENTAL|CEP-1347 50mg|CEP-1347 was administered at a dosage of 50mg twice daily (bid); capsule strengths were 5, 12.5, and 25 mg. Each patient took 2 capsules at each dosing time, approximately 12 hours apart, within 30 minutes after the morning and evening meals) for a total of 4 capsules per day.Patients were randomly assigned to CEP-1347 or placebo treatment in a 1:1:1:1 ratio. A blocked randomization scheme was used to ensure approximately equal numbers of patients in each of the 4 treatment groups at each center.
62012969|NCT00040404|PLACEBO_COMPARATOR|Placebo|Placebo capsules matching the CEP-1347 capsules were administered in the same manner.
62578730|NCT01521390|OTHER|Treatment Arm|Subjects receive one inhalation from each intervention
62012970|NCT01672125||women who have completed treatments|women who have completed breast cancer treatments, with a diagnosis of unilateral arm lymphedema, in the intensive phase of lymphedema treatment
62012971|NCT01672125||women who have completed treatment in maintenance phase|women who have completed breast cancer treatment and are in the maintenance phase of lymph edema treatment
62012972|NCT01672125||healthy women|healthy women adjusted in age and BMI
62012973|NCT04138927|EXPERIMENTAL|Fostamatinib|"Subjects who at any time during the C-935788-057 study achieved a hemoglobin response will continue at their dose and regimen from the Week 22 visit in the C-935788-057 study.~All other subjects who enter the extension study will initially receive fostamatinib 100 mg PO bid. Starting at Week 4, the initial fostamatinib dose of 100 mg PO bid will be increased to fostamatinib 150 mg PO bid if subjects have adequately tolerated the study drug, based on the Investigator's judgment."
62012974|NCT01117116|ACTIVE_COMPARATOR|fluticasone propionate and salmeterol|
62201001|NCT04685837|EXPERIMENTAL|Tele-rehabilitation group|The participants randomly assigned to the tele-rehabilitation group will use a computer application to know and execute the exercise protocol. Before starting the protocol, each participant will be assessed by the principal investigator. He will explain how the application works. They will perform 2 sessions of therapeutic exercise for 8 weeks. At the end of the protocol, they will be re-evaluated by the principal investigator.
62578731|NCT05619354||Individuals with headache|"Individuals with primary or secondary headache forms.~The Headache Disability Index will be applied:~In the translation phase:~1. Complete and assess the Dutch translation of the HDI questionnaire. The questionnaire and its evaluation can be completed online. If desired, the questionnaire can also be completed on paper, whereby the questions can be asked orally by a researcher.~   OR~   In the validation phase:~2. To complete the Dutch questionnaire, in combination with other questionnaires (RAND-36 questionnaire and HIT-6 questionnaire).The questionnaires can be completed online. If desired, the questionnaires can also be completed on paper. Afterwards participants will be asked to complete the HDI questionnaire again after 1 month."
62578732|NCT02880475|EXPERIMENTAL|OXN prolonged release tablet 5/2.5mg|The subjects were randomized to receive a single dose of OXN prolonged release tablet 5/2.5mg for one time.
62012975|NCT01117116|ACTIVE_COMPARATOR|budesonide and formoterol|
62012976|NCT04689113|EXPERIMENTAL|Intervention Group|ıntervention group After determining the women according to the research criteria, they were randomized into intervention and control groups.Firstly, Pre-tests were applied to the women in the experimental group. The Incontinence Health Belief Development Program was applied to the women in the experimental group as 5 sessions.This program includes the following topics; urinary system anatomy and physiology, urinary incontinence and risk factors, definition of kegel exercise and its place in urinary incontinence treatment, kegel exercise applied expression, health motivation. A WhatsApp group was established to remind women in the intervention group about the kegel exercise 3 times a day for 3 months to increase their self-efficacy. In addition, a facebook group was opened and posts about urinary incontinence and kegel exercises were made. Posttests were made 3 months after the training ended
62012977|NCT04689113|NO_INTERVENTION|Control Group|Firstly, Pre-tests were applied to the women in the control group. No intervention was applied to this group.Posttests were made 3 months after pre-test.
62012978|NCT00453765|EXPERIMENTAL|A|montelukast
62201002|NCT04685837|EXPERIMENTAL|Face to face group|Participants randomly assigned to the face-to-face group will use the physical therapy clinic to do the exercises controlled by the principal investigator. Before starting the protocol, each participant will be assessed by the principal investigator. He will explain how the protocol works. They will perform 2 sessions of therapeutic exercise for 8 weeks. At the end of the protocol, they will be re-evaluated by the principal investigator.
62201003|NCT02926222|EXPERIMENTAL|ARM A - Regorafenib|Patients receive REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity.
62578733|NCT02880475|EXPERIMENTAL|OXN prolonged release tablet 20/10mg|The subjects were randomized to receive a single dose of OXN prolonged release tablet 20/10 mg for one time.
62012979|NCT00453765|PLACEBO_COMPARATOR|B|placebo
62012980|NCT06548451|EXPERIMENTAL|AR-guided group|Application of augmented reality technique for percutaneous lung nodule localization.
62012981|NCT06548451|NO_INTERVENTION|CT-guided group|Computerized tomography (CT) guided percutaneous lung nodule localization.
62012982|NCT01416805|EXPERIMENTAL|Computerized Cognitive Behavioral Therapy|
62012983|NCT01416805|ACTIVE_COMPARATOR|Treatment as Usual|
62201004|NCT02926222|ACTIVE_COMPARATOR|ARM B - Lomustine|Patients receive LOMUSTINE 110 mg/m2 orally on day 1, every 6 weeks (q6w), until disease progression or unacceptable toxicity.
62201005|NCT00585858||1|Subjects on mimimal or no immunosuppression and no rejection history
62201006|NCT00585858||2|Subjects who have had rejection on conventional immunosuppression
62201007|NCT00585858||3|Subjects who have not had acute or chronic rejection who are on conventional immunosuppression
62201008|NCT03840005|PLACEBO_COMPARATOR|Placebo|2:1 in favour of UDCA
62201009|NCT03840005|EXPERIMENTAL|Ursonorm (Ursodeoxycholic acid)|UDCA 30 mg/kg daily, tablet form taking orally , administered 3 monthly for 12 months, dose titration during the 1st month will occur.
62201010|NCT05756712|ACTIVE_COMPARATOR|Wonderlab Product plus Placebo|"Wonderlab product: White Kidney Bean Pressed Candy, 4g/tablet, per serving 750mg extracts of the white kidney bean.~Placebo: 4g/tablet, per serving 750mg Maltodextrin"
62401823|NCT02847663|EXPERIMENTAL|Whole-body cryotherapy|The effects of whole-body cryotherapy (-135°C for 2 minutes) are investigated after a muscle damage protocol.
62401824|NCT02847663|OTHER|Cold-water immersion|The effects of cold-water immersion (10°C for 15 minutes) are investigated after a muscle damage protocol.
62401825|NCT02675699|EXPERIMENTAL|Optimisation + HENRY|
62578734|NCT01962077|EXPERIMENTAL|MedCem MTA pulpotomies|
62012984|NCT06521918||Term infants|"The inclusion criterion is: gestational age 37-42 weeks, birth body weight \>2,500 grams, and age at 2-18 months.~The exclusion criterion is: parents can not read Chinese."
62012985|NCT06521918||Preterm infants|"The inclusion criterion is: gestational age \< 37 weeks, birth body weight \< 2,500 grams, and corrected age of 2-18 months.~The exclusion criterion is: parents can not read Chinese."
62012986|NCT06521918||Clinicians|"The inclusion criterion is: who provide early intervention to the participating infants in this study.~The exclusion criterion is: can not read Chinese"
62012987|NCT05455567||patients with pre perimetric open angle glaucoma|
62012988|NCT05455567||patients with perimetric open angle glaucoma|
62012989|NCT05455567||healthy patients|
62012990|NCT01034397|EXPERIMENTAL|1|
62012991|NCT01034397|PLACEBO_COMPARATOR|2|
62012992|NCT05866003|ACTIVE_COMPARATOR|Active conventional tDCS plus CCFES|The conventional tDCS montages involves placing the surface anode electrode on the scalp of the lesioned hemisphere and the surface cathode electrode on the scalp of the non-lesioned hemisphere. TDCS will deliver a low current while participants are undergoing CCFES-mediated functional task practice.
62012993|NCT05866003|ACTIVE_COMPARATOR|Active unconventional tDCS plus CCFES|The unconventional tDCS montages involves placing the surface anode electrode on the scalp of the non-lesioned hemisphere and the surface cathode electrode on the scalp of the lesioned hemisphere. TDCS will deliver a low current while participants are undergoing CCFES-mediated functional task practice.
62201011|NCT05756712|ACTIVE_COMPARATOR|Placebo plus Wonderlab Product|Placebo: 4g/tablet, per serving 750mg Maltodextrin Wonderlab product: White Kidney Bean Pressed Candy, 4g/tablet, per serving 750mg extracts of the white kidney bean.
62201012|NCT05504850|OTHER|All participants will receive the intervention|
62401826|NCT02675699|ACTIVE_COMPARATOR|HENRY as standard|
62401827|NCT03487159|OTHER|Liver biopsy ,Elastography and MRE|Performance of routine Liver biopsy,Shear Wave Elastography and investigational MRE (Magnetic Resonance Elastography) in order to evaluate liver fibrosis stage.
62401828|NCT03487159|OTHER|Elastography and MRE|Performance of routine Shear Wave Elastography and investigational MRE (Magnetic Resonance Elastography) in order to evaluate liver fibrosis stage.
62401829|NCT00777790|EXPERIMENTAL|Menactra® Group|Received Menactra® vaccine in Study MTA02
62401830|NCT00777790|EXPERIMENTAL|Menomune® Group|Received Menomune® vaccine in Study MTA02
62401831|NCT00777790|EXPERIMENTAL|Control Group|Meningococcal vaccine-naïve Control Group.
62401832|NCT01848392||physical activity CF cohort|adult patients with CF at time of their yearly assessment at Cochin adult CF centre
62401833|NCT05550103|ACTIVE_COMPARATOR|RIC+Standard medical treatment|RIC+Standard medical treatment. Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days from thrombolysis.
62578735|NCT03198065|EXPERIMENTAL|Hand-made glove setting|The patients receive Hand-made glove setting
62578736|NCT03198065|EXPERIMENTAL|commercialized multiport setting|The patients receive commercialized single-incision multiport setting
62578737|NCT04087720|EXPERIMENTAL|Pegloticase|Participants receive 8 mg pegloticase every 2 weeks from Day 1 through Week 22
62578738|NCT01634048|EXPERIMENTAL|High protein low calorie meal replacements|Meal replacements with added protein powder(1.34g pro/kg).
62578739|NCT01634048|SHAM_COMPARATOR|Normal protein, low calorie meal replacement group|The control group will have standard meal replacements (0.8g protein/kg body weight).
62201013|NCT04278027|EXPERIMENTAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy. CRT will be based on CIRCuiTS, a computerized program.
62201014|NCT04278027|NO_INTERVENTION|Treatment as usual|Treatment as usual
62201015|NCT05946720|EXPERIMENTAL|Taining group|Nurses in the training group were given training on aggression and the use of BVC.
62201016|NCT05946720|NO_INTERVENTION|Control group|Nurses in the control group were not trained, till the study ends.
62201017|NCT02345590|EXPERIMENTAL|Eplerenone|25mg Eplerenone once daily for 12 months
62201018|NCT02345590|PLACEBO_COMPARATOR|Matching placebo|Matching placebo once daily for 12 months
62201019|NCT05232747||Study|Participants' pain level and pain-related behaviors will be questioned.
62201020|NCT00455221|EXPERIMENTAL|Peptide Vaccine|
62201021|NCT05774288|EXPERIMENTAL|Cera™ patent foramen ovale occluders|Patients with cryptogenic stroke complicated with patent foramen ovale will be implanted with the Cera™ patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
62201022|NCT05774288|ACTIVE_COMPARATOR|Another patent foramen ovale occluders|Patients with cryptogenic stroke complicated with patent foramen ovale will be implanted with the Another patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
62201023|NCT00567567|ACTIVE_COMPARATOR|Consolidation Arm A: single myeloablative consolidation|Patients receive melphalan IV over 15-30 minutes on days -7 to -5, etoposide IV over 24 hours and carboplatin IV over 24 hours on days -7 to -4, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Patients undergo autologous PBSCT on day 0.
62201024|NCT00567567|EXPERIMENTAL|Consolidation Arm B: tandem myeloablative consolidation|Patients receive thiotepa IV over 2 hours on days -7 to -5, cyclophosphamide IV over 1 hour on days -5 to -2, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Following clinical recovery from initial myeloablative therapy, patients also receive melphalan, etoposide, and carboplatin as in Arm A. Patients undergo autologous PBSCT on day 0.
62201025|NCT01606670||Neupro® Treatment|Routine treatment with Neupro® (2, 4, 6, 8, 10, 12, 14, 16 mg/24 h) as per approved label in the EU, which is applicable in the EU member state Germany.
62201026|NCT03219957|EXPERIMENTAL|AT-527|
62401834|NCT05550103|PLACEBO_COMPARATOR|Sham RIC+Standard medical treatment|Sham RIC+Standard medical treatment. Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days from thrombolysis.
62401835|NCT02191033|EXPERIMENTAL|Text messaging|Smoking counseling, nicotine patch, text messaging
62401836|NCT02191033|ACTIVE_COMPARATOR|Standard of care|Smoking counseling, nicotine patch
62401837|NCT05335161|EXPERIMENTAL|Home-based leg heat therapy|Patients will be provided with the Aquilo heat therapy device and will be instructed on how to operate the equipment. The device will be used in accordance to the manufacturers recommendations. Patients will be asked to apply the therapy daily in the home setting for 12 week (90 min/day, 7 days/week).
62578740|NCT05989347|EXPERIMENTAL|Dapagliflozin|All participants (with insulin resistance and Estrogen Receptor (ER)+HER2-negative or ER/Progesterone receptor (PR)/HER2-negative breast cancer) will receive current standard of care neoadjuvant chemotherapy as determined by the treating physician, plus dapagliflozin 10 mg orally taken daily throughout chemotherapy treatment.
62578741|NCT04059705|EXPERIMENTAL|Dual-Task Intervention|This study arm will receive the dual-task training program.
62578742|NCT02640677||Pregnant women exposed to 4CMenB|Pregnant women within the United States (U.S) who received at least 1 dose of 4CMenB vaccine within 30 days prior to Last Menstrual Period (LMP) or at any time during pregnancy
62578743|NCT03271281|EXPERIMENTAL|Experimental: Angiogenesis PET/CT|One injection of the radioligand 68Ga-NODAGA-E\[c(RGDyK)\]2 followed by PET/CT
62578744|NCT03764397|EXPERIMENTAL|Prehabilitation group|A 4-week prehabilitation educational programme (i.e., a behavioral change intervention) and to pilot that prehabilitation in combination with a 6-week gentle self-paced walking programme (with weekly telephone support) in people with FM.
62401838|NCT06502002|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine infusion arm
62401839|NCT06502002|PLACEBO_COMPARATOR|Placebo|Normal saline infusion arm
62401840|NCT03415815||T1-T3 esophageal cancer|Pathologically diagnosed patients with T1-T3 esophageal cancer who received surgeries
62578745|NCT02504905|EXPERIMENTAL|PAR-CD|CD and age/sex matched HV control
62578746|NCT02504905|EXPERIMENTAL|PAR-WC|WC and age/sex matched HV control
62201027|NCT03219957|PLACEBO_COMPARATOR|Placebo|
62201028|NCT06236633|NO_INTERVENTION|Control group|In the control group, patients will undergo standard management.
62201029|NCT06236633|EXPERIMENTAL|Ischemic preconditioning group|"In the experimental group, patients will undergo preoperative arteriography and ischemic preconditioning One blood sample will be taken before and two samples taken after embolization of the IMA.~These patients will receive a phone call on Day 7 post embolization. A blood sample will also be taken at the time of surgery."
62201030|NCT04221672|EXPERIMENTAL|Terlipressin plus standard care|Immediately after hepatectomy, 1 mg terlipressin was given intravenously after hemostasis was achieved. After surgery, participants were routinely managed, and terlipressin were administrated at a dosage of 2 mg per day for 4 days.
62201031|NCT04221672|OTHER|Standard care|Participants were not administrated with terlipressin during surgery and were routinely managed after surgery.
62201032|NCT00917800||suspected coronary artery disease|patients referred to angiography because of suspected coronary artery disease
62201033|NCT04127981|ACTIVE_COMPARATOR|Patients with cancer cachexia|20 patients with advanced/metastatic colorectal, non-small cell lung cancer (NSCLC), or pancreatic cancer with documented cachexia.
62201034|NCT04127981|ACTIVE_COMPARATOR|Patients without cancer cachexia|20 patients with advanced/metastatic colorectal, non-small cell lung cancer (NSCLC) or pancreatic cancer without cachexia.
62401841|NCT05669612|ACTIVE_COMPARATOR|Dairy based protein|"Milk protein isolate~For bioavailability sessions: 20 grams of protein dissolved in water 200 ml water Then 50g per day (2 x 25g serves dissolved in 200 ml water) over 2 weeks"
62012994|NCT05866003|SHAM_COMPARATOR|Sham tDCS plus CCFES|The sham tDCS montages involves placing the surface electrodes on the scalp over the lesioned and the non-lesioned hemisphere. TDCS will not be delivered during CCFES-mediated functional task practice.
62012995|NCT03713489|EXPERIMENTAL|Platelet transfusion group|Besides standard medical treatment, up to 9 units of platelets will be transfused per protocol within 4 weeks
62012996|NCT03713489|NO_INTERVENTION|standard medical treatment group|standard medical treatment
62012997|NCT05635747||Patients who have completed the Relizorb Trial and consented into the 90 day extension trial|Patients aged 2-18 who have completed the 90 day open label phase 3 Relizorb trial who consent to the 90 day observational Relizorb extension trial
62012998|NCT06309199|EXPERIMENTAL|Probiotics|Limosilactobacillus reuteri DSM 17938 with sunflower oil and MCT oil were packed into a container. Infants will received 5 drops per day in the morning for 60 +/- 20 days
62012999|NCT06309199|PLACEBO_COMPARATOR|Placebo|Sunflower oit and MCT oil were paced into a container. Infants will received 5 drops per day in the morning for 60+/- 20 days
62013000|NCT04387162|EXPERIMENTAL|Immediate|Participants will enter treatment after one week baseline
62013001|NCT04387162|EXPERIMENTAL|Delayed|Participants will enter treatment after two week baseline
62013002|NCT00129519|ACTIVE_COMPARATOR|Imiquimod cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
62013003|NCT06271551|EXPERIMENTAL|Transdermal estradiol|Participants (n=155) receiving transdermal estradiol and androgen deprivation therapy.
62013004|NCT06271551|ACTIVE_COMPARATOR|Androgen deprivation therapy|Participants (n=155) receiving solely androgen deprivation therapy.
62013005|NCT01298284|NO_INTERVENTION|EVL\GVS Alone|Endoscopic ligation treatment in the 2nd prevention of gastroesophageal variceal bleeding in patients with HCC
62013006|NCT01298284|ACTIVE_COMPARATOR|EVL\GVS Combined Propranolol|"Propranolol and endoscopic ligation treatment is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.~\<EVL\\GVS Combined Propranolol\>"
62013007|NCT03202316|EXPERIMENTAL|Cohort I (atezolizumab, cobimetinib, eribulin)|Patients receive atezolizumab IV over about 30-60 minutes every 2 weeks, cobimetinib PO daily for 3 weeks on, 1 week off for 4 weeks of the safety lead-in course. Patients then receive atezolizumab IV over about 30-60 minutes every 2 weeks, cobimetinib PO daily for 3 weeks on, 1 week off, and eribulin IV over 2-5 minutes on days 1 and 8 of cycles 1-4. Cycles 1-4 repeat every 21 days and subsequent cycles with atezolizumab and cobimetinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62013008|NCT03202316|EXPERIMENTAL|Cohort II (atezolizumab, eribulin)|Patients receive atezolizumab IV over about 30-60 minutes every 3 weeks for cycles 1-6 and every 4 weeks for subsequent cycles, and eribulin IV over 2-5 minutes on days 1 and 8 of cycles 1-6. Cycles 1-6 repeat every 21 days and subsequent cycles with atezolizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62013009|NCT06339827|EXPERIMENTAL|Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List|Participants are provided with a question prompt list
62013010|NCT06339827|NO_INTERVENTION|No administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List|Participants will not be provided with the question prompt list
62013011|NCT05544461|EXPERIMENTAL|Intervention group|Those in the intervention group will receive eNutri PN advice after completing the eNutri FFQ at baseline only. At weeks 1 and 3 of the study, participants will also receive coaching emails which includes reminders of their PN advice, questions asking them to reflect on their goal progress (if any), and tips and recipes to help them follow the PN advice.
62401842|NCT05669612|EXPERIMENTAL|Mixed protein|"Milk and plant based protein mix~For bioavailability sessions: 20 grams of protein dissolved in water 200 ml water Then 50g per day (2 x 25g serves dissolved in 200 ml water) over 2 weeks"
62578747|NCT02246543|PLACEBO_COMPARATOR|Treatment 1 - Control|Water, Toast \& Egg (Yolk only) + 0.1g 13C Octanoic Acid
62578748|NCT02246543|ACTIVE_COMPARATOR|Treatment 2 - HPL|High Protein Smoothie (Liquid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
62578749|NCT02246543|ACTIVE_COMPARATOR|Treatment 3 - LPL|Low Protein Smoothie (Liquid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
62578750|NCT02246543|ACTIVE_COMPARATOR|Treatment 4 - HPS|High Protein Milk Jelly (Solid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
62578751|NCT02246543|ACTIVE_COMPARATOR|Treatment 5 - LPS|Low Protein Milk Jelly (Solid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
62578752|NCT05931341|EXPERIMENTAL|Dosage 1|
62201035|NCT05445947|EXPERIMENTAL|Intervention Group|Educators working at childcare centers in the intervention group will be trained and provided with ongoing coaching in the EASEL Approach.
62401843|NCT05669612|EXPERIMENTAL|Plant-based protein 1|"Plant based protein mix~For bioavailability sessions: 20 grams of protein dissolved in water 200 ml water Then 50g per day (2 x 25g serves dissolved in 200 ml water) over 2 weeks"
62401844|NCT05669612|EXPERIMENTAL|Plant-based protein 2|"Plant based protein mix with fiber~For bioavailability sessions: 20 grams of protein dissolved in water 200 ml water Then 50g per day (2 x 25g serves dissolved in 200 ml water) over 2 weeks"
62401845|NCT04782882|EXPERIMENTAL|intervention group|In the first session of the researcher (S.K.), the participants were explained the effects of anxiety and stress on the treatment in simple terms for 5 min. Then, information was given about the effects of laughter therapy and progressive muscle relaxation on the body. Laughter therapy was applied for 15-20 min. Then, the lights were turned off and progressive muscle relaxation exercises were performed for 15-20 min under candlelight and accompanied by music. The procedures were received as a group (2-6 people) in 3-4 face-to-face sessions.
62401846|NCT04782882|NO_INTERVENTION|Control group|The control group then received routine care
62578753|NCT05931341|EXPERIMENTAL|Dosage 2|
62578754|NCT05931341|EXPERIMENTAL|Dosage 3|
62784803|NCT02695693|EXPERIMENTAL|TeachTown|Students in kindergarten-through-second-grade autism support classrooms in this arm receive access to TeachTown, an online academic and pre-academic intervention designed for students with autism. Their teachers also receive coaching in the use of TeachTown, as well as coaching in other evidence-based practices for students with autism, including discrete trial training, pivotal response training, and teaching in functional routines
62013012|NCT05544461|NO_INTERVENTION|Control group|Those in the control group will not receive any PN advice from eNutri and hence, will not receive any coaching emails. They will only record their diet using the eNutri FFQ.
62401847|NCT04017416||Standard Care|Audiologists in the standard care group were instructed to manage the patients in the same way as they would do in their routine clinics which were in accordance with national practice guidelines and were typical of National Healthcare Services (NHS) audiology departments across the UK.
62401848|NCT04017416||I-PLAN|Audiologists were instructed to deliver the I-PLAN in addition to standard care at the hearing aid fitting consultation.
62401849|NCT01338311|ACTIVE_COMPARATOR|salbutamol|
62784804|NCT02695693|ACTIVE_COMPARATOR|Control|Teachers in kindergarten-through-second-grade autism support classrooms in this arm receive coaching in evidence-based practices for students with autism, including discrete trial training, pivotal response training, and teaching in functional routines
62784805|NCT04374240|EXPERIMENTAL|AdNRGM followed on day 2 by CB1954|The proposed dose levels for AdNRGM are 10\^10, 3x10\^10, 10\^11, 3x10\^11, 10\^12 vp while the prodrug CB1954 will be given at a standard dose of 24 mg/m\^2
62013013|NCT06200805|EXPERIMENTAL|High Intensity Taijiquan Exercise Group|60 minutes of tai chi exercise 5 times a week
62013014|NCT06200805|EXPERIMENTAL|Moderate Intensity Taijiquan Exercise Group|60 minutes of tai chi exercise 3 times a week
62401850|NCT01338311|PLACEBO_COMPARATOR|placebo|200mcg twice daily for a total of 7 doses
62401851|NCT00058097|EXPERIMENTAL|Treatment (tipifarnib)|"INDUCTION THERAPY: Patients receive oral tipifarnib twice daily for 3 weeks. Treatment repeats every 4 weeks for up to 3 courses.~RADIOTHERAPY: Within 14 days after the completion of induction therapy, patients undergo radiotherapy daily, 5 days a week, for 6 weeks.~MAINTENANCE THERAPY: Two weeks after the completion of radiotherapy, patients receive additional tipifarnib as in induction therapy.~Treatment continues in the absence of disease progression or unacceptable toxicity."
62578755|NCT02467790|EXPERIMENTAL|Mild renal insufficiency|PEX 168: 200µg,Subcutaneous,one time.
62201036|NCT05445947|NO_INTERVENTION|Control Group|Educators in the control group will continue with business-as-usual. Control group educators will be offered the opportunity to receive training in the EASEL Approach after completion of the trial.
62578756|NCT02467790|EXPERIMENTAL|Moderate renal insufficiency|PEX 168: 200µg,Subcutaneous,one time.
62578757|NCT02467790|EXPERIMENTAL|Normal renal function|PEX 168: 200µg,Subcutaneous,one time.
62201037|NCT00590655|ACTIVE_COMPARATOR|2|Treatment B includes a four month weight loss programme (10 weeks on a VLED and 17 weeks behavior modification visits). Treatment lasts 17 weeks and after that there will be one and two year control visits including weighing and questionnaires for eating behavior and quality of life.
62578758|NCT05930626||SMC-C|Swedish Mammography Cohort-clinical (SMC-C) is a clinical sub-cohort established between 2003 and 2008, consisting of 5022 women, 56-80 years of age, living in Uppsala. These women have completed a detailed questionnaire on diet and lifestyle factors and underwent a health examination, dual-energy X-ray absorptiometry and biological sampling.
62013015|NCT06200805|NO_INTERVENTION|control subjects|The control group did not implement any intervention and maintained a normal life and study status.
62013016|NCT01169389|ACTIVE_COMPARATOR|Durolane|
62578759|NCT05930626||60YO|The cohort of 60-years olds (60YO) was established with the aim to study CVD etiology and consists of 4,232 men and women aged 60 years who were randomly selected from Stockholm County and with baseline examination during 1 year in 1997-98. The study participants underwent a health examination, completed a questionnaire, and donated blood samples.
62013017|NCT01169389|PLACEBO_COMPARATOR|Bupivacaine|
62013018|NCT01083381|ACTIVE_COMPARATOR|treatment group|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months. MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months.
62013019|NCT01083381|PLACEBO_COMPARATOR|Control group|Receives the same dosage of Risperidone. Placebo is given to this group in same form and appearance as MS14 in the other arm of the study.
62578760|NCT00410735|PLACEBO_COMPARATOR|P|
62578761|NCT00410735|EXPERIMENTAL|E|
62578762|NCT04664023||Patients with severe SARS-CoV-2 infection|Patients with severe SARS-CoV-2 infection hospitalised in intensive care unit
62013020|NCT05468840|EXPERIMENTAL|Intravenous ketamine infusion|Participants in the intervention group will receive 0.5mg/kg of 1mg/mL intravenous ketamine (50 mg maximum) over 40 minutes.
62013021|NCT05468840|PLACEBO_COMPARATOR|Intravenous normal saline infusion|Participants in the control group will receive 0.5mL/kg intravenous normal saline (50 ml maximum) over 40 minutes.
61978317|NCT05417165|EXPERIMENTAL|Arm B (Experimental ARM-No Booster)|Patients receive PCV 20 IM at week 0 and PSV23 IM at week 8. Titers will be checked 4 weeks after the first dose and at 12 weeks (4 weeks after the second dose). Booster Vaccine: None. Annual titers will be checked for 5 years.
62013022|NCT00466193|EXPERIMENTAL|Zolpidem 3.5mg|
62013023|NCT00466193|PLACEBO_COMPARATOR|Placebo|
62013024|NCT01997359||Key Informant Interviews|Eligible patients will undergo a one hour structured interview about barriers and facilitators to early ART initiation.
62013025|NCT01997359||Prospective Cohort|The prospective cohort will include all patients initiating ART at one of the six study sites, estimated at 1,200 patients. Cases will be adults initiating ART with either: CD4 count \<150 cells/µL. Controls will be adults who initiate ART with CD4≥200 . Individuals initiating ART with CD4 counts of 150-199 cells per µL and at WHO Stage I-III will be excluded from the case-control analysis in order to ensure meaningful distinction between the two groups. We will enroll 720 patients for the case control study nested in the prospective cohort, which will include 360 cases and 360 controls, who will be frequency matched by sex, month of ART initiation, and clinic.
62013026|NCT02605512|OTHER|Breast cancer patients with 3DCRT|Measures of subclinical functional and anatomical cardiac lesions and circulating biomarkers 'Subclinical cardiac lesions and biomarkers'
62013027|NCT04163549|EXPERIMENTAL|Safe at Home Cycle 1|The experimental arm will receive the Safe at Home program which is a community-based discussion group series aiming to prevent and respond to intimate partner violence and child maltreatment in conflict-affected communities. It includes once weekly, single-sex discussion groups with coupled men and women and once monthly family discussion groups with couples and children. During the weekly sessions men and women reflect critically and engage in dialogue related to gender, power, and privilege, learn about the causes and consequence of violence against women and children and gain skills in stress management, psychosocial support and positive parenting strategies. Family sessions focus on improving relationship quality and shared decision-making among partners and participation of children in family decision-making.
62401852|NCT02208518||Elastography analysis|Consecutive patients undergoing for upper endoscopy ultrasound
62401853|NCT02890420||Female children|Female children in third year of preschool in Thionville (north-eastern France)
62401854|NCT02890420||Male children|Male children in third year of preschool in Thionville (north-eastern France)
62401855|NCT03521622|EXPERIMENTAL|brief counseling interventions|"For smoking patients the brief intervention is 5 As model for motivated patients and 5Rs for not motivated patients.~For risky alcohol drinkers the brief intervention is simple advise for motivated patients and brief intervention for not motivated patients."
62401856|NCT03521622|PLACEBO_COMPARATOR|Control group|written informative material about healthy lifestyles
62401857|NCT02267031|ACTIVE_COMPARATOR|normoxia and normocapnia|Normoxia PaO2 of 70-140 mm Hg Normocapnia PaCO2 of 35-48 mmHg
62578763|NCT04664023||Patients with intermediate SARS-CoV-2 infection|Patients with intermediate SARS-CoV-2 infection hospitalised in infectious and tropical diseases department
62578764|NCT04664023||Little symptomatic patients with SARS-CoV-2 infection|Little symptomatic ambulatory patients with SARS-CoV-2 infection
62201038|NCT00590655|EXPERIMENTAL|1|Treatment includes a four month weight loss programme (10 weeks on a VLED and 17 weeks behavior modification visits). After that a maintenance programme starts with monthly sessions for one year. Weight loss, quality of life, and eating behavior will be assessed at the end of the maintenance program and one year later.
62201039|NCT04700553|EXPERIMENTAL|Conventional physical therapy intervention plus localized muscle vibration|physical therapy intervention plus localized muscle vibration
62201040|NCT04700553|SHAM_COMPARATOR|Conventional physical therapy intervention|physical therapy intervention
62201041|NCT00919191|EXPERIMENTAL|Two interventions in split-face model|"Once daily use in a split face model:~1. Tretinoin gel~2. Adapalene Benzoyl peroxide"
62578765|NCT04664023||Patients with SARS-CoV-2 infection hospitalised in geriatry department|Patients with SARS-CoV-2 infection hospitalised in geriatry department to study influence of age on the studied mechanisms
62578766|NCT04664023||Subjects above 65 years wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine|Subjects above 65 years wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine
62578767|NCT04664023||Subjects below 65 years wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine|Subjects below 65 years wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine
62578768|NCT05527327|EXPERIMENTAL|Prospective arm|All prospective participants will be consented to use of the intervention, a pannus retractor at time of detailed obstetric ultrasound.
62578769|NCT05458401||Trastuzumab Deruxtecan (T-DXd) Cohort|Patients with advanced/metastatic HER2-positive breast cancer who are receiving treatment (or previously treated) with trastuzumab deruxtecan (T-DXd).
62578770|NCT02620163|EXPERIMENTAL|YH22162|YH22162 40/5/12.5 mg (telmisartan 40/amlodipine 5mg/chlorthalidone 12.5mg) for the first 2 weeks, then force titrated to YH22162(telmisartan 80mg/amlodipine 5mg/chlorthalidone 25mg) for the remaining 6weeks
62578771|NCT02620163|ACTIVE_COMPARATOR|telmisartan/amlodipine|Twynsta(telmisartan 40/amlodipine 5mg) for the first 2 weeks, then force titrated to Twynsta(telmisartan 80mg/amlodipine 5mg) for the remaining 6weeks
62201042|NCT03470259|EXPERIMENTAL|EMI-137 0.09mg/kg administration|"Three patients will be once administered with EMI-137 0.09 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
62401858|NCT02267031|ACTIVE_COMPARATOR|hyperoxia and normocapnia|Hyperoxia 150-300 mm Hg Normocapnia PaCO2 of 35-48 mmHg
62401859|NCT02267031|ACTIVE_COMPARATOR|normoxia and hypocapnia|Normoxia PaO2 of 70-140 mm Hg Hypocapnia PaCO2 of 25-35 mmHg
62401860|NCT02267031|ACTIVE_COMPARATOR|hyperoxia-hypocapnia|Hyperoxia 150-300 mm Hg Hypocapnia PaCO2 of 25-35 mmHg
62578772|NCT02497560|ACTIVE_COMPARATOR|Treatment|all natural dietary supplement
62578773|NCT02497560|OTHER|Treatment + Omega-3s|all natural dietary supplement + omega-3s
62410069|NCT01035229|PLACEBO_COMPARATOR|Placebo + Best Supportive Care|Placebo Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the control drug. In addition to taking Placeb Everolimus, all patients also received BSC as per normal local practice.
62410070|NCT00075101|EXPERIMENTAL|Study Cycle|
62578774|NCT02497560|PLACEBO_COMPARATOR|Placebo|vegetable oil
62578775|NCT02112045|EXPERIMENTAL|Experimental: Granix and high dose melphalan (HDM)|"Granix on Day -7 through Day -2.~HDM intravenously (IV) on Day -2.~Autologous stem cell transplantation on Day 0"
62578776|NCT02112045|ACTIVE_COMPARATOR|Control: High dose melphalan (HDM)|"HDM intravenously (IV) on Day -2.~Autologous stem cell transplantation on Day 0."
62578777|NCT06308692|OTHER|Biological samples|Residual anonymized samples stored at -80°C at the Tropica Biobank of the DITM and for which diagnostic analysis for germ infection has previously been carried out at the DITM by blood culture and MDR surveillance in routine diagnostic rectal swab will be used.
62784806|NCT03320135|ACTIVE_COMPARATOR|Enamel matrix derivative proteins|Open flap debridement to enamel matrix derivative application in proximal class-II furcation.
62201043|NCT03470259|EXPERIMENTAL|EMI-137 0.13mg/kg administration|"Three patients will be once administered with EMI-137 0.13 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
62578778|NCT05733065|OTHER|Monozygotic Twin|we will include natural conceived twin pairs born before 2002, with known birth weight, sex and gestational age, and where both twins were live born without congenital abnormality. Twins born after pregnancies complicated by conditions such as TTTS will be excluded. MZ twins pairs will be ranked according to intra-pair birth weight difference. Next, we intend to include the 120 most discordant monozygotic twin pairs, stratified by chorionicity (1:1 ratio) and in the case of DC by fusion of the placentas (1:1 ratio). Only pairs where both twins consent to inclusion in the study will be included.
62578779|NCT03296410|EXPERIMENTAL|EV71 and two measles attenuated live vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) and two measles attenuated live vaccine at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
62578780|NCT03296410|EXPERIMENTAL|EV71 and attenuated Japanese encephalitis vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) and live attenuated Japanese encephalitis vaccine at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
62578781|NCT03296410|ACTIVE_COMPARATOR|two measles attenuated live vaccine|infants vaccinated with two measles attenuated live vaccine at 8 months old
62578782|NCT03296410|ACTIVE_COMPARATOR|live attenuated Japanese encephalitis vaccine|infants vaccinated with live attenuated Japanese encephalitis vaccine at 8 months old
62578783|NCT03296410|ACTIVE_COMPARATOR|EV71 vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
62578784|NCT03877601|EXPERIMENTAL|Topical administration of bevacizumab-800CW|The tracer will be topically administered 5 minutes prior to the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform).
62578785|NCT06574984||Turoctocog alfa|Participants received turoctocog alfa intravenously.
62578786|NCT05921292|EXPERIMENTAL|Omeza® Products Used in Combination|Subjects in this single-arm study will have the targeted wound/ulcer treated with a combination therapy which includes the use of a wound preparation (2mL vial), a skin protectant (2mL vial), and a wound matrix (1.6g vial). Patients will be treated weekly for four weeks. Treatment may be continued weekly for an additional 8 weeks with participant and investigator agreement.
62578787|NCT02752061|EXPERIMENTAL|Kweneng East District|Patient presenting with possible cancer symptoms/sign to a clinic or hospital in Kweneng East District during study period.
62578788|NCT02752061|NO_INTERVENTION|All other districts|Patient presenting with possible cancer symptoms/sign to a clinic or hospital in all other districts of Botswana (or Kweneng East prior to implementation of intervention).
62578789|NCT06274073|EXPERIMENTAL|Single injection palmar digital block|The needle was inserted into the subcutaneous region from the palmar side to the root of the proximal phalanx, perpendicular to the frontal plane and the finger. For anesthesia, 3 ml of anesthetic agent (prilocaine hydrochloride) was applied to the described point with this single injection and the needle was slowly removed.
62013028|NCT04163549|NO_INTERVENTION|Safe at Home Cycle 2|During the period of the study, this group will not receive an intervention. Rather, this arm will receive the Safe at Home program after endline data collection is completed for a waitlisted group.
62215052|NCT04713891|EXPERIMENTAL|Phase Ib, Cohort 3|KF-0210 (dose RP2D, orally once daily)+ Atezolizumab (1200 mg every 3 weeks) continuously until disease progression/recurrence or death from any cause, or serious adverse events (SAE) observed (whichever occurs earlier) for up to 2 years.
62578790|NCT06274073|EXPERIMENTAL|Double injection dorsal digital block|The needle was inserted into the proximal dorsal root of the proximal phalanx, into both the medial and lateral parts, perpendicular to the fingers and the frontal plane. After the aspiration, the injection was performed slowly and the needle was withdrawn concurently. A total of 3 ml of anesthetic agent (prilocaine hydrochloride) was injected into both the medial and lateral parts of the finger, 1.5 ml for each side.
62578791|NCT05425576|EXPERIMENTAL|Drug OT-101 plus pembrolizumab|"OT-101 will be administered at a RP2D dose/m2/day for 4 days continuously and 10 days off every two weeks via a portable infusion pump.~Pembrolizumab will be administered with the standard regimen of 400 mg intravenously (IV) every six weeks."
62578792|NCT03061136|PLACEBO_COMPARATOR|Placebo|Placebo administered orally
62578793|NCT03061136|EXPERIMENTAL|Clonazepam 0.1mg|0.1mg clonazepam administered orally
62578794|NCT03061136|EXPERIMENTAL|Clonazepam 0.2mg|0.2mg clonazepam administered orally
62578795|NCT03061136|EXPERIMENTAL|Clonazepam 0.3mg|0.3mg clonazepam administered orally
62578796|NCT02466815|EXPERIMENTAL|Treatment A, then Treatment B and then Treatment C|Participants will receive treatment A (JNJ-42756493 10 milligram \[mg\] tablet, current clinical formulation \[G-018\] which uses milled active pharmaceutical ingredient \[API\]) in period 1, treatment B (JNJ-42756493 10 mg tablet, Prototype Formulation I \[G-025\] which uses coarser API) in period 2 and then treatment C (JNJ-42756493 10 mg tablet, Prototype Formulation II \[G-025\] which uses coarser API) in period 3.
62578797|NCT02466815|EXPERIMENTAL|Treatment B, then Treatment C and then Treatment A|Participants will receive treatment B in period 1, treatment C in period 2 and then treatment A in period 3.
62578798|NCT02466815|EXPERIMENTAL|Treatment C, then Treatment A and then Treatment B|Participants will receive treatment C in period 1, treatment A in period 2 and then treatment B in period 3.
62215053|NCT01488877|EXPERIMENTAL|PF03882845|
62201044|NCT03470259|EXPERIMENTAL|EMI-137 0.18mg/kg administration|"Three patients will be once administered with EMI-137 0.18 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
62201045|NCT03470259|EXPERIMENTAL|EMI-137 0.045mg/kg administration|"If we have a excellent tumor to background ratio ((tumor fluorescence)/(surrounding tissue fluorescence)) in the 0.09 mg/kg group, we will de-escalate back to a 0.045 mg/kg group to evaluate TBR and reduce possible tracer toxicity in a thyroid cancer population with 90% 20 year survival.~Three patients will be once administered with EMI-137 0.045 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
62201046|NCT06056843|EXPERIMENTAL|Intervention arm|Triage of clinical breast examination positive women using handheld ultrasound by non-radiologists.
62201047|NCT03439267|ACTIVE_COMPARATOR|Proactive Current National Guidelines Group|Standard Interventional Control Group. Will receive treatment recommendation according to the current National guidelines for statin initiation and follow-up.
62201048|NCT03439267|EXPERIMENTAL|Proactive CAC Group|Investigational Interventional Group. Will undergo coronary artery calcium screening and will receive statin recommendation based on the cardiovascular risk algorithm.
62201049|NCT00245180|NO_INTERVENTION|control|Primary and secondary data collected as in intervention arm. Dental screenings will be done once a year as a service.
62401861|NCT02341482|EXPERIMENTAL|PF-04958242 and itraconazole|"PF-04958242 will be provided in a capsule. Participants will receive a 0.10 mg loading dose of PF-04958242 twice daily (BID) on Day 1 then 0.025 mg BID on Day 2-Day 16, with the last dose occurring in the morning on Day 17.~Itraconazole will be provided as a solution starting on Day 4. On Day 4, a 200 mg dose of itraconazole will be administered approximately 1 hour before PF-04958242 morning administration and for 13 additional days (Day 4-Day 17)."
62410071|NCT05010915|EXPERIMENTAL|dorsolateral prefrontal cortex|"1. Age \> 50 years.~2. Major depressive disorder (MDD).~3. Right handiness~4. with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD"
62578799|NCT02466815|EXPERIMENTAL|Treatment A, then Treatment C and then Treatment B|Participants will receive treatment A in period 1, treatment C in period 2 and then treatment B in period 3.
62578800|NCT02466815|EXPERIMENTAL|Treatment B, then Treatment A and then Treatment C|Participants will receive treatment B in period 1, treatment A in period 2 and then treatment C in period 3.
62578801|NCT02466815|EXPERIMENTAL|Treatment C, then Treatment B and then Treatment A|Participants will receive treatment C in period 1, treatment B in period 2 and then treatment A in period 3.
62013029|NCT00016094|EXPERIMENTAL|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for a maximum of 24 courses in the absence of disease progression or unacceptable toxicity.
62578802|NCT01582854|ACTIVE_COMPARATOR|Actovegin|Actovegin 2000 mg solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin 200 mg, tablets, orally, 3 times a day for up to 6 months.
62784807|NCT03320135|ACTIVE_COMPARATOR|Open Flap Debridement|Open flap debridement in proximal class-II furcation.
62784808|NCT03214406|EXPERIMENTAL|Arm & Hammer Advance White Brilliant Sparkle (Test product)|2X daily brushing for 12 weeks with Arm \& Hammer Advance White Brilliant Sparkle (Test product). Return to pre-study hygiene regimen for 4 weeks and final evaluation at 16 weeks.
62784809|NCT03214406|ACTIVE_COMPARATOR|Crest Cavity Protection Regular Toothpaste (Negative Control)|2X daily brushing for 12 weeks with Crest Cavity Protection Regular Toothpaste (Negative Control). Return to pre-study hygiene regimen for 4 weeks and final evaluation at 16 weeks.
62784810|NCT01903629|EXPERIMENTAL|magnetic-controlled capsule endoscocpy (MCE)|patients were assigned to swallow MCE first, followed by the gastroscopy
62784811|NCT06284668|PLACEBO_COMPARATOR|Placebo Group of patients undergoing oocyte retrieval with normal saline|Patients undergoing oocyte retrieval were given 5ml 0.9% saline before anesthesia and surgery
62784812|NCT06284668|ACTIVE_COMPARATOR|Group of patients undergoing oocyte retrieval with esketamine|Patients undergoing oocyte retrieval were given esketamine 0.2mg/kg before anesthesia and surgery
62784813|NCT06284668|ACTIVE_COMPARATOR|Group of patients undergoing oocyte retrieval with remimazolam|Patients undergoing oocyte retrieval were given remimazolam 0.2mg/kg before anesthesia and surgery
62784814|NCT03548467|EXPERIMENTAL|VB10.NEO intervention|Treatment with individualized VB10.NEO immunotherapy will commence as soon as the patient-specific VB10.NEO vaccine is available and if the patient-specific vaccine meets all pre-specified product release criteria after manufacturing to patients within the selected tumor types.
62013030|NCT01609556|EXPERIMENTAL|Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W)|Participants will receive mirvetuximab soravtansine intravenous (IV) infusion on Day 1 of every 21-day (every 3 weeks \[Q3W\]) cycle. Dose escalation for this group schedule will start at 0.15 milligrams per kilogram (mg/kg) and proceed through 7.0 mg/kg. Doses calculated initially based on participant's total body weight (TBW); then from protocol amendment 5 onwards, calculated based on adjusted ideal body weight (AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
62013031|NCT01609556|EXPERIMENTAL|Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly)|Participants will receive mirvetuximab soravtansine IV infusion on Days 1, 8, and 15 of every 28-day cycle. Dose escalation for this group schedule will start at 1.1 mg/kg (calculated based on AIBW) and proceed through 2.5 mg/kg. Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
62578803|NCT01582854|PLACEBO_COMPARATOR|Placebo|Actovegin placebo-matching solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin placebo-matching, tablets, orally, 3 times a day for up to 6 months.
62578804|NCT01497925|EXPERIMENTAL|ADI-PEG 20|
62401862|NCT05537259||Observation Group|Researchers will collect data on maternal mental health symptoms, as well as health and psychosocial factors, via short interviews (sessions 1 and 4) and via self-report questionnaires completed through REDCap at each session. Participating women will also provide one small hair sample (session 4) for measurement of the stress hormone cortisol and several finger stick blood spot samples (sessions 1,2, and 4) for measurement of immune markers.
62401863|NCT01519700|EXPERIMENTAL|EP2006|Eligible patients will be teated with EP2006
62401864|NCT01519700|ACTIVE_COMPARATOR|Filgrastim|Eligible patients will be teated with Filgrastim
62401865|NCT03712462|EXPERIMENTAL|ABBT Weight Loss Therapy for BED|Acceptance-Based Behavioral Weight Loss Therapy for BED
62401866|NCT03712462|ACTIVE_COMPARATOR|Standard Behavior Therapy|Standard Behavioral Weight Loss Therapy
62578805|NCT02999269|EXPERIMENTAL|600 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
62578806|NCT02999269|EXPERIMENTAL|700 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
62578807|NCT02999269|ACTIVE_COMPARATOR|800 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
62578808|NCT02154711||Mitochondrial Disease|Individuals with genetic diagnoses (nuclear or mitochondrial) of mitochondrial disease
62578809|NCT02154711||Unaffected|Healthy individuals, without mitochondrial disease
62578810|NCT01371864||Pediatric Cardiothoracic Team|This group consists of members of the cardiothoracic surgery team: The attending physician, the fellow physician, the nurses, and the physician assistants.
62201050|NCT04211090|EXPERIMENTAL|Camrelizumab with pemetrexed / carboplatin|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer
62401867|NCT05872165|EXPERIMENTAL|Experimental group|this group of 20 subjects will receive the ozonated media phonophoresis plus conventional physical therapy program 3 times weekly for 4 weeks.
62578811|NCT01371864||Critical Care Team|This group consists of the nurses and physicians who work in the pediatric intensive care unit and the neonatal intensive care unit caring for patients who require cardiothoracic surgery.
62578812|NCT01371864||Subspecialty Team|This group consists of physicians and nurses from pediatric cardiology and pediatric anesthesiology who care for children who require cardiothoracic surgery.
62578813|NCT01371864||Parent|This group consists of the parent or legal guardian of the pediatric patient who requires cardiothoracic surgery.
62578814|NCT01023945|EXPERIMENTAL|ASP1941 high dose group|oral
62578815|NCT01023945|EXPERIMENTAL|ASP1941 low dose group|oral
62578816|NCT01023945|PLACEBO_COMPARATOR|Placebo group|oral
62578817|NCT06601296|EXPERIMENTAL|SAbR with Intratumoral STING agonist IMSA101 and IO with Anti-PD1|"Only one arm will be maintained in this phase II study with all patients undergoing the following treatment:~SOC treatment: Nivolumab 480 mg monthly PULSAR: 36 Gy in 3 fractions, Q4weeks IMSA101: five intra-tumoral injections of one of the progressive lesions at 1200 mcg (C1D1, C1D8, C1D15, C2D1, C3D1)"
62201051|NCT00671177|EXPERIMENTAL|Water Immersion Colonoscopy|Water Immersion Colonoscopy
62201052|NCT00671177|ACTIVE_COMPARATOR|Standard Air Colonoscopy|Standard Air Colonoscopy
62201053|NCT04457349|EXPERIMENTAL|Therapeutic Plasma Exchange (TPE)|Each patient will undergo two sessions. TPE will be done through filtration technique using a plasma filter at a dose of (1-1.5) plasma volume/session. Fresh frozen plasma or albumin 5% will be used to replace plasma.
62578818|NCT04109391|EXPERIMENTAL|Test Product (TX05)|"IV trastuzumab (TX05) 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles TX05 (trastuzumab): Subjects will receive up to 13 cycles of adjuvant treatment.~These subjects received TX05 on the TX05-03 study and continued to receive TX05 in this extension study."
62578819|NCT04109391|ACTIVE_COMPARATOR|Reference Therapy (Herceptin)|"IV trastuzumab (Herceptin) TX05 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles Herceptin (trastuzumab): Subjects will receive up to 13 cycles of adjuvant treatment.~These subjects received Herceptin on the TX05-03 study and were randomized to receive Herceptin in this extension study."
62578820|NCT04109391|EXPERIMENTAL|Test Product (Herceptin/TX05 Transition)|"IV trastuzumab (TX05) 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles TX05 (trastuzumab): Subjects will receive up to 13 cycles of adjuvant treatment.~These subjects received Herceptin on the TX05-03 study and were randomized to receive TX05 in this extension study."
62578821|NCT00707681|ACTIVE_COMPARATOR|I|MS-20
62578822|NCT00707681|PLACEBO_COMPARATOR|2|Placebo
62578823|NCT03387280||proximal RCA stenosis|The stenosis site is before the the right ventricular branch of right coronary artery (RCA) according to the coronary angiograms.
62578824|NCT03387280||distal RCA stenosis|The stenosis site is after the the right ventricular branch of right coronary artery (RCA) according to the coronary angiograms.
62578825|NCT03387280||left circumflex coronary artery stenosis|The stenosis site is located at the left circumflex coronary artery according to the coronary angiograms.
62578826|NCT04616638|EXPERIMENTAL|RT-POWER Intervention|Six familiarization sessions and 20 RT-POWER sessions.
62578827|NCT04616638|ACTIVE_COMPARATOR|Control Intervention|Six control familiarization sessions and 20 traditional RT sessions.
62578828|NCT04713254|EXPERIMENTAL|Lu AG06466|
62578829|NCT04240639|EXPERIMENTAL|AuroShell particle infusion|Single intravenous infusion of AuroShell particles 12 to 36 hours prior to MRI/US guided laser irradiation using an FDA cleared laser and an interstitial optical fiber diffuser.
62578830|NCT06479967|EXPERIMENTAL|Virtual Reality|"The Virtual Reality glasses group watched a cartoon video of Rafadan Tayfa Gizli Hazine The VR glasses group watched a cartoon video of Rafadan Tayfa Gizli Hazine After the SPT, the VR glasses group took a 1-minute break from watching videos and the child's pain was assessed with WBFPS. During the 15-minute SPT assessment, the VR glasses group continued watching cartoon"
62578831|NCT06479967|EXPERIMENTAL|Music|"The music group listened to classical piano The Best of Chopin.~After the music group took a 1-minute break from listening to music, and the child's pain was assessed with WBFPS. During the 15-minute SPT assessment, the music group continued to listen to the music. During the SPT evaluation, the music group took a 1-minute break from listening to music at 5, 10, and 15 minutes, and the child evaluated the level of itching from 1 to 10."
62578832|NCT06479967|NO_INTERVENTION|Control|Before, during, and after the skin prick test evaluation (15 minutes), no intervention was provided to the children assigned to the control group.
62578833|NCT05463094|EXPERIMENTAL|First Test GXR RM (Fasted), Then Reference GXR RM (Fasted)|Participants will receive a single dose of Test Glucophage Extended Release Reduced Mass (GXR RM) tablet on Day 1 in treatment period 1 followed by a single dose of Reference GXR RM tablet on Day 8 in treatment period 2 under fasted condition. There will be separate washout period of 7 days between each treatment period.
62578834|NCT05463094|EXPERIMENTAL|First Reference GXR RM (Fasted), Then Test GXR RM (Fasted)|Participants will receive a single dose of Reference GXR RM tablet on Day 1 in treatment period 1 followed by a single dose of Test GXR RM tablet on Day 8 in treatment period 2 under fasted condition. There will be separate washout period of 7 days between each treatment period.
62578835|NCT05463094|EXPERIMENTAL|First Test GXR RM (Fed), Then Reference GXR RM (Fed)|Participants will receive a single dose of Test GXR RM tablet on Day 1 in treatment period 1 followed by a single dose of Reference GXR RM tablet on Day 8 in treatment period 2 under fed condition. There will be separate washout period of 7 days between each treatment period.
62578836|NCT05463094|EXPERIMENTAL|First Reference GXR RM (Fed), Then Test GXR RM (Fed)|Participants will receive a single dose of Reference GXR RM tablet on Day 1 in treatment period 1 followed by a single dose of Test GXR RM tablet on Day 8 in treatment period 2 under fed condition. There will be separate washout period of 7 days between each treatment period.
62201054|NCT02349152|EXPERIMENTAL|Remifentanil group|Half of subjects enrolled will be randomized to the remifentanil group
62201055|NCT02349152|ACTIVE_COMPARATOR|Fentanyl group|Half of subjects enrolled will be randomized to the fentanyl group
62201056|NCT03572647|EXPERIMENTAL|Test ERITROMAX|Blausiegel Industria e Comercio Ltda. Recombinant Human Erythropoietin (ERITROMAX)
62201057|NCT03572647|ACTIVE_COMPARATOR|EPREX|Janssen-Cilag Recombinant Human Erythropoietin (EPREX)
62201058|NCT01147536|EXPERIMENTAL|HSPPC-96 Vaccine|Participants will receive up to 8 administrations of HSPPC-96 25 µg intradermally over 3 months (4 weekly doses, followed by 4 bi-weekly doses \[at Weeks 14, 15, 16, 17 19, 21, 23, and 25 in Part 1a and at Weeks 1-4, 6, 8, 10, 12 in Part 1b). Participants will remain untreated with HSPPC-96 for the initial 3-month period in Part 1a for immune monitoring blood draw.
62201059|NCT00773799||rehabilitation center's hospitalized patients|
62201060|NCT01133834||patients with meningococcemia|Patients with meningococcemia admitted at the Intensive Care Unit
62201061|NCT00968526|EXPERIMENTAL|GSK2340272A 2D Group|Healthy male or female adults, aged 18 to 60 years (18-60y) and above (\>60y), who received two doses (2D) of GSK2340272A vaccine, one administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and the other one, administered intramuscularly in the deltoid region of the dominant arm at Day 21.
62215054|NCT01488877|ACTIVE_COMPARATOR|Spironolactone|25 mg once daily
62215055|NCT01488877|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62578837|NCT02868190|OTHER|Two micro-bypass stents (iStent inject)|Standalone implantation of two trabecular micro-bypass stents (iStent inject)
62578838|NCT06631937|EXPERIMENTAL|Human Milk Oligosaccharides|Human Milk Oligosaccharides (HMO)
62201062|NCT00968526|EXPERIMENTAL|GSK2340272A 1D Group|Healthy male or female adults, aged 18 to 60 years (18-60y) and above (\>60y), who received a single dose (1D) of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
62201063|NCT06345469||PBM only|The Study group received comprehensive Patient Blood Management without allogeneic transfusions to treat their severe anemia.
62201064|NCT06345469||PBM with transfusion|The Control group opted to be treated with allogeneic transfusions together with convenience measures of PBM.
62578839|NCT06631937|PLACEBO_COMPARATOR|Placebo|Identical commercial Infant Formula without human milk oligosaccharides, fed daily ad libitum from enrollement to 6 months of age
62784815|NCT03548467|EXPERIMENTAL|VB10.NEO in combination with bempegaldesleukin (NKTR-214)|Bempegaldesleukin (NKTR-214) will be given in combination with VB10.NEO in up to 10 patients with SCCHN. Treatment with individualized VB10.NEO immunotherapy will commence as soon as the patient-specific VB10.NEO vaccine is available and if the patient-specific vaccine meets all pre-specified product release criteria after manufacturing. Bempegaldesleukin (NKTR-214) will be given after at least 4 doses of VB10.NEO.
62784816|NCT01098305|ACTIVE_COMPARATOR|Varenicline|
62784817|NCT01098305|PLACEBO_COMPARATOR|Placebo|
62784818|NCT05161286||Healthy pain-free cohort|Healthy pain-free Dutch-speaking men and women between the age of 18 and 65 years
62784819|NCT00475189|ACTIVE_COMPARATOR|1|
62784820|NCT00475189|ACTIVE_COMPARATOR|II|loestrin 1/20 given 1 tab 21/7
62784821|NCT00195663|EXPERIMENTAL|Adalimumab|Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase and then adalimumab 40 mg every other week for up to 8 years in the open-label extension.
62784822|NCT00195663|EXPERIMENTAL|Adalimumab + methotrexate|Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.
62784823|NCT00195663|EXPERIMENTAL|Methotrexate|Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.
62201065|NCT02868606||Historical control group (H)|Winthrop patients with diabetes hospitalized between August 1, 2010 and March 31, 2011
62784824|NCT06383260||Age group|18-20 21-22 22-24
62784825|NCT06383260||ASRS V1.1 scores(%)|Score of Ahdh self report scale questionnaire
62784826|NCT06383260||ADHD symptom prevalence|People who got more than 4 in part A of questionnaire and more than 6 in Part B
62784827|NCT04305847||Qual'AXI group|patients for whom distal arm surgery was performed under Axillary Brachial Plexus Block
62784828|NCT03197376|EXPERIMENTAL|Pneumosil Lot 1|Pneumosil Lot 1
62784829|NCT03197376|EXPERIMENTAL|Pneumosil Lot 2|Pneumosil Lot 2
62201066|NCT02868606||Intervention group (I)|Winthrop patients with diabetes hospitalized between August 1, 2011 and March 31, 2012
62201067|NCT02868606||Parallel control group (P-sub-H)|Patients with diabetes hospitalized between August 1, 2010 and March 31, 2011 at 7 control hospitals located in the New York City metropolitan region
62201068|NCT02868606||Parallel control group (I-sub-H)|Patients with diabetes hospitalized between August 1, 2011 and March 31, 2012 at 7 control hospitals located in the New York City metropolitan region
62201069|NCT05101382||Cohort of CRC patients|Stage-mixed cohort of at least 500 CRC patients that cannot be reached for informed consent (death or lost-to-follow-up)
62201070|NCT04878315|EXPERIMENTAL|Treatment sequence TRR|Participants will receive Capoten (T) in period 1 followed by Captopril (R) in period 2 followed by Captopril (R) in period 3.
62578840|NCT06631937|NO_INTERVENTION|Breastfed reference group|
62578841|NCT04562246||PCR positive subjects|Patients who receive positive test result from RT-PCR for SARS-CoV-2.
62578842|NCT00716014|ACTIVE_COMPARATOR|Foot 1|An active drug injection of TD101 is injected into a callus on the bottom of one foot.
62784830|NCT03197376|EXPERIMENTAL|Pneumosil Lot 3|Pneumosil Lot 3
62784831|NCT03197376|ACTIVE_COMPARATOR|Synflorix|Synflorix
62784832|NCT00682526||Pre-study Period (Group 1 and Group 2).|"The TIME-MC study was conducted from June 2003 to June 2008 at NEMC (Figure 1) and from May 2005 to September 2008 at the six larger medical centers (Figure 2). Two groups were studied. Group 1 included patients at NEMC and Group 2 included patients at the other six medical sites. The study was divided into three periods:~Pre-study period (Group 1 and Group 2). No PH-ECG transmission system was available."
62201071|NCT04878315|EXPERIMENTAL|Treatment sequence RTR|Participants will receive Captopril (R) in period 1 followed by Capoten (T) in period 2 followed by Captopril (R) in period 3.
62201072|NCT04878315|EXPERIMENTAL|Treatment sequence RRT|Participants will receive Captopril (R) in period 1 followed by Captopril (R) in period 2 followed by Capoten (T) in period 3.
62201073|NCT00371098|EXPERIMENTAL|active vaccine|patients received active influenza vaccine for season 2004/2005
62201074|NCT00371098|PLACEBO_COMPARATOR|placebo vaccine|patients received placebo influenza vaccine for season 2004/2005 containing all vaccine compounds except viral antigens
62201075|NCT01987362|EXPERIMENTAL|RO6870810 (Part 1)|Participants will receive escalated doses of RO67870810 SC. RO6870810 will be escalated at a starting dose of 0.03 milligrams per kilogram (mg/kg) to a maximum of 0.85 mg/kg. Treatment will be administered in treatment cycles of either 21 days or 28 days and continued until PD, adverse events which justify treatment withdrawal, non-adherence, non-compliance, investigator decision, lost to follow-up, enrollment in other clinical study, or unacceptable toxicity.
62578843|NCT00716014|PLACEBO_COMPARATOR|Foot 2|An injection of placebo (normal saline) is injected into a callus on the bottom of one foot.
62578844|NCT06284057||Culotte Group|Data regarding patient with performed PCI- bifurcation with subsequent implantation of two stents using the Culotte technique
62578845|NCT06284057||Double Kiss (DK) Culotte Group|"Data regarding patient with performed PCI- bifurcation with subsequent implantation of two stents using the Double Kiss- Culotte technique. DK-Culotte technique is a variety of classical Culotte techniques in which one additional kissing balloon dilation is performed just after SB stenting, and prior to MB stent implantation."
62201076|NCT01987362|EXPERIMENTAL|RO6870810 (Part 2)|Participants will receive RO6870810 at doses up to the MTD or up to the highest dose tested if the MTD is not defined. Treatment will be administered in treatment cycles of either 21 days or 28 days and continued until PD, adverse events which justify treatment withdrawal, non-adherence, non-compliance, investigator decision, lost to follow-up, enrollment in other clinical study, or unacceptable toxicity.
62201077|NCT02519140|EXPERIMENTAL|Cook medical EMR Gel|"Prospective study involving excised human stomachs and colon harvested from sleeve gastrectomies and colectomies performed for benign or malignant disease.~Different Cook submucosal injections of varying viscosities will be injected into different areas of the excised stomachs or colons.~Data collected will involve lifting characteristics and dissection adequacy of the varying viscosities of gel."
62578846|NCT00675012|EXPERIMENTAL|A|
62201078|NCT04472884|EXPERIMENTAL|mWACh-PrEP|
62578847|NCT01186692|EXPERIMENTAL|Melody TPV Implant|Melody® Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.
62578848|NCT03740087|EXPERIMENTAL|Omnivorous diet|This group was assigned a meal containing beef (test meal) that consisted of 200 g roast beef with salad (lettuce, tomato, lentils) and a cup of rice.
62784833|NCT00682526||Study Period (Group 1 and Group 2)|Study period (Group 1 and Group 2). PH-ECG transmission to a cardiologist's hand-held device was attempted through pre-assigned EMS ambulances equipped with a wireless ECG transmission device in addition to a STEMI code system. In Group 1, this referred to the pilot study at NEMC from June 2003 to May 2005.
62201079|NCT04472884|OTHER|Standard of Care|
62201080|NCT05548660|EXPERIMENTAL|PGx-guided|Pharmacogenetic testing using a 16 gene panel with a pharmacist consult providing genotype-guided recommendations for post-surgery analgesic selection based on CYP2D6 and CYP2C9 results. Pharmacist recommendations for all 16 gene results will also be provided in a detailed note.
62401868|NCT05872165|OTHER|Control group|this group of 20 subjects will receive only conventional physical therapy program 3 times weekly for 4 weeks.
62578849|NCT03740087|ACTIVE_COMPARATOR|Vegan diet|This group was assigned a control meal consisted of salad (lettuce, tomato, lentils) and a cup of rice.
62578850|NCT05010564|EXPERIMENTAL|Autologous TRICAR-ALL T-Cells and lymphodepletion chemotherapy|Three dose levels will be evaluated. The TRICAR-ALL T-cells will be administered after lymphodepletion chemotherapy with Cyclophosphamide and fludarabine.
62784834|NCT00682526||Post-study period (Group 1)|Post-study period (Group 1). PH-ECG transmission and a STEMI code system implemented after the pilot study period.
62784835|NCT02661867||VD|Vaginal delivery group - women who gave birth of offspring through the vagina without the use of special instruments such as forceps or a vacuum extractor (instrumental vaginal delivery)
62013032|NCT01609556|EXPERIMENTAL|Dose Expansion:EOC Participants(Mirvetuximab Soravtansine Q3W)|Participants with epithelial ovarian cancer (EOC) will receive mirvetuximab soravtansine 6.0 mg/kg (maximum tolerated dose \[MTD\]) IV infusion on Day 1 of every 21-day (Q3W) cycle (calculated based on AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminated the study.
62201081|NCT05548660|OTHER|Usual care|Pharmacogenetic testing using a 16 gene panel. Post-surgery analgesic selection will be based on usual care (not the PGx results). Pharmacist recommendations for all 16 gene results will be provided in a detailed note with a delayed return of results (30 days post surgery)
62201082|NCT02592876|EXPERIMENTAL|19A+RICE|Denintuzumab mafodotin plus rituximab, ifosfamide, carboplatin, and etoposide
62201083|NCT02592876|ACTIVE_COMPARATOR|RICE|Rituximab, ifosfamide, carboplatin, and etoposide
62201084|NCT04611165|EXPERIMENTAL|single|"Nivolumab 3mg/kg IV is administered as 30-minute IV infusion every 2 weeks.~Prescription dose to PTVs as according to the following schema:~PTV1: 30 - 50 Gy /10 fx, 5Gy fraction dose, 5 days/week (The prescribed dose to PTV will be decided by physician depending on the dose-volume histogram (DVH) constraints of the normal tissues, such as liver, bowel, etc. The detail of DVH constraints of normal tissues are summarized in the following table) PTV2: 30 Gy /10 fx, 3Gy fraction dose, 5 days/week"
62401869|NCT06101940||DM1 patients|Patient cohort
62401870|NCT04493255|EXPERIMENTAL|E7090|Participants will receive 100 microcurie (μCi) of \[14C\]E7090 as a single 35 milligram (mg), capsule, orally on Day 1.
62401871|NCT04718792|EXPERIMENTAL|Psilocybin|10 patients will receive a single administration of psilocybin
62201085|NCT04765917|ACTIVE_COMPARATOR|Selected Physical Therapy group|The Control group will receive a selected physical therapy program for 60 minutes, 3 times/week for 3 successive months including the following exercises
62201086|NCT04765917|EXPERIMENTAL|Motor imagery training|Children allocated to the study group will receive the same selected physical therapy program given to the control group for 30 min in addition to 30 minutes motor imagery training program
62401872|NCT03138265|EXPERIMENTAL|High intensity exercise training|HIT training protocol.
62401873|NCT05710666|EXPERIMENTAL|T-DXd|
62401874|NCT03778021|EXPERIMENTAL|Intervention Group|"Intervention schools receive a raised bed school garden and a curriculum of healthy eating and gardening lessons.~3rd and 4th grade students in the intervention group received the curriculum and exposure to the school garden during the academic school year (2019-20)~Behavioral Gardening Exposure: Assistance provided with planting and maintaining the school garden~Healthy Eating and Gardening Curriculum: 14 to 17 lessons (about 45 minutes each) throughout the school year, during the normal school day, that are focused on healthy eating and gardening, coordinated with the growing season."
62784836|NCT02661867||CS|Cesarean section group - women delivered by surgical procedure in which one or more incisions are made through a mother's abdomen and uterus to deliver a baby. Cesarean section is performed when a vaginal delivery would put the baby's or mother's life or health at risk.
62401875|NCT03778021|NO_INTERVENTION|Comparison Group|"For the comparison group schools, no program was provided in school year (2019-2020).~After the trial, and the follow-up evaluation, in school year 2020-2021 comparison schools received delayed intervention components as follows: School gardens were created during the 2020-2021 school year (subject to delays due to pandemic restrictions). Curriculum materials were supplied to the school for use by teachers as they saw fit, after pandemic restrictions were lifted."
62201087|NCT04263038|ACTIVE_COMPARATOR|Anticoagulation|Patients in the anticoagulation group will receive rivaroxaban 15 mg twice daily for the first 21 days, followed by 20 mg once daily for an overall treatment duration of 90 days.
62401876|NCT03540602|PLACEBO_COMPARATOR|Placebo|Rice flour capsule
62401877|NCT03540602|ACTIVE_COMPARATOR|Polyphenol Rich Supplement|NordicCherry Tart Cherry Extract Powder 500 mg in capsule form
62784837|NCT05675501|EXPERIMENTAL|Study Drug|Daily Encapsulated Benzoyl Peroxide (E-BPO) Cream, for 8 weeks (period 1). Subjects will then switch treatments to the vehicle cream for a period of 4 weeks (period 2),
62013033|NCT01609556|EXPERIMENTAL|Dose Expansion: EC Participants(Mirvetuximab Soravtansine Q3W)|Participants with endometrial cancer (EC) will receive mirvetuximab soravtansine 6.0 mg/kg (MTD) IV infusion on Day 1 of every 21-day (Q3W) cycle (calculated based on AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
62013034|NCT01023659|ACTIVE_COMPARATOR|Bupropion + motivational emails|participants receive Zyban (300mg/day) plus weekly motivational emails for 12 weeks.
62201088|NCT04263038|PLACEBO_COMPARATOR|No anticoagulation|Patients in the group without anticoagulation will receive placebo twice daily for the first 21 days, followed by one tablet daily for an overall treatment duration of 90 days.
62201089|NCT00954889|EXPERIMENTAL|Tamsulosin|
62784838|NCT05675501|PLACEBO_COMPARATOR|Vehicle|Daily Vehicle Cream, for 8 weeks (period 1). Subjects will then switch treatments to the study drug encapsulated E-BPO for a period of 4 weeks (period 2),
62784839|NCT03963648|EXPERIMENTAL|CRSwNP|Study group that will undergo fractioned exhaled nitrogen oxide measurements as well as tests of lungfunction and sleep studies. All tests are non-invasive.
62784840|NCT04467034|EXPERIMENTAL|Receives Stanford tobacco education curriculum|Stanford Tobacco Prevention Toolkit is administered.
62784841|NCT04467034|NO_INTERVENTION|Does not receive Stanford tobacco education curriculum|Receives another curriculum or no tobacco education.
62784842|NCT04584957|ACTIVE_COMPARATOR|VAC therapy|Prophylactic ciNPWT therapy positioning YES. Patients enrolled for placement of the device over a closed incision immediately post-operatively.
62784843|NCT04584957|NO_INTERVENTION|Standard Closure|Prophylactic ciNPWT therapy positioning NO. Patients enrolled for standard laparotomic closure without ciNPWT positioning
62784844|NCT01822392|ACTIVE_COMPARATOR|Online treatment, High therapist contact|Participants receive online Parent Management Training (interactive).
62784845|NCT01822392|EXPERIMENTAL|Online treatment, Low therapist contact|Participants receive online Parent Management Training (recorded).
62201090|NCT00954889|PLACEBO_COMPARATOR|placebo|
62784846|NCT04166097|EXPERIMENTAL|Heart Smart Interventional Program|"Subjects participate in this 6-week intervention which include a weekly didactic session, with each week devoted to a different theme (food, exercise, etc). The intervention will follow the program outlined in the book Heart Smart for Women: Six S. T. E. P. S. in Six Weeks to Heart-Healthy Living."
62784847|NCT01921764|EXPERIMENTAL|Workplace physical exercise|Physical exercise (kettlebells, elastic bands, exercise balls) performed at the workplace with coaching
62784848|NCT01921764|ACTIVE_COMPARATOR|Home physical exercise|Physical exercise performed at home with elastic bands and bodyweight exercises with instruction to follow the exercises at http://www.jobogkrop.dk/Oevelser-til-nakke-og-ryg/Oevelser
62784849|NCT02151890|EXPERIMENTAL|Laparoscopic Stem Cell Transplantation.|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H\&E stain and by IH staining by stem cell marker OCT4. Immunohistochemical expression of stem cell marker OCT4 was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS)Laparoscopic injected of stem cell Sample in the ovaries.. Participants were followed up monthly for a period of six months by hormonal (FSH, LH and E2), clinical (resuming menstruation), US (folliculometry), histopathological (HP), and IH expression of stem cell marker OCT4 of the endometrial biopsy (stem cell positivity according to ESS) outcome.
62784850|NCT00870545|EXPERIMENTAL|Telephone support|12 telephone support group sessions based on the letters of the word BATTLEMIND
62784851|NCT04205617|EXPERIMENTAL|Healthy Food Prescription|Participants receive services through the Living Hungry program for food insecure diabetic patients.
62784852|NCT01966224|EXPERIMENTAL|2mg CryJ2-DNA-LAMP plasmid vaccine Group 1|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 1, who were skin test negative at Day 0 and remained negative at Day 132.~Group 1: These subjects will be re-vaccinated with one dose of 2mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered by Intramuscular injection (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study. These subjects will receive the same batch vaccine used in Phase 1A."
62201091|NCT00785811|EXPERIMENTAL|1|L-arginine aspartate (Targifor)
62201092|NCT00785811|PLACEBO_COMPARATOR|2|Placebo
62201093|NCT05078541|EXPERIMENTAL|RFA Warthins Tumor Group|Group of patients who will under RFA for Warthin's tumor.
62201094|NCT02765334|EXPERIMENTAL|nBETTER and Conventional Therapy|Intervention: nBetter therapy
62201095|NCT02320513||Control Group|Subjects will wear the activity monitoring device to track their activity between dialysis treatments, however, the feedback from the device will not be shared with them.
62201096|NCT02320513||Feedback Group|The feedback from the activity monitoring device will be shared with subjects at each visit.
62201097|NCT01213524|ACTIVE_COMPARATOR|Active nicotine replacement (NRT) + denicotinized cigarettes|42 mg nicotine replacement plus sensorimotor replacement
62201098|NCT01213524|ACTIVE_COMPARATOR|Placebo NRT + denicotinized cigarettes|inactive transdermal patches plus sensorimotor replacement
62201099|NCT01213524|ACTIVE_COMPARATOR|Active NRT + no cigarettes|42 mg nicotine replacement with no sensorimotor replacement
62201100|NCT01213524|PLACEBO_COMPARATOR|Placebo NRT + No cigarettes|Double placebo: No nicotine or sensorimotor replacement
62784853|NCT01966224|EXPERIMENTAL|2mg CryJ2-DNA-LAMP plasmid vaccine Group 2|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 2, who were skin test positive at Day 0 and remained positive or converted to negative for any JRC-related allergens at Day 132.~Group 2: These subjects will be re-vaccinated with one dose of 2mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered Intramuscularly (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study. These subjects will receive the same batch vaccine used in Phase 1A."
62201101|NCT01213524|ACTIVE_COMPARATOR|usual brand smoking|positive control: usual brand smoking
62201102|NCT03025750|EXPERIMENTAL|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
62201103|NCT03025750|ACTIVE_COMPARATOR|IPV SSI|IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
62201104|NCT02797652||Neoadjuvant chemotherapy|ctDNA of operable breast cancer patients with neoadjuvant chemotherapy before surgery in different periods: before neo-chemotherapy, during neo-chemotherapy, on surgery day, after surgery and follow-up time.
62201105|NCT02797652||Surgery|ctDNA of operable breast cancer patients with surgery followed by adjuvant chemotherapy in different periods: on surgery day, after surgery, before adjuvant chemotherapy, during adjuvant chemotherapy, and follow-up time.
62201106|NCT05837377|EXPERIMENTAL|Control- standard medication education|The control group will receive a traditional medication administration proficiency training program.
62784854|NCT01966224|EXPERIMENTAL|2mg CryJ2-DNA-LAMP plasmid vaccine Group 3|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 3, who were skin test positive at Day 0 and remained positive or converted to negative for any JRC-related allergens at Day 132.~Group 3: These subjects will be re-vaccinated with one dose 2mg of Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered Intramuscularly (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study."
62784855|NCT06049030|EXPERIMENTAL|Phase Ia dose escalation|Participants will be assigned to pre-specified dose level to identify the MTD/MAD of HS-10516.
62784856|NCT06049030|EXPERIMENTAL|Phase Ib dose expansion arm|Participants will be assigned to the recommended dose level determined in Phase Ia to evaluate the safety, pharmacokinetics and antitumor efficacy of HS-10516
62784857|NCT02082600|EXPERIMENTAL|Sleep deprivation|Exercise induced-muscle damage protocol followed by 60h of sleep deprivation (two nights) and one night of normal sleep (rebound).
62201107|NCT05837377|EXPERIMENTAL|Experiment- cognitive load theory based on medication education|The experiment group will receive a cognitive load theory-based medication administration training program.
62201108|NCT01492153||NovoLet® device|
62201109|NCT04255472|EXPERIMENTAL|WHO caregiver skills training program|Strategies to support children's communication skills by learning to engage in play activities and daily home routines activities with their caregivers.
62784858|NCT02082600|EXPERIMENTAL|Normal sleep|Exercise induced-muscle damage protocol followed by 3 nights of normal sleep
62784859|NCT00898833||Group 1|Previously collected plasma and urine samples are analyzed for VEGF via ELISA, plasma samples are analyzed for CgA and IL-6 via ELISA, hK2 via immunometric assay, plasma samples are analyzed for PSA via Tandem-R PSA kit, plasma samples are analyzed for TNF-alpha, sTNF-R1, and IL-8 via quantikine IL-8 immunoassay.
62784860|NCT02331667|EXPERIMENTAL|Seafood|Intervention with meals consisting of seafood (herring and mackrell).
62784861|NCT02331667|EXPERIMENTAL|Non-seafood|Intervention with meals constisting of non-seafood (meat).
62013035|NCT01023659|ACTIVE_COMPARATOR|Varenicline + motivational emails|participants receive Champix (2mg/day) plus weekly motivational emails for 12 weeks.
62784862|NCT00842543|EXPERIMENTAL|Overweight|Overweight Boys receiving either Fruit and Vegetable Juice Concentrate (FVJC) or Placebo, 1 capsule, twice a day, for 6 months
62201110|NCT04255472|EXPERIMENTAL|Treatment as usual (TAU)|TAU in primary healthcare centers for childhood developmental disorders and delays usually consists of no treatment, or a range of alternate treatment regimes, such as multi-vitamin syrups and tablets.
62784863|NCT00842543|EXPERIMENTAL|Lean|Lean Boys receiving either Fruit and Vegetable Juice Concentrate (FVJC) or Placebo, 1 capsule, twice a day, for 6 months
62784864|NCT06576401|EXPERIMENTAL|[14C] HDM1002|A single dose of HDM1002 and \[14C\] HDM1002 administered orally.
62201111|NCT05417295|EXPERIMENTAL|Inflating air into the bronchial cuff before changing position|Before changing from supine position to lateral position, inflate air into the bronchial cuff of double lumen endotracheal tube (DLT) and adjust cuff pressure to 25-30 mmHg.
62201112|NCT05417295|PLACEBO_COMPARATOR|Inflating air into the bronchial cuff after changing position|Do not inflate air into the bronchial cuff before changing position.
62013036|NCT01023659|ACTIVE_COMPARATOR|Motivational emails|participants receive weekly motivational emails for 12 weeks.
62013037|NCT00985348|EXPERIMENTAL|Treatment 1/Treatment 2|
62013038|NCT00985348|EXPERIMENTAL|Treatment 2/Treatment 1|
62013039|NCT00690638|PLACEBO_COMPARATOR|1|Placebo
62013040|NCT00690638|EXPERIMENTAL|2|PHX1149T 200 mg
62013041|NCT00690638|EXPERIMENTAL|3|PHX1149T 400 mg
62201113|NCT04000984|EXPERIMENTAL|Mindfulness-Based Intervention|Participants in this arm will complete baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. They will attend the in the Mindfulness-Based Training program that will meet weekly for 8 weeks. Each session will last approximately one-and-a-half hours.
62201114|NCT04000984|ACTIVE_COMPARATOR|Cognitive Rehabilitation Training|Participants in this arm will complete baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. They will attend the Cognitive Rehabilitation program that will meet weekly for 8 weeks. Each session will last one-and-a-half hours.
62401878|NCT04031469||General Population|The general population will have their microbiome sequenced from stool samples provided.
62784865|NCT02815592|EXPERIMENTAL|Experimental Arm 1|BMS-986012/Cisplatin/Etoposide
62784866|NCT02815592|EXPERIMENTAL|Experimental Arm 2|BMS-986012/Carboplatin/Etoposide
62013042|NCT01451294|ACTIVE_COMPARATOR|Ephedrine|
62013043|NCT01451294|ACTIVE_COMPARATOR|Phenylephrine|
62013044|NCT03009071|EXPERIMENTAL|Doin with Acupuncture|An acupuncture physician will administer acupuncture at 6-12 acupoints in the upper and middle trapezius area (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels). Cervical Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise (rotation) as needed.
62201115|NCT04000984|NO_INTERVENTION|Treatment As Usual|Participants in the Treatment As Usual group were only required to attend baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. Participants in this group will not receive an intervention for the duration of the study. They received treatment as usual which is 6 months to 1-year follow up visits with their attending neurologist of psychologist.
62201116|NCT02056626|ACTIVE_COMPARATOR|arm 2|partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)
62201117|NCT02056626|ACTIVE_COMPARATOR|arm 3|controlled dosing schedule 6.25 mg twice daily (15 days)
62201118|NCT02056626|ACTIVE_COMPARATOR|arm 4|controlled dosing schedule 6.25 mg twice daily, every other day (15 days)
62201119|NCT02056626|ACTIVE_COMPARATOR|arm 1|standard therapy, 25 mg twice daily (15 days)
62784867|NCT02815592|EXPERIMENTAL|Experimental Arm 3A|BMS-986012/Platinum/Etoposide
62784868|NCT02815592|ACTIVE_COMPARATOR|Active Comparator Arm 3B|Platinum/Etoposide
62784869|NCT02669121|PLACEBO_COMPARATOR|Placebo|NoV placebo-matching 0.5 mL solution for injection, intramuscularly (IM), once, on Day 1.
62201120|NCT05276089|EXPERIMENTAL|Intervention arm|A total of 50 practices who use System 1 will be in the intervention arm to send out the video to their eligible patients.
62784870|NCT02669121|EXPERIMENTAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|NoV GI.1/GII.4 bivalent virus-like particle (VLP) vaccine, 0.5 mL injection, intramuscularly (IM), once, on Day 1.
62784871|NCT05864547||Stroke patients|Patients with first time stroke admitted to the stroke unit, St. Olavs hospital, Trondheim, Norway. The planned cohort size is 15-20 patients.
62201121|NCT05276089|NO_INTERVENTION|Control arm|50 practices who use EMIS will be in the control arm to deliver care as usual
62201122|NCT01619189|EXPERIMENTAL|Tranplantation of cultured LSC in stage 3 limbal deficiency|Transplantation of Allogeneic or Autologous Limbal Epithelial Stem Cells Cultured on Human Amniotic Membrane with no Feeders in stage 3 unilateral or bilateral limbal stem cell deficiency.
62201123|NCT02917772|EXPERIMENTAL|Nivolumab/Ipilimumab|"* Induction: Mono-Therapy with Nivolumab~* If CR/PR: Nivolumab Maintenance Mono-Therapy~* If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy~* If CR/PR: Nivolumab Maintenance Mono-Therapy~* If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy~* If CR/PR/SD: Nivolumab Maintenance Mono-Therapy"
62201124|NCT05973123|EXPERIMENTAL|BLOOM Group Outings|6 weeks of nature based anxiety intervention for families with children who have at least one ACE and higher than average anxiety. Three of the outings will be group outings; the family will conduct 3 of the outings on their own independently.
62784872|NCT05864547||Healthy controls|Age and gender matched healthy volunteers without previous stroke. The same number of healthy controls as recruited patients will be recruited through ads in the local newspaper.
62784873|NCT06480318|NO_INTERVENTION|Standart Care|Application in the Preoperative Period: Before the surgery, HTBF and SAS will be applied to both groups and pain assessment will be made once. In addition, the intestinal functions of both groups will be questioned and recorded during each procedure. TENS will not be applied to the control group, and to the TENS group, 11.,-23.,-35.,-47. TENS will be applied a total of 4 times for 20 minutes between hours. There will be no intervention in the routine analgesic application of the clinic for both groups.
62013045|NCT03009071|ACTIVE_COMPARATOR|Acupuncture|An acupuncture physician will administer acupuncture at 6-12 acupoints in the upper and middle trapezius area (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels).
62201125|NCT05973123|EXPERIMENTAL|BLOOM Independent Outings|This group receives text support in going outdoors as a family once a week for 6 weeks to gain skills in managing anxiety.
62784874|NCT06480318|EXPERIMENTAL|TENS (Transcutaneous electrical nerve stimulation)|In the postoperative period, an information form regarding the surgery will be filled out in both groups. In addition, 11th and 12th in the control and TENS groups; 23rd and 24th; Pain assessment will be made with PSA a total of 8 times at the 35th and 36th hours, and at the 47th and 48th hours. In the TENS group, at the 11th hour (just before TENS), at the 12th hour (1 hour after TENS), at the 23rd hour (just before TENS), at the 24th hour (1 hour after TENS), at the 35th hour. Pain will be re-evaluated at 30 hours (just before TENS), 36 hours (1 hour after TENS), 47 hours (just before TENS), 48 hours (1 hour after TENS).
62784875|NCT01059994|PLACEBO_COMPARATOR|placebo sildenafil young|Younger subjects (ages 20-35) were administered placebo sildenafil orally daily for 1 week.
62784876|NCT01059994|EXPERIMENTAL|sildenafil young|Younger subjects (ages 20 -35) were administered sildenafil daily (25 mg/day) orally for 1 week.
62784877|NCT01059994|PLACEBO_COMPARATOR|placebo sildenafil older|Older subjects (ages 60-80) were administered placebo sildenafil orally daily for 1 week.
62784878|NCT01059994|EXPERIMENTAL|sildenafil older|Older subjects (ages 60 - 80) were administered sildenafil daily (25 mg/day) orally for 1 week.
62784879|NCT06144047|OTHER|Epilepsy|33 participants with drug-resistant epilepsy will be implanted with the EEGTM SubQ device under local anaesthesia, and will collect 2-channel EEG data, as well as completing an electronic seizure diary, for 6 months
62784880|NCT01611194|EXPERIMENTAL|HBO2 at 1.5 Atomspheres Absolute (ATA)|Hyperbaric oxygen (HBO2) at 1.5 atms. Stratified by site and time from injury (less than one year versus one year or more), in which participants are randomized. Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization.
62784881|NCT01611194|SHAM_COMPARATOR|Sham Control (1.2 Atomspheres)|Sham control 1.2 atms. Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
62201126|NCT05973123|NO_INTERVENTION|Control|Wait listed control. Receives standard of care referral to mental health resources on enrollment. At the end of study receives information on health benefits of being outdoors in nature and an invitation to group outings through the SHINE program at UCSF Benioff Children's Hospital Oakland.
62401879|NCT01953380|ACTIVE_COMPARATOR|extended information|Extended information on specific allergy
62401880|NCT01953380|NO_INTERVENTION|Information according to clin. routine|Information according to clinical routine
62401881|NCT01171274|ACTIVE_COMPARATOR|Hatha Yoga|"* 9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.~* One class of 90 minutes per week, 10 minutes training at home each day."
62401882|NCT01171274|ACTIVE_COMPARATOR|Exercise information|"* 9 weeks of exercises practiced at home.~* Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients."
62401883|NCT04369040|OTHER|High-flow nasal oxygen therapy|Ventilation with High-flow nasal oxygen therapy
62784882|NCT01737216|EXPERIMENTAL|Zoledronic acid plus First-line chemotherapy|
62784883|NCT01737216|ACTIVE_COMPARATOR|First-line chemotherapy|
62784884|NCT01583842|EXPERIMENTAL|124I-MIBG no-carrier added|Patients are 3 years of age and older with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG.
62784885|NCT01583842|EXPERIMENTAL|124I-MIBG carrier added|Patients are 3 years of age and older with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG.
62784886|NCT01583842|ACTIVE_COMPARATOR|Imaging Only|Participants with high-risk neuroblastoma will receive imaging only without 124I-MIBG
62201127|NCT00513877|EXPERIMENTAL|Bortezomib 1.6mg/m2|
62784887|NCT04010591||UDS group|All enrolled patients with urodynamic study
62784888|NCT02458781|PLACEBO_COMPARATOR|Placebo|"Placebo capsule:~To be provided by BAMC Pharmacy. It will be made and stored by BAMC pharmacy. The matching placebo will be a gelatin capsule filled with methylcellulose powder only. Patient will take 2 capsules two times a day for 14 days."
62201128|NCT01346072|OTHER|Tolvaptan|Single arm study
62201129|NCT06227546|EXPERIMENTAL|MCG018|
62201130|NCT04397211|ACTIVE_COMPARATOR|Angiography-derived FFR-guided PCI group|Percutaneous coronary intervention using drug-eluting stent(s) will be performed by Angiography-derived FFR-guided strategy
62401884|NCT04369040|EXPERIMENTAL|Flow Controlled Ventilation|Ventilation with laryngeal tri-tube with Flow Controlled Ventilation technique
62401885|NCT02869373|EXPERIMENTAL|Exercise|spinal stabilization exercise program was applied
62201131|NCT04397211|ACTIVE_COMPARATOR|IVUS-guided PCI group|Percutaneous coronary intervention using drug-eluting stent(s) will be performed by IVUS-guided strategy
62401886|NCT02869373|NO_INTERVENTION|Control|
62401887|NCT03560765|EXPERIMENTAL|Using MED assigned buddy|Participant has been randomly assigned a student volunteer buddy, and has chosen to purchase an MED following training
62401888|NCT03560765|ACTIVE_COMPARATOR|Using MED training only|Participant has been randomly assigned to not have a student volunteer buddy, and has chosen to purchase an MED following training
62401889|NCT03560765|ACTIVE_COMPARATOR|No MED, assigned buddy|Participant has been randomly assigned a student volunteer buddy, and has chosen not to purchase an MED following training
62201132|NCT04724447|EXPERIMENTAL|Valganciclovir|900 milligrams (mg) valganciclovir (VGCV) to be taken orally once per day for 8 weeks.
62201133|NCT04724447|PLACEBO_COMPARATOR|Placebo|Placebo equivalent of 900 milligrams (mg) VGCV to be taken orally once per day for 8 weeks.
62401890|NCT03560765|NO_INTERVENTION|No MED, no buddy|Participant has been randomly assigned to not have a student volunteer buddy, and has chosen not to purchase an MED following training
62201134|NCT02984007|EXPERIMENTAL|Motivational Interviewing|Educational session based on the motivational interviewing
62201135|NCT02984007|OTHER|Information flyer|Information flyer on childhood vaccines
62201136|NCT03822429||women < 35 years old|
62013046|NCT04431102|EXPERIMENTAL|PILATES METHOD|"It was intended the Pilates program were low supervision and easily realizable by all patients, which implied flexibility in the schedule. In this sense the sessions of Pilates was adjusted to these assumptions and the Pilates monitor offered several schedules on diferent days of the week.~The pregnant women assigned to the intervention group were supervised by the midwifery of reference and trained by a Pilates monitor who explained the training program. The women received eight sessions of Pilates, given with a frequency of two classes per week and one hour of duration during a period of four weeks. The exercises for each session were determined beforehand. In addition, the participants maintained the usual monitoring of pregnancy valued by the reference average, attending the sessions of the maternal education program of their health center.~The therapeutic control were carried out by telephone call and clinical history review between the eighth and tenth day postpartum."
62013047|NCT04431102|NO_INTERVENTION|MATERNAL EDUCATION|"The control group maintained the usual monitoring of pregnancy valued by the reference average, attending the sessions of the maternal education program of their health center.~Therapeutic control was carried out by phone call and review of the clinical history between the eighth and tenth day postpartum."
62013048|NCT03873285|EXPERIMENTAL|Genodermatosis patients|Children between 0 to 18 years old with the presence of dermatological symptoms suggesting genodermatosis or presence of systemic symptoms in an undiagnosed patient associated with dermatological manifestations suggestive of a more rare genetic disorder with cutaneous expression
62201137|NCT03822429||women between 36 and 38 years old|
62201138|NCT03822429||women between 39 and 40 years|
62201139|NCT03822429||women > 41 years old|
62201140|NCT00230750|EXPERIMENTAL|2|100 subjects to receive 90 mcg of inactivated influenza A/H5N1 vaccine on days 0, 28, and 6 months following the 1st vaccination.
62201141|NCT00230750|PLACEBO_COMPARATOR|3|40 subjects to receive saline placebo on days 0, 28, and 6 months following the 1st vaccination.
62201142|NCT00230750|EXPERIMENTAL|1|100 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine on days 0, 28, and 6 months following the 1st vaccination.
62401891|NCT01589185|EXPERIMENTAL|KBSA301, a monoclonal antibody dose 1|1 mg/kg KBSA301
62784889|NCT02458781|ACTIVE_COMPARATOR|Ciprofloxacin|"Ciprofloxacin 250mg capsule:~To be provided by BAMC pharmacy. It will be made and stored by BAMC Pharmacy. Ciprofloxacin 250mg tablet will be encapsulated with a gelatin capsule filled with methylcellulose. Patient will take 2 capsules of Ciprofloxacin 250mg two times a day for 14 days."
62201143|NCT02278484|OTHER|Balloon Sinus Dilation|
62201144|NCT03731897|EXPERIMENTAL|prolotherapy|"Experimental: Plantar fasciitis injection with prolotherapy total 5cc. Procedure: Plantar fascia will be injected to the places where it adheres to the bone.~Drug: 5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine. This treatment, known as regenerative injection therapy, stimulates tissue repair and reduces pain."
62201145|NCT03731897|PLACEBO_COMPARATOR|control|"Placebo Comparator: Plantar fasciitis injection with 9cc salin + 1 cc 2% lidocaine total 5cc.~Procedure: Plantar fascia will be injected to the places where it adheres to the bone.~Drug: 9 cc salin + 1cc 2% lidocaine. This treatment is safe for Plantar fasciitis injection."
62201146|NCT01114880|PLACEBO_COMPARATOR|Placebo|Blinded placebo from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.
62201147|NCT01114880|EXPERIMENTAL|Adalimumab|Blinded adalimumab from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.
62201148|NCT05854407|OTHER|pasteurized skim milk|300 mL of commercial pasteurized skim milk (heated for 15s at \~72 °C)
62201149|NCT05854407|OTHER|High-pasteurized skim milk|300 mL of High-pasteurized skim milk prepared by heating commercial pasteurized skim milk for 30 min at 80 °C
62401892|NCT01589185|EXPERIMENTAL|KBSA301, a monoclonal antibody dose 2|3 mg/kg KBSA301
62013049|NCT01696032|EXPERIMENTAL|SGI-110 + Carboplatin|Stage 1 was a safety lead-in stage with a dose escalation design. Participants were evaluated with the combination of SGI-110 (guadecitabine) plus carboplatin (G+C), given as 28-day treatment cycles: guadecitabine administered subcutaneous (SC) daily on Days 1-5, at a starting dose of 45 mg/m2/day in Cohort 1, followed by carboplatin intravenous (IV) based on a targeted dose of area under the curve (AUC) 5 on Day 8. After dose limiting toxicities were noted, guadecitabine dose was reduced to 30 mg/m2/day for subsequent cycles for 4 participants. Cohort 2 received 30 mg/m2/day guadecitabine and carboplatin IV AUC 4.
62013050|NCT01696032|EXPERIMENTAL|SGI-110 + Carboplatin or TC|Stage 2 was an open-label, randomized, controlled trial. Eligible participants were randomly assigned in a 1:1 ratio to receive either (1) G+C combination treatment in 28-day cycles at 30 mg/m2 SC once daily on Days 1-5 and carboplatin IV AUC 4 on Day 8, or (2) treatment of choice (TC) of topotecan, pegylated liposomal doxorubicin (PLD), paclitaxel, or gemcitabine based on recommended dosing in 28-day cycles; participants initially randomized to TC were able to cross over to receive 30 mg/m2 G+C due to disease progression.
62013051|NCT02795286|EXPERIMENTAL|ASIST A|Artis Haemodialysis Machine w/ ASIST Software - Isonatremic
62201150|NCT00307762|EXPERIMENTAL|1|Gait trainer exercise actively for 20 minutes + 55 minutes other gait-oriented physiotherapy
62201151|NCT00307762|ACTIVE_COMPARATOR|2|Overground walking exercises actively for 20 minutes + 55 minutes other gait-oriented physiotherapy
62201152|NCT00307762|NO_INTERVENTION|3|Control patients with ordinary therapy
62201153|NCT01478451|EXPERIMENTAL|Massage|massage will be provided for 10 minutes at the left or right trapezius (randomized)
62401893|NCT01589185|EXPERIMENTAL|KBSA301, a monoclonal antibody dose 3|10 mg/kg KBSA301
62401894|NCT01589185|EXPERIMENTAL|KBSA301, a monoclonal antibody dose 4|20 mg/kg KBSA301
62401895|NCT01589185|EXPERIMENTAL|Placebo|KBSA301-placebo
62013052|NCT02795286|EXPERIMENTAL|ASIST B|Artis Haemodialysis Machine w/ ASIST Software - Isotonic
62013053|NCT02795286|ACTIVE_COMPARATOR|Conventional HD|Artis Haemodialysis Machine w/o ASIST Software
62013054|NCT05634265|EXPERIMENTAL|Pilot|Participants will be offered the Vijana-SMART WhatsApp group intervention
62013055|NCT04917198|EXPERIMENTAL|median sternotomy|median sternotomy in penetrating cardiac trauma and hemodynamically unstable patients, does it affect morbidity and mortality.
62013056|NCT00844545|EXPERIMENTAL|Eculizumab|
62013057|NCT03662750|EXPERIMENTAL|Acute stroke cohort|Acute stroke cohort
62013058|NCT06517537||ARE|The ARE group underwent modified ARE+AVR surgery
62401896|NCT03662477|EXPERIMENTAL|EGFR+NK+|The EGFR mutation positive patients were with the principles of randomized and NK cells treatment.
62013059|NCT06517537||TAVR|TAVR group undergoes routine TAVR surgery
62784890|NCT02458781|ACTIVE_COMPARATOR|Metronidazole|"Metronidazole 250mg capsule:~To be provided by BAMC pharmacy. It will be made and stored by BAMC Pharmacy. Metronidazole 250mg will be encapsulated with a gelatin capsule filled with methylcellulose. Patient will take 2 capsules of metronidazole 250mg two times a day for 14 days."
62784891|NCT04747587||Patients with stroke|
62784892|NCT04747587||Controls|
62013060|NCT02659865|PLACEBO_COMPARATOR|Part A: Placebo|Single oral dose of placebo administered in one of three study periods
62013061|NCT02659865|EXPERIMENTAL|Part A: LY3039478 new formulation|Escalating single oral dose of LY3039478 administered in two of three study periods
62013062|NCT02659865|EXPERIMENTAL|Part B: LY3039478 original formulation|Single oral dose of LY3039478 administered in one of two study periods
62013063|NCT02659865|EXPERIMENTAL|Part B: LY3039478 new formulation|Single oral dose of LY3039478 administered in one of two study periods
62013064|NCT04258813|EXPERIMENTAL|Control|40 PCP clinics; 400 patients
62013065|NCT04258813|EXPERIMENTAL|iGuide Intervention|40 PCP clinics; 400 patients
62201154|NCT01478451|EXPERIMENTAL|Exercise|exercise (shoulder shrugs with elastic resistance) will be performed for 10 minutes at the left or right trapezius (randomized)
62201155|NCT01478451|NO_INTERVENTION|Control|control shoulder (randomized)
62201156|NCT04283539||CPI with ircAE|Participants on check point inhibitors with immune related cutaneous adverse event
62201157|NCT04283539||no ircAE|Participants who do not have a cutaneous adverse event
62013066|NCT03398993|ACTIVE_COMPARATOR|Scratch group|"Induction of ovulation will be done by clomophine citrate from 3rd day of cycle till 7th day of cycle and HMG 75IU (MerionaL) given from 6th day of cycle till 8th of cycle once daily. folliculometry done regularly during induction of ovulation till dominant follicle reached 18_20mm in size.~Then endometrial injury performed in pre ovulatory day by a thin pipelle (a fine, flexible, sterile, plastic tube) The procedure was carried out in preovulatory day (known when dominant follicle reached 18_20 mm in diameter), usually, done around day 14-day of the cycle"
62013067|NCT03398993|ACTIVE_COMPARATOR|Non scratch group|They will receive the same induction of ovulation as first group but without performing endometrial injury in preovulatory day
62013068|NCT01587547||IVF and ICSI patients|Subjects undergoing IVF or ICSI treatment with a maximum of 2 embryos transferred
62013069|NCT06572696||Rheumatoid Arthritis Patients|Tuberculum greater cortical surface irregularity, biceps and supraspinatus tendinopathy, supraspinatus and subscapularis dynamic compression and acromiohumeral distance will be evaluated bilaterally by ultrasound.
62201158|NCT04408053|EXPERIMENTAL|Preventive fixation of the contralateral femoral neck|Mini-invasive preventive fixation of the contralateral femoral neck : 6.5mm titanium cannulated self-tapping/self-drilling screws (Stryker Trauma and Depuy Synthes) : 2 screws per patients
62201159|NCT04408053|NO_INTERVENTION|No fixation|
62201160|NCT00088933|EXPERIMENTAL|Arm I|Three weeks after treatment with vaccinia-CEA-TRICOM vaccine, patients receive fowlpox-CEA-TRICOM vaccine SC on day 1 and GM-CSF SC into each vaccination site on days 1-4.
62201161|NCT00088933|EXPERIMENTAL|Arm II|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and lower-dose docetaxel IV over 30 minutes on days 1 and 8.
62784893|NCT00777361|EXPERIMENTAL|AZD3480 iv|Single iv infusion AZD3480
62784894|NCT00777361|EXPERIMENTAL|Oral [14C] AZD3480|Single oral dose \[14C\]AZD3480
62784895|NCT04241471|ACTIVE_COMPARATOR|traditional incision and drainage (I&D)|
62784896|NCT04241471|EXPERIMENTAL|incision and loop drainage|incision and loop drainage utilizing the rolled ring of a sterile glove technique
62784897|NCT00214916|ACTIVE_COMPARATOR|A|conventional insulin therapy (using Actrapid IV)
62784898|NCT00214916|EXPERIMENTAL|B|intensive insulin therapy (using actrapid IV)
62013070|NCT06572696||Healthy individuals|Tuberculum greater cortical surface irregularity, biceps and supraspinatus tendinopathy, supraspinatus and subscapularis dynamic compression and acromiohumeral distance will be evaluated bilaterally by ultrasound.
62201162|NCT00088933|EXPERIMENTAL|Arm III|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and standard-dose docetaxel IV over 30 minutes on days 1 and 8.
62201163|NCT00088933|EXPERIMENTAL|Arm IV|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and full-dose docetaxel IV over 1 hour on day 1.
62201164|NCT00088933|EXPERIMENTAL|Arm V|Patients receive full-dose docetaxel IV over 1 hour on day 1, fowlpox-CEA-TRICOM vaccine SC on day 8, and GM-CSF SC into each vaccination site on days 8-11.
62401897|NCT03662477|NO_INTERVENTION|EGFR+NK-|The EGFR mutation positive patients were with the principles of randomized and without NK cells treatment .
62401898|NCT03662477|EXPERIMENTAL|EGFR-NK+|The EGFR mutation negative patients were with the principles of randomized and NK cells treatment .
62401899|NCT03662477|NO_INTERVENTION|EGFR-NK-|The EGFR mutation negative patients were with the principles of randomized and without NK cells treatment.
62784899|NCT02599779|EXPERIMENTAL|Treatment arm A|"Arm-A: Pembrolizumab will be started and Stereotactic Body Radiation Therapy will be given at the time of progression on pembrolizumab and pembrolizumab will be continued.~Pembrolizumab will continue until progression as per immune related response criteria (irRC)."
62784900|NCT02599779|EXPERIMENTAL|Treatment arm B|"Arm B: Pembrolizumab will be started. Stereotactic Body Radiation Therapy will be given before the 2nd course of pembrolizumab and pembrolizumab will be continued.~Pembrolizumab will continue until progression as per immune related response criteria (irRC)."
62784901|NCT05613023|ACTIVE_COMPARATOR|P-SBRT|Participants allocated P-SBRT will receive 36.25Gy in 5 fractions to the prostate and seminal vesicles on alternate days (40Gy to prostate CTV).
62784902|NCT05613023|EXPERIMENTAL|PPN-SBRT|Participants allocated PPN-SBRT will receive 36.25Gy in 5 fractions to the prostate and seminal vesicles on alternate days (40Gy to prostate clinical target volume (CTV)) and 25Gy in 5 fractions to pelvic nodes on alternate days.
62784903|NCT03517228|EXPERIMENTAL|total laparoscopic or robotic-assisted hysterectomy|All patients who are consented for a total laparoscopic or robotic-assisted hysterectomy will be eligible for the trial, unless the surgeon does not plan to use a uterine manipulator.
62784904|NCT02177682|EXPERIMENTAL|Afuresertib|"Three subjects will be enrolled and given afuresertib 125 mg orally and monitored for toxicity. After completion of PK sampling in 3 days (Cycle 0), daily repeated dose of 125 mg will be given for 21 days (Cycle 1). If no DLT event is found after 21 days of repeated dosing, up to 6 subjects will be enrolled and given afuresertib 150 mg. If afuresertib 150 mg is assessed to be tolerable, up to 6 subjects can be enrolled and given afuresertib 200 mg. If afuresertib 200 mg is assessed to be intolerable, up to 6 subjects will be enrolled and given afuresertib 150mg or 175 mg. In any Dose levels, if DLT occurs in more than 2 subjects, that Dose level will be considered as intolerable."
62784905|NCT04688255|EXPERIMENTAL|Intervention group (MSTEP)|REHABILITATIVE EXERCISE: Participants will be asked to exercise at home daily for 6 weeks, meeting with an RA weekly via video conference to gradually increase the intensity and duration of exercise based on symptom tolerance. The eventual goal will be to achieve 60 minutes of MVPA daily (US Federal recommendations). They will wear a personal fitness device (Fitbit) to track whether they are achieving their HR goals.
62784906|NCT04688255|ACTIVE_COMPARATOR|Control group (Stretching)|STRETCHING: Participants will be asked to complete stretches daily. They will initially be given two stretches, primarily focused on the neck and upper back. Additional stretches will be added through weekly discussions with the study RA.
62013071|NCT06532695||Preterm|150 premature infants aged 0-3 years will be collected.
62013072|NCT06532695||Fullterm group|60 full-term children aged 0-3 years will be collected.
62013073|NCT04737785||Case group|HSCT recipients who developed a CNS disorder after HSCT
62013074|NCT04737785||Control group|HSCT recipients whom did not develop a CNS disorder
62013075|NCT04645212||1|Subjects with wet AMD who received any dose of ADVM-022 in a prior clinical study.
62201165|NCT00088933|EXPERIMENTAL|Arm VI|Patients receive full-dose docetaxel as in arm V, fowlpox-CEA-TRICOM vaccine SC on day 15, and GM-CSF SC into each vaccination site on days 15-18.
62201166|NCT03079297|EXPERIMENTAL|L-leucine|4 gm L-leucine by mouth twice daily for two weeks
62201167|NCT03079297|PLACEBO_COMPARATOR|Maltodextrin|4 gm maltodextrin by mouth twice daily for two weeks
62201168|NCT05035147|EXPERIMENTAL|Low dose strength: albumin-bound paclitaxel + gemcitabine|albumin-bound paclitaxel 125mg/m2+ gemcitabine1000mg/m2:day1,8 q3w
62201169|NCT05035147|ACTIVE_COMPARATOR|High dose strength: albumin-bound paclitaxel + gemcitabine|albumin-bound paclitaxel 125mg/m2+ gemcitabine1000mg/m2:day1,8,15 q4w
62201170|NCT03339739|EXPERIMENTAL|Isometric exercise Group|Group of participants which perform Isometric mandibular exercises, once a day, for 21 days
62401900|NCT03015662|EXPERIMENTAL|Dry Needling Therapy|Active or latent MTrPs (myofascial trigger points) will be remarked in black or red, respectively. Active or latent MTrPs will be needled in the same position employed by the blinded examiner for diagnosis. All dry needling procedures will be performed by the same investigator, and the technique used will be similar to the Hong method, using sterile Ener-Qi needles (EQ 1661) for the punction of TrPs (trigger points).
62410072|NCT05010915|EXPERIMENTAL|ventrolateral prefrontal cortex|"1. Age \> 50 years.~2. Major depressive disorder (MDD).~3. Right handiness~4. with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD"
62784907|NCT01725594|EXPERIMENTAL|Cohort A1, Dose Level 1: CAT 2003 or placebo fasting|Single dose
62201171|NCT03339739|ACTIVE_COMPARATOR|Isotonic exercise Group|Group of participants which perform Isotonic mandibular exercises, once a day, for 21 days
62784908|NCT01725594|EXPERIMENTAL|Cohort A2, Dose Level 2: CAT 2003 or placebo fasting|Single dose
62784909|NCT01725594|EXPERIMENTAL|Cohort A3, Dose Level 3: CAT 2003 or placebo fasting|Single dose
62784910|NCT01725594|EXPERIMENTAL|Cohort A4, Dose Level 4: CAT 2003 or placebo fasting|Single dose
62201172|NCT03339739|PLACEBO_COMPARATOR|Counseling Group|Group of participants which receive education brochure and no further interventions.
62410073|NCT05010915|PLACEBO_COMPARATOR|sham comparator|"1. Age \> 50 years.~2. Major depressive disorder (MDD).~3. Right handiness~4. with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD"
62784911|NCT01725594|EXPERIMENTAL|Cohort A5, Dose Level 5: CAT 2003 or placebo fasting|Single dose
62784912|NCT01725594|EXPERIMENTAL|Cohort A2: Dose Level 2: CAT 2003 or placebo fed|Single dose
62013076|NCT01771406|EXPERIMENTAL|Nebivolol then CPAP|8 weeks of Nebivolol treatment (5m/day), 6 weeks of washout, 8 weeks of CPAP and if the patient is still hypertensive 8 weeks of Nebivolol plus CPAP treatment
62201173|NCT05223010|ACTIVE_COMPARATOR|1|39 participant will receive melatonin 0.05 mg/kg
62784913|NCT01725594|EXPERIMENTAL|Cohort A3: Dose level 3:CAT 2003 or placebo fed|Single dose
62201174|NCT05223010|ACTIVE_COMPARATOR|2|39 participant will receive melatonin 0.2 mg/kg
62201175|NCT05223010|ACTIVE_COMPARATOR|3|39 participant will receive melatonin 0.4 mg/kg
62201176|NCT02209090|EXPERIMENTAL|maternal modified sims position|"Women in this group will adopt the modified Sims position, lying on the side of the foetal back.~This position is maintained for the greater part of labour, at least 40 minutes, every hour. The mother can use other positions during resting time of no more than 20 minutes each hour, but never use a lateral position against the side of the foetal back."
62201177|NCT02209090|SHAM_COMPARATOR|maternal free positions|Women can adopt the position they wish and which is most comfortable, except for lateral positions which can only be used for a maximum of 20 minutes each hour to avoid confounding factors.
62201178|NCT03615560||Preeclampsia (mild)|
62201179|NCT03615560||Preeclampsia (severe)|
62784914|NCT01725594|EXPERIMENTAL|Cohort B1: Dose level 6: CAT 2003 or placebo|Multiple dose for 14 days
62201180|NCT03615560||Gestational hypertension|
62784915|NCT01725594|EXPERIMENTAL|Cohort B2: Dose level 7: CAT 2003 or placebo|Multiple dose for 14 days
62784916|NCT01725594|EXPERIMENTAL|Cohort B3: Dose level 8: CAT 2003 or placebo|Multiple dose for 14 days
62784917|NCT01725594|EXPERIMENTAL|Cohort B4: Dose level 9: CAT 2003 or placebo|Multiple dose for 14 days
62013077|NCT01771406|EXPERIMENTAL|CPAP then Nebivolol|8 weeks of CPAP treatment, 6 weeks of washout, 8 weeks of Nebivolol and if the patient is still hypertensive 8 weeks of Nebivolol plus CPAP treatment
62013078|NCT02537080|EXPERIMENTAL|Nimodipine group|1 tbl of 30 mg nimodipine will be administered orally with premedication
62201181|NCT03615560||Control group|
62201182|NCT04737876|EXPERIMENTAL|BX002-A|BX002-A: 1 mL liquid for multiple dose oral administration
62784918|NCT03794154|EXPERIMENTAL|Duloxetine hydrochloride|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
62784919|NCT03794154|ACTIVE_COMPARATOR|Cymbalta|Duloxetine hydrochloride hard gelatinous capsule 60 mg as Cymbalta by mouth on Day 1 of period 1 or 2
62013079|NCT02537080|EXPERIMENTAL|Control group|1 tbl of placebo will be administered orally with premedication
62013080|NCT05368597||Native vessel PCI|Native vessel PCI, which choose native coronary artery as the target vessel
62013081|NCT05368597||Bypass graft PCI|Bypass graft PCI, which choose the graft vessel as the target vessel
62201183|NCT04737876|PLACEBO_COMPARATOR|Placebo|Placebo: 1 mL liquid for multiple dose oral administration
62784920|NCT05934903|EXPERIMENTAL|Stimulation|The tDCS device will stimulate with a 2mA current during sessions. Both arms receive application of the device for 3 sessions of 2x 30 minute active application with 30 minutes rest in between.
62401901|NCT03015662|ACTIVE_COMPARATOR|Myofascial Release Therapy|Patients will develope a myofascial therapy protocol, administered in the following order: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
62578851|NCT05829538|EXPERIMENTAL|Su Jok|Su Jok Experimental Group (A): In this study, the seed therapy technique was applied using live buckwheat seeds. Hands were used because it was reported in the literature that hands were used for gynecological pain and were more suitable (Şimşek and Alpar, 2022). The acupuncture point, which is the reflection of the painful area, was determined on the women's hands. This point was massaged for a few minutes by the researcher, and then the buckwheat seed was fixed to this point with a bandage and the area where the seed was applied was massaged for 30 minutes. After each application, VAS evaluation was taken from the women. Su Jok was applied to women in the first three days of menstruation for three cycles.
62578852|NCT05829538|EXPERIMENTAL|Massage|Experimental Group (B) classical massage techniques (eufluorage, petrissage, friction, tapotman, vibration) was used. Massage was attempted for a total of 20 minutes, 10 minutes on the back and waist, and 10 minutes on the abdominal region, in the first three days of the three cycles. Massage application was started from the back and waist region. Efflorage, petrissage, friction, vibration, taputman and efflorage for one minute were applied to this area, respectively. Afterwards, three minutes of efflorage, petrissage, friction, and one-minute efflorage were applied to the abdominal region, respectively. Odorless, lubricating gel was used during the application. After each application, VAS evaluation was taken from the women. The women were massaged in the first three days of menstruation for three cycles.
62578853|NCT05829538|NO_INTERVENTION|Control|VAS evaluation was taken on the first three days during three cycles.
62784921|NCT05934903|SHAM_COMPARATOR|Sham Stimulation|The tDCS device will stimulate with a 0mA current during sessions (sham). Both arms receive application of the device for 3 sessions of 2x 30 minute active application with 30 minutes rest in between.
62784922|NCT02471222|EXPERIMENTAL|ADS-5102 (amantadine HCl extended release)|
62784923|NCT02471222|PLACEBO_COMPARATOR|Placebo|
62013082|NCT06653647|ACTIVE_COMPARATOR|Immediate Treatment|Participants randomized to the Immediate Treatment arm will receive immediate access to the guided imagery therapy mobile application intervention.
62013083|NCT06653647|OTHER|Delayed Treatment|Participants randomized to the Delayed Treatment arm will be placed on waitlist status and will not have any intervention from weeks 3 to 10. Participants will continue their usual care for their abdominal pain during this time. Then, this study arm will cross over to the guided imagery therapy mobile application intervention from weeks 11 to 18.
62201184|NCT01508949|EXPERIMENTAL|NNC 90-1170|
62784924|NCT02128880|EXPERIMENTAL|CARRII|CARRII: This is a highly interactive Internet intervention consisting of 6 Cores of Intervention material, including Core 1, Overview, Core 2: Your Risk for AEP, Core 3: Drinking, Core 4: Contraception, Core 5: Thoughts and Decisions, and Core 6: Commit to It.
62201185|NCT01508949|PLACEBO_COMPARATOR|Placebo|
62201186|NCT02604823|EXPERIMENTAL|Group A (Naïve Participants)|Participants who never received any HBV treatment, will receive peginterferon alfa-2a (180 micrograms \[mcg\]) subcutaneously once weekly for 48 weeks.
62201187|NCT02604823|EXPERIMENTAL|Group B (Conventional Interferon Pretreated Participants)|Participants who received conventional interferon treatment and had relapse or did not respond, will receive peginterferon alfa-2a (180 mcg) subcutaneously once weekly for 48 weeks.
62201188|NCT02604823|EXPERIMENTAL|Group C (Lamivudine Pretreated Participants)|Participants who received lamivudine and had relapse or did not respond, will receive peginterferon alfa-2a (180 mcg) subcutaneously once weekly for 48 weeks.
62201189|NCT04168983|NO_INTERVENTION|Control|Usual care: local anesthesia + nitrous oxide and oxygen administration
62013084|NCT06654999||All patients|All patients will have their skin lesion imaged in the same way
62201190|NCT04168983|EXPERIMENTAL|Experimental|"Usual care: local anesthesia + nitrous oxide and oxygen administration~In this arm : sophrology is added"
62784925|NCT02128880|ACTIVE_COMPARATOR|Patient Education|CARRII Education: This is a static website containing educational information on the following topics: What is Alcohol Exposed Pregnancy (AEP)?, Fetal Alcohol Spectrum Disorders, Impact of AEP, Prevalence of AEP, Causes and Prevention of AEP, Treatment for AEP, and Links to related information.
62784926|NCT01240135|OTHER|FID 114576A / renu fresh|FID 114675A used for contact lens care per protocol-specified instructions for 14 days, followed by a minimum 1-day washout period, after which renu fresh used for contact lens care for an additional 14 days.
62201191|NCT04938570||University-level and amateur rugby players|"University-level and amateur rugby players will be recruited and assessed (motor, visual and symptom assessment) over one season ( June 2021 to August 2022).~Participants will be stratified according to gender (males n≈100, and females n≈100). Although the number of SRC that will be observed during the season is not known, the investigators will compare a number of head injuries/SRC to the results from cohort baseline testing. Participants that do not sustain a concussion will also have follow up testing at the end of the season."
62201192|NCT04055090|EXPERIMENTAL|Subjects who received Engensis (VM202)|VM202, Engensis
62201193|NCT04055090|PLACEBO_COMPARATOR|Subjects who received Placebo|Placebo, vehicle
62201194|NCT03843697|EXPERIMENTAL|Patients with IBD who develop resistance to anti TNF|Patients with inflammatory bowel disease who developed partial or complete resistance to anti TNF based drugs
62201195|NCT01541800||Patients|All children who are in treatment for leukemia, lymphoblastic lymphoma and central nervous system tumors between 3 years and 21 years of age
62401902|NCT06060912|EXPERIMENTAL|LAmbre occlusion device|Left atrial occlusion will be performed with the LAmbre occlusion device (Lifetech Scientific, Shenzhen, China)
62401903|NCT06060912|ACTIVE_COMPARATOR|AMPLATZER Amulet occlusion device|Left atrial occlusion will be performed with AMPLATZER Amulet occlusion device (Abbott Medical, Chicago, ILL, USA)
62401904|NCT03107065|EXPERIMENTAL|single treatment|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation Used To Contract Tissue Associated With Axillary Sweat Glands
62784927|NCT01240135|OTHER|renu fresh / FID 114675A|Renu fresh used for contact lens care per protocol-specified instructions for 14 days, followed by a minimum 1-day washout period, after FID 114675A used for contact lens care for an additional 14 days.
62784928|NCT04358224|OTHER|open-label|open-label
62784929|NCT02941224|EXPERIMENTAL|SELUTION DCB|The SELUTION™ DCB (coated with sirolimus) is intended for use as a Percutaneous Transluminal Angioplasty (PTA) balloon catheter to dilate de-novo or restenotic vascular lesions, for the purpose of improving limb perfusion and decreasing the incidence of restenosis.
62784930|NCT00520910|EXPERIMENTAL|Polypodium leucotomos extract|Subject is given a 7.5 mg/kg dose of Polypodium leucotomos.
62784931|NCT00520910|NO_INTERVENTION|No intervention|Subject is not given any treatment.
62784932|NCT05295108|EXPERIMENTAL|Caring Connections intervention|The Caring Connections intervention will consist of non-demanding, messages of care and concern delivered to individuals with SCI/D who had moderate to high social isolation and/or loneliness scores on the baseline survey. The caring messages will be in the form of structured, yet personalized mailed letters from one consistent peer with SCI/D, providing long-term and steady contact. Intervention participants will receive a letter every month over a 6-month period. Following a standardized set of principles, letters will contain cheerful expressions of care and micro-moments of positivity. The PI/Co-Is will provide a brief training and work with volunteer peers with SCI/D to write the letters.
62784933|NCT05295108|ACTIVE_COMPARATOR|Attention control|We will mail informational materials to individuals with SCI/D in our control group at the same timepoints over 6 months as our intervention letter mailings. The informational materials will discuss life domains that are important to a good quality of life. Topics include community living, physical/healthy living, safety and security, social/spirituality, advocacy/engagement, and employment/volunteering. We will draw information for each topic from the Knowledge Translation Center SCI Factsheets (MSKTC 2021) and the LifeCourse Nexus library (2021).
62013085|NCT03102476|OTHER|Patients with Type 1 Diabetes|Using euglycaemic clamp, the effect of different temperatures and humidity levels will be assessed on the pharmacokinetic and pharmacodynamic profiles of short-acting insulin Humalog.
62401905|NCT05833269|EXPERIMENTAL|Mindfulness and compassion based intercare program|"This 8-week intervention aims to reduce parental burnout by adapting the Mindfulness-based Inter-care Program and incorporating elements from MBSR, MBCT, and CBCT. The program includes 8 modules with practical and theoretical activities, weekly tasks, journaling, and daily meditation practices such as body exploration, seated and moving meditation, walking and eating meditation, acceptance, compassion, and gratitude.~The program also promotes values such as time management, attentive parenting, and emotional management while addressing factors of risk for parental burnout such as perfectionism, low emotional intelligence, lack of parenting practices, excessive responsibilities, and lack of support. Participants will receive two weekly reminders via email to perform the practices and review information. Additionally, they will have the option to participate in a virtual group via the WhatsApp platform with other participants."
62013086|NCT01717573|ACTIVE_COMPARATOR|Deferred stenting|During primary PCI in STEMI, when TIMI 3 flow has been re-established with guide-wire, aspiration thrombectomy and/or balloon angioplasty, stenting is then deferred for a period of 4-16 hours following reperfusion. During this time, patients remain in the Coronary Care Unit and will receive intravenous tirofiban and subcutaneous low molecular weight heparin (enoxaparin 1 mg/kg)
62401906|NCT05833269|ACTIVE_COMPARATOR|Audio guide relaxation control group|"The active control group in this study will be provided with a 20-minute relaxation audio containing Jacobson's progressive relaxation instructions. This intervention aims to control for attention and time while allowing for comparison to the experimental group. Also, journaling was included.~Additionally, the program will include information on risk factors for parental burnout, such as parental perfectionism, low emotional intelligence, lack of parenting practices, excessive responsibilities, and lack of support. Two weekly email reminders will be sent to encourage daily practice and review of the information provided. Participants will also have the option to participate in a virtual support group through the WhatsApp platform with other participants. This active control group intervention aims to improve participant well-being by providing relaxation techniques and support for the challenges of parenting."
62401907|NCT05833269|NO_INTERVENTION|Waiting List Group|The waiting list group will receive the intervention after the primary outcome is measured. No intervention was provided before this point.
62401908|NCT02120690|EXPERIMENTAL|Trigeminal nerve stimulation - active|10-day TNS interventional protocol over an 10-day follow-up
62401909|NCT02120690|SHAM_COMPARATOR|Trigeminal nerve stimulation|10-day sham interventional protocol over an 10-day follow-up
62410074|NCT06545019|EXPERIMENTAL|Group V ( Informative Video )|"Receive QR code of the informative video. Participants can watch it on their phones as many times as they wish.~During day of surgery , will receive standard care as per protocols ."
62013087|NCT01717573|SHAM_COMPARATOR|Conventional treatment|Conventional treatment in STEMI, with immediate stenting
62013088|NCT04808609|EXPERIMENTAL|Intervention|The Intervention group receives standard smoking cessation counseling and nicotine replacement therapy AND access to the Lumme app that tracks smoking behaviors and provides cessation support.
62013089|NCT04808609|OTHER|Control|The Control group receives standard smoking cessation counseling and nicotine replacement therapy
62013090|NCT05236790|EXPERIMENTAL|Artificial intelligence for real-time detection and monitoring of colorectal polyps|Colonoscopies will be performed according to the standard of care. Patients will undergo colonoscopies using CAD-eye (CADe and CADx) and Scale-eye. All optically diagnosed (CADx) polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards. CADx will be combined with human input for final diagnosis.
62201196|NCT02922023|ACTIVE_COMPARATOR|Chronotherapy|Chronotherapy group automatically receives a shift in 1 anti-hypertensive medication to night-time without assessment of ambulatory blood pressure monitor results.
62201197|NCT02922023|ACTIVE_COMPARATOR|ABPM|ABPM group will have their ambulatory blood pressure monitor results reviewed prior to deciding to change regimen.
62201198|NCT06530004||Sequential prevention group|According to the situation of B cells to rebuild the preventive use of rituxan, each 375 mg/m2.
62201199|NCT06530004||Recurrent sequential group|In patients with recurrence after the use of rituxan, each 375 mg/m2.
62578854|NCT06093360||flapless group|Patients were treated in 1-2 sessions within a period of 7 days, with a minimum of 90 minutes per session. Implant-supported restorations were unscrewed and modified if they were not cleansable. After local anesthesia, a periodontal ultrasonic stainless-steel tip was used for supra- and sub-mucosal mechanical debridement . Next, a Columbia 4R/4L curette was used around the implant in a circular motion until a bone exposure of 2-3 mm was achieved. Mucosal curettage was performed. After obtaining access to the implant surface, ultrasonic instrumentation was repeated and air polishing with an erythritol powder was applied submucosally with the aim of a periodontal probe. Hydrogen peroxide 3% was used to irrigate the implant surface for 2 minutes, followed by a rinse with saline. Systemic antibiotics, when prescribed, were metronidazole or azithromycin.
62401910|NCT02129257|EXPERIMENTAL|FOLFIRI-AFLIBERCEPT|Aflibercept 4 mg/kg administered over 1 hour on Day 1, followed by FOLFIRI regimen. Treatment will be repeated every 2 weeks. FOLFIRI regimen: Irinotecan 180 mg/m² intravenous (IV) infusion and folinic acid 400 mg/m² IV infusion followed by: 5-fluorouracil (5-FU) 400 mg/m² IV bolus followed by: 5-FU 2400 mg/m² continuous IV infusion over 46 hours. FOLFIRI administration will immediately follow the aflibercept one. In the absence of PD after 6 months of the combination of chemotherapy and aflibercept, the patient will be treated with a maintenance therapy with aflibercept alone until PD or unacceptable toxicities, investigator's decision or patient's refusal of further treatment or death, whichever comes first.
62784934|NCT05192655||HNSCC-patients treated with primary radio(chemo)therapy (R(C)T)|Patients, older than 18 years, with diagnosed HNSCC, attending the Department of Radiooncology and Radiotherapy at Charité for a treatment with curative intension (R(C)T) . All patients received as pretherapeutic diagnostic method a 18F-Fluorodesoxyglucose (FDG) positron emission tomography (PET) imaging.
62784935|NCT05192655||HNSCC-patients treated with primary surgery|Patients, older than 18 years, with diagnosed HNSCC, attending the Department of Oral and Maxillofacial Surgery or ENT Department at Charité for a treatment with curative intension ( primary surgery +/- combined with adjuvant (R(C)T)). All patients received as pretherapeutic diagnostic method a 18F-Fluorodesoxyglucose (FDG) positron emission tomography (PET) imaging.
62784936|NCT06477913|EXPERIMENTAL|Active Rauha Therapy|Qualified intend to treat (ITT) population evaluating Rauha and access to Mental Health Coaches
62201200|NCT05496153|EXPERIMENTAL|Cardiovascular diseases Patients|Subjects were recruited from outpatients with CVDs, under 18 years of age. All pa-tients have been verified the willingness of participating before the experiment. Patients was excluded if having abnormal blood pressure response, unstable angina pectoris, acute heart failure, congenital heart disease, and severe musculoskeletal diseases limiting.
62201201|NCT02473289|EXPERIMENTAL|Sirukumab 50 milligram (mg)|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
62201202|NCT02473289|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
62401911|NCT02012751|EXPERIMENTAL|Nevus doctor program|Use of Nevus doctor program to assess the diagnostic category of pigmented skin lesions
62784937|NCT03707470|EXPERIMENTAL|Custom fitted compression garments (CF)|Custom fitted compression garments (Isobar, Manchester, UK) designed to provide 35 mmHg at the ankle and \>20 mmHg at the mid-thigh (equivalent to European class 2 compression garments)
62784938|NCT03707470|ACTIVE_COMPARATOR|Standard-sized compression garments (SSG)|Off-the-shelf, standard-sized garments (2XU, Campbelltown, Australia), typically providing pressures equivalent to European grade 1 compression or below (5 - 15 mmHg at both the ankle and thigh)
62784939|NCT03707470|SHAM_COMPARATOR|Sham ultrasound (CON)|Sham ultrasound using an unplugged machine. Sham treatment for 5 minutes on each of the thighs, calves and hamstrings
62784940|NCT02560012|OTHER|Personalized therapy|"Subjects will receive one of the four first-line therapy agents based on their tumor's profile. The first-line agents are sunitinib, temsirolimus, sorafenib, or pazopanib. These are all routine drugs for RCC treatment and will be given at their approved doses and dosing schedules.~Upon disease progression, subject's tumor(s) will be biopsied again to create another tumor profile. The second-line agents are everolimus or axitinib. Both of these are routine drugs for RCC treatment and will be given at their approved doses and dosing schedules."
62784941|NCT02267161|EXPERIMENTAL|neuropsycological tests|Psychometric scales for infants at 3 years of age
62784942|NCT01921127||Symbicort|BFC patients new to ICS/LABA therapies
62784943|NCT01921127||Advair|FSC patients new to ICS/LABA therapies.
62784944|NCT04385134||General parturient|Observe the enterovirus infection in general parturients and their neonates.
62784945|NCT04385134||Puerpera with fever|Observe the enterovirus infection in puerpera with fever and their neonates.
62784946|NCT04385134||Febrile newborns|Observe the enterovirus infection in neonates
62784947|NCT04312347|EXPERIMENTAL|Personalized dosing of tamoxifen|Increase tamoxifen dose into 40 mg/day for patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype.
62784948|NCT04601805||Group (1) : Patient diagnosed with IBD with no treatment received|
62784949|NCT04601805||Group(2): Patient diagnosed with IBD and received treatment for a long time|
62784950|NCT02006979|EXPERIMENTAL|Exercise|an acute bout of exercise performed ≤24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post
62784951|NCT02006979|NO_INTERVENTION|No exercise|no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines
62784952|NCT04479202|EXPERIMENTAL|berberine group (B group)|Patients in the B group were given berberine hydrochloride tables 0.3g tid orally or tube feed daily, until the 14th day of the study. Other treatments include general support therapy, oxygen therapy, antiviral drugs, in combination with antibiotics and small doses of glucocorticoids if necessary, nutritional and organ function support.
62201203|NCT02140853||MDR group|patients of MDR pathogen infection
62201204|NCT02140853||non-MDR group|patients of non-MDR pathogen infection
62201205|NCT03652441|EXPERIMENTAL|Maintenance|Brentuximab Vedotin will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
62201206|NCT00295815|EXPERIMENTAL|A|
62401912|NCT04259398|EXPERIMENTAL|TIVA|propofol infusion targeting bispectral index 40-60
62578855|NCT03558763|ACTIVE_COMPARATOR|Normal Care|During normal care the subjects will get the possibility to call the COPD-center via telephone on their own initiative e g with worsening symptoms as usual.
62578856|NCT03558763|ACTIVE_COMPARATOR|Telemonitoring|"Twice a week subject will perform additional vital functions:~Blood pressure and heart rate will be measured using the Electronic Sphygmomanometers Track.~Weight will be taken using the Scale lite Oxygen saturation will be measured using Pulse Oximeter Air And~Complete two PRO´s (integrated in the application):~CAT MRC All this is estimated to take approximately 20-30 min each time.~For the first 4 weeks there will be weekly video calls with a COPD-center nurse discussing health condition and vital parameters.~Thereafter there will be monthly video calls with a COPD-center nurse for the remaining 5 months, i.e. 4 further calls. The video calls will take approximately 15 min."
62578857|NCT04366843|EXPERIMENTAL|The chair massage group|chair massage 15 min,, 2 x week; measurement before and after each treatment
62201207|NCT00295815|ACTIVE_COMPARATOR|B|
62201208|NCT05036980|EXPERIMENTAL|0.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 0.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
62201209|NCT05036980|EXPERIMENTAL|1.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 1.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
62201210|NCT05036980|EXPERIMENTAL|2.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 2.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
62201211|NCT05057871|EXPERIMENTAL|PEMF+exercise|A total of 20 sessions of pulse electromagnetic field therapy using an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057, Italia), five times a week and once a day for four weeks, were applied to the patients. The patients were then given a daily exercise program once a day by a physiotherapist.
62201212|NCT05057871|SHAM_COMPARATOR|Sham PEMF+exercise|Sham therapy was applied in five sessions a week for four weeks, with a total of 20 sessions, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist.
62201213|NCT03812029|EXPERIMENTAL|Vonafexor 100 mg BID|Oral dose twice daily for 12 weeks (84 days)
62201214|NCT03812029|EXPERIMENTAL|Vonafexor 200 mg QD|Oral dose once daily for 12 weeks (84 days)
62201215|NCT03812029|EXPERIMENTAL|Vonafexor 400 mg QD|Oral dose once daily for 12 weeks (84 days)
62201216|NCT03812029|PLACEBO_COMPARATOR|Placebo|Oral dose twice daily for 12 weeks (84 days)
62578858|NCT04366843|EXPERIMENTAL|The exercise program group|excercises 15 min., 2 x week; measurement before and after each treatment
62578859|NCT04366843|NO_INTERVENTION|The control group|control 2 measurements, 4 weeks apart
62578860|NCT05020665|EXPERIMENTAL|Intensive Chemotherapy + Entospletinib (ENTO)|Participants received intensive chemotherapy (cytarabine and anthracycline \[daunorubicin or idarubicin\]) in combination with entospletinib (ENTO).
62201217|NCT03812029|EXPERIMENTAL|Vonafexor 100 mg QD|Oral dose once daily for 12 weeks (84 days)
62201218|NCT02303600|EXPERIMENTAL|biomarker treatment arm|Patients in biomarker guided positive treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . Patients in biomarker guided negative treatment arm were given placebo tablets (main excipient lactose monohydrate).
62201219|NCT02303600|ACTIVE_COMPARATOR|standard treatment arm|Patients in standard treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
62201220|NCT00214019|PLACEBO_COMPARATOR|Placebo Diskus|Placebo comparator
62401913|NCT04259398|ACTIVE_COMPARATOR|inhalation (Sevoflurane)|sevoflurane targeting bispectral index 40-60
62401914|NCT00240331|EXPERIMENTAL|Rosuvastatin 10mg|
62401915|NCT00240331|PLACEBO_COMPARATOR|Placebo|matching Placebo
62578861|NCT05020665|PLACEBO_COMPARATOR|Intensive Chemotherapy + Placebo|Participants received intensive chemotherapy (cytarabine and anthracycline \[daunorubicin or idarubicin\]) in combination with the matching placebo.
62578862|NCT00725361|EXPERIMENTAL|Active|Ambrisentan
62401916|NCT03024294|OTHER|Patients undergoing VATS lobectomy or segmentectomy|Patients undergoing VATS lobectomy or segmentectomy performed by one of the surgeons in the Division of Thoracic Surgery who are then placed on this specific post-operative care pathway to determine the rate of discharge of these patients by post-operative day (POD) three.
62578863|NCT02539433|EXPERIMENTAL|F-18-F-DOPA i.v.|F-18-F-DOPA i.v. one injection of a dose of up to 8.5 mCi (millicurie). Standard PET scanning started 60-90 minutes post injection.
62401917|NCT01452386||Experimental Group|
62401918|NCT01452386||Control Group|
62401919|NCT02147015|EXPERIMENTAL|Personalized variable dose of glucocorticoids arm|Use of personalized variable dose of glucocorticoids according to a rating scale starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, Inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA), Long-Acting Muscarinic Antagonists(LAMA), short-acting beta2-agonist (SABA), and other physical treatments.
62578864|NCT00252525||Group 1|This is an observational study of patients who are enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2@.
62578865|NCT00717834|EXPERIMENTAL|Cohort 1, Treatment Arm 1|Randomization of a total of approx. 200 subjects to one of four treatment arms at 1:1:1:1 ratio to receive 1.25 µg of the RRV Vaccine with/without adjuvant (Al(OH)3), or 2.5 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Cohort 1 is subdivided into Cohort 1a (n = 60, i.e. 15 subjects per dose/adjuvantation combination) to receive the first vaccination on Day 0, with Day 7 safety data being reviewed by a Data Monitoring Committee and, following DMC recommendation, to receive the second vaccination at Day 21; Cohort 1b (n=140, i.e. 35 subjects per dose/adjuvantation combination) is to be vaccinated twice 21 days apart upon availability of DMC recommendation. Booster vaccination to follow 180 days after first vaccination.
62401920|NCT02147015|OTHER|Fixed dose of glucocorticoids arm|Use of fixed term of glucocorticoids (40mg) starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, ICS, LABA, LAMA, SABA, and other physical treatments.
62401921|NCT02568111|EXPERIMENTAL|brimonidine tartrate|Participants will apply gel to injection site erythema area after IRE development post peginterferon beta-1a injection
62401922|NCT02568111|PLACEBO_COMPARATOR|Vehicle Gel|Participants will apply vehicle gel placebo to injection site erythema area after IRE development post peginterferon beta-1a injection
62401923|NCT00961727||PEWS System of Care|
62401924|NCT02168465|OTHER|teaching self-management of intermittent catheter|Single group pre-post test of feasibility, teaching self-management
62401925|NCT01353209|EXPERIMENTAL|Letrozole|Patients are placed on letrozole, 1 tablet (2.5 mg) daily for one year
62401926|NCT01353209|PLACEBO_COMPARATOR|Placebo|Patients are placed on placebo, 1 tablet daily for one year
62401927|NCT01471652|ACTIVE_COMPARATOR|Nutraceuticals|Subjects will receive a combination of 4 nutraceuticals (CoEnzyme Q10, acetyl-L-carnitine, alpha-lipoic acid, docosahexaenoic acid (DHA)) and a multivitamin.
62401928|NCT01471652|PLACEBO_COMPARATOR|Placebo|
62401929|NCT05334576|OTHER|Single Arm: Crizanlizumab|Single-arm: Patients with sickle cell disease and increased risk of silent cerebral infarcts
62578866|NCT00717834|EXPERIMENTAL|Cohort 1, Treatment Arm 2|Same as Cohort 1, Treatment Arm 1
62578867|NCT00717834|EXPERIMENTAL|Cohort 1, Treatment Arm 3|Same as Cohort 1, Treatment Arm 1
62784953|NCT04479202|SHAM_COMPARATOR|control group (C group)|Patients in the C group were given montmorilonite orally if they presence of diarrhea. The other treatments were the same as in B group.
62784954|NCT00778908|EXPERIMENTAL|A|Late-course accelerated hyperfractionated IMRT with concomitant cisplatin chemotherapy
62784955|NCT00778908|OTHER|B|Conventionally fractionated IMRT with concomitant cisplatin chemotherapy
62784956|NCT00544037||Group 1|
62784957|NCT05144867|ACTIVE_COMPARATOR|Arm 1|The WBRT dosage schedule will be 30 Gy in 10 fractions over 2 weeks. For Arm 1, Treatment planning is to be done using CT simulation or conventional simulation (fluoroscopy). Simple beam arrangements, such as parallel opposed beams, will be favoured wherever possible.
62784958|NCT05144867|EXPERIMENTAL|Arm 2|Metastases with a maximum diameter of up to 2 cm will be treated with doses of 22 to 25 Gy and those larger than 2 cm will be treated with doses of 18 to 20 Gy.
62201221|NCT00214019|EXPERIMENTAL|Salmeterol Diskus 50 mcg twice per day|Salmeterol Diskus 50 mcg twice per day
62401930|NCT04056650|ACTIVE_COMPARATOR|Single caffeinated beverage/supplement|
62401931|NCT04056650|ACTIVE_COMPARATOR|Combination caffeine and L-theanine|
62401932|NCT05728658|EXPERIMENTAL|ICP-248|ICP-248 was divided into 6 dose groups, and each dose group was given progressively
62401933|NCT01643967|EXPERIMENTAL|Ozone therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
62013091|NCT05236790|NO_INTERVENTION|Real time polyp detection using a standard colonoscopy without CAD eye|Real time polyp detection using a standard colonoscopy without CAD eye and without CADe. Patients will undergo a standard colonoscopy. Polyp size measurement will be assessed visually (phase 1 and 2) or with instruments such as snare or forceps (phase 3 or later) and polyp classification will be done by CADx without further input by the endoscopist. All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.
62013092|NCT03650426|ACTIVE_COMPARATOR|Onlay patellar resurfacing technique|
62013093|NCT03650426|EXPERIMENTAL|Inlay patellar resurfacing technique|
62013094|NCT05242614|EXPERIMENTAL|A hybrid Mindfulness-based Dementia Caregiving Program (MBDCP)|Participants from the experimental group will receive a hybrid Mindfulness-based Dementia Caregiving Program (MBDCP). It is a 6-week program. In the 1st, 2nd and 6th session, it is delivered through face to face, while in the 3rd, 4th and 5th sessions, it will be delivered via online approach.
62013095|NCT05242614|ACTIVE_COMPARATOR|Control group|The family caregivers in the control group will receive 6 week education programme on dementia. It is a control for the social effects of the MBDCP. In the 1st, 2nd and 6th session, it is delivered through face to face, while in the 3rd, 4th and 5th sessions, it will be delivered via online approach.
62013096|NCT01968434|EXPERIMENTAL|protective cough syrup|"syrup containing honey, plantago lanceolata, grindelia robusta, helichrysum italicum ina syrup form. The cough syrup is a CE marked medical device acting in a non pharmacological way to reduce cough.~Dosage: 20 ml divided in three doses per day for the duration of the study (4 nights, 3 days)"
62013097|NCT01968434|ACTIVE_COMPARATOR|carbocisteine cough syrup|Dosage 20-25 mg/kg/day three times a day (3 days/4 nights)
62013098|NCT01497379|EXPERIMENTAL|intra-individual implant ON|intra-individual implant activation
62013099|NCT01497379|PLACEBO_COMPARATOR|intra-individual implant OFF|intra-individual implant deactivation
62013100|NCT06410105|EXPERIMENTAL|Groub(1): 13 patient treated with CLEAR ALIGNERS|The CA group included 13 patients treated with clear aligners Tree-dimensional images were captured using a CBCT scan (KaVo® Dental GmbH, Bismarckring, Germany). Te pre-treatment imaging parameters were 120 kV, 5 mA, 0.3 mm voxel size, and a feld of view of 230×170 mm
62013101|NCT06410105|EXPERIMENTAL|Groub(2): 13 patient treated with a fixed orthodontic|. The FA group included 13 patients treated with a fxed orthodontic appliance (american orthodontics, WI.Sheboygam, USA). Tree-dimensional images were captured using a CBCT scan (KaVo® Dental GmbH, Bismarckring, Germany). Te pre-treatment imaging parameters were 120 kV, 5 mA, 0.3 mm voxel size, and a feld of view of 230×170 mm, which
62401934|NCT01643967|ACTIVE_COMPARATOR|sunflower oil|"The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.~Other Names:~Sunflower oil"
62401935|NCT06323655|EXPERIMENTAL|Tasimelteon|single dose
62401936|NCT06323655|PLACEBO_COMPARATOR|Placebo|single dose
62401937|NCT06323655|ACTIVE_COMPARATOR|Active Control|single dose
62401938|NCT03315780|EXPERIMENTAL|Dulaglutide, Placebo|Dulaglutide 0.75 mg administered subcutaneously (SC) once weekly for 4 weeks in period 1 followed by placebo administered SC once weekly for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
62401939|NCT03315780|EXPERIMENTAL|Placebo, Dulaglutide|Placebo administered SC once weekly for 4 weeks in Period 1 followed by Dulaglutide 0.75 mg administered SC for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
62401940|NCT00690573|EXPERIMENTAL|Adalimumab|
62401941|NCT05206669|EXPERIMENTAL|Cancer Messages - Young Adults|Messages providing information about the use of HPV vaccines to prevent cancer.
62401942|NCT05206669|EXPERIMENTAL|Cancer Messages - Parents of Adolescents|Messages providing information about the use of HPV vaccines for their adolescent children to prevent cancer.
62578868|NCT00717834|EXPERIMENTAL|Cohort 1, Treatment Arm 4|Same as Cohort 1, Treatment Arm 1
62578869|NCT00717834|EXPERIMENTAL|Cohort 2, Treatment Arm 1|Randomization of a total of approx. 100 subjects to one of two treatment arms at 1:1 ratio to receive 5 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Vaccinations take place upon review of Cohort 1a Day 7 safety data by DMC and recommendation to proceed. Booster vaccination to follow 180 days after first vaccination.
62013102|NCT03839667|EXPERIMENTAL|intensive diet intervention group|The participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
62013103|NCT03839667|EXPERIMENTAL|Enhanced physical activity group|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
62013104|NCT03839667|EXPERIMENTAL|Standard education group|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
62013105|NCT02948413||Single Group of patients with Cancer|Patients with cancer (lymphoma, leukemia, prostate cancer, and mesothelioma) on clinical trials at the NIH Clinical Center.
62401943|NCT05206669|EXPERIMENTAL|Genital Wart Messages - Young Adults|Messages providing information about the use of HPV vaccines to prevent genital warts.
62578870|NCT00717834|EXPERIMENTAL|Cohort 2, Treatment Arm 2|Same as Cohort 2, Treatment Arm 1
62013106|NCT05600400|EXPERIMENTAL|Arm 1|Two weekly fractions of 13.5 Gy
62013107|NCT05600400|ACTIVE_COMPARATOR|Arm 2|Five every other day fractions of 8 Gy
62201222|NCT00214019|EXPERIMENTAL|Placebo diskus, fluticasone|placebo diskus, fluticasone MDI 88 mcg twice per day
62201223|NCT00214019|EXPERIMENTAL|Salmeterol, Fluticasone|Salmeterol diskus 50 mcg BID, fluticasone MDI 88 mcg twice per day
62201224|NCT03258723|EXPERIMENTAL|Intervention|Highest risk pre-diabetic patients
62401944|NCT05206669|EXPERIMENTAL|Genital Wart Messages - Parents of Adolescents|Messages providing information about the use of HPV vaccines or their adolescent children to prevent genital warts.
62013108|NCT01316627|EXPERIMENTAL|Crooked Mirror Externalization Therapy|"Of recent, the crooked mirror externalization therapy, developed by Dr. Eda Gorbis, has been put to use with much success (Gorbis 2004). This method involves the use of crooked or fun house mirrors made from highly reflective surfaces that can be bent in different directions, which distort and exaggerate the patient's perceived defects (Gorbis 2005). In turn, this process externalizes or reverses the patient's internalized distorted body image, and allows the patient to habituate to the reflection of the imagined defect that is even more distorted than the internalized image (Rosen et al. 1995)."
62013109|NCT01316627|ACTIVE_COMPARATOR|Mirror Retraining Method|"In treating BDD, the cognitive-behavioral technique, mirror retraining, uses ordinary and/or magnifying mirrors to amplify the supposed defect, which teaches patients to see their appearance in a more holistic way. Since BDD patients tend to only focus on their perceived flaws when looking in the mirror, and tend to think about their flaws in negative terms, in mirror retraining, patients learn how to change their negative evaluations of their appearance into more objective and nonjudgmental descriptions. Generally, this method is designed to intentionally exaggerate anxiety regarding appearance concerns through exposures with mirrors. However, using exclusively ordinary and/or magnifying mirrors does not address the internal distorted image that many patients with BDD experience (Rosen et al. 1995, Osman et al. 2004, Veale 2004)."
62013110|NCT02637934|EXPERIMENTAL|Biodistribution|"The Biodistribution cohort will include up to 4 patients who will undergo a series of vertex to mid-thigh biodistribution \[18F\]FTT PET/CT scans over a period of approximately 4 hours.~Up to 10 subjects were initially planned for this cohort, however, the first 4 subjects have been enrolled and initial data analysis for these completed. The decision was made to close enrollment for this cohort as we do not believe that we need to complete the up to 10 subjects originally planned for this cohort as the initial data shows consistent and repeatable data that we do not believe would change significantly with the addition of 6 more subjects."
62013111|NCT02637934|EXPERIMENTAL|Dynamic|The Dynamic cohort will include up to 36 patients who will undergo 1 static skull base to mid-thigh scans imaging post injection of \[18F\]FTT.
62013112|NCT06536010|EXPERIMENTAL|VAG regimen in the treatment of newly diagnosed acute myeloid leukemia (AML)|"AZA: 75mg/m2 on days 1-7 VEN: 100mg on day 1, 200mg on day 2, 400mg on days 3-28 G-CSF: 50-600ug/day, starting on day 1 (adjusted based on WBC count of 10-25\*10E9/L)~In the induction phase of the ND-AML treatment protocol, VEN+AZA+G-CSF is administered. At the end of the induction phase, the efficacy is evaluated. If the patient achieves complete remission (CR), the original treatment protocol is continued for consolidation. If the patient achieves partial remission (PR), the original treatment protocol is repeated for induction until the patient achieves CR or shows no response (NR), progressive disease (PD), or relapse (PR/NR/PD). If the patient shows no response or progressive disease, the study is concluded."
62013113|NCT00592449|NO_INTERVENTION|1|Participants with knee OA who meet research diagnostic criteria for insomnia will partake in Phase 1
62013114|NCT00592449|NO_INTERVENTION|2|Participants with knee OA who meet research diagnostic criteria for normal sleep will partake in Phase 1
62013115|NCT00592449|NO_INTERVENTION|3|Participants without knee OA or a pain syndrome who meet research diagnostic criteria for primary insomnia will partake in Phase 1
62013116|NCT00592449|NO_INTERVENTION|4|Participants without knee OA or a pain syndrome who meet research diagnostic criteria for normal sleep will enroll in Phase I
62013117|NCT00592449|EXPERIMENTAL|5|Phase 1 participants with knee OA who meet research diagnostic criteria for insomnia will enroll in Phase 2 of the study and are assigned to receive behavioral desensitization treatment for insomnia
62401945|NCT05206669|ACTIVE_COMPARATOR|Control Messages - Young Adults|Messages providing information about HPV vaccines that did not mention prevention of other diseases or conditions.
62401946|NCT05206669|ACTIVE_COMPARATOR|Control Messages - Parents of Adolescents|Messages providing information about HPV vaccines for their adolescent children that did not mention prevention of other diseases or conditions.
62401947|NCT04002466||Children (6-59 months)|
62401948|NCT04002466||Women of Reproductive Age (15-49 years)|
62401949|NCT04002466||Adult Men (15-49 years)|
62401950|NCT04245982||group (C)|healthy controls group
62201225|NCT03258723|NO_INTERVENTION|Control|Control participants in existing ECHORN sites (Puerto Rico, Barbados and Trinidad) will be recruited. ECS does not have a recruitment site in New York; therefore, the New York LIME sites will need to recruit their own control participants, through random assignment of consented participants into the intervention and control groups.
62013118|NCT00592449|EXPERIMENTAL|6|Phase 1 participants with knee OA who meet research diagnostic criteria for insomnia will enroll in Phase 2 of the study and are assigned to receive cognitive behavior therapy for insomnia
62013119|NCT01144338|EXPERIMENTAL|Exenatide Once Weekly|
62201226|NCT00953277|EXPERIMENTAL|Avance Nerve Graft|Processed Human Nerve Tissue Scaffold
62201227|NCT00688129|EXPERIMENTAL|KITS Program|The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
62201228|NCT00688129|NO_INTERVENTION|Services as usual|
62201229|NCT01022905|EXPERIMENTAL|High-risk patients ( 5 cohorts)|
62201230|NCT01022905|ACTIVE_COMPARATOR|Healthy controls|
62201231|NCT02206061|EXPERIMENTAL|School-Based Asthma Care for Teens (SB-ACT)|"SB-ACT consists of 2 components: Motivational Interviewing (MI) and Directly Observed Therapy (DOT) For the first 6-8 weeks, the teen will visit the school nurse to receive a daily dose of preventive asthma medication as directly observed therapy (DOT). The purpose of DOT is to establish a relationship with the nurse, learn proper medication technique, and experience potential benefits of consistent preventive therapy.~The second component, Motivational Interviewing (MI) counseling , will start 4-6 weeks after the start of DOT. A counselor will conduct 3 in-person MI sessions with the teen at school to enhance the teen's motivation to adhere to their asthma treatment plan. The 3 sessions consist of an initial 40 minute counseling session (4-6 weeks after start of DOT), and two 30 minute follow-up sessions 2 and 6 weeks later. This component consists of an evidence-based self-management program to help the teen begin to transition to independence with preventive medication use."
62201232|NCT02206061|ACTIVE_COMPARATOR|Directly Observed Therapy|For the first 6-8 weeks after enrollment, the teen will visit the school nurse once a day to receive a daily dose of preventive asthma medication as directly observed therapy (DOT).
62013120|NCT01144338|PLACEBO_COMPARATOR|Placebo|
62013121|NCT06192628|ACTIVE_COMPARATOR|Parkinson's Education and Exercise Programme [PEEP]|12 week programme of exercises and educational sessions
62201233|NCT02206061|ACTIVE_COMPARATOR|Asthma Education|Asthma educators will provide an in-school asthma education program that will match the time and attention of the MI counseling portion of the primary intervention. Each teen will receive three 1-on-1 educational sessions at school, and sessions will cover 3 main topics: 1) lung physiology and asthma basics, 2) triggers, symptoms, and warning signs, and 3) medications and self-advocacy.
62201234|NCT00494520|EXPERIMENTAL|Errorful training condition|A type of anomia rehabilitation paradigm which allows for errors. The intervention involves providing minimal auditory cues to allow for errors in picture naming.
62201235|NCT00494520|EXPERIMENTAL|Errorless training condition|A type of anomia rehabilitation paradigm in which the situation surrounding the performance of the desired task (i.e., picture naming) is controlled to prevent errors. The intervention involves providing maximal auditory cues to prevent errors in picture naming.
62201236|NCT01011868|EXPERIMENTAL|BI 10773 low dose|Patients receive BI 10773 low dose daily
62201237|NCT01011868|EXPERIMENTAL|BI 10773 high dose|Patients receive BI 10773 high dose daily
62201238|NCT01011868|PLACEBO_COMPARATOR|placebo|Patients receive placebo to match BI 10773 daily
62784959|NCT02136628|EXPERIMENTAL|RTL|"The method consists of two lines of suture, each, over the fascial wound edge. It starts with a suture strand (in this study was used PDS number 0) in one end of the fascial wound where the suture is run longitudinally and parallel to the aponeurotic edge. The needle should go in and out at intervals of 1 cm away and always kept at 0.5 cm from the edge of the fascia. Upon reaching the opposite angle of the wound suture strand another repeating the same process on the fascial edge otherwise used. The ends of the two suture strands are tied in fascial angles.~Thus the fascial wound is sutured with two lines of strengthening its edges. Then proceed to close the wound with continuous súrgete always ensuring that the suture lines remain anchored on suture reinforcement."
62013122|NCT06192628|EXPERIMENTAL|Parkinson's Education and Exercise Programme and Behavioural Change [PEEP-BC]|12 week programme of exercise and education with additional behavioural change techniques to promote exercise adherence and exercise self-efficacy.
62201239|NCT00737698|EXPERIMENTAL|Exercise|Exercise
62201240|NCT00737698|EXPERIMENTAL|Repetitive magnetic stimulation|Repetitive magnetic stimulation of femoral nerve
62013123|NCT03206021|EXPERIMENTAL|Phase I Dose-escalation|5'azacytidine will be administered on Days 1-7 at a dose of 75mg/m2/day, followed by escalating doses of Carboplatin on Day 14 in a rolling 6 design. Carboplatin will be dosed initially at AUC 4. Dose level -1 will reduce 5'azacytidine to 50mg/m2/day.
62013124|NCT03206021|EXPERIMENTAL|Posterior Fossa Ependymoma Expansion Arm|5'azacytidine will be administered on days 1-7 and carboplatin will be administered on day 14 at the maximum tolerated dose achieved in the Phase I dose escalation to 20 patients with recurrent/refractory posterior fossa ependymoma.
62013125|NCT03206021|EXPERIMENTAL|Recurrent Brain and Solid Tumour Expansion Arm|5'azacytidine will be administered on days 1-7 and carboplatin will be administered on day 14 at the maximum tolerated dose achieved in the Phase I dose escalation up to 12 patients with recurrent/refractory brain and solid tumour.
62201241|NCT00737698|NO_INTERVENTION|Control|No active treatment
62201242|NCT03513926||Non-OSA group|Patients with out sleep apnea.
62201243|NCT03513926||OSA group|Patients with OSA, without cardiovascular comorbidities who could be treated with Continuous Positive Airway Pressure
62201244|NCT03513926||OSA with hypertension group|Patients with OSA, with hypertension who could be treated with Continuous Positive Airway Pressure
62201245|NCT03513926||OSA with CVE group|Patients with OSA, with a previous ictus or stroke who could be treated with Continuous Positive Airway Pressure
62201246|NCT03890003|EXPERIMENTAL|AID System Containing Insulin Lispro|The automated insulin delivery (AID) system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a PLGS algorithm, and a continuous glucose monitor (CGM) component.
62201247|NCT02883595|EXPERIMENTAL|thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
62401951|NCT04245982||group (P)|periodontitis group
62401952|NCT04245982||group (DP)|diabetes and periodontitis group
62401953|NCT01319994|EXPERIMENTAL|Metformin|Metformin 850mg TDS (12 weeks)
62401954|NCT01319994|PLACEBO_COMPARATOR|Placebo|Placebo 850mg TDS (12 weeks)
62401955|NCT00700115|EXPERIMENTAL|Kaletra + Isentress|Kaletra + Isentress
62013126|NCT06368583||Vaginal delivery with neuraxial analgesia|Patients who have a vaginal delivery with neuraxial analgesia.
62013127|NCT06137300|EXPERIMENTAL|Urinary Kallidinogenase group|Patients are treated with urinary kallidinogenase and guideline-prescribed basic medical therapy.
62013128|NCT06137300|OTHER|Control group|Patients are only treated with guideline-prescribed basic medical therapy.
62013129|NCT01373944||Stress Only SPECT MPI with Anger Camera|Patients undergoing clinically-indicated stress-only sestamibi studies who are imaged on the traditional Anger camera
62013130|NCT01373944||Stress Only SPECT MPI with SD Camera|Patients undergoing clinically-indicated stress-only sestamibi studies who are imaged on the Spectrum Dynamics camera system.
62013131|NCT05676385|ACTIVE_COMPARATOR|Dietary supplement/First concept Product 1 (containing 50 grams of carbohydrates)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62013132|NCT05676385|ACTIVE_COMPARATOR|Dietary supplement/First concept Product 2 (containing 50 grams of carbohydrates)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized
62013133|NCT05676385|ACTIVE_COMPARATOR|Reference product (containing 50 grams of carbohydrates)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized
62013134|NCT02304094|EXPERIMENTAL|manipulation|Those in the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique. They will be asked to return once each week for a further five weeks. At each visit the VAS and PTM measurements shall be repeated, as will the manual manipulation. They shall also be asked to return for a review in the sixth week.
62013135|NCT02304094|ACTIVE_COMPARATOR|Steroid|Those randomised to the steroid group shall receive a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine. They shall then be asked to return for review in six weeks. A second injection may be offered at this point if clinically indicated.
62401956|NCT00700115|ACTIVE_COMPARATOR|Standard HAART|Pre-study Antiretroviral regimen
62401957|NCT02925650|EXPERIMENTAL|Low Dose|The study drug Posiphen dosage of 60mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
62401958|NCT02925650|EXPERIMENTAL|Medium Dose|The study drug Posiphen dosage of 120mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
62401959|NCT02925650|EXPERIMENTAL|High Dose|The study drug Posiphen dosage of 180mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
62401960|NCT02925650|PLACEBO_COMPARATOR|Placebo|The Placebo comparator is to be taken orally in divided doses, three times per day for a total 23-25 days.
62401961|NCT05798624||One CS with isthmocele|
62401962|NCT05798624||More than one CS with Isthmocele|
62401963|NCT05798624||One or more CS without isthmocele|
62401964|NCT05798624||With previous vaginal delivery|
62401965|NCT05798624||With first ongoing pregnancy|
62401966|NCT00591552|ACTIVE_COMPARATOR|Group A|Electrocautery used for dissection.
62401967|NCT00591552|ACTIVE_COMPARATOR|Group B|Harmonic Scalpel used for dissection
62401968|NCT02381366|EXPERIMENTAL|PNEUMOSTEM®|Dose A: PNEUMOSTEM® 10 million cells per kg Dose B: PNEUMOSTEM® 20 million cells per kg
62401969|NCT05427968||Supine group|Spinal anaesthesia was administered in sitting position and then supine position was maintained.
62401970|NCT05427968||Left tilt group|Spinal anesthesia was administered in sitting position was then maintained on supine position until full anesthetic effect (motor and sensory loss) and then table was tilted 15 degrees to the left.
62401971|NCT06248866|EXPERIMENTAL|Extracorporeal Shock Wave Therapy|patients will receive Extracorporeal Shock Wave Therapy and traditional treatment three times a week for six weeks
62401972|NCT06248866|ACTIVE_COMPARATOR|traditional treatment|patients will receive traditional treatment three times a week for six weeks
62201248|NCT02883595|PLACEBO_COMPARATOR|Placebo|Subcutaneous injections of placebo (saline) twice per day for seven days
62201249|NCT06508294|EXPERIMENTAL|8 week artifical intelligence based posture exercises|"An artificial intelligence application called Musclewiki will be used for healthy adults to continue their exercise training at home. For 8 weeks, exercise will be practiced 3 times a week in the company of a physiotherapist, accompanied by a physiotherapist through artificial intelligence."
62201250|NCT06508294|NO_INTERVENTION|Control|This group of healthy adults will be evaluated before and after 8 weeks and no exercise will be performed.
62201251|NCT05067153|EXPERIMENTAL|Intervention|Intervention group (n=50, anticipated) receives 30 days postoperative treatment with 5000 IE LMWH daily.
62201252|NCT05067153|ACTIVE_COMPARATOR|Control|Control group (n=50, anticipated) receives standard 10 days postoperative treatment with 5000 IE LMWH daily.
62201253|NCT03415633|ACTIVE_COMPARATOR|Diagnostic Randomizing|Randomizing to start with home respiratory polygraphy (APNIA) or Standard Polysomnography (PSG)
62201254|NCT03415633|ACTIVE_COMPARATOR|Therapeutic Randomizing|Randomizing for therapeutic decision taken with home respiratory polygraphy (APNIA) or Standard Polysomnography (PSG)
62201255|NCT03439813|EXPERIMENTAL|TASK-CBT|Web and telephone-delivered cognitive behavioural therapy designed for anxiety after stroke and TIA. Six personalized telephone CBT sessions, one week apart by a trained and supervised medical professional using the TASK Therapist's Manual. Treatment website contains multimedia content to cover key CBT skills with weekly online tasks.
62201256|NCT03439813|ACTIVE_COMPARATOR|TASK-Relax|Web and telephone-supported relaxation therapy. Treatment website contains five relaxation exercises: i) audio- and visually-guided breathing exercise, ii) relaxing imagery and sounds, iii) music for relaxation, iv) audio-guided progressive muscle relaxation, and v) a selection of sounds of nature. Telephone instruction given and treatment website contains multimedia content to explain to participant how to practice relaxation regularly during the trial period.
62578871|NCT00717834|EXPERIMENTAL|Cohort 3, Treatment Arm 1|Randomization of a total of approx. 100 subjects to one of two treatment arms at 1:1 ratio to receive 10 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Vaccinations take place upon review of Cohort 1b and Cohort 2 Day 7 safety data by DMC and recommendation to proceed. Booster vaccination to follow 180 days after first vaccination.
62401973|NCT02219477|EXPERIMENTAL|Group 1: GT1B|ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) + ribavirin (RBV) for 12 weeks in hepatitis C virus (HCV) genotype (GT) 1b-infected participants
62401974|NCT02219477|EXPERIMENTAL|Group 2: GT1 Non-B|ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + dasabuvir 250 mg BID + RBV for 24 weeks in HCV GT1non-b (including GT1a)-infected participants
62401975|NCT02219477|EXPERIMENTAL|Group 3: GT4|ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + RBV for 24 weeks in HCV GT4-infected participants
62401976|NCT06415188|EXPERIMENTAL|Therapeutic play group|Children in the experimental group received a therapeutic video game intervention in addition to the pre-treatment routine.
62401977|NCT06415188|NO_INTERVENTION|Control Group|Children in the control group underwent routine clinical practice. No other intervention was performed.
62578872|NCT00717834|EXPERIMENTAL|Cohort 3, Treatment Arm 2|Same as Cohort 3, Treatment Arm 1
62401978|NCT06176222|EXPERIMENTAL|Precedex Group|Drug: PRECEDEX INJ★ 2ML Dosage form: 100 mcg/ml dexmedetomidine Dosage: 0.1\~0.4 mcg/kg/hr intravenous infusion Frequency and Duration: intrvenous infusion 12 hours after the surgery immediately
62578873|NCT03350646|OTHER|Low volume (20-25 μl)|Low volume (20-25 μl)
62578874|NCT03350646|OTHER|High volume (40-45 μl)|High volume (40-45 μl)
62578875|NCT01568034|EXPERIMENTAL|Treatment Sequence A|"Treatment Sequence A Period 1 - 25 mg BIA 9-1067 Period 2 - 50 mg BIA 9-1067 Period 3 - 100 mg BIA 9-1067 Period 4 - Placebo~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
62578876|NCT01568034|EXPERIMENTAL|Treatment Sequence B|"Treatment Sequence B Period 1 - Placebo Period 2 - 25 mg BIA 9-1067 Period 3 - 50 mg BIA 9-1067 Period 4 - 100 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
62784960|NCT02136628|NO_INTERVENTION|Control|Conventional midline mass closure technique. Upon completion of the surgical procedure was the closure of abdominal wall which will be made with the number 0 monofilament PDS, starting with knot at one end of the wound, continuous with continuous súrgete, moving each point to a centimeter away from the other. Each point will be a distance of one centimeter from the edge of the fascia. At the opposite end of the wound the same procedure was initiated and found the two suture lines at the midpoint of the wound will proceed to tying the two sutures with 4 square knots.
62784961|NCT05170321||patients undergoing knee arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent knee arthroplasty and was recorded in HQMS were included in this group
62784962|NCT05170321||patients undergoing hip arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent hip arthroplasty and was recorded in HQMS were included in this group
62013136|NCT05723523|EXPERIMENTAL|CI-CDS|In clinics randomized to the CI-CDS, the providers will be given the option to use the CI-CDS tool during eligible patient encounters.
62013137|NCT05723523|NO_INTERVENTION|Usual Care (UC)|In clinics randomized to UC, patients will receive usual care at their primary care visits over the accrual period (no intervention will be given).
62013138|NCT05038488|EXPERIMENTAL|MIB-626|Oral administration of MIB-626 substantially raises the intracellular NAD+ levels and activates signaling mechanisms that regulate inflammation and cell survival, downregulates the NLRP3 inflammasome, and attenuates the inflammatory response in a number of experimental models, and protects against tissue damage induced by pro-inflammatory cytokines.
62013139|NCT05038488|PLACEBO_COMPARATOR|Placebo Tablet|"A placebo control will be supplied. Participants randomized to placebo will receive matching tablet.~Matching placebo tablets will be provided by the study's Sponsor, Metro International Biotech, LLC."
62013140|NCT05038488|OTHER|Home Treatment|Participants, who are discharged from the hospital before the completion of the 14-day intervention period, will be provided sufficient study medication to take home with them so they can continue to take the medication twice daily for the remaining duration of the 14-day intervention period.
62013141|NCT02708745|PLACEBO_COMPARATOR|Placebo Arm|Parent participants will receive a placebo survey about their attitudes toward common child health topics before their child's health supervision visit.
62013142|NCT02708745|EXPERIMENTAL|Intervention Arm|Parent participants will also receive the intervention survey about their attitudes toward childhood vaccines before their child's health supervision visit.
62201257|NCT06149897|SHAM_COMPARATOR|Control group|"* Therapeutic education about post-stroke fatigue~* Sham stimulation with tDCS: Anode placed in F3 and cathode in O2, 20 minutes.~* Aerobic exercise measured with Borg scale (moderate intensity)"
62201258|NCT06149897|ACTIVE_COMPARATOR|Experimental group|"* Therapeutic education about post-stroke fatigue~* Stimulation with tDCS: Anode placed in F3 and cathode in O2, intensity 2mA during 20 minutes.~* Aerobic exercise measured with Borg scale (moderate intensity)"
62201259|NCT05134987|EXPERIMENTAL|NNC0363-0845 followed by insulin detemir|Participants will get subcutaneous (under the skin) injections of insulin NNC0363-0845 (study medicine) up to 6 times daily for 3 days. After a 4-21 days wash-out period with no injections they will get subcutaneous injections of insulin detemir up to 6 times daily for 3 days.
62201260|NCT05134987|EXPERIMENTAL|Insulin detemir followed by NNC0363-0845|Participants will get subcutaneous (under the skin) injections of insulin detemir up to 6 times daily for 3 days. After a 4-21 days wash-out period with no injections they will get subcutaneous injections of NNC0363-0845 (study medicine) up to 6 times daily for 3 days.
62578877|NCT01568034|EXPERIMENTAL|Treatment Sequence C|"Treatment Sequence C Period 1 - 100 mg BIA 9-1067 Period 2 - Placebo Period 3 - 25 mg BIA 9-1067 Period 4 - 50 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
62578878|NCT01568034|EXPERIMENTAL|Treatment Sequence D|"Treatment Sequence D Period 1 - 50 mg BIA 9-1067 Period 2 - 100 mg BIA 9-1067 Period 3 - Placebo Period 4 - 25 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
62578879|NCT06199089|EXPERIMENTAL|Intervention (CM313)|30 from 45 enrolled subjects receive CM313: once a week x 8 doses
62578880|NCT06199089|PLACEBO_COMPARATOR|Intervention (Placebo)|15 from 45 enrolled subjects receive placebo: once a week x 8 doses
62578881|NCT04282941|EXPERIMENTAL|Ibuprofen in continuous (24 hours) iv infusion and EchoG|The first dose of ibuprofen will be 10 mg / kg to be administered as a continuous infusion for 24 hours. An echocardiogram will be performed before each of the following 2 doses of 5 mg / Kg and will only be administered if it meets echocardiographic criteria that indicate open DA (observation of ductus permeability with color Doppler regardless of its size). Each dose will be administered as a 24-hour continuous infusion.
62013143|NCT02875106||Atrial Fibrillation Patients|Adult female and male patients with diagnosed atrial fibrillation
62013144|NCT02875106||Sinus Rhythm Patients|Adult female and male patients with diagnosed sinus rhythm
62013145|NCT04283734|EXPERIMENTAL|Intervention group|Long/diffuse coronary lesion should be evaluated and guided by iFR pullback with Syncvision software to achieve a final iFR of 0.90
62013146|NCT04283734|NO_INTERVENTION|Control group|Long/diffuse coronary lesion should be treated guided by angiography
62201261|NCT03269487||Healthcare professionals in partner sites|NHS employee or student nurse involved in the delivery of care to patients on partner wards in which the PERFECTED ERP is being implemented.
62201262|NCT05153928||fibroid cases|Norethisterone acetate for 5 months
62201263|NCT05153928||adenomyosis|Norethisterone acetate for 5 months
62201264|NCT05367700|EXPERIMENTAL|HS-10382 (Part 1: Dose escalation)|There are five escalation dose cohorts.
62201265|NCT05367700|EXPERIMENTAL|HS-10382 (Part 2: Dose expansion)|The recommended dose from the dose-escalation stage and other potential doses will be further explored.
62201266|NCT03680352|EXPERIMENTAL|cefepime/AAI101 combination|Investigational drug
62201267|NCT01914770||Adults with systemic lupus erythematosus (SLE)|Subjects with SLE receiving ongoing stable SLE treatment
62201268|NCT01815086|EXPERIMENTAL|124I-labeled anti-amyloid mAb 11-1F4|124I-labeled anti-amyloid mAb 11-1F4 will be infused on day 0. Two and 5 days later, PET/CT scans will be performed.
62201269|NCT03064399|EXPERIMENTAL|lateral ligament repairment|
62201270|NCT03064399|EXPERIMENTAL|without lateral ligament repairment|
62201271|NCT02807272|EXPERIMENTAL|Tipifarnib, Oral|Single arm
62201272|NCT04152057|EXPERIMENTAL|Pyrotinib Combined With Albumin Paclitaxel and Trastuzumab|"Preoperative~-Drug: Pyrotinib Maleate Tablets combined with Albumin Paclitaxel and Trastuzumab.~Surgery:Subjects should be evaluated by tumor-enhanced MRI combined with mammary gland ultrasound during the preoperative neoadjuvant administration, and evaluated every 2 cycles. The subjects who were evaluated for CR and PR for the first time should be confirmed after at least 4 weeks. The confirmed tumor assessment cannot change the previously fixed examination time point.~Postoperative~* Drug: Epirubicin hydrochloride combined with Cyclophosphamide~* At the same time, according to the recommendation of the clinician, choose whether to accept the same anti-HER2 treatment plan before surgery. For patients with tumors positive for estrogen receptor (ER) and/or progesterone receptor (PR), endocrine therapy should be given at the end of adjuvant chemotherapy, and if there is clinical indication at the end of adjuvant chemotherapy, radiotherapy should be given."
62401979|NCT06176222|PLACEBO_COMPARATOR|Placebo Group|Drug: 0.9% Normal Sline Dosage: 0.1 ml/kg/hr intravenous infusion Frequency and Duration: intrvenous infusion 12 hours after the surgery immediately
62401980|NCT05900674|ACTIVE_COMPARATOR|IV thrombolysis|Local institutional IV thrombolysis: IV alteplase (0.9 mg/kg) or IV Tenecteplase (TNK) (0.25 mg/kg) according to local institutional practice.
62201273|NCT01968993|EXPERIMENTAL|nanOss Bioactive - posterolateral gutter|Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side. Autograft alone will be used in the opposite posterolateral gutter.
62784963|NCT05170321||patients undergoing shoulder arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent shoulder arthroplasty and was recorded in HQMS were included in this group
62784964|NCT05170321||patients undergoing ankle arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent ankle arthroplasty and was recorded in HQMS were included in this group
62784965|NCT05170321||patients undergoing elbow arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent elbow arthroplasty and was recorded in HQMS were included in this group
62201274|NCT00384397|EXPERIMENTAL|Group 1: Menactra® Vaccine|Participants will receive Menactra® vaccine at age 9 months and 12 months, respectively.
62201275|NCT00384397|EXPERIMENTAL|Group 2: Menactra® + MMRV|Participants will receive Menactra® at age 9 months followed by Menactra® and Measles-Mumps-Rubella-Varicella (MMRV) vaccines at Age 12 Months
62201276|NCT00384397|EXPERIMENTAL|Group 3: Menactra® + PCV|Participants will receive Menactra® at age 9 months followed by Menactra® and Pneumococcal Conjugate (PCV) vaccines at Age 12 Months
62201277|NCT01375413|EXPERIMENTAL|Integrated dual task training|Integrated dual task training delivered by a physiotherapist. In this training mode walking practice will be combined with simultaneously carrying out cognitive discrimination, verbal fluency and memory tasks.
62784966|NCT03592563||Red group|"Those participants who had established diagnosis of one or more neurological and/or psychiatric conditions~Baseline: The participants' medical history, signs, symptoms and diagnoses of neurological and/or psychiatric disorders would be recorded. Neuro-QoL questionnaire plus an additional subset of questions based on their clinical diagnosis should be done."
61978318|NCT05417165|EXPERIMENTAL|Arm C (Experimental ARM-Annual Booster)|Patients receive PCV 20 IM at week 0 and PSV23 IM at week 8. Titers will be checked 4 weeks after the first dose and at 12 weeks (4 weeks after the second dose). Booster Vaccine: PCV23 booster vaccination dose will be administered yearly for 5 years. Pre-vaccination and post-vaccination (at 4 weeks) titers will be checked each time yearly for 5 years.
61978319|NCT02177045|EXPERIMENTAL|Microbubbles contrast media for US|Sonovue, Bracco, microbubbles contrast media
62201278|NCT01375413|ACTIVE_COMPARATOR|Consecutive task training|Consecutive task gait training delivered by a physical therapist. In this training mode, walking practice will be conducted separately, focusing on the motor task only. Training of cognitive discrimination, verbal fluency and memory tasks will be done consecutively while the subjects are sitting.
62401981|NCT05900674|EXPERIMENTAL|IV reteplase (9 U bolus)|
62401982|NCT05900674|EXPERIMENTAL|IV reteplase (9 U bolus+9 U bolus)|
62401983|NCT05992558||Very elderly HFpEF|Prospective cohort of very elderly patients (≥80 years old) with heart failure with preserved ejection fraction (HFpEF) consecutively admitted for acute HF
62401984|NCT04505176||1|20 patients being in the HHHNFC. In this study, it was aimed to monitor continuous oxygen saturation, PI, PVI, transcutaneous PO2 and PCO2 measurements just before, during and after the surfactant application and to compare the results of babies who received nCPAP and HHHFNC support.
62401985|NCT04505176||2|20 patients in the CPAP group. In this study, it was aimed to monitor continuous oxygen saturation, PI, PVI, transcutaneous PO2 and PCO2 measurements just before, during and after the surfactant application and to compare the results of babies who received nCPAP and HHHFNC support.
61978320|NCT04120831|EXPERIMENTAL|Rituximab + Abatacept + MTX|all participants receive Rituximab. Study subjects will be randomized into one of two treatment arms (Abatacept+MTX vs MTX) following a 1:1 randomization at Visit 3, at the day of the 2nd Rituximab Infusion.
62013147|NCT04403295|EXPERIMENTAL|collaborative specialty care|In specialty collaborative care, the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics.
62401986|NCT01587716|EXPERIMENTAL|1. Inhaled GSK2339345/Placebo Single Dose (Cohort 1)|administered three ascending doses of GSK2339345 or placebo as a solution via an aqueous droplet inhaler over four treatment periods, with at least 5 days washout between doses
62401987|NCT01587716|EXPERIMENTAL|2. Inhaled GSK2339345/Placebo Repeat Dose (Cohort 2)|administered a dose of GSK2339345 or placebo, four times a day on two consecutive days. Each subject will receive either GSK2339345 or matching placebo as a solution administered via an aqueous droplet inhaler
62013148|NCT04403295|ACTIVE_COMPARATOR|e-consultation|In e-consultation the specialty provider team will make a onetime recommendation to the primary care team that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization.
62401988|NCT00681434|EXPERIMENTAL|1|bilateral training
62401989|NCT00681434|ACTIVE_COMPARATOR|2|Unilateral training
62401990|NCT00493701|OTHER|Lifestyle|Measurement of body weight in a fown with light undercloting (30 minutes) and height.
62401991|NCT00493701|OTHER|DEXA Scanner|Low-dose X0rays to determine the amount of fat, bone and muscle in your body.
62401992|NCT04731740|EXPERIMENTAL|Pembrolizumab + Lenvatinib|"Experimental treatment:~Lenvatinib p.o. once a day, pembrolizumab 200 mg i.v. every 21 days started 21 days after start of Lenvatinib~Duration of treatment per patient:~until the end of month 36 after registration of the last patient or disease progression or toxicity (whichever occurs first)"
62401993|NCT04731740|EXPERIMENTAL|Pembrolizumab + Chemotherapy|"Experimental treatment:~Investigators' choice of the Сhemotherapy, pembrolizumab 200 mg i.v. every 21 days started 21 days after the start of chemotherapy~Duration of treatment per patient:~until the end of month 36 after registration of the last patient or disease progression or toxicity (whichever occurs first)"
62401994|NCT05138510||Stage 0|Ductal carcinoma in situ. Timing: start of endocrine therapy
62578882|NCT04282941|EXPERIMENTAL|IV bolus Ibuprofen slow (15 minutes) and EchoG|The first dose of ibuprofen of 10 mg / Kg to be administered in slow iv bolus (15 minutes). Before each of the following 2 doses of 5 mg / Kg, echocardiography will be performed and will only be administered if it meets the echocardiographic criteria indicated by open DA (observation of ductus permeability in color Doppler regardless of its size). Each dose will be administered in iv boluses in 15 minutes
62784967|NCT03592563||Yellow group|"Those participants who are high-risk to develop one or more neurological and/or psychiatric conditions, for example:~1. family history (first degree relative) one or more neurological and/or psychiatric conditions;~2. examination, imaging or laboratory findings consistent with pre-symptomatic stages of one or more neurological and/or psychiatric disorders.~Baseline: The participants' medical history, signs, symptoms and diagnoses of neurological and/or psychiatric disorders would be recorded. Neuro-QoL questionnaire should be done."
62784968|NCT03592563||Green group|"Those participants who are not meeting criteria for Red or Yellow groups, but interested in longitudinal research on maintenance and/or improvement of their brain health.~Baseline: The participants' medical history would be recorded and Neuro-QoL questionnaire should be done."
62013149|NCT04418206|OTHER|Samples With DNA|Nasopharyngal swab and blood samples
62401995|NCT05138510||Stages I-III Surgery first|Invasive cancer. Surgery first Timing: start of endocrine therapy
62401996|NCT05138510||Stages I-III, neoadjuvant chemotherapy first|Invasive cancer. Neoadjuvant chemotherapy first Timing: during neoadjuvant chemotherapy
62401997|NCT05138510||Stage IV|Metastatic cancer, chemotherapy only, no invasive surgery Timing: 2 months into treatment
62401998|NCT05138510||Survivors|Timing: any time
62578883|NCT01560598||Reflux esophagitis|those with endoscopically proven reflux esophagitis
62578884|NCT01560598||Normal|those with normal GFS finding (without definite mucosal break at Z-line)
61978321|NCT04120831|ACTIVE_COMPARATOR|Rituximab + MTX (standard of care)|all participants receive Rituximab. Study subjects will be randomized into one of two treatment arms (Abatacept+MTX vs MTX) following a 1:1 randomization at Visit 3, at the day of the 2nd Rituximab Infusion.
62013150|NCT02664038|EXPERIMENTAL|CRT+IDC|Cognitive Remediation Therapy for 13 weeks plus Individual Drug Counseling
62401999|NCT03713112|ACTIVE_COMPARATOR|Weekly MDT deprescribing rounds|Weekly MDT deprescribing rounds for certain drugs will be performed on top of usual care.
62402000|NCT03713112|NO_INTERVENTION|Control (Usual Care)|"Usual Care includes the following:~* De-prescribing at the discretion of the ward doctors~* Initial medication reconciliation by pharmacist on admission~* Ward rounds to be conducted 3 weekdays per week for rehabilitative patients and daily on weekdays for sub-acute patients."
62402001|NCT04554355|EXPERIMENTAL|Intervention group|Participants in this group will receive a three-month PA intervention (60 minutes/session, two sessions/week).
62402002|NCT04554355|NO_INTERVENTION|Control group|No intervention will be provided, participants in this group need to attend the regular school activities as normal.
62402003|NCT01593761|EXPERIMENTAL|Single Arm for CG400549|All the patients will be administered with CG400549.
62410075|NCT06545019|NO_INTERVENTION|Group C ( Control Group )|Will not receive the informative video . During day of surgery , will receive standard care as per protocols .
62784969|NCT04233541||Fallers|Participants who reported one or more falls within the 12 months preceding the study consist the group of ''fallers''.
62784970|NCT04233541||Non-fallers|Participants with no fall history consist the group of ''non-fallers''
62784971|NCT00406536|ACTIVE_COMPARATOR|1|
62784972|NCT00406536|PLACEBO_COMPARATOR|2|
62784973|NCT04864951|OTHER|Transpeople|"1x urine sampling for HPV analysis~1x survey"
62784974|NCT00586885|EXPERIMENTAL|1|Single arm, active treatment
62784975|NCT04314583|ACTIVE_COMPARATOR|Attention Control Group|Adult patients attending cardiovascular rehabilitation.
62402004|NCT05920057|EXPERIMENTAL|interventional group|senior citizens aged 60 and more were randomly assigned into two equal groups at and placed in the study group, which received the constructive emotional management interventions
62402005|NCT05920057|NO_INTERVENTION|control group|the control group, which received the elderly clubs' regular services
62013151|NCT02664038|ACTIVE_COMPARATOR|Computer Game Play+IDC|Computer arcade games for 13 weeks plus Individual Drug Counseling
61978322|NCT03996954|ACTIVE_COMPARATOR|Normal ECGs|Patients with normal ECGs
62013152|NCT04660123|EXPERIMENTAL|Quadruple therapy with colloidal bismuth pectin granules|colloidal bismuth pectin granules 150 mg, Selection of 2 antibiotics and 1 proton pump inhibitor based on China's fifth national consensus report on the management of H. pylori infection.All medication is taken orally, twice a day.
62013153|NCT06204822||blood pressure measurement|"1. Participants sit in a comfortable posture with hands naturally placed on the table or thighs, palms facing up without obstruction, facing the camera lens. Rest for 2 minutes.~2. First blood pressure measurement is taken, and images and data are recorded for 2 minutes.~3. Participants place both feet on a stool, exerting pressure on the instep (hooking towards the knee) for 1 minute.~4. Maintain the instep pressure and perform the second blood pressure measurement, recording images and data for 2 minutes.~5. Participants place both feet flat on the ground, resting for 1 minute.~6. Third blood pressure measurement is taken, and images and data are recorded for 2 minutes.~7. The examiner adjusts the program settings, and the participant repeats steps 2 to 6 once."
62201279|NCT01173432|ACTIVE_COMPARATOR|continuous positive airway pressure|using continuous positive airway pressure (CPAP) device during sleep, for the study period (4 weeks)
62201280|NCT01173432|NO_INTERVENTION|control|observation for the study period (4 weeks, no CPAP)
62402006|NCT02603341|ACTIVE_COMPARATOR|Photon|Photon therapy: once a day, 5 days a week, for 5 to 7 weeks
62784976|NCT04314583|EXPERIMENTAL|Gratitude Journaling Group|Adult patients attending cardiovascular rehabilitation.
62201281|NCT05097391|EXPERIMENTAL|Experimental group|i - Warm-up (5 minutes) ii- Conventional physiotherapy exercise (15 minutes) iii - Over-ground training with lower limb loading (15-25 minutes)
62201282|NCT05097391|ACTIVE_COMPARATOR|Control group|i - Warm-up (5 minutes) ii- Conventional physiotherapy exercise (15 minutes) iii - Over-ground training WITHOUT lower limb loading (15-25 minutes)
62784977|NCT06388798|EXPERIMENTAL|intervention group|Psychoeducational training was given to the intervention group, nurses working in the Psychiatry clinic, for a total of 4 sessions, with two sessions of 50 minutes each.
62201283|NCT02740725|ACTIVE_COMPARATOR|Recommendation of Patching|Patients will receive two hours of patching in the case of one line difference of best corrected visual acuity(BCVA) between two eyes during one month.
62201284|NCT02740725|ACTIVE_COMPARATOR|Recommendation of Patching and interactive binocular treatment|Patients will receive interactive binocular treatment addition to patch therapy in the least of 4 to 5 days of a week within 20-30 minutes in each day during one month.
62201285|NCT00368927|EXPERIMENTAL|Arm I|Patients receive oral sulindac twice daily for 6 months.
62784978|NCT06388798|NO_INTERVENTION|control group|No psychoeducational training was given
62201286|NCT00368927|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo twice daily for 6 months.
62201287|NCT03202017|ACTIVE_COMPARATOR|Expiratory Muscle Strength Testing (EMST)|EMST is a treatment method that has been used to improve cough function and swallowing in ALS. EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
62201288|NCT03202017|ACTIVE_COMPARATOR|EMST + Lung Volume Recruitment (LVR)|"EMST is a treatment method that has been used to improve cough function and swallowing in ALS. EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough."
62402007|NCT02603341|ACTIVE_COMPARATOR|Proton|Proton therapy: once a day, 5 days a week, for 5 to 7 weeks
62402008|NCT02468973|OTHER|Life style counseling|Students will meet chronic patients and will counsel for life style
62402009|NCT05849051|EXPERIMENTAL|Newly developed warnings with images|Participants receive newly developed warnings intervention
62784979|NCT05118373|OTHER|Exposure|The campaign targets 3 TV stations, 8 radio stations, 2 billboard companies and social media platforms including YouTube, Twitter, Facebook, Instagram and LinkedIn with an anticipated reach of 1,433,201 people in Lusaka and Copperbelt provinces. Of the targeted TV and radio media houses, two each are national stations and will reach beyond these two intervention provinces including to Central and Southern province with an estimated 8% and 11% mass-media penetration compared to 21% and 38% for Copperbelt and Lusaka respectively.
62784980|NCT03085745|EXPERIMENTAL|Transcranial Magnetic Stimulation (TMS)|15 patients suffering from a writer's cramp, aged 20-80 who are currently treated with botulinum toxin will receive single pulse TMS
61978323|NCT03996954|ACTIVE_COMPARATOR|Abnormal ECGs|Patients with different kinds of abnormal heart rhythms will be enrolled in order to compare whether Alivecor can accurately differentiate between these abnormal heart rhythms and normal sinus rhythm/sinus tachycardia. Also, Alivecor diagnostic accuracy in differentiating between different kinds of arrhythmias will be assessed.
61978324|NCT01059786|EXPERIMENTAL|Arm 1 - Non-Randomized to 70 mg/m^2 Bendamustine-Rituximab|Rituximab + Bendamustine at 70 mg/m\^2 for initial tolerability study (closed)
62402010|NCT05849051|EXPERIMENTAL|FDA proposed text-only warnings|Participants receive FDA proposed text only warning intervention
62784981|NCT01304004|EXPERIMENTAL|Experimental drinking yogurt|
61978325|NCT01059786|EXPERIMENTAL|Arm 2 - Non-randomized to 90 mg/m^2 Bendamustine-Rituximab|Rituximab + Bendamustine at 90 mg/m\^2 for initial tolerability study (closed)
62201289|NCT01008800|EXPERIMENTAL|Center-Based classroom intervention|Four days a week for 2.5 hours a day the child will participate in a classroom with peers in an attempt to increase social communication, language abilities, and other skills. Parents will also receive education sessions 1-3 times per month for 1-2 hours each. Treatment will last for 6 months.
62201290|NCT01008800|ACTIVE_COMPARATOR|Parent Training|Parents are taught strategies on how to interact with their children to increase their skills. Parent training sessions are given 2 times a month at our center and once a month at home for 60-90 minutes each. Treatment will last for 6 months.
62201291|NCT02461004|EXPERIMENTAL|TR group|CKD-391 and combination dose of Atrovastatin and Ezetimibe in order
62201292|NCT02461004|EXPERIMENTAL|RT group|combination dose of Atrovastatin and Ezetimibe and CKD-391 in order
62402011|NCT05849051|NO_INTERVENTION|Control group, no intervention|Participants do not receive an intervention
62402012|NCT06091826|EXPERIMENTAL|NFL-101|100 μg per subcutaneous injection (in each arm), two injections at day 1
62578885|NCT03080064|EXPERIMENTAL|Health Coach Intervention|The investigators connected participants at enrollment (median gestation of 12.5 weeks, IQR: 11-15) with a trained health coach who called participants every 2-3 weeks until 36 weeks of gestation. During these phone calls, health coaches helped participants adopt and maintain new healthful lifestyle behaviors that were evidence-based, simple, and easy to track. Goals aimed to promote appropriate gestational weight gain and covered several domains including diet, physical activity, screen time, and sleep.
62578886|NCT03831464|EXPERIMENTAL|Metformin treatment group|
62578887|NCT03831464|PLACEBO_COMPARATOR|Placebo control group|
62578888|NCT04818840||Resurfaced/non patella|Undergoing Total Knee Replacement with JOURNEY II CR Total Knee System
62784982|NCT01304004|PLACEBO_COMPARATOR|Placebo drinking yogurt|
62784983|NCT01238302|PLACEBO_COMPARATOR|Conventional group|
62784984|NCT01238302|EXPERIMENTAL|PRP group|
62784985|NCT05006482|ACTIVE_COMPARATOR|Arm I (usual care)|Patients receive routine survivorship follow-up care at their doctor's office for 5 visits over 12 months. Caregivers will be followed for 3 visits over 6 months.
62784986|NCT05006482|EXPERIMENTAL|Arm II (GEMS intervention)|Patients and caregivers participate in GEMS consultation over 1 hour that includes discussion of results and recommendations from geriatric assessment. Patients also participate in survivorship health education sessions over 75 minutes twice weekly for 4 weeks. They will participate in the EXCAP program as part of these sessions, which includes daily walking and resistance exercises.
62784987|NCT06106191|EXPERIMENTAL|Mindfulness based stress reduction (MBSR) program|Participants will be enrolled in a 8-week mindfulness clinical pain program + Primary Care Provider (PCP) Usual Care.
62784988|NCT01812265|EXPERIMENTAL|PF-06305591 Dose 1|
61978326|NCT01059786|ACTIVE_COMPARATOR|Arm 3 - Randomized to 90 mg/m^2 Bendamustine-Rituximab|Rituximab + Bendamustine (at the tolerated dose)
62201293|NCT00672737||Males at risk for OSA|"Males at risk for obstructive sleep apnea were invited to have a sleep study either at home or at Stanford Sleep Center.~A week after their sleep study (Polysomnography), all volunteers underwent quantitative sensory testing in the laboratory, during which their pain thresholds and tolerances to heat (Heat pain threshold and tolerance) and cold (Cold pain threshold and tolerance) stimuli were assessed, under two different concentrations (1 and 2 mcg/mL, in randomized order) of remifentanil, a short-acting opioid, given as a computer-controlled infusion."
62201294|NCT06112353|ACTIVE_COMPARATOR|Neostigmine plus Glycopyrrolate|"0.07 mg/kg Neostigmine plus 0.014 mg/kg glycopyrrolate~2 syringes numbered 1 and 2~1. Syringe #1: Glycopyrrolate~2. Syringe #2: Neostigmine"
62402013|NCT06091826|PLACEBO_COMPARATOR|Placebo|Water for Injection (WFI), two injections at day 1
62784989|NCT01812265|EXPERIMENTAL|PF-06305591 Dose 2|
62784990|NCT01812265|PLACEBO_COMPARATOR|Placebo|
62784991|NCT03733496||Participants from VY-AADC01 clinical studies:|Participants who have completed participation in VY-AADC01 clinical studies (PD-1101 or PD-1102) will be invited to participate in this extension study
62784992|NCT02290977|EXPERIMENTAL|Scheduled TACE-RT|RT will be delivered at two weeks after TACE for HCC combined PVTT.
61978327|NCT01059786|ACTIVE_COMPARATOR|Arm 4 - Randomized to Pentostatin-Rituximab|Rituximab + Pentostatin
61978328|NCT01059786|EXPERIMENTAL|Non-randomized to Bendamustine 90mg/m^2 or Pentostatin 4mg/m^2 with Rituximab|After initial tolerability studies are completed. Non-randomize up to 4 total participants to Bendamustine and/or Pentostatin with Rituximab
62402014|NCT03698058|EXPERIMENTAL|A2 Growing Up Milk|
62402015|NCT03698058|NO_INTERVENTION|Traditional non-A2 milk|
62402016|NCT03698058|ACTIVE_COMPARATOR|Other Growing Up Milk|
62578889|NCT04818840||un-resurfaced patella|Undergoing Total Knee Replacement with JOURNEY II CR Total Knee System
62578890|NCT05724251||Healthy|participants without periodontitis
62578891|NCT05724251||periodontitis|participants with stage-3 periodontitis
62578892|NCT04805801||Hemophilia A with FVIII inhibitors|Hemophilia A patients with FVIII inhibitors will administer Emicizumab at a loading dose of 3 mg/kg/week SC for the first 4 weeks of treatment followed by 1.5 mg/kg QW SC or 3mg/kg Q2W or 6mg/kg Q4W
62578893|NCT04805801||Hemophilia A without FVIII inhibitors|Hemophilia A patients without FVIII inhibitors will administer Emicizumab at a loading dose of 3 mg/kg/week SC for the first 4 weeks of treatment followed by 1.5 mg/kg QW SC or 3mg/kg Q2W or 6mg/kg Q4W
62784993|NCT00973687|PLACEBO_COMPARATOR|10 mg/mL Unsweetened Formulation|no prior vomiting
62784994|NCT00973687|EXPERIMENTAL|1 mg/mL Ora Sweet Formulation|no prior vomiting
62784995|NCT00973687|ACTIVE_COMPARATOR|10 mg/mL Unsweetened with prior vomiting|with prior vomiting
62784996|NCT00973687|EXPERIMENTAL|1 mg/mL Ora Sweet with prior vomiting|with prior vomiting
62784997|NCT06049303|EXPERIMENTAL|Paraffin wax bath therapy and Maitland joint mobilization techniques|Paraffin wax bath therapy and Maitland joint mobilization techniques
62784998|NCT06049303|ACTIVE_COMPARATOR|Maitland knee joint mobilization|Maitland knee joint mobilization
62784999|NCT03722394|EXPERIMENTAL|Pain Neuroscience Education|Subjects received a 15-minute verbal, one-on-one Pain Neuroscience Education (PNE) session
62578894|NCT04263441|EXPERIMENTAL|NICE Intervention|The proposed intervention will engage clients in the health care enrollment and navigation process in-person, at the time of the HIV testing event. Subjects will be asked to share thoughts on the satisfaction survey.
62578895|NCT04263441|NO_INTERVENTION|Control Intervention|Subjects will be offered a handout on how to enroll in healthcare coverage This group will be provided with the site's standard healthcare enrollment and linkage to care, which is specific to the health care clinic they are visiting. Subjects will be followed for 1 year and information including lab tests and insurance coverage status will be collected. This information will be collected from medical record review. Subjects will be asked to share thoughts on the satisfaction survey.
62785000|NCT05665803|EXPERIMENTAL|Pediatric rotary files|Biomechanical preparation will be done using pediatric rotary file system (Kedo-SG blue file system). D1 and E1 files will be used at 300 rpm and 2.4 N/cm torque.
62578896|NCT02418156||Single Arm|Subjects undergoing femoral arterial reconstruction using CorMatrix ECM for vascular repair.
62785001|NCT05665803|ACTIVE_COMPARATOR|Manual flare files|Biomechanical preparation will be done using manual flare files (Mani) No. 15-35.
62578897|NCT03330704|ACTIVE_COMPARATOR|Standard Therapy|This group will receive 3% hypertonic sodium chloride for the management of their cerebral edema. 3% Sodium Chloride is the generic name of this intravenous fluid preparation.
62578898|NCT03330704|EXPERIMENTAL|Balanced Therapy|This group will undergo two simultaneous infusions. 23.4% sodium chloride and 8.4% sodium bicarbonate will be infused at the same time in various ratios for management of cerebral edema with a balanced approach
62785002|NCT02523573||Study population|Adult ARF ICU patients needing BAL with HFNC
62785003|NCT04193592|EXPERIMENTAL|Oral Pirfenidone 2403 mg per day|Enrolled subjects will receive oral pirfenidone 801 mg taken three times a day. Pirfenidone will be supplied in 267 mg capsules.
62785004|NCT03326206||COPE participants|Individuals living with diabetes seen at a study site who were enrolled in the COPE programmatic intervention during the study period. Participation in COPE consists of receiving home visits by a Navajo Community Health Representative (CHR) once or twice a month for a period of at least 12 months. CHRs use structured patient coaching materials to support behavior change. CHRs also check vital signs, monitor blood glucose levels through finger sticks, and facilitate access to appointments and medical refills. CHRs communicate regularly with providers through electronic health record documentation and case management rounds. In-person or telephone communication is be used to address acute issues that may arise.
62785005|NCT03326206||Non-COPE participants|Individuals living with diabetes seen at a study site, did not participate in the COPE programmatic intervention, and had comparable baseline characteristics.
62785006|NCT01991041||Rufinamide|
62785007|NCT01991041||Anti-Epileptic Drugs|Includes those used off label as part of local clinical practice
62785008|NCT04951505|EXPERIMENTAL|cefepime-taniborbactam|
61978329|NCT04670081|PLACEBO_COMPARATOR|Nicotinamide|1st dose: 100 mg Nicotinamide (Vitamin B3) - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 25 mg Psilocybin
61978330|NCT04670081|EXPERIMENTAL|Psilocybin (low-dose)|1st dose: 5 mg Psilocybin - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 25 mg Psilocybin
62578899|NCT00957593|ACTIVE_COMPARATOR|Oxytocin|Continuation of oxytocin per protocol once the patient reaches active labor
62578900|NCT00957593|ACTIVE_COMPARATOR|Oxytocin discontinuation|Oxytocin will be stopped once the patient reaches active labor
62201295|NCT06112353|ACTIVE_COMPARATOR|Sugammadex|"2.0 mg/kg of Sugammadex plus saline equivalent~2 syringes numbered 1 and 2~1. Syringe #1: 0.9% sodium chloride~2. Syringe #2: : full Sugammadex dose + 0.9 sodium chloride (QS to match volume)"
62201296|NCT05631938|EXPERIMENTAL|Group 1: Normal Renal Function|Participants with normal renal function receive a 3 mg single dose of cytisinicline.
62201297|NCT05631938|EXPERIMENTAL|Group 2: Mild Renal Impairment|Participants with mild renal impairment receive a 3 mg single dose of cytisinicline.
62201298|NCT05631938|EXPERIMENTAL|Group 3: Moderate Renal Impairment|Participants with moderate renal impairment receive a 3 mg single dose of cytisinicline.
62201299|NCT05631938|EXPERIMENTAL|Group 4: Severe Renal Impairment|Participants with severe renal impairment receive a 3 mg single dose of cytisinicline.
62201300|NCT05631938|EXPERIMENTAL|Group 5: ESRD Participants Undergoing Dialysis|Participants with ESRD undergoing dialysis receive a 3 mg single dose of cytisinicline on 2 occasions: after and prior to a dialysis session.
62402017|NCT05079984|EXPERIMENTAL|Graded Exposure Intervention|For Aim 2, adolescents with chronic pain will be enrolled in a single-arm feasibility trial examining acceptability, feasibility, and preliminary effectiveness of a novel, digitally delivered, graded exposure treatment.
62402018|NCT05654116|EXPERIMENTAL|CIP training group|Participants assigned to the CIP training group will receive either an individual 5-week CIP training or a pairwise 6-week CIP training, both with weekly sessions.
62402019|NCT05654116|NO_INTERVENTION|Waiting-list control group|Participants assigned to the waiting-list control group will receive no intervention while data collection is ongoing; after data collection is finished they will also receive the CIP training.
62402020|NCT04008290|EXPERIMENTAL|0.6 mg Liraglutide|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 100 µl containing 0.6 mg liraglutide.
61978331|NCT04670081|EXPERIMENTAL|Psilocybin (high-dose)|"1. 1st dose: 25 mg Psilocybin - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 5 mg Psilocybin~2. 1st dose: 25 mg Psilocybin - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 25 mg Psilocybin"
62201301|NCT02144103|EXPERIMENTAL|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected into subtenon space of patient's eye.
62201302|NCT02702323|EXPERIMENTAL|Apatinib & TACE|Apatinib 500mg tablet by mouth per day, until disease progression, combined with TACE therapy one times every 4-6 weeks.
62201303|NCT02702323|ACTIVE_COMPARATOR|TACE|TACE therapy one times every 4-6 weeks.
62201304|NCT00747227|EXPERIMENTAL|ZV9003|modified light transmission intraocular lens
62201305|NCT00747227|ACTIVE_COMPARATOR|ZA9003|monofocal acrylic intraocular lens
62201306|NCT04906681|EXPERIMENTAL|Arthroplasty, hip or knee|Minimum 5x/week (of which minimal 3x/week with therapists and 2x/week during weekend), 30-60 minutes training, for 4 weeks, with i-ACT system. i-ACT provides individualised exercises based on patients own goalsetting.
62201307|NCT04906681|EXPERIMENTAL|Neurology: stroke or Parkinson disease|Minimum 5x/week (of which minimal 3x/week with therapists and 2x/week during weekend), 30-60 minutes training, for 4 weeks, with i-ACT system. i-ACT provides individualised exercises based on patients own goalsetting.
62402021|NCT04008290|PLACEBO_COMPARATOR|Placebo|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 100 µl saline (0.9%) solution.
62402022|NCT01934101|EXPERIMENTAL|CHR-5154|CHR-5154
62402023|NCT01934101|PLACEBO_COMPARATOR|Placebo|Placebo
62785009|NCT00600899|EXPERIMENTAL|A|Group A patients will receive perisciatic continuous infusion of ropivacaine 2 mg/ml through an elastomeric pump (Baxter, Deerfield, IL, USA)) 8 ml/h (reservoir of 500 ml)as postoperative analgesia.
62785010|NCT00600899|ACTIVE_COMPARATOR|B|Group B patients will receive standard treatment: continuous perisciatic infusion of 2 mg/ml ropivacaine 5 ml/t (Baxter infusor with 275 ml reservoir)
62785011|NCT02717052|EXPERIMENTAL|(S)-ketamine|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)~all patients and 10 HC (randomized, double blind)~Interventions:~Drug: (S)-ketamine (Main study) Other: Main study: PET1 Other: Main study: PET2"
62785012|NCT02717052|PLACEBO_COMPARATOR|Placebo|"0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)~10 HC (randomized, double blind)~Interventions:~Drug: Placebo Other: Main study: PET1 Other: Main study: PET2"
62785013|NCT02717052|EXPERIMENTAL|(S)-ketamine (Pilot Study II, 5 subj.)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.10mg/kg bodyweight bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight applied over the course of 130 minutes.~Pilot-study II is cross-over design!~Interventions:~Drug: (S)-ketamine (Pilot II) Other: PILOT Study II: PET1 Other: PILOT Study II: PET2"
62785014|NCT02717052|EXPERIMENTAL|(R,S)-ketamine (Pilot Study II, 5 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.20mg/kg bodyweight bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied over the course of 130 minutes.~Pilot-study II is cross-over design!~Interventions:~Drug: (R,S)-ketamine (Pilot II) Other: PILOT Study II: PET1 Other: PILOT Study II: PET2"
62402024|NCT06506526|ACTIVE_COMPARATOR|Control group|The teeth will be irrigated by 2 ml 1% NaOCl after each file.
62402025|NCT06506526|EXPERIMENTAL|One-minute NaOCL+Chitosan|The teeth will be irrigated by 2 ml 1% NaOCl after each file then with 5 ml of 0.2% chitosan for one minute.
62402026|NCT06506526|EXPERIMENTAL|Three-minute NaOCL+Chisosan|The teeth will be irrigated by 2 ml 1% NaOCl after each file then with 5 ml of 0.2% chitosan for three minute.
62402027|NCT01813760|EXPERIMENTAL|Diode laser|Diode laser to treat peri-orbital and peri-oral wrinkles
62785015|NCT02717052|EXPERIMENTAL|(R,S)-ketamine (Pilot Study I, 12 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 5 minutes before PET measurement)~Interventions:~Drug: (R,S)-ketamine (Pilot I) Other: PILOT Study I: PET1 Other: PILOT Study I: PET2"
62785016|NCT02717052|EXPERIMENTAL|(R,S)-ketamine (Pilot Study III, 12 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.80mg/kg bodyweight i.v. over 50 Minutes~Interventions:~Drug: (R,S)-ketamine (Pilot III) Other: PILOT Study III: PET1 Other: PILOT Study III: PET2"
62785017|NCT05842018|EXPERIMENTAL|Toripalimab, Chemotherapy and Antiangiogenic Agents|
62785018|NCT00579072||Longitudinal Study|Take part in this study because subject has prostate cancer and are over 64 years old. To run this study,need men from two groups. First, we need men who are about to start hormone treatment. Second, we need men who do not plan to use this treatment in the future. We will use this second group as a control group and compare this group to the men who are using this treatment.
62785019|NCT00579072||Group Comparison|Take part in this study because subject has prostate cancer and are over 64 years old. Also, because subject has been on hormone therapy for about two to three years.
62785020|NCT06366360|ACTIVE_COMPARATOR|Immersive virtual reality rehabilitation first|Each patient received 2 rehabilitations: both an immersive virtual reality and a conventional rehabilitation first (during 2 weeks), and then conventional rehabilitation alone (during 2 weeks)
62785021|NCT06366360|ACTIVE_COMPARATOR|Conventional rehabilitation first|Each patient received 2 rehabilitations: a conventional rehabilitation alone first (during 2 weeks), and then both conventional rehabilitation and immersive virtual reality rehabilitation (during 2 weeks)
62785022|NCT00185224|EXPERIMENTAL|Arm 1|
62785023|NCT00185224|ACTIVE_COMPARATOR|Arm 2|
62785024|NCT03250208|PLACEBO_COMPARATOR|Control Group|Participants randomized to this group will take two placebo capsules daily during days 21-60.
62785025|NCT03250208|EXPERIMENTAL|Intervention group|The intervention in this study is a probiotic. Participants randomized to this group will take two capsules of a probiotic daily during days 21-60
62785026|NCT02210975|EXPERIMENTAL|Electrical Stimulation Therapy|
62785027|NCT06054139||the treated patients in ICU|Patients receiving nutrition while receiving treatment in intensive care
62785028|NCT05152576|PLACEBO_COMPARATOR|Placebo|Placebo will be injected into the forehead on Day 1.
62785029|NCT05152576|EXPERIMENTAL|OnabotulinumtoxinA X Dose A|OnabotulinumtoxinA X will be injected into the forehead on Day 1.
62785030|NCT05152576|EXPERIMENTAL|OnabotulinumtoxinA X Dose B|OnabotulinumtoxinA X will be injected into the forehead on Day 1.
62785031|NCT05152576|EXPERIMENTAL|OnabotulinumtoxinA X Dose C|OnabotulinumtoxinA X will be injected into the forehead on Day 1.
62785032|NCT03821610|ACTIVE_COMPARATOR|Fludarabine / Melphalan / Alemtuzumab|Day -7 Fludarabine 30mg/m2 od IV Day -6 Fludarabine 30mg/m2 od IV Day -5 Fludarabine 30mg/m2 od IV Day -4 Fludarabine 30mg/m2 od IV Day -3 Fludarabine 30mg/m2 od IV Day -2 Melphalan 140mg/m2 od IV, Alemtuzumab 20 mg od IV (unrelated transplants only) Day -1 Alemtuzumab 20mg od IV Day 0 Infusion of sibling or unrelated donor peripheral blood stem cells
62785033|NCT03821610|EXPERIMENTAL|Cyclophosphamide / TBI (8Gy)|Day -6 Cyclophosphamide 50 mg/kg od IV , Mesna 20 mg/kg od IV, Mesna 76mg/kg od IV Day -5 Cyclophosphamide 50 mg/kg od IV, Mesna 20 mg/kg od IV, Mesna 76 mg/kg od IV Day -4 Rest Day -3 TBI (2Gy) bd Day -2 TBI (2Gy) bd, Alemtuzumab 20mg od IV (unrelated transplants only) Day -1 Alemtuzumab 20mg od IV Day 0 Infusion of sibling or unrelated donor peripheral blood stem cells or bone marrow
62785034|NCT00555217|EXPERIMENTAL|Combination of ARB and ACEI|Combination of an angiotensin converting enzyme inhibitor (ACEI) with an angiotensin receptor blocker (ARB)
62785035|NCT00555217|ACTIVE_COMPARATOR|Monotherapy ARB|Mono therapy arm. Standard treatment with angiotensin receptor blocker (ARB)
62785036|NCT02425059|EXPERIMENTAL|IRE Group|irreversible electroporation for Unresectable Rectal Neoplasms
62201308|NCT02775370|EXPERIMENTAL|Apatinib group|Apatinib Mesylate administered as a daily oral treatment
62201309|NCT01885169||Cohort A|Participants with CF; Flumist®-naïve
62201310|NCT01885169||Cohort B|Siblings of Cohort A without CF; Flumist®-naïve
62201311|NCT01885169||Cohort C|Participants with CF; Flumist®-experienced
62201312|NCT00500344|OTHER|1|
62201313|NCT04652505||Observational (questionnaires)|Patients complete 3 questionnaires online over 15 minutes regarding coping strategies that may have been used, mental health and physical well-being in the past month, and if they have been following certain behaviors which the WHO has recommended during the coronavirus pandemic, such as regular hand washing and social distancing.
62201314|NCT03452852|OTHER|NPWT (PICO device)|In this arm, investigators will use the PICO system (Smith and Nephew) for compression therapy after split thickness skin graft of leg ulcers.
62201315|NCT03452852|OTHER|Compression bandaging (Coban 2 lite)|In this arm, investigators will use the Coban 2 lite compression bandaging for compression therapy after split thickness skin graft of leg ulcers.
62201316|NCT05899062|OTHER|Control group|"The patients in the control group will be given education about constipation, which lasts about 45-60 minutes, with the telerehabilitation method. In addition, a Constipation Training Booklet will be sent via e-mail or WhatsApp, related to the training content given to all patients and to reinforce the training. Definition of constipation in education, its causes, medications that cause constipation, risk factors, suggestions for prevention of constipation (such as regular defecation, not delaying defecation, best position for defecation, not straining for a long time), constipation treatment and the importance of individual management, healthy and balanced diet, nutrition Types, adequate fluid intake, benefits of exercise and appropriate exercise selection, abdominal massage, toilet training and individual methods of preventing constipation will be included."
62578901|NCT01352351|EXPERIMENTAL|Breastfeeding promotion intervention|"Intervention:~* Group breastfeeding counseling during monthly microcredit borrower group meetings~* Weekly cell phone messages about breastfeeding"
62785037|NCT02425059|NO_INTERVENTION|Control|The patients without treatment
62785038|NCT03052595||SM|Patients with newly diagnosed multiple sclerosis undergo Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load Patients undergo testing of autonomous nervous system function and testing of cognitive function (Stroop test)
62785039|NCT03052595||Control|Age, sex, Body Mass Index (BMI) matched healthy subjects undergo Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load Healthy controls undergo testing of autonomous nervous system function and testing of cognitive function (Stroop test)
62785040|NCT00793325||Somatropin|Patients administered Somatropin.
62785041|NCT03141632|ACTIVE_COMPARATOR|Dulaglutide|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.
62785042|NCT03141632|PLACEBO_COMPARATOR|Placebo|0.5 ml normal saline (0.9% sodium chloride), sc once weekly for 3 weeks.
62785043|NCT06335017|ACTIVE_COMPARATOR|group 1 - study group|Candidates will drink a mixture of 60 ml of castor oil and 140 ml of orange juice. 30 minutes later, A 22-French Foley catheter will be inserted above internal cervical os and will be filled with 60 mL of normal saline.
62201317|NCT05899062|OTHER|Intervention group|The patients in intervention group will be given an exercise program in addition to all the practices in the control group. Training and exercise practices will be carried out with the telerehabilitation method. Exercise training, which will last 40-60 minutes, 3 days a week for 6 weeks, will consist of warm-up and breathing exercises, exercises for constipation and cooling movements. Patients will be asked to walk for at least 30 minutes, 2 days a week, on days without exercise training.
62201318|NCT02799394|EXPERIMENTAL|Activity modification, exercises and gradual return to sport|
62402028|NCT01400607|ACTIVE_COMPARATOR|Neocartilage Implant|Neocartilage Implant surgically implanted and affixed to subchondral bone using commercial fibrin during mini-open knee arthrotomy.
62402029|NCT01400607|OTHER|Microfracture|Standard of care cartilage repair technique.
62578902|NCT01352351|NO_INTERVENTION|No intervention|The no intervention group will participate in their regular microcredit borrower group meetings, but will not receive breastfeeding counseling or cell phone messages.
62578903|NCT01942486|EXPERIMENTAL|Investigational Coating|
62785044|NCT06335017|ACTIVE_COMPARATOR|group 2- control|A foley catheter will be inserted into cervical canal as described above according to the department protocol without ingestion of castor oil.
62785045|NCT04801862||Patients diagnosed of C.difficile infection|Open cohort of consecutive patients diagnosed of Clostridioides difficile infection
62785046|NCT04375059|ACTIVE_COMPARATOR|Study group|3 months of interactive attention training programs, 2 times per week, 15 min per session, a total of 24 sessions, with conventional rehabilitation programs
62785047|NCT04375059|NO_INTERVENTION|Control group|3 months of conventional rehabilitation programs without interactive attention training programs
62785048|NCT05230784|EXPERIMENTAL|HEPA Air Purifier|Air purifier is installed in participants' households by the research team. Twice per year, participants will wear a GPS as well as a backpack containing a particulate matter 2.5 (PM2.5) personal exposure monitor for a 24-hour monitoring period.
62402030|NCT04249934|EXPERIMENTAL|Caffeinated Coffee|
62013154|NCT06204822||blood oxygen saturation measurement|"1. Participants sit in a comfortable posture with both hands placed naturally on the table or thighs, palms facing up without obstruction, and facing the camera lens. They rest for 2 minutes.~2. Participants breathe normally while recording images and data for 1 minute.~3. Participants hold their breath until discomfort (aiming for at least 40 seconds) while recording images and data for 1 minute.~4. Participants return to normal breathing, and images and data are recorded for 3 minutes.~5. The experimenter adjusts program settings, and participants repeat steps 2 to 4 once."
62201319|NCT03301155|EXPERIMENTAL|Anaferon for children|"Tablet for oral use. One tablet per intake, once daily (approximately at the same time).~The product is administered outside a meal (in the interval between meals or 15 min prior to meal or fluid intake), the tablets should be held in mouth until complete dissolution. For young children (aged 1 month to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature."
62402031|NCT04249934|ACTIVE_COMPARATOR|Decaffeinated Coffee|
62402032|NCT03198819||Rifampisin group|"Researchers will administer topical Rifampicin and intravenous cefotaxime~1. For Rifampicin; 10 mg/kg/day, 24 h infusion on defect area during 3 days~2. For cefotaxime; 50 mg/kg/day, twice a day, intravenous during 5 days."
62402033|NCT03198819||Control group|"Researchers will only administer intravenous cefotaxime~1) Doses; 50 mg/kg/day, twice a day, intravenous during 5 days."
62201320|NCT03301155|PLACEBO_COMPARATOR|Placebo|Tablet for oral use. Placebo using Anaferon for children scheme.
62013155|NCT05495750|ACTIVE_COMPARATOR|Maxillary block group|"The ultrasound probe will be placed in the infra zygomatic area, with an inclination of 45 degrees in the transverse plane. A 27-gauge 38-mm needle will be used for the injection. The needle will be inserted perpendicular to the skin at the frontozygomatic angle and advanced to the greater wing of the sphenoid. The needle will be then redirected and advanced to the pterygopalatine fossa.~Loss of resistance after passing through the temporalis muscle will assist in determining the puncture depth, and real-time ultrasound guidance will allow seeing the spread of local anesthetic in the pterygopalatine fossa."
62201321|NCT00476164|EXPERIMENTAL|Rituximab|Infusion of 2 x 1g of rituximab, 14 days apart
62402034|NCT01875900|ACTIVE_COMPARATOR|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) digital video disc (DVD) will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
62013156|NCT05495750|NO_INTERVENTION|Control group|Patients will receive only general anesthesia with regulated doses of IV opioids.
62201322|NCT00476164|SHAM_COMPARATOR|2|
62201323|NCT05626153|ACTIVE_COMPARATOR|Routine anesthesia care|• Implementing anesthesia management according to current routine practice.
62402035|NCT01875900|EXPERIMENTAL|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
62402036|NCT00470301|EXPERIMENTAL|Arm I|Tipifarnib plus sequential weekly paclitaxel followed by doxorubicin plus cyclophosphamide
62402037|NCT00588120|EXPERIMENTAL|C-13 labeled oxalate|Hyperoxaluric patients
62402038|NCT00823875|EXPERIMENTAL|1|
62402039|NCT00823875|EXPERIMENTAL|2|
62402040|NCT00823875|EXPERIMENTAL|3|
62402041|NCT00823875|OTHER|4|Control Group
62402042|NCT03506334|EXPERIMENTAL|Pediatric Scoliosis Patients|Tether group
62402043|NCT03506334|ACTIVE_COMPARATOR|Pediatric Scoliosis Control Patients|Fusion (control) group
62402044|NCT01195662|EXPERIMENTAL|Dapagliflozin 10 mg|Dapagliflozin 10 mg tablets
62402045|NCT01195662|PLACEBO_COMPARATOR|Placebo matching Dapagliflozin|Placebo tablets matching dapagliflozin tablets
62402046|NCT00270400|EXPERIMENTAL|001|nesiritide
62402047|NCT05463393|EXPERIMENTAL|Group Xn|Patients who received extract from Humulus lupus L rich in Xanthohumol (Hop-RXn™, BioActive-Tech Ltd, Lublin, Poland; http://xanthohumol.com.pl/) as an adjuvant therapy. Based on pharmacokinetics and bioactivity, Xn was administered enterally three times a day every 8 hours at a dose of 1.5 mg/kg body weight (4.5 mg/kg body weight/day) for 7 days. The first dose of Xn was administered within 4 hours after admission to the ICU.
62013157|NCT01744730|ACTIVE_COMPARATOR|Clindamycin IV-ages 2 to 11 Years Old (BMI 85-95th Percentile)|Clindamycin IV: Children ages 2 to 11 years old with BMI 85th to 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
62013158|NCT01744730|ACTIVE_COMPARATOR|Clindamycin IV-ages 2 to 11 Years Old (BMI Greater Than 95th)|Clindamycin IV: Children ages 2 to 11 years old with BMI greater than 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
62013159|NCT01744730|ACTIVE_COMPARATOR|Clinidamycin IV-ages 12 to 17 (BMI 85-95th Percentile)|Clindamycin IV: Children ages 12 to 17 years old with BMI 85th to 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
62013160|NCT01744730|ACTIVE_COMPARATOR|Clindamycin IV-ages 12 to 17 (BMI Greater Than 95th)|Clindamycin IV: Children ages 12 to 17 years old with BMI greater than 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
62013161|NCT02778204|EXPERIMENTAL|Cohort 1 Stratum 1A|Infants in this cohort received a single dose of 8 mg/kg maraviroc solution within 3 days of birth and at Week 1 (7-14 days) of life; without in utero exposure to maternal efavirenz.
62201324|NCT05626153|EXPERIMENTAL|Improved anesthesia care|"* Encourage regional anesthesia or combined regional-general anesthesia.~* Encourage goal-directed fluid therapy, lung-protective ventilation, and active warming during surgery.~* Encourage extubation in the operating room at the end of surgery.~* Encourage multimodal analgesia after surgery.~* Encourage strict indication for ICU admission after surgery."
62201325|NCT03466047|EXPERIMENTAL|Protein stomach|Encapsulated protein released in the stomach
62013162|NCT02778204|EXPERIMENTAL|Cohort 1 Stratum 1B|Infants in this cohort received a single dose of 8 mg/kg maraviroc solution within 3 days of birth and at Week 1 (7-14 days) of life; with in utero exposure to maternal efavirenz.
62201326|NCT03466047|EXPERIMENTAL|Protein distal small intestine|Encapsulated protein released in the distal small intestine
62201327|NCT03466047|EXPERIMENTAL|CHO stomach|Encapsulated CHO released in the stomach
62013163|NCT02778204|EXPERIMENTAL|Cohort 2 Stratum 2A|Infants in this cohort received 8 mg/kg maraviroc solution twice daily starting within 3 days of birth and continuing up to Week 6 (35-42) days of life; without in utero or breast milk exposure to maternal efavirenz.
62013164|NCT02778204|EXPERIMENTAL|Cohort 2 Stratum 2B|Infants in this cohort received 8 mg/kg maraviroc solution twice daily starting within 3 days of birth and continuing up to Week 6 (35-42) days of life; with in utero and breast milk exposure to maternal efavirenz
62013165|NCT03737461|EXPERIMENTAL|Allogenic BM-MSCs Injection|Injection of a dose of 20.106 allogenic BM-MSCs via imaging control into the disk affected by DDD where they are expected to exert their therapeutic effects.
62013166|NCT03737461|SHAM_COMPARATOR|Sham Procedure|anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment
62013167|NCT01310413|EXPERIMENTAL|Influenza A (H5N1) adjuvanted 6-<36M Group|Subjects aged at enrolment between 3 and 36 months, 36 months excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly. For children aged up to 12 months, 12 months excluded (\< 12 months), Dose 1 was administered in the left anterolateral thigh and Dose 2 in the right anterolateral thigh. For children older than (\>=) 12 months, Dose 1 was administered in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
62201328|NCT03466047|EXPERIMENTAL|CHO distal small intestine|Encapsulated CHO released in the distal small intestine
62201329|NCT03466047|EXPERIMENTAL|Fat stomach|Encapsulated Fat released in the stomach
62201330|NCT03466047|EXPERIMENTAL|Fat distal small intestine|Encapsulated Fat released in the distal small intestine
62201331|NCT02212652|ACTIVE_COMPARATOR|Standard of Care plus Vitamin D|If randomized to this arm, each participant will receive a 30 day supply of 10,000 IU of VitD3 for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
62402048|NCT05463393|PLACEBO_COMPARATOR|Group C|Patients who received 0.9% NaCl at the oral volume 1 mL (similar to Xn volume) three times a day every 8 hours. The first dose of Xn was administered within 4 hours after admission to the ICU.
62201332|NCT02212652|PLACEBO_COMPARATOR|Standard of Care plus Placebo|If randomized to this arm, each participant will receive a 30 day supply of placebo supplements for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
62201333|NCT04596839|EXPERIMENTAL|Remdesivir with Standard of Care Treatment for COVID-19 Infection|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
62201334|NCT04596839|OTHER|Standard of Care Treatment for COVID-19 Infection|Participants will receive continued standard of care therapy.
62201335|NCT01912404|EXPERIMENTAL|IDN-6556|IDN-6556 capsules, 25 mg BID
62201336|NCT01912404|PLACEBO_COMPARATOR|Placebo|Placebo capsules BID
62201337|NCT05044507|SHAM_COMPARATOR|BQ 2.0 sham stimulation group|45 sessions over a period of 9 weeks (5 treatments per week) of sham study intervention with BQ 2.0 including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.
62201338|NCT05044507|ACTIVE_COMPARATOR|BQ 2.0 active stimulation group|45 sessions over a period of 9 weeks (5 treatments per week) of active study intervention with BQ 2.0 including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.
62201339|NCT03055962|EXPERIMENTAL|E2609 50 mg|Participants will receive E2609 50 milligrams (mg) orally once a day for 14 days.
62201340|NCT03055962|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo orally once a day for 14 days.
62785049|NCT05230784|PLACEBO_COMPARATOR|EGAPA Air Purifier|Air purifier is installed in participants' households by the research team. Twice per year, participants will wear a GPS as well as a backpack containing a particulate matter 2.5 (PM2.5) personal exposure monitor for a 24-hour monitoring period.
62201341|NCT03566004|OTHER|endoscoped patients|Patients addressed for endoscopy with indication of biopsies for H. pylori detection will be enroled to provide stool specimen
62201342|NCT04061369|EXPERIMENTAL|Meal 1|Meal consisting of conventional foods that is low (20% of energy) in fat calories.
62785050|NCT01262534||1|Clinical profile of patients Comorbidities and associated type of treatments will be collected.
62785051|NCT01262534||2|Quality of Life The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire to analyze the overall quality of life of patients and Dermatology Life Quality Index (DLQI) to analyze the quality of life of patients in dermatological terms).
62785052|NCT01262534||3|Patient Preferences about treatment Patient Benefit Index (PBI) for treatment to record patient preferences regarding psoriasis treatment.
62785053|NCT02112292|EXPERIMENTAL|T-C-P|Order of administrations: tetrahydrocannabinol - cannabidiol - placebo
62785054|NCT02112292|EXPERIMENTAL|T-P-C|Order of administrations: tetrahydrocannabinol - placebo - cannabidiol
62785055|NCT02112292|EXPERIMENTAL|C - T - P|Order of administrations: cannabidiol - tetrahydrocannabinol - placebo
62785056|NCT02112292|EXPERIMENTAL|C - P - T|Order of administrations: cannabidiol - placebo - tetrahydrocannabinol
62201343|NCT04061369|EXPERIMENTAL|Meal 2|Meal consisting of conventional foods that is moderate (40% of energy) in fat calories.
62201344|NCT04061369|EXPERIMENTAL|Meal 3|Meal consisting of conventional foods that is high (60% of energy) in fat calories.
62201345|NCT04061369|EXPERIMENTAL|Meal 4|"A liquid meal, similar to a smoothie, that is high (60% of energy) in fat calories."
62201346|NCT02299947|EXPERIMENTAL|Haemocomplettan P|Study patients that receive Haemocomplettan P
62201347|NCT02299947|PLACEBO_COMPARATOR|NaCl 0.9%|Study patients that receive NaCl 0.9%
62402049|NCT05665257|EXPERIMENTAL|Inspiratory muscle training|Participants in the intervention group were using a handheld device, Powerbreathe K3, aiming at increasing inspiratory muscle strength by applying an inspiratory resistance. They were instructed to use it twice a day for at least 14 days. Starting load was based on the baseline assessment of the participant's inspiratory muscle strength and increased during the intervention period.
62785057|NCT02112292|EXPERIMENTAL|P - T - C|Order of administrations: placebo - tetrahydrocannabinol - cannabidiol
62201348|NCT04958577||Wing A (Ada WRA)|Patients in this group will be filling out the Ada assessment themselves and then heading to a normal consultation by first the usual care doctor and then the study-provided physician.
62201349|NCT04958577||Wing B (Ada HDA)|Patients in this group will be asked questions from the Ada assessment by a health care practitioner and then heading to a normal consultation by first the usual care doctor and then the study-provided physician.
62201350|NCT03416660|ACTIVE_COMPARATOR|Low density|Fractional carbon dioxide laser: Lesion A or part A parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 900µm spacing (7.4% density).
62201351|NCT03416660|ACTIVE_COMPARATOR|Medium density|Fractional carbon dioxide laser : Lesion B or part B parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 600µm spacing (12.6% density).
62201352|NCT03416660|ACTIVE_COMPARATOR|High density|Fractional carbon dioxide laser : Lesion C or part C parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 300 µm spacing (25.6% density).
62201353|NCT00613899|OTHER|Telesurveillance|"At time of discharge from hospital, 40 ALS patients willbe enrolled in a telesurveillance program (TP) for the management of cought at home.~Two hours of an in-hospital educational training will be provided to patients and caregivers on the use of:~1. air stacking with Ambu balloon~2. manual manoeuvres and~3. in-Exoflator device indications and use"
62785058|NCT02112292|EXPERIMENTAL|P - C - T|Order of administrations: placebo - cannabidiol - tetrahydrocannabinol
62785059|NCT02659436|ACTIVE_COMPARATOR|Verbal-linguistic CBT|Participants will receive 4 sessions of verbal cognitive restructuring and exposure therapy delivered in an individual therapy format.
62785060|NCT02659436|EXPERIMENTAL|Imagery-based CBT|Participants will receive 4 sessions of imagery-based cognitive work and behavioural experiments delivered in an individual therapy format.
62785061|NCT00793169||lidocane|Patients undergoing Mohs micrographic surgery of the face or neck will have their blood drawn before, during, and after the procedure.
62785062|NCT02610946|PLACEBO_COMPARATOR|Paper-based|Use of paper-based calenders, reminders, medication list, and blood pressure, fluid intake tracking methods in adolescent renal transplant care
62578904|NCT04061928|EXPERIMENTAL|Combination of toripalimab with preoperative chemoradiotherapy|"This is a one arm study, enrolled locally advanced EGJ patients will receive toripalimab and combined with preoperative chemoradiotherapy and operation.~generic name：PD-1 dosage form：Injection dosage：240mg (6ml) frequency：every 3 weeks duration：4 times before operation and 4 times after operation"
62578905|NCT03874481||PCI|Patients who had stent
62578906|NCT05216861|EXPERIMENTAL|Experimental|The rehabilitation coordinators are trained in the intervention (0,5 day).
62578907|NCT05216861|OTHER|Active comparator|Participants in the experimental arm will be matched with controls from the Micro Data for the Analysis of Social Insurance register (MiDAS) from the Social Insurance Agency, Sweden.
62402050|NCT05665257|SHAM_COMPARATOR|Mini-PEP|Participants in the control arm were instructed to use a handheld PEP-device traditionally used to facilitate deep breathing. The PEP-device does not provide any inspiratory resistance and therefore, it was considered a sham treatment. The control group were also instructed to use the device twice a day for at least two weeks.
62402051|NCT00822185|EXPERIMENTAL|vatreptacog alfa, 5 mcg/kg|
62402052|NCT00822185|EXPERIMENTAL|vatreptacog alfa, 10 mcg/kg|
62402053|NCT00822185|EXPERIMENTAL|vatreptacog alfa, 20 mcg/kg|
62402054|NCT00822185|EXPERIMENTAL|vatreptacog alfa, 30 mcg/kg|
62402055|NCT03049592|EXPERIMENTAL|HIBISCUS counseling|Subject receives a third trimester prenatal appointment with a family planning specialist for contraceptive counseling (utilizing the Contraceptive CHOICE counseling script emphasizing the WHO birth-to-pregnancy recommendation of 18 months) and a follow up postpartum contraception visit with a family planning specialist.
62402056|NCT03049592|NO_INTERVENTION|Standard counseling|Subect receives standard high-risk prenatal care and postpartum contraception provision by the referring community clinic. The community clinic offer standard family planning counseling that does not emphasize utilizing of long-acting reversible contraception to promote birth-to-pregnancy spacing of 18 months. This scenario is current the standard practice at the institutions.
62402057|NCT04544748|OTHER|Cohort 1|GNR-051 (0.1 mg/kg)
62402058|NCT04544748|OTHER|Cohort 2|GNR-051 (0.3 mg/kg)
62402059|NCT04544748|OTHER|Cohort 3|GNR-051 (1 mg/kg)
62578908|NCT01132248|EXPERIMENTAL|Mefloquine|15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
62578909|NCT01132248|PLACEBO_COMPARATOR|S/P|sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
62578910|NCT03106363|ACTIVE_COMPARATOR|Alcohol/Placebo Cannabis|Participant will drink an alcoholic beverage to obtain a target blood alcohol content of 0.08mg% and will smoke a placebo delta 9 tetrahydrocannabinol (\< 0.03%) cigarette.
62402060|NCT04544748|OTHER|Cohort 4|GNR-051 (3 mg/kg)
62402061|NCT04544748|OTHER|Cohort 5|GNR-051 (10 mg/kg)
62578911|NCT03106363|ACTIVE_COMPARATOR|Placebo Alcohol/Cannabis|Participant will drink tonic water (capped with a minimal amount of alcohol to enhance alcohol cues) and will smoke a delta 9 tetrahydrocannabinol (potency 12.5%) cigarette.
62578912|NCT03106363|ACTIVE_COMPARATOR|Alcohol/Cannabis|Participant will drink an alcoholic beverage to obtain a target blood alcohol content of 0.08mg% and will smoke a delta 9 tetrahydrocannabinol (potency 12.5%) cigarette.
62578913|NCT03106363|PLACEBO_COMPARATOR|Placebo Alcohol/Placebo Cannabis|Participant will drink tonic water (capped with a minimal amount of alcohol to enhance alcohol cues) and will smoke a placebo delta 9 tetrahydrocannabinol (\< 0.03%) cigarette.
62578914|NCT04606394|OTHER|Open label treatment|All subjects receive Trelegy and Ventolin for 2 weeks
62578915|NCT02317276|EXPERIMENTAL|Treatment|Topical Triamcinolone 0.1% ointment will be provided for twice daily application, during treatment periods.
62578916|NCT01011751|EXPERIMENTAL|Cyproterone acetate|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, cyproterone acetate 50 mg, tablet-in-capsule, along with cyproterone acetate placebo-matching capsule, orally, once daily in the morning and cyproterone acetate 50 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Cyproterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks.
62785063|NCT02610946|EXPERIMENTAL|Electronic application|Use of electronic apps (iphone or i-Pad mini) to determine whether it can improve compliance with transplant care and readiness to transition to adult care.
62402062|NCT04392882|EXPERIMENTAL|Legume enriched diet group|"* Replacing 1/3 refined rice intake with legumes three times per day~* Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~* Regular 30-min walk after dinner each day"
62402063|NCT04392882|NO_INTERVENTION|Usual diet group|"* Maintaining usual diet~* Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~* Regular 30-min walk after dinner each day"
62402064|NCT00903357|EXPERIMENTAL|Montelukast first, then placebo|The group received active medication (montelukast 4 mg or 5mg once daily) for 8 weeks followed by a crossover to 8 weeks of placebo after 2-weeks washout period.
62201354|NCT05788627|PLACEBO_COMPARATOR|Placebo arm / tap water enema arm|This arm will receive oral lactulose as per treatment protocol for hepatic encephalopathy i.e. 30ml twice daily. And will receive tap water enema as placebo i.e. 1000ml tap water enema twice daily.
62201355|NCT05788627|EXPERIMENTAL|Lactulose enema arm|This arm will receive oral lactulose in a dose of 30ml twice daily alongwith lactulose enema (300ml lactulose plus 700ml water) twice daily.
62201356|NCT01261117|ACTIVE_COMPARATOR|intravenous ibuprofen|Extremely low birth weight patients receiving iv ibuprofen
62201357|NCT01261117|ACTIVE_COMPARATOR|Oral ibuprofen|Extremely low birth weight patients receiving oral ibuprofen
62201358|NCT05238753|EXPERIMENTAL|Intervention, stimulated|Electromagnetic stimulation of the phrenic nerve in critically ill patients.
62201359|NCT05238753|NO_INTERVENTION|Control, not stimulated|Control group, no stimulation of the phrenic nerve.
62201360|NCT01381575|EXPERIMENTAL|Cervarix 1 Group|Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Day 0 and at Month 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
62201361|NCT01381575|ACTIVE_COMPARATOR|Cervarix 2 Group|Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Day 0, at Month 1 and at Month 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
62201362|NCT01381575|EXPERIMENTAL|Cervarix 3 Group|Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Day 0 and at Month 12, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
62578917|NCT01011751|EXPERIMENTAL|Medroxyprogesterone acetate|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, medroxyprogesterone acetate 10 mg, tablet-in-capsule, along with medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning and medroxyprogesterone acetate 10 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks.
62785064|NCT03202134||opioid free anesthesia (OFA)|The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.
62785065|NCT03202134||opioid anesthesia (OA)|OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.
62785066|NCT03322410|EXPERIMENTAL|Patients|
62201363|NCT05353075|OTHER|Sub Occipital Muscle Inhibition|Subjects in this group will receive only Sub Occipital Muscle Inhibition Technique and heating pad for 10 minutes.
62201364|NCT05353075|EXPERIMENTAL|Sub Occipital Inhibition with Hold Relax Agonist Contraction|Subjects in this group will receive Sub Occipital Inhibition and Hold Relax Agonist Contraction of hamstrings.
62201365|NCT04554719|EXPERIMENTAL|68Ga-DOTA-FAPI PET/MR|Investigators select subjects from patients with suspected or diagnosed or treated malignant tumors who have completed 18F-FDG PET/CT imaging, focusing on malignant tumors with poor results of FDG PET/CT imaging, such as brain tumors, liver tumors, digestive system tumors and peritoneal, greater omentum, and mesenteric metastatic tumors. Patients undergo 68Ga-DOTA-FAPI PET/MR imaging within one week.
62201366|NCT06269094|EXPERIMENTAL|CGM|
62578918|NCT01011751|EXPERIMENTAL|Venlafaxine|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, venlafaxine 75 mg, capsule, orally, once daily in the morning and venlafaxine placebo-matching capsule, orally, once daily in the evening for 8 weeks. Venlafaxine 37.5 mg, capsule, orally, once daily in the evening for the next 2 weeks.
62578919|NCT01677312|ACTIVE_COMPARATOR|19G FNA needle|Evaluate median number of passes to diagnosis (Diagnostic accuracy) and ability to procure histological samples using a 19G FNA needle when performing pancreatic biopsy.
62785067|NCT06584058|EXPERIMENTAL|All healthy subjects|
62785068|NCT01188304|EXPERIMENTAL|1|
62785069|NCT01188304|PLACEBO_COMPARATOR|2|
62201367|NCT00168389|EXPERIMENTAL|Dexamethasone 700 μg|700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
62201368|NCT00168389|EXPERIMENTAL|Dexamethasone 350 μg|350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
62201369|NCT00168389|SHAM_COMPARATOR|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
62785070|NCT03722524||Patients with arterial hypertension|"The patient is included in the program if prior to the study his/her doctor decided to adjust treatment, targeted at the BP control improvement, by prescription of a triple FDC of amlodipine / indapamide / perindopril arginine. The prescription of the triple FDC of amlodipine / indapamide / perindopril arginine during the program is made by the doctor's decision according to the instructions for medical use of this FDC.~Presumably, each doctor will include 4 patients in average. It is planned to include 1,300 patients."
62785071|NCT04397562|EXPERIMENTAL|LVL group|Single subcutaneous administration of levilimab at a dose of 324 mg in combination with standard therapy
62785072|NCT04397562|PLACEBO_COMPARATOR|Placebo group|Single subcutaneous administration of placebo in combination with standard therapy
62785073|NCT06096662|EXPERIMENTAL|Experimental: Treatment group|"Participants will receive 35 hours of training, twice a week in ten weeks using Verb Network Strenghtening Treatment (VNeST).~Treatment will be administered by a speech-language pathologist thought an online platform."
62201370|NCT04912830||20 years follow-up after TVT surgery|Women who had tension free vaginal tape surgery during January 2001-December 2002 in Norway, identified in the National Incontinence Registry
62201371|NCT04912830||10 years follow-up after TVT surgery, age 42 or younger|Women who had tension free vaginal tape surgery and aged \< 42 years at the time of surgery during 2011-2012 in Norway, identified in the National Incontinence Registry
62201372|NCT02593877|EXPERIMENTAL|VHA algorithm|Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) and VHA-guiding further resuscitation with blood products and procoagulant factors
62201373|NCT02593877|NO_INTERVENTION|Control|Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) and conventional coagulation tests guiding further resuscitation with blood products and procoagulant factors
62201374|NCT05630729|OTHER|My Kidney Guru Intervention|Youth Participants with CKD will complete the 9 My Kidney Guru modules over the 6-month intervention period, at a rate of approximately one module every 2-3 weeks. Parent participants will complete the parent module within the first t2 weeks of the intervention period, and to review the remaining youth modules by the end of the trial period. Participants will complete outcomes measures within 1 month prior to beginning the intervention. Software usage data will be gathered regarding fidelity and dosage of the My Kidney Guru intervention. Within 1 month of completing the intervention period, participants will complete the same set of outcomes assessments, along with an evaluation survey of the intervention. Once post-intervention data collection has been completed and the intervention period has ended, participants will participate in a 45 minute follow up Web-Ex focus group to provide feedback on their experiences with My Kidney Guru and collect additional suggestions for improvement.
62201375|NCT06530927||Control Group|Patients without previous documented stroke
62201376|NCT06530927||Chronic Stroke Group|Patients with previous stroke ≥1year ago
62402065|NCT00903357|EXPERIMENTAL|Placebo first, then Montelukast|The group received placebo medication (ascorbic acid) for 8 weeks followed by a crossover to 8 weeks of active medication (montelukast 4 mg or 5mg once daily) after 2-weeks washout period.
62402066|NCT00852657|ACTIVE_COMPARATOR|Surgical treatment|Open or mini-open tendon repair with acromioplasty
62402067|NCT00852657|ACTIVE_COMPARATOR|Physiotherapy|Physiotherapy by exercises
62402068|NCT04156113|EXPERIMENTAL|Athletes Group|"The athletes group will be composed of healthy, non obese (body mass index \< 30), male basketball, volleyball and handball players aged between 18 and 35 years who have been training regularly for at least 3 months. Participants must not be regular consumer of cigarettes, alcohol, drugs and antioxidant substances.~Intervention: Yo-Yo intermittent recovery test (level 1) is administered."
62578920|NCT01677312|ACTIVE_COMPARATOR|25G FNA needle|Evaluate median number of passes to diagnosis (Diagnostic accuracy) and ability to procure histological samples using a 25G FNA needle when performing pancreatic biopsy.
62785074|NCT06096662|NO_INTERVENTION|Control group|"Participants in the control group will not receive speech-and-language treatment targeting word-finding.~Treatment for word finding will be provided by a speech-language pathologist after participation to the study."
62013168|NCT01310413|EXPERIMENTAL|Influenza A (H5N1) Virus monovalent vaccine 3-<9Y Group|Subjects aged at enrolment between 3 and 9 years, 9 years excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
62013169|NCT01310413|EXPERIMENTAL|Influenza A (H5N1) Virus monovalent vaccine 9-<18Y Group|Subjects aged at enrolment between 9 and 18 years, 18 years excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
62013170|NCT01310413|PLACEBO_COMPARATOR|Placebo 6-<36M Group|Subjects aged at enrolment between 3 and 36 months, 36 months excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly. For children aged up to 12 months, 12 months excluded (\< 12 months), Dose 1 was administered in the left anterolateral thigh and Dose 2 in the right anterolateral thigh. For children older than (\>=) 12 months, Dose 1 was administered in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
62201377|NCT06530927||Acute Stroke No Therapy Group|Patients with acute stroke, but without intravenous thrombolysis or mechanical thrombectomy
62201378|NCT06530927||Acute Stroke IVT only Group|Patients with acute stroke and intravenous thrombolysis
62201379|NCT06530927||Acute Stroke MT-Group|Patients with acute stroke and mechanical thrombectomy
62201380|NCT04089189|EXPERIMENTAL|IMP4297|100 subjects to receive IM4297 orally.
62215056|NCT05007080|EXPERIMENTAL|Group 1: Ad26.COV2.S Dose Level 1 (Lower Volume): 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 1 on Day 1 and placebo on Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination. Participants will receive booster vaccination at dose level 1 on Day 184.
62402069|NCT04156113|EXPERIMENTAL|Sedentary Group|"The sedentary group will be composed of healthy, non obese (body mass index \< 30), male aged between 18 and 35 years who have not been training regularly for at least 3 months. Participants must not be regular consumer of cigarettes, alcohol, drugs and antioxidant substances.~Intervention: Yo-Yo intermittent recovery test (level 1) is administered."
62402070|NCT01616992||Interstitial Cystitis|
62402071|NCT01616992||Myofascial Pelvic Pain|
62402072|NCT01616992||Healthy|
62785075|NCT03990428||Caregivers of Patients|This is an observational study of informal caregivers (ICs) of patients with Erdheim-Chester Disease (ECD) and other histiocytic diseases. That will collect data cross-sectionally, at a single time point. Caregiver-reported data will be completed in the form of online surveys by the participants themselves using the Research Electronic Data Capture Platform \[RedCAP\] platform.
62785076|NCT02735954||Marijuana Users|Individuals who use marijuana
62785077|NCT02735954||Combined Marijuana and Tobacco Users|Individuals who use marijuana and also smoke cigarettes
62013171|NCT01310413|PLACEBO_COMPARATOR|Placebo 3-<9Y Group|Subjects aged at enrolment between 3 and 9 years, 9 years excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
62785078|NCT02735954||Non-Marijuana Users|Individuals who do not use marijuana
62013172|NCT01310413|PLACEBO_COMPARATOR|Placebo 9-<18Y Group|Subjects aged at enrolment between 9 and 18 years, 18 years excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
62013173|NCT01310413|EXPERIMENTAL|Placebo/Influenza A (H5N1) adjuvanted Group|Subjects in this group were those who were administered the saline placebo solution in the Blinded Phase of the study (either in the Placebo 6-\<36M, Placebo 3-\<9Y or Placebo 9-\<18Y Group). These were subjects aged at enrolment between 6 months and 18 years, 18 years excluded, who had received 2 doses of saline placebo at Days 0 and 21 in the Blinded Phase of the study, as per described in the descriptions of the Placebo 6-\<36M, Placebo 3-\<9Y and Placebo 9-\<18Y groups. After consenting to participating to the Unblinded Phase of the study, these subjects received in addition 2 doses of Influenza A (H5N1) Virus monovalent vaccine at Days 385 (Day U0) and Day 385 + 21 days (Day U21). Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly. Dose 1 of was administered in the deltoid region of the non-dominant arm and Dose 2 in the deltoid region of the dominant arm.
62201381|NCT04508127||Active Procedure|The patients will receive targeted Percutaneous Spinal Cord Stimulation at suitable DRG with Axium SCS system as part of their standard treatment for lumbar pain. The lead placement will happen in 2 stages. First stage involves placement of leads and an externalised device and is a trial stage. Patient deemed to have a good response to first stage will proceed to the second stage to have the permanent implant. Again this is part of our standard care. Normally our drop out rate after first stage is less than 10% and these patients will not have subsequent tests including PET-CT scan and questionnaires.
62578921|NCT03107585|EXPERIMENTAL|bilateral cervical plexus block (GP1)|arm intervention GP1 : after skin disinfection and oral premedication , ultrasound guided cervical bilateral bloc ,with10 ml of bupivacaine 0.25 was realized in each side of deep cervical space; then general anesthesia was performed with local protocol
62578922|NCT03107585|PLACEBO_COMPARATOR|control(GP2)|GP2 control no specific intervention only general anesthesia was performed with local protocol
62785079|NCT03330639|EXPERIMENTAL|Experimental Group|This group will receive the capsaicin. The Study Drug ICX72 or sinus buster which is a homeopathic blend of capsicum annum and eucalyptol, that is readily available over the counter.
62785080|NCT03330639|PLACEBO_COMPARATOR|Placebo Group|This group will receive saline. The Placebo formulation contained saline and eucalyptol in a concentration that matched the control.
62785081|NCT03829722|EXPERIMENTAL|Nivolumab, Carboplatin/Paclitaxel, Radiotherapy|Therapy will continue for 21 weeks total. This includes 4 doses of of nivolumab (240mg/m2) before and concurrent with RT/carboplatin/paclitaxel and 4 adjuvant nivolumab doses (480mg/m2) after the end of RT.
62785082|NCT00603122|EXPERIMENTAL|1|fast ascent
62785083|NCT00603122|ACTIVE_COMPARATOR|2|slow ascent
62785084|NCT02473367|EXPERIMENTAL|Raltegravir Pre- and 4 Period Sequence|Starting five days prior to Period 1 participants will be treated with 1200 mg raltegravir, once daily for five days. In Period 1 participants will be treated with 1200 raltegravir alone; this is followed by Period 2 where participants will be treated with 1200 mg raltegravir and TUMS concomitantly; this is followed by Period 3 where participants will be treated with 1200 mg raltegravir and 12 hours later with Leader Antacid; followed by Period 4 where participants will be treated with 1200 mg raltegravir and 12 hours later with TUMS. The wait between Periods is 2-7 days.
62785085|NCT00475605||1. Protopic Exposure|Pediatric subjects whose ages are/were \<16 years at the time of first tacrolimus ointment exposure
62013174|NCT04866394|EXPERIMENTAL|Hypofractionated Pelvic Radiation|
62785086|NCT04429724|EXPERIMENTAL|health workers at hospital|Three blood samples will be taken at day 1, month 3 and month 6. A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.
62785087|NCT02609789|EXPERIMENTAL|Part A: Dose 1|Drug JNJ-55920839 or Placebo administered IV infusion Dose 1.
62785088|NCT02609789|EXPERIMENTAL|Part A: Dose 2|Drug JNJ-55920839 or Placebo administered IV infusion Dose 2.
62013175|NCT02504866|EXPERIMENTAL|Aerobic Exercise Intervention (AET)|Participant with traumatic brain injury performed aerobic exercise on an elliptical trainer at a vigorous intensity for 30 minutes three times a week for 12 weeks
62201382|NCT04651790|ACTIVE_COMPARATOR|Vaccine 0-14|Inactivated vaccine against SARS-CoV-2 2 doses on day 0 and 14
62201383|NCT04651790|EXPERIMENTAL|Vaccine 0-28|Inactivated vaccine against SARS-CoV-2 2 doses on day 0 and 28
62201384|NCT05063877|PLACEBO_COMPARATOR|Placebo|"Matched placebo control 10 mg capsule or 20 mg capsules totaling to 10 mg, 20 mg, 40mg or 60 mg will be administered once daily orally for 12 weeks with the option for open-label extension.~Intervention: Drug: Placebo"
62785089|NCT02609789|EXPERIMENTAL|Part A: Dose 3|Drug JNJ-55920839 or Placebo administered IV infusion Dose 3.
62785090|NCT02609789|EXPERIMENTAL|Part A: Dose 4|Drug JNJ-55920839 or Placebo administered IV infusion Dose 4.
62785091|NCT02609789|EXPERIMENTAL|Part A: Dose 5|Drug JNJ-55920839 or Placebo administered IV infusion Dose 5.
62785092|NCT02609789|EXPERIMENTAL|Part A: Dose 6|Drug JNJ-55920839 or Placebo subcutaneous injection Dose 6.
62785093|NCT02609789|EXPERIMENTAL|Part B|Participants will receive 6 doses of JNJ-55920839 or placebo (every 2 weeks) as an IV infusion.
62785094|NCT03222401|NO_INTERVENTION|Control Group|Control subjects will not receive an infusion or placebo
62785095|NCT03222401|EXPERIMENTAL|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
62785096|NCT03222401|EXPERIMENTAL|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
62785097|NCT03222401|EXPERIMENTAL|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
62785098|NCT06330207|EXPERIMENTAL|Intervention|ED providers who will test the clinical decision support tool when prescribing for patients with non traumatic dental conditions
62785099|NCT02022163|EXPERIMENTAL|Low dose of H7 VLP vaccine + Alhydrogel|Biological: Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
62201385|NCT05063877|EXPERIMENTAL|Study drug EQU-001|"10mg capsules or 20 mg EQU-001 capsules totally 10 mg, 20 mg, 40 mg, 60 mg will be administered once orally daily to active-treatment subjects for 12-weeks with the option for open-label extension. During the open-label extension, subjects taking 60 mg dose for 4 weeks or longer may increase to 80 mg per day dose, at the discretion of the PI.~Intervention: Drug : EQU-001"
62201386|NCT04225572|NO_INTERVENTION|Control Group|Patient will not receive physical therapy treatment or further instruction from the research team. The patient will receive standard care recommended by their medical provider which may or may not include physical therapy treatment.
62201387|NCT04225572|EXPERIMENTAL|Physical Therapy Group|
62578923|NCT04690231|EXPERIMENTAL|Apatinib+IE|
62201388|NCT03192475|ACTIVE_COMPARATOR|Group Lifestyle Balance plus phone contacts|Group Lifestyle Balance is the core behavioral lifestyle intervention delivered from 0-4 months using an in-person group format. The active comparator receives 8 additional sessions of group interactive telephone contact delivered from 5-12 months
62201389|NCT03192475|PLACEBO_COMPARATOR|Group Lifestyle Balance plus newsletter contacts|Group Lifestyle Balance is the core behavioral lifestyle intervention delivered from 0-4 months using in-person group format. The placebo comparator receives 4 additional educational newsletters delivered from 5-12 months.
62402073|NCT01616992||First Degree Relative|
62402074|NCT03792880|ACTIVE_COMPARATOR|Control arm|Usual follow-up in Healthcare System for patients with obstructive sleep apnea and CPAP treatment
62402075|NCT03792880|EXPERIMENTAL|Intervention arm|Usual follow-up in the Healthcare System for patients with obstructive sleep apnea and CPAP treatment and a telematic control and self-management program
62785100|NCT02022163|EXPERIMENTAL|Med dose of H7 VLP vaccine + Alhydrogel|Biological: Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
62785101|NCT02022163|EXPERIMENTAL|High dose of H7 VLP vaccine + Alhydrogel|Biological: High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
62785102|NCT02022163|EXPERIMENTAL|High dose of H7 VLP vaccine|Biological: High dose of H7 VLP vaccine, 2 doses given 21 days apart
62201390|NCT00512655|EXPERIMENTAL|1|Intervention: 5 week training program, 2 sessions per week (total of 10 sessions). Training includes both the patient and the caregiver. The training consists of two components: a cognitive and a physical component.
62201391|NCT00512655|NO_INTERVENTION|2|Usual care.
62402076|NCT04056234||Rheumatoid arthritis group|Patients with rheumatoid arthritis
62402077|NCT04056234||Control group|Patients with osteoarthritis / joint effusion.
62410076|NCT05990946|EXPERIMENTAL|Intervention Group|Participants randomized to the intervention group will complete ePRO symptom severity scores on the PSA-Lung questionnaire via the smartphone app on discharge and post-discharge days 3, 7, 14, 21, 28. Alerts are triggered if any of 5 core symptoms scored ≥4, prompting remote clinician feedback and guidance on symptom management.
62410077|NCT05990946|NO_INTERVENTION|Control Group|Participants randomized to the control group will complete ePRO symptom severity scores on the PSA-Lung questionnaire via the smartphone app on discharge and post-discharge days 3, 7, 14, 21, 28, without clinician alerts.
62410078|NCT06651762|EXPERIMENTAL|lumber epidural anesthesia|Patients will receive epidural anesthesia intra operative
62578924|NCT04690231|ACTIVE_COMPARATOR|IE|
62578925|NCT02954029|EXPERIMENTAL|Study group (transradial cohort)|device-assisted compression with ezClot pad
62578926|NCT02954029|EXPERIMENTAL|Study group (transfemoral cohort)|manual compression with ezClot pad
62578927|NCT02954029|ACTIVE_COMPARATOR|Control group (transradial cohort)|Rotary compression device
62578928|NCT02954029|ACTIVE_COMPARATOR|Control group (transfemoral cohort)|manual compression with BloodSTOP ix pad
62785103|NCT02022163|PLACEBO_COMPARATOR|Placebo|Placebo, 2 doses given 21 days apart
62785104|NCT03991429||Group 1|Patients with BPH and significant improvement in storage symptoms after BOO procedures
62785105|NCT03991429||Group 2|Patients with BPH who have persistent storage symptoms after BOO procedures
62785106|NCT03991429||Group 3 (Control group)|Men without LUTS who are planning to undergo radical prostatectomy
62578929|NCT00668980||Study group|20 infants with Down syndrome
62578930|NCT00668980||Control Group|15 typically developing children
62578931|NCT06106412|EXPERIMENTAL|GROUP 1 IONOMYCIN SIGMA|The oocytes obtained from the patients allocated to this group will be subdivided again in two groups Group 1a: Oocytes treated with SIGMA ionomycin (treatment). Group 1b: Oocytes that will not be treated with any activator (Control).
62785107|NCT00979927|PLACEBO_COMPARATOR|Saline|
62785108|NCT00979927|ACTIVE_COMPARATOR|SPC3649|
62785109|NCT06418659|EXPERIMENTAL|CD-801 treatment|The subjects with advanced HCC will be treated by CD-801 intravenously via a peripheral vein.
62785110|NCT00245037|EXPERIMENTAL|Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)|Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
62785111|NCT03002883|PLACEBO_COMPARATOR|Usual Care|"Students referred to student health for tobacco cessation resources including campus Quit Kits"
62785112|NCT03002883|ACTIVE_COMPARATOR|Brief Motivational Interviewing|Students received brief motivational interviewing by a student peer educator about tobacco cessation
62013176|NCT02504866|EXPERIMENTAL|Rapid-Resistive Exercise Intervention (RET)|Participant with traumatic brain injury performed rapid reciprocal exercise on an elliptical trainer at light to moderate intensity for 30 minutes three times a week for 12 weeks
62201392|NCT00871286|EXPERIMENTAL|CT scan (sinus) pre-tx|Sinus CT scan performed at initial otolaryngology (ear, nose, and throat)visit
62201393|NCT00871286|OTHER|CT scan (sinus) post-tx|Sinus CT scan performed after 3-4 weeks of antibiotic treatment and any other indicated medical treatment(s), per insurance company guidelines
62402078|NCT05277909|EXPERIMENTAL|The expert assessment of shoulder impairments and individualised treatment plan|Participants randomised to the Intervention group will be referred to an expert assessment of their shoulder impairments at the Shoulder Sector, Vejle Hospital - Orthopaedic Department. The expert assessment will be performed by experienced specialists (e.g. physician and physiotherapist) who are specialised in shoulder diagnostics using x-ray, ultrasound, anamnesis/history and standard clinical tests such as Neers, Hawkins, Jobe´s Empty Can, Painful Arc and Resisted External Rotation. The participant's diagnosis based on the history, symptoms and clinical findings will be used to guide the individualised treatment plan. The individualised treatment plan will typically contain a referral to physiotherapeutic treatment at the municipality or private practice, receive specialised physiotherapeutic rehabilitation at Vejle Hospital, get an ultrasound guided corticosteroid injection in the shoulder or offer surgery.
62402079|NCT05277909|ACTIVE_COMPARATOR|A minimal physiotherapeutic rehabilitation program delivered in a pamphlet|Participants randomised to the Control comparator group will receive a pamphlet from the secretary and perform the exercises at home. This pamphlet contains a program with minimal exercise recommendations for the shoulder consisting of mobility, stretching, strength exercises and tissue treatment. The purpose is to stimulate circulation, improve shoulder function (mobility), increase muscle strength and reduce shoulder pain. The program consists of three warm-up exercises (arm swing, shoulder rolling and scapula-back pocket exercise) followed by three stretching exercises for the breast and shoulder area. Furthermore the pamphlet includes a tissue treatment and four strength exercises for the shoulder (external rotation, extension and flexion of the shoulder and diagonal pull apart). Mobility (with 5-10 repetitions), stretching exercises (in 30 seconds) and tissue treatments will be performed twice a day, while the strength exercises will be performed once a day with 3x12 repetitions.
62402080|NCT05146999|ACTIVE_COMPARATOR|Active arm - QM1114-DP|a Botulinum Toxin Type A (BoNT-A)
62402081|NCT05146999|PLACEBO_COMPARATOR|Inactive arm - Placebo|
62402082|NCT05732610|EXPERIMENTAL|Individuals - ages 14 and older|This test is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older.
62402083|NCT05732610|EXPERIMENTAL|Individuals - ages 2 to 13|"This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples.~If the subject is under the age of 14, an adult lay-user will collect the sample."
62402084|NCT02177370|EXPERIMENTAL|Fenoterol metered dose inhaler (MDI)|
62402085|NCT02177370|ACTIVE_COMPARATOR|DSCG MDI|
62013177|NCT02504866|NO_INTERVENTION|Waitlist Control (CON)|Participant with traumatic brain injury were waitlisted and did not perform any exercise intervention in the first 12 weeks. They were randomized to either AET or RET after the initial 12 weeks
62013178|NCT03006666|ACTIVE_COMPARATOR|Control Group (Data Only)|The teams randomly allocated to the Control Group will not have access to CHWs.
62201394|NCT03021980|EXPERIMENTAL|SuperFIT|This is the intervention group. They will receive the intervention SuperFIT.
62013179|NCT03006666|EXPERIMENTAL|Intervention Group: (CHW Health Coaching Integrated into Team)|Teams randomly allocated to the Intervention Group will also receive regular panel data on their pre-DM patients and will have a CHW join the team, attend team meetings, and provide an outreach intervention to all prediabetic patients in the panel, as described below. CHWs and the researchers will provide regular updates to the team on these activities.
62201395|NCT03021980|NO_INTERVENTION|Control|This is the control group. Participants will receive 'care as usual' in this arm.
62201396|NCT04870008|ACTIVE_COMPARATOR|2 mm|The side of patient's scar that will receive the sutures placed at 2 mm from wound edge.
62201397|NCT04870008|ACTIVE_COMPARATOR|5 mm|The side of patient's scar that will receive the sutures placed at 5 mm from wound edge.
62201398|NCT06136104|EXPERIMENTAL|Mixhers HERTIME|1 daily powder stick packet (3.0-3.3 g) of Mixhers HERTIME herbal supplement mixed into water
62410079|NCT06651762|EXPERIMENTAL|lumber Epidural and unilateral genicular nerve ablation:|Patient will receive lumber epidural anesthesia and unilateral genicular nerve cooled radio frequency ablation pre-operative
62785113|NCT03002883|ACTIVE_COMPARATOR|Direct referral to quitline|Students were directly referred to the state quitline for follow-up counseling
62785114|NCT02346253|EXPERIMENTAL|Treatment (HDR brachytherapy, ADT and LHRH agonist therapy)|Patients undergo high-dose-rate brachytherapy over 2 fractions. Patients also receive ADT comprising bicalutamide PO QD. Patients may also receive LHRH agonist therapy comprising leuprolide acetate IM or SC, goserelin acetate SC, triptorelin pamoate IM, or degarelix SC for 4-6 months (intermediate-risk patients receiving ADT) or 6-36 months (high-risk patients) at the discretion of the treating physician.
62785115|NCT04253002|EXPERIMENTAL|Robinson's Culturally Adapted Coping with Stress Course|
62785116|NCT04253002|ACTIVE_COMPARATOR|Standard Care Control Condition|
62578932|NCT06106412|ACTIVE_COMPARATOR|GROUP 2 A23187|The oocytes obtained from the patients allocated to this group will be subdivided again in two groups Group 2a: Oocytes treated with A23187 (treatment). Group 2b: Oocytes that will not be treated with any activator (Control).
62578933|NCT00419848|EXPERIMENTAL|1|
62013180|NCT00803023|EXPERIMENTAL|1|Sodium Oxybate Oral Solution (4.5 grams)
62785117|NCT02153580|EXPERIMENTAL|Group I (lymphodepletion, cellular immunotherapy)|"LYMPHODEPLETING REGIMEN: Patients receive a chemotherapy regimen based on disease type and extent of disease comprising of cyclophosphamide, bendamustine hydrochloride, fludarabine phosphate, etoposide.~CELLULAR IMMUNOTHERAPY: Beginning 3-10 days later after lymphodepletion, patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes IV over 10-15 minutes on day 0. Patients with relapsed, residual or progressive disease may receive an optional second infusion of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes \>= 28 days post T cell infusion.~Disease status: Patients with Non-Hodgkin lymphoma (NHL)."
62013181|NCT00803023|EXPERIMENTAL|2|Sodium Oxybate taken as a combination of an Oral Solution and Placebo Tablets (4.5 grams)
62013182|NCT00803023|EXPERIMENTAL|3|Sodium Oxybate Oral Solution (6 grams)
62013183|NCT00803023|EXPERIMENTAL|4|Sodium Oxybate taken as a combination of an Oral Solution and Placebo Tablets (6 grams)
62013184|NCT05166122|ACTIVE_COMPARATOR|AI workflow|In AI work flow, patients will be screened by taking normal retinal images and all images will be assessed for the severity of diabetic retinopathy by a computerized artificial intelligence system immediately after the photograph is taken via the Internet and retinal images will be sent to the retinal ophthalmologist for overreading.
62013185|NCT05166122|NO_INTERVENTION|Manual workflow|Volunteers who have been screened by manual workflow will be screened by imaging the retina and image that are not normal will be sent to assess the severity of diabetic retinopathy by specialist staff.
62013186|NCT01478698|EXPERIMENTAL|Single dose|The first 5 consented participants will be administered t-PA 10mg + DNase 5mg instilled into a dialysate bag and infused for a 4 hour intraperitoneal dwell.
62013187|NCT01478698|EXPERIMENTAL|2 doses|The next 5 consented participants will be administered t-PA 10mg + DNase 5mg instilled twice a day for one day
62578934|NCT00419848|ACTIVE_COMPARATOR|2|
62578935|NCT04950270||Group|Critically ill adult patients meeting all eligibility criteria with MRI-based PRES diagnosis within the last 48 hours
62013188|NCT01478698|EXPERIMENTAL|4 doses|The next 5 consented participants will be administered tPA 10mg + DNase 5mg twice a day for 2 days.
62013189|NCT01478698|NO_INTERVENTION|control|Any potential participants that have not consented into the intervention arms will be approached to be consented into a non-intervention observational control group. A maximum of 5 participants will be recruited into this control group.
62013190|NCT05227079|ACTIVE_COMPARATOR|Group A (double bite forceps)|Participants in group A will proceed to have their biopsies during endoscopy taken with the conventional double bite forceps. Meaning, they will have two biopsies taken each time the forcep is passed through the endoscope. To obtain a total of six biopsies, the forceps will be passed through the endoscope a total of three times.
62013191|NCT05227079|EXPERIMENTAL|Group B (multiple bite forceps)|Participants in group B will have their biopsies during endoscopy retrieved with the multiple bite forceps. Meaning, they will have six consecutive biopsies taken with each pass through the endoscope.
62013192|NCT04337567|ACTIVE_COMPARATOR|Patients over 75 years_RF ablation|Patients randomized to receive pulmonary vein isolation by means of radiofrequency ablation.
62013193|NCT04337567|ACTIVE_COMPARATOR|Patients over 75 years_ballon cryoablation|Patients randomized to receive pulmonary vein isolation by means of ballon cryoablation.
62013194|NCT02436382|NO_INTERVENTION|Ambient Temperature of 67F|These patients will have an operating room temperature of 67F for cesarean delivery, the standard of care at our institution.
62013195|NCT02436382|ACTIVE_COMPARATOR|Ambient Temperature of 73F|These patient will have an operating room temperature of 73F for cesarean delivery, a temperature more consistent with WHO recommendations.
62013196|NCT06222996|EXPERIMENTAL|Arms|the experimental group will be given web page supported training created by the researcher
62013197|NCT06222996|NO_INTERVENTION|Control|there will be no interference
62578936|NCT03556839|ACTIVE_COMPARATOR|Arm A|Cisplatin 50mg/m2 or carboplatin AUC 5 + paclitaxel 175mg/m2+ bevacizumab 15mg/kg i.v D1 Q3W. Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologic therapy, namely bevacizumab, upon investigator discussion.
62578937|NCT03556839|EXPERIMENTAL|Arm B|cisplatin 50mg/m2 or carboplatin AUC 5 + paclitaxel 175mg/m2 + bevacizumab 15mg/kg + atezolizumab 1200mg i.v, D1 Q3W.Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologics therapy, namely bevacizumab plus atezolizumab, upon investigator discussion.
62578938|NCT04159454|EXPERIMENTAL|PITA Participants|"All patients in the study are part of the PITA arm, where PITA will be on for Weeks 0-8, and off from Weeks 8-12."
62785118|NCT02153580|EXPERIMENTAL|Group II (lymphodepletion, cellular immunotherapy)|"LYMPHODEPLETING REGIMEN: Patients receive a chemotherapy regimen based on disease type and extent of disease comprising of cyclophosphamide, bendamustine hydrochloride, fludarabine phosphate, etoposide.~CELLULAR IMMUNOTHERAPY: Beginning 3-10 days later after lymphodepletion, patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes IV over 10-15 minutes on day 0. Patients with relapsed, residual or progressive disease may receive an optional second infusion of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes \>= 28 days post T cell infusion.~Disease status: Patients with Chronic lymphocytic leukemia (CLL) and/or Prolymphocytic Leukemia (PLL)."
62785119|NCT03218176|ACTIVE_COMPARATOR|Proximal single upper limb|Laying a single tourniquet on the root of the upper limb
62201399|NCT06136104|PLACEBO_COMPARATOR|Placebo|1 daily powder stick packet (3 g) of a matching placebo powder supplement mixed into water
62201400|NCT00041457||Physicians' Health Study I|
62201401|NCT00041457||Physicians' Health Study II|
62201402|NCT00041457||Women's Health Study|
62201403|NCT00041457||Women's Antioxidant Cardiovascular Health Study|
62201404|NCT01055847|EXPERIMENTAL|AI 75 mg|Aztreonam for Inhalation 75 mg twice daily
62201405|NCT01055847|EXPERIMENTAL|AI 225 mg|Aztreonam for Inhalation 225 mg twice daily
62201406|NCT01055847|PLACEBO_COMPARATOR|Placebo|Placebo
62201407|NCT03794700|NO_INTERVENTION|Control|
62201408|NCT03794700|OTHER|Intervention|Participants will receive hospice decisional support materials and be asked to review them. Participants will provide feedback on tools and complete feasibility, efficacy and knowledge assessments.
62201409|NCT04609488||COVID|
62201410|NCT04609488||non-COVID|
62201411|NCT00669877|EXPERIMENTAL|Hyper-CVAD|Hyper-CVAD (odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses. Rituximab 375 mg/m2 days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses. Cyclophosphamide 300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3. Doxorubicin 50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses). Vincristine 2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses). Dexamethasone 40 mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses). G-CSF 10 mg/kg/day (rounded) until neutrophil recovery 1 x 10\^9/L or higher can be substituted or can be added to pegfilgrastim if neutrophils have not recovered to 1 x 10\^9/L by day 21.
62201412|NCT00280215|ACTIVE_COMPARATOR|1|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker. Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients \< 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients \< 40 kg) to be taken for 24 months.
62201413|NCT00280215|PLACEBO_COMPARATOR|2|Patients will take placebo for 24 months.
62201414|NCT03808792||Ovarian cancer patients|Patients with abdominal or pelvic mass suspicious of primary ovarian, tubal or peritoneal cancer submitted to the index test (Ultrasound, CT and WB/DWI-MRI) with perspective of primary surgery
62578939|NCT02642120|EXPERIMENTAL|Receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
62578940|NCT02642120|NO_INTERVENTION|Do not receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the control group.
62578941|NCT02454816|EXPERIMENTAL|Single HIV RDT and single syphilis RDT|It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
62578942|NCT02454816|ACTIVE_COMPARATOR|Dual HIV/syphilis RDT|It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
62201415|NCT03926195|EXPERIMENTAL|Filgotinib|Participants received filgotinib 200 milligrams (mg) tablet, orally, once daily up to Week 13 in the double-blind (DB) phase. At Week 13, participants who were arthritis responders, were unblinded and received open-label (OL) treatment filgotinib 200 mg, tablet, orally, once daily up to approximately 143 weeks (until Week 156) in the extension (EXT) phase and participants who were arthritis nonresponders discontinued blinded study drug and started standard of care (SOC) treatment in the EXT phase. Participants on DB treatment or OL filgotinib who entered the monitoring phase (if their sperm parameters met ≥50% decrease threshold in pre-specified semen parameters) discontinued the study drug and started SOC for up to 52 weeks.
62201416|NCT03926195|PLACEBO_COMPARATOR|Placebo|Participants received placebo (matched to filgotinib) tablet, orally, once daily up to Week 13 in the DB phase. At Week 13, participants were unblinded and started SOC treatment in the EXT phase for up to approximately 143 weeks (until Week 156). Participants who entered the monitoring phase (if their sperm parameters met ≥50% decrease threshold in pre-specified semen parameters) continued on SOC treatment.
62578943|NCT03512444|EXPERIMENTAL|Negative pressure|"Negative pressure system is applied with negative pressure (Active)~at a participant's unilateral arm"
62578944|NCT03512444|NO_INTERVENTION|No negative pressure|"Negative pressure system is applied without negative pressure (Inactive)~at a participant's contralateral arm"
62201417|NCT02459457|ACTIVE_COMPARATOR|Paclitaxel and Cisplatin (TP)|Patients receive TP concurrent with radiotherapy (1.8Gy/d, d1-5/week, 34Fx) Paclitaxel: 175mg/m2/d, ivgtt over 3 hours, d1; Cisplatin: 25mg/m2/d, ivgtt, d1-3, q4w\*4
62201418|NCT02459457|ACTIVE_COMPARATOR|Paclitaxel and Fluorouracil (TF)|Patients receive TF concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; 5-FU 300mg/m2, civ 96h, d1-4, qw\*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; 5-FU 1800mg/m2, civ 72h, d1-3, q4w\*2
62201419|NCT02459457|ACTIVE_COMPARATOR|Paclitaxel and Carboplatin（TC）|Patients receive TC concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=2, ivgtt, d1, qw\*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=5, ivgtt, d1, q4w\*2
62201420|NCT06317324||Surgery Group|Diagnosed as primary lung cancer by imaging/pathology, meeting the indications for surgical treatment; The clinical staging is cIB-IIIB stage (cT2-3N0M0), regardless of whether the staging is overestimated or underestimated as confirmed by pathology.
62201421|NCT06317324||SBRT Group|Diagnosed as primary lung cancer by imaging/pathology, meeting the indications for SBRT treatment; The clinical staging is cIB-IIIB stage (cT2-3N0M0), regardless of whether the staging is overestimated or underestimated as confirmed by pathology.
62201422|NCT04948762||Open|Patients who underwent an open approach to pelvic exenteration
62201423|NCT04948762||Laparoscopic|Patients who underwent a laparoscopic approach to pelvic exenteration
62201424|NCT04948762||Robotic|Patients who underwent a robotically-assisted pelvic exenteration
62201425|NCT03501953|EXPERIMENTAL|Nature Exposure|6-week physical activity course in a natural environment
62201426|NCT03501953|ACTIVE_COMPARATOR|Urban Exposure|6-week physical activity course in an urban environment
62201427|NCT03983967|EXPERIMENTAL|Immuncell-LC group|Adjuvant adoptive immune therapy using a CIK cell agent(Cytokine-Induced Killer cells; Immuncell-LC) 3 times(3 treatments at a frequency of once per week) or 6 times(3 treatments at a frequency of once per week followed by 3 treatments every 2 weeks)
62201428|NCT00429780|NO_INTERVENTION|Alum-ALM + BCG|Alum-ALM + BCG
62201429|NCT00429780|NO_INTERVENTION|Placebo|BCG diluent
62201430|NCT00569023|EXPERIMENTAL|A,1,I|
62201431|NCT01417624|PLACEBO_COMPARATOR|Control Group - Standard|"This will be a randomised controlled unblinded prospective study recruiting patients in sinus rhythm with LBBB (QRS width ≥ 120ms) and a LV ejection fraction of below 35% who meet the current guidelines for CRT implantation. Patients will be randomised to one of two groups (1:1 randomisation)~Conventional LV lead placement - the LV lead will be placed according to standard techniques without knowledge of the patient's CMR findings"
62578945|NCT05001542|EXPERIMENTAL|Experimental Arm|VR simulation exercise with a digital follow-up component to help assess the physiological and psychological indicators of moral distress
62578946|NCT02889939|OTHER|UC + ETT|"An enriched comprehensive task-specific therapy (ETT) program combining intensive and task-specific therapy with the sensory-motor, social, and cognitive stimulation inherent to environmental enrichment.~The intervention was preceded by a baseline period of usual care (UC) for 3 weeks, which also served as a control."
62578947|NCT06578286|EXPERIMENTAL|ARX788|ARX788，1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle
62578948|NCT04215003|ACTIVE_COMPARATOR|A|6 cycles of Paclitaxel,Carboplatin, Herceptin and Pertuzumab treatment with a good clinical benefit response depending on HR/HER-2 status.
62201432|NCT01417624|ACTIVE_COMPARATOR|Active CMR guided Arm|"This will be a randomised controlled unblinded prospective study recruiting patients in sinus rhythm with LBBB (QRS width ≥ 120ms) and a LV ejection fraction of below 35% who meet the current guidelines for CRT implantation.Patients will be randomised to one of two groups (1:1 randomisation):~CMR guided LV lead placement - an expert panel will decide pre-operatively the optimal branch of the coronary sinus for LV lead placement based on the presence of myocardial scar tissue and coronary sinus anatomy. The operator will informed as to the optimal vein to target for delivery of the LV lead. Should this be technically unfeasible (e.g. due to pacing considerations or stability of LV lead position), then the most suitable vein will be used at the time of implantation."
62201433|NCT05528523|OTHER|Writing a clinical narrative|The participants had to write a clinical narrative regarding a significant encounter with a patient.
62201434|NCT03513705|EXPERIMENTAL|Best practice|Enhanced implementation of best practices in pancreatic cancer care
62201435|NCT03513705|NO_INTERVENTION|Current practice|Pancreatic cancer care according to current practice
62201436|NCT01478997|EXPERIMENTAL|Flexsure Capsules|Investigational Product
62201437|NCT01478997|PLACEBO_COMPARATOR|Carboxy Methyl Cellulose Capsules|Placebo
62578949|NCT04215003|EXPERIMENTAL|B|2 cycles of Paclitaxel,Carboplatin, Herceptin treatment with a good clinical benefit response depending on HR/HER-2 status following surgery
62578950|NCT04215003|EXPERIMENTAL|CL4|HR+ and HER2-; No correlated pathway variation
62578951|NCT01861951|EXPERIMENTAL|Pazopanib|"Pazopanib 800 mg, p.o., daily~Duration of treatment:~Until disease progression, treatment failure, or death due to any cause, whichever occurs first"
62578952|NCT01861951|ACTIVE_COMPARATOR|Doxorubicin|"Doxorubicin 75 mg/m² BSA, d1, q3wk, i.v.~Duration of treatment:~Six cycles (approximately 18 weeks) or until disease progression, treatment failure, or death due to any cause, whichever occurs first"
62785120|NCT03218176|EXPERIMENTAL|Proximal staggered upper limb|Laying two staggered tourniquets : one on the root of the upper limb and a second 5 cm below the previous one
62785121|NCT03218176|EXPERIMENTAL|Distal single upper limb|Laying a single tourniquet on the forearm
62785122|NCT03218176|EXPERIMENTAL|Distal staggered upper limb|Laying two staggered tourniquets : one on the forearm and a second 5 cm below the previous one
62785123|NCT03218176|ACTIVE_COMPARATOR|Proximal single lower limb|Laying a single tourniquet on the root of the lower limb
62785124|NCT03218176|EXPERIMENTAL|Proximal staggered lower limb|Laying two staggered tourniquets : one on the root of the lower limb and a second 5 cm below the previous one
62785125|NCT03218176|EXPERIMENTAL|Distal single lower limb|Laying a single tourniquet on the calf
62785126|NCT03218176|EXPERIMENTAL|Distal staggered lower limb|Laying two staggered tourniquets : one on the calf and a second 5 cm below the previous one
62785127|NCT02650063|EXPERIMENTAL|DE-117 ophthalmic solution|
62785128|NCT01003652||Harmonic Focus /conventional haemostasis|
62785129|NCT01003652||Harmonic Focus|
62785130|NCT01003652||new surgical device|
62402086|NCT03026426|EXPERIMENTAL|CONEMO|"Participants in the intervention arm will receive a smartphone with CONEMO, an application with 18 sessions that are delivered 3 times a week for 6 weeks.~Additionally, all study participants, including those in the intervention arm, who present a high risk of suicide and/or have a PHQ-9 score ≥20 are referred to the system for follow up. Participants with lower levels of depressive symptoms receive the recommendation of going to a mental health professional."
62785131|NCT01003652||Harmonic Focus / conventional haemostasis|Harmonic Focus group refers to the use of ultracision shears for haemostasis and conventional haemostasis group refers to the tie-and-clamp technique in total thyroidectomy
62785132|NCT03113981|EXPERIMENTAL|ACTISURF-CERAFIT|Total hip arthroplasty (CERAFIT) grafted by PolyNass
62013198|NCT04485533|EXPERIMENTAL|VisuXL® Gel/HYLO®|Patients treated with VisuXL® ophthalmic gel for the first 30 days (1 treatment period) and with HYLO® for the second 30 days (2 treatment period).
62013199|NCT04485533|ACTIVE_COMPARATOR|HYLO®/VisuXL® Gel|Patients treated with HYLO® for the first 30 days (1 treatment period) and with VisuXL® ophthalmic gel for the second 30 days (2 treatment period).
62013200|NCT03864497||Orthotopic liver transplantation candidates|No intervention, imaging test and risk stratification as part of routine clinical care.
62013201|NCT00439140|EXPERIMENTAL|botulinum toxin Type A 200U|Botulinum toxin Type A 200U injection into the detrusor on Day 1 followed by a repeat botulinum toxin Type A 200U injection after a minimum of 12 weeks (if applicable).
62013202|NCT00439140|EXPERIMENTAL|botulinum toxin Type A 300U|Botulinum toxin Type A 300U injection into the detrusor on Day 1 followed by a repeat botulinum toxin Type A 300U injection after a minimum of 12 weeks (if applicable).
62013203|NCT00439140|OTHER|Placebo/botulinum toxin Type A 200U|Placebo (Normal Saline) injection into the detrusor on Day 1 followed by a botulinum toxin Type A 200U injection after a minimum of 12 weeks (if applicable).
62013204|NCT00439140|OTHER|Placebo/botulinum toxin Type A 300U|Placebo (Normal Saline) injection into the detrusor on Day 1 followed by a botulinum toxin Type A 300U injection (200U after discontinuation of 300U) after a minimum of 12 weeks (if applicable).
62013205|NCT05010759|EXPERIMENTAL|Ablation Arm|Subjects in this arm of the study will have focal ablation of the prostate cancer lesion with the NanoTherm technology. This ablation will be followed-up transperineal prostate biopsy at 4 months after treatment.
62201438|NCT05395195|EXPERIMENTAL|Erythropoietin|Intravenous or subcutaneous injections of erythropoietin (500 U/kg/dose). Total of 9 doses will be administered. First dose will be given within 6 hours of birth. Second dose between 12 to 24 hours from the first dose. Subsequent 7 doses every 24 hours from the second dose.
62013206|NCT02629146|EXPERIMENTAL|Midazolam|Drug: Midazolam (experimental)
62013207|NCT02629146|PLACEBO_COMPARATOR|Isotonic saline|Drug: Isotonic saline (placebo)
62013208|NCT02629146|ACTIVE_COMPARATOR|Fentanyl|Drug: Fentanyl (active comparator)
62201439|NCT05395195|SHAM_COMPARATOR|Control|Mock administration of injections (pretend) behind a screen by a dedicated personal
62201440|NCT02888574|EXPERIMENTAL|Intranasal Oxytocin|Oxytocin nasal spray delivered bi-daily over a 14-day period at 24-IU per dose
62201441|NCT02888574|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray containing the same ingredients as the active nasal spray minus the oxytocin and packaged in an identical bottle. To be delivered bi-daily over a 14-day period at 24-IU per dose
62201442|NCT03408977|EXPERIMENTAL|Men|
62201443|NCT03408977|EXPERIMENTAL|Women|
62402087|NCT03026426|NO_INTERVENTION|Control Group|Participants in the control group will receive enhanced usual care. Participants who present a high risk of suicide and/or have a PHQ-9 score ≥20 are referred to the system for follow up. Participants with lower levels of depressive symptoms receive the recommendation of going to a mental health professional.
62402088|NCT01115166||Cardiac surgery|Patients subjected to open cardiac surgery with the help of extracorporal circulation.
62785133|NCT03113981|ACTIVE_COMPARATOR|CERAFIT|Total hip arthroplasty (CERAFIT) with HydroxyApatite (HA) no grafted by PolyNass
62201444|NCT02080962|EXPERIMENTAL|30 Gy in 5 fractions of 6 Gy|tumors ≤ 2 cm in diameter: 5 fractions of 600 cGy, once a day, five times a week - TDF: 89
62201445|NCT02080962|EXPERIMENTAL|40 Gy in 10 fractions of 4 Gy|tumors \> 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
62785134|NCT02103972|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin
62785135|NCT02103972|ACTIVE_COMPARATOR|GM080|GM080
62785136|NCT01604291||Cohort|
62785137|NCT04039217|EXPERIMENTAL|Sample collection 2, 48, and 96 hours after first dose of Biktarvy|Participants in this study arm (Arm A) will provide biological specimens 2, 48, and 96 hours after the in-clinic dose of Biktarvy. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre-wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at one of the study visits.
62201446|NCT03473600|EXPERIMENTAL|study group|•The first group (20 patients) will be treated with cryotherapy using liquid nitrogen spray, two cycles each one 3-5 seconds, one session every two weeks, for three months.
62785138|NCT04039217|EXPERIMENTAL|Sample collection 4, 26, and 120 hours after first dose of Biktarvy|Participants in this study arm (Arm B) will provide biological specimens 4, 26, and 120 hours after the in-clinic dose of Biktarvy. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre-wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at one of the study visits.
62201447|NCT03473600|ACTIVE_COMPARATOR|control group|•The second group (20 patients) will be treated with intralesional injection of 4mg/ml/ session of triamcinolone-acetonide, it will be injected into deep dermis or upper subcutaneous tissue using a 0.5-inch long 30-gauge needle at multiple sites, 1 cm apart and 0.1 ml into each site, once every three weeks, for three months, using insulin syringes.
62201448|NCT04225481||SVF from healthy subjects from aesthetic plastic surgery|Subjects undergoing plastic surgery as scheduled by clinic routine to obtain waste adipose tissue
62201449|NCT04225481||OA patients|Subjects undergoing prosthetic surgery as scheduled by clinic routine to obtain waste synovium and cartilage
62201450|NCT01722370|PLACEBO_COMPARATOR|Medical air equivalent|Oxygen-nitrogen mix equivalent to medical air when inhaled from a cylinder at 2l/min
62201451|NCT01722370|EXPERIMENTAL|Oxygen|Ambulatory oxygen delivered at 2l/min on any activity performed by the patient, using a blinded cylinder
62201452|NCT04179916|EXPERIMENTAL|Healthy volunteers|Participants between 21 and 25 years, the Faculty of Physical Education and Physiotherapy of the Opole University of Technology Students
62201453|NCT06282653||Group 1|1st Year Students
62201454|NCT06282653||Group 2|2nd year students
62201455|NCT02153151||In vitro effect of AMP-514|Patients undergo blood sample collection at baseline, during the second week of RT, at the end of RT, and at 1 month after the end of RT
62201456|NCT01156376|EXPERIMENTAL|PO-019|Formula 12027-019 Mouthwash
62201457|NCT01156376|EXPERIMENTAL|PO-020|Formula 12027-020 Mouthwash
62201458|NCT01156376|ACTIVE_COMPARATOR|PO-116-A|Cool Mint Listerine
62201459|NCT06240013|EXPERIMENTAL|Group 1 Training Program|5 minutes of light aerobic cycling, unilateral 2\*60 sec on dominant leg - 2 min foam rolling training in total
62201460|NCT06240013|EXPERIMENTAL|Group 2 Training Program|5 minutes of light aerobic cycling, unilateral 4\*30 seconds on the dominant leg - 2 minutes in total proprioceptive neuromuscular facilitation stretching training
62201461|NCT02360735|ACTIVE_COMPARATOR|Control|Patients randomized to this arm will follow the current standard for post-operative care.
62201462|NCT02360735|EXPERIMENTAL|Experimental|Patients randomized to this arm will follow the current standard for post-operative care as well as 2 daily sessions of manual lymphatic drainage.
62201463|NCT01219907|EXPERIMENTAL|Arm I|"VACCINE THERAPY: Patients receive HER2 peptide vaccine intradermally once weekly for 3 weeks.~CHEMOTHERAPY: Patients receive cyclophosphamide IV on day -1.~IMMUNOTHERAPY: Patients receive ex vivo-expanded HER2 specific T-cell IV over 30 minutes on days 1, 10, and 20."
62201464|NCT00541177|EXPERIMENTAL|1|use 0.25% atropine once a week
62201465|NCT00541177|ACTIVE_COMPARATOR|2|use 0.5% tropicamide everyday
62201466|NCT01187381||Participants with Breast Cancer|Participants with early or metastatic HER2-positive breast cancer who were receiving treatment with trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines, will be observed. Dosing and treatment duration of the trastuzumab will be at the discretion of the treating physician.
62785139|NCT04039217|EXPERIMENTAL|Sample collection 24, 28, and 72 hours after first dose of Biktarvy|Participants in this study arm (Arm C) will provide biological specimens 24, 28, and 72 hours after the in-clinic dose of Biktarvy. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre-wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at one of the study visits.
62785140|NCT05860153|EXPERIMENTAL|Group (A)|• Group (A) will receive oral levetiracetam at a dose of 15-20 mg/kg/day twice daily at the onset of fever (temperature \>37.5 c) for 48h after subsiding of fever.
62201467|NCT00577070|ACTIVE_COMPARATOR|H1|"Includs 20 patients.These patients will be given 4 weeks (5 days a week) of deep TMS,20 minutes each session, to the left prefrontal cortex using H1 coil, in frequency of 20 HZ, with intensity of 120 % of motor threshold. H1-coil is an extracorporeal device positioned on the patient's scalp, designed to stimulate deep prefrontal brain regions, preferentially in the left hemisphere. The effective part of the coil, which has contact with the patient's scalp, includes 14 strips of 7-12 cm length. These strips are oriented in an anterior-posterior axis.This coil stimulates neuronal fibers in anterior-posterior orientation.~During deep TMS exposure patients will listen to a clinical interview in which they describe the different expressions of their depression including their ruminations and depressive schemas."
62215057|NCT05007080|EXPERIMENTAL|Group 2: Ad26.COV2.S Dose Level 2: 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 2 on Day 1 and placebo on Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination. Participants will receive booster vaccination at dose level 1 on Day 184.
62410080|NCT06651762|EXPERIMENTAL|Epidural and bilateral genicular nerve ablation|Patient will receive lumber epidural anesthesia and bilateral genicular nerve cooled radio frequency ablation pre-operative
62785141|NCT05860153|EXPERIMENTAL|Group (B)|• Group (B) will receive diazepam at a dose of 0.3 mg/kg/dose was given every eight hours for 48h after subsiding of fever Children were followed up for 12 months to find out seizure frequency associated with febrile events and febrile seizure recurrence rate during 12 months follow-up
62785142|NCT02465203|OTHER|Follow up from feeder studies|Follow up arm
62785143|NCT02544919|NO_INTERVENTION|Control group|No Intervention group: Patients do not receive any lipid emulsion of any type during the study period
62785144|NCT02544919|ACTIVE_COMPARATOR|SMOF Group|Intervention Group: Patients receive 1 gm.kg.day-1 SMOFlipid for 48 hours before the operation and 5 days post-operatively.
62785145|NCT04686383|EXPERIMENTAL|Cohort 1: 20 mg CAL056 mesylate|Patients will receive oral dose of 20 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
62785146|NCT04686383|EXPERIMENTAL|Cohort 2: 40 mg CAL056 mesylate|Patients will receive oral dose of 40 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
62201468|NCT00577070|EXPERIMENTAL|H2|Includs 20 patients.These patients will be given 4 weeks (5 days a week) of deep TMS, 20 minutes each session, to the prefrontal cortex bilateraly using H2 coil, in frequency of 0.1 HZ, with intensity of 120 % of motor threshold. H2-coil is designed to stimulate deep prefrontal brain regions bilaterally (without any preferencefor either hemisphere). The effective part of the coil, which has contact with the patient's scalp, includes 10 strips of 14-22 cm length.These strips are oriented in a right-left direction (lateral-medial axis).This coil is destined to stimulate lateral-medial neuronal fibers. During deep TMS exposure patients will listen to a clinical interview in which they describe the different expressions of their depression including their ruminations and depressive schemas.
62785147|NCT04686383|EXPERIMENTAL|Cohort 3: 80 mg CAL056 mesylate|Patients will receive oral dose of 80 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
62785148|NCT04686383|EXPERIMENTAL|Cohort 4: 120 mg CAL056 mesylate|Patients will receive oral dose of 120 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
62785149|NCT04686383|EXPERIMENTAL|Cohort 5: 160 mg CAL056 mesylate|Patients will receive oral dose of 160 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
62785150|NCT02682992|EXPERIMENTAL|Low Level Laser Therapy|Patients meeting the eligibility criteria will be enrolled to receive prophylactic LLLT in addition to standard of care measures for oral mucositis or other toxicity of therapy. The radiation and chemotherapy dose, schedule, modality, technique, and any required adjustments will not be influenced by this protocol and will follow standard existing institutional practices.
62201469|NCT01796379|EXPERIMENTAL|High Intensity Interval Training|
62785151|NCT04384055||Covid-19 Positive Patients|This group includes individuals who were diagnosed with Covid-19 based on reverse transcriptase polymerase chain reaction (RT-PCR) of the nasopharynx
62785152|NCT04384055||Covid-19 Negative Patients|This group includes individuals who did NOT have a positive test for Covid-19 based on reverse transcriptase polymerase chain reaction (RT-PCR) of the nasopharynx.
62201470|NCT01796379|OTHER|Moderate Training|Regular exercise training offered as usual care to all heart transplant recipients.
62785153|NCT06293768|EXPERIMENTAL|Group A continuous monitoring|Group A includes patients admitted to the acute ward who are considered transferable to the ward for subacute by the seventh day of hospitalization. These patients receive continuous telemonitoring of the patient's clinical condition for 5 days after transfer to the subacute ward
62785154|NCT06293768|NO_INTERVENTION|Group A standard monitoring|Group A includes patients admitted to the acute ward who are considered transferable to the ward for subacute by the seventh day of hospitalization. These patients receive standard telemonitoring of the patient's clinical condition for 5 days after transfer to the subacute ward
61978332|NCT02855216|EXPERIMENTAL|Manual technique of sub-occipital inhibition|"The technique applied to Manual Group was performed with the patient supine position. Physiotherapist in a sitting position at the head of the subject with forearms resting on the table . Suboccipital region was located , and flexing the metacarpophalangeal joints 90º a pressure was made ventrally , relaxing the rest of the head in the heel of the hand.~The technique was performed for 5 minutes"
62402089|NCT01578109|EXPERIMENTAL|Treatment (sorafenib tosylate and transplant)|Patients receive sorafenib tosylate PO BID beginning at least 30 days after completion of induction therapy and/or transplant and no more than 120 days after transplant continuing for up to 2 years after transplant in the absence of disease progression or unacceptable toxicity.
62402090|NCT05872113|PLACEBO_COMPARATOR|Placebo|The subjects who were on a placebo were put on the cream two times per day for 4 weeks. The questionnaire for testing the effects progressed when before using the cream, after 2 weeks, and after 4 weeks.
62785155|NCT06293768|EXPERIMENTAL|Group B continuous monitoring|Group B includes patients admitted to the acute ward who are considered dismissible by the seventh day of hospitalization. These patients receive continuous telemonitoring of the patient's clinical condition for 5 days after discharge to the home
62785156|NCT06293768|NO_INTERVENTION|Group B standard monitoring|Group B includes patients admitted to the acute ward who are considered dismissible by the seventh day of hospitalization. These patients receive standard telemonitoring of the patient's clinical condition for 5 days after discharge to the home
62785157|NCT04077515|ACTIVE_COMPARATOR|high blood concentration group|The blood concentration is maintained at 10-15ng/ml (not including 10ng/ml).
62785158|NCT04077515|EXPERIMENTAL|low blood concentration group|The blood concentration is maintained at 7-10ng/ml (including 10ng/ml).
62402091|NCT05872113|EXPERIMENTAL|Experiment|The subjects who were on experimental were put on the cream two times per day for 4 weeks. The questionnaire for testing the effects progressed when before using the cream, after 2 weeks, and after 4 weeks.
62402092|NCT02714413|PLACEBO_COMPARATOR|Sucrose 50g + placebo|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
62785159|NCT02622893|ACTIVE_COMPARATOR|Transperitoneal laparoscopic nephrectomy|Patients in this group underwent transperitoneal laparoscopic nephrectomy in 45-60º modified flank position after receiving epidural catheter in the sitting position before the surgery.
62785160|NCT02622893|ACTIVE_COMPARATOR|Retroperitoneal laparoscopic nephrectomy|Patients in this group underwent retroperitoneal laparoscopic nephrectomy in lateral decubitis position after receiving epidural catheter in the sitting position before the surgery.
62785161|NCT02119663|EXPERIMENTAL|Ruxolitinib plus capecitabine|
62201471|NCT01644084|EXPERIMENTAL|HA (priming)-HES (up to 15 ml/kg after CPB)|
62201472|NCT01644084|ACTIVE_COMPARATOR|HES (priming)-HES (up to 15 ml/kg after CPB)|
62201473|NCT01644084|ACTIVE_COMPARATOR|HA (priming)-nonHES (only crystalloids after CPB)|
62201474|NCT06381453|EXPERIMENTAL|Belimumab|200mg subcutaneous injection once a week
62201475|NCT00905320|ACTIVE_COMPARATOR|Metallic Fasteners and Sutures|Laparoscopic ventral hernia repair with mesh fixation using both metallic fasteners and transabdominal sutures
62201476|NCT00905320|EXPERIMENTAL|Metallic Fasteners Alone|Laparoscopic ventral hernia repair with mesh fixation using metallic fasteners alone
62201477|NCT03480477||Pelvic Floor Disorders Group|Will collect patient information from new patients who present to the Urogynecology Clinic
62013209|NCT04303260|ACTIVE_COMPARATOR|Interventional arm|"Patients in the interventional arm will be asked to complete 3 different videos repeatedly, as many days a week as possible. This repetition is to be maintained even if a patient missed one day of training.~The interventional exercise regimen will include specific exercises postulated to increase blood flow to the intestine and colon and thereby promote normal peristaltic s and decrease inflammation."
62013210|NCT04303260|PLACEBO_COMPARATOR|controled arm|"Patients in the controled arm will also be asked to practice generally recommended exercises in 3 different videos repeatedly, as many sets as possible..~The control arm will practice generally recommended exercises, without particular attention to the abdomen."
62013211|NCT04901884|EXPERIMENTAL|One arm / exploratory study|Injection of 18F-FDG.The 18F-FDG cardiac PET-MR scanning visit will take up to 1.5 hours.
62013212|NCT05561686||Pyrotinib-based combination therapy|Pyrotinib, 400mg po qd, 21 days/cycle
62013213|NCT02376127||pts with known spinal metastases|(20 patients from any solid cancer) who are to undergo radiation treatment (RT) will be recruited. The patients will undergo DCE-MRI before and after RT. RT will be classified as success based on evidence of tumor contraction on conventional MRIs, negative PET, or stability for more than 11 months and blinded from DCE MRI sequencing. For each patient, a scanning profile for the first scan will be saved and used for the follow-up scans to acquire the same locations over time. Each patient will be scanned 4 times (one pre-treatment and 3 follow up post treatment) during their consecutive clinical visits. The DCE MRI sequence is a part of MR sequences for standard care. No additional scans will be added in the standard clinical sequences.
62013214|NCT04381104|ACTIVE_COMPARATOR|Paracetamol|Capsule Paracetamol 1000 mg 1 hour before the mammography procedure
62013215|NCT04381104|PLACEBO_COMPARATOR|Placebo|The control arm will receive 2 capsules of placebo.
62201478|NCT03480477||Control Group|Will collect patient information from patients who present to Gynecologic Clinic for their annual examination
62201479|NCT03480477||Chronic Pelvic Pain Group|Will collect patient information from patients who present to their Chronic Pelvic Pain Clinic appointment
62402093|NCT02714413|EXPERIMENTAL|Sucrose 50g + D-allulose 2.5 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
62402094|NCT02714413|EXPERIMENTAL|Sucrose 50g + D-allulose 5.0 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
62402095|NCT02714413|EXPERIMENTAL|Sucrose 50g + D-allulose 7.5 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
62402096|NCT02714413|EXPERIMENTAL|Sucrose 50g + D-allulose10.0 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
62402097|NCT02899273||Dentistry students|Dentistry students of the University of Göttingen
62402098|NCT02899273||Psychology students|Psychology students of the University of Hildesheim
62402099|NCT03558906||Aggressive Periodontitis|These individuals had minimum PD ≥6 mm and CAL ≥5 mm on eight or more teeth; at least three of these were other than central incisors or first molars. Radiographic alveolar bone loss was ≥30% of root length affecting at least three permanent teeth other than first molars and incisors. The severe destruction pattern was not commensurate with amount of plaque accumulation.
62402100|NCT03558906||Chronic periodontitis|These individuals had at least four non-adjacent teeth with sites with PD ≥6 mm and CAL ≥5 mm. They had also ≥50% alveolar bone loss in at least two quadrants that was commensurate with amount of plaque accumulation. BOP was \>50% in the whole mouth.
62402101|NCT03558906||Gingivitis|Gingivitis patients exhibited no sites with CAL \>2 mm and no detectable alveolar bone loss in the radiography. BOP was \>50% in the whole mouth.
62402102|NCT03558906||Healthy|Periodontally healthy volunteers exhibited no sites with PD \>3 mm and CAL \>2 mm as well as no radiographic evidence of alveolar bone loss. BOP was \<15% in the whole mouth.
62013216|NCT02780349|EXPERIMENTAL|WIRION EPS|Single arm study. All patients undergo procedure with the WIRION EPS
62201480|NCT03342274|EXPERIMENTAL|Lifestyle Program Intervention|Participants receive usual care and group weight loss sessions adapted from the Diabetes Prevention Program delivered by Community Health Workers.
62201481|NCT03342274|OTHER|Wait list|Participants receive usual care and after 1 year receive the Lifestyle Program intervention
62201482|NCT00409721|EXPERIMENTAL|Memantine Low Dose|
62201483|NCT00409721|EXPERIMENTAL|Memantine High Dose|
62785162|NCT02119663|ACTIVE_COMPARATOR|Placebo plus capecitabine|
62201484|NCT01016262|EXPERIMENTAL|MAX-002|
62201485|NCT01016262|PLACEBO_COMPARATOR|Placebo|
62201486|NCT01016262|ACTIVE_COMPARATOR|Canasa®|
62201487|NCT04317391|EXPERIMENTAL|Pain management program|All enrolled patients participate in a 20 hour pain management program over a period of 8 weeks. The program is based on Mindfulness Based Stress Reduction with modifications to fulfill needs of the Taiwanese chronic pain population.
62201488|NCT02122575||1|Males and females between the ages of 21 and 37
62402103|NCT00576940|EXPERIMENTAL|IMEN: 1|Enteral nutrition with immunostimulating diet (IMEN group: formula supplemented with arginine, glutamine, omega-3 fatty acids)
62402104|NCT00576940|ACTIVE_COMPARATOR|SEN|postoperative enteral nutrition - standard oligopeptic diet
62402105|NCT00314275|EXPERIMENTAL|ENDEAVOR|Drug Eluting Stent
62402106|NCT06405048|EXPERIMENTAL|Mock-up fact-checking extension intervention group|"Intervention group participants will engage with three modules:~In Module 1, participants will examine six Weibo post screenshots, each featuring a mock-up of a Chinese fact-checking extension. Participants in the intervention group will assess a statement linked to the content of each post, which aligns with predefined HPV vaccine knowledge from section (b). Their response options will be: 1) Correct, 2) Incorrect, or 3) I don't know, taking into account both the post and the extension's feedback.~In the module 2, participants will review four additional Weibo post screenshots, two of which include false information. Responses will follow the same format used in Module 1.~In Module 3, participants will choose whether to view Weibo post screenshots with the fact-checking extension enabled or disabled. If they choose Yes, the screenshot will be displayed with the extension; if No, it will be shown without the extension."
62402107|NCT06405048|NO_INTERVENTION|Control group|"Control group participants will participate in three modules:~In Modules 1 and 2, they will review six and four Weibo post screenshots, respectively, without the mock-up Chinese fact-checking extension. Participants will evaluate statements linked to the content of each post, aligning with predefined HPV vaccine knowledge from section (b). Their response options will be: 1) Correct, 2) Incorrect, or 3) I don't know, based solely on the content of the posts.~In Module 3, participants will choose whether to view Weibo post screenshots with the fact-checking extension enabled or disabled. If they choose Yes, the screenshot will be displayed with the extension; if No, it will be shown without the extension."
62402108|NCT03000075|PLACEBO_COMPARATOR|Placebo (Part A)|Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
62402109|NCT03000075|EXPERIMENTAL|Risankizumab 75 mg (Part A)|Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
62013217|NCT04027660||Exposed Immediate Zirconia Implants|"Group Formation : patients that require a tooth extraction and have the following clinical indications to be enrolled in an immediate implant.~1. No Active Infection~2. No loss of buccal plate~3. ASA 1 or ASA 2 Patient~Extraction of the tooth will be performed and in the same clinical act, a zirconia dental implant will be placed toghether with a provisional or an individualized customs healing abutment. The jumping gap will be filled with a xenograft biomaterial.~Final Zirconia Crown delivered 3 month after healing.~3 STL files will be generated - Before extraction, at Final impression level 3 month after implant placement, at 3 month after final prosthesis insertion~Measure 1,2 and 3 will be at the gingival margin(measure 1), at 2mm (measure 2) and 4 mm (measure 3) apical to gingival margin. Both palatal and buccal references are joined by a line that gives a distance.Difference on the dimensions of each line with different time of evaluation represent ridge loss."
62201489|NCT03774810|EXPERIMENTAL|Continuous|Nightly active dose (QHS). The intervention is zolpidem tartrate 5 mg or 10 mg.
62402110|NCT03000075|EXPERIMENTAL|Risankizumab 150 mg (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
62402111|NCT04980196||(1) URODYNAEMICS GROUP|30 patients allocated for group (1) had been thoroughly evaluated by history and examination. A standardized questionnaire was obtained to evaluate the symptoms of stress urinary incontinence, urge urinary incontinence and obstructive symptoms. Clinical staging of pelvic organ prolapse by POP Q Staging .Ultrasound examination had been also carried out to rule out any pelvic pathology. Patients had completed a 3-day bladder diary (frequency volume chart) to assist in arriving at an urodynamic diagnosis. Urinalysis was performed. And to urodynamic studies were performed before surgical intervention and then corrective procedures for POP had been done uroflowmetry and cystometry. All participants were followed-up with same questionnaire and clinical examination after 12 weeks post -operatively
62402112|NCT04980196||(2)NON URODYNAMICS GROUP|30 patients allocated for group (2) had been thoroughly evaluated by history and examination. A standardized questionnaire was obtained to evaluate the symptoms of stress urinary incontinence, urge urinary incontinence and obstructive symptoms. Clinical staging of pelvic organ prolapse by POP Q Staging .Ultrasound examination had been also carried out to rule out any pelvic pathology. Patients had completed a 3-day bladder diary (frequency volume chart) to assist in arriving at an urodynamic diagnosis. Urinalysis was performed and then corrective procedures for POP had been done.All participants were followed-up with same questionnaire and clinical examination after 12 weeks post-- operatively
62410081|NCT05039931|EXPERIMENTAL|GNC-035|Patients receive GNC-035 as a 24-hour continuous intravenous infusion (cIV, QD) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles.
62785163|NCT04951466|EXPERIMENTAL|Mindfulness-based therapy for insomnia (MBTI)|Participants randomly assigned to the MBTI will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
62201490|NCT03774810|EXPERIMENTAL|Partial Reinforcement 1|1 active dose per week with 6 placebos interspersed between the active dose. The intervention is zolpidem tartrate 5 mg or 10 mg.
62201491|NCT03774810|EXPERIMENTAL|Partial Reinforcement 3|3 active doses per week with 4 placebos interspersed between the active doses. The intervention is zolpidem tartrate 5 mg or 10 mg.
62785164|NCT04951466|ACTIVE_COMPARATOR|Healthy Lifestyle Education|Participants in the control group will receive sessions on the following topics: Introduction to health promotion, disease prevention and screening, healthy eating, physical activity, communication, and endings.
62201492|NCT03774810|EXPERIMENTAL|Low Frequency Intermittent Dosing|1 to 3 active doses per week, on night chosen by participant (as needed). The intervention is zolpidem tartrate 5 mg or 10 mg.
62402113|NCT02956980|EXPERIMENTAL|Group 1: non-pubescent children|70 non-pubescent children (25 healthy boys, 25 healthy girls, 10 boys with Klinefelter syndrome and 10 girls with Turner syndrome) Two 7 ml tubes of blood will be taken to perform the functional assays as well as the quantification of Blood Plasmacytoid dendritic cells (pDCs) absolute number in this 70 non-pubescent children.
62402114|NCT02956980|EXPERIMENTAL|Group 2: pubescent healthy children|50 pubescent healthy children (25 boys and 25 girls) Two 7 ml tubes of blood will be taken to perform the functional assays as well as the quantification of Blood Plasmacytoid dendritic cells (pDCs) absolute number in this 50 pubescent healthy children.
62402115|NCT03310281|ACTIVE_COMPARATOR|ALK-T03|AKL-T03 is a digital intervention that requires the subject to navigate a character through a game-like space, while collecting objects, in a fixed period of time.
62402116|NCT03310281|ACTIVE_COMPARATOR|AKL-T09|AKL-T09 is a digital intervention that requires the subject to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time.
62402117|NCT05082922|NO_INTERVENTION|No treatment waiting period|Participants are randomized to a 4, 5, or 6 week waiting period. Weekly measurements are collected throughout this period.
62402118|NCT05082922|EXPERIMENTAL|Hybrid treatment|Hybrid treatment. Weekly measurements are collected throughout treatment.
62402119|NCT03661346|EXPERIMENTAL|Esmolol|Patients receiving esmolol when intra-operative MAP \> 80 mmHg.
62402120|NCT03661346|ACTIVE_COMPARATOR|Labetalol|Patients receiving labetalol when intra-operative MAP \> 80 mmHg
62201493|NCT02469142|EXPERIMENTAL|ADM tension-free hernia reparation|Use ADM to repair incarcerated inguinal hernia by tension-free
62402121|NCT01744834||18-year-old males|18-year-old males, representative random sample of the Dresden/Berlin (Germany) area, categorized as high and as low-risk drinkers respectively
62402122|NCT02612766|OTHER|Single Arm|This is a single-arm interventional study, in which each patient gets 50 grams/day of pure, uncontaminated oats
62402123|NCT04899570|EXPERIMENTAL|Zanubrutinib combined with R-CHOP|"The experimental arm will be treated zanubrutinib combined with R-CHOP regimen for 8 cycles. The interim evaluation will be performed after 4 cycles, and the patients who can't achieve PR or CR will be withdrawn from this trial and receive salvage regimens.~After 8 cycles of ZR-CHOP, the patients will be followed for 2 years to evaluate the PFS."
62402124|NCT01097174||CyPass Micro-stent|Patients in whom CyPass Micro-stent implantation was attempted.
62402125|NCT00919607|ACTIVE_COMPARATOR|1|quetiapine fumarate extended-release 300mg,administered once-daily Day1\~5
62402126|NCT00919607|EXPERIMENTAL|2|quetiapine fumarate extended-release 300mg/Day1,600mg/Day2\~6,administered once-daily
62201494|NCT02469142|PLACEBO_COMPARATOR|traditional tension hernia reparation|Just repair incarcerated inguinal hernia by nothing in tension condition
62402127|NCT00919607|EXPERIMENTAL|3|quetiapine fumarate extended-release 300mg/Day1,600mg/Day2,800mg/Day3\~7,administered once-daily
62402128|NCT01697124|EXPERIMENTAL|SPARK-EC|SPARK-EC curriculum for preschoolers offered instruction and practice in a comprehensive program designed to promote motor development through increased physical activity.
62402129|NCT00382499|EXPERIMENTAL|Lidocaine|IV lidocaine in OR as described in methods
62013218|NCT04027660||Non-exposed delayed Zirconia implants|"Group Formation : patients that require a tooth extraction and have the following clinical indications not to be enrolled in an immediate implant.~1. Active Infection~2. Loss of the buccal plate.~Extraction will be performed but a classical implant approach will be made, that include a waiting period of 3 month before implant placement and 3 month after osseointegration period before place final crown.~Implant placement with Guided bone regeneration (xenograft), if needed. Final Zirconia Crown 3 month after implant placement.~4 STL files will be generated - Before extraction, before implant placement, at Final impression level 3 month after implant placement, at 3 month after final prosthesis insertion~Measure 1,2 and 3 the same has the other group"
62402130|NCT02881866|ACTIVE_COMPARATOR|Air Hunger|"Previous studies have shown that inhaled furosemide relieves 'air hunger'.~Each volunteer has 3 mists per visit. The mists are either in the order of Furosemide-Saline-Furosemide or Saline-Furosemide-Saline. The furosemide mist is 40mg (10mg/ml) nebulised and the saline mist is 4ml nebulised.~Induced air hunger (hypercapnia with constrained ventilation) is the active comparator and will be the type of breathlessness induced, before and after each mist inhalation on one day. ."
62402131|NCT02881866|EXPERIMENTAL|Work Effort|Induced sense of breathing effort (raised ventilation with external resistive load) is the 'experimental arm' and will be the type of breathlessness induced, before and after each mist inhalation on the other day. .
62013219|NCT04372615|ACTIVE_COMPARATOR|Inebilizumab|"Approximately 58 patients will receive Inebilizumab in addition to first line immunotherapy.~(Approximately 116 participants will be randomized in a 1:1 ratio to 2 treatment groups; approximately 58 participants to each treatment group).~All participants will also receive a 3 day course of IVIg."
62013220|NCT04372615|PLACEBO_COMPARATOR|Placebo|"Approximately 58 patients will receive placebo in addition to first line immunotherapy.~(Approximately 116 participants will be randomized in a 1:1 ratio to 2 treatment groups; approximately 58 participants to each treatment group).~All participants will also receive a 3 day course of IVIg."
62013221|NCT06024954|EXPERIMENTAL|music group|"The research is planned as a randomized controlled trial. The individuals in the research group are divided into four groups as music group, aromatherapy group, music and aromatherapy and control group. The relaxing music group will listen to specially composed MusiCure® compositions in soft rhythm, including melodies with harp, cello, strings and natural sound elements (eg rain, bird, forest sound). The patients in the experimental group will listen to the music with headphones for 20 minutes for three consecutive days.~Before and at the end of the intervention, data collection tools \[Patient Description Form, Vısual analog scale, facial anxiety scale , Distress Thermometer, Edmonton Symptom Scale\] will record the characteristics of pain, anxiety and vital parameters."
62013222|NCT06024954|EXPERIMENTAL|aromatherapy group|"Patients in the aromatherapy group use 5% lavender oil with a diffuser for 15-20 minutes in accordance with the Aromatherapy-Clinical Guideline For Midwives. NHS.~Trust 1-15) has been applied. The diffuser was placed 30 cm from the participants and five (5) drops of essential lavender oil were placed on the filter paper. Within 10-15 minutes after the completion of the inhalation, data collection forms were applied again, and pain, anxiety, blood pressure, pulse and respiratory rate were evaluated."
62013223|NCT06024954|EXPERIMENTAL|aromatherapy and music group|Inpatients in the palliative care service will be given music with headphones for three consecutive days with the effect of aromatherapy inhaler. Within 10-15 minutes after the completion of the inhalation, data collection forms will be applied again and pain, anxiety, blood pressure, pulse and respiratory rate will be evaluated.
62013224|NCT06024954|NO_INTERVENTION|control group|Participants were not interfered with.
62013225|NCT00529932|ACTIVE_COMPARATOR|1|Enriched CD133+, bone marrow-derived, autologous progenitor cells for this trial will be infused in the coronary arteries
62013226|NCT00529932|PLACEBO_COMPARATOR|2|Control group patients will receive 3 injections of 0.3 mL each of buffered normal saline (the vehicle used for cell suspension) into comparable vessels. Subjects will have an identical intra-coronary injection procedure to those randomized to autologous CD133+ progenitor cell injections.
62013227|NCT06270121|EXPERIMENTAL|Living-lab digital intervention group|Digital devices (wearable and motion sensor) and mobile application will be utilized to monitor mental and physical health status and provide daily individualized health status information to an older adult user and their community and family caregivers. The older adult users are also asked to participate in pre-mid-post surveys to evaluate health, usability, effectiveness, and safety of the developed platform service.
62013228|NCT06270121|NO_INTERVENTION|Control group|The participated in the control group are asked to participate in pre-mid-post surveys to evaluate health status.
62402132|NCT05603975|ACTIVE_COMPARATOR|EsKetamine Group|"The Esketamine was administered intravenously at 0.1mg per kilogram of body weight 1min before the dressing change.~Esketamine Hydrochloride Injection 2ml：50mg"
62402133|NCT05603975|PLACEBO_COMPARATOR|Control Group|
62402134|NCT01226992|EXPERIMENTAL|Fecal Transplant|2 weeks of oral vancomycin pre-treatment followed by single dose fecal transplant administered by rectal enema. Fecal transplant (slurry) consists of 50 grams healthy donor stool blended in 500ml of Normal Saline.
62402135|NCT01226992|ACTIVE_COMPARATOR|Oral Vancomycin Taper|2 weeks of oral vancomycin pre-treatment followed by 6-week taper of oral vancomycin
62785165|NCT04791618|ACTIVE_COMPARATOR|Health360x only (High tech)|"Access to Health360x technology only for 6 months Behavioral: Health360x Participants will receive Access to health360x which provides monitoring, in the moment color coded feedback and goal setting for self- management skills. Every participant will view an orientation video which will include information on how to access Health360 from home and other internet connected devices; how to use activity monitors provided by the study and sphygmomanometer. They will receive an introduction to heart health curriculum, quizzes and discussion forums. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the Helath360x application will be available online and by phone.~The Health360x application will send messages to participants in this arm reminding them to perform study related activities."
62785166|NCT04791618|EXPERIMENTAL|Health360x plus Coach (High tech High touch)|"Health360x technology plus health coach Behavioral: Health360x plus health coach Participants will receive all of the resources in Arm A and Health coach interactions.~The Health coach will send messages to participants in this arm reminding them to perform study related activities. The coach interactions will be focused on helping with attainment of self- management behaviors"
62785167|NCT00042991|EXPERIMENTAL|Treatment (gefitinib and radiation therapy)|"Phase I portion: Patients receive oral gefitinib once daily. Treatment repeats every 4 weeks for 13 courses (1 year). Patients also receive standard brain irradiation once daily, 5 days a week, for 6 weeks beginning concurrently with initiation of the first course of gefitinib. Treatment continues in the absence of disease progression or unacceptable toxicity.~Phase II portion: Once the MTD or the recommended Phase-II dose is determined, additional patients who have newly diagnosed BSG are treated at the MTD or the recommended Phase-II dose."
62785168|NCT04770948|EXPERIMENTAL|19G|19 gauge EBUS-TBNA needle
62201495|NCT05278819|EXPERIMENTAL|upper extremity elevation|performing intervention A (5 repetitions of upper extremity elevation), and then crossed over to intervention B (5 repetitions of upper extremity with deep breathing).
62201496|NCT05278819|EXPERIMENTAL|upper extremity elevation with deep breathing|performing intervention B (5 repetitions of upper extremity with deep breathing), and then crossed over to intervention A (5 repetitions of upper extremity elevation).
62201497|NCT05953649|ACTIVE_COMPARATOR|Control group|In the control condition, patients received conventional physiotherapy (CPT) according to standard clinic procedures.
62201498|NCT05953649|EXPERIMENTAL|experimental group 1|the experimental group uses Extracorporeal Diaphragm Pacing (EDP) on the basis of the control group.
62402136|NCT02917421|EXPERIMENTAL|Cohort 1|"(Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.~Radiation therapy : Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost."
62201499|NCT05953649|EXPERIMENTAL|experimental group 2|the experimental group used Extracorporeal Diaphragm Pacing (EDP) combined with Tilt Table Verticalization (TTV) on the basis of the control group.
62201500|NCT04659824||Healthy|
62201501|NCT05359887|EXPERIMENTAL|Unsuccessful BS (Total Weight Loss (TWL) < 20%)|Fifteen who had unsuccessful BS (Total Weight Loss (TWL) \< 20%)
62201502|NCT05359887|EXPERIMENTAL|Successful BS (TWL > 25%).|Fifteen who had successful BS (TWL \> 25%).
62402137|NCT02917421|EXPERIMENTAL|Cohort 2|"In addition to receiving radiation to the original tumor bed, patients will also receive radiation to Level III axillary nodes and Supraclavicular nodes: 3D-CRT or IMRT at 2.7 Gy X 15 fraction (40.50 Gy)~Radiation Therapy : Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost."
62402138|NCT02997852|EXPERIMENTAL|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
62402139|NCT02997852|NO_INTERVENTION|Control|Usual care in the intensive care unit.
62785169|NCT04770948|ACTIVE_COMPARATOR|22G|22 gauge EBUS-TBNA needle
62785170|NCT01726218||Stroke patients|
62785171|NCT01726218||Healthy Control|
62201503|NCT05167422|EXPERIMENTAL|Trusted Messenger|"The trusted messenger patient intervention will involve training a small number of staff trusted messengers to engage patients informally and assist with building vaccine confidence in brief one- on-one sessions, supported by trusted messengers weekly consultations with a content expert who can answer specific vaccine related questions that patients have over a 3-week period. Trusted messengers will be full time unit employees, selected with the assistance of the nursing supervisor for having excellent rapport with patients (assessed with the Nurse Coordinator Questionnaire) and for having been vaccinated. Mental health workers or nurses may serve in this role. Both inpatient units involved in this study will be grouped into the same vaccination cohort within the hospital, to provide patients in the intervention and the wait list similar opportunities to be vaccinated."
62201504|NCT05167422|NO_INTERVENTION|Standard Care|After a 3-week study period, up to 24 patients on the second unit will receive the trusted messenger intervention and followed for a period of 3 weeks. The trusted messenger intervention will consist of staff who are trained to engage patients informally and assist building social norms for vaccine uptake supported by weekly and as-needed check-ins with a content expert who can answer specific vaccine related questions over a 3 week period.
62201505|NCT01375998||Group 1|
62201506|NCT00438672|ACTIVE_COMPARATOR|Dequervains|The de Quervain's injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and DeQuervain's is also fairly uncommon. Therefore, the trial wasn't feasible for this diagnosis.
62201507|NCT00438672|ACTIVE_COMPARATOR|Lateral Epicondylitis|
62201508|NCT00438672|ACTIVE_COMPARATOR|CMC Arthritis|The CMC Arthritis injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and it was decided that the trial wasn't feasible for this diagnosis.
62201509|NCT00581893|EXPERIMENTAL|1|Phenytoin administration
62201510|NCT00581893|PLACEBO_COMPARATOR|2|Placebo
62201511|NCT00560846|EXPERIMENTAL|Nutrition|Pre-operative immunonutritrion, pre-operative glucose load, post-operative early immunonutrition
62201512|NCT00560846|NO_INTERVENTION|Control|No immunonutrition, no glucose load, no early enteral immunonutrition
62201513|NCT05926778||Fibrosis Cohort|Adult(10 patients) and pediatric(10 patients) liver transplant recipients with fibrosis determined by histological examination of liver biopsy
62578953|NCT03194880||HIV testing|At each visit, the DIC HIV testing algorithm will be performed, and additionally, HIV testing by the Anonymous Clinic Algorithm, the Alere™ HIV Combo and the Alere™ q HIV-1/2 Detect. The latter two tests will be performed at the DICs. In case of an invalid result for the Alere™ HIV Combo or the Alere™ q HIV-1/2 Detect, the test will be repeated. If the repeated test is invalid after the second attempt, it is recorded as 'invalid result'.
62578954|NCT02995174|EXPERIMENTAL|Intervention (dichoptic video game play)|Mild amblyopic subjects will be asked to play dichoptic video game in an i-Pod touch device for 1 hour per day in 6 weeks.
62578955|NCT02995174|PLACEBO_COMPARATOR|Control (video game play)|Mild amblyopic subjects will be asked to play video game in an i-Pod touch device for 1 hour per day in 6 weeks.
62578956|NCT05498441|EXPERIMENTAL|Personalized HD-tDCS|"The experimental arm will receive the personalized HD-tDCS treatment with parameters as follows:~1. Neuroimaging biomarker-guided personalized selection for central electrode polarity: anode or cathodal;~2. Neuroimaging biomarker-guided personalized selection for stimulation site: dorsalmedial prefrontal cortex or occipital cortex;~3. Schedule: 2 sessions per day, five days per week for a total of 20 sessions over 2 weeks."
62013229|NCT05323383|EXPERIMENTAL|Mindfulness meditation|Participants in the mindfulness meditation condition will practice one, 20-minute breath and body focused meditation.
62013230|NCT05323383|ACTIVE_COMPARATOR|Self-Hypnosis|Participants in self-hypnosis will practice one, 20-minute audio-guided hypnosis session with suggestions tailored towards enhancing positive affect and fostering decentering.
62201514|NCT05926778||Control Cohort|Adult(20 patients) and pediatric(20 patients) liver transplant recipients without fibrosis determined by histological examination of liver biopsy
62201515|NCT02712749|EXPERIMENTAL|Group A : Sound with Binaural Beats|"Acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz through generated by the software Gnaural in stereo option"
62578957|NCT05498441|ACTIVE_COMPARATOR|Routine HD-tDCS|Routine stimulation arm will receive the same scheme of HD-tDCS, but the stimulation target is L-DLPFC with anode as central electrode.
62201516|NCT02712749|ACTIVE_COMPARATOR|Group B : Sound without Binaural Beats|"Acoustic frequencies of 256 Hz in both ears to perceive one tone without beats generated by the software Gnaural in mono option"
62201517|NCT04851353|ACTIVE_COMPARATOR|GT+VC|Gentle touch +Verbal comfort
62201518|NCT04851353|EXPERIMENTAL|GT+VC+Smell|Gentle touch +Verbal comfort+ Smell breast milk
62201519|NCT04851353|EXPERIMENTAL|GT+VC+Smell+Taste|Gentle touch +Verbal comfort+ Smell breast milk+ Taste milk
62201520|NCT05976139|EXPERIMENTAL|inherited retinal dystrophies with macular oedema|"Laser treatment will be performed in patients with macular edema in IRD (experimental arm) who:~* underwent treatment with diuretics or nutritional drainage products for 3 months and subsequent 'wash-out' of one month 17,18 and had no reduction in macular oedema, in terms of central retinal thickness, of at least 20% compared with the initial assessment~* they have had an intravitreal injection of anti-VEGF or steroids, and after 3 months there is no reduction in central retinal thickness (CRT) of at least 20% compared to the initial assessment~* have after 3 months a thickness reduction \<10% compared to baseline assessment, following initial treatment with micropulsed laser, and may be candidates for repeating treatment;~* are not eligible for diuretic therapy due to the presence of comorbidities."
62201521|NCT04489810|PLACEBO_COMPARATOR|Meal A + Placebo|350 mg Placebo capsule, taken by mouth, once, with Meal A
62201522|NCT04489810|EXPERIMENTAL|Meal A + Elevase®|350 mg Elevase® capsule, taken by mouth, once, with Meal A
62201523|NCT04489810|EXPERIMENTAL|Meal A + DE111®|350 mg DE111® capsule, taken by mouth, once, with Meal A
62578958|NCT04844749|EXPERIMENTAL|Either VERU-111 32mg or 26mg dose will be supplied as capsules 1 orally once a day|32mg of VERU-111 26mg of VERU-11
62578959|NCT04844749|ACTIVE_COMPARATOR|Active control alternative androgen receptor targeting agent|The alternative androgen receptor targeting agent will be administered according to the dosing instructions in the current product prescribing information.
62578960|NCT05577208|EXPERIMENTAL|renal denervation|Renal denervation shall be performed by echo-guided catheterization of the femoral artery, and subsequent cannulation of the renal arteries with a guide catheter. A renal denervation catheter shall be advanced through the guide catheter to the distal portion of the artery. The procedures shall be aimed to deliver as many radiofrequency applications as possible, 0.5 cm apart, intended duration of 60 sec, to all four quadrants of the renal arteries and main branch vessels with \> 3 mm diameter.
62578961|NCT02757833|OTHER|Late Life Depressed Arm|Participants in the Late Life Depressed arm will have a confirmed diagnosis of late-life depression.
62578962|NCT02757833|OTHER|Healthy Control Arm|Participants in the Healthy Control Arm will have no history of mental illness.
62578963|NCT05932693|EXPERIMENTAL|WS-3 (1), no nicotine|WS-3 block: 0.05%
62201524|NCT04489810|EXPERIMENTAL|Meal B + Placebo|350 mg Placebo capsule, taken by mouth, once, with Meal B
62402140|NCT01876901|EXPERIMENTAL|2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)|Patients treated with 2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) in centers who routinely performing this intervention.
62402141|NCT01876901|EXPERIMENTAL|Colo-anal anastomosis (CAA)|Patients operated with colo-anal anastomosis (CAA) in centers who routinely performing this intervention.
62402142|NCT03131375|ACTIVE_COMPARATOR|Group A|In Group A: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group A receives a 50 ml NS infusion containing the drug Dexmedetomidine 1 mcg kg-1 slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.16 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.
62402143|NCT03131375|PLACEBO_COMPARATOR|Group B|In Group B: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group B receives a volume matched normal saline infusion slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.2 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.
62402144|NCT00061269|EXPERIMENTAL|VARD|Videoscopic-Assisted Retroperitoneal Debridement (VARD)
62402145|NCT00660101|EXPERIMENTAL|1|5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
62402146|NCT00660101|EXPERIMENTAL|2|2.5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
62402147|NCT00660101|EXPERIMENTAL|3|0.5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
62402148|NCT02391194|EXPERIMENTAL|AVB-620|Eligible subjects will receive a single dose of AVB-620 as an intravenous infusion before the surgical procedure.
62402149|NCT05100693|EXPERIMENTAL|Procedure FETO with the Smart-TO balloon|Fetal endoscopic tracheal occlusion using the Smart-TO balloon. Balloon removal procedure by peripheral course around the MR scanner
62402150|NCT00379639|EXPERIMENTAL|Romidepsin / Gemcitabine|Participants were to receive 7, 10 or 12 mg/m\^2 of romidepsin intravenously on either Days 1, 8 and 15 (Schedule A) or Days 1 and 15 (Schedule B) of each 28-day cycle, followed by 800 or 1000 mg/m\^2 of gemcitabine. Subsequent doses of both drugs were based on treatment-related toxicities. The planned duration of study therapy was 6 cycles or until disease progression occurred. Patients who responded could continue beyond 6 cycles until disease progression or until a withdrawal criterion was met.
62402151|NCT03704285||Propofol|Severe burn adult under general anesthesia with propofol + remifentanil evaluation of propofol effect using BIS
62013231|NCT05323383|OTHER|Control|Participants in the attention control condition will listen to a 20-minute natural history recording.
62402152|NCT05921539|EXPERIMENTAL|hydrodilatation and axillary nerve injection|patient received ultrasound-guided steroid hydrodilatation via posterior recess
62402153|NCT05921539|ACTIVE_COMPARATOR|hydrodilatation only|patient received ultrasound-guided steroid hydrodilatation only
62402154|NCT04276532|EXPERIMENTAL|Sentinel lymph node sampling|Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN)
62402155|NCT04276532|ACTIVE_COMPARATOR|Pelvic lymphadenectomy|Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with para-aortic sampling
62013232|NCT05394337|EXPERIMENTAL|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg Q3W (1200 mg on Day 1 of each 21 day cycle),
62013233|NCT05394337|EXPERIMENTAL|Tiragolumab|Tiragolumab will be administered at a fixed dose of 600 mg intravenously Q3W on Day 1 of each 21-day cycle.
62402156|NCT04842318|EXPERIMENTAL|BR+R|Induction Therapy: Rituximab Combined With Bendamustine Maintenance Treatment: Rituximab
62402157|NCT04842318|EXPERIMENTAL|RCHOP+R|Induction Therapy: Rituximab Combined With Cyclophosphamide, Vincristine, Doxorubicin, Prednisone Maintenance Treatment: Rituximab
62201525|NCT02923791|EXPERIMENTAL|Filgrastim Hospira|
62402158|NCT04842318|EXPERIMENTAL|R2+R2|Induction Therapy: Lenalidomide Combined With Rituximab Maintenance Treatment: Lenalidomide Combined With Rituximab
62410082|NCT04155775|EXPERIMENTAL|Best Practice Alert|Platelet transfusion orders for patients with a recent platelet count exceeding 50,000 per microliter (50k/uL) will trigger an alert in the electronic health record that displays current guidelines for platelet transfusion. The alert will allow providers to bypass the recommendation and continue with platelet ordering by selecting a clinical acknowledgement / exception to recommendation.Exclusions will be built into the alert to avoid triggering in operative or procedural settings, for neurosurgery providers, or patients on anti-platelet medications.
62201526|NCT02923791|ACTIVE_COMPARATOR|US-Approved Neupogen|
62201527|NCT01584960|EXPERIMENTAL|Prostate cancer, endurance training|Prostate cancer patients doing 2 years of home-based endurance training Cross over design with a control group with no intervention
62201528|NCT00033618|EXPERIMENTAL|Arm I (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62578964|NCT05932693|EXPERIMENTAL|WS-3 (2), no nicotine|WS-3 block: 0.1%
62785172|NCT05843929|EXPERIMENTAL|Group with Laser speckle contrast imaging technique (LSCI) and 3D foot creator use|"The proposed solution is based on the process synthetized in, and hereafter described:~* A technician delivers a service at the home of the diabetic patient, who may be subject to different risk of ulcer, with the aim to analyse his/her foot through an integrated set of measurement technologies, based on:~  * the piezoelectric insole that replaces missing pain sensation;~ * Laser speckle contrast imaging technique (LSCI) that measures the blood flow;~ * the multi points temperature device.~* Data collected by the technician are sent via internet to the reference Hospital or Primary Care Unit where a specialist physician evaluates the acquired information;~* On the basis of the clinical evaluation and doctor's report on points of foot sensitivity, a 3D model of the foot is created and used by the chiropodist;~* Using the 3D model of the foot, the chiropodist uses a 3D Editor to design the 3D Model of the insole"
62785173|NCT05843929|NO_INTERVENTION|Group not use laser speckle contrast imaging technique (LSCI) and not use 3D foot creator use|"* The patients of this group will be visited in the hospital:~* An assessment of the patient's risk of presenting problems due to diabetic foot will be carried out.~* In this group, the control measures will be established within the usual practice in consultations.~* No visits will be made to the patient's home. You will always visit the doctor's office.~* If any problem is detected, the patient will be visited by health personnel and the usual treatments in these patients at present will be applied."
62785174|NCT04542031|OTHER|Survey|Survey to be distributed at 6 and 12 months
62785175|NCT04426539||Amyloid PET-Positive|Those for whom a beta amyloid PET scan is consistent with underlying AD as causing or contributing to cognitive impairment
62013234|NCT02760238||Patients with a diagnosis of MPN|"Patients with a myeloproliferative neoplasm (MPN) diagnosis:~Atypical chronic myeloid leukemia (aCML), chronic eosinophilic leukemia-not otherwise specified (CEL NOS), chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia (CNL), polycythemia vera (PV), essential thrombocythemia (ET), JMML, mastocytosis, MPN unclassifiable, myeloproliferative neoplasm/myelodysplastic syndrome unclassifiable (MPN/MDS unclassifiable), primary myelofibrosis (PMF), post-ET MF, post-PV MF, or (refractory anemia with ringed sideroblasts associated with marked thrombocytosis) RARS-T"
62013235|NCT01369628|EXPERIMENTAL|Arm 1|"1 arm with the 3 following dose regimens:~1. Regimen 1: Atacicept 25 mg weekly for 12 weeks~2. Regimen 2: Atacicept 75 mg weekly for 12 weeks~3. Regimen 3: Atacicept 150 mg weekly for 12 weeks"
62785176|NCT04426539||Amyloid PET-Negative|Those for whom a beta amyloid PET scan has ruled out AD (i.e. not consistent with underlying AD as causing or contributing to cognitive impairment)
62785177|NCT05018078|EXPERIMENTAL|Coronavirus vaccination|Patients in the experimental need to accept the coronavirus vaccination
62785178|NCT03830346|EXPERIMENTAL|Experimental|In the experimental group, instrument-assisted soft tissue mobilization techniques and post-isometric horizontal adduction stretches were performed. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment.
62013236|NCT03755063|EXPERIMENTAL|Treatment arm|Tablet with speech therapy apps
62013237|NCT03755063|NO_INTERVENTION|Standard of Care|The standard care provided by speech language therapists.
62013238|NCT01701466|EXPERIMENTAL|Arm B: standard of care plus NeoVIDERM cream|Patients will apply NeoVIDERM cream to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. Patients will also perform standard of care skin treatment.
62013239|NCT01701466|ACTIVE_COMPARATOR|Arm A: standard skin care|Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatments. If they develop dry desquamation, they will be asked to apply Flamazine twice a day until dermatitis resolves.
62013240|NCT04455386||stable|The anterior drawer test and/or talar tilt test are negative and the ankle joint is stable.
62013241|NCT04455386||slightly instable|The anterior drawer test and/or talar tilt test are slightly positive and the ankle joint is partially instable.
62013242|NCT04455386||obviously instable|The anterior drawer test and/or talar tilt test is significantly positive, with significantly instable. The ankle joint is completely instable and can featured with dimple sign.
62578965|NCT05932693|EXPERIMENTAL|WS-3 (3), no nicotine|WS-3 block: 0.5%
62578966|NCT05932693|EXPERIMENTAL|WS-3 (4), no nicotine|WS-3 block: 1.0%
62578967|NCT05932693|EXPERIMENTAL|WS-3 (5), no nicotine|WS-3 block: 2.0%
62578968|NCT05932693|EXPERIMENTAL|Menthol (1), no nicotine|Menthol block: 0.05%
62578969|NCT05932693|EXPERIMENTAL|Menthol (2), no nicotine|Menthol block: 0.1%
62578970|NCT05932693|EXPERIMENTAL|Menthol (3), no nicotine|Menthol block: 0.5%
62578971|NCT05932693|EXPERIMENTAL|Menthol (4), no nicotine|Menthol block: 1.0%
62402159|NCT04957628||Control group|2500 participants will be recruited before the intervention procedures are implemented at the respective hospitals. Baseline data on alcohol, psychoactive medicinal and illicit drug use (AUDIT-4 and DUDIT), stages-of-change questionnaire on alcohol, medicinal drugs and illicit drug use, and mental distress will be recorded. Left-over full blood from routine diagnostic testing will be collected and analyzed for alcohol biomarkers (ethanol and phosphatidylethanol (PEth)) and psychoactive medicinal and illicit drugs. The participants in the control group will receive acute medical treatment according to hospital procedures. After 12 months, the data from baseline will be coupled to data from patient journals and data from relevant registries.
62785179|NCT03830346|EXPERIMENTAL|Control|Control group only underwent soft tissue mobilization. With the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times.
62785180|NCT00038233|EXPERIMENTAL|Thalidomide|200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
62013243|NCT02339818||HCPs|HCPs involved in using Eliquis (apixaban)
62013244|NCT02339818||Patients|Patients taking Eliquis for any of the three currently approved indications
62013245|NCT04532112|EXPERIMENTAL|Intubated Subjects with the Biocontainment Device|Subjects undergoing scheduled airway procedures under general anesthesia with the Biocontainment Device by anesthesiologists trained in device use.
62013246|NCT04532112|PLACEBO_COMPARATOR|Intubated Subjects without the Biocontainment Device|Subjects undergoing scheduled airway procedures under general anesthesia with the Biocontainment Device by same cohort of anesthesiologists trained in device use.
62013247|NCT02541240|EXPERIMENTAL|Resilience Curriculum|The intervention is exposure to an 8-hour Resilience Curriculum. It will provide education for participants about methods to increase protective factors against stress, the use of effective coping strategies, and the importance of accessing social support, with the goal of better managing stress and enhancing resilience. The curriculum will include a didactic component, skills-building training, and homework exercises to encourage the application of the skills.
62013248|NCT02541240|NO_INTERVENTION|No Resilience Curriculum|The Waitlist Control group will receive no exposure to the Resilience Curriculum. After the final data is collected, this group will be offered the opportunity to attend a condensed 2-hour version of the curriculum.
62013249|NCT01038518||Health2010|Cross-sectional general population study
62201529|NCT00033618|EXPERIMENTAL|Arm II (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62410083|NCT04155775|NO_INTERVENTION|No Best Practice Alert|For this group, no visible best practice alert will activate in the electronic health record for platelet transfusion orders and recent counts above 50k/uL.
62578972|NCT05932693|EXPERIMENTAL|Menthol (5), no nicotine|Menthol block: 2.0%
61978333|NCT02855216|EXPERIMENTAL|Self-treatment by way of Occipivot®|The technique applied to the Instrumental Group was performed with the patient supine in the same position as the Manual Group . It was previously instructed the subject how to proceed with the cushion Occipivot® , indicating the installation location and method of affixing , correcting him if the application was inadequate. The subject placed the cushion Occipivot® under the suboccipital region and told him he had to stay in that position for 5 minutes. A physiotherapist warned the patient at the end of the application time so that the subject had to be aware not to control it.
61978334|NCT01778933|EXPERIMENTAL|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
62013250|NCT06023095|EXPERIMENTAL|LY3502970|LY3502970 administered orally
62013251|NCT06023095|PLACEBO_COMPARATOR|Placebo|Placebo administered orally
62013252|NCT00513422|EXPERIMENTAL|1|Glucosamine sulfate 1500mg and chondroitin sulfate 800mg (low molecular weight, bovine)
62013253|NCT00513422|EXPERIMENTAL|2|Glucosamine sulfate 1500mg
62013254|NCT00513422|EXPERIMENTAL|3|Chondroitin sulfate 800mg
62013255|NCT00513422|PLACEBO_COMPARATOR|4|Matching glucosamine/chondroitin placebo capsules
62013256|NCT05461885|EXPERIMENTAL|Vega Exercise Community|Participants will be offered one hour of tailored supervised, gym-based exercise training three times per week for a period of four months. In addition, participants are offered free-of-charge membership to the gym for six months and are invited to take part in training classes and use fitness equipment provided by the gym to regular members. The supervised program is tailored to meet the needs and requirements of this particular group of young adults and will include three weekly sessions of moderate-to-high intensity and mobility exercises.
62578973|NCT05932693|EXPERIMENTAL|WS-23 (1), no nicotine|WS-23 block: 0.05%
62578974|NCT05932693|EXPERIMENTAL|WS-23 (2), no nicotine|WS-23 block: 0.1%
62201530|NCT02815579|EXPERIMENTAL|Intervention|The Shamba Maisha Intervention includes: a) a loan (\~$175) from a well-established Kenyan bank for purchasing agricultural implements and commodities; b) agricultural implements to be purchased with the loan including the KickStart treadle pump, seeds, fertilizers and pesticides; and c) education in financial management and sustainable farming practices occurring in the setting of patient support groups.
62201531|NCT02815579|NO_INTERVENTION|Control|Participants in the control arm will receive the standard of care.
62201532|NCT06463782|EXPERIMENTAL|68Ga-LNC1007 Injection|a single dose of 68Ga-LNC1007 Injection will be administered
62201533|NCT03667976|NO_INTERVENTION|Control Group|All participants in the control group will receive a study pedometer and a physical activity logbook. Participants will also receive the Canadian Society of Exercise Physiology/ParticipACTION physical activity guidelines for adults ages 18 to 64.
62402160|NCT04957628||Case group|2500 participants will be recruited after the intervention procedures are implemented. Baseline data on alcohol, psychoactive medicinal and illicit drug use, stages-of-change questionnaires, and mental distress will be recorded. Left-over blood from diagnostic testing will be collected and analyzed for alcohol biomarkers (ethanol and phosphatidylethanol (PEth)) and psychoactive medicinal and illicit drugs. The participants in the case group will receive treatment according to new hospital procedures, including screening for harmful alcohol use and non-prescribed use of psychoactive medicinal drugs and intervention. If feasible, a new blood sample will be collected 2 months after inclusion, which will be analyzed for PEth. After 12 months, the data from baseline will be coupled to patient journals and relevant registries.
62402161|NCT05367895||Exposure group 1|Adults (≥ 18 years of age) registered in the E-SUS or SIVEP-gripe RWD source data from August 16th, 2021 through April 21st, 2022 and received a three-dose homologous vaccination with CoronaVac. Specifically, ≥14 days after receipt of the third vaccine dose using a homologous regimen with CoronaVac.
62402162|NCT05367895||Exposure group 2|Adults (≥ 18 years of age) registered in the E-SUS or SIVEP-gripe RWD source data from August 16th, 2021 through April 21st, 2022, who received a two-dose vaccination with CoronaVac and did not receive any booster vaccine. Specifically, ≥14 days after receipt of the second vaccine dose and before the third dose of CoronaVac.
62402163|NCT05367895||Exposure group 3|Adults (≥ 18 years of age) registered in the E-SUS or SIVEP-gripe RWD source data from August 16th, 2021 through April 21st, 2022, who received only one dose vaccination with CoronaVac and did not receive any other vaccine dose. Specifically, ≥14 days after receipt of the first vaccine dose and before the second dose of CoronaVac.
62578975|NCT05932693|EXPERIMENTAL|WS-23 (3), no nicotine|WS-23 block: 0.5%
62201534|NCT03667976|EXPERIMENTAL|Intervention Group|All participants in the intervention group will receive a study pedometer and a physical activity logbook. Participants will also receive the South Asian women Together in a Health Initiative (SATHI) intervention which consists of a gender and culturally specific South Asian physical activity education booklet and video and 2) a matched peer. Peers will encourage physical activity and provide motivation and suggestions for incorporating physical activity into daily life of a South Asian woman based on Bandura's Self-Efficacy construct. Peer contact will occur via telephone, text/email messaging or in person at least once weekly and more often as determined by participants.
62201535|NCT03823573|EXPERIMENTAL|Rapid recovery protocol|They will start walking the day of surgery. Levobupivacain 5mg/ml will be placed in the knee tissues. Tranexamic acid inside the knee. No drains.
62201536|NCT03823573|ACTIVE_COMPARATOR|Classic protocol|They will start walking 3 days after surgery. Levobupivacain 5 mg/ml will be placed in the femoral nerve. Tranexamic acid inside the knee. A Redon drain will be used.
62201537|NCT02845232||Intensive chemotherapy|First group: 68 patients receiving a combination of intermediate-dose cytarabine and an anthracycline. One patient with acute promyelocytic leukaemia (APL) also received all-trans retinoic acid (ATRA).
62215058|NCT05007080|EXPERIMENTAL|Group 3: Ad26.COV2.S Dose Level 3: 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 3 on Day 1 and placebo on Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination. Participants will receive booster vaccination at dose level 1 on Day 184.
62215059|NCT05007080|EXPERIMENTAL|Group 4: Ad26.COV2.S Dose Level 1: 2-Dose Regimen|Participants will receive 2-dose of Ad26.COV2.S at dose level 1 on Day 1 and 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination.
62785181|NCT02286232|EXPERIMENTAL|Stretching exercise|A series of 12 standardized, weekly stretching exercise classes will be held at the Wilton Family YMCA, designed for people with chronic low back pain unaccustomed to stretching. Participants will be asked to practice the identical routine of that week's stretching exercise class on off days and will be given handouts and CD's to assist in this.
62785182|NCT02286232|ACTIVE_COMPARATOR|Self-care book|The Back Pain Helpbook (Moore JE, Lorig K, Von Korff M, Gonzalez VM, Laurent DD. The Back Pain Helpbook. Reading, MA: Perseus Books; 1999)provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
62201538|NCT02845232||Lower-intensity treatments|The second study group comprised 70 patients who were treated on frontline by lower-intensity treatments \[LD-AraC(39 patients), azacitidine (16 patients), decitabine (11 patients),tipifarnib (3 patients), or ATRA (1 patient)\]. Patients received LD-AraC 20 mg once or twice daily (according to physician'schoice) by subcutaneous injection for 10 consecutive days. Azacitidine was given at the dose of 75 mg/m2/day for 7 consecutive days by sc injection. Decitabine was administered by intravenous route once daily at 20 mg/m2 for 5 consecutive days. Tipifarnib was given at 600 mg administered orally twice daily for 21 consecutive days in 4-week cycles. ATRA was given at 45 mg/m2until CR achievement followed by maintenance combining 6-mercaptopurine with methotrexate.
62201539|NCT02845232||Best Supportive Care|The last study group comprises 76 patients: 31 patients received supportive care, while 36 patients also received hydroxyurea and 9 patients received 6-mercaptopurine.
62201540|NCT06148363|ACTIVE_COMPARATOR|real stimulation|The central electrode was placed over F3, with return electrodes at Fp1, Fz, F7 and C3. Fourteen 2-mA sessions (ramp-up and ramp-down periods of 15 and 15 seconds, respectively) were applied for 20 minutes per session, twice daily over 7 consecutive days.
62402164|NCT05367895||Non-Exposure group|Adults (≥ 18 years of age) registered in the E-SUS or SIVEP-gripe RWD source data from August 16th, 2021 through April 21st, 2022, who were not vaccinated. No history of vaccination for any type of COVID-19 vaccine, or \<14 days after receipt of the first vaccine of CoronaVac.
62402165|NCT02545699|EXPERIMENTAL|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
62402166|NCT02545699|ACTIVE_COMPARATOR|Standard Colonoscopy|Standard Colonoscopy
62402167|NCT02116374||HIV-1 patients|
62402168|NCT02780206|EXPERIMENTAL|obese|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~3 study days (one baseline, one approx 2 weeks of diet, one post-diet): muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
62785183|NCT05878951|EXPERIMENTAL|Intra-detrusor OnabotulinumtoxinA Injection|Injection of intra-detrusor OnabotulinumtoxinA into the bladder will be performed.
62785184|NCT05878951|NO_INTERVENTION|No intra-detrusor OnabotulinumtoxinA Injection|Injection of intra-detrusor OnabotulinumtoxinA into the bladder will not be performed.
62785185|NCT00516867|ACTIVE_COMPARATOR|UVB 0.5%|
62201541|NCT06148363|SHAM_COMPARATOR|sham stimulation|In the sham condition, tDCS was delivered only during the ramp-up and ramp-down periods (15 and 15 s); no current was delivered during the 20-minute intervention. Participants will receive sham tDCS twice daily for two weeks.
62402169|NCT03542175|EXPERIMENTAL|Rucaparib Administered With Radiation|"Treatment will consist of rucaparib at one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.~Radiotherapy will consist of 50 Gy in 2 Gy per fraction to the breast or chest wall with or without regional nodes plus a 10 Gy boost to the lumpectomy cavity, to a total dose of 60 Gy. A 10 Gy boost to the post-mastectomy scar is allowed at the discretion of the treating physician."
62578976|NCT05932693|EXPERIMENTAL|WS-23 (4), no nicotine|WS-23 block: 1.0%
62785186|NCT00516867|NO_INTERVENTION|Controls|
62578977|NCT05932693|EXPERIMENTAL|WS-23 (5), no nicotine|WS-23 block: 2.0%
62201542|NCT02463045|EXPERIMENTAL|TOP1288 1mg (or placebo)|TOP1288 1mg single dose or placebo
62578978|NCT05932693|EXPERIMENTAL|WS-23 (6), no nicotine|WS-23 block: 4.0%
62785187|NCT00516867|ACTIVE_COMPARATOR|UVB 1.4%|
62785188|NCT01078649|EXPERIMENTAL|Debio 1143 (AT-406)|Open label study. All patients participating in the study will receive Debio 1143 (AT-406).
62578979|NCT05690607||HIV: Phase 1|People (over 18 years) living with HIV-1 attending London Mortimer Market Centre for routine blood tests as part of their HIV care.
62578980|NCT05690607||HIV: Phase 2|Subset of HIV participants sent TINIES test kit to use in home environment
62578981|NCT05690607||HBV: Phase 1|People (over 18 years) living with HBV patients attending London Mortimer Market Centre for routine blood tests as part of their HBV care.
62785189|NCT02335606||Patients treating with Abatacept|Patients who are abatacept naive and are initiating abatacept treatment (either IV or SC) including those that are switching from another bDMARD, as well as, patients currently being treated with IV or SC abatacept some of which may have switched from IV abatacept to SC abatacept
62785190|NCT03363620|EXPERIMENTAL|self ligation brackets damon ormco®|the self ligation bracket (damon system) in the orthodontic treatment, was used in the experimental group with the recommended protocol damon arches sequence.
62785191|NCT03363620|ACTIVE_COMPARATOR|conventional brackets orthos ormco®|the conventional bracket (orthos system) in the orthodontic treatment, was used in the active comparator group with the recommended protocol damon arches sequence as used in the experimental group.
62785192|NCT01306916||Group 1 of 1|diagnosis of primary and secondary hyperparathyroidism scheduled to undergo parathyroid resection.
61978335|NCT03070574|EXPERIMENTAL|2400 MG mesalamine (5-ASA) total|2400mg (1200mg mesalamine/1200mg) mesalamine once daily in the morning for the treatment phase of the study (24 months)
62785193|NCT01548066|EXPERIMENTAL|Sodium valproate|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
62785194|NCT01548066|PLACEBO_COMPARATOR|Control|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
62785195|NCT05168020|EXPERIMENTAL|Safety Behavior Fading|"Participants will be asked to identify their five most common SBs from the SAFE. Participants will then be shown a sample checklist with instructions to fill it out. For the next 14 days, participants will receive the following text message Please remember to avoid using SBs you selected. As you drop them, you'll be able to go into social situations with greater confidence! with a link for their daily checklist to complete. Participants will be asked to rate how often they engaged in each SB over the past 24 hours"
62785196|NCT05168020|ACTIVE_COMPARATOR|Unhealthy Behavior Fading|"Participants will be asked to pick five unhealthy behaviors they engage in most often to decrease. Participants will then be shown the same sample checklist as the Safety Behavior Fading Group. For the next 14 days participants will receive the following text message Please try to remember to decrease your unhealthy behaviors. As you decrease them you will feel better, and you'll be able to go into social situations with greater confidence! with a link for their daily checklist to complete. Participants will be asked to rate how often they engaged in each Unhealthy Behavior over the past 24 hours."
62785197|NCT01835223|EXPERIMENTAL|Treatment (tivozanib - 1 mg)|Patients receive tivozanib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62785198|NCT01835223|EXPERIMENTAL|Treatment (tivozanib - 1.5 mg)|Patients receive tivozanib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62785199|NCT04965532|EXPERIMENTAL|chemotherapy patients using sevoflurane anesthesia|Following induction of anesthesia and laryngeal mask placement, anesthesia will be maintained by inhalation of sevoflurane (approximately 1.3 × minimum alveolar concentration) and IV fentanyl according to clinical need.
62785200|NCT04965532|ACTIVE_COMPARATOR|chemotherapy patients using total intravenous anesthesia|Following induction of anesthesia and laryngeal mask placement, maintenance of anesthesia will consist of target-controlled infusion of propofol at a plasma target concentration of 1.5-3.0µg/ml and IV fentanyl according to clinical need.
62785201|NCT04965532|ACTIVE_COMPARATOR|nonchemotherapy patients using sevoflurane anesthesia|Following induction of anesthesia and laryngeal mask placement, anesthesia will be maintained by inhalation of sevoflurane (approximately 1.3 × minimum alveolar concentration) and IV fentanyl according to clinical need.
62785202|NCT04965532|ACTIVE_COMPARATOR|nonchemotherapy patient using total intravenous anesthesia|Following induction of anesthesia and laryngeal mask placement, maintenance of anesthesia will consist of target-controlled infusion of propofol at a plasma target concentration of 1.5-3.0µg/ml and IV fentanyl according to clinical need.
62785203|NCT04375514|EXPERIMENTAL|ARO-ENaC|ARO-ENaC Inhalation
62785204|NCT04375514|PLACEBO_COMPARATOR|Placebo|Sterile normal saline (0.9% NaCl)
62785205|NCT05002491|EXPERIMENTAL|High protein feeding|Two isocaloric feeding phases of 2 weeks followed by an ad-libitum feeding phase of 3 months
62785206|NCT03653728||Traumatic brain injury with cerebral contusions|
62785207|NCT02439034|ACTIVE_COMPARATOR|Arm A|Paracetamol
62785208|NCT02439034|EXPERIMENTAL|Arm B|Paracetamol + Ketoprofen
62785209|NCT02736344||BioNIR Ridaforolimus (drug eluting stent (DES)|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:~* Stent - a mounted Cobalt Chromium (CoCr) alloy based stent~* Delivery System - Rapid Exchange (RX) Coronary System~* Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~* Ridaforolimus drug - CAS Registry Number: 572924-54-0~The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
62785210|NCT04569227|EXPERIMENTAL|Active EC-18|
62785211|NCT04569227|PLACEBO_COMPARATOR|Placebo|
62785212|NCT04274335|EXPERIMENTAL|Intravenous tranexamic acid|
62785213|NCT04274335|EXPERIMENTAL|Intramuscular tranexamic acid|
62785214|NCT04274335|EXPERIMENTAL|Oral liquid tranexamic acid|
62785215|NCT04274335|NO_INTERVENTION|No tranexamic acid|
62785216|NCT05196191|EXPERIMENTAL|Viagenex Max|VIAGENEX Max graft will be placed in the incision at the end of surgery prior to closing.
62785217|NCT05196191|ACTIVE_COMPARATOR|Standard of care|Hibiclens wash will be performed.
62785218|NCT00650845|EXPERIMENTAL|Dotarem®-enhanced MRI|Patients undergoing Dotarem®-enhanced MRI for diagnostic purposes
62785219|NCT00650845|OTHER|Non-enhanced MRI|Patients undergoing non-enhanced MRI for diagnostic purposes
62785220|NCT05490940|NO_INTERVENTION|Microsurgical end-to-end neurorrhaphy alone|This group of patients receives a simple, tension-free, end-to-end microsurgical neurorrhaphy alone (without fibrin glue)
62785221|NCT05490940|EXPERIMENTAL|Microsurgical end-to-end neurorrhaphy in combination with an enwrapping with fibrin sealant Tisseel®|This group of patients receives a simple, tension-free, end-to-end microsurgical neurorrhaphy in combination with an enwrapping with fibrin sealant Tisseel®.
62785222|NCT00277784||1|Individuals with age related macular degeneration
62785223|NCT04532905|SHAM_COMPARATOR|without previous strength training experience|control (untrained) group will receive intervention as five exercises: dumbbell bent row over, dumbbell deadlift, dumbbell lunge. dumbbell shoulder press, and dumbbell squat
62785224|NCT04532905|EXPERIMENTAL|with previous strength training experience|experimental (trained) group will receive intervention as five exercises: dumbbell bent row over, dumbbell deadlift, dumbbell lunge. dumbbell shoulder press, and dumbbell squat
62785225|NCT00001582||1|Suspected or known disorder of the immune system or cancer; or, known or potential carrier of autoimmune disorder or immunodeficiency disease.
62785226|NCT06413238|OTHER|curcumin|curcumin
62785227|NCT06413238|OTHER|saffron|saffron
62785228|NCT06413238|OTHER|Combination|Combination of saffron and curcumin
62785229|NCT06413238|PLACEBO_COMPARATOR|placebo|placebo
62785230|NCT02397057|ACTIVE_COMPARATOR|Injectafer|Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.
62785231|NCT02397057|PLACEBO_COMPARATOR|Normal Saline|IV Placebo (15ml of Normal Saline) IV push at 2ml/minute
62785232|NCT05494437|EXPERIMENTAL|PP-01 High Dose|Oral PP-01 High Dose tapered/titrated over 34 days
62785233|NCT05494437|EXPERIMENTAL|PP-01 Low Dose|Oral PP-01 Low Dose tapered/titrated over 34 days
62785234|NCT05494437|PLACEBO_COMPARATOR|Placebo|Oral placebo, given daily for 34 days
62785235|NCT05494437|ACTIVE_COMPARATOR|Nabilone|oral nabilone, tapered/titrated over 28 days
62013257|NCT05461885|NO_INTERVENTION|Usual care|Participants will receive treatment as usual and be informed of the official physical activity guidelines as part of the information on group allocation. Moreover, they will be advised to continue their daily living, as they normally would do, not guiding them to other interventions neither preventing them to do so. In addition, participants in the usual care group will be given a subsidized membership including access to the exercise classes for four months after the 12 months follow up.
62013258|NCT03856229|ACTIVE_COMPARATOR|Group A conventional steroid regimen|Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally every 24 hours; and Day 11 to 21: 20 mg orally every 24 h.
62013259|NCT03856229|EXPERIMENTAL|Group B shortened steroid regimen|"Subjects will receive the shortened steroid regimen for the severity of pneumonia with prednisone or equivalent with methylprednisolone, depending the severity of pneumonia:~* Moderate PCP. 40 mg orally every 12 h (Day 1 to 5);40 mg orally every 24 hours (Day 6 to 8).~* Severe PCP. 40 mg orally every 12 h (Day 1 to 5),40 mg orally every 24 hours (Day 6 to 10); and 20 mg orally every 24 h (Day 11 to 14)."
62013260|NCT04978246||Study Group|The study group consists of 50 individuals aged 18-50 years who have received a positive COVID-19 RT-PCR test in the past 60 days.
62013261|NCT04978246||Control Group|The control group consists of 50 healthy individuals aged 18-50 years who have not had COVID-19.
62013262|NCT03995238|EXPERIMENTAL|Error-augmentation training|A 4-week, 8 session, treadmill-based gait training program, with error-augmentation of step asymmetry delivered on a split-belt treadmill. Each training session will adhere to the same schedule. During the training blocks on the treadmill, the belt under the limb with the shorter step length will be set at 3/4 of the pre-intervention over-ground self-selected walking speed while the belt under the limb with the longer step length will be set to 1/2 of the fast belt speed (2:1 ratio between belts).
62013263|NCT03995238|EXPERIMENTAL|Error-correction training|A 4-week, 8 session, treadmill-based gait training program, with error-correction of step asymmetry delivered with an auditory metronome signal while walking on a treadmill. During each training block, the metronome will be set to overcorrect stance time asymmetry through use of asymmetrical metronome tones, 2:1 ratio.
62013264|NCT03995238|ACTIVE_COMPARATOR|Supervised waking|A 4-week, 8 session, treadmill-based supervised walking program. The active comparator group will participate in a supervised treadmill walking program of the same frequency and duration, to the two experimental groups.
62402170|NCT06723964|EXPERIMENTAL|AP505 0.035 mg/kg|AP505 0.035 mg/kg Open Label
62402171|NCT06723964|EXPERIMENTAL|AP505 0.12 mg/kg|AP505 0.12 mg/kg Open Label
62013265|NCT00048724|EXPERIMENTAL|PegIntron|PegIntron (peginterferon alfa-2b) 0.5 µg/kg subcutaneously once weekly as maintenance therapy for 60 months with a 4-week post-treatment follow-up
62201543|NCT02463045|EXPERIMENTAL|TOP1288 10mg (or placebo)|TOP1288 10mg single dose or placebo
62201544|NCT02463045|EXPERIMENTAL|TOP1288 100mg (or placebo)|TOP1288 100mg single dose or placebo
62402172|NCT06723964|EXPERIMENTAL|AP505 0.4 mg/kg|AP505 0.4 mg/kg Open Label
62402173|NCT06723964|EXPERIMENTAL|AP505 1.2 mg/kg|AP505 1.2 mg/kg Open Label
62201545|NCT02463045|EXPERIMENTAL|TOP1288 200mg single dose or placebo|TOP1288 200mg single dose or placebo
62201546|NCT02463045|EXPERIMENTAL|TOP1288 400mg dose or placebo|TOP1288 400mg (200mg bid) dose or placebo
62201547|NCT02463045|EXPERIMENTAL|TOP1288 A mg or placebo|TOP1288 A mg daily for 4 days
62201548|NCT02463045|EXPERIMENTAL|TOP1288 B mg or placebo|TOP1288 B mg daily for 4 days
62402174|NCT06723964|EXPERIMENTAL|AP505 4.0 mg/kg|AP505 4.0 mg/kg Open Label
62402175|NCT06723964|EXPERIMENTAL|AP505 8.0 mg/kg|AP505 8.0 mg/kg Open Label
62402176|NCT06723964|EXPERIMENTAL|AP505 11.0 mg/kg|AP505 11.0 mg/kg Open Label
62402177|NCT06723964|EXPERIMENTAL|AP505 15.0 mg/kg|AP505 15.0 mg/kg Open Label
62402178|NCT06723964|EXPERIMENTAL|AP505 20.0 mg/kg|AP505 20.0 mg/kg Open Label
62402179|NCT06723964|EXPERIMENTAL|AP505 25.0 mg/kg|AP505 25.0 mg/kg Open Label
62402180|NCT02686437|EXPERIMENTAL|Increasing Tension|"The kinesiology tape will be applied to the shoulder complex to influence proper activation of the rotator cuff muscles, specifically the supraspinatus and infraspinatus. The clinician applied the tape in an I strip from the vertebral border of the scapula to the lesser tubercle of the humerus. Over the course of the 4 weeks of care, the tension of the Intervention Group's tape will systemically increase based on the following timelines:~Week 1: 0% tension Week 2: 25% tension Week 3: 50% tension Week 4: 75% tension"
62578982|NCT05690607||HBV: Phase 2|Subset of participants sent TINIES test kit to use in home environment
62785236|NCT05494437|ACTIVE_COMPARATOR|Gabapentin|oral gabapentin, tapered/titrated over 34 days
62785237|NCT00984555||A1 (Inoculation with 7 timepoints)|Semen exposure via inoculation, Vaginal swabs at 7 time points
62785238|NCT00984555||A2 (Inoculation with 4 timepoints)|Semen exposure via inoculation, Vaginal swabs at 4 time points
62785239|NCT00984555||B1 (intercourse with 7 timepoints)|Semen exposure via unprotected intercourse, Vaginal swabs at 7 time points
62785240|NCT00984555||B2 (Intercourse with 4 timepoints)|Semen exposure via unprotected intercourse, Vaginal swabs at 4 time points
62785241|NCT02709603|EXPERIMENTAL|Group A|oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
62785242|NCT02709603|PLACEBO_COMPARATOR|Group B|oral 2 tablets (PLACEBO) 30 minutes before the procedure
62785243|NCT00306527|ACTIVE_COMPARATOR|cTIV\cTIV (adults)|Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.
62013266|NCT00048724|NO_INTERVENTION|Untreated Control|
62013267|NCT02461589|EXPERIMENTAL|Semaglutide 0.05 mg/day|
62013268|NCT02461589|ACTIVE_COMPARATOR|Liraglutide 0.3 mg/day|
62013269|NCT02461589|PLACEBO_COMPARATOR|Placebo 50 µL|
62013270|NCT02461589|EXPERIMENTAL|Semaglutide 0.05/0.1 mg/day|
62013271|NCT02461589|ACTIVE_COMPARATOR|Liraglutide 0.3/0.6 mg/day|
62013272|NCT02461589|PLACEBO_COMPARATOR|Placebo 50/100 µL|
62013273|NCT02461589|EXPERIMENTAL|Semaglutide 0.05/0.1/0.2 mg/day|
62013274|NCT02461589|ACTIVE_COMPARATOR|Liraglutide 0.3/0.6/1.2 mg/day|
62013275|NCT02461589|PLACEBO_COMPARATOR|Placebo 50/100/200 µL|
62013276|NCT02461589|EXPERIMENTAL|Semaglutide 0.05/0.1/0.2/0.3 mg/day|
62013277|NCT02461589|ACTIVE_COMPARATOR|Liraglutide 0.3/0.6/1.2/1.8 mg/day|
62013278|NCT02461589|PLACEBO_COMPARATOR|Placebo 50/100/200/300 µL|
62013279|NCT02461589|EXPERIMENTAL|Semaglutide flexible escalation from 0.05 mg/day to 0.3 mg/day|
62013280|NCT00403455|OTHER|Paroxetine Arm|This is a single arm, single site, open-label clinical trial to treat veterans with PTSD. It is a 12-week trial to investigate the efficacy of paroxetine in reducing PTSD symptoms, with the primary outcome measure using CAPS. Genetic information is included to understand why some respond and some do not respond to paroxetine treatment.
62201549|NCT02463045|EXPERIMENTAL|TOP1288 C mg or placebo|TOP1288 C mg daily for 4 days
62201550|NCT02463045|EXPERIMENTAL|TOP1288 D mg or placebo|TOP1288 D mg bid for 4 days
62201551|NCT02463045|EXPERIMENTAL|TOP1288 Xmg or placebo|TOP1288 X mg od or bid for 4 days
62201552|NCT00753064|ACTIVE_COMPARATOR|AScVS|a clinical scoring system for dose requirement for AScVS is evolved based on sweating, pulse rate, respiratory rate, blood pressure, CNS effects and presence of priapism. Computed doses were given according to clinical grading as intravenous bolus slowly.
62402181|NCT02686437|SHAM_COMPARATOR|Control Tension|"The kinesiology tape will be applied to the shoulder complex to influence proper activation of the rotator cuff muscles, specifically the supraspinatus and infraspinatus. The clinician applied the tape in an I strip from the vertebral border of the scapula to the greater tuberosity of the humerus. Over the course of the 4 weeks of care, the tension of the Control Group's tape will remain at 0% tension"
62578983|NCT05142631|EXPERIMENTAL|Fruquintinib in soft tissue sarcoma|Fruquintinib : 5mg, once a day (QD), oral on an empty stomach or after a meal, taken with 100 \~ 200ml drinking water for 3 weeks and stopped for 1 week.
62785244|NCT00306527|ACTIVE_COMPARATOR|cTIV\TIV (adults)|Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
62201553|NCT00753064|ACTIVE_COMPARATOR|Prazosin.|Prazosin therapy Prazosin (30 micrograms/Kg/dose): 500 micrograms for pediatric patient, and 1mg for adult patients) will be given every 3 hourly orally till complete recovery.
62013281|NCT04620434||patient|39 patients who are planning surgeries that require general anesthesia and tracheal intubation
62013282|NCT01978405|EXPERIMENTAL|alpha-lipoic acid group|Alpha lipoic acid 600 mg in 0.9% sodium chloride 250 ml was given before and after contrast agent was administrated.
62013283|NCT01978405|PLACEBO_COMPARATOR|Placebo intervention group|Only 0.9% sodium chloride 250 ml was given for this group.
62013284|NCT03367533|EXPERIMENTAL|ketamine plus perampanel|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive 6 milligrams (mg) oral perampanel and intravenous ketamine. Participants will then undergo a 2-hour magnetic resonance imagining (MRI) scan. The following day, participants will return for an additional scan and symptom assessment.
62013285|NCT03367533|PLACEBO_COMPARATOR|ketamine plus placebo|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive an oral placebo (in lieu of 6 mg oral perampanel) and intravenous ketamine. Participants will then undergo a 2-hour MRI scan. The following day, participants will return for an additional scan and symptom assessment.
62013286|NCT03819868|ACTIVE_COMPARATOR|High Cost|Restoration using a high-cost sealant
62013287|NCT03819868|EXPERIMENTAL|Low Cost|Restoration using a low-cost sealant
62013288|NCT03042312|EXPERIMENTAL|177Lu-PSMA-617 (6.0 GBq)|Repeated i.v. application of 6.0 GBq (gigabequerel)(+/- 10%, arm 1) every 8+/- 1 weeks; RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
62013289|NCT03042312|EXPERIMENTAL|177Lu-PSMA-617 (7.4 GBq)|Repeated i.v. application of 7.4 GBq (gigabequerel)(+/- 10%, arm 2) of drug every 8+/- 1 weeks; RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
62013290|NCT05824884|EXPERIMENTAL|Experimental 1|positive visual feedback during VR-height-exposure combined with SE-enhancement after exposure.
62013291|NCT05824884|ACTIVE_COMPARATOR|Active Comparator 1|positive visual feedback during VR-height-exposure, and a placebo intervention after exposure.
62013292|NCT05824884|ACTIVE_COMPARATOR|Active Comparator 2|no visual feedback during exposure but SE-enhancement after exposure.
62013293|NCT05824884|PLACEBO_COMPARATOR|Placebo Comparator|no visual feedback during exposure and placebo intervention after exposure.
62013294|NCT00600821|ACTIVE_COMPARATOR|B|Bevacizumab will be administered in combination with carboplatin and paclitaxel.
62013295|NCT00600821|EXPERIMENTAL|A|AG-013736 will be administered in combination with carboplatin and paclitaxel.
62201554|NCT00753064|ACTIVE_COMPARATOR|AScVS + Prazosin|Combination AScVS and Prazosin therapy In this group, AScVS therapy will be given as mentioned in AScVS therapy group and in addition, prazosin (500 micrograms for pediatric patient and 1mg for adult patients,30 micrograms/Kg/dose) every 3 hourly will be given.
62201555|NCT00545415|EXPERIMENTAL|1|
62201556|NCT00545415|EXPERIMENTAL|2|
62201557|NCT00545415|EXPERIMENTAL|3|
62201558|NCT00545415|EXPERIMENTAL|4|
62201559|NCT00545415|EXPERIMENTAL|5|
62201560|NCT00545415|EXPERIMENTAL|6|
62201561|NCT00770744|EXPERIMENTAL|Zicronapine|
62201562|NCT00770744|ACTIVE_COMPARATOR|Olanzapine|
62201563|NCT02852356|NO_INTERVENTION|Control Incubator|Standard Incubator
62201564|NCT02852356|EXPERIMENTAL|MIRI-TL Timelapse Incubator|Timelapse incubator
62201565|NCT02852356|EXPERIMENTAL|Culture Coin Dish|Culture Coin dish for embryo culture
62201566|NCT02852356|NO_INTERVENTION|Control dish|Control Dish for embryo culture
62201567|NCT06422000|NO_INTERVENTION|control group (group I)|will include 25 preterm neonates with NEC who will receive traditional therapy of NEC including antibiotics and normal incubator care measures
62201568|NCT06422000|ACTIVE_COMPARATOR|pentoxifylline group (group II)|will include 25 preterm neonates with NEC who will receive traditional therapy of NEC in association with IV pentoxifylline at a dose of 30 mg/kg given over 6 hours daily (Schüller et al., 2020) until discharge from the unit after clinical and laboratory improvement .
62201569|NCT06422000|ACTIVE_COMPARATOR|probiotic group (group III)|will include 25 preterm neonates with NEC who will receive traditional therapy of NEC in association with probiotics sachets supplementation, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement .
62201570|NCT00304759|EXPERIMENTAL|1|6000 cGy / 20 fractions in 4 weeks
62201571|NCT00304759|ACTIVE_COMPARATOR|2|7800 cGy / 39 fractions in 8 weeks
62201572|NCT01442922||Human Meniscus Allograft (HMA)|Patients with degenerative disk disease at L3-L4, L4-L5, or L5-S1 scheduled to undergo surgery for (HMA) implantation to replace the nucleus pulposus.
62201573|NCT03905343|EXPERIMENTAL|A: endocrine therapy + ribociclib|
62201574|NCT03905343|ACTIVE_COMPARATOR|B: mono-chemotherapy|
62201575|NCT01161238||Lower-limb amputee|Subjects with at least one lower limb amputated at the trans-tibial level
62402182|NCT04366258|EXPERIMENTAL|Patients with MDD|Participants will undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose (50 mW/cm2; 300 mW/cm2; 770 mW/cm2), as well as a sham dose (0 mW/cm2), once over the 4 treatment visits.
62402183|NCT01995656|PLACEBO_COMPARATOR|Placebo - Healthy|Part A. Healthy participants will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.
62402184|NCT01995656|EXPERIMENTAL|LY3108743 - Healthy|Part A. Healthy participants will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
62402185|NCT01995656|PLACEBO_COMPARATOR|Placebo - Diabetes|Part B. Participants with diabetes mellitus will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.
62402186|NCT01995656|EXPERIMENTAL|LY3108743 - Diabetes|Part B. Participants with diabetes mellitus will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
62402187|NCT01995656|PLACEBO_COMPARATOR|Placebo - Solution|Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of placebo matching LY3108743 in 1 of 2 study periods.
62402188|NCT01995656|EXPERIMENTAL|LY3108743 - Solution|Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of LY3108743 in 1 of 2 study periods.
62402189|NCT02254629|EXPERIMENTAL|laxative-probiotic sequential|laxative：2000 ml. Probiotic：2 tablets/ times, 3 times / day for the first 2 weeks，immediately after colonoscopy
62402190|NCT02254629|ACTIVE_COMPARATOR|probiotic|Probiotic：2 tablets/ times, 3 times / day for the first 2 weeks.
62402191|NCT02254629|ACTIVE_COMPARATOR|Laxative followed by Probiotic 2 weeks later|laxative：2000 ml. Probiotic：2 tablets/ times, 3 times / day for the last 2 weeks with two weeks interval after colonoscopy.
62402192|NCT06165575|EXPERIMENTAL|Press needle and medication|
62402193|NCT06165575|SHAM_COMPARATOR|Sham press needle and medication|
62402194|NCT03547921||operative|operative
62201576|NCT01022541|OTHER|This is a single arm study|This is a single arm study
62201577|NCT00631267|PLACEBO_COMPARATOR|1|Manual Manipulation
62201578|NCT00631267|ACTIVE_COMPARATOR|2|Finger Trap Traction
62201579|NCT00966121|ACTIVE_COMPARATOR|Endoscopic band ligation|Perform endoscopic band ligation (EBL) until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
62201580|NCT00966121|ACTIVE_COMPARATOR|EBL+Propranolol|Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
62201581|NCT03970538|EXPERIMENTAL|Treatment Arm|Treated with the LimFlow System
62201582|NCT03411083||Knee replacement|Patients assigned for total or unicompartmental knee replacement surgery
62201583|NCT02700360|EXPERIMENTAL|Part 1(1,000mg dose): group 1|period 1: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, after high-fat diet intake; period 2: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, on an empty stomach; cross-over period: 7 days
62201584|NCT02700360|EXPERIMENTAL|Part 1(1,000mg dose): group 2|period 1: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, on an empty stomach; period 2: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, after high-fat diet intake; cross-over period: 7 days
62201585|NCT02700360|EXPERIMENTAL|Part 2(500mg dose): group 3|period 1: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, after high-fat diet intake; period 2: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, on an empty stomach; cross-over period: 7 days
62402195|NCT03547921||non operative|non operative
62402196|NCT00939068|EXPERIMENTAL|Telbivudine|Drug administration and follow up: the subjects in Telbivudine group start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continue to one month after delivery.And their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.
62402197|NCT00939068|OTHER|Control|The pregnant subjects in Control group are intervented with no drugs, but their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.
62402198|NCT05923372||Patients with indolent systemic mastocytosis (IMS)|Patients with IMS, included in the CEREMAST registry and who have given their consent to participate
62402199|NCT01156974|EXPERIMENTAL|care guide|patients receive education about care goals and work with a care guide to achieve goals
62402200|NCT01156974|ACTIVE_COMPARATOR|no care guide|patients receive education about care goals and usual care to achieve goals
62201586|NCT02700360|EXPERIMENTAL|Part 2(500mg dose): group 4|period 1: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, on an empty stomach; period 2: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, after high-fat diet intake; cross-over period: 7 days
62402201|NCT01005810|ACTIVE_COMPARATOR|N-Acetylcysteine|
62402202|NCT01005810|PLACEBO_COMPARATOR|Placebo|
62402203|NCT05765318|EXPERIMENTAL|QLB group|"At the end of surgery, before emergence of anesthesia, participants will receive bilateral QLB and intravenous (IV) ketoprofen 100 mg. Ketoprofen 100 mg IV will be repeated every 12 hours.~For breakthrough pain patients will receive an IV bolus of morphine 5 mg. IV bolus can be repeated after 20 min. The maximum is 8 boluses for 4 hours."
62402204|NCT05765318|NO_INTERVENTION|Control group|"At the end of surgery, before emergence of anesthesia, participants will receive IV ketoprofen 100 mg. Ketoprofen 100 mg IV will be repeated every 12 hours.~For breakthrough pain patients will receive an IV bolus of morphine 5 mg. IV bolus can be repeated after 20 min. The maximum is 8 boluses for 4 hours."
62402205|NCT04567680|EXPERIMENTAL|Acceptance and Commitment Therapy to Improve Social Support|This treatment is designed to help Veterans with PTSD increase social support in family, partner, and peer relationships by reducing experiential avoidance. ACT-SS is specifically designed to address deficits in the entire social support network for Veterans with PTSD.
62402206|NCT04567680|ACTIVE_COMPARATOR|Present-Centered Therapy|"PCT is designed to provide the emotional support for individuals with PTSD that will assist with recovery. The focus of PCT is on the here and now, including current life difficulties that are directly or indirectly related to the experience of trauma. PCT aims to help the patient consider ways to react to these difficulties."
62402207|NCT04537286|EXPERIMENTAL|nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w
62402208|NCT02043626|EXPERIMENTAL|Physical Activity Only|Students in 3 designated study schools will receive educational intervention and increased opportunities for physical activity.
62578984|NCT06524869||ACL reconstruction group|All sports patients who had a muscle evaluation at 6 to 12 months after ACLR since March 2024
62785245|NCT00306527|ACTIVE_COMPARATOR|cTIV\cTIV (elderly)|Subjects (≥61 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.
62785246|NCT00306527|ACTIVE_COMPARATOR|cTIV\TIV (elderly)|Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
62013296|NCT03976986|EXPERIMENTAL|cPOC - pPOC|Randomized crossover study (according to a random number table): Patients are allocated randomly to two study groups (cPOC/pPOC). In case of Sat.O2 drop ≤ 85% during HCT, oxygen is administered by cPOC (continuous-flow). For patients who show a positive POC hypoxic reversal, HCT is repeated at 24 hours and oxygen is administered by pPOC (pulsed-flow).
62785247|NCT00306527|ACTIVE_COMPARATOR|TIV\TIV (adults)|Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
61978336|NCT03070574|EXPERIMENTAL|1200 MG mesalamine (5-ASA) total|placebo/1200mg mesalamine once daily in the morning for the treatment phase of the study (24 months)
62013297|NCT03976986|EXPERIMENTAL|pPOC - cPOC|Randomized crossover study (according to a random number table): Patients are allocated randomly to two study groups (cPOC/pPOC). In case of Sat.O2 drop ≤ 85% during HCT, oxygen is administered by pPOC (pulsed-flow). For patients who show a positive POC hypoxic reversal, HCT is repeated at 24 hours and oxygen is administered by cPOC (continuous-flow).
62201587|NCT02700360|EXPERIMENTAL|Part 2(2,000mg dose): group 5|period 1: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, after high-fat diet intake; period 2: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, on an empty stomach; cross-over period: 7 days
62201588|NCT02700360|EXPERIMENTAL|Part 2(2,000mg dose): group 6|period 1: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, on an empty stomach; period 2: EC-18 2,000 mg(500 mg/cap, 4 capsule) once daily, after high-fat diet intake; cross-over period: 7 days
62201589|NCT02614378|ACTIVE_COMPARATOR|Subject receiving treatment|participant receiving air insufflation
62201590|NCT02614378|PLACEBO_COMPARATOR|Subject receiving placebo|participant not receiving air insufflation
62201591|NCT02642692|EXPERIMENTAL|Patellar Tendon Graft|Kind of graft that will be used for acl reconstruction
62201592|NCT02642692|EXPERIMENTAL|Hamstring Graft|Kind of graft that will be used for acl reconstruction
62201593|NCT05183568|EXPERIMENTAL|Mindful Self-Compassion|"Participants will undergo an 8-week self-help program consisting of assigned weekly chapters in the workbook entitled The Mindful Self-Compassion Workbook: A Proven Way to Accept Yourself, Build Inner Strength, and Thrive (Neff \& Germer, 2018), paired with daily guided meditations provided through a free smartphone app that was developed by the Centre for Mindfulness Studies, a Canadian-based mental health charity."
62201594|NCT00227942|EXPERIMENTAL|1|Participants will receive estrogen replacement therapy
62201595|NCT00227942|EXPERIMENTAL|2|Participants will receive treatment with zolpidem
62201596|NCT00227942|PLACEBO_COMPARATOR|3|Participants will receive treatment with placebo
62785248|NCT00306527|ACTIVE_COMPARATOR|TIV\cTIV (adults)|Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.
62785249|NCT00306527|ACTIVE_COMPARATOR|TIV\TIV (elderly)|Subjects (≥61 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
62013298|NCT05905185|EXPERIMENTAL|Treatment|Sime Darby Bioganic Sdn. Bhd, Malaysia provided the TRF pills that were used in the study. The 50 mg of vitamin E isomers in the TRF included 17.1 mg of α-tocopherol ,18.28 mg of α- tocotrienol, 2.02 mg of β-tocotrienol, 22.3 mg of γ-tocotrienol and 7.4 mg of δ-tocotrienol. During a period of six months, the patients were instructed to consume oral TRF (50 mg) daily
62013299|NCT05905185|PLACEBO_COMPARATOR|Placebo|During a period of six months, the patients were instructed to consume oral placebo (50 mg) pills daily.
62013300|NCT01351740|EXPERIMENTAL|Switch|switch to unboosted atazanavir 400mg daily with the same nucleoside (NRTI) backbone
62201597|NCT00953186|ACTIVE_COMPARATOR|HBOT|100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks
62201598|NCT00953186|PLACEBO_COMPARATOR|Placebo|air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks
62201599|NCT01738659|EXPERIMENTAL|normal sodium diet (120 mmol/die)|active comparator: low sodium diet (80 mmol/die)
62201600|NCT01802177|EXPERIMENTAL|UVB excimer light|Patches of alopecia will be treated twice weekly with UVB excimer light. Only one half of a single alopecia areata patch will be treated. In order to treat the same half during each visit, a transparent sheet will be marked, using a marking pen, to delineate the borders of the treatment area with a central dividing line. The other half will be covered and used as a control. Treatments will be given randomly (by sealed envelope randomization method) into one of the two halves in different patients but will be given into the same half in each patient in all treatment sessions. Only one investigator will know the intervention each half has received. A total of 23 treatments will be given over 12 weeks.
62402209|NCT02043626|NO_INTERVENTION|Delayed Interventions Only|Students in 3 designated schools will receive educational interventions on health topics not related to nutrition or physical activity (i.e. peer relations, sleep, dental care, etc.)
62013301|NCT01351740|ACTIVE_COMPARATOR|Continuation|continue on current regimen of atazanavir/ritonavir 300mg/100mg with the same nucleoside (NRTI) backbone
62013302|NCT03019497|EXPERIMENTAL|CBT-E|CBT-E refers to Cognitive Behavioral Therapy with specific modules. In the CBT-E condition and following the identification of the needs identified during the evaluation, additional strategies will be added to the CBT strategies for PTSD to address one or more of the seven related problem types that emerged as a result of the traumatic event: 1) major depression, 2) sleep disorders, 3) pain, 4) stressors, 5) inadequate social support, 6) substance use disorder, and 7) anxiety disorder.
62013303|NCT03019497|ACTIVE_COMPARATOR|CBT-C|CBT-C refers to Cognitive Behavioral Therapy without specific modules. CBT-C participants will be offered only cognitive-behavioral intervention strategies to alleviate the symptoms of each of the PTSD diagnostic criteria.
62785250|NCT00306527|ACTIVE_COMPARATOR|TIV\cTIV (elderly)|Subjects (≥61 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.
62013304|NCT04369469|EXPERIMENTAL|Group 1 - Ravulizumab + BSC|
62013305|NCT04369469|OTHER|Group 2 - BSC alone|
62013306|NCT02039531|EXPERIMENTAL|Plasma rich in growth factors (PRGF)|"Patients in this group will receive one cycle of three intra-articular injections of PRGF every 15 days.~Procedure for the application of the treatment:~1. Study Group or PRGF group~* Blood sample :~  * Taken minimum after 4 hours of fasting and drinking only water in order to maintain low levels of glucose.~ * 20 cc of peripheral blood will be taken by sterile systems with Sodium Citrate buffer to avoid hemolysis.~* Spinning of the sample:~  * 8 minutes at 1800 rpm .~ * getting the blood fraction containing the PRGF~ * activation of PRGF with 50 ul of 10% CaCl2 per ml of plasma.~ * the application of PRGF should not exceed 90 minutes after the blood sample extraction in order to avoid risk of contamination."
62013307|NCT02039531|ACTIVE_COMPARATOR|Hyaluronic acid (Durolane®)|Patients in this group will receive a single intra-articular injection at visit 1.
62013308|NCT04442594|EXPERIMENTAL|personalized video|Each subject of the reminiscence group will have two personalised virtual surroundings (after data being collected from team and/or families).
62013309|NCT04442594|ACTIVE_COMPARATOR|generic vidéo|The subjects of the control group will be exposed to two generic virtual settings (beach, mountain etc.)
62013310|NCT05983653|ACTIVE_COMPARATOR|150 ml of normal saline lavage|in the first arm, 150 ml of normal saline lavage alone without PRP
62013311|NCT05983653|ACTIVE_COMPARATOR|150 ml arthrocentesis with PRP|in the second arm, 150 ml of normal saline arthrocentesis with PRP
62201601|NCT01802177|NO_INTERVENTION|No treatment (covered)|
62201602|NCT03616496|EXPERIMENTAL|ATTR amyloidosis patients|Intervention by this arm: PET/CT with injection of Neuraceq \[4 MegaBecquerel /Kilogram (MBq/kg)\], blood and urine sampling for protein electrophoresis, bone scintigraphy
62402210|NCT02043626|EXPERIMENTAL|Nutrition and Physical Activity|Students in 3 designated schools will receive nutrition education, nutrition standards for foods sold, and opportunities for physical activity.
62402211|NCT02043626|EXPERIMENTAL|Nutrition Only Interventions|Students in 3 designated study schools will receive multiple interventions regarding nutrition education and nutrition standards for foods sold.
62402212|NCT00563602|ACTIVE_COMPARATOR|2|Standard Therapy: Endoscopic ligation (LEV) + Nadolol + Isosorbide mononitrate (MNI)(drugs carefully titrated until achieve maximum tolerated dose)
62578985|NCT03073031|ACTIVE_COMPARATOR|Intervention|Patients report their adverse events on a tablet once a week (intervention) as a supplement to having them monitored every 3 weeks by a physician
62013312|NCT05586867||Hemodialysis patient|
62013313|NCT00922610|EXPERIMENTAL|1|
62785251|NCT02964442|EXPERIMENTAL|Capsinoids|8 gel capsules equivalent to 12mg
62785252|NCT02964442|EXPERIMENTAL|Cooling Vest|Using Cooling vest (at approxiamately14 degrees Celsius) to cool the body.
62785253|NCT01126944|EXPERIMENTAL|system heart mate II|left ventricular assist device
62013314|NCT06214455|EXPERIMENTAL|Arm AB (Diet then Fasting)|"2 week baseline with a low sugar diet and 10-12 eating window~Treatment A: Eat a low sugar diet, 10-12 hour eating window for four weeks~Treatment B: Eat a low sugar diet, 8 hour eating window, 23 to 60 hour fast once a week for four weeks"
62013315|NCT06214455|EXPERIMENTAL|Arm BA (Fasting then Diet)|"2 week baseline with a low sugar diet and 10-12 eating window~Treatment B: Eat a low sugar diet, 8 hour eating window, 23 to 60 hour fast once a week for four weeks~Treatment A: Eat a low sugar diet, 10-12 hour eating window for four weeks"
62013316|NCT06377553||Endometriosis|Patient with clinical diagnosis of endometriosis, in any stage, candidate for diagnostic or therapeutic laparoscopic surgery.
62013317|NCT02473575|EXPERIMENTAL|Caffeine gum|caffeine (300 mg) in gum form x 1 ingestion
62013318|NCT02473575|PLACEBO_COMPARATOR|Placebo gum|placebo gum consumed x 1 ingestion
62013319|NCT02473575|NO_INTERVENTION|Non-intervention group|A third group of runners will be used to adjust for changes in environmental conditions. They will complete 2 runs without consuming either placebo or experimental treatment
62013320|NCT00904774||premature neonates|gestational age less than 28 weeks
62013321|NCT00876317|ACTIVE_COMPARATOR|1|Etoricoxib 60 mg per oz for 14 days
62013322|NCT00876317|ACTIVE_COMPARATOR|2|Etoricoxib 90 mg per oz for 14 days
62013323|NCT01099124|EXPERIMENTAL|M2ES combined with chemotherapy|
62013324|NCT00780962|EXPERIMENTAL|N-Acetylcysteine group|Subjects in this group will receive 3 grams of N-acetylcysteine in 500 cc normal saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, they will receive a continuous infusion of 200 mg N-acetylcysteine per hour. This dose will be administered as an infusion of 67 cc per hour of a solution of 3 grams of N-acetylcysteine in 1000 cc of normal saline. The infusion will be administered for a minimum of two hours and then stopped after 24 hours, or when the patient is discharged from the Emergency Department or the hospital, whichever comes first.
62013325|NCT00780962|PLACEBO_COMPARATOR|0.9% Sodium-chloride group|Subjects in this group will receive 500 cc Normal Saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, they will receive a continuous infusion of 67 cc per hour of normal saline. The infusion will be administered for a minimum of two hours and then stopped after 24 hours, or when the patient is discharged from the Emergency Department or the hospital, whichever comes first.
62013326|NCT02762669|NO_INTERVENTION|Control (no oxytocin) + No recovery|A control experiment will be undertaken in which the myometrial explants will be exposed to PSS for 2-hours without any oxytocin. No recovery time.
62013327|NCT02762669|ACTIVE_COMPARATOR|Continuous oxytocin + No recovery|10-5M oxytocin for 2 hours. No recovery time.
62785254|NCT01126944|NO_INTERVENTION|normal medical care|Optimal medical treatment for heart failure according to international guidelines
62013328|NCT02762669|ACTIVE_COMPARATOR|Continuous oxytocin + 30 minute recovery|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 30 minutes.
62013329|NCT02762669|ACTIVE_COMPARATOR|Continuous oxytocin + 60 minute recovery|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 60 minutes.
62013330|NCT02762669|ACTIVE_COMPARATOR|Control (no oxytocin) + No recovery + 10-7 oxytocin|A second control experiment will be undertaken in which the myometrial explants will be exposed to PSS for 2-hours without any oxytocin. After 2 hours, the solution will be drained from the organ baths, and replaced with fresh PSS. Following this, the strip will be exposed to 10-7 oxytocin for 10 minutes.
62013331|NCT02762669|ACTIVE_COMPARATOR|Continuous oxytocin + No recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to 10-7 oxytocin for 10 minutes.
62013332|NCT02762669|ACTIVE_COMPARATOR|Continuous oxytocin + 30 minute recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 30 minutes. The strip will then be exposed to 10-7 oxytocin for 10 minutes.
62201603|NCT03616496|EXPERIMENTAL|AL amyloidosis patients|Intervention by this arm: PET with injection of Neuraceq (4 MBq/kg), blood and urine sampling for protein electrophoresis, bone scintigraphy
62785255|NCT02561442|ACTIVE_COMPARATOR|IV ceftriaxone (0.5hr) 1 gm|ceftriaxone for injection, (total dose = 1.0 g) administered IV over 30 minutes via infusion pump (Open Label)
62785256|NCT02561442|EXPERIMENTAL|subcutaneous ceftriaxone, (2hr), 1 gm|ceftriaxone for injection, (total dose = 1.0 g) administered subcutaneous over 2 hours (Blinded).
62785257|NCT02561442|EXPERIMENTAL|subcutaneous ceftriaxone, (2 hr), 2 gm|ceftriaxone for injection, (total dose = 2.0 g) administered subcutaneous over 2 hours (Blinded).
62785258|NCT04384939|EXPERIMENTAL|Double-J ureteral stent|Pediatric patient with an uropathy or kidney graft need the insertion of Double-J ureteral stent in a routine care
61978337|NCT03070574|PLACEBO_COMPARATOR|Placebo|placebo/placebo once daily in the morning for the treatment phase of the study (24 months)
61978338|NCT03282188|EXPERIMENTAL|GROUP A (Reovirus only)|Group A patients will receive an initial low 'immunisation' dose of intravenous reovirus (1x108 TCID50), to ensure that neutralising antibody (NAB) levels have risen by the time a full cycle of reovirus is given. Group A patients will then receive only 1 cycle of treatment which will comprise of reovirus only at 1x1010 TCID50 as a 1-hour IV infusion on 2 consecutive days.
62201604|NCT03616496|ACTIVE_COMPARATOR|Control subjects with aortic stenosis|"Intervention by this arm: PET with injection of Neuraceq (4 MBq/kg), blood and urine sampling for protein electrophoresis, bone scintigraphy.~Control subjects are patients with aortic stenosis and left ventricular hypertrophy treated by surgery or by Transcatheter Aortic Valve Implantation (TAVI)"
62201605|NCT00968071|EXPERIMENTAL|Decitabine + Gemtuzumab Ozogamicin|Decitabine 20 mg/m\^2 intravenously (IV) over an hour and half daily for 5 days, Gemtuzumab Ozogamicin 3 mg/m\^2 IV on day 5.
62201606|NCT03153553|ACTIVE_COMPARATOR|Ischaemic Preconditioning Group|The participant will rest in a sitting position for 10 minutes before measuring resting blood pressure. Blood pressure will be measured on the arm. IPC will be administered to the upper arm using cuff inflation pressures of 30mm Hg above the systolic BP using a manual BP. The IPC cycles comprised of three cycles of cuff inflation each lasting 5 min in duration followed by 5-min period of cuff deflation
62201607|NCT03153553|SHAM_COMPARATOR|Control group|The participant will rest in a sitting position for 10 min before measuring resting blood pressure. Blood pressure will be measured on the upper arm. Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
62201608|NCT04968717||HIV elite controllers|"Non-viremic elite controller:~HIV-positive , \> 1 year without cART AND with \>3 consecutive HIV-RNA \< 75 copies/ml spanning \>12 months AND stable CD4\> 500 cells/uL.(i.e. \>75% of measurements)~OR on cART, but before start cART \> 1 year without cART AND with \>3 consecutive HIV-RNA \< 75 copies/ml spanning \>12 months AND stable CD4\> 500 cells/uL. (i.e. \>75% of measurements)~Viremic elite controller:~HIV-positive \>5 year without cART AND with always HIV-RNA \>50-10.000 copies/ml AND always CD4\> 500 cells/uL.~OR on cART, but before start cART \>5 year without cART AND with always HIV-RNA \>50-10.000 copies/ml AND always CD4\> 500 cells/uL"
62201609|NCT04968717||First-degree relatives of HIV elite controllers|
62201610|NCT04968717||cART-treated non-controller HIV patients|
62201611|NCT04968717||First-degree relatives of cART-treated non-controller HIV patients|
62201612|NCT03610672|ACTIVE_COMPARATOR|OD prevention/response training|Immediately following the baseline assessment, trained research staff will conduct a brief (20 min.) OD training with each participant. Participants will be asked to view the NYC Department of Health and Mental Hygiene's 13-minute OD prevention and response training video (available online free-of-charge). Following the video, research staff will review key information, answer any questions participants may have, demonstrate assembly of the intranasal naloxone atomizer and ensure participants are able to execute this assembly procedure. A prescription for naloxone, as well as a standard naloxone kit containing two doses of the medication and atomizers for intranasal administration, will be given to participants, along with printed literature reviewing key training information.
62201613|NCT03610672|EXPERIMENTAL|OD training + mobile PI intervention|Participants will complete the same baseline assessment and OD training (plus naloxone) as those in the first condition. Participants also will receive mobile phones pre-loaded with the PI App and will be sent daily prompts. As part of the PI App, participants will be asked to share information about avoiding problems associated with opioid use with peers in their social network, and to encourage their peers to download the PI App for their own use.
62201614|NCT04890405|ACTIVE_COMPARATOR|FMT group|Standardized FMT once.Extract all the flora from the feces provided by the donor to make fecal bacteria transplant capsules. The patient took orally on an empty stomach, each time using 3.2g of fecal bacteria.
62201615|NCT04890405|EXPERIMENTAL|JZ group|1.6g Po perday,for 28 days. probiotics that are effective against diarrhea were selected to make precise flora capsules, which are taken when the patient is on an empty stomach, once a day, using 1.6 g of bacteria per day, orally for 28 consecutive days.
62201616|NCT02518035|PLACEBO_COMPARATOR|Control|No silicone gel treatment after remove of stitches
62201617|NCT02518035|EXPERIMENTAL|Experimental|Silicone gel applied for twice per day
62201618|NCT05268536|ACTIVE_COMPARATOR|resistance exercise|Participants will perform Squat walking with resistance band, Butt blaster, Mussel with resistance band, Hip extension with resistance band, and Ankle dorsiflexion exercises with resistance band. All the participants will perform exercise for 6 weeks, 2 days a week for approximately 30-45 (including warm-up and cool-down).
62201619|NCT05268536|ACTIVE_COMPARATOR|core stabilization exercise|Patients will perform Plank, Bird dog, Double leg lifts, Prone cobra, Oblique twists exercises under the supervision of experienced Physiotherapist. All the participants will perform exercise for 6 weeks, 2 days a week for approximately 30-45 (including warm-up and cool-down).
62201620|NCT01419470|EXPERIMENTAL|YHD1044 I|
62402213|NCT00563602|EXPERIMENTAL|1|"Hemodynamic guided therapy:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
62402214|NCT02426164|ACTIVE_COMPARATOR|Liposomal bupivacaine|Periarticular infiltration of 20cc of liposomal bupivacaine with 20cc of normal saline administered prior to cementation of knee implants
62578986|NCT03073031|NO_INTERVENTION|Control|Patients have their side effects monitored by a physician every 3 weeks (control)
62578987|NCT00567658|PLACEBO_COMPARATOR|A 1|Arm I: placebo group receives BID placebo
62201621|NCT01419470|EXPERIMENTAL|YHD1044 III|
62201622|NCT01419470|EXPERIMENTAL|YHD1044 V|
62201623|NCT02997826|OTHER|1 to 21-days old child|
62201624|NCT03883100|EXPERIMENTAL|HQP1351|
62201625|NCT00317018|OTHER|Arm 1|Implementation Group
62201626|NCT00317018|NO_INTERVENTION|Arm 2|Control Group
62201627|NCT00703066|EXPERIMENTAL|1|three doses of 30µg GMZ2,
62201628|NCT00703066|EXPERIMENTAL|2|3 doses of 100 µg of GMZ2
62201629|NCT00703066|ACTIVE_COMPARATOR|3|Rabies vaccine
62785259|NCT01142622|EXPERIMENTAL|Ropivacaine nebulization|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
62201630|NCT03942692||Children with anaphylactic reaction|Children who underwent an anaphylactic reaction between the 1st July 2014 and the 31st June 2016 treated in Paediatric Emergency Department of Femme-Mère-Enfant Hospital in Lyon in France.
62201631|NCT02838992|EXPERIMENTAL|ATG, Cy and cord blood transfusion group|"ATG 3mg/kg/d for 5 days Cy 50mg/kg/d for 2 days CSA Started from 5mg/kg/d and adjusted to maintain trough serum concentration of 200-400ng/ml One unit of cord blood having no more than 3 HLA-A,B and DRB1 mismatches is transfused 24h after last dose of ATG administration.~Intervention:~Drug: Rabbit ATG, Thymoglobuline (Genzyme) plus Cyclophosphamide plus CSA Biological: Cord blood transfusion"
62785260|NCT01142622|ACTIVE_COMPARATOR|Ropivacaine instillation|Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity before surgery
62785261|NCT00857857|EXPERIMENTAL|13 day repeat dose|
62785262|NCT02679170||Routine clinical practice group (NSCLC ALK+, ROS1)|Patients diagnosed and treated following routine clinical practice, for their NSCLC ALK+ or ROS1
62785263|NCT02942485|EXPERIMENTAL|Metronidazole|Patients will be given rectal metronidazole (Flagyl) 500 mg/dose for children weighing 10-14,9 kg, 1000 mg/dose for those weighing 15-29,9 kg and 1500 mg/dose for those weighing 30-44,9 kg. Suppositories will not be halved. Patients will be given 1 dose/day for 3 days.
62201632|NCT02838992|ACTIVE_COMPARATOR|ATG and CSA group|ATG 3mg/kg/d for 5 days CSA started from 5mg/kg/d and adjusted to maintain trough serum concentration of 200-400ng/ml Intervention: Drug: Rabbit ATG, Thymoglobuline (Genzyme) plus CSA
62201633|NCT01913834|ACTIVE_COMPARATOR|Forsteo|Synthetic PTH 1-34 Single dose Subcutaneous administration 20.0 micrograms
62201634|NCT01913834|EXPERIMENTAL|CP046 PTH CriticalSorb 22.5 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 22.5 micrograms
62201635|NCT01913834|EXPERIMENTAL|CP046 PTH CriticalSorb 45.0 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 45.0 micrograms
62201636|NCT01913834|EXPERIMENTAL|CP046 PTH CriticalSorb 90.0 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 90.0 micrograms
62785264|NCT02942485|ACTIVE_COMPARATOR|Tinidazole|Patients will be treated with a standard regimen of oral tinidazole (Fasigyn) at a single dose of 50 mg/kg, maximum 2 g/dose
62785265|NCT02173171||Previously treated with T-VEC|Received at least 1 dose of talimogene laherparepvec on Amgen or BioVEX-sponsored clinical trial
62201637|NCT01913834|EXPERIMENTAL|CP046 PTH CriticalSorb 90.0 O|Synthetic PTH 1-34 Single dose Nasal administration 90 micrograms
62201638|NCT04709588|PLACEBO_COMPARATOR|placebo group|subjects drank 50 ml every night for 14, 28 days
62402215|NCT02426164|ACTIVE_COMPARATOR|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone administered prior to cementation of knee implants
62402216|NCT06397248||Healthy women|Healthy volunteers that do not have vaginal complaints or symptoms, and did not have any in the past 12 months.
62402217|NCT06397248||Women with an acute episode of vulvovaginal candidiasis|Women that have sporadic/acute vulvovaginal Candida infection. It's the first time or the first time in a longer period (1-2 years) that these women have an infection.
62785266|NCT00766714|EXPERIMENTAL|1|Cook K-SOFT-5100 catheter
62785267|NCT00766714|ACTIVE_COMPARATOR|2|Frydman classical catheter
62785268|NCT00180583|EXPERIMENTAL|1|Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
62785269|NCT05370833|EXPERIMENTAL|Standard protocol|5 tDCS sessions in 1 week
62201639|NCT04709588|EXPERIMENTAL|collagen drinks|subjects drank 50 ml every night for 14, 28 days
62201640|NCT05756296||Intervention group|Children aged 9 years old with NE-TH meeting study inclusion criteria.
62201641|NCT05756296||Control group|A comparison group of sex and age matched children with no NE-TH meeting similar study inclusion criteria to intervention group. Specific exclusion criteria for matched control group include a previous history of neurodevelopmental delay or disorder, or a traumatic brain injury, and born at term (gestational age ≥37 weeks), or born without neonatal complication.
62201642|NCT03979534|EXPERIMENTAL|Diet group|"Diet follow-up to personalize a low-protein diet for each patient. All patients following a low protein diet one month or more compose the diet group."
62201643|NCT03979534|NO_INTERVENTION|Control group|Patients who accepted to take part of the study but refused the low protein diet and patients who discontinued the diet on the first month compose the control group.
62785270|NCT05370833|EXPERIMENTAL|Enhanced protocol|11 tDCS sessions devised in 4 weeks
62201644|NCT04246164|ACTIVE_COMPARATOR|HD-tDCS combined with CT|HD-tDCS combined with CT, administered to participants with amnestic MCI (aMCI) in blocks of 5 daily treatments for a total of 15 sessions. There will be one treatment block/month for a total of 3 months
62201645|NCT04246164|SHAM_COMPARATOR|sham HD-tDCS combined with CT|sham HD-tDCS combined with CT, administered to participants with amnestic MCI (aMCI) in blocks of 5 daily treatments for a total of 15 sessions. There will be one treatment block/month for a total of 3 months
62201646|NCT00584077||Stable lung transplant recipients|All enrolled subjects receive the same procedures; bronchoscopy with administration of mechanical and chemical irritants to the airway mucosa
62201647|NCT00267514|OTHER|1|sevelamer carbonate powder x 4 weeks then, sevelamer hydrochloride x 4 weeks
62201648|NCT00267514|OTHER|2|sevelamer hydrochloride x 4 weeks then, sevelamer carbonate powder x 4 weeks
62201649|NCT02822430||Patients|"Patients with psychiatric disorders will be assessed using five evaluation of pain scales :~* Visual analogic scale pain~* Pain behaviour scale~* Short-FormHealth Survey (SF-36)~* Global Clinical Impression (GCI) for severity and improvement~* Mini International Neuropsychiatric Interview (MINI)"
62201650|NCT02976077|EXPERIMENTAL|RC2S+|"RC2S+~Preparation sessions (sessions 1 \& 2):~* Functional Outcomes Scale - Social Cognition (ERF-CS)~* Psychoeducation about social cognitive impairments~* Concrete objectives~Cognitive remediation (sessions 3 to 22):~* Paper-and-pencil session~* Simulation session~* Home-based task~Transfer sessions (sessions 23 \& 24):~* Transfer of skills in dayly life - generalization~* Assessment of the achievement of objectives"
62201651|NCT02976077|ACTIVE_COMPARATOR|Control therapy|"Control therapy~Preparation sessions (sessions 1 \& 2):~* Functional Outcomes Scale - Neurocognition~* Psychoeducation about cognitive impairments~* Concrete objectives~Cognitive remediation (sessions 3 to 24):~* Paper-and-pencil session~* Simulation session~* Home-based task"
62201652|NCT00657969||1|CAD-group (Cervical Artery Dissection - group): consecutive patients with cervical artery dissection, with or without associated cerebral ischemia, hospitalized in one of the participating neurological centers; standardized inclusion and exclusion criteria apply
62201653|NCT00657969||2|IS-group (Ischemic Stroke - Group): patients selected among consecutive patients hospitalized for an ischemic stroke without CAD, in the same centers as patients from group1, frequency-matched on age and gender with group1; standardized inclusion and exclusion criteria apply
62201654|NCT00657969||3|HC-group (Healthy Control - Group): DNA of healthy individuals from existing DNA-databases will be used as controls for the Belgian, French, German and Swiss centers; the other centers are recruiting their own age- and sex-matched healthy controls; individuals from the 3 groups (CAD, IS and HC) are strictly matched on geographical origin in order to avoid stratification bias
62201655|NCT01574196||Young adult survivors of childhood cancer|Young adult survivors of childhood cancer diagnosed between 1987 and 1992 in the Rhône-Alpes and Auvergne regions of France.
62201656|NCT01582230|EXPERIMENTAL|Vildagliptin|Eligible patients will receive vildagliptin 50 mg in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
62201657|NCT01582230|PLACEBO_COMPARATOR|Placebo|Eligible patients will receive matching placebo in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
62201658|NCT04577053|EXPERIMENTAL|PEMF Therapy|Pulsed ElectroMagnetic Field Therapy using square wave forms. In addition to set, pre-defined frequencies to aid the body's own immune system, the Artificial Intelligence incorporated into the software used will suggest a variety of frequencies to be administered during treatment. Due to the software's selection, these recommendations or selections from the software will likely be different in each treatment session.
62201659|NCT04577053|NO_INTERVENTION|Control|Control group will not receive treatment.
62201660|NCT02783573|EXPERIMENTAL|Lanabecestat 20 milligrams (mg)|Participants received Lanabecestat 20 mg film-coated tablets orally once daily until week 156.
62201661|NCT02783573|EXPERIMENTAL|Lanabecestat 50 mg|Participants received Lanabecestat 50 mg film-coated tablets orally once daily until week 156.
62201662|NCT02783573|EXPERIMENTAL|Placebo/ Lanabecestat 20 mg|Placebo given orally once daily for 78 weeks and then 20 mg of lanabecestat given orally once daily until week 156.
62201663|NCT02783573|EXPERIMENTAL|Placebo/ Lanabecestat 50 mg|Placebo given orally once daily for 78 weeks and then 50 mg of lanabecestat given orally once daily until week 156.
62201664|NCT00734591||Previously treated with Exubera|
62201665|NCT00734591||Previously treated with comparator|Subjects who had been treated with a comparator (other diabetes treatment such as injected insulin) in a prior Exubera controlled trial.
62402218|NCT06397248||Women that suffer from recurrent episodes of vulvovaginal candidiasis|These women encounter such infections at least 3 times a year. These women are targeted both during an infection and in between infections.
62201666|NCT05846958|EXPERIMENTAL|laser acupuncture|Each patient in this group will receive laser acupuncture based on the recommended LLLT treatment doses for CTS of the World Association of Laser Therapy.
62785271|NCT03656991|EXPERIMENTAL|0 month group|Receive the bicycle intervention at 0 months after enrollment.
62201667|NCT05846958|ACTIVE_COMPARATOR|control group|Each patient in this group will wear night splint every night for 4 weeks
62785272|NCT03656991|EXPERIMENTAL|2 month group|Receive the bicycle intervention at 2 months after enrollment.
62785273|NCT03656991|EXPERIMENTAL|4 month group|Receive the bicycle intervention at 4 months after enrollment.
62785274|NCT03656991|EXPERIMENTAL|6 month group|Receive the bicycle intervention at 6 months after enrollment.
62785275|NCT02130596|EXPERIMENTAL|Acceptance-Based Behavioral Intervention|
62785276|NCT02130596|ACTIVE_COMPARATOR|Nutritional Counselling|
62785277|NCT04860141|EXPERIMENTAL|Gabapentin group|The patient in this group will take gabapentin 600mg PO 2 hours prior to his or her surgery.
62201668|NCT06208904|EXPERIMENTAL|GIPRA (Glucose-dependent Insulinotropic Polypepetide Receptor Antagonist)|Intravenous infusion of GIP(3-30)NH2 in a concentration of 1,000 pmol/kg/min
62201669|NCT06208904|PLACEBO_COMPARATOR|Saline|Intravenous infusion of isotonic saline 9 mg/ml added 0,5% human serum albumin
62201670|NCT05262517|EXPERIMENTAL|BHV3000 (rimegepant)|One dose of rimegepant 75 mg ODT
62201671|NCT05262517|PLACEBO_COMPARATOR|Matching Placebo|One dose of matching placebo
62201672|NCT04623749|ACTIVE_COMPARATOR|Percutaneous US guided FNAC in pancreatic masses|
62201673|NCT04623749|ACTIVE_COMPARATOR|EUS guided FNAC in pancreatic masses|
62201674|NCT01355276|EXPERIMENTAL|1|
62201675|NCT01355276|ACTIVE_COMPARATOR|2|
62201676|NCT03766776|EXPERIMENTAL|Anlotinib Arm|
62201677|NCT04646291||Heterosexual Females with a Male partner|This cohort consists of heterosexual females with a male partner who have used the Mosie Baby Kit for insemination during at least one cycle
62201678|NCT04646291||Females in LGBTQ Relationships|This cohort consists of females in LGBTQ Relationships who have used the Mosie Baby Kit for insemination during at least one cycle.
62201679|NCT04646291||Solo parent|This generally will be a female without a partner who has used the Mosie Baby Kit for insemination during at least one cycle. However, it might also be a male who is using a surrogate female.
62201680|NCT02986191|EXPERIMENTAL|Mucograft|One side of the mouth will be subjected to Mucograft in this split-mouth study design.
62201681|NCT02986191|ACTIVE_COMPARATOR|Connective tissue graft|The opposite side of the mouth will be subjected to a connective tissue graft.
62201682|NCT05908851|NO_INTERVENTION|Regional Brachial Plexus Blockade|Ultrasound guided brachial plexus blocade with 10 ml of 0.5% ropivacaine using a high frequency linear array transducer.
62201683|NCT05908851|EXPERIMENTAL|Local Infiltration Anesthesia|High volume local infiltration anesthesia with 100 mL of 0.9% normal saline (57ml), 0.5% ropivacaine (40 ml), 10 mg morphine (10 mg/ml), 0.1 mg of epinephrine (0.1 mg/ml), and 30 mg of ketorolac (30 mg/ml) divided equally into a 20 ml five-zone field infiltration into the suprascapular notch/posterior capsule (suprascapular and axillary nerves), coracobrachialis muscle, anterior deltoid muscle, superior pectoralis major muscle, and skin incision at the conclusion of the procedure by the treating surgeon.
62201684|NCT02368457|EXPERIMENTAL|Pentoxifylline and Tocopherol|Drug: pentoxifylline with tocopherol Combination of pentoxifylline and tocopherol during a minimum of 6 months and a maximum of 24 months.
62201685|NCT02368457|NO_INTERVENTION|CONTROL|No drug treatment
62201686|NCT05990790|EXPERIMENTAL|Desflurane Group|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±10.
62201687|NCT05990790|ACTIVE_COMPARATOR|Sevoflurane Group|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±10.
62201688|NCT05990790|ACTIVE_COMPARATOR|Propofol Group|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of propofol with an intraoperative goal of bispectral index (BIS) 50±10.
62201689|NCT03557671|EXPERIMENTAL|TRHF - Placebo|Each subjects will receive both TRHF and placebo formula during the 1st part of the study
62201690|NCT03557671|PLACEBO_COMPARATOR|Placebo - TRHF|Each subjects will receive both TRHF and placebo formula during the 1st part of the study
62201691|NCT03876470||All Participants|All participants will receive HCV treatment as determined by their provider. HCV treatment is not assigned by the study.
62201692|NCT05352841||Caries free children|Children old 72 months or younger with no caries lesion
62201693|NCT05352841||Children with severe form of early childhood caries|Children with severy form of early childhood caries, S-ECC are those having 3 to 5 years , and have more than four, five and six tooth surfaces affected in the primary front teeth at 3, 4 and 5 years, respectively. Caries in children under 3 years of age involving one or more smooth surfaces and in children under 6 years of age affecting one or more smooth surfaces in the front teeth or total dmfs score equal or higher than 6 would be also classified as S-ECC.
62785278|NCT04860141|PLACEBO_COMPARATOR|Placebo group|The patient in this group will take a placebo that looks like gabapentin PO 2 hours prior to his or her surgery.
62785279|NCT05063682|EXPERIMENTAL|Treatment|Patients receive EGFRvIII -CAR T cells intracerebroventricular over 15 minutes on day 1. Patients may receive additional cycles based on the persistence of the cells.
62785280|NCT02715986|EXPERIMENTAL|Severly depressed patients|Recruitment of twenty depressive subjects will be conducted within the hospital service adult psychiatry.These patients are referred for indication of ECT sessions for severe resistant depression. Four MRI evaluations (3T MRI examination) are programmed in such patients to analyze structural changes in the hippocampus.
62013333|NCT02762669|ACTIVE_COMPARATOR|Continuous oxytocin + 60 minute recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 60 minutes. The strip will then be exposed to 10-7 oxytocin for 10 minutes.
62013334|NCT00812812|EXPERIMENTAL|paroxetine group|paroxetine 10-40mg/day
62201694|NCT04654949|EXPERIMENTAL|Horticultural Therapy|The Horticultural Therapy group receives 30 minutes of horticultural therapy activities using mobile horticulture kits conducted by therapists or therapy assistants to engage participants at their bedside.
62201695|NCT04654949|NO_INTERVENTION|Existing Care|The existing Care group receives 30 minutes of routine ward-based engagement leisure activities (e.g. watching television, reading newspapers, etc).
62201696|NCT01512316|ACTIVE_COMPARATOR|d-Cycloserine Acquisition|d-Cycloserine will be given on day1, before acquisition
62201697|NCT01512316|ACTIVE_COMPARATOR|d-Cycloserine Extinction|d-Cycloserine will be administered on day2, before extinction
62201698|NCT01512316|PLACEBO_COMPARATOR|Placebo|A placebo pill will be administered on day1 and 2
62201699|NCT03697122|EXPERIMENTAL|HHBC and Forced Air Warming|Patients admitted to intensive care unit hypothermic (≤ 35 C) following surgical procedures involving cardiopulmonary bypass. Will be rewarmed with heated humidified breathing circuits (ANAPOD) and standard forced air warming blankets.
62201700|NCT01170793|NO_INTERVENTION|2|no educative telephone coaching (ETC)
62201701|NCT01170793|EXPERIMENTAL|1|with educative telephone coaching (ETC)
62201702|NCT00458081|EXPERIMENTAL|Rimonabant|
62013335|NCT00812812|PLACEBO_COMPARATOR|placebo group|matched placebo to paroxetine
62201703|NCT00458081|PLACEBO_COMPARATOR|Placebo|
62201704|NCT01523067|ACTIVE_COMPARATOR|Vasomera (PB1046)|
62201705|NCT01523067|PLACEBO_COMPARATOR|0.9% Sodium Chloride|
62201706|NCT02318615|EXPERIMENTAL|Immediate Axillary Plasty|Immediate Axillary Plasty ：After axillary lymph node dissection, a pedicled flap named Partial Latissimus Dorsi Muscle Flap is filled in the cavity of axilla, and fixed around the axillary vessels.
62201707|NCT02318615|NO_INTERVENTION|Education|Education：After surgery, education on the prevention of lymphedema. In patients suffering with upper limb lymphedema during follow-up, any treatment except axillary or breast reconstruction can be used.
62201708|NCT00777764|EXPERIMENTAL|Healthy Volunteers|Healthy participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and 1:1000, 1:100, 1:10 dilution and full concentrations of both omalizumab and omalizumab excipients.
62402219|NCT02478606|NO_INTERVENTION|Control Group|Without intervention
62402220|NCT02478606|EXPERIMENTAL|Static Group|Will receive passive static stretching in hamstring muscle
62013336|NCT05121116|EXPERIMENTAL|Active intervention condition|Participation in an 8-week, online, self-directed MBSR program.
62013337|NCT05121116|NO_INTERVENTION|Waitlist control condition|Participants in the waitlist control condition received no active intervention during the trial period but received a link to the MBSR program after completing the post-intervention assessments.
62013338|NCT04113252|EXPERIMENTAL|Group 1--Diary and Possible Opioid Return Incentive|Participants in this arm will be given incentives upon return of completed diary and will have the possibility to earn incentives for returning any leftover tablets to the study team.
62013339|NCT04113252|EXPERIMENTAL|Group 2--Diary, Coaching, Possible Opioid Return Incentive|Participants in this arm will be given coaching. They will also be given incentives upon return of completed diary and will have the possibility to earn incentives for returning any leftover tablets to the study team.
62201709|NCT00777764|EXPERIMENTAL|Allergic Asthma Participants|Allergic asthma participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and a succession of 1:1000, 1:100, 1:10 dilutions and full concentration of both omalizumab and omalizumab excipients.
62201710|NCT05176938|EXPERIMENTAL|Ultrasound guided Thoracic Interfascial plane Block (TIFB)|Patients will receive (20ml) (plain bupivacaine 0.25% injected in the serratus intercostal space at 6 ribs midaxillary line and (20ml) in pecto-intercostal space at 2 ribs parasternal.
62201711|NCT05176938|EXPERIMENTAL|Ultrasound guided Erector Spinae plane Block (ESPB)|Patients will receive (20ml) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the fourth thoracic segment (T4).
62201712|NCT05176938|NO_INTERVENTION|General anesthesia|Patients will receive general anesthesia only without blocks.
62201713|NCT04407689|EXPERIMENTAL|CYT107|Intra-muscular administration of CYT107 twice a week for a total of 5 administrations
62201714|NCT04407689|PLACEBO_COMPARATOR|Saline|Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations
62201715|NCT04458922|EXPERIMENTAL|Treatment (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on ay 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scans and undergo biopsy and collection of blood samples on study.
62201716|NCT04915274|EXPERIMENTAL|Adult cancer patients|Patients will be provided with the QuestOnco application for monitoring
62201717|NCT03686423|EXPERIMENTAL|Patients with Type 2 Diabetes and Clinical Symptoms of DPN|Patients will be individually prescribed to a 10-week exercise program with both aerobic and resistance components. Prior to beginning the intervention, patients will participate in a maximal graded exercise test (VO2R) using a cycle ergometer with a metabolic cart and integrated ECG.
62215060|NCT05007080|EXPERIMENTAL|Group 5: Ad26.COV2.S Dose Level 2: 2-Dose Regimen|Participants will receive 2-doses of Ad26.COV2.S at dose level 2 on Day 1 and Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination.
62402221|NCT02478606|EXPERIMENTAL|PNF Group|Will receive passive proprioceptive neuromuscular facilitation stretching in hamstring muscle
62402222|NCT02823223|EXPERIMENTAL|ELVR with Endobronchial Valves|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Endobronchial Valves (Zephyr valve) inserted into the target lobe of the lung with the aim of complete lobar exclusion.
62402223|NCT02823223|NO_INTERVENTION|Standard of Care|Patients will receive optimal drug therapy and medical management according to clinical practice
62402224|NCT04554563|EXPERIMENTAL|Training group|4-week core stability training
62402225|NCT04554563|NO_INTERVENTION|Control group|Standard physical therapy
62201718|NCT03807895|EXPERIMENTAL|REBT Career Intervention|High-school students in the experiment group attend to eight modules of career intervention with rational emotive behavioral therapy (REBT) techniques. The eight modules aim a different component: Psychoeducation, Information about the self and the world of work, Steps of Decision making, Relationship between cognitive distortions/irrational beliefs and emotions, Cognitive Restructuring, Exposure/behavior activation and problem solving, Planning, Goal Setting.
62201719|NCT03807895|ACTIVE_COMPARATOR|Regular Career Intervention|High-school students in the treatment as usual group attend to eight modules of career intervention with regular career intervention techniques. The eight modules aim a different component: Psychoeducation, Information about the self and the world of work, Steps of Decision making, Problem solving, Planning, Goal Setting.
62201720|NCT04419129|ACTIVE_COMPARATOR|Mobile bearing unicompartmental knee arthroplasty|50 mobile bearing UKA
62578988|NCT00567658|EXPERIMENTAL|A2|subjects receive active drug, esomeprazole 40 mg BID
62578989|NCT01563822|EXPERIMENTAL|follicular fluid group|Follicular fluid group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is done.
62578990|NCT01563822|NO_INTERVENTION|control group|Control group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is not done.
62013340|NCT04113252|EXPERIMENTAL|Group 3--Diary and coaching|Participants in this arm will be given coaching. They will also be given incentives upon return of completed diary.
62013341|NCT03231384|EXPERIMENTAL|RIC group|The upper limb ischemic conditioning is composed of five cycles of upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 2 hours after r-tPA thrombolytic therapy. In addition, all participants receive a standard clinical therapy.
62013342|NCT03231384|NO_INTERVENTION|Control group|The participants received r-tPA thrombolytic therapy after diagnosed ischemic stroke. In addition, all participants receive a standard clinical therapy.
62013343|NCT06533709||SYSU cohort|Patients cohort from Sun Yat-sen Memorial Hospital, as the training cohort.
62013344|NCT06533709||ZJCH cohort|Patients cohort from Zhejiang Cancer Hospital, as the external validation cohort.
62013345|NCT00192179|EXPERIMENTAL|CAIV-T|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
62013346|NCT00192179|PLACEBO_COMPARATOR|Placebo|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
62013347|NCT03652324|OTHER|randomized|
62013348|NCT01132079|EXPERIMENTAL|Pimecrolimus cream treatment|
62013349|NCT01132079|ACTIVE_COMPARATOR|Betamethasone valerate cream treatment|
62013350|NCT03850886|EXPERIMENTAL|Niacinamide group|Niacinamide oral tablets as Nature's Life 1000 mg tablets once daily for 3 months diabetes management including metformin or Sulphonylurea
62013351|NCT03850886|ACTIVE_COMPARATOR|Control group|diabetes management including metformin or Sulphonylurea
62013352|NCT04578314|EXPERIMENTAL|Relating module + Treatment as usual|Participants in this arm will receive 16 weekly sessions with Relating Therapy (RT) over 5 months in addition to their treatment as usual.
62013353|NCT04578314|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include Cognitive Behavior Therapy or psychodynamic interventions.
62013354|NCT06566274|ACTIVE_COMPARATOR|thumbtack needle (TTN) group|The main acupoints of treatment are CV1, SP, and bilateral ST36, with a total of 5 acupoints. Patients with liver and stomach disharmony should be added bilateral BL17, patients with phlegm-dampness obstruction should be added bilateral ST40, and patients with weak spleen and stomach should be added bilateral BL21. The above acupoints are treated with TTN. The TTN will be reserved in the acupoints for 3 days. After 3 days of retention of TTN, the patient is instructed to go to the hospital and receive the next TTN treatment. A total of 5 treatments were applied for a duration of 15 days.
62201721|NCT04419129|ACTIVE_COMPARATOR|posterior stabilized fixed bearing total knee arthroplasty|50 posterior stabilized fixed bearing cemented total knee arthroplasty
62201722|NCT04068233|EXPERIMENTAL|Eligible patients - pacing mode sequence 1|Echo assessment of parameters of diastolic function, systolic function, and atrial function. Then, the stroke volume and cardiac output are measured during AV-asynchronous and AV-synchronous pacemaker stimulation: AV-synchronous pacing mode first, then AV-dyssynchronous pacing mode.
62402226|NCT00638950|PLACEBO_COMPARATOR|Placebo|
62402227|NCT00638950|ACTIVE_COMPARATOR|n-3 LC-PUFA|
62578991|NCT02120833|ACTIVE_COMPARATOR|EPI|
62578992|NCT02120833|EXPERIMENTAL|NEE|
62578993|NCT05108636|EXPERIMENTAL|Therapeutic Touch|"TD process:~* After the procedure was explained, the focus was on the child to be treated,~* Intended to help the child's treatment and sleep,~* The patient's energy field was scanned with the hands at a distance of 8-12 cm from the patient's skin (2 times)~* To remove the blockages determined regarding the energy flow and to facilitate the energy flow, manual cleaning was performed (2 times),~* Imbalances in the energy fields were tried to be treated by using mental visualization techniques such as dreaming, positive thinking and visualization, by directing the universal life energy to sick individuals with calm and rhythmic hand movements (2 times),~* Reassessed to determine whether success has been achieved in treating imbalances in the energy field."
62785281|NCT01304537|EXPERIMENTAL|Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 40 mg/kg throughout the study.
62785282|NCT01304537|EXPERIMENTAL|Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 60 mg/kg throughout the study.
62402228|NCT03333564|EXPERIMENTAL|VD3 group|treated with 50,000 IU VD3 / week
62578994|NCT05108636|EXPERIMENTAL|Music Rest|"* Parents and children will be informed about the Music Rest before the procedure.~* One day before the Music Rest practice, the child's sleep will be evaluated with Actigraphy. Starting the day after the first measurement, the Music Rest will be held for three days as a 20-minute practice period per day. In order to help the child sleep, the child will be listened to music (such as lullaby, classical music) preferred by the patient or his family.~* Before the Music Rest application, the patient's room will be ventilated and a spacious and quiet environment will be provided during the application.~* The sound level of the music played will be kept between 45-65 dB.~* Nursing interventions will be written in more detail after the data of the research is collected."
62578995|NCT03070002|EXPERIMENTAL|Treatment (denosumab)|Patients receive denosumab SC on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression, unexpected toxicity, or patient withdrawal or death.
62785283|NCT01304537|EXPERIMENTAL|Alpha-1 Antitrypsin 80mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 80 mg/kg throughout the study.
62785284|NCT05507151||Endoscopic Sleeve Gastroplasty|endoscopic suturing of the stomach
62201723|NCT04068233|EXPERIMENTAL|Eligible patients - pacing mode sequence 2|Echo assessment of parameters of diastolic function, systolic function, and atrial function. Then, the stroke volume and cardiac output are measured during AV-asynchronous and AV-synchronous pacemaker stimulation: AV-dyssynchronous pacing mode first, then AV-synchronous pacing mode.
62201724|NCT02906826|NO_INTERVENTION|Reported adherence|During a 4 month period the investigators will measure adherence to therapy as reported in a daily diary by participants against actual adherence which will be measured by a digital manometer attached to the participants therapy device which uploads real time data to the cloud.
62402229|NCT03333564|EXPERIMENTAL|omega3-FA group|1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
62578996|NCT01511029|EXPERIMENTAL|Dexpramipexole|
62785285|NCT04190732|EXPERIMENTAL|Physician phone call|Participants will receive a five-minute phone call from one physician 3 to 4 days after a fresh or frozen embryo transfer. The physician will not have access to patient specific IVF cycle details. The phone call will follow scripted questions and utilize scripted phrases to help minimize variation.
62785286|NCT04190732|NO_INTERVENTION|Routine care|Participants will receive routine care and no physician phone call will be performed during the waiting period between embryo transfer and the pregnancy test.
62578997|NCT01511029|PLACEBO_COMPARATOR|Dexpramipexole (placebo)|
62785287|NCT05515991|EXPERIMENTAL|SUPPORT-DIALYSIS with Access to Output Report and Information Hub|Feasibility of SUPPORT-Dialysis at Toronto General Hospital
62785288|NCT05515991|EXPERIMENTAL|SUPPORT-DIALYSIS Only|Usual Treatment at Humber River Hospital
62785289|NCT05089864|OTHER|Early stent placement|Stent placement 5-7 weeks post-STAR procedure
62785290|NCT05089864|OTHER|Later stent placement|Stent placement 12-14 weeks post-STAR procedure
62013355|NCT06566274|SHAM_COMPARATOR|sham TTN group|The acupoints of sham TTN group are the same as those of TTN group. The use of sham TTN was the same as that of the TTN group. After 3 days retention of sham NNT, the patient was instructed to go to the hospital, where the doctor removed the sham TTN, and conducted the next treatment after local skin disinfection. A total of 5 treatments were given for a duration of 15 days.
62201725|NCT02906826|ACTIVE_COMPARATOR|Adherence with a video game|During the second 4 month period, participants will be given a video game on a tablet which is operated through the digital manometer by their performing their therapy correctly.Actual adherence will be measure again during this time and be compared to the no intervention arm
62785291|NCT04563962|EXPERIMENTAL|Contingency Management-ART|Contingency management intervention with incentives tied to provision of urine samples with detectable levels of Tenofovir (TFV).
62402230|NCT03333564|EXPERIMENTAL|VD3 and Omega-3FA group|50,000 IU VD3 / week and 1000 mg wild salmon and fish oil complex (contains 300 mg of omega-3FA) once daily
62402231|NCT03333564|OTHER|Control group|No intervention was given
62785292|NCT04563962|ACTIVE_COMPARATOR|Contingency Management-Methamphetamine|Contingency management intervention with incentives tied to provision of urine samples with no detectable levels of methamphetamine (MA).
62785293|NCT02106403|EXPERIMENTAL|Prototype disinfectant spray formulation|0.13% w/w Benzalkonium Chloride (BAC) and 1% Menthone Glycerin Acetal (MGA). After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
62785294|NCT02106403|ACTIVE_COMPARATOR|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
62785295|NCT02106403|PLACEBO_COMPARATOR|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
62013356|NCT00928148|EXPERIMENTAL|SPD465 (50 or 75 mg)|
62013357|NCT00928148|ACTIVE_COMPARATOR|Immediate Release Amphetamine salt (25 mg)|
62013358|NCT00928148|PLACEBO_COMPARATOR|Placebo|
62402232|NCT06282263|EXPERIMENTAL|Intervention Group|"Awareness Development Program on Suicide Prevention for Oncology Nurses was applied to the nurses in the experimental group."
62402233|NCT06282263|NO_INTERVENTION|Control Group|No programme was applied to the control group.
62402234|NCT06442111|EXPERIMENTAL|The experimental group|inclusion criteria : patients with periampullary tumor for whom pancreaticoduodenectomy is planned.
62578998|NCT01511029|ACTIVE_COMPARATOR|Moxifloxacin|
62578999|NCT02966886|ACTIVE_COMPARATOR|Participants with 10-15 degrees of glenoid retroversion|
62579000|NCT02966886|ACTIVE_COMPARATOR|Participants with >15 degrees of glenoid retroversion|
62579001|NCT02807727|ACTIVE_COMPARATOR|Intralipid 20%|Intravenous single bolus of 1.5 ml/kg of Intralipid 20% over 3 minutes.
62785296|NCT02183233|EXPERIMENTAL|Eschscholtzia Californica|
62785297|NCT02183233|PLACEBO_COMPARATOR|Eschscholtzia Californica Placebo|
62785298|NCT01886703|EXPERIMENTAL|Walking Intervention|Pedometer Walking Program
62013359|NCT02928341|NO_INTERVENTION|No intervention|Current water supply access
62215061|NCT05007080|EXPERIMENTAL|Group 6: Ad26.COV2.S Dose Level 3: 2-Dose Regimen|Participants will receive 2-doses of Ad26.COV2.S at dose level 3 on Day 1 and Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination.
62402235|NCT06442111|EXPERIMENTAL|The placebo group|inclusion criteria : patients with periampullary tumor for whom pancreaticoduodenectomy is planned.
62785299|NCT00005949|EXPERIMENTAL|Treatment (gp100:209-217, aldesleukin )|Patients receive gp100:209-217(210M) emulsified in Montanide ISA-51 SC on day 1 and interleukin-2 SC on days 1-5 and 8-13. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Patients with a CR receive 3 additional courses after achieving CR.
62785300|NCT01916343|EXPERIMENTAL|Study Laparoscopic Curriculum|Residents will perform a salpingectomy in the operating room, which will be video-recorded through the laparoscopic camera. The residents in the intervention group will then complete the salpingectomy at the conclusion of the curriculum. Following the completion of the curriculum, residents in the intervention group will undergo a multiple-choice examination as well as a repeat skills examination.
62785301|NCT01916343|NO_INTERVENTION|Standard Clinical Education|Residents will perform a salpingectomy in the operating room, which will be video-recorded through the laparoscopic camera. The standard clinical education residents will perform the procedure as per standard of care.
62785302|NCT04879173||Hyperthyroidism caused by Graves' disease|
62785303|NCT04879173||Hyperthyroidism caused by painless/subacute thyroiditis|
62785304|NCT02806453|ACTIVE_COMPARATOR|Group A|Group A: Mg alginate/thickened formula
62785305|NCT02806453|ACTIVE_COMPARATOR|Group B|Group B: thickened formula/Mg alginate
62785306|NCT00235144|EXPERIMENTAL|1|drug-eluting stent
62785307|NCT00235144|ACTIVE_COMPARATOR|2|bare-metal stent
62785308|NCT03910114||Dotarem Enhancement Group|
62013360|NCT02928341|EXPERIMENTAL|Intervention|Received water supply improvement intervention designed to improve access to tap water, consisting of community managed public taps, improved tap water distribution network, refurbished tap connections and promotion of new household tap connections.
62013361|NCT03714633|EXPERIMENTAL|Stockholm Preterm Interaction-Based Intervention (SPIBI)|Home-based post-discharge intervention for extreme premature babies and their parents. The intervention consists of one hospital visit, nine home-visits and two telephone calls during the first year corrected age, specifically from one week before discharge to 12 months corrected age. The intervention is strengths-based working with the infant-parent interaction, supporting infant development and strengthening the parent in his/her role.
62013362|NCT03714633|NO_INTERVENTION|Control|The participants of the Control Group receives treatment as usual, which consists of a regular follow-up program with neurodevelopmental assessment at term age, 3 months corrected age, 12 months corrected age, 24 months corrected age and 66 months corrected age. Compared to children not participating in the study, the control group will receive an extended follow-up program, with assessment and questionnaires at term age, 3 months corrected age, 12 months corrected age, 24 months corrected age and 36 months corrected age. Participants in the control group will be referred to specialized care when needed.
62013363|NCT02424916|EXPERIMENTAL|Autologous somatic cell therapy|Patients treated with melanoma antigens-specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
62402236|NCT00501969|EXPERIMENTAL|Rotigotine|Rotigotine
62402237|NCT05894824|OTHER|Single arm, Trastruzumab deruxtecan, Ramucirumab|
62402238|NCT01355237||OCC Patients|Patients being treated for chronic low back pain at the Osher Clinical Center of Brigham and Women's Hospital
62402239|NCT01355237||Comparison|Patients being treated for chronic low back pain at Brigham and Women's Hospital, other than at Osher Clinical Center
62579002|NCT02807727|PLACEBO_COMPARATOR|Modified Ringers Lactate|Intravenous single bolus of 1.5 ml/kg of MRL over 3 minutes.
62785309|NCT03910114||Gadovist Enhancement Group|
62785310|NCT03910114||Magnevist Enhancement Group|
62785311|NCT03849222|ACTIVE_COMPARATOR|Ca(OH)2 Apexification|Apexification was performed with calcium hydroxide. calcium hydroxide dressing was applied directly against the open apex .The canals were back filled with Ca(OH)2 dressing, followed by proper coronal seal. Patients were recalled every 3, 6 and 12 months for evaluation clinically and radiographically. Once the calcific apical barrier was detected the root canals were then obturated and final restoration was done.
62410084|NCT02355366|EXPERIMENTAL|Family Focused Therapy (FFT)|Participants will receive Family-Focused Therapy (FFT). It will consist of twelve, 1-hour long sessions, over a period of 4 months. The 12 sessions will include psychoeducation (sessions 1-4), training in communication enhancement (sessions 5-8) and training in relation to problem-solving skills (sessions 9-12).
62215062|NCT02942433|EXPERIMENTAL|Radio Program|Married couple participants will be asked to interact with a radio program and participate in weekly, sex-separate listening and discussion groups (LDG) that each last for between 75 and 120 minutes over the course of 9 months.
62402240|NCT02835989|EXPERIMENTAL|CP@Home Intervention|"The experimental group will receive the CP@Home program. The main elements of this program include BP assessment, diabetes risk assessment, falls risk assessment, heart failure risk assessment, neurologic assessment, psychiatric assessment, depression screening, health-related quality of life analysis (including pain, mobility, anxiety/depression, ADLs), social isolation screening, and food and income security. The program is targeted at referrals to appropriate community resources, identification and referral of high-risk patients to their family physician (FP), as well as regular communication of participants' health information to their physician.~The intervention will be implemented by community paramedics from the local paramedic service who have undergone a structured training program (4 hours of online, interactive training modules, including case studies and the observation of an intervention visits led by another paramedic) to assure intervention fidelity."
62402241|NCT02835989|NO_INTERVENTION|Control|Usual Care
62402242|NCT02027831|EXPERIMENTAL|Indocyanine Green|Intravenous injection of 0,25 mg/kg Indocyanine Green
62402243|NCT03586427|EXPERIMENTAL|AGN-241751 Dose 1|AGN-241751 Dose 1 administered as 1 tablet taken orally every day
62402244|NCT03586427|EXPERIMENTAL|AGN-241751 Dose 2|AGN-241751 Dose 2 administered as 1 tablet taken orally every day
62402245|NCT03586427|EXPERIMENTAL|AGN-241751 Dose 3|AGN-241751 Dose 3 administered as 1 tablet taken orally every day
62013364|NCT01540227||Syphilis Patients|Individuals presenting for treatment of primary, secondary or early latent syphilis at the Ottawa Hospital Immunodeficiency Clinic, the Ottawa Sexual Health Clinic or its satellite GayZone, the Montreal Chest Institute Immunodeficiency Clinic, or the Toronto General Immunodeficiency Clinic will be invited by their attending health care worker to participate in this study. Only patients presenting for and requiring treatment of infectious syphilis will be asked to participate.
62013365|NCT00637169|EXPERIMENTAL|1|Supplemental oxygen to maintain functional arterial oxygen saturations in the range of 85-89%. Dose of oxygen is determined by the individual infant's need to achieve the target oxygen saturations.
62013366|NCT00637169|ACTIVE_COMPARATOR|2|Supplemental oxygen to maintain functional arterial oxygen saturations in the range of 91-95%. Dose of oxygen is determined by the individual infant's need to achieve the target oxygen saturations.
62013367|NCT02873104|ACTIVE_COMPARATOR|Treatment|truSculpt rf device, therapeutic settings
62013368|NCT02873104|SHAM_COMPARATOR|Sham|truSculpt rf device, non-therapeutic settings
62013369|NCT04886167|ACTIVE_COMPARATOR|120U abobotulinumtoxinA|"Treatment of platysmal bands using a total of 120 U abobotulinumtoxinA. This will involve 24 injection sites (6 injections per each of 4 platysmal bands), with each injection site receiving 0.025mL (5 U).~At the 14 day visit, an optional touch-up using up to 90 U of abobotulinumtoxinA can be performed. This will involve up to 18 injection sites, with each injection site receiving 0.025mL (5 U)."
62013370|NCT04886167|ACTIVE_COMPARATOR|180U abobotulinumtoxinA|"Treatment of platysmal bands using a total of 180 U abobotulinumtoxinA. This will involve 24 injection sites (6 injections per each of 4 platysmal bands), with each injection site receiving 0.0375mL (7.5 U).~At the 14 day visit, an optional touch-up using up to 90 U of abobotulinumtoxinA can be performed. This will involve up to 12 injection sites, with each injection site receiving 0.0375mL (7.5 U)."
62013371|NCT04886167|ACTIVE_COMPARATOR|240U abobotulinumtoxinA|"Treatment of platysmal bands using a total of 240 U abobotulinumtoxinA. This will involve 24 injection sites (6 injections per each of 4 platysmal bands), with each injection site receiving 0.05mL (10 U).~At the 14 day visit, an optional touch-up using up to 120 U of abobotulinumtoxinA can be performed. This will involve up to 12 injection sites, with each injection site receiving 0.05mL (10 U)."
62013372|NCT02536521||Hemodynamically stable|
62013373|NCT02536521||Hemodynamically unstable|Hemodynamically unstable patients are defined as those with a 20% decrease in systolic blood pressure according to the change of intraabdominal pressure.
62013374|NCT01046955|ACTIVE_COMPARATOR|1mg/kg Thymoglobulin|LD kidneys receiving 1mg/kg Thymoglobulin for 7 days starting at the day of surgery.
62013375|NCT01046955|ACTIVE_COMPARATOR|Campath-1H at 0.3 mg/kg|Recipients of LD kidneys receiving Campath-1H at 0.3 mg/kg once on the day of surgery and again 3 days post-operatively.
62013376|NCT01046955|ACTIVE_COMPARATOR|Zenapax 1 mg/kg|Recipients of LD kidneys receiving Zenapax 1mg/kg on the day of surgery followed by the same dose every 2 weeks for a total of 5 dosages.
62013377|NCT00997997||Group 1|
62013378|NCT05163912|EXPERIMENTAL|Intervention|Virtual home intervention
62013379|NCT04993352|EXPERIMENTAL|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody.
62402246|NCT03586427|EXPERIMENTAL|AGN-241751 Dose 4|AGN-241751 Dose 4 administered as 1 tablet taken orally every day
62402247|NCT03586427|PLACEBO_COMPARATOR|Placebo|Placebo administered as 1 tablet taken orally every day
62402248|NCT05671042||Patients with Upper excretory tract tumors|Adult patient with Upper excretory tract tumors Neoadjuvant chemotherapy treatment received between 2010 and 2020.
62402249|NCT01487746||treatment|Stroke patients
62402250|NCT01487746||Controls|healthy controls
62785312|NCT03849222|EXPERIMENTAL|Ca(OH)2 Apexification with apical matrix|Treated by condensation of calcium hydroxide dressing against an internal matrix , a piece (4X4mm) of resorbable collagen membrane (Biocollagen; Bioteck:Turin, Italy) was gently compacted toward the apex before insertion of Ca(OH)2 dressing, followed by proper coronal seal. Patients were recalled every 3, 6 and 12 months for evaluation clinically and radiographically. Once the calcific apical barrier was detected the root canals were then obturated and final restoration was done.
62201726|NCT04912427|EXPERIMENTAL|Isatuximab + Boretezomib + Dexamethasone|"* Each cycle is 28 days~* Cycle 1~  * Days 1, 8, 15, and 22: Dexamethasone at start time, Bortezomib at 30 minutes after start time, and Isatuximab at 60 minutes after start time~* Cycles 2-8~  * Days 1 and 15: Dexamethasone at start time, Bortezomib at 30 minutes after start time, and Isatuximab at 60 minutes after start time~ * Days 8 and 22: Dexamethasone at start time and Bortezomib at 30 minutes after start time~* Cycles 9+~  * Days 1 and 15: Dexamethasone at start time and Isatuximab at 30-60 minutes after start time"
62785313|NCT03849222|ACTIVE_COMPARATOR|MTA Apexification|Apexification was performed with MTA as apical plug. A 3-5 mm thickness of MTA using a hand plugger was applied as apical plug and verified radiographically. Moist cotton pellet was placed over the MTA followed by application of coronal seal. After 48 h, the set of the MTA was checked and final obturation of the root canal was done
62201727|NCT02016677||observation|no specific treatment. Long term observation the results of any breast lifting or reduction surgeries
62201728|NCT02037620|EXPERIMENTAL|Epidural Stimulation|80 sessions each of epidural spinal cord stimulation for 1) cardiovascular function; 2) voluntary movement; and 3) standing.
62201729|NCT01979406|ACTIVE_COMPARATOR|AVA|Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
62201730|NCT01979406|EXPERIMENTAL|Ad4-PA-1|"Given at 10\^9, 10\^10 and 10\^11 vp~Ad4-PA at Day 1 + oral placebo on Day 15 + AVA boost at Day 29"
62201731|NCT01979406|EXPERIMENTAL|Ad4-PA-2|"Given at 10\^9, 10\^10 and 10\^11 vp~Ad4-PA at Days 1, 15 and 29"
62201732|NCT01979406|EXPERIMENTAL|Ad4-PA-3|"Ad4 given at 10\^9, 10\^10 and 10\^11 vp~Ad4 PA-GPI at Day 1 + AVA boost at Day 15 + placebo on Day 29"
62201733|NCT01979406|EXPERIMENTAL|Ad4-PA-GPI-1|"Given at 10\^9, 10\^10 and 10\^11 viral particles~Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15"
62201734|NCT01979406|EXPERIMENTAL|Ad4 PA-GPI-2|"Given at 10\^9, 10\^10 and 10\^11 viral particles~Ad4 PA-GPI at Day 1 + placebo on Day 15 + AVA boost at Day 29"
62201735|NCT01979406|EXPERIMENTAL|Ad4-PA-GPI -3|"Given at 10\^9, 10\^10 and 10\^11 viral particles~Ad4-PA-GPI at Days 1, 15 and 29"
62201736|NCT00253682||1|HIV-uninfected infants born to HIV-infected women with in-utero exposure to HIghly Active Ani-Retroviral Therapy (HAART) who were enrolled in the Women and Infants Transmission Study (WITS).
62201737|NCT00253682||2|Historical cohort of HIV-uninfected infants born to HIV-infected women from the Pediatric Pulmonary and Cardiovascular Complications of HIV Study (P2C2 HIV) who were not exposed to HAART.
62201738|NCT03963869|EXPERIMENTAL|Arm A: New Malaria Camp (MC) village|"Receives MC intervention in year 1 and year 2.~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual) in the 2 year time frame of phase 1."
62201739|NCT03963869|ACTIVE_COMPARATOR|Arm B: No Malaria Camp (MC) village|"Receives Standard Malaria Control in Year 1 and MC intervention in Year 2.~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual) in the 2 year time frame of phase 1."
62201740|NCT03963869|ACTIVE_COMPARATOR|Arm C: Old Malaria Camp (MC) village|"Villages already in receipt of MCs prior to study initiation to study longer term effects.~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual)) in the 2 year time frame of phase 1."
62402251|NCT06179823||DOAC direct oral anticoagulants|pregnant women exposed to doac
62785314|NCT03849222|EXPERIMENTAL|MTA Apexification with apical matrix|An internal (apical) matrix was used as a base for condensation of MTA apical plug, a pieces of (4X4mm) of resorbable collagen membrane (Biocollagen; Bioteck:Turin, Italy)were compacted toward the apex with premeasured suitable size schilder plugger. Moist cotton pellet was placed over the MTA followed by application of coronal seal. After 48 h, the set of the MTA was checked and final obturation of the root canal was done
62785315|NCT00685789|EXPERIMENTAL|Acupuncture with Deqi|Needles were inserted and manipulated manually using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation of soreness, numbness, fullness, aching, cool, warmth, heaviness and radiating sensation (Deqi) occurred. The needles were retained for 30 min.
62785316|NCT00685789|ACTIVE_COMPARATOR|Acupuncture without Deqi|Needles were simply inserted and retained for 30 min, without any other stimulation.
62785317|NCT02080299|ACTIVE_COMPARATOR|Remote ischemic preconditioning (RIPC)|RIPC-protocol before TAVI: after induction of conscious sedation/anesthesia, but prior to TAVI procedure, remote ischemic preconditioning (RIPC) protocol is performed, consisting of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion, followed by a time interval between the end of the last deflation and local groin anaesthesia with subsequent skin puncture of 30 min.
62785318|NCT02080299|PLACEBO_COMPARATOR|Placebo|Placebo protocol before TAVI: After induction of conscious sedation/anesthesia and before TAVI, the cuff is left uninflated for 30 min, followed by a further time interval of 30 min until local groin anaesthesia with subsequent skin puncture.
62201741|NCT02132832|EXPERIMENTAL|Buspirone|Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
62201742|NCT02132832|PLACEBO_COMPARATOR|Placebo|Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
62785319|NCT00555672|EXPERIMENTAL|A|
62402252|NCT06179823||VKA vitamin K antagonist|pregnant women exposed to vitamin K antagonist
62201743|NCT05689242|EXPERIMENTAL|Group I|Receive initial loading dose of (Dexmedetomidine 1 μg/kg I.V) diluted up to 10 ml with normal saline infused over 10 min, followed by a continuous infusion of 0.2-0.8 μg/kg/h through a 50 ml syringe and an electronic infusion pump
62201744|NCT05689242|EXPERIMENTAL|Group II|Receive (Nalbuphine 0.1 to 0.2 mg/kg I.V) diluted up to 10 ml with normal saline infused slowly over 10 min.
62402253|NCT06179823||Heparin|pregnant women exposed to Heparin
62402254|NCT00682006|EXPERIMENTAL|A|In this arm we recruited 2,400 subjects who received Intervention.
62402255|NCT00682006|EXPERIMENTAL|B|In this Arm, we recruited 2,400 subjects who received intervention.
62402256|NCT00682006|EXPERIMENTAL|C|In this Arm, we recruited 2,400 subjects who received intervention.
62402257|NCT00682006|NO_INTERVENTION|D|In this Arm, we recruited 2,400 subjects for Observation and comparison. This was the prime control group.
62402258|NCT05244902|EXPERIMENTAL|Obese pediatric patient|Obese children aged 6-14 years, over 95% percentile, fasted for the night before planned surgery.
62402259|NCT05244902|ACTIVE_COMPARATOR|Non-obese pediatric patient|Non-obese children aged 6-14 years, between 5-85% percentile, fasted for the night before planned surgery.
62402260|NCT03256591|EXPERIMENTAL|HBB plus simulation training|Participants receive training from facilitators for HBB training with simulation skills
62402261|NCT03256591|NO_INTERVENTION|Control|Participants receive training from facilitators for HBB training without simulation skills
62579003|NCT02620176|EXPERIMENTAL|Transcutaneous vagal nerve stimulation|Active vagal nerve stimulation to the left auricular branch of the vagus nerve.
62579004|NCT02620176|PLACEBO_COMPARATOR|Sham vagal nerve stimulation|Placebo vagal nerve stimulation stimulation. The stimulator is attached to the left ear, but rotated 180 degrees, so that it is not stimulating the auricular branch of the vagal nerve.
62785320|NCT05056506|ACTIVE_COMPARATOR|Endoscopic papillary large balloon dilation group|Endoscopic papillary large balloon dilation to extract bile duct stones
62785321|NCT05056506|EXPERIMENTAL|Endoscopic papillary Large balloon dilation combined with limited endoscopic sphincterotomy group|Endoscopic papillary large balloon dilation combined with limited endoscopic sphincterotomy to extract bile duct stones
62201745|NCT04494451|EXPERIMENTAL|Vitamin C + Standard Medical Treatment|vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 days along with iv antibiotics as per institutional protocol along with iv antibiotics
62402262|NCT00914511|EXPERIMENTAL|Healthy young males|Healthy young males age 18-45, inclusive
62402263|NCT00914511|EXPERIMENTAL|Elderly males|Elderly males 65 years of age and older
62402264|NCT01307189|ACTIVE_COMPARATOR|Tiotropium|
62402265|NCT01307189|PLACEBO_COMPARATOR|Placebo|
62402266|NCT05216289|ACTIVE_COMPARATOR|probiac + topical fixed combination|
62402267|NCT05216289|PLACEBO_COMPARATOR|placebo + topical fixed combination|
62402268|NCT05228327|ACTIVE_COMPARATOR|Occlusal Splint Group|Only occlusal splint was made for this patients.
62579005|NCT03139578|EXPERIMENTAL|C 8.5\C 9.0\T 8.5\T 9.0|Subjects randomized to this sequence received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.
62785322|NCT05325333|EXPERIMENTAL|Retrieval practice during word learning: expanding schedule|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) . Four nouns will be learned in an expanding spaced retrieval practice condition; four will be learned in a standard spaced retrieval practice condition. In the standard spaced retrieval practice condition, the number of other words intervening between hearing the target and an attempt to retrieve it will increase from 0 to 3 words. In the expanding spaced retrieval practice condition, the number of other words intervening between hearing the target and an attempt to retrieve it will increase gradually from 0 to 1 to 3 words."
62785323|NCT01559766||4-6 years old group|
62785324|NCT01559766||7-9 years old group|
62785325|NCT06583616||Survival Group|Patient with acute pulmonary embolism who survive after hospitalization
62785326|NCT00975949||Fluconazole Group|These subjects received fluconazole in our NICU fluconazole prophylaxis study during 1998-2000
62785327|NCT00975949||Placebo Group|These subjects received a placebo during our NICU fluconazole prophylaxis study during 1998-2000
62785328|NCT00032357|OTHER|Arm 1|Usual care plus Ferritin reduction to a calculated nadir of 25 ng/mL by phlebotomy
62785329|NCT00032357|NO_INTERVENTION|Arm 2|Usual care only; no intervention control
62013380|NCT03533400|ACTIVE_COMPARATOR|Group 1|Group 1 (control group) will be given the standard Jamboxx musical device. They will be trained to use the device during two 20 minute training session with a respiratory therapist, and will be instructed to play the device for a minimum of 30 minutes, 3 times a week. The Jamboxx musical device is a hands-free breath controlled musical device designed for people with quadriplegia. The mouthpiece acts as a transducer, changing air pressure created by the user's lungs to a joystick signal to the computer via a differential pressure sensor. The Jamboxx can produce musical sounds of many instruments (trumpet, drums, etc.) in many different scales and in any key.
62201746|NCT04494451|ACTIVE_COMPARATOR|Standard Medical Treatment|iv antibiotics alone
62201747|NCT01397422|PLACEBO_COMPARATOR|Treatment A|
62201748|NCT01397422|ACTIVE_COMPARATOR|Treatment B|Low dose ADS-5102 (amantadine extended release)
62402269|NCT05228327|ACTIVE_COMPARATOR|Masticatory muscle injection group|Only intramuscular injection was applied to this patients. Intramuscular injectable form of Lidocaine Hydrochloride (20mg/ml, Jetokain Simplex, ADEKA, Samsun, Turkey) was injected. 0,3 ml was injected to all trigger points.
62402270|NCT05228327|ACTIVE_COMPARATOR|Occlusal splint and masticatory muscle injection combination group|Intramuscular injectable form of Lidocaine Hydrochloride (20mg/ml, Jetokain Simplex, ADEKA, Samsun, Turkey) was injected. 0,3 ml was injected to all trigger points. Patients were started to use their occlusal splints in the evening of the injection day.
62402271|NCT05228327|NO_INTERVENTION|Control group|16 healthy volunteers was involved. Not given any treatment to these volunteers.
62579006|NCT03139578|EXPERIMENTAL|C 9.0\C 8.5\T 9.0\T 8.5|Subjects randomized to this sequence received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.
62785330|NCT03217994|ACTIVE_COMPARATOR|37.5% gel|37.5% gel to bleach teeth
62785331|NCT03217994|EXPERIMENTAL|6% gel|6% gel to bleach teeth
62785332|NCT06330259||Group A|25 younger women, aged 18 to 25 y.
62201749|NCT01397422|ACTIVE_COMPARATOR|Treatment C|A mid-dose ADS-5102 (amantadine extended release)
62201750|NCT01397422|ACTIVE_COMPARATOR|Treatment D|High dose ADS-5102 (amantadine extended release)
62785333|NCT06330259||Group B|25 less young women, aged 26 to 39 y.
62785334|NCT04627207|EXPERIMENTAL|Reference-Reference-Test|Sequence 1
62785335|NCT04627207|EXPERIMENTAL|Reference-Test-Reference|Sequence 2
62215063|NCT02942433|OTHER|Control|The control group participants will be exposed to the radio program only, and will not participate in the LDGs, nor will they or their family members participate in the workshops and community activities.
62785336|NCT04627207|EXPERIMENTAL|Test-Reference-Reference|Sequence 3
62215064|NCT00776217|EXPERIMENTAL|1|loratadine 10 mg orally disintegrating tablets
62215065|NCT00776217|ACTIVE_COMPARATOR|2|loratadine 10 mg orally disintegrating tablets
62215066|NCT05420376|ACTIVE_COMPARATOR|Whole Mesh|For the patients in the first group, the whole patch will be laid on the area without being fixed.
62402272|NCT05574673||Ovarian cancer patients|Newly diagnosed patients with ovarian cancer, fallopian tube cancer or primary peritoneal cancer
62579007|NCT03139578|EXPERIMENTAL|T 8.5\T 9.0\C 8.5\C 9.0|Subjects randomized to this sequence received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.
62785337|NCT04278976|EXPERIMENTAL|CoBaTriCE|Implementation of CoBaTrICE. The implementation of CoBaTrICE is based on: 1. Training the trainers; 2. Multiple Workplace-based assessment exercices; 3. The use of an electronic portfolio.
62785338|NCT04278976|NO_INTERVENTION|Control|The participants of the control group will follow the current official model of training in ICM in Spain, which is based on exposure to experiences through time-based clinical rotations; a generic report, non-based on formal assessment, about knowledge, technical and nontechnical skills is performed after every clinical rotation, and yearly by the tutor.
62785339|NCT03160820|OTHER|one dose of MMR|Subjects are vaccinated with MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 months old.
62402273|NCT04884204|EXPERIMENTAL|Symptom management with Lee Symptom Scale|Participants will receive disease specific questionnaires electronically, cGVHD-PRO (Lee Symtpom Scale), one week prior to their scheduled visit in the outpatient clinic. The participants will be asked to answer the questionnaire from home without any involvement from clinicians. Afterwards the PRO data will be used during the scheduled clinical consultations as an instrument to discover symptoms on chronic GVHD and systematically to monitoring symptoms developing over time.
62410085|NCT02355366|ACTIVE_COMPARATOR|Brief Educational Treatment|Participants will be receive 1-2 educational sessions which will include diagnostic feedback, recommendations for further treatment and crisis intervention if required.
62785340|NCT03160820|OTHER|30 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 4 years old, sequentially.
62402274|NCT00846573|EXPERIMENTAL|Asthmatic Participants|This population is made up of only confirmed asthmatics. Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
62402275|NCT00846573|EXPERIMENTAL|Healthy|"This population is made up of subjects who are considered clinically healthy. This means that there are no records of any chronic disorders or pulmonary history.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
62785341|NCT03160820|OTHER|42 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 5 years old, sequentially.
62785342|NCT03160820|OTHER|54 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 6 years old, sequentially.
62785343|NCT01802125||Basic science (SNP array analysis)|Tissue samples are analyzed using laboratory biomarker analysis for LOH and SNP array profiling using microarray and immunohistochemistry.
62785344|NCT05795985||abdominal pain|patients with abdominal pain
62785345|NCT00892775|EXPERIMENTAL|Priorix-Tetra new WS Group|Subjects received 2 doses of Priorix-Tetra vaccine formulated with new measles and rubella working seeds at Day 0 and Week 12.
62013381|NCT03533400|EXPERIMENTAL|Group 2|Group 2 (treatment group) will be given the Jamboxx musical device plus the Jamboxx respiratory therapy device. The respiratory therapy device is similar to the music device, but with specially designed games that guide the user through breathing exercises intended to strengthen the lungs.
62402276|NCT00846573|EXPERIMENTAL|COPD Patients|"This population is made up of only confirmed COPD patients. Diagnosis must be confirmed through their doctor prior to enrollment.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
62785346|NCT00892775|EXPERIMENTAL|Priorix-Tetra current WS Group|Subjects received 2 doses of Priorix-Tetra vaccine manufactured with current working seed virus at Day 0 and Week 12.
62013382|NCT03519230|EXPERIMENTAL|Treatment arm|
62013383|NCT03519230|PLACEBO_COMPARATOR|Placebo arm|
62785347|NCT03190278|EXPERIMENTAL|Dose Escalation|"UCART123v1.2 tested at several dose levels with different lymphodepletion regimens to establish Maximum Tolerated Dose (MTD) and identify Recommended Phase 2 Dose (RP2D)~Dose Expansion: UCART123v1.2 administered at the RP2D determined from the dose escalation phase"
62785348|NCT00988091|PLACEBO_COMPARATOR|IA-SA|Each participant received a single intra-articular (IA) injection of buffered saline (SA) into the target knee, and was followed for a total of 26 weeks in the double-blind period. Participants had the option of continuing into the open-label period in which they could receive a single intra-articular injection of 1.2% sodium hyaluronate (IA-BioHA) into the target knee and be followed for an additional 26 weeks.
62013384|NCT04874922|EXPERIMENTAL|Case group|The case group will first receive standard diabetes training from the hospital. After 28-30. Diabetes training based on Planned Behavior Theory will be given three times between gestational weeks. Each training will take an average of 45 minutes. After that, the data evaluation phase will be started.
62013385|NCT04874922|OTHER|Control Group|The control group will only receive standart diabetes training from the hospital. Then, only follow-up will be done and the data will be evaluated.
62013386|NCT01693601|EXPERIMENTAL|Panobinostat and Ruxolitinib|Combination of Panobinostat and Ruxolitinib
62215067|NCT05420376|ACTIVE_COMPARATOR|Split Mesh|The patients in the second group will be given a patch of the same size, but partially divided horizontally and wrapped around the spermatic cord.
62785349|NCT00988091|EXPERIMENTAL|IA-BioHA|Each participant received a single intra-articular (IA) injection of 1.2% sodium hyaluronate (BioHA) into the target knee, and was followed for a total of 26 weeks in the double-blind period. Participants had the option of continuing into the open-label period in which they received a single intra-articular injection of 1.2% sodium hyaluronate (IA-BioHA) into the target knee and were followed for an additional 26 weeks.
62785350|NCT00373178|ACTIVE_COMPARATOR|Metformin,lifestyle counselling|
62785351|NCT03546114||Patients referring to an osteopathic clinic - CMO, Milan|Adults, age\>18 years, first visit at osteopathic clinic (Centro di Medicina Osteopatica)
62785352|NCT02048163||Short infusion meropenem|Meropenem 20 mg/ml IV will be administered at a dose of 40 mg/kg (maximum 2,000 mg) every eight hours for 12 doses and will be infused over a 30 minute period. An equal volume of normal saline will be infused at the same time over four hours.
62785353|NCT02048163||Prolonged infusion meropenem|Meropenem 20 mg/ml IV will be administered at a dose of 40 mg/kg (maximum 2,000 mg) every eight hours for 12 doses and will be infused over a four hour period. An equal volume of normal saline will be infused at the same time over 30 minutes.
62785354|NCT00118742|EXPERIMENTAL|CellCept + CNI (tacrolimus or cyclosporine)|
62785355|NCT00118742|ACTIVE_COMPARATOR|CellCept + sirolimus|
62785356|NCT00006773|EXPERIMENTAL|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62402277|NCT00846573|EXPERIMENTAL|Cystic Fibrosis Patients|"This population is made up entirely of confirmed cystic fibrosis patients. Diagnosis must be confirmed through their physician.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
62402278|NCT03805763|EXPERIMENTAL|Large extent of ILM Peeling|Extent of ILM peeling is 4DD and the ILM flap is inserted
62785357|NCT03625336||Prostate Calcifications|Men with prostate calcifications
62785358|NCT06455865|EXPERIMENTAL|experimental group|The intervention group received instruction based on the TPACK (Technological Pedagogical Content Knowledge) framework, incorporating a blended learning approach that combined online and offline methods. The curriculum included the same fundamental theories and skills as the control group but integrated digital tools and resources. Online components consisted of interactive MOOC videos, online assignments, peer assessments, and real-time virtual discussions via platforms like DingTalk. Offline components included traditional face-to-face classroom sessions, hands-on practice, group discussions, and collaborative projects. The blended approach aimed to enhance students' engagement and understanding by leveraging technology to facilitate a more interactive and flexible learning experience.
62785359|NCT06455865|NO_INTERVENTION|control group|The control group employed traditional in-person teaching methods, including face-to-face classroom instruction, reading from printed textbooks, and completing homework assignments. The curriculum covered the fundamental theories and skills related to information resource retrieval and usage but did not specifically utilize the TPACK framework. Students primarily received lectures and guidance from the instructor during class and completed assignments and learning tasks independently after class.
62013387|NCT01176591|EXPERIMENTAL|Placebo Session 1, Aprepitant Session 2|Participants receive placebo in session 1 and Aprepitant in session 2 of a psychological stressor presentation and receive placebo in session 1 and Aprepitant in session 2 of a physiological stressor presentation. Participants take Aprepitant (80 mg) or placebo tablets for 7 days prior to each session.
62013388|NCT01176591|PLACEBO_COMPARATOR|Placebo Session 1, Placebo Session 2|Participants receive placebo in session 1 and placebo in session 2 of a psychological stressor presentation and receive placebo in session 1 and placebo in session 2 of a physiological stressor presentation. Participants take placebo tablets for 7 days prior to each session. The placebo group is used for analysis purposes in order to control for any order effects found in the Experimental group.
62013389|NCT00698958|ACTIVE_COMPARATOR|1|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
62013390|NCT00698958|EXPERIMENTAL|2|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
62013391|NCT01639898|EXPERIMENTAL|"Group 1 (2-cycles trial)"|"The 2-cycles trial will be available to patients who can be treated by radiation or intensive treatment (75 % of cases occurring in front line); they will then undergo 2 cycles of the lenalidomide-dexamethasone combination before radiation or intensive treatment (Group 1)."
62013392|NCT01639898|EXPERIMENTAL|"Group 2 ( 9 cylces Trial)"|"The 9-cycles trial will be available to all other front-line patients (25 % of front-line patients) or patients in relapse or resistant, they will undergo 9 cycles of the lenalidomide-dexamethasone combination followed by maintenance therapy with lenalidomide alone for one year (Group 2)."
62785360|NCT04227132|EXPERIMENTAL|Labyrinth training, then Standard training|Patients will receive at first the Labyrinth training for 10 sessions of 45 minutes, delivered 4 days per week. The, they will undergo the Standard training for 10 sessions of 45 minutes, for around 4 days per week. Before and after each training patients are tested for primary and secondary outcomes with standardized tests.
62785361|NCT04227132|EXPERIMENTAL|Standard training, then Labyrinth training|Patients will receive at first the Standard training for 10 sessions of 45 minutes, delivered 4 days per week. Then they will undergo the Labyrinth training for 10 sessions of 45 minutes, for around 4 days per week. Before and after each training patients are tested for primary and secondary outcomes with standardized tests.
62785362|NCT03268941|PLACEBO_COMPARATOR|Part 1: Placebo|TAK-906 placebo-matching (4x0 mg), capsule, orally, twice daily (BID) on Days 1-8 and once on Day 9 under fasted conditions.
62785363|NCT03268941|EXPERIMENTAL|Part 1: TAK 906 Maleate 5 mg|TAK-906 maleate 1x5 mg, capsule, orally, BID and TAK-906 maleate placebo-matching (3x0 mg), capsules, orally, BID on Days 1-8, followed by TAK-906 maleate 1x5 mg, capsule, orally once on Day 9 under fasted conditions.
62785364|NCT03268941|EXPERIMENTAL|Part 1: TAK 906 Maleate 25 mg|TAK-906 maleate 1x25 mg, capsule, orally, BID and TAK-906 maleate placebo-matching (3x0 mg), capsules, orally, BID on Days 1-8 followed by TAK-906 maleate 1x25 mg, capsule, orally, once on Day 9 under fasted conditions.
62785365|NCT03268941|EXPERIMENTAL|Part 1: TAK 906 Maleate 100 mg|TAK-906 maleate 100 mg (4x25 mg), capsules, orally, BID on Days 1-8 and once a day on Day 9 under fasted conditions.
62785366|NCT03268941|EXPERIMENTAL|Part 2: TAK-906 Maleate 25 mg Fed Condition|TAK-906 maleate 1x25 mg, capsule, orally, once on Day 1 of Period 1 under fed conditions (high fat breakfast), followed by a minimum 7- day washout.
62785367|NCT03268941|EXPERIMENTAL|Part 2: TAK-906 Maleate 25 mg Fasted Condition|TAK-906 maleate 1x25 mg, capsule, orally, once on Day 1 of Period 2 under fasted conditions.
62785368|NCT03268941|ACTIVE_COMPARATOR|Part 2: Metoclopramide 10 mg|Metaclopramide 10 mg, tablet, orally, once, 1 hour prior to breakfast on Day 1 in Part 2.
62785369|NCT00916019|EXPERIMENTAL|exercise|mild exercise training
62785370|NCT04688229|EXPERIMENTAL|Hummingbird intervention group|10 one-hour sessions of focused hand training (affected or dominant hand) using the Hummingbird device in addition to standard of care inpatient rehabilitation
62785371|NCT04688229|ACTIVE_COMPARATOR|Comparison (sham) group|10 one-hour sessions of activity focused on playing games or puzzles gaged to the ability of the subject in addition to Standard of care inpatient rehabilitation
62785372|NCT02219958||RAMP-HT and Non-RAMP-HT|
62013393|NCT02954913|EXPERIMENTAL|Simultaneous Resection|Patients will undergo resection of the colon or rectum and liver in the same anesthetic setting. The type of colorectal and liver resection will be decided by the treating physician. The type of liver resection will be described according to the Couinaud classification and the Brisbane terminology of liver anatomy.
62201751|NCT06028243|EXPERIMENTAL|Intervention Group|"The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB) was implemented in three stages.~Information stage: The researchers provided the intervention group participants with online training in healthy living awareness to prevent osteoporosis. The training consisted of four sections: osteoporosis and diagnosis-treatment methods, current approaches to the prevention of osteoporosis, osteoporosis and nutrition, and osteoporosis and physical exercise. At the end of the training, the participants were informed about the healthy life diary and record.~Motivation stage: The researchers regularly texted reminder notifications concerning the prevention of osteoporosis. The records in their diaries were reviewed. The researchers provided individual counseling to the participants by telephone.~Behavior skills stage: The target behavior skills were improved self-efficacy in doing weight-bearing exercises, taking calcium, and engaging in physical activity."
62201752|NCT06028243|NO_INTERVENTION|Control Group|The control group was not trained. Data collection forms applied to the intervention group were also applied to the control group simultaneously.
62201753|NCT05320510|EXPERIMENTAL|Se-yeast|Selenium-enriched yeast tablet (Se, 50 μg/d)
62201754|NCT05320510|PLACEBO_COMPARATOR|Placebo|placebo-yeast tablet
62785373|NCT03406117|EXPERIMENTAL|HAT1-EPBF2|"CIT was conducted over a period of approximately 15 days for each subject to determine the irritation and/or sensitization potential of a test material(s) under occlusion by 14 repeated closed occlusive patch application every 24 hrs. A final grade was taken 24 hours following the last patch application.~PT was conducted over a period of approximately 6 days for each subject to determine the phototoxicity of the test product.~HRIPT was conducted over a period of approximately 6-8 weeks for each subject to confirm that the test substances will not produce evidence of delayed contact sensitization following external contact with the skin by means of a repeated patch application procedure."
62785374|NCT03406117|EXPERIMENTAL|HAT1-HMF3|"CIT was conducted over a period of approximately 15 days for each subject to determine the irritation and/or sensitization potential of a test material(s) under occlusion by 14 repeated closed occlusive patch application every 24 hrs. A final grade was taken 24 hours following the last patch application.~PT was conducted over a period of approximately 6 days for each subject to determine the phototoxicity of the test product.~HRIPT was conducted over a period of approximately 6-8 weeks for each subject to confirm that the test substances will not produce evidence of delayed contact sensitization following external contact with the skin by means of a repeated patch application procedure."
62785375|NCT03406117|ACTIVE_COMPARATOR|Saline Solution: Sodium Chloride|Saline, Sodium Chlorine (NaCl; 0.9%), was used as the negative irritant control in the CIT portion of the study
62201755|NCT03423329|EXPERIMENTAL|Group A|"Intervention:Drug: Brufen \& Placebo~Brufen syrup 10 ml, once, 1 hour before local anesthesia"
62201756|NCT03423329|EXPERIMENTAL|Group B|"Intervention: Drug: Cital and Placebo~Cital Syrup 10 ml, once 1 hour before Local anesthesia"
62201757|NCT03423329|PLACEBO_COMPARATOR|Group C|"Intervention: Drug: Placebo~Other names:~(Placebo for Brufen) (Placebo for Cital)~Sansovit Iron Multivitamin syrup, an orange-coloured, orange-flavoured"
62201758|NCT02878694|EXPERIMENTAL|Myoblast autologous graft|30 million autologous myoblasts in 6 intramuscular injections
62201759|NCT03112824|EXPERIMENTAL|Ashwagandaha Root Extract Capsule|Participants will take one 300 mg. Ashwaganda capsule twice a day for 12 weeks.
62201760|NCT03112824|PLACEBO_COMPARATOR|Placebo Capsule|Participants will take one placebo capsule twice a day for 12 weeks.
62402279|NCT03805763|EXPERIMENTAL|Small extent of ILM Peeling|Extent of ILM peeling is 2DD and the ILM flap is inserted
62013394|NCT00821691|OTHER|1|"Amantadin - Placebo: 5 amantadin caps - 4 days wash out - 5 placebo caps~5 amantadin caps (100mg); 2 caps a day during 3 days; after wash out period (4 days): 5 placebo caps (2 caps a day during 3 days)"
62201761|NCT02917603|EXPERIMENTAL|Intervention|These family members and residents will use web conferencing technology to attend their quarterly care conferences
62201762|NCT02917603|NO_INTERVENTION|Control|These family and residents will receive usual care
62201763|NCT04468594|EXPERIMENTAL|rigid tape|the rigid tapping technique using zinc oxide tape and protective tape (reference). With the participant assuming a relaxed standing position, the tape was applied bilaterally starting from the first to the last thoracic vertebra. A second tape was then applied to form a position of scapular depression and retraction. This tape was applied bilaterally and extended from the midpoint of the spine of the scapula to the last thoracic vertebra (figure ). This taping was applied for 12 weeks and changes every 3 days
62201764|NCT04468594|EXPERIMENTAL|scapular stabilizing exercises|scapular stabilizing exercises in the form of (1)wall slides with squat, (2) Wall push-ups with ipsilateral leg extension, (3) lawnmower with diagonal squat, (4) resisted retraction to scapula with opposite leg squat (5) robbery with squat. ten repetitions / exercises/ session were perform
62402280|NCT01860066|EXPERIMENTAL|QVA149|QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.
62402281|NCT01860066|ACTIVE_COMPARATOR|fluticasone/salmeterol|Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.
62785376|NCT03825211|EXPERIMENTAL|Continuous suture|All parts of the perineal lesion (vaginal mucosa , perineal muscle and skin) be sutured with the same suture thread. A single suture for perineal lesion
62785377|NCT03825211|ACTIVE_COMPARATOR|Discontinuous suture|Interrupted suture technique: vaginal mucosa, perineal muscle and skin are sutured with separate and different threads, that is, the vaginal mucosa is sutured with a thread, then independently the perineal muscle is sutured with another type of thread and finally the skin is also sutured independently with another different thread. Three independent sutures for each of the parts that form a single perineal lesion
62579008|NCT03139578|EXPERIMENTAL|T 9.0\T 8.5\C 9.0\C 8.5|Subjects randomized to this sequence received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.
62013395|NCT00821691|OTHER|2|"Placebo - Amantadin: 5 placebo caps - 4 days wash out - 5 amantadin caps~5 placebo caps: 2 caps a day during 3 days after wash out period (4 days): 5 amantadin caps(100mg) (2 caps a day during 3 days)"
62579009|NCT01368705|ACTIVE_COMPARATOR|Control Group|
62579010|NCT01368705|EXPERIMENTAL|Intervention Group 1|
62785378|NCT00321867|ACTIVE_COMPARATOR|1|Native tissue repair
62785379|NCT00321867|EXPERIMENTAL|2|Posterior repair with graft
62579011|NCT01368705|EXPERIMENTAL|Intervention Group 2|
62579012|NCT00889876|EXPERIMENTAL|Metformin|
62785380|NCT01802710|EXPERIMENTAL|Psychological support|Ten weekly sessions, which the first 8 were in group and the last 2 were individuals. It consists on a) an informational session; b) Beck's cognitive-behavioural therapy; and c) progressive-muscle relaxation according to Jacobson
62785381|NCT01802710|ACTIVE_COMPARATOR|No psychological support|Patients of this group only received the conventional medical treatment, not receiving any psychological support
62785382|NCT04519281||Group (A)|consists of 50 patients undergoing open heart surgeries who will receive IV ascorbic acid
62785383|NCT04519281||Group (B)|consists of 50 patients undergoing open heart surgeries who will not receive ascorbic acid or will receive a placebo (Control Group).
62785384|NCT05271760||S group|Single-shot Spinal group
62402282|NCT00234533|EXPERIMENTAL|NutropinAq 10 mg/2 mL (30 IU)|"Patients received daily subcutaneous (s.c.) injections of NutropinAq 10 milligrams (mg)/2 milliliters (mL) for 6 months. The therapeutic daily doses administered were as follows:~* GHD patients: 0.025 - 0.035 mg/ kilogram (kg) bodyweight~* TS patients: up to 0.05 mg/kg bodyweight~* CRI patients: up to 0.05 mg/kg bodyweight~Patients visited the study clinic for a baseline visit and for 2 other visits every 3 months (Weeks 12 and 24). Additional home assessments were made at Weeks 21, 22 and 23.~The investigator determined the dose administered to each patient, and it was recommended to perform the injection in the evening."
62402283|NCT03711747||Post-traumatic Ankle OA|Post-traumatic ankle OA and requiring osteochondral allograft to tibia and/or talus in ankle
62013396|NCT04788732||1-Inhalation Anesthesia|patients in this group will be anesthetized only with an inhaled anesthetic ( Sevoflurane ).
62402284|NCT05628337|EXPERIMENTAL|Texting intervention group|Subjects will receive specific health-related texts
62402285|NCT05628337|PLACEBO_COMPARATOR|Control group|Subjects will receive general text messages without health information
62402286|NCT00570492|PLACEBO_COMPARATOR|Placebo nasal spray|
62402287|NCT00570492|EXPERIMENTAL|Fluticasone furoate nasal spray|
62402288|NCT04908787|EXPERIMENTAL|BD0801+chemotherapy|BD0801 is in combination with one of three chemotherapies: Paclitaxel, Topotecan or Doxorubicin liposomes.
62402289|NCT04908787|PLACEBO_COMPARATOR|Placebo+chemotherapy|Placebo is in combination with one of three chemotherapies: Paclitaxel, Topotecan or Doxorubicin liposomes.
62402290|NCT00270738|EXPERIMENTAL|1|TrA training group
62402291|NCT00270738|ACTIVE_COMPARATOR|2|PFMT group
62402292|NCT00270738|ACTIVE_COMPARATOR|3|control group (PFM exercise at home)
62402293|NCT05359289|EXPERIMENTAL|Forest therapy training|Participants will expect to have an improvement of cognitive functions via a serial nature-based therapy/intervention.
62402294|NCT05359289|ACTIVE_COMPARATOR|Senior fitness training|Participants will expect to have an improvement of cognitive functions through a structural senior fitness program.
62402295|NCT05359289|PLACEBO_COMPARATOR|Board Games|Participants will play boards games under a schedule matching the Experimental and Active Comparator arms.
62402296|NCT06566937|EXPERIMENTAL|Intervention|Participants in this group will receive the e-health intervention
62402297|NCT06566937|NO_INTERVENTION|Control|Participants in the control group will receive standard care and Ministry of Health pamphlets without the digital intervention
62402298|NCT04817410|EXPERIMENTAL|Oral Naloxone|Oral Naltrexone initiation
62402299|NCT05084118|ACTIVE_COMPARATOR|Landiolol group|Randomized patients receiving low dose landiolol after cardiac surgery
62402300|NCT05084118|PLACEBO_COMPARATOR|Placebo group|Randomized patients receiving 0,9% saline solution after cardiac surgery
62402301|NCT05784142|EXPERIMENTAL|CHIC single arm|Patients who have received induction immunotherapy plus chemotherapy for 2-6 cycles and met the hypoRT criteria will be enrolled into the study.
62402302|NCT02058940|EXPERIMENTAL|Exenatide|
62410086|NCT04112927||OSA Participants|"Inclusion Criteria: 1) age between 18 to 70 years; 2) suspected of OSA and referred to full PSG study by a doctor.~Exclusion Criteria: 1) being diagnosed with a chronic respiratory disease including pulmonary fibrosis, emphysema, respiratory infectious disease, nocturnal asthma, obstructive pulmonary lung disease, pulmonary hypertension, congestive heart failure, sleep related hypoventilation and neuromuscular disorders; 2) having insomnia or restless leg; 3) drug addiction; and 4) under the current, direct supervision of the PI of this study."
62785385|NCT05271760||E group|Continuous Epidural
62785386|NCT05271760||C group|combined spinal-epidural
62785387|NCT06082856|EXPERIMENTAL|Dexmedetomidine|
62785388|NCT06082856|ACTIVE_COMPARATOR|Sufentanil|
62785389|NCT01195480|EXPERIMENTAL|Prophylaxis arm|Patients who have relapsed in the bone marrow after previous myeloablative HSCT and achieve remission after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells after a second HSCT with reduced intensity conditioning.
62201765|NCT04468594|ACTIVE_COMPARATOR|control|a standard physical therapy protocol will be introduced. This protocol consisted of (1) progressive strengthening exercises for rotator cuff muscles. The resistance was applied first by a red-colored elastic Thera-band. Then progressed, using the green-colored band. Each exercise was performed 10 times /session, (2) Self-stretching exercises for levator scapula, posterior deltoid, pectoralis minor, and latissimus dorsi muscles. Five repetitions of stretching were performed for each muscle per session
62201766|NCT00630734|EXPERIMENTAL|SLCO1B1 Group 1|Participants with the SLCO1B1 \*1A/\*1A diplotype; Interventions: pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
62201767|NCT00630734|EXPERIMENTAL|SLCO1B1 Group 2|Participants with the SLCO1B1 \*1A/\*1B or \*1B/\*1B diplotype; Interventions: Pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
62402303|NCT02440490|EXPERIMENTAL|Computerised cognitive training|The cognitive training protocol will be run using pre-validated software, HappyNeuronPro, that delivers cognitive training games. The games are designed to be visually interesting and engaging, and are varied so that each session will comprise multiple different games, to avoid boredom. They begin with easy-to-follow instructions and demonstrations, then as the participant progresses, the difficulty is automatically increased in correspondence with their performance, to avoid ceiling or plateau effects. Participants will be assigned a program targeting multiple facets of cognition found to be compromised in chronic pain states, including divided attention, working memory, mentally planning a sequence of items to form a pattern or complete a puzzle, and response inhibition.
62579013|NCT00889876|EXPERIMENTAL|Exercise|
62579014|NCT00942591|EXPERIMENTAL|1|Interferon beta-1b AND atorvastatin
62579015|NCT00942591|ACTIVE_COMPARATOR|2|Interferon beta-1b
62579016|NCT05460819|EXPERIMENTAL|Treatment group A|Treatment group A was given endocrine and acupuncture treatment for 8 weeks (24 times in total, 3 times a week); followed up for 16 weeks, no acupuncture treatment.
62013397|NCT04788732||2-Total Intravenous Anesthesia|the patients in this group will be anesthetized with only intravenous drugs such as benzodiazepícos (midazolam), opioids (alfentanil, fentanyl, sufentanil, remifentanil), hypnotics ( propofol and etomidate ), associated or not to relaxing neuromuscular (nondepolarizing/depolarizing), and adjuvant drugs such as dextrocetamina, dexmedetomidine, lidocaine, and magnesium sulfate.
62013398|NCT04788732||3-Balanced anesthesia|the patients in this group will be anesthetized with blends of anesthetic inhaled (Sevoflurane) and intravenous drugs such as benzodiazepine (midazolam), opioids (alfentanil, fentanyl, sufentanil, remifentanil), hypnotics ( propofol and etomidate ), associated or not with neuromuscular relaxants (nonpolarizing/depolarizing) and adjuvant drugs such as dextrocetamine, dexmedetomidine, lidocaine, and magnesium sulfate.
62013399|NCT02772068|ACTIVE_COMPARATOR|Healthy Senior Control|Fifteen healthy senior subjects will perform light exercise at a fixed heart rate of 100 beats per minute. Subjects will then be given either placebo infusion (normal saline) or Istaroxime infusion for one hour. Subjects will be blinded to which infusion they are receiving. Subjects will then repeat light exercise at a fixed heart rate of 100 beats per minute. Primary outcome is changes in cardiac filling pressures during exercise.
62013400|NCT02772068|EXPERIMENTAL|Heart failure patients|Fifteen HFpEF subjects will perform light exercise at a fixed heart rate of 100 beats per minute. Subjects will then be given either placebo infusion (normal saline) or Istaroxime infusion for one hour. Subjects will be blinded to which infusion they are receiving. Subjects will then repeat light exercise at a fixed heart rate of 100 beats per minute. Primary outcome is changes in cardiac filling pressures during exercise.
62013401|NCT01177072|EXPERIMENTAL|Components-Based Interventions (CBI)|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
62013402|NCT01177072|EXPERIMENTAL|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
62013403|NCT01177072|NO_INTERVENTION|Wait List Control|Eligible clients will not be provided therapy at enrollment. After the study period has completed, control clients will be re-interviewed. Those that remain eligible due to symptom cutoff scores will be offered therapy. In the interim, controls will receive a phone call once a month; those with indications of possible harm to self or others will be referred to a psychiatrist.
62013404|NCT04028388|ACTIVE_COMPARATOR|Docetaxel IV|This study arm will receive docetaxel at 75 mg/m2 given i.v. as a one-hour infusion on day 1 every 21 days plus 5 mg oral prednisone twice daily.
62013405|NCT04028388|EXPERIMENTAL|ModraDoc006/r|This cohort will receive ModraDoc006/r 30 mg oral docetaxel in combination with 200 mg ritonavir in the morning and 20 mg oral docetaxel in combination with 100 mg ritonavir in the evening (7-12 hours after the morning dose), on Day 1, 8 and 15 of a 21-day cycle, plus 5 mg oral prednisone twice daily.
62013406|NCT06486545|EXPERIMENTAL|Liposomal irinotecan + Albumin-paclitaxel|"Liposomal irinotecan, intravenous infusion 90min, d1:~Grade 1:50mg/m2； Grade 2:60mg/m2； Grade 3:70mg/m2；~Albumin-paclitaxel, 150mg/m2, intravenous infusion, d1"
62013407|NCT01999010|NO_INTERVENTION|"Treatment as usual (A Stage)"|The treatment as usual (TAU) group will continue to receive their usual treatment from their current treatment team - i.e. MHT will not be introduced during this phase.
62013408|NCT01999010|EXPERIMENTAL|"MHT (B Stage)"|Patients will be given software for Mental Health Telemetry (MHT), which allows them to record symptom intensity, hospital / ER visits, life events, etc., and to visualize their MHT data. Patients will be encouraged to make MHT entries once daily at a pre-determined time while in this arm, and will be prompted via text message by the MHT software to do so.
62785390|NCT01195480|EXPERIMENTAL|Pre-emptive arm|In this arm, patients identified at high (\> 50%) risk of relapse will be eligible for generation of donor-derived EBV CTL immediately prior to HSCT. These patients will be monitored for evidence of MRD in regular bone marrow aspirates for the first year post-HSCT. MRD positivity post-HSCT is highly predictive of subsequent relapse. In those patients who become MRD+ in the marrow at a level of minimum 5 x 10-4, cryopreserved CTL that have been transduced with a retroviral vector carrying the CD19-zeta transgene will be thawed and administered to the patient pre-emptively.
62785391|NCT04010877|EXPERIMENTAL|Multiple CAR T cells to treat AML|Multiple CAR T cells to treat AML
62785392|NCT01462617|EXPERIMENTAL|Pi3K|Experimental
62785393|NCT01462617|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62013409|NCT01999010|EXPERIMENTAL|"Choice (A'  Stage)"|Patients exiting the MHT arm will be given the choice to continue with MHT for a further two months or whether to resume TAU (i.e., no further use of MHT) for the remaining two months.
62579017|NCT05460819|SHAM_COMPARATOR|Treatment group B|Treatment group B was given endocrine and sham acupuncture treatment for 8 weeks, followed up for 16 weeks, no acupuncture during the period, and after 16 weeks, received standardized acupuncture for 8 weeks (24 times in total, 3 times a week).
62579018|NCT05460819|NO_INTERVENTION|control|The control group was given conventional adjuvant endocrine therapy, premenopausal patients received tamoxifen therapy, and postmenopausal patients received aromatase inhibitor or tamoxifen therapy.
62013410|NCT00948805|EXPERIMENTAL|GnRH agonist|3,6 mg of goserelin acetate (GnRH agonist) will be administered on the 21st day of the menstrual cycle previous to ovarian stimulation. 250 mg of hCG will be administered on the first day of menses and a starting dose of 150 IU of FSH will be started 2 days later as a part of a long ovarian stimulation protocol. Ovulation will be triggered with a 250 mg of hCG when at least 2 follicles attain 18mm and to accommodate oocyte retrieval within 36 hours.
62201768|NCT00630734|EXPERIMENTAL|SLCO1B1 Group 3|Participants who carry at least one SLCO1B1 \*5, \*15, or \*17 diplotype; Interventions: Pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
62201769|NCT01002677|EXPERIMENTAL|Curriculum|
62402304|NCT02440490|ACTIVE_COMPARATOR|Video watching|This group will be provided with a variety of videos to watch, the content of which will be in the style of documentaries on general interest topics such as nature, travel, culture, and history. Each video is followed by multiple-choice questions that participants will answer, to ensure attention was engaged. The videos are visually stimulating and engaging, but involve no increment in difficulty or requirement to improve skills. They may provide some distraction from pain and may be relaxing, interesting and informative.
62402305|NCT06149000|EXPERIMENTAL|Avulux Lenses|This group will be receiving migraine treatment using Avulux lenses
62402306|NCT06149000|PLACEBO_COMPARATOR|Placebo Lenses|This group will be using identical placebo lenses as treatment
62402307|NCT00465101|OTHER|GreenLight HPS|
62402308|NCT05963685||pre implementation period|stroke patients transferred within the 6 months before introduction of the alarming system
62402309|NCT05963685||implementation period|stroke patients transferred within the 6 months after introduction of the alarming system
62402310|NCT05963685||post implementation period|stroke patients transferred within the 6-12 months after introduction of the alarming system
62402311|NCT04918186|EXPERIMENTAL|Durvalumab + BA3011 (Arm Closed)|
62785394|NCT01291407|EXPERIMENTAL|S-1,peroral BID,capsule|
62579019|NCT03243032|EXPERIMENTAL|Local Anesthetic Group 1|Group 1 (Pre-emptive analgesia with long acting local anesthesia - experimental group): Ibuprofen 600mg given 30 minutes prior to beginning of surgery. Surgery will be performed only using 0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg four times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
62785395|NCT03536234|EXPERIMENTAL|Triptorelin (GnRH analogue)|
62785396|NCT03536234|NO_INTERVENTION|Control group|
62402312|NCT04918186|EXPERIMENTAL|Durvalumab + BA3021 (Arm Closed)|
62402313|NCT04918186|EXPERIMENTAL|Sub Study X (etc.)|
62402314|NCT03193424|EXPERIMENTAL|Apatinib|
62402315|NCT03193424|ACTIVE_COMPARATOR|docetaxel|
62402316|NCT00710840|EXPERIMENTAL|1|
62402317|NCT00710840|ACTIVE_COMPARATOR|2|
62402318|NCT03112759|EXPERIMENTAL|Cognitive Behavioral Therapy|Patients randomly selected for CBT will attend 8 weekly one-on-one therapy sessions. Patients will be prescribed conventional narcotic therapy as needed.
62402319|NCT03112759|NO_INTERVENTION|No Cognitive Behavioral Therapy|Patients randomly selected for no CBT will be treated with conventional narcotic therapy alone.
62402320|NCT02531074|EXPERIMENTAL|Mobile Application plus Usual Care|
62785397|NCT04146935|EXPERIMENTAL|Patients with XLH|Patients will receive Burosumab monthly at visits 1,2 and 3 subcutaneously at a dose of 1.0 mg/kg. Dose may be adjusted as needed.
62785398|NCT06094790|EXPERIMENTAL|Cohort 1|Subjects will receive CORT125134 150 mg once daily for 14 days
62785399|NCT06094790|EXPERIMENTAL|Cohort 2|Subjects will receive CORT125134 250 mg once daily for 14 days
62785400|NCT06094790|EXPERIMENTAL|Cohort 3|Subjects will receive CORT125134 once daily for 14 days at a dose level decided based on evaluation of steady state exposure from Cohorts 1 and 2
62013411|NCT00948805|ACTIVE_COMPARATOR|Control|250 mg of hCG will be administered on the first day of menses and a starting dose of 150 IU of FSH will be started 2 days later as a part of a long ovarian stimulation protocol. Ovulation will be triggered with a 250 mg of hCG when at least 2 follicles attain 18mm and to accommodate oocyte retrieval within 36 hours.
62013412|NCT00491244|EXPERIMENTAL|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
62013413|NCT00491244|EXPERIMENTAL|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
62013414|NCT01991834|PLACEBO_COMPARATOR|Placebo|Patients in this arm will receive intravenous sterile saline 30 minutes before the gynecologic laparoscopy.
62013415|NCT01991834|ACTIVE_COMPARATOR|Cefazolin|Patients in this arm will receive intravenous cephazolin 1g, 30 minutes before the gynecologic laparoscopy.
62013416|NCT02155439|ACTIVE_COMPARATOR|Triamcinolone|kortikosteroid
62013417|NCT02155439|ACTIVE_COMPARATOR|5-fluorouracil|antimitotic drug
62013418|NCT01815671|OTHER|Lateral horizontal body position|Subjects randomized to receive colonoscopy in the lateral horizontal position, This is the standard position. The other position - tilt down is the intervention
62402321|NCT02531074|ACTIVE_COMPARATOR|Food Journal plus Usual Care|
62785401|NCT06094790|EXPERIMENTAL|Cohort 4 (optional)|Subjects will receive CORT125134 once daily for 14 days at a dose level decided based on evaluation of steady state exposure from Cohorts 1, 2, and 3, if it is considered that this cohort would aid achievement of the study objectives
62785402|NCT03536507|ACTIVE_COMPARATOR|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
62785403|NCT03536507|PLACEBO_COMPARATOR|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
62785404|NCT03207633|ACTIVE_COMPARATOR|First group|First group (20 patients) receive for 10 sessions of low frequency rTMS targeting right DLPFC by means of a Butterfly coil using the following parameters: 120% RMT, 1 Hz, 3 trains, each of 500 pulses with a 40 seconds inter-train interval allowing the coil to cool.
62785405|NCT03207633|ACTIVE_COMPARATOR|Second group|The second group (20 patients) will receive 10 sessions of low-frequency rTMS over the right orbitofrontal cortex (OFC) by means of a Butterfly coil using the following parameters: 120% motor threshold, 1 Hz, 3 trains, each of 500 pulses with a 40 seconds inter-train interval allowing the coil to cool.
62013419|NCT01815671|OTHER|Lateral tilt down body position|Subjects randomized to receive colonoscopy in the lateral tilt down position
62402322|NCT04920838|ACTIVE_COMPARATOR|Paracetamol|Patients in this arm will receive paracetamol during 14 days
62013420|NCT00760240||Glaucoma patients|This is a group of patients with restricted visual fields or ETDRS visual acuity of 20/60 or worse
62013421|NCT00760240||Retina patients|A group of patients with retinal pathology(ARMD, CME, diabetic retinopathy) contributing to their decreased vision.
62013422|NCT06237426|EXPERIMENTAL|Treatment (Methylone)|
62013423|NCT05007873|EXPERIMENTAL|Treatment (dasatinib, decitabine and cedazuridine)|"Patients receive dasatinib PO QD on days 1-28. Beginning cycle 4, patients also receive decitabine and cedazuridine PO QD on days 1-3. Cycles repeat every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days for up to 12 years in the absence of disease progression or unacceptable toxicity."
62013424|NCT04578223||Study group|Patients with pulmonary arterial hypertension treated with prostacyclin analogues on top of ERA or PDE-5i.
62013425|NCT04578223||Control group|Patients with pulmonary arterial hypertension treated with ERA or PDE-5i only.
62013426|NCT01103297|OTHER|Variable Angle Distal Radius Plate|
62013427|NCT01921972|ACTIVE_COMPARATOR|Galantamine and Placebo|Subjects in this group will receive 4 weeks of 8 mg/day galantamine CR, followed by 4 weeks of 16 mg/day and from week 9 up to the end of the trial of 24 mg/day.
62402323|NCT04920838|EXPERIMENTAL|Nitazoxanide and Ciclésonide|Patients in this arm will receive the combination of ciclezonide (Alvesco® 160 µg ) / nitazoxanide (Netazox® 500 mg) during 14 days
62402324|NCT04920838|EXPERIMENTAL|Telmisartan|Patients in this arm will receive telmisartan (Micardis® 20 mg) during 10 days
62402325|NCT04920838|EXPERIMENTAL|Fluoxétine and Budésonide|Patients in this arm will receive the combination of Fluoxétine (Fluoxétine Arrow® 40 mg ) / Budésonide (Budecort® 2\*400 mcg) during 7 days
62201770|NCT01002677|ACTIVE_COMPARATOR|Self-directed|
62201771|NCT04497389|EXPERIMENTAL|Intervention|10ml intravenous hAF QD (once daily) for 5 consecutive days
62201772|NCT04497389|NO_INTERVENTION|Standard of Care|10 mL normal saline QD (once daily) for 5 days
62201773|NCT01955187|EXPERIMENTAL|Sequential therapy: Tacrolimus-Rituximab|Tacrolimus: Initial dose of 0.05 mg/Kg/day PO, adjusted to blood levels (5- 7 ng/ml) for six months. Starting at the end of month 6, tacrolimus will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
62201774|NCT01955187|ACTIVE_COMPARATOR|Cyclical therapy: Corticosteroids and Cyclophosphamide|Month 1, 3 and 5: 1g IV methylprednisolone daily for three doses, oral methylprednisolone (0.5mg/kg/day) Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day)
62201775|NCT01779570|EXPERIMENTAL|Macrolide treatment|Azithromycin 500 mg daily for 5 days
62201776|NCT01779570|NO_INTERVENTION|No macrolide treatment|No azithromycin
62201777|NCT05153876||Participants|Participants filling in the questionnaires
62201778|NCT05765643|EXPERIMENTAL|Nurse parental support in symptom management using a mobile health App over 3 months|
62201779|NCT05765643|NO_INTERVENTION|Wait-listed control|Parents in this group can join the usual community social or health care services as usual.
62402326|NCT05006820||No intervention|
62402327|NCT04411030|EXPERIMENTAL|Part 1|Oral administration of ASTX660 and itraconazole at specific time points.
62013428|NCT01921972|EXPERIMENTAL|Galantamine and Memantine|Galantamine titration will be performed as described above. Memantine titration will be performed over 4 weeks in steps of 5 mg/day up to 20mg/day (10 mg b.i.d.). 50 % of this group will receive galantamine first, 50 % of the group will receive memantine first to allow for differential qualitative evaluation of tolerability of a combination therapy.
62201780|NCT01531777|EXPERIMENTAL|Apatinib 500mg|500mg,p.o.,qd
62201781|NCT01531777|EXPERIMENTAL|Apatinib 750mg|750mg,p.o.,qd
62201782|NCT02136953|EXPERIMENTAL|Exercise|12-weeks of structured, individual aerobic exercise, 3 times a week, increasing from 15-30 minutes to 30-40 minutes per session.
62201783|NCT02136953|ACTIVE_COMPARATOR|Cognitive Behavioural Therapy (CBT)|12-weeks of manual-based group CBT, 2 hours per week, 8 participants per group.
62402328|NCT04411030|EXPERIMENTAL|Part 2|Oral administration of ASTX660 and midazolam at specific time points.
62402329|NCT05332171|NO_INTERVENTION|physical activity counseling|Home exercises will be taught to the physical activity counseling group and will be followed up under the supervision of a physiotherapist with weekly controls. Evaluation will be done before and after treatment.
62402330|NCT05332171|ACTIVE_COMPARATOR|training group|Breathing exercises and calisthenic exercises will be taught to the training group, and they will be followed under the supervision of a physiotherapist for 8 weeks, 3 days a week. Evaluations will be made before and after treatment. Individuals in the calisthenic exercise group will be given exercise training at the level of 65%-80% of the maximal heart rate for 30-40 minutes, 3 days a week for 8 weeks.
62785406|NCT03207633|SHAM_COMPARATOR|Third group|The third group (the sham condition) (20 patients) will receive sham stimulations of rTMS with the same pulse delivery as the other groups but with the coil placed perpendicular to the scalp.
62402331|NCT01169623|EXPERIMENTAL|Educational Intervention|55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
62402332|NCT01169623|PLACEBO_COMPARATOR|CONTROL|55 of head nurses who will not participate in educational intervention will be considered as a control arm
62402333|NCT01012531|ACTIVE_COMPARATOR|highly polymerized allergen extract|
62785407|NCT03265457||patient with pseudoexfoliation syndrome|The corneal Endothelial cell count will be measured by specular microscopy
62785408|NCT03265457||Normal people at same age|
62013429|NCT01116089|ACTIVE_COMPARATOR|PARI LC® PLUS nebulizer|
62013430|NCT01116089|ACTIVE_COMPARATOR|PARI eFlow® rapid electronic nebulizer|
62201784|NCT02136953|EXPERIMENTAL|Exercise and CBT|Combined 12-week Exercise program and CBT.
62201785|NCT02136953|NO_INTERVENTION|Waitlist Condition|12-week waitlist control condition, after which participants will have the chance to receive CBT group treatment.
62201786|NCT00004139|EXPERIMENTAL|Gemcitabine + Irinotecan|
62201787|NCT00004139|EXPERIMENTAL|Gemcitabine + Docetaxel|
62201788|NCT03990792|EXPERIMENTAL|e-predictD intervention|In this arm, patients will receive a personalized intervention to prevent depression based on ICTs, risk predictive algorithms and decision support systems (DSS) for patients and General Practitioners (GPs).
62201789|NCT03990792|ACTIVE_COMPARATOR|m-Health control|In this arm, patients will continue receiving the usual care from their GPs. In addition, they will use an App with the same appearance as the e-predictD App but it will only send weekly messages about physical and mental health management. This intervention is not personalized and does not include GP training and GP-patient interview.
62201790|NCT00623259|EXPERIMENTAL|1|
62201791|NCT01720576|EXPERIMENTAL|Cohort 1|Dose 1 of REGN1033 (SAR391786) or Placebo
62201792|NCT01720576|EXPERIMENTAL|Cohort 2|Dose 2 of REGN1033 (SAR391786) or Placebo
62201793|NCT01720576|EXPERIMENTAL|Cohort 3|Dose 3 of REGN1033 (SAR391786) or Placebo
62402334|NCT01012531|PLACEBO_COMPARATOR|Placebo|
62402335|NCT00455572|EXPERIMENTAL|Cohort 1|Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will receive chemo-and immunotherapy in parallel.
62785409|NCT03689816|EXPERIMENTAL|bone density|bone density
62201794|NCT04315753||cancer patients (clinical stage I and II) +controls|70 lung cancer patients (clinical stage I and II) diagnosed outside screening and candidates to surgical resection at Humanitas Hospital, and 70 controls with benign nodules. Cancer patients will undergo blood collection before and at 4 months after surgical resection. Blood will be used for CTC analysis, exosome antigens and circulating free DNA (cfDNA) mutational analysis.
62201795|NCT04315753||prospective screening cohort of high risk individuals|a prospective screening cohort of high risk individuals enrolled at Humanitas Hospital (1000) will allow to recruit 50 patients with screening detected lung cancer and a large number of negative controls. Analysis of CTC, exosome antigens and cfDNA mutation profile will be performed.
62201796|NCT05357976|ACTIVE_COMPARATOR|Patients with a BMI of 18-24.9 kg/m2|The needle will be advanced to the paravertebral area with an ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.
62201797|NCT05357976|ACTIVE_COMPARATOR|Patients with a BMI of 25-29.9 kg/m2|The needle will be advanced to the paravertebral area with an ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.
62013431|NCT04143347||Community Hospitals - CH|Patients with head injury managed at Community Hospitals
62013432|NCT04143347||Level 1 Trauma Center - L1TC|Patients with head injury presenting to level 1 trauma center directly
62013433|NCT04143347||Transfer|Patients with head injury presenting at a community hospital but then getting transferred to the level 1 trauma center
62013434|NCT04984642|EXPERIMENTAL|healty subject|
62013435|NCT03930745|EXPERIMENTAL|Arm 1|TOL-463 insert administered vaginally twice a week for twelve weeks. N=125
62013436|NCT03930745|PLACEBO_COMPARATOR|Arm 2|Matching placebo insert administered vaginally twice a week for twelve weeks. N=125
62201798|NCT05357976|ACTIVE_COMPARATOR|Patients with a BMI of 30-40 kg/m2|The needle will be advanced to the paravertebral area with an ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.
62201799|NCT01780259|EXPERIMENTAL|Cohort 1: Treatment A|Participants will receive 1 spray of esketamine solution in each nostril once (total dose: 28 mg).
62201800|NCT01780259|EXPERIMENTAL|Cohort 1: Treatment B|Participants will receive 1 spray of esketamine solution in each nostril twice, with 5 minutes interval (total dose: 56 mg).
62402336|NCT00455572|EXPERIMENTAL|Cohort 2|Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will first receive chemotherapy and then immunotherapy
62402337|NCT00455572|EXPERIMENTAL|Cohort 3|Patients with resected stage IB, II or IIIA tumors who are not due for chemotherapy. These patients will receive immunotherapy only.
62402338|NCT00455572|EXPERIMENTAL|Cohort 4|Patients with unresectable stage III tumors, following standard chemotherapy and/or radiotherapy. These patients will receive immunotherapy only.
62402339|NCT02646566|EXPERIMENTAL|APD421 standard|Single (standard) dose IV APD421
62402340|NCT02646566|EXPERIMENTAL|APD421 high|Single (high) dose IV APD421
62402341|NCT02646566|PLACEBO_COMPARATOR|Placebo|Single IV placebo
62013437|NCT05104398||Baseline therapy|Group 1 (n=29) continued to receive standard treatment.
62013438|NCT05104398||Basic therapy + Efferon CT|group 2 (n=13) received HP procedure once, for 3-4 hrs, using Efferon CT adsorbers containing mesoporous SDC beads uptaking 6-60 kD molecules followed by continuous veno-venous hemodiafiltration. Group 2 included more severe patients requiring HP support.
62013439|NCT00600964|EXPERIMENTAL|GX15-070MS|GX15-070MS at various doses and schedules
62402342|NCT03710681|EXPERIMENTAL|Cohort 1|Multiple subcutaneous injections of SHR-1314 at 160mg every two weeks
62402343|NCT03710681|EXPERIMENTAL|Cohort 2|Multiple subcutaneous injections of SHR-1314 at 240mg every two weeks
62402344|NCT02980484|EXPERIMENTAL|Active rTMS|Subjects will receive a full course of 20 rTMS treatments over 20 consecutive weekdays as described above.
62402345|NCT02980484|SHAM_COMPARATOR|Sham/crossover rTMS|Rather than receiving active treatment, subjects will receive sham treatment designed to be indistinguishable from active treatment to the patient. After completion of the sham course, patients will have the option to receive open-label active treatment at no cost.
62402346|NCT02088359||Cycled light|Approximately 12 hours of light on and 12 hours of light off.
62402347|NCT02088359||Near darkness|Continue near darkness
62402348|NCT06353581|EXPERIMENTAL|Neulapeg|Neulapeg
62785410|NCT02328534||Density Gradient semen|"ICSI Cases processed using DG semen processing and evaluated by~Blastocyst Formation Rate Blastocyst Rate Pregnancy Rate"
62785411|NCT02328534||Swimming down semen|"ICSI Cases processed using SD semen processing and evaluated by~Blastocyst Formation Rate Blastocyst Rate Pregnancy Rate"
62013440|NCT01653431|EXPERIMENTAL|Transcranial direct current stimulation|Transcranial direct current stimulation combined with cognitive training
62013441|NCT01653431|SHAM_COMPARATOR|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation combined with cognitive training
62013442|NCT03006328|EXPERIMENTAL|Participants with Obesity + GEM|Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity. Will be assigned to GEM Tool and a health coach.
62201801|NCT01780259|EXPERIMENTAL|Cohort 1: Treatment C|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 5 minutes interval between each repeated sprays (total dose 84 mg).
62402349|NCT06353581|NO_INTERVENTION|Control|If grade 3-4 neutropenia or neutropenic fever occurs, patients will be crossover to Neulapeg.
62402350|NCT02696382|ACTIVE_COMPARATOR|Usual Care (UC)|"Participants in the Usual Care (UC) group will receive standard, low-intensity physical therapy following discharge from acute hospitalization."
62785412|NCT00465647|EXPERIMENTAL|≥ 28 Days to < 13 Months|infant and toddler
62013443|NCT03006328|ACTIVE_COMPARATOR|Participants with Obesity + Enhanced Usual Care|Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity. Will receive receive non-tailored weight management handouts by health coaches.
62013444|NCT03991741|EXPERIMENTAL|melanoma|
62201802|NCT01780259|EXPERIMENTAL|Cohort 1: Treatment D|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 10 minutes interval between each repeated sprays (total dose 84 mg).
62201803|NCT01780259|EXPERIMENTAL|Cohort 2: Treatment D|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 10 minutes interval between each repeated sprays (total dose 84 mg).
62201804|NCT01780259|EXPERIMENTAL|Cohort 3: Treatment E|Participants will receive 1 spray of esketamine solution in each nostril, 4 times with 10 minutes interval between each repeated sprays (total dose: 112 mg). Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution.
62579020|NCT03243032|PLACEBO_COMPARATOR|Local Anesthetic Control|Group 2 (Control / standard of care group): Placebo oral capsule (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery. Surgery will be performed using 2% lidocaine with 1:100,000 epinephrine as the local anesthesia. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg 4 times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
62579021|NCT04147676||TB suspects|"Sputum specimens will be collected from TB suspects enrolled in the study.~The specimens will be tested with~1. Roche cobas MTB - for the detection of Mycobacterium tuberculosis complex~2. Roche cobas MTB-RIF/INH - all specimens that are Mycobacterium tuberculosis complex positive will be reflexed to the Roche cobas MTB-RIF/INH test for the detection of resistance to rifampicin and isoniazid~3. Hain FluoroType MTBDR - for the detection of Mycobacterium tuberculosis complex and the detection of resistance to rifampicin and isoniazid"
62579022|NCT05388643|EXPERIMENTAL|Enhanced First Trimester GDM Screening|Women who are randomly assigned to this condition will be required to have early glucose screening with a prediction model composed of additional clinical risk factors and serum biomarkers (triglycerides, PAPP-A, and lipocalin-2) with their initial prenatal laboratory assessment.
62579023|NCT05388643|ACTIVE_COMPARATOR|Standard of Care GDM Screening|Women who will be randomized to the comparison condition of usual standard of care will undergo routine standard of care. The standard of care will consist of routine screening for diabetes in pregnancy between 24 to 28 weeks of gestation via the two-step screening method with possible early screening with either plasma fasting glucose, oral glucose tolerance test, or hemoglobin A1c at the providers discretion to represent true clinical practice.
62785413|NCT00465647|EXPERIMENTAL|≥ 13 months to < 5 years|young child
62785414|NCT00465647|EXPERIMENTAL|≥ 5 years to < 12 years|older child
62785415|NCT00465647|EXPERIMENTAL|≥ 12 years to < 17 years|adolescent
62201805|NCT01780259|EXPERIMENTAL|Cohort 3: Treatment F|Participants will receive 1 spray of placebo solution in each nostril, 4 times with 10 minutes interval between each repeated sprays (total dose: 112 mg). Single 0.25-mg oral dose of triazolam will be administered 5 minutes before the first intranasal spray of placebo solution.
62201806|NCT04221464|EXPERIMENTAL|Tumors and blood collection|"For all the patients include in the study :~* Blood samples will be collected at different times : before any treatment, at every surgery, one month after any surgery, at progression.~* Tumours and not tumours tissues will be collected at different times : Before any surgery, one month after any surgery~In parallel to this biological collection, standardized clinical data will be entered into a database treatment, at every surgery"
62402351|NCT02696382|EXPERIMENTAL|Progressive High Intensity Therapy|"Participants in the Progressive High Intensity Therapy (PHIT) group will receive high intensity physical therapy following discharge from acute hospitalization."
62402352|NCT05573425|ACTIVE_COMPARATOR|Group on Treatment:Tazarotene Gel|"In group A, patients were instructed to apply a thin film of tazarotene gel 0.1% over the affected area once daily in the evening by placing a pea-sized amount of gel in the palm of the hand and using tip of a finger to cover the entire half of the face. Patients who experienced facial dryness were allowed to use a moisturizing cream during the day on entire face but use of any other medication on the face was prohibited.~Intervention - Tazarotene gel 0.1%"
62410087|NCT04112927||Healthy Controls|"Inclusion Criteria: 1) age between 18 to 70 years; 2) non-snorer, and being free of any sleep disorders.~Exclusion Criteria: same as the OSA Participants. All participants must not have any cold or any other respiratory illness at the time of recording.~Illiterate participants may still participate in the study; however, there must be a witness who is not involved in the study (i.e. PI, Co-PI, study coordinator, research assistants (RA)/students, etc.) present to witness the consent process between the participant and the individual obtaining consent."
62785416|NCT02258646|EXPERIMENTAL|Telerehabilitation|Exercise training at home, telemonitoring, and education/self-management
62579024|NCT05468528|EXPERIMENTAL|linear ablation group|The linear ablation is performed on the basis of Ω-type linear ablation. Further stepwise ablation of the left atrial anterior wall increases the blockage of the LA roof and the MVA isthmus. Ablation in CS or ethanol ablation of vein of Marshall. Also, epicardial ablation on the roof or rigid between LAA-LPVs may be applied if necessary.
62013445|NCT03991741|EXPERIMENTAL|head and neck cancer|
62013446|NCT00617240|EXPERIMENTAL|1|metformin in doses from 250mg to 2000mg/day for 26 weeks
62785417|NCT02258646|EXPERIMENTAL|Unsupervised exercise training at home|Unsupervised exercise training at home
62013447|NCT00617240|PLACEBO_COMPARATOR|2|Matched placebo to metformin, doses between 250/0mg and 2000/0mg per day
62785418|NCT02258646|NO_INTERVENTION|Usual care|Usual care
62785419|NCT06066398|OTHER|medical thoracoscope|medical thoracoscope will be done during which pleural brush, pleural forceps biopsy and pleural lavage will be taken to compare yield of diagnosis and safety between them
62785420|NCT04619498|EXPERIMENTAL|PediAppRREST app|The teams assigned to the PediAppRREST arm will manage the simulated scenario of pediatric cardiac arrest using the new PediAppRREST tablet app as a cognitive aid.
62785421|NCT04619498|ACTIVE_COMPARATOR|CtrlPALS+|The teams assigned to the CtrlPALS+ arm will manage the simulated scenario of pediatric cardiac arrest using the American Heart Association Pediatric Advanced Life Support (AHA-PALS) pocket reference card.
62013448|NCT01423513|EXPERIMENTAL|Fibular Taping|With the ankle in a neutral position, two strips of nonrigid hypoallergenic tape will be applied beginning at the distal aspect of the fibula, wrapping around the posterior aspect of the leg, and finishing superior and medial to the starting point. Next,a strip of rigid zinc oxide tape will be applied to the distal aspect of the fibula with tension.
62013449|NCT01423513|SHAM_COMPARATOR|Sham Taping|Sham taping will be applied in the same manner as the fibular taping, but tension will not applied to the zinc oxide tape
62013450|NCT02137200|ACTIVE_COMPARATOR|Delayed pushing|
62013451|NCT02137200|EXPERIMENTAL|Immediate pushing|
62402353|NCT05573425|ACTIVE_COMPARATOR|Group on Treatment:Microneedling|"In group B, microneedling was performed with a standard dermaroller (192 needles of length 1.5 mm) by the same investigator, once per month for 6 months. A topical anesthetic mixture of lignocaine and prilocaine was applied over the face in a thick layer under occlusion 1 hour before the procedure.~Microneedling was performed by rolling the dermaroller with uniform and firm pressure in 4 different directions (i.e, perpendicular and diagonal to each other) with to-and-fro motion up to 8 times (a total of 32 passes) or until the end point of uniform pinpoint bleeding was achieved. After treatment, the area was wetted with saline pads. The participants were instructed to follow strict photoprotective measures including the application of a broad-spectrum sunscreen with sun protection factor 30 over the entire face.~Intervention - Microneedling via dermarolller"
62402354|NCT02277665|ACTIVE_COMPARATOR|CUD Treatment Only|12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD
62402355|NCT02277665|EXPERIMENTAL|CUD and Tobacco Treatment|12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD, and behavioral counseling and nicotine replacement therapy (NRT) for tobacco
62402356|NCT00390338|EXPERIMENTAL|peptide-pulsed type-1-polarized dendritic cells|intralymphatic vaccination with peptide-pulsed type-1-polarized dendritic cells (aDC1)
62402357|NCT00390338|EXPERIMENTAL|peptide-pulsed mature non-polarized dendritic cells (cDCs)|intralymphatic vaccination with peptide-pulsed mature non-polarized dendritic cells (cDCs)
62402358|NCT03247608|EXPERIMENTAL|Ambio Health Remote Monitoring|Ambio Health is an end-to-end remote patient monitoring system which includes a weight scale, blood pressure meter and blood glucose meter with wireless transmission of biometric readings through a home gateway to a web-based care management application that provides population health remote patient monitoring and engagement with automated delivery of the CarePlans.
62013452|NCT06238505|EXPERIMENTAL|Virtual|
62402359|NCT03217058|NO_INTERVENTION|Pre-implementation|The pre-implementation cohort includes data from 5000 HIV primary care clinic patients in Kaiser Permanente Northern California, who receive services prior to implementation of computerized screening and behavioral intervention in the clinics.
62402360|NCT03217058|EXPERIMENTAL|Post-implementation|The post-implementation cohort includes data from 5000 HIV primary care clinic patients in Kaiser Permanente Northern California, who receive services after computerized screening and behavioral intervention have been implemented in the clinics.
62402361|NCT04269317|EXPERIMENTAL|Tixel C|Tixel Treatment, between 3-5 treatment session according to investigator's review of subject response follow by 3 Follow up sessions, 1,3 and 6 month after last treatment visit. Subject would be questioned about pain levvel, subjective dountime assessment and subjective response assessment. Images would be taken before treatment visit and in Follow-Up.
62013453|NCT06238505|EXPERIMENTAL|biodex|
62013454|NCT04632940|EXPERIMENTAL|Pamrevlumab|Pamrevlumab 35 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally for up to 52 weeks
62013455|NCT04632940|PLACEBO_COMPARATOR|Placebo|Matching placebo IV every 2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally for up to 52 weeks
62013456|NCT00476424|ACTIVE_COMPARATOR|1|400 mg EFV
62013457|NCT00476424|ACTIVE_COMPARATOR|2|600 mg EFV
62013458|NCT06662890|EXPERIMENTAL|Supersaturated oxygen therapy using radial artery access|Supersaturated O2 (SSO2) therapy immediately following primary percutaneous coronary intervention using radial artery access in the cardiac catheter laboratory.
62013459|NCT06662890|SHAM_COMPARATOR|Control group|Control (sham) procedure in addition to standard care
62013460|NCT03280355|EXPERIMENTAL|Singing Training|Singing Training as training activity in Pulmonary Rehabilitation: 10 weeks, twice a week for 1 1/2 hour, leading to a total of 20 sessions.
62013461|NCT03280355|ACTIVE_COMPARATOR|Physical Training|Physical Training as training activity in Pulmonary Rehabilitation: 10 weeks, twice a week for 1 1/2 hour, leading to a total of 20 sessions.
62201807|NCT00546208||1|adolescents and young adults who underwent, as newborns, unilateral low loop cutaneous ureterostomy for severe bilateral hydro-ureteronephrosis, and that, afterwards, underwent stomal closure
62201808|NCT01749267|EXPERIMENTAL|partial caries removal|partial caries removal only at enamel dentin junction (EDJ) without carious tissue removal at the pulpal site
62201809|NCT05787327|EXPERIMENTAL|Active treatment (Yinqiaosan-Maxingganshitang )|Chinese Medicine granules
62201810|NCT05787327|PLACEBO_COMPARATOR|Placebo|Placebo granules
62402362|NCT02553486||Internationally adopted children|All internationally adopted children, who arrived in France between 2008 and 2013, living in four French districts
62402363|NCT02885831||A - Abduction splintage|Treatment by abduction splintage. Sonographic, clinical and radiographic surveillance. 45 patients.
62402364|NCT02885831||B - Surveillance|No treatment by abduction splintage. Sonographic, clinical and radiographic surveillance. 45 patients
62402365|NCT04373265|EXPERIMENTAL|Relacorilant in Combination with Pembrolizumab|Participants will be treated on Day -3 to Day 1 (Cohort 1 under fasting conditions) or Day -6 to Day 1 (Cohort 2 under fed conditions) for Cycle 1 only. During the lead-in period, 300 mg relacorilant will be administered daily for 4 -7 days. Patients will receive their first pembrolizumab infusion on Cycle 1 Day 1. The participants will then receive combined treatment from Cycle 1 Day 1 until confirmed PD or unacceptable toxicity. Pembrolizumab will be administered every 6 weeks (on Day 1 of each 42-day cycle) and relacorilant will be administered daily. Optional Cohort 3 will lead-in with 400 mg relacorilant once daily for 7 days and combined treatment of relacorilant and pembrolizumab, depending on PD and toxicity.
62402366|NCT03773159||Patients|Patients with von Willebrand disease or major constitutional thrombopathy or patients on antiplatelet drugs
62402367|NCT03773159||Controls|Blood donors at the French blood establishment in Burgundy Franche-Comté
62201811|NCT00569114|OTHER|1|
62402368|NCT03353025|EXPERIMENTAL|transsphenoidal surgery treatment|Transsphenoidal surgery treat non-invasive prolactinoma by experienced neurosurgeon
62402369|NCT03353025|EXPERIMENTAL|dopamine agonist treatment|Minimum effective dose of dopamine agonist, bromocriptine, treat non-invasive prolactinoma
62579025|NCT05468528|OTHER|PVI group|pulmonary vein isolation ablation alone
62013462|NCT04124549|SHAM_COMPARATOR|Stand of Care|Patients in the control group received usual care with sham exercise.
62013463|NCT04124549|EXPERIMENTAL|Combined Exercise|The intervention was a 24-week progressive intradialytic combined cycling exercise which proceed in the first HD 2 hours. Each exercise lasted about 40 minutes.
62201812|NCT03285607|EXPERIMENTAL|Dose Level 1:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"* MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~* The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~  * doxorubicin 60 mg/m\^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~ * cyclophosphamide 600 mg/m\^2 Q2W during Weeks 1 through 8 (total of 4 doses)~ * paclitaxel 80 mg/m\^2 IV QW during Weeks 9 through 20 (total of 12 doses)~* Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
62402370|NCT02500134||Normal|Healthy volunteer control without ocular surface disease or prior ophthalmic surgery history
62402371|NCT01609608|EXPERIMENTAL|vibration|
62402372|NCT01609608|PLACEBO_COMPARATOR|placebo|
62579026|NCT06156163|EXPERIMENTAL|Perturbation Group|Exercise program with progressive perturbation conditions
62579027|NCT06156163|ACTIVE_COMPARATOR|Exercise Group|Exercise program
62785422|NCT04619498|NO_INTERVENTION|CtrlPALS-|The teams assigned to the CtrlPALS- arm will manage the simulated scenario of pediatric cardiac arrest using no PALS-related cognitive aids.
62579028|NCT01681212|EXPERIMENTAL|Ipilimumab, 10 mg/kg + Dacarbazine, 850 mg/m^2|During the Induction Period, participants received ipilimumab, 10 mg/kg, as tolerated by intravenous (IV) infusion as 1 single dose during Weeks 1 (Day 1), 4, 7, and 10 for a total of 4 separate doses. During the Maintenance Phase, participants received ipilimumab, 10 mg/kg, as tolerated by IV infusion every 12 weeks, beginning at Week 24, until disease progression or unacceptable toxicity occurred or the patient withdrew consent. Participants also received dacarbazine, 850 mg/m\^2, by IV infusion over 30 to 60 minutes, starting on Week 1 and repeated every 3 weeks until Week 22. Dacarbazine was dosed on the same day as ipilimumab, when applicable, after the ipilimumab dose.
62013464|NCT03393598|EXPERIMENTAL|pre-expansion using Kiwi® VAC-6000M|Expansion will be performed using a complete vacuum delivery system called Kiwi® VAC-6000M with the PalmPumpTM (Clinical Innovations, South Murray, Utah, USA).
62013465|NCT03393598|EXPERIMENTAL|pre-heating using Hilotherm Calido®.|Pre-Heating will be preformed using a Hiloterm Calido® System.
62402373|NCT00561041|EXPERIMENTAL|1|Brief phone aftercare intervention composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
62785423|NCT03405649|EXPERIMENTAL|Group A|Participants train 60 min per session for 10 weeks on non-consecutive days. All training sessions will be supervised by a qualified exercise instructor. Each training session will include a warm up phase of 5 minutes of dynamic and static stretching and a cool down phase consisting of 5 minutes of static stretching. Whole-body exercises and weights, elastic bands and balls will be used. Babies less than 20 weeks of age will be included in the exercise routine. Participants will perform 1-3 sets per exercise, 8-12 repetitions per set and a 90-s rest interval between sets.
62785424|NCT03405649|EXPERIMENTAL|Group B|Participants train 60 min per session for 10 weeks on non consecutive days. All training sessions will be supervised by a qualified exercise instructor. Each training session will include a warm up phase of 5 minutes of dynamic and static stretching and a cool down phase consisting of 5 minutes of static stretching. Whole-body exercises and different equipment such as weights, elastic bands and balls will be used. Babies older than 20 weeks will be included in the exercise routine. Participants will perform 1-3 sets per exercise, 8-12 repetitions per set and a 90-s rest interval between sets.
62785425|NCT03666689||MHV reconstruction|Both ends of middle hepatic vein tributaries V8 and/or V5 of modified right lobe graft will be anastomosed to side of a single synthetic graft which will be anastomosed to recipient's middle/left hepatic vein orifice.
62579029|NCT06189781|EXPERIMENTAL|Pain Injection|The local anesthetic group will be injected with a combination of ropivacaine, epinephrine, and ketorolac.
62013466|NCT03393598|EXPERIMENTAL|pre-expansion-heating|Both preconditioning methods Hilotherm Calido® plus Kiwi® VAC-6000M- will be applied.
62013467|NCT03393598|NO_INTERVENTION|Control|No preconditioning methods will be applied.
62402374|NCT00561041|EXPERIMENTAL|2|Individual aftercare therapy - composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
62402375|NCT00561041|NO_INTERVENTION|3|No intervention
62579030|NCT06189781|ACTIVE_COMPARATOR|Epidural|The control group will receive epidural anesthesia. Lumbar epidural anesthesia will be started intra-operatively.
62579031|NCT06517784||Patients|Patients with type 2 diabetes
62579032|NCT06517784||Health care providers|Health care providers who treat patients with type 2 diabetes
62785426|NCT03666689||Separate tributaries reconstruction|End of V8 middle hepatic vein tributary of modified right lobe graft; if present, will be anastomosed to end of a synthetic graft which will be anastomosed to recipient's middle/left hepatic vein orifice, and end of V5; if present; will be anastomosed to end of a synthetic graft which will be anastomosed to recipient's Inferior Vena Cava directly.
62785427|NCT01045694|EXPERIMENTAL|Botulinum Toxin Type A|Arm investigates the efficacy of Botulinum Toxin A injection for the treatment of basal thumb joint arthritis
62013468|NCT03826329||Study Cohort|The observational study included all patients who had been admitted for their first ACDF surgery during the 16-year span, began on January 1st, 1998 till the end of 2013, recorded in the NHIRD. The admission for cervical disc herniation and spondylosis were identified using the ICD9-CM diagnostic codes of 722.0, 722.4 and 722.71, while the surgery of ACDF was confirmed with the procedure codes of 80.51, 81.00 and 81.02 during the same hospitalization.
62013469|NCT05166967|EXPERIMENTAL|Individual dose of ATG|Individual dose of ATG: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg), and the active ATG concentration ranges from 110 to 148.5UE/ml.
62013470|NCT05166967|ACTIVE_COMPARATOR|Fixed dose of ATG|A total amount of 10mg/kg ATG was divided into 4 days (from day -5 to day -2). The specific usage: 1.5mg/kg for day -5, 2.5mg/kg for day -4 and day -3, 3.5 mg/kg for day -2.
62013471|NCT04978038|EXPERIMENTAL|Pfizer-BioNtech mRNA- COVID-19|Eligible participants will be vaccinated with the Pfizer-BioNtech mRNA- COVID-19. A 0.3ml dose of the vaccine will be administered intramuscularly.
62402376|NCT01846039|EXPERIMENTAL|JUVÉDERM VOLUMA®|Participants treated with JUVÉDERM VOLUMA® up to 3 mLs administered by intradermal injection.
62402377|NCT05950529|EXPERIMENTAL|Group A|Experimental lozenge with the enzyme Polyphenol oxidase plus green coffee extract
62402378|NCT05950529|EXPERIMENTAL|Group B|Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor
62402379|NCT05950529|PLACEBO_COMPARATOR|Group C|Placebo lozenge Control (sorbitol only)
62402380|NCT05950529|OTHER|Group D|No Product Control
62402381|NCT02545270|EXPERIMENTAL|Group 1: 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation after surgery is completed.
62013472|NCT04978038|ACTIVE_COMPARATOR|Pneumococcal Prevnar-13|Eligible participants will be vaccinated with Pfizer Prevar-13 (pneumococcal vaccine) in a blinded manner such that the vaccination with Pfizer-BioNtech mRNA- COVID-19 will be mimicked. That is, a 0.5ml dose of the vaccine will be administered intramuscularly. After completion of the study participants in the control arm will be given a fourth dose of Pfizer-BioNtech mRNA- COVID-19.
62201813|NCT03285607|EXPERIMENTAL|Dose Level 2:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"* MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~* The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~  * doxorubicin 60 mg/m\^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~ * cyclophosphamide 600 mg/m\^2 Q2W during Weeks 1 through 8 (total of 4 doses)~ * paclitaxel 80 mg/m\^2 IV QW during Weeks 9 through 20 (total of 12 doses)~* Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
62201814|NCT03285607|EXPERIMENTAL|Dose Expansion:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"* MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~* The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~  * doxorubicin 60 mg/m\^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~ * cyclophosphamide 600 mg/m\^2 Q2W during Weeks 1 through 8 (total of 4 doses)~ * paclitaxel 80 mg/m\^2 IV QW during Weeks 9 through 20 (total of 12 doses)~* Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
62201815|NCT00006501||ECG recording|After the tests are completed, people who enroll in this study are followed by telephone, 1, 4, 8, 12 16, 20 and 24 months. During these follow-up telephone calls a research coordinator asks about the participant's health condition and about cardiovascular medications that are being taken.
62402382|NCT02545270|EXPERIMENTAL|Group 2: 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation after surgery is completed.
62402383|NCT02545270|EXPERIMENTAL|Group 3: 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation after surgery is completed.
62402384|NCT02620566|ACTIVE_COMPARATOR|Bupivacain -Caudal|Single shot Caudal Block will receive Group C with 1ml per kg Bupivacain 0,25%.
62579033|NCT05970523|EXPERIMENTAL|Exercise Group|Intervention includes core stabilization exercises for 45 minutes 3 times a week. Participants do exercise face to face under supervision of a physiotherapist and via an online application under the supervision of a physiotherapist once a week. Also participants do home exercise once a week. Exercise group walk for an hour in other two days.
62402385|NCT02620566|ACTIVE_COMPARATOR|Bupivacain- Local|Single shot Local Infiltration will receive Group L with 0,2ml per kg Bupivacain 0,25%.
62402386|NCT02950285|EXPERIMENTAL|Baseline alert|For patients randomly selected for the baseline alert arm, their physicians will be alerted via email that a patient(s) under their care has atrial fibrillation, is at high risk of stroke, and is not currently anticoagulated. Physicians will also be asked to complete a survey related to anticoagulation for each patient and will be provided with educational resources and consultation services.
62579034|NCT05970523|NO_INTERVENTION|Control Group|There is no exercise or intervention for control group.
62201816|NCT05217667|EXPERIMENTAL|ARO-ANG3 Dose 1|ARO-ANG3 Dose Level 1 subcutaneous (SC)
62201817|NCT05217667|EXPERIMENTAL|ARO-ANG3 Dose 2|ARO-ANG3 Dose Level 2 SC
62201818|NCT06373198||i. Strategy to re-engage HCV patients in a high complex hospital with a network|An evaluation of the positivity of the hepatitis C test will be carried out. Positive patients will be included in the follow-up and specific treatment will be requested to achieve a cure. Standard of care will be applied.
62201819|NCT03262649||Crohn's Disease Cohort|250 individuals in the Crohn's Disease Cohort
62785428|NCT01045694|ACTIVE_COMPARATOR|Steroid - Triamcinolone Acetonide|Arm uses the standard of care - Steroid injection - as an active comparator to the experimental injection of Botulinum Toxin A for the treatment of basal thumb joint arthritis
62013473|NCT04763772|EXPERIMENTAL|Detailed Report|A detailed body composition profile report that consists of the following elements: basic demographic data, percent body fat, weight to muscle ratio, visceral fat and abdominal subcutaneous fat volume, visceral fat ratio (the fraction of visceral divided by total abdominal fat), muscle fat infiltration and liver fat (%), and thigh muscle volumes (also separated into right and left, anterior and posterior compartments). Each parameter is presented on a visual scale in the context of the individual value, general population defined by reference data (from United Kingdom (UK) Biobank population), a metabolic disease-free population (also from UK Biobank), low/high and very low/very high, corresponding to 15th and 5th percentiles, respectively. There are also descriptions of each biomarker and how they are derived to provide context for the recipient.
62201820|NCT03262649||ulcerative colitis cohort|108 individuals in the ulcerative colitis cohort
62013474|NCT04763772|PLACEBO_COMPARATOR|Basic Weight Information|A simple informational report consisting of weight, BMI, and a visual representation of their BMI. This report also categorizes their BMI into underweight, normal weight, overweight, or obese categories according to the World Health Organization categorization schema.
62579035|NCT02557581|EXPERIMENTAL|Terbutaline|Beta2-adrenergic stimulation with terbutaline
62785429|NCT01045694|PLACEBO_COMPARATOR|Lidocaine|Arm uses plain lidocaine injection to serve as a baseline for evaluating the efficacy of Botulinum toxin as compared to steroid injection for the treatment of basal thumb joint arthritis.
62785430|NCT01775605|ACTIVE_COMPARATOR|Synera|Synera Pain Patch
62785431|NCT01775605|NO_INTERVENTION|No patch control|No intervention group
62013475|NCT04763772|EXPERIMENTAL|Patient Provided|Report provided directly to the patient.
62013476|NCT04763772|PLACEBO_COMPARATOR|Physician Provided|Report provided directly to the provider to translate/counsel the patient.
62013477|NCT04942080|EXPERIMENTAL|CALRSUIVI cohort|
62201821|NCT03156881|EXPERIMENTAL|Treatment group|"The participants in the treatment group (anticipating 24) will be receiving four global osteopathic treatments in a six week period alongside their standard care. Their standard care is to improve diet and increase exercise.Blood work done about every 3 months to check liver enzyme levels to observe improvements or monitor severity of the disease.~This group will also complete questionnaires evaluating their quality of life (CLDQ) and their readiness to change before and after the treatment series."
62201822|NCT03156881|NO_INTERVENTION|Control Group|This group will have an anticipated 24 participants and will continue their standard care as explained above along with completing two questionnaires evaluating their quality of life and readiness to change. This group will not be receiving any osteopathic treatment.
62201823|NCT06448949||TB and PED|
62201824|NCT03339232|NO_INTERVENTION|Usual Care|Participants will receive standardized information about a healthy diet, including the potential benefit of small, frequent meals and nighttime snacking . In addition, the treating hepatologist will counsel participants on the benefits of increased physical activity. These recommendations will be provided at the beginning of the study. The usual care arm reflects current clinical practice. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity.
62201825|NCT03339232|OTHER|BCAA Supplement|BCAA powder (Bulk Supplements®) will be provided as the powder was found to be easier to swallow. Each teaspoon contains 1788 mg of BCAA and participants will take 7 teaspoons (12.5 grams of BCAA) per day divided into three separate servings. Each teaspoon contains L-leucine, isoleucine and valine in a 2:1:1 ratio. BCAA will be provided by the study investigators and half will be provided at baseline study visit and the second half at the week 6 visit. In addition, the treating hepatologist will provide standardized information about the potential benefits of small, frequent meals, nighttime snacking and increased physical activity at the beginning of the study. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity.
62201826|NCT03339232|OTHER|BCAA supplement plus supervised physical activity|BCAA supplement will be as described for group 2, above. Study coordinators will supervise the physical activity program for study participants at the Loyola Fitness Center. Participants will attend the fitness center one hour each week; the fitness session will consist of low-impact aerobic physical activity, beginning with walking on the indoor track and possibly building to a recumbent exercise bicycle and light resistance training. Participants will be given a list of exercises to perform at home at least two times during the week with a goal of \>90 minutes of physical activity per week. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity which they will return during the weekly fitness center sessions. In addition, the treating hepatologist will provide standardized information about the potential benefits of small, frequent meals, nighttime snacking and increased physical activity at the beginning of the study.
62201827|NCT05584683|EXPERIMENTAL|Pediatric patients with a bacterial infection|
62201828|NCT01739023|EXPERIMENTAL|Autologous Human Schwann Cells|
62579036|NCT02557581|PLACEBO_COMPARATOR|Placebo|Placebo
62579037|NCT02557581|EXPERIMENTAL|Clenbuterol|Beta2-adrenergic stimulation with clenbuterol
62785432|NCT01775605|SHAM_COMPARATOR|Control|Sham
62785433|NCT01137370||Patients with TB|
62785434|NCT01137370||People without TB|
62201829|NCT01208103|EXPERIMENTAL|Treatment (oxaliplatin, bevacizumab, capecitabine)|Participants receive oxaliplatin via CVC over 2 hours and bevacizumab IV over 30-90 minutes on day 1. Participants also receive capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62201830|NCT02297490|PLACEBO_COMPARATOR|Placebo|Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
62201831|NCT02297490|EXPERIMENTAL|Allergovit 6-grasses immunotherapy|Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.
62201832|NCT02057211|PLACEBO_COMPARATOR|sham transplantation of mesenchymal stem cells|control arm with sham transplantation
62579038|NCT06217237||AD FDT DBL GROUP|All participants will undergo an MRI session. The MRI protocol will include the clinical diagnostic protocol defined within the Network and research sequences as specified above (T1 3D, DTI, FLAIR 3D, QSM).
62402387|NCT02950285|NO_INTERVENTION|3-month alert arm|For patients randomly selected for the 3-month alert arm, their physicians will not be notified during the 3-month study follow-up period. Instead, PCPs will be sent alerts after 3-months via email for these patients.
62201833|NCT02057211|ACTIVE_COMPARATOR|autologous mesenchymal stem cell transplantation|Active arm with transplantation of cells
62201834|NCT04530383|EXPERIMENTAL|Metformin dose regimen A|Participants with CFRD on elexacaftor/tezacaftor/ivacaftor who meet criteria and agree to participation in the study will be placed on metformin 500 mg twice daily on study week 0 after undergoing study procedures through week 14. They will then undergo a two week washout period. For the second half of the study metformin will be resumed and, if tolerated, dose will be increased by 500mg on weeks 17 and 18 to a final dose of 1000 mg twice daily through end of study (week 30).
62402388|NCT03580746||Taping and posteromedial release|Children with clubfoots are treated by taping and posteromedial release
62402389|NCT03580746||Treatment by Ponseti|Children with clubfoots are treated by Ponseti
62579039|NCT06217237||CONTROL GROUP|All participants will undergo an MRI session. The MRI protocol will include the clinical diagnostic protocol defined within the Network and research sequences as specified above (T1 3D, DTI, FLAIR 3D, QSM).
62579040|NCT02608983|EXPERIMENTAL|Treatment 1|
62579041|NCT02608983|EXPERIMENTAL|Treatment 2|
62201835|NCT04530383|EXPERIMENTAL|Metformin dose regimen B|Participants with CFRD on elexacaftor/tezacaftor/ivafactor who meet criteria and agree to participation in the study will be placed on metformin 500 mg twice daily on study week 0 after undergoing study procedures. If tolerated, dose will be increased by 500mg on weeks 1 and 2 to a final dose of 1000 mg twice daily through week 14.They will then undergo a two week washout period. For the second half of the study metformin will be resumed at a dose of 500 mg twice daily through the end of study (week 30).
62201836|NCT02979249|EXPERIMENTAL|Oral Iron|standard dose of iron pills
62201837|NCT02741453|ACTIVE_COMPARATOR|Standard Practice|Placement of a CVC by standard practice
62402390|NCT01553708|EXPERIMENTAL|Epidermal growth factor with silver sulfadiazine cream|Epidermal growth factor with silver sulfadiazine cream was applied to the experimental wounds completely and then covered with sterile gauze. The wound was cleaned every 24 h and the cream was then applied again after cleaning process.
62785435|NCT02321345|EXPERIMENTAL|Palliative Care Support|Palliative care meetings will address the following issues: 1) values and meaning of life 2) greatest hopes and fears 3) communication preferences 4) proxy readiness to make decisions, and patient preferences, if the patient were to become seriously ill, and 5) symptom management strategies.
62402391|NCT01553708|ACTIVE_COMPARATOR|Silver zinc sulfadiazine cream|Silver sulfadiazine cream was applied to cover the controlled-wound completely and then covered with sterile gauze. The wound was cleaned every 24 h and the cream was then applied again after cleaning process.
62402392|NCT00594334|EXPERIMENTAL|E, I|
62402393|NCT04704908||9-17y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
62402394|NCT04704908||9-14y (0,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
62402395|NCT04704908||18-26y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
62579042|NCT02608983|PLACEBO_COMPARATOR|Treatment 3|
62201838|NCT02741453|EXPERIMENTAL|Bilateral IJ Ultrasound Scanning|Placement of a CVC after mandatory ultrasound scanning of both right and left internal jugular veins
62201839|NCT00756457|ACTIVE_COMPARATOR|Active Treatment Group|Participants in Group A will undergo bracing and perform stretching exercises.
62201840|NCT00756457|EXPERIMENTAL|Passive Treatment Group|Participants in Group B will undergo bracing and perform stretching and strengthening exercises.
62579043|NCT06506695|EXPERIMENTAL|Early loading of craniofacial prosthesis|
62201841|NCT02073240||Enhanced TB IC Package|"Facilities randomized to the intervention group will receive the following:~1. Skills-based training for TB IC focal points~2. Audits and Feedback of performance data~3. TB IC collaborative (including mentoring)~4. Checklists"
62201842|NCT02073240||Usual Care Group|Usual Care group will receive available TB IC training/education alone.
62579044|NCT05982483|EXPERIMENTAL|ESP cohort|Randomized to receive the ultrasound-guided ESP block.
62579045|NCT05982483|ACTIVE_COMPARATOR|Usual care cohort|Randomized to usual care as dictated by the treating emergency physician
62579046|NCT03034174||tigecycline|"Each patient will receive: tigecycline (200 mg q 12 hours i.v.), meropenem (2 g q 8 hours i.v). In each case CVVHD will be started.~Blood samples (3 mL) will be collected 2, 4, 8 and 12 hours after each dose of tigecycline for 3 consecutive days."
62201843|NCT01353118|NO_INTERVENTION|gastric bypass|Group A: Patients will undergo gastric bypass surgery within 3 months after randomisation without any pre operative optimisation of glycaemic control.
62402396|NCT03349203|EXPERIMENTAL|Icotinib|Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks before surgery and 2 years as adjuvant therapy after surgery or till progressive disease or unaccepted toxicity.
62579047|NCT04167098|EXPERIMENTAL|Platelet-Rich Plasma|
62579048|NCT04167098|ACTIVE_COMPARATOR|Corticosteroid|
62579049|NCT04167098|PLACEBO_COMPARATOR|0.9% saline|
62579050|NCT02458456|SHAM_COMPARATOR|IHG 5% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 5% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
62579051|NCT02458456|EXPERIMENTAL|IHG 30% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 30% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
62579052|NCT02458456|EXPERIMENTAL|IHG 30% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 30% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
62785436|NCT00147121|ACTIVE_COMPARATOR|1|Rituximab+Standard CHOP
62785437|NCT00147121|EXPERIMENTAL|2|Rituximab+bi-Weekly CHOP
62785438|NCT02909374|EXPERIMENTAL|Balance training|"The program includes exercise with dual- and multi task performance and is progressive as the exercises can be performed at different levels (basic, moderate, and advanced). The 12-week balance training program will be performed two times per week for one hour each. The training will be lead by physiotherapists or trained leaders. After the balance training the participants will get recommendations for continued physical activity and training, i.e. Physical activity on prescription."
62579053|NCT02458456|SHAM_COMPARATOR|IHG 5% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 5% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
62013478|NCT06535256|OTHER|bupivacaine with dexamethasone|40 mL of 0.25% bupivacaine + 16 mg dexamethasone with 5 ml normal saline).
62785439|NCT05275101|NO_INTERVENTION|Control|Individuals who have not experienced suicidal ideation will not complete a suicide intervention.
62013479|NCT06535256|OTHER|bupivacaine with dexmedetomidine|40 mL of 0.25% bupivacaine + dexmedetomidine 1 μg/kg with normal saline 5 ml).
62013480|NCT06084585|ACTIVE_COMPARATOR|Study Product A (High-dose 2X)|"Amway uric acid lowering product: 5g/sachet, containing the following active ingredients:~* Celery seed (functional raw material)~* Dasiphora mandshurica (functional raw material)~* Cichorium intybus L. (functional raw material)~* Lotus leaf (functional raw material)~* Tart cherry (functional raw material)~* γ-cyclodextrin~* Erythritol~* Silicon dioxide~* Resistant dextrin~* Black tea essence"
62201844|NCT01353118|ACTIVE_COMPARATOR|Gastric bypass 2|Gastric bypass 2 (Group B):Patients will undergo gastric bypass 3-6 months after randomisation. During this period the group will receive modern best medical care based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines. Glycaemic optimisation will be achieved in a gradual manner with particular attention to the avoidance of hypoglycaemia
62201845|NCT03478449|EXPERIMENTAL|Fine sorting lymph node group|
62201846|NCT03478449|NO_INTERVENTION|Regional sorting lymph node group|
62402397|NCT02582593|ACTIVE_COMPARATOR|Cognitively Normal Group NIR|Transcranial Near Infrared Stimulation for cognitively normal participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
62579054|NCT02458456|EXPERIMENTAL|IHG 10% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 10% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
62579055|NCT02458456|EXPERIMENTAL|IHG 10% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 10% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
62579056|NCT02030340||Testing Lower urinary tract dysfunction|All patients with lower urinary tract dysfunction where urodynamic diagnosis is required according to standards and (international) practice guidelines will have a synchronous double system (combination of air-charged and water filled) urodynamic test.
62579057|NCT06364930|ACTIVE_COMPARATOR|Dapagliflozin|10mg QD for 60 months
62579058|NCT06364930|PLACEBO_COMPARATOR|Placebo|10mg QD for 60 months
62579059|NCT00821964|EXPERIMENTAL|Treatment (biological therapy, chemo)|Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
62785440|NCT05275101|EXPERIMENTAL|Crisis Response Planning (CRP)|The crisis response planning (CRP) session will last between 30 minutes to 1-hour. It will occur face-to-face with a trained study therapist. The CRP session involves the following standard suicide intervention strategies: supportive listening, provision of crisis resources, and referral to a mental health professional (if not already established). The CRP active component involves a collaborative process in which the therapist invites the patient to share the events, symptoms, and contextual factors leading up to and surrounding the participant's suicidal crisis. Next, the patient and therapist identify the patient's personal warning signs for an emotional crisis, self-management coping skills, patient's reasons for living, and sources of social support. These components are written, by the patient, on an index card. The index card serves as a concrete reference for patients in the real-world.
62013481|NCT06084585|ACTIVE_COMPARATOR|Study Product B (Low-dose X)|"Amway uric acid lowering product: 5g/sachet, containing the following active ingredients:~* Celery seed (functional raw material)~* Dasiphora mandshurica (functional raw material)~* Cichorium intybus L. (functional raw material)~* Lotus leaf (functional raw material)~* Tart cherry (functional raw material)~* γ-cyclodextrin~* Erythritol~* Silicon dioxide~* Resistant dextrin~* Black tea essence"
62201847|NCT02308397|EXPERIMENTAL|Group 1|Begins with Normal gluten containing bread
62201848|NCT02308397|EXPERIMENTAL|Group 2|Begins with Bread with reduced gliadins content
62201849|NCT02308397|EXPERIMENTAL|Group 3|Begins with Bread with reduced ATIs content
62579060|NCT05623540||bisphosphonates users|Patients who underwent primary total joint arthroplasty with bisphosphonates use
62402398|NCT02582593|SHAM_COMPARATOR|Cognitively Normal Group - Sham|Cognitively Normal Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
62402399|NCT02582593|ACTIVE_COMPARATOR|Amnestic MCI Groups - Amnestic and Nonamnestic NIR|Transcranial Near Infrared Stimulation for amnestic and nonamnestic participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
62402400|NCT02582593|SHAM_COMPARATOR|Amnestic MCI Groups - Amnestic and Nonamnestic - Sham|Amnestic and Nonamnestic Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
62402401|NCT02582593|ACTIVE_COMPARATOR|Parkinson Disease Group NIR|Transcranial Near Infrared Stimulation for Parkinson Disease participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
62402402|NCT02582593|SHAM_COMPARATOR|Parkinson Disease Group Sham|Parkinson Disease Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
62402403|NCT01758991|ACTIVE_COMPARATOR|real tDCS|"patients will receive non-invasive and painless brain stimulation over the rain areas involved in swallowing.~tDCS will be applied during swallowing therapy, during 20 minutes"
62402404|NCT01758991|PLACEBO_COMPARATOR|sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
62402405|NCT00814762|EXPERIMENTAL|HIV 732462 Group|Subjects received 2 doses of the HIV Vaccine 732462 into the deltoid muscle of the dominant arm, on a 0, 1 Month schedule.
62402406|NCT00814762|PLACEBO_COMPARATOR|Placebo Group|Subjects received 2 doses of the placebo vaccine into the deltoid muscle of the dominant arm, on a 0, 1 Month schedule.
62402407|NCT04314115|ACTIVE_COMPARATOR|Mindfulness|A brief intervention in mindfulness will be administered
62402408|NCT04314115|ACTIVE_COMPARATOR|Systemic therapy|A brief systemic therapy intervention will be administered
62402409|NCT04314115|ACTIVE_COMPARATOR|Cognitive behavioral therapy and positive psychology|A brief intervention of traditional cognitive behavioral therapy with positive psychology elements will be administered
62402410|NCT04314115|NO_INTERVENTION|Waiting list|Waiting list, as a control group
62013482|NCT06084585|PLACEBO_COMPARATOR|Placebo|"Placebo product: 5g/sachet, containing the following active ingredients:~* Maltodextrin~* Pigment~* Erythritol~* Bitters~* Essence of flavor"
62402411|NCT01604512|EXPERIMENTAL|Pts with a brain tumor|The study will prospectively enroll patients who have increasing size and/or enhancement of brain lesion(s) after brain radiation therapy for a neoplasm (either primary or metastatic), where. it is unclear if a lesion represents radiation injury or progressive tumor. At the discretion of PI the RSI sequence may be repeated at SOC FDG or other radiotracer imaging carried out while the patient is still on study, if deemed clinically necessary.
62402412|NCT02748096|EXPERIMENTAL|Patient Specific Instrumentation|Patients undergoing unicompartmental knee replacement with the additional aid of patient specific instrumentation.
62402413|NCT02748096|ACTIVE_COMPARATOR|Conventional Instrumentation|Patients undergoing unicompartmental knee replacement using standard instrumentation.
62402414|NCT03653780|EXPERIMENTAL|Ekso GT gait training|20-minute Ekso GT gait training
62402415|NCT05864209|EXPERIMENTAL|Intervention Group|Half of the participants will be randomly assigned to the intervention group and will receive a three-month supply of phthalate- and bisphenol-free baby products (e.g., wipes, diaper cream) and a subscription to a cloth diaper service. Participants will be contacted after 2 and 6 weeks over the phone and administered a brief adherence survey.
62402416|NCT05864209|ACTIVE_COMPARATOR|Control Group|Half of the participants will be randomly assigned to the control group and provided with a three-month supply of conventional disposable diapers (e.g., Huggies or Pampers) and baby products (e.g., wipes, diaper cream). Participants will be contacted after 2 and 6 weeks over the phone and administered a brief adherence survey.
62402417|NCT01692990|EXPERIMENTAL|Fish oil|5 g/d in 10 capsules, providing 3.5 g of long-chain n-3 fatty acids
62402418|NCT01692990|PLACEBO_COMPARATOR|Soy bean oil|5 g/d in 10 capsules
62579061|NCT05623540||bisphosphonates nonusers|Patients who underwent primary total joint arthroplasty without bisphosphonates use
62579062|NCT03979807||Subjects with Chronic obstructive pulmonary disease|
62013483|NCT03124394||CRS and intraoperative chemotherapy|Patients receiving cytoreductive surgery and intraoperative chemotherapy (HIPEC/PIPAC)
62013484|NCT03348267|EXPERIMENTAL|Protein|On the match day, 25g of protein consumed immediately after the match and then 30g at 3h (+3h) and 25g at 6h (+6h). On each day of the remaining days, 20 g of protein consumed with breakfast.
62201850|NCT02308397|EXPERIMENTAL|Group 4|Begins with Bread with reduced overall protein content
62013485|NCT03348267|ACTIVE_COMPARATOR|Placebo|On the match day, 500 ml received received orally immediately post-match and then at +3h and +6h. On the remaining days, 500 ml daily with breakfast.
62013486|NCT00982189|EXPERIMENTAL|Lisinopril|Lisinopril 10mg once daily
62013487|NCT00982189|PLACEBO_COMPARATOR|Lisinopril Placebo|Placebo pill (matched to lisinopril) once daily
62013488|NCT00982189|EXPERIMENTAL|Pravastatin|Pravastatin 20mg once daily
62201851|NCT04441944||Telemedicine Cases|Patients presenting to rural emergency departments who had real-time provider-to-provider telemedicine used to supplement their emergency department care.
62201852|NCT04441944||Non-Telemedicine Cases|Patients presenting to rural emergency departments who did not have real-time provider-to-provider telemedicine used to supplement their emergency department care.
62201853|NCT03556800|EXPERIMENTAL|0.5 gm of EstroCream (VML-0203)|
62201854|NCT03556800|EXPERIMENTAL|0.75 gm of EstroCream (VML-0203)|
62201855|NCT03556800|EXPERIMENTAL|1.25 gm of EstroCream (VML-0203)|
62201856|NCT03556800|ACTIVE_COMPARATOR|1.25 EstroGel|
62201857|NCT01613482|ACTIVE_COMPARATOR|Arm A|Without cerebral prophylactic radiation
62201858|NCT01613482|EXPERIMENTAL|Arm B|With cerebral prophylactic radiation
62402419|NCT03297710|EXPERIMENTAL|Treatment (TAS-102, radiation therapy)|Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 PO BID and undergo radiation therapy in 10 fractions on days 1-5 and 8-12 in the absence of disease progression or unacceptable toxicity.
62785441|NCT05275101|ACTIVE_COMPARATOR|Crisis Risk Counseling|The crisis risk counseling session will last between 30 minutes to 1-hour. It will occur face-to-face with a trained study therapist. It will include the following standard suicide intervention strategies: supportive listening, provision of crisis resources, and referral to a mental health professional (if not already established). The therapist will conduct a semi-structured suicide risk assessment interview, after which subjects will complete a self-guided safety plan worksheet. The worksheet takes approximately 10-minutes to complete and will be done independently.
62013489|NCT00982189|PLACEBO_COMPARATOR|Pravastatin placebo|Placebo pill (matched to pravastatin) once daily
62013490|NCT02520531|ACTIVE_COMPARATOR|Scorpio PS|Patients on the waiting list for a total knee prosthesis who fulfil the inclusion and exclusion criteria will be asked to participate in this study and are randomized to receive the Scorpio PS Total Knee Replacement.
62013491|NCT02520531|ACTIVE_COMPARATOR|Scorpio NRG PS|Patients on the waiting list for a total knee prosthesis who fulfil the inclusion and exclusion criteria will be asked to participate in this study and are randomized to receive the Scorpio NRG PS Total Knee Replacement.
62013492|NCT03509701||Subject (RCVS)|Patients who meet the definition of RCVS. (1) acute and severe headache with or without focal deficits or seizures, (2) uniphasic course without new symptoms more than 1 month after clinical onset, (3) segmental vasoconstriction of cerebral arteries shown by computed tomography angiography (CTA), magnetic resonance angiography (MRA) or transfemoral cerebral angiography (TFCA),(4) normal or near normal cerebrospinal fluid analysis and (5) complete or substantial normalisation of arteries shown by follow-up angiography within 12 weeks.
62013493|NCT03509701||Control|Patients with thunderclap headache and intracranial stenosis, but not diagnosed as RCVS.
62013494|NCT03260816|EXPERIMENTAL|Internet-Delivered Parent Training|Families will receive weekly sessions of Internet-delivered Parent-Child Interaction Therapy (I-PCIT), a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
62201859|NCT01342198|EXPERIMENTAL|1|Single Dose Pregabalin Controlled Release
62201860|NCT01342198|EXPERIMENTAL|2|Single Dose Pregabalin Controlled Release with Multiple Doses of Erythromycin
62201861|NCT00376077|ACTIVE_COMPARATOR|Placebo and IVIG|"The trial site is blinded to the randomization process. Patients are assigned an arm by a research pharmacist. Patients on this arm receive an infusion of placebo (0.9% NaCl) over one hour. Immediately following this dosing, 1 g/kg IVIG (Gammunex ©) is infused over 2 - 3 hours. Following this treatment, complete blood counts are drawn at:~* completion of IVIG infusion,~* 8 hours following the start of the placebo/solumedrol infusion~* 24 hours following the start of the placebo/solumedrol infusion~* 72 hours following the start of the placebo/solumedrol infusion~* 7 days post infusion~* 21 days post infusion"
62201862|NCT00376077|EXPERIMENTAL|Methylprednisolone and IVIG|"The trial site is blinded to the randomization process. Patients are assigned an arm by a research pharmacist.Patients on this arm receive IV Methylprednisolone 30 mg/kg (1 gram maximum) infused over one hour. Immediately following this dosing, 1 g/kg IVIG Gammunex © is infused over 2 - 3 hours. Following this treatment, complete blood counts are drawn at:~* completion of IVIG infusion,~* 8 hours following the start of the placebo/solumedrol infusion~* 24 hours following the start of the placebo/solumedrol infusion~* 72 hours following the start of the placebo/solumedrol infusion~* 7 days post infusion~* 21 days post infusion"
62201863|NCT03147703|EXPERIMENTAL|Early Eating (EE)|The intervention is Food Timing, Early Eating is defined at 13:00 hours for lunch
62201864|NCT03147703|EXPERIMENTAL|Late Eating (LE)|The intervention is Food Timing, Late Eating is defined for 17:30 hours for lunch
62013495|NCT03260816|ACTIVE_COMPARATOR|Referrals as Usual (RAU)|Families in the referrals as usual (RAU) group will be referred to services as usual in their Early Intervention exit interview, which includes a variety of clinic-based mental health services at local community agencies. At each assessment, the access and extent of participation in other services will be monitored.
62402420|NCT02850159|EXPERIMENTAL|dual-mode group|the dual-mode NIBS with high-frequency rTMS and tDCS simultaneously
62402421|NCT02850159|ACTIVE_COMPARATOR|rTMS group|high-frequency rTMS and sham tDCS
62402422|NCT01121224|ACTIVE_COMPARATOR|BMS Group|Patients who receive a bare metal stent in the saphenous vein graft target lesion(s).
62201865|NCT02950610||Healthy|Healthy volunteer: self-declared healthy individual (no known illness or medications) with Normal BMI
62201866|NCT02950610||Nonalcoholic steatohepatitis|NAFLD without cirrhosis: Metabolic syndrome with known liver disease (NAFLD, excluding other coexisting liver condition) without cirrhosis
62785442|NCT02671097|EXPERIMENTAL|BAY1841788 (ODM-201) + Rosuvastatin|All subjects will receive a single dose BAY1841788 (ODM-201) (600 mg) followed by multiple doses BAY1841788 (ODM-201) (600 mg BID) as well as 2 times a single dose rosuvastatin (5 mg), once alone and once in combination with BAY1841788 (ODM-201).
62201867|NCT02950610||NAFLD Cirrhosis|NAFLD cirrhosis: well characterised NAFLD compensated cirrhosis (Child's A-B)
62201868|NCT01626508||breast-milk bank|breast milk collected and processed by the breast-milk bank before being used
62201869|NCT01626508||breast milk|breast milk used without any treatment, directly by children
62785443|NCT04374006|EXPERIMENTAL|propolis 50|we do sonde everyday to the rat that given treatment of 50mg/kg propolis for 2, 4, and 6 weeks
62402423|NCT01121224|EXPERIMENTAL|DES Group|Patients who receive a drug-eluting stent in the saphenous vein graft target lesion(s).
62402424|NCT05395845|EXPERIMENTAL|value of platlet rich plasma|
62402425|NCT03754400|EXPERIMENTAL|Albumin|All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.
62402426|NCT03754400|ACTIVE_COMPARATOR|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment.
62402427|NCT04395625|EXPERIMENTAL|Group 1|Patients had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding.
62402428|NCT04395625|EXPERIMENTAL|Group 2|Patients had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.
62402429|NCT02233673|EXPERIMENTAL|Behavioral, incentives|Participants receive behavioral intervention and financial incentives for meeting gestational weight gain goals
62785444|NCT04374006|EXPERIMENTAL|propolis 100|we do sonde everyday to the rat that given treatment of 100mg/kg propolis for 2, 4, and 6 weeks
62785445|NCT04374006|ACTIVE_COMPARATOR|dienogest|we do sonde everyday to the rat that given treatment of 25mg/kg dienogest for 2, 4, and 6 weeks
62785446|NCT04374006|PLACEBO_COMPARATOR|water|we do sonde everyday to the rat that given 0,2 ml water placebo for 2, 4, and 6 weeks
62201870|NCT03221166|EXPERIMENTAL|Thalidomide|Thalidomide is a immunomodulatory and antiangiogenetic drug with anti tumor necrosis factor (TNF) alpha properties
62785447|NCT04374006|SHAM_COMPARATOR|sham group|after the 2nd laparotomy, we do nothing about sonde, just giving food and drink everyday
62785448|NCT02486393||type of surgery|patients undergoing parotid surgery
62785449|NCT02504580|EXPERIMENTAL|Part A, Cohort A|HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg by injection.
62785450|NCT02504580|EXPERIMENTAL|Part A, Cohort B|HTX-011(bupivacaine/meloxicam), 400 mg/12 mg by injection.
62785451|NCT02504580|EXPERIMENTAL|Part A, Cohort C|HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg by instillation.
62785452|NCT02504580|EXPERIMENTAL|Part A, Cohort D|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg by instillation.
62201871|NCT03221166|ACTIVE_COMPARATOR|Infliximab|Infliximab is a chimeric monoclonal antibody against TNF alpha
62201872|NCT03787342|EXPERIMENTAL|"DFI Double Flap Incision"|A full-thickness crestal incision will be made over the edentulous ridge, and then one partial-thickness vertical incision will be made on the buccal side. A partial-thickness flap will be raised first to separate the mucosal layer from the overlying periosteum. Subsequently, the periosteal layer will be elevated to expose the underlying alveolar process. Xenograft and Ti-mesh will be used to augment the defective site then periosteal flap will be sutured first, with periosteal sutures securing the regenerative site. Then the mucosal flap will be closed.
62201873|NCT03787342|EXPERIMENTAL|"MPRI Modified PRI"|"A full-thickness muco-periosteal flap is reflected on the buccal side (crestal incision and two vertical releasing incisions). Near the base of mucoperiosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The shallow incision helps in preventing damage to the submucosal layer. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade with sweeping motion to allow flap advancement."
62402430|NCT02233673|NO_INTERVENTION|Standard care|Participants receive standard obstetrical care from their provider
62402431|NCT01741727|EXPERIMENTAL|ABT-414|Subjects with solid tumors (Phase 1) and squamous non-small cell lung cancer (NSCLC) (Phase 2)
62785453|NCT02504580|EXPERIMENTAL|Part A, Cohort E|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg by injection and instillation (combination).
62785454|NCT02504580|PLACEBO_COMPARATOR|Part A, Cohort F|Saline placebo by injection.
62785455|NCT02504580|EXPERIMENTAL|Part B, Cohort A|HTX-011A (bupivacaine/meloxicam), 200 mg/6 mg by injection.
62785456|NCT02504580|EXPERIMENTAL|Part B, Cohort B|HTX-011A (bupivacaine/meloxicam) 400 mg12 mg by injection.
62785457|NCT02504580|EXPERIMENTAL|Part B, Cohort C|HTX-011B (bupivacaine/meloxicam), 200 mg/6 mg by injection.
62785458|NCT02504580|EXPERIMENTAL|Part B, Cohort D|HTX-011B (bupivacaine/meloxicam), 400 mg/12 mg by injection.
62201874|NCT03787342|EXPERIMENTAL|"CALF Coronally Advanced Lingual Flap"|A full-thickness crestal incision will be performed in the keratinized tissue from the distal surface of the more distal tooth to the retromolar pad. The flap design will be continued intrasulcularly on both vestibular and lingual sides of the mesial portion of the flap, buccally, it will be finished with a vertical releasing incision. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. Then, using a blunt instrument it will be localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. The blunt instrument will be inserted below this connective band, and, with gentle traction in the coronal direction, this muscular insertion will be detached from the lingual flap.
62201875|NCT03787342|ACTIVE_COMPARATOR|"PRI Periosteal Releasing Incision"|A full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured as a whole unit.
62785459|NCT02504580|PLACEBO_COMPARATOR|Part B, Cohort E|Saline placebo by injection.
61978339|NCT03282188|EXPERIMENTAL|GROUP B (Reovirus plus GM-CSF)|Group B patients will receive an initial low 'immunisation' dose of intravenous reovirus (1x108 TCID50), to ensure that neutralising antibody (NAB) levels have risen by the time a full cycle of reovirus plus GM-CSF is given. Group B patients will be given a subcutaneous injection of GM-CSF (50mcg/day) for 3 days, followed by only 1 cycle of treatment which will comprise of reovirus at 1x1010 TCID50 as a 1-hour IV infusion on 2 consecutive days
62013496|NCT04175262||Patients with mRCC|Patients diagnosed with metastatic RCC receiving first line (1L) combination of IOs therapies followed by Sunitinib as a second line (2L) treatment
62013497|NCT05784428|ACTIVE_COMPARATOR|Multiple fraction SABR (Arm 1)|Participants randomized to this arm will receive multiple fraction SABR
62013498|NCT05784428|EXPERIMENTAL|Single fraction SABR (Arm 2)|Participants randomized to this arm will receive single fraction SABR
62013499|NCT05784428|ACTIVE_COMPARATOR|Patient-reported outcome (PRO) collection : QoL reporting alone (Arm A)|Participants will complete the EuroQoL-5Dimensions-5levels (EQ-5D-5L) and Functional Assessment of Cancer Therapy-General (FACT-G) prior to each scheduled follow-up (FU).
62013500|NCT05784428|EXPERIMENTAL|QoL reporting and healthcare provider (HCP) intervention guided by symptom screen (Arm B)|"* Patients complete EQ-5D-5L and FACT-G prior to each scheduled FU~* Patient complete online adaptive symptom screen with HCP intervention, prior to each scheduled appointment"
62013501|NCT05181605|NO_INTERVENTION|No Intervention: No intervention - standard of care|A group of patients with pancreatic carcinoma plus risk factors will be treated per standard of care on site (surgical resection and adjuvant therapy)
62013502|NCT05181605|EXPERIMENTAL|Experimental: Neoadyuvant therapy plus standard of care|A group of patients with pancreatic carcinoma plus risk factors will be treated with neoadjuvant therapy before surgical resection and adjuvant therapy
62013503|NCT02192684|ACTIVE_COMPARATOR|pioglitazone|pioglitazone 45 mg, oral, daily
61978340|NCT05585151|EXPERIMENTAL|Evolocumab treatment group|Evolocumab treatment, 1ml：140mg, every 2 weeks, for 26 weeks
61978341|NCT05585151|ACTIVE_COMPARATOR|Intensive statin treatment group|Atorvastatin 40mg/day or rosuvastatin 20mg/day, for 26 weeks
62201876|NCT04524377|EXPERIMENTAL|DBS for Parkinsons Disease|
62013504|NCT02192684|PLACEBO_COMPARATOR|placebo|Placebo, one pill daily
62785460|NCT02504580|EXPERIMENTAL|Part C, Cohort A|HTX-002, 200 mg by injection or instillation.
62201877|NCT03293524|EXPERIMENTAL|Treatment Arm 1|Subjects will be randomized to treatment arm 1 or treatment arm 2 in a 1:1 allocation. Subjects in treatment arm 1 will receive intravitreal GS010 in both eyes.
62785461|NCT02504580|EXPERIMENTAL|Part B, Cohort F|HTX-002, 400 mg by injection or instillation.
62785462|NCT02504580|EXPERIMENTAL|Part C, Cohort B|HTX-011B (bupivacaine/meloxicam), 200 mg/6 mg by instillation.
62785463|NCT02504580|EXPERIMENTAL|Part B, Cohort G|HTX-011B (bupivacaine/meloxicam), 400 mg/12 mg by instillation.
62785464|NCT02504580|PLACEBO_COMPARATOR|Part C, Cohort C|Saline placebo by instillation.
62785465|NCT02504580|ACTIVE_COMPARATOR|Part C, Cohort D|Bupivacaine HCI (Marcaine), 75 mg by injection.
62402432|NCT05007938|EXPERIMENTAL|Icotinib + Befotertinib|"* Icotinib（125 mg orally, three times daily）~* Befotertinib（25 mg orally, three times daily）"
62785466|NCT02504580|EXPERIMENTAL|Part D, Cohort A|HTX-011B (bupivacaine/meloxicam), 400 mg/13 mg via a combination of injection and instillation.
62785467|NCT02504580|EXPERIMENTAL|Part E, Cohort A|HTX-009, 12 mg by injection and instillation (combination).
62785468|NCT02504580|EXPERIMENTAL|Part F, Cohort A|HTX-011B (bupivacaine/meloxicam), 300 mg/9 mg by instillation.
62785469|NCT02504580|EXPERIMENTAL|Part F, Cohort B|Bupivacaine HCI (Marcaine), 75 mg by injection.
62785470|NCT02504580|PLACEBO_COMPARATOR|Part F, Cohort C|Saline placebo by injection.
61978342|NCT00934154|EXPERIMENTAL|Thalidomide|MPT
62201878|NCT03293524|PLACEBO_COMPARATOR|Treatment Arm 2|Subjects will be randomized to treatment arm 1 or treatment arm 2 in a 1:1 allocation. Subjects in treatment arm 2 will receive GS010 in one eye and placebo intravitreal injection in the other eye.
62402433|NCT00806806|PLACEBO_COMPARATOR|Placebo|
62402434|NCT00806806|EXPERIMENTAL|SKY0402|
62402435|NCT03220880||Intranasal dexmedetomidine|Intranasal dexmedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
62402436|NCT02049008|EXPERIMENTAL|Photodynamic Therapy|
62402437|NCT02049008|SHAM_COMPARATOR|Sham Photodynamic Therapy|
62402438|NCT02071823|EXPERIMENTAL|Group A Fed/Fasted|"A single 50 mg dose of BIA 9-1067 (2 x 25 mg capsules) was to be administered on:~Period 1: Fed Washout Period (7days) Period 2: Fasted"
62402439|NCT02071823|EXPERIMENTAL|Group B Fasted/Fed|"A single 50 mg dose of BIA 9-1067 (2 x 25 mg capsules) was to be administered on:~Period 1: Fasted Washout Period (7days) Period 2: Fed"
62402440|NCT03271580||Diabetic patients infected ulcers|"Diabetic patients with HbA1c\<9 with who have wound 4weeks or longer with infection with following interventions:~1. Finger prick test for HbA1c measurement~2. Punch biopsy~3. VAC sponge collection~4. Ankle brachial index"
62402441|NCT03271580||Diabetic patients non infected Ulcers|"Diabetic patients with HbA1c\<9 who have wound 4 weeks or longer without infection with following interventions:~1. Finger prick test for HbA1c measurement~2. Punch biopsy~3. VAC sponge collection~4. Ankle brachial index"
62402442|NCT05620966||Patients with transient neurological symptoms and CT-negative for stroke|Patients may have transient neurological symptoms at any time point
62579063|NCT01998932||Chronic Venous Ulcer|Patients with a chronic venous ulcer defined as a wound of greater than four weeks in duration between the foot and the ankle with an Ankle Brachial Pressure Index greater than 0.85 and a colour venous duplex evidence of chronic venous insufficiency showing either reflux or obstruction.
61978343|NCT00934154|ACTIVE_COMPARATOR|Control|MP
62402443|NCT05620966||Patients with known stroke confirmed either on imaging or by stroke physician|
62402444|NCT05620966||Patients with no prior history of stroke|
62402445|NCT03058549|EXPERIMENTAL|Intervention: Family Expectations|Family Expectations includes 36 hours of relationship education and parenting content, coaching sessions for couples, and group case management/referral information about local resources. Each couple will also complete an initial case management assessment, followed by referrals to any needed services, such as employment, substance abuse, mental health, housing, etc. Based on need, couples will have the option of additional case management/coaching services during their involvement in Family Expectations.
62402446|NCT03058549|NO_INTERVENTION|Control Group|The control group will not receive the intervention though they are able to seek and obtain any services they wish in the community (Treatment as Usual).
62013505|NCT04861623|ACTIVE_COMPARATOR|Orange Juice then Placebo juice (Fanta)|Participants will be provided orange juice for 84 days in this arm. After 28 days wash-out period, participants will receive Fanta for 84 days.
62013506|NCT04861623|ACTIVE_COMPARATOR|Placebo (Fanta) then Orange juice|Participants will be provided Fanta for 84 days in this arm. After 28 days wash-out period, participants will receive Orange juice for 84 days.
62201879|NCT00974194|EXPERIMENTAL|SinglePort CCK|CCK using Triport
62402447|NCT05868031|EXPERIMENTAL|Art work|The artwork group was tasked with preparing anatomical models by hand. This hands-on approach was designed to engage the students in a more active and creative manner, allowing them to develop a deeper understanding of the subject matter. By visualizing and creating the anatomical structures themselves, the students were able to retain the information better and apply it in a practical context.
62402448|NCT05868031|EXPERIMENTAL|Atlas groups|The atlas group was provided with a selection of anatomical pictures from atlases and encouraged to use them as a resource to aid their learning throughout the semester. This approach focused on visual learning and aimed to provide the students with a comprehensive and detailed understanding of the anatomical structures and how they interact with one another.
62402449|NCT01405040||EV1000 Observational Group|Patient must have an indwelling femoral arterial catheter and central venous catheter considered necessary for routine clinical monitoring; Patient, or legal guardian, will give consent prior to study enrollment and data capture; Patient must be at least 18 years old; Patient height and weight are available prior to study.
62402450|NCT04964076||COPD patients in the plateau|We consecutively enrolled COPD patients visiting the outpatient of Respiratory Medicine at Tibet Autonomous Region People's Hospital from January 2018 to December 2021.
62402451|NCT04964076||COPD patients in the plain|We consecutively enrolled COPD patients visiting the outpatient of Respiratory Medicine at Peking University Third Hospital from January 2018 to December 2021.
62402452|NCT03341559||With Existing Diabetic Ulcers|Current DFU
62402453|NCT03341559||Diabetic Ulcers in remission|DFU in remission
62402454|NCT03690102|EXPERIMENTAL|No BLS course. With T-CPR.|"The participant is presented for a cardiac arrest scenario before attending the ERC standardized BLS course.~During the scenario test, the participant will receive T-CPR."
62579064|NCT05422378|EXPERIMENTAL|STP705, 120ug/mL, 0.5 cc|Volume of Injection 0.5cc
62579065|NCT05422378|EXPERIMENTAL|STP705, 120ug/mL, 1.0 cc|Volume of Injection 1.0cc
62579066|NCT05422378|EXPERIMENTAL|STP705, 240 ug/mL, 0.5 cc|Volume of Injection 0.5cc
62579067|NCT05422378|EXPERIMENTAL|STP705, 240ug/mL, 1.0 cc|Volume of Injection 1.0cc
62579068|NCT05422378|EXPERIMENTAL|STP705, 320ug/mL, 0.5 cc|Volume of Injection 0.5cc
61978344|NCT03761147|EXPERIMENTAL|Paula Method|
61978345|NCT03761147|NO_INTERVENTION|Standard of Care|
61978346|NCT01584687|EXPERIMENTAL|Omalizumab|All patients will receive omalizumab.
62013507|NCT01243944|EXPERIMENTAL|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg once a day (QD) to 25 mg BID based on safety and efficacy
62013508|NCT01243944|OTHER|Best Available Therapy|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
62201880|NCT00974194|ACTIVE_COMPARATOR|LS CCK|CCK using three or four trocars
61978418|NCT02069366|PLACEBO_COMPARATOR|Placebo|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to fMRI scanning and task performance in 40 patients with PTSD, 40 trauma-exposed controls without PTSD (TEC), and 40 non-exposed healthy controls (HC).~Within each of the three groups half of the participants will receive dronabinol and the other half will received placebo to create the following 6 groups:~1. PTSD-dronabinol (20)~2. PTSD-placebo (20)~3. TEC-dronabinol (20)~4. TEC-placebo (20)~5. HC-dronabinol (20)~6. HC-placebo (20)"
62013509|NCT01679899|EXPERIMENTAL|Vildagliptin|Vildagliptin 50 mg bid for 12 months
62013510|NCT01679899|ACTIVE_COMPARATOR|Gliclazide MR|Gliclazide MR 60 or 120mg once a day for 12 months
62201881|NCT05917652||RedCap surverys|The study team will use REDCap to send an IRB approved secure electronic survey
62785471|NCT02421289|EXPERIMENTAL|CYP2B6 guided group|Patients were assigned to perform CYP2B6 study before ART initiation. If CYP2B6 \*6/\*6 was found in CYP2B6 \*6/\*6, the patients will be initiated a low dose of 400 mg of efavirenz (2 tablets of 200 mg) with tenofovir 300 mg and lamivudine 300 mg.
62785472|NCT02421289|NO_INTERVENTION|control group|Patients were promptly ART initiation regardless CYP2B6 results. Treatments were efvirenz 600 mg, tenofovir 300 mg and lamivudine 300 mg.
62785473|NCT05602701||Patients awaiting TKA|Patients awaiting unilateral total knee arthroplasty due to end-stage knee osteoarthritis.
62785474|NCT02506023|ACTIVE_COMPARATOR|Hemophilia A carriers with mild mutation|Hemophilia A carriers with a mild type mutation will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
62785475|NCT02506023|ACTIVE_COMPARATOR|Hemophilia A Carriers with severe mutation|Hemophilia A carriers with a severe type mutation will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
62785476|NCT02506023|ACTIVE_COMPARATOR|Control|Subjects with a mild qualitative platelet dysfunction will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
62785477|NCT03765892||Adult Case Group|Adults with type 1 narcolepsy according to the ICSD3
62785478|NCT03765892||Adult Control Group|Parents, cousins and / or friends of included narcoleptic adult patients, at least 18 years old and not suffering from narcolepsy.
62785479|NCT03765892||Children Case Group|Children with type 1 narcolepsy according to the OCSD3
62785480|NCT03765892||Children Control Group|Close friends and cousins of included narcoleptic children, minor and not suffering from narcolepsy.
62785481|NCT04317989|EXPERIMENTAL|Practice Facilitation|All enrolled practices will receive practice facilitation for the duration of the intervention period.
62785482|NCT04474015|ACTIVE_COMPARATOR|Part A, Group 1|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 1 will receive forearm stimulation at 0.75 Hz with an oscillating direct current (DC) waveform while awake.
62785483|NCT04474015|ACTIVE_COMPARATOR|Part A, Group 2|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 2 will receive forearm stimulation at 0.75 Hz with a modified alternating current (AC) waveform while awake.
62785484|NCT04474015|ACTIVE_COMPARATOR|Part A, Group 3|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 3 will receive forearm stimulation at 3.0 Hz with an alternating current (AC) sinusoidal waveform while awake.
62201882|NCT05917652||Interviews|The study team plans to do about 18-23 one-on-one interviews with clinicians (burn care nurses, physicians, advanced practice providers, therapists) or will progress until data saturation is reached.
62785485|NCT04474015|ACTIVE_COMPARATOR|Part B, Group 4|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). roup 4 will receive scalp stimulation at 0.75 Hz with an oscillating direct current (DC) waveform during sleep.
62579069|NCT05422378|EXPERIMENTAL|STP705, 320ug/mL, 1.0 cc|Volume of Injection 1.0cc
62579070|NCT05422378|PLACEBO_COMPARATOR|Vehicle|1.0cc placebo
62579071|NCT06250920|EXPERIMENTAL|Virtual reality-based visual training group|
62579072|NCT06250920|NO_INTERVENTION|Single-Vision Spectacle Group|
62201883|NCT04542967|NO_INTERVENTION|Control group|They will receive the standard care for critically ill inpatients.
62201884|NCT04542967|EXPERIMENTAL|Convalescent plasma group.|They will receive standard care for patients with severe COVID-19 disease and convalescent plasma disease.
62201885|NCT03080168||Actigraph|"All participants will wear an Actigraph (monitoring device) for the duration of their inpatient stay.~NOTE: In clarification, for both this section and Section 4, this devices is an FDA-regulated monitoring device, but NOT an Intervention in this study."
62201886|NCT01718808|ACTIVE_COMPARATOR|Arm A: Cetuximab|Cetuximab 500 mg/m2 every 2 weeks
62013511|NCT00801684|PLACEBO_COMPARATOR|Placebo|Represents Dose A in the Dosing Sequence assignments.
62201887|NCT01718808|ACTIVE_COMPARATOR|Arm B: Cetuximab and Capecitabine|"Cetuximab 500 mg/m2 every 2 weeks plus Capecitabine 1000 mg/m2 (\*) bid d1-14 every 3 weeks~\* 750 mg/m2 if creatinine-clearance 30-50 ml/min"
62579073|NCT03951883|ACTIVE_COMPARATOR|Typical Diet (TD)|Participants will be instructed to continue habitual dietary intake.
62785486|NCT04474015|ACTIVE_COMPARATOR|Part B, Group 5|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). Group 5 will receive scalp stimulation at 0.75 Hz with a modified alternating current (AC) waveform during sleep.
62013512|NCT00801684|EXPERIMENTAL|TrIP-2D (100mcg)|Represents Dose B
62013513|NCT00801684|EXPERIMENTAL|TrIP-2SS (100mcg)|Represents Dose C
62013514|NCT00801684|EXPERIMENTAL|TrIP-2D (400mcg)|Represents Dose D
62013515|NCT00801684|EXPERIMENTAL|TrIP-2SS (100mcg) + Foradil (12mcg)|Represents Dose E. All subjects received Dose E as their final (5th) dose, after completing their initial 4 single doses according to their sequence assignment.
62201888|NCT00640770|ACTIVE_COMPARATOR|balloon angioplasty|balloon angioplasty
62201889|NCT00640770|EXPERIMENTAL|Drug eluting stent|CYPHER SELECT+ Coronary or Infrapopliteal Stent
62201890|NCT05125926|EXPERIMENTAL|low-dose LYB001 in participants aged 18-59 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
62579074|NCT03951883|EXPERIMENTAL|Increased Egg Consumption (IE)|Participants will be prescribed an additional 2 eggs per day to their diet.
62579075|NCT02531971|ACTIVE_COMPARATOR|Fentanyl citrate (36 h), Duragesic (192 h), Mylan (192 h)|Volunteers received a single-dose of 100 µg fentanyl citrate infusion (Study Session I) and blood samples obtained 0-36 h, washout at least one week, then wore a Duragesic® fentanyl TDDS (25 µg/h) for 72 h (Study Session II) and blood samples obtained 0-192 h, washout at least one week, then wore a Mylan fentanyl TDDS (25 µg/h) for 72 h (Study Session III) and blood samples obtained 0-192 h
62579076|NCT02531971|ACTIVE_COMPARATOR|Fentanyl citrate (36 h), Mylan (192 h), Duragesic (192 h)|Volunteers received a single-dose of 100 µg fentanyl citrate infusion (Study Session I) and blood samples obtained 0-36 h, washout at least one week, then wore a Mylan fentanyl TDDS (25 µg/h) for 72 h (Study Session II) and blood samples obtained 0-192 h, washout at least one week, then wore a Duragesic® fentanyl TDDS (25 µg/h) for 72 h (Study Session III) and blood samples obtained for 0-192 h
62013516|NCT06346977||LM group;|Leptomeningeal Metastasis Group
62013517|NCT06346977||NLM group|Non-Leptomeningeal Metastasis Group
62201891|NCT05125926|PLACEBO_COMPARATOR|Placebo comparator Ⅰ in participants aged 18-59 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
62579077|NCT03600402|EXPERIMENTAL|Experimental Group|
62579078|NCT03600402|OTHER|Control Group|
62579079|NCT06035770|EXPERIMENTAL|Mental Health First Aid training program|The intervention is a 12-hour face-to-face training course given in small groups. It was delivered as four 3-hour sessions over 4 consecutive weeks.
62013518|NCT00896220||ICU Survivors and Their Family Caregiver|ICU Survivors who required one week or more of mechanical ventilation during their critical illness and their primary family caregiver
62201892|NCT05125926|EXPERIMENTAL|high-dose LYB001 in participants aged 18-59 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
62201893|NCT05125926|PLACEBO_COMPARATOR|Placebo comparator Ⅱ in participants aged 18-59 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
62579080|NCT06035770|NO_INTERVENTION|control group|The control group received no intervention during the intervention period. However, they will participate in surveys at three time points (before the intervention, 3 months after the intervention and one year after the intervention). Once their final assessment is completed, controls will be offered the opportunity to take the MHFA training course, if they wish.
62579081|NCT03255447|EXPERIMENTAL|Immunoadsorption therapy|Peptide GAM immunoadsorption therapy
62785487|NCT04474015|ACTIVE_COMPARATOR|Part B, Group 6|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). Group 6 will receive scalp stimulation at 3.0 Hz with an alternating current (AC) sinusoidal waveform during sleep.
62402455|NCT03690102|EXPERIMENTAL|With BLS course. No T-CPR.|"The participant is presented for a cardiac arrest scenario after completion of the ERC standardized BLS course.~During the scenario test, the participant will not receive T-CPR."
62785488|NCT04474015|ACTIVE_COMPARATOR|Part C, Group 7|Pulsed Stimulation: Group 7 (Part C)will receive a series of brief stimulations of up to 500 millisecond duration and of up to 5 milliamperes of current, using either metal electrodes or sponge electrodes as stimulating electrodes.
62785489|NCT05766176||Health worker|A health worker who received a second dose of booster COVID19 vaccine
62402456|NCT03690102|EXPERIMENTAL|With BLS course. With T-CPR.|"The participant is presented for a cardiac arrest scenario after completion of the ERC standardized BLS course.~During the scenario test, the participant will receive T-CPR."
62402457|NCT03135873|ACTIVE_COMPARATOR|Mastiha|This arm of patients will receive natural Mastiha supplements at a daily dosage of 2.1 g for a 6 month period.
62402458|NCT03135873|PLACEBO_COMPARATOR|Placebo|This arm of patients will receive placebo for a 6 month period.
62402459|NCT06042556|EXPERIMENTAL|Guide|Randomized to use of our IUD self-removal guide
62402460|NCT06042556|NO_INTERVENTION|No guide|Randomized to use of no additional resource
62402461|NCT00190385|ACTIVE_COMPARATOR|A|
62402462|NCT01481064|ACTIVE_COMPARATOR|Multifaceted approach|After baseline measurement a multifaceted approach will start for 1 year, including audit and feedback, an educational outreach visit, and patient-mediated interventions.
62402463|NCT01481064|NO_INTERVENTION|Usual care|After baseline measurement no intervention will occur in these hospitals.
62402464|NCT03374709|EXPERIMENTAL|Treatment Group|This arm includes subjects who have been prescribed Oxtellar XR 150Mg Extended Release Tablets.
62402465|NCT05696665|ACTIVE_COMPARATOR|Group A|conventional therapy only
62402466|NCT05696665|EXPERIMENTAL|Group B|conventional therapy +500 mg chamomile 15 mg saffron twice daily
62402467|NCT05696665|EXPERIMENTAL|Group C|conventional therapy +500mgApigenin +30mg Crocin once daily
62402468|NCT00483119|ACTIVE_COMPARATOR|Group A|IVIg alone (intravenous immunoglobulin)
62402469|NCT00483119|EXPERIMENTAL|Group B|IVIg with cyclophosphamide
62402470|NCT02147132|EXPERIMENTAL|Order 1|Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
62402471|NCT02147132|EXPERIMENTAL|Order 2|Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
62402472|NCT02147132|EXPERIMENTAL|Order 3|Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
62402473|NCT02147132|EXPERIMENTAL|Order 4|Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
62785490|NCT05636761||group EliteHRV|the group (Elite) that started the assessment with the EliteHRV mobile application
62785491|NCT05636761||group Polar|the (Polar) group that started the evaluation with the Polar V800 watch
62785492|NCT05704660|EXPERIMENTAL|Adjusted and modified Cognitive-Biased Modification Task|The intervention is based on a Go/No-Go task.
62785493|NCT05704660|PLACEBO_COMPARATOR|Normal Cognitve-Biased modification Task|The Sham-intervention is based on a Go/No-Go task.
62402474|NCT02405182||Patients|ALS patients (as well as patients with other motor neuron diseases such PLS and PMA) will be recruited from ALS clinics under the direction of ALS neurologists who are participating in this study. ALS patients should meet research criteria for possible, probable, probable laboratory-supported, or definite ALS. Patients with a history of CNS disease (e.g. stroke, head injury) or significant psychiatric disease will be ineligible. Patients must be able to undergo a brain MRI for approximately an hour.
62402475|NCT02405182||Controls|Healthy controls who are age and gender matched to patients will be recruited. Controls with a history of CNS disease (e.g. stroke, head injury) or significant psychiatric disease will be ineligible. Controls must be able to undergo a brain MRI for approximately an hour.
62402476|NCT01415999||patient|adult survivors of childhood malignancies
62402477|NCT01415999||control|healthy age-matched individuals
62402478|NCT01407965|EXPERIMENTAL|Ertapenem|"Free tissue kinetics of ertapenem in fatty tissue and intraperitoneal fluid in mg/L~Free and bound plasma concentration of ertapenem or meropenem in mg/L"
62402479|NCT01407965|EXPERIMENTAL|Meropenem|Free tissue kinetics of meropenem in fatty tissue and intraperitoneal fluid in mg/L up to 24 hours after administration. Free and bound plasma concentration of meropenem in mg/L.
62013519|NCT05976334|EXPERIMENTAL|[14C] Subasumstat 90 mg|Participants will receive a single dose of \[14C\] Subasumstat 90 mg, IV infusion on Day 1 in Part A of the study. Following Part A, participants will have an option to receive subasumstat 90 mg, IV infusion on Days 1, 4, 8, and 11 of a 21 day cycle for 3 cycles followed by weekly maintenance dosing in Part B of the study up to maximum treatment duration of 1 year.
62201894|NCT05125926|EXPERIMENTAL|low-dose LYB001 in participants aged over 60 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
62201895|NCT05125926|PLACEBO_COMPARATOR|Placebo comparator Ⅲ in participants aged over 60 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
62201896|NCT05125926|EXPERIMENTAL|high-dose LYB001 in participants aged over 60 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
62201897|NCT05125926|PLACEBO_COMPARATOR|Placebo comparator Ⅳ in participants aged over 60 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
62201898|NCT03691077|EXPERIMENTAL|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300-mg IV infusions (600 mg total) in 250 mL 0.9% sodium chloride each separated by 14 days (i.e., Days 1 and 15), followed by one 600-mg IV infusion in 500 mL 0.9% sodium chloride every subsequent doses (i.e., every 24 weeks) for 72 weeks.
62201899|NCT00144495|EXPERIMENTAL|1|patient whose ΔHb is less than 1.0g/dL on the day of 7th administration
62201900|NCT00144495|EXPERIMENTAL|2|patient whose ΔHb is 1.0g/dL or above on the day of 7th administration
62201901|NCT00604708|EXPERIMENTAL|IC51|6 mcg (microgram) i.m. (intramuscular) on Day0, 14 and 28
62201902|NCT00604708|ACTIVE_COMPARATOR|JE-VAX|given s.c. on Day 0, 7 and 28
62201903|NCT02701881|EXPERIMENTAL|Long stenting group|
62201904|NCT02701881|ACTIVE_COMPARATOR|Short stenting group|
62201905|NCT00777738|EXPERIMENTAL|bortezomib|bortezomib
62201906|NCT03655782|EXPERIMENTAL|PATH neurotraining|Subject looks at computer screen to determine whether dim gray stripes in fish-shaped window move left or right relative to stationary background stripes. The subject reports which way center stripes move by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes contrast of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern more similar to that in fish, by increasing pattern's complexity level, and by increasing number of directions of movement from one to two directions of motion. Intervention will be trained for one training cycle, 15 minutes, 3 times each week for 16 weeks. Fifteen minutes of working memory practice, recalling the correct sequence of digits, each presented for 500 msec, from 5 digits up to 10 digits will be completed for 15 minutes following PATH training.
62201907|NCT03655782|SHAM_COMPARATOR|Orientation Discrimination training|The sham intervention will be Orientation Discrimination training that is identical to PATH training except instead of low contrast sinewave gratings moving left or right, 100% contrast stationary test and background sinewave gratings are used, both red, green, and black and white gratings, see patterns in Fig. 4 below. These patterns are randomly oriented left or right, at decreasing tilt angles as the test grating's orientation is identified correctly. These patterns only activate parvocells in ventral pathways (Ungerleider \& Mishkin, 1982; Kaplan \& Shapley, 1986) instead of activating dorsal pathways, the key component of PATH neurotraining. Therefore, this task does not speed up the brain's visual timing, which is a function of the dorsal stream. For the Orientation Discrimination task, the subject pushes the left arrow key when the test pattern is tilted left and the right arrow key when pattern is tilted right. Otherwise the two training tasks use the same paradigm.
62201908|NCT03655782|EXPERIMENTAL|N-Back Working Memory Task|Participants are required to compare each item on a computer screen to the item that they saw n-items back in the sequence. The participant plays a simple game where they control the movement of an astronaut that needs to collect correct gems, avoid incorrect gems, and also obstacles, to succeed at the game. If the participants performs well then they can be advanced to the 2-back, 3-back, 4-back, etc where they make similar matches but to earlier items in the sequence. This gamified task consists of a color n-back with 6 colors (a new color every 3 seconds, requiring subjects respond to targets by tapping the screen and navigating the astronaut to the targets, and avoiding the distractors) with 30% targets, and where the n-level will change every 2 minutes depending on performance (increase if performance is \>85% and decrease if \<75%). Sessions consist of 10 \~2 minute blocks, each with n-level as determined by the adaptive procedure and with user paced breaks between blocks.
62201909|NCT02536820|OTHER|Conventional treatment + PNIT|PNIT: Psychoneuroimmuno therapy Conventional treatment: Usual treatment that each diabetic patient recieved
62402480|NCT00812968|EXPERIMENTAL|Lenalidomide|Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
62785494|NCT04629690|NO_INTERVENTION|Control Arm|The control group will obtain usual medical care in the Emergency Department and Acute Medical Assessment Unit
62013520|NCT04694833|EXPERIMENTAL|Stroke patients|Stroke patients with hemiparesis and/or cognitive impairments (such as apraxia, aphasia and hemineglect)
62201910|NCT02536820|ACTIVE_COMPARATOR|Conventional treatment|Conventional treatment: Usual treatment that each diabetic patient recieved
62201911|NCT05410639|EXPERIMENTAL|Study group|Parents of premature infants in the experimental group received online education consist of information to support infants motor,social-communication development.and to manage the parents stress.
62013521|NCT04694833|EXPERIMENTAL|Healthy subjects|Subjects who do not suffer from any pathology that could affect upper-limb motor function or cognition
62013522|NCT01167946|EXPERIMENTAL|Group A|will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks
62201912|NCT05410639|PLACEBO_COMPARATOR|Control group|The parents of premature babies in the control group did not receive any education programs
62013523|NCT01167946|ACTIVE_COMPARATOR|Group B|will receive 2 consecutive daily pulses every 3 weeks for 24 weeks
62201913|NCT04557358||Rheumatic diseases outpatients|"All the rheumatic diseases outpatients from the National Institute of Medical Sciences and Nutrition that will assist their usual medical care posterior of stopped it during the COVID-19 pandemic.~In order to explore how the patient´s disease activity, patient´s quality of life, and psychopathology will change with the reintegration at medical care, randomization 200 rheumatic diseases outpatients that will respond RAPID-3 (disease activity/disease severity), WHOQOL-BREF instrument (quality of life), DASS-21 instrument (depression and anxiety), IER-R (posttraumatic stress)"
62201914|NCT02793739|EXPERIMENTAL|20 subjects|20 subjects will be enrolled to take part in this study and followed for a period of 12 months. Subjects will receive hyaluronic acid filler injection in the dorsal fingers (2-4 syringes) at the initial visit for volume restoration. If warranted, subjects will receive touch-up of hyaluronic acid at day 14 (1-2 syringes). The investigators expect volume restoration to last 9-12 months.
62579082|NCT02326935|EXPERIMENTAL|Adipose derived mesenchymal cells|"Intervention: Autologous adipose derived mesenechymal stem cells, 150 million cells deployed via two (2) treatments via intravenous injection~Other Names:~ADSC, mesenchymal cells, stromal cells"
62579083|NCT00911469|EXPERIMENTAL|1|
62785495|NCT04629690|EXPERIMENTAL|SOLAR arm|The SOLAR arm will obtain a comprehensive geriatric assessment which will be provided by a geriatric doctor, physiotherapist, occupational therapist, social worker, pharmacist and specialist nurse.
62785496|NCT00680459|EXPERIMENTAL|1|70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
62785497|NCT00680459|PLACEBO_COMPARATOR|2|heparin flush 10 units/ml lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. heparin flush solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
62013524|NCT01167946|ACTIVE_COMPARATOR|Group C|will receive 3 consecutive daily pulses every 3 weeks for 24 weeks.
62201915|NCT01277887|ACTIVE_COMPARATOR|Cognitive-Behavioral Counseling|The intervention consists of 8 sessions provided over 10 weeks. Counseling commences 4 weeks before quitting smoking. Participants will also receive the nicotine patch for 6 weeks starting on the day of quit date.
62579084|NCT00911469|PLACEBO_COMPARATOR|2|
62579085|NCT02527434|EXPERIMENTAL|treme mono to be sequenced to MEDI4736 mono or combination|tremelimumab monotherapy, with the option for eligible patients to be sequenced to MEDI4736 monotherapy or MEDI4736 + tremelimumab combination therapy after progressive disease (PD)
62785498|NCT03152591|EXPERIMENTAL|LIK066|LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test
62785499|NCT03152591|PLACEBO_COMPARATOR|Placebo|Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test
62013525|NCT04041505|ACTIVE_COMPARATOR|Breastfeeding|Infant consumes mother's milk directly from the breast.
62013526|NCT04041505|EXPERIMENTAL|Bottle-feeding|Infant consumes mother's expressed milk from a bottle.
62579086|NCT02199288||Cohort|
62013527|NCT05694559|EXPERIMENTAL|Genetic Testing and Counseling|Participants will be given a saliva collection kit to collect a saliva sample for hereditary cancer and genetic testing.
62201916|NCT01277887|PLACEBO_COMPARATOR|Smoking Cessation Counseling|The intervention consists of 8 sessions provided over 10 weeks. Counseling commences 4 weeks before quitting smoking. Participants will also receive the nicotine patch for 6 weeks starting on the day of quit date.
62579087|NCT03565159|ACTIVE_COMPARATOR|Prevenar 13|A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.
62579088|NCT03565159|PLACEBO_COMPARATOR|Sodium chloride 0.9%|A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.
62785500|NCT02412046|ACTIVE_COMPARATOR|Time of the first biopsy: H0|For the patients in arm H0, the first biopsy is done as soon as the patient is lying on the air mattress.
62785501|NCT02412046|ACTIVE_COMPARATOR|Time of the first biopsy: H1|For a patient in arm H1, it is done after 1 hour lying on the air mattress.
62785502|NCT02412046|ACTIVE_COMPARATOR|Time of the first biopsy: H2|For a patient in arm H2, it is done after 2 hour lying on the air mattress.
62785503|NCT02412046|ACTIVE_COMPARATOR|Time of the first biopsy: H3|For a patient in arm H3, it is done after 3 hour lying on the air mattress.
62785504|NCT01732016|OTHER|Normobaric hypoxia chamber|Study subjects will be put into a hypoxic state by exposing them to normobaric (sea-level atmospheric pressure) hypoxia (low oxygen) by administrating an air mix containing a reduced O2 concentration. This is achieved in a hypoxia chamber where O2 concentration is gradually reduced to simulate high altitude (around 4500 m).
62785505|NCT00656435|EXPERIMENTAL|A|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
62013528|NCT05694559|EXPERIMENTAL|Screening Form|"Participants will complete a screening form to assess your risk of hereditary breast and colorectal cancers. You will be asked to provide your:~* Name and contact information (including your address, phone number, and email)~* Demographic information (including your age, race, and ethnicity)~* Health insurance status~* Annual household income~* Personal and family history of cancer, including diagnosis and age at diagnosis"
62013529|NCT05222568||BCVmin=0|This study was a prospective observational study, and the patients was divided into two groups with BCVmin=0 or BCVmin \>0, according to the BCVmin which was naturally determined during anesthesia in each patient.
62013530|NCT05222568||BCVmin>0|The patients was divided into two groups with BCVmin=0 or BCVmin \>0, according to the BCVmin which was naturally determined during anesthesia in each patient.
62013531|NCT03859232|EXPERIMENTAL|Delta Dry® Pantaloon Group|
62013532|NCT03859232|ACTIVE_COMPARATOR|Cotton Padding Group|
62013533|NCT03264157|EXPERIMENTAL|BPL HRIG + RabAvert|20 IU/kg dose HRIG + active rabies vaccine
62013534|NCT03264157|ACTIVE_COMPARATOR|Comparator HyperRab + RabAvert|20 IU/kg dose HRIG + active rabies vaccine
62013535|NCT04590547|EXPERIMENTAL|GLS-1027 120 mg|One 120 mg pill of GLS-1027 + 2 Placebo pills given by mouth once daily
62579089|NCT06574412|EXPERIMENTAL|Neoadjuvant -surgery-adjuvant therapy group|Preoperative: Cardenilimab was administered at a dose of 10 mg/kg intravenously once daily, with one cycle every 21 days, for a total of 4 cycles. Lenvatinib was prescribed as follows: for patients weighing less than 60 kg, 8 mg was given orally once daily for 4 cycles; for those weighing more than 60 kg, 12 mg was administered orally once daily for a total of 4 cycles. Surgery: The patient underwent standard radical nephrectomy 30 to 40 days after completing the 4 cycles of lenvatinib treatment. Postoperative: Cardenilimab was continued at a dose of 10 mg/kg intravenously once daily, with one cycle every 21 days, for a total of 8 cycles. Lenvatinib dosing postoperatively was as follows: for patients weighing less than 60 kg, 8 mg was given orally once daily for a total of 8 cycles; for those weighing more than 60 kg, 12 mg was administered orally once daily for a total of 8 cycles.
62013536|NCT04590547|EXPERIMENTAL|GLS-1027 360 mg|Three 120 mg pills of GLS-1027 given by mouth once daily
62013537|NCT04590547|PLACEBO_COMPARATOR|Placebo|Three Placebo pills given by mouth once daily
62579090|NCT03469128|ACTIVE_COMPARATOR|Cognitive processing therapy|Cognitive Processing Therapy (CPT) in which participants completed 12 sessions of CPT
62579091|NCT03469128|ACTIVE_COMPARATOR|Sertraline|Patients with co-occurrence PTSD \& SUD disorders were treated by Sertraline.
62579092|NCT03469128|PLACEBO_COMPARATOR|Control group|Placebo Control group
62013538|NCT05487170|EXPERIMENTAL|RNK05047|Dose-escalation of RNK05047 IV infusion
62579093|NCT05688384|NO_INTERVENTION|Control arm (LA)|Patients in this arm will undergo SVP insertion in local anesthesia (LA)
62579094|NCT05688384|ACTIVE_COMPARATOR|Study arm (LA+PCS)|Patients in this arm will undergo SVP insertion in local anesthesia and PCS (LA+PCS)
62013539|NCT03798808|EXPERIMENTAL|Family Nutriathlon group|Web-based nutrition program (encouraging consumption of fruits, vegetables and dairy products through an online platform)
62013540|NCT03798808|NO_INTERVENTION|Control group|General nutrition guidelines (e.g. following Canada's Food Guide)
62013541|NCT00380640|EXPERIMENTAL|1|
62013542|NCT00380640|EXPERIMENTAL|2|
62013543|NCT02851576|EXPERIMENTAL|Infusion of ADV specific T cells|This one arm study consists in ADV-specific T cell infusion after HSCT from a (M)MUD or, for the first time, from a haploidentical donor for patients having undergone previous UCB transplantation, in the event of refractory ADV infection or disease. Specific anti-ADV immune reconstitution was observed in all patients, and viral load clearance in all but one.
62402481|NCT06167304|EXPERIMENTAL|Technology-implemented exercise therapy|Therapy plans performed at home overseen by a remote physical therapist via SimpleTherapy. Allocation to this group will require using smart devices or a computer/laptop to receive care. Remote visits with a PT typically last 45min long and home exercises suggested by the app are self-paced.
62013544|NCT06573749|EXPERIMENTAL|Bioactive whey protein concentrate supplement group|This group will consume a supplement called bioactive whey protein concentrate, a whey protein concentrate that contains milk fat globule membrane.
62013545|NCT06573749|PLACEBO_COMPARATOR|Placebo group|This group will consume an isocaloric, isonitrogenous pea based protein supplement that does not contain phospholipids or sphingomyelin.
62013546|NCT05868694||Group 1|Patients suspected of having obstructive apnea
62013547|NCT05384847|EXPERIMENTAL|Experimental Phase IA|In Phase IA two participants (1 and 2) will receive ascending dose levels of the study drug (5 µg T3 orally twice daily for the first 2 days and 10 µg T3 orally twice daily for the next 3 days).
62013548|NCT05384847|EXPERIMENTAL|Experimental Phase IB|In Phase IB, dose adjustments will be calculated while accounting for laboratory and safety data from the first two participants (Phase IA) for the remaining 3 participants within the treatment arm of Phase I. Participants 3 to 5 will receive 10 µg T3 orally twice daily on day 1 and 20 µg T3 twice daily from day 2 to 5.
62013549|NCT05384847|PLACEBO_COMPARATOR|Control Group-Phase IA and IB|The control group will have testing as the experimental group but will not be given any medications.
62013550|NCT05384847|EXPERIMENTAL|Experimental Phase II|Patients who were enrolled in the open-label control group of Phase I and who have completed the 3-month follow-up will be permitted to enroll in Phase II. This Phase will start treatment after completion of Phase I and approval from the Data and Safety Monitoring Board (DSMB) to proceed with a single cohort that will receive a stable dose of the study drug (20 µg T3 orally twice daily for 5 days).
62013551|NCT00890461||Defibrillator|The subject population will be obtained by approaching the Principal and Co- Investigators' patients who have been referred for ICD implantation or who already have an ICD. This population ranges in age from 18 years on, and includes both males and females. A maximum of 50 subjects will be enrolled in this study.
62013552|NCT01632059||septical patients|inclusion criteria are severe sepsis and septical shock and must be \> 18 y/o
62013553|NCT04177108|EXPERIMENTAL|Cohort 1 Arm A: Ipatasertib + Atezolizumab + Paclitaxel|TNBC participants with programmed death-ligand 1 (PD-L1) non-positive received a combination of paclitaxel, 80 milligrams per meter square (mg/m\^2), intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle and ipatasertib, 400 mg, orally (PO), once daily (QD), from Day 1 to Day 21 of each 28-day cycle and atezolizumab, 840 mg, IV infusion on Day 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent, whichever occurred first.
62201917|NCT03113318|EXPERIMENTAL|Lymph node dissection and pulmonary metastasectomy|Total mediastinal lymph node dissection and pulmonary metastasectomy from colorectal cancer
62402482|NCT06167304|ACTIVE_COMPARATOR|Traditional Physical Therapy|Participants will be prescribed an exercise plan by a physical therapist as normally would occur as part of standards of care outside the context of a research study. In-person assessments and at-home exercise suggestions will be decided by the physical therapist. Duration of PT appointments is typically 45 minutes long two times per week and are supplemented by PT recommended self-paced at-home exercises.
62402483|NCT02182076|ACTIVE_COMPARATOR|fasted administration of BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules in fasting state
62402484|NCT02182076|EXPERIMENTAL|fed administration of BIBF 1120|three 50 mg BIBF 1120 soft gelatine capsule immediately after a high fat, high caloric meal
62402485|NCT02002429|EXPERIMENTAL|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine
62402486|NCT02002429|ACTIVE_COMPARATOR|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine
62402487|NCT02002429|SHAM_COMPARATOR|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline
62579095|NCT02328469||unidentified aseptic meningitis|Patients with etiologically unidentified aseptic meningitis will be treated with symptomatic therapy and will be asked to complete a questionnaire.
62201918|NCT03113318|ACTIVE_COMPARATOR|Pulmonary metastasectomy only|Only pulmonary metastasectomy from colorectal cancer
62201919|NCT02876289||patients treated with Perampanel|
62201920|NCT05338125|EXPERIMENTAL|Intervention arm|Patients undergoing the extra intra-operative electrophysiological measurement
62201921|NCT00612872|EXPERIMENTAL|Assess [123-I]CLINDE and brain imaging|Subjects will be injected with up to 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) of 123-I CLINDE followed by serial SPECT imaging.
62402488|NCT01980186||Individuals with autism|Both individuals with autism and their siblings will be evaluated with (TUS)transcranial 2D ultrasound.
62402489|NCT01980186||Siblings of individuals with autism|Non-autistic siblings with no other obvious health issues will be screened
62402490|NCT06235086|EXPERIMENTAL|TG103, 7.5 mg|TG103 (7.5 mg) will be administered via subcutaneous injection once a week in subjects with type 2 diabetes.
62402491|NCT06235086|EXPERIMENTAL|TG103, 15 mg|TG103 (15 mg) will be administered via subcutaneous injection once a week in subjects with type 2 diabetes.
62579096|NCT02328469||tick-borne encephalitis|Patient with aseptic meningitis in whom serological diagnosis of tick-borne encephalitis will be established. Patients will be treated with symptomatic therapy and will be asked to complete a questionnaire.
62785506|NCT00656435|NO_INTERVENTION|B|Patients will not receive bevacizumab pretreatment
62785507|NCT06282913|EXPERIMENTAL|Mindfulness Meditation Group|During the first meeting, before the planned training, data will be collected face to face using the personal information form, Compassion Fatigue Brief Scale, Maslach Burnout Scale, Psychological Well-Being Scale. Physicians and nurses in the intervention group were given group counseling sessions by the researcher, in groups of 10-15 people, for 20 minutes once a week for 8 weeks. An online meditation practice will be provided for a long time. At the end of the mindfulness meditation application (in the 8th week) and four weeks after the end of the application (in the 12th week) for follow-up purposes, data will be collected through an online survey for physicians and nurses using Compassion Fatigue Brief Scale, Maslach Burnout Scale, Psychological Well-Being Scale.
62785508|NCT06282913|NO_INTERVENTION|Control Group|During the first meeting, data will be collected face to face using the personal information form, MY-KÖ, MTÖ and PİÖÖ. In the 8th and 12th weeks of the research, the data will be re-administered to the physicians and nurses in the control group via an online survey using Compassion Fatigue Brief Scale, Maslach Burnout Scale, Psychological Well-Being Scale. After the implementation process of the research is completed, mindfulness meditation application will be applied online once to the physicians and nurses in the control group.
62785509|NCT04740216|EXPERIMENTAL|exercise therapy plus jaw device|exercise therapy plus jaw device
62785510|NCT04740216|PLACEBO_COMPARATOR|exercise therapy|exercise therapy
62785511|NCT06366425|OTHER|Population with a chronic liver disease risk factor|Patient aged ≥ 40 years, with no known liver disease, consulting a general practitioner and having at least one risk factor for chronic liver disease: risky consumption of alcoholic beverages according to the AUDIT questionnaire, the presence of a metabolic syndrome, diabetes or a risk factor for viral hepatitis B/D or C.
62013554|NCT04177108|EXPERIMENTAL|Cohort 1 Arm B: Ipatasertib + Placebo + Paclitaxel|TNBC participants with PD-L1 non-positive received a combination of paclitaxel, 80 mg/m\^2, IV infusion on Days 1, 8, and 15 of each 28-day cycle and ipatasertib, 400 mg, PO, QD, from Day 1 to Day 21 of each 28-day cycle and atezolizumab-matching placebo, IV infusion on Day 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent, whichever occurred first.
62579097|NCT02328469||Lyme neuroborreliosis|Patients with acute aseptic meningitis in whom Lyme neuroborreliosis will be proven or suspected according to microbiological criteria. Patients will be treated with antibiotic therapy (ceftriaxone or doxycycline) and will be asked to complete a questionnaire.
62579098|NCT02328469||healthy controls|Patients will be asked to refer a spouse to serve as a control . If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control.
62579099|NCT02328469||identified aseptic meningitis|Patients with microbiologically identified cause of acute aseptic meningitis/meningoencephalitis will receive symptomatic therapy. If the identified causative agent will be Herpes Simplex Virus or Varicella Zoster Virus, patients will be treated with acyclovir and will be asked to complete a questionnaire.
62579100|NCT01750697|EXPERIMENTAL|Rituximab|
62579101|NCT01448343|EXPERIMENTAL|FMS|Patients who received blood transfusion using FMS
62579102|NCT04850430|EXPERIMENTAL|Gastric venous congestion following total pancreatectomy|The gastric venous outflow will be reconstructed after TP. The patients will be assessed concerning gastric venous congestion and gastric ischemia intraoperatively before and after venous outflow reconstruction through onsite evaluation by the surgeon, endoscopic examination, indocyanine green, gastric venous drainage flowmetry, and spectral imaging.
62785512|NCT01438450|NO_INTERVENTION|Supportive|Supportive therapy
62785513|NCT01438450|ACTIVE_COMPARATOR|Oral|Oral thalidomide and capecitabine
62785514|NCT00931775|PLACEBO_COMPARATOR|Citalopram + placebo|Citalopram 20 mg/day t.i.d
62013555|NCT04177108|EXPERIMENTAL|Cohort 1 Arm C: Placebo + Placebo + Paclitaxel|TNBC participants with PD-L1 non-positive received a combination of paclitaxel, 80 mg/m\^2, IV infusion on Days 1, 8, and 15 of each 28-day cycle and ipatasertib-matching placebo, PO, QD, from Day 1 to Day 21 of each 28-day cycle and atezolizumab-matching placebo, IV infusion on Day 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent, whichever occurred first.
62579103|NCT05472129||Cases|"Cases were defined, with respect to bowel, bladder or prolapse symptoms using the question: How much do your symptoms bother you? and the following choice of answers: Not applicable - I do not have symptoms, not at all, a little, quite a lot and very much."
62579104|NCT05472129||Control|"Controls were identified as women answering Not applicable - I do not have symptoms or not at all, otherwise patients were defined as cases."
62579105|NCT06147947||study group|All participants included will be in one study group.
62201922|NCT00594880|ACTIVE_COMPARATOR|Pegasys 180 mcg/week|ART replacement treatment with Pegylated Interferon-alpha 2a, 180 mcg/week sc
62013556|NCT04177108|EXPERIMENTAL|Cohort 2 Arm A: Ipatasertib + Atezolizumab + Paclitaxel|TNBC participants with PD-L1 positive received a combination of paclitaxel, 80 mg/m\^2, IV infusion on Days 1, 8, and 15 of each 28-day cycle and ipatasertib, 400 mg, PO, QD, from Day 1 to Day 21 of each 28-day cycle and atezolizumab, 840 mg, IV infusion on Day 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent, whichever occurred first.
62013557|NCT04177108|EXPERIMENTAL|Cohort 2 Arm B: Placebo+ Atezolizumab + Paclitaxel|TNBC participants with PD-L1 positive received a combination of paclitaxel, 80 mg/m\^2, IV infusion on Days 1, 8, and 15 of each 28-day cycle and ipatasertib-matching placebo, PO, QD, from Day 1 to Day 21 of each 28-day cycle and atezolizumab, 840 mg, IV infusion on Day 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent, whichever occurred first.
62013558|NCT06147505|EXPERIMENTAL|Experimental|Subjects With Tumor
62013559|NCT01142245|ACTIVE_COMPARATOR|oral esomeprazole|"* Esomeprazole placebo IV loading bolus~* Esomeprazole placebo intravenous infusion for 72 hours~* Oral Esomeprazole: 80 mg/Day on Day 1, 2 and Day 3, and the drug will be given as 40 mg q12h."
62013560|NCT01142245|ACTIVE_COMPARATOR|Intravenous Esomeprazole|"Esomeprazole IV loading bolus 80mg~• Esomeprazole intravenous infusion 8mg/hr for 72 hours"
62785515|NCT00931775|EXPERIMENTAL|Citalopram + pindolol|Citalopram 20 mg/day t.i.d Pindolol 15 mg/day t.i.d.
62013561|NCT06109948|EXPERIMENTAL|Part A Cohort 1-4 Single Dose (active)|Subjects will receive 1 single IV dose of ABX1100 on Day 1.
62013562|NCT06109948|PLACEBO_COMPARATOR|Part A Cohort 1-3 Single Dose (placebo)|Subjects will receive 1 single IV dose of placebo on Day 1.
62013563|NCT06109948|EXPERIMENTAL|Part B Multi-dose (active)|Subjects will receive 1 IV dose of ABX1100 on Day 1 and Day 29 each.
62013564|NCT06109948|PLACEBO_COMPARATOR|Part B Multi-dose (placebo)|Subjects will receive 1 IV dose of placebo on Day 1 and Day 29 each.
62013565|NCT06109948|EXPERIMENTAL|Part C|Late onset Pompe Disease patients will receive 1 dose of ABX1100 at Day 1 and Day 29 respectively.
62013566|NCT04079855|EXPERIMENTAL|Diet composition 1|A diet with a specified macronutrient composition different from arms 2 and 3.
62013567|NCT04079855|EXPERIMENTAL|Diet composition 2|A diet with a specified macronutrient composition different from arms 1 and 3.
62201923|NCT00594880|ACTIVE_COMPARATOR|Pegasys 90 mcg/week|ART replacement treatment with Pegylated Interferon-alpha 2a, 90 mcg/week sc
62402492|NCT06235086|EXPERIMENTAL|Dulaglutide|Dulaglutide will be administered via subcutaneous injection once a week in subjects with type 2 diabetes.
62785516|NCT05931549||Patients in treatment for severe anorexia nervosa|Treatment as usual.
62402493|NCT02873598|EXPERIMENTAL|FOLFIRINOX or gemcitabine/abraxane followed by SBRT Dose level 1|SBRT will be administered in 3 fractions, every other day, on an outpatient basis, following chemotherapy with either FOLFIRINOX or gemcitabine/abraxane. Dose level 1- 9 Gy x 3 fractions.
62785517|NCT05931549||Age matched healthy controls|No treatment.
62785518|NCT05374551|OTHER|All participants|All participants will complete all experimental conditions, which include transcranial magnetic stimulation (continuous theta-burst stimulation) to a brain region of experimental interest and to a control brain region.
62785519|NCT00718692|EXPERIMENTAL|1|Patients treated with Sym001
62785520|NCT03073993|ACTIVE_COMPARATOR|Nasogastric|Feeding tube insertion in nasogastric group
62785521|NCT03073993|ACTIVE_COMPARATOR|Orogastric|Feeding tube insertion in orogastric group
62785522|NCT01857297|EXPERIMENTAL|Adults (aged 18 to 59 years)|The study vaccine (Enzira® vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
62785523|NCT01857297|EXPERIMENTAL|Older Adults (aged 60 years or older)|The study vaccine (Enzira® vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
62013568|NCT04079855|EXPERIMENTAL|Diet composition 3|A diet with a specified macronutrient composition different from arms 1 and 2, based on the current information about the US macronutrient composition.
62013569|NCT02786615|EXPERIMENTAL|Peer Unity|Subjects assigned to this arm would receive a 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
62013570|NCT02786615|NO_INTERVENTION|Pre-implementation|Subjects assigned to this arm would not receive the group-delivered intervention.
62013571|NCT05795699|EXPERIMENTAL|K-321|K-321 ophthalmic solution four times daily (QID) for 12 weeks followed by a two-week gradual dose taper phase and 38-week follow-up phase
62013572|NCT05795699|PLACEBO_COMPARATOR|Placebo|Placebo ophthalmic solution QID for 12 weeks followed by a two-week gradual dose taper phase and 38-week follow-up phase
62013573|NCT03775005|ACTIVE_COMPARATOR|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
62013574|NCT03775005|EXPERIMENTAL|short course treatment|patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
62201924|NCT04942366|EXPERIMENTAL|HIIT Group|High intensity interval training will be performed thrice a week using a treadmill.
62201925|NCT04942366|ACTIVE_COMPARATOR|ST Group|Strength training will be performed thrice a week, each session will consist of eight dynamic drills (with resistance of 60 - 70 % of 1 repetition maximum).
62013575|NCT05474144|EXPERIMENTAL|Verum|Patients received probiotic supplement SmartProbio C, one capsule twice a day - mornings and evenings before meal - for a period of 2 weeks.
62013576|NCT05474144|PLACEBO_COMPARATOR|Placebo|Patients received placebo consisting of purified maltodextrin, one capsule twice a day - mornings and evenings before meal - for a period of 2 weeks.
62013577|NCT03553745|EXPERIMENTAL|Gentle Yoga Program|Program will meet twice a week for a 10-week period. Participants will be a part of gentle yoga sessions led by instructors specializing in the area.
62013578|NCT03553745|EXPERIMENTAL|Rigorous Yoga Program|Program will meet twice a week for a 10-week period. Participants will be a part of rigorous yoga sessions led by instructors specializing in the area.
62013579|NCT03553745|EXPERIMENTAL|Cardiovascular Exercise Program|Program will meet twice a week for a 10-week period. Participants will be a part of cardiovascular exercise sessions led by instructors specializing in the area.
62201926|NCT03758989|EXPERIMENTAL|Baseline PET|R-CHOP
62201927|NCT05765305||Letrozole|Letrozole versus letrozole with chromium
62201928|NCT05260177|EXPERIMENTAL|Active|Exposure to LTS device set to 40 Hz invisible spectral flicker for 1 hour a day for consecutive days
62402494|NCT02873598|EXPERIMENTAL|FOLFIRINOX or gemcitabine/abraxane followed by SBRT Dose level 2|SBRT will be administered in 3 fractions, every other day, on an outpatient basis, following chemotherapy with either FOLFIRINOX or gemcitabine/abraxane. Dose level 2 -10 Gy x 3 fractions
62013580|NCT01136824||Sarcoma Subjects|Soft tissue sarcoma patients treated with the adjuvant and neoadjuvant chemotherapy protocol of doxorubicin plus ifosfamide (AI)
62013581|NCT06467318|ACTIVE_COMPARATOR|Participants post mechanical pleurodesis taking classic pain management with NSAID|
62201929|NCT05260177|SHAM_COMPARATOR|Sham|Exposure to LTS device set to continuous color matched white light for 1 hour a day for consecutive days
62013582|NCT06467318|ACTIVE_COMPARATOR|Participants post mechanical pleurodesis taking classic pain management without NSAID|
62013583|NCT03985813|EXPERIMENTAL|Screening Wizard|Youth and parents receiving Screening Wizard will be screened for depression and suicidal risk within their pediatric primary care provider's office. Screening will be analyzed in real-time to produce a decision support tool meant to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
62013584|NCT04537845||with cancer pain|
62013585|NCT04537845||without cancer pain|
62013586|NCT03765281|EXPERIMENTAL|Navigation|Navigation intervention plus Resource List
62201930|NCT00788242|EXPERIMENTAL|1|Administration of glucose-insulin-potassium
62201931|NCT00788242|PLACEBO_COMPARATOR|2|
62201932|NCT04025489|EXPERIMENTAL|Vitamin D and Placebo|Doses of cholecalciferol (commercial name, Calcirol) 60,000IU (sachets, dissolved in half glass milk) once per week for eight weeks to intervention group and placebo (Lactose Granules) to the placebo group according to the random numbers generated by the computer.
62215068|NCT01566877|ACTIVE_COMPARATOR|AVI-7288|AVI-7288 is a phosphorodiamidate morpholino oligomer with positive charges (PMOplus™) that targets Marburg virus nucleoprotein (NP). AVI-7288 is supplied in 5 mL vials containing 5 mL AVI-7288 at a concentration of 50 mg/mL. The dose levels of AVI-7288 will vary in four cohort's.
62215069|NCT01566877|PLACEBO_COMPARATOR|Placebo|Placebo control consists of approximately 150 mL normal saline solution administered by IV infusion over 30 minutes once a day for 14 days.
62579106|NCT06684574|ACTIVE_COMPARATOR|Nordic walking program|Patients randomly allocated this arm participated in a nordic walking program to improve their pain symptoms and quality of life
62201933|NCT05646576|EXPERIMENTAL|Palliative Care Intervention (PEACE) Group|"Participants will be randomly assigned, and stratified by disease, to the PEACE Group.~* Participants will meet with palliative care (PC) clinician within 1 week of T-cell collection and within 72 hours of hospital admission for ACT.~* Participants will meet with PC clinician at least 2 x weekly during hospitalization.~* PC clinician will follow participants up to one year after randomization (or enrollment for the open pilot) and will meet participant at least 2 x weekly during inpatient hospitalizations.~* Participants will complete follow-up study assessments on pre-determined days per protocol. The assessments will be filled out remotely or via paper.~* Participants will complete exit interviews in the open pilot only."
62579107|NCT06684574|PLACEBO_COMPARATOR|Control group|Patients randomly assigned to this group received only one educational session to advice the convenience of exercising on their own initiative.
62579108|NCT00497289|EXPERIMENTAL|1|Lipidem 20 %
62785524|NCT04331002|EXPERIMENTAL|Experimental|The experimental group will receive a single 32 mg Zilretta injection approximately 8 weeks after meniscus surgery.
62785525|NCT04331002|PLACEBO_COMPARATOR|Placebo|The placebo group will receive a single 5 mL injection of normal saline approximately 8 weeks after meniscus surgery.
62013587|NCT03765281|ACTIVE_COMPARATOR|Self-Navigation|Resource List intervention
62013588|NCT03388073|EXPERIMENTAL|Berry extract I|Plant-based antioxidant-rich berry-based extract.
62402495|NCT02873598|EXPERIMENTAL|FOLFIRINOX or gemcitabine/abraxane followed by SBRT Dose level 3|SBRT will be administered in 3 fractions, every other day, on an outpatient basis, following chemotherapy with either FOLFIRINOX or gemcitabine/abraxane. Dose level 3 - 11 Gy x 3 fractions.
62579109|NCT00497289|ACTIVE_COMPARATOR|2|Lipofundin MCT/LCT 20%
62579110|NCT05591976|EXPERIMENTAL|Exercise group|Participants are assessed for outcomes prior to intervention, mid-way through intervention and immediately after intervention.
62579111|NCT03942458|EXPERIMENTAL|Vicagrel|Vicagrel 24mg loading followed by 6mg/day for 6 days
62579112|NCT03942458|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 300mg loading followed by 75mg/day for 6 days
62579113|NCT06684249|EXPERIMENTAL|Nerve Block Therapy|Participants in this group will receive supratrochlear and greater occipital nerve injections consisting of a combination of local anesthetics and corticosteroids. Injections will be administered once every 12 weeks for a total of 6 months.
62785526|NCT05310331|EXPERIMENTAL|Patients with recurrent cervical cancer|Eligible patients according to inclusion and exclusion criteria.
62785527|NCT04520256|EXPERIMENTAL|Core Program Only|
62785528|NCT04520256|EXPERIMENTAL|Social Support|
62785529|NCT04520256|EXPERIMENTAL|Dysregulated Eating|
62785530|NCT04520256|EXPERIMENTAL|Social Support, Dysregulated Eating|
62785531|NCT04520256|EXPERIMENTAL|Exercise|
62785532|NCT04520256|EXPERIMENTAL|Social Support, Exercise|
62785533|NCT04520256|EXPERIMENTAL|Dysregulated Eating, Exercise|
62785534|NCT04520256|EXPERIMENTAL|Social Support, Dysregulated Eating, Exercise|
62785535|NCT04520256|EXPERIMENTAL|Feedback|
62579114|NCT06684249|ACTIVE_COMPARATOR|Botulinum Toxin A (Botox) Therapy|Participants in this group will receive Botulinum toxin A (Botox) injections according to the standard PREEMPT injection protocol for chronic migraine. Injections will be administered once every 12 weeks for a total of 6 months.
62579115|NCT04981808|EXPERIMENTAL|Telemonitoring|The subjects will be telemonitored. All subject will use a CGM, a fit bit, and a smart pen during the entire trial period. Staff at the endocinology clinics will monitor the data and contact the subjects continuously throughout the trial (depending on the individual needs of each subject)
62785536|NCT04520256|EXPERIMENTAL|Social Support, Feedback|
62785537|NCT04520256|EXPERIMENTAL|Dysregulated Eating, Feedback|
62579116|NCT04981808|NO_INTERVENTION|Usual Care|The subjects will wear a blinded CGM the first and final 20 days of the trial. The subjects will use a blinded smart pen throughout the trial period. Hence, the subjects are unable to see their measured data during the trial, and they will not be monitored.
62785538|NCT04520256|EXPERIMENTAL|Social Support, Dysregulated Eating, Feedback|
62785539|NCT04520256|EXPERIMENTAL|Exercise, Feedback|
62201934|NCT05646576|ACTIVE_COMPARATOR|Usual Care Group|Participants will be randomly assigned, and stratified by disease, to the Usual Care Group and will receive standard care for ACT.
62201935|NCT05254080|EXPERIMENTAL|Active taVNS then Sham taVNS|Participants will receive active then sham (placebo) ear stimulation.
62201936|NCT05254080|EXPERIMENTAL|Sham taVNS then Active taVNS|Participants will receive sham (placebo) then active ear stimulation.
62579117|NCT06184646|NO_INTERVENTION|Control (0 g prune/day)|Participants only receive 500 mg calcium and 400 IU vitamin D daily for 24 months.
62201937|NCT02537210|ACTIVE_COMPARATOR|Mesalazine|mesalazine 2g od po for 12 months
62579118|NCT06184646|EXPERIMENTAL|30 g prune/day|Participants receive 500 mg calcium and 400 IU vitamin D daily for 24 months and 30 g of prune daily for 24 months.
62579119|NCT04795934|ACTIVE_COMPARATOR|Laparoscopic Nissen Fundoplication (LNF)|Control
62579120|NCT04795934|ACTIVE_COMPARATOR|Combo Transoral Incisionless Fundoplication (CTIF)|Treatment
62579121|NCT01468194|EXPERIMENTAL|Breathing procedure 1|"Walking with breathing procedure 1."
62201938|NCT02537210|PLACEBO_COMPARATOR|Placebo oral capsule|placebo 5 capsules od po for 12 months
62201939|NCT00505154|PLACEBO_COMPARATOR|2|Placebo tablets
62201940|NCT00505154|ACTIVE_COMPARATOR|1|rosuvastatin
62201941|NCT02666664|EXPERIMENTAL|ETC-1002|ETC-1002 180 mg/day
62201942|NCT02666664|PLACEBO_COMPARATOR|Placebo|Placebo control
62201943|NCT05009784|ACTIVE_COMPARATOR|Traffic Sound|600 seconds of traffic sound
62201944|NCT05009784|EXPERIMENTAL|Traffic and Masking Sounds|600 seconds of traffic and masking sound
62201945|NCT05009784|ACTIVE_COMPARATOR|Silence|600 seconds of no sound
62215070|NCT02503033|EXPERIMENTAL|HMPL-523|"Oral administration, at a dose of 100, 200, 400, 600, 800 and 1000mg once daily or 300mg and 400mg twice daily at Dose-escalation stage.~At the Dose-expansion stage, HMPL-523 600mg will be dosed once daily."
62215071|NCT01710644|EXPERIMENTAL|Burlulipase|Burlulipase orally, per meal
62785540|NCT04520256|EXPERIMENTAL|Social Support, Exercise, Feedback|
62785541|NCT04520256|EXPERIMENTAL|Dysregulated Eating, Exercise, Feedback|
62785542|NCT04520256|EXPERIMENTAL|Social Support, Dysregulated Eating, Exercise, Feedback|
62785543|NCT04520256|EXPERIMENTAL|VR|
62785544|NCT04520256|EXPERIMENTAL|Social Support, VR|
62785545|NCT04520256|EXPERIMENTAL|Dysregulated Eating, VR|
62785546|NCT04520256|EXPERIMENTAL|Social Support, Dysregulated Eating, VR|
62785547|NCT04520256|EXPERIMENTAL|Exercise, VR|
62785548|NCT04520256|EXPERIMENTAL|Social Support, Exercise, VR|
62785549|NCT04520256|EXPERIMENTAL|Dysregulated Eating, Exercise, VR|
62785550|NCT04520256|EXPERIMENTAL|Social Support, Dysregulated Eating, Exercise, VR|
62785551|NCT04520256|EXPERIMENTAL|Feedback, VR|
62785552|NCT04520256|EXPERIMENTAL|Social Support, Feedback, VR|
62201946|NCT04001647|EXPERIMENTAL|TUDCA|Young and older healthy weight and obese participants will visit the lab for assessment of vascular function prior to the intervention. Aortic stiffness will be evaluated non-invasively using carotid-femoral pulse-wave velocity. A physician will place a catheter in the brachial artery for endothelial cell biopsies and local vasodilator infusions. A venous catheter will also be placed for the systemic ascorbic acid infusion. Aortic stiffness measures and vascular responses to vasodilator infusions will be performed before and after the ascorbic acid infusion. Following the completion of the vascular assessments, participants will receive 1750 mg/day of the dietary supplement tauroursodeoxycholic acid (TUDCA) for 8 weeks. Participants will return to the lab after the 8 week intervention and the vascular assessments described above will be repeated.
62201947|NCT04001647|PLACEBO_COMPARATOR|Placebo|Older obese participants will visit the lab for assessment of vascular function prior to the intervention. Aortic stiffness will be evaluated non-invasively using carotid-femoral pulse-wave velocity. A physician will place a catheter in the brachial artery for endothelial cell biopsies and local vasodilator infusions. A venous catheter will also be placed for the systemic ascorbic acid infusion. Aortic stiffness measures and vascular responses to vasodilator infusions will be performed before and after the ascorbic acid infusion. Following the completion of the vascular assessments, participants will receive oral capsules containing a placebo treatment for 8 weeks. Participants will return to the lab after the 8 week intervention and the vascular assessments described above will be repeated.
62201948|NCT05959759|EXPERIMENTAL|Dimethyl fumarate|dimethyl fumarate enteric capsule (the initial dose is 120 mg twice a day, and after 7 days, the dose will be increased to the maintenance dose of 240 mg twice a day, for 6 months)
62402496|NCT03804554||Patients taking nivolumab|
62785553|NCT04520256|EXPERIMENTAL|Dysregulated Eating, Feedback, VR|
62785554|NCT04520256|EXPERIMENTAL|Social Support, Dysregulated Eating, Feedback, VR|
62201949|NCT05959759|PLACEBO_COMPARATOR|Placebo|placebo with the same appearance (color, taste, size, shape)
62215072|NCT01710644|PLACEBO_COMPARATOR|Placebo (Caramel in sterile water)|Placebo orally, per meal
62215073|NCT04598568||balanSys UNI knee prosthesis|Participants treated with a balanSys® UNI knee prosthesis
62215074|NCT00543374|PLACEBO_COMPARATOR|Placebo|Placebo
62785555|NCT04520256|EXPERIMENTAL|Exercise, Feedback, VR|
62785556|NCT04520256|EXPERIMENTAL|Social Support, Exercise, Feedback, VR|
62215075|NCT00543374|ACTIVE_COMPARATOR|PROCHYMAL Low dose|Low dose (total of 600 million cells)
62215076|NCT00543374|ACTIVE_COMPARATOR|PROCHYMAL High dose|High dose (total of 1200 cells)
62215077|NCT00703937|EXPERIMENTAL|Ferric Carboxymaltose (FCM)|750 mg of iron as undiluted FCM (15 mg/kg up to a maximum of 750 mg) at 100 mg per minute weekly until the calculated iron deficit dose has been administered (to a maximum cumulative dose of 2,250 mg).
62402497|NCT04331431|OTHER|spinal cord tumors|
62402498|NCT01322061|ACTIVE_COMPARATOR|Vitamin C|
62402499|NCT01322061|PLACEBO_COMPARATOR|mirinda|
62402500|NCT06264076|EXPERIMENTAL|Single interventional group|Patients that need ligament balancing will receive the procedure using a novel instrument
62402501|NCT05685446|EXPERIMENTAL|175 ml ice water|Ingestion of 175 ml ice water 15 minutes prior to gastroscopy
62579122|NCT01468194|EXPERIMENTAL|Breathing procedure 2|"Walking with breathing procedure 2."
62579123|NCT01468194|NO_INTERVENTION|Control group|Walking without any reglementation of breathing
62579124|NCT06682091||Cohort of patients admitted for an abdominal mesh infection at Hospices Civils de Lyon|No intervention. Retrospective data collection.
62579125|NCT03550092|EXPERIMENTAL|Aphasia|Abstract Semantic Association Network Training (AbSANT) Each session will be 2 hours long and will occur twice each week for a total of 20 sessions.
62785557|NCT04520256|EXPERIMENTAL|Dysregulated Eating, Exercise, Feedback, VR|
62785558|NCT04520256|EXPERIMENTAL|Social Support, Dysregulated Eating, Exercise, Feedback, VR|
62215078|NCT00703937|ACTIVE_COMPARATOR|Standard Medical Care (SMC) for the treatment of IDA|SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA).
62215079|NCT02156726||Low dose FCR in Elderly/Comorbid CLL|low dose FCR
62215080|NCT01315210|EXPERIMENTAL|D-Ribose|
62215081|NCT01315210|PLACEBO_COMPARATOR|Placebo|
62215082|NCT05016362||Group A|blepharoplasty with repositioning of the nasal fat pad to the central arcus marginalis of the superior orbital rim during surgery.
62215083|NCT05016362||Group B|blepharoplasty with repositioning of the nasal fat pad to orbitoglabellar groove during surgery.
62215084|NCT00958503|PLACEBO_COMPARATOR|Placebo|Placebo
62215085|NCT00958503|ACTIVE_COMPARATOR|Thiamphenicol|Active comparator
62215086|NCT04357054|ACTIVE_COMPARATOR|Normal uterus|Darwish test
62215087|NCT04357054|ACTIVE_COMPARATOR|Myomatous uterus|Darwish test
62215088|NCT01034176|ACTIVE_COMPARATOR|Levofloxacin|Levofloxacin 500 mg every day (dose adjusted for renal function) for 30 days
62215089|NCT01034176|PLACEBO_COMPARATOR|placebo|placebo identical to levofloxacin drug daily for 30 days
62215090|NCT02835118|EXPERIMENTAL|Surotomycin 0.5 g|Two oral doses of 0.25 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
62215091|NCT02835118|EXPERIMENTAL|Surotomycin 1 g|Two oral doses of 0.5 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
62013589|NCT03388073|EXPERIMENTAL|Berry extract II|Plant-based antioxidant-rich berry-based extract.
62013590|NCT03388073|EXPERIMENTAL|Berry extract blend|Blend of plant-based antioxidant-rich berry-based extracts.
62013591|NCT03388073|PLACEBO_COMPARATOR|Placebo|
62013592|NCT06369740||Hemophilia A patients - case scenario focus groups|60 patients with hemophilia A aged 12 years and older that partake in the case scenario focus groups
62013593|NCT06369740||Healthcare providers - case scenario focus groups|30 healthcare providers with experience in the field of hemophilia A that partake in the case scenario focus groups
62402502|NCT05685446|NO_INTERVENTION|Fasting|Continued fasting
62402503|NCT05858216|OTHER|Chlor-Trimeton|Package recommended dose of over the counter Chlor-Trimeton will be administered to assess voice function before and 3 hours after taking it.
62402504|NCT03116958|ACTIVE_COMPARATOR|Standard care|"Patients diagnosed as OSA, treated with CPAP and followed up in sleep unit as per usual care.~Patients will be fitted with a mask and given a CPAP and instructed on how to use the device. Each CPAP machine will be provided with a modem sending daily compliance and adherence information to MyOSA web site but no intervention based on these data is planned in this group. All patients will be visited at 1,3 and 6 months at sleep unit. Patients will be checked about progress and adherence to therapy and any problems with their machine. Information will be downloaded from their machines (CPAP adherence, applied CPAP pressure, mask leak, and residual respiratory events...)."
62013594|NCT06369740||Hemophilia A patients - use scenarios|6 patients with hemophilia A aged 12 years and older that partake in the use scenarios usability evaluation
62013595|NCT06369740||Healthcare providers - use scenarios|6 healthcare providers with experience in the field of hemophilia A that partake in the use scenarios usability evaluation
62013596|NCT03140891|EXPERIMENTAL|NHFOV|NHFOV is used as the supporting mode after extubation
62013597|NCT03140891|ACTIVE_COMPARATOR|NCPAP|NCPAP is used as the supporting mode after extubation
62402505|NCT03116958|EXPERIMENTAL|Telemedicine|"Patients diagnosed as OSA and treated with CPAP, followed up in sleep unit, adding a telemedicine integrated system.~Patients will be fitted with a mask , given a CPAP, and instructed on how to use the device. Using patients' baseline and initial follow-up data a software will provide a prediction of CPAP compliance at 6 months, and propose personalized interventions to increase compliance (smartphone app). All patients will be visited at 3 and 6 months at sleep unit. Patients will be checked about progress and adherence to therapy and any problems with their machine."
62402506|NCT03133429|EXPERIMENTAL|Patients with MER stent|Patients eligible for Carotid Artery Stenting
62402507|NCT04427423|EXPERIMENTAL|Positional Distraction plus Stabilization Exercise group|The treatment group will receive positional distraction with stabilization exercises
62402508|NCT04427423|ACTIVE_COMPARATOR|Stabilization Exercise group|control group will be treated with stabilization exercises only.
62013598|NCT01297218|EXPERIMENTAL|NEUROSTEM®-AD|
62013599|NCT03060824||CABG with the aid of CPB.|Cardiac surgical patients subjected to coronary artery bypass grafting with the aid of Cardiopulmonary Bypass. Perioperative measurements of osmolality in plasma.
62013600|NCT03969771|EXPERIMENTAL|Frequently Absent|8 weeks of training in Mindfulness-Based Stress Reduction
62013601|NCT03969771|ACTIVE_COMPARATOR|Normal Attendees (Controls)|8 weeks of training in Mindfulness-Based Stress Reduction
62402509|NCT05951894||Hypertension|This group consists of obese adolescents with hypertension, defined as systole blood pressure \>130 mmHg or diastole blood pressure \>85 mmHg, or both
62402510|NCT05951894||Non-hypertension|This group consists of obese adolescents without hypertension
62402511|NCT05951894||Normal (non-obese)|This group consist of normal subjects (non-obese)
62402512|NCT04747691||Patients assessed with postoperative bedside gastric ultrasound|This patient population will include postoperative patients who received a gastrointestinal surgery and are being assessed with the bedside gastric ultrasound.
62785559|NCT01590693|EXPERIMENTAL|Group 2|Children treated with four weeks of below knee walking casts and botulinum toxin A injections
62402513|NCT06309069||Patients with CCE|CCE patients identified between 2015 and 2023
62785560|NCT01590693|ACTIVE_COMPARATOR|Group 1|Children treated with four weeks of below knee walking casts.
62013602|NCT04363606|EXPERIMENTAL|"Non-fatigued patients who have been in intensive care units"|
62013603|NCT04363606|EXPERIMENTAL|"Fatigued patients who have been in intensive care units"|
62013604|NCT04363606|EXPERIMENTAL|patients who have not been in intensive care units|
62013605|NCT06432010|OTHER|Group nutrition and physical activity coaching|Initial health check-up → 7 weeks nutrition and physical activity coaching → 2 telephone follow-ups at 3 and 6 months after → Final health check-up (12 months after)
62013606|NCT06432010|OTHER|Group cognition coaching|Initial health check-up → 7 weeks cognition coaching → 2 telephone follow-ups at 3 and 6 months after → Final health check-up (12 months after)
62013607|NCT06432010|NO_INTERVENTION|control group|The study is controlled by the presence of a control group (non-coaching group). 25 people will be included in the control group. They will only benefit from the initial and final health check-up.
62013608|NCT06415799||Healthy Volunteers|
62013609|NCT04140669||Fetal Surgery Procedures|All pregnant women with a fetus diagnosed with a fetal abnormality and planning to undergo a fetal surgical procedure will be included in this single arm of the study.
62013610|NCT01946308|EXPERIMENTAL|conformational positioner & mattress|conformational positioner \& mattress, five hours on each
62785561|NCT04836845|ACTIVE_COMPARATOR|Focus extracorporeal shock wave therapy|
62013611|NCT06270303|EXPERIMENTAL|Access flap + bone substitute|Furcation defect will be treated by access flap debridement followed by application of a bone substitute material.
62013612|NCT06270303|ACTIVE_COMPARATOR|Access flap|Furcation defect will be treated by access flap debridement alone.
62013613|NCT02698501|EXPERIMENTAL|MEDI9929|MEDI9929 is a human monoclonal antibody immunoglobulin IgG2λ directed against TSLP. MEDI9929 binds with human TSLP and prevents its interaction with thymic stromal lymphopoietin receptor (TSLPR).
62013614|NCT02698501|PLACEBO_COMPARATOR|Placebo|Apart from the active substance, the placebo is otherwise identical to IMP.
62013615|NCT05627440|EXPERIMENTAL|Experimental arm|30 g/day protein supplementation (1 Ensure Max Protein® bottle)
62013616|NCT05627440|ACTIVE_COMPARATOR|Sham comparator arm|9 g/day protein supplementation (1 Ensure Original® bottle)
62013617|NCT05627440|NO_INTERVENTION|No intervention arm|0 g/day protein supplementation (no Ensure bottles)
62402514|NCT04940624|EXPERIMENTAL|Soticlestat|Participants weighing \<45kg: Soticlestat, mini-tablets, at the dose of 40mg to 200mg, orally or via gastrostomy tube (G-tube) or low-profile gastric tube (MIC-KEY button) or jejunostomy tube (J-tube), twice daily (BID) based on the body weight up to 4 weeks in Titration Period. Participants will continue to receive dose that they are on at the end of Titration Period, for 12 weeks in Maintenance Period. The total duration of the treatment will be up to 16 weeks (Treatment Period). The dose will be tapered down if participants decide to discontinue the treatment. Participants weighing ≥45kg: Soticlestat mini-tablets or tablets with a starting dose of 100mg BID followed by 200 mg BID and, then 300mg BID, up to 4 weeks in Titration Period. Participants will continue to receive 300mg BID for 12 weeks in the Maintenance Period. The total duration of the treatment will be up to 16 weeks (Treatment Period). The dose will be tapered down if participants decide to discontinue the treatment.
62402515|NCT04940624|PLACEBO_COMPARATOR|Placebo|Soticlestat placebo-matching mini-tablets or tablets, orally or via G-tube or MIC-KEY button or J-tube, BID, up to 4 weeks in the Titration Period. Participants will continue to receive the soticlestat placebo-matching mini-tablets or tablets for 12 weeks in the Maintenance Period. The total duration of the treatment will be up to 16 weeks. Soticlestat matching tapering will be done to maintain the blind if participants decide to discontinue the treatment.
62402516|NCT02672475|EXPERIMENTAL|Treatment (Paclitaxel, Galunisertib)|Patients receive Paclitaxel IV on days 1, 8, and 15. Patients also receive GalunisertibPO BID on days 1-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62201950|NCT03191513|EXPERIMENTAL|Interesterified|Interesterified blend of palm kernal and plam stearin. 50g fat.
62201951|NCT03191513|ACTIVE_COMPARATOR|Un-interesterified|Un-interesterified blend of palm kernal and plam stearin. 50g fat.
62402517|NCT05534958||Healthy|
62402518|NCT05534958||Mild Cognitive Impairment|
62402519|NCT05534958||Early Dementia|
62402520|NCT01388036|EXPERIMENTAL|esmolol infusion|infusion of esmolol during rest and exercise
62402521|NCT03780673|EXPERIMENTAL|Simvastatin 20 mg + Rifaximin 400 mg|Simvastatin 20 mg/day and rifaximin 400 mg/8 hours orally for 12 months
62402522|NCT03780673|PLACEBO_COMPARATOR|Placebo of Simvastatin + Placebo of Rifaximin|Placebo of simvastatin and placebo of rifaximin orally for 12 months
62402523|NCT05790252|EXPERIMENTAL|Bridge Induction Arm|
62402524|NCT05790252|PLACEBO_COMPARATOR|Standard Arm|
62402525|NCT03628573|OTHER|Intermittent Theta burst stimulation.|Procedure: repetitive transcranial magnetic stimulation (iTBS) to the left Dorsolateral Prefrontal Cortex; 3 sessions per day, for 20 days.
62402526|NCT03744208|EXPERIMENTAL|Anti-EGFR monoclonal antibody|DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
62201952|NCT03191513|ACTIVE_COMPARATOR|Control|Rapeseed oil. 50g fat.
62201953|NCT04693039|EXPERIMENTAL|FLZ-150mg|Drug：Phenlarmide；Dosage：150mg；
62402527|NCT03392922|EXPERIMENTAL|Uniblocker|The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery
62402528|NCT03392922|EXPERIMENTAL|Left-sided Double-lumen Tube|the double-lumen tube (DLT) is the most commonly used device for OLV
62013618|NCT05010109|EXPERIMENTAL|Standard Treatment Plan (Cohort One)|Patients undergo SPECT/CT with stress test and echocardiogram with strain before RT, 6-8 weeks and 12 months after completion of RT. Patients also participate in 6 MWT before RT, 2-3 and 6-7 weeks during RT, then 6-8 weeks, 4-6 months and 12 months after completion of RT. Patients undergo blood sample collection and complete questionnaires over 3-5 minutes before RT, 2-3, 4-5, 6-7 weeks after the initiation of RT, then at 3, 6, 12, and 24 months after completion of RT.
62402529|NCT00731094|EXPERIMENTAL|Physical Activity Intervention|Expert system-based physical activity counseling: Individualized baseline counseling and guided goal setting to increase physical activity gradually to at least 150 minutes/week of moderate intensity, with a 12-month follow-up via postal mail of 14 additional counseling contacts generated by responses to a physical activity questionnaire and individually tailored computer-generated expert system feedback messages for physical activity based on stages of the motivational readiness for change model
62013619|NCT05010109|EXPERIMENTAL|Model Based Personalized Treatment Plan (Cohort Two)|Patients undergo SPECT/CT with stress test and echocardiogram with strain before RT, 6-8 weeks and 12 months after completion of RT. Patients also participate in 6 MWT before RT, 2-3 and 6-7 weeks during RT, then 6-8 weeks, 4-6 months and 12 months after completion of RT. Patients undergo blood sample collection and complete questionnaires over 3-5 minutes before RT, 2-3, 4-5, 6-7 weeks after the initiation of RT, then at 3, 6, 12, and 24 months after completion of RT.
62013620|NCT04726982|EXPERIMENTAL|Low dose acetazolamide|Unembellished white tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.
62013621|NCT04726982|EXPERIMENTAL|High dose acetazolamide|Unembellished white tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.
62013622|NCT04726982|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.
62013623|NCT01360034|EXPERIMENTAL|Nifedipine|108 patients will receive nifedipine as tocolytic for 48 hours.
62013624|NCT01360034|EXPERIMENTAL|Indomethacin|108 patients will receive indomethacin as tocolytic for 48 hours.
62013625|NCT02248922|EXPERIMENTAL|Tobramycin ALL|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)twice a day (BID) 28days on / 28 days off
62013626|NCT00515333|PLACEBO_COMPARATOR|1|Placebo: 0 milligrams; t.i.d.
62579126|NCT06140017|ACTIVE_COMPARATOR|In-Person Group Delivery|"A total of 30 villages will receive a traditional in-person group-based delivery for Msingi Bora, an ECD parenting intervention featuring 16 biweekly village sessions over 8 months, followed by monthly booster meetings for 16 additional months. Sessions will be delivered within by existing village Community Health Volunteers (CHVs). Mothers and children will be invited to attend a total of 32 in-person sessions of roughly 1.5-2 hours apiece over 24 months."
62785562|NCT04836845|ACTIVE_COMPARATOR|Radial extracorporeal shock wave therapy|
62785563|NCT04836845|SHAM_COMPARATOR|Sham extracorporeal shock wave therapy|
62013627|NCT00515333|ACTIVE_COMPARATOR|2|Treatment group: 30 milligrams; t.i.d.
62013628|NCT00515333|ACTIVE_COMPARATOR|3|Treatment group: 60 milligrams; t.i.d.
62013629|NCT00515333|ACTIVE_COMPARATOR|4|Treatment group: 100 milligrams; t.i.d.
62013630|NCT03213093|OTHER|Diabetic patients with a risk of diabetic foot ulcer|
62013631|NCT00780572|EXPERIMENTAL|Arm 1: ADE Alerts|Arm 1 is a random intervention group in which half of the patients admitted to the VASLCHCS during study time period will be randomly selected. Providers will see ADE alerts for all patient in the randomly selected experimental group
62013632|NCT00780572|NO_INTERVENTION|Arm 2: Control/No Alerts|The second arm is the control. Alerts will not be displayed for these patients.
62013633|NCT01973829|OTHER|Baseline arm|baseline data (50 patients or 3 months per center)
62013634|NCT01522859|NO_INTERVENTION|standard care|A standardised home based programme of specialist respiratory assessment and monitoring provided by the local Community Respiratory Team (CRT) and General Practitioner (GP) for a period of six months.
62013635|NCT01522859|EXPERIMENTAL|Telehealth monitoring|Daily monitoring of patient's health status using a small telecommunications device.
62013636|NCT05841810|EXPERIMENTAL|Stage 1 mHealth Outreach|
62785564|NCT06332105|ACTIVE_COMPARATOR|Sequence AB: GMP-AA -> L-AA|After an initial washout period of 2 weeks, participants randomised to Sequence AB will consume GMP-AA for 3 months whilst keeping a food diary and sending blood spots for twice weekly analysis. At the end of 3 months there is a further 2 week washout period with L-AA, after which the participant will consume L-AA for 3 months whilst keeping a food diary and sending blood spots for twice weekly analysis.
62785565|NCT06332105|PLACEBO_COMPARATOR|Sequence BA: L-AA -> GMP-AA|After an initial washout period of 2 weeks, participants randomised to Sequence BA will consume L-AA for 3 months whilst keeping a food diary and sending blood spots for twice weekly analysis. At the end of 3 months there is a further 2 week washout period with L-AA, after which the participant will consume GMP-AA for 3 months whilst keeping a food diary and sending blood spots for twice weekly analysis.
62013637|NCT05841810|EXPERIMENTAL|Stage 2 mHealth Outreach|
62013638|NCT05841810|NO_INTERVENTION|Stage 1 Standard of Care|
62013639|NCT05841810|NO_INTERVENTION|Stage 2 Standard of Care|
62013640|NCT05841810|EXPERIMENTAL|Stage 2 mHealth Outreach + Care Coordination|
62013641|NCT06611436|EXPERIMENTAL|Part 1 - Dose Escalation, Dose Level 1|
62013642|NCT06611436|EXPERIMENTAL|Part 1 - Dose Escalation, Dose Level 2|
62013643|NCT06611436|EXPERIMENTAL|Part 1 - Dose Escalation, Dose Level 3|
62013644|NCT06611436|EXPERIMENTAL|Part 2 - Dose Expansion, Cohort 2a Adult Expansion, Optimal Dose Selected in Part 1 Dose Escalation|
62201954|NCT04693039|EXPERIMENTAL|FLZ-300mg|Drug：Phenlarmide；Dosage：300mg；
62201955|NCT04693039|EXPERIMENTAL|FLZ-600mg|Drug：Phenlarmide；Dosage：600mg；
62201956|NCT04693039|EXPERIMENTAL|FLZ-900mg|Drug：Phenlarmide；Dosage：900mg；
62201957|NCT04693039|PLACEBO_COMPARATOR|Placebo-150mg|Drug：Placebo；Dosage：150mg；
62201958|NCT04693039|PLACEBO_COMPARATOR|Placebo-300mg|Drug：Placebo；Dosage：300mg；
62201959|NCT04693039|PLACEBO_COMPARATOR|Placebo-600mg|Drug：Placebo；Dosage：600mg；
62201960|NCT04693039|PLACEBO_COMPARATOR|Placebo-900mg|Drug：Placebo；Dosage：900mg；
62201961|NCT01344772|ACTIVE_COMPARATOR|Internal fixation|Displaced femoral neck fracture treated with internal fixation using two parallel cannulated screws.
62201962|NCT01344772|ACTIVE_COMPARATOR|Total hip replacement|Displaced femoral neck fracture treated with total hip replacement through a posterior approach.
62201963|NCT02872805|ACTIVE_COMPARATOR|PEPFAR Enhanced Standard of Care (PESCA)|This arm reflects an enhanced standard of care comparison group for PEPFAR supported sites. We will provide standardized materials to be used by current clinical staff to help support whatever the site specific activities are related to transition from pediatric to adult medical care
62201964|NCT02872805|EXPERIMENTAL|Peer Transition Advocate (PTA)|The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.
62201965|NCT03473353|OTHER|Pediatric Clinicians|Survey data will be gathered from pediatric clinicians and also parents of pediatric patients at two time periods. At baseline, no Medical Scribes will be working with the clinicians, and then several months later, data will be gathered when Medical scribes ARE working with clinicians.
62579127|NCT06140017|EXPERIMENTAL|Hybrid mHealth/In-Person Group Delivery|30 CHVs will deliver a hybrid intervention that combines in-person meetings with remote delivery for Msingi Bora, an ECD parenting intervention. Mother-child dyads will be invited to participate in roughly 10 in-person group sessions in the first 8 months, followed by 5 in-person group sessions over the next 16 months. For those sessions delivered remotely, mothers will receive videos demonstrating the practices, SMS messages, be invited to participate in group SMS/WhatsApp chats with the CHV and other village mothers, and periodic phone calls. The project will provide smartphones to all mothers assigned to this arm for facilitation.
62013645|NCT04413318|EXPERIMENTAL|electronic device followed by pneumatic device|Children receive continuous control of tracheal cuff pressure with the electronic device (VBM©) for 6-hours followed by continuous control of tracheal cuff pressure with the pneumatic device (Nosten©) for 6-hours.
62201966|NCT04934956|EXPERIMENTAL|Intervention: Split-belt walking; Multiple transitions between split-belt and tied-belt walking|"Split-belt walking will be used in all experiments and consists of a time period during which the legs move at different speeds (0.5 m/s vs. 1 m/s). The investigators select those speeds since the investigators have observed in our preliminary data and published study (Sombric et al. 2017) that older individuals adapted at these speeds exhibit large deficits at motor switching when transitioning to overground walking. This large reference signal will facilitate the detection of a change in motor switching (Aim 2) following the Intervention.~This second intervention consists of multiple short adaptation blocks (i.e., 6 blocks of 200 strides each) interleaved with short de-adaptation blocks (i.e., 5 blocks of 200 strides of tied-belt walking each). It was designed based on several studies showing improvements in adaptation rate in young adults with a similar protocol (Malone et al. 2011; Day et al. 2018; Leech et al. 2018)."
62201967|NCT05119842|EXPERIMENTAL|Treatment|Treatment with the VOIS Implant
62201968|NCT06228716|EXPERIMENTAL|Experimental|Subcutaneous biological drug self-administration training was given by the researcher in two stages, theoretical and practical, face to face. Power point presentation and training brochure were used in theoretical training. The practical training given after the theoretical training was given using the Hybrid simulation method. The Wearable Subcutaneous Injection Hybrid Simulator developed by the researcher was worn by the individuals after being informed about its purpose and function. A medicine pen similar to their own medicine pens (demo pen without medicine), dry cotton, alcohol swab (similar to the ones that come in medicine pen boxes), and a small notepad and pen were left in a clean medicine tray on a clean table. Afterwards, they were expected to apply the subcutaneous application step by step as explained to them. Each application step they made incorrectly was corrected and repeated with the support of the researcher.The training took approximately 40 minutes.
62201969|NCT06228716|OTHER|Kontrol Group|Subcutaneous biological drug self-administration training was given theoretically face to face by the researcher using a power point presentation and training brochure. The training lasted approximately 25 minutes and was given in the same room where the experimental group received training.
62201970|NCT01245374|EXPERIMENTAL|Nordiflex Norditropin®|Individually adjusted dose administered with Norditropin NordiFlex® for 6 weeks. Dosage depended on age, weight, etiologies and according to the summary of product characteristics (SPC)
62201971|NCT04297631|EXPERIMENTAL|Vancomycin Powder|All patients getting vancomycin to see concentration after 24hrs in knee drain and serum levels.
62201972|NCT04297631|EXPERIMENTAL|Tobramycin Powder|All patients getting Tobramycin to see conceration after 24hrs in knee drain and serum levels.
62201973|NCT01361542|EXPERIMENTAL|Anti TNF|Anti TNF alpha therapy including either infliximab or etanercept with data obtained before and after the study duration.
62201974|NCT01934790|EXPERIMENTAL|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
62215092|NCT02835118|EXPERIMENTAL|Surotomycin 2 g|Two oral doses of 1 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
62579128|NCT06140017|NO_INTERVENTION|Control Group|Mothers and children in 30 villages will not receive any intervention beyond information about child feeding during a baseline survey.
62579129|NCT03488758|ACTIVE_COMPARATOR|CMF|infant formula based on cow milk protein fractions
62013646|NCT04413318|EXPERIMENTAL|pneumatic device followed by electronic device|Children receive the reverse sequence (continuous control using the pneumatic device (Nosten©) for 6-hours followed by the electronic device (VBM©) for 6-hours
62579130|NCT03488758|EXPERIMENTAL|GMF|infant formula based on whole goat milk
62785566|NCT05486611|EXPERIMENTAL|W-GenZD Mobile Application Group|Participants assigned to the W-GenZD mobile application group will be asked to download and use the W-GenZD mobile application that will provide information and tools through a chatbot (a computer program designed to communicate with users). Participants will be invited to use the mobile application as often as they like during the 4-week treatment period - we will encourage 5 to 10 minutes of daily use.
62785567|NCT05486611|SHAM_COMPARATOR|Digital Education Application Group|Participants assigned to the Digital Education mobile app group will be given instructions on how to download and access the application that will provide general health information. A new article will be provided to the participant at a rate of once per week across the 4 weeks (4 articles total) and they will receive a weekly notification when a new article is available. Each article will be available for one week from release date. We expect a target dosage of roughly 30 minutes per week (120 min), which would make it comparable to Woebot (about 5 min per day X 28 days = 140 min).
62785568|NCT04325620|EXPERIMENTAL|HIP1601 Amg|The participants will receive tretment of HIP1601 Amg, orally, once daily for 4weeks.
62785569|NCT04325620|PLACEBO_COMPARATOR|HGP1805|The participants will receive tretment of HGP1805(Placebo of HIP1601), orally, once daily for 4weeks.
62785570|NCT01210586|ACTIVE_COMPARATOR|Nicotine Patch|Nicotine Patch for Smoking Cessation
62785571|NCT01210586|PLACEBO_COMPARATOR|Placebo Patch|
62785572|NCT06527417|EXPERIMENTAL|electromyography-triggered electrical stimulation|"EMG ES was applied to the bilateral multifidus and erector spina muscles of the experimental group 3 times a week for 10 minutes in each session for 4 weeks. At the beginning of each session, the participants were instructed to position themselves in a comfortable sitting position.~EMG ES was performed using six self-adhesive electrodes (37 × 64 mm) and two Neuro Trac Myo Plus Pro devices."
62785573|NCT06527417|ACTIVE_COMPARATOR|trunk eccentric exercises|The control group performed back eccentric exercises for 4 weeks, 3 times a week, 3 times in each session.
62785574|NCT06015087|EXPERIMENTAL|Intervention group|
62013647|NCT00841126|EXPERIMENTAL|Magnesium iron hydroxycarbonate|
62013648|NCT00841126|ACTIVE_COMPARATOR|Lanthanum carbonate|
62013649|NCT00841126|PLACEBO_COMPARATOR|Placebo|
62013650|NCT00413413|EXPERIMENTAL|Valsartan/amlodipine 80/5 mg|
62579131|NCT00886444|EXPERIMENTAL|Ferucarbotran|
62579132|NCT06198829||Clinical parameter assessment group|Various assessments will be conducted on patients with femoroacetabular cam impingement.
62785575|NCT06015087|NO_INTERVENTION|Control group|
62013651|NCT00413413|ACTIVE_COMPARATOR|Valsartan 80 mg|
62013652|NCT00413413|ACTIVE_COMPARATOR|Valsartan 160 mg|
62579133|NCT01146899|EXPERIMENTAL|Provider Alert|Provider receives alert for patient visit
62579134|NCT01146899|NO_INTERVENTION|No Alert|No alert provided
62013653|NCT03004534|EXPERIMENTAL|Presurgical Molecular Assessment|Oral 300 mg darolutamide tablet; dose of 600 mg (2 x 300 mg tablets) b.i.d.
62013654|NCT05133648||Hip Surgery without COVID-19 infection|January to December 2021
62013655|NCT05133648||Hip Surgery with COVID-19 infection|January to December 2021
62013656|NCT05133648||Hip Surgery pre-pandemic|January 2017 to December 2019
62013657|NCT02785367|EXPERIMENTAL|Cord blood samples|8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml washed with Heparin.
62013658|NCT05693922|EXPERIMENTAL|Delta-beta tACS|Participants will receive a single session intervention of behavioral activation (BA) psychotherapy. Stimulation will be delivered via the NeuroConn DC-STIMULATOR MC at 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA zero to-peak amplitude at the return electrode. The tACS will be delivered using the cross-frequency stimulation waveform delta-beta (3-20Hz).
62013659|NCT05693922|SHAM_COMPARATOR|Active-sham tACS|Participants will receive a single session intervention of behavioral activation (BA) psychotherapy. The active sham condition includes brief stimulation, mimicking the skin sensations associated with tACS, assisting with blinding the participant's assignment.
62013660|NCT06309082||Diabetic foot ulcer limb salvage group|The patient was treated without amputation
62013661|NCT06309082||Diabetic foot ulcer without limb salvage group|The treatment option for the patient was amputation
62201975|NCT06507462||Patients with clinical suspicion of prostate cancer and have PI-RADS score of 3|Patients with clinical suspicion of prostate cancer (see inclusion criteria) and have PI-RADS score (results of mpMRI) of 3.
62201976|NCT02474719|EXPERIMENTAL|conventional scheme followed by alternate schem|"The first day of the study, patients receive an adapted conventional peritoneal dialysis scheme: 2 cycles of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 2 cycles of purification (stasis: 110 mn ; volume 1200cc/m²).~The second day, patients receive an adapted and alternate scheme: 1 cycle of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 1 cycle of purification (stasis: 110 mn ; volume 1200cc/m²), the two cycles being repeated once."
62215093|NCT02835118|PLACEBO_COMPARATOR|Placebo|Two oral doses of placebo for surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
62402530|NCT00731094|NO_INTERVENTION|Attention Control|Generalized baseline healthy lifestyle education and suggestion to increase physical activity, with a 12-month follow-up via postal mail of 14 wellness newsletters focused on health issues other than physical activity
62402531|NCT04156802|EXPERIMENTAL|Real TBS to the mPFC|Two sessions of real Theta Burst Stimulation (TBS) will be delivered to the medial prefrontal cortex (mPFC) over the course of the treatment and maintenance phase of the study
62402532|NCT04156802|SHAM_COMPARATOR|Sham TBS to the mPFC|Two sessions of sham Theta Burst Stimulation (TBS) will be delivered to the medial prefrontal cortex (mPFC) over the course of the treatment and maintenance phase of the study
62402533|NCT04156802|EXPERIMENTAL|Real TBS to the MC|Two sessions of real Theta Burst Stimulation (TBS) will be delivered to the somatomotor cortex (MC) over the course of the treatment and maintenance phase of the study
62013662|NCT02242877||Isolated systolic hypertension|
62013663|NCT02242877||Systolic and diastolic hypertension|
62013664|NCT01498926|EXPERIMENTAL|Glycerol|
62013665|NCT01498926|ACTIVE_COMPARATOR|Mannitol|
62215094|NCT00610740|EXPERIMENTAL|Patients Treated with CerviPrep™|CerviPrep™, a novel drug delivery device, was developed specifically for applying pharmaceuticals directly on the cervix. It consists of a syringe-like tube attached to a plastic cap that covers the cervix. Drug can be delivered through the tube, directly to the cervix without spillage onto vaginal or vulvar tissues.
62215095|NCT00482690|EXPERIMENTAL|Nicotine replacement therapy (NRT)|open label NRT self comparator design
62215096|NCT05402696||Large non-pedunculated colorectal polyp (LNPCP)|Patients referred to St. Paul's Hospital for endoscopic management of a large (≥20mm) non-pedunculated colorectal polyp (LNPCP).
62013666|NCT05436457||18-24 Year Olds in Emergency Department|Individuals age 18-24 recruited from one of the four study sites in Flint (1 hospital), Seattle (1 hospital), and Philadelphia (2 hospitals)
62013667|NCT03374124||postoperational CRS|observe the symptoms and endoscopic appearance
62013668|NCT04948944|EXPERIMENTAL|active transcranial direct current stimulation|The investigators use Soterix mini-CT Stimulator to deliver 30 minutes 2mAmp tDCS to the bilateral DLPFC (optimized lateral electrode placement montage), with the the anode on the left hemisphere and the cathode on the right hemisphere. The electrodes are rubber and are placed in an MRI compatible holder and affixed with conductive paste. The investigators will use a bespoke headstrap to place the electrodes, which are held in place by the conductive paste.
62215097|NCT00741390|OTHER|Arm A|In Visit 1 subjects tested BD/33G, OTM/33G, and OTM/28G devices. In Visit 2 subjects tested BD/33G and OTM/28G. See purpose for additional information.
62215098|NCT00741390|OTHER|Arm B|In Visit 1 subjects tested BD/33G, OTM/33G and OTU/28G devices. In Visit 2 subjects tested BD/33G and OTU/28G. See purpose for additional information.
62215099|NCT00741390|OTHER|Arm C|In Visit 1 subjects tested BD/33G, OTM/33G and ACC/28G devices. In Visit 2 subjects tested BD/33G and ACC/28G. See purpose for additional information.
62215100|NCT00741390|OTHER|Arm D|In Visit 1 subjects tested BD/33G, OTM/33G and OTM/28G devices. In Visit 2 subjects tested OTM/33G and OTM/28G. See purpose for additional information.
62215101|NCT00935818|ACTIVE_COMPARATOR|varenicline and buproprion SR|Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
62215102|NCT00935818|PLACEBO_COMPARATOR|varenicline and placebo|Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
62215103|NCT02831543|EXPERIMENTAL|Motireb 5/100 mg t.i.d|Motireb 5/100 mg t.i.d + Placebo of Mosapride citrate t.i.d
62201977|NCT02474719|EXPERIMENTAL|alternate scheme followed by conventional scheme|"The first day of the study, patients receive an adapted and alternate peritoneal dialysis scheme: 1 cycle of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 1 cycle of purification (stasis: 110 mn ; volume 1200cc/m²), the two cycles being repeated once.~The second day, patients receive an adapted conventional scheme: 2 cycles of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 2 cycles of purification (stasis: 110 mn ; volume 1200cc/m²)."
62201978|NCT00557557|EXPERIMENTAL|IHP with Oxaliplatin and 5-Fluorouracil (5-FU)|Isolated Hepatic Perfusion with Oxaliplatin and 5-Fluorouracil (5-FU)
62201979|NCT00384735||1A|Intensive - 3 monthly follow up
62201980|NCT00384735||1B|Intensive - 6 monthly follow up
62201981|NCT00384735||IIA|Cost Effective - 3 monthly follow up
62201982|NCT00384735||IIB|Cost Effective - 6 monthly follow up
62201983|NCT00802347|EXPERIMENTAL|I5NP|
62201984|NCT00802347|PLACEBO_COMPARATOR|Saline|
62785576|NCT01808235|EXPERIMENTAL|Oral health intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
62013669|NCT04948944|SHAM_COMPARATOR|sham transcranial direct current stimulation|In the sham stimulation mode, the device shows pseudorandom numbers on the screen that look like real stimulation is being delivered. The device gives a low level of stimulation at the very beginning and at the very end of the stimulation session (30 seconds ramp up and 30 seconds ramp down) in order to recreate the feeling of tingling that subjects perceive at the beginning and end of real stimulation.
62013670|NCT02668380||Apatinib|Apatinib Tablets: 850 mg,po, once daily , 28 days for a cycle
62201985|NCT00605332|EXPERIMENTAL|1|Investigative Device (Crux Biomedical IVC Filter) will be evaluated for its ability to capture thrombus for the prevention of pulmonary embolism.
62013671|NCT03766009|ACTIVE_COMPARATOR|Arm I (surgical consultation)|Prior to institutional crossover, participants receive care as per usual care.
62013672|NCT03766009|EXPERIMENTAL|Arm II (web-based breast cancer surgery decision aid)|Following a 10 week implementation period, at the time of institutional crossover, participants will receive a web-based decision aid prior to the surgical consultation..
62013673|NCT05281367|EXPERIMENTAL|Breast milk odor group|It is a non-pharmacological method of pain control in which 3 cc of breast milk will be dripped onto a sterile pad and It will be placed at a distance of 10 cm from the nose of the newborn. Precisely, premature newborns' own mothers' milk will be used. For this, mothers of newborns will be contacted and breast milk will be provided for the day of the procedure.
62201986|NCT02042027|ACTIVE_COMPARATOR|Group A|Gamunex-C 50 mg subconjunctival injections, in addition to standard of care treatment (steroids and cyclosporine). One dose of Gamunex-C injection delivered four weeks prior to corneal transplant surgery and one dose at the time of corneal transplantation. Dose to be repeated if recurrence of corneal neovascularization
62201987|NCT02042027|ACTIVE_COMPARATOR|Group B|Gamunex-C 50 mg subconjunctival injections, one dose injected for patients with active disease from corneal melts (peripheral ulcerative keratitis; Mooren's ulcer), ocular cicatricial pemphigoid, or anterior uveitis refractory to conventional therapy.
62201988|NCT03514316|ACTIVE_COMPARATOR|Scalpel Gingivectomy|Patients treated with Scalpel Gingivectomy on the labial side of the anterior maxillary teeth
62201989|NCT03514316|ACTIVE_COMPARATOR|Laser Gingivectomy|Patients treated with Laser Gingivectomy on the labial side of the anterior maxillary teeth
62201990|NCT03514316|ACTIVE_COMPARATOR|Nonsurgical periodontal treatment|Patients treated with a full-mouth periodontal debridement
62215104|NCT02831543|ACTIVE_COMPARATOR|Mosapride citrate t.i.d|Placebo of Motireb 5/100 mg t.i.d + Mosapride citrate t.i.d
62215105|NCT02831543|PLACEBO_COMPARATOR|Placebo t.i.d|Placebo of Motireb 5/100 mg t.i.d + Placebo of Mosapride citrate t.i.d
62013674|NCT05281367|EXPERIMENTAL|Facilitated tucking group|It is a non-pharmacological method of pain control in which the arms and legs are slowly contracted and placed close to the body. In this method, the baby is placed on its side, the baby's back is gently bent, the legs are folded at an angle of more than 90 degrees, the shoulders are folded up to 90 degrees, and the care hands are placed either on the head near the mouth or Placed on the baby's face.
62201991|NCT02120287|EXPERIMENTAL|BZ-SRS with Bevacizumab|"All patients will receive Border Zone Stereotactic Radiosurgery (BZ-SRS) and additionally receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by 10 mg/kg/day every 14 days until progression.~One to 14 days before BZ- SRS procedure, patients at centers with MRS experience will undergo standard brain MRI /MRS"
62201992|NCT04264377||Healthy|26 healthy subjects
62201993|NCT04264377||Asthma|26 subjects with asthma
62201994|NCT05884177||Greenlanders|Subjects born in Greenland with parents born in Greenland
62201995|NCT05884177||non-Greenlanders|Subjects not born in Greenland with parents not born in Greenland
62201996|NCT05852665|EXPERIMENTAL|Ultrasound-guided surgery|
62201997|NCT05222204|EXPERIMENTAL|IP|intravenous AG+ IP cisplatin
62201998|NCT04365231|EXPERIMENTAL|Hydroxychloroquine and azithromycin treatment|"hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.~- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days."
62201999|NCT04365231|ACTIVE_COMPARATOR|conventional management of patients|Regular management of patients
62013675|NCT05281367|EXPERIMENTAL|Non-nutritive sucking group|It is a non-pharmacological method used to control pain in infants. In this method, babies suck without receiving the nutrient. This can be done by a pacifier, a parent's hand or a nurse.
62202000|NCT03620539|NO_INTERVENTION|Control|Participants randomized to the control condition will be asked to maintain their normal daily habits.
62202001|NCT03620539|EXPERIMENTAL|Sauna|The sauna intervention will consist of 20 to 30 minute sauna bathing sessions within a dry Finnish sauna, performed 4 times per week.
62202002|NCT05105776|NO_INTERVENTION|Physiotherapy only|
62202003|NCT05105776|EXPERIMENTAL|Active galvanic stimulation (GVS; week 1) to sham GVS (week 2)|Physiotherapy + translingual neurostimulation provided throughout
62202004|NCT05105776|EXPERIMENTAL|Sham GVS (week 1) to active GVS (week 2)|Physiotherapy + translingual neurostimulation provided throughout
62202005|NCT05105776|EXPERIMENTAL|Active GVS throughout weeks 1 + 2|Physiotherapy + translingual neurostimulation provided throughout
62202006|NCT01934764||autoimmune disease|
62202007|NCT00429013|NO_INTERVENTION|2|no medical device
62202008|NCT00429013|EXPERIMENTAL|1|medical device
62202009|NCT01529320|EXPERIMENTAL|Adventan® (metilprednisolona aceponato 0,1%)|
62202010|NCT03312023|EXPERIMENTAL|Group A (LDV/SOF for low replicative HBV)|12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B in low replicative state.
62202011|NCT03312023|EXPERIMENTAL|Group B (LDV/SOF for viral suppressed HBV)|12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B, virally suppressed.
62202012|NCT03312023|EXPERIMENTAL|Group C (SOF for low replicative HBV)|"12 weeks treatment with sofosbuvir (Sovaldi) for chronic hepatitis B in low replicative state.~Randomized 1:1 with Group D."
62202013|NCT03312023|EXPERIMENTAL|Group D (LDV for low replicative HBV)|"12 weeks treatment with ledipasvir for chronic hepatitis B in low replicative state.~Randomized 1:1 with Group C."
62202014|NCT01549704|OTHER|Arm RP|first blockade: ropivacaine 7,5mg/ml 30 ml second blockade: placebo: saline 30 ml
62202015|NCT01549704|OTHER|Arm PR|first blockade: placebo: saline 30 ml second blockade: ropivacaine 7,5mg/ml 30 ml
62202016|NCT01290276|EXPERIMENTAL|Ond-PR1 followed by (Ond-PR1 + MPh-IR)|Oral dose of 8 mg of ondansetron pulsatile-release formulation 1 followed by Oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)
62402534|NCT04156802|SHAM_COMPARATOR|Sham TBS to the MC|Two sessions of sham Theta Burst Stimulation (TBS) will be delivered to the somatomotor cortex (MC) over the course of the treatment and maintenance phase of the study
62579135|NCT02410915|EXPERIMENTAL|Study Group|Intervention: Hybrid Assistive Limb (HAL); gait training in combination with conventional training. Training with the exosceleton Hybrid Assistive Limb (HAL) is performed in 1 session per day, 4 days per week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective time). Training with HAL is performed in combination with body-weight support system and on a treadmill. The training program is performed by 2 physiotherapists, who have been trained in the HAL method.
62579136|NCT02410915|ACTIVE_COMPARATOR|Control Group|Intervention: Conventional gait training is individualized and performed according to current practice (approximately 30-60 minutes/session, 5 days a week) and may include standing, weight shifting, stepping, over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support. Conventional gait training is offered to both study groups.
62579137|NCT01697098|EXPERIMENTAL|12 hours Dexamethasone|Those patient will be given 12 hours dexamethasone after randomization
62579138|NCT01697098|EXPERIMENTAL|24 hours Dexamethasone|Those patient will be give 24 hours dexamethasone after randomization
62579139|NCT05791136|EXPERIMENTAL|Radiotherapy Sequential Toripalimab|Radiotherapy:Intensity-modulated radiotherapy (IMRT) Immunotherapy: Toripalimab
62202017|NCT01290276|EXPERIMENTAL|Ond-PR2 followed by (Ond-PR2 + MPh-IR)|Oral dose of 8 mg of ondansetron pulsatile-release formulation 2 followed by Oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
62202018|NCT05350046|EXPERIMENTAL|Physically active adults|A cohort of physically-active adults will use ear-worn prototype devices and established gold standard and comparator devices during rest periods, physical activity, and various activities of daily living.
62202019|NCT03916406|EXPERIMENTAL|Sequence 1|midazolam alone followed by combination of PF 06835919 and midazolam
62402535|NCT02455960|EXPERIMENTAL|Arginine|Participants need to take arginine 3 g/day orally for 3 days before CT with contrast media injection
62402536|NCT02455960|PLACEBO_COMPARATOR|Placebo|Participants need to take placebo (corn powder) 3 g/day orally for 3 days before CT with contrast media injection
62402537|NCT04433260||Cases|Doctors, nurses and other healthcares ≥ 18 years of age in direct contact with patients potentially infected with COVID-19
62402538|NCT04433260||Internal Control|Healthcare /NHS Administrative staff who are working in the hospital, but not directly in contact with patients potentially infected with COVID-19.
62402539|NCT04433260||Population Control|Non-healthcare/non-NHS academic staff who are not working in the environment where patient exposure is expected.
62402540|NCT04433260||Follow-up cases|Doctors, nurses and other healthcare workers ≥ 18 years of age in direct contact with patients potentially infected with COVID-19 consenting to receive follow-up surveys (n \~ 400)
62402541|NCT04433260||Follow-up controls|Healthcare Administrative staff who are working in the hospital, not at risk of work-related exposure to patients potentially infected with COVID-19 (n\~80)
62402542|NCT02620826|EXPERIMENTAL|Indirect pulp therapy|Primary molars will be treated with indirect pulp therapy using resin-modified glass ionomer (Vitrebond Plus).
62402543|NCT02620826|ACTIVE_COMPARATOR|Pulpotomy|Primary molars treated with MTA pulpotomy.
62579140|NCT04615169|EXPERIMENTAL|multi-component cognitive intervention using simulated everyday tasks (MCI-SET)|the 12-week intervention, 2 hours weekly session of MCI-SET.
62579141|NCT03299179||Natural cycle|15 female volunteers, not using hormonal contraception, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 3 times: during the follicular phase, during ovulation and during luteal phase.
62579142|NCT03299179||Anti-conception|15 female volunteers, using hormonal contraception pill Deso 20, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 2 times: during the pill-week and during the pill-free week.
62579143|NCT02552069||Tritanium® cup|
62579144|NCT04328129|EXPERIMENTAL|Primary case|Subject with laboratory-confirmed coronavirus SARS-CoV-2 infection by polymerase chain reaction (PCR)
62579145|NCT04328129|EXPERIMENTAL|Family contact|Subject who lived in the household of the primary case while the primary case was symptomatic
62579146|NCT03868982|EXPERIMENTAL|NAVA group|Participent in this group will received NAVA for two days
62579147|NCT03868982|NO_INTERVENTION|Control group|Participent in this group will received standard care
62579148|NCT05886140|EXPERIMENTAL|Carrilizumab with albumin-binding paclitaxel|All enrolled patients received carrilizumab combined with albumin-binding paclitaxel.
62579149|NCT02118727|ACTIVE_COMPARATOR|Memantine|Up to 20 mg memantine taken by mouth twice a day for 36 weeks
62579150|NCT02118727|PLACEBO_COMPARATOR|Placebo|Up to 2 placebo tablets taken by mouth twice a day for 36 weeks
62579151|NCT00030667|EXPERIMENTAL|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62579152|NCT03683927|EXPERIMENTAL|Probiotics|Probiotics consist on Bacillus clausii in a plastic vial that will be administered to the infant 4 times a week
62579153|NCT03683927|PLACEBO_COMPARATOR|Placebo group|Sterile water contained in a plastic vial will be administered to the infant 4 times a week
62579154|NCT02397499|EXPERIMENTAL|LIPO-202|Experimental arm
62402544|NCT02730832|EXPERIMENTAL|Patients with schizophrenia|
62402545|NCT03172910|EXPERIMENTAL|Cohort 1|ciraparantag (60 mg)
62402546|NCT03172910|EXPERIMENTAL|Cohort 2|ciraparantag (120 mg)
62402547|NCT03172910|EXPERIMENTAL|Cohort 3|ciraparantag (180 mg)
62402548|NCT03172910|EXPERIMENTAL|Cohort 4|ciraparantag (30 mg)
62402549|NCT03172910|PLACEBO_COMPARATOR|Placebo|placebo (saline for injection)
62402550|NCT03841591|ACTIVE_COMPARATOR|Insulin Group|This includes women with GDM allocated to receive insulin treatment. Starting dose will be 30unit (20 unit intermediate dose + 10 unit rapid acting insulin) in the morning and before breakfast). In the 2nd trimester, we will start with half of the previous dose and if post dinner glucose level remain elevated additional injection of rapid acting insulin will be given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin.
62202020|NCT03916406|EXPERIMENTAL|Sequence 2|PF 06835919 in combination with midazolam followed by midazolam alone
62202021|NCT04849767||Transgender people living with HIV|Transgender person Living with HIV Followed in clinical service
62202022|NCT05690997|OTHER|Intensive Treatment Group|SBP target 120-129 mmHg
62202023|NCT05690997|OTHER|Standard Treatment Group|SBP target 130-140 mmHg
62202024|NCT03328104|EXPERIMENTAL|Everolimus in combination with standard chemotherapy|A treatment course lasts 28 days, during which participants take everolimus by mouth every day and also get standard chemotherapy via IV on certain days.
62202025|NCT01682772|EXPERIMENTAL|Olaparib 400mg|Oral Olaparib at a dose of 400mg twice daily, continuously on a 28 day cycle
62202026|NCT01682772|EXPERIMENTAL|Olaparib 300mg|Oral Olaparib at a dose of 300mg twice daily, continuously on a 28 day cycle
62202027|NCT03459872||Acupuncture Intervention group|RU-Fit gathers measurements of fine motor control were gathered from this group before and after acupuncture treatments.
62202028|NCT03459872||Control/ Non-Intervention|This group received no intervention but still had measurements of fine motor control gathered from RU-Fit medical device.
62202029|NCT02594657|EXPERIMENTAL|pedal rate ON 50 RPM|
62579155|NCT02397499|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62579156|NCT02088060|EXPERIMENTAL|Cannabidiol|Cannabidiol capsules 2x200 mg twice a day and placebo olanzapine capsule once a day over 4 weeks
62579157|NCT02088060|ACTIVE_COMPARATOR|Olanzapine|Olanzapine capsule 15mg once a day and placebo cannabidiol capsules twice a day over 4 weeks
62202030|NCT02594657|EXPERIMENTAL|pedal rate on 80 RPM|
62202031|NCT05646563|EXPERIMENTAL|Cohort 1|6 Soliris-treated patients will receive an intravenous (IV) dose of NM8074 at 10 mg/kg weekly for 4 weeks. Patients will then discontinue Soliris treatment and be administered NM8074 at 20 mg/kg IV every 2 weeks for the remainder of the treatment period (8 weeks). At the end of the treatment period, patients will resume Soliris monotherapy as prescribed.
62202032|NCT05646563|EXPERIMENTAL|Cohort 2|6 Soliris-treated patients will receive an intravenous (IV) dose of NM8074 at 10 mg/kg for 4 weeks. Patients will then continue receiving Soliris while being administered NM8074 as a combination therapy at 20 mg/kg IV every 2 weeks for the remainder of the treatment period (8 weeks). At the end of the treatment period, patients will resume Soliris monotherapy as prescribed.
62202033|NCT03808818|ACTIVE_COMPARATOR|Arm A (smoking assessment, quitting advice, Quitline referral)|Patients receive an assessment of smoking status and provision of quitting advice through the screening and referral process, and are referred to the NCI Smoking Quitline.
62202034|NCT03808818|EXPERIMENTAL|Arm B (virtual counseling sessions, NRT)|Patients receive an initial virtual counseling session with a study-designated tobacco treatment coach via MGH TeleHealth over 40 minutes and up to 10 more virtual counseling sessions over 15 minutes for approximately 6 months. Patients also receive up to 12 weeks of NRT (patch and lozenge combined or alone).
62202035|NCT04395300||Healthcare workers|Physicians, Nurses, Laboratory workers, radiology technicians
62202036|NCT04822077|EXPERIMENTAL|Proton radiotherapy|"Proton radiotherapy with RBE doses:~* Patients with radical surgery and unfavourable histology (B2, B3, C) and/or Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).~* Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)~* Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)"
62202037|NCT06045715||follow-up|patients were follow-up with different time intervals
62202038|NCT05003024|ACTIVE_COMPARATOR|TOF scan train of four ratio monitoring|Recovery of train of four ratio after sugammadex administration
62202039|NCT05003024|EXPERIMENTAL|ITF device tetanus stimulation monitoring|Recovery of tetanus 100 Hz ratio after sugamamdex administration
62202040|NCT04761432|EXPERIMENTAL|Intervention arm|Thirty (30) adult patients will be enrolled in this study. Each patient will be monitored simultaneously with the neoGuard device and a conventional patient monitor. Paired readings for temperature, respiratory rate, pulse rate and oxygen saturation will be captured every second for a maximum observation period of 1 hour.
62202041|NCT01546870||pediatric heart transplant recipients|
62202042|NCT01409629||Activity choices|Observe individuals' activity choices after playing a computer game.
62202043|NCT03333213|EXPERIMENTAL|Gua Sha therapy|Patients' backs were first covered with Tumarol N Balsam. The study physician then applied a round-edged instrument (the inside smooth edged lip of a metal cap) to patients' skin in downward strokes. Patients were treated twice with a 7-day interval.
62202044|NCT03333213|NO_INTERVENTION|Waitlist control group|Treatments in the control group were not regulated but patients were asked to continue their self-directed medical care. They were offered the Gua Sha therapy once the trial was concluded.
62202045|NCT03031496|EXPERIMENTAL|Test A followed by Ref B of HCTZ 50mg+ Amiloride HCl 5mg|Eligible participants following an overnight fast of at least 10 hours, will be administered the study drug orally with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
62202046|NCT03031496|EXPERIMENTAL|Ref B followed by test A of HCTZ 50mg + Amiloride HCl 5mg|Eligible participants following an overnight fast of at least 10 hours, will be administered the study drug orally with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
62202047|NCT01886287|EXPERIMENTAL|Octreotide Long-acting Release (LAR)|Octreotide LAR will be administered at a dose of 60 mg intramuscularly (IM) every 4 weeks.
62202048|NCT04148989|NO_INTERVENTION|Pre-implementation usual care (intervention site)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the intervention hospital emergency department before implementation of sepsis care reorganization (Code Sepsis implementation). The primary analysis will focus on the subset of patients with sepsis.
62202049|NCT04148989|EXPERIMENTAL|Code Sepsis post-implementation (intervention site)|Adult patients age ≥18 years presenting to the ED of the intervention hospital emergency department after implementation of sepsis care reorganization (Code Sepsis implementation). The primary analysis will focus on the subset of patients with sepsis.
62202050|NCT04148989|NO_INTERVENTION|Pre-implementation usual care (control sites)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the control hospital emergency department before implementation of sepsis care reorganization (Code Sepsis implementation) at the intervention hospital. The primary analysis will focus on the subset of patients with sepsis.
62202051|NCT04148989|NO_INTERVENTION|Post-implementation usual care (control sites)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the control hospital emergency department after implementation of sepsis care reorganization (Code Sepsis implementation) at the intervention hospital. The primary analysis will focus on the subset of patients with sepsis.
62202052|NCT03232931|EXPERIMENTAL|Multisensory Intervention|Preterm infants in the NICU who are randomized to receive a multisensory intervention, in addition to the standard of care. The multisensory intervention uses recordings of the parents' voices and nurturing touch administered in the NICU during 12 to 23 sessions of standardized, therapist-administered, auditory-tactile stimulation, dispersed over a 2 to 3 week period. The intervention includes 2 components: (1) holding and light pressure containment of the infant against the hospital-gown covered chest of the therapist for tactile and non-specific auditory stimulation simultaneous with (2) playing of mother's voice contingent on infant pacifier sucking. Additionally, a gauze square scented with parent's skin will be used to provide olfactory stimulation.
62202053|NCT03232931|OTHER|Standard of Care|Preterm infants in the NICU who are randomized to receive the standard of care. The standard care for preterm infants in the NICU currently follows medical protocols of skin-to-skin holding and exposure to recordings of parent's voice.
62202054|NCT06431100||cell therapy interventional single arm|According to the cell transfusion protocol, GK01 cells were given at a certain dose level to observe the safety and tolerability of the patients after the transfusion, explore the pharmacokinetic/pharmacodynamic characteristics after the transfusion, and preliminarily evaluate the effectiveness of the experimental drug GK01 cells according to the RECIST 1.1 standard.
62202055|NCT06387108|EXPERIMENTAL|2 hours online training|2 hours online training for educational professionals about depression and mental health in youths
62202056|NCT04835792||Previously Treated for Lyme Disease|
62202057|NCT04835792||Healthy Volunteers|
62202058|NCT01384162|EXPERIMENTAL|sNN0029, ICV infusion|
62202059|NCT00780559|OTHER|Tailored Diet and Physical Activity|Subjects will receive an individually tailored diet and physical activity enhancement program
62202060|NCT00780559|OTHER|Standard of Care|Subjects will be told to reduce their baseline weight by 7% and exercise for 150 minutes/week. There is no tailored, directed program.
62579158|NCT02088060|PLACEBO_COMPARATOR|Placebo|Placebo cannabidiol capsules twice a day and placebo olanzapine capsule once a day over 4 weeks
62579159|NCT04444206|EXPERIMENTAL|CL and CCI screening|The Cervical lenght (CL) and the Consistence Cervix Index (CCI) will be evaluated by transvaginal ultrasound. CL and CCI measurements will be expected in the first trimester, between 11 and 13 weeks + 6 days, in the second trimester, between 19 and 22 weeks and in the third trimester between 29 and 32 weeks during the ultrasound examinations required by the monitoring routine of pregnancy, in accordance with current national guidelines.
62579160|NCT04444206|NO_INTERVENTION|No CL and CCI screening|The investigators collect data of these pregnant women without any additional ultrasound examination
62579161|NCT02367222||Exposed to Arepanrix™ Cohort|All individuals with Manitoba Immunization Monitoring System (MIMS) record of H1N1 (Arepanrix™) and/or seasonal influenza vaccination during the influenza season 2009/2010 (15 September 2009 to 15 March 2010).
62579162|NCT02367222||Unexposed to Arepanrix™ Cohort|All individuals registered with Manitoba Health (MH) during the study period but with no MIMS record for H1N1 (Arepanrix™) and seasonal influenza vaccination during the influenza season 2009/2010 (15 September 2009 to 15 March 2010).
62579163|NCT06502158|EXPERIMENTAL|Mifepristone|Patients will be randomized to Mifepristone-alone in a 1:1 manner prior to procedural abortions. A paracervical block of 20 cubic centimeters (cc) 1% lidocaine, with or without vasopressin, will be administered in accordance with standard practices.
62579164|NCT06502158|EXPERIMENTAL|Misoprostol|Patients will be randomized to Misoprostol-alone in a 1:1 ratio prior to procedural abortions. A paracervical block of 20cc 1% lidocaine, with or without vasopressin, will be administered in accordance with standard practices.
62579165|NCT01972438|EXPERIMENTAL|ASEDs - Saline|Participants administer autologous serum eye drops (ASEDs) daily for the first three months, then crossover to administer control (normal saline) eye drops daily beginning at Month 3 through Month 6.
62579166|NCT01972438|PLACEBO_COMPARATOR|Saline - ASEDs|Participants administer control (normal saline) eye drops daily for the first three months, then crossover to administer autologous serum eye drops (ASEDs) daily beginning at Month 3 through Month 6.
62579167|NCT01682226|EXPERIMENTAL|A: standard risk group|This is a 2 arm phase 2 study to obtain an estimate of the speed of neutrophil recovery after myeloablative CBT with abrogation of prolonged cytopenia by infusion of haploidentical family member T-cell depleted PBSC in patients with high-risk or advanced hematologic malignancies.
62579168|NCT01682226|EXPERIMENTAL|B: high risk group|This is a 2 arm phase 2 study to obtain an estimate of the speed of neutrophil recovery after myeloablative CBT with abrogation of prolonged cytopenia by infusion of haploidentical family member T-cell depleted PBSC in patients with high-risk or advanced hematologic malignancies.
62579169|NCT02841280|EXPERIMENTAL|Chlorthalidone|Subjects with stage 4 chronic kidney disease (CKD) and poorly controlled hypertension confirmed by 24 hour ambulatory blood pressure monitoring will be randomized into two groups, one receiving placebo and one receiving a diuretic called chlorthalidone (12.5 mg at randomization). Doubling of the dose of the diuretic (up to 50 mg) or placebo will occur every 4 weeks if required by home blood pressure (BP) results.
62579170|NCT02841280|PLACEBO_COMPARATOR|Placebo|Subjects with stage 4 CKD and poorly controlled hypertension confirmed by 24 hour ambulatory blood pressure monitoring will be randomized into two groups, one receiving placebo and one receiving a diuretic called chlorthalidone (12.5 mg at randomization). Doubling of the dose of the diuretic (up to 50 mg) or placebo will occur every 4 weeks if required by home BP results.
62579171|NCT01798810|EXPERIMENTAL|Supplemental Perioperative Oxygen (80% FiO2)|After intubation, patients in the Treatment Group will receive intraoperative inspired oxygen set at 80 percent (FiO2 of 0.80). Post-extubation, patients in the treatment arm will be placed on high flow non-re-breather mask at 15L/min for up to 2 hours postoperatively and then transitioned to nasal cannula, which will be weaned as tolerated.
62579172|NCT01798810|NO_INTERVENTION|Control (30% FiO2)|After intubation, patients in the control arm will receive typical standard of care intraoperative inspired oxygen of 30 percent (FiO2 of 0.30). Post-extubation, patients in the control arm of the study will be placed on a nasal cannula at 4L/min to maintain SaO2≥92% as determined by pulse oximetry. This will be maintained for up to 2 hours and then weaned as tolerated.
62579173|NCT00327873|EXPERIMENTAL|A|Oxygen
62013676|NCT05281367|EXPERIMENTAL|control grup|The control group will consist of 36 premature newborns who are routinely applied in the clinic. In the clinic where the research was conducted, no attempt is made to reduce pain during heel stick.
62013677|NCT06573528|EXPERIMENTAL|Cohort A1: 0.2 mg CS060380|Eight healthy subjects were randomly assigned to take 0.2 mg of CS060380 or placebo, Six of the subjects were on study drug and two on placebo (About 240L of water on an empty stomach).
62013678|NCT06573528|EXPERIMENTAL|Cohort A2: 1 mg CS060380|Eight healthy subjects were randomly assigned to take 1 mg of CS060380 or placebo, Six of the subjects were on study drug and two on placebo (About 240L of water on an empty stomach).
62013679|NCT06573528|EXPERIMENTAL|Cohort A3: 2 mg CS060380|Eight healthy subjects were randomly assigned to take 2 mg of CS060380 or placebo on day 1, Six of the subjects were on study drug and two on placebo (About 240L of water on an empty stomach). Followed by a 10 day washout period, subjects in fed state will receive the same single oral dose of CS060380 2mg or placebo on day 11.
62013680|NCT06573528|EXPERIMENTAL|Cohort A4: 5 mg CS060380|Eight healthy subjects were randomly assigned to take 5 mg of CS060380 or placebo, Six of the subjects were on study drug and two on placebo (About 240L of water on an empty stomach).
62202061|NCT01981226|EXPERIMENTAL|Extracoporeal shock wave|Extracoporeal shock wave, 3000 shots/time, once a week for 3 weeks, treatment duration:30 minutes/time, shock wave freqency：2-4Hz, energy level:0.8-1.0 mJ/mm2
62202062|NCT05028114|EXPERIMENTAL|Part 1 (Formulation Optimisation)|Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided 30 minutes after study drug administration. There will be 4 different formulations of the study drug and participants will be randomised to one of 4 sequences. There will be a washout of 2 days between each administration.
62202063|NCT05028114|EXPERIMENTAL|Part 2 (Placebo Assessment)|"Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided either 30 minutes before or after study drug administration, depending on the results of the food effect assessment.~Participants are randomised to 1 of 2 sequences (tricaprilin formulation - matching placebo; matching placebo - tricaprilin formulation) with a 2-day washout between periods."
62202064|NCT05028114|EXPERIMENTAL|Part 3 (Titration Tolerability)|"Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided either 30 minutes before or after study drug administration, depending on the results of the food effect assessment.~Participants will be randomised to either study drug or the matching placebo."
62402551|NCT03841591|ACTIVE_COMPARATOR|Metformin Group|This includes women with GDM allocated to receive metformin treatment. They will receive an initial metformin dose of 500 mg once or twice daily (according to initial blood glucose level) with food and increased 500 mg every one or two weeks toward targets or up to a maximum daily dose of 2500 mg divided doses with each meal.
62579174|NCT00327873|ACTIVE_COMPARATOR|B|Medical Air
62785577|NCT05529836|EXPERIMENTAL|electroacupuncture(EA) group|The participants in EA group will receive acupuncture with PSD at bilateral Hegu (LI4), bilateral Quchi (LU5), bilateral Xuehai (SP10) and bilateral San Yinjiao (SP6). After skin disinfection, followed at an angle of 90°, acupuncture needles were inserted approximately 50 to 60 mm into the skin. When achieving qi, connect the four pairs of electrodes, two each on bilateral Quchi (LI4) and Hegu (LI11), two each on bilateral Xuehai (SP10) and San Yinjiao (SP6), and they are all ipsilateral to one another. The duration of the electroacupuncture stimulation is 30 minutes, and the current intensity ranges from 1 to 5 mA with a continuous wave of 20 Hz. For two weeks straight, the participants will have three therapy sessions each week (preferably every other day), for a total of six sessions.
62202065|NCT02436291|EXPERIMENTAL|CURE-EX device|twice daily treatment with CURE-EX device for 24-30 weeks
62202066|NCT00728910|ACTIVE_COMPARATOR|Atorvastatin|atorvastatin 10 mg/day by mouth for a total duration of 4 weeks
62202067|NCT00728910|ACTIVE_COMPARATOR|ABT335|ABT335 135 mg/day by mouth added to atorvastatin for a total duration of at least 8
62202068|NCT00728910|ACTIVE_COMPARATOR|ER niacin|ER niacin titrated up to 2 g/day with aspirin 325 mg/day by mouth added to atorvastatin and ABT335 for 10 weeks
62202069|NCT06066411|EXPERIMENTAL|Massage Ball Group|A massage ball will be applied to the patients' hands and feet for 20 minutes.
62202070|NCT06066411|NO_INTERVENTION|Control Group|No application will be made to this group by the researcher.
62202071|NCT00315991|EXPERIMENTAL|BGAT Intervention|Blood Glucose Awareness Training for Parents
62402552|NCT02950727|EXPERIMENTAL|3 bicortical screw|1st group:3 bicortical screws will be used to fix the sagittal split ramus osteotomy.
62402553|NCT02950727|ACTIVE_COMPARATOR|adjustable plate and 2 bicortical screws|adjustable plate and 2 bicortical screws will be used to fix the sagittal split ramus osteotomy.
62402554|NCT00913874|EXPERIMENTAL|1|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
62402555|NCT00913874|ACTIVE_COMPARATOR|2|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
62402556|NCT02799576|EXPERIMENTAL|Curved needle|This will utilize the curved block needle of performance of regional block
62579175|NCT01544842|ACTIVE_COMPARATOR|Tacrolimus|Tacrolimus ointment 0.1%, three times a day for 6-9 weeks.
62579176|NCT01544842|ACTIVE_COMPARATOR|Triamcinolone|Triamcinolone paste 0.1%, three times a day for 3-6 weeks.
62579177|NCT01544842|PLACEBO_COMPARATOR|Placebo|Orabase paste, three times a day for 3-6 weeks.
62579178|NCT02273882||Preterm Infants 29-35 Weeks Gestation <12 months of age|Preterm Infants 29-35 Weeks Gestation \<12 months of age
62202072|NCT00315991|NO_INTERVENTION|Control|Enter PDA data and complete questionnaires only. No intervention received.
62202073|NCT05473611||closed reduction percutaneous fixation method|Patients with closed reduction percutaneous sacroiliac screw fixation of posterior pelvic ring due to unstable pelvic injury
62215106|NCT01639560|ACTIVE_COMPARATOR|Varenicline|1 mg of varenicline twice per day for 12 weeks.
62215107|NCT01639560|PLACEBO_COMPARATOR|placebo|1 placebo tablet twice a day for 12 weeks
62215108|NCT03689660|EXPERIMENTAL|Virtual Reality Training|Virtual reality treatment will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.
62215109|NCT03689660|EXPERIMENTAL|Biofeedback Training|Biofeedback training will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.
62215110|NCT03689660|OTHER|Conventional Rehabilitation|Participants will continue this rehabilitation program if they are already getting rehabilitation in a rehabilitation center. If they do not participate in any rehabilitation program, they will be included in the conventional rehabilitation program by us.
62215111|NCT05769647|EXPERIMENTAL|Virtual Reality Glasses Group|"* Volunteer Information and Approval Form will be filled.~* Physician request, the name and surname of the individual will be checked.~* Patient Information Form and State Anxiety Scale will be filled.~* The video containing the nature walk will be watched by virtual reality. 3 minutes after the individual starts watching the video, the IV catheter insertion attempt will be performed while continuing to watch the video.~* Visual Pain Scale and State Anxiety Scale will be filled within one minute after intravenous catheter placement is completed."
62402557|NCT02799576|NO_INTERVENTION|Traditional needle|This will utilize the traditional block needle of performance of regional block
62785578|NCT05529836|SHAM_COMPARATOR|sham electroacupuncture(SEA) group|Participants in the SEA group will receive sham electroacupuncture with PSD, but not energizing the electropuncture device. Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no electricity output only.
62013681|NCT06573528|EXPERIMENTAL|Cohort A5: 10 mg CS060380|Eight healthy subjects were randomly assigned to take 10 mg of CS060380 or placebo, Six of the subjects were on study drug and two on placebo (About 240L of water on an empty stomach).
62202074|NCT05473611||open reduction anterior sacroiliac approach|Patients with fixation of the posterior pelvic ring by open reduction anterior approach due to unstable pelvic injury
62202075|NCT05473611||open reduction posterior sacroiliac approach|Patients with fixation of the posterior pelvic ring by open reduction posterior approach due to unstable pelvic injury
62402558|NCT01154530|ACTIVE_COMPARATOR|Chlorhexidine mouthwash|Participants randomized to chlorhexidine mouthwash prior to gastroscopy
62579179|NCT06152328|ACTIVE_COMPARATOR|VR group|During the exercise, games will be selected from the movements that focus on upper extremity function and require the use of both extremities. These functions will be to grasp the object with both hands, to throw the object, and to provide the object's rotation by revealing the hand's supination-pronation movement. During these movements, the image of the healthy side will be mirrored to the affected side. Before each exercise, what kind of movement requested from the patient will be shown in the VR environment.
62579180|NCT06152328|ACTIVE_COMPARATOR|Control group|In addition to mirror therapy, Bobath therapy, walking exercises, upper extremity active exercises, proprioceptive neuromuscular facilitation techniques, which are traditional physical therapy and rehabilitation methods, will be applied to the control group. In addition, a virtual environment monitoring session will be conducted in non-interactive virtual environments for 10 minutes after their treatment.
62579181|NCT06098339|EXPERIMENTAL|Lens A, then Lens B|Participants wore Lens A for one month and then Lens B for one month.
62785579|NCT05529836|PLACEBO_COMPARATOR|sham acupuncture(SAC) group|Participants in the SAC group will receive sham acupuncture with PSD and PSN on sham acupoints (the non-meridian and non-acupuncture points). Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no skin penetration, electricity output, or needle manipulation for achieving qi.
62785580|NCT01827527||Healthy Adult|This is a protocol development study, with no interventions or treatments.
62013682|NCT06573528|EXPERIMENTAL|Cohort A6: 20 mg CS060380|Eight healthy subjects were randomly assigned to take 20 mg of CS060380 or placebo, Six of the subjects were on study drug and two on placebo (About 240L of water on an empty stomach).
62202076|NCT04549649|EXPERIMENTAL|Group A (Experimental oocyte triggering approach)|0.2 mg Triptorelin (Decapeptyl; Ferring GmbH) associated with two ampoules of Ovitrelle (Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) will be administered subcutaneously simultaneously for final oocyte triggering.
62402559|NCT01154530|NO_INTERVENTION|No mouthwash|Mouthwash is not performed prior to gastroscopy as is the standard today.
62402560|NCT06084442|ACTIVE_COMPARATOR|combined lateral rectus muscle recession 7mm and hang back technique.|"The technique of combined LR recession 7mm and hang back technique:~A. The muscle is exposed in the usual manner and locking suture is passed through full thickness of the LR muscle using nonabsorbable ethibond suture.~B. The muscle is cut from its insertion site. C. Marking the sclera for the rectus muscle recession. a Measurement from the limbus, or b measurement from the original insertion site.~D. Passage of the needles in the sclera using the crossed swords Technique E. The muscle has been pulled up to its new insertion point and the sutures have been tied and cut and the remainder of the procedure is identical to the standard hang-back method.~The"
62579182|NCT06098339|EXPERIMENTAL|Lens B, then Lens A|Participants wore Lens B one month and then Lens A for one month.
62579183|NCT01385332|ACTIVE_COMPARATOR|Early luteal phase -COH-|We perform an standard antagonist protocol beginning the second day of the menstrual cycle compared with an antagonist protocol beginning in the early luteal phase.
62579184|NCT01385332|ACTIVE_COMPARATOR|Late folicular phase - COH -|We perform an standard antagonist protocol beginning the second day of the menstrual cycle compared with an antagonist protocol beginning in the late follicular phase.
62579185|NCT01831739||Multi-organ|Non-acute presentation, any Scadding stage, evidence of 5 or more organ systems involved, chronic or uncertain clinical course.
62785581|NCT06183073|ACTIVE_COMPARATOR|Caudal block with bupivacaine and dexmedetomidine|Caudal block with bupivacaine 0.25% in a dose of (1 ml / kg) and dexmedetomidine 1μg/ kg.
62785582|NCT06183073|ACTIVE_COMPARATOR|TAP block with bupivacaine|TAP block with bupivacaine 0.25% in a dose of (0.5 ml / kg).
62013683|NCT06573528|EXPERIMENTAL|Cohort B1: 1 mg CS060380|Elevated LDL-C subjects were randomly assigned to take 1 mg of CS060380 or placebo, Six of the subjects were on study drug and two on placebo once daily for a consecutive 14 days.
62013684|NCT06573528|EXPERIMENTAL|Cohort B2: 2 mg CS060380|Elevated LDL-C subjects were randomly assigned to take 2 mg of CS060380 or placebo, Six of the subjects were on study drug and two on placebo once daily for a consecutive 14 days.
62785583|NCT05165758||Diabetic subjects without foot ulcer|27 diabetic subjects without foot ulcer will answer to the SF-36 score (mental health items) and to a french precarit index (EPICES:Evaluation de la précarité et des inégalités de santé dans les Centres d'examens de santé)
62013685|NCT06573528|EXPERIMENTAL|Cohort B3: 5 mg CS060380|Elevated LDL-C subjects were randomly assigned to take 5 mg of CS060380 or placebo, Six of the subjects were on study drug and two on placebo once daily for a consecutive 14 days.
62013686|NCT06573528|EXPERIMENTAL|Cohort B4: 10 mg CS060380|Elevated LDL-C subjects were randomly assigned to take 10 mg of CS060380 or placebo, Six of the subjects were on study drug and two on placebo once daily for a consecutive 14 days.
62013687|NCT05040412|EXPERIMENTAL|Diabetic mellitus patients using insulin|The trachea will be intubated by direct laryngoscopy.
62013688|NCT05040412|EXPERIMENTAL|Diabetic patients using oral antidiabetic drug|The trachea will be intubated by direct laryngoscopy.
62202077|NCT04549649|NO_INTERVENTION|Group B (Routine oocyte triggering approach)|Two ampoules of Ovitrelle® (Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) will be injected subcutaneously for final oocyte triggering.
62785584|NCT05165758||Diabetic subjects with foot ulcer|54 diabetic subjects presenting foot ulcer will answer to the SF-36 score (mental health items) and to a french precarit index (EPICES:Evaluation de la précarité et des inégalités de santé dans les Centres d'examens de santé)
62402561|NCT06084442|ACTIVE_COMPARATOR|combined lateral rectus muscle recession 7mm and Z- tenotomy technique.|"The technique of lateral rectus muscle Z-tenotomy:~A. The muscle is exposed in the usual manner and two hemostats are each placed 80% of the way across the muscle (or tendon) from opposite borders. The hemostats are placed 3 or 4 mm apart.~B. The posterior hemostat is removed, and scissors are used to cut across the muscle in the crushed area. By cutting the muscle in the crushed area, bleeding is kept to a minimum.~C. The hemostat nearer the insertion is removed, and the muscle is cut along the crushed area using small snips with scissors.~D. lengthening of the muscle will occur. Any bleeding is controlled with pressure.~E. After the distal myotomy has been performed, in a very tight muscle, a No. 15 Bard Parker blade can be used to divide the tendon fibers, cutting against the muscle hook. This can be accomplished with a scraping motion with the knife blade at nearly right angles to avoid scleral perforation."
62785585|NCT01280695|PLACEBO_COMPARATOR|Placebo|Placebo capsule once daily
62785586|NCT01280695|EXPERIMENTAL|MSDC-0602 100 mg|MSDC-0602 capsule 100 mg once daily
62785587|NCT01280695|EXPERIMENTAL|MSDC-0602 250 mg|MSDC-0602 capsule 250 mg once daily
62785588|NCT01280695|EXPERIMENTAL|MSDC-0602 500 mg|MSDC-0602 capsule 500 mg once daily
62785589|NCT01280695|ACTIVE_COMPARATOR|Pioglitazone 45 mg|Pioglitazone capsule 45 mg once daily
62785590|NCT02768519|EXPERIMENTAL|OTS167IV|Cohort 1: 0.5 mg, Cohort 2: 1.0 mg, and Cohort 3: 2.0 mg without food on Period 1 Day 1 and with food on Day 1 Period 2.
62785591|NCT02768519|PLACEBO_COMPARATOR|Placebo|Cherry syrup
62785592|NCT03731247|EXPERIMENTAL|OCTAV Patient|The patients who will have a biopsy of skin suspected to be a melanoma, basal cell carcinoma or squamous cell carcinoma will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
62402562|NCT01398540|EXPERIMENTAL|elderly|subjects are at least 60 years old (with no upper age limit), receiving 2 immunisations with IXIARO
62785593|NCT03731247|EXPERIMENTAL|OCTAV Control group|Control group (patients without skin cancer) will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
62785594|NCT03941626|EXPERIMENTAL|CAR-T/TCR-T cells immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
62785595|NCT05998577|EXPERIMENTAL|ESM/Traqq|Use of ESM and Traqq for one week to get a personalised analysis of the abdominal pain and triggerfactors that can be used at the outpatient clinic visit to select an effective treatment option.
62785596|NCT05998577|NO_INTERVENTION|Standard care|Will not be using ESM and Traqq, but will only get a standard outpatient clinic visit together with PDSkeuzehulp to make a decision for a treatment.
62785597|NCT04924998||AL-CM|
62785598|NCT04352023|EXPERIMENTAL|A (IV-PCA group)|IV-PCA drug: Fentanyl 3000 mcg and Oxycodone 100 mg were mixed Normal saline 200 ml
62785599|NCT04352023|EXPERIMENTAL|B (PCEA group)|"PCEA drug: Morphine 5 mg and Ropivacaine 750 mg were mixed Normal saline 400 ml~loading of preadministered Morphine 1 mg and Ropivacaine 11.25 mg"
62785600|NCT05760768|EXPERIMENTAL|Individualized exercise guidance group|Participants accept individualized exercise guidance. They are also managed continuously through WeChat group chat during prenatal clinical interval.
62013689|NCT06448481|EXPERIMENTAL|Intra-dermal purse-string closure on Side A|For all participants, one wound side half will be labeled as A and the other side as B. Side A will be closed with a intra-dermal purse-string closure, and Side B will be closed with a transcutaneous purse-string closure.
62013690|NCT06448481|EXPERIMENTAL|Intra-dermal purse-string closure on Side B|For all participants, one wound side half will be labeled as A and the other side as B. Side B will be closed with a intra-dermal purse-string closure, and Side A will be closed with a transcutaneous purse-string closure.
62402563|NCT01398540|EXPERIMENTAL|young|subjects 18 to 40 years old, receiving 2 immunisations with IXIARO
62402564|NCT06157346||High-altitude|Children live in a high-altitude area of more than 3000 meters.
62402565|NCT06157346||Low-altitude|Children live in a low-altitude area of less than 500 meters.
62785601|NCT05760768|NO_INTERVENTION|Standard clinic prenatal care (control) group|Participants accept regular routine prenatal care following Chinese standard.
62785602|NCT01521663|EXPERIMENTAL|IPX159|IPX159 90 mg daily at week 1 with titration to 180 mg daily at week 2 with possible titration to 270 mg daily at week 3.
62785603|NCT01521663|PLACEBO_COMPARATOR|Sugar Pill|IPX159 90 mg matching placebo daily at week 1 with titration to 180 mg matching placebo daily at week 2.
62785604|NCT01792115|ACTIVE_COMPARATOR|Vit E 200 IU/d|Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.
62785605|NCT01792115|ACTIVE_COMPARATOR|Vitamin E 400|Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.
62785606|NCT01792115|ACTIVE_COMPARATOR|Vitamin E 800|Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.
62785607|NCT02718092|ACTIVE_COMPARATOR|Plastic Stent|Three 7 Fr OR two 10 Fr Plastic Stents will be used
62785608|NCT02718092|ACTIVE_COMPARATOR|Axios FCSEMS|15 mm Axios Fully Covered Self Expanding Metal Stent
62785609|NCT01445080|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62785610|NCT03288922|EXPERIMENTAL|Limited BF OL-HDF with SHF|Limited blood flow pre-dilution online hemodiafiltration using super high-flux dialyzer which had larger pore size than standard high-flux dialyzer was assigned as the new intervention to compare the efficacy of protein-bound toxin removals with the control period.
62785611|NCT03288922|ACTIVE_COMPARATOR|High-efficiency OL-HDF|High-efficiency post-dilution online hemodiafiltration using standard high-flux dialyzer was assigned as the control period.
62785612|NCT04293107||Phase 1: Content Validity Testing|Cohort of 6 parents/carers of children with cerebral palsy and GORD, who will be interviewed regarding the content validity of the PGSQ when used to assess symptoms of GORD in children with cerebral palsy.
62785613|NCT04293107||Phase 2: Reliability (test-retest) Testing|Cohort of 20 parents/carers of children with cerebral palsy and GORD, who will review and complete the adapted version of the PGSQ (post Phase 1) at two time points, two weeks apart.
62579186|NCT01831739||Non-acute, Stage I, untreated|Non-acute presentation, Scadding stage I, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
62579187|NCT01831739||Stage II-III, treated|Non-acute presentation, Scadding stages II or III, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, treated for at least 3 months.
62785614|NCT02953574|EXPERIMENTAL|daily sleep enhancement nursing protocol|"A 7 step nursing protocol. Each step is daily provided to the demented patient through a nurse by bedtime.~Step 1: serve a late snack Step 2: evening care (brush teeth, get pyjama on, go to toilette) Step 3: note and treat physical circumstances that restrain sleep (pain, obstipation,...) Step 4: ensure comfortable position abed Step 5: assist to eliminate stressful situation (calm, reorientating conversation) Step 6: turn off the light Step 7: care for a silent environment (turn off Television, radio and do not disturb-sign at the door)"
62785615|NCT02953574|NO_INTERVENTION|usual nursing care|
62785616|NCT03333629|EXPERIMENTAL|Enhanced early detection|Providers will receive training to administer enhanced early detection strategies.
62013691|NCT03266445|ACTIVE_COMPARATOR|FULL-BUPRENORPHINE|Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone
62013692|NCT03266445|NO_INTERVENTION|LOW-BUPRENORPHINE (control)|Participants will be randomly assigned to have their daily dose of buprenorphine/naloxone reduced to 8mg on the day of surgery
62202078|NCT06106139|NO_INTERVENTION|Normal diet group|"This group of patients follows the Dietary Guidelines for Chinese Residents (2022) to ensure balanced nutrition, with daily calorie intake ranging from 1600 to 2400 kcal."
62402566|NCT05784168|EXPERIMENTAL|Manual therapy|"6 weeks, 12 sessions in total, 2 times a week of manual therapy: spinal manipulation, specific mobilisations and stretches. Manual therapy treatments are carried out by a physiotherapist with more than 10 years of experience.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
62402567|NCT05784168|EXPERIMENTAL|Exercise therapy|"6 weeks, 12 sessions in total, 2 times a week therapeutic exercise programme under the supervision of a physiotherapist. The exercise programme consisted of muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
62579188|NCT01831739||Stage II-III, untreated|Non-acute presentation, Scadding stage II or III, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
62579189|NCT01831739||Stage IV treated|Non-acute presentation, Scadding stage IV, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, treatment current and for at least 3 months.
62785617|NCT03333629|NO_INTERVENTION|Usual care|Providers will not change their early detection strategies, but will be monitored.
62579190|NCT01831739||Stage IV untreated|Non-acute presentation, Scadding stage IV, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
62579191|NCT01831739||Acute Sarcoidosis, untreated|Acute presentation, Scadding stages I, II, or III, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
62013693|NCT06211634|EXPERIMENTAL|Single or Multiple ascending dose of HMB-001|Open-label, single or multiple ascending dose of HMB-001
62579192|NCT01831739||Remitting, untreated|Remitting clinical course, no treatment for at least 3 months.
62579193|NCT01831739||Cardiac defining therapy|Chronic or uncertain clinical course, no multi-organ involvement, cardiac manifestations defining need for systemic corticosteroid and/or immunomodulatory therapy.
62785618|NCT06474312|EXPERIMENTAL|Intervention Nae Disha|"Nae Disha for Life is a brief, multi-component, psychosocial promotion and resilience tool developed by Emmanuel Hospital Association, New Delhi. The purpose of this research work is to evaluate the feasibility, acceptance, and effectiveness of Nae Disha for Life tool in reducing suicide ideation among youth in Bundelkhand region. This will be implemented among the targeted schools of Nowgong block, Chhatarpur district."
62013694|NCT03515148|EXPERIMENTAL|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion. Previously subjects should cold their leg in ice water during sexteen minutes at a temperature of 8ºC (+/-2ºC)
62013695|NCT03515148|EXPERIMENTAL|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
62785619|NCT06474312|NO_INTERVENTION|Control arm|The control arm will not get any intervention,
62785620|NCT05930184|ACTIVE_COMPARATOR|local wound infiltration|0.25% Bupivacaine 20ml was injected into the wound subcutaneous tissue after the laparoscopic port was removed
62785621|NCT05930184|EXPERIMENTAL|peri-wound Transversus Abdominis Plane Block|0.25% Bupivacaine 20ml was injected into the transversus abdominis plane around the wound before the laparoscopic port was removed
62202079|NCT06106139|EXPERIMENTAL|Strict ketogenic diet group|the patients ate ketogenic biscuits or ketogenic foods provided by the researchers every day. During the study, the patients were not allowed to drink any drinks or eat other foods except drinking water, so as to ensure that the daily intake of calories was roughly the same as that of the normal diet group.
62579194|NCT01551914|EXPERIMENTAL|ultrasonic scissors|
62579195|NCT01551914|ACTIVE_COMPARATOR|conventional techniques of haemostasis|clips, ligatures, and bipolar coagulation
62202080|NCT06106139|EXPERIMENTAL|Cyclic ketogenic diet group|"the patients took 7 days as a cycle, and 7 days of strict ketogenic diet+7 days of normal diet as a cycle. During the strict ketogenic diet, the patient should eat the ketogenic biscuit or ketogenic food provided by the researcher every day, and should not drink any beverage or eat other food except drinking water; During the normal diet period, patients followed the Dietary Guidelines for Chinese Residents (2022) to ensure nutritional balance. During the study period, patients were guaranteed to eat approximately the same amount of calories per day as the normal diet group."
62579196|NCT02454465|EXPERIMENTAL|Intervention group|The first group at the top of the waiting list will receive the Acceptance and Commitment Therapy group intervention, which is 1 hour per week for six weeks.
62579197|NCT02454465|NO_INTERVENTION|Waiting list group|The outcomes of those on the waiting list will be compared with those in the intervention group. Once the intervention group completes, those on the waiting list will be invited to attend the Acceptance and Commitment Therapy group intervention.
62579198|NCT05502640|OTHER|sponge group|Control group
62579199|NCT05502640|EXPERIMENTAL|Chicken group|
62579200|NCT05499754||pLMA(n=30)|
62202081|NCT06106139|EXPERIMENTAL|Autonomous ketogenesis group|Patients choose ingredients for cooking and consumption under the guidance of researchers, ensuring that the nutritional composition is about 90% fat, 10% protein, and can contain a small amount of carbohydrates (10%). The daily calorie intake is around 1600\~2400 kcal.
62202082|NCT04210427|EXPERIMENTAL|Intervention with polyethylene glycol & SmartPill|Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.
62402568|NCT00828009|EXPERIMENTAL|Tecemotide/bevacizumab after chemoradiation|"Concomitant Chemoradiotherapy: Patients (pts) receive paclitaxel intravenously (IV) over 1 hour and carboplatin IV over 15-30 minutes weekly for 6 weeks. Pts also receive radiotherapy 5 days a week for 6½ weeks. Pts with CR, PR, or SD proceed to consolidation chemotherapy.~Consolidation chemotherapy: Pts receive paclitaxel IV over 3 hours and carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression (PD) or unacceptable toxicity. Pts with CR, PR, or SD proceed to maintenance therapy.~Maintenance therapy: Pts receive a single dose of cyclophosphamide IV over 15-30 minutes 3 days before the first dose of bevacizumab and tecemotide. Pts then receive bevacizumab IV over 30-90 minutes on day 1 and tecemotide subcutaneously on days 1, 8, and 15 of courses 1 and 2 and on day 1 of every other course beginning in course 4. Treatment repeats every 21 days for up to 34 courses in the absence of PD or unacceptable toxicity."
62402569|NCT04121832|EXPERIMENTAL|Case|"32 women with fibromyalgia diagnosis corresponding to the diagnostic criteria of the American College of Rheumatology (ACR) will be taken in charge at the pain therapy centre of San Giovanni di Dio Hospital. All patients over the age of 18 will be included.~Other patients with rheumatologic diagnoses in comorbidity with fibromyalgia will be considered exclusion criteria/will be excluded. Patients with cognitive difficulties and / or diagnoses of intellectual disability and male patients will not be included in the study. In addiction to standard therapies, the sample will be treated with 10 sessions of biofeedback training."
62402570|NCT04121832|ACTIVE_COMPARATOR|Controls|32 women with fibromyalgia diagnosis corresponding to the diagnostic criteria of the American College of Rheumatology (ACR) will be taken in charge at the pain therapy centre of San Giovanni di Dio. All patients over the age of 18 will be included. Other patients with rheumatologic diagnoses in comorbidity with fibromyalgia will be considered exclusion criteria/will be excluded. Moreover, patients with cognitive difficulties and / or diagnoses of mental retardation and male patients will not be included in the study. The sample will be treated only with standard therapies without the use of biofeedback training
62402571|NCT00965458|EXPERIMENTAL|Alefacept|Subjects in this group receive weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
62402572|NCT00965458|PLACEBO_COMPARATOR|Placebo|Subjects in this group received weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
62579201|NCT05499754||sLMA(n=30)|
62785622|NCT00879203||Type 1 Diabetes (T1DM)|Youth and young adults with T1DM
62202083|NCT03854747|NO_INTERVENTION|control group|
62402573|NCT03772210|ACTIVE_COMPARATOR|Current Intensity 1 mA|tDCS will be administered at an intensity of 1 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
62579202|NCT05499754||I-jel(n=30)|
62579203|NCT01118793||double dosing of Clopidogrel|This is a Scripps pilot study on the effect of high clopidogrel maintenance dosing and its relationship to cytochrome P450 2C19 polymorphism status \[STSI/CTSA\].
62579204|NCT04824326|EXPERIMENTAL|Pythagorean Self Awareness Intervention for Children and Adolescence(PSAI-CA)|"The intervention is based on the principles of the teaching of the ancient Greek philosopher Pythagoras. These principals set a basic framework for behavior on the basis of experiential learning and weekly evaluation of the implementation of 12 virtues. The technique is practiced twice a day(before night sleep and in the morning before getting up from bed) and evolves into five successive steps;1)reading of the 12 virtues and diaphragmatic breathing, 2)recall every event og the day,3)third person visualization and self-observation, 4)self-dialogue What have I done wrong?, What have I done right?, What have I omitted that I ought to have done? Endorsement or disapproval of actions according to the 12 virtues and the instructions for a healthy lifestyle, 5) next morning brief revision of the previous night's conclusions and setting of goals for the upcoming day."
62202084|NCT03854747|EXPERIMENTAL|working group|
62013696|NCT06210789|EXPERIMENTAL|Surgical treatment|Surgical excision and periodontal reconstruction according to the remaining amount of keratinized gingiva
62202085|NCT00925678|EXPERIMENTAL|1|
62013697|NCT02996721|NO_INTERVENTION|Standard of Care|Patients randomized to the standard of care arm will have a 25\[OH\] Vit D test performed, a sample taken and stored for future tests, and completion of a PHQ-9 depression survey at baseline and at study conclusion. No other contact is planned with the standard of care patients. Follow-up will be done by the querying of electronic records, which includes any 25\[OH\] Vit D testing, use of vitamin D supplementation, and outcomes.
62202086|NCT00925678|PLACEBO_COMPARATOR|2|
62202087|NCT03525262|NO_INTERVENTION|SAbR WITHOUT Neurovascular sparing|"* GTV represents MR defined dominant radiographic disease, if identifiable.~* CTV encompasses the full prostate. At physician's discretion, the insertion of the seminal vesicle upon the prostate on slices containing prostate may be included.~* PTV1_30Gy will not be used or created on this arm~* PTV2_SAbR40Gy OR PTV2_SAbR45Gy will be generated by a 3mm expansion on the CTV. PTV2_SAbR will receive 8-9 Gy per fraction for 5 fractions (40-45 Gy)."
62202088|NCT03525262|EXPERIMENTAL|SAbR WITH Neurovascular sparing|"* GTV represents MR defined dominant radiographic disease, if identifiable.~* CTV encompasses the full prostate. At physician's discretion, the insertion of the seminal vesicle upon the prostate on slices containing prostate may be included.~* PTV1_30Gy represents a 3mm expansion on the CTV, excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).~* PTV2_SAbR40Gy OR PTV2_SAbR45Gy will be generated by subtracting a 5mm expansion around the neurovascular elements to be spared (at least one side, left or right) from PTV1. These neurovascular structures consist of the neurovascular bundle, penile bulb, and internal pudendal arteries (see 4.1.5.2.16). PTV2 will receive 8-9 Gy per fraction for 5 fractions (40-45 Gy)."
62202089|NCT01736943|EXPERIMENTAL|Bortezomib + Doxil|Bortezomib will be given subcutaneously at 1.5mg/m2 on days 1, 4, 8 and 11 of a 3 week cycle. Doxil will be administered once every three weeks as a single intravenous infusion at a dose of 40 mg/m2 (day 4 of each cycle).
62202090|NCT05693298|EXPERIMENTAL|High Flow Nasal Cannula|High Flow Nasal cannula is a system to deliver heated and humidified oxygen with an inspired oxygen fraction between 21 and 100% through large bore nasal cannula. The system delivers a flow up to 60 liters/min.
62202091|NCT05693298|ACTIVE_COMPARATOR|Standard Treatment|If peripheral oxygen saturation will be \< 95%, conventional oxygen therapy will be administered through common nasal cannula with a flow up to 6 Liters per minute
62202092|NCT01655953|EXPERIMENTAL|Campaign 1|
62202093|NCT01655953|EXPERIMENTAL|Campaign 2|
62202094|NCT02239874|PLACEBO_COMPARATOR|Vitamin D placebo and fish oil placebo|vitamin D placebo + fish oil placebo
62202095|NCT02239874|ACTIVE_COMPARATOR|Fish oil and vitamin D placebo|Vitamin D placebo and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
62202096|NCT02239874|ACTIVE_COMPARATOR|Vitamin D and fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
62202097|NCT02239874|ACTIVE_COMPARATOR|Vitamin D and fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
62402574|NCT03772210|SHAM_COMPARATOR|Sham 1 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 1 mA tDCS.
62579205|NCT01532960|EXPERIMENTAL|9 Peptides from Her-2/neu, CEA, & CTA, peptide-tet, poly-ICLC|9 class I MHC-restricted synthetic peptides (100 mcg each peptide) derived from breast cancer associated proteins, a class II MHC-restricted tetanus derived peptide (200 mcg), plus polyICLC (1 mg).
62202098|NCT04038164|EXPERIMENTAL|Dog-Assisted Therapy (DAT) and pharmacological treatment|The DAT program comprised 12 manualized sessions and included two phases: 1) individual intervention (6 sessions) and 2) group activity (6 sessions). Patients participated in weekly sessions for about 3 months. Each session lasted 45 minutes. The groups were formed by 3-4 patients. Sessions included the participation of two certified therapy dogs, two technicians specialized in DAT and a psychologist. Participants in this group were visited by their psychiatrist in order to monitor their adherence to medications.
62402575|NCT03772210|ACTIVE_COMPARATOR|Current Intensity 1.5 mA|tDCS will be administered at an intensity of 1.5 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
62402576|NCT03772210|SHAM_COMPARATOR|Sham 1.5 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 1.5 mA tDCS.
62402577|NCT03772210|ACTIVE_COMPARATOR|Current Intensity 2 mA|tDCS will be administered at an intensity of 2 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
62402578|NCT03772210|SHAM_COMPARATOR|Sham 2 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 2 mA tDCS.
62402579|NCT03772210|EXPERIMENTAL|Structural, Diffusion and MREIT Imaging|"Structural and High angular resolution diffusion weighted imaging will be performed.~Magnetic Resonance Electrical Impedance Tomography imaging will be performed using electrode locations F3-F4."
62579206|NCT04420533|ACTIVE_COMPARATOR|Behavior therapy alone|Behavior therapy alone
62579207|NCT04420533|EXPERIMENTAL|Behavior therapy plus mirabegron 50mg|Behavior therapy plus Betmiga prolonged-release tablets (mirabegron) 50mg QDAC PO
62579208|NCT03865316|EXPERIMENTAL|SedLine Vs Comparator Test Group|
62579209|NCT04591366|ACTIVE_COMPARATOR|Control|Standard skin prep prior to procedure will be performed and an adhesive iodine-infused barrier dressing will be applied post procedure but prior to taking the culture swab and closing the incision.
62785623|NCT00879203||Non diabetic siblings|Non diabetic, young siblings of T1DM participants
62785624|NCT01166204|EXPERIMENTAL|Single group|
62202099|NCT04038164|ACTIVE_COMPARATOR|Treatment as usual (TAU, pharmacological treatment)|Participants received their usual treatment. They were visited by their psychiatrist in order to monitor their adherence and continuation on medications as prescribed. Inclusion and exclusion criteria were the same as for the experimental group. Participants in the TAU group did not receive DAT sessions.
62202100|NCT02071290|SHAM_COMPARATOR|Sham Remote Ischemic Conditioning|Sham inflation of pneumatic tourniquet pressure cuff at 0 mmHg on the thigh for 5 minutes and release for 5 minutes (repeated for 4 cycles) applied to trauma patients on arrival to hospital
62785625|NCT00231413|ACTIVE_COMPARATOR|HPV-16/18 Group|Female subjects who received 3 doses of the HPV-16/18 L1 AS04 vaccine intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
62785626|NCT00231413|EXPERIMENTAL|HPV-TETRA A Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 1 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
62785627|NCT00231413|EXPERIMENTAL|HPV-TETRA B Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 2 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
62785628|NCT00231413|EXPERIMENTAL|HPV-TETRA C Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 3 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
62785629|NCT00231413|EXPERIMENTAL|HPV-TETRA D Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 4 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
62013698|NCT02996721|EXPERIMENTAL|Treatment|Patients randomized to the treatment arm will have a 25\[OH\] Vit D test performed, a sample taken and stored for future tests, and completion of a PHQ-9 depression survey. If at baseline a patient has a 25\[OH\] Vit D \>40 ng/mL then follow-up testing will occur 1 year from baseline and the patient will continue current treatment strategy (no supplementation or current supplementation dosage). If baseline 25\[OH\] Vit D levels are \<40 ng/mL then the patient will initiate or increase dose and return in 3 months (±15 days) to determine 25\[OH\] Vit D level. At 3 months, if 25\[OH\] Vit D \>40 ng/mL then current dose should be kept and the patient will return in 1 year for follow-up testing. However, if 25\[OH\] Vit D \<40 ng/mL then patients should double current dose and test again in 3 months. This should occur until 25\[OH\] Vit D reaches a level \>40 ng/mL and once achieved, the patient will return in 1 year for follow-up 25\[OH\] Vit D testing.
62013699|NCT05345691|EXPERIMENTAL|Bmab 1000|
62202101|NCT02071290|EXPERIMENTAL|Remote Ischemic Conditioning|Inflation of pneumatic tourniquet pressure cuff at 250mmHg on the thigh for 5 minutes and release for 5 minutes (repeated for 4 cycles) applied to trauma patients on arrival to hospital
62202102|NCT05857592|EXPERIMENTAL|Experimental|Persons with Mild Intellectual Disability (MID) or Borderline Intellectual Functioning (BIF) complete the ABAS-3 in assisted form on two occasions: the original version the first time and an adapted version after a few weeks.
62202103|NCT01792791||Single Arm|
62785630|NCT00231413|EXPERIMENTAL|HPV-TETRA E Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 5 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
62785631|NCT00231413|EXPERIMENTAL|HPV-TETRA F Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 6 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
62013700|NCT05345691|ACTIVE_COMPARATOR|Prolia®:|
62013701|NCT00935103|ACTIVE_COMPARATOR|Psychoeducation|Psycheducation
62013702|NCT00935103|NO_INTERVENTION|Control|The control group will not take any intervention
62202104|NCT00536653|ACTIVE_COMPARATOR|Osteporosis Group|Patients with a presenting T score \< -2.5 (osteoporosis), treated with bicalutamide and Ca/VitD
62785632|NCT02436538||Mullerian duct anomalies|Anti Mullerian hormone level; Mullerian duct anomaly type
62013703|NCT03614013||Immunotherapy responders/non-responders|paraffin samples and relevant clinical data including RECIST 1.1 will be obtained from metastatic gastric cancer patients
62013704|NCT02939105|EXPERIMENTAL|CoolSculpting Treatment in the Upper Arm|"Subjects in the study were treated with the CoolSculpting System with one of two vacuum applicator types for bilateral fat reduction in the upper arms. Applicators were used concurrently, with an applicator on each arm. Each subject received 1 or 2 cooling cycles on each arm for 35 minutes at protocol-defined temperatures.~The Investigator selected the applicator for each subject based on the intended fat volume of the treatment area."
62202105|NCT00536653|ACTIVE_COMPARATOR|Osteopenia Group|Patients with a presenting T score between -1.0 and -2,4 (osteopenia), treated with LHRH agonists and Ca/VitD
62202106|NCT00536653|ACTIVE_COMPARATOR|Normal Group|Patients with a presenting T score \> -1.0(normal BMD), treated with LHRH agonists
62785633|NCT05716360||Group 1|Aneuryms treated with Flow-Diverting Stents and had a diameter above 8 mm
62785634|NCT05716360||Group 2|Aneuryms treated with Flow-Diverting Stents and had a diameter below 8 mm
62202107|NCT01616004|EXPERIMENTAL|N2O|N20 70% inhalation 5 minutes O2 100 % inhalation for 5 minutes
62202108|NCT01616004|SHAM_COMPARATOR|Air|
62785635|NCT05716360||Group 3|Aneurysms treated with metalic bare stents
62785636|NCT03180125|EXPERIMENTAL|sodium hyaluorinate ultrasound guided|median nerve hydro-dissection using 1% lidocain followed by low molecular weight sodium hyaluronate (Hyalgan) injection ultrasonographically guided
62785637|NCT03180125|PLACEBO_COMPARATOR|corticosteroid with ultrasound guided|median nerve hydro-dissection using 1% lidocain followed by injection of corticosteroid Ultrasonographically guided
62785638|NCT01477489|EXPERIMENTAL|Treatment|
62785639|NCT01022099|ACTIVE_COMPARATOR|navigated TKA|
62785640|NCT01022099|OTHER|conventional TKA|
62785641|NCT05177367|EXPERIMENTAL|Sequential Variety, Small Portion|3 courses each consisting of a different food served in a small portion.
62785642|NCT05177367|EXPERIMENTAL|Sequential Variety, Large Portion|3 courses each consisting of a different food served in a large portion.
62785643|NCT05177367|EXPERIMENTAL|Simultaneous Variety, Small Portion|3 courses each consisting of 3 foods served in small portions.
62785644|NCT05177367|EXPERIMENTAL|Simultaneous Variety, Large Portion|3 courses each consisting of 3 foods served in large portions.
62785645|NCT05177367|EXPERIMENTAL|Single Food, Small Portion|3 courses each consisting of the same food served in a small portion.
62202109|NCT04747197|EXPERIMENTAL|440 ug, single dose|EYP-1901 440 ug, single dose
62202110|NCT04747197|EXPERIMENTAL|2060 ug, single dose|EYP-1901 2060 ug, single dose
62202111|NCT04747197|EXPERIMENTAL|3090 ug, single dose|EYP-1901 3090 ug, single dose
62202112|NCT00452907|EXPERIMENTAL|1|Arsucam® (AS 50mg/Aq153mg),oad, per os, 3 days of treatment
62202113|NCT00452907|ACTIVE_COMPARATOR|2|Arsumax (AS 50mg) + Sulfadoxine-Pyrimethamine (SP=SDX 500mg/PYR 25mg), oad, per os
62785646|NCT05177367|EXPERIMENTAL|Single Food, Large Portion|3 courses each consisting of the same food served in a large portion.
62785647|NCT05787925|EXPERIMENTAL|Topical corticosteroid and Vitamin E|
62785648|NCT05787925|ACTIVE_COMPARATOR|Topical corticosteroid|
62202114|NCT00452907|ACTIVE_COMPARATOR|3|Coartem (arthemether 20mg+ lumefantrine 120 mg), bid, per os. Duration of treatment: 3 days
62785649|NCT05513053|EXPERIMENTAL|Group 9 to 17 years old|Participants of 9 to 17 years old who received RIV4 single intramuscular (IM) injection at D01
62013705|NCT05913804|EXPERIMENTAL|YTS104 cells injection|Subjects will receive cell infusion, with the initial cell dose of 1E6/kg. 1-6 subjects will be enrolled. The second dose group was 3E6 cells /kg with 1-6 subjects; The third and fourth dose groups were 6E6 cells /kg and 1E7 cells /kg, respectively, with 3-6 subjects.
62202115|NCT00441259|EXPERIMENTAL|JE-CV Group|Participants will receive Japanese encephalitis chimeric virus vaccine (JE-CV)
62202116|NCT00441259|ACTIVE_COMPARATOR|MBDV Group|Participants will receive the mouse brain-derived vaccine (MBDV)
62202117|NCT02470676|ACTIVE_COMPARATOR|Progesterone|200 mg daily of vaginal progesterone suppositories (Utrogestan)
62202118|NCT02470676|EXPERIMENTAL|Progesterone plus Experimental device|Experimental device + 200 mg daily progesterone vaginal suppositories (Utrogestan)
62202119|NCT01681992|EXPERIMENTAL|Inv_MMR_Min Group|Subjects receive one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a minimum potency lot (Inv_MMR_Min), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
62785650|NCT05513053|EXPERIMENTAL|Group 18 to 49 years old|Participants of 18 to 49 years old who received RIV4 single intramuscular (IM) injection at D01
62785651|NCT01755871|EXPERIMENTAL|Fingolimod|Gilenya 0,5mg per day, oral
62785652|NCT00874848|EXPERIMENTAL|Imprime PGG|Imprime PGG Injection + Cetuximab + Paclitaxel/Carboplatin
62785653|NCT00874848|ACTIVE_COMPARATOR|Control|Cetuximab + Paclitaxel/Carboplatin
62785654|NCT02604563||Arm A: Clonal hematopoiesis|"* Complete several self-administered health assessments at baseline and every 6 months until death.~* Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.~* Peripheral blood draw will occur at baseline and no more than every 6 months until death.~* Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death~* May be approached about optional bone marrow biopsy"
62785655|NCT02604563||Arm B: No clonal hematopoiesis|"* Complete several self-administered health assessments at baseline and every 6 months until death.~* Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.~* Peripheral blood draw will occur at baseline and no more than every 6 months until death.~* Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death~* May be approached about optional bone marrow biopsy"
62215112|NCT05769647|EXPERIMENTAL|Ball Squeezing Group|"* Volunteer Information and Approval Form will be filled.~* Physician request, the name and surname of the individual will be checked.~* Patient Information Form and State Anxiety Scale will be filled.~* Patients will be given a ball and instructed to tighten and loosen with their free hand during IVC placement. The IV catheter insertion attempt will be made while the patient continues to squeeze the ball.~* Visual Pain Scale and State Anxiety Scale will be filled within one minute after intravenous catheter placement is completed."
62402580|NCT00920582|EXPERIMENTAL|Herold Regimen|14-day cycle of teplizumab consisting of daily IV doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, and 413 µg/m2 on Study Days 1-4, respectively, and one dose of 826 µg/m2 on each of Study Days 5-14. Repeat at Week 26
62579210|NCT04591366|EXPERIMENTAL|Intervention|Standard skin prep prior to procedure plus an adhesive iodine-infused barrier dressing prior to incision, post procedure a culture swab will be taken and the incision closed.
62579211|NCT05198037|EXPERIMENTAL|Active transcranial direct current stimulation (tDCS)|Weak direct currents with 2 mA are delivered 20 minutes per session (including 30s ramp-up and 30s ramp-down) during tailored upper extremity task practice. Total sessions are 20 over 10 days.
62579212|NCT05198037|SHAM_COMPARATOR|Sham tDCS|The device is automatically shut down after 2-minute stimulation. Treatment sessions and frequency are the same as the Experimental arm.
62579213|NCT01166438|EXPERIMENTAL|Botox A|A single intradetrusor injection of 100U botulinum toxin A (Botox A®) plus daily oral placebo tablets
62579214|NCT01166438|ACTIVE_COMPARATOR|Standardized Anticholinergic Regimen|A standardized 3-step anticholinergic regimen of daily oral solifenacin 5mg, solifenacin 10mg, and/or trospium chloride XR 60mg, as well as a single intradetrusor injection of saline (placebo). All subjects will begin on solifenacin 5 mg for 2 mo. If a subject's symptoms are not adequately controlled at 2 mo, she will be escalated to solifenacin 10mg, and similarly at 4 mo to trospium XR 60mg. If a subject's symptoms are adequately controlled on solifenacin 5 mg, she may continue that study medication for the entirety of the study (6 mo). Additionally, if a subject is dose-escalated to solifenacin 10mg at study mo 2 or 4, and her symptoms are adequately controlled, she may continue the solifenacin 10mg dose for the remainder of the study.
62579215|NCT03973528|EXPERIMENTAL|traditional Chinese medicine|The experimental group use traditional Chinese medicine
62579216|NCT03973528|NO_INTERVENTION|non- traditional Chinese medicine|The no intervention group no use traditional Chinese medicine.
62579217|NCT05691335|OTHER|Standard CXL|Patients treated according to Dresden Protocol with epithelium-off CXL.
62579218|NCT05691335|EXPERIMENTAL|Accelerated CXL|Patients treated according to accelerated Protocol with epithelium-off CXL.
62579219|NCT05691335|EXPERIMENTAL|Transepithelial CXL|Patients treated according to transepithelial Protocol with epithelium-on CXL.
62579220|NCT04411394||Healthy Participants|There is no intervention
62402581|NCT00920582|EXPERIMENTAL|33.3% Herold Regimen|Subjects received a 14-day cycle of teplizumab consisting of daily IV doses of 17 µg/m2, 34 µg/m2, 68 µg/m2, and 136 µg/m2 on Study Days 1-4, respectively, and one dose of 273 µg/m2 on each of Study Days 5-14. Repeat at Week 26
62579221|NCT04411394||Anxiety Participants|There is no intervention
62579222|NCT03602664||Thoracic surgery|Patients undergoing thoracic surgery
62579223|NCT05883384||patient with cow milk protein allergy|apply CoMiSS on patient suspected to have cow milk protein allergy.
62579224|NCT02856126|EXPERIMENTAL|HAIC plus sorafenib|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: HAIC Regimen Drug: Oral Sorafenib
62579225|NCT02856126|ACTIVE_COMPARATOR|TACE plus sorafenib|Procedure/Surgery: Transarterial chemoembolization Drug: TACE regimen Drug: Oral Sorafenib
62579226|NCT05912426|EXPERIMENTAL|Reduced-sodium potassium-enriched salt|Reduced-sodium potassium-enriched salt
62579227|NCT03140696|EXPERIMENTAL|Chicken egg alone|A chicken egg alone will be offered for 2 days by mouth for once a day
62579228|NCT03140696|EXPERIMENTAL|Egg and RUSF|A chicken egg and Ready to use supplementary food (RUSF) will be offered for 2 days by mouth for once a day
62579229|NCT03140696|EXPERIMENTAL|Egg and breast milk|A chicken egg and Mother's breast milk will be offered for 2 days by mouth for once a day
62579230|NCT06577558|EXPERIMENTAL|SR1375 capsule 3mg|SR1375 capsule 3mg quaque die(QD) orally with CAP regular treatments for 8 weeks
62579231|NCT06577558|EXPERIMENTAL|SR1375 capsule 1mg|SR1375 capsule 1mg QD orally with CAP regular treatments for 8 weeks
62579232|NCT06577558|EXPERIMENTAL|SR1375 capsule 0.3mg|SR1375 capsule 0.3mg QD orally with CAP regular treatments for 8 weeks
62579233|NCT06577558|PLACEBO_COMPARATOR|placebo capsule|Placebo capsule QD orally with CAP regular treatments for 8 weeks
62579234|NCT04249726|EXPERIMENTAL|Direct composite resin restoration|Root filled teeth with occlusal cavities and at least 3 intact axial walls will receive composite resin restorations
62579235|NCT04249726|ACTIVE_COMPARATOR|Full coverage metal-ceramic crown|Root filled teeth with occlusal cavities and at least 3 intact axial walls will receive composite resin restorations followed by full coverage metal-ceramic crown
62579236|NCT03448731|EXPERIMENTAL|Doxycycline|Doxycycline 50 mg p.o. daily during 6 weeks
62402582|NCT00920582|EXPERIMENTAL|Curtailed Herold Regimen|Subjects received a 6 day cycle of teplizumab consisting of daily IV doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, and 413 µg/m2 on Study Days 1-4, respectively, and one dose of 826 µg/m2 on each of Study Days 5-6, followed by 8 days of IV placebo (Study Days 7-14). Repeat at Week 26
62402583|NCT00920582|PLACEBO_COMPARATOR|Placebo|14-day cycle of placebo consisting of daily IV doses. Repeat at Week 26
62402584|NCT00647309||1|
62785656|NCT02604563||Arm C: No clonal hematopoiesis & no follow-up|"* Complete several self-administered health assessments at baseline with no further follow-up~* Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline with no further follow-up~* Peripheral blood draw will occur at baseline with no further follow-up~* Buccal swabs will occur at baseline with no further follow-up"
62785657|NCT02604563||Arm D: Hip replacement|"* Complete several self-administered health assessments at baseline and every 6 months until death.~* Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.~* Participants with or without clonal hematopoiesis who are undergoing hip replacement~* Peripheral blood draw will occur at baseline and no more than every 6 months until death.~* Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death~* May be approached about optional bone marrow biopsy"
62202120|NCT01681992|EXPERIMENTAL|Inv_MMR_Med Group|Subjects receive one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a mid-range or medium potency lot (Inv_MMR_Med), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
62202121|NCT01681992|ACTIVE_COMPARATOR|Com_MMR Group|Subjects receive one dose of M-M-R II (Com_MMR) vaccine (Lot 1 or Lot 2), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose of Com_MMR vaccine (Lot 1 or Lot 2), for the second dose. Com_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
62202122|NCT01532804|EXPERIMENTAL|Arm A|FOLFOX6 + bevacizumab (D1=D15, 12 cycles)
62202123|NCT01532804|EXPERIMENTAL|Arm B|Raltitrexed + Oxaliplatin + Bevacizumab (D1=D21, 8 cycles)
62202124|NCT06177392|EXPERIMENTAL|RADIAL|RADIAL ARTERY ACCESS AS SECONDARY ACCESS IN TAVI PROCEDURE
62202125|NCT06177392|ACTIVE_COMPARATOR|FEMORAL|FEMORAL ARTERY ACCESS AS SECONDARY ACCESS IN TAVI PROCEDURE
62202126|NCT02194504|NO_INTERVENTION|No dietary advice|No dietary intervention
62202127|NCT02194504|EXPERIMENTAL|Dietary advice, Targeted|12-wk dietary advice
62402585|NCT00647309||2|
62402586|NCT05959174|ACTIVE_COMPARATOR|3d printed appliance|
62402587|NCT05959174|ACTIVE_COMPARATOR|side chair appliance|
62202128|NCT02194504|EXPERIMENTAL|Dietary advice, Western|12-wk dietary advice
62202129|NCT02830477||BAY81-8973|Previously treated patients receiving IV infusion of KOVALTRY for routine prophylaxis
62215113|NCT05769647|NO_INTERVENTION|Control Group:|"* Volunteer Information and Approval Form will be filled.~* Physician request, the name and surname of the individual will be checked.~* Patient Information Form and State Anxiety Scale will be filled.~* An intravenous catheter will be placed.~* Visual Pain Scale and State Anxiety Scale will be filled within one minute after intravenous catheter placement is completed."
62215114|NCT04159623|EXPERIMENTAL|Belk Device|With Belk Device
62402588|NCT05477927|EXPERIMENTAL|CAR-T cell therapy|Dual-targeting VEGFR1 and PD-L1 CAR-T cells
62402589|NCT03306875|EXPERIMENTAL|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
62402590|NCT06145945|EXPERIMENTAL|Ropivacaine|20ml 0.5% ropivacaine is sprayed intraperitoneally
62402591|NCT06145945|PLACEBO_COMPARATOR|Saline|20ml saline is sprayed intraperitoneally
62402592|NCT00717899|ACTIVE_COMPARATOR|1|School children from Haifa bay region, Israel.
62402593|NCT04704791|EXPERIMENTAL|Procedure arm|At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
62402594|NCT01896518|NO_INTERVENTION|Counseling|
62402595|NCT01896518|EXPERIMENTAL|Nicotine lozenge|Participants will receive nicotine lozenge to use as needed for 12 weeks.
62402596|NCT01896518|EXPERIMENTAL|Tobacco lozenge|Participants will receive tobacco lozenge to use as needed for 12 weeks.
62402597|NCT04051931||stable COPD group|include COPD patients with stable state
62402598|NCT04051931||AECOPD group|include COPD patients with acute exacerbation
62402599|NCT01518894|EXPERIMENTAL|PF-04958242|
62402600|NCT01518894|PLACEBO_COMPARATOR|Placebo|
62402601|NCT02249546|EXPERIMENTAL|Acetylcysteine + PPI-amoxicillin-clarithromycin|N-acetylcysteine 600mg bid Dexlansoprazole 60mg qd Amoxicillin 1000mg bid Clarithromycin 500mg bid All for 14 days
62202130|NCT06013631|EXPERIMENTAL|Phantom Exercises|"The phantom exercises involved visualizing and then trying to perform the movements of the phantom limb.~1. Place the limb at the angle at which they were sensing their phantom limb.~2. Put their healthy limb in the identical spot as they perceived their phantom limb.~3. Move their two limbs in opposition to one another.~4. Go back to where they started. The movements included ankle inversion and eversion, flexion and extension, and adduction and abduction with toe flexion and extension, respectively.~5. Once the patient is at ease, movements like hip or knee flexion/extension are performed until the PLP is gone.~6. Phantom exercises will be performed as many times as possible in a single session up to 15 times until the PLP fully subsided."
62402602|NCT02249546|ACTIVE_COMPARATOR|PPI-amoxicillin-clarithromycin|Dexlansoprazole 60mg qd Amoxicillin 1000mg bid Clarithromycin 500mg bid All for 14 days
62202131|NCT06013631|ACTIVE_COMPARATOR|Prosthesis Training|Training for prostheses at the appropriate amputation level will be provided. Conventional gait training protocols include Tandem walk, within parallel bar, controlled environment, full length Mirror on one side, weight shifting, shifting onto the Prosthetic Side, Pelvic rotation, Stepping on multiple heights and positions, Tandem walk, within parallel bar, and weight shifting. Gait training will last six weeks in total.
62402603|NCT03572621|EXPERIMENTAL|Experimental group|Patients in the experimental group are offered to participate in a 6-session therapeutic education program on sexuality, ranging from 15 days before surgery to approximately 3 months after. This in addition to the current care by the teams of care about sexual rehabilitation (information and medication prescriptions).
62579237|NCT06397365|EXPERIMENTAL|Hypnosis|"Baseline study visit (V1): signature of the informed consent form, verification of eligibility criteria, collection of demographic data, polygraphy or polysomnography features, data provided by the CPAP machine (one month), questionnaires.~During the second visit (V2), the patient randomized in HYP group will come for the hypnosis sessions.~Follow-up visit (V4): 28-42 days (4-6 weeks) after V3 for HYP group and 2 months (+/- 14 days) after V1 for SOC group. Collection of data provided by the CPAP machine (one month), questionnaires."
62202132|NCT05127980||patients with confirmed primary EBV infection|"40 patients with confirmed primary EBV infection as confirmed by the treating clinician and defined by:~- Compatible clinical (infectious mononucleosis symptoms including but not limited to malaise, headache, fever, tonsillitis, pharyngitis, cervical lymph nodes enlargement) and laboratory picture (lymphocyte count elevation, LUC cells, reactive lymphocytes in manual differential, elevated liver enzymes; of note, not all typically described features have to be fulfilled)~AND~- serology compatible with primary EBV infection (anti-EBNA IgG negative, anti-VCA IgG negative, anti-VCA IgM positive OR anti-EBNA IgG negative, anti-VCA IgG positive, anti- VCA IgM positive)"
62579238|NCT06397365|NO_INTERVENTION|standard of care|"Baseline study visit (V1): signature of the informed consent form, verification of eligibility criteria, collection of demographic data, polygraphy or polysomnography features, data provided by the CPAP machine (one month), questionnaires.~Usual management of CPAP treatment by the home care provider and the prescribing doctor without any change in management.~Follow-up visit (V4): 28-42 days (4-6 weeks) after V3 for HYP group and 2 months (+/- 14 days) after V1 for SOC group. Collection of data provided by the CPAP machine (one month), questionnaires."
62579239|NCT01991509|EXPERIMENTAL|LBR-101 IV Dose 1|LBR-101 Dose 1 Administered Intravenously
62579240|NCT01991509|EXPERIMENTAL|LBR-101 SC Dose 1|LBR-101 Dose 1 Administered Subcutaneously
62579241|NCT01991509|PLACEBO_COMPARATOR|Placebo IV|Placebo Administered Intravenously
62579242|NCT01991509|PLACEBO_COMPARATOR|Placebo SC|Placebo Administered Subcutaneously
62579243|NCT01991509|EXPERIMENTAL|LBR-101 Dose 2 IV|LBR-101 Dose 2 Administered Intravenously
62402604|NCT03572621|SHAM_COMPARATOR|Control group|Patient without therapeutic education.
62402605|NCT03572621|OTHER|Partner|Patient's partner.
62402606|NCT01024894|EXPERIMENTAL|CYT107|
62402607|NCT01642862|EXPERIMENTAL|Liquid formulation of Simvastatin|
62402608|NCT01642862|ACTIVE_COMPARATOR|Tablet formulation of Simvastatin|
62402609|NCT02727374|EXPERIMENTAL|EXPERIMENTAL|Physiotherapy intervention, plus cognitive-behavioural intervention
62402610|NCT02727374|ACTIVE_COMPARATOR|CONTROL|Physiotherapy intervention
62402611|NCT02451631|ACTIVE_COMPARATOR|Traditional care|Traditional care with paper(SMBG) and healthcare staff advice in office
62402612|NCT02451631|EXPERIMENTAL|Health-On G App.+ Physician web portal|Patient self-mgmt using Health-On G Application on smartphone; Healthcare staffs monitoring through physician web to review data
62579244|NCT01991509|EXPERIMENTAL|LBR-101 Dose 2 SC|LBR-101 Dose 2 Administered Subcutaneously
62579245|NCT04161339|EXPERIMENTAL|Hydroxychloroquine|400mg/daily of hydroxychloroquine for 8 weeks
62579246|NCT04161339|PLACEBO_COMPARATOR|Placebo|
62579247|NCT03448471||Group 1: severe-fatigued recipients|These recipients had Fatigue Severity Scale score ≥36. All recipients evaluated with similar methods. Meaurements were Pulmonary function tests, Respiratory muscle strength, Peripheral muscle strength, Functional exercise capacity, Dyspnea, Fatigue, Depression and Quality of life.
62579248|NCT03448471||Group 2: non-severe-fatigued recipients|These recipients had Fatigue Severity Scale score \<36. All recipients evaluated with similar methods. Meaurements were Pulmonary function tests, Respiratory muscle strength, Peripheral muscle strength, Functional exercise capacity, Dyspnea, Fatigue, Depression and Quality of life.
62579249|NCT05953532|OTHER|All Participants|All participants will perform the same study activities
62579250|NCT01691495||Superficial Vein Thrombosis (SVT)|A representative of geographical regions of patients with Superficial Vein Thrombosis (SVT) who live in several EU countries.
62579251|NCT03775265|ACTIVE_COMPARATOR|Arm I (RT, chemotherapy)|Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks. Patients also receive chemotherapy based on physician's choice of gemcitabine IV twice weekly for 6 weeks concurrent with RT, or cisplatin IV weekly for 6 weeks concurrent with RT, or fluorouracil IV on same days as doses 1-5 and 16-20 of radiation therapy and mitomycin IV on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5.
62202133|NCT05127980||control patients|40 control patients (Clinical picture of upper respiratory tract infection (including but not limited to tonsillitis/pharyngitis, malaise, headache, cough, rhinitis, cervical node enlargement)) and/ or confirmed primary Cytomegalovirus (CMV) infection
62202134|NCT00677534|EXPERIMENTAL|1|Cholecalciferol (Vitamin D)
62202135|NCT01824589|ACTIVE_COMPARATOR|Group A|tidal volume setting of 6ml/kg with the -7cm H2O ITPR as first device
62202136|NCT01824589|ACTIVE_COMPARATOR|Group B|tidal volume setting of 8ml/kg with the -7cm H2O ITPR as first device
62402613|NCT01453296|ACTIVE_COMPARATOR|COHORT 1 (RANDOMISATION AB or BA)|"8-11 years old; Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence.~Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home).~Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods."
62579252|NCT03775265|EXPERIMENTAL|Arm II (RT, chemotherapy, atezolizumab)|Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks and receive chemotherapy based on physician's choice as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5.
62202137|NCT01824589|ACTIVE_COMPARATOR|Group C|tidal volume setting of 6ml/kg with the -12cm H2O ITPR as first device
62202138|NCT01824589|ACTIVE_COMPARATOR|Group D|tidal volume setting of 8ml/kg with the -12cm H2O ITPR as first device
62202139|NCT00799981|EXPERIMENTAL|AABB|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 7 cm then 10 cm then 10 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
62202140|NCT00799981|EXPERIMENTAL|ABAB|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 10 cm then 7 cm then 10 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
62202141|NCT00799981|EXPERIMENTAL|ABBA|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 10 cm then 10 cm then 7 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
62202142|NCT00799981|EXPERIMENTAL|BAAB|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then 7 cm then 7 cm then 10 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
62202143|NCT00799981|EXPERIMENTAL|BABA|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then then 7 cm then 10 cm then 7 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
62202144|NCT00799981|EXPERIMENTAL|BBAA|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then 10 cm then 7 cm then 7 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
62202145|NCT03762200|OTHER|SURGICEL Powder - Single arm|Single arm clinical trial where all qualified subjects will be treated SURGICEL Powder
62579253|NCT05569460||Numeric Rating Scale (NRS) score after surgery <4|
62579254|NCT05569460||Numeric Rating Scale (NRS) score after surgery ≥ 4|
62579255|NCT04180514||Intradialytic hypotension|subjects with intradialytic hypotension episode
62202146|NCT01431820|EXPERIMENTAL|Luliconazole Solution, 10% Regimen 1|
62202147|NCT01431820|EXPERIMENTAL|Luliconazole Solution, 10% Regimen 2|
62202148|NCT01431820|PLACEBO_COMPARATOR|Vehicle Solution Regimen 1|
62202149|NCT01431820|PLACEBO_COMPARATOR|Vehicle Solution Regimen 2|
62202150|NCT05341739|EXPERIMENTAL|Pre-Operative Stereotactic Radiosurgery (SRS)|Subjects are treated using the standard of care SRS to a total dose of 24-27 Gray (Gy) in 3 fractions with a once daily fractionation or every other day at treating physician discretion. The preferred dose will be 27 Gy, with ability to drop dose down to 24 Gy if normal tissue constraints cannot be met. It should be noted, that while the dosing remains within standard of care, the timing of the radiation (pre-operative) is still not considered standard of care but is supported by emerging data as described in the study background. Additional metastatic lesions may be treated using SRS according to institutional practices. The radiation dose prescribed to the non-index lesions is at the discretion of the treating physicians. Surgical resection will be performed within 2 weeks of completion of SRS.
62202151|NCT00310557|EXPERIMENTAL|Arm 1|
62202152|NCT03274895|EXPERIMENTAL|PHMB 0.08% plus placebo|polihexanide (PHMB) 0.08% and placebo were administered in the affected eye until clinical resolution for a maximum of 12 months
62202153|NCT03274895|ACTIVE_COMPARATOR|PHMB 0.02% plus propamidine 0.1%|polihexanide (PHMB) 0.02% and propamidine 0.1% were administered in the affected eye until clinical resolution for a maximum of 12 months
62202154|NCT00196157|EXPERIMENTAL|1|linear lesions to ablate persistent atrial fibrillation
62202155|NCT00196157|EXPERIMENTAL|2|focal electrophysiologically guided ablations to treat persistent atrial fibrillation
62215115|NCT04159623|OTHER|Standard Rehabilitative treatment|With the standard rehabilitative treatment
62215116|NCT00287703|EXPERIMENTAL|1|Active Pulsating Electro Magnetic Fields (PEMF) treatment
62402614|NCT01453296|ACTIVE_COMPARATOR|COHORT 2 (RANDOMISATION AB or BA)|"5-7 years old. Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence.~Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home).~Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods."
62402615|NCT05234073|EXPERIMENTAL|Experimental: A (first group to receive the intervention)|The class will be instructed in the social emotional and ethical learning (SEELearning) for 4 weeks.
62402616|NCT05234073|EXPERIMENTAL|Experimental: B (second group to receive the intervention)|This arm will not receive intervention in the first month and will receive SEE Learning after this period.
62402617|NCT04804579|EXPERIMENTAL|Fall Prevention Intervention|"The Intervention involves 3 primary components: virtual group sessions, at-home exercises, and weekly phone check-ins.~Virtual Group Session will be held via phone/video call for approximately 30 minutes per week for 10 weeks.~At-Home Exercises will be assigned by a registered occupational therapist member of the study team, and participants will be instructed to complete them independently at home 3 times per week. Participants will record the exercises that they complete.~Weekly Phone Check-Ins will occur once per week. These check-ins will be used to provide support and problem solving as needed, and individualized reminder systems will be set up to prompt the participant to engage in their weekly exercises (e.g., set up alarm on phone, notifications through calendar app)."
62402618|NCT04804579|NO_INTERVENTION|Control Group|Participants will be provided with an educational pamphlet that includes resources related to falls and alcohol use.
62402619|NCT06457659|EXPERIMENTAL|Early Rehab Group|
62402620|NCT06457659|OTHER|Delayed Rehab Group|
62402621|NCT02255045|EXPERIMENTAL|Dose 1 of meloxicam in vaginal ring|2.4 g of meloxicam in a vaginal ring
62402622|NCT02255045|EXPERIMENTAL|Dose 2 of meloxicam in vaginal ring|3.0 g of meloxicam in a vaginal ring
62402623|NCT02255045|ACTIVE_COMPARATOR|Oral non-steroidal anti-inflammatory drug|Diclofenac potassium
62402624|NCT02255045|PLACEBO_COMPARATOR|Placebo vaginal ring and oral pill|Placebo vaginal ring and placebo oral pill
62402625|NCT00692198|EXPERIMENTAL|Supplemental oxygen therapy|Participants will receive treatment with supplemental oxygen therapy.
62402626|NCT00692198|NO_INTERVENTION|No supplemental oxygen therapy|Participants will receive no supplemental oxygen therapy, unless the participant becomes severely hypoxemic at rest (e.g., meets conventional Medicare criteria for 24-hour supplemental oxygen due to severe hypoxemia at rest).
62402627|NCT00363376|EXPERIMENTAL|Sugar pill|"olanzapine and placebo (sugar pill)"
62579256|NCT04180514||Non-intradialytic hypotension|subjects without intradialytic hypotension episode
62402628|NCT00363376|EXPERIMENTAL|Zonisamide|olanzapine and zonisamide (active drug)
62402629|NCT02044094|EXPERIMENTAL|depot buprenorphine|Participants were treated with RBP-6000 300-mg in a single subcutaneous injection on Days 1 and 29 following a prior 14 day stabilization period (day -14 to day -1) of buprenorphine and naloxone (SUBOXONE) . Challenges consist of participants receiving on three consecutive days intramuscular (IM) injections of hydromorphone 0 mg (placebo), 6 mg and 18 mg doses during weeks 1-12 in randomized sequential order.
62579257|NCT00140465|ACTIVE_COMPARATOR|1|75 mg Clopidogrel Maintenance Doses
62579258|NCT00140465|ACTIVE_COMPARATOR|2|150 mg Clopidogrel Maintenance Doses
62579259|NCT06620172|EXPERIMENTAL|CT-guided RFT|Participants will undergo CT-guided trigeminal ganglion radiofrequency thermocoagulation (RFT) with real-time CT imaging for needle placement and monitoring.
62785658|NCT02604563||Arm E: Trauma|-Blood sample at the time of admission with initial bloodwork. For inpatient participants, weekly follow-up samples will be drawn with morning phlebotomy. A follow-up sample collection will occur 4-7 weeks after discharge.
62785659|NCT02306642||Premature Acute Kidney Injury in NICU|This group of babies born less than 1500 grams will have experienced acute kidney injury based on the modified KDIGO guidelines for acute kidney injury.
62785660|NCT02306642||Premature No Acute Kidney Injury in NICU|This group of babies born less than 1500 grams will have not experienced acute kidney injury in the NICU.
62579260|NCT06620172|ACTIVE_COMPARATOR|Fluoroscopy-guided RFT|Participants will undergo fluoroscopy-guided trigeminal ganglion radiofrequency thermocoagulation (RFT) with fluoroscopic imaging for needle placement and monitoring.
62579261|NCT02548728|EXPERIMENTAL|Oxytocin|Self administration three times on the first day, then twice daily treatment with intranasal oxytocin spray for 4 days.
62579262|NCT02548728|PLACEBO_COMPARATOR|Placebo|Self administration three times on the first day, then twice daily treatment with intranasal spray that does not contain oxytocin for 4 days.
62579263|NCT06280586|NO_INTERVENTION|Control|Usual clinical practice
62013706|NCT01513291|EXPERIMENTAL|MK-6096|Participants were randomized to receive double-blind MK-6096, two 5 mg tablets (10 mg dose), orally, once daily for 12 weeks in the Treatment Period. Those who completed the Treatment Period were randomized 1:1 to receive double-blind MK-6096 or placebo once daily in the 2-week Run-out Period.
62785661|NCT02306642||Term No Acute Kidney Injury|This group of babies born at term will have not experienced any acute kidney injury.
62785662|NCT01557907|EXPERIMENTAL|Intradermal - BD Research Catheter Set|Intradermal delivery of insulin (basal and bolus delivery) using the BD Research Catheter Set with 34G x 1.5 mm side-ported needle and the Animas Vibe insulin pump over a three day period.
62215117|NCT00287703|SHAM_COMPARATOR|2|5 days a week for 5 weeks for 30 minutes Sham PEMF
62402630|NCT05603000|NO_INTERVENTION|Waitlist (delayed intervention)|No treatment will be administered to participants in this arm until after the 4-month follow-up in-lab assessment is completed.
62402631|NCT05603000|EXPERIMENTAL|EFFT intervention|Treatment (6-week group Emotion Focused Family Therapy) will be administered to participants in this arm.
62785663|NCT01557907|ACTIVE_COMPARATOR|Subcutaneous - Medtronic Quick-Set|Subcutaneous delivery of insulin (basal and bolus delivery) using the Medtronic Quick Set with 6 mm Teflon catheter and the Animas Vibe insulin pump over a three day period.
62785664|NCT03406013|ACTIVE_COMPARATOR|Group I|Written Information
62785665|NCT03406013|EXPERIMENTAL|Group II|Written Information Prescription
62202156|NCT05942820|EXPERIMENTAL|BWC0977|"MAD Cohorts: Subjects will receive multiple doses of 240mg BID 7 days, 750mg BID 10 days,1250mg BID 10 days and 1000mg TID 10 days BWC0977 via IV infusion over 2 hours in the first 4 cohorts. The dose for the A5 cohort will be determined based on safety and tolerability data from the previous cohorts Up to five dose groups will be studied.~SAD Cohorts: Subjects will receive single doses of BWC0977 via IV infusion over 2 hours. The planned dose to be studied are 1500mg. Upto 2 cohorts will be studied"
62202157|NCT05942820|PLACEBO_COMPARATOR|Placebo|Compounded solution minus BWC0977 The placebo used during this study is 5% Dextrose for injection. SAD Cohorts: Subjects will receive single infusions of placebo (Compounded solution minus BWC0977) over two hours. MAD Cohorts: Subjects will receive multiple infusions of placebo over 2 hours for 7 or 10 consecutive days.
62202158|NCT00978367|EXPERIMENTAL|Drug, intradermal avotermin (Juvista)|
62202159|NCT00978367|PLACEBO_COMPARATOR|Placebo (vehicle)|
62202160|NCT01541384|EXPERIMENTAL|Medication Dosage Reminders|Subject will receive electronic pill bottle that will track adherence. They will also be able to activate available dosage reminders (text message, phone message, email).
62202161|NCT01541384|EXPERIMENTAL|Medicaiton Dosage Reminders + Coordinator Support|Subject will receive electronic pill bottle that will track adherence. They will also be able to activate available dosage reminders (text message, phone message, email). The study coordinator will also check adherence every 2 weeks and alert the transplant team when it drops below 90%. The transplant team will determine the next best course of action.
62202162|NCT01541384|OTHER|Usual Care with GlowCap|Subject will receive electronic pill bottle that will track adherence but all reminders will be deactivated.
62202163|NCT02328118|EXPERIMENTAL|Ranibizumab 0.5 mg|All subjects in this group will receive Ranibizumab (0.5mg/0.05ml) intravitreal injection.
62202164|NCT02328118|EXPERIMENTAL|Triamcinolone Acetonide 4mg|All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
62402632|NCT00975793|NO_INTERVENTION|Standard Care|Randomised allocation of standard care at the clinician's discretion in accordance with current best practice.
62402633|NCT00975793|EXPERIMENTAL|Early Goal Directed Therapy|Randomised allocation of early goal-directed therapy (EGDT).
62013707|NCT01513291|PLACEBO_COMPARATOR|Placebo|Participants were randomized to receive double-blind placebo, two tablets, orally, once daily for 12 weeks in the Treatment Period. Those who completed the Treatment Period continued to receive double-blind placebo once daily in the 2-week Run-out Period.
62202165|NCT04753086||Gynecologic Cancer Pts|Gynecologic cancer patients being treated with radiation at UNC.
62202166|NCT03931746|EXPERIMENTAL|Porcine Xenograft placement|Porcine xenograft will be placed on the wound.
62202167|NCT03931746|NO_INTERVENTION|No porcine xenograft|The wound will be allowed to heal via second intention.
62785666|NCT03406013|EXPERIMENTAL|Group III|Written Information Prescription Technology
62202168|NCT06158932|EXPERIMENTAL|Myo Inositol and D-Chiro Inositol Supplement|Participants must take 4 capsules per day, with water. The product should be taken with the last meal of the day.
62202169|NCT01721928||ICU patients with AKI|ICU patients with AKI treated with continuous venovenous hemodialysis
62202170|NCT01721928||ICU patients without AKI|ICU patients without AKI defined as RIFLE group O and R
62202171|NCT04990362|EXPERIMENTAL|MD + Seed oil|"Pomegranate oil + Mediterranean Diet 30 patients Mediterranean dietary protocol Dietary Supplement: Pomegranate oil in a glass bottle of 30ml Dietary Supplement: Mediterranean dietary protocol~Intervention:~Mediterranean diet, Pomegranate oil"
62202172|NCT04990362|ACTIVE_COMPARATOR|MD|Mediterranean Diet 30 patients Mediterranean dietary protocol Dietary Supplement: Mediterranean dietary protocol Intervention: Mediterranean diet
62202173|NCT01734239|EXPERIMENTAL|Pneumovax™ 23: Participants Between 2 and 49 Years|Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
62202174|NCT01734239|EXPERIMENTAL|Pneumovax™ 23: Participants >=50 Years|Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
62202175|NCT02199223|EXPERIMENTAL|panitumumab + regorafenib|
62202176|NCT04052815|EXPERIMENTAL|Diabetes prevention program culturally tailored|Adult females with Hispanic background
62202177|NCT04439045|EXPERIMENTAL|VPM1002|A single dose of 0.1 mL of the reconstituted vaccine containing VPM1002 (Mycobacterium bovis rBCGΔureC::hly, live 2-8 × 105 CFU), administered via intradermal injection.
62402634|NCT03077854|EXPERIMENTAL|Functional Lung Avoidance-TRT|"Functional Lung Avoidance Thoracic Radiotherapy~The avoidance thoracic radiotherapy treatment plan will be designed to optimize such that radiation dose to functional lung identified by four-dimensional (4D) CT ventilation imaging is as low as reasonably achievable"
62402635|NCT03077854|ACTIVE_COMPARATOR|Standard-TRT|"Standard Thoracic Radiotherapy~The standard thoracic radiotherapy treatment plan will be designed without reference to the functional lung 4D CT ventilation imaging"
62785667|NCT03406013|EXPERIMENTAL|Group IV|Written Information Prescription Technology Coaching
62785668|NCT02087969|EXPERIMENTAL|Dry Needling|Dry Needling to Triceps Surae
62402636|NCT02575261|EXPERIMENTAL|Experimental:CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen by infusion.
62785669|NCT02087969|EXPERIMENTAL|Stretching|Subjects will be given a home exercise program of stretches which are commonly prescribed to improve ankle dorsiflexion.
62785670|NCT00950248|ACTIVE_COMPARATOR|Idebenone|Idebenone (150mg tablets) administered orally as five tablets, three times per day with food.
62785671|NCT00950248|PLACEBO_COMPARATOR|Placebo|Placebo tablets administered orally as five tablets, three times per day with food.
62785672|NCT02700828|ACTIVE_COMPARATOR|Hydrocortisone|Hydrocortisone is the pharmaceutical term for cortisol, the principal glucocorticoid secreted by the adrenal gland
62202178|NCT04439045|PLACEBO_COMPARATOR|Placebo|A single dose of 0.1 mL of the 0.9% sodium chloride injection, administered via intradermal injection.
62202179|NCT00749957|EXPERIMENTAL|1|Subjects at least 6 y/o treated with a lower dose of the vector by subretinal injection
62402637|NCT02575261|NO_INTERVENTION|No Intervention|
62579264|NCT06280586|EXPERIMENTAL|Intervention|"* bimonthly personalized follow-up with the appropriate specialists (5 in a year) i~* a program of group activities (6 sessions in a year) with a monitor with the aim of reinforcing adherence to the study intervention and adapting it to the circumstances and the physical, personal and social reality around each participant. The sessions will last approximately one hour and will cover:~  * General dietary and hydration recommendations and dietary recommendations for people at risk of malnutrition~ * Dietary and physical exercise recommendations in obese elderly~ * General physical exercise recommendations in the elderly and physical exercise recommendations in the elderly with sarcopenia~ * Physical exercise recommendations for the elderly at risk of falls.~ * Medication management and social resources for the elderly in Mataró."
62785673|NCT02700828|PLACEBO_COMPARATOR|Placebo|Isotonic sodium chloride is an aqueous solution of 0.9 percent sodium chloride which is isotonic with the blood and tissue fluid
62785674|NCT00681733|EXPERIMENTAL|A|Pioglitazone
62785675|NCT00681733|ACTIVE_COMPARATOR|B|Pentoxifylline
62579265|NCT04512196|EXPERIMENTAL|Super-oxidised Solution|Peritoneal lavage with super-oxidised solution of at least 10 cc/kg and wound lavage with super-oxidised solution 1 cc/kg
62785676|NCT05289479|ACTIVE_COMPARATOR|"No pre-heating control group"|resin composite is used at room temperature without preheating
62785677|NCT05289479|ACTIVE_COMPARATOR|0ne cycle pre-heating|one cycle preheating of resin composite at 68 degree Celsius before application
62202180|NCT00749957|EXPERIMENTAL|2|Subjects at least 6 y/o treated with a higher dose of the vector by subretinal injection
62202181|NCT02512731|ACTIVE_COMPARATOR|Goal directed fluid therapy using esophageal doppler monitor|The esophageal doppler monitor directs the fluid therapy.
62202182|NCT02512731|NO_INTERVENTION|Fluid therapy using standard management|The esophageal doppler monitor is in place however blinded to the healthcare providers, fluid management is as per standard clinical practice.
62202183|NCT04617249|ACTIVE_COMPARATOR|Giving median anesthesia|
62402638|NCT04252196|EXPERIMENTAL|Device Usability Study|Usability evaluators of medical device (Healthy volunteers).
62402639|NCT00860756|EXPERIMENTAL|1|Intervention Group
62579266|NCT04512196|PLACEBO_COMPARATOR|Normal Saline|Peritoneal lavage with normal saline 0.9% of at least 10 cc/kg and wound lavage with normal saline 0.9% 1 cc/kg
62785678|NCT05289479|ACTIVE_COMPARATOR|ten cycles pre-heating|ten cycles preheating of resin composite at 68 degree Celsius before application
62785679|NCT02712528|ACTIVE_COMPARATOR|remifentanil-based|remifentanil-based regimen consisting of remifentanil 0.75 mcg/kg/min and supplemental propofol for maintaining BIS 40-60
62785680|NCT02712528|PLACEBO_COMPARATOR|sevoflurane-sufentanil balanced|balanced sevoflurane (end-tidal 1.2-2.8 vol%) and sufentanil (0.015 mcg/kg/min) regimen
62785681|NCT04892771||Experimental group|Patients who have honored two consultations per year for two years.
62785682|NCT04892771||Control group|Patients who have not honored two consultations per year for two years.
62785683|NCT00746694||Caelyx|Participants with metastatic breast or ovarian cancer treated with Caelyx as part of standard treatment and according to data sheet approved indications.
62785684|NCT05917054||Group 1-bipolar sealing|During the back-table preparation stage of these kidney transplant recipients, bipolar sealing method will be used for sealing the small vessels and lymphatics of the renal allograft.
62013708|NCT06663878|EXPERIMENTAL|MWAV201|All subjects will receive a single intravenous (IV) infusion of MWAV201.
62013709|NCT02133326|EXPERIMENTAL|Caldolor|800 mg of Caldolor® will be infused at the rate of 5-7 minutes as per the manufacturer's guidelines or
62202184|NCT04617249|ACTIVE_COMPARATOR|Giving paramedian anesthesia|
62202185|NCT04551677|EXPERIMENTAL|Group 1: Fluzone Quadrivalent Influenza Vaccine: 6 to <36 Months|Participants aged 6 to \<36 months received a 0.5-milliliters (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 1. Participants for whom 2 doses of influenza vaccine were recommended per Advisory Committee on Immunization Practices (ACIP), a second dose was administered at Day 28.
62202186|NCT04551677|EXPERIMENTAL|Group 2: Fluzone Quadrivalent Influenza Vaccine: 3 to <9 Years|Participants aged 3 to \<9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 1. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
62402640|NCT05623189|EXPERIMENTAL|HTD1801|HTD1801,1250 mg, BID
62785685|NCT05917054||Group 2-conventional silk tie|During the back-table preparation stage of these kidney transplant recipients, conventional silk-tie method will be used for sealing the small vessels and lymphatics of the renal allograft.
62202187|NCT04551677|EXPERIMENTAL|Group 3: Fluzone High-Dose Quadrivalent Influenza Vaccine: >=65 Years|Participants aged \>=65 years received a 0.7-mL dose of Fluzone High-Dose Quadrivalent vaccine intramuscularly at Day 1.
62202188|NCT04267965||Group A|Patients who have been successfully operated on with total parathyroidectomy for symptomatic secondary hyperparathyroidism and their PTH levels are below 72 pg/dL within one week after surgery.
62202189|NCT04267965||Group B|Patients who have had regular dialysis and their iPTH levels are around 500 pg/dL
62215118|NCT04454775||group I|50 cases who received raloxifene and calcium therapy
62215119|NCT04454775||group II|30 cases who received only calcium therapy
62785686|NCT02235896|OTHER|Education/Behavior Modification|Education/Behavior modification program
62785687|NCT04844853|EXPERIMENTAL|Preterm 2|2-year-olds born prematurely
62402641|NCT05623189|PLACEBO_COMPARATOR|placebo|placebo, BID
62402642|NCT03273088|EXPERIMENTAL|AryoGen Pharmed etanercept|Altebrel (etanercept prefilled syringe produced by AryoGen Pharmed Company) 25mg/0.5ml in prefilled syringe.
62402643|NCT03273088|ACTIVE_COMPARATOR|Pfizer etanercept|Enbrel® (etanercept prefilled syringe produced by Pfizer Company) 25mg/0.5ml in prefilled syringe.
62785688|NCT04844853|EXPERIMENTAL|Term 2|2-year-olds born at term
62785689|NCT04844853|EXPERIMENTAL|Typical 6|6-year-olds with typical developement
62402644|NCT06187207||Candidates for AVF intervention|Patients requiring hemodialysis who are intervened for AVF creation.
62402645|NCT04901182|ACTIVE_COMPARATOR|White sesame soy milk smoothie (WS)|a formula developed from natural ingredients such as soybean and white sesame
62402646|NCT04901182|ACTIVE_COMPARATOR|Chicken shitake smoothie (CS)|a formula developed from natural ingredients such as chicken and shitake mushroom
62402647|NCT04901182|PLACEBO_COMPARATOR|Ensure|a conventional well-known commercial formula
62402648|NCT00456326||HIT Patients|Patients at Brigham and Women's Hospital diagnosed with Heparin Induced Thrombocytopenia.
62202190|NCT04606498||1- Retrospective|Retrospective Seraph® 100 - this group will be composed of subjects that were treated with Seraph® 100 after the date of the EUA approval (17 April 2020), but before the date that the study is approved at the study site. A waiver of informed consent will be requested from the Institutional Review Board (IRB) to allow the collection of these retrospective data
62202191|NCT04606498||2 - Prospective|Prospective Seraph® 100 - To identify prospective Seraph® 100 patients, the individual site investigators will review currently admitted ICU patients for inclusion criteria and exclusion criteria. The study team will then ask the physician caring for the patient to contact the study team should the patient require therapy with Seraph® 100. Additionally, the study team will review the medical records of admitted patients to see if they have recently been started on Seraph. Patients found to meet eligibility will be offered the opportunity to consent and participate in the study. Note that patients that were started on Seraph® 100 before the date of approval but are still admitted, will not be eligible to give biospecimens.
62202192|NCT04606498||3 - Historical Control|The historical control group will be a sample of convenience, composed of patients admitted to the ICU at participating sites with severe COVID-19 infection, meeting the EUA treatment criteria, but not treated with Seraph® 100 up to the time the PURIFY-OBS protocol is approved at the site. A waiver of informed consent will be requested from the IRB to allow the collection of these retrospective data
62202193|NCT05119062|PLACEBO_COMPARATOR|Control group|Participants in the control group will receive usual care.
62202194|NCT05119062|EXPERIMENTAL|an online intergenerational co-parenting programme|Those who are randomized to the intervention group will receive the intergenerational co-parenting program in addition to the usual care, including 3 weekly antenatal sessions (start from 33-35 weeks gestation) and 2 weekly postnatal sessions (start from the first week after discharge from hospital). The essential components and focus of the intergenerational co-parenting program were developed based on the themes identified from the two qualitative studies, the systematic review of co-parenting interventions, and the proposed intergenerational co-parenting model. The intervention will be delivered online through an education platform of the study hospital.
62402649|NCT04657861|EXPERIMENTAL|Administration of APRIL CAR T-cells|Each subject receive APRIL CAR T-cells by intravenous infusion
62402650|NCT01869231|EXPERIMENTAL|major surgery|colic surgery
62402651|NCT01869231|EXPERIMENTAL|minor surgery|appendectomy; cholecystectomy
62785690|NCT04844853|EXPERIMENTAL|NDD 6|6-year-olds with neurodevelopmental disorders
62013710|NCT02133326|EXPERIMENTAL|Ofirmev|1000 mg of Ofirmev® will be infused at the rate of 15 minutes as per the manufacturer's guidelines.
62202195|NCT00790205|EXPERIMENTAL|Sitagliptin|Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
62402652|NCT01869231|EXPERIMENTAL|ileostomy and colostomy|ileostomy colostomy
62402653|NCT01869231|EXPERIMENTAL|other surgery|all of others abdominal surgical intervention
62402654|NCT02735720||TEVAR group|"Adult patients whose clinician's are managing their thoracic aortic aneurysms or with penetrating aortic ulcers with TEVAR.~Standard work-up examinations for TEVAR will be collected, consisting of computed tomography (CT), echocardiography, blood pressure, heart rate, ECG and blood tests. Prior to the TEVAR procedure, a non-invasive MRI scan and blood samples will be acquired. Intraoperative pressure measurements will be collected during the TEVAR. One year following TEVAR, the subject will undergo a second non-invasive MRI study in addition to the standard clinical imaging follow-up CT-scan. Measurements of blood pressure, heart rate, ECG, and blood testing will also be repeated at follow-up."
62402655|NCT02735720||Non-TEVAR medical treatment group|"Adult patients whose clinician's are managing their thoracic aortic aneurysms or with penetrating aortic ulcers with pharmacological treatment alone.~Patients with stable thoracic aortic aneurysms or with penetrating aortic ulcers not requiring aortic repair are monitored in the outpatient clinic as standard of care. The investigators will collect blood pressures and heart rates in these patients, which are acquired as standard of care. In addition, in this study, these subjects will undergo an ECG, blood testing and one non-invasive MRI scan at baseline. One year after baseline, this group will undergo a second non-invasive MRI study, with subsequent blood pressure and heart rate measurements, ECG and blood testing."
62402656|NCT06283654||1-lead ECG group|Patients after PVI that received a 1-lead ECG
62402657|NCT06283654||standard care group|standard care group
62579267|NCT06682663|EXPERIMENTAL|Live Streaming Exercise|Live Streaming Exercise:Conduct supervised exercise guidance interventions from the 14th week of pregnancy and continuing through the 36+6th week.
62579268|NCT06682663|NO_INTERVENTION|Regular care|Regular care:health education.
62579269|NCT05657522|EXPERIMENTAL|Rapid Molar Intruder|Patients in this group will undergo the interventional procedure, which is the application of the rapid molar intruder appliance. This will help in correcting the open bite.
62785691|NCT02485704|EXPERIMENTAL|Natroba (spinosad)|spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours
62785692|NCT02485704|PLACEBO_COMPARATOR|Placebo|placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad (vehicle). Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.
62785693|NCT06443983|EXPERIMENTAL|AI-supported case lesson group|Students in this group will take an artificial intelligence-supported in-class case analysis lesson.
62785694|NCT06443983|NO_INTERVENTION|Standard case lesson group|Students in this group will receive a standard in-class case lesson narrated by the instructor.
62785695|NCT00556816|ACTIVE_COMPARATOR|Conventional outpatient clinic|Conventional outpatient clinic
62013711|NCT02323464||Before surgery|patients scheduled for surgery of colorectal cancer
62013712|NCT02323464||Control subjects|Controls from the population without colorectal cancer
62202196|NCT00790205|PLACEBO_COMPARATOR|Placebo|Placebo to sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
62402658|NCT04284241|EXPERIMENTAL|Intervention group|"Participants include newborns and their parents. The baseline of newborns includes demographic data, blood cell analysis, urinary tract ultrasonographic examination. Parents will be asked to answer a questionnaire which regarding the knowledge, attitudes, and practices (KAP questionnaire) related to pediatric stone. Parents also undergo and active health education by the investigator with the  Parents' Health-Education Handbook, and Handbook will be given to them. Handbook includes the knowledge of symptoms, hazards, epidemiology, risk factors, therapy, and prevention of pediatric urolithiasis, and also baby's right feeding methods. Follow up is made every year in the first three years, and the program is done as the baseline."
62402659|NCT04284241|NO_INTERVENTION|Control group|Participants include newborns and their parents. The baseline of newborns includes demographic data, blood cell analysis, urinary tract ultrasonographic examination. Newborns' parents will be asked to answer a questionnaire which regarding the knowledge, attitudes, and practices (KAP questionnaire) related to pediatric stone. But parents do not undergo active health education. And Handbook will not be given to them. However, a poster which has the same content as the Handbook is normally displayed in the maternity ward. Parents have the opportunity to see the poster, but without any special remind. Follow up is made every year in the first three years, and the program is done as the baseline.
62013713|NCT05615467|EXPERIMENTAL|LY3556050 + Metformin + Iohexol|LY3556050 administered orally in combination with metformin given orally and iohexol given intravenously (IV).
62202197|NCT06479369|EXPERIMENTAL|Physical Education Teachers (intervention)|PE teachers who will receive the training.
62202198|NCT06479369|NO_INTERVENTION|Physical Education Teachers (non-intervention)|PE teachers who will not receive the training.
62402660|NCT04115488|EXPERIMENTAL|PB006|Patients with relapsing-remitting multiple sclerosis (RRMS) received intravenous (IV) infusions every 4 weeks of PB006 at a dose of 300 milligram (mg) starting at Visit 1 (Week 0) through Visit 12 (Week 44), for a total of 12 infusions.
62402661|NCT04115488|ACTIVE_COMPARATOR|Tysabri|Patients with relapsing-remitting multiple sclerosis (RRMS) received intravenous (IV) infusions every 4 weeks of Tysabri at a dose of 300 milligram (mg) starting at Visit 1 (Week 0) through Visit 12 (Week 44), for a total of 12 infusions. At Week 24, patients in the Tysabri group were re-randomized through a re-randomization step. Patients re-randomized and switched from Tysabri to PB006 at Week 24 still received a total of 12 infusions (6 infusions of Tysabri and 6 infusions of PB006).
62402662|NCT01551238|EXPERIMENTAL|Protein intake of 5 energy percent|
62402663|NCT01551238|EXPERIMENTAL|Protein intake of 30 energy percent|
62402664|NCT04638218|EXPERIMENTAL|Augmented Reality|The system provides visual and audio feedback which makes the rehabilitation training process more relaxing, interesting and convenient to guide the patients performing appropriate upper-limb, lower-limb exercises and balance training.
62402665|NCT04938726|EXPERIMENTAL|Ketone Monoester|The ketone used is from KetoneAid and is commercially available as KE4 and will be consumed at 30 mL twice daily (15 g / dose)
62202199|NCT06479369|EXPERIMENTAL|Students (intervention)|Students of those teachers who will received the training
62202200|NCT06479369|NO_INTERVENTION|Students (non-intervention)|Students of those teachers who will not received the training
62202201|NCT02348944||15 healthy volunteers|Other: serum and urine sample
62202202|NCT05045274|ACTIVE_COMPARATOR|dapagliflozin|(a) Dapagliflozin 10 mg once daily within 24 hours after PPCI for 3 month
62402666|NCT04938726|PLACEBO_COMPARATOR|Placebo|A placebo is being manufactured by KetoneAid to match the taste and other characteristics of the ketone supplement for blinding purposes
62402667|NCT01946295|EXPERIMENTAL|Famotidine|Famotidine 100mg x 2 orally
62402668|NCT01946295|PLACEBO_COMPARATOR|Placebo|Placebo control
62013714|NCT02564471|EXPERIMENTAL|Chloroquine|Chloroquine Phosphate tablet for oral administration 500 mg chloroquine phosphate (equivalent to 300 mg base)
62202203|NCT05045274|PLACEBO_COMPARATOR|conventional therapy|"1. Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.~2. Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.~3. Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload."
62202204|NCT06265714||One ICCU Registry|The cohort was observed receiving all the necessary treatment in the ICCU.
62202205|NCT03771794|ACTIVE_COMPARATOR|Active Comparator: ReguRate RR2 active|Device: ReguRate neurostimulation device
62202206|NCT03771794|SHAM_COMPARATOR|Sham Comparator: ReguRate RR2 sham.|Device: Sham ReguRate neurostimulation - mock sham stimulation mode
62402669|NCT00807859|EXPERIMENTAL|Cohort A1|
62402670|NCT00807859|EXPERIMENTAL|Cohort A3|
62402671|NCT00807859|EXPERIMENTAL|Cohort B1|
62402672|NCT00807859|EXPERIMENTAL|Cohort B3|
62013715|NCT02564471|EXPERIMENTAL|Atovaquone and Proguanil (Malarone)|"Malarone tablet for oral administration 250 mg atovaquone and 100 mg proguanil hydrochloride.~RabAvert rabies vaccine, at least 2.5 IU of rabies antigen."
62202207|NCT05719753|PLACEBO_COMPARATOR|Standard of Care|Bard Catheter
62202208|NCT05719753|EXPERIMENTAL|Camstent Coated Catheter|The Camstent Coated Foley Catheter is an all-silicone two-way Foley-type urinary catheter, to which a proprietary polymeric coating has been applied.
62202209|NCT01448577||Dose 3 x 1011 gc/kg|Subjects received AMT-011 at dose 3 x 1011 gc/kg
62202210|NCT01448577||Dose 1 x 1012 gc/kg|Subjects received AMT-011 at dose 1 x 1012 gc/kg
62202211|NCT02090010|ACTIVE_COMPARATOR|GroupC|Group C means Control group which use Seldinger technique for subclavian catheterization. The aimed vessel(subclavian vein) is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and the needle is removed. After that catheter is passed over the guidewire into the vessel.
62215120|NCT00872989|EXPERIMENTAL|Arm I|Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who progress also receive oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of a second disease progression or unacceptable toxicity.
62013716|NCT02564471|EXPERIMENTAL|Doxycycline|"Doxycycline hyclate tablet for oral administration, contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.~RabAvert rabies vaccine, at least 2.5 IU of rabies antigen."
62013717|NCT02564471|ACTIVE_COMPARATOR|Rabies|RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.
62202212|NCT02090010|EXPERIMENTAL|Group MS|Group MS means experimental group which use modified Seldinger technique for subclavian catheterization. The aimed vessel is punctured with the needle that is covered with guiding sheath. After vessel is punctured, guiding sheath is instatntly slid over the needle into the vessel. The needle is removed, guidewire is advanced through the sheath, central catheter is placed into the vessel.
62202213|NCT05624151|ACTIVE_COMPARATOR|general anesthesia+ infraorbital nerve block by dexmedetomidine plus bupivacaine|
62785696|NCT00556816|EXPERIMENTAL|On demand outpatient clinic|On demand outpatient clinic
62013718|NCT05868798|NO_INTERVENTION|Control|Participants performed each individual test without ammonia inhalants.
62013719|NCT05868798|EXPERIMENTAL|Ammonia inhalants|Participants performed each individual test with ammonia inhalants.
62785697|NCT02274740|EXPERIMENTAL|lixisenatide|"Lixisenatide injection should be performed in the morning, within 1 hour (ie, 0-60 minutes), prior to breakfast (or standardized meal).~Lixisenatide is to be started with once daily injections of 10 μg per day for 2 weeks then to be continued by the maintenance dose (8 weeks) of 20 μg/d up to the end of the treatment period."
62785698|NCT02274740|NO_INTERVENTION|metformin|Greater than or equal than 1.5 g/day as background therapy for 10 weeks
62013720|NCT04961333|EXPERIMENTAL|Rehabilitation group|Rehabilitation group will be provided multidisciplinary interventions online and individually by ExorLive app. The screening with self-scored questionnaires and physical tests will be performed before and after 8 weeks rehabilitation.
62013721|NCT04961333|NO_INTERVENTION|Waiting list controls|Passive waiting list or control group, which will be offered to participate in rehabilitation after at least 8 weeks of waiting time. The group will fulfil screening twice, following the time schedule of intervention group. When invited to rehabilitation a new screening will be asked to be completed if the waiting time after the last screening will be longer than 2 weeks.
62013722|NCT05039905|EXPERIMENTAL|99mTc-MSA-ICG injection|"99mTc-MSA-ICG injection~1mCi of 99mTc~1mg of MSA 0.1mg of ICG Total 1cc injection volume at 2 hours before the surgery"
62785699|NCT03799939|ACTIVE_COMPARATOR|Intervention group|Polyvinylidene fluoride mesh used in this trial (Dynamesh IPST) is synthetic mesh with central tube to accommodate bowel tightly and designed to prevent and treat parastomal hernia.
62785700|NCT03799939|NO_INTERVENTION|Control group|Participants in control group are operated with no preventive mesh.
62785701|NCT04896281|EXPERIMENTAL|phenylalanine-free diet|phenylalanine-free diet for patients with hyperphenylalaninemia
62785702|NCT04771702|EXPERIMENTAL|Edmon arm|
62785703|NCT03813914|EXPERIMENTAL|Sineos|Glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills/day for 3 months
62013723|NCT01646671|EXPERIMENTAL|LCZ696 200 mg|All participants were started on LCZ696 200 mg once daily on day 1. Participants who achieved mean sitting diastolic blood pressure (msDBP) of \< 100 mmHg and mean sitting systolic blood pressure (msSBP) of \< 160 mmHg at week 2 or a msDBP \< 90 mmHg and msSBP \< 140 mmHg at or after week 4 and for the duration of the study continued at 200 mg LCZ696 once daily.
62202214|NCT05624151|ACTIVE_COMPARATOR|general anesthesia+ infraorbital nerve block by magnesium sulphate plus bupivacaine|
62202215|NCT05624151|ACTIVE_COMPARATOR|general anesthesia+infraorbital nerve block by bupivacaine only|
62202216|NCT01221636|OTHER|Low Metal Abatacept|Reference
62785704|NCT03813914|PLACEBO_COMPARATOR|Placebo comparator|placebo 2 pills/day for 3 months
62785705|NCT00523081|EXPERIMENTAL|Experimental|Teens in the experimental group will meet with a research counselor for five to nine individual, 50-minute weekly sessions. They will learn ways to deal with stress and feel better. The study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
62202217|NCT01221636|EXPERIMENTAL|High Metal Abatacept|
62402673|NCT05333861||Full-analysis set (FAS)|The FAS includes all enrolled patients. The FAS will be used for all analyses.
62402674|NCT04762706|EXPERIMENTAL|CRUTCH Pathway|A novel behavioral health program.
62402675|NCT03004612|EXPERIMENTAL|Linagliptin + Metformin plus lifestyle|Patients are randomized to receive for 24 months Linagliptin 2.5mg + metformin 850mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
62202218|NCT02712268|OTHER|After introduction of the checklist|Review of medications of all consecutive admitted patients during the study period using a checklist
62402676|NCT03004612|ACTIVE_COMPARATOR|Metformin plus lifestyle|Patients are randomized to receive for 24 months Metformin 850mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
62402677|NCT04310241||Control subjects|Subjects who state they have no eye or neurologic problems or disease other than perhaps wearing glasses or contact lenses and upon review of medical history.
62402678|NCT04310241||Amblyopia|Clinical diagnosis of amblyopia
62402679|NCT01483495||Diagnostic tool|Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
62402680|NCT06371027|ACTIVE_COMPARATOR|Minimally Invasive Surgery Technique (MIST)|Minimally Invasive Surgery Technique in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
62402681|NCT06371027|EXPERIMENTAL|Minimally Invasive Surgery Technique (MIST) + Collagen Membrane|Minimally Invasive Surgery Technique + Collagen Membrane placement in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
62402682|NCT06371027|EXPERIMENTAL|Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane|Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane placement in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
62402683|NCT06033924|EXPERIMENTAL|Internet-based Walking Program|Internet pages allow participants to see step-count goals, progress over time and access to walking tips
62402684|NCT06033924|EXPERIMENTAL|Telehealth Counseling Walking Program|Telehealth sessions allow participants review step-count goals, progress over time and access to walking tips with the study coordinator
62402685|NCT05776407|EXPERIMENTAL|ThisCART19A cells infusion|In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used to treat patients with r/r B cell Lymphoma.
62402686|NCT00478504|ACTIVE_COMPARATOR|Clomiphene citrate|Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
62402687|NCT00478504|ACTIVE_COMPARATOR|Letrozole|Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
62402688|NCT00501072|EXPERIMENTAL|Open|Real-Time Continuous Glucose monitoring System (RT-CGMS) with alarm setting active and ability to view glucose trend profiles
62579270|NCT05657522|NO_INTERVENTION|Untreated Control Group|Patients in this group will be monitored without any active treatment.
62785706|NCT00523081|ACTIVE_COMPARATOR|Active Control|
62202219|NCT00874731|EXPERIMENTAL|Pt 1. Placebo/Ridaforolimus 100 mg; Pt 2. Ridaforolimus 40 mg|\[Pt 1, Day 1\]: Participants received a single dose of placebo (10 oral tablets) on Day 1 of Part 1. \[Pt 1, Day 2\]: Following completion of Part 1 / Day 1, participants received a single dose of ridaforolimus 100 mg (10 x 10 mg oral tablets) on Day 2 of Part 1. Following completion of Part 1 / Day 2, participants entered a washout period of ≥5 days before the first dose Part 2. \[Pt 2\]: Following completion of Part 1, participants received ridaforolimus 40 mg (4 x 10 mg oral tablets) given once daily (QD) for 5 consecutive days followed by 2 days off-drug.
62402689|NCT00501072|NO_INTERVENTION|Blind|RT-CGMS is applied without alarm setting and without the ability to watch glucose trend profiles
62402690|NCT05083494||Melanoma|
62402691|NCT05083494||clear cell renal cancer|
62402692|NCT05083494||Urothelial Carcinoma of the bladder|
62579271|NCT02860130|EXPERIMENTAL|Prismocitrate 18|
62785707|NCT03686475|EXPERIMENTAL|Biodentine pulpotomy|Biodentine (Septodont, France) Pulpotomy for primary molars Clinical and radiographic evaluation Follow up at 1,3,6 and 12 months
62785708|NCT03686475|ACTIVE_COMPARATOR|MTA pulpotomy|"MTA (Angelus- Londrina, Brazil) Pulpotomy for primary molars . it is fine hydrophilic powder consisting of tricalcium silicate, tricalicum aluminate, tricalcium oxide, silicate oxide and bismuth oxide11.~It is currently being used in pulpotomy of primary molars with a high rate of success.~Clinical and radiographic evaluation. Follow up at 1,3,6 and 12 months"
62579272|NCT02860130|ACTIVE_COMPARATOR|No Regional Anticoagulation of CRRT Circuit|
62579273|NCT00122993|EXPERIMENTAL|1|Multi-component environmental intervention to prevent excess weight gain among bus drivers
62785709|NCT02138968|EXPERIMENTAL|Multidimensional intervention|Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
62402693|NCT05083494||squamous cell carcinomas of the head and neck|
62402694|NCT05083494||non-small cell lung cancer|
62402695|NCT02127866|EXPERIMENTAL|CHF 5259 25 µg plus Foster 100/6 µg|
62402696|NCT02127866|EXPERIMENTAL|CHF 5259 50 µg plus Foster 100/6 µg|
62402697|NCT02127866|EXPERIMENTAL|CHF 5259 100 µg plus Foster 100/6 µg|
62402698|NCT02127866|ACTIVE_COMPARATOR|Foster 100/6 µg|
62579274|NCT00122993|NO_INTERVENTION|2|Control group
62579275|NCT05402410||Training cohort|Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis and clinical manifestations.
62579276|NCT05402410||Validation cohort|Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis and clinical manifestations.
62402699|NCT00726882|OTHER|HCV-infected Participants|"Hepatitis C virus (HCV)-infected participants who received ABT-333 at any dose level or matching placebo in a prior clinical study involving ABT-333.~Participants received no treatment in this follow-up study."
62402700|NCT06653491|EXPERIMENTAL|Experimental|high-speed, low-amplitude talocrural decompression technique and changes at the level of mobility and plantar pressure
62402701|NCT06653491|ACTIVE_COMPARATOR|Active Comparator|simulated ankle technique and changes at the level of mobility and plantar pressure
62402702|NCT05912192|EXPERIMENTAL|Elonide Nasal Spray|Elonide is generic nasal spray Dose: 50 mcg/dose mometasone furoate 140 sprays per nasal spray One pump for both nostrils twice daily
62402703|NCT05912192|ACTIVE_COMPARATOR|Nasonex Nasal Spray|Nasonex Aqueous Nasal Spray Dose: 50 mcg/dose mometasone furoate 140 sprays per nasal spray The usual recommended dose for prophylaxis and treatment is two sprays (50 micrograms/spray) in each nostril once daily (total dose 200 micrograms) One pump for both nostrils twice daily
62402704|NCT05912192|PLACEBO_COMPARATOR|Normal Saline|Placebo used is 0.9% sodium chloride Dose: 50 mcg/dose of 0.9% sodium chloride One pump for both nostrils twice daily
62402705|NCT01040624|EXPERIMENTAL|High-risk arm A (HR-A)|\< 15% risk of + lymph nodes (LN)
62402706|NCT01040624|EXPERIMENTAL|HR-B|\> 15% risk of + LN
62402707|NCT00862667|EXPERIMENTAL|Treatment A|PF-00241939 300ug using Inhaler A
62402708|NCT00862667|ACTIVE_COMPARATOR|Treatment B|PF-00241939 300ug using Inhaler B
62402709|NCT00862667|ACTIVE_COMPARATOR|Treatment C|PF-00241939 300ug using Inhaler C
62402710|NCT01193478|ACTIVE_COMPARATOR|Cohort 1|GS-5885 (3 mg), once daily or matching placebo, once daily
62402711|NCT01193478|ACTIVE_COMPARATOR|Cohort 2|GS-5885 (10 mg), once daily or matching placebo, once daily
62402712|NCT01193478|ACTIVE_COMPARATOR|Cohort 3|GS-5885 (30 mg), once daily or matching placebo, once daily
62402713|NCT01193478|ACTIVE_COMPARATOR|Cohort 4|GS-5885 ( up to 90 mg), once daily or matching placebo, once daily
62402714|NCT01193478|ACTIVE_COMPARATOR|Cohort 5|GS-5885 (up to 90 mg), once daily or matching placebo, once daily
62402715|NCT01193478|ACTIVE_COMPARATOR|Cohort 6 (optional)|GS-5885 (up to 90 mg), once daily or matching placebo, once daily
62402716|NCT01043809|NO_INTERVENTION|1|Randomly selected schools will not receive handwashing intervention
62402717|NCT01043809|EXPERIMENTAL|2|Randomly selected schools will get standard commercial school-based handwashing promotion
62402718|NCT01043809|EXPERIMENTAL|3|Randomly selected schools will receive standard commercial school-based handwashing promotion program, plus an added level of handwashing promotion (varies by country)
62402719|NCT00698373||1|PET study
62402720|NCT02228148|EXPERIMENTAL|NFS|Cochlear Nucleus Fitting Software
62013724|NCT01646671|EXPERIMENTAL|LCZ696 400 mg|All participants were started on LCZ696 200 mg once daily on day 1. For participants who did not achieve mean sitting diastolic blood pressure (msDBP) of \< 100 mmHg and mean sitting systolic blood pressure (msSBP) of \< 160 mmHg at week 2 or a msDBP \< 90 mmHg and msSBP \< 140 mmHg at or after week 4, and did not have any signs of safety concerns, the LCZ696 dose was increased to 400 mg once daily.
62402721|NCT02228148|ACTIVE_COMPARATOR|CSS|Cochlear Nucleus Custom SoundTM Suite
62402722|NCT02988830|EXPERIMENTAL|Chronic lumbar pain|
62402723|NCT05710367|EXPERIMENTAL|Dapagliflozin 10mg Tab|SGLT2is- Dapagliflozin (Forxiga): 10 mg/d, oral drug
62402724|NCT05710367|PLACEBO_COMPARATOR|Placebo|Placebo tablet will have the same color, taste, smell and package as the verum tablet
62202220|NCT01876277||Adolescent males with cancer|Males aged 13-21 who have been treated at the Royal Marsden Hospital for cancer.
62402725|NCT03068429|EXPERIMENTAL|Sertraline open label|Sertraline hydrochloride up to 200mg/day or maximum tolerated dosage for 4-weeks.
62579277|NCT00979797|EXPERIMENTAL|Maternal & Child Health|Community-based interventions to promoto Maternal and Child Survival in collaboration with GoB, Donors and NGOs.
62215121|NCT00872989|EXPERIMENTAL|Arm II|Patients receive docetaxel IV over 1 hour on day 1 and oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62402726|NCT04243811|EXPERIMENTAL|laser group|local anesthesia applyed with 940 nm diode laser
62402727|NCT04243811|ACTIVE_COMPARATOR|conventional group|local anesthesia applyed with topical anesthesia
62402728|NCT05786027|EXPERIMENTAL|Peer Driven Intervention (PDI)|Participants from two experimental (E) prisons that are HIV-negative will be assigned to this arm. Participants will receive 12 weeks of PDI and weekly opioid urine tests. Prior to intervention participants will receive training by a Health Educator (HE) in Health Advocate (HA) and Peer roles.
62402729|NCT05786027|NO_INTERVENTION|Treatment As Usual (TAU)|Participants from two control (C) prisons that are HIV-negative will be assigned to this arm. Participants will receive treatment as usual (which includes universal access to SSP, MMT, and Atlantis program for individuals with opioid dependence) and weekly urine opioid tests for 12 weeks.
62402730|NCT02778893|EXPERIMENTAL|Conmana and Thalidomide|"Conmana(Icotinib Hydrochloride Tablets) and Thalidomide:~Conmana(Icotinib Hydrochloride Tablets) will be administered at 125mg three times a day(TID）continuously; Thalidomide will be administered at 100mg one a day（QD)at night continuously,If can tolerance after 1 weeks to add to 200mg."
62402731|NCT04890691|EXPERIMENTAL|BLT-1|Light therapy (wavelengths between 470nm and 525nm), 30 minutes/day for 4 weeks.
62402732|NCT04890691|PLACEBO_COMPARATOR|BLT-2|Placebo light (wavelength between 620nm and 750 nm), 30 minutes/day for 4 weeks.
62402733|NCT04867980|EXPERIMENTAL|ABCD|Participant will receive a single oral dose of 4 study treatments with the sequences of ABCD. The washout period will be \>= 5 days between each dose.
62402734|NCT04867980|EXPERIMENTAL|BDAC|Participant will receive a single oral dose of 4 study treatments with the sequences of BDAC. The washout period will be \>= 5 days between each dose.
62402735|NCT04867980|EXPERIMENTAL|CADB|Participant will receive a single oral dose of 4 study treatments with the sequences of CADB. The washout period will be \>= 5 days between each dose.
62402736|NCT04867980|EXPERIMENTAL|DCBA|Participant will receive a single oral dose of 4 study treatments with the sequences of DCBA. The washout period will be \>= 5 days between each dose.
62402737|NCT02668445|EXPERIMENTAL|Low carbohydrate|Subjects will eat a low carbohydrate diet
62785710|NCT02138968|NO_INTERVENTION|Usual care|Usual care
62202221|NCT02881372|EXPERIMENTAL|Oral food desensitization|All of the children enrolled in the study will receive oral food desensitization with his or her specific EoE flare-inducing food antigen (e.g. cow's milk protein). The food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C) to stabilize and preserve the solution. This oral spray will need to be administered twice a day, every day for a total of 4 months.
62402738|NCT02668445|EXPERIMENTAL|High carbohydrate|Subjects will eat a high carbohydrate diet
62202222|NCT02056353|ACTIVE_COMPARATOR|Nurse-directed|Blood glucose control guided by paper protocol
62202223|NCT02056353|EXPERIMENTAL|LOGIC-Insulin|Blood glucose control guided by the LOGIC-Insulin algorithm
62202224|NCT02280876|ACTIVE_COMPARATOR|1 - Andrographis paniculata p/st extract|1 - Andrographis paniculata extract. Active comparator, consists of 15 adult patients with active Recurrent Remitting Multiple Sclerosis, randomly assigned, taking the active test product (Andrographis paniculata p/st extract, oral lozenges, one BID, for 12 months), in addition to base medication (Interferon).
62402739|NCT04555772||Healthy Group|Patients who had been treated and recovered physically and gained cognitive functions completely.
62402740|NCT04555772||Sequel Group|Patients who could not gain their physical and cognitive functions.
62402741|NCT04555772||Exitus Group|Patients who did not respond to the treatments and lost their lives within 28 days of admission.
62402742|NCT01569321|EXPERIMENTAL|Breast cancer|
62402743|NCT04061837|EXPERIMENTAL|MitralStitch repair system|Experimental group is allocated to use novel mitral valve repair system manufactured by Hangzhou Valgen Medtech Co., Ltd
62402744|NCT01681927||1.4kg wt gain 8AM -10 PM|Complete a questionnaire. Measure and record weight in AM and PM.Record for one week,number of times urinated after bedtime and before waking up.
62402745|NCT01681927||>1.4kg wt gain 8AM - 10PM no nocturia.|Complete a questionnaire. Measure and record weight in AM and PM.Record for one week,number of times urinated after bedtime and before waking up.
62402746|NCT01681927||> 1.4 kg wt gain 8AM -10PM with nocturia|Complete a questionnaire. Measure and record weight in AM and PM. Record the number of times and collect all urine passed overnight in separate containers for one week.Collection of blood and interstitial fluid samples, fluorescein dye angiography, and bioimpedance study.
62402747|NCT03143712|EXPERIMENTAL|Treatment A|GLPG1690 oral capsules after breakfast
62402748|NCT03143712|EXPERIMENTAL|Treatment B|GLPG1690 oral tablets after breakfast
62202225|NCT02280876|PLACEBO_COMPARATOR|2 - Excipients|2 - Excipients. Placebo comparator, consists of 15 adult patients with active Recurrent Remitting Multiple Sclerosis, randomly assigned, taking the placebo formulation (Only the excipients of the active test product, in oral lozenges of same shape, one BID, for 12 months), in addition to base medication (Interferon).
62202226|NCT01580540||Group A, subjects with colorectal cancer|Subjects between ages 50 and 84 identified to have CRC. Blood and stool specimens are collected and tested after colonoscopy and prior to surgery or other interventions.
62202227|NCT01580540||Group B, subjects without CRC|Subjects between ages 50 and 84 who provide stool and blood specimens prior to colonoscopy.
62202228|NCT01357122|EXPERIMENTAL|NCI Insertion|
62202229|NCT01357122|ACTIVE_COMPARATOR|Standard Forceps Insertion|
62202230|NCT04558398|EXPERIMENTAL|Resistance exercise training group|Participants randomized to this arm will engage in a 4-week home-based training program with anticipated 12 sessions (3 per week) with participants required to attend a minimum of 9 sessions.
62202231|NCT04558398|EXPERIMENTAL|High-intensity interval training group|Participants randomized to this arm will engage in a 4-week home-based training program with anticipated 12 sessions (3 per week) with participants required to attend a minimum of 9 sessions.
62402749|NCT03143712|EXPERIMENTAL|Treatment C|GLPG1690 oral tablets after overnight fast
62402750|NCT02268214|EXPERIMENTAL|Arm A: Dapagliflozin|Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
62402751|NCT02268214|EXPERIMENTAL|Arm B: Dapagliflozin|Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
62402752|NCT02268214|PLACEBO_COMPARATOR|Arm C: Placebo for Dapagliflozin|Placebo tablet orally, once daily for 52 weeks
62202232|NCT03929874||18 ≤ age ≤ 40|18 ≤ age ≤ 40
62202233|NCT03929874||age ≥ 60|age ≥ 60
62202234|NCT02138786|EXPERIMENTAL|selinexor|"oral tablets~* 10 mg \& 25 mg (bottled); or~* 20 mg (blister pack)"
62402753|NCT01229865|EXPERIMENTAL|VB-111|antiangiogenic and vascular disruptive agent
62402754|NCT00665327|EXPERIMENTAL|Arm 1|
62402755|NCT00665327|ACTIVE_COMPARATOR|Arm 2|
62402756|NCT06532162|EXPERIMENTAL|1% Lidocaine Paracervical Block|"A 22-gauge spinal needle will be loaded with 10 mL of 1% lidocaine with epinephrine.~The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 4 and 10 o'clock. The injection is continuous from superficial to deep (3 cm)."
62402757|NCT06532162|SHAM_COMPARATOR|Normal Saline Paracervical Injection|A 22-gauge spinal needle will be loaded with 10 mL of normal saline. The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 4 and 10 o'clock. The injection is continuous from superficial to deep (3 cm).
62402758|NCT06532162|NO_INTERVENTION|Capped Needle Control|A capped needle will gently be tapped on the cervicovaginal junction at two areas at 4 and 10 o'clock.
62402759|NCT06019169|ACTIVE_COMPARATOR|Workshops around storytelling|"Participate in workshops around storytelling led by the association of storytellers l'Age D'or. 4 sessions are planned (2 face-to-face and 2 remotely) per month for 3 months."
62402760|NCT06019169|EXPERIMENTAL|Yoga classes|Participation in YOGA classes performed by Mme Laura BOGANI from The Blue Fish LAB Association. There are 4 sessions of 45 minutes (2 face-to-face and 2 remote) per month for 3 months.
62013725|NCT01646671|EXPERIMENTAL|LCZ696 400 mg plus other hypertension (HTN) medications|All participants were started on LCZ696 200 mg once daily on day 1. For participants who received LCZ696 400 mg and did not achieve msDBP \< 90 mmHg and msSBP \< 140 mmHg at or after week 4 and had no signs of safety concerns, another class of antihypertensive drugs (other than Angiotensin II receptor blockers or Angiotensin Converting Enzyme Inhibitor (ACEi) could be added, or the dose of concomitant antihypertensive drugs could be increased as per the package insert. Participants who received LCZ696 400 mg once daily did not change their dose for the remainder of the study.
62402761|NCT00645606|NO_INTERVENTION|Observation|Observation every 8 weeks during 2 years
62785711|NCT02850380|OTHER|spatial orientation in weightlessness|"subjects will be asked to flip a series of switches into the off position. On Earth, the off position corresponds to down in all three reference frames: the visual allocentric, the non-visual allocentric as well as the egocentric frames. We expect that flip direction will be dominated by visual allocentric cues when those are available, will be delayed and more variable when confirmatory gravitational cues are absent, and will be biased towards the egocentric reference when tactile cues are added"
62785712|NCT01675193|NO_INTERVENTION|Current screening protocol|Eye screening at age 1-2, 3-4, 6-9, 14-24, 36, 45 and 54-60 months
62785713|NCT01675193|OTHER|Disinvestment protocol|No eye screening at 6-9 and 14-24 months
62013726|NCT06073327|EXPERIMENTAL|Dark Chocolate|Dark chocolate group was provided with 30g of dark chocolate (high in flavanol) for 30 days
62013727|NCT06073327|SHAM_COMPARATOR|White Chocolate|White chocolate group was provided with30g of white chocolate (0 mg/g of polyphenol) for 30 days
62013728|NCT02602574||ERCP- induced acute pancreatitis|"All patients with indication for ERCP will be prepared for ERCP. One hour before and 4-6 hours after the procedure 10 mL of blood sample and urine sample will be collected.~24 hours after the procedure all patients will be taken 30 ml of heparinized peripheral venous blood and urine sample.~Upon clinical and laboratory confirmation of acute pancreatitis according to ESGE guidelines for post-ERCP pancreatitis, will be further monitored during hospitalization for evaluation of the severity of the disease."
62202235|NCT04745975|EXPERIMENTAL|Personalized treatment guided by Mini-PDX|The tumor tissue is used for drug sensitivity test by Mini-PDX, and acquiring the genetic information by RNA-sequence. Patients with mTNBC will receive personalized treatment guided by the experimental results of mini-PDX and RNA sequencing.
62402762|NCT00645606|EXPERIMENTAL|rituximab arm|rituximab :500 mg/m² every 8 weeks during 2 years
62402763|NCT05287165|EXPERIMENTAL|IM96 CAR-T cells|
62402764|NCT04188613|EXPERIMENTAL|HFJV|In preparation for the percutaneous tracheotomy, the patient was covered in a sterile fashion. The patient was extubated, and the jet ventilator catheter was inserted to trachea and ventilation will be start.
62402765|NCT04188613|ACTIVE_COMPARATOR|ETT|In preparation for the percutaneous tracheotomy, the patient was covered in a sterile fashion. Endotracheal tube (ETT) was removed through the vocal cords.
62402766|NCT04188613|ACTIVE_COMPARATOR|LMA|In preparation for the percutaneous tracheotomy, the patient was covered in a sterile fashion. Endotracheal tube (ETT) was removed and laryngeal mask airway device inserted.
62785714|NCT02450162||conventional lateral rectus recession|This is the standard technique for recession with two single-armed sutures.Exposure of the rectus muscle insertion includes freeing the insertion and proximal muscle borders sufficiently to place the sutures. And the needle is passed through the tendon avoiding the anterior ciliary arteries. If the sutures are passed as shown a true knot is formed, and the muscle is detached. Then a caliper measures from the limbus or the original insertion. A passage of the needle through sclera. The recessed muscle is ideally parallel to the old insertion (or nearly so). Conjunctival incision was finally sutured.
62785715|NCT02450162||hang-back lateral rectus recession|"The hang-back recession has been described as a simple, safe alternative to conventional recession. The procedure is said to be less likely to result in scleral perforation because needles are placed through relatively thicker sclera near the insertion site. It is the modified techique for recession with one double-armed sutures."
62785716|NCT03565146|EXPERIMENTAL|Pigmentation|Treatment of Pigmented Lesions Using PiQo4 Laser System
62202236|NCT04745975|ACTIVE_COMPARATOR|Treatment of Physician's Choice (TPC)|TPC will be administered per standard of care. Patients randomized to TPC will receive chemotherapy, including but not limited to the following agents: nab-paclitaxel, eribulin, vinorelbine, gemcitabine, capecitabine.
62402767|NCT04131439||"cochlear implantation group"|"cochlear implantation group: patients undergoing cochlear implantation between December 2019 and December 2021in the ENT department of Assiut university hospital."
62402768|NCT02883400|NO_INTERVENTION|SOC-Standard of care|standard of care, nontreatment
62402769|NCT02883400|EXPERIMENTAL|spironolactone|spironolactone
62402770|NCT01411124|EXPERIMENTAL|Gabapentin Enacarbil|600 mg of Gabapentin Enacarbil
62013729|NCT02602574||non -ERCP acute pancreatitis|"All patients with acute pancreatitis according to Atlanta criteria admitted through Emergency Department will be taken 30 ml of heparinized peripheral venous blood and urine sample upon 24 hours after the clinical symptoms have started. 10 mL of collected blood samples will be examined in the Department of Laboratory Medicine. Other 20 mL of blood samples will be sent to Department of Physiology and Immunology, School of Medicine where immunologic analysis will be performed.~This group of patients will be further monitored during hospitalization for evaluation of the severity of the disease. Severity of the disease will be assessed according to the Atlanta criteria."
62402771|NCT01411124|ACTIVE_COMPARATOR|diphenhydramine|50 mg
62402772|NCT01411124|PLACEBO_COMPARATOR|placebo|placebo to match
62785717|NCT01119092|SHAM_COMPARATOR|Sham intervention plus standard treatment|"This group will receive a laying of hands treatment in addition to standard treatment. The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between."
62402773|NCT03218657|EXPERIMENTAL|experimental group|the patients treated with levamisole hydrochloride 150mg qod +androgens 80mg qd+cyclosporins 3-5mg/kg\*d at least for one year
62402774|NCT03218657|OTHER|control group|the patients treated without levamisole hydrochloride，but androgens 80mg qd+cyclosporins 3-5mg/kg\*d at least for one year
62785718|NCT01119092|NO_INTERVENTION|Control Group|This group will be individuals who suffer from the same injury but will be instructed to stretch at home 5 days a week for 2 weeks.
62785719|NCT01119092|EXPERIMENTAL|Grade IV AP joint mobilization plus standard treatment|This group will receive 3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
62202237|NCT00162916|PLACEBO_COMPARATOR|1|
62202238|NCT00162916|EXPERIMENTAL|2|
62402775|NCT04115501|EXPERIMENTAL|Restrictive Oxygen|The restrictive oxygen patients' Fraction of Inspired Oxygen (FiO2) will be set at a minimum of 0.3 to maintain their oxygen saturations (SpO2) greater than or equal to 95% intraoperatively. During CPB a blended air/oxygen mixture will be titrated to arterial blood gas analysis with aim of maintenance of PaO2 between 100 and 150 mmHg. After transfer to ICU, all patients' FiO2 will be set to 50% initially, and titrate to minimal FiO2 (not less than 21%) for maintain SPO2≥95% until extubation.
62402776|NCT04115501|NO_INTERVENTION|Liberal Oxygen|The liberal oxygen group will consist of subjects exposed to a Fraction of Inspired Oxygen (FiO2) set at 1.0 throughout the intraoperative period, including during cardiopulmonary bypass. After transfer to ICU, all patients' FiO2 will be set to 50% initially, and titrate to minimal FiO2 (not less than 21%) for maintain SPO2≥95% until extubation.
62402777|NCT03199989|ACTIVE_COMPARATOR|adjuvant chemotherapy group|patients enrolled int the adjuvant chemotherapy group will receive adjuvant chemotherapy\[CapeOX（Capecitabine+Oxaliplatin）\] by the current guidelines
62402778|NCT03199989|EXPERIMENTAL|observation group|patients enrolled int the adjuvant chemotherapy group will not receive adjuvant chemotherapy just for observation
62402779|NCT00889928|EXPERIMENTAL|cholecystectomy|transvaginal cholecystectomy
62402780|NCT02903849|EXPERIMENTAL|Control|On the 20th, 50th, and 90th day of the Challenge, Wellness Connection will email employees who participate in this survey. Employees will receive standard reminders generated by Wellness Connection.
62402781|NCT02903849|EXPERIMENTAL|Treatment|On the 20th, 50th, and 90th day of the Challenge, Wellness Connection will email employees who participate in this survey. Employees will see the motivating messages they wrote at the beginning of the Challenge, in addition to Wellness Connection's standard reminders.
62402782|NCT04128059|EXPERIMENTAL|phase 1, component 1|component 1 of vaccine
62402783|NCT04128059|EXPERIMENTAL|phase 1, half dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in half dose
62202239|NCT03728270|EXPERIMENTAL|Patient Specific Titanium Eminoplasty|"* The stages of virtual surgical planning and fabrication of patient specific titanium eminoplasty will be designed my Mimics 15 program.~* Once designed, the virtual design and surgery will be planned on a computer model where vital anatomical structures could be identified and thus could be avoided during surgery.~* After obtaining all the dataset needed from the CT scan, the collected data will be sent to the Egyptian soil, water and environmental institution for manufacturing, packing and sterilization of the patient specific titanium eminence.~* The patient specific titanium eminence will be inserted and secured with two to three screws of individual lengths according to the virtual plan.~* Functional mandibular movements were reproduced to confirm absence of subluxation and checked for interference and any required adjustments made.~* A multilayer closure of the incisions will be accomplished using Vicryl sutures."
62202240|NCT03728270|ACTIVE_COMPARATOR|Inlay Autogenous Bone Graft|"* A safety distance of 5 mm will be maintained from the apex of the mandibular incisor and inferior mandibular border, the mental foramen, and permanent canine follicle.~* One corticocancellous bone block with a maximum depth of 4 mm will be removed by mallet and chisel based on the recommendation that bone from the chin should be harvested at this maximum depth, compatible with the course of the mandibular incisive nerve canal on CT scans.~* After removal of bone from the chin, the intervening bone struts will be removed using rongeur forceps and used as an additional bone graft.~* The bone removed will be trimmed and contoured in a wedge form to be used as an inter-positional graft in the previously down fractured articular eminence to act as an obstacle in front of the mandibular condyle to prevent its hyper movement."
62402784|NCT04128059|EXPERIMENTAL|phase 1, full dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in full dose
62785720|NCT03893682|EXPERIMENTAL|Dose Escalation and Expansion|CG-806 will be given orally in ascending doses in patients with relapsed or refractory CLL/SLL or Non-Hodgkin's Lymphomas (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 100 patients enrolled in the expansion cohort at the recommended dose.
62202241|NCT04064996|ACTIVE_COMPARATOR|Group A|Routine rehabilitation program patient education
62202242|NCT04064996|EXPERIMENTAL|Group B|Routine rehabilitation program + foot exercise training
62202243|NCT05715177|EXPERIMENTAL|Cura kinesio-taping|consisted of 25 subjects who will receive kinesio-taping from origin to insertion on the superficial muscles of Quadriceps femoris (QF) (Vastus Medialis (VM), Vastus Lateralis (VL), Rectus Femoris (RF)
62202244|NCT05715177|PLACEBO_COMPARATOR|Placebo kinesio-taping|consisted of 25 subjects who will receive placebo kinesio-taping across quadriceps.
62202245|NCT06246487|EXPERIMENTAL|Intervention|Occupational Therapy Intervention
62202246|NCT06246487|NO_INTERVENTION|Control|No intervention
62202247|NCT05260879|EXPERIMENTAL|Individuals|"This arm is composed of diabetic or hypertensive men and women who participate without joint participation of their spouse. The intervention consists of exposing participants to bi-monthly educational sessions on diet and exercise. Participants will be organized in groups of 15 led by one community health worker (CHW) assisted by a diabetes peer educator (PE). The basic format for the group sessions will follow the pattern developed with the DPP program, beginning with a discussion of success stories from the past weeks before proceeding to the didactic portion of the session. The sessions will mix the didactic portions facilitated by the PE with group discussions, activities and role plays, facilitated by the CHW."
62202248|NCT05260879|EXPERIMENTAL|Couples|"Women recruited for the couples group will be asked to invite their husbands to participate, regardless of their husband's CVD status, and men whose wives do not have CVD similarly will be asked to enroll with their wife. The intervention consists in exposing them to bi-monthly educational sessions on diet and exercise. The intervention consists in exposing participants with bi-monthly educational sessions on diet and exercise. Participants will be organized in groups of 15 to 30, led by one community health worker (CHW) assisted by a diabetes peer educator (PE). The basic format for the group sessions will follow the pattern developed with the DPP program, beginning with a discussion of success stories from the past weeks before proceeding to the didactic portion of the session. The sessions will mix the didactic portions facilitated by the PE with group discussions, activities and role plays, facilitated by the CHW."
62402785|NCT04128059|EXPERIMENTAL|phase 2, selected dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in selected dose
62402786|NCT04128059|PLACEBO_COMPARATOR|phase 2, placebo|vaccination with placebo with an interval of 21 days
62402787|NCT01919437|EXPERIMENTAL|Web-Enabled Cognitive Neuropsychological Evaluation System|
62402788|NCT04136717|OTHER|COPD patients|Patients with acute exacerbation of COPD and respiratory acidosis under oxygen therapy.
62402789|NCT04136717|OTHER|Bariatric surgery patients|Obese patients after gastric surgery under CPAP.
62402790|NCT04761926|EXPERIMENTAL|single arm|Asessments for the hearing with Ponto 4 sound processor on the implanted ear(s).
62402791|NCT06023485|EXPERIMENTAL|Experimental group (stress ball)|The patients in the experimental group will be given a stress ball before the SC injection during the routine daytime treatment of the ward at 10:00. The patient will be asked to squeeze the stress ball with his hand on the opposite extremity of the upper extremity where SC injection was applied, counting to five, and then to relax his hand. In the meantime, 0.4 ml of LMWH will be administered by SC route according to the doctor's request. During the patient's drug administration and 2 minutes after the application. The level of pain in the area where SC was applied will be evaluated with VAS.
62402792|NCT06023485|NO_INTERVENTION|Control group|For the patients in the control group, 0.4 ml of LMWH will be administered by the nurse in the routine daytime treatment of the service at 10:00, according to the doctor's request. During the patient's drug administration and 2 minutes after the application. The level of pain in the area where SC was applied will be evaluated with VAS.
62402793|NCT01361308|EXPERIMENTAL|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate)
62402794|NCT01361308|PLACEBO_COMPARATOR|Placebo Capsules|Placebo Capsules
62402795|NCT03085940|EXPERIMENTAL|Hydroxychloroquine|
62402796|NCT03085940|PLACEBO_COMPARATOR|Placebo|
62402797|NCT04847427|EXPERIMENTAL|Core exercises training|Participants will perform 4 core exercises
62402798|NCT04847427|EXPERIMENTAL|Structural exercises training|Participants will perform 4 structural (Olympic lifting) exercises
62402799|NCT04847427|EXPERIMENTAL|Accentuated eccentric exercises training|Participants will perform 4 exercises with eccentric loading
62402800|NCT04847427|EXPERIMENTAL|Control trial|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
62402801|NCT05383157|EXPERIMENTAL|Brief mindfulness|A 15-minute mindfulness intervention integrating mindful breathing and mindfulness of pain techniques.
62579278|NCT03748173|EXPERIMENTAL|Treatment|Subjects randomized to the aerosol surfactant evaluation will occur at the end of 60 minutes, with the aerosol continued if the bronchiolitis score is \> 4 or there has been less than a 2-point improvement in the bronchiolitis score. Similar evaluation will be performed, if necessary, at 30-minute intervals (maximum 2 hours) with stoppage of the aerosol for an improved bronchiolitis score (≤ 4 or 2-point improvement) at any of the time points. The aerosol would be stopped at any time for significant sustained deterioration in clinical status or any serious adverse event felt related to the treatment. Retreatment can be given at \> 4 but \< 24 hours if the initial response was positive and there has been subsequent deterioration.
62579279|NCT03748173|NO_INTERVENTION|Usual Care|The only difference in care between treatment and usual care will be treatment with up to two doses of aerosolized Infasurf®.
62579280|NCT06052800||Cohort 1|Patients with Galactosidase Alpha gene (GLA) IVS4 who have already received agalsidase beta treatment
62579281|NCT06052800||Cohort 2|Patients with GLA IVS4 who will initiate agalsidase beta treatment
62579282|NCT06052800||Cohort 3|Enzyme replacement therapy (ERT)-naive Fabry disease patients with GLA IVS4
62579283|NCT01298544|OTHER|All subjects|
62579284|NCT05342441|EXPERIMENTAL|QT-graft|Quadriceps tendon autograft (n=50)
62013730|NCT02602574||Control group|"Control group will consist of patients who underwent ERCP but didn't develop acute pancreatitis. One hour before and 4-6 hours after the procedure 10 mL of blood sample and urine sample will be collected.~24 hours after the procedure all patients will be taken 30 ml of heparinized peripheral venous blood and urine sample."
62402802|NCT05383157|ACTIVE_COMPARATOR|Usual care|15 minutes of usual chronic pain care delivered in an academic pain clinic environment.
62402803|NCT04600206||Patients|Adult patients across all phases of advanced disease (UICC stage IV solid tumor or stage III lung or ovarian tumor) from diagnosis to terminal stages
62402804|NCT04600206||Caregivers|Adult informal caregivers of patients who are diagnosed with stage IV solid tumors or stage III lung or ovarian tumors
62402805|NCT02059681|EXPERIMENTAL|Autologous bone marrow derived-CD133+ cells|CD133+ cells (1-12x10\^6) suspended in 10 ml physiological saline supplemented with 5% human albumin solution will be injected into the myocardium via the endocardial route; the whole 10 ml solution will be divided into 15-20 injections.
62402806|NCT00776828|ACTIVE_COMPARATOR|TAT|triple antiplatelet therapy : aspirin, clopidogrel and cilostazol
62579285|NCT05342441|EXPERIMENTAL|St/Gr-graft|Semitendinosus/gracilis autograft (n=50)
62013731|NCT06058897|EXPERIMENTAL|Experimental|MRI, eye-tracking and cognitive exams will be completed by subjects.
62402807|NCT00776828|PLACEBO_COMPARATOR|DAT|dual antiplatelet therapy : aspirin, clopidogrel
62402808|NCT02122874|ACTIVE_COMPARATOR|Diet|The patients follow only a 1200 Kcal diet
62402809|NCT02122874|EXPERIMENTAL|Diet +PENS dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
62579286|NCT05342441|EXPERIMENTAL|BPTB-graft|Patella tendon autograft (n=50)
62579287|NCT03058250|NO_INTERVENTION|Control|Standard of care, no intervention
62579288|NCT03058250|ACTIVE_COMPARATOR|Transesophageal echocardiography|Patients will have intraoperative transesophageal echocardiography along with standard of care for management.
62013732|NCT03843788|EXPERIMENTAL|Post-CS TENS|The patients in the intervention group will be educated on the proper way to utilize the transcutaneous electrical nerve stimulation (TENS) unit. They will apply the the patches of the TENS unit around the C-section site. Starting 8 hours after C-Section, the TENS unit will be turned on and will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy. Routine pharmacologic care will also be available.
62202249|NCT05260879|NO_INTERVENTION|Comparison|The comparison group is composed of diabetic or hypertensive individuals who agreed to participate in the study but who will not be exposed to the sessions.
62402810|NCT03091907||Case|Children with a history of necrotizing enterocolitis
62402811|NCT03091907||control|Children with no history of necrotizing enterocolitis
62402812|NCT00906776|ACTIVE_COMPARATOR|Emdogain PLUS|Straumann Emdogain in combination with Straumann BoneCeramic
62402813|NCT00906776|ACTIVE_COMPARATOR|Autogenous bone|Autogenous bone from the patient
62402814|NCT03081130||Intravenous laser irradiation treatment|We will recruit 30 poor ovarian responders and thin endometrium patients and treat with intravenous laser irradiation of blood (ILIB) via an intravenous catheter for irradiation of the blood under a period of 60 minutes for 10 days.
62202250|NCT06147349||Experimental|Patients with kidney cancer who underwent radical or partial kidney removal surgery
62402815|NCT03081130||control|We will recruit 30 poor ovarian responders and thin endometrium patients and treat with oral estradiol 8 mg per day and oestrogen gel 4 g per day for 14 days
62579289|NCT06681363||Patients with high-risk AML, ALL or MDS|"Patients with high-risk AML, ALL or MDS treated in the hematology department of Nantes University Hospital.~According to the needs of ongoing biological studies, additional volumes may be collected during blood and bone marrow sampling for diagnosis or relapse at inclusion , with up to one additional sample each month for three months following inclusion"
62579290|NCT03052231|ACTIVE_COMPARATOR|Interactive Mobile Health Information|Receives Interactive Mobile Health Information via caremessage. EAI staff focus group content will include qualitative descriptions of their experiences with training and actual use of the Caremessages.org service, as well as to elicit comments about contributing features and other mitigating or enhancing factors of the intervention's implementation, outreach and promotion, and integration into workflow practices.
62579291|NCT03052231|NO_INTERVENTION|Usual care|Usual care - clinic education, medication refills without reminders, appointments without reminders
62402816|NCT03358017|ACTIVE_COMPARATOR|ARM A - standard NACT|Standard anthracyclines/taxanes based neoadjuvant chemotherapy chosen by the investigator and administered according to clinical practice, for 6 months, or 4.5 months in case of dose dense schedule (unless disease progression, unacceptable toxicity, patient's refusal or investigator's decision)
62402817|NCT03358017|EXPERIMENTAL|ARM B - standard NACT + Zol + atorvastatin|Standard anthracyclines/taxanes based neoadjuvant CT chosen by the investigator and administered according to clinical practice + Zoledronate 4 mg i.v. every 3-4 weeks and Atorvastatin 80 mg/die administered for 6 months, or 4.5 months in case of dose dense schedule (unless disease progression, unacceptable toxicity, patient's refusal or investigator's decision)
62785721|NCT03027349||Study group|"Patients aged between 18-90 years old with primary hyperparathyroidism who had been diagnosed in the Unit of Endocrinology of the University of Modena and Reggio Emilia.~The exclusion criteria will be:~* age younger than 18 years~* renal and liver failure and insufficiency~* active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc)~* any type of cancer~* malnutrition, severe obesity (BMI \> 40 kg/m2) and malabsorption~* transplantation~* sarcoidosis~* endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism~* familial hypocalciuric hypercalcemia~* hypophosphoremia sustained by genetic causes or secondary to other causes."
62785722|NCT03027349||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their parathyroid function and calcium metabolism state with results into the normal ranges.~The exclusion criteria will be:~* age younger than 18 years~* renal and liver failure and insufficiency~* active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc)~* any type of cancer~* malnutrition, severe obesity (BMI \> 40 kg/m2) and malabsorption~* transplantation~* sarcoidosis~* endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism~* familial hypocalciuric hypercalcemia~* hypophosphoremia sustained by genetic causes or secondary to other causes."
62785723|NCT05351112||Patients who received the Anatomical Shoulder 2.0 Fracture|Anatomical Shoulder 2.0 Fracture
62785724|NCT06555328|EXPERIMENTAL|Arm 1 CSU|Lower dose of IFN904 BID
62202251|NCT01791504|EXPERIMENTAL|TissuGlu Surgical Adhesive|Standard wound closure techniques plus TissuGlu and no drains.
62202252|NCT01791504|NO_INTERVENTION|Control - Standard of Care|Standard wound closure techniques with drains.
62202253|NCT06126458||Good shooting performance|archery athletes who had 589 and more
62202254|NCT06126458||Bad shooting performance|archery athletes who had 588 and less
62013733|NCT03843788|EXPERIMENTAL|Opioid Addicted Post-CS TENS|Subjects will be targeted on the basis of opioid addiction and usage of methadone maintenance. The patients in the intervention group will be educated on the proper way to utilize the transcutaneous electrical nerve stimulation (TENS) unit. They will apply the the patches of the TENS unit around the C-section site). Starting 8 hours after C-Section, the TENS unit will be turned on and will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy. Routine pharmacologic care will also be available.
62202255|NCT06222827|EXPERIMENTAL|Group of patients who receive satralizumab|
62202256|NCT06222827|PLACEBO_COMPARATOR|Group of patients who receive placebo|
62202257|NCT00929942|EXPERIMENTAL|DV Stent|"Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented."
62202258|NCT02158923|EXPERIMENTAL|Individualized ventilation|Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs\> 10% a new MRA and optimal PEEP setting will be assessed.
62202259|NCT02158923|EXPERIMENTAL|Individualized vent. + postop. CPAP|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs\> 10% a new MRA and optimal PEEP setting will be assessed. Postoperatively a CPAP of 5 cmH2O (or 10 cmH2O if BMI\> 30) with a FiO2 of 0.5 will be applied.
62402818|NCT02648646|EXPERIMENTAL|Single Arm - Intervention|Receives Otago Exercise Programme and Walk with Ease
62402819|NCT02679924|EXPERIMENTAL|Restylane Silk|Micro-injections of Restylane® Silk Hyaluronic Acid filler for correction of mid to low cheek fine lines and wrinkles.
62402820|NCT02679924|SHAM_COMPARATOR|Sham Comparator|Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
62785725|NCT06555328|EXPERIMENTAL|Arm 2 CSU|Higher dose of IFN904 BID
62785726|NCT06555328|EXPERIMENTAL|Arm 3 CSU|Non responders IgE, higher dose of IFN904 BID
62202260|NCT02158923|NO_INTERVENTION|Standard ventilation|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, PEEP 6 cmH2O and FiO2 0.8. In these groups no recruitment maneuvers or optimal PEEP setting will be performed.
62202261|NCT02158923|ACTIVE_COMPARATOR|Standard vent. + postoperative CPAP|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, PEEP 6 cmH2O and FiO2 0.8. In these groups no recruitment maneuvers or optimal PEEP setting will be performed. Postoperatively, a CPAP of 5 cmH2O (or 10 cmH2O if BMI\> 30) with a FiO2 of 0.5 will be applied.
62202262|NCT02759653||Symptomatic|Symptomatic carotid artery disease
62202263|NCT02759653||Asymptomatic|Asymptomatic carotid artery disease
62202264|NCT02964533|EXPERIMENTAL|TFM|thunder-fire moxibustion therapy
62202265|NCT02964533|ACTIVE_COMPARATOR|MSM|common moxa-stick moxibustion therapy
62202266|NCT06415526||OPERA group|Patients with unilateral breast cancer received robotic-assisted mastectomy and robotic assisted free DIEP flap harvest for breast reconstruction
62202267|NCT04117295|EXPERIMENTAL|Treatment|Subjects implanted with the Carmat TAH
62202268|NCT01735227|EXPERIMENTAL|omeprazole group|omeprazole group:all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and taking omeprazole 20mg/d(1 month).on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization due to cardiovascular disease , bleeding events) .
62202269|NCT01735227|EXPERIMENTAL|pantoprazole group|pantoprazole group: all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term),taking pantoprazole 20mg/d(1 month).
62202270|NCT01627951|ACTIVE_COMPARATOR|NF54|Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
62402821|NCT06358300||Controls|Healthy controls between aged 18-35 years
62402822|NCT06358300||PCOS Subtype 1|Hyperandrogenemia+oligoanovulation+PCO appearance on USG
62579292|NCT05556447|EXPERIMENTAL|Internet delivered pain coping|8 week online pain coping skills training program with weekly, 45-minute modules guided by an automated coach
62579293|NCT02302638|ACTIVE_COMPARATOR|Sage 1-step|"Embryo culture in different single-step media:~Half of each patient's oocytes will be randomly allocated to be cultured in Sage 1-step medium for up to six days following oocyte retrieval."
62579294|NCT02302638|ACTIVE_COMPARATOR|CSCM|"Embryo culture in different single-step media:~Half of each patient's oocytes will be randomly allocated to be cultured in CSC medium for up to six days following oocyte retrieval."
62579295|NCT06253364||Liver resection group|No adjuvant therapy after hepatectomy.
62013734|NCT03843788|NO_INTERVENTION|Post-CS Routine Care|Routine pharmacologic care will be provided.
62202271|NCT01627951|EXPERIMENTAL|NF135|Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
62202272|NCT01627951|EXPERIMENTAL|NF166|Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
62202273|NCT03455270|EXPERIMENTAL|Part 1: Dose Escalation (G1T48)|"Patients in Part 1 will receive a single oral dose of G1T48 on Cycle 1 Day -3 and will begin once-daily dosing on Cycle 1 Day 1.~The initial dose cohort shall receive an identified starting dose and subsequent cohorts shall receive higher doses based on the safety and PK data obtained from the previous dose levels."
62202274|NCT03455270|EXPERIMENTAL|Part 1: Food Effect Cohort (G1T48)|"In Part 1, additional G1T48 cohort(s) of 8 patients may be enrolled to assess the effect of different fat content meals (eg, high fat, moderate fat, or low-fat) on the rate and extent of the absorption of G1T48.~Patients will receive a single oral dose of G1T48 on Cycle 1 Day -10 and on Cycle 1 Day -3. Patients will begin G1T48 once-daily dosing on Cycle 1 Day 1."
62202275|NCT03455270|EXPERIMENTAL|Part 2: Monotherapy Dose Expansion (G1T48)|Patients in Part 2 will receive G1T48 once-daily at the dose determined in Part 1.
62202276|NCT03455270|EXPERIMENTAL|Part 3: Combination Dose Expansion (G1T48+palbociclib)|Patients in Part 3 will receive G1T48 once-daily at the dose determined in Part 2 in combination with palbociclib once-daily on Days 1 to 21 of each 28-day cycle.
62402823|NCT06358300||PCOS Subtype 2|Hyperandrogenemia+oligoanovulation
62579296|NCT06253364||Adjuvant PD-1 group|Adjuvant therapy with PD-1 monoclonal antibody after hepatectomy
62579297|NCT06253364||Adjuvant PD-1 plus Lenvatinib group|Adjuvant therapy with PD-1 monoclonal antibody combined with lenvatinib after hepatectomy.
62579298|NCT05865574|EXPERIMENTAL|BAT1706（New Process）|"Drug: BAT1706~1 mg/kg, the corresponding volume of bulk solution should be drawn according to the actual body weight of the subject, diluted to 100 mL with 0.9% sodium chloride solution, and administered by intravenous drip"
62013735|NCT03843788|NO_INTERVENTION|Opioid Addicted Post-CS Routine Care|Routine pharmacologic care will be provided.
62202277|NCT03290053|EXPERIMENTAL|CE-5S A: Treatment arm|Gets thrombolysis, transcranial ultrasound on the flow limitation and SonoVue infusion
62402824|NCT06358300||PCOS Subtype 3|Hyperandrogenemia+PCO appearance on USG
62202278|NCT03290053|SHAM_COMPARATOR|CE-5S A: Control arm|Gets thrombolysis, sham transcranial ultrasound and placebo (NaCl) infusion
62202279|NCT03290053|EXPERIMENTAL|CE-5S B: Treatment arm|Gets NO thrombolysis (due to contraindications), transcranial ultrasound on the flow limitation and SonoVue infusion
62402825|NCT06358300||PCOS Subtype 4|Oligoanovulation+PCO appearance on USG
62402826|NCT03740854|ACTIVE_COMPARATOR|Pressure Controlled Ventilation|Patients undergoing pressure controlled ventilation
62402827|NCT03740854|ACTIVE_COMPARATOR|Volume Controlled Ventilation|Patients undergoing volume controlled ventilation
62579299|NCT05865574|ACTIVE_COMPARATOR|BAT1706（Old Process）|"Drug: BAT1706~1 mg/kg, the corresponding volume of bulk solution should be drawn according to the actual body weight of the subject, diluted to 100 mL with 0.9% sodium chloride solution, and administered by intravenous drip"
62785727|NCT06555328|EXPERIMENTAL|Arm 4 HS|Lower dose of IFN904 BID
62785728|NCT06555328|EXPERIMENTAL|Arm 5 HD|Medium dose of IFN904 BID
62785729|NCT06555328|EXPERIMENTAL|Arm 6 HD|High dose of IFN904 BID
62785730|NCT01249547|EXPERIMENTAL|axitinib arm|
62785731|NCT04904874|OTHER|flourescein staining, miboscore|
62785732|NCT05465343|EXPERIMENTAL|Furmonertinib|Furmonertinib 160mg orally QD
62785733|NCT05985967|OTHER|Control|Passive recovery for 30 minutes
62785734|NCT05985967|EXPERIMENTAL|PBMT-sMF|Photobiomodulation therapy combined with static magnetic field, with a total treatment duration lasting for around 30 minutes.
62785735|NCT05985967|ACTIVE_COMPARATOR|Shock wave|Shock wave therapy applied for 30 minutes.
62785736|NCT05985967|ACTIVE_COMPARATOR|Pneumatic compression|Pneumatic compression applied for 30 minutes.
62785737|NCT05546229||Controls|Subjects not taking medications for opioid use disorder
62202280|NCT03290053|SHAM_COMPARATOR|CE-5S B: Control arm|Gets NO thrombolysis (due to contraindications), sham transcranial ultrasound and placebo (NaCl) infusion
62579300|NCT01761253||Assessing costs & cost-variability|Data for the approximately 15,000 patients who were continuously enrolled during the calendar years 2006 and 2007 in the Generations Plus/ Northern Manhattan Health Network and 226,000 members of a large self insured union trust fund from 2007-2010 will be combined. The data will include age, gender, length of plan enrollment, whether or not the patient is disabled, their diagnoses, and their use of medical and social services.
62402828|NCT03799237|EXPERIMENTAL|GOS trap and dengue NS1 antigen kit|Gravid Oviposition Sticky (GOS) traps will be placed to trap adult Aedes mosquitoes and changed weekly. NS1 will be used to detect dengue in trapped Aedes mosquitoes. When dengue NS1 positive mosquitoes are found, community will be alerted via flyers, banners and other means. Routine Aedes/dengue control and surveillance will be carried out as usual as per the current Ministry of Health guidelines.
62402829|NCT03799237|NO_INTERVENTION|Control|The GOS traps will be placed randomly in the control arm once per month for entomological survey. Routine Aedes control and surveillance will be carried out as per the current Ministry of Health guidelines. Dengue control measure will be initiated by the health authorities when human cases are reported from this arm.
62785738|NCT05546229||Methadone|Subjects taking methadone for opioid use disorder
62785739|NCT05546229||Buprenorphine|Subjects taking buprenorphine for opioid use disorder
62785740|NCT05729243|EXPERIMENTAL|Cytisine|"Cytisine will be given as 1.5 mg tablet formulations for 25 days.~The following treatment schedule will be followed:~* Days 1 to 3: 1.5 mg taken every 2 hours (6 pills (9 mg)/day)~* Days 4 to 12: 1.5 mg taken every 2.5 hours (5 pills (7.5 mg)/day)~* Days 13 to 16: 1.5 mg taken every 3 hours (4 pills (6 mg)/day)~* Days 17 to 20: Taper down to 1 tablet every 5 hours (3 pills (4.5 mg)/day)~* Days 21 to 25: Taper down to 1-2 tablets daily (1.5-3 mg/day)"
62785741|NCT05729243|PLACEBO_COMPARATOR|Placebo|Placebo will be given following the same schedule as the Cytisine Arm.
62785742|NCT00310817|EXPERIMENTAL|MenACWY-CRM(Ad+) 12 to 35 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine with adjuvant (Ad+) on day 1 and second dose at 28 days or at 6 months or at 12 months after the first vaccination.
62785743|NCT00310817|EXPERIMENTAL|MenACWY-CRM(Ad-) 12 to 35 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine without adjuvant (Ad-) on day 1 and second dose either at 28 days or at 6 months or at 12 months after the first vaccination.
62785744|NCT00310817|EXPERIMENTAL|MenACWY-CRM(Ad-) 36 to 59 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine without adjuvant on day 1 and second dose on day 169 or day 337.
62785745|NCT00310817|ACTIVE_COMPARATOR|MenACWY-PS (36 to 59 Months)|Subjects received one dose of MenACWY polysaccharide (PS) vaccine on day 1 and second dose of MenACWY-CRM conjugate vaccine without adjuvant on day 169 or day 337.
62402830|NCT04561700|EXPERIMENTAL|Reporting of sucking patterns captured by Instrumented Bottle|Weekly reporting on objective measurements of sucking activity during oral feeding
62402831|NCT04561700|SHAM_COMPARATOR|Control|Weekly reporting on traditional measurements of sucking activity during oral feeding (no objective measurements reported)
62402832|NCT03163823|PLACEBO_COMPARATOR|Standard Communication|Standard of Care communication styles will be used. Patients will receive the standard communication protocol identified by the hospital.
62402833|NCT03163823|EXPERIMENTAL|iPad with Speech App|Use of application Proloquo2Go on iPad device. The application being used is called Proloquo2Go which is the intervention portion. The iPad is the device used to access the application.
62402834|NCT01598246||Extubation Success|Patients who do not require re-intubation, upto 72 hours after a planned extubation in the pediatric intensive care unit.
62402835|NCT01598246||Extubation failure|Patients who required re-intubation within 72 hours after a planned extubation in pediatric intensive care unit. To be further classified as early \<12 hour and late 12-72 hour, extubation failures.
62785746|NCT05912972||Cervical cancer|No interventions
62785747|NCT05912972||Endometrial cancer|No interventions
62785748|NCT05912972||Ovarian cancer, Fallopian tube cancer, Peritoneal cancer|No interventions
62785749|NCT04396158|EXPERIMENTAL|intervention|
62785750|NCT03781440|EXPERIMENTAL|Bilateral ESP catheter with Lidocaine|All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
62785751|NCT03781440|PLACEBO_COMPARATOR|Bilateral ESP catheter with saline|All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
62785752|NCT06208995||Arm 1|Polycystic Ovary Syndrome (PCOS)
62785753|NCT06208995||Arm 2|Hypothalamic-Pituitary-Ovarian Axis Dysfunction
62202281|NCT03985696|EXPERIMENTAL|patients with DLBCL|
62785754|NCT03105336|EXPERIMENTAL|axicabtagene ciloleucel|Participants will receive a conditioning chemotherapy regimen of fludarabine and cyclophosphamide, followed by a single infusion of CAR transduced autologous T cells.
62785755|NCT01691040|EXPERIMENTAL|Open-label pilot group|Twice weekly administration of NOX-H94
62202282|NCT03985696|ACTIVE_COMPARATOR|Healthy volunteers|
62202283|NCT00756041|EXPERIMENTAL|TAK-128 100 mg QD|
62734801|NCT05739396|EXPERIMENTAL|rebound therapy|Rebound exercises will be applied for group B. this group will receive rebound exercise training in addition to traditional physical therapy . Rebound exercises were conducted on a mini-trampoline and BOSU ball. Passive bouncing will be conducted while the child was standing with his/her feet a shoulder-width apart. The therapist will held the child's legs while applying upward and downward movement. The bouncing started slowly. The child then will progress to include the rebound exercises, starting with active bounce, where in a hands free manner the therapist will ask the child to speed up or slow down the bounce rate according to the child's abilities
62202284|NCT01209377|EXPERIMENTAL|standard|EMDR treatment with bilateral stimulation via eye movement
62202285|NCT01209377|EXPERIMENTAL|fixed|EMDR treatment with eyes fixed
62202286|NCT01209377|EXPERIMENTAL|no focus|trauma exposition without external stimulus
62402836|NCT02869204|EXPERIMENTAL|Leucocyte - Platelet rich Plasma and Dietary Supplements|"An application of an autologous platelet concentrate (20 ml). This is injected once, locally in the muscle after closure of the inner fascia and before closure of the outer fascia.~A daily dietary supplement of Vitamin C, Zinc and L-Arginine. Provided from POD2-3 until POD30"
62402837|NCT02869204|NO_INTERVENTION|Treatment as usual|Patients are treated as usual.
62402838|NCT02349100||Treated group|Patient group treated with Nellix Endoprosthesis.
62402839|NCT00720668||1|patient with hepatocellular carcinoma after radiofrequency ablation
62402840|NCT05936775|EXPERIMENTAL|Nano-hydroxy apatite arm|in this groups patients will receive nano-hydroxy apatite coated titanium implants
62402841|NCT05936775|ACTIVE_COMPARATOR|SLA arm|in this group patients will receive sandblasted large thread acid etched titanium implants
62402842|NCT04085926|EXPERIMENTAL|Sealed shoe|"Therapeutic footwear including off-the-shelf therapeutic shoes and custom-made insoles. The shoe on the ulcerated foot is sealed, i.e., made irremovable, with a plastic band."
62402843|NCT04085926|ACTIVE_COMPARATOR|Total contact cast|A irremovable custom-made total Contact cast enclosing the foot and shin
62402844|NCT01629121|EXPERIMENTAL|education intervention|The intervention delivered education about the benefits of bicycle helmet use and safety and was designed to be sensitive to the age and educational level of the study participant.
62402845|NCT01629121|NO_INTERVENTION|control|Printed materials were given to the control group, along with a helmet for each participant.
62402846|NCT01538602||PCOS patients|
62402847|NCT01538602||Healthy volunteers|
62402848|NCT06107465|ACTIVE_COMPARATOR|High dose Nitroglycerin|Initial dose of \>100 mic/min will be initiated
62402849|NCT06107465|ACTIVE_COMPARATOR|Low dose Nitroglycerin|Initial dose \< 100 mic /min will be started
62402850|NCT04893915|EXPERIMENTAL|Lead In Cohort Recipient: Cytokine-induced memory-like NK cells|"* Fludarabine and cyclophosphamide beginning on Day -6.~* NK cell product will be infused on Day 0.~* IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.~* NK cell product will be infused into the recipient on Day +14.~* IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 26 for an additional 7 doses, and a total of 14 doses, to a maximum of two vials of rhIL-2 per IL-2 course.~* In the Lead-in Cohort, three patients will receive NK cell product on Day 0 and Day +14, receiving the maximum NK cells generated, capped at 20x10\^6/kg.~* Patients that have an initial response but then subsequently relapse or progress will be able to receive a third dose of NK cell product with or without lymphodepleting chemotherapy depending on the interval duration between the second dose and relapse, after approval by the study PI. The third dose should be administered not less than 45 days from Day 0."
62734802|NCT01865318|EXPERIMENTAL|Part 1 (Once-daily dosing regimen, high concentration)|
62202287|NCT03313492|ACTIVE_COMPARATOR|E-Pamphlet|"A free non-interactive e-pamphlet (Skin Cancer Prevention and Early Detection from the American Cancer Society) will be accessible via our website."
62202288|NCT03313492|ACTIVE_COMPARATOR|Original UV4.me|Participants will view the original UV4.me web intervention, which includes educational modules, personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individuals, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator. The website content will remain the same, with the exception of updating photos, statistics, and cultural references for the current year.
62202289|NCT03313492|EXPERIMENTAL|Enhanced UV4.me2|Participants will view an enhanced version of the UV4.me website. Improvements to the website are based on user feedback from the original UV4.me trial, as well as reviews and models of effective e-Health interventions and implementation strategies.
62202290|NCT01185275||Severe Asthma Patients|Severe asthma patients symptomatic despite high dose inhaled corticosteroid and long acting beta-agonist
62202291|NCT00636805|EXPERIMENTAL|1|Patient receives IV Aloxi
62402851|NCT04893915|EXPERIMENTAL|Phase II Recipient: Cytokine-induced memory-like NK cells|"* Fludarabine and cyclophosphamide beginning on Day -6.~* NK cell product will be infused on Day 0.~* IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.~* NK cell product will be infused into the recipient on Day +14.~* IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 26 for an additional 7 doses, and a total of 14 doses, to a maximum of two vials of rhIL-2 per IL-2 course.~* Will receive the NK cell product on Day 0 and Day +14, receiving the maximum NK cells generated, capped at 20x10\^6/kg.~* Patients that have an initial response but then subsequently relapse or progress will be able to receive a third dose of NK cell product with or without lymphodepleting chemotherapy depending on the interval duration between the second dose and relapse, after approval by the study PI. The third dose should be administered not less than 45 days from Day 0."
62402852|NCT04893915|EXPERIMENTAL|Donor|"* The allogeneic donor will undergo non-mobilized large volume (20-L) leukapheresis on Day -1.~* On Day +13 the allogeneic donor will again undergo non-mobilized large volume (20-L) leukapheresis"
62402853|NCT00900328||Ancillary-Correlative (biomarkers in resected AC specimens)|Previously collected tissue samples from patients enrolled in CALGB 140202 are assessed for mutation analysis of c-Met, EGFR, Kras, p53, and c-CBL via standard PCR and sequencing; gene amplification of c-Met via real time quantitative PCR; LOH analysis of c-CBL; expression levels of met/HGF protein in serum via ELISA; and expression levels of c-Met, EGFR, p53, c-CBL, DUB3, ALK, and EMT via IHC.
62402854|NCT05461742|EXPERIMENTAL|Physical activity intervention|All participants will receive a physical activity intervention consisting of goal setting, in-person physical activity sessions, and written materials.
62579301|NCT04105218|EXPERIMENTAL|Evening Exercise|Participants will arrive in the Clinical and Translation Research Center (CTRC) and enter the whole room calorimeter approximately 1 hour after arrival. During the evening exercise condition, participants will perform 45-minutes of moderate intensity continuous exercise on a treadmill 12 hours after habitual wake time in the evening. Participants will begin with a warm-up for 5 minutes at 2.0-2.5 mph. Heart rate will be monitored continuously with a heart rate monitor. Participants will maintain heart rate at 65% of age-predicted maximum heart rate. Throughout the day, participants will be required to eat the standardized meals provided at breakfast lunch and dinner. At the time of bed, participants will be instructed to turn off the lights, lay down in bed and to refrain from using electronic devices. In the morning, a metabolic test will be performed and melatonin levels will be measured in the saliva
62579302|NCT04105218|PLACEBO_COMPARATOR|Control|Participants will arrive in the Clinical and Translation Research Center (CTRC) in the morning within 2 hours of their habitual wake time. Participants will enter the whole room calorimeter approximately 1 hour after arriving at the CTRC. Throughout the day, participants will be required to eat the standardized meals provided at breakfast lunch and dinner. At the time of bed, participants will be instructed to turn off the lights, lay down in bed and to refrain from using electronic devices. In the morning, a metabolic test will be performed and melatonin levels will be measured in the saliva
62579303|NCT04406181|OTHER|operation deferred|Adult patients whose operation date has been deferred due to the pandemic
62579304|NCT04406181|OTHER|no operation date|Patients who did not have had an operation date and who were told to need cardiac surgery before the pandemic started
62579305|NCT04406181|OTHER|postoperative consultation deferred|Patients who have been operating on during the month before the pandemic
62579306|NCT02401659||naïve with CareLink|patients with a first implant of an implanted cardiac device naïve in CareLink or patients with a refill who have not used CareLink until the implant
62785756|NCT05745519||The experimental group|Aged 40-79 years old, complained of insomnia symptoms in the past month, at least three times a week, for a month, such as: difficulty falling asleep, waking up in the middle of the night, waking up unable to fall asleep, waking up in the morning and still not getting enough sleep
62402855|NCT01269528||Born in 2007-2008|Methacholine Challenge Test (MCT). Monthly telephone contact. Visits to the study site. Fractional exhaled nitric oxide. Blood test.
62579307|NCT02401659||users of CareLink|patients with an implanted cardiac device who have used CareLink for more than one year
62202292|NCT06036849|EXPERIMENTAL|Neck pain participants: spinal manipulation first|Spinal manipulation will be delivered first (followed by spinal mobilization at 72 hours).
62202293|NCT06036849|EXPERIMENTAL|Neck pain participants: spinal mobilization first|Spinal mobilization will be delivered first (followed by spinal manipulation at 72 hours).
62215122|NCT04189952|EXPERIMENTAL|Acalabrutinib + R-ICE|Acalabrutinib in combination with rituximab, ifosfamide, carboplatin and etoposide (R-ICE). All participants will receive combination treatment for 3 cycles. Each cycle lasts 21 consecutive days. Combination treatment includes twice daily dose of Acalabrutinib, Rituximab on Day 1 of each cycle, Ifosfamide and Carboplatin on Day 2 of each cycle, and Etoposide on Days 1-3 of each cycle.
62402856|NCT01269528||Born in 2009-2010|Methacholine Challenge Test (MCT). Monthly telephone contact. Visits to the study site. Fractional exhaled nitric oxide. Blood test.
62402857|NCT03445325|EXPERIMENTAL|LiGHT v2.1|Participants will be assigned the intervention (use of the parent or teen app for 4.5 months) and asked to use throughout the intervention period (all participants are assigned to the intervention arm and results will be analyzed pre- and post-intervention).
62402858|NCT06286878|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10 mg tablets given once daily, per oral use
62579308|NCT05250310|ACTIVE_COMPARATOR|Yoga|Patients randomized to Yoga arm will practice chair yoga for 30 minutes at least three days a week for 16 weeks
62579309|NCT05250310|NO_INTERVENTION|Standard of Care|Control group patients will follow standard of care (SOC) treatment.
62579310|NCT05389930|EXPERIMENTAL|THC-dominant cannabis dose|367 mg of cannabis plant material with 9.53% THC and 0.09% CBD and 217 mg of placebo cannabis plant material will be mixed and smoked in a handheld pipe
62579311|NCT05389930|EXPERIMENTAL|CBD-dominant cannabis dose|367 mg of cannabis plant material with 11.27% CBD and 0.35% THC and 217 mg of placebo cannabis plant material will be mixed and smoked in a handheld pipe
62579312|NCT05389930|PLACEBO_COMPARATOR|Placebo|584 mg of cannabis plant material will be smoked in a handheld pipe
62734803|NCT01865318|EXPERIMENTAL|Part 2 (Twice-daily dosing regimen, high concentration)|
62734804|NCT01865318|EXPERIMENTAL|Part 3 (Once-daily dosing regimen, low concentration)|
62785757|NCT05745519||The control group|Healthy volunteer subjects aged 40-79 without insomnia.
62785758|NCT05220358|EXPERIMENTAL|FTR+suppressive regimen|addition of fostemsavir 600 mg PO BID to the stable suppressive HIV regimen in immunologic non responders
62785759|NCT03308253|OTHER|Standard of Care|Patients will receive the standard of care for vascular procedures as it is provided at Hamilton General Hospital
62402859|NCT06286878|PLACEBO_COMPARATOR|Placebo group|Placebo tablets given once daily, per oral use
62579313|NCT05389930|EXPERIMENTAL|Alcohol priming dose|Alcohol: 0.3 g/kg. Alcohol priming drink is designed to raise blood alcohol levels to 0.03 g/dl and be consumed in 5 minutes. The drink is mixed using 80-proof liquor and juice. Participants are randomized to receive either the experimental alcohol priming dose or alcohol placebo.
62013736|NCT03477890|ACTIVE_COMPARATOR|Intervention group (coronary function test results disclosed)|Coronary function tests are measured and disclosed to the clinician for re-evaluation of the initial diagnosis and treatment as compared with initial angiography. The intervention involves measurement of FFR, CFR, IMR and RRR in a major coronary artery followed by reactivity testing using incremental doses of acetylcholine (10-4 Molar (M), 10-5 M, 10-6 M) to assess endothelial function, bolus of ACh (10-4 M; 100 micrograms) for vasospasm, followed by glyceryl trinitrate (300 micrograms). FFR will be measured in all arteries with a diameter \>=2.5 mm and a stenosis 40% to 90% in severity. Endotypes are based on criteria for abnormal coronary vasodilator function, vasospasm and microvascular resistance. The endotypes (diagnostic strata) are: obstructive CAD, vasospastic angina, microvascular angina, mixed (ie both vasospastic and microvascular disorders), endothelial dysfunction (no angina), normal (non-cardiac). A diagnosis may be ruled-in or ruled-out based on the test results.
62402860|NCT02681991|EXPERIMENTAL|test|Renamezin capsule 2g, tid, PO
62013737|NCT03477890|SHAM_COMPARATOR|Usual care group (coronary function results not disclosed)|Coronary function tests are measured but not disclosed to the attending clinician or the participant. The same coronary function tests are undertaken as in the intervention group. Masking is achieved by obscuring the catheter laboratory monitors from the attending clinician and participant. The effectiveness of masking and protocol adherence is prospectively monitored.
62215123|NCT00472810|EXPERIMENTAL|1|20 patients will be recruited according to the enrollment acceptance criteria.Randomisation is performed using a sealed envelope system, where 40 shuffled envelopes designating the surgery to either trabeculectomy with mitomycin-C (MMC) and trabeculectomy with ologen™ Collagen matrix must be open before surgery. Then, patients are allocated and trabeculectomy is performed.If ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
62402861|NCT03174457||Treatment: micafungin|Participants receive once daily by intravenous infusion.
62402862|NCT00382434||EPh Present|the emergency pharmacist is present in the ED when the medical care is provided
62402863|NCT00118209|ACTIVE_COMPARATOR|Arm A - R-CHOP|"Patients receive the following treatment:~* Rituximab 375 mg/m\^2 IV infusion on Day 1 prior to CHOP chemotherapy~* Cyclophosphamide 750 mg/m\^2 IV on Day 1~* Doxorubicin 50 mg/m\^2 IV on Day 1~* Vincristine 1.4 mg/m\^2 IV (2 mg cap) on Day 1~* Prednisone 40 mg/m\^2/day PO on Days 1-5~* filgrastim or pegfilgrastim as defined in the protocol~Required ancillary medications is administered during all cycles as defined in the protocol.~Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6."
62579314|NCT05389930|PLACEBO_COMPARATOR|Alcohol placebo dose|Placebo beverage contains only juice and a negligible trace of alcohol for masking. The weight and sex-adjusted volume of alcohol and non-alcohol containing beverages will be equal. Participants are randomized to receive either the experimental alcohol priming dose or alcohol placebo.
62579315|NCT02638584|EXPERIMENTAL|Ilaprazole|Ilaprazole tab 10mg, 2 tablets once daily for 8 weeks.
62579316|NCT02638584|ACTIVE_COMPARATOR|Rabeprazole|Rabeprazole tab 20mg, 1 tablet once daily for 8 weeks.
62579317|NCT01569139||GPRD MI|Myocardial infarction, as identified in the GPRD data.
62579318|NCT01569139||MINAP MI|Myocardial infarction, as identified in MINAP data.
62579319|NCT01569139||HES MI|Myocardial infarction, as identified in HES data.
62579320|NCT02788409||Medicare CRPC|Men in the US older than 65 years old having CRPC
62579321|NCT00932373|EXPERIMENTAL|1|
62579322|NCT03675165|EXPERIMENTAL|Intervention|Participants receive a tailored version of Laura King's 'Best Possible Self' intervention: a brief, self-administered, psychological intervention. It is fundamentally a writing exercise, whereby recipients are asked to spend 10 minutes writing about their best possible future self and the steps they need to take to become that person. This helps the individual set goals while facilitating positive affect. Our version of the task has people focus on their health-related goals in particular.
62579323|NCT03675165|NO_INTERVENTION|Waiting List Control|Participants are informed that they are on a waiting list and will receive the intervention at the end of the study.
62579324|NCT05769075|EXPERIMENTAL|Escalation stage|Escalation stage: Multiple doses of TY-2136b for oral administration to find the maximum tolerated dose
62579325|NCT05769075|EXPERIMENTAL|Expansion stage|Expansion stage: 4 distinct expansion cohorts
62013738|NCT01950143|ACTIVE_COMPARATOR|Standard broccoli soup|26 volunteers
62579326|NCT02084043|EXPERIMENTAL|Breath-actuated vibrating mesh nebulizer|500 mg/4 mL of Amikacin solution delivered with an experimental breath-actuated vibrating mesh nebulizer associated with a single limb circuit ventilator.
62013739|NCT01950143|EXPERIMENTAL|Beneforte broccoli soup|26 volunteers
62013740|NCT01950143|EXPERIMENTAL|Beneforte extra broccoli soup|26 volunteers
62013741|NCT02838017|EXPERIMENTAL|Tissue Adhesive|Tissue Adhesive will be placed over subcuticular suture closure.
62013742|NCT02838017|ACTIVE_COMPARATOR|Steri-Strips|Sterile strips will be placed over subcuticular suture closure.
62013743|NCT01935011||PD DBS 60 Hz, 130 Hz or DBS off|PD DBS on 60 Hz stimulation, 130 Hz stimulation or DBS off
62579327|NCT02084043|EXPERIMENTAL|Conventional vibrating mesh nebulizer|500 mg/4 mL of Amikacin solution delivered with a conventional vibrating mesh nebulizer (in continuous mode) associated with a single limb circuit ventilator.
62579328|NCT02547389|ACTIVE_COMPARATOR|Intervention Group (IG)|IG additionally received community health programs with health workers(intensive education, consultation services, maintenance of anepilepsy tracking card, and repeated reminders).
62579329|NCT02547389|OTHER|Control Group (CG)|Patients in the CG were supplied with only printed epilepsy educational module
62579330|NCT02371317|EXPERIMENTAL|Mindfulness-Based Stress Reduction|The Mindfulness-Based Stress Reduction intervention includes eight 2.5-hour weekly group sessions and an all-day retreat.
62785760|NCT03308253|EXPERIMENTAL|Antibiotic Impregnated Beads|Patients will have their wound packed with calcium sulfate beads prior to closing. The beads will be infused with the antibiotics vancomycin and tobramycin.
62785761|NCT02420236|EXPERIMENTAL|High-intensity resistance training|Full body, progressive strength training with Theraband® Elastic bands. Three times per week for 12 weeks - 3 weeks with supervised sessions at the clinic, and 9 weeks of home training. Three guided sessions will be offered during the home training period.
62785762|NCT02420236|ACTIVE_COMPARATOR|General physical activity|12 weeks of general physical activity - 3 weeks with supervised sessions at the clinic, and 9 weeks of individually adjusted home training. This include circle-training, low-intensity resistance exercises, endurance exercises, ball playing, body awareness, stretching, and relaxation techniques, and similar activities. Neither moderate nor high-intensity resistance exercise is included for participants in this group.Three guided sessions will be offered during the home training period.
62785763|NCT02074839|EXPERIMENTAL|AG-120|AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle.
62785764|NCT01153724|EXPERIMENTAL|Olodaterol|
62785765|NCT01153724|EXPERIMENTAL|Olodaterol + Fluconazole|
62785766|NCT02781168|EXPERIMENTAL|Use of earmuffs|The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels.
62785767|NCT02781168|ACTIVE_COMPARATOR|No use of earmuffs|No use of earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels.
62785768|NCT00999440|EXPERIMENTAL|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done.Patients who start with any opiate and then switch to methadone, move to methadone follow up
62785769|NCT02725541|EXPERIMENTAL|Experimental|Trastuzumab emtansine at a dose of 3.6 mg/kg will be administered via intravenous infusion for 6 weeks (two 21-day cycles).
62785770|NCT01865643|OTHER|Standard GlideScope intubation|This standard GlideScope (GS) technique involves a midline larygoscopy followed by insertion of a styleted endotracheal tube, once an adequate view of the vocal cords is achieved.
62785771|NCT01865643|EXPERIMENTAL|Alternative GlideScope intubation|"Alternative GlideScope (GS) intubation involves the insertion of the endotracheal tube under direct vision as a fish hook at the side of the mouth before the GS blade is introduced into the oropharynx."
62785772|NCT03549377||Rested|Based on Pittsburgh Sleep Quality Index, participants scoring in the top 10-20% will be assigned to the rested group and will experience deception as part of the delayed gratification task
62785773|NCT03549377||Sleep-deprived|Based on Pittsburgh Sleep Quality Index, participants scoring in the bottom 10-20% will be assigned to the sleep-deprived group and will experience deception as part of the delayed gratification task
62785774|NCT04924270|EXPERIMENTAL|cFMT|
62785775|NCT04924270|PLACEBO_COMPARATOR|Placebo|
62785776|NCT05999500||Irritable bowel syndrome patients participating in temple stay|We plan to observe a group of patients aged 20-69 with diarrhea-predominant irritable bowel syndrome who have voluntarily agreed to participate in a temple stay for up to 8 days. Observations will be made before the temple stay, immediately after, and then followed up for 4 weeks after the experience.
62013744|NCT04090944|ACTIVE_COMPARATOR|1st group (group B)|"The LMA LarySeal Multiple will be inserted using the blind technique which involves holding the LMA like a pen guided into the pharynx with the index finger of the operator at the junction of the tube and the bowl, with the operator at the head of the patient and the LMA facing caudally.~The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading devised by Aoyama et al."
62013745|NCT04090944|ACTIVE_COMPARATOR|2nd group:(group U)|"The LMA LarySeal Multiple will be inserted under the guide of B-mode US on the anterior neck . Transverse scans , Sagittal view and Parasagittal view.~-The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading devised by Aoyama et al."
62013746|NCT03290508||Prolaris Testing|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
62013747|NCT03290508||No Prolaris Testing|Patients with newly diagnosed favorable intermediate-risk localized prostate cancer who DO NOT undergo Prolaris testing
62579331|NCT02371317|ACTIVE_COMPARATOR|Stress Management Education|The Stress Management Education intervention includes eight 2.5-hour weekly group sessions and an all-day retreat.
62202294|NCT06036849|NO_INTERVENTION|Healthy controls|Participants will attend a single session and no intervention will be performed but all experimental procedures will be identical to those occurring in the neck pain cohort. Measurements in individuals without neck pain are necessary for the assessment of potential baseline differences in the outcomes of interest between the patient cohort (with neck pain) and those without neck pain. Without this information, it is not possible to determine if the measured responses to spinal manipulation are due to the intervention or, systematic differences in the baseline outcomes of interest in the symptomatic cohort.
62202295|NCT02224404|EXPERIMENTAL|Fast Gelling Dressing|
62402864|NCT00118209|EXPERIMENTAL|Arm B - DA-EPOCH-R|"Patients receive the following treatment:~Cycle 1 Doses:~* Rituximab 375 mg/m\^2 IV infusion on Day 1 prior to EPOCH chemotherapy~* Doxorubicin 10 mg/m\^2/day CIVI on Days 1-4~* Etoposide 50 mg/m\^2/day CIVI on Days 1-4~* Vincristine 0.4 mg/m\^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours)~* Cyclophosphamide 750 mg/m\^2 IV on Day 5 (following completion of 96 hour infusions)~* Prednisone 60 mg/m\^2 PO BID on Days 1-5~* Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC \> 5000 after the nadir (nadir usually between Days 10-12) or for 10 days (Days 6-15) if the ANC is not being monitored, during every cycle.~Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle.~Required ancillary medications are administered during all cycles as defined in the protocol.~Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6."
62785777|NCT03515356|EXPERIMENTAL|MI-Walk Intervention|"Subjects who are already receiving oxaliplatin prescribed by their oncologist (as standard of care) will receive a physical activity education pamphlet.~In addition, subjects will receive 8-weeks of motivational enhancement therapy- and a home-based aerobic walking intervention. Motivational interviewing will be delivered with concurrent feedback and motivational techniques in 30-45-minute sessions at intervention orientation (T1), 2 weeks (T3), and 4 weeks (T4)."
62785778|NCT03515356|ACTIVE_COMPARATOR|PA Education Alone|Subjects who are already receiving oxaliplatin prescribed by their oncologist (as standard of care) will receive a physical activity education pamphlet.
62785779|NCT05293184||Individuals with Angelman Syndrome|Individuals from birth to adulthood with Angelman Syndrome
62202296|NCT06022341|OTHER|Leukemic transformation of myeloproliferative neoplasms|"120 patients will be studied for :~* Multiomic characterization~* In vitro drug screening"
62734805|NCT01823107|EXPERIMENTAL|Meso BioMatrix Device|All subjects will have the Meso BioMatrix device implanted along with a tissue expander during the first stage of breast reconstruction. During the second stage of breast reconstruction, the tissue expander is replaced with a breast implant.
62734806|NCT04852549|NO_INTERVENTION|No intervention group|The control group continued with routine training after evaluations.
62785780|NCT05321407||X-linked agammaglobulinemia (XLA)|This study is a non-randomized observational cohort study of participants with XLA who have either received, as standard care, the Pfizer BioNTech BNT162b2 mRNA vaccine or the Moderna mRNA-1273 vaccine. In this protocol, vaccination is entirely voluntary and vaccines are not provided by the study.
62013748|NCT01375049|EXPERIMENTAL|Aztreonam for Inhalation Solution (AZLI)|Participants will receive one 28-day course of AZLI, then will be followed for a 24-week period (through Day 196).
62013749|NCT06075602||Treatment|The project ́s main goal is to collect baseline, clinical and procedural data as well as to assess angiographic and clinical outcomes of patients with complex coronary lesions treated with current PCI techniques/ devices, but also CABG strategies in different clinical settings.
62013750|NCT00727389|OTHER|groups of women|To evaluate the capacity of muscular function and articular amplitude in the aged women
62013751|NCT06659315|NO_INTERVENTION|Enhanced Usual Care|Standard of care, e.g., regular HIV care, regular perinatal care, referrals to services for depression
62202297|NCT05348941|NO_INTERVENTION|Control|Hypocaloric balanced diet
62202298|NCT05348941|EXPERIMENTAL|TECADRIOL|Hypocaloric balanced diet plus a food supplement with D-chiro-inositol and alpha-lactalbumin
62202299|NCT03952078|EXPERIMENTAL|CPI-818 Dose Escalation|Participants will receive CPI-818 capsule, orally, twice per day at an assigned dose, till disease progression, complete response or remission (CR) for \>2 months or if dose determined to be unsafe.
62202300|NCT03952078|EXPERIMENTAL|CPI-818 Dose Expansion phase|"Participants with different T-cell lymphoma sub-types will receive CPI-818 capsules at the specific dose selected from the Dose escalation phase of the study.~CPI-818 capsules at the selected dose will be taken orally, twice per day until disease progression or CR for \> 2 months."
62202301|NCT04374539|EXPERIMENTAL|Plasma exchange|Plasma exchange with human serum albumin + Polyclonal immunoglobulin + standard medical treatment
62202302|NCT04374539|ACTIVE_COMPARATOR|Standar medical treatment|Standar medical treatment
62202303|NCT01609062|EXPERIMENTAL|BMN 110 Weekly at 2.0 mg/kg/week|
62202304|NCT01609062|EXPERIMENTAL|BMN 110 Weekly at 4.0 mg/kg/week|
62202305|NCT03738475|EXPERIMENTAL|TIMP-GLIA|8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.
62202306|NCT03738475|PLACEBO_COMPARATOR|Placebo|Normal saline administered intravenously on days 1 and 8.
62202307|NCT04768855|EXPERIMENTAL|LY3540378 (Part A)|Single ascending doses of LY3540378 administered either intravenously (IV) or subcutaneously (SC).
62202308|NCT04768855|EXPERIMENTAL|LY3540378 (Part B)|Multiple ascending doses of LY3540378 administered SC.
62785781|NCT05933707|NO_INTERVENTION|Metabolically healthy lean - Baseline testing only|"Metabolically healthy lean - Lean individuals that have good glucose (sugar) control (defined as normal fasting glucose, glucose tolerance and hemoglobin A1c), normal insulin sensitivity (defined as Homeostatic Model Assessment of Insulin Resistance \[HOMA-IR\] \<2.5) and normal intrahepatic triglyceride (fat) levels.~Dietary intervention - None."
62202309|NCT04768855|EXPERIMENTAL|LY3540378 (Part C)|Multiple ascending doses of LY3540378 administered SC in Japanese Participants.
62785782|NCT05933707|NO_INTERVENTION|People with Metabolically Healthy Obesity - Baseline testing only|"People with Metabolically Healthy Obesity - Persons with obesity that have good glucose (sugar) control, normal insulin sensitivity and normal intrahepatic triglyceride (fat) levels.~Dietary intervention - None."
62785783|NCT05933707|EXPERIMENTAL|People with Metabolically Unhealthy Obesity - Low Calorie Diet|"People with Metabolically Unhealthy Obesity - Persons with obesity with plasma glucose and intrahepatic triglyceride (fat) levels higher than recommended in combination with insulin resistance (defined as HOMA-IR ≥2.5).~Dietary intervention - Low calorie diet."
62202310|NCT04768855|EXPERIMENTAL|LY3540378 (Part D)|Multiple ascending doses of LY3540378 administered SC in Chinese Participants.
62013752|NCT06659315|EXPERIMENTAL|Couple-based problem solving|A couples-based intervention to support perinatal women who are experience symptoms of depression. We will adapt the WHO Problem Management Plus manual for this study. There are 5 sessions that deal with stress management, problem-solving, behavioral activation, and skills to strengthen social support. The final session will be modified to enhance couple communication skills. Because many of our participants will be dealing with food scarcity, we will develop a priori strategies to help couple brainstorm dealing with this issue.
62013753|NCT03334500|EXPERIMENTAL|Cohort 1|Gleason 6 (n=10)
62013754|NCT03334500|EXPERIMENTAL|Cohort 2|Gleason 7-8 (n=10)
62013755|NCT03334500|EXPERIMENTAL|Cohort 3|Gleason 9 or oligometastic disease (n=10)
62013756|NCT02379949|EXPERIMENTAL|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
62013757|NCT02379949|ACTIVE_COMPARATOR|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
62202311|NCT04768855|PLACEBO_COMPARATOR|Placebo (Part A, B, C & D)|Placebo administered either IV or SC.
62202312|NCT05796362|ACTIVE_COMPARATOR|Reference Azithromycin Tablet (Zithromax)|250 mg azithromycin (Zithromax) tablet to be taken once orally.
62202313|NCT05796362|EXPERIMENTAL|Oral Oleogel|250 mg azithromycin/ 15 ml oral oleogel (16.67 mg/ml) to be dosed once orally.
62202314|NCT05796362|EXPERIMENTAL|Rectal Oleogel|250 mg azithromycin/ 15 ml rectal oleogel (16.67 mg/ml) to be dosed once rectally.
62202315|NCT03427151|EXPERIMENTAL|IPP-201101|every 4 weeks
62202316|NCT01934348|EXPERIMENTAL|Psychological First Aid|Behavioral intervention delivered to crime victims during 2-3 in-person interactions within 1 month of the assault.
62202317|NCT01934348|ACTIVE_COMPARATOR|Usual victim advocacy services|Standard victim advocacy services delivered to crime victims within 1 month of the assault.
62202318|NCT05259423|EXPERIMENTAL|Typical Development, Enriched Education Program|Parents of infants with typical development (i.e, not meeting the eligibility criteria for early intervention services in the state of Delaware) will receive enriched play activity education based on key ingredients evidenced to advance infant development.
62013758|NCT02379949|NO_INTERVENTION|Waitlist|Participants assigned to wait list were re-randomized to virtual reality exposure therapy or exposure group therapy following the waiting period.
62202319|NCT05259423|ACTIVE_COMPARATOR|Typical Development, Typical Education Program|Parents of infants with typical development (i.e, not meeting the eligibility criteria for early intervention services in the state of Delaware) will receive typical play education based on usual education found in commonly used websites, apps, and books.
62202320|NCT05259423|EXPERIMENTAL|Developmental Delay, Enriched Education Program|Parents of infants with/at risk for developmental delay (i.e, meeting the eligibility criteria for early intervention services in the state of Delaware) will receive enriched play activity education based on key ingredients evidenced to advance infant development.
62202321|NCT05259423|ACTIVE_COMPARATOR|Developmental Delay, Typical Education Program|Parents of infants with/at risk for developmental delay (i.e, meeting the eligibility criteria for early intervention services in the state of Delaware) will receive typical play education based on usual education found in commonly used websites, apps, and books.
62402865|NCT04099589|EXPERIMENTAL|MIBC Group|Muscle-invasive bladder cancer of T2-4aN0M0 confirmed by pathology after maximal transurethral resection of bladder tumors. Enrollment of 30 patients.
62579332|NCT02371317|OTHER|AHA Recommended Self-Care|All participants will receive the American Heart Association - Understanding and Controlling Your High Blood Pressure Brochure and information on the Dietary Approach to Stop Hypertension from the National Institutes of Health. These brochures describe ways that individuals can improve their lifestyle through better diet and exercise. Participants will get a chance to try and make healthy lifestyle changes on their own, using this information.
62579333|NCT03178188|EXPERIMENTAL|laser treated DLE lesions|DLE which received the pulsed-dye laser
62785784|NCT06167876|EXPERIMENTAL|Stereotactic Body Radiotherapy (SBRT) Treatment Group|This arm of the study encompasses patients who are receiving the non-invasive Stereotactic Body Radiotherapy (SBRT) as the primary treatment for Hypertrophic Obstructive Cardiomyopathy (HOCM). The group will undergo precise imaging-guided radiotherapy targeting the interventricular septum, avoiding critical cardiac structures, and delivering a single high-dose radiation treatment with the aim of alleviating the symptoms of HOCM and improving cardiac function.
62785785|NCT06167876|SHAM_COMPARATOR|Sham Procedure Control Group|Participants in this arm will undergo a sham procedure, which mimics the SBRT treatment process without actual radiation delivery. This group serves as a control to assess the efficacy and safety of the SBRT treatment by providing a comparative baseline. The sham procedure involves aligning patients with the linear accelerator and replicating the treatment environment, including equipment sounds and lighting, without administering any radiation.
62785786|NCT04489472|EXPERIMENTAL|PCD Group|
62013759|NCT06419127||Infertile patients|Infertile patients undergoing IVF with PGT.
62013760|NCT01917045|EXPERIMENTAL|low body fat percentage|body fat percentage less than 30%
62013761|NCT01917045|EXPERIMENTAL|heigh body fat percentage|body fat percentage more than 30%
62202322|NCT00872755|ACTIVE_COMPARATOR|Nissen|Laparoscopic Nissen Fundoplication
62202323|NCT00872755|ACTIVE_COMPARATOR|Gastropexy|Procedure/Surgery Laparoscopic Nissen Fundoplication combined with posterior gastropexy
62202324|NCT06068751|ACTIVE_COMPARATOR|Aerobic Exercise|Aerobic Exercise
62579334|NCT03178188|SHAM_COMPARATOR|sham treated DLE lesions|DLE which received the sham
62579335|NCT06280846|EXPERIMENTAL|Experimental high-intensity laser acupuncture and an exercise therapy program.|The patients will receive high-intensity laser acupuncture and an exercise therapy program.three times a week for four weeks.
62785787|NCT04489472|PLACEBO_COMPARATOR|Control Group|
62402866|NCT04099589|EXPERIMENTAL|UTUC Group|Upper tract urothelial carcinoma of T1-3N0M0 and high grade confirmed by flexible ureteroscope biopsy. Enrollment of 34 patients.
62402867|NCT04992091|EXPERIMENTAL|CONSTRUCTIVE DEBRIEFING|interventional group
62402868|NCT04992091|NO_INTERVENTION|traditional debriefing|noninterventional group
62402869|NCT06439186|ACTIVE_COMPARATOR|Anesthesia|"In the first group, inferior alveolar anesthesia is used. In the second group, infiltrative anesthesia is used.~In both groups, one dose of lidocaine HCl contained in 2 mL ampule is used. It is a standard drug."
62402870|NCT06439186|ACTIVE_COMPARATOR|tooth extraction pain|"In both groups, the patient is asked to evaluate the pain she/he experienced during the extraction. This evaluation is done immediately after the extraction, by using a visual analogue scale (detailed in other sections of this trial record)."
62402871|NCT05541107|EXPERIMENTAL|MAT2203 Induction / MAT2203 Consolidation|2 days IV Amphotericin B (AMB) + flucytosine (5FC) followed by oral MAT2203 + 5FC for 12 days of induction therapy followed by MAT2203 +fluconazole for 4 weeks of consolidation therapy
62402872|NCT05541107|EXPERIMENTAL|MAT2203 Induction / SOC Consolidation|2 days IV AMB + 5FC followed by oral MAT2203 + 5FC for 12 days of induction therapy followed by 4 weeks of standard of care consolidation therapy
62402873|NCT05541107|ACTIVE_COMPARATOR|SOC Induction / SOC Consolidation|Standard of care induction therapy (IV AMB + 5FC) followed by 4 weeks of standard of care consolidation therapy (fluconazole)
62402874|NCT01311531|ACTIVE_COMPARATOR|TriMed fragment-specific fixation|
62402875|NCT01311531|ACTIVE_COMPARATOR|TriMed volar locking plate|
62402876|NCT02035865||Participants from former study 1|Surviving participants from a former study called 'Psykosomale faktorer hos pasienter med hjertesvikt og hos hjertetransplanterte'
62402877|NCT02035865||Participants from former study 2|Surviving participants, included at the Norwegian centre, from a study called 'Scandinavian Heart Transplant Everolimus De Novo Study with Early Calcineurin Inhibitor Avoidance (SCHEDULE)' (NCT01266148)
62402878|NCT04283513|EXPERIMENTAL|Efficacy of IV Ribavirin|The proposed clinical dose is based on drug dosage used in the HFRS clinical trial in China that demonstrated efficacy: Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses).
62402879|NCT01545401|EXPERIMENTAL|EMPOWER-PAR Intervention|"The intervention arm receives the EMPOWER-PAR intervention package consisting of:~1. Chronic Disease Management (CDM) Training Workshops for the staff in the respective clinics~2. The Global CV Risks Self-Management Booklet (patient self-management tool) to empower patients to self-manage their CV risk factors~3. Facilitation and support of the staff in these clinics so that they may implement the interventions"
62402880|NCT01545401|NO_INTERVENTION|Control|"The control arm continues with usual care.~The EMPOWER-PAR intervention package will be made available after the trial ends."
62579336|NCT06280846|EXPERIMENTAL|Experimental low-intensity laser acupuncture and an exercise therapy program.|The patients will receive low-intensity laser acupuncture and an exercise therapy program.three times a week for four weeks.
62402881|NCT00594009|EXPERIMENTAL|Venovenous CO2 Removal (VVCO2R) in COPD|All patients enrolled in the trial will receive VVCO2R which consists of a circuit with a centrifugal pump, tubing, double lumen intravenous catheter and hollow fiber oxygenator
62579337|NCT06280846|SHAM_COMPARATOR|sham laser acupuncture and an exercise therapy program.|The patients will receive a sham laser acupuncture and an exercise therapy program three times a week for four weeks.
62579338|NCT03250754||Pharmacological treatment group|Treatment decision making is based on physician's choice and patient preferences. Patients were referred to the Pain Service Unit. Patients continued with a prophylactic treatment alone
62579339|NCT03250754||Electroacupuncture group|Treatment decision making is based on physician's choice and patient preferences. Patients were referred to the Pain Service Unit. Patients continued with a new prophylactic treatment and additionally, received 12 sessions of acupuncture. The treatments, which included electro-stimulation.
62579340|NCT01654120|EXPERIMENTAL|liraglutide plus insulin|Patients were randomized to receive liraglutide plus insulin (LIRA) for 12 months.
62579341|NCT01654120|ACTIVE_COMPARATOR|Insulin titration only|Patients were randomized to receive insulin only (control) for 6 months. The controls were then crossed over to receive liraglutide plus insulin for 6 months after the initial control period.
62579342|NCT00003140|EXPERIMENTAL|Arm I|Patients receive oral letrozole once daily.
62579343|NCT00003140|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo once daily.
62402882|NCT06470126|ACTIVE_COMPARATOR|2.5% NaOCl|2.5% NaOCl was applied as a root canal irrigation agent.
62402883|NCT06470126|EXPERIMENTAL|0.9% sterile saline solution combined with 80 seconds OzonyTronX®|0.9% sterile saline solution was combined with 80 seconds OzonyTronX® application as a root canal irrigation procedure.
62579344|NCT00603590|EXPERIMENTAL|Polypill|Fixed dose combination therapy with Aspirin 81mg, Hydrochlorothiazide 12.5mg, Enalapril 2.5mg and Atorvastatin 20mg
62579345|NCT00603590|PLACEBO_COMPARATOR|Control|Identical placebo
62579346|NCT01842984|EXPERIMENTAL|I-SOCIAL intervention|Participants in this group will have up to 10 personal meetings with activities counselors and several group meetings.
62579347|NCT01842984|NO_INTERVENTION|Control group|Participants in this group will not have meetings with the activities counselors, and will not take part in the group meetings.
62579348|NCT04052243|OTHER|All patients|Exercise is added to resting right heart catheterization
62785788|NCT03964324|EXPERIMENTAL|Severe snorers|Study group that will undergo fractioned exhaled nitrogen oxide measurements as well as tests of lungfunction and sleep studies. All tests are noninvasive.
62785789|NCT03492034|ACTIVE_COMPARATOR|IUD during CS|
62785790|NCT03492034|ACTIVE_COMPARATOR|IUD after puerperium|
62402884|NCT06470126|EXPERIMENTAL|2.5% NaOCl with 80 seconds OzonyTronX®|2.5% NaOCl was applied as an intracanal medicament in combination with 80 seconds OzonyTronX®
62402885|NCT04899531||Longitudinal observation|No specific intervention, pre-post measurements only
62579349|NCT05004493||Plasma arm|Patients receiving plasma as one of the main replacement fluids
62579350|NCT05004493||No Plasma|Patients receiving saline and/or 5% albumin as the replacement fluid.
62785791|NCT01444846|ACTIVE_COMPARATOR|SPI-1005 Low dose|200mg SPI-1005, capsule, bid, po, x4d
62202325|NCT06068751|ACTIVE_COMPARATOR|Neck Exercises|Neck Exercises
62402886|NCT04975867|EXPERIMENTAL|Hypothermia group|Hypothermia group is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After therapeutic hypothermia ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.
62202326|NCT06161207|EXPERIMENTAL|3D-4K-ICG|Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection
62785792|NCT01444846|ACTIVE_COMPARATOR|SPI-1005 Middle Dose|400mg SPI-1005, capsule, bid, po, x4d
62013762|NCT00820339|ACTIVE_COMPARATOR|Selective Hepatic Vascular Exclusion|Patients with HCC received Selective Hepatic Vascular Exclusion in hepatectomy.
62013763|NCT00820339|EXPERIMENTAL|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
62402887|NCT04975867|ACTIVE_COMPARATOR|Normothermia group|For normothermia group, it will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.
62402888|NCT02198820||General|All patients included who underwent surgery with general anesthesia
62402889|NCT02198820||Loco Regional|All patients included who underwent surgery with loco regional anesthesia
62202327|NCT06161207|EXPERIMENTAL|4K-ICG|Indocyanine Green Tracer Using in Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection
62202328|NCT06161207|PLACEBO_COMPARATOR|3D|3D Laparoscopic Gastrectomy with Lymph Node Dissection
62202329|NCT04883359||Healthy Volunteers|From the Washington, D.C. metropolitan area
62202330|NCT00970762|EXPERIMENTAL|Rocuronium 0.6 INT, 0.1 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.
62202331|NCT00970762|EXPERIMENTAL|Rocuronium 0.6 INT, 0.15 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.
62202332|NCT00970762|EXPERIMENTAL|Rocuronium 0.6 INT, 0.2 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.
62202333|NCT00970762|EXPERIMENTAL|Rocuronium 0.9 INT, 0.1 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.
62202334|NCT00970762|EXPERIMENTAL|Rocuronium 0.9 INT, 0.15 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.
62202335|NCT00970762|EXPERIMENTAL|Rocuronium 0.9 INT, 0.2 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.
62202336|NCT00970762|ACTIVE_COMPARATOR|Vecuronium 0.1 INT, 0.025 MNT|Participants in this group received a 0.1 mg/kg intubating dose of vecuronium followed by 0.025 mg/kg maintenance dose of vecuronium.
62402890|NCT00938275|EXPERIMENTAL|0.5g SRT2104|"Cohort 1 (10 males) \& Cohort 2 (10 females) must attend the clinic on 4 separate treatment visits during the study; each treatment visit will be one week apart. At each treatment visit, subjects will receive one of the following 4 treatments:~A) 0.5g SRT2104 administered as an oral suspension in the fasted state B) 0.5g SRT2104 administered as an oral suspension following consumption of a standard meal C) 0.5g SRT2104 administered as two 0.25g capsules in the fasted state D) 0.5g SRT2104 administered as two 0.25g capsules following consumption of a standard meal.~For treatments A and C, subjects will have fasted for at least 10 hours overnight. Water will be restricted from 1h prior to dosing until 1h post dose. A light lunch will be provided 4h post dose. For treatments B and D, subjects will receive SRT2104 within 30 min following the start of consumption of a standardized non high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat)."
62402891|NCT04595825|EXPERIMENTAL|Anti-human CCL24 monoclonal antibody (CM-101)|Anti-human CCL24 monoclonal antibody CM-101 Intravenous Infusion over 60 minutes (±5 minutes)
62402892|NCT04595825|PLACEBO_COMPARATOR|Placebo|Placebo - intravenous infusion
62402893|NCT06505473||pre-operative results|pre-operative period test results, baseline data.
62785793|NCT01444846|ACTIVE_COMPARATOR|SPI-1005 High Dose|600mg SPI-1005, capsule, bid, po, x4d
62785794|NCT01444846|PLACEBO_COMPARATOR|Placebo|0mg SPI-1005, capsule, bid, po, x4d
62785795|NCT06583902||prospective|Data obtained in patients prospectively included in the study will be compared with those from a retrospective case-control population of patients treated consecutively in the previous two years.
62785796|NCT06583902||Retrospective|Data obtained in patients prospectively included in the study will be compared with those from a retrospective case-control population of patients treated consecutively in the previous two years.
62785797|NCT04435028||control group|55 patients received their standard therapy (anthracycline-containing chemotherapy without ketotifen)
62579351|NCT05672147|EXPERIMENTAL|Treatment (anti-CD33 CAR T-cells)|Patients undergo lymphodepletion therapy 3-5 days prior to CAR T cell infusion and receive anti-CD33 CAR T-cells IV on day 0. Patients with persistent CD33+ AML who are \> 28 days past the initial CAR T infusion, have additional product available and did not experience a dose-limiting toxicity, may optionally receive anti-CD33 CAR T-cells IV.
62785798|NCT04435028||ketotifen group|Ketotifen Group: 56 patients received anthracycline-containing chemotherapy plus ketotifen as a cardioprotective agent. Ketotifen will be given orally as one tablet (1 mg/tablet) 3 times daily, before and during the chemotherapeutic cycle for 6 cycles of treatment
62785799|NCT01387464|EXPERIMENTAL|ISV-303|
62785800|NCT01387464|ACTIVE_COMPARATOR|Bromday™|
62013764|NCT01709227|EXPERIMENTAL|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output \<1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output \>1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
62785801|NCT01389037|EXPERIMENTAL|Health Literacy-focused Self-help|
62785802|NCT01389037|PLACEBO_COMPARATOR|Delayed intervention control|
62785803|NCT01438606|EXPERIMENTAL|1 x 10^4 PFU VSV-Indiana HIV gag vaccine (Group 1)|Participants will receive 1 x 10\^4 PFU of the study vaccine by intramuscular (IM) injection in each deltoid at baseline and Week 8. (1 x 10\^4 PFU is the nominal dose; the actual dose is 4.6 x 10\^3 PFU given as 2.3 x 10\^3 PFU in each deltoid)
62202337|NCT03901001|ACTIVE_COMPARATOR|oseltamivir and adjunctive sirolimus|Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
62202338|NCT03901001|PLACEBO_COMPARATOR|oseltamivir alone|oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
62202339|NCT02774811|ACTIVE_COMPARATOR|Selective laser trabeculoplasty|Selective laser trabeculoplasty
62202340|NCT02774811|ACTIVE_COMPARATOR|Prostaglandin analogue|Prostaglandin analogue topical medical therapy
62579352|NCT01452542|EXPERIMENTAL|Sequence 1|Participants will receive a single oral dose of the following two study treatments under fasting conditions, in accordance with a randomly allocated treatment sequence: three 50-mg Phase 3 capsules of eliglustat (Reference Treatment \[R\]) or one 150-mg common blend capsule of eliglustat (Test Treatment \[T\]) according to the following treatment sequence: TRTR, with a 7-day washout between dosing in each period.
62579353|NCT01452542|EXPERIMENTAL|Sequence 2|Participants will receive a single oral dose of the following two study treatments under fasting conditions, in accordance with a randomly allocated treatment sequence: three 50-mg Phase 3 capsules of eliglustat (Reference Treatment \[R\]) or one 150-mg common blend capsule of eliglustat (Test Treatment \[T\]) according to the following treatment sequence: RTRT, with a 7-day washout between dosing in each period.
62579354|NCT06088485||low bone mineral density|bone mineral density according to t and z score.
62579355|NCT06088485||normal bone mineral density|bone mineral density according to t and z score.
62202341|NCT00773331|EXPERIMENTAL|1|
62785804|NCT01438606|PLACEBO_COMPARATOR|Placebo injection (normal saline) (Group 1)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
62785805|NCT01438606|EXPERIMENTAL|1 x 10^5 PFU VSV-Indiana HIV gag vaccine (Group 2)|Participants will receive 1 x 10\^5 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10\^5 PFU is the nominal dose; the actual dose is 4.6 x 10\^4 PFU given as 2.3 x 10\^4 PFU in each deltoid)
62785806|NCT01438606|PLACEBO_COMPARATOR|Placebo injection (normal saline) (Group 2)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
62785807|NCT01438606|EXPERIMENTAL|1 x 10^6 PFU VSV-Indiana HIV gag vaccine (Group 3)|Participants will receive 1 x 10\^6 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10\^6 PFU is the nominal dose; the actual dose is 4.8 x 10\^5 PFU given as 2.4 x 10\^5 PFU in each deltoid)
62785808|NCT01438606|PLACEBO_COMPARATOR|Placebo injection (normal saline) (Group 3)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
62785809|NCT01438606|EXPERIMENTAL|1 x 10^7 PFU VSV-Indiana HIV gag vaccine (Group 4)|Participants will receive 1 x 10\^7 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10\^7 PFU is the nominal dose; the actual dose is 4.2 x 10\^6 PFU given as 2.1 x 10\^6 PFU in each deltoid)
62785810|NCT01438606|PLACEBO_COMPARATOR|Placebo injection (normal saline) (Group 4)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
62202342|NCT00773331|ACTIVE_COMPARATOR|2|
62202343|NCT02113683||MMS test|therapy monitoring of patients with colo-rectal or stomach disease or with melanoma
62202344|NCT00387426|EXPERIMENTAL|Arm I|Patients receive oral sunitinib malate once daily for 6 weeks.
62402894|NCT06505473||post-operative results|post-operative period test results, review data.
62402895|NCT06505473||healthy control|Subjects with no tinnitus and matched baseline information
62013765|NCT01709227|EXPERIMENTAL|Peritoneal dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management will be directed by CICU attending and Nephrology service
62013766|NCT00852397|EXPERIMENTAL|Apixaban 2.5 mg|
62013767|NCT00852397|EXPERIMENTAL|Apixaban 5.0 mg|
62013768|NCT00852397|PLACEBO_COMPARATOR|Placebo|
62013769|NCT05734092|ACTIVE_COMPARATOR|Control group|The strength of the nickel-titanium coil will be adjusted every 4 weeks to the required strength of 40 g on each end until reaching normal coverage
62013770|NCT05734092|EXPERIMENTAL|Low-Level Laser Therapy group|In the experimental group (LLLT), where a (Ga-Al-As) diode laser, will be used with 808 nm wavelength in continuous mode, 250 milli-Watt power output, 4 Joules/point energy density, 16 s per point. In addition to adjusting the force gauge every 4 weeks until the end of the intrusion stage and reaching normal coverage
62013771|NCT06075511||Renal Failure Sleeve Gastrectomy|Subjects that have renal failure and are undergoing a sleeve gastrectomy per standard clinical care will perform a 6-minute walk distance (6MWD) evaluation, activity monitoring, continuous glucose monitor (CGM), blood pressure monitoring, complete mixed meal test, and composition body scan to gather additional information for researchers.
62013772|NCT02930434|ACTIVE_COMPARATOR|Standard daily vitamin D3|Cholecalciferol 600 IU daily during one year or exit from Antarctica.
62202345|NCT03026959|EXPERIMENTAL|Mindfulness Group|Participants assigned to the mindfulness group will attend four weekly sessions that are each 1.5 hours in length. The sessions will follow the structure described by Short, Mazmanian, Ozen, \& Bédard (2015). The structure is designed to first enhance learners' foundation skills in mindfulness and progresses into teaching learners more advanced mindfulness skills.
62202346|NCT03026959|NO_INTERVENTION|Social (control) Group|Participants assigned to the social group will also attend four weekly sessions that are each 1.5 hours in length. Each session will have participants focus on a creative tasks while permitting task related discussion. In this way the format is designed to parallel the mindfulness group, where participants engage in a new activity each week and have an opportunity to discuss the activities with the group without engaging in any formal intervention.
62402896|NCT06152666||Staff|Members of healthcare teams involved in the delivery of day-case endourology operations.
62402897|NCT04701957|EXPERIMENTAL|Modified Atkins 2 :1 Ketogenic diet|The Atkins 2: 1 diet as prescribed for the participants of our intervention group (N = 35) is based on a diet moderately rich in protein (meat, fish, cheese, eggs, vegetable proteins) and without restriction of fats, provided they are balanced, but limiting the carbohydrate intake (bread, pasta, rice) to 50 grams / day. The ratio calories from fat / calories from protein + carbohydrates will be 3 to 1
62402898|NCT04701957|NO_INTERVENTION|Control diet|
62402899|NCT04177862|EXPERIMENTAL|Sublingual Sufentanil|Single dose of sublingual sufentanil for acute pain.
62402900|NCT04177862|ACTIVE_COMPARATOR|IV Fentanyl|single dose of IV fentanyl for acute pain.
62402901|NCT05040295|EXPERIMENTAL|Treatment sequence 1|Treatment sequence 1 will receive a single 30 milligrams (mg) ritlecitinib intact adult capsule during the first period, three 10 mg ritlecitinib pediatric capsules during the second period and 30 mg ritlecitinib spray congealed beads in the third period.
62402902|NCT05040295|EXPERIMENTAL|Treatment Sequence 2|Treatment sequence 2 will receive three 10 mg ritlecitinib pediatric capsules during the first period, a single 30 mg intact adult capsule during the second period and 30 mg ritlecitinib spray congealed beads in the third period.
62013773|NCT02930434|ACTIVE_COMPARATOR|Higher weekly vitamin D3|Cholecalciferol 25000 IU once weekly during one year or exit from Antarctica.
62013774|NCT01816139|EXPERIMENTAL|Vehicle (2 Times/Week)|Vehicle applied to the vagina daily for 2 weeks followed by dosing 2 times a week for 10 weeks.
62013775|NCT01816139|PLACEBO_COMPARATOR|WC3011 Estradiol Vaginal Cream (2 Times/Week)|WC3011 estradiol vaginal cream applied daily for 2 weeks followed by dosing 2 times a week for 10 weeks.
62013776|NCT06573554|ACTIVE_COMPARATOR|Total Contact Cast (TCC) Comparator Arm|standardised non-walking, non-removable, knee high, fibre-glass total contact cast
62013777|NCT06573554|ACTIVE_COMPARATOR|Posterior Slab Comparator Arm|posterior non-removable knee high slab
62013778|NCT06152211|EXPERIMENTAL|Choir|For each choir session, the choir director will be supported by an accompanist who will provide the music accompaniment for the songs and four section leaders who will provide musical leadership for choral sections (soprano, alto tenor \& bass). At the beginning of each choir group, participants will be asked about their favorite songs to help ensure that the music will be appropriate for the participants' interest and cultural background. Each choir group will rehearse once a week for two hours with a short break in the middle for snacks for a total of 16 consecutive weeks. The choir rehearsals will follow a general routine, beginning with announcements and warm-ups, work on the repertoire, a break, additional work on the repertoire in sections, and a short group practice at the end. Participants will also be given at-home activities, in the form of pre-recorded videos and music theory exercises to complete outside of class for an estimated 1.5 hours per week.
62013779|NCT06152211|ACTIVE_COMPARATOR|Music Listening|Over the course of 16-weeks, the group will meet for two hours per week to talk about a set of musical recordings. Recorded music will be previously assigned and provided as a playlist via a web platform to track the time duration of engagement. Regular attendance will be required. The discussion group will meet as a full group each week to listen to a subset of that week's recordings, with a guided and brief discussion after each of the six selected songs. The group will then pause for a brief break and will divide into four smaller discussion groups where a volunteer facilitator from that group would guide a discussion about the selected music, to include personal reflections, its cultural context, and ideas around societal impacts.
62013780|NCT05101564|EXPERIMENTAL|IC1:Alpelisib in combination with Tamoxifen (closed to enrollment)|Integrative subtype IC1, Treatment (14 days, - 2 or + 7 days): Take assigned alpelisib pills, 300 mg (two 150 mg tablets) with food, once daily by mouth. Tamoxifen pills, 20 mg once daily by mouth
62402903|NCT00855634|ACTIVE_COMPARATOR|1|"COHORT 1 (minimal metastatic disease):~* Arm 1 (intervention): resection of the primary tumor, followed by resection of the liver metastasis/metastases~* Arm 2 (control): exploration and/or gastroenterostomy and/or hepaticojejunostomy/choledochojejunostomy"
62785811|NCT01438606|EXPERIMENTAL|1 x 10^8 PFU VSV-Indiana HIV gag vaccine (Group 5)|Participants will receive 1 x 10\^8 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10\^8 PFU is the nominal dose; the actual dose is 3.4 x 10\^7 PFU given as 1.7 x 10\^7 PFU in each deltoid)
62202347|NCT05025592||cTACE/DEB-TACE-HAIC+regorafenib±anti-PD1 antibody|patients will receive the combination treatment of cTACE/DEB-TACE plus HAIC and combined with regorafenib and anti-PD1 antibody or not. The anti-PD-1 antibody will be used depended on the contraindications or wishes of patients.
62402904|NCT00855634|ACTIVE_COMPARATOR|2|"COHORT 2 (venous infiltration):~* Arm 1 (intervention): resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV)~* Arm 2 (control): resection of the primary tumor with dissection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV) plus tumor masses adjacent to these veins; no venous resection"
62402905|NCT04105465|NO_INTERVENTION|Surgery without trial (PJ) device|All steps of surgery are conducted as per standard practice in accordance with the current practice at the time. In all cases a bilateral inguino-femoral groin node dissection was performed, with en-bloc removal of the superficial and deep inguinal nodes with conservation of the long saphenous vein.
62402906|NCT04105465|ACTIVE_COMPARATOR|Surgery with trial (PJ) device|Use of the PJ was limited to the randomised side only. All steps of surgery are conducted as per standard practice in accordance with the current practice at the time. In all cases a bilateral inguino-femoral groin node dissection was performed, with en-bloc removal of the superficial and deep inguinal nodes with conservation of the long saphenous vein. Haemostasis was ensured with diathermy and ties and just prior to wound closure, the surgeon used the PlasmaJet on the indicated groin to seal the lymph vessels and channels at a setting of 40% by spraying the argon plasma over the entire exposed surgical field at a distance of 10 mm from the surface to the tip of the instrument.
62402907|NCT02983357||Case Series Study|Subjects who received a total shoulder replacement with an anchor peg glenoid and autologous bone grafting at the department of Orthopaedic Surgery at University of Nebraska Medical Center / Nebraska Medicine and are now at least 9 years out from surgery.
62402908|NCT02223624|EXPERIMENTAL|eccentric aerobic exercise group|Eccentric aerobic exercise group: Participants in this group will participate in an eccentric aerobic exercise rehabilitation program for a total of eight weeks, two sessions per week. Outcome measurements will be taken post exercise program and also after a 3 month follow-up period. Each session will be approximately 60 minutes in duration and include approximately 10 minutes of warm up (stretches), eccentric stepper aiming for 20 minutes, walking and light weights, followed by a five minute cool-down period.
62402909|NCT02223624|ACTIVE_COMPARATOR|Concentric aerobic exercise group|"Concentric aerobic exercise group (usual care): The length of the concentric aerobic exercise based rehabilitation program will be the same as the study group- twice weekly exercise sessions for 8 weeks. Outcome measurements will also be taken after a 3-month follow-up period.~Participants in the concentric aerobic exercise group will participate in the same warm-up and cool down period as the eccentric group. They will also complete walking and light weights. To replace the 20 minutes of eccentric exercise, concentric participants will complete approximately 20 minutes of exercise bike, stair climbing and rowing as able with required rests."
62402910|NCT02223624|NO_INTERVENTION|Waiting list control|Waiting list (no exercise): Participants assigned to this group will not receive any intervention during the study period. They will be assessed like other participants at baseline and after eight weeks, but not at three-month follow-up due to ethical concerns around withholding care known to be effective. Given that there is a waiting list for the current exercise program of 4-12 weeks, it is felt that delaying care for a set period of eight weeks is not of ethical concern. Following the completion of assessments, waiting list participants will be able to complete the traditional exercise program as usual but not as participants of the study's experimental groups.
62202348|NCT03312413|EXPERIMENTAL|Dexmedetomidine low dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.2μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
62402911|NCT00131937|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62402912|NCT02357017|ACTIVE_COMPARATOR|Low salt diet|The low-salt meals will be formulated to provide 50 mmol of sodium per day. Two diets with different caloric amounts (2000 or 2500) will be available.
62579356|NCT06208202|ACTIVE_COMPARATOR|Fruit flavored e-cigarette with synthetic cooling agents added|Synthetic cooling agents will be added to fruit flavored e-liquid for this condition.
62579357|NCT06208202|ACTIVE_COMPARATOR|Fruit flavored e-cigarette|Fruit flavored e-liquid will be used for this condition.
62785812|NCT01438606|PLACEBO_COMPARATOR|Placebo injection (normal saline) (Group 5)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
62785813|NCT03392818|EXPERIMENTAL|formula|Calculate the depth of intubation according to the formula of 0.1977\* patient's height - 4.2423
62785814|NCT03392818|EXPERIMENTAL|Fiberoptic bronchoscope|intubation of Uniblocker under the Under the guidance of Fiberoptic bronchoscope
62785815|NCT03392818|EXPERIMENTAL|The measured distance|To measure the distance between the upper edge of the thyroid cartilage to the upper edge of the sternum add the distance from the upper edge of the sternum to the carina calculated according to the chest CT scans as a guide to the placement of Uniblocker without the aid of FOB.
62202349|NCT03312413|EXPERIMENTAL|Dexmedetomidine median dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.5μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
62202350|NCT03312413|EXPERIMENTAL|Dexmedetomidine high dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.7μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
62202351|NCT03312413|PLACEBO_COMPARATOR|Control group (normal saline group)|Patients in this group are received saline iv infusion of 5mL·h-1 from incision to 20-30 minutes before the end of surgery
62013781|NCT05101564|ACTIVE_COMPARATOR|IC1:Tamoxifen (closed to enrollment)|Integrative subtype 1, Treatment (14 days, -2 to +7 days): Take assigned tamoxifen pills, 20 mg once daily by mouth
62013782|NCT05101564|EXPERIMENTAL|IC2:Zotatifin in combination with Fulvestrant|Integrative subtype 2, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
62013783|NCT05101564|ACTIVE_COMPARATOR|IC2:Fulvestrant|Integrative subtype 2, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
62013784|NCT05101564|EXPERIMENTAL|IC3:Zotatifin in combination with Fulvestrant|Integrative subtype 3, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
62013785|NCT05101564|ACTIVE_COMPARATOR|IC3:Fulvestrant|Integrative subtype 3, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1. on Day 1.
62013786|NCT05101564|EXPERIMENTAL|IC4:Zotatifin in combination with Fulvestrant|Integrative subtype 4, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
62013787|NCT05101564|ACTIVE_COMPARATOR|IC4:Fulvestrant|Integrative subtype 4, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1..
62013788|NCT05101564|EXPERIMENTAL|IC6:Zotatifin in combination with Fulvestrant|Integrative subtype 6, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
62202352|NCT02217215||Negative and Referral Cytology Results|CNDS Advanced Cervical Scan Colposcopy
62402913|NCT02357017|ACTIVE_COMPARATOR|High salt diet|High dietary salt intake, NaCl tablets (6 grams/day) will added to the subject's study diet in order to increase dietary sodium intake to \>250 mmol/day.
62579358|NCT06208202|ACTIVE_COMPARATOR|Tobacco flavored e-cigarette with synthetic cooling agents added|Synthetic cooling agents will be added to tobacco flavored e-liquid for this condition.
62579359|NCT06208202|ACTIVE_COMPARATOR|Tobacco flavored e-cigarette|Tobacco flavored e-liquid will be used for this condition.
62013789|NCT05101564|ACTIVE_COMPARATOR|IC6:Fulvestrant|Integrative subtype 6, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
62013790|NCT05101564|EXPERIMENTAL|IC7:Zotatifin in combination with Fulvestrant|Integrative subtype 7, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
62013791|NCT05101564|ACTIVE_COMPARATOR|IC7:Fulvestrant|Integrative subtype 7, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
62013792|NCT05101564|EXPERIMENTAL|IC8:Zotatifin in combination with Fulvestrant|Integrative subtype 8, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
62013793|NCT05101564|ACTIVE_COMPARATOR|IC8:Fulvestrant|Integrative subtype 8, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
62013794|NCT04819685|EXPERIMENTAL|test group|Intervention:Anti-radiation spray (liquid dressing)
62013795|NCT04819685|NO_INTERVENTION|control group|
62579360|NCT05580627|EXPERIMENTAL|Livestream Modality|The livestream modality is considered the treatment group for the purpose of this quasi-experimental study.
62579361|NCT05580627|EXPERIMENTAL|Live Modality|The live modality is considered the control group for the purpose of this quasi-experimental study.
62013796|NCT05981651||training session|A total of 150 facial expression videos of healthy volunteers and facial palsy patients were collected as a training set for the algorithm
62013797|NCT05981651||test set|A total of 50 cases of healthy volunteers and patients with facial palsy were used as the test set for the algorithm
62202353|NCT04862442|EXPERIMENTAL|Group 1=Video-conference based Qigong exercises|After initial result evaluation, participants of Group A will perform Qigong exercises for 40 to 45 minutes per session for 3 days a week for 6 weeks via the online video conference method.
62202354|NCT04862442|EXPERIMENTAL|Group 2=A-synchronized video Qigong exercises|"Group B will perform the same routine via a-synchronized video sections for 6 weeks.~Basic Qigong exercises will be performed by volunteers for 6 weeks and progression will be logged."
62202355|NCT02049645||faculty staff and their adult family members|faculties and their adult family members of the Third Xiang-Ya Hospital
62402914|NCT01454037||Prostate cryoablation|Subjects receiving cryotherapy for prostate cancer
62402915|NCT01454037||Radical prostatectomy|Subjects receiving radical prostatectomy
62402916|NCT01454037||Radiation|Subjects receiving radiation for prostate cancer
62202356|NCT03856983|NO_INTERVENTION|Control group|Control group who will do usual rehabilitation.
62202357|NCT03856983|EXPERIMENTAL|Experimental group|Experimental group who will do usual rehabilitation and visualization of point-light human actions
62202358|NCT03156192|EXPERIMENTAL|Caregivers of ICU patients|Caregivers (family member) aged over 20 who provides care to ICU patients
62202359|NCT01869504|EXPERIMENTAL|Balloon-tipped intercostal drain|Subjects who have given written informed consent and who fulfill the inclusion and exclusion criteria will proceed to have the study drain inserted at the earliest opportunity as per standard hospital protocols using local anaesthetic, and conscious sedation where appropriate. All other aspects of their treatment will be identical to usual clinical care, including chest drain checks and fluid drainage strategies.
62202360|NCT03137043||Severe Asthmatic Subjects|Subjects requiring high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic glucocorticosteroids) to prevent it from becoming 'uncontrolled' or which remains 'uncontrolled' despite the therapy.
62202361|NCT03137043||Non-Severe Asthmatic Subjects|Subjects with intermittent, persistent mild or moderate asthma.
62202362|NCT05952726|EXPERIMENTAL|Prolonged expiratory cycling|15% expiratory cycling during pressure support ventilation
62202363|NCT05952726|EXPERIMENTAL|Late expiratory cycling|30% expiratory cycling during pressure support ventilation
62202364|NCT05952726|EXPERIMENTAL|Medium expiratory cycling|45% expiratory cycling during pressure support ventilation
62202365|NCT05952726|EXPERIMENTAL|Early expiratory cycling|60% expiratory cycling during pressure support ventilation
62202366|NCT06334705|OTHER|participants can take part in any examinations they wish|
62202367|NCT05639608|EXPERIMENTAL|systemically healthy females with gingivitis|scaling will be done at baseline
62202368|NCT05639608|NO_INTERVENTION|systemically and periodontally healthy females|data will be recorded at baseline and no intervention will be done
62202369|NCT01585155|EXPERIMENTAL|TA-650|
62202370|NCT04274491||Pelvic Organ Prolapse Surgery Patients|Participants with greater than or equal to stage II pelvic organ prolapse who are scheduled for reconstructive surgery will be recruited. Participants will be asked to complete a preoperative online survey regarding their health, recovery expectancy, and different roles. Additional online surveys will be send on postoperative days 14 and 42 to measure postdischarge surgical recovery
62202371|NCT03170687|EXPERIMENTAL|foot cast|
62202372|NCT03170687|ACTIVE_COMPARATOR|short leg cast|
62202373|NCT05495321|EXPERIMENTAL|low-dose IL-2|"The first stage (double-blind treatment period): One million IU of IL-2 was injected subcutaneously once every other day for 12 weeks.~The second stage (open treatment period): One million IU of IL-2 was injected subcutaneously once every other day for 12 weeks."
62202374|NCT05495321|PLACEBO_COMPARATOR|Placebo|"The first stage (double-blind treatment period): Placebo was injected subcutaneously once every other day for 12 weeks.~The second stage (open treatment period): One million IU of IL-2 was injected subcutaneously once every other day for 12 weeks."
62202375|NCT04087811||Superion® Indirect Decompression System (IDS)|Superion® Indirect Decompression System (IDS) - Interspinous Spacer
62202376|NCT01817322|EXPERIMENTAL|Myfortic® (Enteric-coated Mycophenolate Sodium)|reduced cyclosporine+steroids+standard dose of myfortic
62202377|NCT01817322|ACTIVE_COMPARATOR|Myfortic|Conventional Dose+cyclosporine+steroid+Reduced Dose of Myfortic
62202378|NCT02936843|EXPERIMENTAL|Salsalate|Salsalate, 1 gram by mouth, 3 times daily (3 grams per day) for 12 months.
62202379|NCT02936843|PLACEBO_COMPARATOR|Comparator|Placebo for Salsalate, 2 tablets by mouth, 3 times daily for 12 months
62202380|NCT00941070|EXPERIMENTAL|Treatment (cisplatin, triapine, radiation therapy)|"Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, and 30 and triapine IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Patients also undergo pelvic external beam radiotherapy 5 days a week during weeks 1-5. Patients may undergo parametrial boost radiation and intracavitary low-dose or high-dose rate brachytherapy as clinically indicated.~Patients undergo whole-body F-18 fluorodeoxyglucose-PET/CT imaging at baseline, at 3 months after completion of study treatment, and at disease progression. Patients complete Sexual Function-Vaginal Changes Questionnaire and a smoking behavior questionnaire at baseline, at 3 months after completion of study treatment, and at disease progression."
62202381|NCT05650762|EXPERIMENTAL|Cinnamon|
62202382|NCT03447301|EXPERIMENTAL|Extra virgin olive oil|Extra virgin olive oil (30mL) daily
62202383|NCT03447301|NO_INTERVENTION|Control|No consumption of extra virgin olive oil
62202384|NCT00304304|ACTIVE_COMPARATOR|Intervention - asthma education|CCC received asthma education in the first 6 months of the study
62202385|NCT00304304|PLACEBO_COMPARATOR|Wait-list control|CCC received asthma education in second 6 months of study
62202386|NCT06159179|OTHER|undiagnosed transudative and exudative pleural effusion|Subjects with undiagnosed transudative and exudative pleural effusion will undergo medical thoracoscopy as per studies protocols.
62202387|NCT00730873|EXPERIMENTAL|A|continuous positive airway pressure
62202388|NCT01845506|EXPERIMENTAL|Wireless pressure transducer|Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
62202389|NCT01845506|ACTIVE_COMPARATOR|Cardiorespiratory Monitor|Following informed consent, each subject will be also be fitted with ECG leads (five), and an oxygen saturation monitor. This information as well as blood pressure and temperature will be recorded at 5-minute intervals by a nurse.
62202390|NCT00601263|ACTIVE_COMPARATOR|1a|Low dose ASHMI (2 caps bid).
62202391|NCT00601263|PLACEBO_COMPARATOR|1b|Placebo 2 caps bid.
62202392|NCT00601263|ACTIVE_COMPARATOR|2a|Medium dose ASHMI (4 caps bid).
62202393|NCT00601263|PLACEBO_COMPARATOR|2b|Placebo 4 caps bid.
62202394|NCT00601263|ACTIVE_COMPARATOR|3a|High dose ASHMI (6 caps bid).
62202395|NCT00601263|PLACEBO_COMPARATOR|3b|Placebo 6 caps bid.
62202396|NCT01546077|ACTIVE_COMPARATOR|Hydrolocalization technique group|Technique of placement of popliteal perineural catheter using the hydrolocalization technique with ultrasound
62202397|NCT01546077|ACTIVE_COMPARATOR|Stimulating Catheter technique group|A technique for placement of popliteal catheter with the aid of a neurostimulator
62202398|NCT04985578|EXPERIMENTAL|Dry needling Group|The experimental extremity will be assigned randomly and will receive a single treatment session of TrP dry needling as follows: the therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrP for 60 seconds.
62202399|NCT04985578|PLACEBO_COMPARATOR|Sham dry needling|The experimental extremity will be assigned randomly and will receive a single treatment session of TrP sham dry needling as follows: the therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, sham dry needling technique will be performed on the TrP for 60 seconds with a needle without tip.
62202400|NCT04985578|NO_INTERVENTION|Control|No Treatment will be perfomed in this group
62202401|NCT04383470||General population, during COVID pandemic|General population during COVID-19 pandemic. Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
62202402|NCT04383470||General population, 6 months after COVID pandemic|General population, 6 months after COVID pandemic Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
62202403|NCT04383470||General population, 12 months after COVID pandemic|General population, 12 months after COVID pandemic Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
62202404|NCT01681277|EXPERIMENTAL|BI 113608 high dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
62202405|NCT01681277|EXPERIMENTAL|BI 113608 low dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
62202406|NCT01681277|EXPERIMENTAL|BI 113608 medium dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
62202407|NCT01681277|EXPERIMENTAL|BI 113608 high dose qd|powder in the bottle for oral solution, oral administration with 240 ml water
62202408|NCT05922982|ACTIVE_COMPARATOR|Standard care arm|MAP-based (MAP \> 65 mmHg) norepinephrine weaning protocol
62202409|NCT05922982|EXPERIMENTAL|Experimental arm (HPI-guided)|MAP-based (MAP \> 65 mmHg) norepinephrine weaning protocol and guided by the HPI (HPI\<80) delivered by the Acumen IQ medical device.
62202410|NCT06114303||"Mother"|Healthy women
62202411|NCT06114303||"Daughter"|"Healthy daughter from Mother subjects"
62579362|NCT04557241|EXPERIMENTAL|Brief Intervention arm|The primary intervention in this study will be an infographic that is designed to build trust in the scientific process (as described in the Intervention section). This arm will introduce the intervention and then instruct the participant to review it carefully (including a mandated pause on the infographic screen) before continuing to the remaining data collection.
62202412|NCT03349151|ACTIVE_COMPARATOR|Early feeding|This group will be served soft meal diet served on postoperative 2nd hour on return to the ward.
62202413|NCT03349151|PLACEBO_COMPARATOR|On- demand feeding|This group will be served soft meal diet served whenever they wanted to eat on return to the ward.
62202414|NCT05591053|EXPERIMENTAL|ActivSight Group|Patients undergoing esophagectomy with ActivSight (n=70)
62202415|NCT05799105|EXPERIMENTAL|Open-capsule|Subjects in this arm will be treated with omeprazole 40 milligrams twice daily (or alternative medication if not covered by the subject's insurance) taken as an open-capsule until confirmed ulcer healing.
62202416|NCT05799105|ACTIVE_COMPARATOR|Intact-capsule|Subjects in this arm will be treated with omeprazole 40 milligrams twice daily (or alternative medication if not covered by the subject's insurance) taken as an intact-capsule until confirmed ulcer healing or potential cross-over.
62202417|NCT02551653|EXPERIMENTAL|[11C]-GSK2256098|Subjects will receive single IV bolus injection of \[11C\]-GSK2256098 over about 30 seconds. Each unit dose will contain up to 500 millibecquerel (MBq) of \[11C\]-GSK2256098 with maximum \[11C\]-GSK2256098 mass \<=10 microgram (mcg).
62202418|NCT00234702|EXPERIMENTAL|1|
62202419|NCT00234702|PLACEBO_COMPARATOR|2|
62202420|NCT02499523|ACTIVE_COMPARATOR|THR with conventional technique|Use of conventional technique in THR
62202421|NCT02499523|EXPERIMENTAL|THR with ACOG|THR with Acetabular Cup Orientation Guides (ACOG)
62202422|NCT05519566|EXPERIMENTAL|Pulsed Fluoroscopy Retrograde Urethrogram|
62202423|NCT05519566|ACTIVE_COMPARATOR|Traditional Retrograde Urethrogram|
62202424|NCT01509547|EXPERIMENTAL|varenicline|Participants \>55 kg will take varenicline 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily for 11 weeks. Participants ≤55 kg will take varenicline 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily for 11 weeks.
62202425|NCT01509547|PLACEBO_COMPARATOR|placebo|Participants \>55 kg will take placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily for 11 weeks. Participants ≤55 kg will take placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily for 11 weeks.
62202426|NCT04185129|EXPERIMENTAL|Foster|uncontrolled asthma patients were randomized into Foster treatment group
62202427|NCT04185129|ACTIVE_COMPARATOR|Relvar|uncontrolled asthma patients were randomized into Relvar treatment group
62202428|NCT01828762|EXPERIMENTAL|DC-TC+GM-CSF|
62202429|NCT04210921|EXPERIMENTAL|Treatment group|"In the treatment group, the Park needle with a real acupuncture will be penetrated in an appropriate angle into a depth of 10-15 mm. Acupuncture manually manipulated by lifting, thrusting, and twirling methods to produce a characteristic sensation known as De Qi (feeling of needle sensation refers to tenseness around the needle felt by the practitioner and numbness, distension, soreness, and heaviness around the point felt by the patient), and needles will be stimulated manually at least 10 s, then the needles will be retained for 30 minutes."
62202430|NCT04210921|PLACEBO_COMPARATOR|Control group|In the control group, the Park sham needle will instead of the real needle. It is retractile and adopts the sleeve type blunt needle design. When the blunt needle goes through the adhesive and contact with skin, it will move back into the hollow centre of the handle rather than penetrate into skin. The sham needle may be manipulated by lifting, thrusting or twirling as the real one, but it will not insert into the skin authentically.
62579363|NCT04557241|PLACEBO_COMPARATOR|Placebo Control arm|"The comparator in this study will be a control (placebo) infographic that is completely unrelated to science (As described in the Placebo Control section). This arm will introduce the control infographic and then instruct the participant to review it carefully (including a mandated pause on the infographic screen) before continuing to the remaining data collection."
62579364|NCT04700579||TB Cases|"* n= 50 (25 HIV positive and 25 HIV negative)~* Xpert MTB/RIF Ultra-confirmed TB"
62579365|NCT04700579||Healthy Household Contacts|"* n= (25 HIV positive and 25 HIV negative)~* Culture negative TB result"
62202431|NCT06314100||THS smokers|Each subject undergoes a routine intraoral examination and anamnesis. Samples of supragingival dental biofilm and saliva are taken for microbiological analysis
62202432|NCT06314100||cigarette smokers|Each subject undergoes a routine intraoral examination and anamnesis. Samples of supragingival dental biofilm and saliva are taken for microbiological analysis
62202433|NCT06314100||nonsmokers|Each subject undergoes a routine intraoral examination and anamnesis. Samples of supragingival dental biofilm and saliva are taken for microbiological analysis
62202434|NCT02408991|EXPERIMENTAL|AA and Neopogen|Patient undergoes treatment with Art-assist device and Neupogen
62202435|NCT04197362|EXPERIMENTAL|ASICS Women's Gel-Venture 6 Running-Shoe|ASICS Women's Gel-Venture 6 Running-Shoe
62402917|NCT05227534|EXPERIMENTAL|Participants 40 years of age or older with cancer risk|The study will aim to enroll participants 40 years of age or older with cancer risk. Specific cancer risks will be enriched to increase the number of cancer events that are observed during the study.
62579366|NCT04700579||Sick controls|"* n=50~* Diseases: Asthma, Chronic obstructive pulmonary disease (COPD), Cancer, Bronchiectasis (including post-TB) and Pneumonia"
62402918|NCT00069069|EXPERIMENTAL|1|single center, Phase 1, open label, dose escalation trial assessing safety profile of four doses of intranasal recombinant human E-selectin
62402919|NCT03334201|OTHER|Western diet first|To receive Western diet controlled feeding first, followed by non-Western diet controlled feeding
62402920|NCT03334201|OTHER|Non-Western diet first|To receive non-Western diet controlled feeding first, followed by Western diet controlled feeding
62402921|NCT03896802|EXPERIMENTAL|Low PEEP|PEEP 5 cmH2O
62402922|NCT03896802|EXPERIMENTAL|High PEEP|PEEP 15 cmH2O
62402923|NCT06355518|EXPERIMENTAL|Preoperative Immunonutrition|Preoperative administration of a high-calorie, high-protein liquid oral nutritional supplement containing immunonutrients \[Impact® Oral (237 mL per serving); Nestlé Health Science - Creully Sur Seulles - France\]. Two units of Impact® Oral per day will be administered for 7 days before surgery.
62402924|NCT06355518|ACTIVE_COMPARATOR|Preoperative Standard Oral Nutritional Supplement|Preoperative administration of a standard high-calorie-high-protein liquid oral nutritional supplement \[Meritene® Protein Drink (200 mL per serving); Nestlé Health Science - Creully Sur Seulles - France\]. Two units of Meritene® Protein Drink per day will be administered for 7 days before surgery.
62402925|NCT05696691|EXPERIMENTAL|Ketamine and Crisis Response Plan (CRP)|Individuals randomized to the experimental arm will receive 100mg intramuscular ketamine injection before completing the Crisis Response Plan. The average timeframe for the experimental arm is anticipated to be approximately 60 minutes of active treatment. Following ketamine administration, the subject will be monitored for 45 minutes with pulse oximetry and recurrent vital signs. The study team will record when the CRP is completed in relation to the ketamine injection.
62579367|NCT01168466|NO_INTERVENTION|Neurofeedback|Waitlist control group.
62579368|NCT01168466|EXPERIMENTAL|QEEG-based Neurofeedback Training|A randomly selected half of participants waits 15 weeks for the other half to complete treatment, and are then reassessed, serving as controls. They then receive the same treatment as the experimental group.
62579369|NCT01560312|EXPERIMENTAL|Renal denervation|Renal denervation (Symplicity® Catheter System™) + conventional antihypertensive medical treatment without spironolactone (spironolactone can be taken only if started before randomization)
62579370|NCT01560312|NO_INTERVENTION|Medical treatment|"Conventional antihypertensive treatment including spironolactone (if not contraindicated).~One year after randomization, renal denervation can be performed according to the physician's decision based on the BP levels and if patient desires the procedure."
62579371|NCT05832853|EXPERIMENTAL|Wu Qin Xi exercise|The training schedule for Wu Qin Xi consisted of two phases: the first phase lasted for eight weeks, while the second phase lasted for 16 weeks. In the first phase, Wu Qin Xi group was given twice repetitions of the intervention. The second phase consisted of three repetitions of the Wu Qin Xi group.
62785816|NCT03559933|EXPERIMENTAL|PEPNS System|The pdSTIM lead will be temporarily inserted near the right and left phrenic nerves and connected to the PEPNS system console in order to stimulate the phrenic nerves and activate the diaphragm on the patients until extubated/removed from mechanical ventilation or until 48 hours has elapsed, whichever comes first.
62202436|NCT04197362|EXPERIMENTAL|Nike Air Max 270|Nike Air Max 270
62202437|NCT04197362|EXPERIMENTAL|La Vida+|La Vida+
62202438|NCT03969368|EXPERIMENTAL|Treatment Group|Treatment with the investigational device - rPMS
62202439|NCT03969368|ACTIVE_COMPARATOR|Control Group|Control group
62202440|NCT06341686|EXPERIMENTAL|Letermovir|Patients randomized to the prophylaxis group: Letermovir 480mg, 1x/day, from D14 to D98. Letermovir prophylaxis will start on day 14 after kidney transplantation. In both groups, CMV DNAemia will be monitored weekly until day 98 (21, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91 and 98), and after any acute rejection treatment occurring between 3 months and 6 months after kidney transplantation.
62215124|NCT00472810|ACTIVE_COMPARATOR|2|Following ethics committee approval, 20 patients with uncontrolled glaucoma will be randomised to trabeculectomy with mitomycin -C. Randomisation is performed. Then, trabeculectomy is performed
62402926|NCT05696691|NO_INTERVENTION|Treatment as Usual|Individuals randomized to the no intervention arm will receive routine care from emergency providers and psychiatry staff.
62785817|NCT01679873|PLACEBO_COMPARATOR|Control group|Assess abstract not reporting funding sources or conflicts of interest
62579372|NCT05832853|EXPERIMENTAL|Wu Qin Xi, resistance training and endurance training|The trial was divided into three cycles, each lasting eight weeks. Participants performed a hybrid program of Wu Qin Xi exercise, resistance training and endurance training of varying duration and intensity in each cycle. Each session lasted one hour, three times a week for 24 weeks.
62013798|NCT01866189|EXPERIMENTAL|PET and MRI|Included patients will have F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF) as soon as possible after stroke onset (less than 36 hours). A second brain MRI (MRI-2) will be performed on day 7.
62202441|NCT06341686|ACTIVE_COMPARATOR|Preemptive therapy|"Patients randomized to the preemptive treatment group:~Preemptive treatment (PET) will begin on day 21, assessing CMV DNAnemia weekly until day 98 (21, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91 e 98). The threshold for starting treatment with Ganciclovir is a CMV DNAemia \> 5,000 IU in a single measurement (CMV infection). measurement (CMV infection) OR any CMV DNAemia with any signs or symptoms associated with CMV (syndrome or disease).c. In both groups, CMV DNAemia will be monitored weekly until day 98 (21, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91 and 98), and after any acute rejection treatment occurring between 3 months and 6 months after kidney transplantation."
62202442|NCT05400577|EXPERIMENTAL|Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)|
62202443|NCT06419153||SPF Block Group|"In this RCT, all patients enrolled will be undergoing Emergency HemiArthroplasty in the theatre complex in University Hospital Galway.~Under ultrasound-guidance the SPF will be performed by the experienced consultant anaesthesiologist, whereby 30ml of 0.75% Ropivicaine will be slowly injected into the subpsoas fascial plane, whilst at all times throughout and following the procedures the patient will be closely haemodynamically monitored. The patient will be followed up in the recovery post-anaesthetic care unit up to four hours following their surgery. They will then be reviewed by the one of the co-investigators at a timeframe of 0-24 hours and 24-48 hours post-operatively to further establish their analgesic efficacy, their pain scores (see supplementary appendix), quality of recovery, time to remobilization and opioids requirements, ensuring the patient is comfortable and aiming to maximize their recovery period."
62013799|NCT02990663|EXPERIMENTAL|Bedtime BP Meds|Use of blood pressure lowering medication at bedtime
62202444|NCT06419153||No SPF Block Group|"In this RCT, all patients enrolled will be undergoing Emergency HemiArthroplasty in the theatre complex in University Hospital Galway~Participants randomized to 'standard care' will receive the standard care required as determined by the treating team in the form of intravenous analgesia."
62202445|NCT03452215|EXPERIMENTAL|Study|
62202446|NCT03452215|SHAM_COMPARATOR|Control|
62202447|NCT04016155|ACTIVE_COMPARATOR|SMBG|Patients use their own glucometers as control
62402927|NCT06542393|EXPERIMENTAL|Randomized Anemia Group for non-PBM protocol (GNPBM)|Patients \> 18 years admitted to Hospital São Paulo for Coronary Artery Bypass Grafting (CABG) surgery who are hospitalized in the Cardiovascular Surgery department or another specialty unit and are anemic (Hemoglobin - Hb \< 12g/dl in women and \< 13g/dl in men)
62402928|NCT06542393|EXPERIMENTAL|Randomized Anemia Group for PBM protocol (GPBM)|Patients \>18 years admitted to Hospital São Paulo for Coronary Artery Bypass Grafting (CABG) surgery who are hospitalized in the Cardiovascular Surgery department or another specialty unit and are anemic (Hb \< 12g/dl in women and \< 13g/dl in men)
62402929|NCT06542393|NO_INTERVENTION|Control Group (GC)|Patients \> 18 years admitted to Hospital SãoPaulo for Coronary Artery Bypass Grafting (CABG) surgery who arehospitalized in the Cardiovascular Surgery department or another specialty unit and do not have anemia (Hb \> 13g/dl in men and \> 12g/dl in women)
62402930|NCT05671822|EXPERIMENTAL|Arm 1A: SHR-A1811 and SHR-1701|
62013800|NCT02990663|ACTIVE_COMPARATOR|Morning BP Meds|Use of blood pressure lowering medication in the morning
62013801|NCT03246529|EXPERIMENTAL|BL-8040 1.25 mg/kg + G-CSF|Double-blind placebo-controlled setting designed to assess the safety, tolerability and efficacy of G-CSF + BL-8040 as compared to G-CSF + Placebo, for stem cell mobilization in MM.
62202448|NCT04016155|EXPERIMENTAL|Flash CGMS|
62202449|NCT01933243|EXPERIMENTAL|Fish oil|Fish oil for 12 weeks
62402931|NCT05671822|EXPERIMENTAL|Arm 1B: SHR-A1811 and capecitabine|
62402932|NCT05671822|EXPERIMENTAL|Arm 1C: SHR-A181,SHR-1701,and capecitabine|
62579373|NCT05832853|EXPERIMENTAL|Resistance training and endurance training|The trial was divided into three cycles, each lasting eight weeks. Participants performed a hybrid program of resistance training and endurance training of varying duration and intensity in each cycle. Each session lasted one hour, three times a week for 24 weeks.
62579374|NCT05876832|EXPERIMENTAL|XY0206|XY0206 will be administered orally once a day in continuous 28-day cycles.
62013802|NCT03246529|ACTIVE_COMPARATOR|Placebo + G-CSF|Double-blind placebo-controlled setting designed to assess the safety, tolerability and efficacy of G-CSF + BL-8040 as compared to G-CSF + Placebo, for stem cell mobilization in MM.
62202450|NCT01933243|PLACEBO_COMPARATOR|Placebo pill|Placebo pills for 12 weeks
62202451|NCT01827046|EXPERIMENTAL|MIS plus rt-PA management|Subjects randomized to the Minimally Invasive Surgery (MIS) plus rt-PA management arm will undergo minimally invasive surgery followed by up to 9 doses of 1.0 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
62202452|NCT01827046|NO_INTERVENTION|Medical management|Subjects randomized to medical management will receive the standard medical therapies for the treatment of intracerebral hemorrhage, which includes ICU care only and no planned surgical intervention.
62402933|NCT05671822|EXPERIMENTAL|Arm 1D: SHR-A1811,capecitabine,and oxaliplatin|
62402934|NCT05671822|EXPERIMENTAL|Arm 2A: SHR-A1811 and SHR-1701|
62785818|NCT01679873|EXPERIMENTAL|Funding sources|Assess one type of abstract in the randomized arm. Assess abstract reporting funding sources only.
62013803|NCT03760549||Extension of NasoVAX high dose|A serum sample will be collected from each eligible subject who received NasoVAX at the 1×10(11th) vp dose in Study ALT-103-201 for evaluation of influenza hemagglutination assay against influenza A/California/07/2009(H1N1), a strain homologous to the one used for NasoVAX (monovalent AdcoCA09.HA). Ad5 antibody neutralization assay may also be performed.
62202453|NCT03332043|EXPERIMENTAL|HIRREM|Subjects in the experimental arm will receive an in-office, open-label course of acoustic stimulation linked to brain activity (High-resolution, relational, resonance-based, electroencephalic mirroring, HIRREM).
62202454|NCT03332043|ACTIVE_COMPARATOR|Ambient Nature Sounds|Subjects in the active comparator arm will receive an in-office, open-label course of acoustic stimulation not linked to brain activity (ambient natures sounds).
62202455|NCT04640831|EXPERIMENTAL|GH001 dose A|
62202456|NCT04640831|EXPERIMENTAL|GH001 dose B|
62202457|NCT04640831|EXPERIMENTAL|GH001 dose C|
62402935|NCT05671822|EXPERIMENTAL|Arm 2B: SHR-A181,SHR-1701,and capecitabine|
62013804|NCT04008134|NO_INTERVENTION|Standard recommendation (ORS)|Participants received the standard recommendation on oral rehydration solution use
62013805|NCT04008134|EXPERIMENTAL|mHealth with no home visits|Participants received the health facility delivery of CHoBI7, plus bi-weekly mHealth (voice and text) reminders for 12 months
62013806|NCT04008134|EXPERIMENTAL|mHealth with home visits|Participants received the health facility delivery of CHoBI7, plus two home visits and bi-weekly mHealth (voice and text) reminders for 12 months
62013807|NCT05540886|NO_INTERVENTION|Control|Standard practices are expected at hospitals before the education intervention is deployed
62202458|NCT04640831|EXPERIMENTAL|GH001 dose D|
62013808|NCT05540886|EXPERIMENTAL|Intervention|"The main intervention - the training of trainers/champions (ToT) will be delivered to selected facility cleaning champions from three or four hospitals within a certain month. Four sets of ToT are expected to happen during the study period."
62013809|NCT02897843|SHAM_COMPARATOR|sham tDCS|Sham tDCS sessions will last 20 minutes, but a real stimulus of 2 milliamps (mA) will be applied only during the first minute
62013810|NCT02897843|EXPERIMENTAL|tDCS|20 minute tDCS sessions
62013811|NCT05313516|EXPERIMENTAL|OKKO Health app|Use of OKKO Health app for home monitoring.
62202459|NCT04640831|EXPERIMENTAL|GH001 Individualized Dosing|
62734807|NCT04852549|EXPERIMENTAL|Oculomotor exercise group|After the evaluation, the intervention group performed oculo-motor exercises for 4 weeks, 6 days a week, morning and evening, twice a day for 10 minutes, in addition to normal ball training. While doing the exercises, individuals were taught to focus on the purpose they held in their hands, move their head, and aim fast enough to see the image clearly. Two repetitions each week were added to the exercise numbers. Ten seconds rest between two sets and five seconds rest between movements.
62785819|NCT01679873|EXPERIMENTAL|Funding sources/Conflicts of Interests|Assess one type of abstract in the randomized arm. Assess abstract reporting funding sources and conflicts of interest
62013812|NCT02845271|EXPERIMENTAL|GZ389988|Single intraarticular injection of GZ389988 in the knee joint
62202460|NCT02474862|EXPERIMENTAL|Prenatal Walking Program|The Prenatal Walking Program (PWP) is a gentle walking intervention tailored for pregnant women. The PWP intervention consists of 3 components: 1) biweekly session with a study interventionist; 2) the use of activity monitors to increase motivation and self-monitoring; 3) incentives to promote intervention adherence.
62402936|NCT05671822|EXPERIMENTAL|Arm 2C: SHR-A1811,capecitabine,and oxaliplatin|
62402937|NCT02507609|ACTIVE_COMPARATOR|M group|moderate neuromuscular blockade group by intermittent injection of rocuronium bromide
62402938|NCT02507609|ACTIVE_COMPARATOR|D group|deep neuromuscular blockade group by continuous infusion of rocuronium bromide
62402939|NCT02547064|ACTIVE_COMPARATOR|90 degree|The ETT with the 90° angle stylet was bent at a point 8 cm from its distal end.
62402940|NCT02547064|EXPERIMENTAL|70 degree|The ETT was bent by 70° at a point 6 cm from its distal end and the proximal portion of the ETT was formed as the shape of the GL blade until the point of the handle.
62402941|NCT04064450||Heart Failure|Individuals with asymptomatic or symptomatic heart failure
62785820|NCT01590160|EXPERIMENTAL|Cisplatin/Pemetrexed|Cisplatin 75mg/m2, Day 1 every 21 days Pemetrexed 500mg/m2, Day 1 every 21 days
62785821|NCT01590160|EXPERIMENTAL|Carboplatin/Pemetrexed|Carboplatin AUC5, Day 1 every 21 days Pemetrexed 500mg/m2, Day 1 every 21 days
62785822|NCT00837993||Survival Analysis|Survival Analysis Based on Reclassification to a Two-tier Grading System: Review of Pathology Slides for Patients participating on Protocol COG 158.
62785823|NCT01047163||Statin|Men aged 65-75yr on Simvastatin therapy presenting with muscle soreness
62013813|NCT02845271|PLACEBO_COMPARATOR|Placebo|Single intraarticular injection of placebo for GZ389988 in the knee joint
62013814|NCT03323905|EXPERIMENTAL|MR Guided High Intensity Focused Ultrasound|
62013815|NCT05489094|ACTIVE_COMPARATOR|Intervention Group|First group will be given nutrition education and iron intake from growing up milk approximately 2 - 3 servings/day for four months intervention period
62202461|NCT02474862|ACTIVE_COMPARATOR|Postpartum Prep Program|In the Postpartum Prep Program control condition (PPP) participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn wellbeing.
62402942|NCT04064450||Population Controls|Individuals free of heart failure and echocardiographic cardiac dysfunction
62402943|NCT00937430|EXPERIMENTAL|Bowel preparation group|Patients randomized to this arm will perform a bowel preparation prior to their pelvic organ prolapse surgery.
62785824|NCT01047163||Control|Men, aged 65-75yr not on Statin therapy
62785825|NCT01760772|PLACEBO_COMPARATOR|Saline|0.9% saline
62785826|NCT01760772|EXPERIMENTAL|Exendin-9 (Ex-9)|Bolus of Ex-9 (7,500 pmol/kg) followed by a continuous infusion at 750 pmol/kg/min
62202462|NCT02306551||Psychotic Disorder|Biological and psycho-social risk and resilience factors
62579375|NCT05876832|ACTIVE_COMPARATOR|Salvage chemotherapy|Participants will receive salvage chemotherapy in 28-day cycles. Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) injection for 10 days. Participants on azacitidine will receive 75 mg/m\^2 daily by SC or IV injection for 7 days.Participants on fludarabine, cytarabine and granulocyte colony-stimulating factor (G-CSF) (FLAG) will receive 30 mg/m\^2 of fludarabine daily by IV for 5 days (day 2 to 6), 1\~2 g/m2 of cytarabine daily by IV for 5 days (day 2 to 6), and 300 μg/m\^2 of G-CSF daily by SC or IV for 5 days (days 1 to 5). After completion of chemotherapy, G-CSF will be administered continually until absolute neutrophil count(ANC)\>0.5 x 10\^9 / L. Participants on mitoxantrone, etoposide, cytarabine(MEC) will receive 8 mg/m\^2 of mitoxantrone daily by IV for 3 days (day 1 to 3), 100 mg/m2 of etoposide daily by IV for 7 days (day 1 to 7), and 100 mg/m\^2 of cytarabine daily by IV for 7 days (days 1 to 7)
62785827|NCT01760772|EXPERIMENTAL|GLP-1|GLP-1 infusion at 0.3 pmol/kg/min
62785828|NCT01839812|OTHER|cosyntropin stimulation test|All patients enrolled in the study are administered cosyntropin stimulation tests to assess their adrenal response.
62579376|NCT01328977|ACTIVE_COMPARATOR|emails, book|
62579377|NCT01328977|ACTIVE_COMPARATOR|didactic teaching from experts|
62785829|NCT04578184|OTHER|Epithelial thickness map evaluation in keratoconus patients|Patients included in the study will be measured with the corneal acquisition mode, also allowing for epithelium thickness data, on each device without pupil dilatation Each patient will be measured three times with both devices. The corneal epithelial thickness will be measured as the distance between the air-tear and the epithelium-Bowman interfaces.
62785830|NCT04578184|OTHER|Epithelial thickness map evaluation in healthy cornea patients|Patients included in the study will be measured with the corneal acquisition mode, also allowing for epithelium thickness data, on each device without pupil dilatation Each patient will be measured three times with both devices. The corneal epithelial thickness will be measured as the distance between the air-tear and the epithelium-Bowman interfaces.
62785831|NCT04922307|EXPERIMENTAL|Blood Sparing Protocol|The intervention group (120 patients) will undergo radical nephrectomy with blood-sparing techniques. Acute Normovolemic Hemodilution (ANH) collects patients own blood prior to the start of surgical procedure; Cell saver is the collection of blood lost during surgery with subsequent auto-transfusion of the patients own cells; Veno-venous bypass will be used for patients with anticipated large loss of blood during surgery (\>1L). The patients in the interventional group will be blinded to which blood sparing techniques utilized.
62785832|NCT04922307|ACTIVE_COMPARATOR|Standard Blood Replacement|The control group of one hundred and twenty (120) patients will undergo radical nephrectomy without blood sparing techniques (ie. Standard of care). Patients who need blood transfusion will receive cross-matched allogenic blood products.
62785833|NCT02908789|EXPERIMENTAL|Antimicrobial photodynamic therapy (aPDT)|1)Selective caries removal: caries dentin was partially removed with hand excavators (Fava, Pirituba, Brazil). 2)The laser technique: 0.01% methylene blue solution was applied, and a pre-irradiation period of 5 minutes was done with an Indium Gallium Aluminum Phosphorus diode laser (InGaAlP) with a wavelength of 660 nm (visible red), a spot area of 3mm2, and fixed output power of 100 mW (energy of 9 J with 90 seconds). 3) The restorative technique was done as described in comparator group.
62785834|NCT02908789|SHAM_COMPARATOR|Group without Antimicrobial photodynamic therapy (aPDT)|1) Selective caries removal 2) The restorative technique was done by etching with 37% CondacTM phosphoric acid conditioner (FGM) for 15 s in enamel and 7 s in dentin was performed followed by washing for 30 s until the conditioner was completely removed. The excess of dentin moisture was removed with sterile cotton balls, and the enamel was air-dried until it had an opaque appearance. Subsequently, two consecutive layers of Adper Single Bond 2TM (3M ESPE) were applied with a KG Brush (KG Sorensen) on the enamel and dentin for 15 s and subjected to light air blast to promote solvent evaporation. The adhesive was photoactivated for 10 s with a light-emitting diode (LED) unit (BioLuz Plus; BioArt) with an intensity of 460 mW/mm2. The cavity was restored with a Filtek Z250TM composite resin (3M Dental Products) according to the incremental technique. Each increment was photo-activated for 40 s.
62013816|NCT05489094|PLACEBO_COMPARATOR|Control Group|Second group will be given nutrition education only for four months intervention period
62785835|NCT03704909|ACTIVE_COMPARATOR|Group Adrenaline: Group A|All parturients received a prophylactic i.v bolus of Epinephrine 0.15µg/Kg at time of SA. In this group, rescue boluses of Epinephrine 0.15µg/Kg, will be given if maternal BP decreased more than 20% from the baseline value.
62785836|NCT03704909|ACTIVE_COMPARATOR|Group Ephedrine: Group E|All parturients received a prophylactic i.v bolus of Ephedrine 0.1mg/Kg at time of SA. In this group, rescue boluses of Ephedrine 0.1mg/Kg, will be given if maternal BP decreased more than 20% from the baseline value.E
62785837|NCT00626171|OTHER|1|Allergen challenge
62202463|NCT02306551||Bipolar Disorder|Biological and psycho-social risk and resilience factors
62202464|NCT02306551||Depressive Disorder|Biological and psycho-social risk and resilience factors
62202465|NCT02306551||Non-psychiatric Control|Biological and psycho-social risk and resilience factors
62202466|NCT00022581|EXPERIMENTAL|Treatment (thalidomide)|Patients receive oral thalidomide once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
62202467|NCT05504252|EXPERIMENTAL|Experimental Arm|"The study has a start-up single-arm design consisting of 2 cycles of the Nordic FLOX regimen followed by 2 cycles of nivolumab for a total of 4 individual cycles before radiologic response assessment and patient stratification to continued therapy or not.~Patients who present less than 10% target lesion reduction at the first radiologic response assessment will proceed to standard-of-care treatment at the Clinical Investigator's discretion.~Patients who present 10% or higher target lesion reduction at the first radiologic response assessment will continue with alternating 2 cycles of the Nordic FLOX regimen and 2 cycles of nivolumab in a go-and-stop schedule until progressive disease on ongoing therapy (defining PFS), intolerable toxicity, withdrawal of consent, or death, whichever occurs first."
62202468|NCT04211597|SHAM_COMPARATOR|Group 1: Control|Participants receive no scar prevention and treatment for Cesarean wounds.
62202469|NCT04211597|ACTIVE_COMPARATOR|Group 2: Silicone gel|Each participant in Group 2 brought home two tubes of silicone gel when they returned for their follow-up visits on day 14. They were instructed to start applying silicone gel evenly to the wound twice a day for two months.
62202470|NCT04211597|EXPERIMENTAL|Group 3: Silicone gel plus Me-EGF|"1. The day of Cesarean delivery was recorded as Day 0. For participants in Group 3, on day 0 prior to final dermal closure, 4ml of Me-EGF (containing 40mcg microencapsulated polysaccharide and rhEGF) was sprayed evenly along the incision site, subsequently covered with antibiotic ointment and sterile gauze. Another 0.5 ml (5 mcg of Me-EGF) was sprayed during dressing change on day 1 and day 5 respectively. At each dressing change, the sutured wound was cleaned by sterile normal saline, followed by Me-EGF sprays, and waited for two minutes to allow for absorption, then covered with dry sterile gauze.~2. Each participant in Group 3 brought home two tubes of silicone gel when they returned for their follow-up visits on day 14. They were instructed to start applying silicone gel evenly to the wound twice a day for two months."
62202471|NCT05834062|EXPERIMENTAL|Medication arm|"Individuals randomized to this group will be offered lifestyle-based weight gain prevention counseling. Participants will initiate treatment at 3.75 mg/23 mg orally once in the morning for 14 days, which will then be increased to 7.5 mg/46 mg orally once daily in the morning for the remainder of the trial. Participants who are unable to tolerate the dosing regimen will be maintained at the maximally tolerated dose. To further safeguard the risk/benefit balance we will utilize a down-titration protocol for participants who experience a reduction in BMI below a threshold of 20 kg/m2. In this case, participants will be reduced to the lowest-dose level (3.75 mg/23 mg) for 12 weeks. If the BMI remains below 20 kg/m2 at the lowest dose after 12 weeks, active treatment will be fully withdrawn.~Participants at the end of the study will be down-titrated gradually with instructions to take the medication every other day for 7 days before stopping treatment altogether."
62202472|NCT05834062|PLACEBO_COMPARATOR|Placebo arm|"Individuals randomized to this group will be offered lifestyle-based weight gain prevention counseling. Participants will initiate treatment with a placebo (to keep the blind) and be asked to up-titrate the placebo dose after the first 14 days and then maintain the placebo dose for the remainder of the study.~Individuals who are unable to tolerate the dosing regimen will have a down-titration protocol (to maintain the blind) as described in the medication arm. Likewise, we will employ a down-titration protocol for participants who experience a reduction in BMI below a threshold of 20 kg/m2. In this case, participants would be reduced to the lowest dose level of placebo for 12 weeks. If the BMI remains below 20 kg/m2 after 12 weeks, placebo treatment will be fully withdrawn.~Individuals in the placebo arm will also have a placebo-based down-titration with instructions to take the placebo every other day for 7 days before stopping treatment altogether, to maintain the blind."
62202473|NCT04413305|EXPERIMENTAL|WGS-based screen and control group|For intervention group, we screen admitted patients for carbapenem-resistant Klebsiella pneumoniae and carry out 'Bundle' infection and control measures. When outbreak or tranmission of CRKP was observed, we take whole-genome sequencing to track origin and transmission route to decease CRKP rate.
62202474|NCT04413305|NO_INTERVENTION|Non-intervention|Non-intervention
62202475|NCT01167491|OTHER|Disease group|Physiopathology
62402944|NCT00937430|NO_INTERVENTION|No Bowel preparation group|Patients randomized to this group will not be performing a bowel preparation prior to their pelvic organ prolapse surgery.
62402945|NCT00744029|ACTIVE_COMPARATOR|Intervention group|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
62402946|NCT00744029|NO_INTERVENTION|Control group|No intervention was performed
62402947|NCT06650423||Aromatase inhibitor + abemaciclib|Adult women with early HR+ HER2- breast cancer, eligible for treatment with aromatase inhibitor + abemaciclib, both prescribed prior inclusion into study, irrespective of protocol, as per regular clinical practice
62579378|NCT01328977|EXPERIMENTAL|personal coaching by development profs|
62202476|NCT03026075|EXPERIMENTAL|Colonoscopy with MCS|Standard colonoscopy procedure with Motus Cleansing System
62202477|NCT05249647|EXPERIMENTAL|Instrument based fascial abrasion technique|IASTM using tools over Myofascial trigger points of the length of targeted muscles (SCM, descending fiber of trapezius, suboccipitalis muscles) in a multidirectional stroking fashion applied to the skin at 30°- 60° for 5 minutes. Participants were in a comfortable position during treatment. Emollient (anti-allergic) was applied to prevent skin irritation prior to Fascial Abrasion application. Each session included 1 minute of sweeping (longitudinal strokes performed parallel to the muscle fibers similar to compression with oscillations) directly over the Myofascial trigger points, 2 minutes of fanning (one end of the instrument was held in place \& the other end moved through a semicircular pattern similar to petrissage) and concluded with 1 min of sweeping.
62202478|NCT05249647|ACTIVE_COMPARATOR|Myofascial release technique|All participants will get Conventional therapy i.e heating pad for 10 minutes. For the application of technique, the patient position will be supine lying with head fully supported on therapist hands and therapist places 3 middle fingers just inferior to the nucle line, lifts the finger tips towards the ceiling while resting the head on the table and then therapist applied a gentle upward pull. This procedure done for 2-3 minutes, 5-7 repetitions, 3 sessions per week on alternate days given for 6 weeks.
62202479|NCT04557553|EXPERIMENTAL|Lagenbone|Lagenbone 500mg capsules, 8 capsules by mouth every day for 12 months.
62202480|NCT04677218|NO_INTERVENTION|First Group|First group of fixation will be standar procedure ( without knotted and retensioned the hamstring autograft after tibial fixation)
62202481|NCT04677218|EXPERIMENTAL|Second Group|In the second group, the hamstring autograft will be retensioned after tibial fixation.
62202482|NCT04677218|ACTIVE_COMPARATOR|Third Group|In the third group, the hamstring autograft will be knotted and retensioned after tibial fixation.
62202483|NCT03270410||Neonates|Babies born in Rennes University Hospital
62202484|NCT04020315|EXPERIMENTAL|Generalized aggressive periodontitis|Non-surgically performed scaling and root planing.
62202485|NCT04606901|ACTIVE_COMPARATOR|Sugammadex|Patients in this arm of the study will receive Sugammadex as the drug used to reverse neuromuscular blockade.
62202486|NCT04606901|ACTIVE_COMPARATOR|Neostigmine/Glycopyrrolate|Patients in this arm of the study will receive Neostigmine/Glycopyrrolate as the drugs used to reverse neuromuscular blockade
62202487|NCT01621776|ACTIVE_COMPARATOR|Humalog|Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
62202488|NCT01621776|ACTIVE_COMPARATOR|Apidra|Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
62202489|NCT01621776|ACTIVE_COMPARATOR|Novolog|Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
62202490|NCT03287895|EXPERIMENTAL|Intervention - Decision Support|In addition to the regular conversation about CPR that a patient's physician may have with them, participants will be given a two-part intervention. First, the participant will receive a values clarification tool which helps them rate and understand which relevant values are most important to them. There are two forms of this tool, a full and simplified version. All participants in this arm will receive both, in randomized order. The second aspect of the intervention is an educational video about the potential risks and benefits of CPR, which all participants in this arm will receive.
62202491|NCT03287895|NO_INTERVENTION|Control|Participants in this arm will receive usual care, the regular conversation about CPR that their physician may have with them.
62202492|NCT05891808||Healthy Controls|Healthy subjects without present or past history of headache according to ICHD-III criteria.
62202493|NCT05891808||Episodic Migraine|Patients with a diagnosis of migraine without or with aura, with episodic pattern, according to ICHD-III criteria.
62202494|NCT05891808||Chronic Migraine|Patients with a diagnosis of chronic migraine with or without medication overuse headache according to ICHD-III criteria.
62215125|NCT01733537|EXPERIMENTAL|Vest and Education|Motorcycle Taxi Drivers provided with a reflective, fluorescent vest and basic education about recommended measures to increase their visibility
62215126|NCT01733537|OTHER|Education Alone|Motorcycle Taxi Drivers provided with basic education about recommended measures to increase their visibility
62785838|NCT04569981|ACTIVE_COMPARATOR|Climbing Group (CG)|The patients in the Climbing Group (CG) followed a 12-weeks long climbing trainings course in small groups of 3-4 participants with a certified climbing instructor.
62215127|NCT01825733|EXPERIMENTAL|ramosetron|
62215128|NCT01825733|ACTIVE_COMPARATOR|palonosetron|
62402948|NCT06650423||Aromatase inhibitor|Adult women with early HR+ HER2- breast cancer, eligible for treatment with aromatase inhibitor, prescribed prior inclusion into study, irrespective of protocol, as per regular clinical practice
62013817|NCT00375193|EXPERIMENTAL|1|Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until cycle 6 or no longer beneficial.
62013818|NCT04638205||Suicide attempt cases|Adolescents and young adults who attempted suicide between 7 and 30 days prior the inclusion
62013819|NCT04638205||Non-suicidal controls|Adolescents and young adults without history of suicide attempt or ideation
62013820|NCT02091518|EXPERIMENTAL|MRI|"Add-On Research Patients will include patients who are scheduled for a routine clinical MRI who meet the eligibility requirements for this protocol. Protocol participation will consist of an add-on research. MRI scan, which will be performed any point during of the routine clinical MRI scan.~Volunteers will be subjects expressing interest in participation and who meet the eligibility requirements for this protocol. No contrast enhanced research MRIs including gadolinium-based or other contrast agents will be performed in volunteers."
62013821|NCT05787522||Independent manual contouring|Manual contouring refers to physicians using the brush tool on the contouring platform to segment thoracic organs at risk manually, without the use of auto-segmentation tools.
62013822|NCT05787522||AI contouring|AI contouring refers to the auto-segmentation results generated by the Res-SE Net model, with the model integrated into the auto-segmentation software.
62013823|NCT05787522||AI-assisted contouring|After generating the AI contouring results, investigators will import them into the contouring platform and perform manual modifications, producing the AI-assisted contouring.
62013824|NCT02205619|EXPERIMENTAL|Ultrasonic instrumentation|Prior to extraction, the teeth (N = 12) were randomly included into ultrasonic instrumentation (Air Flow Master Piezon®, EMS SA, Nyon - Swiss) treatment group
62013825|NCT02205619|EXPERIMENTAL|Hand instrumentation|Prior to extraction, the teeth (N = 12) were randomly included into hand curette (Gracey curettes, American Eagle, Missoula, MT, USA) treatment group hand instrumentation (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA)
62785839|NCT04569981|ACTIVE_COMPARATOR|Unsupervised active group (UAG)|The patients in the unsupervised activity group (UAG) received education European physiotherapy guidelines for physical activity recommended by the WHO of recommended activity and followed their self-selected activities over 12 weeks.
62013826|NCT02205619|EXPERIMENTAL|subgingival airpolishing with glycine|"Prior to extraction, the teeth (N = 12) were randomly included into air-polishing (Air Flow Master Piezon®, EMS SA, Nyon - Swiss) with the glycine powder (Air-flow® Powder Perio, EMS) treatment group.~subgingival airpolishing with glycine(Air-flow® Powder Perio, EMS SA, Nyon, Swiss)"
62202495|NCT02919215|EXPERIMENTAL|Teacher Help Intervention|The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as the online support for teachers. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
62202496|NCT02919215|NO_INTERVENTION|Wait-list Control|These participants will not receive access to the Teacher Help intervention until September of the following academic year. Teachers, students, guardians, and collaborating psychologists are free to access and/or provide usual services. The psychologists will provide Teacher Help access codes to the Wait-list group in September of the following academic year:
62202497|NCT02635893|ACTIVE_COMPARATOR|D-Cycloserine/Placebo + Stimulation|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation.
62202498|NCT02635893|ACTIVE_COMPARATOR|Training+Med/Placebo+Stimulation|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation followed by training.
62202499|NCT02635893|ACTIVE_COMPARATOR|Training+Med+Stimulation/Placebo Stim|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation or placebo stimulation followed by training.
62202500|NCT02946853|ACTIVE_COMPARATOR|CRT-D|Patients will be randomized at enrollment. Patients in this arm of the study will receive cardiac resynchronization therapy with defibrillator (CRT-D).
62202501|NCT02946853|EXPERIMENTAL|CRT-D and AVJ Ablation|Patients in this arm of the study will receive CRT-D and undergo atrioventricular junctional (AVJ) ablation.
62013827|NCT02205619|EXPERIMENTAL|ultrasonic following airpolishing|Prior to extraction, the teeth (N = 12) were randomly included into ultrasonic following airpolishing ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) with the glycine powder treatment group
62013828|NCT03058406||Eribulin mesylate|
62202502|NCT03149549|EXPERIMENTAL|CX-2009 Monotherapy: 21-Day Dosing Regimen-Escalation|Dose escalation and determination
62202503|NCT03149549|EXPERIMENTAL|CX-2009 Monotherapy: 21-Day Dosing Regimen-Determination|Additional enrollment into previously cleared monotherapy dose levels
62202504|NCT03149549|EXPERIMENTAL|CX-2009 Monotherapy: 21-Day Dosing Regimen-Expansion|Dose expansion
62202505|NCT03149549|EXPERIMENTAL|CX-2009 Monotherapy: 14-Day Dosing Regimen-Expansion|Dose escalation and determination in selected tumor types
62202506|NCT05616676|EXPERIMENTAL|Brief digital imagery-competing task|Access to a brief digital imagery-competing task for 24 weeks (first 4 weeks with optional researcher support).
62785840|NCT00959205|ACTIVE_COMPARATOR|Angiography|Conventional fluoroscopically guided activation mapping
62785841|NCT00959205|EXPERIMENTAL|CARTO 3D|CARTO (3D Electroanatomic imaging)
62579379|NCT03284814|ACTIVE_COMPARATOR|Standard product group|This group will be included in a single dose cross over study, and in multiple dose study with standard product (SP: CoQ10 hard capsules; 100 mg)
62579380|NCT03284814|ACTIVE_COMPARATOR|Comparative product group|This group will be included in a single dose cross over study, and in multiple dose study with comparative product (CP: CoQ10 soft-gel capsules; 100 mg)
62579381|NCT03284814|EXPERIMENTAL|Investigational product group|This group will be included in a single dose cross over study, and in multiple dose study with investigational product (IP: CoQ10 syrup; 100 mg)
62579382|NCT04080388|ACTIVE_COMPARATOR|Control Group|Patients prior to discharge for acute heart failure admission will be examined with a lung impedance device for their suitability for discharge according to their level of pulmonary congestion. Only patients who are unsuitable for discharge according to the lung impedance assessment will be enrolled in the study. The control group (half of the patients) will be discharged without additional intervention.
62579383|NCT04080388|ACTIVE_COMPARATOR|Interventional Group|Patients prior to discharge for acute heart failure admission will be examined with a lung impedance device for their suitability for discharge according to their level of pulmonary congestion. Only patients who are unsuitable for discharge according to the lung impedance assessment will be enrolled in the study. The interventional group (half of the patients) will continue anti-congestive treatment while hospitalized until achieving a suitable level of decongestion.
62579384|NCT02271152|EXPERIMENTAL|FAST ablation + PVI|FAST mapping and ablation will be performed in addition to PVI
62579385|NCT02271152|ACTIVE_COMPARATOR|PVI|Pulnonary vein isolation will be performed
62579386|NCT01959464|EXPERIMENTAL|Crinone vaginal progesterone gel|"Crinone is a bioadhesive vaginal gel containing micronized progesterone in an emulsion system containing a water swellable but insoluble polymer, polycarbophil. Crinone 8% is formulated to provide a long-acting vaginal retention, and is prescribed daily. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg of progesterone. The reported time to maximum progesterone concentration is 6.8 +/- 3.3 hours with use of a single dose of Crinone 8%. Absorption half-life is approximately 25-50 hours and an elimination half-life of 5-20 minutes.~On the evening of day 3, the female will insert the applicator into the vagina, administer the gel, and have intercourse within 1 hour of insertion of the cream."
62579387|NCT01959464|PLACEBO_COMPARATOR|Placebo vaginal gel|The couple will be given a prefilled applicator containing either Crinone gel (progesterone) or placebo vaginal gel, data collection sheets and laboratory requisitions. On the evening of day 3, the female will insert the applicator into the vagina, administer the gel, and have intercourse within 1 hour of insertion of the cream.
62579388|NCT03447561|EXPERIMENTAL|Anticipatory + consummatory food reward|PET-MR scan session with a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake). This scan session will consist of four blocks with a duration of 45 minutes each and 15 minute breaks in between. The first three blocks represent the 'control condition' (viewing neutral images and drinking sips of water) and the fourth block the 'food reward condition' (viewing high-calorie food images and drinking sips of chocolate milkshake).
62734808|NCT04959227||whirling dervish group|Beck Anxiety Inventory (min 0- max 63, As the score increases, the level of anxiety also increases.) Beck Depression Inventory (min 0- max 63, As the score increases, the level of depression also increases.) International Physical Activity Questionnaire
62785842|NCT06359080|EXPERIMENTAL|CognilumTM|During the study participants will be wearing the photobiomodulation device Cognilum. The device will administer the stimulation of near infrared light (830nm) to specific areas of the child's brain.
62202507|NCT05616676|EXPERIMENTAL|Brief digital music-listening task|Access to a brief digital music-listening task for 24 weeks (first 4 weeks with optional researcher support).
62202508|NCT05616676|EXPERIMENTAL|Treatment As Usual|Access to routine care that participants would otherwise receive if having intrusive memories of traumatic events for 24 weeks.
62785843|NCT04681963||Suspected pneumonia diagnosis|Acutely admitted patients suspected having pneumonia.
62202509|NCT03820297|OTHER|Anti-Stigma Group|Complete a 10 weekly anti-stigma group intervention (ASGI) in addition to several self-report internalized stigma and psychiatric measures.
62785844|NCT03577678|EXPERIMENTAL|observational|orthopaedic Surgery to fix lateral half prosthesis for clavicle
62202510|NCT00873028|EXPERIMENTAL|1|
62202511|NCT00873028|NO_INTERVENTION|2|Those patients assigned to Control were followed by their own physicians, received routine nursing assistance, were visited daily by the one of the investigators (CPM), but were not exposed to any specific respiratory or motor physical intervention.
62202512|NCT06609655||adults|Adults 18 years old and more, male and female, having participated in one research project and agreeing that data are integrated in the databank
62785845|NCT05099835|ACTIVE_COMPARATOR|Botulinum Toxin|injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)
62202513|NCT05140226|EXPERIMENTAL|Physical Training (PT)|Participants in the PT group will perform eight weeks of home-based physical exercise training.
62202514|NCT05140226|EXPERIMENTAL|Cognitive-Physical Training (C-PT)|Participants in the C-PT will perform eight weeks of home-based cognitive and physical training.
62202515|NCT01006252|EXPERIMENTAL|Tasisulam-sodium|Individualized tasisulam-sodium dose was dependent on participant's height, weight, and gender. Dose was adjusted based on laboratory parameters. Treatment was administered intravenously on Day 1 of a 28-day cycle, until disease progression.
62785846|NCT05099835|ACTIVE_COMPARATOR|steroid|injected 10 mL of 0.25% bupivacaine with triamcinolonacetonide 4 mg/ml
62202516|NCT01006252|ACTIVE_COMPARATOR|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m\^2) administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
62785847|NCT06348667|EXPERIMENTAL|Experimental|"16 subjects who will perform BB exercises twice a week for 5 weeks under the supervision of a physiotherapist.~Each session (50') will include a warm-up of 10' of slow walking, joint mobility, and stretching. Then, BB exercises will be performed, followed by 10' of relaxation and stretching to cool down.~BB exercises:~* Ankle mobility: single-leg ankle dorsiflexion movements in a standing position on the BB with slight assistance from the parallel bars to perform the movement correctly. The BB will be set with the forefoot fixed and the rearfoot with medial drop, to facilitate dorsiflexion by combining dorsal flexion and pronation. 3 sets of 15 repetitions, with a 1' rest between sets.~* Balance: BB will be set with instability in the forefoot and fixed rearfoot, to produce mediolateral instability of the CoP. The exercise will be maintaining balance on the BB while attempting to keep the lateral edges of the board from touching the ground. Five rounds of 40 work and 1' rest."
62402949|NCT04044404||A on C group|Acute on Chronic Kidney Disease patients
62202517|NCT02294903|EXPERIMENTAL|ProRAFT|Procedure/Surgery: Coiled Bipolar Radiofrequency Ablation
62202518|NCT02527824|EXPERIMENTAL|Oxaliplatin, Irinotecan, S-1(OIS)|"intervention with triple combination chemotherapy with oxaliplatin, irinotecan, and S-1 Treatment will be delivered as a 2-week cycle.~1. Oxaliplatin 65 mg/m2 iv on day 1~2. Irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day on day 1-7"
62202519|NCT05994131|EXPERIMENTAL|Experimental Group in cohort 1, cohort 2, and cohort 3|IN10018+Furmonertinib
62202520|NCT05994131|ACTIVE_COMPARATOR|Control Group in cohort 3|Furmonertinib
62402950|NCT04044404||functional delayed graft function group|patients with functional delayed graft function(fDGF) after kidney transplantation
62402951|NCT04044404||Normal|without functional kidney injury
62202521|NCT04822779|ACTIVE_COMPARATOR|Active Group|"This group will receive ultrasound therapy.~Respondents will conduct individual medical-gymnastics: unloading pendular exercises if strength exercises cannot be started immediately, shoulder range exercises, and rotator cuff and scapula stabilizer exercises for 30 minutes per treatment."
62202522|NCT04822779|SHAM_COMPARATOR|Control Group|"This group will receive sham ultrasound therapy.~Respondents will conduct the same individual medical-gymnastics, as in the active group: unloading pendular exercises if strength exercises cannot be started immediately, shoulder range exercises, and rotator cuff and scapula stabilizer exercises for 30 minutes per treatment."
62202523|NCT01539369|EXPERIMENTAL|High fibre diet|
62202524|NCT01539369|ACTIVE_COMPARATOR|Healthy eating diet|
62202525|NCT00722280|EXPERIMENTAL|Hand Transplantation|Described above
62202526|NCT05662189|OTHER|long standing type 1 diabetes (> 20 yrs)|68Ga-exendin4 PET-CT scan +mixed meal test
62202527|NCT05662189|OTHER|newly diagnosed type 1 diabetes (< 5yrs)|68Ga-exendin4 PET-CT scan +mixed meal test
62402952|NCT05033691|EXPERIMENTAL|Early SRS treatment with SoC|Stereotactic surgery (SRS) to the brain metastases and continuation of Osimertinib, at 2 month (8 weeks) post Osimertinib start
62402953|NCT05033691|ACTIVE_COMPARATOR|SoC Tagrisso treatment only|continuation of osimertinib alone
62579389|NCT03447561|EXPERIMENTAL|Consummatory food reward|PET-MR scan session with purely consummatory food reward (drinking sips of chocolate milkshake). This scan session will consist of four blocks with a duration of 45 minutes each and 15 minute breaks in between. The first three blocks represent the 'control condition' (drinking sips of water) and the fourth block the 'food reward condition' (drinking sips of chocolate milkshake).
62579390|NCT04424420|EXPERIMENTAL|Paracetamol|Study phase 1 (single dosing): 1000 mg once. Study phase 2 (multiple dosing): 1000 mg twice daily for a minimum of 12 and a maximum of 14 days.
62579391|NCT04424420|ACTIVE_COMPARATOR|Ibuprofen|Study phase 1 (single dosing): 800 mg once.
62402954|NCT04227730||group A|group A (+ve GBS) 300 pregnant of gestational age 35-37 weeks were screened by a group B streptococcal (GBS) conventional PCR assay. Patients who were followed till delivery without prolonged rupture of membrane were eligible to enter the study and details with regard to labor and delivery were recorded. Infant data were also recorded.
62579392|NCT04424420|PLACEBO_COMPARATOR|Placebo|Study phase 1 (single dosing): Once. Study phase 2 (multiple dosing): Twice daily for a minimum of 12 and a maximum of 14 days.
62579393|NCT02846155|PLACEBO_COMPARATOR|clear water group|the patients only drink 1000ml clear water before checking
62579394|NCT02846155|EXPERIMENTAL|simethicone group|the patients drink 950ml clear water and 15ml simethicone before checking
62579395|NCT02846155|EXPERIMENTAL|simethicone combined with pronase group|the patients drink 900ml clear water and 15ml simethicone and 20，000iu pronase before checking
62579396|NCT04357067|EXPERIMENTAL|Lingual brackets|Patients with moderate crowding without extraction treated with Incognito lingual bracket (3M Unitek, Bad Essen, Germany)
62579397|NCT04357067|EXPERIMENTAL|Labial brackets|Patients with moderate crowding without extraction treated with labial bracket (3M Unitek, Ca, USA
62202528|NCT05662189|OTHER|long standing type 2 diabetes (> 20 yrs)|68Ga-exendin4 PET-CT scan +mixed meal test
62202529|NCT05662189|OTHER|newly diagnosed type 2 diabetes (<6 months)|68Ga-exendin4 PET-CT scan +mixed meal test
62202530|NCT05662189|OTHER|pre-diabetes|68Ga-exendin4 PET-CT scan +mixed meal test
62202531|NCT05662189|OTHER|hyperinsulinemic|68Ga-exendin4 PET-CT scan +mixed meal test
62202532|NCT05662189|OTHER|control|68Ga-exendin4 PET-CT scan +mixed meal test
62202533|NCT02468362|ACTIVE_COMPARATOR|Laparoscopic group|
62202534|NCT02468362|ACTIVE_COMPARATOR|Open group|
62202535|NCT00211068||Epoetin alfa|Four control patients will be matched to each index patients enrolled in protocol EPO-IMU-301 identified as having chronic kidney disease and an immune-mediated cause of pure red cell aplasia (PRCA) indicated by the presence of anti-erythropoietin (EPO) antibodies in their serum at the time of loss of efficacy.
62202536|NCT02710227||liver cirrhosis|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
62202537|NCT02710227||control|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
62579398|NCT00280397|EXPERIMENTAL|1|
62202538|NCT03433677|EXPERIMENTAL|LY900014|100 units per milliliter (U/mL) LY900014 administered by individualized, continuous, subcutaneous insulin infusion (CSII)
62202539|NCT03433677|EXPERIMENTAL|Insulin Lispro|100 U/mL insulin lispro (Humalog®) administered by individualized CSII
62579399|NCT04404517|ACTIVE_COMPARATOR|40mg1w|Adalimumab at an administration of 40 mg weekly for 6 weeks, followed by Adalimumab at an administration of 80 mg every two weeks
62579400|NCT04404517|ACTIVE_COMPARATOR|80mg2w|Adalimumab at an administration of 80 mg every two weeks
62202540|NCT03245047|EXPERIMENTAL|Intervention group|Dietary Supplement: Oral Nutritional Supplement with AN777 Participants in the intervention group will be asked to consume two servings of oral nutritional supplement per day for 180 days. (Oral Consumption)
62202541|NCT03245047|PLACEBO_COMPARATOR|Control group|Participants in the control group will be asked to consume two servings of Oral nutritional supplement per day for 180 days.(Oral Consumption)
62202542|NCT00666900|EXPERIMENTAL|1|
62202543|NCT00666900|EXPERIMENTAL|2|
62202544|NCT00666900|PLACEBO_COMPARATOR|3|
62202545|NCT03750786|EXPERIMENTAL|Group A|ARFOX (Arfolitixorin and 5-FU and Oxaliplatin) and Bevacizumab
62202546|NCT03750786|ACTIVE_COMPARATOR|Group B|mFOLFOX-6 (Leucovorin and 5-FU and Oxaliplatin) and Bevacizumab
62202547|NCT02631577|EXPERIMENTAL|Atezolizumab-G-lena 15mg|Participants were administered obinutuzumab, Atezolizumab, and 15 mg of Lenalidomide.
62202548|NCT02631577|EXPERIMENTAL|Atezolizumab-G-lena 20mg|Participants were administered obinutuzumab, Atezolizumab, and 20 mg of Lenalidomide.
62202549|NCT01739439|EXPERIMENTAL|Treatment (chemoradiation and radiosurgery)|Patients receive gemcitabine hydrochloride IV over 30 minutes once weekly and undergo hyperfractionated IMRT 5 days a week in weeks 1-3. Patients then undergo a single fraction of radiosurgery boost in week 5 and then receive gemcitabine hydrochloride IV over 30 minutes once weekly in weeks 6-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
62402955|NCT04227730||group B|group B (-ve GBS) 300 pregnant of gestational age 35-37 weeks were screened by a group B streptococcal (GBS) conventional PCR assay. Patients who were followed till delivery without prolonged rupture of membrane were eligible to enter the study and details with regard to labor and delivery were recorded. Infant data were also recorded.
62402956|NCT06429813|EXPERIMENTAL|Arm A|HIIT Cycling Intervention
62402957|NCT06429813|EXPERIMENTAL|Arm B|Walking Intervention
62202550|NCT02700542|ACTIVE_COMPARATOR|Intervention|"Participants randomly assigned to the intervention group will receive the Integrated Pest Management (IPM) treatment 2-4 weeks of completion of the baseline assessment.The IPM protocol for this research will focus on pest control in the bathrooms and kitchen and will include an assessment of the pest problem, thorough cleaning, patching of small holes, identification and referral of any necessary large repairs, and targeted application of safe pesticides as needed. In cases of severe infestation, a second treatment visit might be required in the home.~In addition to the intervention, the family will be provided with basic information about good pest-control practices, such as appropriate food storage, and be given a set of food storage containers."
62402958|NCT00204542|ACTIVE_COMPARATOR|A|Solaraze(R) 2x/day for 3 months
62402959|NCT00204542|ACTIVE_COMPARATOR|B|Solaraze(R) 2x/day for 6 months
62402960|NCT04746001||Infection|
62202551|NCT02700542|PLACEBO_COMPARATOR|Control|Participants randomly assigned to the control group will be offered the equivalent intervention, information, and food storage containers after completion of their 12-month assessment.
62202552|NCT03327272|ACTIVE_COMPARATOR|Local injection of methylprednisolone|Drug: methylprednisolone Injection of 80mg methylprednisolone injectable suspension at surgical site prior to incision closure
62202553|NCT03327272|PLACEBO_COMPARATOR|Local injection of saline|Administration of saline at surgical site prior to incision closure.
62202554|NCT00002622|ACTIVE_COMPARATOR|Talc slurry via chest tube|talc slurry via chest tube
62202555|NCT00002622|ACTIVE_COMPARATOR|Talc via insufflation|4 to 5 grams talc via insufflation through direct or videoscopic thoracoscopy, one time
62202556|NCT00852176||On-label treatment|"Patients treated in routine clinical practice following FDA Pre-Market Approval of the Beta-Cath(TM) 3.5F System within the parameters of the approved indications for use for the System (on-label)."
62202557|NCT00422812|PLACEBO_COMPARATOR|Inhaled Placebo|Inhaled Staccato Placebo
62402961|NCT04746001||Tumours|
62402962|NCT01952873|ACTIVE_COMPARATOR|Rapid|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but \<30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
62402963|NCT01952873|EXPERIMENTAL|Prolonged|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with \<0.3 atm drop during that period.
62402964|NCT04503109|OTHER|Nalu SCS System|All eligible subjects will receive the Nalu Neurostimulation System
62402965|NCT04037826|EXPERIMENTAL|L. reuteri Gastrus|L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475)
62402966|NCT04037826|PLACEBO_COMPARATOR|Placebo|Placebo chewable tablets
62402967|NCT01716546|EXPERIMENTAL|1|Panitumumab plus DCF
62202558|NCT00422812|EXPERIMENTAL|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
62202559|NCT00422812|EXPERIMENTAL|Inhaled PCZ 7.5 mg|Inhaled Staccato Prochlorperazine 7.5 mg
62202560|NCT00422812|EXPERIMENTAL|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
62402968|NCT02623569|EXPERIMENTAL|Ivabradine|Ivabradine 5 mg twice a day for first 4 weeks and 7.5mg twice a day when positive ETT and HR（heard rate）\>60times/min or negative ETT and HR（heard rate）\>80times/min of subjects.
62402969|NCT02623569|ACTIVE_COMPARATOR|Atenolol|Atenolol 12.5 mg twice a day for first 4 weeks and 25mg twice a day when positive ETT and HR（heard rate）\>60times/min or negative ETT and HR （heard rate）\>80times/min of subjects.
62402970|NCT02307175||Cyclotec|The first 10 consecutively enrolled patients will have thyroid and whole body scan with CycloTec
62013829|NCT03548610|EXPERIMENTAL|Nanofat-seeded biological scaffold on surgical defect|Nanofat is obtained via lipoaspiration of 10cc of fat from abdomen under moderate local tumescent anesthesia w/ saline. Cannula access point is anesthetized by local lidocaine infiltration. Lipoaspirate is processed into nanofat using the Tonnard method, after 3-minute decantation. Aspiration is performed using a multihole 3mm cannula. Wound margin + bed is treated w/ topical \& local injections of nanofat, then covered w/ a biological scaffold, the inferior surface of which is soaked in nanofat; scaffold is fixed w/ external dressings or resorbable sutures; external covering includes polyurethane film \& 3 layers of dressings. Topical application creates a fine \<1mm nanofat layer. Scaffold (Puracol Plus) is left in place to integrate w/ surrounding skin, while external dressings changed at 7 \& 15 days. Lipoaspirate donor site needs mild to moderate compression for 24 hours \& suture removal (if not absorbed) at 7 days.
62013830|NCT03548610|NO_INTERVENTION|Standard of Care dressings|Immediately after surgical resection, each patient will be treated following the SOC, therefore with a local skin flap, rather than with a skin graft, based on surgeon assessment. Sutures, and moulage, if present, will be removed at 7 days and patient instructed to apply a daily silicone cream and sunscreen for 2 months.
62013831|NCT03050086|EXPERIMENTAL|BPX-04 1% Minocycline Topical Gel|once daily topical administration of 1% minocycline gel to the face
62013832|NCT03050086|EXPERIMENTAL|BPX-04 2% Minocycline Topical Gel|once daily topical administration of 2% minocycline gel to the face
62202561|NCT02650713|EXPERIMENTAL|Dose-Escalation (Part IA): RO6958688 + Atezolizumab|Participants will receive RO6958688 weekly (QW) at escalating doses starting at 5 mg, in combination with a fixed dose (1200 mg) of atezolizumab every 3 weeks (Q3W). RO6958688 dosage will not exceed the MTD if defined in the BP29541 study.
62202562|NCT02650713|EXPERIMENTAL|Dose/Schedule Finding (Part IB): RO6958688 + Atezolizumab|"Part IB will explore different RO6958688 administration schedules in combination with atezolizumab, consisting of:~Cohort A: will compare the QW vs Q3W dosing schedules at a flat dose of RO6958688.~Step Up dosing schedules: RO6958688 dose will start at 40 mg and increase with each administration up to the MTD or 1200 mg, whichever occurs first."
62202563|NCT00552929|EXPERIMENTAL|Sugammadex 0.5 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the second twitch (T2) response to Train-of-four (TOF) stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
62202564|NCT00552929|EXPERIMENTAL|Sugammadex 1.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
62202565|NCT00552929|EXPERIMENTAL|Sugammadex 2.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
62202566|NCT00552929|EXPERIMENTAL|Sugammadex 4.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
62202567|NCT00552929|EXPERIMENTAL|Sugammadex 8.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
62202568|NCT00552929|EXPERIMENTAL|Sugammadex 0.5 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
62202569|NCT00552929|EXPERIMENTAL|Sugammadex 1.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
62402971|NCT02307175||generator produced Tc99m-pertechnetate|20 subsequent case-matched controls will have thyroid and whole body scan with conventional Tc99m-pertechnetate
62402972|NCT04177901|ACTIVE_COMPARATOR|Brachial plexus blockage group|
62402973|NCT04177901|ACTIVE_COMPARATOR|local anesthesia group|
62402974|NCT03605277|EXPERIMENTAL|Normal renal function|healthy volunteers with normal renal function
62402975|NCT03605277|EXPERIMENTAL|Severe renal impairment|subjects with severe renal impairment
62402976|NCT03605277|EXPERIMENTAL|Moderate renal impairment|subject with moderate renal impairment
62402977|NCT03605277|EXPERIMENTAL|Mild renal impairment|subjects with mild renal impairment
62402978|NCT05056311|EXPERIMENTAL|Parent Utilization of Decision Aid Website|All enrolled parents will view the decision aid website for as long and as frequently as they wish before the initial visit to the urologist.
62402979|NCT03156426||Study population|Adults with a histological, clinical or radiological diagnosis of cirrhosis who are admitted to RIE over a 4-month period will be approached by a member of their clinical care team for potential participation. Eligible patients may be recruited from accident and emergency, the acute medical unit, hepatology ward, high dependency or intensive care units. Recurrent admissions are common, so only the first admission for each recruited patient will be included. Patients will be monitored to identify acute kidney injury (AKI) during admission.
62402980|NCT01914107|EXPERIMENTAL|standard cancer pain care|the standard cancer pain care group: 1.will be follow-up by the cancer nurse once a week to acknowledge the cancer pain intensity, the current analgesic medication, and the side effects. and also give recommendations. 2.filled in the patient'diary and hand over to researchers.
62402981|NCT01914107|EXPERIMENTAL|real-time monitoring and instruction of cancer pain|"real-time monitoring and treatment instruction of cancer pain group~1.follow the same pattern of standard cancer pain care. 2. using the cloud computing concept system, install the software in the mobile phone of patients. the patients will fill in the content of brief pain inventory, medication and side effect, and upload to researchers every 2 days. 3. Researcher monitor the cancer pain treatment in realtime and give instructions."
62013833|NCT03050086|PLACEBO_COMPARATOR|BPX-01 Vehicle Topical Gel|once daily topical administration of vehicle gel to the face
62202570|NCT00552929|EXPERIMENTAL|Sugammadex 2.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
62202571|NCT00552929|EXPERIMENTAL|Sugammadex 4.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
62202572|NCT00552929|EXPERIMENTAL|Sugammadex 8.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
62013834|NCT01117311|EXPERIMENTAL|VNB off first, then VNB on|Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB off first for the first intervention (Mixed Meal 2), then VNB on for the second intervention (Mixed Meal 3).
62202573|NCT04821297|EXPERIMENTAL|Supportive care (message)|Patients receive text messages for 1-2 months before scheduled appointment. Patients also complete a survey at baseline and after standard of care colposcopy and an interview after standard of care colposcopy.
62202574|NCT03388268|ACTIVE_COMPARATOR|Oral vancomycin|125mg of oral vancomycin four times per day
62202575|NCT03388268|PLACEBO_COMPARATOR|Placebo|Placebo four times per day
62202576|NCT04839822|EXPERIMENTAL|Intervention Arm: Psychoeducation with elements of CBT & mood chart.|Patients will receive full access to edupression.com® immediately after inclusion. This intervention includes all medical mechanisms of action of edupression.com®: Psychoeducation with elements of CBT (learning content and exercises) and a mood chart (depression symptom monitoring).
62202577|NCT04839822|ACTIVE_COMPARATOR|Active control arm: (occupational) interventions and progress monitoring.|These patients will also receive an edupression.com® account with different content. This content will be limited to medically useful tips, that have have not been shown to be effective in improving depressive symptoms in RCTs. Patients of both arms will be instructed to use chat functions to contact study personnel and to fill out questionnaires and tests to collect outcome and additional measures.
62202578|NCT02517814|EXPERIMENTAL|Patients with cardiomyopathy|Patients with vitamin D deficiency and cardiomyopathy will receive supplementation with vitamin D 400 units per day for 6 months.
62202579|NCT05114343|EXPERIMENTAL|Exercise group|Participants will be instructed to perform 3 sessions of weight-bearing exercise per week, for 12 weeks. Exercise intensity and duration will be low-to-moderate in the first 4 weeks, and will progressively increase during the program. Participants will be supported by educational materials, a heart rate monitor, and by means of periodic contact with an exercise specialist via video and phone calls, and text messages.
62202580|NCT05114343|NO_INTERVENTION|Usual care (control group)|Participants in the control group will receive usual care and general instructions about physical activity.
62202581|NCT01675453|ACTIVE_COMPARATOR|7.2% NaCl /hydroxyethyl starch 200/0.5|On-pump CABG. 7.2% NaCl plus 6% hydroxyethyl starch 200/0.5 solution (HyperHAES) 4 mL/kg for 30 min, IV (in the vein), once, starting after the first hemodynamic measurement is obtained (before the beginning of CPB)
62402982|NCT02205281|NO_INTERVENTION|Standard Care|
62202582|NCT01675453|PLACEBO_COMPARATOR|0.9% NaCl|On-pump CABG. 0.9% NaCl (isotonic saline) 4 mL/kg for 30 min, IV (in the vein), once, starting after the first hemodynamic measurement is obtained (before the beginning of CPB)
62202583|NCT03482089|EXPERIMENTAL|Cystoprostatectomy|(Open, laparoscopic or robot-assisted ) cystoprostatectomy with urinary diversion surgery and extended pelvic lymph node dissection; without adjuvant androgen deprivation therapy;
62202584|NCT03482089|ACTIVE_COMPARATOR|Radiotherapy|Radiotherapy by external beam radiotherapy (81 Gy，2.4-4 Gy per fraction over 4-6 weeks); with adjuvant androgen deprivation therapy for the least 3 years
62202585|NCT06395051|EXPERIMENTAL|Experimental|Ketone monoesters
62202586|NCT06395051|PLACEBO_COMPARATOR|Placebo|Taste- and volume-matched placebo
62402983|NCT02205281|EXPERIMENTAL|Lifestyle Intervention|
62402984|NCT00883766|ACTIVE_COMPARATOR|Long agonist protocol|
62402985|NCT00883766|EXPERIMENTAL|Antagonist protocol|
62402986|NCT04846010|ACTIVE_COMPARATOR|antigen|The antigen is the cell that is destroyed by inflammation, which can perform as swollen, fatty, apoptosis, necrosis, and lethal pathological states. Some pathological cells can be saved and returned to customary conditions, like swollen, fatty, early apoptosis, but necrosis, lethal.
62215129|NCT02293213|ACTIVE_COMPARATOR|Counseling only|All participants who receive EMR referral to CTIS because they are taking class D or X medications AND are randomized to counseling only will receive: CTIS Counseling, Baseline Questionnaire, 3 Month Follow up Questionnaire, and 6 Month Follow up Questionnaire.
62402987|NCT04846010|ACTIVE_COMPARATOR|Internal environment|The internal environment is critical to the damaged cells recovering. Mainly it is covered by two major parts: metabolites and thrombus.
62013835|NCT01117311|EXPERIMENTAL|VNB on first, then VNB off|Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB on first for the first intervention (Mixed Meal 2), then VNB off for the second intervention (Mixed Meal 3).
62013836|NCT00187798|OTHER|Metformin|Metformin HCl
62013837|NCT05991141|EXPERIMENTAL|Experimental Group|Experimental Group
62013838|NCT05991141|SHAM_COMPARATOR|Control Group|Control Group
62402988|NCT04846010|ACTIVE_COMPARATOR|Communication between cells|The communication between organs, cells, helps the damaged cells recover and reduce symptoms.
62202587|NCT04617340|NO_INTERVENTION|Usual care group|No pharmacist will be actively involved in the medication review, counseling or discharge and post-discharge procedure. In both groups the best possible preadmission drug list will be compiled for inpatients within 72 hours after admission to the geriatric ward. If potentially dangerous or life-threatening drug errors are observed in the usual care group, this will be communicated to the treating physician
62202588|NCT04617340|EXPERIMENTAL|Intervention group|"The clinical pharmacist-collaborative service in the intervention group comprises six steps based on the clinical pharmacy intervention proposal of Van der Linden et al (Drugs Aging 2020).~The first three steps focus on optimizing the drug therapy of geriatric inpatients. The remaining steps target a safe transition from the hospital to the community."
62202589|NCT06450847|ACTIVE_COMPARATOR|Interventional group|
62202590|NCT06450847|PLACEBO_COMPARATOR|Control group|
62202591|NCT00902746|EXPERIMENTAL|NPC-01|Norethisterone, Ethinyl Estradiol
62013839|NCT03160430|EXPERIMENTAL|Part A PK Arm|a single 100 mg dose of RVX000222 (apabetalone) on the day of dialysis, followed by a one (1) week washout period, and a second dose of RVX000222 (apabetalone) administered on a non-dialysis day (total of two (2) 100 mg RVX000222 doses)
62013840|NCT03160430|PLACEBO_COMPARATOR|Part B Sequence A|RVX000222 (apabetalone) 100 mg b.i.d (total 200 mg/day) for 6 weeks; 4 Week Washout (No RVX000222/placebo administration); Placebo b.i.d for 6 weeks
62202592|NCT04616729|EXPERIMENTAL|GnRH agonist Depot form|Ovarian stimulation will be performed using a fixed antagonist protocol with Follitropin Alfa (daily in the evening) and Ganirelix or Cetrorelix (daily in the morning). Selection of the daily gonadotropin dose will be based on ovarian reserve parameters (AMH and AFC) and BMI. Co-administration of 5 mg of letrozole daily (in the morning) commencing on the first day of gonadotropin administration and continuing throughout the ovarian stimulation will be performed as this reduces oestradiol concentrations. GnRH agonist Triptorelin 3.75 mg Depot form will be used for final oocyte maturation. Ganirelix/Cetrorelix 0.25mg daily (in the morning) will resume for 7 days from the evening of the day of oocyte retrieval onwards. Hormone analysis, analysis of haematology and biochemistry and a pelvic ultrasound scan will be done on days 3, 5 and 7 after oocyte retrieval.
62202593|NCT04616729|ACTIVE_COMPARATOR|GnRH agonist Daily form|Ovarian stimulation will be performed using a fixed antagonist protocol with Follitropin Alfa (daily in the evening) and Ganirelix/Cetrorelix (daily in the morning). Selection of the daily gonadotropin dose will be based on ovarian reserve parameters (AMH and AFC) and BMI. Co-administration of 5 mg of letrozole daily (in the morning) commencing on the first day of gonadotropin administration and continuing throughout the ovarian stimulation will be performed as this reduces oestradiol concentrations. GnRH agonist Triptorelin 0.2 mg Daily form will be used for final oocyte maturation. Hormone analysis, analysis of haematology and biochemistry and a pelvic ultrasound scan will be done on days 3, 5 and 7 after oocyte retrieval. The first administration of Triptorelin 3.75mg depot will be scheduled on the first day of the menstrual cycle after oocyte retrieval. To prevent the flare-up produced by the GnRH agonist, daily doses of 0.25mg of Ganirelix/Cetrorelix will be given for seven days.
62202594|NCT00603525|EXPERIMENTAL|Ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each treatment cycle consisting of two IV infusion taken 14 days apart. A total of 8 infusion cycles given over a 144 week period
62202595|NCT00603525|PLACEBO_COMPARATOR|1000 ml Saline|1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
62202596|NCT03867695|EXPERIMENTAL|Serratus Block|"At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.~Under ultrasonography assistance, block will be performed at the fifth rib in the midaxillary line. Local anesthetic will be injected either superficial to the serratus anterior muscle or deep underneath the muscle.~Anesthesiologists, and all the nurses and caring staff involved in this study will be blinded. Solutions of ropivacaine will be prepared identically by the central pharmacy, without any possible identification of the product."
62402989|NCT00517452||Platelet Rich Plasma|Group received platelet rich plasma and observed over a period of 30 days or until wound closure
62402990|NCT00517452||Standard Wound Care|Group was treated as per standard care
62402991|NCT02584972||children with Autism Spectrum Disorder|no intervention required
62402992|NCT02584972||heathy children|no intervention required
62402993|NCT00859313|EXPERIMENTAL|Sufentanil NanoTab PCA System/15 mcg|
62402994|NCT04536480|EXPERIMENTAL|Control: 12 hour eating period|Control: Habitual daily eating period (no meal time restrictions)
62402995|NCT04536480|EXPERIMENTAL|Time Limited Eating|Time Limited Eating: 8-hour eating period (16 hours of daily fasting).
62402996|NCT01445834||Incontinent women|
62402997|NCT02293720|EXPERIMENTAL|EndoBarrier Device|Subjects who participated in the control arm of study #09-1 who are not treatment failures and have completed 12 months of the study. These subjects will have the EndoBarrier device implanted for 12 months.
62402998|NCT02001662|EXPERIMENTAL|Intervention group, block no. 1 - Ropivacain|"Adductor-Canal-Block no.1: 30mL ropivacaine (7.5 mg/ml) when postoperative VAS-score is \> 40mm (on a 0-100 mm VAS-scale) during a 45 degree active flexion of the knee.~Adductor-Canal-Block no.2: after 45 min (t45) - 30mL isotonic saline."
62579401|NCT04771598|EXPERIMENTAL|İntervention|Respiratory exercises will be instructed to the individuals forming the intervention group and participants will be asked to do 3 times a day during one month and the exercises will be done by the researchers together with the individuals by establishing a connection with the phone application (zoom, watsapp) once a week from home. In terms of physical activity, the patient will be encouraged to participate in the program by suggesting exercises such as walking and cycling at least three times a week for 20 minutes per week
62013841|NCT03160430|PLACEBO_COMPARATOR|Part B Sequence B|Placebo b.i.d for 6 weeks; 4 Week Washout (No RVX000222/placebo administration); RVX000222 (apabetalone) 100 mg b.i.d (total 200 mg/day) for 6 weeks
62402999|NCT02001662|SHAM_COMPARATOR|Control group, block no. 1 - saline|"Adductor-Canal-Block no.1: 30mL isotonic saline when postoperative VAS-score is above 40mm (on a 0-100 mm VAS-scale) during a 45 degree active flexion of the knee.~Adductor-Canal-Block no.2: after 45 min (t45) - 30mL ropivacaine (7.5 mg/ml)"
62403000|NCT05056363|ACTIVE_COMPARATOR|Control Group|The control group will be given home based traditional scoliosis exercise training for 8 weeks, 5 days a week for 45 minutes.
62202597|NCT03867695|PLACEBO_COMPARATOR|Placebo Block - Control Group|"Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution. Under ultrasonography assistance, placebo will be injected at the fifth rib in the midaxillary line, either superficial to the serratus anterior muscle or deep underneath the muscle.~Anesthesiologists, and all the nurses and caring staff involved in this study will be blinded. Solutions of sterile saline will be prepared identically by the central pharmacy, without any possible identification of the product."
62202598|NCT05471284|SHAM_COMPARATOR|Control|The control condition was a kernel message that included study information present in all conditions but did not include any of the message factors.
62202599|NCT05471284|EXPERIMENTAL|Proximal x Cost x Loss|Message frame: proximal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.
62202600|NCT05471284|EXPERIMENTAL|Proximal x Cost x Gain|Message frame: proximal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.
62202601|NCT05471284|EXPERIMENTAL|Proximal x Benefit x Gain|Message frame: proximal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.
62403001|NCT05056363|EXPERIMENTAL|Training Group|In addition to conventional home based traditional scoliosis exercises, patients in this group will also receive core stabilization exercise training for 45 minutes, 5 times in a week for 8 weeks. Every two sessions will be supervised in a clinic per week.
62403002|NCT01285180||DINO|
62403003|NCT00591916|EXPERIMENTAL|1|Microbial Nanocellulose (NC), an inert material produced by Acetobacter xylinum is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
62579402|NCT04771598|OTHER|Control|Breathing exercises will be explained to the control group and visual material will be given. The participants will be asked to do 3 times a day during one month. In terms of physical activity, the patient will be encouraged to participate in the program by suggesting exercises such as walking and cycling at least three times a week for 20 minutes per week
62202602|NCT05471284|EXPERIMENTAL|Proximal x Benefit x Loss|Message frame: proximal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.
62202603|NCT05471284|EXPERIMENTAL|Distal x Cost x Gain|Message frame: distal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.
62403004|NCT00591916|EXPERIMENTAL|2|fine mesh gauze impregnated with hyaluronan and thrombin (HT) is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
62403005|NCT00591916|ACTIVE_COMPARATOR|3|Scarlet Red is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
62579403|NCT03625466|PLACEBO_COMPARATOR|Part 1: Placebo|Participants received placebo matched to LUM/IVA in placebo-controlled period for 48 weeks.
62202604|NCT05471284|EXPERIMENTAL|Distal x Cost x Loss|Message frame: distal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.
62202605|NCT05471284|EXPERIMENTAL|Distal x Benefit x Loss|Message frame: distal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.
62202606|NCT05471284|EXPERIMENTAL|Distal x Benefit x Gain|Message frame: distal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.
62202607|NCT05045651|EXPERIMENTAL|patient specific knee prosthesis|TKA with Gender Solution® posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA
62202608|NCT05045651|EXPERIMENTAL|Unisex knee prosthesis|TKA with posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA
62403006|NCT02163525|ACTIVE_COMPARATOR|Ablation vs Embolization|Women are randomized 1:1 to either global fibroid ablation (GFA) or uterine artery embolization (UAE)
62013842|NCT04901117|EXPERIMENTAL|10-day treatment group|"Use the following drug combination option for 10 days. Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole + Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's situation.~The dosage of each drug is:~Amoxicillin (Amoxicillin, United Laboratories Co., Ltd.) 1000mg bid Clarithromycin (Klacid, Abbott S.r.l) 500mg bid Tetracycline 500mg qid Metronidazole400mg qid Bismuth Potassium Citrate (Livzon Pharmaceutical Group Inc.) 220mg bid Colloidal Bismuth Pectin (North China Pharmaceutical Co., Ltd.) 200mg bid Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid"
62013843|NCT04901117|ACTIVE_COMPARATOR|14-day treatment group|"Use the following drug combination option for 14 days. Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole + Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's situation.~The dosage of each drug is:~Amoxicillin (Amoxicillin, United Laboratories Co., Ltd.) 1000mg bid Clarithromycin (Klacid, Abbott S.r.l) 500mg bid Tetracycline 500mg qid Metronidazole400mg qid Bismuth Potassium Citrate (Livzon Pharmaceutical Group Inc.) 220mg bid Colloidal Bismuth Pectin (North China Pharmaceutical Co., Ltd.) 200mg bid Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid"
62013844|NCT00559897|EXPERIMENTAL|3'-deoxy-3'-[18F]FLT PET & zoledronic acid|"Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid~Single photon emission computed tomography. Patient should receive the dose of zoledronic acid within 48 hrs of the first '3'-deoxy-3'-\[18F\]FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid."
62013845|NCT06574321|EXPERIMENTAL|TTHSR Intervention|"Intervention: Students in schools in this group will receive the Teen Talk High School Refresher, a 5-session SHE booster program"
62013846|NCT06574321|NO_INTERVENTION|Comparison|"Business-as-usual control: Students in schools in this group will receive their school's normal classroom teaching"
62013847|NCT01142258|EXPERIMENTAL|Trazodone|Study group will receive trazodone 50mg
62202609|NCT05512351|EXPERIMENTAL|Cohort 1|Subjects with ctDNA-level-relapse Oligodendroglioma before clinical relapse, determined according to the dynamics of TISF ctDNA.
62403007|NCT02163525|ACTIVE_COMPARATOR|Ablation vs Myomectomy|Women are randomized 1:1 to either global fibroid ablation (GFA) or myomectomy (laparoscopic or abdominal)
62013848|NCT01142258|PLACEBO_COMPARATOR|Placebo|Inert pill
62013849|NCT02443038|ACTIVE_COMPARATOR|Home Exercise|Participants will practice 10 minutes of yoga in addition to 5 minutes of relaxation exercises at home each day when not in class.
62013850|NCT02443038|PLACEBO_COMPARATOR|Relaxation Exercise|Participants will practice 5 minutes of relaxation exercises at home each day when not in class.
62202610|NCT05512351|EXPERIMENTAL|Cohort 2|Subjects with clinical-relapse Oligodendroglioma, determined according to the response assessment in neuro-oncology (RANO) criteria for gliomas.
62202611|NCT05512351|NO_INTERVENTION|Cohort 3|Subjects without ctDNA-level-relapse and clinical-relapse Oligodendroglioma.
62202612|NCT04672408|ACTIVE_COMPARATOR|His bundle pacing|Pacing programmed from the His bundle lead
62403008|NCT00036868|EXPERIMENTAL|CMF + Herceptin|
62403009|NCT00471237|NO_INTERVENTION|Placebo|All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
62403010|NCT00471237|ACTIVE_COMPARATOR|Alendronate|All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
62403011|NCT00471237|ACTIVE_COMPARATOR|Teriparatide|Open-label arm. All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
62202613|NCT04672408|PLACEBO_COMPARATOR|Right ventricular pacing|Pacing programmed from the right ventricular lead
62202614|NCT02954198|ACTIVE_COMPARATOR|Tacrolimus + MMF|Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Tacrolimus Daily (5 -12ng/mL) + mycophenolate mofetil 1g BID + prednisone x 6 months
62734809|NCT04959227||control group|Beck Anxiety Inventory (min 0- max 63, As the score increases, the level of anxiety also increases.) Beck Depression Inventory (min 0- max 63, As the score increases, the level of depression also increases.) International Physical Activity Questionnaire
62013851|NCT02476565|EXPERIMENTAL|LMA-Supreme supraglottic device|The LMA-Supreme is a single-use disposable supraglottic airway that utilizes an inflatable cuff
62403012|NCT00471237|EXPERIMENTAL|Ronacaleret|4 arms, 100mg, 200mg, 300mg, 400mg. All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study.
62579404|NCT03625466|EXPERIMENTAL|Part 1: LUM/IVA|Participants weighing less than (\<)14 kilograms (kg) at screening received LUM 100 milligrams (mg)/IVA 125 mg fixed-dose combination (FDC) every 12 hours (q12h) in placebo-controlled period for 48 weeks. Participants weighing greater than or equals to (\>=)14 kg at screening received LUM 150 mg/IVA 188 mg FDC q12h in placebo-controlled period for 48 weeks.
62785848|NCT06348667|ACTIVE_COMPARATOR|Control|"16 participants who will perform their conventional exercises protocol. The group exercise sessions (45') take place twice a week. Participants sit in a circle in the room, with the physiotherapist in the center to provide instructions, and perform:~* Warm-up: 5' of joint mobility exercises. Shoulder rotations, elbow flexion and extension, knee flexion and extension, ankle rotations, and standing up and sitting down 5 times.~* Main part: 25-30' (with music). Energetic arm movements, e.g. raising and lowering, front and back, inward and outward arm circles, and lateral shoulder raises like little birds... These exercises are performed fast within a controlled ROM. CORE work is done while seated on the edge of the chair, bringing knees to the shoulders and moving the legs up and down. Finally, they stand up and sit down several times, and try to maintain an isometric squat position.~* Cool down: 5-7' of stretching, mainly consisting of active neck mobility and arm stretching."
62785849|NCT01085864||Patients with lung nodules on CT scan.|Patients with lung nodules on CT scan.
62785850|NCT02240355|EXPERIMENTAL|Part 1|Up to 2 cohorts of patients, within each cohort patients will receive either RO6885247 or placebo once daily for 12 weeks
62785851|NCT02240355|EXPERIMENTAL|Part 2|1 cohort of patients, within each cohort patients will receive either RO6885247 or placebo once daily for 12 weeks
62013852|NCT02476565|ACTIVE_COMPARATOR|I-gel supraglottic device|The I-gel is an alternative supraglottic device made from thermoplastic elastomer which provides the seal over the airway versus an inflatable cuff.
62202615|NCT02954198|ACTIVE_COMPARATOR|Envarsus + Everolimus|Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Envarsus Daily (2-5ng/mL) + Everolimus Daily (3-8ng/mL) + prednisone x 6 months
62202616|NCT01035567|ACTIVE_COMPARATOR|Hybrid revascularization|
62202617|NCT01035567|ACTIVE_COMPARATOR|Coronary Artery Bypass Grafting|
62202618|NCT01840410|EXPERIMENTAL|Ranibizumab|A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
62202619|NCT01840410|SHAM_COMPARATOR|Sham control|Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.
62202620|NCT04176731|EXPERIMENTAL|Treatment|All subjects wearing the Omnipod Horizon™ Automated Glucose Control System using the closed-loop algorithm
62202621|NCT01293253|EXPERIMENTAL|Stair walking|Participants of this group is encouraged to use the stairs for 10 minutes a day at the workplace
62202622|NCT01293253|ACTIVE_COMPARATOR|Control|Receives a health examination before and after the intervention period, and are advised to stay active
62202623|NCT00872209|ACTIVE_COMPARATOR|Ciloxan Ear Drops|Ciloxan (Alcon, Inc.) Sterile Ophthalmic and Ear Drops
62785852|NCT02240355|EXPERIMENTAL|Part 3|1 cohort of patients, within each cohort patients will receive RO6885247 once daily for 12 weeks or 20 weeks
62785853|NCT01918280|EXPERIMENTAL|Young group|Patient aged 15-22 years for seminal analyses and testicular biopsy
62785854|NCT01918280|OTHER|Adult group|Patient aged 23-55 years for seminal analyses and testicular biopsy
62785855|NCT04701567||Liver disease|
62785856|NCT04701567||Pancreatic disease|
62013853|NCT01299077||Lumbar disc degenerative disease|Triple therapy (MBL+ MYO+ NSAIDs) which prescribed by doctors (Drs) based on disease condition
62013854|NCT01123018||Older Adults|Persons over age 60 Participants will complete the Memtrax memory screening test
62013855|NCT01196871|EXPERIMENTAL|Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg)|
62202624|NCT00872209|EXPERIMENTAL|Foam Otic Cipro|Patients randomized to this study arm will receive the experimental product
62202625|NCT01820520|EXPERIMENTAL|Double staining with brilliant blue G during vitrectomy|
62202626|NCT05766527|EXPERIMENTAL|KM602 monotherapy|Dose escalation and expansion
62785857|NCT02120326|EXPERIMENTAL|active tDCS|
62785858|NCT02120326|PLACEBO_COMPARATOR|simulated tDCS|
62013856|NCT01196871|EXPERIMENTAL|Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg)|
62202627|NCT04907019|EXPERIMENTAL|Group-drugs interaction|24 subjects were enrolled in this study. The effects of rifampicin single dose and steady-state on the pharmacokinetics of sy-004 will be analyzed.
62202628|NCT04713969|EXPERIMENTAL|Functional dyspepsia patients before and after PPI|Pantoprazole 40mg twice daily in functional dyspepsia patients for 4 weeks
62202629|NCT04713969|NO_INTERVENTION|Healthy controls before PPI|Baseline investigations
62579405|NCT03625466|EXPERIMENTAL|Part 2: Overall LUM/IVA|Participants who received either placebo or LUM/IVA in placebo-controlled period administered LUM/IVA (either LUM 100 mg/IVA 125 mg FDC q12h or LUM 150 mg/IVA 188 mg FDC q12h as per their body weight for participants \<6 years of age at week 48 and LUM 200 mg/IVA 250 mg FDC q12h regardless of their body weight for participants \>=6 years of age at week 48) in open-label period for 48 weeks.
62579406|NCT02896062|EXPERIMENTAL|Treatment group|In the treatment phase subjects receive a sleep-coaching
62579407|NCT02896062|ACTIVE_COMPARATOR|Waiting group control|The waiting group receives the treatment after a waiting period of up to 6 weeks
62013857|NCT01196871|EXPERIMENTAL|Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg)|
62013858|NCT01196871|EXPERIMENTAL|Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg)|
62013859|NCT01196871|EXPERIMENTAL|Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg)|
62013860|NCT01196871|EXPERIMENTAL|Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg)|
62013861|NCT00774787|EXPERIMENTAL|Imiquimod, treatment, topical cream|Imiquimod 5% cream, 1 packet (250 mg cream), applied to left or right treatment area on the face and/or balding scalp
62202630|NCT00941967|EXPERIMENTAL|Arm I|Patients receive oral sorafenib tosylate as in arm I. Patients also receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV over 2 hours on day 2. Treatment with gemcitabine hydrochloride and oxaliplatin repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.
62202631|NCT00941967|EXPERIMENTAL|Arm II|Patients receive oral sorafenib tosylate twice daily on days 1-14.
62202632|NCT04796077|EXPERIMENTAL|Pop-Up Book|Patients read an interactive pop-up book about general anesthesia induction in addition to standard consultation with an anesthesia provider.
62202633|NCT04796077|NO_INTERVENTION|Standard Care|Patients received standard consultation with an anesthesia provider (standard care).
62202634|NCT04735068|EXPERIMENTAL|Binimetinib and Hydroxychloroquine|"Hydroxychloroquine (HCQ)in combination with Binimetinib (B). The starting dose for HCQ will be 400mg. Tablets of HCQ are available in 200 mg strength. HCQ will be administered in divided doses (every 12 hours) with or without food.~The starting dose of B is 45mg. B will be administered in divided doses (every 12 hours) with or without food"
62202635|NCT01279018||Patients treated with docetaxel|Patients treated according to the DBCG 07 protocol, that have received docetaxel as part of the adjuvant treatment.
62202636|NCT05997628||18-40 years|Each group has 20 subjects, and the sex ratio of 18-40 years group is 1:1. After each participant is enrolled, peripheral blood samples are taken before breakfast and before lunch to detect NAD+/NADH levels in peripheral blood and determine the physiological baseline levels of NAD+/NADH in different age groups
62202637|NCT05997628||41-60 years|Each group has 20 subjects, and the sex ratio of 41-60 years group is 1:1. After each participant is enrolled, peripheral blood samples are taken before breakfast and before lunch to detect NAD+/NADH levels in peripheral blood and determine the physiological baseline levels of NAD+/NADH in different age groups
62202638|NCT05997628||61-80 years|Each group has 20 subjects, and the sex ratio of 61-80 years group is 1:1. After each participant is enrolled, peripheral blood samples are taken before breakfast and before lunch to detect NAD+/NADH levels in peripheral blood and determine the physiological baseline levels of NAD+/NADH in different age groups
62202639|NCT01810458||AATD ZZ and Rare Alleles Group|Participants will get a history and physical (H\&P) and have an intravenous catheter (IV) placed, for blood draws, at the screening and years 1-3 visits. An IV will also be placed at the liver biopsy visit(s) for the administration of medication. An abdominal ultrasound will be done at the screening and year 3 visits along with the completion of a liver questionnaire. Finally, participants will have a liver biopsy done, with the use of lidocaine, lorazepam, or midazolam and fentanyl, after the screening visit and potentially at the year 3 study visit, depending on the results of the first liver biopsy. Participants who experience pain after the liver biopsy may receive acetaminophen or oxycodone/acetaminophen. Any subject experiencing nausea may receive ondansetron.
62403013|NCT02628197|ACTIVE_COMPARATOR|CONTROL GROUP|34 osteopenic postmenopausal women with chronic periodontitis who received calcium (500mg) and vitamin D (250I.U.) supplementation twice a day for 6 months.Scaling and root planing was not done in this group.
62403014|NCT02628197|ACTIVE_COMPARATOR|TEST GROUP|34 osteopenic postmenopausal women with chronic periodontitis who received scaling and root planing along with calcium (500mg) and vitamin D (250I.U.) supplementation twice a day for 6 months.
62403015|NCT05847621|EXPERIMENTAL|In-person peer recovery coaching with linkage to recovery resources|"PRCs will meet patients at bedside (in person). They will also schedule and perform follow up calls after the participant is discharged from the ED to provide ongoing support and facilitate re-linkage to recovery resources, if needed.~Follow-up data collection on day 7, 30, 90 post discharge."
62403016|NCT05847621|EXPERIMENTAL|Telemedicine-based peer recovery coaching with linkage to recovery resources|"PRCs will meet patients via a tablet-based video call (telemedicine). They will also schedule and perform follow up calls after the participant is discharged from the ED to provide ongoing support and facilitate re-linkage to recovery resources, if needed.~Follow-up data collection on day 7, 30, 90 post discharge."
62403017|NCT05847621|ACTIVE_COMPARATOR|Usual Care|"Participants in the usual care arm will be provided with a list of community recovery resources. No callbacks or re-linkage to recovery resources.~Follow-up data collection on day 7, 30, 90 post discharge."
62403018|NCT02301949|ACTIVE_COMPARATOR|Thalidomide Retreatment Group|
62013862|NCT00774787|NO_INTERVENTION|Control, Untreated|No treatment of treatment area on the other half of the face and/or balding scalp
62403019|NCT02301949|PLACEBO_COMPARATOR|Placebo Group|
62403020|NCT05952154|EXPERIMENTAL|Nonbstructive Hypertrophic Cardiomyopathy|Transapical beating-heart septal myectomy for the patient with nonobstructive hypertrophic cardiomyopathy and Heart Failure.
62013863|NCT00636454|ACTIVE_COMPARATOR|1|This group will serve as the control group and will receive only the care usually given to OA patients.
62403021|NCT05915780|EXPERIMENTAL|Experimental|The experimental group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 8-week period
62403022|NCT05915780|OTHER|Controlled|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises (if required);
62785859|NCT02596789|OTHER|state dependency TMS|TMS performed at rest and during a cognitive/emotional task
62013864|NCT00636454|EXPERIMENTAL|2|This group will take part in the 10-session treatment program that will teach patients cognitive and behavioral skills to cope with pain.
62013865|NCT01264861|EXPERIMENTAL|Arm 1:|Arm 1: Eligible subjects will receive escalating doses of safinamide for the 6-week duration of treatment. Each dose level will be last 10-14 days. Doses 200mg and 300mg will have a 3 day intermediate step up dose, 150mg and 250mg dose.
62013866|NCT03212586|EXPERIMENTAL|Dose escalation BAY1902607|Dose 1 to 9 of BAY1902607
62013867|NCT03212586|PLACEBO_COMPARATOR|Dose escalation Placebo|Dose 1 to 9 of matching placebo
62013868|NCT01513317|EXPERIMENTAL|Siltuximab|15 mg/kg of siltuximab administered as a 1-hour infusion every 4 weeks + best supportive care (BSC)
62202640|NCT03664102||Sutures with hand-tied knots|Minimally-invasive isolated aortic valve replacement with Sutures were secured with hand-tied knots
62403023|NCT06219148|EXPERIMENTAL|Collaborative|"Social workers and music therapists work together, and information collected during music therapy informs social work wellness sessions following a protocol developed during the feasibility study.~There are 3 blocks of activities, identical to the non-collaborative arm:~* Weeks 1-2: enrollment, stratification, random assignment~* Weeks 3-6: music therapy and social work interventions~* Weeks 7-8: social work follow up."
62403024|NCT06219148|SHAM_COMPARATOR|Non-Collaborative|"Social workers and music therapists operate independently.~There are 3 blocks of activities, identical to the collaborative arm:~* Weeks 1-2: enrollment, stratification, random assignment~* Weeks 3-6: music therapy and social work interventions~* Weeks 7-8: social work follow up."
62013869|NCT01513317|EXPERIMENTAL|Placebo|Placebo administered as a 1-hour infusion every 4 weeks + BSC
62403025|NCT02861404||Salicylate ointment|patients included in VRAIE study, treated with salicylate ointment (VRAIE study, NCT01059110)
62403026|NCT02861404||Imiquimod|patients included in VRAIE study, treated with Imiquimod (VRAIE study, NCT01059110)
62403027|NCT02861404||5-Fluoro-Uracil|patients included in VRAIE study, treated with 5-Fluoro-Uracil (VRAIE study, NCT01059110)
62785860|NCT01806909|OTHER|Intranasal|Ad4-H5-VTN intranasal vaccine administered in cohorts of 3 at increasing dosages
62202641|NCT03664102||Sutures with automated fastener device (Cor-Knot)|Minimally-invasive isolated aortic valve replacement with Sutures were secured with automated fastener device (Cor-Knot)
62202642|NCT05717491||Main group|Cross-sectional study
62202643|NCT05717491||Sub group|Case control study
62202644|NCT02993185|EXPERIMENTAL|Your Move|Sex education intervention
62202645|NCT02993185|ACTIVE_COMPARATOR|Eat Smart|Nutrition education intervention
62202646|NCT06250959|EXPERIMENTAL|Reduced-dose Chemotherapy Followed by Blinatumomab|Reduced-dose Chemotherapy(including 1 dose of Idarubicin 8 mg/m2, 1 dose of Vincristine 1.4 mg/m2\[max 2mg\], and 7 days of Dexamethasone 9 mg/m2/d) followed by 2 weeks of Blinatumomab (9 ug/d d8-14, 28 ug/d d15-21) immediately. If not achieved CR/CRi, Blinatumomab 28 ug for another 14 days should be continued.
62202647|NCT06250959|ACTIVE_COMPARATOR|hyperCVAD|CTX 300mg/m2 q12h D1-3 VCR 1.4mg/m2 (max 2mg) D4,D11 DNR 50mg/m2, D4 DEX 40mg/d D1-4, D11-14
62403028|NCT02861404||Cryotherapy|patients included in VRAIE study, treated with cryotherapy (VRAIE study, NCT01059110)
62403029|NCT02861404||placebo|patients included in VRAIE study, receiving placebo (VRAIE study, NCT01059110)
62403030|NCT05101473|EXPERIMENTAL|Exercise therapy|Exercises will be performed with minimal weight bearing on foot soles, as recommended in the literature for people with diabetic peripheral neuropathy.
62403031|NCT00987506||XIENCE V®|Participants receiving XIENCE V® EESS
62403032|NCT02551874|EXPERIMENTAL|Saxagliptin/Dapagliflozin/Metformin|Oral route. Saxagliptin/Dapa adminsitered once daily for 24 weeks at a dose of 5 mg Saxagliptin and 10 mg Dapagliflozin
62785861|NCT00872690||Group 1|OEF/OIF veterans with polytrauma who have been referred by the Tampa VA Polytrauma Rehabilitation Center (PRC) to the VA VR\&E Regional Office in St. Petersburg, Florida for Chapter 31 (IL) services.
62785862|NCT00872690||Group 2|Caregivers of the veterans who enroll in the study
62785863|NCT02580461|EXPERIMENTAL|Immediate Exercise Group|One half of the participants enrolled in the 24 week center-based structured exercise and education program will be randomized to the immediate exercise group. The immediate exercise group will receive a 12 week center based structured exercise program followed by a 12 week maintenance of exercise program.
62013870|NCT05535166|EXPERIMENTAL|Stratum S-2|"Patients with Sonic Hedgehog subgroup 2 (SHH-2), 0-2.99 years, or M0 and 3-4.99 years, will receive systemic high-dose methotrexate (HD-MTX) and conventional chemotherapy.~Interventions: Surgery, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Pegfilgrastim, Filgrastim"
62013871|NCT05535166|EXPERIMENTAL|Stratum S-1|"Patients with SHH-1, SHH-3, SHH-4, or SHH-Not otherwise specified (NOS), 0-2.99 years, will receive intraventricular methotrexate (IVT-MTX) in parallel with systemic HD-MTX and conventional chemotherapy.~Interventions: Surgery, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Pegfilgrastim, Filgrastim"
62013872|NCT05535166|EXPERIMENTAL|Stratum N|"Patients with Medulloblastoma (MB) group 3 or group 4 (G3/G4) or MB \[including Non-WNT non-SHH medulloblastoma (NWNS) NOS or otherwise indeterminate cases\] (0-2.99 years) will receive systemic HD-MTX and conventional chemotherapy only for radiation delaying purposes. At 3 years of age, these patients will receive risk-stratified craniospinal irradiation (CSI).~Interventions: Surgery, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Etoposide, Pegfilgrastim, Filgrastim, Radiation"
62013873|NCT05535166|EXPERIMENTAL|Cognitive Study Group I (educational video and games)|Educational video and games
62013874|NCT05535166|ACTIVE_COMPARATOR|Cognitive Study Group II (standard-of-care control)|Standard-of-care (SOC) followed by educational video and games
62013875|NCT02091167|EXPERIMENTAL|real tDCS|Ten sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
62013876|NCT02091167|SHAM_COMPARATOR|sham-tDCS|Ten sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current was delivered for 30 seconds and was turned off for the rest of the stimulation period. In this way, subjects experienced the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
62013877|NCT01383941||Subjects with Mild to Severe Asthma|This is an epidemiologic, multi-center, cross-sectional study to define the phenotypic characteristics of Difficult-to-Treat asthma, among children receiving one year of guidelines-based therapy for asthma and rhinitis/rhinosinusitis.
62013878|NCT01175655|EXPERIMENTAL|MSC|
62013879|NCT05691075||Metatarsophalangeal arthrodesis of the hallux with large diameter screws|Patient who can benefit from first-line arthrodesis using large-diameter screws
62403033|NCT02551874|ACTIVE_COMPARATOR|Insulin Glargine, Lantos/Metformin|Insulin glargine administered once a day with starting dose of 0.2 Unit per kg or 10 units.
62403034|NCT05931601|EXPERIMENTAL|Intervention|"Peripheral noradrenaline will be infused at rates of 0.05-0.15 mcg/kg/min for up to 24 hours after randomization in the ED until shock control is achieved.~If shock control cannot be achieved, patients will be transferred to the ICU for further treatment of their condition but without further trial intervention.~Weaning of intervention will be completed during the 24 hours, and if possible, terminated.~If termination of treatment is not achievable within 24 hours, participants will be transferred to the ICU."
62785864|NCT02580461|NO_INTERVENTION|Delayed Exercise Group|One half of the participants enrolled in the 24 week center-based structured exercise and education program will be randomized to the delayed exercise group. This will be a wait list control group and the participants will receive no active intervention for 12 weeks. The wait list control group will then be enrolled in the 12 week structured exercise intervention.
62785865|NCT01992263|EXPERIMENTAL|Vitamin D (600 IU)|
62013880|NCT05691075||Metatarsophalangeal arthrodesis of the hallux by plate|Patient who can benefit from a first intention arthrodesis by dorsal plate
62403035|NCT05931601|NO_INTERVENTION|Control|No ED administered noradrenaline. Standard care of hypotension and shock in the Danish ED's are fluid therapy and if not possible to achieve shock control, they are transferred to the ICU for administration of vasopressors if they are eligible for ICU admittance.
62403036|NCT01280305|EXPERIMENTAL|raloxifene|
62403037|NCT01280305|PLACEBO_COMPARATOR|Placebo|
62403038|NCT04734366|EXPERIMENTAL|"Uterine closure with Baseball suture technique"|"Participants will undergo Baseball suture closure of the hysterotomy site at the time of cesarean section."
62403039|NCT04734366|ACTIVE_COMPARATOR|Single Layer Continuous Locked|Participants will undergo Single Layer Continuous Locked suture closure of the hysterotomy site at the time of cesarean section.
62403040|NCT02618096|ACTIVE_COMPARATOR|Oxytocin & Membrane sweeping|"Women assigned to Concurrent oxytocin with membrane sweeping had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, followed by oxytocin infusion the next day"
62403041|NCT02618096|ACTIVE_COMPARATOR|Oxytocin & Dinoprostone|"Women assigned to Concurrent oxytocin with dinoprostone vaginal insert: The 10mg dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening, followed by oxytocin infusion the next day"
62403042|NCT04856852|EXPERIMENTAL|Iodine-125+Chemotherapy|Iodine-125; Temozolomide
62403043|NCT04856852|ACTIVE_COMPARATOR|Surgical resection+Radiochemotherapy|Surgical resection; Radiotherapy; Temozolomide:
62403044|NCT03568136|EXPERIMENTAL|Treatment Arm A|Patients in treatment arm A receive 300 mg Secukinumab administered as 2 subcutaneous injections of 150 mg (i.e. 2x 150 mg) at baseline day 1 and week 1, 2, 3, 4, 8, 12 and injections with placebo at week 5, 6, 7 and 16. For assessments of the study endpoints were followed up visits at week 20 and 24. Placebo will be administered as 2 subcutaneous injections.
62403045|NCT03568136|PLACEBO_COMPARATOR|Treatment Arm B|Patients in treatment arm B receive placebo until visit 3 (week 3) and will switch to Secukinumab 300 mg s.c. up from visit 4 (week 4), visit 5, 6, 7, 8, 12 and16. For assessments of the study endpoints were followed up visits at week 20 and 24.
62785866|NCT01992263|EXPERIMENTAL|Vitamin D (2000 IU)|
62785867|NCT01992263|EXPERIMENTAL|Vitamin D (4000 IU)|
62785868|NCT01992263|PLACEBO_COMPARATOR|Placebo|
62785869|NCT02069392|ACTIVE_COMPARATOR|Cognitive remediation training with nicotine|Participants will complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
62013881|NCT04777344|EXPERIMENTAL|Intervention group|The intervention group will receive the multi-component intervention (counseling with intake assessment, follow-up, help obtaining nicotine replacement therapy, and CF-specific smoke exposure education)
62013882|NCT04777344|NO_INTERVENTION|Control group|The control group will receive usual care plus CF-specific smoke exposure education.
62013883|NCT04900974|EXPERIMENTAL|Doravirine|100mg doravirine given by mouth once at each sampling visit.
62202648|NCT01014611||Class II NYHA Heart Failure|Fraction of ejection between 40% and 30%
62202649|NCT01014611||Class III NYHA Heart Failure|Fraction of ejection lower than 30%
62403046|NCT01967810|EXPERIMENTAL|Arm 1|ANG1005 administered to bevacizumab-naive recurrent GBM participants
62403047|NCT01967810|EXPERIMENTAL|Arm 2|ANG1005, with or without bevacizumab, administered to bevacizumab-refractory recurrent GBM participants
62403048|NCT01967810|EXPERIMENTAL|Arm 3|ANG1005 administered to recurrent WHO Grade III anaplastic glioma participants
62403049|NCT01301157|EXPERIMENTAL|25ug M518101|
62403050|NCT01301157|PLACEBO_COMPARATOR|Vehicle|
62403051|NCT01301157|ACTIVE_COMPARATOR|Dovonex|
62403052|NCT01301157|EXPERIMENTAL|50ug M518101|
62202650|NCT01014611||Healthy volunteers|Matched with patients on age and physical activity
62202651|NCT03378453|OTHER|NarCo|Narcolepsy type 1 over 65 years old
62202652|NCT03378453|OTHER|CoS|Cognitevement healthy controls
62202653|NCT05419622|EXPERIMENTAL|lung MRI|The procedure under study is lung MRI, performed on a 1.5T magnet (AERA dot 1.5T, Siemens), without anesthesia and without injection or inhalation of contrast agent.
62202654|NCT01670253|NO_INTERVENTION|Group 2|6 hours of total fast for all solid and liquid food / drinks
62202655|NCT01670253|EXPERIMENTAL|Group 1|"* 6 hour fast from all solid foods and milk beverages~* 2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)~* Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like."
62202656|NCT05520853|EXPERIMENTAL|SBRT combined with PD-1 inhibitors and thoracic hyperthermia|At least one lesion (primary or metastatic) was selected for SBRT treatment, and the radiotherapy dose of each lesion was 32Gy/4Fx. SBRT was combined with thoracic hyperthermia from the first fraction, and hyperthermia was performed 6 times, twice a week. PD-1 inhibitor was used on the second day after the completion of SBRT. The PD-1 inhibitor was administered at a dose of 200mg every time, every 3 weeks for 2 years (35 times total), or until the investigators deem that the patient need to discontinue the drug because of treatment-related toxicity or disease progression.
62202657|NCT03921502|EXPERIMENTAL|ERCP with sphincterotomy + gall bladder drainage with LAMS|An ERCP with biliary sphincterotomy will be performed. The performance of other techniques (balloon extraction, dilation, placement of biliary prosthesis ...) is at the expense of the endoscopist. After this, transmural drainage of the gallbladder will be performed by placing a LAMS Axios (Boston Scientific) usually 15x10 mm or 10x10 mm to allow direct cholecystoscopy with a conventional gastroscope or transnasal gastroscope. The placement of the drainage will be performed in the same endoscopic act, by means of an Olympus® sectorial echoendoscope, assisted with X-rays, which allows puncturing the vesicle from the gastric antrum or the duodenal bulb to generate a cholecysto-gastrostomy or cholecysto-duodenostomy respectively. After the puncture of the vesicle from the most optimal anatomical point, it will be tutored with guidance and a Hot Axios® PAL will be placed on it to generate the anastomosis between the aforementioned structures.
62202658|NCT03921502|ACTIVE_COMPARATOR|ERCP with sphincterotomy|An ERCP with biliary sphincterotomy will be performed. The performance of other techniques (balloon extraction, dilation, placement of biliary prosthesis ...) is at the expense of the endoscopist.
62202659|NCT05136053|EXPERIMENTAL|Part A: Lu AG22515|Participants will receive a single intravenous (IV) infusion of Lu AG22515.
62403053|NCT02315651|EXPERIMENTAL|Coenzyme Q10|30 children aged 6-12 will consume daily a snack containing 60 mg of CoQ10 for 8 weeks.
62403054|NCT02315651|PLACEBO_COMPARATOR|Placebo|30 children aged 6-12 years will consume an identical snack without CoQ10 for 8 weeks
62579408|NCT06175026|EXPERIMENTAL|Health messages|Messages shown will be related to the health impacts of making certain dietary substitutions (replacing beef with chicken and vegetarian entrees; replacing juice with whole fruit; replacing dairy milk with non-dairy milk; replacing sugar-sweetened beverages with water).
62579409|NCT06175026|EXPERIMENTAL|Environment messages|Messages shown will be related to the environmental impacts of making certain dietary substitutions (replacing beef with chicken and vegetarian entrees; replacing juice with whole fruit; replacing dairy milk with non-dairy milk; replacing sugar-sweetened beverages with water).
62013884|NCT05205603|PLACEBO_COMPARATOR|Biologics group|"Biologics including infliximab and vedolizumab. infliximab: 5mg/kg, intravenously administration at week 0, 2, and 6 as induction therapy; subsequently by maintenance therapy at a dose of 5mg/kg every 8 weeks.~vedolizumab: 300mg, intravenously administration at week 0, 2, and 6 as induction therapy; subsequently by maintenance therapy at a dose of 300mg every 8 weeks."
62785870|NCT02069392|PLACEBO_COMPARATOR|Cognitive remediation training without nicotine|Participants will complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a placebo lozenge prior to the training.
62013885|NCT05205603|EXPERIMENTAL|5-ASA group|"5-ASA combined with biologics (including infliximab and vedolizumab). infliximab: 5mg/kg, intravenously administration at week 0, 2, and 6 as induction therapy; subsequently by maintenance therapy at a dose of 5mg/kg every 8 weeks.~vedolizumab: 300mg, intravenously administration at week 0, 2, and 6 as induction therapy; subsequently by maintenance therapy at a dose of 300mg every 8 weeks.~mesalazine: at a dose of 4-6g/d systemic or topical therapy"
62579410|NCT06175026|EXPERIMENTAL|Health and environment messages|Messages shown will be related to the health and environmental impacts of making certain dietary substitutions (replacing beef with chicken and vegetarian entrees; replacing juice with whole fruit; replacing dairy milk with non-dairy milk; replacing sugar-sweetened beverages with water).
62785871|NCT03170960|EXPERIMENTAL|Dose Escalation|"Subjects will accrue in cohorts of 3-6 subjects for evaluation of cabozantinib tablet dose of either 20 mg, 40 mg, and 60 mg orally qd in combination with standard dosing regimen of atezolizumab (1200 mg infusion q3w). A standard 3 plus 3 design will be utilized to determine a recommended combination dosing regimen for the Expansion Stage."
62785872|NCT03170960|EXPERIMENTAL|Expansion Cohort 1|RCC subjects with clear cell histology who have not received prior systemic anticancer therapy.
62013886|NCT03058796|ACTIVE_COMPARATOR|CCFES Therapy|CCFES uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. CCFES enables stroke survivors to open and close their paretic hand and practice using it in therapy sessions. The treatment regimen includes CCFES-mediated: 1) home-based self-administered hand opening exercises, and 2) lab-based therapist-guided functional task practice.
62013887|NCT03058796|EXPERIMENTAL|CCFES Video Game Therapy|CCFES Video Game Therapy integrates custom designed hand therapy video games with CCFES which enables participants to use the video game component at home instead of repetitive hand opening exercises.
62785873|NCT03170960|EXPERIMENTAL|Expansion Cohort 2|UC subjects (including bladder, renal pelvis, ureter, urethra) who have progressed on or after platinum-containing chemotherapy.
62202660|NCT05136053|PLACEBO_COMPARATOR|Part A: Placebo|Participants will receive a single IV infusion of placebo matching to Lu AG22515.
62202661|NCT05136053|EXPERIMENTAL|Part B: Lu AG22515 and Immune System Activator|Participants will receive a single IV infusion of Lu AG22515 and a subcutaneous (SC) injection of immune system activator 14 days prior to and 14 days following the start of Lu AG22515 IV infusion.
62579411|NCT06175026|ACTIVE_COMPARATOR|Neutral messages|Messages shown will be neutral and unrelated to the health or environmental impacts of making certain dietary substitutions (replacing beef with chicken and vegetarian entrees; replacing juice with whole fruit; replacing dairy milk with non-dairy milk; replacing sugar-sweetened beverages with water).
62785874|NCT03170960|EXPERIMENTAL|Expansion Cohort 3|UC subjects (including bladder, renal pelvis, ureter, urethra) who are ineligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy.
62013888|NCT04229719|EXPERIMENTAL|Melatonin group|Melatonin powder (N-Acetyl-5-methoxytryptamine) 1.2mg topical application in osteotomy site.
62202662|NCT05136053|PLACEBO_COMPARATOR|Part B: Placebo and Immune System Activator|Participants will receive a single IV infusion of placebo matching to Lu AG22515 and an SC injection of immune system activator 14 days prior to and 14 days following the start of placebo IV infusion.
62579412|NCT04391673||Dizzy group|Patients attending the dizziness and balance exercise programme at Guy's Hospital, London. Patients data will be included if they complete at least 4 sessions.
62579413|NCT01355575|EXPERIMENTAL|Rifaximin for 6-weeks followed by 6-week observation period|All patients receiving 6 weeks Rifaximin 400mg twice daily, followed by a 6 week observation period.
62579414|NCT04170738|EXPERIMENTAL|Adderall|dosage = start at 0.25-0.50mg/kg, adjusted as necessary pills by mouth
62579415|NCT02304731|EXPERIMENTAL|Exercise and Pollution Groups|Physical Exercise performed in a clean environment and in a polluted environment.
62785875|NCT03170960|EXPERIMENTAL|Expansion Cohort 4|UC subjects (including bladder, renal pelvis, ureter, urethra) eligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy.
62785876|NCT03170960|EXPERIMENTAL|Expansion Cohort 5|UC subjects (including renal pelvis, ureter, urinary bladder, urethra) who have radiographically progressed on or after one prior immune check-point inhibitor (ICI) (anti-PD1 or anti-PD-L1) therapy.
62785877|NCT03170960|EXPERIMENTAL|Expansion Cohort 6|CRPC subjects who have radiographically progressed in soft tissue on or after enzalutamide and/or abiraterone acetate for metastatic disease.
62013889|NCT04229719|NO_INTERVENTION|Control group|No drug intervention
62013890|NCT02906007|EXPERIMENTAL|Bedaquiline (BDQ)|Participants will receive bedaquiline (BDQ) once a day for 2 weeks. For the next 22 weeks, participants will take BDQ 3 times a week on Monday, Wednesday, and Friday.
62013891|NCT05573516|EXPERIMENTAL|Fixation with 4mm lag screws|
62202663|NCT05136053|EXPERIMENTAL|Part C: Lu AG22515|Participants will receive a single intravenous (IV) infusion of Lu AG22515.
62202664|NCT05136053|PLACEBO_COMPARATOR|Part C: Placebo|Participants will receive a single IV infusion of placebo matching to Lu AG22515.
62785878|NCT03170960|EXPERIMENTAL|Expansion Cohort 7|Stage IV non-squamous NSCLC subjects who have radiographically progressed on or after treatment with one prior immune checkpoint inhibitor (ICI) (anti-PD-1 or anti-PD-L1) therapy.
62785879|NCT03170960|EXPERIMENTAL|Expansion Cohort 8|Stage IV non-squamous NSCLC subjects with positive PD-L1 expression and without prior systemic anticancer therapy.
62785880|NCT03170960|EXPERIMENTAL|Expansion Cohort 9|Stage IV nonsquamous NSCLC subjects with sensitizing EGFR mutation who have radiographically progressed during or following prior treatment with an EGFR-targeting TKI. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
62013892|NCT05573516|ACTIVE_COMPARATOR|Fixation with 4mm fully-threaded positional screws|
62013893|NCT04707235||Sickle cell disease patients treated with Siklos|
62013894|NCT02682420|OTHER|endoAVF|
62013895|NCT01602276|EXPERIMENTAL|Active Stimulation|Transcranial direct current stimulation using Anodal or Cathodal stimulation over the area of interest
62013896|NCT01602276|SHAM_COMPARATOR|Sham Stimulation|Transcranial direct current stimulation (tDCS) that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS.
62013897|NCT01699425|EXPERIMENTAL|Ajust|Experimental group: surgery to treat stress urinary incontinence with the sling Ajust®
62013898|NCT01699425|ACTIVE_COMPARATOR|Classical transobturator tape|Control group: surgery to treat stress urinary incontinence with the Align® sling.
62013899|NCT06227780|EXPERIMENTAL|Fragile X Syndrome|Fragile X Syndrome with full FMR1 mutations (\>200 CGG repeats; at least partial FMR1 gene methylation)
62202665|NCT01640405|ACTIVE_COMPARATOR|Control|modified FOLFOX6 + bevacizumab
62202666|NCT01640405|EXPERIMENTAL|Experimental|FOLFOXIRI+bevacizumab
62579416|NCT04791189||Patients with juvenile rheumatoid arthritis aged from 18 to 45 years|"* Major male or female patient \[18 to 45 years of age\] with juvenile idiopathic arthritis reported before the age of 16.~* - Able to understand and complete the questionnaire online (speaking and reading French, with an internet connection for completion via RedCap°). ¬~* - Able to give informed consent to participate~* - Involving one's parents in the survey is not a prerequisite for inclusion."
62013900|NCT06227780|ACTIVE_COMPARATOR|Autism Spectrum Disorder Controls|Age and sex-matched with FXS cohort
62013901|NCT06227780|ACTIVE_COMPARATOR|Typically Developing Controls|Subjects with neither disorder who have met normal developmental milestones
62013902|NCT04097067|EXPERIMENTAL|Treatment (low-dose radiation therapy)|"Patients undergo low-dose radiation therapy with daily 2 Gy ad 20 Gy (ISRT with IMRT \& IGRT).~Blood draw for biomarker-analysis (at baseline visit/ after 4 Gy/ after 10 Gy / after 20 Gy RT/ at 3 and 6 months after RT)"
62013903|NCT04589585|EXPERIMENTAL|DiVeRt treatment|DiVeRt device to be used in the single arm
62013904|NCT05089734|EXPERIMENTAL|Sacituzumab Govitecan-hziy (SG)|Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle (ie, 2 weekly doses plus 1 week without treatment) until progressive disease (PD), death, unacceptable toxicity, or another treatment discontinuation criterion is met.
62202667|NCT01875029|SHAM_COMPARATOR|sham-tDCS + Back School|"This group will receive sham-tDCS for 5 days before back school beginning. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 30 seconds, with an intensity of 1 milliampere.~The back school session, a behavioural intervention,will be given 10 times for 4 weeks."
62202668|NCT01875029|EXPERIMENTAL|real-tDCS + Back School|"This group will receive continuous stimulation lasting 20 minutes daily, for 5 days before back school beginning. The back school session, a behavioural intervention,will be given 10 times for 4 weeks.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 20 minutes, with an intensity of 1 milliampere."
62202669|NCT00236379|EXPERIMENTAL|001|Risperidone Target oral dose of 6 milligrams per day for for 6 months
62202670|NCT00236379|EXPERIMENTAL|002|Olanzapine Target oral dose of 20 milligrams per day for 6 months
62202671|NCT01013038|ACTIVE_COMPARATOR|Conventional percutaneous coronary intervention|
62202672|NCT01013038|EXPERIMENTAL|Thrombus aspiration|
62202673|NCT01661764|ACTIVE_COMPARATOR|rs174535 (GG), fish oil supplements|Eicosapentanoic acid and docosahexanoic acid
62202674|NCT01661764|PLACEBO_COMPARATOR|rs174535 (GG), placebo|Oleic Acid
62785881|NCT03170960|EXPERIMENTAL|Expansion Cohort 10|RCC subjects with non-clear cell histology who have had up to one prior VEGFR-targeting TKI therapy.
62013905|NCT05089734|ACTIVE_COMPARATOR|Docetaxel|Participants will receive docetaxel 75 mg/m\^2 on Day 1 of a 21-day cycle (ie, once every 3 weeks) until PD, death, unacceptable toxicity, or another treatment discontinuation criterion is met.
62785882|NCT03170960|EXPERIMENTAL|Expansion Cohort 11|TNBC subjects who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
62785883|NCT03170960|EXPERIMENTAL|Expansion Cohort 12|OC subjects (including primary peritoneal cancer and fallopian tube cancer) who have platinum-resistant or refractory disease who have had up to two lines of prior systemic anticancer therapy.
62013906|NCT03405467||lightning accident|patients suffered injuries due to lightning strike
62013907|NCT03405467||frostbite|patients suffered injuries due to local hypothermia leading to frostbite injuries
62013908|NCT03405467||cpr and aed|patients suffered cardiac arrest in alpine region treated with or without automated external defibrillatior
62013909|NCT03405467||flight accident|patients suffered injuries due to use of a flying vehicle in mountainous regions.
62013910|NCT06663826||people with Parkinson's disease|
62013911|NCT06663826||Atypical parkinsonism|
62013912|NCT01603550|EXPERIMENTAL|Energy Restriction|
62013913|NCT01603550|EXPERIMENTAL|Sleep Deprivation|
62785884|NCT03170960|EXPERIMENTAL|Expansion Cohort 13|EC subjects (serous or endometrioid histology) who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy.
62785885|NCT03170960|EXPERIMENTAL|Expansion Cohort 14|HCC subjects (Child-Pugh score A) who have not received prior systemic anticancer therapy.
62202675|NCT01661764|ACTIVE_COMPARATOR|rs174535 (GT), fish oil supplements|Eicosapentanoic acid and docosahexanoic acid
62785886|NCT03170960|EXPERIMENTAL|Expansion Cohort 15|GC/GEJC/LEC subjects who have radiographically progressed during or following platinum-containing or fluoropyrimidine-containing chemotherapy.
62579417|NCT04791189||Parents of patients with juvenile rheumatoid arthritis aged from 18 to 45 years|"Parents of adult patients with JIA~* - Parents able to understand and complete the questionnaire online (speaking and reading French, having an internet connection for completion via Red Cap°).~* - Able to give informed consent to participate~* - The parents must have been in charge of the patient as a teenager."
62013914|NCT02670629|ACTIVE_COMPARATOR|Anatomic Closed Reduction + Short Cast|"Patients in this group were treated by performing a closed anatomic reduction under anesthesia by using sedatives and then placing the child in a short arm cast for 6 weeks. The follow up was done at week 1, 3, 6 and 10 with new X rays in each consult.~The intervention in this control group was performing a closed anatomic reduction under anesthesia."
62013915|NCT02670629|EXPERIMENTAL|Partial reduction overriding position|"Patients in this group were only given oral medications, the fracture was not reduced, instead it was left with a partial reduction with overriding position placed in a short arm cast for 6 weeks. The follow up was done at week 1, 3, 6 and 10 with new X rays in each consult.~The intervention in this control group was not performing a closed anatomic reduction under anesthesia."
62013916|NCT04354831|EXPERIMENTAL|ICU Cohort|Patients who are in the ICU at the time of enrollment. Patients will receive anti-SARS-CoV-2 convalescent plasma.
62579418|NCT02625532|ACTIVE_COMPARATOR|Follicular phase|Controlled ovarian stimulation starts during follicular phase on day 2-3 of the menstrual cycle
62579419|NCT02625532|EXPERIMENTAL|Luteal phase|Controlled ovarian stimulation starts during luteal phase on day 3 to 5 after first LH positive urine test
62579420|NCT03128138|EXPERIMENTAL|25 mg SPH3127 tablet-Dose 1|"6 Volunteers, Single dose of SPH3127 tablet, 25mg, po. 1 tablet.~2 Volunteers, Single dose of Placebo tablet, 25mg, po. 1 tablet."
62579421|NCT03128138|EXPERIMENTAL|50 mg SPH3127 tablet-Dose 2|"6 Volunteers, Single dose of SPH3127 tablet, 50mg, po. 1 tablet.~2 Volunteers, Single dose of Placebo tablet, 50mg, po. 1 tablet."
62579422|NCT03128138|EXPERIMENTAL|100 mg SPH3127 tablet-Dose 3|"6 Volunteers, Single dose of SPH3127 tablet, 100mg, po. 1 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 1 tablet."
62579423|NCT03128138|EXPERIMENTAL|200 mg SPH3127 tablet-Dose 4|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 2 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 2 tablet."
62579424|NCT03128138|EXPERIMENTAL|400 mg SPH3127 tablet-Dose 5|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 4 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 4 tablet."
62579425|NCT03128138|EXPERIMENTAL|800 mg SPH3127 tablet-Dose 6|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 8 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 8 tablet."
62579426|NCT01869205|EXPERIMENTAL|Endobronchial valve:|Endobronchial valve (size 4.0 - 7.0 mm or 5.5 - 8.5 mm) insertion for target bronchi
62579427|NCT00570193|EXPERIMENTAL|I|Combined treatment with verteporfin (Visudyne) and ranibizumab (Lucentis)
62579428|NCT00570193|EXPERIMENTAL|II|Treatment with ranibizumab (Lucentis)
62013917|NCT04354831|EXPERIMENTAL|Non-ICU Cohort|Patients who are NOT in the ICU at the time of enrollment. Patients will receive anti-SARS-CoV-2 convalescent plasma.
62013918|NCT05156229|EXPERIMENTAL|CDK-003|CDK-003 administered subcutaneously every 2 weeks.
62013919|NCT01782677|EXPERIMENTAL|Bilateral Surgical Resection of Carotid Bodies|Patients undergoing Bilateral Surgical Resection of Carotid Bodies.
62579429|NCT04517201|EXPERIMENTAL|AI group|iGMS+iNCDSS group (Artificial intelligence assisted insulin titration system group)
62202676|NCT01661764|PLACEBO_COMPARATOR|rs174535 (GT), placebo|Oleic Acid
62202677|NCT01661764|ACTIVE_COMPARATOR|rs174535 (TT), fish oil supplement|Eicosapentanoic acid and docosahexanoic acid
62202678|NCT01661764|PLACEBO_COMPARATOR|rs174535 (TT), placebo|Oleic Acid
62579430|NCT04517201|ACTIVE_COMPARATOR|Control group|iGMS+routine treatment group (Physicians decided insulin titration group)
62579431|NCT04374695||patients with COVID-19|Patients with positive RT-PCR for SARS-CoV-2, and patients with négative RT-PCR for SARS-CoV-2 but clinical presentation highly suggestive of COVID-19, and typical COVID-19 abnormalities on chest CT-Scan.
62579432|NCT04374695||patients without COVID-19|Patients with négative RT-PCR for SARS-CoV-2 and chest CT-Scan or chest X-ray not suggestive of COVID-19
62785887|NCT03170960|EXPERIMENTAL|Expansion Cohort 16|CRC subjects who have radiographically progressed during or following systemic chemotherapy that contained fluoropyrimidine in combination with oxaliplatin or irinotecan.
62785888|NCT03170960|EXPERIMENTAL|Expansion Cohort 17|H\&N cancer subjects who have radiographically progressed during or following prior platinum-containing chemotherapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
62785889|NCT03170960|EXPERIMENTAL|Expansion Cohort 18|DTC subjects (follicular, papillary, and poorly differentiated histologies) who are radioactive iodine (RAI) refractory or deemed ineligible for treatment with RAI.
62785890|NCT03170960|EXPERIMENTAL|Expansion Cohort 19 (SAC)|UC subjects (including renal pelvis, ureter, urinary bladder, urethra) who have radiographically progressed on or after one prior ICI (anti-PD-1 or anti-PD-L1). Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
62785891|NCT03170960|EXPERIMENTAL|Expansion Cohort 20 (SAC)|Stage IV non-squamous NSCLC subjects who have radiographically progressed on or after treatment with one prior ICI (anti-PD-1 or anti-PD-L1). Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
62202679|NCT02086890|EXPERIMENTAL|Electro-acupuncture|Electro-acupuncture applied to acupoints around the eye and traditional needle acupuncture applied to acupoints throughout the body at 10 half-hour sessions over 2 weeks
62202680|NCT02086890|SHAM_COMPARATOR|Sham Electro-acupuncture|No electro-acupuncture applied to non-acupoints around the eye and traditional needle acupuncture applied to non-acupoints throughout the body; i.e., to locations not on the acupuncture meridians; at 10 half-hour sessions over 2 weeks
62579433|NCT03164278|EXPERIMENTAL|Immediate Training (no follow up)|Individuals may decide to participate in the research study training program, but not in any follow up questionnaires. This group will have immediate access to the independent transfer training materials. They will complete data collection measures embedded in the transfer training program, including demographics, Online Learning Readiness Scale (OLRS), Moorong Self Efficacy Scale (MSES), Patient Reported Outcome Measurement Information System (PROMIS), Transfer Assessment Instrument Questionnaire (TAI-Q), and the Wheelchair User Shoulder Pain Index (WUSPI).
62579434|NCT03164278|EXPERIMENTAL|Immediate Training (with follow up)|Individuals may decide to participate in the research study, but do not want to be randomized. After consent is obtained, these individuals will be directed immediately to the baseline questionnaires (see above) before and after the independent transfer training. Participants may also be asked to complete a user satisfaction survey.
62579435|NCT03164278|EXPERIMENTAL|Randomized Training|Individuals may decide to participate in the research study and agree to be randomized. These individuals will be immediately randomized into an immediate or a wait list control group. The immediate will receive the independent transfer training program after completing the baseline questionnaires. The wait list control group will wait approximately 6 months before receiving the independent transfer training program.
62579436|NCT03551171|EXPERIMENTAL|ZL-2306 (niraparib)|Subjects will be randomised into 100mg, 200mg, 300mg dose group at the first day of the first cycle.
62579437|NCT05162703|EXPERIMENTAL|Intervention group|Participants will be equipped with a spirometer and and the AsthmaTuner mobile phone app to perform an exercise tests in their natural training environment. Feasibility will be evaluated using questionnaires.
62579438|NCT02539927||Controlled|
62579439|NCT02539927||Not controlled|
62579440|NCT02539927||Control status yet to be clarified|
62785892|NCT03170960|EXPERIMENTAL|Expansion Cohort 21 (SAC)|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC. Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
62013920|NCT06498050|EXPERIMENTAL|Brolucizumab 6mg|Brolucizumab 6 mg will be given via intravitreal injections following two treatment patterns: Treatment pattern 1: q6w\*5; Treatment pattern 2: q6w\*3 +q12w\*1
62202681|NCT02086890|EXPERIMENTAL|Laser acupuncture|Laser applied to acupoints throughout the body at 10 sessions each lasting 15 minutes over a 2 week period
62202682|NCT02086890|SHAM_COMPARATOR|Sham Laser acupuncture|An inactive sham laser (red light only) applied to non-acupoints throughout the body; i.e., to locations not on the acupuncture meridians; at 10 sessions each lasting 15 minutes over a 2 week period
62202683|NCT02086890|EXPERIMENTAL|Transcorneal Electrical Stimulation|Transcorneal Electrical Stimulation at 150% individual phosphene threshold applied to both eyes using DTL electrodes at 6 weekly 30 minute sessions
62202684|NCT02086890|SHAM_COMPARATOR|Sham Transcorneal Electrical Stimulation|Sham Transcorneal Electrical Stimulation at 0% individual phosphene threshold (no stimulation) applied to both eyes using DTL electrodes at 6 weekly 30 minute sessions
62202685|NCT02145338|EXPERIMENTAL|Antibiotic prophylaxis|Nitrofurantoin or Trimethoprim or Cefalexin. Daily antibiotic prophylaxis: nitrofurantoin 50 mg (or 100 mg dependent on participant weight), or trimethoprim 100 mg, or cefalexin 250 mg.
62202686|NCT02145338|OTHER|No prophylaxis|The control arm will be a strategy of no prophylaxis. Participants will self-monitor their symptoms as usual and report to their General Practitioner if they develop symptoms and signs suggestive of UTI requiring treatment.
62202687|NCT00767429|EXPERIMENTAL|1|subjects with fall risk
62013921|NCT03754699|EXPERIMENTAL|Patients with a therapeutic educational intervention|Arm 1 : Interventional group: A therapeutic educational intervention is performed following pre-anesthesia assessment
62013922|NCT03754699|ACTIVE_COMPARATOR|Patients without therapeutic educational intervention|Arm 2 : Control group: standard information on pain is performed following pre anesthesia assessment
62013923|NCT01369290||Drug 1|Venlafaxine
62013924|NCT01369290||Drug 2|Bupropion
62013925|NCT01369290||Drug 3|Escitalopram
62013926|NCT01369290||Drug 4|Duloxetine
62013927|NCT01369290||Psychotherapy|Cognitive behaviour therapy
62013928|NCT00132444|ACTIVE_COMPARATOR|1|0.25% gel
62013929|NCT00132444|ACTIVE_COMPARATOR|2|0.1% gel
62013930|NCT00132444|PLACEBO_COMPARATOR|3|
62013931|NCT04420806|ACTIVE_COMPARATOR|HIT-exercise|13 months of high intensity endurance and resistance exercise - 3 months of exercise break
62013932|NCT04420806|SHAM_COMPARATOR|control|no exercise intervention that affect the present study outcomes
62013933|NCT05521893|EXPERIMENTAL|Telemedicine group|
62013934|NCT05521893|ACTIVE_COMPARATOR|Standard care group|
62013935|NCT04771741||Multimodal Pain Pathway|"This group will receive the multimodal pain pathway cocktail of medications. This cocktail includes:~* Tylenol (acetominophen), 1000 mg, every 6 hours as needed for pain~* Ketorolac (Toradol), 10 mg, every 6 hours as needed for pain until post-op day 3~* Mobic (Meloxicam), 15 mg once daily, beginning on post-op day 4~* Flexeril (Cyclobenzaprine), 10 mg every 8 hours as needed for pain~* Pregabalin (Lyrica), 75 mg every 12 hours as needed for pain"
62013936|NCT03156465|EXPERIMENTAL|Hybrid L24 and Standard CI|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
62202688|NCT00484484|EXPERIMENTAL|1|Ketamine
62202689|NCT00484484|EXPERIMENTAL|2|Ketamine
62202690|NCT04167423||Healthy|No thyroid disease in pregnancy defined as plasma TSH (thyrotropin), TPOAb (thyroperoxidase auto antibodies) or FT4 (free thyroxin) out of the ranges proposed by 2014 European Thyroid Association Guideline.
62202691|NCT04167423||hyperthyroidism|Thyroid disease in pregnancy defined as plasma TSH, or FT4 out of the ranges proposed by 2014 European Thyroid Association Guideline.
62202692|NCT04167423||hypothyroidism|Thyroid disease in pregnancy defined as plasma TSH, or FT4 out of the ranges proposed by 2014 European Thyroid Association Guideline.
62403055|NCT02978729|ACTIVE_COMPARATOR|Telephone|Telephone telegenetics counseling: A trained Penn genetic counselor will conduct genotype disclosure visits with the participant via telephone. The participant will be in a private room at the study site. Telephone sessions will utilize a private phone line. The genetic counselor will use standardized disclosure checklist and visual aids for the disclosure session.
62403056|NCT02978729|EXPERIMENTAL|Videoconference|Two-way videoconferencing telegenetics counseling: A trained Penn genetic counselor will conduct genotype disclosure visits with the participant via two-way videoconferencing. The participant will be in a private room at the study site. Videoconferencing sessions will utilize tablets or laptops with web cameras and secure/confidential software for teleconferencing. The genetic counselor will use standardized disclosure checklist and visual aids for the disclosure session.
62403057|NCT00633217|ACTIVE_COMPARATOR|arm 1|
62403058|NCT00633217|EXPERIMENTAL|arm 2|
62579441|NCT01387516|EXPERIMENTAL|Motivational Intervention|Motivational Interviewing (MI) will be a 60-90 minutes individual session.The focus is on establishing rapport and building motivation. The counselor explores youth's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancy, and perceptions of self-efficacy. A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
62579442|NCT01387516|ACTIVE_COMPARATOR|Relaxation Intervention|The Relaxation Therapy intervention is a 60-90 minute individual session. The session encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and as a whole is really a meditation protocol.
62579443|NCT01387516|EXPERIMENTAL|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy (CBT) Intervention is administered during two 90 minute group sessions. The focus is on the interrelationship between thoughts, feelings, and behaviors. It is used to address specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.
62579444|NCT01387516|ACTIVE_COMPARATOR|Self-Help Programming|"Self Help intervention is administered during two 90 minute group sessions. The intervention modules are based on the principles of Nicotine Anonymous (NicA), to provide those who use nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. Elements incorporated in this intervention include the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine."
62013937|NCT03606798|EXPERIMENTAL|Multidisciplinary and personalized care|Personalized care and proposals bring by a team of experts : neurologists ; geriatrician ; psychologist.
62202693|NCT04167423||thyroid autoimmunity|Thyroid disease in pregnancy defined as plasma TPOAb out of the ranges proposed by 2014 European Thyroid Association Guideline.
62013938|NCT03606798|NO_INTERVENTION|Reference care|Standard clinical evaluations of patient with Frontotemporal Lobar Degeneration.
62013939|NCT04214691|EXPERIMENTAL|Treatment Sequence 1: Reference Drug + Test Drug (RT)|Participants will receive 8 hour (H) extended-release (ER) acetaminophen tablet orally in period 1 (Reference) followed by newly formulated acetaminophen tablet orally in period 2 (Test). Each period will be separated by a washout period of at least 7 days.
62013940|NCT04214691|EXPERIMENTAL|Treatment Sequence 2: Test Drug + Reference Drug (TR)|Participants will receive newly formulated acetaminophen tablet orally in period 1 (Test) followed by 8H ER acetaminophen tablet orally in period 2 (Reference). Each period will be separated by a washout period of at least 7 days.
62579445|NCT04781920||Patients having undergone an Anterior Cruciate Ligament (ACL) reconstruction|Patients having undergone an ACL reconstruction will be included.
62579446|NCT05581849|EXPERIMENTAL|Prolonged Nightly Fasting (PNF)|Participants will engage in the PNF (14+ hours a night of fasting and no calorie containing food or beverages) for 8 weeks.
62579447|NCT05581849|ACTIVE_COMPARATOR|Health Education Control (HEC)|Participants in HEC group will receive weekly 15-minute videos (once weekly) focused on non-diet/non-fasting health educational content for 8 weeks.
62579448|NCT04889976|EXPERIMENTAL|Double-active|Active portable transcranial electrical stimulation (ptES) and active internet-based behavioral therapy (iBT).
62579449|NCT04889976|ACTIVE_COMPARATOR|ptES-only|Active portable transcranial electrical stimulation (ptES) and sham internet-based behavioral therapy (iBT).
62013941|NCT00679991|ACTIVE_COMPARATOR|PRT-201|
62013942|NCT00679991|PLACEBO_COMPARATOR|2|
62202694|NCT01770847||Healthy controls|Healthy age matched controls
62202695|NCT01770847||Chronic kidney diease|Chronic kidney disease patients stage 2-4
62202696|NCT03240653||Patients Type III|Stratified response to EnzymeTherapy Substrate Reduction Therapy (expected) Splenectomy (and interactions)
62202697|NCT03240653||Patients Type I|Stratified response to Enzyme Therapy and Substrate Reduction Therapy- Splenectomy (and interactions)
62202698|NCT02833324|EXPERIMENTAL|Fitbit with ambulation reminder alarms|Study participants who are postoperative for colorectal surgery will wear a Fitbit (a wireless activity tracking device) to count steps taken during their postoperative hospitalization. In addition to being educated on the importance of postoperative ambulation, this arm will have 5 alarms every day reminding them to ambulate.
62403059|NCT00220311|EXPERIMENTAL|Arm 1|
62403060|NCT01881711|EXPERIMENTAL|SCMP plus Imaging|SCMP plus Imaging will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery.
62403061|NCT01881711|ACTIVE_COMPARATOR|Imaging Alone|Imaging alone will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery.
62202699|NCT02833324|ACTIVE_COMPARATOR|Fitbit without ambulation reminder alarms|Study participants who are postoperative for colorectal surgery will wear a Fitbit (a wireless activity tracking device) to count steps taken during their postoperative hospitalization. Participants will be educated on the importance of postoperative ambulation but will not have ambulation reminder alarms.
62785893|NCT03170960|EXPERIMENTAL|Expansion Cohort 22 (SAA)|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC. Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
62785894|NCT03170960|EXPERIMENTAL|Expansion Cohort 23|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC
62785895|NCT03170960|EXPERIMENTAL|Expansion Cohort 24|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with at least one NHT and have received docetaxel for mCRPC
62785896|NCT01630291|EXPERIMENTAL|Electrical stimulation|
62785897|NCT05162313|OTHER|all patients undergoing tracheal intubation procedure|"In current practice, the endotracheal intubation procedure includes the systematic use of the capnometer, which is immediately connected to the tube after its insertion by direct laringoscopy. Confirmation of the correct tube positioning is established by color change of the capnometer from violet to yellow. Then, the colorimetric capnometer is usually removed before connecting the endotracheal tube to the flow-sensor of the ventilator.~For the purpose of our study, after the tube insertion the care provider will connect in line both the capnometer and the ventilator flow-sensor to the tracheal tube."
62785898|NCT01248741|EXPERIMENTAL|HDR prostate brachytherapy|An array of 17 gauge steel needles, 20 cm in length, is inserted under Ultrasound (US) guidance into the prostate and advanced to the base of the prostate. A template is used to maintain spacing and parallelism and the needles are individually locked into the template once positioned. A continuously acquired set of US images is obtained for treatment planning purposes. Each needle is connected to a Varisource afterloader and treatment is delivered using a 10 Curie Iridium-192 source. The needles are then removed.
62785899|NCT01657292|EXPERIMENTAL|Oleogel-S10 ointment|Intra-individual comparison. Oleogel-S10 ointment is administered to one randomly assigned wound half.
62785900|NCT01657292|OTHER|Octenilin® wound gel|Intraindividual comparison: The other wound half receives disinfectant Octenilin® wound gel.
62785901|NCT01561053|EXPERIMENTAL|High Albumin + Immunoglobulin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with high dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
62785902|NCT01561053|EXPERIMENTAL|Low Albumin + Immunoglobulin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
62785903|NCT01561053|EXPERIMENTAL|Low Albumin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% (maintenance treatment period)
62785904|NCT01561053|NO_INTERVENTION|Control (sham) group|Simulated plasma exchange procedure
62785905|NCT02431078||ZEB1 high-expression group|Participants with ZEB1 high-expression(ZEB1 expression values\>the ZEB1 cut-off point) in CTCs for gastric cancer will be assigned to this group.The ZEB1 cut-off point was set at the top quartile.Routine comprehensive treatment will be performed.
62202700|NCT03435913|EXPERIMENTAL|Standard PEEP ventilation|During pneumoeperitoneum insufflation the patient is ventilated with 7 ml/kg per ideal body weight, inspiration:expiration (I:E) ratio 1:2, and respiration rate (RR) to maintain EtCO2 at 35-38 mmHg and 5 cmH20 of PEEP at every intra-abdominal pressure (IAP) step (8, 12 and 15 mmHg).
62202701|NCT03435913|EXPERIMENTAL|Matched PEEP Ventilation|"During pneumoeperitoneum insufflation the patient is ventilated with 7 ml/kg per ideal body weight, inspiration:expiration (I:E) ratio 1:2, and respiration rate (RR) to maintain EtCO2 at 35-38 mmHg and a level of PEEP matched to every IAP step (8, 12 and 15 mmHg).~1 mmHg = 1,36 cmH20.~Between the standard and matched PEEP intervention there is a washout period that with a recruitment maneuver to re-establish baseline lung condition."
62202702|NCT04756102||FBS lower than 80|Those pregnant patients with FBS less than 80 mg/dl
62579450|NCT04889976|SHAM_COMPARATOR|Double-sham|Sham portable transcranial electrical stimulation (ptES) and sham internet-based behavioral therapy (iBT).
62785906|NCT02431078||ZEB1 low-expression group|Participants with ZEB1 low-expression(ZEB1 expression values\<the ZEB1 cut-off point) in CTCs for gastric cancer will be assigned to this group.The ZEB1 cut-off point was set at the top quartile.Routine comprehensive treatment will be performed.
62785907|NCT02487862|NO_INTERVENTION|Screening|Participants were screened for the inclusion and exclusion criteria to select the study group. No intervention has been done.
62785908|NCT02487862|PLACEBO_COMPARATOR|catagerizing the study population|The selected participants where assigned into respective groups
62785909|NCT02487862|NO_INTERVENTION|Stress Reduction Protocol|Participants were evaluated for the outcome of the intervention.
62785910|NCT02865902|EXPERIMENTAL|Test Group|In Test group, the free gingival graft donor sites of each experimental group received low-level laser therapy by Ezlase; Biolase® at doses of 8.6 J/cm2.
62202703|NCT04756102||FBS 80-120|Those pregnant patients with FBS between 80-120
62202704|NCT03894072|ACTIVE_COMPARATOR|HFHO-CPAP|This group will have HFHO before CPAP
62202705|NCT03894072|ACTIVE_COMPARATOR|CPAP-HFHO|This group will have CPAP and then HFHO
62202706|NCT05509049|EXPERIMENTAL|Treatment|Behavioral science and reinforcement learning-driven hyper-personalized messages
62202707|NCT05509049|ACTIVE_COMPARATOR|Control|Standard of care message
62202708|NCT02812940|EXPERIMENTAL|Everolimus as part of GvHD prophylaxis after allogeneic SCT|Everolimus from day +5 to day +100
62202709|NCT04224402|OTHER|mFOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion
62403062|NCT01881711|EXPERIMENTAL|SCMP Rule Out for Low Risk Cases|"SCMP results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Negative Predictive Value in ruling out shunt malfunction"
62403063|NCT01881711|ACTIVE_COMPARATOR|Imaging Rule for Low Risk Cases|"Imaging results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Negative Predictive Value in ruling out shunt malfunction"
62403064|NCT01881711|EXPERIMENTAL|SCMP plus Imaging in Uncertain Cases|"SCMP plus imaging results in patients who are admitted for observation results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Positive and Negative Predictive Value"
62202710|NCT02397668|EXPERIMENTAL|CorMatrix Cor TRICUSPID ECM Valve|Tricuspid valve replacement in patients for the surgical management of tricuspid valve disease, including tricuspid valve disease secondary to congenital heart disease. Enrollment will include up to 60 adults subjects and up to 18 pediatric subjects.
62202711|NCT01809860|EXPERIMENTAL|isavuconazole and sirolimus|Single dose of sirolimus on Days 1 and 26, isavuconazole 3 times a day (TID) for 2 days (Days 22 to 23) followed by once a day (QD) for 11 days
62403065|NCT01881711|ACTIVE_COMPARATOR|Imaging alone in Uncertain Cases|"Imaging results in patients who are admitted for observation results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Positive and Negative Predictive Value"
62403066|NCT04904952|ACTIVE_COMPARATOR|Experimental|This arm includes 30 OCD patients receiving SSRIs
62403067|NCT04904952|PLACEBO_COMPARATOR|Control|This arm includes 30 OCD patients receiving SSRIs
62403068|NCT04465591||Myocardial infarction|Recruited patients with STEMI or NSTEMI and elevated Troponin T
62202712|NCT02653612|EXPERIMENTAL|Experimental Arm|This cohort will receive the contrast agent
62202713|NCT03231358|EXPERIMENTAL|Intervention|"Participants randomized to the behavioral intervention called Our Family Our Future. These participants will receive an intervention to prevent sexually transmitted infections (STIs) including HIV, Chlamydia trachomatis and Neisseria gonorrhoeae; sexual risk behavior; and depression onset. This is a behavioral intervention involving adolescent-parent dyads, delivered in a group setting over 3-4 consecutive weeks."
62202714|NCT03231358|NO_INTERVENTION|Control|The control arm will receive usual care (consisting of a packet of existing available brochures on HIV, STIs, mental health including places to access care).
62202715|NCT04819061|ACTIVE_COMPARATOR|Active group|In the group G1 will be administered: tDCS active + dual-task motor training
62202716|NCT04819061|SHAM_COMPARATOR|Sham group|In the group G2 will be administered: tDCS sham + dual-task motor training
62202717|NCT03582800|EXPERIMENTAL|Treated|M0-M6: run-in phase (control) M6-M12: STS treatment phase
62403069|NCT04465591||Myocardial injury|Recruited patients with myocardial injury based on elevated Troponin T and associated with renal failure, severe infection, strenouos exercise, atrial fibrillation, myocarditis, takotsubo cardiomyopathy or other similar conditions
62403070|NCT06190860|OTHER|Control|"Post-extraction sockets will be sutured and left to heal spontaneously with physiological blood clot.~First intervention: intraoral scan and intraoral scan and Cone Beam Computed Tomography in the treated zone. Clinicians will make a post-surgical control to evaluate how healing will be performed Four months after the first Intervention, participants will recall getting a second scan and Cone Beam Computed Tomography in the treated zone. Images will be used for implant treatment planification. Before implant placement, a biopsy (2 mm in diameter) will be taken. The biopsy will be analyzed by Micro-computed tomography and decalcified and included in paraffin for histological sections."
62403071|NCT06190860|EXPERIMENTAL|L-PRF Treatment|Post-extraction sockets will be treated with L-PRF plugs and membranes. First intervention: intraoral scan and intraoral scan and Cone Beam Computed Tomography in the treated zone. Clinicians will make a post-surgical control to evaluate how healing will be performed Four months after the first Intervention, participants will recall getting a second scan and Cone Beam Computed Tomography in the treated zone. Images will be used for implant treatment planification. Before implant placement, a biopsy (2 mm in diameter) will be taken. The biopsy will be analyzed by Micro-computed tomography and decalcified and included in paraffin for histological sections.
62202718|NCT04489290|EXPERIMENTAL|D005 Vaginal Mousse|
62202719|NCT04489290|PLACEBO_COMPARATOR|Placebo|
62202720|NCT02865512|ACTIVE_COMPARATOR|supine position|thoracic epidural catheterization with supine position
62202721|NCT02865512|ACTIVE_COMPARATOR|flexed lateral position|thoracic epidural catheterization with flexed lateral position
62202722|NCT00547014|EXPERIMENTAL|Cohort 1 1mg|
62202723|NCT00547014|EXPERIMENTAL|Cohort 2|
62202724|NCT00547014|EXPERIMENTAL|Cohort 3|
62202725|NCT00547014|EXPERIMENTAL|Cohort 4|
62202726|NCT00547014|EXPERIMENTAL|Cohort 5|
62403072|NCT03808298|EXPERIMENTAL|Treatment Sequence 1: A, B, C|
62202727|NCT02990988||Iron repletion|Subjects participating in the associated study under the Iron Repletion arm will also provide stool collection and answers to questionnaire and diet diary.
62785911|NCT02865902|SHAM_COMPARATOR|Control Group|In Control Group, the low-level laser therapy by Ezlase; Biolase® was performedin a same manner with test group at free gingival graft donor sites. However, no irradiation was occurred because of not pushing the start button.
62013943|NCT03623828|EXPERIMENTAL|Apomorphine treatment|"Treatment by apomorphine hydrochloride subcutaneous infusion 12 hours per day during 30 days: 5-days titration phase (increasing doses from 0 to 4 mg/h), 7 days of maintenance at 4 mg/h and 18 days of maintenance phase with possible increase up to 6 mg/h if well tolerated.~Two days before the initiation of apomorphine, domperidone 20mg t.i.d per os (or via gastric tube) will be initiated to reduce common side effects. It will be maintained at least 7 days before an optional tapering off in the absence of nausea of vomiting."
62013944|NCT03708341|EXPERIMENTAL|Melatonin|Patients will be administered melatonin 5 mg at a fixed time every day during their ICU stay (from day of admission till day of discharge from ICU)
62013945|NCT03708341|PLACEBO_COMPARATOR|Placebo|Patients will be administered a placebo pill that is identical in shape and color to the melatonin pill, at a fixed time every day during their ICU stay
62013946|NCT04975763|EXPERIMENTAL|Soybean Oil|Consumption of study foods each day made with soybean oil
62202728|NCT02990988||Placebo|Subjects participating in the associated study under the Placebo arm will also provide stool collection and answers to questionnaire and diet diary.
62202729|NCT01371292|EXPERIMENTAL|Transformational teaching condition|Teachers allocated to this condition will receive the transformational teaching intervention.
62202730|NCT01371292|ACTIVE_COMPARATOR|Standard practice control condition|Teachers allocated to this condition will not receive the transformational teaching intervention. Instead they will take part in a parallel workshop offered by their respective school board (unrelated to transformational leadership training).
62403073|NCT03808298|EXPERIMENTAL|Treatment Sequence 2: A, C, B|
62403074|NCT03808298|EXPERIMENTAL|Treatment Sequence 3: B, A, C|
62202731|NCT02091206|EXPERIMENTAL|GWP42003-P 5 mg/kg/day Dose|Participants received GWP42003-P 5 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 5 mg/kg/day over 3 days and remained at this dose for the rest of the 21-day treatment period (19 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
62202732|NCT02091206|EXPERIMENTAL|GWP42003-P 10 mg/kg/day Dose|Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the rest of the 21-day treatment period (15 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
62403075|NCT03808298|EXPERIMENTAL|Treatment Sequence 4: B, C, A|
62403076|NCT03808298|EXPERIMENTAL|Treatment Sequence 5: C, A, B|
62403077|NCT03808298|EXPERIMENTAL|Treatment Sequence 6: C, B, A|
62403078|NCT03808298|EXPERIMENTAL|Treatment Sequence 7: A, B, D|
62403079|NCT03808298|EXPERIMENTAL|Treatment Sequence 8: A, D, B|
62403080|NCT03808298|EXPERIMENTAL|Treatment Sequence 9: B, A, D|
62403081|NCT03808298|EXPERIMENTAL|Treatment Sequence 10: B, D, A|
62403082|NCT03808298|EXPERIMENTAL|Treatment Sequence 11: D, A, B|
62013947|NCT04975763|PLACEBO_COMPARATOR|Palm Oil|Consumption of study foods each day made with palm oil
62013948|NCT06573424||combination group|Patients who have been treated with anlotinib + tislelizumab
62013949|NCT06573424||control group|Patients who have been treated with anlotinib monotherapy
62013950|NCT04231435|EXPERIMENTAL|Treatment Administration|"All subjects will receive the following oral doses of IP following an overnight fast in the fixed-sequence below:~* Day 1 (Period 1): 1 × 0.25-mg digoxin tablet, 1 × 10-mg rosuvastatin tablet, and 1 × 1000-mg metformin tablet.~* Day 7 (Period 2): 6 × 100-mg fedratinib capsules PLUS (after approximately 1 hour from the time of fedratinib administration) 1 × 0.25 mg digoxin tablet, 1 × 10-mg rosuvastatin tablet, and 1 × 1000-mg metformin tablet."
62013951|NCT01626976|EXPERIMENTAL|Cohort 1|
62403083|NCT03808298|EXPERIMENTAL|Treatment Sequence 12: D, B, A|
62403084|NCT01636011|EXPERIMENTAL|OMM Treatment|In this group the subjects are given 5 different OMM treatments addressing the thoracic cage.
62403085|NCT01636011|SHAM_COMPARATOR|Light Touch sham|In this group the physician uses the dorsum of his hand to the same areas and for the same time that the OMM treatment arm receives.
62013952|NCT01626976|EXPERIMENTAL|Cohort 2|
62013953|NCT01626976|EXPERIMENTAL|Cohort 3|
62403086|NCT06653582|EXPERIMENTAL|Postural reeducation|They will receive a program of postural reeducation with a home program for 12 weeks.
62785912|NCT04233450||Patient group|
62013954|NCT01626976|EXPERIMENTAL|Cohort 4|
62013955|NCT01626976|EXPERIMENTAL|Cohort 5|
62013956|NCT05081739|EXPERIMENTAL|Prospera Surveillance|Subjects will undergo Prospera testing in accordance with the institution's Control Group EMB surveillance standard of care schedule, which is expected to be approximately every other week months 2 and 3, then monthly through months 4 through 6, then every 1-3 months during months 7 through 12. Prospera test results will be provided to investigators. Prospera cfDNA level \< 0.15 % will be interpreted as negative, and screening EMB will be omitted. EMB will be performed for cfDNA level ≥ 0.15 %. At any time, the clinical team may perform for cause EMB for standard clinical indications (e.g., evidence of graft failure) as per the treating team's discretion.
62403087|NCT06653582|EXPERIMENTAL|Pelvic floor exercises|They will receive a program of pelvic floor exercises with a home program for 12 weeks.
62403088|NCT01347905||Obese women and men|Obese women and men undergoing restrictive bariatric surgery. Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
62013957|NCT05081739|ACTIVE_COMPARATOR|EMB Surveillance|Subjects will undergo surveillance EMB per the institution's standard clinical care, which is expected to be approximately every other week months 2 and 3, then monthly through months 4 through 6, then every 1-3 months during months 7 through 12. At any time, the clinical team may perform for cause EMB for standard clinical indications (e.g., evidence of graft failure) as per the treating team's discretion.
62013958|NCT03985553|OTHER|Parenting Self-Management Program|Participants were provided a Parenting Self -Management Program booklet with the twenty-four fact sheets at the beginning of the four-week program on topics such as adaptive babycare techniques, advocacy in the courts, emergency planning, safety in the community, talking to children about disability, managing pain/fatigue, connecting to other parents with SCI/D, and wheelchair adjustment/management during and after pregnancy. Sessions included topic introduction, participant interaction, goal setting, resource utilization, and program evaluation. Participants were allowed to choose which resources they wanted and what tips to incorporate into their parenting roles. Participants were asked to develop a weekly goal to encourage achievement, allowing individuals to identify what they wanted or decided to do that could be related to parenting directly or indirectly, such as health and wellness goals that gave them more energy or strength to complete parenting tasks.
62013959|NCT02690246||patients with HHT|patients with Hereditary Haemorrhagic Telangiectasia
62013960|NCT02690246||control cohort|indirectly only as a control cohort in questionnaire of affected persons
62202733|NCT02091206|EXPERIMENTAL|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the rest of the 21-day treatment period (11 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
62202734|NCT02091206|PLACEBO_COMPARATOR|Placebo|Participants received placebo (0 mg/mL CBD), volume matched to one of the 3 dose levels (5, 10, or 20 mg/kg/day), administered orally, half in the morning and half in the evening for 21 days. To maintain the blinded aspect of the study, participants titrated the placebo dose over 3 to 11 days according to the matched investigational medicinal product (IMP) group (3, 7, and 11 days for the 5, 10, or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the rest of the 21-day treatment period. The 21-day treatment period was followed by a 10-day taper (10% per day of the matched dose) period.
62202735|NCT04682860|PLACEBO_COMPARATOR|Placebo|In the placebo arm, patients will be slowly injected with 2 ml of normal saline within 30 seconds
62403089|NCT04324814|EXPERIMENTAL|Dose level 1|Subjects will receive a single dose of SHR-1701 at Dose level 1 on Day 1 of each cycle
62403090|NCT04324814|EXPERIMENTAL|Dose level 2|Subjects will receive a single dose of SHR-1701 at Dose level 2 on Day 1 of each cycle
62403091|NCT04324814|EXPERIMENTAL|Dose level 3|Subjects will receive a single dose of SHR-1701 at Dose level 3 on Day 1 of each cycle
62785913|NCT04407741|EXPERIMENTAL|SHR2554+ SHR1701|Drug: SHR2554 recommended dose from phase Ⅰstudy, PO, twice a day, every 3 weeks SHR1701 30mg/kg IV over 30 minutes on day 1, every 3 weeks
62785914|NCT04407741|EXPERIMENTAL|SHR1701|Drug: SHR1701 30mg/kg IV over 30 minutes on day 1, every 3 weeks
62202736|NCT04682860|ACTIVE_COMPARATOR|Hyoscine N butylbromide|In the treatment arm, the patient will be injected intravenously with 1ml 20 mg of Hyoscine butylbromide and 1 ml of normal saline intravenously within 30 seconds.
62202737|NCT05172050|EXPERIMENTAL|Group 1: Raloxifene 60 mg|After an administration of two oral doses in the first day of treatment (one dose in the morning and one dose in the evening, each dose administered with 2 capsules containing 60 mg of the active substance or placebo), a single daily oral dose of raloxifene 60 mg was administered; the treatment was taken by the patients for two weeks.
62403092|NCT04324814|EXPERIMENTAL|Dose level 4|Subjects will receive a single dose of SHR-1701 at Dose level 2 1 on Day 1 and Day 15 of each cycle
62403093|NCT04324814|EXPERIMENTAL|Dose level 5|Subjects will receive a single dose of SHR-1701 at Dose level 3 on Day 1 and Day 15 of each cycle
62403094|NCT04324814|EXPERIMENTAL|Dose expansion 1|Subjects will receive a single dose of SHR-1701 on a selected dose level Day 1 of each cycle
62403095|NCT04324814|EXPERIMENTAL|Dose expansion 2|Subjects will receive a single dose of SHR-1701 on a selected dose level on Day 1 of each cycle
62403096|NCT00796367|PLACEBO_COMPARATOR|Placebo|Placebo
62403097|NCT00796367|EXPERIMENTAL|VI-0521 Mid|7.5 mg phentermine and 46 mg topiramate
62013961|NCT03347994|EXPERIMENTAL|Minnelide 0.40 (Dose Level -1)|"Dose Level -1: 25% decrease from prior dose level~- 0.40 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
62403098|NCT00796367|EXPERIMENTAL|VI-0521 Top|15 mg phentermine and 92 mg topiramate
62785915|NCT03226470|EXPERIMENTAL|T512 group|Subjects will receive suppository with T512 at 2 intervals for one month.
62785916|NCT05346406|ACTIVE_COMPARATOR|Peripherally Inserted Central Catheter|
62785917|NCT05346406|EXPERIMENTAL|Long Peripheral Catheter|
62785918|NCT06435923|EXPERIMENTAL|Darigabat|Participants will receive a single oral dose of darigabat.
62785919|NCT04607811|NO_INTERVENTION|Control arm|Participants will wear the Fitbit device and record their daily step counts during the baseline and 8 week intervention period. Participants will complete study surveys at baseline and the end of the 8 week intervention.
62785920|NCT04607811|EXPERIMENTAL|Gamification arm|Participants will wear the Fitbit device and record their daily step counts during the baseline and 8 week intervention period. Participants will have a weekly step goal they are encouraged to meet. Participants will engage in a social incentive-based gamification based on points and levels that leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. Participants will receive daily feedback for the step counts and weekly feedback for levels. Participants will be asked to identify a support partner, who will receive weekly reports with the the participant's points and levels balance.
62785921|NCT00958646|EXPERIMENTAL|Osteopathic Manipulation|Standardized OMT procedure
62785922|NCT00958646|PLACEBO_COMPARATOR|Placebo|Light touch placebo procedure
62785923|NCT02176239||Gammaplex® IVIg|
62785924|NCT02338700|ACTIVE_COMPARATOR|Control|Patients in this group will be receiving standard treatment according to National Comprehensive Cancer Network (NCCN) guide line
62785925|NCT02338700|EXPERIMENTAL|MV+control|Patients in this group will be receiving both standard treatment according to NCCN guide line and simultaneous injection of mix vaccine (MV)
62785926|NCT03806686|EXPERIMENTAL|Low dose ID93+GLA-SE|Participants will receive 0.5 mL (2 μg ID93 + 5 μg GLA-SE) intramuscular injection (IM) into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
62785927|NCT03806686|EXPERIMENTAL|High dose ID93+GLA-SE|Participants will receive 0.5 mL (10 μg ID93 + 5 μg GLA-SE) IM injection into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
62785928|NCT03806686|PLACEBO_COMPARATOR|Control group|Participants will receive 0.5 mL Placebo (physiological saline) IM injection into deltoid area, three times on 4-week intervals on Days 0, 28, and 56.
62785929|NCT05300789||pT4 colon cancer patients after curative resection|
62785930|NCT05761002|EXPERIMENTAL|treatment group|"All patients will be subjected to:~* A thorough history taking and proper dermatological examination.~* Skin sampling from anogenital wart lesions: skin sterilization followed by injection of local anesthesia at the base of lesions, then the part of wart above skin surface will be removed using shave biopsy technique.~* DNA extraction of skin samples.~* Conventional PCR for low-risk HPV genotypes (6,11) and RT-PCR for high-risk HPV genotypes.~* Intralesional injection of the quadrivalent HPV vaccine (Gardasil) at a dose of 0.5ml, into the largest wart at 4-week intervals until complete clearance is achieved or for a maximum of three sessions."
62785931|NCT04456192|EXPERIMENTAL|Women with Obesity|23 healthy, obese (BMI ≥ 30 kg/m2; waist circumference \> 80) women, aged 34-62, screened at the outpatient clinic of the Department of Internal Medicine, Metabolic Disorders, and Hypertension, University of Medical Sciences, Poznań, Poland were enrolled based on the inclusion criteria and the willingness to participate in the research.
62785932|NCT04456192|ACTIVE_COMPARATOR|Normal-weight Women|"8 healthy, normal-weight (≤ 24.9 and ≥ 18.5 kg/m2) women, aged 34-62 were enrolled to intervention from the announcement.~Random selection for groups was not applicable due to the planned body mass difference in the studied groups."
62785933|NCT03370224|EXPERIMENTAL|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
62785934|NCT03370224|PLACEBO_COMPARATOR|Placebo|The placebo group will receive placebo control memory exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
62013962|NCT03347994|EXPERIMENTAL|Minnelide 0.53 (Dose Level 1)|"Starting Dose Level 1:~* 0.53 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
62403099|NCT01687127|EXPERIMENTAL|Folic acid supplementation|Folic acid will be given orally in form of tablets. A supplement of 1 mg will be taken daily for 12 weeks. Thereafter, a supplement of 5 mg will be taken daily for 12 weeks (i.e., until Week 24). At baseline, Week 12, and Week 24, subjects will receive a 9-hour primed constant infusion of amino acids in saline solution for quantification of kinetics of one-carbon metabolism.
62013963|NCT03347994|EXPERIMENTAL|Minnelide 0.67 (Dose Level 2)|"Dose Level 2: 25% increase from Dose Level 1~- 0.67 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
62403100|NCT01687127|EXPERIMENTAL|5-MTHF supplementation|"The calcium salt of 5-methyltetrahydrofolate (5-MTHF; Brand name Metafolin) will be given orally in form of tablets. A supplement of 1 mg will be taken daily for 12 weeks. Thereafter, a supplement of 5 mg will be taken daily for 12 weeks (i.e., until Week 24). At baseline, Week 12, and Week 24, subjects will receive a 9-hour primed constant infusion of amino acids in saline solution for quantification of kinetics of one-carbon metabolism."
62013964|NCT03347994|EXPERIMENTAL|Minnelide 0.80 (Dose Level 3)|"Dose Level 3: 25% increase from Dose Level 2~- 0.80 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
62013965|NCT00439400|ACTIVE_COMPARATOR|A|
62013966|NCT00439400|PLACEBO_COMPARATOR|B|
62202738|NCT05172050|EXPERIMENTAL|Group 2: Raloxifene 120 mg|After an administration of two oral doses in the first day of treatment (one dose in the morning and one dose in the evening, each dose administered with 2 capsules containing 60 mg of the active substance or placebo), a single daily oral dose of raloxifene 120 mg was administered; the treatment was taken by the patients for two weeks.
62202739|NCT05172050|PLACEBO_COMPARATOR|Group 3: Placebo.|After an administration of two oral doses in the first day of treatment (one dose in the morning and one dose in the evening, each dose administered with 2 capsules containing placebo), a single daily oral dose of placebo (2 capsules guarantee the blinding design) was administered; the treatment was taken by the patients for two weeks.
62403101|NCT04864704|ACTIVE_COMPARATOR|Infraspinatus|Subjects infraspinatus stiffness was measured and observed
62403102|NCT04864704|ACTIVE_COMPARATOR|Erector spinae|Subjects erector spinae stiffness was measured and observed
62403103|NCT04864704|ACTIVE_COMPARATOR|Gastrocnemius|Subjects gastrocnemius stiffness was measured and observed
62403104|NCT02568501|EXPERIMENTAL|Daily feedback|Participants receive daily feedback from wireless glucometers that transmit data on glucose monitoring adherence.
62202740|NCT05824000|EXPERIMENTAL|Eyedrops treatment arm|
62202741|NCT02915419|ACTIVE_COMPARATOR|group A|prp revascularization
62202742|NCT02915419|EXPERIMENTAL|group B|treatment of affected teeth using platelet rich fibrin by applying prf in steril root canal
62215130|NCT02293213|EXPERIMENTAL|Counseling + Contraception Appointment|All participants who receive EMR referral to CTIS because they are taking class D or X medications AND are randomized to counseling + Contraception Appointment will receive: CTIS Counseling, Baseline Questionnaire, Contraception Provision Appointment, 3 Month Follow up Questionnaire, and 6 Month Follow up Questionnaire.
62403105|NCT02568501|EXPERIMENTAL|Daily Feedback, incentives|Participants receive daily feedback from wireless glucometers that transmit data on glucose monitoring adherence. Participants are eligible for a financial incentive if adherent.
62785935|NCT06369116|EXPERIMENTAL|Performance|INSTI HCV Self Test devices are provided to the enrolled participants to conduct the self test using the provided instruction for use (IFU) as they are observed by a healthcare professional. The healthcare professional records observations while the participant is performing the self test and interpret the results. The trained healthcare professional is responsible for verifying the self-test result interpreted by the participant and further running another INSTI HCV Self-test to compare the results.
62785936|NCT06369116|NO_INTERVENTION|Usability and Label Comprehension|Participants are provided a usability and label comprehension questionnaire to score their experience with the INSTI HCV Self Test by referring to the provided Instruction For Use (IFU).
62785937|NCT00565123|EXPERIMENTAL|Group A|Experimental dosage
62785938|NCT00565123|ACTIVE_COMPARATOR|Group B|Classical dosage
62013967|NCT01187589|EXPERIMENTAL|Pulsehaler|Fully operational Pulsehaler, with protocol enabled
62403106|NCT05806658|EXPERIMENTAL|Intervention group|Eligible participants will be randomly assigned to receive usual care with the four-week visual arts-based intervention.
62403107|NCT05806658|NO_INTERVENTION|Control group|Eligible participants will be randomly assigned to receive usual stroke care.
62785939|NCT01635881|EXPERIMENTAL|Emerge|Single arm with investigational Emerge™ 1.20 mm PTCA Dilatation Catheter
62785940|NCT03872856|ACTIVE_COMPARATOR|BP-ICAN|Participants in the BP-ICAN arm will receive a home blood pressure monitor to be used twice daily for 12 months. Participants' home blood pressure measurements will be shared with their provider and participants will receive a series of text messages including topics on the importance of managing hypertension, reminders to measure blood pressure with their device, and motivational messages on diet and exercise.
62013968|NCT01187589|ACTIVE_COMPARATOR|Nebulizer|Deactivated Pulsehaler (protocol disabled), so only the nebulizer is active
62013969|NCT02029924|EXPERIMENTAL|BioChaperone insulin lispro|BioChaperone insulin lispro
62013970|NCT02029924|ACTIVE_COMPARATOR|Humalog®|Humalog®
62013971|NCT05414240|ACTIVE_COMPARATOR|Ibudilast|IBUD at a dosage of 20 mg twice daily for 2 days, with an increase to 50 mg twice daily on day 3. The dosage will remain at 50 mg twice daily through most of the rest of the 6-week treatment period. However, for the last three days of week 6, participants will reduce the dosage gradually to 20 mg twice daily prior to discontinuing it at the end of the treatment period.
62785941|NCT03872856|NO_INTERVENTION|Control|Participants in the control arm will receive care as usual for the treatment of hypertension
62785942|NCT06546852|EXPERIMENTAL|Experimental group|"The experimental group will be informed about the purpose and method of the research and will be informed in writing.~Informed consent was obtained. Patient Tracking Form, which is a data collection tool, The researcher filled out the Fluid Restriction Scale in Hemodialysis Patients through face-to-face interviews with the patients.~The results of the biochemical parameters requested by the physician were recorded. Later Patients will be given a 15-20 minute individual session on fluid restriction in chronic renal failure.~A training and education booklet was provided. At the end of the training, the Fluid Restriction Scale in Hemodialysis Patients was applied to the experimental group as a posttest."
62785943|NCT06546852|NO_INTERVENTION|Control group|As for the control group, Information was given about the purpose and method of the research, and a written Informed consent was obtained. Data collection tools: Patient Follow-up Form, Hemodialysis patients fluid restriction scale The researcher completed it during face-to-face interviews with the patients. At the end of the follow-up period, the hemodialysis patients completed the fluid restriction scale as a final test.
62785944|NCT00437411|EXPERIMENTAL|Workshop|Affective Self Awareness intervention
62785945|NCT00437411|NO_INTERVENTION|Control|Waiting-list control.
62785946|NCT03828851|EXPERIMENTAL|Experimental group|ADL training program.
62785947|NCT03828851|NO_INTERVENTION|Control group|Receive rehabilitation program in the hospital.
62785948|NCT01351961|OTHER|Elderly hypertensive patients with mnemonic subjective|"Elderly hypertensive patients with mnemonic subjective without dementia. Interventions :~blood sampling brain MRI Assessment of cognitive functions brain MRI and TEP cerebral Electrocardiogram and blood pressure Pulse wave velocity Quality of life questionnaire Urine sample Vascular explorations"
62785949|NCT03007602|EXPERIMENTAL|Treatment group: aerobic exercise|The upper extremity aerobic exercise training with an arm ergometer will be performed in the treatment group so that training intensity will be between 60% and 80% of the maximum heart rate, dyspnea perception will be 3-4 according to Modified Borg Scale and fatigue perception will be 5-6 according to Modified Borg Scale, training duration will be a 6-week.
62785950|NCT03007602|NO_INTERVENTION|Control group: deep breathing exercise|Deep breathing exercises combinated with arm movements will be given as a home schedule in the control group. Training duration will be a 6-week.
62785951|NCT03144375|ACTIVE_COMPARATOR|Medical Optimization|Medical treatment and education x 4 months, re- eval at 4 months and possible cross-over to surgery
62785952|NCT03144375|ACTIVE_COMPARATOR|Surgical treatment|Surgical treatment up front
62785953|NCT02481245|EXPERIMENTAL|Bipolar I and Bipolar II Disorder|30 currently depressed patients with DSM-IV bipolar I or bipolar II disorder who are currently taking an adequate dose of an FDA-approved anti-manic medication will receive Bezafibrate treatment.
62202743|NCT00770887||Study participants|This study will enroll 50 English-speaking/literate women at least 18 years of age of any race who have sought contraception with DMPA at the Planned Parenthood of Southwest and Central Florida clinics in Tampa and Fort Myers. Patients who choose to begin DMPA or who have already been using DMPA will be approached regarding voluntary participation in the study. Because DMPA is contraindicated in pregnancy, women with a positive urine pregnancy will not be eligible. Should a woman become pregnant during the study, she will receive no further DMPA injections
62785954|NCT05669872|EXPERIMENTAL|patient blood management group|"1. before surgery (within 2-6 weeks before surgery)~   - 7 ≤ Hb \< 12 g/dL : ferric carboxymaltose 1000mg~2. during surgery~   - In case of hemodynamically unstable, transfusion according to the judgment of the operating surgeon and anesthesiologist~3. after surgery (POD #1)~   * 7 ≤ Hb \< 12 g/dL : ferric carboxymaltose 1000mg~  * Hb \<7 g/dL : pRBC 2 packs transfusion"
62785955|NCT05669872|ACTIVE_COMPARATOR|conventional management group|"1. before surgery (within 2-6 weeks before surgery)~   * 8 ≤ Hb \< 10 g/dL: pRBC 1 pack transfusion~  * Hb \< 8 g/dL: pRBC 2 packs transfusion \* Use of oral iron supplements, EPO, in control patients is permitted. (no IV iron supplements)~2. during surgery~   - In case of hemodynamically unstable, transfusion according to the judgment of the operating surgeon and anesthesiologist~3. after surgery (POD #1)~   * 8 ≤ Hb \< 10 g/dL: pRBC 1 pack transfusion~  * Hb \< 8 g/dL: pRBC 2 packs transfusion \* Use of oral iron supplements, EPO, in control patients is permitted. (no IV iron supplements)"
62013972|NCT05414240|PLACEBO_COMPARATOR|Inactive placebo|Placebo twice daily for 6-week treatment period. Placebo will match active medication in appearance and size.
62013973|NCT03324165|NO_INTERVENTION|Usual Care Arm|Patients randomized to Usual Care Arm will be managed as per current best practice that is based on the individual doctor's discretion.
62785956|NCT03851198|EXPERIMENTAL|Mild Cognitive Impairment patients|Subjects diagnosed with mild cognitive impairment, who will receive the best treatment of clinical practice, will be recruited. They must be more than 60 years old.
62785957|NCT03851198|ACTIVE_COMPARATOR|Healthy Subjects/ Match control|Healthy subjects of the same age as people with mild cognitive impairment.
62785958|NCT04410406|ACTIVE_COMPARATOR|IA (Ivermectin + Albendazole)|Participants will receive one oral dose of Ivermectin (IVM) 200 µg/kg + Albendazole (ABZ) 400 mg (IA) annually for 24 months.
62785959|NCT04410406|ACTIVE_COMPARATOR|MoxA (Moxidectin + Albendazole)|Participants will receive one oral dose of Mox 8 mg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxA at the same dosage.
62785960|NCT04410406|ACTIVE_COMPARATOR|IDA (Ivermectin + Diethylcarbamazine + Albendazole)|Participants will receive one oral dose of IVM 200 µg/kg + Diethylcarbamazine (DEC) 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with IDA at the same dosage.
62013974|NCT03324165|EXPERIMENTAL|Intervention Arm|Patients randomized to Intervention Arm will be managed as per the proposed algorithm, which is based on the computation of Alvarado Score.
62013975|NCT06569043|EXPERIMENTAL|Breakfast Bar|Packaged breakfast bar available in retail stores
62013976|NCT06569043|NO_INTERVENTION|Control|No intervention (i.e., no food provided)
62013977|NCT04982029|EXPERIMENTAL|Cannabidiol 600mg|All subjects will receive 600mg of oral cannabidiol in a double-blind fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL. Following administration, a battery of tests will be conducted to examine reward- and stress-related neurocognitive processes.
62785961|NCT04410406|ACTIVE_COMPARATOR|MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)|Participants will receive one oral dose of Mox 8 mg + DEC 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxDA at the same dosage.
62785962|NCT00625781|EXPERIMENTAL|B2|IGT randomized to treatment
62785963|NCT00625781|NO_INTERVENTION|B1|"IGT randomized to no treatment"
62785964|NCT00635882|EXPERIMENTAL|MF/F MDI 100/10 mcg|
62785965|NCT00635882|EXPERIMENTAL|MF/F MDI 200/10 mcg|
62785966|NCT00635882|EXPERIMENTAL|MF/F MDI 400/10 mcg|
62785967|NCT00635882|EXPERIMENTAL|MF DPI 200 mcg|
62785968|NCT00635882|EXPERIMENTAL|MF MDI 200 mcg|
62785969|NCT00635882|EXPERIMENTAL|Placebo|
62785970|NCT00077324||Surgery + blood and serum collection|"Patients undergo lung resection. Patients also undergo preoperative and postoperative collection of whole blood and serum for proteomic profiling using surface-enhanced laser desorption/ionization-time of flight mass spectrometry. A lung tissue biopsy taken at surgery is also analyzed.~Patients are followed at 60-90 days and then annually for 2-5 years."
62785971|NCT03682913|EXPERIMENTAL|P-CIT protocol|OCD patients who receive the P-CIT intervention.
62202744|NCT05630534|EXPERIMENTAL|Minocycline|This intervention arm will receive oral or intranasal minocycline capsules 100 mg Q12H, first dose 200 mg, start on the fifth day of cerebral hemorrhage, for 14 days
62202745|NCT05630534|PLACEBO_COMPARATOR|Control（starch）|This arm will receive oral or intranasal administration of identically packaged placebo capsules (starch) 100 mg Q12H, first dose 200 mg, start on the fifth day of cerebral hemorrhage, for 14 days
62202746|NCT00479882|EXPERIMENTAL|Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg|After a 2-week placebo run-in, participants will receive MK-0524B (0.9 g/simvastatin 10 mg) for 4 weeks, then MK-0524B 1.8g /20 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 20 mg for 8 weeks.
62202747|NCT00479882|EXPERIMENTAL|Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg|After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 10 mg for 4 weeks, then co-administered MK-0524A 2g +simvastatin 20 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/20 mg combination tablet for 8 weeks.
62202748|NCT00479882|EXPERIMENTAL|Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg|After a 2-week placebo run-in, participants will receive MK-0524B 0.9g/40 mg combination tablet for 4 weeks, then MK-0524B 1.8g /40 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 40 mg for 8 weeks.
62202749|NCT00479882|EXPERIMENTAL|Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg|After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 40 mg for 4 weeks, then co-administration MK-0524A 2g +simvastatin 40 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/40 mg combination tablet for 8 weeks.
62202750|NCT04300465|EXPERIMENTAL|Rheumatoid arthritis - With Partner Group|In this group patients with stable rheumatoid arthritis and their partners both undergo an initial assessment, the 10 week intervention phase and then an end of program assessment together. The intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications.
62785972|NCT03682913|PLACEBO_COMPARATOR|Placebo|OCD patients who don't receive the P-CIT intervention.
62202751|NCT04300465|ACTIVE_COMPARATOR|Rheumatoid arthritis - Without Partner Group|"In this group patients with stable rheumatoid arthritis undergo an initial assessment, the 10 week intervention phase and then the end of program assessment. Their partners attend the initial assessment and the end of program assessment but do not partake in the 10 week intervention phase. During the 10 week period these partners receive usual care from their GP's.~For the patients with rheumatoid arthritis, the 10 week intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications."
62202752|NCT04300465|EXPERIMENTAL|Chronic Kidney Disease - With Partner Group|In this group patients with stable stage 3 or 4 chronic kidney disease and their partners both undergo an initial assessment, the 10 week intervention phase and then an end of program assessment together. The intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications.
62215131|NCT05598073|EXPERIMENTAL|1-hour vinyasa yoga session|Participants will complete a 1-hour vinyasa yoga DVD.
62579451|NCT02516267|NO_INTERVENTION|Control Group|Patients who will discontinue inhibitor-ADP for 5 days before surgery, and must be operated on the first working day after completing the 5 days without the drug. This group will have its aggregability evaluated by platelet function testing (Multiplate ADP®) immediately before the transport to the operating room.
62785973|NCT00119366|EXPERIMENTAL|Dose Level 1: 12 Gy iodine-131 monoclonal antibody BC8|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
62785974|NCT00119366|EXPERIMENTAL|Dose Level 7: 22 Gy iodine-131 monoclonal antibody BC8|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
62202753|NCT04300465|ACTIVE_COMPARATOR|Chronic Kidney Disease - Without Partner Group|"In this group patients with stable stage 3 or 4 chronic kidney disease undergo an initial assessment, the 10 week intervention phase and then the end of program assessment. Their partners attend the initial assessment and the end of program assessment but do not partake in the 10 week intervention phase. During the 10 week period these partners receive usual care from their GP's.~For the patients with chronic kidney disease, the 10 week intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications."
62202754|NCT02440425|EXPERIMENTAL|Combination Therapy|Combination Therapy: Pembrolizumab (experimental use) and Paclitaxel (standard use). All trial treatments will be administered on an outpatient basis. One cycle equals 21 days. The first cycle is 28 days with Pembrolizumab given on day 8 in order to determine paclitaxel tolerance.
62403108|NCT04768881|EXPERIMENTAL|Arm A: Primary resistance to Initial CPI Therapy|Participants will receive a dose of 80 milligrams (mg) selinexor orally once weekly (QW) and a dose of pembrolizumab 400 mg intravenously (IV) once in every six weeks (Q6W), both on Day 1 of a 6-week cycle until progressive disease (PD), intolerable toxicity or withdrawal from the study, whichever occurs first.
62579452|NCT02516267|ACTIVE_COMPARATOR|Intervention Group|Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained\> 46 AU, when they will be immediately released to CABG, to be held on the first working day after release.
62579453|NCT05050617||Acute Pulmonary Embolism|Subjects in this single cohort will undergo point-of-care echocardiography at the time of presentation and subsequent follow up to assess for short term adverse events or complications.
62579454|NCT00667823|EXPERIMENTAL|ACT-064992|ACT-064992
62202755|NCT04515290|EXPERIMENTAL|TSG-01-H|Two tablets of TSG-01 per time.
62202756|NCT04515290|EXPERIMENTAL|TSG-01-L|One tablet of TSG-01 and One tablet of Placebo per time.
62403109|NCT04768881|EXPERIMENTAL|Arm B: Acquired Resistance to Initial CPI Therapy|Participants will receive a dose of 80 mg selinexor orally once weekly (QW) and a dose of pembrolizumab 400 mg IV Q6W, both on Day 1 of a 6-week cycle until PD, intolerable toxicity or withdrawal from the study, whichever occurs first.
62403110|NCT04435431|EXPERIMENTAL|Mesdopetam dose 1|Mesdopetam capsule (mg), dose 1, 1 capsule b.i.d. for 84 days.
62202757|NCT04515290|PLACEBO_COMPARATOR|Control|Two tablets of Placebo per time.
62734810|NCT00023933|EXPERIMENTAL|Treatment (monoclonal antibody)|"Patients receive a tracer dose of iodine I 131 monoclonal antibody CC49-deltaCH2 IV on day 1 and a therapy dose over 30 minutes on day 8.~Cohorts of 3-5 patients receive escalating doses of iodine I 131 monoclonal antibody CC49-deltaCH2 until the MTD is determined. The MTD is defined as the dose at which 3 of 5 patients experience grade 3 or greater toxicity while 0-2 of 5 patients experience reversible grade 4 hematologic toxicity."
62202758|NCT00201877|EXPERIMENTAL|Velcade and Rituximab|"Rituximab 375 mg/m2 IV day 1 of weeks 4, 5, 7, 8, 10, 11, 13, and 14 prior to Velcade™ administration.~Velcade™ 1.3 mg/m2 IV days 1 and 4 of weeks 1, 2, 4, 5, 7, 8, 10, 11, 13, and 14"
62403111|NCT04435431|EXPERIMENTAL|Mesdopetam dose 2|Mesdopetam capsule (mg), dose 2, 1 capsule b.i.d. for 84 days.
62403112|NCT04435431|EXPERIMENTAL|Mesdopetam dose 3|Mesdopetam capsule (mg), dose 3, 1 capsule b.i.d. for 84 days.
62403113|NCT04435431|PLACEBO_COMPARATOR|Placebo|Placebo capsule, 1 capsule b.i.d. for 84 days
62403114|NCT01260064|ACTIVE_COMPARATOR|Open appendectomy|The subjects will have open appendectomy procedure.
62785975|NCT00119366|EXPERIMENTAL|Dose Level 8: 24 Gy iodine-131 monoclonal antibody BC8|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
62785976|NCT00119366|EXPERIMENTAL|Dose Level 9: 26 Gy iodine-131 monoclonal antibody BC8|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
62785977|NCT00119366|EXPERIMENTAL|Dose Level 10: 28 Gy iodine-131 monoclonal antibody BC8|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
62785978|NCT05519007|EXPERIMENTAL|The Next Science treatment|The surgical site will be irrigated with NS prior to closure, which will be suctioned at the end of the treatment time
62785979|NCT05519007|ACTIVE_COMPARATOR|Standard of Care|Saline irrigation
62785980|NCT02792153|EXPERIMENTAL|Estrogen|AN participants receive a course of transdermal estradiol treatment.
62785981|NCT04453189|EXPERIMENTAL|Treatment Sequence: AB(Part 1) followed by C(Part 2-Optional)|Participants will received Treatment A (single dose of JNJ-64417184 in fed condition on Day 1) in period 1 followed by Treatment B (lansoprazole on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5) in period 2 of part 1. There will be a washout period of 7 days between each treatment. Participants will receive Treatment C: optional (famotidine under fasted conditions administered 12 hours before and 12 hours after a single dose of JNJ-64417184 under fed conditions on Day 1) in Part 2, Period 3.
62785982|NCT04453189|EXPERIMENTAL|Treatment Sequence: BA(Part 1) followed by C(Part 2-Optional)|Participants will receive Treatment B in period 1 followed by Treatment A in period 2, Part 1. There will be a washout period of 7 days between each treatment. Participants will receive Treatment C: optional (famotidine under fasted conditions administered 12 hours before and 12 hours after a single dose of JNJ-64417184 under fed conditions on Day 1) in Part 2, Period 3.
62403115|NCT01260064|ACTIVE_COMPARATOR|Metal endoclip|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
62785983|NCT03579810|EXPERIMENTAL|Investigational|"An education intervention was implemented in 5 schools including 516 children, 360 parents and 240 teachers.~The Pedagogical Intervention last two and a half years. In children, the intervention included class activities (1/week) and the use of educational materials for the development of pedagogical activities (posters and educative guide).~In parents included 3 workshops/year (2 hours each) about the areas of the intervention; sending healthy notes (1/month) and celebration of healthy family day (1/year).~In teachers included 3 workshops/year (2 hours each) about the areas of the intervention; planning and realization of pedagogical activities to develop with the students (1/week) and follow-up visits to school (1/month)."
62785984|NCT03579810|ACTIVE_COMPARATOR|Control|"The control group consisted of 4 schools including 354 children, 305 parents and 110 teachers.~The activities in control group last two and a half years. Children received the standard curriculum in health and physical activity of the national Ministry of Education.~In parents and teachers included 3 workshops/year (2 hours each) about the first aid and accident prevention."
62785985|NCT06575374|EXPERIMENTAL|Open label Single arm: Letermovir|Participants will be identified/recruited/screened from the Lymphoma and Stem Cell Transplantation and Cellular Therapy services at MD Anderson Cancer Center.
62785986|NCT01839149|EXPERIMENTAL|TI-001 (intranasal oxytocin)|TI-001 is intranasal oxytocin
62785987|NCT01839149|PLACEBO_COMPARATOR|Placebo|Placebo for TI-001 is the same intranasal formulation without oxytocin
62403116|NCT01260064|ACTIVE_COMPARATOR|Intracorporeal suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
62785988|NCT02176161|EXPERIMENTAL|Surgery - High Risk, Undetectable prostate-specific antigen (PSA)|
62403117|NCT01821131|EXPERIMENTAL|30g ground flaxseed per day|consume 1 muffin containing 30g ground flaxseed every day for 4 weeks
62403118|NCT01821131|EXPERIMENTAL|20g ground flaxseed per day|consume 1 muffin containing 20g ground flaxseed every day for 4 weeks
62403119|NCT01821131|PLACEBO_COMPARATOR|0g ground flaxseed per day|consume 1 muffin containing 0g ground flaxseed every day for 4 weeks
62403120|NCT00103389|ACTIVE_COMPARATOR|docetaxel|treated with docetaxel alone
62403121|NCT00103389|EXPERIMENTAL|PI-88+docetaxel|treated with docetaxel and PI-88
62403122|NCT04132206||ScS patients|Patients will provide two stool samples: one collected the day of inclusion and a second, six months later
62403123|NCT04132206||Healthy subjects|Healthy subjects will provide one stool sample at inclusion.
62403124|NCT00917904|PLACEBO_COMPARATOR|vehicle placebo gel|
62403125|NCT00917904|EXPERIMENTAL|dapivirine gel|
62202759|NCT03461770|NO_INTERVENTION|Control group|Patients will receive anesthesia induction with Sevoflurane using a circular circuit without CPAP. Protective ventilation with 5 cmH20 of positive end-expiratory pressure (PEEP) will be initiated after induction. At the end of surgery, mechanical ventilation will stop allowing spontaneous ventilation. Patients will be extubated without CPAP. Lung ultrasound examinations will be performed at different times-points: before anesthesia induction, during surgery, at the end of surgery and before extubation, and after extubation.
62785989|NCT02176161|EXPERIMENTAL|Radiation - Rising PSA|
62785990|NCT02176161|EXPERIMENTAL|Surgery - Rising PSA|
62785991|NCT04971720|EXPERIMENTAL|Sacubitril/Valsartan Morning Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the morning and a placebo pill in the evening for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
62785992|NCT04971720|EXPERIMENTAL|Sacubitril/Valsartan Evening Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the evening and a placebo pill in the morning for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
62785993|NCT04971720|ACTIVE_COMPARATOR|Valsartan Morning Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the morning and a placebo pill in the evening for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
62785994|NCT04971720|ACTIVE_COMPARATOR|Valsartan Evening Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the evening and a placebo pill in the morning for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
62403126|NCT03796572|EXPERIMENTAL|Infraclavicular Regional Block|This group is given ropivacaine 0.5% up to a max of .5 ml/kg until appropriate ultrasound guided spread is achieved.
62403127|NCT03796572|SHAM_COMPARATOR|Puncture Wound|This group is given the same puncture wound and dressing given to the experimental group.
62403128|NCT04240782|EXPERIMENTAL|Education with Produce Allocations|Participants will attend nutrition education and hands-on cooking classes with weekly produce allocations from a local farm.
62403129|NCT04240782|EXPERIMENTAL|Education only|Participants will attend nutrition education and hands-on cooking classes (with produce coupons provided after intervention).
62403130|NCT04240782|NO_INTERVENTION|Control group|Participants will receive a delayed intervention once the study period is over.
62403131|NCT04911569|EXPERIMENTAL|Cryoneurolysis|All 25 patients will receive cryoneurolysis
62403132|NCT02863588|EXPERIMENTAL|seropositive for Toxoplasma gondii|
62403133|NCT05190094|EXPERIMENTAL|Palbociclib + Aromatase Inhibitors (AI) (Letrozole or Anatrozole)|The participants will receive a combination of: Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os). This combination will continue until progression for an average duration of 2 years.
62403134|NCT06479317|EXPERIMENTAL|HCQ plus DEX group|This group is experiment group. Participants will take DEX every day for consecutive 4 days ( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, take DEX every day for another consecutive 4 days) with HCQ twice a day for 1 year
62215132|NCT05089253|ACTIVE_COMPARATOR|Dry needling|The standard 9- point dry needling technique will be applied for 20 minutes per session 3 times a week for 4 weeks.
62013978|NCT04982029|PLACEBO_COMPARATOR|Placebo|All subjects will receive a matching placebo in a double-blind fashion. Following administration, a battery of tests will be conducted to examine the impact on reward- and stress-related neurocognitive processes.
62403135|NCT06479317|PLACEBO_COMPARATOR|DEX group|This group is control group.Participants will take DEX every day for consecutive 4 days ( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, take DEX every day for another consecutive 4 days)
62785995|NCT04532775|OTHER|group C|"This study was conducted on 100 patients. Patients were divided according to the injected drugs into two equal groups (50 patients each):~1- Group (C): where all patients received through the transforaminal epidural approach 2 ml of bupivacaine (0.5%), 1ml of methylprednisolone (40 mg) and 1 ml of normal saline (0.9 %) with a total volume of 4 ml."
62785996|NCT04532775|OTHER|group M|2- Group (M): where all patients received through the transforaminal epidural approach 2 ml of bupivacaine (0.5%), 1ml of methylprednisolone (40 mg) and 1 ml of preservative free magnesium (200 mg) with a total volume of 4 ml. Methylprednisolone which was used in this study was supplied from E.I.P.I.C.O pharmaceuticals -Egypt under license of UPJOHN s.a Puurs-Belgium (Depo-Medrol). Preservative free magnesium which was used in the study was prepared in McGuff Pharmaceuticals, Inc. Laboratories and supplied in 50 ml vials containing magnesium (200 mg/ml).
62785997|NCT00193180|EXPERIMENTAL|Intervention|All patients in this study received docetaxel 30 mg/m2 weekly for 3 consecutive weeks of each 28-day cycle, along with continuous imatinib mesylate. Initially, imatinib mesylate was given at a dose of 600 mg orally daily, beginning concurrently with the first dose of docetaxel; however, after the first 15 patients were treated it became evident that this imatinib dose was not tolerable, and subsequent patients received imatinib mesylate 400 mg orally daily.
62785998|NCT05419544|EXPERIMENTAL|The intervention group/ Holy Quran Recital|The intervention group, listened to holy Quran recitation for 10 minutes twice a day 4 hours a part (10 am and 2 pm) for 2 consecutive days (usually the 2nd and the 3rd day post-operative) after extubation and gaining alertness. We have chosen Surah Al-Rehman because it is considered as the most rhythmic surah of the Quran and the recitation of Qari Abdul Basit is very soothing and effective as he has recited from the deep of the heart. The listing was by a disposable head phones for an I pad for each hospital.
62785999|NCT05419544|NO_INTERVENTION|The control group/ Usual care by the nurse|The control group received usual care by their nurses.
62786000|NCT00699660|EXPERIMENTAL|CAPS/WHODAS|PTSD assessed using Clinical Assessment of PTSD Symptoms (CAPS) and WHODAS functional impairment structured evidence-based interview
62215133|NCT05089253|ACTIVE_COMPARATOR|kinesio taping|The Kinesio tape will be applied to the participants in supine with the knee in 90 flexions. Two Y-shaped tapes are applied above and below the patella. The tape will be removed after 48 hours after application. The Kinesio tape will be applied 3 times a week for 4 weeks
62403136|NCT01441882|EXPERIMENTAL|Treatment (dasatinib)|Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62786001|NCT00699660|ACTIVE_COMPARATOR|Nonstructured Interview|Usual clinical interview to assess PTSD, without CAPS or WHODAS
62786002|NCT02109809|EXPERIMENTAL|Supportive Care (TLI)|Patients undergo LD-TLI daily for 1-2 days.
62786003|NCT00550381|PLACEBO_COMPARATOR|1|10mg
62786004|NCT00550381|PLACEBO_COMPARATOR|2|20mg
62786005|NCT00550381|PLACEBO_COMPARATOR|3|40mg
61978419|NCT02069366|ACTIVE_COMPARATOR|Dronabinol|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to fMRI scanning and task performance in 40 patients with PTSD, 40 trauma-exposed controls without PTSD (TEC), and 40 non-exposed healthy controls (HC).~Within each of the three groups half of the participants will receive dronabinol and the other half will received placebo to create the following 6 groups:~1. PTSD-dronabinol (20)~2. PTSD-placebo (20)~3. TEC-dronabinol (20)~4. TEC-placebo (20)~5. HC-dronabinol (20)~6. HC-placebo (20)"
62013979|NCT05272852|EXPERIMENTAL|FARAPULSE™ Pulsed Field Ablation System Plus|Ablation using FARAPULSE™ Pulsed Field Ablation System Plus
62215134|NCT06610487|EXPERIMENTAL|Single-dose FT1|A single dose of FT1 will be administered, subcutaneous injection
62013980|NCT02167035|ACTIVE_COMPARATOR|Combigan Two Times Daily (BID)|Combigan 0.2%/0.5% one drop Two Times Daily (BID)
62013981|NCT02167035|ACTIVE_COMPARATOR|Simbrinza Three Times Daily (TID)|Simbrinza 1/0.2% one drop Three Times Daily (TID)
62013982|NCT05943860|EXPERIMENTAL|Pantovigar vegan treatment|
62013983|NCT03799458|ACTIVE_COMPARATOR|Active Stimulation|Active HD-tDCS will be delivered while subjects perform sensory training tasks.
62013984|NCT03799458|SHAM_COMPARATOR|Sham Stimulation|Sham HD-tDCS will be delivered while subjects perform sensory training tasks.
62013985|NCT03799458|NO_INTERVENTION|Imaging Only|40 subjects will undergo initial testing only as a healthy control group.
62013986|NCT04574622|EXPERIMENTAL|Five true ESWT sessions|"A total of five sessions (1x/week) were conducted.~A total of 1,500 pulses were delivered to each gastrocnemius muscle. The energy flux density was constant at 0.1 mJ/mm2 and the repetition frequency was at 4 Hz, with a pressure of 1.5 bars."
62013987|NCT04574622|EXPERIMENTAL|Three true ESWT sessions and two sham ESWT sessions|"A total of three true ESWT (week 1, 3 and 5) and two sham ESWTs in (week 2 and 4) were conducted.~For true ESWT sessions, a total of 1,500 pulses were delivered to each gastrocnemius muscle. The energy flux density was constant at 0.1 mJ/mm2 and the repetition frequency was at 4 Hz, with a pressure of 1.5 bars.~For sham ESWT sessions, a total of 1,500 pulses were delivered to each gastrocnemius muscle with a 1 cm gap between between the probe and subject's skin. The energy flux density was constant at 0.1 mJ/mm2 and the repetition frequency was at 4 Hz, with a pressure of 1.5 bars."
62215135|NCT06610487|PLACEBO_COMPARATOR|Single-dose FT1 Placebo|A single dose of FT1 Placebo will be administered, subcutaneous injection
62579455|NCT02921880|EXPERIMENTAL|Cardiac Rehabilitation|Patients will return to the out-patient clinic at 4 weeks post - TAVR and research consent will be re-affirmed. Patients will be randomised to receive a programme of cardiac rehabilitation or routine care at this point. Patients randomised to receive cardiac rehabilitation will meet the cardiac rehab team and undergo baseline assessment for the programme. This involves recording height, weight, blood pressure, oxygen saturation and heart rate and rhythm. An individualised programme will be established to meet the needs of each patient. The patients will undergo a 6 week programme of cardiac rehab. Patients who are not allocated to the intervention group will not receive a cardiac programme and will have access to the TAVR nurse specialist team as would be usual care.
62579456|NCT02921880|NO_INTERVENTION|Standard of care|15 patients will be randomised to receive a programme of cardiac rehabilitation, and 15 patients will receive standard of care which does not include a routine rehabilitation programme.
62013988|NCT01953484|EXPERIMENTAL|Acute Respiratory Distress Syndrome|Acute hypoxemia, bilateral pulmonary infiltrates and no evidence of primary left atrial hypertension
62013989|NCT01953484|EXPERIMENTAL|Chronic Obstructive Pulmonary Disease|Acute-on-Chronic Respiratory Insufficiency (patients with Chronic Obstructive Pulmonary Disease)
62013990|NCT01953484|EXPERIMENTAL|Bridge to Lung Transplant|Acute-on-Chronic Respiratory Insufficiency (patients awaiting lung transplant)
62013991|NCT03847181||NVAF-patients_1|Adult patients with non-valvular atrial fibrillation (NVAF) and one year health records in the British THIN-database, who have not yet used rivaroxaban, apixaban and warfarin.
62215136|NCT06610487|EXPERIMENTAL|Multiple-dose FT1|FT1 will be administered once weekly for 3 weeks, subcutaneous injection
62579457|NCT00601939|EXPERIMENTAL|Psychoeducational intervention (PEI)|Culturally competent group empowerment psychoeducational treatment (group intervention that is culturally informed and educational in nature)
62579458|NCT00601939|ACTIVE_COMPARATOR|Enhanced Treatment as Usual|Enhanced treatment as usual that includes an adherence protocol (regular care at the hospital plus an adherence protocol)
62579459|NCT05322941|EXPERIMENTAL|AEF0117|The current study tests 3 doses of AEF0117 (1.0, 0.3, and 0.1 mg).AEF0117 capsules ; dose range 0.1 to 1.0mg by mouth, once a day for 12 weeks.
62579460|NCT05322941|PLACEBO_COMPARATOR|Placebo|corn oil capsules once a day for 12 weeks.
62579461|NCT01488383|EXPERIMENTAL|Stevioside capsules 200mg|Capsules of 200mg Stevioside
62579462|NCT01488383|ACTIVE_COMPARATOR|Sodium Saccharin 250 capsules|Capsules of 250mg Saccharin
62786006|NCT00550381|PLACEBO_COMPARATOR|4|80mg
62786007|NCT00550381|PLACEBO_COMPARATOR|5|160mg
62013992|NCT03847181||NVAF-patients_2|Adult patients with non-valvular atrial fibrillation (NVAF) and one year health records in the British THIN-database, who have not yet used rivaroxaban, apixaban and warfarin.
62215137|NCT06610487|PLACEBO_COMPARATOR|Multiple-dose FT1 Placebo|FT1 Placebo will be administered once weekly for 3 weeks, subcutaneous injection
62215138|NCT02828540|EXPERIMENTAL|HT047 High-dose group|three times a day dosing schedule 3 tablets per dose
62579463|NCT03397706|EXPERIMENTAL|Phase 1b Dose Escalation|"VRx-3996 (cohort 1) and valganciclovir~VRx-3996 (cohort 2) and valganciclovir~VRx-3996 (cohort 3) and valganciclovir~VRx-3996 (cohort 4) and valganciclovir~VRx-3996 (cohort 5) and valganciclovir"
62579464|NCT03397706|EXPERIMENTAL|Phase 2 Dose Expansion|VRx-3996 (RP2D: recommended phase 2 dose) and valganciclovir
62579465|NCT03397706|EXPERIMENTAL|PK Cohort|Assessment of VRx-3996 tablet and valganciclovir PK parameters at the RP2D
62579466|NCT02649439|EXPERIMENTAL|A/PROSTVAC treatment|PROSTVAC treatment for 6 months with an additional optional year of maintenance for eligible patients
62786008|NCT00550381|PLACEBO_COMPARATOR|6|240mg
62786009|NCT00550381|PLACEBO_COMPARATOR|7|400mg
62786010|NCT00550381|PLACEBO_COMPARATOR|8|640mg
62013993|NCT03847181||NVAF-patients_3|Adult patients with non-valvular atrial fibrillation (NVAF) and one year health records in the British THIN-database, who have not yet used rivaroxaban, apixaban and warfarin.
62013994|NCT03431194|ACTIVE_COMPARATOR|midodrine group|Patients will receive midodrine tablets
62013995|NCT03431194|PLACEBO_COMPARATOR|placebo group|Patients receive sugary oral tablets therapy
62013996|NCT06175559|EXPERIMENTAL|Healing Town: Embedded Narrative in Interactive Game Design|"The game-based medication intervention game Wanping Town in this study employed a multidisciplinary participatory design approach rooted in narrative theory and behavioral psychology models. The game consists of two perspectives: narrative decision stories and cognitive games. The investigators initially employed participatory design methods to determine the plot and elements within the game, then embedded the conclusions into the therapeutic elements of the game."
62013997|NCT02904252||Study group|Population : The participants are thalassemia patients who regularly visit Hematology Clinic, Department of Medicine, Faculty of Medicine Siriraj Hospital Clinical data, Laboratory data (Blood samples) and Transient elastography data will be collected from all participants, as previously described.
62579467|NCT02649439|EXPERIMENTAL|B/ Delayed PROSTVAC treatment|Surveillance for 6 months followed by PROSTVAC treatment for 6 months with an additional year of maintenance for eligible patients
62579468|NCT03090529|EXPERIMENTAL|Exercise group|The 12-week exercise-training program will include three sessions of aerobic exercise per week
62579469|NCT03090529|NO_INTERVENTION|Control group|The control group will receive usual medical care
62579470|NCT00596687|EXPERIMENTAL|1|Glargine once daily plus glulisine given before meals plus supplemental glulisine for BG \> 140
62579471|NCT00596687|ACTIVE_COMPARATOR|2|Sliding scale regular insulin four-times daily achs.
62579472|NCT05599022|PLACEBO_COMPARATOR|Sham Stimulation|With the coil directed away from the patient, 600 pulses of TcMS will be delivered at minimal energy output.
62786011|NCT00550381|PLACEBO_COMPARATOR|9|960mg
62786012|NCT00550381|PLACEBO_COMPARATOR|10|placebo
62786013|NCT01128192|EXPERIMENTAL|Pasireotide 600 µg sc bid|n=19. Pasireotide 600 µg sc bid
62579473|NCT05599022|ACTIVE_COMPARATOR|Low Frequency TcMS|With the coil directed at the stellate ganglion, 60 minutes of 1Hz stimulation will be delivered targeting the stellate ganglion.
62579474|NCT05599022|ACTIVE_COMPARATOR|Theta Burst Stimulation TcMS|With the coil directed at the stellate ganglion, 600 pulses of continuous theta burst stimulation will be delivered targeting the stellate ganglion.
62786014|NCT01128192|EXPERIMENTAL|Pasireotide 900 µg sc bid|n=19. Pasireotide 900 µg sc bid
62786015|NCT01128192|EXPERIMENTAL|Pasireotide 1200 µg sc bid|n=7. Due to increased severity of gastro-intestinal side effects, this arm was discontinued. These participants were only included in the safety analysis.
62786016|NCT04020497|EXPERIMENTAL|Ensemble + SAU (Support as usual)|The five-session Ensemble program provided to informal caregivers targeted support + SAU
62786017|NCT04020497|ACTIVE_COMPARATOR|SAU (Support as usual)|SAU alone which was chosen as a control condition.
62786018|NCT02567019|EXPERIMENTAL|periodontal diseases|blood samples will be done for patients suffering of periodontal diseases
62786019|NCT02567019|ACTIVE_COMPARATOR|healthy volunteers|blood samples will be done for healthy volunteers
62202760|NCT03461770|EXPERIMENTAL|CPAP group|Patients will receive anesthesia induction using 5 cmH20 of CPAP until the moment of intubation. After induction patients will receive the same protective ventilation than the control group. A lung recruitment maneuver will be applied if these patients present atelectasis during surgery. At the end of surgery, patients will be extubated under the modality of CPAP with 5 cmH20. Lung ultrasound examinations will be performed at different times-points: before anesthesia induction, during surgery, at the end of surgery and before extubation, and after extubation.
62202761|NCT01254552|EXPERIMENTAL|Dotarem and Xenetix 350|
62403137|NCT00227591|EXPERIMENTAL|Treatment (lenalidomide, prednisone)|For courses 1 and 2, patients receive oral lenalidomide once daily and oral prednisone once daily on days 1-28. For course 3, patients receive oral lenalidomide once daily on days 1-28 and oral prednisone once on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Patients with stable or responding disease after course 3 receive oral lenalidomide alone once daily on days 1-28 for courses 4-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62786020|NCT04109326|EXPERIMENTAL|Adapted Physical Activity and Dietetique|tailored PA program associated with individual nutritional counseling whilst hospitalization and at home during the 26-week duration of adjuvant treatment
62202762|NCT03296670|EXPERIMENTAL|alprostadil|alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
62202763|NCT03296670|PLACEBO_COMPARATOR|nitroglycerin|nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
62403138|NCT05071521|ACTIVE_COMPARATOR|Eating disorders prevention|"The Body Project. The Body Project is a dissonance-based eating disorders prevention programme. It is a manualised evidence-based programme that targets eating pathology and body image dissatisfaction in young women. The objective of the programme is to create cognitive dissonance to encourage participants to decrease pursuing ideal-thinness. It includes group discussion, written and behavioural exercises and role-play to achieve cognitive dissonance (Stice, Rohde, \& Shaw, 2013). It involves four group sessions for an hour each in consecutive weeks. At the beginning of each meeting, the facilitator reinforces voluntary commitment. Homework is explained and given at the end of each meeting and reviewed at the beginning of the following meeting.~References:~Stice, E., Rohde, P., Shaw, H. (2013). The body project a dissonance-based eating disorders prevention intervention (updated edition). New York: Oxford University Press."
62579475|NCT04836273|EXPERIMENTAL|120 µg dasiglucagon|Subcutaneous 120 µg dasiglucagon self-administration
62579476|NCT04836273|PLACEBO_COMPARATOR|Placebo|Subcutaneous placebo self-administration
62013998|NCT05046782|EXPERIMENTAL|MRI technique|restriction spectrum imaging (RSI) can detect prostate cancer better than a standard-of-care MRI.
62579477|NCT04500990||Single agent PD-1/PD-L1 inhibitor|Patients will receive single agent PD-1/PD-L1 inhibitor in a predefined group.
62579478|NCT04500990||Combined immunotherapy|Patients will receive combined immunotherapy in a predefined group. PD-1/PD-L1 inhibitor will be combined with target therapy, such as lenvatinib, enrotinib, herceptin et al.
62013999|NCT03898804|EXPERIMENTAL|BCI and FES|Surgical implantation of the device and testing for 13 months with an optional 5 year extension study.
62579479|NCT04398303|EXPERIMENTAL|ACT-20-MSC in ACT-20-CM|Conventional treatment plus ACT-20-MSC in ACT-20-CM administered intravenously
62579480|NCT04398303|EXPERIMENTAL|ACT-20-CM|Conventional treatment plus ACT-20-CM administered intravenously
62579481|NCT04398303|PLACEBO_COMPARATOR|Placebo|Conventional treatment plus placebo (MEM-α) administered intravenously
62579482|NCT03192306|ACTIVE_COMPARATOR|Merlin|glycolic acid and ethanol mixture
62786021|NCT04109326|NO_INTERVENTION|Control|Standard of care
62786022|NCT05464823|OTHER|Molecular Testing|Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.
62202764|NCT00613743|PLACEBO_COMPARATOR|1|D1-D3 receive placebo
62202765|NCT00613743|ACTIVE_COMPARATOR|2|receive D1 D3 morphine
62579483|NCT03192306|PLACEBO_COMPARATOR|Ethanol|
62786023|NCT06583525|EXPERIMENTAL|Intervention|
62786024|NCT04116125|PLACEBO_COMPARATOR|Sentinel lymph node biopsy|Perform conventional sentinel lymph biopsy
62786025|NCT04116125|EXPERIMENTAL|Adjuvant radiation without Sentinel lymph node biopsy|Perform radiotherapy instead of sentinel lymph node biopsy
62786026|NCT02615340|ACTIVE_COMPARATOR|Enteral melatonin 0.5 mg|Melatonin 0.5 mg from the 1mg/mL oral suspension qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration of 0.1 mg/mL; final volume in the oral syringe will be 5 mL)
62786027|NCT02615340|ACTIVE_COMPARATOR|Enteral melatonin 2 mg|Melatonin 2 mg from the 1mg/mL oral suspension qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration 0.4 mg/mL; final volume in the oral syringe will be 5 mL)
62014000|NCT06327126||two-session treatment group|two-session ERCP
62014001|NCT06327126||single-session treatment group|single-session ERCP
62014002|NCT05349669|NO_INTERVENTION|Conventional CPB|Elective cardiopulmonary bypass (CPB) procedures with an expected time \>120 minutes for each extracorporeal procedure.
62202766|NCT02736240|ACTIVE_COMPARATOR|Control Arm|7-valent pneumococcal conjugate vaccine
62202767|NCT02736240|EXPERIMENTAL|Test Arm|13-valent pneumococcal conjugate vaccine
62786028|NCT02615340|PLACEBO_COMPARATOR|Enteral matched placebo|Melatonin 0 mg qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration 0 mg/mL; final volume in the oral syringe will be 5 mL)
62202768|NCT03514277|ACTIVE_COMPARATOR|Local infiltration of EXPAREL and Bupivacaine|
62202769|NCT03514277|ACTIVE_COMPARATOR|Local infiltration of Exparel|
62202770|NCT03514277|ACTIVE_COMPARATOR|Local infiltration of Bupivacaine|
62014003|NCT05349669|EXPERIMENTAL|CPB with Jafron|Elective cardiopulmonary bypass (CPB) procedures with Jafron use with an expected time \>120 minutes for each extracorporealprocedure.
62403139|NCT05071521|SHAM_COMPARATOR|Healthy eating education|"The control group were asked to read educational material in Arabic about healthy nutrition and active lifestyle from the Saudi branch of the World Obesity Federation (Kayl Association for Combatting Obesity, 2021). The material includes information about body mass index; easy ways to measure food units without a scale; benefits of working out; means to adopt healthier daily habits; and healthier food alternatives. The material was chosen because it was designed to be easy to understand by any individual.~References:~Kayl Association for Combatting Obesity. (2021). Kayl association for combatting obesity. Retrieved from https://www.kayl.org.sa"
62202771|NCT05364567|EXPERIMENTAL|Study group|They were treated with phototherapy including 308-nm excimer laser or narrowband ultraviolet B (NB-UVB). They had vitamin D supplementation through the injection of cholecalciferol additionally. The study group with vitamin D deficiency was treated with intramuscular injection of 200,000 IU cholecalciferol (Kwangdong Pharmaceutical Co., Seoul, Korea) once at baseline. Total study period was 6 months and the clinical assessments with checking adverse events were conducted every month.
62202772|NCT05364567|ACTIVE_COMPARATOR|Control group|They were treated with phototherapy including 308-nm excimer laser or narrowband ultraviolet B (NB-UVB). Total study period was 6 months and the clinical assessments with checking adverse events were conducted every month.
62202773|NCT03526653|OTHER|Intervention 1|exercise on an ergometer or motomed in an environment without other visual stimuli
62202774|NCT03526653|OTHER|Intervention 2|exercise on an ergometer or motomed while watching the National Geografics channel on television
62202775|NCT03526653|OTHER|Intervention 3|exercise on an ergometer or motomed with the interactive software program MemoRide with which participants can exercise in real life on a virtual manner
62202776|NCT03526653|NO_INTERVENTION|Control group|Rest during 30 minutes
62403140|NCT04001270||Patients anti leucine rich glioma inactivated-1 encephalitis|Biomarkers from patients with anti-leucine rich glioma inactivated 1 encephalitis (anti LGI1-E) will be studied. This is a non-interventional study involving biological samples (CSF biomarkers) already stored in biobank repositories. All stored samples were collected as part of the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population.
62579484|NCT00984568|EXPERIMENTAL|Top-Hold|Level 1: Infliximab IV 5 mg/kg at Weeks 0, 2, and 6, and every 8 weeks thereafter. Level 2: Infliximab IV 5 mg/kg every 4 weeks. Level 3: Prednisolone induction + AZA 2.0-2.5 mg/kg/day.
62786029|NCT02649894|EXPERIMENTAL|Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)|Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)
62786030|NCT02649894|ACTIVE_COMPARATOR|Approved Uncoated PleurX Indwelling Pleural Catheter|Approved Uncoated PleurX Indwelling Pleural Catheter
61978420|NCT04588792|EXPERIMENTAL|Inhaled Furosemide|40 mg furosemide per dose, given by nebulization (4 mL of 10 mg/mL furosemide in 0.9% saline solution) over 30 mins four times daily (Q6H) for up to 28 days
62014004|NCT06534294|EXPERIMENTAL|GROUP1|Reflexology procedure will applied to patients in calm, quiet patient room with adequate light and in the supine position. For the relaxation of patients 10 minutes of relaxation techniques and stimulation of the reflexology points before reflexology, Reflex therapy was done for each patient for 30 minutes, first for the right foot and then for the left foot (15 minutes each)
62202777|NCT01060839|EXPERIMENTAL|Single session counseling|
62202778|NCT01060839|NO_INTERVENTION|Standard of care|
62579485|NCT00984568|ACTIVE_COMPARATOR|Step-Up|Level 1: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral 5-aminosalicylic acid (5-ASA) 2 g/day. Level 2: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral azathioprine (AZA) at a dose of 2.0-2.5 mg/kg/day. Level 3: Infliximab 5 mg/kg at Weeks 0, 2, and 6 and every 8 weeks thereafter.
62579486|NCT01452893||Type I diabetes|Adult patients with diabetes mellitus type I but normal adrenal function
62202779|NCT04857424||ERCP|Subjects with benign and malignant biliary obstruction who have or will undergo endoscopic retrograde cholangiopancreatography (ERCP)
62202780|NCT04857424||PTBD|Subjects with benign and malignant biliary obstruction who have or will undergo percutaneous trans-hepatic biliary drainage (PTBD).
62202781|NCT03156972|ACTIVE_COMPARATOR|Group a|
62202782|NCT03156972|ACTIVE_COMPARATOR|Group b|
62202783|NCT06533085|ACTIVE_COMPARATOR|Adductor canal block by surgeon|The method described by Pepper et al. was employed \[20\]. Accordingly, the anatomical landmarks were first determined by the surgeon post-implantation. The medial femoral cavity was dissected with finger dissection. The vastus medialis obliquus muscle was dissected laterally. The needle was advanced posterior-superiorly by resting it on the anteromedial aspect of the femur at a 45° angle, approximately four finger breadths (7 cm) proximal to the joint line. It was ensured that the needle was not within an artery, and a 22G 10 cm needle was used to inject 7 ml of 0.5% bupivacaine + 8 ml of 0.9% saline. No additional peri-articular injection was performed
62215139|NCT02828540|EXPERIMENTAL|HT047 Low-dose group|three times a day dosing schedule 3 tablets per dose
62215140|NCT02828540|PLACEBO_COMPARATOR|Placebo|three times a day dosing schedule 3 tablets per dose
62403141|NCT03195270|EXPERIMENTAL|Single Arm|\[18F\]FDG PET/MRI
62403142|NCT04946773||Malignancy Cohort|Patients with hepatic or hepatobiliary malignancy at enrolment
62403143|NCT04946773||Control Cohort|Patients with chronic liver disease but no hepatic or hepatobiliary malignancy at enrolment
62579487|NCT01452893||Addison's disease|Adult patients with Addison's disease
62202784|NCT06533085|ACTIVE_COMPARATOR|Adductor canal block by anesthesiology specialist|The anesthesiologist used an ultrasound-guided technique without a stimulator aid to apply the adductor canal block. While the patient was supine, the leg position was done with a slight external thigh rotation.Our target zone for the adductor canal block was the inner mid-thigh, where the vasoadductor membrane can be seen on the medial border of the vastus medialis muscle and the lateral side of the femoral artery. After ultrasonography visualization of the vasoadductor membrane, the needle was targeted to the membranous structure beside the femoral artery. A mixture of 7 ml 0.5% bupivacaine with 8 ml of %0.9 isotonic saline solution was injected slowly into the particular area as peri-articular filling lateral to the femoral artery was seen
62579488|NCT01452893||Type I diabetes and Addison's disease|Patients suffering from both, diabetes mellitus type I and Addison's disease
62579489|NCT01452893||healthy controls|healthy controls with normal adrenal function and normal glucose regulation
62579490|NCT04728841|EXPERIMENTAL|Treatment group|Arm of GS001
62202785|NCT06533085|ACTIVE_COMPARATOR|Control group|The posterior capsular infiltration analgesia procedure was performed following irrigation procedures before implantation. The PCI procedure involves injecting 20 mL of the PCI cocktail (consisting of 0.2% ropivacaine and 2.0 mg/mL epinephrine) into the posterior aspect of the capsule through the intercondylar space of the femur. The PCI cocktail was prepared by an anesthesiologist who was not a part of the study
62579491|NCT01469130|EXPERIMENTAL|MEK162|"MEK162 will be administered orally once on Day 1 of Cycle 1 and continuously on a BID schedule, starting on Day 2 of Cycle 1 and on Day 1 of subsequent cycles. Each cycle will be 28 days in duration. Dose will be escalated and starting dose is 30 mg. Any doses that are missed should be skipped and should not be replaced or made up during the evening dosing or on a subsequent day, whichever applies.~The prescribed BID doses should be taken 12 ± 2 hrs apart."
62579492|NCT01517763|PLACEBO_COMPARATOR|Conventional CPAP|Fisher \& Paykel HC244™
62579493|NCT01517763|ACTIVE_COMPARATOR|CPAP without Humidification|Fixed pressure ICON™ without ThermoSmart™
62579494|NCT01517763|EXPERIMENTAL|APAP with all technologies|Auto ICON™ with SensAwake™ and ThermoSmart™
62215141|NCT05827861|NO_INTERVENTION|Usual Care|Standard care in which the participant will receive their health screening results using the format used by Health Promotion Board guidelines and a link to a publicly-available website with information on how to manage the risk of heart disease
62579495|NCT01832792|EXPERIMENTAL|Self-help|In this condition, participants complete a self-help intervention with the support of a therapist. This lasts 12 weeks.
62579496|NCT01832792|OTHER|Waiting List|One third of participants will be allocated to a treatment waiting list, after which they will be randomised to one of the other two arms.
62579497|NCT04790461|EXPERIMENTAL|1. experimental group: face to face education+PMR exercise|The education and PMR exercises prepared in line with the face-to-face Roy adaptation model will be applied. In groups of 8-10 people, the first 4 sessions in rehabilitation centers will last for the first 4 sessions, and then PMR exercises will be taught and applied (between the 2nd and the 5th weeks, they will be encouraged to do PGE twice at home). The next 4 weeks will be provided with PMR consultancy (3 times a week application / total 24 sessions of PMR application). PMR exercises will be given a follow-up schedule and the caregivers will be followed up by the caregivers themselves and the researchers.
62579498|NCT04790461|EXPERIMENTAL|2. experimental group: mobile health education + PMR exercise|Access to mobile applications will be provided for 8 weeks, including the Roy adaptation model-based training and PMR exercises, which include video and training presentations prepared by the consultant and researcher, as a power point presentation. PMR exercises will be uploaded to the system by uploading a follow-up schedule to the system, and it will be ensured that the person can follow himself / herself at least 3 times a week (24 sessions in total) and the researchers can follow the participants.
62579499|NCT04790461|EXPERIMENTAL|3rd experimental group: face to face and mobile health education + PMR exercise|4 sessions prepared in line with the Roy adaptation model face to face and held in rehabilitation centers, training in groups of 8-10 people, teaching PMR exercises and installing phone applications that can be accessed for 8 weeks), 8-week intervention including training (enabling them to do progressive relaxation exercises and access to training content) will be provided. . The PMR exercises will be uploaded to the system / given as a printout according to the caregiver's preference, and it will be ensured that the person can follow himself / herself at least 3 times a week (24 sessions in total) and the researchers watch the participant.
62579500|NCT04790461|OTHER|Control group|Without applying any intervention, the post-test YBYKA, ASÖ and SBÇYA scales will be applied in the 10th week of the study. After all the tests for the study are measured and finished, they will be provided with training and relaxation exercises.
62579501|NCT00650247|EXPERIMENTAL|1|Sumatriptan Succinate Tablets 100 mg
62579502|NCT00650247|ACTIVE_COMPARATOR|2|Imitrex® Tablets 100 mg
62579503|NCT03079141|ACTIVE_COMPARATOR|Half-dose photodynamic therapy (PDT)|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment."
62579504|NCT03079141|ACTIVE_COMPARATOR|Oral eplerenone treatment|"Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment."
62579505|NCT06192381|NO_INTERVENTION|traditional health education group (control group)|Traditional health education group (control group) (n = 68) who received health education with the traditional face-to-face method
62579506|NCT06192381|EXPERIMENTAL|web-based health education group (intervention group)|Web-based health education group (intervention group) (n = 68) who received health education with the Web-Based Learning Module (WBL).
62202786|NCT04056988|EXPERIMENTAL|Acute spinal cord injury patients to undergo contrast-enhanced|"Perflutren lipid microsphere preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound.~A hand-held intraoperative ultrasound probe will be used to collect sagittal images of the spinal cord centered above the spinal cord injury. A bolus IV injection of DEFINITY® contrast agent (1.5ml DEFINITY®/8.5ml saline) will be given. Continuous imaging will be obtained to record contrast inflow and washout."
62202787|NCT04151836|EXPERIMENTAL|exercise group|exercise education: A 12-week regimen of home-based walking exercises, include moderate intensity 30 minutes of exercise in week 1-4,40 minutes of exercise in 5-8 weeks,50 minutes in the 9-12 week,three times weekly in three month.We explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. Participants were instructed that the exercises would be effective only if they reached 65%-70% of the target Maximal heart rate(HRmax).
62202788|NCT04151836|NO_INTERVENTION|control group|These participants follows the standard post surgery follow-up consisting of counseling by dietitians, nurses and doctors.
62202789|NCT02084758|ACTIVE_COMPARATOR|Nitrate supplementation|Sodium nitrate solution
62202790|NCT02084758|PLACEBO_COMPARATOR|Placebo supplementation|Sodium chloride solution
62014005|NCT06534294|EXPERIMENTAL|GROUP2|patients carried out breathing exercises AS 3 stages(13), stage one Beginning stage for 5 minutes will ask the patients to Sit , Flatten the shoulders, open the legs, and place your arms at your sides naturally , Close eyes and focus on present feelings , stage two deep breathing stage for 10 minutes Exercises were deep breathing exercises; deep inspiration for 5 seconds and slow prolonged expiration for next 5 seconds, at a rate of 6 breaths/min, rest for one minute after each cycle , then apply the exercises again , end stage ; Close eyes and focus your present feelings, Then Relax the whole body for 5 minutes.
62403144|NCT01225601||Histocytosis|Adult with isolated pulmonary Langerhans cell histiocytosis (pulmonary LCH)
62403145|NCT02659657|EXPERIMENTAL|Interleukin-2 interventions|Patients with standard risk hematologic malignancies undergoing an unmodified haploidentical HCT will be eligible. Once patients achieved neutrophil engraftment will be given IL-2, 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days).
62403146|NCT01729559|EXPERIMENTAL|5000 Units unfractionated Heparin Q 8 hr|Low Dose Unfractionated Heparin (5000 Units) given every eight hours until primary or secondary outcome measure reached, discharge, or \>30 days on trauma service.
62403147|NCT01729559|ACTIVE_COMPARATOR|30mg enoxaparin Q12 hr|Randomly assigned trauma patients to receive Low Molecular Weight Heparin (30mg enoxaparin) given subcutaneously every twelve hours until primary or secondary outcome measure reached, discharge, or \>30 days on trauma service.
62579507|NCT03545685|EXPERIMENTAL|SMART|The subjects in SMART training group will receive add-on SMART intervention for 3 months. Subjects will play cognitive games for 1 hour per day, five days per week. SMART will track game time, resource use, and text messaging information on a daily basis, which allows researchers/clinicians to monitor subjects' daily SMART activities. Daily end-of-day RedPocket incentives will be delivered to subjects' designated account based on their resource use and game time. Top 5 APS subjects who play the game for the most time in a week will be rewarded
62579508|NCT03545685|OTHER|Control group|Participants in this group will serve as control group
62579509|NCT00555815||1|Extended hygiene measures
62579510|NCT00555815||2|Standard hygiene measures
62786031|NCT01487772||Hip-fracture patients|Hip-fracture patients admitted to Orthopaedic Department of Danderyd Hospital
62014006|NCT06534294|EXPERIMENTAL|GROUP3|procedure that will done in reflexology and deep breathing will applied
62014007|NCT06534294|OTHER|GROUP4|In this group: will received only standard care
62014008|NCT06532227||Group control : patient without resistance|control patients with susceptible Aspergillus.
62202791|NCT05155670|EXPERIMENTAL|Robotic therapy|All participants will receive a program of robot-assisted rehabilitation exercises., including passive, active-assisive and active MCP Range-of-Motion Exercises, and active bidigital pinching movements in the transparent mode.
62014009|NCT06532227||Group resistant : patient without resistance|Cases are patients with resistant Aspergillus
62014010|NCT05403827|EXPERIMENTAL|K-161|K-161 Ophthalmic Solution
62202792|NCT02773004|OTHER|EndoPredict (EP)clin testing|Once the patient is registered, the most representative block of the primary tumor from surgery (or 10 paraffin slides) are sent to the central analysis platform for EP clin testing. The EPclin method is based on analysis of tumour genes in combination with the classical prognostic factors of nodal status and tumour size.
62014011|NCT05403827|PLACEBO_COMPARATOR|Placebo|Vehicle Solution
62202793|NCT03912051|EXPERIMENTAL|asymmetric balloon|Asymmetric air filled (max 25 cc, Leur lock syringe) epistaxis balloon
62202794|NCT04756076||Control|age and gender matched controls
62202795|NCT04756076||Pulmonary Hypertension Group|Pulmonary Hypertension Patients with Various Degree of Severity
62403148|NCT06181552||Participants with CVD|"Meeting any of the following:~1. Established coronary heart disease, including previously diagnosed myocardial infarction, previous treatment with coronary intervention or coronary artery bypass grafting, coronary artery stenosis ≥50%, or chest pain with objective evidence of myocardial ischemia (indicated by stress electrocardiogram or stress imaging)~2. Stroke"
62403149|NCT06181552||Participants with high CVD risk|"Participants without CVD, but meeting at least two of the following:~1. Men aged ≥ 60 years old, or women aged ≥ 65 years old;~2. Diabetes;~3. Total cholesterol\>5.2 mmol/L, or LDL-C\>3.4 mmol/L, or HDL-C\<1.0 mmol/L;~4. Currently smoking, defined as daily smoking lasting for 1 year or more."
62786032|NCT04760405|EXPERIMENTAL|Tai Chi Easy Intervention|Tai Chi Easy: TCE is a standardized protocol used in several prior studies. TCE has been manualized and has a formal training program for instructors. The protocol is taught as a series of repeated and simple-to-learn movements. Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.
62202796|NCT05358041||Electromagnetic Navigational Fixed Angle Bronchoscopy with CBCT Guidance|Patient is undergoing electromagnetic navigation bronchoscopy using Medtronic super D version 7 EMN system, peripheral endobronchial ultrasound and Cone Beam CT Guidance using the Philips Azurion 7 C20 FlexMove with Embo Guide and Overlay software to create CT Augmented Fluoroscopy under general anesthesia.
62202797|NCT05358041||Robotic Shape Sensing Bronchoscopy with CBCT Guidance|Patient is undergoing robotic navigation bronchoscopy using IOn robotic platform, peripheral endobronchial ultrasound and Cone Beam CT Guidance using the Philips Azurion 7 C20 FlexMove with Embo Guide and Overlay software to create CT Augmented Fluoroscopy under general anesthesia.
62202798|NCT01310231|ACTIVE_COMPARATOR|Metformin|Metformin plus standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
62403150|NCT01874379|EXPERIMENTAL|Guided Imagery|The therapist will instruct the patient on the Guided Imagery protocol and will provide the patient with headphones and an MP-3 player to use for the guided imagery intervention. The patient will listen to the Guided Imagery for 18min 30 sec.
62403151|NCT01874379|ACTIVE_COMPARATOR|Standard of Care|This group will serve as the control arm
62403152|NCT01874379|EXPERIMENTAL|'M'-Technique®|The 'M'-Technique will be administered to the patient's hands and feet for a total of 18-20 minutes, to be equally divided between extremities used according to limitations as outlined. Any hand or foot that is accessed by an IV will be avoided.
62403153|NCT05018533|EXPERIMENTAL|Cohort 1|TAKC-02 0.15mg Single dose
62403154|NCT05018533|PLACEBO_COMPARATOR|Placebo (to Cohort 1)|
62403155|NCT05018533|EXPERIMENTAL|Cohort 2|TAKC-02 0.5mg Single dose
62403156|NCT05018533|PLACEBO_COMPARATOR|Placebo (to Cohort 2)|
62403157|NCT05018533|EXPERIMENTAL|Cohort 3|TAKC-02 1.5mg Single dose
62014012|NCT05852353|EXPERIMENTAL|Single arm longitudinal assessment|Single arm longitudinal assessment of the feasibility of a digital pediatric bladder health patient education curriculum. The intervention consists of 7 videos that can be viewed over a 4-week time period. Impact on the study objectives will be measured using a longitudinal pre-post intervention study design.
62014013|NCT01896895|EXPERIMENTAL|IncobotulinumtoxinA (Xeomin) 25U per eye|Main Period: one injection session, 25 Units per eye. Open-Label Extension: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
62403158|NCT05018533|PLACEBO_COMPARATOR|Placebo (to Cohort 3)|
62786033|NCT06537674||Group A|The patient received six cycles of neoadjuvant therapy (pyrotinib and trastuzumab purplitol and platinum-based drugs) and underwent radical mastectomy (breast-conserving surgery or total mastectomy) after treatment. After the operation, the doctor will give the corresponding treatment according to the results of the postoperative medical examination
62202799|NCT01310231|PLACEBO_COMPARATOR|Placebo|Placebo and standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
62403159|NCT05018533|EXPERIMENTAL|Cohort 4|TAKC-02 5mg Single dose
62403160|NCT05018533|PLACEBO_COMPARATOR|Placebo (to Cohort 4)|
62403161|NCT05018533|EXPERIMENTAL|Cohort 5|TAKC-02 15mg Single dose
62202800|NCT04483180|PLACEBO_COMPARATOR|Control|Beverage containing a sucrose solution. Same aspect and flavor than the experimental beverages. About 1/4 of participants will start with this beverage first.
62202801|NCT04483180|EXPERIMENTAL|Sucralose / acesulfame K|Beverage containing a blend of sweeteners based on sucralose and acesulfame K. Same aspect and flavour than the control beverage. About 1/4 of participants will start with this beverage first.
62202802|NCT04483180|EXPERIMENTAL|Stevia rebaudioside A / thaumatin|Beverage containing a blend of sweeteners based on stevia rebaudioside A and thaumatin. Same aspect and flavour than the control beverage. About 1/4 of participants will start with this beverage first.
62403162|NCT05018533|PLACEBO_COMPARATOR|Placebo (to Cohort 5)|
62403163|NCT05018533|EXPERIMENTAL|Cohort 6|TAKC-02 Multiple dose (low)
62403164|NCT05018533|PLACEBO_COMPARATOR|Placebo (to Cohort 6)|
62403165|NCT05018533|EXPERIMENTAL|Cohort 7|TAKC-02 Multiple dose (high)
62403166|NCT05018533|PLACEBO_COMPARATOR|Placebo (to Cohort 7)|
62403167|NCT03779373|ACTIVE_COMPARATOR|EV1000 monitoring|This group of patients will receive fluid administration during surgery based on a manual GDFT protocol actually in place in the department using the EV1000 monitoring device (Edwards Lifesciences, Irvine, USA)
62403168|NCT03779373|EXPERIMENTAL|EV1000 monioring with the decision (AFM)|This group of patients will receive fluid administration during surgery based on a novel clinical decision support system for GDFT guidance using the EV1000 monitoring device (Edwards Lifesciences, Irvine, USA)
62403169|NCT01297738|EXPERIMENTAL|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a liquid meal which is high in fat and sugar (Nutridrink®)
62403170|NCT01297738|EXPERIMENTAL|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume this caloric surplus with their meals, which results in an increase in meal size.
62403171|NCT01297738|EXPERIMENTAL|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a liquid meal which has a high fat and sugar content(Nutridrink®). Subjects consume the Nutridrink 3 times a day in between meals. which results in an increase in meal frequency.
62403172|NCT01297738|EXPERIMENTAL|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
62403173|NCT01297738|NO_INTERVENTION|Control group|Subjects will not follow any diet but their own ad-libitum, healty diet.
62579511|NCT05923619|EXPERIMENTAL|Total pulpotomy|The coronal pulp tissue was completely removed with a high-speed sterile carbide bur under abundant water coolant. A cotton pellet moistened with 2.5% sodium hypochlorite was used to achieve hemostasis. Following the achievement of hemostasis, an average of 3 mm thick MTA material (Angelus, Londrina, PR, Brazil) was used to cover the pulp chamber. In the same session, the pulp chamber was closed with approximately 2 mm thick flowable glass ionomer cement (Glass Liner, WP), and coronal restoration was completed with composite filling (Estelıte® Sıgma Quıck, Tokuyama).
62734811|NCT04519216|ACTIVE_COMPARATOR|Traditional education|Participants in the control group will complete an online unfolding case scenario. Then these same participants will participate in a videoconferencing case based lecture with the academic pediatric fellow
62014014|NCT01896895|EXPERIMENTAL|IncobotulinumtoxinA (Xeomin) 12.5U per eye|Main Period: one injection session, 12.5 Units per eye. Open-Label Extension Period: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
62014015|NCT01896895|PLACEBO_COMPARATOR|Placebo|"Main Period: Placebo to IncobotulinumtoxinA (Xeomin)(12.5 or 25U/eye), one injection session.~Open-Label Extension: IncobotulinumtoxinA (Xeomin), one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection."
62014016|NCT05609097|EXPERIMENTAL|PRIME + COMBO|PRIME training (Phase 1), followed by 8 weeks of progressive whole-body COMBO training.
62202803|NCT04483180|EXPERIMENTAL|Mogroside V / stevia rebaudioside M|Beverage containing a blend of sweeteners based on mogroside V and stevia rebaudioside M. Same aspect and flavour than the control beverage. About 1/4 of participants will start with this beverage first.
62202804|NCT02985840|ACTIVE_COMPARATOR|Ondansetron|Ondansetron (4 mg) followed by two 5 ml normal saline flush
62202805|NCT02985840|EXPERIMENTAL|Ondansetron plus dexamethasone|Ondansetron (4 mg), followed by dexamethasone (4 mg), followed by a single 5 ml normal saline flush
62202806|NCT04709289|EXPERIMENTAL|Conventional Photodynamic Therapy(C-PDT) group|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 140 J/cm2) after applying 5% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once every two weeks for 3 times.
62202807|NCT05645601|EXPERIMENTAL|CD19 CAR-NK(JD010)|CD19-CAR-NK is an allogenic CD19-Targeted chimeric antigen receptor NK-cell (CAR-NK) therapy.
62202808|NCT03451019|ACTIVE_COMPARATOR|sevelamer hydrochloride|the subject receive a single dose of 2,4 g
62202809|NCT03451019|ACTIVE_COMPARATOR|lanthanum carbonate|the subject receive a single dose of 1.0 g
62403174|NCT06091176|EXPERIMENTAL|Arm 1|Subjects assigned to ID1 treatment arm will receive Amicomed® for 90 days, together with Usual Care (UC) procedures.
62403175|NCT06091176|PLACEBO_COMPARATOR|Arm 2|Subjects assigned to ID2 treatment arm, will receive a digital Placebo, together with UC for 90 days.
62403176|NCT06045910|EXPERIMENTAL|Safety Lead-In Phase|
62403177|NCT06045910|EXPERIMENTAL|Dose Expansion Phase|
62403178|NCT05002738|EXPERIMENTAL|Overall Cohort|Combined oral contraceptive pill containing 0.15mg desogestrel and 0.03mg ethinyl estradiol for 21 days
62403179|NCT00790270|ACTIVE_COMPARATOR|Cyclobenzaprine|
62403180|NCT00790270|ACTIVE_COMPARATOR|Ibuprofen|
62403181|NCT00790270|EXPERIMENTAL|Ibuprophen plus Cyclobenzaprine|
62014017|NCT05609097|OTHER|COMBO only|4 weeks of standard progressive whole-body aerobic plus resistance training (COMBO) followed by 8 weeks continued COMBO training.
62403182|NCT01477541|EXPERIMENTAL|PM/ON integration arm|Health centers where professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
62403183|NCT01477541|NO_INTERVENTION|Control|
62014018|NCT03205085|EXPERIMENTAL|CTEPH PATIENTS|Patients undergoing pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
62014019|NCT03205085|EXPERIMENTAL|PAH PATIENTS|patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation
62014020|NCT02252289||Problematic severe asthmatics|"Approximately 75 Children aged 5 to 17 years with problematic severe asthma (PSA). Two groups of PSA children will be recruited: those who have already been assessed as part of the Difficult Asthma protocol and classified as DA (difficult asthma)/ STRA (severe therapy resistant asthma) (training set) and those newly referred to the protocol (validation set).~Previous enrolment or new referral to the Royal Brompton Hospital Difficult Asthma Protocol."
62403184|NCT03686085|EXPERIMENTAL|dinoprostone arm|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
62403185|NCT03686085|PLACEBO_COMPARATOR|placebo|one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
62403186|NCT01965600|EXPERIMENTAL|Cohort 1|
62202810|NCT02801695|EXPERIMENTAL|L-Citrulline|Bolus (9g) after patient stabilization, then 3g 3 times a day until delivery
62202811|NCT02801695|PLACEBO_COMPARATOR|Lactose|Bolus (9g) after patient stabilization, then 3g 3 times a day until delivery
62202812|NCT04536129|EXPERIMENTAL|Group A: glaucoma|OSD patients with glaucoma
62202813|NCT04536129|ACTIVE_COMPARATOR|Group B: no glaucoma|OSD patients without glaucoma
62202814|NCT04922229|ACTIVE_COMPARATOR|Root canal treatment (RCT)|For cases with this diagnosis RCT is the standard of care and will be done according to clinically approved protocols
62403187|NCT01965600|EXPERIMENTAL|Cohort 2|
62403188|NCT03878108|ACTIVE_COMPARATOR|LCHF diet then LFHC diet|Low carbohydrate, high fat (LCHF) diet then low fat, high carbohydrate diet (LFHC) diet
62403189|NCT03878108|ACTIVE_COMPARATOR|LFHC diet then LCHF diet|Low fat, high carbohydrate diet (LFHC) diet then low carbohydrate, high fat (LCHF) diet
62403190|NCT03233009|EXPERIMENTAL|Test Product 1|Participants will topically apply test product 1 via semi occlusive patch.
62403191|NCT03233009|EXPERIMENTAL|Test Product 2|Participants will topically apply test product 2 via semi occlusive patch.
62579512|NCT05923619|ACTIVE_COMPARATOR|Root canal treatment|The working length was determined using a 15 K type file and apex locator (Morita Root ZX, Tokyo, Japan) and checked by radiography. The chemomechanical preparation was completed using the R25 (Resiproc, VDW, Munich, Germany) file in the mesial root canals and the R25, R40, and R50 files in the distal root canals, respectively, at the WL. During the chemomechanical preparation, the root canals were irrigated with 2.5% NaOCl after every three pecking motions; and total volume of NaOCl was 10 ml. In the final irrigation, the root canal was irrigated with 5 ml 17% Ethylene diamine tetraacetic acid (EDTA), for 1 minute, following with 2 ml distilled water. Following the retention of 5 ml of 2.5% NaOCl in the root canal for 1 minute, 5 ml of distilled used to neutralize the effect of NaOCl in the root canal.Tthe root canals were filled with the lateral condensation using epoxy-resin-based sealer (AH Plus, Dentsply DeTrey GmbH, Konstanz, Germany).
62579513|NCT02618603|EXPERIMENTAL|BoNT-A treatment group|Ultrasound guided sub-acromial bursa injection with BoNT-A (100 u);
62579514|NCT02618603|ACTIVE_COMPARATOR|Triamcinolone acetonide treatment group|Ultrasound guided sub-acromial bursa injection with Triamcinolone acetonide (40mg)+1% Lidocaine 2 ml;
62579515|NCT01483963|EXPERIMENTAL|AA4500 0.29 mg/1 mL|Up to three injections
62579516|NCT01483963|EXPERIMENTAL|AA4500 0.58 mg/2 mL|Up to three injections
62579517|NCT01483963|EXPERIMENTAL|AA4500 0.58 mg/1 mL|Up to three injections
62579518|NCT01483963|EXPERIMENTAL|AA4500 0.58 mg/0.5 mL|Up to three injections
62579519|NCT01483963|OTHER|Shoulder exercises|Home shoulder exercises for 64 days
62579520|NCT05736640|ACTIVE_COMPARATOR|Denosumab|
62579521|NCT05736640|PLACEBO_COMPARATOR|Placebo|
62579522|NCT02349932||Healthy Adults|The following samples will be collected: fecal, blood, and saliva
62579523|NCT02013141|EXPERIMENTAL|Telavancin|Telavancin 10 mg/kg IV administered over approximately 60 minutes one time.
62014021|NCT02252289||Control group of moderate asthmatics|A control group of 30 children aged 5 to 17 years with mild to moderate asthma.
62403192|NCT03233009|EXPERIMENTAL|Test Product 3|Participants will topically apply test product 3 via semi occlusive patch.
62403193|NCT03233009|EXPERIMENTAL|Test Product 4|Participants will topically apply test product 4 via semi occlusive patch.
62403194|NCT03233009|SHAM_COMPARATOR|Reference Product|Participants will topically apply Reference product via semi occlusive patch.
62403195|NCT04249908|ACTIVE_COMPARATOR|Healthy Subjects|
62403196|NCT04249908|EXPERIMENTAL|Mild Renal Impairment (RI)|
62403197|NCT04249908|EXPERIMENTAL|Moderate RI|
62403198|NCT04249908|EXPERIMENTAL|Severe RI|
62403199|NCT03444129|ACTIVE_COMPARATOR|Control|This group will participate in a health education workshop with weekly sessions (control group)
62403200|NCT03444129|EXPERIMENTAL|Game|This group will participate in the health education workshop plus the interactive health game (intervention group).
62403201|NCT05174208||CD|
62403202|NCT02821546|PLACEBO_COMPARATOR|standard hydration|Patients underwent first-time ERCP to receive standard fluid hydration with Lactated Ringer's solution at a rate calculated by the Holliday-Segar method given peri-procedurally starting 2 hours prior to procedure, and continued during and after procedure to complete 24 hours.
62579524|NCT01221272|EXPERIMENTAL|Ranolazine/Placebo|Participants received ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.
62579525|NCT01221272|EXPERIMENTAL|Placebo/Ranolazine|Participants received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.
62579526|NCT04414020|NO_INTERVENTION|Control|Control group receiving conventional treatment without progesterone
62579527|NCT04414020|ACTIVE_COMPARATOR|progesterone group|1mg pregesterone intramusculer given 7 days pre and post operative , Biopsy was achieved from brain tumor interface
62579528|NCT01557374|ACTIVE_COMPARATOR|Maintenance Tocilizumab, Abatacept|No modification in biotherapy dose and administration frequency
62579529|NCT01557374|EXPERIMENTAL|Decrease Tocilizumab, Abatacept|Progressive decrease by predetermined pattern. Progressive injection interval increase (by stage)
62579530|NCT01570361|EXPERIMENTAL|Catheter Ablation|Radiofrequency catheter ablation treatment in subjects with Paroxysmal Atrial Fibrillation (PAF)
62215142|NCT05827861|EXPERIMENTAL|HeartAge only|Participants will be directed to HeartAge, a risk assessment tool available online. Then, they will be directed to a publicly-available website with information on how to manage the risk of heart disease
62403203|NCT02821546|ACTIVE_COMPARATOR|aggressive hydration|Patients underwent first-time ERCP to receive aggressive fluid hydration with Lactated Ringer's solution at a rate of 150 ml/hr starting 2 hours prior to procedure, and continued during and after procedure to complete 24 hours.
62403204|NCT02189538|EXPERIMENTAL|ω-3 PUFA|Modular low fat diet (18%) including 9% as ω-3 PUFA
62403205|NCT02189538|ACTIVE_COMPARATOR|Low fat enteral diet|Modular low fat (18%)
62579531|NCT01570361|ACTIVE_COMPARATOR|Drug Treatment|Drug therapy (either rate or rhythm control) using current AF management guidelines
62579532|NCT04359940||Repaired Tetralogy of Fallot|Patients undergoing routine clinical aand CMR surveillance
62579533|NCT01213784|EXPERIMENTAL|optimized diabetic control|each participant will be assigned to be optimized in a dedicated diabetic clinic
62579534|NCT01213784|NO_INTERVENTION|control|participants will be assigned to follow what ever control they were in before the study and not to change any antidiabetic treatment during the interventions period.
62579535|NCT01800929|EXPERIMENTAL|N6|The N6 system comprises an investigational sound processor, remote assistant and fitting software
62014022|NCT06280313||Treatment (Splenectomy+Targeted therapy+ Immunotherapy)|Eligible patients with unresectable hepatocellular carcinoma accompanied by cirrhotic portal hypertension were enrolled in the trial, and all participants underwent either open or laparoscopic splenectomy, with or without devascularization around the cardia. Starting two weeks post-surgery, patients began intravenous infusion of PD-1 monoclonal antibody, Tislelizumab, at a dosage of 200mg every three weeks. Three weeks post-surgery, patients commenced oral administration of the targeted therapy, Lenvatinib, with a dosage based on body weight: 8mg (≤60kg) or 12mg (\>60kg), once daily.
62014023|NCT01110239|EXPERIMENTAL|remote limb preconditioning|Subjects with subarachnoid hemorrhage will undergo escalating times of limb ischemia to determine tolerability and safety. The leg will be made transiently ischemic with application of a blood pressure cuff for up to 3 cycles of 10 minutes.
62014024|NCT01075659|EXPERIMENTAL|LHN1548|Two single doses of an experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
62202815|NCT04922229|EXPERIMENTAL|Pulpotomy|Pulpotomy with tricalcium silicates has shown high clinical success in these cases. However, it is not known how this success compares to RCT under similar conditions and with an intent-to-treat study design, which will be employed here.
62202816|NCT00819702|EXPERIMENTAL|Model Care|The Model Care approach was implemented in 7 practices, where PCPs were trained to address major risk factors for CM, including maternal depression, alcohol/substance abuse, intimate partner violence, food insecurity, harsh punishment and major stress. We taught how they can be briefly assessed and initially addressed. The initial training consisted of one 4-hour in-person session. Use of the Parent Screening Questionnaire (PSQ) was discussed, as was the importance of applying it universally during regular checkups. PCPs SEEK Parent Handouts on each targeted problem. We held 1-hour booster sessions every 6 months over the subsequent 2.5 years.
62202817|NCT00819702|NO_INTERVENTION|Standard Care|PCPs in Standard Care group served as the controls. They continued to practice as usual.
62202818|NCT04243746|EXPERIMENTAL|Time Restricted Feeding +Standard Malaysian Healthy Plate(QQH)|Subjects practise time restricted feeding (TRF) in addition to the Standard Malaysian Healthy Plate (QQH).
62202819|NCT04243746|ACTIVE_COMPARATOR|Standard Malaysian Healthy Plate (QQH)|Subjects practise the QQH dietary plan.
62202820|NCT00807339|EXPERIMENTAL|1|Phase I dose escalation
62202821|NCT01555177||Peri-operative NSTEMI patients|Patients with POMI undergoing cardiac catheterization within 72 hours of first troponin elevation and within 2 weeks of their non-cardiac surgery.
62579536|NCT01800929|ACTIVE_COMPARATOR|N5|The current commercially-available cochlear implant system Performance of N5 will be compared to performance with N6 using a within-subject design.
62014025|NCT01075659|ACTIVE_COMPARATOR|2019706|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
62014026|NCT01075659|ACTIVE_COMPARATOR|2020005|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
62202822|NCT01555177||Non-surgery related NSTEMI patients|Patients with NSTEMI undergoing cardiac catheterization within 72 hours of symptom onset.
62202823|NCT04098562|EXPERIMENTAL|Treatment|0.5 mg/mL LL-37 cream, administered twice a week for 4 weeks
61978421|NCT04588792|PLACEBO_COMPARATOR|Nebulized Saline|Placebo, given by nebulization (4 mL of 0.9% saline solution) over 30 mins four times daily (Q.I.D.) for up to 28 days
62202824|NCT04098562|PLACEBO_COMPARATOR|Placebo|Placebo cream, administered twice a week for 4 weeks
62579537|NCT05053022|EXPERIMENTAL|Microneedling with Skinpen Precision System|"Skinpen precision system will be used in accordance with the instructions in the IFU on the treatment area. A numbing cream will be applied at least 20-30 minutes before the Skinpen Precision system treatment is done. The affected areas will be treated at depths of up to 2.50mm. Treatment depth will be recorded for each treatment at every visit.~Subjects will be dispensed with the Blue Lizard sunscreen and trained on proper use."
62579538|NCT04119375|ACTIVE_COMPARATOR|Control|The standard-of-care protocol in Kenya includes diagnosis, the provision of medications - typically administered for a 1-2 week period at which point patients are expected to return to the clinical site - periodic on-the-ground follow-up by community health volunteers (CHVs)(at the discretion of local clinicians and CHVs) and nutritional support, as is sometimes provided.
62202825|NCT02212353||Site 1 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 1 in delivering to care to neck of femur patients.
62202826|NCT02212353||Site 2 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 2 in delivering to care to neck of femur patients.
62786034|NCT06537674||Group B|The patient went on to complete six cycles of neoadjuvant therapy (pyrotinib and trastuzumab) and underwent radical mastectomy (breast-conserving surgery or total mastectomy) after treatment. After the operation, the doctor will give the corresponding treatment according to the results of the postoperative medical examination
62786035|NCT05232331|NO_INTERVENTION|Control|This group will receive non-surgical periodontal treatment, however they will not receive any modification to their diet
62786036|NCT05232331|EXPERIMENTAL|Intervention|This group will receive non-surgical periodontal treatment, and also as a treatment of interest, will receive the indication to consume \~ 350 mg of nitrate from vegetables, as well as an accompaniment to achieve this objective.
62786037|NCT05354271|EXPERIMENTAL|High-intensity interval training|Patients will cycle or walk/run four intervals of four-min at high intensity with the aim to reach 80-90% of peak oxygen consumption, 90-95% of peak heart rate, 15-17 Borg scale, shortness of breath). Each interval is separated by a three-min active recovery, at 50-60% of peak oxygen consumption or 70-75% of peak heart rate. Total exercise time will be 38 min including the warm-up and cool-down.
62786038|NCT05354271|ACTIVE_COMPARATOR|Moderate-intensity continuous training|Patients will cycle or walk/run continuously at moderate intensity (50-60% of peak oxygen consumption, 70-75% of peak heart rate) for 37 min. Total exercise time will be 47 min for the moderate-intensity continuous training group including warm-up and cool-down (isoenergetic compared to high-intensity interval training).
62202827|NCT02212353||Site 3 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 3 in delivering to care to neck of femur patients.
62202828|NCT03338296|EXPERIMENTAL|Lorcaserin hydrochloride XR 20 mg QD|Participants will receive lorcaserin hydrochloride extended release (XR) 20 milligrams (mg) once daily (QD) for up to 52 weeks.
62202829|NCT03338296|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo QD for up to 52 weeks.
62202830|NCT04445740|EXPERIMENTAL|Intervention|Participants will receive an intervention and will participate in assessments
61978422|NCT02404285|PLACEBO_COMPARATOR|Vehicle|"Subjects will be treated with once daily vehicle and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:~1. Lesions will be counted and right, left and forward facing photographs will be taken~2. Investigator Global Assessment~3. Acne Quality of Life Questionnaire~4. Treatment Area Assessment by Investigator"
62202831|NCT04445740|NO_INTERVENTION|Control|Participants will not receive an intervention, but will participate in assessments
62202832|NCT01052610|ACTIVE_COMPARATOR|Active group|Group of children with bronchial asthma and/ or allergic rhinitis 6-18 years old receiving annually house dust mites sublingual allergen extract
62403206|NCT00683670|EXPERIMENTAL|Dendritic Cell Vaccine (First Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 3 weeks for a total of 6 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 and dose #6 in order to collect PBMC for immune monitoring. Patients with stable disease or better after 6 doses will be eligible to receive additional vaccinations as maintenance therapy every 2 months until progression.
61978423|NCT02404285|ACTIVE_COMPARATOR|NAG (Next Science Acne Gel)|"Subjects will be treated with once daily NAG and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:~1. Lesions will be counted and right, left and forward facing photographs will be taken~2. Investigator Global Assessment~3. Acne Quality of Life Questionnaire~4. Treatment Area Assessment by Investigator"
61978424|NCT00510133|EXPERIMENTAL|GRNVAC1|Autologous dendritic cell vaccine
62014027|NCT05907356|EXPERIMENTAL|Study Group One|sciatic nerve slider technique in a slump lying position in combination with Conventional physiotherapy
62202833|NCT01052610|PLACEBO_COMPARATOR|Placebo group|Group of children with bronchial asthma and/or allergic rhinitis 6-18 years old receiving placebo in sublingual applicator
62202834|NCT05926453||Maximal CPET|One maximal cardiopulmonary exercise test with simultaneous registration of direct gas measurements and the variables necessary for estimated cardiorespiratory fitness.
62202835|NCT01430468|EXPERIMENTAL|Glenoid Positioning System|For the patients randomized to the GPS group, the surgeon will be given the GPS patient specific instrumentation and a model of the glenoid surface showing the exact placement and fit of the GPS alignment instruments.
62579539|NCT04119375|EXPERIMENTAL|SMS-Only|"Patients in the SMS reminder group will receive a single, medication reminder SMS once daily at their indicated treatment time. The reminder message will read Please take the medication on time consistent with messages used by Liu and colleagues (2015)."
62202836|NCT01430468|NO_INTERVENTION|Standard Group|Each surgeon will use their standard methods of pre-operative planning using the pre-operative x-rays and CT scan.
62202837|NCT00383539|EXPERIMENTAL|1|Lot 1
62786039|NCT05354271|NO_INTERVENTION|Control|The control group will continue their habits without increasing the level of physical activity nor participate to any supervised exercise training.
62786040|NCT03746717|EXPERIMENTAL|Prineo|Skin closure with Dermabond Prineo occlusive wound closure system
62786041|NCT03746717|ACTIVE_COMPARATOR|Staples|Skin closure with staples
62202838|NCT00383539|EXPERIMENTAL|2|Lot 2
62202839|NCT00383539|EXPERIMENTAL|3|Lot 3
62202840|NCT00383539|ACTIVE_COMPARATOR|4|Control
62202841|NCT05183529|EXPERIMENTAL|Patients undergoing polysomnography|
62202842|NCT00250549|NO_INTERVENTION|HIV counselor|Patients who tested for HIV and consent to participate in the study receive a posttest educational session with an HIV counselor. Afterwards, patients complete an assessment tool concerning HIV prevention and transmission.
62202843|NCT00250549|EXPERIMENTAL|Post test video|Patients who tested for HIV and consent to participate in the study watch a a 15-minute HIV posttest educational video available in English/Spanish. Afterwards, patients complete an assessment tool concerning HIV prevention and transmission.
62579540|NCT04119375|EXPERIMENTAL|Social Behavior Change Communication (SBCC)|"Patients assigned to this intervention will have access to a mobile health platform that provides reminders, information and motivation - designed with behaviorally-informed strategies - but no follow up support from a human beyond what the standard of care allows. Further details of the intervention can be found in the study protocol section.~The intervention will send automated motivational messages and regular prompts for patients to self-verify their adherence. Messages include reminders about the community benefits of adherence, and a measure of the patient's adherence performance relative to successful peers. Clinicians can view individual or aggregate patient histories to leverage limited resources."
62014028|NCT05907356|EXPERIMENTAL|Study Group Two|sciatic nerve slider technique in a supine position in combination with Conventional physiotherapy
62202844|NCT03235752|EXPERIMENTAL|TJ301 300mg|TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
62014029|NCT05907356|EXPERIMENTAL|Control Group|Conventional physiotherapy alone
62014030|NCT02304042|ACTIVE_COMPARATOR|Carbetocin|125 women will receive carbetocin after delivery of the anterior shoulder. The drug will be diluted in 10ml saline and will be given by the slowly intravenously after delivery of the anterior shoulder
62202845|NCT03235752|EXPERIMENTAL|TJ301 600mg|TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
62202846|NCT03235752|PLACEBO_COMPARATOR|Placebo|Placebo administrations will occur on Days 0, 14, 28, 42, 56, and 70.
62202847|NCT02571595|EXPERIMENTAL|Immediate dCBT-I group|Digital cognitive behavioural therapy for insomnia (dCBT-I) is a 6 session training program (spanning 6 to 12 weeks) designed to improve sleep. Participants in the immediate dCBT-I group will receive the Sleepio intervention shortly after enrollment.
62202848|NCT02571595|EXPERIMENTAL|Waitlist control group|Participants in the waitlist control group will receive sleep hygiene recommendations from validated online resources for HIV patients (http://www.catie.ca/en/positiveside/winter-2013/sleep-tight) around the time of enrollment. They will start the digital cognitive behavioural therapy for insomnia (dCBT-I) intervention 12-14 weeks after the initial enrollment.
62202849|NCT00599443|EXPERIMENTAL|1|
62014031|NCT02304042|ACTIVE_COMPARATOR|Oxytocin|125 women will receive carbetocin oxytocin after delivery of the anterior shoulder. The drug will be diluted in 10ml saline and will be given by the slowly intravenously after delivery of the anterior shoulder
62734812|NCT04519216|EXPERIMENTAL|Telesimulation|Participants in the intervention group will complete an online unfolding case scenario. Then these participants will complete a telesimulation case with a standardized patient via video conferencing.
62786042|NCT04523883|EXPERIMENTAL|concurrent PD-1|Concurrent Immunotherapy With Postoperative Radiotherapy
62202850|NCT00599443|PLACEBO_COMPARATOR|2|
62202851|NCT03361605|EXPERIMENTAL|Propofol Administration|
62202852|NCT04083820||Semaglutide s.c. once-weekly|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
62202853|NCT01135303|EXPERIMENTAL|VistaO2 device|This device combines the transcutaneous oxyhemoglobin saturation (allowing to compute the oxyhemoglobin desaturation index), the slow variations in heart rate and an index of nocturnal respiratory events calculated by analyzing the movements of the chest performed by chest impedance variations.
62202854|NCT04948177||Group A|Group A: Individuals who had normal pyloric orifice structure;
62202855|NCT04948177||Group B|Group B: Individuals who have abnormal pyloric orifice structure
62202856|NCT00570284|EXPERIMENTAL|LBH589|
62202857|NCT05082168||Respiratory tract infection|Patients diagnosed with viral or bacterial pneumonia and admitted to ICU for mechanical ventilatory support
62202858|NCT05082168||Sepsis|Patients diagnosed with sepsis and admitted to ICU for mechanical ventilatory support
62202859|NCT05082168||Cardiac surgery|Patients admitted to ICU for mechanical ventilatory support following cardiac surgery
62202860|NCT03582787|EXPERIMENTAL|Mcgrath group|Orotracheal intubation with McGrath MAC videolaryngoscopy
62202861|NCT03582787|PLACEBO_COMPARATOR|Macintosh group|Orotracheal intubation with Macintosh laryngoscopy
62734813|NCT01146184|EXPERIMENTAL|Single-Incision Cholecystectomy|Extracting the gallbladder laparoscopically is made difficult through a single incision.
62786043|NCT04523883|ACTIVE_COMPARATOR|Radiotherapy alone|Postoperative Radiotherapy alone
62202862|NCT00085787|EXPERIMENTAL|ARRY-142886|
62202863|NCT01696045|EXPERIMENTAL|Ipilimumab 3 mg/kg|Ipilimumab (3 mg/kg) was administered intravenously (IV) over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
62202864|NCT01696045|EXPERIMENTAL|Ipilimumab 10 mg/kg|Ipilimumab (10 mg/kg) was administered intravenously (IV) over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
62202865|NCT01038375||Adherence counseling|
62202866|NCT01038375||Usual care|
62202867|NCT00691587|EXPERIMENTAL|1|Low-dose KB001, a monoclonal antibody
62202868|NCT00691587|EXPERIMENTAL|2|High-dose KB001, a monoclonal antibody
62202869|NCT00691587|PLACEBO_COMPARATOR|3|Placebo
62202870|NCT04267705|ACTIVE_COMPARATOR|Black bean|A cup of black bean 7 days/week over a 12-week period
62202871|NCT04267705|ACTIVE_COMPARATOR|Chickpea|A cup of chickpea 7 days/week over a 12-week period
62202872|NCT04267705|PLACEBO_COMPARATOR|Control|A cup of white rice 7 days/week over a 12-week period
62786044|NCT01528722|SHAM_COMPARATOR|Saline sham injection|Sham wash and injection with normal saline (09%)
62786045|NCT01528722|ACTIVE_COMPARATOR|Bupivacaine|Bupivacaine injection/wash treatment arm
62014032|NCT03085927|EXPERIMENTAL|Arm 1-Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
62202873|NCT01770977|ACTIVE_COMPARATOR|Effective Light-emitting diode therapy|Effects of light-emitting diode therapy on clinical, biochemical and biomechanical of muscle performance in athletes
62202874|NCT01770977|PLACEBO_COMPARATOR|Placebo light-emitting diode therapy|Effect of placebo light-emitting diode therapy on clinical, biochemical and biomechanical of muscle performance in athletes
62014033|NCT03085927|EXPERIMENTAL|Arm II- Audio-Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
62014034|NCT02885363|EXPERIMENTAL|Patients with newly diagnosed Left Ventricular Non Compaction|Patient newly diagnosed with Left Ventricular Non Compaction (diagnose \< 6 months), confirmed by echocardiography associated or not with MRI, after centralized review
62202875|NCT00047697|EXPERIMENTAL|Donepezil HCl|Donepezil HCL 5 mg and 10 mg
62202876|NCT00047697|PLACEBO_COMPARATOR|Placebo|Placebo
62014035|NCT02885363|ACTIVE_COMPARATOR|Patients with Idiopathic Dilated Cardiomyopathy|Patient newly diagnosed with Idiopathic Dilated Cardiomyopathy (diagnose \< 6 months), confirmed by echocardiography associated or not with MRI, after centralized review
62202877|NCT03918369|EXPERIMENTAL|Laparoscopic Intracorporeal anastomosis|Laparoscopic right hemicolectomy with intracorporeal mechanical side-to-side isoperistaltic anastomosis.
62202878|NCT03918369|ACTIVE_COMPARATOR|Laparoscopic extracorporeal anastomosis|Laparoscopic right hemicolectomy with extracorporeal anastomosis.
62202879|NCT04411329|ACTIVE_COMPARATOR|group A|patients will receive 30 ml of 0.125% bupivacaine with 8 mg dexamethasone (20 ml before skin incision and 10 ml at end of surgery
62202880|NCT04411329|ACTIVE_COMPARATOR|group B|we will add 50µg dexmedetomidine to the previous mixture given to group A (20 ml before skin incision and 10 ml at end of surgery
62579541|NCT04119375|EXPERIMENTAL|Keheala|"An automated system sends motivational messages and regular prompts for patients to self-verify their adherence. Messages include reminders about the community benefits of adherence, and a measure of the patient's adherence performance relative to successful peers. If a patient fails to correctly verify her compliance, the system automatically alerts the support-sponsor, who then intervenes with a supportive dialogue. Clinicians can view individual or aggregate patient histories to leverage limited resources.~Further details of the intervention can be found in the study protocol section."
62202881|NCT04411329|ACTIVE_COMPARATOR|group c|we will add 1500 IU hyalurodinase to the mixture given to group A. (20 ml before skin incision and 10 ml at end of surgery
62202882|NCT03821103|EXPERIMENTAL|Standard training arm|The standard training arm will consist of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department administration within 3 month study period.
62579542|NCT06576388|EXPERIMENTAL|single Arm-experimental group|"The dose escalation study included two cohorts with three dose levels: 0.67×1014 vg/kg, 1.1×1014 vg/kg, and 1.5×1014 vg/kg. Among them, the first queue contains two levels, the first dose levels (0.67 x 1014 vg/kg) using the accelerated titration method (i.e. after the first dose levels in group 1 case subjects, when the subjects to 28 days after complete treatment of safety assessment, if not present dose limiting toxicity (DLT), increasing the dose to the next dose levels; Otherwise the study will be terminated .~Study treatment name:EXG001-307 injection; Dosage form: injection; frequency and duration: single dose"
62579543|NCT05284032|EXPERIMENTAL|Isatuximab (Sarclisa)|4 weekly doses of isatuximab
62786046|NCT02745028|OTHER|With monosodium glutamate|Results of one time gastric emptying study with a single dose of monosodium glutamate; 1 g for weight greater than 45 kg, 700mg between 35 and 44,900 kg, 600mg between 25 and 34,900, 500mg between 15 and 25 kg and 250mg in less than 15 kg
62786047|NCT03316703|ACTIVE_COMPARATOR|Conventional open surgery|Fixation of a proximal vertebra, a vertebra distal to the fractured vertebra, and also of the fractured vertebra with a pedicle fixation system using the conventional open to implant placement without subsequent arthrodesis.
62014036|NCT06663254|EXPERIMENTAL|6% hydroxyethyl starch 130/0.4|
62014037|NCT06663254|OTHER|Sodium acetate Ringer|
62014038|NCT06663462||EzPAP group|EzPAP users
62014039|NCT06663462||Non-invasive group|BPAP users
62014040|NCT03637751|EXPERIMENTAL|Experimental design|Testing will be carried out in Penn State's Clinical Research Center (CRC). The CRC has rooms for conducting the Trier Social Stress Test (TSST) stress-task and for resting. Participants will make two visits to the CRC, one week apart, on the same day of the weekday. Sessions will be scheduled from 11:00 am to 4:15 pm. We will use a randomized counter-balanced order for the two sessions (i.e., TSST and control conditions) with group membership blind to the subjects and lab personnel.
62215143|NCT05827861|EXPERIMENTAL|HeartAge and HOPE Platform|Participants will be directed to HeartAge, a risk assessment tool available online. Then, they will be led to download the HOPE-CVD mobile app, an evidence-based behaviour change platform.
62579544|NCT06486077|EXPERIMENTAL|Power Line Program|Daily supplementation with Power Line program consisting of 4 nutritional supplements: a meal replacement shake, a vegetable based green drink, a vascular health product, and a pre-meal fiber supplement. Subjects will maintain their current lifestyle (specifically diet, exercise, and nutritional supplements) during intervention.
62014041|NCT03637751|EXPERIMENTAL|Control design|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
62014042|NCT01127438|ACTIVE_COMPARATOR|fospropofol disodium Subgroup 1 Lower Dose|
62786048|NCT03316703|EXPERIMENTAL|Minimally invasive percutaneous surgery|Fixation of a proximal vertebra, a vertebra distal to the fractured vertebra, and also of the fractured vertebra with a pedicle fixation system using the percutaneous minimally invasive approach to implant placement without subsequent arthrodesis.
62579545|NCT04138472|EXPERIMENTAL|Dexmedetomidine|Group A patients receive intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.
62786049|NCT04680481|EXPERIMENTAL|Stimulation Theta Group|Participants will experience traveling wave transcranial alternating current stimulation over the fronto-parietal regions at 4 Hz (theta condition).
62786050|NCT04680481|EXPERIMENTAL|Stimulation Beta Group|Participants will experience traveling wave transcranial alternating current stimulation over the fronto-parietal regions at 23 Hz (beta condition).
62786051|NCT00947115|EXPERIMENTAL|Cervarix 15-25 years group|Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study HPV-014 (NCT00196937).
62786052|NCT00947115|EXPERIMENTAL|Cervarix 26-45 years group|Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study HPV-014 (NCT00196937).
62786053|NCT00947115|EXPERIMENTAL|Cervarix 46-55 years group|Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study HPV-014 (NCT00196937).
62786054|NCT03775512|EXPERIMENTAL|Main Arm|Subjects will be ablated with the QDOT Micro Catheter for Pulmonary Vein Isolation with nMARQ RF Generator
62786055|NCT03775512|EXPERIMENTAL|Second Arm (variable flow)|subjects will be treated with QDOT Micro catheter with variable flow nMARQ RF generator
62786056|NCT00338923|ACTIVE_COMPARATOR|Treatment arm|One Arm - Active Compound (HO/03/03)
62786057|NCT04286659||Control Group|90 Apparently healthy individuals
62786058|NCT04286659||IBD group|90 Previously or Newly Diagnosed Ulcerative Colitis and Crohn's disease
62786059|NCT00721188|EXPERIMENTAL|Pharmacokinetic Population|All subjects who received study drug and completed Pharmacokinetic testing through 24 hours post-dose.
62786060|NCT04348981|EXPERIMENTAL|Wearable|All patients eligible to enroll in the Enhanced Recovery after Cardiac Surgery pathway will be offered a wearable fitness tracking device.
62786061|NCT00697372|ACTIVE_COMPARATOR|SES|Patients with coronary bifurcation lesions treated by Sirolimus eluting stent
62786062|NCT00697372|ACTIVE_COMPARATOR|EES|Patients with coronary bifurcation lesions treated by Everolimus eluting stent
62786063|NCT04102072|EXPERIMENTAL|Trendelenburg Maneuver|The Trendelenburg position is a common treatment in medicine.It is used either as a diagnostic tool to assess fluid loading response or as a therapeutic maneuver pending fluid resuscitation.With the advantage of autotransfusion readily available,the Trendelenburg position is used for expected instantaneous effect on cardiovascular performance.
62786064|NCT04102072|EXPERIMENTAL|dobutamine stress test|Dobutamine is a selective beta 1 receptor agonist. It \[\<10 ug/(kg.min)\] can effectively increase myocardial contractility.
62786065|NCT04511858|EXPERIMENTAL|Running endurance|Athletes wiil run for 5 hours in a row.
62786066|NCT04511858|EXPERIMENTAL|Cycling endurance|Athletes wiil cycle for 5 hours in a row.
62786067|NCT00657579|EXPERIMENTAL|1|
62014043|NCT01127438|ACTIVE_COMPARATOR|: fospropofol disodium Subgroup 1 Approved Dose|
62786068|NCT00657579|EXPERIMENTAL|2|
62786069|NCT00657579|EXPERIMENTAL|3|
62786070|NCT00657579|PLACEBO_COMPARATOR|4|
62014044|NCT01127438|ACTIVE_COMPARATOR|fospropofol disodium Subgroup 2 Lower Dose|
62014045|NCT01127438|ACTIVE_COMPARATOR|fospropofol disodium Subgroup 2 Approved Dose|
62014046|NCT01127438|ACTIVE_COMPARATOR|fospropofol disodium Subgroup 3 Lower Dose|
62014047|NCT01127438|ACTIVE_COMPARATOR|fospropofol disodium Subgroup 3 Approved Dose|
62786071|NCT01465815|EXPERIMENTAL|Treatment (adjuvant enzyme inhibitor and radiation therapy)|"Optional non-therapeutic (biomarker) portion: Patients are randomized to 1 of 3 treatment arms.~Arm A: Patients receive erlotinib hydrochloride PO QD and linsitinib PO BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
62786072|NCT01465815|EXPERIMENTAL|Erlotinib and Placebo (Sugar Pill)|"Arm B: Patients receive erlotinib hydrochloride PO QD and placebo PO QD or BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
62014048|NCT04401449||Acutely illl subjects|COVID-19 subjects treated at the Clinical Center, followed through recovery and into convalescence
62014049|NCT04401449||Recovered subjects|COVID-19 subjects who were treated at other hospitals, followed through recovery and into convalescence
62014050|NCT06250725|EXPERIMENTAL|Cognitive Behavioral Therapy for Insomnia (CBTi)|Participant dyads will receive CBTi via videoconferencing sessions
62014051|NCT03271437|EXPERIMENTAL|PC-trained therapists|
62014052|NCT03271437|EXPERIMENTAL|EMDR-trained therapists|
62014053|NCT04614428|NO_INTERVENTION|Standard Care Group|Participants will receive the standard care provided by their institution.
62014054|NCT04614428|ACTIVE_COMPARATOR|RESILIENCE Program group|Participants will receive the RESILIENCE Program on top of the standard care provided by their institution.
62014055|NCT03541733|EXPERIMENTAL|Tubing-group|mid-gut tubing prior to the MRE examination, administer contrast solution through the mid-gut tube
62579546|NCT04138472|EXPERIMENTAL|Fentanyl|Group B receives intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.
62202883|NCT03821103|EXPERIMENTAL|Behavioral economic enhanced arm|The behavioral economic enhanced training arm will consist of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department administration within 3 month study period in addition to an opt-out invitation, loss-framed incentivization, and weekly tailored text message-based reminders
62202884|NCT05902325|EXPERIMENTAL|Mepolizumab 100mg injection|Mepolizumab 100mg SC once every 4 weeks for 48 weeks (twelve injections)
62786073|NCT01465815|EXPERIMENTAL|OSI-906 and Placebo (Sugar Pill)|"Arm C: Patients receive linsitinib PO BID and placebo PO QD or BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
62014056|NCT03541733|NO_INTERVENTION|Oral-group|administer contrast solution orally, mid-gut tubing after the MRE examination
62202885|NCT06292949|EXPERIMENTAL|Resistant starch intervention group|or the recruited patients with functional constipation, stool samples were collected and 2 packets of resistant starch were taken every day, each packet of 10g. The resistant starch was brewed with 200ml warm water for 14 days, and the fecal samples of volunteers were collected on the 0th, 7th and 14th day. Patients filled out questionnaires on days 0 and 14 to evaluate the improvement of constipation symptoms.
62202886|NCT03434444|ACTIVE_COMPARATOR|Low Dose Oxytocin|The myometrial samples are bathed in an oxytocin solution at increasing concentrations (from 10 -12M to 10 -9M)
62014057|NCT03615651|PLACEBO_COMPARATOR|Placebo|All study participants will receive the study product and the placebo in a randomized, double-blind crossover fashion. Probiotic and placebo products have similar appearance and taste.
62202887|NCT03434444|ACTIVE_COMPARATOR|Propranolol|The myometrial samples are bathed in a propranol solution at 10 -6M
62014058|NCT03615651|EXPERIMENTAL|Probiotic|All study participants will receive the study product and the placebo in a randomized, double-blind crossover fashion. Probiotic and placebo products have similar appearance and taste.
62014059|NCT02507102|EXPERIMENTAL|Investigational Voyager Therapy|Investigational treatment with Voyager Therapy
62202888|NCT03434444|ACTIVE_COMPARATOR|Propranolol + low dose oxytocin|The myometrial samples are bathed in an oxytocin solution at increasing concentrations (from 10 -12M to 10 -9M) plus propranol (10 -6M)
62202889|NCT03434444|ACTIVE_COMPARATOR|High Dose Oxytocin|The myometrial samples are bathed in an oxytocin solution (10 -5M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M)
62202890|NCT03434444|ACTIVE_COMPARATOR|High Dose Oxytocin, Propranolol-pretreated|The myometrial samples are bathed in an oxytocin solution (10 -5M) plus propranolol (10 -6M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M)
62202891|NCT03434444|ACTIVE_COMPARATOR|High dose oxytocin + propranolol|The myometrial samples are bathed in an oxytocin solution (10 -5M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M) plus propranolol (10 -6M)
62202892|NCT05936723|ACTIVE_COMPARATOR|Voluntary Isocapnic Hyperpnoea (VIH)|Group performing respiratory muscle training with Voluntary Isocapnic Hyperpnoea (VIH) method.
62579547|NCT04138472|EXPERIMENTAL|Lidocaine|Group C patients receives intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.
62786074|NCT06104332||ProRhinel Naturel spray nasal/ Allergic Rhinitis|
62202893|NCT05936723|ACTIVE_COMPARATOR|Inspiratory Pressure Threshold Loading (IPTL)|Group performing respiratory muscle training with Inspiratory Pressure Threshold Loading (IPTL) method.
62202894|NCT06185231|EXPERIMENTAL|Percussion Massage Group|Both groups will undergo a progressive exercise program given as Phase-1, Phase-2, and Phase-3 for 6 weeks. The Percussion massage group will receive percussion massage therapy for a total of 5 minutes for each muscle group.The application will be done to the Quadriceps and Hamstring muscle groups before exercise. The device will be used with a soft connection head at 33-40 Hz. A total of 5 minutes of percussion massage will be applied to each muscle group. In the first 2.5 minutes of the massage therapy, the medial side of the focus muscle will be targeted, and in the second 2.5 minutes, the lateral side of the focus muscle will be targeted. Neuromuscular Electrical Stimulation (NMES) will be applied to the Quadriceps muscle group for facilitation and reeducation purposes.
62786075|NCT06104332||ProRhinel Naturel spray nasal/ URTI|
62786076|NCT06104332||ProRhinel EXTRA Eucalyptus spray nasal/ URTI|
62786077|NCT06104332||RESPIMER Enfant/ URTI|
62786078|NCT06104332||Phytosun Aroms spray nasal MAX/ URTI|
62786079|NCT06104332||PHYSIOMER RHUME TRIPLE ACTION/ URTI|
62579548|NCT05766059|EXPERIMENTAL|[Phase 1] Stroke patients with upper-limb hemiparesis|
62579549|NCT05766059|EXPERIMENTAL|[Phase 2] Patients with phantom limb pain (PLP)|
62579550|NCT00232739|EXPERIMENTAL|1|
62579551|NCT04190940|EXPERIMENTAL|High Intensity Focused Ultrasound|Patients receiving high intensity focused ultrasound as a treatment will be asked to complete the behavioral task pre and post their treatment.
62786080|NCT06104332||Phytosun Aroms spray nasal decongestionnant/ URTI|
62786081|NCT03422497||Male hip fracture surgery patients|Individuals 65 years or older admitted non-electively to hospital with a diagnosis of hip fracture who have surgery for their hip fracture and have male sex listed in their discharge abstract
62786082|NCT03422497||Female hip fracture surgery patients|Individuals 65 years or older admitted non-electively to hospital with a diagnosis of hip fracture who have surgery for their hip fracture and have female sex listed in their discharge abstract
62786083|NCT04360837|EXPERIMENTAL|PEEP incremental-decremental alveolar recruitment|"1. installing EIT belt over the chest at the level of the 5th intercostal space and adjustment of the default recruitment settings in pressure control ventilation mode: pressure control 15 cmH20, PEEP 10 cmH2O, fraction of inspired oxygen (FiO2) and respiratory rate according to the discretion of the attending physician, recording basal parameters~2. implementation of recruitment:~   * increment phase: increasing PEEP by 3 cmH2O in every two minutes from 10 cmH2O until top of PEEP 25 cmH2O~  * decrement phase: decreasing PEEP by 3 cmH20 in every two minutes from 25 cmH20 until the basal PEEP 10 cmH20~  * end inspiratory hold manoeuvre at every PEEP level~3. recording closing parameters~Repeating the above detailed intervention once daily as long as the patient is controlled ventilation."
62786084|NCT00806728|EXPERIMENTAL|1|MEDI-507
62786085|NCT00806728|EXPERIMENTAL|2|MEDI-507
62786086|NCT03239444|OTHER|Assigned Intervention|Device: Foresight ICE System The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird console. The Foresight ICE system will be used in guiding the physician during the trans-septal puncture and provide physiological information during the course of the procedure.
62786087|NCT01110369|EXPERIMENTAL|Resistance exercise training and protein drink|
62786088|NCT01110369|PLACEBO_COMPARATOR|Resistance exercise training and placebo drink|
62202895|NCT06185231|ACTIVE_COMPARATOR|Conventional Group|"Conventional group undergo a progressive exercise program given as Phase-1, Phase-2, and Phase-3 for 6 weeks.~Neuromuscular Electrical Stimulation (NMES) will be applied to the Quadriceps muscle group for facilitation and reeducation purposes.~NMES Parameters:~Electrode placement: will be applied to motor points and the muscle belly to achieve optimal contraction.~Frequency: 50-70 Hz Duration: 20 minutes."
62403207|NCT00683670|EXPERIMENTAL|Dendritic Cell Vaccine (Second Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 3 weeks for a total of 6 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 and dose #6 in order to collect PBMC for immune monitoring. Patients with stable disease or better after 6 doses will be eligible to receive additional vaccinations as maintenance therapy every 2 months until progression.
62786089|NCT06583265||Infertility patients planning for FET|
62786090|NCT00766051|EXPERIMENTAL|Intervention Group|The infants in the intervention group were problem eaters with various diagnosis
62786091|NCT00766051|NO_INTERVENTION|Matched Historical Comparison Group|The matched historical comparison group were also problem eaters and these infants did not receive the neurophysiologically based occupational therapy Intervention.
62786092|NCT01000324|EXPERIMENTAL|Twinrix Group|Pooled group of subjects from groups who were vaccinated with either Lot 1, Lot 2 or Lot 3 of Twinrix in the primary study according to a 0, 1, 6-Month schedule
62202896|NCT02954978|PLACEBO_COMPARATOR|Placebo|"Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 1 will receive the placebo (sugar pill) one (1) capsule by mouth once daily (taken without a meal) for 12 months and 3 months follow up."
62786093|NCT02345213|EXPERIMENTAL|E2020|"Treatment period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, Weeks 7-12 E2020 10 mg.~Extension period: Weeks 1-6 E2020 10 mg, After Week 7 up to week 60 E2020 10 mg."
62786094|NCT02345213|PLACEBO_COMPARATOR|Placebo|"Treatment period: Weeks 1-12 placebo~Extension period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, After Week 7 up to week 60 E2020 10 mg."
62786095|NCT02534246|EXPERIMENTAL|Pro Core EUS guided Fine Needle Biopsy|Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) with reverse bevel design for diagnosis of pancreatic lesions.
62786096|NCT02534246|EXPERIMENTAL|Shark Core EUS guided Fine Needle Biopsy|SharkCore ultrasound biopsy needle (Medtronic \[Beacon\] 25 gauge) with six cutting edge surfaces and an opposing bevel design for diagnosis of pancreatic lesions.
62786097|NCT03192761|ACTIVE_COMPARATOR|ACL-reconstruction hamstrings|ACL reconstruction hamstrings
62786098|NCT03192761|ACTIVE_COMPARATOR|ACL-reconstruction patella tendon|ACL reconstruction patella tendon
62786099|NCT03192761|ACTIVE_COMPARATOR|ACL-reconstruction iliotibial tract|ACL reconstruction iliotibial tract
62786100|NCT01376414||Non specific upper abdominal pain|Cohort is patients who present to the Emergency Department with primary complaint of upper abdominal pain without obvious cause.
62786101|NCT05712278|EXPERIMENTAL|SAR445419|Treatment consists of chemotherapy with fludarabine 30mg/m2/day and cytarabine 2g/m2/day administered for 5 days (Day -6 to Day -2), followed by 6 doses of SAR445419 given thrice weekly for 2 weeks beginning Day 1.
62786102|NCT01424033|EXPERIMENTAL|N-Acetylcysteine|This is an open label trial, all patient will be entered into one treatment arm.
62786103|NCT02110095|EXPERIMENTAL|Picosure Laser System|Picosure Laser System for the treatment of unwanted tattoos
62786104|NCT00130611|PLACEBO_COMPARATOR|BNP blinded therapy|Clinical treatment without knowledge of BNP levels
62786105|NCT00130611|EXPERIMENTAL|BNP guided therapy|Clinical treatment based on clinical examination and BNP-levels
62786106|NCT02734303||Potentially Exposed NM Residents|residents of the state of New Mexico (NM) potentially exposed to radioactive fallout fromthe Trinity nuclear test conducted in 1945
62786107|NCT02424175|EXPERIMENTAL|Patients with PSC|This is an open label study. All patients enrolled will receive a fecal microbiota transplantation.
62786108|NCT06491784|NO_INTERVENTION|Standard Care|Routine clinical follow-up
62786109|NCT06491784|ACTIVE_COMPARATOR|Exercise Therapy (Intervention)|12 week multi-modal exercise and wellbeing programme
62786110|NCT04880369|EXPERIMENTAL|Lignan capsule|1 capsule/day from baseline to end-of-follow-up (approx. 4 months)
62786111|NCT04880369|EXPERIMENTAL|Isoflavones capsule|1 capsule/day from baseline to end-of-follow-up (approx. 4 months)
62786112|NCT04880369|PLACEBO_COMPARATOR|Placebo capsule|1 capsule/day from baseline to end-of-follow-up (approx. 4 months)
62786113|NCT02453503|ACTIVE_COMPARATOR|Triamcinolone acetonide|Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
62786114|NCT02453503|EXPERIMENTAL|Licorice|Licorice mucoadhesive films 1 mg every 6 hours for two weeks.
62786115|NCT02578186|EXPERIMENTAL|Diphenhydramine Hydrochloride|Diphenhydramine (50 mg) elixir taken when subjects had trouble falling asleep
62786116|NCT02578186|PLACEBO_COMPARATOR|Placebo|Placebo elixir taken when subjects had trouble falling asleep
62786117|NCT06386991|ACTIVE_COMPARATOR|Ethylenediamine tetraacetic acid (EDTA)|Regenerative endodontic treatments require the use of irrigation solutions to break down inorganic and organic tissue residues in the root canals. Sodium hypochlorite (NaOCl) and Ethylenediamine tetraacetic acid (EDTA)will be used when disinfecting root canals. (GROUP 1)
62786118|NCT06386991|ACTIVE_COMPARATOR|CITRIC ACID (MONO/ANH)|Regenerative endodontic treatments require the use of irrigation solutions to break down inorganic and organic tissue residues in the root canals. Sodium hypochlorite (NaOCl) and CITRIC ACID (MONO/ANH) be used when disinfecting root canals. (GROUP 2)
62786119|NCT06386991|ACTIVE_COMPARATOR|ETİDRONİC ACID (HEBP)|Regenerative endodontic treatments require the use of irrigation solutions to break down inorganic and organic tissue residues in the root canals. Sodium hypochlorite (NaOCl) and ETİDRONİC ACID (HEBP) be used when disinfecting root canals. (GROUP 3)
62786120|NCT05615740|ACTIVE_COMPARATOR|Healthy pediatric patients|Healthy pediatric patients will undergo optical coherence tomography.
62786121|NCT05615740|ACTIVE_COMPARATOR|Children with diabetes mellitus|Children with diabetes mellitus will undergo optical coherence tomography.
62786122|NCT04180904|ACTIVE_COMPARATOR|Diet 1|Diet 1 will focus on the dietary pattern and monitor types of foods, supplementary nutrition, and provide nutritional support with a dietitian.
62786123|NCT04180904|ACTIVE_COMPARATOR|Diet 2|Diet 2 will focus on the dietary pattern and monitor the amount of food, complimentary nutrition, and nutritional support with a dietitian.
62786124|NCT04180904|NO_INTERVENTION|Diet 3|Diet 3 will focus on healthy dietary patterns and provide nutritional support with a dietitian.
62786125|NCT00940498|EXPERIMENTAL|1|PF-05212384 (also known as PKI-587)
62786126|NCT01257945|EXPERIMENTAL|Flexibility & Function|Subjects take part in an exercise program based on flexibility and function.
62786127|NCT01257945|EXPERIMENTAL|Aerobic Exercise|Subjects will take part in an aerobic exercise program
62786128|NCT01257945|OTHER|Home exercise|Standard of care home exercise program
62786129|NCT05030350|EXPERIMENTAL|PH94B 3.2 micrograms|100 microliter nasal spray to each nostril up to four times a day as needed for acute anxiety
62786130|NCT00576225|EXPERIMENTAL|Experimental|
62786131|NCT00576225|ACTIVE_COMPARATOR|Control|
62786132|NCT04266925|EXPERIMENTAL|3 referees|Three referees were present on the field during these youth soccer matches.
62786133|NCT04266925|ACTIVE_COMPARATOR|1 referee|One referee was present on the field during these youth soccer matches.
62786134|NCT00891384|EXPERIMENTAL|1|25 mg lenalidomide
62786135|NCT00891384|EXPERIMENTAL|2|5 mg lenalidomide
62786136|NCT03469791|ACTIVE_COMPARATOR|Micro-decompression alone|In Surgical treatment of Degenerative Spondylolisthesis patients are operated on with a midline-precerving decompression without fusion
62786137|NCT03469791|ACTIVE_COMPARATOR|Decompression and instrumented fusion|In Surgical treatment of Degenerative Spondylolisthesis patients are operated on with a decompression followed by an instrumental fusion with or without an additional Cage
62786138|NCT03364309|EXPERIMENTAL|Ixekizumab 80mg Q4W|Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period.
62786139|NCT03364309|EXPERIMENTAL|Ixekizumab 80mg Q2W|Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period.
62786140|NCT03364309|PLACEBO_COMPARATOR|Placebo|Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.
62786141|NCT03512392|EXPERIMENTAL|Conservative fluid and deresuscitation|"* Fluid restriction (avoidance of maintenance intravenous fluid and minimisation of drug diluent volumes)~* Daily assessment of eligibility for deresuscitation for 3 days (eligible if oedema in more than 1 site and cumulative fluid balance \> 2 litres)~* Deresuscitation to target negative daily fluid balance of 1 to 3 litres:~  5mg Indapamide daily (enteral) 100mg Spironolactone daily (enteral) 0.5mg/kg furosemide once (intravenous, max 40mg) 2.5-20mg/hr furosemide infusion titrated to effect OR continuous renal replacement therapy with fluid removal"
62786142|NCT03512392|ACTIVE_COMPARATOR|Usual care|Usual care at the discretion of the treating team
62786143|NCT00973323|EXPERIMENTAL|Arm 1|
62786144|NCT00973323|EXPERIMENTAL|Arm 2|
62786145|NCT00973323|EXPERIMENTAL|Arm 3|
62786146|NCT00973323|ACTIVE_COMPARATOR|Arm 4|
62786147|NCT03536559|EXPERIMENTAL|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
62786148|NCT03536559|EXPERIMENTAL|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
62786149|NCT03536559|PLACEBO_COMPARATOR|Placebo|The matched placebo to be used in this study will consist of water, sodium bicarbonate, and food coloring to match volume and color of the experimental treatments.
62014060|NCT04991740|EXPERIMENTAL|Part 1: Dose Escalation|Participants with renal cell carcinoma (RCC), ovarian cancer, colorectal cancer (CRC), and other tumor types with sponsor approval will receive JNJ-78306358. The dose will be escalated sequentially based on the decisions of the study evaluation team until the recommended phase 2 dose (RP2D) regimen(s) have been identified.
62014061|NCT04991740|EXPERIMENTAL|Part 2: Dose Expansion|Participants with RCC, ovarian cancer, CRC and other types of tumors will receive JNJ-78306358 at the RP2D regimen(s) determined in Part 1.
62014062|NCT02565797|EXPERIMENTAL|DabirAIR overlay-ORICU|Patients scheduled for neurosurgical procedures will be placed over DabirAIR alternating pressure overlay (placed on top of standard of care support surface) in the operating room and in the post-op ICU.
62014063|NCT02565797|EXPERIMENTAL|DabirAIR overlay-OR|Patients scheduled for neurosurgical procedures will be placed over DabirAIR alternating pressure overlay (placed on top of standard of care support surface) in the operating room alone and on standard of care support surface in the post-op ICU.
62014064|NCT02565797|NO_INTERVENTION|Control-SOC|Patients scheduled for neurosurgical procedures will be placed on standard of care support surface in the operating room and post-op ICU. Data will be abstracted through retrospective chart review.
62014065|NCT03488381|EXPERIMENTAL|Soccer Heading|
62014066|NCT03488381|SHAM_COMPARATOR|Kicking-Control|
62579552|NCT04190940|EXPERIMENTAL|Deep Brain Stimulation|"Patients receiving deep brain stimulation as a treatment will be asked to complete the behavioral task while their DBS electrode is on and off."
62014067|NCT04536844|EXPERIMENTAL|Telehealth follow-up group|Rheumatoid arthritis patients in remission who will be followed by an electronic app
62014068|NCT04536844|PLACEBO_COMPARATOR|Conventional follow-up group|Rheumatoid arthritis patients in remission who will attend conventional prescheduled visits in the outpatient clinic
62014069|NCT02002767|EXPERIMENTAL|Participants with renal impairment|Participants with severe renal impairment will receive a single dose of velpatasvir.
62014070|NCT02002767|ACTIVE_COMPARATOR|Participants with normal renal function|Participants with normal renal function will receive a single dose of velpatasvir.
62014071|NCT05278156|EXPERIMENTAL|CPL500036 low dose|Patients are to receive 20 mg of CPL500036 administered once dail for 28-days treatment period.
62014072|NCT05278156|EXPERIMENTAL|CPL500036 high dose|Patients are to receive 40 mg of CPL500036 administered once dail for 28-days treatment period.
62014073|NCT05278156|PLACEBO_COMPARATOR|Placebo|Patients are to receive placebo administered once dail for 28-days treatment period.
62786150|NCT02990039|EXPERIMENTAL|Counseling letter (intervention group)|Participants of the intervention group received a brief counseling letter intervention aiming to reduce sedentary time and to increase physical activity. The intervention comprised up to three tailored letters based on separate questionnaires.
62786151|NCT02990039|NO_INTERVENTION|No counseling letter (control group)|Participants of the control group did not received the brief counseling letter intervention.
62786152|NCT02222376|ACTIVE_COMPARATOR|Conventional treatment|Weekly ulcer debridement and daily cleansing
62786153|NCT02222376|EXPERIMENTAL|Pirfenidone|Weekly ulcer debridement, daily cleansing, plus twice a day topical pirfenidone application
62786154|NCT03631134|EXPERIMENTAL|SGLT2i treatment|The patients who are using basal insulin therapy with or without oral hypoglycemic drugs will be added SGLT2 inhibitor treatment
62786155|NCT06331988||resectable colorectal cancer patient|patients with resectable CRC candidate to radical surgery and - after approximately 4-8 weeks - adjuvant chemotherapy (if indicated), accordingly to standard of care (SOC)
62202897|NCT02954978|ACTIVE_COMPARATOR|Nilotinib 150mg|Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
62579553|NCT06234293|EXPERIMENTAL|near-infrared light device|the device used is the AccuVein AV500® (Accuvein, New York USA). Nurses will have to find the vein for the PIVC using the near-infrared light device. Nurses will have to proceed as follows: apply the tourniquet, put on the near infrared light onto the upper limb. PIVC on the lower limbs is forbidden in this study. The recommended projection distance is around 20 cm, however, the optimal distance of projection can vary between 10 and 45 cm. After finding the vein, Nurses proceed to PIVC with the device turned on, the peripheral venous network visible on the skin of the patient. After the cannulation and to confirm the functionality of the peripheral intravenous access a flash of 10cc of an isotonic solution (NaCl 0.9%) will be injected
62579554|NCT06234293|NO_INTERVENTION|landmark approach|PIVC will be done by a nurse on an upper limb according to the standard approach. The nurse will proceed as follows: apply the tourniquet and find a vein for the catheterization, standard techniques to highlight veins can be used (apply alcohol, tap veins ...). After finding a vein, the nurses proceed to the PIVC according to his / her habits. The use of any device is forbidden. After the cannulation and to confirm the functionality of the peripheral venous access a flash of 10cc of an isotonic solution (NaCl 0.9%) will be injected.
62579555|NCT02423330|EXPERIMENTAL|Strattice-LIFT|
62579556|NCT02009085||Individuals undergoing skin excision.|Skin lesions are under suspicion for skin cancer.
62579557|NCT05991336||Gene therapy group|TDT Children who have received gene therapy between 3\~14 years old.
62579558|NCT05991336||Supportive therapy group|TDT Children who received lifelong treatment with blood transfusions and iron chelation. They were selected based on the age and sex of the gene therapy group.
62579559|NCT05991336||Healthy children group|Healthy children were selected based on the age and sex of the gene therapy group.
62579560|NCT03935776|EXPERIMENTAL|Risk Factors Modification Programme|"* Patients in the intervention arm will attend a 12-week intensive lifestyle programme.~* The intervention includes weekly exercise class and educational workshops, serial blood pressure, body mass index, glucose and lipid measurements.~  * Weekly multidisciplinary team meetings and targeted and protocol pharmacotherapy to support lifestyle changes."
62579561|NCT03935776|ACTIVE_COMPARATOR|Standard Healthcare|The control group will receive information and advice to the patients to modify their lifestyles but without providing a structured intervention or an individualised plan.
62579562|NCT04115930||Patient|Fatigue, cognition and quality of life measurements with different kind of tests and forms. EDSS and SFMC. Daily physical activity measurement 7days. Berg´s scale. Sit-Up 30 s and 6-minutes walking test. Length, weight and waist measurements.
62579563|NCT04115930||Control|Healthy volunteers. Fatigue, cognition and quality of life measurements with different kind of tests and forms. SFMC. Daily physical activity measurement 7days. Berg´s scale. Sit-Up 30 s and 6-minutes walking test. Length, weight and waist measurements.
62014074|NCT03995004|EXPERIMENTAL|Melatonin|"Oral Melatonin 10mg at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.~IV Normal Saline (1mL) on induction and continued q12h for 4 more doses."
62014075|NCT03995004|ACTIVE_COMPARATOR|Dexamethasone|"Placebo capsules at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.~IV Dexamethasone 4mg/1mL on induction and continued q12h for 4 more doses"
62579564|NCT06577883||Chest X-ray Tomosynthesis Participants|Participants who had a recent, routine clinical chest computed tomography scan for lung cancer screening or evaluation of nodule suspicious for lung cancer will undergo an additional chest X-ray tomosynthesis scan.
62014076|NCT03995004|EXPERIMENTAL|Dexa_Melatonin|"Oral Melatonin 10mg at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.~IV Dexamethasone 4mg/1mL on induction and continued q12h for 4 more doses"
62202898|NCT02954978|ACTIVE_COMPARATOR|Nilotinib 300mg|Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
62202899|NCT01023958|EXPERIMENTAL|single arm|open label
62202900|NCT03530748||Patients with Renal Artery Stenosis|Patients with simple renal artery stenosis or aortic dissection with renal artery obstruction
62202901|NCT04743609||Bronchiolitis|"- Children under 24 months of age (≤) with First episode of bronchiolitis.~Aims :~- For city physicians: Enrrollment of 1000 children with Bronchiolitis not associated with otitis~- In the hospital (at pediatric emergencies): Enrrollment of 900 children with bronchiolitis"
62579565|NCT04141501|PLACEBO_COMPARATOR|Control: Placebo|30 Patients will receive placebo
62579566|NCT04141501|ACTIVE_COMPARATOR|Intervention: Psilocybin|30 Patients will receive psilocybin
62579567|NCT03408301||Tourniquet deflation|Tourniquet deflation after insertion of the prosthetic components during total knee replacement arthroplasty under spinal anesthesia
62786156|NCT01973413|EXPERIMENTAL|Closed-Loop Control with DiAs System|Subjects will use the Diabetes Assistant (DiAs) and will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. Subjects will be remotely monitored throughout the night in real time.
62202902|NCT04743609||Acute otitis media|"Define with Paradise Criteria) or otorrhea~Enrrollment only for city physicians :~* 500 children with Otitis not associated with Bronchiolitis~* 500 children with Otitis associated with Bronchiolitis"
62202903|NCT04743609||Pneumonia|"Defined by the presence of opacity of parenchymal condensation and/or pleural effusion on chest X-ray associated with fever.~Aims:~- For city physicians: Enrrollment of 100 children with pneumonia~- In the hospital (pediatric emergencies): Enrollment of 500 children with pneumonia"
62202904|NCT02517762|EXPERIMENTAL|Stay active|Receive the advice by the physician to stay as active as possible in spite of the pain experienced
62202905|NCT02517762|EXPERIMENTAL|Adjust activity|Receive the advice by the physician to adjust the activity according to the pain, i.e. to avoid activities, movements or positions that cause or worsen the pain
62202906|NCT01807338||saline|Saline administration to patients with idiopathic Parkinson's disease (PD) of moderate severity, who have previously been treated with sNN0031
62202907|NCT00508053|ACTIVE_COMPARATOR|1|Mass closure
62202908|NCT00508053|EXPERIMENTAL|2|Small stitches
62202909|NCT06138652|EXPERIMENTAL|App|Participants completed surveys at baseline and again after 8 weeks. Participants completed app-based games and consultation with a mentor over an 8 week period focused on alleviating anxiety.
62202910|NCT06138652|NO_INTERVENTION|Control|Participants completed surveys at baseline and again after 8 weeks.
62202911|NCT05105334|EXPERIMENTAL|Nonablative fractional laser alone|
62202912|NCT05105334|EXPERIMENTAL|Nonablative fractional laser alternating with microneedling with radiofrequency|
62202913|NCT01200342|EXPERIMENTAL|Genasense + Paclitaxel + Carboplatin|Genasense 900 mg intravenous (IV) on a fixed-dose as a 1-hour infusion on Days 1, 3, and 5 of a 21 day cycle; Paclitaxel 175 mg/m\^2 IV over 3 hours Day 3 after Genasense; Carboplatin dose in mg (target area under the concentration \[AUC)\]=6) administered over 30 minutes IV Piggyback (IVPB) on Day 3 after Paclitaxel.
62202914|NCT04341467|EXPERIMENTAL|Amisulpride group|The initial dose of amisulpride group is 50mg/d, and the maximum dose is 800mg/d.
62202915|NCT04341467|ACTIVE_COMPARATOR|Olanzapine group|The initial dose of olanzapine is 2.5 mg/d, and the maximum dose is 20 mg/d.
62202916|NCT01730950|ACTIVE_COMPARATOR|Bevacizumab|Bevacizumab every 2 weeks
62202917|NCT01730950|EXPERIMENTAL|Bevacizumab + RT|Radiation therapy with bevacizumab every 2 weeks
62202918|NCT05287490|EXPERIMENTAL|treatment|
62202919|NCT05692700|EXPERIMENTAL|Aromatherapy lavender group|Stage 1: Patient information form, follow-up form, State Continuity Anxiety Scale, Richard-Campbell Sleep Scale were filled.Stage 2: On the second day of the surgery, at 20:00 in the evening, they were asked to inhale 2-3 drops of lavender essential oil, which was dripped onto the pillow pouches, at 21:00, and these bags were placed 10 cm away from the patient after 20 minutes. These bags were taken from the bedside of the patient at 08:00 in the morning.. Stage 3: Before the evening application, the patient follow-up form, State-Continuity Anxiety Scale, Richard Campbell Sleep Scale were filled and they were asked to inhale 2-3 drops of lavender essential oil, which was dropped on the pillow bags prepared at 20:00, and inhaled at 21:00. Afterwards, these sacs were placed 10 cm away from the patient. These sacs were taken from the bedside of the patient at 08:00 in the morning and the patient follow-up Form, State-Trait Anxiety Scale, Richards-Campbell Sleep Scale were filled
62202920|NCT05692700|EXPERIMENTAL|Aromatherapy bergamot group|Stage1:Patient information form, follow-up form, State Continuity Anxiety Scale, Richard Campbell Sleep Scale were filled. Stage 2:On the second day of the surgery, at 20:00 in the evening, they were asked to inhale 2-3 drops of bergamot essential oil, which was dripped onto the pillow pouches,at 21:00, and these bags were placed 10 cm away from the patient after 20 minutes. These bags were taken from the bedside of the patient at 08:00 in the morning.Stage 3:Before the evening application, the patient follow-up form, State-Continuity Anxiety Scale, Richard Campbell Sleep Scale were filled and they were asked to inhale 2-3 drops of bergamot essential oil, which was dropped on the pillow bags prepared at 20:00, and inhaled at 21:00. Afterwards, these sacs were placed 10 cm away from the patient.These sacs were taken from the bedside of the patient at 08:00 in the morning and the patient follow-up Form, State-Trait Anxiety Scale, Richards-Campbell Sleep Scale were filled.
62579568|NCT00520533|EXPERIMENTAL|On Study|"Treatment (cycle 1):~* cG250 10mg/m² IV weekly x 5 doses (1st \& 5th doses trace-labelled with 124I)~* Sunitinib 50 mg/day orally x 4 weeks commencing day 8~* Followed by two-week break~Treatment (cycle 2 - investigator discretion):~* cG250 10mg/m² IV weekly x4 doses~* Sunitinib 50 mg/day orally x 4 weeks (commencing concurrently)~* Followed by two-week break"
62014077|NCT06219655|ACTIVE_COMPARATOR|Extended symathectomy|
62202921|NCT05692700|PLACEBO_COMPARATOR|Plasebo group|Stage 1:Patient identification form, follow-up form, State Continuity Anxiety Scale, Richard Campbell Sleep Scale were filled in.Stage2: 2-3 drops of distilled water dripped onto the prepared pillow bags at 21:00 on the second and third days of the surgery by inhalation. They were asked to breathe and after 20 minutes, these sacs were taken and placed 10 cm away from the patient.Stage 3:These sacs were taken from the bedside of the patient at 08:00 in the morning and the patient follow-up form, State-Trait Anxiety Scale, Richards Campbell Sleep Scale were filled again.
62202922|NCT00513305|ACTIVE_COMPARATOR|Low-dose cytarabine plus arsenic trioxide|Cycle 1 cytarabine 10 mg/m\^2 was administered subcutaneously (sc) twice daily (bid) on days 1-14. 0.25 mg/kg arsenic trioxide was administered intravenously (iv) on days 1-5 and days 8-12. Cycle 2 A second identical cycle of cytarabine and arsenic trioxide was given to patients with persistent disease. Patients who achieved complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine and arsenic trioxide with the doses and schedule identical to the initial cycle. A recovery period of up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of arsenic trioxide 0.25 mg/kg iv on days 1 and 4 and cytarabine 10 mg/m\^2 sc bid on days 1 through 7 of a 28-day cycle.
62202923|NCT00513305|ACTIVE_COMPARATOR|Low-dose cytarabine alone|Cytarabine was administered at a dose of 10 mg/m\^2 sc bid from days 1-14 of cycle 1. A second identical cycle of cytarabine was given to patients with persistent disease. Patients who achieved a complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine with the doses and schedule identical to the initial treatment cycle. Recovery period up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of cytarabine at 10 mg/m\^2 sc bid on days 1-7 of a 28-day cycle. Patients started maintenance treatment within 42 days after platelet count recovery. Maintenance treatment continued for 2 years or until unacceptable toxicity or disease progression.
62014078|NCT06219655|ACTIVE_COMPARATOR|limited sympathectomy|
62014079|NCT05647824||All Subjects|Consists of people with Diabetes and people without Diabetes
62014080|NCT05573295||Children with CLP|
62014081|NCT05573295||Healthy controls with gender-age match|
62403208|NCT00683670|EXPERIMENTAL|Dendritic Cell Vaccine (Third Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 6 weeks for a total of 3 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 in order to collect PBMC for immune monitoring.
62579569|NCT02659007|EXPERIMENTAL|yoga|yoga, 2 times a week for 8 weeks
62579570|NCT02097563|EXPERIMENTAL|High Intensity Training|High intensity training: clinician attends a 6-hr live workshop in family-focused treatment techniques, and then, after taking on a case, gets weekly technical consultation sessions (by telephone) in FFT from an expert after every session;
62579571|NCT02097563|ACTIVE_COMPARATOR|Low Intensity Training|Low Intensity Training: clinician completes online workshop in FFT and then, after taking on a case, gets telephone consultation sessions after every third session.
62579572|NCT05999435|EXPERIMENTAL|LAU-7b for 3 cycles|Each study arm will consist of three (3) cycles of 14 days of treatment intake each spaced by a treatment holiday of 14 days.
62579573|NCT05999435|EXPERIMENTAL|LAU-7b for 1 cycle, then placebo|Each study arm will consist of three (3) cycles of 14 days of treatment intake each spaced by a treatment holiday of 14 days.
62579574|NCT05999435|PLACEBO_COMPARATOR|Placebo for 3 cycles|Each study arm will consist of three (3) cycles of 14 days of treatment intake each spaced by a treatment holiday of 14 days.
62579575|NCT00945711||1|Eating Disorder Diabetes Mellitus T1 patients
62579576|NCT00945711||2|Eating Disorder only patients
62579577|NCT04554810|ACTIVE_COMPARATOR|Intervention group|Intervention group participants are the refugees who received the medication management review service and pharmacist's counselling. They have been assessed at baseline and at follow-up after 3 months) home visits.
62579578|NCT04554810|NO_INTERVENTION|Control group|Control group participants are the refugees who did not received the medication management review service and no pharmacist's counselling wsa provided to them during the study period. They have been assessed at baseline and at follow-up (after 3 months) home visits.
62579579|NCT04037475|PLACEBO_COMPARATOR|Control (placebo)|The patients will receive an agent with the same vehicle as methylene blue to mimic irrigation with the photosensitizer and the laser will be switched off at the time of application. The placebo PDT procedures will be performed on the lesion: Application of methylene blue placebo with a carpule syringe and needle (with stop and without bevel) inside the lesions; 1 minute of pre-irradiation will be expected. The irradiations will be performed with the same device positioned in the same way and at the same time of application, however, the laser will be turned off. The beep sound will be recorded and turned on during application to blind treatment to the patient. The patient will receive a catheter with acyclovir cream and will be advised to spread on the lesions four times a day for 7 days, which will be their return for reevaluation. It will be washed in abundance with saline (saline solution) until the total removal of the placebo from the photosensitizer.
62579580|NCT04037475|EXPERIMENTAL|experimental group|Patients will be treated with photodynamic therapy and will receive a placebo ointment simulating acyclovir cream. If the lesions are in the vesicle phase, they will be ruptured with a sterile needle. The methylene blue solution at 0.005% concentration will be gently placed on the lesions. Application of methylene blue on the lesions.1 minute of pre-irradiation will be expected. The irradiations will be performed with the Laser Duo® with a wavelength of 660 nm, with a power of 100 mW(milliwatts), the energy density of 300 J / cm², with the energy of 3 J (joules) in the center of the lesion for 30 seconds. The laser will be positioned in direct contact with the lesion, perpendicular, applied centrally to each lesion with energy per point of 3J. Wash in abundance with saline solution until the removal of the photosensitizer is complete. Patients will receive a tube with a placebo cream simulating aciclovir and the same will be advised to spread the cream 4 times per day for 7 days.
62734814|NCT06277856|EXPERIMENTAL|peer interaction|The rooms will be arranged for two people and experienced and inexperienced mothers will be accommodated together. At a time when the mothers are available, the researcher will visit the mothers in their rooms, explain the purpose of the study and start the peer interaction session. In providing peer interaction, firstly, introductions will be made and the general condition of mothers and babies will be evaluated. The researcher will assess the breastfeeding status of the mothers and provide training on breastfeeding and breastfeeding.
62403209|NCT02213627|EXPERIMENTAL|Corifollitropin alfa|From day 2-3 of mense, a single 100 microgram dose of corifollitropin alfa is administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
62403210|NCT02213627|EXPERIMENTAL|Recombinant FSH|From day 2-3 of mense, daily injections of 150 IU of recombinant FSH will be administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
62403211|NCT02213627|EXPERIMENTAL|HP-hMG|From day 2-3 of mense, daily doses of 225 IU of HP-hMG will be administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
62403212|NCT02400697||<30 wks gestation or 1500 grams|Preterm infants born at participating hospitals
62403213|NCT02400697||30 wks to <34 wks gestation|Preterm infants born at participating hospitals
62014082|NCT05600218||Cohort 1|Patients with pulmonary arterial hypertension on treatment with prostacyclin IP receptor agonists because they are at intermediate risk of mortality at one year
62579581|NCT04075071|EXPERIMENTAL|TCIT-U|Four teachers from two Head Start classrooms will be assigned to Teacher-Child Interaction Training - Universal (TCIT-U). TCIT-U occurs in two phases (6 weeks per phase): Child-Directed Interaction (CDI; focusing on relationship building) and Teacher-Directed Interaction (TDI; focusing on managing behavior problems). The TCIT-U Trainer (a licensed clinical child psychologist) will provide teachers with group didactic sessions (6 hours per phase) and individualized live coaching in their classrooms (20 minutes, once per week). Strategies include the use of PRIDE skills (Praise, Reflection, Imitation, Behavior Description, and Enthusiasm) or specific verbalizations that promote warm, responsive interactions, as well as classroom-appropriate behavior modification strategies which include using effective commands, prompts, natural consequences, differential social attention, and a modified time-out appropriate for use in a classroom.
62014083|NCT06063941|ACTIVE_COMPARATOR|1% iodine solution arm|Esophageal chromoendoscopy will be performed with a 15 ml volume of 1% Lugol iodine solution.
62579582|NCT04075071|NO_INTERVENTION|Usual Care|Four teachers from 2 PreK Counts classrooms will be assigned to the Usual Care (UC) group. They will continue their existing behavioral management strategies and techniques. Teachers will report on specific training in and use of other behavior management and social-emotional learning programs at baseline. At the conclusion of the study, UC teachers and staff will be offered didactic training in TCIT-U principles and strategies.
62014084|NCT06063941|EXPERIMENTAL|5% iodine solution arm|Esophageal chromoendoscopy will be performed with a 3 ml volume of 5% iodine stock solution.
62579583|NCT06433778||Participants diagnosed With Congenital VWD|Participants who have been diagnosed with congenital VWD and prescribed rVWF within the index date range (defined as the first administration of rVWF and must fall between 1st October 2020 and 30th June 2022) will be assessed using data obtained from medical records to evaluate the treatment outcome of rVWF in real-world clinical practice.
62579584|NCT03570164|EXPERIMENTAL|Sevoflurane|Anesthesia is maintained with sevoflurane.
62579585|NCT03570164|EXPERIMENTAL|Desflurane|Anesthesia is maintained with desflurane.
62579586|NCT01876810|EXPERIMENTAL|Gemfibrozil|600 mg of gemfibrozil (one capsule) twice daily for two weeks.
62579587|NCT01876810|PLACEBO_COMPARATOR|Placebo pill|One lactose pill twice a day for two weeks.
62579588|NCT02251418|EXPERIMENTAL|Extracorporeal shockwave therapy|6 times extracorporeal shockwave therapy in 3 weeks. This arm also receives standard care treatment.
62579589|NCT02251418|NO_INTERVENTION|Control|Standard care treatment
62579590|NCT00706576|EXPERIMENTAL|Infusion of opioid growth factor|Volunteers will be treated with an intravenous infusion of opioid growth factor(OGF) starting at 100 µg/kg with a 50 µg/kg dose escalation with each succeeding group. The investigational drug, OGF, will be diluted in sterile saline to its appropriate concentration based upon the body weight of the volunteer and administered in a volume of 60 ml over 45 minutes (rate of 2 ml/min)
62579591|NCT05082272||Preterm neonates with bronchopulmonary dysplasia with pulmonary hypertension|Preterm neonates who continued need for respiratory support persisting at 36 weeks corrected postmenstrual age and diagnosed with pulmonary hypertension on echocardiographic examination
62579592|NCT05082272||Preterm neonates with bronchopulmonary dysplasia and without pulmonary hypertension|Preterm neonates who continued need for respiratory support persisting at 36 weeks corrected postmenstrual age and whose echocardiographic examination were normal
62579593|NCT05082272||Healty preterm neonates|preterm neonates with neither bronchopulmonary dysplasia nor pulmonary hypertension
62579594|NCT05126394|EXPERIMENTAL|Group A ( SAPB) group|this group of patients receives serratus anterior plane block, just after induction of anesthesia.
62579595|NCT05126394|NO_INTERVENTION|Group B: control group|this group of patients does not receive any blockade, they receive conventional IV analgesics.
62014085|NCT05050188|EXPERIMENTAL|cohort 1: H008 20mg|H008 20mg tablets, orally, once, daily, for 7 days
62014086|NCT05050188|EXPERIMENTAL|cohort 1: H008 placebo 20mg|H008 placebo 20mg tablets, orally, once, daily, for 7 days
62014087|NCT05050188|EXPERIMENTAL|cohort 1: Lansoprazole 30mg|Lansoprazole 30mg capsule, orally, once, daily, for 7 days
62014088|NCT05050188|EXPERIMENTAL|cohort 2: H008 40mg|H008 40mg tablets, orally, once, daily, for 7 days
62579596|NCT06325384|ACTIVE_COMPARATOR|Cuff Arm|Blood Pressure Cuff
62579597|NCT06325384|EXPERIMENTAL|LifeLight Arm|Contactless Vital Signs Monitor using RPPG
62579598|NCT03253549|EXPERIMENTAL|SMArTVIEW|
62014089|NCT05050188|EXPERIMENTAL|cohort 2: H008 placebo 40mg|H008 placebo 40mg tablets, orally, once, daily, for 7 days
62202924|NCT01468181|EXPERIMENTAL|LY2189265 + Sulfonylureas (SU)|"LY2189265: 0.75 milligrams (mg) administered subcutaneously (SC), once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of SU monotherapy throughout the study."
62202925|NCT01468181|EXPERIMENTAL|LY2189265 + Biguanides (BG)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of BG monotherapy throughout the study."
62579599|NCT03253549|NO_INTERVENTION|Standard Care|
62579600|NCT01259362|ACTIVE_COMPARATOR|Transcranial Magnetic Stimulation|Cocaine addicted will receive a 20 day TMSr to right dorsolateral prefrontal cortex.
62202926|NCT01468181|EXPERIMENTAL|LY2189265 + alpha-glucosidase inhibitor (a-GI)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of a-GI monotherapy throughout the study."
62403214|NCT06249087|EXPERIMENTAL|the observation group|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
62403215|NCT06249087|ACTIVE_COMPARATOR|the control group|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the control group was given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements."
62403216|NCT00990366|ACTIVE_COMPARATOR|biliary stent without an antireflux valve|patients with biliary obstruction who need a biliary stent, selected for the stent without an antireflux valve arm
62403217|NCT00990366|ACTIVE_COMPARATOR|biliary stent with an antireflux valve|patients with biliary obstruction, who need a biliary stent, selected for the stent with an antireflux valve arm
62202927|NCT01468181|EXPERIMENTAL|LY2189265 + Thiazolidinedione (TZD)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of TZD monotherapy throughout the study."
62202928|NCT01468181|EXPERIMENTAL|LY2189265 + Glinides|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of glinides monotherapy throughout the study."
62202929|NCT00949000|OTHER|ICD Implant|Implantation of a commercially available AnalyST or AnalyST Accel ICD
62403218|NCT05144919|NO_INTERVENTION|Control|The control group will continue to receive routine health check and nutrition education from health staff at commune health facilities. Access to agriculture extension services as offered by provincial staff will also continue as normal.
62579601|NCT01259362|SHAM_COMPARATOR|Transcranial Magnetic Stimlation|cocaine addicted will receive a 20 day sham TMSr to right dorsolateral prefrontal cortex
62579602|NCT03975140|EXPERIMENTAL|Hypersensitive acupoint group|
62579603|NCT03975140|ACTIVE_COMPARATOR|Hyposensitive acupoint group|
62579604|NCT01584986|ACTIVE_COMPARATOR|ACP treated|Autologous angiogenic cell precursors (ACPs) were injected into the ischemic gastrocnemius muscle in addition to the conventional treatment.
62579605|NCT01584986|NO_INTERVENTION|Control|Control patients were treated with the conventional therapy.
62202930|NCT02311647||Post Tamoxifen exposure group|Breast cancer patients receiving or formerly received Tamoxifen for at least 1 year.
62202931|NCT02311647||Control group|Breast cancer patients who did not receive endocrine treatment
62202932|NCT02893839|OTHER|Prick to prick|
62202933|NCT02758067|EXPERIMENTAL|brexpiprazole|
62202934|NCT02758067|EXPERIMENTAL|risperidone|
62202935|NCT03987971|EXPERIMENTAL|Deep acupuncture on GB26|
62202936|NCT03987971|SHAM_COMPARATOR|Superficial acupuncture on GB26|
62202937|NCT03987971|NO_INTERVENTION|waiting list|
62202938|NCT04815980|NO_INTERVENTION|Control|The control group performed no Pilates intervention. They continued with their typical activities of daily living.
62014090|NCT05050188|EXPERIMENTAL|cohort 2: Lansoprazole 30mg|Lansoprazole 30mg capsule, orally, once, daily, for 7 days
62014091|NCT02279810||Medical students, medical staff|Survey about Knowledge, Attitude and Practice About Organ Transplantation
62786157|NCT01973413|PLACEBO_COMPARATOR|Control Group, Sensor-Augmented Pump Therapy|Subjects will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. They will not use the Diabetes Assistant (DiAs) nor have remote monitoring.
62786158|NCT04044742|EXPERIMENTAL|Resiniferatoxin|12.5 ug of Resiniferatoxin in 5 mL volume is administered as a one-time dose, intra-articularly
62786159|NCT04044742|PLACEBO_COMPARATOR|Placebo|Placebo formulation in 5 mL volume administered intra-articularly
62202939|NCT04815980|EXPERIMENTAL|Pilates|Participants in this group performed a 30 minute mat-based Pilates intervention 3 times/week for 12 weeks.
62202940|NCT00933790|ACTIVE_COMPARATOR|2EHRZ3/4HR3|Regimen 3. Intermittent - 2EHRZ3/4HR3 (E 1200mg, H 600 mg, R 450/600 mg depending on Weight \<60, 600 mg for 60 kg or more, Z 1500 mg given thrice weekly)
62403219|NCT05144919|EXPERIMENTAL|Intervention|The intervention group will receive capacity building sessions on both Agriculture and Nutrition, in addition to access to routine health and nutrition checks, and agriculture extension as offered by commune and provincial staff as normal.
62403220|NCT06523322|EXPERIMENTAL|Culinary Medicine plus Caregiver Coaching|8-week culinary medicine program, including 4 biweekly culinary medicine workshops and biweekly caregiver coaching.
62786160|NCT00013013|OTHER|Arm 1|
62786161|NCT05041972|EXPERIMENTAL|Cohort 1: HER2 Mutated Non-Small Cell Lung Cancer (NSCLC)|Intervention: Drug: ARX788
62786162|NCT05041972|EXPERIMENTAL|Cohort 2: HER2 Mutation Breast Cancer|Intervention: Drug: ARX788
62786163|NCT05041972|EXPERIMENTAL|Exploratory Cohort A: Other HER2-Mutated tumors|Intervention: Drug: ARX788
62786164|NCT05041972|EXPERIMENTAL|Cohort 3: HER2 Amplification Biliary Tract Cancer (BTC)|Intervention: Drug: ARX788
62786165|NCT05041972|EXPERIMENTAL|Cohort 4 HER2 Amplification Colorectal (CRC), Ovarian Endometrial, NSCLC, and other solid tumors|Intervention: Drug: ARX788
62786166|NCT05041972|EXPERIMENTAL|Cohort 5: HER2 Mutation or HER2 Amplification Solid Tumors|Intervention: Drug: ARX788
62786167|NCT01922791|ACTIVE_COMPARATOR|Probiotic|Comparison of probiotics, fish oil and their combination to placebo
62014092|NCT06570096|EXPERIMENTAL|Sequential Injections group|Patients will receive 10 ml of lidocaine 2% then 10 ml of bupivacaine 0.5% with a delay of 120s between injections.
62014093|NCT06570096|ACTIVE_COMPARATOR|Premixed Injections group|Patients will receive 20 ml of freshly prepared mixtures of 10 ml of lidocaine 2% and 10 ml of bupivacaine 0.5%
62014094|NCT02481687||Ulcerative colitis|"Consecutively admitted patients with active ulcerative colitis, confirmed by histopathology.~I-SCAN and pCLE will be applied in all patients."
62014095|NCT02481687||Crohn's disease|"Consecutively admitted patients with active Crohn's disease, confirmed by histopathology.~I-SCAN and pCLE will be applied in all patients."
62014096|NCT01692197|EXPERIMENTAL|E7070 + Idarubicin + Cytarabine|E7070 400 mg/m2 IV over 1 hour on day 1 and day 8 (+/- 2 days on Day 8 only) followed by, Idarubicin 8 mg/m2 IV over 1 hour daily for 3 days (days 9-11) and Cytarabine 1.0 g/m2 IV over 24 hours daily on day 9-12 (age \<60 years) or days 9-11 (age \> 60 years). Dexamethasone 10 mg IV daily for 3-4 days with cytarabine.
62014097|NCT04865679|EXPERIMENTAL|Axoguard Nerve Cap®|"Active Comparator: Porcine derived extracellular matrix (ECM) based Nerve Termination Device~Implantation of appropriate diameter of Axoguard Nerve Cap® (sizes 5-7 mm) at the time of surgery"
62202941|NCT00933790|EXPERIMENTAL|2EHRZ7/4HR7|Regimen 1. Daily - 2EHRZ7/4HR7 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight \<60, 600 mg for 60 kg or more, Z 1500 mg daily)
62202942|NCT00933790|EXPERIMENTAL|2EHRZ7/4HR3|Regimen 2. Part Daily - 2EHRZ7/4HR3 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight \<60, 600 mg for 60 kg or more, Z 1500 mg daily in the intensive phase followed by H-600 mg ,R-450/600 mg in the continuation phase thrice weekly)
62202943|NCT05169697|EXPERIMENTAL|YH002 in combination with YH001|Dose escalation:A traditional 3+3 dose escalation algorithm will be utilized to identify MTD and/or RP2D Dose expansion:One selected dose after the escalation stage will be expanded to enroll additional 20 subjects. The subjects will be divided into two groups：A and B.
62202944|NCT02611453|EXPERIMENTAL|Single arm|"All patients will undergo endoscopic retrograde cholangiopancreatography (ERCP) that is indicated for suspected or confirmed choledocholithiasis or biliary strictures. Air contrast cholangiography using carbon dioxide gas will be performed with standard fluoroscopy and digital subtraction fluoroscopic image capture followed by routine cholangiography using iodinated contrast and standard fluoroscopy. Carbon dioxide (CO2) is routinely used in ERCP procedures and would flow into the biliary tree of patients at the time of ERCP, irrespective of this study's interventions. Digital subtraction image capture is a commercially available setting on certain fluoroscopy units that optimizes resolution with air or CO2 used as a contrast medium."
62786168|NCT01922791|ACTIVE_COMPARATOR|Fish oil|Comparison of probiotics, fish oil and their combination to placebo
62786169|NCT01922791|ACTIVE_COMPARATOR|Probiotics and Fish oil|Comparison of probiotics, fish oil and their combination to placebo
62786170|NCT01922791|PLACEBO_COMPARATOR|Placebo|Comparison of probiotics, fish oil and their combination to placebo
62786171|NCT06262464|EXPERIMENTAL|Prevention|6 group, online sessions over two weeks. A prevention program using cognitive and behavioral strategies to reduce OCD risk factors and related symptoms.
62786172|NCT06262464|NO_INTERVENTION|Control|Treatment as Usual
62786173|NCT03657849|EXPERIMENTAL|Sampling with 19-gauge and 21-gauge|All patients will be allocated to the same arm. All patients will have EBUS TBNA done with both 19-gauge and 21-gauge needles during the procedure.
62579606|NCT05340127|EXPERIMENTAL|Subjects examined by the study participants using CEREBO®|"CEREBO® - A non-invasive intracranial haemorrhage detector~Scan Duration - 40 seconds per subject~Frequency - Every operator will perform CEREBO® scan on at least 10 different subjects~Adverse Effect: None"
62579607|NCT03953495|EXPERIMENTAL|Better Together|Participants will be recruited with e-mail, print, and social media announcements and advertisements distributed through the professional contacts and networks of the investigators. The experimental group will consist of randomly assigned volunteers who meet the eligibility requirements (i.e., same-sex female couple over the age of 18 who lives in Central Appalachia).
62786174|NCT03862235||Anabolic androgenic steroids users|"This group had been involved in strength training for at least 2 years, self-administering anabolic androgenic steroids in periodic cycles lasting from 8 to 12 weeks for at least 2 years with 2-4 cycles per year. All participants were on a cycle over the course of the study.~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
62786175|NCT03862235||Anabolic androgenic steroids nonusers|"This group had been involved in strength training for at least 2 years and they have never took anabolic androgenic steroids.~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
62014098|NCT02247310||Cohort 1|Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome and be on treatment with Betaferon using the BETACONNECT auto-injector device.
62579608|NCT04683393||Healthy Subjects|To compare the markers of frailty (MoF) in patients with multiple myeloma (MM) with the healthy subjects.
62014099|NCT01275924|ACTIVE_COMPARATOR|Tightrope|Treatment with Tightrope Syndesmosis Repair Kit
62014100|NCT01275924|ACTIVE_COMPARATOR|Syndesmotic screw|Treatment with a quadricortical syndesmotic screw
62014101|NCT04535596|EXPERIMENTAL|Conventional Exercises|12 week long strength training exercise with the higher loading (%70-80 of 1 Repetitive Maximum)
62014102|NCT04535596|EXPERIMENTAL|Blood Flof Restriction Exercises|12 week long strength training exercise with the lower loading (%20-30 of 1 Repetitive Maximum) by using cuff around the thigh
62014103|NCT02877485|ACTIVE_COMPARATOR|Triamcinolone acetonide then Ayr spray|This study arm will start with 6 weeks of therapy with the intranasal steroid, followed by 6 weeks of therapy with a placebo, with a two week washout period in between treatments.
62014104|NCT02877485|ACTIVE_COMPARATOR|Ayr spray then triamcinolone acetonide|This study arm will start with 6 weeks of placebo, followed by 6 weeks of therapy with the intranasal steroid, with a two week washout period in between treatments.
62014105|NCT02237105|EXPERIMENTAL|Cognitive Behavioral Therapy Group|This group will undergo Cognitive Behavioral Therapy (CBT) before having spinal surgery
62014106|NCT02237105|NO_INTERVENTION|control group|This group will not undergo any psychological intervention before the spinal surgery.
62014107|NCT05262361|EXPERIMENTAL|Office based Vergence and Accommodative Therapy immediately after enrollement|This arm will start immediately after baseline assessment. The participant will have two sessions of one hour each for 6 weeks (12 office-based vergence and accommodative therapy sessions). The first outcome measurement will be attained by a masked optometrist. Then, the participant will have 2 more weeks of therapy (4 office-based vergence and accommodative therapy sessions). The second and final outcome measurement will be attained. Assessments include a masked optometric vision exam, objective eye movement recordings and an functional MRI scan.
62014108|NCT05262361|NO_INTERVENTION|Office based Vergence and Accommodative Therapy Delay 6 weeks post enrollment|This arm will start with a 6 week delay (no vision therapy) after baseline assessment to evaluate natural recovery. After 6 weeks, the first outcome assessment will be attained by a masked optometrist. The participant will have two sessions of one hour each for 8 weeks (16 office-based vergence and accommodative therapy sessions). The second and final outcome measurement will be attained. Assessments include a masked optometric vision exam, objective eye movement recordings and an functional MRI scan.
62014109|NCT06127134|ACTIVE_COMPARATOR|Straight-line flow (Group A)|treating less diseased arteries which is in line with distal run off the foot
62014110|NCT06127134|SHAM_COMPARATOR|Angiosome-targeted (Group B)|treating specific angiosome through a targeted vessel which mainly supplies this angiosome
62786176|NCT03862235||Sedentary control|"This group were sedentary men without cardiovascular disease.~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
62014111|NCT01587183|OTHER|Educational materials control|Enhanced usual care
62014112|NCT01587183|ACTIVE_COMPARATOR|Group running style B|Basic running instruction using group based training.
62014113|NCT01587183|EXPERIMENTAL|Group running style A|Form focused running instruction using group based training.
62014114|NCT05020743||Patients with ALSP|
62014115|NCT05020743||Patients with Prodromal ALSP|
62014116|NCT02098343|EXPERIMENTAL|Phase Ib. APR-246 (35mg/kg) + Carboplatin/PLD.|Dose escalation of APR-246.
62579609|NCT04683393||MM Patients|Patients with multiple myeloma (MM), the aim is to assess if any of the proposed parameters and markers of frailty (e.g. biomarkers of cellular senescence and organ damage, inflammatory markers, physical tests such as gait speed and hand grip test) are associated with frailty status, defined according to the GA, at baseline.
62579610|NCT05175118|OTHER|Minimally invasive fixation|Minimally Invasive Surgical Fixation for Unstable Fractures of the distal end Radius in Adults
62734815|NCT06277856|NO_INTERVENTION|control group|Women in this group benefit from all routine postnatal care services of the hospital. Each mother is guided to breastfeeding by the breastfeeding counsellor and receives training. This group will also be given a brochure by the researcher, their breastfeeding status will be evaluated and if they have any questions, they will be answered.
62014117|NCT02098343|EXPERIMENTAL|Phase II: Arm A. APR-246 + Carboplatin/PLD.|Experimental
62014118|NCT02098343|ACTIVE_COMPARATOR|Phase II: Arm B. Carboplatin/PLD.|Active Comparator
62014119|NCT02098343|EXPERIMENTAL|Phase Ib. APR-246 (50mg/kg) + Carboplatin/PLD.|Dose escalation of APR-246.
62014120|NCT02098343|EXPERIMENTAL|Phase Ib. APR-246 (67.5mg/kg) + Carboplatin/PLD.|Dose escalation of APR-246.
62202945|NCT00732862|EXPERIMENTAL|1|Baseline clamp study before treatment phase.
62579611|NCT01419067|OTHER|Craniopharyngioma Patients|"Craniopharyngioma patients will have limited surgery and a 5mm clinical target volume margin in combination with proton therapy. Proton therapy will be indicated for patients with diagnosed craniopharyngioma who are not treated with radical surgery (gross-total resection). Patients who have had radical surgery or limited surgery prior to enrollment on this study and have no evidence of tumor will be observed for 5 years.~Participants receive \^1\^8F-fluorodeoxyglucose and \^1\^1C-methionine will be given to aid in tumor visualization."
62579612|NCT03425396|EXPERIMENTAL|Omadacycline 300/300 once every 24 hours|Participants received omadacycline 300 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 300 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
62579613|NCT03425396|EXPERIMENTAL|Omadacycline 450/300 once every 24 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 300 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
62579614|NCT03425396|EXPERIMENTAL|Omadacycline 450/450 once every 24 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 450 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
62579615|NCT03425396|EXPERIMENTAL|Omadacycline 450/450 once every 12 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 450 milligrams orally, once every 12 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
62579616|NCT03425396|ACTIVE_COMPARATOR|Nitrofurantoin 100/100 once every 12 hours|Participants received nitrofurantoin 100 milligrams orally, once every 12 hours, fed on Day 1 and nitrofurantoin 100 milligrams orally, once every 12 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
62579617|NCT05677256|EXPERIMENTAL|IPV-primed Group|Approximately 250 subjects to receive 3 doses of IPV administered at approx. 6, 10, 14 weeks of age and an nOPV2-002 challenge at approx. 18 weeks of age.
62579618|NCT05677256|ACTIVE_COMPARATOR|bOPV-primed Group|Approximately 250 subjects to receive 3 doses of bOPV administered at approx. 6, 10, 14 weeks of age and an nOPV2-002 challenge at approx. 18 weeks of age.
62579619|NCT01916681|EXPERIMENTAL|Cervical foley & Misoprostol|Patients randomized to this arm will receive a cervical foley and misoprostol to induce their labor.
62579620|NCT01916681|EXPERIMENTAL|Misoprostol only|Patients randomized to this arm will receive misoprostol only to induce their labor.
62579621|NCT01916681|EXPERIMENTAL|Cervical foley alone|Patients randomized to this arm will receive a cervical foley to induce their labor.
62579622|NCT01916681|EXPERIMENTAL|Cervical foley & Pitocin|Patients randomized to this arm will receive a cervical foley and pitocin to induce their labor.
62734816|NCT00575107|EXPERIMENTAL|VSC-VLC|velocity-controlled variable resistance, lengthening contraction
62202946|NCT00732862|ACTIVE_COMPARATOR|2|Final clamp experiment after 6 months intensive therapy.
62202947|NCT05915949|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10 mg once daily will be given to participants.
62014121|NCT06022159|EXPERIMENTAL|Neo-adjuvant Cohort|
62202948|NCT05915949|ACTIVE_COMPARATOR|Lobeglitazone|Lobeglitazone 0.5 mg once daily will be given to participants.
62202949|NCT05915949|ACTIVE_COMPARATOR|Dapagliflozin and Lobeglitazone combined|Dapagliflozin 10 mg and lobeglitazone 0.5 mg once daily together will be given to participants.
62786177|NCT04346446|EXPERIMENTAL|Convalescent Plasma+Supportive Care|Convalescent Plasma+Supportive Care Convalescent plasma from recovered COVID-19 patients will be transfused to severely sick COVID-19 infected patients
62786178|NCT04346446|ACTIVE_COMPARATOR|Random Donor Plasma+Supportive Care|Random Donor Plasma+Supportive Care
62786179|NCT04007419|EXPERIMENTAL|Single Arm|The Promotoras de Donación eLearning module will be launched and 40 participating lay health educators trained. Access to the module will be provided via a link to the website embedded in an announcement email. To assess the impact of the Promotoras de Donación eLearning module on lay health educators' knowledge of organ donation and the need for Hispanic donors, and confidence communicating about donation and promoting the act of donor registration, participating lay health educators will complete a brief online survey upon enrollment (pre) and after completing the module (post). Then, trained lay health educators will hold at least 2 small group sessions with mature Latina (6-8 per session); in all, 80 sessions are anticipated with 480 to 640 mature Latina. Participating mature Latina will complete anonymous paper-pencil surveys before and after each session to assess changes in attitudes toward organ donation and donor registration and intent to register as posthumous organ donors.
62202950|NCT02338453|ACTIVE_COMPARATOR|Attention Bias Modification Treatment|Participants will receive an attention bias modification protocol designed to divert attention away from socially-threatening stimuli via repeated trials of a dot-probe task.
62786180|NCT02783092|EXPERIMENTAL|Cannabidiol|Concentration unit: 200mg/ml; 5 - 25 mg/Kg/day ; Oral solution
62786181|NCT02783092|PLACEBO_COMPARATOR|Placebo|Oral solution
62786182|NCT06232213||experimental group|The results of PTC microtumor model were used to guide treatment, including 12 cases of ovarian cancer and 8 cases of endometrial cancer.
62786183|NCT06232213||control group|Patients who did not use the PTC model to guide treatment during the same period included 12 cases of ovarian cancer and 8 cases of endometrial cancer.
62786184|NCT02430116|NO_INTERVENTION|negative control group|The myocardial tissues of the right atrial appendage were obtained at 3 min before CPB was established in the NEG group.
62786185|NCT02430116|ACTIVE_COMPARATOR|I/R group|The myocardial tissues of the right atrial appendage were obtained at 45 min after opening the aorta in the I/R group.
62202951|NCT02338453|PLACEBO_COMPARATOR|placebo-control condition|Participants will receive an placebo control protocol using the same task and stimuli but not designed to change attention patterns
62579623|NCT02126189||Head and neck cancer|All patients presenting to the Head and Neck Cancer Clinic at the Princess Alexandra Hospital, Brisbane, Australia are invited to participate.
62579624|NCT06152237|EXPERIMENTAL|Cohort 1|Dose Level 1
62579625|NCT06152237|EXPERIMENTAL|Cohort 2|Dose Level 2
62579626|NCT06576323|OTHER|Case Series|In Aim 3, all recruited participants will receive the intervention.
62579627|NCT04453280||Cohort 1 - Prague and Central Bohemian Region|A population cohort of cured patients based on epidemiologically defined demographic parameters - Prague and Central Bohemian Region population
62579628|NCT04453280||Cohort 2 - South Moravian Region|A population cohort of cured patients based on epidemiologically defined demographic parameters - South Moravian Region population.
62579629|NCT01029301|EXPERIMENTAL|Experimental: Endymed study group|
62202952|NCT06135740|ACTIVE_COMPARATOR|Intervention|Notification on Nutrition, Sleep, and Physical Activity based on fitbit-based data
62202953|NCT06135740|SHAM_COMPARATOR|Control|Regular Care
62202954|NCT04662229|EXPERIMENTAL|Experimental: 10 hz stimulatión|Eco-guided percutaneous electrical stimulation application of low frequency electrical current at 10 hz, 240 microsecond, over the median and ulnar nerve in the arm, for 1 minute on each nerve. The intensity of the current will reach the excitomotor threshold, causing visible but comfortable contractions.
62202955|NCT04662229|SHAM_COMPARATOR|Sham stimulation|Application of the needles only on the median and ulnar nerve of the arm, for 1 minute on each nerve without current intensity and a sound will be applied.
62215144|NCT05827861|EXPERIMENTAL|HeartAge, HOPE Platform, and Genetic Risk Communication|Participants will be directed to HeartAge, a risk assessment tool available online. Then, they will be led to download the HOPE-CVD mobile app, an evidence-based behaviour change platform. Additionally, participants will also receive a report of their genetic risk of CVD.
62579630|NCT01540487|EXPERIMENTAL|linagliptin/metformin(high dose)|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (high dose) tablets single dose in randomized order
62786186|NCT02430116|EXPERIMENTAL|I-postC group|The procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
62786187|NCT02058563|EXPERIMENTAL|INV_MMR Group|Subjects will receive 1 dose of GSK Biologicals' trivalent Measles, Mumps, and Rubella Virus Vaccine (Priorix®).
62786188|NCT02058563|ACTIVE_COMPARATOR|COM_MMR Group|Subjects will receive 1 dose of Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine.
62786189|NCT06443684||Direct surgery|"Stage III NSCLC eligible for direct surgery~Interventions:~Diagnostic Test: MRD（LC-10）include 10 lung cancer-related driver gene mutation site"
62786190|NCT06443684||Neoadjuvant and surgery|"Stage III NSCLC eligible for neoadjuvant therapy followed by surgery~Interventions:~Diagnostic Test: MRD（LC-10）include 10 lung cancer-related driver gene mutation site"
62786191|NCT06443684||Chemoradiotherapy|"Unresectable Stage III NSCLC eligible for Chemoradiotherapy.~Interventions:~Diagnostic Test: MRD（LC-10）include 10 lung cancer-related driver gene mutation site"
62786192|NCT02692001|NO_INTERVENTION|Current MealTrain menu|This is the current menu being employed for food ordering in the pediatric inpatient wards.
62786193|NCT02692001|EXPERIMENTAL|Intervention MealTrain menu|The intervention menu included child-friendly labeling (attractive characters, fun food names and traffic light system) to encourage healthier choices.
62215145|NCT04294927|EXPERIMENTAL|Risk-reducing salpingectomy with delayed oophorectomy|Risk-reducing salpingectomy after the completion of childbearing with delayed oophorectomy.
62786194|NCT04309708|EXPERIMENTAL|Original Perfusor Line(Art.No.8723017)|
62202956|NCT05110690|EXPERIMENTAL|Patient Participants|"* Behavioral activation (BA) will span across 3 months postoperatively \& will begin pre-operatively, with sessions approximately weekly or biweekly, depending on patient preference \& health condition.~* Medications will be reviewed \& optimized by a team of interventionists including a psychiatrist, pharmacologist, \& pharmacists. While the participant is in-hospital, the interventionist's role will include coordinating with the hospital team to ensure that medication changes that were introduced preoperatively are maintained in-house \& that no new inappropriate medications are initiated. After discharge, \& up to approximately 3 months postoperatively, the interventionist will ensure that medication changes are reconciled during transitions of care. The interventionists will ensure the agreed-upon changes are implemented, or an alternative course of action is justified."
62786195|NCT04309708|ACTIVE_COMPARATOR|Original Perfusor Line(Art.No.8723010)|
62202957|NCT05116826|EXPERIMENTAL|Healthy Control Match (Normal hepatic function)|NTZ 500 mg twice a day for 7 days
62202958|NCT05116826|EXPERIMENTAL|Moderate Child-Pugh B (Moderate hepatic impairment)|NTZ 500 mg twice a day for 7 days
62202959|NCT05116826|EXPERIMENTAL|Severe Child-Pugh C (Severe hepatic impairment)|NTZ 500 mg twice a day for 7 days
62202960|NCT02305277|EXPERIMENTAL|BIA 9-1067 5 mg Sequence 1|"volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
62202961|NCT02305277|EXPERIMENTAL|BIA 9-1067 25 mg Sequence 1|"volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
62202962|NCT02305277|EXPERIMENTAL|BIA 9-1067 50 mg Sequence 1|"volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
62202963|NCT02305277|EXPERIMENTAL|BIA 9-1067 5 mg Sequence 2|"volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
62202964|NCT02305277|EXPERIMENTAL|BIA 9-1067 25 mg Sequence 2|"volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
62202965|NCT02305277|EXPERIMENTAL|BIA 9-1067 50 mg Sequence 2|"volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
62202966|NCT01824745|EXPERIMENTAL|Arm I (SCP-BCS template booklet and counseling)|Participants receive SCP-BCS template booklet and receive counseling sessions with a patient navigator for 40 minutes twice weekly for 4 sessions.
62202967|NCT01824745|ACTIVE_COMPARATOR|Arm II (SCP-BCS template booklet)|Participants receive SCP-BCS template booklet and receive standard follow-up care.
62202968|NCT02181153|OTHER|siblings of patients with IBD|Blood and fecal samples from 100 siblings of children affected with IBD will be collected at the day of enrolment. Clinical risk factors for IBD will be also recorded in a case report form.
62202969|NCT02181153|OTHER|patients without family history of IBD|Blood and fecal samples of 100 healthy children without a family history of IBD will be collected at the day of enrolment. Clinical risk factors for IBD will be also recorded in a case report form
62014122|NCT06022159|EXPERIMENTAL|Adjuvant Cohort|
62202970|NCT03711292|EXPERIMENTAL|Stepped Wedge Cluster Randomized|Antibiotic stewardship intervention
62202971|NCT06132542|EXPERIMENTAL|Experimental|Open label study
62202972|NCT04148651|EXPERIMENTAL|CO2RE® Treatment|All eligible subjects will undergo up to 5 treatments at 4±1-week intervals to the vulva with a fractional CO2 laser.
62202973|NCT04957147||Group A: patients with dilated cardiomyopathy|Patients with recent-onset dilated cardiomyopathy
62202974|NCT04957147||Group B: healthy volunteers|Healthy volunteers with no known heart disease
62202975|NCT05689892|EXPERIMENTAL|Intervention group|Participants who have been diagnosed with IBD and are recommended a new biologic therapy will be recruited to this arm. Participants and their families will be referred to a decision coach (DC), who will provide support in gaining knowledge of treatment and care options. They will also be given decision aids (DA) as outlined in the study description.
62202976|NCT05689892|NO_INTERVENTION|Comparator group|Participants who have been recommended a new biologic therapy within the last 12 months and have commenced treatment will be recruited to this arm.
62202977|NCT01301040|ACTIVE_COMPARATOR|Epirubicin/Cyclophosphamide|Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles
62202978|NCT01301040|ACTIVE_COMPARATOR|docetaxel/cyclophosphamide|Treatment Arm 2: TC - docetaxel (Taxotere) (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.
62202979|NCT04353505|EXPERIMENTAL|Intra-Arterial Delivery of Ketorolac and Dexamethasone|
62215146|NCT04294927|ACTIVE_COMPARATOR|Risk-reducing salpingo-oophorectomy|Risk-reducing salpingo-oophorectomy.
62215147|NCT05726032|ACTIVE_COMPARATOR|Empagliflozin|Empagliflozin vs placebo for 14 days, followed by 14 day washout period, before crossing over to the alternate drug.
62215148|NCT05726032|PLACEBO_COMPARATOR|Placebo|Empagliflozin vs placebo for 14 days, followed by 14 day washout period, before crossing over to the alternate drug.
62786196|NCT06535620|EXPERIMENTAL|red wine with alcohol|The red wine group
62786197|NCT06535620|PLACEBO_COMPARATOR|red wine without alcohol|The non-alcoholic wine group
62786198|NCT00785473|ACTIVE_COMPARATOR|1|cholecalciferol, calcium carbonate
62786199|NCT00785473|PLACEBO_COMPARATOR|2|capsules not containing cholecalciferol, otherwise identical to Active comparator; calcium carbonate
62786200|NCT02209896|EXPERIMENTAL|BlueWind Reprieve System|The Reprieve implant will be implanted for eligible patients. Implant parameters settings will be set according to patient's sensations.
62014123|NCT02570321|EXPERIMENTAL|Bacterial ulcer cross-linking|Standard of care topical treatment for bacterial ulcer plus cross-linking
62014124|NCT02570321|ACTIVE_COMPARATOR|Bacterial ulcer control|Standard of care topical treatment for bacterial ulcer
62014125|NCT02570321|EXPERIMENTAL|Fungal ulcer cross-linking plus natamycin|Standard of care topical treatment for fungal ulcer with natamycin plus cross-linking
62014126|NCT02570321|ACTIVE_COMPARATOR|Fungal ulcer control with natamycin|Standard of care topical treatment for fungal ulcer with natamycin
62215149|NCT01593345|EXPERIMENTAL|Mentor|
62215150|NCT01593345|ACTIVE_COMPARATOR|Guidebook|
62579631|NCT01540487|EXPERIMENTAL|linagliptin/metformin(low dose)|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (low dose) tablets single dose in randomized order
62579632|NCT00163761|ACTIVE_COMPARATOR|Commence VGF treatment|Drug. Vinorelbine, gemcitabine and filgrastim 21 day cycle
62786201|NCT02502825|EXPERIMENTAL|asthma|methacholine(0.031-16mg/ml) bronchial provocation tests. this is a crossover,normal-control study. nebulized with Wright nebulizer for 2 minutes with an output of 0.13ml/min.
62786202|NCT02502825|EXPERIMENTAL|normal controls|methacholine(0.031-16mg/ml) bronchial provocation tests. this is a crossover,normal-control study. nebulized with Devilbiss646 nebulizer for 2 minutes with an output of 0.13ml/min
62786203|NCT03687346||High Risk Group|Parental history of eating pathology
62403221|NCT03118401|EXPERIMENTAL|Ritual of stool|During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
62403222|NCT03118401|OTHER|Usual practice|"During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.~At the end of this second period, data will be collected on an individual stool diary in for 4 weeks"
62579633|NCT00163761|ACTIVE_COMPARATOR|Commence F-GIV treatment|Drug. Gemcitabine, ifosfamide, Vinorelbine and filgrastim 21 day cycle
62014127|NCT02570321|EXPERIMENTAL|Fungal ulcer cross-linking plus amphotericin|Standard of care topical treatment for fungal ulcer with amphotericin plus cross-linking
62215151|NCT02577822|OTHER|Short Stem Group|Short femoral stem
62786204|NCT03687346||Low Risk Group|No parental history of eating pathology
62014128|NCT02570321|ACTIVE_COMPARATOR|Fungal ulcer control with amphotericin|Standard of care topical treatment for fungal ulcer with amphotericin
62014129|NCT04006158|EXPERIMENTAL|LightStim LED Bed|Full body LED bed device.
62014130|NCT03031912|ACTIVE_COMPARATOR|Group 1: 50 HIV-infected adults CD4 ≥ 500 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
62014131|NCT03031912|ACTIVE_COMPARATOR|Group 2: 50 HIV-infected adults CD4 > 350 and < 500 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
62215152|NCT02577822|OTHER|Long Stem Group|standard-length stem
62215153|NCT03250234|OTHER|Adequate Carbohydrate|Carbohydrate beverage (1 g/kg/hr) Adequate carbohydrate diet 6.0 g/kg/d
62403223|NCT05033769|EXPERIMENTAL|Eribulin|Arm A. Eribulin 1.23 mg/m\^2, administered as an injection on day 1 and 8 q 21d for a maximum of 4 therapy cycles
62403224|NCT05033769|ACTIVE_COMPARATOR|Paclitaxel|Paclitaxel 80 mg/m\^2, administered as an injection on day 1, 8 and 15 q21d for a maximum of 4 therapy cycles
62786205|NCT03087903|EXPERIMENTAL|150 mg of Grape Seed Extract (GSE)|150 mg of GSE twice daily in the form of 75 mg capsule of Leucoselect Phytosome preparation.
62786206|NCT02210416||LAP repair|patients receiving laparoscopic inguinal hernia repair
62014132|NCT03031912|ACTIVE_COMPARATOR|Group 3: 50 HIV-infected adults CD4 ≥ 200 and ≤ 350 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of theV920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
62215154|NCT03250234|OTHER|Low Carbohydrate|Non-nutritive control beverage. Low carbohydrate diet 1.2 g/kg/d
62403225|NCT02341339|EXPERIMENTAL|Fallopian Tube Co-culture|fallopian tube biopsy for co-culture of embryos
62579634|NCT01564446|EXPERIMENTAL|secure message regarding post-discharge medication|Participants will be sent a secure message to confirm compliance with post-discharge medication.
62579635|NCT02650258||Young Adult|80 Adults 21-40 years of age: 10 Male and 10 Female in each 5 year increment (21-25, 26-30, 31-35, 36-40).
62579636|NCT02650258||Middle Aged Adults|80 Adults 41-60 years of age: 10 Male and 10 Female in each 5 year increment (41-45, 46-50, 51-55, 56-60).
62579637|NCT02650258||Older Adults|100 Adults 61-85 years of age: 10 Male and 10 Female in each 5 year increment (61-65, 66-69, 70-75, 76-80, 81-85).
62579638|NCT03521102|EXPERIMENTAL|Acetaminophen 1000mg IV|NRS pain score will be obtained at baseline, 15, 30, 45, 60, 90, 120, and 180 minutes following completion of intervention. Adverse events will be recorded every 15 minutes for the duration of the study protocol. Participants will be reassessed for the need of additional pain control at 60 minutes.
62734817|NCT00575107|ACTIVE_COMPARATOR|SC|Constant weight shortening contraction
62786207|NCT02210416||open repair|patients receiving open flat mesh repair of inguinal hernia
62786208|NCT05122091|EXPERIMENTAL|Fruquintinib group|"Two-four preoperative cycles of Fruquintinib plus SOX. One cycle consists of Day 1-14 Fruquintinib 5mg oral (daily), Day 1 Oxaliplatin 130mg/M2 intravenous, Day 1-14 Tegafur gimeracil oteracil potassium capsule 40-60mg bid（dosage according to body surface area）.~Repeated every 21st day"
62786209|NCT02563938|EXPERIMENTAL|AK001|Up to six single ascending doses of AK001.
62786210|NCT02563938|PLACEBO_COMPARATOR|Saline Solution|Saline solution will be administered as a single infusion.
62786211|NCT06256744|EXPERIMENTAL|Protein supplementation|Protein supplementation
62014133|NCT03031912|ACTIVE_COMPARATOR|Group 4: HIV infected adolescents CD4 ≥ 200 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
62403226|NCT04233255||Patients with muscle disease(myositis, hereditary myopathy)|Includes 32 symptomatic patients with muscle disease subdivided into two subgroups (a) 16 patients with acute inflammatory myositis; And (b)16 patients with hereditary myopathy. The patients will be subjected to neuromuscular ultrasound (US) and electrophysiology at baseline,after 6 months and after 12 months. The number and location of studied muscles will be determined according to pattern of clinical presentation.
62579639|NCT03521102|ACTIVE_COMPARATOR|Hydromorphone 0.5mg IV|NRS pain score will be checked at 5 minutes and every 15 minutes thereafter for 120 minutes. Adverse events will be recorded every 15 minutes for the duration of the study protocol. The need for additional pain control will be assessed at 60 minutes.
62579640|NCT00478803|EXPERIMENTAL|1, preservation|aortic valve surgery(Remodeling associated with a subvalvular aortic ring annuloplasty or double sub and supra valvular aortic annuloplasty)
62579641|NCT00478803|SHAM_COMPARATOR|2, Bentall|Mechanical aortic valve replacement(isolated or composite valve and graft replacement);actual surgical standard for dystrophic aortic roots
62579642|NCT05751980|EXPERIMENTAL|Med Wise Rx|An evidence-informed two-session interactive behavioral workshop. Participants will begin intervention within 3 weeks of enrollment.
62579643|NCT05751980|ACTIVE_COMPARATOR|Waitlist Control|Participants will be crossed over to Med Wise Rx intervention up to 2 months after enrollment.
62579644|NCT00919373|ACTIVE_COMPARATOR|ICD-Implantation|Implantation of an Implantable Cardioverter Defibrillator (ICD) alone.
62579645|NCT00919373|ACTIVE_COMPARATOR|ICD + Ablation|Stratified Catheter Ablation of Ventricular Tachycardia and ICD Implantation
62579646|NCT01814696|NO_INTERVENTION|Control|Subjects will continue to receive usual medical care from their doctor(s).
62579647|NCT01814696|EXPERIMENTAL|MedSentry System|Subjects will continue to receive usual medical care from their doctor(s). Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
62579648|NCT05707741|PLACEBO_COMPARATOR|Group A|normal saline infusion rate 0.4uq/kg /hour
62579649|NCT05707741|ACTIVE_COMPARATOR|Group B|dexmetomedine 0.2 µg/kg/hr
62579650|NCT05707741|ACTIVE_COMPARATOR|Group C|dexmetomedine 0.4 µg/kg/hr
62579651|NCT03652571|EXPERIMENTAL|Nortriptyline|"Nortriptyline in an escalating dose regimen:~Week 1-2: 10mg daily Week 3-4: 25mg daily Week 5-12: 50mg daily"
62579652|NCT03652571|PLACEBO_COMPARATOR|Placebo|Placebo
62579653|NCT06437795|EXPERIMENTAL|Dry Needling Group|
62579654|NCT06437795|OTHER|Cupping Therapy Group|
62786212|NCT03558490|EXPERIMENTAL|ZEMY software|
62014134|NCT03031912|ACTIVE_COMPARATOR|Group 5: HIV infected adults and adolescents CD4 ≥ 200 cells/mm^3 with 2 doses|Participants will be randomly assigned to receive two dosse of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
62014135|NCT05301933|EXPERIMENTAL|Intervention Group|
62403227|NCT04233255||Healthy volunteers as control group|Includes 32 healthy volunteers as control group. They will be subjected to neuromuscular ultrasound (US) and electrophysiology at baseline. Their age, sex, number and location of studied muscles will be matched with patients' group.
62403228|NCT03890731|OTHER|Adult patients|Adult patients from completed Bayer-sponsored regorafenib trials who are benefitting from regorafenib treatment.
62403229|NCT04943627|EXPERIMENTAL|Monotherapy with Balstilimab (BAL)|300 mg IV once every 3 weeks for up to 24 months
62403230|NCT04943627|ACTIVE_COMPARATOR|Monotherapy with Investigator Choice (IC) Chemotherapy per Institutional guidelines|Topotecan: 1 or 1.25 mg/m\^2 IV on Days 1 to 5, every 21 days or Vinorelbine: 30 mg/m\^2 IV on Days 1 and 8, every 21 days or Gemcitabine: 1000 mg/m\^2 IV on Days 1 and 8, every 21 days or Irinotecan: 100 or 125 mg/m\^2 IV weekly for 28 days, every 42 days or Pemetrexed: 500 mg/m\^2 IV on Day 1, every 21 days
62403231|NCT05031559|EXPERIMENTAL|Episodic Future Thinking|
62403232|NCT05031559|EXPERIMENTAL|Compassion|
62403233|NCT05031559|SHAM_COMPARATOR|Control|
62403234|NCT00619658|EXPERIMENTAL|1|All women undergoing medical abortion will have telephone follow-up approximately one week after using mifepristone and misoprostol.
62403235|NCT02868294|EXPERIMENTAL|Patient receiving the Fassier-Duval Nail|Implementation of a telescopic system intramedullary
62403236|NCT03589066|EXPERIMENTAL|Formulation A|LY03003 28 mg intramuscular suspension, single dose, 1 day duration
62403237|NCT03589066|EXPERIMENTAL|Formulation B|LY03003 28 mg intramuscular suspension, single dose, 1 day duration
62403238|NCT06404294|EXPERIMENTAL|External Diaphragm Pacemaker treatment group|On the basis of conventional treatment, the patients in this group were treated with external diaphragm pacemaker for 2 weeks or until extubation.
62579655|NCT06129435|EXPERIMENTAL|Visuospatial Task (VST)|
62579656|NCT06129435|SHAM_COMPARATOR|Word Association Task (WAT)|
62579657|NCT06129435|NO_INTERVENTION|No Game Play (NT-CTRL)|
62579658|NCT03054155|EXPERIMENTAL|Treatment Arm|For each patient, one side of the body will be treated with the Alexandrite laser (the treatment arm) and the other will not be treated to serve as control (the control arm). For example, if a patient has the disease in both axillae, one will treatment and the other control
62579659|NCT03054155|NO_INTERVENTION|Control Arm|For each patient, one side of the body will be treated with the Alexandrite laser (the treatment arm) and the other will not be treated to serve as control (the control arm). For example, if a patient has the disease in both axillae, one will treatment and the other control
62579660|NCT04638764|ACTIVE_COMPARATOR|Aerobic interval training with high loads resistance training|"Patient to be randomised into combined aerobic training with high loads resistance training group."
62579661|NCT04638764|ACTIVE_COMPARATOR|Aerobic interval training with low loads resistance training|"Patient to be randomised into combined aerobic training with low loads resistance training group."
62579662|NCT04638764|ACTIVE_COMPARATOR|Aerobic interval training|"Patient to be randomised into aerobic training training group."
62579663|NCT02056015|EXPERIMENTAL|[68Ga]MLN6907|
62579664|NCT01069510|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo
62579665|NCT01069510|EXPERIMENTAL|Spironolactone|Spironolactone 25 mg daily
62014136|NCT05535192|ACTIVE_COMPARATOR|HEALTH EDUCATION AND SUPPORT CONTROL GROUP|The research study procedures include screening for eligibility and a baseline visit to collect measurements and questionnaires. After the baseline appointment, participants randomized into the Heath Education Support Program will receive a tablet from the study that is pre-loaded with material to help support them during chemotherapy. The tablet materials will include supportive care and resources that focus on movement (light stretching and gentle yoga), soothing music, meditation/mindfulness, and recipes/cooking demos. Participants in this arm will be asked to fill out questionnaires at the start of each chemotherapy cycle to indicate any side effects from chemotherapy and the amount of time they spend engaging with the tablet. At the end of participants' chemotherapy, they will be asked to complete end-of-study measures.
62403239|NCT06404294|NO_INTERVENTION|No External Diaphragm Pacemaker treatment group|The patients in this group were treated with conventional treatment.
62403240|NCT00763126|ACTIVE_COMPARATOR|Spouse present,|
62403241|NCT00763126|ACTIVE_COMPARATOR|spouse absent|
62579666|NCT05203848|EXPERIMENTAL|Dance program intervention|The community dance program (CDP) will be developed to promote older adults' physical and mental well-being through dancing. The contents of the program are developed based on the literature review (Rossberg-Gempton \& Poole, 2008). The CDP will be delivered over a period of 8 weeks.
62786213|NCT05700383|EXPERIMENTAL|GetActive-Fitbit|GetActive-Fitbit is an adaptation of the original GetActive-Fitbit program, a mind-body program for the unique needs of individuals with chronic musculoskeletal pain that incorporates activity skills to help individuals improve all aspects of physical function. The GetActive-Fitbit sessions address mind-body skills (e.g., mindfulness, deep breathing, self-compassion), walking skills (e.g., step goals, quota-based pacing), and skills to change thinking (e.g., identify unhelpful thoughts about pain and activity, challenging thoughts). The format is a 10-week program delivered in-person with weekly group sessions and home practice of skills and walking.
62786214|NCT05700383|ACTIVE_COMPARATOR|Healthy Living for Pain|Healthy Living for Pain is an active intervention that will be dose, attention, and time matches to the GetActive-Fitbit program. Healthy Living for Pain is an adaptation of the Health Enhancement Program, developed by Dr. Vranceanu and colleagues from Stony Brook, with adjustments for patients with chronic musculoskeletal pain. The Healthy Living for Pain sessions provide educational information on chronic musculoskeletal pain, the role of sleep and nutrition, physical activity, healthcare management, medication use, and social connection. The format is a 10-week program delivered in-person with weekly group sessions and home practice journaling.
62786215|NCT03470402|EXPERIMENTAL|Intervention group|"Women who screen as eligible for BRCA genetic counseling will receive the education and decision support tool, RealRisks, along with standard educational material and a high-risk message. The high-risk status of the women will also be flagged in the online tool used by the hospital to visualize electronic health record data (iNYP).~The enrolled health care providers of these women will be given access to BNAV, which summarizes their enrolled patients' breast cancer risk profiles and provides educational resources on genetic testing and prevention options. Before their clinical encounter with an enrolled patient, these providers will also be sent the personalized breast cancer risk summary that is created by data the patient entered into RealRisks."
62786216|NCT03470402|ACTIVE_COMPARATOR|Control group|Women who screen as eligible for BRCA genetic counseling will receive standard educational material and a high-risk message. The high-risk status of the women will also be flagged in the online tool used by the hospital to visualize electronic health record data (iNYP).
62786217|NCT00742716|EXPERIMENTAL|CTA018 Injection low dose|Low dose IV 3 times a week for 4 weeks
62786218|NCT00742716|EXPERIMENTAL|CTA018 Injection low to mid dose|low to mid dose IV 3 times a week for 4 weeks
62786219|NCT00742716|EXPERIMENTAL|CTA018 Injection mid to high dose|mid to high dose IV 3 times a week for 4 weeks
62786220|NCT00742716|EXPERIMENTAL|CTA018 Injection high dose|high dose IV 3 times a week for 4 weeks
62786221|NCT06029335||Diffuse cutaneous Systemic sclerosis|Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
62786222|NCT06029335||Limited cutaneous Systemic sclerosis|Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
62579667|NCT05203848|PLACEBO_COMPARATOR|Control group|There will be no dance intervention among control group participants.
62786223|NCT06029335||Primary Raynaud's|Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
62403242|NCT02305069|PLACEBO_COMPARATOR|Placebo|"Placebo tablet taken once daily for 12 weeks.~For study visits performed pre- and post 12-week placebo treatment for the assessment of muscle protein synthesis and leg protein breakdown, the following substances are administered as part of the analytical technique: insulin, octreotide, glucose, mixed amino acids, \[2H5\]phenylalanine and \[1-13C\]leucine. The doses administered change as the analytical technique is conducted and for clarity are described in detail in the protocol."
62579668|NCT03854825||AKI|patients with postoperative AKI defined by KDIGO
62579669|NCT03854825||no AKI|patients without postoperative AKI defined by KDIGO
62579670|NCT03620123|EXPERIMENTAL|Nivolumab and Ipilimumab|Nivolumab 3 mg/kg of body weight intravenous infusion every two weeks and ipilimumab 1 mg/kg of body weight intravenous infusion every six weeks
62579671|NCT03620123|OTHER|Docetaxel|docetaxel 75 mg/m² intravenous infusion every three weeks
62579672|NCT02146196|EXPERIMENTAL|Heart failure, robotic assisted training|4 weeks robotic assisted training with the Lokomat®
62579673|NCT02146196|EXPERIMENTAL|Post cardiac surgery|One week robotic assisted gait training with the Lokomat®
62579674|NCT05883072||Intervention|Patients will be provided access to Chatbot to enquire their querries regarding diabetic complications.
62579675|NCT05356520|EXPERIMENTAL|The experimental group|Endoscopic ivor-Lewis operation was performed for siwert type II adenoma at the esophagogastric junction
62579676|NCT05356520|ACTIVE_COMPARATOR|The control group|Laparoscopic transabdominal enlarged gastrectomy for siwert TYPE II adenoma at the esophagogastric junction was performed
62579677|NCT00185263|EXPERIMENTAL|1|Ad5FGF-4
62579678|NCT00185263|EXPERIMENTAL|2|Ad5FGF-4
62579679|NCT00185263|PLACEBO_COMPARATOR|3|Placebo
62579680|NCT01125241|EXPERIMENTAL|Wuling capsule|
62579681|NCT01125241|PLACEBO_COMPARATOR|Placebo|
62579682|NCT05506566|EXPERIMENTAL|Part I: safety, tolerability, biodistribution and dosimetry|PET imaging will begin at 30s (30s/bed), 15min (1 min/bed), 30min (2 min/bed), 60min (2 min/bed) and 120min (2 min/bed) after injection, and whole-body low-dose CT needed to be re-acquired at 120 minutes
62579683|NCT05506566|EXPERIMENTAL|Part II: diagnostic efficacy|Participants with various types of cancer will have PET imaging 50-100 minutes after injection of 68Ga-FAP-CHX and another agent (68Ga-FAPI-04 or 18F-FDG).
62579684|NCT02913274|EXPERIMENTAL|"DEB arm"|dilation by a high-pressure conventional angioplasty balloon (sized to fit the reference native vein diameter) until disappearance of the stenotic obstructive area and achievement of technical success (possibility of changing balloon size or dilation pressure) then dilation by a DEB.
62579685|NCT02913274|ACTIVE_COMPARATOR|"conventional angioplasty arm"|dilation will be performed by a conventional high-pressure balloon until technical success is achieved (possibility of changing balloon size or dilation pressure), then by a sham balloon i.e a conventional low-pressure balloon (placebo)
62579686|NCT05390567||Standard of Care in-clinic Pap-Test|Participant cervical cancer screening method of choice: Standard of Care Pap-Test
62579687|NCT05390567||HPV Self-Test|Participant cervical cancer screening method of choice: HPV Self-Test
62579688|NCT03041753||Intervention group|ischemic stroke patients in the anterior circulation territory (NIHSS ≥7) within 12 hours from last seen well, treated either with systemic thrombolysis or endovascular treatment.
62579689|NCT02919969|EXPERIMENTAL|Pembrolizumab|"* Pembrolizumab is administered every 3 week intravenously~* Dosage to be determine by physician"
62579690|NCT05995821||Upper Aerodigestive Malignancies|Patients with cancer of the head and neck, thorax and upper gastrointestinal tract, who are receiving or may receive treatments known or hypothesized to have an immunomodulatory antitumor effect.
62579691|NCT02993146|EXPERIMENTAL|Treatment (ropidoxuridine, WBRT)|Patients receive ropidoxuridine PO QD on days 1-28 and undergo WBRT daily for not more than 5 days per week beginning on day 8 for a total of 15 fractions in the absence of disease progression or unacceptable toxicity.
62579692|NCT03055481|ACTIVE_COMPARATOR|High level irradiation|High level irradiation: the target irradiance level is 30-35uW per square centimeter per nano-meter of wavelength.
62579693|NCT03055481|EXPERIMENTAL|Low level irradiation|Low level irradiation: the target irradiance level is 12-15uW per square centimeter per nano-meter of wavelength.
62579694|NCT02246101||WTC responders|WTC responders who were enrolled in the WTC-CHEST program.
62579695|NCT05099029|EXPERIMENTAL|EV71 Vaccine|
62786224|NCT06029335||Healthy|Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
62786225|NCT06029335||Rheumatoid arthritis|Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
62202980|NCT04993105|EXPERIMENTAL|B (exercise + graston):|"In graston + exercises treatment will be same but after exercises added with proper application of graston which included application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin.The Graston tools will be then used to mobilize the tissues of the triceps surf and plantar foot. In areas of increased tissue restriction, more aggressive pressure with graston was applied using increased force and shorter strokes over the areas of restriction was offered as needed for pain management after each session. This will be continued for three sessions. NPRS score, score on FADI and dorsiflexors range will be assessed after treatment of two weeks. Along with conventional treatment.~."
62202981|NCT04993105|ACTIVE_COMPARATOR|A (exercise only)|Exercises only. Patients will be given gastrocnemius stretching, plantar fascia stretching, myofascial release and then graston will be given as sham treatment for 10 minutes after applying cream (applying graston on skin but not giving enough pressure).
62202982|NCT01745692|ACTIVE_COMPARATOR|Intravenous rtPA|IV alteplase (rtPA) 0.9mg/kg (10% of dose as bolus followed by 90% as infusion over 1 hour, to a maximum dose of 90mg total) given within 4.5 hours of onset of stroke symptoms
62202983|NCT01745692|EXPERIMENTAL|Intravenous rtPA and Mechanical Thrombectomy|IV alteplase (rtPA) 0.9mg/kg (10% of dose as bolus followed by 90% as infusion over 1 hour, to a maximum dose of 90mg total) given within 4.5 hours of onset of stroke symptoms + additional mechanical thrombectomy procedure to commence within 90 minutes of start of IV rtPA infusion
62202984|NCT04725916|ACTIVE_COMPARATOR|Study Arm 1|Subjects assigned to Arm 1 will be instructed to shower daily beginning on post-operative Day 2 and maintain this daily schedule until the subject's 3-month standard of care clinic follow-up visit. They will receive specific instructions on caring for the incision site and drains until they are removed.
62202985|NCT04725916|ACTIVE_COMPARATOR|Study Arm 2|Subjects assigned to Arm 2 will be instructed not to shower post-operatively until their surgical drains are removed. They will receive specific instructions on bathing and caring for the incision sites and drains.
62579696|NCT05099029|PLACEBO_COMPARATOR|Placebo|
62579697|NCT02713256|EXPERIMENTAL|CFZ533 10mg/kg|CFZ533 intravenously over approximately one hour
62579698|NCT01740752|EXPERIMENTAL|UCAN+CBT|This condition includes 22 UCAN sessions and 22 CBT sessions, totaling 44 psychotherapy sessions. UCAN is a manualized, 22-session Cognitive Behavioral Couple Therapy (CBCT) intervention that engages the couple to target the core psychopathology of AN and address the uniquely challenging stress that AN places on intimate relationships. The CBT proposed for this study is a 22 session adaptation of the manualized intervention that has been employed successfully as an outpatient post-hospitalization therapy and in an National Institute of Mental Health multisite study of fluoxetine with elements from the CBT manual used in McIntosh et al (PubMed 15800147).
62579699|NCT01740752|EXPERIMENTAL|CBT|"In this condition, participants will receive a higher dose of individual CBT, with 44 total sessions. Our experience with patients in the pilot strongly suggests that a higher dose of CBT will allow for further, fruitful discussion and exploration of key individual issues and is unlikely to be experienced as diluted or a slow approach to treatment. Most of these patients have complicated histories, long-standing eating disorders, and complex comorbid conditions."
62579700|NCT02313493|EXPERIMENTAL|Baby Triple P parent training group|The 8- session program delivered in four group sessions before birth and four telephone sessions after birth is developed for parents at the transition to parenthood or with a baby (up to 12 months of age).
62579701|NCT02313493|NO_INTERVENTION|Care as usual control group|
62579702|NCT02148757|OTHER|DVT|Doppler Ultrasound
62579703|NCT02888262||Patients with bipolar disorder|Patients with newly diagnosed bipolar disorder
62579704|NCT02888262||Healthy first generation relatives|Healthy first generation relatives to the included patients
62579705|NCT02888262||Healthy individuals|Healthy individuals without a family history of psychiatric disorders
62579706|NCT06683300||3 months DAPT|dual antiplatelet therapy (DAPT) for 3 months
62579707|NCT02316275|ACTIVE_COMPARATOR|Standard post-operative activity restriction|As a traditional method, patients will be restricted from activity for six weeks after sling surgery.
62202986|NCT05591261|EXPERIMENTAL|ePREP condition|The ePREP program is the online version of the Prevention and Relationship Enhancement Program. It consists of 6 self-directed online sessions and accompanying homework and brief coach calls.
62786226|NCT06029335||Inflammatory myopathies|Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
62786227|NCT06029335||Systemic lupus erythematosus|Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
62202987|NCT02476175|EXPERIMENTAL|Add-on Mirabegron|Experimental: Add-on Mirabegron Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. They will keep the antimuscarinic and Mirabegron will be added (dual therapy).
62202988|NCT04904198|EXPERIMENTAL|Care Management Intervention for Non-cardiac chest pain|Multicomponent care management intervention.
62786228|NCT03922620|EXPERIMENTAL|Liposomal Bupivacaine Group|No peripheral nerve block will be given. Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area.
62786229|NCT03922620|ACTIVE_COMPARATOR|Peripheral Nerve Block Group|Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block). No local analgesic agent infiltration
62786230|NCT01279616|EXPERIMENTAL|Hematopoietic Stem Cell Transplant|Stem cell infusion on Day 0.
62786231|NCT02218593||WREX orthosis|When the subject used the WREX Orthosis
62786232|NCT02396563||epidural analgesia|women in labor with epidural analgesia
62786233|NCT02396563||no epidural analgesia|
62786234|NCT05723107|EXPERIMENTAL|Chemotherapy plus EUS-RFA|"Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and chemotherapy will be administered as part of standard of care treatment for PDAC in patients receiving palliative second- or third-line therapy for unresectable non-metastatic pancreatic cancer.~Study participants will undergo 3 identical EUS-RFA procedures, administered during Study Window 2 (Weeks 1-3), Window 3 (Weeks 5-7), and Window 4 (Weeks 9-11). During each EUS-RFA procedure, a tumor biopsy will also be taken for single cell RNA sequencing.~Chemotherapy will be administered during Study Window 2 (Weeks 1-3), Window 3 (Weeks 5-7), Window 4 (Weeks 9-11), and Window 5 (Weeks 13-15)."
62786235|NCT04280731|EXPERIMENTAL|Fermented drink|
62202989|NCT00760253||1|pure propofol by TCI pump with titration.
62202990|NCT00760253||2|10ug/kg alfentanyl bolus and propofol TCI pump infusion with titration
62202991|NCT00760253||3|20ug/kg alfentanyl bolus and propofol TCI pump infusion with titration
62202992|NCT06480292|EXPERIMENTAL|Telerehabilitation exercise program|This group will receive a structured tele rehabilitation exercise protocol of low to moderate intensity warm up ,aerobic ,resistance and cool down exercises for 3 times a week progressively increased for 8 weeks. along with routine medical care will be provided.
62579708|NCT02316275|EXPERIMENTAL|No post-operative activity restrictions|Patients are to resume regular activity immediately after mid-urethral sling surgery.
62202993|NCT06480292|ACTIVE_COMPARATOR|Routine medical care|The control group will receive routine medical care including oral medication (metformin), dietry precautions and advised to do regular walk for 20-30minutes.
62202994|NCT03583775||Patients with congenital heart disease|Patients with congenital heart disease who are greater than 40 kg and are referred for a clinically indicated 2D CMR exam with a gadolinium-based contrast agent.
62202995|NCT00657735|EXPERIMENTAL|1|Deep TMS treatment
62202996|NCT00657735|SHAM_COMPARATOR|2|inactive stimulation
62202997|NCT02677870|OTHER|Diet treatment|In part 1 of the study, patients will not receive any medication. Each patient will DIET treatment alone. They will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week. Based on these diaries, average weekly Phe intake and Phe tolerance will be calculated and recorded.
62579709|NCT02327715|EXPERIMENTAL|Chinese naive pregnant HBsAg positive patients|single group patients were enrolled to receive emtricitabine(200mg one time per day) till 24 weeks after dilivery,patients and followed up for 24 weeks.
62579710|NCT04240717|EXPERIMENTAL|Patient Decision Aid|Patients review an interactive, web-based Patient Decision Aid regarding their treatment options. Afterwards they receive medical consultation.
62579711|NCT04240717|NO_INTERVENTION|Treatment As Usual|Patients receive medical consultation.
62579712|NCT05243433|EXPERIMENTAL|Procedure using the Maestro Platform|Study participants will be adults aged ≥ 18 to ≤ 75 years scheduled for a non-emergent laparoscopic cholecystectomy, laparoscopic hernia repair, laparoscopic appendectomy, laparoscopic bariatric surgery (gastric sleeve or gastric bypass), or laparoscopic colectomy.
62579713|NCT01028547|ACTIVE_COMPARATOR|dexamethasone 8mg|
62579714|NCT01028547|PLACEBO_COMPARATOR|normal saline|
62579715|NCT01603849|EXPERIMENTAL|A Prophylactic Cranial Irradiation|Patients will received PCI 25 Gy in 10 fractions WBRT 4 weeks after initial treatment in the absence of disease progression.
62579716|NCT01603849|NO_INTERVENTION|B Observation Group|Patients in this arm will be observed (not receiving WBRT)
62579717|NCT00633815||Fontan patients|Subjects will undergo exercise testing in both the supine and upright positions
62579718|NCT00633815||Healthy controls|Subjects will undergo exercise testing in both the supine and upright positions
62734818|NCT00404378|EXPERIMENTAL|Cohort 1 Treatment Period 1|Subjects will receive single oral dose of 100 milligram (mg) of Casopitant. There will be wash out period of 7 days.
62786236|NCT05641922|EXPERIMENTAL|BioTrace|Use of the BioTraceIO 360 device for planning, monitoring and assessment of liver tissue ablations
62786237|NCT03009734|OTHER|ATx201 (2% dermal formulation A) and Placebo|
62786238|NCT03009734|OTHER|ATx201 (2% dermal formulation B) and Placebo|
62786239|NCT03009734|OTHER|ATx201 (2% dermal formulation C) and Placebo|
62579719|NCT01135329|EXPERIMENTAL|Transplant|Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.
62579720|NCT01720654|NO_INTERVENTION|Control|Standardized partner notification counseling.
62579721|NCT01720654|EXPERIMENTAL|EPT|Standardized partner notification counseling and provision of 5 partner treatment (EPT) packets.
62579722|NCT06117293|EXPERIMENTAL|Treatment Arm|Subjects will be treated up to 5 times with a 30- and 90-day post final-treatment follow-up. Subjects may be asked to participate in an elective biopsy collected from normal skin simultaneously.
62786240|NCT05287893|EXPERIMENTAL|IBSM challenge and pyronaridine PK/PD population profile|"Up to 18 healthy, malaria naïve adult participants are planned to be enrolled into this study, in cohorts of up to six participants each. on Day 0 participants will be inoculated intravenously with approximately 2,800 viable P. falciparum-infected erythrocytes.~Day 8 participants will be dosed with pyronaridine when parasitaemia for the majority of participants is expected to be above 5,000 parasites/mL.~Different doses of pyronaridine will be administered across and within cohorts in order to effectively characterise the PK/PD relationship.~The highest dose of pyronaridine administered will be no more than 720 mg; the lowest dose administered will be no less than 180 mg.~Regular safety assessments will be performed and blood will be collected to monitor parasite clearance and pyronaridine concentration.~Participants will receive compulsory antimalarial rescue treatment with Riamet® (artemether/lumefantrine) on Day 47±2, or earlier."
62202998|NCT02677870|ACTIVE_COMPARATOR|Standard dose saproterin dihydrochloride|"Study numbers will be randomized into standard-dose saproterin dihydrochloride (Kuvan) or high-dose saproterin dihydrochloride (Kuvan)  groups (treatment group A or treatment group B). Both groups will receive a trial of both standard and high dose saproterin dihydrochloride before the end of the study. Standard-dose saproterin dihydrochloride will be 20mg/kg (rounded up to the nearest 100mg) provided in the form of 100mg tablets. Dosing of the tablets will be unidentifiable to patients. Medication will be given orally once daily."
62579723|NCT02616146|EXPERIMENTAL|ENG-E2 125 μg/300 μg|Participants will receive up to 13 cycles of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
62579724|NCT02616146|ACTIVE_COMPARATOR|LNG-EE 150 μg/30 μg|Participants will receive up to 13 cycles of LNG-EE 150 μg/30 μg. Each cycle will consist of one tablet per day for 21 days, followed a 7-day tablet-free interval.
62579725|NCT04110340|ACTIVE_COMPARATOR|Ciprofloxacin Arm|"Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days;~Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days."
62734819|NCT00404378|EXPERIMENTAL|Cohort 1 Treatment Period 2|Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 100 mg along with ketoconazole.
62202999|NCT02677870|EXPERIMENTAL|High dose saproterin dihydrochloride|"Study numbers will be randomized into standard-dose saproterin or high-dose saproterin groups (treatment group A or treatment group B). Both groups will receive a trial of both standard and high dose saproterin dihydrochloride before the end of the study. Goal high-dose saproterin dihydrochloride dosing will be 40mg/kg (rounded up to the nearest 500mg), provided in the form of pre-packaged 500mg packets of powder. Labeled dosing on these packets will be covered by the investigational drug pharmacy and unidentifiable to patients. Dosing of the tablets will be unidentifiable to patients. Medication will be given orally once daily."
62203000|NCT03581903|EXPERIMENTAL|H7N3 pLAIV + H7N9 pIIV|Participants will receive H7N3 pLAIV on Days 0 and 28, followed by H7N9 pIIV on Day 84.
62786241|NCT01371552|EXPERIMENTAL|delefilcon A|Part 1: Delefilcon A contact lenses, followed by filcon II 3 contact lenses and narafilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
62786242|NCT01371552|ACTIVE_COMPARATOR|filcon II 3|Part 1: Filcon II 3 contact lenses, followed by narafilcon A contact lenses and delefilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
62403243|NCT02305069|EXPERIMENTAL|Pioglitazone|"30mg pioglitazone encapsulated and taken once daily for 12 weeks.~For study visits performed pre- and post 12-week pioglitazone treatment for the assessment of muscle protein synthesis and leg protein breakdown, the following substances are administered as part of the analytical technique: insulin, octreotide, glucose, mixed amino acids, \[2H5\]phenylalanine and \[1-13C\]leucine. The doses administered change as the analytical technique is conducted and for clarity are described in detail in the protocol."
62403244|NCT01695707|PLACEBO_COMPARATOR|Placebo|"Subjects randomized to placebo will receive opaque size 00 gelatin capsules containing 240mg lactose. As with the intervention group, 1 capsule will be taken by each day throughout the treatment period."
62403245|NCT01695707|EXPERIMENTAL|Pioglitazone|"Subjects randomized to pioglitazone will receive opaque size 00 gelatin capsules containing pioglitazone. For the first 3 weeks, capsules will contain 30 mg pioglitazone. For the remaining 9 weeks of the treatment period, capsules will contain 45 mg pioglitazone unless subjects are unable to tolerate this increased dose.~One capsule will be taken by each day throughout the treatment period."
62403246|NCT02000466||Exposed cohort|
62403247|NCT04425876|EXPERIMENTAL|Fluzoparib+mFOLFIRINOX|Fluzoparib combined with FOLFIRINOX followed by maintenance Fluzoparib monotherapy
62403248|NCT01399619|EXPERIMENTAL|BI201335 12W|patient to receive two capsules of BI 201335 once a day for 12 weeks and pegIFN/RBV for 24 or 48 weeks
62403249|NCT01399619|EXPERIMENTAL|BI 201335 24W|patient to receive two capsules of BI 201335 once a day for 24 weeks and PegIFN/RBV for 24 or 48 weeks
62403250|NCT01399619|EXPERIMENTAL|BI 201335 24 W|patient to receive one capsule of BI 201335 once a day for 24 weeks and pegIFN/RBV for 24 or 48 weeks
62403251|NCT01153659|EXPERIMENTAL|1|
62403252|NCT01153659|ACTIVE_COMPARATOR|2|
62403253|NCT01153659|ACTIVE_COMPARATOR|3|
62403254|NCT03935282|EXPERIMENTAL|Intervention - AH-HA tool|With assistance from the study team, the clinic will implement the AH-HA tool in the clinics' EPIC EHR. Providers at the intervention sites will be trained to use the tool during routine follow-up care with survivors. During a routine follow-up care appointment, the provider will use the AH-HA tool with enrolled patients.
62403255|NCT03935282|NO_INTERVENTION|Usual Care|Usual care practices will conduct routine follow-up care visits for enrolled survivors following typical clinic practice, without use of the AH-HA tool.
62786243|NCT01371552|ACTIVE_COMPARATOR|narafilcon A|Part 1: Narafilcon A contact lenses, followed by filcon II 3 contact lenses and delefilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
62786244|NCT06003153|OTHER|GLUCOSE-MGH Study|"Day 1: Mixed meal tolerance test~Day 3-15: 7 mg oral semaglutide, once daily~Day 16: 1 dose of 7 mg oral semaglutide, Mixed meal tolerance test in the presence of semaglutide"
62734820|NCT00404378|EXPERIMENTAL|Cohort 2 Treatment Period 1|Subjects will receive single oral dose of 50 mg of Casopitant. There will be wash out period of 7 days.
62786245|NCT01105273|EXPERIMENTAL|HAPLO|
62786246|NCT01086371|EXPERIMENTAL|RAS walking|Subjects will walk while listening to music 20 minutes per day every day during the study period.
62203001|NCT02905448|EXPERIMENTAL|Low fat plant-based diet|Low fat plant-based nutrition: low fat plant-based diet supplemented with plant-based meal replacements
62203002|NCT04721613||Hypoactive ICU delirium|
62203003|NCT04721613||Hyperactive or mixed ICU delirium|
62203004|NCT04721613||Critically ill patients not suffering form ICU delirium|
62203005|NCT05461833|EXPERIMENTAL|Fecal transplantation group|Fecal transplantation of frozen prepared feces from healthy donor. Application by colonoscope in proximal half of colon.
62203006|NCT05461833|ACTIVE_COMPARATOR|Standard-care group|FODMAP diet, Otilonium Bromide, oral, (40mg, 1 tablet TID) and a multi-strain probiotic, oral, (1 capsule BID)
62203007|NCT05154331||Women of reproductive age|Women 15-49 years of age
62203008|NCT03864198|OTHER|Genante (Tm)|Genante tablets One tablet in the morning and one tablet in the evening for 3 months
62403256|NCT04600531|EXPERIMENTAL|Group 1a - Conventional tDCS - Anodal first|Half of all subjects will receive Conventional tDCS (randomly assigned). Within this Conventional tDCS condition, half of the subjects will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive sham (placebo) tDCS.
62403257|NCT04600531|SHAM_COMPARATOR|Group 1b - Conventional tDCS - Sham first|Half of all subjects will receive Conventional tDCS (randomly assigned). Within this Conventional tDCS condition, half of the subjects will receive sham (placebo) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive active (anodal, real) tDCS.
62403258|NCT04600531|EXPERIMENTAL|Group 2a - HD tDCS - Anodal first|Half of all subjects will receive High Definition (HD) tDCS (randomly assigned). Within this HD tDCS condition, half of the subjects will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive sham (placebo) tDCS.
62579726|NCT04110340|OTHER|Control arm|"Adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those who cannot take it orally) for an additional 7 days.~OR~2.5mg/kg IV gentamicin twice daily for 3 days followed by ciprofloxacin 500 mg orally twice daily (or ciprofloxacin 400 mg twice daily IV for those who cannot take oral) for a further 7 days.~Children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days.~OR~2.5mg/kg IV gentamicin twice daily for 3 days, followed by ciprofloxacin 15mg/kg (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take the oral route) for a further 7 days."
62579727|NCT03829254|EXPERIMENTAL|NUC-7738|NUC-7738 administered by intravenous infusion on a weekly or fortnightly schedule. In the weekly dosing schedule, NUC-7738 is administered on Days 1 and 8 of a 14-day cycle. In the fortnightly dosing schedule, NUC-7738 is administered on Day 1 of a 14-day cycle.
62579728|NCT03829254|EXPERIMENTAL|NUC-7738 + pembrolizumab|NUC-7738 administered by intravenous infusion on a weekly schedule on Days 1, 8 and 15 of a 21-day cycle. Pembrolizumab administered by intravenous infusion every 3 weeks on Day 1 of a 21-day cycle.
62403259|NCT04600531|SHAM_COMPARATOR|Group 2b - HD tDCS - Sham first|Half of all subjects will receive High Definition (HD) tDCS (randomly assigned). Within this HD tDCS condition, half of the subjects will receive sham (placebo) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive active (anodal, real) tDCS.
62579729|NCT05566470||Control Group|1. Healty adults aged between 30-65 years old who do not have any pathology related to the shoulder joint and have not undergone surgery and being a volunteer to participate in the study.
62734821|NCT00404378|EXPERIMENTAL|Cohort 2 Treatment Period 2|Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 50 mg along with ketoconazole.
62786247|NCT01086371|ACTIVE_COMPARATOR|RAS no walking|Subjects will be listening to music but not performing walking exercise, for 20 minutes per day every day during the study period.
62786248|NCT01086371|ACTIVE_COMPARATOR|Walking no RAS|Subjects will be walking without listening to music for 20 minutes per day every day during the study period
62786249|NCT05327972|EXPERIMENTAL|1- Botulinum toxin|"The investigational medicinal product is incobotulinumtoxinA (XEOMIN®).~The dosage is:~Two milliliters of a mixture comprised of XEOMIN® 100 U and saline solution 0.9% will be once injected in the supra-spinatus muscle using ultrasonography guidance."
62203009|NCT03253445|EXPERIMENTAL|Acceptance and commitment therapy|All participants are given a brief educational talk on encouraging quitting smoking, a self-help leaflet on smoking cessation and an additional 10-session face-to-face ACT on a weekly basis.
62203010|NCT03253445|PLACEBO_COMPARATOR|Control|All participants are given a brief educational talk on encouraging quitting smoking , a self-help leaflet on smoking cessation and 10-sessions of face-to-face social support on a weekly basis.
62203011|NCT03563326|EXPERIMENTAL|CAR-T cell and chemotherapy|Biological: CAR-T cells targeting EpCAM Chemotherapy: determined by medical Oncologist
62203012|NCT03563326|ACTIVE_COMPARATOR|chemotherapy|Chemotherapy: determined by medical Oncologist
62203013|NCT01766115|EXPERIMENTAL|Telaprevir|750 mg oral tablet of telaprevir will be given three times per day for 4 weeks within a five (5) day period from health care worker exposure.
62786250|NCT05327972|PLACEBO_COMPARATOR|2- PLACEBO|"The placebo comparator represents a saline solution containing an inactive lyophilisate.~The dosage is:~Two milliliters of a saline solution containing an inactive lyophilisate will be once injected in the supra-spinatus muscle using ultrasonography guidance."
62786251|NCT00762047|EXPERIMENTAL|Durasphere|
62786252|NCT00762047|SHAM_COMPARATOR|Sham|
62786253|NCT05159570|EXPERIMENTAL|Ketone ester|
62786254|NCT05159570|PLACEBO_COMPARATOR|Placebo|
62786255|NCT04983420|EXPERIMENTAL|non-alcoholic Pilsner|1 L non-alcoholic Pilsner per day for 2 weeks
62786256|NCT04983420|EXPERIMENTAL|non-alcoholic wheat beer|1 L non-alcoholic wheat beer per day for 2 weeks
62786257|NCT04983420|ACTIVE_COMPARATOR|apple spritzer|1 L apple spritzer per day for 2 weeks
62786258|NCT04983420|PLACEBO_COMPARATOR|lemonade|1 L lemonade per day for 2 weeks
62786259|NCT00671229||1|African American
62786260|NCT00671229||2|Caucasian
62014137|NCT05535192|EXPERIMENTAL|THRIVE: EXERCISE INTERVENTION WITH PROTEIN INTAKE SUPPORT|The research study procedures include screening for eligibility and a baseline visit to collect measurements and questionnaires. After the baseline appointment, participants randomized into the THRIVE Exercise and Diet Intervention will work with a coach to gradually build exercise and stay active during chemotherapy treatment. Participants will work with an exercise coach to reach the muscle strengthening and aerobic exercise goals of the study. Participants will also consult with a dietician to ensure adequate protein intake during the study. Participants in this arm will be asked to fill out questionnaires at the start of each chemotherapy cycle to indicate any side effects from chemotherapy. At the end of participants' chemotherapy, they will be asked to complete end-of-study measures.
62786261|NCT00458458|ACTIVE_COMPARATOR|NA alone|Norethindrone Acetate (NA) 5mg taken 1-3 tabs orally every night for duration of treatment
62786262|NCT00458458|ACTIVE_COMPARATOR|LD then NA|Lupron Depot(LD) given intramuscularly every 12 weeks for total of 24 weeks then switched to Norethindrone Acetate (NA) taken 1-3 tablets orally every night for remainder of treatment
62014138|NCT05383170|EXPERIMENTAL|Arm A: advanced or metastatic HNSCC|The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 30 subjects in total with advanced or metastatic HNSCC. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC).
62786263|NCT04984577|EXPERIMENTAL|Compound Edaravone Injection-Low dose|
62786264|NCT04984577|EXPERIMENTAL|Compound Edaravone Injection-High dose|
62786265|NCT04984577|ACTIVE_COMPARATOR|Edaravone Injection|
62786266|NCT04984577|PLACEBO_COMPARATOR|Placebo Injection|
62014139|NCT05383170|EXPERIMENTAL|Arm B: advanced or metastatic melanoma|The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 30 subjects in total with advanced or metastatic melanoma. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC).
62014140|NCT05383170|EXPERIMENTAL|Arm C: advanced or metastatic TNBC|The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 30 subjects in total with advanced or metastatic TNBC. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC).
62014141|NCT05132335|EXPERIMENTAL|Experimental: Imaging Biomarkers|Each study subject is is studied in four session: twice after overnight fast and twice after liquid meal injestion using PETMRI imaging. Adipose and skeletal muscle pefusion and fatty adic uptake are measured and and the repeability of results tested for these two situations. In PEt studies PET/MRI Scan with radioactive water (\[15O\]-H2O) and \[18F\]-FTHA are used as tracers. In this experimental study number of subjects studied is rather small. Therefore volunteers with and without T2 diabetes are analysed together and not on different arms.
62014142|NCT05760092|EXPERIMENTAL|Photobiomodulation Therapy|Institutional standard treatment for xerostomia and COVID Longa + PBM therapy
62786267|NCT05895240|NO_INTERVENTION|Control Group Arm|Standard of care treatment arm, study medication will not be given
62786268|NCT05895240|EXPERIMENTAL|Active Intervention Arm|This group will receive Nine MiU Ulinastatin in three divided doses 8 hourly
62786269|NCT05492786|ACTIVE_COMPARATOR|Standard Alert|Standard flu alert
62786270|NCT05492786|EXPERIMENTAL|High-risk Alert|Flu alert that indicates patient is at high risk for flu and its complications
62786271|NCT05492786|EXPERIMENTAL|High-risk Alert with Risk Factors|Flu alert that indicates patient is at high risk for flu and its complications and presents the factors contributing to this high risk
62786272|NCT03749278|EXPERIMENTAL|ALMA Intervention Group|Latina Friends Motivating the Soul (ALMA). This group receives the intervention after baseline assessment.
62786273|NCT03749278|ACTIVE_COMPARATOR|ALMA Delayed Intervention Control Group|Latina Friends Motivating the Soul (ALMA). This group receives the intervention six months after the baseline assessment (after the post-intervention, and 3 month assessments have been completed).
62786274|NCT06578351||Healthy Infants|Healthy. no atopic dermatitis
62786275|NCT06578351||Infants with early onset of eczema|diagnosed with early onset eczema
62786276|NCT01671917|EXPERIMENTAL|Educational and exercise program|
62786277|NCT01671917|ACTIVE_COMPARATOR|Usual care|
62786278|NCT01645410|EXPERIMENTAL|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
62786279|NCT01645410|ACTIVE_COMPARATOR|Lipitor® 40 mg Tablets|Lipitor® 40 mg Tablets of Pfizer Ireland Pharmaceuticals
62786280|NCT05621993||Combination therapy group|Patients who are treated with the combination therapy of Azvudine and Chinese herbal medicine will be included in this group. The combination therapy is Azvudine treatment (5 mg once a day) within 48 hours of first positive nucleic acid testing for COVID-19, combined with Chinese herbal medicine treatment.
62786281|NCT05621993||Sequential therapy group|Patients who are treated with the sequential therapy of Azvudine and Chinese herbal medicine will be included in this group. The sequential therapy is Azvudine treatment (5 mg once a day) after 48 hours of first positive nucleic acid testing for COVID-19, combined with Chinese herbal medicine treatment.
62786282|NCT05621993||Non-standard therapy group|Patients are treated with Azvudine combined with Chinese herbal medicine treatment. But Azvudine treatment is discontinued before the nucleic acid turns negative.
62786283|NCT05621993||The control group|Patients are treated with Chinese herbal medicine without Azvudine.
62203014|NCT01681121|EXPERIMENTAL|ADX-N05|ADX-N05 to be taken once a day for 12 weeks
62203015|NCT01681121|PLACEBO_COMPARATOR|Placebo|Placebo to match ADX-N05 to be taken once a day for 12 weeks
62203016|NCT01427777||HPV Vaccine|People that receive HPV vaccine in V501-030
62203017|NCT03357419|ACTIVE_COMPARATOR|prophylactic antibiotic|"Each active arm patient will be given the tested drug on admission, 30-60 minutes before the surgery, by the nurses.~2 g dose of cephalexin (or Clindamycin 600 mg for patients suffering from allergy) will be given once, orally, 30-60 minutes prior to skin lesion excision"
62203018|NCT03357419|PLACEBO_COMPARATOR|placebo oral capsule|Each placebo arm patient will be given the placebo drug on admission, 30-60 minutes before the surgery, by the nurses
62203019|NCT03178370||Diabetic Gastroparesis|
62203020|NCT03178370||Idiopathic Gastroparesis|
62203021|NCT06011434||Patient: Conversation Aid On Mammography Screening|"Participants will complete study procedures as follows:~* Pretest questionnaires.~* PCP Appointment with introduction to conversation aid website.~* Post-test questionnaires within two weeks of PCP visit."
62203022|NCT06011434||Family: Conversation Aid On Mammography Screening|"Caretakers/Family members to participants will complete study procedures as follows:~* Pretest questionnaires.~* Attend with participant PCP Appointment with introduction to conversation aid website.~* Post-test questionnaires within two weeks of PCP visit."
62579730|NCT05566470||Patient Group|"1. Individuals between 30-65 years old who have been diagnosed with massive rotator cuff tear,~2. At least 6 months have passed after the surgery,~3. In the last 6 months, patients have not undergone shoulder surgery except for rotator cuff tear surgery,~4. Arthroscopic surgical method was performed by Prof. Dr. Gazi Huri,~5. The absence of another lesion involving the shoulder joint, such as SLAP (Superior Labrum Anterior Posterior), recurrent shoulder dislocation, arthroplasty, except for massive complete tear in the patient will be included in the study"
62579731|NCT03436693|EXPERIMENTAL|Canagliflozin 100mg|
62579732|NCT03436693|PLACEBO_COMPARATOR|Placebo|
62579733|NCT00659477|EXPERIMENTAL|single arm|
62579734|NCT00285207|PLACEBO_COMPARATOR|Placebo|Placebo administered topically to the cervix via intravaginal applicator for 5 consecutive days of a 28-day cycle for 2 cycles.
62579735|NCT00285207|EXPERIMENTAL|A007|0.25% A007 administered topically to the cervix via intravaginal applicator for 5 consecutive days of a 28-day cycle for 2 cycles.
62579736|NCT01696929|EXPERIMENTAL|Tocilizumab|Following a screening evaluation, participants will receive two infusions of tocilizumab, one at baseline and another at week 4 of the study. All subjects will receive a 4 mg/kg infusion of tocilizumab, the recommended starting dose for adults with rheumatoid arthritis.
61978425|NCT04987957|EXPERIMENTAL|Experimental group|"4 music genres with expert opinion will be presented to the preference of the participants in the intervention group, these types of music; Classical Music, Turkish Classical Music, Turkish Folk Music and Sufi Music. The music is instrumental, 70 decibels and non-verbal. Participants will listen to a genre they choose and download to their mobile phones once for 5 days for 15 minutes. They will listen to the music in the environment they live in, at a time convenient for them, at the desired volume level and with headphones in accordance with the determined therapy program.~At the beginning of the research, an Introductory Questionnaire will be applied to all participants. Trait Anxiety Inventory will be administered before music therapy on the 1st day of the study and after the music therapy application on the 5th day."
62203023|NCT06011434||Clinician: Conversation Aid On Mammography Screening|"Clinicians will complete study procedures as follows:~* Pretest questionnaires.~* Post-test questionnaires."
62203024|NCT04161053|ACTIVE_COMPARATOR|Rifaximin|550 mg Rifaximin tablets twice daily for six months.
62203025|NCT04161053|EXPERIMENTAL|Nitazoxanide|500 mg Nitazoxanide tablets twice daily for six months.
62203026|NCT01796626|EXPERIMENTAL|Wrinkle treatment|Wrinkle treatment with ResurFX 1565nm module
62203027|NCT01796626|EXPERIMENTAL|Striae treatment|Striae treatment with the REsurFX 1565nm module
62203028|NCT05183776|EXPERIMENTAL|Study patients|study patients will receive holmium radioembolization using a novel administration device.
62203029|NCT02461953|EXPERIMENTAL|low flux hemodialysis|low flux hemodialysis alone, 3 times a week, 4 hours per session
62203030|NCT02461953|EXPERIMENTAL|high flux hemodialysis|high flux hemodialysis alone, 3 times a week, 4 hours per session
62203031|NCT02461953|EXPERIMENTAL|low flux hemodialysis + hemoperfusion|low flux hemodialysis 2times a week and the HD+HP once a week
62203032|NCT02461953|EXPERIMENTAL|high flux hemodialysis + hemoperfusion|high flux hemodialysis 2times a week and the HD+HP once a week
62734822|NCT01471795||Study Population|150 subjects with end-stage heart failure who have been scheduled to undergo device implantation with a VAD, either as a bridge to cardiac transplantation or for destination therapy.
62786284|NCT03416127|EXPERIMENTAL|Propolis|Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
62786285|NCT03416127|EXPERIMENTAL|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
62786286|NCT03416127|PLACEBO_COMPARATOR|Placebo|Placebo capsules, two times per day before break-fast and dinner during 12 weeks.
62786287|NCT04429698|OTHER|POCUS group|Patients in this group underwent POCUS after primary clinical evaluation with the knowledge of their primary physician. This procedure was performed in the first hour after the patients' primary clinical evaluations to evaluate the predetermined parameters in the study form for the heart, lungs, hepatobiliary, aortic and deep veins.
62786288|NCT04429698|NO_INTERVENTION|Control group|All processes and results were followed without any intervention in the processes related to the patients in this group and the results were recorded in the study form
62786289|NCT03318016|EXPERIMENTAL|Cohort -1|3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide on day 4 as a single IV
62786290|NCT03318016|EXPERIMENTAL|Cohort 1|3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide on day 4 as a single IV
62786291|NCT03318016|EXPERIMENTAL|Cohort 2|3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide on day 4 as a single IV
62786292|NCT03318016|EXPERIMENTAL|Cohort 3|3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide on day 4 as a single IV
62786293|NCT03318016|EXPERIMENTAL|Cohort 4|3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide on day 4 as a single IV
62786294|NCT03382054||Older robust surgical patients|Male and female patients with age 65 years and above scheduled for surgery, which are robust according to Fried's Modified Frailty Score.
62014143|NCT05760092|PLACEBO_COMPARATOR|Placebo Photobiomodulation|Institutional standard treatment for xerostomia and COVID Longa + PBM placebo therapy
62786295|NCT03382054||Older pre-frail surgical patients|Male and female patients with age 65 years and above scheduled for surgery, which are pre-frail according to Fried's Modified Frailty Score.
62786296|NCT03382054||Older frail surgical patients|Male and female patients with age 65 years and above scheduled for surgery, which are frail according to Fried's Modified Frailty Score.
62014144|NCT01435005|ACTIVE_COMPARATOR|High Volume|Participate in one year of high volume (300 minutes per week) aerobic exercise with free provision of a personal trainer, membership to an exercise facility, body composition assessment.
62203033|NCT02031653||Study Group|
62203034|NCT02731079|ACTIVE_COMPARATOR|Covidien|Group that will have sleeve gastrectomy performed using the Covidien iDrive powered stapler with absorbable polymer membrane staple line reinforcement.
62786297|NCT04793113|EXPERIMENTAL|Intervention|Low carbohydrate, high protein meals
62786298|NCT04584593|OTHER|SARV-Cov|Men will give semen, saliva, urine and blood specimens
62786299|NCT05686291|EXPERIMENTAL|Treatment group|Participants in the treatment condition start the online volunteer training immediately after randomization and completed the online module within 2-week. Then they are invited to attend the face-to-face training within 1-week. They will complete the post-intervention assessment right after they finish the face-to-face training, and be invited to participate in an interview.
62786300|NCT05686291|NO_INTERVENTION|Wait-list control group|Participants in the waitlist control group will wait for 4 weeks without the training and then complete the post-intervention assessment. The waitlist control participants will start training (equivalent to that of the treatment group) immediately after completing the post-intervention assessment.
62786301|NCT03057652|EXPERIMENTAL|ReWalk, then EKSO, then REX|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
62786302|NCT03057652|EXPERIMENTAL|ReWalk, then REX, then EKSO|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
62786303|NCT03057652|EXPERIMENTAL|EKSO, then ReWalk, then REX|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
62786304|NCT03057652|EXPERIMENTAL|EKSO, then REX, then ReWalk|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
62786305|NCT03057652|EXPERIMENTAL|REX, then EKSO, then ReWalk|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
62786306|NCT03057652|EXPERIMENTAL|REX, then ReWalk, then EKSO|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
62579737|NCT05305885|EXPERIMENTAL|Group 1|Intrathecal administration, intraventricular administration or via lumbar puncture, pemetrexed plus dexamethasone, first induction intra-cerebrospinal fluid chemotherapy twice per week for 2 weeks, then once per week for 4 times, 6 weeks in total. Concurrent radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40 Gy.
62786307|NCT04379401|OTHER|Biventricular Pacing deactivated|The primary objective of the study is to determine, whether short term activation/deactivation of biventricular pacing (BivP) of the CRT (during routine CRT interrogation) has an effect on vascular function
62786308|NCT04379401|OTHER|Biventricular Pacing activated|The primary objective of the study is to determine, whether short term activation/deactivation of biventricular pacing (BivP) of the CRT (during routine CRT interrogation) has an effect on vascular function
62786309|NCT05736601||UKA MAKO|Prospective group- Patient Reported Outcomes (PROs) will be assessed using the FocusMotion app survey
62786310|NCT05736601||TKA MAKO|Control group-Already collected data on patient reported out comes using the FocusMotion app survey
62786311|NCT03514875|EXPERIMENTAL|MitoQ-Placebo|Subjects will be tested on two different days, first day will be baseline and MitoQ intake, and second day will be placebo intake. Testing will take place 40-minutes after MitoQ and placebo intake. There will be a 2-week washout between testing days.
62786312|NCT03514875|EXPERIMENTAL|Placebo-MitoQ|Subjects will be tested on two different days, first day will be baseline and placebo intake, and second day will be MitoQ intake. Testing will take place 40-minutes after placebo and MitoQ intake. There will be a 2-week washout between testing days.
62786313|NCT02623582|EXPERIMENTAL|Cohort 1|The first 3 subjects to receive RNA CART123 cells will receive up to 3 doses of RNA CART123 cells, with no lymphodepleting chemotherapy prior to infusion.
62786314|NCT02623582|EXPERIMENTAL|Cohort 2|"The remaining 12 subjects of the study will receive up to six IV doses of RNA CART123 cells.~Subjects in Cohort 2 may be given lymphodepleting chemotherapy 4 days (+/- 1 day) prior to the first CART123 cell infusion (if ALC\> 500/uL).~Lymphodepleting chemotherapy may be repeated before the fourth dose of RNA CART123 cells (if ALC\> 500/uL).~Lymphodepleting chemotherapy includes a single dose of cyclophosphamide (1g/m2) Weight used for dosing will be the weight obtained prior to the apheresis procedure Cell numbers are based on CAR+ cells with CAR expression determined by flow cytometry Based on the product release criteria, at least 20% of the total cells will be RNA CART123 cells.~Dosing will not be changed for changes in subject weight The indicated doses are +/- 20% to account for manufacturing variability."
62786315|NCT03848936||adult cerebral palsy patients|\>18 age cerebral palsy diagnosed patients evaluated with a survey.
62786316|NCT02487004||chronic hemodialysis patients|
62786317|NCT00599755|EXPERIMENTAL|Gem/Cis or Gem/Carbo|
62786318|NCT05113537|EXPERIMENTAL|Part A: Abemaciclib, 177Lu-PSMA-617|Patients receive abemaciclib lead-in on days 1-14 and lutetium Lu 177 vipivotide tetraxetan IV over 30 minutes on day 15. Treatment repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62579738|NCT05305885|EXPERIMENTAL|Group 2|Intrathecal administration, intraventricular administration or via lumbar puncture, pemetrexed plus dexamethasone, first induction intra-cerebrospinal fluid chemotherapy twice per week for 2 weeks, then once per week for 4 times, 6 weeks in total.
62786319|NCT05113537|EXPERIMENTAL|Part B: Recommended Phase 2 dose of Abemaciclib, 177Lu-PSMA-617|Patients receive the recommended phase 2 dose of abemaciclib lead-in on days 1-14 and lutetium Lu 177 vipivotide tetraxetan IV over 30 minutes on day 15. Treatment repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62579739|NCT03877029||Study II|"* Women with a screen-detected breast cancer after attending BreastScreen Norway~* Women with symptomatic breast cancer, who have never been screened in BreastScreen Norway~* Women with interval breast cancer after attending BreastScreen Norway~* Women free from breast cancer"
62579740|NCT03877029||Study III|"* Women with a screen-detected breast cancer after attending BreastScreen Norway~* Women with interval breast cancer after attending BreastScreen Norway and women with symptomatic breast cancer, who have never been screened in BreastScreen Norway"
62579741|NCT02237196|EXPERIMENTAL|AMG 157+Cat Immunotherapy|"AMG 157 will be administered every four weeks.~Cat immunotherapy will be administered weekly."
62786320|NCT01128946|EXPERIMENTAL|Fluoride Toothpaste 1|Fluoride toothpaste containing sodium fluoride (NaF)
62786321|NCT01128946|EXPERIMENTAL|Fluoride Toothpaste 2|Fluoride toothpaste containing stannous fluoride (SnF) and NaF.
62786322|NCT01128946|EXPERIMENTAL|Fluoride Toothpaste 3|Fluoride toothpaste containing sodium monofluorophosphate (NaMFP) and NaF.
62786323|NCT01128946|ACTIVE_COMPARATOR|Reference Dentifrice|Low fluoride toothpaste containing NaF
62786324|NCT02711007|EXPERIMENTAL|apatinib|apatinib 750mg tablet or 500mg tablet by mouth, Qd half an hour after dinner
62786325|NCT03182517||chronic kidney diseases|patients with chronic renal failure on dialysis since 3-5 years
62786326|NCT01209429|EXPERIMENTAL|42 hour fast/GH infusion|
62786327|NCT01209429|EXPERIMENTAL|42 hour fast/Placebo infusion|
62786328|NCT01209429|EXPERIMENTAL|12 hour fast/GH infusion|
62786329|NCT01209429|PLACEBO_COMPARATOR|12 hour fast/Placebo infusion|
61978426|NCT04987957|NO_INTERVENTION|Control group|No application will be made to the participants in the control group, and the data collection tools will be applied with the same frequency as in the intervention group.
61978427|NCT03388333||Atrial fibrillation ablation group|Patients undergoing catheter ablation for the treatment of atrial fibrillation.
62203035|NCT02731079|ACTIVE_COMPARATOR|Ethicon|Group that will have sleeve gastrectomy performed using the Ethicon Echilon powered stapler with absorbable polymer membrane staple line reinforcement.
62579742|NCT02237196|ACTIVE_COMPARATOR|AMG 157 Placebo+Cat Immunotherapy|"Placebo for AMG 157 of similar appearance will be administered every four weeks.~Cat immunotherapy will be administered weekly."
62579743|NCT02237196|EXPERIMENTAL|AMG 157+Cat Immunotherapy Placebo|"AMG 157 will be administered every four weeks.~Placebo for Cat immunotherapy will be administered weekly."
62579744|NCT02237196|PLACEBO_COMPARATOR|Placebo-Placebo|"Placebo for AMG 157 will be administered every four weeks.~Placebo for cat immunotherapy will be administered weekly."
62579745|NCT01778868||Overweight and obese individuals|
62579746|NCT01778868||Normal weight individuals|
62579747|NCT06526975|EXPERIMENTAL|Gamification 10-20'|This group will perform between 10 and 20 minutes of exercise through different videogames.
62579748|NCT06526975|EXPERIMENTAL|Gamification 20-30'|This group will perform between 20 and 30 minutes of exercise through different videogames.
62579749|NCT04333095|ACTIVE_COMPARATOR|Liposomal Bupivacaine Block|Liposomal Bupivacaine (1.3%) solution (20 mL dose). This solution has demonstrated increased efficacy in prolonged analgesia following injection. This solution will be injected as an ultrasound-guided subpectoral interfacial plane block.
62579750|NCT04333095|PLACEBO_COMPARATOR|Saline Block|Normal saline (0.9%) will be used as the control solution for patients not receiving the liposomal bupivacaine solution. Injection procedure of this solution will be identical to that of the liposomal bupivacaine solution.
62579751|NCT01357070|ACTIVE_COMPARATOR|Brocco-sprout homogenate|
62579752|NCT01357070|SHAM_COMPARATOR|Alfalfa sprout homogenate|
62579753|NCT05812235||Esophagectomy|48 patients with esophagectomy due to esophageal cancer before no more than 3 years
62579754|NCT05812235||Healthy Control|70 patients without gastrectomy , who are similar background in other group, are collected from date Pathologic analysis of primary osteoporosis: investigating age and osteoporosis related changes of bone microstructure by using HR-pQCT (UMIN000023535)
62579755|NCT03280602|ACTIVE_COMPARATOR|Tension band wiring (TBW)|TBW following the AO principles with 2 x 1.6 mm K-wires and wire wire cerclage.
62579756|NCT03280602|ACTIVE_COMPARATOR|Plate fixation|Plate fixation with Syntes VA-LCP olecranon plates 2.7/3.5
62579757|NCT02439528|OTHER|Combined pulmonary fibrosis and emphysema syndrome|Genetic analysis on patients with combined pulmonary fibrosis and emphysema syndrome.
62579758|NCT02439528|OTHER|Pulmonary fibrosis|Genetic analysis on patients with pulmonary fibrosis.
62579759|NCT02439528|OTHER|Emphysema|Genetic analysis on patients with emphysema.
62203036|NCT03586908|EXPERIMENTAL|PHP-201 0.5%|PHP-201 0.5%, ophthalmic solution, topical eye drop, OU
62203037|NCT00509249|EXPERIMENTAL|Arm I|Patients will receive aflibercept IV at 4 mg/kg over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62579760|NCT02439528|OTHER|Healthy subject|Genetic analysis on healthy subject.
62579761|NCT04707677|ACTIVE_COMPARATOR|CONTROL GROUP|Implant surgery placement. Tissue Level SLA Titanium implant (Straumann Standard Plus Narrow Neck CrossFit®; Institut Straumann, Basel, Switzerland). The implant had a diameter of 3.3 mm and a polished neck of 1.8 mm. The length of the implants was 8, 10 and 12 mm and was chosen according to the patient's anatomy.
62579762|NCT04707677|EXPERIMENTAL|TEST GROUP|Implant surgery placement. Tissue Level Ceramic monotype implant was placed (Straumann PURE Ceramic implants®; Institut Straumann, Basel, Switzerland). The implant had a diameter of 3.3 mm and a polished neck of 1.8 mm. The length of the implants was 8, 10 and 12 mm and was chosen according to the patient's anatomy.
62579763|NCT04059029||Morbidly obese patients with NAFLD|Morbidly obese patient with Nonalcoholic fatty liver disease. The starting point for each patient is the day of surgery and the end-point is 1 year after the operation. During bariatric surgery, all patients would undergo a wedge liver biopsy under laparoscopic guidance. The diagnosis of NASH would be made histologically.
62786330|NCT03679624|EXPERIMENTAL|Cohort A - Ibrutinib naive|Cohort A will consist of subjects who are ibrutinib naïve and appropriate for ibrutinib based treatment. Treatment naïve subjects will be eligible to enroll in this cohort. All subjects in this cohort will receive ibrutinib plus daratumumab
62786331|NCT03679624|EXPERIMENTAL|Cohort B - Ibrutinib response plateau|Cohort B will consist of subjects who have had at least 6 months of exposure to single agent ibrutinib and who have demonstrated an IgM response plateau defined by two IgM measurements, at least 8 weeks apart that have changed \<15% from the previous mark. All subjects in this cohort will receive ibrutinib plus daratumumab
62786332|NCT01718444|EXPERIMENTAL|Group A (No PIES)|"Subjects randomized to this group will receive clomiphene citrate (CC) without using progestin throughout their treatment course.~* CC 50 mg oral for 5 days (Days 3-7)~* If no ovulation, CC 100 mg for 5 days (Days 12-16)~* If no ovulation, CC 150 mg for 5 days (Day 21-25)~* Exit study if no response to 150 mg CC, or if no pregnancy after 5 ovulatory cycles"
62203038|NCT03683823|EXPERIMENTAL|Attention guidance|In addition to the components included in the control intervention the experimental attention guidance condition consists of three unique components: (1) the rationale will include information about the importance of visually attending to the faces of the audience; (2) in addition to being given a speech topic, participants will be given target audience members to focus their gaze on during the speech. They will be told that they should look at and focus on the target audience member for the whole speech; (3) between speeches, the researcher will tell participants the percentage of time they were focused on the target face.
62403260|NCT02824042|EXPERIMENTAL|Anetumab ravtansine|The evaluation of multiple ECG parameters and the drug-drug interaction (DDI) potential of anetumab ravtansine parameters when administered alone and together with itraconazole 100 mg oral capsules will be conducted in 2 sequential parts. On Cycle 1 Day 1, anetumab ravtansine will be given alone at a dose of 6.5 mg/kg in Part 1 and Part 2. On Cycle 2 Day 1, anetumab ravtansine will be given together with itraconazole at a dose of 0.6 mg/kg in Part 1, and at a dose of 6.5 mg/kg (planned) in Part 2.
62403261|NCT05554666|EXPERIMENTAL|ASKG315|Single or multiple ascending dose of ASKG315
62403262|NCT03283033|EXPERIMENTAL|Experimental 3|Introduction of a new salad bar and marketing conditions during second semester of school year
62579764|NCT04136340|ACTIVE_COMPARATOR|In-person follow-up|Due to the COVID-19 pandemic, patients originally randomized to the in-person group received telemedicine visits. Thus, the researchers will expand our sample for these interviews to include patients who have completed at least 2 telemedicine follow-up visits whether they were originally randomized to the in-person group or the home telemedicine group.
62579765|NCT04136340|EXPERIMENTAL|Home Telemedicine follow-up|
62579766|NCT04116060|EXPERIMENTAL|Nitrate|Dietary nitrate dissolved in water (0,12 mmol sodium-nitrate/kgBW/day) Dietary Supplement: Dietary nitrate 200 ml tab water with 0,12 mmol/kgBW sodium-nitrate
62403263|NCT03283033|EXPERIMENTAL|Experimental 2|Introduction of marketing conditions during second semester of school year
62403264|NCT03283033|EXPERIMENTAL|Experimental 1|Introduction of a new salad bar during second semester of school year
62403265|NCT03283033|NO_INTERVENTION|Control|No introduction of a new salad bar and no introduction of marketing conditions
62403266|NCT01521975|EXPERIMENTAL|HBeAg Negative Hepatitis|HBeAg Negative Hepatitis patients.
62403267|NCT06294327|EXPERIMENTAL|Reactive static air support surfaces (Repose®)|"Intervention with Repose® devices~Standard repositioning protocol is applied."
62403268|NCT06294327|NO_INTERVENTION|Alternating air pressure mattress (ArjoHuntleigh® Alpha Response)|"Standard care with mattress type: ArjoHuntleigh® Alpha Response~Standard repositioning protocol is applied."
62403269|NCT03292731|EXPERIMENTAL|hydroxyprogesterone caproate 500 mg|For safety assessment of the 500 mg dose, subjects will be randomized to the 500 mg dose of 17-OHPC.
62403270|NCT03292731|ACTIVE_COMPARATOR|hydroxyprogesterone caproate 250 mg|For safety assessment of the 500 mg dose, subjects will be randomized to the 250mg dose of 17-OHPC.
62403271|NCT03292731|ACTIVE_COMPARATOR|Ancillary cohort 250 mg dose|Receiving 250 mg as part of routine care
62579767|NCT04116060|PLACEBO_COMPARATOR|Control|Dietary sodium-chloride dissolved in water (0,12 mmol sodium-chloride/kgBW/day) Dietary Supplement: Dietary sodium-chloride 200 ml tab water with 0,12 mmol/kgBW sodium-chloride
62579768|NCT03567395|ACTIVE_COMPARATOR|Melatonin|Melatonin (5 mg sublingual tablet)
62579769|NCT03567395|EXPERIMENTAL|Honey|raw honey (1.5 tablespoons)
62579770|NCT02597153|EXPERIMENTAL|Mitoxantrone HCL Liposome Injection|Each treatment cycle lasts for 28 days with 20mg/m2
62579771|NCT01772888||Patients with ALS|All subjects aged \> 18 years, diagnosed with an ALS and included in the multidisciplinary follow-up of the HUG at time of diagnosis will be considered and included, if possible, at their first visit.
62786333|NCT01718444|ACTIVE_COMPARATOR|Group B (PIES Group)|"Women randomized to this group will receive progestin to induce endometrial shedding before starting any doses of clomiphene citrate (CC)~* Progestin 10 mg oral for 10 days to induce endometrial shedding (PIES)~* CC 50 mg oral for 5 days (Day 3-7)~* If no ovulation, progestin 10 mg for 10 days to induce endometrial shedding (starting on CD28) and CC 100 mg x 5 days, starting on day 3 of induced menses~* If no ovulation, progestin 10 mg for 10 days to induce endometrial shedding, and CC 150 mg for 5 days~* Exit study if no response to 150 mg CC, or if no pregnancy after 5 ovulatory cycles"
62786334|NCT03282097|EXPERIMENTAL|Mammogram decision aid|Family caregivers and patients with dementia will be mailed the DECAD decision aid about mammography and breast cancer screening before the patients next PCP visit to test if the aid improves decision making about breast cancer screening in older women with dementia.
62786335|NCT03282097|ACTIVE_COMPARATOR|Home safety guide|Family caregivers and patients with dementia will be mailed a home safety guide, which is a two-page paper pamphlet developed by the American Geriatrics Society Foundation for Health in Aging. It provides tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards. We selected the home safety guide to account for the attention given to the intervention group but not to provide information that would bias the control group about mammography.
62786336|NCT01485549||MSA Patients|Patients suffering from Multiple system atrophy (MSA)
62786337|NCT01485549||Controls|Patients requiring spinal tap without being affected by a neurodegenerative disorder.
62786338|NCT04239690|EXPERIMENTAL|Micromethods for blood sample analysis|Blood gases are analysed using 0.045 ml whole blood Levels of C-reactive protein (CRP) are analysed using 0.010 ml whole blood
62786339|NCT04239690|NO_INTERVENTION|Standard clinical methods for blood sample analysis|Blood gases are analysed using 0.3 ml whole blood Levels of CRP are analysed using 0.5 ml whole blood
62786340|NCT04994301||Patient with Cystic Fibrosis|Patients (male, female) age 5-11 with confirmed diagnosis of Cystic Fibrosis. These patients will begin clinically prescribed FDA-approved Trikafta therapy.
62786341|NCT04454073||Bipolar patients|In euthymic state or with mild to moderate symptoms
62786342|NCT04658043|EXPERIMENTAL|ASD Intervention Group|Participants in the ASD intervention group will receive training to help children improve socioemotional functioning.
62786343|NCT04658043|NO_INTERVENTION|Wait List Control Group|Participants in this group will be placed on the wait list and receive the ASD intervention training 2 months after the other groups
62579772|NCT01772888||Healthy age and gender-matched subjects|Controls matched for age and gender and dental status and without a medical history for neurological or otolaryngologic disease (1 control for 1 patient). They will be recruited among hospital staff and patients of the dental school.
62786344|NCT05958680|EXPERIMENTAL|ASDactive|Theoretically derived behaviour change intervention aimed at promoting habitual physical activity uptake
62786345|NCT03482492|ACTIVE_COMPARATOR|Tramadol|Group Tramadol patients received tramadol 1 mg kg-1 iv
62203039|NCT03683823|ACTIVE_COMPARATOR|Control intervention|"Participants will complete two intervention sessions within one week. The intervention will use a manualized protocol.~1. On the first session, participants will receive a brief standardized psychoeducation module, presented via a 15-minute video recording. This video will explain the intervention, its rationale, and the procedure.~2. Participants will then have 5 minutes to plan and outline a speech based on a topic given to them. All participants will receive the same topic. Participants will not be allowed to use the outline during the public speaking exposure trials.~3. Participants will then give six speeches that are each 3 minutes long on the same topic. Participants will give all the speeches in the immersive 360º-video environment.~4. Between speeches participants will have a 1-minute break."
62203040|NCT05538026|ACTIVE_COMPARATOR|standard care group|mesalazine (Pentasa) at a daily dose of 3 g (2 g orally + 1 g rectally)
62203041|NCT05538026|EXPERIMENTAL|Fecal transplantation|Fecal transplantation of fresh prepared feces from healthy donor. Application by colonoscope in proximal half of colon.
62203042|NCT06378684|OTHER|Group 1|"Treatment A: administration of 1 tablet of JW0104 Treatment B: administration of 1 tablet of C2207 Treatment A+B: Co-administration of 2 tablets of JW0104 and C2207~Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration"
62579773|NCT05704374|EXPERIMENTAL|Fibromyalgia group|"In the first phase of the experiment, the effect of sympathetic tone change on T- and H-reflexes will be evaluated.~In the second phase of the experiment, 150 mg (single dose) of pregabalin will be given to these patients to reduce sympathetic activity and evaluate its effect on T- and H-reflexes."
62579774|NCT05704374|OTHER|Healthy control group|The effect of sympathetic tone changes on T- and H-reflexes will be evaluated in healthy cases.
62786346|NCT03482492|ACTIVE_COMPARATOR|Tramadol-Paracetamol|Group Tramadol-Paracetamol patients received paracetamol 1 gr iv in addition to tramadol 1 mg kg-1 iv 30 minutes before the end of the operation and after the operation at 6 hour intervals for 24 hours
62786347|NCT02679287|EXPERIMENTAL|Group A|"Order of intervention will be 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d)~1. SAP=sensor-augmented pump only~2. USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight~3. USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control"
62786348|NCT02679287|EXPERIMENTAL|Group B|"Order of intervention will be 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP~1. SAP=sensor-augmented pump only~2. USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight~3. USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control"
62786349|NCT04338763|EXPERIMENTAL|Arm A: RP72 monotherapy|
62786350|NCT04338763|EXPERIMENTAL|Arm B: RP72 in combination with Gemcitabine|
62786351|NCT02644577|EXPERIMENTAL|metformin group|Metformin 1000mg/day
62786352|NCT02644577|PLACEBO_COMPARATOR|placebo group|starch
62786353|NCT03970369|EXPERIMENTAL|Monitor|Activity monitoring with feedback. Participants in the Monitor group will wear a step counter to track if the activity prescription is being met.
62786354|NCT03970369|ACTIVE_COMPARATOR|Usual care|All children will receive the usual care, which includes personalized goals and an activity prescription. Participants in the usual care group will not receive a step counter.
62786355|NCT01517464|EXPERIMENTAL|SGT-94|Dose escalation of experimental therapeutic SGT-94 to assess safety
62786356|NCT02112864|EXPERIMENTAL|dexamethasone 10 mg|Dexamethasone 10 mg will be given as a single-dose, pre incision, intravenously
62786357|NCT02112864|PLACEBO_COMPARATOR|normal saline|Patients in this group will receive 2.5 mL of normal saline intravenously, pre-incision
62786358|NCT03034330|EXPERIMENTAL|Two-Tier Stroke Family Empowerment|The intervention is individualized, tailor-made according to caregivers' needs. The intervention will last for 2 to 3 months with 6 to 10 weekly sessions at the home of caregivers or stroke survivors. Each session will last for 60 to 90 minutes. The care managers will determine the intensity of the intervention after the initial family assessment.
62203043|NCT06378684|OTHER|Group 2|"Treatment A: administration of 1 tablet of JW0104 Treatment B: administration of 1 tablet of C2207 Treatment A+B: Co-administration of 2 tablets of JW0104 and C2207~Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration"
62579775|NCT05925387|EXPERIMENTAL|Experimental Group|All volunteers completed a pre-test, which includes an additional two scales along with the sociodemographic data form, and two post-tests, which only include the scales. Both groups will receive the Child Abuse and Neglect Awareness Training, which will last approximately 60 minutes. Both groups will complete the pre-test and post-tests at the same time. However, immediately after the pre-test, the experimental group will receive the training and then complete the 1st post-test, followed by the 2nd post-test one month later. Additionally, the second post-test will be administered to both groups simultaneously one month after the completion of the first post-test. After the completion of all the tests, the control group also received the same training, and both groups received participation certificates. Apart from these tasks, there are no other responsibilities.
62579776|NCT05925387|NO_INTERVENTION|Control Group|"Participants in the control group do not receive the intervention. They took both pretest and post-tests. The control group, on the other hand, did not receive the training but completed the first post-test simultaneously with both groups, without distinguishing between the experimental and control groups.~They only complete online surveys. However, to follow the ethical rules, at the end of the trial, all nursing students will take the same education as their peers."
62579777|NCT02365389|ACTIVE_COMPARATOR|Group A received in situ MTZ vaginal gel|Received in situ MTZ vaginal gel once daily for 5 days. Treatment in this group was offered in the form of a bottle of an aqueous liquid (100 mL of a preparation composed of 0.8% MTZ, 20% pluronic F-127, 10% pluronic F-68, and 0.01% benzalkonium chloride). Women were asked to put 5 cc of the liquid into the vagina once daily for 5 days using a graded syringe and 10-cm long soft applicator.
62203044|NCT06378684|OTHER|Group 3|"Treatment A: administration of 1 tablet of JW0104 Treatment B: administration of 1 tablet of C2207 Treatment A+B: Co-administration of 2 tablets of JW0104 and C2207~Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration"
62403272|NCT04158518|EXPERIMENTAL|Toxicities reduced treatment|Patients receive docetaxel(75mg/m2 d1) and cisplatin(25 mg/m2 d1-3) every 3 weeks for 3 cycles as induction chemotherapy, followed by omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).
62403273|NCT04158518|ACTIVE_COMPARATOR|Conventional treatment|Patients receive docetaxel(75mg/m2 d1) and cisplatin(25 mg/m2 d1-3) every 3 weeks for 3 cycles as induction chemotherapy, followed by concurrent cisplatin chemotherapy with standard radiation dose when responses to induction chemotherapy are less than 50% Partial Response(PR).
62579778|NCT02365389|ACTIVE_COMPARATOR|Group B received conventional MTZ vaginal gel|Group B (control group) received conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days, using the supplied nozzle, which applies about 5 gm of gel again in the same laying back position.
62734823|NCT02151916|EXPERIMENTAL|Dental care, AG, MI & fluoride varnish|The intervention comprises four components; provision of dental care to the mother during pregnancy (2nd trimester), preventive treatment with fluoride varnish to the teeth of children, and two behavioral interventions, namely oral health anticipatory guidance and motivational interviewing with the caregiver/mother.
62203045|NCT06378684|OTHER|Group 4|"Treatment A: administration of 1 tablet of JW0104 Treatment B: administration of 1 tablet of C2207 Treatment A+B: Co-administration of 2 tablets of JW0104 and C2207~Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration"
62403274|NCT01440075|OTHER|Patients KD|Adults with a history of KD disease in childhood
62403275|NCT01440075|OTHER|Case Control|Control group, healthy volunteers matched for age and sex with the KD group
62403276|NCT04963751|ACTIVE_COMPARATOR|pre-operative counseling with their caregiver|Patients will be asked to attend a standard-of-care pre-operative teaching session with their parent.
62403277|NCT04963751|PLACEBO_COMPARATOR|caregiver-only counseling.|Parents-only will attend a standard-of-care pre-operative teaching session.
62203046|NCT06378684|OTHER|Group 5|"Treatment A: administration of 1 tablet of JW0104 Treatment B: administration of 1 tablet of C2207 Treatment A+B: Co-administration of 2 tablets of JW0104 and C2207~Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration"
62403278|NCT03076710||Opioids delivered through PCA|PCA devices used to deliver opioids
62403279|NCT03076710||EXPAREL® infiltration|EXPAREL® infiltration at the site of surgery and nurse-administered opioid as needed
62786359|NCT03034330|ACTIVE_COMPARATOR|Volunteer Support Psychoeducation|The intervention will last for 2 months with 4 weekly sessions at the home of caregivers or stroke survivors in the first month and 2 telephone contacts in the second month (6 contact points in total). Each session will last for 60 to 90 minutes. Care managers will not provide any direct intervention for participants in the control group.
62786360|NCT00305539|ACTIVE_COMPARATOR|1|
62203047|NCT06378684|OTHER|Group 6|"Treatment A: administration of 1 tablet of JW0104 Treatment B: administration of 1 tablet of C2207 Treatment A+B: Co-administration of 2 tablets of JW0104 and C2207~Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration"
62203048|NCT03711422|EXPERIMENTAL|Part A|Standard dose oral afatinib. If patients in Part A do not benefit from the regimen, they can be enrolled into Part B
62203049|NCT03711422|EXPERIMENTAL|Part B|Intermittent high dose oral afatinib
62203050|NCT06117670|EXPERIMENTAL|amniotic membrane graft|women with posterior vaginal prolapse will be enrolled and posterior colporrhaphy will be done with the application of sterilized (gamma irradiated) amniotic membrane as a graft.
62203051|NCT03232580|EXPERIMENTAL|rhAnnexin V-128|All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
62203052|NCT06408701||Subjects presenting with an ocular developmental anomaly|Biological samples will be collected in the normal diagnosis and follow-up process
62203053|NCT04487678|EXPERIMENTAL|Low-dose KE|141 mg/kg bodyweight of ketone esters
62203054|NCT04487678|EXPERIMENTAL|High-dose KE|282 mg/kg bodyweight of ketone esters
62203055|NCT03042923||Treatment|Twenty patients, known to us through care at Women's Surgery Center and the private practice of Dr. R. Scott Furr, will be invited to enroll based on a history of pelvic pain and a plan for surgical evaluation and intervention
62403280|NCT02662075|EXPERIMENTAL|E-cigarette/tobacco Smoking Exposure|
62403281|NCT01829321|EXPERIMENTAL|GLPG0974|1 capsule of 200 mg GLPG0974 twice daily
62786361|NCT00305539|PLACEBO_COMPARATOR|2|placebo
62203056|NCT03042923||Control|Ten healthy female patients, without pelvic pain or history of autoimmune disease, will be asked to participate as controls.
62203057|NCT04953598||acetabular labrum tears|Patients with clinically diagnosed acetabular labrum tears
62203058|NCT04953598||Patients with non-hip injuries|For non-hip joint reasons, come to the ultrasound department of our hospital to diagnose patients at the same time, and exclude other past and current hip diseases
62203059|NCT03242967|EXPERIMENTAL|Vadadustat|Oral tablet
62203060|NCT03242967|ACTIVE_COMPARATOR|Darbepoetin alfa|subcutaneous or intravenous
62403282|NCT01829321|PLACEBO_COMPARATOR|Placebo|1 capsule placebo twice daily
62403283|NCT02270021|EXPERIMENTAL|Provider Mobile Application (ProvAPP)|Mobile phone application for providers.
62215155|NCT02920489|EXPERIMENTAL|Individualized epidural analgesia|Epidural catheterization will be performed after the beginning of the first stage of labor. Epidural analgesia will begin when asked by parturients and the numeric rating scale of pain is 5 or higher. A loading dose (10 ml mixture of 0.1% ropivacaine and 0.5 ug/ml sufentanil) will be administered through the epidural catheter. After a 20-minute observation, a patient-controlled analgesia pump (containing a mixture of 0.08% ropivacaine and 0.4 ug/ml sufentanil) will be connected to the epidural catheter and programmed to deliver a 6-ml bolus with a 20-minute lockout interval and a 4 ml/h background infusion. Analgesia will be terminated at the end of the third stage of labor.
62403284|NCT02270021|EXPERIMENTAL|ProvAPP + Patient Educational Tool (Tab)|Patient educational tool; plus the Mobile phone application for providers.
62403285|NCT02270021|NO_INTERVENTION|ProvAPP Control Group|Clinics in this group are those NOT randomized - receiving no intervention. These clinics will be chosen at random for comparison using Family PACT claims data.
62403286|NCT02270021|NO_INTERVENTION|ProvAPP+Tab Control Group|Clinics in this group are those NOT randomized - receiving no intervention. These clinics will be chosen at random for comparison using Family PACT claims data.
62403287|NCT00167414|EXPERIMENTAL|Hypofractionated Stereotactic Body Radiation Therapy|Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.
62403288|NCT01014104|EXPERIMENTAL|Case|Administration of Methylprednisolone
62786362|NCT06185075|ACTIVE_COMPARATOR|Straight transmucosal contour|Implant crown will be designed with a straight transmucosal contour
62786363|NCT06185075|ACTIVE_COMPARATOR|Concave transmucosal contour|Implant crown will be designed with a concave transmucosal contour
62786364|NCT01907425|OTHER|Pre-natal Patient|
62403289|NCT01014104|SHAM_COMPARATOR|Control|
62403290|NCT05005923|NO_INTERVENTION|Periodontal healthy|
62403291|NCT05005923|ACTIVE_COMPARATOR|Periodontitis Stage III Grade B|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
62786365|NCT06307093|EXPERIMENTAL|RPH-075|"Pembrolizumab will be administered as an intravenous infusion every 3 weeks, at a fixed dose of 200 mg, for 30 minutes (it is permissible, but not desirable, to carry out an infusion in the range from 25 to 40 minutes).~Premedication before administration of pembrolizumab is not mandatory."
62014145|NCT01435005|ACTIVE_COMPARATOR|Moderate Volume|Participate in one year of moderate volume (150 minutes per week) aerobic exercise with free provision of a personal trainer, membership to an exercise facility, body composition assessment.
62786366|NCT06307093|ACTIVE_COMPARATOR|Keytruda®|"Pembrolizumab will be administered as an intravenous infusion every 3 weeks, at a fixed dose of 200 mg, for 30 minutes (it is permissible, but not desirable, to carry out an infusion in the range from 25 to 40 minutes).~Premedication before administration of pembrolizumab is not mandatory."
62014146|NCT01970761||scar, Fat Graft, Visual Analogue Scale|patients received autologous fat grafting in scar areas
62014147|NCT02894021|ACTIVE_COMPARATOR|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
62014148|NCT02894021|EXPERIMENTAL|padding|areas of padding and stiching between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h.
62014149|NCT00689676||Study Group|20 very low birth weight preterm toddlers
62014150|NCT00689676||Control Group|20 full-term toddlers
62403292|NCT05005923|ACTIVE_COMPARATOR|Periodontitis Stage III Grade C|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
62403293|NCT04436497|EXPERIMENTAL|Zilucoplan|"Drug: Zilucoplan Administration: Subcutaneous injection~Dosage: 0.3mg/kg administered daily"
62014151|NCT00974428|ACTIVE_COMPARATOR|Wobenzym® N and placebo|Wobenzym® N 2 tablets of the treatment and 2 placebo tablets three times per day
62014152|NCT00974428|ACTIVE_COMPARATOR|Wobenzym® N|Wobenzym® N 4 tablets three times per day
62014153|NCT00974428|PLACEBO_COMPARATOR|Placebo|Placebo 4 tablets three times per day
62014154|NCT00938431|EXPERIMENTAL|Lacosamide - Age 5 - 11 years|Cohort 1 (Age 5 - 11 years); up to 8 mg/kg/day
62014155|NCT00938431|EXPERIMENTAL|Lacosamide - (Age 12 - 17 years)|Cohort 2 (Age 12 - 17 years); 12 mg/kg/day.
62403294|NCT04436497|PLACEBO_COMPARATOR|Matching Placebo|"Administration: Subcutaneous injection~Dosage: Daily subcutaneous injection"
62014156|NCT00938431|EXPERIMENTAL|Lacosamide (Age 2 - 4 years)|Cohort 3 (Age 2 - 4 years); 12 mg/kg/day.
62014157|NCT00938431|EXPERIMENTAL|Lacosamide (Age 5 - 11 years)|Cohort 4 (Age 5 - 11 years); 12 mg/kg/day.
62403295|NCT05099744|EXPERIMENTAL|Electrostimulation Therapy|Participants will undergo six electrostimulation sessions, which will take place once a week and will last 20 minutes. Participants complete a set of questionnaires at the following times: pre-test (T0), post-test (T1), and 1-month post-intervention follow-up (T2). The first session will include a psychoeducational component, where it will be explained that psychological morbidity and stress influence the immune system, with repercussions on QoL.
62403296|NCT05099744|EXPERIMENTAL|Relaxation + Electrostimulation Therapy|Participants have sessions of relaxation and electrostimulation therapy during 20 minutes. They will receive two sessions in the same week, one of electrostimulation therapy and another of relaxation. Also, participants complete a set of questionnaires at the following times: pre-test (T0), post-test (T1), and 1-month post-intervention follow-up (T2).
62403297|NCT05099744|ACTIVE_COMPARATOR|Relaxation (standard)|Participants will receive relaxations sessions weekly, and complete a set of questionnaires at the following times: pre-test (T0), post-test (T1), and 1-month post-intervention follow-up (T2).
62403298|NCT05099744|PLACEBO_COMPARATOR|Placebo|Participants will be connected to the handles but will not receive any frequency during the 20 minutes. The sessions will take place at the same location and with the same weekly frequency as EG1 and EG2. Also, they will complete a set of questionnaires at the following times: pre-test (T0), post-test (T1), and 1-month post-intervention follow-up (T2).
61978428|NCT03388333||Electrophysiological study group|Patients undergoing a diagnostic electrophysiological study without ablation.
61978429|NCT03388333||Atrial flutter ablation group|Patients undergoing catheter ablation of right atrial flutter at the cavotricuspid isthmus.
61978430|NCT03398057|EXPERIMENTAL|Health education group(intervention group)|Standardized heath education Program(SHEP) applied to this group participants .
62014158|NCT00938431|EXPERIMENTAL|Lacosamide (Age 1 month - < 2 years)|Cohort 5 (Age 1 month to \< 2 years); 12 mg/kg/day
62014159|NCT04600648|ACTIVE_COMPARATOR|Weight loss with bariatric surgery|Patients scheduled to undergo bariatric surgery will be tested pre and post bariatric surgery. Interventions to be measured are serum Insulin and leptin levels, sweet taste responsiveness, body fat percentage, and z-BMI
62014160|NCT04600648|ACTIVE_COMPARATOR|Weight Loss|Patients to receive lifestyle weight loss treatment will be tested pre and post bariatric surgery. Interventions to be measured are serum Insulin and leptin levels, sweet taste responsiveness, body fat percentage, and z-BMI
62014161|NCT03920397|EXPERIMENTAL|Adipose tissue-derived stem/stromal cells|Safety of adipose tissue-derived stem/stromal cells (ASCs) for 24 months in patients with recente onset type 1 diabetes.
62014162|NCT03920397|EXPERIMENTAL|Daily 2000 UI of daily oral cholecalciferol|To investigate the efficacy of daily 2000 UI Cholecalciferol/day for 24 months in patients with recente onset type 1 diabetes.
62203061|NCT01213537||Patients undergoing clinically indicated CRT implantation|"Patients may be included in the study if they fulfil the following;~1. Age ≥18 years old~2. Fulfil the current guidance for the implantation of a CRT device; optimal medical treatment for heart failure, broad QRS complex on electrocardiogram with or without evidence of cardiac dyssynchrony as appropriate, LVEF \<35%, functional impairment as defined by an NYHA class of III-IV~3. Clinically stable with no unplanned admission to hospital for preceding 4 weeks~4. No changes in medications for heart failure in preceding 4 weeks~5. Able to read and understand patient information sheet and give informed consent~Patients must be excluded from the study if they fulfil they the following;~1. On positive pressure treatment for known sleep disordered breathing at the time of inclusion~2. Other known condition (untreated) likely to significantly disturb sleep eg. Restless legs syndrome, pain from any cause etc.~3. Pregnancy"
62203062|NCT01576380|EXPERIMENTAL|TKI258|TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
62403299|NCT00883129|EXPERIMENTAL|Mycophenolate Arm|Participants will receive oral mycophenolate mofetil for 2 years.
62403300|NCT00883129|EXPERIMENTAL|Cyclophosphamide Arm|Participants will receive oral cyclophosphamide for 1 year, followed by placebo for 1 year.
62403301|NCT05098678|EXPERIMENTAL|Zinc gluconate|zinc gluconate tablet daily (120 mg each tablet containing 30 mg elemental zinc)
62786367|NCT06254287|EXPERIMENTAL|Avatrombopag group|The Avatrombopag group was given Avatrombopag: 40 mg/ time, once a day, orally, for 3 months
62786368|NCT06254287|OTHER|Avatrombopag +rhTPO group|Avatrombopag: 40 mg/ time, once a day, orally; rhTPO: 15000U/ time, once a day, subcutaneous injection; Both were 3 months.
62786369|NCT03975686|EXPERIMENTAL|intervention|
62786370|NCT03975686|NO_INTERVENTION|control|
62786371|NCT03629353|EXPERIMENTAL|intubation group|The enrolled patients will be oxygenated by endotracheal tube during operation.
62786372|NCT03629353|EXPERIMENTAL|THRIVE group|The enrolled patients will be oxygenated by intubationless high flow nasal cannula during operation.
62786373|NCT00002812|EXPERIMENTAL|Arm A - Standard BFM of Standard Duration (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow. Consolidation (Phase II) (5 weeks) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
62203063|NCT02235311|ACTIVE_COMPARATOR|Pantoprazole twice daily|Pantoprazole 40mg orally twice daily x 8 weeks after acute management of UGIB
62403302|NCT05098678|PLACEBO_COMPARATOR|Control|Placebo (microcrystalline cellulose): 1 tablet (120 mg each)
62403303|NCT06308523|EXPERIMENTAL|AP303|
61978431|NCT03398057|PLACEBO_COMPARATOR|Control group|Placebo health education.
62403304|NCT06308523|PLACEBO_COMPARATOR|Placebo|
62203064|NCT02235311|ACTIVE_COMPARATOR|Pantoprazole once daily|Pantoprazole 40mg orally once daily x 8 weeks after acute management of UGIB
62203065|NCT01005082|EXPERIMENTAL|Low salt diet plus water therapy|
62203066|NCT01005082|ACTIVE_COMPARATOR|water therapy alone|
62203067|NCT03934151||intracorporeal anastomosis|patients who underwent elective right hemicolectomy whose ileocolic anastomosis was performed with intracorporeal technique
62203068|NCT03934151||extracorporeal anastomosis|patients who underwent elective right hemicolectomy whose ileocolic anastomosis was performed with extracorporeal technique
62203069|NCT04515433|EXPERIMENTAL|real tACS|Single session of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus)
62203070|NCT04515433|PLACEBO_COMPARATOR|sham tACS|Single session of sham tACS over the superior parietal cortex (Precuneus)
62203071|NCT05104203|ACTIVE_COMPARATOR|Thoracolumbar Interfascial Plane block|Patient will receive Thoracolumbar Interfascial Plane block
62203072|NCT05104203|EXPERIMENTAL|Modified Thoracolumbar Interfascial Plane block|Patient will receive modified Thoracolumbar Interfascial Plane Block
62203073|NCT01969851|EXPERIMENTAL|Lacosamide|
62203074|NCT05240326|ACTIVE_COMPARATOR|exercise training group|Clinical pilates exercises
62203075|NCT05240326|SHAM_COMPARATOR|control training group|Relaxation exercises
62203076|NCT05910905|EXPERIMENTAL|Prefabricated pediatric zirconia crown group|Zirconia crowns (ZK; EZ Crowns, Spring Oral Health Technologies, Inc:, Loomis, Calif., USA).
62203077|NCT05910905|ACTIVE_COMPARATOR|Prefabricated stainless steel crown group|Stainless Steel Crown (SSC, Kids Crown, Shinghung, Seoul, Korea)
62403305|NCT02808559|EXPERIMENTAL|Bodystudio ATBM|The PASI of the patients will be evaluated by two dermatologists then by the bodystudio ATBMs.
62403306|NCT02350868|EXPERIMENTAL|Arm 1|Subjects will be treated with oral doses of MPT0E028 in consecutive, 28-day cycles, and will be evaluated regularly for safety. Subjects who tolerate the drug and who do not experience progressive disease may continue to receive MPT0E028 at the discretion of the principal Investigator for up to 6 cycles.
62403307|NCT02848781|EXPERIMENTAL|ICD with Ablation|Patient will receive an implantable cardioverter defibrillator (ICD) with catheter ablation and standard medical management.
62786374|NCT00002812|EXPERIMENTAL|Arm B - Standard BFM with Double Delayed Intensification (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (5 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
62203078|NCT00573859|EXPERIMENTAL|ADHD medication versus placebo|For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication (e.g., Dextroamphetamine; Amphetamine mixed salts; Atomoxetine; O-Methylphenidate; Lisdexamfetamine). For the placebo condition, a placebo pill was administered.
62403308|NCT02848781|ACTIVE_COMPARATOR|ICD Only|Patient will receive an implantable cardioverter defibrillator (ICD) and standard medical management.
62203079|NCT03599752|EXPERIMENTAL|Group 1A (chemotherapy, metastasectomy)|Low risk patients receive standard of care chemotherapy for 3 months prior to and 3 months after undergoing metastasectomy in the absence of disease progression or unacceptable toxicity.
62203080|NCT03599752|EXPERIMENTAL|Group 1B (metastasectomy)|Low risk patients undergo metastasectomy.
62203081|NCT03599752|EXPERIMENTAL|Group 2A (metastasectomy)|High risk patients undergo metastasectomy.
62203082|NCT03599752|EXPERIMENTAL|Group 2B (chemotherapy)|High risk patients continue standard of care chemotherapy for 6 months in the absence of disease progression or unacceptable toxicity. Patients with stable disease or radiographic response after 6 months may then cross over to Group 2A.
62203083|NCT00709228||PegIntron plus Rebetol|Those with chronic Hepatitis C infected with HCV LVL G1
62203084|NCT00528619|EXPERIMENTAL|A|
62203085|NCT01307683|ACTIVE_COMPARATOR|Mindful Moms|Based on the Mindful Motherhood Training (developed by Cassandra Vieten, PhD), Mindfulness-Based-Eating and Awareness Training (MB-EAT) (developed by Jean Kristeller, PhD), and other mindfulness- and acceptance-based interventions
62403309|NCT02848781|ACTIVE_COMPARATOR|Ablation Only (Registry)|The registry will enroll patients who refuse an implantable cardioverter defibrillator (ICD) and are thus not randomized. This arm will assess the efficacy of catheter ablation in the absence of background ICD therapy.
62403310|NCT05361200|EXPERIMENTAL|Adaptive dynamic cycling|For the patient-specific adaptive dynamic cycling group, the optimization process will be done after the 3rd, 6th, and 9th sessions. The optimization procedure is based on sample entropy of cadence calculation from the previous session's cycling performance. After optimization, participants will receive specific settings for the next session.
62734824|NCT02151916|OTHER|Delayed intervention|Three fluoride varnish applications to the teeth of children and oral health anticipatory guidance and motivational interviewing for the caregiver when the child is aged 24, 30 and 36 months. Dental care also will be offered to the mothers/caregivers in the delayed intervention group when their children are aged 2 to 3 years old. Before the children are aged 2 years, standard dental care will be the comparator, which usually involves provision of dental care only if the participant is in pain.
62203086|NCT01307683|NO_INTERVENTION|Comparison Group|Usual prenatal care
62203087|NCT04846777|EXPERIMENTAL|Mindfulness ecological momentary intervention|The SMP condition was developed to parallel the treatment while eliminating its theorized active therapeutic elements - open monitoring, acceptance, attending to small moments, breathing retraining, continual practice of mindfulness. Therefore, it did not mention anything about mindfulness at all. Instead, SMP participants were instructed to notice their cognitions and emotions and how distress they might be. No instruction on accepting their thoughts and feelings as they are were given.
62203088|NCT04846777|PLACEBO_COMPARATOR|Self-monitoring placebo|The SMP condition was developed to parallel the treatment while eliminating its theorized active therapeutic elements - open monitoring, acceptance, attending to small moments, breathing retraining, continual practice of mindfulness. Therefore, it did not mention anything about mindfulness at all. Instead, SMP participants were instructed to notice their cognitions and emotions and how distress they might be. No instruction on accepting their thoughts and feelings as they are were given.
62203089|NCT05034159|EXPERIMENTAL|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. Five CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
62203090|NCT05034159|NO_INTERVENTION|Waitlist|No intervention for 8 weeks.
62203091|NCT03657602|EXPERIMENTAL|Contraceptive Kyleena|Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Kyleena Intrauterine System
62203092|NCT03657602|EXPERIMENTAL|Contraceptive Mirena|Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Mirena Intrauterine System
62203093|NCT01224977|OTHER|azithromycin|
62203094|NCT04110925|OTHER|MDS patients|All Canadian MDS patients on the MDS-database to be included.
62203095|NCT01365481|EXPERIMENTAL|valsartan|Valsartan starting dose: ≥18 kg to \<35 kg is 40 mg, ≥35 kg to \<80 kg is 80 mg, ≥80 kg to ≤160 kg is 160 mg for 1 week then Valsartan maintenance dose: ≥18 kg to \<35 kg is 80 mg, ≥35 kg to \<80 kg is 160 mg, ≥80 kg to ≤160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study.
62203096|NCT05315570|EXPERIMENTAL|Intervention arm|Study participants will be followed up as per clinical practice and will receive the investigational electronic platform, including an Android-based app. Study subjects will be asked to fill in questionnaires at study entry and during follow-up.
62203097|NCT05315570|NO_INTERVENTION|Control arm|No specific mobile apps will be provided to study participants, who will be followed as per clinical practice. Study subjects will be asked to fill in questionnaires at study entry and during follow-up.
62203098|NCT04200638|EXPERIMENTAL|ProTaper Next group|Clean and shape the necrotic canals with ProTaper instruments. In case of pain or inflammation 800mg Ibuprofen 3 times a day
62203099|NCT04200638|EXPERIMENTAL|WaveOne Gold group|Clean and shape the necrotic canals with Wave One Gold instruments. In case of pain or inflammation 800mg Ibuprofen 3 times a day
62203100|NCT01632540||Perennial Allergic Rhinitis patients|
62203101|NCT00843505|EXPERIMENTAL|1|Participants will take part in a telemedicine smoking cessation program.
62734825|NCT00248911|EXPERIMENTAL|Mindfulness based meditation program|Meditation and Breast Cancer: Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
62734826|NCT06231875||Press|
62734827|NCT06231875||Vacuum|
62203102|NCT00843505|ACTIVE_COMPARATOR|2|Participants will take part in a telephone quitline smoking cessation program.
62786375|NCT00002812|EXPERIMENTAL|Arm C - Augumented BFM of Standard Duration (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (9 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
61978432|NCT03434054|EXPERIMENTAL|Losartan|single dose of 50mg losartan, tablet, over-encapsulated, to be taken orally
62203103|NCT03011567|EXPERIMENTAL|Severe HDP- NSAID|This arm will be assigned a postpartum analgesic regimen with ibuprofen.
62203104|NCT03011567|EXPERIMENTAL|Mild HDP- NSAID|This arm will be assigned a postpartum analgesic regimen with ibuprofen.
62203105|NCT03011567|EXPERIMENTAL|Severe HDP- No NSAID|This arm will be assigned a postpartum analgesic regimen with acetaminophen.
62203106|NCT03011567|EXPERIMENTAL|Mild HDP- No NSAID|This arm will be assigned a postpartum analgesic regimen with acetaminophen.
62203107|NCT02548286|ACTIVE_COMPARATOR|Candesartan and Amlodipine|Candesartan 8mg and Amlodipine 5mg, PO, 1day or 22day
62203108|NCT02548286|EXPERIMENTAL|CKD-330|CKD-330 8/5mg, PO, 1day or 22day
62203109|NCT01376453|EXPERIMENTAL|Sorafenib Dose Escalation|Pre-operative Continuous 5-FU, and Sorafenib with External Radiation Therapy. Dose level -1 will only be evaluated if dose level 1 exceeds MTD. The sorafenib and infusional 5-FU will only be given Day 1-5(Monday-Friday) with radiation only.
62203110|NCT00508313||With Lung Cancer|Patients with lung cancer.
62734828|NCT01903122|ACTIVE_COMPARATOR|Cevimeline|Single Dose 30 mg Capsule
62203111|NCT00508313||Healthy Participants|Healthy participants without cancer.
62203112|NCT06169462||Pericapsular nerve group (PENG) block|Patients who underwent PENG in Hip surgery under spinal anesthesia will be evaluated retrospectively in terms of opioid consumption and NRS scores.
62734829|NCT01903122|ACTIVE_COMPARATOR|Evoxac|Single dose 30 mg capsule
62403311|NCT05361200|ACTIVE_COMPARATOR|Non-adaptive dynamic cycling|For the non-adaptive group, individuals will cycle on the dynamic bike with pre-determined settings that will stay constant throughout the exercise protocol.
62403312|NCT06567444|EXPERIMENTAL|ADHD Group|This experimental group received the working memory training conducted in primary schools in Hong Kong. This group was led by trained research assistants.
62403313|NCT06567444|EXPERIMENTAL|RD Group|This experimental group received the working memory training conducted in primary schools in Hong Kong. This group was led by trained research assistants.
62786376|NCT00002812|EXPERIMENTAL|Arm D - Augmented BFM with Dbl Delayed Intensification (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (9 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
62786377|NCT00216216|ACTIVE_COMPARATOR|1|Pemetrexed for patients with chemosensitive and chemoresistant relapsed small cell lung cancer.
62786378|NCT02479815|OTHER|1gm MNP, 15 sachets per month|Quasi experimental matched control cluster design where for every child 1gm Micronutrient Powder (MNP) for two days, is given which totlas to 15 sachets per month
62786379|NCT05015569|ACTIVE_COMPARATOR|Patient Gown + COVR garment|Patients will receive the standard of care patient gown and a COVR garment. Patients undergoing unilateral lower extremity surgery will receive a half short. Patients undergoing upper extremity or spine surgery will receive the brief (bilateral) style COVR garment.
62786380|NCT05015569|ACTIVE_COMPARATOR|Patient Gown|Patient will receive the standard of care patient gown only without undergarments.
62786381|NCT05311787|OTHER|Early oral feeding|The part of our investigation was prostective randomised trial which compared the result of patients with early oral feeding (since first day) and traditional group (oral feeding since 5th day)
62014163|NCT04866134|EXPERIMENTAL|Dose Escalation (Part A): ERAS-007 Monotherapy, BID-QW dosing|ERAS-007 monotherapy will be administered BID-QW in sequential ascending doses to participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.
62014164|NCT04866134|EXPERIMENTAL|Dose Expansion (Part B): ERAS-007 Monotherapy, QW dosing|ERAS-007 monotherapy will be administered at 250 mg QW to participants with advanced or metastatic solid tumors that harbor specific molecular alterations.
62014165|NCT04866134|EXPERIMENTAL|Dose Expansion (Part C): ERAS-007 Monotherapy, BID-QW dosing (if necessary)|Depending on data generated from Part A, ERAS-007 monotherapy may be administered at the BID-QW RD to participants with advanced or metastatic solid tumors that harbor specific molecular alterations.
62014166|NCT04866134|EXPERIMENTAL|Dose Escalation (Part D): ERAS-007 BID-QW dosing in combination with ERAS-601|Experimental: Dose Escalation (Part D): ERAS-007 BID-QW dosing in combination with ERAS-601 ERAS-007 will be administered BID-QW in combination with ERAS-601 administered BID 3/1 to study participants with advanced or metastatic solid tumors that harbor specific molecular targets in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
62403314|NCT06567444|EXPERIMENTAL|ADHD+RD Group|This experimental group received the working memory training conducted in primary schools in Hong Kong. This group was led by trained research assistants.
62403315|NCT06567444|NO_INTERVENTION|TD Group|The participants in the TD group did not receive any training.
62403316|NCT05472480||Chronic Venous Disease Patients|Consecutive patients admitted to Vascular Surgery Units.
62403317|NCT05472480||Carotid Stenosis Patients|Consecutive patients admitted to Vascular Surgery Units.
62786382|NCT06579911|EXPERIMENTAL|Group U|Use of high-frequency micro-ultrasound target biopsy, multiparametric MRI target biopsy and systematic biopsy for tumor detection
62786383|NCT06579911|ACTIVE_COMPARATOR|Group S|Use of multiparametric MRI target biopsy and systematic biopsy (current standard of care) for tumor detection
62786384|NCT01631461||1. Deep pain group|1. Deep pain group; Pain in the breast
62203113|NCT06169462||Suprainguinal fascia compartment block (SIFCB) + PENG|Patients who underwent PENG+SIFCB in Hip surgery under spinal anesthesia will be evaluated retrospectively in terms of opioid consumption and NRS scores.
62203114|NCT00943852|ACTIVE_COMPARATOR|1|losartan 100 mg
62203115|NCT00943852|ACTIVE_COMPARATOR|2|ISMN 60 mg
62203116|NCT00943852|ACTIVE_COMPARATOR|3|losartan 100 mg + ISMN 15 mg
62203117|NCT00943852|ACTIVE_COMPARATOR|4|losartan 100 mg + ISMN 60 mg
62403318|NCT05472480||Abdominal Aortic Aneurysm Patients|Consecutive patients admitted to Vascular Surgery Units.
62403319|NCT05472480||Peripheral Artery Disease Patients|Consecutive patients admitted to Vascular Surgery Units.
62403320|NCT05471882||Single neuromuscular blocking agent dose|Patients receiving a single dose of neuromuscular blocking agent
62403321|NCT05471882||Incremental doses of neuromuscular blocking agents|Patients receiving repetitive doses of neuromuscular blocking agents
62403322|NCT05471882||Pharmacological reversal|Patients receiving pharmacological reversal of neuromuscular block
62403323|NCT05317949|EXPERIMENTAL|Integrated neuromuscular training program group|Integrated neuromuscular training program group will perform exercise in three major domains
62403324|NCT05317949|ACTIVE_COMPARATOR|General fitness exercises program group|General fitness exercises program group will perform general fitness exercises
62014167|NCT06572735||Patients with advanced ovarian cancer|Patients of 70 years and elder with an advanced ovarian cancer who are scheduled to start a maintenance therapy with PARP inhibitors for the first time. The PARP inhibitors are administrated according to the marketing authorization and will be Olaparib (which may by administrated in combination with Bevacizumab) and Niraparib. There is no specific medical visit for this study, patient are followed in a routine care. Some medical data about the disease follow-up will be collected at inclusion and at each visit, every 3 months over a 12-months period. Furthermore, two quality of life surveys (OV28 and ELD14) and one geriatric assessment will be performed at each visit every 3 months and one 8ml-blood sample will be done at inclusion, and after 6 and 12 months of PARP inhibitors treatment.
62786385|NCT01631461||2. Superficial pain group|Pain on the nipple and/or aereola
62014168|NCT02563340|EXPERIMENTAL|MSCs group|cAMR patients in this group receive additional intravenous allogeneic BM-MSCs (1\*10\^6/kg) every two weeks for four consecutive doses, besides current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.
62014169|NCT02563340|ACTIVE_COMPARATOR|Control group|cAMR patients in this group receive current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.
62014170|NCT04979221|EXPERIMENTAL|Cyproheptadine and usual care|"Patients allocated to the intervention group will receive cyproheptadine within 6 hours after randomization, at a dose of 8mg every 8 hours for 10 days.~Usual care (diagnostic testing, antibiotic administration, fluid resuscitation, hemodynamic management, and ventilatory support) will be applied in accordance with the clinical practice of each institution."
62014171|NCT04979221|NO_INTERVENTION|Usual care|Usual care (diagnostic testing, antibiotic administration, fluid resuscitation, hemodynamic management, and ventilatory support) will be applied in accordance with the clinical practice of each institution.
62014172|NCT03125889|EXPERIMENTAL|Treatment Arm|Subjects will receive treatment with the AquaBeam System to remove prostatic tissue.
62014173|NCT03069690|EXPERIMENTAL|HABITpreg; TAUpost|Participants will receive study intervention during pregnant and treatment as usual postpartum.
62014174|NCT03069690|EXPERIMENTAL|HABITpreg, HABITpost|Participants will receive study intervention during pregnancy and study intervention during the postpartum period.
62014175|NCT03069690|EXPERIMENTAL|TAUpreg; HABITpost|Participants will receive treatment as usual during pregnancy and study intervention during the postpartum period.
62014176|NCT03069690|NO_INTERVENTION|TAUpreg; TAUpost|Participates will receive treatment as usual during pregnancy and treatment as usual during the postpartum period.
62014177|NCT02855502|ACTIVE_COMPARATOR|Prednisolone|dose: 15 mg per day(divided 5 mg TDS) dosage form: tablet duration administration: 30 days
62014178|NCT02855502|PLACEBO_COMPARATOR|Placebo|placebo given to patient: 3 tablet (divided TDS) dosage form: tablet duration administration: 30 days
62014179|NCT03099382|EXPERIMENTAL|camrelizumab|
62014180|NCT03099382|ACTIVE_COMPARATOR|Investigator's Choice of Standard Therapy|Docetaxel or Irinotecan
62014181|NCT05724004|EXPERIMENTAL|Radiotherapy + alectinib|All patients receive consolidation radiation therapy to all active tumour lesions after induction treatment with alectinib.
62203118|NCT00943852|PLACEBO_COMPARATOR|5|Placebo
62203119|NCT00690664||B|Caucasian women
62203120|NCT00690664||A|African American women
62014182|NCT00226434|EXPERIMENTAL|1|
62203121|NCT02470780|EXPERIMENTAL|Three-month follow-up|
62786386|NCT01631461||3. Control group|No pain or other breastfeeding problems
61978433|NCT03434054|PLACEBO_COMPARATOR|Placebo|single dose of placebo (main ingredient microcrystalline cellulose), tablet, over-encapsulated, to be taken orally
62014183|NCT00226434|ACTIVE_COMPARATOR|2|
62014184|NCT06145828||Cytokine Adsorption Combined with Standard Treatment Group|This group receives cytokine adsorption combined with standard treatment, specifically via hemoperfusion using the standard 211 protocol: two hemoperfusions within the first 24 hours, followed by one hemoperfusion daily. Each hemoperfusions session does not exceed 6 hours, lasting a total of 3 days. All patients also undergo blood perfusion treatment with the addition of a plasma separator.
62203122|NCT02470780|EXPERIMENTAL|Six-month follow-up|
62203123|NCT02162004|EXPERIMENTAL|Continuous correction|The insulin pump is set to automatically deliver the patient's usual insulin basal rate. The insulin pump bolus calculator is run every 10 minutes by the attending physician. Bolus calculations are based on glucose sensor values.
62203124|NCT02162004|NO_INTERVENTION|Control|Regular sensor-augmented pump therapy.
62203125|NCT04545333||ALL|patients diagnosed with acute lymphoblastic leukemia
62203126|NCT04545333||CLL|patients diagnosed with chronic lymphocytic leukemia
62203127|NCT04545333||MM|patients diagnosed with multiple myeloma
62203128|NCT04545333||NHL|patients diagnosed with non-Hodgkin lymphoma
62403325|NCT01472666|EXPERIMENTAL|Fat rich in MC-SFA|63 gram milk fat with high content of MC-SFA (C6-C12=8.5 g) incorporated in rolls, muffin and as butter.
62786387|NCT06340893|EXPERIMENTAL|Exercise|This group will receive treatment 3x/week for 6 weeks
62786388|NCT06340893|SHAM_COMPARATOR|Restful Play|This group will receive treatment 3x/week for 6 weeks.
62786389|NCT04079998|EXPERIMENTAL|Procellera® dressing|The Procellera® dressing will be applied to the wound site after standard of care cleaning and debridement. The dressing will be maintained according to the manufacturer's instructions for use.
62734830|NCT00434980|EXPERIMENTAL|Treatment|Participant and family take part in FCA treatment program.
62014185|NCT06145828||Standard Treatment Group|This group receives only standard treatment . Standard treatment includes symptomatic supportive therapy, etiological therapy, fluid resuscitation, application of vasopressors, and non-invasive or invasive ventilation therapy.
62014186|NCT06461104|EXPERIMENTAL|Intervention Group|Participants will engage in a 12-week structured PA programme, preceded by three weekly psychoeducational sessions focused on nutrition. This includes three 60-minute PA sessions per week supervised by a personal trainer.
62014187|NCT06461104|ACTIVE_COMPARATOR|Control Group|Participants will receive a 12-week psychoeducational programme on nutrition and PA. This programme includes 8 sessions divided into modules of 2 or 3 lessons each, covering topics such as the benefits of PA and sports, healthy eating habits, and health risks associated with a sedentary lifestyle. Sessions will be conducted by a dietitian and a clinical psychologist. At the end of the trial, control group participants will be offered the opportunity to participate in the same PA programme as the intervention group at no cost.
62014188|NCT00136708|EXPERIMENTAL|NRP Training (Intervention)|Training in AAP neonatal resuscitation training program
62203129|NCT00967902|EXPERIMENTAL|Combo|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
62203130|NCT00967902|ACTIVE_COMPARATOR|Taxus® Liberté® Stent|Commercially available product
62203131|NCT02456519||PaedQoR-15 Questionnaire|Questionnaire to be completed by all participants
62203132|NCT01741805||Severe Asthma|Patients with severe asthma as specified under inclusion, exclusion criteria
62203133|NCT04260178|EXPERIMENTAL|Experimental groups|For the experimental group, EBIP was implemented in three stages:(1) hospital training;(2) home visits + training, which includes motivational interventions that facilitate chronic disease self-care and symptom management with nurse-patient cooperation; and (3) telephone follow-ups and assistance. A handbook was developed in line with the relevant literature and input from two specialist physicians (1,17-20). The handbook consisted of 4 sections that concerned improving breathing exercises, drug compliance, nutrition and illness self-care behavior. The trainings sessions were conducted in a hospital seminar room using PowerPoint presentations. Afterward, patients were asked to demonstrate what they learned, and the parts that were not clear were explained again. The training was concluded after deciding for the first home visit appointment. For patients that could not effectively use the handbook, a close relative was included to all steps of the study.
62203134|NCT04260178|OTHER|Control groups|Control groups were evaluated with an introductory survey form, PFT, BDI, BMI and SCMP-G scales before and after the study. There were no additional interventions to the control group.
62786390|NCT04079998|ACTIVE_COMPARATOR|Standard of Care|The Standard of care as prescribed will be followed for the dressing application for the wound site. Dressings will be applied to the wound site after standard of care cleaning and debridement.
62014189|NCT00136708|OTHER|Control|
62203135|NCT03724253|EXPERIMENTAL|Phase II dosimetry group|All eligible participants were to receive recommended dose of \[68Ga\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\].
62403326|NCT01472666|EXPERIMENTAL|Fat low on MC-SFA|63 gram milkfat with low content of MC-SFA (C6-C12=6.9 g) incorporated in rolls, muffin and as butter
62734831|NCT04998916|EXPERIMENTAL|Real TBS to the mPFC|For continuous theta burst stimulation (cTBS), participants will receive 3 sessions of stimulation per visit over the left medial prefrontal cortex (mPFC) (each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec, 600 pulses/session, 60 sec intertrain interval; 120% RMT, MagPro; 10-15 min inter session interval) using a figure 8 coil (Coil Cool-B65 A/P).
62786391|NCT04027894|EXPERIMENTAL|Rifamycin SV MMX plus ORT|Each tablet contains 200mg Rifamycin SV MMX for oral administration
62014190|NCT03609060|EXPERIMENTAL|DEXAML|"Induction therapy:~Idarubicin 8 mg/m²/day, IV over 15 minutes, D1 to D5 + Cytarabine 100 mg/m²/d, IV continuous 24h-infusion D1 to D7 + Lomustine 200 mg/m²/d, orally at D1 + Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3. Addition of midostaurin in patients with Fms-like tyrosine kinase 3-internal tandem ( FLT3-ITD) or Fms-like tyrosine kinase 3-tyrosine kinase domain (FLT3-TKD) mutations is allowed.~Post remission therapy:~Idarubicin 8 mg/m², IV over 15 minutes, D1 + Cytarabine 50 mg/m²/12h, subcutaneous, D1 to D5 + Dexamethasone 20 mg/d, IV over 30 minutes, D1. Addition of midostaurin in patients with FLT3-ITD or FLT3-TKD mutations is allowed. Intermediate dose cytarabine is allowed for patients with Core Binding Factor AML (CBF-AML).~Allogeneic stem-cell transplantation allowed after 2 to 4 cycles"
62203136|NCT03724253|EXPERIMENTAL|Phase II non-dosimetry group|All eligible participants were to receive recommended dose of \[68Ga\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\].
62203137|NCT02954744|EXPERIMENTAL|Treatment arm|HIFU treatment
62403327|NCT01472666|EXPERIMENTAL|Casein protein|60 gram casein protein (Miprodan 30) ingested twice daily with 600 ml water.
62403328|NCT01472666|EXPERIMENTAL|Whey protein|60 gram whey protein (Lacprodan DI-9224) ingested twice daily with 600 ml water.
62579779|NCT05473949|ACTIVE_COMPARATOR|Propofol|"ASA Standard monitorization and nasal spectacle capnography (OC) were used. Supplementary supply of O2 is placed at 2-3 L/min also by OC.~The drugs were randomized of the study begins. The investigators didn't know whether ketamine is present in syringes prepared with propofol or not, acting in the same way for both drug combinations.~Sedation was performed with:~1. Propofol: induction with a bolus of 1% propofol (10mL syringe) administered at a dose of 0.75mg/kg; maintenance with 1% propofol infusion (20mL syringe), at an infusion rate of 6-7mg/kg/h.~In both arms:~* 4 mg of I.V. dexamethasone were administered.~* At the beginning of the procedure and atropine and ephedrine were prepared.~* At the end of the procedure, paracetamol I.V. 15mg/kg was administered.~* If the patient reports VAS\>3 pain in recovery, metamizole magnesium 15mg/kg is also administered.~* In case of post-procedure nausea and/or vomiting, 4 mg of ondansetron would be administered as a rescue."
62786392|NCT04027894|PLACEBO_COMPARATOR|Placebo tablets plus ORT|Placebo tablets identical to Rifamycin tablets with respect to size, taste and appearance.
61978434|NCT02895906|EXPERIMENTAL|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as capsules for oral administration.
62014191|NCT03747081|EXPERIMENTAL|Rivoroxaban|Patients would be administered Enoxaparine (60 mg/SC/BID)in first day, after dicontinuing Enoxaparin in second day, Rivoroxaban 20 mg per day will use. .it would be given once a day.The total duration of Rivoroxaban would be 3 months.
62014192|NCT03747081|ACTIVE_COMPARATOR|warfarin|Patients would be administered Warfarin with overlap of Enoxaparine utill INR adjust to 2-3 then enoxaparine will disconstinue.it would be given once a day.The total duration of Warfarin would be 3 months
62014193|NCT02685163|EXPERIMENTAL|Antioxidant Ice-cream|Natural antioxidant Ice-cream
62014194|NCT02685163|PLACEBO_COMPARATOR|Control Ice-cream|Natural control ice-cream
62014195|NCT01503489||Bipolar depressed patients|Bipolar I or II outpatients, current major depressive episode (HDRS-17 over 20).
62014196|NCT05801627|EXPERIMENTAL|SAL067|SAL067 12mg once daily
62403329|NCT02900131|EXPERIMENTAL|trial group 1|Participants will receive Jaungo and placebo once a day for three weeks.
62403330|NCT02900131|EXPERIMENTAL|trial group 2|Participants will receive Jaungo twice a day for three weeks.
62403331|NCT02900131|PLACEBO_COMPARATOR|control group|Participants will receive placebo twice a day for three weeks.
62403332|NCT03217916||normotensive groups|pregnant women with normal blood pressure
62786393|NCT03258775|ACTIVE_COMPARATOR|250ml|
62786394|NCT03258775|ACTIVE_COMPARATOR|500ml|
61978435|NCT01747941|EXPERIMENTAL|Cohort 1|Single ascending oral doses in fasted conditions
62014197|NCT05801627|PLACEBO_COMPARATOR|Placebo|placebo once daily
62014198|NCT02460640|ACTIVE_COMPARATOR|Tap Block|the intervention will be tap block after induction of anesthesia with ropivacaine 0,5% 15ml and continuous patient-controlled analgesia with morphine
62014199|NCT02460640|ACTIVE_COMPARATOR|No Tap Block|the patients who not receive tap block but they will be as intervention intravenous Patient controlled analgesia
62014200|NCT02722694|EXPERIMENTAL|Subcutaneous(SC) Abatacept|
62014201|NCT02722694|PLACEBO_COMPARATOR|Placebo|
62014202|NCT04741659|PLACEBO_COMPARATOR|spontaneous breathing trial|the patients will be asked to breathe spontaneously using their actual low oxygen flow
62014203|NCT04741659|ACTIVE_COMPARATOR|High Flow Nasal cannula (HFNC)|The patients will be asked to breathe with HFNC of 40 L/min
62014204|NCT04741659|ACTIVE_COMPARATOR|Helmet CPAP|the patients will be asked to breathe with the Helmet CPAP
62203138|NCT04223804|PLACEBO_COMPARATOR|Stage 1: Arm A|Participants will receive placebo.
62203139|NCT04223804|EXPERIMENTAL|Stage 1: Arm B|Participants will receive ABBV-181 dose A.
62203140|NCT04223804|EXPERIMENTAL|Stage 1: Arm C|Participants will receive ABBV-181 dose B.
62403333|NCT03217916||hypertensive groups|pregnant women with severe preclampsia
62403334|NCT03410693|EXPERIMENTAL|Rogaratinib|"Rogaratinib treatment study arm, comprising~1. Pre-treatment period, including FGFR testing and screening,~2. Treatment period, and~3. Follow-up period, including active follow-up and long-term follow-up. Patients will be considered on study during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered off study."
62014205|NCT04741659|ACTIVE_COMPARATOR|Non Invasive Ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
62203141|NCT04223804|PLACEBO_COMPARATOR|Stage 2: Arm D|Participants will receive Placebo.
62203142|NCT04223804|EXPERIMENTAL|Stage 2: Arm E|Participants will receive ABBV-181 dose C.
62786395|NCT04009395||Pregnant women|One-on-one in-depth interviewing
62014206|NCT04313192|EXPERIMENTAL|Pulse rate 2Hz (hertz)|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 2 Hz, intensity setting to patient's tolerance, duration 30 days
62014207|NCT04313192|EXPERIMENTAL|Pulse rate 10Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
62203143|NCT01409551|ACTIVE_COMPARATOR|VATS hyperthermic pleural chemoperfusion|The patients undergo a VATS drainage of pleural effusion with adhesiolysis and complete mobilization of the lung, following by a 1 hour hyperthermic (40oC)chemoperfusion by means of a pump machine.
62203144|NCT01409551|ACTIVE_COMPARATOR|Bedside talc slurry pleurodesis|The patients undergo tube thoracostomy under local anesthesia. When the lung is fully expanded, talc slurry bed-side pleurodesis is performed.
62203145|NCT01869023|OTHER|6 h infusion Gemcitabine and Cisplatin|Gemcitabine 250 mg/m2 Cisplatin 30 mg/m2
62203146|NCT03015129|EXPERIMENTAL|Durvalubmab|Patients will receive intravenous infusion of durvalumab 1500mg Fixed Dose every 4 weeks until patient develops a loss of clinical benefit or experiences unacceptable toxicities.
62203147|NCT03015129|EXPERIMENTAL|Durvalubmab + Tremelimumab|Patients will receive 1500mg Flat Dose durvalubmab via intravenous infusion every 4 weeks for up to 4 cycles and 75mg tremelimumab via intravenous infusion every 4 weeks for up to 4 cycles, and then continue 1500mg Fixed Dose durvalumab every 4 weeks until patient develops a loss of clinical benefit or experiences unacceptable toxicities.
62203148|NCT00461981|EXPERIMENTAL|FluMist, Influenza Virus Vaccine Live|FluMist, Influenza Virus Vaccine Live, Intranasal
62203149|NCT00461981|ACTIVE_COMPARATOR|TIV, Trivalent Inactivated Influenza Virus Vaccine|TIV, Trivalent Inactivated Influenza Virus Vaccine, Intramuscular
62203150|NCT06233890||Fatigue|"Group 1: Fatigue present for more than 6 months with impairment in daily life activities.~Fatigue will be assessed using two validated fatigue questionnaires completed at the screening visit. The Chalder fatigue scale (CFQ) is an 11 item scale which assesses the severity of fatigue over the last 90 days and the Modified Fatigue Impact scale (MFIS), commonly used to determine the impact of fatigue on quality of life, assesses fatigue over the previous 30 days. Both scales are diagnostic tools in chronic disease associated fatigue. Scores on these scales will determine if patients are eligible. For this group a score \> or = 5 for Chalder score and \> or = 43 for the MFIS score."
62203151|NCT06233890||Non -Fatigue|Group 2: no significant symptoms of fatigue on TKI therapy. Fatigue will be assessed using two validated fatigue questionnaires completed at the screening visit. The Chalder fatigue scale (CFQ) is an 11 item scale which assesses the severity of fatigue over the last 90 days and the Modified Fatigue Impact scale (MFIS), commonly used to determine the impact of fatigue on quality of life, assesses fatigue over the previous 30 days. Both scales are diagnostic tools in chronic disease associated fatigue. Scores on these scales will determine if patients are eligible. For this group a score \< or = 2 for Chalder score and \< or = 33 for the MFIS score.
62203152|NCT03211117|EXPERIMENTAL|Cohort A (pembrolizumab, surgery, chemoradiation)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients undergo surgery. Within 42 days of surgery, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
62203153|NCT03211117|EXPERIMENTAL|Cohort B (pembrolizumab, chemoradiation)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
62579780|NCT05473949|ACTIVE_COMPARATOR|Ketofol|"2. Sedation with ketofol in a 1:4 dilution: induction of sedation with bolus of ketofol (dilution containing 9.5 mL of 1% propofol + 0.5 mL of 5% ketamine) (10mL syringe), administered at a dose of 0.75 mg/kg; maintenance with ketofol infusion (dilution containing 19 mL of 1% Propofol + 1 mL of 5% Ketamine), (20mL syringe), at an infusion rate of 6-7mg/kg/h.~The dose used for bolus induction of sedation in both arms of the study is titrated to the needs of each individual patient, although the target approximates the usual recommended dose. If a propofol or ketofol syringe is insufficient considering the patient's weight, another syringe will be prepared with exactly the same dilution as the first.~The study was always blind to the investigators."
62579781|NCT01835795|ACTIVE_COMPARATOR|Radial Extracorporeal Shock Wave|Swiss DolorClast® CLASSIC applicator
62579782|NCT01835795|PLACEBO_COMPARATOR|Placebo|Swiss DolorClast® CLASSIC placebo applicator
62579783|NCT01312883|NO_INTERVENTION|Treatment as usual|Participants will receive standard postpartum education and discharge materials provided by the hospital and a list of community and Internet resources by mail.
62579784|NCT01312883|EXPERIMENTAL|Behavioral education|Participants will receive behavioral education on postpartum depression and a list of community and Internet resources by mail.
62579785|NCT04666701|EXPERIMENTAL|Escócia association|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:~1 tablet Escócia association, oral~1 dragee Placebo Scopolamine, oral~1 tablet Placebo Ketorolac, sublingual"
62579786|NCT04666701|ACTIVE_COMPARATOR|Ketorolac|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:~1 tablet Ketorolac, sublingual~1 tablet Placebo Escócia association, oral~1 dragee Placebo Scopolamine, oral"
62579787|NCT04666701|ACTIVE_COMPARATOR|Scopolamine|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:~1 dragee Scopolamine, oral~1 tablet Placebo Ketorolac, sublingual~1 tablet Placebo Escócia association, oral"
62579788|NCT04037163||CCTA-FFR|Patients who underwent CCTA within 90 days before FFR measurement will be included in the present study.
62579789|NCT01730443||On progesterone treatment|The group assigned to progesterone treatment.
62203154|NCT04252274|EXPERIMENTAL|Darunavir, Cobicistat and conventional treatments|After randomization, subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments.
62203155|NCT04252274|NO_INTERVENTION|Conventional treatments|After randomization, subjects take conventional treatments without darunavir and cobicistat.
62203156|NCT02656719|EXPERIMENTAL|Ultrasound|Ultrasound guided percutaneous tracheostomy
62203157|NCT02656719|ACTIVE_COMPARATOR|Bronchoscopy|Bronchoscopy guided percutaneous tracheostomy
62203158|NCT00557908||VWF/FVIII product infusions|One to three infusions of factor replacement as needed to control bleeding.
62203159|NCT00876824|EXPERIMENTAL|Amphotericin B lipid emulsion|Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A Drug: Amphotericin B lipid emulsion
62203160|NCT00876824|ACTIVE_COMPARATOR|Liposomal Amphotericin B|Liposomal Amphotericin B in visceral leishmaniasis - 15mg/kg on day 1 in Group B
62203161|NCT02035618|EXPERIMENTAL|Exercises and manual therapy|
62203162|NCT02035618|ACTIVE_COMPARATOR|Exercises|
62203163|NCT02779114|OTHER|Control group|After 1:1:1 randomization patients in the control group receive their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during 12 months of the study.
62203164|NCT02779114|OTHER|Reduction group 1|Patients in reduction group 1 receive exactly 50% of their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study.
62579790|NCT01730443||group assigned to placebo|The group that will not be receiving progesterone treatment
62786396|NCT04009395||Midwives|One-on-one in-depth interviewing or focus group discussions
62203165|NCT02779114|OTHER|Reduction group 2|Patients in reduction group 2 receive exactly 50% of their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study. If they are still in remission they will discontinue their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study.
62203166|NCT04079634|EXPERIMENTAL|Treatment|Placement of study device (EnsoETM) for temperature management
62203167|NCT04079634|ACTIVE_COMPARATOR|Control|Placement of standard temperature probe
62203168|NCT00002745|EXPERIMENTAL|aminocamptothecin|aminocamptothecin
62203169|NCT03377478|EXPERIMENTAL|Lung Transplant|Patients will be transplanted with HCV positive lung. Recipients whom test positive for HCV viremia for 2 consecutive tests at any point will complete 12 weeks of Epclusa (Sofosbuvir/velpatasvir).
62786397|NCT05154318|EXPERIMENTAL|Pericapsular Nerve Group Block|30ml 0.3% Ropivacaine will be injected between psoas muscle and iliopubic eminence.
62203170|NCT03461159|EXPERIMENTAL|H-reflex conditioning - Healthy|Operant conditioning of H-reflexes in healthy volunteers
62014208|NCT04313192|EXPERIMENTAL|Pulse rate 150Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 150 Hz, intensity setting to patient's tolerance, duration 30 days
62203171|NCT03461159|EXPERIMENTAL|H-reflex conditioning - Stroke|Operant conditioning of H-reflexes in people post-stroke
62579791|NCT02971358|EXPERIMENTAL|Radical prostatectomy arm|In this arm the investigators will include patients with locally advanced or metastatic prostate cancer, who will undergo cytoreductive radical prostatectomy with extended lymph node dissection.
62014209|NCT03919175|EXPERIMENTAL|Umbralisib+Rituximab|"* A treatment cycle is defined as 28 consecutive days.~* Umbralisib will be administered at 800 mg by mouth once daily on days 1-28 of cycles 1-24.~* Rituximab will be administered at 375 mg/m2 by intravenous infusion on Cycle 1 Day 1 and may be administered at 375 mg/m2 by intravenous infusion or at 1400 mg by subcutaneous injection on days 8, 15, 22 of cycle 1, day 1 of cycles 2 to 6, then every 8 weeks starting on day 1 of cycle 7 until completion of 24 cycles of umbralisib (i.e. every other cycle for 18 cycles or 9 doses, for a total of 15 doses of rituximab), or until progression or intolerance."
62203172|NCT03461159|EXPERIMENTAL|MEP conditioning - Healthy|Operant conditioning of motor evoked potentials in healthy volunteers
62203173|NCT03461159|EXPERIMENTAL|MEP conditioning - Stroke|Operant conditioning of motor evoked potentials in people post-stroke
62203174|NCT02777892||pulmonary valve replacement|SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection
62203175|NCT05049057|EXPERIMENTAL|Active Drug|Erenumab administered once monthly via two 70-mg subcutaneous injections at 3 time points over a 12-week period.
62203176|NCT05049057|PLACEBO_COMPARATOR|Placebo|Placebo administered once monthly via two subcutaneous injections at 3 time points over a 12-week period.
62579792|NCT05357703|EXPERIMENTAL|Standard treatment + Active B-Cure laser|Subjects from Standard treatment + Active B-Cure laser will receive standard care and in addition will self-treat at home with the B-Cure device.
62579793|NCT00647738|EXPERIMENTAL|1|
62786398|NCT05154318|ACTIVE_COMPARATOR|Fascia iliaca compartment block|30ml 0.3% Ropivacaine will be injected into fascia iliaca compartment.
62786399|NCT03998969|EXPERIMENTAL|Pantoprazole and DA-5204|Pantoprazole 40mg once daily and 'DA-5204' twice daily by mouth, administered for 4 weeks
61978436|NCT01747941|EXPERIMENTAL|Cohort 2|Single ascending oral doses in fasted conditions
62014210|NCT05798507|EXPERIMENTAL|Arm I (Defactinib)|Patients receive 1 dose of defactinib PO while on study, prior to planned tumor resection. Patients undergo blood collection and donate resected tumor tissue while on study.
62014211|NCT05798507|EXPERIMENTAL|Arm II (Avutometinib)|Patients receive 1 dose of avutometinib PO while on study, prior to planned tumor resection. Patients undergo blood collection and donate resected tumor tissue while on study.
62014212|NCT04417491|EXPERIMENTAL|Dry Needling|The intervention group will receive real dry needling (fast in and fast out needling technique) in an active MTrP within upper trapezius muscle.
62014213|NCT04417491|SHAM_COMPARATOR|Sham Needling|The placebo group will receive sham needling in an active MTrP within the upper trapezius muscle. A sham needle will be used as placebo. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin.
62203177|NCT03005353|EXPERIMENTAL|Cumin seed extract|Group A (study group) will receive Cumin seed extract vaginal suppositories once daily for 7 days.
62203178|NCT03005353|ACTIVE_COMPARATOR|clotrimazole|Group B will receive conventional clotrimazole vaginal suppositories once daily for 7 days.
62579794|NCT00647738|ACTIVE_COMPARATOR|2|
62203179|NCT02179177|ACTIVE_COMPARATOR|Apixaban|Active drug Apixaban 2.5mg taken by mouth twice a day
62203180|NCT02179177|PLACEBO_COMPARATOR|Placebo|Sugar pills that look like Apixaban that will be taken by mouth twice a day
62203181|NCT06274931||ICU patients|Patients admitted to the Intensive Care Unit with a diagnosis of acute respiratory failure
62203182|NCT06274931||non ICU patients|Outpatient patients with a diagnosis of pneumonia
62203183|NCT06274931||Controls|In the control group, an alveolar bronchial lavage was performed directly on lung tissue taken from deceased individuals who did not have any known lung pathologies.
62203184|NCT03417570|EXPERIMENTAL|Arm 1: EGD with cap first, followed by EGD without cap|-Participants in the first arm will undergo EGD with cap first, followed by EGD without cap in the same procedural period.
62203185|NCT03417570|EXPERIMENTAL|Arm 2: EGD without cap first, followed by EGD with cap|-Participants in the second arm will undergo EGD without cap first, followed by EGD with cap in the same procedural period.
62203186|NCT02457377|EXPERIMENTAL|Laparoscopic cerclage|The vesico-uterine peritoneum is opened \& the urinary bladder is dissected downwards . Both needles are passed through the lower uterine tissue medial to uterine vessels on the right \& left sides . Then, both needles are passed through the remaining cervical tissue medial to uterosacral ligaments towards the posterior vaginal fornix (on the right \& left sides) guided by laparoscopic illumination . When the needles' blunt ends pierce the vaginal vault, the assistant pull them through the posterior vaginal fornix . After trimming of both needles, the Mersilene tape is tied tightly behind the intravaginal segment of the cervix with five knots \&
62203187|NCT00406692|EXPERIMENTAL|Zonisamide|In open-label non-placebo controlled trial subjects are treatment with zonisamide 400 mg during the maintenance phase of this study
62203188|NCT05369559|ACTIVE_COMPARATOR|Mini Bolus 50|"receiving a mini-bolus A:50 ml of crystalloid solution, regularly infused over 30 seconds"
62203189|NCT05369559|OTHER|PLR|Passive leg raising technique: Initially, the patient is placed semi-recumbent with the head of the bed at 45°. After recording baseline measurement, the head of the bed is lowered and the legs are elevated to 45° for 2 minutes
62203190|NCT02866032|EXPERIMENTAL|MOB015B|
62203191|NCT02866032|ACTIVE_COMPARATOR|Ciclopirox 80 mg/g|
62203192|NCT03297177|EXPERIMENTAL|Microcannula Harvest Adipose|Acquisition AD-tSVF Via Closed Syringe Microcannula
62203193|NCT03297177|EXPERIMENTAL|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (tSVF) via enzymatic digestive isolation \& concentration in Centricyte 1000 closed system to create AD-cSVF
62203194|NCT03297177|EXPERIMENTAL|Sterile Normal Saline Infusion|Sterile Normal Saline to Re-Suspend Autologous cSVF pellet for delivery via intravascular (IV) route
62203195|NCT00523640|EXPERIMENTAL|I|"Combination of gemcitabine, capecitabine, and bevacizumab~gemcitabine 1000 mg/m\^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle"
62203196|NCT05017090|SHAM_COMPARATOR|Group N|The patients in Group N will not receive any intervention. In the intervention and control groups, block sites will be covered with dressings, and patients and other health care workers will be blinded to treatment allocation. The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.
62203197|NCT05017090|EXPERIMENTAL|Group M-TAPA|After tracheal intubation, a high-frequency linear probe will be placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will be inserted with in-plane technique and 25 ml 0.25 bupivacaine will be applied to the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side. The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.
62203198|NCT00045773||1|
62403335|NCT03410693|ACTIVE_COMPARATOR|Chemotherapy|"Chemotherapy treatment study arm, comprising~1. Pre-treatment period, including FGFR testing and screening,~2. Treatment period, and~3. Follow-up period, including active follow-up and long-term follow-up. Patients will be considered on study during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered off study."
62579795|NCT05397392||acute kidney injury|Acute kidney injury caused by heart disease or cardiac dysfunction due to acute renal damage
62579796|NCT05397392||chornic kidney disease|Chornic kidney injury caused by heart disease or cardiac dysfunction due to chronic kidney disease
62014214|NCT02104089||Endovascular treatment|Zenith® t-Branch™ Thoracoabdominal Endovascular Graft
61978437|NCT01747941|EXPERIMENTAL|Cohort 3|Single ascending oral doses in fed conditions
62014215|NCT04315285|ACTIVE_COMPARATOR|Control group|12 sessions of treadmill training with instruction of 'swing your arms'
62014216|NCT04315285|EXPERIMENTAL|Heel-strike group|12 sessions of treadmill training with instruction of 'strike the ground with your heel'
62403336|NCT02664974|EXPERIMENTAL|HEN group|Home Enteral Nutrition
62786400|NCT03998969|ACTIVE_COMPARATOR|Pantoprazole and placebo|Pantoprazole 40mg once daily and 'placebo' twice daily by mouth, administered for 4 weeks
62786401|NCT05020210||Sivelestat Sodium group|Patients treated with Sivelestat Sodium within 72 hours of the diagnosis of ARDS.
62203199|NCT04635969|EXPERIMENTAL|Experimental: Children training|All registered participants in intervention group will participate in a series of trainings on sexuality education.
62203200|NCT04635969|NO_INTERVENTION|Control: No intervention|All registered participants in control group will not participate in a series of trainings on sexuality education.
62203201|NCT02815943|OTHER|Before DBP-DS surgery|
62403337|NCT02664974|ACTIVE_COMPARATOR|Control group|Dietary Counseling
62403338|NCT02181543|EXPERIMENTAL|Clonidine|Clonidine 1μg/Kg, IV, single dose, anesthesia intraoperative.
62403339|NCT02181543|NO_INTERVENTION|No Clonidine|Usual care of Instituto de Medicina Integral Prof. Fernando Figueira.
62403340|NCT00145795|EXPERIMENTAL|Kaletra + Current Dual NRTI Backbone|Patients in this arm received Kaletra in addition to their current Dual NRTI Backbone.
62403341|NCT00145795|ACTIVE_COMPARATOR|Current Regimen|Patients in this study arm continued their current regimen.
62403342|NCT04393987|EXPERIMENTAL|Arms|Treatment Compliance Training The treatment compliance training consists of five sessions in total and was given individually. Each session of the treatment compliance training given once a week took 45 minutes on average.
62403343|NCT04393987|NO_INTERVENTION|Control Group|No intervention was performed on the patients in the control group, and routine follow-up (arranging treatment by the doctor, answering the patient's and family's questions about treatment) continued in the polyclinic.
62403344|NCT02353234|ACTIVE_COMPARATOR|WHOLEGRAIN BREAD|Subjects feed with wholegrain bread, for which ferulic acid content has been quantified.
62403345|NCT02353234|ACTIVE_COMPARATOR|WHITE BREAD WITH ALEURONE - 4|Subjects feed with white bread with aleurone fraction in the same portion as wholegrain bread.
62403346|NCT02353234|ACTIVE_COMPARATOR|WHITE BREAD WITH ALEURONE - 8|Subjects feed with white bread with aleurone fraction, which contains the same quantity of ferulic acid as wholegrain bread.
62786402|NCT05020210||Conventional treatment group|Patients not treated with Sivelestat Sodium/Normal Saline after the diagnosis of ARDS
62786403|NCT03654885|ACTIVE_COMPARATOR|XEN-45 Gel Stent|Participants underwent at least one preoperative visit and had XEN-45 gel stent implantation on Day 0 (The day of surgery).
62403347|NCT00812045|EXPERIMENTAL|1|
62403348|NCT00812045|PLACEBO_COMPARATOR|2|
62403349|NCT03737357|EXPERIMENTAL|SLActive® implant|
62403350|NCT03737357|ACTIVE_COMPARATOR|SLA® implant|
62403351|NCT06650085|EXPERIMENTAL|Loop ileostomy|
62786404|NCT03654885|ACTIVE_COMPARATOR|Trabeculectomy|Participants underwent at least one preoperative visit and had trabeculectomy as per standard of care in each investigative center on Day 0 (The day of surgery).
62786405|NCT02863328|EXPERIMENTAL|14 mg oral semaglutide|
62786406|NCT02863328|ACTIVE_COMPARATOR|25 mg empagliflozin|
62786407|NCT05062486|EXPERIMENTAL|Resveratrol, Quercetin, Curcumin (RQC)|Resveratrol (100mg BID), Quercetin (120mg BID), Curcumin (1000mg BID); 24 months
62203202|NCT02815943|EXPERIMENTAL|After DBP-DS surgery|It is a bariatric surgery. BPD consists in the exclusion of the duodenum from the alimentary tract with re-anastomosis of the blind loop 100 to 150 cm proximal to the ileo-coecal valve. This leads to bypass of the biliopancreatic secretions towards the distal small intestine, resulting in fat malabsorption. BPD also entails a distal gastrectomy to avoid the occurrence of peptic ulceration of the gastrointestinal anastomosis.
62203203|NCT02815943|OTHER|Before SG surgery|
62203204|NCT02815943|EXPERIMENTAL|After SG surgery|It is a bariatric surgery where the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.
62203205|NCT05574283|EXPERIMENTAL|ESPB group|ESPB group: 30 patients will receive bilateral ultrasound-guided erector spinae plane block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side.
62203206|NCT05574283|EXPERIMENTAL|TQLB group|TQLB group: 30 patient will receive bilateral ultrasound-guided transmuscular quadratus lumborum block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side.
62203207|NCT02182050|EXPERIMENTAL|BIBF 1120 ES low dose|
62203208|NCT02182050|EXPERIMENTAL|BIBF 1120 ES high dose|
62203209|NCT02182050|PLACEBO_COMPARATOR|Placebo|
62403352|NCT06650085|ACTIVE_COMPARATOR|Loop colostomy|
62403353|NCT03321773|EXPERIMENTAL|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
62403354|NCT03321773|ACTIVE_COMPARATOR|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
62403355|NCT04144140|EXPERIMENTAL|Dose Escalation: Advanced Solid Tumors or Lymphomas|
62403356|NCT04144140|EXPERIMENTAL|Dose Expansion: Advanced Solid Tumors or Lymphomas|Dose identified from dose escalation part for E7766 will be used in dose expansion part.
62403357|NCT01882166|EXPERIMENTAL|fostimon|subcutaneous 150 IE Fostimon®. When leading follicles are \> 17 mm ovulation will be induced by Ovitrelle® 500μg sc(hCG-injection). Ovum pick up (OPU) will be performed 32-36 hours later.
62786408|NCT05062486|ACTIVE_COMPARATOR|Curcumin|Curcumin (1000mg BID); 24 months
62786409|NCT01386775||HED Affected Males|
62786410|NCT01386775||Controls|
62579797|NCT04737135||Patients|Patients with Tetralogy of Fallot
62579798|NCT02877875|EXPERIMENTAL|Child STEPS|Child STEPs includes (1) a treatment protocol, Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems (MATCH-ADTC;Chorpita \& Weisz, 2009), and (2) a youth monitoring and feedback system (MFS).
62014217|NCT04315285|EXPERIMENTAL|Big step group|12 sessions of treadmill training with instruction of 'lift your foot up high'
62203210|NCT03517943|EXPERIMENTAL|Test treatment|Healthy adult subjects under fed conditions
62203211|NCT03517943|ACTIVE_COMPARATOR|Reference treatment|Healthy adult subjects under fed conditions
62203212|NCT01228318|EXPERIMENTAL|Zoledronic acid|Subjects in this arm will receive 5 milligram (mg) per 100 milliliter (mL) solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.
62203213|NCT01228318|PLACEBO_COMPARATOR|Placebo|Subjects in the placebo arm will receive placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered iv over 15-30 minutes under the supervision of study personnel.
62203214|NCT04488523|EXPERIMENTAL|Family-based Telehealth Treatment|A family-based telehealth intervention.
62203215|NCT04148664|ACTIVE_COMPARATOR|Standard Catheter Settings|Group 1 - Standard RF ablation settings
62203216|NCT04148664|EXPERIMENTAL|High Power Short Duration (HPSD)|Group 2 - High power short duration RF
62403358|NCT01882166|EXPERIMENTAL|puregon|subcutaneous 150 IE Puregon®. When leading follicles are \> 17 mm ovulation will be induced by Ovitrelle® 500μg sc(hCG-injection). Ovum pick up (OPU) will be performed 32-36 hours later.
62403359|NCT02728141|PLACEBO_COMPARATOR|Water|Newborn infants with ID numbers ending in odd numbers offered 2ml distilled water by syringe once in the side of the infant's mouth 2 minutes before heel stick.
62403360|NCT02728141|ACTIVE_COMPARATOR|Sucrose|Newborn infants with ID numbers ending in even numbers offered 2 ml 25% sucrose in distilled water by syringe once in the side of the infant's mouth 2 minutes before heel stick.
62403361|NCT03824015|EXPERIMENTAL|KAPA intervention arm|KAPA participants who completed the 24-week commissioned Falls Management Exercise program received six sessions of motivational interviewing over a six-month period. KAPA intervention sessions were held in accessible, community venues located within the local authorities of Derby City, Leicestershire and Rutland Counties. The KAPA intervention was delivered face-to-face by Postural Stability Instructors, in a group setting, using motivational interviewing. Sessions lasted between 60 to 90 minutes. Postural Stability Instructors delivered KAPA intervention sessions by telephone if a participant did not, or was unable to, attend a face-to-face session.
62403362|NCT03824015|OTHER|Usual care|The usual care participants finished the original Falls Management Exercise program and went on to being offered the service provider's usual care package.
62403363|NCT01135251|EXPERIMENTAL|dimiracetam|Capsules containing 400 mg of dimiracetam will be administered orally, twice a day for 8 weeks in ascending schedule, contingent on tolerability of the previous dose, as follows: 1 capsule for two weeks (800mg/day), two capsules for the next two weeks (1600mg/day)and 4 capsules for the final 4 weeks (3200mg/day).
62203217|NCT04808076|ACTIVE_COMPARATOR|iNPH patients|Shunt operation
62203218|NCT04808076|NO_INTERVENTION|Healthy Individuals|Healthy individuals without any neurological disease.
62403364|NCT01135251|PLACEBO_COMPARATOR|sugar pill|capsules containing 400 mg of inert material will be orally administered twice a day with the same modalities used for the dimiracetam arm: one capsule for 2 weeks, 2 capsules for another 2 weeks and 4 capsules for 4 weeks
62403365|NCT05527249|EXPERIMENTAL|Dietary supplement group|20g of protein powder + 1 tablet of pomegranate extracts / day for 21 days of the dietary supplement, to be taken every day before lunch time.
62579799|NCT02877875|ACTIVE_COMPARATOR|Usual Care|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective, and researchers will not influence their work.
62014218|NCT04315285|EXPERIMENTAL|Internal focus heel-strike|12 sessions of treadmill training with instruction of 'strike the ground with your heel'
62014219|NCT04315285|EXPERIMENTAL|External focus shoe-strike|12 sessions of treadmill training with instruction of 'strike the ground with your shoe-heel'
62014220|NCT05005546|EXPERIMENTAL|Experimental: Yoga|
62014221|NCT05005546|EXPERIMENTAL|Experimental: Laughter Yoga|
62203219|NCT04684823|EXPERIMENTAL|Use of Patch Cap and Patch App|Subjects will use Patch Technologies to track their medication regimen compliance
62203220|NCT02352519|EXPERIMENTAL|UGBRSB|Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.
62203221|NCT02352519|ACTIVE_COMPARATOR|Local infiltration|In those patients randomized to the LAI group, the surgeon will perform infiltration of 0.5 ml/kg of 0.25% bupivacaine (maximum, 10 ml) around the incision.
62203222|NCT03637218|EXPERIMENTAL|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
62203223|NCT03637218|EXPERIMENTAL|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
62203224|NCT04348253|ACTIVE_COMPARATOR|Berger|Bergers capsulodesis
62203225|NCT04348253|ACTIVE_COMPARATOR|3LT|Three ligament tenodesis
62203226|NCT02164903||Imatinib|Patients in first line treatment with imatinib for no more than 3 years.
62203227|NCT02164903||Dasatinib|Patients in first line treatment with dasatinib for no more than 3 years.
62203228|NCT05396651|EXPERIMENTAL|LOW FODMAP Diet group|"42 Children aged 5-15 years old fulfilling ROME IV criteria of IBS diagnosis, and didn't have any of the following :o Abdominal pain or diarrhea that wakes the child from sleep~* Delay in onset or progression of puberty.~* Faltering growth.~* Family history of inflammatory bowel disease, celiac disease.~* History of significant weight loss .~* Bleeding per rectum.~* Persistence of severe vomiting or diarrhea~* . Persistent joint pain.~* Recurrent unexplained fever.~* Unexplained pallor they followed the low fodmapdiet for 6 weeks"
62203229|NCT05396651|PLACEBO_COMPARATOR|NICE guidelines group|"42 Children aged 5-15 years old fulfilling ROME IV criteria of IBS diagnosis and didn't have one of the following : o Abdominal pain or diarrhea that wakes the child from sleep~* Delay in onset or progression of puberty.~* Faltering growth.~* Family history of inflammatory bowel disease, celiac disease.~* History of significant weight loss .~* Bleeding per rectum.~* Persistence of severe vomiting or diarrhea~* . Persistent joint pain.~* Recurrent unexplained fever.~* Unexplained pallor~they followed NICE guidelines for irritable bowel syndrome for 6 weeks"
62203230|NCT06029023|ACTIVE_COMPARATOR|MTA|Mineral trioxide aggregate MTA, The cement is made up of calcium, silicon and aluminium. The main constituent phases are tricalcium and dicalcium silicate and tricalcium aluminate.
62203231|NCT06029023|EXPERIMENTAL|Nano propolis|Propolis is a resinous substance that honey bees collect from different plant species. The most important pharmacologically active constituents in propolis are flavonoids, phenolics, and aromatics.
62203232|NCT06029023|EXPERIMENTAL|Nano curcumin|Curcumin (CUR), 7-bis (4-hydroxy-3-methoxyphenyl)-1,6- heptadien-3, 5-dione
62786411|NCT01229722|ACTIVE_COMPARATOR|Beeper|Patients randomized to the control arm (Beeper) will receive the standard of care at each clinic visit. The subjects will bring their HIV medications every 3 weeks (MEMS measure, pill count) and questioned on their adherence to antiretroviral therapy (ART) in the past 7 days. They will not receive any text messages addressing their adherence to ART between each study visit. Their providers will not be receiving any adherence reports but will be asked to assess their adherence at at the start of the trial (Time 1 or T1) and at subsequent clinic visit scheduled according to a frequency defined by standard of care.
62203233|NCT05177887|EXPERIMENTAL|Traumacel PULVIS|Traumacel PULVIS will be poured into the bleeding area directly or using an applicator Traumacel ENDO Applicator.
62203234|NCT01506440||Supportive Care (cognitive assessment)|Patients complete cognitive assessments, comprising HVLT-R, TMT-A, TMT-B, DSC, Animals, MoCA, and DST. Patients also complete the Beck Depression Inventory. Assessments are administered on day 1 of chemotherapy and at 6-8 weeks and 12-16 weeks after day 1 of chemotherapy.
62203235|NCT03822975|EXPERIMENTAL|Bivalirudin|Bivalirudin with prolonged full dose infusion during primary PCI
62203236|NCT03822975|ACTIVE_COMPARATOR|Heparin|Heparin alone during primary PCI
62203237|NCT02374723|EXPERIMENTAL|NuCornea (Biosynthetic corneas)|6 patients will receive biosynthetic corneas when undergoing corneal transplantation
62203238|NCT02374723|ACTIVE_COMPARATOR|Donated human corneas|6 patients will receive a donated human cornea when undergoing corneal transplantation
62203239|NCT05932901||Dapagliflozin 10mg initiators|Adult patients (aged ≥18 years) with chronic kidney disease, who received a dapagliflozin 10mg prescription on or after the country-specific CKD indication approval date, and who did not previously have a prescription for dapagliflozin.
62203240|NCT05932901||Dapagliflozin 10mg eligible but untreated|Adult patients (aged ≥18 years) with chronic kidney disease, who meet the country-specific approved dapagliflozin 10mg treatment criteria for CKD on or after the local CKD indication approval date, but have not received a prescription
62203241|NCT05932901||Incident CKD|Adults patients (aged ≥18 years) who newly meet the CKD definition (diagnosis or laboratory indication) during the study period.
62203242|NCT05844059||Patients undergoing instillation therapy with BCG|All patients that undergo therapy with BCG after diagnosis of non-muscle-invasive bladder cancer
62203243|NCT05844059||Patients undergoing instillation therapy with Mitomycin C|All patients that undergo therapy with Mitomycin C after diagnosis of non-muscle-invasive bladder cancer
62203244|NCT02291939||Parotidectomy|Patients with an indication for surgical intervention for a parotidectomy.
62203245|NCT06457282||Case ( breast cancer patients)|
62203246|NCT06457282||Control ( Healthy people without breast cancer)|
62203247|NCT03834324|EXPERIMENTAL|intervention|FES
62203248|NCT02703259|ACTIVE_COMPARATOR|Gabapentin|"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen, celecoxib, and gabapentin x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:~Gabapentin 600 mg (two capsules of gabapetin 300 mg); Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (two capsules of celecoxib 200 mg) = Total 3 tablets, 4 capsules"
62203249|NCT02703259|PLACEBO_COMPARATOR|Control|"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen and celecoxib x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:~Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (four capsules of celecoxib 100 mg) = Total total 3 tablets, 4 capsules"
62403366|NCT05527249|PLACEBO_COMPARATOR|Placebo group|20g of protein powder + 1 tablet of maltodextrin / day for 21 days of the dietary supplement, to be taken every day before lunch time.
62403367|NCT01674010|EXPERIMENTAL|Lamotrigine or Valproic acid + ELND005|Lamotrigine or valproic acid plus ELND005 film coated tablets, 500mg BID for up to 48 weeks
62014222|NCT05005546|NO_INTERVENTION|Control|
62403368|NCT01674010|PLACEBO_COMPARATOR|Lamotrigine or Valproic acid + placebo|Lamotrigine or valproic acid plus matched placebo BID for up to 48 weeks
62014223|NCT06658340|EXPERIMENTAL|Intervention: Positivity in Post-COVID|Participants will go through the training using a workbook for 12 consecutive days, once a day for 10-15 minutes.
62403369|NCT04194138||Operative|"A. Multicenter, prospective, nonrandomized analysis of operatively treated complex ASD patients meeting the following Inclusion Criteria~1. 18 years of age or greater at the time of treatment~2. Diagnosis of adult congenital, degenerative, idiopathic or iatrogenic spinal deformity~3. Full body EOS radiographic assessment (sagittal and coronal visualization from skull to foot)~4. Complex patients are defined as and meeting any one of the subsequent criteria:~   a. Radiographic criteria: i. PI-LL ≥ 25 degrees ii. TPA ≥ 30 degrees iii. SVA\>15cm iv. Thoracic scoliosis ≥ 70 degrees v. Thoracolumbar/lumbar scoliosis ≥ 50 degrees vi. Global coronal malalignment \>7cm b. Procedural criteria: i. Posterior spinal fusion \> 12 levels ii. 3 column osteotomy or ACR c. Geriatric criteria: i. Age \>65 years and minimum 7 levels of spinal instrumentation during surgery"
62203250|NCT06090188|EXPERIMENTAL|experimental group|Subjects in the experimental group received a series of culture-based multicomponent cognitive training activities via research assistants (RAs) and caregivers of the centres for 8 weeks, then provided by caregivers of the day care centre for 8 weeks with RAs providing assistance with the activity process.
62203251|NCT06090188|ACTIVE_COMPARATOR|comparison group|Participants in the comparison group received these activities via two RAs and day care caregivers for 16 weeks.
62203252|NCT05431218|NO_INTERVENTION|normal vitamin D levels|Patients with normal vitamin D levels (30-100ng/ml) No interference is implied. Observation only
62203253|NCT05431218|ACTIVE_COMPARATOR|Mild vitamin D deficiency|Patients with mild vitamin D deficiency (20-29 ng/ml)They will receive 4000 IU of cholecalciferol per day for 3 months
62203254|NCT05431218|ACTIVE_COMPARATOR|Moderate vitamin D deficiency|Patients with moderate vitamin D deficiency (10-19 ng/ml) will receive cholecalciferol at a dose of 5000-6000 IU daily for 3 months
62203255|NCT05431218|ACTIVE_COMPARATOR|Severe vitamin D deficiency|Patients with moderate vitamin D deficiency (10-19 ng/ml) will receive cholecalciferol at a dose of 7000-8000 IU daily for 3 months
62403370|NCT05182840|EXPERIMENTAL|Run-in period: 10 mg empagliflozin|
62403371|NCT05182840|PLACEBO_COMPARATOR|Run-in period: Placebo to empagliflozin 10 mg|
62403372|NCT05182840|EXPERIMENTAL|Treatment period: 10 mg empagliflozin + 3 mg BI 690517|
62403373|NCT05182840|EXPERIMENTAL|Treatment period: 10 mg empagliflozin + 10 mg BI 690517|
62579800|NCT06614920|EXPERIMENTAL|Plant-Based Food Provision + Plant-Based Nutrition Education (dual intervention)|"Participants will enroll in one of four study arms based on their eligibility and interest. In Arm 1 (dual intervention- food prescription and nutrition education), we will ask participants to attend 5 nutrition classes where they will be asked to complete one survey and two brief nutrition knowledge tests (one before the class starts and one after the class is finished) each class, one survey every 3 months thereafter and one additional nutrition test 1 year after starting the program. Each class will divide participants by age (detailed in Arm 2 description).~Participants in Arm 1 only (dual intervention) will be provided with a food prescription at the end of each class. Participants will bring this food prescription to Village FREEdge, where it will function as a voucher. Each voucher will allow for participants to pick up enough food for 6 meals per person in their household (with household maximum of 5 people)(enough meals for 3 days- 2 meals per person per day)."
62579801|NCT06614920|EXPERIMENTAL|Plant-Based Nutrition Education Only (single intervention 1)|Participants will enroll in one of four study arms based on their eligibility and interest. In Arm 1 (dual intervention- food prescription and nutrition education) and Arm 2 (single intervention 1- nutrition education only) we will ask participants to attend 5 nutrition classes where they will be asked to complete one survey and two brief nutrition knowledge tests (one before the class starts and one after the class is finished) each class, one survey every 3 months thereafter and one additional nutrition test 1 year after starting the program. Each class will divide participants by age. If participants are 14 years old or older, they will listen to a 45-minute plant-based nutrition lecture and engage in a 45-minute interactive activity, including but not limited to plant-based meal preparation. Participants younger than 14 years old will be guided through age-appropriate interactive activities for the full 1.5 hours in a nearby classroom.
62579802|NCT06614920|NO_INTERVENTION|Neither Intervention (no intervention)|Participants in Arm 4 will be recipients of non-plant-based meals from Village FREEdge (up to two meals per day with a maximum of two meals per pick-up), however, will be enrolled in neither intervention (neither the plant-based food prescription or the nutrition education course) and will be asked to complete one survey and a nutrition knowledge test at the beginning of the study, one survey every 3 months thereafter and one additional nutrition test 1 year into the study.
62203256|NCT04061876|EXPERIMENTAL|Ruxolitinib combined with Corticosteroids|Participants began oral administration of ruxolitinib at 5 mg QD; Methylprednisolone: 1mg/kg/d , iv or iv gtt for at leas 5 days, then taper according to the clinical response.
62203257|NCT04061876|ACTIVE_COMPARATOR|Corticosteroids|Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.
62203258|NCT04415320|EXPERIMENTAL|X-396(Ensartinib) Capsule|
62203259|NCT02252770|ACTIVE_COMPARATOR|Nitric oxide supplement arm|During this arm, subjects will receive a lozenge with nitric oxide supplement
62203260|NCT02252770|PLACEBO_COMPARATOR|Placebo Arm|During this arm, subjects will receive placebo
62203261|NCT04684017|EXPERIMENTAL|Anlotinib plus etoposide and carboplatin|Etoposide and carboplatin plus anlotinib for 4 cycles and anlotinib as maintenance therapy
62203262|NCT06019559|EXPERIMENTAL|K-757+K-833|
62203263|NCT06019559|EXPERIMENTAL|K-757 alone|
62203264|NCT06019559|EXPERIMENTAL|Placebo to K-757 and K-833|
62403374|NCT05182840|EXPERIMENTAL|Treatment period: 10 mg empagliflozin + 20 mg BI 690517|
62403375|NCT05182840|PLACEBO_COMPARATOR|Treatment period: 10 mg empagliflozin + Placebo to BI 690517|
62403376|NCT05182840|EXPERIMENTAL|Treatment period: Placebo to empagliflozin 10 mg + 3 mg BI 690517|
62403377|NCT05182840|EXPERIMENTAL|Treatment period: Placebo to empagliflozin 10 mg + 10 mg BI 690517|
62203265|NCT00667225|PLACEBO_COMPARATOR|I|Subjects in this group will have topical application of cantharidin's vehicle at each visit.
62403378|NCT05182840|EXPERIMENTAL|Treatment period: Placebo to empagliflozin 10 mg + 20 mg BI 690517|
62786412|NCT01229722|EXPERIMENTAL|Cell Phone|Participants will receive a text message reminder via ARemind at scheduled intervals, with varying frequency. They will also be subject to a remote adherence assessment, over text messages, interactive voice response (IVR), or a remote pill count with assistance over the phone from a counselor. Those who demonstrate lower adherence rates may receive a call from a counselor.
62786413|NCT03487185|EXPERIMENTAL|Continuous Positive Airway Pressure|Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling
62786414|NCT03487185|OTHER|Sleep Advice Control|Initial sleep advice counseling alone
62786415|NCT02218008|EXPERIMENTAL|High Dose|
62786416|NCT02218008|EXPERIMENTAL|Low Dose|
62786417|NCT02218008|PLACEBO_COMPARATOR|Placebo|
62786418|NCT04955327|EXPERIMENTAL|A. Paniculata150 mg|Extract from Andrographis Paniculata
62786419|NCT04955327|EXPERIMENTAL|A. Chilensis 300 mg|Extract from A. Chilensis
62786420|NCT04955327|EXPERIMENTAL|A. Panicluata 150 mg + A. Chilensis 300 mg.|combination of extract of A. Paniculata and A. Chilensis
62014224|NCT01734746|EXPERIMENTAL|Tracerinjection|The intervention concerns tracerinjection (both blue dye and the radioactive isotope beingtechnetium-99-m-labeled albumin nanocolloid) in the ligamentum ovarii proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), close to the ovary and just below the peritoneum.
62203266|NCT00667225|EXPERIMENTAL|II|Subjects in this group will have topical application of cantharidin at each visit.
62203267|NCT06340477|EXPERIMENTAL|Thoracic SNAGs with conventional therapy|"Thoracic (T1- T5) SNAGs 3 repetitions x 1 set, 2 days/week Hot pack for 10 minutes Stretching of upper trapezius, levator scapulae, 5 reps x 1 set x 15 sec hold 2 days/week and Pectoralis Major 10 reps x 1 set x 10 sec hold~Strengthening of deep neck flexors and shoulder retractors (rhomboids) 10 reps x 1 set x 10 sec hold 2 days/week 2 days/week"
62203268|NCT06340477|OTHER|Conventional therapy|"Hot pack for 10 minutes Stretching of upper trapezius, levator scapulae, 5 reps x 1 set x 15 sec hold 2 days/week and Pectoralis Major 10 reps x 1 set x 10 sec hold~Strengthening of deep neck flexors and shoulder retractors (rhomboids) 10 reps x 1 set x 10 sec hold 2 days/week 2 days/week"
62203269|NCT04706897|SHAM_COMPARATOR|Normal saline (Control) group|A loading infusion of the 50 ml syringe (A) containing normal saline was started at rate of 0.2 ml/ kg/hr ten minutes before induction (as masking for mixture in group S). Then anesthesia was induced with 2 mg/kg ideal body weight (IBW) of propofol , patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (C) containing fentanyl (1 mic/kg of IBW).
62403379|NCT05182840|PLACEBO_COMPARATOR|Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517|
62579803|NCT06614920|EXPERIMENTAL|Plant-Based Food Provision Only (single intervention 2)|In Arm 3 (single intervention 2- plant-based food provision only), participants will be given plant-based meals from Village FREEdge (up to two meals per day with a maximum of two meals per pick-up) only and will have no classes. Although these participant will not be provided a food prescription as part of the food prescription program the plant-based meals that Village FREEdge will have available to the community members as part of their community service will be the exact same plant-based meals provided through the food prescription program.These subjects will be asked to complete one survey and a nutrition knowledge test at the beginning of the study, one survey every 3 months thereafter and one additional nutrition test 1 year into the study.
62786421|NCT04955327|PLACEBO_COMPARATOR|Microcrystalline Cellulose +/-450 mg|Comparator
62786422|NCT04885413|EXPERIMENTAL|study arm|Sintilimab： 200mg i.v., d1, 21days one cycle Niraparib： 200mg p.o qd，d1-d21, 21days one cycle
62786423|NCT01126788||PADnet + testing|
62786424|NCT01126788||Parks Flo-lab Test|
62786425|NCT02466009|EXPERIMENTAL|Regorafenib|"120 mg qd, 3 weeks on/1 week off (each cycle is 28 days)~Three 40 mg tablets should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (\< 30% fat) breakfast."
62786426|NCT01365858|EXPERIMENTAL|Virtual reality-based cognitive training|
62786427|NCT01365858|ACTIVE_COMPARATOR|Cognitive rehabilitation (without extra computer training)|
62786428|NCT03570359|ACTIVE_COMPARATOR|Interferon beta 1a|"Part 1- Interferon beta 1a once a day for 3 days via inhalation~Part 2 - Interferon beta 1a once a day for 14 days via inhalation"
62786429|NCT03570359|PLACEBO_COMPARATOR|Placebo|"Part 1- placebo once a day for 3 days via inhalation~Part 2 - placebo once a day for 14 days via inhalation"
62786430|NCT03070899|EXPERIMENTAL|OBE2109 dose 1 (100mg) + Placebo Add-back|
62786431|NCT03070899|EXPERIMENTAL|OBE2109 dose 1 (100mg) + Add-back|
62786432|NCT03070899|EXPERIMENTAL|OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-back|
62786433|NCT03070899|EXPERIMENTAL|OBE2109 dose 2 (200mg) + Add-back|
62786434|NCT03070899|PLACEBO_COMPARATOR|Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-back|At W24, half of the patients switched to active treatment, while half remained on Placebo; the switch was defined at randomization.
62786435|NCT05270239|EXPERIMENTAL|Working Memory Training in MS patients|This group of patients will perform a computerized n-back training, which includes a sequence of 2-back and 3-back blocks.
62786436|NCT05270239|EXPERIMENTAL|Virtual Reality Training in MS patients|"This group of patients will perform a Virtual Reality Ball Task training. This task contains 6 trials of increasing difficulty."
62786437|NCT05219058||Patients undergoing abdominoperineal excision|
62786438|NCT05219058||Patient undergoing pelvic exenteration|
62786439|NCT01192919||Patients with lung cancer|Patients with lung cancer requiring therapy
62786440|NCT04480632|EXPERIMENTAL|ABO compatible convalescent plasma|A 500 ml dose of convalescent plasma (from a single donor or two 250 ml units from one or two donations) collected by apheresis will be administered. In case of plasma storage, plasma unit will be thawed following parameters of blood bank. Administration will take place slowly and over the course of four hours. When two 250 ml units are administered, second unit must be administered after the first unit in a period not exceeding 12 hours.
62786441|NCT04480632|NO_INTERVENTION|Usual care|Usual medical care for critically ill patients at ICU
62786442|NCT04153045|PLACEBO_COMPARATOR|Control|Participants will review the 500 chest radiographs without the assistance of xrAI
62403380|NCT06276647|EXPERIMENTAL|Patient Education Pamphlet and Partner Sheet|The study intervention consists of a patient education pamphlet and partner sheet (physically and virtually accessible) that will educate and prepare post-partum participants about health conditions (hypertension, diabetes, and depression), important health behaviors , physical and emotional postpartum symptoms, teach self-management skills, enhance social support, and connect post-partum participants with community resources. The education materials will provide simple actions that participants can utilize to address symptoms, realistic time frames for healing, danger signs to look out for and contact their physicians, and a list of resources for specific issues. The patient navigator will spend approximately 20 minutes with participants after enrollment, in the hospital. Following discharge, the patient navigator will contact each patient between 4 and 20 times, by phone and/or text with a research phone, to address questions and link participants to medical and community resources.
62403381|NCT06276647|NO_INTERVENTION|Standard Postpartum Care|These patients will receive Standard postpartum care.
62403382|NCT02015312|EXPERIMENTAL|Epigallocatechin-3-gallate (EGCG)|EGCG 400 mg/d p.o. for 3 months; 800 mg/d p.o. for 3 months, 1200 mg/d p.o. for 6 months
62403383|NCT02015312|PLACEBO_COMPARATOR|Placebo|"capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
62403384|NCT05628818|EXPERIMENTAL|Anodal tDCS combined with cognitive training, stroke patients|To stimulate the left DLPFC, the anode electrode will be placed over F3 and the cathode will be placed over the right supraorbital region (Fp2). Each stimulation will be applied for 20 min at 2mA intensity. Stimulation will be continued with the performance of three cognitive training exercises specifically designed to improving working memory, inhibitory control and cognitive flexibility.
62403385|NCT05628818|SHAM_COMPARATOR|Sham tDCS combined with cognitive training, stroke patients|To stimulate the left DLPFC, the anode electrode will be placed over F3 and the cathode will be placed over the right supraorbital region (Fp2). Each stimulation will be applied for 1 min at 2mA intensity (sham stimulation). Stimulation will be continued with the performance of three cognitive training exercises specifically designed to improving working memory, inhibitory control and cognitive flexibility.
62403386|NCT01084824|ACTIVE_COMPARATOR|Liquid nitrogen and canthardin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterwards.
62579804|NCT02728505|ACTIVE_COMPARATOR|SinuSurf irrigation twice daily|This arm is going to get low-concentration SinuSurf sinus irrigation solution, then a washout period, then standard NeilMed Sinus rinse.
62786443|NCT04153045|EXPERIMENTAL|Treatment|Participants will review the 500 chest radiographs with the assistance of xrAI
62786444|NCT03261453|EXPERIMENTAL|Treatment|Patients randomized to treatment will receive the Elipse device.
62203270|NCT04706897|EXPERIMENTAL|Dexmedetomidine, ketamine and lidocaine (Study) group|A loading infusion of syringe (B) containing the mixture was started at rate of 0.2 ml/kg/h ten minutes before induction. Then anesthesia was induced with 2 mg/kg IBW of propofol, patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (D) containing normal saline (as masking for fentanyl in the control group).
62203271|NCT03232918|NO_INTERVENTION|Standard Dose Oxytocin|Patients randomized to the standard dose oxytocin will have their oxytocin infusion maintained at the standard of care protocol prior to placement of a combined spinal epidural for labor analgesia
62203272|NCT03232918|EXPERIMENTAL|Half Dose Oxytocin|Patients randomized to the half dose oxytocin will have their oxytocin infusion reduced by 50 % prior to placement of a combined spinal epidural for labor analgesia.
62203273|NCT00924742|EXPERIMENTAL|Test drug|
62203274|NCT02839889|PLACEBO_COMPARATOR|Placebo|Placebo once daily for two weeks
62203275|NCT02839889|ACTIVE_COMPARATOR|Naloxegol|Naloxegol 25mg tablets once daily for two weeks
62203276|NCT00071461|EXPERIMENTAL|1|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~* Target dose: - body weight \> 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~* body weight \< 40 kg (90 lb): 62.5 mg b.i.d."
62203277|NCT00071461|PLACEBO_COMPARATOR|2|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~* Target dose: - body weight \> 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~* body weight \< 40 kg (90 lb): 62.5 mg b.i.d."
62403387|NCT01084824|PLACEBO_COMPARATOR|Liquid nitrogen and placebo|Liquid nitrogen applied to wart(s) then placebo vehicle afterwards.
62403388|NCT05829746|EXPERIMENTAL|Intervention group|Microport NeuroTech Tubridge flow-diverter Stent
62403389|NCT02070952|EXPERIMENTAL|CyberKnife|CyberKnife Stereotactic Ablative Body Radiation Therapy
62403390|NCT00111007|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg orally, 2 tablets (200 mg each) bid (bis in die \[twice daily\]) on Study Days 2 to 19 + Paclitaxel (225 mg/m\^2 iv \[Intravenous\]) and Carboplatin (AUC \[area under the curve\] 6 iv) on Study Day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
62579805|NCT02728505|PLACEBO_COMPARATOR|NeilMed Sinus rinse irrigation twice daily|This arm is going to get standard NeilMed Sinus rinse, then a washout period, then low-concentration SinuSurf sinus irrigation solution.
62579806|NCT05749978|EXPERIMENTAL|Trendelenburg position|
62579807|NCT05749978|NO_INTERVENTION|Procumbent|
62579808|NCT05348317|EXPERIMENTAL|MI-CBT Teletx|The intervention consists of an initial 30-60 min phone-delivered Engagement session that focuses on MI to help participants build self-efficacy and motivation to engage and to empower them to plan change and use Elicit-Provide-Elicit (EPE) to address treatment barriers (e.g., stigma, appeal, accessibility). Participants will then complete up to 8 \~50 minute Teletx weekly sessions via videoconference (or phone if needed). The intervention is highly patient-centered, by meeting and assessing patients where they are including in their unique context (i.e. rural community), helping them identify reasons and motivations for change, and centered around their goals (e.g. substance use reduction or abstinence).
62786445|NCT03261453|SHAM_COMPARATOR|Control|Patients randomized to the control arm will receive the sham device.
62786446|NCT01204021|EXPERIMENTAL|Tai Chi Chih|12 weeks of physical exercise in the form of Tai Chi Chih
62786447|NCT01204021|ACTIVE_COMPARATOR|Stress Education Control|Stress management education
62014225|NCT04879303|EXPERIMENTAL|Robot-assisted social skill intervention|Social robotics will be used by the instructor to conduct the social skill training activities.
62203278|NCT06479213|EXPERIMENTAL|REACH Peer Coaching Program|Participants will receive access to the REACH mobile health application and a REACH peer coach with whom they will meet weekly during the 12 weeks of the program.
62203279|NCT06479213|ACTIVE_COMPARATOR|REACH Mobile Health Application|Participants will receive access to the REACH mobile health application which they will use during the 12 weeks of the program.
62579809|NCT02893150|ACTIVE_COMPARATOR|TAU (treatment as usual)|The Treatment as Usual (TAU) will be considered as following: 1) In the cases of individuals presenting overweight (BMI of 25 kg/m ² to 29.9 kg/m ²), but without comorbidities, primary care teams propose the improvement of the life style (more physically active, and with a better eating behaviour) in order to return to the track of normal BMI (BMI of 18.5 kg/m ² to 24.9 kg/m ²). 2) For those who have comorbidities such as hypertension and diabetes, in addition to including individuals in group activities (psycho-education), it is evaluated the need for individual dietary prescription by a nutritionist.
62579810|NCT02893150|ACTIVE_COMPARATOR|TAU+MBHP|"The Mindfulness-based Health Promotion (MBHP) developed by our research group (generic protocol) will be adapted from the Mindfulness-based Stress Reduction program (MBSR), It is based on the original model developed by Jon Kabat-Zinn and colleagues (MBSR), and subsequently adapted by our research group in order to fit it better into the context and needs of Primary Care (PC) and national and local Health Systems\], which has been applied by the Center Mente Aberta in Brazil (www.mindfulnessbrasil.com), and by the University of Zaragoza, in Spain (www.webmindfulness.com). One of the sessions (the sixth one) is developed in silence, with the goal of deepening the mindfulness practice."
62579811|NCT02893150|EXPERIMENTAL|TAU+MB-EAT|The Mindfulness-based Eating Awareness (MB-EAT) protocol consists in ten weekly sessions of 2,5 hour to improve compulsive eating, and to promote conscious eating.
62579812|NCT04916626|EXPERIMENTAL|OPUS YOUNG|OPUS YOUNG is a two years out-patients specialized early intervention services for children and adolescents with a first episode psychosis. OPUS YOUNG is characterized by a multidisciplinary team, assertive outreach, tailored cognitive behavioral case management, and low caseload and insensitive psychoeducational family involvement
62786448|NCT01189981|EXPERIMENTAL|eHealth intervention|Standard lifestyle counseling. Short Message Service (SMS) encouragements for physical activity,
62014226|NCT04879303|ACTIVE_COMPARATOR|Human-only instruction program on social skill training|The children will receive only the human-delivered social skill training.
62014227|NCT04879303|NO_INTERVENTION|Control|There will be no intervention conducted during the tested period
62014228|NCT05220696||Critically ill patients with shock|Critically ill patients with shock
62579813|NCT04916626|ACTIVE_COMPARATOR|Treatment as Usual, TAU|Treatment as Usual will be carried out by outpatient clinic in Child and Adolescent Mental Health Services (CAMHS). Patients will be offered treatment following national Danish guidelines and local guidelines, provided by a multidisciplinary team, case-management (no defined upper-case load), family support. In general, office visits take place in outpatient clinics.
62786449|NCT01189981|ACTIVE_COMPARATOR|Lifestyle counseling|Standard lifestyle counseling. No Short Message Service (SMS) encouragements for physical activity.
62786450|NCT06251583|EXPERIMENTAL|Experimental group or Duramesh group|Umbilical trocar closure using Suture-mesh (Duramesh suture).
62786451|NCT06251583|ACTIVE_COMPARATOR|Control group or poli(4)hidroxibutirate group|Umbilical trocar closure using conventional monofilament suture.
62014229|NCT01241734|EXPERIMENTAL|Revlimid (Lenalidomide) in Combination|Study of Lenalidomide in Combination with Rituximab, Ifosphamide, Etoposide, and Carboplatin (RICE-R) as Salvage Therapy with Single Agent Lenalidomide as Maintenance Therapy Post-Autologous Stem Cell Transplantation
62014230|NCT06494735|EXPERIMENTAL|MyMCT Group|Use of the bibliotherapy program
62014231|NCT06494735|NO_INTERVENTION|Witness Group|Not using the bibliotherapy program
62014232|NCT01557660|EXPERIMENTAL|inhaled treprostinil|
62014233|NCT00534352|EXPERIMENTAL|001|TMC125; darunavir; ritonavirTMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
62014234|NCT04331080|EXPERIMENTAL|Granexin® gel 100 μM|"Within-subject comparison of Granexin® Gel versus vehicle gel (placebo).~Granexin® gel 100 μM will be applied four times over three days: twice during surgery, 24 hours after surgery and 48 hours after surgery. Granexin® will be applied on the right or left breast according to a randomization list."
62014235|NCT04331080|EXPERIMENTAL|Granexin® gel 200 μM|"Within-subject comparison of Granexin® Gel versus vehicle gel (placebo).~Granexin® gel 200 μM will be applied four times over three days: twice during surgery, 24 hours after surgery and 48 hours after surgery. Granexin® will be applied on the right or left breast according to a randomization list."
62014236|NCT04331080|PLACEBO_COMPARATOR|Vehicle Gel|"Within-subject comparison of Granexin® Gel versus vehicle gel (placebo).~Vehicle gel will be applied four times over three days: twice during surgery, 24 hours after surgery and 48 hours after surgery. Granexin® will be applied on the right or left breast according to a randomization list."
62014237|NCT02097875|EXPERIMENTAL|BLZ-100|A single dose of BLZ-100 (1, 3, 6, 12 or 18 mg) will be administered by intravenous injection approximately 48 hours prior to planned excision of skin tumor.
62014238|NCT04603924|EXPERIMENTAL|ANA001|Subjects in the ANA001 treatment arm will receive 1,000 mg (4 capsules; 250 mg each) by mouth twice per day for 7 consecutive days with a meal. If the participant requires mechanical ventilation over the course of the study, ANA001 may be administered via nasogastric (NG), percutaneous endoscopic gastrostomy (PEG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.
62014239|NCT04603924|PLACEBO_COMPARATOR|Matching Placebo|Subjects in the comparator arm will receive matching placebo (hydroxypropylmethylcellulose (HPMC)) (4 capsules, by mouth twice a day) for the 7-day treatment duration.
62203280|NCT02849444||Moderate kidney failure|30 ≤ CrCl \< 50 mL/min/1.73 m2
62203281|NCT02849444||Severe kidney failure|CrCl \< 30 mL/min/1.73 m2
62203282|NCT00198770|EXPERIMENTAL|Crossover design - 1 arm|Meat week followed by mushroom week, counterbalanced order
62203283|NCT04525794|EXPERIMENTAL|BRight DCB|
62203284|NCT01223547|NO_INTERVENTION|Control group|Participants in this arm continues their usual insulin therapy
62203285|NCT01223547|ACTIVE_COMPARATOR|Carb counting|Participants in this arm are taught carb counting
62014240|NCT05890027|EXPERIMENTAL|Phenylephrine and Eye Taping Group|Participants in this group will initially have superior visual field testing done with the upper eyelid manually taped. Then, participants will have superior visual field testing done after receiving Phenylephrine 2.5% ophthalmic solution. Participants will be in each group for up to 60 minutes.
62014241|NCT04113759|PLACEBO_COMPARATOR|Control Group|The control group will receive sham BFR, in which a non-occlusive pressure is applied with the cuff. The exercises performed will be identical to the BFR group.
62014242|NCT04113759|EXPERIMENTAL|BFR Postoperative Rehabilitation|The experimental group will receive BFR postoperative rehabilitation, which will involve performing a series of blood flow restriction exercises identical to the control group.
62786452|NCT05077345||1/Venous blood sampling|The vessel was determined for cannulation and an anatomical tourniquet was applied. Skin antiseptic was prepared. The plastic wings of the winged angioket were held open. The skin over the vein to be accessed was stretched with the fingers of the free hand. The needle was inserted into the skin a few millimeters distal to the point to be inserted, and the blood was vascularized until the education. The cannula was advanced by retracting the stylet. The tourniquet was removed and the cannula was fixed.
62014243|NCT01797224||Cohort 1 - Exposed Cohort|Pregnant women with a current diagnosis of an approved indication who have used Cimzia (certolizumab pegol) in the first trimester of pregnancy for any length of time from the date of conception.
62014244|NCT01797224||Cohort 2 - Diseased Comparison Cohort|Pregnant women with a current diagnosis of a Cimzia approved indication who have not used Cimzia (certolizumab pegol) during the current pregnancy.
62014245|NCT01797224||Cohort 3 - Non-Diseased Comparison Cohort|Pregnant women without a current diagnosis of an autoimmune disease and who have not used Cimzia (certolizumab pegol) at any time in pregnancy, nor have they been exposed to any known human teratogen during pregnancy.
62014246|NCT01797224||Group 4 -Cimzia Registry, Not Qualified for the Cohort Study|Women who have used Cimzia (certolizumab pegol) for any length of time following the first day of the last menstrual period until the end of pregnancy who do not qualify for the prospective cohort study.
62014247|NCT01194297|EXPERIMENTAL|Live attenuated influenza vaccine|One dose of live attenuated influenza vaccine, according to routine immunization recommendations
62014248|NCT01194297|ACTIVE_COMPARATOR|Inactivated influenza vaccine|One dose of inactivated influenza vaccine, according to routine immunization recommendations
62014249|NCT02066558|ACTIVE_COMPARATOR|carbon monoxide|Inhalation of carbon monoxide up to a carboxyhemoglobin concentration of 12% and 22%.
62014250|NCT02066558|PLACEBO_COMPARATOR|placebo|Atmospheric air
62014251|NCT01347021|ACTIVE_COMPARATOR|sacrospinous, pelvic prolapse.|Women with pelvic prolapse grade III/IV were randomly allocated to the sacrospinous colpopexy (25 women) or high uterosacral (26 women)
62014252|NCT01347021|ACTIVE_COMPARATOR|uterosacral , pelvic prolapse.|Women with pelvic prolapse grade III/IV were randomly allocated to the sacrospinous colpopexy (25 women) or high uterosacral (26 women)
62014253|NCT06214585|EXPERIMENTAL|Intermittent Heat & cold Therapy|There will be one group that will be receiving warm water application on the mother's back and then receiving ice pack application on the same region.
62014254|NCT06214585|EXPERIMENTAL|Heat- Only Therapy|This group of mothers will receive a warm application by hot water bag only on her back
62014255|NCT06214585|NO_INTERVENTION|Control Group|This group will receive just standard care as hospital protocol
62014256|NCT02162628||Exair for Total Repair|Total repair with Exair Prolapse Repair System alone or in combination with native tissue repair
62014257|NCT02162628||Total Native Tissue Repair|Total repair with native tissue only
62786453|NCT05077345||2/Heel puncture|The skin was prepared with an antiseptic. The baby's heel was placed at an angle between the thumb and forefinger, with the other fingers grasping the ankle from behind. Pressure was applied to the back of the ankle with the other fingers by taking support against the thumb. The first drop of blood was wiped with sterile gauze by inserting the needle, and the next drops of blood were absorbed into the paper by touching the middle of the ring on the filter paper. An adhesive bandage was applied by applying pressure to the puncture site.
62014258|NCT04868201|EXPERIMENTAL|0-anxiety|0-anxiety is based on the principles of VRT and CBT, which currently is the most researched and used treatment for anxiety disorders. The 0-anxiety intervention is an app-based intervention consisting of six modules that can be followed according to a user's own timing and without the intervention of a therapist.
62014259|NCT04868201|NO_INTERVENTION|wait-list condition|
62403391|NCT00111007|ACTIVE_COMPARATOR|Carboplatin/Paclitaxel (C/P)|Placebo, 2 tablets bid on Study Days 2-19 + Paclitaxel (225 mg/m\^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
62014260|NCT06534697|ACTIVE_COMPARATOR|Naropin 0.25% in sodium chloride|Preoperative supra inguinal fascia iliaca block with 40 ml naropin 0,25% in sodium chloride.
62014261|NCT06534697|ACTIVE_COMPARATOR|Naropin 0.25% in dextrose 5%|Preoperative supra inguinal fascia iliaca block with 40 ml naropin 0,25% in dextrose 5%.
62014262|NCT06534697|PLACEBO_COMPARATOR|Placebo|Preoperative supra inguinal fascia iliaca block with 40 ml dextrose 10%.
62014263|NCT04892901||c-ESPB group|Postoperative analgesia ensured by continuous ultrasound-guided ESPB performed at the end of surgery.
62014264|NCT04892901||c-SAPB group|Postoperative analgesia ensured by continuous SAPB performed by surgeons at the end of surgery.
62014265|NCT04892901||ICNB-group|"Postoperative analgesia ensured by one-shot ICNB + continuous intravenous administration of tramadol by elastomeric pump."
62203286|NCT01223547|ACTIVE_COMPARATOR|Carb counting and bolus calculator|Participants in this arm are taught carb counting and are provided with an integrated glucose meter and bolus calculator.
62203287|NCT02735928|EXPERIMENTAL|PIPAC|PIPAC stands for Pressurized IntraPeritoneal Aerosol Chemotherapies. Enrolled patients will undergo to explorative laparoscopy as usual and PC index will be determined according to Fagotti score (PIV). Pathological response will be determined by serial peritoneal biopsies. Then a pressurized aerosol containing cisplatin followed by doxorubicin will be applied via a nebulizer. The PIPAC procedure can be repeated after 4-6 weeks until progression or limiting toxicity
62579814|NCT04180449||Dysphagia screening positive|
62579815|NCT04180449||Dysphagia screening negative|
62403392|NCT03093129|ACTIVE_COMPARATOR|artesunate|Patients will receive 200 mg artesunate (Arinate®) per oral (PO) once daily (OD) for fourteen days prior to their planned surgery and then be followed up for 5 years following surgery.
62014266|NCT06085105|EXPERIMENTAL|CPIPE Intervention arm|1. Training: A two-day training that addresses the following topics: Stress \& positive coping mechanisms; Bias awareness and mitigation; Person-centered maternity care; Dealing with difficult situations; and Teamwork and communication. 2. Peer support: Groups for healthcare providers to meet with other healthcare providers of their cadre, to debrief, discuss issues they are facing, brainstorm solutions, and provide support to one another. 3. Leadership engagement: Engagement of County leadership at the onset of the project through a community advisory board to guide and help address sources of stress. 4. Mentorship: mentor-mentee relationships that provide the opportunity to coach less experienced healthcare providers on professional development, work-life balance, clinical skills, career advancement and other topics. 5. Embedded champions: facility champions to lead in organizing and facilitating peer support groups and refreshers at their facilities and serve as role models.
62014267|NCT06085105|NO_INTERVENTION|CPIPE control arm|The control group will not receive the CPIPE intervention during the 12-month data collection period but will maintain their usual facility level activities.
62403393|NCT03093129|PLACEBO_COMPARATOR|placebo|Patients will receive matching placebo tablets per oral (PO) once daily (OD) for fourteen days prior to their planned surgery and then be followed up for 5 years following surgery.
62579816|NCT04771221|EXPERIMENTAL|Main group|Patients with complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching.
62014268|NCT04323553||ESBL E.coli strains from 24 contact-index patients|48 ESBL-E. coli strains from 24 contact-index patients
62579817|NCT04771221|EXPERIMENTAL|Control group 1|Patients with an early diagnosis of Gastroesophageal reflux disease
62579818|NCT04771221|EXPERIMENTAL|Control group 2|Patients without complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching.
62579819|NCT03409289||ROSC RUSH Exam|The study population will include out of hospital cardiac arrest (both traumatic and non-traumatic causes) with return of spontaneous circulation after the cardiac arrest while in the emergency department .
62579820|NCT05523895|PLACEBO_COMPARATOR|Placebo|Placebo given once daily, as one capsule matching in size and color the respective pimavanserin treatment
62403394|NCT02854202|EXPERIMENTAL|Arm 1-Whey protein|In the Arm 1-Whey protein Breakfast the participant will consume 42 g protein at breakfast mainly from whey
62014269|NCT00461526|EXPERIMENTAL|125 mg crofelemer|
62014270|NCT00461526|PLACEBO_COMPARATOR|placebo|
62403395|NCT02854202|ACTIVE_COMPARATOR|Arm 2 Breakfast- other proteins|In the Arm 2 Breakfast- other proteins sources (No Whey) the participants will consume 42 g protein from other sources (no Whey) at breakfast
62403396|NCT02854202|PLACEBO_COMPARATOR|Arm 3 Breakfast- low protein|In the Arm 3: breakfast with low proteins content, the participant will consume 22 g protein at breakfast
62014271|NCT04550962||Participants with asthma|Eligible participants are initiating treatment with Dupixent for asthma according to the prescribing information in effect in each country
62014272|NCT04641923|EXPERIMENTAL|Seprafilm|Antiadhesion barrier applied
62014273|NCT04641923|NO_INTERVENTION|No seprafilm|No barrier applied
62014274|NCT00608829|EXPERIMENTAL|GORE TAG® Thoracic Endoprosthesis|Gore 45mm TAG Thoracic Endograft Implantation
62403397|NCT05371262|ACTIVE_COMPARATOR|10-12.5 μg/kg/day of L-T4|Children with congenital hypothyroidism who received an initial L-T4 dose of 10-12.5 μg/kg/day.
62403398|NCT05371262|ACTIVE_COMPARATOR|12.6-15 μg/kg/day of L-T4|Children with congenital hypothyroidism who received an initial L-T4 dose of 12.6-15 μg/kg/day.
62579821|NCT05523895|EXPERIMENTAL|Pimavanserin low dose|"Patients aged 5 to 12 years: 10 mg/day pimavanserin Patients aged 13 to 17 years: 20 mg/day pimavanserin~Pimavanserin given once daily, as capsule of 10 or 20 mg dose strength, respectively, according to the patient's age"
62579822|NCT05523895|EXPERIMENTAL|Pimavanserin high dose|"Patients aged 5 to 12 years: 20 mg/day pimavanserin Patients aged 13 to 17 years: 34 mg/day pimavanserin~Pimavanserin given once daily, as capsule of 20 or 34 mg dose strength, respectively, according to the patient's age"
62579823|NCT04797780|EXPERIMENTAL|Tamibarotene + Azacitidine|"Tamibarotene: 6 mg administered orally twice per day (BID) on Days 8 through 28 of each 28-day treatment cycle.~Azacitidine: 75 mg/m\^2 administered intravenously or subcutaneously each day on Days 1 through 7 of each 28-day treatment cycle."
62579824|NCT04797780|PLACEBO_COMPARATOR|Tamibarotene Matched Placebo + Azacitidine|"Placebo: Tamibarotene-matching tablets administered orally BID on Days 8 through 28 of each 28-day treatment cycle.~Azacitidine: 75 mg/m\^2 administered intravenously or subcutaneously each day on Days 1 through 7 of each 28-day treatment cycle."
62579825|NCT01419444|ACTIVE_COMPARATOR|Traditional, Onsite Treatment|Onsite treatment using airflow exercises. Patients will receive face-to-face treatment with the research speech pathologist two times per week.
62786454|NCT05077345||3:Orogastric Catheter insertion|The head of the bed was raised and the newborn was placed on his back. The midpoint distance from the tip of the nose to the ear, xiphoid and umbilicus was measured to determine the insertion length. With one hand, the infant's mouth was opened while his head was stabilized. With the other hand, the MV probe was advanced to the specified depth. The position of the OG probe was confirmed and fixed.
62579826|NCT01419444|EXPERIMENTAL|Telemedicine Treatment|Participants will receive treatment via telemedicine at select AHEC sites around the state of Arkansas. Treatments will occur twice per week with the research speech pathologist.
62579827|NCT05732194|EXPERIMENTAL|Cohort 1: 0.75 mg ITI-333 or placebo once daily for 14 days|
62786455|NCT05077345||4:Umbilical Catheter insertion|The system was filled with liquid by connecting the tap to the UK. The faucet was turned off, sterile gauze was placed around the umbilical clamp and lifted out of the sterile area. The other assistant held the cord with a clamp and lifted it vertically up and away from the sterile field. The cord and its surroundings were prepared with an antiseptic solution and covered. The umbilicus was tied with a single knot and the cord was cut horizontally with a scalpel. Bleeding on the surface of the cord was wiped with sterile gauze. The cord stump was grasped with toothed forceps close to the vessel to be catheterized. The catheter was placed in the lumen of the vessel and advanced in the vessel. When the catheter exceeded 5 cm, it was aspirated to confirm the intraluminal position. The blood that came with an average of 0.5 ml bolus solution was cleaned and the catheter was fixed.
62786456|NCT05077345||5:Tracheal Intubation|The head of the infant was positioned in the midline, slightly extended, with the chin up. The head was stabilized with the right hand by turning on the light of the laryngoscope. The blade of the laryngoscope was inserted by sliding the blade over the tongue until the tip of the blade rested on the Vallecula. The blade of the laryngoscope was slid up to open the mouth even more. The other assistant gently dipped it into the suprasternal notch. The concave edge of the tube was held with the right hand, and it was advanced approximately 2 cm, passing it between the vocal cords when the vocal cords and trachea were seen.
62014275|NCT06227494|EXPERIMENTAL|Fiber Intervention|Individuals in this arm will be given instruction on how to increase fiber intake,
62014276|NCT06227494|ACTIVE_COMPARATOR|Standard Weight Loss Education|Individuals in this arm will be given standard weight loss education
62579828|NCT05732194|EXPERIMENTAL|Cohort 2: 1.5 mg ITI-333 or placebo once daily for 14 days|
62579829|NCT05732194|EXPERIMENTAL|Cohort 3: 3 mg ITI-333 or placebo once daily for 14 days|
62014277|NCT06227494|EXPERIMENTAL|Fiber Intervention + Standard Weight Loss Education|Individuals in this arm will be given education on both fiber and standard weight loss
62014278|NCT00677339|ACTIVE_COMPARATOR|1|Active L-arginine plus active vitamin D
62014279|NCT00677339|ACTIVE_COMPARATOR|2|Placebo L-arginine plus active Vitamin D
62014280|NCT00677339|ACTIVE_COMPARATOR|3|Active L-arginine plus placebo vitamin D
62014281|NCT00677339|PLACEBO_COMPARATOR|4|placebo L-arginine plus placebo vitamin D
62014282|NCT02164682||IV PCA group|
62014283|NCT02164682||IV PCA+ caudal block group|
62014284|NCT01697306|ACTIVE_COMPARATOR|Gemcitabine-arm|7-15 days after TUR patients received six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline. Maintenance consisted in monthly instillations up to 1 year
62579830|NCT05732194|EXPERIMENTAL|Cohort 4: 6 mg ITI-333 or placebo once daily for 14 days|
62579831|NCT02615431||MitraClip Intervention|the influence of MitraClip on Apnoea Asleep
62579832|NCT01981941|EXPERIMENTAL|Treatment group|Oral
62579833|NCT02042950|EXPERIMENTAL|Carfilzomib|Carfilzomib given at a dose of 20\*/56 mg/m\^2 (\* CFZ 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m\^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
62579834|NCT02737943|EXPERIMENTAL|Arm1 Mebo|20 : receiving Moist Exposed Burn Ointment (MEBO) at sites of donor graft and recipient at time of operation and in dressing
62786457|NCT05466331|EXPERIMENTAL|Mobile Tele-HCV Care|Direct Acting Antiviral (DAA) treatment for HCV on a mobile van via telemedicine
62786458|NCT05466331|ACTIVE_COMPARATOR|Enhanced Usual Care|Referral with care navigation to a local or regional HCV treatment provider
62786459|NCT06583330|EXPERIMENTAL|experimental group|Low molecular weight heparin should be initiated for drug prevention within 24 hours after surgery, with a preventive course of 14 days
62786460|NCT06583330|ACTIVE_COMPARATOR|control arm|All patients should initiate low molecular weight heparin for drug prophylaxis within 24 hours after surgery, with a prophylaxis course of 28 days
62786461|NCT05096000|EXPERIMENTAL|InterMob: a behavioral and economical intervention|"* 6 months of free transport/bicycle (12.5 Adding objects in the BCT, Michie et al., 2011)~* Two meetings with a coach :~  1. st meeting: discussion about the motivations to change (motivational interviewing and 5.2 Salience of consequences, BCT), personalized advice of transport (4.1 Instruction on how to perform the behavior, BCT), mobility change goals, and action planning (1.1 Goal setting and 1.4 Action planning, BCT), solutions to possible obstacles (1.2 Problem solving, BCT)~ 2. nd meeting: discussion about the goals and the obstacles lived and resolved. If needed, personalized transport advice is given.~* Goals notebook to fill up for 6 months (goals need to be set every 2 weeks and obstacles if experienced)~* Weekly SMS during 6 months, prompting a) to set and adapt goals (1.7 Review outcome, BCT) and b) to do a self-feedback related to mobility change (e.g. a more important well-being) (2.4 Self-monitoring of outcomes, BCT's taxonomy)"
62403399|NCT06409741|ACTIVE_COMPARATOR|Biliary sphincterotomy|"In the group assigned to receive endoscopic treatment, ERCP for biliary sphincterotomy will be performed during the index admission for acute pancreatitis, prior to discharge or up till one month from discharge.~The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anesthesia according to the usual practice of the Endoscopy Unit of each collaborating center.~For ERCP biliary cannulation, the usual techniques available in each center will be used, including advanced cannulation techniques if necessary.~If biliary cannulation is not possible, a new ERCP attempt will be performed within a maximum of one month. If biliary cannulation is still not achieved, it will be counted as a technical failure."
62403400|NCT06409741|NO_INTERVENTION|Conservative treatment|Patients allocated to this group will be discharged without any intervention. The inhospital management of patients with AP in the conservative treatment group, before and after randomization, will be under the care of their responsible physicians on the hospitalization wart at the corresponding collaborating center who will follow the management recommended by the clinical guidelines. Their discharge will be decided by their regular physician. Patients will be evaluated at one month, six months and one year and both clinical variables (clinical BPE recurrence) and quality of life will be assessed (quality of life by a survey- EORTC QLQ-C30,
62403401|NCT03484858|OTHER|High glycaemic index meal and exercise|
62014285|NCT01697306|ACTIVE_COMPARATOR|BCG-arm|7-15 days after TUR patients received an induction cycle of six weekly instillations of Connaught strain Bacillus Calmette-Guerin (BCG Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline. Maintenance consisted of 3 weekly instillations at 3, 6 and 12 months
62014286|NCT02833740|OTHER|Click-MUAC & regular MUAC tape screening|"Each child will have nutritional status classified 11 times:~* 3 times with each of the 3 Click-MUAC prototypes by the mother/caregiver~* 1 time with a regular MUAC tape by the mother/caregiver~* 3 times with each of the 3 Click-MUAC prototypes by the case-finding/programme staff~* 1 time with a regular MUAC tape by the case-finding/programme staff~* 3 times with a regular MUAC tape by the data collection team (gold standard)"
62014287|NCT00965848|EXPERIMENTAL|Nosocomial Pneumonia|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with nosocomial pneumonia up to maximum of 14 days.
62014288|NCT00965848|EXPERIMENTAL|Complicated Intra-Abdominal Infections|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with complicated intra-abdominal infections up to maximum of 14 days.
62014289|NCT00965848|EXPERIMENTAL|Complicated Urinary Tract Infections|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with complicated urinary tract infections up to maximum of 10 days.
62014290|NCT01168934|EXPERIMENTAL|1|Each subject will receive single oral and IV doses of crizotinib separated by at least 14 days.
62014291|NCT00890903||NSCLC|Patients with advanced non-small cell lung cancer
62014292|NCT00890903||MBC|Female patients with metastatic, Anthracycline-resistent breast cancer
62014293|NCT01984723|EXPERIMENTAL|EVP-6124, single dose|Single dose, Tablet, single administration, Day 1
62014294|NCT02009150||Women at high risk for breast cancer|Proven carriers of deleterious BRCA1 or BRCA2 mutations Or Women that were found to have a lifetime risk of developing breast cancer greater or equal to 20% based on Tyrer-Cuzick, Gail or Clause risk models.
62014295|NCT05795933|EXPERIMENTAL|Study group|Children receive a single dose of intramuscular 200,000 IU vitamin D3
62014296|NCT05795933|NO_INTERVENTION|Control group|Children receiving only the standard recommended dose of vitamin D3 as 400 IU/day orally
62014297|NCT00440271|OTHER|Standard of Care (SoC)|Standard of Care (SOC) Arm = Tipranavir/ritonavir (TPV/r) capsules taken orally at a dose of 500 mg/200 mg twice a day (BID) plus optimized background regimen (OBR). No TPV/r dose changes were permitted.
62014298|NCT00440271|OTHER|Therapeutic Drug Monitoring (TDM)|Therapeutic Drug Monitoring (TDM) Arm = Patients began by receiving standard of care (SOC) tipranavir/ritonavir (TPV/r) capsules orally at a dose of 500 mg/200 mg twice a day (BID) plus optimized background regimen (OBR) followed, if needed, by TPV or ritonavir (RTV) dose adjustments at Week 4, 6, 10, 14, 18, 22, 26 and 30 based on viral response, phenotypic inhibitory quotient (IQ), and TPV trough concentrations.
62014299|NCT02379598||Amino acid based formula|
62014300|NCT02379598||Whey protein formula|
62203288|NCT06261632|EXPERIMENTAL|Experimental group|"The intervention will consist of carrying out a physiotherapy protocol, consisting of strength training through blood flow restriction, with an occlusion pressure of 40-50% of the LOP (Limb Occlusion Pressure) and a load of 20-30%. of 1RM performed ad hoc for patients with hemophilic arthropathy.~The intervention protocol will be carried out in person under the supervision of the main researcher. The intervention will last 4 weeks, with a frequency of 3 weekly sessions. In total there will be 12 sessions lasting approximately 30-45 minutes"
62203289|NCT06261632|NO_INTERVENTION|Control group|The patients included in the control group will not receive any Physiotherapy intervention and will continue with their usual routine, being evaluated in the same periods as the rest of the patients.
62203290|NCT03414177|ACTIVE_COMPARATOR|Telemedicine Group|Telemedicine participants will have asthma subspecialty follow-up visits conducted via real-time audio and video conferencing in conjunction with electronic examination peripherals and remote pulmonary function testing (PFT). Participants will receive a survey link to complete an electronic survey to assess Asthma Control Test (ACT) score, healthcare utilization, and satisfaction.
62203291|NCT03414177|ACTIVE_COMPARATOR|In-Person Group|In-Person participants will have asthma subspecialty follow-up visits at a subspecialty clinic. They will receive pulmonary function testing (PFT). Participants will receive a survey link to complete an electronic survey to assess Asthma Control Test (ACT) score, healthcare utilization, and satisfaction.
62203292|NCT04496245|ACTIVE_COMPARATOR|Wait-list control|One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment.
62203293|NCT04496245|EXPERIMENTAL|Initial treatment wtih OM85|One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.
62203294|NCT00710905|EXPERIMENTAL|ReSTOR|Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, Acrysof ReSTOR +4 IOL in the other eye.
62203295|NCT02886039|OTHER|patients|Patient with cardiac arrest benefiting an electroencephalogram
62203296|NCT01899898|EXPERIMENTAL|Simplified Modified Atkins Diet|
62203297|NCT01899898|ACTIVE_COMPARATOR|Antiepileptic drugs alone|
62203298|NCT06503692|EXPERIMENTAL|DKutting PTA Scoring Balloon Dilatation Catheter|Subjects in this group are treated with DKutting PTA Scoring Balloon Dilatation Catheter
62203299|NCT06503692|ACTIVE_COMPARATOR|Peripheral Balloon Catheter|Subjects in this group are treated with Peripheral Balloon Catheter
62203300|NCT02595775|EXPERIMENTAL|Round 1: Intervention arm|"Half of the endoscopists in Ontario will receive an individualized audit \& feedback report.~Individualized A/F report."
62203301|NCT02595775|NO_INTERVENTION|Round 1: Control|Half of the endoscopists in Ontario will NOT receive an individualized audit \& feedback report.
62203302|NCT02595775|OTHER|Round 2: Month 12|"All endoscopists in Ontario will receive an individualized audit \& feedback report at month 12.~Individualized A/F report"
62203303|NCT02595775|OTHER|Round 2: Poor performers|"In Round 2, selected 60 poorer performers will be randomly assigned to receive one of the following interventions at month 12:~1. A/F report plus a high intensity intervention~2. A/F report plus a low intensity intervention~3. A/F report alone"
62203304|NCT06373562|EXPERIMENTAL|Hypoxia|Live High-Train Low method was used.
62203305|NCT06373562|NO_INTERVENTION|Control group|The control group was participating in the same training protocol.
62403402|NCT03484858|OTHER|High glycaemic index meal and rest|
62203306|NCT00449605|EXPERIMENTAL|Rimonabant|Rimonabant 20 mg once daily on top of metformin
62203307|NCT00449605|ACTIVE_COMPARATOR|Glimepiride|Glimepiride from 1 mg up to 6 mg once daily on top of metformin
62203308|NCT02531555|ACTIVE_COMPARATOR|Group M|Mechanical periodontal treatment (Group M): Scaling and root planing were performed with Gracey curettes until the operator feels that root surface is clean, hard and smooth.
62403403|NCT03484858|OTHER|Low glycaemic index meal and exercise|
62403404|NCT03484858|OTHER|Low glycaemic index meal and rest|
62403405|NCT00819923|EXPERIMENTAL|1|Patients receiving bio-active stent during the intervention
62579835|NCT02737943|PLACEBO_COMPARATOR|Arm2 Placebo|20 : receiving Standard cream Zagazig University Hospital (Antibiotics \& analgesics)
62014301|NCT01879397||CEA Group|Subjects with atherosclerotic stenosis of the carotid artery and are scheduled for a clinically indicated Carotid Endarterectomy (CEA) procedure to remove the atherosclerotic plaque. Prior to CEA procedure, a research ultrasound exam will be performed. The plaque tissue removed during the CEA will be collected and processed into histological slides.
62203309|NCT02531555|EXPERIMENTAL|Group L|Pocket disinfection with diode laser (Group L): Subgingival irradiation with a GaAlAs diode laser (CHEESE®, Gigaa Laser, China) was applied to residual pockets each for 20 sec in continious mode. The diode laser had a wavelenght of 810 nm and power output of 1 W for subgingival irradiation (Maximum output power of device was 7 W). Diode laser application was performed parallel to root surface by a 200 µm fiber tip inserted at the bottom of periodontal pocket and slowly moved from apical to coronal direction in a sweeping motion without local anesthesia.
62203310|NCT02531555|EXPERIMENTAL|Group M+L|Combined treatment (Group M+L): Following mechanical periodontal treatment, pocket irradiation with diode laser was performed as mentioned above.
62403406|NCT00819923|ACTIVE_COMPARATOR|2|Patients receiving everolimus-eluting stent during the intervention
62403407|NCT00347776|ACTIVE_COMPARATOR|Control|topical tetracycline
62403408|NCT00347776|ACTIVE_COMPARATOR|Intervention 1|oral azithromycin, single 1g dose to subject
62403409|NCT00347776|ACTIVE_COMPARATOR|Intervention 2|single oral azithromycin dose to subject and immediate family members
62579836|NCT04238247|NO_INTERVENTION|Enhanced Usual Care|"Participants will be randomized after completion of the baseline survey and receive a basic information sheet (print or electronic).~Months 1-12: Participants receive monthly, unscheduled requests to submit photographs as their child usually travels. Feedback is provided for critical errors and misuse. Follow-up occurs at 6 months. Outcomes are assessed at 12 months."
62579837|NCT04238247|EXPERIMENTAL|Basic Intervention|"Participants will be randomized after completion of the baseline survey and receive a basic information sheet (print or electronic). Participants receive a counseling session, access to the study's tailored, educational website, and tailored informational and motivational text messages.~Months 1-6: Participants receive monthly, unscheduled requests to submit photographs as their child usually travels. Feedback is provided. Follow-up occurs at 6 months.~After completion of their 6 month follow-up, participants in the Basic Intervention group will be eligible for re-randomization if they continue to not adhere to guidelines or plan a premature transition.~Months 7-12: Participants continue to receive monthly, unscheduled requests to submit photographs as their child usually travels. Feedback is provided. Outcomes are assessed at 12 months."
62786462|NCT05096000|OTHER|Air pollution information: an informational group|"Active control group focused on air pollution information:~* Two meetings with a coach:~  1. st meeting: Discussion about air pollution (definition, sources, population most affected, levels in Grenoble, the consequences on health, pollution peaks), air pollution and car use (video about the pollution exposure of car drivers and the consequences of fine particles) and, a discussion about the benefit and disadvantages of using a car (5.2 Salience of consequences according to BCT's taxonomy)~ 2. nd meeting: Discussion about air quality during the last weeks and they check the quality of air of the last week.~* Observation notebook to fill up for 6 months (quality of air in Grenoble and the pollution peaks every 2 weeks)~* Weekly SMS during 6 months prompting a) to write down the air quality of the air every two weeks and b) write down any pollution peak announced in the television/radio/telephone"
62786463|NCT00763841|EXPERIMENTAL|1|Stimulation will be given daily at a particular site for three days a week
62014302|NCT01879397||Normal Group|Subjects who are not scheduled for a Carotid Endarterectomy (CEA) procedure and have had no prior carotid artery interventions. Subjects will have a Research Ultrasound Exam performed.
62014303|NCT00865527|ACTIVE_COMPARATOR|Fecal Occult Blood Test|fecal occult blood test
62403410|NCT06650176||Workers on sick leave|"This cohort consists of workers currently on sick leave due to mental health issues, specifically anxiety and depression, being managed by a Mutua Colaboradora de la Seguridad Social in Spain. The intervention targets this population to assess and improve mental health through the Metrikamind digital platform, aiming to facilitate their recovery and return to work. Participants are adult employees from various sectors, ensuring a diverse and representative sample. The study focuses on employing the Metrikamind platform's advanced psychometric tools, including bifactor models, to accurately assess and manage the participants' mental health. This intervention seeks to validate the effectiveness of digital health tools in reducing the duration of sick leave and improving overall mental well-being, thereby supporting employees in their transition back to regular work activities."
62403411|NCT04328168|ACTIVE_COMPARATOR|Group1|Conventional Physiotherapy
62403412|NCT04328168|ACTIVE_COMPARATOR|Group2|robot-assisted gait training
62403413|NCT04997577|EXPERIMENTAL|Auditory training paradigm|Participants perform speech-in-noise perception tasks with real-world scenarios.
62786464|NCT00763841|SHAM_COMPARATOR|2|
62786465|NCT04262128||Type 2 Diabetes Mellitus|women age 60-75 years with uncomplicated type 2 diabetes mellitus
62403414|NCT04997577|EXPERIMENTAL|Auditory-cognitive training paradigm|Participants perform speech-in-noise perception tasks with real-world scenarios. A short-term memory component is added to the training paradigm to make the task more engaging and challenging.
62403415|NCT05968469|EXPERIMENTAL|High Intensity Interval Training (HIIT) protocol|Patients who underwent cycling ergometry program including high-intensity interval (HIIT) in the cardiopulmonary rehabilitation unit and stretching exercises for the cervical, thoracic and lumbar regions under the guidance of a physiotherapist
62403416|NCT05968469|ACTIVE_COMPARATOR|Exercise program only:|Patients undergoing cervical, thoracic and lumbar stretching exercises in the hospital with a physiotherapist
62403417|NCT05791123|EXPERIMENTAL|a bone graft mixed with PRF & covered by PRF membrane in fresh extraction socket|
62403418|NCT04836832|EXPERIMENTAL|Treatment (acalabrutinib, duvelisib)|Patients receive acalabrutinib PO BID, and duvelisib PO BID on days 1-28. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 19, patients receive acalabrutinib PO BID for up to 60 months in absence of disease progression or unacceptable toxicity.
62203311|NCT03174431|ACTIVE_COMPARATOR|Continence Pessary|Participants randomized to the continence pessary will be fitted for a pessary by a clinician at enrollment and they will be taught how to remove and reinsert the device. Per usual clinical practice they will be instructed to call with any concerns and scheduled for a return visit in 2 weeks for a follow-up to assess fit and comfort and undergo refitting if necessary.
62203312|NCT03174431|ACTIVE_COMPARATOR|Disposable Intravaginal Device|Participants randomized to the intravaginal device will be given a sizing kit in the office, asked to select a size and provided with a 2-week supply of the appropriately sized devices. In accordance with manufacturer guidelines, participants will be instructed that the device is to be used for no more than 8 hours per 24-hour period and that each device is single use only. Participants will return in 2 weeks for a follow-up visit to assess fit and comfort, undergo resizing as necessary and receive an additional 2 week supply of the appropriately sized devices.
62403419|NCT04281147||No Ra-223 received|Patients did not receive Ra-223
62579838|NCT04238247|EXPERIMENTAL|Enhanced Intervention|"After completion of their 6 month follow-up, participants re-randomized to Enhanced Intervention receive Basic Intervention components plus an additional counseling session (Months 7/8) and additional tailored text messages (Months 7-12).~Months 7-12: Participants continue to receive monthly, unscheduled requests to submit photographs as their child usually travels. Feedback is provided. Outcomes are assessed at 12 months."
62579839|NCT00819845|EXPERIMENTAL|Ramipril|
62403420|NCT04281147||Early Ra-223 (2nd line)|Patients received Ra-223 in 2nd line
62579840|NCT00819845|EXPERIMENTAL|Carvedilol|
62579841|NCT06326307|EXPERIMENTAL|Group 1|Children who received puppet behavior guidance during their first visit and tell-show-do guidance in their second visit, 2 weeks later. (P-TSD)
62579842|NCT06326307|EXPERIMENTAL|Group 2|Children who received the tell-show-do behavior guidance during their first visit and puppet behavioral guidance in their second visit, 2 weeks later.(TSD-P)
62579843|NCT06155812|ACTIVE_COMPARATOR|STEPWISE VASOPRESSOR SEPTIC SHOCK MANAGEMENT|Regimen: Norepinephrine increases of 0.05-0.1 mcg/kg/min up to 0.5 mcg/kg/min, followed by vasopressin (administered at a fixed dose of 0.03 IE/min). If MAP remains \< 65 mmHg, norepinephrine will be titrated above dose of 0.5 mcg/kg/min until MAP ≥ 65 mmHg. Maximum norepinephrine dose as per clinical team decision. Initiation of additional vasoactive drugs (epinephrine, methylene blue, angiotensin II, dobutamine, or dopamine) as per clinical team decision.
62786466|NCT04262128||Healthy Controls|healthy women age 60-75 years
62014304|NCT00865527|ACTIVE_COMPARATOR|Virtual Colonoscopy|virtual colonoscopy
62014305|NCT00865527|ACTIVE_COMPARATOR|Optical Colonoscopy|optical (conventional / endoscopic) colonoscopy
62403421|NCT04281147||Late Ra-223 (3rd or later lines)|Patients received Ra-223 in 3rd or later lines
62403422|NCT04335760||Patients with Coronary Artery Disease|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
62403423|NCT04335760||healthy subjects|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
62579844|NCT06155812|EXPERIMENTAL|BALANCED MULTIMODAL VASOPRESSOR SEPTIC SHOCK MANAGEMENT|Regimen: Simultaneous administration of norepinephrine, angiotensin II and vasopressin at equivalent starting doses (equivalent to approximately 0.05 mcg/kg/min of norepinephrine). Increments of 0.05 mcg/kg/min of equivalent doses of all three vasopressors every 3-5 min until MAP ≥ 65 mmHg is reached (vasopressin will be administered at a maximum dose of 0.03 IE/min).
62786467|NCT03042143|EXPERIMENTAL|Human umbilical cord derived CD362 enriched MSCs|Maximum tolerated dose from the phase 1 trial will be infused over 30 to 90 mins
62014306|NCT06317805|EXPERIMENTAL|Initial triple therapy|Assigned treatment: double oral (background therapy consisting of 1 endothelin receptor antagonist ERA and 1 phosphodiesterase type-5 inhibitor PDE-5i) with subcutaneous (SC)/intravenous (IV) treprostinil on top
62014307|NCT06317805|ACTIVE_COMPARATOR|• Initial double therapy|double oral (background therapy consisting of 1 endothelin receptor antagonist ERA and 1 phosphodiesterase type-5 inhibitor PDE-5i)
62579845|NCT05856773|ACTIVE_COMPARATOR|Arm A - Standard Fractionation|"50-50.4 Gy (RBE) in 25-28 daily fractions of 1.8-2.0 Gy (RBE) plus a Tumor Bed Boost (for intact breast) of 10 Gy (RBE) in 4-5 daily fractions of 2-2.5 Gy (RBE)~\*\*Additional boost of 10-20 Gy (RBE) in 2-2.5 Gy (RBE) fractions to clinically involved lymph nodes or chest wall/scar allowed at the treating physician's discretion\*\*"
62579846|NCT05856773|OTHER|Arm B - Hypofractionation|"40.05 Gy (RBE) in 15 daily fractions of 2.67 Gy (RBE) plus a Tumor Bed Boost (for intact breast) of 10 Gy (RBE) in 4-5 daily fractions of 2-2.5 Gy (RBE)~\*\*Additional boost of 10-20 Gy (RBE) in 2-2.5 Gy (RBE) fractions to clinically involved lymph nodes or chest wall/scar allowed at the treating physician's discretion\*\*"
62579847|NCT04683692|EXPERIMENTAL|Cerebral protection with the Sentinel device|Subjects who received the Sentinel device in the parent study
62786468|NCT03042143|PLACEBO_COMPARATOR|Placebo (Plasma-Lyte 148) infusion|Plasma-Lyte 148 infused over 30 to 90 mins
62203313|NCT01868425|EXPERIMENTAL|multimodal:acetaminophen, gabapentin, ketamine, bupivacaine|aggressive multimodal plus standard care, which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
62203314|NCT01868425|PLACEBO_COMPARATOR|placebo pills and injectables|standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
62203315|NCT04523428|EXPERIMENTAL|Venetoclax/Acalabrutinib|All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.
62203316|NCT02086877||ICU Survivors who required > 72 hrs mechanical ventilation|No intervention
62203317|NCT03049553|OTHER|HPV-test|Cobas HPV-DNA test is performed on the cervical sample in addition to the routine cytology
62203318|NCT03049553|NO_INTERVENTION|Routine|Screening with cytology as usual in the cervical screening program
62203319|NCT00133809|EXPERIMENTAL|Islet Transplant|All subjects who are found eligible and who can be matched to an appropriate donor will receive/have received an islet transplant
62203320|NCT05691751|EXPERIMENTAL|limited application|Will go primary unilateral TKA with the tourniquet inflated only during cementation and final components of the prosthesis application
62579848|NCT04683692|ACTIVE_COMPARATOR|Control group without cerebral protection|Subjects who did not received the Sentinel device in the parent study
62579849|NCT02401048|EXPERIMENTAL|Phase 1b/ 2: Follicular lymphoma expansion cohort|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.
62786469|NCT01755039||Patients with invasive out-of-hospital ventilation|
62786470|NCT01832155|EXPERIMENTAL|yoga intervention|The yoga intervention received eight 60 minute weekly Hatha yoga intervention classes and asked to practice additional 30 minute yoga per day at home.
62786471|NCT01832155|OTHER|wait list control|The wait list control group received the same 8-week Hatha yoga intervention involving group and home-based exercise sessions after the yoga intervention group completed the intervention at the end of 8 weeks.
62786472|NCT04342117||Duvelisib|Patients who take duvelisib.
62786473|NCT04342117||Other PI3K-inhibitors|Patients who take a PI3K-inhibitor other than duvelisib
62786474|NCT05357508|EXPERIMENTAL|Intervention group|Participants in the Intervention group receive a brochure with their personalized risk score for colorectal cancer and screening recommendations (FIT or colonoscopy) corresponding to their risk level.
62014308|NCT02239458|PLACEBO_COMPARATOR|Placebo|Placebo intake during 3 months
62014309|NCT02239458|ACTIVE_COMPARATOR|Saxagliptin 5mg|Saxagliptin dose of 5mg for 3 months
62014310|NCT06660316||Nursing Students - Computer Vision Syndrome Prevalence|
62203321|NCT05691751|EXPERIMENTAL|full-time application|will go unilateral primary TKA with inflating the tourniquet prior to incision and releasing it after closure and compression bandage application
62203322|NCT00642408|EXPERIMENTAL|MMN|multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
62203323|NCT00642408|ACTIVE_COMPARATOR|IFA|iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
62203324|NCT01410305||HIV+|HIV Positive children or young people between the ages of 8 and 25
62203325|NCT01410305||HIV Negative|HIV Negative matched controls by age and race
62203326|NCT01021618|ACTIVE_COMPARATOR|Vasodilator-exercise stress|Four-minute infusion of dipyridamole (0.56 mg/kg) followed by symptom-limited exercise; injection of technetium-99m labeled radiopharmaceutical at peak hyperemia or peak exercise followed by SPECT myocardial perfusion imaging
62203327|NCT01021618|EXPERIMENTAL|Exercise-vasodilator stress|Symptom-limited exercise followed by a bolus intravenous injection of regadenoson (0.4 mg/5 mL) in patients failing to achieve a standard clinical endpoint; injection of technetium-99m labeled radiopharmaceutical 15 seconds after administration of regadenoson (or at peak exercise if regadenoson not administered) followed by SPECT myocardial perfusion imaging.
62203328|NCT01453400|EXPERIMENTAL|Arm 1|
62203329|NCT01453400|ACTIVE_COMPARATOR|Arm 2|
62203330|NCT01453400|PLACEBO_COMPARATOR|Arm 3|
62203331|NCT00783276|PLACEBO_COMPARATOR|Sugar Pill|Placebo
62203332|NCT00783276|ACTIVE_COMPARATOR|SYN115|
62203333|NCT05031949|EXPERIMENTAL|Hyperbaric oxygen therapy plus Camrelizumab|Subjects receive Camrelizumab intravenous at the dose 3mg/kg on Day 1 every 3 weeks, and breath pressurized (0.25 MPa) 100% oxygen (O2) indirectly by a head hood or mask for 60 minutes in multiplace chambers at Day 1 of every week.
62403424|NCT05334992|EXPERIMENTAL|Mindfulness Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) combines the ideas of cognitive therapy with meditative practices and attitudes based on the cultivation of mindfulness. The heart of this work lies in becoming acquainted with the modes of mind that often characterize mood disorders while simultaneously learning to develop a new relationship to them.
62403425|NCT05334992|EXPERIMENTAL|Behavior Activation|BA Increase reinforcing behaviors in order to influence emotions and cognitions.
62403426|NCT02510131|ACTIVE_COMPARATOR|Pelvic floor exercise|"Participants randomized to Kegel's exercises will be asked to contract their pelvic floor muscle for 1-10 seconds, followed by 10 seconds' relaxation.~Length of duration of exercise is tailored to individual's ability in contracting her pelvic floor muscle.~Each cycle is equivalent to 1 contraction and 1 relaxation phase. Participants will be asked to perform 3 sessions per day, and to perform their Kegel exercises at home daily.~1 session of Kegel's exercise is consists of 20 cycles of slow twitch fibre contraction and 30 repetitions of fast twitch fibre for 1 minute."
62579850|NCT02401048|EXPERIMENTAL|Phase 1b/ 2: Diffuse large B-cell lymphoma expansion cohort|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.
62786475|NCT05357508|ACTIVE_COMPARATOR|Usual care group|Participants in the Usual care group receive the standard brochure designed by the Vaud screening program. This brochure recommends screening to all individuals beginning at age 50 and presents both FIT and colonoscopy as equal options.
62014311|NCT05772065|ACTIVE_COMPARATOR|CDC/NTCA guidelines only|The control group will have a link to US guidelines only and use it as a resource to answer the case vignettes.
62203334|NCT03260777||children with Alopecia Areata|
62203335|NCT03260777||children with tinea capitis|
62403427|NCT02510131|EXPERIMENTAL|Hyacinth exercise|"In this arm participants are also taught Kegel's exercises but will be additionally taught extra steps which mirrored Muslim's praying steps.~As well as their Kegel's exercises, participants will be asked to perform the extra steps at least 63 minutes per week.~Participants may choose to perform these at the same time or at a different time from their Kegel's exercises. Participants will be asked to perform 1 cycle (3 minutes and 1 second) for 3 sessions a day for daily.~Each cycle is consists of repetition of 4 positions: standing upright- 90 degree bow- prostration-sitting."
62579851|NCT00089063|EXPERIMENTAL|Arm I (vaccine therapy)|Patients receive vaccination comprising tyrosinase peptide, gp100 antigen, and MART-1 antigen emulsified with Montanide ISA-51 and ISA-51 VG SC on day 1 of weeks 0, 26, 52, 78, and 104 (total of 5 vaccinations).
62579852|NCT00089063|EXPERIMENTAL|Arm II (vaccine therapy, sargramostim)|Patients receive vaccination comprising tyrosinase peptide, gp100 antigen, and MART-1 antigen emulsified with Montanide ISA-51 and ISA-51 VG as in arm I. Patients also receive sargramostim (GM-CSF) SC on days 1-5 of weeks 0, 26, 52, 78, and 104.
62579853|NCT00892151|EXPERIMENTAL|Intended Users of the Software|10 Healthcare Professionals and 40 persons with diabetes (of which 6 were parents/legal guardians of children with diabetes) using a diabetes data management program.
62786476|NCT05028868||Large artery atherosclerosis(LAA)|
62786477|NCT05028868||Cardiogenic stroke(CS)|
62786478|NCT05028868||Penetrating artery disease(PAD)|
62786479|NCT05028868||Other etiology(OE)|
62203336|NCT03260777||children with trichotillomania|
62203337|NCT03260777||children with tractional alopecia|
62203338|NCT02385240|EXPERIMENTAL|Test product|Brimonidine Topical Gel, 0.33 percent
62203339|NCT02385240|ACTIVE_COMPARATOR|Reference Product|Brimonidine Topical Gel, 0.33 percent (Reference)
62203340|NCT02385240|PLACEBO_COMPARATOR|Placebo gel|Placebo
62203341|NCT03925805||Chronic disease|Cardiovascular disease (including diabetes), mental disease, musculoskeletal disease
62203342|NCT03241459|EXPERIMENTAL|Surmodics SurVeil DCB|Surmodics SurVeil Drug-Coated Balloon is an investigational device coated with paclitaxel.
62203343|NCT03241459|ACTIVE_COMPARATOR|Medtronic IN.PACT Admiral DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
62203344|NCT02790827|EXPERIMENTAL|CETA|Participants in the experimental arm will receive the CETA intervention. The intervention period will last for approximately 4 months with weekly sessions. There will be separate groups for men, women, and children. Each group will have approximately six participants. Individuals who cannot attend group therapy (e.g., conflicting work schedules) may be offered the therapy individually.
62203345|NCT02790827|ACTIVE_COMPARATOR|Treatment as usual|There is no standard of care for domestic violence or alcohol use problems in Zambia. We will track any treatment or care that families receive during the course of the study. The active comparator arm will not receive any formal services provided by the study.
62203346|NCT04449380|EXPERIMENTAL|IFNβ 1a|
62203347|NCT04449380|ACTIVE_COMPARATOR|Standard care|
62215156|NCT02920489|ACTIVE_COMPARATOR|Routine epidural analgesia|Epidural catheterization will be performed after the beginning of the first stage of labor and the cervix is dilated to 1 cm or more. Epidural analgesia will then begin. A loading dose (10 ml mixture of 0.1% ropivacaine and 0.5 ug/ml sufentanil) will be administered through the epidural catheter. After a 20-minute period observation, a patient-controlled analgesia pump (containing a mixture of 0.08% ropivacaine and 0.4 ug/ml sufentanil) will be connected to the epidural catheter and programmed to deliver a 6-ml bolus with a 20-minute lockout interval and a 4 ml/h background infusion. Analgesia will be terminated at the end of the third stage of labor.
62786480|NCT05028868||undetermined etiology(UE)|
62203348|NCT06504160|EXPERIMENTAL|ShA9 Topical Gel|"From Baseline to Week 2, ShA9 topical gel and TCS will be applied twice daily to areas selected at baseline, as well as any new lesions that arise. Once an area is treated, it will continue to be treated, regardless of lesional status.~Clobetasol ointment will be applied immediately before the ShA9 in non-sensitive areas (e.g., arms). When necessary, fluocinonide ointment is a permissible alternative during this initial co-treatment. Hydrocortisone ointment will be applied with the ShA9 in sensitive areas (e.g., face).~After two weeks of co-treatment, participants will continue using ShA9 without TCS for 12 more weeks. Participants will continue to apply ShA9 to any areas that received treatment during the first two weeks of the trial. If new lesions arise, these areas will also be treated. Once an area is treated, it will continue to be treated until the Week 14 visit regardless of lesional status."
62203349|NCT06504160|PLACEBO_COMPARATOR|Placebo (Vehicle) Topical Gel|"From Baseline to Week 2, placebo (vehicle) topical gel and TCS will be applied twice daily to areas selected at baseline, as well as any new lesions that arise. Once an area is treated, it will continue to be treated, regardless of lesional status.~Clobetasol ointment will be applied immediately before the placebo (vehicle) in non-sensitive areas (e.g., arms). When necessary, fluocinonide ointment is a permissible alternative during this initial co-treatment. Hydrocortisone ointment will be applied with the placebo (vehicle) in sensitive areas (e.g., face).~After two weeks of co-treatment, participants will continue using placebo (vehicle) without TCS for 12 more weeks. Participants will continue to apply placebo (vehicle) to any areas that received treatment during the first two weeks of the trial. If new lesions arise, these areas will also be treated. Once an area is treated, it will continue to be treated until the Week 14 visit regardless of lesional status."
62203350|NCT00278447|ACTIVE_COMPARATOR|1) CDM|Chronic Disease Management
62203351|NCT00278447|ACTIVE_COMPARATOR|2) Standard care|Standard care
62203352|NCT05923853|EXPERIMENTAL|Oxygen (FiO2) Titration per E-alerts|All eligible mechanically ventilated patients, FiO2 titration and SpO2 goal range will be based on the correlation between SpO2 and arterial oxygen saturation (SaO2). E-alerts will be sent in the intervention arm as reminders for FiO2 titration.
62203353|NCT05923853|NO_INTERVENTION|Oxygen Titration per Standard of Care|In the control arm, patients will have oxygen titrated per current standard of care (SpO2=88-92%, titrate FiO2 at least every 4 hours). Physician place oxygen titration orders in EMR and respiratory therapists conduct FiO2 titration without electronic alerts.
62203354|NCT04188873|ACTIVE_COMPARATOR|12-week Varenicline with Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
62215157|NCT04876235|EXPERIMENTAL|LAMS group|place LAMS under endoscopic ultrasound. Direct endoscopic necrosectomy(DEN) was performed through the LAMS with a forward viewing gastroscope if necessary
62215158|NCT04876235|ACTIVE_COMPARATOR|DPPS group|Place DPPS under endoscopic ultrasound. When required, DEN was performed once the cystogastrostomy/duodenostomy tract had matured. This was done by first removing the stents followed by dilation of the tract with a radial expansion balloon and insertion of a forward viewing gastroscope through the tract for DEN
62215159|NCT02334423|EXPERIMENTAL|Botulinum toxin, Type A|Botulinum toxin, Type A
62215160|NCT02334423|PLACEBO_COMPARATOR|Placebo|0.9 % sterile, unpreserved saline
62403428|NCT01429727||SCAD Registry|Individuals who have experienced at least one episode of spontaneous coronary artery dissection.
62403429|NCT05863780|EXPERIMENTAL|Carpal bone mobilization|Carpal bone mobilization will be done
62403430|NCT05863780|EXPERIMENTAL|Flexor retinaculum stretch|Flexor retinaculum stretch will be given.
62579854|NCT04299893|EXPERIMENTAL|Ozone Group|"Drug: Ozone Ozone Group: Usual treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.~Other Names: O3"
62403431|NCT05863780|EXPERIMENTAL|Carpal bone mobilization and flexor retinaculum stretch|Carpal bone mobilization and flexor retinaculum stretch will be given together
62579855|NCT04299893|PLACEBO_COMPARATOR|Control Group|"Drug: Oxygen Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.~Other Names: O2"
62579856|NCT04450082||One anastomosis gastric bypass|One anastomosis gastric bypass in Sleeve Gastrectomy failure
62579857|NCT03014895|PLACEBO_COMPARATOR|Cohort 1: Placebo|Intravenous placebo infusion
62579858|NCT03014895|EXPERIMENTAL|Cohort 1: E3112|Intravenous E3112 infusion
62579859|NCT03014895|PLACEBO_COMPARATOR|Cohort 2: Placebo|Intravenous placebo infusion
62014312|NCT05772065|EXPERIMENTAL|LTBI ASSIST and CDC/NTCA guidelines|The intervention group will have a link to both US guidelines, and the LTBI-ASSIST tool as resources to answer the case vignettes.
62014313|NCT01088061||lean women with PCOS|
62403432|NCT05059470|EXPERIMENTAL|Pembrolizumab|The infusions are given every 6 weeks
62403433|NCT01932541|EXPERIMENTAL|Latuda (Lurasidone)|
62403434|NCT02189928|EXPERIMENTAL|With per-CID protocol|Usual care patients (thrombolysis or not ) with remote ischemic per-conditioning using an electronic tourniquet .
62014314|NCT01088061||Obese women with PCOS|
62014315|NCT01088061||lean control women|
62579860|NCT03014895|EXPERIMENTAL|Cohort 2: E3112|Intravenous E3112 infusion
62014316|NCT01088061||Obese control women|
62403435|NCT02189928|OTHER|Without per-CID protocol|Usual care patients (thrombolysis or not).
62403436|NCT00674440|EXPERIMENTAL|Subjects who had PET and surgery|Children diagnosed with hyperinsulinism who have failed other non-surgical interventions and are candidates to be scheduled for surgery for partial pancreatectomy. Eligible children will undergo PET imaging with F-DOPA prior to surgery.
62579861|NCT03014895|PLACEBO_COMPARATOR|Cohort 3: Placebo|Intravenous placebo infusion
62579862|NCT03014895|EXPERIMENTAL|Cohort 3: E3112|Intravenous E3112 infusion
62579863|NCT03014895|PLACEBO_COMPARATOR|Cohort 4: Placebo|Intravenous placebo infusion
62579864|NCT03014895|EXPERIMENTAL|Cohort 4: E3112|Intravenous E3112 infusion
62203355|NCT04188873|ACTIVE_COMPARATOR|12-week Varenicline with 4-Week Preparation Varenicline and Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 12 weeks post-TQD. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
62203356|NCT04188873|ACTIVE_COMPARATOR|24-week Varenicline with Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 23 weeks post-TQD. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
62403437|NCT02279082|EXPERIMENTAL|DFN-02|DFN-02 to be taken during migraine attack
62403438|NCT03005717|EXPERIMENTAL|Active High|Drug: LIPO 202 (Salmeterol Xinafoate for Injection), 0.2 mcg SX/mL Total Weekly Dose: up to 3.0 mcg SX
62403439|NCT03005717|EXPERIMENTAL|Active Low|Drug: LIPO 202 (Salmeterol Xinafoate for Injection), 0.02 mcg SX/mL Total Weekly Dose: up to 0.3 mcg SX
62403440|NCT03005717|PLACEBO_COMPARATOR|Placebo|Placebo for LIPO 202 (Salmeterol Xinafoate for Injection)
62403441|NCT01301625||MitraClip Implant|Eligible patients undergoing a MitraClip procedure in Australia and New Zealand
62403442|NCT04712968|EXPERIMENTAL|Group 1 (intervention group)|Regular exposure to morning daylight
62403443|NCT04712968|NO_INTERVENTION|Group 2 (control group)|Treatment as usual.
62403444|NCT01800500|EXPERIMENTAL|Arm I (fixed rate ST product prices)|Participants purchase ST products using a fixed rate of product prices once weekly and record their consumption of ST products and cigarettes smoked daily for 3 weeks
62403445|NCT01800500|EXPERIMENTAL|Arm II (escalating ST product prices)|Participants purchase ST products using escalating product prices once weekly and record their consumption of ST products and cigarettes smoked daily for 3 weeks.
62579865|NCT03014895|PLACEBO_COMPARATOR|Cohort 5: Placebo|Intravenous placebo infusion
62579866|NCT03014895|EXPERIMENTAL|Cohort 5: E3112|Intravenous E3112 infusion
62579867|NCT06270264|EXPERIMENTAL|The NOL|The caregiver nurse assessed pain by NOL monitorization along with a pain assessment tool (CPOT) and applied one mcg/kg fentanyl if NOL \>25 over one minute at the monitor.
62579868|NCT06270264|NO_INTERVENTION|The Control|If CPOT values were still high, then one mcq/kg bolus of fentanyl at each time would be applied and repeated at five-minute intervals, if necessary, during care and 30 minutes after.
62579869|NCT03138759|EXPERIMENTAL|Pexidartinib then Probenecid|Participants receive Sequence AB: Treatment A (pexidartinib) first, then Treatment B (probenecid), with a washout period between them
62215161|NCT05478850||Radiotherapy under anesthesia|
62215162|NCT01929785||Pre and Post Transplant|Research blood samples will be drawn pre-transplant, and at monthly post transplant visits at times corresponding to post-transplant, standard of care ImmKnowo and AlloMap clinical testing. A minimum of 12 visits per patient is expected
62403446|NCT01211210|ACTIVE_COMPARATOR|A: 5Fu with Radiation|Patients receive fluorouracil IV continuously and undergo radiotherapy once daily 5 days a week for 5-6 weeks.
62403447|NCT01211210|EXPERIMENTAL|B: FOLFOX with radiation|Patients receive FOLFOX for 5 cycles and undergo radiotherapy as in arm I from the second cycle of FOLFOX
62403448|NCT01211210|EXPERIMENTAL|C: FOLFOX alone|Patients receive FOLFOX for 4 cycles
62579870|NCT03138759|EXPERIMENTAL|Probenecid then Pexidartinib|Participants receive Sequence BA: Treatment B (probenecid) first, then Treatment A (pexidartinib), with a washout period between them
62579871|NCT03131414||Irritable bowel syndrome|"A total of 2000 patients with IBS who have met Rome IV criteria are 13 years of age or older will be consented and recruited for this study.~IBS patients will be categorized into diarrhea predominant IBS (IBS-D), constipation predominant IBS (IBS-C) or alternating constipation and diarrhea (IBS-A) or unclassified IBS (IBS-U). A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
62579872|NCT03131414||Ulcerative colitis|"2000 CD and 2000 UC cases over the age of 4 years will be enrolled.~Montreal Classification will be used for adult UC patients, and the Paris classification for pediatric UC. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
62403449|NCT00908375|ACTIVE_COMPARATOR|Pregabalin|A 75mg pregabalin capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
62786481|NCT04933487|EXPERIMENTAL|Ankoris IOL Implantation experimental|Monolateral implantation of toric intraocular lenses Ankoris
62403450|NCT00908375|PLACEBO_COMPARATOR|Surgar Pill|One Sugar pill capsule will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 Sugar pill capsules twice a day. The total duration of the treatment will be 3 weeks.
62403451|NCT04803032|EXPERIMENTAL|Superficial parotidectomy using trident landmark technique|A modified Blair incision was made along the preauricular skin crease with the same steps of the routine parotid surgery. Dissection was performed using bipolar cautery and blunt instrument; from the tragal cartilage (the anterior surface) until the bony anterior wall of the external auditory canal (EAC); from there, the dissection was done using a blunt instrument. The styloid process's base is the upper point of the trident landmark; it is the superior portion of the trident landmark. Identification of the posterior belly of the digastric muscle till its origin was performed deep to the sternocleidomastoid muscle; it is the lower point of the landmark. The facial nerve is located in the region between these two structures.
62403452|NCT02514434|EXPERIMENTAL|Ultrasonography|Subjects will be regularly screened for HCC by ultrasonography with serum AFP(alpha fetoprotein).
62403453|NCT02514434|EXPERIMENTAL|Non-contrast MRI|Subjects will be regularly screened for HCC by non-contrast magnetic resonance imaging(MRI) with serum AFP(alpha fetoprotein).
62403454|NCT03260621|OTHER|echocardiographic increase in left atrial pressure|
62403455|NCT03260621|OTHER|echocardiographic no increase in left atrial pressure|
62403456|NCT01934777|EXPERIMENTAL|TREATED GROUP|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg by mouth every day in association with lifestyle intervention \[hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity\] for 6 months
62403457|NCT01934777|PLACEBO_COMPARATOR|PLACEBO GROUP|placebo: this group will treated with identical placebo pearls given orally in association with lifestyle intervention \[hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity\] for 6 months
62014317|NCT05191498|EXPERIMENTAL|Study patients|All patients receive intratumoral holmium microsphere injections ones, if surgery is suspended. Patient specific treamtent planning is performed for every individual patient.
62014318|NCT00887341|EXPERIMENTAL|1|
62403458|NCT00594568|PLACEBO_COMPARATOR|Placebo|Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 milligrams (mg) orally once daily until Week 88.
62403459|NCT00594568|EXPERIMENTAL|100 mg LY450139|Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.
62579873|NCT03131414||Crohn's disease|"2000 CD cases over the age of 4 years will be enrolled.~Montreal Classification will be used for adult CD patients, and the Paris classification for pediatric CD. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
62014319|NCT00887341|ACTIVE_COMPARATOR|2|
62014320|NCT03448367||SMBG/FreeStyle Libre|During the intervention phase, subjects will use FreeStyle Libre Flash Glucose Monitoring System for 6 months to managed their diabetes.
62014321|NCT05091567|EXPERIMENTAL|Arm A: Atezolizumab+Lurbinectedin|"Induction phase: participants will receive standard of care atezolizumab on Day 1 of each 21-day cycle in combination with carboplatin on Day 1 and etoposide on Days 1, 2, and 3 of each 21-day cycle for 4 cycles.~Maintenance phase: participants will receive atezolizumab on Day 1 of each 21-day cycle in combination with lurbinectedin on Day 1 of each 21-day cycle."
62215163|NCT01929785||One year post transplant|The second group will include heart transplant recipients at one year post transplant who consent to participate in the study. Research blood samples will be drawn at quarterly post transplant visits (standard of care in Year 2 post transplant) corresponding to ImmunKnow and AlloMap testing. A minimum of 4 visits per patient is expected.
62786482|NCT04673578|EXPERIMENTAL|Celecoxib|Celecoxib 50 mg orally twice daily (if weight 10-25 kg) or 100 mg orally twice daily (if weight \> 25 kg) for 12 weeks. Used as adjunct to treatment-as-usual.
62786483|NCT04673578|PLACEBO_COMPARATOR|Placebo (microcrystalline cellulose)|Placebo capsules identical to celecoxib. One capsule orally twice daily for 12 weeks. Used as adjunct to treatment-as-usual.
62786484|NCT04039737|EXPERIMENTAL|Treatment Group|Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
62786485|NCT04039737|NO_INTERVENTION|Control Group|
62014322|NCT05091567|ACTIVE_COMPARATOR|Arm B: Atezolizumab|"Induction phase: participants will receive standard of care atezolizumab on Day 1 of each 21-day cycle in combination with carboplatin on Day 1 and etoposide on Days 1, 2, and 3 of each 21-day cycle for 4 cycles.~Maintenance phase: participants will receive atezolizumab on Day 1 of each 21-day cycle."
62014323|NCT00718042|EXPERIMENTAL|1|All subjects will have their blood tested by the investigational Chagas screening assay.
62014324|NCT00718042|EXPERIMENTAL|2|Testing of blood donor samples with the investigational Chagas screening assay. Samples that test positive will be also tested with the Chagas confirmatory assay.
62014325|NCT04842240||Patients undergoing implant based immediate breast reconstruction.|Patients will undergo either pre- or sub-pectoral implant based immediate breast reconstruction.
62014326|NCT03887481|EXPERIMENTAL|Active HD-tDCS + Language/Cognitive Intervention(s) first|Participants will receive active HD-tDCS + Language/Cognitive Intervention(s) first and then receive Sham + Language/Cognitive Intervention(s) after a three-month washout period.
62014327|NCT03887481|EXPERIMENTAL|Sham + Language/Cognitive Intervention(s) first|Participants will receive Sham + Language/Cognitive Intervention(s) first and then receive active HD-tDCS + Language/Cognitive Intervention(s) after a three-month washout period.
62014328|NCT04298255|EXPERIMENTAL|ROSI only|Option 1: injecting extracted round spermatids (less mature form of haploid germ cells than elongated spermatid or spermatozoon) from male partner into the harvested egg of a female partner
62014329|NCT04298255|EXPERIMENTAL|Half ROSI-half Sperm Donor Fertilization|Option 2: Harvested eggs from the female partner will be separated in two groups, with one group being fertilized with round spermatids and the other group fertilized with donor sperm
62403460|NCT00594568|EXPERIMENTAL|140 mg LY450139|Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.
62403461|NCT00006001|EXPERIMENTAL|Arm I|Patient receive SU5416 IV over 60 minutes twice weekly for 4 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
62403462|NCT01108861|EXPERIMENTAL|Endoprosthesis|GORE VIABAHN® Endoprosthesis
62403463|NCT01108861|ACTIVE_COMPARATOR|Plain old balloon angioplasty|Plain old balloon angioplasty
62403464|NCT06231992|ACTIVE_COMPARATOR|opioid based anesthesia|I.V Fentanyl (1-2ug/kg) before induction of general anesthesia with I.V propofol (1-2mg/kg), atracurium (0.5mg/kg). Intermittent boluses of fentanyl will be given intraoperatively when needed to maintain the change in hemodynamics within 20 % of the baseline.
62786486|NCT01840345|EXPERIMENTAL|N-acetyl-L-cysteine|n-acetyl-l-cysteine 1200 mg BID x 4 weeks
62786487|NCT05776953|ACTIVE_COMPARATOR|15mg IV Ketorolac|Patients will be randomized to 15mg IV ketorolac
62786488|NCT05776953|ACTIVE_COMPARATOR|30mg IV Ketorolac|Patients will be randomized to 30mg IV ketorolac
62786489|NCT03125551|ACTIVE_COMPARATOR|Ginger|Ginger ( Zingiber officinale) 4 grams po dly for 14 days
62203357|NCT04188873|ACTIVE_COMPARATOR|24-week Varenicline with 4-Week Preparation Varenicline and Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 weeks prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 24 weeks post-TQD. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
62203358|NCT04188873|ACTIVE_COMPARATOR|12-week Varenicline with Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
62203359|NCT04188873|ACTIVE_COMPARATOR|12-week Varenicline with 4-Week Preparation Varenicline and Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 11 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
62403465|NCT06231992|ACTIVE_COMPARATOR|opioid free anesthesia|- IV Ketamine (0.25-0.5 mg/kg) before induction of general anesthesia with I.V propofol (1-2 mg/kg), atracurium (0.5mg/kg) followed by(0.25mg /min) infusion of ketamine for maintenance. Dexamethasone I.V (8 mg) will be given before induction of general anesthesia. magnesium sulphate (20 mg/kg)in 100ml saline within 10 mints Followed by infusion of magnesium sulphate at rate of (10mg/kg/h).
62403466|NCT05672277|EXPERIMENTAL|Group 1|Group 1 will be applied TENS three days per week
62403467|NCT05672277|ACTIVE_COMPARATOR|Group 2|Group 2 will be applied TENS one day per week
62403468|NCT02341326||Healthy nonsmokers|"n=20 for Aim 1 n=20 for Aim 2~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 2.To test the hypothesis that FGFR2 signaling is necessary for normal SAE BC stem cell function and suppression of FGFR2 caused by inhibitors and smoking associated factors (EGF and TGF- beta)leads an altered stem cell functional phenotype similar to SAE BC from COPD smokers with reduced capacity as characterized by Aim 1."
62579874|NCT03131414||Healthy control|"A total of 2000 healthy family members, relative or friends of cohort participants over the age of 4 will be consented and recruited for this study.~Each control that agrees to participate will undergo an initial screening questionnaire to confirm that they are healthy and have no gastrointestinal symptoms using the ROME IV Questionnaire. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
62579875|NCT05555940|EXPERIMENTAL|TMS true stimulation group|Transcranial magnetic stimulation and medication. The stimulation parameters were 10Hz frequency and 120%MT intensity. 50 treatment sequences were given each time, with 60 stimulation times for each sequence, the sequence interval was 30 seconds, and a total of 3000 stimulation times for each treatment. The patients were treated once a day for 15 days. Medical treatment is selective serotonin reuptake inhibitors/serotonin-noradrenaline reuptake inhibitors (SSRIs/SNRIs).
62579876|NCT05555940|SHAM_COMPARATOR|TMS sham stimulation group|Sham stimulation and medication. The pseudo-stimulation method was to flip the magnetic head at 90 degrees with the scalp, The stimulation parameters were 10Hz frequency and 120%MT intensity. 50 treatment sequences were given each time, with 60 stimulation times for each sequence, the sequence interval was 30 seconds, and a total of 3000 stimulation times for each treatment. The patients were treated once a day for 15 days. Medical treatment is selective serotonin reuptake inhibitors/serotonin-noradrenaline reuptake inhibitors (SSRIs/SNRIs).
62579877|NCT01693588|EXPERIMENTAL|Pain Management Bundle|The Pain Management Bundle will be implemented for all postoperative neurosurgical patients admitted to nursing units at the University of Florida.
62579878|NCT01828814||RUSF (500kcal/day) and cash transfer|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 500kcal per day associated with cash transfer during hunger gap (5 months) then RUSF 500kcal/day for 10 months
62579879|NCT01828814||Super Cereal Plus (SC+)|Monthly distributions of SC+ 800kcal per day during hunger gaps (5 months twice) and SC+ 400kcal per day in-between (5 months)
62579880|NCT01828814||RUSF|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 500kcal per day during hunger gaps (5 months twice) and RUSF 250kcal per day in-between (5 months)
62579881|NCT01828814||RUSF (250kcal/day) and cash transfer|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 250kcal per day associated with cash transfer during hunger gap (5 months) then RUSF 250kcal/day for 10 months
62786490|NCT03125551|ACTIVE_COMPARATOR|Garlic|Garlic (Allium sativum) 4-12 mg alliin po dly for 14 days
62014330|NCT05108493|EXPERIMENTAL|Dry needling and home exercise|"The experimental intervention will consist of 3 sessions of dry needling of the lateral epicondyle region, once per week with disposable acupuncture needles (0.25x25mm).~Range of motion, stretching exercises, ulnar and radial deviation, forearm pronation, supination, elbow extensor, and flexor strengthening exercises will be given to all participants.~The exercise program will be performed for 10 repetitions 2 times a day. All participants will be advised to continue the exercise program for 12 weeks."
62786491|NCT03125551|ACTIVE_COMPARATOR|Ginkgo Biloba|Ginkgo Biloba 40mg po tds for 14 days
62786492|NCT03125551|ACTIVE_COMPARATOR|Ginseng|Ginseng 400mg po dly for 14 days
62786493|NCT03125551|PLACEBO_COMPARATOR|Placebo|Placebo po dly for 14 days
62014331|NCT05108493|ACTIVE_COMPARATOR|Home exercise|"Range of motion, stretching exercises, ulnar and radial deviation, forearm pronation, supination, elbow extensor, and flexor strengthening exercises will be given to all participants.~The exercise program will be performed for 10 repetitions 2 times a day. All participants will be advised to continue the exercise program for 12 weeks."
62014332|NCT04442737|EXPERIMENTAL|D/C/F/TAF FDC Arm (Immediate Switch)|Participants will be immediately switched to a regimen of darunavir 800 milligram (mg)/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily for 48 weeks.
62579882|NCT01828814||SC+ and cash transfer|Monthly distributions of Super Cereal Plus (SC+) 800 kcal per day associated with cash transfer during hunger gap (5 months)
62786494|NCT01900652|EXPERIMENTAL|Arm A: Emibetuzumab plus Erlotinib|750 milligram (mg) Emibetuzumab flat dose given as a 1.5 hour intravenous (IV) infusion on Days 1 and 15 of a 28-day cycle and Erlotinib 150 mg given orally once daily on a 28-day cycle.
62014333|NCT04442737|ACTIVE_COMPARATOR|INI + TAF/FTC Arm (Delayed Switch)|Participants will continue to receive current baseline integrase (INI)-based regimen plus Tenofovir Alafenamide/Emtricitabine (TAF/FTC) antiretroviral (ARV) regimen for 24 weeks. After 24 weeks participants will switch to a regimen of D/C/F/TAF FDC once daily for an additional 24 weeks.
62014334|NCT04950608|EXPERIMENTAL|PATH|"The research study procedures include screening for eligibility, and study intervention including preparation, evaluations, one psilocybin session and follow up visits.~-The treatment regimen consists of a single administration of psilocybin 25 mg orally combined with a supportive psychotherapy including 2 preparation sessions and 2 integration sessions"
62014335|NCT02720484|EXPERIMENTAL|Treatment (Nivolumab)|Patients receive nivolumab IV over 30 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity.
62014336|NCT04376996||General cohort|General population cohort aged 0-100 years from Slovenia
62014337|NCT05245812|EXPERIMENTAL|Treatment arm (SPrNSM)|Patients will undergo Single Port robotic Nipple Sparing Mastectomy (SPrNSM) with immediate breast reconstruction with tissue expanders/implants and acellular dermal matrix (Alloderm)
62014338|NCT06271096|EXPERIMENTAL|Group A IM-Midazolam|Group A received IM midazolam at a dose of 0.2 mg/kg gently injected into the vastus lateralis muscle
62014339|NCT06271096|EXPERIMENTAL|Group B IV Diazepam|Patients in group B were cannulated in the dorsum of the hand or foot, or the great saphenous vein at the ankle first and then administered diazepam at a dose of 0.2mg/kg
62014340|NCT06460701|ACTIVE_COMPARATOR|Active comparator: modified constraint induced movement therapy without Kinesiotaping.|in this group m-CIMT will be applied without kinesiotaping.
62014341|NCT06460701|EXPERIMENTAL|Experimental: modified constraint induced movement therapy along with kinesio taping.|in this group m-CIMT will be applied along with kinesiotaping.
62014342|NCT05425810|EXPERIMENTAL|Transtibial patient|All the recruited participants will be included in this arm and will go through the socket manufacturing, fitting, and testing procedure.
62203360|NCT04188873|ACTIVE_COMPARATOR|24-week Varenicline with Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 23 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
62215164|NCT01940224|ACTIVE_COMPARATOR|Pregabalin & Morphine|Administration of pregabalin 300 mg to patients undergo laparoscopic colorectal surgery.Patients receive oral Pregabalin 150 mg the night before surgery, and another one dose of 150 mg 1 hour prior to surgery. Postoperative administration of morphine via PCA pump for 48 hours
62579883|NCT01828814||SC+ and household ration|Monthly distributions of Super Cereal Plus (SC+) 800 kcal per day associated with food ration for household support during hunger gap (5 months)
62786495|NCT01900652|EXPERIMENTAL|Arm B: Emibetuzumab|750 mg Emibetuzumab flat dose given as a 1.5-hour IV infusion on Days 1 and 15 of a 28-day cycle.
62786496|NCT02975674|EXPERIMENTAL|MT-12 dental implant|MT-12 dental implant with Morse taper implant-abutment connection
62014343|NCT04518124|EXPERIMENTAL|Propranolol|
62014344|NCT01010984|EXPERIMENTAL|Transcatheter Arterial Chemoembolization|TACE using LC beads loaded with Doxorubicin
62014345|NCT05769673|EXPERIMENTAL|Customized Healing Abutments|Placement of a customized CAD/CAM healing abutment after implant placement.
62014346|NCT05769673|ACTIVE_COMPARATOR|Stock Healing Abutments|Placement of a stock healing abutment after implant placement.
62014347|NCT05960682||Questionnaire|Men will complete the French version of the Brief Index of Sexual Functioning for Men paper questionnaire.
62014348|NCT00653224|PLACEBO_COMPARATOR|Placebo|Matched placebo tablets
62014349|NCT00653224|EXPERIMENTAL|LCTZ|5 mg tablet
62014350|NCT01229436|EXPERIMENTAL|Xiapex Injection|
62786497|NCT02975674|ACTIVE_COMPARATOR|CON.INT dental implant|CON.INT dental implant with internal hexagon implant-abutment connection
62579884|NCT01828814||Cash transfer|Monthly distributions of cash transfer only during hunger gap (5 months)
62786498|NCT01588600|ACTIVE_COMPARATOR|Control|Breakfast without fiber
62014351|NCT06573151|EXPERIMENTAL|Chemo|Patients receive 3 cycles of Selinexor, anti-PD-1 antibody plus P-GemOx.
62014352|NCT06165003|EXPERIMENTAL|Experimental group|Peripheral Intravenous Catheter Insertion Procedure - Broselow Band Selection - Experimental Group Urinary Catheter Insertion Procedure - Broselow Tape Selection - Experimental Group Aspiration process - Broselow Band Selection - Experimental group Nasogastric/Orogastric Catheter Insertion Procedure - Broselow Band Selection - Experimental Group
62014353|NCT06165003|NO_INTERVENTION|Control Group|Peripheral Intravenous Catheter Insertion Procedure - Routine Application - Control Group Urinary Catheter Insertion Procedure - Routine Application - Control Group Aspiration process - Routine Application - Control Group Nasogastric/Orogastric Catheter Insertion Procedure - Routine Practice - Control Group
62014354|NCT05371210|EXPERIMENTAL|SAIF|After completion of baseline assessment, participants were required to interact with the SAIF system for 4 months. They were followed up at 2-month (mid-way of intervention), 4-month (end of intervention), and 7-month (3 months post-intervention).
62203361|NCT04188873|ACTIVE_COMPARATOR|24-week Varenicline with 4-Week Preparation Varenicline and Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 weeks prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 24 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
62203362|NCT04188873|ACTIVE_COMPARATOR|12-week C-NRT with Minimal Counseling|Participants randomized to this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges to use starting on their quit day. Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
62203363|NCT04188873|ACTIVE_COMPARATOR|12-week C-NRT with 4-Week Preparation C-NRT and Minimal Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Then, starting on the TQD, participants will receive 12 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke \>10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants will receive a brief 15-30 minute phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
62203364|NCT04188873|ACTIVE_COMPARATOR|24-week C-NRT with Minimal Counseling|Participants randomized to this intervention will receive 24 weeks of nicotine patches and nicotine mini-lozenges, starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
62203365|NCT04188873|ACTIVE_COMPARATOR|24-week C-NRT with 4-Week Preparation C-NRT and Minimal Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Then, starting on the TQD, participants will receive 24 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
62203366|NCT04188873|ACTIVE_COMPARATOR|12-week C-NRT with Intensive Counseling|Participants randomized to this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges to use starting on their quit day. Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
62014355|NCT05371210|NO_INTERVENTION|Control|Participants received a one-time health pamphlet after completing baseline assessment. They were followed up at 2-month, 4-month and 7-month thereafter.
62203367|NCT04188873|ACTIVE_COMPARATOR|12-week C-NRT with 4-Week Preparation C-NRT and Intensive Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Starting on the TQD, participants will receive 12 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke \>10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
62203368|NCT04188873|ACTIVE_COMPARATOR|24-week C-NRT with Intensive Counseling|Participants randomized to this intervention will receive 24 weeks of nicotine patches and nicotine mini-lozenges, starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
62786499|NCT01588600|EXPERIMENTAL|Low-dose|Low-dose of fiber in breakfast
62579885|NCT06459414|EXPERIMENTAL|Interventional group recieveing Oropharyngeal Of Colostrum for 3 days|The first interventional group will receive colostrum of their mother's breast milk through oropharyngeal route for 3 days on 1 ml/kg/day
62203369|NCT04188873|ACTIVE_COMPARATOR|24-week C-NRT with 4-Week Preparation C-NRT and Intensive Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Starting on the TQD, participants will receive 24 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke \>10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
62203370|NCT04633525|EXPERIMENTAL|Optimum Cup Orientation|
62203371|NCT06412354|EXPERIMENTAL|VIV-FIH|"The VIVHEART EasyCross™ fist-in human (VIV-FIH) study is a single center, prospective, open-label, non-randomized, single-group assignment, first-in-human feasibility trial of the VIVHEART EasyCross™ catheter used according to the indication of use. The experimental part of the trial which differs from the traditional TAVR procedure is the use of the self-centering catheter from its insertion in an artery and up to its removal from the patient body (henceforth investigational procedure)."
62203372|NCT05204797|EXPERIMENTAL|Robot-assisted UKA|Unicompartmental knee replacement (Journey II UKA, Smith and Nephew, USA) positioned via CORI surgical system (Smith \& Nephew, USA).
62203373|NCT05204797|ACTIVE_COMPARATOR|Standard technique UKA|Unicompartmental knee replacement (Journey II UKA, Smith and Nephew, USA) positioned via standard technique.
62203374|NCT04520503||Pre EEG group|This cohort includes all participants in this study. EEG sensor will be attached to the patient's forehead before induction of anesthesia. Patterns of EEG and data will be obtained
62203375|NCT05483413|EXPERIMENTAL|Progressive Relaxation Exercises|Progressive relaxation exercises will be applied to this group for 8 weeks.
62203376|NCT05483413|NO_INTERVENTION|Standard of Care|This group will continue their routine coping habits against sleep and fatigue problems in the postmenopausal period for 8 weeks.
62579886|NCT06459414|EXPERIMENTAL|Interventional group recieveing Oropharyngeal Of Colostrum for 10 days|The second interventional group will receive colostrum of their mother's breast milk through oropharyngeal route for 10 days on 1 ml/kg/day
62203377|NCT03796377|OTHER|Rivaroxaban|Single oral dose of 20 mg rivaroxaban
62203378|NCT03796377|OTHER|Rivaroxaban after CYP- and P-gp induction|Single oral dose of 20 mg rivaroxaban after pretreatment with St. John's wort extract (Jarsin®) twice daily 450 mg po for 2 weeks.
62203379|NCT04548284|EXPERIMENTAL|Periorbitally Injected Glucocorticoids|Glucocorticoids periorbital injection. Once every 3 weeks, the number of injections was determined according to the condition of the eyes during the follow-up.
62203380|NCT04548284|NO_INTERVENTION|Observe|Observe and wait.
62403469|NCT02341326||Healthy smokers|"n=20- for Aim 1 n=20 for Aim 3~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 3.To assess the hypothesis that increasing FGFR2 signaling and suppressing smoking induced EGF receptors and TGF-beta pathways will restore the FGFR2 expression and normalize the capacity of SAE BC stem cells to generate and maintain normally differentiated SAE."
62403470|NCT02341326||COPD smokers|"n=20- for Aim 1 n=20 for Aim 3~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 3.To assess the hypothesis that increasing FGFR2 signaling and suppressing smoking induced EGF receptors and TGF-beta pathways will restore the FGFR2 expression and normalize the capacity of SAE BC stem cells to generate and maintain normally differentiated SAE."
62403471|NCT03225950||Chronic periodontitis donors|"* Donors are medically healthy.~* Slow to moderate attachment loss and bone destruction.~* Good correlation between etiological factors and serverity of attachment loss."
62579887|NCT06459414|NO_INTERVENTION|Control group recieving only the standard care|The control group will receive only the standard care
62786500|NCT01588600|EXPERIMENTAL|High-dose|high dose of fiber added to breakfast
62786501|NCT00176462|EXPERIMENTAL|Arm 1 Standard Risk|6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE METHOTREXATE Leucovorin
62579888|NCT02004574|EXPERIMENTAL|PRN treatment|Group 1: PRN treatment Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel) once daily as needed (PRN)
62579889|NCT02004574|EXPERIMENTAL|Continuous treatment|Group 2: Continuous treatment Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel)once daily
62786502|NCT00176462|EXPERIMENTAL|Arm 2 High Risk|6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE 6-THIOGUANINE CYTARABINE AMINOPTERIN CYCLOPHOSPHAMIDE ARABINOSIDE-C
62786503|NCT06018623||grup 1.Optimum range|Group 1 BMI = 18.5-24.9,
62786504|NCT06018623||Group 2.Overweight|BMI = 25-29.9,
62786505|NCT06018623||Group 3.Class I obesity|BMI=30-34.9
62203381|NCT04393194|EXPERIMENTAL|Vaginal estrogen cream|subjects will be treated with the prescribed vaginal medication, 1g per time, q d for the first 2 weeks and then 1g per time, twice a week.
62786506|NCT03373838||Census|Epidemiological study. Sociodemographic and medical survey.
62786507|NCT03373838||Qualitative interview|Individual qualitative interview.
62403472|NCT03225950||Aggressive periodontitis donors|"* Donors are medically healthy.~* Rapid attachment loss and bone destruction.~* Familial aggregation.~* No correlation between etiological factors and serverity of attachment loss."
62403473|NCT03225950||Control donors|"* Donors are medically healthy.~* No sign of inflammatory conditions."
62403474|NCT05653648|EXPERIMENTAL|Potato Starch Supplement|Participants will consume a 24 grams of potato starch on Days 1-15 and 48 grams of potato starch on Days 16-30.
62203382|NCT04393194|PLACEBO_COMPARATOR|vaginal placebo cream|Subjects will be treated with the prescribed vaginal medication, 1g per time, q d for the first 2 weeks and then 1g per time, twice a week.
62203383|NCT05909826|EXPERIMENTAL|Weekly carfilzomib-oral cyclophosphamide-dexamethasone|Weekly carfilzomib-oral cyclophosphamide-dexamethasone
62403475|NCT04961944||Hypersensitivity pneumonitis|see elegibility criteria
62786508|NCT01356446|NO_INTERVENTION|before surgical checklist|
62786509|NCT01356446|ACTIVE_COMPARATOR|after implementation surgical checklist|
62786510|NCT05397249|EXPERIMENTAL|Mindfulness only training|Face to face twice weekly 10 minutes training of Mindfulness only training.
62786511|NCT05397249|EXPERIMENTAL|Mindfulness with spirituality|Face to face twice weekly 10 minutes training of Mindfulness only training plus the Spirituality components.
62786512|NCT05397249|EXPERIMENTAL|Low dose Mindfulness only|Face to face once weekly 10 minutes training of Mindfulness only training.
62786513|NCT05397249|EXPERIMENTAL|Low dose Mindfulness with Spirituality|Face to face once weekly 10 minutes training of Mindfulness only training plus the Spirituality components.
62786514|NCT05397249|NO_INTERVENTION|No treatment|No intervention is being delivered, however, participants are led to believe that they are receiving some degree of a mindfulness training embedded in their regular course curriculum.
62786515|NCT01324362|ACTIVE_COMPARATOR|Fluticasone propionate|
62014356|NCT04463901|ACTIVE_COMPARATOR|Group CAG|After pterygium excision, intraoperative mitomycin c (0.02%) for 5 minutes will be applied topically onto the exposed surgical area and then conjunctival autograft without limbal tissue will be used to cover the bare sclera.
62014357|NCT04463901|ACTIVE_COMPARATOR|Group LCAG|After pterygium excision, intraoperative mitomycin c (0.02%) for 5 minutes will be applied topically onto the exposed surgical area and then limbal conjunctival autograft will be used to cover the bare sclera.
62203384|NCT02089568|EXPERIMENTAL|Drug: co-amoxiclav|experimental
62203385|NCT02089568|PLACEBO_COMPARATOR|Control|comparator
62203386|NCT04302688||modeling cohort|The 445 patients were grouped in chronological order.
62203387|NCT04302688||validating colort|The remaining 224 patients.
62203388|NCT02406677|EXPERIMENTAL|Copayment Intervention Arm|Sites in the intervention arm will provide patients with a study voucher card to offset any patient copayments or medication card for the filling of any prescriptions of clopidogrel or ticagrelor.
62203389|NCT02406677|NO_INTERVENTION|Usual Care Arm|For hospitals randomized to the control arm, all patients receive usual care and no study intervention is performed.
62203390|NCT04827472|EXPERIMENTAL|Part1(Cohort1) : DWJ1521 Amg|
62203391|NCT04827472|EXPERIMENTAL|Part1(Cohort2) : DWJ1521 Bmg|
62203392|NCT04827472|EXPERIMENTAL|Part1(Cohort3) : DWJ1521 Cmg|
62203393|NCT04827472|EXPERIMENTAL|Part1(Cohort4) : DWJ1521 Dmg|
62203394|NCT04827472|EXPERIMENTAL|Part2 : DWJ1521 Xmg|
62203395|NCT04827472|EXPERIMENTAL|Part2 : DWP14012 Tablet|
62203396|NCT04993482||type 2 diabetes mellitus group|124 adults with type 2 diabetes mellitus will be included
62403476|NCT03799445|EXPERIMENTAL|Treatment (nivolumab, ipilimumab, IMRT)|Patients receive nivolumab IV over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 30 minutes on day 1. Treatment repeats every for 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of cycle 2, patients also undergo IMRT 5 days a week (Monday-Friday) for 6 weeks in the absence of disease progression or unacceptable toxicity.
62403477|NCT05320926|EXPERIMENTAL|Short-term DAPT followed by clopidogrel monotherapy|atients who received zotarolimus-eluting Onyx stents implantation for treating ischemic heart disease at de novo coronary lesion will maintain 1-3 months DAPT. Patients will be randomized to stop aspirin and maintain clopidogrel after DAPT.
62403478|NCT05320926|ACTIVE_COMPARATOR|Short-term DAPT followed by aspirin monotherapy|Arm Description: Patients who received zotarolimus-eluting Onyx stents implantation for treating ischemic heart disease at de novo coronary lesion will maintain 1-3 months DAPT. Patients will be randomized to stop clopidogrel and maintain aspirin after DAPT.
62403479|NCT05623774|ACTIVE_COMPARATOR|Dose Calibration|In Part A, cohorts will consist of 8 subjects who will receive a single dose of Ikt-001Pro and then cross over to a single does of imatinib following a 7 day washout.
62786516|NCT01324362|ACTIVE_COMPARATOR|Fluticasone propionate/salmeterol combination|
62786517|NCT02445521||PKU (low phe-level)|A subject diagnosed with phenylketonuria (PKU) with low phenylalanine levels, defined as 1-5 mg/dL
62786518|NCT02445521||PKU (mid phe-level)|A subject diagnosed with phenylketonuria (PKU) with middle phenylalanine levels, defined as 6-10 mg/dL
62786519|NCT02445521||PKU (high mid phe-level)|A subject diagnosed with phenylketonuria (PKU) with high middle phenylalanine levels, defined as 11-15 mg/dL
62203397|NCT04993482||control group|124 control adults will be included
62203398|NCT01259089|EXPERIMENTAL|Arm I|Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62403480|NCT05623774|ACTIVE_COMPARATOR|Dose Equivalance|In Part B, up to 16 subjects will receive IkT001-Pro and up to 16 subjects will receive 400mg of imatinib mesylate. After a 7 day washout period the subjects will switch to receive the drug they did not previously receive.
62403481|NCT05623774|ACTIVE_COMPARATOR|Dose Equivalence at 600 mg):|In Part C, up to eight (8) subjects will be administered a single dose of 800 mg IkT-001Pro. After a 7-day washout period, the subjects will switch to 600 mg imatinib.
62403482|NCT03018756|ACTIVE_COMPARATOR|Fentanyl Citrate|Single dose, nebulized 100 mcg fentanyl citrate. This is a double-blind, placebo-controlled, two-period crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate to that of a placebo (0.9% saline). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and placebo at the second treatment visit, patients in the other arm will receive placebo first and fentanyl second.
62403483|NCT03018756|PLACEBO_COMPARATOR|Placebo|Single dose, nebulized 0.9% saline solution. This is a double-blind, placebo-controlled, two-period crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate to that of a placebo (0.9% saline). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and placebo at the second treatment visit, patients in the other arm will receive placebo first and fentanyl second.
62203399|NCT05512689|NO_INTERVENTION|Control group|In the control group, the healthcare professional ventilates the infants without any feedback about the ventilation. This represents the normal clinical setting. The RFM will be recording data on the ventilation quality.
62403484|NCT02103985|EXPERIMENTAL|Treatment A|Participants will receive 100 mg JNJ-39823277 under fed (after a high fat) condition.
62403485|NCT02103985|EXPERIMENTAL|Treatment B|Participants will receive 100 mg JNJ-39823277 under fasted condition.
62203400|NCT05512689|ACTIVE_COMPARATOR|Interventional group|In the interventional group, healthcare professionals will ventilate the infants using the RFM and are able to adapt their ventilations according to the RFM feedback.
62203401|NCT06186921|EXPERIMENTAL|Intraligamentary injection of dexamethasone|After endodontic instrumentation and placement of temporary restoration, the patients shall receive Intraligamentary injection of dexamethasone
62403486|NCT02992782|ACTIVE_COMPARATOR|Standard Care|Standard care Intervention: including a home program of therapeutic (decongestive) exercise, which will include active, non-resistive motion of the involved limb. Participants will perform the exercise once daily for about 10 minutes and will be required to wear their compression sleeve for at least 12 hours per day, each day of the week. After 24 weeks, they will be given the opportunity to take part in the decongestive progressive resistance exercise program and will be provided with an adjustable compression garment to use during exercise.
62786520|NCT02445521||PKU (high phe-level)|A subject diagnosed with phenylketonuria (PKU) with high phenylalanine levels, defined as 16-20+ mg/dL
62786521|NCT02445521||Control|A normal subject without phenylketonuria (PKU)
62014358|NCT05306106|OTHER|Glucose|The control product, said to be the reference product, is an oral solution of 50 g of glucose.
62014359|NCT05306106|OTHER|a truffle match|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
62786522|NCT01810497|ACTIVE_COMPARATOR|Seven-day bandage use|Patients randomized and instructed to use of ear bandage 24h/day for seven days after otoplasty
62786523|NCT01810497|ACTIVE_COMPARATOR|Thirty-day bandage use|Patients randomized and instructed to use of ear bandage 24h/day for thirty days after otoplasty
62786524|NCT05984485|EXPERIMENTAL|Primary total mesorectal excision|Patients with low-risk locally advanced rectal cancer received total mesorectal excision alone.
62014360|NCT05306106|OTHER|a hazelnut chocolate cookie|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
62014361|NCT05306106|OTHER|a Paris Brest style eclair|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
62014362|NCT05306106|OTHER|a hazelnut chocolate finger|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
62014363|NCT05306106|OTHER|a lemon finger|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
62014364|NCT05306106|OTHER|a elderflower madeleine|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
62014365|NCT06522451|ACTIVE_COMPARATOR|Conventional Physical Therapy|This group receives conventional physical therapy
62014366|NCT06522451|EXPERIMENTAL|Conventional physical therapy with cuevas medek exercises|This group receives conventional physical therapy along with cuevas medek exercises
62014367|NCT01919385|EXPERIMENTAL|type 1 diabetes|Predictive Low Glucose Minimizer (PLGM) System
62014368|NCT00660010|EXPERIMENTAL|1|
62203402|NCT06186921|EXPERIMENTAL|Intraligamentary injection of diclofenac sodium|After endodontic instrumentation and placement of temporary restoration, the patients shall receive Intraligamentary injection of dexamethasone
62203403|NCT06186921|EXPERIMENTAL|Intraligamentary injection of 0.5% bupivacaine|After endodontic instrumentation and placement of temporary restoration, the patients shall receive Intraligamentary injection of dexamethasone
62203404|NCT06186921|ACTIVE_COMPARATOR|Intraligamentary injection of 2% lidocaine|After endodontic instrumentation and placement of temporary restoration, the patients shall receive Intraligamentary injection of dexamethasone
62203405|NCT01345864|OTHER|Cohort A|Parallel design with 5 unique treatment groups Donepezil tablets and matching placebo tablets may be overencapsulated as needed.
62786525|NCT05984485|ACTIVE_COMPARATOR|Neoadjuvant chemotherapy plus TME|Patients with low-risk locally advanced rectal cancer received neoadjuvant chemotherapy and total mesorectal excision.
62786526|NCT05345301|EXPERIMENTAL|Measuring neural activity|While completing hand opening/closing, individuals will have the following measured (1) Neural activity (specifically sensorimotor rhythms) using a EEG cap; (2) muscle activity (specifically finger flexors and extensors) using EMG sensors.
62786527|NCT03062111|ACTIVE_COMPARATOR|ProTouch Laser Enucleation of Prostate|The intervention for this group is that the patient will undergo endoscopic ProTouch Laser Enucleation of Prostate (LEP).The laser is used to enucleate large pieces of prostatic tissue which is followed by further ablation of the tissue so that no fragments are left in the bladder
62014369|NCT03459417|ACTIVE_COMPARATOR|intrathecal morphine+LA|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine.
62014370|NCT03459417|ACTIVE_COMPARATOR|intrathecal morphine+LA+Mg sulp. 50|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 50 mg.
62014371|NCT03459417|ACTIVE_COMPARATOR|intrathecal morphine+LA+ Mg sulp.100|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
62014372|NCT02956629|EXPERIMENTAL|HCV GT1|Male and female participants with HCV GT1a or GT1b infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
62014373|NCT02956629|EXPERIMENTAL|HCV GT2|Male and female participants with HCV GT2 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
62014374|NCT02956629|EXPERIMENTAL|HCV GT3|Male and female participants with HCV GT3 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
62014375|NCT02956629|EXPERIMENTAL|HCV GT4|Male and female participants with HCV GT4 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
62014376|NCT02956629|EXPERIMENTAL|HCV GT5|Male and female participants with HCV GT5 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
62203406|NCT06465225||Patients in nursing homes or long-stay geriatrics department|
62786528|NCT03062111|ACTIVE_COMPARATOR|Transurethral Resection of Prostate|The intervention for this group that the patient will undergo endoscopic Transurethral Resection of Prostate (TURP) using bipolar cautery. The prostate is essentially shaved down using sequential cuts and cautery.
62786529|NCT01696890|ACTIVE_COMPARATOR|integrated care|telemonitoring-assisted follow-up with intensive collaboration between general practitioner and specialized Heart failure clinic.
62786530|NCT01696890|ACTIVE_COMPARATOR|standard care|telemonitoring- assisted follow-up with usual care by general practitioner, without supervision of heart failure clinic
62786531|NCT04247295|EXPERIMENTAL|Wood cast|Participants will be trialling the woodcast plaster method
62786532|NCT04247295|PLACEBO_COMPARATOR|Traditional Cast|Traditional cast used to be compared to.
62014377|NCT02956629|EXPERIMENTAL|HCV GT6|Male and female participants with HCV GT6 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
62014378|NCT03950492|EXPERIMENTAL|OUD DBS|This is a single arm study. Participants will be followed in an inpatient service for two weeks to gather baseline data followed by DBS placement and up to 6 weeks inpatient for clinical stabilization and DBS titration. All participants will then be followed twice a week for 12 weeks in the outpatient setting and then once a week for a total of 52 weeks post-titration.
62014379|NCT02635438|EXPERIMENTAL|Arm A|Test Product: Clotrimazole troche/ lozenges USP, 10 mg (Unique Pharmaceutical Laboratories, India) 10mg troche 5 times a day for 14 consecutive days
62203407|NCT00712972||1|"Patients enrolled in this study are those whom present to our institution for elective knee arthroscopy. All patients scheduled to receive a knee arthroscopy scheduled through the office of Dr. Harold Battenfield will be asked to participate in the study on the day of their procedure as long as they do not fall into one of the exclusion criteria categories.~Patients will not be allowed to participate in this study if they have an allergy to iodine or shell fish, if they have a knee effusion diagnosed clinically on the day of surgery, if the knee or surrounding tissues display cellulitis or other signs of infection, or if the patient has had a traumatic accident to their knee which significantly changes its anatomical relationships"
62203408|NCT02490033|OTHER|Contact force unblinded|
62203409|NCT02490033|OTHER|Contact force blinded|
62203410|NCT02490033|OTHER|ECI unblinded|
62203411|NCT02490033|OTHER|ECI blinded|
62203412|NCT02038387|EXPERIMENTAL|Diet|
62786533|NCT02243735|ACTIVE_COMPARATOR|Ferrous fumarate|Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery
62014380|NCT02635438|ACTIVE_COMPARATOR|Arm B|Reference Product: Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) troche 5 times a day for 14 consecutive days
62203413|NCT03004001|EXPERIMENTAL|Alirocumab and atorvastatin|Alirocumab 150 mg bi-weekly and atorvastatin 20 mg/d
62203414|NCT03004001|PLACEBO_COMPARATOR|Alirocumab placebo and atorvastatin|Alirocumab placebo biweekly and atorvastatin 20 mg/d
62203415|NCT03520738|OTHER|Chronic Kidney Disease|"Blood and urinary samples on the following patients:~10 Stage 1 and 2 CKD patients 10 patients 6 weeks after graft 10 patients on maintenance dialysis."
62203416|NCT03520738|OTHER|Pseudoxanthoma elasticum (PXE)|"Blood and urinary samples on the following patients:~10 patients with pseudoxanthoma elasticum (PXE) with low PPi levels and vascular calcifications and patients with hypophosphatasia (HPP) with high PPi levels and bone decalcification."
62203417|NCT03520738|OTHER|Hypophosphatasia (HPP)|"Blood and urinary samples on the following patients:~4 patients with hypophosphatasia (HPP) with high PPi levels and bone decalcification."
62203418|NCT04797052|EXPERIMENTAL|Post operative patients|Post operative patient in orthopedic and digestive surgery
62203419|NCT01173965|ACTIVE_COMPARATOR|Endometrial ablation with microwaves|Endometrial ablation with the use of MEA(microwaves endometrial ablation device)
62203420|NCT01173965|ACTIVE_COMPARATOR|Endometrial ablation with bipolar diathermy|Endometrial ablation with Novasure(bipolar impedence control system)
62203421|NCT03524196|EXPERIMENTAL|MYLO|"Manage Your Life Online (MYLO) is accessed online using a username and password. Client's type into the MYLO conversation box about a problem they are currently experiencing. MYLO operates by analysing the client's input of text for key terms and themes. It responds with questions about the problem aimed at encouraging higher level awareness.~Participants will decide how often to use the MYLO programme over a two week period. This is likely to be a reasonable length of time to allow at least one use of the programme with no upper limit on usage."
62203422|NCT05568953|EXPERIMENTAL|Arm 1 (JE-YF17D vaccine followed by YF17D vaccine)|28 subjects will receive one dose of the JE-YF17D vaccine (Imojev, Sanofi Pasteur, 0.5mls (4.0 - 5.8 log plaque forming units \[PFU\])) on Day 0 followed by one dose of the YF17D vaccine (Stamaril, Sanofi Pasteur, 0.5mls (3 - 4 log PFU) ) on Day 28.
62203423|NCT05568953|EXPERIMENTAL|Arm 2 (YF17D vaccine followed by JE-YF17D vaccine)|28 subjects will receive one dose of the YF17D vaccine (Stamaril, Sanofi Pasteur, 0.5mls (3 - 4 log PFU)) on Day 0 followed by one dose of the JE-YF17D vaccine (Imojev, Sanofi Pasteur, 0.5mls (4.0 - 5.8 log plaque forming units \[PFU\]) on Day 28.
62203424|NCT05568953|EXPERIMENTAL|Arm 3 (Inactivated JE vaccine followed by YF17D vaccine)|14 subjects will receive one dose of the inactivated JE vaccine (Ixiaro, Valneva, 0.5mls) on Day 0 followed by one dose of the YF17D vaccine (Stamaril, Sanofi Pasteur, 0.5mls (3 - 4 log PFU)) on Day 28.
62203425|NCT03514329|EXPERIMENTAL|Vapor Ablation|Patients treated with Bronchoscopic Thermal Vapor Ablation for lung cancer
62203426|NCT04498364|EXPERIMENTAL|Habit Reversal Training|Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics. It will be delivered over 8 hours of treatment.
62203427|NCT03934177|EXPERIMENTAL|Blueberry powder|4 weeks of supplementation of 24 g whole blueberry powder
62203428|NCT03934177|PLACEBO_COMPARATOR|Placebo powder|4 weeks of supplementation of 24 g placebo powder (maltodextrin)
62203429|NCT01495598|EXPERIMENTAL|Phase 1 Pomalidomide 5mg Daily|Up to six subjects will initially be treated with for 21 days of a 28 day cycle
62203430|NCT01495598|EXPERIMENTAL|Phase 2 Pomalidomide 5mg Daily|15 human immunodeficiency virus (HIV) positive and 10 HIV negative subjects evaluable for response will be treated with Pomalidomide 5mg daily for 21 days of a 28 day cycle
62203431|NCT03609892|EXPERIMENTAL|berberine plus amoxicillin quadruple therapy|Berberine 500mg three time daily for 14days, amoxicillin 1000 mg, esomeprazole 20 mg, and Bismuth 200mg by mouth, twice daily for 14 days.
62203432|NCT03609892|ACTIVE_COMPARATOR|tetracycline plus furazolidone quadruple therapy|Tetracycline 500mg three time daily for 14days，furazolidone 100 mg, esomeprazole 20 mg, and Bismuth 200mg by mouth, twice daily for 14 days.
62203433|NCT01593787|EXPERIMENTAL|LCZ696 100 mg|All participants were started on LCZ696 100 mg once daily on day 1.
62203434|NCT01593787|EXPERIMENTAL|LCZ696 200 mg|All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP \<80 mmHg and msSBP \<130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.
62203435|NCT01593787|EXPERIMENTAL|LCZ696 400 mg|All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP \<80 mmHg and msSBP \<130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.
62203436|NCT03859063|EXPERIMENTAL|Intervention|Regular follow up by a community based stroke coordinator
62203437|NCT03859063|ACTIVE_COMPARATOR|Control|Usual care
62203438|NCT04400487|EXPERIMENTAL|Voxelotor|Participants will receive voxelotor at 1500 mg
62203439|NCT06267144||immunotherapy and chemotherapy|Participants received two to three cycles of neoadjuvant chemoimmunotherapy before surgery. Adjuvant chemotherapy was also administered for 2-3 cycles after surgery. In addition, MRD was detected within 30 days before surgery, 1 week after surgery, 1 month ±7days after surgery, 6 months after surgery.
62014381|NCT05412550|EXPERIMENTAL|Exercise self-management|The EXP intervention will integrate conventional telehealth care with exercise self-management training and include structured 1:1 sessions (six) with an interventionist, peer group sessions (six), real-time step count feedback throughout the 18 months using a wrist-worn Fitbit with an LED interface, and tailored messaging with text messages designed using six key behavior-change techniques promoting exercise self-management.
62014382|NCT05412550|ACTIVE_COMPARATOR|Attention control|The CTL intervention will incorporate the annual multidisciplinary team telehealth sessions, 12 attention-control telehealth sessions (six individual, six peer-group), and general health education text message prompts to match the timing and duration of the EXP group.
62014383|NCT00533949|ACTIVE_COMPARATOR|60 Gy RT|60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
62203440|NCT04109781|OTHER|Patients with Lumbar disc herniation|Patients with lumbar disc herniation with no response to conservative treatment and were treated with Microdiscectomy
62203441|NCT00644163|EXPERIMENTAL|1|Participants will receive Eban HIV/STD Risk Reduction Intervention.
62203442|NCT00644163|ACTIVE_COMPARATOR|2|Participants will receive Eban Health Promotion Intervention.
62203443|NCT03981848||Relapse|Relapse of tumor within two years after liver transplantation
62786534|NCT02243735|ACTIVE_COMPARATOR|ferric(III)carboxymaltose|Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
62203444|NCT03981848||Non-relapse|Non-relapse of tumor within two years after liver transplantation
62014384|NCT00533949|EXPERIMENTAL|74 Gy RT|74 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
62014385|NCT00533949|EXPERIMENTAL|60 Gy RT + Cetuximab|60 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin
62014386|NCT00533949|EXPERIMENTAL|74 Gy RT + Cetuximab|74 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin
62014387|NCT03617679|ACTIVE_COMPARATOR|Active Ingredient|1:1 Randomization. Participants in this arm receive the active ingredient medication.
62203445|NCT02037477|EXPERIMENTAL|Sequence A (Cohort 1): Vonoprazan + Esomeprazole|Vonoprazan (TAK-438) 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then esomeprazole 20 mg, orally, once daily for 7 days.
62403487|NCT02992782|EXPERIMENTAL|Exercise and Compression Garment|Intervention will include having participants wear a compression sleeve during exercise. They will wear the sleeve while carrying out the decongestive progressive resistance exercise program and will continue wearing their day-time compression garment for at least 12 hours per day, each day of the week. They will attend a supervised decongestive progressive resistance exercise program twice a week for 12 weeks at the Cancer Rehabilitation Clinic in Corbett Hall at the University of Alberta. Exercise session will take approximately 60-90 minutes. After 12 Weeks, participants will continue the same program twice weekly for an additional 12 weeks in a community-based fitness center or at home.
62579890|NCT02004574|EXPERIMENTAL|Weekends treatment|Group 3: Weekends treatment (twice weekly) Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel) once daily at weekends (on Saturdays and Sundays)
62579891|NCT04941625||non-AKI|patients do not have post-HIPEC AKI
62579892|NCT04941625||AKI|patients have post-HIPEC AKI
62579893|NCT04382755|ACTIVE_COMPARATOR|Group A (active)|Standard of Care (SoC) + subcutaneous Zilucoplan® + prophylactic antibiotics until 14 days after last Zilucoplan®
62579894|NCT04382755|PLACEBO_COMPARATOR|Group B (control)|Standard of Care (SoC) + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)
62014388|NCT03617679|PLACEBO_COMPARATOR|Placebo|1:1 Randomization. Participants in this arm receive the placebo medication. (Placebos do not contain active ingredients).
62203446|NCT02037477|EXPERIMENTAL|Sequence B (Cohort 1): Esomeprazole + Vonoprazan|Esomeprazole 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.
62203447|NCT02037477|EXPERIMENTAL|Sequence C (Cohort 2): Vonoprazan + Rabeprazole Sodium|Vonoprazan 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then Rabeprazole sodium 10 mg, orally, once daily for 7 days.
62203448|NCT02037477|EXPERIMENTAL|Sequence D (Cohort 2): Rabeprazole Sodium + Vonoprazan|Rabeprazole sodium 10 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.
62203449|NCT01406470|EXPERIMENTAL|IVIG-SN™|Immune Globulin Intravenous (Human) 5% Liquid
62579895|NCT00457002|EXPERIMENTAL|Arm 1|"While hospitalized, Apixaban plus Placebo~Apixaban (Tablets, Oral, 2.5 mg), Placebo (Syringes, SC)~After hospital discharge, Apixaban~Apixaban (Tablets, Oral, 2.5 mg)"
62579896|NCT00457002|ACTIVE_COMPARATOR|Arm 2|"While hospitalized, Enoxaparin plus Placebo~Enoxaparin (Syringes, SC, 40 mg), Placebo (Tablets, Oral)~After hospital discharge: Placebo~Placebo (Tablets, Oral)"
62579897|NCT06575946|OTHER|Vestibular Hypofunction Group|
62579898|NCT06685588|ACTIVE_COMPARATOR|Calcipotriol / Dovonex|Randomised to PDT pre-treatment with calcipotriol
62579899|NCT06685588|ACTIVE_COMPARATOR|Calcipotriol /Dovonex|Calcipotriol pre-treatment prior to PDT
62579900|NCT03376646|EXPERIMENTAL|Cohort A: Dissolve™|
62579901|NCT03376646|ACTIVE_COMPARATOR|Cohort A: Resolute™ Integrity|
62579902|NCT03376646|EXPERIMENTAL|Cohort B: Dissolve™-2.00mm|Cohort B is single arm.
62579903|NCT05432791|EXPERIMENTAL|Arm 1 (olaparib, temozolomide)|Patients receive temozolomide PO QD on days 1-7 of each cycle and olaparib PO BID on days 1-7 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI and/or bone scans throughout the trial. Patients also undergo collection of blood samples throughout the trial.
62786535|NCT06153368|EXPERIMENTAL|Cadonilimab|Drug：Cadonilimab 6 mg/kg，IVD，D1，Q2W Drug：mFOLFIRINOX mFOLFIRINOX（Oxaliplatin 85 mg/m2 IV over 4 hours ; Irinotecan 150 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion.） on days 2 of a 14-day cycle.
62403488|NCT02992782|EXPERIMENTAL|Exercise and Adjustable Compression Wrap|Intervention will include having participants will be fitted for an adjustable compression wrap. They will be required to wear the adjustable compression wrap during the decongestive progressive resistance exercise program and will continue wearing their compression sleeve at least 12 hours per day, each day of the week. They will attend a supervised decongestive progressive resistance exercise program twice a week for 12 weeks at the Cancer Rehabilitation Clinic in Corbett Hall at the University of Alberta. Exercise session will take approximately 60-90 minutes. After 12 weeks, participants will continue the same program twice weekly for an additional 12 weeks in a community-based fitness centre or at home.
62403489|NCT05665946||AIN patients|Surgical verified AIN patients. A blood sample is drawn just after inclusion and stored for later analysis.
62403490|NCT05665946||Controls.|Non-AIN patients. A blood sample is drawn just after inclusion and stored for later analysis.
62579904|NCT05432791|ACTIVE_COMPARATOR|Arm 2 (trabectedin, pazopanib)|Patients receive trabectedin IV continuously over 24 hours on day 1 of each cycle or pazopanib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI and/or bone scans throughout the trial. Patients also undergo TTE or MUGA on study and as clinically indicated, as well as collection of blood samples throughout the trial.
62579905|NCT02211482|OTHER|Dolutegravir , lamivudine|Dolutegravir 50 mg QD plus lamivudine 300 mg QD
62579906|NCT01816711||Hip fracture, Frail elderly, Non-supplemented|Frail elderly with a hip fracture who did not received vitamin D supplementation
62579907|NCT01816711||Hip fracture, Frail elderly, Supplemented|Frail elderly with a hip fracture who received vitamin D supplementation
62579908|NCT04783623||Non-recurrence group|
62579909|NCT04783623||Recurrence group|
62579910|NCT04959981|EXPERIMENTAL|Dose Escalation (Part 1): ERAS-007 plus osimertinib|ERAS-007 will be orally administered in combination with osimertinib to study participants with EGFRm NSCLC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
62579911|NCT04959981|EXPERIMENTAL|Dose Escalation (Part 2): ERAS-007 plus sotorasib|ERAS-007 will be orally administered in combination with sotorasib to study participants with KRAS G12Cm NSCLC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
62203450|NCT03969680|EXPERIMENTAL|BMSCs plus PRP group|Three intra-articular injections in total and autologous bone marrow-derived mesenchymal stem cells (BMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
62403491|NCT06604806|ACTIVE_COMPARATOR|opioid consumption|opioid consumption of the patients in patient controlled analgesia device
62014389|NCT05383846|EXPERIMENTAL|Experimental: Narrative Exposure Therapy|This is a multiple baseline single case series design which focuses on assessing the posited exposure and autobiographical memory integration components of Narrative Exposure Therapy; no comparator will be included.
62203451|NCT03969680|ACTIVE_COMPARATOR|PRP group|Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
62403492|NCT06604806|ACTIVE_COMPARATOR|Visual Analogue Scale scores of the patients|Visual Analogue Scale scores of the patients
62403493|NCT06539845|EXPERIMENTAL|Intervention|Randomly selected Orang Asli villages will receive the intervention package along with educational brochures, through a workshop they will need to participate in once.
62403494|NCT06539845|ACTIVE_COMPARATOR|Control|Randomly selected Orang Asli villages that will receive the educational brochures only.
62403495|NCT03728166|EXPERIMENTAL|Alert|"On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis."
62403496|NCT03728166|NO_INTERVENTION|No Alert|No notification to the provider.
62403497|NCT04640168|EXPERIMENTAL|Remdesivir plus Baricitinib|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
62579912|NCT04959981|EXPERIMENTAL|Dose Escalation (Part 3): ERAS-601 plus sotorasib|ERAS-601 will be orally administered in combination with sotorasib to study participants with KRAS G12Cm NSCLC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
62579913|NCT04959981|EXPERIMENTAL|Dose Expansion (Part 4): ERAS-007 plus osimertinib|ERAS-007 will be orally administered at the recommended dose (as determined from Part 1) in combination with osimertinib to study participants with EGFRm NSCLC.
62579914|NCT04959981|EXPERIMENTAL|Dose Expansion (Part 5): ERAS-007 plus sotorasib|ERAS-007 will be orally administered at the recommended dose (as determined from Part 2) in combination with sotorasib to study participants with KRAS G12Cm NSCLC.
62579915|NCT04959981|EXPERIMENTAL|Dose Expansion (Part 6): ERAS-601 plus sotorasib|ERAS-601 will be orally administered at the recommended dose (as determined from Part 3) in combination with sotorasib to study participants with KRAS G12Cm NSCLC.
62579916|NCT03040804|EXPERIMENTAL|Low Dose Radiotherapy|Patients will receive skin-directed radiotherapy, using a total prescription dose of 7.5 gy in five fractions of 1.5 gy over one week
62579917|NCT05429281|ACTIVE_COMPARATOR|Pilates-based Core Strengthening Group|Participants in this group performed eight PsCS exercises geared predominantly to the core muscles.
62579918|NCT05429281|ACTIVE_COMPARATOR|Plyometric-based Muscle Loading Group|Participants in this group performed 10 PlyoML exercises primarily focused on the lower body.
62014390|NCT04132947||Cohort|Cohort Study correlating self reported exercise activity and spiroergometry results
62203452|NCT00658905|ACTIVE_COMPARATOR|rhBSSL|
62203453|NCT00658905|PLACEBO_COMPARATOR|Placebo|
62203454|NCT01383655|EXPERIMENTAL|Magnesium|i.v. magnesium infusion 40mg/kg in 20 min
62579919|NCT05429281|EXPERIMENTAL|Combined training group|Participants in this group performed the same exercises as the PsCS and PlyoML groups, although with half the number of sets/repetitions.
62014391|NCT04666649|EXPERIMENTAL|Cohort 400mg of Venetoclax, 500 IU/m ² of Pegcrisantaspase|The subject will take 400mg of Venetoclax every day as a pill by mouth and a dose of 500 IU/m ² of Pegcrisantaspase in an IV every 14 days ( per cycle)
62203455|NCT01383655|PLACEBO_COMPARATOR|Placebo|i.v. 0.9 % NaCl
62203456|NCT00490152||1|Participants use Vivagel™, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
62203457|NCT00490152||2|Participants use VivaGel™ Placebo, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
62203458|NCT00490152||3|Participants use HEC Placebo Gel (HEC Gel), applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
62203459|NCT03420248|EXPERIMENTAL|Non-spherical polyvinyl alcohol particle|For embolic material, non-spherical polyvinyl alcohol particle is used.
62203460|NCT03420248|EXPERIMENTAL|Tris-acryl gelatin microsphere|For embolic material, Tris-acryl gelatin microsphere is used.
62203461|NCT04697940|EXPERIMENTAL|Refractory or Relapsed Non-Hodgkin's Lymphoma|"A conditioning chemotherapy regimen of fludarabine and cyclophosphamide (FC regimen) will be administered followed by investigational treatment, autologous decitabine-primed Tandem CAR19/20 engineered T cells.~Post leukapheresis, administration of short half-life chemo-agents, Bruton tyrosine kinase inhibitor (BTKi) and/or dexamethasone should be considered to bridge the following FC regimen in patients with bulky tumor burden, rapidly aggressive progression, and/or indications of imperious symptom control."
62203462|NCT03913572||REVOLVE|Patients that have agreed to be prospectively enrolled in the study and undergo Injection of adipose-derived stem cells into perianal fistula with the REVOLVE system
62203463|NCT03913572||Retrospective cohort|Patients that have undergone treatment of perianal disease without use of adipose-derived stem cell injection.
62203464|NCT05050825|EXPERIMENTAL|CDSA strategy|Children and adolescents presenting with non-severe acute febrile illness or diarrhea managed by healthcare workers trained on the CDSA strategy
62203465|NCT05050825|NO_INTERVENTION|Routine practice|Children and adolescents presenting with non-severe acute febrile illness or diarrhea managed by healthcare workers according to routine practice at the health facility
62203466|NCT03020459|EXPERIMENTAL|peeling-reposition|"After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany) with the help of Constellation 23-gauge vitrectomy system (Alcon Laboratories Inc, Fort Worth, TX), the intervention of peeling-reposition was used to peel and unfold the ILM. And the postoperative posture would be prone position in two weeks for all patients after the operation."
62203467|NCT03020459|ACTIVE_COMPARATOR|peeling|"After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany) with the help of Constellation 23-gauge vitrectomy system, the intervention of peeling was used to grasped ILM with end-gripping forceps. And the postoperative posture would be prone position in two weeks for all patients after the operation."
62203468|NCT03599102|EXPERIMENTAL|LOVED intervention|Intervention group receives the LOVED program, an 8-week program where participants receive video education modules, and weekly video chat sessions with other end-stage renal disease patients and a prior living kidney African American recipient. The program aims to increase knowledge and skills on how to promote individual strategies on how to ask for a kidney from others.
62203469|NCT03599102|NO_INTERVENTION|Standard Care|Standard interaction with transplant center and physician care.
62203470|NCT01122303||SJS|Stevens-Johnson syndrome patients with dry eye
62579920|NCT06123221|EXPERIMENTAL|Osseodensification|Sinus floor elevation with osseodensification and concomitant implant installation
62203471|NCT01122303||Control|Non-autoimmune dry eye patients
62203472|NCT02018653|EXPERIMENTAL|Calcium Alumina-Silicate (CASAD)|CASAD 1 gram orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.
62203473|NCT02018653|PLACEBO_COMPARATOR|Placebo|Placebo orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.
62203474|NCT05104489|EXPERIMENTAL|Low Dose|50 mcg of antigen with 250 mcg of Al(OH)3
62203475|NCT05104489|EXPERIMENTAL|Median Dose|100 mcg of antigen with 250 mcg of Al(OH)3
62203476|NCT05104489|EXPERIMENTAL|High Dose|100 mcg of antigen with 500 mcg of Al(OH)3
62203477|NCT05104489|PLACEBO_COMPARATOR|Placebo|250 mcg of Al(OH)3
62203478|NCT04239131|OTHER|All Patients|It is a single arm study. Skin prick testing and laboratory Tests are carried out on all patients in the same way
62203479|NCT02259023|EXPERIMENTAL|Liquid: Sugar sweetened beverage consumption|Consumption of sugar-sweetened beverages
62203480|NCT02259023|EXPERIMENTAL|Solid: Grain based desserts and candy consumption|Consumption of grain based desserts and/or candy
62203481|NCT00599573|EXPERIMENTAL|1|Ondansetron
62203482|NCT03553108|EXPERIMENTAL|Olaparib Treatment Sequence ABCD|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~A - Olaparib Tablet 25 mg B - Olaparib Tablet 100 mg C - Olaparib Tablet 150 mg D - Olaparib Tablet 250 mg"
62203483|NCT03553108|EXPERIMENTAL|Olaparib Treatment Sequence BDAC|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~B - Olaparib Tablet 100 mg D - Olaparib Tablet 250 mg A - Olaparib Tablet 25 mg C - Olaparib Tablet 150 mg"
62579921|NCT06123221|ACTIVE_COMPARATOR|Lateral window|Sinus floor elevation with lateral window and concomitant implant installation
62579922|NCT02915757|EXPERIMENTAL|Depressive patients|EDOR test on depressed patients with or without personal history of suicidal behavior
61978438|NCT04609787|EXPERIMENTAL|All participants|Quantitative sensory testing will be completed and current pain levels obtained. 20-minutes of immersive virtual reality will be completed, and then complete quantitative sensory testing again. We will compare pre-IVR quantitative sensory testing with post IVR levels.
62579923|NCT05055284|EXPERIMENTAL|Experimental group|Experimental: Participants in this group will receive electromyography biofeedback (EMG-BF) guided strength training along with patellar taping
62579924|NCT05055284|SHAM_COMPARATOR|Control group|No Intervention: Control: Participants in this group will receive Sham EMG-BF guided strength training without patellar taping
62203484|NCT03553108|EXPERIMENTAL|Olaparib Treatment Sequence CADB|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~C - Olaparib Tablet 150 mg A - Olaparib Tablet 25 mg D - Olaparib Tablet 250 mg B - Olaparib Tablet 100 mg"
62203485|NCT03553108|EXPERIMENTAL|Olaparib Treatment Sequence DCBA|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~D - Olaparib Tablet 250 mg C - Olaparib Tablet 150 mg B - Olaparib Tablet 100 mg A - Olaparib Tablet 25 mg"
62579925|NCT00505492|EXPERIMENTAL|Radiation + Chemotherapy|Radiation with weekly Cisplatin 40 mg/m\^2 intravenously (IV) Followed by Carboplatin (AUC 5 IV)/Paclitaxel (135 mg/m\^2 IV) Chemotherapy every 28 days
62203486|NCT05432336||Complex ocular infections (COI)|All patients with an COI (endophtalmitis or hospitalized keratitis)
62203487|NCT05106777|EXPERIMENTAL|Surufatinib|Drug: Surufatinib Surufatinib will be given orally.
62203488|NCT03560024|ACTIVE_COMPARATOR|PACAP27|12 healthy volunteers will receive PACAP27 (10 picomole/kg/min) over 20 min
62203489|NCT03560024|PLACEBO_COMPARATOR|Placebo|6 healthy volunteers will receive placebo (Saline) over 20 min
62203490|NCT04655027|EXPERIMENTAL|Roxadustat|Patients will receive oral dose of roxadustat three times a week (TIW) for 2- weeks during treatment period.
62203491|NCT04655027|ACTIVE_COMPARATOR|rHuEPO|Patients will receive uniform brand of short acting intravenous or subcutaneous dose of rHuEPO two times a week (BIW) or TIW based upon their previous dose of rHuEPO for 2- weeks during treatment period.
62203492|NCT05624905||PCI group|All consecutive patients with coronary artery disease who underwent percutaneous coronary intervention
62203493|NCT05867277|EXPERIMENTAL|music|"Support was received from the Turkish Music Research and Promotion Group (TÜMATA) in choosing the music. To increase attention before and during the PIVC catheter placement skill practice in the intervention group, Acemaşiran music was played, which increases the sense of concentration and creativity. To reduce anxiety, Pentatonic melodies were played, which gave self-confidence and determination. The music was played from a computer in the vocational skills laboratory using a loudspeaker. During the entire skill practice, the students continued to listen to the music in a light tone."
62203494|NCT05867277|NO_INTERVENTION|control|The students in the control group were given standard skills laboratory training without any intervention
62203495|NCT04628156||Outpatients in Cerebral Palsy Greece - Open Door|Outpatients with a diagnosis of cerebral palsy
62203496|NCT04678505|EXPERIMENTAL|Panel A: Mild Renal Impairment|Participants with mild renal impairment will receive a single dose of 100 mg MK-3402 via intravenous (IV) infusion on Day 1.
62579926|NCT05804422|ACTIVE_COMPARATOR|Probiotic lysate (postbiotic and metabiotc) group|oral, 2 capsules per day (BID) for 3 month treatment
62579927|NCT05804422|PLACEBO_COMPARATOR|Placebo group|placebo, oral, 2 capsules per day (BID) for 3 month treatment
62579928|NCT06573606||HA-CS|Diabetic subjects affected by dry eye disease are treated with the new ophthalmic solution containing cross-linked hyaluronic acid (CX-HA) and Chondroitin sulphate (CS).
62579929|NCT06683365|EXPERIMENTAL|Nerve Graft Recipients|
62579930|NCT06683365|PLACEBO_COMPARATOR|Placebo Group|
62579931|NCT05025644|EXPERIMENTAL|Preoperative Transesophageal Echocardiogram (TEE) PG under anesthesia <50mmHg (Group A)|"* Pre-cardiopulmonary bypass (CPB) (pre-myectomy) echocardiographic parameters: PG under DBT stress test at 5, 10, 15 and 20 mcg/kg/min or until a PG ≥ 50mmHg is achieved, will be recorded.~* Post-CPB (post-myectomy) echocardiographic parameters: PG at DBT peak dose (DBT-pd) will be recorded.~If LVOT PG post myectomy are \>16 mmHg, the surgeon will be advised, for surgical management considerations."
62014392|NCT04666649|EXPERIMENTAL|Cohort 400mg of Venetoclax, 750 IU/m ² of Pegcrisantaspase|The subject will take 400mg of Venetoclax every day as a pill by mouth and a dose of 750 IU/m ² of Pegcrisantaspase in an IV every 14 days ( per cycle)
62014393|NCT04666649|EXPERIMENTAL|Cohort 400mg of Venetoclax, 1000 IU/m² of Pegcrisantaspase|The subject will take 400mg of Venetoclax every day as a pill by mouth and a dose of 1000 IU/m² of Pegcrisantaspase in an IV every 14 days ( per cycle)
62014394|NCT04666649|EXPERIMENTAL|Cohort 600mg Venetoclax, 1000 IU/m ² of Pegcrisantaspase|The subject will take 600mg of Venetoclax every day as a pill by mouth and a dose of 1000 IU/m ² of Pegcrisantaspase in an IV every 14 days ( Per cycle)
62014395|NCT04498897|ACTIVE_COMPARATOR|Test group|Vortioxetine + Acamprosate
62014396|NCT04498897|PLACEBO_COMPARATOR|Placebo Group|Placebo + Acamprosate
62014397|NCT01259661|EXPERIMENTAL|Experimental Group|
62014398|NCT01259661|ACTIVE_COMPARATOR|Control Group|
62014399|NCT05634681|EXPERIMENTAL|Intervention arm|
62014400|NCT05634681|ACTIVE_COMPARATOR|Control arm|
62014401|NCT06168175|EXPERIMENTAL|Lactate|
62014402|NCT06168175|PLACEBO_COMPARATOR|Placebo|
62014403|NCT05838222|EXPERIMENTAL|Intervention Group|The intervention group will receive 3 sessions of SFBT from a licensed therapist in addition to treatment as usual
62014404|NCT05838222|ACTIVE_COMPARATOR|Control|This group will be the treatment as usual group who will receive primary care treatment without the SFBT intervention
62403498|NCT04640168|EXPERIMENTAL|Remdesivir plus Dexamethasone|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
62403499|NCT03517657|EXPERIMENTAL|Bilateral motor priming + Task specific training (BMP + TST)|A combination of bilateral motor priming (BMP) plus task specific training (TST) for 30 hours over 5 weeks.
62403500|NCT03517657|ACTIVE_COMPARATOR|Control Priming + TST (CP + TST)|The control priming is transcutaneous electric stimulation (TENS) set at a low threshold followed by the same task specific training protocol for 30 hours over 5 weeks.
62403501|NCT03230331||STN DBS|Parkinson's disease (PD) patients who underwent deep brain stimulation (DBS) of the subthalamic nucleus (STN)
62403502|NCT03230331||CONTROL|Parkinson's disease (PD) patients received optimized medical treatment according to published evidence based guidelines
62203497|NCT04678505|EXPERIMENTAL|Panel B: Moderate Renal Impairment|Participants with moderate renal impairment will receive a single dose of 100 mg MK-3402 via IV infusion on Day 1.
62203498|NCT04678505|EXPERIMENTAL|Panel C: Severe Renal Impairment|Participants with severe renal impairment will receive a single dose of 100 mg MK-3402 via IV infusion on Day 1.
62203499|NCT04678505|EXPERIMENTAL|Panel D: Healthy Participants|Healthy matched control participants will receive a single dose of 100 mg MK-3402 via IV infusion on Day 1.
62579932|NCT05025644|EXPERIMENTAL|Preoperative PG under anesthesia ≥ 50mmHg (Group B)|"* Pre-cardiopulmonary bypass (CPB) (pre-myectomy) echocardiographic parameters: PG without DBT stress test will be recorded.~* Post-CPB (post-myectomy) echocardiographic parameters: PG at 5, 10, 15, 20 mcg/kg/min DBT stress test or until the postoperative provocable PG is \>16 mmHg will be recorded."
62203500|NCT04678505|EXPERIMENTAL|Panel E: End-Stage Renal Disease (ESRD) Undergoing Hemodialysis|Participants with ESRD undergoing HD will receive a single dose of 100 mg MK-3402 via IV infusion after HD on Day 1 of Period 1 and before HD on Day 1 of Period 2. There will be at least a 6-day washout period before dosing in Period 2.
62203501|NCT01214642|EXPERIMENTAL|LY2523355 Days 1, 5, 9|LY2523355 administered intravenously on Days 1, 5 and 9, starting dose is 2 milligrams per meter squared (mg/m\^2) for 2 planned 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
62203502|NCT01214642|EXPERIMENTAL|LY2523355 Days 1, 8|LY2523355 administered intravenously on Days 1 and 8, starting dose is 8 mg/m\^2 for 2 planned 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
62203503|NCT01214642|EXPERIMENTAL|LY2523355 Days 1, 5 + pegfilgrastim|LY2523355 administered intravenously on Days 1 and 5, starting dose is 8 mg/m\^2 for 2 planned 21-day cycles and 6 mg pegfilgrastim administered subcutaneously on Day 6 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
62579933|NCT03686228|ACTIVE_COMPARATOR|PB-MNC therapy|The patientsin PB-MNC therapy group will be injected with G-CSF mobilized PB-MNC into calf or thigh muscle of ischemic limb and Aspirin 81 mg/day and supportive treatment including wound care and pain killer drug.
62579934|NCT03686228|ACTIVE_COMPARATOR|No PB-MNC therapy|In patients in No PB-MNC therapy, they will receive aspirin 81 mg/day and supportive treatment including wound care and pain killer drug.
62579935|NCT05209464|EXPERIMENTAL|Tele-Tai Chi|Study participants will follow a 12-week simplified Tele-Tai-Chi (TC) program delivered via a mobile application.
62579936|NCT02169141||PK of Levofloxacin-Capreomycin|Pharmacokinetics (PK) in M/XDR-TB patients receiving at least Levofloxacin and Capreomycin as part of their WHO treatment for M/XDR-TB
62203504|NCT01214642|EXPERIMENTAL|LY2523355 Days 1, 4 + pegfilgrastim|LY2523355 administered on Days 1 and 4, starting dose is 12 mg/m\^2 for 2 planned 21-day cycles and 6 mg pegfilgrastim administered subcutaneously on Day 5 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
62403503|NCT02405624|EXPERIMENTAL|CPAP training|Patients will be instructed and follow the continuous positive airway pressure (CPAP) training procedure
62403504|NCT03246152|EXPERIMENTAL|Bevacizumab group|Monthly intravitreal injection of 2.5 mg of Bevacizumab for at least 3 consecutive months. This is followed by treat and extend regimen after resolution of macular edema.
62403505|NCT02489682|EXPERIMENTAL|Informed Consent Format - short written|"Intervention to be administered:~- Short-form written informed consent information, followed immediately by outcomes questionnaire"
62403506|NCT02489682|EXPERIMENTAL|Informed Consent Format - long written|"Intervention to be administered:~- Long-form written informed consent information, followed immediately by outcomes questionnaire"
62579937|NCT03749746|ACTIVE_COMPARATOR|Usual care|Participants will be counseled on routine postpartum care and will receive additional information on cardiovascular risk following preeclampsia as well as information on support groups and registries as well as online resources for lifestyle modification.
62403507|NCT02489682|EXPERIMENTAL|Informed Consent Format - video|"Intervention to be administered:~- Video informed consent information, followed immediately by outcomes questionnaire"
62403508|NCT00632866|EXPERIMENTAL|1|Active treatment : Hydroxychloroquine
62403509|NCT00632866|PLACEBO_COMPARATOR|2|Placebo
62403510|NCT04983589|PLACEBO_COMPARATOR|Vehicle|Participants received vehicle, one drop bilaterally (in each eye), twice daily (BID), with a gap of 6 hours between both doses, for up to 14 days.
62403511|NCT04983589|EXPERIMENTAL|AGN-190584|AGN-190584 ophthalmic solution, one drop bilaterally (in each eye), BID, with a gap of 6 hours between both doses, for up to 14 days.
62579938|NCT03749746|EXPERIMENTAL|Home Blood Pressure Monitoring|In addition to usual care outlined above, each participant will receive a Bluetooth-enabled blood pressure cuff along with a checklist of proper technique and instructions on use. Women will be prompted to measure their BP across the first week of each month during the intervention. Based on guidelines, participants will take their blood pressure in the morning and evening, each time taking two readings separated by one minute.
62203505|NCT04854876|EXPERIMENTAL|Vaccinated with 1st dose of COVID-19 Vaccine & treated with 5-ALA Phosphate/SFC|100 subjects that were vaccinated with the first dose of a COVID-19 Vaccine (any brand approved in Bahrain is permitted) and that will be treated with 150mg 5-ALA Phosphate/SFC for 28 days
62203506|NCT04854876|NO_INTERVENTION|Vaccinated with 1st dose of COVID-19 Vaccine|100 subjects that were vaccinated with the first dose of a COVID-19 Vaccine (any brand approved in Bahrain is permitted) only (Control)
62203507|NCT00744562|EXPERIMENTAL|Open-label OMP-21M18|
62203508|NCT04174001||Neuro group|"Patients who meet the following criteria:~* 18 years of age or younger~* diagnosed with one or more of the following neurological disorders: moyamoya disease, congenital anomalies of the brain, hypoxic-ischemic encephalopathy, brain tumor, Chiari malformation, epilepsy and stroke~* planned for any surgical procedures that require general anesthesia~* planned to receive intraoperative and/or postoperative invasive arterial blood pressure monitoring~Patients who have a surgical procedure that contraindicates the placement of a NIRS probe on the forehead or are scheduled for a cardiac procedure will be excluded."
62203509|NCT04174001||Control group|"Patients who meet the following criteria:~* 18 years of age or younger-planned for any surgical procedures that require general anesthesia~* planned postoperative invasive blood pressure monitoring~Patients who have a surgical procedure that contraindicates the placement of a NIRS probe on the forehead or have symptoms of neurological disorders will be excluded."
62203510|NCT04287699|EXPERIMENTAL|labor dance group|The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment.The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing.
62203511|NCT04287699|NO_INTERVENTION|Control group|Only routine practices were performed with the control group, and data were recorded as in the experimental groups.
62203512|NCT00878826|ACTIVE_COMPARATOR|Enoxaparin 40 mg per day|
62203513|NCT00878826|ACTIVE_COMPARATOR|Enoxaparin 1 mg per kg daily|
62203514|NCT00878826|ACTIVE_COMPARATOR|Pre prescribed regimen of Enoxaparin|Current enoxaparin dose at time of first prenatal visit.
62403512|NCT05011162|OTHER|Digital Acceptance and Commitment Therapy (ACT) Arm|Pragmatic
62403513|NCT04480554|EXPERIMENTAL|Methadone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone (MET) and antiretroviral therapy (cART).
62014405|NCT02265705|EXPERIMENTAL|Baricitinib|"4 milligrams (mg) baricitinib administered orally once a day for 52 weeks. Participants with renal impairment will receive 2 mg baricitinib orally once a day for 52 weeks.~Participants will continue to take background methotrexate (MTX) therapy throughout study. Other background therapies, including non-steroidal anti-inflammatory drugs (NSAIDs) and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline."
62579939|NCT03749746|EXPERIMENTAL|Heart Health 4 New Moms|Participants randomized to this group will receive instruction on the use of Heart Health 4 New Moms internet-based lifestyle intervention and home blood pressure monitoring. The internet-based intervention is comprised of four key components: an online curriculum with modules on healthy eating and physical activity, a self-monitoring and tracking program, a registered dietitian will act as a lifestyle coach for participants and a customized online toolbox.
62579940|NCT02137421|EXPERIMENTAL|CAD, Metabolic syndrome .|"Arm1:coronary artery disease with metabolic syndrome . Intervention:Resveratrol (3, 4´, 5 trihydroxystilbene), 50 micromolar,12hour treatment .~Each experiment repeats three times ."
62014406|NCT02265705|PLACEBO_COMPARATOR|Placebo|"Placebo administered orally once a day through week 24. At week 24, participants will be given 4 mg or 2 mg (participants with renal impairment) baricitinib orally once a day through Week 52.~Participants will continue to take background MTX therapy throughout study. Other background therapies, including NSAIDs and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline."
62203515|NCT00968825|ACTIVE_COMPARATOR|Dose D|RT001
62014407|NCT04133831|NO_INTERVENTION|Condition 1: Combined only|Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals.
62203516|NCT00968825|PLACEBO_COMPARATOR|Dose E|Placebo
62403514|NCT04480554|EXPERIMENTAL|Buprenorphine/naloxone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone and antiretroviral therapy (cART).
62403515|NCT04480554|EXPERIMENTAL|XR-Naltrexone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with monthly injection extended-release naltrexone (XR-NTX) and antiretroviral therapy (cART).
62403516|NCT02795481||Stroke patients|Adult stroke patients with suspected stroke will be recruited on admission to hospital. Recruitment will continue until 100 patients have received an MRI at 24h-72h post admission, up to a maximum recruitment threshold of 300 patients.
62403517|NCT02795481||Control patients|50 adult control patients will be recruited from the non-vascular, non-oncological surgical lists at each participating site
62579941|NCT02137421|EXPERIMENTAL|Healthy subjects .|"Arm2:healthy subjects Intervention:Resveratrol (3, 4´, 5 trihydroxystilbene), 50 micromolar,12hour treatment .~Each experiment repeats three times ."
62014408|NCT04133831|EXPERIMENTAL|Condition 2: Combined plus Total|Participants randomized to Condition 2 will view combined transplant survival and total survival outcome information when making a choice between the two hospitals.
62014409|NCT04133831|EXPERIMENTAL|Condition 3: Stratified only|Participants randomized to Condition 3 will view only stratified transplant survival outcome information when making a choice between the two hospitals.
62014410|NCT04133831|EXPERIMENTAL|Condition 4: Stratified plus Total|Participants randomized to Condition 4 will view stratified transplant survival and total survival outcome information when making a choice between the two hospitals.
62014411|NCT04133831|EXPERIMENTAL|Condition 5: Total only|Participants randomized to Condition 5 will view only total survival outcome information when making a choice between the two hospitals.
62203517|NCT04853446|PLACEBO_COMPARATOR|Placebo|Encapsulated glucosemonohydrate will be used as placebo. Two capsules containing placebo will be administered in the placebo arm.
62203518|NCT04853446|EXPERIMENTAL|Dexamethasone 12 mg|Dexamethasone tablets of 4 mg encapsulated in pairs of three. One capsule containing 12 mg dexamethasone and one capsule containing placebo will be administered in the 12mg dexamethasone arm for a total dose of 12 mg of dexamethasone.
62403518|NCT02795481||Feeding control participants|15 healthy adult members of NHS staff will be recruited to participate in the feeding control sub-study at University Hospitals Coventry and Warwickshire NHS Trust only.
62203519|NCT04853446|EXPERIMENTAL|Dexamethasone 24 mg|Dexamethasone tablets of 4 mg encapsulated in pairs of three. Two capsules containing 12 mg dexamethasone will be administered in the 25mg dexamethasone arm for a total dose of 24 mg of dexamethasone.
62203520|NCT03808142||Treatment|During a 3-months period all patients with an active myBETAapp account were invited to participate in the study (3-month invitation period=enrollment period). Patients seek more information about the study were able to access a detailed informed consent form via their app providing step-by-step background information. Those patients were wishing to participate in the study were able to provide (electronic) informed consent (ICF).
62579942|NCT00823147|EXPERIMENTAL|Pain Catastrophizing Induction Group|"Collect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest.~Catastrophizing group: 10-minute catastrophizing induction. Participants self-rate their level of emotional distress.~Subsequent blood draws occur per protocol time points:~1. 25 minutes following IV placement (BASELINE)~2. 15 minutes post catastrophizing induction (stress experiment)~3. 90 minutes (1.5 hours) post-induction~4. 150 minutes (2.5 hours) post-induction~5. 210 minutes (3.5 hours) post-induction~6. 270 minutes (4.5 hours) post-induction"
62579943|NCT00823147|NO_INTERVENTION|Control Group|"Collect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest.~Control group: Persons in this group will rest, complete puzzles, read emotionally-neutral material or watch videos provided to them.~Blood draws and saliva samples gathered per protocol time points:~1. 25 minutes following IV placement (BASELINE- T1)~2. 25 minutes following baseline T2~3. 115 minutes (1 hour 55 min) post baseline T3~4. 175 minutes (2 hours 55 min) post baseline T4~5. 235 minutes (3 hours 55 min) post baseline T5~6. 295 minutes (4 hours 55 min) post baseline T6"
62014412|NCT06456294|EXPERIMENTAL|MHC Early Outreach Intervention|Early implementation of a MHC outreach intervention program. Clinics in the early outreach intervention arm will be assigned to the MHC Direct patient outreach, where MHC staff will encourage patients to schedule an appointment with the MHC and primary care (PC) staff will be educated to encourage MHC visits.
62014413|NCT06456294|NO_INTERVENTION|MHC Delayed Outreach Intervention|Clinics in the usual care/delayed intervention arm will deliver usual care through the health plan, pharmacy and clinicians. As part of usual care, patients at these clinics can access naloxone through physician prescription or standing orders.
62203521|NCT03448770|ACTIVE_COMPARATOR|Lactulsoe|Lactulose : 20-30gm 2-3 doses per day
62203522|NCT03448770|EXPERIMENTAL|Polyethlene Glycol|PEG (Polyethlene Glycol)- 17 gm sachet 3-4 times per day
62203523|NCT05977608|EXPERIMENTAL|Group 1|Participants will be asked to participate in the reminiscence program during the first 6 weeks of the study.
62203524|NCT05977608|EXPERIMENTAL|Group 2|Participants will be asked to participate in the reminiscence program during the second 6 weeks of the study.
62215165|NCT01940224|PLACEBO_COMPARATOR|Placebo & Morphine|Administration of placebo to patients undergo laparoscopic colorectal surgery.Patients receive oral Placebo the night before surgery, and another one dose 1 hour prior to surgery.Postoperative administration of morphine via PCA pump for 48 hours
62403519|NCT02795481||Spasticity sub-group controls|10 healthy adult members of NHS staff at University Hospitals of North Midlands, will be recruited to take part as spasticity sub-study controls
62403520|NCT02795481||Traumatic brain injury patients|10 adult patients with an isolated traumatic brain injury at University Hospitals Coventry and Warwickshire NHS Trust and Imperial College Healthcare NHS Trust.
62403521|NCT03722459|EXPERIMENTAL|All participants|All participants will receive the investigational MR Fingerprinting sequence.
62579944|NCT02399436|EXPERIMENTAL|School-Based Healthy Snacking Campaign|Students who attend middle and high schools in the experimental county that participate in the healthy snacking campaign intervention.
62579945|NCT02399436|NO_INTERVENTION|Comparison Schools|Students who attend middle and high schools in the comparison county, which does not receive any intervention components.
62786536|NCT05842148||Patients undergoing oncoplastic surgery with type 1 (unilateral) techniques.|"All patients with clinical-instrumental diagnosis of breast cancer, candidates for conservative oncoplastic surgery who give informed consent to the study, will be included in the study.~Type 1 procedures generally involve a unilateral approach, able to guarantee good resective quality, without a significant alteration of the volume with respect to the contralateral breast.~Post-surgical histopathological data and any associated postsurgical complications will be collected through the compilation of a database.~Aesthetic and functional post-surgical results related to the quality of life, as data perceived by the surgeon and by the patient, will be collected through the administration of a questionnaire."
62786537|NCT05842148||Patients undergoing oncoplastic surgery with type 2 (bilateral) techniques.|"All patients with clinical-instrumental diagnosis of breast cancer, candidates for conservative oncoplastic surgery who give informed consent to the study, will be included in the study.~Type 2 procedures (therapeutic mammoplasty), offer a greater resective potential, but generally require the use of contralateral surgery to obtain symmetry, simultaneous or delayed.~Post-surgical histopathological data and any associated postsurgical complications will be collected through the compilation of a database.~Aesthetic and functional post-surgical results related to the quality of life, as data perceived by the surgeon and by the patient, will be collected through the administration of a questionnaire."
62014414|NCT06161454|EXPERIMENTAL|Population 1: Transplant Recipients|Participants who are a CHOP kidney, heart, liver or lung single or multiple transplant recipients aged 5 years or older will receive a single dose of Baloxavir.
62014415|NCT06161454|EXPERIMENTAL|Population 2: Waitlisted Patients for Transplant|Participants who are waitlisted CHOP kidney, heart, liver or lung single or multiple transplant recipients aged 5 years or older will receive a single dose of Baloxavir marboxil.
62786538|NCT04887753|EXPERIMENTAL|persons with cerebellar lesions|
62786539|NCT04887753|ACTIVE_COMPARATOR|Healthy controls|
62786540|NCT01450098|EXPERIMENTAL|Cohort A: Fixed Sequence of Meal Conditions|LY2484595 (evacetrapib): 200 milligrams (mg) of LY2484595 administered orally, one time only, as an SDSD-PG tablet given with no food. There was a washout of at least 14 days before crossing over and receiving a 200 mg of LY2484595 administered orally, one time only, as a SDSD-PG tablet given with low-fat breakfast. There was another washout period of at least 14 days before crossing over and receiving a 200 mg of LY2484595 administered orally, one time only, as a SDSD-PG tablet given with high-fat breakfast.
62786541|NCT01450098|EXPERIMENTAL|Cohort B: Comparison of Randomized Treatments|LY2484595 (evacetrapib): 100 mg of LY2484595 administered orally as an RF tablet given with a low-fat breakfast. There was a washout period of at least 14 days before crossing over and receiving 100 mg of LY2484595 administered orally as a SDSD-PG tablet given with a low-fat breakfast. There was another washout of at least 14 days before crossing over and receiving 300 mg of LY2484595 as a SDSD-PG tablet given with a low-fat breakfast.
62014416|NCT06161454|EXPERIMENTAL|Population 3: Household Members (Non-Transplant)|Non-Transplanted Household Members aged 5 years or older will receive a single dose of Baloxavir marboxil.
62014417|NCT06161454|NO_INTERVENTION|Population 4: Non-Baloxavir treatment subjects|"CHOP transplant recipients and all other non-transplanted household members who are 2-4 years of age.~Subjects 5 years and up who are Influenza positive but whom do not receive Baloxavir treatment"
62014418|NCT01461590|ACTIVE_COMPARATOR|20ml/kg of whole blood transfusion|Standard care recommended by WHO
62014419|NCT01461590|EXPERIMENTAL|30ml/kg of whole blood|Higher volume than currently recommended
62014420|NCT06160024|OTHER|Long-term care facilities|All participating facilities will be offered the same bundle of measures, with core and optional or adaptable components based on the identified needs.
62203525|NCT05985226|EXPERIMENTAL|scanning strategies|"6 experimental groups will be created based on the strategy-scan body used (1.- zigzag with conventional scan body (ZZ-SBL), 2.- circumferential with conventional scan body (C-SBL), 3.- surface blocking with scan conventional body (B-SBL), 4.- zigzag with low profile scan body (ZZ-SBL), 5.- a standard strategy with low profile scan body (STD-SBL), 6.- single pass with low profile scan body ( OP-SBL) These experimental groups will be scanned directly in the patient's mouth, to later be compared with the reference model, called the master model."
62014421|NCT01677195|ACTIVE_COMPARATOR|ACCS100 High Dose|Participants will receive a total daily dose of 3 grams of ACCS100; 1 gram three times a day with meals.
62014422|NCT01677195|ACTIVE_COMPARATOR|ACCS100 Low Dose|Participants will receive a total daily dose of 1.5 grams of ACCS100; 500 mgs three times a day with meals.
62014423|NCT01677195|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo capsules shown not to absorb mycotoxins three times a day with meals.
62014424|NCT02421991|EXPERIMENTAL|TALK study group|This is the experimental arm of the study. This includes 5 weekly sessions of experimental therapy via telephone. Therapy description withheld to protect the integrity of the study.
62403522|NCT02563366|EXPERIMENTAL|MSCs group|Patients with early poor graft function receive allogeneic BM-MSCs at the dose of 1\*10\^6/kg every week for four consecutive doses.
62579946|NCT02399436|EXPERIMENTAL|Community Cooking Classes|Adults in the intervention county who enroll in group cooking classes (single-group pretest-posttest)
62579947|NCT00527293|EXPERIMENTAL|MammoSite Brachytherapy|Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
62579948|NCT00527293|EXPERIMENTAL|3-dimensional conformal radiotherapy|3-dimensional conformal radiotherapy twice daily for 5-10 days.
62579949|NCT03468114|EXPERIMENTAL|Intervention|Participant households will receive 4 visits by health extension workers delivering intervention
62579950|NCT03468114|ACTIVE_COMPARATOR|Control|Participant households will receive 4 visits by health extension workers delivering standard care
62786542|NCT05332652|EXPERIMENTAL|Anodal tDCS stimulation to the ipsilesional M1|"Participant will receive 1 mA anodal tDCS stimulation to the ipsilesional M1 of cortical representation of the affected upper limb.~Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training."
62786543|NCT05332652|EXPERIMENTAL|Anodal tDCS to the contralesional premotor cortex|Participant will receive 1mA anodal tDCS to the contralesional premotor cortex. Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training.
62786544|NCT05332652|SHAM_COMPARATOR|Sham tDCS|"Participant will receive sham tDCS stimulation with anode placed over the scalp area corresponding to ipsilesional M1.~Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training."
62786545|NCT05332652|NO_INTERVENTION|Control group|Subjects who fulfill the inclusion criteria of Study 2 but refuse tDCS stimulation.
62014425|NCT02421991|ACTIVE_COMPARATOR|TALK control group|This is the control arm of the study. This includes 5 weekly sessions of control therapy via telephone.Therapy description withheld to protect the integrity of the study.
62014426|NCT04496609|EXPERIMENTAL|Stimulation-automated rehabilitation/automated rehabilitation|"* Stimulation and automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days~* Washout 30 days~* Automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days"
62014427|NCT04496609|EXPERIMENTAL|Automated rehabilitation/Stimulation-automated rehabilitation|"* Automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days~* Washout 30 days~* Stimulation and automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days"
62014428|NCT01300702||lung cancer surgery|Patients undergoing thoracotomy for lung cancer
62014429|NCT01871948|NO_INTERVENTION|Patient survey at 2 points in time|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later.
62014430|NCT01871948|EXPERIMENTAL|"WeWant to Know campaign, patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
62403523|NCT02563366|PLACEBO_COMPARATOR|Control group|Patients with early poor graft function receive placebo of MSCs, i.e. saline every week for four consecutive doses.
62014431|NCT06161376||multiple sclerosis|Patients diagnosed with MS requiring urodynamic assessment will be recruited during outpatient visits at Toulouse University Hospital. Initial consultations will involve questionnaire completion, 72-hour voiding diaries, and urine sample collection just before urodynamic assessments.
62203526|NCT06052709|ACTIVE_COMPARATOR|Individuals with bruxism|After the sociodemographic information of individuals is questioned, the presence and severity of temporomandibular joint disorders with the Fonseca Anamnestic Index, self-reported occupational balance with the Activity-Role Balance Questionnaire, and the individuals' stress levels with the Perceived Stress Scale will be evaluated.
62403524|NCT02945501|EXPERIMENTAL|Subjects Who Received TES SO|Participants will sleep for approximately a two hour period and receive TES SO via the NeuroConn DC Stimulator PLUS during the second hour of that two hour sleep period. They will then experience a 46 hour period of sleep deprivation, during which cognitive performance, mood and subjective and objective aspects of sleepiness will be assessed approximately every 75 minutes beginning on the night of restricted sleep/treatment.
62403525|NCT02945501|SHAM_COMPARATOR|Received SHAM (no TES SO)|Participants will sleep for approximately a two hour period and receive a SHAM (no TES SO) during the second hour of that two hour sleep period. They will then experience a 46 hour period of sleep deprivation, during which cognitive performance, mood and subjective and objective aspects of sleepiness will be assessed approximately every 75 minutes beginning on the night of restricted sleep/treatment.
62403526|NCT03911557|EXPERIMENTAL|Patients with moderate to high tumor mutational burden|Patients with recurrent or refractory disease in solid tumors naïve to anti-PD-1/PD-L1 or anti-CTLA-4 immunotherapy and have moderate to high tumor mutational burden (TMB)
62203527|NCT06052709|PLACEBO_COMPARATOR|Individuals without bruxism|After the sociodemographic information of individuals is questioned, the presence and severity of temporomandibular joint disorders with the Fonseca Anamnestic Index, self-reported occupational balance with the Activity-Role Balance Questionnaire, and the individuals' stress levels with the Perceived Stress Scale will be evaluated.
62203528|NCT01020877|EXPERIMENTAL|1|Metronidazole Vaginal Gel
62203529|NCT01020877|ACTIVE_COMPARATOR|2|MetroGel-Vaginal®
62203530|NCT03364075|ACTIVE_COMPARATOR|Duloxetine Treatment|patients treated with Duloxetine
62203531|NCT03364075|ACTIVE_COMPARATOR|Propranolol Treatment|patients treated with Propranolol
62203532|NCT03364075|PLACEBO_COMPARATOR|Placebo Treatment|patients treated with placebo
62579951|NCT04010747|EXPERIMENTAL|Motivational Interviewing for Loved Ones (MILO)|"MILO consists of four sessions of coaching in communication skills called motivational interviewing. Participants meet with a trainer/therapist for each session. At the first session, participants learn about the ideas behind motivational interviewing. In the second session, participants practice motivational interviewing skills. In the third and fourth sessions, the participant and therapist discuss the participant's efforts to communicate with their loved one using MI skills. Participants will also be offered direct assistance with a referral to mental health treatment for their loved one."
62786546|NCT06043908|EXPERIMENTAL|0.05% cyclosporine eyedrops combined with artificial tear eyedrops|0.05% cyclosporine eyedrops combined with artificial tear eyedrops
62786547|NCT06043908|ACTIVE_COMPARATOR|artificial tear eyedrops|artificial tear eyedrops
62203533|NCT01841268||Preterm Infants|Infants born prematurely will have their skin, sebum, microbiota, blood, and mother's breast milk analyzed for changes between 0, 2, and 4 weeks of life.
62203534|NCT01841268||Term Infants, Control|Term infants enrolled in the UC Davis Lactation Study (protocol # 216198) will serve as the control group for this study; they will have their skin, sebum, microbiota, and mother's breast milk analyzed for changes between 0, 2, and 4 weeks of life.
62203535|NCT03664440|PLACEBO_COMPARATOR|continuation arm|patients who currently received TDF/3TC/NVP (group A) or TDF/FTC/NVP (group B) were block 4 randomly assigned (1:1) by computer-generated random numbers, to continue their current regimen of NVP 200 mg twice daily plus TDF/3TC (group A1) and plus TDF/FTC (groupB1)
62203536|NCT03664440|ACTIVE_COMPARATOR|switch arm|patients who currently received TDF/3TC/NVP (group A) or TDF/FTC/NVP (group B) were block 4 randomly assigned (1:1) by computer-generated random numbers to switch from NVP to RPV 25 mg once-daily plus TDF/3TC (group A2) and plus TDF/FTC (groupB2)
62203537|NCT05675254||EP with ASMs|Epilepsy patients who administered Anti-seizure Medications(ASMs)
62203538|NCT05675254||EP without ASMs|Epilepsy patients who were not administered ASMs
62203539|NCT05675254||No EP|Non-epileptic children and had never taken any ASMs
62203540|NCT03235700|EXPERIMENTAL|Adenosine followed by nicorandil|
62203541|NCT03235700|EXPERIMENTAL|Nicorandil followed by adenosine|
62203542|NCT01312259|ACTIVE_COMPARATOR|Interstim Parameter Frequency 14 HZ|Subjects in this arm will receive 14 Hx as their frequency for the first three months. For the second 3 months, these patients will receive 40 Hz. Six months after the devise has been implanted, the patient has the option to choose which frequency they feel allows for better symptom control, and this is how the devise will be programmed.
62786548|NCT00856726|EXPERIMENTAL|PTH infusion|(1-34) PTH infusion at a rate of 0.055 ug/kg/hour for six hours
62786549|NCT00728091|EXPERIMENTAL|Satavaptan Dose 1|Fixed Low dose up to day 4, followed by optional titration up to day 30
62786550|NCT00728091|EXPERIMENTAL|Satavaptan Dose 2|Fixed High dose up to day 4, followed by optional titration up to day 30
62786551|NCT00728091|PLACEBO_COMPARATOR|Placebo|
62403527|NCT03890133|EXPERIMENTAL|Ba-Duan-Jin group|The participants will be guided by a research staff to do the Ba-Duan-Jin therapy for 50 minutes twice weekly for 12 weeks, in the outpatient section of the hospital; Pregabalin placebo treatment will be administered at bedtime once a day, starting at 150 mg for the first week, and increase to the dose of 300 mg from the second week. After one week, if 300 mg dose is tolerable, then maintain it for 10 additional weeks, if not, then go back to the 150 mg dose for 10 additional weeks.
62403528|NCT03890133|ACTIVE_COMPARATOR|Pregabalin group|"Wellness education and muscle relaxation exercise program: This program will be held for 50 minutes twice weekly for twelve weeks, containing 10-minute wellness education, 10-minute doctor-patient discussion, and 30-minute guided muscle relaxation exercise.~Active pregabalin capsules: As same usage as the placebo pregabalin capsules."
62786552|NCT00066963|NO_INTERVENTION|Counseling Only|Counseling Only
62786553|NCT00066963|EXPERIMENTAL|FV every 12mo for 24mo + Counsel|Preventive fluoride varnish every 12mo for 24mo plus Counseling
62786554|NCT00066963|EXPERIMENTAL|FV every 6mo for 24mo + Counseling|Preventive fluoride varnish every 6mo for 24mo plus Counseling
62014432|NCT05944263|EXPERIMENTAL|The gratitude, kindness and hope (GKH) program|"This gratitude, kindness and hope (GKH) program will be a structured manual-based intervention that has been adapted and contextualized from the previous work that has been done in this field. Each intervention session will be conducted in the school and community settings by 2 youth trainers aged 18 - 24 and who will be trained in the delivery of the intervention.~The sessions will be held twice a week, concurrently in schools and in the community. Fifty per cent of the sessions will be supervised by master trainers (who are experts in charge of training the youth trainers on the intervention). The rest of the sessions will be audio-recorded and reviewed randomly during supervision meetings.~The total duration of each session will be 45 minutes distributed as shown below:~iv. 5 minutes warm up activity v. 30 minutes practice and explanation of concepts through interactive activities and discussions vi. 10 mins answering questions and designing homework"
62203543|NCT01312259|EXPERIMENTAL|Interstim Parameter Frequency 40 HZ|Subjects in this arm will receive 40 Hz as their frequency for the first three months. For the second 3 months, these patients will receive 14 Hz. Six months after the devise has been implanted, the patient has the option to choose which frequency they feel allows for better symptom control, and this is how the devise will be programmed.
62579952|NCT04010747|ACTIVE_COMPARATOR|Mental Health Services Consultation and Waitlist|This consultation will consist of a 30 minute appointment in which participants can speak with a clinician knowledgeable about psychosis treatment resources. He/she can recommend specific programs, educational websites, and/or support groups that might be relevant for the participant's family. Participants will then be placed on a 6-week waitlist, after which they will have the opportunity to participate in the active intervention (four sessions of MILO).
62579953|NCT01289639|PLACEBO_COMPARATOR|Placebo|matching placebo 1 po qd
62786555|NCT03213834|ACTIVE_COMPARATOR|Thoracoscopy Arm|Consisting of chest thoracoscopy
62786556|NCT03213834|ACTIVE_COMPARATOR|Fibrinolytic Therapy Arm|Consisting of chest fibrinolytic therapy
62786557|NCT03060278|ACTIVE_COMPARATOR|Standard Treatment|Participants randomized to Standard Treatment will receive a smartphone with active service, brief advice to quit smoking (self-help materials), an 8-week supply of nicotine replacement therapy (patches), and provided 5 proactive phone counseling sessions by a trained Certified Tobacco Treatment Specialist.
62786558|NCT03060278|EXPERIMENTAL|Automated Treatment|Participants randomized to Automated Treatment will receive smartphone-delivered automated treatment that will provide tailored smoking cessation treatment by way of video clips, text and graphical messages. Participants will receive notifications on study provided smartphone once a week for an 8-week treatment period. Content delivered will be specific to the participants smoking status and motivation to quit.
62786559|NCT05813002|ACTIVE_COMPARATOR|standard neurodynamic sequence|Participants in the first group will receive the standard neurodynamic sequence. The starting position for this sequence will be shoulder in extension with lateral rotation, elbow in full flexion and wrist in neutral position. Passively the shoulder is abducted till 90 degrees followed by wrist extension then ended by elbow extension. Ipsilateral movement of the head bending till 45 degrees with movement of the wrist towards the body for 10 repetitions
62203544|NCT02292862||MG Main Group|lymph node and blood sampling
62203545|NCT03917862|NO_INTERVENTION|Control|This group include patients which will be undergone to conventional ascending aortic surgery, according to stablished techniques.
62786560|NCT05813002|ACTIVE_COMPARATOR|Distal to proximal neurodynamic sequence|The second group participants will receive the distal to proximal neurodynamic sequence. For this sequence the starting position will be shoulder in full extension with lateral rotation, elbow fully extended and wrist in neutral position. the sequence will start with wrist extension, going to elbow extension, and ending with shoulder abduction. Ipsilateral movement of the head bending till 45 degrees with movement of the wrist towards the body for 10 repetitions
62203546|NCT03917862|ACTIVE_COMPARATOR|TDM-621|This group include patients which will be undergone to conventional ascending aortic surgery, according to stablished techniques and will receive the TDM-621 for complementary hemostasis.
62203547|NCT02583529|EXPERIMENTAL|Back Tibial Nerve Electrostimulation|They will be assessed before and after 12 weeks of treatment with home PTNE through specific form of questionnaires assessing incontinence, quality of life and voiding diary. After the end of treatment will be made up of patients to verify the effectiveness of treatment in 30 to 90 days.
62403529|NCT03890133|NO_INTERVENTION|Healthy control group|
62403530|NCT04498975||Patients with IHD|No intervention
62403531|NCT00834366|EXPERIMENTAL|Tramadol HCl 200 mg Film-coated Tablets|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet based on randomization schedule.
62786561|NCT05813002|ACTIVE_COMPARATOR|proximal to distal neurodynamic sequence|The participants in the third experimental group will receive the proximal to distal sequence which will start with shoulder abduction, elbow extension and then wrist extension. The starting position is shoulder in extension and laterally rotated, elbow in full flexion, and wrist in neutral position. The shoulder will be passively mobilized to 90 degrees of abduction, elbow into full extension and wrist in full extension. Ipsilateral movement of the head bending till 45 degrees with movement of the wrist towards the body for 10 repetitions
62579954|NCT01289639|EXPERIMENTAL|Fenofibrate|micronized fenofibrate 200 mg 1 po qd
62579955|NCT01289639|EXPERIMENTAL|Pioglitazone|pioglitazone 30 mg po qd
62403532|NCT00834366|EXPERIMENTAL|Tramadol HCl 200 mg Uncoated Tablets|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Uncoated Tablet based on randomization schedule.
62403533|NCT04249557|EXPERIMENTAL|EIM group|This contains: A 12-week Exercise is medicine teaching class containing 6-18 patients per group (class size may be limited by social distancing policy in Hong Kong), homework are prescribed to participants to encourage regular exercise. The exercise level will be recorded by a tracker and provides feedback to the participants and physical trainer. The physical parameters such as fat percentage and blood pressure level will be feedback to the patients to encourage exercise. (If sports center are closed by the Government, the classes will be conducted online)
62014433|NCT05944263|ACTIVE_COMPARATOR|The [adapted] Stan Kutcher Teen Mental Health (TMH) program|"The program delivered to the control group is adapted from the Stan Kutcher Teen Mental Health Curriculum. It was initially developed to help enhance the mental health literacy of students and was developed for ages 13 to 15 years which was further adapted for a slightly lower age group (12-14 yrs) as that targeted in this study through simplification of terminologies to ensure age-appropriate content.~Just like the GKH program, the TMH sessions will be delivered by 2 trained youth trainers in the school and community settings. The program will be delivered over 8 sessions, two sessions a week (i.e. over a span of 4 weeks). Half of the sessions will be supervised by master trainers. Like the GKH program, each session will go for 45 minutes each ."
62203548|NCT02583529|PLACEBO_COMPARATOR|Placebo Electrostimulation|They will be assessed before and after 12 weeks of treatment with home PTNE through specific form of questionnaires assessing incontinence, quality of life and voiding diary. After the end of treatment will be made up of patients to verify the effectiveness of treatment in 30 to 90 days.
62203549|NCT01152814|EXPERIMENTAL|Arm 1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
62203550|NCT04406506||Group A|Group A received nasogastric feeding (NG), insure through ngt pump
62203551|NCT04406506||Group B|"* receive feeding throughThe nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.~* Patients were placed in right lateral position"
62403534|NCT01994369|EXPERIMENTAL|EC17 Injection group|This group with receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, they will be imaged with a camera and an imaging probe the investigators have developed.
62403535|NCT01147432|EXPERIMENTAL|PF-04427429|
62403536|NCT01147432|PLACEBO_COMPARATOR|Placebo|
62403537|NCT01147432|ACTIVE_COMPARATOR|EMLA|
62403538|NCT01419834|EXPERIMENTAL|Humanized 3F8 Monoclonal Antibody (Hu3F8)|This phase I single arm trial assesses the toxicity of escalating doses of hu3F8.
62403539|NCT03386630|EXPERIMENTAL|Hyperbaric bupivacaine+Sufentanil|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
62403540|NCT03386630|EXPERIMENTAL|Hyperbaric bupivacaine+morphine|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
62403541|NCT01172860|EXPERIMENTAL|EndoVe treatment|Use of the EndoVe device to safely and effectively ablate rectal tumor tissue
62786562|NCT05350852|EXPERIMENTAL|ThisCART19A 5×10^6 cells/kg for dose level 1|Patients will receive 5×10\^6 cells/kg of ThisCART19A
62786563|NCT05350852|EXPERIMENTAL|ThisCART19A 8×10^6 cells/kg for dose level 2|Patients will receive 8×10\^6 cells/kg of ThisCART19A
62014434|NCT06573580|NO_INTERVENTION|Usual primary health care for COPD|
62014435|NCT06573580|EXPERIMENTAL|The essential public health primary care for COPD|
62203552|NCT00004853|EXPERIMENTAL|1|single dose of intervention after each cycle of Standard 5 drug dose-intensive chemotherapy
62203553|NCT00004853|EXPERIMENTAL|2|single dose of interventionafter each cycle of Standard 5 drug dose-intensive chemotherapy
62203554|NCT00311389|EXPERIMENTAL|Travoprost/Timolol|1 drop in the affected eye(s) once daily in the morning for 12 months
62403542|NCT06519201|EXPERIMENTAL|SRT with SpineCare|The Trial Group underwent Spinal realignment therapy with SpineCare
62403543|NCT06519201|ACTIVE_COMPARATOR|SRT without SpineCare|The Control Group underwent Spinal realignment therapy without SpineCare
62403544|NCT06046404|ACTIVE_COMPARATOR|closed reduction followed by plaster casting|
62403545|NCT06046404|EXPERIMENTAL|only plaster casting|no closed reduction will be performed
62403546|NCT02513901|EXPERIMENTAL|Chidamide|"Step 1 - Six participants will receive Chidamide 10 mg twice a week(BIW) for 4 consecutive weeks.~Step 2 - Another six participants will receive Chidamide 30 mg twice a week(BIW) for 4 consecutive weeks.~Participants will be enrolled into Step 1 first; if the dose given to Step 1 is well tolerated and no safety concerns are noted, Step 2 will be enrolled."
62403547|NCT04149366||group 1 (Wrapround retainer)|
62403548|NCT04149366||Group 2 (Essix retainer 1mm)|
62403549|NCT04149366||Group 3 (Essix retainer 1.5 mm)|
62403550|NCT04149366||Group 3 (Essix retainer 2mm)|
62403551|NCT01754311||HTLV-1 infected patients|HAM/TSP patients and HTLV-1 Asymtomatic patients
62403552|NCT01754311||control|Blood donors
62403553|NCT04498260|EXPERIMENTAL|Local steroid-triamcinolone acetonide|Local steroid (triamcinolone acetonide) injection to the ulcer immediately after ESD. Total amount of injected triamcinolone is 100 mg.
62403554|NCT04498260|ACTIVE_COMPARATOR|Oral steroid-predonisolone|(predonisolone) administration three days after ESD. Predonisolone is administered over 8 weeks, started at 30 mg/day and tapered 30, 30, 25, 25, 20, 15, 10 and 5 every 7 days, totaling 8 weeks of treatment.
62403555|NCT06336629|EXPERIMENTAL|Winlevi (clascoterone) 1% & Duac gel|
62403556|NCT02022566|EXPERIMENTAL|Supported self-management of osteoarthrits program|Treatment with an supported self-management program for osteoarthritis.
62403557|NCT02022566|NO_INTERVENTION|Control group|No intervention
62403558|NCT03879824|EXPERIMENTAL|Radial Artery Secondary Access During TAVI|"Patients randomized to this arm will undergo primary access for valve placement through the femoral artery and will have secondary vascular access for placement of the pigtail catheter through the radial artery (right radial artery only) during their transcatheter aortic valve implantation (TAVI)~The active intervention in this arm of the study is secondary radial artery access during TAVI"
62014436|NCT05565612|EXPERIMENTAL|Probiotic group|"Normodigest Classic~Multi-strain probiotic mixture (15 strains) with a concentration of 7,5 x 10\^9 + fructooligosaccharides~1 vial of 10 ml per day for 12 weeks"
62403559|NCT03879824|ACTIVE_COMPARATOR|Femoral Artery Secondary Access During TAVI|"Patients randomized to this arm will undergo primary access for valve placement through the femoral artery and will have secondary vascular access for placement of the pigtail catheter through the contralateral femoral artery artery during their transcatheter aortic valve implantation (TAVI)~The active intervention in this arm of the study is secondary femoral artery access during TAVI"
62403560|NCT02222246|EXPERIMENTAL|Patient Specific dose of Morphine Sulfate or Hydromorphone|A patient-specific analgesic protocol for use in the ED to manage VOC crises. Following randomization, a patient's healthcare team will develop a specific analgesic protocol for use during future ED visits for VOC occurring during the study period (up to 5 visits). Treatment protocols will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous). Dosage and frequency will be based on a patient's prior treatment history.
62403561|NCT02222246|ACTIVE_COMPARATOR|Standard dose of Morphine Sulfate or Hydromorphone|A standardized analgesic protocol (based on recent NHLBI recommendations) for use in the ED to manage VOC crises. Treatment protocol will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous), with dosage based on weight. Repeat doses of opioids may be administered every 20-30 minutes as needed, although dosage will be maintained or provided at no more than 25% above the initial dose.
62579956|NCT05236387||Intent to Treat group|All patients meeting entrance criteria, injected with 99m Tc-TM, and having one or more lymph nodes removed for which the pathologist confirms the type (lymph node versus non-lymph node) and contents (e.g., tumor cells) of the excised tissues will comprise the intent-to-treat population (ITT). This definition also carries over to the lymph nodes; i.e., nodes used for the ITT analysis must come from patients included in the ITT population. The ITT population will serve as the analysis population for all efficacy endpoints, unless indicated otherwise in the description of analyses.
62579957|NCT03641326|EXPERIMENTAL|Participants With Primary Gliosarcoma|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest. Participants will be given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
62579958|NCT03641326|EXPERIMENTAL|Participants With Secondary Gliosarcoma|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest. Participants will be given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
62579959|NCT03641326|EXPERIMENTAL|Participants With Primary Central Nervous System (CNS) Sarcoma|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest. Participants will be given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
62579960|NCT02270047|ACTIVE_COMPARATOR|A|Orange nectar with NAXUS fibre, 5g/100mL
62579961|NCT02270047|PLACEBO_COMPARATOR|B|Orange nectar
62579962|NCT03758417|EXPERIMENTAL|LCAR-B38M Chimeric Antigen Receptor T Cell|"Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).~In addition, participants will enroll in additional cohort to further characterize the safety profile and accumulate efficacy data of LCAR-B38M CAR-T cells."
62579963|NCT02179905||Irritable bowel syndrome, Control|
62579964|NCT06682559|EXPERIMENTAL|Prefabricated healing abutment with scan peg (Neoss implant system, Harrogate, England)|12 participants will receive single posterior implants by fully guided implant protocol followed by placement of prefabricated healing abutment with scan peg having convex emergence profile
62579965|NCT06682559|ACTIVE_COMPARATOR|Customized healing abutment|12 participants will receive single posterior implants by fully guided implant protocol followed by placement of custom healing abutment having concave emergence profile
62579966|NCT05322889|EXPERIMENTAL|Intervention with Telmisartan|"Telmisartan (open), 80 mg daily p.o. (after run-in phase with 40 mg for 7 days).~for 12 weeks"
62579967|NCT03661931|EXPERIMENTAL|DQPN Validation|We are planning to recruit 150 individuals who are patients in the Boston Heart Lifestyle Program and are already having fatty acids measured as part of clinical care, and ask them to complete the DQPN, FFQ, and a User Experience Questionnaire for each dietary assessment method.
62786564|NCT05350852|EXPERIMENTAL|ThisCART19A 12×10^6 cells/kg for dose level 3|Patients will receive 12×10\^6 cells/kg of ThisCART19A
62786565|NCT05813704|EXPERIMENTAL|Coronary Crossing System|Subjects in experimental group will be treated with the Coronary Crossing System manufactured by Shanghai Microport Rhythm Co. Ltd.
62786566|NCT04046224|EXPERIMENTAL|Sequential dose escalation|"ST-920 is administered as a single infusion:~1. Cohort 1: 0.5e13 vg/kg~2. Cohort 2: 1.0e13 vg/kg~3. Cohort 3: 3.0e13 vg/kg~4. Cohort 4: 5.0e13 vg/kg"
62786567|NCT04046224|EXPERIMENTAL|Expansion Cohorts|"1. Anti Alpha-Gal A Antibody Positive Cohort~2. Anti Alpha-Gal A Antibody Negative Cohort~3. Female Cohort~4. Renal Cohort~5. Cardiac Cohort"
62786568|NCT04767503|ACTIVE_COMPARATOR|Propofol|Maintence of anesthesia during the operation using target control infusion with propofol 1mg/ml with bispetral index(BIS) in the range 40-60.
62786569|NCT04767503|SHAM_COMPARATOR|Desflurane|Maintence of anesthesia during the operation using inhalational agent desflurane with 0.5 to 1.5 minimal alveolar concentration (MAC) with bispetral index(BIS) in the range 40-60.
62786570|NCT02105038|EXPERIMENTAL|Knob|Steering in a driving simulator using a steering wheel spinner knob.
62786571|NCT02105038|ACTIVE_COMPARATOR|No Knob|Steering in a driving simulator immediately following surgical treatment of hip fractures.
62786572|NCT01635855|EXPERIMENTAL|Belotero|Belotero® Hyaluronic acid dermal filler
62786573|NCT03929640|PLACEBO_COMPARATOR|Ibuprofen and placebo|Oral administration of ibuprofen 600 mg tablet and placebo tablet every 6 hours
62786574|NCT03929640|ACTIVE_COMPARATOR|Ibuprofen and acetaminophen|Oral administration of ibuprofen 600 mg tablet and acetaminophen 650 mg tablet every 6 hours
62786575|NCT06315946|EXPERIMENTAL|Pixie® skin tag|A skin tag is selected and treated with the test device Pixie® skin tag according to the instructions for use.
62786576|NCT06315946|ACTIVE_COMPARATOR|Wortie® skin tag remover|A skin tag is selected and treated with the comparator Wortie® skin tag remover.
62403562|NCT04851704|EXPERIMENTAL|Intervention: Tuning in to Kids parenting program|Intervention groups receive the Tuning in to Kids parenting program
62579968|NCT06683976||Standard Treatment Group Label: Conventional Chest Drainage|This group includes patients with chest trauma who receive standard chest drainage using commercial chest tubes and underwater seal systems. This intervention follows established guidelines and protocols for chest drainage in trauma care. Patients in this group serve as the control group for comparing outcomes with those receiving improvised drainage systems.
62786577|NCT02296255|NO_INTERVENTION|no HPV vaccine|No delivery of HPV vaccine
62786578|NCT02296255|EXPERIMENTAL|HPV vaccine (Cervarix®, GlaxoSmithKline)|Delivery of HPV vaccine (Cervarix®, GlaxoSmithKline) at 0, 1, 6 months
62786579|NCT02967510|EXPERIMENTAL|0.005% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
62786580|NCT02967510|EXPERIMENTAL|0.002% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
62786581|NCT02967510|EXPERIMENTAL|0.0008% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
62786582|NCT02967510|PLACEBO_COMPARATOR|estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
62786583|NCT05824169|EXPERIMENTAL|Low dosage group|2.4x10\^14 vg/person of GC101 delivered one-time intrathecally (n=3)
62786584|NCT05824169|EXPERIMENTAL|High dosage group|4.8x10\^14 vg/person of GC101 delivered one-time intrathecally (n=3)
62786585|NCT02575170|EXPERIMENTAL|Amino acid|Intravenous infusion of amino acid solution started approximately one hour prior to spinal anaesthesia after recording the baseline vital parameters. Each patient in experimental group received a total of 200 ml at 2 ml/kg/min.
62786586|NCT02575170|PLACEBO_COMPARATOR|Ringer's Lactate solution|Intravenous infusion of Ringer's lactate solution started approximately one hour prior to spinal anaesthesia after recording the baseline vital parameters. Each patient in experimental group received a total of 200 ml at 2 ml/kg/min.
62786587|NCT01708135|OTHER|Smartphone Arm|This is a feasibility trial and thus all participants in the study will be provided a smartphone app to assist them in preparing for bariatric surgery.
62786588|NCT01037738|ACTIVE_COMPARATOR|ACS - Orthokin|Autologous conditioned serum (ACS) - Orthokin containing endogenous anti-inflammatory cytokines including IL-1Ra and growth factors (IGF-1, PDGF and TGF-ß1, among others) in the liquid blood phase.
62786589|NCT01037738|PLACEBO_COMPARATOR|Placebo|Physiologic solution
62786590|NCT04573608|EXPERIMENTAL|Papacarie-Duo|
62786591|NCT04573608|ACTIVE_COMPARATOR|Atraumatic Restorative Treatment|
62786592|NCT05383456||Study Participants|Waist and hip circumferences, CT Scan and FibroScan and Quality of Life questionnaire, vital signs, urine and blood testing in Adults with HIV on continuous Anti-Retroviral Therapy treatment.
62786593|NCT02461940|NO_INTERVENTION|Standard care|The control group will receive the standard care provided by the STI clinic.
62786594|NCT02461940|ACTIVE_COMPARATOR|Adolescent Behavioral intervention|Participants allocated to the intervention arm receive 4 on-site personalised counselling and 2 phone/online sessions over a 12-month period, targeting individual, relational, sociocultural and environmental factors pertaining to the acquisition of STI/HIV.
62786595|NCT04436172|NO_INTERVENTION|pre intervention|Before intervention
62786596|NCT04436172|EXPERIMENTAL|post intervention|Received soinal anesthesia
62786597|NCT03749772|EXPERIMENTAL|Cognitive|The participants of the COGNITIVE group performed cognitive training during 12 sessions during the 3 months of hypocaloric treatment. The training was carried out with the PC game Brain Exercise TM (Bandai Namco Games Ltd.). The participants made a total of 12 practice exercises, which implies approximately 30 minutes of duration per session.
62786598|NCT03749772|NO_INTERVENTION|Control|As a control group, we used nutrition education sessions of approximately the same duration (30 min) where we simply reinforced the knowledge that was already provided during the sessions with the patient, such as concepts about the balanced diet, nutrient composition and micronutrients, etc. The objective of this control group was to avoid the effect of time with the researcher.
62786599|NCT00465023|EXPERIMENTAL|Proton Beam Radiation|Proton radiation therapy
62786600|NCT02057159|EXPERIMENTAL|NeuroVax|NeuroVax
62786601|NCT02057159|PLACEBO_COMPARATOR|IFA Placebo|IFA Placebo
62786602|NCT05526287|EXPERIMENTAL|Dual-Task Group|Participants will receive 8 weeks of dual-task training twice a week and home exercise program.Dual-task training will include motor-motor and motor-cognitive dual-task activities.Home exercise program will include core and lower extremity exercises.Home exercises will be performed three times a week.
62786603|NCT05526287|ACTIVE_COMPARATOR|Control Group|Participants will receive 8 weeks of home exercise program.Home exercise program will include core and lower extremity exercises.Home exercises will be performed three times a week.
62786604|NCT01206582|ACTIVE_COMPARATOR|Hemin|Panhematin®, Ovation Pharmaceuticals, Deerfield, Illinois (IL). Hemin was diluted in 25% albumin to obtain a concentration of 2.4 mg/mL and administered at a dose of 1.25 mL/Kg and at a rate of 60 mL/hour. 10 iv infusions for 8 weeks
62579969|NCT06683976||Improvised Treatment Group Label: Improvised NG Tube Drainage|This group includes patients with chest trauma who receive chest drainage using improvised methods, specifically nasogastric (NG) tubes as chest drains and intravenous (IV) drip sets adapted to function as underwater seals. This alternative intervention is used due to resource constraints and aims to evaluate the safety and effectiveness of improvised methods in a low-resource, conflict-affected setting
62403563|NCT04851704|NO_INTERVENTION|Control: Business as usual|"Control groups have business as usual, and then get offered the intervention program after 6 months follow-up assessment."
62014437|NCT05565612|PLACEBO_COMPARATOR|Placebo group|"Maltodextrin-based placebo~1 vial of 10 ml per day for 12 weeks"
62014438|NCT01329497|EXPERIMENTAL|interventional group|
62014439|NCT03243331|EXPERIMENTAL|Gedatolisb + PTK7-ADC|
62403564|NCT03186794|EXPERIMENTAL|Aerobic exercise training (AET)|Participants with systemic lupus erythematosus participated in a 12-week aerobic exercise training program. Exercise was performed on a treadmill, three times a week for 30 minutes at target training intensity of 70 - 80% of heart rate reserve \[0.7 to 0.8 \* (peak heart rate - resting heart rate) + resting heart rate\]
62014440|NCT02946294|ACTIVE_COMPARATOR|modified pectoral nerves block|Modified pectoral nerves block with general anesthesia. Using the ultrasound, 10 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the pectoralis major and minor muscles. And another 20 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the pectoralis minor and the serratus anterior muscles.
62579970|NCT01842633|EXPERIMENTAL|Paracetamol/ Caffeine Caplets|Two caplets of paracetamol/caffeine combination plus 2 placebo caplets to be administered
62579971|NCT01842633|ACTIVE_COMPARATOR|Ibuprofen Caplets|Two ibuprofen caplets plus two placebo caplets to be administered
62403565|NCT05980637|ACTIVE_COMPARATOR|Shaoyao Gancao Decoction with Addition|11g of Shaoyao Gancao Decoction with Addition granules twice daily for 4 weeks
61978439|NCT04258345|OTHER|Active Feeding Arm|This is a feeding study.
62014441|NCT02946294|ACTIVE_COMPARATOR|serratus plane block|Serratus plane block with general anesthesia. Using the ultrasound, 0.4 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the serratus anterior muscle and the underlying ribs.
62014442|NCT01639209|EXPERIMENTAL|Vitrectomy|
62014443|NCT01639209|EXPERIMENTAL|Pneumatic retinopexy|
62014444|NCT06127420||All patients|All patients referred to angiography and undergo assessment with coronary pressure sensor
62014445|NCT05070897||Population A|65 years old and more
62014446|NCT05070897||Population B|18 to 64 years old
62014447|NCT03913117|EXPERIMENTAL|pNGVL4aCRTE6E7L2 0.3mg dose|Low dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.
62203555|NCT00311389|ACTIVE_COMPARATOR|Latanoprost/Timolol|1 drop in the affected eye(s) once daily in the morning for 12 months
62403566|NCT05980637|PLACEBO_COMPARATOR|Placebo|11g of placebo granules twice daily for 4 weeks
62579972|NCT01842633|PLACEBO_COMPARATOR|Placebo Caplets|Four placebo caplets to be administered
62786605|NCT01206582|PLACEBO_COMPARATOR|Albumin|10 iv infusions for 8 weeks
62203556|NCT04944745|EXPERIMENTAL|Myofascial release (MFR)|The pectoral MFR will be completed by an experienced registered massage therapist (RMT). They will stand on the participant's right side slightly rotated to the left facing towards the participant's left hip and apply a cross-hand MFR technique to the superficial pectoral fascia on the right side. The therapist will begin by placing the distal region of the anterior palm of the anchoring hand (therapist's right hand) on the right edge of the anterior sternum at the level of the 3rd to the 6th ribs on the skin and the draping over the pectoral fascia. They will then apply a gentle posterior pressure to hold the fascia in place. The forearm of the mobilizing hand (RMT's left hand) will be directed to the right shoulder wit hate right forearm crossing over the left and the contact of are of the mobilizing hand will be the skin superficial to the pectoral fascia and insertion of pectorals major on the anterior aspect of the humerus. This will be held for four minutes.
62786606|NCT02088021|EXPERIMENTAL|Portico Transcatheter Aortic Valve Implantation|Placement of the SJM Portico aortic valve with a ALC delivery system
62203557|NCT04944745|SHAM_COMPARATOR|Soft-touch Control (CON)|This control treatment will be set up the same way in regards to the RMT's hand placement, except no pressure will be applied. The RMT's hands will simply be resting over the contact points. This treatment will also be held for four minutes.
62203558|NCT01343758|ACTIVE_COMPARATOR|5% dextrose in normal saline|This group will receive a bolus of normal saline that contains 5% dextrose
62203559|NCT01343758|NO_INTERVENTION|Normal Saline Bolus|
62203560|NCT01791998|EXPERIMENTAL|Treatment (MR-thermal image guided LITT)|Patients undergo MR-thermal image guided LITT over 1 hour.
62203561|NCT04855409||Bipolar Depression|Subjects with bipolar type I disorder depressive episode diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)
62403567|NCT06566781||Obsessive-compulsive disorder group|Obsessive-compulsive disorder group: Adult patients (18 to 65 years-old) with obsessive-compulsive (OCD) disorder will be recruited both at Champalimaud Clinical Center and collaborating clinical centers, namely Centro Hospitalar Psiquiátrico de Lisboa, Centro Hospitalar de Lisboa Ocidental and Hospital Garcia de Orta.
62403568|NCT06566781||Healthy subjects group|Control subjects group: Adult individuals (18 to 65 years-old) age- and sex-mateched without past or current diagnosis of major neuropsychiatric disorders, including OCD.
62786607|NCT02474407|EXPERIMENTAL|diazepam nasal spray (DZNS)|One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
62786608|NCT02474407|ACTIVE_COMPARATOR|diazepam rectal gel (DRG)|A single rectal dose of diazepam will be administered to subjects according to the Diastat prescribing information.
62786609|NCT00269854|EXPERIMENTAL|Infliximab 5 mg/kg|
62786610|NCT00269854|EXPERIMENTAL|Infliximab 10 mg/kg|
62786611|NCT00269854|EXPERIMENTAL|Infliximab 20 mg/kg|
62786612|NCT00269854|PLACEBO_COMPARATOR|Placebo|
61978440|NCT05356247|EXPERIMENTAL|LTP-B Intervention|Families will take part in an online semi-structured assessment and video feedback paradigm of family interactions, with an emphasis on co-parenting and parent-child relations.
62403569|NCT06021769||Women being fitted with pessaries|Women being fitted with pessaries as standard of care will be eligible to participate. They will be asked to complete a recorded verbal interview and written questionnaires the day they have their pessaries fitted and at their follow-up clinic appointments at 4-6 weeks, 3 months, 6 months, and 12 months. Another recorded video interview will be completed at the 12 month appointment.
62786613|NCT00902460|EXPERIMENTAL|Treatment Sequence 1|
62786614|NCT00902460|EXPERIMENTAL|Treatment Sequence 2|
62786615|NCT04957121||on-hours|"Hip surgeries with the start time of anesthesia between 8:00 and 17:59 were coded as on-hours."
62786616|NCT04957121||off-hours|"Hip surgeries with anesthesia beginning between 18:00 and 7:59 were coded as off-hours. Besides, taking the long duration of hip surgery into account, if the anesthesia began before 18:00 but ended after 20:00, it was also defined as off-hours."
62786617|NCT00564213|EXPERIMENTAL|1|A single intraoperative topical application of mitomycin C 0.02% for 15 seconds
62786618|NCT00564213|EXPERIMENTAL|2|A single intraoperative topical application of mitomycin C 0.02% for 30 seconds
62786619|NCT04891354|EXPERIMENTAL|Part I: single ascending dose (SAD)|In Part I, each subject will receive a 30 minute i.v. infusion of placebo followed by a 1-hour i.v. infusion of PDNO in parallel with a carrier sodium bicarbonate buffer, the infusion of which will start 5 minutes prior to start of placebo infusion and continue until 15 minutes after end of PDNO infusion. Between the end of placebo infusion and prior to the start of PDNO infusion, there will be a 20-minute stabilisation period with infusion of sodium bicarbonate buffer only.
62786620|NCT04891354|EXPERIMENTAL|Part II: ascending doses of PDNO|In Part II, each subject will receive a 30 minute i.v. infusion of placebo followed by 2 x 30 minute infusions of PDNO at 2 ascending dose levels and one 3-hour infusion of PDNO at a third dose level.
62203562|NCT04855409||Healthy|Healthy control subjects matched with bipolar depressive patients by age and sex
62786621|NCT06584526|ACTIVE_COMPARATOR|Physical Therapy (PT)|"30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the experimental groups).~Education: a series of recommendations to correct inappropriate behaviors such as parafunctions.~Manual therapy:~* Bilateral myofascial pressure of 60'' applied to the masseter, temporalis, sternocleidomastoid, and upper trapezius muscles.~* Dorsal glinding of the Occipital-Atlas segment, performed at Grade III intensity (3sets of 30'', with 15'' of rest).~Therapeutic exercise:~* Controlled opening and closing of the jaw: 6 repetitions with 30'' of rest~* Isometric exercices of the jaw in opening, protrusion, and lateral excursion:3 sets of 10'' for each movement, 15'' of rest~* Deep neck flexors training using StabilizerTM biofeedback, without contracting the superficial muscles: baseline pressure at 20 mmHg, perform craniocervical flexion at 22, 24, 26, 28, and 30 mmHg, 10'' per stage)."
62203563|NCT05724927|EXPERIMENTAL|Animal Assisted İntervention|A total of four study interviews will be held within the scope of animal-supported activities, two days a week, from the elderly individuals in the nursing home to the participants included in the study.
62203564|NCT05732753|EXPERIMENTAL|Experimental group|An experimental group (GE) that after an initial evaluation and with their consent, will be subjected to a program that includes an intervention based on Mindfulness and an 8-week Education intervention, one day a week with a duration of 120 minutes. The sessions will be divided into two parts, a part of 60' of Mindfulness and another of 60' of Education. In the Mindfulness part, formal Meditation practices and conscious movements based on yoga will be carried out. In the Education part, participants will be instructed in concepts related to the basic neurophysiology of pain.
62203565|NCT05732753|ACTIVE_COMPARATOR|Control group|The control group (CG) will receive an Education intervention, which will be evaluated in the pre and post phase of the study. Participants assigned to this group will receive 8 sessions, 60' long, with a frequency of one session per week.
62203566|NCT01562353||Case|Subject has a diagnosis of current prescription opioid dependence (confirmed by the MINI). Subject had no history of dependence on alcohol or illicit or prescription drugs, including opioids, prior to prescription opioid exposure for the treatment of chronic pain.
62203567|NCT01562353||Control|Subject's prescribing physician has reported absence of significant problematic behavior with respect to prescription opioids or other substances while under the physician's care. Subject has a negative urine drug screen for alcohol, illicit drugs, and nonprescribed controlled substances at screening. Subject has no current or past substance abuse or dependence (confirmed by the MINI and medical history).
62203568|NCT02797522|EXPERIMENTAL|NHV Participants: Cohort 1|NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.
62203569|NCT02797522|EXPERIMENTAL|NHV Participants: Cohort 2|NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.
62579973|NCT04008381|EXPERIMENTAL|Ex-vivo Expanded γδ T Lymphocytes|Patients receive ex-vivo expanded γδ T Lymphocytes (Dose escalation, 2\*10\^6, 4\*10\^6, 8\*10\^6 of cells per kg of body weight).
62786622|NCT06584526|EXPERIMENTAL|Physical Therapy and Aerobic Exercise (PT+AE)|"Physical therapy combined with aerobic exercise: 30 minutes of physical therapy (same programme than the other experimental group and the active comparator), combined with a 30 minutes aerobic exercise programme on a cycle ergometer.~The AE will consist of:~* Warm-up: Participants cycled for 5 min at a heart rate reserve (HRR) of 50%.~* Main work: For 24 min, participants performed an interval exercise divided into four intervals, with 4 min at 85%\* of the HRR and 2 min of recovery at 50-60% of the HRR in each cycle.~* Active recovery: The last minute allowed participants to engage in active recovery at 50% of the HRR.~  \*: The value of the higher HHR will be reached through a weekly progression:~* Week 1: 65% HHR~* Week 2: 70% HHR~* Week 3: 75% HHR~* Week 4: 80% HHR~* Week 5-6: 85% HHR~The HRR was calculated using the Karvonen formula used in similar studies:~HRtarget = \[HHR x %intensity\] + HRrest~HRR = HRmax - HRrest HRmax = 207 - (0.7 x age)~HR assessed with a Polar10 sensor."
62203570|NCT02797522|EXPERIMENTAL|NHV Participants: Cohort 3|NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.
62203571|NCT02797522|EXPERIMENTAL|NHV Participants: Cohort 4|NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.
62203572|NCT02797522|EXPERIMENTAL|NHV Participants: Cohort 5|NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.
62203573|NCT02797522|EXPERIMENTAL|NHV Participants: Cohort 6|NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.
62403570|NCT02613559|EXPERIMENTAL|TK001 0.1mg|Injection:single Intravitreal Injection
62403571|NCT02613559|EXPERIMENTAL|TK001 0.5mg|Injection:single Intravitreal Injection
62403572|NCT02613559|EXPERIMENTAL|TK001 1.0mg|Injection:single Intravitreal Injection
62579974|NCT02811146|EXPERIMENTAL|Cardiopulmonary exercise testing|Assess whether people who wore noninvasive ventilation during aerobic exercise have greater functional capacity than those who did not wear.
62579975|NCT02811146|EXPERIMENTAL|ADL Glitre test|Check that people who wore noninvasive ventilation during aerobic exercise have greater submaximal functional capacity than those who did not wear. Compare a ventilatory metabolic response of the ADL Glitre test with an six-minute walk test. .
62203574|NCT02797522|PLACEBO_COMPARATOR|NHV Participants: Placebo|NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.
62203575|NCT02797522|EXPERIMENTAL|CHB Participants: Cohort 3b|Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual nucleoside analog (NUC) therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).
62014448|NCT03913117|EXPERIMENTAL|pNGVL4aCRTE6E7L2 1 mg dose|Intermediate dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.
62203576|NCT02797522|EXPERIMENTAL|CHB Participants: Cohort 4b|Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).
62203577|NCT02797522|EXPERIMENTAL|CHB Participants: Cohort 3c|Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks.
62786623|NCT06584526|EXPERIMENTAL|Physical Therapy and Strength Exercise (PT+ST)|"Physical therapy combined with aerobic exercise: 30 minutes of physical therapy (same programme than the other experimental group and the active comparator), combined with a 30 minutes strength exercise (ST) programme.~The ST exercise will consist of:~* Warm-up (5'): circuit, 3 sets of: jumping jacks (20''), mountain climbers (20''), abdominal crunch (20''), active stretching of the quadriceps (20'').~* Main work: For 24 min, a circuit of multiarticular exercise (body weight). Four cycles of 4' of work, with 2' of rest between them. Each exercise will have a work time of 30'' guided with a timer. Intensity will be increased each 2 weeks (W) (higher difficulty and speed).~  * Lunge: W1-2 bilateral 10x / W3-4 unilateral 12x / W5-6 walking 14x~ * Push up: W1-2 inclined 8x / W3-4 normal 10x / W5-6 declined 10x~ * Squat: W1-2 normal 10x / W3-4 lateral lunge 12x / W5-6 step up 10x~ * Core: W1-2 front plank 10x / W3-4 up and down plank 12x / W5-6 superman 12x~* Active recovery: Walk for 1'."
62786624|NCT04302233|EXPERIMENTAL|New pharmaceutical support (NPS)|"An NPS is an interview comprising the following elements:~The delivery of the identification sheet of their implants with:~* a quiz to focus the patient's attention~* a description of the characteristics of their prosthesis using a specific photo of their implant~* a presentation of the medical device vigilance.~* an explanation of the value of the identification sheet for their implant, An in-depth presentation of an information booklet on living at home with their prosthesis and on medical and paramedical monitoring.~For patients in orthopedic surgery: a booklet specific to their prosthesis and the surgical approach For plastic surgery patients, the information sheets published by the French Society of Plastic Reconstructive and Aesthetic Surgery (SOF.CPRE).~A time to answer any questions the patient may have"
62786625|NCT04302233|NO_INTERVENTION|Usual pharmaceutical support (UPS)|"An UPS is an interview comprising the following elements:~* The delivery of the same patient-implant sheet as in arm 1, but without additional oral information.~* The delivery and oral presentation of the same booklet as practiced in the arm 1 (NPS).~* And a time to answer any questions from the patient months"
62786626|NCT05748457||2015-2017|Patients treated for anorexia nervosa in the years 2015-2017 at Nedre Romerike outpatient clinic, Department of child and adolescent mental health services, Akershus university hospital.
62786627|NCT05748457||2018-2020|Patients treated for anorexia nervosa in the years 2018-2020 at Nedre Romerike outpatient clinic, Department of child and adolescent mental health services, Akershus university hospital.
62203578|NCT02797522|EXPERIMENTAL|CHB Participants: Cohort 4c|Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks.
62203579|NCT02481570|EXPERIMENTAL|Anesthesia optimization|Information from the pharmacokinetic simulation during an anesthetic regimen of a propofol based Total Intravenous Anesthetic (TIVA)
62203580|NCT04301895|OTHER|Interactive|Subject will be asked to continually interactive with the investigators, answering a series of standard questions during the remifentanil infusion and recovery periods.
62403573|NCT02613559|EXPERIMENTAL|TK001 2.0mg|Biological: TK001 Injection:single Intravitreal Injection
62014449|NCT03913117|EXPERIMENTAL|pNGVL4aCRTE6E7L2 3 mg dose|High dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.
62014450|NCT03913117|EXPERIMENTAL|PVX-6|Selected dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0 and 4, and the TA-CIN protein is administered by intramuscular injection at week 8.
62014451|NCT05112835||brolucizumab|brolucizumab intravitreal injections in patients with nAMD treated in the UK
62786628|NCT06464562|EXPERIMENTAL|LiveWell: Adapted Dialectical Behavioral Therapy Skills Training|Participants randomized to LiveWell will receive the refined intervention protocol as informed by Aim 1 (K99). LiveWell is an 8-session protocol of Dialectical Behavioral Therapy Skills Training, adapted specifically for patients with metastatic lung cancer. Sessions are delivered one on one via telehealth, approximately weekly. Participants learn concrete, easy-to-use skills to: 1) tune into the present moment, and how they are thinking and feeling (mindfulness), understand emotions, how to change them, and how to experience more positive feelings (emotion regulation), tolerate distressing emotions and symptoms (e.g., fatigue, pain, dyspnea) and to accept reality as it is (distress tolerance), and tools to communicate wants and needs effectively with others (interpersonal effectiveness). The goal is to teach patients skills to live well, with metastatic cancer. All sessions follow a standardized structure that is customary in skills training and grounded in social cognitive theory.
62786629|NCT06464562|NO_INTERVENTION|Enhanced Usual Care|All participants will receive usual medical treatment as per their medical team (e.g., oncology, palliative care). Participants will also be provided with written materials that describe free services (e.g., legal and financial assistance, support groups, counseling) available through the Duke Cancer Patient Support Program.
62786630|NCT01658761|EXPERIMENTAL|Myopic traction maculopathy|The 71 eyes of 64 patients (14 men and 50 women) with myopic traction maculopathy in highly myopic eyes (refractive errors ≤-8.0 diopters and axial length ≥26.0 mm) who underwent vitrectomy were retrospectively reviewed.
62786631|NCT01873625|PLACEBO_COMPARATOR|placebo|Normal salin injection in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
62786632|NCT01873625|ACTIVE_COMPARATOR|mesencymal stem cell|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
62786633|NCT01970267|ACTIVE_COMPARATOR|Laser Treated|Laser will direct the laser at vitreous opacities. The power of the laser will be adjusted from 0.3-12 millijoules (mJ) with the end point being laser induced optical breakdown and the production of a small gas bubble 50% of the time. The treatment will attempt to reduced or eliminate symptomatic floaters in the visual axis. Each treatment session will be limited to 300 laser applications. Participants will be retreated based on continued symptoms for up to 5 sessions
62786634|NCT01970267|SHAM_COMPARATOR|Not Treated|
62786635|NCT03227666|EXPERIMENTAL|Intervention Group|The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
62786636|NCT03227666|NO_INTERVENTION|Control group|The control group recieves a health consultation that highlights the importance of physical activity and balance exercise according to standard practice within the HAI project. They are asked to return after 4 weeks for follow up.
62786637|NCT04045379|ACTIVE_COMPARATOR|LASER|The patients will receive 3 consecutive applications of intravaginal and vulvar CO2 (carbon dioxide)LASER, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
62786638|NCT04045379|ACTIVE_COMPARATOR|Micro Ablative Radiofrequency|The patients will receive 3 consecutive applications of intravaginal and vulvar MIcro ablative radiofrequency, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
62786639|NCT04045379|ACTIVE_COMPARATOR|Estriol|The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.
62786640|NCT00887926|EXPERIMENTAL|IMC-EB10 5 milligrams/kilogram (mg/kg)|All participants will receive intravenous infusions of IMC-EB10, with the dose depending on which cohort they are enrolled into.
62786641|NCT00206336|EXPERIMENTAL|topiramate|Topiramate open label
62786642|NCT05368194|EXPERIMENTAL|Isocaloric Arm|Participants within the isocaloric arm will be provided with food provisions in accordance with their nutrition needs. Participants within this arm will be further randomised to the order of first and second dietary interventions for the crossover design; unprocessed diet or processed diet.
62403574|NCT02613559|EXPERIMENTAL|TK001 2.5mg|Biological: TK001 Injection:single Intravitreal Injection
62579976|NCT02811146|EXPERIMENTAL|Minnesota Living with Heart Failure|Check if people undergoing heart rehabilitation has improved quality of life.
62786643|NCT05368194|EXPERIMENTAL|Excess Calorie Arm|Participants within the excess calorie arm will be provided with food provisions in accordance with their nutrition needs plus an additional 500 kilocalories per day. Participants within this arm will be further randomised to the order of first and second dietary interventions for the crossover design; unprocessed diet or processed diet.
62786644|NCT04357808|EXPERIMENTAL|Sarilumab plus standard of care|Sarilumab 200 mg, 2 sc injections in pre-filled syringe or pen, single dose. Treatment with drugs or procedures in routine clinical practice that the clinician responsible for the patient deems necessary is allowed
62786645|NCT04357808|ACTIVE_COMPARATOR|Standard of care|Treatment with drugs or procedures in routine clinical practice
62786646|NCT00765570|ACTIVE_COMPARATOR|Treatment Group 1|Treatment Group 1-one treatment of Grid therapy followed by 15 treatments with standard radiation
62403575|NCT02613559|EXPERIMENTAL|TK001 3.0mg|Injection:single Intravitreal Injection
62403576|NCT02046993|EXPERIMENTAL|Smart phone based telemonitoring of HBP|"1. . Patients do HBP monitoring~2. . record their BP readings into the smart phone with downloaded application."
62403577|NCT02046993|ACTIVE_COMPARATOR|Enhanced usual care|"1. . Patients to do HBP measurement~2. . Record BP readings in their diary"
62579977|NCT02811146|EXPERIMENTAL|Bioimpedance balance|Check if people undergoing heart rehabilitation has improved the body composition.
62579978|NCT02811146|NO_INTERVENTION|Six-minute walk test|Compare a ventilatory metabolic response of the six-minute walk test with an ADL Glitre test.
62579979|NCT02811146|EXPERIMENTAL|Metabolic ventilatory response|"To verify if non-invasive ventilation during aerobic exercise modifies the ventilatory metabolic response in patients with heart failure.~Check the metabolic ventilatory response during the Glittre ADL test and six-minute walk test."
62786647|NCT00765570|ACTIVE_COMPARATOR|Treatment Group-2|Treatment Group 2-15 treatments with standard radiation
62786648|NCT01157026|EXPERIMENTAL|Tocotrienol Rich Fraction plus Tamoxifen|
62014452|NCT04908813|EXPERIMENTAL|HLX22(25mg/kg)+Trastuzumab + Chemotherapy (XELOX)|Participants receive 25mg/kg HLX22 IV every 3 weeks (Q3W) plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with XELOX chemotherapy
62014453|NCT04908813|EXPERIMENTAL|HLX22(15mg/kg)+Trastuzumab + Chemotherapy (XELOX)|Participants receive 15mg/kg HLX22 IV Q3W plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with XELOX chemotherapy
62014454|NCT04908813|ACTIVE_COMPARATOR|Placebo +Trastuzumab + Chemotherapy (XELOX)|Participants receive placebo IV Q3W plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with XELOX chemotherapy
62014455|NCT06573268||SPRA|patients who received da-Vinci SP robot thyroid surgery by SPRA method (Single Port Robotic Areolar)
62014456|NCT06573268||BABA|patients who received da-Vinci SP robot thyroid surgery by BABA method (Bilateral Axillary Breast Approach)
62014457|NCT04317586|OTHER|Trident II Tritanium Acetabular Shell for Revision|
62014458|NCT05797805|EXPERIMENTAL|Tegavivint single agent dosing regimen|Tegavivint as monotherapy
62579980|NCT03297320|ACTIVE_COMPARATOR|Team Referrals|In-depth conversations about Goals of Care and ACP (the intervention) will be held for the patients referred to the research team by the three healthcare teams in Internal Medicine at London Health Sciences Centre (University Campus)
62579981|NCT03297320|ACTIVE_COMPARATOR|Random selection|A random selection of patients (not referred to the research team by the healthcare team) in Internal Medicine at London Health Sciences Centre (University Campus) will be selected to have in-depth conversations about Goals of Care and ACP (the intervention)
62203581|NCT04301895|OTHER|Non-interactive|All verbal interaction will be avoided and extraneous sounds will be eliminated from the environment during the remifentanil infusion and recovery periods.
62403578|NCT04357756|EXPERIMENTAL|YH001 combined with Toripalimab|All the patients will receive YH001 intravenously as single agent for 21 days followed by combination phase.
62403579|NCT02064400||Observational study group|Musculoskeletal ultrasound (all patients) and semi-structured patient interview (anticipated maximum 15 patients)
62579982|NCT02702557|OTHER|Elastic Band Exercises|Unsupervised Elastic band exercises performed once a day until the patient is discharged from the hospital. One exercise for the upper extremity (row exercise level 1-3) and one exercise for the lower extremity (knee extension level 1-3). The two exercises are both performed as 3 sets of 10 repetitions.
62579983|NCT01223625|ACTIVE_COMPARATOR|Rosuvastatin 5mg/day|Rosuvastatin 5mg/day
62014459|NCT05797805|EXPERIMENTAL|Tegavivint plus pembrolizumab combination dosing regimen|Tegavivint in combination with pembrolizumab
62014460|NCT04382326|EXPERIMENTAL|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
62014461|NCT04382326|ACTIVE_COMPARATOR|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
62014462|NCT02804607||skin lesion|severe skin traumatism occurring during childhood and which had required an initial graft.
62014463|NCT05889858||"medical secretaries of general practitioners group"|Men and women working as a secretary for a general practitioner, face-to-face in the medical practice.
62014464|NCT00928317|EXPERIMENTAL|ART621 A|ART621 0.75mg/kg per week
62203582|NCT01593605|ACTIVE_COMPARATOR|Dietary Supplement/insulin sensitivity|The first study supplement contains resveratrol that may improve insulin sensitivity and Leucine.Resveratrol 50mg with leucine 1.11 g. - one tablet taken twice a day by mouth
62579984|NCT01223625|ACTIVE_COMPARATOR|Rosuvastatin 40mg/day|Rosuvastatin 40mg/day
62579985|NCT02048982|EXPERIMENTAL|Guideline and Cost|The Choosing Wisely guideline and the cost of the test at our institution: $60.35 for a basic metabolic panel.
62579986|NCT02048982|PLACEBO_COMPARATOR|Guideline|"The Choosing Wisely guideline: Don't perform blood chemistry panels in asymptomatic, healthy adults."
62579987|NCT02048982|ACTIVE_COMPARATOR|Guideline and Victim|The Choosing Wisely Guideline and a clinical scenario with a patient as an identifiable victim who suffered harm from having an unnecessary test done
62203583|NCT01593605|PLACEBO_COMPARATOR|Sugar Pill|Neutral treatment Placebo - one tablet taken twice a day by mouth
62014465|NCT00928317|EXPERIMENTAL|ART621 B|ART621 1.5 mg/kg per week
62014466|NCT00928317|EXPERIMENTAL|ART621 C|ART621 3.0mg/kg per week
62014467|NCT00928317|PLACEBO_COMPARATOR|Placebo arm|
62014468|NCT03243916|EXPERIMENTAL|combination|TACE plus cyber knife
62014469|NCT05280574||Monitoring without any interventions|All patients will only be monitored with the GE Portrait Monitor with out any interventions.
62014470|NCT05280574||Patients will be randomized to blinded or unblinded GE Portrait monitoring.|All patients will be monitored with the GE Portrait Monitor. Patients who are randomized to the unblinded GE Portrait monitoring might be intervened if the clinicians believe that the alarm is clinically meaningful. Blinded GE Portrait Monitoring will not receive clinicians believe clinically
62014471|NCT05760794|EXPERIMENTAL|Non-barbed delayed absorbable suture|Participants assigned to Non-barbed delayed absorbable suture group will have Non-barbed delayed absorbable suture used for vaginal mesh attachment at time of SCP
62014472|NCT05760794|EXPERIMENTAL|Barbed delayed absorbable suture|Participants assigned to Barbed delayed absorbable suture group will have Barbed delayed absorbable suture used for vaginal mesh attachment at time of SCP
62014473|NCT00537524|EXPERIMENTAL|Arm 1|0.5mL of H5N1 vaccine 7.5ug
62203584|NCT01593605|ACTIVE_COMPARATOR|Dietary Supplement 2|2nd study supplement contains resveratrol and HMB which may stimulate protein building.
62403580|NCT02335229||Axium DRG Neurostimulator|All eligible subjects recruited and treated with the Axium Neurostimulator
62403581|NCT05696457|EXPERIMENTAL|AML-E|Acute myeloblastic leukemia - experimental
62403582|NCT05696457|NO_INTERVENTION|AML-C|Acute myeloblastic leukemia - control
62014474|NCT00537524|ACTIVE_COMPARATOR|Arm 2|0.25 or 0.5mL of H5N1 vaccine
62014475|NCT01650389|EXPERIMENTAL|MVA85A|1 x 10(superscript'8') pfu MVA85A vaccine intradermal within 96 hours of birth
62014476|NCT01650389|ACTIVE_COMPARATOR|Candin|Equal volume intradermal administration within 96 hours of birth
62014477|NCT01363778|EXPERIMENTAL|tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
62014478|NCT04689984|EXPERIMENTAL|Experimental Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline and astaxanthin 6 mg tablet once daily (experimental group).
62014479|NCT04689984|ACTIVE_COMPARATOR|Control Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline.
62014480|NCT03740217|OTHER|Treatment A|Single oral dose of 400 mg GKT137831 administered as 4 x 100 mg capsules in fasting conditions.
62014481|NCT03740217|OTHER|Treatment B:|Single oral dose of 400 mg GKT137831 administered as 1 x 400 mg tablets in fasting conditions.
62014482|NCT03740217|OTHER|Treatment C|Single oral dose of 400 mg GKT137831 administered as 1 x 400 mg tablets in fed conditions.
62014483|NCT02690545|EXPERIMENTAL|ATLCAR.CD30 cells|"Phase Ib: In adults, and separately, in children, two doses will be investigated 1x10\^8 cells/m2 and 2x10\^8 cells/m\^2. The study team will run two independent dose-escalation sequences, one for adults and another one for children. The study team plans to use the 3+3 design and start with a low dose of 1x10\^8 cells/m2. If there are no DLT in first 3 patients, the study team will go up to the dose of 2 x 10\^8 cells/m2. If there is toxicity in 1/3 patients in the initial cohort, the study team would expand to enroll up to 6 patients. If there are dose limiting toxicities (DLT) at the dose of 2 x 10\^8 cells/m\^2, the study team will initially decrease the dose to an intermediate dose of 1.5 x 10\^8 cells/m\^.~Phase II: The study team planning to enroll 31 patients to contribute data. Sequential boundary will be used to monitor DLT rate."
62014484|NCT03395795|OTHER|Single arm|Single arm trial, every patient enroll in this study will follow the same protocol with classic and NAVA mode non-invasive ventilation.
62014485|NCT05132231||Brodalumab initiator|Eligible adult participants who are enrolling into the SILIQ (brodalumab) Patient Support Program (PSP) and initiating brodalumab as per routine care.
62014486|NCT05132231||Matched cohort|Participants treated with other therapies, with similar characteristics as the subgroup (participants who can be linked to an administrative health services database) of brodalumab treated participants such as age, gender/sex, comorbidities, and prior biologic experience.
62014487|NCT00847574|EXPERIMENTAL|Moderate-fat|35% of calories from fat
62014488|NCT00847574|EXPERIMENTAL|Lower-fat|20% of calories from fat
62014489|NCT06663839|EXPERIMENTAL|NILK-2301 Single Agent|NILK-2301 will be evaluated in patients with locally advanced or metastatic low tumor volume colorectal cancer
62014490|NCT01997775|EXPERIMENTAL|METFORMIN|For patients with stage IV lung adenocarcinoma and IL-6 level higher than 2.0 pg/ml after 2 cycles of standard treatment, metformin 500mg tid orally will be given.
62014491|NCT05286905|ACTIVE_COMPARATOR|Patients who receive cephalomedullary nail|Patients who receive cephalomedullary nail
62014492|NCT05286905|ACTIVE_COMPARATOR|Patients who receive proximal femur locking plate|Patients who receive proximal femur locking plate
62014493|NCT06295133|EXPERIMENTAL|Stress intervention|One arm : all volunteers will receive a stress management intervention.
62014494|NCT02294201|PLACEBO_COMPARATOR|Placebo|Placebo Repellent product with no active ingredient
62014495|NCT02294201|ACTIVE_COMPARATOR|Intervention|Spatial Repellent product with active ingredient
62203585|NCT04145700|EXPERIMENTAL|Ramucirumab + Gemcitabine + Docetaxel|Participants received intravenous (IV) infusions of ramucirumab 9 milligrams per kilogram (mg/kg), gemcitabine 900 milligrams per meter square (mg/m2) on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.
62403583|NCT05696457|EXPERIMENTAL|AlloSCT-E|Allogeneic stem cell transplantation - experimental
62014496|NCT00124150|EXPERIMENTAL|M|Intravenous magnesium sulfate infusion for 14 days.
62786649|NCT01157026|ACTIVE_COMPARATOR|Placebo plus tamoxifen|
62579988|NCT02048982|EXPERIMENTAL|Guideline, Cost, and Victim|The Choosing Wisely guideline and a clinical scenario with a physician as an identifiable victim who suffered harm when he ordered an unnecessary test.
62014497|NCT00124150|NO_INTERVENTION|S|Saline infusion without additional magnesium sulfate.
62786650|NCT00612196|EXPERIMENTAL|1|
62014498|NCT02360917|EXPERIMENTAL|Intervention|Participants in the intervention group will undergo 6 weeks of psycho-educational classes provided in a live setting at Cedars Sinai and a web based setting at The University of Kansas. Each class will focus on a different realm of coping with chemo-brain.
62014499|NCT02360917|OTHER|Waitlist|Participants assigned to the control group will be placed on a wait list for the Haze program. While they are waiting for admittance to the program, they will receive the same surveys as the participants who are taking the Haze class. Additionally, participants assigned to the control group will receive the surveys again when taking the class in order to allow comparison of the effects of the program on the control group. Participants assigned to the wait list will be enrolled in the following Haze series.
62014500|NCT01586442|ACTIVE_COMPARATOR|Spironolactone|spironolactone 12.5mg once daily titrated to 25mg once daily
62014501|NCT01586442|EXPERIMENTAL|Eplerenone|Eplerenone 25mg once daily titrated to 50mg once daily
62014502|NCT01179594|PLACEBO_COMPARATOR|A|
62014503|NCT01179594|EXPERIMENTAL|B|
62014504|NCT01179594|PLACEBO_COMPARATOR|C|
62014505|NCT01179594|EXPERIMENTAL|D|
62014506|NCT02030678|EXPERIMENTAL|irinotecan Hydrochloride|Irinotecan monotherapy (trade name: Aili; batches 180103AG \[40 mg\] and 171231AG \[100 mg\]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
62014507|NCT05437679||Active Surveillance (AS) Controls|Patients with low or very low risk prostate cancer who have been on active surveillance for 5 or more years with a stable PSA or on active surveillance for 2 or more years with negative multiparametric MRI (mpMRI) or mpMRI with a fusion biopsy(ies) confirming low risk disease.
62014508|NCT05437679||High Risk Localized Prostate Cancer (HRLPC)|Men with high-risk localized prostate cancer, defined as stage pT3a or Gleason score greater than or equal to 8 and/or pre-prostatectomy PSA of greater than or equal to 20 ng/mL.
62014509|NCT05437679||Biochemically Recurrent Localized Prostate Cancer (BCRLPC)|Systemic and/or hormonal treatment naive men with localized prostate cancer (pathological stages pT2, pT3a or pT4 with TNM N0 or N1 and M0 disease) who have clinical suspicion of biochemical recurrence 2 - 5 months following radical prostatectomy and are scheduled to undergo NGI (i.e., Axumin® or PSMA PETCT) within the next 45 days or have already undergone NGI within the past 45 days.
62203586|NCT04145700|ACTIVE_COMPARATOR|Gemcitabine + Docetaxel|Participants received intravenous infusions of gemcitabine 900 mg/m2 on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.
62203587|NCT02859090|EXPERIMENTAL|patient|
62203588|NCT03722225|EXPERIMENTAL|Descriptive, single arm, interventional study|The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during physical exercise and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control
62403584|NCT05696457|NO_INTERVENTION|AlloSCT-C|Allogeneic stem cell transplantation - control
62403585|NCT05696457|EXPERIMENTAL|AutoSCT-E(I)|Autologous stem cell transplantation - experimental (inpatient)
62579989|NCT06111859|EXPERIMENTAL|Liver Biopsy Cohort|
62786651|NCT00612196|EXPERIMENTAL|2|
62786652|NCT00612196|EXPERIMENTAL|3|
62786653|NCT00612196|EXPERIMENTAL|4|
62786654|NCT00612196|EXPERIMENTAL|5|
62786655|NCT00612196|EXPERIMENTAL|6|
62786656|NCT00612196|EXPERIMENTAL|7|
62786657|NCT00612196|EXPERIMENTAL|8|
62786658|NCT00612196|EXPERIMENTAL|9|
62786659|NCT00612196|PLACEBO_COMPARATOR|10|
62786660|NCT06030167|OTHER|Assessment of attachment and psychosocial functioning in adults with ASD|Questionaires about attachment, psychosocial functioning, depressive symptoms, paranoid ideation, and emotion regulation were administered to 83 autistic adults (50 males, 33 females).
62786661|NCT02612922|ACTIVE_COMPARATOR|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
62786662|NCT02612922|PLACEBO_COMPARATOR|Placebo|Two Placebo tablets orally twice daily (b.i.d.) for 5 days
62786663|NCT03406338|ACTIVE_COMPARATOR|Surgical fasciectomy|Fasciectomy according to usual care (surgery), implying excision of Dupuytren's cords and tissues to release the finger joint contractures
62786664|NCT03406338|EXPERIMENTAL|Collagenase Clostridium Histolyticum|Injection of 0.8 mg collagenase clostridium histolyticum into multiple spots in the Dupuytren cords followed by finger manipulation 1-2 days later to release the finger joint contractures
62786665|NCT03576859|OTHER|cirrhotic patients with chronic liver failure|
62786666|NCT03576859|OTHER|cirrhotic patients without chronic liver failure|
62786667|NCT04988750|EXPERIMENTAL|FUS + re-RT or FUS + SRS|"The SRS treatment will be administered for 3 consecutive days (one fraction of 7-9 Gy per day; total dose 21-27 Gy), including SRS treatment 1 (SRS 1), SRS treatment 2 (SRS 2), and SRS treatment 3 (SRS 3). At the SRS 1 and SRS 3, the patients will be shaved their hair at first, and the patient registration will be performed for the neuronavigation system according to the instruction of the system.~cRT will be administered for 5 consecutive days within one week, and a full course is two weeks (one fraction of 3-4 Gy per day; total dose: 30-40 Gy), including cRT treatment 1 to cRT treatment 10 (cRT 1-cRT 10). At the cRT 1, cRT 3, cRT 6, and cRT 8, the patients will be shaved their hair at first, and the patient registration will be performed for the neuronavigation system according to the instruction of the system."
62786668|NCT01388140||psychiatric inpatients, regardless of clinical diagnoses|
62014510|NCT05437679||Non-Metastatic Castration-Resistant Prostate Cancer (NMCRPC)|Patients with evidence of non-metastatic castration-resistant prostate cancer (i.e. localized prostate cancer patients with clinical symptoms of disease progression and/or evidence of a rising PSA following hormone therapy) who are scheduled to undergo NGI (i.e., Axumin® or PSMA PETCT) within the next 45 days or have already undergone NGI within the past 45 days and who have not started a new therapy for treatment of their castration-resistant prostate cancer.
62014511|NCT01903694|ACTIVE_COMPARATOR|sorafenib|800 mg of sorafenib twice daily orally.
62014512|NCT01903694|EXPERIMENTAL|sorafenib-pravastatin|800 mg of sorafenib twice daily oral doses associated with 40 mg of pravastatin in a taken per os. Pravastatin will be taken during dinner.
62014513|NCT06500078|EXPERIMENTAL|Intermittent dietary restriction group (ILCD or ICR)|Intermittent dietary restriction group will receive ILCD or ICR intervention. ILCD will be conducted as a carbohydrate intake restriction of ≤ 50 g/day for two consecutive or discontinuous days per week, and ICR will be conducted as a calorie intake restriction of 500-600 kcal/day for two consecutive or discontinuous days per week.
62014514|NCT06500078|ACTIVE_COMPARATOR|Health education group|Health education group will receive health education based on Chinese guidelines for school-aged children.
62786669|NCT02638168|ACTIVE_COMPARATOR|Immediate Release Methylphenidate|With-in subjects trial. Subjects will be randomized to 0.3 mg/kg of Immediate Release Methylphenidate versus placebo over 3-weeks duration
62786670|NCT02638168|PLACEBO_COMPARATOR|Placebo|inert placebo ingredient
62786671|NCT02670694||Rett Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Rett Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
62403586|NCT05696457|NO_INTERVENTION|AutoSCT-C(I)|Autologous stem cell transplantation - control (inpatient)
62403587|NCT05696457|EXPERIMENTAL|AutoSCT-E(O)|Autologous stem cell transplantation - experimental (outpatient)
62014515|NCT04819360|ACTIVE_COMPARATOR|Vesicare|Group 1: will be treated with an anticholinergic (Vesicare® 10 mg per day for 12 weeks)
62786672|NCT02670694||Angelman's Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Angelman's Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
62786673|NCT02670694||Prader-Willi Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Prader-Willi Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
62786674|NCT02670694||Control|Siblings of RTT, AS and PW subjects will serve as control subjects.
62014516|NCT04819360|ACTIVE_COMPARATOR|Botox|Group 2: will receive an intra-detrusor injection of a low dose of botulinum toxin type A (100 U of BOTOX®).
62014517|NCT00753441|EXPERIMENTAL|A|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
62215166|NCT03814031||EAD after orthotopic liver transplantation|Early allograft dysfunction (EAD), which was defined by the presence of one or more of the following: total bilirubin (t-bil) ≥ 10 mg/dL (171 μmol/L) or, INR ≥ 1.6 on day 7, and ALT/AST \> 2,000 IU/L within the first 7 days.
62786675|NCT06438055|EXPERIMENTAL|Organoid-Guided therapy|All patients will be included in a single-arm. Participants will undergo biopsy of tumor tissue for subsequent organoid generation and drug sensitivity tests.
62786676|NCT01561742|EXPERIMENTAL|Minocycline|
62786677|NCT01561742|PLACEBO_COMPARATOR|Placebo|
62786678|NCT00652951|ACTIVE_COMPARATOR|Synflorix + Infanrix hexa Group|Subjects received 3 doses of SynflorixTM vaccine co-administered with Infanrix hexaTM at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (SynflorixTM) or left (Infanrix hexaTM) thigh or deltoid.
62786679|NCT00652951|EXPERIMENTAL|Synflorix + Pediacel Group|Subjects received 3 doses of SynflorixTM vaccine co-administered with PediacelTM at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (SynflorixTM) or left (PediacelTM) thigh or deltoid.thigh or deltoid.
62786680|NCT00652951|ACTIVE_COMPARATOR|Prevenar + Pediacel Group|Subjects received 3 doses of PrevenarTM co-administered with PediacelTM vaccine at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (PrevenarTM) or left (PediacelTM) thigh or deltoid.
62786681|NCT06490042||study group|The study group consists of children between 6 and 18 years presenting at the ED of the Erasmus Medical Centre (Erasmus MC) in Rotterdam after a bicycle accident between January 2017 and June 2024.
62786682|NCT06490042||control group|The control group consists of children between 6 and 18 years in primary and secondary schools without a presentation at a ED after a bicycle accident in the past.
62786683|NCT01629758|EXPERIMENTAL|Part 1-Arm A: BMS-982470 (weekly x 4) + BMS-936558|Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
62786684|NCT01629758|EXPERIMENTAL|Part 1-Arm B: BMS-982470 (3 times/week) + BMS-936558|Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: 3 times/week during weeks 1 and 3, Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
62786685|NCT01629758|EXPERIMENTAL|Part 2-Arm A: BMS-982470 (weekly x 4) + BMS-936558|Cohort Expansion BMS-982470 (dose selected in Part 1) Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
62014518|NCT00753441|ACTIVE_COMPARATOR|B|Endoscopic biliary stenting using metal stent (completed by duodenal stent, if necessary)
62014519|NCT05464511|NO_INTERVENTION|Patients with Amulet device using non-steerable fixed curve sheath|Patients undergoing left atrial appendage occlusion with the dual mechanism closure Amulet device using non-steerable fixed curve sheath.
62014520|NCT05464511|ACTIVE_COMPARATOR|Patients with Amulet device using a novel steerable sheath|Patients undergoing left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.
62014521|NCT06571786|EXPERIMENTAL|SHAPE for ICP diagnosis|
62014522|NCT04212507||1|50 psoriatic patients
62215167|NCT03814031||No EAD after orthotopic liver transplantation|No EAD
62403588|NCT05696457|NO_INTERVENTION|AutoSCT-C(O)|Autologous stem cell transplantation - control (outpatient)
62014523|NCT04212507||2|30 age and sex-matched healthy volunteers as a control group
62014524|NCT05179954|OTHER|Control group|Healthy control group
62014525|NCT05179954|ACTIVE_COMPARATOR|T1D group|T1D group
62014526|NCT04798586|EXPERIMENTAL|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
62403589|NCT03080207|EXPERIMENTAL|Platelets / Platelet Enriched Plasma Regard (PRP) Method|
62403590|NCT03080207|EXPERIMENTAL|Complex Decongestive Physiotherapy|
62403591|NCT03080207|EXPERIMENTAL|Low Level Laser|
62403592|NCT04614480|OTHER|Metastatic breast cancers|
62403593|NCT04614480|OTHER|Metastatic prostate cancers|
62403594|NCT04614480|OTHER|Metastatic lung cancers|
62403595|NCT04614480|OTHER|Metastatic colorectal cancers|
62403596|NCT04614480|OTHER|metastatic otorhinolaryngeal cancer|
62403597|NCT04614480|OTHER|metastatic ovarian cancer|
62403598|NCT04614480|OTHER|Pancreatic cancers|
62403599|NCT04614480|OTHER|Others metastatic cancers|
62403600|NCT04614480|OTHER|Metastatic sarcoma|
62579990|NCT00813813|EXPERIMENTAL|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
62579991|NCT04927130||Women in age 35 to 65 with confirmed breast cancer|
62579992|NCT04927130||Healthy Volunteers|
62579993|NCT01077154|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injections once every 4 weeks for 6 months followed by placebo subcutaneous injections once every 3 months for 4.5 years.
62579994|NCT01077154|EXPERIMENTAL|Denosumab|Participants received denosumab 120 mg subcutaneous injections once every 4 weeks for 6 months followed by denosumab 120 mg subcutaneous injections once every 3 months for 4.5 years.
62786686|NCT00661817|ACTIVE_COMPARATOR|1|Participants in this group will receive usual medical care and reading materials on weight loss.
62403601|NCT01224600||1|patient with newly diagnosed PAD (\< 1 year)
62014527|NCT03455855|EXPERIMENTAL|treated with the Jetstream System|It is intended that all patients with qualifying lesions would be considered for enrollment and treated with the Jetstream System.
62014528|NCT06043557|ACTIVE_COMPARATOR|left side lateral and right side medial|left side lateral and right side medial
62014529|NCT06043557|ACTIVE_COMPARATOR|right side lateral with left side medial|right side lateral with left side medial
62403602|NCT02246205|EXPERIMENTAL|DPC DN|Roux-en Y reconstruction after pancreaticoduodenectomy
62403603|NCT02246205|ACTIVE_COMPARATOR|DPC UN|Child reconstruction after pancreaticoduodenectomy
62403604|NCT00205361||1|well-nourished
62403605|NCT00205361||2|malnourished
62403606|NCT00656669|EXPERIMENTAL|1|The study will be conducted in 3 sequential treatment segments.
62403607|NCT01863394|ACTIVE_COMPARATOR|Screening by community health workers|"One Community Health Worker (CHW) will be trained per village in the comparator arm. The training the CHWs receive will be identical to that delivered in the Community Management of Acute Malnutrition program run by ALIMA/BEFEN (Bien Être de la Femme et l'Enfant Niger) over the last 3 years. This involves 6 hours theoretical training and a practical session in the health centre.~CHWs will screen children 06-59 months in their village once a month"
62403608|NCT01863394|EXPERIMENTAL|Screening by mothers|"Mothers in the intervention health district will be trained in small womens' groups in their village. Training will have a theoretical component and a practical demonstration component on children in the village~During the first baseline door to door mass screening campaign, mothers will also receive individual training on conducting a Mid Upper Arm Circumference (MUAC) classification and looking for pedal oedema. they will receive a brief recap during the three monthly door-to-door mass screening campaigns~Mothers will be asked to check their child's MUAC and look for pedal oedema~* whenever the child does not seem to be in 'good health' to the mother~* whenever the mother feels that the child is 'unwell' or 'sick'~* whenever it seems to the mother that her child has lost weight~* whenever the mother thinks that it is necessary to do so"
62403609|NCT01355380||Group 1|Drug (incl. Placebo)
62403610|NCT02665754|EXPERIMENTAL|Active group|In active group, extract of causal allergen will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
62403611|NCT02665754|PLACEBO_COMPARATOR|Placebo group|In placebo group, normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
62403612|NCT01400191|ACTIVE_COMPARATOR|Homozygote wildtype OCT1|
62403613|NCT01400191|ACTIVE_COMPARATOR|Heterozygote OCT1|
62403614|NCT01400191|ACTIVE_COMPARATOR|Homozygote OCT1 variant|
62403615|NCT03158454|OTHER|Capsula Closure|
62579995|NCT05127876|EXPERIMENTAL|Group E|Monitoring with pulse oximetry, noninvasive blood pressure measurement and electrocardiogram was established on arrival to the operating room Group E: were administered intravenous ephedrine 10 mg diluted in 10 mL 0.9% saline over 1 minute; Then under aseptic precautions, spinal anesthesia was administered.
62579996|NCT05127876|EXPERIMENTAL|Group OL|Monitoring with pulse oximetry, noninvasive blood pressure measurement and electrocardiogram was established on arrival to the operating room Group OL: were administered intravenous ondansetron 4 mg diluted in 10 mL 0.9% saline over 1 minute; Then under aseptic precautions, spinal anesthesia was administered.
62579997|NCT05127876|EXPERIMENTAL|Group OH|Monitoring with pulse oximetry, noninvasive blood pressure measurement and electrocardiogram was established on arrival to the operating room Group OH: were administered intravenous ondansetron 8 mg diluted in 10 mL 0.9% saline over 1 minute; Then under aseptic precautions, spinal anesthesia was administered.
62786687|NCT00661817|EXPERIMENTAL|2|Participants in this group will take part in the lifestyle modification program.
62786688|NCT00580385|EXPERIMENTAL|1|
62786689|NCT01969435|EXPERIMENTAL|Melphalan, carmustine, etoposide, cytarabine (BEAM)|"* Day -7, carmustine intravenous (IV) infusion~* Days -6, -5, -4, and -3, etoposide and cytarabine (IV) infusions twice a day~* Day -2, melphalan HCl (propylene glycol-free)(IV) infusion~* Day 0, stem cell transplant."
62786690|NCT03165916|EXPERIMENTAL|Reconstruction with stent placement|Subjects will undergo biliary reconstruction with stent placement at the anastomosis site.
62203589|NCT06143592|EXPERIMENTAL|Low-Intensity Inspiratory Muscle Training Group (LI-IMT)|"Before the training, the MIP value is recorded in cmH2O. The inspiratory muscle training intensity in the first four weeks is determined by taking 30% of the MIP value and the resistance of the device is adjusted to this level. The pressure measurements of the participants are repeated in the 4th week and the new MIP value is determined. Then, 30% of the new MIP value is taken to determine the training intensity in the 4th to 8th week and the resistance of the device is adjusted to this new level. This situation is repeated in the same way in the 8th week and the new training intensity in the 8th to 12th week is determined by taking 30% of the new MIP value. According to the MIP values obtained during the entire training period, participants are asked to work at home for 12 weeks, three to five days a week, 2 times a day, 15-minutes each, 30 minutes total."
62403616|NCT03158454|OTHER|Non-Capsula Closure|
62579998|NCT05127876|PLACEBO_COMPARATOR|Group P|"Monitoring with pulse oximetry, noninvasive blood pressure measurement and electrocardiogram was established on arrival to the operating room Group P: was a control group who received 0.9% saline 10 mL over 1 minute as a placebo.~Then under aseptic precautions, spinal anesthesia was administered."
62786691|NCT03165916|NO_INTERVENTION|Reconstruction without stent placement|Subjects will undergo biliary reconstruction without stent placement.
62403617|NCT01985880||Hunner's ulcer interstitial cystitis|Hunner's ulcer interstitial cystitis
62403618|NCT01985880||non-ulcer interstitial cystitis|non-ulcer interstitial cystitis
62403619|NCT01985880||Control|Control
62403620|NCT00694070||health care professionals and lay users|h= 8 health care professionals p= 43 lay users
62403621|NCT05116410|EXPERIMENTAL|HS-20094 (Single dose)|Escalating doses of HS-20094 administered subcutaneously (SC) once in healthy participants.
62403622|NCT05116410|EXPERIMENTAL|HS-20094 (Multiple doses)|Escalating doses of HS-20094 administered SC once weekly for four weeks in healthy participants.
62403623|NCT05116410|PLACEBO_COMPARATOR|Placebo (Single dose)|Placebo administered SC once in healthy participants.
62403624|NCT05116410|PLACEBO_COMPARATOR|Placebo (Multiple doses)|Placebo administered SC once weekly for four weeks in healthy participants.
62403625|NCT04647773|EXPERIMENTAL|HSK16149 20mg BID|
62403626|NCT04647773|EXPERIMENTAL|HSK16149 40mg BID|
62403627|NCT04647773|EXPERIMENTAL|HSK16149 60mg BID|
62203590|NCT06143592|EXPERIMENTAL|Modarate-Intensity Inspiratory Muscle Training Group (MI-IMT)|"Before the training, the MIP value is recorded in cmH2O. The inspiratory muscle training intensity in the first four weeks is determined by taking 50% of the MIP value and the resistance of the device is adjusted to this level. The pressure measurements of the participants are repeated in the 4th week and the new MIP value is determined. Then, 50% of the new MIP value is taken to determine the training intensity in the 4th to 8th week and the resistance of the device is adjusted to this new level. This situation is repeated in the same way in the 8th week and the new training intensity in the 8th to 12th week is determined by taking 50% of the new MIP value. According to the MIP values obtained during the entire training period, participants are asked to work at home for 12 weeks, three to five days a week, 2 times a day, 15-minutes each, 30 minutes total."
62203591|NCT06143592|EXPERIMENTAL|Control Group (Sham Group)|Participants in the control group are given a POWERbreathe® device with the resistance set to the lowest level (0 cmH2O) at the end of the session where the initial assessments are made. As in the training group, participants are asked to work at home for 12 weeks, three to five days a week, 2 times a day, 15-minutes each, 30 minutes total. In order to eliminate the learning effect on the participants, pressure measurements are made in the 4th and 8th weeks, but the training intensity is kept constant at the lowest level during the 12 weeks.
62203592|NCT02032589|EXPERIMENTAL|Self-generation treatment|self-generation strategy treatment, embedded within practice of various activities
62203593|NCT02032589|PLACEBO_COMPARATOR|memory training|Treatment consists on traditional memory training
62203594|NCT02748889|ACTIVE_COMPARATOR|Carboplatin plus etoposide|Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles
62203595|NCT02748889|EXPERIMENTAL|Carboplatin, etoposide and MPDL3280A|Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles MPDL3280A (Atezolizumab) 1200mg iv on day 1 every 21 days until progression
62203596|NCT00655018|EXPERIMENTAL|Vitamin group|alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention \[hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity\].
62203597|NCT00655018|PLACEBO_COMPARATOR|2|placebo and lifestyle intervention \[hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity\].
62203598|NCT01862380|EXPERIMENTAL|Cases|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively in female patients with non classical 21-hydroxylase deficiency.
62203599|NCT01862380|EXPERIMENTAL|Control|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively in healthy female controls.
62203600|NCT05092126|ACTIVE_COMPARATOR|6MST VO2|Completion of 6MST exercise protocol
62203601|NCT05092126|ACTIVE_COMPARATOR|DASI VO2|Completion of DASI fitness activity questionnaire
62203602|NCT01146600|EXPERIMENTAL|Random Group A|Subjects will be randomized to group A or group B. The order of presentation of placebo and clarithromycin will be opposite in these two groups, but investigators and subjects will remain blinded to group allocation and order of treatment presentation within the groups.
62203603|NCT01146600|EXPERIMENTAL|Random Group B|Subjects will be randomized to group A or group B. The order of presentation of placebo and clarithromycin will be opposite in these two groups, but investigators and subjects will remain blinded to group allocation and order of treatment presentation within the groups.
62203604|NCT06195930|EXPERIMENTAL|Overall study|At Visit 1 participants will receive 1x 5 mg Vericiguat (BAY1021189) tablet daily (on top of standard of care) for at least 14 days to max 18 days (+4 days time window allowed)
62203605|NCT04605289|EXPERIMENTAL|Group I (study group)|Scaling and root planing + intra-pocket application of 2% Cymbopogon citratus (lemon-grass) gel
62203606|NCT04605289|PLACEBO_COMPARATOR|Group II (control group)|Scaling and root planing +intra-pocket application of placebo gel
62203607|NCT06020183|EXPERIMENTAL|Hybrid Hyrax|these patents will be treated using Four mini-screws supported hyrax
62203608|NCT06020183|NO_INTERVENTION|untreated control group|Ethically ,these patents will be treated at the end of the study using the same appliance used for the experimental group
62203609|NCT00082875|EXPERIMENTAL|Arm I|"Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11\*, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: \*For the first course only, treatment is omitted on day 11"
62203610|NCT00082875|EXPERIMENTAL|Arm II|Patients receive cilengitide as in arm I at a higher dose.
62203611|NCT03151070||Zone 1|"Zone 1 includes the following communities from Huehuentenango Distric:~* San Rafael Petzal~* San Sebastian Huehuetenango~* San Gaspar Ixchil~* Santa Bárbara~* Colotenango~* Aguacatán"
62203612|NCT03151070||Zone 2|"Zone 2 includes the following communities from Alta Verapaz district:~* Tamahú~* San Miguel Tucurú~* Panzós~* Senahú~* Telemán"
62203613|NCT03151070||Zone 3|"Zone 3 includes the following communities from Huehuetenango district:~* San Idelfonso Ixtahuacán~* La Democracia~* San Juan Atitán~* Tectitán~* Santiago Chimaltenango"
62403628|NCT04647773|EXPERIMENTAL|HSK16149 80mg BID|
62403629|NCT04647773|ACTIVE_COMPARATOR|Pregabalin 150mg BID|
62014530|NCT03239041|ACTIVE_COMPARATOR|Intervention Arm|"The intervention group will have access to the services of a social navigation team. The social navigation team will consist of trained community health liaisons, a clinician and a social worker.~The social navigation team will function as follows:~The research assistant will then instruct the community health intern to review the results of the completed computerized survey. The community health intern will review the results, create a plan of action, i.e. specific referrals to community agencies and next steps needed by the caregiver and or adolescent (e.g., documents to gather, appointments to make, etc.), following pre-developed protocols for each risk area. Each plan will be reviewed with the social worker prior to presentation to the family. Each family will also receive a packet of community resources relevant to each social domain covered in the screening survey, similar to that provided to the enhanced usual care group."
62014531|NCT03239041|NO_INTERVENTION|Enhanced Usual Care Arm|The enhanced usual care arm will only receive printed information regarding community resources.
62014532|NCT05415098|EXPERIMENTAL|Cohort 1 in Dose expansion|
62014533|NCT05415098|EXPERIMENTAL|Cohort 2 in Dose expansion|
62014534|NCT03424421|EXPERIMENTAL|subscapular sling|semitendinosus subscapular sling procedure
62014535|NCT05409924|EXPERIMENTAL|Phase A|ATR-258 Single Ascending Dose or placebo
62014536|NCT05409924|EXPERIMENTAL|Phase B|ATR-258 Multiple Ascending Dose or placebo
62014537|NCT05409924|EXPERIMENTAL|Phase C|ATR-258 Repeated dosing or placebo
62014538|NCT02229955|EXPERIMENTAL|T-sporin eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
62014539|NCT02229955|ACTIVE_COMPARATOR|Restasis eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
62014540|NCT04846140|EXPERIMENTAL|tDCS group|This group is defined as the participants who will receive tDCS at the first session. Participants in this group will receive 4 stimulation types (active a-tDCS, tACS, tRNS, and sham) in random order with at least a 48-hour separation between visits.
62014541|NCT04846140|EXPERIMENTAL|tACS group|This group is defined as the participants who will receive tACS at the first session. Participants in this group will receive 4 stimulation types (active a-tDCS, tACS, tRNS, and sham) in random order with at least a 48-hour separation between visits.
62014542|NCT04846140|EXPERIMENTAL|tRNS group|This group is defined as the participants who will receive tRNS at the first session. Participants in this group will receive 4 stimulation types (active a-tDCS, tACS, tRNS, and sham) in random order with at least a 48-hour separation between visits.
62786692|NCT03161106|EXPERIMENTAL|Nutrional Therapy Group|Nutritional group- Protein of 1.5 gm/kg thrice daily for 6 months
62014543|NCT04846140|EXPERIMENTAL|sham group|This group is defined as the participants who will receive sham stimulation at the first session. Participants in this group will receive 4 stimulation types (active a-tDCS, tACS, tRNS, and sham) in random order with at least a 48-hour separation between visits.
62014544|NCT03880578||surgery (withdrawn, not continuing recruiting)|thyroid patients receiving replacement treatment with levothyroxine (LT4) after thyroidectomy
62014545|NCT03880578||radioiodine|thyroid patients receiving replacement treatment with levothyroxine (LT4) following radioiodine treatment
62014546|NCT03880578||control|thyroid patients followed without surgery or radioiodine treatment
62014547|NCT02366572|PLACEBO_COMPARATOR|Cereal control|100% Wheat Flour
62014548|NCT02366572|EXPERIMENTAL|Cereal with pea protein|Pea protein
62014549|NCT02366572|EXPERIMENTAL|Cereal with pea starch|Pea starch
62014550|NCT02366572|EXPERIMENTAL|Cereal w/ pea starch + pea fibre: 5g|Pea starch + pea fibre: 5g
62203614|NCT03151070||Zona 4|"Zone 4 includes the following communities from Alta Verapaz district:~* Lanquín~* Santa María Cahabón~* Chisec~* Chahal~* Raxruhá~* Campur"
62203615|NCT03151070||Zona 5|"Zone 5 includes the following communities from Huehuetenango district:~* Nenton~* Jacaltenango~* Todos Santos Cuchumatán~* Santa Eulalia~* San Mateo Ixtatán~* San Juan Ixcoy"
62203616|NCT03151070||Zona 6|"Zone 6 includes the following communities from Alta Verapaz district:~* Santa Cruz Verapaz~* Tactic~* San Pedro Carchá~* San Juan Chamelco"
62203617|NCT02865239|PLACEBO_COMPARATOR|Supine position|3.0 tesla MRI in supine position
62203618|NCT02865239|ACTIVE_COMPARATOR|Prone position|3.0 tesla MRI in prone position
62203619|NCT05703906|EXPERIMENTAL|Telerehabilitation|"All patients will receive a kit home-based consisting of a tablet home, an exercise equipment and access to a daily individualized training program based on their needs (i.e., motor, language and/or cognitive training programs).~The exercise program and patients' sessions will be remotely supervised by therapists."
62203620|NCT01049451|EXPERIMENTAL|ACTH IM monthly|Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
62403630|NCT04647773|PLACEBO_COMPARATOR|Placebo BID|
62403631|NCT06291870||COVID+|Patients with post-acute sequelae of SARS-COV-2 infection (PSAC) and obstructive sleep apnea (OSA)
62403632|NCT06291870||Control|Patients with obstructive sleep apnea and no history of COVID-19
62014551|NCT02366572|EXPERIMENTAL|Cereal w/ pea protein + pea starch: 10g|Pea protein + pea starch: 10g
62403633|NCT05277987|EXPERIMENTAL|HEC-016|Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells
62786693|NCT03161106|ACTIVE_COMPARATOR|Lactulose Group|Lactulose - 20 mL thrice daily (maximum) for 6 months
62014552|NCT02366572|EXPERIMENTAL|Cereal w/ pea protein + pea fibre + pea starch: 20g|Pea protein + pea fibre + pea starch: 20g
62014553|NCT01063010|PLACEBO_COMPARATOR|Placebo|Placebo IV for 90 minutes (+ 15 minutes)
62014554|NCT01063010|EXPERIMENTAL|Bevicizumab|IV infusion over 90 minutes
62014555|NCT00134277|ACTIVE_COMPARATOR|Infragenual dilatation with stenting|
62014556|NCT00134277|ACTIVE_COMPARATOR|Infragenual dilatation with cutting balloon|
62014557|NCT00134277|ACTIVE_COMPARATOR|Laser therapy|
62014558|NCT00134277|PLACEBO_COMPARATOR|Infragenual dilatation|
62014559|NCT06571461|EXPERIMENTAL|NASOX：Liposomal Irinotecan; Oxaliplatin; S-1|Liposomal irinotecan at a dose of 50 mg/m² is administered intravenously over 90 minutes on D1. Oxaliplatin is administered at a dose of 60 mg/m² intravenously over 2 hours on D1. S-1 at a dose of 40 to 60mg twice daily is taken orally for 7 consecutive days, followed by a 7-day break. These medications are administered once every 2 weeks for a total of 12 cycles.
62014560|NCT06571461|ACTIVE_COMPARATOR|GX：Gemcitabine; Capecitabine|Gemcitabine at a dose of 1000mg/m² is administered via intravenous infusion over 30 minutes on D1, 8, and 15 of a 28-day cycle. Capecitabine at a dose of 1660mg/m² per day in two divided oral doses is taken for 21 consecutive days, followed by a 7-day rest period. These medications are administered once every 4 weeks for a total of 6 cycles.
62203621|NCT01049451|ACTIVE_COMPARATOR|MP IV monthly|Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months.
62203622|NCT04542213|EXPERIMENTAL|DPP4 inhibitor + insulin|Patients assigned to this group of treatment will receive Linagliptin 5mg orally once daily plus a basal-bolo insulin scheme
62203623|NCT04542213|ACTIVE_COMPARATOR|Insulin scheme alone|Patients assigned to this group will receive only a basal-bolus insulin scheme
62203624|NCT00571181|EXPERIMENTAL|1|
62203625|NCT00571181|ACTIVE_COMPARATOR|2|
62786694|NCT06058325|NO_INTERVENTION|Control group|Students will bring their own lunch box in the control period.
62014561|NCT02501330||Bosutinib|
62014562|NCT06460311|EXPERIMENTAL|Group A|PEDAL and EMS
62014563|NCT06460311|ACTIVE_COMPARATOR|Group B|PEDAL
62014564|NCT06186388|OTHER|Pathology|Subjects with glaucoma-affected eyes
62014565|NCT06186388|OTHER|Normal|Subjects with healthy eyes
62014566|NCT06146244||Native bone|the evolution of the SSI and its change after 3 months of placing the implant in native bone in the antral area
62014567|NCT06146244||Regenerated Bone|the evolution of the SSI and its change after 3 months of placing the implant in regenerated bone in the antral area
62014568|NCT01813604|ACTIVE_COMPARATOR|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
62203626|NCT04735848|EXPERIMENTAL|6mg iron-supplement|All participants will be in this arm. Everyone will take all three different doses of iron-supplement (6mg; 30mg;60mg).
62203627|NCT04735848|EXPERIMENTAL|30mg iron-supplement|All participants will be in this arm. Everyone will take all three different doses of iron-supplement (6mg; 30mg;60mg).
62203628|NCT04735848|EXPERIMENTAL|60mg iron-supplement|All participants will be in this arm. Everyone will take all three different doses of iron-supplement (6mg; 30mg;60mg).
62203629|NCT04735848|NO_INTERVENTION|Baseline|Baseline measurement
62203630|NCT03215940|ACTIVE_COMPARATOR|Delta-9-Tetrahydrocannabinol's (Delta-9-THC) effects on pain|This arm will be testing the analgesic effects of orally dosed Delta-9-Tetrahydrocannabinol on subjects with chronic non-cancer pain.
62203631|NCT03215940|ACTIVE_COMPARATOR|Cannabidiol's (CBD) effects on pain|This arm will be testing the analgesic effects of orally dosed Cannabidiol on subjects with chronic non-cancer pain.
62203632|NCT03215940|PLACEBO_COMPARATOR|Placebo|This Placebo arm will act as the control as standard of care medications will be continued through the study. This arm will allow us to compare the analgesic effects of the other two arms with the standard of care treatments for chronic non-cancer pain.
62203633|NCT05461170|EXPERIMENTAL|Cohort 1a (VIR-2218)|Participants will receive multiple doses of VIR-2218 for up to 96 weeks total.
62203634|NCT05461170|EXPERIMENTAL|Cohort 1b (VIR-3434)|Participants will receive multiple doses of VIR-3434 for up to 96 weeks total.
62203635|NCT05461170|EXPERIMENTAL|Cohort 2a (VIR-2218)|Participants will receive multiple doses of VIR-2218 for up to 192 weeks.
62203636|NCT05461170|EXPERIMENTAL|Cohort 2b1 (VIR-3434)|Participants will receive multiple doses of VIR-3434 for up to 192 weeks.
62203637|NCT05461170|EXPERIMENTAL|Cohort 2b2 (VIR-3434)|Participants will receive multiple doses of VIR-3434 for up to 192 weeks.
62203638|NCT05461170|EXPERIMENTAL|Cohort 2c (VIR-2218 + VIR-3434)|Participants will receive multiple doses of VIR-2218 + VIR-3434 for up to 192 weeks.
62786695|NCT06058325|EXPERIMENTAL|Intervention group|Students will get a healthy lunch at school in the intervention period.
62014569|NCT01813604|ACTIVE_COMPARATOR|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
62014570|NCT01813604|ACTIVE_COMPARATOR|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
62014571|NCT01813604|ACTIVE_COMPARATOR|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
62014572|NCT01813604|ACTIVE_COMPARATOR|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
62786696|NCT04269876|EXPERIMENTAL|Marine Lipid Oil concentrate|Dietary Supplement: Marine Lipid oil concentrate softgel and dietary supplement capsules
62786697|NCT04269876|PLACEBO_COMPARATOR|Placebo|Placebo softgels with Placebo capsules
62014573|NCT00120042|NO_INTERVENTION|1|No specific oxytocic to assist in placental delivery
62014574|NCT00120042|ACTIVE_COMPARATOR|2|Intramuscular oxytocin injection
62014575|NCT00120042|ACTIVE_COMPARATOR|3|Oral misoprostol to assist in placental delivery
62014576|NCT01003431|EXPERIMENTAL|1|RotaTeq™ + DTwP
62014577|NCT01003431|ACTIVE_COMPARATOR|2|Rotarix™ + DTwP
62014578|NCT01003431|ACTIVE_COMPARATOR|3|RotaTeq™ + DTaP
62014579|NCT06440525|EXPERIMENTAL|RSLV-132|Intravenous infusions of 10 mg/kg RSLV-132 solution on Days 1, 8, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, and 155) for a total of 22 weeks of treatment
62014580|NCT06440525|PLACEBO_COMPARATOR|Placebo|Intravenous infusions of placebo solution on Days 1, 8, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, and 155) for a total of 22 weeks of treatment
62014581|NCT04551105|ACTIVE_COMPARATOR|First session: manual review first and then review with CADx|"Reader Group X interpret the Dataset A cases in different random order without any assistance of AI first, and then interpret the Dataset B cases in different random order with TaiHao AI system."
62014582|NCT04551105|ACTIVE_COMPARATOR|First session: review with CADx first and then manual review|"Reader Group Y interpret the Dataset A cases in different random order with TaiHao AI system first, and then interpret the Dataset B cases in different random order without any assistance of AI."
62014583|NCT04551105|ACTIVE_COMPARATOR|Second session: manual review first and then review with CADx|"At least 4 weeks after first session for memory washing out. Reader Group X interpret the Dataset A cases in different random order with TaiHao AI system first, and then interpret the Dataset B cases in different random order without any assistance of AI."
62786698|NCT02276443|EXPERIMENTAL|Arm A (predictive results given)|Patients undergo baseline molecular and IHC evaluation of their tumor biopsy, and receive the results. Patients then receive standard anthracycline-based chemotherapy and undergo standard ultrasound at baseline, after 2 cycles, after 4 cycles of treatment, and after completion of treatment (before surgery). Patients and physicians are notified of the results of the molecular evaluation. Patients may then choose to continue with standard taxane +/- platinum-based chemotherapy or participate in an experimental clinical trial designed to match the molecular profile and triple-negative subtype. Patients with tumors predicted to be insensitive to chemotherapy are advised to participate in a clinical trial treating their tumor subtype.
62203639|NCT05461170|EXPERIMENTAL|Cohort 3 (VIR-3434)|Participants will receive multiple doses of VIR-3434 for up to 192 weeks.
62014584|NCT04551105|ACTIVE_COMPARATOR|Second session: review with CADx first and then manual review|"At least 4 weeks after first session for memory washing out. Rader Group Y interpret the Dataset A cases in different random order without any assistance of AI first, and then interpret the Dataset B cases in different random order with TaiHao AI system."
62014585|NCT04589559|EXPERIMENTAL|Intervention: Heart Rate Variability Biofeedback|Participants in this intervention group complete at-home heart rate variability biofeedback (HRVB) training using a chest-worn heart rate monitor and a smartphone app. They complete at least 10 minutes per day of HRVB training on at least 5 days per week for 3 weeks.
62014586|NCT06460194|ACTIVE_COMPARATOR|Botulinum toxin|100 IU botulinum toxin injection in the palm of the hand
62014587|NCT06460194|PLACEBO_COMPARATOR|Placebo|Saline injection in the palm of the hand
62203640|NCT05461170|PLACEBO_COMPARATOR|Cohort 4 (NRTI)|Participants will receive NRTI for 12 weeks, then assign to Cohort 2c or Cohort 3.
62203641|NCT05461170|EXPERIMENTAL|Cohort 5 (VIR-2218)|Participants will receive multiple doses of VIR-2218 for 12 weeks, then assign to Cohort 2c.
62203642|NCT04243551|ACTIVE_COMPARATOR|Latiglutenase|IMGX003
62203643|NCT04243551|PLACEBO_COMPARATOR|Placebo|Placebo
62403634|NCT02464176|EXPERIMENTAL|4 mg dexamethasone group|Following lumbar plexus nerve block administration using bupivacaine and epinephrine, 4 mg of systemic dexamethasone will be administered to this group intravenously. The volume given intravenously will be identical for all groups.
62203644|NCT03430180|PLACEBO_COMPARATOR|placebo nasal spray|Drug: placebo nasal spray One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
62203645|NCT03430180|ACTIVE_COMPARATOR|Naloxone hydrochloride 40mg/ml nasal spray|Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
62203646|NCT03248882|PLACEBO_COMPARATOR|Placebo|Double-Blind, PF-05221304-matching Placebo
62203647|NCT03248882|ACTIVE_COMPARATOR|PF-05221304 - 2 mg|PF-05221304 - 2 mg, once-daily
62203648|NCT03248882|ACTIVE_COMPARATOR|PF-05221304 - 10 mg|PF-05221304 - 10 mg, once-daily
62203649|NCT03248882|ACTIVE_COMPARATOR|PF-05221304 - 25 mg|PF-05221304 - 25 mg, once-daily
62203650|NCT03248882|ACTIVE_COMPARATOR|PF-05221304 - 50 mg|PF-05221304 - 50 mg, once-daily
62203651|NCT02944201|EXPERIMENTAL|Carvedilol|Carvedilol will be started at 6.25 mg by mouth twice daily. Patients will take carvedilol for 28 days prior to prostatectomy. They will be seen every 7 days and adjustments in the dose will be considered at those visits.
62203652|NCT04792619|EXPERIMENTAL|Control|
62203653|NCT04792619|ACTIVE_COMPARATOR|Study|
62203654|NCT01355861|EXPERIMENTAL|1|Exercise group 1: Negative work exercise
62203655|NCT01355861|OTHER|2|Exercise group 2: Negative work exercise (delayed start for single-arm crossover trial)
62203656|NCT04676061|PLACEBO_COMPARATOR|Control Group|Placebo to Norethindrone acetate (NTA)
62403635|NCT02464176|EXPERIMENTAL|8 mg dexamethasone group|Following peripheral nerve block using bupivacaine and epinephrine administration, 8 mg of systemic dexamethasone will be administered to this group intravenously. The volume given intravenously will be identical for all groups.
62786699|NCT02276443|EXPERIMENTAL|Arm B (predictive results given)|Patients undergo baseline molecular and IHC evaluation of their tumor biopsy, and receive the results. Patients then receive standard anthracycline-based chemotherapy and undergo standard ultrasound at baseline, after 2 cycles, and after 4 cycles of treatment. Patients and physicians are notified of the results of the molecular evaluation. Patients may then choose to continue with standard taxane +/- platinum-based chemotherapy or participate in an experimental clinical trial designed to match the molecular profile and triple-negative subtype. Patients with tumors predicted to be insensitive to chemotherapy are advised to participate in a clinical trial treating their tumor subtype.
62786700|NCT02276443|EXPERIMENTAL|Arm C (predictive results given)|Patients undergo baseline molecular and IHC evaluation of their tumor biopsy, and receive the results. Patients then receive standard anthracycline-based chemotherapy with immunotherapy and undergo standard ultrasound at baseline, after 2 cycles, and after 4 cycles of treatment. Patients and physicians are notified of the results of the molecular evaluation. Patients may then choose to continue with standard taxane +/- platinum-based chemotherapy or participate in an experimental clinical trial designed to match the molecular profile and triple-negative subtype. Patients with tumors predicted to be insensitive to chemotherapy are advised to participate in a clinical trial treating their tumor subtype
62786701|NCT03304119||Patellar instability group|Group of patients with patellar instability stemming from a recurrent patellar dislocation
62786702|NCT03304119||Control group control|Group that has not been checked for patellar instability.
62786703|NCT01176812||Dermal Fillers|Facial Wasting
62786704|NCT03587441|ACTIVE_COMPARATOR|The Intervention Group (N)|Neostigmine Methylsulfate intervention : A one milliliter syringe will contain 20 µg of Neostigmine methyl sulfate. 0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 µg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
62786705|NCT03587441|PLACEBO_COMPARATOR|The Control Group (P)|Dextrose 5% in water intervention : an equal volume (0.2 ml) of dextrose 5% will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
62014588|NCT02308202|ACTIVE_COMPARATOR|doxazosin|Subjects will be randomized to receive either doxazosin XL or placebo. Participants will receive doses of study medication as over-encapsulated doxazosin XL or placebo dosed once in the morning. Study medication will be initiated as one capsule of doxazosin XL 4 mg or placebo given in the morning. The dose will be titrated up to 16 mg/d doxazosin XL or placebo as follows: Days 1-4: 4mg, Days 5-8: 8mg, Day 9-12: 12 mg, Days 13-16: 16 mg.
62203657|NCT04676061|ACTIVE_COMPARATOR|Treatment Group|Norethindrone acetate (NTA)
62786706|NCT01359202|ACTIVE_COMPARATOR|Niastase RT|Niastase RT 80ug/kg IV bolus
62786707|NCT01359202|PLACEBO_COMPARATOR|Placebo|saline IV bolus
62786708|NCT02120391|SHAM_COMPARATOR|Control (Arm A)|"Patients randomized to Arm A(control group) will receive an iPhone application without any of the adherence intervention turned on. The control phone application will allow patients to record their medications and how many refills they have remaining. The application will also provide patients with links about their medication.~No adherence intervention will be done to these patients."
62786709|NCT02120391|EXPERIMENTAL|Cases (Arm B)|"Patients randomized to Arm B will receive an iPhone application with the adherence intervention turned on. The study coordinator will help with the installation of the iPhone application.~Participants in this group will not need to pay for the iPhone application."
62786710|NCT01578122|EXPERIMENTAL|25mmHg ECS|Thigh-length graduated elastic compression stockings applying 25mmhg of targeted pressure at the ankle worn daily for two years
62786711|NCT01578122|ACTIVE_COMPARATOR|35mmHg ECS|Thigh-length graduated elastic compression stockings applying 35 mmhg of targeted pressure at the ankle worn daily for two years
62786712|NCT00470925|EXPERIMENTAL|Access [123I]MZINT and SPECT Imaging|
62786713|NCT04177212|EXPERIMENTAL|3 MRZF111 injection cycles|Enrolled subjects will receive 3 injection cycles in total at time points Day 1, Week 8, and Week 16.
62403636|NCT02464176|PLACEBO_COMPARATOR|Control Group|Normal saline will be used as a placebo control group given at the same time and in the same manner as the experimental groups following peripheral nerve block administration. The volume given intravenously will be identical for all groups.
62786714|NCT04177212|EXPERIMENTAL|2 MRZF111 injection cycles|Enrolled subjects will receive 2 injection cycles in total at time points Day 1, and Week 16.
62203658|NCT01923467|EXPERIMENTAL|Project Quit plus NRT patches|All participants in the program will be offered the opportunity to complete the Project Quit stop smoking program. Project Quit is an individually-tailored, web-based program which has been scientifically proven to help people succeed at their quit attempts. All eligible participants will also receive a 2-week supply of Nicotine patches 21 mg.
62203659|NCT04659330|OTHER|Intervention group|All patients underwent intervention
62203660|NCT06393725|EXPERIMENTAL|Asynchronous|This arm involves a 1 year behavioral weight loss program delivered in private Facebook groups led by a professional weight loss counselor. At the end of 1 year, volunteer participants will take over the leadership role of the group for the following year. Volunteers will receive a brief training on how to lead a private Facebook group.
62579999|NCT05569668||Neoadjuvant chemotherapy group|Standard NAC comprised 2 cycles. Platinum plus paclitaxel or docetaxel was repeated once every 3 weeks. Cis-platinum was administered at a total dose of 75 mg/m2 by continuous infusion on d1 or equal divided on Days 2-4 or Days 1-3. Paclitaxel, 175 mg/m2, d1, or paclitaxel, 87.5 mg/m2, d1, d8. If the docetaxel was adopted, it was given as 75 mg/m2 on Day 1. Then surgery----esophagectomy and two-field extensive mediastinal lymphadenectomy. After surgery, there might be a adjuvant chemotherayp for pathologically positive lymph nodes patients.
62014589|NCT02308202|ACTIVE_COMPARATOR|perindopril|Subjects will be randomized to receive either perindopril 16mg or placebo for 8 days. Participants will receive doses of study medication as over-encapsulated perindopril or placebo dosed once in the morning.
62014590|NCT02308202|PLACEBO_COMPARATOR|placebo|Subjects will be randomized to receive either doxazosin XL or placebo. Participants will receive placebo for doxazosin XL for 16 days and placebo for perindopril for 8 days.
62014591|NCT04526691|EXPERIMENTAL|Datopotamab deruxtecan (Dato-DXd)|Dose Escalation and Dose Expansion: Datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic NSCLC
62014592|NCT00883571|ACTIVE_COMPARATOR|house advancement flap|house advancement flap
62014593|NCT00883571|ACTIVE_COMPARATOR|Rhomboid flap|rhomboid flapa was incised in the ischiorectal fossa. Without undermining of its fatty base, the flap was then mobilized into the anal canal so that the tip could be sutured to the top of the strictured area using Vicryl 3/0 sutures
62014594|NCT00883571|ACTIVE_COMPARATOR|Y-V anoplasty|Y-V anoplasty
62014595|NCT04486287|EXPERIMENTAL|Sintilimab Arm|Sintilimab after Stereotactic Ablation Brachytherapy.
62014596|NCT06055322|EXPERIMENTAL|Adapted Dialectical Behavior Therapy|Adapting Dialectical Behavior Therapy to focus on reducing suicide ideation for family caregivers of persons with AD/ADRD
62014597|NCT06133621||cases|Patients treated at HCL who have had an increased dRVVT ratio during pregnancy, investigated in the context of the development of VDP during pregnancy
62014598|NCT06133621||Controls|Patients with normal pregnancies followed at the Croix Rousse maternity hospital
62014599|NCT05226104|OTHER|Healthy Participants|Subjects who are interested in treatment for facial fine lines and wrinkles will be recruited for the study.
62014600|NCT02697019|EXPERIMENTAL|Internet-delivered ERITA|
62203661|NCT06393725|ACTIVE_COMPARATOR|Synchronous|This arm involves a 1 year behavioral weight loss program delivered via weekly videoconference meetings led by a professional weight loss counselor. At the end of 1 year, volunteer participants will take over the leadership role of the meetings for the following year. Volunteers will receive a brief training on how to lead videoconference meetings.
62203662|NCT04263168|EXPERIMENTAL|Bariatric Surgery Candidates|All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
62403637|NCT03705221|EXPERIMENTAL|Group programme|Healthy Parent Carers group programme: A group-based peer led manualised programme called Healthy Parent Carers. The programme content is organised into 12 modules, which can be delivered over six longer (4-hour) sessions or 12 shorter (2-hour) sessions.
62580000|NCT05569668||Primary surgery group|The patients would receive primary surgery----esophagectomy and two-field extensive mediastinal lymphadenectomy. After surgery, there might be a adjuvant chemotherayp for pathologically positive lymph nodes patients. .
62014601|NCT03649126||Dutch pathologists hospital I|"Pathologists in hospital I using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
62014602|NCT03649126||Dutch pathologists hospital II|"Pathologists in hospital II using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
62014603|NCT03649126||Dutch pathologists hospital III|"Pathologists in hospital III using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
62014604|NCT03649126||Dutch pathologists hospital IV|"Pathologists in hospital IV using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
62014605|NCT03649126||Dutch pathologists hospital V|"Pathologists in hospital V using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
62014606|NCT03649126||Dutch pathologists hospital VI|"Pathologists in hospital VI using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
62014607|NCT05002101|ACTIVE_COMPARATOR|zinc group|The children were randomized to receive daily zinc sulphate. The elemental zinc dose was 3 mg/ day to children whose weight is less than 10 kg and 7 mg/ day to children whose weight is 10 kg or more.
62014608|NCT05002101|PLACEBO_COMPARATOR|placebo group|The placebo was non-nutritious and vitamin-free, designed to be identical to the zinc syrup in colour, odour, consistency and taste. Zinc and placebo syrups were packaged in similar bottles.
62014609|NCT04654689|EXPERIMENTAL|Intervention group|30 patients will be given the combination of resveratrol and curcumin liposomed with G04CB02, in a single daily dose for 4 months.
62014610|NCT04654689|PLACEBO_COMPARATOR|Control group|30 patients, who will receive a placebo with the same dosage pattern and for the same period of time. The placebo will consist of water with sucrose replacing the liposomal polyphenols, and a soft capsule of microcrystalline methylcellulose instead of G04CB02. Both the packaging and the capsule format will be identical to those of the treatment administered in the intervention group
62014611|NCT02317640|ACTIVE_COMPARATOR|Stand Training Alone|Standing training will be prescribed 3 days/week (1.5 hours/sessions) for 60 sessions. All individuals randomized to stand training will train with BWST with manual assistance and will undergo a stand evaluation. During the evaluation the participants will be placed on the treadmill in an upright position and suspended in a harness by an overhead cable (i.e. BWST). A trainer will be positioned to assist the participant while standing and to provide manual assistance if needed. The amount of BWS and level of assistance given for each body segment will be recorded. The BWS level at which the participant can independently support good standing posture will also be recorded. Standing time while on treadmill and overground will be recorded daily as part of the training sessions.
62014612|NCT02317640|EXPERIMENTAL|ST with placebo or testosterone|Stand Training as described above with Placebo or testosterone Gel applied by a pump. After a baseline testing period, TRT will begin in the treatment groups by application of a daily dose of 40.5 mg of testosterone or placebo gel. The gel is to be applied to the upper arms and shoulders and is absorbed and eliminated over the course of a day. To ensure proper dosing serum T concentration will be assessed at screening, baseline, 2 weeks, 1 month and 3 month time points. As such, follow-up with the participant will be necessary to determine the correct replacement dose of TRT, and adjustment of dose if needed, (i.e. 40.5 mg up to 81 mg of gel). If serum T levels are not within normal range at the 2 week time point, the dose will be increased in increments of 20.25 mg up to 81 mg.
62786715|NCT03238625|ACTIVE_COMPARATOR|Group 1|"Consisting of 24 individuals between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.~Intervention: Every individual receives four injections IMP1: Lidocaine and sodium bicarbonate ratio 3:1, IMP 2: Lidocaine and sodium bicarbonate ratio 9:1, IMP 3: Lidocaine, and IMP 4: Sodium cloride 0.9% (=placebo), namely two in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the four areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes."
62403638|NCT03705221|ACTIVE_COMPARATOR|Online resources|Healthy Parent Carers online resources: Online resources from the Healthy Parent Carers programme, including materials for 12 modules and related videos and audio files to illustrate the content.
62403639|NCT04288960||Chronic Stroke|Twenty chronic stroke patients (\>3months post-stroke) will complete a one off session in a biomechanics lab. This session will include the Fugl Meyer Questionnaire and several walking trials along a flat, level 10m walkway. During this participants will wear a belt mounted accelerometer and small reflective markers on joints.
62403640|NCT02800382|OTHER|Lung Malignancy|"Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.~The samples (fine-needle aspiration biopsy and fine-needle aspiration cytology) were diagnosed by pathological examination."
62580001|NCT04864860|EXPERIMENTAL|intervention arm|"The intervention product used in this study is a dietary supplement called Seanol that contain 13% pholoratannic polyphenol per capsule as stated by the manufacture company (Seanol inside, 4215 95th St SW Lakewood, WA 98499 USA). Other ingredients are dextrin, magnesium stearate and silica (in neglected percentage). The intervention supplement is encapsulated in vegetable cellulose that contains 500 Ecklonia cava extract (Seanol). This dose was selected to be similar to previous studies that shows no harm or sever adverse effect on participants (12, 14)."
62786716|NCT03238625|PLACEBO_COMPARATOR|Group 2|"Consisting of 24 different individuals than those belonging to Group 1. Between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.~Intervention: Every individual receives two injections:~IMP 3 Lidocaine, and IMP 4 Sodium cloride 0.9% (=placebo), namely one in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the two areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes."
62786717|NCT01574651|EXPERIMENTAL|QVA149 plus placebo to tiotropium and placebo to formoterol|QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use.
62203663|NCT04263168|SHAM_COMPARATOR|Laparoscopy Cholecystectomy|All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
62203664|NCT03729375|EXPERIMENTAL|10cc Patients|Intervention: Group 1 will receive 10cc of intra-operative intra-carpal tunnel anesthetic injection (bupivacaine/Marcaine). Postoperatively, patients will also be prescribed an opioid pain medication in congruence with current standard medical practice. Patients will be contacted at 24-hours, 48-hours, 72-hours, and at 2-week clinic follow-up by research staff and evaluated for pain levels through the LIKERT scale.
62580002|NCT04864860|PLACEBO_COMPARATOR|placebo arm|"The placebo will be dextrin (BETA CYCLODEXTRIN, NF) ordered from a pharmaceutical company MEDISCA (https://www.medisca.co.uk/). Dextrin was selected to account for the similar complex carbohydrate content of the intervention supplement. Placebo will be encapsulated in vegetable cellulose capsules that is identical in size and coulure to the intervention capsules. The empty capsules will be ordered from MEDISCA and will be encapsulated in by SPIMACO ADDWAIEH (SFDA registered pharmaceutical company) (http://www.spimaco.com.sa/)."
62580003|NCT03084627|NO_INTERVENTION|Generic dietary advice for pregnancy|
62203665|NCT03729375|ACTIVE_COMPARATOR|20cc Patients|Intervention: Group 2 will receive 20cc of intra-operative intra-carpal tunnel anesthetic injection (bupivacaine/Marcaine). Postoperatively, patients will also be prescribed an opioid pain medication in congruence with current standard medical practice. Patients will be contacted at 24-hours, 48-hours, 72-hours, and at 2-week clinic follow-up by research staff and evaluated for pain levels through the LIKERT scale.
62203666|NCT00573053|ACTIVE_COMPARATOR|High|Arterial oxygen saturations in the range of 91-95%
62203667|NCT00573053|EXPERIMENTAL|Low|Arterial oxygen saturations in the range of 85-89%
62203668|NCT06466278|EXPERIMENTAL|Medication|
62203669|NCT06466278|PLACEBO_COMPARATOR|Placebo|
62203670|NCT01755572|EXPERIMENTAL|Liraglutide|Liraglutide 0.6mg for 7 days, liraglutide 1.2mg for 7 days, liraglutide 1.8mg for 7 days
62580004|NCT03084627|EXPERIMENTAL|Generic dietary advice for pregnancy + Tailored dietary advice|
62580005|NCT03577613||Early stage Cervical Cancer- Open Radical Hysterectomy(RH)|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a open RH at our institution as primary treatment were included in the study
62580006|NCT03577613||Early stage Cervical Cancer- Laparoscopic Radical Hysterectomy|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a laparoscopic RH at our institution as primary treatment were included in the study
62580007|NCT03577613||Early stage Cervical Cancer- Robotic radical Hysterectomy(RRH)|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a robotically assisted RH at our institution as primary treatment were included in the study
62580008|NCT03300635|OTHER|Fibromyalgia patients|All study subjects, both patients and healthy controls, will attend all three interventions: Mental distress and relaxation test, Glucose tolerance test, and Exercise test
62580009|NCT03300635|OTHER|Healthy controls|All study subjects, both patients and healthy controls, will attend all three interventions: Mental distress and relaxation test, Glucose tolerance test, and Exercise test
62786718|NCT01574651|ACTIVE_COMPARATOR|Tiotropium plus Formoterol and placebo to QVA149|Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
62403641|NCT02800382|OTHER|Lung bening Diseases|Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
62403642|NCT01987570|EXPERIMENTAL|Allopurinol|One tablet of allopurinol is administrated orally at a dose of 300 mg/24 hours, during the time that the patient remains immobilized for 15 days.
62014613|NCT02317640|EXPERIMENTAL|ST with Placebo or Testosterone and ES|"Stand Training described above with Placebo or testosterone gel applied by a pump. Electrical stimulation will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points (both legs) on the following muscles: gluteus maximus (GL), rectus femoris (RF), biceps femoris (BF), gastrocnemei (GC), and anterior tibialis (TA) of both legs. Two electrodes will be used for each muscle. One RT300 portable stimulator (Restorative Therapies, Inc., Baltimore, MD) will be used to induce the electrical stimulation with 10 sets of electrodes for stimulation."
62014614|NCT02317640|EXPERIMENTAL|ST with ES|Stand Training as described above in Stand Training alone and Electrical Stimulation as described above in ST with Placebo or Testosterone and ES.
62203671|NCT01755572|PLACEBO_COMPARATOR|Placebo|Placebo 0.6mg sc for 3 weeks, Placebo 1.2mg sc for 3 weeks, Placebo 1.8mg for 3 weeks.
62203672|NCT03937518|OTHER|strontium ranelate|included 15 patients who received oral strontium ranelate and physiotherapy program. The age of the patients ranged from 50 to 62 years,
62203673|NCT03937518|OTHER|physiotherapy|included 15 patients who received physiotherapy program. The age of the patients ranged from 50 to 62 years
62203674|NCT04059640|EXPERIMENTAL|LiquiBand FIX8® OHMF Device|Subjects will undergo hernia mesh fixation and topical wound closure using the LiquiBand FIX8® OHMF device.
62580010|NCT03566069|EXPERIMENTAL|Experimental Group|After a double-blind rabdomization, patients allocated to the experimental group will be followed for four weeks beginning at the start of their hospitalization, after signing a consent form. After completing baseline self-report measurements, they will be assessed for the severity of their symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal OT will be administered twice a day (at 08:00 a.m. and at 17:00 p.m.). The experimental group will receive - 32IU (16IU\*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water. OT will be inhaled in two sprays, one in each nostril.The substance for both study groups will be prepared in the hospital pharmacy, (in identical bottles), after randomization that will be conducted by the pharmacist. A month post intervention, patients will complete self-report measurements as part of a follow-up evaluation.
61978441|NCT02463474|EXPERIMENTAL|mHealth Intervention|Each week for 10 weeks, participants will receive two text messages on their cell phone. The first text message will contain a link to a culturally tailored, informational video clip about living with breast cancer. The second text message that provides a supportive message about the video content.
62734832|NCT04998916|SHAM_COMPARATOR|Sham TBS to the mPFC|The MagVenture MagPro system has an integrated, active sham which passes current through two surface electrodes placed on the scalp. The electrodes will be placed on the left frontalis muscle for all sessions. A patient identification card will randomize participants to receive either real or sham stimulation. This system maintains blinding by a gyroscope in the coil which indicates to the clinical staff whether the coil should be rotated up or down for this participant once the card is entered into the machine. One side of the coil is active, the other is sham. The integrity of the double-blind procedure will be assessed by asking the patients and study personnel rate their confidence regarding whether they thought they received real or sham (scale 1-10).
61978442|NCT03762109|EXPERIMENTAL|Dantrolene Group|Patients will receive 25 mg of Dantrolene orally at four different time points: immediately before surgery, as well as at 12, 24 and 36 hours after surgery.
62014615|NCT00874744|EXPERIMENTAL|bevacizumab|
62014616|NCT00874744|EXPERIMENTAL|Triamcinolone|
62014617|NCT02031276|PLACEBO_COMPARATOR|Double-blind Placebo IV|Participants randomized to receive double-blind placebo for risankizumab by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
61978443|NCT03762109|PLACEBO_COMPARATOR|Placebo Oral Tablet Group|Patients will receive a 25 mg of a placebo pill orally at four different time points: immediately before surgery, as well as at 12, 24 and 36 hours after surgery.
62014618|NCT02031276|EXPERIMENTAL|Double-blind Risankizumab 200 mg IV|Participants randomized to receive double-blind risankizumab 200 mg by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
62014619|NCT02031276|EXPERIMENTAL|Double-blind Risankizumab 600 mg IV|Participants randomized to receive double-blind risankizumab 600 mg by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
62203675|NCT02390453|EXPERIMENTAL|Combined Cognitive and Physical|This consists of 45 minutes of Cognitive arm + 45 minutes of Physical arm (90 minutes total), 3 days a week for 12 weeks (36 sessions).
62203676|NCT02390453|ACTIVE_COMPARATOR|Cognitive|This consists of 45 minutes of cognitive modules from Posit Science, 3 days a week for 12 weeks (36 sessions).
62203677|NCT02390453|ACTIVE_COMPARATOR|Physical|This consists of 45 minutes of multi-modal physical exercise, 3 days a week for 12 weeks (36 sessions).
62203678|NCT02390453|ACTIVE_COMPARATOR|Active Control|This consists of 45 minutes of group discussion of health and successful aging, 2 days a week for 12 weeks (24 sessions).
62203679|NCT02574845|EXPERIMENTAL|R (Reference) Rosuvastatin|1film-coated tablet as single dose, fasted
62203680|NCT02574845|EXPERIMENTAL|T1 (Test 1) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (10 mg) as single dose, fasted
62203681|NCT02574845|EXPERIMENTAL|T2 (Test 2) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (50 mg) as single dose, fasted
62203682|NCT02574845|EXPERIMENTAL|T3 (Test 3) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (500 mg) as single dose, fasted
62203683|NCT02574845|EXPERIMENTAL|T4 (Test 4) Rosuvastatin + Furosemide|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (1 mg) as single dose, fasted
62203684|NCT02574845|EXPERIMENTAL|T5 (Test 5) Rosuvastatin + Furosemide|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (5 mg) as single dose, fasted
62203685|NCT00625651|EXPERIMENTAL|AMG 655 Low Dose|AMG 655 (low dose) + mFOLFOX6 + Bevacizumab
62403643|NCT01987570|PLACEBO_COMPARATOR|Placebo|One tablet/24 hours of placebo orally, during the time that the patient remains immobilized for 15 days.
62403644|NCT06160258|EXPERIMENTAL|Ready-to-Eat condition|Participants will be provided precooked and individually packaged whole grains in the ready-to-eat condition for reheating and consumption at home.
62403645|NCT06160258|EXPERIMENTAL|Dried condition|Participants will be provided with whole grains of barley, buckwheat, and quinoa in the dried, bulk condition for home cooking and consumption.
62403646|NCT04996212|EXPERIMENTAL|Walking APP Group|
62014620|NCT05169879|EXPERIMENTAL|Early acoronal flaring|In group A, ProGlider PG (size 16, .02 taper) instrument with a length of 25 mm will be used to the working length, then early coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone
62014621|NCT05169879|ACTIVE_COMPARATOR|Non coronal flaring|In group B no coronal flaring will be performed following minimally invasive approach.
62014622|NCT03284268|EXPERIMENTAL|Dose escalation of VCN-01|Dose lower : 2E+9 viral particules/eye Dose medium: 2E+10 viral particules/eye Dose high: 2E+11 viral particules/eye
62014623|NCT04192396||RIF patients|Repeated implantation failure patients
62014624|NCT04192396||Oocyte/embryo donation program|Patients awaiting for oocyte/embryo-donation recipient patients
62203686|NCT00625651|PLACEBO_COMPARATOR|Placebo|Placebo + mFOLFOX6 + Bevacizumab
62203687|NCT00625651|EXPERIMENTAL|AMG 655 High Dose|AMG 655 (high dose) + mFOLFOX6 + Bevacizumab
62203688|NCT00237731|EXPERIMENTAL|1|morphine 0.05
62203689|NCT00237731|ACTIVE_COMPARATOR|2|morphine 0.10
62203690|NCT06256081|ACTIVE_COMPARATOR|Children with hearing loss secondary to glue ear|Children accessing the community audiology NHS services due to concerns about hearing loss who have a diagnosis of glue ear (also known as otitis media with effusion, OME)
62203691|NCT06256081|SHAM_COMPARATOR|Children with normal hearing|Children accessing the community audiology NHS services due to concerns about hearing loss who do not have a diagnosis of glue ear (also known as otitis media with effusion, OME) and are confirmed as having normal hearing.
62203692|NCT03061422|EXPERIMENTAL|xylitol chewing gum|intervention
62203693|NCT03061422|EXPERIMENTAL|xylitol with bicarbonate chewing gum|intervention
62203694|NCT03061422|ACTIVE_COMPARATOR|Paraffin pellet|comparator
62403647|NCT04996212|EXPERIMENTAL|Functional APP Group|
62403648|NCT06396806|NO_INTERVENTION|radical sigmoidectomy|radical sigmoidectomy
62403649|NCT06396806|EXPERIMENTAL|radical sigmoidectomy combined with indocyanine green fluorescence imaging|At the end of routine operation, indocyanine green was used for lymph node tracing, and further lymph node dissection was performed according to the tracer results.
62403650|NCT00552656||1|the group of patients with angiographic results of complex coronary lesions(refer to the definition of protocol)are enrolled and given a clinical follow up and angiographic follow up during the following one year.
62403651|NCT01719263|EXPERIMENTAL|Treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System and Optimal Medical Therapy
62403652|NCT01719263|ACTIVE_COMPARATOR|Optimal Medical Therapy|Patients will be treated according to Optimal Medical Therapy
62403653|NCT06143176|EXPERIMENTAL|Stroke patients|
62403654|NCT04269161|EXPERIMENTAL|Automatic Oxygen Control|In this arm, an automatic oxygen control device will be used to make adjustments to the blend of oxygen and air supplied to the subject.
62403655|NCT04269161|NO_INTERVENTION|Manual Oxygen Control|In this arm, a nurse will manually make adjustments to the blend of oxygen and air supplied to the subject as in the standard of care.
62786719|NCT00970229|EXPERIMENTAL|Assess [123I]MNI-420 and SPECT Imaging|To assess \[123I\]MNI-420 and SPECT Imaging in PD, HD subjects and similarly aged healthy subjects.
62786720|NCT06479941||Mother-infant cohort with antibiotic treatment group|E.g., Bacterial infection during pregnancy
62580011|NCT03566069|PLACEBO_COMPARATOR|Placebo Group|After a double-blind rabdomization, patients allocated to the placebo group will be followed for four weeks beginning at the start of their hospitalization, after signing a consent form. After completing baseline self-report measurements, they will be assessed for the severity of their symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal Placebo will be administered twice a day (at 08:00 a.m. and at 17:00 p.m.). The placebo group will receive - 32IU (16IU\*2) of Sorbitol, Benzyl, alcohol glycerol, distilled water, meaning all ingredients except for the OT and will be inhaled in two sprays, one in each nostril.The substance for both study groups will be prepared in the hospital pharmacy, (in identical bottles), after randomization that will be conducted by the pharmacist. A month post intervention, patients will complete self-report measurements as part of a follow-up evaluation.
62786721|NCT06479941||Mother-infant cohort (Prophylactic antibiotics therapy)|E.g., cesarean section
62786722|NCT06479941||Mother-infant cohort (Natural delivery)|E.g., Natural delivery
62786723|NCT04467281|EXPERIMENTAL|89Zr-DFO-daratumumab PET/CT|"Pre treatment evaluation: 1) Standard of Care (SoC) labs, imaging, blind bone marrow biopsy. 2) Baseline research 89 Zr DFO daratumumab PET/CT 3) Possible biopsy of 89 Zr DFO daratumumab avid lesion Treatment: Daratumumab containing combination therapy (up to 12 cycles, 4 weeks/cycle). SoC labs, imaging, and blind bone marrow biopsies until complete response (CR) is suspected or 12 cycles are completed.~Post treatment evaluation:1) SoC labs, imaging, and blind bone marrow biopsy 2) SoC minimal residual disease (MRD) analysis by next generation sequencing 3) Follow up research 89 Zr DFO daratumumab PET/CT 4) Possible biopsy of 89 Zr DFO daratumumab avid lesion"
62786724|NCT01834352|ACTIVE_COMPARATOR|Walnut protein flour|Walnut protein flour that is ingested in gradually increasing amounts up to a maintenance dose.
62786725|NCT01834352|PLACEBO_COMPARATOR|Oat flour|Oat flour administered in identical increasing amounts as the active walnut protein flour.
62786726|NCT02106520|EXPERIMENTAL|Bevacizumab 25mg|Three administrations of 25 mg of Bevacizumab spaced of 14 days
62014625|NCT03568916||Rivaroxaban vs dabigatran|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with rivaroxaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
62014626|NCT03568916||Apixaban vs dabigatran|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
62403656|NCT02267174|OTHER|Standardized OR to ICU handoff|A standardized handoff process for conducting OR to ICU handoffs will be implemented in two intensive care units without a standard process.
62580012|NCT00707525|NO_INTERVENTION|1|Natural cycle oocyte donation
62734833|NCT02518165|ACTIVE_COMPARATOR|Proprietary spearmint extract|Subjects randomized into the active treatment group will be asked to consume 900 mg/day of the proprietary spearmint extract.
62734834|NCT02518165|PLACEBO_COMPARATOR|Microcrystalline cellulose|Subjects randomized into the placebo group will be asked to consume 900 mg/day of the excipient, microcrystalline cellulose.
62786727|NCT02106520|EXPERIMENTAL|Bevacizumab 50mg|Three administrations of 50 mg of Bevacizumab spaced of 14 days
62786728|NCT02106520|EXPERIMENTAL|Bevacizumab 75mg|Three administrations of 75 mg of Bevacizumab spaced of 14 days
62786729|NCT02106520|PLACEBO_COMPARATOR|Placebo|Three administrations of placebo spaced of 14 days
62786730|NCT03878680||13-14 years age group|Children with age 13-14 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.
62786731|NCT03878680||6-7 years age goup|Children with age 6-7 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.
62786732|NCT00315016|PLACEBO_COMPARATOR|1|placebo (double dummy)
62786733|NCT00315016|ACTIVE_COMPARATOR|2|eplerenone
62786734|NCT00315016|ACTIVE_COMPARATOR|3|doubling of fosinopril dose
62786735|NCT02373774|NO_INTERVENTION|Standard Anatomic Palpation Technique|Participants randomized to this group will receive standard of care treatment with providers using the palpation technique to select an interspace to perform lumbar puncture.
62786736|NCT02373774|EXPERIMENTAL|Pre-Procedural Ultrasound|Participants randomized to this group will receive an ultrasound of the interspace selected via the palpation method prior to performance of the lumbar puncture to determine measurements of appropriate angle and depth and evaluation of any overlying vasculature.
62786737|NCT01053039|ACTIVE_COMPARATOR|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
62786738|NCT01053039|PLACEBO_COMPARATOR|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
62786739|NCT04958174||Users|Users of the web-application
62786740|NCT02355210|PLACEBO_COMPARATOR|Placebo|5 g lactose given as a placebo
62786741|NCT02355210|EXPERIMENTAL|Probiotic 1|Bifidobacteria adolescentis BD1, 10\^9
62786742|NCT02355210|EXPERIMENTAL|Probiotic 2|Bifidobacteria animalis subsp. lactis BB-12, 10\^9
62786743|NCT02355210|EXPERIMENTAL|Prebiotic|galactooligosaccaride, 5 g
62786744|NCT02355210|EXPERIMENTAL|Synbiotic 1|galacto-oligosaccharide (5 g) and Bifidobacteria adolescentis BD1 (10\^9)
62786745|NCT02355210|EXPERIMENTAL|Synbiotic 2|galacto-oligosaccharide (5 g) and Bifidobacteria animalis subsp. lactis BB-12 (10\^9)
62786746|NCT02639520|ACTIVE_COMPARATOR|Group Canephron® N|Canephron® N \& fosfomycin trometamol-placebo
62786747|NCT02639520|ACTIVE_COMPARATOR|Group Fosfomycin Trometamol|Canephron® N-placebo \& fosfomycin trometamol
62786748|NCT05013203||Aseptic (uninfected) Revision Spine Surgery|Aseptic revision for indications including but not limited to hardware failure, adjacent segment pathology, radiculopathy, instability, cord compression.
62203695|NCT03106753|ACTIVE_COMPARATOR|Spinal anesthesia immediately for ECV.|The patient will have a spinal administered by the on call anesthesiologist using standard protocol (intrathecal bupivacaine 7.5 mg). The patient will then be administered 0.25 mg Terbutaline subcutaneously and the ECV will be attempted. Under ultrasound guidance the provider will attempt to lift the breech upward from the pelvis with one hand and guide the head with the other hand to produce a forward roll. If forward roll fails, a backward roll somersault may be attempted. ECV attempt will be abandoned if there is significant fetal bradycardia, discomfort to the patient, or if the procedure cannot be completed easily with these maneuvers. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.
62580013|NCT00707525|ACTIVE_COMPARATOR|2|"Stimulated cycle oocyte donation.~* Long protocol down-regulation with a GnRH agonist, starting on the midluteal phase of the previous cycle with leuprolide acetate (0.2mg/day).~* Once evidence of downregulation is documented, leuprolide will be halved to 0.1 mg daily.~* COH with be carried on with gonadotropins (150UI/day of rFSH and 75 UI/day of HP-hMG). The dose can be adjusted according to ovarian response as judged by ultrasound and by serum oestradiol (E 2 ) concentrations."
62786749|NCT05013203||Spine Surgery for Degenerative Disease|Primary degenerative pathology surgery where a disc sample is extracted to enable spinal decompression or fusion. The potential primary surgeries include but are not limited to microdiscectomy, laminectomy, and lumbar and cervical fusion
62786750|NCT05013203||Septic (infected) Revision Spine Surgery|Spine surgery for known infection specifically: epidural abscess or septic revision. Epidural abscess must be managed surgically for inclusion. Septic revision cases include any surgery to address infected hardware from a previous spinal surgery.
62786751|NCT05465291|NO_INTERVENTION|Conventional care|Control Group
62786752|NCT05465291|EXPERIMENTAL|Exercise Group|Passive/active range of motion exercises group
62786753|NCT05465291|EXPERIMENTAL|Neuromuscular Electrical Muscle Stimulation group|Neuromuscular Electrical Muscle Stimulation group
62786754|NCT05465291|EXPERIMENTAL|Combined therapy (Neuromuscular Electrical Muscle Stimulation pulse limb exercise)|Combined therapy (Neuromuscular Electrical Muscle Stimulation pulse limb exercise).
62786755|NCT06245668|ACTIVE_COMPARATOR|SaCoVLM™ video laryngeal mask|SaCoVLM™ video laryngeal mask
62786756|NCT06245668|ACTIVE_COMPARATOR|LMA Supreme|LMA Supreme
62786757|NCT05677009|OTHER|BUFEO vs Standard Condition|In the BUFEO vs Standard Condition arm, the patient will receive both treatments. The order in which the subject receives the treatment will be randomized.
62786758|NCT02652260|EXPERIMENTAL|Immediate Switch to Doravirine, Tenofovir, Lamivudine|Participants on a baseline regimen of ATRIPLA™ for at least 12 weeks prior to screening will be switched to blinded doravirine, tenofovir, lamivudine orally, once daily for 12 weeks, followed by open-label doravirine, tenofovir, lamivudine orally, once daily for an additional 12 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label doravirine, tenofovir, lamivudine for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 216 weeks. Participants who meet eligibility criteria can enter study extension 3 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 312 weeks.
62203696|NCT03106753|EXPERIMENTAL|Spinal anesthesia if no intervention fails for ECV.|The patient will be administered terbutaline 0.25 mg subcutaneously and the version will be attempted using the same procedure as above. If successful, the patient will be monitored for 30 minutes and discharged if fetal and maternal status is reassuring. If the attempt fails, the patient will be administered spinal anesthesia as above and the same maneuvers will be attempted. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.
62580014|NCT02467062|ACTIVE_COMPARATOR|4Dflow MRI parallel imaging|4D flow MRI with conventional parallel imaging
62580015|NCT02467062|OTHER|4D flow ktARC parallel imaging|4D flow MRI kt ARC spatiotemporal parallel imaging
62786759|NCT02652260|EXPERIMENTAL|Deferred Switch to Doravirine, Tenofovir, Lamivudine|Participants will continue on their ongoing ATRIPLA™ regimen orally, once daily for 12 weeks, followed by open-label doravirine, tenofovir, lamivudine orally, once daily for 24 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label doravirine, tenofovir, lamivudine for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 228 weeks. Participants who meet eligibility criteria can enter study extension 3 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 324 weeks.
62786760|NCT03368846|EXPERIMENTAL|[14C]-Varlitinib|
62786761|NCT03117478|OTHER|1. Participants without meditation experience|Novices. Note that there is no meditation intervention in this study but that the two groups differ in their lifetime meditation experience.
62786762|NCT03117478|OTHER|2. Participant with a significant meditation experience|Experts : \> 5000 hours of practice during their life. Note that there is no meditation intervention in this study but that the two groups differ in their lifetime meditation experience.
62786763|NCT03117478|OTHER|3. Participants without meditation experience|Novices. There is no meditation intervention during the study but the investigators investigate the effects of meditation by comparing 2 groups who differ in their life time meditation experience (i.e., novices vs. experts).
62014627|NCT03568916||Apixaban vs rivaroxaban|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or rivaroxaban at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
62014628|NCT03525834|EXPERIMENTAL|Everolimus|Participants targeted to receive Everolimus tablets 10 mg orally once daily for 48 weeks.
62014629|NCT02430077|EXPERIMENTAL|Active capsule of Obeticholic acid|Patient will receive obeticholic acid (OCA) in the dose of 25 mg/day for a period of 4 months.
62014630|NCT02430077|PLACEBO_COMPARATOR|Pacebo for Obeticholic acid|Patient will recieve placebo in the dose of 25 mg/day for a period of 4 months.
62014631|NCT03363594||1|Diabetes Mellitus
62014632|NCT04572347||Nurses working in PUTH|Participants will be recruited from Peking University Third Hospital through cluster sampling. Female registered nurses, licensed practical nurses and/or midwives with informed consent are included in this study. The exclusion criteria are student nurses and training nurses.
62014633|NCT03527992|OTHER|Automated oxygen therapy|An automated oxygen therapy is a system that allows administration of oxygen with a flow that is automatically adjusted to the patient's saturation, which is continuously monitored. Patients will receive O2 automated intervention.
62203697|NCT04808752|EXPERIMENTAL|Almonertinib high-dose group|Patients who meet the criteria for inclusion and exclusion will be included in the high-dose almonertinib treatment group and receive oral almonertinib 165 mg once a day
62203698|NCT03491891||derivation cohort|no interventions will be administrated
62203699|NCT03491891||validation cohort|no interventions will be administrated
62203700|NCT02721992||Graves' Disease|Patients with Graves' disease, without Graves' Orbitopathy
62203701|NCT02721992||Graves' Orbitopathy|Patients with Graves' disease, with Graves' Orbitopathy
62203702|NCT04931368|ACTIVE_COMPARATOR|Control treatment (Arm A)|Patients receive four courses of MATRix (Rituximab 2 x 375 mg/m2, HD-Methotrexate 3.5 g/m2, HD-Cytarabine 2 x 2 g/m2, Thiotepa 30 mg/m2; i.v.) as induction treatment. Response assessment with gadolinium-enhanced brain MRI (centrally reviewed) takes place after course two and four. Patient with at least PR proceed to 3rd course of MATRix after first response assessment and to HCT-ASCT (BCNU 400 mg/m2, Thiotepa 4 x 5 mg/kg; i.v.) after second response assessment. Collection of autologous stem cells is planed after the second course of MATRix.
62203703|NCT04931368|EXPERIMENTAL|Experimental treatment (Arm B)|As induction treatment, patients receive one course of Rituximab/HD-Methotrexate (Rituximab 375 mg/m2, HD-Methotrexate 3.5 g/m2; i.v.). In the absence of clinical signs of progression, patients proceed to two courses of MATRix (Rituximab 2 x 375 mg/m2, HD-Methotrexate 3.5 g/m2, HD-Cytarabine 2 x 2 g/m2, Thiotepa 30 mg/m2; i.v.) followed by a response assessment with gadolinium-enhanced brain MRI (centrally reviewed). Patients with at least PR will proceed to HCT-ASCT (BCNU 400 mg/m2, thiotepa 4 x 5 mg/kg; i.v.). Collection of autologous stem cells is planed after the first course of MATRix
62203704|NCT01148329||Single arm observational study|To evaluate real world clinical outcomes data for the PROMUS™ Element™ Coronary Stent System in unselected patients in routine clinical practice
62203705|NCT01448629|EXPERIMENTAL|River|
62580016|NCT00077298|EXPERIMENTAL|Arm A (cetuximab, bevacizumab, irinotecan)I|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36; bevacizumab IV over 30-90 minutes on days 1\*, 15, and 29 OR on days 1 and 22; and irinotecan IV over 30-90 minutes (at the same dose and schedule that the patient previously received) beginning on day 1.~NOTE: \*Bevacizumab is given on day 2 (instead of day 1) of course 1, and is given on day 1 of subsequent courses."
62580017|NCT00077298|EXPERIMENTAL|Arm B (cetuximab and bevacizumab)|"Patients receive cetuximab as in Arm A and bevacizumab IV over 30-90 minutes on days 1\*, 15, and 29.~NOTE: \*Bevacizumab is given on day 2 (instead of day 1) of course 1, and is given on day 1 of subsequent courses."
61978444|NCT02175498|EXPERIMENTAL|Homoeopathic medicines|4 pills once a week of the indicated similium for a period of one year
62014634|NCT03527992|OTHER|Standard Oxygen therapy|Patients will receive O2 standard therapy
62014635|NCT04777461|EXPERIMENTAL|Group 1|Pilot the structured education in women with PCOS
62014636|NCT06534138||Non-Chronic Pancreatitis (Non-CP)|Patients diagnosed without chronic pancreatitis based on imaging results were categorized into the Non-CP group.
62014637|NCT06534138||Chronic Pancreatitis-non-exercise (CP-non-exercise)|Patients diagnosed with chronic pancreatitis based on imaging results, while simultaneously not engaging in physical exercise, were categorized into the CP-non-exercise group.
62014638|NCT06534138||Chronic Pancreatitis-exercise (CP-exercise)|Patients diagnosed with chronic pancreatitis based on imaging results, while concurrently adhering to physical exercise, were categorized into the CP-exercise group.
62014639|NCT04452825|EXPERIMENTAL|Cancer and Aging: Reflections for Elders (CARE) Intervention|Session content and timing was developed and confirmed in our qualitative work (Expert Panel) and the CARE pilot study. Five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
62014640|NCT04452825|EXPERIMENTAL|Social Work and Supportive Counseling (SWSC)|The SWSC will include a social work assessment and follow-up augmented with additional components of supportive psychotherapy that have been shown to be an effective form of treatment for patients with cancer. Five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
62014641|NCT05754086||Parkinsons (PD) Group|This cohort includes individuals who have been diagnosed with Parkinson's disease.
62786764|NCT03117478|OTHER|4. Participant with a significant meditation experience|Experts : \> 5000 hours of practice during their life. There is no meditation intervention during the study but the investigators investigate the effects of meditation by comparing 2 groups who differ in their life time meditation experience (i.e., novices vs. experts).
62014642|NCT05754086||Neurotypical (NT) Group|This group consists of age-matched control participants. They are neurologically healthy and do not have any neurological diagnoses.
62786765|NCT00774800|EXPERIMENTAL|First Humalog+PH20, then Humalog, Humulin-R+PH20, Humulin-R|"Humalog + Recombinant human hyaluronidase PH20 (rHuPH20) (Intervention 1): 24 units (U) of rHuPH20 per unit of Humalog, injected subcutaneously (SC), for up to 3 visits until an appropriate dose was identified.~Humalog alone (Intervention 2): a single SC injection of the appropriate identified dose of Humalog, delivered before a liquid meal.~Humulin-R + rHuPH20 (Intervention 3): 24 U of rHuPH20 per unit of Humulin-R, injected SC, for up to 2 visits until an appropriate dose was identified.~Humulin-R alone (Intervention 4): a single SC injection of the appropriate identified dose of Humulin-R, delivered before a liquid meal.~Appropriate dose of either Humalog or Humulin-R was that at which blood glucose following a liquid meal was \<160 milligrams per deciliter (mg/dL) for more than 30 minutes during the first 4 hours after injection and never fell below 60 mg/dL.~All dose finding visits and interventions were separated by 3-10 days."
62786766|NCT03430232|EXPERIMENTAL|Part I (Panel 1): STR-324 or placebo|Subjects will receive STR-324 dose level 1, 3, 5, 7 or placebo as a short infusion according to randomization.
62786767|NCT03430232|EXPERIMENTAL|Part I (Panel 2): STR-324 or placebo|Subjects will receive STR-324 dose level 2, 4, 6, 8 or placebo as a short infusion according to randomization.
62786768|NCT03430232|EXPERIMENTAL|Part II (Panel 1): STR-324 or placebo|Subjects will receive STR-324 dose level A or placebo as a long infusion according to randomization.
62786769|NCT03430232|EXPERIMENTAL|Part II (Panel 2): STR-324 or placebo|Subjects will receive STR-324 dose level B or placebo as a long infusion according to randomization.
62786770|NCT03430232|EXPERIMENTAL|Part II (Panel 3): STR-324 or placebo|Subjects will receive STR-324 dose level C or placebo as a long infusion according to randomization.
62786771|NCT00174369|EXPERIMENTAL|PD0325901|15 mg BID
62786772|NCT05307042||2012-cohort|
62786773|NCT01447953|EXPERIMENTAL|Activity targeted pain rehabilitation|A new activity and life-role targeting pain rehabilitation program (ALAR) has been developed to reduce psychosocial barriers to rehabilitation progress, promote re-integration into life-role activities and facilitate return-to-work.
62014643|NCT01094275||wild / normal type allele of CYP2C gene|clopidogrel 75 mg alone.
62014644|NCT01094275||wild / normal type allele of CYP2C|clopidogrel 75 mg + omeprazole 20 mg.
62014645|NCT01094275||Loss of Haplotype CYP2C19|clopidogrel 75mg alone
62014646|NCT01094275||Loss of function haplotype of CYP2C|clopidogrel 75mg + omerprazole 20mg.
62014647|NCT01911533|EXPERIMENTAL|extracorporeal CO2|
62580018|NCT02901067|EXPERIMENTAL|Experimental|Administration of 325mg Aspirin and 20mg of Rosuvastatin mixture in a single capsule daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.
62786774|NCT01447953|ACTIVE_COMPARATOR|Treatment as usual|Usual treatment consisting of multimodal rehabilitation provided by multi-professional teams in primary health care in the County of Dalarna, Sweden.
62014648|NCT05372198|EXPERIMENTAL|Cohort 1: Surufatinib Monotherapy|Patients who met the eligibility criteria took Surufatinib 300mg qd, every 3 weeks as a cycle
62786775|NCT03151330|OTHER|Screened arm|This will be an arm of women who are prospectively screened and receive a risk score for preterm birth. They will be recommended treatment strategies and their outcomes compared to an historical control.
62014649|NCT05372198|EXPERIMENTAL|Cohort 2: Surufatinib with immunotherapy|"Patients who met the eligibility criteria took Surufatinib with immunotherapy:~Surufatinib:250mg qd, every 3 weeks as a cycle Immunotherapy: Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle"
62014650|NCT00078390|EXPERIMENTAL|S-3304 plus chemo-irradiation|The tolerable dose of S-3304 determined in the Phase 1 part of the study will be dosed BID along with a standard of care regimen of radiation and paclitaxel/carboplatin chemotherapy
62014651|NCT00078390|ACTIVE_COMPARATOR|Chemo-irradiation|The standard of care regimen of radiation and paclitaxel/carboplatin chemotherapy will be administered
62203706|NCT01448629|ACTIVE_COMPARATOR|Standard Care|Standard Care can have several manufacture and brand names. Standard Care is defined af the participants currently used stoma care product.
62203707|NCT05331690|ACTIVE_COMPARATOR|Group 1 NSAIDs pre|Topical nepafenac (Nevanac) 3 mg/ml started 1 day before surgery
62203708|NCT05331690|ACTIVE_COMPARATOR|Group 2 NSAIDs post|Topical nepafenac (Nevanac) 3 mg/ml started the day after surgery
62580019|NCT02901067|PLACEBO_COMPARATOR|Control|Administration of the placebo, which is identical-looking to the Aspirin and Rosuvastatin single capsule mixture, daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.
62014652|NCT01224496|EXPERIMENTAL|Treatment with Chinese herbal concoction|"Patients must have a marrow study to confirm diagnosis of MDS, AA or MF. MDS is classified according to the WHO criteria and scored according to IPSS. The AA group is further classified into AA, SAA or VSAA . MF is defined by the Italian criteria and risk stratified by the Lilles Scoring system. Diagnosis of thal intermedia and major is based on previously done Hb electrophoresis and severity of disease is assessed by degree of anaemia.and frequency of blood transfusions~TCM diagnosis: Syndrome differentiation according to TCM theory will be assessed as a baseline by experienced TCM collaborators and classified into one of the few defined syndromes as follows~1. Yin deficiency of spleen and kidney~2. Yang deficiency of spleen and kidney~3. Deficiency of both Yin and Yang~4. Stagnation of dampness and poison in the blood~5. Excessive heat and poison"
62014653|NCT02210299|OTHER|Exposure study|2-6 months-old children and 12-18 months-old children
62203709|NCT05331690|ACTIVE_COMPARATOR|Group 3 NSAIDs and steroids|Topical nepafenac (Nevanac) 3 mg/ml + topical dexamethasone (Spersadex) started the day after surgery
62203710|NCT00354757|ACTIVE_COMPARATOR|2 arms|PPI 1
62786776|NCT06525896|EXPERIMENTAL|NSSD|This group will receive non-surgical spinal decompression (20x over 6-8 weeks). Non-surgical spinal decompression is performed by securing the pelvis in a brace and stabilizing the upper torso. The decompression device provides an inferior force along a vector targeting the level of pathology by pulling on the pelvic brace. This causes a comfortable decompression of the spine.
62786777|NCT06525896|SHAM_COMPARATOR|Sham NSSD|This group will receive sham non-surgical spinal decompression (20x over 6-8 weeks). Sham non-surgical spinal decompression is performed by securing the pelvis in a brace and stabilizing the upper torso. The decompression device provides an inferior force along a vector targeting the level of pathology by pulling on the pelvic brace, but at a force that does not cause decompression of the spine. This is not perceivable by the participant.
62786778|NCT02965430|EXPERIMENTAL|AL-SENSE diagnostic pantyliner|AL-SENSE diagnostic pantyliner of amniotic fluid compared with standard clinical diagnosis methods.
62786779|NCT01603485|EXPERIMENTAL|Lersivirine|
62786780|NCT03494582|EXPERIMENTAL|Sacral Hysteropexy|Abdominal approach for uterine suspension
62786781|NCT03494582|EXPERIMENTAL|sacrospinous Hysteropexy|Transvaginal approach for uterine suspension
62786782|NCT05297188||experimental group|Patients will be divided into experimental and control groups by block randomization. No application will be applied to the experimental group for first night sleep. On the morning of the first night, patients' comfort levels and sleep quality will be measured by Visual Analogue Scale and Richard-Campbell Sleep Scale. The second night, an ergonomic sleep mask will be worn to this group. In the morning of the second night, patients' comfort and sleep quality will be measured with the same scales. The patients will be asked to sleep between 22.00 and 24.00 on the second night, and intensive care lights will decrease, the noise level will be minimized, and patients will not wake up during the night outside their treatment.
62580020|NCT03350789|EXPERIMENTAL|Real acupuncture|manual acupuncture + electroacupuncuture on acupoints, twice a week, for 4 weeks
62580021|NCT03350789|SHAM_COMPARATOR|Sham acupuncture|sham acupuncture (no skin penetration) + placebo electroacupuncture without electrical stimulation on acupoints, twice a week, for 4 weeks
62014654|NCT06165705|EXPERIMENTAL|Amblyopia therapy with Curesight outside FDA limited ranges|Severity of amblyopia and age range outside FDA study
62203711|NCT00354757|ACTIVE_COMPARATOR|PPI|PPI 2
62203712|NCT02927197|EXPERIMENTAL|LearningRx Cognitive Training|The intervention is a 60-hour one-on-one cognitive training program
62580022|NCT04001218|EXPERIMENTAL|Painful condition|Participants will be injected with 0.5ml hypertonic saline (5.8%) into a neck muscle
62580023|NCT04001218|EXPERIMENTAL|Control condition|Participants will be injected with 0.5ml Isotonic saline (0.9%) into a neck muscle
62734835|NCT04852055|NO_INTERVENTION|Usual Care|Patients and proxies in assisted living centers randomized to the usual care arm have advance care planning discussions with a clinician at admission, annually, and sometimes with a hospitalization or other change in condition. There is no standardized decision- or conversation-support tools used to have these discussions.
61978445|NCT00528398|EXPERIMENTAL|Treatment (idarubicin, cytarabine)|Patients receive cytarabine IV over 3 hours every 12 hours on days 1-4 and idarubicin IV over 5-10 minutes on days 1-3. Patients undergo bone marrow aspirate and biopsy 7 days after completion of induction chemotherapy. Patients with \> 25% cellular biopsy or \> 10% abnormal cells on aspirate receive 4 more doses of cytarabine and 1 dose of idarubicin.
62014655|NCT04704414|EXPERIMENTAL|Validation of smartphone face scanner|Validation of smartphone face scanner in comparison to Hertel Exophthalmometer and high-definition face scanner.
62014656|NCT05018845|EXPERIMENTAL|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
62203713|NCT02927197|NO_INTERVENTION|Waitlist Control|The treatment-as-usual control group will begin the intervention when the experimental arm has completed the intervention.
62580024|NCT03534336|NO_INTERVENTION|Control|"Participants are enrolled in a 12-week, self-administered online weight loss program. The program is delivered through 12 weekly sessions; each includes educational videos and a health literacy quiz. Each quiz contains 10 questions, and a quiz is considered passed when at least 7 questions are answered correctly. All participants are encouraged to follow the program, take the quizzes, and lose 5% of their baseline body weight by the end of the program.~No financial incentives are given for losing weight or passing quizzes."
62580025|NCT03534336|EXPERIMENTAL|Incentive for Education|"Same 12-week, self-administered online weight loss program as in the Control arm.~Each participant is also given a $150 Incentive for Education for passing at least nine quizzes by the end of the program."
62580026|NCT03534336|EXPERIMENTAL|Incentive for Weight Loss|"Same 12-week, self-administered online weight loss program as in the Control arm.~Each participant is also given a $150 Incentive for Weight Loss for losing 5% of their baseline body weight."
62580027|NCT05411666|OTHER|Arm 1|Saline solution maintenance of the Central venous catheter (CVC)
62014657|NCT02063646|PLACEBO_COMPARATOR|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.~Dose: 2 capsules per day, one capsule at least 1 hour after breakfast and one capsule at least one hour after dinner, with a glass of water."
62014658|NCT02063646|EXPERIMENTAL|Polyphenol-rich extract|"The test product is a food supplement named Neurophenol. It is presented as a hard-shell capsule containing polyphenol-rich extracts.~Dose: 2 capsules per day, one capsule at least 1 hour after breakfast and one capsule at least one hour after dinner, with a glass of water."
62203714|NCT03506074||General population|"Adult volunteers (≥18 years of age) selected as part of a project to investigate the role of lifestyle in preventing chronic diseases supported by the Campus Salute association (www.campussalute.it).~All volunteers performed the flavor test as described in Maione et al, Endocrine, 2016 (doi:10.1007/s12020-015-0690-y)."
62203715|NCT01006980|EXPERIMENTAL|Vemurafenib|
62203716|NCT01006980|ACTIVE_COMPARATOR|Dacarbazine|
62203717|NCT00472849|EXPERIMENTAL|OFAR (Phase I)|Oxaliplatin starting dose 30 mg/m\^2/day over 2 hours on days 1-4 before Fludarabine. Fludarabine 30 mg/m\^2 daily intravenous (IV) over 30 minutes on days 2-3, 2-4, or 2-5 until maximum tolerated dose reached. Cytarabine 500 mg/m\^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose (MTD) reached. Rituximab 375 mg/m\^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
62203718|NCT00472849|EXPERIMENTAL|OFAR MTD (Phase II)|Oxaliplatin 25 mg/m\^2 IV per day MTD on days 1-4 before Fludarabine. Fludarabine 30 mg/m\^2 daily IV over 30 minutes on days 2-4. Cytarabine 500 mg/m\^2 daily IV, 2-hour infusion starting 4 hours after fludarabine dose started, on days 2-4. Rituximab 375 mg/m\^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
62203719|NCT06213038|EXPERIMENTAL|Dose Level 1|SKG0106 One-Time Intraocular Injection Dose Level 1
62580028|NCT05411666|EXPERIMENTAL|Arm 2|No maintenance of the Central venous catheter (CVC)
62580029|NCT03272295|EXPERIMENTAL|Arm A|Reference product (product 1) x 2, Single ingredients products 2, 3, 4, 5, 6 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
62203720|NCT06213038|EXPERIMENTAL|Dose Level 2|SKG0106 One-Time Intraocular Injection Dose Level 2
62203721|NCT06213038|EXPERIMENTAL|Dose Level 3|SKG0106 One-Time Intraocular Injection Dose Level 3
62203722|NCT05343169|EXPERIMENTAL|CENS Intervention|Peer outreach workers will deliver Overdose Education and Naloxone to participants and provide education, navigation, and support during the 9-month intervention
62014659|NCT06387472|EXPERIMENTAL|DermAI and Patch Allergen Testing|Subjects will have two allergen patches on their forearms for 48 hours and a photograph image of where the patches were placed afterwards for human review and AI predictions of reactions.
62203723|NCT05343169|OTHER|Control|Participants will receive Overdose Education and Naloxone and referrals to treatment
62203724|NCT04745169|OTHER|Intervention|Participants will be asked to complete an 8-week home-based exercise intervention
62203725|NCT03228628|EXPERIMENTAL|Nitrous oxide|will inhale experimental treatment (50% N2O - 50% O2)
62203726|NCT03228628|PLACEBO_COMPARATOR|Placebo|will inhale medical air (22% O2 - 78% N2)
62203727|NCT04590157|EXPERIMENTAL|study group|received pelvic floor muscle training in addition to laser acupuncture on neurogenic acupoints
62203728|NCT04590157|EXPERIMENTAL|control group|received pelvic floor muscle training
62403657|NCT04917588|EXPERIMENTAL|Saypha® FILLER HQ|"Eligible subjects will undergo bilateral lip augmentation treatments with Saypha® FILLER Lidocaine manufactured in the Croma Pharma HQ Facility in order to correct moderate to severe deficiency of lip volume.~The treatment will be administered at the Baseline visit (Day 0)."
62580030|NCT03272295|EXPERIMENTAL|Arm B|Reference product (product 1), Single ingredients products 7, 8, 9, 10, 11 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
62014660|NCT04275648|EXPERIMENTAL|Asthmatuner field tests vs laboratory tests|Each participant will perform two standardized field tests either before or after Eucapnic Voluntary Hyperpnea or Methacholine bronchial provocation test. In addition, unstandardized field tests will be performed in case of exercise induced respiratory symptoms.
62014661|NCT03487913|EXPERIMENTAL|High dose lixivaptan / CKD1 or CKD2|Oral high dose lixivaptan in participants with CKD1 or CKD2
62203729|NCT03739853|ACTIVE_COMPARATOR|Standard care|Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard NHS practice following international recommendations and National requirements for the prescription of biologic therapy\[19-22\]. Commonly Initial therapy will be with methotrexate alone (15mg/week rising to 25mg/week as tolerated by week 8 of therapy) unless this is contraindicated. In cases of non-response or intolerance to methotrexate, participants will have an alternative DMARD (most commonly sulfasalazine or leflunomide) added or switched to. In cases of failure of two DMARDs, treatment can be escalated to biologic therapy as per National Institute for Health and Clinical Excellence (NICE) recommendations. If the requisite disease activity is not met or if there are contraindications to biologics, alternative DMARD combinations will be used.
62203730|NCT03739853|EXPERIMENTAL|Combination csDMARD|Arm 2 - Combination DMARD arm. All participants will be prescribed methotrexate with an additional DMARD (either sulfasalazine or leflunomide) at baseline. Response will be assessed after 12 weeks of therapy using the Minimal Disease Activity (MDA) criteria. Participants who achieve the MDA criteria by week 12 on this combination therapy will continue . Participants who show a significant response by in week 12 (a reduction in tender and swollen joint counts of at least 20%) but do not yet meet the MDA criteria should continue on this therapy for an additional 12 weeks before review. Participants failing to show significant response (reduction in joint counts by less than 20%) by week 12 on this combination therapy or those failing to meet MDA criteria by week 24 will be eligible for rescue therapy
62203731|NCT03739853|EXPERIMENTAL|Early TNF inhibition|Early biologic arm. All participants will be prescribed methotrexate (given weekly) with a TNF inhibitor (adalimumab given every two weeks) at baseline. Treatment with TNF inhibitor will be continued until week 24 at which time the TNF inhibitor will be tapered to week 32. The TNF inhibitor will be stopped completely after week 32 and participants will continue on methotrexate. In case of flare of disease, participants will be eligible for rescue therapy
62203732|NCT06055504|OTHER|Control Strategy|
62203733|NCT06055504|EXPERIMENTAL|Personalized precision ICD implantation Strategy based in genetic findings and CMR results|
62014662|NCT03487913|EXPERIMENTAL|Low dose lixivaptan / CKD1 or CKD2|Oral low dose lixivaptan in participants with CKD1 or CKD2
62014663|NCT03487913|EXPERIMENTAL|High dose lixivaptan / CKD3|Oral high dose lixivaptan in participants with CKD3
62014664|NCT03487913|EXPERIMENTAL|Low dose lixivaptan / CKD3|Oral low dose lixivaptan in participants with CKD3
62014665|NCT01867684|NO_INTERVENTION|Treatment as usual|Standard NHS care for the patient group (NHS care will vary as participants will be recruited from a variety of NHS clinics).
62014666|NCT01867684|EXPERIMENTAL|Psychotherapy|Brief psychotherapy intervention delivered over 8 weeks in addition to standard care.
62403658|NCT04917588|ACTIVE_COMPARATOR|Saypha® FILLER C1|"Eligible subjects will undergo bilateral lip augmentation treatments with Saypha® FILLER Lidocaine manufactured in the Croma Pharma C1 Facility in order to correct moderate to severe deficiency of lip volume.~The treatment will be administered at the Baseline visit (Day 0)."
62403659|NCT03371602|EXPERIMENTAL|control group|non-septic mesocolic programmed abdominal or thoracic surgery: gastrectomy, esophagectomy, pancreatectomy, hepatectomy
62403660|NCT03371602|EXPERIMENTAL|sepsis group|Abdominal or thoracic surgery in a septic context (peritonitis, mediastinitis, pleural abscess)
62403661|NCT03371602|EXPERIMENTAL|mechanical ventilation group|Patient in brain death for whom a multi-organ sampling is planned
62580031|NCT00529308|ACTIVE_COMPARATOR|Active|
62203734|NCT05637359||Patients scheduled for navigated abdominal cancer surgery|Patients are 18 years old or older. Patients are scheduled for tumor surgery in the abdominal/pelvic area and navigation surgery with a scheduled Cone Beam CT-scan in the operating room. Patients provide written 'informed consent'. The to be administered intervention is a percutaneous tracked ultrasound measurement of the patient's pelvic bone on the operating room after anesthesia.
62203735|NCT04081129||ICU patients with early mobilization|
62403662|NCT03371602|EXPERIMENTAL|mechanical ventilation - sepsis group|Patient under controlled mechanical ventilation to undergo abdominal or thoracic surgery in a septic context (peritonitis, mediastinitis, pleural abscess)
62403663|NCT03825887|ACTIVE_COMPARATOR|Group A-PCA Morphine|Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10 mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40 mcg /kg/ hour.
62403664|NCT03825887|EXPERIMENTAL|Group B-PCA Nalbuphine|Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10 mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40 mcg /kg/ hour.
62403665|NCT03195946|EXPERIMENTAL|Lu AF35700 and Cocktail of CYP450 substrates|Day 1 oral midazolam administration, Day 2 Cocktail of CYP450 substrates administration. Daily Lu AF35700 administration from Day 5 to Day 28 with co-administration on Day 27 with oral midazolam and Day 28 with CYP450 substrate cocktail
62403666|NCT02113904|EXPERIMENTAL|Adalimumab|
62403667|NCT00494234|EXPERIMENTAL|Olaparib 100 mg|Participants will receive two 50 mg capsules in the morning and two 50 mg capsules in the evening in 28-days cycle until confirmed disease progression, continuous treatment interruption, unacceptable toxicity or any other discontinuation criterion is met.
62403668|NCT00494234|EXPERIMENTAL|Olaparib 400 mg|Participants will receive eight 50 mg capsules in the morning and eight 50 mg capsules in the evening in 28-days cycle until confirmed disease progression, continuous treatment interruption, unacceptable toxicity or any other discontinuation criterion is met.
62014667|NCT03853707|EXPERIMENTAL|Arm A (ipatasertib, carboplatin, paclitaxel)|Patients receive ipatasertib PO QD on days 1-28. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62014668|NCT03853707|ACTIVE_COMPARATOR|Arm B (ipatasertib and carboplatin)|Patients receive ipatasertib PO QD on days 1-28. Patients also receive carboplatin IV over 30 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62403669|NCT03621566||Central Sleep Apnea|Subjects with an apnea/hypopnea index ≥ 15/h of sleep and proportion of non-obstructive events \> 50%, derived from polysomnography (diagnostic or during positive airway pressure treatment)
62403670|NCT03615742|PLACEBO_COMPARATOR|Placebo and Filtered Air|Volunteers will use an inhaler that does not contain any medication, before sitting in a booth and being exposed to high-efficiency particulate air (HEPA) filtered air for 2 hours.
62403671|NCT03615742|ACTIVE_COMPARATOR|Budesonide and Filtered Air|Volunteers will inhale 1.6mg of budesonide before sitting in a booth and being exposed to HEPA filtered air for 2 hours.
62403672|NCT03615742|ACTIVE_COMPARATOR|Placebo and Diesel Exhaust|Volunteers will use an inhaler that does not contain any medication, before sitting in a booth and being exposed to 300µg/m³ concentration of diesel exhaust for 2 hours.
62403673|NCT03615742|EXPERIMENTAL|Budesonide and Diesel Exhaust|Volunteers will inhale 1.6mg of budesonide before sitting in a booth and being exposed to 300µg/m³ concentration of diesel exhaust for 2 hours.
62580032|NCT00529308|SHAM_COMPARATOR|Sham|
62580033|NCT01497912|ACTIVE_COMPARATOR|Atorvastatin|Atorvastatin 80mg once daily
62580034|NCT01497912|PLACEBO_COMPARATOR|Placebo|Matched placebo tablets
62580035|NCT05180825|EXPERIMENTAL|Trametinib experimental arm|the experimental arm will be Mekinist© (Trametinib) taken orally each day with a 18-course schedule of 4 weeks each.
62403674|NCT04028739|EXPERIMENTAL|Theracurmin CR-033P|1 Capsule with 150mL water, Single, curcumin 90mg/day
62403675|NCT04028739|EXPERIMENTAL|Theracurmin CR-031P|3 Capsule with 150mL water, Single, curcumin 90mg/day
62403676|NCT04028739|EXPERIMENTAL|Curcumin|1 Capsule with 150mL water, Single, curcumin 90mg/day
62403677|NCT04025866|ACTIVE_COMPARATOR|Conventional rehabilitation|Conventional rehabilitation treatment for inpatients with femur fracture
62403678|NCT04025866|ACTIVE_COMPARATOR|Aerobic exercise|Addition of cycle ergometer for upper limb to conventional rehabilitation treatment for femur fracture
62580036|NCT05180825|ACTIVE_COMPARATOR|Vinblastine control arm|the control arm will be the weekly intra-venous Vinblastine (Velbe©) during 18 courses of 4 weeks each
62580037|NCT05923138|EXPERIMENTAL|NUTRITIONAL INTERVENTION|
62580038|NCT05923138|PLACEBO_COMPARATOR|CONTROL|
62580039|NCT05835063|EXPERIMENTAL|We Chatt communication tool|
62580040|NCT05835063|PLACEBO_COMPARATOR|Usual care|
62786783|NCT05297188||control group|Patients will be divided into experiment and control groups by block randomization. No application will be made to the control group for sleep on the first night. On the morning of the first night, patients' comfort levels and sleep quality will be measured by Visual Analogue Scale and Richard-Campbell Sleep Scale. On the second night, ear plugs and eye mask will be worn to this group. In the morning of the second night, patients' comfort and sleep quality will be measured with the same scales. Patients will be asked to sleep between 22.00 and 24.00 on the second night, and intensive care lights will decrease, noise level will be minimized and patients will not wake up during the night outside their treatment. It will be collected using the form.
62786784|NCT00915707|EXPERIMENTAL|Baseline|Subjects are tested under normal sleep conditions for carbohydrate metabolism and appetite regulation.
62786785|NCT00915707|EXPERIMENTAL|Sleep restriction|Subjects are tested under sleep restriction for carbohydrate metabolism and appetite regulation.
62786786|NCT00915707|EXPERIMENTAL|Reduced sleep quality|Subjects are tested under a poor sleep quality condition for carbohydrate metabolism and appetite regulation.
62786787|NCT03662594|OTHER|ECMO tube|
62786788|NCT03878784|ACTIVE_COMPARATOR|PACAP38 + Imigran|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Imigrane infusion (0.4 mg/min) for 10 mins"
62786789|NCT03878784|PLACEBO_COMPARATOR|PACAP38 + Isotonic Saline|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Isotonic saline for 10 mins (placebo)"
62014669|NCT03853707|EXPERIMENTAL|Arm C (ipatasertib, capecitabine, atezolizumab)|Patients receive ipatasertib PO QD on days 1-21, capecitabine PO BID on days 1-7 and 15-21, and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62786790|NCT00612560|EXPERIMENTAL|2|Flaxseed 25 mg per day and 1 placebo pill per day
62786791|NCT00612560|EXPERIMENTAL|3|25 mg flaxseed per day and 1 mg anastrozole pill per day
62786792|NCT00612560|PLACEBO_COMPARATOR|4|Placebo pill 1 per day
62786793|NCT00612560|EXPERIMENTAL|1|Anastrozole 1 mg pill per day
62786794|NCT06010511||Memory clinic patients|We will prospectively include patients with memory complaints and/or vascular brain abnormalities (n=50; over 65 years of age) from the memory clinic (or geriatric clinic) at one of their first visits, prior to any diagnosis.
62786795|NCT06351059||A: healthy participants|20 healthy participants judging themselves to be of good subjective health without any knee problems
62786796|NCT06351059||B1: 2 years normal|20 patients from the knee registry at 2 years post-op with normal outcomes
62786797|NCT06351059||B2: 2 years poor|20 patients from the knee registry at 2 years post-op with poor outcomes
62786798|NCT06351059||C1: 5 years normal|20 patients from the knee registry at 5 years post-op with normal outcomes
62786799|NCT06351059||C2: 5 years poor|20 patients from the knee registry at 5 years post-op with poor outcomes
62786800|NCT06351059||D: TKA patients|20 patients booked for unilateral TKA surgery for severe OA
62786801|NCT04256681|EXPERIMENTAL|patients affected by hereditary spastic paraplegia|40 subjects affected by genetically determined hereditary spastic paraparesis or subjects without defined genetics but who unequivocally show a dominant or recessive familiarity with exclusive involvement of the pyramidal system.
62786802|NCT04256681|ACTIVE_COMPARATOR|healthy subjects|40 healthy subjects will also be recruited to whom the questionnaire will be submitted to assess the variability of the score within a healthy population.
62786803|NCT01085877|ACTIVE_COMPARATOR|Trial part 1|
62786804|NCT01085877|EXPERIMENTAL|Trial part 2|
62786805|NCT03860805|ACTIVE_COMPARATOR|Laparoscopic tubal ligation|Patients who seek for surgical permanent contraception and randomized to laparoscopic tubal ligation
62786806|NCT03860805|ACTIVE_COMPARATOR|Laparoscopic bilateral salpingectomy|Patients who seek for surgical permanent contraception and randomized to laparoscopic bilateral salpingectomy
62786807|NCT00328458|EXPERIMENTAL|Cohort 1 Brain Tumors|The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.
62786808|NCT00328458|EXPERIMENTAL|Cohort 2 Head and Neck Tumors|The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.
62786809|NCT00896025|ACTIVE_COMPARATOR|N-acetycylcysteine|Each eligible Acute Liver Failure patient will be given N-acetylcysteine (NAC), beginning at a dose of 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour, followed by 50 mg/kg in 500 ml 5% dextrose over four hours, and 125 mg/kg in 1000 ml 5% dextrose over 19 hours, then 150 mg/kg in 1000 ml 5% dextrose per 24 hours for an additional 48 hours. The patient will be on continuous N-acetylcysteine infusion for a total of 72 hours.
62786810|NCT00896025|NO_INTERVENTION|Standard of care|Each eligible Acute Liver Failure patient for whom the investigator chooses not to utilize N-acetylcysteine may serve as a control and receives standard of care.
62786811|NCT05942443|ACTIVE_COMPARATOR|MCP blocking orthosis|Patients received the MCP blocking orthosis
62786812|NCT05942443|EXPERIMENTAL|RME orthosis|Patients received the RME orthosis for six weeks
62786813|NCT00475904|ACTIVE_COMPARATOR|amitriptyline 4% ketamine 2% cream, placebo capsules|Np-1 cream and placebo gabapentin
62786814|NCT00475904|ACTIVE_COMPARATOR|gabapentin capsules, placebo cream|gabapentin caps and placebo cream
62786815|NCT00475904|PLACEBO_COMPARATOR|placebo cream and capsules|placebo cream and capsules
62786816|NCT05015270||Less disease group|"Patients with coronary artery diameter stenosis \<70% confirmed by coronary angiography;~Patients will be treated using guideline recommended medications or percutaneous coronary intervention at physician's discretion"
62014670|NCT03207282||Participants with Diagnosis of Depression|Study population consists of participants with a clinical diagnosis of depression, being treated in a psychiatry reference site (example, clinic, ambulatory, hospital, day-hospital) in 4 Latin American countries. Participants with Major Depressive Disorder (MDD) enrolled in Phase 1, will be assessed to estimate the prevalence of Treatment Resistant Depression (TRD) and participants with this diagnosis will be included in Phase 2. Participants with TRD will be followed-up for 1 year.
62014671|NCT01083550|EXPERIMENTAL|DA intervention|Decision aid exposure + usual care
62786817|NCT05015270||Severe disease group|"Patients with coronary artery stenosis ≥70% confirmed by coronary angiography;~Patients will be treated using guideline recommended medications or percutaneous coronary intervention at physician's discretion"
62786818|NCT03161080|EXPERIMENTAL|Dry Eye Neovis|20 Patients with dry eye syndrome receiving Neovis Total Multi Eyedrops
62786819|NCT03161080|EXPERIMENTAL|Dry Eye Vismed|20 Patients with dry eye syndrome receiving Vismed Multi Eyedrops
62786820|NCT03161080|EXPERIMENTAL|Dry Eye Hydrabak|20 Patients with dry eye syndrome receiving Hydrabak Eyedrops
62786821|NCT01181869||Oxygen therapy|Database of patients on oxygen
62786822|NCT01181869||ventilation|database of patients on ventilatory support
62786823|NCT01181869||Continuous positive airway pressure|Sleep apnoea patients on CPAP
62786824|NCT01609881|OTHER|Acuvail|Acuvail as preventive for inflammation and possible decrease or prevent diabetic retinopathy. The study has four arms - diabetic ketorolac, diabetic control, normal eyes ketorolac, normal eyes control. patients are randomized to ketorolac or control.
62786825|NCT01609881|PLACEBO_COMPARATOR|Placebo|Placebo using artificial tear drops
62786826|NCT04480658|EXPERIMENTAL|Bryophyllum pinnatum|Bryophyllum pinnatum (BP) muscle relaxing substance
62786827|NCT05678257|EXPERIMENTAL|NUFIRI-bev on a Q1W NUC-3373 schedule|"Arm A: Study treatment will be administered in 28-day cycles as follows:~1. Bevacizumab 5 mg/kg on Days 1 and 15:~   * 90 minutes for the first dose~  * 60 minutes for the second dose (if first dose is tolerated)~  * 30 minutes for subsequent doses (if second dose is tolerated)~2. LV 400 mg/m2 (or equivalent levo-LV) over 120 minutes on Days 1, 8, 15, and 22.~3. Irinotecan 180 mg/m2 over 90 minutes (concurrently with the LV infusion) on Days 1 and 15.~4. NUC-3373 1500 mg/m2 over 120 minutes on Days 1, 8, 15, and 22."
62786828|NCT05678257|EXPERIMENTAL|NUFIRI-bev on a Q2W NUC-3373 schedule|"Arm B: Study treatment will be administered in 28-day cycles as follows:~1. Bevacizumab 5 mg/kg on Days 1 and 15:~   * 90 minutes for the first dose~  * 60 minutes for the second dose (if first dose is tolerated)~  * 30 minutes for subsequent doses (if second dose is tolerated)~2. LV 400 mg/m2 (or equivalent levo-LV) over 120 minutes on Days 1 and 15.~3. Irinotecan 180 mg/m2 over 90 minutes (concurrently with the LV infusion) on Days 1 and 15.~4. NUC-3373 1500 mg/m2 over 120 minutes on Days 1 and 15."
62786829|NCT05678257|ACTIVE_COMPARATOR|FOLFIRI-bev on a Q2W schedule|"Arm C: Study treatment will be administered in 28-day cycles as follows:~1. Bevacizumab 5 mg/kg on Days 1 and 15:~   * 90 minutes for the first dose~  * 60 minutes for the second dose (if first dose is tolerated)~  * 30 minutes for subsequent doses (if second dose is tolerated)~2. LV 400 mg/m2 (or equivalent levo-LV) over 120 minutes on Days 1 and 15.~3. Irinotecan 180 mg/m2 over 90 minutes (concurrently with the LV infusion) on Days 1 and 15.~4. 5-FU 400 mg/m2 bolus on Days 1 and 15.~5. 5-FU 2400 mg/m2 infusion over 46 hours on Days 1 and 15."
62786830|NCT02503150|EXPERIMENTAL|APDC + Chemotherapy|Patients in Arm APDC + Chemotherapy will receive APDC combined with chemotherapy.
62786831|NCT02503150|ACTIVE_COMPARATOR|Chemotherapy|Patients in Arm Chemotherapy will receive chemotherapy only.
62786832|NCT04543292|EXPERIMENTAL|MATFILL|Prosthetic chimney filling with MATFILL prior to other sealing materials to protect the screww head.
62786833|NCT01911117||Cardiac Surgical Patients|"Patients who undergo cardiac surgery will be included in this study.~1. Patients undergo cardiac surgery and are over 18 years of age.~2. Patients need bypass machine for their cardiac surgery and traditional CO measurement.~3. Patients who are competent to understand the study and provide written informed consent and participate in outcome measurements."
62786834|NCT04152408|EXPERIMENTAL|FiberSense System|6 diabetic patients will wear a FiberSense system at the upper arm for up to 30 days. and a comparator CGM system at the abdomen (replaced every 7 days).
62786835|NCT01061502|EXPERIMENTAL|Procellera Wound Dressing|Dressing indicated for partial and full-thickness wounds. Dressing changes every 5-7 days, more frequently if needed
62014672|NCT01083550|NO_INTERVENTION|Control|Usual care
62786836|NCT01061502|ACTIVE_COMPARATOR|Opsite Transparent Adhesive Dressing|Polyurethane film dressing. Dressing changes every 5-7 days, more frequently if needed
62014673|NCT00175136|ACTIVE_COMPARATOR|I-beam|I-beam stem design of tibial component for Total Knee Arthroplasty.
62786837|NCT03323177|EXPERIMENTAL|Nutritional supplementation gender specific formula|Patients at this arm will continue to consume the study formula until final height. The formula is a gender specific powder added to water containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
62786838|NCT03323177|OTHER|Follow-up only|Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
62786839|NCT00609570|EXPERIMENTAL|Fruit and vegetables|Fruits and vegetables
62786840|NCT00609570|ACTIVE_COMPARATOR|Whey protein|Whey protein
62786841|NCT00609570|ACTIVE_COMPARATOR|Ca|Calcium pills
62786842|NCT05545683|EXPERIMENTAL|VLA 2001|"One dose (0.5 mL) contains no less than 25 Antigen Units (AU) of inactivated SARS-CoV-2.~Highly purified whole virus SARS-CoV-2 antigen, inactivated and adjuvanted with CpG 1018 in combination with aluminum hydroxide."
62786843|NCT00390039|EXPERIMENTAL|A|MNS075 7.5mg
62786844|NCT00390039|PLACEBO_COMPARATOR|B|Placebo
62786845|NCT00390039|ACTIVE_COMPARATOR|C|IV Morphine
62786846|NCT00390039|EXPERIMENTAL|E|MNS075 15mg
62786847|NCT00390039|PLACEBO_COMPARATOR|D|Placebo
61978446|NCT04741061|ACTIVE_COMPARATOR|Sputnik Light Vaccine|study group (4500 receiving the Sputnik-Light vector vaccine) against the SARS-СoV-2-induced coronavirus infection.
61978447|NCT04741061|PLACEBO_COMPARATOR|Placebo Group|control group (1500 subjects receiving placebo)
61978448|NCT04358575|EXPERIMENTAL|All-polyethylene tibial components|Triathlon CS Knee System with all-polyethylene tibial components
62014674|NCT00175136|ACTIVE_COMPARATOR|wedge|Wedge stem design of tibial component for Total Knee Arthroplasty.
62014675|NCT04504227|PLACEBO_COMPARATOR|Thin liquid swallows|Thin liquid swallows of formula or breastmilk or other liquid
62014676|NCT04504227|EXPERIMENTAL|Slightly thick liquid swallows|Slightly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
62786848|NCT00390039|PLACEBO_COMPARATOR|F|Placebo
62786849|NCT02133092||Patients with respiratory syncytial virus (RSV) infection|The RSV infection is laboratory confirmed
62786850|NCT02992392|EXPERIMENTAL|Liposic|Liposic was applied to one eye of patients in this group
62786851|NCT02992392|EXPERIMENTAL|Tears Naturale Forte|Tears Naturale Forte was applied to one eye of patients in this group
62786852|NCT03179397|EXPERIMENTAL|Model SC9|Investigational IOL
62786853|NCT03179397|ACTIVE_COMPARATOR|Model LI61SE|FDA Approved IOL
62786854|NCT01110031|EXPERIMENTAL|Treatment|Six months treatmet with ofatumumab will be given to subjects with chronic lymphocytic leukemia.
62203736|NCT04617275|EXPERIMENTAL|Arm 1-PF-06882961 starting dose of 5 milligram (mg) BID titrated to 120 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 5 mg BID to reach the target dose of 120 mg BID. Titration steps include: 5 mg BID, 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID
62403679|NCT05468866|ACTIVE_COMPARATOR|group (I)|Group (I): represents the healthy control individuals (30 person) (recruited from the blood donors at the blood bank)
62014677|NCT04504227|EXPERIMENTAL|Mildly thick liquid swallows|Mildly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
62403680|NCT05468866|ACTIVE_COMPARATOR|Group (II)|Group (II): represents the cases of immune thrombocytopenia (70 cases).
62403681|NCT02554084|EXPERIMENTAL|Dry Eye Disease|Optical Coherence Tomography
62403682|NCT02554084|ACTIVE_COMPARATOR|Normals|Optical Coherence Tomography
62403683|NCT04679116|OTHER|Laparoscopic|laparoscopic inguinal hernia repair, TAPP
62403684|NCT04679116|OTHER|Open|open inguinal hernia repair
62786855|NCT03662516|OTHER|Sequence 1|In Treatment Sequence 1, Period 1 Day 1, subjects will be dosed with a single administration of OC in the form of 1 PORTIA (EE and LN) or equivalent tablet, orally. OC (EE and LN) PK will then be assessed at pre dose and over 48 hours after OC dosing. Period 1 will be immediately followed by Period 2 with no washout. The 48 hours post-OC dose PK sample for Period 1 must be collected prior to receiving the first dose of PF 04965842 in Period 2. In Period 2, subjects will be dosed with 200 mg PF 04965842 PO QD for 9 days followed by administration of a single dose of OC oral tablet immediately after administration of a 200 mg dose of PF-04965842 on the morning of Day 10. OC PK in Period 2 will be assessed at pre dose and over 48 hours after OC dosing. Dosing with 200 mg PF 04965842 PO QD will continue until Day 11.
62203737|NCT04617275|EXPERIMENTAL|Arm 2-PF-06882961 starting dose of 10 mg BID titrated to 100 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 120 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID
62403685|NCT01617031||Diabetic patients with coronary artery disease|Type 2 diabetic patients with previous coronary artery disease. All patients are routinely treated with aspirin in secondary prevention of cardiovascular disease. Coronary artery disease is defined as a previous coronary angiography with at least 1 coronary artery stenosis \>50%. Type 2 diabetes is defined as patients with diabetes discovered after 30 years old and insulin was not the first treatment except in case of acute coronary syndrome.
62403686|NCT04179929|OTHER|CHEMOTHERAPY|Pediatric-type of chemotherapy
62403687|NCT04179929|OTHER|allogeneic HSCT|allogeneic HSCT
62403688|NCT00280839|ACTIVE_COMPARATOR|topiramate|
62403689|NCT00280839|PLACEBO_COMPARATOR|placebo|
62403690|NCT05765994||ICU patients|Adult ICU patients on mechanical ventilation
62403691|NCT03764241|EXPERIMENTAL|Rivaroxaban|rivaroxaban will be added in addition to dual antiplatelet therapy
62403692|NCT03764241|ACTIVE_COMPARATOR|Vitamin K Antagonist|warfarin will be added in addition to dual antiplatelet therapy
62403693|NCT05888545|EXPERIMENTAL|anti-adhesion diaphragm|Participants will be asked to place an anti-adhesion diaphragm in the uterus for 3-7 days after the abortion procedure.
62786856|NCT03662516|OTHER|Sequence 2|In Treatment Sequence 2, Period 1, subjects will be dosed with 200 mg PF 04965842 PO QD for 9 days followed by administration of a single dose of OC oral tablet immediately after administration of a 200 mg dose of PF-04965842 on the morning of Day 10. OC PK will be assessed at pre dose and over 48 hours following OC dosing. Dosing with 200 mg PF 04965842 PO QD will continue until Day 11. Subjects will then undergo a washout period of at least 10 days (Day -1 of Period 2 starts 10 days after Day 12 of Period 1). In Period 2 subjects will be dosed with a single OC administration on Day 1. OC PK will then be assessed at pre dose and over 48 hours after OC dose.
62786857|NCT01732770|EXPERIMENTAL|Denosumab 60 mg|Participants received denosumab 60 mg subcutaneous injection once every 6 months for 12 months and placebo to zoledronic acid by intravenous infusion on Day 1.
62786858|NCT01732770|ACTIVE_COMPARATOR|Zoledronic Acid 5 mg|Participants received zoledronic acid 5 mg by intravenous infusion on Day 1 and placebo to denosumab by subcutaneous injection on Day 1 and at Month 6.
62786859|NCT05246709|ACTIVE_COMPARATOR|Control Group|This group will be received the current standard of care (SOC) dressing method for PICC lines.
62786860|NCT05246709|EXPERIMENTAL|Cyanoacrylate Glue Group|This group will receive a few drops of cyanoacrylate glue on PICC line site prior to application of usual standard film dressing over the PICC line site.
62786861|NCT03928717|EXPERIMENTAL|Text-Based Adherence Game|Participants in the experimental condition will receive the Text Based Adherence Game. They will receive semi-automated text messages sent by study staff throughout the trial period.
62786862|NCT03928717|ACTIVE_COMPARATOR|Standard of Care (SOC)|SOC participants will receive the Standard of Care Intervention which includes receiving a brief adherence counseling session and access to clinic resources, including counseling services, throughout the trial period.
62786863|NCT05047952|EXPERIMENTAL|Vortioxetine|"Participants aged 18-64 years: start at 10 mg vortioxetine once daily for the first 2 weeks, then dosed up to 20 mg vortioxetine once daily for weeks 2-8.~Participants aged 65+ years: start at 5 mg vortioxetine once daily for the first 2 weeks, then dosed up to 10 mg vortioxetine once daily for weeks 2-8."
62786864|NCT05047952|PLACEBO_COMPARATOR|Placebo|Placebo capsule taken once daily for weeks 0-8.
62786865|NCT05852236|EXPERIMENTAL|Control Group|The standard care of the clinic was applied to the control group.
62786866|NCT05852236|EXPERIMENTAL|Study Group|The pressure ulcer care package developed for this study was applied to the study group.
62786867|NCT06464445|EXPERIMENTAL|Intermittent theta burst stimulation (iTBS)|All participants will understand 3 different iTBS protocols, each separated by one week. The order of the iTBS protocols will be randomized.
62014678|NCT04504227|EXPERIMENTAL|Moderately thick liquid swallows|Moderately thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
62786868|NCT00829114|ACTIVE_COMPARATOR|1|ART/COC group
62786869|NCT00829114|ACTIVE_COMPARATOR|2|COC group
62786870|NCT03836911|ACTIVE_COMPARATOR|serious game|the effect on physical performance of a personalized, 12-weeks rehabilitation program using a serious game
62786871|NCT03836911|OTHER|Classic program|the effect on physical performance of a personalized, 12-weeks rehabilitation program using a classical exercise program in older subjects living in a nursing home
62786872|NCT00847886|EXPERIMENTAL|LX3305|Daily oral intake of LX3305 for 14 days.
62786873|NCT00847886|PLACEBO_COMPARATOR|LX3305 Placebo|Matching placebo dosing with daily oral intake for 14 days.
62203738|NCT04617275|EXPERIMENTAL|Arm 3-PF-06882961 starting dose of 5 mg BID titrated to 80 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 5 mg BID to reach the target dose of 80 mg BID. Titration steps include: 5 mg BID, 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID
62403694|NCT05888545|NO_INTERVENTION|control group|Participants will be treated routinely with no other interventions.
62403695|NCT02119858|EXPERIMENTAL|Diagnostic (ICG, diffuse optical imaging, surgery)|Patients receive indocyanine green transperineally and undergo diffuse optical imaging during robot-assisted laparoscopic radical prostatectomy with bilateral lymph node dissection using the da Vinci Robotic Surgical System.
62403696|NCT00965562|ACTIVE_COMPARATOR|I|Fluoxetine
62403697|NCT00965562|ACTIVE_COMPARATOR|II|Calcium
62403698|NCT00965562|PLACEBO_COMPARATOR|III|
62786874|NCT00583037|EXPERIMENTAL|NAVA|Implementation of NAVA for 24 hours
62786875|NCT03190889|NO_INTERVENTION|STAN|Patients in the STAN group will participate in twelve sessions of supervised physical therapy over a six week period. Patients will participate in agility and plyometric drills, and continue strength exercises from the previous treatment phase. The clinic program will be performed in conjunction with a home running program. Patients in this group will not receive feedback from the therapist regarding movement quality during activities.
62203739|NCT04617275|EXPERIMENTAL|Arm 4-PF-06882961 starting dose of 10 mg BID titrated to 80 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 80 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID
62203740|NCT04617275|PLACEBO_COMPARATOR|Arm 5 - Placebo in subjects with T2DM and Obesity|Matching Placebo tablets taken twice a day (BID)
62786876|NCT03190889|OTHER|HOME|HOME Program is distinguished by patients participating in a home only intervention that consists of running and strengthening exercises performed twice a week for six weeks. No plyometric or agility drills are performed in this study arm. This represents the minimal intervention to prepare for a return to sports. No neuromuscular training or movement training beyond the sagittal plane will be performed.
62786877|NCT03190889|EXPERIMENTAL|TNMT|Patients who are enrolled in the TNMT group will participate in 12 sessions of supervised outpatient physical therapy over a six week period. The TNMT protocol is distinguished by performance of exercises designed to enhance core and hip strength, performance of neuromuscular training exercise that are designed to correct movement flaws associated with second ACL injury25, providing verbal and visual feedback and performance of single leg drills on both legs.
62786878|NCT03276546|EXPERIMENTAL|SHARE-D decision tool use|The intervention, a shared decision-making tool ('SHARE-D'), which is a paper-based questionnaire, will be used jointly by a health professional and patient to facilitate decision-making about initiating change in physical activity or diet behaviour
62786879|NCT01760343|EXPERIMENTAL|Berinert, then CSL830|A single intravenous dose of Berinert at 1500 units (1500 IU), followed by a single intravenous dose of CSL830 at 1500 IU.
62203741|NCT04617275|EXPERIMENTAL|Arm 6-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID,140 mg BID, 160 mg BID, 180 MG BID, 200 mg BID
62786880|NCT01760343|EXPERIMENTAL|CSL830, then Berinert|A single intravenous dose of CSL830 at 1500 IU, followed by a single intravenous dose of Berinert at 1500 IU.
62786881|NCT04503720|EXPERIMENTAL|CLoWI|"CLoWI (ropivacaine) and PCA (normal saline)~The local anaesthetic infusion will be administered via 2 catheters using a ON-Q® (Halyard) delivery system that will be placed under direct vision by the surgeon at the time of wound closure. 40 mls of 0.25% ropivacaine are infiltrated in the preperitoneal plane. 0.5% ropivacaine will be infused at a rate of 4mls/hour (2mls/hour in each catheter).~The dosage 40 mls of 0.25% ropivacaine and 0.5% ropivacaine at 4mls/hr (20mg/hr) over 4 days will be less than the recommended toxic dose of 3-4 mg/kg."
62786882|NCT04503720|ACTIVE_COMPARATOR|PCA|"PCA (Morphine) and CLoWI (normal saline)~Morphine will be administered via the standard PCA protocol in accordance to the hospital's Acute Pain Service Programme:~* Concentration: 1mg/ml~* Bolus (Loading): 1mg~* Lockout Interval: 5 minutes~* Maximum hourly dose of 10mg"
62786883|NCT01925547|EXPERIMENTAL|Micellar curcumin|Subjects receive three times per day four capsules of curcumin micelles. One capsule contains 20 mg of curcumin. At the beginning, after three and six weeks of intake, blood samples are collected.
62786884|NCT01925547|PLACEBO_COMPARATOR|Placebo|Subjects receive three times per day four capsules of placebo preparation. At the beginning, after three and six weeks of intake, blood samples are collected.
62786885|NCT03971448|ACTIVE_COMPARATOR|Fiberglass above-knee walking cast (AKWC)|The standard treatment arm will be a posterior splint placed in the ED by the ED clinical team (nurse/physician) and then a fiberglass AKWC to be placed ideally within 72 hours in the fracture clinic. This AKWC will be in place for 3 weeks, which is currently the most common strategy to manage TF.
62786886|NCT03971448|EXPERIMENTAL|Landmark Pediatric Walker Boot (LPWB)|The Landmark Pediatric Walker Boot (LPWB) will be placed in the ED and will be kept on for a minimum of one week, and then for a duration dictated by the patient's comfort.
62203742|NCT04617275|EXPERIMENTAL|Arm 7-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with Obesity|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID,140 mg BID, 160 mg BID, 180 MG BID, 200 mg BID
62203743|NCT02810145||TBI with GCS <or= 8|Adult patients admitted to the surgical intensive care unit with traumatic brain injury and a Glasgow coma score less than or equal to 8.
62203744|NCT00436605|EXPERIMENTAL|Treatment (kinase inhibitor therapy)|Patients receive oral dasatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62203745|NCT05293977|ACTIVE_COMPARATOR|Control|Patients in the control group received routine care by the dispensing pharmacist and seen by research assistant for data collection only
62203746|NCT05293977|EXPERIMENTAL|Intervention|Patient in the intervention group was verbally provided with pharmaceutical education/counseling about his/her prescribed antibiotic.
62580041|NCT05894941|ACTIVE_COMPARATOR|Corrective Exercises Group|The researcher will teach a total of 6 evidence-based corrective exercises and stretches. The participants will perform this for the prescribed time for a minimum of 3 and 5 times a week for a total of 6 weeks of the trial.
62580042|NCT05894941|ACTIVE_COMPARATOR|Postural Education Group|Postural guidelines for doing daily activity especially sitting for prolonged periods and using electronic devices like computers and other electronic devices.
62580043|NCT05894941|NO_INTERVENTION|Control Group|This group will not receive either of the above mentioned treatments.
62580044|NCT05047705|EXPERIMENTAL|Distress Tolerance Skills Training|Distress tolerance skills training is a multicomponent intervention drawn from third-wave cognitive-behavioral therapy (CBT) protocols.
62580045|NCT03300856||Chart Review|Existing records of patients within the NINDS database who have had TMS performed to measure central motor conduction time (CMCT).
62580046|NCT04551274|EXPERIMENTAL|Music Therapy|Participants in the music therapy group will complete a 4 week music therapy program, with a minimum of 2 sessions per week.
62580047|NCT04551274|NO_INTERVENTION|Control|Control group participants will not experience any intervention
62580048|NCT01820624|EXPERIMENTAL|Treatment (tretinoin, lithium carbonate)|Patients receive tretinoin PO every 12 hours on days 1-7 and 15-21 and lithium carbonate PO TID on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62580049|NCT06577571|EXPERIMENTAL|CKM-EMPOWER|Training videos
62580050|NCT06577571|NO_INTERVENTION|Usual education|No training videos
62580051|NCT06319612|EXPERIMENTAL|Stellate ganglion block+routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy.The experimental group was given Stellate Ganglion Block.
62580052|NCT06319612|PLACEBO_COMPARATOR|placebo+routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy.
62580053|NCT03551002||Retrospective|
62580054|NCT03551002||Prospective|
62580055|NCT04586816|PLACEBO_COMPARATOR|vehicle only-placebo|Vehicle cream base containing no maple leaf extract to be applied twice daily to the face
62580056|NCT04586816|EXPERIMENTAL|1% red maple leaf extract|lotion preparation with 1% red maple leaf extract to be applied twice daily to the face
62786887|NCT05587192|EXPERIMENTAL|18F-PSMA-1007 PET/CT based on USTC diagnostic model|Patinets will complete the 18F-PSMA-1007 PET/CT based USTC diagnostic model firstly. If clinically significant prostate cancer is considered by 18F-PSMA-1007 PET/CT. Patinets will receive radical prostatectomy directly or undergo prostate biopsy according to patients own decisions, patients with negative results in prostate biopsy will be asked to complete rebiopsy after 3 months.
62786888|NCT00349778|EXPERIMENTAL|High-Dose Sequential Therapy|Cyclophosphamide + Etoposide + Melphalan + Carmustine with Filgrastim
62786889|NCT05159115|ACTIVE_COMPARATOR|Low-FODMAP diet|Patients with IBS on a 4-week low-FODMAP diet.
62786890|NCT05159115|EXPERIMENTAL|Starch- and Sucrose Reduced Diet|Patients with IBS on a s 4-week Starch- and Sucrose Reduced Diet (SSRD).
62786891|NCT05451563|EXPERIMENTAL|Double-S arm|Participants will be asked to use the wearable penile device during intercourse.
62786892|NCT03749811|EXPERIMENTAL|Pupillometry group|A group of participants who receive remifentanil infusion under pupillometry monitoring.
62580057|NCT04586816|EXPERIMENTAL|5% red maple leaf extract|lotion preparation with 5% red maple leaf extract to be applied twice daily to the face
62580058|NCT06140056|ACTIVE_COMPARATOR|Control|Duration: 3 hours
62580059|NCT06140056|EXPERIMENTAL|Intervention|Duration: 3 hours
62580060|NCT01872117|EXPERIMENTAL|Applications of shortwave diathermy|
62580061|NCT01872117|EXPERIMENTAL|Applications of microwave diathermy|
62580062|NCT06447207|EXPERIMENTAL|Occupational Therapy Led Social Prescription|(1) A baseline occupational therapy assessment including a social prescription, (2) Six monthly occupational therapy follow-up sessions focused on behavior-change techniques to encourage participation in the social prescription, and include: review of the social prescription, self-monitoring strategies, facilitators review, barriers review, problem-solving, provision of feedback, action planning, and rating confidence with the action plan, and (3) Post Occupational Therapy Assessment
62580063|NCT04998123|SHAM_COMPARATOR|Sham Stimulation|
62580064|NCT04998123|EXPERIMENTAL|ISP Stimulation|
62580065|NCT04998123|NO_INTERVENTION|Perpheral Stimulation|
62203747|NCT02200653|EXPERIMENTAL|Low dose of MICARDIS®|
62203748|NCT02200653|EXPERIMENTAL|High dose of MICARDIS®|
62203749|NCT02200653|ACTIVE_COMPARATOR|Low dose of COZAAR® / LORZAAR®|
62786893|NCT03749811|NO_INTERVENTION|Conventional group|A group of participants who receive remifentanil infusion without pupillometry monitoring; their analgesic dose is mainly determined via hemodyamic change.
62786894|NCT01145339|EXPERIMENTAL|Lactase EUF|1 chewable tablet of the test drug 30 minutes before the standard lactose dose (25 g).
62014679|NCT02438241|ACTIVE_COMPARATOR|Conventional physiotherapy Group|Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.
61978449|NCT04358575|ACTIVE_COMPARATOR|Metal-backed modular components|Triathlon CS Knee System with metal-backed modular components
62014680|NCT02438241|PLACEBO_COMPARATOR|Placebo TENS Group|Will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
62014681|NCT02438241|EXPERIMENTAL|TENS group|Patients randomized to this group will receive conventional physical therapy for the control group, and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.
62014682|NCT04932174|EXPERIMENTAL|High-intensity Interval Training|Group 2: the included 15 subjects will participate in High intensity Interval training exercise running on treadmill for 12 weeks, 3 times / week.
62014683|NCT04932174|ACTIVE_COMPARATOR|Low-intensity Continuous Training|Group 1: the included 15 subjects will participate in low intensity continuous exercise on treadmill for 12 weeks, 3 times / week
62014684|NCT06573788|EXPERIMENTAL|Internet+wearble device prehabilitation model|"Pre-rehabilitation components include smoking cessation, aerobic training, anaerobic exercise, nutritional optimization and psychological support.~Internet+ group using online application + wearable device management model"
62014685|NCT06573788|ACTIVE_COMPARATOR|traditional prehabilitation model|The traditional prehabilitation group used the traditional management model of preoperative education + paper records + regular weekly reminders from healthcare professionals
62014686|NCT01816620|EXPERIMENTAL|Lenalidomide, dexamethasone|Lenalidomide 10mg qd d1-21 \& dexamethasone 40mg qw d1,8,15,22
62014687|NCT01260441|ACTIVE_COMPARATOR|Standard CPR|"Individuals will learn the Standard form of CPR (30:2, compressions:breathes) Main data points being collected over various increments are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect and 3) CPR Skills"
62203750|NCT02200653|ACTIVE_COMPARATOR|High dose of COZAAR® / LORZAAR®|
62786895|NCT01145339|ACTIVE_COMPARATOR|Lactase Ref|1 chewable tablet of the comparative drug 30 minutes before the standard lactose dose (25 g).
62786896|NCT02893696|ACTIVE_COMPARATOR|Immediately Supine Position|Women placed in supine position within 30 seconds after spinal injection of local anesthetic drug.
62786897|NCT02893696|ACTIVE_COMPARATOR|Delayed Supine Position|Women placed in supine position after three minutes of seating after spinal injection of local anesthetic drug.
62786898|NCT06572124|ACTIVE_COMPARATOR|Universal adhesive without acid resistant silane coupling agent|Universal adhesive with normal silane (comparator) After the acid etching and rinsing and drying step, the universal adhesive with normal silane will be actively applied for 20 second , then light cured for 20 seconds then the restoration will be placed
62203751|NCT04530097|EXPERIMENTAL|RFA+MLT|Radiofrequency ablation was performed immediately after enrollment, and melatonin treatment was given for 6 months after 1 week after radiofrequency.
62203752|NCT04530097|NO_INTERVENTION|RFA|Radiofrequency ablation was performed immediately after enrollment, and a placebo treatment program was given for 6 months after 1 week after radiofrequency.
62203753|NCT04032184|ACTIVE_COMPARATOR|Fluoride toothpaste|
62203754|NCT04032184|EXPERIMENTAL|fluoride toothpaste and chlorhexidine mouthwash|
62203755|NCT04032184|EXPERIMENTAL|fluoride toothpaste, chlorhexidine mouthwash, MI varnish|
62203756|NCT05195346||People Living with HIV (PLHIV)|Thai people living with HIV, aged 18 or above, who are on Antiretroviral Therapy (ART)
62203757|NCT05195346||HIV Healthcare Providers|Thai healthcare providers, including but not limited to doctors, nurses, counsellors, lay providers, pharmacists, lab technicians, etc., who take care of any persons living with HIV. All aged 18 or above
62203758|NCT06043258|EXPERIMENTAL|(Group I) study group|eight patients with missing anterior or premolar tooth with insufficient horizontal (bucco/labio palatal) bone width were treated with dental implants and Bond Apatite (AugmaBio, United States of America) as a bone graft material to fill the defect.
62203759|NCT06043258|ACTIVE_COMPARATOR|(Group II) positive control group|eight patients with missing anterior or premolar tooth with insufficient horizontal (bucco/labio palatal) bone width were treated with dental implants and Bio-Oss (Bio-Oss, GeistlichPharmaAG, Wolhusen, Switzerland) as a bone graft material to fill the defect and pericardium resorbable membrane.
62203760|NCT02075281|EXPERIMENTAL|HM11260C|HM11260C 4 mg weekly sc injection
62203761|NCT02075281|PLACEBO_COMPARATOR|Placebo|Placebo weekly sc injection
62203762|NCT02075281|EXPERIMENTAL|HM11260C 6 mg/week|HM11260C 6 mg weekly sc injection
62203763|NCT02075281|EXPERIMENTAL|HM11260C 6 mg/biweekly|HM11260C 6 mg biweekly sc injection
62203764|NCT02075281|EXPERIMENTAL|HM11260C 8 mg/biweekly|HM11260C 8 mg biweekly sc injection
62786899|NCT06572124|EXPERIMENTAL|Universal adhesive with acid resistant silane coupling agent|Universal adhesive with acid resistant silane coupling agent (Intervention) After the acid etching and rinsing and drying step, the universal adhesive with acid resistant silane coupling agent will be actively applied for 20 second , then light cured for 20 seconds then the restoration will be placed
62786900|NCT03520907|EXPERIMENTAL|Transversalis Fascia Plane Block|receive transversalis fascia plane block with 0.4 ml/kg of 0.25% levobupivacaine after establishment of general anesthesia.
62786901|NCT03520907|ACTIVE_COMPARATOR|Ilioinguinal/iliohypogastric Nerve Block|receive ilioinguinal/iliohypogastric nerve block with 0.1 ml/kg of 0.25% levobupivacaine after establishment of general anesthesia.
62786902|NCT01924494||Endoscopy procedures|Patients undergoing elective flexible gastrointestinal endoscopy procedures
62014688|NCT01260441|ACTIVE_COMPARATOR|Chest Compressions Only CPR|"Individuals will learn the chest compression only form of CPR (no rescue breathes) Main data points being collected at various increments are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect and 3) CPR Skills"
62014689|NCT04690608|EXPERIMENTAL|resistant diabetic macular edema and central retinal vein occlusion|"* Prospective non randomized interventional study on 60 eyes of 40 patients with previously diagnosed macular edema secondary to type 1 or 2 diabetes mellitus will be included.~* The study will be conducted from January 2021 to June 2021.~* For transition to suprachoroidal injection of TAAC a diagnosis of resistant DME is required.~Cases with recent onset central retinal vein occlusion less than 2 months duration will be included"
62014690|NCT05513638||The First Affiliated Hospital of Nanjing Medical University|
62014691|NCT05513638||The First Affiliated Hospital of Soochow University|
62014692|NCT05306067||Children at low transmission health facilities|
62014693|NCT05306067||Children at medium-to-high transmission health facilities|
62014694|NCT05306067||Pregnant women at low transmission ANC|
62014695|NCT05306067||Pregnant women at medium-to-high transmission transmission ANC|
62014696|NCT04863950|EXPERIMENTAL|Imipramine Hydrochloride/Lomustine|
62014697|NCT06198439|EXPERIMENTAL|Transcranial magnetic stimulation|All study subjects undergo five sessions of rTMS. The 40-minute sessions target the supplemental motor area (inhibitory stimulation) and prefrontal cortex (excitatory stimulation)
62014698|NCT05393310|EXPERIMENTAL|post-isometric relaxation|effects of post-isometric relaxation on pain, disability and dynamic balance in athletes with chronic ankle sprain
62014699|NCT05393310|EXPERIMENTAL|mulligan mobilization with movement|effects of mulligan mobilization with movement on pain, disability and dynamic balance in athletes with chronic ankle sprain
62014700|NCT06110546|EXPERIMENTAL|Methadone group|
62014701|NCT06110546|ACTIVE_COMPARATOR|Non-Methadone group|
62014702|NCT04986059|EXPERIMENTAL|Pre-event massage|
62014703|NCT04986059|NO_INTERVENTION|Control|
62014704|NCT04341922|EXPERIMENTAL|Intervention: Online Cognitive-Behavioral intervention|The three-week intervention is a structured self-guided program without therapist support, administered via a secure web platform and organized in five brief modules. The treatment is provided through an encrypted online platform (login through BankID and double authentication) provided by the eHealth Core facility at Karolinska Institutet
62014705|NCT04341922|NO_INTERVENTION|Wait-list|The wait-list controlled composes of no intervention for three weeks. Participants randomized to the wait-list group will be crossed over to receive the Online Cognitive-Behavioral intervention after three weeks (post-treatment).
62014706|NCT06393361|EXPERIMENTAL|Chidamide+Decitabine+ Anti-PD-1 Antibody|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance. Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function. Immune checkpoint inhibitors have emerged as effective therapies for many cancers by promoting the reactivation and restoring function of T cells.
62014707|NCT06393361|ACTIVE_COMPARATOR|Standard of care|Brentuximab Vedotin+ anti-PD-1 antibody
62014708|NCT05122845|EXPERIMENTAL|Healthy volunteers comparators to dialysis subjects|Creation of a biological collection for biological analysis
62014709|NCT03400397||Intervention|Treatment with the Cool Kids programme. The Cool Kids programme is a manualised cognitive behavioural treatment programme for children with anxiety disorders.
62014710|NCT02928692|PLACEBO_COMPARATOR|Placebo|Placebo administered before surgery
62014711|NCT02928692|EXPERIMENTAL|Minocycline|Minocycline was administrated before surgery
62014712|NCT02928692|NO_INTERVENTION|Volunteers|Health people for calculate the incidence of POCD
62014713|NCT03639155|EXPERIMENTAL|Regimen A|vadadustat reference tablets
62014714|NCT03639155|EXPERIMENTAL|Regimen B|vadadustat test tablets
62786903|NCT03511157|EXPERIMENTAL|Ischemic Preconditioning|A standard blood pressure cuff will be placed on the right or left thigh, depending on the affected side, to occlude blood flow. The cuff will be inflated to 225 mmHg to prevent blood flow. Each session will consist of 4 cycles of 5 minute IPC applications, followed by 5 minutes of reperfusion for a total of 35 minutes.
62786904|NCT03511157|SHAM_COMPARATOR|Control|The sham intervention protocol will be identical to the IPC protocol except blood flow to the affected leg is unchanged as cuff pressure will be raised to between the venous and diastolic pressures
62786905|NCT03559647||Cohort 1|Participants who have demonstrated a lack of Clinical Benefit from Atezolizumab
62014715|NCT02760186|EXPERIMENTAL|Altitude Exposure|Acute high altitude exposure followed by 7 day acclimatization and reexposure after 7 days at low altitude
62014716|NCT05059392|EXPERIMENTAL|Training for Awareness, Resilience and Action (TARA)|12 weekly sessions, each 90 minutes, up to 14 participants/group. Manual-based: Session 1: Introducing group members; establishing guidelines; investigating attitudes and previous experiences, introducing contemplative practices. All sessions: participants sit on yoga mats. Facilitators open and briefly check-in. Participants are guided through a breathing practice, yoga-based movement (a flow of positions synchronized with the breath) and then a meditation focusing primarily on interoceptive and sensory awareness. After a short break, a psychoeducational presentation is held followed by group exercises and discussions. The sessions conclude with feedback and questions regarding the practice, followed by a description of the home practice for the coming week. Finally, participants gather their attention and have the opportunity to express their reflections and current state.
62014717|NCT03486041|EXPERIMENTAL|immediate ComB|12 weekly sessions of ComB treatment in individual therapy, following a detailed manual.
62014718|NCT03486041|PLACEBO_COMPARATOR|Minimal Attention Control|Weekly brief phone call from therapist to check on participant safety, medication changes if any, and recent stressors. After week 12, participants in this arm received delayed ComB \[as in the Experimental condition -- 12 weekly sessions of individual therapy for TTM based on ComB model\].
62786906|NCT03559647||Cohort 2|Participants who demonstrated durability of Clinical Benefit and Tumor Response to Atezolizumab
62786907|NCT05441852||Ambulatory Emergency Department Patients at risk for hyperkalemia|Patients who are at elevated risk for hyperkalemia identified during a visit to the emergency department. Elevated risk individuals are defined in this study as: \>50 years of age, eGFR \<45, or prior K \>5.2
62786908|NCT02192177||Group 1|Pregnant subjects diagnosed with obstetric cholestasis who didn't have any foreknown systemic disease.
62786909|NCT02192177||Group 2|entirely healthy pregnant subjects, the control group.
61978450|NCT01230801|EXPERIMENTAL|BMN 701|IV infusion
61978451|NCT01403714|NO_INTERVENTION|Medical Management|Patients may be randomized to medical management alone
61978452|NCT01403714|ACTIVE_COMPARATOR|Renal Artery Stenting|Those patients with recent heart failure exacerbations that cannot be attributed to poor left ventricular function and have a hemodynamically significant renal artery stenosis may be randomized to renal artery stenting
62014719|NCT00206674|EXPERIMENTAL|Arm 1|
62014720|NCT00206674|PLACEBO_COMPARATOR|Arm 2|
62014721|NCT01023126|NO_INTERVENTION|EO|Exercise three times a week, one under supervision and two freely chosen by the participant
62786910|NCT00293995|OTHER|Laparoscopic repair|Laparoscopic repair, with closure of contralateral patent processus vaginalis
62786911|NCT00293995|OTHER|Open repair|Open repair
62786912|NCT06026878|EXPERIMENTAL|gemcitabine, nimotuzumab and toripalimab induction treatment|"Gemcitabine at a dose of 1 g per square meter of body-surface area on days 1 and 8 every 3 weeks for two cycles.~nimotuzumanb 400mg every 3 weeks for two cycles. toripalimab 240mg every 3 weeks for two cycles."
62786913|NCT06026878|ACTIVE_COMPARATOR|gemcitabine and cisplatin|Gemcitabine at a dose of 1 g per square meter of body-surface area on days 1 and 8 and cisplatin at a dose of 80 mg per square meter on day 1 were administered intravenously once every 3 weeks for two cycles.
61978453|NCT01725438|EXPERIMENTAL|Pregnant women accepting an invasive prenatal diagnosis|Pregnant women accepting an invasive prenatal diagnosis and a sample blood (non invasive diagnosis)
62014722|NCT01023126|EXPERIMENTAL|EGT|Exercise three times a week, one under supervision and two freely chosen by the participant
62014723|NCT05958992|EXPERIMENTAL|E-Liquid 1|Participants will self-administer an assigned e-liquid.
62014724|NCT05958992|EXPERIMENTAL|E-Liquid 2|Participants will self-administer an assigned e-liquid.
62014725|NCT05958992|EXPERIMENTAL|E-liquid 3|Participants will self-administer an assigned e-liquid.
62580066|NCT03747120|ACTIVE_COMPARATOR|Arm A: THP|"Arm A: Paclitaxel weekly x12 + Trastuzumab + Pertuzumab~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
62580067|NCT03747120|EXPERIMENTAL|Arm B: THP-K|"Arm B: Paclitaxel weekly x12 + Trastuzumab + Pertuzumab + Pembrolizumab~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
62580068|NCT03747120|EXPERIMENTAL|Arm C: TH-K|"Arm C: Paclitaxel weekly x12 + Trastuzumab + Pembrolizumab~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
62786914|NCT02413489|EXPERIMENTAL|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram \[mg/kg\]) as intravenous infusion once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
62786915|NCT06583278|ACTIVE_COMPARATOR|Real rTMS group|Participants will receive real transcranial magnetic stimulation (TMS) daily for 1 week.
62580069|NCT02528110|SHAM_COMPARATOR|Radical gastrectomy without HIPEC|Patients will be treated with a D2 radical gastrectomy for locally advanced gastric cancer and postoperative chemotherapy (SOX or XELOX)
62580070|NCT02528110|EXPERIMENTAL|Radical gastrectomy with HIPEC|Patients will be treated with a D2 radical gastrectomy for locally advanced gastric cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (SOX or XELOX)
62580071|NCT05001633|EXPERIMENTAL|Intervention|modified media content experience
62786916|NCT06583278|SHAM_COMPARATOR|Sham rTMS group|Participants will receive sham transcranial magnetic stimulation (TMS) daily for 1 week.
62786917|NCT02663622|EXPERIMENTAL|Efprezimod alfa 240 mg|Efprezimod alfa in 240 mg as intravenous (IV) infusion at Day -1 + Tacrolimus (begin on day -3. IV \[0.03 mg/kg/day\] or PO \[0.045 mg/kg/dose\] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
62786918|NCT02663622|EXPERIMENTAL|Efprezimod alfa 480 mg|Efprezimod alfa in 480 mg as intravenous (IV) infusion at Day -1 + Tacrolimus (begin on day -3. IV \[0.03 mg/kg/day\] or PO \[0.045 mg/kg/dose\] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
61978454|NCT04366076||nonlaboring term singleton pregnancies|A total of 51 nonlaboring term singleton pregnancies were enrolled.
61978455|NCT05314855||Obese individuals with normal insulin sensitivity|
62014726|NCT05958992|EXPERIMENTAL|E-liquid 4|Participants will self-administer an assigned e-liquid.
62014727|NCT05958992|NO_INTERVENTION|No e-liquid|Participants will not receive an e-liquid to self-administer.
62786919|NCT02663622|EXPERIMENTAL|Efprezimod alfa 960 mg|Efprezimod alfa (480 mg (day -1), 240 mg (day +14) and 240 mg (day +28)) + Tacrolimus (begin on day -3. IV \[0.03 mg/kg/day\] or PO \[0.045 mg/kg/dose\] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
61978456|NCT05314855||Obese individuals with impaired insulin sensitivity|
61978457|NCT05314855||Obese patients with type 2 diabetes|
62014728|NCT05053282||master endurance athletes|men aged 65 to 75 with more than 150 minutes of running activity per week at least 15 years history of running
62014729|NCT05053282||elderly sedentary|men aged 65 to 75 with no history of regular physical activity training and no more practice than 150 minutes of moderate or 75 minutes of vigorous intensity per week according the ACSM recommendations
62014730|NCT05053282||young endurance athletes|men aged 20 to 30 with more than 150 minutes of running activity per week at least 3 years history of running
62014731|NCT05053282||young sedentary|men aged 20 to 30 with no history of regular physical activity training and no more practice than 150 minutes of moderate or 75 minutes of vigorous intensity per week according the ACSM recommendations
62014732|NCT00844194|OTHER|DPNP with depression (1)|Patients that have diabetic polyneuropathy and depression and are responder to 60 mg duloxetine QD (\>30% pain reduction after week 6)
62580072|NCT05001633|ACTIVE_COMPARATOR|Control|media content experience
62014733|NCT00844194|OTHER|DPNP with depression (2)|Patients that have diabetic polyneuropathy and depression and are non-responder to 60 mg duloxetine QD (\<30% pain reduction after week 6)
62014734|NCT00844194|OTHER|DPNP without depression (1)|Patients that have diabetic polyneuropathy and no depression and are responder to 60 mg duloxetine QD (\>30% pain reduction after week 6)
62014735|NCT00844194|OTHER|DPNP without depression (2)|Patients that have diabetic polyneuropathy and no depression and are non-responder to 60 mg duloxetine QD (\<30% pain reduction after week 6)
62014736|NCT02799082|PLACEBO_COMPARATOR|Vehicle|Topical application of matched placebo gel (without containing active ingredient). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1.0 cm surrounding margin.
62580073|NCT02693145|NO_INTERVENTION|standard of care (SOC) arm|Individuals found to be out of HIV medical care will receive standard of care to re-engage. This will not include use of disease intervention specialist to locate and recruit back to HIV medical care or use of the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention.
62580074|NCT02693145|EXPERIMENTAL|Intervention arm|Individuals randomized to the intervention arm will receive field services to locate, contact, and provide assistance to access HIV medical care. Intervention may include use of disease intervention specialist to locate and recruit back to HIV medical care or use of the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention.
62580075|NCT06413901|EXPERIMENTAL|Vicryl group|TIP hypospadias repair
62580076|NCT06413901|EXPERIMENTAL|PDS group|TIP hypospadias repair
62580077|NCT02175940||Myopic Choroidal Neovascularization patients|
62580078|NCT02175940||Control patients undergoing cataract surgery|
62580079|NCT02502812|EXPERIMENTAL|Treatment Sequence A (Innovator) - B (Clop F1) - C (Clop F2)|Subjects will receive a single 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 1, 75 mg tablet Clop F1 (Treatment B) in treatment period 2, and 75 mg tablet Clop F2 (Treatment C) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
62580080|NCT02502812|EXPERIMENTAL|Treatment Sequence A(Innovator) -C(Clop F2)-B (Clop F1)|Subjects will receive a single 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 1, 75 mg tablet Clop F2 (Treatment C) in treatment period 2, and 75 mg tablet Clop F1 (Treatment B) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
62580081|NCT02502812|EXPERIMENTAL|Treatment Sequence B (Clop F1) - A (Innovator) - C (Clop F2)|Subjects will receive a single 75 mg tablet Clop F1 (Treatment B) in treatment period 1, 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 2, and 75 mg tablet Clop F2 (Treatment C) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
62580082|NCT02502812|EXPERIMENTAL|Treatment Sequence B (Clop F1) - C (Clop F2) - A (Innovator)|Subjects will receive a single 75 mg tablet Clop F1 (Treatment B) in treatment period 1, 75 mg tablet Clop F2 (Treatment C) in treatment period 2, and 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
62786920|NCT02663622|PLACEBO_COMPARATOR|Placebo|Placebo to efprezimod alfa (saline IV injection solution) on day -1 or days -1, 14, and 28 + Tacrolimus (begin on day -3. IV \[0.03 mg/kg/day\] or PO \[0.045 mg/kg/dose\] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
62786921|NCT01385241|EXPERIMENTAL|Received video intervention|The group of women who received an Ipod Touch with the video loaded onto it and told to view it at least once a week for the first 4 weeks, and as often as desired in weeks 5-12.
62014737|NCT02799082|ACTIVE_COMPARATOR|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1.0 cm surrounding margin.
62403699|NCT06428734||hydrocephalus|high throughput sequencing and electromyography Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics and imaging, such as DTIALPS
62403700|NCT06428734||Normal group|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
62580083|NCT02502812|EXPERIMENTAL|Treatment Sequence C (Clop F2) - A (Innovator) - B (Clop F1)|Subjects will receive a single 75 mg tablet Clop F2 (Treatment C) in treatment period 1, 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 2, and 75 mg tablet Clop F1 (Treatment B) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
62786922|NCT01385241|NO_INTERVENTION|Did not receive video|This group does not receive the video intervention during the study period, and will complete surveys at baseline, 30 days and 90 days for comparison to the intervention group.
62786923|NCT06040164||Ob/Pre/H|obesity, prediabetes and healthy mouth
62786924|NCT06040164||Ob/Pre/OCD|obesity, prediabetes and oral cavity disease
62786925|NCT06040164||Ob/Diab/H|obesity, diabetes and healthy mouth
62203765|NCT03780361|EXPERIMENTAL|Aflibercept injection group|"drug: Eylea (aflibercept) (11.12mg/0.278ml) dose: 2mg (0.05ml) usage: With topical anesthesia and intravitreal injection of aflibercpt in aseptic condition.~frequency and duration: monthly intravitreal aflibercept injections."
62203766|NCT04449419||very severe COPD|Patients diagnosed with COPD and FEV1 less than 30
62203767|NCT04449419||Severe COPD|Patients diagnosed with COPD and FEV1 less than 50
62786926|NCT06040164||Ob/Diab/OCD|obesity, diabetes and oral cavity disease
62786927|NCT06361017||favorable outcome group|The favorable outcome group was defined as the modified Rankin Scale (mRS) score ≤2 in the AIS patients at 3 months after endovascular thrombectomy.
62014738|NCT04725175|EXPERIMENTAL|PIPE-307|
62014739|NCT04725175|PLACEBO_COMPARATOR|Placebo|
62014740|NCT01072487|EXPERIMENTAL|Capnography|Arm with capnographic monitoring
62014741|NCT01072487|NO_INTERVENTION|Standard|Standard monitoring.
62014742|NCT05247944||F-BEVAR|Patients with complex abdominal aortic aneurysm who underwent fenestrated and branched endovascular aortic repair (F-BEVAR) at the Aortic Center of Lille (ACL; Lille, France).
62014743|NCT05247944||OPEN SURGERY REPAIR|Patients with complex abdominal aortic aneurysm who underwent open surgery repair the Unit of Vascular Surgery of Policlinic Gemelli (FPUG; Rome, Italy).
62203768|NCT04449419||Moderate COPD|Patients diagnosed with COPD and FEV1 less than 80
62203769|NCT04449419||Mild COPD|Patients diagnosed with COPD and FEV1 80 or more.
62203770|NCT04449419||CONTROL|Non-copd control group
62203771|NCT04449419||Exacerbated Patients|Patients 48 hours after hospital admission for COPD exacerbation.
62203772|NCT02881346||Enstilar®|Patients with psoriasis vulgaris plaques on body and/or extremities will apply Enstilar® (calcipotriol /betamethasone dipropionate (50 micrograms/g + 0.5 mg/g) cutaneous foam) once daily for up to 4 weeks, according to the approved labelling of Enstilar® in Germany.
62403701|NCT03868956|EXPERIMENTAL|Diagnostic strategy|Colour doppler ultrasound (CDUS) with or without D-dimer test to rule-in or rule-out deep vein thrombosis recurrence
62403702|NCT05375942||characteristics of patients newly initiated on Inflectra|
62403703|NCT05375942||outcomes after initiating Inflectra|
62403704|NCT03832426|EXPERIMENTAL|Narlaprevir single - Healthy|2 tablets of 100 mg Narlaprevir once a day
62403705|NCT03832426|EXPERIMENTAL|Narlaprevir single - Hepatic Impairment|2 tablets of 100 mg Narlaprevir once a day
62403706|NCT03832426|EXPERIMENTAL|Narlaprevir+Ritonavir - Healthy|Narlaprevir 100 mg (1 tablet of 100 mg) and Ritonavir 100 mg (1 tablet of 100 mg) once a day
62403707|NCT03832426|EXPERIMENTAL|Narlaprevir+Ritonavir - Hepatic Impairment|Narlaprevir 100 mg (1 tablet of 100 mg) and Ritonavir 100 mg (1 tablet of 100 mg) once a day
62786928|NCT06361017||unfavorable outcome group|The unfavorable outcome group was defined as the modified Rankin Scale (mRS) score with 3-6 in the AIS patients at 3 months after endovascular thrombectomy.
62403708|NCT05797142|EXPERIMENTAL|: Virtual reality glasses|"Beginning 1-2 minute before the start of the procedure, the patients will be watched (30 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30 minutes)."
62580084|NCT02502812|EXPERIMENTAL|Treatment Sequence C (Clop F2) - B (Clop F1) - A (Innovator)|Subjects will receive a single 75 mg tablet Clop F2 (Treatment C) in treatment period 1, 75 mg tablet Clop F1 (Treatment B) in treatment period 2, and 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
62580085|NCT01309360|ACTIVE_COMPARATOR|group A : 40ml Prilocaine 1%|40 outpatients : 40ml Prilocaine 1% were administered for axillary plexus block
62580086|NCT01309360|ACTIVE_COMPARATOR|group B : 30ml Prilocaine 1%|40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
62203773|NCT03300505|EXPERIMENTAL|ARRx + Enzalutamide|"Phase 1b: All registered subjects will be treated with ARRx (ASO) in combination with enzalutamide. ARRx will be given intravenously on Days 1, 4, 8, 11, 15 on cycle 1, then on days 1, 8, 15 in subsequent 21-day cycles. Enzalutamide will be taken daily in 21 day cycles starting Day 1 of cycle 1. Treatment will continue until clinical or radiologic progression or unacceptable toxicity.~Phase 2: Subjects will be treated with ARRx (ASO) at the maximum tolerated (MTD), in combination with enzalutamide until clinical or radiologic progression or unacceptable toxicity. (Schedule of administration as in phase 1b.)"
62203774|NCT01978951|EXPERIMENTAL|Integrated Chronic Kidney Disease care|standard guidelines of CKD treatment + Integrated CKD care consisting of multidisciplinary team care and home visit by community care network
62203775|NCT01978951|ACTIVE_COMPARATOR|Conventional CKD care|standard guidelines of CKD treatment
62786929|NCT06361017||HT group|HT group was defined as the AIS patients have hemorrhage transformation in 7 days after endovascular thrombectomy.
62786930|NCT06361017||non-HT group|Non-HT group was defined as the AIS patients do not have hemorrhage transformation in 7 days after endovascular thrombectomy.
62580087|NCT01309360|ACTIVE_COMPARATOR|group C : 20ml Prilocaine 1%|40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block
62786931|NCT00407303|EXPERIMENTAL|1|30mg obatoclax, 1.0mg/m2 bortezomib
62786932|NCT00407303|EXPERIMENTAL|2|obatoclax 30 mg, bortezomib 1.3 mg/m2
62580088|NCT04874077||Case|
62786933|NCT00407303|EXPERIMENTAL|3|Obatoclax 45 mg, Bortezomib 1.3 mg/m2
62203776|NCT03117998|EXPERIMENTAL|35 mg REMD-477|Administered as a repeated subcutaneous (SC) doses in subjects with Type 1 Diabetes
62580089|NCT04874077||Control|
62580090|NCT00858455|EXPERIMENTAL|Healthy Volunteers|4 period cross over
62580091|NCT02145260|ACTIVE_COMPARATOR|Lower dialysate sodium|Dialysate sodium concentration of 138 mmol/L
62580092|NCT02145260|EXPERIMENTAL|Higher dialysate sodium|Dialysate sodium concentration of 142 mmol/L
62786934|NCT03203083||physically active individuals|subjects who perform sports activities more than 6 hours per week
62786935|NCT03203083||non-physically active individuals|subjects who perform less than 2 hours per week of sport activities
62786936|NCT01773187|EXPERIMENTAL|Pacritinib|Pacritinib 400 mg QD
62203777|NCT03117998|EXPERIMENTAL|70 mg REMD-477|Administered as a repeated SC doses in subjects with Type 1 Diabetes
62203778|NCT03117998|PLACEBO_COMPARATOR|Matching placebo|Administered as a repeated SC doses in subjects with Type 1 Diabetes
62786937|NCT01773187|ACTIVE_COMPARATOR|Best Available Therapy|BAT includes any physician-selected treatment for primary or secondary myelofibrosis with the exclusion of JAK inhibitors (inhibitors of Janus kinases)
62786938|NCT00342992||Healthy Volunteers|Male smokers in Southwestern Finland
62786939|NCT01357551|EXPERIMENTAL|Maintenance intervention|Participants receive a theoretically-informed maintenance intervention for 42 weeks, followed by 14 weeks of no intervention contact to examine sustainability. The maintenance intervention involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
62786940|NCT01357551|NO_INTERVENTION|Usual care|Participants receive usual care for 56 weeks
62786941|NCT04489082|EXPERIMENTAL|Near Infrared Laser Therapy|"On the days of each near-infrared therapy session, patients will undergo 10 minutes of transcranial infrared laser stimulation.~The laser dose for all conditions will be a 3.4 W continuous laser wave, at a 1064 wavelength, with irradiance (power density) at 250 milli-Watts/cm2. All groups will have treatment once a week (10 minutes per session) for 5-6 weeks. For Alzheimer's, the site targeted will be the right prefrontal cortex. Parkinson's patients will have laser delivered to the brain stem, bilateral temporal lobes. TBI/CTE patients will have the laser stimulation site dependent on location of injury. Patients with depression/anxiety will have laser stimulation applied to the prefrontal area of the head."
62203779|NCT01828905|EXPERIMENTAL|Cerament|"CERAMENT™\|BONE VOID FILLER as bone graft substitute"
62403709|NCT05797142|NO_INTERVENTION|Control group|Routine maintenance will be applied
62403710|NCT02430545|EXPERIMENTAL|Glasdegib, Rifampin|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
62403711|NCT00703222|EXPERIMENTAL|Dose Level 1|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP
62403712|NCT00703222|EXPERIMENTAL|Dose Level 2|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP
62580093|NCT02430246|EXPERIMENTAL|Primary prevention - Urex Plus|Patients with Normal vaginal flora in the experimental arm will be treated with UREX PLUS
62580094|NCT02430246|PLACEBO_COMPARATOR|Primary prevention - Placebo|Patients with Normal vaginal flora in the Placebo arm will be treated with a capsule without active ingredient
62580095|NCT02430246|EXPERIMENTAL|Secondary prevention - Urex Plus|Patients with abnormal vaginal flora in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given UREX PLUS
62580096|NCT02430246|PLACEBO_COMPARATOR|Secondary prevention - Placebo|Patients with abnormal vaginal flora in the Placebo arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given placebo without active ingredient
62580097|NCT02430246|EXPERIMENTAL|Eradication - Urex Plus|Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the experimental arm will be treated with UREX PLUS
62403713|NCT05307926||PD-1 based therapy cohort|Patients who received PD-1 inhibitors or PD-1 inhibitors plus Lenvatinib therapy 2-4 weeks after the operation were included in the PD-1-based therapy cohort.
62580098|NCT02430246|PLACEBO_COMPARATOR|Eradication - Placebo|Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the placebo arm will be treated with placebo without active ingredient
62580099|NCT02430246|OTHER|Lactobacilli transfer - probiotic capsule|Patients with Normal vaginal flora will be treated with a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months afterwhich they will receive no treatment for additional two months. Lactobacili colonization in the vaginal flora will be tested
62580100|NCT02430246|OTHER|Lactobacilli transfer - probiotic capsule after 2 months|Patients with Normal vaginal flora will be followed for two months without intervention afterwhich they will receive a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months. Lactobacili colonization in the vaginal flora will be tested.
62580101|NCT05138588|EXPERIMENTAL|VERUM|"In the verum experimental condition, participants will receive the experimental rTMS stimulation sessions, meaning the rTMS sessions targeting the insular cortex, taking into account the insular hypoperfusion (through MRI images) of each patient."
62203780|NCT01828905|ACTIVE_COMPARATOR|Bone graft|Autologous cancellous bone graft (iliac crest)
62403714|NCT05307926||TACE cohort|Patients who received 1 TACE about a month after the operation were included in the control cohort.
62403715|NCT01852786||Contraceptives, Oral, Combined|The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy.
62786942|NCT03475589|OTHER|single group|
62786943|NCT05235542|EXPERIMENTAL|Phase Ib#Dosage regimen 1#|Subjects receive AK104 plus AK117 every 3- week cycle (Q3W) until progression
62786944|NCT05235542|EXPERIMENTAL|Phase Ib#Dosage regimen 2#|Subjects receive AK104 plus AK117 every 6- week cycle (Q6W) until progression
62786945|NCT05235542|EXPERIMENTAL|Phase II#Cohort 1#|Gastric Cancer or Gastroesophageal Junction Cancer: AK104 + XELOX (Oxaliplatin + Capecitabine)+AK117 every 3- week cycle (Q3W) until progression
62786946|NCT05235542|EXPERIMENTAL|Phase II#Cohort 2#|Esophageal squamous cell cancer: AK104 + 5-FU/Paclitaxel+Cisplatin± AK117 every 3- week cycle (Q3W) until progression
62786947|NCT05235542|EXPERIMENTAL|Phase II#Cohort 3#|Gastric Cancer or Gastroesophageal Junction Cancer or Esophageal squamous cell cancer: AK117 +Paclitaxel/Docetaxel/Irinotecan every 3- or 4- week cycle (Q3W or Q4W) until progression
62786948|NCT01957813|OTHER|Standard Health Services|Service currently being provided to FSW in Naivasha include peer education and health services delivered through a drop-in center (DIC) staff by a counselor and a nurse. For peer education, there are six modules that the peer educators walk all peers through with sessions being held once a week.
62786949|NCT01957813|EXPERIMENTAL|LifeStyle Counseling|A package of enhancements to the current package of services delivered to FSW will be implemented and evaluated.
62203781|NCT04115657|EXPERIMENTAL|Starch 1|Tapioca starch
62203782|NCT04115657|EXPERIMENTAL|Starch 2|High amylose
62203783|NCT04115657|EXPERIMENTAL|Starch 3|Kithul flour
62403716|NCT01852786||Controls|The women, presenting for non- hormonal contraception- barrier contraception methods -BCM- or natural family planning methods- NFPM.
62403717|NCT04778397|EXPERIMENTAL|Magrolimab + Azacitidine|Participants will receive an escalating dose of magrolimab and a fixed dose of azacitidine.
62403718|NCT04778397|ACTIVE_COMPARATOR|Control Arm: Venetoclax + Azacitidine|Participants who are appropriate for non-intensive therapy will receive an escalating dose of venetoclax and a fixed dose of azacitidine.
62580102|NCT05138588|SHAM_COMPARATOR|CONTROL|"In the control experimental condition, participants will receive the control rTMS stimulation sessions, meaning the rTMS sessions will target the occipital cortex."
62203784|NCT04115657|EXPERIMENTAL|Starch 4|Sago flour
62203785|NCT04115657|EXPERIMENTAL|Sugar 1|Pure palatinose
62203786|NCT04115657|EXPERIMENTAL|Sugar 2|Blend of sucrose and palatinose
62203787|NCT00565487|EXPERIMENTAL|Single arm|This is a single arm dose escalation study with a cohort expansion.
62203788|NCT04684667|OTHER|Propranolol Therapy|This arm will involve patients with infantile hemangiomas who will be admitted at the Assiut University Children Hospital between January 2021 and December 2021.
62203789|NCT05629312|EXPERIMENTAL|Maxillary expansion|"All included patients (in all arms) present (at least one) maxillary canine impaction.~Patients in this arm present also lack of space in the upper jaw and are treated with maxillary expansion"
62403719|NCT04778397|ACTIVE_COMPARATOR|Control Arm: 7+3 Chemotherapy|Participants who are appropriate for intensive therapy will receive 7+3 chemotherapy: 7 day treatment with cytarabine and 3 day treatment with daunorubicin or idarubicin during induction and high-dose cytarabine and steroidal eye drops during consolidation.
62786950|NCT00958165|EXPERIMENTAL|EAS-AC|PVI with EAS-AC
62786951|NCT02945813|EXPERIMENTAL|Arm A: Metformin|"* Metformin - 850mg PO BID; 48 weeks~* Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks"
62786952|NCT02945813|ACTIVE_COMPARATOR|Arm B: Salvage Radiotherapy|- Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks
62786953|NCT06584318|EXPERIMENTAL|patients|Participants will receive 14 times intermittent hypoxia (oxygen concentration: 13%) intervention before the surgery.
62786954|NCT04343755|EXPERIMENTAL|Convalescent Plasma|Fresh or frozen plasma will be infused one time to patients
62786955|NCT02716623|EXPERIMENTAL|CR Diet and Exercise|Participants will be asked to follow specific diet intervention and exercise regimen.
62786956|NCT04441255|EXPERIMENTAL|TAK-788 160 mg Fasted + TAK-788 160 mg Fed|TAK-788 160 milligram (mg), capsule, orally, once on Day 1 of Period 1 under fasted conditions (Treatment A), followed by 10 days washout period, followed by TAK-788 160 mg, capsule, orally, once on Day 1 of Period 2 under fed conditions (Treatment B).
62203790|NCT05629312|EXPERIMENTAL|Extraction of deciduous canines|"All included patients (in all arms) present (at least one) maxillary canine impaction.~Patients in this arm present also lack of space in the upper jaw and are treated with extraction of deciduous canines"
62403720|NCT02095834|EXPERIMENTAL|Treatment (dexamethasone, bendamustine, carfilzomib)|Patients receive dexamethasone PO or IV over 20 minutes on days 1, 2, 8, 9, 15, 16, 22, and 23 of courses 1-3; on days 1, 2, 15, and 16 of courses 4-12; and on days 1 and 2 of all subsequent courses. Patients also receive bendamustine hydrochloride IV over 10 minutes on days 1 and 2 of courses 1-3 and on day 1 of all subsequent courses and carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 of courses 1-12 and on days 1, 2, 15, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62403721|NCT01744275|PLACEBO_COMPARATOR|Placebo|Placebo
62403722|NCT01744275|EXPERIMENTAL|Omega 3 fatty acids supplementation|Omega 3 fatty acids capsules
62403723|NCT02396849|EXPERIMENTAL|Continuous Positive Airway Pressure (CPAP)|Use of a CPAP machine for at least 5 days per week for 28 days
62786957|NCT04441255|EXPERIMENTAL|TAK-788 160 mg Fed + TAK-788 160 mg Fasted|TAK-788 160 mg, capsule, orally, once on Day 1 of Period 1 under fed conditions (Treatment B), followed by 10 days washout period, followed by TAK-788 160 mg, capsule, orally, once on Day 1 of Period 2 under fasted conditions (Treatment A).
62786958|NCT01379196|EXPERIMENTAL|Azithromycin PO three times weekly|Tablets Azithromycin 500 mg PO three times weekly for three months
61978458|NCT04422223||Cohort|Patients newly diagnosed with liver cirrhosis form the Gastro Unit, Amager Hvidovre Hospital, Denmark. All patients with clinically verified diagnosis, irrepsective of disease stage and etiology is included.
61978459|NCT02894931|SHAM_COMPARATOR|Control|Dietary Interventions: Control- water, Flavered Chilled water, will be administered once after O.N fasting.
61978460|NCT02894931|ACTIVE_COMPARATOR|Glucose|Dietary Interventions: Glucose, Monosaccharides, at the dose of 50 g, based on oral loading tests, once.
62203791|NCT05629312|NO_INTERVENTION|No intervention|"All included patients (in all arms) present (at least one) maxillary canine impaction.~Patients in this arm present also lack of space in the upper jaw and no intervention is performed"
62203792|NCT05629312|NO_INTERVENTION|Control|"All included patients (in all arms) present (at least one) maxillary canine impaction.~Patients in this arm do not present lack of space in the upper jaw and no intervention is performed"
62203793|NCT03072524||Stroke patients|Stroke patients who will undergo the FAST PLUS test within 12 hours from the stroke onset.
62203794|NCT05709301|EXPERIMENTAL|Donepezil|
62203795|NCT05709301|PLACEBO_COMPARATOR|Placebo|
62203796|NCT01457898|EXPERIMENTAL|VPAP II®|VPAP II® Group
62203797|NCT01258257|ACTIVE_COMPARATOR|Lumbar drain (LD) / Tuohy drain|Intervention: Insertion of a lumbar drain All patients in the LD group receives a lumbar drain during anesthesia required for aneurysm treatment. Drainage of CSF is started after the post-procedural CT scan on day one after aneurysm securement.
61978461|NCT02894931|EXPERIMENTAL|Fructose|Dietary Interventions: Fructose, Monosaccharides, at the dose of 50 g, once.
61978462|NCT02894931|EXPERIMENTAL|Galactose|Dietary Interventions: Monosaccharides, at the dose of 50 g, once.
61978463|NCT02894931|EXPERIMENTAL|Mannose|Dietary Interventions: Monosaccharides, at the dose of 50 g, once.
61978464|NCT02894931|EXPERIMENTAL|Maltose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
61978465|NCT02894931|EXPERIMENTAL|Sucrose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
61978466|NCT02894931|EXPERIMENTAL|Lactose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
61978467|NCT02894931|EXPERIMENTAL|Saccharin|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
61978468|NCT02894931|EXPERIMENTAL|Aspartame|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
61978469|NCT02894931|EXPERIMENTAL|Sucralose|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
61978470|NCT02894931|EXPERIMENTAL|Steviol|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
61978471|NCT02894931|EXPERIMENTAL|Leucine|Dietary Interventions: The dose of the different BCAAs Amino acids- 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
61978472|NCT02894931|EXPERIMENTAL|Isoleucine|Dietary Interventions: The dose of the different BCAAs Amino acids - 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
61978473|NCT02894931|EXPERIMENTAL|Valine|Dietary Interventions: The dose of the different BCAAs Amino acids- 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
61978474|NCT01472081|EXPERIMENTAL|Arm S: Nivolumab + Sunitinib|"Nivolumab 0.3, 2.0 (starting dose), 5.0 mg/kg solution intravenously every 21 days until Progressive disease (PD), toxicity or discontinue for other reasons~Sunitinib 50 mg capsule by mouth on Days 1-28 of 42 day cycle until Progressive disease (PD), toxicity or discontinue for other reasons"
61978475|NCT01472081|EXPERIMENTAL|Arm P: Nivolumab + Pazopanib|"Nivolumab 0.3, 2.0 (starting dose), 5.0 mg/kg solution intravenously every 21 days until Progressive disease (PD), toxicity or discontinue for other reasons~Pazopanib 800 mg tablet by mouth daily until Progressive disease (PD), toxicity or discontinue for other reasons"
62403724|NCT02396849|SHAM_COMPARATOR|Continuous Positive Airway Pressure (CPAP) Sham|Use of a sham CPAP machine for at least 5 days per week for 28 days
62014744|NCT05310825|EXPERIMENTAL|Dry Wiping Bath with Single-Use Wipes|Cleaning wipes will be used in the bathing process which do not contain alcohol, paraben or latex. Before taking them out of the packet, the wipes to be used in the bathing will be heated according to usage instructions at 850 W for 50 seconds in a microwave oven which will be brought by the researcher. After heating, the temperature of the cleaning towels will be measured with an infrared thermometer. The reason for heating the wipes is to bring them to the same temperature as the bath water and thus to prevent any factors arising from a temperature difference.
62014745|NCT05310825|OTHER|Traditional Body Wiping Bath|Before bathing, two basins will be filled with a suitable amount (2/3 of the basin) of water at a suitable temperature (43°C). Water temperature will be measured by the researcher with a water thermometer. This thermometer will be used to bring the bath water to the correct temperature. Neutral soap will be added to the water of one basin, while the water of the other basin will be used for rinsing. The neutral soap to be used will not dry the skin or cause chafing or irritation, and it will be noon-allergenic. At the same time, soap with these characteristics is one which is routinely used for patient hygiene in the intensive care unit where the study will be conducted. The rubbing cloth to be used with both the soapy and the rinsing water in the routine procedure will have an inner layer of pure cotton with an outer layer of hydrophilic gauze. The patient's body wash will be performed with this cloth, using foam from the soapy water.
62014746|NCT01785745|ACTIVE_COMPARATOR|Traditional therapeutic exercise|The traditional exercise protocol contains mainly strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance.
62014747|NCT01785745|EXPERIMENTAL|Neurocognitive therapeutic exercise|The neurocognitive exercise protocol contains ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture).
62014748|NCT03959501|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10mg daily PO for 24 weeks
62014749|NCT03959501|ACTIVE_COMPARATOR|Sitagliptin|Sitagliptin 100mg daily PO for 24 weeks
62203798|NCT01258257|NO_INTERVENTION|No Lumbar drain (NoLD)|Patients randomized to the control group should not receive a lumbar drain before the planned control angiography to be performed on day 7 to 10 after SAH. If the patient develops hydrocephalus, and no EVD was placed initially for CSF drainage, a lumbar drain may be installed at the discretion of the local investigator. These patients are analyzed in the intention-to-treat analysis, but are not suitable for per-protocol analysis.
62203799|NCT05319912|EXPERIMENTAL|Sequence 1: ABC|"Participants received each treatment on 1 occasion:~Period 1 (Treatment A): ALXN1840 tablets following an overnight fast. Period 2 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1.~There was a washout period of at least 14 days between each ALXN1840 dosing."
62203800|NCT05319912|EXPERIMENTAL|Sequence 2: ACB|"Participants received each treatment on 1 occasion:~Period 1 (Treatment A): ALXN1840 tablets following an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 3 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
62203801|NCT05319912|EXPERIMENTAL|Sequence 3: BAC|"Participants received each treatment on 1 occasion:~Period 1 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 2 (Treatment A): ALXN1840 tablets following an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1.~There was a washout period of at least 14 days between each ALXN1840 dosing."
62203802|NCT05319912|EXPERIMENTAL|Sequence 4: BCA|"Participants received each treatment on 1 occasion:~Period 1 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 3 (Treatment A): ALXN1840 tablets following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
62203803|NCT05319912|EXPERIMENTAL|Sequence 5: CAB|"Participants received each treatment on 1 occasion:~Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 2 (Treatment A): ALXN1840 tablets following an overnight fast. Period 3 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
62403725|NCT05288335|EXPERIMENTAL|Circular cylindrical mirror modulated frame glasses (compact)|Subjects that were randomized to receive the Circular cylindrical mirror modulated frame glasses (compact) throughout the entire course of the study.
62403726|NCT05288335|EXPERIMENTAL|Circular cylindrical mirror modulated frame glasses (strong defocus)|Subjects that were randomized to receive the Circular cylindrical mirror modulated frame glasses (strong defocus) throughout the entire course of the study.
62403727|NCT05288335|EXPERIMENTAL|single vision frame glasses|Subjects that were randomized to receive the single vision frame glasses throughout the entire course of the study.
62403728|NCT04661865|OTHER|Control group|Routine care only They will receive routine antenatal care that included iron supplementation with follow up of hemoglobin level
62403729|NCT04661865|EXPERIMENTAL|Intervention group|They will receive the Heath Information Package Program (HIP program)
62403730|NCT02413723|ACTIVE_COMPARATOR|Videolaryngoscope McGrath Mac|McGrath Mac videolaryngoscope will be used for laryngoscopy for patient's intubation
62403731|NCT02413723|PLACEBO_COMPARATOR|Standard laryngoscope|Macintosh laryngoscope will be used for laryngoscopy for patient's intubation
62403732|NCT00821600|EXPERIMENTAL|001|risperidone IR and LAI formulation 1 mg risperidone IR single injection followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
62014750|NCT01263873|ACTIVE_COMPARATOR|Mallinckrodt (ETT)|Artifical Airway Device
62014751|NCT01263873|EXPERIMENTAL|Parker Flex Tip (ETT)|Artifical Airway Device
62014752|NCT06572722|EXPERIMENTAL|Atezolizumab|
62203804|NCT05319912|EXPERIMENTAL|Sequence 6: CBA|"Participants received each treatment on 1 occasion:~Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 2 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 3 (Treatment A): ALXN1840 tablets following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
62203805|NCT05611827|EXPERIMENTAL|Quercetin LipoMicel (250 mg)|Each participant receives their treatment of Quercetin LipoMicel at a total dose of 250 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin and at 25, 47, 48, 71 and 72hrs after a repeated oral total dose of 250 mg LipoMicel (once daily for 72hrs). A washout period of at least 7 days between each treatment will be used.
62203806|NCT05611827|EXPERIMENTAL|Quercetin LipoMicel (500 mg)|Each participant receives their treatment of Quercetin LipoMicel at a total dose of 500 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin and at 25, 47, 48, 71 and 72hrs after a repeated oral total dose of 500 mg LipoMicel (once daily for 72hrs). A washout period of at least 7 days between each treatment will be used.
62203807|NCT05611827|EXPERIMENTAL|Quercetin LipoMicel (1000 mg)|Each participant receives their treatment of Quercetin LipoMicel at a total dose of 1000 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin and at 25, 47, 48, 71 and 72hrs after a repeated oral total dose of 1000 mg LipoMicel (once daily for 72hrs). A washout period of at least 7 days between each treatment will be used.
62203808|NCT05611827|EXPERIMENTAL|Regular/standard Quercetin (500 mg)|Each participant receives their treatment of standard/raw Quercetin at a total dose of 500 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). A standardized lunch and dinner are served after 4h and 8h of product administration. Capillary whole blood samples are collected (after a 10hr overnight fast) at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin. A washout period of at least 7 days between each treatment will be used.
62203809|NCT03479775||Youth female athletes with poor muscle function|Youth female athletes (floorball, football and handball) with assessed poor muscle function at baseline.
62203810|NCT03479775||Youth female athletes with good muscle function|Youth female athletes (floorball, football and handball) with assessed good muscle function at baseline.
62203811|NCT00643292|EXPERIMENTAL|1|
62203812|NCT00643292|EXPERIMENTAL|2|
62203813|NCT02538952|EXPERIMENTAL|Xpert package|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the experimental phase therefore include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; (c) training health facility personnel in TB diagnostic algorithms; and (d) Xpert device activation. The combination of the ICF interventions and rollout of the Xpert device is referred to as the Xpert package in this protocol."
62203814|NCT02538952|ACTIVE_COMPARATOR|Active comparator|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the active comparator phase therefore include only: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only standard of care microscopy-based TB diagnostic algorithms are available during this phase."
62403733|NCT03922048|EXPERIMENTAL|Cohort 1 Part A: HTX-011|Adolescents ≥12 to \<17 years of age. A single dose of HTX-011 via instillation into the surgical site.
62403734|NCT03922048|ACTIVE_COMPARATOR|Cohort 1 Part A: bupivacaine HCl|Adolescents ≥12 to \<17 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site.
62403735|NCT03922048|EXPERIMENTAL|Cohort 1 Part B: HTX-011|Adolescents ≥12 to \<17 years of age. Dose to be determined from Cohort 1 Part A.
62403736|NCT03922048|ACTIVE_COMPARATOR|Cohort 1 Part B: bupivacaine HCl|Adolescents ≥12 to \<17 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
62786959|NCT01154426|EXPERIMENTAL|Treatment (gemcitabine hydrochloride and ABT-888)|Patients receive oral ABT-888 twice daily on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 21\* days in the absence of disease progression or unacceptable toxicity.
62786960|NCT06426836|OTHER|Amoxicillin-clavulanate|Patients receiving amoxicillin-clavulanate as part of routine clinical care. Study procedure: blood sampling
62786961|NCT06426836|OTHER|Piperacillin-tazobactam|Patients receiving piperacillin-tazobactam as part of routine clinical care. Study procedure: blood sampling
62786962|NCT06426836|OTHER|Meropenem|Patients receiving meropenem as part of routine clinical care. Study procedure: blood sampling
62014753|NCT06572722|EXPERIMENTAL|Nivolumab|
62014754|NCT06572722|EXPERIMENTAL|Pembrolizumab|
62014755|NCT01826149|EXPERIMENTAL|Propofol 1.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 1.0mcg/ml using target controlled infusion.
62014756|NCT01826149|EXPERIMENTAL|Propofol 2.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 2.0mcg/ml using target controlled infusion.
62203815|NCT02538952|NO_INTERVENTION|Standard of Care|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. There are no interventions in the standard of care arm (retrospective cohort). There are no ICF interventions and no Xpert device activations in this phase. Only the standard of care TB case finding procedures and microscopy-based TB diagnostic algorithm are available during this phase."
62203816|NCT05842499|EXPERIMENTAL|Line set strategy|Pulmonary vein isolation, roof line, posterior wall isolation (posterior box), anterior septal line and cavo-tricuspid isthmus.
62203817|NCT05842499|ACTIVE_COMPARATOR|Conventional strategy|Mapping and ablation of the present flutter and those that could be induced later until sinus rhythm is obtained.
62403737|NCT03922048|EXPERIMENTAL|Cohort 2 Part A: HTX-011|Children ≥6 to \<12 years of age. Dose to be determined from Cohort 1.
62403738|NCT03922048|ACTIVE_COMPARATOR|Cohort 2 Part A: bupivacaine HCl|Children ≥6 to \<12 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
62014757|NCT01826149|EXPERIMENTAL|Propofol 3.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 3.0mcg/ml using target controlled infusion.
62403739|NCT03922048|EXPERIMENTAL|Cohort 2 Part B: HTX-011|Children ≥6 to \<12 years of age. Dose to be determined from Cohort 1.
62403740|NCT03922048|ACTIVE_COMPARATOR|Cohort 2 Part B: bupivacaine HCl|Children ≥6 to \<12 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
62403741|NCT03922048|EXPERIMENTAL|Cohort 3: HTX-011|Children ≥3 to \<6 years of age. Dose to be determined from Cohorts 1 and 2.
62403742|NCT03922048|ACTIVE_COMPARATOR|Cohort 3: bupivacaine HCl|Children ≥3 to \<6 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
62403743|NCT03312504|EXPERIMENTAL|Neuromuscular Training Warm-up|Schools randomized to the intervention arm receive a workshop outlining a neuromuscular training program to be used as a warm-up for 15 minutes at the beginning of each physical education class. The warm-up consist of high-intensity aerobic, strengthening, agility, plyometric, and balance components. The workshop is designed to last two hours, and includes a video outlining the warm-up components, practice time, and group discussions for action planning to address potential barriers to the program.
62403744|NCT03312504|PLACEBO_COMPARATOR|Control Standard-of-practice Warm-up|Schools randomized to the control arm receive a workshop outlining a standard-of-practice program to be used as a warm-up for 15 minutes at the beginning of each physical education class. The warm-up consists of aerobic exercises and static stretching. The workshop is designed to last one hour, and includes an explanation and demonstration of the exercises, but no video or practice time.
62403745|NCT01796769|EXPERIMENTAL|Conventional|
62014758|NCT03702465|ACTIVE_COMPARATOR|Control Arm|Pre-diabetic participants will receive general health guidelines according to the NICE guidelines, as per standard care. These will be delivered via an initial consultation with a dietitian. Participants in the control group will receive 2 follow up phone calls from the dietitian to answer any questions they may have during the study.
62403746|NCT01796769|ACTIVE_COMPARATOR|Telemedicine|
62403747|NCT01615965|EXPERIMENTAL|micrometastases|Molecular biologic detection of micrometastases in lymph nodes of patients with localized prostate cancer treated with radical prostatectomy and lymphadenectomy.
62014759|NCT03702465|ACTIVE_COMPARATOR|Intervention Arm|DNA-based dietary intervention: participants will receive DNA-based health guidelines via a genetic report. These will be delivered via an initial consultation with a dietitian. Participants in the control group will receive 2 follow up phone calls from the dietitian to answer any questions they may have during the study.
62403748|NCT02151552|EXPERIMENTAL|Endotoxin and [18F](+/-)NOS|All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation. They will also be imaged before and after endotoxin instillation with the novel PET tracer \[18F\](+/-)NOS.
62403749|NCT05957159|EXPERIMENTAL|Alcohol Use Disorder population completing Detoxification|Subjects will be asked to complete both 90 minute \[11C\]CFN and 90 minute \[11C\]PKAB PET Imaging after 1-3 days of a detoxification program.
62580103|NCT05967299|PLACEBO_COMPARATOR|Placebo|Placebo for ZMA001 is supplied in a single-use 10 mL glass vial. Each vial contains 30 mg/mL of sucrose.Placebo drug is manufactured using the same ingredients as active drug (20 mM histidine-HCl buffer \[pH 5.6\], 30 mg/mL sucrose, 0.070 w/v% polysorbate 80) excluding ZMA001 antibody and is packed in the same vial.
62786963|NCT06426836|OTHER|Cefazolin|Patients receiving cefazolin as part of routine clinical care. Study procedure: blood sampling
62786964|NCT06426836|OTHER|Vancomycin|Patients receiving vancomycin as part of routine clinical care. Study procedure: blood sampling
62786965|NCT06426836|OTHER|Teicoplanin|Patients receiving teicoplanin as part of routine clinical care. Study procedure: blood sampling
62786966|NCT06426836|OTHER|Ciprofloxacin|Patients receiving ciprofloxacin as part of routine clinical care. Study procedure: blood sampling
62786967|NCT06426836|OTHER|Amikacin|Patients receiving amikacin as part of routine clinical care. Study procedure: blood sampling
62786968|NCT05865717||Teachers|A professional whose teaching at an academic institution from the past 3 years. e.g College or university
62786969|NCT05865717||Bankers|A professional who has a desk job of at least 8-10 hours per day working in the corporate sector.
62203818|NCT02526966|OTHER|patient with primitive form of IgA nephropathy|
62203819|NCT00781105|EXPERIMENTAL|1|
62203820|NCT01956604|EXPERIMENTAL|Clonidine|"Clonidine administered orally:~Day 1/loading doses: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days."
62403750|NCT05957159|EXPERIMENTAL|Healthy Control population|Subjects will be asked to complete both a 90 minute \[11C\]CFN and a 90 minute \[11C\]PKAB PET Imaging.
62203821|NCT01956604|PLACEBO_COMPARATOR|Placebo (sugar pill)|"Placebo administered orally (identical capsula as for expirimental drug):~Day 1/loading doases: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days."
62203822|NCT05820399|EXPERIMENTAL|Organic Guayusa Extract + High Intensity Exercise|Participants will consume an organic guayusa extract supplement that contains caffeine and antioxidants each day for 6 weeks while completing the exercise training program on 3 days/week. On days that participants exercise, they will consume the supplement 30-60 minutes before exercise training. On days they do not exercise, they will consume the capsules upon waking.
62403751|NCT01564680|EXPERIMENTAL|Lornoxicam|Lornoxicam 16 mg will be given at skin closure and 8 mg will be given 12 hours postoperatively
62403752|NCT01564680|PLACEBO_COMPARATOR|Control|Patients will receive normal saline at skin closure, at 6, 12, 18 hours postoperatively.
62203823|NCT05820399|PLACEBO_COMPARATOR|Placebo + High Intensity Exercise|Participants will consume a placebo consisting of maltodextrin each day for 6 weeks while completing the exercise training program. The placebo will be provided in capsule identical in appearance to the active supplement. On days that participants exercise, they will consume the placebo 30-60 minutes before exercise training. On days they do not exercise, they will consume the capsules upon waking.
62203824|NCT02398669|EXPERIMENTAL|lorcaserin 10 mg|Cohort 1 - obese pediatric participants between age group of 6 and 8 years (inclusive) Cohort 2 - obese pediatric participants between age group of 9 and 11 years (inclusive)
62203825|NCT05937867|EXPERIMENTAL|HS-10353 Capsules|
62203826|NCT05937867|EXPERIMENTAL|Placebo for HS-10353 Capsules|
62403753|NCT01564680|EXPERIMENTAL|Paracetamol|1 gm of paracetamol will be given at skin closure, 6, 12, 18 hours postoperatively
62786970|NCT05865717||IT experts|A person who uses computers for work or communication, having a desk job of at least 8-10 hours per day
62203827|NCT05753436|ACTIVE_COMPARATOR|Group 1, Curcumin group|Group 1, Curcumin group (n=36): Patients will receive conventional treatment co-administrated with Turmeric Curcumin 500 mg thrice daily for 14 weeks.
62203828|NCT05753436|NO_INTERVENTION|Group 2, Control group|Group 2, Control group (n= 36): Patients will receive conventional therapy alone for 14 weeks.
62403754|NCT00665028||1|Postoperative myocardial ischemia
62786971|NCT05865717||Doctors|Physicians having a desk job in their outpatient clinic for at least 8-10 hours per day
62203829|NCT06409234||Exposed group|5500 exposed group will be patients in whom Transthoracic Echocardiography was performed within 3 months before surgery. Controls will be patients in whom Transthoracic Echocardiography was NOT performed.
62403755|NCT03696420||DBS surgery targeting the VIM|Patient who underwent a DBS surgery targeting the VIM at Bordeaux University Hospital
62403756|NCT04334356|EXPERIMENTAL|App Intervention|All participants will receive the web app for prevention of posttraumatic stress.
62403757|NCT01825421|NO_INTERVENTION|Control (continue antibiotics) group|The antibiotics will be continued for at least another 24h i.e. for 48h, pending blood culture results at 48h, as per standard practice in the NICU.
62403758|NCT01825421|ACTIVE_COMPARATOR|Study (discontinue antibiotics) group|The intervention is to discontinue antibiotics at 24h, and he/she will be kept under observation in the NICU for at least an additional 24h, pending blood culture results at 48h.
62786972|NCT05865717||Administrative job personal|Personals working in the human resource department or administration department whose job involves desk work 10 hours per day.
62403759|NCT04361669||Intervention|Patients that receive pharmacist-delivered services in the pilot program
62403760|NCT04361669||Control|Patients that do not receive pharmacist-delivered services in the pilot program
62403761|NCT01711424||OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
62403762|NCT04261153|OTHER|cognitive stimulation|3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
62403763|NCT00461591|EXPERIMENTAL|Apaziquone|TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
62403764|NCT00461591|PLACEBO_COMPARATOR|Placebo|TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT
62014760|NCT03702465|EXPERIMENTAL|Exploratory Arm|DNA-based dietary intervention using an app: participants will receive DNA-based health guidelines via the DnaNudge App.
62014761|NCT01626365|ACTIVE_COMPARATOR|non-thermosoftening|Double-lumen tube is put into a bottle of normal saline at room temperature (25°C) before intubation.
62203830|NCT00713986|SHAM_COMPARATOR|Noanalgesia|Patients in this group wil receive 2 mL of water PO 2 minutes prior to vaccination, then they will rest in crib during cleansing of the right tigh, during injection of the right tigh for hepatitis B vaccination and 2 minutes after the injection. Infants will not receive any handling during the whole procedure outside the prespecified above.
62403765|NCT03082079|EXPERIMENTAL|ESD group|Patient in this group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate.
62403766|NCT03082079|NO_INTERVENTION|Follow-up group|Patient in this group are given no intervention,the investigators record the tumor size and EUS features of the first endoscopic examination.Regular follow-up are carried out for these patients on 3 month,6 month,1 year,2 year,3 year,4 year,5 year after this check.Then,tumor size and EUS features of each time are collected accurately.
62403767|NCT02039882||Controls/Normals|control subjects without known cardiac disease, age ± 5 years and sex matched
62403768|NCT02039882||Acute Coronary Syndrome requiring Percutaneous Intervention|Subjects presenting to ER with Acute chest pain requiring cardiac catheterization
62403769|NCT02039882||Acute Coronary Syndrome, no intervention|Acute Coronary Syndrome, not requiring Percutaneous intervention
62403770|NCT03991520|EXPERIMENTAL|Active Treatment with Anakinra|10 subjects will be enrolled in this group. Initial treatment will consist of 100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection from within 24 hours of the onset of menses until within 24 hours of last menstrual day.
62014762|NCT01626365|EXPERIMENTAL|thermosoftening|Double-lumen tube is put into a bottle of warm normal saline (40°C) before intubation.
62014763|NCT01933334|EXPERIMENTAL|Pirfenidone: 4-Week Titration Group|Participants will receive one 267 milligrams (mg) oral pirfenidone capsule three times daily (TID) (801 mg per day \[mg/day\]) for 2 weeks followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 2 weeks (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 12 weeks maintenance period).
62014764|NCT01933334|EXPERIMENTAL|Pirfenidone: 2-Week Titration Group|Participants will receive one 267 mg oral pirfenidone capsule TID (801 mg/day) for 1 week followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 1 week (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 14 weeks (maintenance period).
62014765|NCT00752505|EXPERIMENTAL|A|
62203831|NCT00713986|EXPERIMENTAL|Skin-to-skin|Patients in this group wil receive 2mL of water 2 minutes prior vaccination and will be put on skin-to-skin contact with their mothers at the same time. After this time cleansing of the right tigh will be done followed by intra-muscular injection for hepatitis B vaccination. Patients will stay on skin-to-skin contact with their mothers for the following 2 minutes after injection. Infants will not receive any additional sensorial stimulation during the whole procedure outside the prespecified above.
62403771|NCT03991520|PLACEBO_COMPARATOR|Standard Comparison|10 subjects will be enrolled in this group. This group will be given placebo injections as their initial treatment. The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection. These individuals will self-administer the placebo each evening by subcutaneous injection from within 24 hours of the onset of menses until within 24 hours of last menstrual day.
62014766|NCT00752505|EXPERIMENTAL|B|
62403772|NCT04852185|EXPERIMENTAL|Vi-TT Arm|A single dose of Vi-TT to children 9 months to 15 years of age.
62403773|NCT04852185|ACTIVE_COMPARATOR|MCV-A arm|A single dose of MCV-A vaccine to the comparator group.
62403774|NCT01065246|EXPERIMENTAL|catumaxomab|
62403775|NCT03208621||Observational group|The diagnostic tests to be investigated in this study is the use of PET and DLS in addition to the initial staging with gastroscopy and CT of patients with an advanced tumor (cT3-4)
62403776|NCT02302118||Surgical approach|Group A: Esophagogastrectomy Group B: Extended gastrectomy
62580104|NCT05967299|EXPERIMENTAL|ZMA001 (BC-NKA-20008)|ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH).
62014767|NCT05932316|OTHER|Salbutamol first|Individuals included in this arm will receive 4 puffs of Salbutamol prior to the second set of spirometry testing, and 4 puffs of Placebo prior to the third set of spirometry.
62014768|NCT05932316|OTHER|Placebo First|Individuals included in this arm will receive 4 puffs of placebo prior to the second set of spirometry testing and 4 puffs of Salbutamol prior to the third set of spirometry testing.
62014769|NCT05087043|EXPERIMENTAL|Oral Stimulation and Supplemental Nursing System group|Oral motor Stimulation (OMS) and an Supplemental Nursing System (SNS) were applied to preterm infants in the experimental group.
62786973|NCT05533424|ACTIVE_COMPARATOR|Group quadratus lumborum|the patient will be positioned supine with lateral tilt , and the transducer was placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles were clearly identified. The external oblique muscle was followed posterolaterally until its posterior border was visualized . The probe was tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip was placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle was proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine was applied
62014770|NCT05087043|NO_INTERVENTION|control group|The clinic's routine feeding protocol was applied to the babies in the control group.
62014771|NCT01470027|ACTIVE_COMPARATOR|N-acetylcysteine 1800mg|N-acetylcysteine 1800mg/day for 30 days
62014772|NCT01470027|ACTIVE_COMPARATOR|N-acetylcysteine 3600mg|N-acetylcysteine 3600mg daily for 30 days
62014773|NCT01470027|PLACEBO_COMPARATOR|Placebo|Placebo effervescent tablets daily for 30 days
62014774|NCT04596852|EXPERIMENTAL|Healthy children|
62014775|NCT04596852|EXPERIMENTAL|Children with cerebral palsy|
62014776|NCT04067141|EXPERIMENTAL|somofilcon A, then nelfilcon A|Subjects will bilaterally wear the somofilcon A lenses, then crossover to nelfilcon A lenses after one week of wear. Both lenses will be worn on a daily wear basis for one week.
62014777|NCT04067141|EXPERIMENTAL|nelfilcon A, then somofilcon A|Subjects will bilaterally wear the nelfilcon A lenses, then crossover to somofilcon A lenses after one week of wear. Both lenses will be worn on a daily wear basis for one week.
62014778|NCT05068765|NO_INTERVENTION|control group|Once enrolled and consent is documented, eligible subject's will participate in the study for approximately six months.
62580105|NCT06333756|EXPERIMENTAL|Cross education training group|Cross education on elbow flexor
62014779|NCT05068765|EXPERIMENTAL|communication skills psychoeducation|Communication skills focused psychoeducation group will be given a communication skills-focused psychoeducation program for eight weeks, one session per week, for a total of eight sessions. The number of sessions was planned with reference to the study in which the effect of the psychoeducation program on general health and communication skills in caregivers of individuals with schizophrenia was investigated.Session groups will be formed from a single session of 60-90 minutes for each topic.
62014780|NCT05068765|EXPERIMENTAL|general psychoeducation|General psychoeducation group will be given a general psychoeducation program for four weeks, one session per week, in total. Session groups will be formed from a single session of 60-90 minutes for each topic.
62014781|NCT03106896||postherpetic neuralgia (PHN group)|"persist more than 3 months after the resolution of the acute shingles episode and have pain intensity greater than 4 on the visual analog scale (VAS 0, no pain; 10, worst pain imaginable)."
62014782|NCT03106896||acute herpetic pain (AHP group)|have pain (VAS≧4 ) duration of within 7 days after zoster onset at initial interview
62014783|NCT03106896||healthy control (CON group)|healthy population
62014784|NCT02174094|EXPERIMENTAL|Clobazam|Clobazam - 1.0, 1.5 or 2.0 mg/kg/day (maximum 60 or 80 mg/day) twice daily (BID); Clobazam oral suspension 2.5 mg/mL, clobazam scored tablets 10 mg, orally
62786974|NCT05533424|ACTIVE_COMPARATOR|Group transversus abdominis plane|the probe will located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall were identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique was used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine was injected. The same technique will be performed on the other side
62014785|NCT02174094|PLACEBO_COMPARATOR|Placebo|Placebo to clobazam oral suspension 2.5 mg/mL and placebo to clobazam scored tablets 10 mg, orally
62014786|NCT05078723|EXPERIMENTAL|CYP2C19*2 and CYP2C19*3 Variants|The group of participants has been genotyped to have the CYP2C19\*2 and/or CYP2C19\*3 variant during the first part of the study. The participants will consume 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract) and be asked to swish 5 times and swallow. All participants will then provide breath samples over the course of 2 hours. The breath sample outcomes will be compared to those of the wild-type CYP2C19 study subjects.
62014787|NCT05078723|EXPERIMENTAL|Wildtype CYP2C19|The group of participants has been genotyped to have wild-type CYP2C19. The participants will consume 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract) and be asked to swish 5 times and swallow. All participants will then provide breath samples over the course of 2 hours. The breath sample outcomes will be compared to those of the CYP2C19\*2 and/or CYP2C19\*3 study subjects.
62014788|NCT03229551|EXPERIMENTAL|Xylitol|This arm will evaluate the effect of topical xylitol therapy on biofilm production with the use of PCR bacterial sequencing before and after medical intervention.
62014789|NCT03229551|ACTIVE_COMPARATOR|Control|This arm is the standard of care saline irrigation solution.
62786975|NCT00868127|EXPERIMENTAL|Lapaquistat Acetate 100 mg QD|
62786976|NCT00868127|EXPERIMENTAL|Lapaquistat Acetate 100 mg QD + Added Therapy|
62786977|NCT03361982|NO_INTERVENTION|Fresh surgical testicular sperm|Fresh, surgically obtained testicular sperm
62786978|NCT03361982|EXPERIMENTAL|Frozen surgical testicular sperm|Surgically obtained testicular sperm that will undergo slow freezing and thawing
62786979|NCT03079596|ACTIVE_COMPARATOR|ERAS perioperative cares|Patients planned to undergoing laparoscopic total gastrectomy, following the ERAS protocols
62786980|NCT03079596|ACTIVE_COMPARATOR|Conventional perioperative cares|Patents will be managed by our hospital's critical pathways
62786981|NCT00544336||Supportive|
62786982|NCT04578067|EXPERIMENTAL|Intervention|culturally tailored intervention package on changes in lifestyle-habits
62786983|NCT04578067|NO_INTERVENTION|Control|
62786984|NCT06451081|EXPERIMENTAL|Opt-out+ group|Brief cessation advice + Opt-out active referral + behavioural economics mobile messaging
62786985|NCT06451081|EXPERIMENTAL|Opt-out group|Brief cessation advice + Opt-out active referral
62786986|NCT06451081|ACTIVE_COMPARATOR|Opt-in group|Brief cessation advice + Opt-in active referral
62786987|NCT05460143||Dementia with Lewy Bodies|These subjects should meet the criteria for dementia with Lewy Bodies (McKeith et al. (2005). Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology. 65:1863-72.).
62786988|NCT05460143||Alzheimer's Disease|These subjects should have a clinical diagnosis of AD in accordance with the National Institute of Neurological Disorders and Stroke-Alzheimer Disease and Related Disorders criteria (McKhann, G. M., et al. 2011. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7:263-9.).
62014790|NCT03923127|EXPERIMENTAL|Elan and HealthDot|Patients with elective surgery will wear two devices (HealthDot and Elan) after surgery in hospital and after discharge at home for up to 2 weeks (HealthDot) or 3 weeks (Elan).
62203832|NCT00713986|EXPERIMENTAL|Glucose|Patients in this group wil receive 2mL of glucose 25% 2 minutes prior vaccination, then they will rest in crib during cleansing of the right tigh, during injection of the right tigh for hepatitis B vaccination and 2 minutes after the injection. Infants will not receive any handling during the whole procedure outside the prespecified above.
62203833|NCT00713986|EXPERIMENTAL|Skin&Glucose|Patients in this group wil receive 2mL of glucose 25% PO 2 minutes prior vaccination and will be put on skin-to-skin contact with their mothers at the same time. After this time cleansing of the right tigh will be done followed by intra-muscular injection for hepatitis B vaccination. Patients will stay on skin-to-skin contact with their mothers for the following 2 minutes after injection. Infants will not receive any additional sensorial stimulation during the whole procedure outside the prespecified above.
62580106|NCT01263782|EXPERIMENTAL|Carboplatin + Pemetrexed|"The chemotherapy will be Carboplatin (AUC 6) and Pemetrexed (500 mg/m2) every 3 weeks for 4 cycles.~Then maintenance Pemetrexed (500 mg/m2 every 3 weeks) will be administered until disease progression or excessive toxicity.~If patients are randomized into one of the arms with a biologic therapy, patients will take the chemotherapy prescribed above, but will also receive the biologic therapy during the same time period."
62786989|NCT05460143||Mild Cognitive Impairment - LB|Mild Cognitive Impairment in a single or a multiple domain (Jak et al., 2009) with at least one LB symptom (MCI-LB; McKeith, I. G., et al. 2020. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 94(17): 743-55.).
62014791|NCT02278497|OTHER|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
62014792|NCT04972435|EXPERIMENTAL|Multifocal intraocular lens group|Cataract patients with PAC or PACG who underwent phacoemulsification with multifocal intraocular lens implantation.
62014793|NCT04972435|SHAM_COMPARATOR|Monofocal intraocular lens group|Cataract patients with PAC or PACG who underwent phacoemulsification with monofocal intraocular lens implantation which are the standard IOL.
62014794|NCT06103370|EXPERIMENTAL|Peer-educator-based network intervention|Indexes randomized to the intervention arm will complete a training program that emphasizes effective communication, frequent HIV testing, and awareness of evidence-based HIV prevention and treatment services. An important innovation to the network intervention will be training indexes to use and distribute HIV self-test kits and naloxone to their network members (NMs).
62014795|NCT06103370|NO_INTERVENTION|Equal-attention control|This group will receive training sessions that will be focused on the opioid overdose epidemic and will not include any training to serve as a peer educator.
62014796|NCT06663995|PLACEBO_COMPARATOR|SRP|The participants were randomly assigned to receive medicated with SRP combined with intrasulcular application of placebo gel. After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort. Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).
62014797|NCT06663995|ACTIVE_COMPARATOR|PROPOLIS group|"After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).~3-Base line visit (Local delivery application): Propolis gel will be applied by syringe with blunt tip gently and removed slowly in order not to harm the tissue for group 1 patients (Test group) after phase 1 therapy at the second day (48 hours) following non-surgical periodontal therapy"
62014798|NCT00634647|EXPERIMENTAL|Satraplatin|satraplatin - 80 mg/m\^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days
62014799|NCT05919238|EXPERIMENTAL|Part A|"will be a monotherapy light dose escalation with single dose of Padeliporfin at light laser doses of 200, 400 and 600 mW/cm for 10 minutes.~Part A will proceed with light dose escalation and will continue until the maximum tolerated light dose (MTD) and/or recommended phase 2 dose (RP2D) is defined."
62014800|NCT05919238|EXPERIMENTAL|Part B|will be a dose expansion part at MTD/RP2D dose level identified in Part A to further assess the safety, tolerability, and treatment effect of the MTD and/ or RP2D
62014801|NCT05789875|EXPERIMENTAL|Intervention|All YLWH who choose to enroll in the study will receive access to AiCure, the mobile health application. The participants will be asked to use the app for 3 months, during which the investigators will assess the feasibility and acceptability of AiCure.
62014802|NCT04760470|EXPERIMENTAL|Technology-assisted upper extremity rehabilitation|Technology-assisted upper extremity rehabilitation.
62203834|NCT06013553|ACTIVE_COMPARATOR|control group|Standard physiotherapy (1st Group): It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.
62786990|NCT05460143||Mild Cognitive Impairment - AD|Mild Cognitive Impairment in a single or a multiple domain (Jak et al., 2009) with AD symptoms (MCI-AD; Dubois, B., et al. 2009. Early detection of Alzheimer's disease: new diagnostic criteria. Dialogues Clin Neurosci. 11(2): 135-9.).
62786991|NCT05460143||Healthy controls|These subjects should have MMSE scores above 26, no regular memory complaints, no signs/symptoms of dementia and no unstable or significant medical illness.
62014803|NCT04760470|NO_INTERVENTION|Wait list control|Continue their normal lives.
62014804|NCT05897359|EXPERIMENTAL|bCBTMI|bCBTMI care for IA.
62014805|NCT05897359|PLACEBO_COMPARATOR|Control|Routine care for IA.
62014806|NCT01717417||group 1|Patient treated with Trans Palatal Arch as anchorage for canine traction
62014807|NCT01717417||Group 2|Patient treated with miniscrew as anchorage for canine traction
62014808|NCT03015077|ACTIVE_COMPARATOR|Glutamine|"intake of 5g glutamine and 10g maltodextrin. Oral glutamine is a food additive issued by food and drug government in Taiwan with number 009929.L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin.~The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy."
62203835|NCT06013553|EXPERIMENTAL|Experimental: Aerobic Exercises group|Aerobic exercise will be given with bicycle ergometer in addition to Standard physiotherapy (It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises)
62203836|NCT00158197|EXPERIMENTAL|continuous voucher schedule|Those in the continuous condition will receive a contingency management voucher each time they test negative for methamphetamine. The initial voucher value will be $2.50. Each consecutive instance of abstinence will increase the magnitude of the voucher by $1.50. Three consecutive abstinences will result in the delivery of a $10.00 bonus. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again. All participants will provide observed urine samples three times a week (e.g., M, W, \& F) for twelve weeks and will complete study-related measures one time per week.
62786992|NCT06259539|EXPERIMENTAL|Intervention|This group completed an 8-week virtual, YouTube-delivered nutrition education intervention. They were expected to watch the assigned videos per week at least once and practice the skills and strategies with their child with autism. This group completed all the baseline, mid-point, and end-point data using the questionnaires/surveys on Qualtrics.
62786993|NCT06259539|NO_INTERVENTION|Control|This group completed all surveys but received no intervention. They received access to all study materials at the end of the study.
62786994|NCT05244083|EXPERIMENTAL|Experimental Group|The experimental group will perform a 5-week motor program consisting of 4 bimanual exercises with mirror therapy, to be done at home 30 minutes a day, 5 days a week.
62014809|NCT03015077|PLACEBO_COMPARATOR|placebo|intake of 15g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
62014810|NCT05852444|EXPERIMENTAL|Group A|Manual Dynamic Agitation Group: Irrigation in this group shall be done using a master gutta percha cone during root canal therapy
62014811|NCT05852444|EXPERIMENTAL|Group B|Passive Ultrasonic Activation Group: In this group, final activation during endodontic therapy shall be done using an ultrasonic activation device (Ultra X)
62014812|NCT01569334|OTHER|HTC with Cardiac allograft vasculopathy|HTC:heart transplanted recipients
62014813|NCT01569334|OTHER|HTR without Cardiac allograft vasculopathy|
62014814|NCT01569334|OTHER|untransplanted|
62014815|NCT02984176|ACTIVE_COMPARATOR|Simethicone|Arm 1 or Group I or Simethicone 40mg. 3 tablets (one tablet after each meal) and to fast overnight the day before the operation.
62014816|NCT02984176|PLACEBO_COMPARATOR|placebo|Arm 2 or group 2 or placebo group. 3 tablets (one tablet after each meal) and to fast overnight the day before the operation.
62014817|NCT05352074|ACTIVE_COMPARATOR|total colectomy with ileorectal anastomosis|After a complete mobilization of the colon, a resection 2-3 cm proximal to the ileocecal junction is conducted. Use a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The ileorectal anastomosis is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
62014818|NCT05352074|EXPERIMENTAL|subtotal colectomy with cecal-rectal anastomosis|After a complete mobilization of the colon, a resection 2-3cm distal to the ileocecal junction and at the upper part of the rectal ampulla are conducted; the cecum is then lowered into the pelvis, without any rotation, and an antiperistaltic cecorectal anastomosis is performed between the cecal fundus (after appendectomy) and the rectum, after introduction of a stapler through the cecal resection line. Use a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The cecal-rectal anastomosis is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
62014819|NCT01546493|EXPERIMENTAL|Controls|Asymptomatic control subjects with no deformity. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis.
62786995|NCT05244083|ACTIVE_COMPARATOR|Control Group|The control group will perform a 5-week motor program consisting of 4 bimanual exercises without mirror therapy, to be done at home 30 minutes a day, 5 days a week.
62014820|NCT01546493|EXPERIMENTAL|Symptomatics|Subjects with bilateral cam deformity and unilateral symptoms. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis. Select patients will be asked to participate in a PET-MRI scan being conducted at The Royal Ottawa.
62014821|NCT01546493|EXPERIMENTAL|Asymptomatic|Asymptomatic subjects with cam deformity. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis. Select patients will be asked to participate in a PET-MRI scan being conducted at The Royal Ottawa.
62014822|NCT00194012|ACTIVE_COMPARATOR|Aripiprazole-Randomized Phase|Patients randomly assigned to aripiprazole received medication in pill form with dosing at 2mg, 5mg, 7mg, 10mg, 12mg or 15mg depending on their response.
62014823|NCT00194012|PLACEBO_COMPARATOR|Placebo-Randomized Phase|Patients randomly assigned to placebo received pills/dosing made to look identical to the aripiprazole.
62203837|NCT00158197|EXPERIMENTAL|intermittent predictable schedule|Those in the intermittent predictable condition will earn a contingency management voucher when they provide three consecutive methamphetamine-negative urine tests. Participants in the intermittent predictable condition will receive $22.00 for the provision of their first three consecutive methamphetamine-negative urine samples, $35.50 for the provision of their second set of three consecutive instances of methamphetamine-negative urine samples, and so forth. There are no bonuses for consecutive instances of abstinence in the intermittent predictable condition. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again. All participants will provide observed urine samples three times a week (e.g., M, W, \& F) for twelve weeks and will complete study-related measures one time per week.
62580107|NCT01263782|EXPERIMENTAL|Chemo (Carbo/Peme) + Bevacizumab|Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle. Bevacizumab 15 mg/kg by vein on day 1 of each 21 day cycle.
62580108|NCT01263782|EXPERIMENTAL|Chemo (Carbo/Peme)|Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle.
62786996|NCT00248586|EXPERIMENTAL|Standard CBT (S-CBT)|
62786997|NCT00248586|EXPERIMENTAL|Minimal contact CBT (MC-CBT)|
62014824|NCT04705077|EXPERIMENTAL|Single Dose Treatment|"Each subject will be assigned to the fixed period sequence.~* Period 1: SR419 suspension in the fasted state;~* Period 2: SR419 capsule in the fasted state;~* Period 3: SR419 capsule in the fed state (high-fat meal)."
62014825|NCT04705077|EXPERIMENTAL|Repeated Dose Treatment|Each subject will receive 30 mg of SR419 capsule, once every 8 hours (Q8h), for 5 days.
62014826|NCT02293005|EXPERIMENTAL|Alisertib|Alisertib administered by mouth at 50 mg twice a day for 7 days in each treatment cycle, followed by a 14-day, treatment-free period.
62786998|NCT00248586|NO_INTERVENTION|Control|
62786999|NCT03944408|EXPERIMENTAL|A metal bare stent with 125I seeds|125I seeds fixed on the metal bare stent, then stent implantation
62787000|NCT03944408|OTHER|A metal bare stent|A metal bare stent implantation
62787001|NCT03842449|EXPERIMENTAL|Smoking pregnant woman withCO measurement|
62787002|NCT03842449|OTHER|Smoking pregnant woman without CO measurement|
62787003|NCT03842449|OTHER|Non Smoking pregnant woman|
62403777|NCT05853081||FEV1 < 30%|open groups with forced expiratory flow in the first second (FEV1) \< 30%. It will be followed for at least two years.The fat-free mass index (FFMI) will be measured instead of the body mass index (BMI) with bioelectrical impedance analysis.
62403778|NCT05853081||FEV1 30-50%|open groups with forced expiratory flow in the first second (FEV1) \< 30%. It will be followed for at least two years.The fat-free mass index (FFMI) will be measured instead of the body mass index (BMI) with bioelectrical impedance analysis.
62403779|NCT05853081||FEV1 > 50%|open groups with forced expiratory flow in the first second (FEV1) \< 30%. It will be followed for at least two years.The fat-free mass index (FFMI) will be measured instead of the body mass index (BMI) with bioelectrical impedance analysis.
62403780|NCT05319509|EXPERIMENTAL|gameChange|
62403781|NCT01731821|EXPERIMENTAL|Nonstented stump-closed anastomosis|Nonstented stump-closed anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
62403782|NCT01731821|ACTIVE_COMPARATOR|Duct-to-mucosa anastomosis|Duct-to-mucosa technique is used for pancreaticojejunostomy after pancreaticoduodenectomy.
62403783|NCT03721614|EXPERIMENTAL|BioMime™ Morph - Sirolimus Eluting Coronary Stent System|
62403784|NCT03721614|ACTIVE_COMPARATOR|Xience family Everolimus Coronary Stent Systems|
62403785|NCT05289921|EXPERIMENTAL|HU-014 Inj|HU-014 Inj was given an injection to 5 Upper limb muscle(Total 360U/, IM)
62403786|NCT05289921|ACTIVE_COMPARATOR|Clostridium botulinum type A|Clostridium botulinum type A Inj was given an injection to 5 Upper limb muscle(Total 360U/, IM)
62014827|NCT02573987|ACTIVE_COMPARATOR|Oxygen/nitrous oxide equimolar mix|96 participants undergoing chorionic villi sampling. self administered inhalation of equimolar mixture of oxygen and nitrous oxide (MEOPA)
62014828|NCT02573987|ACTIVE_COMPARATOR|Lidocaine|96 participants undergoing chorionic villi sampling infiltrative local anaesthesia of 1% lidocaine
62403787|NCT01958619|EXPERIMENTAL|Treatment A: 1440mg PQP tablets & 800mg OZ439 + TPGS|Piperaquine phosphate tablets (1440mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
62403788|NCT01958619|EXPERIMENTAL|Treatment B: 960mg PQP tablets & 800mg OZ439 + TPGS|Piperaquine phosphate tablets (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
62403789|NCT01958619|EXPERIMENTAL|Treatment C: 960mg PQP granules & 800mg OZ439 + TPGS|Piperaquine phosphate granules for oral solution (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
62014829|NCT03781518|EXPERIMENTAL|ridge splitting|Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic mandible and splinting with screws
62014830|NCT03781518|ACTIVE_COMPARATOR|khoury shell technique|bone block is taken from the ramus to augment deficient posterior mandible and splinting with screws
62403790|NCT01958619|EXPERIMENTAL|Treatment D: 800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
62014831|NCT06128135||Prosthesis Users|30 participants, aged between 18 and 60, will be part of the study. The users must have at least 6 months of experience using upper limb prostheses. They will be asked a 15-question survey about their upper limb prostheses.
62014832|NCT06128135||Therapists|10 therapists that have experience working with prostheses. They will be asked a 9-question survey about upper limb prostheses that they usually handle.
62014833|NCT06128135||Relatives|30 of the prosthesis users' relatives who live with the person and see the daily difficulties of using the device. They will be asked a 9-question survey about the device that their relatives costume to use.
62014834|NCT02203019|ACTIVE_COMPARATOR|Propofol|Propofol will be administered for sedation.
62014835|NCT02203019|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine will be administered for sedation
62403791|NCT01367626|ACTIVE_COMPARATOR|letrozole|2.5 mg tablet
62403792|NCT01367626|ACTIVE_COMPARATOR|Fermara|2.5 mg tablet
62403793|NCT03019666|EXPERIMENTAL|Multiple Myeloma|After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and elotuzumab for Multiple Myeloma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
62580109|NCT01263782|EXPERIMENTAL|Chemo (Carbo/Peme) + Cixutumumab|"Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle.~Cixutumumab 20 mg/kg by vein on day 1 of each 21 day cycle."
62580110|NCT06335199|EXPERIMENTAL|Unilateral tVNS|Electrical stimulation to the vagus nerve area of the outer ear on the left side.
62014836|NCT05999409|EXPERIMENTAL|d1|NBSAF's first rating on a full-reality birth simulator. During the first normal delivery practice of the student in the hospital environment, the second evaluation of NBSAF and the second application of SSSCSL and ESSBL were made.
62014837|NCT05999409|EXPERIMENTAL|d2|An initial evaluation of NBSAF was performed on a medium reality labor stimulator. During the first normal delivery practice of the student in the hospital environment, the second evaluation of NBSAF and the second application of SSSCSL and ESSBL were made.
62014838|NCT05999409|NO_INTERVENTION|d3 (control)|Without any simulation application, the second evaluation of NBSAF and the second application of SSSCSL and ESSBL were performed during the first normal delivery practice of the student in the hospital environment.
62014839|NCT02165722|EXPERIMENTAL|Intervention: Toolkit|4 Pillars Toolkit
62014840|NCT02165722|NO_INTERVENTION|No Intervention: Standard practice|11 Clinical Practices \[control sites\]
62014841|NCT03143829|EXPERIMENTAL|Intervention group|electronic Symptom Self-Management Training- CINV (eSSET-CINV) is an educational intervention administered once at the start of treatment
62014842|NCT03143829|ACTIVE_COMPARATOR|Wait Control group|The Wait control group receives the electronic Symptom Self-Management Training- CINV (eSSET-CINV) at the last study visit. Outcomes will be compared to the Intervention group at the end of the study.
62014843|NCT00863538|EXPERIMENTAL|1|
62014844|NCT03169153|OTHER|Lotrafilcon B, then senofilcon C|Lotrafilcon B contact lenses worn first, followed by senofilcon C contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
62014845|NCT03169153|OTHER|Senofilcon C, then lotrafilcon B|Senofilcon C contact lenses worn first, followed by lotrafilcon B contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
62014846|NCT05577897|EXPERIMENTAL|Patient Education|The intervention group was given 45 minutes of training.
62014847|NCT05577897|NO_INTERVENTION|Control Group|Routine nursing care was given to the patients in this group without any training.
62014848|NCT03741959|EXPERIMENTAL|Experimental|The experimental group will undergo three groups of exercises: 1) active self-correction exercises (20 minutes) defined as the best possible trunk alignment the patient can achieved in the three-dimensional planes; 2) passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint and to counteract the evolution of the misalignment; 3) functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015).Training will consist of individualized treatment 60 mins/day, 2 days/week, for 5 consecutive weeks.
62014849|NCT03741959|ACTIVE_COMPARATOR|Control|The control group will undergo strengthening exercises and gait training as the usual practice in Parkinson Disease. Training will consist of individualized treatment 60 mins/day, 2 days/week, for 5 consecutive weeks (Bartolo et. al., 2010).
62014850|NCT04898218|ACTIVE_COMPARATOR|Group A (Aerobic Exercise Group)|Warm-up exercises were performed by the participants on a cycle ergometer for a duration of 5-10 minutes. Group A was advised to start walking at a comfortable speed on a treadmill for the duration of 30-60 minutes; the intensity of the exercises was 55-75% of MHR, calculated by using a Karvonen method. Initially with the minimum intensity that was gradually raised up to the intensity of Targeted Heart Rate (THR). Once the THR is achieved the intensity was gradually decelerated and patient proceeded for the cool-down phase for 5-10 min.
62580111|NCT06335199|EXPERIMENTAL|Bilateral tVNS|Electrical stimulation to the vagus nerve area of the outer ear on both sides.
62014851|NCT04898218|ACTIVE_COMPARATOR|Group B (Resistance Exercise Group)|Group B was instructed for strengthening exercises of ten major muscle groups that include Biceps, Triceps, Pectoralis Major, Deltoid, Latissimus Dorsi, Abdominals, Back Extensors, Hamstrings, Quadriceps and Calf. The intensity of the weight-bearing exercises was calculated using 1 Repetition Maximum (RM) method.
62403794|NCT03019666|EXPERIMENTAL|Non-Hodgkin Lymphoma|After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and rituximab for Non-Hodgkin Lymphoma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
62787004|NCT06186258||Patients who underwent successful percutaneous pulmonary revalvulation with the Melody valve|"Data from patients managed for a pulmonary revalvulation procedure with the Melody valve between 01/01/2007 and 31/12/2021 will be collected.~Cases of infective endocarditis will be meticulously examined and classified as certain, possible or refuted, according to the modified Duke algorithm proposed by the European Society of Cardiology.~Cases of endocarditis occurring within one year of pulmonary revalvulation will be classified as early IE and other cases as late IE"
62787005|NCT06186258||Patients who underwent successful percutaneous pulmonary revalvulation with the Sapien 3, XT valve|"Data from patients managed for a pulmonary revalvulation procedure with the Sapien 3, XT valve between 01/01/2007 and 31/12/2021 will be collected.~Cases of infective endocarditis will be meticulously examined and classified as certain, possible or refuted, according to the modified Duke algorithm proposed by the European Society of Cardiology.~Cases of endocarditis occurring within one year of pulmonary revalvulation will be classified as early IE and other cases as late IE"
62787006|NCT01448499|EXPERIMENTAL|Clozapine|Clozapine monotherapy
62787007|NCT01448499|EXPERIMENTAL|Amisulpride|Amisulpride monotherapy
62787008|NCT01448499|EXPERIMENTAL|Augmentation|Augmentation of clozapine with amisulpride
62787009|NCT00882960|ACTIVE_COMPARATOR|1|patients who are randomized to receive intravenous fentanyl for control of their pain
62787010|NCT00882960|ACTIVE_COMPARATOR|2|patients who are randomized to receive intra-nasal fentanyl for control of their pain
62014852|NCT04898218|EXPERIMENTAL|Group C (Osteoanabolic Exercise Group)|"Group C was performed Osteoanabolic exercise divided into two different phases:~Aerobic Conditioning Phase Participants were instructed to walk on treadmill for 30-60 min. The intensity of the exercises was 55-75% MHR, calculated by Karvonen method. Intensity gradually raised up to the Targeted Heart Rate (THR). Once the THR is achieved the intensity was gradually decelerated and patient proceeded for the cool-down phase. The participants performed 3 days per week for 12 weeks on alternative days.~Anaerobic (Resistance) Conditioning Phase Resistance training was started on every alternative day of the aerobic conditioning (3 days per week) for 45 min. The intensity of the weight-bearing exercises was calculated using 1 RM method. Resistance training muscle and protocol was the same as for Group B. The participants performed warm-up and cool down similar to that of group A and group B."
62014853|NCT06061458|NO_INTERVENTION|control group|normal hearing
62014854|NCT06061458|EXPERIMENTAL|the group with hearing aids|children with hearing aids
62014855|NCT06061458|EXPERIMENTAL|the group with cochlear implant|children with cochlear implant
62014856|NCT06061458|EXPERIMENTAL|the group with bimodal hearing|children with bimodal hearing
62014857|NCT05245968|EXPERIMENTAL|Dose Escalation Part|Pimitespib in combination with imatinib
62403795|NCT03539419||Patients with plaque psoriasis on apremilast|Adult patients with moderate to severe plaque who have started apremilast treatment for first time 3 months (+/- 4 weeks) before their inclusion in the study, according to the specifications of the drug's prescribing information and under usual clinical practice.
62787011|NCT01986608|EXPERIMENTAL|Lacosamide 30-minute iv|A 30-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial).
62787012|NCT01986608|EXPERIMENTAL|Lacosamide 60-minute iv|60-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial).
62014858|NCT05245968|EXPERIMENTAL|Expansion Part-A|Pimitespib in combination with imatinib
62403796|NCT01519635|ACTIVE_COMPARATOR|Aliskiren|Aliskiren 150 to 300 mg once a Week for 8 weeks
62787013|NCT01986608|EXPERIMENTAL|Lacosamide oral tablet|Oral administration of Lacosamide (LCM) 200 mg (2 x 100 mg film-coated tablet) with 200 mL of water.
62787014|NCT03850535|EXPERIMENTAL|Dose-Escalation Phase|Participants with newly diagnosed, previously untreated, favorable or intermediate risk AML (according to European LeukemiaNet \[ELN\] 2017 criteria) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
62787015|NCT03850535|EXPERIMENTAL|Post-Consolidation Phase|Participants who are idasanutlin treatment-naive, had received induction and chemotherapy consolidation for AML outside of the study, and were in minimal residual disease (MRD)-positive remission after induction will be enrolled in this cohort to receive maintenance treatment with single-agent idasanutlin.
62203838|NCT00158197|EXPERIMENTAL|intermittent unpredictable schedule|Those in the intermittent unpredictable condition will be eligible to receive a contingency management voucher on one day a week. Participants in this group will receive a voucher for $22.00 following their first 3 methamphetamine-negative urine tests. They will then be eligible to receive a voucher one day a week if all of their urine tests since the receipt of their last voucher were methamphetamine negative. They will receive a voucher for $35.50 for the provision of their second set of 3 consecutive instances of methamphetamine-negative urine samples, $49.00 for their third set of 3 consecutive instances, and so forth. The day of the week on which the voucher will be available will be randomly selected for each week and the participants will not know which day of the week they will be eligible to receive a voucher until they have provided their urine test. All participants will provide observed urine samples M, W, \& F for 12 wks and complete measures 1x/wk.
62787016|NCT03850535|EXPERIMENTAL|Expansion Phase: Favorable/Intermediate-Risk AML|Participants with newly diagnosed, previously untreated, favorable or intermediate risk AML (according to ELN 2017 criteria) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
62203839|NCT00158197|NO_INTERVENTION|standard|Participants assigned to the standard condition will not receive vouchers for the provision of clean urines. All participants will provide observed urine samples three times a week (e.g., M, W, \& F) for twelve weeks and will complete study-related measures one time per week.
62203840|NCT03251729|EXPERIMENTAL|Cerclage|Cervical cerclage placement along with vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.
62203841|NCT03251729|OTHER|Control|Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.
62403797|NCT01519635|ACTIVE_COMPARATOR|Hydrochlorothiazide|HCTZ 12.5 - 25 mg/d once a day for 8 weeks
62403798|NCT04231799|EXPERIMENTAL|Bathing within 24-48|Participants who will have their first bath in 24-48th hours after birth.
62403799|NCT04231799|EXPERIMENTAL|Bathing within 48-72|Participants who will have their first bath in 48-72th hours after birth.
62403800|NCT02780180|EXPERIMENTAL|QGC001|QGC001 from 50mg to 500mg capsule twice daily, for 28 days, oral use
62014859|NCT05245968|EXPERIMENTAL|Expansion Part-B|Pimitespib followed by imatinib
62014860|NCT05245968|EXPERIMENTAL|Expansion Part-C|Sunitinib
62403801|NCT02780180|PLACEBO_COMPARATOR|Placebo|Placebo, capsule twice daily, for 28 days, oral use
62403802|NCT05347173|NO_INTERVENTION|Bupivacaine group (B gp)|Patients will receive 2.5 ml hyperbaric bupivacaine (0.5%) plus 0.5 ml normal saline
62403803|NCT05347173|ACTIVE_COMPARATOR|Bupivacaine-Dexmedetomidine group (BD gp)|Patients will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus 10 µg Dexmedetomidine in 0.5 mL normal saline
62403804|NCT05347173|ACTIVE_COMPARATOR|Bupivacaine-Nalbuphine group (BN gp)|Patients will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus 1 mg Nalbuphine in 0.5 mL normal saline
62403805|NCT04060901|EXPERIMENTAL|CCSH Interventions for Teams in Cohort 1|Participants in the first cohort will receive the CCSH Interventions for Teams during the fall session (first intervention period).
62014861|NCT00575588|EXPERIMENTAL|Saxagliptin|
62014862|NCT00575588|EXPERIMENTAL|Glipizide|
62403806|NCT04060901|EXPERIMENTAL|CCSH Interventions for Teams in Cohort 2|Participants in the second cohort will receive the CCSH Interventions for Teams during the spring session (second intervention period).
62403807|NCT00137306|OTHER|Arm 1|
62403808|NCT05401552|ACTIVE_COMPARATOR|Convenience breakfast meal|One cheese tea biscuit and Eggo waffle
62014863|NCT02061462|NO_INTERVENTION|Standard Group|Recipients of lungs procured from brain dead donors.
62403809|NCT05401552|ACTIVE_COMPARATOR|Healthy breakfast meal|One cup of All-Bran breakfast cereal with milk and a piece of fruit
62403810|NCT03965754||No email|No email will be sent out to this subset of GHP members during the week that the other emails are sent.
62014864|NCT02061462|ACTIVE_COMPARATOR|EVLP-DCD Group|Recipients of lungs procured from DCD donors, reconditioned/evaluated by EVLP
62014865|NCT04555746|EXPERIMENTAL|Physical activity|Physical activity
62014866|NCT04555746|NO_INTERVENTION|Control|Waiting list
62014867|NCT02555410||Brain Sentinel Seizure Detection and Warning System|To test the usability of the Brain Sentinel Seizure Detection and Warning System(also known as the SPEAC system) in a patient home setting.
62014868|NCT04606238|NO_INTERVENTION|Group without DA|adult patients with incurable, stage IV disease (Prostate-, Breast-, Pancreatic-, Stomach- and Colorectal cancer) in an advanced treatment stage.
62403811|NCT03965754||Standard email reminder|The standard email reminder mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location.
62014869|NCT04606238|OTHER|Group with DA|adult patients with incurable, stage IV disease (Prostate-, Breast-, Pancreatic-, Stomach- and Colorectal cancer) in an advanced treatment stage.
62580112|NCT06335199|SHAM_COMPARATOR|Unilateral Sham|Electrical stimulation to the non-vagus nerve area of the outer ear on the left side.
62403812|NCT03965754||Social norms email|The social norms email notes that a majority (78%) of GHP members' colleagues had enrolled in 2018, it provides a testimonial from a medical director at Geisinger's Commonwealth School of Medicine, stating the ways in which myHealth Rewards helped that doctor personally, and it emphasizes the simplicity and ease of taking the first step toward enrollment.
62403813|NCT03965754||Loss framing|"The loss framing email suggests that GHP members are currently throwing away a precise dollar amount (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action."
62403814|NCT01927159|EXPERIMENTAL|10 mcg ID93 + 2 mcg GLA-SE Vaccine (QFT-)|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant. This group limited to adults with negative Quantiferon Gold TB (QFT) test.
62403815|NCT01927159|EXPERIMENTAL|2 mcg ID93 + 2 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. Low dose of antigen and low dose of adjuvant.
62403816|NCT01927159|EXPERIMENTAL|10 mcg ID93 + 2 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant.
62403817|NCT01927159|EXPERIMENTAL|10 mcg ID93 + 5 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and high dose of adjuvant.
62403818|NCT01927159|PLACEBO_COMPARATOR|Saline|Three intramuscular injections of saline at Days 0, 28, and 112.
62403819|NCT02937727|EXPERIMENTAL|MRI compatible and LFP recordable implantable stimulator|
62403820|NCT01144572||1|Chinese postmenopausal HR(+) EBC patients during adjuvant Aromatase Inhibitors(AIs) treatment
62014870|NCT01312961|PLACEBO_COMPARATOR|Placebo (for Dupilumab)|Placebo (for Dupilumab) subcutaneous (SC) injection once weekly (qw) for 12 weeks added to background therapy of inhaled corticosteroids/long-acting beta2-adrenergic agonist (ICS/LABA) (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.
62203842|NCT02169570|ACTIVE_COMPARATOR|Vitamin D|Vitamin D supplementation Anti Tuberculosis Treatment with 600,000 IU of (I/M) vitamin D3 for 3 doses at 0, 4 and 12 weeks and color and taste matched placebo for calcium for 3 months
62403821|NCT01103375|EXPERIMENTAL|Treatment (enzyme inhibitor, immunotherapy)|Patients receive isotretinoin PO QD on days 1-21 and erlotinib hydrochloride PO QD on days 1-28.
62580113|NCT06335199|SHAM_COMPARATOR|Bilateral Sham|Electrical stimulation to the non-vagus nerve area of the outer ear on both sides.
62014871|NCT01312961|EXPERIMENTAL|Dupilumab 300 mg qw|Dupilumab 300 mg SC injection qw for 12 weeks added to background therapy of ICS/LABA (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.
62203843|NCT02169570|PLACEBO_COMPARATOR|Placebo|Anti Tuberculosis Treatment with placebo color matched for vitamin D and color and taste matched placebo for calcium
62203844|NCT02169570|EXPERIMENTAL|Vitamin D and Calcium|Vitamin D and Calcium supplementation Anti TuberculosisTreatment with 600,000 IU of (I/M) vitamin D3 for 3 doses at 0, 4 and 12 weeks with daily 1000 mg calcium carbonate for 3 months
62403822|NCT05423639|EXPERIMENTAL|Control group 1|Testing Palodent sectional matrix system only when placing Class II resin composite restorations is to increase proximal contact tightness.
62580114|NCT06209216||Total Hip Replacement|No intervention
62580115|NCT01919866|EXPERIMENTAL|Transplantation of CD3/CD19 depleted stem cells|Patients receive a minimum dosage of 10x10E6/kg bodyweight CD3/CD19 depleted CD34+ stem cells. Maximum dosage of residual T cells will be 1x10E5/kg BW
62580116|NCT06054009|EXPERIMENTAL|Treatment|In Study 1: x4 CBT sessions addressing cognitive appraisals of dissociation. In Study 2: x4 CBT sessions addressing rumination/worry. In Study 3: x4 CBT sessions addressing affect intolerance.
62580117|NCT04246216|EXPERIMENTAL|Percutaneous Electrical Nerve Stimulation|The experimental group will receive 3 sessions (once per week) of ultrasound-guided Percutaneous Electrical Nerve Stimulation targeted the median nerve. Once the median nerve is ultrasound identified, the needles will be left in situ at the identified points connected to an electrostimulator (ES-160 ITO co.) applying a biphasic continuous waveform, at low frequency (2 Hz)19 and with 250 microseconds pulse duration for 30mins.
61978476|NCT01472081|EXPERIMENTAL|Arm I-1: Nivolumab + Ipilimumab|"Nivolumab 3 mg/kg solution intravenously (IV) every 21 days during Induction phase and every 14 days during Maintenance phase until Progressive disease (PD), toxicity or discontinue for other reasons~Ipilimumab 1mg/kg solution intravenously (IV) every 21 days during Induction phase (Ipilimumab will not be administered during Maintenance phase) until Progressive disease (PD), toxicity or discontinue for other reasons"
62014872|NCT00583492|EXPERIMENTAL|Ad5-yCD/mutTKSR39rep-ADP + IMRT|Gene Therapy + IMRT
62014873|NCT00583492|ACTIVE_COMPARATOR|IMRT Alone|IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
62403823|NCT05423639|ACTIVE_COMPARATOR|Intervention group 2|A pre-contoured instrument called Optra contact (Ivoclar, Vivadent) will be used with group 2. For testing palodent matrix systems with Optracontact when placing Class II resin composite restorations is to increase proximal contact tightness with adjacent teeth when compared with group 1.
62403824|NCT02492152|NO_INTERVENTION|Control group|Women who will not be using this medicine that is checked.
62403825|NCT02492152|EXPERIMENTAL|Study group|Women who will use DIANATAL according to manufacturer's protocol from the stage of active labor.
62403826|NCT04494191|EXPERIMENTAL|T test|Test drug (AphroFemine) 1 tablet contains 100 mg Flibanserin
62403827|NCT04494191|ACTIVE_COMPARATOR|B reference|Reference drug (Addyi) 1 tablet contains 100 mg Flibanserin
62403828|NCT01588899|EXPERIMENTAL|MR-HIFU Treatment|Patients in this arm will receive MR-HIFU uterine fibroid treatment
62403829|NCT03957343|EXPERIMENTAL|Pacing and Planning App|The Pacing and Planning Program is a points system to aid individuals with an acquired brain injury/concussion in planning daily activities and managing symptoms. Activities are allotted various points, depending on the energy the task requires and the symptoms they create. Activities can include anything from grocery shopping to driving or watching TV, etc. Patients are allotted a number of points for a day, and therefore learn to sparingly perform activities. This results in a reduction of symptoms and improved recovery time.
62787017|NCT03850535|EXPERIMENTAL|Expansion Phase: High-Risk AML|Participants with newly diagnosed, previously untreated, high-risk AML (defined as adverse risk according to ELN 2017 criteria, and secondary AML) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
62787018|NCT01152034|EXPERIMENTAL|Psychoeducation group therapy|The structured group program comprised of an initial block of 12 weekly sessions with three additional monthly booster sessions, designed to support participants in the application of knowledge and skills to everyday life situations. All participants also received standard psychiatric care as well.
62787019|NCT01152034|PLACEBO_COMPARATOR|Treat as Usual|Patients who were assigned to the control group received standard psychiatric care and standard pharmacological treatment without group-based psychosocial intervention. Weekly phone calls to the control group over the initial 12 weeks were controlled for any extra contact time with researchers outside of the structured intervention group.
62787020|NCT04345315||asymptomatic population at high risk of infection|healthy individuals at high risk of infection, including individuals who have had contact with a patient tested positive for COVID-19, voluntary health workers and oncological patients candidate to immunosuppressive therapy
62787021|NCT04345315||COVID-19 patients|patients with confirmed diagnosis of COVID-19
62014874|NCT02385955|EXPERIMENTAL|Myeloablative dUCBT|Myeloablative conditioning with (1) TBI, cyclophosphamide, and cytarabine, or (2) thiotepa, busulfan, and fludarabine, followed by double unit umbilical cord blood transplant
62014875|NCT05706259|ACTIVE_COMPARATOR|Soft gelatin vit D supplement|In this arm subjects will receive a weekly single dose 200000 IU soft gelatin capsule of vitamin D3 for 3-weeks
62203845|NCT02897050|EXPERIMENTAL|T+mCX followed by FEC|Docetaxel 75mg/m2, iv, d1 + CTX 50 mg/d, po, d1-d21 + capecitabine 1200mg/m2/d, po, d1-d21 \* 3 cycles (21 days per cycle) followed by fluorouracil 500mg/m2,iv,d1 + epirubicin 100mg/m2,iv,d1 + cyclophosphamide 500mg/m2,iv,d1 \* 3 cycles (21 days per cycle)
62014876|NCT05706259|EXPERIMENTAL|Orodispersible vit D supplement|In this arm subjects will receive a weekly single dose 200000 IU orodispersible (sachet) vitamin D3 for 3-weeks
62203846|NCT02897050|ACTIVE_COMPARATOR|T followed by FEC|Docetaxel 100mg/m2, iv, d1 \* 3 cycles (21 days per cycle) followed by fluorouracil 500mg/m2,iv,d1 + epirubicin 100mg/m2,iv,d1 + cyclophosphamide 500mg/m2,iv,d1 \* 3 cycles (21 days per cycle)
62014877|NCT05831852||one group|
62014878|NCT03000465||Patients|Patients undergoing laparoscopic colorectal surgery
62203847|NCT00384774|EXPERIMENTAL|Lasmiditan|Participants received escalating doses of 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 45 mg of lasmiditan as intravenous injection.
62203848|NCT00384774|PLACEBO_COMPARATOR|Placebo|Participants received intravenous infusion of placebo solution.
62014879|NCT01511887|EXPERIMENTAL|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
62014880|NCT01511887|NO_INTERVENTION|No treatment|No treatment
62014881|NCT01866072||AVH|AVH: Patients with Acute Viral Hepatitis
62014882|NCT01866072||ACLF|ACLF: Patients with Acute on Chronic Liver Failure
62014883|NCT03735420|EXPERIMENTAL|Xanthohumol|Participants will receive 24 mg of 98% pure xanthohumol in a rice protein vehicle by mouth once daily with the first daily meal.
62014884|NCT03735420|PLACEBO_COMPARATOR|Placebo oral capsule|Participants will receive vehicle (rice protein) by mouth once daily with the first daily meal.
62787022|NCT01511913||Ipilimumab treatment cohort of 1106 prospective participants|
62787023|NCT01511913||Non-Ipilimumab treatment cohort of 305 prospective participants|
62787024|NCT01511913||Retrospective cohort of 177 participants|
62014885|NCT03104504|NO_INTERVENTION|No Intervention|Baseline Retrospective Chart Reviews that are conducted on subjects for the one year period prior to the implementation of the study will serve as the control.
62787025|NCT03658824|OTHER|3 week wait|Participant waits for 3 weeks after their baseline assessment before commencing therapy.
62787026|NCT03658824|OTHER|4 week wait|Participant waits for 4 weeks after their baseline assessment before commencing therapy.
62787027|NCT03658824|OTHER|5 week wait|Participant waits for 5 weeks after their baseline assessment before commencing therapy.
62787028|NCT03658824|OTHER|6 week wait|Participant waits for 6 weeks after their baseline assessment before commencing therapy.
62787029|NCT03658824|OTHER|7 week wait|Participant waits for 7 weeks after their baseline assessment before commencing therapy.
62787030|NCT03658824|OTHER|8 week wait|Participant waits for 8 weeks after their baseline assessment before commencing therapy.
62787031|NCT05741112|OTHER|Control: study provided wearables|Following consent and the completion of the baseline assessments the control group will receive basic education on symptom management. At the 3 month timepoint they will be prompted to order their device and receive enhanced education that will provide information on how wearable devices can be used to monitor and manage symptoms.
62787032|NCT05741112|OTHER|Treatment: study provided wearables|Following consent and the completion of the baseline assessments the treatment group will be prompted to order their device and receive basic education on symptom management along with the enhanced education on wearable devices.
62787033|NCT05741112|OTHER|Control: self provided wearables|Following consent and the completion of the baseline assessments the control group will receive basic education on symptom management. At the 3 month timepoint they will be receive enhanced education that will provide information on how wearable devices can be used to monitor and manage symptoms.
62787034|NCT05741112|OTHER|Treatment: self provided wearables|Following consent and the completion of the baseline assessments the treatment group will receive basic education on symptom management along with the enhanced education on wearable devices.
62014886|NCT03104504|OTHER|Intervention|"The intervention targets will be the following suicide-related clinician behaviors.~* suicide risk screening~* safety planning~* means restriction counseling~* Post-acute care follow-up calls A Lean Implementation Strategy: The Implementation of the intervention targets guided by Lean; is expected to increase suicide-related clinician behaviors"
62014887|NCT03221413|EXPERIMENTAL|PD tACS|Persons with Parkinson disease who will be treated with tACS: Intervention: tACS (transcranial alternating current stimulation)
62403830|NCT02052206|EXPERIMENTAL|Computer-assisted 3D planning|Realization of the fracture reconstruction according to the computer-assisted 3D preoperative plan
62787035|NCT01041820|EXPERIMENTAL|Exercise group|Children will participate in a 10-week moderate to vigorous exercise program
62787036|NCT01041820|NO_INTERVENTION|non-exercising|Participants will receive no intervention
62787037|NCT05727657|EXPERIMENTAL|Satralizumab|Subjects will receive satralizumab 120mg subcutaneous Day 0 and Day 14 after enrollment.
62787038|NCT01600989||Patients with severe sepsis / septic shock|30 Adult patients (age \> 18years), with severe sepsis or septic shock as defined by the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference guidelines at the time of admission to ICU.
62787039|NCT01600989||Healthy volunteers|Healthy volunteers
62014888|NCT03221413|EXPERIMENTAL|Pain tACS|Persons with neuropathic pain who will treated with tCAS. Intervention: tACS (transcranial alternating current stimulation)
62014889|NCT01858194|EXPERIMENTAL|Renal sympathetic denervation|Catheter-based Renal Sympathetic Denervation Ablation Arm
62787040|NCT01500486||PenMate device|
62787041|NCT06061835|EXPERIMENTAL|"Non-contrast MRA (MRA -)"|Participants in this group underwent preoperative planning with a contrast-free magnetic resonance angiography (MRA) using an enhanced protocol that eliminates the use of potentially hazardous contrast agent and radiation exposure while providing high accuracy of visualization.
62014890|NCT01858194|PLACEBO_COMPARATOR|VT ablation alone|No further therapy in addition to VT ablation
62014891|NCT02896231|EXPERIMENTAL|PLB1001|There are 5 dose cohorts, including 50mg BID, 100mg BID, 150mg BID, 200mg BID and 275mg BID in the dose escalation stage and PLB1001 will be administered orally to patients twice daily for each dose cohort.
62787042|NCT06061835|OTHER|"CTA with contrast (CTA +)"|Control group. Participants in this group underwent preoperative planning using the standard commonly used method - computed tomography angiography (CTA) with IV (intravenous) iodine-containing contrast injection.
62787043|NCT01180296|EXPERIMENTAL|Progesterone Group|Oral Micronized Progesterone
62787044|NCT01180296|PLACEBO_COMPARATOR|Placebo|Identical Placebo Tablet
62787045|NCT04093440|OTHER|Observation|lifestyle modification: nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization
62403831|NCT03511391|EXPERIMENTAL|Experimental arm|"Stereotactic body radiotherapy concurrent with checkpoint inhibitor treatment:~Nivolumab or Pembrolizumab or Atezolizumab + SBRT"
62787046|NCT00765063|EXPERIMENTAL|Active|Active study treatment
62787047|NCT03809494|EXPERIMENTAL|Treatment Arm|Patients assigned to the treatment arm will be injected with autologous concentrated total nucleated cells (TNCs) three times at six week intervals.
62787048|NCT03809494|PLACEBO_COMPARATOR|Saline (Control Arm)|Patients assigned to the control arm will be injected with saline three times at six week intervals.
62014892|NCT00234884||Adalimumab|RA patients in treatment with commercial adalimumab
62014893|NCT01475526|EXPERIMENTAL|Intervention|El Valor de Nuestra Salud Store Intervention
62014894|NCT01475526|NO_INTERVENTION|Control|No intervention. Business as usual
62014895|NCT01032694||Z-max treated group|Patients with Community-Acquired Pneumonia
62014896|NCT01032694||Amoxiclav treated group|Patients with Community-Acquired Pneumonia
62403832|NCT03511391|ACTIVE_COMPARATOR|Control arm|"Checkpoint inhibitor treatment only:~Nivolumab or Pembrolizumab or Atezolizumab monotherapy"
62787049|NCT04238507|ACTIVE_COMPARATOR|Guedel airway (OPA)|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a Guedel airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
62787050|NCT04238507|ACTIVE_COMPARATOR|McKay Airway (MA)|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a USASK airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
62014897|NCT01192594|EXPERIMENTAL|MAPP Trained Case Managers|Consumers assigned to case managers who receive training in the Milestones of Adjustment Post-Psychosis Recovery Model
62014898|NCT01192594|ACTIVE_COMPARATOR|Non-MAPP trained case managers|Consumers of case managers not trained in the Milestones of Adjustment Post-Psychosis Recovery Model
62787051|NCT05712954|NO_INTERVENTION|control group|The study will start with the women in the control group. The women in the control group, who were selected in accordance with the sample selection criteria and agreed to be a participant, will be given data collection tools for the pre-test on the day of the procedure and no intervention will be made other than the counseling given at the hospital. VAS and State-Trait Anxiety Inventory will be applied after the procedure. After 24 hours, the women will be reached and questioned whether they use analgesics.
62787052|NCT05712954|EXPERIMENTAL|music group|The women in the 1st group will be pre-tested with data collection tools before the HSG, then after they are taken to the table, headphones will be put on and music will be played. VAS and State-Trait Anxiety Inventory will be applied after the procedure. After 24 hours, the women will be reached and questioned whether they use analgesics. After the women in this group are completed, the 2nd group will be started.
62787053|NCT05712954|EXPERIMENTAL|video group|2. The women in the group will be pre-tested with data collection tools before the HSG, and after they are taken to the table, a video with natural landscape pictures prepared by the researcher will be opened on the iPad. VAS and State-Trait Anxiety Inventory will be applied after the procedure. After 24 hours, the women will be reached and questioned whether they use analgesics.
62787054|NCT02775916|EXPERIMENTAL|CDZ173|Capsule
62787055|NCT02775916|PLACEBO_COMPARATOR|Placebo|Capsule matching Placebo
62787056|NCT06100913|EXPERIMENTAL|Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)|Healthy adults who are at no risk for exposure to Ebola Virus and are not prior recipients of an Ebola vaccine receive a single dose of recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP).
62787057|NCT06437977|EXPERIMENTAL|Experimental|Participants receive SBRT for primary lung tumor, sequential receive totally 4 cycles of Toripalimab combined with platinum doublet chemotherapy during perioperative period ; participants receive consolidation therapy of Toripalimab Intervention: SBRT: 24Gy/3fractions; Drug: 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab
62787058|NCT06437977|ACTIVE_COMPARATOR|Active Comparator|Participantsreceive totally 4 cycles of Toripalimab combined with platinum doublet chemotherapy during perioperative period ; participants receive consolidation therapy of Toripalimab Intervention: Drug: 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab
62014899|NCT00902616|ACTIVE_COMPARATOR|1. L-arginine|3 gm TDS for 3 months
62014900|NCT00902616|PLACEBO_COMPARATOR|2. Placebo - Lactose powder|3 gm TDS for 3 months
62203849|NCT01409577||FFR|Patients with intermediate coronary stenosis Patients with successful fractional flow measurement Feasible \> 9months clinical follow-up
62203850|NCT01818531|EXPERIMENTAL|Adductor canal block|Patients in this arm will receive an adductor canal block prior to undergoing a medial compartment knee arthroplasty.
62203851|NCT01818531|ACTIVE_COMPARATOR|Lumbar plexus block|Patients in this arm will receive a lumbar plexus block prior to undergoing a medial compartment knee arthroplasty.
62203852|NCT01390870||Patient Survey|Men from the United States aged 50 years or older who initiated medication for EP within the past 12 months.
62787059|NCT00285402|EXPERIMENTAL|A|
62787060|NCT00285402|EXPERIMENTAL|B|
62014901|NCT00414934||metastatic bone lesion for patients with cancer|
62014902|NCT01384539|EXPERIMENTAL|Cholecalciferol|Cholecalciferol 4000 IU capsule by mouth daily x 1 month then 2000 IU capsule by mouth daily x 5 months
62203853|NCT05249738||Study Group|Patients followed up with a mechanical ventilator for 4 days or longer were included in the study group.
62014903|NCT01384539|EXPERIMENTAL|Calcitriol|Calcitriol 0.25 mcg capsule by mouth daily x 1 month then 0.5 mcg capsule by mouth daily x 5 months
62014904|NCT05988216|EXPERIMENTAL|BRL-301|Allogeneic CD19-targeted Chimeric AntigenReceptor (CAR) T Cells
62014905|NCT04898010|EXPERIMENTAL|Selective Cytopheretic Device|Subjects will be placed on Selective Cytopheretic Device (SCD) for planned daily 24 hour therapy for up to 7 consecutive days.
62014906|NCT06664593||women in the perinatal period, from pregnancy until 6-8 weeks postpartum|women from pregnancy until 6-8 weeks postpartum with and without mental health problems
62014907|NCT00693953||1|Year one
62014908|NCT00693953||2|Year two
62014909|NCT03036514|EXPERIMENTAL|Case|Sublingual sufentanil tablet system (SSTS) for postoperative pain relief after laminectomy or spinal fusion in the first 72 hour period. Orange-coloured tablets containing 15mcg sufentanil, the patient-controlled device is designed to deliver a single tablet with a minimum lockout interval of 20 minutes.
62203854|NCT05249738||Control Group|Patients followed up with mechanical ventilation for 3 days or less were included in the control group.
62787061|NCT00285402|PLACEBO_COMPARATOR|C|
62787062|NCT04427020|EXPERIMENTAL|Milk Protein + Probiotic|25 gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086
62787063|NCT04427020|ACTIVE_COMPARATOR|Milk Protein|25 gram dose of milk protein concentrate
62787064|NCT01600833||Obese women|BMI\>25
62787065|NCT01600833||Non obese women|BMI\<25
62014910|NCT03036514|ACTIVE_COMPARATOR|Control|Patient-controlled intravenous analgesia (PCIA) for postoperative pain relief after laminectomy or spinal fusion in the first 72 hour period. This classic patient-controlled IV-pump contains 1mg/ml morphine and 50mcg/ml dehydrobenzperidol. Pump characteristics include 1ml each asked bolus, lockout interval of 8 minutes.
62014911|NCT06533839|EXPERIMENTAL|IPST mesh placement|A three-dimensional, funnel-shaped mesh will be used.
62014912|NCT06533839|ACTIVE_COMPARATOR|No mesh|No mesh will be applied.
62014913|NCT03105843|EXPERIMENTAL|Cough Variant Asthma|Individuals diagnosed with Cough variant asthma
62014914|NCT03105843|EXPERIMENTAL|Methacholine-induced cough|Individuals with chronic cough and negative methacholine challenge
62014915|NCT03105843|EXPERIMENTAL|Control|Individuals with no history of asthma or chronic cough
62203855|NCT02224703|EXPERIMENTAL|10 mg/kg/day GWP42003-P|GWP42003-P oral solution (100 mg/milliliter \[mL\] cannabidiol in sesame oil with anhydrous ethanol with added sweetener \[sucralose\] and strawberry flavoring). The 10 mg/kg/day dose was defined as 50% of the 20 mg/kg/day dose.
62203856|NCT02224703|EXPERIMENTAL|20 mg/kg/day GWP42003-P|GWP42003-P oral solution (100 mg/mL cannabidiol in sesame oil with anhydrous ethanol with added sweetener \[sucralose\] and strawberry flavoring). The 20 mg/kg/day dose was recommended by the DSMC after assessment of safety and pharmacokinetic data from Part A of study GWEP1332 (NCT02091206).
62203857|NCT02224703|PLACEBO_COMPARATOR|Placebo Control|Excipients only. Participants were pooled from 2 placebo cohorts, half receiving 10 mg/kg/day dose-volume equivalent and half receiving 20 mg/kg/day dose-volume equivalent.
62203858|NCT01940432|EXPERIMENTAL|electroacupuncture group|Bilateral BL33 are given acupuncture of 50-60mm with 30-45°angle to inward and downward. Bilateral BL35 are given acupuncture of 50-60mm to outward and upward. The electric stimulator is applied to bilateral BL33 and BL35.Every session lasts for 30 min per day.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all.
62203859|NCT01940432|EXPERIMENTAL|pelvic floor muscle training group|Standing/sitting/lying on back, knees bent to chest. A set consists of three contractions, each lasting 10s, with a 10s break between contractions. Counting or measuring the duration of contractions and breaks is accomplished without effort by taking advantage of the duration of normal breaths. As most men take about 10 breaths per minute, each breath can be used as 6s timing device.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all.
62203860|NCT03560752|EXPERIMENTAL|Donor (multi-peptide CMV-modified vaccinia Ankara vaccine)|Donors receive multi-peptide CMV-modified vaccinia Ankara vaccine injection between days -60 and -10 prior to granulocyte colony stimulating factor mobilization.
62203861|NCT03560752|EXPERIMENTAL|Receipient (multi-peptide CMV-modified vaccinia Ankara vaccine)|Participants undergo hematopoietic cell transplantation on day 0 and receive multi-peptide CMV-modified Vaccinia Ankara vaccine injection on days 28 and 56.
62203862|NCT03129126|EXPERIMENTAL|LP-10 2mg|LP-10 (intravesical tacrolimus), 2mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
62203863|NCT03129126|EXPERIMENTAL|LP-10 4mg|LP-10 (intravesical tacrolimus), 4mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
62203864|NCT03129126|EXPERIMENTAL|LP-10 8mg|LP-10 (intravesical tacrolimus), 8mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
62203865|NCT03416322|NO_INTERVENTION|Second Examination of the right colon|Second forward view examination of the right colon once the right colon (cecum to hepatic flexure) has been examined
62203866|NCT03416322|EXPERIMENTAL|Water exchange|"Water infusion during colonoscope insertion in the right colon (from hepatic flexure to cecum) and remove water during withdrawn (Exchange method)."
62403833|NCT01535209|EXPERIMENTAL|SBRT to resection cavity|18Gy in 1 fraction for resection cavity \<2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity \>4cm in maximum diameter
62787066|NCT04098861|EXPERIMENTAL|once daily group|"Latanoprost/Timolol Fixed Combination (LTFC) will be administered once daily for 4 weeks. The IOP will be determined on Day 14 and 28. The following examinations will be performed: evaluation of conjunctiva hyperemia, anterior chamber reaction, applanation tonometry, measurement of blood pressure and heart rate.~For once daily dosing, the eye drops will be instilled at 8am every morning. The IOP will be taken at 9am-12pm on study day."
62787067|NCT04098861|EXPERIMENTAL|twice daily group|"Latanoprost/Timolol Fixed Combination (LTFC) will be administered twice daily for 4 weeks. The IOP will be determined on Day 14 and 28. The following examinations will be performed: evaluation of conjunctiva hyperemia, anterior chamber reaction, applanation tonometry, measurement of blood pressure and heart rate.~For twice dosing, the eye drops will be instilled at 8am and 8pm. The IOP will be taken at 9am-12pm on study day."
62787068|NCT01958983|EXPERIMENTAL|Music Therapy Group Session|Participants will receive 60-minute group session twice a week over 2 months of period. Each session will be led by a music therapist. The contents of the music therapy session include drumming, rhythm imitation, score reading, lyrics comprehension, singing, and song discussion.
62787069|NCT01958983|NO_INTERVENTION|No Music Therapy Session|Participants will receive pre- and post-assessments and evaluations at 0 and 2 months. No intervention will be provided. Music therapy sessions will be offered to participants in completion of their study participation.
62787070|NCT03274063|ACTIVE_COMPARATOR|Supported self-management|Escalation of urate lowering therapy will be supervised by clinical research team based on results of participant self-testing
62014916|NCT05336500|EXPERIMENTAL|Pilates method exercises associated with education to keep the abdomen relaxed|The group will receive guidance to perform the exercises in a relaxed and smooth way
62014917|NCT05336500|ACTIVE_COMPARATOR|Pilates method exercises associated with education to keep the abdomen contracted|The group will receive guidance on the specific activation of the center of strength (the powerhouse)
62014918|NCT05173467|EXPERIMENTAL|Robot-assisted Invasion-controlled Surgery|
62203867|NCT04855006|EXPERIMENTAL|Vaginal Microbiome Transplant|Women are given the vaginal microbiome transplant at least one time and up to three times. If the woman receives the transplant more than once, it will be 28 days after the first transplant and again 28 days after the second transplant.
62203868|NCT04855006|PLACEBO_COMPARATOR|Vaginal Microbiome Transplant Placebo|Women are given the vaginal microbiome transplant placebo at least one time and up to three times. If the woman receives the transplant more than once, it will be 28 days after the first transplant and again 28 days after the second transplant.
62403834|NCT01535209|ACTIVE_COMPARATOR|WBRT|30Gy in 10 fractions over 12 days to whole brain
62403835|NCT02402608|ACTIVE_COMPARATOR|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture (32 g)
62403836|NCT02402608|PLACEBO_COMPARATOR|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
62403837|NCT03106701|EXPERIMENTAL|Ablation|Radiofrequency epicardial ablation
62580118|NCT04246216|ACTIVE_COMPARATOR|Surgery|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
62580119|NCT03909347|EXPERIMENTAL|PLAN (intervention)|Group 1 will receive the study intervention during the 6 months of the study, after the first baseline questionnaire. The intervention is as follows: participants will be asked to take part in a one-time, one-hour education in participants' home or any community location that is most convenient for the participants by a trained community health worker. An educational resource that participants can read at home will be provided at the end of education session. Participants' community health worker will call the participants monthly to identify barriers to dementia care and help participants and participants' elder with making an appointment or transportation to the health care facility, when participants request for assistance.
62403838|NCT05097261|EXPERIMENTAL|Ketamine|"Racemic ketamine® will be administered by continuous infusion in a prefilled 50 ml syringe at a concentration of 50 mg/ml, undiluted. The ketamine dose is 1 mg/kg/h, to a maximum dose of 120 mg/hour, which corresponds to an infusion rate of 0.02 ml/kg/h to a maximum rate of 2.4 ml/h. Study patients weighing over 120 kg will not exceed the maximum dose of 120mg/kg of ketamine.~The study medication will be started within 6 hours after randomization. The IMP, ketamine, will be provided directly to each Participating Site by the official supplier of ketamine for Belgium (Pfizer)."
62580120|NCT03909347|ACTIVE_COMPARATOR|Standard of care (control)|Group 2 will receive a signs and treatment of dementia pamphlet by the Alzheimer's Association and will be referred to the elder's primary physician.
62580121|NCT03670836|EXPERIMENTAL|Dilapan group|"Patients who are randomized to receive Dilapan, will have 3-5 rods of Dilapan-S® inserted in their cervix by the supervising provider, under aseptic precautions with a speculum exam, either digitally or using a sponge forceps, as per manufacturer's recommendations. The Bishop score at the time of eligibility assessment and number of rods inserted will be recorded. Dilapan will be left in cervix for 12 hours. Patients will be allowed to ambulate, shower and have light meals as long as they meet the criteria based on institutional guidelines for intermittent fetal heart monitoring. Nothing per vagina including douching and no bathing is allowed."
62014919|NCT05173467|PLACEBO_COMPARATOR|Traditional-open Surgery|
62203869|NCT04855006|EXPERIMENTAL|Vaginal Microbiome Donors|Women allocated in the donor group will donate their vaginal secretion, which will be processed and analyzed throughy before it is used as a transplant. In total, the donors will each provide approximately 10 donations of vaginal secretion.
62580122|NCT03670836|EXPERIMENTAL|Misoprostol group|Patients who are randomized to Misoprostol group, after the baseline assessment and a reassuring cardiotocograms (CTG) monitoring for 20 minutes to a maximum of 6 doses. All subjects will have continuous fetal monitoring. A dose will be held if patient is noted to have uterine tachysystole, hyperstimulation, fetal heart tracing abnormalities or 3 or more painful uterine contractions over a period of 10 minutes (indicating onset of labor). Administration of Misoprostol will be done by the nurse assigned to the patient.
62580123|NCT01960907|NO_INTERVENTION|Observational|"Subjects in the observational arm will receive monthly interviews for collecting informations about their status and level of utilization of healthcare resources.~They will follow their usual care path as provided by their local NHS"
62580124|NCT01960907|EXPERIMENTAL|Interventional|"Patients will receive a system form monitoring their health status.~The system is composed by:~* a touch-screen pc for the administration of daily questionnaires~* RESMONPRO DIARY for the measurement of lung mechanical impedance and breathing pattern~* a Medic4all Wrist Clinic for the assessment of heart rate, blood pressure, saturation, 1 lead ECG, body temperature.~Subjects will receive medical treatment following the activation of alarms by the monitoring devices.~Monthly phone interviews will be performed to collect data about their level of utilization of the health care system."
62580125|NCT03710382|EXPERIMENTAL|Walking epidural|Parturients will receive a lower concentration of bupivacaine in their epidural infusion and will be encouraged to walk during labor.
62787071|NCT03274063|SHAM_COMPARATOR|Usual care|Escalation of urate lowering therapy will remain the responsibility of the participants primary care physician.
62787072|NCT02681289|EXPERIMENTAL|physiotherapy group|Early goal directed neuromotor therapy applied by physiotherapist
62014920|NCT04260581|EXPERIMENTAL|PD patients who have taken amantadine|
62014921|NCT06663774|EXPERIMENTAL|Judokas|Judokas between the age of 18-45 with at least 3 years of judo experience who are actively doing judo training minimum of 300 minutes in a weak.
62403839|NCT05097261|ACTIVE_COMPARATOR|Placebo|The placebo (NaCl 0.9%) will be provided in the same type syringes and administered at the same infusion rate as the IMP (0.02 ml/kg/h to a maximum rate of 2.4 ml/h).
62014922|NCT06573892|ACTIVE_COMPARATOR|Probiotic. Heart Failure|"The patient sample will be divided into three main groups based on clinical phenotypes determined by echocardiographic examination:~HF with preserved ejection fraction (EF) (EF \> 50%) HF with mildly reduced EF (EF 49-40%) HF with reduced EF (EF \< 40%) 30 patients in each group"
62203870|NCT02597712|EXPERIMENTAL|Treatment|Patients will take 25 mg YF476 once daily for 12 weeks
62203871|NCT02597712|PLACEBO_COMPARATOR|YF476 Placebo|Patients will take matching placebo once daily for 12 weeks
62203872|NCT03705598|PLACEBO_COMPARATOR|Light physical exercise|Usual-pace walking, strength exercise, stretching exercise, and balance exercise.
62203873|NCT03705598|ACTIVE_COMPARATOR|Tai Chi|Tai Chi walking drills and Yang-style Tai Chi 8 forms.
62203874|NCT01387191||Subjects prescribed epoprostenol|Subjects with pulmonary arterial hypertension prescribed epoprostenol injection during study period
62203875|NCT01205789||Universal Registry|Subjects who are either not eligible for randomization or for other reasons are not randomized will be consented for the Universal Registry
62203876|NCT01220245|EXPERIMENTAL|Heparin-bonded endoluminal fempop bypass|Heparin-bonded ePTFE endoluminal femoro-popliteal bypass versus surgical femoro-popliteal bypass
62203877|NCT01220245|ACTIVE_COMPARATOR|Surgical femoro-popliteal bypass|Surgical femoro-popliteal bypass.
62203878|NCT00645268|ACTIVE_COMPARATOR|Arm 1|
62203879|NCT00645268|PLACEBO_COMPARATOR|Arm 2|
62203880|NCT00645268|OTHER|Open-Label Arm|
62203881|NCT03982251|EXPERIMENTAL|High frequency whole body vibration|This group will receive a single 8-minute session of WBV therapy. The frequency of the vibration signals will be set at 30Hz.
62203882|NCT03982251|ACTIVE_COMPARATOR|low frequency whole body vibration|This group will receive a single 12-minute session of WBV. The frequency of the vibration signals will be set at 20 Hz.
62203883|NCT00825539|PLACEBO_COMPARATOR|Placebo|
62203884|NCT00825539|EXPERIMENTAL|AQW051|
62403840|NCT05957939|EXPERIMENTAL|a case study with TNBC or ER positive , PR positive HER2 negative ,|researchers will study a case with metastatic breast cancer stage 4 and the source of nutrition either glucose source as energy fuel of cells or another nutrition ( alkaline glucosodiene)
62403841|NCT04868838|EXPERIMENTAL|Daratumumab|Subjects diagnosed with lupus nephritis will receive Daratumumab once weekly for 8 weeks and then once every 2 weeks for 8 additional does (+/- 4 days). Subjects will be followed for a total of 24 months (18 months after the last daratumumab administration).
62203885|NCT04680767|EXPERIMENTAL|[¹⁴C]-LY3502970|A single dose of LY3502970 and \[¹⁴C\]-LY3502970 administered orally.
62203886|NCT01423591|EXPERIMENTAL|infliximab|
62203887|NCT01423591|PLACEBO_COMPARATOR|inactive powder|
62203888|NCT03752970|NO_INTERVENTION|Screening Cohort|Patients enrolled in the Screening Cohort did not receive study treatment. This was a feasibility phase for fistula preparation and seton placement to determine the tissue samples that were suitable for analysis of the primary endpoint in the Study Cohort.
62203889|NCT03752970|PLACEBO_COMPARATOR|Study Cohort - Placebo|Patients with perianal fistulising Crohn's disease received Placebo intravenously every 4 weeks (week 0, 4, 8). At week 12 achievement of combined perianal fistula remission was determined, patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20). Patients with combined perianal fistula remission remained on Placebo and were treated with placebo intravenously every 4 weeks (week 12, 16 and 20).
62203890|NCT03752970|EXPERIMENTAL|Study Cohort - Spesolimab|Patients with perianal fistulising Crohn's disease received Spesolimab 1200 milligram intravenously every 4 weeks (week 0, 4, 8, 12, 16 and 20). At week 12 Placebo patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20).
62203891|NCT04362943||Complete sample|"Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 in the Perpetuo Socorro Hospital of Albacete (Spain)"
62203892|NCT04362943||Baricitinib|Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 and receiving Baricitinib.
62403842|NCT02430168|ACTIVE_COMPARATOR|RIRS|Retrograde intrarenal surgery
62403843|NCT02430168|ACTIVE_COMPARATOR|PCNL|Percutaneous nephrolithotomy
62203893|NCT04362943||Anakinra|Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 and receiving Anakinra.
62203894|NCT03202953|EXPERIMENTAL|1:1 I:E ratio VCV (Group I)|volume controlled ventilation with 1:1 inspiratory to expiratory ratio After trendelenburg position, Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:1, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used.
62203895|NCT03202953|ACTIVE_COMPARATOR|autoflow VCV (Group A)|autoflow volume-controlled ventilation After trendelenburg position, Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:2, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used.
62203896|NCT02137317|EXPERIMENTAL|LAPPE/DP|In the LAPPE experiment the farmer will work as usual (mixing/loading/application/cleaning). wearing the LAPPE solution and carrying a new hand pressured backpack sprayer with a standardized nozzle. Conditions such as dosage, work practices and weather conditions will remain uncontrolled but be observed. After one week this process will be repeated wearing the DP solution.
62203897|NCT02137317|ACTIVE_COMPARATOR|DP/LAPPE|In the DP experiment the farmer will work as usual (mixing/loading/application/cleaning) wearing the DP solution and carrying his usual backpack sprayer with his usual nozzle. Conditions such as dosage, work practices and weather conditions will remain uncontrolled but be observed. After one week this process will be repeated wearing the LAPPE solution.
62203898|NCT06186297|EXPERIMENTAL|Cranberry extract|
62203899|NCT06186297|ACTIVE_COMPARATOR|Baseline|
62203900|NCT04295967||1|presence of recurrence of urothelial carcinoma
62203901|NCT04295967||2|absence of recurrence of urothelial carcinoma
62203902|NCT03330626|ACTIVE_COMPARATOR|IO group|Fluid overload will be removed in the patients who received continuous renal replacement therapy, but the amount of fluid removal are guided by the intake-output balance.
62403844|NCT04066842||1 - Controls|Control Healthy controls
62403845|NCT04066842||2 - SSc|SSc Systemic Sclerosis
62403846|NCT04066842||3 - Cardiovascular|Cardiovascular Cardiovascular disease
62403847|NCT04066842||4 - SSc+Periodontitis|SSc+ Periodontitis Systemic Sclerosis with Periodontitis
62403848|NCT06214429||Carotid Atherosclerotic Plaque Stenosis >50%|Main cohort, composed by subjects with carotid stenosis above 50% confirmed by at least methods (eg. Doppler ultrasound peak systolic velocity \> 140cm/s and MRI residual lumen measurement).
62403849|NCT02687815|EXPERIMENTAL|vitamin D3|Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily
62403850|NCT02687815|PLACEBO_COMPARATOR|placebo|placebo formulations will be in gel cap form and identical to the active drug
62014923|NCT06573892|PLACEBO_COMPARATOR|Placebo. Heart Failure|"The patient sample will be divided into three main groups based on clinical phenotypes determined by echocardiographic examination:~HF with preserved ejection fraction (EF) (EF \> 50%) HF with mildly reduced EF (EF 49-40%) HF with reduced EF (EF \< 40%) 30 patients in each group"
62014924|NCT01455883|EXPERIMENTAL|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
62014925|NCT01455883|ACTIVE_COMPARATOR|glimepiride|glimepiride up-titrated to 8 mg/day over first 13 weeks
62014926|NCT06422988||Exposed to probiotics|"Receipt of any probiotic in the first 14 days of life. Probiotics to include: Labinic, Proprems probiotic, Acidophillus, Bifidobacterium, Bio-kult, Infloran, LB2.~To address potential recording error, infants whose NNRD records show minimal (one day) of probiotic exposure will only be classed as exposed if they are cared for in a probiotic unit. Probiotic units are defined as:~* units who have confirmed that a guideline was in place to provide probiotics to infants born before 32 weeks gestation and that the guideline was in place at any point in the year that the infant was born OR~* units where more than 50% of the infants eligible to be part of the cohort received probiotics in the six months after the infant was born."
62014927|NCT06422988||No probiotic exposure|Did not receive any probiotic in the first 14 days of life.
62014928|NCT00335244|EXPERIMENTAL|1|Intravenous L-citrulline
62014929|NCT00335244|PLACEBO_COMPARATOR|2|Placebo of intravenous L-citrulline
62014930|NCT02443298|EXPERIMENTAL|Risankizumab|Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20).
62014931|NCT02443298|PLACEBO_COMPARATOR|Placebo|Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20).
62014932|NCT04262258|EXPERIMENTAL|Blueberry Enriched Diet|The blueberry intervention will consist of participants ingesting two servings of 19 g freeze dried blueberry powder (equivalent to 250 g whole blueberries) daily for six weeks. Subjects will ingest the freeze dried blueberries orally. Freeze dried blueberry powder will be mixed with 8-10 ounces of water and consumed. Subjects will be asked to rinse the cup to wash any remaining blueberries off of the cup and consume the rinse water. Subjects will be given a two week supply at baseline (week 0) and a four week supply when they return for their blood draw at week 2. Subjects will be asked to return empty packets and check-off daily records as a measure of compliance.
62014933|NCT01842009|EXPERIMENTAL|Active anodal HD-tDCS|Subjects will undergo 20 minutes active HD-tDCS.
62014934|NCT06161363||The Morisky Medication Adherence Scale (MMAS-8)|The Morisky Medication Adherence Scale completed by the patients
62014935|NCT02774109|EXPERIMENTAL|Experimental group|Participants in the experimental group will take fish oil (five 1000mg fish oil soft capsules per day, each capsule containing 350mg EPA and 250mg DHA) and receive physical modality treatment (hotpacking 15min and transcutaneous electrical nerve stimulation (TENS) 15min, three times a week) for 8 weeks
62014936|NCT02774109|PLACEBO_COMPARATOR|Control group|Participants in the control group will take placebo (five 1000mg sunflower oil soft capsules per day) and receive physical modality treatment (hotpacking 15min and transcutaneous electrical nerve stimulation (TENS) 15min, three times a week) for 8 weeks
62014937|NCT05063097||CCU patients|All consecutive patients over 18 years admitted to the CCU.
62014938|NCT02879461|ACTIVE_COMPARATOR|Lumbar Decompression plus Physical Therapy|First group will be submitted to lumbar decompression L3 to S1 and physical therapy with exercise Application of questionnaires Oswestry Rolland moris Sf 36 Of 6minutos walk test Likert scale Use of paracetamol
62014939|NCT02879461|ACTIVE_COMPARATOR|Physical Therapy|Second group physical therapy alone, with exercises Application of questionnaires Oswestry Rolland moris Sf 36 Of 6minutos walk test Likert scale Use of paracetamol
62403851|NCT01680757|EXPERIMENTAL|LAA exclusion with LARIAT & Accessories|Permanent exclusion of the LAA using the LARIAT Suture Delivery Device and Accessories
62403852|NCT06509217|EXPERIMENTAL|Moderate-intensity Group|Participants performed water aerobics at moderate intensities. Water aerobics classes lasted approximately 45 minutes and were held twice a week for 12 weeks
62403853|NCT06509217|EXPERIMENTAL|High-intensity Group|Participants performed water aerobics at high intensities. Water aerobics classes lasted approximately 45 minutes and were held twice a week for 12 weeks
62403854|NCT05327517|EXPERIMENTAL|Surgery|Patients receive esophagectomy or neoadjuvant therapy plus esophagectomy
62403855|NCT05327517|ACTIVE_COMPARATOR|Definitive chemoradiotherapy|Patients receive definitive chemoradiotherapy
62014940|NCT03678181|ACTIVE_COMPARATOR|Information-Only Arm|The HMP 2.0 Information-Only Control Arm will feature a streamlined version of the website that provides tailored information and content for YBLMT. This follows the design of HMP 1.0 where control arm participants had access to HIV-related Knowledge Center articles of the main intervention without access to the engagement features, interactive forums, or doctor Q\&A. HIV-negative and sero-unknown participants also will be able to request HIV home test kits. The choice of control arm balances equipoise with research study design; in HMP 1.0, control arm participants also experienced a statistically significant intervention benefit.
62014941|NCT03678181|EXPERIMENTAL|HMP 2.0 Arm|Participants in this experimental arm will receive access to HMP 2.0, an interactive site that includes a Knowledge Center focused on HIV prevention content, interactive forums, and a provider question \& answer platform.
62580126|NCT00542399|EXPERIMENTAL|1|once a day
62580127|NCT00542399|EXPERIMENTAL|2|twice a day
62787073|NCT02681289|EXPERIMENTAL|family group|Early goal directed neuromotor therapy applied by family
62580128|NCT02547142|EXPERIMENTAL|Early Palliative Care Group|This is the intervention group and will consist of patients that have been randomized into the early palliative group, with a consultation expected to take place within one week of randomization. Patients in this group will still receive appropriate guideline based oncologic care including any surgical, brachytherapy, chemotherapy or radiotherapy services, along with palliative services.
62787074|NCT06154356|EXPERIMENTAL|Action observation and motor imagery therapy for rehabilitation|Action observation and motor imagery therapy for rehabilitation in Parkinson's Disease in addition to conventional rehabilitation programs.
62787075|NCT06154356|SHAM_COMPARATOR|Sham action observation and motor imagery therapy for rehabilitation|Sham comparator for action observation and motor imagery therapy for rehabilitation in Parkinson's Disease in addition to conventional rehabilitation programs.
62787076|NCT06574516|EXPERIMENTAL|Study group 1 (bimodal)|participants were given Ibuprofen and Paracetamol alternately every 8 hours for 3 days,
62787077|NCT06574516|EXPERIMENTAL|study group 2|Participants were given Ibuprofen three times daily for 3 days
62787078|NCT06574516|ACTIVE_COMPARATOR|Control group|Paracetamol PRN based on parental assessment of pain
62787079|NCT03680183||Pre-exposure|Entecavir 1Mg Oral Tablet
62787080|NCT03680183||Post-exposure|Entecavir 1Mg Oral Tablet
62787081|NCT01939327|EXPERIMENTAL|Lenalidomide/Rituximab|Association of Lenalidomide and Rituximab
62787082|NCT06115590|NO_INTERVENTION|Low Stress|Reference Group
62787083|NCT06115590|NO_INTERVENTION|Elevated Stress|Half of the Participants(n=40) with elevated stress (PSS score \>13) will be randomly assigned to this group
62014942|NCT03678181|EXPERIMENTAL|Peer-referred HMP network arm|Participants randomized to Intervention Arm 2 (peer-created network) will be enrolled into a parallel (but separate) version of HMP 2.0. The only difference between the two intervention arms is that the peer-referred HMP network arm will allow participants to refer and enroll 2 peers of their choosing into the study.
62580129|NCT00864019|EXPERIMENTAL|A|Sertraline HCl 100 mg tablets, single dose
62203903|NCT03330626|EXPERIMENTAL|InBody group|Fluid overload will be removed in the patients who received continuous renal replacement therapy, but the amount of fluid removal are guided by the bioimpedance analysis (InBody S10).
62580130|NCT00864019|ACTIVE_COMPARATOR|B|Zoloft® 100 mg tablets, single dose
62787084|NCT06115590|EXPERIMENTAL|Elevated Stress intervention|Half of the Participants(n=40) with High stress (PSS score \>13) will be randomly assigned to this group
62787085|NCT01847040||TBI while Deployed|Active duty service members returning from Afghanistan or Iraq who were screened positive for Mild TBI
62787086|NCT01847040||No TBI while Deployed|Active duty service members returning from Afghanistan or Iraq who screened negative for mild TBI.
62787087|NCT02621294|EXPERIMENTAL|Measuring protein requirement|Measuring protein requirement of athletes by feeding different amount of protein in the form of amino acid mixture and measuring their oxidation through expired CO2
62787088|NCT00258817|EXPERIMENTAL|Influenza Virus Vaccine Naïve|Subjects have never received Influenza virus vaccine in the past
62787089|NCT00258817|EXPERIMENTAL|Influenza Virus Vaccine-primed|Subjects have received Influenza virus vaccine in the past
62787090|NCT00787189|ACTIVE_COMPARATOR|The Hearing Laser|Active low level laser light therapy of 635 nanometers (nm)
62787091|NCT00787189|PLACEBO_COMPARATOR|Placebo Laser|inactive low level laser light therapy with no therapeutic output
62787092|NCT02881762|ACTIVE_COMPARATOR|Immediate start maraviroc|To start maraviroc immediately after randomization.
62787093|NCT02881762|ACTIVE_COMPARATOR|Delayed start maraviroc|To start maraviroc 8 weeks after enrollment.
62787094|NCT01435629||Norditropin®|
62787095|NCT02234804|EXPERIMENTAL|Medtronic Resolute Integrity stent|Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium
62787096|NCT02234804|EXPERIMENTAL|OCT|OCT to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.
62787097|NCT02234804|ACTIVE_COMPARATOR|Angiography|Angiography to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.
62787098|NCT02234804|ACTIVE_COMPARATOR|Xience Prime stent|Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium
62787099|NCT03061929||Undernourised|Mother's with BMI less than 18.5
62787100|NCT03061929||Normally Nourished|Mother's with BMI greater than or equal to 18.5 to less than or equal to 25.
62787101|NCT03061929||Overnourished|Mother's with BMI over 25 to less than or equal to 35.
62014943|NCT05544877|EXPERIMENTAL|Brain2Business (B2B)|"The Brain2Business (B2B) technique aims to improve creative thinking. It is a game-based conceptual combination method that is performed by the participant with support of one trained B2B administrator in a laboratory session and without support in 5 at-home sessions. In this technique, thirty-six different images are randomly selected on a board by throwing two dices. Inspired by these images, participants are asked to create new ideas regarding three questions for a total of at least 39 minutes over a period of 5 days. One question is from a standardized creativity test and two questions are part of psychotherapeutic techniques (idea generation for pleasurable activities within behavioral activation (PA-BA) and for a gratefulness exercise (GE)). The B2B technique is based on the principles of solo brainstorming (SBS). A trained B2B administrator is documenting the answers of the participant, and mentioning the principles of SBS (see SBS group)."
62014944|NCT05544877|ACTIVE_COMPARATOR|Solo Brainstorming (SBS)|Solo brain storming (SBS) is the active control condition. The technique aims to improve creative thinking through the principles of SBS. SBS principles include i) idea quantity goes before quality, ii) no criticism and evaluation of ideas during idea generation, iii) original ideas are encouraged. The principles are provided to participants in the same way, with the same questions to be answered, and over the same time period as in the B2B group. A trained SBS administrator is documenting the answers of the participant, and mentioning the principles of SBS.
62014945|NCT01959581|OTHER|Movement enhancing device|Guided play while wearing a movement assisting device
62014946|NCT00685815|EXPERIMENTAL|24 participants|Intravenous Iron (FCM)
62014947|NCT00685815|PLACEBO_COMPARATOR|12 participants|Placebo
62014948|NCT01736852|EXPERIMENTAL|CRB plus Pitocin|
62014949|NCT01736852|ACTIVE_COMPARATOR|Pitocin|
62014950|NCT01336127|EXPERIMENTAL|occupational therapy|10 weeks occupational therapy according to a protocol (OTiP protocol) based on the Dutch guidelines of occupational therapy in Parkinson's disease
62014951|NCT01336127|NO_INTERVENTION|No occupational therapy|Patients and their caregivers in the control group will have no occupational therapy intervention until their last measurement has taken place (6 months).
62014952|NCT02732847|OTHER|Post-Dated Prescription|a delayed prescription dated 2 days after clinical office visit
62014953|NCT02732847|OTHER|Usual|usual date
62014954|NCT03028376||Moderate TBI patients|GCS 9-13
62014955|NCT04352933|ACTIVE_COMPARATOR|Hydroxychloroquine - Daily dosing|"Hydroxychloroquine Daily (loading phase: 800mg for first 2 days; maintenance phase: 1 x 200mg tablet every day) + weekly placebo, for approximately 90 days.~Route: Oral. Pharmaceutical form: Tablet"
62014956|NCT04352933|ACTIVE_COMPARATOR|Hydroxychloroquine - Weekly dosing|"Hydroxychloroquine weekly (loading phase: 800mg for first 2 days; maintenance phase: 2 x 200mg tablets every 7th day/weekly) + daily placebo, for approximately 90 days.~Route: Oral. Pharmaceutical form: Tablet"
62014957|NCT04352933|PLACEBO_COMPARATOR|Placebo|"Placebo arm - 2 tablets twice daily for first 2 days (loading phase), followed by 1 tablet every day for 90 days plus 2 tablets every 7th day, for approximately 90 days.~Route: Oral. Pharmaceutical form: Tablet"
62014958|NCT00023673|EXPERIMENTAL|Phase I: 75.25 Gy/36 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 75.25 Gy given in 36 fractions (2.15 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
62014959|NCT00023673|EXPERIMENTAL|Phase I: 74 Gy/37 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 74 Gy given in 37 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
62014960|NCT00023673|EXPERIMENTAL|Phase I: 70 Gy/35 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 70 Gy given in 35 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
62014961|NCT00023673|EXPERIMENTAL|Phase II: 74 Gy/37 fx + chemotherapy|Phase II: Three-dimensional conformal radiation therapy (3DRT) of 74 Gy given in 37 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
62014962|NCT06213597|EXPERIMENTAL|repetitive transcranial magnetic stimulation group|Randomization was performed by a staff member of our hospital, who was not involved in the implementation or evaluation of the trial, and who randomly assigned subjects to either the rTMS group or the sham rTMS group in a 1:1 ratio through the use of an electronic random sequence generator. Opaque, sealed envelopes were used to mask the randomization tables.
62403856|NCT02316574|EXPERIMENTAL|Cognitive Behavioral Coping Skills|Cognitive Behavioral Coping Skills Therapy is an individual psychotherapy for alcohol use disorders that has been previously shown to reduce drinking. The focus of this treatment is the teaching of coping skills for managing alcohol craving and negative emotions as a way to reduce drinking behavior.
62787102|NCT04616222||CELSIOR® group|Patient who received Celsior® during their transposition of the great vessels surgery
62014963|NCT06213597|SHAM_COMPARATOR|sham repetitive transcranial magnetic stimulation|Randomization was performed by a staff member of our hospital, who was not involved in the implementation or evaluation of the trial, and who randomly assigned subjects to either the rTMS group or the sham rTMS group in a 1:1 ratio through the use of an electronic random sequence generator. Opaque, sealed envelopes were used to mask the randomization tables.
62014964|NCT03327480|EXPERIMENTAL|neoprene CMC orthosis|We will prescribe a neopren CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2
62580131|NCT06490536|ACTIVE_COMPARATOR|Trial-1 (ctDNA+) Strata-1 (MSS/MMRp extendend RAS/RAFmut) Standard Therapy|CAPOX/FOLFOX for 6 months or until toxicity
62787103|NCT04616222||Saint-Thomas group|Patient who received Saint-Thomas during their transposition of the great vessels surgery
62787104|NCT04996485|EXPERIMENTAL|Experimental group №1 (Secukinumab )|Secukinumab - subcutaneous injections into the shoulder according to the schedule of 0,1,2,3 weeks, then injections 1 time in 3 months up to 52 weeks of therapy.
62203904|NCT06003322|EXPERIMENTAL|non - Incised Papilla surgical approach NIPSA for intrabony defect|Group I will be allocated to non - Incised Papilla surgical approach NIPSA for intrabony defect with DBBM and PRF
62203905|NCT06003322|ACTIVE_COMPARATOR|single-flap approach|group II will be allocated to single-flap approach SFA for intrabony defect with DBBM and PRF
62203906|NCT04680195|EXPERIMENTAL|Thalidomide treatment Group|"Induction period:~Thalidomide tablets: 50-100 mg/d, qn, po.~Maintenance period:~Thalidomide tablets: 50-75 mg/d qn, po."
62203907|NCT05294653||Type 1 Diabetes|Classified according to American Diabetes Association \[ADA\] 2021 guidelines
62203908|NCT05294653||Type 2 Diabetes|Classified according to American Diabetes Association \[ADA\] 2021 guidelines
62203909|NCT01431495|ACTIVE_COMPARATOR|plavix|patient treated by the princeps
62203910|NCT01431495|ACTIVE_COMPARATOR|Pidogrel|patient treated by Pidogrel
62203911|NCT04809324|EXPERIMENTAL|Gross examination|measurement of the surgical margins will be done by the surgeon in the operating room using sterile scale after resection of the primary tumor .
62203912|NCT04809324|ACTIVE_COMPARATOR|Frozen section|frozen section examination of surgical margins will be done by the pathologist.
62203913|NCT06116747|NO_INTERVENTION|No intervention Group|Group receiving care as usual
62203914|NCT06116747|EXPERIMENTAL|Intervention Group|Complex Intervention under development in collaboration with fathers' health care professionals in primary and secondary sectors.
62203915|NCT06336018|EXPERIMENTAL|Mild hepatic impairment: Etavopivat dose 2|Participants will receive a single dose of oral etavopivat.
62203916|NCT06336018|EXPERIMENTAL|Moderate hepatic impairment: Etavopivat dose 2|Participants will receive a single dose of oral etavopivat.
62203917|NCT06336018|EXPERIMENTAL|Healthy matched controls: Etavopivat dose 2|Participants will receive a single dose of oral etavopivat.
62203918|NCT06336018|EXPERIMENTAL|Severe hepatic impairment: Etavopivat dose 1|Participants will receive a single dose of oral etavopivat.
62203919|NCT06336018|EXPERIMENTAL|Healthy matched controls: Etavopivat dose 1|Participants will receive a single dose of oral etavopivat.
62203920|NCT01217177|EXPERIMENTAL|2.5 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (2.5mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
62203921|NCT01217177|EXPERIMENTAL|5.0 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (5.0mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
62203922|NCT01217177|EXPERIMENTAL|10 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (10mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
62203923|NCT03535831|EXPERIMENTAL|18F-DCFPyL PET/ MR or PET/CT imaging|"Will use a newer technology called PET-MR that combines a Positron Emission Tomography (PET) scan with Magnetic Resonance Imaging (MRI) scan. This new combined imaging test, where PET and MRI data is gathered at one time, will be performed on an integrated PET-MR scanner located at Toronto General Hospital.~Or technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data is gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.~Choice of imaging method (PET/CT or PET/MR) will be made by one of the study PIs, based on clinical judgement taking into account the specific exam indication, prior recent imaging, and suitability for MR imaging."
62203924|NCT01609426||children with idiopathic nephrotic syndrome|children below 16 years of age with a steroid dependent nephrotic syndrome
62203925|NCT02234505|EXPERIMENTAL|Trans-tibial prosthesis users|prosthetic alignment perturbation
62203926|NCT01498887|EXPERIMENTAL|Naive or de novo participants|Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.
62203927|NCT01498887|EXPERIMENTAL|Previously treated with first-line DMTs participants|Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.
62203928|NCT06341777|EXPERIMENTAL|Immediate Intervention (IM group)|HVDFs patients who start the audio-visual telerehabilitation immediately
62403857|NCT00564382|OTHER|1|Patients with ACS in the emergency department and primary tests (ECG, TNT) negative for myocardial ischemia
62403858|NCT01778296|EXPERIMENTAL|Surgical flap|The neurocutaneous island flap is based on the dorsal branch of the digital nerve
62403859|NCT03998696|ACTIVE_COMPARATOR|Weekly Cisplatin|Inj. Cisplatin 40 mg /m2 intravenous infusion delivered concurrently with radiotherapy on a weekly basis.
62580132|NCT06490536|EXPERIMENTAL|Trial-1 (ctDNA+) Strata-1 (MSS/MMRp extendend RAS/RAFmut) Tailored Therapy|CAPOX for 3 months with an interventional liquid biopsy at the end of the treatment. Patients still resulting ctDNA+ will be switched to a tailored therapy (FOLFIRI for RAS/RAF-mutated and MGMT-positive tumors or TEMIRI for RAS/RAF-mutated and MGMT-negative tumors) for 6 months or until toxicity. On the other hand, ctDNA- patients will continue CAPOX up to 3 months, and their ctDNA status will be re-assessed at the end of the treatment. Patients remaining ctDNA- will enter into follow-up, while patients resulting ctDNA+ will be switched to the tailored therapy.
62787105|NCT04996485|EXPERIMENTAL|Experimental group №2 (Ustekinumab)|Ustekinumab - subcutaneous injections in the shoulder on schedule 0; 1 month, then every 2 months up to 52 weeks of therapy.
62014965|NCT03327480|EXPERIMENTAL|thermoplastic CMC orthosis|We will prescribe a neoprene CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2
62203929|NCT06341777|EXPERIMENTAL|WaitList Delayed Intervention (WL group)|HVDFs patients waiting 1 month before receiving the audio-visual telerehabilitation.
62203930|NCT06341777|NO_INTERVENTION|Healthy Participants|A group of 12 healthy participants is recruited for comparisons of MRI-based connectivity metrics
62203931|NCT06415110||Allosync Expand|All enrolled patients will received Allosync Expand at 1-3 contiguous levels (L1-S1).
62203932|NCT02576119|EXPERIMENTAL|Part 1: Sentinal Cohorts|Study is in 2 sequential cohorts (BMS-955176 or placebo) each to evaluate the safety, tolerability, and PK following multiple-dose administration of BMS-955176.
62203933|NCT02576119|EXPERIMENTAL|Part 2: Main QTc Study|3 period nested crossover study.
62203934|NCT03766477||Individuals with sleep bruxism|"Individuals with sleep bruxism evaluated in three different methods regarding their sleep quality:~* Pittsburgh Sleep Quality Index (IQSP) and Johansson~* Smartphone APP~* Polysomnography"
62203935|NCT02957032|EXPERIMENTAL|F16IL2 + cytarabine|Patients will be enrolled sequentially in cohorts and treated at different dose levels of F16IL2 and a fixed dose of cytarabine.
62203936|NCT04292704|EXPERIMENTAL|Laser group|Fractional CO2 laser therapy in consolidation treatment once a month for 3 months and treatment was prohibited during menstrual period.
62203937|NCT04292704|OTHER|Clotrimazole group|Clotrimazole tablets 500mg PV biw q3d in consolidation treatment once a month for 6 months and treatment was prohibited during the menstrual period.
62203938|NCT05332964||stroke (right)|stroke patient with lesions at right hemisphere
62203939|NCT05332964||stroke (left)|stroke patient with lesions at left hemisphere
62403860|NCT03998696|EXPERIMENTAL|Three weekly Cisplatin|Inj. Cisplatin 100 mg/m2 intravenous infusion delivered on a three weekly basis on days 1, 22 and 43 delivered concurrently with radiotherapy.
62403861|NCT01005186|EXPERIMENTAL|Active|Active
62403862|NCT01005186|EXPERIMENTAL|Active 2|Active
62787106|NCT04996485|EXPERIMENTAL|Experimental group №3 (Dupilumab)|"Dupilumab - subcutaneous injections in the shoulder:~for patients weighing from 15 to \<30 kg: initial dose - 600 mg (2 injections of 300 mg), then 300 mg every 4 weeks; for patients weighing from 30 to \<60 kg: initial dose - 400 mg (2 injections of 200 mg), then 200 mg every 2 weeks; for patients weighing 60 kg or more: the initial dose is 600 mg (2 injections of 300 mg), then 300 mg every 2 weeks."
62787107|NCT04996485|ACTIVE_COMPARATOR|Control group (Symptomatic therapy)|symptomatic therapy with emollients + systemic retinoids
62787108|NCT05897892|EXPERIMENTAL|Treatment Group|Treatment group received 50 g mangrove sword bean food bar each day during 15 days.
62403863|NCT04612465|EXPERIMENTAL|ASC (test arm)|(Autologous Adipose-derived Mesenchymal Stem Cells)
62787109|NCT05897892|PLACEBO_COMPARATOR|Control Group|Control group received 50 g sword bean food bar per day during 15 days.
62787110|NCT00406679|EXPERIMENTAL|1|
62787111|NCT00406679|PLACEBO_COMPARATOR|2|
62014966|NCT03732248|ACTIVE_COMPARATOR|Rapamycin (sirolimus) 15mg|Rapamycin (sirolimus) is administered in three 5mg oral capsules. This administration happens once during the first visit.
62203940|NCT05332964||control|age-matched group for the stroke patients
62203941|NCT02092597|ACTIVE_COMPARATOR|GLP-1 agonist|Exenatide 5 ug s.c. bid for the 1st month, 10 ug s.c. bid for the next 2 months
62203942|NCT02092597|ACTIVE_COMPARATOR|DPP-4 inhibitor|Linagliptin 5 mg tbl qd for 3 months
62203943|NCT02092597|ACTIVE_COMPARATOR|Sulfonylurea derivate|Gliclazid 30 mg tbl qd for 3 months
62403864|NCT04612465|PLACEBO_COMPARATOR|Fibringlue|Standard comparator
62580133|NCT06490536|ACTIVE_COMPARATOR|Trial-1 (ctDNA+) Strata-2 (MSI-H/MMRd & MSS/MMRp extended RAS/RAFwt) Standard Therapy|CAPOX/FOLFOX for 6 months or until toxicity
62787112|NCT00406679|ACTIVE_COMPARATOR|3|
62787113|NCT05325021||Axial myopia|children have anisometropia due to axial myopia, axial length will be measured by optical biometry device in millimeter (mm).
62787114|NCT05325021||Refractive myopia|children have anisometropia due to refractive myopia, axial length will be measured by optical biometry device in mm.
62787115|NCT05325021||Axial hyperopia|children have anisometropia due to axial hyperopia, axial length will be measured by optical biometry device in mm.
62014967|NCT03732248|PLACEBO_COMPARATOR|Placebo|Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
62014968|NCT02760394|ACTIVE_COMPARATOR|Treated group|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
62203944|NCT04776642||MARK_AF|MARKers of ATrial Remodeling in Patietns with Atrial Fibrillation. Patients with paroxysmal and persistent atrial fibrillation undergoing thoracoscopic atrial fibrillation ablation surgery
62203945|NCT04776642||INDICO AF|Atrial Fibrillation in Patients With an Implantable Cardioverter Defibrillator and Coronary Artery Disease. Investigate the incidence of new-onset AF in patients with coronairy artery disease and an impaired LVEF, who will receive a single chamber ICD as primary prevention for sudden cardiac death.
62203946|NCT04776642||PREDICT AF|PREDICT AF, Tissue, Blood and biomarkers to predict future Atrial Fibrillation. Patients without a history of atrial fibrillation undergoing cardiothoracic surgery
62203947|NCT04776642||WEIGHTLOSS AF|The change of adipose tissue characteristics upon drastic weight loss: Implications for atrial fibrillation.
62203948|NCT04776642||MAD AF|(123I-mIBG And Defibrillation for Atrial Fibrillation) Enhanced sympathetic activity as a mechanism of Atrial Fibrillation. Patients will undergo 123I-mIBG scintigraphy within 7 days before and six week after an elective cardioversion is performed.
62203949|NCT04776642||Adapt Biobank - AF surgery|Patients with Atrial Fibrillation who only donate blood and tissue for the biobank. Patients undergo thorascopic surgery, LAA will be amputated, blood will be collected.
62787116|NCT05325021||Refractive hyperopia|children have anisometropia due to refractive hyperopia, axial length will be measured by optical biometry device in mm.
62787117|NCT00543387|EXPERIMENTAL|MK-5108 200 mg BID (Panel 1)|Participants receive 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
62014969|NCT02760394|OTHER|Control group|Following 2 months of follow up the group will be crossed over to receive the same treatment as the treated group
62734836|NCT04852055|EXPERIMENTAL|Information|Patients and proxies in assisted living centers randomized to the information arm will receive a letter from their clinician with a link to an educational video describing the goals of care and how specific treatment decisions align with these goals. Patients and proxies will also continue to receive usual care advance care planning conversations.
62014970|NCT00807781|EXPERIMENTAL|Mammaglobin-A DNA vaccine|"Patients will receive vaccine day 1 (week 1), week 4 (day 29 +/- 7), week 8 (day 57 +/- 7) with at least 21 days between injection days.~All injections will be given intramuscularly using a jet delivery device.~Patients will be administered the vaccine in lateral shoulder and buttocks positions that will be rotated with each administration in the above order."
62014971|NCT02770391|EXPERIMENTAL|Apalutamide + Leuprolide Acetate|All participating patients will receive a single dose of leuprolide 7.5 mg intramuscularly (IM) in addition to Apalutamide 240 mg orally daily for four weeks prior to radical prostatectomy (RP). Treatment will be started on day (-28) ± 3 from the scheduled RP date to minimize the variability of treatment duration. Apalutamide may be continued up to and including the day before
62014972|NCT06211582|EXPERIMENTAL|Cention N (Ivoclar Vivadent, Schaan, Liechtenstein)|Powder: Calcium-fluoro-silicate glass, barium glass, calcium-barium-aluminium fluoro-silicate glass, iso-fillers, ytterbium trifluoride, initiators and pigments. Liquid: Dimethacrylates, initiators, stabilizers, additives and mint flavour. The mixing ratio was 2 parts powder and 2 drops of liquid or 3 parts powder and 3 drops.After distributing the powder and liquid side by side on a mixing pad, the liquid was spread to expand the surface.The first part of the powder was mixed with the entire liquid dispensed on the mixing pad.After the components have been thoroughly mixed, add the remaining powder and stirred again until a homogeneous consistency is obtained (45 - 60 seconds). After careful adaptation to the cavity and densification, occlusal excesses were removed.
62014973|NCT06211582|EXPERIMENTAL|Equia Forte HT ( GC, Tokyo, Japan)|"Powder: 95% strontium fluoroalumino-silicate glass. Liquid: 5% polyacrilic acid.~Equia Forte HT was mixed in a capsule (10 seconds) and injected into the cavity. After a 2.5 min curing time, occlusal excesses were removed. Equia Coat (GC, Tokyo, Japan) was then applied and light-cured (D-Light Pro, GC, Tokyo, Japan 1,400 mW/cm2) for 20 seconds."
62787118|NCT00543387|EXPERIMENTAL|MK-5108 400 mg BID (Panel 1)|Participants receive 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
62203950|NCT04776642||Adapt Biobank - blood|Patients with cardiac arrhythmias who only donate blood for the ADAPT biobank.
62787119|NCT00543387|EXPERIMENTAL|MK-5108 800 mg BID (Panel 1)|Participants receive 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
62787120|NCT00543387|EXPERIMENTAL|MK-5108 1200 mg BID (Panel 1)|Participants receive 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
62014974|NCT06211582|EXPERIMENTAL|Gradia Direct Posterior ( GC, Tokyo, Japan)|"Matrix: Urethanedimethacrylate (UDMA), dymethacrylate camphorquinone. Filler: fluoro-alumino-silicate glass silica powder.~After completing the cavity, the enamel surface was selectively roughened using 37% orthophosphoric acid for 30 seconds. Subsequently, GC Solare Universal Bond adhesive agent (GC Corp., Tokyo, Japan) was utilized. It was applied in 2mm layers in accordance with the composite manufacturer's instructions. Each layer was polymerized for 20 seconds."
62014975|NCT01151553|OTHER|Patients with CHF with CRT Therapy|Patients with CHF with CRT Therapy
62203951|NCT04546425|EXPERIMENTAL|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
62203952|NCT04546425|ACTIVE_COMPARATOR|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
62203953|NCT04206202|EXPERIMENTAL|PSI group|3D-printed patient-specific instrumentation (PSI) will be used in the total knee arthroplasty (TKA) of this group.
62787121|NCT00543387|EXPERIMENTAL|MK-5108 1500 mg BID (Panel 1)|Participants receive 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
62787122|NCT00543387|EXPERIMENTAL|MK-5108 1800 mg BID (Panel 1)|Participants receive 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
62787123|NCT00543387|EXPERIMENTAL|MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.
62014976|NCT03832192|EXPERIMENTAL|care.coach Avatar|
62014977|NCT03832192|NO_INTERVENTION|Control|
62014978|NCT06573476|EXPERIMENTAL|Intervention Arm-1: PRC supported text+ AI driven CSDH-enhanced text|Individuals randomized to Arm-1 will receive PRC-supported text check-ins and AI-driven CSDH-enhanced text messaging.
62014979|NCT06573476|EXPERIMENTAL|Intervention Arm-2: AI driven CSDH-enhanced text only|Individuals randomized to Arm-2 will receive the AI-driven CSDH-enhanced text messaging only
62014980|NCT06573476|PLACEBO_COMPARATOR|Control Arm 3- Treatment as Usual|Individuals randomized to the control arm will receive treatment as usual.
62014981|NCT05663489||Patients with obsessive-compulsive, social anxiety or panic disorder|Patients with obsessive-compulsive disorder. The MRI substudy will also include patients with social anxiety or panic disorder
62014982|NCT05663489||For MRI substudy: Healthy controls|Healthy controls demographically matched to the patient group on age, sex and years of education
62014983|NCT05427110||asymptomatic|Runners without iliotibial band syndrome
62014984|NCT05427110||Iliotibial band syndrome|Runners with iliotibial band syndrome
62014985|NCT03985319|EXPERIMENTAL|YYD601 20mg|Esomeprazole IR 10mg + esomeprazole SR 10mg
62014986|NCT03985319|ACTIVE_COMPARATOR|Nexium tab 20mg|Esomeprazole magnesium trihydrate 22.3mg. Astrazeneca
62014987|NCT05508334|EXPERIMENTAL|Experimental: RC88|Subjects will receive intravenous infusion of RC88 once every 2 weeks in a dose escalation fashion until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs
62014988|NCT03705754|ACTIVE_COMPARATOR|Tattoo arm|Tattoo will be placed by endoscopic submucosal injection of carbon black suspension
62203954|NCT02893384|EXPERIMENTAL|Local Anesthetic Injection|"The intervention involves injection of local anesthetic (0.25% bupivacaine with 1:200,000 epinephrine) under direct vision in the serratus anterior muscle plane at the end of surgery.~Local Anesthetic Injection above the serratus anterior"
62203955|NCT02893384|NO_INTERVENTION|Control Arm|Retrospective control group who have not had the new injection technique.
62014989|NCT03705754|NO_INTERVENTION|Control arm|Tattoo will not be placed but case will follow standard procedure
62014990|NCT05169294|EXPERIMENTAL|Intervention|
62014991|NCT05169294|ACTIVE_COMPARATOR|Control|
62014992|NCT01544244|EXPERIMENTAL|GSC physcial therapy|Patients included in this arm of the study will follow the Global Shoulder Concept physical therapy sequence.
62014993|NCT01544244|ACTIVE_COMPARATOR|Standard|Patients in this arm of the study will follow the standard physical therapy sequence.
62203956|NCT06306170||Gynecologic cancer patients|Gynecologic cancer patients treated with IGRT, IMRT, SBRT (advanced radiotherapy-ART)
62203957|NCT00413205|PLACEBO_COMPARATOR|Placebo|po daily
62203958|NCT00413205|EXPERIMENTAL|RAR Gamma|5mg po daily
62014994|NCT05987891||Healthy controls|Volunteers will perform treadmill exercise tests. It will be monitored electrocardiogram, heart rate, and blood pressure in the rest state, under exercise, and in the recovery.
62014995|NCT01274637|EXPERIMENTAL|low molecular weight heparin|Prophylactic-dose (5000 IU/0.2ml)low molecular weight heparin (LMWH), administered subcutaneously once daily in pre-filled glass syringes for 10 days (+/- 3 days) for a total of 10 (+/-3) study drug injections.
62014996|NCT01274637|NO_INTERVENTION|Control Group|No treatment control group.
62014997|NCT04590391|OTHER|Visual and Auditory Breathing-swallowing Coordinated Training device|
62203959|NCT02378038|EXPERIMENTAL|PNT2258|PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle for 8 induction cycles followed by continuation phase therapy at a dose of 100 mg/m2 on days 1-4 of a 28-day cycle.
62203960|NCT01615289|ACTIVE_COMPARATOR|Green tea extract, 250 ml|Single intragastric instillation of 250 ml green tea extract
62203961|NCT01615289|ACTIVE_COMPARATOR|Green tea extract, 500 ml|Intragastric instillation of 500 ml green tea extract solution
62203962|NCT01615289|PLACEBO_COMPARATOR|Control solution, 250 ml|Intragastric instillation of 250 ml control solution
62203963|NCT01615289|PLACEBO_COMPARATOR|Control solution, 500 ml|Single intragastric instillation of 500 ml control solution
62014998|NCT04442516||Adults receiving Cisplatin as part of their cancer therapy|
62014999|NCT04442516||Children receiving Cisplatin as part of their cancer therapy|
62015000|NCT03351894|PLACEBO_COMPARATOR|Conventional|Conventional phacoemulsification surgery
62203964|NCT01538641|EXPERIMENTAL|1|
62203965|NCT02895204|EXPERIMENTAL|Test group (F-MRP)|Fermented Maillard reacted whey protein (F-MRP) supplementation
62015001|NCT03351894|ACTIVE_COMPARATOR|Femtosecond laser|Ziemer femtosecond laser assisted cataract surgery Intervention: Ziemer femtosecond laser assisted cataract surgery
62015002|NCT06383364|ACTIVE_COMPARATOR|Interventions group|The Medication Coordinator facilitates the medication reviews in close collaboration with the patients by applying concepts of motivational interview in combination with My Medication Plan
62203966|NCT02895204|PLACEBO_COMPARATOR|Placebo group|Placebo supplementation
62203967|NCT05337098|ACTIVE_COMPARATOR|Aspartame|Controlled feeding study. Dosage of aspartame will follow 50% of the acceptable daily intake (equivalent to 25 mg/kg for aspartame). This amount represents 1,500 mg/day of aspartame for a 60 kg adult.
62203968|NCT05337098|ACTIVE_COMPARATOR|Sucralose|Controlled feeding study. Dosage of sucralose will follow 50% of the acceptable daily intake (equivalent to 2.5 mg/kg for sucralose). This amount represents 150 mg/day of sucralose for a 60 kg adult.
62203969|NCT05337098|SHAM_COMPARATOR|No NNS|Controlled feeding study with no non-nutritive sweeteners.
62203970|NCT06142110|ACTIVE_COMPARATOR|Assessment of professional football player|Respiratory muscle strength and functional movement quality of professional football players were evaluated. Functional movement screen and portable spirometer were used for evaluation.
62203971|NCT06142110|ACTIVE_COMPARATOR|Assessment of sedantery individuals|Respiratory muscle strength and functional movement quality of sedantery individuals were evaluated. Functional movement screen and portable spirometer were used for evaluation.
62203972|NCT02088957|EXPERIMENTAL|Brivaracetam|"Subjects will receive an acute intravenous (iv) dose of Brivaracetam (BRV) 200 mg as a bolus on Day 1. If seizures recur, a second iv bolus of BRV 100 mg can be given no sooner than 15 minutes after the first bolus. If the second acute bolus is not needed within12 hours after first iv bolus, BRV will be continued as 100 mg iv dose every 12 hours (bid). The total dose for the first 24 hours of treatment should not exceed a maximum dose of 400 mg. The rate of bolus administration is 50 mg (5 mL) undiluted BRV/min. On study Day 5 (or earlier), subjects will transition from iv to oral formulation, at comparable dosing for a maximum of 6 months.~Subjects should transition to oral medication as soon as they are able to swallow tablets."
62203973|NCT02088957|ACTIVE_COMPARATOR|Phenytoin|"Subjects will receive an acute intravenous (iv) dose of Phenytoin (PHT) 20 mg/kg at a rate of 50 mg/min on Day 1. If seizures recur, a second acute dose of PHT iv will be given no sooner than 15 minutes after the first dose. Treatment with PHT iv will be continued with at least 2 daily divided doses according to site practice. Daily PHT dose can be adapted according to investigator's clinical judgment. On study Day 5 (or earlier), subjects will transition from iv to oral formulation at comparable dosing for a maximum of 6 months.~Subjects should transition to oral medication as soon as they are able to swallow tablets."
62203974|NCT01908504|OTHER|PET-CT|
62203975|NCT02795364|ACTIVE_COMPARATOR|Structural Image Guidance|In this arm, the patients will receive maximum resection of the tumor with the MRI T1W-enhanced image guidance, in addition to the standard therapy
62203976|NCT02795364|EXPERIMENTAL|Metabolic Image Guidance|In this arm, the patients will receive quantitative resection of the tumor with both the MRI T1W-enhanced and the MRS Cho-to-NAA index (CNI) image guidance, in addition to the standard therapy.
62203977|NCT01169922|EXPERIMENTAL|SEXUAL PLUS ALCOHOL RISK REDUCTION|Intervention contains information geared toward sexual risk reduction as well as alcohol risk reduction.
62203978|NCT01169922|ACTIVE_COMPARATOR|INFORMATION-ONLY SEXUAL RISK REDUCTION|Intervention contains information geared toward sexual risk reduction only.
62203979|NCT05679089||Cancer Arm|Participants with newly diagnosed intracranial malignant tumors, from whom blood samples will be collected.
62203980|NCT05679089||Benign Arm|Participants with newly diagnosed benign central nervous system disorders, from whom blood samples will be collected.
62203981|NCT05679089||Healthy arm|Participants without known presence of malignancies or certain benign diseases, from whom blood samples will be collected.
62203982|NCT00443924|PLACEBO_COMPARATOR|1|Arm 1
62203983|NCT00443924|EXPERIMENTAL|2|Arm 2
62203984|NCT00443924|EXPERIMENTAL|3|Arm 3
62203985|NCT00443924|EXPERIMENTAL|4|Arm 4
62403865|NCT02392377|EXPERIMENTAL|Arm I (paclitaxel, carboplatin, radiation therapy, surgery)|"INDUCTION: Patients receive chemotherapy with carboplatin and paclitaxel. Patients receive carboplatin (AUC=2) and paclitaxel (90 mg/m2) intravenously on days 1 and 8 of a 21 day treatment cycle for two cycles (total of 6 weeks).~CHEMORADIATION THERAPY: Patients receive carboplatin (AUC=2) and paclitaxel (50 mg/m2) intravenously once weekly for five weeks throughout the duration of their radiation which is daily (Monday through Friday).~SURGERY: Approximately 4-10 weeks after completion of chemoradiation therapy, patients undergo esophagectomy at the discretion of the treating team."
62580134|NCT06490536|EXPERIMENTAL|Trial-1 (ctDNA+) Strata-2 (MSI-H/MMRd & MSS/MMRp extended RAS/RAFwt) Tailored Therapy|Tailored therapy (nivolumab+ipilimumab for MSI-H/MMRd: MSI-H/MMRd tumors and MSS/MMRp tumors with POLE mutations and a high TMB or trastuzumab + pertuzumab for MSS/MMRp HER2-amplified tumors or panitumumab+folfox for MSS/MMRp RAS/RAF/HER2 wild-type) for 3 months, at the end, the ctDNA status of patients will be reassessed to further guide their subsequent treatments. Patients still ctDNA+ at will be switched to standard therapy. On the other hand, patients undergoing seroconversion will continue the same therapy for 3 further months and will be then re-assessed at the end of the treatment. Patients resulting ctDNA- will enter into Follow-up, while patients resulting ctDNA+ will be switched to the standard therapy.
62580135|NCT06490536|ACTIVE_COMPARATOR|Trial-2 (ctDNA-) Standard Therapy|Chemotherapy regimen at prior declared physician choice (CAPE/CAPOX/FOLFOX/5-FU±LV).
62580136|NCT06490536|NO_INTERVENTION|Trial-2 (ctDNA-) Intensive Follow-up|Intensive follow-up for 6 months (except for MSS Stage III High-risk patients which will be treated with CAPE).
62203986|NCT00443924|EXPERIMENTAL|5|Arm 5
62203987|NCT01124383|ACTIVE_COMPARATOR|General anesthesia|
62203988|NCT01124383|ACTIVE_COMPARATOR|Local anesthesia with sedation|
62580137|NCT05420363|EXPERIMENTAL|traditional physical therapy + gait training on different surfaces.|Children in study group will receive designed physical therapy program in addition to gait training on different surfaces.
62203989|NCT01282853|ACTIVE_COMPARATOR|A1|one biopsy specimen taken from gastric antrum was put into RUT kit
62203990|NCT01282853|EXPERIMENTAL|A4|4 biopsy specimens taken from gastric antrum were put into RUT kit
62203991|NCT01282853|EXPERIMENTAL|B1|one biopsy specimen taken from gastric body was put into RUT kit
62203992|NCT06104553|EXPERIMENTAL|SHR-A1912 combined with R-Chemo (Phase 1b)|
62203993|NCT06104553|EXPERIMENTAL|SHR-A1912 combined with R-Chemo (Phase 2)|
62203994|NCT00956176|EXPERIMENTAL|Cidofovir|
62203995|NCT04630704||Non vascular repeatibility|This cohort of patients with palpable pulses will be used to test inter- and intra- observer variability for the Pedra system
62203996|NCT04630704||Non vascular physiology|This cohort of patients with palpable pulses will assess the ability of Pedra to detect perfusion changes in response to physiologic stimuli.
62203997|NCT04630704||CLTI physiology|This cohort of patients with CLTI will assess the ability of Pedra to detect perfusion changes in response to physiologic stimuli.
62203998|NCT03076073|NO_INTERVENTION|Evaluating Tendons Structures|Ultrasound measurements of Patellar Tendon and Achilles Tendon Structures
62203999|NCT03076073|ACTIVE_COMPARATOR|Impact of physical activity on tendons|Ultrasound measurements of Patellar Tendon and Achilles Tendon Structures following different types and different intensity of physical activity
62204000|NCT05276908|EXPERIMENTAL|mTLIP10|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 20 ml 0.25%bupivacaine (10 ml on each side).
62015003|NCT06383364|NO_INTERVENTION|Control group|Usual treatment from a team consisting of hospital physicians, nurses, nurse assistants, and as needed occupational therapists, physiotherapist, and clinical dieticians. Medication reconciliation might be a part of the patients' usual care performed by physicians or pharmacologist present at the acute ward. Hospital physicians and/or nurses might perform patient counselling about medication treatment during hospitalization
62015004|NCT03991195|EXPERIMENTAL|Probiotic supplemented group with aMCI|Thirty participants in this group will take Bifidobacterium for three months.
62015005|NCT03991195|PLACEBO_COMPARATOR|Placebo group with aMCI|Thirty participants in this group will take placebo for three months.
62015006|NCT05067075|EXPERIMENTAL|Blinded CGM|Blinded continuous glucose monitor Dexcom G6Pro
62015007|NCT00857194||Group 2|Chronic, stable spinal cord injury
62015008|NCT04273464|EXPERIMENTAL|Brava-group|External tissue expanders will be used 3 weeks prior to operation and 2 weeks postoperatively in order to enhance the volume and survival of fat cells. We expect that each patient in the fat transplantation group will need 4-6 transplantation sessions of about 1.5 to 2 hours each to achieve satisfactory volume and shape of the breast.31 participants.
62015009|NCT04273464|ACTIVE_COMPARATOR|DIEP-group|26 participants. We expect 1-2 operative sessions of respectively 5-7 and 2-3 hours duration in the DIEP group. The risk of reoperation (second operation during the first postoperative week) in the DIEP group is 5-10 %
62015010|NCT05801978|EXPERIMENTAL|YF-17D Vaccination|Yellow Fever Vaccine (YF-17D) vaccination: Eligible participants will be asked to read the Vaccine Information Sheet for YF-17D per the Centers for Disease Control and Prevention (CDC) guidelines. Participants will then receive the YF-17D vaccine. They will be observed for a minimum of 20 minutes for any immediate hypersensitivity reactions. They will also be given the International Certificate of Vaccination documenting receipt of YF-17D.
62015011|NCT05801978|EXPERIMENTAL|QIV Vaccination|Quadrivalent seasonal influenza vaccine (QIV) vaccination: Eligible participants will be asked to read the Vaccine Information Sheet for QIV per the CDC guidelines. Participants will then receive QIV. They will be observed for a minimum of 20 minutes for any immediate hypersensitivity reactions.
62015012|NCT00927017|ACTIVE_COMPARATOR|Liquorice 66 g/day|Liquorice given 66 grams per day for two weeks
62015013|NCT00927017|ACTIVE_COMPARATOR|Liquorice 102 g/day|Liquorice given 102 grams per day for two weeks
62204001|NCT05276908|EXPERIMENTAL|mTLIP20|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 40 ml 0.25%bupivacaine (20 ml on each side).
62204002|NCT05758948||Patients diagnosed with de novo metastatic breast cancer|Blood and tissue sample from patients diagnosed with DN-MBC will be analyzed using next generation sequencing (NGS)
62403866|NCT02392377|EXPERIMENTAL|Arm II (combination chemotherapy, radiation therapy, surgery)|"INDUCTION: Patients receive mFOLFOX6 where they get oxaliplatin 85 mg/m2 intravenously on day 1, leucovorin 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV on day 1 and then 5FU at 2400 mg/m2 IV to be administered over a 46 hour period. This is repeated every 2 weeks for 3 cycles (total of 6 weeks).~CHEMORADIATION THERAPY: Patients receive oxaliplatin 85 mg/m2 IV on day 1 every 2 weeks for a total of 3 cycles (6 weeks) as well as 5FU 300 mg/m2/day over 96 hours via continuous infusion each week of radiation for a total of 6 weeks.~SURGERY: Approximately 4-10 weeks after completion of chemoradiation therapy, patients undergo esophagectomy at the discretion of the treating team."
62403867|NCT04903938||Criminal-Antisocial Personality Disorder|The study groups were determined as those with criminal antisocial personality disorder, those with non-criminal antisocial personality disorder and the control group. Those with antisocial personality disorder were divided into criminal and non-criminal groups according to their criminal records. The number of groups was determined as three with the control group.
62403868|NCT04903938||Non-criminal group|The study groups were determined as those with criminal antisocial personality disorder, those with non-criminal antisocial personality disorder and the control group. Those with antisocial personality disorder were divided into criminal and non-criminal groups according to their criminal records. The number of groups was determined as three with the control group.
62403869|NCT04903938||Control group|The study groups were determined as those with criminal antisocial personality disorder, those with non-criminal antisocial personality disorder and the control group. Those with antisocial personality disorder were divided into criminal and non-criminal groups according to their criminal records. The number of groups was determined as three with the control group.
62403870|NCT03619512||Richter Syndrom at diagnosis|patients diagnosed with Richter Syndrom, for whom a suitable lymph node biopsy at diagnosis is available.
62403871|NCT03619512||Primitive Diffuse Large B-Cell Lymphoma|patients diagnosed with a primitive Large B-Cell Lymphoma, for whom a suitable lymph node biopsy at diagnosis is available.
62403872|NCT03619512||Other secundary Diffuse Large B-Cell Lymphoma|patients diagnosed with a secundary Large B-Cell Lymphoma (different from Richter Syndrom), for whom a suitable lymph node biopsy at diagnosis is available.
62580138|NCT05420363|EXPERIMENTAL|traditional physical therapy + traditional gait training|-Children in control group will receive designed physical therapy program in addition to traditional gait training hard surface .
62015014|NCT05943301|EXPERIMENTAL|Experimental group|Self-hypnosis/self-care intervention : It is an 8-week 2 hour-session (one session per week) of self-hypnosis/ self-care learning. Participants are given strategies to learn self-care (knowing your own needs, self-respect, communication, etc.), each strategie is discussed for participant to understand them and thus applie them correctly in daily living. An hypnosis exercice is also realised at the end of each session.
62015015|NCT05943301|NO_INTERVENTION|Control group|The control goup has usual care and no intervention.
62015016|NCT05989399||ASyS patients|Patients with antisynthetase syndrome
62015017|NCT01180075||TDF/FTC/EFV Intensive Sampling-Group A|Patients receiving TDF/FTC/EFV who undergo intensive pharmacokinetic sampling over 24 hours
62015018|NCT01180075||TDF/FTC/ATV/r Intensive Sampling Group A|Patients receiving TDF/FTC/ATV/r who undergo intensive pharmacokinetic sampling over 24 hours
62015019|NCT01180075||TDF/FTC/EFV Sparse Sampling Group B|Patients receiving TDF/FTC/EFV who undergo sparse pharmacokinetic sampling on 1 or 2 visits depending on subject's availability
62204003|NCT03183505|EXPERIMENTAL|Anyu Peibo|Anyu Peibo Capsule, oral, 0.8g twice per day
62204004|NCT03183505|PLACEBO_COMPARATOR|Placebo|Placebo,oral, twice per day
62015020|NCT01180075||TDF/FTC/ATV/r Sparse Sampling Group B|Patients receiving TDF/FTC/ATV/r who undergo sparse pharmacokinetic sampling on 1 or 2 visits depending on subject's availability
62204005|NCT01877148|EXPERIMENTAL|Physiotherapy + anodal tDCS|The patients will be submit to anodal tDCS applied in the motor cortex and after the patient will be submit to a 30 minutes of physiotherapy protocol.
62204006|NCT01877148|SHAM_COMPARATOR|Physiotherapy + sham tDCS|The patients will be submit to sham tDCS and after the patient will be submit to a 30 minutes of physiotherapy protocol.
62204007|NCT04193787|EXPERIMENTAL|EPIC-P|Participants will enroll in a bio-behavioral intervention aimed at preventing HIV transmission in people who inject drugs.
62204008|NCT03582527||observation group|All these patients who have been tested will be observed for further treatment and been recorded for toxicity.
62204009|NCT05290753|OTHER|Prokinetic use in accelerate healing of urgent intestinal anastomosis|Prikinetic agents administered immediately post operative and time of stay at hospital twice daily
62204010|NCT02932540||Healthy controls|healthy controls subjects who have age, sex and Blood pressure matched with the acute ischaemic stroke patient
62204011|NCT02932540||AIS patient-transient arm|transient change of head position from lying flat (0 degree) to sitting up (30 degree)
62204012|NCT02932540||AIS patient - persistent lying flat|lying flat (0 degree) head position for the first 24 hours in the hospital admission
62204013|NCT02932540||AIS patient - persistent sitting up|sitting up ( 30 degree) head position for the first 24 hours in the hospital admission
62204014|NCT01092429||one,two,and three vessels disease; mortality|
62204015|NCT05769556|EXPERIMENTAL|Group A|will receive brain gym exercises and physiotherapy .
62580139|NCT06370000|EXPERIMENTAL|Oral Azacitidine|Starting dose is oral azacitidine 300 mg orally once daily with or without food days 1-14 in a 28-day cycle
62204016|NCT05769556|ACTIVE_COMPARATOR|Group (B)|will receive physiotherapy alone.
62580140|NCT02490046|EXPERIMENTAL|MS and rec UTIs not using a catheter|people with multiple sclerosis and recurrent urinary tract infections with spontaneous voiding Intervention- will be given D-mannose
62580141|NCT02490046|EXPERIMENTAL|MS and rec UTIs using a catheter|people with multiple sclerosis and recurrent urinary tract infections using either urethral or suprapubic indwelling catheter or intermittent catheterisation Intervention- will be given D-mannose
62204017|NCT06381180|EXPERIMENTAL|THC Group|Cannabis with 2.5 mg THC; up to a maximum of 5 doses/day (max dose = 12.5 mg THC)
62580142|NCT06382246|EXPERIMENTAL|Exercise (EX): exercise snacks condition|Bodyweight-style exercise snacks lasting 1-minute each performed with vigorous effort 4 times per day on two consecutive days.
62204018|NCT06381180|EXPERIMENTAL|CBD Group|Cannabis with 2.5 mg CBD; up to a maximum of 5 doses/day (max dose = 12.5 mg CBD)
62204019|NCT06381180|EXPERIMENTAL|THC & CBD Group|Cannabis with 2.5 mg THC and 2.5 mg CBD; up to a maximum of 5 doses/day (max doses = 12.5 mg THC and 12.5 mg CBD)
62204020|NCT06381180|ACTIVE_COMPARATOR|Placebo Group|Cannabis with \<1mg THC and \<1mg CBD; up to a maximum of 5 doses/day (max dose = \<5 mg THC and \<5 mg CBD)
62204021|NCT03349619|EXPERIMENTAL|Resveratrol plus Carboxymethyl-β-Glucan|
62204022|NCT03349619|PLACEBO_COMPARATOR|Placebo|
62204023|NCT03362385||OSA|
62204024|NCT03362385||Non-OSA|
62580143|NCT06382246|NO_INTERVENTION|Control (CON): Non-exercise condition|No structured exercise on two consecutive days.
62580144|NCT01161030|EXPERIMENTAL|almonds|1-oz raw almonds: 173 kcal, 4.6 g carbohydrate, 14.6 g fat
62580145|NCT01161030|PLACEBO_COMPARATOR|Control|cheese stick
62580146|NCT03265392|OTHER|Part 1 - Bread + Water|Participants in this arm will randomly consume bread and 250 mL of water on 1 out of 3 visits of Part 1.
62204025|NCT04631159|EXPERIMENTAL|Mobile app group|They are required to wear fitness watches to record steps ,patients will need to download and use the Health2Sync app and report blood glucose data weekly, and be monitored and advised by medical personnel.
62204026|NCT04631159|PLACEBO_COMPARATOR|Control group|they are required to wear fitness watches to record steps ,patients will be asked to self-manage and there is no intervention during the tracking process.
62204027|NCT04481698||Mesoglycan|All patients received the standard post-operative therapy (a recommended oral dose of ketorolac tromethamine of 10 mg every 4-6 hours, not exceeding 40 mg per day and not exceeding 5 post-operative days according to the indications for short-term management of moderate/severe acute post-operative pain and stool softeners) plus mesoglycan (Prisma® 30 mg 2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet twice/day for an additional 30 days, Mediolanum Farmaceutici, Milan, Italy)
62204028|NCT04481698||Control|standard post-operative therapy (a recommended oral dose of ketorolac tromethamine of 10 mg every 4-6 hours, not exceeding 40 mg per day and not exceeding 5 post-operative days according to the indications for short-term management of moderate/severe acute post-operative pain and stool softeners)
62580147|NCT03265392|OTHER|Part 1 - Bread + Lemon Juice|Participants in this arm will randomly consume bread and 250 mL of lemon juice on 1 out of 3 visits of Part 1.
62204029|NCT05783908|NO_INTERVENTION|Without Non-magnetic screen|Radiotherapy treatment with Linac MRI without non-magnetic shielding
62580148|NCT03265392|OTHER|Part 1 - Bread + Tea|Participants in this arm will randomly consume bread and 250 mL of tea on 1 out of 3 visits of Part 1.
62204030|NCT05783908|EXPERIMENTAL|With non-magnetic screen|Radiotherapy treatment with Linac MRI with non-magnetic screen
62204031|NCT01805453|ACTIVE_COMPARATOR|Arm A: Losartan|Arm A: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan 50mg\*2/day until the halting for any reason
62204032|NCT01805453|PLACEBO_COMPARATOR|Arm B: Placebo|Arm B: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
62204033|NCT02056990||training advise|
62204034|NCT03276650||critically ill AOSD patients|no intervention Data collection from hospitalisation reports (administrative, biological, clinical, outcome)
62204035|NCT01607879|EXPERIMENTAL|Standard of care ADT + (HMB + AG)|Standard of care androgen deprivation therapy plus the nutritional supplement HMB + arginine + glutamine (AG)
62204036|NCT01607879|ACTIVE_COMPARATOR|Standard of care ADT|Standard of care androgen deprivation therapy
62204037|NCT03633747|EXPERIMENTAL|propranolol|Propranolol hydrochloride tablets were taken orally three times a day at an initial dose of 30 mg/day, doubled one week later until the daily dose was 1.5 mg/kg. If the dose was unable to increase due to side effects, the maximum dose tolerable was maintained for 6 months.
62204038|NCT05494957|EXPERIMENTAL|New treatment regimen including bedaquiline|Treatment regimens that include bedaquiline, linezolid, clofazimine, and other optional drugs.
62204039|NCT00619047||Observation|
62204040|NCT00805805|EXPERIMENTAL|1|Tetrathiomolybdate with ursodiol
62204041|NCT00805805|PLACEBO_COMPARATOR|2|Placebo with ursodiol
62015021|NCT03411226||re-TREPP|Patients who presented with a recurrent inguinal hernia after previous TREPP repair.
62204042|NCT01839097|EXPERIMENTAL|Dose Finding Phase|"This is a Phase 1 dose finding study using the traditional escalation rule of 3+3 design to evaluate the Maximum Tolerated Dose of Belinostat when administered in combination with CHOP. In Part A of the study, up to three sequential dose cohorts will enroll a maximum of 6 patients each.~Enrollment will begin with the enrollment of patients into Cohort 3.~On Day 1 of each 21-day treatment cycle, the study treatment will start with belinostat followed by CHOP regimen."
62204043|NCT03845231|OTHER|unvaccinated|will receive no Flucelvax vaccination and will receive human challenge virus
62204044|NCT03845231|EXPERIMENTAL|Vaccinated|will receive Flucelvax vaccination and human challenge virus
62204045|NCT03953924|NO_INTERVENTION|Control group|No interventions were performed for the control patients during the study. While those in the control group were given conventional care ( nursing procedure, education about diet, exercise and so on)
62204046|NCT03953924|EXPERIMENTAL|Intervention group|The patients in intervention group received conventional care, transtheoretical model-based (TTM-based) intervention and motivational interviewing (MI).
62204047|NCT02097303|OTHER|Single arm|All subjects receive concurrent administration of Radium Ra223 Dichloride and Abiraterone Acetate plus Prednisone
62204048|NCT01359787|ACTIVE_COMPARATOR|Mapracorat 0.01% Ointment|Lowest concentration
62403873|NCT03619512||Control group with no tumor involvment of lymph nodes|patients for whom a diagnostic lymph node biopsy has been performed, which did not conclude to any tumoral lymph node involvment.
62403874|NCT04386798|OTHER|survey application to mothers|In the neonatal intensive care, the information form, postpartum specific anxiety scale, and neonatal intensive care unit parent-father stress scale will be filled in for the mothers who have a baby.
62403875|NCT00655226|EXPERIMENTAL|CBT skills based group sessions|Cognitive Behavioral Therapy skills based group sessions
62403876|NCT00655226|ACTIVE_COMPARATOR|Hepatitis C educational support groups|Hepatitis C educational support groups
62580149|NCT03265392|OTHER|Part 2 - Bread + water|Participants in this arm will randomly consume bread and 250 mL of water supplemented with 20 peas on 1 out of 3 visits of Part 2.
62580150|NCT03265392|OTHER|Part 2 - Bread+ Lemon Juice|Participants in this arm will randomly consume bread and 250 mL of lemon juice supplemented with 20 peas on 1 out of 3 visits of Part 2.
62580151|NCT03265392|OTHER|Part 2 - Bread+ tea|Participants in this arm will randomly consume bread and 250 mL of tea supplemented with 20 peas on 1 out of 3 visits of Part 2.
62580152|NCT00481351|EXPERIMENTAL|group1 ezetimibe|6 week wash out, followed by 06 week ezetimibe 10mg once a day e then 6 week ezetimibe 10mg plus sinvastatin 20mg for more 6 week.
62015022|NCT06215638|EXPERIMENTAL|Bortezomib|
62015023|NCT02610140|EXPERIMENTAL|BAY94-9343|Drug Anetumab ravtansine given Intravenously (IV)
62015024|NCT02610140|ACTIVE_COMPARATOR|Vinorelbine|Drug Vinorelbine given Intravenously
62015025|NCT02479425|ACTIVE_COMPARATOR|3 point turning|patients nursed by the traditional re-positioning (two hours on back, two hours on right and two hours on left).
62015026|NCT02479425|EXPERIMENTAL|2 points turning|patients nursed on the right and left side sonly in 30ْ avoiding the back
62204049|NCT01359787|ACTIVE_COMPARATOR|Mapracorat 0.03% Ointment|Middle concentration
62204050|NCT01359787|ACTIVE_COMPARATOR|Mapracorat 0.1% Ointment|Highest concentration
62204051|NCT01359787|PLACEBO_COMPARATOR|Vehicle without active|
62403877|NCT01608048|NO_INTERVENTION|control|
62403878|NCT01608048|EXPERIMENTAL|TEAS|
62403879|NCT01608048|EXPERIMENTAL|EA:electro-acupuncture|
62403880|NCT01970423|OTHER|CRT|After randomization and polysomnography the CRT will get activated. After 3-5 months cross over to conventional right ventricular stimulation.
62403881|NCT01970423|OTHER|Right Ventricular Stimulation|After randomization and polysomnography the conventional right ventricular stimulation will get activated. After 3-5 months cross over to CRT activation.
62580153|NCT00481351|ACTIVE_COMPARATOR|group 2 simvastatin|6 week simvastatin 20mg once a day followed by 6 week simvastatin 80mg once a day.
62580154|NCT05473923|EXPERIMENTAL|Receiving chemotherapeutic or targeted drugs recommended by molecular tumor board.|These drugs included all the FDA-approved drugs that have been used in treating gliomas. A single drug or a drug combination for a specific patient will be recommended by the molecular tumor board, comprising neurooncologists, neurosurgeons, pharmacologists, cancer biologists, radiologists and bioinformaticians, will recommend , based on their expertise, patients willingness as well as evidences from PTCs-drug screening and bioinformatic prediction for drug response.
62580155|NCT05167383|ACTIVE_COMPARATOR|Intervention VR group|. In the VRH group the patients received a 30-minute session of virtual reality hypnosis when in active labor and had access to standard care.
62580156|NCT05167383|PLACEBO_COMPARATOR|Standard treatment|Patients in the control group received only standard care.
62015027|NCT06493370|EXPERIMENTAL|Intravenous ascorbic acid/vitamin C|"2 Cycles Carboplatin Day 1 and Gemcitabine Days 1 and 8 (NAC)~+ Intravenous Vitamin C Days 1-28"
62015028|NCT05058274||Single arm|All participants
62204052|NCT04479228|EXPERIMENTAL|NAGI bi-flanged metal stent (BFMS)|The WON will be punctured using a standard 19-gauge FNA needle and the aspirate was sent for biochemical and microbial analysis. A 0.025-inch (Visiglide; Olympus Corporation, Tokyo, Japan) or 0.035-inch stiff guidewire (Jag Wire; Boston Scientific) passed through the needle into the cyst cavity to form at least 1 to 2 loops under fluoroscopic guidance. A 6F cystotome (Endo-flex GmbH Dusseldorf, Germany) will be passed over the guidewire for creating a fistula. Subsequently, a 6-mm balloon dilator (Hurricane; Boston Scientific Corporation or Titan balloon, Wilson Cook) will be used to further dilate the fistula tract. After this, the stent delivery catheter is advanced over the guidewire across the PFC wall and the BFMS (Nagi; Taewoong Medical, Gyeonggi-do, South Korea) deployed using sonographic, fluoroscopic and endoscopic visualization.
62204053|NCT04479228|EXPERIMENTAL|Plastic stents|Double-pigtail plastic stents will be used. A minimum of one 10Fr pigtail plastic stent will be placed. After initial EUS-guided access, the ostomy will be dilated first, using a cystotome, and secondly with a balloon dilation. The plastic stent will be inserted and delivered following the routine technique of each interventional endoscopist. The number of the plastic stents and the size of the balloon used to dilate the ostomy will depend on the WON size and content.
62204054|NCT03271853||SBS II|
62204055|NCT04604574|OTHER|Pre/Post-Intervention|Patients who receive the novel IHSS intervention will be compared to historical controls who received the abstinence-based treatment model.
62204056|NCT04137289|EXPERIMENTAL|Phase Ia: BI 905711 - dose escalation|
62204057|NCT04137289|EXPERIMENTAL|Phase Ib: BI 905711 - dose level 1|
62580157|NCT02673125|EXPERIMENTAL|Double embryo transfer|Patients with both MitoGrade normal and Mitograde elevated PGS normal embryos will have two embryos replaced- one Mitograde normal and one Mitograde elevated.
62204058|NCT04137289|EXPERIMENTAL|Phase Ib: BI 905711 - dose level 2|
62204059|NCT04137289|EXPERIMENTAL|Phase Ib: BI 905711 - dose level 3|
62204060|NCT04137289|EXPERIMENTAL|Phase Ib: BI 905711 - dose level 4|
62204061|NCT02784457|ACTIVE_COMPARATOR|GnRHant|women who received GnRH antagonist
62204062|NCT02784457|NO_INTERVENTION|Control|women who did not receive GnRH antagonist
62204063|NCT04781413|EXPERIMENTAL|Experimental|"The phase I trial is a dose escalation design with standard 3+3 followed by expansion cohorts.~Level Nab-PTX S-1 Sintilimab~1. 80 mg/m2 80mg/m2 200mg~2. 100 mg/m2 80mg/m2 200mg~3. 120 mg/m2 80mg/m2 200mg~We start at level 1. The recommended dose (RD) is defined as dose equal to the maximum tolerated dose (MTD). If 1 of three patients experiences dose-limiting toxicities (DLT), three more patients will be enrolled at the same dose level. The MTD is defined as the dose level at which two or more of three patients, or at least two of 4-6 patients, have DLTs during one cycle."
62015029|NCT03752281||Health and activity|The cohort consists of long-term social assistance recipients where there is need to investigate the health status and working ability.
62204064|NCT05183672|EXPERIMENTAL|Intervention group|Participants will receive three tertiary stroke care consultations provided by stroke nurses via telecare in 3 months.
62204065|NCT05183672|PLACEBO_COMPARATOR|Control group|Participants will receive three usual face-to-face consultations provided by stroke nurses in 3 months
62204066|NCT01559129|PLACEBO_COMPARATOR|Placebo|
62403882|NCT04535518|ACTIVE_COMPARATOR|the standard group|"1. IVIG 2 g/kg once, given within 12 to 24 hours;~2. Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness."
62580158|NCT04266327|EXPERIMENTAL|I-125 Seed Implantation|All the enrolled patients were treated with ct-guided radioactive i-125 seed implantation assisted by 3D printing template.Prescription dose 110-130gy.
62580159|NCT06544954|EXPERIMENTAL|Grape, Then Placebo|Participants consume 40 grams of freeze-dried grape powder (dissolved into water) twice daily for 4 weeks. After a washout period of at least 4 weeks, participants then consume 40 grams of placebo powder matching grape powder (dissolved into water) twice daily for 4 weeks.
61978477|NCT01472081|EXPERIMENTAL|Arm I-3: Nivolumab + Ipilimumab|"Nivolumab 1mg/kg solution intravenously (IV) every 21 days during Induction phase and 3mg/kg solution intravenously (IV) every 14 days during Maintenance phase~Ipilimumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase. Ipilimumab will not be administered during Maintenance phase"
62787124|NCT00543387|EXPERIMENTAL|MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
62787125|NCT00543387|EXPERIMENTAL|MK-5108 225 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
62787126|NCT00543387|EXPERIMENTAL|MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Crossover)|After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
62787127|NCT00543387|EXPERIMENTAL|MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Crossover)|After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
62787128|NCT01406197|EXPERIMENTAL|Vaginal progesterone|vaginal 150 mg micronized progesterone cream delivered via a vaginal applicator; dosed daily (Prochieve, Columbia Laboratories)
62787129|NCT01406197|EXPERIMENTAL|Topical progesterone|topical 150 mg micronized progesterone gel applied to abdomen via a novel applicator; dosed daily
62015030|NCT01306552|ACTIVE_COMPARATOR|Student-intervention only group|"Schools randomized to intervention only (arm 1) will agree to visit the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?).~One school class of students will visit the parcours once during a school day. The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
62015031|NCT01306552|ACTIVE_COMPARATOR|Multi-component intervention|Schools randomized to the student-parent intervention arm also will agree to visit the KARUNA e.V. smoking prevention parcours. In addition, the schools will agree to have one parents' night presented by trained health coaches informing parents about smoking prevention topics in youth during the school year. Trained health coaches will give an evaluated smoking prevention presentation for parents at the parents' nights at the end of the first school year. Also, participating parents will receive information about successful ways to prevent smoking and promote smoking cessation in their children once by mail.
62204067|NCT01559129|EXPERIMENTAL|Pomalidomide|Participants received 1 mg pomalidomide orally once a day for 52 weeks during the treatment phase and for up to 2 years during the open-label extension phase.
62204068|NCT03916679|EXPERIMENTAL|anti-MESO CAR-T cells|Administration with anti-MESO CAR-T cells in the MESO-positive ovarian cancer patients
62204069|NCT00515671|EXPERIMENTAL|Arm 1_IMR|Illness Management and Recovery was offered in small groups (less than 8), co-facilitated by either an experienced masters level clinician or a doctoral level psychologist and by a doctoral student in clinical psychology. Facilitators used the IMR curriculum, incorporating psychoeducation, cognitive-behavioral approaches, relapse prevention, social skills training, and coping skills training. Facilitators worked with groups to set personal recovery goals and address progress towards those goals throughout the intervention. Home assignments helped participants apply newly learned skills and/or make progress on goals. Groups were open to rolling admission across the study period
62204070|NCT00515671|PLACEBO_COMPARATOR|Arm 2_PS|Problem Solving was the active control condition (also offered in groups weekly for 9 months). Participants were encouraged to discuss current concerns and receive group support; we did not use structured problem solving tasks. These groups were led by the same facilitators described above, who helped establish group expectations (attendance, confidentiality), encouraged participation, and provided process-oriented observations; there was no formal curriculum, goal setting, or homework assignments.
62787130|NCT01406197|EXPERIMENTAL|Intramuscular progesterone|injected IM (upper arm or thigh via syringe) 50mg/day micronized progesterone (Watson Pharmaceuticals)
62787131|NCT02406170|EXPERIMENTAL|Regorafenib+Paclitaxel|Regorafenib tolerability will be tested in a dose escalation scheme with a cytotoxic backbone of paclitaxel 80mg/m2.
62015032|NCT01306552|ACTIVE_COMPARATOR|Control Group|Schools randomized to the control school will be offered to participate in the nutrition and exercise prevention program offered by KARUNA e.V. during the 2-year study.
62204071|NCT00542542|ACTIVE_COMPARATOR|Paravertebral Block + General Anesthesia|Group 1: Paravertebral Block + General Anesthesia (Ropivacaine)
62580160|NCT06544954|EXPERIMENTAL|Placebo, Then Grape|Participants consume 40 grams of placebo powder matching grape powder (dissolved into water) twice daily for 4 weeks. After a washout period of at least 4 weeks, participants then consume 40 grams of freeze-dried grape powder (dissolved into water) twice daily for 4 weeks.
62580161|NCT05334810|EXPERIMENTAL|DP303c|Eligible patients will be treated with DP303c at 3.0 mg/kg every 3 weeks.
62580162|NCT01365078|EXPERIMENTAL|Echium oil (SDA-rich oil)|
62580163|NCT01365078|PLACEBO_COMPARATOR|High-oleic acid sunflower oil (HOSO)|low in SDA
62580164|NCT06168942|EXPERIMENTAL|Laminar Device|Treatment with the Laminar Left Atrial Appendage Closure System.
62787132|NCT01882530|PLACEBO_COMPARATOR|Control group C: Placebo|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
62787133|NCT01882530|EXPERIMENTAL|Group P: Paracetamol|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
62787134|NCT01882530|EXPERIMENTAL|Group N: Nefopam|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
62787135|NCT01882530|EXPERIMENTAL|Group K: Ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
62787136|NCT01882530|EXPERIMENTAL|Group PN: paracetamol and nefopam|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
62204072|NCT00542542|ACTIVE_COMPARATOR|General Anesthesia Alone|Group 2: General Anesthesia Alone (Propofol, Midazolam, Fentanyl)
62787137|NCT01882530|EXPERIMENTAL|Group PK: paracetamol and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
62787138|NCT01882530|EXPERIMENTAL|Group NK: nefopam and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
62787139|NCT01882530|EXPERIMENTAL|Group PNK: paracetamol, nefopam and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
62787140|NCT03120715|PLACEBO_COMPARATOR|NLMWH-A|non-low molecular weight heparin-group A(group NLMWH-A).Without administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is \<7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is \>9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
62015033|NCT02663128|EXPERIMENTAL|Lanabecestat Reference Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
62015034|NCT02663128|EXPERIMENTAL|Lanabecestat Test Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
62015035|NCT02663128|EXPERIMENTAL|Lanabecestat Test Non Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
62015036|NCT01954667||obese and overweight|Group1 (n=30): overweight and obese (BMI ≥25 and/ or WHtR≥0.5)
62015037|NCT01954667||average body weight|Group2 (n=30): normal weight (BMI ≥ 18 to \< 25 and/or WHtR ≥0.4 to \<0.5)
62015038|NCT01954667||Control group|Control Group (n= 20): healthy subjects, matched for age and gender, were included in this study. All included controls had average weight (BMI ≥ 18 to \< 25 and/ or WHtR ≥0.4 to \<0.5)
62015039|NCT06527287|EXPERIMENTAL|NATION|NATION is a 6-week evidence-based CAI rehabilitation protocol that incorporates neurocognitive exercises. Participants will complete 18 unsupervised home sessions and 12 supervised sessions over the course of 6-weeks.
62204073|NCT01363570|OTHER|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
62580165|NCT06168942|ACTIVE_COMPARATOR|Control LAAC|Treatment with a commercially-available left atrial appendage closure device.
62580166|NCT06683352|EXPERIMENTAL|Arm A|COVID-19 Vaccine (Dose 1) and Placebo
62580167|NCT06683352|EXPERIMENTAL|Arm B|COVID-19 Vaccine (Dose 2) and Placebo
62580168|NCT06683352|ACTIVE_COMPARATOR|Arm C|COVID-19 Vaccine (Dose 3) and Placebo
62580169|NCT06683352|EXPERIMENTAL|Arm D|Investigational Influenza Vaccine (Dose 1) and Placebo
62580170|NCT06683352|ACTIVE_COMPARATOR|Arm E|Licensed Influenza Vaccine 1 and COVID-19 Vaccine (Dose 3)
62580171|NCT06683352|ACTIVE_COMPARATOR|Arm EE|Licensed Influenza Vaccine 2 and COVID-19 Vaccine (Dose 3)
62580172|NCT06683352|EXPERIMENTAL|Arm F|Investigational Influenza Vaccine (Dose 2) and Placebo
62580173|NCT06683352|EXPERIMENTAL|Arm G|Influenza and COVID Combination Vaccine (Combination 1) and Placebo
62580174|NCT06683352|EXPERIMENTAL|Arm H|Influenza and COVID Combination Vaccine (Combination 2) and Placebo
62580175|NCT06683352|EXPERIMENTAL|Arm I|Influenza and COVID Combination Vaccine (Combination 3) and Placebo
62580176|NCT06683352|EXPERIMENTAL|Arm J|Investigational Influenza Vaccine (Dose 3) and Placebo
62580177|NCT06683352|EXPERIMENTAL|Arm K|Influenza and COVID Combination Vaccine (Combination 4) and Placebo
62580178|NCT06683352|EXPERIMENTAL|Arm L|Influenza and COVID Combination Vaccine (Combination 5) and Placebo
62580179|NCT06683352|EXPERIMENTAL|Arm M|Influenza and COVID Combination Vaccine (Combination 6) and Placebo
62580180|NCT06683352|EXPERIMENTAL|Arm N|Influenza and COVID Combination Vaccine (Combination 7) and Placebo
62580181|NCT06185179|EXPERIMENTAL|Metformin|Metformin pills will be given orally and daily during the 2-week recovery period following single leg immobilization Metformin will be titrated up to a dose 2g/day. 1g dose (two 500 mg pills) will be taken in the morning and a 1g dose will be taken in the evening. This will take place over each day for 14 days during the recovery period.
62580182|NCT06185179|PLACEBO_COMPARATOR|Placebo|Placebo pills will be given orally and daily during the 2-week recovery period following single leg immobilization. Two pills will be taken in the morning and two pills will be taken in the evening. This will take place over each day for 14 days during the recovery period.
62580183|NCT01949701|EXPERIMENTAL|Vaccine|HLA-A\*0201restricted URLC10 peptides
62580184|NCT01652768|ACTIVE_COMPARATOR|Arm A: Usual Care Group|Usual care is defined as standard post-operative care on a surgical unit in University Hospitals Case Medical Center. Discharge planning will be provided by the assigned in-patient social worker. Referrals to the assigned outpatient social worker will be made as appropriate. Patients and caregivers will be seen in the ambulatory medical oncology setting about three to six weeks after surgery, depending on post-operative recovery time. The research assistant will administer the research questionnaires at week one post-surgery and 8-10 weeks post surgery.
62580185|NCT01652768|EXPERIMENTAL|Arm B: PRESENCE Intervention|The unique features of the PRESENCE Project (PP) Intervention are 1) the early palliative care intervention (immediately post-op) provided by the new palliative care brain tumor team (Social worker, advanced practice nurse (APN), medical oncology registered nurse); 2) an educational information session for patients and caregivers; and 3) frequent (every two week and as needed) telephone or clinic visits during the first ten weeks post operatively (Figure 1). In usual care, the patient and caregiver receive little supportive care until they begin cancer treatment. The intervention provides aggressive supportive care from the time of diagnosis.
62015040|NCT06527287|ACTIVE_COMPARATOR|Evidence-based|The Evidence-Based protocol will be identical to the intervention (i.e., NATION protocol), but the exercises will exclude the neurocognitive tasks. Participants will complete 18 unsupervised home sessions and 12 supervised sessions over the course of 6-weeks.
62580186|NCT03526874|EXPERIMENTAL|Greater Occipital Nerve (GON) Block with Lidocaine|"Subjects randomized to this arm receive 2 mL injection of lidocaine 2% over the right and left greater occipital nerve at the baseline study visit.~All subjects then complete daily headache-related questions through a Headache Diary and other assessments for 28 days."
62787141|NCT03120715|EXPERIMENTAL|LMWH-B|low molecular weight heparin-group B(group LMWH-B).With administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is \<7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is \>9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
62015041|NCT06527287|NO_INTERVENTION|Control|Participants assigned to the Control arm will be instructed to continue their normal routine.
62787142|NCT01378767|ACTIVE_COMPARATOR|Krill oil capsules|Two grams per day daily for 21 days
62015042|NCT06105489|EXPERIMENTAL|Tunnel flap design|Participants will undergo a lateral sinus lift procedure in which a single vertical anterior incision will be made at least 10 mm mesially to the expected outline of the bony window.
62015043|NCT06105489|ACTIVE_COMPARATOR|Trapezioidal flap design|Participants will undergo a lateral sinus lift procedure. The incision will be made horizontally on the top of the alveolar ridge, with two additional releasing incisions in the mesial and distal regions.
62015044|NCT06367582||F20 VP|Vertebroplasty
62015045|NCT06367582||F20 KP|Kyphoplasty
62015046|NCT06367582||SPINEFIX VP|Vertebroplasty
62015047|NCT06367582||SPINEFIX KP|Kyphoplasty
62015048|NCT06367582||SPINEFIX PSA|Pedicular Screw Augmentation
62015049|NCT06367582||HIGH V+ VP|Vertebroplasty
62015050|NCT06367582||HIGH V+ KP|Kyphoplasty
62787143|NCT01378767|PLACEBO_COMPARATOR|Coconut oil capsules|Two grams per day for 21 days
62015051|NCT06367582||OPACITY+ VP|Vertebroplasty
62015052|NCT06367582||OPACITY+ KP|Kyphoplasty
62580187|NCT03526874|PLACEBO_COMPARATOR|Greater Occipital Nerve (GON) Block with Saline|"Subjects randomized to this arm receive 2 mL injection of preservative-free normal saline over the right and left greater occipital nerve at the baseline study visit.~All subjects then complete daily headache-related questions through a Headache Diary and other assessments for 28 days."
62015053|NCT02052466||Reverse TSA patients|Patients having undergone reverse TSA at the Cleveland Clinic with a high quality preoperative CT of the operative shoulder and who are at least 24 months post surgery.
62015054|NCT03698955|ACTIVE_COMPARATOR|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks.
62015055|NCT03698955|ACTIVE_COMPARATOR|Mediterranean diet|The diet group will be asked to follow a Mediterranean diet for 16 weeks.
62015056|NCT02778529|OTHER|Upper Limb Assessment on ADLs|Bilateral assessment robots (BiAS) Evaluate upper limb kinematics of Stroke, Amputees, SCI, Cerebral Palsy and Health Subjects will be assessed as they complete unilateral and bilateral activities of daily living. Subjects will complete exercises in 1 session
62015057|NCT04670679|EXPERIMENTAL|Dose Escalation (Part A): ERAS-601 monotherapy|ERAS-601 monotherapy will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.
62015058|NCT04670679|EXPERIMENTAL|Dose Escalation (Part B): ERAS-601 monotherapy|ERAS-601 monotherapy will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.
62580188|NCT05140967|EXPERIMENTAL|High Intensity Interval Training (A)|Exercise training with intermittent bouts of high intensity
62015059|NCT04670679|EXPERIMENTAL|Dose Escalation (Part C): ERAS-601 monotherapy|ERAS-601 will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent.
62015060|NCT04670679|EXPERIMENTAL|Dose Escalation and Dose Expansion (Part D): ERAS-601 in combination with cetuximab|ERAS-601 will be administered in sequential ascending doses with cetuximab to study participants with advanced metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent. Once the combination therapy recommended dose has been determined, this will be administered to study participants with HPV negative advanced or metastatic head and neck squamous cell carcinoma (HNSCC) or colorectal cancer (CRC).
62204074|NCT04255953|ACTIVE_COMPARATOR|Treatment as Usual|Following baseline assessment, patients randomized to the TAU arm will receive monthly dietary pamphlets and web-based obesity prevention educational materials from the U.S. Office of Disease Prevention and Health Promotion (https://healthfinder.gov/HealthTopics/). After the 6-month assessment, TAU patients will begin the weight loss intervention arm.
62204075|NCT04255953|EXPERIMENTAL|Group Telehealth Obesity|Participants will receive 24 weekly group phone counseling sessions and monthly individual sessions that encourage healthy eating and exercise. The planned intervention is guided by a social-cognitive framework and includes self-monitoring, goal setting, stimulus control, social support, cognitive reframing of unrealistic and negative thoughts, and developing positive expectancies for long-term weight control. The primary objective is to decrease caloric intake and increase physical activity to produce weight loss of approximately .4 to.9 kg per week, with the study goal of 10% reduction from baseline.
62204076|NCT05871320|EXPERIMENTAL|[99mTc]Tc-TECANT1|The injection volume will be up to 5 mL over 20 seconds with an activity of 10 MBq/kg body weight (range between min. 500 and max. 800 MBq). To ensure application of the complete activity additionally 10 mL of 0.9% saline will be infused via the same system.
62204077|NCT05518305||All|Blood sampling and an MRI will be conducted alongside standard stroke cognitive tests upon enrollment. A follow-up three-month visit will check for adverse events and a follow-up cognitive stroke test. At 12 months, an MRI will be conducted alongside a cognitive test.
62204078|NCT04625699|EXPERIMENTAL|durvalumab+ tremelimumab|durvalumab will be administered Q4weeks and tremelimumab will be administered Q8 weeks
62204079|NCT00974259|EXPERIMENTAL|pBrO2 and ICP management|Treatment protocol based on pBrO2 and ICP values.
62204080|NCT00974259|ACTIVE_COMPARATOR|ICP management|Treatment protocol based on ICP values only.
62204081|NCT04247334|NO_INTERVENTION|Cautious Participants|Participants who have low scores on a self-report of inhibitory control abilities (BRIEF-Inhibit).
62204082|NCT04247334|EXPERIMENTAL|Impulsive Participants- Active Stimulation|Participants who have high scores on a self-report of inhibitory control abilities (BRIEF-Inhibit) who are randomized to active stimulation.
62204083|NCT04247334|SHAM_COMPARATOR|Impulsive Participants- Sham Stimulation|Participants who have high scores on a self-report of inhibitory control abilities (BRIEF-Inhibit) who are randomized to sham stimulation.
62580189|NCT05140967|EXPERIMENTAL|Moderate Intensity Continous Training (B)|Exercise training with constant workload
62580190|NCT06142994|EXPERIMENTAL|Verum group|"10 days of treatment with 3 daily doses of 420 mg (available in an capsule of 210 mg), as recommended by the manufacturer.~6 capsules daily for 10 days: 2 capsules in the morning (30 minutes before breakfast), 2 capsules at noon (30 minutes before lunch), 2 capsules in the evening (30 minutes before dinner)"
62580191|NCT06142994|PLACEBO_COMPARATOR|Placebo|"10 days treatment with a 3-day dose of 420 mg placebo capsules (available in an indistinguishable capsule of 210 mg).~6 capsules daily for 10 days: 2 capsules in the morning (30 minutes before breakfast), 2 capsules at noon (30 minutes before lunch), 2 capsules in the evening (30 minutes before dinner)"
62580192|NCT02488343|EXPERIMENTAL|Behavioral Intervention|Participants in this group will receive tailored psychological intervention to promote adherence to their drug therapy.
62580193|NCT02488343|NO_INTERVENTION|Non Intervention group|Participants in this group will be observed but will not receive any intervention.
62580194|NCT01017523|EXPERIMENTAL|1 (Couples)|Diabetes self-management education, telephone support and behavior change for couples.
62580195|NCT01017523|ACTIVE_COMPARATOR|2 (Individual)|Diabetes self-management education, telephone support and behavior change for individuals.
62580196|NCT01017523|PLACEBO_COMPARATOR|3 (Control)|Diabetes self-management education only.
62580197|NCT05559801|EXPERIMENTAL|Children with OI receiving Bone marrow-derived MSCs infusion|Intravenously-infused allogeneic, bone marrow-derived mesenchymal stromal cells (MSCs) in children with Osteogenesis Imperfecta Type III that will be infused at 0 months, 4 months, 8 months, 12 months, 16 months, and 20 months, after enrollment.
62580198|NCT03687684|EXPERIMENTAL|Japanese Cohort 1-A; TAK-831 100 mg + TAK-831 300 mg|TAK-831 100 milligrams (mg), tablets, orally, once daily on Day 1, followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.
62580199|NCT03687684|EXPERIMENTAL|Japanese Cohort 1-B; TAK-831 100 mg + Placebo|TAK-831 100 mg, tablets, orally, once daily on Day 1 followed by TAK-831 matching placebo, tablets, orally, once daily on Day 9 in healthy Japanese participants.
62580200|NCT03687684|EXPERIMENTAL|Japanese Cohort 1-C; Placebo + TAK-831 300 mg|TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.
62580201|NCT03687684|EXPERIMENTAL|Japanese Cohort 2; TAK-831 300 mg|TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.
62015061|NCT04670679|EXPERIMENTAL|Dose Escalation and Dose Expansion (Part E): ERAS-601 in combination with pembrolizumab|ERAS-601 will be administered in sequential ascending doses with pembrolizumab to study participants with advanced metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent. Once the combination therapy recommended dose has been determined, this will be administered to study participants with HPV negative advanced or metastatic head and neck squamous cell carcinoma (HNSCC) or non small cell lung cancer (NSCLC).
62015062|NCT05166005|ACTIVE_COMPARATOR|High dose|High dose Vitamin D therapy will initiate at a dosage of 50,000 IU on the first and second week of hospitalization
62015063|NCT05166005|PLACEBO_COMPARATOR|Low dose|Vitamin D therapy will prescribe at a dosage of 2,000 IU/day
62204084|NCT00816790|ACTIVE_COMPARATOR|Dose Adjusted|This arm will receive their broad spectrum antibiotic as an adjusted dose based on their renal function as measured when sepsis is diagnosed and antimicrobials are initiated
62204085|NCT00816790|EXPERIMENTAL|Unadjusted Dose|This arm will receive their broad spectrum antibiotic as an unadjusted dose regardless of their renal function
62204086|NCT03198468|EXPERIMENTAL|Vapor Ablation|
62204087|NCT02341443|EXPERIMENTAL|Rigid|Surgery using mandibulo-maxillary fixation, implants providing rigid fixation on most anterior fracture and non-rigid fixation on the most posterior fracture.
62204088|NCT02341443|ACTIVE_COMPARATOR|Non-rigid|Surgery using mandibulo-maxillary fixation and implants providing non-rigid fixation on both fracture sides.
62403883|NCT04535518|EXPERIMENTAL|the standard + infliximab group|"1. IVIG 2 g/kg once, given within 12 to 24 hours;~2. Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.~3. Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours."
62403884|NCT04946669|EXPERIMENTAL|Refractory Dermatomyositis|Patients who have been receiving glucocorticoids in combination with at least one immunosuppressive therapy for at least 3 months and who have failed therapy or are intolerant to therapy
62580202|NCT03687684|EXPERIMENTAL|Chinese Cohort 3; TAK-831 600 mg|TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Chinese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.
62015064|NCT04306224|EXPERIMENTAL|IMC-002|Dose escalation will follow the traditional 3+3 design.
62015065|NCT01166984|EXPERIMENTAL|AB103 7.5 µg/kg|AB103 7.5 µg/kg administered as a single IV infusion
62204089|NCT00283244|ACTIVE_COMPARATOR|Arm A|Patients receive gemcitabine hydrochloride 1200mg/m2 IV on days 1 and 8. Patients with progressive disease may cross over to arm B.
62204090|NCT00283244|EXPERIMENTAL|Arm B|Patients receive oral erlotinib hydrochloride 150mg p.o. daily on days 1-21.
62204091|NCT00283244|EXPERIMENTAL|Arm C|Patients receive gemcitabine hydrochloride 1000mg/m2 IV on days 1 and 8 and erlotinib hydrochloride 100mg p.o. daily
62015066|NCT01166984|EXPERIMENTAL|AB103 37.5 µg/kg|AB103 37.5 µg/kg administered as a single IV infusion
62204092|NCT02504983|ACTIVE_COMPARATOR|GALNT14 TT|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued.
62204093|NCT02504983|ACTIVE_COMPARATOR|GALNT14 non-TT TACE alone|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued.
62403885|NCT02066909|EXPERIMENTAL|Cohort 1|Dosing in healthy Western subjects.
62403886|NCT02066909|EXPERIMENTAL|Cohort 2|Dosing in healthy Western subjects.
62403887|NCT02066909|EXPERIMENTAL|Cohort 3|Dosing in healthy Western subjects.
62403888|NCT02066909|EXPERIMENTAL|Cohort 4|Dosing in healthy Western subjects.
62403889|NCT02066909|EXPERIMENTAL|Cohort 5|Dosing in healthy Western subjects.
62403890|NCT02066909|EXPERIMENTAL|Cohort 6|Dosing in healthy Western subjects.
62403891|NCT02066909|EXPERIMENTAL|Cohort 7|Dosing in healthy Western subjects.
62403892|NCT02066909|EXPERIMENTAL|Optional Cohort 8|Dosing in healthy Western subjects. Cohort may not be conducted.
62580203|NCT03687684|EXPERIMENTAL|Japanese Cohort 4; TAK-831 600 mg|TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.
62403893|NCT02066909|EXPERIMENTAL|Cohort 9|Dosing in healthy Japanese subjects.
62403894|NCT06333431|EXPERIMENTAL|Glass Waterfall|Except for the preparation the gastroscopy procedure takes approximately 20 minutes, patients will be asked to focus on portative glass waterfall during the procedure.
62403895|NCT06333431|EXPERIMENTAL|White Noise|Except for the preparation of the patient for the procedure, since the gastroscopy procedure takes approximately 20 minutes, 20-minute white noise be listened using phone
62015067|NCT01166984|EXPERIMENTAL|AB103 150 µg/kg|AB103 150 µg/kg administered as a single IV infusion
62015068|NCT01166984|EXPERIMENTAL|AB103 450 µg/kg|AB103 450 µg/kg administered as a single IV infusion
62015069|NCT01166984|PLACEBO_COMPARATOR|Placebo|Normal saline (0.9% sodium chloride) administered as a single IV infusion
62015070|NCT04401007|EXPERIMENTAL|Group 20/30|Two different local anesthetic volumes will be investigated: 20 mL of 1.5% lidocaine (300 mg lidocaine) at one study visit and 30 mL of 1.5% lidocaine (450 mg lidocaine) at the other study visit. Volunteers will be randomized to one of two intervention groups: (1) Group 20/30: A unilateral ESP block with 20 mL of local anesthetic at the first visit, and 30 mL of local anesthetic at the second visit
62015071|NCT04401007|EXPERIMENTAL|Group 30/20|(2) Group 30/20: a unilateral ESP block with 30 mL of 1.5% lidocaine with 1/200,000 epinephrine at the first visit, and 20 mL of the same local anesthetic solution at the second visit. This crossover design allows subjects to serve as their own control.
62015072|NCT04856319|ACTIVE_COMPARATOR|Prophylaxis|2 g amoxicillin+clavulanic acid 1 hour prior to dental implant surgery
62015073|NCT04856319|PLACEBO_COMPARATOR|Placebo|placebo 1 hour prior to dental implant surgery
62015074|NCT06612086|EXPERIMENTAL|we follow up patient who take Dapagliflozin in patient with pulmonary hypertension|we follow up patient who take Dapagliflozin in patient with pulmonary hypertension
62015075|NCT03444168||Candidate for Lumbar Spine Surgery|Participants have been designated to be a candidate for lumbar spine surgery to treat chronic low back and/or leg pain and you have agreed to proceed with the surgery.
62015076|NCT03444168||Lumbar Failed Back Surgery Syndrome|Participants have been diagnosed with having lumbar failed back surgery syndrome and have persistent and moderate-to-severe low back and/or leg pain for more than 6 months after a lumbar spine surgery.
62015077|NCT03444168||Healthy Volunteer|Participants are a healthy volunteer wishing to participate in a research study.
62015078|NCT05090449|ACTIVE_COMPARATOR|A1: Individual formulation of chlorthalidone|(Higroton 50, product of Sandoz, S.A. de C.V.)
62015079|NCT05090449|ACTIVE_COMPARATOR|A2:Individual formulation Losartan|(COZAAR, product of Schering Plough, S.A. de C.V., S.A. de C.V.)
62015080|NCT05090449|ACTIVE_COMPARATOR|A3: Co-administration of individual formulations|Co-administration of individual formulations of chlorthalidone and losartan potassium
62015081|NCT05090449|EXPERIMENTAL|B: Fixed combination of chlorthalidone and losartan potassium|B: Fixed combination of chlorthalidone and losartan potassium (product of Laboratorios Silanes S.A. de C.V.)
62015082|NCT01287572||Conscious sedation group|Pediatric patients 0 to 18 years requiring conscious sedation for procedures done in the pediatric ICU excluding burned patients or patients with severe eczema or other skin disease.
62015083|NCT05861544|EXPERIMENTAL|Experimental group|Patients under medication for addiction treatment (MAT) that are active members of the Greek Organization Against Drugs (OKANA) therapeutic units will be recruited for this investigation. The participants will be stratified into two subgroups, i.e., methadone maintenance treatment (MMT) and buprenorphine maintenance treatment (BMT), according to the maintenance treatment program they attend. Pomegranate juice, which is the examined nutritional intervention, will be administered to the participants of both MMT and BMT subgroups of the experimental group. The juice will be administered to the patients at the following dosage: 250 ml/day, seven days/week, for four months.
62015084|NCT05861544|NO_INTERVENTION|Control group|Patients under medication for addiction treatment (MAT) that are active members of the Greek Organization Against Drugs (OKANA) therapeutic units under methadone or buprenorphine treatment. The participants will be stratified into two subgroups, i.e., methadone maintenance treatment (MMT) and buprenorphine maintenance treatment (BMT), according to the maintenance treatment program they attend. The patients of the control group (both MMT and BMT subgroups) will not consume any similar beverage as a placebo due to the objective difficulties of making one that will be identical to the fresh pomegranate juice.
62015085|NCT03898245|ACTIVE_COMPARATOR|active tDCS|intervention : Intensity 2mA, 30minues, 7 times (post operation in 30min, in 4hrs, and 1 time a day from POD#1 to POD #7) apply tDCS
62015086|NCT03898245|SHAM_COMPARATOR|sham tDCS|Intensity 2mA, 8 seconds (but looks same as an intervention 30mins), 7 times (post operation in 30min, in 4hrs, and 1 time a day from POD#1 to POD #7) apply tDCS (sham mode)
62015087|NCT01098045||HIV-infection with fat redistribution (lipoatrophy)|"1. Evidence of HIV infection~2. Age ≥ 20 and ≤ 60 years of age~3. BMI measurement between 18-24 kg/m2~4. HIV positive, on a stable HAART treatment regimen (including an NRTI) for \> 12 months~5. No evidence of fat redistribution rated by the investigator."
62015088|NCT01098045||Healthy controls|"1. No history of HIV infection~2. Age ≥ 20 and ≤ 60 years of age~3. BMI measurement between 18-29.9 kg/m2"
62015089|NCT01098045||HIV-infected with fat redistribution (lipohypertrophy)|"1. Evidence of HIV infection~2. Age ≥ 20 and ≤ 60 years of age~3. BMI measurement between 25-29.9 kg/m2~4. HIV positive, on a stable HAART treatment regimen (including an NRTI) for \> 12 months~5. Evidence of significant fat redistribution rated by the investigator, including 1) significant fat atrophy of the face, arms or legs, and 2) significant increase in fat accumulation of the neck."
62015090|NCT01098045||Dicer Cohort|30 men \[HV-infected with fat redistribution (n = 10), HIV-infected without fat redistribution (n=10), and healthy controls (n= 10)\] will be recruited for this group.
62015091|NCT06602921|EXPERIMENTAL|Nitrate, caffeine, and cold pressor test (CPT)|All outcome variables will be measured for 24 participants in a trial where they receive 400 mg nitrate in the form of beetroot extract, 6 mg/kg caffeine powder, and undergo a 3 min cold pressor test.
62204094|NCT02504983|EXPERIMENTAL|GALNT14 non-TT TACE plus sorafenib|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation, plus sorafenib adjuvant therapy. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued. patients will receive sorafenib 400 mg/d between each TACE. Patient will start receiving Sorafenib on Day 4 (up to Day 7) after 1st TACE (Day 1) and will interrupt after evening dose 4 days before each next TACE and re-start Sorafenib on Day 4 (up to Day 7) after each TACE cycle.Additional sorafenib treatment is optional and will be judged by investigator in the subject's best medical interest.
62787144|NCT05591391|EXPERIMENTAL|Mallya|Patients use Mallya cap to record the time and dosage of insulin injection
62015092|NCT06602921|PLACEBO_COMPARATOR|Nitrate, placebo caffeine, and CPT|All outcome variables will be measured for 24 participants in a trial where they receive 400 mg nitrate in the form of beetroot extract, 6 mg/kg cornflour (caffeine placebo), and undergo a 3 min cold pressor test.
62015093|NCT06602921|PLACEBO_COMPARATOR|Placebo nitrate, caffeine, and CPT|All outcome variables will be measured for 24 participants in a trial where they receive nitrate-depleted beetroot extract (placebo), 6 mg/kg caffeine powder, and undergo a 3 min cold pressor test.
62015094|NCT06602921|PLACEBO_COMPARATOR|Placebo nitrate, placebo caffeine, and CPT|All outcome variables will be measured for 24 participants in a trial where they receive nitrate-depleted beetroot extract (placebo), 6 mg/kg cornflour (caffeine placebo), and undergo a 3 min cold pressor test.
62015095|NCT02259530|EXPERIMENTAL|Integrated Psychotherapeutic Intervention|Integrated treatment of khat use disorder and PTSD
62204095|NCT06372704||post prostatectomy incontinence|Twenty-seven patients who underwent radical prostatectomy with a mean age of 67.90 ± 3.40, and who had continuous UI complaints, were included in the study.
62015096|NCT06573645|EXPERIMENTAL|High-dose Rituximab Group|Patients will be assigned to the trial group (rituximab 500 mg/m2) and will receive six cycles of R-CHOP (21 days per cycle), followed by two maintenance cycles of rituximab (21 days per cycle).
62015097|NCT06573645|ACTIVE_COMPARATOR|Standard-dose Rituximab Group|Patients will be assigned to the control group (rituxan 375 mg/m2), the participants will receive 6 cycles R - CHOP treatment (21 d for a cycle), and the subsequent 2 cycle rituxan maintenance therapy (21 d for a cycle)
62015098|NCT06168643|EXPERIMENTAL|Core stability|
62015099|NCT06168643|EXPERIMENTAL|Core stability with pregnancy support belt|
62787145|NCT05591391|ACTIVE_COMPARATOR|Standard care|Patients receive standard care.
62787146|NCT06449495|EXPERIMENTAL|coordination and balance disorders|Subjects will undergo treatment with NIRVANA lasting 45 minutes for 5 sessions per week for 4 weeks combined with equal dose of task-oriented physiotherapy treatment.
62787147|NCT02748070|EXPERIMENTAL|Prednisone|Provided oral steroid and topical steroid
62015100|NCT06085417|SHAM_COMPARATOR|Group B (bupivacaine) (n= 30)|"For Group B (control group), 100 mg bupivacaine hydrochloride+ isotonic saline (5ml) was administered in a total volume of 25 ml. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
62787148|NCT02748070|PLACEBO_COMPARATOR|Placebo|Provided oral placebo and topical steroid
62403896|NCT06333431|NO_INTERVENTION|control group|Patients of the control group, will not receive any intervention except for applied routine hospital gastroscopy procedures.
62204096|NCT01627015|EXPERIMENTAL|Modified infant follow-on formula|Infants are fed a modified infant follow-on formula (modified carbohydrate composition) for 4 weeks, according to protocol
62403897|NCT04329156|EXPERIMENTAL|Digitally Flip Technique|
62580204|NCT03687684|EXPERIMENTAL|Japanese Cohort 5; TAK-831|TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.
62204097|NCT01627015|ACTIVE_COMPARATOR|Standard infant follow-on formula|Infants are fed a commercial follow-on formula for 4 weeks, according to protocol
62787149|NCT00538070|PLACEBO_COMPARATOR|Placebo|You will receive two grams of placebo per day. You will take two 500 mg placebo capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
62787150|NCT00538070|EXPERIMENTAL|Sarcosine|You will receive two grams of sarcosine per day. You will take two 500 mg capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
62204098|NCT01855971|ACTIVE_COMPARATOR|Fragile X syndrome experimental group|"1. Administration of 400 mg/day of epigallocatechin-3-gallate (EGCG). Life Extension, Mega Green Tea Extract Decaffeinated, a dietary supplement containing EGCG extract (45% EGCGC).~   Dosage form: capsules of 200mg Route of administration: orally Dosage: 2 capsules per day (400 mg EGCG/day) Frequency: one capsule in the morning (fasting state) and a second capsule in the afternoon (before dinner).~   Treatment period: 3 months (from month 1 to month 4)~2. Cognitive training: non-pharmacological cognitive training 3 sessions per week (1 hour per session) by using the Feskits program."
62204099|NCT01855971|PLACEBO_COMPARATOR|Fragile X syndrome control group|"1. Placebo administration. Placebo consists in capsules containing rice flour. Dosage form: capsules Route of administration: orally Dosage: 2 capsules per day Frequency: one capsule in the morning (fasting state) and a second capsule in the afternoon (before dinner).~2. Cognitive training: non-pharmacological cognitive training 3 sessions per week (1 hour per session) by using the Feskits program."
62204100|NCT00318721|EXPERIMENTAL|Intervention|
62204101|NCT00318721|NO_INTERVENTION|control|
62403898|NCT04329156|ACTIVE_COMPARATOR|Stock Healing Abutment|
62403899|NCT02092207|EXPERIMENTAL|KL7016 900mg|
62403900|NCT02092207|PLACEBO_COMPARATOR|Placebo|
62403901|NCT02092207|EXPERIMENTAL|KL7016 600mg|
62403902|NCT02379442|EXPERIMENTAL|1|Target dose of 2 times 106 MSC/kg for up to 12 doses
62403903|NCT00283621|EXPERIMENTAL|Growth Factors + Adriamycin/Ifosfamide|Growth Factors = Aranesp (Darbepoetin Alfa) and Pegfilgrastim (Neulasta)
62403904|NCT01656109|EXPERIMENTAL|PI-experience group|Using PI-based HAART for ≥6 months at the screening visit HIV-RNA viral load \< 50 copies/ml at the screening visit No history of HIV-RNA ≥ 1,000 copies/ml while using PI-based HAART
62403905|NCT01656109|EXPERIMENTAL|PI-naïve group|Never been exposed to any PI-containing regimen HIV-RNA viral load ≥ 1,000 copies/ml at the screening visit
62403906|NCT04555798|PLACEBO_COMPARATOR|Group A|Group A continue on the same conventional way of management as mentioned above with conventional way of ventilation and broad spectrum antibiotics coverage
62403907|NCT04555798|ACTIVE_COMPARATOR|Group B|group B who connected to (A-VECMO).with venous access from femoral vien and arterial cannulation using the femoral artery
62580205|NCT03191461||Cancer Patients|Cancer patients with Stage I-III breast cancer or lymphoma that have received an anthracycline agent during treatment at least 2 years prior to enrollment in this study. Adenosine stress test MRI will be performed.
62580206|NCT03191461||Healthy Controls|Age-matched Healthy Control to cancer survivor with no history of cancer or anthracycline treatment. Adenosine stress test MRI will be performed.
62580207|NCT04028804||FDG PET|FDG PET imagaing
62580208|NCT04028804||FLT PET|FLT PET imaging
62580209|NCT05031195||1st tertile|
62580210|NCT05031195||2nd tertile|
62580211|NCT05031195||3rd tertile|
62580212|NCT01965886|ACTIVE_COMPARATOR|Medial approach|Medial parapatellar approach (classic approach)
62580213|NCT01965886|EXPERIMENTAL|Keblish approach|Lateral parapatellar approach (Keblish approach)
62580214|NCT06299761|EXPERIMENTAL|Single Agent Dose Escalation|Single agent BBI-825, administered orally, twice daily, in 28-day cycles
62580215|NCT04057560||SIBO Group|
62204102|NCT05412251|NO_INTERVENTION|contrl|provide an irregular nutrition counselling to case by nutritionist
62204103|NCT05412251|EXPERIMENTAL|intervention|Multi-domain intervention included exercise,cognitive training and diet education was conducted for five hours per week in the first month, second month and third month.
62580216|NCT04057560||Control Group|
62787151|NCT02391181|EXPERIMENTAL|test product|Iron sucrose injection solution 100mg (5 mL single dose ampoule 20mg/mL elemental iron as iron sucrose in water for injection)
62015101|NCT06085417|EXPERIMENTAL|Group Group B+D (bupivacaine + dexamethasone group) (n= 30)|For Group B+D (bupivacaine + dexamethasone group), 100 mg bupivacaine hydrochloride + 4 mg dexamethasone phosphate+ isotonic saline (4 ml) was administered in a total volume of 25 ml. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded. During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy.
62204104|NCT05730231|EXPERIMENTAL|Early time-restricted eating with calorie restriction|Participants will follow calorie restriction with early day time-restricted eating protocol with three planned meals from 8:00 AM to 4:00 PM.
62204105|NCT05730231|EXPERIMENTAL|Mid-day time-restricted eating with calorie restriction|Participants will follow calorie restriction with mid-day time-restricted eating protocol with three planned meals from 1:00 PM to 9:00 PM.
62204106|NCT05730231|EXPERIMENTAL|Daily calorie restriction|Participants will follow daily calorie restriction protocol with three planned meals from 8:00 AM to 9:00 PM.
62204107|NCT02604875||observational|Blood samples will be taken for measuring copeptin levels in healthy subjects.
62204108|NCT03749317|EXPERIMENTAL|Treatment|IVIEW-1201; four times per day (QID) for 7 days
62204109|NCT03749317|PLACEBO_COMPARATOR|Placebo|Placebo; four times per day (QID) for 7 days
62204110|NCT00568178|EXPERIMENTAL|Losartan Double-Blind Base Study (12-weeks)|"Normotensive participants received losartan.~Hypertensive participants received either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo)."
62204111|NCT00568178|ACTIVE_COMPARATOR|Amlodipine Double-Blind Base Study (12-weeks)|Hypertensive participants were randomized to receive either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo) for 12 weeks.
62403908|NCT06375902||Schizophrenia group|"We will enroll 32 patients selected according to the presence of Schizophrenia diagnosis (DSM V criteria), which will be tested for metaphor comprehension, as well as for the other variables included in the study, and the electrical brain activity will be registered through a 128 channel EEG.~Patients will be assigned either to a rehabilitative training (PragmaCom), or to a standard rehabilitative program to test if the altered neurophysiological patterns associated to the fragility of metaphor comprehension in schizophrenia can be restored."
62580217|NCT06685432|EXPERIMENTAL|intervention|
62580218|NCT05206084|EXPERIMENTAL|IBS|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System
62580219|NCT05206084|ACTIVE_COMPARATOR|XIENCE|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
62787152|NCT02391181|ACTIVE_COMPARATOR|reference product|Iron sucrose injection solution 100mg (5 mL single dose vial 20mg/mL elemental iron as iron sucrose in water for injection)
62787153|NCT04102995|EXPERIMENTAL|Sepranolone (UC1010) low dose|Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine
62403909|NCT06375902||Healthy controls group|32 healthy subjects, as control sample, that will be tested for metaphor comprehension, as well as for the other variables included in the study, and the electrical brain activity will be registered through a 128 channel EEG.
62787154|NCT04102995|EXPERIMENTAL|Sepranolone (UC1010) high dose|Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine
62580220|NCT03313466|EXPERIMENTAL|iCBTI|Intervention: An internet-based cognitive behavioral therapy program for insomnia (iCBTI) that is tailored to the individual's needs based on responses to questions.
62580221|NCT03313466|ACTIVE_COMPARATOR|Usual care|Intervention: A group class on insomnia provided at each Kaiser Permanente Southern California medical center.
62580222|NCT03486080|ACTIVE_COMPARATOR|Dutogliptin/filgrastim combination|Twice daily SC injections of 60 mg dutogliptin tartrate for 14 days in combination with 10 µg/kg filgrastim injectable product for 5 days
62580223|NCT03486080|PLACEBO_COMPARATOR|Placebo control|Twice daily dutogliptin SC placebos for 14 days in combination with matching filgrastim SC placebos for 5 days
62787155|NCT04102995|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine
62787156|NCT01847989|EXPERIMENTAL|rFXIII|
62580224|NCT04894916|EXPERIMENTAL|My Diabetes Care Mobile (MDC-m)|Patients have access to a patient web portal embedded with the My Diabetes Care Mobile (MDC-m) intervention.
62580225|NCT05875896||Rheumatoid Arthritis wrist destruction|Patients with rheumatoid arthritis who received an APTUS wrist fusion system after 01.01.2014
62787157|NCT01847989|PLACEBO_COMPARATOR|Placebo|
62580226|NCT05875896||Osteoarthritis wrist destruction|Patients with post-traumatic wrist osteoarthritis who received an APTUS wrist fusion system after 01.01.2014
62580227|NCT04231188||Primary Caregiver and infant pair|Primary Caregiver and infant who is less than or equal to 12 months old
62204112|NCT00568178|EXPERIMENTAL|Losartan Open-Label Extension Phase (Month 36)|Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
62204113|NCT00568178|ACTIVE_COMPARATOR|Enalapril Open-Label Extension Phase (Month 36)|Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
62204114|NCT04765332||Included patients|Fill patient questionnaires at inclusion visit, around 3 months and 12 months
62204115|NCT00090740||Asthmatics|People who have asthma
62204116|NCT00090740||Controls|People who do not have asthma
62204117|NCT02548975||Delirium|Patients diagnosed with delirium at any time postoperatively with the CAM-ICU.
62204118|NCT02548975||No delirium|Patients not diagnosed with delirium postoperatively.
62204119|NCT00821340|EXPERIMENTAL|rAAV2-hRPE65|
62204120|NCT03846453|EXPERIMENTAL|0.25% HL036 Ophthalmic Solution|Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment (CAE®) were conducted at Day 1, Day 15, Day 29 and Day 57
62204121|NCT03846453|PLACEBO_COMPARATOR|Placebo|Participants self-administered HL036 placebo (vehicle solution) as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
62204122|NCT06273280|ACTIVE_COMPARATOR|Standard of Care|Up-titration of GDMT at the discretion of the treating physician.
62204123|NCT06273280|EXPERIMENTAL|Intervention|Uptitration of GDMT according to the renal-based approach postulated by the Heart Failure Association of the European Society of Cardiology (HFA-ESC)
62204124|NCT05212727||Healthy Control|Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
62204125|NCT05539443|EXPERIMENTAL|Intensive Clinic Management (ICM)|
62204126|NCT05539443|EXPERIMENTAL|Intensive tailored telehealth management (ITTM)|
62204127|NCT01204931||Gastroesophageal Reflux Disease (GERD) Cases|"Erosive disease - presence of esophageal mucosal injuries documented endoscopically.~Non-erosive disease - normal esophagogastroduodenoscopy with symptoms"
62204128|NCT01204931||Control Group|normal subjects without symptoms of gastroesophageal reflux disease (GERD)
62204129|NCT01255254|EXPERIMENTAL|A: Scaling group|The experimental group will receive oral hygiene instruction (OHI) and full-mouth scaling using standard rigid Gracey curettes (Hu-Friedy® Manufacturing Inc., Chicago, IL, USA) and ultrasonic instrumentation (EMS piezoelectric system, Electro Medical Systems, Nyon, Switzerland) at week 1-2 and at a second reinforcement visit at 6-8 weeks. Subjects will also be instructed to rinse with 10ml of Chlorhexidine 0.2% mouthrinse twice daily for 30 seconds for the duration of the study.
62403910|NCT03462875||Crohn's Disease Patients|Subjects having confirmed diagnosis of Crohn's disease which is defined by endoscopy, radiology and histology; and having documented ileocaecal or right-sided colonic disease
62403911|NCT03462875||Non-household Controls|Non-affected subjects who will under colonoscopy for polyp or colorectal cancer screening, or investigations of gastrointestinal symptoms other than Inflammatory Bowel Disease
62580228|NCT06429787||BALFAXAR® (500 IU)|BALFAXAR will be administered by intravenous (IV) infusion at a rate of 0.12 mL/kg/min (\~3 units/kg/min), up to a maximum rate of 8.4 mL/min (\~210 units/min). Dosing is individualized based on the patient's baseline International Normalized Ratio (INR) value and body weight
62787158|NCT04764227|EXPERIMENTAL|Concurrent chemoradiotherapy group|"Interventions:~* Chemotherapy: Paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; Carboplatin AUC=2, ivgtt, d1; qw\*5~* Radiotherapy: A total dose of 50.4Gy will be delivered in 28 fractions at 1.8Gy/fraction, 5 fractions per week in 6 weeks. The CTV encompassed the bilateral supraclavicular, superior mediastinal, and subcarinal regions."
62204130|NCT01255254|NO_INTERVENTION|B: Control group|The control group will receive no periodontal treatment during the study. After completion of the study, these patients will be given oral hygiene instruction and a full mouth scaling.
62580229|NCT06429787||Kcentra® (500 IU)|KCENTRA will be administered by intravenous infusion at of 0.12 mL/kg/min (\~3 units/kg/min) up to a maximum rate of 8.4 mL/min (\~210 units/min). Dosing is individualized based on the patient's baseline International Normalized Ratio (INR) value and body weight.
62580230|NCT02858297|EXPERIMENTAL|Glucosamine/Corticosteroid 4|Topical steroid (triamcinolone acetonide 0.1 %) four times per day and (glucosamine sulfate 500 mg) orally three times per day for 8 weeks
62787159|NCT01665391|EXPERIMENTAL|fresolimumab 1 mg/kg total body weight|
62787160|NCT01665391|EXPERIMENTAL|fresolimumab 4 mg/kg total body weight|
62787161|NCT01665391|PLACEBO_COMPARATOR|Placebo|
62204131|NCT01663051||Stent|Stent
62204132|NCT06033599|EXPERIMENTAL|MORE and MI|
62204133|NCT06033599|EXPERIMENTAL|MORE and No MI|
62204134|NCT06033599|ACTIVE_COMPARATOR|Support Group and MI|
62204135|NCT06033599|ACTIVE_COMPARATOR|Support Group and No MI|
62204136|NCT04188275||Metastatic Castration Resistant Prostate Cancer|Metastatic Castration Resistant Prostate Cancer patients who are eligible for endocrine therapy with ARTA plus LHRH agonist.
62204137|NCT05293405|EXPERIMENTAL|Patients Group|
62204138|NCT05293405|SHAM_COMPARATOR|Healthy Volunteers Group|
62403912|NCT03462875||First Degree Relatives|Non-affected first degree relatives of cases
62403913|NCT03462875||Household/co-habitant Controls|Non-affected subjects living in the same household with the cases in the recent 6 months
62403914|NCT04254926|EXPERIMENTAL|Revie ⊕ intervention early|participants randomized into (i) the intervention group (IG) receive the Revie ⊕ intervention early on.
62204139|NCT04096170|EXPERIMENTAL|IV Lidocaine|100 mg Lidocaine bolus on induction, then an infusion of 1.5 mg/kg/hr to begin prior to incision, run throughout the operation and continues into PACU for 1 hour OR until one 2gm/250mL D5W bag has been infused, whichever occurs first. The Patient will be monitored by nursing staff with the aid of continuous cardiac monitoring in the PACU for at least 30 minutes after the discontinuation of the lidocaine drip.
62204140|NCT04096170|PLACEBO_COMPARATOR|Placebo|Patients will receive D5W solution at the same volume and rate as the IV lidocaine.
62204141|NCT04995029|EXPERIMENTAL|Induction Phase: Rapid Induction|Participants will receive 4 mg transmucosal buprenorphine on Day 1. Participants meeting eligibility requirements will then receive 300 mg extended-release buprenorphine by subcutaneous injection at least 1 hour later and a second dose on Day 8.
62204142|NCT04995029|EXPERIMENTAL|Induction Phase: Standard of Care Induction|Participants will receive transmucosal buprenorphine for a minimum of 7 days per applicable product labelling information. Participants meeting eligibility requirements will receive 300 mg extended-release buprenorphine by subcutaneous injection on Day 1 and a second dose on Day 8.
62204143|NCT04995029|EXPERIMENTAL|Maintenance Phase: Extended-release Buprenorphine 100 mg|Participants eligible to continue treatment will be randomized at Week 6 to receive maintenance doses of 100 mg extended-release buprenorphine by subcutaneous injection every 4 weeks for a total of up to 8 maintenance injections (Weeks 6 to 34).
62787162|NCT00770601|EXPERIMENTAL|Canakinumab|Participants received body-weight stratified dosage of canakinumab treatment at 300 milligrams (mg) (for participants weighing more than 40 kilograms (kg)) and at 2 mg/kg (for participants weight less than or equal to 40 kg) subcutaneously every 4-8 weeks as per investigator discretion for a treatment period of 6 months. The first 3 Neonatal-Onset Multisystem Inflammatory Disease (NOMID) participants enrolled received a dose of 150 mg (\>40 kg) and 2 mg/kg for children \<40 kg. Since this dose was insufficient to fully control the symptoms of the disease the 300 mg / 4mg/kg dose was introduced by Protocol Amendment 2.
62787163|NCT02559128||HF+T2D+|40 patients with chronic HF and type 2 diabetes or prediabetes without previous pharmacological treatment
62787164|NCT02559128||HF+T2D-|20 subjects with HF without T2D or prediabetes
62403915|NCT04254926|EXPERIMENTAL|Revie ⊕ intervention later|The control group (CG) receives the same intervention Revie ⊕ but later on (i.e., after eight weeks).
62787165|NCT02559128||HF-T2D+|20 subjects with T2D or prediabetes alone
62787166|NCT02559128||HF-T2D-|20 healthy control volunteers
62787167|NCT02146391|EXPERIMENTAL|Androxal 25 mg|
62787168|NCT03731091|EXPERIMENTAL|Calcipotriene/ betamethasone dipropionate topical foam|Topical foam once daily for 4 weeks (28 days)
62787169|NCT03731091|ACTIVE_COMPARATOR|Enstilar®|Topical foam once daily for 4 weeks (28 days)
62787170|NCT03731091|PLACEBO_COMPARATOR|Placebo|Topical foam once daily for 4 weeks (28 days)
62787171|NCT03543137|EXPERIMENTAL|Test Product|Participants will receive a single Nicotine Prototype Mini lozenge (4mg) by oral/buccal route of administration.
62787172|NCT03543137|ACTIVE_COMPARATOR|Reference Product|Participants will receive a single Nicorette Mini lozenge (4 mg) by oral/buccal route of administration.
62787173|NCT01472068|EXPERIMENTAL|Inko RS device|30 minutes of treatment with the Inko RS device, five days each week, for 12 weeks.
62787174|NCT03047239|EXPERIMENTAL|Open angle glaucoma|SENSIMED Triggerfish
62787175|NCT05058924|ACTIVE_COMPARATOR|Prophylactic Low Molecular Weight Heparin (LMWH)|Prophylactic LMWH for 6 weeks postpartum
62787176|NCT05058924|EXPERIMENTAL|Prophylactic Low Molecular Weight Heparin (LMWH) + Low Dose Aspirin|Prophylactic LMWH for 3 weeks followed by low dose Aspirin for 3 weeks.
62787177|NCT04770402|EXPERIMENTAL|Acupuncture|
62787178|NCT04770402|ACTIVE_COMPARATOR|Standard of Care|
62787179|NCT00662116|EXPERIMENTAL|1|
62787180|NCT00662116|PLACEBO_COMPARATOR|2|
62787181|NCT06508671|EXPERIMENTAL|dl-3-n-butylphthalide|Take 200 mg butylphthalide soft capsules (NBP) orally three times a day for 24 weeks
62787182|NCT06508671|PLACEBO_COMPARATOR|placebo|Take 200 mg placebo of the same appearance with NBP orally three times a day for 24 weeks
62787183|NCT04519346|OTHER|Compare to sistemic treatment and mesotherapy.|This is a prospective parallel randomized controlled trial conducted with patients admitted to our emergency department with migraine pain
62787184|NCT03157284|PLACEBO_COMPARATOR|Placebo|Placebo Group will receive 7gr Maltodextrin
62787185|NCT03157284|EXPERIMENTAL|Intervention Rice Flour|The Intervention Group will receive 7gr of the experimental ingredient fermented Rice Flour
62787186|NCT00720343|EXPERIMENTAL|Choline|Oral choline
62787187|NCT00720343|PLACEBO_COMPARATOR|Placebo|Gelatin Capsule
62787188|NCT04520399||violence|
62787189|NCT04520399||non-violence|
62787190|NCT02293603|EXPERIMENTAL|Allogeneic Cardiosphere-Derived Cells|"The Phase I study consists of a Phase Ia portion and a Phase Ib portion. The Phase Ia portion (N=14 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=28 subjects) consists of a double-blind, randomized, placebo-controlled study design.~The Phase Ia portion is an open-label, dose escalation of Allogeneic Cardiosphere-Derived Cells (CDCs)."
62787191|NCT02293603|PLACEBO_COMPARATOR|Placebo|The placebo study arm only applies to the Phase Ib portion of the study design. The Phase Ia portion (N=14 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=28 subjects) consists of a double-blind, randomized, placebo-controlled study design.
62787192|NCT04294602|EXPERIMENTAL|Exercise Program|This group received therapeutic exercises and patient education. For patients to encounter fewer problems and to reduce their problems, some recommendations were made that should be taken into consideration in daily life. These suggestions were given in writing. The exercise program included muscle stretching, massage of painful muscles, guided opening and closing movements, gentle isometric tension exercises against resistance, correction of body posture and relaxation techniques. All exercises were done in 6 repetitions a set, 3 sets a day, 3 days a week, treatment program lasted 4 weeks.
62204144|NCT04995029|EXPERIMENTAL|Maintenance Phase: Extended-release Buprenorphine 300 mg|Participants eligible to continue treatment will be randomized at Week 6 to receive maintenance doses of 300 mg extended-release buprenorphine by subcutaneous injection every 4 weeks for a total of up to 8 maintenance injections (Weeks 6 to 34).
62204145|NCT02716636|NO_INTERVENTION|Fast placement|Placement of the tenaculum quickly and without avoiding ratchet
62204146|NCT02716636|EXPERIMENTAL|Slow placement of the tenaculum|Placement of the tenaculum over a 7-10 second time frame and not allowing the tenaculum to ratchet audibly.
62204147|NCT04774653||MIH Group in short stature from 6-8 years old|Molar Incisor Hypomineralization in stunted children aged from 6-8 years
62204148|NCT04774653||HSPM Group in short stature from 5-8 years old|Hypomineralization of Second Primary Molars in stunted children aged from 5-8 years
62204149|NCT04774653||Both MIH &HSPM Group in stunted (from 5-8) years old|When both primary molars and permanent teeth( First permanent molars \& permanent incisors) are hypo-mineralized in children with short stature with age range from 5-8 years old
62787193|NCT04294602|EXPERIMENTAL|Low Level Laser Therapy Program|This group received LLLT, therapeutic exercises and patient education in the therapy programs. LLLT (max output power: 1200mW, wavelength: 808 nm, dosage: 10j/ cm2 Electronica Pagani Laser Tower Light, Italy) 2.5-4j/TrP dosage was applied to MTrP or sensitive points. The application was applied to MTrP or sensitive points in the mastication and cervical muscles.LLLT program was done in 3 days a week, the treatment program lasted 4 weeks.
62787194|NCT04294602|EXPERIMENTAL|Manual Pressure Release Program|ThisThis group received manual pressure release (MPR), therapeutic exercises and patient education in the therapy programs. MPR technique is a noninvasive method based on pressure on the trigger point in accordance with the patient's tolerance and technique applies supine position relax as much as possible, MTrPs in the mastication and neck muscle. Applied pressure gradually with finger over the MTrPs until the subject reported a 'moderate but easily tolerable' pain value of 7 out of 10. When the pain value decreased to at least 3 or 4 therapist increased pressure again until discomfort and/or pain appeared again. This process was repeated until there was no MTrP tension/tenderness or 60 s had elapsed. MPR program was done in 3 days a week, the treatment program lasted 4 weeks.
62204150|NCT06190106|EXPERIMENTAL|Experimental treatment group|Participants had received 8-10 cognitive behavior therapy-based therapeutic sessions and their feedback was taken to check the positive and negative effects of Psychotherapeutic Intervention (cognitive-behavioral intervention).
62204151|NCT01461811|EXPERIMENTAL|DAILIES® AquaComfort Plus® Toric|Nelfilcon A toric contact lenses (with comfort additives) worn in both eyes on a daily wear, daily disposable basis for three months
62787195|NCT03427723|ACTIVE_COMPARATOR|Standard care|visualization and palpation
62787196|NCT03427723|EXPERIMENTAL|Accuvein|system uses an infrared laser beam to project the image of superficial veins to the skin
62787197|NCT05887050|ACTIVE_COMPARATOR|Active|Tablet containing 400 mcg chromium (delivered as Crominex® 3+, a blend of chromium, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and 325 mg of MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoid Complex)
62787198|NCT05887050|PLACEBO_COMPARATOR|Placebo|Identical size, shape, and weight maltodextrin tablet
62787199|NCT03187444|EXPERIMENTAL|Patients with chronic inflammatory rheumatism|All patients over 18 years, with rheumatoid arthritis treated for the first time with conventional anti-TNF therapy, Abatacept, Tocilizumab, Rituximab or patients with spondyloarthritis treated for the first time with NSAIDs that may be associated with conventional background treatments for peripheral or biological (anti-TNF, Usketinumab) may be included.
62204152|NCT01461811|ACTIVE_COMPARATOR|Focus® DAILIES® Toric|Nelfilcon A toric contact lenses worn in both eyes on a daily wear, daily disposable basis for three months
62204153|NCT02102607||age|subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
62204154|NCT04744545|EXPERIMENTAL|Meru Health Program plus adjunctive curcumin (MHP-CUR)|Meru Health Program (12 week program) with participants taking 2 turmeric supplements (1500mg/day) curcumin.
62204155|NCT04744545|ACTIVE_COMPARATOR|Meru Health Program (MHP-ONLY)|Meru Health Program (12 week program)
62204156|NCT01996462|EXPERIMENTAL|Torrent's of Escitalopram Oxalate Tablet 20 mg|
62204157|NCT01865747|EXPERIMENTAL|Cabozantinib (XL184)|Cabozantinib (XL184) 60 mg tablet once daily.
62204158|NCT01865747|ACTIVE_COMPARATOR|Everolimus (Afinitor)|Everolimus (Afinitor) 10 mg tablet once daily.
62204159|NCT03599258|OTHER|Arm 1|Skylife device
62204160|NCT03599258|ACTIVE_COMPARATOR|Arm 2|Standard therapy
62204161|NCT01291940|EXPERIMENTAL|Pediatric Moisturizer Intervention|Apply one of four moisturizers to one arm daily for four weeks.
62204162|NCT01291940|EXPERIMENTAL|Adult Moisturizer Intervention|Apply moisturizer to one arm once a day for four weeks.
62204163|NCT01291940|NO_INTERVENTION|Adult Control|No intervention.
62204164|NCT05114486|EXPERIMENTAL|Pilocarpine 2% Ophthalmic Spray|2% pilocarpine ophthalmic spray administered with the Optejet dispenser
62204165|NCT05114486|PLACEBO_COMPARATOR|Placebo Spray|Placebo ophthalmic spray administered with the Optejet dispenser
62204166|NCT01134224|EXPERIMENTAL|NN5401 - low dose|
62204167|NCT01134224|EXPERIMENTAL|NN5401 - medium dose|
62204168|NCT01134224|EXPERIMENTAL|NN5401 - high dose|
62204169|NCT01134224|ACTIVE_COMPARATOR|biphasic insulin aspart 30 - low dose|
62204170|NCT01134224|ACTIVE_COMPARATOR|biphasic insulin aspart 30 - medium dose|
62403916|NCT05138458|EXPERIMENTAL|Cohort 1 and Cohort 3|MT-101
62580231|NCT02858297|EXPERIMENTAL|Glucosamine/Corticosteroid 2|Topical steroid (triamcinolone acetonide 0.1 %) twice per day and (glucosamine sulfate 500 mg) orally three times per day for 8 weeks
62580232|NCT02858297|ACTIVE_COMPARATOR|Corticosteroid|Topical steroid (triamcinolone acetonide 0.1 %) four times per day for 8 weeks
62580233|NCT03878615||Elective Hepatic Surgery|Patientes undergoing elective hepatic resection, managed according to departement routine.
62204171|NCT01134224|ACTIVE_COMPARATOR|biphasic insulin aspart 30 - high dose|
62403917|NCT05138458|EXPERIMENTAL|Cohort 2 and Cohort 4|MT-101 preceded by conditioning (lymphodepleting) chemotherapy
62403918|NCT03590158|EXPERIMENTAL|TRF|Participants will follow their regular diet for two weeks before 3-day lead-in food prior to the metabolic testing at visit 0. Participants will then be instructed to eat their habitual diet only within a 10-hour time frame each day for 8 weeks. Participants may self-select the precise window that best suits their lifestyles, however any food and drink must be consumed by 7:30pm.
62403919|NCT05689164|OTHER|All participants|All participants enrolled in the study.
62403920|NCT03732534|EXPERIMENTAL|NBI-98854|NBI-98854 administered once daily for up to 96 weeks
62403921|NCT01382875|NO_INTERVENTION|Conventional care program|
62403922|NCT01382875|EXPERIMENTAL|Multi-disciplinary management program|
62787200|NCT03023293||gestational diabetes mellitus|The investigators plan to establish a prospective GDM cohort and collect n-3 PUFAs consumption and irisin information at 24-28 weeks'gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum, respectively.
62787201|NCT06025981|OTHER|Preliminary Phase|20 healthy subjects will perform an experimental session for characterization of functional status with clinical scales; characterization of gait with SWalker using ROM and EMG at different speeds and weight bearing; and assessment of system usability with VR using standardized questionnaires.
62787202|NCT06025981|OTHER|Phase I and II|In both phases 100 subjects will perform a gait rehabilitation intervention program (phase 1) and maintenance (phase 2), in which they will employ the use of the robotic walker and virtual reality depending on the group and phase. The evolution of functional clinical parameters will be studied for both groups and phases.
62787203|NCT03106974|ACTIVE_COMPARATOR|Macintosh Laryngoscope|orotracheal intubation (OTI) with Macintosh Laryngoscope Direct laryngoscopy
62787204|NCT03106974|ACTIVE_COMPARATOR|Totaltrack VLM|orotracheal intubation (OTI) with Totaltrack VlM Indirect laryngoscopy
62204172|NCT04534608||Asymptomatic children w/out an underlying condition|
62403923|NCT02775409|ACTIVE_COMPARATOR|Subcutaneous|Subcutaneous placement of tissue expander
62403924|NCT02775409|ACTIVE_COMPARATOR|Submuscular|Submuscular placement of tissue expander
62580234|NCT06640335|NO_INTERVENTION|Control (All 24 participants)|Subjects consume 300 g of Russet Burbank mashed Potatoes
62580235|NCT06640335|EXPERIMENTAL|Co-ingestion (All 24 participants)|Subjects co-ingest both (300 g mashed potatoes) and (200 g baby round spinach supplemented with canola oil) in the same time.
62580236|NCT06640335|EXPERIMENTAL|0 min preload (meal sequence) (10 participants)|Subjects consume 200 g baby round spinach supplemented with canola oil first, then directly consume 300 g of mashed potatoes.
62580237|NCT06640335|EXPERIMENTAL|5 min preload (10 participants)|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 5 minutes, then consume 300 g of mashed potatoes.
62580238|NCT06640335|EXPERIMENTAL|10 min preload (10 participants)|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.
62580239|NCT06640335|EXPERIMENTAL|15 min preload (10 participants)|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 15 minutes, then consume 300 g of mashed potatoes.
62580240|NCT06640335|EXPERIMENTAL|20 min preload (10 participants)|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 20 minutes, then consume 300 g of mashed potatoes.
62787205|NCT01734642||PATIENT HOSPITALIZED|ALL THE PATIENTS HOSPITALIZED IN THE INVOLVED UNITS WHO GAVE THEIR INFORMED CONSENT. PATIENTS HOSPITALIZED DURING THE WEEK-END WILL BE ENROLLED ON the next MONDAY
62204173|NCT04534608||Asymptomatic children with underlying condition(s)|
62204174|NCT04534608||Children with COVID-19 symptoms w/out an underlying condition|
62204175|NCT04534608||Children with COVID-19 symptoms with underlying condition(s)|
62204176|NCT06175377|ACTIVE_COMPARATOR|Long dual Aspirin/Clopidogrel therapy|Patients will be treated with usual long dual antiplatelet aggregation for 6 to 12 months
62204177|NCT06175377|EXPERIMENTAL|Short dual Aspirin/Clopidogrel therapy|Patients will be treated with short dual antiplatelet aggregation for 1month
62403925|NCT00666952|EXPERIMENTAL|1|
62403926|NCT00666952|ACTIVE_COMPARATOR|2|
62403927|NCT00743873|PLACEBO_COMPARATOR|2|saline
62403928|NCT00743873|EXPERIMENTAL|1|Plasma Rich in Growth Factors (PRGF)
62403929|NCT01683565|EXPERIMENTAL|LCPUFA Oil Supplement|EPA + DHA + GLA + OA oil supplement
62403930|NCT01683565|PLACEBO_COMPARATOR|Canola Oil Placebo|
62403931|NCT03268252||2x/year MDA|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given twice per year
62403932|NCT03268252||1x/year MDA|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once per year
62403933|NCT05406466|EXPERIMENTAL|Cryoablation in combination with Tislelizumab plus lenvatinib|Cryoablation treatment starts at day 0. Tislelizumab plus lenvatinib will be initiated on day 14 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks plus a lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62403934|NCT05072431|EXPERIMENTAL|Experimental group|The participants in the experimental group received the 3D VR training program.
62403935|NCT05072431|NO_INTERVENTION|Control group|The control group did not receive any intervention.
62015102|NCT06085417|ACTIVE_COMPARATOR|Group B+M (bupivacaine + magnesium group) (n= 30)|"For Group B+M (bupivacaine + magnesium group), 100 mg bupivacaine hydrochloride (20ml 0.5% marcaine aspen, turkey) + 150 mg magnesium sulfate (1ml 15% magnesium sulfate, onfarma, turkey) + isotonic saline (4 ml) was administered in a total volume of 25 ml. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
62015103|NCT06457152|EXPERIMENTAL|Intervention|Participants who are randomized to receive the intervention (i.e., displaying the automated EHR-embedded alert).
62580241|NCT06640335|EXPERIMENTAL|Spinach only /10 min preload (All 24 participants)|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.
62580242|NCT06640335|EXPERIMENTAL|(Spinach + Canola oil) 10 min preload (All 24 participants)|Subjects consume 200 g baby round spinach WITHOUT canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.
62580243|NCT06640335|EXPERIMENTAL|Canola oil only / 10 min preload (All 24 participants)|Subjects consume 20 g of canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.
62580244|NCT05499221|ACTIVE_COMPARATOR|Conventional anchorage|Buccal tubes will be bonded on the lower first molars, an alginate impression will be taken for the lower arch with the buccal tubes in place, and a cast will be poured. A hard vacuum sheet of 1.5- mm thickness will be used to fabricate the Essix appliance. The posterior end of the buccal surface will be trimmed in each lower first molar region, creating a window to allow for attachment of the elastics. Class II elastics will be attached from the maxillary canine to the mandibular first molar bilaterally. During the first month, 1/4-inch heavy elastics will be used. In the following months, 3/16-inch heavy elastics will be used. The patients will be instructed to wear the elastics 24 hours per day, except during mealtimes, and to change them daily.
62787206|NCT06265506|ACTIVE_COMPARATOR|Control Condition (Non-contingent Incentives + CBT4CBT)|Participants will receive 8 weeks of Computer Based Training for Cognitive Behavioral Health (CBT4CBT). CBT4BCT is a self paced web-based program that uses videos and lessons to help people learn skills they can use to cut down or stop drinking. Participants will receive a $10 e-gift card for every PEth sample submitted within 48 hours of the visit regardless of the result. Participants will receive gift card incentives when they attend visits and provide blood samples (PEth Samples). Participants will submit PEth samples weekly for the first four weeks of the study, then every two weeks (weeks six, eight), then every four weeks (weeks 12,16, 20, 24), and at week 26. Each time they submit a PEth sample, they will receive gift cards equal to the average CM earnings during the previous month, resulting in total average earnings equivalent to the CM group. This group will receive incentives regardless of the results of their PEth tests.
62787207|NCT06265506|EXPERIMENTAL|CM Condition (Contingency Management + CBT4CBT)|Participants will receive 8 weeks of CBT4CBT and incentives for timely shipping. In addition, those in the CM Condition will receive at least $20 for each PEth-negative sample. Participants will receive an additional $5 for each week of consecutive negative PEth tests, with a $90 cap. In Initiation Phase, participants will attend virtual visits, provide PEth samples, and be rewarded for a decrease in PEth weekly. Maintenance Phase will begin when a participant's PEth sample is \< 20 ng/mL. In Maintenance Phase, participants will attend visits and submit PEth samples every two weeks for four weeks (i.e., weeks 6 \& 8). They will then attend visits and submit PEth samples every four weeks (weeks 12, 16, 20, 24), and on week 26. If participants submit a positive PEth sample, they will return to Initiation Phase and receive $20 for their next negative sample. Participants will attend visits and submit samples weekly until their PEth level is \< 20 ng/mL and they restart Maintenance Phase.
62787208|NCT03282513|EXPERIMENTAL|Cohort 1A: Mild Hepatic Impairment|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with mild hepatic impairment(Child-Pugh Score A.)"
62787209|NCT03282513|ACTIVE_COMPARATOR|Cohort 1B: Healthy Volunteers|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with normal hepatic function."
62580245|NCT05499221|EXPERIMENTAL|Skeletal anchorage|Closing coil springs will be attached from the maxillary canine to the infrazygomatic miniscrews bilaterally
62580246|NCT02764372|EXPERIMENTAL|Serious games|The experimental group received Serious Games-based upper extremity therapy through Kinect
62015104|NCT06457152|NO_INTERVENTION|Standard of Care|Participants who are randomized to the control group (i.e., not displaying the automated EHR-embedded alert).
62015105|NCT03833544|EXPERIMENTAL|Treatment Arm|Exercise training: Progressive resistance training of hip, knee, and ankle flexors.
62204178|NCT02773173|EXPERIMENTAL|Individualized Pneumoperitoneum Pressure|In Individualized Pneumoperitoneum Pressure (IPP) group, measures to optimize and individualize intra-abdominal pressure (PIA) will be apply.
62015106|NCT06416488|EXPERIMENTAL|HIIT group|HIIT group will follow modified HIIT in Tabata mode, at least 3 times per week, with 3-month compulsory period and 9-month follow-up period. General health education on promoting health diet and exercise will be sent to HIIT group via offline and online promotion materials during the whole study period of 12 months.
62403936|NCT04851509|ACTIVE_COMPARATOR|Dynamic rotational locking|Using a fracture table, the affected leg will be placed into traction and the patient will be prepped and draped in the usual fashion. The fracture will be provisionally reduced using closed techniques. A 3cm incision will be used to gain access to the intramedullary canal and the nail (either a short nail or long nail, at the discretion of the treating surgeon) will be introduced to the femur. The screw will be placed across the fracture and into the femoral head, aiming for a tip-to-apex distance less than 25mm. The compression nut will be used to compress the fracture. The screw will be rotationally locked by using the 5mm hex flexible screwdriver by advancing the set screw until it stops completely. The screw will then be turned counterclockwise by a ½ turn.
62403937|NCT04851509|EXPERIMENTAL|Static locking|Using a fracture table, the affected leg will be placed into traction and the patient will be prepped and draped in the usual fashion. The fracture will be provisionally reduced using closed techniques. A 3cm incision will be used to gain access to the intramedullary canal and the nail (either a short nail or long nail, at the discretion of the treating surgeon) will be introduced to the femur. The screw will be placed across the fracture and into the femoral head, aiming for a tip-to-apex distance of less than 25mm. The compression nut will be used to compress the fracture. The screw will then be statically locked using the 6Nm torque-limiting blue handle with 6mm hex coupling to completely lock the set screw down on the helical screw.
62403938|NCT01173380|SHAM_COMPARATOR|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
62403939|NCT01173380|ACTIVE_COMPARATOR|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
62403940|NCT00843232||Elderly T2DM|Elderly T2DM subjects 65 to 80 years old
62403941|NCT00843232||Middle-age T2DM|Middle-age T2DM subjects 35 to 50 years old
62403942|NCT02689973|EXPERIMENTAL|Self-efficacy|The self-efficacy intervention protocol included following behavior change techniques (BCT; Michie et al., 2011): barrier identification, prompting focus on past success, and prompting self-talk. Applications of all BCT included references to self-efficacy beliefs. The intervention was integrated into health promotion-nutrition education program (8h). The intervention was applied twice (the baseline and 2-month follow-up).
62403943|NCT02689973|EXPERIMENTAL|Planning|"The following BCT were included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning.~The intervention was integrated into health promotion-nutrition education program (8h). The intervention was applied twice (the baseline and 2-month follow-up)."
62580247|NCT02764372|ACTIVE_COMPARATOR|Exergames|The control played the same amount of time with commercial exergames of the Wii
62787210|NCT03282513|EXPERIMENTAL|Cohort 2A: Moderate Hepatic Impairment|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with moderate hepatic impairment (Child-Pugh Score B.)"
62787211|NCT03282513|ACTIVE_COMPARATOR|Cohort 2B: Healthy Volunteers|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with normal hepatic function."
62015107|NCT06416488|ACTIVE_COMPARATOR|General health education group|General health education on promoting health diet and exercise will be sent to general health education group via offline and online promotion materials during the whole study period of 12 months.
62015108|NCT02369133|ACTIVE_COMPARATOR|Group Paracetamol (Group P),|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol
62580248|NCT01515865|EXPERIMENTAL|Midodrine HCl|
62580249|NCT01515865|PLACEBO_COMPARATOR|Placebo|
62580250|NCT01293890||COPD patients with hospital admission for exacerbation|
62787212|NCT06555484|OTHER|Air First|All study participants, completing memory tests while breathing either supplemental oxygen followed by air, or breathing air followed oxygen.
62787213|NCT06555484|OTHER|Oxygen First|All study participants, completing memory tests while breathing either supplemental oxygen followed by air, or breathing air followed oxygen.
62787214|NCT00374933|EXPERIMENTAL|1|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
62015109|NCT02369133|PLACEBO_COMPARATOR|Group Saline (Group S)|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group S (n = 30) received 100 ml iv %0,9 saline
62580251|NCT02692872||1|We plan to perform genetic screening of up to 2,000 individuals of African ancestry, an ethnic group with a high prevalence of alpha thalassemia.
62580252|NCT05045079|OTHER|Severe tricuspid regurgitation due to atrial fibrillation|Subjects will receive standard of care procedure right heart catheterization with a inferior vena caval (IVC) occlusion maneuver.
61978478|NCT01472081|EXPERIMENTAL|Arm IN-3: Nivolumab+Ipilimumab|"Nivolumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase and 3mg/kg solution intravenously (IV) every 14 days during Maintenance phase~Ipilimumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase. Ipilimumab will not be administered during Maintenance phase"
62015110|NCT00477711|EXPERIMENTAL|C225+Chemotherapy|
62015111|NCT05044741||Perforated group|
62015112|NCT05044741||Controlled group|
62580253|NCT03952299|ACTIVE_COMPARATOR|Oral administration|"Oral oxybutynin (5mg) is administered in the preoperative area prior to surgery. The current regimen is to mix the oxybutynin with the standard preoperative Versed so children do not have to take two dosages.~Post-operatively oral oxybutynin (5mg) is administered every 8 hours in the hospital."
62580254|NCT03952299|EXPERIMENTAL|Transdermal administration|Guardian will be given the transdermal patch (3.9mg oxybutynin) at the preoperative appointment with instructions to apply the day prior to surgery. While in the hospital no oral oxybutynin will be prescribed.
62204179|NCT02773173|OTHER|Standard Pneumoperitoneum Pressure|In Standard Pneumoperitoneum Pressure (SPP) group, a conventional operation without optimization measures and PIA preset to 12 mmHg will be conducted.
62204180|NCT02842177|ACTIVE_COMPARATOR|Group I (classic method)|
62580255|NCT01397825|EXPERIMENTAL|Safety Lead-in|Alisertib 50 mg, enteric coated tablets (ECT), orally, twice daily (BID), on Days 1 to 7 followed by a 14-day rest period in 21-day cycles plus rituximab 375 mg/m\^2, intravenous (IV), infusion on Day 1 of each 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
62204181|NCT02842177|ACTIVE_COMPARATOR|uterine sound sparing group|
62204182|NCT00329680|EXPERIMENTAL|1|Experimental arm will receive an enteral diet enriched with EPA, GLA and Antioxidant vitamins
62204183|NCT00329680|PLACEBO_COMPARATOR|2|"This arm will receive an enteral diet considered as a standard ICU diet, isocaloric to the control diet but not enhanced with EPA, GLA and antioxidant vitamins"
62204184|NCT03163927|EXPERIMENTAL|Intervention|Participants receive a 1.5-hour standardized simulation-based training course, with mastery learning.
62204185|NCT03163927|NO_INTERVENTION|Control|Participants observe a procedure performed by a senior.
62204186|NCT02510040||Convergence insufficiency|Eligible adults with convergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
62204187|NCT02510040||Divergence insufficiency|Eligible adults with divergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
62204188|NCT02510040||Small-angle hypertropia|Eligible adults with small-angle hypertropia can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
62580256|NCT01397825|EXPERIMENTAL|Dose Escalation, Alisertib 30 mg|Alisertib 30 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m\^2, IV, infusion on Day 1, plus vincristine 1.4 mg/m\^2 (max 2 mg), IV, on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
62734837|NCT01662557|ACTIVE_COMPARATOR|Family Behavior Modification|Family-based behavior modification with parent and child using goal setting, self monitoring, reinforcement, behavioral skills training, and tasting opportunities.
62787215|NCT03803384|EXPERIMENTAL|ESWT Order A and B|First Endurance Shuttle walk test (A) with supplemental Oxygen therapy via auto-regulated oxygen flow rates (FreeO2) to maintain a oxygen saturation of 92% and second Endurance Shuttle walk (B) test with supplemental Oxygen therapy via constant oxygen flow rates
61978479|NCT02101645|EXPERIMENTAL|LIDC treatment and bioimpedance monitoring of venous ulcers.|Lower extremity venous ulcers will be treated using periodical LIDC stimulation. Wound healing and edema reduction efforts will be monitored using bioimpedance based monitoring.
62204189|NCT03952052|OTHER|Patient enrolled|Recurrent mutations determination
62204190|NCT04162379|OTHER|Prospective quizi-pre-post oral predensolone|single group and will take oral prednisolone (sulopride10 mg) single dose every two days for 4 successive weeks then the next two weeks as washout period (stop dosing gradually by taking 5 mgs for 3 successive dosing every 2nd day over a week, then stop the oral steroid drug totally over the 2nd week of the washout period. The second period of the study will start by taking the oral prednisolone (sulopride10 mg) every fourth day for the next 4 weeks after which the patient will get another washout two weeks period (stop dosing gradually 5 mgs for 3 successive dosing every 4th day then stop the drug totally).
62204191|NCT03956251|EXPERIMENTAL|Combined Mineralized/Demineralized Putty Allograft|Ridge preservation with a Mineralized/Demineralized Putty allograft
62204192|NCT03956251|ACTIVE_COMPARATOR|Demineralized Putty Allograft|Ridge preservation with Demineralized Putty allograft
62204193|NCT02731690|EXPERIMENTAL|Open Label UX001, 6g/day|
62403944|NCT02689973|EXPERIMENTAL|Combined planning+self-efficacy|This condition included all BCT applied in the planning and self-efficacy arms. The intervention was integrated into health promotion-nutrition education program. The intervention was applied twice (the baseline and 2-month follow-up).
62403945|NCT02689973|ACTIVE_COMPARATOR|Education|The education group received extended physical activity education program. The physical activity education was integrated into health promotion-nutrition education program.The education program was applied twice (the baseline and 2-month follow-up).
62403946|NCT02463604|EXPERIMENTAL|Remote Ischemic Preconditioning|"A blood pressure cuff is placed on upper arm and inflated to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle is repeated 3 times in total.~The procedure has to be completed between 5 and 60 minutes prior coronary angiography."
62734838|NCT01662557|OTHER|Minimal Nutrition Information|Weekly mailings emphasizing healthy eating guidelines for families.
62787216|NCT03803384|EXPERIMENTAL|ESWT Order B and A|First Endurance Shuttle walk test (B) with supplemental Oxygen therapy via constant oxygen flow rates and second Endurance Shuttle walk (A) test with supplemental Oxygen therapy via auto-regulated oxygen flow rates (FreeO2) to maintain a oxygen saturation of 92%
62787217|NCT00230932||Group 1|outpatients selected from random visits in primary care, oncology, and cardiology clinics
62787218|NCT00539305|EXPERIMENTAL|Study drug; testosterone transdermal gel|Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl
62787219|NCT00539305|PLACEBO_COMPARATOR|2|
62787220|NCT02091765|NO_INTERVENTION|Minimal intervention control group|Women who are assigned to the control group will be contacted by telephone by a member of the study staff to inform them about this allocation. They will receive a booklet per mail that addresses 80 questions about sexuality and cancer. Six weeks later, they will receive an empathetic phone call from one of the sexologists, during which there is also time available to discuss further questions the participants may have concerning sexuality and cancer. The purpose of keeping in contact with the control group, as opposed to a pure waiting list control group, is creating the opportunity to provide some control for a possible attention placebo-effect. The final questionnaire will be completed twenty weeks post study entry, after which women will be given the opportunity to undergo the internet-based cognitive behavioral program.
62204194|NCT01169012|OTHER|Single Arm Trial|Single Arm Trial
62204195|NCT02275429|OTHER|Runners|Each year, about 1,200 runners residing on Reunion Island take the start of the Madmen's Diagonal ultramarathon. Among those, 500 runners will be selected at random and will receive a letter informing them of the study and requesting their participation. Those who accept are to contact the study team. Among those volunteers, 100 runners will be selected randomly and included in the study. They will undergo a blood test the day before the race starts (day 0, when they retrieve their race number), upon completion of the race, and upon days 7 and 28.
62204196|NCT05634278|PLACEBO_COMPARATOR|Mind wandering|
62204197|NCT05634278|ACTIVE_COMPARATOR|Preoperative Mindfulness|Participants will only listen to the guided meditation practice before surgery.
62204198|NCT05634278|ACTIVE_COMPARATOR|Preoperative and Postoperative Mindfulness|Participant will listen to the guided meditation practice before surgery and during their hospital stay after surgery.
62204199|NCT01245140|ACTIVE_COMPARATOR|Active|to receive study drug (alitretinoin, 20 patients)
62403947|NCT02463604|SHAM_COMPARATOR|Control|"A blood pressure cuff is placed on upper arm and inflated to 10 mmHg for 5 minutes and then deflated for 5 minutes. This cycle is repeated 3 times in total.~The procedure has to be completed between 5 and 60 minutes prior coronary angiography."
62403948|NCT01801306|OTHER|NeMoProbe|The NeMo System is used for intracranial pressure (ICP) and brain temperature monitoring, as well as the determination of the brain tissue oxygenation saturation (SbtO2) and cerebral blood flow. The sensors for NIRS are implemented into a conventional brain tissue probe for ICP monitoring (NeMo Probe).
62403949|NCT03315442|SHAM_COMPARATOR|Caffeine Group|Caffeine group consumed 200mg of caffeine one time.
62403950|NCT03315442|EXPERIMENTAL|Energy Drink Group|The energy drink group consumed 1 16 ounces energy drink one time.
62403951|NCT06301126|EXPERIMENTAL|Virtual reality|Participants will receive VR for 20 minutes followed by conventional physical therapy program for 45 minutes, 5 days/ week for 8 weeks.
62403952|NCT06301126|ACTIVE_COMPARATOR|Control|Participants will receive conventional physical therapy program (Deep diaphragmatic, costal breathing exercises, bronchial hygiene techniques and assisted cough) for 45 minutes, 5 days/ week for 8 weeks.
62403953|NCT01255865||A1 - up to 1 month|Age group 0 up to 1 month
62403954|NCT01255865||A2 - 1 to 3 months|Age group from 1 month to 3 months
62403955|NCT01255865||A3 - 3 months to 1 year|Age group from 3 months to 1 year
62403956|NCT01255865||B - 1 year to 5 years|Age group from older than 1y and younger than 5 years
62403957|NCT01255865||C - 5 years to 12 years|Age group from older than 5y and younger than 12 years
62403958|NCT01255865||D - 12 years to 21 years|Age group from older than 12 years and younger than 21 years
62403959|NCT01255865||E - 21 years and older|Age group older than 21 years
62403960|NCT01489345|EXPERIMENTAL|Arm 1: Experimental|
61978480|NCT05066373|EXPERIMENTAL|EDP1815 capsule A (fasted)|In part 1, 12 healthy volunteers will receive a single dose of EDP1815 capsule A, dosed in the fasted state
62403961|NCT01489345|PLACEBO_COMPARATOR|Arm 2: Placebo Comparator|
62403962|NCT06274281|EXPERIMENTAL|Experimental Group Training|After the intensive 5-days rehabilitation treatment (2 hours/day, 5 days/week, for 1 week), the EG pa-tients will be encouraged to perform the self-management plan at home with the same duration and in-tensity as the CG (1 hour/session, 3 sessions/week, 12 weeks) through a Digital Telemedicine platform (Phoema GPI Platform, GPI Spa, Trento, Italy). The platform will be implemented with wearable digital devices Axivity AX3, 3-axis Logging Accel-erometer to gather objective and subjective information on the patient's motor activity. At discharge (T1), each patient in the experimental group will receive 2 wearable sensors (Axivity AX3,) for moni-toring of movement data (i.e., activity level, number of steps, distance travelled). The data will be transmitted periodically to the research center and processed. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
62403963|NCT06274281|ACTIVE_COMPARATOR|Control Group Training|After the intensive 5-days rehabilitation treatment (2 hours/day, 5 days/week, for 1 week), the CG patients will be encouraged to perform the self-management plan at home with the same duration and intensity as the EG (1 hour/session, 3 sessions/week, 12 weeks) without a Digital Telemedicine platform and wearable devices use.
62403964|NCT06650449|EXPERIMENTAL|Intervention Group (Mobile App-Based Mental Health Support)|Participants in this group will use a mobile app designed to deliver cognitive-behavioral therapy (CBT) techniques over a 3-month period. The app provides 12 weekly tasks aimed at reducing emotional distress and depressive symptoms. Tasks include exercises on emotional regulation, coping strategies, and mindfulness. Progress is tracked via the app, and participants will complete the PHQ-9 and GHQ-12 questionnaires at the start and end of the intervention.
62580257|NCT01397825|EXPERIMENTAL|Dose Escalation, Alisertib 40 mg|Alisertib 40 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m\^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m\^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
62204200|NCT01245140|PLACEBO_COMPARATOR|Placebo|to receive placebo (dummy drug, 10 patients)
62204201|NCT05978206|EXPERIMENTAL|Nandrolone|
62204202|NCT05978206|PLACEBO_COMPARATOR|Placebo|
62204203|NCT03789175|OTHER|Nicotinamide riboside (NR) in Li-Fraumeni syndrome|Nicotinamide riboside (NR) to be initiated at week 0 at dose of 250 mg twice a day. At Week 1, NR will be titrated to 500 mg twice a day. At Week 6, NR will be titrated to 750 mg twice a day. At Week 7, NR will be titrated to 1000 mg twice a day or as tolerated until end of week 12. At week 12, if participant responds to primary endpoint, participant will washout of NR at week 18 then restart NR at week 24 until week 30. If there is not response to NR treatment at week 12, the participant may continue taking NR at a tolerated dose until week 24 and the primary endpoint will be re-measured. If participant has a positive response to NR treatment at week 24, then the participant will washout of NR until week 30, at which time the primary endpoint will be re-measured to ensure return to baseline. If there is no response to continued NR treatment at week 24, the study will be ended.
62015113|NCT05457270|EXPERIMENTAL|Sequence 1 (Formulation A + Formulation B)|Participants will receive a single oral dose of Treatment 1: Formulation A followed by a washout period of at least 14 days from first dose of AZD4831. After the washout period, participants will receive a single oral dose of Treatment 2: AZD4831 Formulation B.
62015114|NCT05457270|EXPERIMENTAL|Sequence 2 (Formulation B + Formulation A)|Participants will receive a single oral dose of Treatment 2: Formulation B followed by a washout period of at least 14 days from first dose of AZD4831. After the washout period, participants will receive a single oral dose of Treatment 1 Formulation A.
62015115|NCT01353339|PLACEBO_COMPARATOR|sugar pill|
62580258|NCT01397825|EXPERIMENTAL|Dose Escalation, Alisertib 50 mg|Alisertib 50 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m\^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m\^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
62015116|NCT01353339|ACTIVE_COMPARATOR|levofloxacin|
62015117|NCT02609126|EXPERIMENTAL|EP-104IAR|15mg EP-104IAR in 4 mL carrier fluid
62015118|NCT02609126|PLACEBO_COMPARATOR|Vehicle|4 mL carrier fluid
62015119|NCT04261816||Operating room extubation group|extubation in the operating room immediately following liver transplantation
62015120|NCT04261816||ICU extubation group|extubation in the ICU following liver transplantation
62015121|NCT03195413|EXPERIMENTAL|Nerve Block Arm|This group of patients will receive an ultrasound-guided forearm block intervention by the study team. The nerve block will be achieved with a solution of 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine (mixed in a 1:1 volume ratio) dosed once. A second dose will be given only in the case of complete block failure.
62015122|NCT03195413|NO_INTERVENTION|Control Arm|This group will receive the standard of care in our emergency department, as determined by their primary team. If a patient here receives a nerve block from the primary team, they will be handled with intention-to-treat analysis.
62015123|NCT01430130|EXPERIMENTAL|All Study Participants|Half of the revised incision was treated with the embrace device. Half of the revised incision was treated according to the Investigator's standard of care. Participant served as his/her own control.
62015124|NCT04011475||Subjects with Tiotropium and Olodaterol|
62015125|NCT04011475||Subjects treated with other LABA/LAMA therapy|
62015126|NCT04011475||Subjects treated with LAMA therapy|
62204204|NCT02297100|EXPERIMENTAL|Botox upper aspect trigone|Subjects in the experimental cohort will receive a one time dose of 100 units of Onabotulinumtoxin A diluted in 10 mL of preservative free normal saline and injected in 1.0 mL boluses in a set pattern across the upper aspect of the trigone of the urinary bladder.
62204205|NCT02297100|ACTIVE_COMPARATOR|botox periphery of trigone|Each group will receive a total of 100 units of botox spread out among 10 separate injections. Subjects in the control group will have 10 injections made about the periphery of the trigone. The control cohort will receive a one time dose of Onabotulinumtoxin A using the same dilution and number of boluses, but boluses will be administered at random sites on the posterior bladder wall (excluding the trigone).
62204206|NCT04324723|EXPERIMENTAL|Intervention|Participants in this group received a WhatsApp message reminding them to seek further medical attention for their measurement indicated hypertensive condition.
62015127|NCT04239508||Minimal Neonatal Dataset MNDS|All Swiss live-born infants below 32 weeks gestational age or 1501g birth weight
62015128|NCT04239508||Below 34, B34|All Swiss live-born infants between 32 0/1 and 33 6/7 weeks gestational age that are above 1500g birth weight
62015129|NCT04239508||Swiss Asphyxia and Cooling Registry, ASP|Infants between 35 0/7 and 42 6/7 weeks' gestational age with moderate or severe encephalopathy due to perinatal asphyxia
62015130|NCT06508554|NO_INTERVENTION|Control|No action will be taken. Surveys and scales will be applied.
62580259|NCT01397825|EXPERIMENTAL|Phase 2: Alisertib|Phase 2: Alisertib (MLN8237) at the Recommended Phase 2 Dose, ECT orally twice/day on Days 1-7 \& rituximab as an IV infusion on Day 1 \& vincristine IV on Days 1 \& 8 in a 21 Day cycle for up to 8 cycles was planned but not conducted.
62403965|NCT06650449|NO_INTERVENTION|Control Group (No Intervention)|Participants in this group will not receive any mental health intervention during the study period. They will complete the PHQ-9 and GHQ-12 questionnaires at the start and end of the 3-month period to assess changes in emotional distress and depressive symptoms for comparison with the intervention group.
62403966|NCT00077766|EXPERIMENTAL|RO0503821 (1x/2 Weeks)|Eligible participants will be administered with RO0503821 (\[methoxy polyethylene glycol-epoetin beta\] {Mircera}) intravenously (IV), every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram \[µg\]) was based on the dose of darbepoetin alfa at the time of randomization (\< 40, 40 to 80, or \> 80 µg per week, respectively).
62403967|NCT00077766|ACTIVE_COMPARATOR|Darbepoetin (1x/1-2 Weeks)|Eligible participants will be administered with darbepoetin alfa IV, every week or every 2 weeks during Weeks 1 through 52.
62403968|NCT05246631|ACTIVE_COMPARATOR|Dexamethasone|5 mg intravenous dexamethasone
62403969|NCT05246631|ACTIVE_COMPARATOR|Haloperidol|1 mg intravenous haloperidol
62403970|NCT02608827|ACTIVE_COMPARATOR|Slow breathing group (GRL)|After randomization and have done aerobic exercise, patients allocated in this arm of the study, using the device-guided breathing - Slow breathing group (GRL), for 15 minutes during the experimental session.
62403971|NCT02608827|PLACEBO_COMPARATOR|Music group (GC)|After randomization and have done aerobic exercise, patients allocated in this study arm will hear slow music - Music group (GC), for 15 minutes during the experimental session.
62403972|NCT02079974|EXPERIMENTAL|Pravastatin|Pravastatin sodium 20mg PO daily
62403973|NCT02951182|PLACEBO_COMPARATOR|Part 1: Placebo - Cohort 1A and 1B Combined|Participants received placebo matched to VX-440/TEZ/IVA as triple combination for 4 weeks.
62580260|NCT03064698||Normal second trimester Doppler|This group consists of women who had normal doppler ultrasound results at second trimester
62580261|NCT03064698||Abnormal second trimester Doppler|This group consists of women who had abnormal doppler ultrasound results at second trimester
62015131|NCT06508554|EXPERIMENTAL|Haptonomy|"1. A face-to-face sitting position will be taken for the application.~2. Throughout the research, the study will be accompanied by the music desired by each pregnant woman. The same music chosen by the woman or couple will be used throughout the work.~3. The application will be done with the pregnant woman's eyes closed.~4. The application will start with breathing exercises and the body will be relaxed with the help of abdominal and chest breathing (hara breathing).~5. With the energy work, we will move on to the stage of harmonizing the intuitive and heart energy fields. The researcher and the pregnant woman will place their left hands on each other's hearts. The aim is to feel the energy flowing from each other, to feel the heart, to open the third eye and to prepare the hands. This study aims to increase the pregnant woman's confidence in her own emotions and body by getting to know her emotions and body."
62015132|NCT01141296|ACTIVE_COMPARATOR|Fenofibrate|
62787221|NCT02091765|EXPERIMENTAL|Internet-based cognitive behavioral therapy|"Each woman who is allocated to the intervention group is assigned a personal sexologist (therapist) who guides her through the internet-based cognitive behavioral therapy (CBT) program and provides feedback on the homework assignments. The CBT program comprises a maximum of ten treatment modules that can be used in varying order. Each module contains three interventions and a personal evaluation form to report on the intervention. Each intervention comprises the following elements: 1) introduction, 2) psycho-education about symptoms, 3) homework assignments (e.g. relaxation techniques (pelvis); discuss intimacy with partner; sensate focus) and 4) reporting back to the therapist and receiving feedback on the homework assignments. Each week there are two practice sessions of 30 minutes each and one hour per week to report on/evaluate the intervention. The therapy has a mean duration of 20 weeks."
62787222|NCT05495165|OTHER|Nutritional educative programme|5 days educative programme before treatment
62787223|NCT04543695|ACTIVE_COMPARATOR|adjuvant chemotherapy group|concurrent chemoradiotherapy → TME → adjuvant chemotherapy (control group)
62787224|NCT04543695|EXPERIMENTAL|consolidation chemotherapy group (CNCT group)|concurrent chemoradiotherapy → consolidation chemotherapy → TME (CNCT group)
62787225|NCT04543695|EXPERIMENTAL|induction chemotherapy group (INCT group)|induction chemotherapy → concurrent chemoradiotherapy →TME ( INCT group).
62787226|NCT02168218|EXPERIMENTAL|high protein|20% protein diet
62015133|NCT01141296|PLACEBO_COMPARATOR|sugar pill|
62015134|NCT04159675||control patients|Patients with idiopathic craniosynostosis
62015135|NCT04159675||HR patients|Patients with craniosynostosis due to HR
62015136|NCT02320019|PLACEBO_COMPARATOR|Placebo group|Placebo
61978481|NCT05066373|EXPERIMENTAL|EDP1815 capsule B (fasted/fed)|In part 1, 2 \& 3, 12 healthy volunteers will receive a single dose of EDP1815 capsule B, dosed in the fasted and/or fed state
62015137|NCT02320019|EXPERIMENTAL|Group A|YH14618 A mg/disc
62015138|NCT02320019|EXPERIMENTAL|Group B|YH14618 B mg/disc
62015139|NCT02320019|EXPERIMENTAL|Group C|YH14618 C mg/disc
62015140|NCT02320019|EXPERIMENTAL|Group D|YH14618 D mg/disc
62787227|NCT02168218|ACTIVE_COMPARATOR|low protein|7.5% protein diet
62787228|NCT00729963|EXPERIMENTAL|1|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (\< 1.8 kg) over the first month of treatment.
62787229|NCT00729963|ACTIVE_COMPARATOR|2|A standard reference group, which was paired according to age and BMI, received CPAP as a treatment for OSA.
62204207|NCT04324723|NO_INTERVENTION|Control|Participants in this group did not received a WhatsApp message reminding them to seek further medical attention for their measurement indicated hypertensive condition.
62403974|NCT02951182|EXPERIMENTAL|Part 1 Cohort 1A: Triple Combination (TC)|Participants received VX-440 200 milligram (mg) every 12 hours (q12h)/TEZ 100 mg once daily (qd)/IVA 150 mg q12h as triple combination for 4 weeks.
62580262|NCT03884530|ACTIVE_COMPARATOR|Ticagrelor ( Brilique) group|the group will receive 180 mg ticagrelor (2 tablets of 90 mg) as a single loading oral dose, and continue on 180 mg ticagrelor (1 tablet of 90 mg every 12 hours) for 3 months
62580263|NCT03884530|ACTIVE_COMPARATOR|Aspirin Group|The group will receive 300 mg Aspirin (4 tablets of 75 mg) as a single loading oral dose, and will then be commenced on 300 mg Aspirin daily for 2 weeks then 75 mg daily after that for 3 months
62015141|NCT06014658|EXPERIMENTAL|Phase 1 Dose Escalation|
62787230|NCT02167516|EXPERIMENTAL|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
62787231|NCT02167516|ACTIVE_COMPARATOR|glucosamine sulfate capsule|glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
62787232|NCT05739461||triangular cross-section neck implant|
62787233|NCT05739461||round cross-section neck implant|
62787234|NCT03646474|ACTIVE_COMPARATOR|tranexamic acid group|
62787235|NCT03646474|PLACEBO_COMPARATOR|placebo group|
62787236|NCT04705506|EXPERIMENTAL|Gemigliptin group|The participants will receive gemigliptin 50 mg daily
62787237|NCT04705506|PLACEBO_COMPARATOR|Control|The control received standard care of diabetes
62787238|NCT00826618|EXPERIMENTAL|Ranibizumab|
62787239|NCT02751476|ACTIVE_COMPARATOR|standard SAM treatment (control group)|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure.
62015142|NCT06014658|EXPERIMENTAL|Phase 1b Expansion|
61978482|NCT05066373|EXPERIMENTAL|EDP1815 tablet (fasted/fed)|In part 1, 3 \& 4, 12 healthy volunteers will receive a single dose of EDP1815 tablet, dosed in the fasted and/or fed state
62015143|NCT04592705|EXPERIMENTAL|Therapeutic plasma exchange|
62015144|NCT00506935|EXPERIMENTAL|1|GVG
62015145|NCT00506935|PLACEBO_COMPARATOR|2|placebo
62204208|NCT04458259|EXPERIMENTAL|Monotherapy Dose Escalation: Part 1|Monotherapy dose escalation of PF-07265807 in participants with select tumor types.
62204209|NCT04458259|EXPERIMENTAL|Doublet Dose Escalation: Part 2|Doublet combination dose escalation of PF-07265807 with sasanlimab in participants with select tumor types. PF-07265807 will dose escalate. Sasanlimab dose will stay constant.
62403975|NCT02951182|EXPERIMENTAL|Part 1 Cohort 1B: TC Low Dose|Participants received VX-440 200 mg q12h/TEZ 50 mg q12h/IVA 150 mg q12h as triple combination for 4 weeks.
62403976|NCT02951182|EXPERIMENTAL|Part 1 Cohort 1B: TC High Dose|Participants received VX-440 600 mg q12h/TEZ 50 mg q12h/IVA 300 mg q12h as triple combination for 4 weeks.
62580264|NCT02857946|EXPERIMENTAL|A Test|Test drug (Prevaglip) 1 tablet contains 5 mg linagliptin
62580265|NCT02857946|ACTIVE_COMPARATOR|B Reference|Reference drug (Trajenta) 1 tablet contains 5 mg linagliptin
62580266|NCT03804229|EXPERIMENTAL|active group|Take two pills (100 mg each) of Butylphthalide soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
62580267|NCT03804229|PLACEBO_COMPARATOR|control group|Take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
62580268|NCT00125242|EXPERIMENTAL|Semantic Feature Analysis (SFA)|Word retrieval treatment for aphasia.
62580269|NCT00125242|NO_INTERVENTION|Participants for Stimuli Development|Non-brain-injured participants provided data for development of treatment stimuli.
62580270|NCT00445588|EXPERIMENTAL|Treatment|"Patients receive oral erlotinib hydrochloride 150mg once daily and oral sorafenib tosylate 400mg twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study"
62580271|NCT01160081||National Health and Nutrition Survey 2006 (ENSANUT 2006)|
62787240|NCT02751476|EXPERIMENTAL|SAM treatment + flocculent-disinfectant|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a flocculent-disinfectant for household level application.
62787241|NCT02751476|EXPERIMENTAL|SAM treatment + chlorine disinfectant|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a chlorine disinfectant for household level application.
62787242|NCT02751476|EXPERIMENTAL|SAM treatment + ceramic water filter|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a ceramic water filter for household level application.
62580272|NCT05903625|EXPERIMENTAL|Control Group - Standard White Bread|This arm serves as the control group in the clinical trial, providing a baseline comparison for the intervention arms. Participants in this arm consume standard white bread
62580273|NCT05903625|EXPERIMENTAL|Lysine Group - Lysine-Fortified Bread|This arm investigates the effect of lysine-fortified bread on glycemic response. Participants in this arm consume bread fortified with lysine, an essential amino acid.
62403977|NCT02951182|ACTIVE_COMPARATOR|Part 2: TEZ/IVA|Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received placebo matched to VX-440 and TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.
62580274|NCT05903625|EXPERIMENTAL|Phosphorus Group - Phosphorus-Fortified Bread|This arm explores the impact of phosphorus-fortified bread on glycemic response. Participants in this arm consume bread fortified with phosphorus, an essential mineral.
62015146|NCT05460624|EXPERIMENTAL|Intervention group|Participants randomized to the intervention group will receive six premade egg-containing breakfast meals per week in the form of a 3-day rotating menu. Each meal contains 2 eggs to provide 12 eggs per week for a duration of 12 weeks.
62580275|NCT05903625|EXPERIMENTAL|Lysine and Phosphorus Group - Double Fortified Bread|This arm examines the combined effect of lysine and phosphorus in double fortified bread on glycemic response. Participants in this arm consume bread fortified with both lysine and phosphorus.
62580276|NCT06120088||The Bupivacaine|Patients in this group received bilateral ultrasound-guided erector spinae plane block at the level of T7 transverse process using 20 mL of bupivacaine 0.25% on each side + 1ml saline placebo.
62580277|NCT06120088||The Bubpivacaine and dexamethasone|Patients in this group received bilateral ultrasound-guided erector spinae plane block at the level of T7 transverse process using 20 mL of bupivacaine 0.25% plus 1ml dexamethasone on each side
62787243|NCT03996031||Study Sample|All participants in this single-arm pilot study will receive access to Plan to Thrive. This mobile care management program is comprised of modules including educational interventions, health behavior trackers containing built-in reminders, symptom monitoring, and navigator services (see attached content). Access to intervention modules and individualized navigator services according to patients' needs as captured by 1) their patient-reported outcome (PRO) assessments via Plan to Thrive's symptom monitoring feature, and 2) patient requests. Following the baseline assessment, participants will engage with the Plan to Thrive app for a 90-day period.
62787244|NCT03071822|EXPERIMENTAL|PIGLETs|Patient will be given this combination of chemotherapy (cisplatin, ifosfamide, gemcitabine, L-asparaginase, etoposide and dexamethasone) for a total of 6 courses
62787245|NCT05258019||Geistlich Bio-Oss ® Particles + Bio-Gide ® collagen membrane|The first group of patients selected for site preservation will be performed with Bio-Oss ® Particles + Bio-Gide ® collagen membrane after tooth extraction
62787246|NCT05258019||Geistlich Bio-Oss ® Collagen + Bio-Gide ® collagen membrane|The second group of patients selected for site preservation will be performed with Bio-Oss ® Collagen + Bio-Gide ® collagen membrane after tooth extraction
62787247|NCT05258019||Conventional healing after tooth extraction, without site preservation|The third group of patients selected will be performed without site preservation after tooth extraction, and only conventional healing
62787248|NCT00332228|ACTIVE_COMPARATOR|CE plus oral +depot naltrexone|Compliance enhancement (CE), simulating standard treatment with oral naltrexone plus two depot naltrexone;
62787249|NCT00332228|PLACEBO_COMPARATOR|CE plus oral naltrexone+ placebo|CE with oral naltrexone plus two placebo injections
62787250|NCT00332228|EXPERIMENTAL|BNT plus Depot naltrexone|BNT plus two doses of depot naltrexone prior to hospital discharge
62580278|NCT06120088||The Bubpivacaine and fentanyl|Patients in this group received bilateral ultrasound-guided erector spinae plane block at the level of T7 transverse process using 20 mL of bupivacaine 0.25% in addition to calculated dose of fentanyl on each side
62580279|NCT04012593||premenopausal women|diary
62580280|NCT02693002|ACTIVE_COMPARATOR|Hormone replacement therapy|Estradiol/norethindrone acetate 1mg/0.5 mg by mouth oral daily for 12 weeks
62580281|NCT02693002|PLACEBO_COMPARATOR|Placebo|Inert ingredients by mouth oral daily for 12 weeks
62734839|NCT01018173|PLACEBO_COMPARATOR|placebo|
62734840|NCT01018173|EXPERIMENTAL|taspoglutide|
62015147|NCT05460624|OTHER|Control group|Participants randomized to the control group will receive breakfast meals in the form of a 3-day rotating menu including typical foods found in American diets excluding eggs, e.g., corn flakes, milk, sausage, granola bars, fruit. Control recipes are matched to the intervention foods on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.
62403978|NCT02951182|EXPERIMENTAL|Part 2: TC-2|Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received VX-440 600 mg q12h/ TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.
62403979|NCT05489016|EXPERIMENTAL|Yuekang Huoxin Pills (concentrated pills)|2 pills at a time, 3 times a day
62403980|NCT05489016|PLACEBO_COMPARATOR|Yuekang Huoxin Pills (concentrated pills) simulant|2 pills at a time, 3 times a day
62734841|NCT01643642|EXPERIMENTAL|Cognitive behavioral treatment/farmacotherapy intervention|Brief intervention; intake, cognitive behavioral treatment/farmacotherapy (SSRI) and ROM
62734842|NCT01643642|OTHER|Treatment As Usual|Control group, TAU
62787251|NCT00332228|PLACEBO_COMPARATOR|BNT plus PBO injection|BNT plus two placebo injections
62787252|NCT04182672|EXPERIMENTAL|FX006|
62403981|NCT00246675|OTHER|Standard Care|Patients will only receive frusemide as per the treating physicians treatment
62787253|NCT03205176|EXPERIMENTAL|AZD5153 Monotherapy|Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine maximum tolerated dose (MTD). AZD5153 will be taken once per day (QD) or two times per day (BID) for 21 days as an oral capsule. Once the MTD is finalized, patients may be enrolled into an expansion cohort at the MTD.
62015148|NCT05718622|EXPERIMENTAL|real EECP|
62015149|NCT05718622|SHAM_COMPARATOR|sham EECP|
62734843|NCT05667610|EXPERIMENTAL|Intervention group (immune-supportive diet)|"* Immune-supportive diet (for 4 months) on top of peanut and/or nut free diet~* Feasibility of adherence to the Immune-supportive diet (intervention group only) and dietary compliance by Likert scale after 2,5 and 4 months of dietary intervention (2x)"
62787254|NCT03205176|EXPERIMENTAL|AZD5153 + Olaparib Combination Therapy|Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine MTD. AZD5153 will be taken as oral capsules BID in combination with 300 mg olaparib BID for 21 days.
62787255|NCT03795220|ACTIVE_COMPARATOR|Vaginal progesterone + transfer 6. day|Lutinus + blastocyst warming and transfer 6 days after hCG trigger
62015150|NCT05718622|NO_INTERVENTION|Health Control|
62015151|NCT00461903|PLACEBO_COMPARATOR|Placebo (for perindopril)|Sugar pill manufactued to mimic perindopril
62015152|NCT00461903|ACTIVE_COMPARATOR|Perindopril|Perindopril (coversyl) 4 mg tablets
62787256|NCT03795220|ACTIVE_COMPARATOR|Vaginal progesterone + transfer 7. day|Lutinus + blastocyst warming and transfer 7 days after hCG trigger
62787257|NCT03795220|ACTIVE_COMPARATOR|No progesterone + transfer 6. day|No Lutinus + blastocyst warming and transfer 6 days after hCG trigger
62787258|NCT03795220|ACTIVE_COMPARATOR|No progesterone + transfer 7. day|No Lutinus + blastocyst warming and transfer 7 days after hCG trigger
62787259|NCT06496165|EXPERIMENTAL|remimazolam|
62787260|NCT06496165|ACTIVE_COMPARATOR|propofol|
62787261|NCT05311267|EXPERIMENTAL|AOT|Participants who, in addiction to standard rehabilitation program after surgery (isometric exercises), underwent two training session of action observation therapy.
62787262|NCT05311267|NO_INTERVENTION|Control group|Participants who received standard rehabilitation program after surgery. The control group, before performing the functional exercises watched two videos of different landscapes lasting 4 minutes each.
62015153|NCT05973487|EXPERIMENTAL|Monotherapy Cohort A|TSC-204-A0201
62015154|NCT05973487|EXPERIMENTAL|Monotherapy Cohort B|TSC-204-C0702
62015155|NCT05973487|EXPERIMENTAL|Monotherapy Cohort C|TSC-200-A0201
62015156|NCT05973487|EXPERIMENTAL|T-Plex Combination Cohort A + B|TSC-204-A0201 and TSC-204-C0702
62015157|NCT05973487|EXPERIMENTAL|T-Plex Combination Cohort B + C|TSC-204-C0702 and TSC-200-A0201
62015158|NCT05973487|EXPERIMENTAL|T-Plex Combination Cohort A + C|TSC-204-A0201 and TSC-200-A0201
62015159|NCT05973487|EXPERIMENTAL|Monotherapy Cohort D|TSC-203-A0201
62015160|NCT05973487|EXPERIMENTAL|T-Plex Combination Cohort A + D|TSC-204-A0201 + TSC-203-A0201
62015161|NCT05973487|EXPERIMENTAL|T-Plex Combination Cohort B + D|TSC-204-C0702 + TSC-203-A0201
62015162|NCT05973487|EXPERIMENTAL|Monotherapy Cohort E|TSC-204-A0101
62015163|NCT05973487|EXPERIMENTAL|Monotherapy Cohort F|TSC-201-B0702
62015164|NCT05973487|EXPERIMENTAL|T-Plex Combination Cohort A + E|TSC-204-A0201 + TSC-204-A0101
62015165|NCT05973487|EXPERIMENTAL|T-Plex Combination Cohort A + F|TSC-204-A0201 + TSC-201-B0702
62015166|NCT05973487|EXPERIMENTAL|T-Plex Combination Cohort B + E|TSC-204-C0702 + TSC-204-A0101
62015167|NCT05973487|EXPERIMENTAL|T-Plex Combination Cohort B + F|TSC-204-C0702 + TSC-201B0702
62015168|NCT05973487|EXPERIMENTAL|T-Plex Combination Cohort C + D|TSC-200-A0201 + TSC-203-A0201
62015169|NCT05973487|EXPERIMENTAL|T-Plex Combination Cohort C + E|TSC-200-A0201 + TSC-204-A0101
62015170|NCT05973487|EXPERIMENTAL|T-Plex Combination Cohort C + F|TSC-200-A0201 + TSC-201B0702
62015171|NCT05973487|EXPERIMENTAL|T-Plex Combination Cohort D + E|TSC-203-A0201 + TSC-204A0101
62015172|NCT05973487|EXPERIMENTAL|T-Plex Combination Cohort D + F|TSC-203-A0201 + TSC-201B0702
62015173|NCT05973487|EXPERIMENTAL|T-Plex Combination Cohort E + F|TSC-204-A0101 + TSC-201-B0702
62015174|NCT01002599|EXPERIMENTAL|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
62204210|NCT04458259|EXPERIMENTAL|Triplet Dose Escalation: Part 3|Triplet combination dose escalation of PF-07265807 with sasanlimab plus axitinib in participants with select tumor types. PF-07265807 will dose escalate. Sasanlimab dose will stay constant. Axitinib dose will follow label.
62204211|NCT04458259|EXPERIMENTAL|Expansion Phase: Part 4, Cohort 1|PF-07265807 monotherapy in participants with METex14 mutant NSCLC.
62204212|NCT04458259|EXPERIMENTAL|Expansion Phase: Part 4, Cohort 2|PF-07265807 with sasanlimab in participants with MSS CRC
62204213|NCT04458259|EXPERIMENTAL|Expansion Phase: Part 4, Cohort 3|PF-07265807 with sasanlimab in participants with PD-L1+ gastric cancer/GEJ
62204214|NCT04458259|EXPERIMENTAL|Expansion Phase: Part 4, Cohort 4|PF-07265807 with sasanlimab plus axitinib in participants with RCC
62204215|NCT00325689|ACTIVE_COMPARATOR|Quetiapine or Risperidone + Aripiprazole|
62734844|NCT05667610|ACTIVE_COMPARATOR|Control group|- Peanut and/or nut free diet only
62787263|NCT02377648|EXPERIMENTAL|ABSORB Bioresorbable Vascular Scaffold|Everolimus-Eluting Bioresorbable Vascular Scaffold implantation
62015175|NCT01002599|ACTIVE_COMPARATOR|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
62015176|NCT04177524|EXPERIMENTAL|Arm 1|Participants alternate between using the Manual Mode of the app for 2 weeks and Auto-Detect Mode of the app for 2 weeks, for a total of 4 periods (8 weeks).
62015177|NCT04177524|EXPERIMENTAL|Arm 2|Participants use the Auto-Detect Mode of the app for 4 weeks, followed by the Manual Mode for 4 weeks.
62015178|NCT04177524|EXPERIMENTAL|Arm 3|Participants use the Background Mode of the app for 4 weeks, followed by the Auto-Detect Mode of the app for 4 weeks.
62015179|NCT00690547||Test Group|
62015180|NCT00030797|ACTIVE_COMPARATOR|Arm A|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;
62015181|NCT00030797|ACTIVE_COMPARATOR|Arm B|Irinotecan i.v. 240 mg/m2 day 1 and day 22; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;
62204216|NCT00325689|PLACEBO_COMPARATOR|Quetiapine or Risperidone + placebo|
62204217|NCT06318338|EXPERIMENTAL|Virtual Reality Program|This is a single arm study. All participants will participate in the study intervention, which involves experiencing a virtual reality program.
62734845|NCT04393597|EXPERIMENTAL|Group 1|Subjects take DWJ1458 on a fasted condition, and after wash-out period, take DWJ1458 with a high-fat diet.
62787264|NCT00572208|ACTIVE_COMPARATOR|1|Gabapentin group
62787265|NCT00572208|NO_INTERVENTION|2|placebo
62015182|NCT03513029|EXPERIMENTAL|Study Device|VytronUS Ablation System
62015183|NCT00023036||1|Patients with known or suspected nonsyndromic SNHL associated with EVA
62015184|NCT00023036||2|Patients with nonsyndromic EVA
62015185|NCT00023036||3|unaffected siblings and parents of affected family members
62015186|NCT00023036||4|Other unaffected relatives; included if there is more than one sibship with affected family
62015187|NCT04832555|EXPERIMENTAL|Open: non elective irradiation|Patients within inclusion criteria will be enrolled in the experimental treatment: a radiation therapy addressed to non elective site of disease and with a simultaneous integrated boost
62015188|NCT03310541|EXPERIMENTAL|Prostate, Previously treated with Enzalutamide|28-DAY CYCLE AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week + Enzalutamide 160 mg PO once daily
62015189|NCT03310541|EXPERIMENTAL|ER+ Breast, Previously treated with Fulvestrant|28-DAY CYCLE AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week + Fulvestrant 500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
62015190|NCT03310541|EXPERIMENTAL|Advanced Solid Tumors|28-DAY CYCLE AZD5363 480mg PO twice daily for 4 days on, 3 days off, every week
62204218|NCT02032082|NO_INTERVENTION|Ex vivo without CO|
62204219|NCT02032082|EXPERIMENTAL|EX Vivo with carbone monoxide|During the Ex Vivo Lung Perfusion reconditioning,the lungs will be ventilated wit h Oxygen (21%) and Carbon Monoxide (250ppm).
62204220|NCT03811613|EXPERIMENTAL|Photobiomodulation group|"17 Parkinson´s disease patients were randomly assigned to the photobiomodulation group (experimental group).~Intervention: Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength in six 1-minute blocks alternating the LEDs between the right and left temples, with a 30-second rest between blocks."
62204221|NCT03811613|SHAM_COMPARATOR|Sham group|"18 Parkinson´s disease patients were randomly assigned to the sham group.~Intervention: Procedures for the sham group were identical as the photobiomodulation one, except that patients received photobiomodulation during only 5 seconds followed by 55 seconds with no treatment (equalling 1/12th of the energy used for the intervention group)."
62403982|NCT00246675|OTHER|Intervention|Patients will be given frusemide to achieve a study specified urine output target of 1-2mls/kg/hour
62734846|NCT04393597|EXPERIMENTAL|Group 2|Subjects take DWJ1458 with a high-fat diet, and after wash-out period, take DWJ1458 on a fasted condition.
62204222|NCT02492230|ACTIVE_COMPARATOR|Control Group|After successful PCI the control group will take Triple therapy (warfarin + clopidogrel+aspirin) during 45 days and after combination of warfarin+clopidogrel to 6 months after procedure and then only warfarin. Patients will be followed at 45 day, and every 3 months during 12 months of follow up.
62204223|NCT02492230|EXPERIMENTAL|Study Group|Left Atrial Appendage Closure Device will be implanted immediately after successful PCI procedure. It will be implanted via a trans-septal approach by use of a catheter based delivery system to seal the ostium of the LAA. The implantation will be guided by fluoroscopy and TEE to verify proper positioning and stability. The study group will take Triple therapy (warfarin+clopidogrel+aspirin) during 45 days following PCI and after control TEE, warfarin will be discontinued. Then patients from the study group will take DAPT combination (clopidogrel+aspirin) to 6 months after procedure and then only aspirin. Patients will be followed at 45 day, and every 3 months during 12 months of follow up
62204224|NCT02803008|EXPERIMENTAL|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62204225|NCT04086277|EXPERIMENTAL|Women in labor with continuous intrapartum support|Continuous intrapartum support was based on three basic aspects: 1) emotional support, 2) physical support and comfort measures and 3) information and advice.
62204226|NCT04086277|NO_INTERVENTION|Women in labor without continuous intrapartum support.|The no intervention group received the usual obstetric care, without continuous intrapartum support.
62204227|NCT05148910|ACTIVE_COMPARATOR|Copper IUD (TCu380A)|Women receiving an intrauterine device (IUD) containing 380mm² of copper.
62204228|NCT05148910|EXPERIMENTAL|Silver and copper IUD (TCu380Ag)|Women receiving an intrauterine device (IUD) containing 380mm² of copper with a silver core.
62204229|NCT04103567|EXPERIMENTAL|Biological collection|"Fecal samples collected at different times : During inclusion consultation with surgeon, after neoadjuvant treatment and before surgery,~In parallel to this fecal collection, standardized clinical data will be entered into a database"
62204230|NCT01346631|EXPERIMENTAL|paleolithic diet|Subjects will adhere to a paleolithic diet for the duration of three months
62204231|NCT03581760|EXPERIMENTAL|Cycling Exercise|Patients randomized into this arm will undergo cycling exercise once a day while on mechanical ventilation at intensive care unit.
62204232|NCT03581760|ACTIVE_COMPARATOR|Conventional Physiotherapy|Patients randomized into this arm will undergo conventional physiotherapy twice a day while on mechanical ventilation at intensive care unit.
62403983|NCT00582634|EXPERIMENTAL|Docetaxel followed by cisplatin|Docetaxel (75mg/m2) given IV followed by cisplatin (75mg/m2) given IV on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for 4 cycles.
62403984|NCT00540982|EXPERIMENTAL|Normal Liver Function|
62204233|NCT04025047||Transvaginal mesh|Patients who undergo pelvic reconstruction surgery using trans-vaginal mesh (commercial mesh kits or self-cut synthesized mesh).
62204234|NCT05593172||Mild traumatic brain injury|15 consecutive patients presenting at the emergency departement with mild traumatic brain injury
62204235|NCT05593172||Minor orthopedic injury|15 patients, recruited during the same time-frame as the mTBI-patients, presenting at the emergency departement with a minor orthopedic injury
62204236|NCT03285698|OTHER|Integra®|Integra® is a bilayer wound matrix made out of bovine tissue.
62204237|NCT03285698|EXPERIMENTAL|DermACELL®|DermACELL® is a bilayer wound matrix made out of human tissue.
62204238|NCT02033083|ACTIVE_COMPARATOR|Laminaria|Patients in this arm will receive laminaria cervical dilators one day before D\&E procedure.
62204239|NCT02033083|ACTIVE_COMPARATOR|Dilapan-S|Patients in this arm will receive Dilapan-S cervical dilators one day before D\&E procedure.
62204240|NCT04589481|EXPERIMENTAL|candy intake|
62403985|NCT00540982|EXPERIMENTAL|Mild Liver Dysfunction|
62403986|NCT00540982|EXPERIMENTAL|Moderate Liver Dysfunction|
62403987|NCT00540982|EXPERIMENTAL|Severe Liver Dysfunction|
62403988|NCT04629209|EXPERIMENTAL|Arm A: ONC201 with Surgical Resection in Glioblastoma|Patients must be eligible for salvage surgical resection as deemed by the site Investigator. ONC201 will be administered orally, twice a week (2 consecutive days on and 5 days off per week) schedule at a dose of 625mg.
62403989|NCT04629209|EXPERIMENTAL|Arm B: ONC201 in Glioblastoma|Unequivocal evidence of recurrence (progressive disease) on contrast-enhanced brain CT or MRI as defined by RANO criteria, or have documented recurrent glioma on diagnostic biopsy. ONC201 will be administered orally, twice a week (2 consecutive days on and 5 days off per week) schedule at a dose of 625mg.
62734847|NCT03349138|ACTIVE_COMPARATOR|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different standard motor training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
62015191|NCT00345579|EXPERIMENTAL|Menhibrix Group|Subjects received 3 doses of Menhibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of Menhibrix vaccine at 12-15 months of age in the study NCT00345683. Menhibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
62015192|NCT00345579|ACTIVE_COMPARATOR|ActHIB Group|Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
62015193|NCT06325995|ACTIVE_COMPARATOR|A (COPORT)|COPORT over 7 weeks.
62204241|NCT04825405|ACTIVE_COMPARATOR|The use of the active Tip Stim device to achieve coordinated of the hand.|Influence of the tested position and the use of the active TipStim Glove device on the improvement of motor coordination and grip force in patients after a stroke.
62204242|NCT04825405|PLACEBO_COMPARATOR|The use of the passive Tip Stim device to achieve coordinated of the hand.|Influence of the tested position and the use of the passive TipStim Glove device on the improvement of motor coordination and grip force in patients after a stroke.
62204243|NCT04157400|EXPERIMENTAL|Epidural Spinal Cord Stimulation|Subjects with chronic pain that have been scheduled to receive spinal cord simulators for standard of care treatment.
62403990|NCT04111939|EXPERIMENTAL|Wave 1 - Intervention|Communities in Wave 1 will receive the CTH intervention during the first 30 months of the trial. The intervention will include 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.
62403991|NCT04111939|OTHER|Wave 2 - Wait-list comparison|Communities in Wave 2 will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.
62403992|NCT04575233|EXPERIMENTAL|Laparoscopic Transversus Abdominis Plane (L-TAP) group|Patients will undergo the planned laparoscopic colectomy according to the standard of treatment. A solution of 15 ml of Ropivacaine (0.2%) is then injected for postoperative pain under laparoscopic control
62403993|NCT04575233|ACTIVE_COMPARATOR|Ultrasound Transversus Abdominis Plane (U-TAP) group|Patients will undergo the planned laparoscopic colectomy according to the standard of treatment. A solution of 15 ml of Ropivacaine (0.2%) is then injected for postoperative pain under ultrasound control
62403994|NCT03890380|EXPERIMENTAL|Magneto Wire|Patients treated with Magneto Wire
62580282|NCT05969015|EXPERIMENTAL|Behavior-changing/Self-Management|This arm is composed by group-based interventions aiming to modify the self-management of the patients through the Prochaska and DiClemente transtheorical model. It is composed by weekly meetings, lasting up to 1 hour and a half, targeting eight patients per group. After the 12nd month of intervention, the meetings will be held each fifteen days untill the trial ending (18 months). The meetings will deal with lifestyle matters, such as nutrition, weight management, and physical activity, as well as medication adherence, blood glucose testing, and others. Whenever a care provider will be assigned to a group, he/she will go over untill the final of the trial, unless unexpected motivations appear. Patients achieving maintenance will receive green flag from the group-based interventions to avoid contamination. It is up to the care provider to perceive the readiness of the patient to another stage.
62580283|NCT05969015|NO_INTERVENTION|Usual Care|Patients randomized to the usual care group will follow the same schedule of the experimental group for outcome assessment; however, the trial team will not intervene in the group - i.e., the group will continue their care routine in their primary care unit.
62015194|NCT06325995|EXPERIMENTAL|B（HYPORT）|HYPORT over 5 weeks.
62204244|NCT02005575|PLACEBO_COMPARATOR|Group 1|an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml normal saline)
62204245|NCT02005575|ACTIVE_COMPARATOR|Group 2|an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml .4% dexamethasone)
62204246|NCT01279928||Type 1 Diabetes Paediatric|Paediatric patients aged 8-18 with diagnosed Diabetes Mellitis Type 1 attending paediatric clinic at John Hunter Hospital.
62204247|NCT06094946||Midwife administered boluses|The epidural analgesia is initiated by a manual bolus of the epidural solution (ropivacaine 1 mg/ml fentanyl 2.5 mug/ml) 10 + 10 ml and then continued on-demand by similar boluses until delivery
62403995|NCT02718573||Non-liver transplants with HCV|
62403996|NCT02718573||Liver transplants with HCV|
62403997|NCT01657591|EXPERIMENTAL|Dose Escalation|The treatment period will include dosing (taking a certain amount on a regular schedule) with vemurafenib along with the study drug, XL888. Everyone in the study will receive both drugs, but the XL888 will be given at different doses (different amounts). Everyone in this study will be given vemurafenib at the standard dose (the amount of the drug that is given as standard treatment) of 960 milligrams (mg) twice per day, unless the first people in the study have severe side effects when taking the lowest dose of XL888 along with vemurafenib. If that happens, the next people in the study may be given a lower dose of vemurafenib (720 mg twice per day) along with the lowest dose of XL888.
61978483|NCT04151667|EXPERIMENTAL|A: Daratumumab & Dexamethasone|All participants will receive 1800 mg in 15 ml Daratumumab by subcutaneous injection weekly and be given 20 mg of Dexamethasone orally once a week for 2 months. Patients who receive a partial response or better will continue on this arm.
62403998|NCT05794126|EXPERIMENTAL|Lens 1|Participants wore Lens 1 for 15 minutes (Period 1)
62403999|NCT05794126|EXPERIMENTAL|Lens 2|Participants wore Lens 2 for 15 minutes (Period 2)
62404000|NCT04940832|ACTIVE_COMPARATOR|radiofrequency with corticosteroids|corticosteroids- 80mg depo-medrol Pulsed radiofrequency to 42 derees celsius for 6 minutes
62404001|NCT04940832|ACTIVE_COMPARATOR|radiofrequency without corticosteroids|Pulsed radiofrequency to 42 derees celsius for 6 minutes
62015195|NCT04988165|EXPERIMENTAL|Treatment arm|
62015196|NCT00944775|EXPERIMENTAL|exercise training|10-month exercise training program
62015197|NCT00944775|NO_INTERVENTION|controls|usual care sedentary lifestyle
62015198|NCT04255095|ACTIVE_COMPARATOR|Nasobiliary drainage|
61978484|NCT04151667|EXPERIMENTAL|B: Daratumumab, Dexamethasone and Lenalidomide|Participants who have less than a partial response to Arm A may have Lenalidomide added to their treatment. Lenalidomide will be given orally on days 1-21 of each 28 day treatment cycle.
62015199|NCT04255095|EXPERIMENTAL|Naso-pancreatic drainage(negative pressure)|
62015200|NCT06387784|EXPERIMENTAL|Early-onset pre-eclampsia beetroot juice|A single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate.
62015201|NCT06387784|PLACEBO_COMPARATOR|Early-onset pre-eclampsia placebo juice|A single dose of 70 ml of a formulation with a similar taste, smell, and texture.
62015202|NCT06387784|EXPERIMENTAL|Late-onset pre-eclampsia beetroot juice|A single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate.
62204248|NCT06094946||Automated and parturient controlled epidural boluses|The epidural analgesia is initiated by a manual bolus of the epidural solution (ropivacaine 1 mg/ml fentanyl 2.5 mug/ml) 10 + 10 ml and then continued by automated boluses of the same solution (6ml every 40 minutes) with possibility for the parturient to administer 6 ml extra doses with a 20 minute lock-out. Maximum hourly dose 20 ml.
62204249|NCT00596882|OTHER|1|Threat only message. Participants hear information about the negative health consequences of smoking
62204250|NCT00596882|OTHER|2|Genetic threat + threat. Participants will bear infomration about genetic influences of smoking in additon to the negative health consequences of smoking.
62580284|NCT05445362|ACTIVE_COMPARATOR|Group I|Thirteen teeth were disinfected by triple antibiotic paste then revascularization was done using the standard method.
62015203|NCT06387784|PLACEBO_COMPARATOR|Late-onset pre-eclampsia placebo juice|A single dose of 70 ml of a formulation with a similar taste, smell, and texture.
62015204|NCT01266772|ACTIVE_COMPARATOR|montelukast group|Children with asthma treated with montelukast and budesonide.
62204251|NCT03621787|EXPERIMENTAL|Single arm study: implant insertion|Participants in trial will be within a single study arm. All participants will have a placebo subcutaneous implant inserted with the device being studied. The implant accuracy will be assess through palpation and ultrasound depth measurements. The implant will then be removed. Safety will be assessed by measuring bruising and bleeding. A follow-up questionnaire will assess bruising and infection risk. A final visit will assess bruising and infection risk by a physician.
62580285|NCT05445362|ACTIVE_COMPARATOR|Group II|Thirteen teeth were Laser disinfected; revascularization was done using the standard method.
62580286|NCT05445362|ACTIVE_COMPARATOR|Group III|Thirteen teeth were disinfected by triple antibiotic paste then revascularization was done using the standard method followed by diode laser bio-stimulation.
62580287|NCT04068584|EXPERIMENTAL|Complete Smart Angel|Smat Angel application with artificial intelligence
62787266|NCT05797636|EXPERIMENTAL|Transcranial magnetic stimulation participants|All participants will be recruited into a single arm where, across two sessions they will receive transcranial magnetic stimulation in separate session to either the dorsolateral prefrontal cortex or the angular gyrus. Session order will be counter-balanced across participants, and stimulation target will be blinded to the participants until after their participation is complete.
62787267|NCT00672906|EXPERIMENTAL|1|Group Parent Training/Adolescent Skills Training
62015205|NCT01266772|PLACEBO_COMPARATOR|Placebo group|Children with asthma treated with placebo tablet and budesonide.
62015206|NCT03189914|EXPERIMENTAL|RX-3117 + Abraxane|"RX-3117: oral, 500 - 700 mg/ day for 5 days on/ 2 days off for 3 weeks. 1 washout week/ cycle.~Abraxane: 75 - 125 mg/m\^2, infused once per week for 3 weeks. 1 washout week/ cycle."
62204252|NCT02381093|ACTIVE_COMPARATOR|Standard BLS Course|Participants will partake in a standard BLS course.
62204253|NCT02381093|EXPERIMENTAL|Contextual Interference|Participants will partake in a BLS course designed using contextual interference scheduling.
62204254|NCT05378334|EXPERIMENTAL|Combination Group|"Standard treatment: 4-6 cycles (3 weeks per cycle) of ICI + chemotherapy followed by ICI maintenance therapy, until tumor progression or at least 1 year.~HGXJT decoction: 1 dose daily, until tumor progression or accumulation for 1 year."
62204255|NCT05378334|PLACEBO_COMPARATOR|Control group|"Standard treatment: 4-6 cycles (3 weeks per cycle) of ICI + chemotherapy followed by ICI maintenance therapy, until tumor progression or at least 1 year.~Placebo: 1 dose daily, until tumor progression or accumulation for 1 year."
62204256|NCT04447508|EXPERIMENTAL|Exercise class and motivational interviewing|Patients receiving the intervention will be enrolled in an online instructor led group exercise class and five online one on one motivational interviewing sessions.
62204257|NCT04447508|NO_INTERVENTION|Usual care|Participants in the control group will receive an exercise booklet and educated on the benefits of exercise for low back pain. They will be advised to exercise for the duration of the study
62015207|NCT02783404|NO_INTERVENTION|Control|Receiving no prophylaxis
62015208|NCT02783404|ACTIVE_COMPARATOR|Amoxicillin|"Receiving 2 gr oral Amoxicillin before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin"
62015209|NCT02783404|EXPERIMENTAL|Amoxicillin-Potassium Clavulanate|"Receiving 2gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate"
62015210|NCT05658926|EXPERIMENTAL|Intervention|Participants will learn a brief, mindfulness skill
62015211|NCT05658926|PLACEBO_COMPARATOR|Education|Participants will receive education about the effects of emotions on pain
62015212|NCT06560268|EXPERIMENTAL|High flow anesthesia|"Group I; After the laryngeal mask is placed, ventilation will be performed with FGF= 4 l/min, Sevoflurane vaporizer setting will be 2.5-3%. When the patients reach 1 MAC Sevoflurane, FGF will be reduced to 2 l/min.~In Group I, the Sevoflurane vaporizer will be turned off at the end of the operation and FGF will be increased to 10 l/min."
62015213|NCT06560268|EXPERIMENTAL|Low flow anesthesia|"Group II; After the laryngeal mask is placed, ventilation will be performed with FGF= 4 l/min, Sevoflurane vaporizer setting will be 2.5-3% and when the patients reach 1 MAC, FGF= 0.5 l/min will be reduced.~In Group II, the Sevoflurane vaporizer will be turned off 10 minutes before the end of the operation and FGF will continue as 0.5 l/min until the end of the operation."
62015214|NCT06560268|EXPERIMENTAL|Low flow wash-in period|"Group III; After the laryngeal mask is placed, ventilation will be performed with FGF= 1 l/min, Sevoflurane vaporizer setting will be 8%, inhaled sevoflurane concentration (Fisevo) will be gradually reduced to \< 4%. When the children reach 1 MAC sevoflurane, TGA= 0.5 l/min will be reduced.~In Group III, the sevoflurane vaporizer will be turned off 10 minutes before the end of the operation and FGF will continue as 0.5 l/min until the end of the operation."
62015215|NCT06075628||Amplatzer Amulet|This is the group of subjects who are implanted with Amplatzer Amulet device.
62015216|NCT06075628||Watchman / Watchman FLX|This is the group of subjects who are implanted with Watchman / Watchman FLX device.
62015217|NCT03178734|OTHER|Indwelling Foley Catheter|These patients will have a traditional foley catheter with attached drainage bag (Indwelling Foley Catheter).
62015218|NCT03178734|OTHER|Self-Contained Valved Catheter|These patients will have a BARD Flip Flo Catheter Valve attached to the original foley catheter (Self-Contained Valved Catheter).
62015219|NCT00638547|EXPERIMENTAL|Intent-to-Treat|All patients who have received at least one dose of Laronidase.
62015220|NCT00690755||Group 1|type 2 diabetic individuals
62204258|NCT00233480|EXPERIMENTAL|active treatment|atorvastatin 10mg QD x 3 months
62204259|NCT00233480|PLACEBO_COMPARATOR|placebo|matched placebo QD x 3 months
62580288|NCT04068584|EXPERIMENTAL|Basic Smart Angel|Smat Angel application without artificial intelligence
62580289|NCT04068584|NO_INTERVENTION|Control|
62787268|NCT00672906|ACTIVE_COMPARATOR|Active Comparator|Family Therapy according to the Maudsley Model
62015221|NCT00690755||Group 2|type 1 diabetic individuals or those with diabetes secondary to pancreatic disease
62015222|NCT00690755||Group 3|non-diabetic individuals who are not considered to be overweight
62015223|NCT00690755||Group 4|non-diabetic individuals who are considered to be overweight
62015224|NCT00690755||Group 5|non-diabetic and type 2 diabetic individuals who will be subjected to an exercise study
62015225|NCT00690755||Group 6|individuals who have or are suspected of having glucose intolerance, including patients who have a history of gestational diabetes and patients who have polycystic ovary syndrome
62015226|NCT00690755||Group 7|healthy non-diabetic subjects who will receive one dose of metformin orally 1-2 hours before performing procedures
62015227|NCT03611803|EXPERIMENTAL|Ekso Group|
62015228|NCT03611803|ACTIVE_COMPARATOR|Control|
62015229|NCT01459406|EXPERIMENTAL|Glucose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g glucose
62204260|NCT00056277|OTHER|Arm 1|
62204261|NCT04920942|EXPERIMENTAL|Treatment group|Ivermectin 0.4mg/kg/day for 5 days + standard-of-care
62204262|NCT04920942|NO_INTERVENTION|Control group|Standard-of-care only
62204263|NCT04954092|EXPERIMENTAL|1/10 of full adult dose|
62015230|NCT01459406|EXPERIMENTAL|Fructose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructose
62015231|NCT01459406|EXPERIMENTAL|Fructan drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructan
62015232|NCT01459406|EXPERIMENTAL|Fructose and glucose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructose and 40 g glucose
62015233|NCT01099995|ACTIVE_COMPARATOR|One HBO session|hyperbaric oxygen therapy one dive at 2 absolute atmosphere (1-hour plateau) - oxygen was delivered via a full face mask - followed by 4 hours of normobaric oxygen therapy
62015234|NCT01099995|EXPERIMENTAL|2 HBO sessions|Two sessions of hyperbaric oxygen therapy at 2 absolute atmosphere (1-hour plateau) with oxygen delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
62015235|NCT05569785|ACTIVE_COMPARATOR|Group 1 Resistance Exercise Therapy Feasibility|One group who have been randomised to receive 4 weeks of Resistance Exercise Therapy to explore the feasibility of introducing such a programme in the bariatric population.
62204264|NCT04954092|EXPERIMENTAL|1/5 of full adult dose|
62204265|NCT04954092|EXPERIMENTAL|Selected dose for second stage of the trial|
62204266|NCT04954092|PLACEBO_COMPARATOR|Placebo for second stage of the trial|
62204267|NCT03480932|ACTIVE_COMPARATOR|SOF+DAC+PEG|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) for 4 weeks with a field-based DOT approach
62204268|NCT03480932|ACTIVE_COMPARATOR|SOF+DAC, DOT|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with a field-based DOT approach
62204269|NCT03480932|ACTIVE_COMPARATOR|SOF+DAC, standard|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with standard of care dispensation (4 monthly doses)
62580290|NCT01129440|ACTIVE_COMPARATOR|Fluoride Varnish|Topical fluoride varnish (FV) applications every 6 months
62787269|NCT02100969|EXPERIMENTAL|HIZENTRA ®|Hizentra is a subcutaneous (under the skin) immunoglobin (SCIg). Participants will receive Hizentra in a minimum of one infusion per week and a maximum of 4 infusions per week. Dose and rate depend on the visit and how each participant tolerates the drug. Max cc per site is 50 cc per site per hour.
62787270|NCT03967054|EXPERIMENTAL|Ivermectin mass drug administration|Ivermectin given monthly from July-October (4 times) as a 3-day course of 300 µg/kg/day to all eligible persons per exclusion/inclusion criteria. Per package insert, dosing of IVM will be according to height to approximate weight: 90-119 cm = 1 tablet/day for 3 days; 120-140 cm = 2 tablets/day for 3 days; 141-158 cm = 3 tablets/day for 3 days; \>158 cm = 4 tablet/day for 3 days.
62787271|NCT03967054|PLACEBO_COMPARATOR|Placebo mass administration|Placebo given monthly from July-October (4 times) as a 3-day course to all eligible persons per exclusion/inclusion criteria. Dosing of placebo will be according to height to approximate weight: 90-119 cm = 1 tablet/day for 3 days; 120-140 cm = 2 tablets/day for 3 days; 141-158 cm = 3 tablets/day for 3 days; \>158 cm = 4 tablet/day for 3 days.
62015236|NCT05569785|NO_INTERVENTION|Group 2 Standard Care|This group have been randomised to receive standard care post surgery.
62015237|NCT04884126||One stage dental implants placement|
62015238|NCT04884126||Second stage dental implants placement|
62015239|NCT02241304||Elective surgery with muscle relaxation|ASA I-II-III patients. Fentanyl (2-3 ug/kg) - Propofol (2 mg/kg) induction, sevoflurane anesthesia, type and dose of muscle relaxant up to the decision of attending anesthetist. Neuromuscular stimulation with TetraGraph (30mA current intensity, 0.2 msce pulse duration, 20 sec intervals)
62015240|NCT06071039|EXPERIMENTAL|3D Spacer Mattress|For the patients in this group, the mattress which developed by the researchers was used. Pressure level between the body and the mattress was measured throughout the surgery.
62015241|NCT06071039|NO_INTERVENTION|Operating Room Mattress|For the patients in this group, the mattress which was in common use was used. The mattress used for the patients in this group was made up of foam. The pressure level between the body and the mattress was measured throughout the surgery.
62015242|NCT04072965|EXPERIMENTAL|Cross eduacation of balance|10 females with Chronic Ankle Instability will receive balance training for the non affected side for a six weeks
62580291|NCT01129440|EXPERIMENTAL|FV + Glass Ionomer Sealants|Topical fluoride varnish (FV) applications every 6 months, and fluoride-releasing glass ionomer sealants (GIS) placed on primary molars at baseline and annually, as needed
62787272|NCT04139356|EXPERIMENTAL|Patients with rest O2 desaturation|Patient will undergo an experimental protocol consisting of 10 deep inspirations to measure and characterize changes on pulse-oxymetry values
62787273|NCT02983864|ACTIVE_COMPARATOR|Alcohol and Relaxation|This arm will receive a brief (2-hour) alcohol intervention based on motivational interviewing termed BASICS and a brief (1.5 hour) relaxation intervention
62787274|NCT02983864|ACTIVE_COMPARATOR|Alcohol and Relationships|This arm will receive a brief (4-hour), two session, integrated alcohol and relationship intervention based on motivational interviewing designed to increase healthy alcohol use and sexual behavior. The interventions are based on an integrated BASICS and integrated Bystander protocols
62787275|NCT01755728|NO_INTERVENTION|No known PDA|For all infants, we do echo cardiogram study only if they are suspected of having PDA, due to sings and symptoms. Hence, we do not do echo cardiogram study to most of the infants.
62787276|NCT01755728|ACTIVE_COMPARATOR|Ibuprofen|If there is a PDA, that should be treated, and the infant is less than 2 weeks of age, we use ibuprofen, as this is the gold standard in literature.
62787277|NCT01755728|ACTIVE_COMPARATOR|Surgical closure of PDA|Infants with symptomatic PDA, who had to be treated, but could not be treated by ibuprofen, either due to age (\> 2 weeks) or due ibuprofen contraindications (thrombocytopenia or renal failure), whose could not be treated by paracetamol (either because of parents' refuse or because they were on nothing per os protocol due to other disease), for whom surgery was the treatment of choice to close the arterial duct.
62787278|NCT01755728|EXPERIMENTAL|Paracetamol|Infants with symptomatic PDA who could not be treated with ibuprofen, and their parents agreed and they could be treated with paracetamol.
62787279|NCT01755728|NO_INTERVENTION|DA closed spontaneously|Infants with PDA, who did not get any treatment for it, and the duct was closed spontaneously.
62787280|NCT02816528||Training program|Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.
62015243|NCT04072965|EXPERIMENTAL|Traditional training|10 females with Chronic Ankle Instability will receive balance training for the affected side for a six weeks
62015244|NCT04072965|NO_INTERVENTION|control|balance of 15 females with Chronic Ankle Instability will be assessed before and after six weeks of no intervention
62015245|NCT02350959|EXPERIMENTAL|High dose statin|In high dose statin group, atorvastatin 40mg will be used
62015246|NCT02350959|ACTIVE_COMPARATOR|Moderate dose statin|in moderate dose statin group, atorvastatin 10mg will be used
62015247|NCT01624545|ACTIVE_COMPARATOR|1|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
62015248|NCT01624545|NO_INTERVENTION|2|Patients in this study arm will undergo neurological evaluation on day 2 and day 30 without follow-up CT scan.
62015249|NCT05437146|EXPERIMENTAL|Puppet|pain and fear
62015250|NCT05437146|NO_INTERVENTION|control|not pain and fear
62015251|NCT00298038|EXPERIMENTAL|Rifaximin|Participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
62015252|NCT00298038|PLACEBO_COMPARATOR|Placebo|Participants were administered a single matching placebo tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
62015253|NCT01575561|EXPERIMENTAL|Lurasidone|Lurasidone 20, 40, 60,80 mg flexible dose
62787281|NCT02816528||Nothing|Not Trained Physicians
62787282|NCT03168178|ACTIVE_COMPARATOR|Standard Antibiotic Treatment|Standard antibiotic treatment provided to patient. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.
62787283|NCT03168178|EXPERIMENTAL|No Antibiotic Treatment|No Antibiotic treatment given. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.
62204270|NCT04980027|EXPERIMENTAL|Insuline Glargine (U300) (Gla-300)|Insulin glargine (U300) once daily for 24 weeks on top of non-insulin antidiabetic drug. Insulin dose will be adjusted according to the recommended titration algorithm
62580292|NCT05197608|EXPERIMENTAL|Intervention - System Navigator|"The intervention group will be connected to a system navigator who is a trained staff member embedded within the primary health clinic team with a focus to address participant's biological, psychological and social needs.~Working with the System Navigator will mean:~* Discussing patients' current health status and concerns~* Receiving support on management of chronic diseases and mental health including connection to local resources e.g. counseling, harm reduction, crisis support services~* Receiving information about benefits that they may be entitled to and learning about free services~* Receiving help from the System Navigator on forms or letters that are required to access resources"
62580293|NCT05197608|ACTIVE_COMPARATOR|Tailored list of community resources|Control group will be provided a tailored list of community resources.
62580294|NCT02754427|EXPERIMENTAL|Prospective Surveillance Group|Women assigned to surveillance group were assessed for arm morbidity at pre-surgery and at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any time-point post-surgery, then a physiotherapy intervention was prescribed.
62580295|NCT02754427|ACTIVE_COMPARATOR|Education Group|Participants in the education group received the usual post-operative follow-up.
62787284|NCT04370353|PLACEBO_COMPARATOR|Placebo|Placebo supplement, each capsule containing: 0mg total flavanols, matched for caffeine and theobromine content as experimental supplement (2.9 mg caffeine and 22.5 mg theobromine) and microcrystalline cellulose volume filler. Participants consume 4x capsules daily (2AM \& 2PM after mixed meal for 7 days.
62580296|NCT05519644|ACTIVE_COMPARATOR|Placebo First|Patients will be randomize to take the placebo for the first trial of the intervention, then after a 2 week washout, participants will perform the same intervention but with a ketone ester.
62580297|NCT05519644|EXPERIMENTAL|Ketone Ester First|Patients will be randomize to take the ketone ester for the first trial of the intervention, then after a 2 week washout, participants will perform the same intervention but with a placebo
62580298|NCT02185742|EXPERIMENTAL|Strength Based Case Management|Strength Based Case Management
62787285|NCT04370353|EXPERIMENTAL|Cocoa Flavanols|Experimental supplement, each capsule containing: 316 mg CocoActiv (Naturex, Netherlands: 100mg total cocoa flavanols, 2.9 mg caffeine and 22.5 mg theobromine) and microcrystalline cellulose volume filler. Participants consume 4x capsules daily (2AM \& 2PM) for 7 days.
62015254|NCT03502603|ACTIVE_COMPARATOR|Cerebral neurological illness (CNI) participants|Identified from the department of Rehabilitation, Psychiatry, and Medicine and referred to the research staff via in-person communication, email or staff message
62015255|NCT03502603|ACTIVE_COMPARATOR|Non-CNI participants|Identified from the department of Rehabilitation, Psychiatry, and Medicine and referred to the research staff via in-person communication, email or staff message
62580299|NCT02185742|NO_INTERVENTION|Contemporary, HIV+ Jail Detainees|No intervention
62580300|NCT05832931|EXPERIMENTAL|Double-Blind Phase PLS240|
62580301|NCT05832931|PLACEBO_COMPARATOR|Double-Blind Phase Placebo|
62580302|NCT05832931|EXPERIMENTAL|Open-Label Extension Phase PLS240|After completion of the Double-Blind Phase, all participants will have the opportunity to enroll in the 26 week Open-Label extension, where they will receive PLS240.
62580303|NCT01859169||Control Group|Group that be administrated biliary drainage only
62580304|NCT01859169||PDT Group|Group that be administrated photodynamic therapy and biliary drainage
62787286|NCT03421106|EXPERIMENTAL|Intervention Food Pantries|Food pantries will transform to offer healthier and more appealing food ; the effect on clients will be measured.
62787287|NCT03421106|ACTIVE_COMPARATOR|Control Food Pantries|Food pantries will make no changes during the evaluation period; the effect on clients will be measured.
62015256|NCT02284997|EXPERIMENTAL|Treatment|Participants will be instructed to use a warming MGDRx® EyeBag for minimum of 10 minutes, twice a day
62015257|NCT02284997|NO_INTERVENTION|Control|No treatment
62787288|NCT02489942||Jardiance|Patients with T2DM to receive Jardiance tablets 10 mg, 25 mg
62015258|NCT06395168|ACTIVE_COMPARATOR|Combined Lactation and Newborn visit|This arm is the intervention where the newborn visit with the pediatric provider is within a lactation consultant visit for a breastfeeding newborn and mother.
62787289|NCT04067414|EXPERIMENTAL|BZ019 treatment|Subjects will receive lymphodepleting chemotherapy of fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 infusion. A 3×3 dose escalation design of BZ019 will be adopted.
62015259|NCT06395168|NO_INTERVENTION|Separate Lactation and Newborn visit|This is current state of care in which a newborn visit is separate and apart from a Lactation Consultation.
62015260|NCT01700816|EXPERIMENTAL|Bright light therapy|2500 Lux gaze directed every morning from 8 am until 8:30 am
62015261|NCT01700816|PLACEBO_COMPARATOR|Sham light|\<1000 Lux gaze directed every morning from 8 am until 8:30 am
62015262|NCT00720616|EXPERIMENTAL|1|Growth hormone or Placebo 0.1 mg/day self-administrated once a day.
62015263|NCT01112085|EXPERIMENTAL|Ranibizumab 0.05mg|Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
62015264|NCT01112085|EXPERIMENTAL|Ranibizumab 0.5mg|Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
62015265|NCT01782196|EXPERIMENTAL|Type A Pouch followed by Type B pouch|Enhanced one piece drainable pouch with Type A mouldable adhesive for Stage 1 and 2 followed by pouch with Type B mouldable adhesive for Stage 3
62015266|NCT01782196|EXPERIMENTAL|Type B Pouch followed by Type A pouch|Enhanced one piece drainable pouch with Type B mouldable adhesive for Stage 1 and 2 followed by pouch with Type A mouldable adhesive for Stage 3
62015267|NCT04840745|EXPERIMENTAL|CKD-841 A-1(=leuprorelin acetate 3.75mg)|Investigational drug(=CKD-841 A-1) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
62580305|NCT06681961|EXPERIMENTAL|squatting with hip adduction (SQU-HA) group|The participants stood equally on both legs on the floor with their feet shoulder-width apart and angled outward at 20°-30°. After a warm-up, the participants performed 45° squats with squeezing a Swiss ball of 18-cm diameter at a slow speed of 2 s for flexion and extension from the standing posture by using a commercial metronome. The squatting with knee flexion from 0° to 45° was the safest for people with PFPS.
62787290|NCT06068036|EXPERIMENTAL|Experimental group|Telehealth intervention involving the HEARTS technical package and the use of Smartwatch Mi Band 7® activity monitor. The HEARTS technical package presents the 5As brief intervention (Ask, Advise, Assess, Assist, Arrange) to promote physical activity participation. Participants will receive a physical activity monitor (as instructed in the HEARTS technical package) and will be monitored by telephone call, once a week, in order to reinforce successes and identify solutions to difficulties (as instructed in the HEARTS technical package) to practice physical activity. These individuals will undertake a 12-week intervention program. In the first week, individuals will perform the first four steps of the 5As brief intervention in person, where they will be instructed on how to use the physical activity monitor, they will receive a diary of regular physical activity practice, will be guided on how to fill it out, and will schedule the best times to receive the weekly telephone call.
62580306|NCT06681961|OTHER|squatting (SQU) group|The participants stood equally on both legs on the floor with their feet shoulder-width apart and angled outward at 20°-30°. After a warm-up, the participants performed 45° squats at a slow speed of 2 s for flexion and extension from the standing posture by using a commercial metronome. The squatting with knee flexion from 0° to 45° was the safest for people with PFPS.
62015268|NCT04840745|EXPERIMENTAL|CKD-841 A-1(=leuprorelin acetate 1.88mg)|Investigational drug(=CKD-841 A-1) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
62015269|NCT04840745|EXPERIMENTAL|CKD-841 D(=leuprorelin acetate 2.92mg)|Investigational drug(=CKD-841 D) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
62015270|NCT04840745|ACTIVE_COMPARATOR|Leuplin Inj.(=leuprorelin acetate 3.75mg)|Investigational drug(=Leuplin Inj.)is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
62015271|NCT01820130|EXPERIMENTAL|Spinal Cord Stimulation system therapy|St Jude Medical EON mini rechargeable system
62015272|NCT02841644||Traumatic Arthrotomy- Treated Nonoperatively|Patient diagnosed with traumatic arthrotomy treated nonoperatively.
62015273|NCT02841644||Traumatic Arthrotomy- Treated Operatively|Patient diagnosed with traumatic arthrotomy treated operatively.
62015274|NCT01046110|EXPERIMENTAL|IDeg OD|
62015275|NCT01046110|EXPERIMENTAL|DPP-IV inhibitor|
62015276|NCT02705131|EXPERIMENTAL|Balance Chiropractic Therapy(BCT)|patients are in the sitting position and receive the Balance Chiropractic Therapy(BCT) .1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.The patients will received BCT 1 time every other day, 20min each time. a total of 10 times in 20 days.
62015277|NCT02705131|ACTIVE_COMPARATOR|Traction Therapy(TT)|patients will receive the Traction Therapy(TT):The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
62204271|NCT06049589|EXPERIMENTAL|Coconut oil|"Participants will perform 10-minute vigorous full-mouth rinses once daily after night (2-minute brushing time) brushing. The amount of coconut oil used will be one teaspoon (5 ml). Each participant will be given a container with volume measurement markings. Patients will be provided with the same toothbrush and toothpaste for their dental hygiene 2 times a day. Participants will be asked not to use products containing xylitol, tea, coffee, systemic antibiotics, or topical fluoride during the study. Any participant who violates these rules will be excluded from the study.~Reevaluation and sampling will be done after 30 days."
62787291|NCT06068036|ACTIVE_COMPARATOR|Control group|Participants will undergo the same intervention as the experimental group, but will not receive the physical activity monitor (Smartwatch Mi Band 7®).
62580307|NCT02016105|EXPERIMENTAL|GP2017 Adalimumab|Study arm with intervention being studied in the protocol. Adalimumab Solution for subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
62580308|NCT02016105|ACTIVE_COMPARATOR|Humira ® Adalimumab|Humira® Adalimumab as a subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
62580309|NCT01604928|EXPERIMENTAL|YM178 Dose 1|low dose
62580310|NCT01604928|EXPERIMENTAL|YM178 Dose 2|high dose
62787292|NCT03463785||Chinese|Chinese mild or moderate OSA patients
62580311|NCT01604928|ACTIVE_COMPARATOR|Tolterodine|Oral
62580312|NCT01604928|PLACEBO_COMPARATOR|Placebo|Oral
62580313|NCT04998604|EXPERIMENTAL|Dupilumab|Dosing every 2 weeks (Q2W)
62580314|NCT04998604|EXPERIMENTAL|Omalizumab|Dosing Q2W or every 4 weeks (Q4W)
62787293|NCT03463785||Dutch|Dutch mild or moderate OSA patients
62787294|NCT05112003|EXPERIMENTAL|TLNS|Translingual neurostimulation will be paired with breathing and awareness training prior to CPT sessions
62787295|NCT05112003|NO_INTERVENTION|Control|No TLNS
62787296|NCT00549445||Azithromycin-treated|Participants in the COPD Network Macrolide Study who received azithromycin for 1 year.
62015278|NCT00927446||Endoscopy screening|Patients with tissue diagnosis of head and neck cancer undergo endoscopy screening with conventional white light system first. Then the entire esophagus is examined under the NBI system by another endoscopist, who is blinded to the result of the conventional endoscopy.
62015279|NCT02804165|OTHER|Target high-risk subjects or subpopulations for T1D|Confirmation of the role of enteroviral infection in T1D and characterization of gene-enterovirus interactions should open up new avenues for understanding the pathogenesis of T1D and give clues on possible new therapeutic perspectives. Clinical applications might be further developed in order to extend the lag period might between positive autoantibodies detection and T1D age at onset in genetically predisposed subjects. This innovative project opens the door of the development of preventive therapy for T1D, as enterovirus vaccination.
62787297|NCT00549445||Placebo-treated|Participants in the COPD Network Macrolide Study who received placebo for 1 year.
62787298|NCT02139488||neoadjuvant or definitive chemoradiation|Esophageal cancer patients planned for neoadjuvant or definitive chemoradiation.
62787299|NCT01339897|ACTIVE_COMPARATOR|5 mg/N6022|Injectable formulation, given at doses per cohort of 5 mg given QD each day over 7 days.
62787300|NCT01339897|PLACEBO_COMPARATOR|Placebo|Injectable formulation normal saline
62787301|NCT01339897|ACTIVE_COMPARATOR|10mg/N6022|Injectable formulation, given at doses of 10 mg given QD each day over 7 days.
62204272|NCT06049589|ACTIVE_COMPARATOR|Chlorhexidine|"Participants will vigorously rinse their entire mouth with Chlorhexidine 0.12% daily after morning (2 minute brushing time) and evening brushing. The amount of chlorhexidine used will be one teaspoon (5 ml). Each participant will be given a container with volume measurement markings. Patients will be provided with the same toothbrush and toothpaste for their dental hygiene 2 times a day. Participants will be asked not to use products containing xylitol, tea, coffee, systemic antibiotics, or topical fluoride during the study. Any participant who violates these rules will be excluded from the study.~Reevaluation and sampling will be done after 30 days."
62204273|NCT06049589|PLACEBO_COMPARATOR|Water|"Participants will vigorously rinse their entire mouth with water daily after morning (2 minute brushing time) and evening brushing. The amount of water used will be one teaspoon (5 ml). Each participant will be given a container with volume measurement markings. Patients will be provided with the same toothbrush and toothpaste for their dental hygiene 2 times a day. Participants will be asked not to use products containing xylitol, tea, coffee, systemic antibiotics, or topical fluoride during the study. Any participant who violates these rules will be excluded from the study.~Reevaluation and sampling will be done after 30 days."
62204274|NCT05171790|EXPERIMENTAL|QL1706 injection|This clinical trail is a single arm study, all the patients that meet the entry criteria will receive treatment until disease progression occurs or meet other criteria for the discontinuation of treatment. QL1706 will be administered by intravenous infusion, 5 mg/kg, Q3W.
62204275|NCT05996419|EXPERIMENTAL|DSB-Intervention|Active intervention group receives text message intervention via ANNIE for 30 days
62787302|NCT01339897|ACTIVE_COMPARATOR|20mg/N6022|Injectable formulation, given at doses per cohort of 20 mg given QD each day over 7 days.
62787303|NCT04022252|EXPERIMENTAL|Tooth Movement|Canine distalization on premolar extracted patients
62787304|NCT04022252|EXPERIMENTAL|Biochemistry measurements|biochemistry analysis of IL-8, OPG, RANKL
62204276|NCT03065257||Endoscopic Resection|Patients undergoing Endoscopic Resection
62204277|NCT01502683|EXPERIMENTAL|Off-pump No Clamp|Off-pump coronary artery bypass patients randomized to no clamp for proximal anastomoses.
62204278|NCT01502683|EXPERIMENTAL|Off-pump Partial Occluding Clamp|Off-pump coronary artery bypass patients randomized to partial occluding clamp for proximal anastomoses.
62204279|NCT01502683|EXPERIMENTAL|On-pump Single Cross Clamp|On-pump coronary artery bypass patients randomized to single cross clamp for cardioplegic arrest and proximal anastomoses.
62787305|NCT04022252|EXPERIMENTAL|periodontal measurements|gingival and plaque index, blooding on probing, pocket depth
62580315|NCT05175911||premature infants|premature infants less than 31 weeks of gestation or weighting less than 1300 g
62580316|NCT03256929|EXPERIMENTAL|depression participants - intervention|personalized diet intervention based on microbiota analysis and health status
62580317|NCT03256929|EXPERIMENTAL|depression participants - control|General information on nutrition and health
62580318|NCT03256929|EXPERIMENTAL|pre-depression participants - control|General information on nutrition and health for pre-depression participants
62580319|NCT03256929|EXPERIMENTAL|pre-depression participants - intervention|personalized diet intervention based on microbiota analysis and health status for pre-depression participants
62787306|NCT05551104|ACTIVE_COMPARATOR|Oral Nifedipine|Participants will receive oral nifedipine for blood pressure control. Dosage may initially start at one 10mg capsule by mouth three times per 24 hours (total of 30mg a day), however dosage may be increased by 30mg increments (i.e. 20mg capsule three times a day for a total of 60mg a day). Maximum dosage for oral Nifedipine will be 120mg per day.
62787307|NCT05551104|ACTIVE_COMPARATOR|Oral Labetalol|Participants will receive oral labetalol for blood pressure control. Dosage may initially start at one 200mg tablet by mouth two times per 12 hours (total of 400mg every a day), however dosage may be increased by 100-200mg increments at a time. Maximum dosage for oral labetalol will be 2400mg per day.
62015280|NCT02673697|EXPERIMENTAL|Perceval|The Perceval sutureless aortic heart valve (Perceval valve) is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The Perceval valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
62204280|NCT01502683|EXPERIMENTAL|On-pump Double Clamp|On-pump coronary artery bypass patients randomized to cross-clamp for cardioplegic arrest and partial-occluding clamp for proximal anastomoses. This strategy involves the application of two clamps.
62404002|NCT00083226|EXPERIMENTAL|Treatment (doxorubicin+bortezomib)|Patients receive doxorubicin IV over 5-15 minutes on days 1 and 8. Patients also receive bortezomib at a dose of 1.3 mg/m\^2 IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with no disease progression may continue to receive bortezomib alone in the absence of disease progression or unacceptable toxicity.
62404003|NCT04559802|EXPERIMENTAL|Transmucosal (Non-Submerged)|Flaps will be adapted to the healing abutments for a trans-mucosal healing up on closure
62404004|NCT04559802|ACTIVE_COMPARATOR|Submerged|Flaps will be advanced to achieve primary wound closure.
62404005|NCT05423665||Fetal growth restricted|Observation of cardiac remodeling perinatal and postnatal
62404006|NCT05423665||Appropriately grown|Observation of cardiac remodeling perinatal and postnatal
62404007|NCT05199649|EXPERIMENTAL|Arm Sintilimab|Sintilimab Combined With Chemotherapy
62787308|NCT06268964|EXPERIMENTAL|Trimebutine + Probiotic|Participants received trimebutine in 200 mg tablets or 20 mg/ml suspension at a dose of 15 mg/kg/day adjusted to their weight, divided into 2 doses (morning and night) + Lactobacillus rhamnosus 5 billion Colony Forming Units (CFUs) in chewable tablets, a single dose (night), for a period of 8 weeks.
62787309|NCT06268964|ACTIVE_COMPARATOR|Trimebutine + Placebo|Participants received trimebutine in 200 mg tablets or 20 mg/ml suspension at a dose of 15 mg/kg/day adjusted to their weight, divided into 2 doses (morning and night) + Placebo, 250 mg microcrystalline cellulose tablets, a single dose (night), for a period of 8 weeks.
62015281|NCT02673697|ACTIVE_COMPARATOR|other Stented biological valves|The comparator will be other commercially approved standard biological sutured stented valves, both bovine and porcine. The choice of the comparator tissue valve will be at the discretion of the participating investigators.
62015282|NCT05269524|EXPERIMENTAL|Treatment|Therapist-guided internet treatment.
62015283|NCT05269524|ACTIVE_COMPARATOR|Attention control|Non-directive supportive contact via email.
62015284|NCT01955876||Group 1|
62204281|NCT03915847|ACTIVE_COMPARATOR|Single layer closure|
62404008|NCT03829995|NO_INTERVENTION|Control group|Participants in the control group received the normal care following the Danish standard procedure.
62404009|NCT03829995|ACTIVE_COMPARATOR|Intervention group|Participants in the intervention group received the normal care following the Danish stadard procedure. Additionally the participants was also offered the possibility to contact a hospital pharmacy department by phone or mail for drug counseling.
62404010|NCT01739946||Implanted subject|Subjects with Interstim implanted
62404011|NCT01739946||Controls|Subjects without Interstim implanted
62404012|NCT02262572|EXPERIMENTAL|Telmisartan /HCTZ - compression tablet (DC)|
62404013|NCT02262572|EXPERIMENTAL|Telmisartan /HCTZ - dry granulation tablet (DG)|
62404014|NCT02262572|ACTIVE_COMPARATOR|Telmisartan /HCTZ - present commercial formulation|
62204282|NCT03915847|ACTIVE_COMPARATOR|Double layer closure|
62204283|NCT03915847|ACTIVE_COMPARATOR|Doble layer closure with trimming|
62404015|NCT06330506|EXPERIMENTAL|Care group|The pressure ulcer care package to be prepared by the researchers will be implemented
62404016|NCT06330506|NO_INTERVENTION|Standard group|Standard maintenance will be applied
62404017|NCT02396524|EXPERIMENTAL|Hockey FIT program|12-week active phase - exercise and healthy living program (1x/week; 90 minutes/session); 40-week maintenance phase (individualized approach)
62404018|NCT02396524|NO_INTERVENTION|Usual-care wait-list control|No active intervention (usual care)
62404019|NCT04768283|NO_INTERVENTION|Control group|Cardiac rehabilitation physical training program included: respiratory muscle training (7 days/week, for 15 minutes) and aerobic exercises on cycle ergometers (6 days/week, for 10-30 minutes, 30-50% watts or 30-50% HRmax).
62404020|NCT04768283|EXPERIMENTAL|Intervention group 1|"Combinated physical training program:~Respiratory exercises, aerobic training will be the same as in the control group.~Additional exercises: balance training and strength exercises with weights, elastic resistance rubbers."
62404021|NCT04768283|EXPERIMENTAL|Intervention group 2|"Combinated physical training program:~Respiratory exercises, aerobic training will be the same as in the control group.~Additional exercises: balance training with static and dynamic balance training device Biodex Balance System TM SD and strength exercises with HUR strength training machines."
62404022|NCT03378024||diabetic mellitus patients|"Measure the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) of pre-exercise and post-exercise by the oscillometric (Omron Colin co.).~And follow up for 3 years to identify of the correlation with PAD outcome."
62787310|NCT06268964|ACTIVE_COMPARATOR|Probiotic + Placebo|Participants received Lactobacillus rhamnosus 5 billion Colony Forming Units (CFUs) in chewable tablets + Placebo, 250 mg microcrystalline cellulose tablets, a single dose (night), for a period of 8 weeks.
62787311|NCT03727932|OTHER|VioOne HIV Profile|HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2. It is intended as an additional, more specific test to confirm the presence of antibodies to HIV-1 and HIV-2 for specimens repeatedly reactive in diagnosis or screening procedures, including pediatric patients (ages 2-20).
62787312|NCT04918511|EXPERIMENTAL|Dose cohort 1|In dose cohort 1, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level of 30 mg/m2 (dose based on body surface area)
62787313|NCT04918511|EXPERIMENTAL|Dose cohort 2|In dose cohort 2, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 1
62787314|NCT04918511|EXPERIMENTAL|Dose cohort 3|In dose cohort 3, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 2
62787315|NCT04918511|EXPERIMENTAL|Dose cohort 4|In dose cohort 4, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 3
62015285|NCT06572878|EXPERIMENTAL|Cognitive training|Each participant will receive cognitive training for 45 minutes per session, three sessions per week, for 12 weeks.
62015286|NCT06572878|EXPERIMENTAL|Physical training|Each participant will receive physical training for 45 minutes per session, three sessions per week, for 12 weeks.
62404023|NCT03743571|ACTIVE_COMPARATOR|anodal tDCS during exposure|anodal transcranial direct current stimulation (2mA) will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
62015287|NCT06572878|EXPERIMENTAL|Combined cognitive and physical training|Each participant will receive combined cognitive and physical training for 45 minutes per session, three sessions per week, for 12 weeks.
62015288|NCT06572878|ACTIVE_COMPARATOR|Passive information activities|Each participant will engage in passive information activities for 45 minutes per session, three sessions per week, for 12 weeks.
62015289|NCT00995449|EXPERIMENTAL|KB003 70 mg|
62404024|NCT03743571|SHAM_COMPARATOR|sham tDCS during exposure|sham transcranial direct current stimulation will be applied over EEG coordinate FpZ during exposure therapy at a level that provides the physical sensations of tDCS but which is non-therapeutic
62015290|NCT00995449|EXPERIMENTAL|KB003 200 mg|
62015291|NCT00995449|EXPERIMENTAL|KB003 600 mg|
62580320|NCT03107884|EXPERIMENTAL|Metformin (Bed Rest)|Metformin will be given to participants incrementally during a 2 week run in period such that they will receive the clinical dose (2 grams per day). During bed rest, participants will be given 1 gram of metformin two times a day (morning and evening). This dosage and frequency will occur during four consecutive days of bed rest.
62580321|NCT03107884|PLACEBO_COMPARATOR|Placebo (Bed Rest)|Placebo will be given to participants incrementally during a 2 week run in period such that they will receive the same amount of pills as the experimental group. During bed rest, participants will be given the same amount of pills and given at the same time of day (morning and evening) as the experimental group. This strategy will occur during four consecutive days of bed rest.
62580322|NCT03107884|EXPERIMENTAL|Metformin (2 week run-in only)|Metformin will be given to participants incrementally during a 2 week run in period such that they will receive the clinical dose (2 grams per day). These participants will not participate in the bed rest portion of the protocol.
62787316|NCT04918511|EXPERIMENTAL|Dose cohort 5|In dose cohort 5, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 4
62787317|NCT04918511|EXPERIMENTAL|Dose cohort 6|In dose cohort 6, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 5
62787318|NCT04918511|EXPERIMENTAL|Dose cohort 7|In dose cohort 7, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 6
62015292|NCT00995449|PLACEBO_COMPARATOR|Placebo|
62015293|NCT00287911|EXPERIMENTAL|Combo Chemotherapy and Radiation|"Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36. Some patients may also undergo brachytherapy. Patients also receive cisplatin intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36 and topotecan IV continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
62015294|NCT03951129||verbal group|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) levels after verbal informing before hemodialysis catheter insertion
62015295|NCT03951129||verbal and video group|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) levels after verbal and video informing before hemodialysis catheter insertion
62404025|NCT01234246||Patients with colorectal cancer|Patients with colorectal cancer are included
62404026|NCT01234246||Partners|Partners of patients with colorectal cancer are included
62404027|NCT03564015|EXPERIMENTAL|Smartphone app|The smartphone group will not be given paper-based discharge instructions in the ED. They will download onto their smartphone device an Intervention App that will allow recording of the above mentioned study outcomes and contains an interactive educational component encompassing the identical information outlined in the paper handout. The app will provide educational guidance towards recovery using a feedback algorithm that will recommend on a daily basis, the use of ice, elevation, range of motion exercises, and/or analgesics based on the participant's report of their pain using the FPS-R.
62787319|NCT04180332|EXPERIMENTAL|Healthy|The patients were healthy subjects without Periodontal disease or any systemic manifestation
62787320|NCT04180332|EXPERIMENTAL|Periodontal disease without diabetes|Patients with periodontal diseases without diabetes
62015296|NCT06572202|EXPERIMENTAL|Positive Psychology Intervention|The experimental group will receive multicomponent of positive psychology intervention with the specific domain related to resilience enhancement in nurses Ciarrochi et al. (2022). The program consists of five resilience domains/ six positive psychology virtues in fourteen sessions. Each session will take 60 minutes, two sessions per week. The program will last for six weeks, followed by posttest immediately after intervention, 3-months, 6-months, and one year follow up.
62015297|NCT06572202|NO_INTERVENTION|Control group|The control group will not receive intervention
62015298|NCT03569956|ACTIVE_COMPARATOR|Razor Group|Subject will use the 556 razor with regular shaving products, and shave at least 5 or more times per week
62015299|NCT03569956|EXPERIMENTAL|Regimen|Subject will use the 556 razor with the Pre-shave Gel, Cleaning Brush, and Shaving Gel and shave at least 5 or more times per week.
62015300|NCT02112786|ACTIVE_COMPARATOR|Intermittent then Continuous|This group will be set to intermittent stimulation first, then after the wash out period they will be switched to continuous stimulation.
62015301|NCT02112786|ACTIVE_COMPARATOR|Continuous Then Intermitent|This group will be set to continuous stimulation first, then switch to intermittent after the wash out time period.
62015302|NCT00088218|ACTIVE_COMPARATOR|Clofarabine|Clofarabine intravenous (IV) 30 mg/m\^2 daily times 5 days
62015303|NCT00088218|ACTIVE_COMPARATOR|Clofarabine Plus Ara-C|Clofarabine IV 30 mg/m\^2 daily times 5 days + Ara-C 20 mg/m\^2 subcutaneously daily times 14 days.
62015304|NCT00759967|ACTIVE_COMPARATOR|Short daily hemodialysis|After a 3 month run-in period patients who are randomized to this arm will receive 3 months of short daily hemodialysis(2 hours/day,6 days/week)B/P will be monitored according to the Canadian hypertension guidelines both pre and post each dialysis session. Antihypertensive medication will be adjusted accordingly to maintain BP within the guidelines.At the end of this 3 month period extracellular fluid volume (bioimpedance) will be measured using bioimpedance as well as sympathetic nerve activity using microneurography. Additionally Catecholamines as well as markers of oxidative stress will be collected.
62015305|NCT00759967|ACTIVE_COMPARATOR|Conventional hemodialysis|After a 3 month run-in period patients who are randomized to this arm will receive 3 months of conventional hemodialysis 3 days/week 3.5-4 hours/ treatment. BP will be monitored according to the Canadian hypertension guidelines both pre and post each dialysis session. Antihypertensive medication will be adjusted accordingly to maintain BP within the guidelines.At the end of this 3 moth period extracellular fluid volume (bioimpedance) will be measured using bioimpedance as well as sympathetic nerve activity using microneurography. Additionally Catecholamines as well as markers of oxidative stress will be collected.
62015306|NCT04318210|EXPERIMENTAL|TDF-FTC as PrEP|Eligible HIV-uninfected participants were offered 12 months of oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet regardless of their original study assignment in randomized phase.
62787321|NCT04180332|EXPERIMENTAL|Periodontal disease with diabetes|Patients with periodontal disease and diabetes
62015307|NCT01970332|NO_INTERVENTION|No Exercise Therapy or Revascularization operation|The patient is evaluated but no intervention
62015308|NCT01970332|EXPERIMENTAL|Revascularization Surgery|The patient undergoes surgery to revascularize the ischemic, symptomatic limb(s)
62015309|NCT01970332|EXPERIMENTAL|Exercise Therapy|The patient undergoes supervised exercise therapy for 6 months
62580323|NCT03107884|PLACEBO_COMPARATOR|Placebo (2 week run-in only)|Placebo will be given to participants incrementally during a 2 week run in period such that they will receive the same amount of pills as the experimental group. These participants will not participate in the bed rest portion of the protocol.
62580324|NCT00990457|ACTIVE_COMPARATOR|Low-carbohydrate Diet Plus Exercise|Participants will follow a low-carbohydrate weight loss diet plus participate in a supervised exercise training program for 6 months.
62015310|NCT04462796|EXPERIMENTAL|Magnesium Citrate|Magnesium Citrate given orally taken once daily for 8 weeks
62580325|NCT00990457|ACTIVE_COMPARATOR|Low-Fat, Low-Calorie Diet Plus Exercise|Participants will follow a low-calorie, low-fat weight loss diet plus participate in a supervised exercise training program for 6 months.
62580326|NCT05269446||STEMI patients|STEMI: patients diagnosed with ST-segment elevation myocardial infarction
62580327|NCT05269446||SA or NSTEMI patients|SA: patients diagnosed with stable angina
62580328|NCT05269446||Healthy subjects|Patients with suspected coronary artery disease, but coronary angiography (CAG) indicates no obvious coronary stenosis
62787322|NCT05310812||Control group (Sepsis - no acute kindey injury)|"Septic patients diagnosed by sepsis criteria but no have an acute kidney injury. (According ot KDIGO classification - creatinin values).~Blood plasma will be taken for biochemical evaluation."
62787323|NCT05310812||Study group (Sepsis induced acute kidney injury)|"Septic patients diagnosed by sepsis criteria, and have an acute kidney injury. (According ot KDIGO classification - creatinin values).~Blood plasma will be taken for biochemical evaluation."
62787324|NCT01771250|EXPERIMENTAL|Insulin Peglispro|Stable dose of insulin peglispro (0.2 - 0.8 units per kilogram \[U/kg\]) administered subcutaneously (SC) once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.
62787325|NCT01771250|ACTIVE_COMPARATOR|Insulin Glargine|Stable dose of insulin glargine (0.2 - 0.8 U/kg) administered SC once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.
62204284|NCT04379505|EXPERIMENTAL|Quad shot radiation|-Radiotherapy will consist of Quad shot radiation delivered on the Ethos ring gantry kV-CBCT combined with linear accelerator system to a dose of 14 Gy in four, twice-daily fractions of 3.5 Gy delivered at least 6 hours apart over two days for a possible total of 3 cycles delivered in 3 to 4 intervals for a cumulative dose of of 42 Gy in 12 fractions. Cycle 2 and 3 of treatment is not mandated per protocol but may be given at the discretion of the treating physician.
62204285|NCT00301938|EXPERIMENTAL|Arm I (enzyme inhibitor, chemotherapy)|Patients receive a loading dose of oral perifosine every 6 hours on day 1 followed by a maintenance dose once daily on days 2-28 of course 1 and then once daily on days 1-28 in all subsequent courses. Patients also receive 7-hydroxystaurosporine IV over 3 hours on day 4. Cohorts of 3-6 patients receive escalating doses of 7-hydroxystaurosporine until the MTD is determined.
62204286|NCT00301938|EXPERIMENTAL|Arm 2 (enzyme inhibitor, chemotherapy)|Patients receive 7-hydroxystaurosporine IV over 3 hours on day 1 at the MTD determined in group I. Patients also receive oral perifosine as a loading dose every 6 hours on day 4 followed by a maintenance dose once daily on days 5-28 of course 1 and then once daily on days 1-28 in all subsequent courses.
62204287|NCT02642562|NO_INTERVENTION|Standard care|Participants in this arm will receive their usual care
62787326|NCT04064762|EXPERIMENTAL|Vagus Nerve Stimulation + Prolonged Exposure Therapy|Study treatment is vagus nerve stimulation (VNS) delivered during Prolonged Exposure Therapy.
62015311|NCT05325086|EXPERIMENTAL|Adapted information arm|"In parallel with an inpatient PR program, 4 visits will be carried out: V0 : Inclusion / V1 : Randomization / V2 : Follow-up / V3: End-stay.~At V1:~* Adapted information to the characteristics of a greater openness to experiences will be delivered to patient.~* The following questionnaires will be filled : Big Five Inventory BFI-FR, St. George's Respiratory SGRQ, Dyspnea-12, Self-efficacy for managing chronic disease SEMCD-6, Brief Illness Perception B-IPQ, COPD Anxiety Revised CAF-R, Patient Health PHQ-9, Montreal Cognitive Assessment Mini-MoCA~At V2:~\*Semi-structured individual interviews will be performed. Questions will relate to the information distributed during V1 (adapted information), allowing to assess the understanding and the appropriation of it.~At V3:~* The following questionnaires will be filled: SGRQ,Dyspnea-12,SEMCD-6,B-IPQ,CAF-R~* In addition, some questions will be asked to verify the adherence to information and the potential contamination bias"
62015312|NCT05325086|SHAM_COMPARATOR|Neutral information arm|"In parallel with an inpatient PR program, 4 visits will be carried out: V0 : Inclusion / V1 : Randomization / V2 : Follow-up / V3: End-stay.~At V1:~* Neutral information will be delivered to patient.~* The following questionnaires will be filled : Big Five Inventory BFI-FR, St. George's Respiratory SGRQ, Dyspnea-12, Self-efficacy for managing chronic disease SEMCD-6, Brief Illness Perception B-IPQ, COPD Anxiety Revised CAF-R, Patient Health PHQ-9, Montreal Cognitive Assessment Mini-MoCA~At V2:~\*Semi-structured individual interviews will be performed. Questions will relate to the information distributed during V1 (neutral information), allowing to assess the understanding and the appropriation of it.~At V3:~* The following questionnaires will be filled: SGRQ,Dyspnea-12,SEMCD-6,B-IPQ,CAF-R~* In addition, some questions will be asked to verify the adherence to information and the potential contamination bias"
62015313|NCT01390558||Persons with Down Syndrome who use orthotics|Orthotic users
62015314|NCT01390558||Persons with Down Syndrome who do not use orthotics|Non orthotic users
62015315|NCT00637546|EXPERIMENTAL|A,1|Physiotherapy
62015316|NCT01193556|ACTIVE_COMPARATOR|Standard of Care|Traditional electrosurgery will be used for the tonsillectomy.
62015317|NCT01193556|EXPERIMENTAL|PlasmaBlade|The PEAK PlasmaBlade will be used for the tonsillectomy.
62015318|NCT05702957|EXPERIMENTAL|letrozole|Patients were given letrozole 2.5 mg-7.5mg per day for 5 days started from 2nd day of menses.
62015319|NCT05702957|ACTIVE_COMPARATOR|Clomiphene citrate|Patients were given clomiphene citrate 50-150mg per day for 5 days started from 2nd day of the menses.
62015320|NCT03208972|EXPERIMENTAL|low dose hCG (Pregnyl)|Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination 150IU low dose hCG from day 7 until final oocyte maturation.
62204288|NCT02642562|EXPERIMENTAL|Standard care plus IV iron infusion|"Iron to be administered as iron (III) isomaltoside 1000 / ferric derisomaltose.~Infused over a minimum of 15 mins for doses up to and including 1000mg, and a minimum of 30 mins for doses \>1000mg~Where Hb ≥10 g/dL, dosage according to body weight is as follows:~Body weight \<50 kg: 20 mg/kg; Body weight 50 to \<70 kg: 1000 mg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 1500 mg.~Where Hb \<10 g/dL, dosage according to body weight is as follows:~Body weight \<50 kg: 20 mg/kg; Body weight 50 to \<70 kg: 20 mg/kg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 2000 mg."
62204289|NCT03602300|ACTIVE_COMPARATOR|Ravidasvir reference formulation|Ravidasvir 200 mg oral single dose manufactured by EEPI
62580329|NCT03971513|NO_INTERVENTION|usual practice|Control group (usual practice): patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen, nefopam and morphine. if necessary. Antimicrobial prophylaxis is performed according to recommendations
62204290|NCT03602300|EXPERIMENTAL|Ravidasvir test formulation|Ravidasvir 200 mg oral single dose manufactured by Doppel
62204291|NCT05903157|ACTIVE_COMPARATOR|Control Group: Delivery of a health literacy flyer|All Control Group participants received, through e-mail, a flyer about health literacy.
62204292|NCT05903157|EXPERIMENTAL|Weekly group sessions for weight management|"Participants in the Experimental Group were integrated into an eHealth 8-week group intervention, based on two theoretical models - the Health Action Process Approach (HAPA), and the Health Belief Model (HBM). Several Behaviour Change Techniques (BCT) were used, to promote the behaviour change.~The experimental intervention consisted of: i) weekly group sessions (by Zoom platform), with a specific theme in each session, ii) weekly challenges, and iii) WhatsApp group interaction."
62580330|NCT03971513|EXPERIMENTAL|TAP block|In addition of usual practice, patients receiving a TAP block at the beginning of the surgery
62204293|NCT03841318|EXPERIMENTAL|Sjogren's Syndrome|
62580331|NCT00835224|EXPERIMENTAL|Midodrine|A drug to treat low blood pressure.
62580332|NCT00835224|EXPERIMENTAL|L-Name|L-Name: A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
62204294|NCT01310608|EXPERIMENTAL|A-View|
62204295|NCT01310608|NO_INTERVENTION|No A-View|
62580333|NCT00835224|PLACEBO_COMPARATOR|Placebo|Placebo: A pill with an inactive substance that looks like the study drug.
62015321|NCT03208972|ACTIVE_COMPARATOR|hp-FSH (Menopur)|Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination with hp-FSH until final oocyte maturation.
62015322|NCT05580575|EXPERIMENTAL|Daily disposable lens worn first, reusable lens worn second|Subject will wear each contact lenses for 30 days during the day only.
62015323|NCT05580575|EXPERIMENTAL|Reusable lens worn first, daily disposable lens worn second|Subject will wear each contact lenses for 30 days during the day only.
62015324|NCT04825223|EXPERIMENTAL|Stage 1: MenB vaccine formulation(s)|Assigned MenB vaccine formulation or Placebo single injection in the respective dosing schedule at Day 01, Day 31 and Day 181
62015325|NCT04825223|ACTIVE_COMPARATOR|Stage 1: vaccine comparator(s)|Bexsero vaccine or Trumenba vaccine or Placebo single injection in the respective dosing schedule at Day 01, Day 31 and Day 181
62204296|NCT03490838|EXPERIMENTAL|Phase I: Dose Escalation Cohort 1|3.70 GBq (100 mCi) x 3 times
62580334|NCT05956470|EXPERIMENTAL|SKY intervention group|Meditation and breath program: includes gentle stretches (office yoga' in a sitting position) and three different types of specific breathing exercises. 3x1,5 hours. Daily practice thereafter for about 30 minutes for 8 weeks. In addition, there are weekly one-hour sessions for group practice and discussion.
62015326|NCT04825223|EXPERIMENTAL|Stage 2: MenB vaccine formulation(s)|Assigned MenB vaccine formulation, MenQuadfi vaccine and Placebo single injection in the respective dosing schedule at Day 01, Day 31, Day 61 and Day 181 + booster dose of leading MenB vaccine formulation single injection at Day 366
62015327|NCT04825223|ACTIVE_COMPARATOR|Stage 2: vaccine comparator(s)|Bexsero vaccine or Trumenba vaccine and Placebo single injection in the respective dosing schedule at Day 01, Day 31, Day 61 and Day 181 + booster dose of Bexsero vaccine single injection at Day 366
62580335|NCT05956470|ACTIVE_COMPARATOR|Control group|Group discussion-based viewing of online educational videos that demonstrate ways to mitigate psychological distress, including the use of cognitive coping techniques. 3x1,5 hours. It includes weekly online meetings with group discussions, experience sharing, and watching brief videos on the key elements of the program for 8 weeks.
62787327|NCT05501834|NO_INTERVENTION|Control Group|Both arms will receive the same Standard of Care procedures but will receive them in a different order. Patients in the control group will: 1. Go to cast room for cast removal, 2. Go to radiology for X-ray, 3. Will be seen in clinic room for pin removal. These steps are our current standard of care. An orthopedic, cast room technician bivalves and removes the top half of the patient's cast. In radiology, anteroposterior (AP) and lateral X-ray views are obtained to confirm radiographic healing. In the clinic room, a surgeon or nurse removes the pins using pin removal pliers. The order of these procedures is the current Standard of Care.
62015328|NCT04825223|EXPERIMENTAL|Stage 3: Men B vaccine formulation(s)|Assigned MenB vaccine formulation and/or MenQuadfi vaccine single injection in the respective dosing schedule at Day 01 and Day 61
62015329|NCT04825223|ACTIVE_COMPARATOR|Stage 3: MenQuadfi vaccine and vaccine comparator|MenQuadfi vaccine single injection at Day 01 or Bexsero vaccine single injection at Day 01 and Day 61
62015330|NCT04825223|EXPERIMENTAL|Stage 4: MenB vaccine formulation(s)|Assigned MenB vaccine formulation, Routine Vaccines (RV)s and MenQuadfi vaccine single injection in the respective dosing at 2 months of ages \[moa\] (Day 01), 4moa (Day 61) and 12 moa
62015331|NCT04825223|ACTIVE_COMPARATOR|Stage 4: MenQuadfi vaccine and vaccine comparator|MenQuadfi vaccine or Bexsero vaccine and RVs in the respective dosing schedule at 2 months of ages \[moa\] (Day 01), 4moa (Day 61) and 12 moa
62580336|NCT06683391|PLACEBO_COMPARATOR|16g CHO at < 4.0 mmol/L (Reactive Approach)|"Participants receive 16 grams of carbohydrate only when their CGM reading falls below 4.0 mmol/L, in line with the traditional reactive approach. This arm serves as a control, reflecting current hypoglycemia treatment guidelines, allowing comparison to proactive interventions."
62580337|NCT06683391|EXPERIMENTAL|8g CHO at 5.0 mmol/L (Proactive Approach)|Participants receive 8 grams of carbohydrate when their CGM reading reaches a proactive threshold of 5.0 mmol/L. This arm tests whether a lower amount of CHO, administered at a higher glucose level, can effectively prevent hypoglycemia with minimal caloric intake.
62580338|NCT06683391|EXPERIMENTAL|16g CHO at 5.0 mmol/L (Proactive Approach)|Participants receive 16 grams of carbohydrate at the proactive threshold of 5.0 mmol/L. This arm examines if a slightly higher dose of CHO at the same proactive threshold provides additional preventive benefits compared to 8 grams, while still aiming to avoid hypoglycemia and limit subsequent glucose fluctuations.
62015332|NCT01415661|EXPERIMENTAL|obese patient|
62204297|NCT03490838|EXPERIMENTAL|Phase I: Dose Escalation Cohort 2|7.40 GBq (200 mCi) up to 4 times
62015333|NCT01415661|EXPERIMENTAL|non obese patient|
62204298|NCT03490838|EXPERIMENTAL|Phase I: Dose Escalation Cohort 3|11.1 GBq (300 mCi) up to 4 times
62204299|NCT03490838|EXPERIMENTAL|Phase I: Dose Escalation Cohort 4|14.8 GBq (400 mCi) up to 4 times
62204300|NCT03490838|EXPERIMENTAL|Phase I: Dose Escalation Cohort 5|18.5 GBq (500 mCi) up to 4 times
62580339|NCT02605343||NeuroIDgenetix-guided Pain Management|The medical provider for the NeuroIDgenetix-guided group will make post-operative pain management recommendations based on test results. Patient outcomes, narcotic consumption, opioid-related adverse effects, time to mobilization, number of adverse drug events and number of hospital and/or medical visits will be measured throughout the study.
62580340|NCT02605343||Historical Control|The retrospective chart review will utilize patient outcomes from patients meeting the study inclusion/exclusion criteria. The medical provider for the control group will not have received the NeuroIDgenetix Test Panel results and would have made post-operative pain management recommendations per standard of care.
62580341|NCT01590043||Control|Healthy 3-18 years old participants
62015334|NCT05194176|NO_INTERVENTION|Control|The control group will receive usual care. Patients will be instructed to perform respiratory exercises 8 times daily for 10 minutes and to extend these exercises 2 times daily with (sitting) physical exercises for an additional 10 minutes. Respiratory exercises include using incentive spirometry and exercises for deep breathing, huffing and coughing. Patients receive a leaflet with the exercises described and the exercises will be performed once daily under supervision of a physiotherapist. The other sessions will be unsupervised.
62015335|NCT05194176|EXPERIMENTAL|Virtual Reality|The intervention group will be instructed to perform the respiratory exercises using the VR-intervention 8 times daily for 10 minutes and to extend these exercises 2 times daily with (sitting) physical exercises for an additional 10 minutes. The respiratory exercises in VR are comparable to the exercises in usual care but performed in a virtual environment and without incentive spirometry. The physical exercises consist of several games through which patients are challenged to reach out to objects while engaging their core. Patients are allowed to continue these exercises or play some relaxation games for up to 30 minutes per session in total. The exercises will be performed once daily under supervision of a physiotherapist. The other sessions will be unsupervised.
62015336|NCT06123767|EXPERIMENTAL|CAS + Intravascular measuring the pressure gradient|"Patients with internal carotid stenosis qualified for angioplasty with stent implantation.~Standard CAS procedure with additional intravascular pressure measurements"
62015337|NCT06123767|ACTIVE_COMPARATOR|CAS (standard)|"Patients with internal carotid stenosis qualified for angioplasty with stent implantation.~Standard CAS procedure."
62204301|NCT03490838|EXPERIMENTAL|Phase I: Dose Escalation Cohort 6|18.5 GBq (500 mCi) up to 3 times
62580342|NCT01590043||Inflammatory bowel disease|3-18 years old patients identified with inflammatory bowel disease
62580343|NCT01590043||Abdominal pain|3-18 years old patients suffering from abdominal pain not related to Inflammatory bowel disease
62580344|NCT03255161|EXPERIMENTAL|Immediate communication education and support group|
62787328|NCT05501834|EXPERIMENTAL|Intervention Group|Both arms will receive the same Standard of Care procedures but will receive them in a different order. Patients in the treatment group will: 1. Go to cast room for cast removal, 2. Have pins immediately pulled after cast removal, 3. Go to radiology for X-ray, 4. Will be seen in clinic room by provider.
62580345|NCT03255161|NO_INTERVENTION|Waitlist|
62580346|NCT03493815|EXPERIMENTAL|Transabdominal Ultrasound Guided IUD Insertion|Ultrasound Guided IUD Insertion: Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
62580347|NCT03493815|ACTIVE_COMPARATOR|Traditional Blind IUD Insertion|Traditional blind IUD insertion: Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
62580348|NCT00024596||Caucasian Families|Largest 3-generational Caucasian Families from Family Heart Study (Classic) with average family size of 10 N=2767 Subjects from 512 families. Approximately half are random sample families from FamHS-Classic, and half are high-familial CHD risk families from FamHS-Classic. 4 Field sites were Raleigh-Durham North Carolina; Minneapolis, MN; Framingham MA; and Salt Lake City, UT.
62787329|NCT05407038|EXPERIMENTAL|Supportive care (remote monitoring with health coaching)|Patients undergo routine exercise using a remote monitoring system (Garmin Vívofit activity monitor, Nonin 3150 WristOx2 pulse oximeter, and an Android tablet) over 30 minutes at least 6 days per week and complete daily questionnaires over 20 minutes for 12 weeks. Patients also receive health coaching telephone calls over 5-20 minutes once a week for 12 weeks. At the end of the 12 weeks, patients complete an audio taped telephone interview.
62015338|NCT04964934|EXPERIMENTAL|AZD9833 + palbociclib, abemaciclib or ribociclib|The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150,100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (PO, once daily) or letrozole placebo (PO, once daily)
62787330|NCT05719675|EXPERIMENTAL|Intervention|A healthcare model for people with Type 2 Diabetes Mellitus, based on Contingency Behavioral Analysis (CBA). The CCA model was constructed in a Mexican population by Ribes et al. (1986), and later operationalized in manuals by Rodriguez (2002). It has proven to be a suitable alternative for working with people with T2DM (Ocampo et al., 2017; Rodriguez et al., 2015; Rodriguez et al., 2016; Rivera et al., 2008; Rodriguez et al., 2013; Rosales et al., 2021). For this intervention, an application manual aimed at the intervention facilitator was developed and evaluated by a panel of experts in the field of nursing, endocrinology, diabetology and social work with experience in the care of people with T2DM. In general, they were asked to evaluate the congruence and adequacy of the activities proposed in the sessions to improve adherence to treatment in people with T2DM. Additionally, they evaluated whether the number of sessions was adequate for the objectives of the research project.
62787331|NCT03394586||UC patients with golimumab|We will retrospectively analyze all ulcerative colitis patients from the Swiss IBD cohort study treated with golimumab.
62787332|NCT02170870|EXPERIMENTAL|Healthy Controls Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
62787333|NCT02170870|PLACEBO_COMPARATOR|Healthy Controls Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
62787334|NCT02170870|EXPERIMENTAL|Diabetics Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
62787335|NCT02170870|PLACEBO_COMPARATOR|Diabetics Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
62787336|NCT02170870|EXPERIMENTAL|Functional Dyspepsia Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
62787337|NCT02170870|PLACEBO_COMPARATOR|Functional Dyspepsia Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
62787338|NCT02189291|EXPERIMENTAL|Immediate catheter removal|The indwelling Foley catheter will be removed prior to exiting the operating room.
62787339|NCT02189291|ACTIVE_COMPARATOR|Post op day 1 catheter removal|Patients assigned to this group will follow the standard of care at present, with removal of indwelling catheter on the morning of postoperative day 1.
62787340|NCT03118089|EXPERIMENTAL|Biscuit style oral nutritional supplement treatment|Participants will take the biscuit style oral nutritional supplement at an intervention level equivalent to their current oral nutritional supplement prescription
62787341|NCT03118089|NO_INTERVENTION|Standard Care|Participants will remain on their current oral nutritional supplement
62787342|NCT06231979|EXPERIMENTAL|Dexmedetomidine group|Patients will receive US-guided ESPB with 18 mL of bupivacaine 0.25 % and 1 μg/kg DEX diluted with saline to reach total volume 20 mL per side.
62787343|NCT06231979|EXPERIMENTAL|Bupivacaine group|Patients will receive US-guided ESPB with 18 mL of bupivacaine 0.25 % and 2 mL normal saline 0.9 % per side as control group.
62787344|NCT04872660|EXPERIMENTAL|GSATP group|Gushen Antai Pill (GSATP, 6g\* 9 bags, Beijing boran Pharmaceutical Inc.) was required to be taken orally, 6g three times daily combined with vaginal progesterone (90 mg/day Crinone, Merck) from the day of embryo transfer until 10th gestational week.
62787345|NCT04872660|PLACEBO_COMPARATOR|Placebo group|Placebo pill is made up of a certain amount of starch and glucose, and is shaped like GSATP according to the National Drug Standards of the State Food and Drug Administration of China. Placebo pill was required to be taken orally, 6g three times daily combined with vaginal progesterone (90 mg/day Crinone, Merck) from the day of embryo transfer until 10th gestational week.
62787346|NCT01487889|EXPERIMENTAL|Rapeseed oil|Study group receive commercial vegetable-potato-meat-meals containing rapeseed oil as part of complementary food
62787347|NCT01487889|EXPERIMENTAL|Fatty fish|Study group receive 2 times per week a vegetable-potato-meat-meals as part of complementary food.
62787348|NCT01487889|ACTIVE_COMPARATOR|Corn oil|Study group receive commercial vegetable-potato-meat-meals containing corn oil as part of complementary food
62787349|NCT01517555|EXPERIMENTAL|Liraglutide|
62787350|NCT01517555|PLACEBO_COMPARATOR|Placebo|
62787351|NCT02470481||Cohort 1|Participants with psoriatic arthritis among psoriasis particiants attending dermatology clinics.
62787352|NCT00466921|EXPERIMENTAL|Lenalidomide|
62787353|NCT05423964|ACTIVE_COMPARATOR|Artificial Intelligence Endoscopy Room|The fellows will be randomized on a daily basis to perform colonoscopies in a room with AI (intervention)
62787354|NCT05423964|ACTIVE_COMPARATOR|Non-Artificial Intelligence Endoscopy Room|The fellows will be randomized on a daily basis to perform colonoscopies in a non-AI endoscopy room (standard of care).
62787355|NCT03601702||EmboTrap ® II Device|The study group consists of the patients with acute ischemic stroke from large vessel occlusion treated with EmboTrap ® II Device (Neuravi)
62787356|NCT04099784||Freeze-only|Children born from freeze-only group and frozen embryo transfer
62787357|NCT04099784||Fresh|Children born from fresh embryo transfer
62787358|NCT06272123||Chronic Sinusitis|
62787359|NCT06272123||Controls|
62787360|NCT02078128|EXPERIMENTAL|oral beta-glucans|Daily give kg per day to 30 mg of β-glucan (30mg/kg/day), taking to the wound healed.
62204302|NCT04218786|ACTIVE_COMPARATOR|Colchicine Group|This group will receive low dose colchicine, 0.5 mg.
62204303|NCT04218786|PLACEBO_COMPARATOR|Placebo group|This group will receive a placebo drug with a similar shape and mass as that to experimental drug
62204304|NCT04618562|EXPERIMENTAL|Revival Active Program|Revival Program included supervised play group, twice a week followed by home practice.
62404028|NCT03564015|ACTIVE_COMPARATOR|Paper handout|The paper handout group will be asked to read the paper-based discharge instructions in the ED, outlining pharmacological and non-pharmacological pain management and return to activity. They will download onto their smartphone device a Recording App that will only allow them to record the following study outcome measures: daily use of ice, analgesia, range of motion exercises, elevation, pain using the Faces Pain Scale - Revised (FPS-R), and ASKp scores on days 3, 5, 7, 10, 12, and 14.
62580349|NCT00024596||African-American Families|622 subjects from 2-3 generational 212 African-American families originally recruited from the HyperGEN study in Birmingham AL. These are hypertension enriched families.
62580350|NCT04696276|EXPERIMENTAL|A-ERAS|will receive ERAS pathways care
62580351|NCT04696276|NO_INTERVENTION|B-nonERAS|will receive traditional non ERAS care
62580352|NCT05908721|EXPERIMENTAL|CM310|Subcutaneous injection
62787361|NCT02078128|PLACEBO_COMPARATOR|oral sugar powder|control group, daily give and the glucose powder 30 mg per kilogram of body weight (30mg/kg/day) a day, taking to the wound healed.
62580353|NCT05632289|EXPERIMENTAL|osteopathic treatment|
62580354|NCT05632289|SHAM_COMPARATOR|sham of osteopathic treatment|
62580355|NCT00002931|EXPERIMENTAL|HD Chemo and Auto Stem Cells|
62580356|NCT03014544||Group 1: Sequence AABB|Participants of main study with Major Depressive Disorder (MDD) will be assigned in test sequence group AABB (Group 1) to undergo sequential cognitive performance evaluations by Test A (Computer- administered test battery) on Test Day 1 (Study Day 1) and Test Day 2 (Study Day 15 to 22) followed by Test B (Examiner-administered test battery) on Test Day 3 (Study Day 29 to 43) and Test Day 4 (Study Day 43 to 64). Each separated by a memory washout period of 14 to 21 days.
62580357|NCT03014544||Group 2: Sequence BBAA|Participants of main study with MDD will be assigned in test sequence group BBAA (Group 2) to undergo sequential cognitive performance evaluations by Test B (Examiner-administered test battery) on Test Day 1 (Study Day 1) and Test Day 2 (Study Day 15 to 22) followed by Test A (Computer- administered test battery) on Test Day 3 (Study Day 29 to 43) and Test Day 4(Study Day 43 to 64). Each separated by a memory washout period of 14 to 21 days.
62580358|NCT05404646|EXPERIMENTAL|Group A|Thoracic mobility exercises
62580359|NCT05404646|EXPERIMENTAL|Group B|Thoracic stretching exercises
62787362|NCT06166368|EXPERIMENTAL|diurnal variations|Venous blood samples were obtained under standardized conditions from 24 healthy young men every third hour through 24 hours
62787363|NCT04826640||Pregnant women who receive COVID-19 vaccine|Pregnant women who receive COVID-19 vaccine
62787364|NCT02744196|EXPERIMENTAL|Acellbia + methotrexate|"106 patients of this group will receive methotrexate in combination with a drug Acellbia to be used at a dose of 600 mg as a slow intravenous infusion carried out on day 1 and day 15.~If a follow-up examination at 24 weeks or later (up to 48 weeks) reveals that the patient still has active arthritis (evaluation index DAS28-4 (ESR)\> 2,6 points), the therapy with Acellbia is repeated by the same scheme - 2 infusion at a dose of 600 mg at intervals of 14 days."
62787365|NCT02744196|PLACEBO_COMPARATOR|Placebo + methotrexate|"53 patients of this group will receive methotrexate in combination with a placebo to be used as a slow intravenous infusion carried out on day 1 and day 15.~If a follow-up examination at 24 weeks or later (up to 48 weeks) reveals that the patient still has active arthritis (evaluation index DAS28-4 (ESR)\> 2,6 points), the patient receives open therapy with Acellbia is initiated: 2 infusion at a dose of 600 mg at intervals of 14 days."
62580360|NCT03658538|ACTIVE_COMPARATOR|Active Treatment|The active treatment arm will receive two portable active HEPA air cleaners as well as 4 sessions of phone based motivational interviewing to support a home smoking ban and SHS reduction (in addition to the smoking cessation counseling received by all study participants).
62580361|NCT03658538|SHAM_COMPARATOR|Control Arm|Homes in the control group will receive Sham air cleaners that have the internal HEPA filter removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status. The control arm will not receive phone based motivational interviewing to support a home smoking ban and SHS reduction, they will receive only smoking cessation counseling.
62204305|NCT03436511||Subjects with COPD|Subjects with a COPD diagnosis confirmed with a post-bronchodilator Forced Expiratory Volume in 1 second/Forced Vital capacity \<70% recorded at any time in the medical record who have a qualifying peripheral blood eosinophil test recorded in the 3 months prior to the inclusion visit attend to a routine follow-up visit during the inclusion period, fulfill the inclusion/exclusion criteria and provide informed consent to participate, will be included in this study.
62204306|NCT04854824||'Recommended algorithm' cohort|COVID-19 patients treated at home by their family doctors according to the proposed recommendations
62204307|NCT04854824||'Historic control' cohort|COVID-19 patients enrolled in the ORIGIN study of the Istituto di Ricerche Farmacologiche Mario Negri IRCCS and treated at home by family physicians with drug regimens that are not necessarily guided by those proposed in the recommendations
62204308|NCT01764893|ACTIVE_COMPARATOR|PTNS and solifenacin|PTNS bladder neuromodulation weekly for 12 treatments; solifenacin 5 mg capsule daily for 15 weeks
62404029|NCT03448562|EXPERIMENTAL|Study Group|CPVI plus electrophysiologic substrate ablation in the left atrium during sinus rhythm (STABLE-SR)
62404030|NCT03448562|ACTIVE_COMPARATOR|Control Group|CPVI alone
62404031|NCT00752206|ACTIVE_COMPARATOR|Saracatinib|Saracatinib will be administered as a once daily, oral dose of 175 mg, for a 28-day cycle, with no breaks between cycles. The duration of treatment with saracatinib will be 13 cycles.
62404032|NCT00752206|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as a once daily, oral dose of 175 mg, for a 28-day cycle, with no breaks between cycles. The duration of treatment with placebo will be 13 cycles.
62404033|NCT06536478|EXPERIMENTAL|exercise|Exercise group will perform 50 minutes of exercise twice a week, including stretching, core exercises, gross motor movements and balance exercises for 5 weeks
62580362|NCT06544291|ACTIVE_COMPARATOR|Dronabinol 5mg|Participants will be randomized to which dronabinol (or placebo) dose they receive. The fixed dose they receive will be administered across all three test sessions. Therefore, participants may receive a single capsule of 5 mg Dronabinol across all three test sessions
62580363|NCT06544291|ACTIVE_COMPARATOR|Dronabinol 10mg|Participants will be randomized to which dronabinol (or placebo) dose they receive. The fixed dose they receive will be administered across all three test sessions. Therefore, participants may receive a single capsule of 10 mg Dronabinol across all three test sessions
62204309|NCT01764893|PLACEBO_COMPARATOR|PTNS and placebo|PTNS bladder neuromodulation weekly for 12 treatments; placebo 1 capsule daily for 15 weeks
62204310|NCT05258422|EXPERIMENTAL|Radiation: 20 Gy in 1 fraction|External beam, stereotactic body radiotherapy of 20 Gy delivered in 1 fraction to the planning target volume (PTV) of the arrhythmogenic substrate
62204311|NCT02022787||Renal cell carcinoma|Patients with renal cell carcinoma scheduled for partial or radical nephrectomy
62204312|NCT01515059||Bariatric sugery patients|Obese patients who are awaiting either a gastric bypass or sleeve gastrectomy
62404034|NCT06536478|OTHER|education|The patient will be given a one-time exercise education session and a 50-minute video that included stretching, core exercises, gross motor movements and balance exercises that could be practiced at home.
62404035|NCT04861688|ACTIVE_COMPARATOR|NeuroAiD II™ (MLC901)|Recommended treatment is 2 capsules orally, 3 times a day (i.e. 6 capsules per day). Treatment is 12 weeks.
62404036|NCT04861688|PLACEBO_COMPARATOR|Placebo|Capsule 2 capsules orally, 3 times a day
62404037|NCT06363552|EXPERIMENTAL|SC0191|
62404038|NCT06363552|EXPERIMENTAL|SC0191 + Bevacizumab|
62404039|NCT06363552|EXPERIMENTAL|SC0191 + 5-FU/LV|
62404040|NCT01826929|EXPERIMENTAL|Therapeutic education|Organized intervention strategy:Informed active patient, shared decision making, appointment planning, primary care doctor-nurse teamwork, actions based on scientific evidence.
62404041|NCT01826929|NO_INTERVENTION|Usual care model|
62404042|NCT03446157|EXPERIMENTAL|Open-label, single arm, Phase II|Cetuximab and palbociclib
62404043|NCT05598762|ACTIVE_COMPARATOR|Children with mild atopic dermatitis|"* age 1-8 years old~* mild degree of atopic dermatitis"
62204313|NCT02657044|ACTIVE_COMPARATOR|EMR|In the EMR-arm, endoscopic resection will be performed using the (p)EMR technique.
62204314|NCT02657044|ACTIVE_COMPARATOR|ESD|In the ESD-arm, endoscopic resection will be performed using the (h)ESD technique.
62204315|NCT00963612|OTHER|Single Arm|"In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo Liver BOLD-MRI before hepatic resection."
62404044|NCT05598762|ACTIVE_COMPARATOR|Children with moderate-severe atopic dermatitis|"* age 1-8 years old~* moderate or severe degree of atopic dermatitis"
62404045|NCT05598762|ACTIVE_COMPARATOR|Children with food allergy and moderate-severe atopic dermatitis|"* age 1-8 years old~* moderate or severe degree of atopic dermatitis~* IgE mediated food allergy"
62404046|NCT05598762|ACTIVE_COMPARATOR|Adult with atopic dermatitis|"* age 18-60 years old~* mild-severe atopic dermatitis"
62404047|NCT05598762|ACTIVE_COMPARATOR|Healthy|"* age 1-60 years old~* no history of atopic diseases"
62404048|NCT05598762|ACTIVE_COMPARATOR|Healthy with Asthma|"* age 1-8 years old~* doctor diagnosed asthma~* no history of chronic or chronic relapsing eczema"
62404049|NCT00727675|OTHER|1|Integrated Cognitive Behavioral Therapy for pain reduction and opioid dependence.
62404050|NCT01855594|EXPERIMENTAL|Lithium treatment group|Lithium carbonate, 250mg/tablet. The dose starts with three times a day and one tablet each time for a week. The daily dose will then be adjusted according to serum lithium level and clinical finding. Target serum lithium level is 0.6 - 1.2mmol/L.
62404051|NCT01855594|PLACEBO_COMPARATOR|Control group|The dose of the placebo will be adjusted according to the dummy serum level report.
62404052|NCT01298362||AIs as first line therapy|Patients in postmenopausal status, with ER-positive early breast cancer, treated with an AI as first line therapy for 12 months.
62404053|NCT01298362||AIs after chemotherapy|Patients in postmenopausal status, with ER-positive early breast cancer, treated with an AI as maintenance therapy for 12 months after initial treatment with anthracycline- and/or taxane-based chemotherapy (chemotherapy treatment duration: 1-6 months).
62015339|NCT04964934|ACTIVE_COMPARATOR|Anastrozole or letrozole + palbociclib, abemaciclib or ribociclib|The patients will recieve anastrozole (1 mg, PO, once daily) or letrozole (2.5 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150, 100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily)
62580364|NCT06544291|PLACEBO_COMPARATOR|Placebo 0mg|Participants will be randomized to which dronabinol (or placebo) dose they receive. The fixed dose they receive will be administered across all three test sessions. Therefore, participants may receive a single capsule of 0 mg Dronabinol across all three test sessions
62787366|NCT06312436||REBOA group|After allocation, access to a femoral artery is swiftly established by either ultrasound-guided puncture or via surgical cut-down. In parallel major haemorrhage protocol transfusion and further diagnostics are being carried out. Balloon occlusion is then achieved by placing a balloon catheter (ER-REBOA catheter, Prytime Medical®, Boerne, TX, USA) into aortic zone I (supradiaphragmatic) or III (aortic bifurcation) according to clinician decision based on injury pattern. Continuing management, including further computed tomography diagnostics and damage control interventions (operative or angioembolisation) and ongoing transfusions are undertaken according to patient status.
62787367|NCT06312436||Control group|After allocation, major haemorrhage protocol transfusion and all resuscitative measures except REBOA are performed. Continuing management, including further computed tomography diagnostics and damage control interventions (operative or angioembolisation) and ongoing transfusions are undertaken according to patient status.
62787368|NCT03443804|EXPERIMENTAL|Test(DW1401)|tid PO, DW1401+Placebo of Stillen tab.
62787369|NCT03443804|ACTIVE_COMPARATOR|Reference(Stillen tab.)|tid PO, Stillen tab.+Placebo of DW1401
62787370|NCT03624595|EXPERIMENTAL|Dexmedetomidine group|Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
62787371|NCT03624595|PLACEBO_COMPARATOR|Placebo group|Placebo (normal saline) infusion is administered from 16:00 to 08:00 in the same speed for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
62787372|NCT00663754|ACTIVE_COMPARATOR|1|Participants will receive a mailed brochure about body image only.
62787373|NCT00663754|ACTIVE_COMPARATOR|2|Participants will receive the 4-hour dissonance-based eating disorder prevention program.
62787374|NCT00663754|EXPERIMENTAL|3|Participants will receive the 8-hour dissonance-based eating disorder prevention program.
62787375|NCT01593592|EXPERIMENTAL|Lactobacillus reuteri group|The active group that will receive the standard triple therapy and Lactobacillus reuteri
62580365|NCT05263089|EXPERIMENTAL|Intervention|Injectable Universal flowable resin composite
62580366|NCT05263089|ACTIVE_COMPARATOR|Control|Conventional resin composite
62580367|NCT00212342|EXPERIMENTAL|Norethisterone,Ethinylestradiol|
62580368|NCT00212342|PLACEBO_COMPARATOR|Sugar pill|
62787376|NCT01593592|PLACEBO_COMPARATOR|Control group|The control group that will receive the standard triple therapy and placebo
62787377|NCT01286025|ACTIVE_COMPARATOR|Video modality|
62787378|NCT01286025|ACTIVE_COMPARATOR|Text modality|
62787379|NCT04068116|EXPERIMENTAL|Postconditioning in primary percutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention with post-conditioning by making 4 cycles of repeated occlusion \& re-perfusion 30-second each by inflation/deflation of an appropriately sized PTCA (per-cutaneous trans-luminal coronary angioplasty) balloon
62015340|NCT05331742||vaccinated|patient between age 18 and above who have received a complete dose of coronavirus disease vaccine patient who has been admitted to critical care unit due to corona virus disease infection
62580369|NCT05127213|EXPERIMENTAL|Intragastric balloon system group|"Operation way: intragastric balloon system~Using the intragastric balloon system to treat obesity."
62580370|NCT05127213|EXPERIMENTAL|Sleeve gastrectomy group|"Operation way: sleeve gastrectomy~Using the sleeve gastrectomy to treat obesity."
62734848|NCT03349138|EXPERIMENTAL|Robotic Glove|Robotic Glove \& Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the robotic glove system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
62787380|NCT04068116|ACTIVE_COMPARATOR|Primary percutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention without post-conditioning
62204316|NCT03415373|EXPERIMENTAL|Intervention arm|Each subject will undergo ID administration by Microneedle Adapter (Model UAR-2S) and hypodermic needle + syringe of 100 μL injectable saline into 3 different regions: the inner forearm, the deltoid and the thigh, at three (3) study visits. A total of 4 injections (2 x 50 μL saline and 2 x 100 μL saline) will be administered to each study participant in the injection sites (2 injections per inner forearm/deltoid/thigh and 2 injection per device).
62204317|NCT04378673||parental involvement group|n=46
62204318|NCT04378673||parental presence group|n=42
62787381|NCT00856947|ACTIVE_COMPARATOR|Vitamin D|Dietary supplement: 2400 IU Vitamin D3 (2 tablets of 1200 IU) from week 24 of gestation to 1 week after delivery
62787382|NCT00856947|PLACEBO_COMPARATOR|Placebo|Placebo: 2 placebo tablets with no active substance, identical to the active tablets, from week 24 of gestation to 1 week after delivery
62787383|NCT00988949|EXPERIMENTAL|PF-04455242 18 mg|Subjects in this arm will receive a single 18 mg oral dose of PF-04455242 prior to spiradoline challenge
62204319|NCT04378673||parental absence group|control group, n=32
62204320|NCT00845962|ACTIVE_COMPARATOR|Chloroprocaine|
62204321|NCT00845962|ACTIVE_COMPARATOR|Bupivacaine|
62404054|NCT03833908|EXPERIMENTAL|patients receiving MAF-1217|patients receiving MAF-1217 from week -2 to week 2 (preand post-surgery, total 4 weeks), standard antibiotic therapy (ofloxacin) from day -3 before surgery, and standard postoperative treatment (topical steroid, dexamethasone for 10 days + antibiotic, ofloxacin for 7 days) from day 0 (post-surgery.
62404055|NCT03833908|NO_INTERVENTION|patients receiving just standard antibiotic therapy|patients receiving just standard antibiotic therapy (ofloxacin) from day -3 before surgery, and standard postoperative treatment (topical steroid, dexamethasone for 10 days + antibiotic, ofloxacin 7 days) from day 0 (postsurgery).
62580371|NCT05695014|EXPERIMENTAL|Teach Back Metod|"The patients in the intervention group, on the other hand, will be trained with the teach-back method after completing the Personal Data Collection Form, Knowledge Test, and the Ready to Discharge Scale. In these trainings, Discharge Training Booklet, which will be prepared by the researcher, will be used as training material. This booklet will include information about discharge after Lumbar Disc Herniation Surgery."
62580372|NCT05695014|NO_INTERVENTION|Control|The discharge training of the patients in the control group will be given by the health professionals responsible for their care and treatment according to their clinical routines.
62580373|NCT06522087|EXPERIMENTAL|40Hz stimulation group|At the start of anesthesia, the subject received 40Hz transcranial stimulation for 1h.
62580374|NCT06522087|NO_INTERVENTION|Control group|At the start of anesthesia, the subject did not receive any additional treatment.
62580375|NCT02782923|EXPERIMENTAL|s-ACDFwith STISIM|Single-level anterior cervical discectomy fusion
62787384|NCT00988949|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive placebo prior to spiradoline challenge.
62404056|NCT01305694|EXPERIMENTAL|MSC|Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with relapsed/refractory aplastic anemia.
62580376|NCT02782923|EXPERIMENTAL|m-ACDF with STISIM|Multi-level anterior cervical discectomy and fusion
62580377|NCT02782923|EXPERIMENTAL|CDR with STISIM|Cervical disc replacement
62580378|NCT02782923|EXPERIMENTAL|PCLF with STISIM|Posterior laminectomy and fusion
62580379|NCT02782923|EXPERIMENTAL|PCD with STISIM|Posterior cervical decompression procedure
62580380|NCT02782923|SHAM_COMPARATOR|Control Group with STISIM|
62580381|NCT00789256|EXPERIMENTAL|Study treatment|All patients will receive the following regimen: 1) Melphalan 2 mg orally, once daily. 2) Bortezomib 1.0 mg/M2 IV on days 1, 4, 8, 11.
62787385|NCT00988949|EXPERIMENTAL|PF-04455242 30 mg|Subjects in this arm will receive a single 30 mg oral dose of PF-04455242 prior to spiradoline challenge.
62787386|NCT03225703|ACTIVE_COMPARATOR|Exercise Leg|Left or right leg randomly assigned as exercise leg in a unilateral, exercise intervention. This will be a progressive exercise programme with the aim being to complete 50 multidirectional hops completed daily. (Hopping)
62787387|NCT03225703|NO_INTERVENTION|Non exercise Leg|Randomly assigned non-exercise, control leg.
62204322|NCT02546921|EXPERIMENTAL|MOv18 IgE Cohort 1|
62204323|NCT02546921|EXPERIMENTAL|MOv18 IgE Cohort 2|
62204324|NCT02546921|EXPERIMENTAL|MOv18 IgE Cohort 3|
62204325|NCT02546921|EXPERIMENTAL|MOv18 IgE Cohort 4|
62204326|NCT02546921|EXPERIMENTAL|MOv18 IgE Cohort 5|
62204327|NCT02546921|EXPERIMENTAL|MOv18 IgE Cohort 6|
62204328|NCT02546921|EXPERIMENTAL|MOv18 IgE Cohort 7|
62204329|NCT03478904|EXPERIMENTAL|4x40mg Enzalutamide Capsule Followed by 160mg Enzalutamide Liquid|Enzalutamide capsule (Treatment A) followed by enzalutamide liquid (Treatment B)
62404057|NCT02100215|EXPERIMENTAL|Expert Modeling|Participants will have access to 70 minutes of expert modeling videos available over 5 weeks on an online learning management system. The investigator will be the expert model in the videos. Expert modeling videos will address content related to seven concepts: Taking report with a graphic organizer worksheet, prioritizing patient care, delegating to unlicensed assistive personnel, safety checks in patient rooms, focused physical assessments, safe medication administration, and using a standardized healthcare provider communication tool on the telephone.
62580382|NCT00247611|OTHER|Control|Participants will receive the control condition
62580383|NCT00247611|EXPERIMENTAL|Intervention|Participants will receive the LifeWindows Intervention sessions
62787388|NCT05370443|EXPERIMENTAL|Life Skills intervention group|The participants in the intervention group will receive eight sessions of the online life skills educational program via the zoom platform for eight weeks. Each session will last for 1-hour. All the participants will receive a short reminder SMS for enrolling in the online session. The assessment for all students will be done at baseline, immediate and 3-months post-intervention.
62787389|NCT05370443|NO_INTERVENTION|control group|Participants in the control group will receive no intervention during the study period. However, they will receive the same educational activities after finishing study. They will answer the same questionnaires at baseline, immediately following the intervention, and three months later.
62580384|NCT05593549|EXPERIMENTAL|Trehalose|10g mixed in 500 mL of water, consumed 1 time per day
62580385|NCT05593549|PLACEBO_COMPARATOR|Placebo|10g microcrystalline cellulose in 500 mL, consumed 1 time per day
62787390|NCT05630677|EXPERIMENTAL|Treatment A|Subjects will receive AZD5055 solution as a 20-minute infusion in overnight fasted state on Day 1 in Period 1.
62787391|NCT05630677|EXPERIMENTAL|Treatment B|Subjects will receive oral suspension of AZD5055 in an overnight fasted state on Day 1 in Period 1.
62787392|NCT05630677|EXPERIMENTAL|Treatment C|Subjects will receive AZD5055 film-coated tablet in overnight fasted state on Day 1 (Study Day 4) in Period 2.
62787393|NCT05630677|EXPERIMENTAL|Treatment D|Subjects will receive a standardized high-fat breakfast 30 minutes before film-coated tablet of AZD5055 administered as On Day 1 (Study Day 8) in Period 3.
62787394|NCT05630677|EXPERIMENTAL|Treatment E|Subjects will receive rabeprazole twice daily on Day 10. On Day 1 (Study Day 13), AZD5055 film-coated tablet will be administered, under fasted conditions, together with rabeprazole and rabeprazole dosing will continue twice daily in Period 4.
62787395|NCT05630677|EXPERIMENTAL|Treatment F|Subjects will receive a low-fat breakfast 30 minutes before AZD5055 film-coated tablet administered together with rabeprazole on Day 17. Rabeprazole will continue twice daily, the last dose is on the evening of Study Day 18 in Period 5.
62015341|NCT05331742||unvaccinated|patients between age 18 and above who has been admitted to critical care unit due to coronavirus disease infection and admitted to critical care unit
62015342|NCT04401228||covid ICU patients|
62580386|NCT02142959|EXPERIMENTAL|omaveloxolone (RTA 408) Lotion 0.5%|Omaveloxolone Lotion at a fixed dose of 0.5% administered topically to the radiation area, twice daily for approximately 9 weeks (up to a maximum of 16 weeks)
62580387|NCT02142959|EXPERIMENTAL|omaveloxolone (RTA 408) Lotion 3%|Omaveloxolone Lotion at a fixed dose of 3% administered topically to the radiation area, twice daily for approximately 9 weeks (up to a maximum of 19 weeks)
62580388|NCT02142959|PLACEBO_COMPARATOR|Vehicle Lotion|Vehicle Lotion administered topically to the radiation area, twice daily for approximately 9 weeks (up to a maximum of 16 weeks)
62787396|NCT02210260|ACTIVE_COMPARATOR|Continuous infusion of local anaesthetic|Continuous infusion of local anaesthetic into the surgical wound
62787397|NCT02210260|EXPERIMENTAL|Spinal and infusion of local anaesthetic|A one off spinal anaesthetic plus a continuous infusion of local anaesthetic into the surgical wound
62787398|NCT01205971|EXPERIMENTAL|Motivational Interviewing|Motivational Interviewing to reduce caregiver risk factors for early childhood caries in their children is delivered by Dental Health Advocates (trained public housing residents) in combination with fluoride varnish applications, oral health assessments and referrals for children.
62787399|NCT01205971|ACTIVE_COMPARATOR|Dental Preventive Services|Fluoride varnish applications, written oral health educational materials regarding early childhood caries prevention, oral health assessments and referrals.
62787400|NCT01224366|EXPERIMENTAL|Vildagliptin|
62787401|NCT01224366|PLACEBO_COMPARATOR|Placebo|
62015343|NCT04401228||covid conventionnal ward|
62580389|NCT05813431|ACTIVE_COMPARATOR|Control - FRENCH grid only|
62580390|NCT05813431|ACTIVE_COMPARATOR|FRENCH grid + QuickSOFA|
62580391|NCT05813431|ACTIVE_COMPARATOR|FRENCH grid + QuickSOFA + Capillary Lactate|
62580392|NCT01742676|EXPERIMENTAL|ADVAGRAF group|
62580393|NCT01742676|ACTIVE_COMPARATOR|PROGRAF group|
62580394|NCT02144298||cold blood cardioplegia|observe the perioperative course of sublingual microcirculatory alterations in patients undergoing coronary artery bypass grafting (CABG) using cold blood cardioplegia.
62580395|NCT02144298||cristalloid cardioplegia|observe the perioperative course of sublingual microcirculatory alterations in patients undergoing coronary artery bypass grafting (CABG) using cristalloid cardioplegia.
62580396|NCT06288295||Score development cohort|Patients over 60 years of age admitted to a general medicine department in the investigating center between October 2021 and February 2022
62580397|NCT06288295||Score validation cohort|Patients over 60 years of age admitted to a general medicine department in the investigating center between October 2022 and February 2023
62787402|NCT00654979|EXPERIMENTAL|Single arm|SafeFlo IVC Filter
62787403|NCT05696756|EXPERIMENTAL|Brief Clinician Motivational Support|Participants will learn to use the EMMA app through a personalized web-based training platform with brief weekly motivational support from a clinician.
62787404|NCT05696756|ACTIVE_COMPARATOR|Technology Support Only|Participants will learn to use the EMMA app through a personalized web-based training platform with technical support and reminders as needed.
62787405|NCT06351449||Patients with allergic contact dermatitis history|Adult patients with allergic contact dermatitis history and requiring patch test during their care pathway and accepting unidentified photographs of patch test results.
62787406|NCT00734968|EXPERIMENTAL|Treatment|Patients randomly assigned to be treated with nitrofurantoin 100mg PO BID x 3 days post-operatively
62015344|NCT05762666|NO_INTERVENTION|Group Standart of care|Patients will be followed with standard monitorization only along with pain scales and receive rescue analgesia according to them
62015345|NCT05762666|EXPERIMENTAL|Group Nociception level index monitor|Patients will acquire NOL monitorization throughout the ICU stay and have the same rescue analgesia under NOL guidance with concurrent pain scales
62204330|NCT03478904|EXPERIMENTAL|160mg Enzalutamide Liquid Followed by 4x40mg Enzalutamide Capsule|Enzalutamide liquid (Treatment B) followed by enzalutamide capsule (Treatment A)
62580398|NCT04964739|OTHER|Cognitive Behavioral Therapy - Men|112 participants identifying as men will be enrolled in 8 weeks of behavioral treatment for cannabis use disorder (CUD). They will receive a motivational interviewing session with a therapist followed by 7 weekly online modules of CBT4CBT with continued monitoring and support from a therapist. Gender and hormonal factors will be examined as predictors of CUD remission and cannabis outcomes.
62580399|NCT04964739|OTHER|Cognitive Behavioral Therapy - Women|112 participants identifying as women will be enrolled in 8 weeks of behavioral treatment for CUD. They will receive a motivational interviewing session with a therapist followed by 7 weekly online modules of CBT4CBT with continued monitoring and support from a therapist. Gender and hormonal factors will be examined as predictors of CUD remission and cannabis outcomes.
62580400|NCT06436950|EXPERIMENTAL|transcutaneous electrical phrenic nerve stimulation (TEPNS) group|The patients in TEPNS group receive TEPNS and usual care.
62580401|NCT06436950|NO_INTERVENTION|Control group|The patients in control group receive usual care only.
62580402|NCT03017378|ACTIVE_COMPARATOR|TB/FLU-01L (intranasal application)|Vaccine safety analysis of TB/FLU-01L at double intranasal application in healthy volunteers aged 18 to 50 years.
62580403|NCT03017378|ACTIVE_COMPARATOR|TB/FLU-01L (sublingual application)|Vaccine safety analysis of TB/FLU-01L at double sublingual application in healthy volunteers aged 18 to 50 years.
62580404|NCT03508726|EXPERIMENTAL|Phase I dose escalation cohort|Participants will receive radiation therapy over 5 weeks, during which time they will be receiving ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation.
62580405|NCT03508726|EXPERIMENTAL|Phase II Cohort|Participants will receive radiation therapy over 5 weeks, during which time they will be receiving intravenous (IV) ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation.
62580406|NCT02993328|EXPERIMENTAL|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
62787407|NCT00734968|PLACEBO_COMPARATOR|Placebo|Arm randomly assigned to receive placebo 1 tablet PO BID x 3 days post-operatively.The incidence of UTI in this group will be compared with group one (1)
62015346|NCT06024746|EXPERIMENTAL|Finerenone plus empagliflozin|
62015347|NCT06024746|NO_INTERVENTION|Usual care|Usual care management
62015348|NCT02634658|EXPERIMENTAL|Medical ICU Subjects|All Medical ICU subjects that meet eligibility criteria and are enrolled in the study will receive muscle Ultrasounds, Nerve Conduction Studies and Electromyography (EMG).
62204331|NCT06458413|EXPERIMENTAL|Single-arm|Patients with HER2-negative breast cancer were treated with Utidelone Capsule combined with Capecitabine tablets.
62204332|NCT02663531|EXPERIMENTAL|Mild cognitive impairment|Patients with mild cognitive impairment
62204333|NCT02663531|EXPERIMENTAL|Alzheimer Disease|Patients with Alzheimer Disease
62204334|NCT02663531|EXPERIMENTAL|Healthy|Healthy volunteers
62204335|NCT02277054|EXPERIMENTAL|Collagen-MPC cornea substitute|Collagen-phosphorylcholine (collagen-MPC) cornea substitute transplantation using anterior lamellar keratoplasty technique.
62204336|NCT04361851|EXPERIMENTAL|Single Arm|Pembrolizumab and Daratumumab
62204337|NCT01504477|EXPERIMENTAL|Combination of Panitumumab and Bortezomib|IV panitumumab and bortezomib
62204338|NCT01390662|ACTIVE_COMPARATOR|Vitamin D3|one tablet of vitamin D3 (70µg) per day for 24 weeks.
62015349|NCT02634658|EXPERIMENTAL|Neuro ICU Subjects|All Neuro ICU subjects that meet eligibility criteria and are enrolled in the study will receive Nerve Conduction Studies and Electromyography (EMG).
62015350|NCT03254563||Obese with NAFLD|Patients who have NAFLD based upon ultrasound
62204339|NCT01390662|PLACEBO_COMPARATOR|placebo|one tablet of sugar pill per day for 24 weeks.
62404058|NCT02100215|ACTIVE_COMPARATOR|Voice Over PowerPoint|Participants will have access to 60 minutes of voice over PowerPoint slides, available over 5 weeks on an online learning management system, specifically to match exposure and content with the expert modeling video group. The script for PowerPoint will contain content related to the aforementioned seven concepts. There will be static photos, but no expert modeling videos, on PowerPoint slides. The investigator will narrate the voice over PowerPoint.
62404059|NCT02100215|PLACEBO_COMPARATOR|Reading|Participants will have access to articles, policies, and procedures on an online learning management system. The estimated time required for participants to review these materials is 45 minutes
62404060|NCT05677412|ACTIVE_COMPARATOR|neutral story|Neutral story before the sleep onset
62404061|NCT05677412|EXPERIMENTAL|suggestive story|Suggestive story to find out the effect of relaxation to sleep structures.
62404062|NCT05903092|EXPERIMENTAL|Durvalumab + Monalizumab + Chemotherapy|"On Day 1 of every Cycle for the first 4 Cycles (Cycle = 21 Days):~Durvalumab 1500mg IV, Monalizumab 1500mg IV, Either Carboplatin AUC 5-6 OR Cisplatin 75-80mg/m\^2~On Days 1-3 of every Cycle for the first 4 Cycles:~Etoposide 80-100mg/m\^2~On Day 1 of Cycles 5+ (Cycle = 28 Days):~Durvalumab 1500mg IV Monalizumab 1500mg IV"
62015351|NCT03254563||Obese without NAFLD|Patients who do not have NAFLD based upon ultrasound
62015352|NCT03063450|EXPERIMENTAL|Nivolumab|Nivolumab 240mg flat dose Q2W over 30 minutes IV until disease progression, to a maximum of 12 months
62015353|NCT03063450|PLACEBO_COMPARATOR|Placebo|Sterile 0.9% sodium chloride Q2W over 30 minutes IV until disease progression, to a maximum of 12 months
62015354|NCT01067079||Arm 1|
62015355|NCT04527263|ACTIVE_COMPARATOR|group A|subjected to institutional protocol of diagnosis of acute appendicitis
62204340|NCT02287298||2006 TO 2010 PATIENTS|PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY
62204341|NCT02287298||CURRENT PATIENTS|PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY AND ADDITION OF 20 MG OF ORAL ZEAXANTHIN
62204342|NCT04845204|ACTIVE_COMPARATOR|Relaxation Treatment|Relaxation treatment (RT) is applied additional to standard physiotherapy treatment. RT includes 8 sessions (2 times a day, for four days after surgery) of relaxation exercises.
62404063|NCT03264573|ACTIVE_COMPARATOR|stem cell, PRP|Adipose derived MSCs, versus Platelet rich plasma
62404064|NCT03264573|ACTIVE_COMPARATOR|Stem cell, Stem cell and PRP|Adipose derived MSCs alone, other group is injected Adipose derived MSCs, and Platelet rich plasma
62404065|NCT05100628|EXPERIMENTAL|Dose-Escalation Cohort 1: NOX66 800 mg + Doxorubicin|
62404066|NCT05100628|EXPERIMENTAL|Dose-Escalation Cohort 2: NOX66 1200 mg + Doxorubicin|
62404067|NCT05100628|EXPERIMENTAL|Dose-Escalation Cohort 3: NOX66 1800 mg + Doxorubicin|
62787408|NCT02595255||High risk|Conditioning therapy for bone marrow transplantation or pelvic irradiation. Fertility preservation is usually already proposed in this group of patients. No intervention.
62015356|NCT04527263|ACTIVE_COMPARATOR|group B|subjected to institutional protocol of diagnosis of acute appendicitis plus measurement of urinary 5-HIAA
62015357|NCT04878705|EXPERIMENTAL|TWP-201|
62015358|NCT04878705|PLACEBO_COMPARATOR|placebo|
62015359|NCT05896592|EXPERIMENTAL|Group 1|Group 1 will undergo EPS, ECVS, CNA with continuation of PM therapy and ILR implantation. Two months later pacing rate, will be assessed. In addition, there will be a non-invasive assessment of the effectiveness of CNA. After another month, EPS and ECVS will be performed and a re-CNA if the ECVS does not show full parasympathetic denervation of the heart. The pacemaker will be set to VVI or AAI 30/min. One month after the second invasive procedure, the pacing rate will be assessed. Patients with zero percentage of PM stimulation will be set to ODO/OVO/OAO-stimulation off mode. Patients will be monitored for the next 12 months. During the next 4 visits repeated every 3 months, patients in this group will undergo non-invasive assessment of the effectiveness of CNA and symptoms of bradycardia. At the 7th visit, patients in this group will be qualified to discontinue of the cardiac pacing treatment, with possible qualification for TLE.
62404068|NCT05100628|EXPERIMENTAL|Dose-Expansion Cohort: NOX66 + Doxorubicin|
62404069|NCT04703465|EXPERIMENTAL|tenofovir alafenamide|tenofovir alafenamide 25mg daily for 48 weeks
62015360|NCT05896592|EXPERIMENTAL|Group 2|Group 2 will undergo EPS and ECVS with continuation of PM therapy, ILR implantation, without CNA. Two months later pacing rate, will be assessed. After another month, EPS, ECVS and CNA will be made. The pacemaker will be set to VVI or AAI 30/min. One month after the second invasive procedure, patients in this group will have their pacing rate assessed. Patients with zero percentage of PM stimulation will be set to ODO/OVO/OAO-stimulation off mode. Patients will be monitored for the next 12 months. During next 4 visits repeated every 3 months, patients in this group will undergo a non-invasive assessment of the effectiveness of CNA and symptoms of bradycardia. At the 7th visit, the qualification for discontinuation of cardiac pacing treatment will take place, with possible qualification for TLE.
62015361|NCT05896592|ACTIVE_COMPARATOR|Group 3|Group 3 patients will only be observed for the duration of the study. The observation period will be 18 months. At subsequent visits 1, 3, 4, 6, 9, 12, 15 months after randomization, they will be assessed for the presence of MAS, paraMAS and assessment of the percentage of stimulation.
62015362|NCT00694460|EXPERIMENTAL|1|
62015363|NCT00694460|EXPERIMENTAL|2|
62015364|NCT00694460|EXPERIMENTAL|3|
62015365|NCT00694460|EXPERIMENTAL|4|
62015366|NCT00694460|ACTIVE_COMPARATOR|5|
62015367|NCT03938701|EXPERIMENTAL|Fluorescence imaging of IBD with adalimumab-800CW|"Fluorescence imaging with adalimumab-800CW in inflammatory bowel disease (IBD). A non-randomised, non-blinded, prospective, feasibility study.~Administration of 4.5 mg, 15 mg or 25 mg of adalimumab-800CW in 15 patients."
62015368|NCT03938701|EXPERIMENTAL|Fluorescence imaging of RA with adalimumab-800CW|"Fluorescence imaging with adalimumab-800CW in rheumatoid arthritis (RA). A non-randomised, non-blinded, prospective, feasibility study.~Administration of 4.5 mg, 15 mg or 25 mg of adalimumab-800CW in 15 patients."
62015369|NCT04121962|EXPERIMENTAL|Peer Mentor|Peer Mentor Training is 5 individual sessions with a 30 day check-in session. This condition is focused on training Index with communication skills to promote HIV and STI testing and treatment and pre-exposure prophalaxis (PrEP) to individuals in their social networks. Peer Mentor training is conducted by a one health educator. The sessions are held once a week and will last approximately 60 minutes.
62015370|NCT04121962|ACTIVE_COMPARATOR|Control|Is one individual-based session which will be conducted by sending a video about the website of a health educator.
62404070|NCT06235060|EXPERIMENTAL|CAST GROUP|After the training given with the demonstration method, the training videos on https://www.montgomerycollege.edu/academics/departments/nursing-tpss/nursing-simulation-scenario-library.html were shown to the participants using interactive training methods in parallel with this training. Each session lasted approximately 30-45 minutes. The sessions were repeated in the same environment on the same day and time, once a week, for a total of four weeks (four times).
62404071|NCT06235060|EXPERIMENTAL|Imagery GROUP|After the training given with the demonstration method, scenarios suitable for the imagery technique were prepared by the second trainer (Ö.S.A.) in parallel with this training and CAST training. The internal mental visualization format (as if the students were doing the events themselves) was preferred for the imagery technique. The content of the scenarios was examined by three academic nurses who completed their doctoral education in addition to the authors, and expert opinions were taken. The flow of the scenarios was discussed with the experts until a consensus was reached and the final scenario was created. This technique lasted approximately 30-35 minutes.
62787409|NCT02595255||Moderate/low risk|"Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML (Acute myeloide leukemia), osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL (acute lymphoblastic hormone), Wilms tumour, retinoblastoma.~This is the study group we will compare with high risk and no risk patients. No intervention"
62787410|NCT02595255||No risk|"Patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.~No intervention"
62015371|NCT05720832|EXPERIMENTAL|Prostate Cancer Patients and their Supporters|"The WINGS smartphone application is being tested on prostate cancer patients for the first time in this pilot study. It provides easy access to prostate cancer-related information and simplifies networking with supporters, such as family and friends. The WINGS smartphone application can be easily downloaded to a personal smartphone via Google Play or the App Store and can be used at any time from home or on the go.~In addition, the WINGS smartphone application also provides supporters, such as family members and friends of prostate cancer patients with easy access to prostate cancer-related information. Moreover, it helps them to support prostate cancer patients by facilitating joint activities, tailored to the needs of the patient."
62015372|NCT04279925|EXPERIMENTAL|Locally-made Miniplate and screw|Locally-made miniplate and screw produced by the Faculty of Engineering Universitas Indonesia.
62015373|NCT04279925|ACTIVE_COMPARATOR|Imported Miniplate and screw|Biomet® miniplate 1.5 and screw 1.5 produced by Biomet, included in the Lorenz® Plating System Midface.
62015374|NCT00358735|EXPERIMENTAL|ActiveCare CECT|The ActiveCare CECT device is a mobile compression device used to prevent venous thromboembolic events, used after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery.
62015375|NCT00358735|ACTIVE_COMPARATOR|LMWH (Enoxaparin)|Enoxaparin (LMWH) will be used, following a protocol that is considered a standard of care for this patient population. 40mg QD for the remainder of the 10 days.
62204343|NCT04845204|ACTIVE_COMPARATOR|Standard Exercises|Standard postoperative rehabilitation program is applied to Control Group. Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures.
62787411|NCT04622449||Chronic liver disease with anemia|All patients with anemia as diagnosed by WHO criteria in patients with liver disease of any etiology.
62204344|NCT04037176|ACTIVE_COMPARATOR|Omalizumab|"Omalizumab is a sterile solution in a prefilled syring for subcutaneous injection. The syrings contains 75 mg or 150 mg omalizumab.~75 patients will have Omalizumab in doses depending of body weight and IgE every 2. or 4. week for 6 month Omalizumab is administered subcutaneously"
62580407|NCT02993328|PLACEBO_COMPARATOR|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
62204345|NCT04037176|PLACEBO_COMPARATOR|Placebo|"Placebo contains sodium chloride 0,9 % in a prefilled syring for subcutaneous injection.~25 patients will have placebo depending of the body weight and IgE every 2. or 4. week in 3 month. They will subsequently get Omalizumab for 3 month if nonresponders.~Placebo is administered subcutaneously"
62580408|NCT03887026|EXPERIMENTAL|NKT Low Dose|NKT single dose - Low
62787412|NCT00858637|EXPERIMENTAL|1 MCI-196|
62787413|NCT00858637|PLACEBO_COMPARATOR|2 Placebo of MCI-196|
62787414|NCT00858637|ACTIVE_COMPARATOR|3 Simvastatin|
62787415|NCT00858637|PLACEBO_COMPARATOR|4 Placebo of Simvastatin|
62787416|NCT01700543||Experimental: Sidus Shoulder|Patients indicated for hemi or total shoulder arthroplasty with good bone stock who fulfill all inclusion and none of the exclusion criteria.
62787417|NCT06399237|NO_INTERVENTION|No orthoses|Walk at a self-selected pace without orthoses.
62015376|NCT01390246|ACTIVE_COMPARATOR|Bupropion SR + cessation counseling|"Bupropion SR and smoking cessation counseling Subjects received Bupropion SR 150 mg tablet orally twice daily (BID) for 12 weeks. Subjects were instructed to begin using study medication (bupropion SR 150 mg orally for 3 days, then BID for 4 days) on study visit day 1, which was approximately 1 week prior to their quit date. Thereafter, they were continued to dose Bupropion SR 150 mg tablet orally BID for a total medication treatment of 12 full weeks.~Smoking cessation counseling included 35-minute counseling sessions at each of the first 2 visits and 10 minutes of smoking cessation counseling at subsequent visits, provided by the trained study nurse."
62015377|NCT01390246|PLACEBO_COMPARATOR|Placebo + cessation counseling|"Placebo and smoking cessation counseling Subjects received matching Bupropion SR placebo tablet orally twice daily (BID) for 12 weeks. Subjects were instructed to begin using study medication (matched placebo tablets orally for 3 days, then BID for 4 days) on study visit day 1, which was approximately 1 week prior to their quit date. Thereafter, they were continued to dose matching Bupropion SR placebo tablet orally BID for a total medication treatment of 12 full weeks of therapy.~Smoking cessation counseling included 35-minute counseling sessions at each of the first 2 visits and 10 minutes of smoking cessation counseling at subsequent visits, provided by the trained study nurse."
62015378|NCT03403634|EXPERIMENTAL|Treatment (celecoxib, interferon alfa-2b, rintatolimod)|Patients receive celecoxib orally PO BID, recombinant interferon alfa-2b IV QD over 20 minutes, and rintatolimod IV QD on days 1, 2, 3, 8, 9, 10, 15, 16 and 17 in the absence of disease progression or unacceptable toxicity.
62015379|NCT01884350|EXPERIMENTAL|Arm 1: Apixaban (Primary SOC information)|Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Primary Standard of Care (SOC) information
62015380|NCT01884350|EXPERIMENTAL|Arm 2: Apixaban (Additional Educational Program)|Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Additional Educational Program
62204346|NCT03574662|EXPERIMENTAL|Frailty assessment in Advanced heart failure|Subjects with advanced heart failure defined as current or recent (within the last 3 months) New York Heart Association (NYHA) class III or IV symptoms.
62204347|NCT02897505|EXPERIMENTAL|Women enrolled in Empower Clinic|Women who are enrolled in the Empower Sanctuary will be asked to participate in a Music Workshop
62204348|NCT01404364|ACTIVE_COMPARATOR|Intravitreal Triamcinolone|Patients with phthisis bulbi received 0,3ml intravitreal triamcinolone injection
62787418|NCT06399237|ACTIVE_COMPARATOR|Prefabricated foot orthoses (PFO)|Walk at a self-selected pace with prefabricated foot orthoses (PFO).
62787419|NCT06399237|ACTIVE_COMPARATOR|Custom-fitted orthoses (CFO)|Walk at a self-selected pace with custom-fitted orthoses (CFO)
62787420|NCT06399237|ACTIVE_COMPARATOR|Custom-fitted orthoses with a 5deg varus (CFVO)|Walk at a self-selected pace with custom-fitted orthoses with a 5deg varus (CFVO)
62787421|NCT03051386|EXPERIMENTAL|VEE Vaccine|0.5 mL of VEE vaccine, Live, Attenuated TC-83, NDBR 102, Lot 4, Run 3
62787422|NCT03644667|EXPERIMENTAL|Tocilizumab + Standard of Care Triple IS|"Tocilizumab plus standard of care triple immunosuppression (IS). Heart transplant recipients will receive tocilizumab (Actemra®) plus standard triple maintenance immunosuppression.~Standard of care triple maintenance immunosuppression includes:~* a calcineurin inhibitor (tacrolimus),~* an anti-proliferative treatment (mycophenolate mofetil) or Myfortic® (enteric-coated mycophenolate sodium), and~* steroids (methylprednisolone/prednisone) as prescribed by site physician investigator.~Participants enrolled in the study will be followed for 24 months after their transplant surgery. Randomization will occur once a participant has weaned from cardiopulmonary bypass and has achieved hemodynamic stability without significant ongoing bleeding within the first 72 hours after transplant."
62204349|NCT01404364|ACTIVE_COMPARATOR|Retrobulbar Chlorpromazine|Patients with refractory glaucoma and blind painful eye were submitted to 2,5mL Chlorpromazine retrobulbar injection
62580409|NCT03887026|EXPERIMENTAL|NKT High Dose|NKT single dose - High
62580410|NCT03887026|PLACEBO_COMPARATOR|Placebo|Placebo single dose
62580411|NCT01862250|EXPERIMENTAL|Clonidine infants with HIE|Infants in this group will receive Intravenous clonidine at 1µg/kg/dose either every 6 or 8 hrs from the start of cooling to the end of re-warming
62580412|NCT00090493|EXPERIMENTAL|MAGE-A3 and NY-ESO-1 Immunotherapy|Treatment will consist of receiving peptide vaccinations as a shot just under the skin (subcutaneous). Peptides are small pieces of proteins. We have chosen to vaccinate with peptides derived from cancer proteins found in myeloma and other cancers. The purpose is to generate anti-myeloma T-cells which will kill myeloma cells and nothing else.
62204350|NCT03973853|EXPERIMENTAL|Active group with virtual reality stimulation|The subjects in this arm will undertake 14 sessions of virtual reality stimulation. The program will be delivered by a nurse, trained to the use of such a tool, and familiar with cognitive remediation techniques. Before and after these 14 sessions, social autonomy, daily life skills, cognitive domains and self-esteem will be measured
62580413|NCT04321174|EXPERIMENTAL|Lopinavir/ritonavir|This arm will receive oral lopinavir/ritonavir 400/100 mg (or equivalent weight-based dosing) twice daily for 14 days.
62580414|NCT04321174|NO_INTERVENTION|Control|This arm will receive no intervention.
62580415|NCT03254303|OTHER|60s (group E)|The Time of catheterization at 60s (group E) was applied in this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 60 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 60 s
62204351|NCT03973853|PLACEBO_COMPARATOR|Treatment as Usual group (TAU)|Patients in this group will carry on benefiting from their usual care with no additional program. They will be assessed before and after a 3 month period for social autonomy, daily life skills, cognitive domains and self-esteem.
62404072|NCT05111548|EXPERIMENTAL|Active stimulation + cognitive training|Participants receive 10 sessions of 'active' non-invasive brain stimulation (tDCS) with concurrent cognitive training (BrainHQ).
62580416|NCT03254303|OTHER|90s (groupe L)|In this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 90 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 90 s
62580417|NCT03254303|OTHER|120s (groupe L)|In this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 120 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 120 s
62580418|NCT03028909|EXPERIMENTAL|Oseltamivir + low dose MEDI8852|Low Dose of MEDI8852 + Oseltamivir will be studied
62787423|NCT03644667|PLACEBO_COMPARATOR|Placebo + Standard of Care Triple IS|"Placebo plus standard of care triple maintenance immunosuppression (IS). Heart transplant recipients will receive placebo plus standard triple maintenance immunosuppression.~Standard of care triple maintenance immunosuppression includes:~* a calcineurin inhibitor (tacrolimus),~* an anti-proliferative treatment (mycophenolate mofetil) or Myfortic® (enteric-coated mycophenolate sodium), and~* steroids (methylprednisolone/prednisone) as prescribed by site physician investigator.~Participants enrolled in the study will be followed for 24 months after their transplant surgery. Randomization will occur once a participant has weaned from cardiopulmonary bypass and has achieved hemodynamic stability without significant ongoing bleeding within the first 72 hours after transplant."
62787424|NCT03233516||Cases with clinical CAP|Children 1-59 months at Sachs' Children and Youth Hospital with clinical CAP (both severe and non-severe) according to WHO-criteria.
62787425|NCT03233516||Control subjects|Children 1-59 months at Sachs' Children and Youth Hospital treated for a minor orthopedic (elective (e.g. hand surgery) or acute) or minor surgical disease, e.g. minor trauma (excluding e.g. appendicitis, major burns, major trauma).
62787426|NCT04766775|OTHER|Application of Silver Diamine Fluoride onto the carious teeth surfaces|The patients will receive Silver Diamine Fluoride (SDF) treatment to the carious primary teeth. These are teeth with no sign or symptom, radiographically the deepest layer of the caries lesion does not involve the pulp, the inter-radicular area appears normal). Procedure: apply vaseline, isolate the tooth with a cotton roll, remove the food debris, and gross plaque on the tooth cavity with a spoon excavator, dry the tooth, apply the SDF (a clear, colorless solution) onto the tooth cavity. This application lasts for one minute. Take the urine and hair sample to assess the silver and fluoride levels. Take the urine sample before the SDF treatment, in the first and second 24 hours after the SDF treatment. Take the hair samples before the SDF treatment, followed by days 7,14,30,60,75, and 90 after the SDF treatment. Send the hair and urine samples to the laboratory to assess the silver and fluoride levels. If caries remains active, restore the SDF treated after the day 90 review.
62787427|NCT01716741|OTHER|Enzyme analysis|Patients invited for evaluation will undergo glucocerebrosidase enzyme analysis
62580419|NCT03028909|EXPERIMENTAL|Oseltamivir + high dose MEDI8852|High dose of MEDI8852 + Oseltamivir will be studied.
62580420|NCT03028909|ACTIVE_COMPARATOR|Oseltamivir + Placebo|Oseltamivir in conjunction with placebo will be studied.
62580421|NCT01137058|EXPERIMENTAL|U-healthcare|glucose meter and U-healthcare
62580422|NCT01137058|ACTIVE_COMPARATOR|SMBG group|Diabetic patients who do self monitoring of blood glucose only were categorized into self monitoring of blood glucose (SMBG) group.
62204352|NCT00981136|ACTIVE_COMPARATOR|SILS|Single Incision Laparoscopic Surgery (SILS) where a single incision in the umbilicus is all that is used to remove the appendix. The specific methods (staple/tie/port use/etc) will vary depending on surgeon.
62204353|NCT00981136|ACTIVE_COMPARATOR|3 port|Standard laparoscopic appendectomy with 3 ports and intracorporeal stapling.
62204354|NCT02206477|EXPERIMENTAL|DMSO treatment group|The treatment group will be exposed to DMSO according to our built protocol. On the seventh post-operative day, the patient will be guided to set 10 cc of DMSO soaked gauze compresses on the breast, twice a day for 20 minutes, for the term of 6 weeks. This treatment will be holed for 24 hours on tissue expander inflation dates. A repeated course of compresses will be taken after adjuvant radiotherapy, starting 24 hours after the last therapy.
62204355|NCT02206477|PLACEBO_COMPARATOR|the control group|The control group will be treated with the same post-operative protocol, but with 0.9% saline instead of DMSO. On the seventh post-operative day, the patient will be guided to set 10 cc 0.9% saline soaked gauze compresses on the breast, twice a day for 20 minutes, for the term of 6 weeks. This treatment will be holed for 24 hours on tissue expander inflation dates. A repeated course of compresses will be taken after adjuvant radiotherapy, starting 24 hours after the last therapy.
62015381|NCT05360095|ACTIVE_COMPARATOR|Usual Care|The usual care group will consist of pregnant women who receive no experimental intervention but will receive the brochure-based education about prenatal screening that is currently recommended by American College of Obstetrics and Gynecology (ACOG), delivered in an electronic format, plus any additional clinic materials or oral information provided in conversation with clinicians (n= 375 total, 125 per site). We are transferring ACOG's prenatal screening education onto the electronic platform to control for any differences in attention that may be due to technology platform and to track time interacting with the material via the web portal.
62015382|NCT05360095|EXPERIMENTAL|Game Intervention|The game intervention group will consist of pregnant women who will interact with the educational intervention also delivered on an electronic platform (n= 375 total, 125 per site). Participants will also receive whatever information is routinely provided in the clinic about prenatal screening such as the brochure and oral information by clinicians.
62015383|NCT05360095|ACTIVE_COMPARATOR|Genetic Counseling|The one-on-one genetic counseling group will receive standard of care for genetic counseling delivered by a board-certified genetic counselor for pre-test education. The counselor will be conducting pre-test education and as with the other study groups, the decision about prenatal screening will be made at the clinical visit with the provider. This group receives also the same clinical materials and oral information by clinicians as the other two groups. Both in-person and tele-health genetic counseling options are available at all sites.
62015384|NCT06298643||Transfusion dependent|Participants that received ≥2 units of red blood cell transfusion during the 8 weeks after initial myelodysplastic syndrome diagnosis date.
62015385|NCT06298643||Non-transfusion dependent|Participants that received 0 units or \<2 units of red blood cell transfusion during the 8 weeks after initial myelodysplastic syndrome diagnosis date.
62015386|NCT03624361|EXPERIMENTAL|Stand-alone|"Patients will receive MINIject Glaucoma implant in a stand-alone procedure.~MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention."
62015387|NCT04183400|EXPERIMENTAL|Safety Awareness For Empowerment (SAFE)|Brief mindfulness-based cognitive-behavioral skill-building intervention
62015388|NCT04183400|NO_INTERVENTION|Usual case management only|Control condition receives only services as usual
62015389|NCT04526808|EXPERIMENTAL|FODMAP diet|
62015390|NCT03555669|NO_INTERVENTION|Screening Phase (Pre) Group|"Patients who screen positive on the PHQ-9 for depression during the pre period will comprise the comparison group. Participants will receive standard of care depression treatment at the providers discretion."
62015391|NCT03555669|EXPERIMENTAL|Treatment Phase (Post) Group|"Patients who screen positive during on the PHQ-9 for depression during the post period will comprise the active group. Participants will receive the depression treatment intervention in the form of anti-depressants and/or problem solving therapy (PST) based on their PHQ-9 score."
62015392|NCT00982319|EXPERIMENTAL|Broccoli sprout extract|Patients will be randomized to 14 day intervention of broccoli sprout extract and mango juice consisting of a dose of 100 µmols of sulforaphane dissolved in 150 mL mango juice once a day.
62015393|NCT00982319|PLACEBO_COMPARATOR|Mango juice|Patients will be randomized to 14 day intervention of 150 mL mango juice without broccoli sprout extract extract once a day.
62204356|NCT02831023|ACTIVE_COMPARATOR|SP-AQ only|Subjects will receive sulphadoxine-pyrimethamine (SP) as single dose and administered in combination with amodiaquine (AQ), which will be given once daily for 3 days.
62204357|NCT02831023|EXPERIMENTAL|SP-AQ plus PQ|Participants in this arm will receive SP-AQ in combination with a single low dose of primaquine at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
62015394|NCT02934139|EXPERIMENTAL|Cavosonstat (N91115) 400 mg|Every 12 hour oral dosing of N91115 for 7 days
62204358|NCT02831023|ACTIVE_COMPARATOR|DP only|Participants in this arm will be treated with dihydroartemisinin-piperaquine (DP), which will be administered once a day for three days.
62204359|NCT02831023|EXPERIMENTAL|DP plus MB|Study participants in this arm will receive DP as described above combined with once-daily methylene blue (MB) for 3 days, at 15 mg/kg/day (45 mg/kg total over 3 days).
62204360|NCT04223986|OTHER|Ultrasound and Troponin T|5 images transferred to cardiologist
62015395|NCT02934139|EXPERIMENTAL|Cavosonstat (N91115) 600 mg|Every 12 hour oral dosing of N91115 for 7 days
62015396|NCT02934139|EXPERIMENTAL|Cavosonstat (N91115) 1200 mg|Once daily oral dosing of N91115 for 7 days
62015397|NCT02934139|EXPERIMENTAL|Cavosonstat (N91115) 800 mg|Every 12 hour oral dosing of N91115 for 7 days
62015398|NCT02934139|PLACEBO_COMPARATOR|Placebo|Matched placebo. Oral dosing every 12 hour or once daily for 7 days
62015399|NCT05130567|EXPERIMENTAL|Single-dose Experimental Group|LP-128 capsule will be adminstrated one time at doses up to 240mg
62015400|NCT05130567|PLACEBO_COMPARATOR|Single-dose Control Group|Placebo capsule will be adminstrated one time at doses up to 240mg
62015401|NCT05130567|EXPERIMENTAL|Multi-dose Experimental Group|LP-128 capsule will be adminstrated once daily, for up to 14 days
62015402|NCT05130567|PLACEBO_COMPARATOR|Multi-dose Control Group|Placebo capsule will be adminstrated once daily, for up to 14 days
62015403|NCT04913493|NO_INTERVENTION|Control group|Patients will only receive FloTrac/Vigileo monitoring which is standard of care.
62015404|NCT04913493|EXPERIMENTAL|Experimental group|Patients will receive an additional medical imaging intervention. Namely sublingual microcirculation imaging with Cytocam-IDF.
62015405|NCT02251535|EXPERIMENTAL|test group 1|Retrospective test group 1 (n=10, ATTUNE® Knee System, rotating platform, cruciate retaining) with intraoperative high level rollback
62015406|NCT02251535|EXPERIMENTAL|test group 2|Retrospective test group 2 (n=10, ATTUNE® Knee System, rotating platform, cruciate retaining)with intraoperative low level rollback
62015407|NCT02251535|EXPERIMENTAL|control group|Control group (n=10, PFC® SIGMA® Knee System, rotatinq platform, cruciate retaininq)
62015408|NCT05966831|EXPERIMENTAL|Metacognitive Self-Control Training (MCT) + Virtual Reality Job Interview Training (VR-JIT)|This group will receive the MCT intervention plus the VR-JIT intervention. We are anticipating 6-8 weeks, with 1-3 sessions per week for each intervention.
62015409|NCT05966831|EXPERIMENTAL|Virtual Reality Job Interview Training (VR-JIT)|This group will receive just the VR-JIT intervention. We are anticipating 6-8 weeks, with 1-3 sessions per week for this intervention.
62204361|NCT01215487||1 - Chronic Myelogenous Leukemia Patients|Patients will be selected from patients referred to the primary hospital site for treatment and assessment. The patients will be approached by the physicians and or the study research nurse to consider participation in the study. Patients may be selected by participating off-site hospital centres and may be enrolled at those collaborating centres.
62204362|NCT04281602||Rheumatoid arthritis patients|Adult patients suffering from rheumatoid arthritis, diagnosed according to American College of Rheumatology/European League Against Rheumatism 2010 criteria and requiring a anti-IL-6 treatment
62204363|NCT04281602||Healthy controls|Healthy controls not suffering from acute or chronic inflammatory disease at inclusion.
62204364|NCT02870829|EXPERIMENTAL|Vitamin K2|Vitamin K comes in various isoforms and we have elected to use the K2 isoform - menaquinone-7. We have chosen a dose of 360mcg 3x/week as previous studies using menaquinone-7 demonstrated an increasing dose efficacy relationship up to this strength. Vitamin K2 is manufactured by Nattopharma
62204365|NCT02870829|NO_INTERVENTION|Standard Therapy|Subjects randomised to standard therapy will continue to receive dialysis and chronic kidney disease-metabolic bone disease (CKD-MBD) management in accordance to current best practise guidelines
62204366|NCT00894205|EXPERIMENTAL|strengthening exercise|"A low intensity strengthening exercise program based on the Tufts University Strong Bones program. Utilizes small free weights and chair exercises."
62204367|NCT02310100|EXPERIMENTAL|TactiCath Quartz|TactiCath Quartz treatment
62580423|NCT01137058|NO_INTERVENTION|control|conventional treatment
62580424|NCT06003179|ACTIVE_COMPARATOR|Cyclophosphamide and fludarabine, standard dose|Fludarabine 25mg/m2 Cyclophosphamide 250mg/m2 Days -4, -3, -2
62580425|NCT06003179|EXPERIMENTAL|Cyclophosphamide and fludarabine, standard dose with radiation|Fludarabine 25mg/m2 Cyclophosphamide 250mg/m2 Days -6, -5, -4 2 Gy in 2 Fractions Days -3, -2
62580426|NCT06003179|EXPERIMENTAL|Cyclophosphamide (intermediate dose) and fludarabine|Fludarabine 25mg/m2 Cyclophosphamide 500mg/m2 Days -4, -3, -2
62015410|NCT05279261|EXPERIMENTAL|Experimental group|Undergo the axillary approach
62015411|NCT01747005||Conventional therapy|
62015412|NCT01747005||ERAS|Oral intake of solid food restriction 6 hours before surgery. Oral intake clear fluids restriction 2 hours before surgery. Intravenous 5% Dextrose-500 ml 1 hour before surgery. Intravenous dexamethasone -4mg before anesthesia. Combined spinal-epidural anesthesia. Intraoperatively 10 ml/kg intravenous of crystalloids. Paracetamol intravenous 1g. Early mobilization of patient. Oral solid food intake 4 hour postoperative. Postoperative continuous epidural analgesia.
62015413|NCT06328959|EXPERIMENTAL|IOE group|IOE groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
62015414|NCT06328959|ACTIVE_COMPARATOR|PNG group|PNG groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
62015415|NCT01260610|ACTIVE_COMPARATOR|Tenofovir|
62015416|NCT01260610|ACTIVE_COMPARATOR|Telbivudine|
62015417|NCT01260610|EXPERIMENTAL|Tenofovir plus Telbivudine|
62015418|NCT01284400|EXPERIMENTAL|Disease management|
62015419|NCT01284400|NO_INTERVENTION|Usual treatment and care|
62015420|NCT03789526|EXPERIMENTAL|Group 1|* Group one: 26 patients DM patients with tenosynovitis were injected by triamcinolone under ultrasound guidance.
62015421|NCT03789526|NO_INTERVENTION|Group 2|Group two: 26 patients DM patients with tenosynovitis were injected by triamcinolone under clinical guidance.
62015422|NCT00499369|EXPERIMENTAL|Arm I (chemotherapy, cetuximab)|Patients receive single-agent irinotecan hydrochloride IV or FOLFIRI IV. They also receive cetuximab IV over 1-2 hours on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
62015423|NCT00499369|EXPERIMENTAL|Arm II (chemotherapy, cetuximab, bevacizumab)|Patients receive single-agent irinotecan hydrochloride or FOLFIRI AND cetuximab as in arm I. Patients also receive bevacizumab IV over 30 minutes on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
62015424|NCT00499369|EXPERIMENTAL|Arm III (closed to accrual as of 4/20/2009)|Patients receive single-agent irinotecan hydrochloride or FOLFIRI AND cetuximab as in arm I. Patients also receive a higher dose of bevacizumab (higher than in arm II) IV over 30 minutes on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
62015425|NCT05212259|EXPERIMENTAL|Collagen type II (40 mg/day)|4 capsules per day for 180 days
62404073|NCT05111548|SHAM_COMPARATOR|Inactive stimulation + cognitive training|Participants receive 10 sessions of 'inactive' non-invasive brain stimulation (tDCS) with concurrent cognitive training (BrainHQ).
62580427|NCT06003179|EXPERIMENTAL|Cyclophosphamide (intermediate dose) and fludarabine with radiation|Fludarabine 25mg/m2 Cyclophosphamide 500mg/m2 Days -6, -5, -4 2 Gy in 2 Fractions Days -3, -2
62580428|NCT06003179|EXPERIMENTAL|Cyclophosphamide (high dose) and fludarabine|Fludarabine 25mg/m2 Cyclophosphamide 750mg/m2 Days -4, -3, -2
62580429|NCT06003179|EXPERIMENTAL|Cyclophosphamide (high dose) and fludarabine with radiation|Fludarabine 25mg/m2 Cyclophosphamide 750mg/m2 Days -6, -5, -4 2 Gy in 2 Fractions Days -3, -2
62015426|NCT05212259|EXPERIMENTAL|Collagen type II (80 mg/day)|4 capsules per day for 180 days
62015427|NCT05212259|EXPERIMENTAL|Collagen type II (120 mg/day)|4 capsules per day for 180 days
62015428|NCT05212259|ACTIVE_COMPARATOR|Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)|4 capsules per day for 180 days
62015429|NCT05212259|PLACEBO_COMPARATOR|Placebo|4 capsules per day for 180 days
62015430|NCT05083767|EXPERIMENTAL|Whole Body Vibration|
62015431|NCT05083767|PLACEBO_COMPARATOR|Control Group|
62404074|NCT03130634|EXPERIMENTAL|prescription of silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
62404075|NCT03130634|NO_INTERVENTION|control|During six cycles of FOLFIRI chemotherapy, the patients will not take silymarin during chemotherapy
62404076|NCT05953610|EXPERIMENTAL|Acetazolamide|Treatment with acetazolamide 500 mg nightly for 1 month.
62404077|NCT05953610|EXPERIMENTAL|Acetazolamide/Eszopiclone|Treatment with acetazolamide 500 mg and eszopiclone 3 mg nightly for 1 month.
62404078|NCT01245829|PLACEBO_COMPARATOR|Matt|A standard non antimicrobial laminated chart which will form the control group (group 1).
62580430|NCT03090958|EXPERIMENTAL|AllyQuest Pilot|The research assistant (RA) will meet with participants in person to explain the study in detail, facilitate app download and login onto participants' phones, and provide an app site tour to highlight features. Participants will complete a baseline demographic and risk assessment administered via a computer assisted survey instrument (CASI). At the end of the one-month field trial, participants will undergo a debriefing session to evaluate their experience using the app, overall satisfaction and any problems they encountered.
62580431|NCT00599287|NO_INTERVENTION|1|No intervention
62580432|NCT00599287|EXPERIMENTAL|2|Methylphenidate
62580433|NCT00599287|EXPERIMENTAL|3|Rivastigmine
62580434|NCT00599287|EXPERIMENTAL|4|Haloperidol
62015432|NCT03728582|EXPERIMENTAL|Active tDCS plus Speech-Language Therapy|Active tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min. Language therapy will be verb naming therapy in a sentence context. This will be followed by sham tDCS plus speech-language therapy after a 2 month washout period.
62015433|NCT03728582|SHAM_COMPARATOR|Sham plus Speech-Language Therapy|Sham tDCS will be applied at the beginning of 45min speech-language therapy session. Language therapy will be oral and written naming. Language therapy will be verb naming therapy in a sentence context. This will be followed by active tDCS plus speech-language therapy after a 2 month washout period.
62015434|NCT06017284|EXPERIMENTAL|Chemotherapy + Thalidomide|nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. Thalidomide 100 mg/day, once a day, orally intake at night.
62015435|NCT06017284|ACTIVE_COMPARATOR|Chemotherapy|"nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.~placebo 100 mg/day, once a day, orally intake at night."
62015436|NCT01326780|EXPERIMENTAL|1.2% Facial Cream|1.2% JNJ 10229570-AAA
62015437|NCT01326780|EXPERIMENTAL|2.4% Facial Cream|2.4% JNJ 10229570-AAA
62015438|NCT01326780|EXPERIMENTAL|3.6% Facial Cream|3.6% JNJ 10229570-AAA
62015439|NCT01326780|PLACEBO_COMPARATOR|0% Facial Cream|Vehicle control
62015440|NCT03653429|ACTIVE_COMPARATOR|Tranexamic acid group|10mg/kg intravenous tranexamic
62015441|NCT03653429|PLACEBO_COMPARATOR|Normal Saline group|10mg/kg intravenous normal saline
62015442|NCT02044081|OTHER|Mouth Rinse Administration|Day 0, three consecutive C16G2 or placebo rinse administrations followed by three single C16G2 or placebo rinse administrations. Days 1 to 6 two additional C16G2 or placebo rinse administrations.
62015443|NCT02044081|OTHER|Dental Tray Gel Administration|Day 0, two C16G2 or placebo gel dental tray applications and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo dental tray applications and two C16G2 or placebo rinse administrations.
62015444|NCT02044081|OTHER|Electric Toothbrush Gel Application|Day 0, four C16G2 or placebo gel administrations applied with an electric toothbrush and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo gel administrations applied with a electric toothbrush and two C16G2 or placebo rinse administrations.
62015445|NCT02044081|OTHER|Manual Toothbrush Gel Application|Day 0, four C16G2 or Placebo gel administrations applied with a manual toothbrush and four C16G2 or Placebo rinse administrations. Days 1 to 6, two C16G2 or Placebo gel administrations applied with a electric toothbrush and two C16G2 or Placebo rinse administrations.
62215168|NCT02706613|OTHER|Face to Face Pulmonary Rehabilitaton|6 week incremental pulmonary rehabilitation (PR) programme. Participants will attend 12 sessions over the 6 week period. The components of the PR programme will include an exercise programme. Education sessions will also be provided and include anatomy of the lungs and what is COPD, anxiety and depression, self management, managing breathlessness, medications and treatments, managing exacerbations of COPD and chest infections, clearing sputum and the Active Cycle of Breathing Technique, nutrition, pacing, smoking cessation. Participants on the face to face arm will also be instructed to carry out the pulmonary rehabilitation exercises an additional three times a week at home.
62404079|NCT01245829|EXPERIMENTAL|Cellomed|Observation charts coated in a laminate with antimicrobial properties (Cellomed) will form group 2.
62015446|NCT06440668|EXPERIMENTAL|Workshop|Psychoeducational and self-care training, pain management, and emotional control, conducted in groups and aimed at patients with non-cancer chronic pain. Therapies applied: relaxation, meditation, cognitive-behavioral therapy, acceptance and commitment therapy, coaching, healthy eating, physical exercise, improving self-esteem, forgiveness technique. This group starts and successfully completes the workshop. A patient is considered to have successfully completed if they: Attend at least 4 out of the 5 sessions; complete all the initial documentation, at the end of the workshop, and at the 3-month mark; perform daily tracking of the 3 mandatory activities throughout the duration of the workshop.
62015447|NCT06440668|NO_INTERVENTION|Traditional treatment|This group meets the inclusion criteria but does not participate in the workshop. They complete all documentation at the beginning, at one month, and at three months. These patients will continue with the usual treatment prescribed by their doctor.
62015448|NCT03156231|ACTIVE_COMPARATOR|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
62015449|NCT03156231|PLACEBO_COMPARATOR|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
62015450|NCT05577052|EXPERIMENTAL|Test group|Metastatic vertebrae treated with SBRT
62404080|NCT01133912|EXPERIMENTAL|paclitaxel, gemcitabine, lapatinib|paclitaxel 80mg/m2 D1, D8 gemcitabine 1000mg/m2 D1, D8, every 3 weeks, 6 cycle lapatinib(Tykerb®)1000mg every day
62404081|NCT04353427|EXPERIMENTAL|Faith based educational group|"A seven-session faith-based small group educational program using the The Seven Pathways to Healing, Health and Wellness curriculum will be delivered."
62404082|NCT03482388|EXPERIMENTAL|Crowdsourced intervention|A multimedia component will deliver two videos and two images promoting HBV and HCV testing developed through a crowdsourcing contest in China. A participatory component will invite men to submit suggestions for how to improve crowdsourced videos and images.
62404083|NCT03482388|OTHER|Control|No images or videos will be viewed, and suggestions for improving hepatitis testing materials will not be collected.
62015451|NCT05577052|OTHER|Control group|Conventional radiation dose to vertebral metastases
62015452|NCT06463535|EXPERIMENTAL|group I|Type 2 Diabetes Mellitus patients with CPD + SRP and Omega-3
62015453|NCT06463535|ACTIVE_COMPARATOR|group II|Type 2 Diabetes Mellitus patients with CPD + SRP
62015454|NCT06338475|EXPERIMENTAL|Goal-Focused Emotion-Regulation Therapy (GET)|A novel behavioral intervention to enhance self-regulation through improved goal navigation skills, improved sense of purpose, and better ability to regulate emotional responses in young adults with testicular cancer.
62404084|NCT06520488|EXPERIMENTAL|Treatment group Part I/Part II/Part III|Treatment group Part I: HRS-4642 combined with SHR-A1921 Treatment group Part II: HRS-4642 combined with SHR-A1904Treatment group Part II: HRS-4642 combined with AG
62404085|NCT05294133|NO_INTERVENTION|control group|no intervention
62015455|NCT06338475|ACTIVE_COMPARATOR|Individual Supportive Listening (ISL)|Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience.
62204368|NCT04090177|EXPERIMENTAL|Intervention-TEAM Wheels|The treatment group will receive the TEAM Wheels program over a 4-week period. Session 1 will be virtually delivered via MS Teams teleconference. The peer trainer is an experienced MWC user trained to deliver the TEAM Wheels program. At least 2 peers will be trained at each site to offer multiple trainer attributes; a male and female, one being at least 50 years old. Participants will pre-select a peer trainer from a biosketch to optimize training effect (e.g., preference for age, sex factors); comparability in age has been identified as preferential among older adults and influential to self-efficacy. After Session 1, participants engage in 4 weeks of eHealth home program training. They are instructed to practice for 75-150 minutes/week. Consistent with motor learning principles, we encourage training in 15-30 minute blocks 1-2 times/day, 3-5 days/week. The peer trainer arranges the remaining two virtual teleconference sessions with the participant, about 1 week apart.
62404086|NCT05294133|EXPERIMENTAL|physical activity|
62404087|NCT00587561|EXPERIMENTAL|1 Social Cognition Interaction Training|Will receive 20-26 sessions of a manualized group treatment called Social Cognition Interaction Training
62404088|NCT00587561|OTHER|2 Wait List Control|Wait list control; 6 months of treatment as usual followed by Social Cognition Interaction Training group
62404089|NCT06650462|NO_INTERVENTION|Control|non-intervention control (participants complete surveys only)
62404090|NCT06650462|EXPERIMENTAL|Intervention|Participants engage in weekly community-led small group discussions about health-related topics and answer surveys at 0, 3, and 6 months time points
62404091|NCT02389621|EXPERIMENTAL|Lusutrombopag|Lusutrombopag 3 mg once daily for up to 7 days.
62580435|NCT05229159||BiPOCS group|All patients of our centers admitted for postoperative care after cardiac surgery with cardiopulmonary bypass and receiving a bioelectrical impedance analysis at the admission.
62787428|NCT01147354|EXPERIMENTAL|experimental group|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
62787429|NCT01147354|PLACEBO_COMPARATOR|control group|The patients in this arm took one placebo capsule daily for 12 weeks.
62787430|NCT01706588|EXPERIMENTAL|Diclofenac sodium 5 mg/mL|
62787431|NCT01706588|EXPERIMENTAL|Diclofenac sodium 12.5 mg/mL|
62015456|NCT05813054|EXPERIMENTAL|HA matrix ingredient|1 cap/day
62015457|NCT05813054|PLACEBO_COMPARATOR|Placebo|1 cap/day
62404092|NCT02389621|PLACEBO_COMPARATOR|Placebo|Placebo once daily for up to 7 days.
62404093|NCT02851069||Participants with Hepatitis C Virus Genotype 1 (HCV + GT1)|ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir \[25 mg/150 mg/100 mg once daily\] with or without dasabuvir \[250 mg twice daily\]), and with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks in HCV + GT1 participants.
62404094|NCT04888377||Antenatal exposure to low dose aspirin|Mothers in the Global Networks ASPIRIN trial were given 81 mg of Aspirin throughout their pregnancy with the follow-up studies participant.
62404095|NCT04888377||Antenatal exposure to Placebo|Mothers in the Global Networks ASPIRIN trial were given placebo throughout their pregnancy with the follow-up studies participant.
62787432|NCT01706588|EXPERIMENTAL|Diclofenac sodium 25 mg/mL|
62787433|NCT01706588|EXPERIMENTAL|Diclofenac sodium 50 mg/mL|
62787434|NCT01706588|PLACEBO_COMPARATOR|Placebo 1 mL|
62787435|NCT05740943|EXPERIMENTAL|Treatment Arm|Patients will receive 12-week induction Lorlatinib followed by radical surgery or local radiotherapy or continue Lorlatinib through MDT and optional consolidation lorlatinib for up to 2 years.
62787436|NCT04731272|EXPERIMENTAL|Dulaglutide|The Mixed Meal Tolerance Test as described in the primary outcome section will be performed at baseline and after 6 weeks of dulaglutide therapy in the intervention period.
62015458|NCT06441513|EXPERIMENTAL|Invention group|On the basis of the intervention measures in the control group, we added the following measures. First, we set up a team for the prevention of hand foot syndrome, including 1 head nurse of the tumor chemotherapy department, 2 doctors, 16 nurses (16 nurses were divided into 4 groups, each group designated a team leader) and the researchers of this experiment. Doctors are responsible for the diagnosis of HFS and the determination of traditional Chinese medicine prescriptions, head nurses and team leaders are responsible for quality control, and nurses are responsible for the assessment, intervention and evaluation of patients.
62404096|NCT04066894|EXPERIMENTAL|Supportive Care (sacral nerve stimulator)|Patients undergo scheduled, elective surgery for placement of the sacral nerve stimulator with external battery pack. After 2 weeks, patients undergo implantation of a subcutaneous internal battery or removal of the leads if the sacral nerve stimulator is working but does not improve symptoms. If the sacral nerve stimulator is not working, it is repositioned and patients return 2 weeks later for implantation of external battery or removal of leads.
62404097|NCT02353273|EXPERIMENTAL|WH-1 ointment|WH-1 ointment(1.25%),15g ointment per tube.
62404098|NCT04619758|EXPERIMENTAL|Emollient Group|Mothers of the neonates in group A will be advised massage with sunflower oil.
62404099|NCT04619758|NO_INTERVENTION|Non-Emollient Group|Mothers of the neonates in group B will be advised massage without any emollient.
62404100|NCT06159946|EXPERIMENTAL|Spinal cord injury|Each subject was asked to place their hand by the motion sensor (motion control), use a speech speaker (voice control), and then move their eyes up, down, left, and right to activate the eye gaze sensor (eye gaze control) to control water outputs for drinking, rinsing, and grooming. Each subject performed the same task/function three times.
62404101|NCT06650865|ACTIVE_COMPARATOR|Traditional Exercise Group|"The routine exercise program applied to individuals with osteoarthritis who applied to the orthopedic clinic where the data will be obtained is given below.~1st week exercises~* Isometric quadriceps set~* Terminal knee extension~* Knee extension at 90 degrees flexion~* Isometric gluteus maximus exercises~Exercises added in week 2~* Four-way straight leg raises~* Bridge exercise~* Fingertip elevation~Exercises added in week 4~* Mini squat (0-30 degrees)~* Getting up from a chair without support~* Leg press exercise with Theraband~Exercises added in week 6~* Stepping up and down~* Exercises for rising on one leg~* Semi squat (0-60 degrees)~The exercise program will be taught to the patient and given as a home program."
62580436|NCT03211260|EXPERIMENTAL|EQUISTASI|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
62580437|NCT05519358||difficult airway|difficult laryngoscopy; Cormack-Lehane grades 3 or 4 or Difficult intubation; Intubation Difficulty Scale (IDS)\> 5 .IDS based on parameters known to be associated with difficult intubation
62580438|NCT05519358||non difficult airway|not difficult intubation or laryngoscopy
62580439|NCT01266720|EXPERIMENTAL|Phase 1 study|"Interventions:~Biological: VEGFR1, VEGFR2 Drug: Gemcitabine"
62015459|NCT06441513|OTHER|Control group|We distributed traditional Chinese medicine to the control group and carried out health education, which mainly included elaborating the symptoms, mechanism and corresponding treatment measures of HFS for patients, reducing the fear of patients, helping them relax and adjust their mentality, and cooperating with observation. At the same time, we should also try to reduce the chance of skin damage on hands / feet, such as wearing long clothes and pants when going out to avoid direct sunlight; Wear loose shoes, socks and gloves to avoid frequent friction and excessive pressure of hands and feet; Avoid heavy physical labor and intense exercise; Avoid contact with supercooled, overheated, sharp and irritating objects.
62015460|NCT00765245|EXPERIMENTAL|Arm I: Lenalidomide|
62015461|NCT00765245|EXPERIMENTAL|Arm II: Lenalidomide and Rituximab IV|Patients receive lenalidomide as in arm I and rituximab IV on day 8 of courses 1, 3, 5, 7, 9, and 11 in the absence of disease progression or unacceptable toxicity.
62015462|NCT03265405|ACTIVE_COMPARATOR|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
62015463|NCT03265405|ACTIVE_COMPARATOR|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
62015464|NCT05873387||Echocardiography ground-truth|Subjects with ECG/PCG recordings labeled against echocardiography
62015465|NCT05873387||Right heart catheterization ground-truth|Subjects with ECG/PCG recordings labeled against right heart catheterization
62015466|NCT01643473|ACTIVE_COMPARATOR|Attention Control|Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
62015467|NCT01643473|EXPERIMENTAL|Tailored Adherence Intervention|Tablet-based tailored adherence intervention matched to patients' most salient adherence barriers
62204369|NCT04090177|NO_INTERVENTION|Control-Wait List|"The control group receives no specific intervention over the course of the 4-week period. This reflects usual practice/typical experience of a MWC user in their provincial context. Control group participants placed on the wait-list will receive the TEAM Wheels program following completion of the study (i.e. after post-treatment data collection). The site Research Coordinator/Assistant will make telephone or email contact with control group participants at the end of weeks 2 and 4 during the study period to deter attrition/drop-out. When contact is made at week 4, the Research Coordinator will schedule an appointment for post-treatment data collection (week 7). Any formal MWC training received during the wait-list period will be documented for potential post-hoc analysis as a confounding variable; research evidence and investigators' clinical experience confirm that in all 3 provinces formal training is not provided once MWC users are discharged from hospital."
62204370|NCT04531098|EXPERIMENTAL|Sci-B-Vac-SciGen|The 3-antigen HepB vaccine, Sci-B-Vac-SciGen (SciGen Israel Ltd., produced in a new production facility located in Rehovot, Israel) contains three recombinant proteins of hepatitis B virus (HBV) envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac-SciGen was supplied in a final volume of 1.2 ml vials
62204371|NCT04531098|ACTIVE_COMPARATOR|Engerix-B|The single antigen HepB vaccine, Engerix-B (GSK), contains the small S recombinant protein. Engerix-B was supplied in 1.0 ml vials.
62204372|NCT04531098|EXPERIMENTAL|Sci-B-Vac-BTG|The 3-antigen HepB vaccine, Sci-B-Vac-BTG (Bio-Technology General (BTG) Ltd., Rehovot, Israel.) contains three recombinant proteins of HBV viral envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac-BTG was supplied in a final volume of 1.2 ml vials
62204373|NCT03632122||Bothersome back pain|The investigators will include community-dwelling older adults at Round 1 or 6 of the NHATS cohort, and will include those with bothersome back pain in the past month based on self-report questions at the respective baseline time point. The investigators will exclude participants who are non-ambulatory (requires wheelchair or scooter).
62204374|NCT01503762|EXPERIMENTAL|Mirror Therapy Group|Mirror Therapy Group
62404102|NCT06650865|EXPERIMENTAL|Baduanjin Exercise Group|"Standard Physical Therapy Program + Baduanjin exercises~Baduanjin exercises An important complementary part of Qigong, the Baduanjin exercise (Eight Part Exercises or Eight Part Brocades) consists of eight different postures (supporting the chest, drawing arcs to both sides, raising one hand, practicing looking back, waving the hand and wagging the tail, touching the feet with both hands, climbing with both hands and relaxing the back).~The exercise program will be taught to the patient and given as a home program."
62404103|NCT06650865|EXPERIMENTAL|Telerehabilitation group|"Baduanjin exercise will be applied simultaneously with the telerehabilitation method.~Standard Physical Therapy Program + Baduanjin exercises~Baduanjin exercises An important complementary part of Qigong, the Baduanjin exercise (Eight Part Exercises or Eight Part Brocades) consists of eight different postures (supporting the chest, drawing arcs to both sides, raising one hand, practicing looking back, waving the hand and wagging the tail, touching the feet with both hands, climbing with both hands and relaxing the back).~The exercise program will be taught to the patient and given as a home program."
62787437|NCT04731272|NO_INTERVENTION|Observation|The Mixed Meal Tolerance Test as described in the primary outcome section will be performed at baseline and after 6 weeks of no intervention in the observation period.
62015468|NCT06521502||Cohort A (full study protocol - written informed consent)|Cohort A is the cohort of APS study participants who have provided written informed consent for participation in the APS phenotyping study. Cohort A may participate in all study procedures in the APS phenotyping study.
62015469|NCT06521502||Cohort B (alteration study protocol - alteration of informed consent)|Cohort B is the cohort of APS study participants who are enrolled in the study under alteration of informed consent. Cohort B will participate in a modified set of procedures which omits procedures considered greater than minimal risk.
62204375|NCT01503762|SHAM_COMPARATOR|Control Group|Control Group receive classical rehabilitation techniques including splinting, tendon gliding, ...
62204376|NCT00780728|ACTIVE_COMPARATOR|Sildenafil|
62204377|NCT05594134|EXPERIMENTAL|Automatic toothbrush with nylon bristles|
62204378|NCT05594134|ACTIVE_COMPARATOR|Automatic toothbrush with silicone bristles|
62204379|NCT05594134|ACTIVE_COMPARATOR|Manual toothbrush used for 2 minutes|
62204380|NCT05594134|ACTIVE_COMPARATOR|Manual toothbrush used for 45 seconds|
62204381|NCT05594134|NO_INTERVENTION|No brushing|
62204382|NCT03992391|NO_INTERVENTION|Qualitative Interviews|Qualitative Interviews with adolescents, their parents and clinicians.
62015470|NCT06521502||Long-term Outcomes Cohort|The Long-term Outcomes Cohort consists of a subset of participants with written informed consent for study participation (Cohort A) who complete in-person post-hospital study assessments. These in-person study visits are scheduled at 3-, 6-, and 12-months after initial enrollment in the hospital. Interventions/exposures are denoted for this group for study procedures that are completed during an in-person post-hospital visit.
62015471|NCT01813526|EXPERIMENTAL|Experimental Infant Formula|Experimental formula to be fed ad libitum.
62015472|NCT02186964|EXPERIMENTAL|tension free primary closure|patients treated by tension free primary closure
62015473|NCT02186964|EXPERIMENTAL|karydakis|patients treated by Karydakis method
62015474|NCT02186964|EXPERIMENTAL|Limberg flap|patients treated by Limberg flap procedure
62015475|NCT05117827|EXPERIMENTAL|Power Wheelchair Standing Device User|
62204383|NCT03992391|EXPERIMENTAL|Open Pilot|Open-label pilot group of adolescents (n=10) in a suicide prevention intensive outpatient program
62204384|NCT03992391|EXPERIMENTAL|Open-label trial|Open-label trial of adolescents (n=40) in a suicide prevention intensive outpatient program
62204385|NCT01653977|ACTIVE_COMPARATOR|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP \> 65mmHg, HR \< 90/min, CVP \>8-12\< cm H20, urinary output \> 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° \> 35.5°C, Sp02 \> 95%, lactate \< 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
62204386|NCT01653977|ACTIVE_COMPARATOR|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
62204387|NCT00770705|EXPERIMENTAL|1|Group receiving phenoxybenzamine
62015476|NCT06251934||Patients with high tumor burden (HTB)|
62204388|NCT00770705|OTHER|2|Historical control
62204389|NCT03438357||Patients with multiple sclerosis|
62580440|NCT02653118||Cohort 1: V503 in the Base Study|Participants received the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543). No study vaccination will be administered in study V503-021.
62787438|NCT06418672|EXPERIMENTAL|Early Intervention|6 worksites will be enrolled. GSSG implementation in May-August 2024
62787439|NCT06418672|ACTIVE_COMPARATOR|Delayed Intervention|6 worksites will be enrolled. GSSG implementation in August- December 2024.
62787440|NCT05810350|EXPERIMENTAL|aumolertinib combined Ommaya reservoir intrathecal chemotherapy|Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed (30 mg was administered on days 1 and 8) once every 3 weeks.
62787441|NCT03567746|EXPERIMENTAL|Underwater EMR|The patients randomized in this arm will be treated by endoscopic resection assisted by the filling of the colonic lumen using water instead of air and avoiding the formation of a submucosal cushion
62787442|NCT03567746|ACTIVE_COMPARATOR|Conventional EMR|The patients randomized in this arm will be treated by endoscopic resection following the traditional technique. It means, by assistance of selective submucosal saline injection to create a submucosal cushion below the polyp.
62787443|NCT02463682|ACTIVE_COMPARATOR|Sensor-Augmented Pump Open-Loop Care (Week 1)|The subjects Sensor-Augmented Pump Open-Loop Care for the first week of the study before any adjustments to pump settings.
62787444|NCT02463682|EXPERIMENTAL|Closed-Loop Control System with Zone MPC and HMS|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device.
62787445|NCT02955537|NO_INTERVENTION|Usual care|Usual care participants will be given a prescription for antihypertensive medications, printed educational materials on hypertension, and a home blood pressure monitor for daily use, but will receive no further intervention.
62787446|NCT02955537|EXPERIMENTAL|MI-BP|MI-BP participants will receive an antihypertensive medication prescription, and be asked to use technology-mediated devices/services linked to positive changes in target behavior/outcome including the MI-BP app, a secure, mHealth platform that will be installed on participant smartphones.
62787447|NCT04702022|OTHER|Humoral Arm|"The renal biopsy shows signs of humoral rejection: the patient is excluded from the study and is treated as usual on the basis of the histological results."
62787448|NCT04702022|OTHER|"Highly Metabolic patients"|"The renal biopsy does not show signs of humoral rejection but the 18FDG PET / CT shows a high metabolic activity of the graft (\> 2.4): the patient is treated as usual on the basis of histological findings."
62787449|NCT04702022|OTHER|" Low metabolic patients"|The renal biopsy does not show signs of humoral rejection and the 18FDG PET / CT shows a weak metabolic activity of the graft (\<2.4): the immunosuppressive treatment is gradually weaned off corticosteroids.
62787450|NCT04904666||Bleach baths with .0125%|
62015477|NCT06251934||Patients with low tumor burden (LTB)|
62015478|NCT06251934||Patients with central nervous system (CNS) metastases|
62015479|NCT06251934||Patients with without CNS metastases|
62015480|NCT06251934||1L IO-refractory patients|
62015481|NCT05352139||Elbow Tendinosis (Epicondylitis)|Treatment of participants who present with either lateral or medial epicondylitis
62015482|NCT05352139||Hip Tendinosis (Gluteal Tendinopathy)|Treatment of participants diagnosed with Recalcitrant Gluteal Tendinopathy
62015483|NCT05352139||Shoulder Calcific Tendinosis (Calcific Shoulder Tendinopathy)|Treatment of participants diagnosed with Calcific Shoulder Tendinopathy
62015484|NCT00510029|OTHER|GAP-134, IV and Oral|Experimental; Active Comparator; Placebo
62015485|NCT03526523|EXPERIMENTAL|Active Treatment|Mindfulness-based stress reduction
62015486|NCT03526523|NO_INTERVENTION|Waitlist control|The active treatment will be received only after the outcomes monitoring period is complete.
62015487|NCT00377676|EXPERIMENTAL|Usual Diabetes Therapy plus placebo|Usual diabetes therapy plus placebo
62015488|NCT00377676|EXPERIMENTAL|Drug Cycloset|
62015489|NCT02595684|EXPERIMENTAL|Tadalafil|Tadalafil capsules
62015490|NCT02595684|PLACEBO_COMPARATOR|Placebo|Calcined magnesia capsules
62015491|NCT03454594|EXPERIMENTAL|low level laser hemotherapy|Watch laser acupuncture and nasal irradiation
62787451|NCT04904666||Clorhexidine 2%|
62787452|NCT04904666||Soap and water|
62015492|NCT03454594|NO_INTERVENTION|control|all the participants in this group did not receive low level laser irradiation during the study period
62015493|NCT06431620|EXPERIMENTAL|rhTSH group|rhTSH is used to raise blood TSH levels to meet the requirements of diagnostic 131I SPECT/CT whole-body scans before and after TKI medication.
62015494|NCT00358267|ACTIVE_COMPARATOR|RFA|Radiofrequency Ablation (RFA) involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
62015495|NCT00358267|ACTIVE_COMPARATOR|PRIT|Partial Resection of Inferior Turbinate (PRIT) involves surgically removing a small piece off the turbinate, which also reduces its size.
62015496|NCT03704545|NO_INTERVENTION|Control group|
62015497|NCT03704545|EXPERIMENTAL|Experimental group from the hospital|
62015498|NCT03704545|EXPERIMENTAL|Experimental group from the city|
62215169|NCT02706613|ACTIVE_COMPARATOR|Online Pulmonary Rehabilitation|Those randomised to receive the online programme will be given log-in details and a password, and instructions to begin the 6 week programme at home. The online programme mirrors the conventional face-to-face PR programme and the exercise and educational components are given by means of instructional videos. Participants will be instructed to exercise five times a week. Participants in the online arm will receive during the PR course telephone contact to record any adverse or serious adverse events.
62404104|NCT05358704|EXPERIMENTAL|Combination of drugs prior to surgery|Receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) prior to surgery and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years. The time in the study will take approximately four - six hours during pre-study, study and end of study visits.
62404105|NCT06129851|EXPERIMENTAL|Arm A (relugolix, brachytherapy, external beam radiation)|Patients receive relugolix PO QD. Cycles repeat every 3 months for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 30 to 180 days after start of relugolix, patients undergo brachytherapy and external beam radiation over 25 fractions. Patients undergo bone scan, CT or MRI or PSMA PET scan during screening. Patients also undergo DEXA scan and may optionally undergo blood sample collection throughout the trial.
62404106|NCT06129851|EXPERIMENTAL|Arm B (relugolix, brachytherapy, external beam radiation)|Patients receive relugolix PO QD. Cycles repeat every 3 months for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 30 to 180 days after start of relugolix, patients undergo brachytherapy and external beam radiation over 25 fractions. Patients undergo bone scan, CT or MRI or PSMA PET scan during screening. Patients also undergo DEXA scan and may optionally undergo blood sample collection throughout the trial.
62787453|NCT04904666||Bleach baths with .005%|
62787454|NCT00832429|EXPERIMENTAL|Diagnostic (SLN localization and biopsy)|Patients receive technetium Tc 99m sulfur colloid ID and then undergo lymph node mapping and SLN biopsy.
62404107|NCT03088566|EXPERIMENTAL|The D-Foot method|The patients are being foot screened following the routine that is programmed in the D-Foot.
62404108|NCT03088566|ACTIVE_COMPARATOR|Conventional foot screening|The patients are being foot screened according to conventional methods.
62404109|NCT03131791|EXPERIMENTAL|shock wave|The interventions were focused in the hypertonic muscles of the upper limb of 3000 impulses, a pressure of 1.5 bar and frequency of 5Hz were used to treat the biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
62404110|NCT03131791|EXPERIMENTAL|Botulinum toxin A|We performed BoNT-A 500 unit in 2cc 0.9% normal saline at biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
62787455|NCT01418079|EXPERIMENTAL|PMS-3000|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
62787456|NCT01749150|EXPERIMENTAL|with cirrhosis|
62787457|NCT01749150|EXPERIMENTAL|without cirrhosis|
62787458|NCT00930878||Promus|Patients intended to be treated with a Promus™ stent system
62787459|NCT00930878||Endeavor|Patients intended to be treated with an Endeavor™ stent system (excluded the Endeavor™ Resolute™ stent)
62787460|NCT00930878||Cypher|Patients intended to be treated with a Cypher™ stent system
62787461|NCT06438432|EXPERIMENTAL|RH-RAIT|A first group of children will continue their usual rehabilitation (RH) for the first 3 months and then have RAIT for the following 9 months.
62787462|NCT06438432|EXPERIMENTAL|RAIT-RAIT|The second group of children will have RAIT from the outset during the 12 months of the study.
62787463|NCT03642496|EXPERIMENTAL|The low dose group|
62787464|NCT03642496|EXPERIMENTAL|The middle dose group|
62787465|NCT03642496|EXPERIMENTAL|The high dose group|
62787466|NCT02937558|EXPERIMENTAL|CSI-Glucagon (Double-Blind Phase - 2 days)|Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
62015499|NCT02838420|EXPERIMENTAL|Alectinib|Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death.
62404111|NCT02908204||Endoscopic treatment|Patients underwent endoscopic treatment including Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Multiband Mucosectomy (MBM), Endoscopic Mucosal Band Ligation(EMBL) and so on.
62404112|NCT02908204||Traditional surgery|Patients underwent traditional surgery
62787467|NCT02937558|PLACEBO_COMPARATOR|Placebo (Double-Blind Phase - 2 days)|Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump.
62787468|NCT02937558|EXPERIMENTAL|CSI-Glucagon (Open-label Phase - Up to 28 days)|Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
62787469|NCT04086914|NO_INTERVENTION|Non nerve block|Receives no nerve block
62787470|NCT04086914|EXPERIMENTAL|Nerve block|Receives nerve block
62015500|NCT02838420|ACTIVE_COMPARATOR|Crizotinib|Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death.
62787471|NCT05799417|EXPERIMENTAL|Acoustic stimuli|Acoustic stimuli and comparison to within-subject baseline
62787472|NCT03512379|EXPERIMENTAL|Robot assisted surgery group|Spinal surgery using TIANJI Robot system.
62787473|NCT03512379|ACTIVE_COMPARATOR|Free hand surgery group|Spinal surgery using fluoroscopy-based free hand technique
62787474|NCT03512379|ACTIVE_COMPARATOR|Navigation-assisted surgery group|Spinal surgery using Navigation-assisted technique
62787475|NCT02478164|EXPERIMENTAL|Ponatinib|Drug will be administered once daily per cycle through oral ingestion.
62787476|NCT02303145||Breast cancer survivor Group|Breast Cancer Survivor Group includes: women between the ages of 18 to 69 who have received a stage I-III diagnosis of breast cancer in the past and completed primary treatment and finished with treatment for at least 6 months; currently employed working part-time or full-time at the time of assessment. Participants working between 1 to 34 hours a week will be considered part-time employees.
62204390|NCT01118013|EXPERIMENTAL|Treatment|"Matched-unrelated donor: Patients receive antithymocyte globulin, tacrolimus, and methotrexate as in HLA-identical donor regimen. Patients also receive oral mycophenolate mofetil twice daily on days 0 to 60.~Allogeneic Stem Cell Transplantation: Patients undergo allogeneic peripheral blood stem cell transplantation on days 0 and 1. Patients then receive filgrastim subcutaneously daily beginning on day 7 and continuing until blood counts recover.~Donor Lymphocyte Infusion (DLI): After day 180 (or day 210 for patients without an HLA-identical donor), patients with stable or progressive disease and no active GVHD may receive up to 3 DLIs every 8 weeks.~Blood samples are collected at baseline and then periodically during study therapy for pharmacokinetic studies.~After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for up to 5½ years."
62204391|NCT04276415|EXPERIMENTAL|Dose Escalation: DS-6157a|Participants with advanced gastrointestinal stromal tumor (GIST) who will receive an intravenous infusion of DS-6157a (escalating doses starting at 1.6 mg/kg).
62204392|NCT04276415|EXPERIMENTAL|Dose Expansion: Cohort 1 (3rd line or later) treated at RDE|Participants with advanced gastrointestinal stromal tumor (GIST) who have progressed on or are intolerant to imatinib (IM) and at least one post-IM treatment will receive DS-6157a at the recommended dose for expansion (RDE) based on the Dose Escalation phase.
62204393|NCT04276415|EXPERIMENTAL|Dose Expansion: Cohort 2 (2nd line) treated at RDE|Participants with advanced gastrointestinal stromal tumor (GIST) who have progressed on imatinib (IM) and had not received a post-IM treatment (2nd line) will receive DS-6157a at the recommended dose for expansion (RDE) based on the Dose Escalation phase.
62204394|NCT03622190||Cohort 1|Music students who are free of pain, PRMDs and/or MSK problems at baseline data collection
62404113|NCT00283517||001|
62404114|NCT04264806|EXPERIMENTAL|Azacitidine: Participants with MDS or CMML|Participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) will receive azacitidine 75 milligram per meter square (mg/m\^2) body surface area (BSA) subcutaneously or Intravenously per local label on Days 1 through Day 7 of each 28-day cycle. Participants will be treated until disease progression; relapse from complete remission (CR), partial remission (PR), or marrow complete remission (mCR); transformation to acute myeloid leukemia (AML); death; or unacceptable toxicity.
62404115|NCT04264806|EXPERIMENTAL|Azacitidine and Cusatuzumab: Participants with MDS or CMML|Participants with higher-risk MDS or CMML will receive azacitidine 75 mg/m\^2 BSA subcutaneously or Intravenously per local label on Days 1 through 7 and cusatuzumab 20 mg/kg IV on Days 3 and 17 of each 28-day cycle. Participants will be treated until disease progression; relapse from CR, PR, mCR; transformation to AML; death; or unacceptable toxicity.
62404116|NCT01786837|EXPERIMENTAL|Treatment|FMS will be administered for 5 weeks
62404117|NCT01786837|SHAM_COMPARATOR|Sham|FMS at 5% intensity for 5 weeks
62404118|NCT01359774|OTHER|Healthy volunteers|
62404119|NCT01359774|OTHER|Huntington patients|
62404120|NCT03280472|EXPERIMENTAL|Cognitive Bias Modification|Participants will complete three session of cognitive bias modification.
62404121|NCT03280472|OTHER|Symptom Tracking|Participants will track their symptoms.
62404122|NCT04773366|EXPERIMENTAL|Group 1|"Multisystem patients (≥2 organs/systems) with involvement of one or more Risk organs, i.e. hematopoietic system, liver or spleen.~All patients in this group receive an initial therapy (Week 1\~6) followed by a consolidation continuation therapy (Week 7\~22) and maintenance continuation therapy (Week 25\~52)."
62404123|NCT04773366|EXPERIMENTAL|Group 2|"Multisystem patients, but without involvement of Risk organs.~All patients in this group receive an initial therapy (Week 1\~6) followed by continuation therapy (Week 7\~52)."
62404124|NCT04773366|EXPERIMENTAL|Group 3|"Includes patients with single system, multifocal or with single system, unifocal and special site (Isolated lesion of special site) or with single system, unifocal and CNS risk or with single system, unifocal i.e. thyroid, lung, thymus, hypothalamic-pituitary or with single system, unifocal and other functionally critical anatomical sites.~All patients in this group receive an initial therapy (Week 1\~6) followed by continuation therapy (Week 7\~52)."
62404125|NCT04773366|EXPERIMENTAL|Group 4|"Patients with single system, unifocal i.e. bone, skin or lymph node (not the draining lymph node of another LCH lesion).~All patients in this group enter into observation after local therapy. Chemotherapy only apply to patients with disease reactivation during observation."
62404126|NCT00302068|EXPERIMENTAL|1|Supervised aerobic exercise, three times per week for 16 weeks.
62404127|NCT00302068|ACTIVE_COMPARATOR|2|Sertraline (Zoloft), for 16 weeks.
62404128|NCT00302068|PLACEBO_COMPARATOR|3|Placebo control, for 16 weeks.
62204395|NCT03622190||Cohort 2|Music students who aren't free of pain, PRMDs and/or MSK problems at baseline data collection
62215170|NCT00281515|EXPERIMENTAL|Lonafarnib / Paclitaxel /Carboplatin|
62215171|NCT00281515|OTHER|Paclitaxel/Carboplatin|Standard Chemotherapy
62404129|NCT04944485|ACTIVE_COMPARATOR|class V cavities treated with putty nanohybrid resin composite|Selective enamel etching will be done and a universal adhesive (Prime\&Bond universal™ ,Dentsply)will be applied to both enamel and dentin. After gentle dryness and solvent evaporation the bonding agent will be cured for 20 seconds. Composite (Neo Spectra™ST, Dentsply, Sirona, USA) will be placed incrementally and light cured for 20 seconds
62404130|NCT04944485|EXPERIMENTAL|class V cavities treated with Self adhesive giomer containing nanohybrid flowable composite|Cleaning and gentle air blowing of the preparation. Then applying FIT SA F03 (Low Flow), SHOFU, USA. Spread in a thin layer (≤0.5mm) on the prepared surface with needle tip, microbrush and gently air-blow leave for 20 seconds then light cure for 5 seconds. Then,apply additional increments (≤2mm) of FIT SA and light cure each increment for 10 seconds then finish and polish
62404131|NCT01874821|EXPERIMENTAL|Dynasplint|Along with standard manual physical therapy, patients will have a stretching device (Dynasplint) used in rehabilitation to regain ROM in stiff joints. Patients will use this device 20-30 minutes 2 times per day at home.
62404132|NCT01874821|OTHER|Control|Patient's in the Physical Therapy Group will have the standard manual treatments during their usual physical therapy visits with no additional intervention
62404133|NCT06008015|EXPERIMENTAL|BR1015|
62404134|NCT06008015|ACTIVE_COMPARATOR|BR1015-1 + BR1015-2|
62404135|NCT05592639|ACTIVE_COMPARATOR|Videoendoscopic Inguinal Lymphadenectomy|Removal of inguinal nodes using Videoendoscopic Inguinal Lymphadenectomy
62404136|NCT05592639|OTHER|Open Inguinal Lymphadenectomy|Removal of inguinal nodes using Open radical inguinal lymphadenectomy
62015501|NCT01849341|EXPERIMENTAL|Roflumilast alternated days|Intervention: 500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
62204396|NCT06509399|EXPERIMENTAL|PRESSURE ULCERS PREVENTION CARE PACKAGE IN INTENSİVE CARE UNIT|This experimental study was carried out in the anesthesia and reanimation intensive care unit of Düzce Atatürk State Hospital. The part with patients was completed with a total of 72 patients, 36 in the control group and 36 in the application group. The occurrence rate of PI was compared between the control group and the application group.
62204397|NCT06509399|NO_INTERVENTION|NURSES' LEVEL OF KNOWLEDGE ABOUT THE CARE PACKAGE|In the section about nurses, no sample was selected and all 50 nurses working in intensive care were included in the study. Nurses' knowledge and attitudes about PI before and after the training were compared.
62404137|NCT04583072||Non-Hispanic/Latino White/Caucasian men|Self-identified as White Non-Hispanic men, with age range (45.0 - 75.0 years), without prior evidence of prostate cancer
62204398|NCT05008939|EXPERIMENTAL|sevoflurane|Those with 1-hour inhalation of 1% sevoflurane/30% oxygen
62015502|NCT01849341|ACTIVE_COMPARATOR|Roflumilast 500 mcg per day|Roflumilast 500μg standard dosage
62204399|NCT05008939|PLACEBO_COMPARATOR|placebo|Those with 1-hour inhalation of 30% oxygen
62204400|NCT01793597||clopidogrel|previous treatment with clopidogrel
62404138|NCT04583072||African/Black men|Self-identified as African or Black men, with age range (45.0 - 75.0 years), without prior evidence of prostate cancer
62404139|NCT04583072||Hispanic/Latino White/Caucasian men|Self-identified as White Hispanic men, with age range (45.0 - 75.0 years), without prior evidence of prostate cancer
62404140|NCT04583072||Asian men|Self-identified as Asian men, with age range (45.0 - 75.0 years), without prior evidence of prostate cancer
62404141|NCT00300261|NO_INTERVENTION|1|receives home care
62404142|NCT00300261|EXPERIMENTAL|2|receives telehealth monitoring in addition to home care
62204401|NCT01793597||ticagrelor|previous treatment with ticagrelor
62404143|NCT03446846|EXPERIMENTAL|5.0 mg MIN-117|MIN-117 5.0 mg (consisting of two 2.5 mg capsules) orally daily for 6 weeks
62404144|NCT03446846|EXPERIMENTAL|2.5 mg MIN-117|MIN-117 2.5 mg (consisting of one 2.5 mg capsule and one placebo capsule) orally daily for 6 weeks
62404145|NCT03446846|PLACEBO_COMPARATOR|Placebo|Placebo (consisting of two placebo capsules) orally daily for 6 weeks
62404146|NCT02598791|ACTIVE_COMPARATOR|IIGI+GIP|4 hour i.v. infusion of glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemic conditions
62404147|NCT02598791|ACTIVE_COMPARATOR|IIGI+GLP-1|4 hour i.v. infusion of glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemic conditions
62404148|NCT02598791|PLACEBO_COMPARATOR|IIGI+NaCl (placebo)|4 hour i.v. NaCl (placebo) during isoglycemic conditions
62404149|NCT02598791|ACTIVE_COMPARATOR|IIGI+GIP+GLP-1|4 hour co-infusion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1
62404150|NCT02598791|OTHER|50 g OGTT|50 g oral glucose tolerance test (OGTT)
62404151|NCT00921934||Vitamin C|Adult patients suffering from acute viral infection, especially herpes zoster, presenting themselves in Primary Care Centers or hospitals all over Germany, and who are treated with standard therapy and add-on vitamin C.
62404152|NCT03742869||Patients with HPV integration|The HPV integration status will be checked by GWAS.
62404153|NCT03742869||Patients without HPV integration|The HPV integration status will be checked by GWAS.
62404154|NCT02422186|EXPERIMENTAL|Intranasal Esketamine plus Oral Antidepressant|Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase. All participants will start with first dose (Day 1 as 28 milligram \[mg\]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability. In addition participants will simultaneously initiate a new, open-label oral antidepressant (Duloxetine, Escitalopram, Sertraline, or Venlafaxine extended release \[XR\]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
62404155|NCT02422186|ACTIVE_COMPARATOR|Placebo plus Oral Antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in Double-Blind Induction Phase using the same titration as Esketamine. In addition participants will simultaneously initiate a new, open-label oral antidepressant (Duloxetine, Escitalopram, Sertraline, or Venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
62015503|NCT02070159|ACTIVE_COMPARATOR|Clopidogrel 600 mg|Patients administer conventional loading dose of clopidogrel 600 mg as active comparators.
62015504|NCT02070159|EXPERIMENTAL|Prasugrel 30 mg|Patients administer lower loading dose of prasugrel 30 mg.
62015505|NCT02070159|ACTIVE_COMPARATOR|Prasugrel 60 mg|Patients administer conventional loading dose of prasugrel 60 mg as active comparators.
62204402|NCT03284203|EXPERIMENTAL|SpiroPD|Participants in the intervention arm will be given a handheld spirometry device to take home and use daily for 30 consecutive days.
62204403|NCT03474926|EXPERIMENTAL|Routine lymph node dissection (LND) during nephroureterectomy|"Template-based LND was carried out in all patients in this group. The anatomical extent of LND is described in previous study. Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
62215172|NCT01534572|EXPERIMENTAL|Probiotics_Lactobacillus|Intervention (2 weeks) with a strain of Lactobacillus
62204404|NCT03474926|ACTIVE_COMPARATOR|LND for lymph nodes enlargement found before or during surgery|LND was carried out only in patients who have lymph nodes enlargement in preoperative imaging (CTU or enhanced MRI) or who were found lymph nodes enlargement during surgery.
62204405|NCT02420951|EXPERIMENTAL|Injection|Will receive injection of 30ml of .5% bupivacaine solution prior to catheter removal
62404156|NCT00732732|EXPERIMENTAL|Green banana|Subjects receiving green banana powder.
62204406|NCT02420951|ACTIVE_COMPARATOR|No Injection|Will not receive injection of bupivacaine prior to catheter removal
62204407|NCT05169892||Aquablation|
62404157|NCT00732732|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose given as placebo
62404158|NCT04538716|EXPERIMENTAL|SVF-gel|Transconjunctival blepharoplasty associated with associated with stromal vascular fraction gel (SVF-gel)
62404159|NCT04538716|EXPERIMENTAL|fat transposition|Transconjunctival blepharoplasty associated with fat transposition
62404160|NCT04279873||Adults with nosocomial pneumonia|Diagnostic procedures on pulmonary secretion collected by tracheal suctioning and bronchoalveolar lavage.
62404161|NCT00734318|EXPERIMENTAL|Flutiform 250/10 micrograms|Flutiform 250/10 micrograms (2 puffs bd)
62404162|NCT00734318|EXPERIMENTAL|Flutiform 50/5 micrograms|Flutiform 50/5 micrograms (2 puffs bd)
62404163|NCT00734318|ACTIVE_COMPARATOR|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|Flixotide pMDI 250 mcg (2 puffs bd) + foradil pMDI 24 50/5 mcg (bd)
62404164|NCT00734318|ACTIVE_COMPARATOR|Flixotide pMDI 250 micrograms|Flixatide pMDI 250 micrograms (2 puffs bd)
62404165|NCT01846442|PLACEBO_COMPARATOR|Placebo|
62404166|NCT01846442|EXPERIMENTAL|0.25% DHEA|
62404167|NCT01846442|EXPERIMENTAL|0.5% DHEA|
62404168|NCT01846442|EXPERIMENTAL|1.0% DHEA|
62404169|NCT03011385|EXPERIMENTAL|Individual Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity) will be formed. Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
62404170|NCT03011385|EXPERIMENTAL|Dyadic Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans as well as coping plans will be formed. Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of only one person in the dyad. This target person will be selected jointly by the participants if both participants are healthy. If one participant has a chronic disease, e.g. diabetes or a cardiovascular disease, the plans are formed for the person with a disease."
62015506|NCT05077254|EXPERIMENTAL|Pfizer-BioNTech COVID-19 Vaccine 2023-2024 + SOC IS Regimen|"Participants will receive a study dose (1 dose) of the Pfizer-BioNTech COVID-19 Vaccine 2023-2024 and will continue to take their standard of care transplant immunosuppressive medications without alterations in schedule and dosing.~SOC IS: Standard of Care transplant immunosuppression regimen"
62204408|NCT03449901|EXPERIMENTAL|Cohort 1: ADI-PEG 20 + Gemcitabine + Docetaxel|"* ADI-PEG 20 will be given on Day -7 of Cycle 1 and then on Days 1, 8, and 15 of each subsequent cycle. Cycles are 21 days. ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m2 via intramuscular injection into either the deltoid or gluteal muscle.~* Gemcitabine will be given intravenously at a dose of 600 mg/m2 over 90 minutes on Days 1 and 8 of each cycle. Docetaxel will be given intravenously at a dose of 60 mg/m2 over 60 minutes on Day 8 of each cycle. Patients started on gemcitabine at a dose of 900 mg/m2 or 750 mg/m2 or docetaxel at a dose of 75 mg/m2 per previous protocol version will be allowed to continue at that dose level~* After Cycle 8, patients may continue on ADI-PEG 20 alone (without gemcitabine and docetaxel) upon request.~* Treatment may continue for up to 34 cycles (103 weeks)"
62215173|NCT01534572|EXPERIMENTAL|Probiotics_Bifidobacterium|Intervention (2 weeks) of daily supplementation of a probiotic strain of Bifidobacterium.
62404171|NCT03011385|EXPERIMENTAL|Collaborative Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans and coping plans will be formed. Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of both persons within the dyad (both partners) and include some plans for joint physical activity."
62404172|NCT03011385|ACTIVE_COMPARATOR|Education|The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a partner-partner dyad and discusses individual guidelines for both dyadic partners.
62404173|NCT03644966|EXPERIMENTAL|Probiotic + Antibiotic|50 subjects to receive probiotic supplement once daily for 6 months in capsule form, in addition to standard antibiotic regimen for treatment of UTI.
62404174|NCT03644966|ACTIVE_COMPARATOR|Placebo + Antibiotic|50 subjects to receive placebo once daily for 6 months in capsule form, in addition to antibiotic regimen for treatment of UTI.
62215174|NCT05115643|EXPERIMENTAL|Immobilized arm|Left arm of participant
62215175|NCT05115643|NO_INTERVENTION|Non-immobilized arm|Right arm of participant
62404175|NCT05417373||The development cohort|The development cohort was composed of patients diagnosed with PAH and healthy control group from 2019.1-2021.5 in RenjiH.
62215176|NCT06429644||Dongtan Sacred Heart Hospital|Department of Surgery, Dongtan Sacred Heart Hospital, Hallym University, Dongtan, Republic of Korea
62215177|NCT06429644||Samsung Medical Center|Division of Breast Surgery, Department of Surgery, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea
62404176|NCT05417373||The validation cohort|The validation cohort was composed of patients are suspected as PAH by echocardiography in 2021.5-2021.12 or suspected patients are form other medical institutions.
62404177|NCT05151874||Range of movement|Change in passive joint mobility (ROM) of the carpus (flexion-extension) affected by spasticity pattern III during a 20-week follow-up.
62404178|NCT02223520|ACTIVE_COMPARATOR|Mupirocin and Chlorhexidine|Participants will apply 2% intranasal mupirocin twice a day for five days and cleanse with 2% chlorhexidine cloths once a day for five days.
62404179|NCT02223520|PLACEBO_COMPARATOR|Placebo ointment and placebo cloths|Participants will apply 2% petrolatum intranasal placebo ointment twice a day for five days and cleanse with 2% non-medicated soap placebo cloths once a day for five days.
62404180|NCT01984840|ACTIVE_COMPARATOR|Telemedicine|A tablet (a Samsung GALAXY TAB 2 (10.1)) that holds information on handling COPD in general and software that automatically instructs the patient in handling COPD during exacerbations. The device can also collect and transmit relevant disease-specific data, which are indicative of their current state of health, via an attached Fingertip Pulse Oximeter (Nonin, Onyx II % SpO2), a Digital Blood Pressure Monitor (Model UA-767, plus BT-C) and a scale. The device can measure four vital signs, which are transferred wirelessly: blood pressure, pulse, blood oxygen saturation and weight. The tablet can be activated and give a sound, when it is time for taking measurements again.
62404181|NCT01984840|NO_INTERVENTION|Usual care|In Denmark, usual practice for treating, monitoring and caring for patients with COPD are the responsibility of the patient's general practitioner (treatment and monitoring) and the municipalities (practical help and nursing care). COPD patients can make appointments with their general practitioner or practice nurse free of charge in order to get help in managing COPD. Community based care and practical help varies. As a rule community care comes at regular intervals based on a clinically based estimate of the patients' needs, but the personnel are not necessarily certified nurses and often not fully educated in COPD and definitely not on call
62404182|NCT02568176|EXPERIMENTAL|Cohort 1|Participants will receive single oral dose of midazolam 6 milligram (mg) on Day 1 and 17. Participants will self-administer esketamine intranasally thrice per day on morning of Day 2, 5, 9, 12 and 16 (84 mg).
62404183|NCT02568176|EXPERIMENTAL|Cohort 2|Participants will receive single oral dose of bupropion 150 mg on Day 1 and 19. Participants will self-administer esketamine intranasally thrice per day on morning of Day 4, 7, 11, 14 and 18 (84 mg).
62404184|NCT02407483|EXPERIMENTAL|Laser Visual Guidance group|Will be tested using simulated laparoscopic tasks with the use of laser visual guidance
62404185|NCT02407483|ACTIVE_COMPARATOR|Normal 2D vision group|Will be tested using simulated laparoscopic tasks without the use of laser visual guidance
62404186|NCT00131027|EXPERIMENTAL|A|HD-MTX
62404187|NCT00131027|ACTIVE_COMPARATOR|B|ID-MTX
62404188|NCT04718363|EXPERIMENTAL|PNF stretching group|
62404189|NCT04718363|EXPERIMENTAL|Non-vibration foam rolling prior to PNF stretching group|
62404190|NCT04718363|EXPERIMENTAL|Vibration foam rolling prior to PNF stretching group|
62404191|NCT04718363|NO_INTERVENTION|Control Group|
62404192|NCT03320980||RALPPS|Patients with initial volume of FLR \< 40% which underwent RALPPS and major liver resection (as the second stage of RALPPS) for hilar and intrahepatic cholangiocarcinoma
62787477|NCT02303145||Control Group|Control Group includes: women between the ages of 18 to 60 who are healthy with no diagnosis of cancer, currently employed working part-time or full-time at the time of assessment. Participants working between 1 to 34 hours a week will be considered part-time employees.
62787478|NCT00550693|PLACEBO_COMPARATOR|A|The patients in this arm continued with the local catheter care protocol.
62015507|NCT05077254|EXPERIMENTAL|Pfizer-BioNTech COVID-19 Vaccine 2023-2024 + SOC IS Reduction|"Participants will receive an additional dose (1 dose) of the Pfizer-BioNTech COVID-19 Vaccine 2023-2024, with concurrent reduction of their standard of care transplant immunosuppression regimen (IS), per protocol.~SOC IS Reduction: Standard of Care transplant immunosuppression regimen reduction, per protocol"
62015508|NCT05077254|EXPERIMENTAL|Moderna COVID-19 Vaccine 2023-2024 + SOC IS Regimen|"Participants will receive an additional dose (1 dose) of the Moderna COVID-19 Vaccine 2023-2024 and will continue to take their standard of care transplant immunosuppressive medications without alterations in schedule and dosing.~SOC IS: Standard of Care transplant immunosuppression regimen"
62215178|NCT06429644||Seoul National University Hospital|Breast Care Center, Department of Surgery, Seoul National University Hospital, Seoul, Republic of Korea
62215179|NCT06429644||Severance hospital|Department of Surgery, Severance hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
62404193|NCT03320980||Portal vein embolization (PVE)|Patients with initial volume of FLR \< 40% undergoing PVE and major liver resection for hilar and intrahepatic cholangiocarcinoma
62404194|NCT02226380|EXPERIMENTAL|mFOLFOX6,chemotherapy regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
62404195|NCT01283659|ACTIVE_COMPARATOR|Standard imaging (coronary angiography)|Subjects will undergo a coronary angiogram as planned by their attending doctor
62404196|NCT01283659|ACTIVE_COMPARATOR|Advanced imaging (CTA)|Subjects will undergo a CTA scan first. Based on the CTA results, subjects may or may not proceed to coronary angiography. CTA results will be reviewed by the attending physician.
62404197|NCT01377207|EXPERIMENTAL|Female Arm|Female gender diagnosed with ST segment Elevation Myocardial Infarction (STEMI)
62404198|NCT01377207|ACTIVE_COMPARATOR|Male Arm|Male Gender diagnosed with ST segment Elevation Acute Myocardial Infarction (STEMI)
62404199|NCT06059508|EXPERIMENTAL|SHR-5495 for injection|
62404200|NCT00198107|PLACEBO_COMPARATOR|1 Placebo|Participants will take placebo
62404201|NCT00198107|ACTIVE_COMPARATOR|2 Aripiprazole|Participants will take aripiprazole
62787479|NCT06433089||group GA+PVB|The patients received General Anesthesia(GA) combined with Paravertebral Block(PVB).
62787480|NCT06433089||group GA only|The patients received general anesthesia only.
62204409|NCT03449901|EXPERIMENTAL|Cohort 2: ADI-PEG 20 + Gemcitabine + Docetaxel|"* ADI-PEG 20 will be given on Day -7 of Cycle 1 and then on Days 1, 8, and 15 of each subsequent cycle. Cycles are 21 days. ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m2 via intramuscular injection into either the deltoid or gluteal muscle.~* Gemcitabine will be given intravenously at a dose of 600 mg/m2 over 90 minutes on Days 1 and 8 of each cycle. Docetaxel will be given intravenously at a dose of 60 mg/m2 over 60 minutes on Day 8 of each cycle. Patients started on gemcitabine at a dose of 900 mg/m2 or 750 mg/m2 or docetaxel at a dose of 75 mg/m2 per previous protocol version will be allowed to continue at that dose level~* After Cycle 8, patients may continue on ADI-PEG 20 alone (without gemcitabine and docetaxel) upon request.~* Treatment may continue for up to 34 cycles (103 weeks)"
62787481|NCT04279522|EXPERIMENTAL|Group 1 - active stimulation|
62015509|NCT05077254|EXPERIMENTAL|Moderna COVID-19 Vaccine 2023-2024 + SOC IS Reduction|"Participants will receive a study dose (1 dose) of the Moderna COVID-19 Vaccine 2023-2024, with concurrent reduction of their standard of care transplant immunosuppression regimen (IS), per protocol.~SOC IS Reduction: Standard of Care transplant immunosuppression regimen reduction, per protocol"
62204410|NCT04239469|ACTIVE_COMPARATOR|KL16-012|Patients will use a liquid standardized extract of cannabis sativa. Each drop will contain 1 mg of THC and 0.45 mg of CBD. Administration will be sublingual, while dosing will begin at 3 drops per day and be escalated to 15 drops per day by week 5 according to an escalation chart.
62204411|NCT04239469|PLACEBO_COMPARATOR|Placebo|Patients will use a liquid placebo identical to the active principle in both appearance and taste.
62204412|NCT02388126|EXPERIMENTAL|MRI|Comparison of targeted transrectal ultrasound guided prostate biopsies based on 3T multiparametric MRI findings to systematic non-targeted transrectal ultrasound guided prostate biopsies
62204413|NCT04777370|EXPERIMENTAL|sleeper stretch + thoracic manipulation|The group will receive the sleeper stretch at session #1, and a thoracic manipulation followed by the sleeper stretch at session #2.
62204414|NCT04777370|EXPERIMENTAL|posterior glenohumeral (PG) mobilization + thoracic manipulation|The group will receive a posterior glide mobilization at session #1, and a thoracic manipulation followed by posterior glide mobilization at session #2.
62204415|NCT03270202|EXPERIMENTAL|PAI group|Participants randomized to the PAI-group will receive a wearable device (Mio Slice PAI wristband) that measure heart rate continuously and via an algorithm calculates a physical activity score called PAI. The weekly goal of 100 PAI can be reached by a combination of different intensities and durations and the participants will get continuous information about their current score and amount of activity needed to reach the goal. 100 PAI is expected to approximate current guidelines of 150 minutes of moderate intensity or 75 minutes of vigorous intensity for the average participant or somewhat less if the intensity of the chosen activity is high. Proper instruction in use of the device and App will be given both oral and written after baseline testing and randomization.
62204416|NCT03270202|ACTIVE_COMPARATOR|Usual care|Usual care: Participants in the control group will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.
62204417|NCT01940133|EXPERIMENTAL|PQR309|Different dose evaluation
62404202|NCT00198107|ACTIVE_COMPARATOR|3 Aripiprazole + D-cycloserine|Participants first will take aripiprazole then will also take D-cycloserine
62204418|NCT06398886|EXPERIMENTAL|Ericksonian Hypnosis Group|Ericksonian hypnotherapy provided an alternative approach, with 8 sessions designed to harness the power of indirect suggestion, metaphors, and personal storytelling to navigate the complexities of prolonged grief. Early sessions focused on establishing a therapeutic alliance and utilizing personal strengths and inner resources. Techniques such as guided imagery were used to facilitate a healthy connection with the symptoms, fostering a sense of peace and acceptance. Subsequent sessions aimed to reframe the loss, integrating it into the individual's life narrative in a way that honored the past while promoting openness to future possibilities. This approach sought to cultivate a sense of personal growth and resilience, emphasizing the individual's capacity to find meaning and continue moving forward.
62204419|NCT06398886|ACTIVE_COMPARATOR|Waiting List (Control)|No intervention has been provided for this group.
62215180|NCT06429644||Kyungpook National University Chilgok Hospital|Department of Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea
62215181|NCT06429644||Gangnam Severance Hospital|Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
62215182|NCT06429644||Hanyang University Medical Center|Department of Surgery, Hanyang University Medical Center, Hanyang University College of Medicine, Seoul, Republic of Korea
62404203|NCT06097416|ACTIVE_COMPARATOR|Neoadjuvant chemoradiotherapy|The NARCT regimen is prescribed specifically as standard 5-FU over several weeks. The CRT regimen consists of the standard algorithms: a total of 5400-5600 cGy of radiation (4500 cGy to the pelvis, with an integrated boost to the primary tumour and involved nodes of 500 cGy followed by an option boost to the primary tumour and involved nodes) delivered in 27-28 fractions, respectively, of 180-200 cGy each over a 5-6 week period.
62404204|NCT06097416|ACTIVE_COMPARATOR|Total Neoadjuvant Therapy|Sequence of TNT regimen can be classified as induction (chemotherapy first) or consolidation (radiation first) treatment. All patients received the same chemotherapy (FOLFOX) and long-course chemoradiotherapy (50.4 Gy in 28 fractions) before surgery. However timing of TNT can differ depending on concerns of local and distal failure.
62734849|NCT03349138|EXPERIMENTAL|Electrical Stimulation|Electrical Stimulation \& Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the electrical stimulation system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
62787482|NCT04279522|PLACEBO_COMPARATOR|Group 2 - sham stimulation|
62787483|NCT01711125|EXPERIMENTAL|Arm 1|Baclofen low dose
62787484|NCT01711125|EXPERIMENTAL|Arm 2|Baclofen high dose
62787485|NCT01711125|PLACEBO_COMPARATOR|Arm 3|Placebo
62015510|NCT01813019|EXPERIMENTAL|AFQ056|"Following baseline, approximately 60 patients who are considered eligible will be randomized to AFQ056 arm and will receive the dosing regimen of 4 weeks AFQ056 b.i.d up-titration period of 50 mg,100 mg, 150 mg and 200 mg , followed by 12 weeks AFQ056 200 mg fixed dose\* and then a 3 week down-titration of 100 mg, 50 mg and 25 mg AFQ056 b.i.d)~\*patients that do not tolerate 200 mg b.i.d may be down-titrated to 150 mg b.i.d."
62580441|NCT02653118||Cohort 2: GARDASIL in the Base Study|Participants received GARDASIL (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543) and were offered the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) at the conclusion of the base study. V503 vaccination was voluntary and not a condition for inclusion in Cohort 2. No study vaccination will be administered in study V503-021.
62580442|NCT02196571|EXPERIMENTAL|Exercise and lifestyle change|Women in the experimental group will be included in structured exercise programme two times per week with duration of 50 minutes.Participants will start with training sessions right after they are diagnosed with GDM and they will exercise until the end of the pregnancy or occurence of contraindications. Programme will consist of aerobic exercises (20 minutes), resistance exercises (20 minutes), plevic floor, stretching and relaxation exercises (10 minutes). Women in control group will receive standard antenatal care.
62204420|NCT06398886|EXPERIMENTAL|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy (CBT) intervention for prolonged grief was carefully structured into an 8-session manualized program, tailored to address the multifaceted nature of grief among university students. Initially, participants were introduced to the CBT model of grief, focusing on understanding the relationship between thoughts, feelings, and behaviors in the context of their loss. Key components included identifying and challenging maladaptive thoughts related to the loss, employing gradual exposure to avoided situations, and developing coping strategies for managing intense emotions and fostering resilience. Special emphasis was placed on rebuilding meaningful life activities and social connections, acknowledging the loss while encouraging engagement with life's ongoing demands.
62204421|NCT00571467|EXPERIMENTAL|PRTX-100 (Staphylococcal protein A)|"Cohort 1: 0.075 mcg/kg~Cohort 2: 0.15 mcg/kg~Cohort 3: 0.30 mcg/kg"
62204422|NCT04637269|EXPERIMENTAL|BCMA CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage."
62204423|NCT03225690|PLACEBO_COMPARATOR|serum physiologic|2 ml serum physiologic will apply via epidural catheter before surgical incision.
62204424|NCT03225690|ACTIVE_COMPARATOR|Preemptive Morphine|1 mg morphine will apply via epidural catheter before surgical incision.
62204425|NCT03225690|ACTIVE_COMPARATOR|Morphine|1 mg morphine will apply via epidural catheter before at the time point of the peritoneum closed.
62204426|NCT01962532|EXPERIMENTAL|Part 1: Dose Escalation (Daily Dosing)|Dose escalation of JNJ-42756493 is to occur until a dose at which \<33 percent of participants experience a dose-limiting toxicity, the maximum concentration of JNJ-42756493 is less than the protocol-defined cardiovascular threshold, and JNJ-42756493 is biologically active. Participants will receive study drug once day on Day 1 of Cycle 1 followed by a 2-day drug-free period (Days 2 and 3 of Cycle 1) and continues throughout the 21 day cycle. For all subsequent cycles once a day for 21 days.
62204427|NCT01962532|EXPERIMENTAL|Part 1: Dose Escalation (Intermittent Dosing)|Intermitting dosing regimen will be 28 days (7 days on and 7 days off). Participants will receive JNJ-42756493 on Days 1 to 7 and Days 15 to 21 of each cycle; JNJ-42756493 will not be administered on Days 8 to 14 and Days 22 to 28 of each cycle.
62404205|NCT05466916|EXPERIMENTAL|Exercise and diet education and instruction|The intervention will be 12 weeks in duration. The five intervention components (e.g., educational sessions and instructional sessions) will be supervised. Research staff will conduct the intervention. Participants will be instructed to gradually aim for 30 minutes of physical activity for five days per week by Week 12 Participants will also aim for improved healthy dietary practices including \> 200 grams/day (g/d) of fruits and vegetables, \> 15 g/d of fiber (whole grains and beans), \< 250 g/d of sugar-sweetened drinks and lower percent of total kcal from fast foods18 by Week 12. Sessions will be about 35- to 50-minutes in duration and be structured as follows: (a) review of previous session and an opportunity to ask questions (\~5 minutes); (b) presentation of content (20- to 30-minutes); (c) opportunity for questions (\~5 minutes); and (d) preview of next sessions and research activity reminders (2- to 3-minutes).
62404206|NCT00151775|EXPERIMENTAL|Period 2|"For Cohorts A and B, olmesartan medoxomil suspension 2.5 mg to 40 mg in patients 6-16 years old, depending on weight.~For Cohort C, olmesartan medoxomil suspension 0.3 mg/kg to in patients 1-5 years old."
62580443|NCT02196571|NO_INTERVENTION|Control|Standard antenatal care
62580444|NCT06682468|EXPERIMENTAL|Patient portal population level substance involvement risk screener|Participants randomized to this group will receive a National Institute on Drug Abuse (NIDA) Quick Screen V1.0 substance involvement screener over the patient portal regardless of having a scheduled appointment with their HIV clinician. If they do not complete the screener via the portal, they will be screened at HIV clinic appointments.
62580445|NCT06682468|OTHER|Usual Care SUD Screening|Participants randomized to this intervention will receive the NIDA Quick Screen V1.0 if they attend their scheduled appointment with their HIV clinician.
62580446|NCT00638222|ACTIVE_COMPARATOR|All Study Participants|All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
62580447|NCT06420466|EXPERIMENTAL|Time-restricted Feeding group|Controlling the eating time to 6 hours per day, but not being prescriptive about the quantity and content of dietary intake.
62404207|NCT00151775|EXPERIMENTAL|Period 3|Cohorts A, B, C - olmesartan medoxomil suspension or placebo taken once daily. Olmesartan medoxomil dose continued as in previous period.
62580448|NCT06420466|NO_INTERVENTION|Control group|
62204428|NCT01962532|EXPERIMENTAL|Part 2: Dose Expansion|Participants will receive the recommended Phase 2 JNJ-42756493 dose determined in Part 1 as Intermitting dosing regimen (28 days, 7 days on and 7 days off). Participants who are tolerating study drug treatment and achieve clinical responses or stable disease will continue to receive study drug at the same dose until disease progression, unacceptable toxicity, or withdrawal of consent.
62215183|NCT06429644||Hallym University Sacred Heart Hospital|Department of Breast \& Endocrine Surgery, Hallym University Sacred Heart Hospital, Hallym University, Anyang, Republic of Korea
62404208|NCT00151775|EXPERIMENTAL|Period 4|"Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg"
62404209|NCT04120116|EXPERIMENTAL|FX-322 Single Dose, Placebo Three Doses|Four intratympanic injections of a hydrogel formulation, FX-322 Single Dose, Placebo Three Doses.
62404210|NCT04120116|EXPERIMENTAL|FX-322 Two Doses, Placebo Two Doses|Four intratympanic injections of a hydrogel formulation, FX-322 Two Doses, Placebo Two Doses.
62404211|NCT04120116|EXPERIMENTAL|FX-322 Four Doses|Four intratympanic injections of a hydrogel formulation, FX-322 Four Doses.
62787486|NCT03225378||Acute circulatory failure|Mechanically ventilated patients displaying acute circulatory failure in whom the physician decides to perform a fluid challenge (fluid loading of 500 mL of crystalloid solution) and a passive leg raising test to predict fluid responsiveness.
62787487|NCT04188704|PLACEBO_COMPARATOR|Anterior cruciate ligament normal|normal Anterior cruciate ligament reconstruction
62787488|NCT04188704|EXPERIMENTAL|Anterior cruciate ligament reconstruction|Anterior cruciate ligament reconstruction and Position screw fixation
62404212|NCT04120116|PLACEBO_COMPARATOR|Placebo Four Doses|Four intratympanic injections of a hydrogel formulation, Placebo Four Doses.
62787489|NCT00004050|EXPERIMENTAL|Leuvectin|2 intratumoral injections of 1000 ug of Leuvectin
62580449|NCT02868814|EXPERIMENTAL|330mg/day|330 mg QD taken orally,1 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
62580450|NCT02868814|EXPERIMENTAL|495mg/day|495 mg QD taken orally,2 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
62787490|NCT03226925|EXPERIMENTAL|Healthy volunteers on ventilation|Dynamic MRI acquisition will be performed at two different time points with 10 healthy volunteers under non-invasive mechanically-assisted ventilation with a respirator. Different modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
62787491|NCT03226925|EXPERIMENTAL|Cancer patients on ventilation|Dynamic MRI acquisition will be performed at two different time points with 10 patients (intended for a radiation treatment of their thoracic or upper abdominal tumours) under non-invasive mechanically-assisted ventilation with a respirator. Different modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
62787492|NCT03226925|EXPERIMENTAL|Planning with patients on ventilation|Planning 4D-CT will be performed with 10 patients (intended for a radiation treatment of their thoracic or upper abdominal tumours) under non-invasive mechanically-assisted ventilation with a respirator. Different ventilation modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
62787493|NCT00738751|EXPERIMENTAL|Dose Escalation Followed by Expansion|Eligible participants were enrolled in a 3+3 dose-escalation design to determine the maximum tolerated dose (MTD) of twice weekly panobinostat plus daily erlotinib at 4 planned dose levels (DLs).
62787494|NCT04503018||Interviewed -implant loss|Patients who have had immediate breast reconstruction and lost the implant due to for example infection.
62015511|NCT01813019|PLACEBO_COMPARATOR|Placebo|Following baseline, approximately 60 patients who are considered eligible will be randomized to Placebo arm and will receive the dosing regimen of 4 weeks Placebo b.i.d up-titration period of 50 mg,100 mg, 150 mg and 200 mg , followed by 12 weeks Placebo 200 mg fixed dose\* and then a 3 week down-titration of 100 mg, 50 mg and 25 mg Placebo b.i.d) \*patients that do not tolerate 200 matching placebo AFQ056 mg b.i.d may be down-titrated to 150 mg b.i.d.
62015512|NCT03598998|EXPERIMENTAL|Treatment (pralatrexate and pembrolizumab)|Patients receive pralatrexate IV over 3-5 minutes on days 1 and 8 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
62015513|NCT05141682|EXPERIMENTAL|Treatment (Oral Azacitidne)|Patients will receive CC-486 orally (PO) D1-14 of a 28-day cycle, in a similar fashion to the QUAZAR study for a minimum of 4 cycles. Patients that achieve a response (CR or PR) will remain on study for a maximum of 12 months. Patients without a response at 4 months will come off the study.
62015514|NCT05841017|EXPERIMENTAL|Intervention group|The intervention group will participate in a psychoeducational group (1) and in individual psychological intervention based in Cognitive Behavioural Therapy (2).
62015515|NCT05841017|NO_INTERVENTION|Control group|Usual clinic care.
62015516|NCT04013451|EXPERIMENTAL|Intervention Group|Participants allocated to the intervention group will participate in the intervention (acts of kindness).
62015517|NCT04013451|NO_INTERVENTION|Control Group|Participants allocated to the control group will not participate in the intervention and will act as the comparison condition.
62015518|NCT02376413||Traditional BCS|Breast-conserving surgery. Modified radical mastectomy.
62015519|NCT02376413||Oncoplastic-BCS|"Breast-conserving surgery. Modified radical mastectomy. Oncoplastic-BCS based on surgeon preference and/or tumor location.~* Superior pedicle mammoplasty / inverted T~* Superior pedicle mammoplasty / V scar~* Batwing~* Inferior pedicle mammoplasty~* Racquet mammoplasty/radial scar~* vertical-scar mammoplasty"
62015520|NCT06535009|EXPERIMENTAL|ONO-7914|
62015521|NCT06535009|EXPERIMENTAL|ONO-7914+ONO-4538|
62015522|NCT01022034|ACTIVE_COMPARATOR|Pexy group|This group of patients with full thickness rectal prolapse will receive standard sacral rectopexy with mesh or sutures
62015523|NCT01022034|SHAM_COMPARATOR|Non-pexy group|These patients will receive full rectal mobilization from the sacrum but without rectopexy
62015524|NCT02671123|ACTIVE_COMPARATOR|Coronary PCI with OCT with Co-Registration|Coronary stenting will be performed with OCT guidance as per local practice. Pre and post stenting procedure will be performed with OCT guidance with the use of the Co-Registration software tool after stent implanted.
62015525|NCT02671123|PLACEBO_COMPARATOR|Coronary PCI with OCT without Co-Registration|"Coronary stenting will be performed with OCT guidance as per local practice. Pre and post stenting procedure will be performed with OCT guidance without the use of the Co-Registration software tool after stent implanted.~I"
62015526|NCT04273100|EXPERIMENTAL|Treatment group|The participants will receive the combined treatment of immunotherapy (PD-1 monoclonal antibody), local therapy (TACE, lobaplatin and epirubicin and anti-angiogenic therapy (lenvatinib)
62204429|NCT00293059|EXPERIMENTAL|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|A blister card consists of 28 pills taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo
62204430|NCT00293059|PLACEBO_COMPARATOR|Placebo|Matching placebo to be taken orally daily
62404213|NCT00235300|ACTIVE_COMPARATOR|1 Control|Simulect (basiliximab)
62404214|NCT00235300|EXPERIMENTAL|2|Thymoglobulin (anti-thymocyte globulin (rabbit))
62204431|NCT04076943|EXPERIMENTAL|Roxadustat|Participants will receive roxadustat as an oral tablet, 3 times per week (TIW) for up to a maximum of 16 weeks.
62404215|NCT06324968|EXPERIMENTAL|Sjögren's disease|SSp patients followed by the Internal Medicine Department of Nice University Hospital will be offered participation in this study as part of their usual follow-up.
62404216|NCT06324968|NO_INTERVENTION|Control|Control subjects will be recruited from the nursing staff of Nice University Hospital on a voluntary basis.
62404217|NCT05354349|EXPERIMENTAL|PRA023 SC/Placebo IV|Participants randomized to receive active subcutaneous injection/placebo intravenous infusion
62204432|NCT01428375|ACTIVE_COMPARATOR|(1) Active (Paracetamol) arm: n=60|(Paracetamol)
62404218|NCT05354349|ACTIVE_COMPARATOR|Placebo SC/PRA023 IV Low Dose|Participants randomized to receive placebo subcutaneous injection/active intravenous infusion
62404219|NCT05354349|PLACEBO_COMPARATOR|Placebo SC/Placebo IV|Participants randomized to receive placebo subcutaneous injection/placebo intravenous infusion
62404220|NCT05354349|EXPERIMENTAL|Placebo SC/PRA023 IV High Dose|
62404221|NCT06465160|EXPERIMENTAL|Autologous CD34+ cells enriched with allogenic placenta-derived mitochondria|Participants will receive a single dose of MNV-201 product by Infusion after 5 days of mobilization by G-CSF and an apheresis procedure.
62404222|NCT02983305|EXPERIMENTAL|Retinal Dystrophy|Subjects with retinal dystrophy will have their visual field, gait and self-reported mobility tested at baseline. Subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.
62787495|NCT04503018||Questionnaires - implant loss|Patients who have had immediate breast reconstruction and lost the implant due to for example infection.
62787496|NCT04503018||Questionnaires - controls|Patients who have had immediate breast reconstruction without complications
62787497|NCT03003403|EXPERIMENTAL|Intervention Program|Balance Intervention Program: Participants randomly assigned to the 12-month digital health behavioral intervention will receive: tailored behavior change goals with interactive self-monitoring and feedback; network-connected scales to track their weight; skills training materials; and stepped coaching (via phone and/or text) from Registered Dieticians serving as health coaches within a local network of community health centers.
62787498|NCT03003403|NO_INTERVENTION|Usual Care Program|Balance Usual Care Program: Participants randomly assigned to the Usual Care program will receive the standard primary care offered by their providers; health information/skills training materials to maintain a healthy weight; and automated (non-tailored) text messages with health information.
62404223|NCT02983305|EXPERIMENTAL|Healthy Age-Matched Controls|Age-matched control subjects without eye disease will have their visual field, gait and self-reported mobility tested at baseline. Control subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.
62787499|NCT05495867|EXPERIMENTAL|NINA- MultiNeO NH|implant with bioactive surface
61978485|NCT04151667|EXPERIMENTAL|C: Daratumumab, Dexamethasone and Bortezomib|Participants who have less than a partial response to Arm A may have Bortezomib added to their treatment. Bortezomib will be given weekly in subcutaneous injections at a starting dose of 1/3 mg/m\^2 Days 1,8 and 15 of each 28 day treatment cycle.
62015527|NCT06572540|ACTIVE_COMPARATOR|Transthoracic cryoablation|Subjects will undergo CT-guided cryoablation. According to the location of the lesion on the chest CT scan, the puncture point, direction of needle entry, and distance of needle entry will be determined. The primary cryoablation needle (via the chest wall) will be punctured into the lesion according to the pre-planed path, and the CT will confirm the correct position. One or more needles will rationally distributed in the lesion for ablation according to the morphology of the lesion.
62015528|NCT06572540|EXPERIMENTAL|Transbronchial cryoablation|Subjects will undergo bronchoscopically guided cryoablation. Appropriate guided bronchoscopic technique will be uesd. Cryoablation needle (flexible) will insert through the working channel of the bronchoscope to the target lesion, CBCT will be used to confirm the correct position and observe the ablation zone.
61978486|NCT00524368|EXPERIMENTAL|DRV/rtv 800/100 mg once daily|Two 400 mg darunavir (DRV) ie, TMC114 tablets + one 100 mg ritonavir (rtv) capsule once daily.
61978487|NCT00524368|EXPERIMENTAL|DRV/rtv 600/100 mg twice daily|One 600 mg TMC114 tablet + one 100 mg capsule of rtv twice daily.
61978488|NCT04830020|ACTIVE_COMPARATOR|HMW-HA|HMW-HA (Yabro - 5 ml of saline containing 0.3% hyaluronic acid sodium salt)
62204433|NCT01428375|PLACEBO_COMPARATOR|(2) Placbo (Sterile water) arm: n=60|Sterile water
62204434|NCT02590900||at delivery|women who underwent cesarean at delivery, and needed iv paracetamol as part of multimodal analgesia. In these cases, paracetamol was administered q6h (2g loading dose, 1g q6h for 24 h), and blood and urine samples were collected to describe paracetamol disposition at delivery.
62204435|NCT02590900||postpartum|a subgroup of 8 women initially included in at delivery, underwent a second PK study 2-3 months postpartum and another PK study about 1 year after delivery. This PK study was based on a single iv paracetamol administration (2 g), and blood and urine samples were collected to describe paracetamol disposition in postpartum
62204436|NCT02590900||healthy female volunteers|"a group of 8 young healthy women not on oral contraceptives underwent a single PK study (2 g intravenous paracetamol) and blood and urine samples were collected to described paracetamol disposition in healthy female volunteers, not on oral contraceptives.~Raw data as published by Gregoire et al (Clin Pharm Ther 2007) were available in 14 young women, all on contraceptives."
62204437|NCT03704675|EXPERIMENTAL|Group I (Fasted->Fed)|Group 1 received a single oral dose in a fasting condition in Period 1, followed by a single oral dose after a high-fat diet in Period 2
62404224|NCT03827031|NO_INTERVENTION|Control group|
62404225|NCT03827031|EXPERIMENTAL|B1 interventional group|
62404226|NCT03827031|EXPERIMENTAL|B2 interventional group|
62404227|NCT04780126||COVID-19 pneumonia patients|Patients over 18 years of age who are admitted to the hospital and whose main diagnosis and reason for staying is COVID-19 pneumonia will be included.
62580451|NCT02868814|PLACEBO_COMPARATOR|Placebo|1 or 2 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
62787500|NCT05495867|ACTIVE_COMPARATOR|MultiNeO CS|implant with traditional surface
62204438|NCT03704675|EXPERIMENTAL|Group II(Fed->Fasted)|Group 2 received a single oral dose after a high-fat diet in Period 1, followed by a single oral in a fasting condition in Period 2
62204439|NCT05861245|EXPERIMENTAL|Skull base chordomas and chondrosarcomas|"* Patients \> 18 years old.~* With a baseline classification on the Karnofsky performance status scale ≥ 70%.~* With confirmed histological diagnosis of chordoma or chondrosarcoma of the skull base.~* With a maximum tumor size of 50 cc.~* Whose relationship to organs at risk (OARs) allows compliance with the necessary dose restrictions to receive hypofractionated proton therapy in 5 fractions.~Patients included in the study must meet dosimetric parameters that include:~* Clinical Target Volume (CTV) coverage of at least D95\>90%.~* Correct compliance with the dose restrictions, at least in the nominal scenario, for critical organs (optic pathway, brain stem and spinal cord) according to the guidelines published and available in the literature."
62204440|NCT01667094|ACTIVE_COMPARATOR|Intermittent, short infusion|"Infusion over 30 minutes of either:~Cefepime 1g q8/24 OR Ceftazidime 2g q8/24 OR Meropenem 1g q8/24 OR Piperacillin-Tazobactam 4.5g q8/24 OR Ticarcillin-clavulanate 3.1g q6/24~Antibiotic chosen by treating physician"
62204441|NCT01667094|EXPERIMENTAL|Continuous infusion|"Continuous infusion of either:~Cefepime 1.5g over 12h, q12/24 after initial loading dose of 500mg OR Ceftazidime 3g over 12h, q12/24 after initial loading dose 1g OR Meropenem 1.5g over 12h, q12/24 after initial loading dose 500mg OR Piperacillin-tazobactam 13.5g over 24h after initial loading dose 2.25g OR Ticarcillin-clavulanate 12.4g over 24h after initial loading dose 1.55g~Antibiotic chosen by treating physician"
62404228|NCT00781482|EXPERIMENTAL|1|This is a crossover study. Each study drug will be administered (one at a time and in random order) to each subject on separate occasions over the course of the study.
62015529|NCT03120650|EXPERIMENTAL|Scalp acupuncture|number:58 The needle will be maintained in place for 30 minutes. Patients in both groups will receive rehabilitation five times per week (Monday through Friday) for 8 consecutive weeks.
62404229|NCT04429776|EXPERIMENTAL|Feedback Arm|Trough blood samples taken and analysed at baseline, 6m and 12m. Results fed back to recruiting clinical team who can choose to use these to influence their tapering decisions.
62580452|NCT03617614||Collaborative Care Model|Participants who received care from the Medical Psychiatry Alliance Seniors Outpatient Collaborative Care Program at Trillium Health Partners.
62787501|NCT05456620|EXPERIMENTAL|Low Tendon Compression Rehabilitation (LTCR)|A progressive, criteria-based, 4-stage exercise protocol in which the amount of tendon compression is limited (12 weeks).
62787502|NCT05456620|ACTIVE_COMPARATOR|High Tendon Compression Rehabilitation (HTCR)|A progressive, criteria-based, 4-stage exercise protocol in which the amount of tendon compression is not limited (12 weeks).
62787503|NCT03893500|EXPERIMENTAL|Initiating a new PAH medication|Participants will start a new PAH medication
62015530|NCT03120650|ACTIVE_COMPARATOR|Conventional rehabilitation|number:58 Rehabilitation will be conducted for 1 hour five times per week (Monday through Friday) for 8 weeks.
62204442|NCT01190059|EXPERIMENTAL|EVLP Group|EVLP Group are those recipient lung transplant patients that received donor lungs that had been placed on the ex vivo lung perfusion system with Steen Solution™ .
62204443|NCT04204746||3 lt/min|Patients in the study were divided into two main groups according to the standard fresh gas flow administered (3-6 L/min). Each main group was then divided into subgroups as follows: sevoflurane + remifentanil, desflurane + remifentanil, or propofol + remifentanil (TIVA). These six groups were further divided into two groups according to use or non-use of a heat and moisture exchanger (HME) filter.
62204444|NCT04204746||6 lt/min|Patients in the study were divided into two main groups according to the standard fresh gas flow administered (3-6 L/min). Each main group was then divided into subgroups as follows: sevoflurane + remifentanil, desflurane + remifentanil, or propofol + remifentanil (TIVA). These six groups were further divided into two groups according to use or non-use of a heat and moisture exchanger (HME) filter.
62204445|NCT04403087|EXPERIMENTAL|Trimebutine add group|Addition of Trimebutine on the Bismuth-containing quadruple regimen
62204446|NCT04403087|NO_INTERVENTION|Control group|Bismuth-containing quadruple regimen
62204447|NCT01491724||pCLE images|
62404230|NCT04429776|ACTIVE_COMPARATOR|No Feedback Arm|Trough blood samples taken and analysed at baseline, 6m and 12m. Results not fed back to recruiting clinical team.
62787504|NCT03893500|ACTIVE_COMPARATOR|Continuing previous PAH medication regimen|Participants will continue the medication regimen that they were on prior to enrollment
62787505|NCT06337812|EXPERIMENTAL|Potato starch supplement|Participants will take the supplement for approximately 4 weeks.
62787506|NCT03683953|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride intratracheal instillate on 14 days after birth
62015531|NCT04151862|ACTIVE_COMPARATOR|tight eye bandage|Both eyes will be operated at two separate sessions. In the first session the first 25 patients will be bandaged postoperatively with tight eye bandage patching.
62015532|NCT04151862|ACTIVE_COMPARATOR|therapeutic contact lenses (TCL)|Both eyes will be operated at two separate sessions. In the second session the 25 patients will be bandaged postoperatively with therapeutic contact lenses (TCL).
62580453|NCT03617614||Mood Consult|Participants who received a one time mood consultation at the Centre for Addiction and Mental Health.
62787507|NCT03683953|EXPERIMENTAL|mesenchymal stem cells|mesenchymal stem cells intratracheal instillate on 14 days after birth ,dose is 25 million cells/kg
62787508|NCT01121432||Mediastinal lymphadenopathy|
62787509|NCT05014191||Radiation therapy in frog leg position|
62787510|NCT05014191||Radiation therapy in straight leg position|
62787511|NCT02806960|EXPERIMENTAL|Treatment 1|Treatment 1, single nasal glucagon (NG) dose of 3 milligram (mg).
62787512|NCT02806960|EXPERIMENTAL|Treatment 2|Treatment 2, NG dose of 3 mg plus 3 mg NG dose in same nostril 15 minutes later.
62787513|NCT02806960|EXPERIMENTAL|Treatment 3|Treatment 3, NG dose of 3 mg plus 3 mg NG dose in the opposite nostril 15 minutes later.
62787514|NCT02806960|EXPERIMENTAL|Treatment 4|Treatment 4, NG dose of 3 mg then immediately 3 mg NG dose in the opposite nostril.
62787515|NCT03818451|NO_INTERVENTION|Control Group|"All patients are treated by standard treatments according to patterns of severity and in the light of different variables, mainly represented by the conditions of cerebral hemodynamics. These procedures can be summarized as follows:~* Surgical evacuation of hemorrhagic masses and brain contusion~* Medical management aimed to maintenance of euvolemia and adequate brain perfusion. Prevention of secondary complications of critical illness included: preventive treatment of venous thromboembolism (VTE) and seizures~* Patient who undergo surgical treatment, will recieve also postoperative intensive care treatments including: position of the head high, lower values of end-tidal CO2, sedation with reduced metabolic consumption of O2, increase in plasma osmolarity by administration of mannitol in controlled doses or hypernatremia, therapeutic CSF drainage"
62787516|NCT03818451|EXPERIMENTAL|Study Group|Standard treatment plus specific treatment. The investigational agent, the co-ultraPEALut, is administered orally twice daily (every 12 h) for 180 days in association with the specific therapy (e.g., antiplatelet agents, anticoagulants, antiepileptic drugs) commonly administered to these patients and/or with drugs prescribed for comorbidities (i.e. diabetes, arterial hypertension).
62204448|NCT05455034|EXPERIMENTAL|Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis|Single-cell Sequencing of BLF is detected before treatment, and then patients will receive the treatment of Radiation Pneumonitis according to the result.
62204449|NCT05455034|EXPERIMENTAL|Single-cell Sequencing of BLF to Guide the Treatment of Immune Checkpoint Inhibitor Pneumonitis|Single-cell Sequencing of BLF is detected before treatment, and then patients will receive the treatment of Immune Checkpoint Inhibitor Pneumonitis according to the result.
62204450|NCT04651478|EXPERIMENTAL|Action Observation+Motor Imagery through BCI|"Action Observation+Motor Imagery through a Brain-Computer Interface training paradigm in Virtual Reality using the NeuRow platform during 10 sessions of 20 minutes, divided in 4 series of 5 minutes."
62204451|NCT04651478|PLACEBO_COMPARATOR|Action Observation through non-related with movement illustrations|Control Action Observation protocol of non-related with movement illustrations during 10 sessions of 20 minutes, divided in 4 series of 5 minutes.
62204452|NCT03610347|EXPERIMENTAL|Bare metal Stent plus Paclitaxel Balloon|Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux®)
62204453|NCT03610347|ACTIVE_COMPARATOR|Drug-Eluting Stent (DES)|Sirolimus Eluting Stent (Orsiro®)
62204454|NCT01232738|EXPERIMENTAL|rasagiline|Treated for 12 months with rasagiline 2mg orally, once daily.
62204455|NCT03532659|EXPERIMENTAL|Active video game|The adolescents will be submitted to physical activity with active video game for 50 minutes, 3 times a week, for a period of eight weeks. The XBOX360® platform will be used with the Kinect accessory (Microsoft®) and Just Dance will be the selected game. The music used for intervention will be previously selected, including those that can lead to moderate intensity, and assembled in blocks of 10. For each week, a new block and challenges must be elaborated to increase the motivation to carry out the physical activity.
62580454|NCT05673577|EXPERIMENTAL|Camrelizumab+cetuximab+chemotherapy|"Camrelizumab: 200mg vgtt q3w, 3 weeks as a cycle; Cetuximab first dose 400mg/m2, vgtt, following by 250 mg/m2 after first dose, qw, 3 weeks as a cycle; albumin paclitaxel: 125mg/m2, vgtt, d1, 8, q3w，for up to 6 cycles; cisplatin: 75mg/m2, vgtt，d1，q3w, for up to 6 cycles;~Then, in maintenance therapy, Camrelizumab: 200mg vgtt q2w; Cetuximab 500mg/m2, vgtt q2w until intolerable toxicity or disease progression"
62015533|NCT03147105|EXPERIMENTAL|arm ergometry|Home-based treatment after education in center, training following interval training plan on chip cards for 12 weeks at least 4-5 times/week
62204456|NCT03532659|NO_INTERVENTION|control|A follow-up will be done for eight weeks to compare the variables. The adolescents in this group will be interviewed monthly to detect changes in eating habits and lifestyle.
62204457|NCT02243670|EXPERIMENTAL|AiCure monitoring and intervention|Participants will use the AiCure app to monitor ingestion of all prescribed doses of Zubsolv®.
62215184|NCT06429644||Kangbuk Samsung Hospital|Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
62580455|NCT00911612|EXPERIMENTAL|Colesevelam|Participants received colesevelam 1.875 g twice daily
62580456|NCT00911612|PLACEBO_COMPARATOR|Placebo|Participants received an inert capsule matching the study drug twice daily, as prepared by the Mayo Clinic research pharmacy
62787517|NCT05429398|EXPERIMENTAL|Linperlisib +Camrelizumab 200mgQ3w|Linperlisib will be administrated orally from 40mgQD, 60mgQD to 80mgQD in sequence during dose excalation part and a selected dose in dose expansion part,for 21 consecutive days as a treatment cycle; Camrelizumab will be administrated intravenously 200mg every 3 weeks in all patients just before the administration of Linperlisib.
62787518|NCT06104111|EXPERIMENTAL|Vitamin D3 (cholecalciferol)|1000 IU vitamin D3 (cholecalciferol)/kg body mass will be taken in form of individual number of pills (4000 IU each, e.g. 20 pills for a person of 80 kg) in the morning together with a breakfast at days 0, 28 and 56
62787519|NCT03384641|EXPERIMENTAL|Bedaquiline|Participants will receive bedaquiline 200 (milligram) mg (2\*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet three times a week (tiw) for 6 weeks with at least 48 hours between doses.
62787520|NCT05492864|EXPERIMENTAL|open bite with extrusion arch|single arm study, measures will be recorded before and after
62787521|NCT04016259|EXPERIMENTAL|Self-CES|
62787522|NCT04016259|PLACEBO_COMPARATOR|Sham-CES|
62787523|NCT05487911|EXPERIMENTAL|rTMS|20 sessions of rTMS
62787524|NCT01090440|EXPERIMENTAL|Three-way cross- over|Three regimens will be administered in this study: A: GSK1144814 Tablet (100mg) Fasted State; B: GSK1144814 Tablet (200mg) Fasted State and C: GSK 1144814 Tablet (100mg) Fed State (FDA high fat breakfast).
62787525|NCT00934128|EXPERIMENTAL|Group 1: BiPAP then Vapotherm|Bilevel positive airway pressure device (BiPAP) then Vapotherm air delivery.
62787526|NCT00934128|EXPERIMENTAL|Group 2: Vapotherm then BiPAP|Vapotherm air delivery then BiPAP.
62204458|NCT03971591|EXPERIMENTAL|Immediate Lifestyle program|The Intervention will be conducted in cohorts of 15-20. We anticipate there will be 5-6 cohorts over the course of the study. Men assigned to the Guided Lifestyle Program will participate in twice weekly sessions - the first weekly session will be 120 minutes in length with the first hour addressing lifestyle change education and strategies, the second hour will be supervised exercise with strength training. The second weekly session will be a one-hour supervised exercise session with strength training. Men will also receive 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
62015534|NCT03147105|ACTIVE_COMPARATOR|waiting group|training after 12 weeks.
62204459|NCT03971591|OTHER|Waitlist Control|In the waitlist control arm, the men will not receive any intervention for 16-weeks. After the 16-week assessment, men randomized to this arm will crossover to the intervention arm.
62204460|NCT05324683||Study population (cohort)|No study arms; one patient population will be observed.
62204461|NCT04594044|EXPERIMENTAL|Individual HRT and ERP|Individual treatment with habit reversal training (HRT) and exposure response prevention (ERP) according to a protocol
62204462|NCT04594044|EXPERIMENTAL|Group HRT and ERP|Group treatment with habit reversal training (HRT) and exposure response prevention (ERP) according to a protocol
62204463|NCT00768170|EXPERIMENTAL|1|MK0633
62204464|NCT03591653|EXPERIMENTAL|LXI-15028 50mg group|
62204465|NCT03591653|PLACEBO_COMPARATOR|Placebo group|
62204466|NCT01201577|ACTIVE_COMPARATOR|Placebo/Probiotic|
62204467|NCT01201577|ACTIVE_COMPARATOR|Placebo/Prebiotic|
62580457|NCT04388475|EXPERIMENTAL|All patients|All patients enrolled in this study
62580458|NCT01849081|EXPERIMENTAL|CPAP|Subjects in this arm with receive treatment with CPAP for fatty liver disease.
62580459|NCT01849081|ACTIVE_COMPARATOR|Lifestyle Intervention|Subjects in the lifestyle arm will undergo 12 weeks of dietary counseling.
62580460|NCT02610543|EXPERIMENTAL|UCB5857|UCB5857 once daily for 12 weeks
62580461|NCT02610543|PLACEBO_COMPARATOR|Placebo|Placebo once daily for 12 weeks
62787527|NCT01247194|ACTIVE_COMPARATOR|Cohort A|"PPI-461 50 mg~or placebo"
62015535|NCT05212636|EXPERIMENTAL|MDD patient with HRSD score of at least 18|MDD patients who meet the DSM-5 diagnostic criteria of MDD and their current episode show a 17-Item Hamilton Rating Scale for Depression (HRSD) score of at least 18
62204468|NCT01201577|ACTIVE_COMPARATOR|Prebiotic/Probiotic|
62204469|NCT01201577|PLACEBO_COMPARATOR|Placebo/Placebo|
62204470|NCT01943175||Genetic High Risk|
62204471|NCT01943175||Healthy Control|
62204472|NCT03916458||Subjects with reported metastatic renal cell carcinoma|The subjects have been treatment with sunitinib and they reached complete remission
62580462|NCT06006533|EXPERIMENTAL|kinesio taping|kinesio taping Technique: It is used to provide support to the joint range of motion and tissues. It has a wide range of uses for purposes such as correcting functional disorders, healing, protecting, reducing pain and inflammation. There are differences in cutting shapes according to the applied area and the target to be achieved.
62787528|NCT01247194|ACTIVE_COMPARATOR|Cohort B|"PPI-461 100 mg~or placebo"
62787529|NCT01247194|ACTIVE_COMPARATOR|Cohort C|"PPI-461 200 mg~or placebo"
62787530|NCT01504685|ACTIVE_COMPARATOR|Unbanded laparoscopic gastric bypass|Laparoscopic Roux- en-Y gastric bypass without any band around de gastric reservoir
62787531|NCT01504685|ACTIVE_COMPARATOR|Banded laparoscopic gastric bypass|Placement of a premeasured band or ring around the gastric reservoir, adjacent to the gastroenterostomy.
62787532|NCT01769196|EXPERIMENTAL|Simtuzumab|Participants will receive simtuzumab for up to 254 weeks.
62787533|NCT01769196|PLACEBO_COMPARATOR|Simtuzumab Placebo|Participants will receive simtuzumab placebo for up to 254 weeks.
62204473|NCT02849613|EXPERIMENTAL|Adipose derived Stem Cells ADSC|ADSC, single IV, 1.106 cells/kg
62787534|NCT03306511||Case|Football players with a previous self-reported hamstring strain injury in the preceding 12 months
62787535|NCT03306511||Control|Football players without a previous self-reported hamstring strain injury in the preceding 12 months
62787536|NCT00385138|EXPERIMENTAL|Cangrelor|cangrelor bolus (30 mcg/kg) \& infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion
62787537|NCT00385138|ACTIVE_COMPARATOR|Clopidogrel|placebo bolus \& infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion
62787538|NCT05481489|EXPERIMENTAL|PRO-230|Healthy volunteers will apply one drop of PRO-230 ophthalmic solution (atropine sulphate) on both eyes, QD (one time per day) for 14 days.
62787539|NCT02684149|EXPERIMENTAL|A|Relational touch before the first arterial puncture and the second arterial puncture without relational touch
62787540|NCT02684149|EXPERIMENTAL|B|First arterial puncture without relational touch and relational touch before the second arterial puncture
62787541|NCT02000297|ACTIVE_COMPARATOR|Allogenic bone graft group|Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
62787542|NCT02000297|EXPERIMENTAL|Synthetic bone substitute (geneX®) group|Patients in this arm is treated with synthetic bone substitute(geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
62787543|NCT00866073|EXPERIMENTAL|A|Decitabine 15 mg/m2 i.v. - single arm
62787544|NCT03478033|ACTIVE_COMPARATOR|Rifampicin group|"Rifampicin group: Intensive treatment（4 types of anti-TB medicines）for 2 months, then isoniazid and rifampicin for 4 months of consolidation therapy.~isoniazid: 10-15mg/kg rifampicin: 10-20mg/kg pyrazinamide: 30-40mg/kg thambutol: 0.75(W\<50kg)；1.0 g/d（W≥50kg）"
62204474|NCT02849613|SHAM_COMPARATOR|Vehicle media|IV infusion of cell excipients, 1ml/kg
62204475|NCT06479031|NO_INTERVENTION|Control Group - Standard Protocol|"* Early Mobilization Protocol performed by the physiotherapy team twice a day. Institutional protocol for mechanical restraint to prevent physical restriction.~* Education for Family Members.~* Family member/companion present 24 hours a day with authorized visits at least twice a day.~* Minimum as possible sedation."
62787545|NCT03478033|EXPERIMENTAL|Rifabutin group|"Rifabutin group: Intensive treatment（4 types anti-TB medicines）for 2 months,then isoniazid and rifabutin for 4 months of consolidation therapy.~isoniazid: 10-15mg/kg rifabutin: 0.45g/d(W\<50kg); 0.6g/d( W≥50kg） pyrazinamide: 30-40mg/kg thambutol: 0.75(W\<50kg)；1.0 g/d（W≥50kg）"
62787546|NCT04683367|EXPERIMENTAL|clinical hernia|developing clinical hernia
62787547|NCT03209856|EXPERIMENTAL|Vitamin D supplement|This group will receive weekly oral 50000 international units of vitamin D supplement for 8 weeks before the start of ICSI cycle. In addition, the routine care will be given.
62787548|NCT03209856|NO_INTERVENTION|Routine care|This group will receive the routine care.
62787549|NCT01699165|SHAM_COMPARATOR|Placebo Nasal filter|Placebo treatment
62787550|NCT01699165|ACTIVE_COMPARATOR|Nasal Filter|Active treatment
62787551|NCT05355948|EXPERIMENTAL|MEMO Patch PLUS ECG monitoring for One-day|
62787552|NCT05355948|EXPERIMENTAL|MEMO Patch PLUS ECG monitoring for More than 8-days|
62787553|NCT01267942|EXPERIMENTAL|Intravenous intraoperative Enhancin|Patients received a dose of intravenous Enhancin at induction and only oral Paracetamol in the postoperative period.
62787554|NCT01267942|ACTIVE_COMPARATOR|Postoperative oral Enhancin.|Patients received postoperative oral Enhancin for five days in addition to oral Paracetamol for the same duration. They did not receive an antibiotic during the operation.
62015536|NCT03143244|ACTIVE_COMPARATOR|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
62787555|NCT00870987|EXPERIMENTAL|1|DNA vaccine prime Given at 0, 4, and 8 weeks
62787556|NCT00870987|EXPERIMENTAL|2|adenovirus type 5 vaccine boost Given at 24 weeks
62787557|NCT00313105|EXPERIMENTAL|Smokeless Tobacco|Smokeless Tobacco and individual visits
62787558|NCT00313105|ACTIVE_COMPARATOR|Nicotine tablets|Nicotine tablets
62787559|NCT00313105|PLACEBO_COMPARATOR|3|7-mg nicotine patch acts as placebo
62787560|NCT04348032|ACTIVE_COMPARATOR|PLD|PLD 40 mg/m2 D1 ivgtt q4w
62787561|NCT04348032|EXPERIMENTAL|PLD + Apatinib|PLD 40 mg/m2 D1 ivgtt q4w + Apatinib 250mg po qd
62787562|NCT05888987||Before|
62787563|NCT05888987||After|
62787564|NCT00225498|EXPERIMENTAL|1|ziprasidone
62787565|NCT00225498|ACTIVE_COMPARATOR|2|risperidone or olanzapine
62787566|NCT02902393||Success of revascularisation|
62787567|NCT02113033|EXPERIMENTAL|Treated with Equilia system|Implantation and activation of the Vagus Nerve Stimulator, nerve electrode and cardiac lead
62787568|NCT02241902||No pyuria|
62787569|NCT02241902||Persistent pyuria|
62787570|NCT03607955|EXPERIMENTAL|AVB-S6-500 + Paclitaxel + Carboplatin|"* Paclitaxel will be given intravenously at a dose of 175 mg/m\^2 on an outpatient basis over 3 hours on Day 1 of each 21-day cycle~* Carboplatin will be given intravenously at a dose of AUC 6 over 30 minutes on Day 1 of each cycle of chemotherapy~* AVB-S6-500 will be given at doses based on the dose escalation schema~* The investigators will continue dosing AVB-S6-500 until 1 week prior to surgery and continuing after surgery. Maintenance dosing q2 weeks will begin with Cycle 7A/7B and be given every 2 weeks for 12 months through Cycle 19 (total of 13 maintenance cycles)."
62787571|NCT05618067|EXPERIMENTAL|Training|
62787572|NCT05504993||High comorbidity group|CCI equal or higher than 2 COTE equal or higher than 4 COMCOLD equal or higher than 4
62787573|NCT05504993||Low comorbidity group|CCI lower than 2 COTE lower than 4 COMCOLD lower than 4
62787574|NCT01393639|EXPERIMENTAL|PF-04171327 1 mg QD|
62787575|NCT01393639|EXPERIMENTAL|PF-04171327 5 mg QD|
62787576|NCT01393639|EXPERIMENTAL|PF-04171327 10 mg QD|
62204476|NCT06479031|EXPERIMENTAL|Intervention Group - Standard Protocol + Occupational Therapy|"1. \*Occupational Engagement\*: the occupational therapist will encourage the patient's participation in meaningful activities. Adaptations and resources may be utilized to facilitate occupational performance.~2. \*Cognitive Activities\*: Individualized and personalized cognitive activities will be conducted, based on the patient's preferences.~3. \*Environmental Enrichment\*: Installation of a clock and calendar within the patient's visual range on the wall."
62204477|NCT05150977||Idiopathic hypersomnia|Observation
62204478|NCT04263272|EXPERIMENTAL|Upper Body Exercise|Seated upper body circuit training program for 16-weeks. Frequency - 1 to 3 one-hour sessions per week.
62580463|NCT06006533|EXPERIMENTAL|percussive massage|Percussive Massage Technique: It is one of the instrument-assisted soft tissue mobilization techniques that emerged as a result of combining the effects of traditional massage and vibration therapy. With the mechanical oscillation effect that occurs in the Percussive Massage Technique, the muscle fiber is stimulated and an increase in reflex activity is observed.
62787577|NCT01393639|EXPERIMENTAL|PF-04171327 15 mg QD|
62787578|NCT01393639|ACTIVE_COMPARATOR|prednisone 5 mg QD|
62787579|NCT01393639|ACTIVE_COMPARATOR|prednisone 10 mg QD|
62787580|NCT01393639|PLACEBO_COMPARATOR|placebo|
62015537|NCT03143244|ACTIVE_COMPARATOR|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
62204479|NCT00685698|OTHER|Nemonoxacin|Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
62580464|NCT02986542|ACTIVE_COMPARATOR|USG with the in-plane technique|Intervention: Femoral artery catheterization under USG guidance with the in-plane technique.Patients will have their femoral arterial lines inserted under the guidance of USG. The ultrasound equipment used is LOGIQ e GE medical system(China) CO.LTD
62580465|NCT02986542|ACTIVE_COMPARATOR|USG with the out-of-plane technique|Intervention: Under USG guidance femoral artery catheterization will be done with the probe placed for the out-of-plane technique. The ultrasound equipment used is LOGIQ e GE medical system(China) CO.LTD
62787581|NCT04611087||Observational (focus group, interview)|"PHASE I: Participants attend 4 sessions of focus groups.~PHASE II: Participants attend virtual Zoom interviews or one-on-one interviews."
62787582|NCT04130672|OTHER|Hot saline irrigation|. After adenoidectomy, tonsil tampon at room temperature or 50 ° C was placed in the nasopharynx. Five minutes later, the tampon was removed, and 50 ° C saline irrigation was applied.
62787583|NCT04130672|OTHER|Cold saline irrigation|. After adenoidectomy, tonsil tampon at room temperature or 22 ° C was placed in the nasopharynx. Five minutes later, the tampon was removed, and 22 ° C saline irrigation was applied.
62787584|NCT05347706|EXPERIMENTAL|AAF-fed group|Amino Acid-Based Formula(NeocateⓇ; Nutricia, London, UK)
62787585|NCT05347706|EXPERIMENTAL|EHF-fed group|Extensively Hydrolyzed Formula(AlfareⓇ; Nestle, Netherlands)
61978489|NCT04830020|PLACEBO_COMPARATOR|placebo|5 ml of saline via nebulizer b.i.d.
62015538|NCT03143244|PLACEBO_COMPARATOR|Control group (Normal Saline) (C)|Patients received same volume of normal slaine in two sets.
62204480|NCT02600390|EXPERIMENTAL|SANGUINATE™ (4-week)|This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 4-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.
62404231|NCT03066466|EXPERIMENTAL|Arm A: Atorvastatin|The preventative atorvastatin treatment 40mg daily by mouth for GVHD will start at 14 days prior to transplant \& continue until 365 days post-transplant or if significant adverse events occur. Patients will also receive our standard of care for graft versus host disease prevention which consists of two drugs, Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate 5mg/metered square will be administered IV post-transplant on Days 1, 3 \& 6. Tacrolimus will be administered 2 days prior to transplant \& continue approximately 180 days post-transplant. Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth.
62404232|NCT03066466|ACTIVE_COMPARATOR|Arm B: Standard of Care|Patients will receive our standard of care for graft versus host disease prevention which consists of two drugs, Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate 5mg/metered square will be administered IV post-transplant on Days 1, 3 \& 6. Tacrolimus will be administered 2 days prior to transplant \& continue approximately 180 days post-transplant. Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth.
62404233|NCT01737203|ACTIVE_COMPARATOR|Viagra|Oral tablet of sildenafil citrate (Japanese commercial tablet: Viagra® tablet) 50 mg as a single oral dose under fasted conditions
62404234|NCT01737203|EXPERIMENTAL|ODT without water|Sildenafil ODT 50 mg without water as a single oral dose under fasted conditions
62404235|NCT01737203|EXPERIMENTAL|ODT with water|Sildenafil ODT 50 mg with water as a single oral dose under fasted conditions
62404236|NCT05326958|EXPERIMENTAL|Normal Eyes of Subjects without DM|Study Part 1 conducted at only site 1 . Single measurement made on 3 separate visits at site 1 (total 3 images acquired) with HRT RCM and HRT RCM-E functional module (investigational).
62404237|NCT05326958|EXPERIMENTAL|Eyes of DM Type 2 subjects without coexisting DPN|"Study part 2 conducted at site 2.~1 image acquired with HRT RCM-E functional module (investigational)."
62787586|NCT01640444|EXPERIMENTAL|A|FOLFIRI+bevacizumab
62787587|NCT01640444|EXPERIMENTAL|B|FOLFIRI + cetuximab
62787588|NCT02800525|EXPERIMENTAL|Picosecond laser|"The pigmented lesions on this half-side of the face would be treated with picosecond laser.~For epidermal lesions, 1 laser treatment would be performed. For dermal lesions, 5 laser treatments would be performed every 3 month-interval.~The wavelength of 532 or 1064 nm would be chosen for appropriate lesions"
62787589|NCT02800525|ACTIVE_COMPARATOR|Q-switched Nd:YAG laser|"The pigmented lesions on this half-side of the face would be treated with q-switched Nd:YAG laser.~For epidermal lesions, 1 laser treatment would be performed. For dermal lesions, 5 laser treatments would be performed every 3 month-interval.~The wavelength of 532 or 1064 nm would be chosen for appropriate lesions"
62204481|NCT02600390|EXPERIMENTAL|SANGUINATE™ (6-week)|This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 6-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.
62204482|NCT05521815|ACTIVE_COMPARATOR|Study group|The group that are going to receive the coma arousal therapy program
62404238|NCT05326958|EXPERIMENTAL|Eyes of DM Type 2 subjects with coexisting early to moderate DPN|"Study part 2 conducted at site 2.~1 image acquired with HRT RCM-E functional module (investigational)."
62404239|NCT05419960||Patients|Patients between the ages of 12-20 years with a diagnosis of Osteogenesis Imperfecta of any type and followed by a physician at the Centre de Référence des Maladies Rares des maladies osseuses constitutionnelles (CRMR OI) of Hôpital Necker-Enfants malades.
62404240|NCT02837250|EXPERIMENTAL|Pos4Health|Pos4Health is a 6 Core Internet intervention focusing on improving adherence to ART among nonadherent substance users living with HIV in non urban areas. Pos4Health Cores each present a topic, show videos of HIV+ peers discussing that topic, and how they have coped with it, and use interactions to teach about the topic and to develop knowledge and skills. Each core ends with tips to try that include tips mentioned by peers or from expert material. Content is personalized to the user and users receive tailored feedback. Cores are metered out weekly after each Core is completed.
62404241|NCT02837250|ACTIVE_COMPARATOR|Patient Education|Patient Education is a static (unchanging) website that presents accurate information about the same topics in Pos4Health, but without personalization, peer videos, or interactivity.
62404242|NCT03358407|EXPERIMENTAL|Part A: Cohort 1|Cohort 1 will be 5-way crossover with 5 treatment periods. Subjects will be randomized in the ratio 4:1 to receive either single dose of GSK2983559 or placebo.
62404243|NCT03358407|EXPERIMENTAL|Part A: Cohort 2 fasting|Cohort 2 will be 4-way crossover design with one additional period of open-label. Subjects will be randomized in the ratio 3:1 to receive either single dose of GSK2983559 or placebo in fasted conditions
62404244|NCT03358407|EXPERIMENTAL|Part A: Cohort 2 fed|In Cohort 2, treatment period 5 will be open-label period. This open-label period is to determine food effect and subjects will receive GSK2983559 under fed conditions.
62580466|NCT01725022|EXPERIMENTAL|Home Care|This is the arm for patients who receive their transplant care in their homes.
61978490|NCT03989557|EXPERIMENTAL|Monitoring Arm|Randomization: based on light transmittance aggregometry, modified dose of antiplatelet therapy(aspirin and ticagrelor) was used for high platelet reactivity(HPR) patients with intracranial stent placement, and standard antiplatelet regimen(aspirin and clopidogrel) was used in non-HPR patients.
62015539|NCT03753958|EXPERIMENTAL|Control group|The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
62204483|NCT05521815|PLACEBO_COMPARATOR|Control group|This group will receive only traditional treatment program
62204484|NCT00233974|EXPERIMENTAL|PET negative|Traditional breast Surgery and full axillary dissection
62204485|NCT00233974|EXPERIMENTAL|PET positive|PET-probe-guided breast resection and full axillary dissection
62204486|NCT03134677|EXPERIMENTAL|Bupivacaine|We were performed spinal anesthesia sitting position by midline. After confirming the free flow of cerebrospinal fluid, bupivacaine was administered without aspiration.ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
62204487|NCT03134677|EXPERIMENTAL|Sevoflurane|We were performed general anesthesia with sevoflurane. Anesthesia was maintained with 2-3% sevoflurane. ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
62204488|NCT00557375||1|Brain tumor patients
62204489|NCT00557375||2|Caregivers of brain tumor patients
62404245|NCT03358407|EXPERIMENTAL|Part B|Part B is repeat ascending dose sequential period. There will four cohorts (3-6) of 10 healthy subjects. In each cohort subjects will be randomized to receive GSK2983559 or placebo in ratio 4:1. Subjects will receive GSK2983559 or placebo QD and twice daily dose will be decided based upon the pharmacokinetic, safety and tolerability observed in Part A.
62580467|NCT01725022|NO_INTERVENTION|Hospital Care|Standard of care for stem cell transplant recipients where the aftercare is done in hospital.
62580468|NCT01725022|NO_INTERVENTION|Clinic Care|Standard of care for stem cell transplant recipients who live at home but receive aftercare in the daily outpatient clinic.
62580469|NCT03150511|EXPERIMENTAL|Tesamorelin treatment|
62580470|NCT03150511|NO_INTERVENTION|No Drug|
62580471|NCT04920396|EXPERIMENTAL|IRPL|Three treatments with IRPL (manufacturer: E-Swin, France) on days 0, 15 and 45
62580472|NCT04920396|ACTIVE_COMPARATOR|Warm compress|Daily use of a warm compress (manufacturer: The Eye Doctor, UK) with Sterileyes® twice a day for 5 minutes
62787590|NCT04306588|EXPERIMENTAL|Tele-rehabilitation exercise Group|Participants who are suffering from a chronic illness such as COPD or CHF and are referred for tele-rehabilitation intervention at the VA-Houston will be qualified for the purpose of this study.
62787591|NCT01366885|EXPERIMENTAL|Intervention during pregnancy|5000 IU Vitamin D3 to be given to the mother during pregnancy. 7000 IU Vitamin D3 to be given during breast feeding if breast feeding. If not breastfeeding, infant to be given 400 IU Vitamin D3 during first year of age, then increased to 1000 IU D3 until completion of research trial.
62787592|NCT05224453|OTHER|Physical training and high protein diet|Subjects in this group underwent integrated physical training for 8 weeks. In addition to the integrated physical training exercises, group A received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (\>1 g/kg aBW/d).
62787593|NCT05224453|OTHER|Physical training and low protein diet|Subjects in this group underwent integrated physical training for 8 weeks. In addition to the integrated physical training exercises, group B received a low protein diet in the range of 0.7 - 0.9 g/kg protein/ ideal body weight/day (\<1 g/kg aBW/d)
62787594|NCT04909658|EXPERIMENTAL|ACT matrix protocol|Parents of childrens with Autism Spectrum Disorders (ASD). The ACT protocol group received exercises to improve the psychological well-being of the parents.
62787595|NCT04909658|ACTIVE_COMPARATOR|PT protocol|Parents of childrens with Autism Spectrum Disorders (ASD).
62787596|NCT03256201|EXPERIMENTAL|Standard Exercise Group|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
62787597|NCT03256201|EXPERIMENTAL|Enhanced Exercise Group|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
61978491|NCT03989557|EXPERIMENTAL|Conventional Arm|Randomization: without light transmittance aggregometry, standard antiplatelet regimen was used for unruptured aneurysm patients with intracranial stent.
62204490|NCT04654377|EXPERIMENTAL|Personalised education|"* Greetings~* Recording clinical/imaging data.~* Questionnaires administration.~* Explaining the disease and possible outcome in the context of clinical/lab/imaging data.~* Answering specific queries from patients and care givers."
62204491|NCT04654377|NO_INTERVENTION|Standard communication|"* Greetings~* Recording clinical/imaging data.~* Administration of questionnaire.~* Addressing general queries from patients and care givers."
62404246|NCT06192407|EXPERIMENTAL|High Palmitic Acid Diet (HPA)|Participants will ingest the HPA diet for one week. The saturated fatty acid will be high in palmitic acid which is the most prevalent saturated fatty acid in the American diet. The HPA diet will be proceeded by a one week controlled diet were the fat content is balanced between monounsaturated and saturated fatty acids.
62404247|NCT06192407|EXPERIMENTAL|High Oleic Acid/Low Palmitic Acid Diet (HOA)|Participants will ingest the HOA diet for one week. The monounsaturated fatty acid will be high in oleic acid which is the most prevalent monounsaturated fatty acid in the Mediterranean diet. The HOA diet will be proceeded by a one week controlled diet were the fat content is balanced between monounsaturated and saturated fatty acids.
62404248|NCT00996073|ACTIVE_COMPARATOR|Autograft|Lumbar Interbody Fusion with Autograft
62404249|NCT00996073|EXPERIMENTAL|Low Dose|Lumbar Interbody Fusion with NeoFuse-Low Dose
62404250|NCT00996073|EXPERIMENTAL|High Dose|Lumbar Interbody Fusion with NeoFuse-High Dose
62404251|NCT00730366|EXPERIMENTAL|1|Experimental: IPTp-SP + promotion: Active Comparator
62404252|NCT00730366|EXPERIMENTAL|2|IPTp-SP alone (without promotion)
62404253|NCT00730366|ACTIVE_COMPARATOR|3|Weekly CQ prophylaxis
62404254|NCT03096249|EXPERIMENTAL|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716) will be used for intranasal administration of a single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
62404255|NCT03096249|PLACEBO_COMPARATOR|Placebo|Physiological water (sodium chloride (NaCl) solution) Administration via nasal spray
62404256|NCT00350935||Healthy volunteers|Healthy controls
62787598|NCT01835665|EXPERIMENTAL|Nimodipine|
62787599|NCT01196832||Chronic obstructive pulmonary disease patients|"COPD patients with exacerbation will be recruited during hospitalization in Intensive care unit or as outpatients in the clinical investigation centre of the CHU de Bordeaux.~Inclusion visit: blood sample for fibrocytes analysis. Second visit 2 months ± 7 days after the exacerbation: clinical and functional evaluation (plethysmography, TLCO, arterial gaz), blood sample for fibrocytes analysis."
62787600|NCT01196832||Control group|Subjects without any history of lung disease and with normal lung function testing
62787601|NCT01913002|EXPERIMENTAL|Treatment A|LX4211 800 mg
62787602|NCT01913002|EXPERIMENTAL|Treatment B|LX4211 2000 mg
62787603|NCT01913002|ACTIVE_COMPARATOR|Treatment C|moxifloxacin 400 mg
62404257|NCT00350935||Patients|Patients with schizophrenia
62404258|NCT05195385|OTHER|Procedure|Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules
62787604|NCT01913002|PLACEBO_COMPARATOR|Treatment D|Placebo
62580473|NCT02776436|EXPERIMENTAL|Breast cancer|"Dose of prophylactic dexamethasone will be reduced as follows:~STEP 1: 12 mg dexamethasone per day (8-4mg/day) for 3 days starting 1 day before administration. (n=6)~STEP 2: 8mg dexamethasone per day (8mg once a day) for 3 days starting 1 day before administration. (n=6)~STEP 3: day -1: 4 mg, day 0: 8 mg, day 1: 4 mg. (n=6)~STEP 4: day -1: 0 mg, day 0: 8 mg, day 1: 4 mg. (n=6)~STEP 5: day -1: 0 mg, day 0: 8 mg, day 1: 0 mg. (n=6)~STEP 6: day -1: 0 mg, day 0: 4 mg, day 1: 0 mg. (n=6)"
62787605|NCT00881647|EXPERIMENTAL|1|Participants will receive an 8-week course of cognitive behavioral therapy for insomnia.
62787606|NCT00881647|NO_INTERVENTION|2|Participants will be placed on a waitlist for 8 weeks.
62787607|NCT00851786|EXPERIMENTAL|1|Participants with CD4 cell counts of 200 cells/uL or greater in Stages 1 and 2, stratified by CD4 cell counts (200-349 cells/uL vs. \>=350 cells/uL), will be given one dose of ZOSTAVAX (Zoster Vaccine Live) at Day 0 and Week 6 and will be followed for at least 42 days after each vaccination after which a safety assessment will be conducted.
62204492|NCT05479032|EXPERIMENTAL|Treatment group|Intensive care patients suffering from reduced consciousness not otherwise explained treated with Amantadine
62204493|NCT06493825|EXPERIMENTAL|Experimental|Subjects will undergo 4 weeks of immersive virtual reality exposure using the Aurora Mindfulness app (Invincikids) delivered using a Meta Quest 2 headset at the frequency of 10 minutes per session, 5 days out of a 7-day week. Subjects will undergo baseline, 2-week and 4-week measurement of symptoms using 5 validated instruments.
62204494|NCT06493825|SHAM_COMPARATOR|Placebo|Subjects will undergo 2 weeks of immersive virtual reality exposure using the Aurora Mindfulness sham app (Invincikids) delivered using a Meta Quest 2 headset at the frequency of 10 minutes per session, 5 days out of a 7-day week. Subjects will undergo baseline and 2-week measurement of symptoms using 5 validated instruments.
62204495|NCT02686177|EXPERIMENTAL|1: Liraglutide|Liraglutide 1,2 mg once daily subcutaneous injection for 1 month (4 weeks)
62204496|NCT02686177|ACTIVE_COMPARATOR|2: Add on oral antidiabetic medication|Metformin or sulfonylurea depending on monotherapy
62404259|NCT02637518||Hospital Universitario de Getafe|"Assessment of frailty tools in elderly people~The Geriatric Department attends patients:~1800/year - acute unit. 800/year - Orthogeriatrics and Interconsultation Unit. 300/year - Day Hospital. 4000/year - Outpatient office. 1200/year - Domiciliary Care."
62404260|NCT02637518||Diabetes Frail Ltd.|Assessment of frailty tools in elderly people Has significant experience in managing research studies in older people.
62404261|NCT02637518||Università Cattólica del Sacro Cuore|"Assessment of frailty tools in elderly people~The Geriatric Unit is compounded by:~24 beds of Acute Care Ward 46 beds of Intensive Rehabilitation Unit 20 beds of Day Hospital Outpatient clinic"
62404262|NCT02637518||Gérontopole de Toulouse|"Assessment of frailty tools in elderly people~The Geriatric Unit is compounded by:~5 Acute Care Units - 100 beds. 3 Rehabilitation Unit - 75 beds. Long term care Unit - 140 beds. 2 Day Hospitals Outpatient Clinic"
62404263|NCT02637518||Jagiellonian University Medical College|Assessment of frailty tools in elderly people The Department of Internal Medicine and Gerontology is the largest centre in Poland limited to the Geriatric market.
62204497|NCT05252442||Pre-COVID-19|
62204498|NCT05252442||COVID-19|
62404264|NCT03039829|EXPERIMENTAL|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine; 1.0 gram nitrate, 3.0 grams dextrose)
62404265|NCT03039829|ACTIVE_COMPARATOR|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine; 2.0 grams nitrate)
62404266|NCT03039829|PLACEBO_COMPARATOR|Placebo|Placebo at 6.0 grams dextrose
62404267|NCT06260462|EXPERIMENTAL|Conventional steroid treatment|Cortisone acetate and hydorocortisone will be administered in two daily doses
62787608|NCT00851786|PLACEBO_COMPARATOR|2|Participants with CD4 cell counts of 200 cells/uL or greater in Stages 1 and 2, stratified by CD4 cell counts (200-349 cells/uL vs. \>=350 cells/uL), will be given one dose of placebo at Day 0 and Week 6 and will be followed for at least 42 days after each vaccination after which a safety assessment will be conducted
62787609|NCT03204370||MPS4A patients|
62787610|NCT01740401|EXPERIMENTAL|Cyclophosphamide, Ipilimumab|"Treatment:~Cyclophosphamide 300 mg/m2 po - Day 1 of Weeks 1, 4, 7, and 10, for a total of 4 doses; (premedication prior to each dose of Cyclophosphamide 8mg Zofran po, then prn)~Ipilimumab 10 mg/kg iv - Day 3 of Weeks 1, 4, 7, and 10 for a total of 4 doses Maintenance treatment will be given on Weeks 24, 36, and 48 Ipilimumab 10 mg/kg iv"
62204499|NCT05252442||COVID-19 vaccination roll-out|
62204500|NCT05844670|EXPERIMENTAL|Vincristine|A dose advice for vincristine will be given based on vincristine concentrations in blood samples and toxicity monitoring.
62204501|NCT02410460|OTHER|PKA-BIS (intravenous anesthesia)|"Received the following medications:~clonidine 0.1-0.2mg glycopyrrolate 0.2mg propofol infusion titrated to BIS of 60-75 ketamine 50mg + additional ketamine not to exceed 200mg aggregate dosage throughout the case local anesthetic (lidocaine/marcaine mix)"
62204502|NCT02410460|OTHER|Inhalational anesthesia|"Received the following:~Pre-operatively:~famotidine 20mg scopolamine 1.5mg transdermal patch midazolam 2mg ondansetron 8mg metoclopramide 10mg glycopyrrolate - dose determined by anesthesiologist~During the case, medication choices and dosing were dependent on the anesthesiologist - all general anesthesia cases received inhalational anesthetic (type of anesthetic - desfluorane vs. sevofluorane - also varied based on anesthesiologist's choice)"
62215185|NCT06429644||Incheon St. Mary's Hospital|Department of Surgery, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea
62215186|NCT06429644||Kyung Hee University Hospital|Department of Surgery, Kyung Hee University Hospital, Seoul, Republic of Korea
62215187|NCT06429644||Keimyung University School of Medicine|Department of Surgery, Keimyung University School of Medicine, Daegu, Republic of Korea
62404268|NCT06260462|EXPERIMENTAL|Dual-release hydrocortisone|Dual-release hydrocortisone will be administered once daily
62404269|NCT02009111|EXPERIMENTAL|Couple CARE for Parents|Couple CARE for Parents is a couple-focused intervention that addresses interpersonal processes within relationships and promotes healthy relationship and parenting skills among couples with a newborn. Couple CARE for Parents uses a highly disseminable model (i.e., home-visitation and video- and telephone-assisted skills training) developed in Australia.
62404270|NCT02009111|OTHER|Wait-list control|The control group will be wait-listed until after the 24-month assessment, at which point they are eligible to receive Couple CARE for Parents (tailored for their children's ages).
62404271|NCT00835861|EXPERIMENTAL|Metformin|Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation. After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.
62787611|NCT03111329|EXPERIMENTAL|GRASS - Intervention group|"The intervention group (GRASS) will receive 3 hourly feeds, with no gastric residuals being aspirated. Solely opening of the nasogastric tube once every 6 hours to relieve possible backflow of gastric content will be allowed. Amount of enteral feeds given and increase in dose will be specified in an enteral feeding plan prior to start of the study. Amount of enteral feeds given will increase every six hours with a calculated overall increase of 20 ml/kg of birth weight in the total amount given every 24 hours.~Intervention = NO aspiration of gastric residuals"
62787612|NCT03111329|NO_INTERVENTION|Standard Approach group|Standard Approach group serving as control group will be treated as per standard approach - participants will be fed 3 hourly and gastric residuals checked via nasogastric tube prior to each feed. Amount of enteral feeds given and increase in dose will be specified in an enteral feeding plan prior to start of the study. Amount of enteral feeds given will increase every six hours with a calculated overall increase of 20 ml/kg of birth weight in the total amount given every 24 hours.
62787613|NCT05367544|EXPERIMENTAL|Health Education & Peer Coaching|Participants will have access to online health education materials and will also be matched with a community health worker who will offer support through peer coaching
62787614|NCT05367544|ACTIVE_COMPARATOR|Health Education Only|Participants will have access to online health education materials but will not receive individualized peer support
62787615|NCT04264364||laparoscopic sleeve gastrectomy|Patients who underwent laparoscopic sleeve gastrectomy
62787616|NCT04264364||endoscopic sleeve gastroplasty|Patients who underwent endoscopic sleeve gastroplasty
62787617|NCT05467358||Patients with preendoscopic ppi order|Patients receiving 80 mg esomeprazole loading and 8 mg esomeprazole infusion per hour before endoscopic treatment
62787618|NCT05467358||Patients with preendoscopic cannot be ppi order|patients who could not get ppi before endoscopy
62787619|NCT04042324|EXPERIMENTAL|Triferic post-dialyzer; UFH via continuous infusion|Patients will receive Triferic 6.75 mg IV over 3 hours into the post-dialyzer blood line (or drip chamber) administered by an infusion pump. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin using the on-machine infusion pump. The infusion of heparin to be stopped at hour 3 of hemodialysis.
62404272|NCT00835861|ACTIVE_COMPARATOR|Insulin|Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation. After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.
62404273|NCT06192875||Observational|Patients undergo blood and urine sample collection on study. Patients' medical records are reviewed.
62787620|NCT04042324|EXPERIMENTAL|UFH and Triferic admixture|"Patients will receive Triferic 6.75 mg IV plus the appropriate volume of unfractionated heparin for continuous infusion over 3 hours into the pre-dialyzer heparin line. This mixture will be administered by the on-machine syringe infusion pump for continuous infusion. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of Triferic + heparin. The infusion of Triferic + heparin will be stopped at hour 3 of hemodialysis."
62215188|NCT06429644||Asan Medical Center|Division of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
62215189|NCT02736461||Group 1- With strabismus|Study group with strabismus happening after floor fracture repair
62404274|NCT01975506||head start practitioners|
62404275|NCT02696980|EXPERIMENTAL|Rescue|Intervention: Positive expiratory pressure (PEEP) 10 will be applied after the administration of methacholine
62404276|NCT02696980|EXPERIMENTAL|Prophylaxis|Intervention: Positive expiratory pressure (PEEP) 10 will be applied during the administration of methacholine
62404277|NCT02696980|PLACEBO_COMPARATOR|No PEEP|Intervention: Positive expiratory pressure (PEEP) 0 will be applied during the administration of methacholine
62404278|NCT00646217|EXPERIMENTAL|1|SELF CARE Talk
62404279|NCT00646217|NO_INTERVENTION|2|Comparison Group
62404280|NCT01396252|EXPERIMENTAL|Arm1: BMS-820836|Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)
62404281|NCT01396252|PLACEBO_COMPARATOR|Arm 2: Placebo matching BMS-820836|Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)
62787621|NCT04042324|EXPERIMENTAL|UFH via continuous infusion pre-dialyzer|Patients will receive no Triferic. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin via the on-machine syringe pump. The infusion of heparin to be stopped at hour 3 of hemodialysis
62787622|NCT03374540||Rivaroxaban|Patients who initiated Oral anticoagulant (OAC) treatment with rivaroxaban
62204503|NCT01853202|EXPERIMENTAL|Group 1 - Supervised aerobic exercise training|This group will participate in 3 supervised exercise sessions/week at an intensity of 50%-70% of the individually determined VO2max between 30-45 min/session for 12 weeks. The aerobic training intervention will closely mimic the standard exercise-based guidelines adopted in cardiac rehabilitation. All intervention sessions will be performed in a supervised setting with one-on-one supervision by an American College of Sports Medicine-certified exercise physiologist. Aerobic exercise training will be prescribed based on the guiding ACSM principles with the aim of improving VO2max. Walking was chosen because it is the preferred mode of exercise training in cancer patients.
62404282|NCT01476527|EXPERIMENTAL|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
62404283|NCT06465459||Patients scheduled for percutaneous left atrial closure with Lambre device implantation.|
62580474|NCT02776436|EXPERIMENTAL|Prostate cancer|"Dose of prophylactic dexamethasone will be reduced as follows:~STEP 1: 2dd 8 mg at 12 and 1 hr before treatment (besides standard prednisone 5mg bid) (n=6)~STEP 2: 8mg dexamethasone 1 hour before treatment (and standard prednisone 5mg bid). (n=6)~STEP 3: 4mg dexamethasone 1 hour before treatment (and standard prednisone 5mg bid). (n=6)~STEP 4: 0mg dexamethasone (only standard prednisone 5mg bid). (n=6)"
62580475|NCT04412161||Extra-Malatya|Liver transplant patients with MTD\>6 cm of HCC
62580476|NCT01735578||Premature infants with anemia|Inpatient premature infants at the University of Utah Neonatal Intensive Care Unit (NICU) with Hct \< or = to 28 who are being fed and are stable.
62787623|NCT03374540||Vitamin K antagonist (VKA)|Patients who initiated OAC treatment with VKA
62787624|NCT03369912|EXPERIMENTAL|Active|CSJ148
62204504|NCT01853202|NO_INTERVENTION|Group 2|The 12-week program will consist of monthly phone contacts to check in with patient and review their exercise log entries for that month in order to capture physical activity done outside of the intervention setting.
61978492|NCT02579850|EXPERIMENTAL|CHF 5993 + Ultibro matched placebo|"Fixed triple therapy with BDP/FF/GB 100/6/12.5 mcg (CHF 5993) administered 2 puffs twice daily via pMDI + Fixed combination of indacaterol and of glycopyrronium (Ultibro® Breezhaler®) matched placebo administered once daily via DPI for 52-week treatment.~Patient used to take pMDI medication using a spacer will be provided with a new spacer for the study.~7 study visits including : central spirometry tests, Local laboratory, COPD assessment test (visit 1 only), Local laboratory Assessments Saint George's Respiratory Questionnaire EXACT-pro questionnaire"
62204505|NCT06186271||E4/DRSP|"E4/DRSP: estetrol/drospirenone~new users (starters and restarters with at least two months break)"
62204506|NCT06186271||EE/DRSP|"EE/DRSP: ethinyl estradiol/drospirenone~new users (starters and restarters with at least two months break)"
62215190|NCT02736461||Group 2- Without strabismus|No strabismus happening after floor fracture repair
62404284|NCT00582127||1|Mild-moderate Alzheimer's Disease
62404285|NCT00582127||2|Age-matched Controls
62404286|NCT02079493||Total Knee Arthroplasty patients|TKA patients
62404287|NCT02888782|EXPERIMENTAL|Pharmacist Consultation|Meet with pharmacist for consultation in addition to regular physician follow up
62404288|NCT02888782|NO_INTERVENTION|Control|Receive regular physician follow up
62404289|NCT04712058|EXPERIMENTAL|Same-day initiation with BIC/F/TAF|
62580477|NCT04594070|ACTIVE_COMPARATOR|Daily iron supplementation|Oral ferrous sulfate, 325 mg, take once daily
62580478|NCT04594070|EXPERIMENTAL|Alternate day iron supplementation|Oral ferrous sulfated, 650mg, taken once daily every other day
62580479|NCT04996498|ACTIVE_COMPARATOR|Group A (Oxytocin group):|30 women will undergo a hysteroscopic myomectomy with the use of 10 IU of oxytocin for every 1000 ml of the distending medium (1,5% Glycine ).
62580480|NCT04996498|PLACEBO_COMPARATOR|Group B (Placebo group):|30 women will undergo hysteroscopic myomectomy with the use of a sterile bacteriostatic water ampule in the distending medium (1,5% glycine).
62787625|NCT03369912|PLACEBO_COMPARATOR|Placebo|5% dextrose
62787626|NCT00727792|EXPERIMENTAL|Group 2 - Research MRI|Subjects will have additional sequences and/or modification to MRI sequences.
62787627|NCT00727792|ACTIVE_COMPARATOR|Group 1 - Clinical MRI|Clinically ordered MRI scan. Subjects will not have any additional sequences or modifications to their clinically ordered MRI
62787628|NCT02187068|EXPERIMENTAL|Dexmedetomidine obese 1|10 obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.25 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
62787629|NCT02187068|EXPERIMENTAL|Dexmedetomidine obese 2|10 obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.5 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
62204507|NCT06186271||EE/LNG and EE/NETA and EE/NGM|"EE/LNG: ethinyl estradiol/levonorgestrel~EE/NETA: ethinyl estradiol/norethisterone/norethindrone acetate~EE/NGM: ethinyl estradiol/norgestimate~new users (starters and restarters with at least two months break)"
62204508|NCT01872559||3D sonographic analysis|The study is designed to evaluate a new imaging modality, 3D sonographic volumetric analysis, and compare it to the conventional 2-dimmensional analysis that is currently in place. Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do no require any additional sonograms, tests, or interventions.
62580481|NCT05101746|EXPERIMENTAL|Nitric oxide group|Participants in this group will receive Nitric Oxide (NO) while undergoing Cardiopulmonary bypass (CPB)
62580482|NCT05101746|ACTIVE_COMPARATOR|Standard of care cardiopulmonary bypass procedure|Participants in this group will receive standard of care
62580483|NCT02907918|EXPERIMENTAL|Palbociclib + letrozole + trastuzumab +/- goserelin|"* Neoadjuvant palbociclib + letrozole (plus goserelin if premenopausal) + trastuzumab for a total of 16 weeks, consisting of (4) 28-day cycles~* Definitive surgery will be performed preferably within 6 weeks after the end of Cycle 4. Letrozole and trastuzumab will continue until the day of surgery. Letrozole will continue to be taken daily and trastuzumab will be given every 3 weeks per standard of care guidelines. Adjuvant therapy following definitive surgery will be at the discretion of the treating physician"
62580484|NCT03423758||Healthy controls|Healthy subjects with age more than 60 years
62580485|NCT03423758||Pseudoexfoliation Glaucoma|Already diagnosed Pseudoexfoliation glaucoma patients with age more than 50 years
62787630|NCT02187068|EXPERIMENTAL|Dexmedetomidine non-obese 1|10 non-obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.25 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
62580486|NCT03423758||Angle closure Glaucoma|Already diagnosed Angle closure Glaucoma patients with age more than 21 years
62580487|NCT03423758||Primary open-angle Glaucoma|Already diagnosed primary open-angle glaucoma with age more than 30 years
62580488|NCT06603155|EXPERIMENTAL|Time Restricted Eating (TRE)|
62580489|NCT06416436|EXPERIMENTAL|SBRT with concurrent and adjuvant atezolizumab immunotherapy|
62580490|NCT01662817||Intervention|Intervention group primary care physician (PCP) receives one day training in depression screening guidelines and uses guidelines for six months
62580491|NCT01662817||Control|Control group PCP manages depression in the usual way for six months
62580492|NCT04432012|EXPERIMENTAL|arm-A Intra-venous dexamethasone|9 mg of Intra-venous dexamethasone
62580493|NCT04432012|EXPERIMENTAL|arm-B intra-articular dexamethasone|9 mg of intra-articular dexamethasone
62580494|NCT04432012|NO_INTERVENTION|arm-C routine|No steroid supplementation or other drugs will be added to the routinely performed anaesthesia protocol in the control group
62580495|NCT04721847|EXPERIMENTAL|Pain Neuroscience Education|Pain Neuroscience Education (PNE) sessions. Additionally, treated with Transcutaneous Electrical Nerve Stimulation (TENS), Stretching and Strengthening exercises similar as in control group
61978493|NCT02579850|ACTIVE_COMPARATOR|Ultibro + CHF 5993 matched placebo|"Fixed combination of indacaterol 85 mcg and of glycopyrronium 43 mcg (Ultibro® Breezhaler®) administered once daily via DPI + Fixed triple therapy with BDP/FF/GB (CHF 5993) matched placebo administered 2 puffs twice daily via pMDI for 52-week treatment.~Patient used to take pMDI medication using a spacer will be provided with a new spacer for the study.~7 study visits including : central spirometry tests, Local laboratory, COPD assessment test (visit 1 only), Local laboratory Assessments, Saint George's Respiratory Questionnaire, EXACT-pro questionnaire"
62204509|NCT03355339|EXPERIMENTAL|Binasal occlusion|Participants will be fitted with glasses covered with occlusive tape from the inner canthi to the nasal border on each lens.
62204510|NCT03355339|ACTIVE_COMPARATOR|No binasal occlusion|Participants will be fitted with non-occluded glasses.
62580496|NCT04721847|ACTIVE_COMPARATOR|Conventional Physical therapy|Control group will be treated by TENS, stretching and strengthening exercises.
62204511|NCT04116736||TEST Lens|Eligible subjects that are at least 18 years old, who have been recently fitted (within the last 2 months) with the ACUVUE® OASYS with Transitions™ will be asked to complete follow-up assessments performed online at approximately 2-weeks, 4-months, and 12-months following Visit 1.
62580497|NCT06082518|EXPERIMENTAL|Immediate start of hyperbaric treatments|HBOT treatments will be scheduled to start immediately after referral.
62580498|NCT06082518|EXPERIMENTAL|Delayed start of hyperbaric treatments|HBOT treatments will be scheduled to start 60 days after referral.
62580499|NCT02769975||Case Only|Children ages 3 months to 100 with known or suspected endocrine or metabolism disorders. Family members ages 3 months to 100. They may participate in the DNA part of the study
62580500|NCT06681103|EXPERIMENTAL|Personalized Normative Feedback Group A|Participants in this group will complete a pre-assessment, which includes measuring their intention to change, help-seeking behavior, and gambling/trading behaviors (e.g., frequency and spending). After this, they will receive personalized online normative feedback (PONF) about their gambling and trading behaviors. They will then complete a post-assessment, which measures the same variables.
62580501|NCT06681103|EXPERIMENTAL|Personalized Normative Feedback Group B|Like PONF A, participants in this group will complete a pre-assessment and post-assessment on the same variables. However, the key difference is that they will complete the post-assessment on gambling and trading behaviors before receiving the personalized online normative feedback (PONF). This design allows the study to evaluate whether compares one's own behaviour with that of the reference group could affects the participants' self-reports on their gambling and trading behaviors (i.e., social desirability)
62580502|NCT06681103|NO_INTERVENTION|Control group 1 (Assessment group)|Participants in this group will complete both pre- and post-assessments on intention to change, help-seeking behavior, and gambling/trading behaviors. However, they will not receive any feedback. This group serves as a comparison to both intervention groups.
62215191|NCT05382143|EXPERIMENTAL|Intervention|All the participants in this pilot study will receive atosiban
62204512|NCT04116736||CONTROL Lens|Eligible subjects that are at least 18 years old, who have been recently fitted (within the last 2 months) with spherical non-photochromic reusable marketed silicone hydrogel contact lenses (of any brand) will be asked to complete follow-up assessments performed online at approximately 2-weeks, 4-months, and 12-months following Visit 1.
62204513|NCT02344264|OTHER|RP|first blockade: ropivacaine 7,5mg/ml 8 ml second blockade: placebo: saline 8 ml
62204514|NCT02344264|OTHER|PR|first blockade: placebo: saline 8 ml second blockade: ropivacaine 7,5mg/ml 8 ml
62204515|NCT05071638|EXPERIMENTAL|ACBMNC infusion group|Those assigned to the ACBMNC group will receive intravenous autologous cord blood mononuclear cells infusion. Cell dose for all patients was targeted at 5×107 cells per kilogram.
62580503|NCT06681103|NO_INTERVENTION|Control group 2 (Delayed Assessment Group)|This group will complete only the post-assessment, measuring intention to change, help-seeking behavior, and gambling/trading behaviors, without completing a pre-test or receiving feedback, to independently analyze the immediate effects of the pre-test.
62580504|NCT01015131|EXPERIMENTAL|All Participants|18F-FLT-PET imaging
62580505|NCT01002430|EXPERIMENTAL|Gene therapy|
62580506|NCT01002430|NO_INTERVENTION|Control|Control patients will have electroanatomic mapping procedure but no gene injections.
62580507|NCT02436369|EXPERIMENTAL|low fat yogurt enriched with flaxseed|200 gr low fat yogurt enriched with 30 gr flaxseed
62580508|NCT02436369|PLACEBO_COMPARATOR|low fat yogurt|200 gr low fat yogurt
62580509|NCT05542784||Patients with choledocholithiasis secondary to choledocholithiasis undergoing LERV surgery|
62580510|NCT05542784||Patients with choledocholithiasis secondary to choledocholithiasis undergoing PreERCP+LC surgery|
62580511|NCT01698892|EXPERIMENTAL|I.V. sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation
62580512|NCT01698892|ACTIVE_COMPARATOR|sublingual sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
62580513|NCT03019601|EXPERIMENTAL|Group education|Non pregnant HIV+ mothers were exposed to a structured educational intervention on family planning facilitated by Peer Champions.
62204516|NCT05071638|NO_INTERVENTION|control group|The control group received standardized treatment without special treatment.
62204517|NCT03704168|EXPERIMENTAL|CRYOABLATION ARM|
62204518|NCT02165813|ACTIVE_COMPARATOR|Nitazoxanide|oral nitazoxanide suspension twice daily for 3 days
62204519|NCT02165813|PLACEBO_COMPARATOR|Placebo|oral placebo suspension twice daily for 3 days
62204520|NCT01546532|EXPERIMENTAL|RLX030|RLX030 as intravenous infusion for 24 hours.
62204521|NCT01546532|PLACEBO_COMPARATOR|Placebo|Placebo as intravenous infusion for 24 hours.
62204522|NCT01714661|EXPERIMENTAL|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
62204523|NCT01714661|EXPERIMENTAL|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
62580514|NCT00466388|EXPERIMENTAL|Cevimeline|Evoxac tid for xerostomia
62580515|NCT00466388|PLACEBO_COMPARATOR|Placebo|sugar pill
62787631|NCT02187068|EXPERIMENTAL|Dexmedetomidine non obese 2|10 non-obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.5 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
62787632|NCT05309148|EXPERIMENTAL|Training on eye tracker based device|Patients will undergo a primary diagnostics of cognitive functions (memory, thinking skills, language, visual-spatial and communicative functions) and an diagnostics of the visual attention index on an eye tracker-based device. Based on the results of the diagnosis, participants will be offered a scheme of correctional training and secondary diagnostics at the end of training. Correctional training on an eye tracker-based device consists, firstly, of a 10-minute exercise at the beginning of each lesson aimed at improving visual functions and attention. Patients had to follow a spontaneously moving object. Secondly, correctional training includes a block of neurorehabilitation (simple cognitive exercises similar to the tasks presented in the assessment).
62204524|NCT01714661|PLACEBO_COMPARATOR|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day -14 through Day 182
62204525|NCT00392925|EXPERIMENTAL|Placebo and Metreleptin|Placebo-pramlintide 600 microliters (µL) twice a day (BID) and metreleptin (recombinant-methionyl human leptin) 5 milligram (mg) BID, 20 weeks
62204526|NCT00392925|EXPERIMENTAL|Pramlintide Acetate and Placebo|Lead-in period: 2 weeks pramlintide acetate 180 mcg BID, then 2 weeks pramlintide acetate 360 mcg BID Study period: Pramlintide acetate 360 mcg BID and placebo-metreleptin 1 mL BID, 20 weeks
62204527|NCT00392925|EXPERIMENTAL|Pramlintide Acetate and Metreleptin|Lead-in period: 2 weeks pramlintide acetate 180 mcg BID, then 2 weeks pramlintide acetate 360 mcg BID Study period: Pramlintide acetate 360 mcg BID and metreleptin (recombinant-methionyl human leptin) 5 mg BID, 20 weeks
62204528|NCT00392925|OTHER|Lead-In Period|During the Lead-In Period before a participant was randomized to a study arm, the participant received 180 mcg pramlintide acetate twice a day (BID) for 2 weeks, followed by 360 mcg pramlintide acetate BID for 2 weeks (total of 4 weeks in the Lead-In Period).
62204529|NCT01986764|ACTIVE_COMPARATOR|lisdexamfetamine|lisdexamfetamine 20 mg/d to 60 mg/d for 12 weeks
62204530|NCT01986764|ACTIVE_COMPARATOR|Estradiol|Estradiol 1 mg/d to 3 mg/d for 12 weeks
62580516|NCT00704080|EXPERIMENTAL|1|
62015540|NCT03753958|EXPERIMENTAL|aPDT group|aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
62204531|NCT01986764|PLACEBO_COMPARATOR|Placebo|
62204532|NCT06563999|EXPERIMENTAL|Treatment 1-Sunvozertinib|Patients with EGFR exon20ins mutation receive Sunvozertinib 300 mg orally once a day, 28 days as one cycle for 3 cycle.
62204533|NCT06563999|EXPERIMENTAL|Treatment 2-Crizotinib|Patients with ROS1 fusion mutation receive Crizotinib 250mg orally once a day, 28 days as one cycle for 3 cycle.
62204534|NCT06563999|EXPERIMENTAL|Treatment 3-Pralsetinib|Patients with RET fusion mutation receive Pralsetinib 400mg orally once a day, 28 days as one cycle for 3 cycle.
62204535|NCT06563999|EXPERIMENTAL|Treatment 4-Larotrectinib|Patients with NTRK fusion mutation receive Larotrectinib 100 mg orally twice daily, 28 days as one cycle for 3 cycle.
62204536|NCT06563999|EXPERIMENTAL|Treatment 5-Savolitinib|Patients with MET 14 exon mutation receive Savolitinib 600 mg or 400 mg (weight \<50 kg) orally once a day, 28 days as one cycle for 3 cycle.
62204537|NCT06563999|EXPERIMENTAL|Treatment 6-Pyrotinib|Patients with HER2 mutation receive Pyrotinib 400 mg orally once a day, 28 days as one cycle for 3 cycle.
62204538|NCT06563999|EXPERIMENTAL|Treatment 7-Dabrafenib+Trametinib|Patients with BRAF V600E mutation receive Dabrafenib plus Trametinib, 28 days as one cycle for 3 cycle.
62204539|NCT06563999|EXPERIMENTAL|Treatment 8-Glecirasib|Patients with KRAS G12C mutation receive Glecirasib 800 mg daily orally, 28 days as one cycle for 3 cycle.
62204540|NCT06563999|EXPERIMENTAL|Treatment 9-Ensartinib|Patients with ALK fusion mutation receive Ensartinib 225 mg daily orally, 28 days as one cycle for 3 cycle.
62204541|NCT06457685|EXPERIMENTAL|Pulse Intravascular Lithotripsy™ (Pulse IVL™)|Pulse Intravascular Lithotripsy™ (Pulse IVL™) to open vessels with calcific walls
62204542|NCT05197283|EXPERIMENTAL|Glucose as reference food|Fourteen healthy, normal body weight adults (male: 6, female: 10) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from white bread, tested two times; and 50 gr available carbohydrates from spaghetti No7 types, regular, whole wheat and low carbohydrates - high fibre, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose and salivary insulin sample was taken exactly 15min after the first bite of food or drink.
62204543|NCT05197283|EXPERIMENTAL|White bread|Fourteen healthy, normal body weight adults (male: 6, female: 10) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from white bread, tested two times; and 50 gr available carbohydrates from spaghetti No7 types, regular, whole wheat and low carbohydrates - high fibre, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose and salivary insulin sample was taken exactly 15min after the first bite of food or drink.
62204544|NCT05197283|EXPERIMENTAL|Regular spaghetti No 7|Fourteen healthy, normal body weight adults (male: 6, female: 10) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from white bread, tested two times; and 50 gr available carbohydrates from spaghetti No7 types, regular, whole wheat and low carbohydrates - high fibre, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose and salivary insulin sample was taken exactly 15min after the first bite of food or drink.
62787633|NCT05309148|ACTIVE_COMPARATOR|Training with a neuropsychologist|Patients will undergo primary and secondary diagnostics on an eye tracker-based device, then participants will have a conventional correctional training with a neuropsychologist according to an individual correction plan.
62787634|NCT05309148|ACTIVE_COMPARATOR|Training on eye tracker based device and with a neuropsychologist|Patients will undergo primary and secondary diagnostics and correctional training on an eye tracker-based device, in the same time participants will have a conventional correctional training with a neuropsychologist according to an individual correction plan.
62787635|NCT03348176|EXPERIMENTAL|Vegetable exposure|Repeated exposure to a variety of vegetables from the start of complementary feeding
62787636|NCT03348176|EXPERIMENTAL|VIPP-Feeding Infants|Promotion of responsive feeding practices from the start of complementary feeding
62787637|NCT03348176|EXPERIMENTAL|Exposure + VIPP-FI|Combination of repeated exposure to vegetables and promotion of responsive feeding practices
62787638|NCT03348176|SHAM_COMPARATOR|Control|Phone calls on development child with no information on complementary feeding
62787639|NCT01620814|EXPERIMENTAL|Dinoprostone and misoprostol|"For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.~After drugs administration, cervical canal will be again evaluated with above mentioned way by bougie before hysteroscopy"
62787640|NCT01620814|EXPERIMENTAL|Misoprostol and control|For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.
62787641|NCT01620814|EXPERIMENTAL|dinoprostone and control|For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.
62787642|NCT04649463|ACTIVE_COMPARATOR|Open ABPM results|ABPM results were used in the decision making for adjustments in antihypertensive medication at follow up visit.
62787643|NCT04649463|SHAM_COMPARATOR|Concealed ABPM results|ABPM results were not used in the decision making for adjustments in antihypertensive medication at follow up visit.
62787644|NCT01966835|EXPERIMENTAL|High intensity aerobic interval training|The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
62787645|NCT01966835|NO_INTERVENTION|control group|no exercise intervention
62787646|NCT03408613|EXPERIMENTAL|Positive Airway Pressure (PAP)|A registered polysomnographic technologist will perform a titration starting at 4 cm water (H2O) and adjust this value as needed to identify the optimal pressure to achieve an Apnea Hypopnea Index (AHI) \<5 (including rapid eye movement sleep in the supine position). After PAP titration, subjects will be instructed to use the machine at the optimal pressure every night for 3 months. Compliance will be defined as: ≥4 hours use on 70% of nights and average use ≥6 hours per night.
62015541|NCT04088786|EXPERIMENTAL|Active|Cytoreductive surgery (CRS) followed by study treatment with nanoliposomal irinotecan administered intraperitoneally.
62015542|NCT03246009|EXPERIMENTAL|single injection-1.8mg|rHSA/GCSF,injection,1.8mg,Single subcutaneous injection,Duration 1 day
62015543|NCT03246009|EXPERIMENTAL|single injection-2.1mg|rHSA/GCSF,injection,2.1mg,Single subcutaneous injection,Duration 1 day
62015544|NCT03246009|EXPERIMENTAL|single injection-2.4mg|rHSA/GCSF,injection,2.4mg,Single subcutaneous injection,Duration 1 day
62015545|NCT03246009|EXPERIMENTAL|multiple injection-1.8mg|rHSA/GCSF,injection,1.8mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
62015546|NCT03246009|EXPERIMENTAL|multiple injection-2.1mg|rHSA/GCSF,injection,2.1mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
62015547|NCT03246009|EXPERIMENTAL|multiple injection-2.4mg|rHSA/GCSF,injection,2.4mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
62404290|NCT05570734|EXPERIMENTAL|LUNA Group|The LUNA Group is a culturally appropriate, E-Health enhanced, patient-centered, team-care model that includes: 1) care coordination by a Care Coordinator (CC) trained in electronic health records (EHR) clinical decision support and health promotion methods; 2) visits with a specially trained Behavioral Health Provider (BHP) with knowledge of diabetes and psychosocial aspects of diabetes; 3) care integration with primary care provider (PCP) implemented using the clinical decision support dashboard and/or synchronous communication during visits; and 4) a video adapted, evidence-based diabetes self-management education and support curriculum delivered through a learning management system.
62404291|NCT05570734|NO_INTERVENTION|Care Coordination|The Care Coordination group applies the current methods of the federally qualified health center (FHQC) Patient Centered Medical Home initiative. Participants assigned to the care coordination group will continue with their regular medical visits with their primary care provider. In addition, they will receive care coordination and brief targeted health education provided by a specially trained medical assistant/care coordinator. This will involve 1 or more brief sessions with a care coordinator to provide health education, assist with appointments and referrals, and review medications. The care coordinator will work closely with their primary care provider. The care coordinator will also assist with referrals to behavioral health that may be initiated by the primary care provider.
62404292|NCT03832907|EXPERIMENTAL|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|"The Dexcom G6 CGM is a commercially available factory-calibrated sensor system. The system measures interstitial glucose every 5-15 minutes, providing real-time and more complete glycemic profile during 24-hours compared to standard POC glucose testing, and replaces the need for finger sticking. Potential limitations include the need for removing the sensor before MRI or diathermy treatment, and the potential interference in patients with severe dehydration.~In parallel, same participants will be monitored by the standard of care point-of-care (POC) capillary glucose tests. Diabetes guidelines recommend bedside capillary POC testing before meals and at bedtime to assess glycemic control and to adjust insulin therapy in the hospital."
62015548|NCT05720624|ACTIVE_COMPARATOR|Cohort I, Arm A (standard of care therapy)|Patients in Cohort I, Arm A receive standard of care therapy. Patients also undergo MRS imaging, collection of CSF, and collection of blood on study.
62404293|NCT06462924|EXPERIMENTAL|DeepGad|The dataset comprises a total of 500 patients, with 300 patients used for model training and 200 patients reserved for model testing. Each patient had approximately 350 2D brain slices of the coregistered 3D volumes excluding the five slices at the base and five slices at the top of the acquired volume due to their low signal-to-noise ratio (SNR). For robustness and to avoid overfitting, standard DL data augmentation techniques consisting of eight types of transformations were applied to each case in the training set.
62404294|NCT03582098||Idelalisib and Rituximab|Individuals who received treatment for CLL with at least one dose of idelalisib and rituximab in accordance with the marketing authorisation.
62404295|NCT06176417|EXPERIMENTAL|group 1|Eight implants were placed in patients of missing single tooth / teeth in posterior mandible with subsequent horizontal ridge augmentation by decompression technique.
62404296|NCT06176417|EXPERIMENTAL|group 2|Eight implants were placed in patients of missing single tooth / teeth in posterior mandible with subsequent horizontal ridge augmentation by ridge splitting technique using piezosurgery.
62404297|NCT03075826|OTHER|Open Label-Single Arm|This is a single arm, open-label study of SGI-110 in patients with MPN. SGI-110 will be administered subcutaneously at a dose of 60 mg/m2 on days 1-5, repeated every 28 days. Toxicity will be evaluated using the NCI Common Terminology Criteria for Adverse Events Active Version 4. The frequency of toxicities per organ system will be tabulated using descriptive statistics. All patients who receive any amount of the study drug will be evaluable for toxicity
62404298|NCT02783300|EXPERIMENTAL|Part 1: Dose Escalation, Food effect and Relative Bioavailability of Capsule formulation to Tablet|Participants will receive escalating doses of GSK3326595 until the maximum tolerated dose level is reached. The recommended phase 2 dose (RP2D) will be determined. Participants will be dosed in a fed (high-fat, high-calorie meal) and fasted state to determine the effect of food on bioavailability of GSK3326595, and will be dosed with tablet and capsule to compare two formulations of GSK3326595 (capsule versus tablet).
62404299|NCT02783300|EXPERIMENTAL|Part 2: Disease-Specific Expansion cohort|Participants with triple-negative breast cancer (TNBC), metastatic transitional cell carcinoma of the urinary system (mTCC), Grade IV anaplastic astrocytoma (glioblastoma multiforme \[GBM\]), non-Hodgkin's lymphoma (NHL), adenoid cystic carcinoma (ACC), hormone receptor-positive adenocarcinoma of the breast (ER+BC), human papillomavirus (HPV)-positive solid tumors of any histology, and p53-wild type non-small cell lung cancer (NSCLC) will be administered GSK3326595 at the recommended phase 2 dose (RP2D) as determined in Part 1.
62404300|NCT02783300|EXPERIMENTAL|Part 3: GSK3326595 in combination with pembrolizumab|Participants with selected solid tumors will be administered GSK3326595 in combination with pembrolizumab as part of this dose determination study.
62404301|NCT03423004|EXPERIMENTAL|Patient with lesional skin|the sample will be taken by superficial cutaneous biopsy in psoriasic patients
62404302|NCT03423004|NO_INTERVENTION|Patients with healthy skin|the skin will be recovered during a surgical procedure (surgical waste) for patients who will not be opposed
62404303|NCT00615407||Alcohol Drinkers|Asthmatics who consume 3 or more alcoholic beverages per day (on average)
62404304|NCT00615407||Non Drinkers|Asthmatics who do not drink alcohol or consume less than or equal to 2 alcoholic beverages per month
62404305|NCT02770534||Sickle patients in steady state|Well sickle cell patients attending the outpatient clinic
62204545|NCT05197283|EXPERIMENTAL|Whole wheat spaghetti|Fourteen healthy, normal body weight adults (male: 6, female: 10) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from white bread, tested two times; and 50 gr available carbohydrates from spaghetti No7 types, regular, whole wheat and low carbohydrates - high fibre, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose and salivary insulin sample was taken exactly 15min after the first bite of food or drink.
62204546|NCT05197283|EXPERIMENTAL|High fiber - low carbohydrate spaghetti|Fourteen healthy, normal body weight adults (male: 6, female: 10) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from white bread, tested two times; and 50 gr available carbohydrates from spaghetti No7 types, regular, whole wheat and low carbohydrates - high fibre, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose and salivary insulin sample was taken exactly 15min after the first bite of food or drink.
62204547|NCT05716724||Participants with T2D|The study is non-interventional as there are no interventions involved and the decision to initiate oral semaglutide treatment is at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study. Participants will be treated with oral semaglutide (at least 4 weeks on maintenance dose) once daily with or without other oral antidiabetics (OADs) as per local label at the discretion of the treating physician.
62404306|NCT02770534||Sickle cell patients admitted in crisis|Inpatients with acute vaso-occlusive crisis
62404307|NCT02770534||Sickle patients on transfusion program|Sickle patients managed on a regualar transfusion program
62404308|NCT02770534||Sickle patients on Hydroxycarbamide|Sickle cell patients managed on hydroxycarbamide and on a stable dose for at least 3 months
62404309|NCT02770534||Health controls|Well age and race matched individuals without a known diagnosis of sickle cell anaemia
62404310|NCT04114461|EXPERIMENTAL|HL-TOF tab. 5mg|Tofacitinib freebase
62404311|NCT04114461|ACTIVE_COMPARATOR|Xeljanz tab. 5mg|Tofacitinib citrate (5mg as tofacitinib)
62404312|NCT03678649|EXPERIMENTAL|the treatment arm|"1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .~it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent"
62404313|NCT03678649|NO_INTERVENTION|the control arm|clinical observation
62404314|NCT01001195|EXPERIMENTAL|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
62404315|NCT01001195|EXPERIMENTAL|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
62404316|NCT01001195|EXPERIMENTAL|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
62204548|NCT05502783|EXPERIMENTAL|Fostamatinib Arm|The subjects will receive oral fostamatinib daily for 12 weeks.
62204549|NCT04521751|EXPERIMENTAL|EMP16-02 120 mg orlistat/40 mg acarbose|"Dosage form: Oral, modified-release (MR) fixed dose combination (FDC) of orlistat and acarbose formulated in capsules.~Dosage: 120 mg O/40 mg A (given as 2 capsules EMP16-02-60/20). Frequency: Three times daily (TID) together with the three main daily meals .Taken halfway through each meal, together with approximately 100-200 mL water (or other drink).~Duration: 26 weeks."
62215192|NCT00751361|ACTIVE_COMPARATOR|1|Treatment group: Patients receive 10 Rheopheresis treatments within 17 weeks
62404317|NCT01001195|ACTIVE_COMPARATOR|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
62404318|NCT04524351|ACTIVE_COMPARATOR|Posiphen, 80mg (Parkinson's Participants)|Posiphen Oral Capsule, 80mg, taken once per day for 25±2 days.
62404319|NCT04524351|ACTIVE_COMPARATOR|Posiphen, 40mg (Parkinson's Participants)|Posiphen Oral Capsule, 40mg, taken once per day for 25±2 days.
62404320|NCT04524351|ACTIVE_COMPARATOR|Posiphen, 20mg (Parkinson's Participants)|Posiphen Oral Capsule, 20mg, taken once per day for 25±2 days.
62404321|NCT04524351|ACTIVE_COMPARATOR|Posiphen, 10mg (Parkinson's Participants)|Posiphen Oral Capsule, 10mg, taken once per day for 25±2 days.
62404322|NCT04524351|ACTIVE_COMPARATOR|Posiphen, 5mg (Parkinson's Participants)|Posiphen Oral Capsule, 5mg, taken once per day for 25±2 days.
62404323|NCT04524351|PLACEBO_COMPARATOR|Placebo (Parkinson's Participants)|Placebo Oral Capsule, taken once per day for 25±2 days.
62404324|NCT04524351|PLACEBO_COMPARATOR|Placebo (Alzheimer's Participants)|Placebo Oral Capsule, taken once per day for 25±2 days.
62404325|NCT04524351|ACTIVE_COMPARATOR|Posiphen, 80mg (Alzheimer's Participants)|Posiphen Oral Capsule, 80mg, taken once per day for 25±2 days.
62404326|NCT03526848|EXPERIMENTAL|Group 1|HIV infected participants on ART will undergo analytical treatment interruption 2 days after the first infusion of 3BNC117 and 10-1074, and will receive 6 additional infusions of both antibodies at weeks 2, 4, 8, 12, 16 and 20 (Part A). Participants will remain off ART until week 38, if viral suppression is maintained (Part B).
62404327|NCT03526848|EXPERIMENTAL|Group 2|HIV infected participants on ART will remain on ART and will be administered seven infusions of 3BNC117 and 10-1074 at weeks 0, 2, 4, 8, 12, 16 and 20 (Part A). Analytical treatment interruption will begin at week 26 until week 38, if viral suppression is maintained (Part B).
62404328|NCT04034329||ASVAL - group|GSV diameter ≤ 6 mm
62404329|NCT04034329||EVLA-group|GSV diameter \> 6 mm
62215193|NCT00751361|NO_INTERVENTION|2|No treatment control group
62215194|NCT06390878|EXPERIMENTAL|Rewilding|The kindergarten yards are modified with natural elements to increase children's exposure to biodiversity and playground equipment are incorporated to the yards to increase children's physical activity.
62404330|NCT06289959|ACTIVE_COMPARATOR|Group1（Plasma cfDNA-negative patients）|Continue to receive monotherapy with rituximab （375mg/m2 q3w）for 2 cycles
62404331|NCT06289959|EXPERIMENTAL|Group2（plasma cfDNA-positive patients）|Continue monotherapy with rituximab （375mg/m2 q3w）for 2 cycles
62404332|NCT06289959|EXPERIMENTAL|Group3（plasma cfDNA-positive patients）|Receive the original regimen for 2 cycles（R-CHOP like）
62404333|NCT01339273|EXPERIMENTAL|TAP block|Patients in this arm will receive ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
62580517|NCT05263050|EXPERIMENTAL|Cabozantinib|Cabozantinib treatment will start at 40 mg of cabozantinib daily and dose escalate or de-escalate based on pre-specified criteria and at set dosing schedules to allow for smaller median dose changes between adjustments. The de-escalation would be fine-tuned and adjustments would be made in 10 mg average daily dosing increments by utilizing alternate day dosing schedules (e.g 60 mg/40 mg every other day) rather than decreasing by 20 mg. The maximum dose of cabozantinib is 60 mg daily. Cycles would be 28 days, with weekly follow-up for cycle 1 and bi-weekly follow-up for cycle 2 to allow for prompt dose adjustments, and then monthly. At each check-in, patients that have met the established protocol criteria and were not yet at the maximum dose of 60 mg daily would be eligible for dose-escalation. Patients would also be dose de-escalated as determined by the investigator. Patients who de-escalate may be allowed to re-escalate in the future.
62580518|NCT05263050|EXPERIMENTAL|Cabozantinib and nivolumab|Cabozantinib treatment will receive monthly fix-dosed nivolumab infusions, and start at 40 mg of cabozantinib daily and dose escalate or de-escalate based on pre-specified criteria and at set dosing schedules to allow for smaller median dose changes between adjustments. The de-escalation would be fine-tuned and adjustments would be made in 10 mg average daily dosing increments by utilizing alternate day dosing schedules (e.g 60 mg/40 mg every other day) rather than decreasing by 20 mg. The maximum dose of cabozantinib is 60 mg daily. Cycles would be 28 days, with weekly follow-up for cycle 1 and bi-weekly follow-up for cycle 2 to allow for prompt dose adjustments, and then monthly. At each check-in, patients that have met established protocol criteria and were not yet at the maximum dose of 60 mg daily would be eligible for dose-escalation. Patients would also be dose de-escalated as determined by the investigator. Patients who de-escalate may be allowed to re-escalate in the future.
62787647|NCT03408613|EXPERIMENTAL|Supplemental Oxygen (O2)|Subjects randomized to night-time supplemental oxygen will complete an overnight oxygen titration protocol in the clinical research unit. Initially, subjects will receive 0.5 liters oxygen (O2)/min; the delivery rate will then be increased by 0.5 l/min until oxygen saturation (SaO2) is ≥88%. The optimal O2 delivery rate determined during this study will be used for the intervention. The oxygen concentrators used at home will record cumulative hours of use to provide an objective measure of adherence (monitored weekly). Compliance will be defined as ≥6 h average use per night..
62015549|NCT05720624|EXPERIMENTAL|Cohort I, Arm B ( standard of care therapy, AEO)|Patients in Cohort I, Arm B receive standard of care therapy and receive AEO PO BID for 1 month on study. Patients also undergo MRS imaging, collection of CSF, and collection of blood on study.
62015550|NCT05720624|ACTIVE_COMPARATOR|Cohort II, Arm A (standard of care therapy)|Patients in Cohort II, Arm A receive standard of care therapy. Patients also undergo MRS imaging, collection of CSF, and collection of blood on study.
62015551|NCT05720624|EXPERIMENTAL|Cohort II, Arm B (standard of care therapy, AEO)|Patients in Cohort II, Arm B receive standard of care therapy and receive AEO PO BID for 3 months on study. Patients also undergo MRS imaging, collection of CSF, and collection of blood on study.
62015552|NCT02129179|EXPERIMENTAL|GLP-1|
62015553|NCT01936961|EXPERIMENTAL|CTLA-4 Antibody + hypofractionated radiotherapy|Hypofractionated radiotherapy completed at least 3 days prior to receipt of CTLA-4 Antibody
62015554|NCT05174975|EXPERIMENTAL|App-based Positive Psychological Intervention group|The intervention will be conducted on the app, including 2-week PPI, diabetes-related health education, physical records, and online consultation.
62015555|NCT05174975|NO_INTERVENTION|control group|usual care which will educated by certificated educators in terms of self-management
62015556|NCT05854290|EXPERIMENTAL|CRT plus CBT and Lifestyle modifications|
62015557|NCT05854290|ACTIVE_COMPARATOR|Usual care Psychoeducation|
62015558|NCT01145079|EXPERIMENTAL|Endeavor arm|
62015559|NCT01145079|ACTIVE_COMPARATOR|Endeavor resolute arm|
62015560|NCT01145079|ACTIVE_COMPARATOR|Xience arm|
62015561|NCT01145079|ACTIVE_COMPARATOR|Cypher arm|
62015562|NCT05825287|ACTIVE_COMPARATOR|Trained by teaching back method|The course method will determine which group to assign the first patient to meet the criteria for inclusion in the study by the researcher. Subsequent patients will be distributed to groups in turn. It is planned to include 40 participants in the study, as losses may occur among the participants. The study will begin on the day that cancer-treated participants receive chemotherapy for the first time. Considering that the participants would be more comfortable and the training would be healthy, the training was planned 30 minutes before the application. The training was planned by the researcher in the chemotherapy case manager's room as face-to-face meetings with each participant separately. Each training will be accompanied by a chemotherapy case manager. Training time is between 20-30 minutes as planned.
62204550|NCT04521751|EXPERIMENTAL|EMP16-02 150 mg orlistat/50 mg acarbose|"Dosage form: Oral, modified-release (MR) fixed dose combination (FDC) of orlistat and acarbose formulated in capsules.~Dosage: 150 mg O/50 mg A (given as 1 capsule EMP16-02-90/30 and 1 capsule EMP16-02-60/20).~Frequency: Three times daily (TID) together with the three main daily meals .Taken halfway through each meal, together with approximately 100-200 mL water (or other drink).~Duration: 26 weeks."
62204551|NCT04521751|PLACEBO_COMPARATOR|Placebo|"Dosage form: Matching, oral capsule. Identical in appearance but contain only cellulose.~Dosage: Placebo (given as 2 placebo capsules) Frequency: Three times daily (TID) together with the three main daily meals .Taken halfway through each meal, together with approximately 100-200 mL water (or other drink).~Duration: 26 weeks."
62580519|NCT03466515|EXPERIMENTAL|intervention|Patients enrolled in the study will be treated for their anal fistula by surgical closure of the internal opening, debridement of the fistula and injection of patients own stem cells enriched fatty tissue around the fistula.
62580520|NCT06574698||High risk Neuroblastoma|High risk Neuroblastoma
62580521|NCT06267313|EXPERIMENTAL|Attention Bias Modification|
62580522|NCT06267313|ACTIVE_COMPARATOR|Attention Control Training|
62580523|NCT06267313|PLACEBO_COMPARATOR|Neutral Training|
62580524|NCT02411448|EXPERIMENTAL|Ramucirumab + Erlotinib|"Part A: 10 milligrams per kilogram (mg/kg) ramucirumab administered every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally.~Participants may continue to receive treatment until discontinuation criteria are met.~Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met."
62204552|NCT01741103|EXPERIMENTAL|Sitagliptin|
62204553|NCT01741103|PLACEBO_COMPARATOR|Placebo|
62204554|NCT05842551|EXPERIMENTAL|Experimental|Patients will receive anodic tEs combined with prismatic lenses for two weeks
62204555|NCT05842551|SHAM_COMPARATOR|Control|Patients will receive sham tEs combined with prismatic lenses for two weeks
62204556|NCT03789331||Transgender Male individuals|"* Group Description: This group consists of transgender male individuals who come to the gynecology clinic for medico-legal evaluation before the sex reassignment surgery.~* Intervention: Anogenital distance measurement with a digital caliper in centimeters in the lithotomy position."
62204557|NCT03789331||Normal healthy female individuals|"* Group Description: Healthy women with normal sexual orientation.~* Intervention: (The same) Anogenital distance measurement with a digital caliper in centimeters in the lithotomy position."
62204558|NCT04956874|EXPERIMENTAL|Experimental Group|Participants will complete the FL-REACH annualized caregiver intervention.
62580525|NCT02411448|PLACEBO_COMPARATOR|Placebo + Erlotinib|"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.~Participants may continue to receive treatment until discontinuation criteria are met."
62580526|NCT02411448|EXPERIMENTAL|Ramucirumab + Gefitinib or Osimertinib|"Part C: 10 mg/kg ramucirumab administered every 2 weeks intravenously (IV) + 250 mg Gefitinib or 80 mg Osimertinib daily orally.~* Ramucirumab and gefitinib administered during period 1.~* Ramucirumab and osimertinib administered during period 2."
62580527|NCT02907892|NO_INTERVENTION|Control|Standard cesarean section surgical technique per surgeon preference
62580528|NCT02907892|EXPERIMENTAL|Glove Change|Cesarean section including changing of sterile surgical gloves immediately prior to abdominal closure
62580529|NCT05025176||Surgery requiring Invasive arterial pressure monitoring|Patients undergoing elective surgery that requires Invasive arterial pressure monitoring as standard of care.
62580530|NCT05445414|EXPERIMENTAL|Intervention group|"Participants randomized to the intervention group will be asked to use the SteWARdS Antibiotic Defense app-an evidence-based serious game app developed by the study team-for a minimum of five days. They will also need to complete three sets of questionnaires - one set at baseline, one set after completing the quest in the app, and another set 6-10 weeks after they complete the quest in the app."
62204559|NCT04956874|NO_INTERVENTION|Control Group|No-intervention control group
62215195|NCT06390878|EXPERIMENTAL|Control|The kindergarten yards are not rewilded with natural elements and the biodiversity is low at the yards. Playground equipment are incorporated to the yards to increase children's physical activity.
62580531|NCT05445414|NO_INTERVENTION|Control group|Participants randomized to the intervention group would be asked to complete two sets of questionnaires - one set at baseline and another set 6-10 weeks later.
62580532|NCT05177276|EXPERIMENTAL|Dose Level -1|Selinexor 12mg po twice weekly (Monday \& Wednesday or Tuesday \& Thursday); Irinotecan 50mg/m2 IV once daily on days 1, 8 \& 15
62580533|NCT05177276|EXPERIMENTAL|Dose Level 1|Selinexor 15mg po twice weekly (Monday \& Wednesday or Tuesday and Thursday); Irinotecan 75mg/m2 IV once daily on days 1, 8 \& 15.
62580534|NCT05177276|EXPERIMENTAL|Dose Level 2|Selinexor 20mg po twice weekly (Monday \& Wednesday or Tuesday and Thursday); Irinotecan 100mg/m2 IV once daily on days 1, 8 \& 15.
62204560|NCT02632604|ACTIVE_COMPARATOR|Bottom-up to top-down cognitive training|Participants are given 20 hours of cognitive training with exercises that involve essentially bottom-up cognitive processes, followed by 20 hours of cognitive training with exercises that involve essentially top-down cognitive processes
62204561|NCT02632604|ACTIVE_COMPARATOR|Top-down to bottom-up cognitive training|Participants are given 20 hours of cognitive training with exercises that involve essentially top-down cognitive processes, followed by 20 hours of cognitive training with exercises that involve essentially bottom-up cognitive processes
62204562|NCT02632604|PLACEBO_COMPARATOR|Computer games|Participants are given 40 hours of computer games commonly found on the internet and which do not involve a high demand in cognitive functions (e.g. fishing game, pinball game, tetris, etc).
62204563|NCT01088984|EXPERIMENTAL|Bendamustine|Bendamustine 90 or 120 mg/m\^2 administered as an intravenous (IV) infusion over 60 minutes on Days 1 and 2 of each 21-day cycle (maximum of 12 total cycles), with delays up to 2 weeks for neutrophil and platelet count recovery, for up to a 35-day cycle.
62204564|NCT05510427|EXPERIMENTAL|Part A (Dose Escalation)|The first group of participants will receive the lowest dose level of infigratinib.
62204565|NCT05510427|EXPERIMENTAL|Part B (Dose Expansion)|Participants will receive infigratinib at the recommended dose that was found in Part A.
62204566|NCT01728337|ACTIVE_COMPARATOR|Dysport and Xeomin|30 U of Dysport® was injected on the right side of the forehead and 12 U Xeomin® was injected on the left side of the forehead (dose-equivalence 2.5:1).
62204567|NCT01728337|ACTIVE_COMPARATOR|Xeomin and Dysport|30 U Dysport® was injected on the left side of the forehead and 12 U Xeomin® was injected on the right side of the forehead (dose-equivalence 2.5:1).
62204568|NCT04462783|EXPERIMENTAL|Patient's symptom data without pulse oximeter|Some patients may not be given a pulse oximeter to enter heart rate and O2 saturation into the CovidX application.
62204569|NCT04462783|EXPERIMENTAL|Patient's symptom data with a pulse oximeter|Some patients will be given (or may have) a pulse oximeter in order to enter heart rate and O2 saturation data into the CovidX application.
62204570|NCT05305170||HF|Patients with heart failure.
62204571|NCT05305170||Controls|Controls without heart failure.
62204572|NCT00402012|NO_INTERVENTION|1|
62204573|NCT00402012|EXPERIMENTAL|2|
62204574|NCT01533844||Neonates|Neonates with CDAD
62404334|NCT01339273|ACTIVE_COMPARATOR|Local anaesthetic infiltration|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
62787648|NCT03408613|SHAM_COMPARATOR|Sham|Subjects in the sham treatment group will complete the oxygen titration protocol described for the night-time supplemental oxygen group, except that their oxygen concentrator will have been covertly modified to deliver room air at a rate of 0.5 l/min.
62204575|NCT00827476|EXPERIMENTAL|ovarian transplantation|tissue will be used for xenotransplantation or in vitro culture
62204576|NCT04288518|EXPERIMENTAL|Primary Brain Tumor|"The tested injected doses of 99mTc-1-thio-D-glucose 500 megabecquerels (MBq).~At least five (5) evaluable subjects with primary brain tumor. The tested injected dose 500 MBq."
62204577|NCT04288518|EXPERIMENTAL|Recurrence of Brain Tumor|"The tested injected doses of 99mTc-1-thio-D-glucose 500 MBq.~At least five (5) evaluable subjects with recurrence of brain tumor. The tested injected dose 500 MBq"
62204578|NCT04288518|EXPERIMENTAL|Benign intracranial lesions|"The tested injected doses of 99mTc-1-thio-D-glucose 500 MBq.~At least five (5) evaluable subjects with benign intracranial lesions. The tested injected dose 500 MBq"
62204579|NCT02747823|EXPERIMENTAL|CBT124|CBT124, single dose of 1 mg/kg, IV infusion
62204580|NCT02747823|ACTIVE_COMPARATOR|EU Sourced Avastin®|EU Sourced Avastin®, single dose of 1 mg/kg, IV infusion
62204581|NCT02747823|ACTIVE_COMPARATOR|US Sourced Avastin®|US Sourced Avastin®, single dose of 1 mg/kg, IV infusion
62204582|NCT05520372|EXPERIMENTAL|autologous immune enhancement therapy (AIET) for treating cancer|A total of 60 cancer patients received one to seven sittings of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) infusions.
62204583|NCT02567760|ACTIVE_COMPARATOR|MP1 group|Subjects receive the MP1 product at the dose of 400 mg/day for 8 weeks.
62204584|NCT02567760|PLACEBO_COMPARATOR|Placebo group|Subject receive the Placebo product for 8 weeks.
62204585|NCT06716021|PLACEBO_COMPARATOR|Placebo|Patients will self-administer an initial dose of placebo for a perceived episode of AF with RVR, followed by an optional second dose 10 minutes later if symptoms persist.
62204586|NCT06716021|EXPERIMENTAL|Etripamil|Patients will self-administer an initial dose of etripamil for a perceived episode of AF with RVR, followed by an optional second dose 10 minutes later if symptoms persist.
62404335|NCT05735860|EXPERIMENTAL|Virtual Reality Exposure Therapy (VRET)|
62404336|NCT05735860|ACTIVE_COMPARATOR|Progressive Muscle Relaxation (PMR)|
62404337|NCT03504501|EXPERIMENTAL|Exp. I: Noonan Syndrome - Lovastatin|200 mg Lovastatin daily for four days / Lovastatin-placebo (cross-over) prior to transcranial magnetic stimulation and test of attentional performance
62204587|NCT02078401||Neurofibromatosis type 1 children|
62204588|NCT02543983|EXPERIMENTAL|1|Ketamine Hydrochloride infusion
62204589|NCT02605551|ACTIVE_COMPARATOR|OMT Group|During the initial visit, the subject will have his BP recorded manually by the osteopathic physician in a standardized fashion. The subject will then undergo the OMT protocol and have his BP recorded again immediately afterwards. This will represent the conclusion of the initial visit. There will be 2 subsequent visits about 2-3 weeks apart that will be identical to this visit. Following the third visit, the next follow-up will be 2 months afterwards. However, the patient will only have his BP checked, and will not undergo an OMT treatment. The final visit will be another 2 months afterwards and will also be a simple BP check with no OMT treatment. The principles of lifestyle modification (diet/exercise/weight loss) will also be discussed at each visit.
62404338|NCT03504501|EXPERIMENTAL|Exp. II: Noonan Syndrome - Lamotrigine|300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance
62204590|NCT02605551|PLACEBO_COMPARATOR|Control Group|Patients in this arm will only receive lifestyle modification recommendations at each visit, along with a BP check. No antihypertensive medication changes will be made unless indicated by the guidelines.
62204591|NCT03846180||Terlipressin group|Cirrhotic patients with acute gastrointestinal bleeding received terlipressin with or without somatostatin/octreotide.
62204592|NCT03846180||Somatostatin/Octreotide group|Cirrhotic patients with acute gastrointestinal bleeding received somatostatin and/or octreotide without terlipressin.
62580535|NCT05177276|EXPERIMENTAL|Dose Level 3|Selinexor 30mg po twice weekly (Monday \& Wednesday or Tuesday and Thursday); Irinotecan 75mg/m2 IV once daily on days 1, 8 \& 15.
62204593|NCT05788874||18F-FDG|
62204594|NCT05788874||18F-FAPI|
62787649|NCT03408613|NO_INTERVENTION|Controls|Subjects without OSA will be recruited and complete all testing for primary outcome measures, but will not undergo any intervention.
62787650|NCT00928694|ACTIVE_COMPARATOR|1|Fenofibrate U.S. Formulation
62204595|NCT04058275||Control|Deployed to 1990-1991 Persian Gulf War Do not meet Kansas Criteria for Gulf War Illness \[Steele L. Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. Am J Epidemiol. 2000 Nov 15; 152:992-1002. PubMed PMID: 11092441.\] Good general medical and psychiatric health
62204596|NCT04058275||Gulf War Illness|Deployed to 1990-1991 Persian Gulf War Meet Kansas Criteria for Gulf War Illness \[Steele L. Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. Am J Epidemiol. 2000 Nov 15; 152:992-1002. PubMed PMID: 11092441.\] plus Center for Disease Control criteria for Chronic Multisymptom Illness (CMI) \[Fukuda K, Nisenbaum R, Stewart G, Thompson WW, Robin L, Washko RM, Noah DL, Barrett DH, Randall B, Herwaldt BL, Mawle AC, Reeves WC. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA. 1998 Sep 16;280(11):981-8. PubMed PMID: 9749480.\]
62204597|NCT01689935|NO_INTERVENTION|Control|No drug, no treatment
62204598|NCT01689935|ACTIVE_COMPARATOR|ALA-PDT|Drug- topical 20% Aminolevulinic acid - ALA followed by red light irradiation - conventional photodynamic therapy -PDT
62404339|NCT03504501|EXPERIMENTAL|Exp. III: Neurofibromatosis Type 1 - Lamotrigine|300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance
62404340|NCT04489862|EXPERIMENTAL|CAR T cells therapy|The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10\^5 CAR+ T cells/kg, 3×10\^5 CAR+ T cells/kg, 1×10\^6 CAR+ T cells/kg, and 3×10\^6 CAR+ T cells/kg.
62580536|NCT05177276|EXPERIMENTAL|Dose Level 4|Selinexor 30mg po twice weekly (Monday \& Wednesday or Tuesday and Thursday); Irinotecan 125mg/m2 IV once daily on days 1, 8 \& 15.
62204599|NCT01689935|EXPERIMENTAL|i-PDT|Drug - topical 20% Aminolevulinic acid - followed by inhibitory light during incubation time, then red light for photodynamic therapy
62204600|NCT01689935|ACTIVE_COMPARATOR|Red Light only|Red light only - no drug
62204601|NCT01689935|ACTIVE_COMPARATOR|Blue light only|Blue light only - no drug
62204602|NCT05048498|ACTIVE_COMPARATOR|Azacitidine|"Treatment phase 1: the patients will receive regular treatment with azacitidine for 4 days.~Treatment phase 2: the patients will receive regular treatment with azacitidine for 3 days."
62204603|NCT05048498|EXPERIMENTAL|NEX-18a|"Treatment phase 1: the azacitidine dose for day 5 will be replaced by a single dose NEX-18a~Treatment phase 2: the azacitidine dose for day 4 and 5 will be replaced by a single dose NEX-18a"
62204604|NCT03572426||Bipolar|Diagnosed as having at least 1 lifetime manic episode by the MINI
62204605|NCT03572426||Depression|Diagnosed as having at least 1 Major Depressive Episode by the MINI
62204606|NCT03572426||Healthy Controls|Does not meet Criteria for any mood disorder diagnosis (MDD, BD, dysthymia)
62404341|NCT06230276|EXPERIMENTAL|Intervention with and without premeal bolus|
62404342|NCT01993238|EXPERIMENTAL|Liposonix with pre-treatment analgesia|Liposonix System (Model 2) treatment of subcutaneous adipose tissue with pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
62404343|NCT02682966||PMI|Postoperative Myocardial injury, postoperative troponin levels ≥ 60 ng/L
62580537|NCT05563298|ACTIVE_COMPARATOR|Active Neuro Rx Device|The active device will deliver light for the 20 minutes session duration.
62404344|NCT02682966||Control|postoperative troponin levels \< 60 ng/L
62404345|NCT01913613|EXPERIMENTAL|Treatment|Treatment with the IASD device
62580538|NCT05563298|SHAM_COMPARATOR|Sham Neuro Rx Device|The Sham device is indistinguishable from the active device. The sham device will not deliver light for the 20 minutes session duration.
62787651|NCT00928694|ACTIVE_COMPARATOR|2|Fenofibrate UK Formulation
62204607|NCT01109680|EXPERIMENTAL|14 C labelled Neramexane, capsule|
62204608|NCT03377361|EXPERIMENTAL|Part 1 Cohort 1 3rd Line (3L): nivolumab + trametinib|
62204609|NCT03377361|EXPERIMENTAL|Part 1A Cohort 2 2nd Line (2L): nivolumab + ipilimumab + trametinib|
62204610|NCT03377361|EXPERIMENTAL|Part 1A Cohort 3 (2L): nivolumab + ipilimumab + trametinib|
62204611|NCT03377361|EXPERIMENTAL|Part 2 Cohort 4 (3L): nivolumab + ipilimumab + trametinib|
62204612|NCT03377361|EXPERIMENTAL|Part 2 Cohort 5 (3L): Regorafenib|
62204613|NCT03377361|EXPERIMENTAL|Part 1B Cohort 6 (2L): nivolumab + ipilimumab + trametinib|
62580539|NCT01069185|EXPERIMENTAL|Necessity endotracheal suctioning|Endotracheal suctioning depends on clinical manifestations
62580540|NCT01069185|OTHER|Routine endotracheal suctioning|Endotracheal suctioning every two hours
62787652|NCT03015935||Optical|visual-assisted entry
62787653|NCT03015935||Veress|Veress entry
62787654|NCT01079494|ACTIVE_COMPARATOR|intervention group|physician-pharmacist teamwork
62787655|NCT01079494|NO_INTERVENTION|control|physician only team
62787656|NCT05696496|EXPERIMENTAL|Patients with sleep disorders (TS+)|"video polysomnography; the new ESM intelligent duvet device"
62787657|NCT05696496|EXPERIMENTAL|control group without sleep disorder (TS-)|"video polysomnography; the new ESM intelligent duvet device"
62204614|NCT05716295|EXPERIMENTAL|MDK-703 Monotherapy|MDK-703 will be administered in sequential ascending doses as a monotherapy until unacceptable toxicity, disease progression, or withdrawal of consent.
62204615|NCT05716295|EXPERIMENTAL|MDK-703 in combination with a checkpoint inhibitor|MDK-703 will be administered in sequential ascending doses in combination with a checkpoint inhibitor until unacceptable toxicity, disease progression, or withdrawal of consent.
62204616|NCT01940939|ACTIVE_COMPARATOR|Active rTMS|Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 100 stimulation trains of 20 stimuli each (i.e., 2000 stimuli) and an inter-train interval of 9 sec. Treatment will be applied in sequential order to the left dorsolateral prefrontal cortex (DLPFC). Intervention: Device: Repetitive Transcranial Magnetic Stimulation
62204617|NCT01940939|SHAM_COMPARATOR|Sham rTMS|Sham rTMS stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but the coil will be reversed. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.Intervention: Device: Repetitive Transcranial Magnetic Stimulation
62204618|NCT01518959|PLACEBO_COMPARATOR|Placebo|no treatment
62204619|NCT01518959|ACTIVE_COMPARATOR|Cholecalcipherol|Treatment with 180 000 IU cholecalcipherol monthly
62204620|NCT03613376|NO_INTERVENTION|No Compression|Patients in this group will not receive any compression after treatment
62204621|NCT03613376|ACTIVE_COMPARATOR|Compression|Patients in this group will use class II compression stockings continuously until next evening and then next 4 days during daytime.
62204622|NCT06010277|EXPERIMENTAL|Folinic acid arm|Patients in the intervention-arm will receive oral folinic acid orally 4 times 45mg / day for 3 days, starting 24 hours after the administration of pemetrexed.
62204623|NCT06010277|NO_INTERVENTION|No folinic acid arm|Patients will be treated according to regular care.
62204624|NCT02988050|OTHER|Propofol-dexmedetomidine|Propofol-dexmedetomidine Bupivacaine; Lidocaine (local anaesthetics) Epinephrine (with local anaesthetics for skin infiltration)
62204625|NCT02988050|OTHER|Propofol-remifentanil|Propofol-remifentanil Bupivacaine; Lidocaine Epinephrine (with local anaesthetics for skin infiltration)
62404346|NCT05174429|EXPERIMENTAL|Risk-Targeted Behavioral Activation|The treatment program consisted of a 10-week standardized behavioral activation intervention supplemented by techniques to target two psychosocial risk-factors for delayed recovery, namely, catastrophic thinking and perceptions of injustice.
62404347|NCT03329404|EXPERIMENTAL|Mirasol Red Blood Cells (MIR RBCs)|MIR RBCs: RBCs will be derived from WB collected in CPD solution, treated with the Mirasol System for WB, LR, and stored in AS-3 for ≤ 21 days at 1-6°C
62787658|NCT01920308||5 mm Bard LifeStent Vascular Stent|"The study population will be comprised of subjects who present with moderate lifestyle-limiting claudication to mild tissue loss (Rutherford Category 2-5) that are candidates for PTA and stenting.~Subjects with lesion(s) in the infra-inguinal segment (SFA and/or popliteal artery) will be considered for enrollment. The reference vessel diameter will be appropriate for treatment with available stent diameter of 5.0 mm (by visual estimate)."
62787659|NCT03060954|EXPERIMENTAL|MINI WELL READY ®|BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY
62787660|NCT03060954|OTHER|FineVision ®|FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
62204626|NCT03635099|PLACEBO_COMPARATOR|Part I - Placebo (fasted)|Part I - Placebo matching BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). Participants who failed to achieve a Psoriasis Area Severity Index score (PASI) 75 response at Week 12 were switched to a 200 mg dose, participants switching dose were imputed as failure for records after week 12, under original randomized treatment arm.
62204627|NCT03635099|EXPERIMENTAL|Part I - BI 25 mg (fasted)|Part I - 25 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). Participants who failed to achieve a Psoriasis Area Severity Index score (PASI) 50 response at Week 12 were switched to a 50 mg dose, participants switching dose were imputed as failure for records after week 12, under original randomized treatment arm.
62215196|NCT04323176|EXPERIMENTAL|Village Model|Participate as a member of the Village using a website for 12 months.
62015563|NCT05825287|EXPERIMENTAL|Management training|The course method will determine which group to assign the first patient to meet the criteria for inclusion in the study by the researcher. Subsequent patients will be distributed to groups in turn. It is planned to include 40 participants in the study, as losses may occur among the participants. The study will begin on the day that cancer-treated participants receive chemotherapy for the first time. Considering that the participants would be more comfortable and the training would be healthy, the training was planned 30 minutes before the application. The training was planned by the researcher in the chemotherapy case manager's room as face-to-face meetings with each participant separately. Each training will be accompanied by a chemotherapy case manager. Training time is between 20-30 minutes as planned.
62015564|NCT02144675|EXPERIMENTAL|Arm I (choline magnesium trisalicylate and chemotherapy)|Patients receive choline magnesium trisalicylate PO every 8 hours on days 0-7, idarubicin IV on days 1-3, and cytarabine IV continuously on days 1-7.
62015565|NCT02144675|ACTIVE_COMPARATOR|Arm II (chemotherapy)|Patients receive idarubicin IV on days 1- 3 and cytarabine IV continuously on days 1-7.
62015566|NCT02199691|EXPERIMENTAL|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine on Day 0.
62015567|NCT02199691|ACTIVE_COMPARATOR|Group 2: MENVEO® Vaccine|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MENVEO® vaccine on Day 0.
62015568|NCT02199691|EXPERIMENTAL|Group 3: MenACYW Conjugate Vaccine+Tdap+HPV|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine, Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap), and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
62015569|NCT02199691|ACTIVE_COMPARATOR|Group 4: Tdap+HPV|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of Tdap and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
62015570|NCT03827798|EXPERIMENTAL|CFZ533|s.c.
62015571|NCT03827798|EXPERIMENTAL|LYS006|p.o.
62015572|NCT03827798|PLACEBO_COMPARATOR|Placebo to CFZ533|Matching placebo (s.c.)
62015573|NCT03827798|PLACEBO_COMPARATOR|Placebo to LYS006|Matching placebo (p.o.)
62787661|NCT02389036|NO_INTERVENTION|Control group- standard care|Standard care- In Australia there are no national guidelines so local policy is determined by each ICU. We are recommending (but not mandating) that control and SDD group management be in line with these national guidelines. We will recommend control and SDD group management is in line with current national standards of practice that may or may not include a VAP bundle. We will monitor record data regarding the nature and delivery of the control and SDD group co-interventions.
62787662|NCT02389036|EXPERIMENTAL|SDD intervention group|"The intervention will entail:~1. A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx~2. A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10\^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube~3. A four-day course of an IV antibiotic. Patients not already receiving a therapeutic antibiotic will be prescribed cefotaxime 1g six-hourly or ceftriaxone 1g daily, with dose adjusted as appropriate for organ dysfunction. Ciprofloxacin (400mg 12-hourly) may be used as an alternative if there is a contraindication to cephalosporins (e.g. allergy). Patients already receiving an alternative IV antibiotic to treat infection will not receive this additional IV antibiotic, but will continue the prescribed antibiotic for the usual duration of therapy."
62015574|NCT03827798|EXPERIMENTAL|MAS825|s.c.
62015575|NCT03827798|PLACEBO_COMPARATOR|Placebo to MAS825|Matching placebo (s.c.)
62015576|NCT03827798|ACTIVE_COMPARATOR|LOU064 25mg|p.o.
62404348|NCT03329404|ACTIVE_COMPARATOR|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs); LR apheresis RBCs or WB-derived RBCs will be per site standard inventory
62787663|NCT01598922|EXPERIMENTAL|Internet Cognitive Behavioral Therapy|Participants with major depressive disorder receive an 8-week long internet-based cognitive behavioral therapy program.
62787664|NCT01598922|NO_INTERVENTION|Monitored Attention Control|Participants with major depressive disorder receive no treatment but are monitored closely for 8 weeks. Participants in this arm are offered the treatment at the end of the study.
62787665|NCT01162902|EXPERIMENTAL|Diltiazem treated group|Diltiazem 180mg treated group
62787666|NCT01162902|ACTIVE_COMPARATOR|Bisoprolol treated group|Bisoprolol 5mg treated group
62787667|NCT01162902|ACTIVE_COMPARATOR|Candesartan treated group|Candesartan 32mg treated group
62787668|NCT05512169||Newly diagnosed ALL Children with age group of >1 and ≤18 years old|Newly diagnosed ALL Children who are likely to receive anti-cancer drugs or chemotherapy as a part of IciCLE treatment protocol.
62787669|NCT06339307||with LNM|Patients with gastric cancer who underwent curative gastrectomy and developed lymph node metastasis.
61978494|NCT03794414|EXPERIMENTAL|fluid responder|patients with 10% or more increase in stroke volume after fluid challenge. Both arms receive PEEP challenge.
62580541|NCT03781635|ACTIVE_COMPARATOR|bolus of intravenous ketamine|A bolus of 0.25mg.kg-1 of ketamine will be first administered at the time of incision (T0) then every single hour for the rest of the surgery. Study starts at incision (T0) for ketamine administration and ends when the surgical team starts closing the deep layers of the abdominal incision.
62580542|NCT03781635|EXPERIMENTAL|continuous infusion of intravenous ketamine|An infusion of 0.25 mg.kg-1.h-1 is started at T0 (incision) with an infusion pump and is kept at the same rate until the surgical team starts closing the deep layers of the abdominal incision. Consumption of the infusion pump is noted at T0 (incision) and at each hour during the surgery until the infusion is discontinued.
62580543|NCT03815045|ACTIVE_COMPARATOR|Landmark-based lumbar puncture|Landmark-based LP
62580544|NCT03815045|ACTIVE_COMPARATOR|Ultrasound-guided lumbar puncture|Ultrasound-guided LP
62580545|NCT05745194|EXPERIMENTAL|Interventional Group|Interventional group with six nutritional counselling consultations promoting the adherence to the MedDiet and TAU for MDD
62580546|NCT05745194|NO_INTERVENTION|Control Group|Individuals with TAU for MDD
62580547|NCT03687905||Lupus nephritis III or IV/chloroquine|receiving chloroquine with daily dose 5 mg/kg
62404349|NCT04504292|EXPERIMENTAL|Oral sulfate solution (SuPREP arm)|"Per the package insert: The dose for colon cleansing requires administration of two bottles of SUPREP Bowel Prep Kit. Each bottle is administered as 16 oz of diluted SUPREP solution with an additional 1quart of water taken orally. The total volume of liquid required for colon cleansing (using two bottles) is 3 quarts (approximately 2.8 L) taken orally prior to the colonoscopy outlined below under frequency.~Two 6 oz bottles of oral solution: Each 6 oz bottle contains: sodium sulfate 17.5 g, potassium sulfate 3.13 g, magnesium sulfate 1.6 g."
62404350|NCT04504292|ACTIVE_COMPARATOR|Polyethelene Glycol (GoLytely arm)|Polyethylene Glycol Bowel Prep Kit
62404351|NCT05679570|EXPERIMENTAL|Satralizumab （Genetical Recombination）|
62580548|NCT03687905||Lupus nephritis III or IV/hydroxychloroquine|receiving hydroxycholorquine with daily dose 5 mg/kg
62404352|NCT03677609|EXPERIMENTAL|Intervention|Physicians will receive a training or trainings to improve their communication and interaction with patients. The primary trainings will involve teaching physicians how to understand and leverage patient psychology as part of clinical care. Impact on patient health will then be assessed.
62015577|NCT03827798|ACTIVE_COMPARATOR|LOU064 100mg|p.o.
62015578|NCT03827798|PLACEBO_COMPARATOR|Placebo to LOU064|Matching placebo p.o.
62404353|NCT03677609|NO_INTERVENTION|Control|
62015579|NCT03827798|EXPERIMENTAL|VAY736|s.c.
62015580|NCT03827798|PLACEBO_COMPARATOR|Placebo to VAY736|Matching placebo (s.c.)
62015581|NCT01818336|EXPERIMENTAL|all subjects|"Intervention: Penicillin skin test kit~Subjects with negative intradermal tests will be given single oral amoxicillin challenge dose and followed for 72 hours for IgE dependent reactions."
62015582|NCT05239026|EXPERIMENTAL|Advanced Training Group|This arm will receive a single session treadmill training session in which both cadence and treadmill speed are controlled.
62015583|NCT05239026|EXPERIMENTAL|Traditional Training Group|This arm will receive a single session treadmill training session in which only treadmill speed is controlled.
62015584|NCT01160107|EXPERIMENTAL|RP followed MPR|
62015585|NCT03176108|EXPERIMENTAL|CBT Group|"The CBT group benefits of an intervention based on the program Better manage its anger and its frustrations of 15 sessions for the children.~Parents participate in an CBT intervention of 8 sessions every 15 days. The session allow to develop adapted behaviors, to manage the disruptive behaviors and to improve the relations parents/children."
62404354|NCT02184988|EXPERIMENTAL|Botulinum neurotoxin, Type A|DWP-450 (Botulinum purified neurotoxin, Type A) Injection
62404355|NCT00344968|EXPERIMENTAL|1|
62404356|NCT00344968|EXPERIMENTAL|2|
62404357|NCT00344968|SHAM_COMPARATOR|3|
62404358|NCT00322517|EXPERIMENTAL|SU014813|
62404359|NCT03062852|EXPERIMENTAL|Medication safety vest|During administration rounds, nurses will wear the medication safety vest.
62404360|NCT03062852|NO_INTERVENTION|Control|During administration rounds, nurses will be dressed as usual without a safety vest.
62404361|NCT01473602|PLACEBO_COMPARATOR|Placebo|Administered once daily by subcutaneous (SC) injection for 6 months
62404362|NCT01473602|EXPERIMENTAL|Teriparatide|20 microgram (µg) administered once daily by SC injection for 6 months
62404363|NCT00883831|EXPERIMENTAL|Individualized manual acupuncture|
62015586|NCT03176108|SHAM_COMPARATOR|Control Group|"The control group participates in an intervention of body mediation (theatre) of 15 session for the children.~Parents participate in an CBT intervention of 8 sessions every 15 days. The session allow to develop adapted behaviors, to manage the disruptive behaviors and to improve the relations parents/children."
62404364|NCT01159652|PLACEBO_COMPARATOR|Bedtime Placebo|
62404365|NCT01159652|PLACEBO_COMPARATOR|Middle of the Night Placebo|
62404366|NCT01159652|EXPERIMENTAL|Zolpidem|
62404367|NCT01159652|EXPERIMENTAL|Zaleplon|
62404368|NCT04281121|ACTIVE_COMPARATOR|supplemented|Life style modification, diet regimen and Omega-3 fatty acids supplementation
62404369|NCT04281121|ACTIVE_COMPARATOR|non supplemented|Life style modification and diet regimen
62204628|NCT03635099|EXPERIMENTAL|Part I - BI 50 mg (fasted)|Part I - 50 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). Participants who failed to achieve a Psoriasis Area Severity Index score (PASI) 50 response at Week 12 were switched to a 100 mg dose, participants switching dose were imputed as failure for records after week 12, under original randomized treatment arm.
62204629|NCT03635099|EXPERIMENTAL|Part I - BI 100 mg (fasted)|Part I - 100 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). Participants who failed to achieve a Psoriasis Area Severity Index score (PASI) 50 response at Week 12 were switched to a 200 mg dose, participants switching dose were imputed as failure for records after week 12, under original randomized treatment arm.
62204630|NCT03635099|EXPERIMENTAL|Part I - BI 200 mg (fasted)|Part I - 200 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
62404370|NCT01315626||Immediately preceding intervention|3 months immediately before the education event. Charts of patients with a primary respiratory complaint will be reviewed so evaluate if they 1) have experienced 3 or more suppurative respiratory infections and 2) have required 3 or more courses of antibiotic therapy for respiratory infection over the period of one year. 4) Whether or not they underwent a HRCT, and if so, and 5) Were the patients diagnosed with BE.
62404371|NCT01315626||3 months after educational event|3 months immediately after the education event. An active assessment will be preformed as per the proposed diagnostic algorithm (attachment B) Patients that meet all criteria in the algorithm are considered at risk for bronchiectasis and based on these criteria, physicians will be encouraged to order HRCT, and the number/ proportion of patients identified with BE will be noted and compared to the other time periods.
62404372|NCT01315626||Seasonal prior year|As respiratory illnesses are commonly seasonal, an assessment of rate of Bronchiectasis diagnosis during the months of Period 2 in the year prior to the educational intervention will also be assessed as described in Period 1
62404373|NCT04575415||Arm 1:Bevacizumab plus Erlotinib/Gefitinib/Icotinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus first-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks. Erlotinib 150 mg tablets once daily or Gefitinib 250mg once daily or Icotinib 125mg three times a day would be administered.
62404374|NCT04575415||Arm 2:Bevacizumab plus Afatinib/Dacomitinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus second-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks.Afatinib 40 mg or clinical routine dose once daily or Dacomitinib 45mg or clinical routine dose once daily or clinical routine dose would be administered.
62404375|NCT04575415||Arm 3:Bevacizumab plus Osimertinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus third-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks. Osimertinib 80 mg tablets once daily would be administered.
62404376|NCT00944528|EXPERIMENTAL|Single dose radiosurgery: Dose Level 1|A single 15 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
62580549|NCT03687905||Systemic lupus erythematosus|not received hydroxychloroquine nor chloroquine .
62580550|NCT04187872|EXPERIMENTAL|Patients with Recurrent Brain Metastes|Adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis that have failed SRS treatment will receive LITT per standard of care in combination with Pembrolizumab 200mg IV every 3 weeks (+/-3 days) up to 2 years.
62580551|NCT01895374|EXPERIMENTAL|amniotic membrane dressing|We compare the efficacy of amniotic membrane and hydrocolloid in same subjects to avoid confounders.
62580552|NCT01895374|ACTIVE_COMPARATOR|Hydrocolloid dressing|Same subjects received amniotic membrane and hydrocolloid dressing at the same time in different wound.
62204631|NCT03635099|PLACEBO_COMPARATOR|Part II - Placebo (fed)|Part II - 4 film-coated tablets of matching Placebo were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
62204632|NCT03635099|EXPERIMENTAL|Part II - BI 400 mg once daily (fed)|Part II - 4 film-coated tablets of 100 milligram (mg) BI 730357 (400 mg in total) were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
62580553|NCT03806725||Liver transplant (LTx) candidates with eGFR>=60|Liver transplant candidates with renal function defined by eGFR above or equal to 60 ml/min/1.73m2, eGFR is determined by Cystatin C measurement.
62580554|NCT03806725||LTx candidates with eGFR<60|"Liver transplant candidates with decreased renal function.~Defined by eGFR less than 60 ml/min/1.73m2, eGFR is determined by Cystatin C measurement."
62580555|NCT01579422|EXPERIMENTAL|social cognitive training|
62787670|NCT06339307||without LNM|Patients with gastric cancer who underwent curative gastrectomy and did not develop lymph node metastasis.
62787671|NCT05882149|EXPERIMENTAL|Probiotic|Sugar-free chewing gum with single strain probiotic and zinc. A daily dose of 2 chewing gums containing 1x10\^10 Colony Forming Unit (CFU) for 12 weeks.
62787672|NCT05882149|PLACEBO_COMPARATOR|Placebo|Sugar-free chewing gum for 12 weeks.
62787673|NCT00825903|EXPERIMENTAL|1|Aquatic based exercise
62015587|NCT02604589|PLACEBO_COMPARATOR|PCA only|Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
62015588|NCT02604589|EXPERIMENTAL|Bupivicaine 0.25% (LOW DOSE)|"Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.~Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter."
62204633|NCT03635099|EXPERIMENTAL|Part II - BI 200 mg twice daily, 400 mg total (fed)|Part II - 2 film-coated tablets of 100 milligram (mg) BI 730357 were taken orally with a meal in the morning and evening (twice daily; total daily dosage: 400 mg) for 12 weeks.
62204634|NCT04175561|EXPERIMENTAL|Intervention|Participants in the intervention arm will be given a green prescription (gardening activities).
62404377|NCT00944528|EXPERIMENTAL|Single dose radiosurgery: Dose Level 2|A single 18 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
62404378|NCT00944528|EXPERIMENTAL|Single dose radiosurgery: Dose Level 3|A single 21 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
62404379|NCT01481480|EXPERIMENTAL|Latissimus dorsi tendon transfer|A Latissimus dorsi tendon transfer is performed
62404380|NCT01481480|ACTIVE_COMPARATOR|Arthroscopic repair|An arthroscopic repair is performed
62404381|NCT02962440|EXPERIMENTAL|Somapacitan|
62404382|NCT05245461||Anterior Cruciate Ligament Reconstruction|Patients who had remnant-preserving anterior cruciate ligament reconstruction
62404383|NCT05245461||Healthy Group|People who had no knee surgery or injury
62404384|NCT00605969|ACTIVE_COMPARATOR|FAI patients|This group consists of participants diagnosed with femoroacetabular impingement that are undergoing surgical correction.
62404385|NCT00605969|PLACEBO_COMPARATOR|Control|This group consists of healthy control participants with no hip problems.
62580556|NCT03208478|ACTIVE_COMPARATOR|Adductor Canal Nerve Block group|Adductor Canal perineural catheter placement. Adductor Canal continuous perineural infusion. Ropivacaine 0.2% will be administered at a continuous rate of 5 mL/hour through a perineural catheter placed in the adductor canal. A Nimbus pump (Infutronix) will be delivering the medication.
62787674|NCT06434246|EXPERIMENTAL|Intervention Group|16 Children will undergo a pulley system exercise regimen tailored to improve upper limb function in addition to designed physical therapy program for CP.
62404386|NCT03564977|EXPERIMENTAL|CD19-targeted CAR-T cells|
62404387|NCT04456062|EXPERIMENTAL|Caring Contacts Group|
62787675|NCT06434246|ACTIVE_COMPARATOR|Control Group|Children will receive designed physical therapy program for CP only
62787676|NCT06109207|EXPERIMENTAL|Camrelizumab+Dalpiciclib(100mg) 3 patients|"Camrelizumab will be given at at a dose of 200 mg intravenously every three weeks on day 1 of a planned 21-day cycle, and two doses before surgery~Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.~For dalpiciclib, there is 2 dose levels, 100mg qd and 150 mg qd, and if no patients experience DLT on 100mg level, 150mg level will be administered."
62204635|NCT04175561|NO_INTERVENTION|Control|Participants in the control arm will not be given the intervention.
62204636|NCT04502017|ACTIVE_COMPARATOR|Standard Antithrombotic Therapy|OAC for 6 weeks followed by DAPT until 6 month-follow-up, then aspirin alone
62204637|NCT04502017|ACTIVE_COMPARATOR|Genetic-Tailored AntiThrombotic Strategy|OAC for 6 weeks followed by DAPT (clopidogrel responders) or aspirin plus half-dose OAC (clopidogrel non-responders) until 6 month-follow-up, then aspirin alone
62204638|NCT04502017|ACTIVE_COMPARATOR|Half-Dose NOAC|Half Dose of Novel OAC
62204639|NCT03638167|EXPERIMENTAL|ARM A (Tumor Cavity Infusion)|Patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity
62204640|NCT03638167|EXPERIMENTAL|ARM B (Ventricular System Infusion)|Patients with either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the fourth ventricle or lateral ventricle, respectively
62404388|NCT04456062|NO_INTERVENTION|Standard Treatment Group|
62404389|NCT05022121|EXPERIMENTAL|Supported Biopsychosocial Self-Management (SBSM)|Supported Biopsychosocial Self-Management (SBSM)
62404390|NCT05022121|ACTIVE_COMPARATOR|Medical Care|Medical Care
62404391|NCT00194038|EXPERIMENTAL|1|
62404392|NCT05751824|EXPERIMENTAL|With automatic surveillance system|Patients were reminded of the surveillance time by an automatic surveillance system before the surveillance time.
62404393|NCT05751824|ACTIVE_COMPARATOR|With manual reminder|Patients were reminded of the surveillance time manually before the surveillance time.
62404394|NCT05751824|NO_INTERVENTION|Normal group|The patients in the control group were observed in the clinical natural state of surveillance without automatic surveillance system or manual reminder.
62404395|NCT01662076|EXPERIMENTAL|Sublingual or Oral Liquid Homeopathy|The homeopathic remedy will be administered as 1 lactose/sucrose globule 2.5 mm in diameter to be administered sublingually up to 3 times per day or as 0.2 ml of a 30% ethanol based liquid homeopathic remedy administered orally up to 3 times per day. The homeopathic remedy and/or the homeopathic remedy potency can be changed on a daily basis during the course of treatment. However, only one homeopathic remedy and potency will be administered at a given time.
62404396|NCT01393574|EXPERIMENTAL|Melatonin treatment|Treatment with Melatonin before sleep for 1 month - 3 mg for body weight \<40kg, 6mg for body weight \>40kg
62404397|NCT01393574|ACTIVE_COMPARATOR|Stimulants treatment|Treatment with Methylphenidate with a formulary and dose as decided by the treating neurologist, for 1 month.
62580557|NCT03208478|ACTIVE_COMPARATOR|Femoral Nerve Block group|Femoral Nerve perineural catheter placement. Femoral continuous perineural infusion. Ropivacaine 0.2% will be administered at a continuous rate of 5 mL/hour through a perineural catheter placed near the femoral nerve. A Nimbus pump (Infutronix) will be delivering the medication.
62580558|NCT02216942|ACTIVE_COMPARATOR|Vitapex|Endodontic treatment using Vitapex
62204641|NCT01298687|EXPERIMENTAL|Trav 0.00013%|Travoprost Ophthalmic Solution, 0.00013%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
62204642|NCT01298687|EXPERIMENTAL|Trav 0.00033%|Travoprost Ophthalmic Solution, 0.00033%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
62204643|NCT01298687|EXPERIMENTAL|Trav 0.001%|Travoprost Ophthalmic Solution, 0.001%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
62787677|NCT06109207|EXPERIMENTAL|Camrelizumab+Dalpiciclib(150mg) 3 patients|"Camrelizumab will be given at at a dose of 200 mg intravenously every three weeks on day 1 of a planned 21-day cycle, and two doses before surgery~Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.~For dalpiciclib, there is 2 dose levels, 100mg qd and 150 mg qd, and if no patients experience DLT on 100mg level, 150mg level will be administered."
62787678|NCT02602418|EXPERIMENTAL|HIV Positive participants|Intervention; 90 HIV positive participants will be trained. Half the participants will have the Adaptive WM Cogmed training, and half will have the non-adaptive WM Cogmed training.
62404398|NCT04409509|EXPERIMENTAL|CSL312|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
62204644|NCT01298687|EXPERIMENTAL|Trav 0.00267%|Travoprost Ophthalmic Solution, 0.00267%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
62204645|NCT01298687|ACTIVE_COMPARATOR|TRAVATAN|Travoprost Ophthalmic Solution, 0.004%, 1 drop administered in each eye at 8 pm for 5 days, with 1 drop of vehicle administered at all other timepoints (2-hour intervals)
62204646|NCT01298687|PLACEBO_COMPARATOR|Vehicle|Travoprost vehicle, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
62204647|NCT03043703|EXPERIMENTAL|AirSense 10 AutoSet for Her|Treatment for 1 night with ResMed AirSense 10 AutoSet for Her. Intervention: Administration of PAP Treatment with suboptimal pressure for 1 night.
62404399|NCT04409509|PLACEBO_COMPARATOR|Placebo|CSL312 diluent administered intravenously
62787679|NCT02602418|OTHER|Seronegative particpiants|Intervention; 90 seronegative participants will be trained. Half the participants will have the Adaptive WM Cogmed training, and half will have the non-adaptive WM Cogmed training.
62404400|NCT02638818||minimally invasive whipple|Surgical technique (minimally invasive vs open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
62787680|NCT02440685|EXPERIMENTAL|Part A ASN002 Dose Escalation|Multiple ascending doses of ASN002 will be administered to determine the maximum tolerated dose (MTD). Arm Closed
62787681|NCT02440685|EXPERIMENTAL|Part B ASN002 Recommended dose (RD)|ASN002 administered at the recommended dose
62787682|NCT02703324|EXPERIMENTAL|LY900014|LY900014 delivered via an insulin pump as a continuous infusion under the skin with intermittent bolus doses during meals for two 3-day periods
62787683|NCT02703324|ACTIVE_COMPARATOR|Insulin Lispro|Insulin lispro delivered via an insulin pump as a continuous infusion under the skin with intermittent bolus doses during meals for two 3-day periods
62787684|NCT02003092|EXPERIMENTAL|RX-5902|RX-5902 will be taken daily for 4 weeks in each 4 week cycle. Subjects will be fasting for 8 hours before and food may be ingested approximately 3 hours after the dose has been administered.
62787685|NCT06324396|EXPERIMENTAL|Assessment Arm|Assessment group will receive a single dose of oral sildenafil and oral pravastatin.
62787686|NCT02641301|EXPERIMENTAL|Subjects Roux-en-Y-gastric bypass (RYGB)|Sustained release morphine sulfate, 30 mg
62787687|NCT02641301|ACTIVE_COMPARATOR|Control volunteers matched with RYGB|Sustained release morphine sulfate, 30 mg
62787688|NCT01301833|EXPERIMENTAL|teneligliptin|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )
62787689|NCT01301833|EXPERIMENTAL|teneligliptin and glinide|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide
62787690|NCT01301833|EXPERIMENTAL|teneligliptin and biguanide|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide
62787691|NCT01301833|EXPERIMENTAL|teneligliptin and alpha-glucosidase inhibitor|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor
62787692|NCT04047979|EXPERIMENTAL|Younger Group|Participants between the ages of 50 to 60 years will receive two doses of Zoster vaccine recombinant, adjuvanted (Shingrix®)
62787693|NCT04047979|EXPERIMENTAL|Older Group|Participants who are ≥70 year old will receive two doses of Zoster vaccine recombinant, adjuvanted (Shingrix®)
62787694|NCT04660474||Early reperfusion group|All patients hospitalized and diagnosed as STEMI according to the 4th universal definition of myocardial infarction underwent coronary angiography and PCI treatment. Patients with SO2RT\<24 hours were assigned to Early reperfusion group.
62787695|NCT04660474||Intermediate reperfusion group|All patients hospitalized and diagnosed as STEMI according to the 4th universal definition of myocardial infarction underwent coronary angiography and PCI treatment. Patients with SO2RT ranging from 24 hours to 7days were assigned to Intermediate reperfusion group.
62787696|NCT04660474||Late reperfusion group|All patients hospitalized and diagnosed as STEMI according to the 4th universal definition of myocardial infarction underwent coronary angiography and PCI treatment. Patients with SO2RT\>7days were assigned to Late reperfusion group.
62787697|NCT00182338||Peritoneal Dialysis Patients|
62787698|NCT00731146|ACTIVE_COMPARATOR|1 - Ultrasound|Participants will receive an ultrasound guided interscalene brachial plexus block
62787699|NCT00731146|ACTIVE_COMPARATOR|2 - Nerve Stimulator|Participants will receive a nerve stimulator guided interscalene brachial plexus block
62787700|NCT01609504|EXPERIMENTAL|Transanal Endoscopic Microsurgery|Patients were treated by TEM as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT (ELRR- Endo Luminal Loco Regional Resection)
62787701|NCT01609504|ACTIVE_COMPARATOR|Total Mesorectal Excision|
62787702|NCT03315572||Pediatric subject/caregiver dyads-first interview set|The first interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
62787703|NCT03315572||Pediatric subject/caregiver dyads-second interview set|The second interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
62787704|NCT03733613||Healthy adults|Subjects will receive pre and post-test, in order to verify the test-retest reliability of the Somatosensory detector
62787705|NCT02682082|EXPERIMENTAL|Neurolysis without Bupivacaine|Experimental Group: Endoscopic ultrasound guided celiac plexus Neurolysis without Bupivacaine so only with Absolute Alcohol 20 mL
62787706|NCT02682082|ACTIVE_COMPARATOR|Neurolysis with Bupivacaine|Endoscopic ultrasound guided celiac plexus Neurolysis with Bupivacaine (0.5% Bupivicaine 20mL + Absolute Alcohol 20 mL)
62787707|NCT06078436|EXPERIMENTAL|Pulmonary artery catheter monitoring group|Within 8 hours of random allocation, a pulmonary artery catheter will be inserted to monitor hemodynamic parameters.
62787708|NCT06078436|ACTIVE_COMPARATOR|No pulmonary artery catheter monitoring group|After random allocation, a pulmonary artery catheter will not be inserted during cardiogenic shock management.
62787709|NCT06552650|EXPERIMENTAL|Exercise Group|
62787710|NCT06552650|EXPERIMENTAL|Usual Care Group|
62787711|NCT02699320||"Asymptomatic"|"Asymptomatic meaning patients showed well tolerance to parenteral nutrient (PN) administration and there were no complications occurred within two months (n=7);"
62787712|NCT02699320||CLABSI|with central catheter-related blood stream infections (CLABSI) meaning patients had fever, increased neutrophils, documented positive catheter blood culture but exclude other source of infection (n=5)
62787713|NCT02699320||PNALD|with parenteral nutrient associated liver disease (PNALD), meaning SBS patients showed elevated liver enzymes and bilirubin (n=14).
62787714|NCT02699320||healthy controls|Seven healthy infants who had added complementary were served as controls (n=7).
62787715|NCT01585571||Control|50 individuals of typical development with no known neuromuscular issues.
62204648|NCT00684151||1|Patients with high cardiovascular risk who have been treated with lipid-lowering drugs at least 3 months
62204649|NCT05141552|EXPERIMENTAL|dapa group|subjects will be treated with dapagliflozin (10mg per day) and standard anti-heart failure therapy (including RAS inhibitors, beta-blocker, Aldosterone inhibitors)
62204650|NCT05141552|NO_INTERVENTION|control group|subjects will be treated with standard anti-heart failure therapy (including RAS inhibitors, beta-blocker, Aldosterone inhibitors)
62204651|NCT03772587|PLACEBO_COMPARATOR|Group 1|
62204652|NCT03772587|EXPERIMENTAL|Group 2|
62787716|NCT01585571||Adults with CP|50 Individuals with a pediatric diagnosis of spastic, hemiplegic, diplegic or quadriplegic cerebral palsy.
62204653|NCT03772587|EXPERIMENTAL|Group 3|
62787717|NCT02239952|EXPERIMENTAL|sunitinib|
62787718|NCT02239952|EXPERIMENTAL|vandetanib|
62787719|NCT02239952|EXPERIMENTAL|Erlotinib|
62787720|NCT00791908|EXPERIMENTAL|electrodessication (ED)|Treatment over 6 weeks using electrodessication (ED) to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
62787721|NCT00791908|EXPERIMENTAL|pulsed dye laser (PDL)|Treatment over 6 weeks using pulsed dye laser (PDL) to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
62787722|NCT00791908|EXPERIMENTAL|potassium titanyl phosphate (KTP) laser|Treatment over 6 weeks using potassium titanyl phosphate (KTP) laser to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
62787723|NCT01623375|EXPERIMENTAL|s.c.|
62204654|NCT03772587|EXPERIMENTAL|Group 4|
62204655|NCT03772587|EXPERIMENTAL|Group 5|
62787724|NCT01623375|EXPERIMENTAL|i.v.|
62787725|NCT01821703|EXPERIMENTAL|LY3045697|Escalating dose (0.1 milligrams \[mg\] up to 100 mg) of LY3045697 administered once daily, orally, for 8 days in 2 of 3 dosing periods
62787726|NCT01821703|ACTIVE_COMPARATOR|Spironolactone|25 mg spironolactone administered once daily, orally, for 8 days in up to 1 of 3 dosing periods
62787727|NCT01821703|PLACEBO_COMPARATOR|Placebo|Placebo matching LY3045697 administered once daily, orally for 8 days in up to 1 of 3 dosing periods
62787728|NCT06367283|EXPERIMENTAL|Metformin|
62787729|NCT06367283|PLACEBO_COMPARATOR|Placebo|
62787730|NCT01111344|EXPERIMENTAL|Glizigen + Viusid|
62787731|NCT01111344|PLACEBO_COMPARATOR|Placebo|
62787732|NCT01898429|ACTIVE_COMPARATOR|Left-sided SCC DBS|Active Stimulation of the left-sided electrode
62787733|NCT01898429|ACTIVE_COMPARATOR|Right-sided SCC DBS|Active stimulation of the right-sided electrode
62787734|NCT05454657|EXPERIMENTAL|Heart rate variability biofeedback + treatment as usual|The experimental group will participate in 8 weeks of heart rate variability biofeedback practice using the Lief heart rate variability biofeedback Smart Patch and smartphone app + treatment as usual. Participants will be asked to, 1) wear the Lief Smart Patch for at least 8 hours per day, 2) do 15mins of scheduled heart rate variability biofeedback practice daily, and 3) use it as needed in response to negative affect in-the-moment.
62787735|NCT05454657|ACTIVE_COMPARATOR|Treatment as usual only|The control group will participate in 8 weeks of treatment as usual only.
62204656|NCT02876445|OTHER|Caregiver Evaluation|ZARIT Burden Interview
62204657|NCT01594775|ACTIVE_COMPARATOR|nasal spray|
62204658|NCT01594775|PLACEBO_COMPARATOR|Placebo|
62204659|NCT01255631|SHAM_COMPARATOR|Sham PEMF device|
62204660|NCT01255631|ACTIVE_COMPARATOR|PEMF Device|
62204661|NCT05362045|EXPERIMENTAL|Mavacamten- Dose A|
62204662|NCT05362045|EXPERIMENTAL|Mavacamten- Dose B|
62204663|NCT00588978|ACTIVE_COMPARATOR|1|Diet alone
62204664|NCT00588978|ACTIVE_COMPARATOR|2|Exercise alone
62204665|NCT00588978|ACTIVE_COMPARATOR|3|Diet and exercise (combined)
62015589|NCT02604589|EXPERIMENTAL|Bupivicaine 0.5% (HIGH DOSE)|"Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.~Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter."
62204666|NCT03619447|ACTIVE_COMPARATOR|ESP block group|Under general anaesthesia, Ultrasound guided ESP block will perform at the T6 level with15 ml bupivacain+ 5ml lidocaine, bilaterally. Morphine 0.1 mg/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with morphine will apply to the all patients. Postoperative pain assessment and morphine consumption will record till the postoperative 24 th hours.
62204667|NCT03619447|ACTIVE_COMPARATOR|serratus block group|Under general anaesthesia, Ultrasound guided SAP block will perform at the T6 level with15 ml bupivacain+ 5ml lidocaine, bilaterally. Morphine 0.1 mg/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with morphine will apply to the all patients. Postoperative pain assessment and morphine consumption will record till the postoperative 24 th hours.
62204668|NCT06046105|SHAM_COMPARATOR|Bupivacaine group (Group B) (control group)|Patients will receive 50 ml of Bupivacaine 0.25% (125mg) diluted in 100 ml of normal saline. The drug will be injected intraperitoneally through trocars at the end of the surgery.
62204669|NCT06046105|EXPERIMENTAL|Bupivacaine/Ibuprofen group (Group BI)|Patients will receive 50 ml of Bupivacaine 0.25% (125 mg) + 400 mg Ibuprofen diluted in 100 ml normal saline. The drug will be injected intraperitoneally through trocars at the end of the surgery.
62204670|NCT06046105|ACTIVE_COMPARATOR|Bupivacaine/Dexmedetomidine group (Group BD):|Patients will receive 20 ml of bupivacaine 0.25% (125 mg) + 1 µq/kg dexmedetomidine diluted in 100 ml normal saline. The drug will be injected intraperitoneally through trocars at the end of the surgery.
62404401|NCT02638818||traditional whipple|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
62404402|NCT05811507||Cases group of patients:|It will include patients with autism spectrum disorder..
62404403|NCT05811507||control group of patients:|It will include healthy boys who don't have any manifestations of ASD according to DSM-V Criteria and CARS score, and are age and Tanner stage matched to cases.
62404404|NCT00843817|EXPERIMENTAL|DRUG|PULMOZYME
62404405|NCT04423107|ACTIVE_COMPARATOR|No opioid|Acetaminophen every 6 hours and Ibuprofen every 6 hours
62404406|NCT04423107|ACTIVE_COMPARATOR|Opioid|Acetaminophen every 6 hours, Ibuprofen every 6 hours, and Oxycodone every 6 hours as needed for breakthrough pain for 10 doses.
62404407|NCT04595617|EXPERIMENTAL|Patients with diagnosis of Glanzmann Thrombastenia (GT)|Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months
62404408|NCT01422031||Regular Family Doctor (RFD)|People had a regular primary care doctor who is a family doctor
62404409|NCT01422031||Regular not Family doctor (RnFD)|People had a regular primary care doctor who is not a family doctor
62015590|NCT06346561|ACTIVE_COMPARATOR|Dexmedetomidine group|
62015591|NCT06346561|ACTIVE_COMPARATOR|Labetalol group|
62015592|NCT01070927|EXPERIMENTAL|cohort 1|
62015593|NCT01070927|EXPERIMENTAL|cohort 2|
62015594|NCT02012387|ACTIVE_COMPARATOR|Active|Omalizumab 300 mg Subcutaneous route 300 mg dose (independent from total IgE, weight or high)
62015595|NCT02012387|PLACEBO_COMPARATOR|Placebo|Placebo Saline serum Subcutaneous route 0.6 ml saline serum with same volume as an active treatment
62204671|NCT04445987|EXPERIMENTAL|Long-term safety of ARQ-154|Open-label, Long-term Safety of ARQ-154
62215197|NCT05732051|ACTIVE_COMPARATOR|Treatment Arm|The patients randomised into this arm of the trial will receive 500 mg Nicotinamide Riboside b.i.d. The duration of blinded therapy will depend on the duration of anthracycline therapy, and will for some patients last for 3 months, others for 6 months.
62404410|NCT01422031||Not regular doctor (NRD)|People had no regular primary care doctor
62404411|NCT04775693|EXPERIMENTAL|RE|Participants use the robotic exoskeleton (RE) in addition to their standard of care gait training as both an inpatient (2 days a week RE) and an outpatient (3 days a week RE).
62404412|NCT04775693|ACTIVE_COMPARATOR|SOC|Participants receive standard of care gait training only as both an inpatient (at least 2 days a week) and an outpatient (at least 3 days a week).
62404413|NCT04775693|EXPERIMENTAL|RE/SOC|Participants use the robotic exoskeleton (RE) in addition to their standard of care gait training as an inpatient (2 days a week RE) and standard of care only as an outpatient (at least 3 days a week).
62015596|NCT02012387|ACTIVE_COMPARATOR|Open labeled|After the double blinded period, all patients from both arms will receive the active drug for 8 more months.
62015597|NCT05343312|ACTIVE_COMPARATOR|Artemether-Lumefantrine (AL)|AL (Coartem™) will be administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.
62015598|NCT05343312|ACTIVE_COMPARATOR|Amodiaquine-Artesunate (AS-AQ)|AQ-AS (Coarsucam™) will be administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children \>18-35kg.
62580559|NCT02216942|EXPERIMENTAL|Guedes Pinto Paste|Endodontic treatment using Guedes Pinto
62787736|NCT01491997|ACTIVE_COMPARATOR|Mind Body Medicine Course 1|The subject of each course is Mind/Body medicine. One course is learning about the mind and the body through experiences. The other is learning about the mind and the body through experiences. Both courses will follow the same format, meeting once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. . You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary ½ day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
62787737|NCT01491997|ACTIVE_COMPARATOR|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
62787738|NCT04282707|EXPERIMENTAL|Endoscopic closure|Prospectively collected patients for gastric ESD and would undergo closure of defect
62787739|NCT04282707|OTHER|Historical control|Historical control of patients who underwent gastric ESD
62404414|NCT05385783|EXPERIMENTAL|A: MDD Participants - CYB003 in 2 of 2 Medicine Sessions|Arm A MDD participants will receive CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. The CYB003 dose received will depend on the cohort/time of enrollment. All MDD participants will receive supportive EMBARK psychotherapy throughout the study.
62015599|NCT05343312|ACTIVE_COMPARATOR|Dihydroartimisin+Piperaquine (DHP)|DHP will be administered once daily according to body weight: tablet (40 mg dihydroartimisin+artesunate) half in children 5 \< 10kg, one in children 10 \< 20kg and 2 tablets for those children over 20 kg.
62404415|NCT05385783|PLACEBO_COMPARATOR|B: MDD Participants - Placebo in Medicine Session 1, CYB003 in Medicine Session 2|Arm B MDD participants will receive placebo in Medicine Session 1, and approximately three weeks later will receive CYB003 in Medicine Session 2. The CYB003 dose received will depend on the cohort/time of enrollment. All MDD participants will receive supportive EMBARK psychotherapy throughout the study.
62580560|NCT02119767||Natural gradients|Patients requiring an elective PCI who present with either non-ST-segment elevation myocardial infarction (NSTEMI) or chronic stable angina who will have natural gradients sampled using the LBS
62204672|NCT00900224||Group 1|Previously procured and archived bone marrow aspirate samples, blood and buccal cell samples, and bone marrow biopsy slides are analyzed for FLT3 ITD, MLL PTD, NPM1, KIT, KRAS, NRAS, CEBPA, WT1, JAK2, RUNX1, TET2, ASXL1, IDH1 and IDH2, CBL, and DNMT3A mutations, CBF fusion genes, levels of BAALC, ERG, EVI1, MN1, and APP microarray gene-expression, microRNA gene-expression signature, levels of methylation of genes silenced in AML, and genomic DNA by PCR amplification, RT-PCR, and denaturing high-performance liquid chromatography.
62204673|NCT01784120|EXPERIMENTAL|doxotubicin/Genexol-PM|
62204674|NCT02535091|EXPERIMENTAL|YKP3089|Multiple dose
62204675|NCT04553562|EXPERIMENTAL|Acupuncture group|For acupuncture group, sterile adhesive pads will be placed after skin disinfection on the acupoints. Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) will be inserted through the pads. The participants will be treated three times a week, on alternate days, for 6 successive weeks; 18 sessions for each patient in total.
62404416|NCT05385783|EXPERIMENTAL|C: Healthy Volunteers - CYB003 in 2 of 2 Medicine Sessions|Arm C healthy volunteers will receive CYB003 in 2 of 2 medicine sessions, approximately one to two weeks apart. The CYB003 dose received will depend on the cohort/time of enrollment. All healthy volunteers will receive psychological support throughout the study.
62787740|NCT02830321||case|"Pregnant women who suffered from hyperemesis gravidarum and admitted in the hospital~* Age: 18-40 years old~* Gestational age: less than 16 weeks confirmed by pelvic u/s~* Excessive pregnancy - related nausea and /or vomiting that prevent adequate intake of food and fluids.~All pregnant (case and control) were asked to bring a stool sample in a clean container. Collected samples were tested in a laboratory (Ain Shams Univerisity hospital).~Stool samples were be tested by using one step H.pylori stool antigen test (CER TEST BIOTEC) for the detection of H. pylori antigen."
62787741|NCT02830321||control|Control patients which are selected from pregnant women presenting to the outpatient clinics for routine antenatal care of the same gestational age, same age range and same socioeconomic standard as cases.
62787742|NCT02397044||Implant loading Immediate|Dental implant surgery with immediate loading
62787743|NCT02397044||Implant Loading Early|Dental implant surgery with delayed loading
62787744|NCT03918915|EXPERIMENTAL|Part 1: SYD-101 Dose 1; Part 2: SYD-101 Dose 1|1 drop in each eye at bedtime.
62787745|NCT03918915|EXPERIMENTAL|Part 1: SYD-101 Dose 1; Part 2: Vehicle|1 drop in each eye at bedtime.
62787746|NCT03918915|EXPERIMENTAL|Part 1: SYD-101 Dose 2; Part 2: SYD-101 Dose 2|1 drop in each eye at bedtime.
62787747|NCT03918915|EXPERIMENTAL|Part 1: SYD-101 Dose 2; Part 2: Vehicle|1 drop in each eye at bedtime.
62787748|NCT03918915|PLACEBO_COMPARATOR|Part 1: Vehicle; Part 2: SYD-101 Dose 2|1 drop in each eye at bedtime.
62787749|NCT04833114|EXPERIMENTAL|Experimental Arm: Pola-R-ICE|combination of standard chemotherapy with polatuzumab vedotin (Pola-R-ICE) Application
62787750|NCT04833114|ACTIVE_COMPARATOR|Standard Arm: R-ICE|conventional treatment with rituximab, ifosfamide, carboplatin and etoposide (R-ICE)
62787751|NCT03813589||PMK patients|Patients already implanted with double chamber pacemaker able to detect automatically congestive heart failure and collect atrial events.
62787752|NCT05523050|OTHER|active enterostomy|active enterostomy before serious complications
62787753|NCT05525650|EXPERIMENTAL|1Arm A|As the maintenance UNIT, 200 PAU
62787754|NCT05525650|PLACEBO_COMPARATOR|1Arm B|Placebo arm of 1Arm A.
62787755|NCT05525650|EXPERIMENTAL|2Arm C|As the maintenance UNIT, 400 PAU
62787756|NCT05525650|PLACEBO_COMPARATOR|2Arm D|Placebo arm of 2Arm C.
62787757|NCT05525650|EXPERIMENTAL|3Arm E|As the maintenance UNIT, 800 PAU
62204676|NCT04553562|SHAM_COMPARATOR|Sham acupuncture group|For the sham acupuncture group, aterile adhesive pads will be placed after skin disinfection on the acupoints and needles with a blunt tip will be inserted at the same acupoints in the acupuncture group without penetrating the skin.No manipulation of needles will be conducted. The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
62204677|NCT04553562|NO_INTERVENTION|Waiting list group|For the waiting list group, patients will receive no treatment in the first 6 weeks and will receive the same treatment used in the acupuncture group according to patients' preference.
62204678|NCT03889353|EXPERIMENTAL|BCI sessions|up to 3 test sessions (Day-30) to eliminate BCI illiteracy, then 10 rehabilitation sessions of 90 minutes (Day 1-Day 5 and Day 8-Day 12) - Session content : Guided training - Control of an avatar (VR, first person view) of the affected limb by motor mental imagery decoded by a brain computer interface.
62404417|NCT05385783|PLACEBO_COMPARATOR|D: Healthy Volunteers - Placebo in Medicine Session 1, CYB003 in Medicine Session 2|Arm D healthy volunteers will receive placebo in Medicine Session 1, and approximately one to two weeks later will receive CYB003 in Medicine Session 2. The CYB003 dose received will depend on the cohort/time of enrollment. All healthy volunteers will receive psychological support throughout the study.
62580561|NCT02119767||Induced gradients|Patients requiring an elective PCI who present with either non-ST-segment elevation myocardial infarction (NSTEMI) or chronic stable angina who will have induced gradients sampled using the LBS
62580562|NCT04342637||Practicing gastroenterologists|Practicing physicians performing gastrointestinal endoscpy
62580563|NCT06478212|EXPERIMENTAL|Phase 1b: Vorasidenib and Temozolomide (TMZ)|
62580564|NCT06478212|EXPERIMENTAL|Phase 2: Vorasidenib recommended combination dose (RCD) and Temozolomide (TMZ)|
62580565|NCT01729585|NO_INTERVENTION|control group|control group
62787758|NCT05525650|PLACEBO_COMPARATOR|3Arm F|Placebo arm of 3Arm E.
62787759|NCT01858740|EXPERIMENTAL|Treatment (CD45RA+ T cell depleted PBSCT)|"CONDITIONING REGIMEN: Patients undergo TBI BID on days -10 to -7, receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.~TRANSPLANT: Patients undergo CD34+ enriched, CD45RA+ T cell-depleted allogeneic PBSCT on day 0.~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and continuing through day 50 with taper. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
62787760|NCT03580980|ACTIVE_COMPARATOR|Drug: Morphine|Morphine Group C (n=30) was the control group who received IV morphine in a dose of 0.1 mg/kg after induction of anesthesia
62404418|NCT05385783|EXPERIMENTAL|E: Healthy Volunteers - CYB003 in 3 of 3 Medicine Sessions|Arm E healthy volunteers will receive CYB003 in 3 of 3 medicine sessions, approximately one week apart from each other, to assess bioavailability and food effect. The CYB003 dose received will depend on the safety review committee selection/time of enrollment. All healthy volunteers will receive psychological support throughout the study.
62404419|NCT02259426|ACTIVE_COMPARATOR|Dihydroartemisínin-piperaquine (Artekin)|Dihydroartemisínin-piperaquine combination alone
62404420|NCT02259426|EXPERIMENTAL|Dihydroartemisinin-piperaquine, Primaquine|Dihydroartemisinin-piperaquine with single-dose 0.25mg/kg Primaquine
62404421|NCT06652971|EXPERIMENTAL|Sequence 1|Period 1: A single oral dose of 1 tablet under fasting condition Period 2: A single oral dose of 1 tablet under fed condition
62404422|NCT06652971|EXPERIMENTAL|Sequence 2|Period 1: A single oral dose of 1 tablet under fed condition Period 2: A single oral dose of 1 tablet under fasting condition
62404423|NCT06538493|EXPERIMENTAL|Jumpstart 1|Questionnaire on advance care planning experiences, preferences, and concerns
62580566|NCT01729585|ACTIVE_COMPARATOR|Massage therapy|Treatment group receives pre-determined massage therapy protocol x 5 over 10-12 weeks. massage therapy protocol includes a blend of Swedish strokes and myofascial trigger point therapy. Initially, dosing will be more frequent. Treatments will be spaced out to determine the ability of the body to maintain a more efficient musculoskeletal system, especially related to respiratory and postural efforts. Each session will end with resting hands and relaxation strokes to signal the end of the session. This protocol invites increased mobility in the musculoskeletal system. The ultimate goal is to return connective tissue (including muscles and fascia) to a more relaxed and neutral state, thus allowing expansion and ease of movement of the areas of the musculoskeletal system being worked.
62580567|NCT02533609||Piperacillin/Tazobactam|Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics
62580568|NCT02533609||Imipenem/Cilastatin|Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics
62580569|NCT00076830||Enrolled cohort|All patients enrolled, as this is an evaluation/diagnostic study
62580570|NCT05985980||ETTs will be performed at the early and late follicular phases in premenopausal women|The study population consists of premenopausal women who applied to the outpatient clinic with chest pain between February 2023 and July 2023. ETTs are planned as part of the routine clinical workup. The history of the patient's menstrual cycle is obtained in detail. The early and late follicular phases are determined from the history. Two separate ETTs are performed on each patient. The early follicular phase ETT is planned on the 3rd day of menstrual bleeding, while the menstrual bleeding continues. The late follicular phase ETT is planned on the 3rd day after the menstrual bleeding ends. Hormone levels are measured before each ETT to ascertain the phase of the menstrual cycle.
62580571|NCT04718532||patients|patients with retinal diseases
62580572|NCT05537987|EXPERIMENTAL|ICP-723|
62580573|NCT02551770|ACTIVE_COMPARATOR|Test (with Emdogain)|Scaling and root planing with Emdogain
62580574|NCT02551770|OTHER|Control (without Emdogain)|Scaling and root planing without Emdogain
62580575|NCT04694989|EXPERIMENTAL|Sequence 1|"Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 3: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-386- A single oral dose of 1 tablet under fasting condition"
62580576|NCT04694989|EXPERIMENTAL|Sequence 2|"Period 1: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition"
62580577|NCT06191952|OTHER|Subjective Cognitive Decline Questionnaire (SCD-Q)/no other procedure|Participants will undergo procedure as usual and fill out the questionnaire SCD-Q
62787761|NCT03580980|ACTIVE_COMPARATOR|Procedure/surgery:Caudal levobupivacaine|In Caudal Group (n=30), patients were placed in the lateral position and received caudal epidural block after induction of anesthesia with levobupivacaine 0.125% , 1.1 ml/kg and morphine 0.02 mg/kg with maximum 20ml.
62787762|NCT03580980|ACTIVE_COMPARATOR|Drug: Paracetamol and ketamine|The patients of Multimodal Group (n=30) received paracetamol infusion 10 mg/kg over 10 minutes and ketamine 0.5 mg/kg IV bolus followed by ketorolac 1 mg/kg infusion over 10 minutes.
62404424|NCT06538493|ACTIVE_COMPARATOR|Jumpstart 2|Questionnaire on advance care planning experiences, preferences, and concerns plus feedback form (patient and provider)
62404425|NCT06538493|NO_INTERVENTION|Usual care|
62404426|NCT03496597||Patients|type 1 diabetes patients
62404427|NCT03496597||Healthy controls|non diabetic control subjects of the same age
62404428|NCT03496597||Dyslipidemic controls|non-diabetic control participants with familial dyslipidemia
62580578|NCT06191952|OTHER|SCD-Q + digital cognitive testing using Cognigram|Participants will undergo procedure as usual with their GP, additionally they will fill out the SCD-Q and undergo cognitive testing (Cognigram)
62580579|NCT06191952|OTHER|SCD-Q + Cognigram + blood-based biomarkers|Participants will undergo procedure as usual with their GP, additionally they will fill out the SCD-Q and undergo cognitive testing (Cognigram). The blood-based biomarkers will be determined.
62580580|NCT02048280|EXPERIMENTAL|Intubated|NAVA level from 0.1 to 3
62404429|NCT02345538||Women with Chronic Pelvic Pain|Use of perineometer to measure pelvic resting tone and contraction in women with chronic pelvic pain and determine if resting tone correlates with severity of pain.
62580581|NCT05182710|EXPERIMENTAL|Stress Inoculation Training|Intervention Arm
62404430|NCT02345538||Women without Chronic Pelvic Pain|Use of perineometer to measure pelvic resting tone and contraction in women without chronic pelvic pain
62404431|NCT02951143|EXPERIMENTAL|Single arm|All participants will complete the same experimental events across 6 laboratory sessions.
62580582|NCT05182710|ACTIVE_COMPARATOR|Alternative Training|Best practice/control
62787763|NCT04435275|ACTIVE_COMPARATOR|Donning PPE using VA then doffing PPE using HC|Study subjects will receive VA guidance for donning first, then guidance from a human coach (HC) for doffing.
62787764|NCT04435275|ACTIVE_COMPARATOR|Donning PPE using HC then doffing PPE using VA|Study subjects will receive HC guidance for donning first, then VA guidance for doffing.
62787765|NCT04435275|ACTIVE_COMPARATOR|Intubation using VA then extubation using HC;|Study subjects will receive VA guidance for the intubation first , then HC guidance for extubation procedure
62404432|NCT02951143|EXPERIMENTAL|0.4 mg/g Concentration|Participants in this arm will experience the 0.4 mg/g Concentration
62404433|NCT02951143|EXPERIMENTAL|1.3 mg/g Concentration|Participants in this arm will experience the 1.3 mg/g Concentration
62580583|NCT03082157|EXPERIMENTAL|Mighty Men Intervention|Mighty Men weight-loss intervention including health education and exercise during small group sessions
62787766|NCT04435275|ACTIVE_COMPARATOR|Intubation using HC then extubation using VA|Study subjects will receive HC guidance for the intubation first , then VA guidance for extubation procedure
62787767|NCT02628353|PLACEBO_COMPARATOR|Placebo|control group
62404434|NCT02951143|EXPERIMENTAL|2.4 mg/g Concentration|Participants in this arm will experience the 2.4 mg/g Concentration
62404435|NCT02951143|EXPERIMENTAL|5.2 mg/g Concentration|Participants in this arm will experience the 5.2 mg/g Concentration
62580584|NCT03082157|NO_INTERVENTION|Comparison|Exercise-only small group sessions
62580585|NCT02049814|EXPERIMENTAL|Metformin + Voglibose 0.2 mg|Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12.
62580586|NCT02049814|ACTIVE_COMPARATOR|Metformin + Acarbose 50 mg|Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12.
62580587|NCT04206891||Group 1|Bilateral lobular invasive breast cancer
62787768|NCT02628353|EXPERIMENTAL|Phenolic compound|treated group
62787769|NCT02870101|OTHER|Intervention|Performance of three nucleic acid amplification tests (NAATs) to detect Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) from swabs collected from the pharynx and rectum. Assays include: Nucleic acid amplification test 1 for NG and CT; Nucleic acid amplification test 2 for NG and CT; and, Nucleic acid amplification test 3 for NG and CT.
62787770|NCT03867643||Hepatitis B vaccine booster|Children with anti-HBs at a level of\<10mIU/mL or \[10,100) mIU/mL before booster.
62787771|NCT03867643||Observation|Children with anti-HBs at a level of \>100mIU/mL or \[10,100) mIU/mL before booster.
62787772|NCT04857580|EXPERIMENTAL|CTS device|
62787773|NCT04857580|NO_INTERVENTION|Control|
62404436|NCT02951143|EXPERIMENTAL|15.8 mg/g Concentration|Participants in this arm will experience the 15.8 mg/g Concentration
62404437|NCT01652040|EXPERIMENTAL|RT+Tp|Resistance training using electrical stimulation and ankle weights and Testosterone patches
62404438|NCT01652040|EXPERIMENTAL|Tp|Applying Testosterone patches
62404439|NCT00578448|ACTIVE_COMPARATOR|A|"10mg/kg~6 doses (Day 1, 5, week 2, 4, 8 and 12) for 12 weeks"
62404440|NCT00578448|ACTIVE_COMPARATOR|B|"5mg/kg~33 doses (every 4 weeks) for 144 weeks"
62404441|NCT03733379|PLACEBO_COMPARATOR|Control|Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.
62404442|NCT03733379|EXPERIMENTAL|Probiotic|Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + lozenges of probiotics two times a day for 90 days.
62404443|NCT03733379|EXPERIMENTAL|Antibiotic|Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.
62404444|NCT03733379|EXPERIMENTAL|Antibiotic + probiotic|Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + lozenges of probiotics two times a day for 90 days.
62404445|NCT04025697|PLACEBO_COMPARATOR|Conventional CD|A conventional Complete denture will be constructed and the amount of denture tooth movement will be measured
62404446|NCT04025697|ACTIVE_COMPARATOR|Rapid Prototyped Denture|A digital light processed denture will be constructed and the amount of tooth movement will be measured
62015600|NCT05343312|ACTIVE_COMPARATOR|Pyronaridine +Artesunate (PA)|PA will be administered once daily according to body weight: granule ( 60 mg pyronaridine + 20 artesunate), one in children 5 \< 7kg, two in children 8 \< 15kg and three in children 15 \< 20kg. Tablets ( 180 mg pyronaridine+ 60 mg artesunate), one in children 20 \< 24Kg and two in children 24 \< 45Kg.
62580588|NCT04206891||Group 2|Invasive lobular breast cancer with age at onset \<= 45 years
62015601|NCT04203719|EXPERIMENTAL|Anlotinib and AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
62015602|NCT02266381|OTHER|US-guided group|Patients in US-guided group undergo MPCNL using only US-guided renal access.
62015603|NCT02266381|OTHER|Fluoroscopy-guided group|Patients in Fluoroscopy-guided group undergo MPCNL using only fluoroscopy-guided renal access.
62015604|NCT02266381|OTHER|Combined-guided group|Patients in Combined-guided group undergo MPCNL using US combined with fluoroscopy-guided renal access.
62015605|NCT05676242|EXPERIMENTAL|Jaktinib 100mg BID|Drug: Jaktinib Hydrochloride Tablet 100mg dosage, orally administered, twice a day
62015606|NCT05676242|EXPERIMENTAL|Jaktinib 75mg BID|Drug: Jaktinib Hydrochloride Tablet 75mg dosage, orally administered, twice a day
62015607|NCT05676242|PLACEBO_COMPARATOR|Placebo|Drug: Placebo Orally administered, twice a day
62015608|NCT05580900|EXPERIMENTAL|Livestream Modality|The livestream modality is considered the treatment group for the purpose of this quasi-experimental study.
62015609|NCT05580900|EXPERIMENTAL|Live Modality|The live modality is considered the control group for the purpose of this quasi-experimental study.
62015610|NCT01336465|EXPERIMENTAL|rhuMAb Beta7|
62015611|NCT01336465|PLACEBO_COMPARATOR|placebo|
62580589|NCT04206891||Group 3|Invasive lobular breast cancer with family history for breast cancer
62580590|NCT04206891||Group 4|In situ lobular breast cancer with age at onset \<= 45 years
62580591|NCT04206891||Group 5|In situ lobular breast cancer with family history for breast cancer
62580592|NCT02609620|EXPERIMENTAL|Treatment|In the treatment group: The LunGuard Peristaltic Feeding Tube (PFT) will be positioned in the ICU and positioning will be verified by X-ray. Nutritional formula will be fed into the stomach via the feeding lumen of the PFT
62580593|NCT02609620|ACTIVE_COMPARATOR|Control|Patients in the control group will have a Convatec Levin Duodenal Tube inserted according to standard procedure, which is considered the gold standard.
62787774|NCT01856582|EXPERIMENTAL|CD34+ selected stem cell infusion|An infusion of selected CD34+ stem cells will be given without any preparative regimen.
61978495|NCT03794414|EXPERIMENTAL|fluid non-responder|patients with no increase or less than 10% increase in stroke volume after fluid challenge. Both arms receive PEEP challenge
62015612|NCT01511458||Case|Patient with a trisomy 21 pregnancy confirmed by genetic testing.
62015613|NCT01511458||Control|Patients without a trisomy 21 pregnancy confirmed by either genetic testing or a normal newborn phenotype.
62015614|NCT01125423|ACTIVE_COMPARATOR|Subjects with Fibromyalgia|Subjects with Fibromyalgia have skin biopsies taken from the dominant trapezius and palm. Subjects will receive an eight week supply of milnacipran to be titrated 12.5 mg x one day, 12.5 mg twice a day x 2 days, 25mg twice daily for 4 days, then 50mg twice a day x 7 weeks.
62015615|NCT01125423|OTHER|Control subjects without Fibromyalgia|Subjects without Fibromyalgia have skin biopsies taken from the dominant trapezius and palm.
62580594|NCT05580094|PLACEBO_COMPARATOR|General anesthesia only.|the pediatric patients will receive general anesthesia only.
62580595|NCT05580094|ACTIVE_COMPARATOR|General anesthesia plus supraclavicular block.|the pediatric patients will receive combined supraclavicular block and general anesthesia.
62580596|NCT01878149||VEO® Lateral Access and Interbody Fusion System|
62787775|NCT00711971|ACTIVE_COMPARATOR|EPA-rich fish oil supplement|EPA-rich fish oil supplement
62787776|NCT00711971|ACTIVE_COMPARATOR|DHA-rich fish oil supplement|DHA-rich fish oil supplement
62787777|NCT00711971|PLACEBO_COMPARATOR|Soy Oil placebo|Soy oil
62204679|NCT00320528|EXPERIMENTAL|Pure ADHD|Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
62204680|NCT00320528|EXPERIMENTAL|ADHD+Internalizing Disorders|Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
62404447|NCT04446182|EXPERIMENTAL|Treatment: all patients|Patients will self-administer itacitinib every morning regardless of food. ECP will be administered twice weekly on consecutive days for 8 weeks per institutional standards. At the end of 8 weeks of combination therapy, patients will start a standard ECP taper schedule and itacitinib will be continued at the assigned dose level. After six cycles of therapy, itacitinib may be tapered at the treating investigator's discretion as described below.
62404448|NCT04487886|EXPERIMENTAL|Duvelisib|Participants with severe COVID-19 who do not require mechanical ventilation randomized to receive duvelisib for 14 days.
62404449|NCT04487886|PLACEBO_COMPARATOR|Placebo|Participants with severe COVID-19 who do not require mechanical ventilation randomized to receive a placebo to match duvelisib for 14 days.
62404450|NCT02329834|EXPERIMENTAL|Treatment Sequence 1|Furosemide Injection Solution for subcutaneous administration (80mg) over 5 hours followed by i.v. Furosemide Injection, USP (80 mg)by i.v. bolus in second period
62580597|NCT01878149||eXtreme Lumbar Interbody Fusion (XLIF®)|
62580598|NCT02661269||Septic patients|Septic patients with fluid overload (fluid balance + 4 L)
62580599|NCT02661269||Post-cardiac surgery patients|Patients after cardiac surgery, at arrival on ICU.
62580600|NCT06567379||PAH patients|Patients with heritable, idiopathic PAH or PAH associated with portal hypertension or with drugs.
62580601|NCT00119717|EXPERIMENTAL|1|
62580602|NCT00119717|ACTIVE_COMPARATOR|2|
62580603|NCT02792894|NO_INTERVENTION|Enhanced Usual Care (EUC)|Enhanced Usual Care comprises of normal routine visits conducted by the local community health workers / Lady Health Workers (LHWs). Care is enhanced in 2 ways: (a) LHWs in the EUC arm will receive training in identifying children with developmental disorders and delays, as well as making referrals to their primary care physicians for treatment using the WHO mhGAP training program for developmental disorders and (b) The primary care physicians will receive the training in WHO mental health GAP(mhGAP) program developmental disorders module, by WHO Collaborating Center in Rawalpindi, Pakistan.
62787778|NCT03658447|EXPERIMENTAL|177Lu-PSMA + Pembrolizumab|200mg pembrolizumab given 3 weekly for upto 35 cycles and 6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
62015616|NCT02497326|ACTIVE_COMPARATOR|Polyfax & Lignocain gel or silvazine cream|Polyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash
62015617|NCT02497326|EXPERIMENTAL|Topical heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval."
62015618|NCT00096941|EXPERIMENTAL|Pertuzumab|Participants received the same dose of pertuzumab that they received in their parent Phase II trial, either 420 mg or 1050 mg, intravenously on Day 1 of every 3 week cycle until disease progression.
62015619|NCT04394351|EXPERIMENTAL|Part A - High Dose|Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight
62015620|NCT04394351|EXPERIMENTAL|Part A - Low Dose|Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight
62015621|NCT04394351|EXPERIMENTAL|Part B - High Dose|Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight
62015622|NCT04394351|EXPERIMENTAL|Part B - Low Dose|Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight
62015623|NCT04394351|EXPERIMENTAL|Part C - High Dose|Part C consists of up to 108-week open-label extension period. All patients will receive higher exposure dupilumab subcutaneous (SC) administration at tiered dosing regimens based on body weight. No matching placebo administered in Part C.
62015624|NCT01802411|ACTIVE_COMPARATOR|EXPAREL 266 mg|Intercostal nerve block using single total administration of 20 mL EXPAREL (bupivacaine liposome injectable suspension) 266 mg (approximately 88 mg \[6.6 mL\] to each of three nerve segments)
62015625|NCT01802411|PLACEBO_COMPARATOR|Placebo|Intercostal nerve block using single total administration of 20 mL normal saline (6.6 mL to each of three nerve segments)
62015626|NCT04521010||Staff absenteeism|A retrospective analysis of above-mentioned data, covering the period January-April 2019 and January-April 2020, was carried out. The evaluation of the staff's absence included all workers employed under an employment contract: 713 workers in 2019 and 747 workers in 2020.
62015627|NCT04521010||healthcare services|The variable number of employees was a result of the employment dynamics in the subsequent 2 years, due to variable quantity of healthcare services that were contracted with the national payer and changes in the form of employment of some hospital workers
62015628|NCT04279444|EXPERIMENTAL|Active BKR-017|Open label study. All patients will receive 28 days of active treatment.
62015629|NCT01920295|EXPERIMENTAL|Cryoballoon ablation|Cryoballoon ablation
62015630|NCT01920295|ACTIVE_COMPARATOR|Cryoballoon after medical therapy|Cryoballoon ablation
62015631|NCT01920295|EXPERIMENTAL|Cryoballoon as first-line therapy|Cryoballoon ablation
62204681|NCT00320528|EXPERIMENTAL|ADHD+Externalizing Disorders|Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
62204682|NCT02327351|EXPERIMENTAL|TCR alfa beta depletion|TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.
62204683|NCT05431764|EXPERIMENTAL|Camrelizumab Plus Stereotactic Body Radiotherapy|Patients were treated with gemcitabine, cisplatin and camrelizumab for 6 cycles, followed by whole-target radiotherapy (IMRT for locoregional lesion and SBRT for oligometastatic lesions) and camrelizumab maintenance therapy.
62204684|NCT03682302|EXPERIMENTAL|Group 1: 12 to less than 17 years, undergoing spine surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of spine surgery.
62204685|NCT03682302|ACTIVE_COMPARATOR|Group 1: 12 to less than 17 years, undergoing spine surgery, bupivacine|Single dose of bupivacaine hydrochloride (HCl) 2 mg/kg (not to exceed a maximum total dose of 175 mg) via local infiltration at the end of spine surgery.
62204686|NCT03682302|EXPERIMENTAL|Group 2: 6 to less than 12 years, undergoing spine surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of spine surgery.
62204687|NCT03682302|EXPERIMENTAL|Group 2: 6 to less than 12 years, undergoing cardiac surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of cardiac surgery.
62204688|NCT04323540|ACTIVE_COMPARATOR|Xenograft+collagen membrane|Reconstructive approach (Xenograft+collegen membrane)
62204689|NCT04323540|EXPERIMENTAL|Xenograft+collagen membrane+autologous soft tissue graft|Reconstructive approach (Xenograft+collegen membrane) plus soft tissue graft (autologous, harvested as FGG)
62204690|NCT05526131|ACTIVE_COMPARATOR|Patients with type 2 Diabetes Mellitus and depression|This arm includes patients with type 2 diabetes mellitus that were diagnosed with depression using structured clinical interview for DSM-IV Axis disorder (SCID-I) and Hamilton Depression Rating Scale (HAM-D) for diagnosing depression and exclusion of other psychiatric disorders.
62204691|NCT05526131|ACTIVE_COMPARATOR|Patients with type 2 Diabetes Mellitus and no depression|This arm includes patients with type 2 diabetes mellitus where depression was ruled out using structured clinical interview for DSM-IV Axis disorder (SCID-I) and Hamilton Depression Rating Scale (HAM-D) for diagnosing depression and exclusion of other psychiatric disorders.
62580604|NCT02792894|EXPERIMENTAL|Family Networks program|Intervention is administered once weekly over 9-10 weeks in a group format over 3 hours per sessions. Family networks Program (FaNs) is based on WHO mhGAP module for developmental disorders and incorporates WHO Parent Skills Training program for children with developmental disorders and delays. Parents Skills Training Program includes modules on communication, play, daily living skills, managing challenging behavior, coping with stress. Intervention is provided by the family volunteers (members of community, mostly women, who have a child affected in their families).
62580605|NCT04799730||SLE cases in remission|according to SLE Disease Activity Index (SLEDAI) inactive disease will be considered as SLEDAI \<5
62580606|NCT04799730||SLE cases in activity|according to SLE Disease Activity Index (SLEDAI) Active disease will be defined as SLEDAI ≥ 5
62580607|NCT04799730||Control group|Healthy age and sex matched subjects.
62580608|NCT01014988|OTHER|Single Arm|A single arm open-label design has been selected to achieve the primary objective of providing regulatory authorities with safety data on IV zanamivir in an expedited manner. This study design also facilitates the provision of safety data on a real-time basis, if necessary.
62580609|NCT03383835|EXPERIMENTAL|Omega-3 Supplementation|Participants will take the dose of omega-3 supplementation (600mg DHA and 300mg EPA) daily for 6 months.
62580610|NCT06659536|EXPERIMENTAL|Transcutaneous Tibial Nerve Stimulator (TTNS) with the Cefar Uro Device|"Patients will undergo Transcutaneous Posterior Tibial Nerve Stimulation with the Cefar URO device. The following parameters setting (preset program P4) will be used for treatment of all enrolled subjects:~* frequency of 20Hz~* pulse width of 200 μs~* duration: 30 minutes per treatment.~* treatment frequency: subjects will be recommended to have 7 treatment sessions per week for a total of 12 weeks (84 treatments total), and anyway no less that one treatment per week.~The electrodes will be placed in the medial ankle as according to the device IFU."
62580611|NCT06316232|ACTIVE_COMPARATOR|STIM ON plus/MED ON plus|"Patients were evaluated in two following morning sessions under different treatment conditions:~1. STIM ON plus (intervention 1)~2. MED ON plus (intervention 2)"
62580612|NCT06316232|ACTIVE_COMPARATOR|MED ON plus/STIM ON plus|"Patients were evaluated in two following morning sessions under different treatment conditions:~1. MED ON plus (intervention 2)~2. STIM ON plus (intervention 1)"
62580613|NCT04128254|EXPERIMENTAL|Apixaban|
62015632|NCT01920295|ACTIVE_COMPARATOR|Cryoballoon after failed drug therapy|Cryoballoon ablation
62015633|NCT06444113|EXPERIMENTAL|Ofatunumab|Recommended dose as per ofatumumab label. Injection at weeks 0,1,2 and monthly starting at week 4.
62015634|NCT00962429|ACTIVE_COMPARATOR|Lipoic acid|alpha lipoic acid
62015635|NCT00962429|PLACEBO_COMPARATOR|Placebo|sugar pill
62015636|NCT05479526||Group 1|Control group will consist of 42 healthy individuals, aged between 30-60 years.
62015637|NCT05479526||Group 2|This group will consist of 42 patients with diagnosed Plantar Fasciitis, aged between 30-60 years.
62015638|NCT01202838||Composite Implant|Subject receiving composite implant
62015639|NCT05781035|ACTIVE_COMPARATOR|dexmedetomidine group|
62015640|NCT05781035|ACTIVE_COMPARATOR|general anesthesia group|
62580614|NCT04128254|PLACEBO_COMPARATOR|Placebo|
62787779|NCT03306719||Study Group|The intervention group will be women with premature preterm rupture of membranes (pProm), suffering from IAI
62787780|NCT03306719||Control Group|Pregnant women without IAI
62015641|NCT02691858|EXPERIMENTAL|Hydrocortisone|Hydrocortisone IV 10 mg/kg with Resuscitation before attempting reduction, single dose with Resuscitation before attempting reduction
62015642|NCT02691858|PLACEBO_COMPARATOR|Saline|Saline IV 100 ml with Resuscitation before attempting reduction, single dose with Resuscitation before attempting reduction
62015643|NCT02822794|EXPERIMENTAL|SOF/VEL FDC + RBV 12 weeks|SOF/VEL FDC + RBV for 12 weeks in participants with genotype 1 or 2 HCV infection
62204692|NCT01385852|ACTIVE_COMPARATOR|Longitudinal U/S - low fluidic|ASPIRATION FLOW RATE - 25 CC/MIN, BOTTLE HEIGHT - 90 CMS, LONGITUDINAL ULTRASOUND
62404451|NCT02329834|EXPERIMENTAL|Treatment Sequence 2|Furosemide Injection, USP (80 mg) by i.v. bolus, followed by Furosemide Injection Solution for subcutaneous administration (80mg) over 5 hours in second period.
62580615|NCT03381079|EXPERIMENTAL|Surgical group|In this arm, the adults with high myopia will be given posterior scleral reinforcement.
62580616|NCT03381079|NO_INTERVENTION|Control group|In this arm, the adults with high myopia will not be given any surgical treatment.
62580617|NCT05256927||All Participants|
62580618|NCT04691986|EXPERIMENTAL|NR Supplementation|Participants in this group will receive NR supplementation at 1000 mg per day (given as 2x250mg capsules morning and 2x250mg at night).
62787781|NCT00753454|EXPERIMENTAL|CDP870|Patients having completed the week 34 assessment in C87077 (NCT00580840) or patients having been randomized at Week 18 and having met the pre-defined criteria for flare, will be given the option to enroll in C87084 and receive: 400 mg CZP at Entry, Week 2, and Week 4 followed by 200 mg every two weeks in combination with MTX until the drug is commercially available for the indication of RA in the patient's country or region (or until further notice from UCB).
62015644|NCT02822794|EXPERIMENTAL|SOF/VEL FDC + RBV 24 weeks|SOF/VEL FDC + RBV for 24 weeks in participants with genotype 1 or 2 HCV infection
62580619|NCT04691986|PLACEBO_COMPARATOR|Placebo supplementation|Participants in this group will receive placebo given as 2 pills in the morning and 2 pills at night. Placebo pills contain micro cellulose which is likewise found in NR containing capsules.
62580620|NCT05772221|OTHER|Interviewer-Administered|Screening assessments to measure social determinants of health in relation to cardiovascular disease.
62580621|NCT05500339|EXPERIMENTAL|mHealth App|The mHealth App designed for the support of the first 1000 days of life is provided to pregnant women. Specific contents are presented to the user according to the current trimester of pregnancy or the post-partum period following a scheduled routine; all contents are always available for free consultation during the entire period of use. Links to relevant institutional websites are also reported for any further reading. The app has a frequently asked question (FAQ) section, and a calendar function with the possibility to set appointments and reminders. App contents and topics include information about health prevention behaviors such as vaccination during pregnancy, weight increment during pregnancy, abstinence from smoke and alcohol consumption habits, adherence to child routine vaccination schedule.
62580622|NCT05500339|SHAM_COMPARATOR|Standard care.|Pregnant women receive standard supportive and educational methods.
62580623|NCT05300009|EXPERIMENTAL|topical methotrexate hydrogel 1% coupled with microneedling|patients who will receive topical methotrexate hydrogel 1% coupled with microneedling
62787782|NCT04215900|EXPERIMENTAL|High-Speed Multi-Directional Yoga|The duration of the intervention is 18 weeks, with 16 weeks of training.
62787783|NCT04215900|NO_INTERVENTION|Waitlist control|During the course of the 18 week study this arm will receive no intervention. Participants will be encouraged to maintain their daily schedules.Following the completion of the study the participants will be offered eight yoga sessions over a one month period.
62787784|NCT04842383|ACTIVE_COMPARATOR|Half strength Hemp Oil Preparation|The topical preparation contains only 500mg of cannabinoids per ounce. The other ingredients are the same in both arms.
62787785|NCT04842383|ACTIVE_COMPARATOR|Full strength Hemp Oil Preparation|The topical preparation contains 1000mg of cannabinoids per ounce. The other ingredients are the same in both arms.
62787786|NCT01349712||Coumadin (warfarin)|Subjects are required to be currently receiving coumadin (warfarin) treatment.
62787787|NCT03932760|EXPERIMENTAL|UPLIFT Program|Weekly one-hour group sessions for 10 weeks facilitated by a mental health professional.
62787788|NCT03932760|ACTIVE_COMPARATOR|Pregnancy Skills Group|Weekly one-hour group sessions for 10 weeks facilitated by a registered nurse.
62204693|NCT01385852|ACTIVE_COMPARATOR|Torsional U/S - low fluidic|ASPIRATION FLOW RATE - 25 CC/MIN, BOTTLE HEIGHT - 90 CMS, TORSIONAL ULTRASOUND
62204694|NCT01385852|ACTIVE_COMPARATOR|Longitudinal U/S - high fluidic|ASPIRATION FLOW RATE - 40 CC/MIN, BOTTLE HEIGHT - 110 CMS, LONGITUDINAL ULTRASOUND
62015645|NCT00963664|EXPERIMENTAL|Interferon and lovastatin treatment|Patients receive outpatient treatment with lovastatin (oral) and interferon alfa-2b (subcutaneous injection) as per protocol parameters.
62015646|NCT00726115|PLACEBO_COMPARATOR|1|arm placebo
62015647|NCT00726115|EXPERIMENTAL|2|arm drug
62015648|NCT05481112|EXPERIMENTAL|XR-B Induction at Admission|"Participants will initiate extended-release buprenorphine (XR-B) treatment at the time of admission. XR-B will be continued monthly from the time of induction to the day of release (up to 6 months), and up to 3 monthly injections will be offered in the community following release.~Dosing: XR-B is available in two doses, 300mg and 100mg. Study clinicians will generally adhere to FDA-labeling on XR-B dosing, which recommends two months of 300-mg doses followed by maintenance doses of 100-mg monthly."
62404452|NCT04647175|OTHER|Fermented aronia - aronia - placebo|The participants receive each intervention for 8 weeks in the stated order.
62404453|NCT04647175|OTHER|Fermented aronia - placebo - aronia|The participants receive each intervention for 8 weeks in the stated order.
62404454|NCT04647175|OTHER|Placebo - aronia - fermented aronia|The participants receive each intervention for 8 weeks in the stated order.
62404455|NCT04647175|OTHER|Placebo - fermented aronia - aronia|The participants receive each intervention for 8 weeks in the stated order.
62404456|NCT04647175|OTHER|Aronia - placebo - fermented aronia|The participants receive each intervention for 8 weeks in the stated order.
62580624|NCT05300009|ACTIVE_COMPARATOR|cryotherapy|patients who will receive cryotherapy
62015649|NCT05481112|EXPERIMENTAL|XR-B Induction at Pre-Release|"Participants will initiate extended-release buprenorphine (XR-B) treatment within 30 days of release. Participants will receive at least one XR-B monthly injection prior to release, and XR-B will be continued monthly from the time of induction to the day of release. Up to 3 monthly injections will be offered in the community following release.~Dosing: XR-B is available in two doses, 300mg and 100mg. Study clinicians will generally adhere to FDA-labeling on XR-B dosing, which recommends two months of 300-mg doses followed by maintenance doses of 100-mg monthly."
62580625|NCT04971135|EXPERIMENTAL|SAN711 (SAD)|6 out of 8 participants per cohort (up to 7 cohorts) will be randomized to receive a single dose of SAN711
62580626|NCT04971135|PLACEBO_COMPARATOR|Placebo (SAD)|2 out of 8 participants per cohort (up to 7 cohorts) will be randomized to receive a single dose of Placebo
62580627|NCT04971135|EXPERIMENTAL|SAN711 (MAD)|6 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 14 daily doses of SAN711
62580628|NCT04971135|PLACEBO_COMPARATOR|Placebo (MAD)|2 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 14 daily doses of Placebo
62580629|NCT01999699|EXPERIMENTAL|HEPLISAV|
62580630|NCT06546930|EXPERIMENTAL|Intervention|"Virtual peer groups (VPGs)~Six different VPGs topics will be offered on two dates (same topic) every 4-6 weeks, with topics rotating at 4-6 week intervals during their 12-month study participation period.~In-Person Events~Quarterly in-person events will be offered during their 12-month study participation period."
62580631|NCT06546930|NO_INTERVENTION|Comparator Group|An equal number of eligible non-enrolled patients at each site will be selected and matched to the enrolled cohort based on age, language, HbA1c, insurance type, and diabetes technology use at a population level.
62580632|NCT06565260|EXPERIMENTAL|Supportive Care (exercise/nutrition program)|Patients participate in a supervised, community-based exercise program consisting of aerobic and resistance exercise over 45-60 minutes BIW for 12 weeks. Beginning at week 2, patients also receive nutrition education and training QW for 10 weeks. Patients also wear an activity tracker throughout the study.
62580633|NCT05429762|EXPERIMENTAL|Tusamitamab ravtansine|Participants will receive tusamitamab ravtansine intravenous (IV) infusion until disease progression, unacceptable toxicity, the start of a new anti-cancer therapy, or the participant's or Investigator's decision to stop the treatment, whichever comes first.
62580634|NCT03274999|EXPERIMENTAL|TrueTear™ Intranasal then Extranasal Application|TrueTear™ device, intranasal (test) application, for approximately 3 minutes on Day 0 followed by TrueTear™ device, extranasal (control) application, for approximately 3 minutes on Day 14.
62580635|NCT03274999|EXPERIMENTAL|TrueTear™ Extranasal then Intranasal Application|TrueTear™ device, extranasal (control) application, for approximately 3 minutes on Day 0 followed by TrueTear™ device, intranasal (test) application, for approximately 3 minutes on Day 14.
62580636|NCT05787821||Cohort 1|Cementless Femur Cementless Tibia
62580637|NCT05787821||Cohort 2|Cementless Femur Cementless Tibia
62580638|NCT05787821||Cohort 3|Cemented Femur Cemented Tibia
62580639|NCT05787821||Cohort 4|Cemented Femur Cemented Tibia
62580640|NCT05787821||Cohort 5|Cementless Femur Cemented Tibia
62580641|NCT05787821||Cohort 6|Cementless Femur Cemented Tibia
62580642|NCT05787821||Cohort 7|Cementless Femur Cemented Tibia
62215198|NCT05732051|PLACEBO_COMPARATOR|Placebo Control Arm|The patients randomised into this arm of the trial will receive a matching placebo b.i.d. The duration of treatment is equivalent to the description in the treatment arm.
62580643|NCT05787821||Cohort 8|Cementless Femur Cemented Tibia
62580644|NCT05787821||Cohort 9|Cementless Femur Cementless Tibia
62580645|NCT05787821||Cohort 10|Cementless Femur Cementless Tibia
62580646|NCT05787821||Cohort 11|Intended to capture on-label configurations of newly cleared components not captured in cohorts 1-10.
62580647|NCT05787821||Cohort 12|Cementless Femur Cementless Tibia Cementless Patella
62580648|NCT04588532|EXPERIMENTAL|doxepin|"Drug: Doxepin + BAM8-22 Doxepin will be applied for 1.5 hrs followed by the application of BAM8-22. 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop~Drug: Doxepin + Histamine Doxepin will be applied for 1.5 hrs followed by the application of Histamine. 20 µl of histamine will be applied to a previously determined area on the volar forearm followed by a prick through the drop~Drug: Doxepin + Cowhage Doxepin will be applied for 1.5 hrs followed by the application of cowhage. 25/35 spicules of cowhage will be inserted in the skin through a gentle rubbing on a previously determined area on the volar forearm followed by a prick through the drop~Drug: Doxepin + Placebo Doxepin will be applied for 1.5 hrs followed by the application of placebo. 20 µl of placebo will be applied to a previously determined area on the volar forearm followed by a prick through the drop"
62580649|NCT04588532|EXPERIMENTAL|itch|"Drug: BAM8-22 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop~Drug: Histamine 20 µl of histamine will be applied to a previously determined area on the volar forearm followed by a prick through the drop~Drug: Cowhage 25/35 spicules of cowhage will be inserted in the skin through a gentle rubbing on a previously determined area on the volar forearm followed by a prick through the drop~Drug: Placebo 20 µl of placebo will be applied to a previously determined area on the volar forearm followed by a prick through the drop"
62580650|NCT03788031|EXPERIMENTAL|Perceptual learning group - Amblyopia|Visual training
62580651|NCT03788031|ACTIVE_COMPARATOR|Perceptual learning group - Control|Visual training
62787789|NCT01934010|EXPERIMENTAL|AM-101 injection|AM-101 gel for intratympanic injection
62787790|NCT02917395|EXPERIMENTAL|echo|"Population study- patients with obstructive hypertrophic cardiomyopathy that are treated with disopyramide.~Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide."
62580652|NCT03788031|PLACEBO_COMPARATOR|Occlusion therapy - Amblyopia|Patching
62580653|NCT01327183|EXPERIMENTAL|20 mg/kg RO4905417 before PCI|
62580654|NCT01327183|EXPERIMENTAL|5 mg/kg RO4905417 before PCI|
62580655|NCT01327183|PLACEBO_COMPARATOR|Placebo before PCI|
62580656|NCT06142565|EXPERIMENTAL|Olfactory training with nose plugs|Participants will complete olfactory training with scented nose plugs.
62580657|NCT06142565|ACTIVE_COMPARATOR|Olfactory training with household odors|Participants will complete olfactory training with odors found in their household.
62015650|NCT06572618|EXPERIMENTAL|Treatment (nemtabrutinib and rituximab)|"INDUCTION: Patients receive nemtabrutinib PO QD on days 1-28 of each cycle and rituximab IV on days 1, 8, 15 and 22 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive nemtabrutinib PO QD on days 1-28 of each cycle and rituximab IV on day 1 of event numbered cycles. Cycles repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients may optionally continue to receive nemtabrutinib PO QD in the absence of disease progression or unacceptable toxicity.~Patients undergo bone marrow biopsy during screening and may undergo throughout the trial and PET-CT scan and blood sample collection throughout the study."
62015651|NCT00883389||Safe Kidney Care|Patients with Chronic Kidney Disease (eGFR \< 60 ml/min/1.732)and not expected to need dialysis within 6 months of enrollment
62015652|NCT00786916|PLACEBO_COMPARATOR|Group A|Saline
62015653|NCT00786916|ACTIVE_COMPARATOR|Group B|Lidocaine 0.25 mg/kg
62015654|NCT00786916|ACTIVE_COMPARATOR|Group C|Lidocaine 0.5 mg/kg
62015655|NCT01787864||Cross-Sectional Post-Ablation|"The cross-sectional arm will consist of patients who have undergone ablative therapy for Barrett's Esophagus (BE) and have had at least one clear pathology report with no evidence of Barrett's Esophagus (BE) since their first ablation.~Cross-sectional participants will receive one-time study biopsies during a routine care follow-up endoscopy."
62015656|NCT01787864||Prospective Longitudinal Pre-Ablation|"Concurrently enrolled will be a prospective longitudinal arm which will consist of patients prior to their first ablation procedure. The prospective cohort will be followed for 12 months or longer if Barrett's Esophagus (BE) is not yet clear 6 months after the initial treatment.~Prospective longitudinal participants will receive biopsies prior to ablation therapy and 6 and 12 months after the initial treatment. If Barrett's Esophagus (BE) is not yet clear at 6 months, biopsies will be taken at the first endoscopy after Barrett's Esophagus (BE) clearance and again at the next clinically scheduled follow-up visit."
62015657|NCT01543269|ACTIVE_COMPARATOR|ZYT1 tablets|ZYT1 tablets: Route of administration: Oral Dosage: 0.5mg, 1mg, 2 mg, 4mg, 8 mg, 16mg, 32mg and 64mg
62015658|NCT01543269|PLACEBO_COMPARATOR|Placebo|Placebo tablets: Route of administration: Oral Dosage: 0.5mg, 1mg, 2 mg, 4mg, 8 mg, 16mg, 32mg and 64mg
62015659|NCT06105307|EXPERIMENTAL|RN-SLEEP|Participants assigned to the RN-SLEEP group will access the training program via a mobile app for one month. The training app will include sleep physiology content, shift work strategies to promote sleep, cognitive behavior therapy for insomnia components, and skill-building techniques to support behavior modification.
62580658|NCT04124835|EXPERIMENTAL|Intervention Group|In the intervention group, the use of the Swiss Ball will be performed through active exercises of pelvic anteversion and retroversion, lateralization and circumduction according to the obstetric evaluation.
62015660|NCT06105307|ACTIVE_COMPARATOR|Healthy Habit|Participants assigned to the Healthy Habit education control group will use a mobile app for one month focused on other healthy behaviors such as exercise tracking.
62015661|NCT05297994|EXPERIMENTAL|Flu-M|200 volunteers were vaccinated with the Flu-M inactivated split influenza vaccine with a preservative
62015662|NCT05297994|ACTIVE_COMPARATOR|Vaxigrip|200 volunteers were vaccinated with the Vaxigrip® inactivated split influenza vaccine
62580659|NCT04124835|OTHER|Control Group|The control group will receive the usual routine care of the service.
62580660|NCT01338402|OTHER|AIR OPTIX® AQUA|Lotrafilcon B contact lenses worn in both eyes on a daily wear basis for one week in Phase 1.
62015663|NCT03258476|EXPERIMENTAL|GXR and Mindfulness Skills|Guanfacine Extended Release (GXR) will be started at 1 mg/day at Week 1 and tapered up by 1 mg per week to a maximum dose of 7 mg/day by week 7 (maximum of 6 weeks on drug). GXR dosing will be flexible for the first 5 weeks of the study based upon patient response and tolerability to drug. Optimal dose will be defined as that necessary to achieve ≥ 30% reduction in symptoms and a CGI-Improvement Score ≤ 2. Upon re-evaluation at (T1) and entry into the psychotherapy protocol dosing will become fixed for the remainder of the study. Mindfulness Skills Therapy will occur for the next 10 weeks.
62015664|NCT03258476|ACTIVE_COMPARATOR|Placebo and Mindfulness Skills|"Placebo will be started at 1 mg/day at Week 1 and tapered up by 1 mg per week to a maximum dose of 7 mg/day by week 7 (maximum of 6 weeks on drug). Placebo dosing will be flexible for the first 5 weeks of the study based upon patient response. Optimal dose will be defined as that necessary to achieve ≥ 30% reduction in symptoms and a CGI-Improvement Score ≤ 2. Upon re-evaluation at (T1) and entry into the psychotherapy protocol dosing will become fixed for the remainder of the study. Mindfulness Skills Therapy will occur for the next 10 weeks."
62015665|NCT02262429||ONS QIP|Two (2) hospitals will administer the new rapid, comprehensive oral nutritional supplementation (ONS) QIP.
62015666|NCT02262429||ONS Standard Feeding|"Two (2) hospitals will use their current standard ONS feeding protocol."
62580661|NCT01338402|EXPERIMENTAL|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color randomly assigned to one eye, with phemfilcon A contact lens with color in the fellow eye for contralateral wear. Both products worn on a daily wear basis for 4 weeks in Phase 2. A replacement phemfilcon A lens was dispensed at the Week 2 visit.
62580662|NCT01338402|ACTIVE_COMPARATOR|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color randomly assigned to one eye, with lotrafilcon B contact lens with color in the fellow eye for contralateral wear. Both products worn on a daily wear basis for 4 weeks in Phase 2. A replacement phemfilcon A lens was dispensed at the Week 2 visit.
62580663|NCT06683443|EXPERIMENTAL|Robotic Pet|The intervention group will receive the robotic Joy for All™ pet.
62404457|NCT04647175|OTHER|Aronia - fermented aronia - placebo|The participants receive each intervention for 8 weeks in the stated order.
62404458|NCT05005468|EXPERIMENTAL|Camrelizumab Combined With Famitinib|Drug: Camrelizumab Drug: Famitinib
62404459|NCT05005468|NO_INTERVENTION|Observation|Observation
62404460|NCT02996838|EXPERIMENTAL|TQ-B3234|TQ-B3234 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62404461|NCT02804295|OTHER|Collaborative Care Intervention|All enrolled participants received the collaborative care intervention over 6 months.
62404462|NCT04744935|ACTIVE_COMPARATOR|Standard|1064 Long-pulse Nd:YAG laser Fluence: 120 J/cm2 Number of passes: Single Spot size: 2 cm Pulse width: 8-10 msec
62404463|NCT04744935|ACTIVE_COMPARATOR|Slow|1064 Long-pulse Nd:YAG laser Fluence: 20-30 J/cm2 Number of passes: Multiple Spot size: 2 cm Pulse width: 8-10 msec
62404464|NCT01225029|NO_INTERVENTION|Standard Fluids|Term neonates receive total fluids of 60 mL/kg/day on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
62404465|NCT01225029|EXPERIMENTAL|Restricted Fluids|Term neonates receive total fluids of 40 mL/kg/day on day of life (DOL) 1. Preterm neonates receive total fluids of 60 mL/kg/day on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved
62404466|NCT01798056|EXPERIMENTAL|GSK1437173A Group|Subjects received the first dose of GSK 1437173A at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of GSK 1437173A vaccine was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.
62404467|NCT01798056|PLACEBO_COMPARATOR|Placebo Group|Subjects received the first dose of placebo at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of placebo was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.
62404468|NCT00649714|EXPERIMENTAL|1|Zonisamide Capsules 100 mg
62404469|NCT00649714|ACTIVE_COMPARATOR|2|Zonegran® Capsules 100 mg
62404470|NCT06133465||Pleomorphic Lobular Carcinoma in Situ (PLCIS) of the breast|Patients with diagnosis of pure pleomorphic lobular carcinoma in situ of the breast
62404471|NCT06133465||Florid Lobular Carcinoma in Situ (FLCIS) of the breast|Patients with diagnosis of pure florid lobular carcinoma in situ of the breast
62015667|NCT01835782|ACTIVE_COMPARATOR|2.5 grams BID|5 Patients will be evenly randomized into this group
62015668|NCT01835782|ACTIVE_COMPARATOR|.5 grams BID|5 Patients will be evenly randomized into this group
62404472|NCT01462409|EXPERIMENTAL|heated humidification|
62404473|NCT01462409|EXPERIMENTAL|No Humidification|
62015669|NCT01835782|ACTIVE_COMPARATOR|7.5 grams BID|5 Patients will be evenly randomized into this group
62015670|NCT01835782|ACTIVE_COMPARATOR|15 grams BID|5 Patients will be evenly randomized into this group
62015671|NCT04536896|ACTIVE_COMPARATOR|Traditional face-to-face teaching method|In this arm, participants underwent a 6-hour traditional face-to-face lecture on breastfeeding education in a classroom at a university. Course was divided into 4 1.5-hour sessions during a time span of two weeks.
62015672|NCT04536896|EXPERIMENTAL|Breastfeeding smartphone app|In this group, participants downloaded a smartphone application which contained an online breastfeeding education course. Participants freely navigated through the smartphone app during a time span of two weeks.
62215199|NCT05229042|ACTIVE_COMPARATOR|Active arm|Subjects received ricolinostat
62215200|NCT05229042|PLACEBO_COMPARATOR|Placebo arm|Subjects received placebo
62404474|NCT01462409|EXPERIMENTAL|Controlled heated Humidification with heated tube|
62404475|NCT01717300|EXPERIMENTAL|Anacetrapib 100 mg|
62404476|NCT01717300|EXPERIMENTAL|Anacetrapib 25 mg|
62404477|NCT01717300|PLACEBO_COMPARATOR|Placebo|
62404478|NCT01161212|OTHER|Control group|
62404479|NCT01161212|OTHER|Intervention group|
62404480|NCT00296777|EXPERIMENTAL|escitalopram|escitalopram 10 mg/d, increasing by 10 mg/week if tolerated and not remitted to maximum dose of 40 mg/d
62404481|NCT00296777|EXPERIMENTAL|bupropion|bupropion XL 150 mg/d, increasing by 150 mg/d if tolerated and not remitted to maximum dose of 450 mg/d
62404482|NCT00296777|EXPERIMENTAL|imipramine|imipramine 50 mg/d for 3 days, then 100 mg/d for 4 days, then 150 mg/d for 3 days then 200 mg/d for 4 days then 250 mg/d for a week and then 300 mg/d thereafter, all dose increases if tolerated and not remitted
62404483|NCT00604760|EXPERIMENTAL|A|
62404484|NCT00604760|EXPERIMENTAL|B|
62404485|NCT00604760|EXPERIMENTAL|C|
62404486|NCT00604760|PLACEBO_COMPARATOR|D|
62404487|NCT06651580||Observational (biospecimen collection and questionnaire)|Patients complete QoL assessment and complete questionnaires for over 2 hours every 12 months for 4 years. Patients also undergo collection of blood and/or saliva (if blood samples are not available), urine, or stool at baseline.
62404488|NCT03452722||Study group|Applied rtPA
62404489|NCT03452722||Control study|rtPA not applied
62404490|NCT06004518|EXPERIMENTAL|sexual counselling group|Women with MS who are given sexual counseling along with the training booklet will form the sexual counseling group.
62404491|NCT06004518|NO_INTERVENTION|control group|Women with MS who are not given sexual counseling will form the control group.
62404492|NCT05514327|EXPERIMENTAL|treatment group|ultra-fraction radiotherapy + CAR-T
62015673|NCT06573203|EXPERIMENTAL|Non-contact heart rate and respiratory rate monitoring system|After admission, the non-contact mattress is placed under a normal mattress, and heart rate, respiratory rate, and sleep-related parameters can be collected through induction.
62204695|NCT02995642|EXPERIMENTAL|18F-FPPRGD2|Subjects (with either carotid atherosclerosis stenosis or AAA) will receive a single intravenous injection of 10mCi of 18F-FPPRGD2 and will undergo positron emission tomography/computed tomography (PET/CT) or PET/MRI (PET/magnetic resonance imaging) imaging 45-60 minutes after injection.
62204696|NCT04202367|ACTIVE_COMPARATOR|TAP block with 1 mg.kg-1 bupivacaine 0.25%|Patients had 1 mg.kg-1 bupivacaine 0.25% with US-guided TAP block
62404493|NCT05100927||An MR pulse sequence developing on the MRIdian system|This a pilot study to assess and optimize an MR pulse sequence that we are developing on the MRIdian system. It is a single-center trial recruiting only normal volunteers. Volunteers may be grouped by anatomic region of assessment.
62404494|NCT00975000|EXPERIMENTAL|Cinacalcet|Participants received cinacalcet at a starting dose of 30 mg orally once daily for 52 weeks. Cinacalcet dose was titrated every 4 weeks during the dose-titration phase and during study visits in the maintenance phase based on intact parthyroid hormone (iPTH) values, corrected total serum calcium values, and safety assessments.
62015674|NCT06573203|ACTIVE_COMPARATOR|Electrocardiogram monitor|Measuring vital signs
62015675|NCT06573203|ACTIVE_COMPARATOR|Amplitude-integrated EEG|Sleep parameters were continuously measured by aEEG for 6 hours after admission.
62015676|NCT06573203|ACTIVE_COMPARATOR|Neonatal Sleep-Wake Assessment Tool|It is suitable for all newborns to observe and evaluate the sleep phase, wake period and regularity, and guide the choice of care time. The scale includes four dimensions: eye movement, breathing rate, facial expression and muscle activity. The score range of each dimension is 0 \~ 2 points, and the score range is 0 \~ 8 points.
62015677|NCT02972099|EXPERIMENTAL|TcPRF Group|"According to the standard application of the device, for the PRF procedure one 5 x 13 cm skin electrode will be placed over the forehead, the other one over the posterior aspect of the neck. PRF with a duty load of 14.8 msec/sec and an average pulse frequency of 5.11 Hz will be applied for 25min. The voltage will be set to generate a current of 1 A.~Voltage and impedance will be monitored continuously during treatment and if necessary the voltage will be corrected to ensure the proper current."
62015678|NCT02972099|PLACEBO_COMPARATOR|Placebo Group|The setup will be made as for active treatment but no current will be delivered. The patients will not be able to feel any difference to the real treatment.
62015679|NCT01253616|EXPERIMENTAL|VNS plus tones|
62015680|NCT00532831||Obese asthmatics|Obese subjects with asthma (on inhaled bd only)
62015681|NCT00532831||Non-obese asthmatics|Non-obese subjects with asthma(on inhaled bd only)
62015682|NCT03591692|EXPERIMENTAL|ACAF surgery|Underwent anterior controllable antedisplacement and fusion
62015683|NCT03591692|PLACEBO_COMPARATOR|ACCF surgery|Underwentanterior controllable antedisplacement and fusion
62015684|NCT01743937|ACTIVE_COMPARATOR|Ticagrelor|Coronary occlusion with balloon inflation
62015685|NCT01743937|ACTIVE_COMPARATOR|Clopidogrel|Coronary occlusion with balloon inflation
62015686|NCT06261749||Healthy individuals|"Inclusion criteria:~18-30 age Physical activity level should be at least 5 according to Tegner activity scale"
62015687|NCT06220396|EXPERIMENTAL|Healthy Volunteers|Healthy volunteers with no history of Heart Failure (HF) will undergo a Right Heart Catheterization with Hemodynamics and Limited Echocardiogram, MRI, and DEXA scan.
62015688|NCT05363891|EXPERIMENTAL|Natrunix 200mg with MTX(+Folate)|Natrunix 200mg, subcutaneous injection in combination with Methotrexate (+Folate).This arm will enroll 70 subjects.
62015689|NCT05363891|EXPERIMENTAL|Natrunix 400mg with MTX(+Folate)|Natrunix 400mg, subcutaneous injection in combination with Methotrexate (+Folate).This arm will enroll 70 subjects.
62015690|NCT05363891|PLACEBO_COMPARATOR|Placebo with MTX(+Folate)|Placebo in combination with Methotrexate (+Folate).This arm will enroll 70 subjects.
62015691|NCT04166305||Drug responders|60 patients are drug responders
62015692|NCT04166305||Drug resistant|60 patients are drug resistant
62015693|NCT04166305||The control|The control consists of 60 Age and gender matched healthy individual with negative past and family history of epilepsy and febrile convulsion.
62015694|NCT04691479|EXPERIMENTAL|PIMAGroup|"1. Educational and training program using motivational interview technical.~2. Stratification labels: to determine the personalized intervention plan are obtained from two types of variables: personal and modulation variables. For psychological variables the Perceived Competence Evaluation Questionnaire validated in Adherence to CPAP in OSA (CEPCA) is used. Drowsiness is obtained through the administration of the Epworth Somnolence Test, and the apnoea-hypopnea index is taken from the patient's clinical history.~3. Segmentation: With the psychological and clinical variables, in this first visit, predictive information is obtained on how the patient's adherence will be: high adherence, moderate adherence or low adherence.~4. Taking this information into account, the care plan will start considering how the patient is and their situation with respect to adherence. Depending on their evolution, the care plan is adapted. For patients with low adherence, telemonitoring is used."
62204697|NCT04202367|ACTIVE_COMPARATOR|TAP block with 1 mg.kg-1 bupivacaine 0.125%|Patients had 1 mg.kg-1 bupivacaine 0.125% with US-guided TAP block
62204698|NCT02233803|EXPERIMENTAL|Sequence 1: BFF 400/12mcg to BFF 320/9mcg|Subjects will receive Regimen A in Treatment Period 1 followed by Regimen B in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
62215201|NCT05571345|EXPERIMENTAL|PF614 50 mg|PF614 50 mg capsule (1 x 50 mg capsule over-encapsulated and 1 x placebo to match PF614 capsule)
62215202|NCT05571345|EXPERIMENTAL|PF614 100 mg|PF614 100 mg capsule (1 x 100 mg capsule and 1 x placebo to match PF614 capsule)
62215203|NCT05571345|EXPERIMENTAL|PF614 200 mg|PF614 200 mg capsule (2 x 100 mg capsules)
62787791|NCT02206035|EXPERIMENTAL|Tacrolimus, Methotrexate and Tocilizumab (Tac/MTX/Toc)|Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant. Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m2 Days +3, +6 and +11. Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1
62015695|NCT04691479|EXPERIMENTAL|Control|The patients followed the standard of care, which consists of starting therapy in the hospital, where the nurse performed training in the use of CPAP equipment, mask adjustment, and safety and maintenance instructions. For follow-up, the patient was always referred to the Hospital, with a frequency established by the Spanish Society of Pulmonology and Thoracic Surgery (Day 30, Day 90 and Day 180). The follow-up procedure consisted of reviewing the CPAP hour meter and resolving any incidents that may have arisen, with the necessary corrective actions (change of mask, positive reinforcement, and explanation of specific aspects).
62015696|NCT01975389|EXPERIMENTAL|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous.
62015697|NCT01975389|PLACEBO_COMPARATOR|Placebo|Placebo comparator, every 2 weeks, subcutaneous.
62015698|NCT05946018|OTHER|Education only|This arm only includes a 6-8 minute educational video on ergonomics.
62015699|NCT05946018|OTHER|Education and coaching sessions|This arm includes a 6-8 minute education video on ergonomics and 1:1 15 minute coach sessions at 0, 2, 4, and 6 weeks.
62015700|NCT05290259||Ballroom Basics for Balance Program|The Ballroom Basics for Balance program is a 12-week physical activity program which uses dance to focus on balance for community dwelling adults.
62015701|NCT03565406|EXPERIMENTAL|Unresectable Stage III or Stage IV Melanoma|
62015702|NCT06338995|EXPERIMENTAL|Lebrikizumab every 2 weeks (Q2W)/ every 4 weeks (Q4W)|Lebrikizumab will be given as Subcutaneous (SC) injection. Participants will receive background therapy with intranasal corticosteroids (INCS).
62204699|NCT02233803|EXPERIMENTAL|Sequence 2: BFF 320/9mcg to BFF 400/12mcg|Subjects will receive Regimen B in Treatment Period 1 followed by Regimen A in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
62204700|NCT02473731|EXPERIMENTAL|A|Treatment with KTN3379 in HPV positive head and neck cancer patients
62204701|NCT02473731|EXPERIMENTAL|B|Treatment with KTN3379 in HPV negative head and neck cancer patients
62580664|NCT06683443|NO_INTERVENTION|Control|Control group will receive the current standard of care, no robotic pet.
62580665|NCT01910480|EXPERIMENTAL|NBI-98854 followed by NBI-98854 with ketoconazole|50 mg NBI-98854 on Study Days 1 and 6 and 200 mg ketoconazole twice daily on Study Days 5 through 9.
62015703|NCT06338995|EXPERIMENTAL|Lebrikizumab Q2W/every 8 weeks (Q8W)|Lebrikizumab will be given as SC injection. Participants will receive background therapy with INCS.
62015704|NCT06338995|PLACEBO_COMPARATOR|Placebo Q2W/Q4W|Placebo will be given as SC injection. Participants will receive background therapy with INCS.
62580666|NCT05680246||DHOPE-PRO|Outcomes of recipients who underwent liver transplantation of donor organs that were perfused with prolonged (\>4 hours) DHOPE.
62580667|NCT00182455|EXPERIMENTAL|1|Topiramate 25 - 400 mg/day x 12 weeks
62580668|NCT00182455|PLACEBO_COMPARATOR|2|Placebo
62580669|NCT02851589|EXPERIMENTAL|PCAR-019|Enrolled patients will receive PCAR-019 with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
62580670|NCT04292912|EXPERIMENTAL|GSK2798745|Eligible participants received single dose of GSK2798745 for 28 days. Participants were instructed to have GSK2798745 about the same time each day.
62787792|NCT03469687|OTHER|Symax uncemented hip stem|The Symax hip stem is an uncemented design forged from Ti6Al4V alloy (Stryker EMEA). Primary mechanical stability is provided by anatomical metaphyseal geometry. The hip stem features a size dependent anteversion, neck length and offset, with a CCD angle of 128°. Secondary biological stability is accomplished by fast osseous integration due to the BONIT-HA coating on the metaphyseal part of the stem.
62787793|NCT02702180|EXPERIMENTAL|Double-blind molgramostim once daily|Inhalation of molgramostim nebuliser solution 300 mcg once daily for 24 weeks
62787794|NCT02702180|EXPERIMENTAL|Double-blind molgramostim intermittent|Inhalation of molgramostim nebuliser solution 300 mcg for 7 days and placebo nebuliser solution for 7 days for 24 weeks (12 cycles)
62015705|NCT03173196||Sepsis group|Patients with a septic shock or a severe sepsis (surgical and non-surgical patients), staying on Intensive Care Unit, Non-invasive Multispectral Sonography - measurement
62015706|NCT03173196||Non-septic group|Patients without sepsis (surgical and non-surgical patients), staying at least 24 hours on an Intensive Care Unit, Non-invasive Multispectral Sonography - measurement
62015707|NCT03396744|ACTIVE_COMPARATOR|Morning group|Exposition at 8 a.m +/- 30 min, during 10 active weeks, and assessed 6 months after this intervention
62015708|NCT03396744|ACTIVE_COMPARATOR|Mid-day group|Exposition at 8 a.m +/- 30 min, during 10 active weeks, and assessed 6 months after this intervention.
62015709|NCT01958918|EXPERIMENTAL|Ranibizumab|1 intravitreal injection monthly until maximum stable BCVA with retreatment based on BCVA loss and/or SD-OCT signs of wet AMD disease activity
62734850|NCT03349138|EXPERIMENTAL|Electrical Stimulation and Robotic Glove|Electrical Stimulation \& Robotic Glove \& Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the electrical stimulation system plus 60 minutes of conventional therapy or 30-minute training with the robotic glove system plus 60 minutes of conventional therapy. Half of the sessions are allocated to the electrical stimulation system, and half are allocated to the robotic glove system. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
62734851|NCT00124072|ACTIVE_COMPARATOR|Simvastatin 20 mg + folic acid and B12|Participants received 20 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily
62204702|NCT01868932|EXPERIMENTAL|hypertonic saline|inhalation of 4 ml nebulized study solution containing 3% hypertonic saline (HS, study group). Each dose of study solution will also contain a standard dose of bronchodilator (salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) 1,2 added by the ED staff. Initial therapy will consist of 3 consecutive nebulizations given in rapid succession (back-to-back, approximately every 20 minutes).
62404495|NCT00975000|PLACEBO_COMPARATOR|Placebo|Participants received placebo orally once daily for 52 weeks.
62204703|NCT01868932|ACTIVE_COMPARATOR|saline|inhalation of 4 ml nebulized study solution containing saline 0.9% saline (NS, control group). Each dose of study solution will also contain a standard dose of bronchodilator (salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) 1,2 added by the ED staff. Initial therapy will consist of 3 consecutive nebulizations given in rapid succession (back-to-back, approximately every 20 minutes).
62204704|NCT00876564|OTHER|Trauma patients|Included in trauma registry
62204705|NCT04630288||Clopidogrel|Clopidogrel is a prodrug that requires metabolic activation in two stepsby hepatic CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Consequently, due to the irreversible binding to the P2Y12 receptor,platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days) and recovery of normal platelet function occurs at a rate consistent with the normal platelet turnover. Clopidogrel was approved by the European Commission on 15 July 1998 for the secondary prevention of atherothrombotic events in adult patients with ACS.
62404496|NCT05308134|ACTIVE_COMPARATOR|Standard fortification|
62734852|NCT00124072|ACTIVE_COMPARATOR|Simvastatin 80 mg + folic acid and B12|Participants received 80 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily
62734853|NCT00124072|ACTIVE_COMPARATOR|Simvastatin 20 mg + placebo|Participants received 20 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily
62015710|NCT01958918|ACTIVE_COMPARATOR|Aflibercept|1 intravitreal injection monthly for the first 3 months, followed by 1 intravitreal injection every 2 months
62015711|NCT02605590|EXPERIMENTAL|1.25 mg|Part 1: single inhaled dose of 1.25 mg AIR-DNase followed by Part 2: once daily inhaled dose of 1.25 mg AIR DNase for 5 consecutive days.
62015712|NCT02605590|EXPERIMENTAL|2.5 mg|Part 1: single inhaled dose of 2.5 mg AIR-DNase followed by Part 2: once daily inhaled dose of 2.5 mg AIR DNase for 5 consecutive days.
62015713|NCT02605590|EXPERIMENTAL|5 mg|Part 1: single inhaled dose of 5 mg AIR-DNase followed by Part 2: once daily inhaled dose of 5 mg AIR DNase for 5 consecutive days.
62015714|NCT02605590|PLACEBO_COMPARATOR|Placebo|Placebo comparator for each of the dose levels, administered accordingly as single inhaled dose in Part 1 followed by once daily inhaled dose for 5 consecutive days in Part 2.
62015715|NCT05036187|EXPERIMENTAL|Weight Loss Program Only|Participants complete an online behavioral weight loss program.
62015716|NCT05036187|EXPERIMENTAL|Weight Loss Program + Coping with Stress Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive intervention that teaches strategies for coping with stress \& stigma due to weight, sexual orientation, and gender \& its impact on weight loss.
62204706|NCT04630288||Ticagrelor|Ticagrelor is a nucleoside analogue member of the chemical class cyclopentyltriazolopyrimidines (CPTP), which is a selective and reversible ADP- receptor antagonist acting on the platelet P2Y12 receptor. This prevents the binding of ADP to the receptor which attenuates plateletactivation and aggregation.The drug was approved by the European Commission on December 3, 2010, for the prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in patients with ACS (unstable angina, non ST elevation Myocardial Infarction \[NSTEMI\] or ST elevation Myocardial Infarction \[STEMI\]) including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
62204707|NCT05717894|EXPERIMENTAL|Treatment ( primary )|
62204708|NCT05717894|NO_INTERVENTION|Control|
62204709|NCT01233323||All study patients (single arm study)|All eligible patients will be included in the only study arm and will undergo study testing.
62404497|NCT05308134|EXPERIMENTAL|Target fortification|
62404498|NCT05308134|EXPERIMENTAL|BUN adjustable fortification|
62404499|NCT02415907|EXPERIMENTAL|Idalopirdine|"Period I: Initial administration of Lu AF67709 single dose at baseline.~Period II: Administration of Lu AF67708 single dose (week 4)"
62787795|NCT02702180|PLACEBO_COMPARATOR|Double-blind placebo|Inhalation of placebo nebuliser solution once daily for 24 weeks
62404500|NCT04722627|EXPERIMENTAL|AT-752 250 mg single dose|AT-752 administered orally, 250 mg on Day 1
62787796|NCT02702180|EXPERIMENTAL|Open-label molgramostim intermittent|Inhalation of molgramostim nebuliser solution 300 mcg for 7 days and placebo nebuliser solution for 7 days for 24 or 48 weeks from completion of the double-blind period
62787797|NCT04845763||Intervention|Each patient complete the french version of the QoR-15 score (FQoR-15) at 3 times (before surgery, on Day 1, on Day 2).
62787798|NCT05703581||PD(TRIANGLE)|"Patients with pancreatic head cancer or periampullary cancer underwent Heidelberg Triangle dissection (TRIANGLE operation) combined with Pancreatoduodenectomy and standard lymphadenectomy"
62787799|NCT05703581||PD(non-TRIANGLE)|Patients with pancreatic head cancer or periampullary cancer underwent pancreatoduodenectomy with standard lymphadenectomy
62787800|NCT05703581||DP(TRIANGLE)|"Patients with carcinoma of the body and tail of the pancreas underwent Heidelberg Triangle dissection (TRIANGLE operation) combined with distal pancreatectomy and standard lymphadenectomy"
62787801|NCT05703581||DP(non-TRIANGLE)|Patients with carcinoma of the body and tail of the pancreas underwent distal pancreatectomy with standard lymphadenectomy
62787802|NCT04599465|EXPERIMENTAL|ELX/TEZ/IVA|Participants received ELX 200 mg /TEZ 100 mg /IVA 150 mg in the morning and IVA 150 mg in the evening.
62787803|NCT02956941|EXPERIMENTAL|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|Intervention group will be received 12 months on nutrition behavior change communication using two modes (lecture, and posters).
62787804|NCT02956941|NO_INTERVENTION|Control cluster|Control group will receive routine dietary practices.
62787805|NCT03787355|EXPERIMENTAL|Cone Morse Connection Implants|2 neighboring Morse connection Implants
62015717|NCT05036187|EXPERIMENTAL|Weight Loss Program + Coping with Stress Program + Body Image Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress \& stigma due to weight, sexual orientation, and gender \& its impact on weight loss, and (3) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
62015718|NCT05036187|EXPERIMENTAL|Weight Loss Program + Coping with Stress Program + Body Image Program + Social Support Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress \& stigma due to weight, sexual orientation, and gender \& its impact on weight loss, (3) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts, and (4) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
62015719|NCT05036187|EXPERIMENTAL|Weight Loss Program + Body Image Program + Social Support Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts, and (3) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
62404501|NCT04722627|PLACEBO_COMPARATOR|Placebo -single dose|Matching placebo administered orally on Day 1
62404502|NCT04722627|EXPERIMENTAL|AT-752 500 mg single dose|AT-752 administered orally, 500 mg single doses on Day 1 and Day 7
62404503|NCT04722627|PLACEBO_COMPARATOR|Placebo- single dose|Matching placebo administered orally on Day 1 and Day 7
62404504|NCT04722627|EXPERIMENTAL|AT-752 1000 mg single dose|AT-752 administered orally, 1000 mg single dose on Day 1
62787806|NCT03787355|ACTIVE_COMPARATOR|platform matched implants|2 neighboring platform matched implants.
62787807|NCT01578577|NO_INTERVENTION|Standard Care|This arm will serve as a control group and will not receive any intervention.
62787808|NCT01578577|EXPERIMENTAL|EHMI|Electronic Health Record-based Health Literacy Medication Therapy Management Intervention (EHMI)arm consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
62787809|NCT01578577|EXPERIMENTAL|Nurse Educator + EHMI|
62787810|NCT02181764|EXPERIMENTAL|KRN23|Single SC administration on day 1
62404505|NCT04722627|PLACEBO_COMPARATOR|Placebo - single dose|Matching placebo administered orally on Day 1
62404506|NCT04722627|EXPERIMENTAL|AT-752 1500 mg single dose|AT-752 administered orally, 1500 mg single dose on Day 1
62404507|NCT04722627|PLACEBO_COMPARATOR|Placebo: single dose|Matching placebo administered orally on Day 1
62404508|NCT04722627|EXPERIMENTAL|AT-752 - 1000 mg QD multiple doses|AT-752 - administered orally, 1000 mg once daily (QD) for 7 days
62404509|NCT04722627|PLACEBO_COMPARATOR|Placebo - Administered once daily (QD)|Matching placebo administered orally once daily (QD) for 7 days
62404510|NCT04722627|EXPERIMENTAL|AT-752 - 750 mg twice daily (BID)|AT-752 administered orally, 750 mg twice daily (BID) for 4 days plus one dose on Day 5.
62404511|NCT04722627|PLACEBO_COMPARATOR|Placebo - Administered twice daily (BID)|Matching placebo administered orally twice daily (BID) for 4 days plus one dose on Day 5.
62404512|NCT04722627|EXPERIMENTAL|AT-752 - 750 mg three times daily (TID)|AT-752 administered orally, 750 mg three times daily (TID) for 4 days plus one dose on Day 5.
62204710|NCT04812002|EXPERIMENTAL|Double medicine combined|participants received 200mg of PD-1 inhibitors combined 15mg of bevacizumab per square body surface area intravenously every 3 weeks
62204711|NCT05082961|OTHER|X-ray photon therapy + biological samples|
62204712|NCT05082961|OTHER|Protontherapy + biological samples|
62204713|NCT06329258|EXPERIMENTAL|Deucravacitinib in combination with Enstilar|deucravacitinib in combination with Enstilar
62204714|NCT06329258|EXPERIMENTAL|Deucravacitinib monotherapy|monotherapy
62404513|NCT04722627|PLACEBO_COMPARATOR|Placebo - Administered TID|Matching placebo administered orally (TID) for 4 days plus one dose on Day 5.
62404514|NCT00886626|EXPERIMENTAL|Exenatide|Exenatide
62404515|NCT00886626|NO_INTERVENTION|Control|Control - no intervention
62404516|NCT05547516|ACTIVE_COMPARATOR|Standard infusion chemotherapy (including gemcitabine, mitomycin, Epirubicin, etc.)|Standard infusion chemotherapy (including gemcitabine, mitomycin, epirubicin, etc.) was dissolved in 50mL normal saline or glucose and perfused into the bladder for 60min. Perfusion can be performed within 24 hours after surgery, and then once a week for a total of 8 times, and then once a month until 12 months after surgery.
62404517|NCT05547516|ACTIVE_COMPARATOR|BL-5ALA-PDT|Bl-5ala-pdt protocol: 1.5g 5ALA, dissolved in 50mL normal saline, was infused into the bladder for 2h before surgery and before each cystoscopy, and blue laser irradiation was performed under flexible cystoscopy at 30mW/cm2 for 21min. PDT was performed during the operation and at 3, 6, and 9 months after the operation.
62404518|NCT02047929|ACTIVE_COMPARATOR|Facilitator-Led|This approach to dissemination allows clinics some freedom to tailor the Asthma Shared Decision Making (SDM) Toolkit and training process for their specific environment and patient population while maintaining fidelity of certain key elements that are felt to be essential for success. The expertise of the trained Practice Facilitator will help guide the process of implementation at the practice level.
62404519|NCT02047929|ACTIVE_COMPARATOR|Traditional|"The most commonly used dissemination technique is active diffusion, which includes didactic presentations, academic detailing, exposure to journal publications and subject matter experts, and educational material distribution. We have defined this type of dissemination, traditional dissemination. For the purpose of this study, practices randomized to traditional dissemination will receive a lunchtime presentation by a physician champion / subject matter expert on shared decision making. The presentation will give an overview of the Asthma Shared Decision Making (SDM) Toolkit, access to the internet link with additional information, and a copy of all printed materials associated with the Toolkit."
62404520|NCT02047929|NO_INTERVENTION|Control|A third group will be randomized into an arm with no formal dissemination. This arm will receive information only through passive exposure to the concepts of shared decision making. This would include introduction to the SDM concepts through the media, conferences, or social networks. Having this control in place will allow the research team to isolate the effect of both the FLOW approach and the traditional approach to dissemination.
62404521|NCT00338377|EXPERIMENTAL|Group A: Chemotherapy + IL-2 plus T-cells|"Cyclophosphamide 60 mg/kg/d by vein (IV) over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m\^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10\^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.~Group A has been closed to new patient entry as of January 14, 2016."
62404522|NCT00338377|EXPERIMENTAL|Group B: Chemotherapy + IL-2 plus T-Cells + Vaccine|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m\^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10\^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
62734854|NCT00124072|ACTIVE_COMPARATOR|Simvastatin 80 mg + placebo|Participants received 80 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily
62734855|NCT03704844||Patients with renal congestion|
62015720|NCT05036187|EXPERIMENTAL|Weight Loss Program + Coping with Stress Program + Social Support Program|Participants complete a (1) online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress \& stigma due to weight, sexual orientation, and gender \& its impact on weight loss, and (3) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts.
62204715|NCT00878683|EXPERIMENTAL|1|Device and standard catheter
62204716|NCT00878683|NO_INTERVENTION|2|Standard catheter
62204717|NCT01349153|ACTIVE_COMPARATOR|Facebook-based Self-help Comparison|Participants will receive a pedometer and twelve weekly messages with links to Internet resources that have educational materials related to exercise and cancer survivorship.
62204718|NCT01349153|EXPERIMENTAL|Facebook-based Messages/Website|Participants will receive a pedometer, twelve weekly messages, and be encouraged to participate in sixteen Facebook group discussions and use a website for exercise goal-setting and tracking activity.
62204719|NCT04739969|ACTIVE_COMPARATOR|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
62204720|NCT04739969|SHAM_COMPARATOR|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
62204721|NCT05451004|EXPERIMENTAL|Lympathic Mapping with SPECT-CT guided Radiotherapy|
62204722|NCT05451004|ACTIVE_COMPARATOR|Bilateral Neck Radiotherapy|
62204723|NCT04078295|EXPERIMENTAL|Phase 1b: E7389-LF + Nivolumab|Participants will receive specified doses of E7389-LF (intravenous) and nivolumab (intravenous) on specified days.
62204724|NCT04078295|EXPERIMENTAL|Phase 2, Cohort-1: E7389-LF + Nivolumab|Participants with gastric cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.
62204725|NCT04078295|EXPERIMENTAL|Phase 2, Cohort-2: E7389-LF + Nivolumab|Participants with esophageal cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.
62204726|NCT04078295|EXPERIMENTAL|Phase 2, Cohort-3: E7389-LF + Nivolumab|Participants with small cell lung cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.
62204727|NCT02626455|EXPERIMENTAL|Copanlisib + R-B or R-CHOP / Arm 1|Combination of copanlisib with standard immunochemotherapy (rituximab and bendamustine) \[R-B\] or rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone \[R-CHOP\] (safety run-in and phase III)
62204728|NCT02626455|PLACEBO_COMPARATOR|Placebo + R-B or R-CHOP / Arm 2|Combination of placebo and R-B or R-CHOP (phase III only)
62204729|NCT03518190|EXPERIMENTAL|Suspected pressure injury|Patients evaluated with high-risk for pressure injury
62204730|NCT00403767|EXPERIMENTAL|Rivaroxaban|
62580671|NCT04764981|EXPERIMENTAL|Experimental Group 1: Essences Oils|The individuals of this group are 150 individuals with olfactory disorder related to COVID-19 that will be submitted to clinical exams, olfactory test and MRI imaging, after that, participants will undergo an olfactory training with essences oils. Each participant in this group will receive a kit with four 30 ml bottles, each containing a circular piece of watercolor paper soaked in one of the four essences oils (rose, eucalyptus, lemon and cloves) used in olfactory training, a manual to make the olfactory training at home and a self-assessment diary which should be filled weekly. Each participant of this group will use the training kit for three months, the olfactory training consists of inhaling each of the substances for 30 seconds, with an interval of 30 seconds between them, twice a day, upon waking up and before bed, the participants will be reassessed with CCCRT after each month of training. The results of this group will be compared with the other groups.
62204731|NCT00403767|ACTIVE_COMPARATOR|Warfarin|
62015721|NCT05036187|EXPERIMENTAL|Weight Loss Program + Body Image Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
62204732|NCT05846230|EXPERIMENTAL|BI 1291583 low dose arm|
62204733|NCT05846230|EXPERIMENTAL|BI 1291583 medium dose arm|
62204734|NCT05846230|EXPERIMENTAL|BI 1291583 high dose arm|
62204735|NCT06487130||Menopause/Post-menopause|Menopause/Post-menopause, born with ovaries
62204736|NCT06487130||Peri-menopause|Peri-menopause, born with ovaries
62204737|NCT06487130||Pre-menopause|Pre-menopause, born with ovaries
62734856|NCT03704844||Patients without renal congestion|
62734857|NCT05328869|EXPERIMENTAL|Relaxation group|Jacobson progressive relaxation training will be applied
62015722|NCT05036187|EXPERIMENTAL|Weight Loss Program + Social Support Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts.
62015723|NCT02779218|EXPERIMENTAL|Sequence 1|"The patients will receive in order :~1. Paired Associative Stimulation~2. Paired Associative Stimulation + Motor Imagery exercises~3. Placebo Paired Associative Stimulation + Motor Imagery exercises"
62015724|NCT02779218|EXPERIMENTAL|Sequence 2|"The patients will receive in order :~1. Paired Associative Stimulation + Motor Imagery exercises~2. Placebo Paired Associative Stimulation + Motor Imagery exercises~3. Paired Associative Stimulation"
62015725|NCT02779218|EXPERIMENTAL|Sequence 3|"The patients will receive in order :~1. Placebo Paired Associative Stimulation + Motor Imagery exercises~2. Paired Associative Stimulation~3. Paired Associative Stimulation + Motor Imagery exercises"
62015726|NCT06331208||controls|Subjects without heart failure or pulmonary hypertension undergoing clinically indicated diagnostic evaluation or therapeutic procedure
62015727|NCT06331208||heart failure|Subjects with chronic heart failure due to reduced ejection fraction (EF), undergoing clinically indicated right heart catheterisation (evaluation for left ventricular assist device (LVAD)/transplantation (TX) or other decision)
62015728|NCT03726359|EXPERIMENTAL|Fractionated Stereotactic Radiation Therapy|This study is unique in that it employs a continuous reassessment methodology (CRM) to determine the Maximum Tolerated Dose. Information for the proper dose level for each subsequent patient enrolled will be determined based on DLTs from previous patients enrolled in the trial.
62015729|NCT02978144|OTHER|Healthy volunteers|Healthy controls who never smoked (less than 100 lifetime cigarettes) with normal spirometry will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
62015730|NCT02978144|OTHER|Current smokers|Healthy controls who are currently smoking (\> 10 pack years) with normal spirometry will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
62015731|NCT02978144|OTHER|Patients with moderate COPD|Patients with moderate COPD will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
62015732|NCT02978144|OTHER|Patients with severe COPD|Patients with severe COPD will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
62015733|NCT05334108|OTHER|Cohort 1|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 1 Probe Substrate Cocktail given on 2 separate days:~* midazolam: 1 µg infused IV~* caffeine: 200 mg oral tablet~* omeprazole: two 20 mg oral tablets~* dextromethorphan: 1.6mL (containing \~10 mg) oral solution"
62015734|NCT05334108|OTHER|Cohort 2|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 2 Probe Substrate given on 2 separate days:~- bupropion: 100mg oral tablet"
62015735|NCT05334108|OTHER|Cohort 3|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 3 Probe Substrate Cocktail given on 3 separate days:~* midazolam: 10 µg/mL given as 1mL oral solution.~* dabigatran: 375 µg/mL and pitavastatin: 10 µg/mL given as 1mL oral solution~* rosuvastatin: 25 µg/mL and atorvastatin: 50 µg/mL given as 2mL oral solution"
62204738|NCT06487130||Other|Not born with ovaries
62204739|NCT02354820|NO_INTERVENTION|Control|Patients are identified by the pre-screener form given to parents as having constipation or encopresis. No intervention is given to providers to help them with constipation management.
62204740|NCT02354820|EXPERIMENTAL|Experimental|Patients are identified by the pre-screener form given to parents as having constipation or encopresis. Evidence based reminders and patient educational materials are given to providers to help them with constipation management.
62204741|NCT05428995|ACTIVE_COMPARATOR|C-MAC videolaryngoscope|Patients with anticipated difficult airway will be awake intubated with a C-MAC videolaryngoscopy. Spontaneous breathing will be preserved, and the same protocol of sedation plus upper airways topical anesthesia will be applied in both groups.
62204742|NCT05428995|ACTIVE_COMPARATOR|Airtraq videolaryngoscope|Patients with anticipated difficult airway will be awake intubated with a Airtraq videolaryngoscopy. Spontaneous breathing will be preserved, and the same protocol of sedation plus upper airways topical anesthesia will be applied in both groups.
62204743|NCT04921891|ACTIVE_COMPARATOR|Blocked arm|The investigators performed an infraclavicular nerve block to the operated arm group to provide anesthesia.
62204744|NCT04921891|ACTIVE_COMPARATOR|Unblocked arm|The upper extremity without block was assigned as the control group, and a comparison was made between the two upper extremities.
62204745|NCT03219047|EXPERIMENTAL|Cohort 2 (Co-trial cohort)|Patients receive ibrutinib at standard dose and schedule through an ongoing MD Anderson clinical trial. Patients that respond to ibrutinib but experience relapse or disease progression receive treatment based on the results of the PDX models as in Cohort 1 if they are available. Patients who experience relapse after treatment with ibrutinib are moved to Cohort I if the PDX models are not ready.
62204746|NCT03219047|EXPERIMENTAL|Cohort I (Traditional cohort)|Patients who have previously received ibrutinib, acalabrutinib, PI3K inhibitor ACP-319, or BTK inhibitor BGB-3111 receive treatment through ongoing clinical trials at MD Anderson or standard of care. At the same time, previously collected tissue is used to develop PDX models and suitable drugs/regimens are tested in the PDX models. Patients then receive treatment based on the results of the PDX models through another clinical trial or standard of care.
62204747|NCT03081364||Outpatients|MRI; Critical Care Monitoring, Device Programming
62204748|NCT04270253|EXPERIMENTAL|End-range mobilization|End-range mobilization applied 6 times for 2\*2 min in end-range of flexion and extension end-range of the tibiofemoral and patellofemoral joint beside the same conservative therapy, as used for the Control
62204749|NCT04270253|ACTIVE_COMPARATOR|Control|Conservative therapy including aquatic exercises (5-times), land-based exercises (3-times), balneotherapy (5-times) and TENS therapy (3-times)
62404523|NCT00338377|EXPERIMENTAL|Group C: Prior Treatment with BRAF Inhibitor|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m\^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10\^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
62404524|NCT00338377|EXPERIMENTAL|Group D: Leptomeningeal Disease|"T-cells: 5.0x109 TIL administered on Day 1 and 10x109 TIL on Day 15.~IL-2: 1.2 MIU of IL- 2 on Days 2, 4, 9, 11, 16 and 18 as tolerated. After this period, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks, patients switched to IL-2."
62580672|NCT04764981|NO_INTERVENTION|Experimental Group 2: Clinical follow-up|The individuals of this group are 150 individuals with olfactory disorder related to COVID-19. that will be submitted to clinical exams, olfactory test and MRI imaging, after three months they will be reassessed.
62580673|NCT04764981|NO_INTERVENTION|Control Group|The individuals of this group are 50 healthy individuals, without previous COVID-19 infection, that will be submitted to clinical exams, olfactory test, MRI imaging and the participants will be tested for the ability to identification of the essence oils utilized by Experimental group 1.
62734858|NCT05328869|OTHER|Control group|No intervention will be applied
62204750|NCT01274325|EXPERIMENTAL|Sereflo|Sereflo (25/125)
62787811|NCT06089837|EXPERIMENTAL|EC5026|Multiple Ascending Doses of oral EC5026
62787812|NCT06089837|EXPERIMENTAL|Placebo|Single doses of matching oral placebo
62015736|NCT02661906|EXPERIMENTAL|SKY Pre|Sudarshan Kriya Yoga is provided to all the enrolled participants. The baseline characteristics of patient is compared with that of their characteristics after yoga intervention. All the participants were provided with yoga training for 6 days and then asked to perform the SKY at home daily till 12 week. The questionnaire on anxiety, depression and quality of life were administered at the baseline and at the end of 6 days of yoga. Biochemical parameters such as HbA1c, lipid profile, fasting glucose and post meal glucose were measured at baseline and after 12 week of intervention.
62015737|NCT02661906|ACTIVE_COMPARATOR|SKY post|The enrolled participants were provided with SKY intervention and their pre and post data were recorded.
62204751|NCT01274325|ACTIVE_COMPARATOR|Seretide|Seretide (25/125)
62204752|NCT05925231||People after stroke|Czech people after stroke, aged 20 - 64 years
62204753|NCT05925231||Healthy population|Czech healthy people, aged 20 - 64 years
62204754|NCT02427945|EXPERIMENTAL|Control|Provision of information on safe water
62204755|NCT02427945|EXPERIMENTAL|Treatment traditional|Provision of information on safe water and child nutrition. The information will be targeted to the mother of the child aged between 6 and 24 months old.
62204756|NCT02427945|EXPERIMENTAL|Treatment couple|Provision of information on safe water and child nutrition. The information will be targeted to the mother of the child aged between 6 and 24 months old, and her husband.
62787813|NCT02682199||Whole Brain Radiation|Patients scheduled to receive whole brain radiation with or without chemotherapy/targeted therapy.
62787814|NCT06507826|PLACEBO_COMPARATOR|Control|Descriptive writing.
62787815|NCT06507826|ACTIVE_COMPARATOR|Mindfulness|Writing with mindfulness.
62787816|NCT06507826|ACTIVE_COMPARATOR|Mindfulness with Self-Kindness|Writing with mindfulness and self-kindness.
62787817|NCT06507826|ACTIVE_COMPARATOR|Mindfulness with Common Humanity|Writing with mindfulness and common humanity.
62015738|NCT02211989|EXPERIMENTAL|BI 14332 CL|single rising dose
62015739|NCT02211989|PLACEBO_COMPARATOR|Placebo|
62204757|NCT05144555|EXPERIMENTAL|Group MET|Patients from this group will undergo orthodontic fixed treatment with stainless steel brackets.
62204758|NCT05144555|ACTIVE_COMPARATOR|Group CER|Patients from this group will undergo orthodontic fixed treatment with ceramic brackets.
62204759|NCT03592043||MitraClip|All patients who have undergone percutaneous mitral valve repair with the MitraClip system in Canada
62204760|NCT00415051|EXPERIMENTAL|Single Group Assignment|RVF MP-12
62215204|NCT05571345|ACTIVE_COMPARATOR|Oxycodone IR 40 mg|Oxycodone HCl 40 mg (2 x 20 mg capsules over-encapsulated to match PF614 capsules).
62580674|NCT02024607|EXPERIMENTAL|ARM A- BBI608 in combination with FOLFOX6|BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m\^2 together with leucovorin 400 mg/m\^2 will be administered intravenously. 5-FU 400 mg/m\^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m\^2/day (total 2400 mg/m\^2 over 46-48 hours) continuous intravenous infusion. This regimen will be repeated every 14 days thereafter.
62734859|NCT00332579|ACTIVE_COMPARATOR|A|Naltrexone
62734860|NCT00332579|PLACEBO_COMPARATOR|B|Placebo
62734861|NCT00260832|EXPERIMENTAL|A|Subject's choice of treatment with physician's advice. Subjects preselected their preference of supportive care (including IV fluids, nutrition, and antibiotics) or cytarabine. (These represent one intervention.)
62734862|NCT00260832|ACTIVE_COMPARATOR|B|
62015740|NCT01709318|EXPERIMENTAL|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 500/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
62015741|NCT01709318|EXPERIMENTAL|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 700/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
62015742|NCT01709318|EXPERIMENTAL|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 900/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 900/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
62015743|NCT01709318|EXPERIMENTAL|Etonogestrel-17β-Estradiol (ENG-E2) 75/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2) 75/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
62015744|NCT01709318|EXPERIMENTAL|Etonogestrel-17β-Estradiol (ENG-E2) 100/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2) 100/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
62015745|NCT01709318|EXPERIMENTAL|Etonogestrel-17β-Estradiol (ENG-E2) 125/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2)125/300 μg for three 28-day treatment periods, each treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
62015746|NCT01709318|ACTIVE_COMPARATOR|NuvaRing®|Participants will receive NuvaRing® (etonogestrel-ethinyl estradiol \[ENG-EE\] 120/15 μg) for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
62015747|NCT04508803|EXPERIMENTAL|The main research|Patients diagnosed with HER2 negative metastatic breast cancer with BRCA1/2, PALB2, CHEK2 pathogenic/suspected pathogenic germline mutation are recruited.
62015748|NCT04508803|EXPERIMENTAL|Ancillary Exploration research 1|Patients diagnosed with HER2 negative metastatic breast cancer with DDR gene (include ATM、ATR、BAP1、BARD1、BLM、BRIP1、CHEK1、CDK12、FANCA、FANCC、FANCD2、FANCE、FANCF、FANCM、MRE11A、NBN、PTEN、RAD50、RAD51C、RAD51D、WRN)pathogenic/suspected pathogenic germline mutation except BRCA1/2, PALB2 and CHEK2 are recruited.
62015749|NCT04508803|EXPERIMENTAL|Ancillary Exploration research 2|Patients diagnosed with HER2 positive metastatic breast cancer with DDR gene pathogenic/suspected pathogenic germline mutation are recruited.
62015750|NCT04508803|EXPERIMENTAL|Ancillary Exploration research 3|Patients diagnosed with brain metastases breast cancer with DDR gene pathogenic/suspected pathogenic germline mutation who has not undergone or progressed after brain radiotherapyare recruited.
62015751|NCT06515548|ACTIVE_COMPARATOR|Vitamin D mouthwash|a
62015752|NCT06515548|PLACEBO_COMPARATOR|Placebo mouth wash|
62015753|NCT03030612|EXPERIMENTAL|ARGX-110 with Azacytidine (AZA)|Phase 1: Participants will receive loading dose of ARGX-110 1 milligram per kilogram (mg/kg) body weight (cohort 1), 3 mg/kg body weight (cohort 2), 10 mg/kg body weight (cohort 3) or 20 mg/kg body weight (cohort 4) administered intravenously (IV) in combination with AZA standard dose of 75 milligram per meter square (mg/m\^2) body surface area (BSA) administered subcutaneously (SC) / intravenously (IV). Phase 2: Participants will receive loading dose of ARGX-110 IV at a recommended dose for Phase 2 (RP2D) level from phase 1 in combination with AZA standard dose of 75 mg/m\^2 BSA, administered SC/IV as per local practice.
62015754|NCT03821428|EXPERIMENTAL|Acupuncture|Needling of acupoints P6 and CV24 with indwelling permanent needles, withdrawn after TEE procedure
62015755|NCT03821428|PLACEBO_COMPARATOR|Control|Application of Placebo needles in the areas of P6 and CV24 acupoints
62015756|NCT05187455|EXPERIMENTAL|Renal transplantation(S group)|n=17,CLCR≤30ml/min
62015757|NCT05187455|EXPERIMENTAL|the control group|n=17, CLCR≥80ml/min
62015758|NCT06572358|EXPERIMENTAL|MetProUltima|"Test product Name: MetProUltima Marketed By\| Manufactured By: Meteoric Biopharmaceuticals Private Limited Mode of Usage: Take one capsule after each meal, twice daily. Frequency: Twice a Day Route of Administration: Oral"
62015759|NCT04480164|EXPERIMENTAL|NDMC 40 mg/day|Oral administration of two NDMC 20mg capsules per day over 6 weeks
62015760|NCT04480164|EXPERIMENTAL|NDMC 60 mg/day|Oral administration of three NDMC 20mg capsules per day over 6 weeks
62015761|NCT04480164|EXPERIMENTAL|NDMC 120 mg/day|Oral administration of six NDMC 20mg capsules per day over 6 weeks
62015762|NCT04480164|PLACEBO_COMPARATOR|Placebo|Oral administration respectively, according to the experimental arm considered, of two, three or six placebo capsules per day over 6 weeks
62015763|NCT05264805|EXPERIMENTAL|Bupivacaine group|Patient receiving 20ml of inj. 0.25% Bupivacaine at laparoscopic port site
62015764|NCT05264805|NO_INTERVENTION|Placebo group|No drug infiltration at laparoscopic port site
62787818|NCT06507826|PLACEBO_COMPARATOR|Control with Timed Response|Descriptive writing.
62015765|NCT01700946|ACTIVE_COMPARATOR|Standard Risk|"Interventions: dexamethasone, vincristine sulfate, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, vinblastine, natural killer cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone~Cells for infusion are prepared using the CliniMACS System."
62204761|NCT01521936|EXPERIMENTAL|Arm I (25(OH)-D3 levels 20-31.9 ng/mL [insufficient levels])|Patients receive a loading dose of cholecalciferol PO on day 1. Patients then receive lower-dose cholecalciferol PO beginning on day 8.
62204762|NCT01521936|EXPERIMENTAL|Arm II (25(OH)-D3 levels 20-31.9 ng/mL [insufficient levels])|Patients receive a loading dose of cholecalciferol PO on day 1. Patients then receive higher-dose cholecalciferol PO beginning on day 8.
62204763|NCT03101891|EXPERIMENTAL|Serial amnioinfusions with isotonic fluid|"There are two interventional arms to the trial. Recruitment in the bilateral renal agenesis arm of the trial was stopped in July 2022 after DSMB review.~Recruitment is ongoing in the non-bilateral renal agenesis, fetal renal failure with anhydramnios arm of the trial. Patients will undergo amnioinfusions with isotonic fluid every 2-12 days.. A spinal needle will be used to perform the infusion. The latest infusions will begin is 26 weeks gestation. Standard postnatal care will occur at a RAFT center."
62215205|NCT05571345|PLACEBO_COMPARATOR|Placebo|Placebo capsules to match PF614 (2 x placebo capsules)
62404525|NCT00338377|EXPERIMENTAL|Group E: Chemotherapy + IL-2 plus T-Cells + Vaccine|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m\^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10\^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
62580675|NCT02024607|EXPERIMENTAL|ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab|BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m\^2 together with leucovorin 400 mg/m\^2 will be administered intravenously. 5-FU 400 mg/m\^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m\^2/day (total 2400 mg/m\^2 over 46-48 hours) continuous intravenous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.
62580676|NCT02024607|EXPERIMENTAL|ARM C- BBI608 in combination with CAPOX|BBI608 is administered orally twice daily, continuously. CAPOX regimen will be administered orally (capecitabine) and IV (oxaliplatin). Capecitabine 850 mg/m\^2 will be administered orally twice-daily for 14 consecutive days and be repeated every 21 days. Oxaliplatin will be administered IV and be repeated every 21 days thereafter. If capecitabine is tolerated at the 850 mg/m\^2 twice daily dose, dosage may be increased to 1000 mg/m\^2 twice daily as tolerated after the first cycle.
62580677|NCT02024607|EXPERIMENTAL|ARM D- BBI608 in combination with FOLFIRI|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m\^2 together with leucovorin 400 mg/m\^2 will be administered intravenously. 5-FU 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion. This regimen will be repeated every 14 days thereafter.
62580678|NCT02024607|EXPERIMENTAL|ARM E- BBI608 in combination with FOLFIRI and Bevacizumab|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m\^2 together with leucovorin 400 mg/m\^2 will be administered intravenously 5-FU 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.
62580679|NCT02024607|EXPERIMENTAL|ARM F- BBI608 in combination with Regorafenib|BBI608 is administered orally twice daily, continuously. Regorafenib 120 mg will be administered orally once daily, with a low-fat meal and be continued for 21 consecutive days of every 28 days thereafter. If regorafenib is tolerated in the first cycle, dosage may be increased to 160 mg once daily as tolerated after the first cycle.
62580680|NCT02024607|EXPERIMENTAL|Arm G- BBI608 in combination with Irinotecan|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m\^2 will be administered intravenously. This regimen will be repeated every 14 days thereafter.
62580681|NCT04999163|EXPERIMENTAL|Aortix Arm|Subject receives the Aortix device.
62787819|NCT06507826|ACTIVE_COMPARATOR|Mindfulness with Timed Response|Writing with mindfulness.
62787820|NCT06507826|ACTIVE_COMPARATOR|Self-Kindness with Timed Response|Writing with self-kindness.
62787821|NCT06507826|ACTIVE_COMPARATOR|Common Humanity with Timed Response|Writing with common humanity.
62787822|NCT06507826|PLACEBO_COMPARATOR|Revised Control|Descriptive writing.
62787823|NCT06507826|ACTIVE_COMPARATOR|Self-Compassion|Writing with mindfulness, self-kindness, and common humanity.
62787824|NCT06507826|ACTIVE_COMPARATOR|Self-Compassion Without Mindfulness|Writing with self-kindness and common humanity.
62787825|NCT06196606|EXPERIMENTAL|experimental group|Botulinum toxin type A for injection (Hengli National Drug approval number S10970037) 100U, diluted with 1 ml.9% sodium chloride solution for reserve use.Each patient was injected with 90U
62787826|NCT01202630|EXPERIMENTAL|Probiotic|BIO-K+ CL1285
62015766|NCT01700946|ACTIVE_COMPARATOR|High Risk|"Interventions: dexamethasone, vincristine, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, natural killer cell infusion, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis, therapeutic hydrocortisone~Cells for infusion are prepared using the CliniMACS System."
62015767|NCT05718908||Fibromyalgia patients|All patients will be administered with one sachet of food supplement (FibrofixPlus®) per day, for 8 weeks.
62015768|NCT03511482|EXPERIMENTAL|MyAsthma Application and Lloyds Pharmacy Online Doctor|Web based applications to support people with Asthma management
62015769|NCT03511482|EXPERIMENTAL|MyAsthma Application and Usual care|Web based application to support people with Asthma Management
62015770|NCT03511482|NO_INTERVENTION|Usual care only (control)|Usual care of asthma management
62015771|NCT01223079|OTHER|r-hFSH (Gonal F)|Patients will be treated with r-hFSH throughout the stimulation phase of their first cycle until r-hCG administration.
62204764|NCT03101891|NO_INTERVENTION|Expectant|Patients will be observed serially by ultrasound, fetal echocardiogram and MRI. Standard postnatal care will occur at a RAFT center.
62204765|NCT02579135|EXPERIMENTAL|Project HEART|Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
62204766|NCT02579135|OTHER|Control: Project Growing Minds|Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.
62204767|NCT01089738|EXPERIMENTAL|Dosing|Ascending Doses
62204768|NCT00329810|EXPERIMENTAL|Switch|
62204769|NCT02882425|EXPERIMENTAL|Intravenous selexipag (Pilot phase)|Subjects received a 20-minute intravenous (i.v.) infusion of 50 µg selexipag
62204770|NCT02882425|EXPERIMENTAL|Sequence A-B (Main phase)|Subjects received a 80-minute i.v. infusion of 200 µg selexipag during Period 1, and 2 tablets of oral selexipag (total dose of 400 µg) as a single administration during Period 2. A washout period of 7 to 10 days separated the i.v. infusion from the oral administration.
62404526|NCT05127109|EXPERIMENTAL|Nutrition Ecosystem pathway|"1. parenteral nutrition initiated within 72 hours of operative intervention~2. metabolic cart assessments to determine resting energy expenditure (REE) and guide registered dietitians (RDs)~3. expedited delivery of oral nutrition supplements and~4. a team-based approach on proper documentation of nutrition delivery and intake."
62404527|NCT05127109|OTHER|Comparator|300 historical matched control subjects not having received TPN in the first 7 hospital days will be enrolled from Duke Electronic Health Record between January 2018 and June 2020.
62404528|NCT05508308|ACTIVE_COMPARATOR|Manual oxygen control|Oxygen therapy delivered with bCPAP as per standard practice, except for the addition of continuous pulse oximetry. Nursing staff will make manual adjustments to Fraction of Inspired Oxygen (FiO2) provided to infants on bCPAP. Oxygen saturations (SpO2) will be monitored by continuous pulse oximetry, and nurses asked to target the range of SpO2 91-95%. Pulse oximeter alarms will be set to alert nurses to periods of hypoxaemia (SpO2\<88%) and hyperoxaemia (SpO2\>96%).
62404529|NCT05508308|EXPERIMENTAL|OxyMate Automated Oxygen Control|Automated control of oxygen therapy partnered with bCPAP delivered as per standard practice. The automated oxygen control set-up (OxyMate) will consist of: continuous pulse oximetry input, a computer algorithm (VDL1.1) that calculates changes to delivered FiO2 based on the input SpO2, and a mechanism to automatically effect changes to delivered FiO2. The system will target an SpO2 of 93% (mid-point of the target range). There will be several embedded safety mechanisms, including the ability to manually over-ride OxyMate at any stage. Pulse oximeter alarms will be as for the manual control arm, with additional automated system alarms in place.
62404530|NCT00910000|EXPERIMENTAL|Dose Level 1A|"Vorinostat: 200 mg taken orally once a day for the first two weeks of each three-week cycle~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle~Gemcitabine: 100 mg/m2, given intravenously on day 1 and day 8 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
62404531|NCT00910000|EXPERIMENTAL|Dose Level 2A|"Vorinostat: 300mg, taken orally once a day for the first two weeks of each three-week cycle~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 1 and day 8 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
62404532|NCT00910000|EXPERIMENTAL|Dose Level 1B|"Vorinostat: 200mg, taken orally twice a day for days 1-3 and days 8-10 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 1 and day 8 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
62580682|NCT04999163|NO_INTERVENTION|Non-Aortix Arm|Control Arm consists of subjects who choose not to receive the Aortix device or who do not meet the anatomical requirements to receive the Aortix device.
62580683|NCT00814333|EXPERIMENTAL|1|Thrombin-JMI
62015772|NCT01223079|OTHER|r-hFSH (Gonal F) and r-hLH (Luveris)|Patients will be treated with r-hFSH only until they have 2 follicles greater than or equal to 14mm. Patients will then bring 300IU/day of r-hLH until r-hCG administration.
62580684|NCT00814333|ACTIVE_COMPARATOR|2|Merocel pack
62580685|NCT06577220|ACTIVE_COMPARATOR|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator on behalf of Harris Health System
62787827|NCT01202630|PLACEBO_COMPARATOR|Placebo|Placebo
62015773|NCT05947539|EXPERIMENTAL|Kisoboka Mukwano Intervention (treatment)|A brief couples-based intervention using motivational interviewing, peer navigation, and behavioral economic approaches to target intimate partner violence, alcohol use, and HIV care engagement.
62015774|NCT05947539|ACTIVE_COMPARATOR|Screening & Referral (control)|Brief feedback on intimate partner violence and alcohol use (males), referrals for these conditions, and briefly discuss the importance of HIV care engagement and adherence.
62015775|NCT04334603|EXPERIMENTAL|Home-based exercise training|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at home
62015776|NCT04334603|ACTIVE_COMPARATOR|Clinical-based exercise training|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital
62015777|NCT06464055|EXPERIMENTAL|Dose Escalation|"GQ1010 will be administered intravenously every 21 days. Dose Escalation will be guided by Bayesian Optimal Interval (BOIN) Design.~Multiple dose grouping"
62015778|NCT06464055|EXPERIMENTAL|Dose Expansion1|"GQ1010 at the recommended doses for Expansion (RDEs) will be administered intravenously every 21 days.~Dose expansion will further evaluate the safety and tolerability in advanced malignant solid tumor subjects."
62015779|NCT06464055|EXPERIMENTAL|Dose Expansion2|"GQ1010 at the recommended doses for Expansion (RDEs) will be administered intravenously every 21 days.~Dose expansion will further evaluate the safety and tolerability"
62015780|NCT06464055|EXPERIMENTAL|phase II|"GQ1010 at the recommended phase II dose (RP2D) will be administered intravenously every 21 days.~Dose expansion will evaluate preliminary efficacy in different types of malignant solid tumor in five cohorts."
62204771|NCT02882425|EXPERIMENTAL|Sequence B-A (Main phase)|Subjects received 2 tablets of oral selexipag (total dose of 400 µg) as a single administration during Period 1, and a 80-minute i.v. infusion of 200 µg selexipag during Period 2. A washout period of 7 to 10 days separated the oral administration from the i.v. infusion.
62204772|NCT02682342||Healthy Subjects|Healthy subjects meeting inclusion criteria will be administered a 75 g glucose solution one time (orally). Subjects will be ages 21-70 years with no evidence of diabetes, hypertension, metabolic syndrome, or high cholesterol at the time of screening. Potential subjects with a history of atherosclerotic disease, chronic renal insufficiency (plasma creatinine \> 1.5 men, \> 1.5 women), liver enzymes \> 2.5x normal, pregnant at the time of screening will be excluded
62204773|NCT04423523||Study population|The study population must correspond to the research inclusion criteria: Patient admitted to pediatric intensive care at Nantes University Hospital after cardiac surgery on bypass grafts
62404533|NCT00910000|EXPERIMENTAL|Dose Level 1C|"Vorinostat: 200mg, taken orally twice a day for days 1, 2, 8 and 9 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
62204774|NCT02130323|ACTIVE_COMPARATOR|Loop Electrosurgical Excision Procedure|Excision of the cervical transformation zone by way of the loop electrosurgical excision procedure (LEEP) or cold knife conization (CKC).
62204775|NCT02130323|EXPERIMENTAL|Imiquimod|Imiquimod 12.5mg intravaginally once weekly for 16 weeks
62204776|NCT02729883|EXPERIMENTAL|Supportive care (Take the Fight)|Patients receive patient navigation via strategists from the Take the Fight for 8 weeks. Patients also complete interviews regarding perceived physical, logistical, psychosocial, and informational challenges experienced prior to meeting with strategists/navigators and how challenges were addressed by navigator or others, perceived benefits or limitations of navigator assistance. Strategists also complete interviews regarding their perceptions on how patients benefited from participation, challenges patients experienced that were directly or indirectly related to their cancer diagnosis and treatment, how these concerns were addressed, barriers to addressing these concerns, and patient health literacy.
62204777|NCT00526253|ACTIVE_COMPARATOR|Low Dose|Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.
62204778|NCT00526253|ACTIVE_COMPARATOR|High Dose|Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.
62204779|NCT00526253|PLACEBO_COMPARATOR|Control|Patient will undergo biopsy of muscle tissue and biopsy tissue will be sent to lab.
62204780|NCT04651140|ACTIVE_COMPARATOR|Tremor group|Participants in the tremor group have tremor as the main clinical manifestation
62204781|NCT04651140|ACTIVE_COMPARATOR|Stiff group|Participants in the tremor group have stiff as the main clinical manifestation
62204782|NCT06270043||Focal Therapy|Subjects who have biopsy-proven adenocarcinoma of the prostate, who have met all study inclusion and exclusion criteria, and have elected to receive or have already received focal therapy as part of their routine prostate cancer treatment, will be invited to participate in this observational registry study.
62204783|NCT01242579|ACTIVE_COMPARATOR|Maraviroc Vaginal Gel|Drug: Maraviroc dosage form: vaginal gel dosage: 2.5g frequency: once daily duration: 11 days
62204784|NCT01242579|ACTIVE_COMPARATOR|Dapivirine Vaginal Gel|Drug: Dapivirine dosage form: vaginal gel dosage: 2.5g dapivirine frequency: once daily duration: 11 days
62580686|NCT06577220|EXPERIMENTAL|Mailed HPV Self-Sampling Kit|Participants receive a scripted telephone recall from a patient navigator on behalf of Harris Health System and receive a mailed HPV self-sampling kit with a prepaid return envelope
62580687|NCT06577220|EXPERIMENTAL|Mailed HPV Self-Sampling Kit + Patient Navigation|Participants receive a scripted telephone recall and mailed self-sampling kit with a pre-paid return envelope. Within 3-5 days of the kit's mail-out, participants will receive a telephone call from a patient navigator to provide one-on-one education.
62580688|NCT03195725||Year 2013|Participant's notes will be reviewed from the year 2013
62204785|NCT01242579|PLACEBO_COMPARATOR|Matching Placebo Gel|Drug: placebo dosage form: vaginal gel dosage: 2.5g placebo frequency: once daily duration: 11 days
62204786|NCT01242579|EXPERIMENTAL|Maraviroc/Dapivirine Gel|Drug: Maraviroc/Dapivirine dosage form: combination vaginal gel dosage: 2.5g - Maraviroc 0.1%, Dapivirine 0.05% frequency: once daily duration: 11 days
62204787|NCT00357110|ACTIVE_COMPARATOR|1|Anastrozole monotherapy
62204788|NCT00357110|EXPERIMENTAL|2|Anastrozole + Fulvestrant
62204789|NCT04996446|EXPERIMENTAL|Alpps plus Tislelizumab group|Patients who meet the inclusion criteria will receive ALPPS stage I surgery, treated with Tislelizumab 2-4 weeks after stage I surgery, and receive ALPPS stage II surgery 2-4 weeks after Tislelizumab treatment, and treated with Tislelizumab q3W 6-12 months after stage II surgery.
62204790|NCT04996446|ACTIVE_COMPARATOR|Alpps group|Patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 3-6 weeks after stage I surgery.
62580689|NCT03195725||Year 2015|Participant's notes will be reviewed from the year 2015
62580690|NCT05076721|EXPERIMENTAL|Simulation group|The simulation training group will receive a simulation training of a sepsis case which will see the participants implementing one-hour bundle sepsis with a high-fidelity manikin.
62580691|NCT05076721|EXPERIMENTAL|Conventional group|The conventional training group will receive a case-based discussion of a sepsis case which will see the participants implementing one-hour bundle sepsis.
62580692|NCT06028685|ACTIVE_COMPARATOR|experimental group|The experimental group will receive low-level laser stimulation on seven acupoints. The stimulation will be administered three times per week for a duration of six weeks.
62580693|NCT06028685|PLACEBO_COMPARATOR|control group|The control group will receive sham low-level laser stimulation on the acupoints, without emitting laser beams.
62580694|NCT02056041||Hepatectomy for HCC|Patients submitted to surgery for HCC
62204791|NCT04472416|NO_INTERVENTION|Standardized analgesic protocol alone|Abdominal VAC dressing change using an standardized analgesic protocol alone.
62204792|NCT04472416|EXPERIMENTAL|VRD + standardized analgesic protocol|Abdominal VAC dressing change using standardized analgesic protocol + virtual reality device
62204793|NCT00701649|EXPERIMENTAL|1|
62734863|NCT03901625|ACTIVE_COMPARATOR|ManualTB+Floss|Cleaning teeth with a manual toothbrush and a dental floss three times a day.
62404534|NCT00910000|EXPERIMENTAL|Dose Level 1D|"Vorinostat: 300mg, taken orally once a day for days 1 and 2 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
62404535|NCT00910000|EXPERIMENTAL|Dose Level 2D|"Vorinostat: 400mg, taken orally once a day for days 1 and 2 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
62404536|NCT04885842|EXPERIMENTAL|Study Group|injection I-PRF with brackets
62404537|NCT04885842|NO_INTERVENTION|Control Group|applying brackets only
62404538|NCT05557201||Miscarriage|Patients with at least 3 recurrent early miscarriages (before 14 weeks of gestation)
62404539|NCT01317199|EXPERIMENTAL|Phase 1: Dose-escalation of Muscadine Plus Grape Skin Extract|Muscadine Plus Grape Skin Extract (MPX): Phase I Dose-escalation starts at 500mg daily for 1 cycle (28 days), then increased to 1000mg for 2nd cycle, then increased to 2000mg daily for 3rd cycle, then increased to 3000mg daily for 4th cycle, then increased to maximum dose of 4000mg daily for final cycle. Pills given by mouth once daily for 28 days per cycle.
62404540|NCT01317199|PLACEBO_COMPARATOR|Phase 2: Placebo control|Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
62404541|NCT01317199|EXPERIMENTAL|Phase 2: Low-dose MPX|Randomly-assigned participants receive low-dose (500mg) MPX
62404542|NCT01317199|EXPERIMENTAL|Phase 2: High-dose MPX|Randomly-assigned participants receive high-dose (4000mg) MPX
62404543|NCT02763410||control group|Patients who received between 1 and 5 PRBCs between incision and the 6th hour post-surgery, with no renal failure at the 48th hour after surgery, based on the RIFLE classification, and regardless of the transfusion received after the H6 assessment.
62404544|NCT02763410||Renal failure group|Patients who received between 1 and 5 PRBCs between incision and the 6th hour post-surgery and who developed renal failure before H48 with no new transfusion prior to diagnosis of kidney failure.
62404545|NCT05493059||Patients|"* Mucocutaneous Leishmaniasis proven by culture and/or polymerase chain reaction (PCR)~* Seen in French Guiana between 01/01/2017 and 01/04/2022, in dispensaries (CDPS) or in the Dermatology Department of the CHC~* Having received treatment with Miltefosine~* Patient who consented to participate in the study~* Age equal or superior to 18 years"
62404546|NCT01133366|ACTIVE_COMPARATOR|warfarin alone|
62404547|NCT01133366|EXPERIMENTAL|warfarin with mipomersen|
62404548|NCT02926352|EXPERIMENTAL|Extinction Training with LLLT|Participants will receive one-session of fear extinction training tailored to the participant's specific fear domain. 15 minutes after fear extinction, participants will receive 8 minutes of Low-Level Laser Therapy stimulation. The laser will be directed at two areas on the forehead: bilateral frontal points Fp1 and Fp2 (on the EEG electrode placement system; to stimulate the vmPFC). Each area will be stimulated for 4 minutes. Treatment will consist of alternating between each of these points after each minute.
62404549|NCT02926352|ACTIVE_COMPARATOR|Extinction Training with Sham LLLT|Participants will receive one-session of fear extinction training tailored to the participant's specific fear. 15 minutes after fear extinction, participants will receive 8 minutes of Sham Low-Level Laser Therapy stimulation. The laser will be directed at two areas on the forehead: bilateral frontal points Fp1 and Fp2 (on the EEG electrode placement system). The procedure will consist of alternating between each of these points after each minute. However, each point will receive only a brief (5-second) treatment to the intended site on the forehead, followed by 55 seconds of no treatment, for each one-minute cycle, functioning as a placebo dose of the treatment.
62404550|NCT02926352|EXPERIMENTAL|LLLT alone|Participants will receive 8 minutes of Low-Level Laser Therapy stimulation. The laser will be targeted first at the left forehead point F3 and then at the right forehead point F4 (on the EEG electrode placement system). F3 corresponds with the left dorsolateral prefrontal cortex and F4 corresponds with the right dorsolateral prefrontal cortex. Each area will be stimulated for 4 minutes. Treatment will consist of alternating between each of these points after each minute.
62404551|NCT02926352|SHAM_COMPARATOR|Sham LLLT alone|Participants will receive 8 minutes of Sham Low-Level Laser Therapy stimulation. The laser will be targeted first at the left forehead point F3 and then at the right forehead point F4 (on the EEG electrode placement system). The procedure will consist of alternating between each of these points after each minute. However, each point will receive only a brief (5-second) treatment to the intended site on the forehead, followed by 55 seconds of no treatment, for each one-minute cycle, functioning as a placebo dose of the treatment.
62404552|NCT05460195|EXPERIMENTAL|Combination therapy group|Sintilimab combined with anlotinib
62404553|NCT05460195|EXPERIMENTAL|Single-agent therapy group|Sintilimab monotherapy
62404554|NCT04343508|EXPERIMENTAL|Fortified rice|fortified rice for daily lunch and dinner each day of the week (i.e. 14 meals/week) for six months
62580695|NCT05007743|ACTIVE_COMPARATOR|Stimulation of inner tragus|Comparing autonomic hemodynamic functions and immune responses pre- and post-stimulation of the vagus nerve
62580696|NCT05007743|SHAM_COMPARATOR|Stimulation of ear lobe|Comparing autonomic hemodynamic functions and immune responses pre- and post-stimulation of the vagus nerve
62580697|NCT03658512||TUEDID cohort|
62204794|NCT00701649|PLACEBO_COMPARATOR|2|
62580698|NCT01667510|EXPERIMENTAL|Cardio Mato|Soft gel capsule for oral use (Grade A Lyc-O-Mato, a tomato extracted lycopene)
62204795|NCT04940975|EXPERIMENTAL|Occupation-based sleep intervention program|A program composed of four occupation-based interactive workshops on sleep, insomnia, lifestyle, and change strategies, plus two individual coaching sessions on lifestyle and sleep hygiene.
62204796|NCT04940975|ACTIVE_COMPARATOR|Insomnia educational program (Treatment as Usual Group)|A program composed of four educational talks on sleep hygiene and relaxation training, plus two individual sessions for the reviewing of sleep patterns.
62204797|NCT02104778|EXPERIMENTAL|Dexamethasone|Dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
62580699|NCT01667510|PLACEBO_COMPARATOR|Placebo|Soft gel capsule without test material, for oral use
62404555|NCT05283109|EXPERIMENTAL|Tumor Associated Antigen Peptide Vaccine in Combination with Hiltonol|The study vaccine is comprised of three different peptides (small proteins) mixed with Hiltonol®. The three peptides that make up the study vaccine are called pp65, EphA2, and survivin.
62204798|NCT02104778|PLACEBO_COMPARATOR|Control|Normal saline 1 ml is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
62204799|NCT02104778|EXPERIMENTAL|epinephrine|Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
62204800|NCT05648929|ACTIVE_COMPARATOR|the conventional expander Mentor CPX4 (MENTOR)|"intraindividual comparison of two differentially rough tissue expanders~Arm description: women undergoing prophylactic bilateral NSME and simultaneous tissue-expander based reconstruction with conventionally textured expander with surface roughness 60µM Ra"
62204801|NCT05648929|ACTIVE_COMPARATOR|the expander SmoothSilk(Motiva) with reduced surface roughness|"intraindividual comparison of two differentially rough tissue expanders~Arm description: women undergoing prophylactic bilateral NSME and simultaneous tissue-expander based reconstruction with reduced textured expander with surface roughness 4µM Ra"
62404556|NCT06116357|OTHER|Health volunteers|Evaluate the CB activity of health volunteers as the control
62404557|NCT01767649||Caesarean|Normal pregnant women at term without complication during pregnancy and without inflammatory disorders
62580700|NCT06644118|EXPERIMENTAL|OL-101 infusion|This arm provides CAR-T treatment at the dose the patient is assigned to.
62580701|NCT01669330|ACTIVE_COMPARATOR|Total fundoplication|Procedure: Laparoscopic Nissen fundoplication
62580702|NCT01669330|ACTIVE_COMPARATOR|Anterior partial fundoplication|Procedure: Laparoscopic anterior partial fundoplication
62204802|NCT06236139|EXPERIMENTAL|Treatment (STEAP1 CART, enzalutamide)|Patients undergo leukapheresis then receive cyclophosphamide IV and fludarabine IV on days -5, -4 and -3 and STEAP1 CART IV on day 0. Patients may receive enzalutamide PO on day 0 then QD in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy at baseline, day 14 and optionally at progression. Patients additionally undergo blood sample collection, NM bone scan and CT scan, or MRI or PET scan throughout study. Additionally, patients may undergo ECHO or MUGA at screening.
62204803|NCT04454931||Intensive care patients who underwent neurosurgery|Cerebral oxygenation status will be monitored during and after endotracheal suctioning in each patient included in the study. Non-invasive regional oximetry probes are placed in the frontal region of the patient and the patient will be positioned at the head height of 15 degrees with a 3-motor angle determining bearing system. Then, when the patient's need for endotracheal suctioning arises, endotracheal suctioning will be performed and the cerebral oxygenation status before the procedure, 1 minute, 5 minutes and 30 minutes after the procedure will be recorded on the monitor of the non-invasive regional oximeter device operating with NIRS technology. The same procedure will be applied to the patient at head heights of 30 and 45 degrees. Cerebral oxygenation status measured at each head height will be compared with appropriate statistical methods and the most appropriate head height will be determined.
62404558|NCT01767649||Vaginal Delivery|Normal pregnant women at term without complication during pregnancy and without inflammatory disorders
62404559|NCT05915507|EXPERIMENTAL|pranayama and acupoint stimulation by laser|the 30-geriatric group will receive 3-session per-week laser stimulation for 8 weeks to some selected acupoints and daily pranyama exercises (nearly every session will be one hour, for 8 weeks), the stimulated points will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
62404560|NCT05915507|ACTIVE_COMPARATOR|acupoint stimulation by laser|the 30-geriatric group will receive 3-session per-week laser stimulation for 8 weeks to some selected acupoints (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
62404561|NCT05946629|EXPERIMENTAL|SELUTION SLR 014 PTCA DEB|"SELUTION Sustained Limus Release (SLR) 014 Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon (DEB)~The SELUTION SLR 014 PTCA DEB is a minimally invasive, single use and sterile Sirolimus coated PTCA balloon catheter.~The SELUTION SLR 014 PTCA DEB is available with balloon diameters from 2.0 to 3.0 mm and lengths of 15 to 40 mm for the purpose of the De Novo IDE trial"
62580703|NCT02076724|EXPERIMENTAL|Biological mesh (Strattice Firm)|Strattice Firm is inserted using inlay technique as reinforcement of the abdominal wall where the anterior rectus fascia has been excised.
62404562|NCT05946629|ACTIVE_COMPARATOR|Control Treatment|"any FDA approved limus-based Drug Eluting Stent, as per standard institutional practice"
62580704|NCT02076724|EXPERIMENTAL|Synthetic mesh (Prolene)|Prolene mesh is inserted using inlay technique as reinforcement of the abdominal wall where the anterior rectus fascia has been excised.
62204804|NCT04694170|EXPERIMENTAL|Experimental group|Patients with musculoskeletal pain in the lumbar region. Patients with typical symptoms of functional dysfunction of kidney undergo conventional physiotherapy and an alternative approach by yoga set exercising and regimen restriction according to traditional Chinese medicine.
62204805|NCT04694170|ACTIVE_COMPARATOR|control group|Patients with musculoskeletal pain in the lumbar region. Patients with kidney dysfunction symptoms treated by conventional physiotherapy only.
62204806|NCT05410080||good perinatal outcome|Fasting blood sugar 2 hours postprandial HBA1C Ultrasound and Doppler
62204807|NCT05410080||poor perinatal outcome|Fasting blood sugar 2 hours postprandial HBA1C Ultrasound and Doppler
62204808|NCT02274805||Adults presenting for surgery in the neck area|
62204809|NCT01666587|NO_INTERVENTION|control|Control trial to determine the impact of the ischemic injury on vascular function without intervention
62204810|NCT01666587|EXPERIMENTAL|Antioxidant load|Trial to determine the impact of an antioxidant load before the ischemic injury on vascular function recovery
62204811|NCT01666587|EXPERIMENTAL|Prostaglandin inhibition|Trial to determine the impact of a non-selective prostaglandin inhibitor before the ischemic injury on vascular function recovery
62204812|NCT01666587|EXPERIMENTAL|Combined|Trial to determine the impact of an antioxidant load and prostaglandin inhibitor before the ischemic injury on vascular function recovery
62204813|NCT00647933|EXPERIMENTAL|Org 36286 15 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 15 μg.
62204814|NCT00647933|EXPERIMENTAL|Org 36286 30 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 30 μg.
62204815|NCT00647933|EXPERIMENTAL|Org 36286 60 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 60 μg.
62204816|NCT00647933|EXPERIMENTAL|Org 36286 120 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 120 μg.
62204817|NCT02649738|EXPERIMENTAL|Corneal tissue inlay|The treated cornea will be implanted with a thin disc of preserved corneal tissue
62580705|NCT04577027|EXPERIMENTAL|vitiligo patients|Thirty Patients complaining of generalized non segmental vitiligo will be recruited in this study. They will be chosen from the attendants of the out-patient clinics of Dermatology, Assiut university hospital. six patches will be selected in each patient.
62580706|NCT03955913||Participants with Urothelial Cancer,selected FGFR aberrations|Participants with urothelial cancer (UC) will be evaluated for the prevalence of positive results of selected fibroblast growth factor receptor (FGFR) aberrations and will be assessed for eligibility status for erdafitinib studies. The primary data source for this study will be the medical records of each participant.
62204818|NCT06387628|EXPERIMENTAL|LM-108, toripalimab and eribulin|
62204819|NCT06387628|EXPERIMENTAL|LM-108, toripalimab and nab-paclitaxel|
62204820|NCT02360527||Type 2 diabetic patients with AD|35 patients
62204821|NCT02360527||Type 2 diabetic patients with MCI|35 patients
62204822|NCT02360527||Type 2 diabetic patients controls|35 patients
62204823|NCT02360527||Non-diabetic patients with AD|35 patients
62204824|NCT05135676|ACTIVE_COMPARATOR|Standard Target Group|Standard therapy with glucose target 140-180 mg/dL (ADA guidelines) and masked CGM
62204825|NCT05135676|EXPERIMENTAL|Intensive Target Group|Intensive therapy with glucose target 90-130 mg/dL with real-time CGM
62204826|NCT06179888|ACTIVE_COMPARATOR|Group 1 (monitoring)|Patients undergo disease monitoring at monthly clinic visits until disease progression. Patients also undergo bone marrow aspiration and biopsy throughout the trial, undergo collection of blood samples at screening and on study, and undergo PET/CT and/or skeletal survey x-ray, CT, or MRI at screening and then as clinically indicated.
62204827|NCT06179888|EXPERIMENTAL|Group II (iberdomide)|Patients receive iberdomide PO QD on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy throughout the trial, undergo collection of blood samples at screening and on study, and undergo PET/CT and/or skeletal survey x-ray, CT, or MRI at screening and then as clinically indicated.
62204828|NCT04237532|EXPERIMENTAL|Intranasal Dexmedetomidine|
62204829|NCT04237532|EXPERIMENTAL|Sublingual Dexmedetomidine|
62734864|NCT03901625|EXPERIMENTAL|ManualTB+Waterjet|Cleaning teeth with a manual toothbrush and a waterjet three times a day.
62734865|NCT03901625|EXPERIMENTAL|Electric TB+Floss|Cleaning teeth with an electric toothbrush and dental floss three times a day .
62204830|NCT01641159|ACTIVE_COMPARATOR|Buspirone plus TAU|Buspirone titrated to 60 mg/day for the 15-week active study
62204831|NCT01641159|PLACEBO_COMPARATOR|Placebo plus TAU|Placebo taken daily for the 15-week active study
62204832|NCT04551521|EXPERIMENTAL|BRAF V600E/K|
62204833|NCT04551521|EXPERIMENTAL|ERBB2|
62204834|NCT04551521|EXPERIMENTAL|ALK|
62204835|NCT04551521|EXPERIMENTAL|AKT/PTEN|Recruitment stopped
62204836|NCT04551521|EXPERIMENTAL|PI3K|Recruitment stopped
62204837|NCT04551521|EXPERIMENTAL|MAPK|
62204838|NCT04551521|EXPERIMENTAL|Immune evasion|
62204839|NCT01567631|EXPERIMENTAL|intrahepatic Glisson's approach|
62204840|NCT01567631|ACTIVE_COMPARATOR|classical hepatectomy|
62204841|NCT04037657|EXPERIMENTAL|HSK3486|0.288 mg/kg ，0.432 mg/kg ，0.540 mg/kg ，0.648 mg/kg，0.810 mg/kg There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).
62204842|NCT04037657|ACTIVE_COMPARATOR|Propofol|2.5 mg propofol
62204843|NCT05401006|ACTIVE_COMPARATOR|Acitretin|Patients will Receive Acitretin (0.25-1 mg /kg/day )for 3months .
62204844|NCT05401006|ACTIVE_COMPARATOR|Narrowband ultraviolet B|Patients will receive Narrowband UVB( 3session /week ) for 3months.
62204845|NCT05401006|ACTIVE_COMPARATOR|Combination of Narrowband ultraviolet B and Acitretin|Patients will receive Acitretin (0.25-1 mg /kg/day ) and Narrowband UVB( 3session /week ) for 3 months.
62204846|NCT04293003|EXPERIMENTAL|Fasting|6-hour morning fasting
62204847|NCT04293003|EXPERIMENTAL|Low carbohydrate|Consumption of a zero-carbohydrate breakfast
62204848|NCT04293003|EXPERIMENTAL|Mediterranean|Consumption of a Mediterranean breakfast
62204849|NCT05437640|ACTIVE_COMPARATOR|Protein Redistribution Diet|PD participants may first be randomized to follow the Protein Redistribution Diet followed by the Protein Consistent Diet.
62204850|NCT05437640|ACTIVE_COMPARATOR|Protein Consistent Diet|PD participants may first be randomized to follow the Protein Consistent Diet followed by the Protein Redistribution Diet.
62204851|NCT01162577|EXPERIMENTAL|Intervetion|The intervention group received the 5 standard tobacco calls plus 3 weight calls with a weight coach to address weight concerns related to quitting smoking
62204852|NCT01162577|NO_INTERVENTION|Control|Participants in this arm received only the 5 standard tobacco calls
62204853|NCT03335436|EXPERIMENTAL|Gabapentin|Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery
62734866|NCT03901625|EXPERIMENTAL|Electric TB +Waterjet|Cleaning teeth with an electric toothbrush and a waterjet three times a day .
62787828|NCT05777395|EXPERIMENTAL|Maitland + Conventional PT Group|"Participants of this group will receive the conventional physical therapy protocol mentioned above. In addition to this, they will receive Maitland oscillatory mobilizations. 3 sets of 15 repetitions. Each set is of 30 seconds and each repetition is given in 2 seconds.~* Frequency: 3 times a week for 2 weeks. 6 sessions in total.~* Mobilizations will be performed in Grade 1 initially and then progressed to Grade 2 and 3.~* Techniques used are postero-anterior unilateral vertebral pressure and Maitland rotation."
62787829|NCT05777395|EXPERIMENTAL|Kaltenborn + Conventional PT Group|"Participants of this Group will receive the conventional physical therapy protocol mentioned above. In addition to this, they will receive Kaltenborn sustained stretch mobilizations. 3 sets of 15 repetitions for 3 seconds.~* Frequency: 3 times a week for 2 weeks. 6 sessions in total.~* Mobilizations will be performed in Grade 1 and then progressed to 2 and 3.~* Kaltenborn technique used will be atlas-axis rotation."
62204854|NCT03335436|PLACEBO_COMPARATOR|Placebo|Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery
62204855|NCT03921099|NO_INTERVENTION|Vancomycin only|Vancomycin 15-20mg/kg intravenous every 8-12 hours.
62204856|NCT03921099|EXPERIMENTAL|Vancomycin +Ascorbic acid|Vancomycin 15-20mg/kg intravenous every 8-12 hours. Ascorbic acid 1gm every 12 hours orally just before vancomycin by half an hour for seven days.
62204857|NCT05330676||No shock|Patients who have no evidence of clinical malperfusion or require vasoactive agents after cardiac surgery.
62204858|NCT05330676||Shock|Patients who have evidence of clinical malperfusion or require vasoactive agents after cardiac surgery.
62204859|NCT03193775|ACTIVE_COMPARATOR|chronic HBV with persistent HBsAg|"inactive carriers (n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 6 months after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or DNA disappearance in HBeAg negative patients (n=60). All showed persistent HBs antigenemia.~they were given 30 µg of HBV vaccine initiated 6 months after HBe seroconversion and disappearance of HBV DNA."
62204860|NCT03193775|NO_INTERVENTION|control group|A control group (n=100) did not receive HBV vaccine
62204861|NCT05059678|EXPERIMENTAL|Group I (education material, videoconference session)|Participants receive education materials (brochure and a video) and attend 2 weekly videoconference intervention sessions over 45 minutes each. Caregivers attend 2 additional weekly intervention sessions over 45 minutes each.
62204862|NCT05059678|ACTIVE_COMPARATOR|Group II (waitlist control)|Participants receive standard of care.
62204863|NCT02700854|EXPERIMENTAL|5% carbon-dioxide inhalation|5% carbon-dioxide will be administered through patient circuits to asphyxiated, cooled, mechanically ventilated newborns at risk for hypocapnia
62204864|NCT04995770|EXPERIMENTAL|Praise Text Messages|"The text message praise intervention lasted for 6 months. Each week, transplant coordinators, masked from who enrolled in the study or to which condition participants were randomized, prepared a list of all patients in the study age group whose laboratory blood tests indicated that immunosuppressant medications were within the expected range. A researcher reviewed the list to identify whether any of patients were currently assigned to the intervention, and if so, sent text message praise via REDCap's text message function. We rotated through 14 standardized text messages each week. Examples of messages included: Your labs look very good. Super job taking your meds! and Your labs look great! Thanks for putting in the effort to take care of your health!."
62204865|NCT04995770|NO_INTERVENTION|Usual Care|Participants in the usual care arm did not receive any praise text messages. All participants continued to receive usual care from the multidisciplinary liver transplant team, including phone calls and follow-up care when laboratory blood tests indicated that immunosuppressant medications were outside of the expected range.
62404563|NCT02543918|EXPERIMENTAL|Ixekizumab + Boostrix® + Pneumovax®23|"Ixekizumab administered once by subcutaneous injection (SQ) at week 0 and once at week 2.~Boostrix® and Pneumovax®23 administered once by intramuscular (IM) injection into opposing arms at week 2."
62015781|NCT03614026|EXPERIMENTAL|Teachers and Parents as Partners Intervention|Teachers and Parents as Partners will occur in a series of stages comprised of approximately four structured meetings over approximately 8 weeks. A Teachers and Parents as Partners consultant will meet together with a student's parent(s), teachers, other school personnel (as appropriate), and the student (as appropriate). The Teachers and Parents as Partners team will collaboratively address behavior problem solving objectives. Specific objectives include: identifying strengths and specific behaviors of concern, specifying alternative prosocial behaviors, creating measurable behavior goals, co-constructing behavior intervention/support plans to address the target concerns, creating sustainable conditions to support plan implementation at home and school, and evaluating the plan to assess progress toward goals.
62015782|NCT03614026|NO_INTERVENTION|Business as usual control|In the business-as-usual control condition, participants will have access to any services that a school would routinely provide (e.g., develop and implement a behavior support plan) as well as services families can access in the community (e.g., mental health support).
62015783|NCT05144191|OTHER|Insignia uncemented Hip Stem|"The Insignia™ Hip Stem is a collared stem that features a plasma-sprayed Hydroxyapatite (HA) coating over plasma-sprayed titanium in the proximal region and a plasma-sprayed HA coating over grit blast in the distal region and collar underside.~Insignia™ Hip Stems are intended for 'cement less' use only and are intended for total arthroplasty procedures."
62015784|NCT04561362|EXPERIMENTAL|Part A-1 -BT8009 Monotherapy Dose Escalation|Participants will receive escalating doses of BT8009 via IV.
62015785|NCT04561362|EXPERIMENTAL|Part A-2 -BT8009 in Combination with Pembrolizumab Dose De-Escalation|Participants will receive BT8009 and a standard dose of pembrolizumab.
62015786|NCT04561362|EXPERIMENTAL|Cohort B-1 - BT8009 Monotherapy Dose Expansion|Participants will receive a selected dose of BT8009.
62015787|NCT04561362|EXPERIMENTAL|Cohort B-2- BT8009 Monotherapy Dose Expansion|Participants will receive a selected dose of BT8009.
62015788|NCT04561362|EXPERIMENTAL|Cohort B-3- BT8009 Monotherapy Dose Expansion|Participants will receive a selected dose of BT8009. .
62015789|NCT04561362|EXPERIMENTAL|Cohort B-4- BT8009 Monotherapy Dose Expansion|Participants will receive a selected dose of BT8009.
62015790|NCT04561362|EXPERIMENTAL|Cohort B-5- BT8009 Monotherapy Dose Expansion|Participants will receive a selected dose of BT8009.
62787830|NCT01456065|OTHER|Vaccine weekly administration|
62787831|NCT01456065|OTHER|Vaccine biweekly administration|
62015791|NCT04561362|EXPERIMENTAL|Cohort B-6- BT8009 Monotherapy Dose Expansion|Participants will receive a selected dose of BT8009.
62015792|NCT04561362|EXPERIMENTAL|Cohort B-7- BT8009 in Combination with Pembrolizumab Dose Expansion|Participants will receive a selected dose of BT8009 and standard dose of pembrolizumab.
62015793|NCT04561362|EXPERIMENTAL|Part C - Renal Insufficiency BT8009 Monotherapy Dose Expansion|Participants will receive a selected dose of BT8009.
62015794|NCT04561362|EXPERIMENTAL|Part D - BT8009 Monotherapy Supplementary PK|Participants will receive a selected dose of BT8009.
62015795|NCT04561362|EXPERIMENTAL|Part B-8 - BT8009 Monotherapy Dose Expansion|Participants will receive a selected dose of BT8009.
62015796|NCT04561362|EXPERIMENTAL|Part B-9 - BT8009 Monotherapy Dose Expansion|Participants will receive a selected dose of BT8009.
62015797|NCT01163682|EXPERIMENTAL|Electro-acupuncture|Subjects will receive 45 minute sessions scheduled once a week for 12 weeks with electro-acupuncture.
62015798|NCT01163682|SHAM_COMPARATOR|Sham acupuncture|Subjects will receive 45 minute sessions scheduled once a week for 12 weeks with sham acupuncture.
62015799|NCT00969852|EXPERIMENTAL|Sertraline|Single Arm
62015800|NCT01124890|PLACEBO_COMPARATOR|Conservative|no transfer for early percutaneous coronary intervention after thrombolysis
62015801|NCT01124890|ACTIVE_COMPARATOR|early PCI|transfer for early percutaneous coronary intervention after thrombolysis
62015802|NCT01431508|EXPERIMENTAL|Losartan 50 mg / HCTZ 12.5 mg|Participants with mild to moderate essential hypertension who will receive Losartan 50 mg / HCTZ 12.5 mg once-a-day for 12 weeks.
62015803|NCT05063734|EXPERIMENTAL|Part A, THR-687 1.2 mg|
62015804|NCT05063734|EXPERIMENTAL|Part A, THR-687 2.0mg|
62015805|NCT05063734|EXPERIMENTAL|Part B, treatment naïve subjects, THR-687 selected dose level|Due to the discontinuation of the study after Part A, the dose level for Part B has not been selected
62015806|NCT05063734|ACTIVE_COMPARATOR|Part B, treatment naïve subjects, aflibercept 2.0mg|
62404564|NCT02543918|OTHER|Boostrix® + Pneumovax®23|Boostrix® and Pneumovax®23 administered once by IM injection into opposing arms at week 2.
62404565|NCT00792597||spine or hip surgery|
62404566|NCT00934518|EXPERIMENTAL|Radiation and Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
62204866|NCT04821557|EXPERIMENTAL|Microbial Protease Supplement|A microbial protease supplement (31,875 Hemoglobin Unit Tyrosine base (HUT); protease activity) is taken with a 25g pea protein beverage. The test article will be provided in 250mg capsule form. Capsules will be opened and mixed into protein shake 5 minutes before ingestion.
62204867|NCT04821557|PLACEBO_COMPARATOR|Placebo (Maltodextrin)|The placebo (maltodextrin) article will be provided in 250mg capsule form. Capsules will be opened and mixed into 25g pea protein shake 5 minutes before ingestion.
62204868|NCT00789360|EXPERIMENTAL|Inhaled Placebo crossed over to Inhaled Loxapine|Inhaled Staccato Placebo, 2 inhalations, 8 hours apart; washout of at least 4 days; Inhaled Staccato Loxapine, 10 mg oses x 2, 8 hours apart
62204869|NCT00789360|EXPERIMENTAL|Inhaled Loxapine crossed over to Inhaled Placebo|Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart; washout of at least 4 days; Inhaled Staccato Placebo, 2 inhalations, 8 hours apart;
62204870|NCT04860362|EXPERIMENTAL|Treatment|PEERS weekly sessions - parallel teens and parent/caregiver groups
62204871|NCT04860362|OTHER|Wait List Control|Offered intervention at a later date
62204872|NCT06349356|EXPERIMENTAL|Intense Pulsed Light treated arm|The treatment consists in Intense Pulsed Light C.STIM® with recommended fluence.
62204873|NCT06349356|PLACEBO_COMPARATOR|Very low fluence Intense Pulsed Light arm (placebo)|The treatment consists in Intense Pulsed Light C.STIM® with a very low fluence.
62204874|NCT03778268|EXPERIMENTAL|Undergoing sentinel lymph node biopsy|This group of patients will undergo sentinel lymph node biopsy.
62204875|NCT02698943||Study Group|Participants who underwent phacoemulsification surgery and implantation of the Envista MX-60 IOL
62204876|NCT02451176|ACTIVE_COMPARATOR|Active Comparator: Davol Bard ®Soft Mesh|Device: Davol Bard ®Soft Mesh Synthetic mesh for open ventral hernia repair for clean-contaminated or contaminated abdominal wall hernias Other Name: synthetic mesh SoftMesh™ (CR Bard)
62204877|NCT02451176|ACTIVE_COMPARATOR|Active Comparator: LifeCell Strattice®|Device: LifeCell Strattice® Reconstructive Tissue Matrix Biologic mesh for open ventral hernia repair for clean-contaminated or contaminated abdominal wall hernias Other Name: Biologic mesh Strattice
62204878|NCT00352326|EXPERIMENTAL|Children (with dystonia and controls)|"Participants sat in a chair or their own wheelchair in front of a table whose surface height was adjusted at the midpoint between the hip and the Xiphoid process. They placed the hand that was not used for the task on their lap.~An iPad® (Apple Inc, Cupertino, California) was located on the table in portrait mode in front of the participants at a distance that ranged between 40 and 55 cm. An adjustable metal bookstand supported the iPad® to allow the participants a comfortable screen view. The size of the screen was 19.5 × 14.6 cm. Custom software was developed for the experimental task (XCode 3.2 development environment, iOS 4.2 operating system; Apple Inc, Cupertino, California)."
62015807|NCT05063734|EXPERIMENTAL|Part B, previously treated subjects, THR-687 selected dose level|Due to the discontinuation of the study after Part A, the dose level for Part B has not been selected
62015808|NCT05063734|ACTIVE_COMPARATOR|Part B, previously treated subjects, aflibercept 2.0mg|
62204879|NCT06486792|EXPERIMENTAL|Therapeutic anticoagulation|Choice of the investigator, VKA with target INR 2-3, or apixaban, rivaroxaban or dabigatran)
62204880|NCT06486792|ACTIVE_COMPARATOR|Aspirin 75-300 mg/day|Aspirin is the standard of care treatment.
62204881|NCT04137328|EXPERIMENTAL|liraglutide group|Mecobalamin tablets (0.5mg/day, oral) and liraglutide (0.6mg/day in the first week, if there is no obvious discomfort, 1.2mg/day in the second week, subcutaneous injection) were used for 3 months.
62204882|NCT04137328|ACTIVE_COMPARATOR|control group|Take Mecobalamin (0.5mg/day, oral), add or adjust insulin (when basic insulin is preferred for those who do not use insulin, if insulin has been used, adjust the dose or program according to the condition, inject subcutaneously) for 3 months.
62204883|NCT04519866|EXPERIMENTAL|Electroacupuncture|In addition to usual rheumatological care, patients in the electroacupuncture arm will undergo 2 courses of electroacupuncture treatment. Each treatment course will consist of 10 acupuncture sessions held over 5 weeks. Patient will take a break of 5-7 days in between each course of acupuncture.
62204884|NCT04519866|ACTIVE_COMPARATOR|Manual acupuncture|In addition to usual rheumatological care, patients in the manual acupuncture arm will undergo 2 courses of manual acupuncture treatment. Each treatment course will consist of 10 acupuncture sessions held over 5 weeks. Patient will take a break of 5-7 days in between each course of acupuncture.
62204885|NCT00659555|EXPERIMENTAL|Treatment A receivers|Subjects received pazopanib, single dose as 2 x 40 microliter drops of 5 mg/mL solution in Period 1
62204886|NCT00659555|EXPERIMENTAL|Treatment B receivers|Subjects received ketoconazole, daily 400 mg oral dose on Days 1 to 8; pazopanib, single dose as 2 x 40 microliter drops of 5 mg/mL solution on Day 5 in Period 2
62404567|NCT05483569|OTHER|Complex Decongestive Physiotherapy|CDP program consisting of 4 parameters will be applied to this group. These parameters are MLD, Skin care, Multi-layer bandage application and decongestive exercises. In addition, the Placebo Facial Release technique will be performed by keeping the physiotherapist's hand in contact with the patient's abdominal region without applying any pressure and tension during the breathing exercises. Participants will be treated for a total of 3 weeks, 5 days a week. Each treatment session will last 45 minutes.
62015809|NCT01581346|EXPERIMENTAL|exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
62204887|NCT00632489|EXPERIMENTAL|LBH589 with Capecitabine|MTD, LBH589 with Capecitabine
62204888|NCT00632489|EXPERIMENTAL|LBH589 and Lapatinib|LBH589 and Lapatinib
62204889|NCT00632489|EXPERIMENTAL|LBH589, Capecitabine and Lapatinib|LBH589, Capecitabine and Lapatinib (Breast Cancer Patients)
62204890|NCT06728046|EXPERIMENTAL|ESPB Group|Participants will receive ultrasound-guided ESPB preoperatively, using 40 ml of 0.3% ropivacaine.
62204891|NCT06728046|ACTIVE_COMPARATOR|PCA Group|Participants will receive postoperative PCA with a formulation of 200 µg sufentanil diluted to 100 ml. The PCA settings will include a background dose of 3 ml/hour, a lockout time of 15 minutes, and a bolus dose of 2 ml.
62204892|NCT06724887|EXPERIMENTAL|Brain Health Training and Education|Online and in-person training and education around brain-health strategies and lifestyle practices.
62404568|NCT05483569|EXPERIMENTAL|Multidimensional Diaphragmatic Breathing Exercises and Facial Release Technique|"CDP program consisting of 4 parameters will be applied to this group. These parameters are MLD, Skin care, Multi-layer bandage application and decongestive exercises. In addition, Multidimensional Diaphragmatic Breathing Exercises and Facial Release technique will be applied. These two treatments consist of these sub-exercises. These; Mechanical nose opening techniques, Intermittent Sniffing exercise, Diaphragm Awareness and Exercise Short Protocol, Thorax mobilization exercises, Myofascial diaphragm release techniques, Myofascial release exercises and postures and, Pelvic floor myofascial release postures.~Participants will be treated for a total of 3 weeks, 5 days a week. Each treatment session will last 45 minutes."
62404569|NCT02736734|OTHER|CRH condition|All HV first underwent a baseline manometry measurement. After 30 minutes, an intravenous CRH injection was done. The same measurement was repeated but now with CRH administered.
62404570|NCT03194165||antiretroviral dosage|titration of Dolutegravir, Raltegravir, Rilpivirine, Nevirapine, Atazanavir, Darunavir, Ritonavir
62404571|NCT02469402|ACTIVE_COMPARATOR|Standard infant formula|Standard infant formula
62404572|NCT02469402|EXPERIMENTAL|Protein reduced formula|Protein reduced alpha-lactalbumin formula
62404573|NCT02469402|NO_INTERVENTION|Breast-feeding|Exclusive breast-feeding
62404574|NCT01377857|EXPERIMENTAL|Opt-In|Opt-in refers to a default of no test - patients must ask for the test in order to receive it. Patients are informed of the availability of rapid testing. They are tested only if they request the test.
62404575|NCT01377857|EXPERIMENTAL|Opt-Out|Opt-out has a default to test - patients are informed that they will receive a rapid HIV screening test unless they decline it. Patients will be tested unless they decline.
62787832|NCT00793507|EXPERIMENTAL|1: Intervention Group|All participants in the intervention group will be receiving standard preventive dental care received by children in their dental providers' office. These intervention children will receive dental scaling, cleaning and fluoride varnish at visits every three to six months. All participants in the intervention group will receive active reminder/recall from the hygienist, encouraging the participants to return every three to six months for the oral exam, cleaning, scaling and fluoride application.
62204893|NCT05419011|EXPERIMENTAL|Arm I (Tri-Ad5, N-803)|Participants receive Tri-Ad5 SC and N-803 SC at weeks 0, 4, 8, and 52. Participants also undergo SOC colonoscopy with biopsy at baseline and at 52 and 104 weeks. Participants undergo blood sample collection throughout the study.
62204894|NCT05419011|PLACEBO_COMPARATOR|Arm II (placebo)|Participants receive placebo SC at weeks 0, 4, 8, and 52. Participants also undergo SOC colonoscopy with biopsy at baseline and at 52 and 104 weeks. Participants undergo blood sample collection throughout the study.
62204895|NCT05419011|EXPERIMENTAL|Safety phase I (Tri-Ad5)|Participants receive Tri-Ad5 SC at weeks 0, 4, 8, and 52. Participants also undergo SOC colonoscopy with biopsy at baseline and at 52 weeks and 104 weeks. Participants undergo blood sample collection throughout the study.
62204896|NCT05419011|EXPERIMENTAL|Safety phase II (Tri-Ad5 , N-803)|Participants receive Tri-Ad5 SC and N-803 SC at weeks 0, 4, 8, and 52. Participants also undergo SOC colonoscopy with biopsy at baseline and at 52 weeks and 104 weeks. Participants undergo blood sample collection throughout the study.
62204897|NCT06580912|EXPERIMENTAL|Krill oil|4 grams of krill oil per day
62404576|NCT01377857|EXPERIMENTAL|Active Choice|In the active choice treatment, there is no default; patients must actively accept or actively decline the test.
62787833|NCT00793507|ACTIVE_COMPARATOR|2: Control Group|The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist.
62204898|NCT06580912|PLACEBO_COMPARATOR|Mixed vegetable oil|4 grams of mixed vegetable oil per day
62204899|NCT06487104|EXPERIMENTAL|Arm 1 - HME|24/7 use of TrachPhone HME for the entirety of study
62204900|NCT06487104|ACTIVE_COMPARATOR|Arm 2 - EH|24/7 use of EH until first follow-up (T1), then 24/7 use of TrachPhone HME for the remainder of the study participation.
62204901|NCT03030859|EXPERIMENTAL|Group I (Usual Care)|Patients receive usual care only, without any additional interventions.
62204902|NCT03030859|EXPERIMENTAL|Group II (Usual Care plus LEF-SCP)|Patients undergo LEF-SCP training comprising of MI session over 1 hour and LEF self-care training session over 1 hour weekly for 3 weeks. Patients also review LEF self-care educational manual and watch self-care videos monthly or more frequently as needed.
62404577|NCT01377857|EXPERIMENTAL|$1 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
62404578|NCT01377857|EXPERIMENTAL|$5 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
62404579|NCT01377857|EXPERIMENTAL|$10 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
62204903|NCT03030859|EXPERIMENTAL|Group III (Usual Care plus LEF-SCP plus Follow-Up)|Patients undergo LEF-SCP training comprising of MI session over 1 hour and LEF self-care training session over 1 hour weekly for 3 weeks. Patients review LEF self-care educational manual and watch self-care videos monthly or more frequently as needed. Patients also meet with the study lymphedema therapist over 1 hour at 3, 6, and 9 months.
62204904|NCT05208047|EXPERIMENTAL|Part 1a|CGT9486 plus sunitinib 37.5 mg QD
62204905|NCT05208047|EXPERIMENTAL|Part 2 - Experimental Group|CGT9486 plus sunitinib 37.5 mg QD
62204906|NCT05208047|ACTIVE_COMPARATOR|Part 2 - Control Group|sunitinib 37.5 mg QD
62204907|NCT05208047|EXPERIMENTAL|Part 1b - DDI Cohort 1|CGT9486 plus sunitinib 37.5 mg QD
62204908|NCT05208047|EXPERIMENTAL|Part 1b - DDI Cohort 2|sunitinib 37.5 mg QD plus CGT9486
62204909|NCT05208047|EXPERIMENTAL|DDI Substudy (Midazolam)|Midazolam, CGT9486, sunitinib
62204910|NCT05594797|EXPERIMENTAL|Human BCMA Targeted T Cells Injection|Single administration：6.0×10\^6 CAR+T/kg
62404580|NCT01377857|EXPERIMENTAL|Early Questionnaire|At a time that does not interfere with patients' medical care, patients will be approached by a member of the research team to consent to and complete a short (3 minutes) questionnaire. The questionnaire is designed to elicit two things: subjective risk of infection (e.g., What are the chances you have HIV? \[Not possible, Unlikely, Possible, Likely, Certain\]) and objective risk of infection (e.g., In the past year, have you given anyone drugs or money for sex?). The questionnaire will be administered as one of two timing treatments - a) at the beginning of care, before the patient is offered an HIV test (Early questionnaire) or b) after the patient has been offered an HIV test (Late questionnaire).
62734867|NCT06287242|ACTIVE_COMPARATOR|matched manipulation|For the matched manipulation group, participants with the source of neck pain at the cervical spine determined by the CTDT will receive a cervical manipulation, and participants with the source of neck pain at the thoracic spine determined by the CTDT will receive a thoracic manipulation. The manipulation will be given to the participant's most provocative spinal level as determined by the examiner and side determined by the CTDT. The investigator will be limited to 2 manipulation attempts even if cavitation was not achieved.
62787834|NCT03688464|ACTIVE_COMPARATOR|Melatonin Treatment|Subjects to receive melatonin 0.1 mg/kg (minimum dose of 1 mg, maximum dose of 5 mg) 30 minutes prior to bedtime (1 mg/ml oral compound suspension) for 4 weeks.
62787835|NCT03688464|ACTIVE_COMPARATOR|Diphenhydramine Treatment|Subject to receive diphenhydramine 2.5 mg/ml oral liquid, dosed at 1 mg/kg at bedtime for 4 weeks.
62015810|NCT05283291|EXPERIMENTAL|İmaginary group|"Expert opinion for the scenario will be taken from a psychologist and a psychiatric nurse.~The flow of the script; It will start with breathing exercises and continue with the safe place application, after affirming the functionality that is said while in a safe place in the mind, it will be in the form of waking up by turning to the body and returning to the present.~Headphones will be provided for each patient by the researcher. In the first meeting, the voice recordings will be transferred to the phones of the individuals via the phone in the Neurosurgery Service. Communication with the patient will be provided in accordance with the pandemic rules.~The audio recording will be played twice, in the evening before the operation and on the evening of the operation day."
62204911|NCT05653102||Prospective Subjects|Enrolled in the study pre-surgery. Subjects who agree to participate in the study that have not had surgery prior to being enrolled in the study.
62204912|NCT05653102||Retrospective to Prospective|Subjects enrolled in the study post- surgery then continue to participate in the study prospectively. Subjects who agree to participate in the study that have undergone surgery prior to enrollment in the study. Data for these subjects will collected from the subject's medical record for the time period prior to enrollment in the study containing data pertaining to the index surgery (retrospective data) and from the patient after they are enrolled in the study during the post-operative time period (prospectively).
62204913|NCT05653102||Retrospective Only Subjects|Subjects enrolled in the study post-study surgery with no intent to continue as prospective subjects. Patient's clinical record includes a signed HIPAA waiver allowing for the use of clinical record data for the purpose of clinical research outside of the operating institution.
62204914|NCT00644670|EXPERIMENTAL|Previous Treatment with a Usual Maintenance Dose of a Statin|
62204915|NCT00644670|EXPERIMENTAL|Statin-Naive|
62204916|NCT02371590|EXPERIMENTAL|Lenalidomide-Obinutuzumab|All patients receive the combination of lenalidomide and obinutuzumab. There is no randomization or comparator arm.
62204917|NCT05617729|PLACEBO_COMPARATOR|Saline|this treatment consists of sterile saline that is applied to the nares using a swab
62204918|NCT05617729|ACTIVE_COMPARATOR|Povidone-iodine based gel|this treatment consists of a Povidone-Iodine based gel that is applied to the nares using a swab
62204919|NCT04654637|EXPERIMENTAL|Arm A|fix model of cycle exercise(online supervise) and routine nutrition consult
62204920|NCT04654637|EXPERIMENTAL|Arm B|fix model of cycle exercise(online supervise) and online nutrition consult
62204921|NCT04654637|EXPERIMENTAL|Arm C|individualize cycle exercise(online supervise) and routine nutrition consult
62204922|NCT04654637|EXPERIMENTAL|Arm D|individualize cycle exercise(online supervise) and online nutrition consult
62204923|NCT04230122|EXPERIMENTAL|10 milligram (mg) LY3478006 - Intravenous (IV)|Participants received single dose of 10 mg LY3478006 administered IV. Due to early termination of the study Cohort 2 to 6 (30 mg, 100 mg, 300 mg, 600 mg, and 1000 mg LY3478006 IV) were not explored for safety reasons following dosing of the first 4 participants in Cohort 1.
62204924|NCT04230122|PLACEBO_COMPARATOR|Placebo - IV|Participants received single dose of placebo administered IV. Placebo IV Cohorts 2 through 6 were not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.
62204925|NCT04230122|EXPERIMENTAL|100 mg LY3478006 - Subcutaneous (SC) (Cohort 7)|100 mg LY3478006 cohort 7 SC dose was not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.
62204926|NCT04230122|PLACEBO_COMPARATOR|Placebo - SC (Cohort 7)|Placebo cohort 7 SC dose were not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.
62204927|NCT06633003|ACTIVE_COMPARATOR|Stage I: Antrodia Cinnamomea Products + Stage II: Placebo|"Crossover design:~During 0 week\~8 weeks is Stage I :~• Dietary Supplement: Antrodia Cinnamomea Products~During 16 weeks\~ 24 weeks is Stage II:~• Dietary Supplement: Placebo"
62404581|NCT01377857|EXPERIMENTAL|Late Questionnaire|At a time that does not interfere with patients' medical care, patients will be approached by a member of the research team to consent to and complete a short (3 minutes) questionnaire. The questionnaire is designed to elicit two things: subjective risk of infection (e.g., What are the chances you have HIV? \[Not possible, Unlikely, Possible, Likely, Certain\]) and objective risk of infection (e.g., In the past year, have you given anyone drugs or money for sex?). The questionnaire will be administered as one of two timing treatments - a) at the beginning of care, before the patient is offered an HIV test (Early questionnaire) or b) after the patient has been offered an HIV test (Late questionnaire).
62404582|NCT01377857|EXPERIMENTAL|FITD Questionnaire|"There will be two versions of the early questionnaire: one standard Early questionnaire, and one with an additional question: If you were offered an HIV test as part of your routine health care at no cost, would you get tested? The two questionnaires will be otherwise identical."
62204928|NCT06633003|PLACEBO_COMPARATOR|Stage I: Placebo + Stage II: Antrodia Cinnamomea Products|"Crossover design:~During 0 week\~8 weeks is Stage I :~• Dietary Supplement: Placebo~During 16 weeks\~ 24 weeks is Stage II:~• Dietary Supplement: Antrodia Cinnamomea Products"
62204929|NCT06031103|ACTIVE_COMPARATOR|childhood urolithiasis treated with mini PCNL Procedure|pediatric patients with upper urinary tract calculus treated with mini-PCNL procedure
62015811|NCT05283291|NO_INTERVENTION|Control group|In the routine care applied to the patients, the vitals of the patients are followed, drug treatments are administered and the motor functions of the patients are monitored. In addition, analgesics are routinely administered in the ward for pain and no attempt is made for sleep.
62204930|NCT06031103|ACTIVE_COMPARATOR|childhood urolithiasis treated with RIRS Procedure|pediatric patients with upper urinary tract calculus treated with mini-PCNL procedure
62204931|NCT02758847|OTHER|Critical Limb Ischemia (CLI) and Tissue Loss|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Patients with CLI will receive either Angiogram, Medtronic DCB (paclitaxel)/stent or Angiogram, Bard DCB (paclitaxel)/stent
62204932|NCT04801732|EXPERIMENTAL|mulligan group|Patients in the study group will treated with SNAGS techniques on thoracic spine with traditional treatment consist of ice application, supervised exercises (stretching and strengthening exercise) for 3 times/week for one month.
62204933|NCT04801732|ACTIVE_COMPARATOR|exercising group|will receive only traditional treatment (ice application and supervised exercise ) for 3 times/week for one month.
62204934|NCT02602262||HIV D+/R+|HIV-infected individuals who accept an organ from an HIV-infected deceased donor
62204935|NCT02602262||HIV D-/R+|HIV-infected individuals who accept an organ from an HIV-uninfected deceased donor
62204936|NCT05010343|ACTIVE_COMPARATOR|carbon ion irradation group|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle
62204937|NCT05010343|ACTIVE_COMPARATOR|Carbon Ion Irradiation With SIB group|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle, and with simultaneous integrated boost (SIB) to the gross tumor in the PSMA PET/CT and mpMRI
62204938|NCT02103517|EXPERIMENTAL|Omega-3 fatty acid capsules|Omega-3 fatty acid capsules, 4 g/day, requiring intake 2 capsules (1g each one) in the morning and two at night for 3 months.
62204939|NCT02103517|PLACEBO_COMPARATOR|corn oil|Corn oil in similar presentation as omega-3 fatty acid capsules, requiring intake 2 capsules in the morning and two at night for 3 months.
62204940|NCT04085484||Infants born between 1 Feb 2010 and 18 Feb 2012|Infants born between 1 February 2010 and 18 February 2012, before the concentrated PN regime was implemented (Original PN group: n = 81).
62204941|NCT04085484||Infants born between 19 Feb 2012 and 30 Sep 2013|Infants born between 19 February 2012 and 30 September 2013, after the concentrated PN regime was implemented (Concentrated PN group: n = 53).
62204942|NCT04668040|EXPERIMENTAL|Muscle energy technique|Muscle energy technique applied in the lower cross syndrome muscle pattern.
62404583|NCT01377857|EXPERIMENTAL|Free|When offering the HIV test, study staff will inform subjects that the ED is offering HIV testing (and that the test is also free); no monetary incentive will be offered.
62204943|NCT04668040|ACTIVE_COMPARATOR|Stretching|Stretching technique applied in the lower cross syndrome muscle pattern.
62204944|NCT00453167|EXPERIMENTAL|study arm|
62204945|NCT05378477|EXPERIMENTAL|Test product|Hemisqualane \& beeswax-based lotion (X92001752), killing lice and nits via suffocation.
62204946|NCT05378477|ACTIVE_COMPARATOR|RID Super Max Solution|Oligodecene oil-based lotion, killing lice and nits via suffocation.
62204947|NCT05378477|ACTIVE_COMPARATOR|Nix Crème|Conventional pesticide, containing 1% permethrin.
62204948|NCT05378477|ACTIVE_COMPARATOR|Pouxit Végétal|Fatty acid salt-based lotion, killing lice and nits via suffocation.
62404584|NCT06385509|EXPERIMENTAL|JATENZO® twice daily|Participants receive 237 mg JATENZO twice daily, with the potential to be titrated to a higher or lower dose depending on serum testosterone levels.
62787836|NCT03688464|PLACEBO_COMPARATOR|Placebo|Subjects will receive cherry flavored placebo at bedtime for 4 weeks.
62204949|NCT01525238|EXPERIMENTAL|Dapagliflozin 2.5 mg|
62204950|NCT01525238|EXPERIMENTAL|Dapagliflozin 5 mg|
62204951|NCT01525238|EXPERIMENTAL|Dapagliflozin 10 mg|
62204952|NCT04682938||adrenal incidentalomas in Chinese community adults|On weekdays, the first 100 individuals, aged 18 to 78 years, taking health checkup in the Community Health Examination Center were invited to take part in the study.
62204953|NCT05802316||awake|awake tracheal intubation
62204954|NCT05802316||asleep|standard intubation videolaryngoscopy (VL) and direct laryngoscopy (DL)
62015812|NCT02048956|EXPERIMENTAL|Hydrotherapy intervention|30 people will be recruited in order to the inclusion criteria for the study and they will receive an hydrotherapy intervention.
62015813|NCT02048956|ACTIVE_COMPARATOR|Control group|30 people will be recruited and included in this control group. The are not going to receive hydrotherapy treatment, only the treatment they receive as usual.
62015814|NCT05546606|NO_INTERVENTION|Single standard of care|COPD patients who require respiratory support for severe acute exacerbation (AE), either with NIV or with IMV.
62015815|NCT05546606|OTHER|Strengthen standard of care reinforced with ECCO2R|COPD patients who require respiratory support for severe acute exacerbations (AE), either with NIV or with IMV reinforced with ECCO2R
62015816|NCT00971971|NO_INTERVENTION|Control|Traditional SLED
62015817|NCT00971971|EXPERIMENTAL|Profiling|dialysate temperature reduction with Na and ultrafiltration (UF) profiling
62015818|NCT03632356|EXPERIMENTAL|Stepped Care Intervention (STEP)|In a stepped-care model, all patients start with an evidence-based intervention of low intensity as a first treatment step. Progress is monitored and patients who do not respond adequately can subsequently be 'stepped up' to a higher intensity treatment. This model is now being recommended as the best strategy for treating panic attacks and panic disorder.
62015819|NCT03632356|ACTIVE_COMPARATOR|Screening only|Screening only for panic attacks and panic disorder using a gold standard clinical interview that provides coverage of the core symptoms of panic attacks and panic disorder.
62015820|NCT06533683||Group 1 : ESWT treatment group|ESWT treatment is applied once a week for 5 weeks
62015821|NCT06533683||Group 2 : Kinesio taping treatment group|Kinesio taping was also applied once a week, for a total of 5 sessions. The rake method was used for kinesio taping.
62015822|NCT02148094|EXPERIMENTAL|Truvada|Participants will be initiated on PrEP and asked to select one of two PrEP delivery options. Participants will return to the study site every three months for an additional follow-up visit. At follow-up visits, participants will receive HIV testing and counselling, pregnancy testing, syndromic screening for STIs, and clinical diagnosis of adverse events. Those who test HIV-positive will be discontinued on PrEP, exited from the study and referred for HIV care and treatment. Those who have an adverse event will be clinically evaluated to determine whether they should suspend PrEP use and will be provided with the appropriate management for the adverse event. Participants who test HIV-negative will receive patient-centred counselling around PrEP.
62015823|NCT05501587||Participants with CF|
62015824|NCT05501587||Participants with other Respiratory Disease|
62204955|NCT05849012|EXPERIMENTAL|Low Sulfur Diet|Participants in this group will follow a low sulfur diet. This diet decreases the amount of animal products (including meat, dairy, and eggs) as well as sulfur additives in the diet. The main types of foods in the low sulfur diet include fruits, vegetables, whole grains, nuts, seeds, and soy products.
62204956|NCT05849012|ACTIVE_COMPARATOR|Usual Diet|Participants in this group will follow a standard of care usual diet for 8 weeks.
62204957|NCT00440752||AL|Cohort of study participants receiving treatment with artemether-lumefantrine
62204958|NCT02597244|EXPERIMENTAL|Treatment group|Percutaneous Extraforaminotomy using BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea)
62204959|NCT02865668|EXPERIMENTAL|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 50 milligram (mg) along with one Extended Release (XR) tablet of metformin of 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 XR fixed dose combination \[FDC\] tablet containing canagliflozin 50 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 50 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg along with one metformin (XR) tablets of 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62204960|NCT02865668|EXPERIMENTAL|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62787837|NCT01059318|EXPERIMENTAL|Everolimus|"All patients received a starting dose of everolimus 2.5mg/day for 4 weeks, followed by a dose of 5 mg/day for 4 weeks and finally a dose of 10mg/day for 18 weeks.~The 26 week treatment period was followed by an optional extension period wherein patients continued therapy until the last patient had completed 26-weeks of treatment. The longest period a patient participated in the study was 62 weeks."
62015825|NCT05501587||Healthy Participants|
62787838|NCT01065701|ACTIVE_COMPARATOR|1mcg/kg|1mcg/kg intranasal dexmedetomidine administered 45 minutes befoe anesthesia induction
62015826|NCT00743353|EXPERIMENTAL|A|16 subjects to be enrolled; Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
62204961|NCT02865668|EXPERIMENTAL|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62204962|NCT02865668|EXPERIMENTAL|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62204963|NCT02233959||Healthy Adults|
62204964|NCT01941173|EXPERIMENTAL|Treatment (ziv-aflibercept, FOLFIRI)|Patients receive ziv-aflibercept IV over 15-30 minutes followed by FOLFIFRI chemotherapy comprising leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
62787839|NCT01065701|ACTIVE_COMPARATOR|2mcg/kg|2mcg/kg intranasal dexmedetomidine given 45 minutes prior to anesthetic induction
62787840|NCT03979885|OTHER|Goal-Directed Incentives|
62787841|NCT03979885|OTHER|Outcome-Based Incentives|
62787842|NCT03979885|OTHER|Enhanced Usual Care|
62787843|NCT02737345||Waiting list|Patients on the liver transplant waiting list
62787844|NCT00627367|EXPERIMENTAL|Protocolized|"1mg IV hydromorphone followed by an additional 1mg at 15 minutes if the patient answer yes to the question, Do you want more pain medication?"
62204965|NCT00576563|OTHER|FDG PET CT|To investigate the evolution of the 18F-deoxyglucose (FDG) uptake and the tumour characteristics determined in the plasma of patients with rectal cancer during and after radiotherapy or combined radiotherapy and chemotherapy.
62204966|NCT04770727|EXPERIMENTAL|Workshop Intervention|A psychoeducation workshop will be provided alongside a workbook containing the content to review and refresh skills learnt. The psychoeducational intervention will be delivered by trainee clinical psychologists with interests in food allergy and delivered in line with a protocol.
62204967|NCT04770727|NO_INTERVENTION|Treatment as usual|Adolescents randomised to the control arm will continue treatment as usual and receive the workshop materials after the active treatment group have completed their final follow-up at 3 months.
62204968|NCT04039373|EXPERIMENTAL|Treatment Arm|
62204969|NCT04081870||ICSI cases|All women underwent long agonist protocol for controlled ovarian hyperstimulation The GnRH agonist was started in the previous mid-luteal phase . After the confirmation of pituitary down regulation , the HMG ampoules were started by 225 IU/day . During the follow up of overstimulation, the doses were adjusted according to the response of patient. All women underwent serial TVS until at least three dominant follicles were reached in every woman. When the dominant follicles reached 18-20 mm, HCG 10000 was administered. Three D power Doppler US was done for every woman at the day after HCG administration. Ovum pick up was done after 35 hours following HCG administration. The luteal phase was supported by progesterone 300 mg per day . Five days following ovum pick up, the embryos were transferred at the blastocyst stage.
62204970|NCT03795753|EXPERIMENTAL|F2S Communicator|The F2S Communication System is a communication aid for use with a noninvasive ventilation (NIV) mask covering at least the mouth. It is a two-component system consisting of (1) a disposable, single patient use patch and signal cable and (2) a reusable communicator with power cable.The non-invasive aid for patients receiving BPAP/CPAP therapy delivers communication between the patient and medical personnel.
62204971|NCT03795753|SHAM_COMPARATOR|Non-functioning Communicator|Non-functioning study communication device is used.
62404585|NCT06006026|EXPERIMENTAL|ropivacaine|Patients will receive a TAP block using 1.5 mg/kg, 2.0 mg/kg or 2.5 mg/kg of ropivacaine. If there is no LAST (local anesthetic systemic toxicity) in the three subjects of 1.5 mg/kg group, the next three patients will receive 2.0 mg/kg of ropivacaine. Another three patients will receive 2.5 mg/kg of ropivacaine if there is no LAST in the three subjects of 2.0 mg/kg group. All subjects will be administered an i.v. bolus of lidocaine 2.0 mg/kg (given as an infusion for 10 min) after anaesthesia induction, then continuous infusion at 2 mg/kg/h until the end of surgery.
62404586|NCT03628534|EXPERIMENTAL|single arm|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
62404587|NCT06239207|EXPERIMENTAL|Exosomes|Group A patients are injected exosomes 2 session 3 months apart, intradermally at a dose of 0.1 ml/cm2 of scalp. Exosomes used are GFC CELL(TM) EXO SCALP KIT
62734868|NCT06287242|ACTIVE_COMPARATOR|unmatched manipulation|For the unmatched manipulation group, participants with the source of neck pain at the cervical spine determined by the CTDT will receive a thoracic manipulation, and participants with the source of neck pain at the thoracic spine found during the CTDT will receive a cervical manipulation. The manipulation will be given to the most hypomobile spinal level determined by the physical therapist and to the most provocative side found during the CTDT. The investigator will be limited to 2 manipulation attempts even if cavitation was not achieved.
62787845|NCT00627367|ACTIVE_COMPARATOR|Nonprotocolized|An IV opioid the type and dose of which will be determined by the treating clincian
62015827|NCT03286140|ACTIVE_COMPARATOR|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with deferred treatment of superficial reflux (usually once the ulcer has healed)
62015828|NCT03286140|EXPERIMENTAL|Early arm|Early endovenous treatment of superficial venous reflux(within 2 weeks) in addition to standard compression therapy
62015829|NCT01070290|EXPERIMENTAL|1|ARQ 197
62015830|NCT01070290|ACTIVE_COMPARATOR|2|Investigator's choice of oxaliplatin, capecitabine or irinotecan
62204972|NCT01971801|ACTIVE_COMPARATOR|Vitamin D|Vitamin D3, 50,000 IU, weekly
62204973|NCT01971801|PLACEBO_COMPARATOR|Placebo|Placebo comparator, weekly
62204974|NCT01585077|EXPERIMENTAL|Naive volunteers|Volunteers without previous exposure to malaria, and negative antibody titers (\<1:20) against native protein of P. vivax.
62204975|NCT01585077|EXPERIMENTAL|Pre-immune volunteers|Volunteers with previous exposure to malaria, and positive antibody titers against native protein of P. vivax
62204976|NCT06108518|PLACEBO_COMPARATOR|Control group|Group1 (Placebo group; n=35) which will receive the standard treatment for RA plus placebo tablet for 3 months.
62204977|NCT06108518|ACTIVE_COMPARATOR|Treatment group|Group 2 (Carvedilol group; n=35) which will receive the standard treatment for RA plus carvedilol 12.5mg once a day for 2 days; this is increased to 25 mg once a day or 12.5 mg twice a day for 3 months.
62787846|NCT01023360|EXPERIMENTAL|Clopidogrel and proton pump inhibitors|all participating healthy people should receive clopidogrel and 3 kinds of PPI sequentially with one week interval between each PPI.
62015831|NCT03505476|EXPERIMENTAL|Study Participants|Device: Entac Medical device application Other: Patient Daily Assessment Other: Patient Discharge Assessment
62015832|NCT01946061|EXPERIMENTAL|Treatment group|
62015833|NCT05884437|EXPERIMENTAL|Chiropractic|Chiropractic adjustment
62204978|NCT04265352||Prenetal cardiac echogenic focus|Newborn infants who had prenatal cardiac echogenic focus
62204979|NCT06618014|EXPERIMENTAL|Neoadjuvant TCb+Toripalimab|Patients receive toripalimab (240 mg) plus docetaxel and carboplatin (AUC=4) on day 1 of each 21-day cycle for 6 cycles.
62204980|NCT05380557||Germline Pathogenic Variant in non-BRCA/PALB2 Gene|Patients will receive germline testing and provide streck tube blood samples and archival tissue sample at baseline. After germline testing results have been generated and released, patients and clinicians will be contacted for survey completion at months: 1, 4, 8, 12, 18, 24, 30, 36, 42, 48, 54, 60 and survival collection every 6 months during years 3-10 post germline testing.
62204981|NCT05380557||Strong family history of pancreatic cancer but no identifiable germline pathogenic variant|Patients will receive germline testing and provide streck tube blood samples and archival tissue sample at baseline. After germline testing results have been generated and released, patients and clinicians will be contacted for survey completion at months: 1, 4, 8, 12, 18, 24, 30, 36, 42, 48, 54, 60 and survival collection every 6 months during years 3-10 post germline testing.
62204982|NCT05380557||Negative germline testing and absence of strong family history|Patients will receive germline testing and provide streck tube blood samples and archival tissue sample at baseline. After germline testing results have been generated and released, patients and clinicians will be contacted for survey completion at months: 1, 4, 8, 12, 18, 24, 30, 36, 42, 48, 54, 60 and survival collection every 6 months during years 3-10 post germline testing.
62204983|NCT05380557||Pathogenic Variant in BRCA1/2 or PALB2|Patients will be offered enrollment into the sister trial, APOLLO (NCT04858334). Patients and clinicians will be contacted for survey completion at months: 1, 4, 8, 12, 18, 24, 30, 36, 42, 48, 54, 60 and survival collection every 6 months during years 3-5.
62204984|NCT02745353|ACTIVE_COMPARATOR|A|Patients in Arm A will receive a single daily dose of 25mg naloxegol for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover treatment period in which the patient will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication.
62204985|NCT02745353|ACTIVE_COMPARATOR|B|Patients in Arm B will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover period in which the patient will receive a single daily dose of 25mg naloxegol.
62204986|NCT03046121|EXPERIMENTAL|Fam-FFC|The intervention consists of :Component 1- Environmental and Policy Assessments; Component II- Education of Nursing Staff; Component III-Ongoing Training/Motivation of Nursing Staff. The Fam-FFC Nurse will work with the champions to mentor and motivate nursing staff to provide: (a) role modeling Fam-FFC, reinforcing performance of Fam-FFC, and brainstorming about ways to overcome challenges; (b) highlighting staff role models; Component IV Implementation of the FamPath Pathway which includes: (a) information on the admitting condition, diagnostics, treatment;(b) family/patient education; (c) transitional hand-off to post-acute providers; and (d) post-acute follow-up to provide ongoing education and modification of the function-focused care plan.
62404588|NCT06239207|ACTIVE_COMPARATOR|B PRP|PRP 4 sessions 1 months apart. Group B patients are injected PRP intradermally in scalp. Uunder aseptic around 10ml of blood is collected from the median cubital vein and is transferred into a sodium citrate tube. Then the tubes are rotated in a centrifuge machine at 1500 RPM for 10 minutes.It separates the blood into 2 layers: the lower RBC layer; the upper plasma layer buffy coat. The buffy coat was transferred into another test tube. This tube was again subjected to a second centrifugation at 4000 RPM for 10 minutes. Both the upper layer containing platelet poor plasma and the lower layer of the PRP was collected. The plasma is filled into insulin syringe and then injected evenly into the affected areas of the scalp. Multiple PRP injections of 0.1 mL were given at each site in a linear pattern 1 cm apart
62404589|NCT02784028|EXPERIMENTAL|SGM-101|6 dose levels of SGM-101 (5mg/patient, 7.5mg/patient, 10 mg/patient, 12.5mg/patient , 15 mg/patient - 24 h prior surgery and 15 mg/patient - 48h prior surgery
62404590|NCT06499272|EXPERIMENTAL|Experimental Group (EG)|Experimental Group (EG), which received therapy with NeuronUP, plus their conventional occupational therapy sessions.
62404591|NCT06499272|ACTIVE_COMPARATOR|Control Group (CG|Control Group (CG), which received their usual sessions of conventional occupational therapy.
62787847|NCT04619732|EXPERIMENTAL|Marginal Kidneys|"Transplant patients receiving kidneys from deceased marginal donors: aged \>= 60, or \>= 50 with comorbid renal impairment, hypertension, or cerebrovascular disease.~Following consent, kidneys will be cold perfused with preserving solution for 2-4 hours as per standard of care at the study centre. During this period, the kidneys will be monitored for creatinine, glucose, and lactate concentrations using three microdialysis probes placed into the tissue, the vein, and the ureter. Data will be blinded to clinicians.~The probes will be removed at the end of the perfusion period and the organs will be transplanted or discarded according to clinical protocol. If transplanted, the study will monitor the patient's recovery for the first 30 days."
62787848|NCT03591315||TG group|Patients with visual impairment caused by chiasma compression from sellar area tumors will undergo the following examinations: resting state fMRI, visual tasking state fMRI, diffusion tensor imaging (DTI), visual acuity and automated visual field test.
62404592|NCT03288428|EXPERIMENTAL|nalbuphine|using nalbuphine for patient controlled analgesia
62404593|NCT03288428|ACTIVE_COMPARATOR|morphine|using morphine for patient controlled analgesia
62404594|NCT03556254|EXPERIMENTAL|Genotypic resistance guided therapy|In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given.
62404595|NCT03556254|ACTIVE_COMPARATOR|Susceptibility testing guided therapy|Tailored therapy according to the minimum inhibitory concentration result (susceptibility testing, E-test)
62404596|NCT05597930|EXPERIMENTAL|Thumb then wrist orthosis|
62404597|NCT05597930|EXPERIMENTAL|Wrist then thumb orthosis|
62404598|NCT00626067|ACTIVE_COMPARATOR|1 Fully functional monitoring device|Fully functional monitoring device
62015834|NCT06561113|EXPERIMENTAL|Study group|Participants who meet the inclusion and exclusion criteria will undergo postural control assessment with the Biodex Balance System® and hand-eye coordination test with the Alternate Hand Wall Toss Test. Subjects will be given 65 ml of Turkish coffee (one cup) to ensure oral caffeine intake. The same assessments will be repeated 30 minutes after caffeine intake.
62015835|NCT04111341|EXPERIMENTAL|TCM Gan-Lu-Yin (GLY)|TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks
62015836|NCT04111341|PLACEBO_COMPARATOR|PLACEBO|TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
62204987|NCT03046121|NO_INTERVENTION|Attention Control (Fam- FFC Ed-only)|Education of the nursing staff in participating hospital units (exactly as offered in treatment sites), and education of family caregivers about hospital orientation and reinforcement of discharge teaching (medications/treatments, medical follow-up).
62204988|NCT05905627||breathing exercise group|breathing exercise group
62787849|NCT03591315||HC group|Volunteers with no visual impairment(visual acuity of both eyes \>1.0) or Nervous System disease will undergo the following examinations: resting state fMRI, visual tasking state fMRI, diffusion tensor imaging (DTI), visual acuity and automated visual field test.
62787850|NCT04701736|NO_INTERVENTION|Routine Care|Routine care consists of an oncology pharmacist counselling the patient on supportive care medications prior to the patient getting his or her prescription dispensed.
62787851|NCT04701736|ACTIVE_COMPARATOR|Intervention|The intervention group will encompass the oncology pharmacist using the computer system to print a Picture Medication Calendar for the patient and use the calendar to explain supportive medications, in addition to routine care.
62787852|NCT05830175|EXPERIMENTAL|Craniovertebral angle assesment|Craniovertebral angle is the most widely used measurement to assess Forward head posture. Craniovertebral angle is described as the acute angle formed between a horizontal line passing through the spinous process of the seventh cervical vertebra (C7) and the line connecting the midpoint of the tragus to the spinous process of C7.
62015837|NCT05450289|ACTIVE_COMPARATOR|Control Group|Control group will receive allergen specific immunotherapy and standard pharmacotherapy
62015838|NCT05450289|EXPERIMENTAL|Experimental Group|Experimental group will receive allergen specific immunotherapy, standard pharmacotherapy, and nigella sativa oil
62015839|NCT01884298|EXPERIMENTAL|patients with isolated systolic hypertension|patients combined with isolated systolic hypertension undergoing abdominal surgery
62015840|NCT01085318|ACTIVE_COMPARATOR|Arm 1 MS Patients|Rebif 44 tiw
62015841|NCT01085318|NO_INTERVENTION|Arm 2 Healthy Control|
62015842|NCT00346034|EXPERIMENTAL|1|
62204989|NCT05905627||relaxation exercise group|relaxation exercise group
62204990|NCT05905627||control group|control group
62215206|NCT04565093|EXPERIMENTAL|iPACK|In this group, participants will receive a peripheral nerve anesthetic block that is iPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) to cover posterior knee pain after total knee arthroplasty (TKA). This anesthetic block will be performed by assigned anesthesiologist under ultrasound guidance.
62015843|NCT03888313||Patients participating in the pretreatment group consultation|Patients who chosse to participate in a group consultation (with other patients also in the process of undergoing surgery for colorectal cancer).
62015844|NCT02589119|OTHER|MSC-AFP|Single Treatment Group
62015845|NCT03352115|EXPERIMENTAL|Steroid group|Will recieve 5 day course of oral prednisolone post-operatively
62015846|NCT03352115|PLACEBO_COMPARATOR|Control|Will receive placebo syrup for 5 days post-operatively
62015847|NCT02535195|ACTIVE_COMPARATOR|Ginger|Participants were randomly divided based on age, sex and severity of steatosis in two groups. Randomization lists were computer-generated by a statistician and participants, project managers and employees at the clinic were completely unaware (blind) about intervention and control groups. At the first visit, baseline data were gathered and patients advised to consume 2 capsules content 500 mg of ginger (made in Green Plants of Life Pharmaceutics Co., Iran) or placebo (starch) one hour after breakfast and two capsules after dinner for 3 weeks. Capsules was administrated for all patients in the first week for 3 weeks and in each visit new series of supplement was prescribed.
62015848|NCT02535195|PLACEBO_COMPARATOR|Placebo|2 capsules content 500 mg of placebo(starch) (made in Green Plants of Life Pharmaceutics Co., Iran) one hour after breakfast and two capsules after dinner for 3 weeks. Capsules was administrated for all patients in the first week for 3 weeks and in each visit new series of supplement was prescribed.
62015849|NCT00501449||Multiple Endocrine Neoplasia (MEN)|Patients with multiple endocrine neoplasia (MEN).
62015850|NCT00471601|EXPERIMENTAL|Interviews/Questionnaires|The primary intervention in part 1 includes the interview for item generation with 50 women and the pilot-testing with a separate group of n = 30 women. The primary intervention in part 2 and 3 is the administration of the questionnaire. In part 3, along with the questionnaire being developed, the Body Image Scale (BIS), the Life Orientation Test-Revised (LOT-R), and the upcoming MSKCC BREAST-Q will be given to determine convergent and discriminant construct validity. No other therapeutic or diagnostic agents will be administered.
62204991|NCT01965353|EXPERIMENTAL|Panobinostat|"Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.~* Bortezomib - subcutaneous injection twice a week during the first two weeks of each 21 day cycle.~* Dexamethasone oral dose on the days of and after bortezomib administration during Cycles 1-8, and on days 1, 8 and 15 for Cycles 9 and beyond.~* Lenalidomide - oral dose once daily on days 1-14 of each cycle. Accrual to the next higher dose level will not occur until the safety and tolerability of the prior dose level(s) has been determined at the end of the first cycle.~Each cycle of treatment will consist of 21 days. Accrual to the next higher dose level will not occur until the safety and tolerability of the prior dose level(s) has been determined at the end of the first cycle"
62204992|NCT06530641|ACTIVE_COMPARATOR|Buckberg|Patients who will be administered Buckberg blood cardioplegia.
62204993|NCT06530641|EXPERIMENTAL|Custodiol|Patients who will be administered Custodiol crystalloid cardioplegia.
62404599|NCT00626067|ACTIVE_COMPARATOR|2 Partially functional monitoring device|Partially functional monitoring device
62404600|NCT00626067|SHAM_COMPARATOR|3 Non-functional monitoring device|Non-functional monitoring device
62734869|NCT02704975|EXPERIMENTAL|Rehabilitation and Dry Needling|Standard Rehabilitation Protocol following shoulder stabilization surgery and Dry Needling to the Shoulder girdle 1 time a week for 4 weeks between weeks 4 and 8 post operatively
62015851|NCT06314581||BPPV|
62015852|NCT04064697|NO_INTERVENTION|Control group|Patient will be treated by vedolizumab the standard of care alone.
62015853|NCT04064697|EXPERIMENTAL|Experimental group|Patient will be treated by vedolizumab the standard of care associated at valganciclovir.
62015854|NCT04685577|EXPERIMENTAL|Nefopam|NEFOPAM 3% cream will be applied topically to healing deep dermal scratches in the lateral hip of burn patients daily (twice) for 3 weeks during the proliferative phase of wound healing.
62015855|NCT04685577|PLACEBO_COMPARATOR|Placebo|This will work as a placebo for the experimental drug.
62015856|NCT02677805|EXPERIMENTAL|Botulinum toxin A|Botulinum Toxin A will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into glabellar area.
62204994|NCT01343862|EXPERIMENTAL|D- Cycloserine|
62204995|NCT01343862|PLACEBO_COMPARATOR|sugar pill|
62404601|NCT00519909|OTHER|1|Diet with high content of calcium and high content of fat
62404602|NCT00519909|OTHER|2|Diet with low content of calcium and high content of fat
62404603|NCT00519909|OTHER|3|Diet with high content of calcium and normal content of fat
62404604|NCT00519909|OTHER|4|Diet with low content of calcium and normal content of fat
62404605|NCT00519909|OTHER|5|Diet with high content of calcium fra supplement and high content of fat
62404606|NCT00761969||PAB|Subjects with stable peripheral arterial disease; ankle-brachial pressure index on at least one leg =\< 0.90.
62404607|NCT00761969||Control|Subjects without peripheral arterial disease (palpable pedal pulses and a normal ankle-brachial pressure index of 0.91-1.30), age- and sex-matched to the stuy group with PAD
62015857|NCT02677805|PLACEBO_COMPARATOR|Placebo|Placebo will be administered in double blind fashion in cycle 1 divided in five 0.1 mL injections into the glabellar area.
62015858|NCT02677805|EXPERIMENTAL|Botulinum toxin A open label extension phase|Open Label Extension Phase for all Subjects of Arm 1 and 2 for up to 3 treatment cycles
62015859|NCT02041455|EXPERIMENTAL|Melatonin and Placebo|Melatonin 10mg and placebo, once in the evening, for 6 weeks.
62204996|NCT02728739|EXPERIMENTAL|Acute Heart Failure Patients|Acute Heart Failure patients with elevated levels of BNP ( \>30pg/ml) will undergo Transthoracic Echocardiogram (TTE) for grading of MR severity within 7 days.
62204997|NCT05197998|EXPERIMENTAL|Color Brave Program|The experimental group will be asked to download and complete a 6-week multi-module mobile app program designed to enhance and encourage critical conversations about race and racism among parents and their young children.
62204998|NCT05197998|OTHER|Wait-list Control|The wait-list control group will be placed on the wait-list for the first 6-weeks, the period in which the experimental group will complete the intervention program. Following the 6-week wait-list period they will receive the color brave program.
62204999|NCT02535936|OTHER|3Tesla MRI with DTI-MRI and rsfcMRI|Patients will receive 2 post-operative MRI's with DTI and rsfcMRI at 2 months and 12 months.
62734870|NCT02704975|ACTIVE_COMPARATOR|Rehabilitation|Standard Rehabilitation Protocol following shoulder stabilization surgery alone
62734871|NCT01519141||HIV-negative controls|HIV-negative individuals
62787853|NCT05830175|EXPERIMENTAL|Spatio-temporal gait analyz (LEGSystm)|The gait performance of the cases was evaluated with a spatio-temporal gait analysis device named LEGSystm developed by BioSensicstm The device is controlled from the computer with its own software and instantly sends the raw data it collects to the computer via Bluetooth.The Modified Get Up and Go Test (MKYT), which is also supported by the legsyst, was used for assesment. The test was repeated 2 times and the average time was recorded. Legsystm provides information on double stride length, duration and speed of walking, as well as standing, turning, sitting times and total time.
62015860|NCT02041455|EXPERIMENTAL|Amitriptyline and placebo|Amitriptyline 25mg and placebo, once in the evening, for 6 weeks.
62015861|NCT02041455|ACTIVE_COMPARATOR|Melatonin and Amitriptylin|Melatonin 10mg and Amitriptylin 25mg, once in the evening, for 6 weeks.
62015862|NCT01306136|EXPERIMENTAL|Prolonged Exposure|
62015863|NCT01306136|ACTIVE_COMPARATOR|Usual care|
62205000|NCT00724165|EXPERIMENTAL|1|
62205001|NCT00724165|ACTIVE_COMPARATOR|2|
62205002|NCT03065075|EXPERIMENTAL|Phenazopyridine|Participant is given Phenazopyridine 200mg on postoperative day 1
62205003|NCT03065075|NO_INTERVENTION|No Phenazopyridine|Participant is not given Phenazopyridine on postoperative day 1
62205004|NCT01453127|EXPERIMENTAL|Alzheimer's Disease|Alzheimer's Disease
62205005|NCT01453127|EXPERIMENTAL|Dementia with Lewy Bodies|Dementia with Lewy Bodies
62205006|NCT01453127|EXPERIMENTAL|Frontotemporal Dementia|Frontotemporal Dementia
62205007|NCT01453127|EXPERIMENTAL|Parkinson's Disease|Parkinson's Disease
62205008|NCT01453127|EXPERIMENTAL|Corticobasal Degeneration|Corticobasal Degeneration
62205009|NCT01453127|EXPERIMENTAL|Essential Tremor|Essential Tremor
62205010|NCT01453127|EXPERIMENTAL|Mild Cognitive Impairment|Mild Cognitive Impairment
62734872|NCT01519141||HIV-infected patients|HIV-infected patients who are on a stable antiretroviral drug regimen for at least a year; all plasma HIV RNA levels within the past year must be below conventional levels of detection (\< 50 copies RNA/mL).
62734873|NCT00578851||C2a Taper recipients|Patients who receive a THA with the C2a - Taper™ Acetabular System
62734874|NCT04387006|EXPERIMENTAL|Osteopatic Manipulative Treatment (OMT)|
62205011|NCT01453127|EXPERIMENTAL|REM sleep behavior disorder|REM sleep behavior disorder
62205012|NCT06150859|EXPERIMENTAL|Experimental: Ayahuasca-assisted constructivist therapy.|Constructivist psychotherapy will be delivered over 9 online psychotherapeutic sessions interconnected in 3 modules to process trauma, restore attachment security and reconstruct the self. One preparation session and two integration sessions after two ayahuasca administrations are included to the experimental group.
62015864|NCT05805280|EXPERIMENTAL|intravascular ultrasound-guided group|In the intravascular ultrasound-guided group, intravascular ultrasound will be either automatically (1 mm/sec) or manually (5-10 mm/sec) pulled back at a constant speed according to the lesion length. Stent size and length are selected by information acquired from on-line intravascular ultrasound examination, and adjunct high-pressure dilation is performed to achieve stent optimization based on the intravascular ultrasound finding
62015865|NCT05805280|ACTIVE_COMPARATOR|angiography-guided group|In the angiography-guided group, stent size and length are chosen by visual estimation, and adjunctive high-pressure dilation is performed if an optimal result, defined as angiographic residual diameter stenosis of less than 30% by visual estimation and the absence of angiographically detected dissection, , was not achieved
62015866|NCT02534090||Feeding Intolerant Preterm Infants|32 weeks to 36 weeks 6 days old of post menstrual age infants, feeding intolerants monitored with INVOS device for rSO2
62015867|NCT02534090||Feeding Tolerant Preterm Infants (Controls)|32 weeks to 36 weeks 6 days old of post menstrual age infants without problems through the enteral feedings.
62015868|NCT01578551|EXPERIMENTAL|Arm A|Paclitaxel, Carboplatin, Bevacizumab, and Metformin. Metformin starting at a dose of 500 mg twice a day, orally with meals. After one week, increase the dose of metformin to 1000 mg as the first dose of the day and 500 mg as the second dose. After another week, increase to 1000 mg of metformin two times a day. Metformin treatment will be initiated one week before beginning chemotherapy, if possible, but chemotherapy will not be delayed for metformin loading.
62015869|NCT01578551|ACTIVE_COMPARATOR|Arm B|Paclitaxel, Carboplatin, and Bevacizumab
62205013|NCT06150859|ACTIVE_COMPARATOR|Constructivist Psychotherapy|"Constructivist Psychotherapy will be delivered over 9 online psychotherapeutic sessions interconnected in 3 modules to process trauma, restore attachment security and reconstruct the self.~Once the follow-up period is over (3 months), participants have the option of receiving 2 administrations of ayahuasca if the severity of grief is high."
62205014|NCT06150859|OTHER|No treatment|"Participants received no treatment during the 9-week Control Period.~Once the follow-up period is over (3 months), participants have the option of receiving 2 administrations of ayahuasca if the severity of grief is high."
62205015|NCT01374568|ACTIVE_COMPARATOR|sitagliptin|Sitagliptin
62205016|NCT01374568|PLACEBO_COMPARATOR|Placebo|Placebo
62734875|NCT04387006|PLACEBO_COMPARATOR|Manual Placebo (MP)|
62734876|NCT03665766||IFN group received Cyclosporine|Living donor liver transplantation recipients with recurrent HCV received Peg IFN-α 2a and RBV as antiviral therapy and Cyclosporine A as primary immunosuppression ,this was routinely taken not as intervention according to local practice
62787854|NCT05830175|EXPERIMENTAL|Portable computerized kinesthetic balance device (SportKAT 550)|The gait performance of the cases was evaluated with a spatio-temporal gait analysis device named LEGSystm developed by BioSensicstm The device is controlled from the computer with its own software and instantly sends the raw data it collects to the computer via Bluetooth.The Modified Get Up and Go Test (MKYT), which is also supported by the legsyst, was used for assesment. The test was repeated 2 times and the average time was recorded. Legsystm provides information on double stride length, duration and speed of walking, as well as standing, turning, sitting times and total time.
62787855|NCT00890110|EXPERIMENTAL|Autologus vaccination with suntinib|Combination of autologous dnp irradiated modified cells with sunitinib treatments
62205017|NCT05956275|ACTIVE_COMPARATOR|adductor canal block and infiltration popliteal artery capsule knee block|Adductor canal block and infiltration popliteal artery capsule knee block were performed accompanied by USG, Bupivacaine and 10 mL of 0.9% NaCl were applied in each block application.
62205018|NCT05956275|SHAM_COMPARATOR|Control|No block performed
62205019|NCT01565278|EXPERIMENTAL|Soybean oil + Fish oil|Intralipid (0.25 g/kg/TPN day) + Omegaven (0.4 g/kg/TPN day) for a period of 6 months.
62205020|NCT01565278|ACTIVE_COMPARATOR|Soybean oil (Standard treatment)|Standard treatment: Intralipid (0.25 g/kg/TPN day) for a period of 6 months
62205021|NCT04663412|EXPERIMENTAL|Patients FIGO IB stage|Vulvar Cancer IB stage
62205022|NCT00324558|EXPERIMENTAL|1|Bemiparin 3,500 IU
62205023|NCT00324558|NO_INTERVENTION|Control|
62205024|NCT00854893|EXPERIMENTAL|anodal|anodal stimulation: 20 min during language learning, intensity: 1 mV, anodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
62205025|NCT00854893|EXPERIMENTAL|cathodal|anodal stimulation: 20 min during language learning, intensity: 1 mV, cathodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
62404608|NCT06038669||People with diabetes|Patients who have diabetes will be asked to use a home collection kit to collect a dried blood spot sample which will be compared to the HbA1C result.
62404609|NCT06038669||Health care professionals|Health care professionals who work with diabetic patients will be interviewed and asked about diabetes monitoring in the healthcare setting, comments on current laboratory service, patient engagement, comments on service improvement
62404610|NCT06318494|EXPERIMENTAL|Patients suffering from ankle instability|
62205026|NCT00854893|EXPERIMENTAL|sham (placebo)|sham stimulation (placebo condition): 30 seconds during language learning, intensity: 1 mV, anodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
62205027|NCT04704583|EXPERIMENTAL|Treatment group (active)|Individuals in this group will start treatment after the initial assessment, without a delay.
62205028|NCT04704583|ACTIVE_COMPARATOR|Wait-list control group|Individuals in this group will start treatment after the initial assessment, with a delay of thirteen weeks.
62205029|NCT00450541||Fatigue Questionnaire + Interview|
62404611|NCT06318494|ACTIVE_COMPARATOR|Healthy volunteer subjects not affected by ankle pathology|
62404612|NCT01639625|EXPERIMENTAL|CIGB300|
62404613|NCT00718627|EXPERIMENTAL|HHLivC Therapy Group|
62787856|NCT05373264|ACTIVE_COMPARATOR|Hydrochlorothiazide|Oral hydrochlorothiazide 25mg, once daily, for a total of 156 weeks
62787857|NCT05373264|PLACEBO_COMPARATOR|Placebo|Matching oral placebo, once daily, for a total of 156 weeks. The placebo is inert.
62787858|NCT01877213|EXPERIMENTAL|Coaching with coordinate care|After discharge from hospital, patients randomized in the coaching group will be coached by a coordinator nurse.
62015870|NCT02515019|NO_INTERVENTION|Group Sevo1.8%|Anaesthesia was maintained with a constant inspired concentration of sevoflurane 1.8% (Sevorane; Abbvie, Wiesbaden, Germany) administered via the ventilator. From the beginning of CPB, a constant flow of sevoflurane 1.8% was administered with the oxygenator fresh-gas supply, using a common anaesthetic vaporiser (Draeger Vapor Version 2000; Draeger, Luebeck, Germany). Following successful weaning from CPB, sevoflurane was again administered at an inspired concentration of 1.8% using the ventilator.
62205030|NCT03647904|EXPERIMENTAL|SEMS Project|A comprehensive modular intervention consisting of wellness, fatigue management, cognitive remediation and psychological treatment. Treatment will consist of a total of 12 weeks.
62205031|NCT03647904|OTHER|Wait List Control|Individuals in the wait list control arm will serve as controls for the first intervention group, but will receive the treatment following their three month assessment. The intervention following the waitlist control will be a comprehensive modular intervention consisting of wellness, fatigue management, cognitive remediation and psychological treatment. Treatment will consist of a total of 12 weeks.
62015871|NCT02515019|EXPERIMENTAL|Bispectral index Monitoring|The sevoflurane concentration via the ventilator and the oxygenator fresh gas supply was titrated to maintain a target BIS value between 40 and 60 (BIS-Monitor, Covidien, Boulder, Colorado, USA). However, the concentration of sevoflurane in the oxygenator fresh gas supply was not reduced below 0.3%.
62015872|NCT03323099|EXPERIMENTAL|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
62205032|NCT03311464|EXPERIMENTAL|Arm A|Participants receiving adalimumab for Pyoderma Gangrenosum active ulcer(s).
62404614|NCT03717220|OTHER|flaps|flap transferring is used for reconstruction of multiple small-to-moderate soft-tissue defects
62205033|NCT02305602|EXPERIMENTAL|Post Myocardial Infarction|VentriGel will be injected via a MyoStar catheter after NOGA mapping in the 60 day to 3 year window since the first STEMI myocardial infarction
62205034|NCT03877497|EXPERIMENTAL|SBIRT-T|The screening, brief intervention and referral to treatment (SBIRT-T) will be adapted and used as the intervention in the experimental arm
62205035|NCT03877497|ACTIVE_COMPARATOR|INFO-C|The INFO-C group is a time-matched comparison control where information will be provided on substance use and PrEP services in a non-SBIRT-T format via printed and audio-visual study material
62404615|NCT06538389|EXPERIMENTAL|Arm I (BRC-001)|Participants will be started on a flexible dosing regimen of BC-001, initiating therapy at 200 mg daily and up-titrated based on tolerability over 2 weeks to a maximum of 800 mg daily. Dose increases are recommended to take place in the evening, beginning the evening dose of Day 2. During the Titration Period, study participants may increase the study agent dose every 2 days by 1 mL total (.5 mL per dose) as tolerated. The increment of increase for BRC-001 is 100 mg per 1.0 mL. Patients receive BRC-001 PO BID for up to 3 months. Patients also undergo blood sample collection on study.
62404616|NCT06538389|PLACEBO_COMPARATOR|Arm II (Placebo)|Placebo will be self-administered with twice daily doses according to the Titration Period schedule for the first two weeks to the highest tolerable dose up to 4 mL twice daily. Patients receive placebo PO BID for up to 3 months. Patients also undergo blood sample collection on study.
62404617|NCT01403636|EXPERIMENTAL|mantle cell|50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
62787859|NCT01877213|NO_INTERVENTION|Usual care|After discharge from hospital, patients randomized in the no intervention group will be managed as usually.
62404618|NCT01403636|EXPERIMENTAL|follicular lymphoma|50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
62404619|NCT01403636|EXPERIMENTAL|CLL/SLL|50 mg twice daily:no eating for 2 hours prior and 1 hour after dose
62404620|NCT01403636|EXPERIMENTAL|Diffuse large B cell lymphoma|50 mg twice daily:no eating for 2 hours prior and 1 hour after dose
62015873|NCT03323099|PLACEBO_COMPARATOR|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
62015874|NCT05759091|EXPERIMENTAL|cognitive defusion interventional group|patients with schizophrenia who suffer from persistent delusions participated in cognitive defusion techniques on individual base through sex sessions twice weekly with homework assignments between sessions and skills demonstration by simulation and psychodrama.
62015875|NCT05759091|NO_INTERVENTION|control group|patients with schizophrenia who suffer from persistent delusions participated in usual routine care in the hospital.
62205036|NCT05113745|EXPERIMENTAL|AXS-12 (reboxetine)|"* Up to 24 weeks in open-label period~* Up to 4 weeks in randomized double-blind period"
62205037|NCT05113745|PLACEBO_COMPARATOR|Placebo|Up to 4 weeks in randomized double-blind period
62205038|NCT05681780|EXPERIMENTAL|TIL+ Nivolumab|Nivolumab infusion every 3 weeks prior to lymphodepletion chemotherapy with cyclophosphamide/fludarabine, TIL infusion and interleukin-2. Then nivolumab infusion every 4 weeks up to 12 months.
62404621|NCT00685074|EXPERIMENTAL|Brief computer-delivered intervention for drug use|A single interactive computer intervention based primarily on Motivational Interviewing principles.
62404622|NCT00685074|PLACEBO_COMPARATOR|Time control for drug use|An series of innocuous and therapeutically inactive computer segments.
62404623|NCT02866721|EXPERIMENTAL|Human Allogeneic Mesenchymal Stem Cells|"One time intravenous (IV) Infusion of up to 5 x 10\^6 allogeneic human mesenchymal stem cells per kilogram of body weight (hMSCs/kg). A dose escalation using the 3+3 design will be employed. The three doses are 1 x 10\^6, 3 x 10\^6, and 5 x 10\^6 hMSCs/kg. There is no placebo group. All study participants will receive stem cells."
62404624|NCT05660135||patients with hypertension and dislipidemia|received olomax tablet as treatment.
62404625|NCT02616107|EXPERIMENTAL|Intervention|Family caregivers of breast cancer patients who consent to participate in the study have a 50/50 chance of being randomized to the intervention group and will receive the booklet, Managing Cancer Care: A Caregiver's Guide (MCC-CG) (N=18)
62404626|NCT02616107|ACTIVE_COMPARATOR|Control|Family caregivers of breast cancer patients who consent to participate in the study have a 50/50 chance of being randomized to the control group and will receive the Symptom Management Toolkit (N=17)
62404627|NCT02160184|EXPERIMENTAL|experimental|Night under closed loop system
62404628|NCT00381680|ACTIVE_COMPARATOR|Regimen A: Standard vincristine dosing|See detailed description.
62015876|NCT02773979|ACTIVE_COMPARATOR|Group 1: PfSPZ 51200 sporozoites/Placebo|Chloroquine (CQ)/PfSPZ Challenge 51200 sporozoites or CQ/normal saline (NS). N=12, randomized 3:1
62015877|NCT02773979|ACTIVE_COMPARATOR|Group 2: PfSPZ 102400 sporozoites/Placebo|CQ/PfSPZ Challenge 102400 sporozoites or CQ/NS. N=4, randomized 3:1
62015878|NCT02773979|ACTIVE_COMPARATOR|Group 3: PfSPZ 102400 sporozoites|CQ/PfSPZ Challenge 102400 sporozoites N=9
62015879|NCT03905759|ACTIVE_COMPARATOR|colchicine|Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
62015880|NCT03905759|ACTIVE_COMPARATOR|Dronedarone|Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
62015881|NCT03905759|ACTIVE_COMPARATOR|amiodarone|amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
62205039|NCT04455620|EXPERIMENTAL|Part 1: BNT151|Monotherapy dose escalation in patients with advanced solid malignancies until the maximum tolerated dose (MTD) and/or RP2D
62205040|NCT00556465|EXPERIMENTAL|A, 1,III|in this arm patients took 1200 mg N-acetylcysteine
62205041|NCT00556465|NO_INTERVENTION|B,2, III|
62205042|NCT01182441|EXPERIMENTAL|WATCHMAN|Subjects assigned to receive the WATCHMAN device.
62205043|NCT01182441|ACTIVE_COMPARATOR|Warfarin|Subjects assigned to warfarin therapy.
62404629|NCT00381680|EXPERIMENTAL|Arm B: Randomized High Dose Vincristine regimen|See detailed description. Closed to accrual as of 09/2010).
62015882|NCT01683591||High-risk aspiration group|Among the consecutive stroke patients, categorized to high-risk group in the patient (1) was not on alert mentality (from drowsy to comatose mentality), (2) was not able to sit upright or control his/her head, and (3) failed to pass indirect water swallow test.
62015883|NCT01683591||Low-risk aspiration group|Patents without oropharyngeal neurologic signs
62015884|NCT01683591||Intermediate-risk aspiration group|If any one of following was positive, categorized to intermediate-risk group; (1) dysarthria, (2) motor aphasia, (3) inability to close and open lips or (4) facial weakness, (5) tongue deviation or (6) uvula deviation, (7) loss of gag reflex, and (8) inability to cough voluntarily.
62015885|NCT02248584|EXPERIMENTAL|Vitamin E, C and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
62015886|NCT02248584|PLACEBO_COMPARATOR|Placebo|Capsule containing only lactose
62015887|NCT01313559|ACTIVE_COMPARATOR|Cohort A (pasireotide)|Patients receive pasireotide IM once every 4 weeks
62404630|NCT04828980|ACTIVE_COMPARATOR|Mindfulness Virtual Reality Experience|Patients will be provided with a mindfulness VR experience for use up to 15 minutes at bedside.
62404631|NCT04828980|ACTIVE_COMPARATOR|Gaming Virtual Reality Experience|Patients will be provided with an active gaming VR experience for use up to 15 minutes at bedside.
62404632|NCT06126185|EXPERIMENTAL|Synbiotic treatment|12-week course of synbiotic
62404633|NCT00739830|EXPERIMENTAL|1|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
62404634|NCT00739830|ACTIVE_COMPARATOR|2|Investigator's choice of: oral medroxyprogesterone acetate tablets 200 mg daily or oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily) OR Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
62015888|NCT01313559|EXPERIMENTAL|Cohort B (pasireotide and everolimus)|Patients receive pasireotide as in cohort A and everolimus PO QD
62015889|NCT06573567|EXPERIMENTAL|Bioimpedance|Use overhydration value obtained by bioimpedance analysis to guide fluid management; the measurements will be obtained once per month
62015890|NCT06573567|PLACEBO_COMPARATOR|Control|Bioimpedance analysis done, but the results will be masked to the participants, care providers and outcome evaluators
62015891|NCT02134145||Self Selected Investors|A self selected crowdfunding backers from teh Scanadu Scout Crowdfunding campaign.
62015892|NCT00403091|EXPERIMENTAL|Intervention|
62015893|NCT00403091|ACTIVE_COMPARATOR|Control|
62205044|NCT06627517|EXPERIMENTAL|Overnight wear of study device|Subjects will wear the study device during sleep in addition to their usual basal/bolus therapy.
62205045|NCT02318459|EXPERIMENTAL|high intensity interval training-HIIT|HIIT 4 times a week, 30 minutes duration
62404635|NCT05242900||At-risk for lymphedema|Participants at-risk for leg lymphedema
62404636|NCT05242900||With lymphedema|Participants with leg lymphedema
62404637|NCT05242900||With lymphedema undergoing complete decongestive therapy (CDT)|Participants with leg lymphedema undergoing routine complete decongestive therapy (CDT)
62015894|NCT02517580|EXPERIMENTAL|Vitamin K2 (MK7)|Vitamin K2 (MK7) 360 mcg/day PO once daily for 8 weeks
62015895|NCT02202135|EXPERIMENTAL|Ceftaroline fosamil|Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
62404638|NCT01211158|ACTIVE_COMPARATOR|Propofol alone|Patients receiving propofol alone.
62404639|NCT01211158|ACTIVE_COMPARATOR|Ketofol|0.375 mg/kg each of ketamine and propofol (mixed in the same syringe) as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
62015896|NCT02202135|ACTIVE_COMPARATOR|Vancomycin plus aztreonam|Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function
62015897|NCT06391827|EXPERIMENTAL|[Single dose] DA-7503|6 subjects in each Cohort(Cohort 1-5)
62015898|NCT06391827|PLACEBO_COMPARATOR|[Single dose] Placebo|2 subjects in each Cohort(Cohort 1-5)
62015899|NCT06391827|EXPERIMENTAL|[Multiple dose] DA-7503|6 subjects in each Cohort(Cohort 1-4)
62015900|NCT06391827|PLACEBO_COMPARATOR|[Multiple dose] Placebo|2 subjects in each Cohort(Cohort 1-4)
62015901|NCT06167447||multiple sclerosis group|Demographic data of all participants were recorded. Tampa Scale of Kinesiophobia (TSK), Beck Depression Inventory (BDI), Quality of Life Scale Short Form-36 (SF-36), International Physical Activity Questionnaire Short Form (IPAQ-SF), Functional Ambulation Classification (FAS), Functional Independence Measure (FIM), Expanded Disability Status Scale (EDSS) were implemented.
62205046|NCT02318459|ACTIVE_COMPARATOR|Traditionnal rehabilitation|Traditionnal group rehabilitation 3 times a week, 1 hour duration.
62205047|NCT06729879|EXPERIMENTAL|yoga eye exercises group|Yoga eye exercises include eight steps. These are; closing the eyes with the palms, blinking, sideways gaze, front and sideways gaze, rotational gaze, up and down gaze, nose tip gaze, and near and far gaze. After the initial evaluation, individuals will be taught how to perform the exercises and brochures describing the exercises will be given to the individuals. It will be applied as a home-based program every day for 8 weeks.
62205048|NCT06729879|ACTIVE_COMPARATOR|myofascial release and postural correction exercises group|"In our study, it is planned to apply 15 minutes of myofascial release. It is planned to apply 15 minutes 3 times a week for 8 weeks.~In our study, exercises for the neck will be applied as posture correction exercises. It will consist of a 20-30 minute program. After the first evaluation, the exercises will be done together and taught to the individuals and an exercise brochure will be given. Postural correction exercises will be done together on the treatment days when myofascial release is applied. On other days, the participant will be asked to do the postural correction exercises at home. Exercise training will be applied face to face 3 times a week for 8 weeks and as a home program on other days."
62404640|NCT03754595|ACTIVE_COMPARATOR|2D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 2D Laparoscopic pancreatoduodenectomy
62205049|NCT06729879|PLACEBO_COMPARATOR|yoga eye exercises and myofascial release-postural correction exercises group,|People in this group will practice yoga eye exercises individually every day for 8 weeks and will be followed up once a week. People will be given brochures for the exercises and postural correction exercises in the yoga eye exercises group. People in this group will receive myofascial release therapy 3 days a week, postural correction exercises will be done together and they will be asked to do postural correction exercises on their own on the remaining days.
62205050|NCT06729879|SHAM_COMPARATOR|Control Group|The control group will not receive any intervention and will receive their first evaluation and final evaluations after 8 weeks.
62205051|NCT06008093|EXPERIMENTAL|Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy|Participants will receive durvalumab plus tremelimumab q3w for four 21-day cycles in combination with chemotherapy followed by maintenance therapy (durvalumab plus pemetrexed maintenance) every 4 weeks (q4w) until disease progression or unacceptable toxicity or treatment discontinuation. During the maintenance therapy phase, participants will receive an additional cycle of durvalumab plus tremelimumab (plus pemetrexed, where applicable) at Week 16.
62205052|NCT06008093|EXPERIMENTAL|Arm B: Pembrolizumab + Platinum-based Chemotherapy|Participants will receive pembrolizumab regimen q3w for four 21-day cycles in combination with chemotherapy followed by maintenance therapy (pembrolizumab plus pemetrexed maintenance) q3w until disease progression or unacceptable toxicity for up to 24 months or treatment discontinuation.
62404641|NCT03754595|EXPERIMENTAL|3D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 3D Laparoscopic pancreatoduodenectomy
62404642|NCT01757795|EXPERIMENTAL|SP-8203|Active arm
62404643|NCT01757795|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62404644|NCT02743182|ACTIVE_COMPARATOR|Pegylated interferon alfa-2a|adding Pegylated interferon alfa-2a (180 microgs /week during 48 weeks) in HBeAg-negative patients receiving nucleos(t)ide analogues
62404645|NCT02743182|NO_INTERVENTION|Control|HBeAg-negative patients receiving nucleos(t)ide analogues
62404646|NCT04647448||Healthy volunteers|Participants with no known cardiovascular disease
62404647|NCT04647448||Chest pain|Patients with symptoms of chest pain, undergoing elective coronary artery CT
62404648|NCT05136482|NO_INTERVENTION|Control|Participants will wear the cryocompression device for 30 mins without any cold or pressure being applied to the lower limb by the cuff.
62015902|NCT06167447||control group|Demographic data of all participants were recorded. Tampa Scale of Kinesiophobia (TSK), Beck Depression Inventory (BDI), Quality of Life Scale Short Form-36 (SF-36), International Physical Activity Questionnaire Short Form (IPAQ-SF), Functional Ambulation Classification (FAS)
62205053|NCT05686798|EXPERIMENTAL|Ad5-yCD/mutTKSR39rep-ADP adenovirus and fSRS Arm|Subjects will receive a single intratumoral injection of the Ad5-yCD/mutTKSR39rep-ADP adenovirus at one of three dose levels beginning at 1 x 1011 vp and escalating in half-log (3-fold) increments to 1 x 1012 vp, along with the same dose of fractionated stereotactic radiosurgery until unacceptable toxicity, disease progression, or withdrawal of consent.
62205054|NCT03610711|EXPERIMENTAL|Arm A Nivolumab Only|stereotactic body radiation (SBRT) 8G x 3 followed by Nivolumab 240mg administered IV over 30 minutes every 2 weeks for one year or until evidence of disease progression or unresolved toxicity.
62205055|NCT03610711|EXPERIMENTAL|Arm B Nivolumab + Relatlimab|stereotactic body radiation (SBRT) 8G x 3 followed by Nivolumab 240mg administered IV over 30 minutes every 2 weeks and Relatlimab (anti-LAG3) every 2 weeks for one year or until evidence of disease progression or unresolved toxicity.
62205056|NCT04469049|EXPERIMENTAL|Mindfulness-based cognitive therapy (MBCT)|All participants will receive the MBCT intervention, consisting of 8 90-minute weekly group sessions.
62205057|NCT00565773|EXPERIMENTAL|Immunosuppressive medications|"Renal transplant recipients will be given an experimental combination of immunosuppressive drugs. Participants will receive a single dose of alemtuzumab on the day of transplantation and will receive belatacept and sirolimus for 1 year.~At the time of transplant, all patients will receive a single dose of 500 mg of methylprednisolone IV over 30 minutes, followed within 1 hour by an IV infusion of 30 mg of alemtuzumab over 3 hours."
62205058|NCT05096481|EXPERIMENTAL|PEP-CMV|Participants will receive standard chemotherapy with temozolomide for five days, followed by the study vaccine, PEP-CMV, on day 21. Participants will receive a tetanus diphtheria (Td) booster vaccine and a small dose Td preconditioning vaccine to prepare their immune system to receive their first PEP-CMV vaccine. Participants will receive the first 3 PEP-CMV vaccines every 2 weeks, and after the third vaccine, the rest of the vaccines will be given monthly. The first cycle is 77 days and all subsequent cycles are 28 days. The PEP-CMV vaccine may be received for up to 24 cycles.
62205059|NCT02136134|EXPERIMENTAL|Daratumumab+VELCADE+dexamethasone|Daratumumab, VELCADE and dexamethasone
62205060|NCT02136134|ACTIVE_COMPARATOR|VELCADE+dexamethasone|VELCADE and dexamethasone.
62205061|NCT03385590|EXPERIMENTAL|Soy-fiber-maize|Complementary food composed of soybean, soy fiber and maize flours.
62205062|NCT03385590|ACTIVE_COMPARATOR|Maize|Complementary food composed of maize flour.
62205063|NCT04177043|OTHER|Screening|
62205064|NCT06729372|ACTIVE_COMPARATOR|Error avoidance training|Participants are instructed to avoid errors during simulation-based training
62205065|NCT06729372|ACTIVE_COMPARATOR|Deliberate flawed training|The participants are instructed to train deliberate errors during simulation-based training
62205066|NCT06451640|EXPERIMENTAL|210mg of TQC2731 injection|210mg of TQC2731 injection combined with Mometasone Furoate Aqueous Nasal Spray, 28days as a treatment cycle.
62205067|NCT06451640|EXPERIMENTAL|420mg of TQC2731 injection|420mg of TQC2731 injection combined with Mometasone Furoate Aqueous Nasal Spray, 28days as a treatment cycle.
62205068|NCT04498637||Physiotherapy students|Students enrolled in the Physiotherapy Bachelor´s Degree of the University of Cadiz, Spain
62205069|NCT04498637||Nursing students|Students enrolled in the Nursing Bachelor´s Degree of the University of Cadiz, Spain
62205070|NCT04955249|EXPERIMENTAL|Dexmedetomidine group|Patients in this group receive dexmedetomidine-supplemented patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of dexmedetomidine (1 microgram/ml) and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
62205071|NCT04955249|PLACEBO_COMPARATOR|Control group|Patients in this group receive routine patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of placebo and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
62205072|NCT05434702||Young adult cancer survivors|Adolescent and young adult cancer survivors
62205073|NCT04848389|EXPERIMENTAL|Skin adhesive|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed by applying skin adhesive. A drying time of 25 seconds is necessary to obtain a satisfactory seal.
62205074|NCT04848389|OTHER|Standard suture|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed with the same thread with a subcutaneous stitch.
62205075|NCT05578274|EXPERIMENTAL|SBRT+LDRT|In the experimental group, stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT) are administered concurrently. SBRT is administered three times, at intervals of 1-2 days, with LDRT. LDRT is planned to irradiate EQD2 6 Gy considering the scattered dose caused by SBRT.
62205076|NCT05578274|ACTIVE_COMPARATOR|SBRT alone|In the control group, stereotactic body radiotherapy (SBRT) alone is performed. SBRT is administered three times, at intervals of 1-2 days. The scattered dose should not exceed EQD2 2Gy to the non-irradiated lesion.
62205077|NCT01951352|EXPERIMENTAL|Soap recipient|The forearms of all subjects will eventually be washed with the same soaps. There is only one arm for this study.
62205078|NCT02244970|EXPERIMENTAL|Mindfulness|Subjects are scheduled to receive a 7-week group mindfulness-based intervention (MBI) program.
62787860|NCT04903054|EXPERIMENTAL|Lulizumab + SOC|"N=27 participants will receive a loading dose of lulizumab on Day 0, the day of surgery. This will be followed by a maintenance dose administered on a weekly basis (weeks 1 through 26 post-transplant), followed by administration every two weeks (weeks 28 through 52 post-transplant). Method of administration: subcutaneously. Dose unit of measure: milligrams (mgs).~Plus (+) Standard of Care (SOC) Regimen, per protocol-~Renal transplant recipients will receive FDA-approved, immunosuppressive medications according to standard of care at Emory Transplant Center:~* Induction Thymoglobulin: Administered intravenously, dose unit of measure: mgs.~* Induction Methylprednisolone: Administered intravenously, dose unit of measure: mgs.~* Maintenance: Mycophenolate mofetil (MMF) administered by mouth twice daily, dose unit of measure: mgs.~* Maintenance: Beginning the day after methylprednisolone is completed, prednisone will be administered by mouth daily, dose unit of measure: mgs."
62205079|NCT02244970|ACTIVE_COMPARATOR|Psychoeducation|Subjects will receive 7 weeks of group-based psychoeducation as an active comparison group parallel to the mindfulness group.
62787861|NCT04903054|ACTIVE_COMPARATOR|Tacrolimus + SOC|"N=27 participants will receive tacrolimus initiated according to local standard of care and adjusted over time (maintenance) to target optimal trough levels measured in ng/mL: 0 to 6 months, 7 to 12 months and, thereafter, until completion of study participation. Dose unit of measure: mg/kg.~Plus (+) Standard of Care (SOC) Regimen, per protocol-~Renal transplant recipients will receive FDA-approved, immunosuppressive medications according to standard of care at Emory Transplant Center:~* Induction Thymoglobulin: Administered intravenously, dose unit of measure: mgs.~* Induction Methylprednisolone: Administered intravenously, dose unit of measure: mgs.~* Maintenance: Mycophenolate mofetil (MMF) administered by mouth twice daily, dose unit of measure: mgs.~* Maintenance: Beginning the day after methylprednisolone is completed, prednisone will be administered by mouth daily, dose unit of measure: mgs."
62787862|NCT02434042|ACTIVE_COMPARATOR|BB536|Bifidobacterium longum BB536 (9 log CFU/day) and dextrin
62787863|NCT02434042|PLACEBO_COMPARATOR|Placebo|100% dextrin
62015903|NCT03009110|EXPERIMENTAL|Prophylactic NPWT|Women assigned to prophylactic NPWT will have the Prevena device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4, but longer for up to 7 days for patients who remain hospitalized.
62205080|NCT02858453|EXPERIMENTAL|AQX-1125 100 mg|2 tablets, by mouth, once per day for 12 weeks; followed by a 52-week Extension Period
62205081|NCT02858453|EXPERIMENTAL|AQX-1125 200 mg|2 tablets, by mouth, once per day for 12 weeks; followed by a 52-week Extension Period
62205082|NCT02858453|PLACEBO_COMPARATOR|Placebo|2 placebo tablets, by mouth, once per day for 12 weeks; followed by randomization to 100 mg or 200 mg AQX-1125 for a 52-week Extension Period
62205083|NCT00254826|OTHER|YF-VAX® plus saline|Drug: YF-VAX® plus saline
62205084|NCT00254826|EXPERIMENTAL|17D YF Vaccine plus Ig|Drug: 17D YF Vaccine plus Ig; one vaccine on day 0
62205085|NCT05781191||Employees|
62205086|NCT04199624|EXPERIMENTAL|Experimental: omeprazole and ascorbic acid|
62205087|NCT04701346|EXPERIMENTAL|Low SAA diet|Dietary intervention
62205088|NCT04701346|ACTIVE_COMPARATOR|High SAA diet|Dietary intervention
62205089|NCT03293459|EXPERIMENTAL|Shunt Occlusion +SMT|Shunt Occlusion +SMT
62205090|NCT03293459|ACTIVE_COMPARATOR|Standard Medical Treatment (SMT)|
62205091|NCT04974333|EXPERIMENTAL|Mobile health application|"Participants assigned to the intervention group will use a mobile application on their smart phones that will assist the patients with their diabetes control, provide and update information on their clinical history, offer a monitoring their nutritional and physical activity habits as well as anthropometric measurements, provide recommendations how to improve on nutritional habits and physical activity behavior, assist in planning and reminding on clinical appointments.~The duration of the intervention will be 12 months. Each patient will be invited to follow-up visits and measurements each three months (month 3, month 6, month 9 and month 12)."
62787864|NCT03232866|EXPERIMENTAL|Experimental group|(n = 20) will practice Pilates exercises
62787865|NCT03232866|NO_INTERVENTION|Control group|(n = 20) will not carry out the intervention
62787866|NCT06180239||Single Segmentectomy group|patients underwent single segment resection,
62205092|NCT04974333|NO_INTERVENTION|Standard care|Participants assigned to the control arm will continue their regular standard diabetes care without mobile health technology assistance.
62205093|NCT02585323|ACTIVE_COMPARATOR|Immediate Intervention Group|Education session, Fitbit/FitViz, PT counselling: Participants receive this intervention in Months 1-3. The session will include a presentation on physical activity, an individual goal-setting session with a registered physiotherapist, and an orientation to the Fitbit Flex and the FitViz app. In Months 1 and 2, participants will use the Fitbit/FitViz. The PT will review the progress with participants via 20-minute bi-weekly phone calls, and progressively modify their activities. In Month 3, participants will continue using the Fitbit/FitViz and have access to a PT via email as needed, but no bi-weekly phone calls. In Months 4-9, participants may continue using the Fitbit/FitViz without access to a PT.
62205094|NCT02585323|PLACEBO_COMPARATOR|Delayed Intervention Group|Same intervention with a 3 month delay: The full intervention will be initiated in Month 4 and with a brief education session, use of a Fitbit Flex paired with the FitViz app, and counseling by a physiotherapist. In Months 6-9, participants will continue using Fitbit/FitViz without the PT phone calls.
62205095|NCT03917056|EXPERIMENTAL|Long needle group|Participants were treated with CAES using long needle.
62787867|NCT06180239||Lobectomy group|Patients underwent lobectomy
62787868|NCT06180239||Multiple segmentectomy group|patients underwent multiple segments resection,
62015904|NCT03009110|ACTIVE_COMPARATOR|Standard Dressing|Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
62015905|NCT03892824|EXPERIMENTAL|Vine™ Filter + OAC|Vine™ Filter in each common carotid artery (CCA) with oral anticoagulant treatment (either vitamin K antagonist (VKA) or novel oral anticoagulant (NOAC)) for the duration of the study
62205096|NCT03917056|EXPERIMENTAL|Short needle group|Participants were treated with CAES using short needle.
62580707|NCT00582816|EXPERIMENTAL|1|patients will undergo a standard pre-transplant evaluation, but will also have blood drawn to evaluate their HLA class I killer immunoglobulin-like receptor (KIR) ligand typing. Parents will undergo KIR genotyping and phenotyping, and a donor will be selected based on which parent shows the greatest degree of KIR receptor-ligand mismatching. Once the donor has been selected he/she will undergo a peripheral blood stem cell (PBSC) collection utilizing G-CSF and GM-CSF for stem cell mobilization. The PBSC collection will be performed utilizing standard procedures. The PBSC will then be processed in the UW BMT Laboratory in order to deplete the graft of T cells. This will be accomplished using the CliniMACS cell separation system. T cell depletion is a standard procedure for patients receiving haploidentical stem cell grafts. The resulting stem cell product will be analyzed for T cell, stem cell and NK cell content.
62580708|NCT05438108|EXPERIMENTAL|SBRT sequential chemotherapy, bevacizumab and sitilimab|
62205097|NCT02387190|EXPERIMENTAL|Telenursing monitoring|The protocol for telenursing allows the realization of standardized professional contacts with the patient and educational approach It is possible through questions and answers coded, that indicate the need for educational intervention or reinforcement of appropriate health behavior.1) Contact the patient by telephone, weekly; 2) Distribution and explanation of the educational booklet; 3) Filling a diary of symptoms and signs; 4) Record, management and markdown visits in case of non-elective visits, hospitalization or fatal episodes. Also, the following aspects shall be observed: help requests associated with illness, adaptations for living with the disease, effects of drugs in daily life, availability of financial resources for disease management, self-image; emotional and social support.
62205098|NCT02387190|NO_INTERVENTION|Control group|Placebo is considered as standardized education
62205099|NCT03698253|EXPERIMENTAL|Regorafenib plus FOLFIRI|"Regimen for treatment consists of irinotecan (180 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA6/TA6) and UGT1A1 genotyping (TA6/TA7); 120 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA7/TA7)), followedby Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After every 2 cycles of each different dose of irinotecan, if adverse events (AEs) are under the grade 2, we will escalate the dose of 30 mg/m2. The estimated maximal dose of irinotecan is 260 mg/m2 for UGT1A1 genotyping (TA6/TA6); 240 mg/m2 for UGT1A1 genotyping (TA6/TA7); 180 mg/m2 for UGT1A1 genotyping (TA7/TA7).~Regorafenib is administered at adjusted doseage of 120 mg daily for 3 weeks in a 4-week cycle."
62205100|NCT04909398|EXPERIMENTAL|Dynamic pupillometry sessions|"It is planned to include 60 participants divided into different groups:~* 15 healthy subjects, called controls.~* 15 patients with retinitis pigmentosa.~* 15 patients with Leber's hereditary optic neuropathy.~* 15 patients with Stargardt's disease."
62205101|NCT05189223|OTHER|Open Pilot|In Phase 2, all Veterans will receive the active treatment.
62205102|NCT05189223|EXPERIMENTAL|Active Condition|In Phase 3 (Pilot RCT), half of Veterans will be randomly assigned to the active treatment.
62205103|NCT05189223|ACTIVE_COMPARATOR|Treatment as Usual|In Phase 3 (Pilot RCT), half of Veterans will be randomly assigned to treatment as usual.
62205104|NCT02394626|EXPERIMENTAL|Surgery followed by adjuvant second-line therapy|Surgery followed by adjuvant second-line therapy
62205105|NCT02394626|ACTIVE_COMPARATOR|Second-line therapy alone|Second-line therapy alone
62205106|NCT05141500|EXPERIMENTAL|Healthy adult participants|All participants are enrolled in the test group and receive the noninvasive adhesive reprocessed pulse oximeter sensors
62205107|NCT04004156|EXPERIMENTAL|Nucleus Replacement|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
62205108|NCT04659564|OTHER|Breast-cancer related lymphedema (BCRL)|
62205109|NCT05133973|EXPERIMENTAL|Cohort A|"Subjects will wear 3 FiberSense systems (2x arm and 1x abdomen) and one comparator. The subjects will participate in six clinic in-house sessions on Day 00, 3x between days 01-07, on Days 21 and 28. There will be safety visit at Day 14.~Finger pricking at home use will be intensified during days 00-07."
62205110|NCT05133973|EXPERIMENTAL|Cohort B|"Subjects will wear 3 FiberSense systems (2x arm and 1x abdomen) and one comparator. The subjects will participate in six clinic in-house sessions on Day 00, 4x between days 07-14 and on Day 28. There will be safety visit at Day 21.~Finger pricking at home use will be intensified during days 07-14."
62015906|NCT03711123|EXPERIMENTAL|Group metacognitive therapy (GMCT)|10 weekly sessions of GMCT With 90 minutes duration
62015907|NCT03711123|ACTIVE_COMPARATOR|Clinical Management|10 weekly individual sessions with up to 60 minutes duration
62205111|NCT06518083||one group of patients with septic shock admitted to the ICU|The patients with septic shock admitted to the ICU will be observed for occurrence of cardiac events and their relation to triglyceride-glucose index and procalcitonin
62205112|NCT04161729|ACTIVE_COMPARATOR|Magnesium sulfate|Magnesium sulfate 20 mg/kg intravenous over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
62205113|NCT04161729|PLACEBO_COMPARATOR|Isotonic solution 0.9%|Isotonic solution 0.9% in the same volume as the study drug using identical pattern of administration.
62205114|NCT04723238|EXPERIMENTAL|Duloxetine Test Product|Participants will receive one capsule of the test formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a fasting condition.
62580709|NCT06294366|ACTIVE_COMPARATOR|Bipolar enucleation|Bipolar enucleation of the prostate larger than 60 gm
62580710|NCT06294366|ACTIVE_COMPARATOR|Bipolar TURP|Bipolar transurethral resection of the prostate larger than 60 gm
62580711|NCT02275260|EXPERIMENTAL|All patients|All patients undergo cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI), Transesophageal (or Intracardial) Echocardiography and paperbased neurocognitive testing
62580712|NCT01911338|EXPERIMENTAL|Real Time Feedback|Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
62015908|NCT01711086|ACTIVE_COMPARATOR|Inspiromatic followed by Aerolizer|volunteers will perform lung function pre and post Formoterol (a bronchodilator) inhalation. They will use either the Inspiromatic dry powder inhalers the delivery device. 3-60 days later participants will receive the same drug through the Aerolizer dry powder inhaler.
62015909|NCT01711086|ACTIVE_COMPARATOR|Aerolizer followed by Inspiromatic|volunteers will perform lung function pre and post Formoterol (a bronchodilator) inhalation. They will use either the Aerolizer dry powder inhalers the delivery device. 3-60 days later participants will receive the same drug through the Inspiromatic dry powder inhaler.
62015910|NCT02522897|ACTIVE_COMPARATOR|Ranibizumab|"Patients receive intravitreal injections of 0,5 mg Ranibizumab (Lucentis®) / injection following the treat-and-extend scheme for 12 months."
62015911|NCT02522897|EXPERIMENTAL|Ranibizumab + Laser|"Apart from receiving intravitreal injections of 0,5 mg Ranibizumab (Lucentis®) / injection following the treat-and-extend scheme for 12 months, patients receive a panretinal photocoagulation on visit 3 and / or 4."
62015912|NCT03264625|EXPERIMENTAL|Treatment group|Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
62205115|NCT04723238|ACTIVE_COMPARATOR|Duloxetine Referent Product|Participants will receive one capsule of the marketed reference formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a fasting condition.
62580713|NCT01911338|ACTIVE_COMPARATOR|Tradicional Learning Method|Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8
62404649|NCT05136482|EXPERIMENTAL|Condition A|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 6℃ and a pressure of 25 mmHg is applied to the lower limb by the cuff.
62580714|NCT04360135|EXPERIMENTAL|Preemptive acetominophen|Acetaminophen 975mg BID the day before surgery and again 30-60 minutes preoperatively
62580715|NCT04360135|PLACEBO_COMPARATOR|Standard of care|Placebo the day before surgery and acetaminophen 30-60 minutes preoperatively
62787869|NCT04800146||Cohort 1|patients with solid tumors treated with chemotherapy (ongoing or completed no more than 6 months before enrollment). Specific type of chemotherapy inducing similar immunosuppression will be selected (including but not limited to platinum-based combinations, anthracycline combinations, triweekly docetaxel).
62787870|NCT04800146||Cohort 2|patients with solid tumors treated with single agent immune-check points inhibitors (ongoing or completed no more than 6 months before the enrollment
62787871|NCT04800146||Cohort 3|patients with solid tumors treated with hormonal agents (ongoing or completed no more than 6 months before enrollment): any anti-androgen for prostate cancer and any anti-estrogen for breast cancer patients.
62787872|NCT04800146||Cohort 4|patients with previously untreated mature B cell tumors in watch and wait
62404650|NCT05136482|EXPERIMENTAL|Condition B|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 8℃ and a pressure of 25 mmHg is applied to the lower limb by the cuff.
62404651|NCT05136482|EXPERIMENTAL|Condition C|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 10℃ and a pressure of 25 mmHg is applied to the lower limb by the cuff.
62404652|NCT05136482|EXPERIMENTAL|Condition D|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 12℃ and a pressure of 25 mmHg is applied to the lower limb by the cuff.
62580716|NCT01011465|EXPERIMENTAL|Oxytocin|One primary experimental manipulation is the receipt of intranasal oxytocin vs placebo spray prior to participation in a psychosocial stress protocol
62015913|NCT03264625|PLACEBO_COMPARATOR|Control group|Patients randomized to the placebo group will receive routine therapy for PD.
62015914|NCT05658081|EXPERIMENTAL|Kono-S group|patients in this arm will receive stapled Kono-S anastomosis after bowel resection
62015915|NCT05658081|OTHER|Side-to-side group|patients in this arm will receive stapled antimesenteric isoperistaltic side-to-side anastomosis after bowel resection
62205116|NCT02949362|EXPERIMENTAL|Standard of Care (SOC) Treatment +/- Teduglutide|TED 0.05mg/kg subcutaneous injections once daily as needed in addition to SOC treatment
62205117|NCT01325753|EXPERIMENTAL|Treatment (cryoablation)|Patients undergo CT-guided CA.
62404653|NCT06484816|EXPERIMENTAL|Experimental: TGRX-1942|Patients will be given one of the doses of 4mg, 10mg, 20mg, 30mg, 40mg, 50mg, or 60mg orally once a day
62404654|NCT04420559|EXPERIMENTAL|Virtual Reality|
62404655|NCT04420559|EXPERIMENTAL|Distraction Card|
62404656|NCT04420559|NO_INTERVENTION|Control|
62404657|NCT04383652||Adult cohort|"1. Diagnosed with SARS-CoV-2 infection (COVID-19; by a registered diagnostic facility)~2. Age 16 years or older~3. Have provided informed consent~Blood samples and clinical data related to COVID19 diagnosis, symptoms, and outcomes will be collected."
62787873|NCT04800146||Cohort 5|patients with mature B cell tumors treated with anti-CD20 monoclonal antibody either alone or in combination with chemotherapy (ongoing or completed no more than 12 months before enrollment
62205118|NCT04441177|EXPERIMENTAL|Study group|Participants in the study group receive conventional rehabilitation therapy over 50 minutes on weekdays and 7 sessions (flexible schedule in different day) of PlayStation®VR of 20 minutes each in the main 16-day study period.
62205119|NCT04441177|NO_INTERVENTION|Control group|Participants in the control group receive conventional rehabilitation therapy over 50 minutes on weekdays.
62404658|NCT04383652||Paediatric cohort|"1. Diagnosed with SARS-CoV-2 infection (COVID-19; by a registered diagnostic facility)~2. Age less than 16 years~3. Parent or caregiver has provided informed consent Blood samples and clinical data related to COVID19 diagnosis, symptoms, and outcomes will be collected."
62404659|NCT06592924|ACTIVE_COMPARATOR|Standard ADT + ARPI|
62404660|NCT06592924|EXPERIMENTAL|Docetaxel + Standard ADT + ARPI|
62404661|NCT01898390|EXPERIMENTAL|Transplant|Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
62404662|NCT01898390|NO_INTERVENTION|Control|comparison group of controls, will receive the same observational and scanning assessments but will not receive any surgical procedures
62205120|NCT01892540|EXPERIMENTAL|Cohort 1: Standard positioning device|Patients undergo clinical FDG-PET/CT followed by prone breast PET/CT and/or prone breast PET/MRI with or without DTPA.
62404663|NCT03433482|EXPERIMENTAL|GSK3536820A ACWY_Liq24 Group|Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1.
62404664|NCT03433482|ACTIVE_COMPARATOR|ACWY_1 Group|Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.
62404665|NCT03433482|EXPERIMENTAL|GSK3536820A ACWY_Liq30 Group|Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.
62580717|NCT01011465|PLACEBO_COMPARATOR|Placebo|The comparison condition for receipt of oxytocin is receipt of a saline intranasal spray
62580718|NCT01011465|EXPERIMENTAL|Social Support|Participants bring a friend to the laboratory who sits with them while they engage in the stress protocol tasks
62580719|NCT01011465|PLACEBO_COMPARATOR|No Social Support|Individuals in this condition do not have a friend present while they are engaging in the laboratory protocol.
62580720|NCT01011465|OTHER|Female Gender|Effects of oxytocin and social support are examined among women versus men
62205121|NCT01892540|EXPERIMENTAL|Cohort 2: New positioning device|
62205122|NCT01892540|EXPERIMENTAL|Cohort 3: Current positioning device until new is available|
62205123|NCT04969068|EXPERIMENTAL|The median effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg|The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size).The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement)'
62205124|NCT02290808|EXPERIMENTAL|Theory-based group|The theory-based intervention group will receive strategies based on the Theory of Planned Behaviour to help increase physical activity among couples. Parents will receive materials on how to work together.
62205125|NCT02290808|NO_INTERVENTION|Information group|The information group will serve as the control group and will receive informational materials on the benefits of physical activity.
62205126|NCT00531219||1|Group #1 NOTES Appendectomy - Transgastric approach
62205127|NCT00531219||2|Group #2 NOTES Cholecystectomy - Transgastric approach
62205128|NCT00831662|PLACEBO_COMPARATOR|Arm 2|
62404666|NCT03433482|ACTIVE_COMPARATOR|ACWY_2 Group|Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.
62404667|NCT05669378|EXPERIMENTAL|Intervention group|The experimental group will receive the Appetite to Play + intervention which is a capacity-building intervention that support childcare providers in implementing the best practices for active play. It includes a 3 e-learning online modules and then the are supported with weekly . bi-weekly emails.
62404668|NCT05669378|OTHER|Standard of care waitlist control|The standard of care waitlist control group will receive the intervention at 3-months post-randomization. The standard of care group has access to the Appetite to Play materials which are available to everyone. The site includes resources that childcare providers can use.
62404669|NCT00482664|EXPERIMENTAL|1 mg|
62404670|NCT00482664|EXPERIMENTAL|10 mg|
62404671|NCT00482664|EXPERIMENTAL|3 mg|
62580721|NCT01011465|OTHER|Male Gender|Consider effects of oxytocin and social support in men versus women
62404672|NCT00482664|PLACEBO_COMPARATOR|Placebo|
62404673|NCT05893524||Patients undergoing memory assessments|Patients undergoing memory assessments at two specialist memory clinics (Uppsala University Hospital in Uppsala and Falu Hospital in Falun). This group includes patients with dementia, mild cognitive impairment and subjective cognitive impairment.
62404674|NCT05893524||Cognitively unimpaired community dwelling people|Age matched cognitively unimpaired community dwelling people recruited via advertisements.
62205129|NCT00831662|EXPERIMENTAL|Arm 1|
62205130|NCT02175641|EXPERIMENTAL|Peer-led Group Lifestyle Balance|Group-based behavioral healthy lifestyle program
62205131|NCT02175641|ACTIVE_COMPARATOR|Usual Care Services|Usual wellness and health care services offered to clients at the two supportive housing agencies.
62205132|NCT05111353|EXPERIMENTAL|Arm 1: Vaccine given after neoadjuvant chemotherapy and surgery|"* The neoantigen peptide vaccine will be manufactured during neoadjuvant chemotherapy. Institutional standard of care chemotherapy will be given.~* Peptide and poly-ICLC will be administered intramuscularly on Days 1, 4, 8, 15, 22, 50, and 78 beginning approximately 1 month after surgery. Day 1 should begin approximately 1 month after surgery."
62205133|NCT05111353|EXPERIMENTAL|Arm 2: Vaccine given after neoadjuvant chemotherapy but before surgery|"* The neoantigen peptide vaccine will be manufactured during neoadjuvant chemotherapy. Institutional standard of care chemotherapy will be given.~* Peptide and poly-ICLC will be administered intramuscularly on Days 1, 4, 8, 15, and 22 during the chemotherapy holiday, and Days 50 and 78 post-operatively. Optimal timing for Day 1 is 1 week after end of chemotherapy, but Day 1 may be given up to 3 weeks after end of chemotherapy."
62404675|NCT05893524||Cognitively unimpaired community dwelling people recruited for test-retest reliability analysis|Cognitively unimpaired individuals who agreed to participate in a retesting session.
62015916|NCT04693663|OTHER|ReLex Smile surgery|Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was between -0.75D till -5.50D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(Viscot-Medster).
62015917|NCT06574334|EXPERIMENTAL|The study group received proprioceptive exercises|- The study group included education about definition, components and benefits of proprioceptive exercises for geriatric patients with knee osteoarthritis in the first week. Also, was including proprioceptive exercises that included; One-leg balance, Toe walking, Heel walking, Cross-body leg swings, Blind advanced one leg balance and instructed them to do these 5 exercises (15-20 repetitions of each) per session, 5 day a week.
62015918|NCT06574334|EXPERIMENTAL|the control group received routine exercise (Isometric exercise).|the control group included education about definition, benefits and steps of isometric exercise that included participants taking the long sitting position. A role of towel was placed below the affected knee. The participants were then asked to press the towel down and hold it to one minute and then relax. This was repeated again for the other knee and (10-15 repetitions) per session, 5 day a week.
62015919|NCT05613634|EXPERIMENTAL|Study group|The study group received rTMS in addition to the vestibular physical therapy exercises
62015920|NCT05613634|EXPERIMENTAL|Control group|Patients in control group received the vestibular physical therapy exercises, three sessions a week for four weeks
62015921|NCT03204942|ACTIVE_COMPARATOR|PRF on DRG|Patients will receive Pulsed Radiofrequency (PRF) on Dorsal root ganglion(DRG) of the selected metastatic painful dorsal vertebrae, with temperature 42°C for 480 sec.,2 active cycles per second of 20 milliseconds each , with a voltage output 40 to 60-V range, impedance ranges between 150 and 400 Ohms at all levels using Fluroscopic guidance (FG).
62015922|NCT03204942|ACTIVE_COMPARATOR|TRF on DRG|Patients will receive Thermal Radiofrequency (TRF) on Dorsal root ganglion(DRG) of the selected metastatic painful dorsal vertebrae, with temperature 80°C for 90 sec.,2 cycles, using Fluoroscopic guidance (FG) .
62205134|NCT00575653||11-18 (Primary)|Enrolled members of one of the participating health plans who are ages 11-18 at any time during the study period, March 1, 2005 through August 31, 2008.
62404676|NCT05893524||Persons with cognitive impairment recruited for test-retest reliability analysis|Patients undergoing memory assessment at Uppsala University Hospital who agreed to participate in a retesting session and community dwelling older persons with self-reported subjective or mild cognitive impairment. This group includes patients with dementia, mild cognitive impairment and subjective cognitive impairment.
62015923|NCT03204942|ACTIVE_COMPARATOR|Control group|The control group will have identical needle placement and preparation like the 2 previous groups without the RF lesion, but with the injection of particulate Betamethasone steroids and local anesthetic on DRG of the selected metastatic painful dorsal vertebrae, using Fluoroscopic guidance (FG).
62015924|NCT05323305|ACTIVE_COMPARATOR|Pectointercostal Group (n=30)|They will receive ultrasound-guided pectointercostal fascial block after induction of anesthesia with equal dose before extubation in the intensive care.
62015925|NCT05323305|ACTIVE_COMPARATOR|Transversus thoracic Group (n=30)|They will receive ultrasound-guided ultrasound-guided transversus thoracic plane block after induction of anesthesia with equal dose before extubation in the intensive care.
62205135|NCT00575653||19-21 (Secondary)|Enrolled members of one of the participating health plans who are ages 19-21 at any time during the study period, March 1, 2005 through August 31, 2008.
62404677|NCT01420770|EXPERIMENTAL|SAR02503 300 mg qd|daily X 28 days
62404678|NCT01420770|EXPERIMENTAL|SAR302503 400 mg qd|daily X 28 days
62015926|NCT06401681|EXPERIMENTAL|Balance training (BAL)|Within one day of baseline testing, BAL will begin a progressive balance training protocol on the involved limb. The balance training program consists of three 20-minute sessions per week for eight weeks. Post-test assessments for BAL will completed within one week of completing the 8-week training interval.
62015927|NCT06401681|NO_INTERVENTION|Control (CON)|After baseline testing, CON will be instructed to continue their normal daily routine. They will not participate in the balance training intervention.
62015928|NCT02488044|EXPERIMENTAL|AEB1102|"AEB1102, modified human Arginase I administered IV Part 1 Each patient may receive up to 7 doses given up to every other week over a maximum of 14 weeks.~Part 2 Each patient will receive up to 8 weeks of repeat-dose therapy."
62205136|NCT01696903|NO_INTERVENTION|Conventional anastomosis|"Conventional anastomosis: The pancreaticojejunostomy is carried out in a traditional way according to Cattell's duct-to-mucosa technique."
62205137|NCT01696903|ACTIVE_COMPARATOR|Novel anastomosis|Novel anastomosis: This the active comparator to the conventional anastomosis. A new pancreaticojejunostomy technique is used for the reconstruction. The pancreas is intubated into the jejunum.
62404679|NCT01420770|EXPERIMENTAL|SAR302503 500 mg qd|daily X 28 days
62404680|NCT01966458|EXPERIMENTAL|HeartWare® VAS (HVAD)|Implant of HeartWare® Ventricular Assist System
62205138|NCT01612598|EXPERIMENTAL|Supportive Care (PCI)|"PCI PART I: Patients undergo comprehensive PC assessment based on baseline data and complete goals of care discussion.~PCI PART II: Following the first dose of phase I investigational treatment, patients meet with the IDT, where PC recommendations are made. This is followed by two patient educational sessions that will cover QOL-related domains, including physical, social, emotional, and spiritual well-being. Supportive care referrals are made based on IDT recommendations."
62404681|NCT01966458|ACTIVE_COMPARATOR|Control LVAD|Implant of FDA-approved LVAD approved for destination therapy
62404682|NCT00795886|EXPERIMENTAL|All participants|
62734877|NCT03665766||IFN group received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received Peg IFN-α 2a and RBV as antiviral therapy and Tacrolimus as primary immunosuppression ,this was routinely taken not as interventing according to local practice
62205139|NCT02186600|ACTIVE_COMPARATOR|Control|Women randomized to the control group will receive calcium and vitamin D intake for 12 months. Calcium intake will be determined by analyzing 3 day dietary intake of calcium at baseline and then prescribing calcium carbonate supplements to ensure women have \~1200 mg of calcium daily. Vitamin D intake will be determined using baseline measures of Serum 25 (OH) D. Subjects who have serum D levels of 30 ng/ml or greater will be prescribed 1,000 IU vitamin D3 daily; subjects with levels of 20-29 ng/ml will be prescribed 2,000 IU Vitamin D3; and subjects with levels of 10-19 ng/ml will be prescribed 3,000 IU Vitamin D3.
62205140|NCT02186600|EXPERIMENTAL|Risedronate|"Subjects in the risedronate group will take 35 mg of the bisphosphonate risedronate weekly for 12 months plus CaD. They will be asked to follow the protocol for administration of risedronate including taking the medication upon arising in the morning with an 8 ounce glass of water, remaining upright for at least 30 minutes, and having no oral intake except water for at least 30 minutes."
62205141|NCT02186600|EXPERIMENTAL|Exercise|Subjects in the exercise group will participate in bone-loading exercises three times weekly in addition to taking CaD for 12 months. Women will exercise at community Young Men's Christian Association's fitness centers (YMCA) and exercises will be monitored by on-site Exercise Trainers. Exercises will consist of high-impact weight-bearing exercises (jogging with weighted vests) and resistance exercises for upper and lower extremities. Progressive increases in weight loads will be prescribed to provide maximal strength gains.
62205142|NCT06125145|EXPERIMENTAL|Feasibility Arm|All enrolled participants will receive the pilot Geriatric Assessment and Promotora Coaching intervention.
62205143|NCT02936726|ACTIVE_COMPARATOR|Exercise and Health Coaching|"Walking exercise protocol program, carried out by themselves, over 12 weeks.~Health Coach addresses various topics with participant, half-hour sessions on a weekly (12 sessions)"
62205144|NCT02936726|EXPERIMENTAL|Exercise, Health Coaching and Meditation|"Walking exercise protocol program, carried out by themselves, over 12 weeks.~Health Coach addresses various topics with participant, half-hour sessions on a weekly (12 sessions)~Mindfulness Meditation intervention will incorporate varied types of MBI techniques 3 times per week for 12 weeks, during work hours and/or during their time on campus (after work hours)."
62205145|NCT03301441||Migrainers|Patients experiencing an acute brain infarction complicating the occlusion of the internal carotid artery or the first or second segment of the middle cerebral artery. Migraine status determined by the validated French short questionnaire ef-ID Migraine (Classification into migraine without or with aura)
62205146|NCT03301441||Non migrainers|Patients experiencing an acute brain infarction complicating the occlusion of the internal carotid artery or the first or second segment of the middle cerebral artery. Migraine status determined by the validated French short questionnaire ef-ID Migraine A short questionnaire validating the absence of migraine
62205147|NCT01298557||Traumatic brain injured patients|This group consists of participants who suffered a traumatic brain injury an average of 4 months to 4 years prior to testing. Patients must not have history of prior head injury, substance abuse, psychiatric illness, or contraindications to MRI.
62205148|NCT01298557||Controls (no traumatic brain injury)|This group consists of participants who do not have a history of brain trauma. Furthermore, controls must not suffer from substance abuse, psychiatric illness, or have contraindications to the MRI.
62404683|NCT01530776|EXPERIMENTAL|Healthy Lifestyle Group|Participants randomized to this condition will receive information and strategies to help them eat healthier and be more active during and after pregnancy. They will get this information about eating and activity through handouts, text messages, Facebook updates, and in-person visits and phone calls from a health coach.
62404684|NCT01530776|NO_INTERVENTION|Usual Care|This condition is meant to represent standard clinical care provided to pregnant and postpartum mothers at Temple University.
62404685|NCT00938015||PsA Patients (New)|New patients
62404686|NCT00938015||PsA Patients|CU patients
62404687|NCT00939861|EXPERIMENTAL|1|laparoscopy
62404688|NCT00939861|EXPERIMENTAL|2|laparotomy
62015929|NCT04955938|EXPERIMENTAL|Arm A - Participants with IDH1 Mutations|"After genetic testing, if participants are found to have IDH1 Mutations (a genetic mutation) then they will be assigned to this group and will receive the following study drugs:~Single agent Phase (Cycles 1-3):~The initial phase of treatment will consist of 3 cycles (lasting 28 days) of ivosidenib 500mg daily x 28 days~Combination Phase (Cycle 4 onwards):~If a participant shows clinical benefit (including their disease stabilizing) following the first 3- cycle phase, he or she may go onto the combination phase. Combination treatment will consist of ivosidenib daily x 28 days along with fedratinib daily x 28 days."
62015930|NCT04955938|EXPERIMENTAL|Arm B - Participants with IDH2 Mutations|"After genetic testing, if participants are found to have IDH2 Mutations (a genetic mutation) then they will be assigned to this group and will receive the following study drugs:~Single agent Phase (Cycles 1-3):~The initial phase of treatment will consist of 3 cycles (lasting 28 days) of enasidenib 100mg daily x 28 days~Combination Phase (Cycle 4 onwards):~If a participant shows clinical benefit (including their disease stabilizing) following the first 3- cycle phase, he or she may go onto the combination phase.Combination treatment will consist of enasidenib 100mg daily x 28 days along with fedratinib daily x 28 days."
62015931|NCT05935826|ACTIVE_COMPARATOR|Amino Acid Supplement|Participants are blindly randomized and for this arm, participants will take the Essential Amino Acid Supplement for 2-months, followed by an open label extension period of 10-months of Essential Amino Acid for all participants
62015932|NCT05935826|PLACEBO_COMPARATOR|Placebo|Participants are blindly randomized and for this arm, participants will take the Placebo for 2-months, followed by an open label extension period of 10-months of Essential Amino Acid for all participants
62205149|NCT02562443|EXPERIMENTAL|rigosertib + best supportive care (BSC)|
62205150|NCT02562443|ACTIVE_COMPARATOR|Physician's Choice (PC) + best supportive care (BSC)|
62205151|NCT03266926||Postoperative Patients with premarin|Patients who undergo vaginal surgery at Sunnybrook Health Sciences Centre (SHSC) who require vaginal packing postoperatively and receive premarin vaginal cream coated packing.
62205152|NCT03266926||Postoperative Patients with bupivacaine|Patients who undergo vaginal surgery at Patients who undergo vaginal surgery (SHSC) who require vaginal packing postoperatively and receive bupivacaine soaked packing.
62205153|NCT00678431|PLACEBO_COMPARATOR|Arm 1|Liquid placebo
62205154|NCT00678431|EXPERIMENTAL|Arm 2|Liquid Resveratrol with Glucose, and Malate
62205155|NCT03460808|EXPERIMENTAL|atorvastatin, acetylcysteine & danazol|atorvastatin 20mg qd po plus acetylcysteine 400mg tid po plus danazol 200mg bid po for 12 weeks
62205156|NCT05102877|EXPERIMENTAL|Sensory level stimulation|ten, 45-minute anterior neck sensory level electrical stimulation sessions in addition to traditional dysphagia therapy.
62205157|NCT05102877|EXPERIMENTAL|Motor level stimulation|ten, 45-minute anterior neck sensory level electrical stimulation sessions in addition to traditional dysphagia therapy.
62734878|NCT03665766||Sof plus Rbv group received Cyclosporine|Living donor liver transplantation recipients with recurrent HCV received sofosbuvir and RBV as antiviral therapy and Cyclosporine as primary immunosuppression,this was routinely taken not as intervention according to local practice
62015933|NCT03881241||Study Treatment|EVOS SMALL PLating System
62015934|NCT06573658|EXPERIMENTAL|Perturbation-based balance training group|This group will receive two sessions of treadmill walking at their comfortable speed involving perturbations
62205158|NCT02906436|EXPERIMENTAL|ExVivo lung reconditioning|
62205159|NCT05277168|EXPERIMENTAL|Single Arm|Single Arm : SHR-A1904
62205160|NCT05049577|PLACEBO_COMPARATOR|Control group|To maintain blinding, in the control group, the remifentanil infusion was replaced with 50 ml of normal saline in 50 ml syringe. The remifentanil (or saline) infusion was run until the pump indicated the target Ce had been achieved. Pharmacokinetic model for remifentanil was the Minto model (Height, Weight, and Age) Anesthesia in all patients was induced using 2 mg/kg of 2% propofol. The attending anesthesiologist asked the patients how they felt pain to evaluate pain severity of PIP while half -dose of propofol was administered. After the rest of the propofol was administered, the attending anesthesiologists asked the same question.
62205161|NCT05049577|EXPERIMENTAL|Remifentanil group|Remifentanil 1 mg was diluted into 50 ml of normal saline. A commercial TCI pump (Orchestra Base Primea, Fresenius Vial, France) was used for the effect-site TCI of remifentanil. The study groups received remifentanil to a target Ce of 4 ng/ ml. Pharmacokinetic model for remifentanil was the Minto model (Height, Weight, and Age) Anesthesia induction and the evaluation of pain were same as control group
62404689|NCT01711736|EXPERIMENTAL|GSK2282512A Group|"Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.~Quadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects \< 12 months of age) or the deltoid muscle (subjects ≥ 12 months of age)."
62404690|NCT01711736|ACTIVE_COMPARATOR|Fluarix Group|"Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.~Fluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects \< 12 months of age) or the deltoid muscle (subjects ≥ 12 months of age)."
62404691|NCT02826005|EXPERIMENTAL|cirrhotic patients|if positive for 3 bio-markers- will be followed by MRI for HCC diagnosis
62205162|NCT03453853|EXPERIMENTAL|Mitral Loop Cerclage|Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device
62205163|NCT00130325|ACTIVE_COMPARATOR|A|Isoniazid arm
62205164|NCT00130325|PLACEBO_COMPARATOR|B|Placebo of Isoniazid tablet 300mg
62205165|NCT04218032||blood pressure|blood pressure is measured from the participants, by using two methods. A new developed device and a reference device. The new device measures, using oscillometry, the blood pressure from the finger tip. The reference device is a standard sphygmomanometer.
62205166|NCT06176976|NO_INTERVENTION|Thyroidectomy without lugols solution preparation|euthyroid patients undergoing total thyroidectomy for toxic thyroid disease, no preoperative preparation with 5% lugols solution
62205167|NCT06176976|EXPERIMENTAL|Thyroidectomy with lugols solution preparation|euthyroid patients undergoing total thyroidectomy for toxic thyroid disease, preoperative preparation with 5% lugols solution for 10 days
62205168|NCT00972660|ACTIVE_COMPARATOR|Control group|"Patients with newly diagnosed extensive cGVHD receive prednisone and cyclosporine or tacrolimus.~Patients with refractory extensive cGVHD receive primary treatment (eg,prednisone and cyclosporine or tacrolimus, or plus mycophenolate mofetil, or methotrexate.)"
62205169|NCT00972660|EXPERIMENTAL|Mesenchymal stem cell (MSC)|"Patients with newly diagnosed extensive cGVHD receive MSC plus prednisone and cyclosporine or tacrolimus.~Patients with refractory extensive cGVHD receive MSC plus their primary immunosuppressive treatment (eg. prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate.)"
62205170|NCT00522821|OTHER|Antibiotics|"A: co-trimoxazole prophylactically for 12 months followed by intravenous immunoglobulin treatment for 12 months.~Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given."
62205171|NCT00522821|OTHER|intravenous immunoglobulins|"B: intravenous immunoglobulin treatment for 12 months followed by co-trimoxazole prophylactically for 12 months.~Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given."
62205172|NCT04588805||Colorectal Cancer Patients|
62205173|NCT02248818|EXPERIMENTAL|AZD8108|Subjects will participate in 1 of 7 groups and receive single or multiple doses of AZD8108 or matching placebo. In each group 6 subjects will receive AZD8108
62205174|NCT02248818|PLACEBO_COMPARATOR|Placebo to match AZD8108|Subjects will participate in 1 of 7 groups and receive single or multiple doses of AZD8108 or matching placebo. In each group 2 subjects will receive matching placebo
62205175|NCT02225119||Affected|Participants with macular disease
62205176|NCT02225119||Unaffected|Healthy volunteers
62205177|NCT03098563|EXPERIMENTAL|Arm 1|Blinded study medication. This is a within-subject study so all session procedures will be identical. The specific medications administered that study day will be the only change each session. Study days will last approximately 8 hours and will be conducted on an outpatient basis. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
62404692|NCT02826005|NO_INTERVENTION|non cirrhotic patients|control group - 3 bio-markers will be measured only
62404693|NCT01740297|EXPERIMENTAL|Phase 1b: Talimogene Laherparepvec + Ipilimumab|Participants received talimogene laherparepvec at an initial dose of 10⁶ plaque-forming units (PFU)/mL injected into 1 or more skin, nodal, or subcutaneous tumors. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until complete response (CR), all injectable tumors had disappeared, confirmed disease progression per the modified immune-related response criteria (irRC), or intolerance of study treatment, whichever occurred first. Participants also received 3 mg/kg ipilimumab administered intravenously every 3 weeks for a total of 4 infusions starting at the time of the third dose of talimogene laherparepvec (week 6).
62015935|NCT06573658|ACTIVE_COMPARATOR|Active control|This group will receive two sessions of treadmill walking at their comfortable speed involving no perturbations
62015936|NCT00821626|ACTIVE_COMPARATOR|Rapid test|Returning travelers with fever will have a rapid flu test
62015937|NCT00821626|SHAM_COMPARATOR|Comparator|Returning travelers with fever will benefit of the usual medical care, without rapid flu test
62015938|NCT02490813|PLACEBO_COMPARATOR|Control|This arm will receive the placebo.
62015939|NCT02490813|EXPERIMENTAL|Treatment - Chinese Herbal Formula - X|This arm will receive the Chinese Herbal Formula - CHFX as treatment to their existing fish, shrimp or crab allergy.
62015940|NCT02709070|ACTIVE_COMPARATOR|resection|Resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. The investigators performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
62015941|NCT02709070|EXPERIMENTAL|highly-purified CTL|Peripheral blood (20-30mL) for manufacturing the individualized highly-purified CTL agent was collected from the respective participants who were randomized to the immunotherapy group before starting treatment. The highly-purified CTL agent was prepared at a central manufacturing facility. Participants in the immunotherapy group received a number up to 5×10E9 of the highly-purified CTL agent intravenously over 60 minutes without any premedication and then were observed for at least 30 minutes. Participants were scheduled to receive highly-purified CTL: 4-6 treatments at a frequency of once two-week during 6 months after receiving resection, followed by 6-9 treatments during 6 months to 2 years after receiving resection.
62015942|NCT06664398|ACTIVE_COMPARATOR|1HIIT group|
62015943|NCT06664398|ACTIVE_COMPARATOR|4HIIT group|
62205178|NCT03098563|EXPERIMENTAL|Arm 2|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
62205179|NCT03098563|EXPERIMENTAL|Arm 3|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
62015944|NCT06664398|NO_INTERVENTION|Control group|
62015945|NCT05746338|EXPERIMENTAL|Ring-type wearable device|The ring-type wearable device achieved continuous monitoring of blood oxygen saturation during sleep and established a OSAS screening algorithm based on oxygen saturation, which might become a complement to polysomnography.
62015946|NCT05746338|ACTIVE_COMPARATOR|Polysomnography|Overnight polysomnography (PSG) monitor was used as the gold standard to: 1) examine the accuracy of blood oxygen monitoring assessed via a ring-type wearable device in comparison to traditional finger clip pulse oximeter; 2) assess the agreement between the ring-type wearable device and PSG monitor on OSAS screening.
62015947|NCT01060384|EXPERIMENTAL|Phase 1/Phase II|All participants will receive the same dose of Ofatumumab. There will be three planned dose cohorts for the Lenalidomide in the Phase 1 portion of this trial. A maximum of 18 patients will be enrolled in to Phase 1. Three evaluable patients will be enrolled in to each of the dose cohorts with an additional 3 patients to be enrolled in the maximum tolerated dose (MTD). An additional 29 evaluable patients will be enrolled in to Phase II using the MTD for Lenalidomide that was determined in Phase 1.
62015948|NCT05251233|PLACEBO_COMPARATOR|Placebo|-Visually equivalent placebo once daily from postoperative day 1 and continued for 10 doses or until the day of discharge (whichever is earlier).
62015949|NCT05251233|ACTIVE_COMPARATOR|Proton pump inhibitor|-Pantoprazole once daily from postoperative day 1 and continued for 10 doses or until the day of discharge (whichever is earlier).
62015950|NCT01135979||Arterio-venous fistulae creation|
62015951|NCT01412424|EXPERIMENTAL|Octreotide capsules|Participants received octreotide capsules orally twice a day for up to 13 months. Dosing started at 40 mg per day (20 in the morning + 20 in the evening) and increased to 60 mg per day (40 in the morning + 20 in the evening) or 80 mg per day (40 in the morning + 40 in the evening) if there was inadequate IGF-1 suppression.
62015952|NCT04055129||Birth Control|Hormone levels controlled with subject on birth control pill
62015953|NCT04055129||Non-Birth Control|Hormone (estrogen) levels not controlled but monitored for levels of estrogen at two points in menstrual cycle (Follicular and ovulatory phases)
62015954|NCT05337501|EXPERIMENTAL|Patients group|
62205180|NCT03098563|EXPERIMENTAL|Arm 4|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
62205181|NCT01942200||Carcinoma, Oxaliplatin onkovis (Oxaliplatin)|Treatment in combination therapy for adjuvant treatment of colon carcinoma of stage III (Dukes C) after complete removal of the primary tumor, as well as for treatment of metastasizing colorectal carcinoma.
62205182|NCT01281839|EXPERIMENTAL|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
62015955|NCT05383677|ACTIVE_COMPARATOR|Anifrolumab|20 patients will receive anifrolumab treatment
62015956|NCT05383677|PLACEBO_COMPARATOR|Placebo|10 patients will receive placebo treatment
62015957|NCT03783351|NO_INTERVENTION|Conventional Therapy|Patients randomized to the Conventional Therapy arm will receive either clopidogrel or ticagrelor, according to the clinical and procedural characteristics of patients. CYP2C19 genotyping will be performed at the end of study.
62015958|NCT03783351|ACTIVE_COMPARATOR|CYP2C19 Genotyping|CYP2C19 genotyping will be performed within 48 hours after randomization. CYP2C19 \*2 or \*3 reduced function allele patients will receive ticagrelor 90 mg bid, whereas non-\*2 or -\*3 CYP2C19 patients will receive clopidogrel 75 mg once daily.
62015959|NCT00913159|ACTIVE_COMPARATOR|Using HM3 lithotripter|This is an older generation lithotripter
62015960|NCT00913159|ACTIVE_COMPARATOR|F2 lithotripter|This is a newer generation lithotripter
62015961|NCT03313362|EXPERIMENTAL|Subjects admitted to Epilepsy Monitoring Units in the VAMC|Subjects being monitored by standard of care, video EEG, in the Epilepsy Monitoring Units in the VAMC will all be placed on a Seizure Monitoring and Alerting System (SPEAC System).
62205183|NCT01281839|PLACEBO_COMPARATOR|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
62205184|NCT02523703|OTHER|Healthy Volunteers|Healthy Volunteers
62015962|NCT03767491|EXPERIMENTAL|Smartphone-delivered CBT for OCD|12-week Smartphone delivered CBT for OCD.
62205185|NCT02523703|OTHER|Multiple Sclerosis patient|Multiple Sclerosis patient
62205186|NCT01982305|EXPERIMENTAL|Simulator|One training session with the simulator.
62734879|NCT03665766||Sof plus Rbv received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received sofosbuvir and RBV as antiviral therapy and Tacrolimus as primary immunosuppression,this was routinely taken not as intervention according to local practice
62015963|NCT03767491|OTHER|12 Week Waitlist Control|12-week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for OCD following the 12-week waitlist control).
62015964|NCT04274738|EXPERIMENTAL|Mavorixafor and Ibrutinib|Each participants will initially receive mavorixafor at Dose Level 1 (200 mg QD) in combination with ibrutinib 420 mg. Cohort A will comprise the first 6 participants enrolled in the study that complete at least their first cycle at Dose Level 2 (400 mg QD). Cohort A participants will start at Dose Level 1 and be allowed to dose escalate after the first cycle to Dose Level 2, if no DLTs are observed during the first cycle of each participant. Cohort B will comprise the next 6 participants enrolled into the study that complete at least their 1st cycle at Dose Level 3 (600 mg QD). Cohort B participants will start at Dose Level 1 and be allowed to dose escalate up to Dose Levels 2 and 3. Cohort C will comprise the remainder of participants enrolled up to the total of 18. Cohort C participants will start at Dose Level 1 and be allowed to escalate to 400 and 600 mg after each dose level has been deemed safe by participants from Cohort A and B.
62015965|NCT04257877||Diabetes type 1|Patients= diabetes type1
62015966|NCT04257877||Healthy participants|Healthy participants = Control group
62015967|NCT02864017|EXPERIMENTAL|L-Citrulline group|Enteral nutrition 5-day L-citrulline treatment (10 grams/day)
62015968|NCT02864017|PLACEBO_COMPARATOR|Control group|Enteral nutrition 5-day placebo treatment
62015969|NCT04136938||Intervention group (social marketing campaign)|People aged 60 and over will be included. They will receive a social marketing campaign.
62015970|NCT04136938||Control group|People aged 60 and over will be included.
62205187|NCT01982305|ACTIVE_COMPARATOR|Cadaver|One training session with a cadaver.
62205188|NCT05826873|OTHER|Pediatric Hospitalists|Prescribing physicians and hospital employees will be recruited during regularly held staff meetings prior to the data collection period. The study team will briefly introduce the study aims and methods and let the hospitalists know that the study team will be emailing them separately to ask permission for Dr. Szymczak to shadow them. Only those who have agreed will participate in the ethnographic observations. For the interviews and surveys, the study team will recruit respondents via contact made during ethnographic observations. The study team will also utilize a snowball approach by asking respondents if they know of any other staff who might be interested in participating in an interview. Approximately 120 clinicians will participate in the interviews and surveys.
62205189|NCT05826873|NO_INTERVENTION|Families of hospitalized children|Families of children who were hospitalized at one of the four participating sites will be approached for consent to participate in the study. Families who consent will complete 2 brief REDCap surveys and a wellness tracker after their child is discharged from the hospital.
62205190|NCT04790656|ACTIVE_COMPARATOR|Conventional Therapy|The control program will consist of progressive exercises according to each postoperative day. Two daily sessions with an average duration of 25 min will be performed. In addition to the physiotherapeutic program standardized by the hospital's team of physical therapists, the intervention group will perform physical exercise on a cycle ergometer with CPAP.
62205191|NCT04790656|EXPERIMENTAL|Cycle ergometer combine with CPAP|Physical exercise on a cycle ergometer combine with CPAP will be performed in a single daily session from the second to the fourth postoperative days
62205192|NCT00449618|ACTIVE_COMPARATOR|1|Aspirin 100 mg on awakening
62205193|NCT00449618|ACTIVE_COMPARATOR|2|Aspirin 100 mg at bedtime
62205194|NCT00449618|PLACEBO_COMPARATOR|3|Placebo on awakening
62205195|NCT00449618|PLACEBO_COMPARATOR|4|Placebo at bedtime
62205196|NCT00835653||1|patients with a carpal tunnel syndrome
62205197|NCT00835653||2|patients without a carpal tunnel syndrome
62404694|NCT01740297|ACTIVE_COMPARATOR|Phase 2: Ipilimumab|Participants received ipilimumab 3 mg/kg intravenously every 3 weeks for a total of 4 infusions starting at week 1.
62404695|NCT01740297|EXPERIMENTAL|Phase 2: Talimogene Laherparepvec + Ipilimumab|Participants received talimogene laherparepvec at an initial dose of 10⁶ PFU/mL injected into 1 or more skin, nodal, or subcutaneous tumors. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until CR, all injectable tumors had disappeared, confirmed disease progression per the modified irRC, or intolerance of study treatment, whichever occurred first. Participants also received 3 mg/kg ipilimumab intravenously every 3 weeks for a total of 4 infusions starting at the time of the third dose of talimogene laherparepvec (week 6).
62787874|NCT04800146||Cohort 6|patients with hematological malignancies treated with pathway inhibitors (ongoing or completed no more than 12 months before enrollment). Different type of targeted agents can be considered, including Bruton tyrosine kinase (BTK) inhibitors, B-cell lymphoma 2 (BCL-2) inhibitors or phosphoinositide-3 kinase (PI3K) inhibitors
62787875|NCT04800146||Cohort 7|patients with hematological malignancies who have received autologous stem cell or allogenic transplant within 12 months
62787876|NCT04800146||Cohort 8|non-cancer subjects (age and gender matched) referred to the Division of Infectious Diseases, Lugano, EOC for vaccination against SARS-CoV-2.
62787877|NCT03842241||WIth foot orthoses|Device: Non-custom made foot orthoses
62205198|NCT02193126|EXPERIMENTAL|Treatment|
62205199|NCT02193126|NO_INTERVENTION|Comparison|
62205200|NCT04517097||patient group|patients treated in the french anti-cancer center of the study
62205201|NCT04517097||salaried staff group|all salaried staff of the french anti-cancer center of the study
62205202|NCT02783027|EXPERIMENTAL|SleepTrackTXT2|Participants will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). Participants in the experimental group that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
62205203|NCT02783027|NO_INTERVENTION|Text-Message Assessments Only|Participants in the non-intervention group/arm will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). The inter-shift assessments will query the participant about his/her sleep hours, fatigue, sleepiness, and difficulty with concentration. No intervention messages sent to this group/arm.
62205204|NCT03843853|EXPERIMENTAL|Pemetrexed + S-1 + Bevacizumab|Pemetrexed 500 mg/m2 d1+ S-1 (20mg、25mg), capsule, 40\~60mg, Bid,p.o, d1\~14 + Bevacizumab 7.5 mg/kg d1; Repeated every 3 weeks
62205205|NCT01305239||Postmenopausal ER+ patients treated by Aromasin.|
62205206|NCT00324116|EXPERIMENTAL|Active|
62404696|NCT02513732||XIENCE Xpedition 2.25 mm stent arm|Patients receiving XIENCE Xpedition 2.25 mm stent
62404697|NCT00478218|EXPERIMENTAL|Lenalidomide/Cyclophosphamide/Dexamethasone|
62404698|NCT01441622|EXPERIMENTAL|AL539|Device AL539
62404699|NCT01510340|NO_INTERVENTION|Web sites|Patients assigned to this arm are given a list of Web sites where they can collect information related to their condition at their leisure.
62404700|NCT01510340|EXPERIMENTAL|VIH-TAVIE|Patients assigned to this arm must follow the four interactive computer sessions
62787878|NCT03842241||Without foot orthoses|Other: without foot orthoses
62787879|NCT01610336|EXPERIMENTAL|INC280 100 mg Cap QD Phase Ib|cap=capsule; QD=once daily
62787880|NCT01610336|EXPERIMENTAL|INC280 200 mg Cap QD Phase Ib|cap=capsule; QD=once daily
62787881|NCT01610336|EXPERIMENTAL|INC280 400 mg Cap QD Phase Ib|cap=capsule; QD=once daily
62787882|NCT01610336|EXPERIMENTAL|INC280 800 mg Cap QD Phase Ib|cap=capsule; QD=once daily
62205207|NCT05179070|EXPERIMENTAL|UpTitration|the first is the rapid up-titration group, which will get carvedilol up-titration every day, 3.125mg twice daily on the first day, 6.125mg twice daily on the second day, 12.5mg twice daily on the third day and 25mg twice daily on the fourth day consecutively
62787883|NCT01610336|EXPERIMENTAL|INC280 200 mg Cap BID Phase Ib|cap=capsule; BID=twice daily
62015971|NCT02875119|EXPERIMENTAL|Griffithsin Gel|In the randomized period, duration of treatment will be 14 days; each of the 30 subjects will self-administer Griffithsin Gel once daily for 14 consecutive days, with 5 doses administered under clinical supervision and the remaining 9 doses administered at home.
62015972|NCT02875119|PLACEBO_COMPARATOR|Placebo Gel|In the randomized period, duration of treatment will be 14 days; each of the 30 subjects will self-administer placebo gel once daily for 14 consecutive days, with 5 doses administered under clinical supervision and the remaining 9 doses administered at home.
62015973|NCT01840592|EXPERIMENTAL|Sorafenib plus Doxorubicin|Doxorubicin 60 mg/m2 IV on Day 1 of each 3 weeks cycle until unacceptable toxicity Sorafenib 400 mg PO BID or last dose patient from previous sorafenib based therapy, until unacceptable toxicity or disease progression, after which sorafenib can be continued as a single agent.
62205208|NCT05179070|ACTIVE_COMPARATOR|Control|And the second group will have carvedilol titration according to established guidelines on Heart Failure, start 3.125mg twice daily, and up titrated every 2 weeks
62205209|NCT04393870|EXPERIMENTAL|Maryam's Flower Group|Maryam's flower was placed in a bowl of water and left in the room of the pregnant women who were at 1 cm cervical dilatation and in the first phase of the labor. It was explained to the pregnant women that the leaves of the plant would open up in the water, and they were asked to imagine that the birth canal would simultaneously open up. In effect, they were told to focus on the opening of these leaves during the course of the labor
62205210|NCT04393870|NO_INTERVENTION|Control Group|All the pregnant women, those in the control group, were provided with standard midwifery care.
62404701|NCT04020822|EXPERIMENTAL|Subjects Wearing Guardian Sensor (3)s|Each subject will wear 4 Guardian Sensor (3)s connected to a Guardian Link (3) Transmitter and/or Guardian Connect Transmitter for 11 days of sensor wear.
62787884|NCT01610336|EXPERIMENTAL|INC280 400 mg Cap BID Phase Ib|cap=capsule; BID=twice daily
62787885|NCT01610336|EXPERIMENTAL|INC280 600 mg Cap BID Phase Ib|cap=capsule; BID=twice daily
62015974|NCT05464628|EXPERIMENTAL|Atorvastatin and ASC42|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin.
62015975|NCT02104557||prevention of pregnancy|Non intervention
62015976|NCT02104557||management of endometriosis-associated pain|Non intervention
62015977|NCT00539526|EXPERIMENTAL|1|bimatoprost 0.03%
62015978|NCT00539526|ACTIVE_COMPARATOR|2|travoprost 0.004%
62015979|NCT00539526|ACTIVE_COMPARATOR|3|latanoprost 0.005%
62015980|NCT00829621|ACTIVE_COMPARATOR|75 mmHg suction|IVAC suction 75 mmHg
62205211|NCT06395025|EXPERIMENTAL|One medical device as investigational device|
62205212|NCT06395025|NO_INTERVENTION|control group|
62205213|NCT01834872|EXPERIMENTAL|Amigo|Ablation completed with Amigo
62404702|NCT01278823|EXPERIMENTAL|surgery|Surgery: laparoscopic roux en y gastric bypass operation
62787886|NCT01610336|EXPERIMENTAL|INC280 200 mg Tab BID Phase Ib|tab=tablet; BID=twice daily
62787887|NCT01610336|EXPERIMENTAL|INC280 400 mg Tab BID Phase Ib|tab=tablet; BID=twice daily
62787888|NCT01610336|EXPERIMENTAL|INC280 400 mg Cap BID Phase II|cap=capsule; BID=twice daily
62015981|NCT00829621|EXPERIMENTAL|125 mmHg suction|IVAC suction 125 mmHg
62015982|NCT03495908|EXPERIMENTAL|VGo with Regular Human Insulin|U-100 short-acting insulin, Regular, human insulin rDNA origin, including Humulin® R, Novolin® R, and ReliOn (Novolin R) delivered by V-Go
62015983|NCT03495908|ACTIVE_COMPARATOR|VGo with Rapid Acting Insulin|U-100 fast-acting insulin including Humalog® (insulin lispro, rDNA origin) or NovoLog® (insulin aspart, rDNA origin), which have both been tested by Valeritas, Inc. and found to be safe for use in the V-Go or Apidra® (insulin glulisine, rDNA origin) delivered by V-Go
62015984|NCT05898087|EXPERIMENTAL|Study Group 1 - Intervention|Participants in this group will receive 20cc of subpectoral bupivacaine injected into the fascia
62015985|NCT05898087|PLACEBO_COMPARATOR|Study Group 2 - Control|Participants in this group will receive 20cc of subpectoral saline injected into the fascia
62015986|NCT00129259|EXPERIMENTAL|Anti-CD3 mAb Plus Diabetes Standard of Care Treatment|"Subjects receive 1.) a 14-day course of anti-CD3 monoclonal antibody (mAb) intravenously (IV) comprised of daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 days of 826 µg/m2 \[Cycle 1\] and, when eligible per protocol, receipt of a second 14-day course after a 12-month interval (at month 13)\[Cycle 2\]. Note: Prior to May 2007, the course of IV daily doses of anti-CD3 mAb were: 57 µg/m2, 115 µg/m2, 230 µg/m2, 460 µg/m2, and 10 days of 919 µg/m2 and, when eligible per protocol, a second course after a 12-month interval (at month 13). 2.) and intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.~Iron supplementation initiated status post treatment randomization."
62205214|NCT01834872|ACTIVE_COMPARATOR|Manual|Ablation completed with manual catheter
62205215|NCT00582413||1|Patients who have been diagnosed with Carcinoma of the oral cavity
62015987|NCT00129259|ACTIVE_COMPARATOR|Diabetes Standard of Care Treatment|"Subjects receive intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.~Iron supplementation initiated status post treatment randomization."
62015988|NCT05372484|EXPERIMENTAL|Multi-Modal Optical Imaging|Multi-modal imaging (mobile colposcopy and high resolution imaging) of study participants will be performed during the colposcopy examination. Cervical biopsies will be performed using biopsy forceps per standard protocols.
62015989|NCT01259986|EXPERIMENTAL|Laser treatment|
62205216|NCT04906629|EXPERIMENTAL|INO-4201|One intradermal injection of INO-4201 followed by electroporation
62205217|NCT04906629|PLACEBO_COMPARATOR|Placebo|One intradermal injection of normal saline followed by electroporation
62015990|NCT02200042|EXPERIMENTAL|Radiation therapy|Liver-directed radiation therapy
62015991|NCT02200042|NO_INTERVENTION|Observation|No radiation therapy
62015992|NCT03494010||prospective cohort|Patients will be followed to determine the impact of the hybrid closed-loop (HCL) system that was prescribed at part of clinical care.
62205218|NCT03298477|OTHER|Single Arm|Single Arm Safety and Effectiveness Confirmatory Study of EVAS using the Nellix® System
62205219|NCT00527358|EXPERIMENTAL|SAFER|"The intervention community will receive 4 services:~1. community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;~2. youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, and provide education about avoiding violence;~3. school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;~4. Youth drop-in center: will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training."
62205220|NCT00527358|NO_INTERVENTION|2|Business as usual.
62205221|NCT00853944|NO_INTERVENTION|P|subjects take 1 tablet of placebo daily
62205222|NCT00853944|EXPERIMENTAL|S|subjects take 1 tablet of sitagliptin 100 mg daily
62787889|NCT01610336|EXPERIMENTAL|INC280 400 mg Tab BID Phase II|tab=tablet; BID=twice daily
62787890|NCT04602442|EXPERIMENTAL|EXO-1|Participants (n=30) in this group will receive standard therapy and exosomes of the first type.
62787891|NCT04602442|EXPERIMENTAL|EXO-2|Participants (n=30) in this group will receive standard therapy and exosomes of the second type.
62205223|NCT02509832|OTHER|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after PCI.
62404703|NCT01278823|ACTIVE_COMPARATOR|Medical treatment|Medical Treatment: Comprehensive medical management of diabetes including medications, diet intervention, lifestyle modification, exercise regimen
62404704|NCT03417245|EXPERIMENTAL|Factor On-demand|Participants received on-demand factor concentrates (as needed, for episodic bleeding episodes, and not on a regular regimen intended to prevent spontaneous bleeding) per Investigator discretion for the treatment of breakthrough bleeding episodes from Day 1 up to a total of 9 months.
62404705|NCT03417245|EXPERIMENTAL|Fitusiran 80 mg Prophylaxis|Participants received open-label fitusiran 80 milligram (mg) administered subcutaneously (SC) as prophylaxis once monthly from Day 1 up to a total of 9 months. Participants received on-demand factor concentrates (per investigator's discretion and within bleeding dosing guidelines) for the treatment of breakthrough bleeding episodes.
62404706|NCT02008487|OTHER|Wound powder|In both hospice settings, a registered nurse establishes the wound protocol per principles of wound care and agency guidelines. The cover dressing will be removed and the wound cleansed according to agency protocol (usual care) or as needed. The RGN107 powder, contained in a small squirt bottle, will be squeezed/sprinkled on the wound at each dressing change after cleansing or until a crust is formed. Once formed, the powder will be applied only minimally to reinforce crust integrity. The peri-wound skin will receive care and the cover dressing will be applied. Minimal manipulation of the crusted area will ensue once it has formed. Frequency of dressing changes depends on wound characteristics such as exudate.
62404707|NCT06649656|EXPERIMENTAL|TQB2252 injection|This product is administered via intravenous infusion, with recommended doses of 600mg TQB2223 monoclonal antibody and 200mg penpulimab injection, administered once every 3 weeks.
62404708|NCT04456621|EXPERIMENTAL|PBT arm|
62404709|NCT06286995|ACTIVE_COMPARATOR|Trunatomy file group|Using trunatomy file for chemomechanical preparation for root canal of mandibular premolars
62580722|NCT03875170|EXPERIMENTAL|Proprioceptive neuromuscular facilitation|Each session will last 5 minutes for each subject, taking place two sessions a week, in a period of 6 weeks. The intervention will be made at the beginning of the training session. The technique will be carried out with the subjects in the positions of supine, prone and lateral position, for the flexor muscles of the hip, hamstrings and quadriceps, where the musculature and the joint to be treated will be taken to a range of functional mobility
62205224|NCT02509832|OTHER|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
62205225|NCT05444608|NO_INTERVENTION|Control Group|Data will be collected during heel blood sampling for blood sugar control from newborns randomly assigned to the control group. Babies in the control group will not be allowed to smell breast milk or listen to white noise.The newborn in the control group will continue to receive routine care.Camera recording will start 5 minutes before the procedure and lasting 5 minutes after the procedure.
62205226|NCT05444608|EXPERIMENTAL|Breast Milk Odor Group|Data will be collected during heel blood sampling for blood sugar control from newborns randomly assigned to the breast milk odor group.Before the intervention, 2 ml of breast milk will be dripped into sterile sponge and the sponge will be placed within 3 cm of the newborn's nose.Babies in this group will start to smell their mother's milk 5 minutes before the procedure and will continue to smell for 5 minutes after the procedure.Camera recording will start 5 minutes before the procedure and lasting 5 minutes after the procedure.
62205227|NCT05444608|EXPERIMENTAL|White Noise Group|Data will be collected during heel blood sampling for blood sugar control from newborns randomly assigned to the white noise listening group.Before the intervention , a bluetooth speaker will be placed at the baby's feet. The speaker will be connected to the phone and the sound level will be adjusted to 50 decibels by means of a decibel meter. The baby will be started to listen to white noise 5 minutes before the procedure.Camera recording will start 5 minutes before the procedure and lasting 5 minutes after the procedure.
62404710|NCT06286995|ACTIVE_COMPARATOR|Edgeendo x7 file group|Using edgeendo x7 file for chemomechanical preparation for root canal of mandibular premolars
62015993|NCT03494010||historical controls|Medical record data of these patients, who did not use the HCL system, will be compared with patients in the HCL cohort.
62404711|NCT05821023|NO_INTERVENTION|Group 1 - control (no exposure)|No message at T1 or T2.
62404712|NCT05821023|OTHER|Group 2 - control (single exposure)|Single clinician message at T1 aimed at reducing over-screening. No message at T2.
62787892|NCT04602442|PLACEBO_COMPARATOR|Placebo|Participants (n=30) in this group will receive standard therapy and inhalation placebo solution.
62787893|NCT01047982|ACTIVE_COMPARATOR|myo-inositol|
62787894|NCT01047982|PLACEBO_COMPARATOR|placebo|acid folic 400 mcg twice per day
62404713|NCT05821023|EXPERIMENTAL|Group 3|T1 - message from media source aimed at reducing over-screening. T2 - message from clinician aimed at reducing over-screening
62404714|NCT05821023|EXPERIMENTAL|Group 4|T1 - message from a close family member aimed at reducing over-screening. T2 - message from clinician aimed at reducing over-screening
62404715|NCT05821023|EXPERIMENTAL|Group 5|T1 - message from media source aimed at supporting continued screening. T2 - message from clinician aimed at reducing over-screening
62787895|NCT04767906|OTHER|Cabozantinib|Enrolled patients start with 60mg of Cabozantinib. The maximum duration of treatment is 336 days. The dose can be adjusted by the physician to 40mg or 20mg.
62015994|NCT00893893||1|Lean premenopausal women
62015995|NCT00893893||2|Visceral obese premenopausal women
62015996|NCT01558973||Cocaine dependent|
62015997|NCT01558973||Opioid dependent|
62015998|NCT01558973||Alcohol dependent|
62205228|NCT02119442|OTHER|Transcatheter Valve Implantation|Intervention, Transcatheter Valve Implantation with Melody or Sapien bioprosthetic valve Standard of care intervention.
62205229|NCT04376151|EXPERIMENTAL|Intervention|Participants will work through an Acceptance and Commitment Therapy informed self-help bibliotherapy over a period of eight weeks. The bibliotherapy is called 'Get Out of Your Life and Into your Mind' written by Steve. C. Hayes.
62205230|NCT03921723|EXPERIMENTAL|Subject receiving Dolutegravir 10 mg|Subject will receive a prototype equivalent to DTG 10 mg liquid formulation in period 1, a prototype equivalent to DTG 10 mg liquid formulation in period 2, a DTG 10 mg dispersible tablet in Period 3, each period will be separated by washout period of \>= 7 days, if required a prototype equivalent to DTG 10 mg liquid formulation in period 4, a prototype equivalent to DTG 10 mg liquid formulation in period 5, and a prototype equivalent to DTG 10 mg liquid formulation in period 6 will be evaluated.
62404716|NCT05821023|EXPERIMENTAL|Group 6|"T1 - message from a close family member aimed at supporting continued screening.~T2 - message from clinician aimed at reducing over-screening"
62015999|NCT01558973||Healthy controls|
62016000|NCT01558973||Adolescents|
62205231|NCT04352998|ACTIVE_COMPARATOR|One dose pre-workout supplement condition|One dose/serving of a multi-ingredient pre-workout supplement was administered to the subjects.
62205232|NCT04352998|ACTIVE_COMPARATOR|Two dose pre-workout supplement condition|Two doses/servings of a multi-ingredient pre-workout supplement was administered to the subjects.
62404717|NCT06651008||Conservative treatment completed group|The groupthat completed the conservative treatment for dudenum perforation.
62404718|NCT06651008||Conversion to surgery group|The group that needed conversion to surgery for duodenum perforation.
62016001|NCT01558973||Pathological gamblers|
62016002|NCT04407663||Bariatric Patient|Inclusion criteria were as follows: obese adults (\> 18 years of age, BMI\> 40 or \> 35 with comorbidities) older than 18 years; patients undergoing bariatric surgery within 6 months; patients who required clinical and instrumental control; presence of a caregiver in case of subject with cognitive impairment; patients with a history of bariatric surgery who requested a first outpatients access or established patients who requested an outpatients' visit for an emerging problem.
62016003|NCT01066559|EXPERIMENTAL|High flux polymethylmetacrylate membrane|
62016004|NCT01066559|ACTIVE_COMPARATOR|Polysulfone membranes|
62404719|NCT03563404||Portal Blood Flush|participants that receive the portal blood flush
62404720|NCT03563404||No Portal Blood Flush|participants that don't receive the portal blood flush
62205233|NCT04352998|PLACEBO_COMPARATOR|Placebo condition|One dose/serving of a placebo was administered to the subjects.
62205234|NCT03719417|ACTIVE_COMPARATOR|Unicompartmental Biologic Arthroplasty|Subject will be receiving a unicompartmental biologic arthroplasty only
62205235|NCT03719417|ACTIVE_COMPARATOR|Extensive Biologic Arthroplasty|Subject will be receiving a unicompartmental biologic arthroplasty with at least one additional surface in another compartment being replaced concurrently.
62205236|NCT00951015|EXPERIMENTAL|10 mg GSK1349572|subjects will receive GSK1349572 10mg once daily blinded to dose
62205237|NCT00951015|EXPERIMENTAL|25mg GSK1349572|subjects will receive GSK1349572 25mg once daily blinded to dose
62205238|NCT00951015|EXPERIMENTAL|50mg GSK1349572|subjects will receive GSK1349572 50mg once daily blinded to dose
62205239|NCT00951015|OTHER|efavirenz control|efavirenz will serve as the internal control arm
62205240|NCT02995759||SE before Seizure Action Plan|450 patients with status epilepticus prior to seizure action plan initiation
62205241|NCT02995759||SE after Seizure Action Plan|450 patients with status epilepticus after seizure action plan initiation
62205242|NCT05265273|EXPERIMENTAL|Nipocalimab|Participants age 2 to less than (\<) 18 years of age (globally) and 8 to \<18 years of age (for US sites only) will receive nipocalimab once every two weeks for 24 weeks. After Week 24, all participants will have the option to enroll in long term extension (LTE).
62205243|NCT02304692|SHAM_COMPARATOR|Oticon Medical Machined Abutment|A non surface modified abutment is used
62205244|NCT02304692|EXPERIMENTAL|Oticon Medical Modified Abutment|A surface modified abutment is used
62205245|NCT04834544|EXPERIMENTAL|DCVAC/OvCa arm|
62205246|NCT04834544|PLACEBO_COMPARATOR|Placebo arm|
62580723|NCT03875170|ACTIVE_COMPARATOR|Muscle stretching|Each session will last 5 minutes for each subject, taking place two sessions a week, in a period of 6 weeks. The intervention will be made at the beginning of the training session. It will be done for the hip, quadriceps and hamstring muscles with a voluntary antagonist activation to relax the agonist muscle.
62787896|NCT03066414||non-obese patients with genetic hemochromatosis|"PATIENTS: Non-obese patients with genetic hemochromatosis undergoing a therapeutic bleeding.~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver."
62787897|NCT04371939|EXPERIMENTAL|I (Romiplostim)|"Participants will receive romiplostim at an initial dose of 9 µg/kg subcutaneously per week for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response cross over to arm II."
62016005|NCT05792449|ACTIVE_COMPARATOR|Standard Program|The current standard program for early intervention treatment is in-clinic therapy based on the Foundational Skills Curriculum (FSC): a framework for early intervention developed from outcomes of an Autism research project conducted in the UK. This framework provides a clear and systematic approach to understanding the child's functioning in 3 core areas of development (across 141 items): Play, Social Interaction, and Communication. Children and their parents will receive the standard program which consists of 16 clinic-based intervention sessions of 60 minutes each, separated into 3 intervention blocks, with breaks in between so that parents will have opportunities to practise at home.
62205247|NCT03430947|EXPERIMENTAL|Treatment|all patients will be treated with Vemurafenib + Cobimetinib
62404721|NCT04387812|EXPERIMENTAL|Xtrodes home PSG system|Wireless wearable system incorporates EEG, electrooculography (EOG) and EMG recordings over multiple nights in the home environment. The electrodes are printed on a thin sticker. These printed electrodes are marked by their conformity with the skin, light weight, ease of placement on the skin, and user comfort. The sleep-specific electrode array includes two surface EMG (electrodes 1 and 2), two EOG (electrodes 3 and 4) and four forehead EEG electrodes (electrodes 5-8) .
62404722|NCT00659945|ACTIVE_COMPARATOR|1|Pre-op Aprepitant plus Ondansetron for PONV prophylaxis in patients undergoing outpatient plastic surgery
62580724|NCT02537002|EXPERIMENTAL|Cohort 1- PF-05230907 or Placebo|
62580725|NCT02537002|EXPERIMENTAL|Cohort 2- PF-05230907 or Placebo|
62787898|NCT04371939|EXPERIMENTAL|II (Eltrombopag)|"Participants will receive eltrombopag at a dose of 2-3mg/kg daily (ages 0 to 5 years) and 75 mg/daily (\>6 years) for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response switch to arm I."
62016006|NCT05792449|EXPERIMENTAL|Telerehab Program|The telerehab program will provide parent coaching through video conferencing using the FSC. The telerehabilitation program commences with 2 clinic-based intervention sessions of 60 minutes each followed by 16 video conferencing-based sessions of 45 minutes each. For clinic-based sessions, an additional 15 minutes is allocated to allow parent-child dyads to transit into and out of the therapist's room.
62016007|NCT00993720|EXPERIMENTAL|type 1 DM with betacell function: Liraglutide|
62016008|NCT00993720|EXPERIMENTAL|type 1 DM without betacell function: Liraglutide|
62016009|NCT00993720|NO_INTERVENTION|type 1 DM without betacell function: Insulin|
62205248|NCT02971761|EXPERIMENTAL|Treatment (pembrolizumab, enobosarm)|Patients receive pembrolizumab IV over 30 minutes on day 1 and enobosarm PO QD on days 1-21. Courses repeat every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
62205249|NCT04927247|EXPERIMENTAL|inclacumab 30 mg/kg|Inclacumab 30 mg/kg administered intravenously (IV)
62205250|NCT04927247|PLACEBO_COMPARATOR|placebo|Placebo administered IV
62205251|NCT04073992|EXPERIMENTAL|Cognitive behavioral treatment of insomnia (CBT-I)|Eight weeks of cognitive behavioral treatment of insomnia.
62205252|NCT05981742|ACTIVE_COMPARATOR|Group 1 (M)|25 Patients administered Metformin (Glucophage) Tablets of 500 mg per oral twice daily for 90 days duration.
62404723|NCT00659945|PLACEBO_COMPARATOR|2|Pre-op Placebo plus Ondansetron for PONV prophylaxis in patients undergoing outpatient plastic surgery
62404724|NCT01171794|ACTIVE_COMPARATOR|ibuprofen|600mg ibu TID
62404725|NCT01171794|PLACEBO_COMPARATOR|placebo|visually identical
62404726|NCT03821519|EXPERIMENTAL|Relapsed after Haplo transplant|
62205253|NCT05981742|ACTIVE_COMPARATOR|Group 2 (D)|25 Patients administered Cabergoline (Pergoline) Tablets of 0.5 mg dose per oral once weekly for 90 days duration.
62205254|NCT05981742|ACTIVE_COMPARATOR|Group 3 (MD)|25 Patients administered Metformin (Glucophage) Tablets of 500 mg per oral twice daily and Cabergoline (Pergoline) Tablets of 0.5 mg dose per oral once weekly for 90 days duration.
62205255|NCT02823197|EXPERIMENTAL|active transport lesson|Participants receive a 2-hour lesson (at school) promoting active transport for short distance travel to various destinations.
62205256|NCT02823197|EXPERIMENTAL|active transport lesson and Facebook group|Participants receive a 2-hour lesson (at school) promoting active transport for short distance travel to various destinations. Furthermore, they are asked to join a Facebook group on active transport in which 3 messages per week are posted during an eight-week period. The Facebook posts aim to promote the use of active transport for short distance travel.
62205257|NCT02823197|NO_INTERVENTION|control group|Participants in the control group do not receive the active transport lesson or the Facebook group.
62205258|NCT02724852|ACTIVE_COMPARATOR|HIV-infected adults|"Two-hundreds and forty-nine HIV-infected participants received a single dose of MMR vaccine (GlaxoSmithKline Biologicals) at deltoid region.~Interventions were a single dose of 0.5 ml of MMR vaccine. Each 0.5 ml of vaccine contained at least 1000 TCID50 of Schwarz measles strain, at least 1000 TCID50 of RIT 4385 mumps, and at least 1000 TCID50 of Wistar RA 27/3 rubella strains."
62205259|NCT02724852|EXPERIMENTAL|HIV-uninfected adults|"Forty-six HIV-uninfected participants received a single dose of MMR vaccine (GlaxoSmithKline Biologic) at deltoid region.~Interventions were a single dose of 0.5 ml of MMR vaccine. Each 0.5 ml of vaccine contained at least 1000 TCID50 of Schwarz measles strain, at least 1000 TCID50 of RIT 4385 mumps, and at least 1000 TCID50 of Wistar RA 27/3 rubella strains."
62205260|NCT05084859|EXPERIMENTAL|CRPC (Castration Resistant Prostate Cancer) - SM08502 + Abiraterone/Prednisone|"Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRPC.~Subjects will receive increasing doses of SM08502 with fixed doses of Abiraterone/Prednisone to determine the MTD and recommended Part 2 dose and schedule.~Escalation will follow a 3+3+3 design within each cohort.~Part 2 will further evaluate the recommended dose and schedule of SM08502 in subjects with advanced CRPC. Approximately 20 subjects will be enrolled."
62205261|NCT05084859|EXPERIMENTAL|NSCLC (Non-Small Cell Lung Cancer) - SM08502 + Docetaxel|"Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced NSCLC.~Subjects will receive increasing doses of SM08502 with fixed doses of docetaxel to determine the MTD and recommended Part 2 dose and schedule.~Escalation will follow a 3+3+3 design within each cohort.~Part 2 will further evaluate the recommended dose and schedule of SM0850 in subjects with advanced NSCLC. Approximately 20 subjects will be enrolled."
62205262|NCT05084859|EXPERIMENTAL|CRC (Colorectal Cancer) - SM08502 + FOLFIRI/Panitumumab|"Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRC.~Subjects will receive increasing doses of SM08502 with fixed doses of FOLFIRI plus panitumumab ( RAS wild type tumors) or with fixed doses of FOLFIRI (RAS mutant tumors)~Escalation will follow a 3+3+3 design within each cohort.~Part 2 will further evaluate the recommended dose and schedule of SM08502. Subjects that have RAS wild type tumors will receive FOLFIRI and panitumumab with SM08502 (n=15). Subjects that have RAS mutant tumors will receive FOLFIRI with SM08502 (n=15)."
62205263|NCT01399697|EXPERIMENTAL|A|
62205264|NCT01399697|ACTIVE_COMPARATOR|B|
62205265|NCT01516619|EXPERIMENTAL|romiplostim|
62205266|NCT04940338|EXPERIMENTAL|Bromfenac|Group 1 will receive topical bromfenac (0.9 mg/mL) 2x daily, 7 days before the surgery
62205267|NCT04940338|EXPERIMENTAL|Dexamethasone|Group 2 will receive topical dexamethasone (1mg/mL) 2x daily before the surgery
62205268|NCT04940338|PLACEBO_COMPARATOR|Placebo|Group 3 will receive topical placebo (artificial tears substitute) 2x daily before the surgery
62205269|NCT03660644|EXPERIMENTAL|WhatsApp, Pedometer and Step Diary|Pedometer, step diary and WhatsApp following pulmonary rehabilitation
62205270|NCT03660644|NO_INTERVENTION|Control|Usual care following pulmonary rehabilitation.
62205271|NCT00127205|EXPERIMENTAL|Arm I|Patients receive zoledronate IV over 15 minutes once a month for 6 months and then once every 3 months for 2.5 years.
62205272|NCT00127205|ACTIVE_COMPARATOR|Arm II|Patients receive oral clodronate once daily for 35 months.
62205273|NCT00127205|EXPERIMENTAL|Arm III|Patients receive oral ibandronate once daily for 35 months.
62205274|NCT02758275|EXPERIMENTAL|Teaching: Individual (5606)|People will receive an education session per month for a period of six months with an average duration of 30 minutes. These will be performed by nurses outside the collection of phase base line and follow-up measurements, previously trained for the purpose.
62205275|NCT02758275|NO_INTERVENTION|Usual care|People will continue to receive usual care in the health center where they usually assist to medical controls.
62205276|NCT04374214|ACTIVE_COMPARATOR|Complete Pulpotomy using mineral trioxide aggregate|Twenty-eight patients with curiously exposed permanent molars will be treated with complete pulpotomy by using Mineral Trioxide Aggregate.
62205277|NCT04374214|ACTIVE_COMPARATOR|Complete Pulpotomy using Simvastatin-alphatricalcium phosphate|Twenty-eight patients with curiously exposed permanent molars will be treated with complete pulpotomy by using Simvastatin -alphatricalcium phospahte.
62205278|NCT02001064|EXPERIMENTAL|Care4Today v2.0 mobile application + electronic monitoring of adherence|"Care4Today v2.0 mobile application~Participants in the experimental application arm will use the Care4Today v2.0 mobile application for antiretroviral medication adherence support. Alert messages generated via the app will be targeted to the specific schedule and needs of the individual.~Electronic monitoring of adherence:~Participants' adherence to antiretroviral therapy medication is measured via Medication Event Monitoring System (MEMS) cap."
62404727|NCT01761461|EXPERIMENTAL|Arm A|S-1 40-60mg BID (4weeks - 2weeks off) x 8 cycles
62205279|NCT02001064|NO_INTERVENTION|Electronic monitoring of adherence|Participants' adherence to antiretroviral therapy medication is measured via Medication Event Monitoring System (MEMS) cap.
62205280|NCT01660386|EXPERIMENTAL|Sitagliptin|the subjects are asked to take one pill of sitagliptin(100mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
62205281|NCT01660386|EXPERIMENTAL|Saxagliptin|the subjects are asked to take one pill of saxagliptin(5mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
62404728|NCT01761461|ACTIVE_COMPARATOR|Arm B|{S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 week} x 8 cycles
62787899|NCT01162915|EXPERIMENTAL|Safety|Infusion of autologous bone marrow-derived mesenchymal stem cells.
62404729|NCT01761461|ACTIVE_COMPARATOR|Arm C|{S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 weeks} x 2 cycles → S-1 40mg BID (2weeks - 1week off - 2weeks)+ RT 45 Gy (5weeks) → Rest for 4 weeks → {S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 weeks} x 4 cycles
62404730|NCT00576667|EXPERIMENTAL|Rimonabant|Rimonabant 20 mg once daily.
62787900|NCT05231239|ACTIVE_COMPARATOR|Active tDCS|tDCS will be applied for 20 min with 2 mA
62404731|NCT00576667|PLACEBO_COMPARATOR|Placebo|Placebo (for Rimonabant) once daily.
62016010|NCT00907270|ACTIVE_COMPARATOR|Cholecalciferol: 400 IU/day|Control: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D (Cholecalciferol: 400 IU/day)
62016011|NCT00907270|EXPERIMENTAL|Cholecalciferol 4000 IU/day|Experimental: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D
62404732|NCT05499104|ACTIVE_COMPARATOR|Mepilex Ag|patient will receive Mepilex Ag for their site, standard of care to be followed.
62404733|NCT05499104|ACTIVE_COMPARATOR|Xeroform|patient will receive Xeroform for their site, standard of care to be followed.
62404734|NCT05499104|EXPERIMENTAL|NovaDress|patient will receive NovaDress for their site, standard of care to be followed.
62404735|NCT03188250|EXPERIMENTAL|Chama cha MamaToto|Pregnant women in communities where chama cha mamatoto is taking place will be invited to join and participate in bi-weekly group meetings for a year
62404736|NCT03188250|NO_INTERVENTION|Referent|Pregnant women attending at least one prenatal visit in communities where chama cha mamatoto was implemented three months later served as the comparison
62580726|NCT05209815||Group 1|continuation of NTZ throughout pregnancy and postpartum
62580727|NCT05209815||Group 2|exposure during the first trimester
62787901|NCT05231239|PLACEBO_COMPARATOR|Placebo tDCS|tDCS will be applied for only 20 sec, monatge will be left on the head for 20 min
62787902|NCT01463306|EXPERIMENTAL|Open|Pregabalin open label flexible dose
62787903|NCT00921843|EXPERIMENTAL|Methadone 0.1mg/kg|Methadone 0.1mg/kg
62787904|NCT00921843|EXPERIMENTAL|Methadone 0.2mg/kg|Methadone 0.2mg/kg
62787905|NCT00921843|EXPERIMENTAL|Methadone 0.3mg/kg|Methadone 0.3mg/kg
62787906|NCT00921843|PLACEBO_COMPARATOR|Control|No methadone
62016012|NCT05875662||Mechanical ventilation patients undergoing fiberoptic bronchoscopy|After being included in the patient, the EIT chest strap was worn to measure the end expiratory lung impedance and tidal impedance variable, assess the distribution of lung ventilation in patients and record GI index and CoV. EELI,TIV, GI index, CoV, vital signs of patients, including heart rate, blood pressure, respiratory rate, SpO2, ventilator parameters, including mode, driving pressure, FiO2, PEEP, and lung compliance was recorded before and after bronchoscopy. Patients underwent a recruitment maneuver 5 minutes after bronchoscopy maintaining breaths at a PC of 40 cm H2O with PEEP of 20 cm H2O in pressure control mode for 1 minute, then, PEEP was decreased from 20 to preceding PEEP value in steps of 2 cm H2O with a duration of at least 10 breaths or 30 seconds at each step.
62016013|NCT00752908||Obese patients|Obese patients
62016014|NCT00752908||Normal weight patients and volunteers|Normal weight patients and volunteers
62404737|NCT02841332|EXPERIMENTAL|Patients with glioblastoma|"Patient with histologically proved glioblastoma diagnostic will receive the following interventions :~* Cerebral magnetic resonance imagery~* Tomography emission positron with F-MISO~* Bevacizumab administration~* Clinical examination"
62580728|NCT05209815||Group 3|exposure during the first and the second trimester
62580729|NCT00744965|ACTIVE_COMPARATOR|Glyburide|Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
62580730|NCT00744965|PLACEBO_COMPARATOR|Placebo|Women with mild gestational diabetes will be started ADA diet and placebo.
62016015|NCT06358924|EXPERIMENTAL|After whitening mousse|30 % Xylitol, 4.2 % potassium nitrate, and 1450 ppm fluoride. Topical tooth gel Gel was applied on bleached teeth for 10 minutes according to manufacturer's instructions.
62016016|NCT06358924|EXPERIMENTAL|Mi Paste Plus|Casein-phosphopeptide-amorphous calcium phosphate with 0.2 % sodium fluoride (900ppm) Topical tooth cream Cream was applied on bleached teeth for 3 minutes according to manufacturer's instructions
62016017|NCT06358924|EXPERIMENTAL|Hydroxyapatite and Fluoride (ReminPro)|Hydroxyapatite (calcium and phosphate), ethanolic colophony, fluoride (1450 ppm NaF) and xylitol Topical water based tooth cream Cream was applied on bleached teeth for 3 minutes according to manufacturer's instructions
62016018|NCT06358924|EXPERIMENTAL|"PAMAM poly (amido amine) dendrimer"|PAMAM-succinamic acid dendrimer, 1,4-diaminobutane core, generation 4 solution. 10 wt.% in water Colorless liquid The liquid was applied on bleached teeth for 30 minutes (according to previous studies)
62016019|NCT02503280|EXPERIMENTAL|Group A - Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\^8 (200 million) hMSCs. The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
62580731|NCT03842007|ACTIVE_COMPARATOR|Healthy Individuals|Sixty healthy individuals (20 men and 40 women) will undergo an anorectal study which comprises of a rectal barostat study followed by fecoflowmetry
62580732|NCT03842007|ACTIVE_COMPARATOR|Constipated Individuals|60 constipated individuals (20 men and 40 women) will undergo an anorectal study which comprises of a rectal barostat study followed by fecoflowmetry
62580733|NCT04553471|EXPERIMENTAL|SBRT|5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
62734880|NCT03665766||Sof,dac pus ribavirin received cyclosporine|Living donor liver transplantation recipients with recurrent HCV received daclatasvir, sofosbuvir and RBV as antiviral therapy and Cyclosporine as primary immunosuppression,this was routinely taken not as intervention according to local practice
62580734|NCT05629221|EXPERIMENTAL|TreC Diabete App users|"Sixty individuals allocated to the intervention group are prescribed with the TreC Diabete App for 12 months, one of the App created within the so-called TreC platform, which enables citizens from PAT to access, manage and share information about their health and wellbeing in the context of telemedicine. The use of the App is additional to the standard care, based on the integrated preventive and diagnostic care pathway (called Percorsi Preventivi Diagnostici Terapeutici Assistenziali - PPDTA in Italian).An appointment with the outpatient diabetes clinic staff is scheduled at 6 and 12 month from the first visit (taking place within 30 days of the study entry), either through telemedicine (remote visit) or face-to-face."
62205282|NCT01660386|EXPERIMENTAL|Glimepiride|the subjects are asked to take one pill of glimepiride(2mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
62205283|NCT01660386|OTHER|Blank control|the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
62205284|NCT05082753|EXPERIMENTAL|Ivermectin tablets (3 mg Ivermectin)|
62205285|NCT05082753|ACTIVE_COMPARATOR|Stromectol ® tablets (3 mg Ivermectin)|
62205286|NCT06687655|EXPERIMENTAL|Ketone-IQ first|This is a crossover study where participants will ingest either Ketone-IQ for 2 nights, or placebo for 2 nights before sleep. This arm will ingest Ketone-IQ first, then placebo.
62205287|NCT06687655|EXPERIMENTAL|Placebo first|This is a crossover study where participants will ingest either Ketone-IQ for 2 nights, or placebo for 2 nights before sleep. This arm will ingest Placebo first, then Ketone-IQ.
62787907|NCT03137225|EXPERIMENTAL|Nasal Intermittent Positive Pressure Ventilation (NIPPV) Mode|"After a one hour stabilization period, during which small adjustments to the noninvasive settings can be made to clinically optimize the settings, the study will begin. A Nellcor pulse oximeter probe will be placed on an extremity to provide a continuous non-invasive downloadable measure of saturation (blood oxygen level) and heart rate. Data from the ventilator will be downloaded in real-time to a laptop.~These data will be recorded for 4 hours continuously. After that, the ventilator will be switched to the other mode (NIPPV to NAVA), at the same PEEP (positive end-expiratory pressure) and respiratory rate. One hour will be allowed to adjust the ventilator settings. Data will then be collected for 4 hours on the second ventilation mode (NAVA)"
62787908|NCT03137225|EXPERIMENTAL|Neurally Adjusted Ventilatory Assist (NAVA) Mode|"After a one hour stabilization period, during which small adjustments to the noninvasive settings can be made to clinically optimize the settings, the study will begin. A Nellcor pulse oximeter probe will be placed on an extremity to provide a continuous non-invasive downloadable measure of saturation (blood oxygen level) and heart rate. Data from the ventilator will be downloaded in real-time to a laptop.~These data will be recorded for 4 hours continuously. After that, the ventilator will be switched to the other mode (NAVA to NIPPV), at the same PEEP and respiratory rate. One hour will be allowed to adjust the ventilator settings. Data will then be collected for 4 hours on the second ventilation mode (NIPPV)"
62734881|NCT03665766||sof,dac plus rbv received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received daclatasvir, sofosbuvir and RBV as antiviral therapy and Tacrolimus as primary immunosuppression,this was routinely taken not as intervention according to local practice
62205288|NCT01340248|EXPERIMENTAL|Dilatrend 64mg capsule|"\* Randomized, open-label, single dose, two-period, two-way, crossover study~1. group : Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet~2. group : Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting"
62205289|NCT05044780||Cohort 1/SARS-CoV-2 positive|Participants with molecular testing positive for SARS-CoV-2
62205290|NCT05044780||Cohort 2/SARS-CoV-2 negative|Participants with molecular testing negative for SARS-CoV-2
62404738|NCT00483717|PLACEBO_COMPARATOR|Placebo|Intranasal Placebo
62016020|NCT02503280|EXPERIMENTAL|Group B - Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
62016021|NCT02503280|PLACEBO_COMPARATOR|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline \[PBS\] and 1% human serum albumin \[HSA\]).The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
62016022|NCT04255862|EXPERIMENTAL|Test 1|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with bimekizumab-safety syringe-2 mL presentation (test 1).
62016023|NCT04255862|OTHER|Reference 1|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-safety syringe-1 mL presentation (reference 1).
62016024|NCT04255862|EXPERIMENTAL|Test 2|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-auto-injector-2 mL presentation (test 2).
62016025|NCT04255862|OTHER|Reference 2|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-auto-injector-1 mL (reference 2).
62016026|NCT03421613|EXPERIMENTAL|3VM1001 cream|Patients will be randomized to self treat with 2 g of VM1001 cream times daily for ten days, have a five day wash out period and then 10 days of self treatment with the comparator.
62016027|NCT03421613|PLACEBO_COMPARATOR|Placebo|Patients will be randomized to self treat with either active product or placebo comparator thrice daily for 10 days followed by a 5 day wash out period then 10 days of experimental treatment thrice daily for 20 days.
62205291|NCT02417077||Photographic Review|Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
62205292|NCT05215028||users|users of the web-application MALO
62205293|NCT06514911|ACTIVE_COMPARATOR|primary closure following Laparoscopic cholodochotomy in management of CBD stones|
62205294|NCT06514911|ACTIVE_COMPARATOR|T-tube drainage following Laparoscopic cholodochotomy in management of CBD stones|
62205295|NCT02859129|EXPERIMENTAL|Rosuvastatin|Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
62205296|NCT02859129|EXPERIMENTAL|Epanova®|Multiple oral doses of 2 g (2 x 1 g capsules) Epanova® QD for 10 consecutive days (Days 4 to 13)
62205297|NCT02859129|EXPERIMENTAL|Epanova® + Crestor®|Epanova® multiple oral doses of 4 g (4 x 1 g capsules) QD for 13 consecutive days (Days 14 to 26) with coadministration of single 40 mg (1 x 40 mg tablet) oral dose of rosuvastatin (Crestor®) with the 11th dose of 4 g Epanova® on Day 24
62205298|NCT02859129|ACTIVE_COMPARATOR|Vascepa®|Vascepa® multiple oral doses of 2 g (2 x 1 g capsules) every 12 hours for 20 consecutive days (Days 1 to 20).
62205299|NCT03586791|EXPERIMENTAL|Pupillometry group|In this group, anesthesia is performed using Pupillometry guided anesthesia.
62205300|NCT03586791|ACTIVE_COMPARATOR|SPI group|In this group, anesthesia is performed using SPI guided anesthesia.
62205301|NCT03586791|SHAM_COMPARATOR|Control group|In this group, remifentanil concentration is controlled by the discretion of the anesthesiologist in charge of the patients (Standard management).
62205302|NCT05562674|EXPERIMENTAL|Veteran Voices & Visions (VVV)|This is the experimental condition, testing the manual the investigators have developed.
62787909|NCT02155920|EXPERIMENTAL|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
62787910|NCT02490592|EXPERIMENTAL|G1|Thirty children aged seven to twelve years who had seventy one active white spots lesions in permanent anterior teeth randomly assigned to four or eight weekly intervals applications of fluoride foam, Flúor Care (NaF 1.23%), to verified the activity (visual scores) and the dimensional changes of whit spot lesions (with WHO probe and millimeter ruler), caries Management by Risk Assessment (CAMBRA) and OHI-S (Simplified Oral Hygiene Index) of children.
62787911|NCT02490592|EXPERIMENTAL|G2|Twenty-eight children aged seven to twelve years who had seventy five active white spots lesions in permanent anterior teeth randomly assigned to four or eight weekly intervals applications of fluoride gel, Flugel FFA (NaF 1.23%), to verified the activity (visual scores) and the dimensional changes of whit spot lesions (with WHO probe and millimeter ruler), caries Management by Risk Assessment (CAMBRA) and OHI-S (Simplified Oral Hygiene Index) of children.
62787912|NCT01663064|EXPERIMENTAL|Endovascular|Endovascular treatment
62787913|NCT00281346|EXPERIMENTAL|transthoracic Doppler echocardiography|
62787914|NCT05276921||Patient|Postoperative ICU patient
62205303|NCT05562674|ACTIVE_COMPARATOR|Healthy Lifestyles|This is the control condition, matched for location, format, degree of interaction, and duration.
62787915|NCT04887259|EXPERIMENTAL|LAVA-051|"Part 1 (dose escalation): LAVA-051 will be given to patients via intravenous (IV) infusion with dose escalation. A selected group of patients will also receive a low dose of interleukin 2 via subcutaneous injection.~* Group A: LAVA-051~* Group B: LAVA-051 + low dose interleukin 2~Part 2 (dose expansion): patients will receive LAVA-051 at the dose and regimen established in Part 1 of the study"
62787916|NCT01043991|EXPERIMENTAL|EPO|single bolus of EPO, 150 µg
62787917|NCT01043991|PLACEBO_COMPARATOR|Placebo|NaCl
62787918|NCT05248880|EXPERIMENTAL|AGN-151586|Participants will receive 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may also receive 1 open-label treatment of AGN-151586.
62787919|NCT05248880|EXPERIMENTAL|Placebo|Participants will receive 5 intramuscular injections of Placebo in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may also receive 1 open-label treatment of AGN-151586.
62787920|NCT02315534|EXPERIMENTAL|Arm A|Patients for whom surgery is recommended as part of treatment for recurrent Glioblastoma.
62016028|NCT01092195|ACTIVE_COMPARATOR|Cohort 1|Female subjects post stem cell transplant on no systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
62205304|NCT01709175|EXPERIMENTAL|Once-a-week Strength Training|After completing the introduction to strength training (two sessions in the first week), participants randomized to the once-a-week group will receive 12 additional weeks of progressive strength training. Participants will meet ONCE-A-WEEK to strength train in a supervised exercise group. The program includes nine exercises.
62205305|NCT01709175|EXPERIMENTAL|Twice-a-week Strength Training|After completing the introduction to strength training (two sessions in the first week), participants randomized to the twice-a-week group will receive 12 additional weeks of progressive strength training. Participants will meet TWICE-A-WEEK to strength train in a supervised exercise group. The program includes nine exercises.
62205306|NCT05578118||ICSI + AOA|Children born after ICSI + AOA
62205307|NCT05578118||Control|Children born after ICSI
62205308|NCT02369068|EXPERIMENTAL|Onabotulinumtoxin A|"Intervention is a one time 30 cc intravaginal injection totaling a dose of 200u of onabotulinumtoxin A and saline injected throughout the pelvic floor at 1, 3, 5, 7, 9 and 11 o'clock sites/locations.~An injection of 30 cc of ropivicaine (5cc/6 sites) will be used, followed by a mixture of 200 u of Onabotulinumtoxin A and 6 cc of saline (1cc/injection site)."
62205309|NCT02369068|ACTIVE_COMPARATOR|Kenalog|"Intervention is a one time 30 cc intravaginal injection totaling a dose of 40mg/cc of Kenalog (triamcinolone) and ropivicaine 0.5% (29cc) injected throughout the pelvic floor at 1, 3, 5, 7, 9 and 11 o'clock sites/locations.~A mixture of 40mg/1 cc of triamcinolone (40 mg) and 29cc of ropivicaine 0.5% (5cc/6 sites) will be used, followed by 6 cc of saline (1cc/injection site)."
62205310|NCT06727604|EXPERIMENTAL|Group 1 Period 1 and 2: IMVT-1402|
62205311|NCT06727604|EXPERIMENTAL|Group 2 Period 1 and 2: IMVT-1402|
62205312|NCT06727604|EXPERIMENTAL|Group 2 Period 1: IMVT-1402 and Period 2: Placebo|
62205313|NCT06727604|PLACEBO_COMPARATOR|Group 3 Period 1 and 2: Placebo|
62205314|NCT01527747|PLACEBO_COMPARATOR|Placebo|Placebo arm
62205315|NCT01527747|EXPERIMENTAL|Saxagliptin|Active drug arm
62016029|NCT01092195|ACTIVE_COMPARATOR|Cohort 2|Female subjects post stem cell transplant with chronic GVHD requiring systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
62016030|NCT01092195|ACTIVE_COMPARATOR|Cohort 3|Healthy normal female volunteers. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
62016031|NCT02936076|ACTIVE_COMPARATOR|Exercise condition|Participants randomized to the exercise condition will participate in a 12-week exercise training program. The exercise intervention will consist of both supervised and unsupervised exercise sessions and progress to 200 minutes/week of moderate-intensity exercise. Exercise bouts will be spread across 4-6 days and be at least 20 minutes in duration. During supervised visits, heart rate will be monitored by a member of the research staff to ensure that exercise is within the prescribed intensity range and ratings of perceived exertion and feeling state will be assessed periodically. Unsupervised exercise will be verified using objective physical activity monitors.
62205316|NCT00821951|EXPERIMENTAL|Vorinostat and Radiotherapy|
62205317|NCT01401153|EXPERIMENTAL|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water available on both days.
62205318|NCT01401153|EXPERIMENTAL|Skipping lunch/having lunch|No lunch on test day 1 and lunch ad libitum on test day 2. Water available on both days.
62205319|NCT04403568|EXPERIMENTAL|Ursolic Acid|Administration of Ursolic Acid to subjects who are scheduled to undergo radical prostatectomy
62205320|NCT04403568|EXPERIMENTAL|Curcumin|Administration of Curcumin to subjects who are scheduled to undergo radical prostatectomy
62205321|NCT04403568|EXPERIMENTAL|Ursolic Acid and Curcumin|Administration of Ursolic Acid and Curcumin to subjects who are scheduled to undergo radical prostatectomy
62205322|NCT04387500|EXPERIMENTAL|Sintilimab injection combined with Inlyta|"Sintilimab injection 10ml: 100mg, 200mg intravenously, once every three weeks. Course of treatment: discontinue medication when the disease progresses clinically or radiologically.~Inlyta 5mg orally, twice a day. Course of treatment: continue treatment as long as a clinical benefit is observed, or until an unacceptable toxicity is present that cannot be controlled by combination or dose adjustment.~In the whole research process, if the disease progresses, the attending doctor has the right to carefully choose other anti-tumor methods, including radiotherapy, chemotherapy and other targeted drugs."
62787921|NCT02315534|EXPERIMENTAL|Arm B|Patients for whom surgery is not recommended as part of the treatment for recurrent Glioblastoma.
62787922|NCT02944786|EXPERIMENTAL|HOPE-model|Four person-centred health dialogue sessions that include pain/stress management and education about stress and pain.
62205323|NCT05054803|EXPERIMENTAL|WJ-MSC (XCEL-UMC-BETA)|Pre-filled syringe with 4 ± 1 mL containing WJ-MSC in a balanced saline solution supplemented with human albumin.
62787923|NCT02944786|NO_INTERVENTION|Control|Standard care
62787924|NCT05643651|EXPERIMENTAL|Rivaroxaban+Antiplatelet drug|Rivaroxaban as anticoagulant will be administered with antiplatelet drug for 6 months. Antiplatelet drug can choose Aspirin or Clopidogrel depending on participant medical history and physician's recommendation.
62787925|NCT05643651|ACTIVE_COMPARATOR|Standard antithrombotic care|"Warfarin as anticoagulant will be administered with antiplatelet drug for 6 months. Antiplatelet drug can choose Aspirin or Clopidogrel depending on participant medical history and physician's recommendation. International normalized ratio(INR) should be tested once a month and maintained in target range(1.5\~2.5).~2.Aspirin\[3 \~5mg/(kg·d), once daily\] or Clopidogrel\[ \<2 years: 0.2\~1.0mg/kg, ≥2 years: 1 mg/kg; once daily\] according to experienced clinician recommendation and individual condition."
62787926|NCT03024125|EXPERIMENTAL|High protein diet (HP)|Diet with 1.2 protein g/kg body mass/day for postmenopausal women practitioners of resistance exercise. The physical strength training will be performed equally by both groups
62787927|NCT03024125|PLACEBO_COMPARATOR|Normal protein diet (NP)|Diet with 0.8 protein g/kg body mass/day for postmenopausal women practitioners of resistance exercise. The physical strength training will be performed equally by both groups
62787928|NCT01802190||Deafness patients|Deafness patients
62787929|NCT03413306|EXPERIMENTAL|Eltrombopag + IST (ATG + CsA)|
62787930|NCT03413306|ACTIVE_COMPARATOR|IST (ATG + CsA)|
62205324|NCT05054803|PLACEBO_COMPARATOR|Placebo|Pre-filled syringe with 4 ± 1 mL containing a balanced saline solution supplemented with human albumin
62787931|NCT03209466|EXPERIMENTAL|Standard management and Chlorhexidine gluconate at 0.125%|Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
62787932|NCT03209466|PLACEBO_COMPARATOR|Standard management and physiological saline sterile solution|Application every 24 hours, six weeks Intervention: Other: physiological saline sterile solution
62787933|NCT01224743|PLACEBO_COMPARATOR|Placebo|Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.
62787934|NCT01224743|EXPERIMENTAL|Blend 2|Blend 2 - combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends
62787935|NCT01224743|EXPERIMENTAL|Blend 1|Blend 1 - combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends
62787936|NCT05310981|EXPERIMENTAL|Experimental: CHAMPS and mEIS|"Brief mobile application-based psychological intervention based on the principles of motivational interviewing (MI) and cognitive behavioural therapy (CBT). This e-intervention will be completed by the participant using a smart phone. There will be up to a maximum of 24 individual sessions (which includes 3 booster sessions) each lasting approximately 10-15 minutes.~mEIS: iCC will be administered adjunctively to modified EIS (mEIS), which will include all interventions usually provided through EIS except for any specific psychological interventions (MI, CBT, contingency management) for CUD."
62787937|NCT05310981|NO_INTERVENTION|No Intervention: EIS alone|Early intervention services will be offered as per standard of care following EIS for psychosis and CUD guidelines, at participating clinical sites. Any visits and services offered in control arm will be considered 'usual care' and administered either through in-person clinic visits, community visits, phone calls, or video calls. Relevant service information will be collected for study purposes.
62016032|NCT02936076|PLACEBO_COMPARATOR|Delayed exercise condition|Participants randomized to the delayed exercise condition will be asked not to change their exercise or eating habits over the 12-week period and will complete the same assessment measures as the exercise condition. However, following the completion of the 12-week period, participants will be given two options: 1) receive a one-on-one session with an exercise physiologist at our center and receive a written exercise program, and at this time point all study obligations will be completed, or 2) complete the identical exercise protocol as the 'exercise' condition.
62205325|NCT04441853|EXPERIMENTAL|YouTube video group|The intervention group attended five sessions of weekly-based tutorial, by watching YouTube videos on older people's and their caregivers' lived experience. On each session, they would joined post-video group discussion.
62404739|NCT00483717|EXPERIMENTAL|Ketorolac tromethamine|Intranasal ketorolac tromethamine
62787938|NCT04120402|EXPERIMENTAL|EP-104IAR 25 mg|A single use intra-articular injection containing 25 mg of EP-104IAR
62016033|NCT00917592|EXPERIMENTAL|Short intravenous amoxicillin plus clavulanic acid|Intravenous antibiotic 48 hours followed by oral antibiotic for 10 days
62016034|NCT00917592|ACTIVE_COMPARATOR|Long intravenous amoxicillin plus clavulanic acid|Intravenous antibiotic for 7 days followed by oral antibiotic for 5 days
62787939|NCT04120402|PLACEBO_COMPARATOR|Placebo (vehicle)|A single use intra-articular injection containing no active ingredients
62787940|NCT05225857|EXPERIMENTAL|AGA2118|"In SAD part, various single doses of AGA2118 will be administered to the participants via either SC injection or IV infusion. The starting dose was 0.3 mg/kg, with sequential escalation up to 15 mg/kg.~In MAD part, various multiple doses of AGA2118 will be administered every four weeks (Q4W) to the participants via SC injection for 12 weeks. The starting dose was 1 mg/kg, with sequential escalation up to 12 mg/kg."
62016035|NCT02113020|EXPERIMENTAL|TAK-233|Oral administration
62016036|NCT02113020|PLACEBO_COMPARATOR|Placebo|Oral administration
62016037|NCT02940470|EXPERIMENTAL|Calorie restricted diet plus exercise|See Intervention Description
62404740|NCT04270331|NO_INTERVENTION|A Before group|No protocol assigned
62787941|NCT05225857|PLACEBO_COMPARATOR|Placebo|"In SAD part, a single dose of placebo comparator will be used for each cohort of either SC or IV administration.~In MAD part, multiple doses of placebo comparator will be used for each cohort of SC administration."
62787942|NCT06142617|EXPERIMENTAL|experimental group|Four cycles of platinum and pemetrexed in combination with pembrolizumab will be administered as first line therapy and up to 31 cycles pemetrexed and pembrolizumab maintenance therapy every 3 weeks. Osimertinib will be the sequential treatment strategy at progression until resistance develops.
62787943|NCT01855360|EXPERIMENTAL|TUDCA and Doxycycline|INTERVENTION: Patients meeting study criteria were prescribed TUDCA taken orally, 250 mg three times daily. and doxycycline taken orally, 100 mg twice daily.
62787944|NCT04844268|EXPERIMENTAL|Cohort 1|Intramuscular (IM) injection of VACCINE RNA MCTI CIMATEC HDT(HDT-301) at a dose of 1 µg. Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
62787945|NCT04844268|EXPERIMENTAL|Cohort 2|Intramuscular (IM) injection of VACCINE RNA MCTI CIMATEC HDT(HDT-301) at a dose of 5 µg. Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
62787946|NCT04844268|EXPERIMENTAL|Cohort 3|Intramuscular (IM) injection of VACCINE RNA MCTI CIMATEC HDT(HDT-301) at a dose of 25 µg. Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
62787947|NCT04844268|PLACEBO_COMPARATOR|Placebo|Intramuscular (IM) injection of saline (0.9% sodium chloride). Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
62787948|NCT03853863|EXPERIMENTAL|minimalist shoes walking group (MSW)|Subjects in the MSW group will be given a pair of minimalist shoes for all in-school activities (i.e., in-school walking training with minimalist shoes).
62787949|NCT03853863|ACTIVE_COMPARATOR|traditional shoes walking group (TSW)|Subjects in the TSW group will be given a pair of protective shoes with arch support while following the same wearing pattern as the MSW group (i.e., in-school walking training with protective shoes).
62787950|NCT05340036|ACTIVE_COMPARATOR|Group I (Conventional plates)|"Digital intermediate and final interocclusal wafer splints will be designed to guide the maxilla and mandible in the desired position using CAD software (3-matic 11.0; Materialise NV, Leuven, Belgium).~The designed splints will be then exported in stereolithography (STL) file format to the additive CAM machine (FORMIGA P 110 printer; EOS e-manufacturing solutions, Munich, Germany) and manufactured in white polyamide (PA2200; EOS e-manufacturing solutions, Munich, Germany) using fused deposition modelling (FDM) technology.The splints will be cold sterilized by overnight immersion in 2% glutaraldehyde.~2.0 conventional mini plates will be used for fixation of maxilla and mandible in the new position."
62787951|NCT05340036|EXPERIMENTAL|Group II (Patient specific plates)|"The cutting guides will be designed on the maxilla and mandible to orient the osteotomy and mark reference holes to be used later for the repositioning/ fixation plate, using CAD software.~The designed guide will be then exported in stereolithography (STL) file format to the additive CAM machine and manufactured in white polyamide using fused deposition modelling (FDM) technology. No finishing or polishing was done in order to maintain accuracy. The guides will be cold sterilized by overnight immersion in 2% glutaraldehyde.~The patient-specific osteosynthesis plates will be designed to fix the maxilla and mandible in the desired position making use of the previously established reference holes. The designed plates will be exported in STL file format to be manufactured in grade 5 titanium alloy utilizing selective laser sintering (SLS) technology on an additive CAM machine."
62787952|NCT05386381||Decompression alone|Patients undergone decompression surgery alone
62016038|NCT02940470|ACTIVE_COMPARATOR|Weight management classes|See Intervention Description
62016039|NCT04894435|ACTIVE_COMPARATOR|Group 1: Moderna, Moderna - 28 Days apart|"Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle 28 days apart.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
62016040|NCT04894435|ACTIVE_COMPARATOR|Group 2: Moderna, Moderna - 112 days apart|"Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine at 0.20 mg/mL via intramuscular injection in the deltoid muscle 112 days apart.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
62205326|NCT04441853|ACTIVE_COMPARATOR|No YouTube video group|The control group were offered for five sessions of tutorial with same content without YouTube or other audio-visual tools. They also needed to join for group discussion in each tutorial.
62016041|NCT04894435|ACTIVE_COMPARATOR|Group 3: Moderna, Pfizer/BioNTech - 28 days apart|"Participants will be blinded and receive one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine after 28 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
62016042|NCT04894435|ACTIVE_COMPARATOR|Group 4: Moderna, Pfizer/BioNTech - 112 days apart|"Participants will be blinded and receive one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine after 112 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
62205327|NCT03085836|EXPERIMENTAL|TAK-438 10 milligram (mg) Once Daily|TAK-438 10 mg, tablets, orally, once daily on Days 1, 3-9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.
62016043|NCT04894435|ACTIVE_COMPARATOR|Group 5: Pfizer/BioNTech, Pfizer/BioNTech - 28 days apart|"Participants will be blinded and receive two doses (0.3mL each) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle 28 days apart.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
62016044|NCT04894435|ACTIVE_COMPARATOR|Group 6: Pfizer/BioNTech, Pfizer/BioNTech - 112 days apart|"Participants will be blinded and receive two doses (0.3mL each) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle 112 days apart.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
62016045|NCT04894435|ACTIVE_COMPARATOR|Group 7: Pfizer/BioNTech, Moderna - 28 days apart|"Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 28 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
62205328|NCT03085836|EXPERIMENTAL|TAK-438 20 mg Once Daily|TAK-438 20 mg, tablets, orally, once daily on Days 1, 3-9. Participants were asked to fast for a minimum of 10 hours prior administration of assigned treatment.
62205329|NCT03085836|EXPERIMENTAL|TAK-438 20 mg Twice Daily|TAK-438 20 mg, tablets, orally, once on Day 1 and twice daily on Days 3-9. Participants were asked to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.
62205330|NCT00567203|EXPERIMENTAL|1|
62205331|NCT00567203|EXPERIMENTAL|2|
62205332|NCT00567203|PLACEBO_COMPARATOR|3|
62205333|NCT03968380||Population in Quito|720 randomly chosen people living in District 17D06, Quito (Ecuador)
62205334|NCT03968380||Population in Esmeraldas|720 randomly chosen people living in Eloy Alfaro District, Esmeraldas (Ecuador)
62205335|NCT05827913|EXPERIMENTAL|Polylevolactic Acid Injection|Polylevolactic Acid Injection in SD
62205336|NCT05827913|ACTIVE_COMPARATOR|Fractional Laser|1565nm Non-ablative Fractional Laser treatment in SD
62787953|NCT05386381||Decompression with fusion|Patient undergone decompression and lumbar fusion surgery
62787954|NCT00779025|ACTIVE_COMPARATOR|MINE Alone|Female Personal Lubricant (PD-F-5254)
62787955|NCT00779025|EXPERIMENTAL|YOURS and MINE|Male Personal Lubricant (10855-096) used in conjunction with Female Personal Lubricant (PD-F-5254)
62787956|NCT02110862||Ulcerative colitis patients with ileal-pouch-anal anastomosis|
62787957|NCT01771237|EXPERIMENTAL|MyPeeps Manualized Group Intervention|Highly interactive, HIV prevention skills-based group intervention in 6 sessions. Tailored to YMSM.
62787958|NCT01771237|ACTIVE_COMPARATOR|Standard Sexual Health Education|Educational group intervention focused on HIV and STI knowledge using a lecture-based format in 6 sessions. Non-tailored to YMSM.
62787959|NCT02373644|EXPERIMENTAL|HVLA Thrust Manipulation and DN|
62787960|NCT02373644|ACTIVE_COMPARATOR|Conventional Physical Therapy|
62787961|NCT00757094||I|Patients planning to observe fasting while receiving chemotherapy during the month of Ramadan
62787962|NCT02775448|EXPERIMENTAL|Diet + exercise + Carduus marianus 6cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 6cH, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
62787963|NCT02775448|EXPERIMENTAL|Diet + exercise + Carduus marianus 12cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 12cH, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
62787964|NCT02775448|EXPERIMENTAL|Diet + exercise + Carduus marianus 30cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 30c, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
62787965|NCT02775448|PLACEBO_COMPARATOR|Diet + exercise + placebo|Diet (1600 cal/day) + aerobic exercise (30 min daily) + placebo (87°alcohol), 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
62787966|NCT05639530|EXPERIMENTAL|:treated with different doses of single intravitreal injections of IBI333|"Biological: IBI333 Dose 1 IBI333 of single IVT injections，~Biological: IBI333 Dose 2 IBI333 of single IVT injections"
62787967|NCT05639530|EXPERIMENTAL|treated with different doses of multiple intravitreal injections of IBI333|"Biological: IBI333 Dose 3 IBI333 of multiple IVT injections，~Biological: IBI333 Dose 4 IBI333 of multiple IVT injections"
62787968|NCT01191177|EXPERIMENTAL|Lovaza group|Patients randomized to this group will receive Lovaza 1gram per kilogram of body weight, not exceeding 4grams a day
62787969|NCT01191177|PLACEBO_COMPARATOR|Placebo group|Patients randomized to this group will receive corn oil supplement 1gram per kilogram of body weight, not exceeding 4grams per day
62787970|NCT06256393||Patients|Patients of both sexes, over 18 years of age, with an established diagnosis of IBD (Crohn's desease, ulcerative colitis, unclassified IBD or chronic pouchitis) will be eligible for inclusion in a consultation to schedule surgery or colonoscopy for disease relapse (at diagnosis or prior to initiation of treatment), irrespective of treatment received
62787971|NCT04262076|EXPERIMENTAL|Combination of pulpine with Polyamidoamine Dendrimer|Removal of Caries infected dentin from the walls and floor of the cavity and then apply polyamidoamine Denrimer for 30 secs ,then washed out of the cavity followed by placement of Pulpine over affected Dentin.
62016046|NCT04894435|ACTIVE_COMPARATOR|Group 8: Pfizer/BioNTech, Moderna - 112 days apart|"Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 112 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
62205337|NCT05827913|ACTIVE_COMPARATOR|combination treatment|Polylevolactic Acid injection combined with 1565nm Non-ablative Fractional Laser treatment in SD
62787972|NCT04262076|ACTIVE_COMPARATOR|Pulpine|Removal of Caries infected dentin from the walls and the floor of the cavity followed by application of Pulpine over affected Dentin.
62787973|NCT00379912|EXPERIMENTAL|Investigational Arm A|Azacitidine + Erythropoietin
62787974|NCT00379912|EXPERIMENTAL|Investigational Arm B|Azacitidine
62787975|NCT02290041|EXPERIMENTAL|Mesenchymal stem cells|Intravenous infusion of 4 doses of allogenic adult mesenchymal stem cells from adipose tissue
62787976|NCT02290041|PLACEBO_COMPARATOR|Placebo|Intravenous infusion of 4 doses of Placebo
62787977|NCT02624895||mCRC: Anti-EGFR MAbs + FOLFOX 1st line|• Adult (\>= 18 years old) RAS wild-type metastatic colorectal cancer patients candidate to receive FOLFOX plus panitumumab or FOLFOX plus cetuximab as upfront treatment as per clinical practice.
62787978|NCT02624895||mCRC: Anti EGFR MAbs + FOLFIRI 1st line|Adults (\>= 18 years old) RAS wild-type metastatic colorectal cancer patients candidate to receive FOLFIRI plus panitumumab or FOLFIRI plus cetuximab as upfront treatment as per clinical practice
62205338|NCT02760875||Early Weight Bearing|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from day 1. The orthosis was worn 24 hours / day the first 2 weeks.~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
62787979|NCT05311930|EXPERIMENTAL|2.5mg/d|After the subjects signed the informed consent and passed the screening, they entered the treatment period and received a starting dose of 2.5 mg/d of Hetrabopag. During the treatment process, the clinician adjusted the drug dose according to the patient's own conditions. The maximum drug dose was 7.5 mg qd, 28 d Evaluate efficacy and safety after completion;
62787980|NCT02377999|EXPERIMENTAL|Treatment of genetial warts with Picato|
62787981|NCT03477838|EXPERIMENTAL|CGM Intervention arm|Patients eligible for care at the free clinic with diabetes and A1c greater than 8% on insulin therapy will be identified for CGM use.
62580735|NCT05629221|NO_INTERVENTION|non-App users|"Sixty individuals are allocated to the control group. These participants will receive standard care, which is the best care for T2DM in line with the integrated preventive and diagnostic care pathway (called Percorsi Preventivi Diagnostici Terapeutici Assistenziali - PPDTA in Italian).An appointment with the outpatient diabetes clinic staff is scheduled at 6 and 12 month from the first visit (taking place within 30 days of the study entry), either through telemedicine (remote visit) or face-to-face. Participants are asked to register their data as per routine (e.g. paper diary)."
62016047|NCT04894435|ACTIVE_COMPARATOR|Group 9: Astra Zeneca, Moderna - 28 days apart|"Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S \[recombinant\] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 28 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
62016048|NCT04894435|ACTIVE_COMPARATOR|Group 10: Astra Zeneca, Moderna - 112 days apart|"Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S \[recombinant\] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 112 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
62016049|NCT04894435|ACTIVE_COMPARATOR|Group 11: Astra Zeneca, Pfizer/BioNTech - 28 days apart|"Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S \[recombinant\] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3 mL) of BNT162b2 vaccine after 28 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
62016050|NCT04894435|ACTIVE_COMPARATOR|Group 12: Astra Zeneca, Pfizer/BioNTech - 112 days apart|"Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S \[recombinant\] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3 mL) of BNT162b2 vaccine after 112 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
62016051|NCT04894435|ACTIVE_COMPARATOR|Group 1b|Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.
62016052|NCT04894435|ACTIVE_COMPARATOR|Group 2b|Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.
62016053|NCT04894435|ACTIVE_COMPARATOR|Group 3b|Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.
62016054|NCT04894435|ACTIVE_COMPARATOR|Group 4b|Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.
62016055|NCT04894435|ACTIVE_COMPARATOR|Group 5b|Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.
62787982|NCT03631758|EXPERIMENTAL|Experimental: Evidence + PDA|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources), plus a blog post on PDAs and the relevant decision aid from the Portal database
62205339|NCT02760875||control|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from week 6. The orthosis was worn 24 hours / day the first 2 weeks.~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
62787983|NCT03631758|EXPERIMENTAL|Evidence only|The same evidence-based information as group 1 (Evidence + PDA), but without the PDA to quantify the effect of accessing evidence through the Portal alone
62787984|NCT03631758|SHAM_COMPARATOR|Attention control|Information on how to distinguish high from low-quality health information, not specific to cancer screening or PDAs
62787985|NCT01189695|EXPERIMENTAL|Boosted lopinavir monotherapy|
62016056|NCT04894435|ACTIVE_COMPARATOR|Group 6b|Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.
62016057|NCT04894435|ACTIVE_COMPARATOR|Group 7b|Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.
62016058|NCT04894435|ACTIVE_COMPARATOR|Group 8b|Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.
62016059|NCT04894435|EXPERIMENTAL|Group 9b|Participants will receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.
62016060|NCT04894435|ACTIVE_COMPARATOR|Group 1c|Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.
62016061|NCT04894435|ACTIVE_COMPARATOR|Group 2c|Participants will be blinded and receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.
62016062|NCT04894435|ACTIVE_COMPARATOR|Group 3c|Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.
62580736|NCT03593460|EXPERIMENTAL|sPIF 1 mg/kg (Starting Dose)|Patients will be administered a starting dose of sPIF 1mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
62580737|NCT03593460|EXPERIMENTAL|sPIF 2 mg/kg|Patients will be dosed at 2mg/kg sPIF for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels.
62580738|NCT03593460|EXPERIMENTAL|sPIF 3 mg/kg|Patients will be administered a starting dose of sPIF 3mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
62787986|NCT01189695|ACTIVE_COMPARATOR|boosted lopinavir + optimized background regimens (OBRs)|
62787987|NCT02499705|EXPERIMENTAL|Sucralose|Flavored beverage with sucralose.
62787988|NCT02499705|EXPERIMENTAL|Sucrose|Flavored beverage with sucrose.
62016063|NCT04894435|ACTIVE_COMPARATOR|Group 4c|Participants will be blinded and receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.
62016064|NCT04894435|ACTIVE_COMPARATOR|Group 5c|Participants will be blinded and receive either one dose (0.3mL) of BNT162b2 or one half dose (0.25mL) of mRNA-1273 via intramuscular injection in the deltoid muscle.
62787989|NCT02499705|EXPERIMENTAL|Sucralose + maltodextrin|Flavored beverage with Splenda + maltodextrin .
62787990|NCT05498467|ACTIVE_COMPARATOR|Anakinra|
62787991|NCT05498467|PLACEBO_COMPARATOR|Placebo|
62404741|NCT04270331|EXPERIMENTAL|An After group|PADS (pain, agitation, delirium, sleep deprivation assessment and management) protocol assigned
62404742|NCT00909857|EXPERIMENTAL|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one tablet SH T00658ID (BAY86-5027) plus one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles
62580739|NCT03593460|EXPERIMENTAL|sPIF 4 mg/kg|Patients will be administered a starting dose of sPIF 4mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
62580740|NCT03593460|EXPERIMENTAL|sPIF 5 mg/kg|Patients will be administered a starting dose of sPIF 5mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels.
62580741|NCT06281496|EXPERIMENTAL|Intervention group|The intervention is a stepped-care multi-modal intervention and consists of 4 steps, including screening for vulnerability, digital health support and education. Individual consultations based on PRO data (HM-PRO) and multidisciplinary late effects management based on PRO assessment. The multidisciplinary team will consist of nurses, hematologists, physiotherapists, social workers, and dietitians.
62016065|NCT04894435|ACTIVE_COMPARATOR|Group 6c|Participants will be blinded and receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.
62404743|NCT00909857|ACTIVE_COMPARATOR|Ethinyl estradiol, Levonorgestrel (Miranova)|Daily oral administration of one tablet placebo plus one tablet SH D593B (Miranova) for 28 days without tablet-free interval for 3 treatment cycles
62580742|NCT06281496|NO_INTERVENTION|Control Group|Patients in the control group will receive usual care
62404744|NCT01166126|EXPERIMENTAL|Treatment (temsirolimus and selumetinib)|"Treatment Phase: This period begins with the first intravenous (through the vein) infusion of TEMSIROLIMUS and the first AZD6244 administration by mouth (visit 2, Week 1) and will continue until Week 8 (Visit 4).~As many as 38 patients will receive the same dosage of TEMSIROLIMUS injected in the veins once a week for 8 weeks, and the AZD6244 will be given as capsules by mouth twice a day for 8 weeks. That is one cycle. The TEMSIROLIMUS and AZD6244 will be given to participants as an outpatient, unless admission to the hospital was needed for treatment of related side effects or underlying disease. The subsequent cycles of TEMSIROLIMUS and AZD6244 will be given every 8 weeks. The TEMSIROLIMUS will be injected in a vein over 30 minutes.~The continuation phase begins with visits at weeks 12 in patients who receive at least two cycles of treatments."
62404745|NCT04941014|ACTIVE_COMPARATOR|Light Physical Activity (LPA)|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Leisure Walk for 35 minutes
62016066|NCT04894435|EXPERIMENTAL|Group 7c|Participants will receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.
62016067|NCT03115424|PLACEBO_COMPARATOR|Sleeve Gastrectomy Placebo|Subjects undergoing Sleeve Gastrectomy (SG) will be randomized 1:1 at the time of 3 month visit after bariatric surgery.
62016068|NCT03115424|ACTIVE_COMPARATOR|Sleeve Gastrectomy Saxenda|Subjects undergoing Sleeve Gastrectomy (SG) will be randomized 1:1 at the time of 3 month visit after bariatric surgery.
62016069|NCT03115424|SHAM_COMPARATOR|RYGB|Twenty five subjects will be recruited from the Nutrition Clinic at Mayo Clinic Rochester prior to undergoing RYGB surgery.
62016070|NCT05209191|EXPERIMENTAL|Student Athlete Wellness Portal|Web-based intervention that illustrates opioid misuse and diversion resistance strategies.
62016071|NCT06531733|EXPERIMENTAL|sleep promoting + wake placebo|Participants in this condition will listen to pink noise during a sleep opportunity (sleep promoting) and then have normal light with no nap (sham/placebo).
62016072|NCT06531733|EXPERIMENTAL|sleep placebo + wake promoting|Participants in this condition will have a sleep opportunity with no pink noise (sham/placebo) and then be exposed to blue enriched light (wake promoting) after a nap.
62016073|NCT06531733|EXPERIMENTAL|sleep promoting + wake promoting|Participants in this condition will be exposed to pink noise during a sleep opportunity (sleep promoting) and then be exposed to blue enriched light (wake promoting) after a nap.
62404746|NCT04941014|ACTIVE_COMPARATOR|Moderate Physical Activity (MPA)|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Brisk Walk for 30 minutes
62787992|NCT03976206|EXPERIMENTAL|VSEL Max|We carried out the subdermal application of VSELs with a 1-mL syringe (90,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
62787993|NCT03976206|EXPERIMENTAL|VSEL Medium|We carried out the subdermal application of VSELs with a 1-mL syringe (60,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
62787994|NCT03976206|EXPERIMENTAL|VSEL Mini|We carried out the subdermal application of VSELs with a 1-mL syringe (30,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
62787995|NCT03976206|NO_INTERVENTION|Control|Subcutaneous injection of 0.4 mL platelet-rich plasma in the same part of the experimental group
62787996|NCT03539601|EXPERIMENTAL|Crisaborole ointment, 2%|This treatment arm will be administered both in Cohort 1 and Cohort 2.
62787997|NCT03539601|ACTIVE_COMPARATOR|Hydrocortisone butyrate cream, 0.1%|This treatment arm will be administered in Cohort 1 only.
62787998|NCT03539601|ACTIVE_COMPARATOR|Pimecrolimus cream, 1%|This treatment arm will be administered in Cohort 2 only.
62016074|NCT00389818|EXPERIMENTAL|DR-COP|Single arm interventional study: all subjects receive DR-COP regimen.
62016075|NCT03156023|EXPERIMENTAL|Rozibafusp Alfa|"Participants will receive rozibafusp alfa administered subcutaneously once every 2 weeks for up to 10 weeks (6 doses). Rozibafusp alfa doses will range from 70 to 420 mg.~Escalation to a higher dose cohort will be contingent on a review indicating that the previous dose regimen has been found to demonstrate an acceptable safety and tolerability profile at a dose level review meeting (DLRM)."
62016076|NCT03156023|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo to rozibafusp alfa administered subcutaneously once every 2 weeks for up to 10 weeks (6 doses).
62016077|NCT03223558|EXPERIMENTAL|early rehab group|start of 8 weeks cardiac rehabilitation 2 weeks following surgery
62205340|NCT00517400|ACTIVE_COMPARATOR|Exposure-Stimulation|
62205341|NCT00517400|ACTIVE_COMPARATOR|Sham exposure - Real stimulation|
62205342|NCT00517400|ACTIVE_COMPARATOR|Exposure - Sham Stimulation|
62205343|NCT00013260|OTHER|Arm 1|
62404747|NCT04941014|ACTIVE_COMPARATOR|Vigorous Physical activity (VPA)|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform jogging for 15 minutes
62787999|NCT03539601|PLACEBO_COMPARATOR|Crisaborole Vehicle|This treatment arm will be administered both in Cohort 1 and Cohort 2.
62788000|NCT06288074||Severe community-acquired pneumonia|
62788001|NCT06288074||Non-Severe community-acquired pneumonia|
62788002|NCT06288074||Healthy control|
62788003|NCT05405335|EXPERIMENTAL|Prone Positioned Group|"Intermittent prone positioning for a total of eight hours per day for seven days. Each cycle of prone positioning should not be less than 30 minutes and note more than 3 hours at one time.~Rest of the treatment as per protocols of the institution"
62788004|NCT05405335|NO_INTERVENTION|Control Group|Treatment as per institutional protocols- the protocols does not involve prone positioning of the patients
62788005|NCT00930228|EXPERIMENTAL|Flutamide|Flutamide 250 mg taken by mouth twice a day for 4 weeks. Flutamide is an androgen-receptor blocker.
62788006|NCT00930228|PLACEBO_COMPARATOR|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
62788007|NCT02489383|ACTIVE_COMPARATOR|Continuous Exercise Training|The interventions of active comparator will be education program and exercise training.
62788008|NCT02489383|ACTIVE_COMPARATOR|Interval Exercise Training|The interventions of active comparator will be education program and exercise training.
62205344|NCT06215885||Subsolid nodules group|Patients with pulmonary subsolid nodules were identified by CT examination and intended for surgical treatment. All participants will undergo chest CT, genomic, and proteomic tests to identify related biomarkers and establish a clinical diagnostic model for the invasiveness of subsolid nodules.
62205345|NCT06215885||Volunteers group|Healthy volunteers.
62580743|NCT02570867||normal control group|Normal control group: healthy volunteers will be received Functional magnetic resonance imaging（fMRI) and eye examination including visual acuity, visual field, intraocular pressure, anterior chamber angle, corneal thickness and optic nerve fiber thickness one time.
62580744|NCT02570867||POAG group|POAG: The primary open angle glaucoma cases were will be received Functional magnetic resonance imaging（fMRI) and eye examination including visual acuity, visual field, intraocular pressure, anterior chamber angle, corneal thickness and optic nerve fiber thickness one time.
62404748|NCT05649865||Patients with HPV-positive OPC|Patients with HPV-positive OPC. They will provide blood samples before during and after treatment to evaluate treatment response and for early detection of recurrence
62580745|NCT02632851||Ectoin inhalation solution|treatment according to instructions for use
62580746|NCT02632851||Pari NaCl inhalation solution (0.9%)|treatment according to instructions for use
62788009|NCT00854815|ACTIVE_COMPARATOR|Irrigation|Irrigation of the area with at least 500ml normal saline using the power suction/irrigator
62788010|NCT00854815|ACTIVE_COMPARATOR|No Irrigation|Only suction with the power suction/irrigator without saline attached
62788011|NCT00105690|OTHER|Arm 1|
62404749|NCT04746495|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive 4 weeks of placebo and then 4 weeks of Eplerenone.
62788012|NCT04321434|EXPERIMENTAL|Hyperoxia|"* assessment of forearm skin microcirculatory blood flow by laser Doppler perfusion imager at baseline and during hyperemic tests~* assessment of coronary microcirculatory blood flow at baseline and during hyperemic tests"
62404750|NCT04746495|EXPERIMENTAL|Eplerenone|Participants will be randomized to receive 4 weeks of Eplerenone and then 4 weeks of Placebo.
62404751|NCT00978120|EXPERIMENTAL|H1N1 vaccine high dose|Participants will be stratified according to asthma severity and will receive the high dosage of the H1N1 vaccine.
62788013|NCT04321434|PLACEBO_COMPARATOR|Normoxia|"* assessment of forearm skin microcirculatory blood flow by laser Doppler perfusion imager at baseline and during hyperemic tests~* assessment of coronary microcirculatory blood flow at baseline and during hyperemic tests"
62788014|NCT02914574|OTHER|healthy control|Healthy control group will attend one visit and functional performance, muscle strength and flexibility, quadriceps AMI, patellar position and posture will be measured. No intervention will be applied.
62788015|NCT06069947|EXPERIMENTAL|Surgical group|SALT operation plan for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
62016078|NCT03223558|ACTIVE_COMPARATOR|usual care group|start 8 weeks of cardiac rehabilitation 6 weeks post surgery
62205346|NCT02261753|ACTIVE_COMPARATOR|A: Classical ketogenic diet|The KD is a high fat, low carbohydrate, low protein diet designed to mimic the effects of fasting on the body. It will be administered by calculation as per local standardised classical KD protocol with utilisation of long chain fat in a ratio of 2:1 to 4:1 carbohydrate and protein.
62205347|NCT02261753|NO_INTERVENTION|B: No pretreatment|Following the decision to proceed to surgery, if randomised to this arm a date will be given for surgery as per routine clinical practice. No KD pre-treatment will be undertaken.
62205348|NCT06382675|OTHER|Therapeutic Plasma Exchange (TPE)|Patients with indication for TPE treatment according to American Society for Apheresis (ASFA) guideline
62404752|NCT00978120|EXPERIMENTAL|H1N1 vaccine low dose|Participants will be stratified according to asthma severity and will receive the low dosage of the H1N1 vaccine.
62404753|NCT02010671||Women with a prior cesarean section|Survey of women who had a cesarean section with their last pregnancy and no other prior cesarean section deliveries
62580747|NCT02159157|NO_INTERVENTION|Arm A|"Physical Therapy consult for post op care and general physical activity recommendation 1-4 weeks prior to starting chemotherapy.~Phone calls designed to support the patient to maintain current activity level."
62580748|NCT02159157|PLACEBO_COMPARATOR|Arm B|"Physical Therapy consult for post-op care 1-4 weeks prior to starting chemotherapy.~Exercise prescription aimed at increasing physical activity by a minimum of 10 MET hours/week.~Motivational phone calls aimed at encouraging the patient to adhere to their exercise prescription."
62580749|NCT00117884|EXPERIMENTAL|1|
62580750|NCT00117884|EXPERIMENTAL|2|
62580751|NCT00117884|EXPERIMENTAL|3|
62580752|NCT00117884|EXPERIMENTAL|4|
62580753|NCT00117884|EXPERIMENTAL|5|
62580754|NCT00117884|EXPERIMENTAL|6|
62580755|NCT00117884|EXPERIMENTAL|7|
62580756|NCT00117884|EXPERIMENTAL|8|
62788016|NCT01941459||1 Custodiol|Custodiol
62788017|NCT01941459||2 Blood cardioplegia|Blood cardioplegia
62788018|NCT03999840|EXPERIMENTAL|IMP|Cemdisiran (600 mg) or placebo will be administered subcutaneously every four weeks up to week 32 (end of the Core Study).
62788019|NCT03999840|PLACEBO_COMPARATOR|Placebo|Cemdisiran (600 mg) or placebo will be administered subcutaneously every four weeks up to week 32 (end of the Core Study).
62788020|NCT05517057||success of the medical management|Patients that recovered flatus and stools, and that tolerated solid food within the 3 days after the admission
62016079|NCT06572319|EXPERIMENTAL|Phase Ⅰ/Ⅱ： Disitamab Vedotin(RC48) Plus Tratuzumab|"Dose exploration： Disitamab Vedotin（RC48）: 2.5mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle.~Tratuzumab:3+3Design，1mg/kg Q2W，2.5mg/kg Q2W，4mg/kg Q2W Dose expansion： Disitamab Vedotin（RC48）: 2.5mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle.~Tratuzumab: RP2D"
62016080|NCT05254379|EXPERIMENTAL|Transcranial Direct-Current Stimulation (tDCS)|Participants will be assigned to tDCS intervention. Starting Day 1 of EHVP-IOP, remote-based tDCS will be administered with a constant current intensity for 20 min per session for up to 10 sessions over 2 weeks (one session per day) using a Soterix 1x1 tDCS mini-CT Stimulator with headgear and saline-soaked surface sponge electrodes. Therapy sessions will be performed over Zoom. With the exception of day one when the session will occur on its own, the sessions will occur within one hour of the start of the daily therapy session.
62016081|NCT00721994||1|IDE subjects who received the Cormet Hip Resurfacing device
62016082|NCT06275100|EXPERIMENTAL|Prehabilitation arm|"Participants will be exposed to physical and psychological prehabilitation whilst waiting for surgery. The prehabilitation will not alter the surgical waiting time or any medical intervention but aims to work around patient's essential care.~Physical/ exercise component has a directly supervised component (aerobic exercise) and an unsupervised portion (Inspiratory muscle training and strength training) which is done via an app or leaflet depending on participant's preference. Participants will be given a guide number of exercises to do in their own time throughout the day.~The psychological component consist of a psychoeducation booklet, meditation audio and signposting if they require further assistance. The psychoeducation component is voluntary."
62016083|NCT03345459|EXPERIMENTAL|Internet-Based Treatment (ICare)|ICare Prevent is a 7-week internet-based treatment for depression that is primarily cognitive behavior therapy but targets broad-based mechanisms related to college students.
62016084|NCT03345459|NO_INTERVENTION|Usual Care|Participants are notified that they have elevated distress, and additionally, they are provided a list of on-campus and community resources.
62016085|NCT04358926|ACTIVE_COMPARATOR|Hyperbaric oxygen therapy|8 sessions in 4 days hyperbaric oxygen therapy
62016086|NCT04358926|NO_INTERVENTION|Control|Standard of care
62016087|NCT06413433|EXPERIMENTAL|Solriamfetol 150 mg|Up to 12 weeks
62016088|NCT06413433|EXPERIMENTAL|Solriamfetol 300 mg|Up to 12 weeks
62016089|NCT06413433|PLACEBO_COMPARATOR|Placebo|Up to 12 weeks
62016090|NCT05073536|EXPERIMENTAL|mini-sized MCE|Participants in this group underwent examination of mini-sized MCE.
62016091|NCT05073536|OTHER|normal-sized MCE|Participants in this group underwent examination of normal-sized MCE.
62788021|NCT05517057||failure of the medical management|Patients that did not recover flatus and stools, and that did not tolerate solid food within the 3 days after the admission. These patients had an indication for surgery.
62788022|NCT03944291|ACTIVE_COMPARATOR|Unilateral PNB|Unilateral Pudendal Nerve Block
62788023|NCT03944291|ACTIVE_COMPARATOR|Bilateral PNB|Bilateral Pudendal Nerve Block
62788024|NCT03547895|ACTIVE_COMPARATOR|cases|"patients with decompensated cirrhosis~treated with Sofosbuvir 400 mg (Sovaldi) + Daclatasvir 60mg (Daklinza) + Ribavirin 200 mg (Rebetol)"
62788025|NCT03547895|PLACEBO_COMPARATOR|control group|the control group treated with liver support including silymarin 140 + phytomenadione 10 mg + lasilactone 50 mg + albumin infusion
62788026|NCT05844267|EXPERIMENTAL|Booster Breaks group (led breaks)|Participants will engage in active breaks led by a professional, where they will perform various exercises based on the guidelines provided by the Chilean safety association (ACHS). These breaks will have an average duration of 14-16 minutes per day and will take place from Monday to Friday for a period of 12 weeks.
62016092|NCT06074250|EXPERIMENTAL|Gutopia|Women in this arm will receive dietary modification, fish oil and probiotics from the time of enrollment till completion of last study visit (12 months postpartum). The dietary modification will be conducted by a dietician that will provide feedback on the participants diet at enrollment, ways to improve diet quality to meet pregnancy needs, and increase prebiotic foods. Weekly follow-ups will be conducted by the research team to ensure dietary target is met and to help address challenges in doing so. The initial dietary consult will be 30-45 minutes long with 10-15 minute for each subsequent follow-up.
62016093|NCT06074250|EXPERIMENTAL|Gutboost|Women in this arm will receive a daily probiotic and fish oil supplement from the time of enrollment till 1 year postpartum.
62016094|NCT06074250|EXPERIMENTAL|Gutless|Women in this arm will receive fish oil and placebo probiotic from the time enrollment till 1 year postpartum .
62016095|NCT06074250|ACTIVE_COMPARATOR|Gutnone|Women in this arm will only be receiving standard care by their obstetrician, and a one time, 30 minutes consult on how to improve baseline diet quality to meet pregnancy needs will be provided by a dietician at the time of enrollment.
62016096|NCT00646958|EXPERIMENTAL|1|Radezolid 450 mg PO QD
62016097|NCT00646958|EXPERIMENTAL|2|Radezolid 450 mg PO BID
62016098|NCT00646958|ACTIVE_COMPARATOR|3|Linezolid 600 mg PO BID
62404754|NCT05932979|EXPERIMENTAL|L-arginine|L-arginine 3 grams per day, divided into doses of 1 g every 8 hours during 90 days.
62404755|NCT05932979|PLACEBO_COMPARATOR|Placebo|Starch 1 gr every 8hr, during 90 days.
62404756|NCT04096716|EXPERIMENTAL|Cohort 1: Tc-99m tilmanocept|"* The surgeon will inject up to 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor~* Portable planar imaging will be obtained at 4.5 ± 2.5 hours and 24 +/- 8 hours after injection of Tc-99m tilmanocept."
62404757|NCT04096716|EXPERIMENTAL|Cohort 2A: Tc-99m tilmanocept frontal lobe injection site|"* The surgeon will inject up to 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor~* SPECT/CT of the head and neck will be obtained when practical on the day of surgery.~If the patient is not sufficiently recovered from surgery to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2"
62580757|NCT00117884|EXPERIMENTAL|9|
62580758|NCT00117884|EXPERIMENTAL|10|
62788027|NCT05844267|EXPERIMENTAL|Computer Prompts group (unled breaks)|"Active breaks will be guided by an application called Ponte de Pie por tu Salud, designed by the Chilean Ministry of Health which will be installed on the participants' computers. The application will be configured to generate breaks every hour for a duration of 2 minutes for 8 hours, ensuring that an average of 14-16 minutes of active breaks are accumulated throughout the day."
62788028|NCT05844267|NO_INTERVENTION|Control|The group will participate in evaluations pre-post but not interventions. We will recommend continuing with their usual routine.
62788029|NCT05633888|EXPERIMENTAL|CATAMARAN SI Joint Fusion System|Placement of the Catamaran Fixation Device
62016099|NCT03788889|ACTIVE_COMPARATOR|Lorazepam + Ketamine + Placebo A|"Ketamine - infusion (0.15 - 0.4 mg/kg/hr) and placebo injections titrated by increases of 0.075 mg/kg/hr every 30 minutes for Clinical Institute Withdrawal Assessment for Alcohol (revised version) (CIWA-Ar) greater than or equal to 10 in addition to lorazepam symptom-triggered therapy~Ketamine dosing will be based on ideal body weight~Ketamine infusion will be discontinued once CIWA-Ar less than 10 for 4 hours"
62016100|NCT03788889|ACTIVE_COMPARATOR|Lorazepam + Phenobarbital + Placebo B|"Phenobarbital - IV push (260 mg loading followed by 130 mg q1 hour) with placebo infusion until CIWA-Ar less than 10 with a maximum daily dose of 10mg/kg in addition to lorazepam symptom-triggered dosing for recurrent symptoms (Gold 2007)~Maximum daily dose will be used in order to prevent over sedation as well as provide adequate storage in pharmacy monitored refrigerators for study drugs"
62016101|NCT03788889|PLACEBO_COMPARATOR|Lorazepam + Placebo A + Placebo B|Lorazepam will be administered every 30 minutes as indicated based on CIWA-Ar protocol for Cottage Health in addition to placebo injections and placebo infusion
62788030|NCT03051308|EXPERIMENTAL|First Application in Hour 0|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10\^7 cells) at 'First Application in Hour 0' non-cold ischemia tissue group
62788031|NCT03051308|EXPERIMENTAL|First Application in Hour 6|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10\^7 cells) at 'First Application in Hour 6' cold ischemic tissue group
62016102|NCT05826821||Pirfenidone|Pirfenidone 801mg capsule by mouth, three times a day (target dose) for 12 months
62016103|NCT05826821||Placebo|Placebo capsule by mouth, three times a day (target dose) for 12 months
62404758|NCT04096716|EXPERIMENTAL|Cohort 2B: Tc-99m tilmanocept parietal lobe injection site|"* The surgeon will inject up to 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor~* SPECT/CT of the head and neck will be obtained when practical on the day of surgery.~If the patient is not sufficiently recovered from surgery to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2"
62580759|NCT00117884|EXPERIMENTAL|11|
62580760|NCT02369003|EXPERIMENTAL|Peripheral Nerve Graft|The intervention includes the surgical implantation of autologous peripheral nerve graft into the substantia nigra, basal forebrain, putamen, and/or STN of participants with Parkinson's Disease that are undergoing Deep Brain Stimulation (DBS).
62788032|NCT03051308|EXPERIMENTAL|First Application in Hour 12|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10\^7 cells) at 'First Application in Hour 12' cold ischemic tissue group
62205349|NCT01012401|EXPERIMENTAL|CHESS with Clinician Report + Internet access|An Internet-based system, Comprehensive Health Enhancement Support System for Lung Cancer(CHESS-LC) integrates over 14 services to provide tailored cancer information, support, and interactive tools.
62580761|NCT06533956|EXPERIMENTAL|gait training associated with BFR|The children will receive a 10-week intervention (1 week of habituation without BFR + 9 weeks with BFR) comprising 3 30-minute treadmill sessions per week. At each session, the first 5 minutes will enable a gradual increase in speed, and then the maximum tolerated walking speed will be sought. Maximum speed corresponds to the walking speed maintained by the child for an effort of between 5 and 7 on Borg's 10-point VAS. The rehabilitator will encourage the child to maintain this speed and provide feedback on performance. The BFR setting will maintain an occlusion, at the root level of both lower limbs, of 60% of the total occlusal pressure.
62580762|NCT05878002|OTHER|Patients affected by acute ischemic stroke treated with mechanical thrombectomy|
62580763|NCT06414057||All participants|Investigators will offer Gardasil-9 and HPV self-swab screening to up to 500 individuals across the three study sites, aiming to recruit 120-180 individuals within each of the three participating health boards over a 6-9 month timeframe. Participants will be asked to provide a vaginal swab sample for baseline HPV testing.
62016104|NCT05423509|OTHER|Standard treatment for AIS|These are the participants with AIS that recieved the standard treatment with observation or bracing depending on the size of their curve.
62205350|NCT01012401|ACTIVE_COMPARATOR|Usual care with Internet access|Control group patients will be given a list of URLs for 10-high quality lung cancer-related sites
62205351|NCT00974818|EXPERIMENTAL|pts getting Mitomycin C (MMC)|Patients will receive a induction course of 6 cycles of weekly intravesical therapy of MMC, followed by a maintenance schedule consisting of 3 weekly cycles of the same drug at 3, 6, 12, 18, and 24 months.
62580764|NCT06356662|EXPERIMENTAL|Tenofovir|patients with parkinson's disease
62205352|NCT00974818|EXPERIMENTAL|pts getting Bacillus Calmette-Guerin (BCG)|Patients will receive a induction course of 6 cycles of weekly intravesical therapy of either BCG, followed by a maintenance schedule consisting of 3 weekly cycles of the same drug at 3, 6, 12, 18, and 24 months.
62580765|NCT06356662|PLACEBO_COMPARATOR|Placebo|patients with parkinson's disease
62788033|NCT03051308|EXPERIMENTAL|First Application in Hour 18|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10\^7 cells) at 'First Application in Hour 18' cold ischemic tissue group
62788034|NCT03051308|EXPERIMENTAL|First Application in Hour 24|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10\^7 cells) at 'First Application in Hour' 24 cold ischemic tissue group
62205353|NCT01693900|EXPERIMENTAL|Pre-operative Ultrasound FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under an ultrasound guidance device with an in-plane technique by a single study investigator, in the preoperative area.
62404759|NCT04096716|EXPERIMENTAL|Cohort 2C: Tc-99m tilmanocept temporal lobe injection site|"* The surgeon will inject up to 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor~* SPECT/CT of the head and neck will be obtained when practical on the day of surgery.~If the patient is not sufficiently recovered from surgery to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2"
62580766|NCT05007431||Women asylum seekers|
62580767|NCT03728348||Subject aged 45-49 with Average CRC Risk|Subject aged 45-49 with average risk for development of CRC.
62205354|NCT01693900|ACTIVE_COMPARATOR|Intra-operative FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room.
62205355|NCT03500991|EXPERIMENTAL|ARM A (Tumor Cavity Infusion)|"patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity~Intervention: HER2-specific chimeric antigen receptor (CAR) T cell"
62016105|NCT05423509|EXPERIMENTAL|Treatment with Dynamic Myofascial Manipulation|These are the participants that still received the standard treatment with observation or bracing depending on the size of their curve, but also had weekly treatment with a chiropractor for 6 months for dynamic myofascial manipulation
62016106|NCT04795284||Patients with symptomatic lumbar spinal stenosis|30-meter walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30-meter walking task twice. Inertial sensors are put on each participant foot.
62580768|NCT03224598|EXPERIMENTAL|No medical abrading|A-101 40% without medically abrading the identified DPN prior to treatment
62205356|NCT03500991|EXPERIMENTAL|ARM B (Ventricular System Infusion)|"patients with either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the fourth ventricle or lateral ventricle, respectively~Intervention: HER2-specific chimeric antigen receptor (CAR) T cell"
62205357|NCT03545477|EXPERIMENTAL|Novel treatment, curved-walking training|It consists of 20 sessions of training (three times a week for seven weeks) composed by standard physical therapy and a novel approach to locomotion rehabilitation based on curved-walking training. Each session lasts about 90 minutes.
62205358|NCT03545477|ACTIVE_COMPARATOR|Usual care|It consists of 20 sessions of training (three times a week for seven weeks) of standard physical therapy and conventional straight-walking training. Each session lasts about 90 minutes.
62205359|NCT01786226|EXPERIMENTAL|Mifepristone 2.5 mg daily for three months|Experimental: 1
62205360|NCT01786226|EXPERIMENTAL|Mifepristone 5 mg daily for three months|Experimental: 2
62205361|NCT06487962|EXPERIMENTAL|Continuous Glucose Monitoring (CGM) Intervention Arm|The intervention arm comprises participants receiving care from FQHC sites randomized to deliver the intervention. This arm will receive the 6-month, SEM-informed intervention to promote CGM uptake and maintenance.
62205362|NCT06487962|OTHER|Self-Monitoring of Blood Glucose (SMBG) Arm|The SMBG control arm comprises participants receiving care from FQHC sites randomized to deliver the control condition. This arm will receive the 6-month control condition.
62205363|NCT01074918|EXPERIMENTAL|Potassium Magnesium Citrate|
62205364|NCT01074918|ACTIVE_COMPARATOR|Potassium Chloride|
62205365|NCT06647407|EXPERIMENTAL|Stage 1: MenPenta vaccine formulation 1|MenPenta vaccine formulation 1, children 2-9 years of age
62205366|NCT06647407|EXPERIMENTAL|Stage 1: MenPenta vaccine formulation 2|MenPenta vaccine formulation 2, children 2-9 years of age
62580769|NCT03224598|EXPERIMENTAL|Medically abrading|A-101 40% with the identified DPN lesions medically abraded prior to treatment
62016107|NCT04795284||Healthy elderly|30-meter walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30-meter walking task twice. Inertial sensors are put on each participant foot.
62016108|NCT05809453|EXPERIMENTAL|Cocaine|Prior to entering the warm environmental conditions the participant will receive cocaine intranasally at a dose no higher than 3 mg per kilogram body mass. This dose will be given only once.
62016109|NCT05809453|PLACEBO_COMPARATOR|Lidocaine|Prior to entering the warm environmental conditions the participant will receive lidocaine intranasally at a dose no higher than 3 mg per kilogram body mass. This dose will be given only once.
62205367|NCT06647407|ACTIVE_COMPARATOR|Stage 1: vaccine comparator(s)|Comparator vaccines: Bexsero + MenQuadfi, children 2-9 years of age
62580770|NCT03224598|EXPERIMENTAL|Initial cohort - no medical abrading|A-101 40% without medically abrading the identified DPN prior to treatment
62580771|NCT04956250|EXPERIMENTAL|Traffic Calming Curb Group|Traffic calming curbs are yellow concrete slabs designed by the City of Calgary to be the same height as other roadside curbs and improve safety by reducing the street width, similar to curb extensions.
62580772|NCT04956250|EXPERIMENTAL|In-Street Sign Group|In-street pedestrian signs are regulatory signs placed along the centre line of the street, to remind road users of a pedestrian right-of-way at the marked/unmarked crosswalk.
62580773|NCT04168060|EXPERIMENTAL|Crura Dissection|Participants with a visually detectable hiatal hernia at the time of sleeve gastrectomy procedure will undergo a crura dissection and hiatal hernia repair.
62580774|NCT04168060|EXPERIMENTAL|National Practice|Participants with no detectable hiatal hernia will be randomized to either Group 2 or 3. Group 2 participants will be treated to the national practice patterns of complete dissection of the curvature of the stomach without dissection of the crura.
62016110|NCT06572917|EXPERIMENTAL|Single-dose prophylactic indomethacin - SPIN|Infants randomized to the SPIN group will receive a single 0.1 mg/kg dose of intravenous indomethacin within 12h of birth as a slow infusion over 20 mins.
62016111|NCT06572917|PLACEBO_COMPARATOR|Control|Equal volume saline placebo administered intravenously over 20 mins
62016112|NCT06016972|EXPERIMENTAL|QLS-111 ophthalmic solution|Qlaris' investigational product, QLS-111 ophthalmic solution, provided in 3 concentrations for this study (0.015%, 0.03%. and 0.075%), single use vials, masked, and preservative free (PF).
62016113|NCT06016972|PLACEBO_COMPARATOR|QLS-111 ophthalmic vehicle solution|Inactive control (0.00%). QLS-111 ophthalmic vehicle solution, single use vials, masked, PF.
62016114|NCT06294002|EXPERIMENTAL|Dynamic neuromuscular stabilization group (DNS)|DNS - Dynamic neuromuscular stabilization intervention
62205368|NCT06647407|EXPERIMENTAL|Stage 2: MenPenta vaccine formulation 1|MenPenta vaccine formulation 1 + routine vaccines, toddlers 12-15 months of age
62205369|NCT06647407|EXPERIMENTAL|Stage 2: MenPenta vaccine formulation 2|MenPenta vaccine formulation 2 + routine vaccines, toddlers 12-15 months of age
62205370|NCT06647407|ACTIVE_COMPARATOR|Stage 2: vaccine comparator(s)|Comparator vaccines: Bexsero + MenQuadfi + routine vaccines, toddlers 12-15 months of age
62205371|NCT06647407|EXPERIMENTAL|Stage 3: MenPenta vaccine formulation 1|MenPenta vaccine formulation 1 + routine vaccines, infants approximately 2 months of age
62205372|NCT06647407|EXPERIMENTAL|Stage 3: MenPenta vaccine formulation 2|MenPenta vaccine formulation 2 + routine vaccines, infants approximately 2 months of age
62580775|NCT04168060|EXPERIMENTAL|Standard of Care|Participants with no detectable hiatal hernia will be randomized to either Group 2 or 3. Group 3 participants will undergo the institutional standard of care with the dissection of the crura.
62205373|NCT06647407|ACTIVE_COMPARATOR|Stage 3: vaccine comparator(s)|Comparator vaccines: Bexsero + Nimenrix + routine vaccines, infants approximately 2 months of age
62580776|NCT04711187|EXPERIMENTAL|AT-527 Formulation 1 Dose 1|
62580777|NCT04711187|EXPERIMENTAL|AT-527 Formulation 2 Dose 1|
62580778|NCT04711187|EXPERIMENTAL|AT-527 Formulation 2 Dose 2|
62580779|NCT04711187|EXPERIMENTAL|AT-527 Formulation 1 Dose 3|
62016115|NCT06294002|EXPERIMENTAL|Whole body vibration group (VIBRO)|VIBRO - Whole body vibration intervention
62016116|NCT06294002|EXPERIMENTAL|Dynamic neuromuscular stabilisation with whole body vibration group (MIX)|MIX group - neuromuscular and whole body vibration intervention
62016117|NCT06294002|NO_INTERVENTION|Control group (CONTROL)|Control group - no intervention
62580780|NCT04711187|EXPERIMENTAL|AT-527 Formulation 2 Dose 3|
62580781|NCT04711187|EXPERIMENTAL|AT-527 Formulation 2 Dose 1 Fast/Fed|
62788035|NCT04178720|EXPERIMENTAL|LID018869|Lehfilcon A contact lenses worn in both eyes at least approximately 8 hours per day and approximately 5 days per week during waking hours only. The lenses will be removed nightly for cleaning and disinfection and replaced monthly over the 3-month wear period.
62016118|NCT05019586||Helicobacter pylori resistance|Patients with treatment resistance to Helicobacter pylori treatment registered at GI-unites from 1990-2012 and included from 2010 to 2012. These patients were treated with a triple therapy of levofloxacin, amoxicillin and proton inhibitor for 10 days
62016119|NCT05019586||Newly diagnosed Helicobacter pylori|Patients with newly diagnosed Helicobacter pylori infection from 2010-2012.These patients were treated with a triple therapy of clarithromycin, amoxicillin and proton inhibitor for 10 days
62016120|NCT05019586||Previously eradicated Helicobacter pylori infection|Patients with previously Helicobacter pylori infection included from 2010-2012.
62580782|NCT04711187|EXPERIMENTAL|AT-527 Formulation 2 Dose 3 Fast/Fed|
62580783|NCT01267565|OTHER|intubated and ventilated patients|patients undergoing mechanical ventilation for an anticipated length of more than 48h
62788036|NCT04178720|ACTIVE_COMPARATOR|Biofinity|Comfilcon A contact lenses worn in both eyes at least approximately 8 hours per day and approximately 5 days per week during waking hours only. The lenses will be removed nightly for cleaning and disinfection and replaced monthly over the 3-month wear period.
62788037|NCT04346836|EXPERIMENTAL|Metabolic Syndrome|"Elderly women with Metabolic Syndrome~24 sessions of low-intensity exercise and psychoeducation, twice a week over 12 weeks."
62788038|NCT04346836|EXPERIMENTAL|Non-Metabolic Syndrome|"Elderly women without Metabolic Syndrome.~24 sessions of low-intensity exercise and psychoeducation, twice a week over 12 weeks."
62788039|NCT05496569|EXPERIMENTAL|TQB3616 capsules|TQB3616 capsule (180mg, quaque die, oral), 4 weeks (28 days) as a treatment cycle.
62788040|NCT05496569|PLACEBO_COMPARATOR|TQB3616 placebo|TQB3616 placebo (0mg, quaque die, oral), 4 weeks (28 days) as a treatment cycle.
62788041|NCT04572451|EXPERIMENTAL|Nivolumab (Anti-PD-1) + BMS-986253 (Anti-IL-8) + SBRT|480 mg intravenous nivolumab (BMS-936558-01) every 4 weeks + 2,400 mg intravenous BMS-986253 (Anti-IL-8) every 2 weeks + Stereotactic Body Radiotherapy (SBRT)
62788042|NCT06152107|EXPERIMENTAL|subsegmental BTVA treatment plus optimal medical therapy (GOLD guidelines)|Patients in experimental group will be treated with the InterVapor System in at least 2 subsegments of different segments per single procedure.
62016121|NCT05019586||Never Helicobacter pylori infection|Patients with previously Helicobacter pylori infection included from 2010-2012.
62016122|NCT06573541||group receiving ultrasound|
62016123|NCT06573541||group not receiving ultrasound|
62205374|NCT04605640|EXPERIMENTAL|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating. Participants will be followed by daily self-weighing for 1 year after intervention.
62205375|NCT02620605|ACTIVE_COMPARATOR|Late administration of Cabirgoline 0.5 mg|Cabergoline 0.5mg (Dostinex®, Pfizer Australia Pty Ltd ) administrated once daily started on day of HCG triggering and continued for 8 days.
62205376|NCT02620605|EXPERIMENTAL|Early administration of Cabirgoline 0.5mg|Cabergoline 0.5mg(Dostinex®, Pfizer Australia Pty Ltd ) once daily stared once patients fulfilling the inclusion criteria at any day of cycle and continued for 8 days post HCG trigger.
62205377|NCT03868787|EXPERIMENTAL|Active TENS|The active TENS unit consists of the active unit and electrode pads connected to the unit via direct wires. The program that will be used is a high frequency (80Hz) program that runs for an hour in duration. It will be initiated 5 minutes prior to speculum placement. Participants will be instructed to increase the amplitude of the current as needed to provide analgesia but avoiding discomfort from the TENS stimulation
62404760|NCT04096716|EXPERIMENTAL|Cohort 2D: Tc-99m tilmanocept occipital lobe injection site|"* The surgeon will inject up to 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor~* SPECT/CT of the head and neck will be obtained when practical on the day of surgery.~If the patient is not sufficiently recovered from surgery to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2"
62404761|NCT04096716|EXPERIMENTAL|Cohort 3: Tc-99m tilmanocept stereotactic needle biopsy of tumor|"* The surgeon will inject up to 0.3 mL of reconstituted Tc-99m tilmanocept after completing the stereotactic biopsy of the tumor~* SPECT/CT of the head and neck will be obtained on the day of biopsy, when practical. If the patient is not sufficiently recovered from biopsy to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2"
62404762|NCT02322866|EXPERIMENTAL|Sarecycline|Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
62404763|NCT02322866|PLACEBO_COMPARATOR|Placebo|Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.
62404764|NCT04634565|EXPERIMENTAL|PF-06651600|PF-06651600 200 milligrams(mg) once daily for 10 days
62404765|NCT00118872|ACTIVE_COMPARATOR|LGG yogurt|Lactobacillus (LGG) containing yogurt
62404766|NCT00118872|PLACEBO_COMPARATOR|Placebo yogurt|Regular yogurt, NOT containing LGG
62404767|NCT04649437|OTHER|Symptomatic patients|Subjects with symptoms of atrial fibrillation i.e. AF-6 sum score 30 points or more.
62016124|NCT03823651|EXPERIMENTAL|Patient|These are patients undergoing hematopoetic stem cell transplant. Patients will complete Interval training, undergo psychiatric consult, nutrition/diet evaluation and referral to social worker.
62016125|NCT03823651|EXPERIMENTAL|Caregiver|These are the assigned caregivers for transplant patients. Caregivers will undergo psychiatric consult, nutrition/diet evaluation and referral to social worker.
62404768|NCT04649437|OTHER|Asymptomatic patients|Subjects with no symptoms of atrial fibrillation i.e. AF-6 sum score = 0.
62404769|NCT04478773|EXPERIMENTAL|Experimental|Patient will receive MRI
62016126|NCT00354926|EXPERIMENTAL|AME 133v|All subjects will receive weekly intravenous infusions of AME-133v. Each subject will receive a total of 4 infusions administered once a week for 3 consecutive weeks.
62016127|NCT04666441|EXPERIMENTAL|IV Dose 1|Combination therapy intravenous (IV) single dose
62016128|NCT04666441|EXPERIMENTAL|IV Dose 2|Combination therapy IV single dose
62016129|NCT04666441|EXPERIMENTAL|IV Dose 3|Combination therapy IV single dose
62016130|NCT04666441|EXPERIMENTAL|IV Dose 4|Combination therapy IV single dose
62404770|NCT04818866||Patients hospitalized for Covid-19|
62580784|NCT01267565|OTHER|non intubated patients|non intubated patients with an independant indication of bronchoscopy including an endotracheal aspiration during the procedure
62580785|NCT03132935||Telemedicine group|Telemedical care of acute coronary syndromes in the prehospital phase. Paramedics were supported by a physician in a tele consultation centre.
62580786|NCT03132935||Control group|Conventional on-scene care of acute coronary syndromes by a physician. No telemedicine system was available during this control period.
62016131|NCT04666441|EXPERIMENTAL|Placebo IV Dose|Matching placebo IV single dose
62016132|NCT04666441|EXPERIMENTAL|SC Dose 1|Combination therapy subcutaneous (SC) single dose
62016133|NCT04666441|EXPERIMENTAL|SC Dose 2|Combination therapy SC single dose
62016134|NCT04666441|EXPERIMENTAL|Placebo SC Dose|Matching placebo SC single dose
62016135|NCT05071417|EXPERIMENTAL|Semaglutide|Patients on semaglutide
62016136|NCT01494779|EXPERIMENTAL|Somatropin Test|Somatropin of Blausiegel Indústria e Comércio Ltda.
62016137|NCT01494779|ACTIVE_COMPARATOR|Saizen|Somatropin of Merck Serono
62016138|NCT01183793|OTHER|Bras pair|MR-enterography then barium follow through
62205378|NCT03868787|SHAM_COMPARATOR|Sham TENS|The sham TENS will be the same unit without the true TENS electrical connections. The sham group will be given the active unit and have electrode pads placed but without wire connections. These participants will be told the device is a wireless device. They will also be told they may or may not feel sensation from the TENS. This will allow the device to be powered on and run in the same manner as the active group, but will not allow for electrical transmission between the unit and electrodes
62205379|NCT05976373|ACTIVE_COMPARATOR|Dupilumab drug product 1|A single subcutaneous injection on Day 1
62016139|NCT01183793|OTHER|Bras impair|Barium follow-through then MR-enterography
62016140|NCT03955484||Patients who had benign prostatic hyperplasia|"Male patients presenting with lower urinary tract symptoms to urology outpatient clinic~According to the European Association of Urology Guidelines:~International prostate symptom score\> 8 Prostate volume\> 40 ml Q max \<15 ml /sn Patients who did not receive any treatment for lower urinary tract symptoms and applied for the first time Patients who have not undergone lower urinary tract surgery"
62205380|NCT05976373|EXPERIMENTAL|Dupilumab drug product 2|A single subcutaneous injection on Day 1
62205381|NCT00349934|EXPERIMENTAL|A|IMP321
62205382|NCT05196490||Micro-CT|Samples were scanned before and after air polishing with a high-resolution micro-CT device. The scanning conditions were 100 kVp; 100-mA, 0.5-mm Al/Cu filter; 13.1-μm pixel size; and rotation at 0.2 steps. According to the manufacturer's instructions, each sample was rotated 360°. The mean scanning time was around 1hour.
62205383|NCT05196490||CAD/CAM|The teeth surfaces were digitalized before and after air polishing with an intraoral scanner. The mean scanning time was around 10 second. The virtual images of the scanned teeth were saved in stereolithography (STL) format.
62205384|NCT02734953|EXPERIMENTAL|Intervention|Determination of non-invasive pulmonary pressures by CardioMems device interrogation pre- and post-administration of inhaled nitric oxide at 0.075 mg/kg IBW/hr
62404771|NCT02469558|ACTIVE_COMPARATOR|probiotic|Winclove 851 and 110 consist of 6g of a probiotic mixture containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g and 10g of a prebiotic mixture of galacto-oligosaccharides P11 (GOS), Fructo-oligosaccharides P6 (FOS), Konjac glucomannan P13 (E425), Maltodextrin, Calcium carbonate (E170), Natural Elderflower flavouring, Gum Arabic (E414), Zinc citrate 3-hydrate, Vitamin D3 (Cholecalciferol) and Vitamin B2 (Riboflavin) (E101) daily for 6 months
62404772|NCT02469558|PLACEBO_COMPARATOR|placebo|a similar looking and tasting placebo without bacteria
62205385|NCT03390959|EXPERIMENTAL|Proprioceptive Training|The group participates in proprioceptive training that promotes sensory integration.
62404773|NCT00931866|EXPERIMENTAL|Diclofenac Sodium Patch|
62788043|NCT06152107|ACTIVE_COMPARATOR|segmental BTVA treatment plus optimal medical therapy (GOLD guidelines)|Patients in control group will be treated with the InterVapor System in at least 1 segment per single procedure.
62016141|NCT05281692||Positive|Enhanced Preservation Media (EPM-IX)
62788044|NCT00365924|OTHER|Forteo|
62016142|NCT05281692||Control|Med Schenker's STM viral media
62016143|NCT02272998|EXPERIMENTAL|Treatment (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62016144|NCT05637151|OTHER|ICC in pregnant women with ICP|Immediate cord clamping group in pregnant women with intrahepatic cholestasis of pregnancy
62016145|NCT05637151|EXPERIMENTAL|DCC in pregnant women with ICP|Delayed cord clamping group in pregnant women with intrahepatic cholestasis of pregnancy
62205386|NCT03390959|OTHER|Control Group|The group continues in their daily lives with phone monitoring.
62205387|NCT06273449|NO_INTERVENTION|Group 1|"Conventional:~The Standard of Care (SOC) workflow, which will act as a baseline compared to the other 2 groups.~Teeth Profile Capture Method: Physical impression RPD Design Method: Based on stone model, using wax pattern RPD Fabrication Method: Lost wax casting"
62205388|NCT06273449|EXPERIMENTAL|Group 2|"Partial Digital:~Similar to the SOC, Group 2 adopts the same teeth profile capture method, where a physical impression of teeth profile is taken from the subject. However, instead of using physical wax pattern on the stone model for design, the stone model is scanned and, on the scan, the design is performed digitally. For fabrication of RPD in Group 2, instead of using lost wax casting as per the SOC, the digital design is used for additive manufacturing."
62205389|NCT06273449|EXPERIMENTAL|Group 3|"SmartRPD Digital:~Group 3 adopts a different teeth profile capture method by using the intraoral scanner to digitally scan and save the subject's teeth profile. From the intraoral scan, a digital model of the subject's teeth profile is created. Similar to Group 2, but on the digital model instead, the design of RPD is digitally performed. The digital design, as per Group 2, is used for additive manufacturing."
62016146|NCT05637151|OTHER|ICC in normal pregnant women|Immediate cord clamping group in normal pregnant women
62404774|NCT00931866|PLACEBO_COMPARATOR|Topical Placebo Patch|
62404775|NCT02246244|EXPERIMENTAL|Escitalopram|10 mg once per day
62404776|NCT02246244|PLACEBO_COMPARATOR|Placebo|
62205390|NCT03556904|ACTIVE_COMPARATOR|Standard of Care|Standard of care therapy will be up to the treating medical oncologist and is not the study intervention. Current systemic therapy is most commonly a second generation androgen pathway inhibitor, including enzalutamide or abiraterone, although other standard agents (e.g. docetaxel, cabazitaxel) are allowed. Patients should begin systemic treatment within 3 weeks of randomization. Standard of care systemic therapy may continue in the absence of toxicities or other specific criteria per protocol.
62404777|NCT03830073||Group I:|Seventy patients with pancreatitis
62404778|NCT03830073||Group II:|Thirty healthy controls
62205391|NCT03556904|EXPERIMENTAL|Standard of Care + Ablative Radiation|Standard of care systemic therapy plus radiation. Radiation will start within 8 weeks of randomization and complete by day 84. Standard of care systemic therapy may continue in the absence of toxicities or other specific criteria per protocol.
62205392|NCT03373942||Primary Open Angle Glaucoma (POAG)|The study included 30 eyes of 30 patients diagnosed with POAG who presented to Glaucoma Unit of İzmir Katip Çelebi University Atatürk Training and Research Hospital
62205393|NCT03373942||Pseudoexfoliation Syndrome (PEX)|The study included 30 eyes of 30 patients diagnosed with PEX glaucoma who presented to Glaucoma Unit of İzmir Katip Çelebi University Atatürk Training and Research Hospital
62205394|NCT03373942||Control|The control group included 30 eyes of 30 healthy individuals with similar age distribution with POAG and PEX group
62205395|NCT00894400|EXPERIMENTAL|Targeting of most fractionated electrograms first|During catheter ablation of AF patients will have fractionated electrograms targeted. In the experimental group the fractionated electrograms believed to be most critical will be targeted first.
62205396|NCT00894400|ACTIVE_COMPARATOR|Targeting least fractionated electrograms first|During catheter ablation of AF fractionated electrograms are targeted. In this arm the least fractionated electrograms will be targeted first.
62404779|NCT03418025|EXPERIMENTAL|Group I (Exercising Together program)|"Exercise Intervention. All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment. The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment.~EXERCISING TOGETHER PROGRAM: Participants complete three exercise sessions (approximately 1 hour per session) per week over 5-8 weeks during radiation treatment. Participants also receive a DVD of a partnered strength training exercise program to continue on their own after radiation is completed."
62404780|NCT03418025|ACTIVE_COMPARATOR|Group II (pre and post testing)|Questionnaire Administration \& Survey Administration. All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment. The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment.
62404781|NCT01312948|EXPERIMENTAL|Prototype mask|
62404782|NCT06118216|PLACEBO_COMPARATOR|Group-PCIA|
62016147|NCT05637151|EXPERIMENTAL|DCC in normal pregnant women|Delayed cord clamping group in normal pregnant women
62016148|NCT01723904|EXPERIMENTAL|Rotigotine|"- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.~Duration of the Titration Period: Between 1 week and 5 weeks.~- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.~Duration of the Maintenance Period: Between 3 weeks and 7 weeks."
62016149|NCT06535867||Participants from Varanasi|Participants will be recruited from Varanasi.
62016150|NCT01014286||Advanced Adenocarcinoma|Stage IV adenocarcinoma who have undergone biopsy with remnant tissue.
62404783|NCT06118216|EXPERIMENTAL|Group-IA+PCIA|
62404784|NCT04045054|OTHER|Intervention|The Link Team follows up with the participants for 6 months after they discharge from the hospital
62404785|NCT06542822||IRONHEART Observational Study Group|"16 participants, with non-ischaemic heart failure, with iron deficiency TSATS \<20% and heart failure with a reduced ejection fraction \<40%.~Cohort will have to be established on guideline directed heart failure therapy. Participants meeting eligibility criteria will undergo baseline quality of life questionnaires, hand grip tests and six minute walk tests before receiving intravenous iron derisomaltose and repeating these investigations again after 24 hours and 30 days including a cardiac magnetic resonance imaging."
62016151|NCT06133764|EXPERIMENTAL|Enucleation + Peripheral ostectomy + Carnoy's solution chemical cauterization (E+ PO+ CS)|The odontogenic keratocysts will be treated using enucleation, followed by peripheral ostectomy and then Carnoy's solution
62016152|NCT06133764|EXPERIMENTAL|Decompression/marsupialization (D/M)|The odontogenic keratocysts will be managed by either Decompression or marsupialization
62016153|NCT06133764|EXPERIMENTAL|Enucleation (E)|The odontogenic keratocysts will only be managed by Enucleation (E)
62016154|NCT06133764|EXPERIMENTAL|Enucleation+Carnoy's solution (E+CS)|odontogenic keratocysts will be managed by Enucleation, followed by Carnoy's solution
62016155|NCT06133764|EXPERIMENTAL|Enucleation+ Peripheral Ostectomy (E+PO)|The odontogenic keratocysts will be treated using Enucleation, followed by peripheral ostectomy (E+PO)
62016156|NCT02284737|EXPERIMENTAL|PADN + sildenafil|Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
62016157|NCT02284737|SHAM_COMPARATOR|sham PADN + sildenafil|The radiofrequency ablation catheter placed, no ablations.
62016158|NCT05534282|EXPERIMENTAL|Interaction-focused Music Therapy with Children and Significant Others (INMUT-KB) (exp. group)|Interaction-focused music therapy with children with cancer and their significant others, delivered by trained music therapists
62016159|NCT05534282|EXPERIMENTAL|Music Therapy with Children (MUT-K) (exp. group)|Interaction-focused music therapy with children with cancer without the involvement of significant others, delivered by trained music therapists.
62404786|NCT05137431||High Flow Nasal Oxygenation-HFNO|The current will be adjusted from 50-70 liters. The patient's SpO2 value will be maintained at at least 92%. Arterial blood gas will be checked at the 1st hour
62404787|NCT05137431||Non-Invasive Ventilation-NIV|Tidal volume will be adjusted to be 6-8 ml/kg. The respiratory rate will be \<30. The patient's SpO2 value will be maintained at at least 92%. The PEEP value will be 5 cmH2O. At the 1st hour, arterial blood gas will be checked.
62205397|NCT01977677|EXPERIMENTAL|Treatment (radiation therapy, temozolomide, plerixafor)|Within 4 weeks of surgery, patients undergo radiation therapy and receive temozolomide PO over 42 days. Beginning 8 days prior to completion of chemoradiotherapy, patients receive plerixafor IV continuously for 2-4 weeks. Patients also receive temozolomide PO 5 days a month beginning 35 days after completion of radiation therapy.
62404788|NCT01149174|NO_INTERVENTION|transurethral resection alone|Patients with non-muscle invasive bladder cancer who underwent transurethral resection alone;
62788045|NCT00554047|EXPERIMENTAL|1|Multidisciplinary Memory Clinic
62788046|NCT00554047|ACTIVE_COMPARATOR|2|General practitioner
62016160|NCT05534282|EXPERIMENTAL|Interaction-focused Music Therapy with Children and Significant Others (WG-KB) (control group)|Study participants randomized to this group receive the intervention INMUT 10 weeks after the experimental groups.
62205398|NCT03858829|EXPERIMENTAL|fear of movement scale|
62788047|NCT02781610|OTHER|ERR-10|ERR treatment duration - 10 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
62788048|NCT02781610|OTHER|ERR-14|ERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
62788049|NCT02781610|OTHER|NERR-14|NERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
62788050|NCT02781610|OTHER|NERR-21|NERR treatment duration - 21 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
62788051|NCT00559247|EXPERIMENTAL|or Placebo - Dose Panel 1|Oral Suspension, 10 mg
62788052|NCT00559247|EXPERIMENTAL|or Placebo - Dose Panel 2|Oral Suspension 50 mg
62788053|NCT00559247|EXPERIMENTAL|or Placebo - Dose Panel 3|Oral Suspension, 200 mg
62788054|NCT00559247|EXPERIMENTAL|or Placebo - Dose Panel 4|Oral Suspension or Solution, 2.5 to 600 mg
62788055|NCT02632487|ACTIVE_COMPARATOR|Exercise|This group will receive 8 weeks of center-based exercise followed by recommendations to remain physically active.
62788056|NCT02632487|EXPERIMENTAL|Exercise + Non-Exercise Physical Activity (NEPA)|This group will receive 8 weeks of center-based exercise combined with behavioral counseling and a technology intervention designed to increase daily Exercise + Non-Exercise Physical Activity (NEPA).
62788057|NCT04417153||Mindfulness based intervention, Non Emergency (MBI-NE)|"* 4 week Mindfulness foundation course face to face (MF-NE) or~* 8 week Mindfulness Based stress reduction face to face (MBSR-NE)~The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions. Participants will be provided handouts for the information covered during these talks and discussions.~Classes are done at the Mindfulness centres providing the courses, with face to face sessions with the teacher and up to 30 participants together"
62788058|NCT04417153||Mindfulness based intervention, DORSCON Orange (MBI-Orange))|"* 4 week Mindfulness foundation course face to face (MF-Orange) or~* 8 week Mindfulness Based stress reduction face to face (MBSR-Orange)~The content of these courses are the same as in the non emergency ones, and consist of four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques. Participants will also be provided with the same handouts for the information covered during these talks and discussions.~Classes are done at the Mindfulness centres providing the courses, with face to face sessions with the teacher and up to 30 participants together."
62788059|NCT04417153||Mindfulness based intervention, Partial lockdown (MBI-Covid)|"* 4 week Mindfulness foundation course online (MF-Covid) or~* 8 week Mindfulness Based stress reduction online, partial lockdown situation (MBSR-Covid)~The content of these courses are the same as in the non emergency ones. Participants will also be provided with the same handouts for the information covered during these talks and discussions.~During the partial lockdown, classes can only be held online, using platform as zoom with the teacher and up to around 17 participants together."
62788060|NCT04259008|ACTIVE_COMPARATOR|Standard neonatal trace elements|"Parenteral nutrition containing 5 mCg/kg/day manganese from Multitrace-4 Neonatal."
62788061|NCT04259008|EXPERIMENTAL|Manganese-free neonatal trace elements|"Parenteral nutrition containing the same trace element doses as Multitrace-4 Neonatal minus manganese."
62788062|NCT01969630|ACTIVE_COMPARATOR|PEB|PEB angioplasty plus provisional nitinol stent implantation
62788063|NCT01969630|EXPERIMENTAL|PES|Systematic PES angioplasty
62788064|NCT01947751|ACTIVE_COMPARATOR|CVC exchange|The CVC will be removed immediately.
62788065|NCT01947751|EXPERIMENTAL|CVC maintenance|The CVC will be maintained, and exchanged only if confirmed catheter-related infection or worsening of sepsis
62788066|NCT03616509|EXPERIMENTAL|Placebo and Growth Hormone|2 months on placebo followed by 12 months on GH
62788067|NCT00988273||Control|In patients undergoing endoscopy for indications other than Crohn's disease or ulcerative colitis
62788068|NCT00988273||Diseased group|Patients with Crohn's disease or ulcerative colitis undergoing endoscopy.
62205399|NCT01692951||Lung adenocarcinoma patients|Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung adenocarcinoma was based on pathologic analysis.
62205400|NCT01692951||Control matched to adenocarcinoma|Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
62404789|NCT01149174|ACTIVE_COMPARATOR|intravesical mitomycin-C|Patients with non-muscle invasive bladder cancer who underwent one intravesical instillation of mitomycin-C immediately after transurethral resection
62404790|NCT01149174|EXPERIMENTAL|electromotive mitomycin-C|Patients with non-muscle invasive bladder cancer who underwent single immediate intravesical instillation of electromotive mitomycin-C immediately before transurethral resection
62404791|NCT02980666|EXPERIMENTAL|Teduglutide|Participants will receive teduglutide 0.05 milligram per kilogram per day (mg/kg/day) subcutaneous (SC) injection once daily for 24 weeks.
62404792|NCT05607056|EXPERIMENTAL|Probiotic|During the antibiotic dosing (from 5 to 10 days): 2 capsules once a day 2 hours before or 2 hours after antibiotic administration. 14 days following completion of antibiotic dosing: 1 capsule a day.
62016161|NCT06664203|ACTIVE_COMPARATOR|with 15 ml SeTb group|This group will receive a SeTB (Selective Trunk Block) with a total of 15 ml of bupivacaine
62016162|NCT06664203|ACTIVE_COMPARATOR|With 25 ml bupivacain SeTb|This group will receive a SeTB (Selective Trunk Block) with a total of 25 ml of bupivacaine
62016163|NCT02815111||Control Group|Intensivists will proceed with analgesia utilizing conventional opioid based pain order sets.
62016164|NCT02815111||Study Group|The investigators plan to study an analgesic regimen of Ketamine and lidocaine as infusions with Neurontin and Acetaminophen delivered orally for postoperative analgesia and the subsequent effect on ventilator days and ICU stay.
62404793|NCT05607056|PLACEBO_COMPARATOR|Placebo|During the antibiotic dosing (from 5 to 10 days): 2 capsules once a day 2 hours before or 2 hours after antibiotic administration. 14 days following completion of antibiotic dosing: 1 capsule a day.
62404794|NCT04179188||Bariatric OSA Group|Bariatric surgery plannified intervention patient with obstructive sleep Apnéa
62404795|NCT04179188||Bariatric without OSA Group|Bariatric surgery plannified intervention patient without obstructive sleep Apnéa
62788069|NCT05280600||NMDAR-antibody encephalitis|Children and young people (ages 8-24 years) with a diagnosis of NMDAR-antibody encephalitis.
62205401|NCT01692951||Lung squamous cell carcinoma patients|Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung squamous cell carcinoma was based on pathologic analysis.
62016165|NCT03881462|EXPERIMENTAL|Axillary nerve block|Axillary nerve block is performed in standardized manner and muscle force is measured before and after the block.
62016166|NCT00014144|EXPERIMENTAL|ZD 1839|
62016167|NCT02192268|ACTIVE_COMPARATOR|HFOO|Children of the HFOO group will be subjected to two daily sessions of this resource which should be the same throughout her hospitalization with Shaker equipment.
62016168|NCT02192268|ACTIVE_COMPARATOR|Assisted Coughing|The children in the control group will be subjected to two daily sessions of assisted coughing.
62016169|NCT02192268|ACTIVE_COMPARATOR|PEP|The children will be subjected to PEP group two daily sessions of this resource which should be the same throughout her hospitalization with facial mask and valve Spring load with expiratory pressure of 10cmH2O.
62016170|NCT06155786|ACTIVE_COMPARATOR|tDCS group|In tDCS, direct electrical currents at the intensity of 2 mA are generated by an electrical stimulator and are noninvasively delivered to the left and right dorsolateral prefrontal cortex through a pair of saline-soaked sponge electrodes (7×5 cm) for 30 minutes.
62016171|NCT06155786|ACTIVE_COMPARATOR|tRNS group|In tRNS, direct electrical currents at the intensity of 2 mA amplitude (offset at 1 mA) and frequency of 100-640 Hz are generated by an electrical stimulator and are noninvasively delivered to the left and right dorsolateral prefrontal cortex through a pair of saline-soaked sponge electrodes (7×5 cm) for 30 minutes.
62016172|NCT06155786|SHAM_COMPARATOR|sham group|In sham group, placebo stimulation is generated by an electrical stimulator and is noninvasively delivered to the left and right dorsolateral prefrontal cortex through a pair of saline-soaked sponge electrodes (7×5 cm) for 30 minutes.
62016173|NCT02979834||Early perception group|The group with early perception of fetal movement (\<25th percentile)
62016174|NCT02979834||Average perception group|The group with average perception of fetal movement (\>25th and \<75th percentile)
62016175|NCT02979834||Late perception group|The group which late perception of fetal movement (\>75 percentile)
62016176|NCT06563323|EXPERIMENTAL|Guselkumab for PG|Subjects with PG will be treated with 100 mg every 4 weeks of guselkumab for 28 weeks in addition to starting stable dose (at least 2 weeks) of prednisone at 20 mg daily. Prednisone will be tapered based on a pre-established algorithm assessed by investigator.
62788070|NCT05280600||Antibody-negative autoimmune encephalitis|Children and young people (ages 8-24 years) with a diagnosis of autoantibody-negative but probable autoimmune encephalitis or definite autoimmune limbic encephalitis.
62580787|NCT06218537|EXPERIMENTAL|Test group|The test group - 10 minutes before upper GI endoscopy, patients will drink a solution of 50ml water + 2 capsules of KREON 25000 UI, opened (with minimicrospheres, pellets) + 1.2g sodium bicarbonate, mixed. Adding sodium bicarbonate is necessary to dissolve the minimicrospheres of KREON.
62205402|NCT01692951||Control matched to squamous cell|Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
62205403|NCT02006524|ACTIVE_COMPARATOR|Screening with MyDiagnostick|All patients eligible for influenza vaccination are screened for atrial fibrillation with the MyDiagnostick, an easy to use and patient friendly device.
62205404|NCT04622553|OTHER|Cohort 1 and 2|7 patients aged 12 to \< 18 years , inclusive in cohort-1 7 patients aged 6 to \< 12 years, inclusive in cohort-2
62205405|NCT03162198||Cirrhosis with HCC|
62580788|NCT06218537|SHAM_COMPARATOR|Control group|The control group - 10 minutes before upper GI endoscopy, patients will drink a solution of 50ml water + 1.2g sodium bicarbonate, mixed.
62580789|NCT02897219|EXPERIMENTAL|Part 1 ASP1941|ASP1941 will be administered for 24 weeks under double blind conditions.
62580790|NCT02897219|PLACEBO_COMPARATOR|Part 1 Placebo|Placebo will be administered for 24 weeks under double blind conditions.
62205406|NCT03162198||Cirrhosis without HCC|
62205407|NCT03101202|EXPERIMENTAL|SSD Arm|In the SSD arm, the patients will be intubated with an endotracheal tube with suglottic suction drainage (SSD tube)
62580791|NCT02897219|EXPERIMENTAL|Part 2 ASP1941|ASP1941 will be administered for 28 weeks under open label conditions.
62580792|NCT06339866|NO_INTERVENTION|Control group|The control group will follow the routine plan of the ward without any intervention planned.
62205408|NCT03101202|NO_INTERVENTION|Standard Arm|In the standard arm, the patients will be intubated with the standard endotracheal tube which does not have subglottic suction.
62205409|NCT05700968||patients diagnosed with cardiac disease|
62205410|NCT03214653|ACTIVE_COMPARATOR|Propofol|Those who received target-controlled infusion of propofol using Schinder technique effect mode with the administration of maintenance agent was adjusted by the depth of sedation using bispectral index monitor with target of 45-50.
62205411|NCT03214653|ACTIVE_COMPARATOR|Sevoflurane|Those who received sevoflurane 1,5-2% as maintenance agent of anesthesia.
62788071|NCT05280600||Healthy control|Healthy children and young people (ages 8-24 years).
62788072|NCT00169156|EXPERIMENTAL|Rituximab + CHOP|Rituximab + CHOP regimen Prednisone - Doxorubicine - Cyclophosphamide - Vincristine
62788073|NCT04922138|EXPERIMENTAL|Arm A|Orally 110 mg Aumolertinib tablets (55 mg/tablet, 2 tablets/day) once a day .
62788074|NCT04922138|NO_INTERVENTION|Arm B|Observation
62788075|NCT01402739|EXPERIMENTAL|PoC algorithm guided transfusions|experimental arm
62016177|NCT00304070|EXPERIMENTAL|Stratum I (surgery, observation)|Patients undergo primary tumor resection and retroperitoneal lymph node sampling followed by observation. Patients who have undergone prior surgery without nodal sampling undergo observation only.
62205412|NCT01137578|OTHER|Cohort A: US, MRI with contrast, MRI without contrast|Subjects with a central venous catheter (CVC) in place and asymptomatic for a CVC-related DVT to have an Ultrasound (US), Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
62788076|NCT01402739|ACTIVE_COMPARATOR|standard of care transfusions|control arm
62788077|NCT05412368||Children and young people (CYP)|Children and young people who have been referred to CAMHS
62788078|NCT05412368||Parents/carers|Parents/carers of CYP who have been referred to CAMHS
62788079|NCT05412368||Key referrers|Key referrers (e.g. Teachers, GPs, SENCOs, Social Workers) who have referred CYP to CAMHS
62788080|NCT05412368||CAMHS Professionals|CAMHS Professionals who have received referrals to CAMHS
62788081|NCT05181124|EXPERIMENTAL|JP-1366 and aceclofenac|
62205413|NCT01137578|OTHER|Cohort B: US, MRI with contrast, MRI without contrast|Subjects with a CVC in place either symptomatic for a CVC-related DVT or having an incidental diagnosis of CVC-related DVT by radiographic imaging performed for other clinical reasons to have an Ultrasound, Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
62788082|NCT05181124|EXPERIMENTAL|JP-1366 and meloxicam|
62788083|NCT05181124|EXPERIMENTAL|JP-1366 and naproxen|
62205414|NCT01137578|OTHER|Cohort C: US, MRI with contrast, MRI without contrast|Subjects with a CVC in place having an MRI for clinical reasons to have an Ultrasound, Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
62205415|NCT03250442|OTHER|Group A: Standard Dry Dressing|The standard dry dressing is comprised of nonadherent dressing, dry gauze, cotton undercast padding, compression, and immobilization.
62205416|NCT03250442|ACTIVE_COMPARATOR|Group B: Foam, Drape, and PrevenaTM|This arm is comprised of foam, drape, the PrevenaTM Device, compression, and immobilization.
62205417|NCT02960087|ACTIVE_COMPARATOR|Arm 1 LDR|Low Dose Rate (LDR) brachytherapy with I-125 to a total dose of 144 Gy
62580793|NCT06339866|EXPERIMENTAL|Educational animation group|After the patients in this group arrive at the ward (after adenotonsillectomy), the Wong Baker pain scale and Child Anxiety Scale-Status (CAS-D) will be filled out by three observers (clinic nurse, parent and child) before the educational animated movie (before analgesic application) containing the surgical process at the 3rd hour (after adenotonsillectomy) and the animation will be watched behind it, and at the end, the same scales will be filled out again by three observers and the patient's pain and anxiety level will be evaluated.
62788084|NCT05181124|EXPERIMENTAL|JP-1366|
62205418|NCT02960087|ACTIVE_COMPARATOR|Arm 3 HDR|High Dose Rate brachytherapy: 27 Gy in 2 fractions
62205419|NCT02754063|ACTIVE_COMPARATOR|ICP Management|
62205420|NCT02754063|EXPERIMENTAL|PbtO2 + ICP Management|
62788085|NCT05385055||Cigarette|Current cigarette smokers
62788086|NCT05385055||THS|THS users with a minimum of 2 years of THS use
62788087|NCT05385055||SA|Former cigarette smokers with minimum of 2 years of smoking abstinence
62788088|NCT02843672|ACTIVE_COMPARATOR|TWO|"Patients with metatarsalgia and without response to non-operative treatment after six months, needing surgical treatment for relief of their symptoms.~Triple´s Weil osteotomy is performed."
62788089|NCT02843672|ACTIVE_COMPARATOR|DMMO|"Patients with metatarsalgia and without response to non-operative treatment after six months, needing surgical treatment for relief of their symptoms.~Distal metatarsal minimally invasive osteotomy is performed."
62788090|NCT05361044|OTHER|Donnor of liver grafts|Blood samples And liver biopsy taken from the donnor
62788091|NCT04102527||Patients|Patients with Terminal Chronic Kidney Disease undergoing Peritoneal Dialysis for at least three months in stable condition
62788092|NCT02091843|EXPERIMENTAL|DBS of the Amygdala-30 days|Deep brain stimulation of the amygdala BLn starting at 30 days post-operatively.
62788093|NCT02091843|EXPERIMENTAL|DBS of the Amygdala-90 days|Deep brain stimulation of the amygdala BLn starting at 90 days post-operatively.
62788094|NCT05639192|EXPERIMENTAL|Standard of Care + Asunercept 100 mg|
62788095|NCT05639192|PLACEBO_COMPARATOR|Standard of Care + Placebo|
62788096|NCT02519595|EXPERIMENTAL|ketamine IV 1 mg/kg|Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
62788097|NCT02519595|EXPERIMENTAL|Ketamine IV 1.5 mg/kg|Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
62788098|NCT02519595|EXPERIMENTAL|Ketamine IV 2 mg/kg|Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
62788099|NCT04558372|EXPERIMENTAL|Group 1- 43 COVID-19 patients|COVID-19 patients breath normally via disposable non-rebreathing mask
62788100|NCT04558372|EXPERIMENTAL|Group 2- 40 non COVID-19 patients|Non COVID-19 patients breath normally via disposable non-rebreathing mask
62016178|NCT00304070|EXPERIMENTAL|Stratum II (exploratory surgery, observation)|Patients undergo primary tumor resection and extended regional lymph node dissection followed by observation. Patients who have undergone prior surgery with simple resection of the primary tumor undergo exploratory surgery with extended regional lymph node dissection followed by observation.
62016179|NCT00304070|EXPERIMENTAL|Stratum III (chemotherapy, surgery)|Patients receive combination chemotherapy with filgrastim (G-CSF) for up to 30 weeks (10 courses) followed by mitotane alone for an additional 2 months. Some patients undergo surgery after chemotherapy course 2 or 4. Some patients undergo additional surgery after finishing all chemotherapy.
62016180|NCT01016834|OTHER|Sumavel(R) DosePro(R)|Single arm study (Sumavel DosePro)
62016181|NCT05341921|ACTIVE_COMPARATOR|Alternate Nostril Breathing Phase I|Alternate nostril breathing for normotensive women in 3rd trimester of pregnancy
62016182|NCT05341921|ACTIVE_COMPARATOR|Bhramari Breathing Phase I|Bhramari breathing for normotensive women in 3rd trimester of pregnancy
62016183|NCT05341921|ACTIVE_COMPARATOR|Sheetali Breathing Phase I|Sheetali breathing for normotensive women in 3rd trimester of pregnancy
62016184|NCT05341921|ACTIVE_COMPARATOR|Alternate Nostril Breathing Phase II|Alternate nostril breathing for hypertensive women in 3rd trimester of pregnancy
62205421|NCT01882543|EXPERIMENTAL|AQX-1125|1 x AQX-1125 Capsule daily
62205422|NCT01882543|PLACEBO_COMPARATOR|Placebo|1 x placebo capsule daily
62580794|NCT06339866|EXPERIMENTAL|Cartoon series group|In this group, the Wong Baker pain scale and Child Anxiety Scale-Disposition (CAS-D) will be filled out by three observers before watching cartoons at the 3rd hour post op (before analgesic administration), and the scales will be filled out again after the cartoon and anxiety and pain levels will be evaluated.
62788101|NCT04558372|EXPERIMENTAL|Group 3- suspected COVID-19 patients|The participants breath normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume through an e-nose tube connected to the Hepa-filter at the inlet.
62016185|NCT05341921|ACTIVE_COMPARATOR|Bhramari Breathing Phase II|Bhramari breathing for hypertensive women in 3rd trimester of pregnancy
62016186|NCT05341921|ACTIVE_COMPARATOR|Sheetali Breathing Phase II|Sheetali breathing for hypertensive women in 3rd trimester of pregnancy
62016187|NCT05761691|EXPERIMENTAL|Children treated for Early childhood caries under general anesthesia (DGA)|GA group (Study group) the dental treatment was provided as a day care surgery under general anasthesia for healthy child patients.
62205423|NCT04869397|EXPERIMENTAL|Allogeneic Wharton's jelly-MSCs (WJ-MSC)|Intravenous administration, 1 dose, for 20 minutes
62205424|NCT04869397|PLACEBO_COMPARATOR|Placebo|Intravenous administration, 1 dose, for 20 minutes
62580795|NCT03795961|EXPERIMENTAL|Active tDCS group|This group will include 42 patients with CTS Intervention (active transcranial direct current electrical stimulation) Stimulation site (M1) Stimulation mode (anodal) Duration of session (20 minutes) Stimulation intensity (2 mA) Number of sessions (5 sessions) Intervals (every another day)
62788102|NCT04674657||caspofungin|Adult critically ill patients on ECMO receiving caspofungin therapy
62788103|NCT04674657||posaconazole|Adult critically ill patients on ECMO receiving posaconazole therapy
62788104|NCT05665296|EXPERIMENTAL|cervicothoracic mobilization|This group will receive cervicothoracic mobilization with comprehensive corrective exercise
62016188|NCT05761691|EXPERIMENTAL|Children treated for Early childhood caries under Local anesthesia (LA)|LA goup (control group) the average number of dental visits was required to finish the treatment plan in local anasthesia group around five to six visits.
62016189|NCT03440632|OTHER|FES start|"Start: 4 weeks 'adaptation phase' and 8 weeks 'FES phase'. Adaption phase: the stimulus (in Volt) will gradually be increased up to an effective level and the wear time has to be increased from 30 minutes to 6 hours a day. FES phase: the participants have to wear the FES device for minimal 6 hours a day during walking. Usual physiotherapy can be continued during the FES phase.~Second: after the FES phase, this group will enter the 'wash-out' period of 6 weeks for fading of the therapeutic effects, in which they return to their conventional therapy. Afterwards, 12 weeks of conventional therapy (orthoses/shoes and usual physiotherapy) with measurements at start and end will follow."
62205425|NCT01508624|NO_INTERVENTION|Control|participants will receive standard usual care
62205426|NCT01508624|EXPERIMENTAL|Interaction|Participants will interact with nurses during their procedure
62205427|NCT01508624|EXPERIMENTAL|Music|Participants will listen to music using head phones during their procedure.
62205428|NCT01508624|EXPERIMENTAL|Touch - stress balls|Participants will be provided with stress balls to use during their procedure
62205429|NCT01508624|EXPERIMENTAL|DVD|Participants will watch a DVD during their procedure and will listen to the accompanying audio through head phones
62788105|NCT05665296|ACTIVE_COMPARATOR|control group: comprehensive corrective exercise (CCE).|This group will receive traditional treatment comprehensive corrective exercise (CCE).
62788106|NCT01237236|EXPERIMENTAL|LEE011|
62788107|NCT01529034|EXPERIMENTAL|USL261|Intranasal midazolam 5 mg
62016190|NCT03440632|OTHER|Conventional start|"Start: wearing usual orthoses/shoes on a daily basis for the first 12 weeks of the study. Usual physiotherapy can be continued.~Second: after 12 weeks this group will enter a 6 week watch out phase, and next be switched to FES treatment for 12 weeks, consisting of: 4 weeks 'adaptation phase' with gradual increase of the treatment and 8 weeks 'FES phase'."
62205430|NCT00834626|OTHER|Surgery group|Interventional study of the effects of a novel metabolic procedure of Ileal Interposition with Sleeve Gastrectomy
62404796|NCT02778269|EXPERIMENTAL|Study Treatment|The patients wear a 12-lead ECG T-shirt for 7 days. During this time period ECG data are measured continuously. In addition the continous glucose monitoring system (CGM) records glucose levels via Dexcom G4-System.
62580796|NCT03795961|SHAM_COMPARATOR|Sham tDCS group|This group will include 42 patients with CTS Intervention (sham or inactive transcranial direct current electrical stimulation) Stimulation site (M1) Stimulation mode (anodal) Duration of session (20 minutes) Stimulation intensity (2 mA) Number of sessions (5 sessions) Intervals (every another day)
62580797|NCT05893251|ACTIVE_COMPARATOR|Protocol group|The treatment plan includes active postural exercises for the cervical spine.
62580798|NCT05893251|EXPERIMENTAL|Manual therapy group|The treatment plan includes active postural exercises and manual therapy for the cervical spine.
62580799|NCT01609699|EXPERIMENTAL|Group A - will undergo 3 successive treatments, 1 week apart|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
62580800|NCT01609699|EXPERIMENTAL|Group B - will undergo 3 successive treatments, 2 weeks apart|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
62580801|NCT02505685||Lung cancer|People that were diagnosed with advanced lung cancer.
62016191|NCT00126048|ACTIVE_COMPARATOR|1|Oral atorvastatin 40mg
62016192|NCT00126048|PLACEBO_COMPARATOR|2|Placebo
62016193|NCT03267238|EXPERIMENTAL|Fecal Microbial transplantation|Fecal Microbial Transplantation will be offered to patients eligible to be part of the study.
62205431|NCT04890548|EXPERIMENTAL|Patients with HFpEF or HFrEF|Patients will be enrolled in 2 cohorts in parallel: 1 cohort of patients with HFpEF and 1 cohort of patients with HFrEF. Patients will receive a sequence of 5 IA infusions into the brachial artery, consisting of a baseline saline infusion of approximately 20 minutes, followed by 3 sequential infusions of AZD3427 at ascending doses of approximately 10 minutes (each) and a washout saline infusion of approximately 15 minutes.
62205432|NCT01581502||NVAF, acute ischemic stroke/TIA|Consecutive acute ischemic stroke/TIA patients with nonvalvular atrial fibrillation; most of these patients begin to receive anticoagulant therapy after index stroke/TIA for secondary prevention
62205433|NCT06729801|EXPERIMENTAL|IRP-Monitoring FANS Group|Patients in this group will undergo retrograde intrarenal surgery (RIRS) using the intrarenal pressure (IRP)-monitoring flexible and navigable suction ureteral access sheath (FANS). This novel device provides real-time IRP monitoring, enabling the surgeon to adjust intraoperative irrigation and suction settings to optimize stone retrieval efficiency while maintaining IRP within a safe range.
62404797|NCT06336603|EXPERIMENTAL|Winlevi (clascoterone) 1% & Adapalene 0.3% gel|Combined use of Winlevi twice daily and Adapalene once daily
62404798|NCT00190294|EXPERIMENTAL|1|MIFEPRISTONE 200 mg and misoprostol 400 µg
62580802|NCT02967328||RP% Measurement by FCM as a Diagnostic Test for ITP|The investigators are undertaking a multi-center, prospective blind trial of 500 adults with thrombocytopenic disorders with a platelet count less than 60000/uL from 4 medical centers in China. In brief, 15 ul aliquots of anti-coagulated whole blood were incubated for 70 min with 5 ul of phycoerythrin-conjugated anti-CD42b monoclonal antibody (BD Pharmingen, Tokyo, Japan) and 1 ml of thiazole orange (Retic-COUNT; Becton-Dickinson, San Jose, CA, USA) diluted 10 times by phosphate-buffered saline. RP% was analyzed on a flow cytometer (FACScan, Becton-Dickinson) by measuring 10,000 events in the CD42b-positive fraction.
62205434|NCT06729801|ACTIVE_COMPARATOR|Conventional FANS Group|Patients in this group will undergo RIRS using a conventional flexible and navigable suction ureteral access sheath (FANS) without intrarenal pressure (IRP) monitoring. The irrigation flow rate and suction pressure will be pre-set and adjusted based on standard clinical practices.
62404799|NCT02272569|EXPERIMENTAL|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant by an ab-externa technique with connection from the anterior chamber to the suprachoroidal space
62404800|NCT04156438|ACTIVE_COMPARATOR|Low tidal volume ventilation|Conventional low tidal volume ventilation
62404801|NCT04156438|EXPERIMENTAL|Airway pressure release ventilation|Early use of airway pressure release ventilation
62205435|NCT06233799|EXPERIMENTAL|XR-NTX/BUP-XL|Participants randomized to the (XR-NTX/BUP-XL) arm will receive 450 mg of once-daily oral extended-release bupropion tablets and once every three weeks (Weeks 1, 4, 7, and 10) injections of extended-release naltrexone (Vivitrol®)
62016194|NCT05252026|EXPERIMENTAL|PROCARE-I (UP-A for indicated purposes)|To ensure cost-effectiveness, PROCARE-I intervention will be designed as a brief 8-session child-focused programme by adapting the core modules from UP-A, along with one individual session with adolescent and parents. Sessions will be delivered in reduced groups, using a typical indicated preventive intervention format focused on cost-effectiveness.
62205436|NCT06233799|PLACEBO_COMPARATOR|PLB/PLB|Participants randomized to the PLB arm will receive once-daily placebo tablets and once every three weeks (Weeks 1, 4, 7, and 10) placebo injections.
62205437|NCT06254937|EXPERIMENTAL|enterprise group|"The research will be conducted as a randomized controlled trial with a pretest-posttest design.~Intervention Group: Participants in the intervention group will be given group training based on the contents of the booklet created by the researcher in line with the literature. Training will be given to participants face to face for 40 minutes, once a week for five weeks. Each training session will include two topics in Reproductive Life Plan Based Training Booklet.~Control Group: A pre-test will be applied to the control group. Reproductive Life Plan Based Training Booklet will be given after the final test.~Post Intervention Phase After the pre-test is applied to the participants in both groups, the data collection form will be applied again 8 weeks later and the post-test phase of the research will be completed. Participants in the control group will be given Reproductive Life Plan Based Training Booklet."
62205438|NCT06254937|NO_INTERVENTION|control group|"Control Group: A pre-test will be applied to the control group. After the final test, the Reproductive Life Plan Based Training Booklet will be given.~Post Intervention Phase Following the application of the pre-test to the participants in both groups, the data collection form will be applied again 8 weeks later and the post-test phase of the research will be completed. Participants in the control group will be given the Reproductive Life Plan Based Training Booklet after the post-test."
62205439|NCT06138613|EXPERIMENTAL|Tradipitant Dose A|"See Drug"
62205440|NCT06138613|EXPERIMENTAL|Tradipitant Dose B|"See Drug"
62205441|NCT01598662|ACTIVE_COMPARATOR|1: IUD insertion 6 Weeks after delivery|"Device:Levonorgestrel-releasing intrauterine device marketed as Mirena.~Subjects randomized to interval placement will have their IUD placed in the office at six weeks postpartum or later. They must return for one visit within a month for a string check."
62404802|NCT03413618|EXPERIMENTAL|Experimental: Rivaroxaban + Diosmin + Stockings|treatment of deep vein thrombosis with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
62404803|NCT03413618|ACTIVE_COMPARATOR|Control: Rivaroxaban + Stockings only|standard treatment of deep vein thrombosis with anticoagulation (rivaroxaban) and elastic compression stockings
62404804|NCT02307695|EXPERIMENTAL|insulin+Saxagliptin|Patients who have diagnosed type 1 diabetes are assigned to receive Saxagliptin tablets 5 mg and insulin for 24-week.
62404805|NCT02307695|ACTIVE_COMPARATOR|insulin|Patients who have diagnosed type 1 diabetes only use insulin.
62404806|NCT06540872|EXPERIMENTAL|Single Arm|All participants receive the drug \[68Ga\]Ga-FAPI-46 and imaging
62404807|NCT05214976|EXPERIMENTAL|Single Group|
62404808|NCT01224223||acute asthma exaecerbtion patients|Patients experiencing acute exacerbation of their asthma
62580803|NCT03532386||Study group|Infertile men with oligoasthenospermia with non-tense vaginal hydrocele subjected to ICSI
62016195|NCT05252026|EXPERIMENTAL|Active control condition|"The active control condition will be based on the U talk programme developed by Prf. Jill Ehrenreich-May at University of Miami and colleagues. It follows a similar structure as the UP-A original programme and allows for one alternative compare condition to PROCARE-I. The U Talk programme support-based group condition will be used as active control condition."
62016196|NCT02284828|EXPERIMENTAL|Group 1 BIA 2-093|A single dose of oral ESL 900 mg was followed by consecutive 7-day periods of: Placebo, ESL 800 mg, and ESL 1200 mg.
62016197|NCT00893490|EXPERIMENTAL|Ahmed Glaucoma Valve (AGV) alone|
62016198|NCT00893490|EXPERIMENTAL|AGV plus MMC|
62016199|NCT00893490|EXPERIMENTAL|AGV plus amniotic membrane coverage|
62016200|NCT05668494|OTHER|immediate loading|Immediate loading of implants by means of one definitive abutment on one side and temporary abutment on the other side of the posterior mandible restored by provisional crown-split mouth design
62016201|NCT03934229|EXPERIMENTAL|Group Active|Bifidobacterium animalis ssp. lactis 420 at 1\*10\^10 colony forming units (CFU) per day
62016202|NCT03934229|PLACEBO_COMPARATOR|Group Placebo|Placebo
62016203|NCT01146938|EXPERIMENTAL|hepatic impairment patients|Hepatic impairment patients group Child-Pugh score A or Child-Pugh score B (not Child-Pugh score C)
62016204|NCT01146938|ACTIVE_COMPARATOR|Healthy volunteers|healthy volunteers group
62016205|NCT02486406|EXPERIMENTAL|Adult tablet, 12-17 yr, Part 1|Participants with HCV GT1b without cirrhosis received the adult 3-DAA (OBV/PTV/RTV and DSV) regimen: two 12.5 mg ombitasvir /75 mg paritaprevir /50 mg ritonavir tablets taken orally every morning (QD) and one dasabuvir 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis received 12-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label.
62205442|NCT01598662|EXPERIMENTAL|2: Immediate Post-placental insertion|"Device: Levonorgestrel-releasing intrauterine device marketed as Mirena~Subjects randomized to immediate post-placental placement within 10 minutes of delivery will have an IUD placed manually under sterile technique and with ultrasound guidance. An ultrasound will be performed within two days postpartum to verify proper placement and again at approximately six weeks postpartum."
62205443|NCT06518031|EXPERIMENTAL|Meditation Group|Meditation practices were administered by the meditation expert for 6 weeks, three times a week for 20 minutes each session, totaling 60 minutes per week
62788108|NCT06289218|EXPERIMENTAL|interferential current plus exercise|interferential current plus exercise group
62788109|NCT06289218|EXPERIMENTAL|kinesio taping plus exercise|kinesio taping plus exercise group
62788110|NCT06289218|OTHER|Control group|Control group
62788111|NCT03833414||(Group1)|Triceps lifting approach .
62788112|NCT03833414||(Group 2)|olecranon osteotomy approach
62788113|NCT04647097|ACTIVE_COMPARATOR|Standard intervention plus repeated intervention|Patients randomized to the standard intervention plus repeated intervention arm
62788114|NCT04647097|ACTIVE_COMPARATOR|Standard intervention only|Patients randomized to the standard intervention only arm
62788115|NCT04119232|NO_INTERVENTION|Control|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment.
62788116|NCT04119232|EXPERIMENTAL|Social incentives-based program|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment. Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
62788117|NCT01712204|PLACEBO_COMPARATOR|Placebo|Placebo plus Febuxostat
62788118|NCT01712204|EXPERIMENTAL|AC-201|AC-201 plus Febuxostat
62404809|NCT01224223||chronic asthma group|Two groups are being enrolled. The first group is chronic asthma patients with FEV1 below 80% and FEV1/FVC ratio reduced by 5%
62788119|NCT00590343|EXPERIMENTAL|1|Intervention=Patients will receive treatment with PTK787/ZK222584 daily. A treatment cycle will be defined as a 28-day period. Subjects will continue on their present treatment regimen of receiving Sandostatin LAR 30mg IM every 4 weeks.
62788120|NCT05612334|EXPERIMENTAL|Experimental|The data collection forms used in the research were applied in the treatment group at the first polyclinic visit (0. month) via face-to-face interviews. First, they were informed about the benefits of exercise and walking. They were also informed about the duration and type of exercise and what should be considered before, during, and after exercises. Then, an informative training booklet prepared by the researcher containing the same information was given to them. An exercise program (5 minutes warm-up-30 minutes walking-5 minutes cooling down) was demonstrated to the patient by the researcher, and then the patient performed the first exercise under the supervision of the researcher. Beginning with the second exercise, the patient performed a 40-minute exercise program, 3 days a week, for 3 months. During this period, the researcher regularly made phone calls once a week to motivate the patient and check whether the patient performed the exercise program.
62788121|NCT05612334|PLACEBO_COMPARATOR|Placebo|The breathing exercise group, which constitutes the placebo-control group, was first informed about correct breathing techniques by the researcher, and an informative training brochure prepared by the researcher, containing correct breathing exercise information, was given to them. The exercise was performed by the researcher and shown to the patient. The first exercise was performed by the patient under the supervision of the researcher. They were informed about the continuation of the breathing exercise program for 3 months, once a day for 10 minutes, starting from the 2nd exercise. Regular phone calls were made once a week.
62404810|NCT02083159||Patients with NAFLD|
62404811|NCT02260596||Cohort Population|Pediatric SOT/HSCT recipients
62788122|NCT05612334|NO_INTERVENTION|No intervention|The control group was contacted by regular phone calls once a week to monitor their compliance with the treatment, to encourage them to express their problems, if any, and to motivate them for the treatment process.
62788123|NCT04342078||Preterm Child group|Preterm children at the age of 5 years; Born before 34 gestation weeks in 2014-2017; Cared in Oulu University Hospital
62788124|NCT04342078||Preterm Adult group|Preterm born adults at the age of 24-25 years; Born before 34 gestation weeks in 1994-1997; Cared in Oulu University Hospital
62788125|NCT04342078||Adult Control group|Age and gender matched term born controls for comparison of the entry assessments in the Preterm Adult group
62205444|NCT06518031|NO_INTERVENTION|Control Group|The research data were collected using a Personal Information Form prepared by the researchers containing introductory information about the nurses, the Perceived Stress Scale for stress, and the Fatigue Severity Scale for fatigue.
62205445|NCT06532734||AN-BP|individuals with a dx of AN-BP, with a \>5-year history of purging, with a frequency of at least once a day.
62205446|NCT02031341||Patients with type 2 diabetes mellitus|
62404812|NCT03077581|ACTIVE_COMPARATOR|Transevrsus abdominus plane block group|
62788126|NCT06508515|ACTIVE_COMPARATOR|Unadapted Research Units in Behavioral Intervention (RUBI) implementation strategy|Participants in this arm will receive the un-adapted RUBI implementation strategy (i.e., RUBI as usual).
62788127|NCT06508515|EXPERIMENTAL|RUBI in Educational Settings (RUBIES) implementation strategy|Participants in this arm will receive an adapted version of the RUBI intervention manual that was iteratively redesigned for use in educational settings (i.e., RUBI for Educational Settings; RUBIES)
62404813|NCT03077581|ACTIVE_COMPARATOR|Rectus sheath block group|
62404814|NCT03077581|ACTIVE_COMPARATOR|local infiltration group|
62404815|NCT04131452||Fresh embryo transfers|those undergoing fresh embryo transfer
62580804|NCT03532386||Control group|infertile men with oligoasthenospermia without hydrocele subjected to ICSI
62580805|NCT03325023|ACTIVE_COMPARATOR|Active Comparator:|Dietary modification + Probiotic supplementation (Sanprobi Super Formula)
62788128|NCT00632619|ACTIVE_COMPARATOR|1|Participants will receive stimulant medication therapy and referrals to community-based psychosocial treatments.
62205447|NCT02031341||Normoglycemic individuals|Control group
62205448|NCT03738423|EXPERIMENTAL|Treatment 1|
62788129|NCT00632619|EXPERIMENTAL|2|Participants will receive stimulant medication therapy and group-based behavior therapy.
62788130|NCT04207060|EXPERIMENTAL|Indomethacin|The study intervention is oral indomethacin. Indomethacin is an FDA approved, commonly prescribed non-steroidal anti-inflammatory drug (NSAID). Commercially available indomethacin will be utilized in this study. Subjects randomized to the indomethacin arm will take one capsule of 50 mg of Indomethacin orally twice a day for 28 days. Participants will be advised not to make up missed doses. They will be advised to take a dose of study medication on the morning of their follow-up endoscopy, 2 hours prior to their scheduled procedure time, with a sip of water. At the time of follow-up endoscopy they will return any unused study medications.
62205449|NCT03738423|EXPERIMENTAL|Treatment 2|
62205450|NCT03738423|EXPERIMENTAL|Treatment 3|
62205451|NCT03738423|EXPERIMENTAL|Treatment 4|
62205452|NCT03738423|EXPERIMENTAL|Treatment 5|Matching placebo
62205453|NCT02626988|EXPERIMENTAL|Intervention|The intervention group will receive capacity building sessions on the 'Promotion of a biodiverse diet' and will include both Agriculture and Nutrition topics, in addition to access to routine health and nutrition checks, and agriculture extension as offered by commune and provincial staff as normal. 5 Sessions will be held in each village over 12 months.
62205454|NCT02626988|NO_INTERVENTION|Control|The control group will continue to receive routine health check and nutrition education from health staff at commune health facilities. Access to agriculture extension services as offered by provincial staff will also continue as normal.
62205455|NCT02651025|EXPERIMENTAL|Resistance Exercise Program|Patients included in intervention group will submit to resistance exercise training during hemodialysis, three times a week, for twelve weeks. This program includes exercises for the upper and lower limbs.
62404816|NCT04131452||Frozen embryo transfers|those undergoing frozen embriyo transfer
62404817|NCT05756166|EXPERIMENTAL|Cohort I (CKM, pembrolizumab)|Patients receive rintatolimod IV, celecoxib PO, interferon alpha-2b IV on days 0, 1, and 2 of week 1 and days 7, 8, and 9 of week 2 on study. Patients receive pembrolizumab IV on day 9 and then every 3 weeks after that for up to 4 doses on study. Patients also undergo CT scan or MRI at screening and follow-up and undergo blood sample collection during screening and on study.
62580806|NCT03325023|PLACEBO_COMPARATOR|Placebo Comparator|Dietary modification + placebo.
62580807|NCT06684470|EXPERIMENTAL|Mirtazapine Group|Subjects will present at Mayo Clinic through a doctor's appointment and a diagnosis of irritable bowel syndrome will be receiving mirtazapine by pill form.
62580808|NCT06684470|PLACEBO_COMPARATOR|Placebo Group|Subjects will present at Mayo Clinic through a doctor's appointment and a diagnosis of irritable bowel syndrome will be receiving placebo by pill form.
62580809|NCT05323448|EXPERIMENTAL|ARISTA|ARISTA-AH will be applied directly within the wound before closure.
62580810|NCT05323448|EXPERIMENTAL|Control group|Participant will not receive the ARISTA-AH hemostatic agent.
62580811|NCT04050878|EXPERIMENTAL|Patient with or without dental prostheses|The patient will be submitted to two facial scans, one with and another without the dental prostheses and the obtained datasets will be compared to assess the differences. Marks will be made in the face to allow for measurements (digital and conventional)
62580812|NCT03821259||Older adults with mental health history|Eligible participants, aged 65 and over, will be established in treatment for PTSD, anxiety or depression in the Older Adult Psychological Therapies service.
62016206|NCT02486406|EXPERIMENTAL|Adult tablet, 12-17 yr, Part 2|Participants with HCV GT1b received the adult 3-DAA (OBV/PTV/RTV and DSV) regimen: two 12.5 mg ombitasvir /75mg paritaprevir /50 mg ritonavir tablets taken orally every morning (QD) and one dasabuvir 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis received 12-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label. Participants with HCV GT1a with compensated cirrhosis received 24-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label. Participants with HCV GT4 received 12-week treatment with the OBV/PTV/RTV formulation and ribavirin 200 mg tablets were administered orally per local label.
62016207|NCT02486406|EXPERIMENTAL|Mini tablet, 9-11 yr, Part 1|Participants with HCV GT1b without cirrhosis were to receive the mini-tablet 3-DAA (OBV, PTV, RTV, and DSV) regimen for 12 weeks: ombitasvir 0.3 mg, paritaprevir 1.0 mg, and ritonavir 1.0 mg mini-tablets administered orally QD based on body weight and dasabuvir taken orally BID as 3.08 mg mini-tablets based on body weight. Participants with HCV GT1a without cirrhosis received 12-week treatment with the mini-tablet 3-DAA regimen and ribavirin was provided as a 40 mg/mL oral solution and administered per local label.
62016208|NCT02486406|EXPERIMENTAL|Mini tablet, 3-8 yr, Part 1|Participants with HCV GT1b without cirrhosis were to receive the mini-tablet 3-DAA (OBV, PTV, RTV, and DSV) regimen for 12 weeks: ombitasvir 0.3 mg, paritaprevir 1.0 mg, and ritonavir 1.0 mg mini-tablets administered orally QD based on body weight and dasabuvir taken orally BID as 3.08 mg mini-tablets based on body weight. Participants with HCV GT1a without cirrhosis received 12-week treatment with the mini-tablet 3-DAA regimen and ribavirin was provided as a 40 mg/mL oral solution and administered per local label.
62016209|NCT02211300|EXPERIMENTAL|Optiscanner values vs YSI|Matched samples up to 12 times per 24 hour period
62016210|NCT01807130|PLACEBO_COMPARATOR|Registry|Patients randomized to the registry arm will be followed per usual standard of care by their primary providers. Those providers may refer to subspecialty HF or electrophysiology care as they see fit.
62016211|NCT01807130|EXPERIMENTAL|Intervention|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology with recommendations to consider those therapies that are not in compliance with guidelines.
62016212|NCT02791139||Control|Healthy Volunteers will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) Echocardiography Tonometry Genetic Testing (Blood) Hand-Grip Strength Measurement Body Fat Mass Analysis
62016213|NCT02791139||Ageing|"Ageing cohort will undergo the following studying procedures:~Cardiovascular Magnetic Resonance Imaging (CMRI) Echocardiography Tonometry Genetic Testing (Blood) Body Fat Mass Analysis"
62016214|NCT02815514||Aortic valve procedures|"1. percutaneous transfemoral aortic valve implantation~2. percutaneous transapical aortic valve implantation~3. percutaneous transaortic aortic valve implantation~4. aortic valve valvuloplasty~5. surgical aortic valve replacement~6. conservative treatment"
62016215|NCT03516916||Australia|Patients with a permanent colostomy after curative surgery for rectal cancer
62016216|NCT03516916||Brazil|Patients with a permanent colostomy after curative surgery for rectal cancer
62016217|NCT03516916||China|Patients with a permanent colostomy after curative surgery for rectal cancer
62016218|NCT03516916||Denmark|Patients with a permanent colostomy after curative surgery for rectal cancer
62016219|NCT03516916||Egypt|Patients with a permanent colostomy after curative surgery for rectal cancer
62016220|NCT03516916||Israel|Patients with a permanent colostomy after curative surgery for rectal cancer
62016221|NCT03516916||Lithuania|Patients with a permanent colostomy after curative surgery for rectal cancer
62016222|NCT03516916||the Netherlands|Patients with a permanent colostomy after curative surgery for rectal cancer
62016223|NCT03516916||Portugal|Patients with a permanent colostomy after curative surgery for rectal cancer
62016224|NCT03516916||Russia|Patients with a permanent colostomy after curative surgery for rectal cancer
62016225|NCT03516916||South Africa|Patients with a permanent colostomy after curative surgery for rectal cancer
62205456|NCT02651025|NO_INTERVENTION|Passive Stretching Program|Patients included in control group will submit to passive stretching program of lower limbs, during hemodialysis, three times a week, for twelve weeks.
62205457|NCT04110353|ACTIVE_COMPARATOR|Conservative dressings|Use of simple dressings on wound post operatively - to be placed at end of operation
62205458|NCT04110353|ACTIVE_COMPARATOR|Prevena dressing|Use of Prevena(KCI) dressing on wound post operatively - to be placed at end of operation
62205459|NCT04110353|ACTIVE_COMPARATOR|ciVAC dressing|Use of closed incision VAC (vacuum assisted closure) dressing on wound post operatively - to be placed at end of operation
62205460|NCT00188942|ACTIVE_COMPARATOR|Fluoxetine + Olanzapine|
62205461|NCT03329469||Experimental: 1: Toshiba CT-FFR Arm|All patients who consent will receive Toshiba CT-FFR and medically acceptable care based on the study protocol, commonly accepted standards of care, and the patients condition.
62580813|NCT05480696|EXPERIMENTAL|Oligofructose Inulin Supplementation|The intervention group will receive a daily fibre supplementation of (fructo-oligosaccharide enriched inulin, 4g twice daily; Orafti®Synergy1, BENEO), a tasteless white powder contained within a tear-able, partitioned 4g sachet, sprinkled and dissolved in 125 mL of water.
62788131|NCT04207060|PLACEBO_COMPARATOR|Placebo|"Participants in both study arms will receive study medication, one capsule orally twice a day for 28 days. Those in the placebo arm will take placebo capsules (one capsule) twice a day for a total of 28 days.~Participants will be advised not to make up missed doses. They will be advised to take a dose of study medication on the morning of their follow-up endoscopy, 2 hours prior to their scheduled procedure time, with a sip of water. At the time of follow-up endoscopy they will return any unused study medication."
62016226|NCT03516916||Spain|Patients with a permanent colostomy after curative surgery for rectal cancer
62788132|NCT01273324||ADM|ADM Cup
62016227|NCT03516916||Sweden|Patients with a permanent colostomy after curative surgery for rectal cancer
62205462|NCT06339853|EXPERIMENTAL|WELT-IP|Eligible subjects were able to access WELT-IP (an investigational digital therapeutic) on a mobile device (iOS and Android) as scheduled to receive cognitive behavioral therapy for insomnia (CBT-I). To collect sleep and environmental data, participants will wear the wearable devices, either (1) Apple Watch (Apple Watch Series 8 41mm (GPS)) or Galaxy Watch 5 40mm (Model: SM-R900NZAAKOO), and (2) Oura Ring (Model: Heritage), during the WELT-IP treatment period.
62205463|NCT00961467|EXPERIMENTAL|RMPT (Arm A -thalidomide 50 mg/day)|
62205464|NCT00961467|EXPERIMENTAL|RMPT (Arm B - thalidomide 100 mg/day)|
62205465|NCT03776539|EXPERIMENTAL|ELX-02|Drug: ELX-02
62205466|NCT04717453||Adult Patients with OTC Deficiency|Eligible subjects will be asked to participate in 5 clinic visits, each lasting up to 3 days. Each visit will assess rate of ureagenesis during the 4 hours following ingestion of \[1-13C\]sodium acetate. Sodium acetate is used as a tracer to measure the rate of ureagenesis. Patient interview, reported outcomes and cognitive assessments will take place over the 3 days.
62205467|NCT01707745|OTHER|Avastin|Bevacizumab(Avastin) 0.75mg in 0.03 ml
62205468|NCT05822739|EXPERIMENTAL|Arm of BBM-P002|single-arm
62404818|NCT05756166|EXPERIMENTAL|Cohort II (CMK, early pembrolizumab)|Patients receive rintatolimod IV, celecoxib PO, and interferon alpha-2b IV on days 0, 1, and 2 of week 1 and days 7, 8, and 9 of week 2 on study. Patients receive pembrolizumab IV on day 2 of week 1 and then every 3 weeks beginning in week 4 on study. Patients also undergo CT scan or MRI at screening and follow-up, undergo blood sample collection during screening and on study, and may undergo tumor biopsy at screening and follow-up.
62404819|NCT02325739|EXPERIMENTAL|Phase I: FGF401 50 mg fasted|Participants received single agent FGF401 50 mg while fasted
62404820|NCT02325739|EXPERIMENTAL|Phase I: FGF401 80 mg fasted|Participants received single agent FGF401 80 mg while fasted
62404821|NCT02325739|EXPERIMENTAL|Phase I: FGF401 80 mg fed|Participants received single agent FGF401 80 mg while fed
62404822|NCT02325739|EXPERIMENTAL|Phase I: FGF401 120 mg fasted|Participants received single agent FGF401 120 mg while fasted
62404823|NCT02325739|EXPERIMENTAL|Phase I: FGF401 120 mg fed|Participants received single agent FGF401 120 mg while fed
62404824|NCT02325739|EXPERIMENTAL|Phase I: FGF401 150 mg fasted|Participants received single agent FGF401 150 mg while fasted
62404825|NCT02325739|EXPERIMENTAL|Phase I: FGF401 80 mg + PDR001 300 mg|Participants received FGF401 80 mg in combination with PDR001 300 mg while fasted
62016228|NCT03516916||Turkey|Patients with a permanent colostomy after curative surgery for rectal cancer
62016229|NCT03516916||the United Kingdom|Patients with a permanent colostomy after curative surgery for rectal cancer
62205469|NCT02061059|OTHER|group 1|"group is assigned to block 1: shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements.~group is assigned to standard: wears shoes produced with standard procedure"
62205470|NCT02061059|OTHER|group 2|"group is assigned to block 1: shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements~group is assigned to with measurements: wears shoes produced with plantar pressure measurements"
62205471|NCT02061059|OTHER|group 3|"group is assigned to block 2: shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements~group is assigned to standard: wears shoes produced with standard procedure"
62205472|NCT02061059|OTHER|group 4|"group assigned to block 2: shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements~group is assigned to with measurements: wears shoes produced with plantar pressure measurements"
62205473|NCT01725126|EXPERIMENTAL|Part A - GSK2890457|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
62404826|NCT02325739|EXPERIMENTAL|Phase I: FGF401 120 mg + PDR001 300 mg|Participants received FGF401 120 mg in combination with PDR001 300 mg while fasted
62205474|NCT01725126|EXPERIMENTAL|Part B - GSK2890457 + Liraglutide|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
62404827|NCT02325739|EXPERIMENTAL|Phase II: Group 1 - FGF401 120 mg QD|Group 1 was comprised of HCC participants from Asian countries who received single agent FGF401 120 mg QD while fasted
62404828|NCT02325739|EXPERIMENTAL|Phase II: Group 2 - FGF401 120 mg QD|Group 2 was comprised of HCC participants from non-Asian countries who took single agent FGF401 120 mg QD while fasted
62404829|NCT02325739|EXPERIMENTAL|Phase II: Group 3 - FGF401 120 mg QD|Group 3 was comprised of participants with other solid malignancies regardless of geography who took single agent FGF401 120 mg QD while fasted
62404830|NCT02279472|OTHER|laser peripheral iridotomy|Laser peripheral iridotomy (LPI) is widely regarded as the first-line intervention for either acute or chronic types of angle-closure glaucoma in early stage ,which relieves pupil block and thus flattening the iris contour and widening the drainage angle,performd by Nd.YAG LASER
62404831|NCT06137794|EXPERIMENTAL|SDM group|"The anticoagulation therapy of AF patients will be determined by clinicians with the use of I-Anticoagulation, and AF patients will be managed using I-Anticoagulation during their anticoagulation therapy."
62404832|NCT06137794|NO_INTERVENTION|Control group|AF patients in the control group will receive standard care.
62016230|NCT02617589|EXPERIMENTAL|Nivolumab + Radiotherapy Arm|Nivolumab IV infusion + Radiotherapy dose as specified
62205475|NCT01725126|EXPERIMENTAL|Part C - GSK2890457 + Metformin|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
62205476|NCT01725126|PLACEBO_COMPARATOR|Part A - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
62205477|NCT01725126|PLACEBO_COMPARATOR|Part B - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
62205478|NCT01725126|PLACEBO_COMPARATOR|Part C - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
62205479|NCT06220162|EXPERIMENTAL|VAC regimen|
62016231|NCT02617589|ACTIVE_COMPARATOR|Temozolomide + Radiotherapy Arm|Temozolomide + Radiotherapy dose as specified
62016232|NCT04545814|EXPERIMENTAL|Stereotactic Radiosurgery|SRS will be delivered utilizing gamma knife or linear accelerator-based techniques.
62016233|NCT01747980|EXPERIMENTAL|PRX-112|250 mL of resuspended carrot cells administered orally in a vehicle
62205480|NCT01430234|OTHER|Panzytrat fixed dose vs. self-dosing|In Phase I (week 1-4) patients will use the fixed amount of lipase as was prescribed by their treating physician. Phase II (week 5-9) patients will start the self-dosage regimen with pancreatic enzymes (without exceeding the maximum amount of 16 capsules per day). They are properly educated by the researcher and dietician how to adjust the amount of pancreatic enzymes to the fat intake in their diet.
62016234|NCT01159418|EXPERIMENTAL|Panobinostat (LBH589), Carboplatin and Paclitaxel|
62016235|NCT00955877|EXPERIMENTAL|DepoDur80|DepoDur will be administered at 80μg/kg (not to exceed 5 mg total/patient) under direct vision in the L1 laminectomy defect prior to wound closure.
62205481|NCT01939444|EXPERIMENTAL|naloxone intranasal|2.0 mg by the nasal route
62205482|NCT01939444|ACTIVE_COMPARATOR|naloxone intravenous|1.0 mg intravenous
62205483|NCT02591953|EXPERIMENTAL|Ultrasound-guided Injection|Injection performed with ultrasound-guidance
62205484|NCT02591953|ACTIVE_COMPARATOR|Landmark-guided Injection|Injection performed at point of maximal tenderness along biceps tendon
62205485|NCT03900910|EXPERIMENTAL|Gastric cancer prevention|13C-urea breath test and anti-H. pylori treatment for those who are tested positive.
62205486|NCT03900910|EXPERIMENTAL|The acceptability and applicability of the mass screening program|Our short-term outcome is the acceptability and feasibility of this screening program, which will be evaluated by answering whether the screening quality indicators can reach the minimal requirements.
62205487|NCT01464840||15 minutes|500 mg of intravenous azithromycin will be administered 15 minutes prior to incision.
62016236|NCT00955877|EXPERIMENTAL|DepoDur120|DepoDur will be administered at 120μg/kg (not to exceed 10 mg total/patient) under direct vision in the L1 laminectomy defect prior to wound closure.
62016237|NCT00955877|PLACEBO_COMPARATOR|Control|Preservative-free normal saline (2.5ml) will be placed in the L1 laminectomy defect and also dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter prior to wound closure.
62205488|NCT01464840||30 minutes|500 mg of intravenous azithromycin will be administered 30 minutes prior to incision.
62205489|NCT01464840||60 minutes|500 mg of intravenous azithromycin will be administered 60 minutes prior to incision.
62580814|NCT05480696|SHAM_COMPARATOR|Maltodextrin Supplementation|The control group will receive a daily supplementation of carbohydrate placebo (isocaloric maltodextrin), identical in colour, packaging, preparation, and dose (4g, twice daily; C\*Dry MD™,Cargill).
62580815|NCT01993901|EXPERIMENTAL|CSRT led telephone follow up|Patients in the experimental arm will be telephoned by the CSRT 4-6 weeks after completion of their treatment to assess any symptoms.
62016238|NCT02286882|EXPERIMENTAL|Cohort 1: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
62016239|NCT02286882|EXPERIMENTAL|Cohort 2: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
62016240|NCT02286882|EXPERIMENTAL|Cohort 3: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
62016241|NCT02286882|EXPERIMENTAL|Cohort 4: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
62205490|NCT05912829||Kowa Group|Patients who had a Kowa lens implanted using the Yamane technique
62205491|NCT05912829||Johnson|Patients who had the ZA9003 (J\&J) lens implanted using the Yamane technique
62788133|NCT00794950|EXPERIMENTAL|Sunitinib treatment|Intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma.
62205492|NCT03551327|EXPERIMENTAL|Intervention plus information|Participants in this arm will receive 6 telephone therapy sessions and 1 booster session. Participants will be followed up at 4 months and 6 months.
62404833|NCT03297593|EXPERIMENTAL|nivolumab and ipilimumab|"Patients start treatment with nivolumab (240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter).~After 2 weeks, ipilimumab (1mg/kg every 6 weeks) will be introduced. As soon as a radiographic complete response (CR) or partial response (PR) is observed, ipilimumab has to be stopped and only the single-agent treatment with nivolumab is continued. Once ipilumimab has been stopped because of a response, it will not be re-started later on."
62016242|NCT02286882|EXPERIMENTAL|Cohort 5: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
62016243|NCT02286882|EXPERIMENTAL|Cohort 6: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
62205493|NCT03551327|OTHER|Information only|Participants in this arm will receive information only. Participants will be followed up at 4 months and 6 months.
62205494|NCT02190903|ACTIVE_COMPARATOR|General endotracheal anesthesia|Standard care general endotracheal anesthesia
62205495|NCT02190903|ACTIVE_COMPARATOR|Regional (spinal) anesthesia|Standard care spinal anesthesia
62205496|NCT05804318|EXPERIMENTAL|Adaptive SBRT with Urethral Sparing|Daily adaptive stereotactic body radiation therapy delivering 40 Gy in 5 fractions to the prostate while delivery 35-36 Gy in 5 fractions to the urethra.
62205497|NCT06144632|EXPERIMENTAL|Treatment Group|Participants with drug refractory, symptomatic paroxysmal atrial fibrillation will receive PFA /radiofrequency (RF) ablation using THERMOCOOL STSF catheter in conjunction with the TRUPULSE generator per the hospital's standard protocol (at discretion of investigator).
62205498|NCT03549390|EXPERIMENTAL|Yoga|The yoga session will be held in a room where lighting, temperature and music can be regulated. The session will be led by a trained instructor and involve a combination of body postures, breathing techniques and meditation. There will be a series of progressive breath centred yoga poses named Sun Salutations A \& B for participants to complete, which have been chosen based on PPI and current relevant yoga practices. Sun Salutations A \& B will be completed in a continuous sequence and aim to be completed with one breath per pose, but can be modified based on participant ability.
62205499|NCT03549390|EXPERIMENTAL|Continuous exercise|The exercise will be 30 minutes of treadmill walking. During the initial stages of walking, participants will gradually be taken up to a speed that registers between 10 and 12 on the Borg Rating of Perceived Exertion (RPE) Scale, up to a maximum of 4.0 km/h. This speed will be fixed for the entire exercise period. This exercise intensity has been chosen as it is the exercise intensity matched to light-moderate physical activity.
62205500|NCT03549390|NO_INTERVENTION|Control|Participants will remain sitting throughout the test period whilst undertaking typical sedentary behaviours such as watching TV, using a computer, reading and writing. Walking and standing will be restricted.
62205501|NCT02383940|PLACEBO_COMPARATOR|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 12 weeks.
62205502|NCT02383940|EXPERIMENTAL|Sotagliflozin 400 mg|Sotagliflozin 400 milligram (mg) (two 200 mg tablets), once daily, orally, before the first meal of the day for 12 weeks.
62404834|NCT02544607|EXPERIMENTAL|Ketamine + MRI|All eligible participants will receive open label ketamine and undergo Magnetic Resonance Imaging (MRI).
62404835|NCT00066859|ACTIVE_COMPARATOR|Arm 1: Sertraline (Zoloft) 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
62404836|NCT00066859|ACTIVE_COMPARATOR|Arm 2 - St. John's Wort 600mg|St. John's wort 600 mg daily for 1 week. If tolerated dose may be increased to 900 mg daily for four months.
62404837|NCT03130556|EXPERIMENTAL|Glasdegib BE and Food|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects receive a 100 mg single dose ICH tablet after a high fat, high calorie meal.
62404838|NCT03130556|EXPERIMENTAL|Glasdegib BE and PPI Effect|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects receive a 100 mg single dose ICH tablet in the fasted state after repeated daily dosing with rabeprazole.
62016244|NCT02286882|EXPERIMENTAL|Cohort 7: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
62016245|NCT02286882|EXPERIMENTAL|Cohort 8: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
62016246|NCT02286882|EXPERIMENTAL|Cohort 9: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
62205503|NCT05169593|OTHER|Endoscopy-driven postoperative biological therapy|"Endoscopic recurrence at week 30~Adalimumab: 160 mg SC at week 32, 80 mg SC at week 34, 40 mg SC at week 36 and every two weeks thereafter.~Infliximab: Induction with 5 mg/kg IV at week 32, and 5 mg/kg IV at week 34; maintenance with 5 mg/kg IV at week 38, week 42 or week 46 and every eight weeks thereafter or with 120 mg SC at week 38 and every two weeks thereafter.~Ustekinumab: 260 mg (body weight ≤55kg) or 390 mg (55-85kg) or 520 mg (\>85kg) IV at week 32, 90 mg SC at week 40, and every eight weeks thereafter.~Vedolizumab: Induction with 300 mg IV at week 32, and 300 mg IV at week 34; maintenance with 300 mg IV at week 38 and every eight weeks thereafter or with 108 mg SC at week 38, week 42 or week 46 and every two weeks thereafter.~Risankizumab: Induction with 600 mg IV at week 32, week 36 and week 40; maintenance with 360 mg SC at week 44 and every eight weeks thereafter."
62215207|NCT04565093|PLACEBO_COMPARATOR|Periarticular local infiltration analgesia (LIA)|In this group, participants will receive a mixture of bupivacaine 0.25% 20 ml + epinephrine 100 mics ± lornoxicam 8 mg ± morphine 10 mg ± tranexamic acid 1 gm in 40 ml normal saline (NS) that will be injected into the posterior capsule and the medial and lateral ligaments just before implantation: after insertion of the implants and into the capsule and retinacular tissues. The remaining solution (approximately 20 mL) will be used to infiltrate the muscle and subcutaneous tissues. This local anesthetic infiltration is commonly performed by the operating orthopedic surgeon during TKA for postoperative pain control.
62215208|NCT00414908|EXPERIMENTAL|A|
62215209|NCT00414908|PLACEBO_COMPARATOR|B|
62215210|NCT02854878|EXPERIMENTAL|treatment|
62404839|NCT05897931|EXPERIMENTAL|Connective tissue massage|Participants will receive TENS and infrared treatment for 25 minutes, 5 days a week. Then Connective Tissue Massage will be applied.
62404840|NCT05897931|EXPERIMENTAL|Kinesio Tape Application|Participants will receive TENS and infrared treatment for 25 minutes, 5 days a week. Kinesio tape application will be applied 2 days a week for 4 weeks.
62016247|NCT03556319|PLACEBO_COMPARATOR|Placebo|Placebo
62016248|NCT03556319|EXPERIMENTAL|2-HOBA Low Dose|2-Hydroxybenzylamine acetate: 500mg dose
62016249|NCT03556319|EXPERIMENTAL|2-HOBA High Dose|2-Hydroxybenzylamine acetate: 750mg dose
62016250|NCT06152276||Standard of Care Arm|Diverting loop ileostomy following low anterior resection of colorectal cancer
62016251|NCT03679260|EXPERIMENTAL|Arm A|Carbohydrate restricted diet and phone counseling with dietitian. After 6 months, patients will crossover to a non-restricted diet.
62016252|NCT03679260|EXPERIMENTAL|Arm B|Non-restricted diet and after 6 months, patients will crossover to a carbohydrate restricted diet and phone counseling with dietitian
62404841|NCT03803371|EXPERIMENTAL|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets by mouth on Day 1 of period 1 or 2
62404842|NCT03803371|ACTIVE_COMPARATOR|Ultracet tablet|Ultracet tablet (Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg) by mouth on Day 1 of period 1 or 2
62404843|NCT05891288|EXPERIMENTAL|bioactive group|Bioactive Pits \& fissures sealant BioCoat® by Premier®.
62788134|NCT02760641|EXPERIMENTAL|Egg-based diet (EBD)|This arm will provide ≤25% energy from CHO, 25% energy from protein, and ≥50% energy from fat. EBD participants will be asked to consume ≥2 eggs per day along with other protein sources including meat, fish, pork, and poultry. Carbohydrate (CHO) sources will be primarily derived from leafy greens and non-starchy vegetables and CHO intake will be equally distributed across meals throughout the day.
62016253|NCT02172313|EXPERIMENTAL|Fed conditions|Fasting for 10 hours overnight followed by a high-fat, high-calorie meal, after the meal dosing of the tablet with 240 mL of water and a post-dose fasting period of 4 hours
62016254|NCT02172313|EXPERIMENTAL|Fasting conditions|Fasting for 10 hours overnight followed by dosing of the tablet with 240 mL of water and a post-dose fasting period of 4 hours
62016255|NCT02172313|EXPERIMENTAL|Reference dosing condition|Fasting for 6 hours overnight followed by dosing of the tablet with 120 mL of water and a post-dose fasting period of 30 min
62016256|NCT05937022|EXPERIMENTAL|Right VLPFC tDCS|Participants who are assigned to the right VLPFC group will receive anodal tDCS over the right ventrolateral prefrontal cortex (VLPFC).
62788135|NCT02760641|PLACEBO_COMPARATOR|Carbohydrate-based diet (CBD)|The CBD group will be asked to avoid whole egg consumption when possible during the 8 week intervention period. They will be counseled to consume a low fat diet with 55:25:20 %energy from CHO:protein:fat. This diet will place an emphasis on consuming lean meats, low fat dairy, whole grains, legumes, fruits and vegetables.
62788136|NCT01659749|OTHER|Metabolic Camp|Metabolic Camp is an educational and social support program for females age 11 through adult with phenylketonuria (PKU) and maple syrup urine disease (MSUD), two inherited metabolic disorders (IMD). Camp provides a supportive environment for adolescent girls and women to learn about the importance of nutrition and diet self-management, with the intention of arresting the disease process and minimizing the instances of miscarriages and severe birth defects, which are high in this population. After 20+ years, Metabolic Camp is established as a unique, national program allowing up to 35 campers to live and learn during a week of nutritional support and productive activities, while simultaneously providing researchers an opportunity to gather important data.
62788137|NCT03747640|EXPERIMENTAL|tDCS with mindfulness-based meditation|Self Transcranial Direct Current Stimulation (tDCS) with Mindfulness-Based Meditation
62788138|NCT03747640|SHAM_COMPARATOR|sham tDCS with sham meditation|Sham self Transcranial Direct Current Stimulation (tDCS) with sham Meditation
62788139|NCT06116006|OTHER|Subjects with 3 experimental conditions|"3 types of upper limb pointing movements:~* movements with robot assistance~* movements without robot assistance~* movements with robot resistance"
62788140|NCT00571805|ACTIVE_COMPARATOR|1|Varenicline
62788141|NCT00571805|PLACEBO_COMPARATOR|2|placebo
62788142|NCT02452450|EXPERIMENTAL|Ibuprofen lysine|
62788143|NCT02452450|EXPERIMENTAL|Ibuprofen sodium|
62788144|NCT02452450|EXPERIMENTAL|Ibuprofen liquid capsules|
62788145|NCT02452450|ACTIVE_COMPARATOR|Ibuprofen acid|
62788146|NCT02452450|ACTIVE_COMPARATOR|Paracetamol|
62788147|NCT04043039|EXPERIMENTAL|FULL THICKNESS PALATAL GRAFT|the full thickness palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membrane or by gelatine sponge
62788148|NCT04043039|ACTIVE_COMPARATOR|FREE GINGIVAL GRAFT|the Epithelialized Free Gingival Grafts palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membrane or by gelatine sponge
62788149|NCT01836302||Patients with Cerebral Desaturation|We will compare the primary and secondary outcomes between the patients who experience cerebral desaturations and those that do not.
62788150|NCT01836302||Patients without cerebral desaturation|We will compare the primary and secondary outcomes between the patients who experience cerebral desaturations and those that do not.
62788151|NCT05879497|EXPERIMENTAL|68Ga-NY104 PET/CT|Each patient will receive one dose of 68Ga-NY104 by intravenous route. Dedicated whole-body PET/CT imaging will be performed.
62016257|NCT05937022|EXPERIMENTAL|Left DLPFC tDCS|Participants who are assigned to the right VLPFC group will receive anodal tDCS over the left dorsolateral prefrontal cortex (DLPFC).
62016258|NCT05937022|SHAM_COMPARATOR|Sham Control tDCS|For the sham protocol, the electrode positioning will be randomly allocated to be identical to either the left DLPFC or the right VLPFC group, but the active stimulation will be delivered for the first 30 seconds only.
62404844|NCT05891288|ACTIVE_COMPARATOR|Comparator group|Fluoride releasing resin based Pits \& fissures sealant 3M™ Clinpro™ Sealant
62404845|NCT00351611|EXPERIMENTAL|Active|Active drug
62788152|NCT02919254|ACTIVE_COMPARATOR|High Dosage|Subjects will receive approximately 8 mmol of dietary nitrate per day delivered as a commercially available beetroot juice supplement for 7 days.
62788153|NCT02919254|ACTIVE_COMPARATOR|Moderate Dosage|Subjects will receive approximately 0.5 mmol of dietary nitrate per day delivered as a commercially available beetroot juice supplement for 7 days.
62788154|NCT02919254|PLACEBO_COMPARATOR|Placebo|Subjects will receive a placebo beverage containing negligible nitrate for 7 days.
62788155|NCT01717001||ConforMIS|Patients with ConforMIS implants
62788156|NCT01717001||Standard Total Knee Implant|Patients implanted with standard total knee implant
62788157|NCT00284219|ACTIVE_COMPARATOR|Real high frequency rTMS|The patients will undergo a series of treatments of high frequency rTMS
62788158|NCT00284219|SHAM_COMPARATOR|Sham high frequency rTMS|The patients will receive a series of sham treatments.
62788159|NCT05977062|OTHER|Coaching arm|
62788160|NCT03439930|ACTIVE_COMPARATOR|Uni-axial|Subjects in this group perform exercises on an uni-axial balance board
62788161|NCT03439930|ACTIVE_COMPARATOR|Multidirectional|Subjects in this group perform exercises on a multidirectional balance board
62788162|NCT02238158||Chronic Obstructive Pulmonary Disease|
62788163|NCT06432335|OTHER|E-Socket Monitoring|
62205504|NCT05169593|ACTIVE_COMPARATOR|Systematic postoperative prophylaxis with a biological|"Adalimumab: 160 mg subcutaneous (SC) at day 0, 80 mg SC at week 2, 40 mg SC at week 4 and every two weeks thereafter.~Infliximab: Induction with 5 mg/kg intravenous (IV) at day 0, and 5 mg/kg IV at week 2; maintenance with 5 mg/kg IV at week 6, week 10 or week 14 and every eight weeks thereafter or with 120 mg SC at week 6 and every two weeks thereafter.~Ustekinumab: 260 mg (body weight ≤55kg), 390 mg (55-85kg) or 520 mg (\>85kg) IV at day 0, 90 mg SC at week 8 and every eight weeks thereafter.~Vedolizumab: Induction with 300 mg IV at day 0, and 300 mg IV at week 2; maintenance with 300 mg IV at week 6 and every eight weeks thereafter or with 108 mg SC at week 6, week 10 or week 14 and every two weeks thereafter.~Risankizumab: Induction with 600 mg IV at day 0, week 4 and week 8; maintenance with 360 mg SC at week 12 and every eight weeks thereafter."
62205505|NCT00799032|OTHER|Stent|Catania Stent
62205506|NCT01484431|EXPERIMENTAL|Tadalafil|"Light Weight \<25 kg Period 1: 2 milligram (mg) or 4 mg tadalafil administered once daily (QD) in oral suspension formulation for 5 weeks then 8 mg,10 mg,15 mg or 20 mg tadalafil was administered QD in oral suspension formulation for 5 weeks.~Middle Weight: 25 kg to \<40 kg Period 1: 5 mg tadalafil tablet administered QD for 5 weeks then 10 mg, 15 mg or 20 mg tablet tadalafil administered QD for 5 weeks.~Heavy: ≥40 kg Period 1: 10 mg tadalafil tablet administered QD for 5 weeks then 20 mg or 40 mg tablet tadalafil administered QD for 5 weeks."
62404846|NCT00351611|PLACEBO_COMPARATOR|Placebo|placebo comparator
62580816|NCT01993901|NO_INTERVENTION|Standard Follow up|"Patients in the control group will have the standard follow up (CT of the chest, abdomen and pelvis prior to follow-up with the radiation oncologist 4 months after the completion of their treatment). In order to control for an attention effect that may be seen in the intervention group, patients in the control group will get a placebo or sham telephone call initiated by a research assistant 4-6 weeks after completion of their treatment. This telephone call will simply confirm their follow up appointment."
62580817|NCT06683755|EXPERIMENTAL|Phase I + IIa: Nivolumab + Relatlimab + Ipilimumab|Participants particiapting on study will be randomized
62580818|NCT04296825|PLACEBO_COMPARATOR|P|Patients received cow milk for 4 consecutive weeks (two times per day, 10 gram each time).
62580819|NCT04296825|ACTIVE_COMPARATOR|CA|Patients received camel milk with Bifidobacterium animalis A6 at a dose of 2×1010 viable cells for 4 consecutive weeks (two times per day, 10 gram each time).
62580820|NCT04296825|EXPERIMENTAL|C|Patients received camel milk for 4 consecutive weeks (two times per day, 10 gram each time).
62580821|NCT04296825|EXPERIMENTAL|A|Patients received Bifidobacterium animalis A6 at a dose of 2×1010 viable cells for 4 consecutive weeks (two times per day, 10 gram each time).
62580822|NCT04722835||Normal RV/TLC Group:|Plethysmographic RV/TLC equal or less than lower limit of normal.
62580823|NCT04722835||Abnormal RV/TLC Group:|Plethysmographic RV/TLC higher than lower limit of normal.
62580824|NCT06489782|EXPERIMENTAL|Model 1|Model 1 examines the impact of alcohol cues and alcohol availability on latency to start drinking and amount consumed of a 0.12 g/dL dose of alcohol during a 2-hour ad-libitum period.
62016259|NCT03865121|EXPERIMENTAL|Nicotine Nasal Spray 10 MG/ML|Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.
62016260|NCT04641468|OTHER|Mediana 010 or 001 left main bifurcation lesion|DCB alone combined with retracted DES implantation if necessary (d-p-d strategy)
62016261|NCT00734838|EXPERIMENTAL|Core needle biopsy|Patients needing a needle biopsy of a breast mass
62205507|NCT01891942|EXPERIMENTAL|COPD patients|All of the COPD patients included in this study were stable with no episodes of exacerbation within the previous 2 months. Patients with COPD were not currently being treated with oral corticosteroids.
62404847|NCT05946096|EXPERIMENTAL|dynamic surface exercise training group|This group includes 19 subjects all of which are children with spastic diplegic cerebral palsy of GMFCS levels 3 and 4. This group received a set of exercises on various dynamic surfaces along with routine physical therapy. This group underwent a 60-minutes vigorous exercise program four days a week for two months
62404848|NCT05946096|ACTIVE_COMPARATOR|conventional physical therapy group|This group includes 19 subjects all of which are children with spastic diplegic cerebral palsy of GMFCS levels 3 and 4. This group received only conventional physical therapy which is based upon principles of NDT. This group underwent a 60-minutes vigorous exercise program four days a week for two months.
62580825|NCT06489782|EXPERIMENTAL|Model 2|Model 2 examines the impact of alcohol cues and alcohol availability and a priming dose of alcohol (.04 g/dL) on latency to start drinking and amount consumed of a 0.12 g/dL dose of alcohol during a 2-hour ad-libitum period.
62580826|NCT01404156|ACTIVE_COMPARATOR|Neoadjuvant Chemotherapy|"NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)~1) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days~2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous intravenous infusionIV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2 PO BID (ECX)"
62016262|NCT00734838|PLACEBO_COMPARATOR|Reduction mammoplasty|Any patients scheduled for a reduction mammoplasty who would like to participate in a study to better understand breast cancer
62205508|NCT01891942|EXPERIMENTAL|normal subjects|Fifteen healthy men with normal lung function
62205509|NCT00124683|EXPERIMENTAL|1|Nicotine Patch + Bupropion
62205510|NCT00124683|PLACEBO_COMPARATOR|2|Nicotine patch + placebo
62205511|NCT05097196|EXPERIMENTAL|Step Aerobic Group|Step aerobic exercise
62788164|NCT02059603|EXPERIMENTAL|Electroacupuncture|Bilateral acupoints relevant to the treatment of abdominal pain, abdominal distension, and constipation, including Zusanli (stomach meridian ST-36), Sanyinjiao (spleen meridian SP-6), Hegu (large intestine meridian LI-4), and Zhigou (triple energizer meridian TE-6), will be used. Electric stimulation at a frequency of 50 Hz will be employed to the acupuncture needles.
62205512|NCT06002711||retrospective study cohort|In the retrospective study, patient cases will be gathered from multi-center repositories, where surgical cases will be confirmed to be high-grade gliomas and will undergo preoperative contrast-enhanced MRI examinations. These patients will possess comprehensive clinical, pathological, and genetic data.
62205513|NCT06002711||Prospective study cohort|The prospective study will encompass a cohort of individuals who are clinically suspected to have high-grade gliomas and will undergo multimodal MRI imaging. Subsequent to surgery, their postoperative pathology will confirm the diagnosis of high-grade gliomas. Following the surgical intervention, these patients will undergo standard procedures for radiotherapy and chemotherapy, as well as regular follow-up assessments.
62205514|NCT00588900|EXPERIMENTAL|irinotecan + cediranib|"Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and oral cediranib once daily on days 1-21. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.~After completion of study therapy, patients are followed up every 3 months for up to 2 years from study entry."
62205515|NCT03231124|EXPERIMENTAL|LEO 32731|"Incremental dosing of LEO 32731 progressing to a maximum of 30 mg.~* Days 1 - 3: 10 mg dose twice a day for three days~* Days 4 - 6: 20 mg dose twice a day for three days~* Days 7 - 11: 30 mg dose twice a day for five days~* Days 12: 30 mg dose once in the morning"
62205516|NCT03231124|PLACEBO_COMPARATOR|Placebo|"Incremental dosing of placebo progressing to a maximum of 30 mg.~* Days 1 - 3: 10 mg dose twice a day for three days~* Days 4 - 6: 20 mg dose twice a day for three days~* Days 7 - 11: 30 mg dose twice a day for five days~* Days 12: 30 mg dose once in the morning"
62788165|NCT02059603|ACTIVE_COMPARATOR|Fast-track program|The design of this program is based on the consensus between our surgeons, anesthetists, physiotherapists, dietitians, and nurses, who have reviewed the relevant literature and made appropriate adjustments to suit the local situation.
62788166|NCT01336153|EXPERIMENTAL|MLC601|MLC601 (NeuroAideTM) is a TCM which is used extensively in China to improve recovery after stroke. It combines several herbal and animal components.
62788167|NCT01336153|PLACEBO_COMPARATOR|Placebo|
62788168|NCT00704860|EXPERIMENTAL|TR|TR- Subjects defined as having treatment resistant depression, who have failed at least 2 adequate trials of an antidepressant. Subjects will be treated in an open label trial for their depression, with the goal of sustained remission.
62788169|NCT05727982||NSTEMI patients|Patients no ST-segment elevation myocardial infarction (NSTEMI)
62788170|NCT05727982||SA patients|Patients with Stable Angina (SA) diagnosis
62788171|NCT05727982||MVD patients|Patients with consecutive Mitral Valve Disease patients (MVD)
62788172|NCT06233006||Non Spesific Neck Pain|Patients with Non Spesific Neck Pain
62788173|NCT06233006||Healthy Control|Individuals with similar age
62788174|NCT05098171|EXPERIMENTAL|Signal Switch Receptor Modified TIL|2x10\^8-1x10\^10 in vitro expanded autologous PD-1 or TGF-β signal switch receptor modified TIL (GC201 TIL) will be infused i.v. to patients with advanced gynecologic tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
62016263|NCT06181669||Standard of Care|There are no interventions in this study. Standard of care activities will be captured in the eCRF and samples will be collected and tested. Results will not be returned to the sites or participants.
62016264|NCT06030193|EXPERIMENTAL|QLS-111 ophthalmic solution|Qlaris' investigational product, QLS-111 ophthalmic solution, provided in 2 concentrations for this study (0.15% and 0.03%), single use vials, masked, and preservative free (PF).
62016265|NCT06030193|PLACEBO_COMPARATOR|QLS-111 ophthalmic vehicle solution|Inactive control. QLS-111 ophthalmic vehicle solution, single use vials, masked, PF.
62016266|NCT05395377|ACTIVE_COMPARATOR|Registered Dietitian/Nutritionist|
62016267|NCT05395377|ACTIVE_COMPARATOR|DPP Group Classes|
62016268|NCT05395377|ACTIVE_COMPARATOR|Weight Watchers, Reimagined|
62016269|NCT05395377|ACTIVE_COMPARATOR|Pharmacological Treatment|
62016270|NCT05395377|ACTIVE_COMPARATOR|Bariatric Surgery Evaluation|
62016271|NCT01170897|OTHER|Maximally Tolerated Dose|To identify the maximally tolerated dose (MTD) of PEGPH20.
62016272|NCT03699306|ACTIVE_COMPARATOR|Conventional r blinded|the participants were allocated to have NG tube inserted in a conventional or blind method.
62016273|NCT03699306|ACTIVE_COMPARATOR|Brake cable|the participants were assigned to have NG tube inserted by use of a bike brake cable as a guide wire.
62016274|NCT03699306|ACTIVE_COMPARATOR|High way man's hitch|they were selected to have NG tube inserted by use of silk thread knot.
62016275|NCT03526224||Aubagio|Individuals diagnosed with multiple sclerosis (MS) who have been treated with teriflunomide (Aubagio).
62016276|NCT03526224||Tecfidera|Individuals diagnosed with multiple sclerosis (MS) who have been treated with dimethyl fumarate (Tecfidera) and matched with the teriflunomide (Aubagio) patients on age, sex, disease duration, and disability level
62016277|NCT04277377||DSA in patients with kidney failure|Patients on kidney transplantation waiting list with DSA detected by Luminex (and mean fluorescence intensity (MFI) \> 1000) in their blood.
62016278|NCT02414087|ACTIVE_COMPARATOR|study group|ICB Medical Insoles
62016279|NCT02414087|PLACEBO_COMPARATOR|control group|without ICB Medical insoles
62016280|NCT02477384|ACTIVE_COMPARATOR|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
62016281|NCT02477384|ACTIVE_COMPARATOR|EVL plus propranolol|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
62404849|NCT05295459|EXPERIMENTAL|LYR-210|Single administration of LYR-210 drug matrix (7500 μg)
62404850|NCT05295459|SHAM_COMPARATOR|Sham procedure control|Single mock administration procedure
62205517|NCT02847390||Pre-implementation group|"The investigators will develop and deliver a diabetes physician and nursing inpatient diabetes education intervention to our staff over a 6-month time frame from August 2016-January 2017. The investigators will use a before and after study design to assess the impact of the educational intervention on hospital-wide hypoglycemia and hyperglycemia.~Adult (\>18 years), non-obstetrical patients admitted to the medical services where housestaff and hospitalist superusers have been trained, with Type 1 diabetes, Type 2 diabetes, or individuals with hospital-related hyperglycemia who do not carry a prior diabetes diagnosis (4/1/16 to 6/30/16)."
62205518|NCT02847390||Post-implementation group|Adult (\>18 years), non-obstetrical patients admitted to the medical services where housestaff and hospitalist superusers have been trained, with Type 1 diabetes, Type 2 diabetes, or individuals with hospital-related hyperglycemia who do not carry a prior diabetes diagnosis (4/1/17 to 6/30/17).
62205519|NCT06107868|EXPERIMENTAL|Part A - Dose Escalation|"RP6306, 40 mg orally, twice a day, continuously or on Days 1 to 3, for 1 or 2 weeks, every 21-day cycle.~Carboplatin, AUC 5 intravenously, on Day 1 of every 21-day cycle.~Paclitaxel, 175 mg/m2 intravenously, on Day 1 of every 21-day cycle."
62205520|NCT06107868|EXPERIMENTAL|Part B - Dose Expansion|"RP6306, 40 mg orally at the best schedule determined in Part A.~Carboplatin, AUC 5 intravenously, on Day 1 of every 21-day cycle.~Paclitaxel, 175 mg/m2 intravenously, on Day 1 every 21-day cycle."
62205521|NCT01941147|EXPERIMENTAL|Pulsed ELF-MF|Nine patients will be treated daily for 5 consecutive days, starting within 48 h from the onset of stroke. Three dose cohorts of three patients each, will be stimulated with pulsed ELF-MF at increasing daily exposure (45, 120, 240 min).
62205522|NCT05072028|EXPERIMENTAL|[14C]DBPR108|Subjects will receive a single oral 100 mg (radioactivity of 150 µCi) dose of \[14C\]DBPR108 on Day 1.
62205523|NCT02755870|EXPERIMENTAL|CNM-Au8|"CNM-Au8 is an orally administered, clean-surface gold nanocrystal suspension drug. It is atomically clean-surface elemental nanocrystals, free of any residual surface chemicals or surface-capping agents.~CNM-Au8 15, 30, 60, 90mg as an oral suspension"
62205524|NCT02755870|PLACEBO_COMPARATOR|Placebo|Placebo oral suspension which matches the volume of the experimental nanocrystal suspension
62205525|NCT04293458|EXPERIMENTAL|EsoCheck vs. EGD with or without biopsies|All subjects will undergo both the EsoCheck (non-invasive esophageal cell sample collection) followed by EGD (with or without biopsies)
62404851|NCT04853953||COVID-19 ARDS patients requiring veno-venous ECMO support|Critically ill COVID-19 patients with ARDS requiring ECMO support will be analyzed in this group. Patients from all three study sites will be assessed for participation.
62404852|NCT04853953||Non-COVID-19 ARDS patients requiring veno-venous ECMO support|Critically ill Non-COVID-19 patients with ARDS requiring ECMO support will be analyzed in this group. Patients from all three study sites will be assessed for participation.
62404853|NCT01700686||Obese subjects|Meal test and dexa scan
62404854|NCT04755491||Chloride transfer by continuous veno-venous hemofiltration|Chloride transfer over 24h of continuous veno-venous hemofiltration in mechanically ventilated ICU patients presenting with stage III AKI according to Kidney Disease: Improving Global Outcome (KDIGO) classification. Chloride concentrations will be measured in the serum, the urine, and the effluent of included patients every 4 to 6h from inclusion to H24.
62404855|NCT04755491||Chloride transfer by continuous veno-venous hemodialysis|Chloride transfer over 24h of continuous veno-venous hemodialysis in mechanically ventilated ICU patients presenting with stage III AKI according to Kidney Disease: Improving Global Outcome (KDIGO) classification. Chloride concentrations will be measured in the serum, the urine, and the effluent of included patients every 4 to 6h from inclusion to H24.
62788175|NCT05320172|EXPERIMENTAL|Treatment group|Participants with persistent epithelial defects will be treated with autologous platelet rich plasma eye drops.
62016282|NCT06347185|ACTIVE_COMPARATOR|Standard of Care|The oncologist will be the main referral of the patient, deciding the therapeutic approach, the assessments requested, in terms of type of exams and timing and the need of possible further support from other expertise. The oncologist will base the choices also upon the results of the Liverpool Head and Neck Patient Concern Inventory (PCI-H\&N) and the patient's preferences. At the end of the first oncological visit, the physician will be asked to predict the survival of the patient.
62016283|NCT06347185|EXPERIMENTAL|Integrated Care|Besides the oncology visit, patient will have the palliative care expert visit and follow up. The oncologist will define the therapeutic approach and the assessments requested, in terms of type of exams and timing. The palliative care clinician and the oncologist will judge the burden of symptoms and together they will propose the suggested interventions to relief the symptoms, with a particular attention to a validated instrument (the PCI-H\&N) and patient priority questionnaire's results.
62016284|NCT04975815||Non-frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores0 will place the participants in Non-frail group.~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
62016285|NCT04975815||Pre-frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores1-2 will place the participants in Pre-frail group.~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
62016286|NCT04975815||Frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores3-5 will place the participants in Frail group.~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
62205526|NCT01824927|ACTIVE_COMPARATOR|First eye (FE)|Phacoemulsification cataract extraction surgery of first eye
62205527|NCT01824927|ACTIVE_COMPARATOR|Second eye (SE)|Phacoemulsification cataract extraction surgery of second eye
62205528|NCT01824927|EXPERIMENTAL|Steroids eye drops|Dexamethasone eye drop, 1 drop, qid, for 3 days before surgery
62205529|NCT00316017|EXPERIMENTAL|1|7.5% hypertonic saline/6% Dextran-70 (HSD)
62205530|NCT00316017|EXPERIMENTAL|2|7.5% hypertonic saline (HS)
62205531|NCT00316017|PLACEBO_COMPARATOR|3|0.9% normal saline
62205532|NCT02790697||Mechanically ventilated ICU patient|Indirect calorimetry measurements will be conducted using the new calorimeter and the mass spectrometer system at the same time for all enrolled patients.
62205533|NCT02026492|OTHER|40 patients aged 6-18 years|All 40 patients with a diagnosis of asthma are recruited from the outpatients clinic of the department of Pediatric Pneumology and Allergology of the University Hospital Frankfurt. Patients undergo a methacholine challenge and two exercise challenges in a cold chamber and one exercise challenge in room temperature.
62205534|NCT02026492|OTHER|40 subjects aged 18-45 years|All subjects show bronchial hyperresponsiveness e.g. dyspnea when exercising in cold environment, in their medical history. Subjects undergo a methacholine challenge and exercise challenge in a cold chamber and one exercise challenge in room temperature.
62205535|NCT04557267|EXPERIMENTAL|Group A (dosage A)|The lower dose of the active drug
62205536|NCT04557267|EXPERIMENTAL|Group B (dosage 2)|The middle dose of the active drug
62205537|NCT04557267|EXPERIMENTAL|Group C (dosage 3)|The higher dose of the active drug
62205538|NCT04557267|PLACEBO_COMPARATOR|Group D (placebo)|Placebo
62205539|NCT05142007|EXPERIMENTAL|Hypnosis|"The first treatment arm (targeted suggestion) consist of suggestions about enhancing working memory functions through the instantiation of preinjury working memory ability in the present using age regression, visualizations of neuroplasticity in the present, and posthypnotic suggestions about continued improvement. The overarching theme of the suggestions is that thinking itself will become effortless and reliable, leading to reduced fatigue, better memory, and the absence of information overload."
62205540|NCT05142007|ACTIVE_COMPARATOR|Mindfulness-based stress reduction|"The second treatment arm (non-targeted suggestion or MBSR) contains no explicit mentioning of brain injury or working memory-related abilities and thus serves to isolate the 'targetedness' of suggestion as well as factoring out other influences from placebo, retest effects, etc."
62205541|NCT05142007|NO_INTERVENTION|Control group|The (passive) control group receives no contact over and beyond testing.
62205542|NCT02914340|EXPERIMENTAL|Treatment|The treatment algorithm is complete occlusion of one lobe of the lung by using valves to occlude all segments of the lobe. The lobe will be selected based on imaging with high resolution computed tomography (HRCT). The lobe to be treated will have severe heterogeneous emphysema based on visual exam. The selected lobe will also have an intact fissure separation with the ipsilateral lobe. An intact fissure will be estimated visually to be ≥ 90% complete after viewing the HRCT in 3 dimensions. If more than one lobe meets criteria, the investigator will determine a primary lobe to treat based on fissure completeness, heterogeneity, disease severity, and the anatomy of the airways that will be treated.
62205543|NCT02311673|EXPERIMENTAL|Setmelanotide 0.5 mg|Participants received setmelanotide 0.5 milligrams (mg) once daily as a subcutaneous injection from Day 15 to Day 41 (4-week, double-blind randomized treatment period) and Day 42 to Day 55 (2-week, randomized withdrawal period).
62205544|NCT02311673|EXPERIMENTAL|Setmelanotide 1.5 mg|Participants received setmelanotide 1.5 once daily as a subcutaneous injection from Day 15 to Day 41 (4-week, double-blind randomized treatment period), Day 42 to Day 55 (2-week, randomized withdrawal period), and Day 56 to Day 69 (optional 2-week, open-label extension period).
62205545|NCT02311673|EXPERIMENTAL|Setmelanotide 2.5 mg|Participants received setmelanotide 2.5 once daily as a subcutaneous injection from Day 15 to Day 41 (4-week, double-blind randomized treatment period), Day 42 to Day 55 (2-week, randomized withdrawal period), and Day 56 to Day 69 (optional 2-week, open-label extension period).
62205546|NCT02311673|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to setmelanotide once daily as a subcutaneous injection from Day 1 to Day 14 (2-week, single-blind run-in period), Day 15 to Day 41 (4-week, double-blind randomized treatment period), and Day 42 to Day 55 (2-week, randomized withdrawal period).
62205547|NCT01986452|ACTIVE_COMPARATOR|Unattended CPAP therapy|Therapy data will be examined by reading out the CPAP device after 6 months. Patients can obtain help on own request, corresponding to the standard CPAP prescription routine.
62205548|NCT01986452|EXPERIMENTAL|Telemonitoring and support|CPAP device therapy data will be downloaded by the study site via GSM modules once a week. In case of poor therapy adherence (defined by a minimum average usage of 3h/night over the week) a contact call will be initiated to motivate patients or solve problems identified by telemonitoring. If active home intervention is required, the study site will inform the healthcare provider to visit the patient in a timely manner.
62205549|NCT03245905|EXPERIMENTAL|Chidamide|Chidamide should be given at a fixed time with fixed dosage
62205550|NCT05701878|EXPERIMENTAL|Intervention (App) Group|Participants in this group will be given access to a COVID-19 self-testing app (SMARTest). Access to the app, given exclusively to this group, will be in addition to the 12 COVID-19 self-test kits participants receive.
62205551|NCT05701878|NO_INTERVENTION|Control (No App) Group|Participants in this group will not be given access to the COVID-19 self-testing app (SMARTest). Participants will only receive the 12 COVID-19 self-test kits.
62205552|NCT04806204|EXPERIMENTAL|music therapy before the angiography|Patients in the Intervention 1 group will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played with headphones for 15-20 minutes before the CAG procedure. Since individuals are in the CAG unit collectively before the procedure, headphones will be used in order not to disturb other individuals. After the interviews, musical types will be arranged as instrumental, non-verbal, at 70 decibels, approximately 60 metronome per minute, in terms of rhythm and duration, and will be played according to the individual's choice. Instrumental works will be uploaded to the portable MP3 player provided by the researchers.
62205553|NCT04806204|EXPERIMENTAL|music therapy during the angiography|Patients in the Intervention 2 group will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played through a speaker that will be placed in the CAG hall during the CAG procedure. After the interviews, musical types will be arranged as instrumental, non-verbal, 75 decibels, approximately 60 metronome per minute, in terms of rhythm and duration, and will be played according to the individual's choice.
62205554|NCT04806204|NO_INTERVENTION|control group|After the polyclinic controls of the patients, on the day of the CAG procedure, data collection forms will be applied in the CAG unit 30 minutes before the procedure. Routine care will be applied to patients in this group and music therapy will not be applied. The physiological parameters of the patient will be measured by the clinical nurse 15 minutes after the procedure, and data collection forms will be applied again 20 minutes later.
62205555|NCT00431353|EXPERIMENTAL|1|
62205556|NCT00431353|EXPERIMENTAL|2|
62205557|NCT01685229||Balloon Sinus Dilation|Subjects with chronic sinusitis electing to have a balloon sinus dilation
62205558|NCT01685229||Medical Management|Subjects with chronic sinusitis electing to continue with medical therapy
62205559|NCT02035059||Women with/without gestational diabetes|Women with/without gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
62205560|NCT05151900|EXPERIMENTAL|Stakeholder Perspectives and Virtual Parent-Led Peer Support Group|Qualitative interviews regarding the impact of COVID-19 will be conducted with youth who have an eating disorder (ED), parents of youth who have an ED, ED clinicians and ED program administrators, as well as get their perspectives on parent-led peer support groups. Three parent-led peer support groups will be started, including psychoeducation in a virtual group setting for parents who have a child or adolescent with an eating disorder.
62205561|NCT00703417||1|Healthy post-menopausal women
62205562|NCT00703417||2|Diabetic without fracture
62205563|NCT00703417||3|Diabetic with fracture
62205564|NCT06198595||Normobaric oxygen therapy group|"Patients Receiving Oxygen from Hospital Circuits at Normal Atmospheric Pressure"
62205565|NCT06198595||Hyperbaric oxygen therapy group|"Patients Receiving High-Pressure Oxygen at Pressures Above Atmospheric Pressure"
62788176|NCT02688985|EXPERIMENTAL|RMS Cohort Arm 1: Ocrelizumab + LP|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 12. Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
62016287|NCT01993719|EXPERIMENTAL|Arm 1N -Standard Chemotherapy Preparative Regimen + TIL + 720,000 IU/kg Aldesleukin|"Standard Chemo Prep Regimen. Young Tumor Infiltrating Lymphocytes (TIL) Plus High Dose Interleukin-2, Standard Chemo Preparative Regimen in participants without prior treatment pembrolizumab or nivolumab Standard preparative regimen + Young Tumor Infiltrating Lymphocytes (TIL) Cells Aldesleukin: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).~Fludarabine: 25 mg/m\^2/day intravenous piggy-back (IVPB) daily for 5 days Cyclophosphamide: 60 mg/kg/day X 2 days intravenous (IV) Young TIL: Day 0: Cells will be infused intravenously (IV)"
62016288|NCT01993719|EXPERIMENTAL|Arm 1P - Standard Chemotherapy Preparative Regimen + TIL + 720,000 IU/kg Aldesleukin|"Standard Chemo Prep Regimen Young Tumor Infiltrating Lymphocytes (TIL) Plus High Dose Interleukin-2, Standard Chemo Preparative Regimen in participants previously treated with pembrolizumab or nivolumab.~Standard preparative regimen + Young Tumor Infiltrating Lymphocytes (TIL) Cells Aldesleukin: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).~Fludarabine: 25 mg/m\^2/day intravenous piggy-back (IVPB) daily for 5 days Cyclophosphamide: 60 mg/kg/day X 2 days intravenous (IV) Young TIL: Day 0: Cells will be infused intravenously (IV)"
62205566|NCT06198595||Noninvasive mechanical ventilation group|"Patients Receiving High PEEP Oxygenation Without Advanced Airway via Mechanical Ventilation"
62205567|NCT06198595||High-flow oxygen therapy group|"Patients Reaching High FiO2 Levels Noninvasively Through High-Flow Oxygen Therapy"
62205568|NCT00354575|EXPERIMENTAL|A|Chinese Herb (CCH1)
62205569|NCT00354575|PLACEBO_COMPARATOR|B|Starch powder as placebo
62205570|NCT06172153||Sun Yat-sen memorial hospital|Patients who were suspected of Spinal infection.
62205571|NCT00371189|EXPERIMENTAL|Group C: Ad35.CS.01-10^10 vp/ml|15 subjects will receive dosage 10\^10 vp/mL; 3 subjects will receive placebo.
62016289|NCT01993719|EXPERIMENTAL|Arm 2/Foll By Arm 1P-Low dose Chemotherapy Preparative Regimen + TIL + 720,000 IU/kg Aldesleukin|Decreased Chemo Prep Regimen+Retreat. Young TIL+High Dose Interleukin-2, Decreased Chemo Preparative Regimen. Young TIL+High Dose Interleukin-2, Standard Chemo (Retreat). Lower dose preparative regimen + Young TIL Cells. Aldesleukin: 720,000 IU/kg IV every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine: 30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days. Cyclophosphamide: Days -5 to -3 (low-dose arm): Cyclophosphamide 300 mg/m\^2 IV over 60 minutes. Young TIL: Day 0: Cells will be infused IV. Retreatment: Standard Chemo Prep Regimen. Aldesleukin: 720,000 IU/kg IV every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine: 25 mg/m\^2/day intravenous piggy-back (IVPB) daily for 5 days. Cyclophosphamide: 60 mg/kg/day X 2 days IV. Young TIL: Day 0: Cells will be infused IV.
62016290|NCT01993719|EXPERIMENTAL|Arm 2- Low Dose Chemotherapy Preparative Regimen + TIL + 720,000 IU/kg Aldesleukin|"Decreased Chemo Prep Regimen. Young Tumor Infiltrating Lymphocytes (TIL) Plus High Dose Interleukin-2 Lower Dose preparative regimen + Young Tumor Infiltrating Lymphocytes (TIL) Cells Aldesleukin: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).~Fludarabine: 30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days Cyclophosphamide: Days -5 to -3 (low-dose arm): Cyclophosphamide 30 mg/kg IV over 60 minutes for 2 days.~Young TIL: Day 0: Cells will be infused intravenously (IV)"
62205572|NCT00371189|EXPERIMENTAL|Group D: Ad35.CS.01-10^11 vp/ml|15 subjects will receive dosage 10\^11 vp/mL; 3 subjects will receive placebo.
62205573|NCT00371189|EXPERIMENTAL|Group A: Ad35.CS.01-10^8 vp/ml|15 subjects will receive dosage 10\^8 vp/mL; 3 subjects will receive placebo.
62205574|NCT00371189|EXPERIMENTAL|Group B: Ad35.CS.01-10^9 vp/ml|15 subjects will receive dosage 10\^9 vp/mL; 3 subjects will receive placebo.
62205575|NCT03585803|OTHER|KMRC011 5μg or Placebo|Cohort 1
62205576|NCT03585803|OTHER|KMRC011 10μg or Placebo|Cohort 2
62404856|NCT04755491||Chloride transfer by continuous veno-venous hemodiafiltration|Chloride transfer over 24h of continuous veno-venous hemodiafiltration in mechanically ventilated ICU patients presenting with stage III AKI according to Kidney Disease: Improving Global Outcome (KDIGO) classification. Chloride concentrations will be measured in the serum, the urine, and the effluent of included patients every 4 to 6h from inclusion to H24.
62205577|NCT03585803|OTHER|KMRC011 15μg or Placebo|Cohort 3
62205578|NCT03585803|OTHER|KMRC011 20μg or Placebo|Cohort 4
62205579|NCT03585803|OTHER|KMRC011 25μg or Placebo|Cohort 5
62205580|NCT05788692|EXPERIMENTAL|electric toothbrush using a toothbrushing assisting application|Children will be brushing with an electric toothbrush two times/day using a toothbrushing assisting application
62205581|NCT05788692|EXPERIMENTAL|electric toothbrush without the application|Children will be brushing with an electric toothbrush two times/day without the toothbrushing assisting application
62205582|NCT05788692|EXPERIMENTAL|manual toothbrush using a toothbrushing assisting application|Children will be brushing with a manual toothbrush two times /day using a toothbrushing assisting application
62205583|NCT05788692|EXPERIMENTAL|manual toothbrush without using the application during brushing|Children will be brushing with a manual toothbrush two times /day without using the toothbrushing assisting application
62205584|NCT04789031|EXPERIMENTAL|Intervention group|Patients received oral nutritional supplementation and standard nutritional counseling for 6 months.
62205585|NCT04789031|NO_INTERVENTION|Control group|Patients received standard nutritional counseling for 6 months.
62205586|NCT04093089|EXPERIMENTAL|Test Group|
62205587|NCT04093089|PLACEBO_COMPARATOR|Control Group|
62205588|NCT02564380|EXPERIMENTAL|Arm A: Pembrolizumab|Pembrolizumab 200 mg every three weeks until disease progression (maximum 2 years)
62205589|NCT02564380|PLACEBO_COMPARATOR|Arm B: Placebo|Placebo i.v. every three weeks until disease progression (maximum 2 years)
62205590|NCT03540758|EXPERIMENTAL|Non-diabetic (Diazoxide)|Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to non-diabetic participants.
62205591|NCT03540758|PLACEBO_COMPARATOR|Non-diabetic (Placebo)|Pancreatic clamp study will be done after giving a taste-matched placebo for Diazoxide (Proglycem) to non-diabetic participants.
62205592|NCT03540758|EXPERIMENTAL|T2D (Diazoxide)|Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to type 2 diabetic participants.
62205593|NCT03540758|PLACEBO_COMPARATOR|T2D (Placebo)|Pancreatic clamp study will be done after giving a taste-matched placebo for Diazoxide (Proglycem) to type 2 diabetic participants.
62205594|NCT03540758|EXPERIMENTAL|T2D (Diazoxide + Nicotinic Acid)|Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to type 2 diabetic participants after lowering free fatty acids with a nicotinic acid (Niacin) infusion.
62205595|NCT03540758|EXPERIMENTAL|T2D (Nicotinic Acid + placebo for diazoxide)|Pancreatic clamp study will be done after lowering free fatty acids with a nicotinic acid (Niacin) infusion in type 2 diabetic participants, and after giving a taste-matched placebo for Diazoxide (Proglycem) to type 2 diabetic participants.
62205596|NCT03540758|EXPERIMENTAL|Non-diabetic (Diazoxide + Nicotinic Acid)|Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to non-diabetic participants after lowering free fatty acids with a nicotinic acid (Niacin) infusion
62205597|NCT03540758|EXPERIMENTAL|Experimental: Non-diabetic (Nicotinic Acid + placebo for diazoxide)|Pancreatic clamp study will be done after lowering free fatty acids with a nicotinic acid (Niacin) infusion in non-diabetic participants, and after giving a taste-matched placebo for Diazoxide (Proglycem) toon-diabetic participants.
62205598|NCT01005069|EXPERIMENTAL|Treatment I|
62205599|NCT01005069|EXPERIMENTAL|Treatment II|
62016291|NCT01993719|EXPERIMENTAL|Arm 1P/Foll By Arm-1P/R-Standard Chemotherapy Preparative Regimen + TIL + 720,000 IU/kg Aldesleukin|Standard Chemo Prep Regimen(SCPR)+Retreat. Young TIL+High Dose(HD) Interleukin-2, SCPR. Young TIL+HD Interleukin-2, SC(Retreat). SCPR+Young TIL Cells retreatment with SCPR+Young TIL Cells+pembrolizumab. Aldesleukin:720,000 IU/kgIV every eight hours (+/-1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine:25 mg/m\^2/day intravenous piggy-back(IVPB) daily for 5 days. Cyclophosphamide:60 mg/kg/day X 2 days IV. Young TIL:Day 0: Cells will be infused IV. Retreatment with standard preparative regimen+Young TIL Cells+pembrolizumab. Aldesleukin:720,000 IU/kg IV every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine:25 mg/m\^2/day intravenous piggy-back (IVPB) daily for 5 days. Cyclophosphamide:60 mg/kg/day X 2 days IV. Young TIL: Day 0:Cells will be infused IV. Pembrolizumab:2 mg/kg IV on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).
62205600|NCT01005069|EXPERIMENTAL|Treatment III|
62205601|NCT01005069|EXPERIMENTAL|Treatment IV|
62205602|NCT01005069|PLACEBO_COMPARATOR|Placebo|
62205603|NCT01268956||Lymphatic progenitor cell|Circulating lymphatic progenitor cell
62205604|NCT01268956||Control|healthy people
62205605|NCT01170676|EXPERIMENTAL|Puff City GA|Puff City is an NHLBI-funded (C. Joseph, PI; Henry Ford Health System, Detroit, MI), web-based intervention that targets three key asthma management issues in youth: 1) smoking reduction or cessation in those who are smokers, 2) improving adherence to asthma controller medication use, and 3) improving compliance of carrying a rescue inhaler at all times for use at the first sign of asthma symptoms. Puff City Ga. is a replication study in the rural southeastern United States that adds biological assessments in addition to self-report data.
62788177|NCT02688985|EXPERIMENTAL|RMS Cohort Arm 2: Ocrelizumab + LP|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 24. Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
62788178|NCT02688985|EXPERIMENTAL|RMS Cohort Arm 3: Ocrelizumab + LP|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
62788179|NCT02688985|EXPERIMENTAL|RMS Cohort Arm 4: Ocrelizumab + LP|Ocrelizumab treatment will be delayed for 12 weeks from pre-treatment baseline. Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP at Week -12 (pre-treatment baseline) and a second LP before the start of dosing (Week 1, treatment baseline). Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
62788180|NCT02688985|EXPERIMENTAL|PPMS Cohort: Ocrelizumab + LP|For the PPMS cohort, ocrelizumab will be administered as two 300-mg IV infusions separated by 14 days at a scheduled interval of every 24 weeks during the treatment period and then as a single 600-mg dose every 24 weeks starting week 72 during the Long-Term Extension period.
62788181|NCT05641415||General population sample|600 participants aged 40 to 75 years will be randomly selected from a nationally representative general population sample of 9,922 individuals
62205606|NCT01170676|ACTIVE_COMPARATOR|General Asthma Education|Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
62205607|NCT01226862||Hub Hospital|Hub Hospital Cohort: Joint Commission-certified Primary Stroke Centers where patients are treated using hospital-based stroke teams and pathways; these hospital personnel also provide telemedicine consultation to satellite hospitals.
62205608|NCT01226862||Spoke Hospital|Spoke Hospital Cohort: non-stroke center certified sites, where patients are treated at an in-network telestroke community hospital using telemedicine technology with consultation provided by physicians from a hub hospital.
62205609|NCT01226862||Control Hospital|Control Hospital Cohort: non-stroke center certified sites with no telemedicine services.
62205610|NCT05314374|EXPERIMENTAL|Bile Acid Supplement Group|Subjects with obesity and abnormal satiety phenotype will receive ileocolonic-release conjugated bile acid supplements
62205611|NCT05314374|PLACEBO_COMPARATOR|Placebo Group|Subjects with obesity and abnormal satiety phenotype will receive matching-placebo
62205612|NCT03203330|ACTIVE_COMPARATOR|Active Treatment (TG-C)|TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
62205613|NCT03203330|PLACEBO_COMPARATOR|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
62205614|NCT05614726|PLACEBO_COMPARATOR|Placebo|Consists of 575 mg rice oligodextrin
62788182|NCT00998088|EXPERIMENTAL|Erythropoietin|
62788183|NCT00998088|NO_INTERVENTION|Control arm|
62205615|NCT05614726|ACTIVE_COMPARATOR|Active|Consists of 575mg \[30 billion colony forming units probiotic blend of Bifidobacterium breve 19bx, Lactobacillus acidophilus 16axg, Lacticaseibacillus rhamnosus 18fx, Saccharomyces boulardii 16mxg, and alpha amylase
62205616|NCT01476449|ACTIVE_COMPARATOR|Monthly Ranibizumab|Patients randomized to the Monthly Ranibizumab arm of the study will be administered intravitreal injections each month for their diabetic macular edema for the duration of the study.
62205617|NCT01476449|EXPERIMENTAL|Treat and Extend Ranibizumab|"Patients randomized to this arm of the study will receive intravitreal injections of ranibizumab until their maculae are anatomically dry, at which point the evaluation and injection interval will be extended."
62205618|NCT00883064|EXPERIMENTAL|1|Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)
62788184|NCT00998088|EXPERIMENTAL|cell saver|
62788185|NCT00998088|EXPERIMENTAL|drain|
62788186|NCT00998088|EXPERIMENTAL|Erythropoietin and cell saver|
62788187|NCT00998088|EXPERIMENTAL|Erythropoietin and drain|
62788188|NCT06524908|EXPERIMENTAL|Exercise and dietary calorie restriction intervention group|Received a twelve-week comprehensive intervention. The number of participants is 50.
62788189|NCT06524908|NO_INTERVENTION|control group|Normal school life without any intervention. The number of participants is 50.
62205619|NCT00883064|ACTIVE_COMPARATOR|2|Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)
62205620|NCT04990011|EXPERIMENTAL|BioXclude amnion chorion membrane|
62205621|NCT02120001|EXPERIMENTAL|ETT cleaning maneuver|Patients randomized to the treatment group will undergo an ETT cleaning maneuver with endOclear three times a day (every 8 hours) for the whole intubation period in addition to the standard of care.
62205622|NCT02120001|NO_INTERVENTION|Standard of care|In the protocol no intervention is planned for the control group, which will therefore be treated with blind suctioning as per caregiver clinical decision.
62205623|NCT04307940|EXPERIMENTAL|Naproxen sodium|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
62205624|NCT04307940|ACTIVE_COMPARATOR|Hydrocodone/Acetaminophen|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
62205625|NCT04307940|PLACEBO_COMPARATOR|Placebo|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
62205626|NCT03617900|PLACEBO_COMPARATOR|Placebo|
62205627|NCT03617900|EXPERIMENTAL|Ginger|
62205628|NCT03617900|ACTIVE_COMPARATOR|Paracetamol|
62205629|NCT05170815||ERISMA® LP/LP EVO|120 subjects with ERISMA® LP/LP EVO implant
62205630|NCT05170815||ERISMA® Deformity|120 subjects with ERISMA® Deformity implant
62205631|NCT05170815||ERISMA® MIS|120 subjects with ERISMA® MIS implant
62205632|NCT05170815||Idys® TLIF PEEK|50 subjects with Idys® TLIF PEEK implant
62205633|NCT05170815||Idys® TLIF TiVAC|50 subjects with Idys® TLIF TiVAC implant
62734882|NCT03481842|EXPERIMENTAL|Vaginal Suppositories|"Daily single administration of vaginal suppository in diagnosed endometriosis. Duration of admission-five days, two days-off. The total duration of treatment is 6 weeks. General course -30 vaginal suppositories ELTA~The composition of the suppository:~* Axitinib (inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit) in a minimally sufficient therapeutic dose~* Afatinib (BIBW2992) EGFR / HER2 including EGFR (wt), EGFR (L858R), EGFR (L858R / T790M) and HER2 inhibitor - minimally sufficient therapeutic dose~* Linifanib (ABT-869) ATP-competitive VEGFR / PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ - minimally sufficient therapeutic dose"
62205634|NCT05170815||Idys® TLIF 3DTi|50 subjects with Idys® TLIF 3DTi implant
62205635|NCT05170815||Idys® ALIF PEEK|50 subjects with Idys® ALIF PEEK implant
62205636|NCT05170815||Idys® ALIF TiVAC|50 subjects with Idys® ALIF TiVAC implant
62205637|NCT05170815||Idys® ALIF 3DTi|50 subjects with Idys® ALIF 3DTi implant
62205638|NCT05170815||Idys® ALIF ZP 3DTi|50 subjects with Idys® ALIF ZP 3DTi implant
62205639|NCT05170815||Idys® LLIF 3DTi|50 subjects with Idys® LLIF 3DTi implant
62205640|NCT01827644|EXPERIMENTAL|Sequence 1|Subjects will receive single doses of AFU HPMC capsule administered in a fasted state, AFU ECT administered in a fasted state, AFU HPMC capsule administered in a fed state and AFU GC administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
62205641|NCT01827644|EXPERIMENTAL|Sequence 2|Subjects will receive single doses of AFU ECT administered in a fasted state, AFU ECT administered in a fed state, AFU GC administered in a fasted state and AFU GC administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period.
62205642|NCT01827644|EXPERIMENTAL|Sequence 3|Subjects will receive single doses of AFU GC administered in a fasted state, AFU GC administered in a fed state, AFU ECT administered in a fed state and AFU HPMC capsule administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period.
62205643|NCT01827644|EXPERIMENTAL|Sequence 4|Subjects will receive single doses of AFU GC administered in a fed state, AFU HPMC capsule administered in a fed state, AFU HPMC capsule administered in a fasted state and AFU ECT administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
62205644|NCT01827644|EXPERIMENTAL|Sequence 5|Subjects will receive single doses of AFU ECT administered in a fed state, AFU HPMC capsule administered in a fasted state, AFU GC administered in a fed state and AFU HPMC capsule administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
62205645|NCT01827644|EXPERIMENTAL|Sequence 6|Subjects will receive single doses of AFU HPMC capsule administered in a fed state, AFU GC administered in a fasted state, AFU ECT administered in a fasted state and AFU ECT administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
62205646|NCT01620918|EXPERIMENTAL|2 types of healing abutment|Patients who are in need of minimal 2 dental implants, who will receive both types of healing abutments.
62205647|NCT05841212|OTHER|DBT for ADHD|"The intervention will consist of a DBT skills group. Its name, length, style and content will be guided by the viewpoints shared in the intervention planning focus group/ individual interviews, and taken into consideration alongside a clinical rational and the evidence-based content. It will include skills from all four of the DBT modules: Mindfulness, Distress Tolerance, emotion regulation and interpersonal effectiveness. There will be an emphasis on the skills relevant to ADHD symptoms plus a core psychoeducational component on ADHD symptoms. The intervention will be adapted from Rathus and Miller's (2014) DBT for adolescents (DBT-A) manual.~The group format will be didactic teaching with group discussion and experiential exercises to aid learning."
62205648|NCT01624077|EXPERIMENTAL|Regulatory T cells|Naïve CD4+ T cells isolated from peripheral blood mononuclear cells were stimulated with GMP anti-CD3/CD28 coated beads in the presence of IL-2 ,TGF-β.
62205649|NCT03410004|EXPERIMENTAL|Experimental|Drug: Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
62404857|NCT04089657|EXPERIMENTAL|Apatinib+Sintilimab|Apatinib 500mg qd p.o and Sintilimab 200mg intravenously on day 1 every 3 weeks until disease progression or intolerable toxicity or patients withdrawal of consent
62788190|NCT01989806|ACTIVE_COMPARATOR|Robotic-assisted body weight supported treadmill training|Robotic assisted body weight supported treadmill training with conventional PT training
62205650|NCT02706405|EXPERIMENTAL|Group I (JCAR014, durvalumab) Early - Dose Level 2|"Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.~Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.~Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells"
62788191|NCT01989806|PLACEBO_COMPARATOR|Passive lower limbs mobilization training|Passive lower limbs mobilization training with conventional PT training
62788192|NCT03143504||Single arm.|All participants in the same arm.
62788193|NCT06530732|EXPERIMENTAL|experimental group|receiving dcLVA surgery plus standard medication
62788194|NCT06530732|ACTIVE_COMPARATOR|control group|receiving standard medication alone
62788195|NCT01481454|EXPERIMENTAL|Group 1: QIV Lot 1|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 1.
62205651|NCT02706405|EXPERIMENTAL|Group I (JCAR014, durvalumab) Late- Dose Level 1|"Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.~Group 1 - late: start durvalumab no earlier than 21 days after JCAR014~Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells~."
62205652|NCT02706405|EXPERIMENTAL|Group I (JCAR014, durvalumab) Late - Dose Level 2|"Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.~Group 1 - late: start durvalumab no earlier than 21 days after JCAR014~Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells"
62734883|NCT01027559|ACTIVE_COMPARATOR|Depressed Group: CBT|Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.
62205653|NCT02706405|EXPERIMENTAL|Group II (durvalumab, JCAR014) - Dose Level 1|"Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.~Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells"
62734884|NCT01027559|NO_INTERVENTION|Healthy Control Group|Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.
62734885|NCT01027559|ACTIVE_COMPARATOR|Depressed Group: SRT|Depressed participants randomized to receive the antidepressant sertraline (SRT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.
62734886|NCT01270932|EXPERIMENTAL|Lenalidomide and Dexamethasone|"Lenalidomide:Daily for 21 days of a 28 day cycle~Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4."
62734887|NCT02929160|EXPERIMENTAL|PCN|Percutaneous nephrostomy
62734888|NCT02929160|EXPERIMENTAL|JJ Stent|Retrograde ureteric JJ stent
62734889|NCT01295138|EXPERIMENTAL|Lactulose group|Group receives 48 hours of lactulose post Caesarean section.
62734890|NCT01295138|NO_INTERVENTION|Non-lactulose group|Group receives no lactulose post Caesarean section.
62734891|NCT05582356|EXPERIMENTAL|Carbohydrate group (Group OC)|Preoperative education will be provided by researchers to the patients on the ward before fluid intake. Solid food will be forbidden starting at 20:00 p.m, and drinking will be forbidden after 22:00 p.m the day before surgery. Group OC will consume carbohydrate fluid at 22.00 p.m. and two hours before the surgery
62734892|NCT05582356|SHAM_COMPARATOR|Placebo group (Group OP)|Preoperative education will be provided by researchers to the patients on the ward before fluid intake. Solid food will be forbidden starting at 20:00 p.m, and drinking will be forbidden after 22:00 p.m the day before surgery. Group OP will consume an equal amount of water 22:00 p.m. and two hours before the surgery.
62734893|NCT06014853|EXPERIMENTAL|Group 1|Period 1: Zytiga® 1000mg / Period 2 : SOL-804-F 302.5mg / Period 3 : SOL-804-F 242.0mg / Period 4 : SOL-804-F 181.5mg
62734894|NCT06014853|EXPERIMENTAL|Group 2|Period 1 : SOL-804-F 181.5mg / Period 2 : Zytiga® 1000mg / Period 3 : SOL-804-F 302.5mg / Period 4 : SOL-804-F 242.0mg
62734895|NCT06014853|EXPERIMENTAL|Group 3|Period 1 : SOL-804-F 242.0mg / Period 2 : SOL-804-F 181.5mg / Period 3 Zytiga® 1000mg / Period 4 : SOL-804-F 302.5mg
62734896|NCT06014853|EXPERIMENTAL|Group 4|Period 1 : SOL-804-F 302.5mg / Period 2 : SOL-804-F 242.0mg / Period 3 : SOL-804-F 181.5mg / Period 4 : Zytiga® 1000mg
62734897|NCT01009970|EXPERIMENTAL|1|R-COMP
62734898|NCT04426175|EXPERIMENTAL|2D LASIK|With the 2D method, the flap resection is created in a planar mode (xy-plane), without vertical cut, at the requested depth.
62734899|NCT04426175|EXPERIMENTAL|3D LASIK|With the 3D method, the flap resection is done in a three-dimensional mode, at the requested depth, with the requested diameter and the desired border (side cut) angle
62734900|NCT01498692|EXPERIMENTAL|PROMUS Element|Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent
62734901|NCT00816491|ACTIVE_COMPARATOR|A|Conventional white light colonoscopy
62734902|NCT00816491|EXPERIMENTAL|B|Chromoendoscopy
62734903|NCT02735057|EXPERIMENTAL|Phase I|"* for chemotherapy 3 levels: 50%, 75% and 100% of the standard Dutch dose (carboplatin AUC 2 and paclitaxel 50 mg/m2)~* for radiotherapy 3 levels: 41.4 Gy/1.8 Gy/f; 45 Gy/1.8 Gy/f; 50.4 Gy/1.8 Gy/f basel level being : 41.4 Gy and 50% of standard CT doses The phase I is conducted with increasing doses of each component with 9 levels."
62734904|NCT04603313||Experimental group|12 departments in mainland France covered by the tele-advice system open to general practitioners
62734905|NCT04603313||Control group|84 departments in mainland France not covered by the tele-advice system.
62734906|NCT06046599||Patients living with amyotrophic lateral sclerosis|Individuals with a known diagnosis of amyotrophic lateral sclerosis will be recruited from King's College Hospital's Motor Nerve Clinic. The cohort will contain 20 individuals and their study partners and will be part of the study for one year.
62734907|NCT01336712|EXPERIMENTAL|Myeloablative Haploidentical Transplant|Haplo transplant
62205654|NCT02706405|EXPERIMENTAL|Group II (durvalumab, JCAR014) - Dose Level 2|"Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.~Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells"
62205655|NCT02706405|EXPERIMENTAL|Group II (durvalumab, JCAR014) - Dose Level 3|"Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.~Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells"
62734908|NCT04424394|EXPERIMENTAL|DualStim Therapy with Wharton's Jelly Injection|DualStim therapy with intracavernosal injection of umbilical cord-derived Wharton's Jelly formulation.
62205656|NCT02706405|EXPERIMENTAL|Group II (durvalumab, JCAR014) - Dose Level 4|"Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.~Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells"
62734909|NCT04424394|ACTIVE_COMPARATOR|DualStim Therapy without Wharton's Jelly Injection|DualStim therapy with intracavernosal injection of normal saline.
62734910|NCT03950544|EXPERIMENTAL|only meropenem therapy,|this group is only meropenem therapy as a single antibiotic treatment
62734911|NCT05653245|PLACEBO_COMPARATOR|Group 1|Fifteen periodontitis patients will receive Phase I therapy, reevaluation after four weeks with modified minimally invasive surgical technique (M-MIST) alone
62205657|NCT02706405|EXPERIMENTAL|Group II (durvalumab, JCAR014) - Dose Level 5|"Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.~Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells"
62205658|NCT05101824|OTHER|Single arm|All recruited patients are treated with SABR.
62205659|NCT03236584|ACTIVE_COMPARATOR|lamivudine adefovir|
62205660|NCT03236584|EXPERIMENTAL|tenofovir|
62205661|NCT03674580||Suicidal patients|No intervention. Follow-up of the suicidal patients
62205662|NCT05726240|EXPERIMENTAL|Ghrelin treatment|Treatment in the intervention group will consist of intravenous acylated ghrelin, 600micrg dissolved in 50cc normal saline, by bolus (short term) infusion in 30 minutes, twice daily, for five days. This treatment will be additional to standard treatment, including intravenous thrombolysis, if indicated.
62404858|NCT04420975|EXPERIMENTAL|Treatment (BO-112, nivolumab)|Patients receive BO-112 intratumorally on days 8 and 15 or 1, 8, and 15 and nivolumab IV over 30-60 minutes on day 8 in the absence of disease progression or unacceptable toxicity. Patients also undergo standard of care radiation therapy on days 8-12 for a total of 5 fractions. Patients then undergo standard of care definitive surgical resection on day 26 to 50.
62404859|NCT01358266|ACTIVE_COMPARATOR|Ophthalmic solution low dose|
62205663|NCT05726240|NO_INTERVENTION|Standard care|Treatment in the standard group consists of local practices for the treatment of stroke, including intravenous thrombolysis, if indicated.
62205664|NCT01093677|EXPERIMENTAL|A|750 mg of LIM-0705 BID for 14 days. Up to 20 subjects.
62205665|NCT01093677|PLACEBO_COMPARATOR|B|Placebo BID for 14 days. Up to 10 subjects.
62205666|NCT02207855||Chloroprocaine|Neonates and infants who have received chloroprocaine for epidural anesthesia.
62404860|NCT01358266|ACTIVE_COMPARATOR|Ophthalmic solution medium dose|
62404861|NCT01358266|ACTIVE_COMPARATOR|Ophthalmic solution high dose|
62404862|NCT00135811|ACTIVE_COMPARATOR|1|Cyclosporin
62404863|NCT00135811|ACTIVE_COMPARATOR|2|MMF and Dexamethasone
62404864|NCT00838175||1|All pts. who have undergone percutaneous intervention who received a suture-mediated closure of the venous access site will be screened for eligibility for this research trial.
62404865|NCT05229718|ACTIVE_COMPARATOR|Usual Care Model|Patients enrolled in this arm will receive diabetes care per usual care at the Massachusetts General Hospital (MGH) Diabetes Center.
62404866|NCT05229718|ACTIVE_COMPARATOR|Diabetes Collaborative Care Model for Young Adults|Patients enrolled in this arm will receive diabetes care per the diabetes collaborative care model for young adults.
62404867|NCT06648603|NO_INTERVENTION|Control|Non-intervened control arm: no community-based larval source management (LSM) or BG-GAT intervention
62404868|NCT06648603|EXPERIMENTAL|Community-based larval source management|LSM intervention arm: Aedes larval source reduction carried out by trained and supervised local community members
62404869|NCT06648603|EXPERIMENTAL|Enhanced Aedes adults trapping (BG-GAT)|BG-GAT intervention arm: Aedes adult mass trapping by BG-GAT set up and maintained by trained and supervised local community members
62404870|NCT06648603|EXPERIMENTAL|Community-based larval source management + Enhanced Aedes adults trapping (BG-GAT)|Combined LSM and BG-GAT intervention arm: simultaneous Aedes larval source reduction and Aedes adult mass trapping by BG-GAT carried out by trained and supervised local community members
62404871|NCT03175068|ACTIVE_COMPARATOR|CBT|The clinical psychologist will use a manualized CBT approach tailored to MDD or gSAD. Over a 12-week period sessions will include core CBT strategies -- psychoeducation, cognitive intervention (e.g., cognitive restructuring), behavioral changes (i.e., fear exposure, behavioral activation strategies) and relapse prevention.
62205667|NCT01921153|EXPERIMENTAL|Short Intervention|All participants will be measured for (1) baseline, (2) two-week environmental intervention: Healthy meal plates and trays, and (3) withdraw of intervention.
62404872|NCT03175068|PLACEBO_COMPARATOR|ST|The clinical psychologist will use an ST approach that resembles client-centered therapy of Carl Rogers (1951) which has been used as a control psychotherapy. The manual is based on supportive psychotherapy principles. Over a 12-week period sessions will emphasize reflective listening and elicitation of affect. In contrast to CBT, therapists allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathetic comments. Therapists will refrain from delineating any CBT theoretical framework and avoided cognitive and behavioral techniques that might overlap with CBT.
62404873|NCT03248557||Study|Comatose survivors (GCS ≤8) after RoSC, in whom neurological prognosis is unknown at the time of admission. Neurological performance of patients from the study group (prospective and retrospective) will be categorized according to a risk score obtained from the multivariate spectral-based model.
62404874|NCT03248557||Control|Patients who are conscious (GCS=15) and whose neurological status is known and good at admission.
62404875|NCT06127862|OTHER|Education group|The forms used in the study were collected by the researcher through face-to-face interviews in seminar halls in schools. First of all, students in the experimental group were educated about environmental health and microplastica, and nursing interventions were made. The training was organized for twenty minutes in each session, with a total of four sessions at two-week intervals. Personal Information Form and Microplastica Pollution Awareness Scale (MPAS) were filled out as a pre-test in the seminar halls of the schools under the supervision of the researcher.
62404876|NCT06127862|OTHER|Control group|"Personal information form and Microplastica Pollution Awareness Scale (MPAS) were applied to the students in the control group as a pre-test. No training was given to the control group. Fifteen days after the end of the fourth training of the intervention group, the MPAS was applied to the control group as a post-test, and data collection was terminated. After the post-test was administered to the groups, training materials were also given to individuals from the control group who requested them."
62734912|NCT05653245|PLACEBO_COMPARATOR|Group 2|Fifteen periodontitis patients will receive Phase I therapy, reevaluation after four weeks with (M-MIST) and hydrogel injection
62016292|NCT04181034|EXPERIMENTAL|PYD|Case managers meet with participating pregnant and parenting females at least two times a month over 12 months. In the short term, the program seeks to improve social competence, problem-solving skills, autonomy, increased sense of purpose, improved knowledge and use of contraceptives, increased linkages and support networks, improved quality of relationships, increased access to and strengthen relationship with a trusted adult, increased knowledge of and access to healthcare and improved health and well-being of expectant or parenting mother. In the long term, the program aims to delay subsequent pregnancy and reduction in health risk behaviors, improved health and well-being of parent and child, improved educational and employment outcomes and increased self-sufficiency.
62404877|NCT01929928||Surgical Patients|
62404878|NCT04984304|EXPERIMENTAL|Mild cough|Mild cough only slightly worsening the quality of life (VAS 1-3)
62404879|NCT04984304|EXPERIMENTAL|Moderate and severe cough|Moderate and severe cough that significantly worsen the quality of life (VAS 4-10)
62205668|NCT01921153|EXPERIMENTAL|Long Intervention|All participants will be measured for (1) baseline, (2) four-week environmental intervention: Healthy meal plates and trays, and (3) withdraw of intervention.
62205669|NCT00635128|EXPERIMENTAL|BOOSTRIX-POLIO GROUP|Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™-Polio vaccine in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
62404880|NCT02398942||Proximal Pole Fracture of the Scaphoid|QuickDASH 6 months after injury CT scan 6 months after injury
62404881|NCT00040326|ACTIVE_COMPARATOR|1|anteromesial temporal resection
62404882|NCT00040326|ACTIVE_COMPARATOR|2|antiepileptic drugs
62404883|NCT04080362|EXPERIMENTAL|MitralStitch repair system|Experimental group is allocated to use novel mitral vavle repair system manufactured by Hangzhou Valgen Medtech Co., Ltd
62404884|NCT03348306|EXPERIMENTAL|All patients|
62404885|NCT03919734||AI ACS/possible ACS|Patients with adrenal incidentalomas and cortisol following overnight 1-mg dexamethasone suppression equal to or above 50 nmol/l. The patients should not have clinical signs of Cushing Syndrome, such as catabolic skin and muscle changes.
62734913|NCT05653245|ACTIVE_COMPARATOR|Group 3|Fifteen periodontitis patients will receive Phase I therapy, reevaluation after four weeks with (M-MIST) and RGD peptide hydrogel.
62734914|NCT05746013|PLACEBO_COMPARATOR|No Fat meal|
62734915|NCT05746013|EXPERIMENTAL|SFA meal|
62788196|NCT01481454|EXPERIMENTAL|Group 2: QIV Lot 2|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 2.
62788197|NCT01481454|EXPERIMENTAL|Group 3: QIV Lot 3|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 3.
62205670|NCT00635128|EXPERIMENTAL|BOOSTRIX + IPV MÉRIEUX GROUP|Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™ and IPV Mérieux® vaccines in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
62205671|NCT01404429|ACTIVE_COMPARATOR|Methotrexate 7.5 mg per week|
62205672|NCT01404429|EXPERIMENTAL|Methotrexate 15 mg per week|
62404886|NCT03919734||AI non-ACS|Patients with adrenal incidentalomas and cortisol following overnight 1-mg dexamethasone suppression below 50 nmol/l.
62404887|NCT03919734||Treatment with Inhalation Steroids|Patients treated with inhalation steroids with and without ACS/possible ACS but not operated with adrenalectomy.
62404888|NCT03919734||Adrenalectomy|Patients with unilateral AI operated with adrenalectomy
62404889|NCT03919734||Controls|"A Group of Controls matched for sex and age, achieved by the government agency Statistics Sweden (SCB)."
62734916|NCT05746013|EXPERIMENTAL|MUFA meal|
62734917|NCT05746013|EXPERIMENTAL|PUFA meal|
62788198|NCT01481454|ACTIVE_COMPARATOR|Group 4: TIV|Participants will receive the Trivalent Influenza Vaccine (TIV).
62788199|NCT04148742|EXPERIMENTAL|daily dose of DZD9008|daily dose of DZD9008
62580827|NCT01404156|EXPERIMENTAL|Neoadjuvant Chemoradiation|"1) -carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29~* paclitaxel: 50 mg / m2 IV over 1 hour~* carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.~  1. Dose specifications:~     1. Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy.~    2. Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment."
62580828|NCT05763485|ACTIVE_COMPARATOR|Anti reflux mucosal ablation (ARMA)|Patients randomized into the intervention arm receive ARMA and a follow up control after 2, 4, 6 and 12 months. PPI treatment is stopped after 2 months until the end of the study or worsening of symptoms. Esophagogastroduodenoscopy, manometry and pH metry is performed after 4 months.
62580829|NCT05763485|SHAM_COMPARATOR|Sham procedure|Patients randomized into the sham procedure arm receive a esophagogastroduodenoscopy in the same setting as if ARMA would be performed. Patients in the Control group receive follow up controls after 2 and 4 months and after unblinding after 4 months are allowed to perform a crossover to receive ARMA. PPI treatment is stopped 2 months after the initial sham procedure until the end of the study or worsening of symptoms. If the patients receive ARMA as a crossover reevaluation is performed 2, 4, 6 and 12 months after the actual ARMA procedure.
62580830|NCT02783469||Diabetic neuropathic pain|Those with type 2 diabetes and painful neuropathy
62580831|NCT02783469||Controls|Type 2 diabetics with non-painful neuropathy, or pain without neuropathy
62580832|NCT06177808|EXPERIMENTAL|Wolverine cutting balloon group|Patients who received PCI with Wolverine cutting balloon to modify calcified coronary lesion
62580833|NCT06177808|ACTIVE_COMPARATOR|NC(Non-compliant) balloon group|Patients who received PCI with Non-compliant balloon to modify calcified coronary lesion
62580834|NCT00627445|EXPERIMENTAL|BIAsp 50-50-30|Biphasic insulin aspart 50 administered before breakfast and lunch + biphasic insulin aspart 30 at dinner combined with metformin
62580835|NCT00627445|ACTIVE_COMPARATOR|BIAsp 30-30|Biphasic insulin aspart 30 administered before breakfast and dinner combined with metformin
62580836|NCT02811354|EXPERIMENTAL|AZD9291|Patient will be treated with AZD9291 at a starting dose of 80mg once a day until the patient completes the study, withdraws from the study or closure of the study. A cycle of treatment is defined as 28 days of once daily AZD9291 treatment. Patients may continue to receive AZD9291 until objective disease progression (determined by RECIST 1.1) or if the subject is no longer receiving clinical benefit in the Investigator's opinion.
62580837|NCT00685399|EXPERIMENTAL|Cohort 1|Participants were administered with AIN457 (Sp2/0derived) 10 milligrams per kilogram (mg/kg) intravenous (i.v.) dose on Day 1 and Day 22.
62580838|NCT00685399|EXPERIMENTAL|Cohort 2|Participants were administered with AIN457 (Sp2/0 or Chinese hamster ovary cell (CHO) derived) 10 mg/kg, (CHO derived) 3 mg/kg or (CHO derived) 1 mg/kg i.v. dose on Day 1 and if needed a second dose of AIN457 10 mg/kg i.v. dose either on Day 15 or Day 22. 3 participants from cohort 1 rolled on into this cohort.
62580839|NCT00685399|EXPERIMENTAL|Cohort 3|Participants were administered with AIN457 10 mg/kg i.v. dose on Day 1 and Day 22.
62580840|NCT00685399|EXPERIMENTAL|Cohort 4|Extension period: Participants were administered with AIN457 10 mg/kg, i.v. (with or without a short course of corticosteroids) once a flare had occurred, or periodically at a frequency of not more than once per month at the discretion of the investigator.
62580841|NCT00685399|EXPERIMENTAL|Cohort 5|Participants were administered with AIN457 30 mg/kg single i.v. dose. A second dose was given when all 4 participants completed at least 29 days, and the 30 mg/kg dose was well tolerated by all.
62580842|NCT00685399|EXPERIMENTAL|Cohort 6 Arm 1|Participants were administered with AIN457 300 mg subcutaneously (s.c.) and saline i.v. infusion every two weeks (Days 1, 15, 29, and 43).
62580843|NCT00685399|EXPERIMENTAL|Cohort 6 Arm 2|Participants were administered with AIN457 10 mg/kg i.v. and s.c. saline injections every two weeks (Days 1, 15, 29, and 43).
62580844|NCT00685399|EXPERIMENTAL|Cohort 6 Arm 3|Participants were administered with AIN457 30 mg/kg i.v. and s.c. saline injections every 4 weeks (Days 1 and 29) and saline i.v. infusions and saline s.c. injections on Days 15 and 43 to maintain masking of treatment groups.
62580845|NCT01371110|ACTIVE_COMPARATOR|Ketamine|Study participants will receive a one-time intravenous infusion of 0.5 mg/kg racemic ketamine hydrochloride
62580846|NCT01371110|SHAM_COMPARATOR|Midazolam|Study participants will receive a one-time intravenous infusion of 0.045 mg/kg midazolam
62580847|NCT01735721|ACTIVE_COMPARATOR|Open Sinus Lift with DFDBA|In each patient, one sinus was chosen at random and filled with DFDBA (Tissue Regeneration Corporation, Iran).
62580848|NCT01735721|EXPERIMENTAL|Open Sinus Lift with Algipore|The contra lateral sinus was filled with Algipore (Dentsply, USA).
62580849|NCT06477263|EXPERIMENTAL|Arm One|All participants
62205673|NCT02799459||General anaesthesia|this group will allow us to compare the results like it is the treatment used in current practice ie general anesthesia.
62580850|NCT05169918|ACTIVE_COMPARATOR|Control group|
62580851|NCT05169918|EXPERIMENTAL|Training Group|
62788200|NCT05037019|EXPERIMENTAL|Single fraction radiotherapy|Single fraction of 21 Gy stereotactic radiation therapy delivered to a single malignant lesion of the breast prior to any other treatment for breast cancer.
62016293|NCT04181034|ACTIVE_COMPARATOR|AFLP|Case managers meet with participating pregnant and parenting females once a month over 24 months to deliver older, business-as-usual version of the program that does not have positive youth development component.
62788201|NCT05651672|EXPERIMENTAL|experimental group|Pemigatinib
62788202|NCT01882699|EXPERIMENTAL|Cereve sleep system|Cereve sleep system
62016294|NCT02348489|EXPERIMENTAL|SGI-110 (guadecitabine)|Guadecitabine 60 mg/m\^2 administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.
62205674|NCT02799459||Hypnosis in conization|This group is the treatment being tested , where hypnosis is used in the conization
62788203|NCT01806675|EXPERIMENTAL|Glioblastoma Multiforme (GBM)|Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)
62788204|NCT01806675|EXPERIMENTAL|Gynecological Cancers|Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)
62788205|NCT01806675|EXPERIMENTAL|Renal Cell Cancer (RCC)|Patients with renal cell cancer (RCC) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)
62788206|NCT01429181|EXPERIMENTAL|Non Racemic Methadone|Non-Racemic Methadone Hydrochloride 5 mg Capsules containing a non-racemic mixture of methadone isomers.
62788207|NCT01429181|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules
62788208|NCT06135935|EXPERIMENTAL|No-added-sugar ice cream|KDD is developing a new line of no-added-sugar products in line with its metabolic reengineering initiative and its metabolic matrix. Four new flavored milks and four new ice creams all have no added sugar. Flavors include chocolate, vanilla, strawberry, and banana. The recipes fundamentally do not alter total saturated fat or protein levels and mainly offer the benefit of no added sugar and a significant reduction in net carbohydrates as well glycemic index.
62788209|NCT06135935|ACTIVE_COMPARATOR|conventional products|KDD has been a leading manufacturer of food and beverages with added sugar (conventional products). The majority of people with type 2 diabetes consume their food products.
62788210|NCT06393647||Frail group|In our study, we aim to investigate the relationship between frailty status assessed using frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36) and preoperative levels of Albumin/Creatinine, B12, Folate, Ferritin, Hemogram, Sedimentation Rate, and CRP in patients undergoing gastrointestinal malignancy surgery.
62788211|NCT06393647||Non-frail group|In our study, we aim to investigate the relationship between frailty status assessed using frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36) and preoperative levels of Albumin/Creatinine, B12, Folate, Ferritin, Hemogram, Sedimentation Rate, and CRP in patients undergoing gastrointestinal malignancy surgery.
62788212|NCT03715244||Study group 1|n=220 patients for routine data of spinal anesthesia with short-acting local anesthetics
62788213|NCT03715244||Study group 2|n= 220 patients for routine data of general anesthesia (current standard)
62788214|NCT03715244||No intervention: Control group postoperative cognitive deficit|n= 90 control subjects aged 18 years or older (without surgery) with a similar health status and age as the study group patients (similar distribution in the American Society of Anaesthesiologists physical status classification and relevant co-morbidities, e.g. diabetes, coronary artery disease, hypertension and hyperlipidemia). The patients are analyzed to correct for learning effects of the cognitive assessment testings in the study groups.
62016295|NCT02348489|ACTIVE_COMPARATOR|Treatment Choice|One of the following treatment regimens: 20 mg cytarabine administered subcutaneously (SC) twice daily (BID) on Days 1-10 every 28 days; 20 mg/m\^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m\^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.
62205675|NCT05944718|EXPERIMENTAL|Arm 1|Arm 1 is those participants randomized to use of CGM in a continuous fashion; CGM use for the duration of 9 months.
62205676|NCT05944718|EXPERIMENTAL|Arm 2|Arm 2 is those participants randomized to intermittent use of CGM; CGM use for 4 time points consisting of 2 weeks of CGM use each, for the duration of 9 months.
62205677|NCT05944718|NO_INTERVENTION|Arm 3|Arm 3 is those participants randomized to standard of care; regular use of self-monitoring of blood glucose (SMBG) for the duration of 9 months.
62734918|NCT04303104|ACTIVE_COMPARATOR|Mobile ACF|Xpert Edge performed at point-of-care employing a low-cost panel van that is staffed by three health care workers. Patients identified with active TB will be initiated on TB treatment on the same day at the nearest clinic. On site HIV testing will also be offered. Thus, the interventional package is one of ACF + POC TB testing (TB testing by Xpert will occur on site at the van).
62734919|NCT04303104|PLACEBO_COMPARATOR|Centralised ACF|Similar to active arm but Xpert Ultra will be performed at a centralized laboratory (samples will be transported to the laboratory with results being available in a few days). Thus, the standard of care package is ACF + distant TB testing (TB testing by Xpert will occur at a distant laboratory site).
62788215|NCT02627989||Diflucortolone valerate (Nerisona/Texmeten)|Adult patients with atopic dermatitis switching from diflucortolone-valerate fatty ointment to ointment (water/oil emulsion) during autumn/ winter (Nov to Feb) or spring/ summer (May to Aug)
62788216|NCT05126836|OTHER|Cilostazol|"First week, Cilostazol 100mg twice a day~Second week, Placebo twice a day~Third week, Cilostazol 100mg twice a day~Forth week, Placebo twice a day"
62788217|NCT05126836|OTHER|Placebo|"First week, Placebo twice a day~Second week, Cilostazol 100mg twice a day~Third week, Placebo twice a day~Forth week, Cilostazol 100mg twice a day"
62788218|NCT03745521||X-linked Hypophosphatemia (XLH)|Hypophosphatemic Rickets/osteomalacia
62788219|NCT01361178|NO_INTERVENTION|Transplant patients who do not receive SQ IVIG|Patients participating in the observational arm of the study who do not need to receive IgG replacement.
62788220|NCT01361178|ACTIVE_COMPARATOR|Transplant patients who receive SQ IVIG|Patients participating in the observational arm of the study who are randomized to receive a dosage of SQ IVIG due to low IgG level.
62788221|NCT05021146|EXPERIMENTAL|Standard care and CEO treatment with standard 20% concentration Copaiba oil|
62788222|NCT05021146|EXPERIMENTAL|Standard care and CEO treatment with 40% concentration Copaiba oil|
62788223|NCT05021146|PLACEBO_COMPARATOR|standard care and placebo treatment with coconut oil|
62016296|NCT06573086|EXPERIMENTAL|High responders (n=30)|This group consists of participants with the highest increase in skeletal muscle hypertrophy of m. vastus lateralis in response to the initial 12 weeks of RT (Intervention I).
62205678|NCT01533818|ACTIVE_COMPARATOR|Amoxicillin|This is an active intervention
62205679|NCT01533818|PLACEBO_COMPARATOR|Sugar Syrup|
62205680|NCT02242097|EXPERIMENTAL|Treatment (ibrutinib)|Patients receive ibrutinib orally PO QD on days 1-28. Courses repeat every 28 days for up to 4 years in the absence of disease progression, unacceptable toxicity, or patient preference.
62205681|NCT04955782||62-84 hours of abstinence|samples will be analyzed for semen volume, pH, count, concentration, motility, morphology and viability
62788224|NCT05021146|ACTIVE_COMPARATOR|Standard care|
62788225|NCT02656953|EXPERIMENTAL|VDU lenses|VDU lenses provide a clear vision of the intermediate zone at a distance of approximately 70 centimeters, which is closer than distant vision at a distance of more than 2 meters (e.g. driving), but further than near vision at a distance of 40 centimeters (e.g. reading), so the computer screen is seen clear without the need for excessive focusing effort or bad postures. In this study Zeiss® Officelens Plus lenses with a Silhouette® frame were used.
62788226|NCT02656953|ACTIVE_COMPARATOR|Progressive lenses|Progressive lenses or multifocal lenses provide a continuous range of focal power between near and far distances.Progressive lenses have some lens power for the intermediate zone as well, but this zone might not be large enough for comfortable and ergonomic computer work. In this study Zeiss® Multifocal Precision Plus lenses with a Silhouette® frame were used.
62788227|NCT03688074|EXPERIMENTAL|Tezepelumab|Tezepelumab subcutaneous injection
62788228|NCT03688074|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection
62788229|NCT04205721|EXPERIMENTAL|Scripted lesson plan life orientation curriculum|Participants in this arm were in schools where the life orientation teachers in grades 7-9 (in 2016 and 2017) and grade 10 in 2018 were trained to use the new life orientation curriculum that included scripted lesson plans for the sexual and reproductive health content of the program. There are eight lessons for grade 7, eight for grade 8, 11 for grade 9, and 10 for grade 10.
62205682|NCT04955782||1-3 hours of abstinence|samples will be analyzed for semen volume, pH, count, concentration, motility, morphology and viability
62788230|NCT04205721|NO_INTERVENTION|Standard life orientation curriculum|Participants in this arm were in schools where the standard life orientation curriculum was used with no additional training and no use of the new materials.
62788231|NCT05769205|EXPERIMENTAL|female with ovarian masses|MRI with contrast according to the kidney function test of the patients
62788232|NCT00349869|EXPERIMENTAL|1|8-week yoga program
62788233|NCT00349869|NO_INTERVENTION|2|Usual care control
62788234|NCT01478724|PLACEBO_COMPARATOR|Placebo|Animal proteins
62788235|NCT01478724|EXPERIMENTAL|Milk protein fraction dose 1|
62788236|NCT01478724|EXPERIMENTAL|Milk protein fraction dose 2|
62016297|NCT06573086|EXPERIMENTAL|Moderate responders (n=30)|This group consists of participants with the moderate increase in skeletal muscle hypertrophy of m. vastus lateralis in response to the initial 12 weeks of RT (Intervention I).
62016298|NCT06573086|EXPERIMENTAL|Low Responders (n=30)|This group consists of participants with the lowest increase in skeletal muscle hypertrophy of m. vastus lateralis in response to the initial 12 weeks of RT (Intervention I).
62016299|NCT06126055|EXPERIMENTAL|Off PPI|No symptoms of reflux
62016300|NCT06567808|EXPERIMENTAL|cefazolin short-term|Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first).
62016301|NCT06567808|EXPERIMENTAL|cefazolin long-term|Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first) and the five post-operative doses in the long-term arms will be 2g every 8 hours.
62016302|NCT06567808|EXPERIMENTAL|cefazolin plus vancomycin short-term|Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first). Vancomycin will be dosed at roughly 15mg/kg body weight intravenously, i.e. 1g or 1.5g if greater than 85kg body weight and is to be administered within 60-90 minutes of the surgical procedure.
62016303|NCT06567808|EXPERIMENTAL|cefazolin plus vancomycin long-term|Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first) and the five post-operative doses in the long-term arms will be 2g every 8 hours. Vancomycin will be dosed at roughly 15mg/kg body weight intravenously, i.e. 1g or 1.5g if greater than 85kg body weight and is to be administered within 60-90 minutes of the surgical procedure. The same dose will be used for the 3 post-operative doses in the long-term arm.
62016304|NCT03054844|EXPERIMENTAL|PREMED|Patients will receive 0.25 mL of IN 4% lidocaine (10 mg) in each naris (total of 0.5 mL/20 mg for both nares) preceding adminstration of IN midazolam.
62016305|NCT03054844|EXPERIMENTAL|PREMIX|Patients will receive midazolam mixed with 0.5 mL of 4% lidocaine (20 mg).
62788237|NCT05687162|ACTIVE_COMPARATOR|(Study 1) 3-week Loneliness Program|The second and third sessions are completed in the second and third week, respectively, after beginning the study.
62788238|NCT05687162|EXPERIMENTAL|(Study 1) Single-session loneliness program|
62788239|NCT05687162|ACTIVE_COMPARATOR|(Study 1) Single-session active control program|
62788240|NCT05687162|EXPERIMENTAL|(Study 2) Popular online content-based single-session intervention for distress|
62788241|NCT05687162|ACTIVE_COMPARATOR|(Study 2) Researcher-created single-session intervention for distress|
62788242|NCT05687162|ACTIVE_COMPARATOR|(Study 2) Online help-seeking as usual|
62788243|NCT05687162|EXPERIMENTAL|(Study 3) Popular online content-based single-session intervention for loneliness|
62788244|NCT05687162|ACTIVE_COMPARATOR|(Study 3) Researcher-created single-session intervention for loneliness|
62788245|NCT05687162|ACTIVE_COMPARATOR|(Study 3) Single-session active control program|
62205683|NCT05078788|EXPERIMENTAL|Laser uretherotomy|Using Holmium laser uretherotomy only in the treatment of bulbar uretheral stricture
62205684|NCT05078788|EXPERIMENTAL|Laser uretherotomy with intralesional steroids|Using holmium laser uretherotomy with injection of 80 mg of triamcinolone (diluted with normal saline to 10 ml) in the treatment of bulbar uretheral stricture
62205685|NCT06322238|EXPERIMENTAL|PGx testing arm|
62205686|NCT06322238|PLACEBO_COMPARATOR|Delayed PGx testing arm|
62205687|NCT00072137|EXPERIMENTAL|Arm A (rf-GM-CSF, closed to accrual 10/2004)|Patients receive recombinant fowlpox GM-CSF vaccine adjuvant intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
62205688|NCT00072137|EXPERIMENTAL|Arm B (rf-TRICOM, closed to accrual 10/2004)|Patients receive recombinant fowlpox-TRICOM vaccine intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
62580852|NCT01713764|EXPERIMENTAL|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate diet: carbohydrate intake 10-50 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
62205689|NCT00072137|EXPERIMENTAL|Arm C (rfTRICOM and rf-GM-CSF)|Patients receive recombinant fowlpox-TRICOM vaccine combined with recombinant fowlpox GM-CSF vaccine adjuvant intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
62205690|NCT02672852|EXPERIMENTAL|Risankizumab|Participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg by subcutaneous injection at Weeks 0 and 4 (Part A1).
62205691|NCT02672852|PLACEBO_COMPARATOR|Placebo|Participants randomized at Baseline to receive double-blind (DB) placebo by subcutaneous injection at Weeks 0 and 4 (Part A1).
62205692|NCT02963155|EXPERIMENTAL|Metastatic prostate cancer blood samples|
62205693|NCT04358770|EXPERIMENTAL|Test|Clocortolone Pivalate Cream, 0.1%
62205694|NCT04358770|ACTIVE_COMPARATOR|Reference|Cloderm® (clocortolone pivalate) Cream, 0.1%
62205695|NCT01731080||Pseudoxanthoma Elasticum|Patients with genetically and clincally proven PXE
62580853|NCT01713764|ACTIVE_COMPARATOR|American Diabetes Association Diet|"Participants in the American Diabetes Association (ADA) diet group will receive standard ADA advice. The diet includes high-fiber foods (such as vegetables, fruits, whole grains, and legumes), low-fat dairy products, fresh fish, and foods low in saturated fat.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
62734920|NCT04356846|EXPERIMENTAL|R/R CLL|Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
62788246|NCT05687162|ACTIVE_COMPARATOR|(Study 4) 23-minute loneliness program|
62016306|NCT06171867|EXPERIMENTAL|Feasibility of the PNEUMACRIT belt|Neonates will be monitored with a PNEUMACRIT electrode belt for 6 to 24 hours. After the study period, patient parents and nurses will give feedback.
62016307|NCT01083433|NO_INTERVENTION|Standard Diabetes Care|Patients will attend diabetes clinic as usual, once every 3 months.
62016308|NCT01083433|EXPERIMENTAL|Intensive Diabetes Clinic|Patients will attend diabetes clinic on a monthly basis for 4 months in a row. Each patient will have a 30 minute visit with a physician, 30 minutes dedicated to diabetes education, and 45 minutes with a child psychologist.
62016309|NCT01083433|EXPERIMENTAL|Intensive Diabetes Clinic plus CGM|Patients in this group will include all procedures as listed for group 2 (intensive diabetes clinic) in addition to wearing a continuous glucose monitor for 3-5 days each month. Patients will also have an additional 30 minutes with a psychology graduate student dedicated to adherence with the CGM.
62016310|NCT06269614|EXPERIMENTAL|Probiotic Treatment|Pediatric Probiotic Treatment
62016311|NCT06269614|NO_INTERVENTION|No Probiotic Treatment|No intervention
62016312|NCT00889421|EXPERIMENTAL|Treatment|Patients receiving apremilast.
62016313|NCT04788147|EXPERIMENTAL|Cohort I: RRFD Cohort|Cohort I seeks to identify the Recommended RefleXion FDG dose (RRFD), which is the dose of administered FDG that allows for functioning of the RefleXion system. This phase of the investigation seeks to optimize the balance between minimizing patient exposure to the radiotracer and achieving satisfactory performance of the RMRS PET subsystem for BgRT. The dose levels of 15 mCi and 20 mCi (if required) will be assessed sequentially in an escalation protocol. To determine the RRFD, a modified 3+3 design will be utilized wherein meeting the Activity Concentration threshold - not dose-limiting toxicity as is typically used - will be the relevant criteria for escalating from one dose to the next. Up to 12 participants will be enrolled in Cohort I, and will undergo one RMRS imaging session and one third-party Positron Emission Tomography (PET) /CT imaging session.
62016314|NCT04788147|EXPERIMENTAL|Cohort II: Emulated Delivery Cohort|"After the RRFD is determined by Cohort I, Cohort II enrollment will start enrollment. Cohort II seeks to determine whether BgRT dose distributions generated from Limited Time Sample (LTS) RMRS PET images obtained at the time of treatment delivery are consistent with the approved BgRT plan. To achieve this objective, RMRS PET scans will be added to the SBRT workflow at timepoints representing some of the instances when the RMRS PET subsystem would be utilized during a BgRT workflow. Specifically, subjects will undergo RMRS PET collections at the time of planning, and then before the first and final fractions of their planned course of SBRT treatment.~Up to 22 participants will be enrolled in Cohort II, and will undergo three RMRS imaging sessions and one third-party Positron Emission Tomography (PET) /CT imaging session."
62580854|NCT05183165|OTHER|Patients with Wilson's disease declaring pregnancy,|Patients with Wilson's disease declaring pregnancy.Followed in the reference, constituent, and competence centers for Wilson's disease and other rare copper-related diseases, spread over French national territory.
62580855|NCT02847091|EXPERIMENTAL|Ipragliflozin Group|Ipragliflozin will be administered orally for 24 weeks.
62580856|NCT04046770|EXPERIMENTAL|Double-Chamber Syringe|Intravenous administration of drugs and flushing with the Double-Chamber Syringe
62580857|NCT04046770|ACTIVE_COMPARATOR|Classical Syringes|Intravenous administration of drugs and flushing with the classical syringe
62580858|NCT03383731|ACTIVE_COMPARATOR|Group 1|Group 1: The patients in Group 1 are treated by the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + air-fluid exchange + silicone oil infusion
62580859|NCT03383731|EXPERIMENTAL|Group 2|Group 2: The patients in Group 2 are treated by the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + inverted internal limiting membrane insertion + air-fluid exchange
62016315|NCT03799575||A|Two samples of ILM per patient are harvested, group A will be immediately fixed and submitted to Optic Microscopy (OM) and Transmission Electron Microscopy (TEM) analysis, and another sample will be incubated in enriched medium 199 (Gibco) for 20 minutes at room temperature, after which it will also be fixed and submitted to OM and TEM analysis.
62205696|NCT01731080||chronic kidney disease|Type 2 diabetic patients with mediacalcosis and matched to PXE patients for gender and age (+/- 5 yrs).
62205697|NCT01731080||Diabetes|patients with chronic kidney disease and matched to PXE patients for gender and age (+/- 5 yrs).
62205698|NCT01605019|EXPERIMENTAL|CoSeal Arm|patient randomized to received Coseal during LVAD implantation
62205699|NCT01605019|PLACEBO_COMPARATOR|BioGlue® Surgical Adhesive|BioGlue® Surgical Adhesive or use of no sealant application
62205700|NCT02546622||Arm A Prospective|"Patients who are switching to a new Factor VIII and Factor IX Replacement Product for Hemophilia A and B which was FDA approved after January 1, 2013.~These patients will be followed prospectively for up to 1 year."
62205701|NCT02546622||Arm B Retrospective|"Patients who have recently switched to a new Factor VIII and Factor IX Replacement Product for Hemophilia A and B which was FDA approved after January 1, 2013.~Patients must have switched products within the past 50 weeks at the time of enrollment.~These patients will be assessed retrospectively and/or followed prospectively for up to 1 year."
62205702|NCT00956553|ACTIVE_COMPARATOR|Cervarix|Three doses of Cervarix at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.
62205703|NCT00956553|ACTIVE_COMPARATOR|Gardasil|Three doses of Gardasil at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.
62404890|NCT05820880|EXPERIMENTAL|Fixed [Per/Ind/Aml]|"From inclusion to Month 2, patients receive the fixed combination of perindopril 5 mg / indapamide 1.25 mg / amlodipine 5 mg (S06593).~From Month 2 to 4, patients either stay at the same dose if the blood pressure is controlled, either are up-titrated to the next dose of the strategy if the blood pressure is not controlled (ie, perindopril 10 mg / indapamide 2.5 mg / amlodipine 5 mg).~From Month 4 to 6, patients either stay at the same dose if the blood pressure is controlled, either are up-titrated to the next dose of the strategy if the blood pressure is not controlled (ie, for patients who were up-titrated at Month 2 visit: perindopril 10 mg / indapamide 2.5 mg / amlodipine 10 mg or for patients who were not yet up-titrated: perindopril 10 mg / indapamide 2.5 mg / amlodipine 5 mg."
62580860|NCT05494814|EXPERIMENTAL|Child Care Centers Served Meals Prepared by Central Kitchen|Children ages 3-5 attending a child care center that purchases meals prepared by a central kitchen.
62016316|NCT03799575||B|Group B sample will be incubated in enriched medium 199 (Gibco) for 20 minutes at room temperature, after which it will also be fixed and submitted to OM and TEM analysis.
62016317|NCT06379841|EXPERIMENTAL|Green Draping|This arm will follow the green draping procedures.
62016318|NCT06379841|ACTIVE_COMPARATOR|Full Draping|This arm will follow the conventional full draping procedures.
62016319|NCT06358898|ACTIVE_COMPARATOR|Standard dCBT-I|Treatment content for insomnia was structured and based on the well-established CBT elements for treating insomnia, with developmental adaptation and age-appropriate modification specific for adolescent population. For example, regularity of sleep wake pattern and circadian component will be further emphasized in this age group given the high prevalence of social jetlag resulting from the early school schedule and their natural development delay in circadian rhythm.
62016320|NCT06358898|EXPERIMENTAL|Modified Mood enhanced CBT-I (M-dCBT-I)|For mood-enhanced dCBT-I (M-dCBT-I), apart from including core CBT-I component, additional depression specific component including behavioral activation and problem solving. More specifically, cognitive restructuring techniques will cover both unhelpful belief relevant to both insomnia and depression. Psychoeducation will also cover both condition and vignette example will be included in the treatment.
62016321|NCT00900991|EXPERIMENTAL|10 ug|10 microgram per dose
62016322|NCT00900991|EXPERIMENTAL|15 ug|15 microgram per dose
62016323|NCT03887936|EXPERIMENTAL|Testosterone arm|Testosterone gel 1.62%
62016324|NCT03887936|PLACEBO_COMPARATOR|Placebo arm|Matching placebo will be prepared by the Michael DeBakey VA Medical Center Pharmacy.
62016325|NCT06533774|EXPERIMENTAL|Audeo Lumity hearing aid with the SpeechSensor and StereoZoom 2.0 features|Audeo Lumity hearing aid and the SpeechSensor and StereoZoom 2.0 features, which is found in the Audeo Lumity devices.
62016326|NCT05416619|EXPERIMENTAL|sEMG-biofeedback Group|Receive 1 hour of sEMG-biofeedback hand training provided by wearable REMO® and 1 hour of daily conventional rehabilitation therapy.
62016327|NCT05030922|EXPERIMENTAL|Diet intervention|Follow up of both mother and offspring 20 years after allocation to an antiatherogenic diet during pregnancy.
62016328|NCT05030922|NO_INTERVENTION|Control|Follow up of both mother and offspring 20 years after allocation to control group during pregnancy.
62016329|NCT06330441|EXPERIMENTAL|A - chronic pancreatitis|Chronic pancreatitis, due to cystic fibrosis
62215211|NCT06102980|ACTIVE_COMPARATOR|MASLD screening patients|"Patients with requirements of screening following the European Association for the Study of the Liver (EASL) 2016 recommendations. The MASLD screening group will be compounded by patients with at least one of the following criteria:~1. Over fifty years old;~2. Body mass index (BMI) over 25 kg/m2;~3. Diabetes mellitus type 2;~4. Metabolic syndrome; or~5. Persistently elevated liver enzymes."
62205704|NCT06064019|OTHER|Nevisense|"This will be a prospective investigator-initiated study to evaluate the accuracy of Nevisense for KC. First evaluation steps include dermatologist's clinical examination (visual inspection) and videodermoscopy. In those cases where the routine diagnostic procedures given above identify any suspicion of a KC, a Nevisense measurement is to be conducted after examination of inclusion and exclusion criteria. Thereafter, surgical excision and histopathologic examination follow.~All skin lesions with a suspicion of BCC, iSCC, BD or AK and destined for excision or biopsy for further histopathological analysis will be considered for inclusion in the study. A maximum of three lesions per patient will be allowed for the study. The study aims to enrol 250 lesions in total."
62404891|NCT05820880|ACTIVE_COMPARATOR|Free [Per/Ind + Aml]|"From inclusion to Month 2, patients receive the free combination of perindopril 4 mg / indapamide 1.25 mg plus amlodipine 5 mg.~From Month 2 to 4, patients either stay at the same dose if the blood pressure is controlled, either are up-titrated to the next dose of the strategy if the blood pressure is not controlled (ie, double dose of perindopril 4 mg / indapamide 1.25 mg plus amlodipine 5 mg for patients).~From Month 4 to 6, patients either stay at the same dose if the blood pressure is controlled, either are up-titrated to the next dose of the strategy if the blood pressure is not controlled (ie for patients who were up-titrated at Month 2 visit: double dose of perindopril 4 mg / indapamide 1.25 mg plus double dose of amlodipine 5 mg or for patients who were not yet up-titrated:double dose of perindopril 4 mg / indapamide 1.25 mg plus amlodipine 5 mg."
62580861|NCT05494814|NO_INTERVENTION|Child Care Centers Not Served Meals Prepared by Central Kitchen|Children ages 3-5 attending a child care center that does not purchase meals prepared by a central kitchen.
62580862|NCT00427921|EXPERIMENTAL|1|Open Label
62016330|NCT06330441|EXPERIMENTAL|B1 - genetic predisposition (STK11, CDKN2A, PRSS1)|Persons with a confirmed diagnosis of Peutz-Jeghers syndrome (STK11 mutation) or familial melanoma syndrome (CDKN2A mutation), hereditary pancreatitis (PRSS1 mutation)
62205705|NCT01519089|EXPERIMENTAL|CP-690,550 10 mg BID|
62205706|NCT01519089|EXPERIMENTAL|CP690,550 5 mg BID|
62205707|NCT02972268|EXPERIMENTAL|Group I|Tamsulosin 0.2mg + Solifenacin 5mg
62205708|NCT02972268|PLACEBO_COMPARATOR|Group II|Tamsulosin 0.2mg + Placebo(Solifenacin)
62205709|NCT01653054|EXPERIMENTAL|IBD patients ON Immunosuppression|
62404892|NCT01340807|EXPERIMENTAL|Prosthetic Feet|Randomized to 4 different prosthetic feet (SACH, SAFE, TALUX, and Proprio Foot)
62404893|NCT03801863||Ultrasound-guided Erector Spinae Block|Patients will then be randomized into one of the two groups above. One group will receive a lumbar erector spinae block at L4 with 30ml of 0.375% ropivacaine with 50 mcg of dexmedetomidine before the procedure using ultrasound guidance. The second group will receive no peripheral nerve block to serve as the control. All patients receiving nerve blocks will have a printed image of the block thus to confirm proper spread of local anesthetic both cranially and caudally.
62205710|NCT01653054|EXPERIMENTAL|IBD Patients OFF Immunosuppression|
62205711|NCT04650087|ACTIVE_COMPARATOR|Apixaban|Drug: Apixaban 2.5 MG Participants will be given study medication at the time of discharge from the hospital. Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening, for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and contact will continue up to day 90 after starting study treatment. Follow up will be through electronic and/or telephone contact depending on the participant's preference, compliance, and medication adherence. Participants will be queried for any clinically relevant endpoints, especially major bleeding or a need to seek healthcare attention for any reason. Follow-up will occur from the time of discharge and through the 30 day study period, with contacts 2 days, 10 days, 20 days, and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
62404894|NCT03801863||No Ultrasound-guided Erector Spinae Block|Patients with no peripheral nerve block to serve as the control.
62404895|NCT04629534|EXPERIMENTAL|Group A|
62404896|NCT04629534|PLACEBO_COMPARATOR|Group B|
62016331|NCT06330441|EXPERIMENTAL|B2 - genetic predisposition of hereditary syndromes|Persons with a confirmed diagnosis of hereditary syndromes and at the same time with the condition of at least one relative of the first or second degree with a diagnosis of pancreatic ductal adenocarcinoma in family anamnesis; i.e. Lynch syndrome (mut: MLH1, MSH2, MSH6 a PMS2, EPCAM), HBOC (mut: BRCA1, BRCA2, PALB2, ATM), familial adenomatous polyposis (mut: APC), Li-Fraumeni syndrome (mut: TP53)
62016332|NCT06330441|EXPERIMENTAL|C - positive family anamnesis|Persons with positive family anamnesis of pancreatic ductal adenocarcinoma without proven hereditary syndrome
62016333|NCT03586869|EXPERIMENTAL|NANT Pancreatic Cancer Vaccine|A combination of agents were administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011 (CEA), ETBX-021 (HER2), ETBX-051 (Brachyury), ETBX-061 (MUC1), GI-4000, GI-6207, GI-6301, haNK for infusion, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, oxaliplatin, and Stereotactic Body Radiation Therapy (SBRT).
62016334|NCT04313153|EXPERIMENTAL|Vadadustat once daily (QD)|
62016335|NCT04313153|EXPERIMENTAL|Vadadustat three times weekly (TIW)|
62404897|NCT05386511||UTD1|UTD1 monotherapy or UTD1 based therapy
62404898|NCT00422058|PLACEBO_COMPARATOR|Lira placebo/Lira 2.4 mg/Lira 3.0 mg|Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
62580863|NCT06685731|EXPERIMENTAL|Participant Group|"Personal Information Form, Mini-Mental State Examination, Active Aging Scale, Pittsburgh Sleep Quality Index, Subjective Vitality Scale, and Quality of Life Scale for Elderly Individuals will be administered to elderly individuals via face-to-face interviews conducted by the researcher.~Elderly individuals will be provided with information about the Laughter Yoga sessions.~The elderly participants will undergo a total of 12 Laughter Yoga sessions, with each session lasting 40 minutes, conducted twice a week for 6 weeks.~Participants' phone numbers will be collected, and they will be contacted twice a week to ensure their attendance at the Laughter Yoga sessions."
62016336|NCT04313153|ACTIVE_COMPARATOR|Darbepoetin alfa|
62788247|NCT05687162|EXPERIMENTAL|(Study 4) 8-minute loneliness program|
62788248|NCT02397538|OTHER|Cohort1|Treatment AB → ABC Treatment A+B (10days) → Treatment A+B+C (6days) Treatment A: Fimasartan Treatment B: Amlodipine Treatment C: Rosuvastatin
62788249|NCT02397538|OTHER|Cohort2|Treatment C → ABC Treatment C (6days) → Treatment A+B+C (10days) Treatment A: Fimasartan Treatment B: Amlodipine Treatment C: Rosuvastatin
62788250|NCT05422937||Children and Young People aged 8-17|All CYP aged 8 years - 17 years \& 11 months whether they have had acute COVID-19 or not. Exposure to COVID-19 will be defined as a self-reported positive Sars-CoV-2 PCR test OR a positive self-reported OR self-reported presumed COVID-19 illness. Participants must have a recorded mobile number in their GP record.
62788251|NCT00289926|EXPERIMENTAL|dehydroepiandrosterone|50.0mg dehydroepiandrosterone capsule, by mouth, daily for 12 months
62788252|NCT00289926|PLACEBO_COMPARATOR|Placebo|Placebo capsule consists of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF manufactured to mimic dehydroepiandrosterone capsule
62788253|NCT00668603|EXPERIMENTAL|2|Postmenopausal women with severe vasomotor symptoms
62788254|NCT00668603|EXPERIMENTAL|1|Postmenopausal women without vasomotor symptoms
62788255|NCT03582891|OTHER|Parkinson's Disease STN Target|Parkinson's disease patients implanted in STN
62788256|NCT03582891|OTHER|Parkinson's disease patients GP Target|Parkinson's disease patients implanted in Globus Pallidus
62404899|NCT00422058|EXPERIMENTAL|Lira 1.2 mg/Lira 3.0 mg|Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
62788257|NCT03582891|OTHER|Dystonia patients|Isolated dystonia patients
62788258|NCT04944849||digital gamer group|Individuals with computer use more than 14 hours a week were included in this group.
62788259|NCT04944849||player group|Individuals with computer use less than 14 hours a week were included in this group.
62788260|NCT04056897|EXPERIMENTAL|BCD-132, 125 mg|72 patients
62788261|NCT04056897|EXPERIMENTAL|BCD-132, 500 mg|72 patients
62788262|NCT04056897|ACTIVE_COMPARATOR|Teriflunomide|72 patients
62404900|NCT00422058|EXPERIMENTAL|Lira 1.8 mg/Lira 3.0 mg|Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
62788263|NCT04056897|PLACEBO_COMPARATOR|Placebo|54 patients
62016337|NCT01663636||SMS Vaccine|Mothers will be sent an SMS message reminding them to come for their scheduled vaccines 1 week prior to the date of 2nd and 3rd doses
62404901|NCT00422058|EXPERIMENTAL|Lira 2.4 mg/Lira 3.0 mg|Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
62788264|NCT06242301|OTHER|The COPE-D intervention|
62788265|NCT01772732|EXPERIMENTAL|Simotinib Treatment|"3+3 design, ascending multiple doses. Simotinib Hydrochloride: 100mg, 200mg, 300mg, 400mg, 500mg, bid, for 28 days"
62788266|NCT02268825|EXPERIMENTAL|MK-3475 treatment arm, all patients|
62788267|NCT05055817||bloody stool group|bloody stool appear in the hospitalized neonate
62788268|NCT05055817||non-bloody stool group|bloody stool do not appear in the hospitalized neonate
62788269|NCT06448624|PLACEBO_COMPARATOR|Intervention|Ampicillin sulbactam 1.5 gram IV preimplantation + ampicillin sulbactam 1.5 gram intrapocket + placebo for 3 days after implantation
62788270|NCT06448624|EXPERIMENTAL|Control|Ampicillin sulbactam 1.5 gram IV preimplantation + ampicillin sulbactam 1.5 gram intrapocket + ampicillin sulbactam 1.5 gram IV BID for 3 days after implantation
62788271|NCT06400953|EXPERIMENTAL|Group 1|Kinetic Brain Exercises and Core Stabilization Exercises were applied to Group 1
62788272|NCT06400953|EXPERIMENTAL|Group 2|Core Stabilization Exercises were applied to Group 2
62788273|NCT01431781|EXPERIMENTAL|stilamin+common daily treatment|
62788274|NCT01431781|ACTIVE_COMPARATOR|common daily treatment|
62788275|NCT03521141|OTHER|Guideline-Based Care (GBC)|GBC participants are 1) referred to the state quitline, 2) provided the NCI Clearing the Air smoking cessation program, and 3) asked to talk to their healthcare provider about potential lung cancer screening (LCS). Medication assignment is guided by standard guidelines and a conversation between the study tobacco counselor and the participant. Groups 1 and 2 also receive GBC counseling.
62788276|NCT03521141|ACTIVE_COMPARATOR|Nicotine Metabolite Ratio (PC-NMR)|Group 1, nicotine metabolism. Medication is guided by nicotine metabolism.
62205712|NCT04650087|PLACEBO_COMPARATOR|Placebo|Drug: Placebo Participants will be given study medication at the time of discharge from the hospital. Participants will take the Placebo twice a day, once in the morning and once in the evening, for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and contact will continue up to day 90 after starting study treatment. Follow up will be through electronic and/or telephone contact depending on the participant's preference, compliance, and medication adherence. Participants will be queried for any clinically relevant endpoints, especially major bleeding or a need to seek healthcare attention for any reason. Follow-up will occur from the time of discharge and through the 30 day study period, with contacts 2 days, 10 days, 20 days, and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
62205713|NCT03538938|EXPERIMENTAL|1-Call, Patch, SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement are for completing the counseling call and for staying enrolled in the SmokefreeTXT program for six weeks.
62205714|NCT03538938|EXPERIMENTAL|1-Call, Patch, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
62205715|NCT03538938|EXPERIMENTAL|1-Call, Patch, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement are for completing the counseling call.
62205716|NCT03538938|EXPERIMENTAL|1-Call, Patch, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokeFreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
62205717|NCT03538938|EXPERIMENTAL|1-Call, Patch+Loz, SmokefreeTXT, Financial Incentive|Participants will receive the following: 1-Call Quitline Counseling, 4 weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. Patch treatment will consist of a 4 week supply of over-the-counter nicotine patches (21 mg if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day \[TQD\] and for 6 weeks following the TQD). The Financial Incentives are for completing the counseling call and for staying enrolled in the SmokefreeTXT program for 6 weeks.
62404902|NCT00422058|EXPERIMENTAL|Liraglutide 3.0 mg|Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
62404903|NCT00422058|ACTIVE_COMPARATOR|Orlistat|Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)
62404904|NCT01254695|ACTIVE_COMPARATOR|Standard settings|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 210 μsec
62404905|NCT01254695|EXPERIMENTAL|Experimental Setting 1|Amplitude: Sensory threshold Frequency:6.9 Hz Pulse width 210 μsec
62404906|NCT01254695|EXPERIMENTAL|Experimental setting 2|Amplitude: Sensory threshold Frequency:31 Hz Pulse width 210 μsec
62404907|NCT01254695|EXPERIMENTAL|Experimental setting 3|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 330 μsec
62404908|NCT01254695|EXPERIMENTAL|Experimental setting 4|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 90 μsec
62580864|NCT06685731|NO_INTERVENTION|Control group|"Personal Information Form, Mini-Mental State Examination, Active Aging Scale, Pittsburgh Sleep Quality Index, Subjective Vitality Scale, and Quality of Life Scale for the Elderly will be administered to elderly individuals through face-to-face interviews conducted by the researcher.~No intervention will be applied to the elderly individuals in this group.~Phone numbers of the participants in this group will be collected, and they will be contacted once a week to check on their status."
62734921|NCT04356846|EXPERIMENTAL|R/R NHL|Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Patients, including SLL, FL, MZL, MCL, DLBCL, WM.
62016338|NCT01663636||Usual care|Mothers under usual care will serve as a control
62016339|NCT01169857|EXPERIMENTAL|Velcade Therapy|
62404909|NCT04299126|EXPERIMENTAL|high absorption pad for blood and pus|High absorption pad for blood and pus with natural antimicrobial agent composes of sericin and chitosan. It will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
62580865|NCT02262312||Patients with myelodysplastic syndrome|Patients with myelodysplastic syndrome among these include also patients with chronic myelomonocytic leukemia with myelodysplasia, patients with acute myeloid leukemia progressed from myelodysplastic syndrome and patients with myelodysplastic/myeloproliferative neoplasm, unclassifiable
62580866|NCT02058537|EXPERIMENTAL|Bethanechol|Oral administration of 25 milligrams of bethanechol taken twice daily for a minimum of 7 days. Total dose taken daily for a minimum of 7 days is 50 mg.
62580867|NCT02838914|EXPERIMENTAL|patients with AF|Before radiofrequency ablation (RFCA)
62580868|NCT02838914|EXPERIMENTAL|Assigned Comparisons|After radiofrequency ablation (RFCA)
62788277|NCT03521141|ACTIVE_COMPARATOR|Respiragene (PC-Respiragene)|Group 2, genetically-informed lung cancer risk score. Medication assignment is guided by standard guidelines and a conversation between the study nurse and the participant.
62788278|NCT00848783|EXPERIMENTAL|A-with IP Floxuridine|"1. Induction treatment:~   Cisplatin 25 mg/m\^2 and Irinotecan 75 mg/m\^2 once a week for 4 weeks, both intravenous; Two weeks without treatment; Repeat the course once.~2. Re-evaluation, surgery if complete response, partial response or stable disease, or off the protocol if progression of disease.~3. Randomization~4. Surgery.~5. Postoperative IP treatment:~   Day 1,2,3: Floxuridine 3 gm/day, IP; Day 3: Cisplatin 60 mg/m\^2, IP; 2 weeks without treatment; repeat the course once~6. Postoperative systemic treatment: courses 1-9: Capecitabine 2,000 mg/m\^2/day x14 every 3 weeks/course, Oral"
62016340|NCT01364064|ACTIVE_COMPARATOR|Conventional adjuvant Temozolomide|TMZ d 1-5 of 28-d cycle 6 cycles
62404910|NCT04299126|ACTIVE_COMPARATOR|commercial wound dressing|Commercial wound dressing is gauze dressing impregnated with paraffin, containing 0.5% chlorhexidine acetate (Bactigras). It will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
62404911|NCT02027246|EXPERIMENTAL|Stem cell|Autologous bone marrow mononuclear cell transplantation
62404912|NCT03843866|ACTIVE_COMPARATOR|Suture & steri-strips|
62404913|NCT03843866|ACTIVE_COMPARATOR|Adhesive Glue|
62404914|NCT02842736|EXPERIMENTAL|Endometrial Cryoablation|
62404915|NCT02048527|ACTIVE_COMPARATOR|Global|In vitro embryo culture in single-step medium (Global)
62580869|NCT04155216|EXPERIMENTAL|Guided imagery|Relaxation and guided imagery program
62580870|NCT00901108|ACTIVE_COMPARATOR|Trabectome-IOL|Combined Trabectome and cataract extraction with intraocular lens insertion
62580871|NCT00901108|ACTIVE_COMPARATOR|Trab-IOL|Combined Trabeculetomy with Mitomycin C and cataract extraction with intraocular lens insertion
62580872|NCT04076553|ACTIVE_COMPARATOR|CBT + ICT|"Participants randomized to the ICT condition will complete a computerized ICT training at home during the first 4 weeks of treatment and ICT boosters following their treatment sessions during weeks 5-12."
62580873|NCT04076553|SHAM_COMPARATOR|CBT + sham|"Participants randomized to the sham condition will complete a computerized sham ICT training at home during the first 4 weeks of treatment and sham ICT boosters following their treatment sessions during weeks 5-12. The shame will contain the same proportion of food as non-food but no inhibitory training component."
62580874|NCT04700917|EXPERIMENTAL|Intervention Group|This group will receive the iCBT for IBD online intervention once enrolled.
62580875|NCT04700917|NO_INTERVENTION|Treatment as Usual|This group will be offered the iCBT for IBD intervention 24 weeks after enrollment.
62580876|NCT01529788|ACTIVE_COMPARATOR|Lateral orbital injection of Botox Cosmetic or Dysport|Lateral orbital injection of either Botox Cosmetic, 10 units or Dysport, 30 units as a single dose in a randomized (right or left sides) double blind fashion in 90 consecutive subjects
62580877|NCT04915820|ACTIVE_COMPARATOR|Immediate iron treatment|intravenous iron carboxymaltose before vaccination
62580878|NCT04915820|NO_INTERVENTION|No iron treatment|no intravenous iron carboxymaltose before vaccination
62580879|NCT04195243|EXPERIMENTAL|Dapagliflozin|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.~Dapagliflozin capsules, 10 mg 1 time daily 5 minutes before the first meal"
62788279|NCT00848783|EXPERIMENTAL|B-Without IP Floxuridine|Same as Arm A except no postoperative IP treatment.
62788280|NCT02879825|EXPERIMENTAL|Group A|Mitral valve prolapse without mitral regurgitation
62788281|NCT02879825|EXPERIMENTAL|Group B|Mitral valve prolapse with trivial mitral regurgitation
62788282|NCT02879825|EXPERIMENTAL|Group C|Mitral valve prolapse with moderate or mild mitral regurgitation and asymptomatic
62788283|NCT02879825|EXPERIMENTAL|Group D|Mitral valve prolapse with severe mitral regurgitation or symptomatic
62016341|NCT01364064|EXPERIMENTAL|Dose intensive Temozolomide|TMZ d 1-21 of 28-d cycle 6 cycles
62016342|NCT04477174||Group A|Twelve health professionals randomised assign to as equally count. The participants match between the images with scale scores. After 2 weeks, the participants match again.
62205718|NCT03538938|EXPERIMENTAL|1-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. Nicotine Patch treatment will consist of a 4-week supply of over-the-counter nicotine patches (21 mg if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a 4-week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
62404916|NCT02048527|ACTIVE_COMPARATOR|Origio|In vitro embryo culture in sequential media (Origio)
62580880|NCT04195243|EXPERIMENTAL|Empagliflozin|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.~Empagliflozin capsules, 25 mg 1 time daily 5 minutes before the first meal"
62016343|NCT04477174||Group B|Twelve health professionals randomised assign to as equally count. The participants match between the images with scale scores.
62580881|NCT04195243|PLACEBO_COMPARATOR|Placebo|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.~Dapagliflozin capsules, 400 mg 1 time daily 5 minutes before the first meal"
62580882|NCT01194999|EXPERIMENTAL|Pubovaginal sling procedure|Patients undergoing pubovaginal slings for stress urinary incontinence.
62580883|NCT06672601||Patients after pancreatic procedures|All patients following pancreatic procedure
62580884|NCT01577953|EXPERIMENTAL|SB010|The drug SB010 is administered in phosphate-buffered saline solution, inhaled via a controlled breathing system over a 5 to 10 min.
62788284|NCT00767819|EXPERIMENTAL|Arm 1|Progressive or metastatic bone or soft tissue sarcomas
62788285|NCT00767819|EXPERIMENTAL|Arm 2|Progressive gastrointestinal stromal tumors (GIST) after failure of prior imatinib and sunitinib 1st and 2nd line
62788286|NCT00767819|EXPERIMENTAL|Arm 3|Progressive or metastatic alveolar soft part sarcoma (ASPS)
62788287|NCT03812315|EXPERIMENTAL|Propolis chewing gum|2 % pure raw propolis, 20-35% gum base, 2.5% flavors, 0.3% sorbitol and 0.3% coloring substance. Children will be instructed to chew the specially prepared propolis chewing gum for at least 20 minutes, twice daily, after breakfast and before bedtime.
62788288|NCT03812315|ACTIVE_COMPARATOR|Propolis mouthwash|The formulation includes 2% pure raw propolis, 40 ml flavors, 150 ml propylene glycol, 60 gm sorbitol, 0.1 g coloring substance and water. Children will be instructed to rinse using the prepared propolis mouthwash for 1 min, twice a day, after breakfast and before bedtime.
62788289|NCT00757055|ACTIVE_COMPARATOR|1|Patients on ivabradine titrated to heart rate
62788290|NCT00757055|PLACEBO_COMPARATOR|2|No therapy given
62788291|NCT05344586|EXPERIMENTAL|Intervention group|Hamstring stretching program with neural load
62788292|NCT05344586|EXPERIMENTAL|Control group|Hamstring stretching program without neural load
62788293|NCT04327726|PLACEBO_COMPARATOR|Control group|received ultrasonic nebulization of 4mL 0.9% saline twice daily for 3 days
62788294|NCT04327726|ACTIVE_COMPARATOR|Dexmedetomidine group|received ultrasonic nebulization of 1 µg/kg dexmedetomidine diluted in 4mL 0.9% saline twice daily for 3 days. The intervention will be continued until achieving a VAS score ≤3 and Lybecker et al. classification score \<2 and or for a maximum of 72 hours. Patients in this group who achieved the target scores before 72 hours will be given 4ml of saline 0.9% nebulization to maintain blinding.
62016344|NCT04725994|OTHER|Group 1|
62788295|NCT05313087||Controls - who are NOT in any of the groups listed below|Adults and children age 5 and over.
62016345|NCT04725994|OTHER|Group 2|
62016346|NCT03238001|EXPERIMENTAL|All qualified participants|Participants received DCTclock, Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and a battery of other traditional pen and paper neuropsychological assessments.
62016347|NCT04166318|ACTIVE_COMPARATOR|Arm A (standard-dose chemoradiation)|Patients undergo 28 fractions of intensity-modulated radiation therapy (IMRT). Within 24 hours, patients also receive mitomycin IV over 30 minutes or less on day 1 and either fluorouracil IV over 24 hours on days 1-4 and 29-32 or capecitabine PO BID 5 days per week (Monday - Friday) until completion of IMRT in the absence of disease progression or unacceptable toxicity.
62016348|NCT04166318|EXPERIMENTAL|Arm B (de-intensified chemoradiation)|Patients undergo 20 or 23 fractions of IMRT. Within 24 hours, patients also receive mitomycin IV over 30 minutes or less on day 1 and either fluorouracil IV over 24 hours on days 1-4 or capecitabine PO BID 5 days per week (Monday - Friday) until completion of IMRT in the absence of disease progression or unacceptable toxicity.
62016349|NCT03787849|ACTIVE_COMPARATOR|Sevoflurane|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction . After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
62016350|NCT03787849|ACTIVE_COMPARATOR|Propofol|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
62016351|NCT02074735|PLACEBO_COMPARATOR|Placebo|Placebo schedule will mimic the schedule of the active comparator citicoline. Placebo will be started at the randomization visit (week 0, mimicking 500 mg/day of citicoline), then increased at week 2 to mimic 1000 mg/day citicoline, then increased to mimic 1500 mg/day of citicoline at week 4, and then increased to mimic 2000 mg/day of citicoline at week 6 until the end of week 12.
62016352|NCT02074735|ACTIVE_COMPARATOR|Citicoline|Citicoline will be started at 500 mg/day at the randomization visit (week 0), then increased to 1000 mg/day at week 2, then 1500 mg/day at week 4, and then 2000 mg/day at week 6 until the end of week 12.
62788296|NCT05313087||Previous COVID infection|Adults and children age 5 and over.
62788297|NCT05313087||Asthma receiving immunomodulator medications|Adults and children age 5 and over.
62788298|NCT05313087||Asthma receiving chronic oral steroids|Adults and children age 5 and over.
62788299|NCT05313087||Asthma - NOT receiving immunomodulator medications or chronic oral steroids|Adults and children age 5 and over.
62788300|NCT05313087||Chronic Obstructive Pulmonary Disease (COPD|Adults
62788301|NCT05313087||Rheumatoid Arthritis receiving immunomodulator medications|Adults and children age 5 and over.
62016353|NCT01003249|ACTIVE_COMPARATOR|Baclofen, Then Placebo|Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. There will be a washout period after three week. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group. Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg
62788302|NCT05313087||Rheumatoid Arthritis NOT receiving immunomodulator medications|Adults and children age 5 and over.
62788303|NCT05313087||Interstitial lung disease|Adults and children age 5 and over.
62788304|NCT05313087||Cancer patients receiving chemotherapy|Adults and children age 5 and over.
62788305|NCT05313087||Bronchiectasis|Adults and children age 5 and over.
62788306|NCT05313087||Cystic fibrosis|Adults and children age 5 and over.
62788307|NCT01957202|EXPERIMENTAL|Arm 1|Each Subject will be assigned to a sequence of three treatments (e.g ABC, BCD, ACD): A=Two, 50 microliter (mcqL) sprays per nostril of FF, total dose 100 microgram (mcg); B=Two, 50 mcqL sprays per nostril of levocabastine, total dose 200 mcg; C=Two, 50 mcql sprays per nostril of FF/levocabastine FDC, total daily dose 100 mcg FF and 200 mcg levocabastine; D=Two, 50 mcql sprays per nostril of placebo. There will be a wash out period of 14-28 days between two treatment periods
62788308|NCT01138488|EXPERIMENTAL|NN5401|
62788309|NCT06407245|EXPERIMENTAL|Exercise Snacks|Vigorous-intensity bodyweight exercises performed 4 times per day on at least 5 days per week.
62788310|NCT06407245|ACTIVE_COMPARATOR|Placebo Exercise|Low-intensity stretching exercises performed 4 times per day on at least 5 days per week.
62788311|NCT06303596|EXPERIMENTAL|Experimental: Experimental group|"The experimental group would receive standard psychiatric treatment.~Additionally, the experimental group would be provided with a 16-session hippotherapy program for 8 weeks, as an adjuvant to standard psychiatric treatment."
62788312|NCT06303596|OTHER|Other: Control group|The control group would receive only standard psychiatric treatment.
62788313|NCT02813239||HCG triggering|Patients were scheduled by prescribing oral contraceptive (OC) for 12-16 days and recombinant FSH and/or highly purified u-hMG according to the patient's age, BMI, antral follicular count, AMH and previous responses to ovarian controlled stimulation. GnRH antagonist was added when at least one follicle reached 13 mm. Ovulation was induced by hCG when at least 2 follicles had a mean diameter of 17 mm.
62788314|NCT02813239||HCG + GnRH agonist triggering|Patients were scheduled by prescribing oral contraceptive (OC) for 12-16 days and recombinant FSH and/or highly purified u-hMG according to the patient's age, BMI, antral follicular count, AMH and previous responses to ovarian controlled stimulation. GnRH antagonist was added when at least one follicle reached 13 mm. Ovulation was induced by hCG and GnRH agonist when at least 2 follicles had a mean diameter of 17 mm.
62205719|NCT03538938|EXPERIMENTAL|1-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). No SmokefreeTXT text messaging in support of cessation will be offered proactively. The Financial Incentives for treatment engagement are for completing the counseling call.
62205720|NCT03538938|EXPERIMENTAL|1-Call, Patch+Loz, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
62205721|NCT03538938|EXPERIMENTAL|4-Call, Patch, SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination:4-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). The Financial Incentives for treatment engagement are for completing each of the four counseling calls and for staying enrolled in the SmokefreeTXT program for six weeks.
62580885|NCT01577953|PLACEBO_COMPARATOR|Placebo|The placebo (phosphate-buffered saline) is administered as a solution inhaled via a controlled breathing system over a 5 to 10 min.
62580886|NCT00324025|EXPERIMENTAL|1|Mycograb
62580887|NCT00324025|ACTIVE_COMPARATOR|2|biological
62580888|NCT03768297|EXPERIMENTAL|immediate implant with dual zone therapeutic concept|
62580889|NCT03768297|ACTIVE_COMPARATOR|immediate implant with buccal bone fill|
62580890|NCT04599153|EXPERIMENTAL|High initial|At the one month follow-up, the shunt is adjusted into a high opening pressure (2.5), which is crossed over to 1.0 at the two months follow-up. At the three months follow-up the opening pressure is set at 0.5 until the next day.
62404917|NCT03330340||Percutaneous vertebroplasty|All PVPs are performed by experienced spine surgeons under optimal fluoroscopic guidance. The procedure takes place under sterile conditions. Local anesthesia is administered to the periosteum of the targeted pedicle via skin. Polymethylmethacrylate bone cement is injected under continuous fluoroscopic guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. Patients are encouraged to stand up and walk with brace immediately after operation and the brace are required to be worn for 3 months. Furthermore, all patients will take oral bisphosphonates treatment together with supplemental calcium and vitamin D.
62580891|NCT04599153|EXPERIMENTAL|Low initial|At the one month follow-up, the shunt is adjusted into a low opening pressure (1.0), which is crossed over to 2.5 at the two months follow-up. At the three months follow-up the opening pressure is set at 0.5 until the next day.
62580892|NCT01745224|EXPERIMENTAL|Revlite Q switched Nd:YAG laser|Revlite Q switched Nd:YAG laser 1064 nm
62580893|NCT01745224|EXPERIMENTAL|TriVantage Q switched Nd:YAG laser|TriVantage Q switched Nd:YAG laser 1064nm
62788315|NCT02843841|OTHER|ATG group|"Renal transplant Patients from Nephrology department of the University Hospital of Besancon receiving induction immunosuppressive therapy of polyclonal antilymphocyte globulin (ATG-Fresenius®) as recommended.~Intervention = blood and fecal sample"
62788316|NCT02843841|OTHER|Anti-CD25 group|"PRenal transplant Patients from Nephrology department of the University Hospital of Besancon receiving induction immunosuppressive therapy of anti-CD25 monoclonal antibodies (basiliximab SIMULECT®) as recommended.~Intervention = blood and fecal sample"
62788317|NCT05992363|ACTIVE_COMPARATOR|single silicone stent|patients with malignant ureteral obstruction that was treated by single large-caliber 8-12Fr silicone stent
62788318|NCT05992363|ACTIVE_COMPARATOR|Tandem polyurethane stents|patients with malignant ureteral obstruction that was treated by tandem 6 Fr Percuflex™ stents
62205722|NCT03538938|EXPERIMENTAL|4-Call, Patch, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
62205723|NCT03538938|EXPERIMENTAL|4-Call, Patch, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. The Financial Incentives for treatment engagement are for completing each of the four counseling calls.
62016354|NCT01003249|PLACEBO_COMPARATOR|Placebo, Then Baclofen|Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. There will be a washout period after three week. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group. Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg
62016355|NCT02124590|EXPERIMENTAL|Acute Exercise|Repeated isometric leg exercises at varying intensities and a second visit with aerobic bike exercise for 30 minutes at 50% peak VO2.
62016356|NCT03120091||Enrolled Patients|A total of 20 patients were enrolled for the place of CGMS. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
62580894|NCT00555464|EXPERIMENTAL|1|Vincristine is a drug that has been used to treat cancers in children (including infants). It has been effective in treating a small number of infants with hemangiomas, most of whom failed previous therapies including steroids. Vincristine must be administered into a vein. Given the encouraging response data and documented safety record, Vincristine is a good choice for a clinical trial treating infants with complicated hemangiomas.
62580895|NCT00555464|ACTIVE_COMPARATOR|2|The standard treatment for hemangioma at most centers is oral steroids (Prednisolone). Prednisolone has been used to stop the growth of infantile hemangiomas that are life threatening, that could harm important functions, or are likely to result in severe disfigurement (scarring) without treatment.
62016357|NCT01429896|EXPERIMENTAL|Arm 1|Exercise followed by sleep restriction followed by control challenge
62205724|NCT03538938|EXPERIMENTAL|4-Call, Patch, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
62404918|NCT03330340||Conservative treatment|In conservative treatment group, the patients were required horizontal bed rest for the initial 2 weeks after diagnosis. Then, they were encouraged to stand up and walk with brace and assistance. The bed rest time was extended if the back pain worsened when they stood up and walked. The brace should be worn in 3 months. For pain medication, nonsteroidal anti-inflammatory drugs (NSAIDs) were prescribed for every patient. Additional analgesics, such as tramadol and morphine, would be added in case NSAIDs were not effective. Two weeks after diagnosis, physical therapy was started. All patients are put on osteoporosis medication, bisphosphonates together with supplemental calcium and vitamin D.
62404919|NCT02507531|EXPERIMENTAL|Treatment|Placement of study device (currently called NeXsys) into target aneurysm via standard endovascular procedure.
62404920|NCT04943523|PLACEBO_COMPARATOR|Placebo|vegetable oil 4g/day
62404921|NCT04943523|ACTIVE_COMPARATOR|Krill Oil|Krill Oil 4g/day
62404922|NCT00413322|EXPERIMENTAL|Single-arm dose escalation|
62404923|NCT04871451|EXPERIMENTAL|ABP-450 - Between Low Dose and High Dose|ABP-450 Between Low Dose and High Dose - Intramuscular injections into affected neck muscles with investigator's determined dose within the range of low dose and high dose - 4 injection cycles at 3-month intervals.
62404924|NCT04800991|EXPERIMENTAL|Rhexium Onco Nutrition(HDT-202)|"subject mobile application and Investigator web portal with no invasive action on the human body"
62404925|NCT06653543|EXPERIMENTAL|mulligan group|20 participants recieving conventional therapy in addition to mulligan mobilization with arm movement
62404926|NCT06653543|SHAM_COMPARATOR|control group|control group that revieves only the conventional therapy
62404927|NCT04706065||GROUP 1|Group 1 (patients with PD) All participants will be subjected to thorough history taking, full clinical and neurological examination. Diagnosis of PD by using Brain Bank Criteria for diagnosis of Parkinson Disease , assessment of the severity of PD by using PDRS and evaluation of cognitive functions using MMSE.
62404928|NCT04706065||Group 2|Group 2 (controls) All participants will be subjected to thorough history taking, full clinical and neurological examination.
62580896|NCT06621290||Patients over the age of 65 visiting the ED|Patients over the age of 65 visiting the ED who is capable of giving informed consent and who are planned to participate in a frailty assessment
62016358|NCT01429896|EXPERIMENTAL|Arm 2|Sleep restriction followed by exercise followed by control challenge
62404929|NCT03907111|EXPERIMENTAL|Chitosan gauze|100cm\^2 Gauze made by chitosan material. Administrate it on surgical wound after surgery directly. Change it daily with necessary wound care.
62580897|NCT05878184|EXPERIMENTAL|SC291 Plus Chemotherapy Regimen|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment with SC291
62016359|NCT01429896|EXPERIMENTAL|Arm 3|control followed by sleep restriction followed by exercise
62016360|NCT01429896|EXPERIMENTAL|Arm 4|control followed by exercise followed by sleep restriction
62016361|NCT01429896|EXPERIMENTAL|Arm 5|Sleep Restriction followed by control followed by exercise
62016362|NCT01429896|EXPERIMENTAL|Arm 6|Exercise followed by control followed by sleep restriction
62016363|NCT06626087|ACTIVE_COMPARATOR|Prototype AI algorithm|In-house prototype deep learning artificial intelligence algorithm
62016364|NCT06626087|PLACEBO_COMPARATOR|LI_RADS interpretation|LI-RADS criteria will be assessed independently by two specified abdominal radiologists with at least 10 years of experience in cross-sectional abdominal imaging
62016365|NCT06531616||Healthcare professionals working at SEHA|SEHA Healthcare employees (doctors, nurses, and allied health staff) will be approached through email to answer the study survey.
62016366|NCT04382118||OWDFO: Open Wedge Distal Femoral Varus osteotomy|
62404930|NCT03907111|PLACEBO_COMPARATOR|Traditional gauze|100cm\^2 Gauze made by traditional cotton yarn. Administrate it on surgical wound after surgery directly. Change it daily with necessary wound care.
62404931|NCT03575806|EXPERIMENTAL|TACE+Tcm group|Experimental arm: TACE plus autologous Tcm immunotherapy to treat HCC.
62404932|NCT03575806|ACTIVE_COMPARATOR|TACE group|Active comparator: TACE to treat HCC.
62404933|NCT04260594|EXPERIMENTAL|Arbidol tablets + basic treatment|
62016367|NCT04382118||CWDFO: Closed Wedge Distal Femoral Varus osteotomy|
62404934|NCT04260594|SHAM_COMPARATOR|basic treatment|
62404935|NCT01083511||Symptomatic|Individuals with signs and symptoms of a respiratory tract infection where it is suspected that such signs and symptoms are caused by a respiratory virus infection.
62016368|NCT02736162||Perampanel|Participants with a diagnosis of epilepsy who received perampanel as primary or secondary (conversion) monotherapy at any time between 1 Jan 2013 and 15 Oct 2015.
62016369|NCT05539950|EXPERIMENTAL|Cardiopulmonary rehabilitation with health education|The participants will participate in cardiopulmonary rehabilitations programs under the supervision of therapists 3 times a week, 12 weeks in total. Recommendations for individualized exercise prescription and lifestyle modification will be given to the participants as well.
62016370|NCT05539950|ACTIVE_COMPARATOR|Health education|The participants will be given recommendations for individualized exercise prescription and lifestyle modification.
62016371|NCT01458171|EXPERIMENTAL|IgPro20|
62016372|NCT04472351|EXPERIMENTAL|ASCEND-I|Computerized WM training with Rehacom will be implemented in daily 30-minute sessions that are scheduled prior to the participant's occupational therapy (OT) session as an adjunct to routine rehabilitation. Tasks are tailored to the participant's current ability level and are adaptive to performance changes. During these sessions, the study staff member will use guided questioning to help the participant anticipate challenges, reflect on performance, and link computerized exercises to the Multicontext sessions. The Multicontext treatment sessions will be delivered within the participant's OT session by an OT. The Multicontext approach helps individuals to self-discover WM-related error patterns and learn to anticipate WM performance challenges through repeated practice using functionally-relevant activities. The OT conducts guided questioning pre- and post-task to help the participant anticipate challenges and self-discover WM strategies.
62404936|NCT04780360|EXPERIMENTAL|Cayanoacrylate tissue adhesives|thin layers of high viscosity blend of n-butyl and 2-octyl cayanoacrylate tissue adhesive will be applied and rinsed with saline at least three times with interval of at least 30 seconds
62016373|NCT04472351|NO_INTERVENTION|Enhanced Usual Care|The control condition will account for the time spent with rehabilitation therapists and study staff and provide more general cognitive stimulation. The control group will receive usual, standard of care occupational therapy during OT by inpatient rehabilitation staff who are not trained in the Multicontext approach. The standard OT session often focuses on cognition in a non-standardized and non-targeted manner without the targeting of WM and guided self-discovery of the Multicontext approach. To control for the cognitive training element of ASCEND, individuals randomized to the control condition will meet with a study staff member for 30 minutes of general cognitive stimulation that includes word-searches, crossword puzzles, and/or jigsaw puzzles.
62016374|NCT01326520|EXPERIMENTAL|Phospholipid enriched dairy product|
62016375|NCT01326520|PLACEBO_COMPARATOR|dairy product|
62016376|NCT03054909|EXPERIMENTAL|Arm 1: ALT-803 subcutaneous only|
62016377|NCT03054909|EXPERIMENTAL|Arm 2: ALT-803 intraperitoneal and subcutaneous|
62016378|NCT04401124||patients treated at surgical emergency rooms|
62404937|NCT04780360|ACTIVE_COMPARATOR|Silk suture material|interrupted knots
62404938|NCT05123066|EXPERIMENTAL|Aquatic group|group I
62404939|NCT05123066|EXPERIMENTAL|Land Exersises group|group II
62404940|NCT01863108|EXPERIMENTAL|GeniusVac-Mel4|Sub-cutaneous injections of GeniusVac-Mel4 in patients with melanoma.
62580898|NCT06520592|EXPERIMENTAL|With AR guided CPAP therapy|OSA patientns were assigned to experimental group, they will be received AR guided CPAP therapy
62580899|NCT06520592|NO_INTERVENTION|Standard of care|OSA patientns were assigned to stand of care group, they will be not received AR guided CPAP therapy
62580900|NCT01598571|EXPERIMENTAL|Fostamatinib 50 mg tablet|
62580901|NCT01598571|EXPERIMENTAL|Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose|
62205725|NCT03538938|EXPERIMENTAL|4-Call, Patch+Loz, SmokefreeTXT, Financial Incentive|Participants will receive: 4-Call Quitline Counseling, 4 weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each counseling call will last approximately 20 min. Patch treatment will consist of a 4 week supply of over-the-counter (OTC) nicotine patches (21 mg for if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a 4 week supply of OTC nicotine lozenges (2-mg dose for those who do not smoke within 30 min of waking; 4-mg dose for those who smoke within 30 min of waking). SmokefreeTXT in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day \[TQD\] and for 6 weeks following the TQD). Financial Incentives are for completing each of the 4 counseling calls and for staying enrolled in SmokefreeTXT for 6 weeks.
62205726|NCT03538938|EXPERIMENTAL|4-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Patch treatment will consist of a 4-week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a 4-week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day and for 6 weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
62580902|NCT00930774|EXPERIMENTAL|FM System|Provision of FM assistive device
62205727|NCT03538938|EXPERIMENTAL|4-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenge, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will not be offered proactively. The Financial Incentives for treatment engagement are for completing each of the four counseling calls.
62580903|NCT00930774|EXPERIMENTAL|Auditory Training|Provision of auditory training
62580904|NCT00930774|EXPERIMENTAL|FM System and Auditory Training|Provision of FM assistive device and auditory training
62580905|NCT00930774|NO_INTERVENTION|Standard-of-Care|Standard-of-care informational counseling
62580906|NCT06152874|ACTIVE_COMPARATOR|glucose solution 1|glucose solution prepared dissolving 55 g of monohydrate glucose powder in 250 mL of water
62580907|NCT06152874|ACTIVE_COMPARATOR|glucose solution 2|glucose solution prepared dissolving 55 g of monohydrate glucose powder in 250 mL of water
62580908|NCT06152874|EXPERIMENTAL|BREAD A|bread made with 95% durum wheat fine semolina (\< 400 micrometer)+ 5% of gluten+ 1.2% of yeast + 1% of salt + 59% of water (portion corresponding to 50 g available carbohydrates) +250 mL water
62580909|NCT06152874|EXPERIMENTAL|BREAD B|bread made with 80% durum wheat fine semolina (\< 400 micrometer)+ 20% of gluten+ 1.2% of yeast + 1% of salt + 59% of water (portion corresponding to 50 g available carbohydrates) +250 mL water
62580910|NCT06152874|EXPERIMENTAL|BREAD C|bread made with 80% durum wheat coarse semolina (\> 500 micrometer)+ 20% of gluten+ 1.2% of yeast + 1% of salt + 59% of water) (portion corresponding to 50 g available carbohydrates) +250 mL water
62580911|NCT05481541|EXPERIMENTAL|written education group|Experimental: The Effect of E-Mobile and Written Education on Quality of Life and Sleep in Patients with Transurethral Prostate Resection According to the randomization, preoperative training will be applied to the patients in the e-mobile training/written training group. The training will be administered by the principal researcher using the face-to-face interview technique.
62580912|NCT05481541|ACTIVE_COMPARATOR|Mobile education application group|Experimental: The Effect of E-Mobile and Written Education on Quality of Life and Sleep in Patients with Transurethral Prostate Resection According to the randomization, preoperative written/mobile education will be applied to the patients in the e-mobile education/written education group. The training will be given by the principal researcher using the face-to-face interview technique.
62580913|NCT05481541|NO_INTERVENTION|Control (standard care) group|Experimental: The Effect of E-Mobile and Written Education on Quality of Life and Sleep in Patients with Transurethral Prostate Resection Routine post-operative care will be given to the control group without any intervention and data collection tools will be applied at the same time as the experimental group, twice at 30-minute intervals.
62580914|NCT02888912|ACTIVE_COMPARATOR|EQUIA|randomly applied
62580915|NCT02888912|ACTIVE_COMPARATOR|Gradia Direct Posterior|randomly applied
62580916|NCT01398618|EXPERIMENTAL|4M-RMP|adult household contacts with latent tuberculosis infection receiving 4-month rifampicin preventive therapy
62580917|NCT01398618|ACTIVE_COMPARATOR|9M-INH|adult household contact with latent tuberculosis infection receiving 9-month isoniazid preventive therapy
62580918|NCT04731012||healthy oocyte-donation pregnancy|healthy pregnancy
62580919|NCT04731012||preeclamptic oocyte-donation pregnancy|preeclampsia
62580920|NCT04731012||healthy IVF or ICSI pregnancy|healthy pregnancy
62580921|NCT04731012||preeclamptic IVF or ICSI pregnancy|preeclampsia
62580922|NCT04731012||healthy spontaneous conception pregnancy|healthy pregnancy
62580923|NCT04731012||preeclamptic spontaneous conception pregnancy|preeclampsia
62580924|NCT01880684||Passive Leg Rising|
62205728|NCT03538938|EXPERIMENTAL|4-Call, Patch+Loz, No SmokefreeTXT,No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
62205729|NCT01484600|EXPERIMENTAL|Group 1|
62205730|NCT01484600|EXPERIMENTAL|Group 2|
62205731|NCT06256328|EXPERIMENTAL|ONO-4578+Nivolumab+chemotherapy|
62205732|NCT06256328|PLACEBO_COMPARATOR|placebo+Nivolumab+chemotherapy|
62205733|NCT04431895|EXPERIMENTAL|tofacitinib 5mg twice a day|
62205734|NCT02449551|EXPERIMENTAL|Volitinib|Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
62205735|NCT05833477|EXPERIMENTAL|Treatment group|Recombinant human erythropoietin treatment three times per week for three weeks
62205736|NCT02687438|EXPERIMENTAL|Treatment|Steroid-releasing sinus implant placement following ethmoidectomy in addition to post-op standard of care (i.e. debridement, irrigation, and topical steroids)
62205737|NCT06688799|EXPERIMENTAL|Experimental : CD19 CAR|Following the lymphodepleting treatment, patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
62205738|NCT03881982|EXPERIMENTAL|PIMPERNEL Novel Electronic Log - intervention|"The display is an electronic version of the 11 point NRS. An audible 'beep' every 15 minutes prompts the patient to record their pain level.~The display measures 122mm x 30mm x 15mm. Through a wireless connection, the data from the display are transmitted to a display unit (a Nexus tablet)."
62734922|NCT00456755|ACTIVE_COMPARATOR|Shi-Bi-Lin|Consist of 6 herbal. 7.5 g Xanthium sibiricum Patrin ex Widder (Asteraceae, Fructus), 20 g Angelica dahurica (Fisch. ex Hoffm.) Benth. (Apiaceae, Radix), 7.5 g Saposhnikovia divaricata (Turcz.) Schischk. (Apiaceae, Radix),15 g Magnolia biondii Pamp., (Magnoliaceae, Flos), 5 g Gentiana scabra Bunge (Gentianaceae, Radix) and 5 g Verbena officinalis L. (Verbenaceae, Herba).
62205739|NCT03881982|OTHER|PIMPERNEL Novel Electronic Log - control|"The display is an electronic version of the 11 point NRS. An audible 'beep' every 15 minutes prompts the patient to record their pain level.~The display measures 122mm x 30mm x 15mm. Through a wireless connection, the data from the display are transmitted to a display unit (a Nexus tablet)."
62016379|NCT04401124||patients receiving surgeries (both elected and emergency)|
62016380|NCT05751135|EXPERIMENTAL|Focal muscle vibration group 1|Focal muscle vibration with frequency of 80 Hz will be provided 3 days along with stretching, strengthening and positioning for 8 weeks
62016381|NCT05751135|EXPERIMENTAL|Focal muscle vibration group 2|Focal muscle vibration with frequency of 100 Hz will be provided 3 days a week along with stretching, strengthening and positioning for 8 weeks.
62016382|NCT05751135|ACTIVE_COMPARATOR|Control group|Stretching, strengthening and positioning in 3 sessions a week for 8 weeks
62205740|NCT00743977|ACTIVE_COMPARATOR|A|
62205741|NCT00743977|EXPERIMENTAL|B|
62205742|NCT00685984||1|
62205743|NCT00685984||2|
62205744|NCT00685984||3|
62205745|NCT05155215|EXPERIMENTAL|IM19 CAR-T cells|
62205746|NCT06043830|EXPERIMENTAL|Placebo followed by acetazolamide|"Subjects will start with a 1-week PLACEBO regimen Day 1-7: Placebo (matching Acetazolamide) nightly~After a 2 week wash-out period, subjects will then cross-over to a 1-week ACETAZOLAMIDE regimen:~Day 1-7: Acetazolamide 500 mg nightly"
62205747|NCT06043830|EXPERIMENTAL|Acetazolamide followed by placebo|"Subjects will start with a 1-week ACETAZOLAMIDE regimen Day 1-7: Acetazolamide 500 mg nightly~After a 2 week wash-out period, subjects will then cross-over to a 1-week PLACEBO regimen:~Day 1-7: Placebo (matching Acetazolamide) nightly"
62205748|NCT00762775|EXPERIMENTAL|1|Calcium supplementation and placebo
62016383|NCT03492307|ACTIVE_COMPARATOR|Standard Flow Protocol|Patients randomized to this arm will receive HFNC according to our current protocol with a maximum of 8L/min.
62016384|NCT03492307|EXPERIMENTAL|Weight-Based Flow Protocol|Patients randomized to this arm will receive HFNC according to a weight-based algorithm at 2L/kg/min.
62016385|NCT06531668|EXPERIMENTAL|Beyond Hormone Supplement|Participants in this arm will receive the Beyond Hormone supplement.
62016386|NCT06531668|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive a placebo consisting of rice flour encapsulated in a vegetable cellulose capsule.
62205749|NCT00762775|EXPERIMENTAL|2|Vitamin D supplementation and placebo
62205750|NCT00762775|EXPERIMENTAL|3|Calcium and Vitamin D supplementation
62205751|NCT00762775|PLACEBO_COMPARATOR|4|Placebos only
62205752|NCT06214741|EXPERIMENTAL|survodutide 3.6 mg|
62205753|NCT06214741|EXPERIMENTAL|survodutide 4.8 mg|
62734923|NCT00456755|PLACEBO_COMPARATOR|Placebo|The placebo contained brown colored starch resembling the SBL powder
62734924|NCT04307368|EXPERIMENTAL|FODMAP diet|Patients with IBS. Interventions: 8 weeks of diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)
62205754|NCT06214741|PLACEBO_COMPARATOR|Placebo|
62205755|NCT00992043|PLACEBO_COMPARATOR|exercise and placebo|
62205756|NCT00992043|EXPERIMENTAL|exercise and creatine|
62205757|NCT00342147||1|This is a high risk population of families for NPC
62404941|NCT02840019|EXPERIMENTAL|60 minute research full MRI scan|"Pregnant women who are able to have an MRI are eligible for the 60 minute research full MRI scan. Pregnant women may have a healthy pregnancy, a concern for fetal/placental abnormalities with a clinical fetal MRI ordered by their doctor, or a concern for fetal/placental abnormalities without a clinical fetal MRI ordered by their doctor.~The investigational MRI coil designed for pregnant women and research MRI sequences will be tested during the 60 minute research scan."
62404942|NCT02840019|EXPERIMENTAL|15 minute research add-on MRI scan|"Pregnant women with a concern for fetal/placental abnormalities with a clinical fetal MRI at Boston Children's Hospital are eligible for the 15 minute research add-on MRI scan.~The research MRI sequences will also be tested during the add-on research MRI scan."
62404943|NCT04485871|EXPERIMENTAL|Omega-3 fatty acids|3.6 g EPA:DHA / day (2:1)
62404944|NCT04717323|EXPERIMENTAL|Patients|Gait with and without pelvic assistance
62404945|NCT04717323|EXPERIMENTAL|Controls|Gait with no pelvic assistance
62580925|NCT05870046|EXPERIMENTAL|power exercise group|"The main part of the muscle power exercise program will have the following exercises: wall push-ups, arm raises, elbow push-ups and extensions, weighted pronosupination, hand press, knee and hip hinge squat, dead weight, front and sagittal plan stride, and heel raises.~It will have different phases:~* 1st phase: exercise adaptation: the correct execution of upper and lower limb exercises will be taught for one month.~* 2nd phase: Resistance training: During the following two months, strength exercises will be performed at slow and normal speed of the movement patterns learned in the training course.~* 3rd phase: Muscle power training: During the last five months. A correct progression of the load and a progressive increase in the speed of execution of the different exercises will be carried out, gradually increasing the levels of difficulty and intensity."
62580926|NCT05870046|ACTIVE_COMPARATOR|multimodal exercise group|"The main part of the multicomponent exercise program integrates different exercise modalities: Aerobic, mobility, strength, balance and coordination exercises, playful activities or games are also included with some activities aimed at working on cognitive functions to reinforce the overall effects of the program, such as games with colors, numbers, letters, right-left laterality, memory, etc.~The progression of the different models is as follows:~* E. Aerobic: Start with continuous work, then intervallic, and decrease rest times in intervallic work.~* E. Strength: Increase sets, repetitions and decrease rest time.~* Balance: start with static and evolve with blindfolds, perturbations, dynamic balance, etc.~* Coordination, and cognitive games will also become more complicated, with more complicated and faster decision making."
62205758|NCT03525067||Patients with Bile Samples|Patients underwent pancreaticoduodenectomy who had intraoperative bile sampling for bacterial examination.
62205759|NCT03857997||Patients|
62205760|NCT03857997||Parents|
62205761|NCT02655926|ACTIVE_COMPARATOR|STN Arm|Participants would only have STN deep brain stimulation switched at optimal settings for that participant on for 12 weeks.
62205762|NCT02655926|ACTIVE_COMPARATOR|VC/VS Arm|Participants would only have VC/VS deep brain stimulation switched on at optimal settings for that participant for 12 weeks.
62205763|NCT05031715|EXPERIMENTAL|Dietary supplement|Berberine Phytosome
62205764|NCT01791075|ACTIVE_COMPARATOR|Tan Endoglide|Patients assigned to this arm will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide.
62205765|NCT01791075|ACTIVE_COMPARATOR|Endosaver/serter|Patients assigned to this arm will have their endothelial donor graft injected into the anterior chamber using the Endosaver/serter injector.
62404946|NCT02558634|EXPERIMENTAL|DBS-on|"Ventral intermediate Nucleus (VIM) Thalamic DBS on~DBS system includes:~* Implantable Pulse Generator (IPG)~* DBS Lead~* DBS Lead Extension Kit"
62404947|NCT02558634|SHAM_COMPARATOR|DBS-off (sham-stimulation)|"Ventral intermediate Nucleus (VIM) Thalamic DBS off~DBS system includes:~* Implantable Pulse Generator (IPG)~* DBS Lead~* DBS Lead Extension Kit"
62404948|NCT00774774|PLACEBO_COMPARATOR|2|No intervention
62404949|NCT00774774|EXPERIMENTAL|1|Mask
62205766|NCT02299414|EXPERIMENTAL|Anti-hypertensive therapy to goal <140/90 mmHg|Labetalol or Nifedipine ER will be used as first-line to achieve goal; if necessary Nifedipine ER or Labetalol will be second-line antihypertensive. Rarely, other antihypertensive medications may also be used
62205767|NCT02299414|ACTIVE_COMPARATOR|No anti-hypertensive unless BP is severe (≥160/105 mmHg|Antihypertensive therapy given only if BP becomes severe (defined as BP ≥160/105). The lowest dose of anti-hypertensive needed to keep blood pressure below this threshold will be given (1st-line - Labetalol or Nifedipine ER and 2nd-line - Labetalol or Nifedipine ER). Rarely other medications may be used
62205768|NCT04355377||Patients|
62205769|NCT00683683|OTHER|Cooling|Cardiac arrest patients will be cooled to 32-34°C within 6 hours of ED arrival
62205770|NCT05926440|EXPERIMENTAL|SCB-2023 arm|Participants will receive one booster dose with SCB-2023 vaccine on Day 1
62205771|NCT05926440|ACTIVE_COMPARATOR|SCB-2019 arm|Participants will receive one booster dose with SCB-2019 vaccine on Day 1
62205772|NCT01520805|EXPERIMENTAL|CPI-613|CPI-613 will be intravenously infused over 2 hours, given twice weekly for 3 weeks followed by a week of rest.
62205773|NCT03507426|ACTIVE_COMPARATOR|Retrobulbar group|Retrobulbar block
62205774|NCT03507426|ACTIVE_COMPARATOR|Ketamine group|Intravenous analgesia
62205775|NCT03507426|NO_INTERVENTION|Control group|General anesthesia alone
62404950|NCT03545568|OTHER|Experimental: sialic acid|
62404951|NCT02027766|EXPERIMENTAL|Stretching|Daily stretching of the calf (dominant side; defined as leg used to kick a ball). 2 stretching exercises are performed daily: 1) stretching of the soleus muscle; 2) stretching of the gastrocnemius muscle.
62404952|NCT02027766|NO_INTERVENTION|Control|
62404953|NCT04186637|EXPERIMENTAL|Dose escalation and expansion|ALPN-202
62404954|NCT04490772||Patients with Covid-19|COVID-19 patients presented with gastrointestinal manifestations
62404955|NCT04124302|ACTIVE_COMPARATOR|IPF|Total meal bolus will consist of insulin for carbohydrates (IC) and insulin for proteins and fats (IPF) based on individual insulin-to-carbohydrate ratio (ICR). Dual bolus will be given 15 minutes before the mixed meal (toast with cheese).
62580927|NCT05870046|NO_INTERVENTION|Control group|Participants in this group should continue with their usual dietary pattern and level of physical activity, without changing their lifestyle habits during the study period. They will not participate in the strength exercise program based on muscle power, nor will they perform systematic, programmed and supervised physical exercise in any other program.
62205776|NCT03140839|EXPERIMENTAL|Imaginal Rescripting|"Imaginal Rescripting (IR) targets imagery-based mental representations embedded within patients negative autobiographical memories related to social anxiety. In IR, patients progress through 3 distinct phases: (1) They relive a past negative event in their imagination, (2) are guided to actively change the original memory in their imagination to create more satisfying outcomes, and (3) relive the memory again while incorporating the new information. The IR intervention will be administered in one 90 minute session."
62205777|NCT03140839|ACTIVE_COMPARATOR|Imaginal Exposure|"Imaginal Exposure (IE) involves repeatedly reliving a negative autobiographical memory related to social anxiety from a first-person perspective and actively considering alternative meanings of the memory, but differs from IR in that the original memory itself is never explicitly modified in any way. The IE intervention will be administered in one 90 minute session."
62205778|NCT03140839|PLACEBO_COMPARATOR|Supportive Counselling|Supportive counselling (SC) provides patients with empathic support regarding a negative autobiographical memory related to social anxiety. The SC condition controls for non-specific clinical factors such as therapeutic attention and alliance. SC will be administered in one 60-90 minute session.
62205779|NCT03585010|EXPERIMENTAL|Supportive Parenting for Anxious Childhood Emotions|Parent-based treatment for childhood anxiety disorders
62205780|NCT03585010|ACTIVE_COMPARATOR|Parent Educational Support or CBT|Parent-based intervention for childhood anxiety disorders (phase 1) or child based treatment for childhood anxiety disorders (phase 2)
62205781|NCT05019404|EXPERIMENTAL|Functional anterior temporal lobectomy (FATL)|FATL via minicraniotomy is a new surgical approach, consisting of amygdalohippocampectomy and the lateral temporal lobotomy.
62404956|NCT04124302|EXPERIMENTAL|30%IC|Total meal bolus will consist of insulin for carbohydrates (IC) calculated based on individual insulin-to-carbohydrate ratio (ICR) and insulin for proteins and fats (IPF) estimated as 30% of IC. Dual bolus will be given 15 minutes before the mixed meal (toast with cheese).
62404957|NCT05841862|EXPERIMENTAL|2C-QD|Single-dose intravitreal injection
62404958|NCT05841862|SHAM_COMPARATOR|Sham 2C-QD|Single-dose intravitreal injection
62404959|NCT05649709|EXPERIMENTAL|vonoprazan and low-dose amoxicillin dual therapy|1000 mg amoxicillin capsules twice daily and 20 mg vonoprazan Fumarate Tablets twice daily for 14 days
62404960|NCT05649709|ACTIVE_COMPARATOR|vonoprazan and high-dose amoxicillin dual therapy|1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
62404961|NCT02822729|EXPERIMENTAL|DE-117 ophthalmic solution (Group1)|Monotherapy
62404962|NCT02822729|EXPERIMENTAL|DE-117 ophthalmic solution (Group2)|Monotherapy
62404963|NCT02822729|OTHER|DE-117 ophthalmic solution + Timolol (Group3)|Concomitant Use
62205782|NCT05019404|ACTIVE_COMPARATOR|Anterior temporal lobectomy (ATL)|ATL via large frontotemporal craniotomy is a conventional surgical approach, consisting of amygdalohippocampectomy and en bloc resection of the lateral temporal lobe.
62404964|NCT01786642||conscious|bronchoscopy without sedative drugs
62404965|NCT01786642||conscious sedation|bronchoscopy under midazolam
62404966|NCT05804695|EXPERIMENTAL|Arthroscopic Temporo-mandibular joint disc repositioning under General anathesia|
62205783|NCT00604825|PLACEBO_COMPARATOR|Placebo|Placebo
62205784|NCT00604825|ACTIVE_COMPARATOR|GSK232802|GSK232802
62404967|NCT03961932|EXPERIMENTAL|Normal Renal Function|Healthy participants with Normal Renal Function (estimated Glomerular Filtration Rate (eGFR) ≥ 90 mL/min/1.73m\^2)
62205785|NCT00604825|EXPERIMENTAL|PREMARIN|PREMARIN
62404968|NCT03961932|EXPERIMENTAL|Mild Renal Impairment|Presence of Mild Renal Impairment (eGFR 60-89 mL/min/1.73m\^2)
62404969|NCT03961932|EXPERIMENTAL|Moderate Renal Impairment|Presence of Moderate Renal Impairment (eGFR 30-59 mL/min/1.73m\^2)
62404970|NCT03961932|EXPERIMENTAL|Severe Renal Impairment|Presence of Severe Renal Impairment (eGFR ≤ 29 mL/min/1.73m\^2), not on hemodialysis
62404971|NCT03961932|EXPERIMENTAL|End-Stage Renal Disease|Presence of End-Stage Renal Disease (ESRD) requiring hemodialysis
62404972|NCT01716442|ACTIVE_COMPARATOR|steroid-resistant|Steroid-resistant group: n=27 , enroll all for treatment
62404973|NCT01716442|ACTIVE_COMPARATOR|steroid-dependent-rituximab|steroid-responsive group: n=38
62404974|NCT01716442|PLACEBO_COMPARATOR|steroid-dependent-placebo|steroid-responsive group: n=23
62404975|NCT03126201||Study Group|Patients with biopsy-proven primary focal segmental glomerulosclerosis.
62404976|NCT03542864|EXPERIMENTAL|Nasogastroduodenal Protocol|Evaluation of a protocol for the treatment of excess body fat through duodenal nutrition
62404977|NCT03542864|ACTIVE_COMPARATOR|Controls|Change from Baseline Body Composition values at 1 and 3 months
62404978|NCT03542864|OTHER|Data analysis|Analysis and publication of data
62404979|NCT05737394|EXPERIMENTAL|Laparoscopy-guided TAP Block|Patients will receive surgically-placed TAP block right after pneumoperitoneum induction and before Trocar insertion with levobupivacaine 0.25%, 0.5 ml/kg.
62788319|NCT04872543|EXPERIMENTAL|ASTX727 (cedazuridine and decitabine)|Patients who meet the eligibility criteria will be treated with oral ASTX727 (INQOVI) on days 1-5 of each 21-day cycle with Pegfilgrastim support on day 7. A delay in the start of subsequent cycles due to holidays, weather, or other circumstances will be permitted up to 7 days and not considered a protocol deviation. Drug dosing will be interrupted for any Grade 4 adverse events or clinically significant laboratory abnormalities. For Grade 3 or 4 AE, if the AE returns to Grade 1 or baseline, the patient may be re-escalated.
62788320|NCT02586727|ACTIVE_COMPARATOR|six week dosing regimen arm|Patients will receive an intravitreal aflibercept injection the first visit, and then again every six weeks. Treatment will be given at each visit.
62016387|NCT02403310|EXPERIMENTAL|Dose Escalation - Selinexor|"Dose escalation of selinexor with fixed doses of daunorubicin and cytarabine.~Induction Therapy may be followed by Consolidation Phase and Maintenance Phase as outlined in the Detailed Description and Intervention Descriptions."
62205786|NCT03724331|EXPERIMENTAL|Light Physical Activity 1|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light (mild) physical activity program that begins approximately within one week after discharge from the hospital with the physical activity program starting approximately within the first week post-discharge from the hospital.
62205787|NCT03724331|EXPERIMENTAL|Light Physical Activity 2|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light (mild) physical activity program that begins approximately within one week after discharge from the hospital with the physical activity program starting approximately 7 weeks post-discharge from the hospital.
62205788|NCT03724331|ACTIVE_COMPARATOR|Support Education Activity|Conventional treatment for cancer as prescribed by the participant's health care providers and will participate in a supportive cancer-related education activity each week for 6-weeks after returning home from the hospital.
62404980|NCT05737394|ACTIVE_COMPARATOR|Ultrasound-guided TAP Block|Patients will receive ultrasound-guided TAP block performed after anesthetic induction and before surgical incision with levobupivacaine 0.25%, 0.5 ml/kg.
62404981|NCT01334502|EXPERIMENTAL|everolimus and RCHOP|Patients registered to the study will receive an assigned dose of everolimus by mouth and RCHOP for a maximum of six cycles. Each cycle is a total of 21 days. RCHOP consists of 375 mg/m2 IV rituximab, 750 mg/m2 IV cyclophosphamide, 50 mg/m2 IV doxorubicin, 1.4 mg/m2 IV vincristine and 100 mg/m2 by mouth QD prednisone. The study includes a Phase I component to determine the maximum tolerated dose of everolimus and the second component determines the feasibility of therapy administered to lymphoma patients.
62404982|NCT04437732|OTHER|Apioc Lens|All subjects will wear either the Apioc-P or Apioc-PT contact lens design
62404983|NCT04749901|OTHER|Patients with epilepsy|
62580928|NCT00459290|EXPERIMENTAL|Mifepristone 200 mg PO daily|Mifepristone 200 mg PO daily administered on a continuous basis (every 4 weeks is considered one cycle) until disease progression or adverse effects prohibit further therapy.
62788321|NCT02586727|ACTIVE_COMPARATOR|treat and extend dosing regimen arm|Patients will receive an intravitreal aflibercept injection the first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward. Patients with decreased radiation maculopathy by one grade or more will extend re-evaluation by two weeks. Patients with increased radiation maculopathy by one grade or more will have re-evaluation decreased by one week. Patients that show no maculopathy grade change will remain at the same re-evaluation interval.
62788322|NCT03962075|OTHER|laparoscopic paravaginal repair|"patient enrolled in this arm were offered laparoscopic paravaginal repair by Using a 10mm laparoscope, video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal technique All cases received diclofenac potassium 100 mg and meperidine hydrochloride 50 mg intramuscular with anesthesia recovery and 12 hours later second dose of diclofenac potassium was given. Also 40-60 mg Enoxaparin was given 6-12 hours postoperatively as subcutaneous injection.~Foley's catheter was removed 6 hours postoperative"
62016388|NCT02082301||Gestational diabetes|Primary cohort is women with diagnosis of gestational diabetes without evidence of overt diabetes
62016389|NCT01478789|EXPERIMENTAL|Water dispersible Plant Sterol (WD-PS)|WD-PS dairy product (a novel formulation for dispersible free sterols in aqueous media produced)2g/d of free plant sterol
62205789|NCT01164618|EXPERIMENTAL|Group 1|The subjects in this arm will begin on the daily remote ischemic preconditioning (RIPC) protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily exercise.
62404984|NCT04749901|OTHER|Patients with PTSD|
62404985|NCT04749901|OTHER|Patients with type 1 diabetes|
62404986|NCT04749901|OTHER|Patients with a heart rhythm disorder|
62404987|NCT04689126|EXPERIMENTAL|intervention|diagnosis and treatment plan before and after cone beam computed tomography scan
62404988|NCT01541644|EXPERIMENTAL|Acupuncture|All participants will receive acupuncture treatments over a total of 10 weeks.
62404989|NCT05473234|EXPERIMENTAL|Azithromycin|Children in this arm will receive one dose of amoxicillin.
62205790|NCT01164618|EXPERIMENTAL|Group 2|The subjects in this arm will begin on the exercise protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily remote ischemic preconditioning (RIPC).
62205791|NCT04398823|ACTIVE_COMPARATOR|Foam sclerotherapy,FS|Participants in this arm will receive the enteroscopic treatment with the sclerosing foam of lauromacrogol.
62205792|NCT04398823|PLACEBO_COMPARATOR|Liquid sclerotherapy,Ls|Participants in this arm will receive the enteroscopic treatment with the liquid of lauromacrogol.
62404990|NCT05473234|ACTIVE_COMPARATOR|Amoxicillin|Children in this arm will receive a 5-day course of amoxicillin (standard care).
62404991|NCT05945368|EXPERIMENTAL|Eribulin+Trastuzumab + Pertuzumab|"* Eribulin mesylate, 1.4 mg/m², days 1 and 8;~* trastuzumab, 8 mg/kg loading dose in cycle 1 and 6 mg/kg thereafter on day 1;~* pertuzumab with a loading dose of 840 mg in cycle 1 and 420 mg in subsequent cycles on day 1; 21 days in a cycle of 4 cycles"
62404992|NCT04125082|OTHER|Type 2 Diabetics|"Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks. Participants will attend study visits at Day 0, Weeks 1, 2, 3, 4, 8, 12 and 16, where insulin titration may be performed based on CGM readings. Participants will receive instruction in carbohydrate counting and corrective insulin dose adjustments.~Participants will wear CMG throughout the study.~At final study visit, CGM system will be collected. A1c, FEV1 and Quality of Life Questionnaires will be collected. Pregnancy test will be collected for all females of child-bearing potential. Participants will be transitioned back to Multiple Daily Injections plus basal or may choose to continue on commercial Afrezza® inhaled insulin plus basal"
62404993|NCT01831297||syncope|
62404994|NCT05443776|EXPERIMENTAL|Study group biomaterial 1|
62404995|NCT05443776|EXPERIMENTAL|Study group biomaterial 2|
62016390|NCT01478789|EXPERIMENTAL|Esterified plant sterol (PS-Ester)|PS-Ester enriched dairy product (2g/d free plant sterol)
62205793|NCT02753517|OTHER|Extended hepatectomy|Hepatic Scintigraphy
62205794|NCT00696943|EXPERIMENTAL|18F-ML-10,|Pre-treatment baseline and post treatment follow-up 18F ML-10 PET/CT sessions.
62205795|NCT00702962|EXPERIMENTAL|Phase I: Vorinostat 200 mg|"Vorinostat 200 mg PO QD D1-14; Administer with Carbo 6 (AUC) D3; Etoposide 100 mg/m2 D1,2,3 Vorinostat, Carboplatin, Etoposide"
62205796|NCT01368029|EXPERIMENTAL|LGG|Lactobacillus rhamnosus GG (LGG) containing 1x10\^10 LGG per capsule will be given to volunteers with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day on an outpatient basis.
62205797|NCT01368029|PLACEBO_COMPARATOR|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis.
62205798|NCT01997905|EXPERIMENTAL|AtriClip LAA Exclusion Device|AtriClip delivered via minimally invasive surgical procedure
62205799|NCT04314635|ACTIVE_COMPARATOR|TAU comparison group|TAU includes standard care modules (psychoeducation, coping, safety planning, problem solving, healthy lifestyle) administered to the teen while they are hospitalized on the inpatient unit. All teens, as part of TAU, also receive skills groups, individual treatment, and family planning meetings. All TAU families will receive a referral to an outpatient provider (standard care procedure) plus referral to specialized CHR case management services.
62205800|NCT04314635|EXPERIMENTAL|Brief intervention group|TAU + experimental intervention. The experimental group will receive all services provided to the TAU group (described above) and, additionally, the experimental intervention.The intervention includes 1 individual session for each teen and parent and 2 family sessions (focused on psychoeducation and motivational enhancement) with both the teen and parent, delivered during hospitalization (\~45-60 minutes per session).
62205801|NCT04263753|EXPERIMENTAL|conservative surgery for bladder in placenta accretta|
62205802|NCT02713061|EXPERIMENTAL|TAK-850 0.5 mL|TAK-850 0.5 mL (15 µg of hemagglutinin \[HA\] antigen per strain), subcutaneous injection, once on Day 1.
62404996|NCT05443776|EXPERIMENTAL|Study group biomaterial 3|
62404997|NCT05443776|EXPERIMENTAL|Study group biomaterial 4|
62580929|NCT03219840|EXPERIMENTAL|CPC + Xylitol chewing gum, then Xylitol only chewing gum|Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum and then Xylitol only chewing gum All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated. Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum will be used for the first 21 days, then there will be a washout period of 21 days, and finally Xylitol only chewing gum will be used for the last 21 days.
62788323|NCT06148883|ACTIVE_COMPARATOR|Electrocardiogram Ambulatory Monitoring for 1 month and immediate discharge|In this group, Pacemaker implantation will be decided, after discharge, on documented Electrocardiogram abnormalities obtained from the 1 month Electrocardiogram Ambulatory Monitoring.
62205803|NCT02912390|ACTIVE_COMPARATOR|Cerclage|- Macdonald cerclage placed in standard fashion
62205804|NCT02912390|ACTIVE_COMPARATOR|Expectant management|- Patient is placed on activity restrictions
62404998|NCT05443776|EXPERIMENTAL|Study group biomaterial 5|
62404999|NCT05443776|EXPERIMENTAL|Study group biomaterial 6|
62788324|NCT06148883|EXPERIMENTAL|Electrocardiogram Ambulatory Monitoring for infra-hisian conduction evaluation|In this group, Pacemaker implantation will be decided, before discharge, in case of prolonged His-Ventricular interval ≥ 70 ms.
62205805|NCT03670095|EXPERIMENTAL|Lactose-free memantine tablet|(treatment A - test) - 10 mg; orally as a single dose in fed and fasted state
62580930|NCT03219840|EXPERIMENTAL|Xylitol only chewing gum, then CPC + Xylitol chewing gum|Xylitol only chewing gum and then Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated. Xylitol only chewing gum will be used for the first 21 days, then there will be a washout period of 21 days, and finally Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum will be used for the last 21 days.
62580931|NCT04538053|ACTIVE_COMPARATOR|Intervention|Children will receive high-dose oral cefalexin 37.5 mg/kg/dose (max 1.5 g) QID 1 to 7 days followed by oral cefalexin 45 mg/kg/dose (max 1.5 g) TDS for a total course of 3 weeks
62788325|NCT04057846|ACTIVE_COMPARATOR|Double pigtail|Plastic stent group EUS-guided drainage shall be performed as follows: a) Puncture of WON with a 19 GA Access needle (Cook Medical), b) aspiration of fluid in WON for microbiological assessment, c) insertion of guidewire (0.035 inch, 450 cm, Dreamwire (Boston Scientific), d) creation of transmural tract with needle knife over the guidewire, e) dilatation of tract to a diameter of 15 mm with dilation balloon (EZDilate, Olympus), f) insertion of two 7-Fr/6 cm double pigtail stents and a 7-Fr naso-cystic irrigation catheter.
62788326|NCT04057846|EXPERIMENTAL|Lumen apposing metal stent|LAMS shall be the Hot AXIOS stent with electrocautery-enhanced delivery system (Boston Scientific). The stent is a through-the-scope, fully covered, self-expandable metal stents with a diameter of 20 mm and a length of 10 mm. Before placement of the LAMS, the WON shall be punctured with a 19 GA Access needle (Cook Medical) and fluid in WON aspirated for microbiological assessment. Thereafter the LAMS shall be placed as follows: After directly puncturing the WON using the electrocautery tip (without the use of a guidewire to assist in stent insertion), the delivery catheter is advanced into the WON and the distal flange is deployed under EUS-guidance. The proximal flange is then released under EUS guidance or endoscopic view. After placement of the LAMS, a 7-Fr/4cm double pigtail and a 7-Fr nasocystic irrigation catheter shall be placed through the LAMS.
62788327|NCT03369249|EXPERIMENTAL|Link2CARE|This arm is comprised of participants randomized to the 4-session Link2CARE intervention.
62788328|NCT03369249|NO_INTERVENTION|Standard of Care|This arm is comprised of participants who will not receive the 4-session Link2CARE intervention.
62788329|NCT05036317|EXPERIMENTAL|Empagliflozin|Standard dose of empagliflozin (Jardiance®; Boehringer Ingelheim GmbH), i. e. 10 mg. Empagliflozin is an orally available inhibitor of SGLT2 and approved for the treatment of type 2 diabetes mellitus and will be given per os once daily in the morning for 28 days.
62788330|NCT05036317|PLACEBO_COMPARATOR|Placebo|Placebo provided by Boehringer Ingelheim Switzerland. Per os once daily in the morning for 28 days.
62788331|NCT01421953|EXPERIMENTAL|Patients|
62580932|NCT04538053|ACTIVE_COMPARATOR|Standard Therapy|Children will receive IV cefazolin 50 mg/kg/dose (max 2 g) three-times daily (TDS) or IV flucloxacillin 50 mg/kg/dise (max 2 g) four-times daily (QID) for 1 to 7 days followed by oral cefalexin 45 mg/kg/dose (max 1.5 g) three-times daily (TDS) for a total course of 3 weeks
62580933|NCT04813575|EXPERIMENTAL|Intervention arm|Experimental arm patients will have cryobiopsies for histological analysis of the ongoing pathology
62205806|NCT03670095|EXPERIMENTAL|Lactose-containing memantine tablet (Ebixa®)|(treatment B - reference) - 10 mg, orally as a single dose in fed and fasted state
62205807|NCT05892705|ACTIVE_COMPARATOR|Study drug (dexmedetomidine intrathecal)|5 mcg dexmedetomidine intrathecally injected with 10 mg hyperbaric bupivacaine during spinal anesthesia for caesarean section.
62580934|NCT04813575|NO_INTERVENTION|control group|This arm will be control group and will be observed prospectively
62580935|NCT04710784|EXPERIMENTAL|I-TEST Intervention Package|Each study site will begin in the baseline, pre-implementation phase, and then be randomized to implement the I-TEST intervention package for a duration of three months, followed by the post-implementation phase.
62788332|NCT06426329|EXPERIMENTAL|Therapeutic touch Group|Therapeutic touch was applied twice to the women in the intervention group in addition to routine practices. The first application was performed in the latent phase of the first stage of labour, and the second was done in the active phase of labour.
62788333|NCT06426329|NO_INTERVENTION|Standard of care Group|The control group did not receive any treatment.
62788334|NCT03079089|OTHER|Relapsed or refractory lymphoid hematological disorders|Patients in refractory or relapses with an indication of allo-HSC used the combination of an SET followed by the RIC with the PDLI
62788335|NCT02601833|EXPERIMENTAL|Silver Diamine Fluoride|This arm will receive Silver Diamine Fluoride applied to their carious lesion, in lieu of restoration placement, with the goal of arresting caries.
62788336|NCT02601833|ACTIVE_COMPARATOR|Conventional Caries Management|Restorative dental care according to American Academy of Pediatric Dentistry guidelines. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
62016391|NCT01478789|PLACEBO_COMPARATOR|placebo|100 g/d yogurt with no added plant sterol
62205808|NCT05892705|PLACEBO_COMPARATOR|Control (saline)|0.2 ml normal saline intrathecally injected with 10 mg hyperbaric bupivacaine during spinal anesthesia for caesarean section.
62205809|NCT06044038|EXPERIMENTAL|Physical activity group|Participation in supervised activities such as walking or Nordic walking groups, gentle gymnastics, soccer, swimming, and volleyball. Each activity was scheduled twice a week.
62205810|NCT06044038|OTHER|Usual care group|Participants in the control group attended weekly 90-minute cognitive rehabilitation sessions according to the usual care procedure in this type of population.
62016392|NCT04934670|EXPERIMENTAL|T-Guard|Participants will be administered four doses of T-Guard intravenously for a 4-hour period every other day
62405000|NCT03504956|OTHER|Healthy Volunteers|"Approximately 100 healthy male/female adult normals or controls will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant."
62788337|NCT03977103|EXPERIMENTAL|High dose irradiation conditioning + Treg/Tcon|High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
62205811|NCT02135562|EXPERIMENTAL|Supportive Care (PSMF)|Participants will take part in a Protein-Sparing Modified Fast (PSMF) Intervention for weight loss. Participants will undergo a dietary intervention high in protein for 6 weeks or until they have loss 15% of their body weight. This intervention will be followed by weight maintenance in which participants reintroduce non-starchy vegetables to their diet. At this time participants will also receive informational material and dietary education which teaches participants how to read nutrition labels and calculate carbohydrate loads in foods. Participants are given the Obesity and Weight-Loss Quality of Life Questionnaire to survey the impact of the intervention
62205812|NCT06331637||Transanal Transection and Single-Stapled anastomosis (TTSS)|Patients will undergo restorative proctectomy with Transanal Transection and Single-Stapled (TTSS) Ileal Pouch-Anal anastomosis (IPAA)
62205813|NCT06331637||Double-stapled anastomosis|Patients will undergo restorative proctectomy with double-stapled Ileal Pouch-Anal anastomosis (IPAA)
62205814|NCT01647555||patient with epidermoid cancer|receiving Cetuximab and radiotherapy
62405001|NCT03504956|OTHER|Coronary Artery Disease (CAD) Patients|40 male/female adult outpatients who are suspected of having or have been diagnosed with coronary artery disease (CAD) will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant.
62405002|NCT01785199|PLACEBO_COMPARATOR|normal (AHI < 5)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
62405003|NCT01785199|ACTIVE_COMPARATOR|mild OSA (AHI between 5 and 15)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
62405004|NCT01785199|ACTIVE_COMPARATOR|moderate OSA (AHI between 15 and 30)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
62405005|NCT01785199|ACTIVE_COMPARATOR|severe OSA (AHI > 30)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
62788338|NCT01318837|EXPERIMENTAL|sofilenacin group|
62405006|NCT02876185||Patients with glaucoma|Patients presenting an open-angle glaucoma or ocular hypertension
62405007|NCT05169866|EXPERIMENTAL|Intravenous Nifekalant|Patients randomized to Nifekalant arm will receive a bolus of 0.3mg/kg IV in the first 5 minutes and a maintenance dose of 0.2-0.4mg/kg/h for 24 hours. If the patient has a recurrence of atrial fibrillation, the maintenance dose can be increased (up to 0.8 mg/kg/h) according to the patient's condition, or receive a bolus of 3mg/kg again at 2 hours intervals. Nifekalant is administered for 24 hours unless meeting the criteria for discontinuation.
62405008|NCT05169866|ACTIVE_COMPARATOR|Intravenous Amiodarone|Patients randomized to an amiodarone arm will receive a bolus of 150mg IV in the first 10 minutes and a maintenance dose of 0.5-1mg/min for 24 hours. If the patient has a recurrence of atrial fibrillation, the dosage can be adjusted according to the patient's condition, but the total dosage administered within 24 hours should not exceed 2g. Amiodarone is administered for 24 hours unless meeting the criteria for discontinuation.
62405009|NCT05602480|EXPERIMENTAL|1A|Subjects received one dose of PCV13 at 18 years of age and above.
62016393|NCT04934670|ACTIVE_COMPARATOR|Ruxolitinib|Participants will take ruxolitinib twice daily for continuous daily dosing
62205815|NCT02602639|EXPERIMENTAL|Functional electrical stimulation rowing|Using an Odstock 4 channel neuromuscular stimulator with Concept 2 Rower
62205816|NCT04466488|NO_INTERVENTION|Standard of care study arm|"The standard TPT implementation is for a clinician to screen for TB and to consider TPT for those who do not have presumptive TB. Clinicians in the study district (and most districts in South Africa) have received training and job aids to assist in appropriate application of the TPT initiation algorithm. Prescribing for TPT and ART is done by writing, by hand, the prescription in the patient's paper file. As part of this study, all study clinic providers will have access to standard Department of Health printed material and clinical training."
62405010|NCT05602480|EXPERIMENTAL|2A|Subjects received one dose of PCV13 at 6\~17 years of age.
62405011|NCT05602480|EXPERIMENTAL|3A|Subjects received one dose of PCV13 at 2\~5 years of age.
62405012|NCT05602480|EXPERIMENTAL|4A|Subjects received two doses of PCV13 at 12\~23 months of age.
62405013|NCT05602480|EXPERIMENTAL|5A|Subjects received three doses of PCV13 at 7\~11 months of age.
62405014|NCT05602480|EXPERIMENTAL|6A|Subjects received four doses of PCV13 at 3 months of age.
62405015|NCT05602480|EXPERIMENTAL|6B|Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old).
62405016|NCT05602480|ACTIVE_COMPARATOR|6C|Subjects received four doses of control PCV13 at 2 months of age (At least 6 weeks old).
62788339|NCT01318837|NO_INTERVENTION|control group|age and sex matched patients without OAB symptom who will answer demographic questionaire and OABSS once
62788340|NCT05348200|ACTIVE_COMPARATOR|Monad 1 cream|Topical cream applied to the peri-anal area twice daily for seven days.
62405017|NCT05602480|EXPERIMENTAL|7A|Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old).
62788341|NCT05348200|ACTIVE_COMPARATOR|Monad 2 cream|Topical cream applied to the peri-anal area twice daily for seven days.
62788342|NCT05348200|ACTIVE_COMPARATOR|Monad 3 cream|Topical cream applied to the peri-anal area twice daily for seven days.
62788343|NCT05348200|EXPERIMENTAL|Combination-CITI-002 (low dose) cream|Topical cream applied to the peri-anal area twice daily for seven days.
62788344|NCT05348200|EXPERIMENTAL|Combination-CITI-002 (high dose) cream|Topical cream applied to the peri-anal area twice daily for seven days.
62016394|NCT01034917|EXPERIMENTAL|Etravirine group|To switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
62215342|NCT04962932|EXPERIMENTAL|Internet-delivered exposure-focused CBT|Internet-delivered CBT over 10 weeks The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that aim to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
62405018|NCT05602480|ACTIVE_COMPARATOR|7B|Subjects received four doses of control PCV13 at 2 months of age (At least 6 weeks old).
62405019|NCT05732025|EXPERIMENTAL|Electrohydraulic shock wave lithotripsy|Pre-treatment of severe calcified coronary lesions with electrohydraulic shock wave lithotripsy
62405020|NCT05732025|ACTIVE_COMPARATOR|Rotary atherectomy|Pre-treatment of severe calcified coronary lesions with Rotary atherectomy
62405021|NCT02871869|ACTIVE_COMPARATOR|Control group A|Control group A was treated with single R-CHOP protocol\[Rituximab 375mg/㎡,one day before CHOP protocol, CHOP protocol included vindesine 3 mg/㎡ (maximum dosage: \<4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5\], 21 d as a cycle, for 4～6 cycles.
62405022|NCT02871869|EXPERIMENTAL|Trial group A|Trial group A was treated with Cinobufacini Tablets combined with R-CHOP protocol\[Rituximab 375mg/㎡,one day before CHOP protocol, CHOP protocol included vindesine 3 mg/㎡ (maximum dosage: \<4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡d1 plus prednisone tablets 100 mg, d1～5\], 21 d as a cycle, for 4～6 cycles.
62405023|NCT02871869|ACTIVE_COMPARATOR|Control group B|Control group B was treated with single CHOP protocol\[vindesine 3 mg/㎡ (maximum dosage: \<4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5\], 21 d as a cycle, for 4～6 cycles.
62405024|NCT02871869|EXPERIMENTAL|Trial group B|Trial group B was treated with Cinobufacini Tablets combined with CHOP protocol\[vindesine 3 mg/㎡ (maximum dosage: \<4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5\], 21 d as a cycle, for 4～6 cycles.
62405025|NCT04065997||Patients implanted with HVAD System|Patients intended to be implanted with a HeartWare HVAD per the current (local) guidelines, are eligible for enrollment into Apogee International and must be consented for Apogee International prior to the HVAD implant.
62405026|NCT02716415|ACTIVE_COMPARATOR|Calmoseptine Ointment|Calmoseptine Ointment as part of a structured skin care regimen.
62405027|NCT02716415|ACTIVE_COMPARATOR|Destin Maximum Strength 40% Zinc|Destin Maximum Strength 40% Zinc as part of a structured skin care regimen.
62405028|NCT01604226||Gynecologic surgery group|Those undergoing gynecologic laparoscopic surgery with TIVA
62405029|NCT01604226||Urologic surgery group|Those undergoing urologic surgery with TIVA
62405030|NCT05772728|EXPERIMENTAL|CAG Group|Cidapenem combined with azacitidine and mitoxantrone liposomes
62405031|NCT03952377|PLACEBO_COMPARATOR|0.9% Sodium Chloride for Injection|
62405032|NCT03952377|EXPERIMENTAL|12.5 mg SX600|Low Dose
62405033|NCT03952377|EXPERIMENTAL|25.0 mg SX600|High Dose
62405034|NCT03843775|EXPERIMENTAL|Binimetinib and Encorafenib|Patients will be initially enrolled to the approved dose of encorafenib 450 mg oral QD and binimetinib 45 mg PO BID, dose level 1. If confirmed this dose level is safely tolerated in the study population, we will then escalate treatment to dose level 2 with the novel dosing regimen of encorafenib 450 mg oral QD continuous and binimetinib 60 mg oral BID 21 days on/7 days off.
62405035|NCT00524901|EXPERIMENTAL|1|25 patients undergoing CABG for three vessel disease, receiving a single dose of erythropoietin periprocedural.
62405036|NCT00524901|PLACEBO_COMPARATOR|2|25 patients undergoing CABG for three vessel disease, receiving placebo (NaCl 0.9%) periprocedural.
62405037|NCT03667781||Patients Interviewed|Patients in cardiology clinic with uncontrolled hypertension despite being on 2 medications
62580936|NCT04213066|ACTIVE_COMPARATOR|Control group|This group received eye-hand practice for drawing pictures.
62580937|NCT04213066|EXPERIMENTAL|Grating group|This group received eye-hand practice for drawing pictures with rotating grating stimuli of various spatial frequencies.
62580938|NCT04213066|EXPERIMENTAL|Random dot group|This group received eye-hand practice for drawing pictures with rotating grating stimuli of various spatial frequencies constructed by random dots of stochastic resonance.
62580939|NCT00505960|EXPERIMENTAL|1|
62580940|NCT05259462|EXPERIMENTAL|Group-active virtual reality gaming|Participants will undergo the intervention.
62016395|NCT01034917|ACTIVE_COMPARATOR|Control group|Continue with the same antiretroviral regimen
62016396|NCT01747759|OTHER|Kruskal-Wallis and qualitative parameters|The evaluations will take place at baseline, the day before surgery and 6 weeks post-surgery on knowledge and beliefs scores at each visit and on a satisfaction score on the last one. Quantitative data will be compared between groups by the Kruskal-Wallis and qualitative parameters via Fisher exact test
62580941|NCT06574763|EXPERIMENTAL|RC48+Carboplatin|
62580942|NCT03970083||Oxygen Levels in Tumors|-Quantitative oxygen measurements will be obtained in a single field of view using T1 sequences
62016397|NCT01747759|OTHER|Fisher exact test|The evaluations will take place at baseline, the day before surgery and 6 weeks post-surgery on knowledge and beliefs scores at each visit and on a satisfaction score on the last one. Quantitative data will be compared between groups by the Kruskal-Wallis and qualitative parameters via Fisher exact test
62405038|NCT03667781||Providers Interviewed|Providers in cardiology clinic
62734925|NCT04307368|EXPERIMENTAL|Elimination-rotational diet|Patients with IBS. Interventions: During the patient's first visit an IgG antibody titration test against specific nutrients will be performed to determine food hypersensitivity. Based on the results of the obtained food panels, patients will be offered an elimination-rotational diet for a period of 8 weeks.
62405039|NCT03667781||Patients Blood Draw|Patients seen in interventional clinic for post PCI followup will have a venous blood draw which will be sent for therapeutic drug monitoring
62405040|NCT01678391|EXPERIMENTAL|Patients with common bile duct stones.|Common bile duct stone removal without fluoroscopy
62788345|NCT01038167|EXPERIMENTAL|Part A|Part A will be administered in two periods, separated by a washout. In Period 1, subjects will receive cyclosporine alone. In Period 2, subjects will receive cyclosporine in combination with telaprevir.
62788346|NCT01038167|EXPERIMENTAL|Part B|Part B will be administered in two periods, separated by a washout. In Period 1, subjects will receive tacrolimus alone. In Period 2, subjects will receive tacrolimus in combination with telaprevir.
62788347|NCT02546492|EXPERIMENTAL|Acthar|The study cohort. In this cohort Acthar gel will be administered to the enrolled patient with chrnic AMR.
62788348|NCT05705557||Patients undergoing laparotomic (open) liver resection|
62788349|NCT06237400|EXPERIMENTAL|Phase 1 Dose Escalation|"Dose escalation will begin with rapid dose escalation for the low-dose groups (50 mg QD 、150 mg QD) and a 3 + 3 dose-escalation protocol for the high-dose groups."
62016398|NCT02247934||Concept elicitation interviews (Step I)|Approximately 20 participants will be included.
62405041|NCT05839366|ACTIVE_COMPARATOR|Remifentanil + propofol + esketamine|esketamine (2ml; 50mg), Remifentanil Hydrochloride for Injection (1mg;), propofol injection (50ml; 0.5g; )； The frequency of use is determined by responsible clinicians.All analgesic and sedative drugs used are adjusted according to the actual situation of the patient.
62405042|NCT05839366|PLACEBO_COMPARATOR|remifentanil + propofol + saline|Remifentanil Hydrochloride for Injection (1mg;), propofol injection (50ml; 0.5g; )； The amount of saline used is equivalent to the amount of esketamine.All analgesic and sedative drugs used are adjusted according to the actual situation of the
62405043|NCT01561573|OTHER|Ultrasound colles fracture|This is a single arm study
62405044|NCT05141110|EXPERIMENTAL|NVP-1705|Tablet formulation for oral administration, single dose of NVP-1705 at Day 1
62405045|NCT05141110|ACTIVE_COMPARATOR|NVP-1705-R|Tablet formulation for oral administration, single dose of NVP-1705-R at Day 1
62405046|NCT04732884|EXPERIMENTAL|Weight sensor with biofeedback|Activation of the feedback function of the weight-bearing sensor as mean to possibly enhance compliance to weight-bearing instructions postoperative.
62734926|NCT04307368|EXPERIMENTAL|Classic diet|Patients with IBS. Interventions: 8 weeks of classic diet treatment (recommended by the gastroenterologist who supervises them).
62788350|NCT06237400|EXPERIMENTAL|Phase 2 Dose Expansion|Upon completing the dose escalation part of the study, dose expansion may proceed with 3 groups consisting of subjects with KRAS G12C mutant advanced solid tumors，Including non-small cell lung cancer, colorectal cancer and Other advanced solid tumors
62788351|NCT02669212|OTHER|Healthy Volunteer Participants|Healthy volunteer participants
62788352|NCT02669212|OTHER|ME/CFS Participants|Participants with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
62788353|NCT04413097|ACTIVE_COMPARATOR|DCC and Low Oxygen Concentration|During 90 seconds of delayed cord clamping, the infant will receive gentle stimulation and start CPAP by 30 seconds of life at an FiO2 .30, with CPAP of 5 cmH20. If the infant is apneic or there is no Pedicap color change the team will begin positive pressure ventilation (starting PIP of 20 cmH20) by 60 seconds of life. The infant will remain on this support up until the umbilical cord is clamped at 90 seconds or greater. Once the cord is clamped the infant resuscitation will continue according to unit protocol.
62788354|NCT04413097|EXPERIMENTAL|DCC and High Oxygen Concentration|During 90 seconds of delayed cord clamping, the infant will receive gentle stimulation and start CPAP by 30 seconds of life at an FiO2 1.0, with CPAP of 5 cmH20. If the infant is apneic or there is no Pedicap color change the team will begin positive pressure ventilation (starting PIP of 20 cmH20) by 60 seconds of life. The infant will remain on this support up until the umbilical cord is clamped at 90 seconds or greater. Once the cord is clamped the infant resuscitation will continue according to unit protocol.
62788355|NCT06294392|EXPERIMENTAL|KEEP-CK|Participants who are randomly assigned to the KEEP-CK condition will participate in 16 weekly group sessions with 8-12 other informal kinship caregivers, and receive manualized content related to positive parenting skills, and peer-to-peer supports and recommendations for services.
62788356|NCT06294392|NO_INTERVENTION|"Services as usual (SAU) waitlist control"|"Participants who are randomly assigned to the services as usual (SAU) waitlist control condition will be eligible to receive SAU that are available to all informal kinship caregivers in Oregon. Participants who ask about receiving supports will be referred to the Oregon Kinship Navigator, which is a statewide kinship navigator program that is available to all informal kinship caregivers in Oregon regardless of their participation in this study. Participants in the SAU waitlist control condition will be offered the opportunity to participate in a KEEP-CK group after 10 months, with these participants only contribute data to the SAU control condition for the impact analyses."
62788357|NCT05413720|OTHER|Patient with leptospirosis|
62016399|NCT02247934||Cognitive interviews (Step II)|Approximately 30 participants will be included.
62405047|NCT04732884|EXPERIMENTAL|Weight sensor without biofeedback|Standard patient education considering postoperative weight-bearing parameters and measurement of actual weight-bearing with the sensor.
62405048|NCT05297604|ACTIVE_COMPARATOR|VPBM group (vascular photobiomodulation)|The participants received a single session of VPBM.
62405049|NCT05297604|PLACEBO_COMPARATOR|Sham group (simulated vascular photobiomodulation)|The participants received the same treatment as the VPBM group, but the equipment was switched off. To ensure blinding, the sound of the device (beep) was activated at the time of simulated PBM using a telephone.
62405050|NCT03762642||Mastectomy|
62405051|NCT03762642||Breast-Conserving Surgery|
62205817|NCT04466488|EXPERIMENTAL|Choice Architecture study arm|"In the choice architecture implementation strategy, all opt-out clinic providers and pharmacists will be trained on the approach. The fundamental tenant of this approach is that TPT will be prescribed with any ART initiation and any ART re-prescribing for 3-12 months of TPT (adherent to current guidelines) if TPT has not been previously prescribed. This will be facilitated by co-prescribing ART and TPT. That is when ART is being prescribed TPT is meant to be prescribed at the same time of the clinic visit.~The simultaneous prescribing will be facilitated through the introduction of an ink stamp or pre-printed sticker to use for quick entry of the ART prescription along with TPT and cotrimoxazole. The stamp/sticker for ART prescription, the prescription for TPT and for cotrimoxazole will be automatically included. Active canceling of these prescriptions (and indicating the reasons) will be needed to not have TPT dispensed."
62580943|NCT05495295|EXPERIMENTAL|Advanced Solid Tumours|"First-in-human clinical trial of the acetylglucosaminyltransferase V inhibitor PhOx430 in patients with advanced solid tumours. The trial includes two parts, a dose escalation phase (part I) which will enroll patients with non-selected tumour types, followed by a cohort expansion phase (part II) in selected tumour types:~* Glioblastoma Multiforme (GBM)~* Triple Negative Breast Cancer (TNBC)~* Selected solid tumours"
62788358|NCT02017925|EXPERIMENTAL|Arm I (early intervention)|Beginning within 2 weeks of starting chemoradiation, patients undergo an individualized rehabilitation program comprising aerobic exercise and strength training, including treadmill walking, stationary bicycle, NU-Step, upper body resistance training and breathing retraining, 3 times per week for 8 weeks (36 sessions).
62205818|NCT05324670|EXPERIMENTAL|Experimental condition|Didactic intervention based on religious teachings and cultural milieu, the experimental group will receive 12 sessions for three months, 4 sessions per month including focused group discussion.
62205819|NCT05324670|OTHER|Control condition|They will have sessions like the experimental group but the control group will get the knowledge in the form of written material without any explanation (Information Leaflet).
62205820|NCT06728579|EXPERIMENTAL|MORE Treatment Group|Participants randomized to the MORE arm will participate in eight weekly, two-hour group sessions following an established protocol. MORE sessions involve instruction in three therapeutic skills: 1) mindfulness to reduce pain and increase self regulation over maladaptive pain coping habits, (2) reappraisal to decrease psychological distress and negative affect, and 3) savoring to amplify natural reward processing and evoke positive emotion (see Figure 2). Participants will be asked to engage in 15 minutes per day of skill practice at home guided by audio recording, and to record the number of minutes they engaged in skill practice via a weekly Research Electronic Data Capture (REDCap) survey.
62205821|NCT06728579|ACTIVE_COMPARATOR|Supportive Psychotherapy Control Group|Participants randomized to SG will participate in eight weekly two-hour SG sessions led by the same instructors who deliver MORE interventions. The instructors will lead discussions on themes pertinent to chronic pain and cancer survivorship (see Figure 3) but will not teach MORE skills. To match the MORE homework requirement, SG participants will be asked to journal for 15 minutes/day on weekly session topics. Providers will employ empathic responding, elicit emotional expression, and promote a positive group climate.
62205822|NCT05945004||Experiment|
62205823|NCT05945004||Control|
62205824|NCT01384370||AHPV positive and negative subjects|
62205825|NCT06441877||Residents site 1|Elderly residents who live in elderly home care service site 1
62205826|NCT06441877||Residents site 2|Elderly residents who live in elderly home care service site 2
62205827|NCT06441877||Managers site 1|Managers who work for the elderly home care service at site 1
62205828|NCT06441877||Managers site 2|Managers who work for the elderly home care service at site 2
62205829|NCT06118099|EXPERIMENTAL|Amlitelimab|Subcutaneous injection (SC) as per protocol.
62205830|NCT06118099|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection as per protocol.
62205831|NCT01012297|EXPERIMENTAL|Arm I Gem+Doce+Placebo|Patients receive a placebo IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim subcutaneously (SC) on days 9-15 or pegfilgrastim SC on day 9 or 10.
62205832|NCT01012297|EXPERIMENTAL|Arm II Gem+Doce+Bev|Patients receive bevacizumab IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10.
62205833|NCT04419376||Patients with pARDS|Within 7 days of known clinical insult Respiratory failure not fully explained by cardiac failure or fluid overload chest imaging findings of new infiltrate(s) consistent with acute pulmonary parenchymal disease patients with an oxygenation index (OI) (\[FIO2 × mean airway pressure × 100\]/PaO2) above 4
62205834|NCT04419376||Patients with non-pARDS|non-pARDS patients who received mechanical ventilation support due to respiratory failure.
62788359|NCT02017925|EXPERIMENTAL|Arm II (late intervention)|Beginning 1 month after completion of chemoradiation, patients undergo an individualized exercise rehabilitation program as in Arm I.
62788360|NCT06271395|EXPERIMENTAL|The observation group|This group will be given Left cricopharyngeal muscle botulinum toxin injection, Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once.
62205835|NCT04842370|EXPERIMENTAL|Dose escalation and expansion of PHI-101|
62016400|NCT00503841|EXPERIMENTAL|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
62205836|NCT02742402|EXPERIMENTAL|Observation|Clinical follow-up for at least 6-8 hours, after follow-up repeated laboratory tests and repeated clinical examination is done. Adult Appendicitis Score is calculated after observation to determine further actions. Observation is continued in patients with decreasing score. Patients with the same or higher score undergo diagnostic imaging (score 11-15) or laparoscopy (score 16 or higher). Diagnostic imaging is abdominal ultrasound first and if the result is inconclusive or negative for appendicitis abdominal computed tomography is done. Laparoscopic appendectomy is done for those patients with appendicitis in diagnostic imaging.
62205837|NCT02742402|ACTIVE_COMPARATOR|Diagnostic imaging|Patients undergo abdominal ultrasound and if the result is inconclusive or negative for appendicitis patients will have abdominal computed tomography. Laparoscopic appendectomy is done for patients with appendicitis in diagnostic imaging.
62016401|NCT03634761|EXPERIMENTAL|Experimental group|Preschools/Children in this group will receive EIBI supervised by an external expert from the habilitation center on a regular basis. In addition, preschool staff in this group are provided with in-service training consisting of a one full day (onset of project) and a half day (middle of project) on autism, applied behavior analysis, evidence-based practices, engagement, participation, inclusion and overall quality factors when working with Children with autism in preschool settings. Preschool staff are also provided with monthly on-site coaching in implementing evidence based practices, goal setting and working with overall intervention setting, through coaching from the habilitation center.
62016402|NCT03634761|ACTIVE_COMPARATOR|Comparison group|"Preschools/Children are in this group receive treatment as usual, which is EIBI supervised by an external expert from the habilitation center at the habilitation center directed toward the paraprofessional. At the offset of the project preschool staff are offered to participate in a one-day learning course/workshop on autism, applied behavior analysis, evidence-based practices, engagement, participation, inclusion and overall quality factors when working with children with autism in preschool settings."
62016403|NCT02259608|EXPERIMENTAL|BCG vaccine SSI|Healthy volunteers are vaccinated with yBCG. Blood will be drawn before and at several timepoints after vaccination. Cytokine production before vaccination will be used as reference to compare later timepoints with.
62205838|NCT00925353|EXPERIMENTAL|lidocaine gel|
62205839|NCT02559427|ACTIVE_COMPARATOR|Immediate SPA treatment|3-week immediate SPA treatment (soon after randomization)
62205840|NCT02559427|SHAM_COMPARATOR|Late SPA treatment|3-week late SPA treatment (soon after primary endpoint at 4 1/2 months visit)
62580944|NCT06377371|EXPERIMENTAL|Patients with MRI findings compatible with meningioma who have an indication for surgery|A diagnostic intervention in which patients will undergo intraoperative meningioma tracing using \[Cu64\]DOTATATE.
62016404|NCT04736784|EXPERIMENTAL|Beetroot juice|115 ml of beetroot juice per day for seven days
62016405|NCT04736784|EXPERIMENTAL|Leafy green vegetable juice|250 ml of green leafy vegetable juice per day for seven days
62016406|NCT00393445|EXPERIMENTAL|Intravenous infusion|intravenous infusion of test substances
62016407|NCT03136068|EXPERIMENTAL|Digoxin|Subjects assigned to the intervention arm will receive a 1 mg intrafetal digoxin injection under ultrasound guidance
62016408|NCT03136068|PLACEBO_COMPARATOR|Placebo|Subjects assigned to the control arm will receive an ultrasound-guided intrafetal saline injection of the equivalent volume
62016409|NCT04296617||Observational (medical chart review)|Patients' medical charts are reviewed.
62016410|NCT03529630|EXPERIMENTAL|Inverted syringe|Participants in this arm will use of the inverted syringe before each breastfeeding starting from the first feed after delivery and continued as long as needed by the mother.
62016411|NCT03529630|NO_INTERVENTION|Standard of care|Participants in the control group will receive standard medical care as dictated by their obstetricians. Any advice regarding infant nutrition or treatment of inverted nipples will be left to the primary physician, including possible use of the inverted syringe technique. .
62205841|NCT04337853|EXPERIMENTAL|Intervention group|N=6
62205842|NCT04337853|ACTIVE_COMPARATOR|Control group|N=7
62016412|NCT02319239|ACTIVE_COMPARATOR|Conventional fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
62016413|NCT02319239|EXPERIMENTAL|hypofractionated|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months.
62016414|NCT02319239|EXPERIMENTAL|Stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months.
62016415|NCT00650949|EXPERIMENTAL|CYT997|
62016416|NCT02805842|ACTIVE_COMPARATOR|Tacrolimus BID|20 patients receiving twice daily (BID) Tacrolimus
62205843|NCT03653208|EXPERIMENTAL|Group 1 (hzVSF-v13 10mg)|Group 1 received a single 10mg dose of hzVSF-v13 on Day 1.
62205844|NCT03653208|EXPERIMENTAL|Group 2 (hzVSF-v13 20mg)|Group 2 received a single 20mg dose of hzVSF-v13 on Day 1.
62205845|NCT03653208|EXPERIMENTAL|Group 3 (hzVSF-v13 50mg)|Group 3 received a single 50mg dose of hzVSF-v13 on Day 1.
62205846|NCT03653208|EXPERIMENTAL|Group 4 (hzVSF-v13 100mg)|Group 4 received a single 100mg dose of hzVSF-v13 on Day 1.
62205847|NCT03653208|EXPERIMENTAL|Group 5 (hzVSF-v13 200mg)|Group 5 received a single 200mg dose of hzVSF-v13 on Day 1.
62580945|NCT01334827|OTHER|Formulations|high volume gel; low volume gel; vaginal film
62788361|NCT01356706||CRLM|patients with colorectal liver metastases (CRLM) who undergo their primary surgery at UZ. Leuven (single-center academic study)
62205848|NCT03653208|EXPERIMENTAL|Group 6 (hzVSF-v13 400mg)|Group 6 received a single 400mg dose of hzVSF-v13 on Day 1.
62205849|NCT03653208|EXPERIMENTAL|Group 7 (hzVSF-v13 800mg)|Group 7 received a single 800mg dose of hzVSF-v13 on Day 1.
62205850|NCT03653208|EXPERIMENTAL|Group 8 (hzVSF-v13 1200mg)|Group 8 received a single 1200mg dose of hzVSF-v13 on Day 1.
62205851|NCT03653208|PLACEBO_COMPARATOR|Placebo|Placebo group received a single placebo on Day 1.
62205852|NCT05234840|ACTIVE_COMPARATOR|Triamcinolone group|Patients were placed in the prone position. Transforaminal triamcinolone injections were performed under a C-arm fluoroscopy.
62205853|NCT05234840|EXPERIMENTAL|Platelet-rich plasma|Patients were placed in the prone position. Transforaminal PRPinjections were performed under a C-arm fluoroscopy.
62205854|NCT06268067||Chronic kidney diseased patiens|chronic kidney diseased patients
62205855|NCT06268067||Normal|normal subjects
62205856|NCT03154970|EXPERIMENTAL|Obstructive sleep apnea group (G OSA)|The cervical stabilization will be performed with craniocervical flexion training aiming to strength the deep cervical flexors. For this purpose a pressure biofeedback device (stabilizer) that allows progressive levels of pressure during exercise(22-30 mmHg) will be used, which will be increased according to the capacity of the individuals (avoiding compensations or pain). The participant will be instructed to perform the craniocervical flexion in the supine position, the duration of the contraction will be 10 seconds followed by 10 seconds of rest (3 sets of 10 repetitions). The sessions will be held 2 times in weeks, for 6 weeks.
62205857|NCT03154970|NO_INTERVENTION|Control group (GC)|The GC will be reassessed after six weeks and the same G OSA treatment will be offered after this period.
62205858|NCT04703205|EXPERIMENTAL|ivermectin|Ivermectin group: Ivermectin approximately 200 μg/kg administered as a single oral dose on Day 1 (fasting state) subjects take the study drug (3 mg tablet of ivermectin) at the dose of the study drug taken once per body weight of the subject.
62205859|NCT04703205|PLACEBO_COMPARATOR|placebo|Placebo group: Placebo without ivermectin as an ingredient, single oral administration on Day 1 (fasting state) the control drug (ivermectin placebo tablet) at the dose of the study drug taken once per body weight of the subject.
62205860|NCT02643472|OTHER|Care Notebook|Parents of infants who were discharged from the Children's National NICU will be randomized to receive enhanced usual care by provision of a NICU care resource notebook. Parents will be notified about group assignment prior to discharge. Stratification will occur according to birth weight.
62016417|NCT02805842|ACTIVE_COMPARATOR|Advagraf QD|40 patients randomized to receive once daily (QD) Advagraf
62405052|NCT05250739|EXPERIMENTAL|Strength training|Participants completed 16 training sessions of strength training during eight weeks.
62788362|NCT00994422|EXPERIMENTAL|0.5% ivermectin cream|
62016418|NCT04280211||COPD Group|Patients who are over 40 years old, diagnosed with COPD
62405053|NCT05250739|EXPERIMENTAL|Neuromuscular training|Participants completed 16 training sessions of neuromuscular training during eight weeks.
62405054|NCT05250739|NO_INTERVENTION|Control group|The Control group received no intervention.
62405055|NCT02818582|ACTIVE_COMPARATOR|GS-5734 100mg given intravenously daily for 5 days|Male Ebola survivors with persistent Ebola virus in their semen were given GS-5734 100mg intravenously daily for 5 days
62788363|NCT00994422|PLACEBO_COMPARATOR|vehicle control|
62788364|NCT02430883|ACTIVE_COMPARATOR|first group|patients who have upper pole kidney stones treated with flexible renoscopy
62788365|NCT02430883|ACTIVE_COMPARATOR|second group|patients u who have mid pole kidney stones treated with flexible renoscopy
62788366|NCT02430883|ACTIVE_COMPARATOR|third group|patients who have lower pole kidney stones treated with flexible renoscopy
62788367|NCT02430883|ACTIVE_COMPARATOR|forth group|patients who have kidney stones in pelvis treated with flexible renoscopy
62788368|NCT02430883|ACTIVE_COMPARATOR|fifth group|patients who have multiple calixes kidney stones treated with flexible renoscopy
62788369|NCT01403493|ACTIVE_COMPARATOR|Multidisciplinary patient education|A multidisciplinary (nurse, gastroenterologist, dietician, physiotherapist, psychologist) group education with six sessions for patients with IBS.
62788370|NCT01403493|ACTIVE_COMPARATOR|Nurse based patient education|A nurse based patient education with three sessions for patients with IBS.
62788371|NCT01009008|EXPERIMENTAL|Post-mastectomy|Post-mastectomy patients undergoing expander reconstruction
62016419|NCT04280211||Control Group|Healthy adults over 40 years old
62016420|NCT04575779||Group A|Cyclosporin of a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h
62016421|NCT04575779||Group B|Administer cyclosporin daily dose of 3 mg/kg/day in a continuous infusion over 23 h every 24 h.
62205861|NCT02643472|EXPERIMENTAL|Care Notebook + Parent Navigator|Parents of infants who were discharged from the Children's National NICU will be randomized to receive a care notebook + Parent Navigation. Parents will be notified about group assignment prior to discharge. Stratification will occur according to the birth weight.
62205862|NCT01004887||Single group|Patients with newly diagnosed high-grade gliomas participating in NCCTG/Alliance or Mayo protocols. Previously collected blood and tissue samples are analyzed via PCR, IHC, flow cytometry, and FISH.
62205863|NCT02654652|EXPERIMENTAL|Symbiotic|Patients will receive the symbiotic product LactoFos twice a day during seven days after surgical treatment. The intervention consists of giving twice a day a sachet of 6g of symbiotic diluted in 20mL of water via nasoenteric tube for seven days, totaling the administration of 14 sachets per intervention.
62205864|NCT02654652|PLACEBO_COMPARATOR|Maltodextrin|Patients will receive 6g of maltodextrin twice a day during seven days after surgical treatment.
62205865|NCT04192253|EXPERIMENTAL|neo-adjuvant Paclitaxel and Carboplatin|Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
62205866|NCT01643551||LVAD Group|18 years and older Planning to undergo VAD implantation
62205867|NCT01643551||Cardiac Surgery Group|18 years or older Planning to undergo valve or coronary bypass surgery
62205868|NCT03042988|EXPERIMENTAL|Heat Stress|Passive heat-stress using a commercial heating pad applied on the trunk
62580946|NCT03304314|EXPERIMENTAL|Pseudotumor cerebri (PTC) patients|
62580947|NCT03304314|EXPERIMENTAL|Control|
62788372|NCT00344500|NO_INTERVENTION|Usual Care|Usual Care
62205869|NCT03042988|SHAM_COMPARATOR|Control (Non-heating)|Commercial heating pad applied on the trunk but turned off
62205870|NCT04608773|OTHER|Biotene Spray, followed by Refresh Spray|The Biotene Spray followed by Refresh Spray Arm will be asked to complete a 2 week trial using Biotene Spray first, then will be asked to complete a 2 week trial using Refresh Spray second. (after the appropriate 1 week washout periods have been completed)
62205871|NCT04608773|OTHER|Refresh Spray, followed by Biotene Spray|The Refresh Spray, followed by Biotene Spray Arm will be asked to complete a 2 week trial using Refresh Spray first, then will be asked to complete a 2 week trial using Biotene Spray second. (after the appropriate 1 week washout periods have been completed)
62205872|NCT04863482|ACTIVE_COMPARATOR|Critical view of Safety (CVS-WL)|Group CVS-WL (control group): the visualization of the biliary tree is achieved in white light, without the utilization of an intraoperative imaging technique, the CVS in white light was selected as the control group since it constitutes the actual recognized standard in clinical practice.
62205873|NCT04863482|EXPERIMENTAL|Intra-operative Cholangiography (IOC)|Group IOC: the visualization of the biliary tree is achieved with the help of intraoperative cholangiography
62205874|NCT04863482|EXPERIMENTAL|Near-Infra Red Cholangiography (NIR-C)|Group NIR-C: the visualization of the biliary tree is achieved with the help of near-infrared fluorescence cholangiography
62205875|NCT00953771|EXPERIMENTAL|Danazol, Plex, Steroids|Everyone will receive Danazol with plasma exchange and corticosteroids
62205876|NCT00953771|NO_INTERVENTION|Historic Control|
62205877|NCT03790553|ACTIVE_COMPARATOR|50.4Gy|Total radiotherapy dose of 50.4Gy.
62205878|NCT03790553|EXPERIMENTAL|61.2Gy|Total radiotherapy dose of 61.2Gy.
62205879|NCT05500677|ACTIVE_COMPARATOR|Lidocaine|10% lidocaine spray was applied on the broken rib from a distance of 10 cm, 1-2 puffs. Each puff contains 10 mg of lidocaine.
62205880|NCT05500677|ACTIVE_COMPARATOR|Tramadol|100 mg of tramadol hydrochloride was placed in 150 cc isotonic saline and given as a 15-minute intravenous infusion.
62205881|NCT05500677|ACTIVE_COMPARATOR|Fentanyl|50 mcg of fentanyl citrate was given as a 15-minute intravenous infusion in 150 cc isotonic.
62205882|NCT06507865||GORE® TAG® Thoracic Branch Endoprosthesis|Patients treated with the TBE Device
62205883|NCT01514305||Type 1 Diabetes Mellitus (TIDM)Type 2 Diabetes Mellitus (T2DM)|Adults that have been diagnosed with insulin-requiring diabetes and are on multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy;
62205884|NCT00743431||1|Women with advanced ovarian cancer
62205885|NCT05601427|ACTIVE_COMPARATOR|Anesthesiologist-Performed Adductor Canal Block (aACB)|Patients will get a pre-operative adductor canal block performed by an anesthesiologist.
62205886|NCT05601427|EXPERIMENTAL|Surgeon-Performed Adductor Canal Block (sACB)|Patients will get an intra-operative adductor canal block performed by the surgeon
62205887|NCT03861026|EXPERIMENTAL|Intervention group|"Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively.~In the interventional group, an alarm threshold at 90% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 90% of the baseline measurements. The intervention will be commenced within 15 seconds of the reduction in rSO2 value."
62016422|NCT04788992|EXPERIMENTAL|Intervention group|receive dementia care training
62205888|NCT03861026|NO_INTERVENTION|Control group|"Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively.~In the control group, the cerebral oximetry monitor screen will be concealed, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in cerebral oximetry application and unaware of the study design."
62205889|NCT00137969|EXPERIMENTAL|Rituximab 1000 mg + prednisone|Participants will receive rituximab 1000 mg intravenously on Days 1, 15, 168, and 182. Participants will also receive an initial dose of prednisone (0.5, 0.75, or 1.0 mg/kg orally once a day) with tapering beginning at Day 16 for 10 weeks to a dose of ≤ 10 mg/day. Participants will also receive acetaminophen 1000 mg orally and diphenhydramine 50 mg orally prior to study drug infusion.
62405056|NCT02818582|PLACEBO_COMPARATOR|Normal saline intravenously for 5 days|Male Ebola survivors with persistent Ebola virus in their semen were given normal saline intravenously daily for 5 days
62016423|NCT04788992|ACTIVE_COMPARATOR|Control group|receive dementia care training without virtual reality activity
62016424|NCT02560129||ICU Survivors|ICU survivors will be seen in a MICU Recovery Clinic where Questionnaires, Physical and Cognitive Function assessments will be measured
62016425|NCT02341196|EXPERIMENTAL|CEA + Polyester patch|225 Patients
62016426|NCT02341196|EXPERIMENTAL|CEA + Patch Polyurethane|225 Patients
62016427|NCT06572904|EXPERIMENTAL|patients will receive a mixture of tenoxicam and HA.|The injection point will be marked Patients will be instructed to open their mouths widely and maintain the mandible in a protruded position A mixture of 1mm of TX and 1ml of HA will be slowly injected intra-articular at the point of entry.
62205890|NCT00137969|PLACEBO_COMPARATOR|Placebo + prednisone|Participants will receive placebo intravenously on Days 1, 15, 168, and 182. Participants will also receive an initial dose of prednisone (0.5, 0.75, or 1.0 mg/kg orally once a day) with tapering beginning at Day 16 for 10 weeks to a dose of ≤ 10 mg/day. Participants will also receive acetaminophen 1000 mg orally and diphenhydramine 50 mg orally prior to study drug infusion.
62215343|NCT04962932|ACTIVE_COMPARATOR|Internet-delivered stress management treatment|Stress management treatment for 10 weeks Participants randomized to The Stress Management Treatment will receive 10 weeks of stress managemen including relaxation technics, standard life style advice regarding physical activity, sleep and and standardized AF-information in line with current guidelines for AF. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
62215344|NCT03222388||IIEF5 paper-electronic|
62215345|NCT03222388||IIEF5 electronic-paper|
62215346|NCT03222388||IIEF15 paper-electronic|
62215347|NCT03222388||IIEF15 electronic-paper|
62215348|NCT03222388||IIEF5 electronic-electronic|
62580948|NCT06133751|EXPERIMENTAL|Supplemented group|"Athletes in the supplemented group (n=7) consumed capsules with highly concentrated 18% chokeberry extract. One capsule contained 200 mg. In addition to chokeberry extract, each capsule also contained chokeberry fiber, E460b magnesium salts of stearic acid (anti-caking agent), E551 silicon dioxide (anti-caking agent), hydroxypropyl methylcellulose (capsule shell) and E171 titanium dioxide (shell color).~The rowers (both supplemented and control group) took 3 capsules a day (at breakfast, lunch and dinner) for 8 weeks. The athletes sipped each capsule with a glass of water."
62580949|NCT06133751|PLACEBO_COMPARATOR|Placebo group|"The control group (n=8) consumed capsules that were made from chokeberry fiber.~The rowers (both supplemented and control group) took 3 capsules a day (at breakfast, lunch and dinner) for 8 weeks. The athletes sipped each capsule with a glass of water."
62580950|NCT03451591|ACTIVE_COMPARATOR|Isosorbide Mononitrate XL (ISMN)|Oral Isotard® 25mg XL (Isosorbide Mononitrate) tablets. Oral Isotard® 25mg XL: Day 1-5 / 25mg daily morning dose. Day 6 to week 52 / 50mg daily morning dose. Week 53 / 25mg daily morning dose. Week 54 / NIL dose. Or Oral Isosorbide mononitrate (ISMN) non-XL 20mg tablets: Day 1-5 / 20mg daily evening dose. Day 6 to week 52 / 20mg twice daily morning \& evening. Week 53 / 20mg daily morning dose. Week 54 / NIL dose.
62788373|NCT00344500|ACTIVE_COMPARATOR|Lifestyle Balance|Behavioral Weight Loss Program
62016428|NCT06572904|EXPERIMENTAL|patients will receive a mixture of PRP and HA.|10 ml of the patient's blood from the ulnar vein into a sterile glass tube containing sodium citrate as an anticoagulant. After mixing the blood with the citrate, using rotating movements, the tubes will be centrifuged at 1500 rpm for 6 min.The injection point will be marked Patients will be instructed to open their mouths widely and maintain the mandible in a protruded position mixture of 1-ml of PRP and 1-ml of HA will be slowly injected intra-articular at the point of entry.
62016429|NCT00642304|EXPERIMENTAL|methoxy polyethylene glycol-epoetin beta|
62016430|NCT01642394|NO_INTERVENTION|Standardized care|The control group will receive usual care for secondary prevention of type 2 diabetes according to usual care in Osakidetza's primary care.
62016431|NCT01642394|EXPERIMENTAL|Self-management education programme|Attendees will receive the Diabetes Self-Management Programme in spanish version (Manejo personal de la diabetes).
62016432|NCT04163276||Group 1|20 patients without anomaly of brain metabolism
62016433|NCT04163276||Group 2|20 patients with Alzheimer's disease
62016434|NCT05517343|NO_INTERVENTION|Ordinary care (OC)|The participants of this arm received the endoscopic optical diagnosis, histological diagnosis of the resected colon polyps and the recommended surveillance colonoscopy schedule at next scheduled clinic visit (around 1 to 2 weeks later).
62016435|NCT05517343|EXPERIMENTAL|Real-time notification (RTN)|The participants of this arm received the endoscopic optical diagnosis of the resected colon polyps and the recommended surveillance colonoscopy schedule right after the sedated colonoscopy. Histological diagnosis will be informed at next scheduled clinic visit (around 1 to 2 weeks later).
62016436|NCT05820750|OTHER|standard root canal treatment|
62016437|NCT05820750|OTHER|photodynamic therapy|
62580951|NCT03451591|ACTIVE_COMPARATOR|Cilostazol|Oral Cilostazol 100mg tablets. Day 1-5 / 50mg daily evening dose. Day 6-10 / 50mg twice daily morning \& evening. Day 11-15 / 50mg daily morning dose \& 100mg daily evening dose. Day 16 to week 52 / 100mg twice daily morning \& evening. Week 53 / 50mg twice daily morning \& evening. Week 54 / NIL dose.
62788374|NCT06085781|OTHER|Cohort A|Participants who are to receive standard of care radiotherapy will have one biopsy and MRI scan before starting radiotherapy and during week two of radiotherapy. Participants will also have an the option to consent to an additional biopsy and MRI scan during week 4 of radiotherapy. Oral pimonidazole will be taken the night before each biopsy.
62205891|NCT06130670|OTHER|Group1:Ultrasound-guided quadratus lumborum block technique|"Ultrasound-guided quadratus lumborum block technique:~the patients were placed in the lateral position. Following disinfecting of the site of injection, a convex probe (2-5 HZ, Edge, Sonosite, Seattle, the USA) was positioned in a parasagittal oblique plane at the L3-L4 level, which is approximately 4 cm from the posterior midline. The iliac crest, erector spinae (ES) muscle, QL muscle, and psoas (PM) muscle were identified, and a an 18-gauge Touhy's epidural needle (BBRAUN epidural set) was directed to the anterior part of the QL. Then, the needle tip was located between the QL and PM using the in-plane technique. Normal saline 5 mL was used to identify the plane. After confirmation of the injection site, 20 ml of 0.25% Bupivacaine bolus was injected and 1 μg/kg of dexmedetomidine dissolved in 2 ml normal saline were injected also between the QL and PM muscles divided equally on each side of the abdominal wall before induction general anesthesia."
62205892|NCT06130670|OTHER|Group2:Lumbar epidural block|"Lumbar epidural block:~Under strict aseptic precautions, lumbar epidural was performed for patients in Group II using a 16-gauge Touhy epidural needle by a median approach. The L3 - L4 interspaces was chosen for the injection. The epidural space identified by the loss of resistance technique. The catheter was advanced 4 cm cephalad. When the aspiration test results for blood and cerebrospinal fluid were negative, a test dose of (3 mL) 2% lidocaine was given after the placement of the epidural catheter.~In the epidural catheter a bolus dose of 15 ml bupivacaine 0.25% and 1 μg/kg of dexmedetomidine dissolved in 2 ml normal saline was injected before induction of general anesthesia."
62205893|NCT06398158||NMOSD|35 people with aquaporin-4 IgG antibody positive neuromyelitis optica spectrum disorder is planned with all individuals treated with commercially supplied ravulizumab at the recommendation of the healthcare provider, with use consistent with the approved indication and labeling. Approximately 50% of the cohort is anticipated to be Black/African American based on existing internal data.
62205894|NCT05912205|EXPERIMENTAL|Disitamab Vedotin combined with radiotherapy|Disitamab Vedotin (RC48) 2.0mg/kg, once every two weeks, intravenous drip (60-90 min); Radiotherapy (SBRT, bladder irradiation field with a total dose greater than 50 Gy)
62205895|NCT06538597|EXPERIMENTAL|Self-compassion intervention|6-week manualized online Self-Compassion for Healthcare Communities course
62205896|NCT01125046|EXPERIMENTAL|Arm I|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months. Patients may then receive bevacizumab IV every 3 weeks for up to 12 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
62205897|NCT03297424|EXPERIMENTAL|PLX2853|"Phase 1b (Dose Escalation): Approximately 45 subjects with advanced malignancies to establish the MTD/RP2D. Up to 6 additional subjects may be enrolled at the MTD/RP2D as a dose confirmation.~Phase 2a (Dose Expansion): There will be 5 total expansion cohorts. Either 10 or 29 subjects per cohort in each of 4 expansion cohorts: advanced SCLC, uveal melanoma, OCCC, and any other advanced malignancy with a known ARID1A mutation (between 40 to 116 subjects total for the solid tumor expansion phase). For the 5th expansion cohort, up to 20 subjects may be enrolled for NHL."
62205898|NCT01635738|EXPERIMENTAL|LP GMNL-133 group|Arm: LP GMNL-133 group One capsule with 2x10\^9 (cfu) LP GMNL-133, once daily, PO
62205899|NCT01635738|EXPERIMENTAL|LF GM-090 group|Arm: LF GM-090 group One capsule with 2x10\^9 (cfu) LF GM-090, once daily, PO
62205900|NCT01635738|EXPERIMENTAL|LP GMNL-133+LF GM-090 group|One capsule with 2x10\^9 (cfu) LP GMNL-133+ 2x10\^9 (cfu)LF GM-090, once daily, PO
62205901|NCT01635738|PLACEBO_COMPARATOR|Placebo|
62205902|NCT03225326|EXPERIMENTAL|Computer controlled 4% articaine delivery by Anaeject|
62734927|NCT05131334|OTHER|intervention group|The pilot study applied an open-label, unblinded, repeated measures design with three time points of pupillometry measurements at two testing days. Patient serving as their own controls
62734928|NCT06658171|EXPERIMENTAL|Relaxation training and stimulus control|
62788375|NCT06085781|OTHER|Cohort B|Participants who are to receive standard of care curative surgery will have an MRI scan within one week prior to surgery. Tumor tissue from the surgery will also be collected for research. Oral pimonidazole will be taken the night before surgery.
62788376|NCT00704288|EXPERIMENTAL|Group A cabozantinib 175 mg|cabozantinib, 175 mg, taken orally once per day (qd).
62788377|NCT00704288|EXPERIMENTAL|Group B cabozantinib 125 mg|cabozantinib, 125 mg, taken orally once per day (qd).
62016438|NCT05820750|OTHER|instrumentation and photodynamic therapy|
62016439|NCT02184468|OTHER|Dual dispatch|Simultaneously dispatching of EMS, firefighters and/or police in OHCA
62016440|NCT05237765|EXPERIMENTAL|midwife-controlled massage|
62016441|NCT05237765|EXPERIMENTAL|self-controlled massage|
62016442|NCT05237765|NO_INTERVENTION|control group|
62016443|NCT03348904|EXPERIMENTAL|Arm A|Nivolumab plus epacadostat in combination with platinum doublet
62016444|NCT03348904|ACTIVE_COMPARATOR|Arm B|Platinum doublet chemotherapy
62016445|NCT03348904|EXPERIMENTAL|Arm C|Nivolumab plus placebo in combination with platinum doublet chemotherapy.
62016446|NCT00081588|EXPERIMENTAL|001|TMC114600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
62016447|NCT04010617|EXPERIMENTAL|Pharyngeal Electrical Stimulation|Orotracheal intubated patients at high risk of extubation failure will receive open-label PES
62205903|NCT03225326|ACTIVE_COMPARATOR|Conventional 4% articaine delivery by carpule syringe|
62205904|NCT00806091||COPD subjects|healthy subjects
62205905|NCT02146404|ACTIVE_COMPARATOR|Euglycemia|Plasma glucose levels will be clamped at a constant value of \~5.0 mmol/l
62205906|NCT02146404|EXPERIMENTAL|Hypoglycemia|Plasma glucose levels will be clamped at a stable value of \~3.0 mmol/l
62205907|NCT04213742|ACTIVE_COMPARATOR|Gratitude diary|
62205908|NCT04213742|NO_INTERVENTION|No intervention|
62205909|NCT04213742|ACTIVE_COMPARATOR|Gratitude visit|
62205910|NCT04702698|EXPERIMENTAL|Part 1: Peposertib: Treatment Sequence A-B-C|Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2, followed by oral suspension dose of peposertib (Treatment C) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
62205911|NCT04702698|EXPERIMENTAL|Part 1: Peposertib Treatment Sequence A-C-B|Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by oral suspension dose of peposertib (Treatment C) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment B) on Day 15 under fed condition in period 3. There will be washout period of 7 days between each treatment period.
62205912|NCT04702698|EXPERIMENTAL|Part 1: Peposertib Treatment Sequence B-A-C|Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2, followed by oral suspension dose of peposertib (Treatment C) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
62205913|NCT04702698|EXPERIMENTAL|Part 1: Peposertib Treatment Sequence B-C-A|Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by oral suspension dose of peposertib (Treatment C) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment A) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
62205914|NCT04702698|EXPERIMENTAL|Part 1: Peposertib: Treatment Sequence C-A-B|Participants will receive oral suspension dose of peposertib (Treatment C) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment B) on Day 15 under fed condition in period 3. There will be washout period of 7 days between each treatment period.
62205915|NCT04702698|EXPERIMENTAL|Part 1: Peposertib Treatment Sequence C-B-A|Participants will receive oral suspension dose of peposertib (Treatment C) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2, followed by single oral dose of peposertib tablet (Treatment A) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
62215349|NCT03222388||IIEF15 electronic-electronic|
62215350|NCT04860167|NO_INTERVENTION|Group A|The intravenous infusion of propofol was administered for ERCP procedure based on clinical judgment and the patient's requirement.
62405057|NCT01477775|ACTIVE_COMPARATOR|Standard of Care|The treating physician will be left free to give the oral P2Y12 receptor blocker, including clopidogrel,prasugrel or ticagrelor, which according to his/her clinical judgement is most appropriate for the individual patient.
62405058|NCT01477775|EXPERIMENTAL|Customized choice of the oral P2Y12 receptor blocker|The choice of the oral P2Y12 receptor blocker will be based on an algorithm which integrates phenotype information, including but not limited to residual on-treatment platelet reactivity assessed via Verifynow P2Y12 assay.
62405059|NCT06375577|EXPERIMENTAL|Voom Pocket Rocket Electro Energy Bar|After at least a 1 week washout period, every participant will undergo a different intervention
62405060|NCT06375577|EXPERIMENTAL|Maurten gel 160|After at least a1 week washout period, every participant will undergo a different intervention
62405061|NCT06375577|EXPERIMENTAL|SIS Go isotonic Gel|After at least 1 week washout period, every participant will undergo a different intervention
62405062|NCT05979389|EXPERIMENTAL|Bicalutamide|50 mg capsule administered orally once daily for 6 months
62405063|NCT05979389|PLACEBO_COMPARATOR|Placebo|Matching placebo capsule administered orally once daily for 6 months
62405064|NCT02923557|NO_INTERVENTION|Blank control|do not use prophylactic intravesical chemotherapy.
62405065|NCT02923557|EXPERIMENTAL|Single intravesical instillation|intravesical instillation within 24 hours postoperatively
62016448|NCT00701389|EXPERIMENTAL|Sequence 1: A→C→D→B|Participants receive the following: Period 1: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A); Period 2: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C); Period 3: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D); Period 4: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B). Each dosing period is separated by a 5-day washout.
62215351|NCT04860167|ACTIVE_COMPARATOR|Group B|The intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.
62215352|NCT04860167|ACTIVE_COMPARATOR|Group C|Patients received 75 mg of inj. Diclofenac sodium (diluted in 100 ml of 0.9 % normal saline) intravenously 30 mins before the start of procedure \& topical pharyngeal anesthesia with 4 squirts of 10% lidocaine spray ( one squirt each to posterior pharyngeal wall, base of tongue, and bilateral palatoglossal and palatopharyngeal folds ) 5 mins before the start of ERCP procedure. Intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.
62215353|NCT03446781|ACTIVE_COMPARATOR|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
62215354|NCT03446781|PLACEBO_COMPARATOR|Placebo|Placebo
62215355|NCT06355505||Graduate APNs|700 participants who hold the state diploma of advanced practice nurse and have been practising for more than 6 months as an APN in a hospital structure, in a health establishment in primary care or via a liberal activity in primary care
62734929|NCT06658171|ACTIVE_COMPARATOR|Sleep hygiene education|
62734930|NCT05257395|EXPERIMENTAL|XZP-3287+ Letrozole/Anastrozole|
62734931|NCT05257395|PLACEBO_COMPARATOR|Placebo + Letrozole/Anastrozole|
62734932|NCT05507125||Control|Participants without inflammatory skin disease
62205916|NCT04702698|EXPERIMENTAL|Part 2: Peposertib Treatment Sequence A-B|Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2. There will be washout period of 7 days between each treatment period.
62205917|NCT04702698|EXPERIMENTAL|Part 2: Peposertib: Treatment Sequence B-A|Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2. There will be washout period of 7 days between each treatment period.
62405066|NCT00483574|EXPERIMENTAL|Group 1: Menactra® and Routine Pediatric Vaccines|Participants received Menactra® alone at age 9 months and Menactra® concomitantly with routine pediatric vaccines (measles-mumps-rubella-varicella \[MMRV: ProQuad\], pneumococcal conjugate \[PCV\], and hepatitis A \[HepA\]) at age 12 months.
62205918|NCT02672943|NO_INTERVENTION|Normal|30 normal volunteers with age, sex and BMI-match as control group
62205919|NCT02672943|ACTIVE_COMPARATOR|treatment group|The Rehabilitation treatment group will receive rehabilitation training once per day, 3 days per week, for 12 weeks. The duration of each session is about 1 hour. Participants will first receive relaxation exercises, positioning and self-stretch exercises (emphasizing on spinal mobility and flexor muscle groups of limbs and trunk) for 15 minutes. Then they will have balance training for 20 minutes. The investigators will use goal-directed tasks, such as different types of ball games, for balance training. At the end, participants will receive walking exercise for 20 minutes, and cool down exercises for 5 minutes.
62205920|NCT02672943|SHAM_COMPARATOR|non-treatment group|The group will not receive non-rehabilitation treatment, before and after the 12 weeks non-rehabilitation training, should accept MRI and Clinical assessments.
62205921|NCT01702272||Dengue Virus|
62205922|NCT03490201|ACTIVE_COMPARATOR|Randomized - Control|Subjects with ICM and randomized to the Control group will undergo mapping and substrate-based ablation for the treatment of ventricular tachycardia with any of the protocol-specified commercially available ablation catheters indicated for patients with ICM. A protocol-specified commercially available mapping system will be used in conjunction with the control catheter in the ablation procedure. Subjects will be followed for 12 months post-procedure.
62205923|NCT03490201|ACTIVE_COMPARATOR|Randomized - Treatment|Subjects with ICM and randomized to the Treatment group will undergo mapping and substrate-based ablation for the treatment of ventricular tachycardia with the investigational FlexAbility SE Catheter. The Ampere Generator, Cool Point Irrigation Pump and the EnSite Precision Cardiac Mapping System or EnSite X EP System will be used in conjunction with the FlexAbility SE catheter in the ablation procedure. Subjects will be followed for 12 months post-procedure.
62734933|NCT05507125||Patients with HS|Patients with HS
62734934|NCT02835612|EXPERIMENTAL|Early stimulation|skin-to skin care by mother (kangaroo care) plus massage therapy by mothers.
62734935|NCT02835612|ACTIVE_COMPARATOR|Conventional care|skin-to skin care by mother (kangaroo care).
62205924|NCT03490201|EXPERIMENTAL|Non-randomized - Treatment|Subjects with NICM will undergo mapping and substrate-based ablation for the treatment of ventricular tachycardia with the investigational FlexAbility SE Catheter. The Ampere Generator, Cool Point Irrigation Pump and the EnSite Precision Cardiac Mapping System or EnSite X EP System will be used in conjunction with the FlexAbility SE catheter in the ablation procedure. Subjects will be followed for 12 months post-procedure.
62205925|NCT03791554|ACTIVE_COMPARATOR|Group A : Lateral closed Tunnel|"Laterally closed tunnel procedure with subepithelial connective tissue graft (sCTG) After local anesthesia, root planing will be performed. Recession defect - a tunneling technique will be prepared using sulcular incision is made through the gingival margin and extends post the mucogingival line leaving the interdental papilla intact.~• Recipient site; Using either single or mattress sutures, the graft will be pulled and fixed mesially and distally at the inner aspect of the pouch. The graft will be adapted to the CEJ by means of a sling suture. Margins of the pouch will be pulled together over the graft and sutured with interrupted sutures to accomplish tension-free complete or partial coverage of the graft as well as the denuded root surface."
62215356|NCT06355505||3 consecutive classes of advanced practice students|900 participants recruited during the 2nd year of training from 3 consecutive classes of students
62215357|NCT04937972|EXPERIMENTAL|SHR-1701 Combined With fluzoparib|
62215358|NCT06445751|EXPERIMENTAL|Step Up for STEM Careers Game Intervention|"Youth in the intervention group will play a six-episode, interactive game on the importance of diversity in STEM and health careers, STEM/health career self-efficacy, and creating an inclusive learning environment for others. This includes featuring diverse youth who model STEM/health self-efficacy; integrating STEM/health professional characters as in-game content experts and role models; and incorporating mini games to reinforce skills and behavior."
62215359|NCT06445751|ACTIVE_COMPARATOR|Educational PowerPoint|Youth in the comparator group will complete an educational PowerPoint presentation on the importance of diversity in STEM and health careers, STEM/health career self-efficacy, and creating an inclusive learning environment for others. This PowerPoint presentation will contain sections that correspond to each episode of the Step Up for STEM and Health Careers intervention.
62016449|NCT00701389|EXPERIMENTAL|Sequence 2: B→D→C→A|Participants receive the following: Period 1: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 2: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D): Period 3: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C); Period 4:single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A). Each dosing period is separated by a 5-day washout.
62215360|NCT03446833|EXPERIMENTAL|All Subjects|Subjects who meet the intraoperative criteria will receive The LFP Beta aDBS System.
62215361|NCT04661800|OTHER|Test de bâton de Sniff|Cohorte
62215362|NCT02644395|ACTIVE_COMPARATOR|Amlodipine|Current treatment of choice
62215363|NCT02644395|EXPERIMENTAL|Chlorthalidone|Testing new indication for approved drug
62215364|NCT01814813|EXPERIMENTAL|Arm 1, HSPPC-96 + concomitant bevacizumab|"HSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles), plus bevacizumab 10 mg/kg intravenous (IV) on day 1 of each cycle, until progression. HSPPC-96 should be administered at least 60 minutes prior to starting bevacizumab infusion. (1 cycle=14 days)~Note: If HSPPC-96 treatment has ended but there is no evidence of disease progression, the patient should continue to receive bevacizumab at the specified dose until progression."
62788378|NCT00704288|EXPERIMENTAL|Group C 125 mg|cabozantinib, 125 mg, taken orally once per day (qd).
62788379|NCT04603118|OTHER|The patients with Idiopathic intracranial hypertension (IIH)|33 patients who applied to the neurology clinic with the pre-diagnosis of IIH were performed lumbar puncture. 25 of them diagnosed with IIH. Optic nerve sheath diameter was measured by optic ultrasonography from both eyes before and after the LP.
62205926|NCT03791554|ACTIVE_COMPARATOR|Group B : Tunneling|"Tunnel procedure with subepithelial connective tissue graft (sCTG) - Control:~At the recipient site (recession defect): a tunneling technique will be prepared using sulcular incision is made through the gingival margin and extends post the mucogingival line leaving the interdental papilla intact.~Then the graft is placed and secured in the recipient site. The flap is displaced to be in a coronal position using a sling suture with no suturing to approximate the margins together."
62205927|NCT05623696|EXPERIMENTAL|Stimulation of Left DLPFC|Intervention applied to Left DLPFC located by the BeamF3 technique
62205928|NCT05623696|ACTIVE_COMPARATOR|Stimulation of Right DLPFC|Intervention applied to Right DLPFC located by the BeamF3 technique
62205929|NCT05623696|SHAM_COMPARATOR|Sham Stimulation|Sham intervention applied to either the left or right DLPFC
62205930|NCT03698110|EXPERIMENTAL|Intervention Group|Participated in one introductory session, in the four sessions of PUEDES program during four weeks and in a closing session.
62205931|NCT03698110|NO_INTERVENTION|Control Group|Participated in one introductory session and in a closing session.
62205932|NCT05441644|PLACEBO_COMPARATOR|frontal BIS|frontal BIS is a standard position
62205933|NCT05441644|ACTIVE_COMPARATOR|infraorbital BIS|Infraorbital BIS is a comparator to find agreement with standard location
62205934|NCT03321877|EXPERIMENTAL|Study group|All included patients underwent dose reduction.
62205935|NCT02893007|EXPERIMENTAL|Brief family-centered care program|The Brief family-centered care (BFCC) program was developed and provided for hospitalized patients with BPD and their family caregivers.The BFCC protocol is outlined as 4 treatment sessions, specific goals, and example questions. Four 90-minute in-depth sessions for each dyad were initially held in a quiet interview room to assess family function, then to provide information about BPD, to support and empower the dyads to change communication styles and resolve conflicts, and to sustain or improve family function in the cognitive, affective, and behavioral domains.
62205936|NCT02893007|NO_INTERVENTION|treatment-as-usual (TAU)|All patients were given the standard hospital-provided services: psychiatric nursing care, occupational therapy, and pharmacotherapy. All of the family caregivers were only to attend a routine 60-minute family discussion group about violence and suicide prevention without any specific patient-family dyad interview.
62205937|NCT01472458|ACTIVE_COMPARATOR|Active Intervention|This stepped-wedge cluster randomized evaluation will randomly allocate 18 hospitals into 4 groups to receive our active intervention at different sequential time points according to the randomly assigned stepped-wedge schedule. Hospitals will function as control hospitals until it is their turn to receive the active intervention, according to the stepped wedge schedule. Each wedge consists of 4-5 hospitals and will last 5 months.
62205938|NCT01472458|NO_INTERVENTION|Control Hospitals|This stepped-wedge cluster randomized evaluation will randomly allocate 18 hospitals into 4 groups to receive our active intervention at different sequential time points according to the randomly assigned stepped-wedge schedule. Hospitals will function as control hospitals until it is their turn to receive the active intervention, according to the stepped wedge schedule. Each wedge consists of 4-5 hospitals and will last 5 months.
62205939|NCT05501977||patients with chronic pain after thoracotomy|patients with chronic pain after thoracotomy
62205940|NCT05501977||patients without chronic pain after thoracotomy|patients without chronic pain after thoracotomy
62788380|NCT04603118|OTHER|Control group|In the control group, optic nerve sheath diameter was measured from both eyes by optic ultrasonography.
62205941|NCT00690053|EXPERIMENTAL|1|
62734936|NCT04300504||normal weight, not dynapenic|BMI 18.5 to 25kg/m2, waist circumference \<= 88cm, healthy women aged 60-80 years, time to complete 5 chair stands \<15 seconds
62788381|NCT04406025||participation in Regional Anesthesia Seminar|this group consists of anesthesiologists that have attended a Regional Anesthesia Seminar taking place once a year
62788382|NCT04406025||no participation in Regional Anesthesia Seminar|this group consists of anesthesiologists that have not attended a Regional Anesthesia Seminar taking place once a year
62788383|NCT04584437|OTHER|Vitality Therapy|"i. 500 to 1000 cubic centimeters of micro-clustered, hydrogen rich alkaline Vital Water.~ii. Irradiation in infrared sauna for 60 minutes at high fever temperature. iii. Supplementation - Multivitamins and Minerals."
62788384|NCT02647424|OTHER|PCOS group|PCOS women with anovulation
62788385|NCT02647424|OTHER|Ovulatory group|Ovulatory group planned for intra-uterine insemination
62405067|NCT00483574|OTHER|Group 2: Routine Pediatric Vaccines|Participants received routine pediatric vaccines (measles-mumps-rubella-varicella \[MMRV: ProQuad\], pneumococcal conjugate\[PCV\], and hepatitis A \[HepA\]) at age 12 months.
62734937|NCT04300504||normal weight, dynapenic|BMI 18.5 to 25kg/m2, waist circumference \<= 88cm,healthy women aged 60-80 years, time to complete 5 chair stands \>15 seconds
62205942|NCT00126503|EXPERIMENTAL|Treatment (bevacizumab and sorafenib tosylate)|"Phase I: Patients receive sorafenib PO twice daily on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of sorafenib and bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.~Phase II: Patients receive sorafenib PO once daily on days 1-28 and bevacizumab IV over 90 minutes on days 1 and 15 at the MTD in the absence of disease progression or unacceptable toxicity."
62205943|NCT01643044|EXPERIMENTAL|Alcohol intervention|Participants in this condition review tailored videos and normed feedback regarding their alcohol use and possible consequences of drinking. Next participants view a goal setting section describing possible ways to quit drinking alcohol and the participant is able to indicate a change goal (if any) and is helped through a specific change plan, should they set a change goal.
62205944|NCT01643044|PLACEBO_COMPARATOR|Control|Participants randomized into the control condition complete assessment and a time-matched interactive session on infant nutrition.
62205945|NCT05147571|ACTIVE_COMPARATOR|Active Group (responsive stimulation ON)|Participants are implanted with the RNS System and are receiving treatment with responsive stimulation.
62405068|NCT04706585||Youth|Young people in Indonesia between the age of 15-24 who are currently attending high school or university-level education to fill in our online survey.
62405069|NCT05376657|PLACEBO_COMPARATOR|Placebo drink|
62405070|NCT05376657|EXPERIMENTAL|Cherry collagen drink|
62405071|NCT06102070||Predisposition|individuals suffering of having previously suffered of severe infectious diseases
62405072|NCT02014909|EXPERIMENTAL|KTN3379|KTN3379
62734938|NCT04300504||obese, not dynapenic|BMI 30 to 40kg/m2, waist circumference \> 88cm, healthy women aged 60-80 years, time to complete 5 chair stands \<15 seconds
62405073|NCT02014909|EXPERIMENTAL|Part II, Arm A|Combination of KTN3379 and cetuximab
62734939|NCT04300504||obese, dynapenic|BMI 30 to 40kg/m2, waist circumference \> 88cm, women aged 60-80 years, time to complete 5 chair stands \>15 seconds
62734940|NCT01463163|ACTIVE_COMPARATOR|Prasugrel|Prasugrel 60mg LD followed by 10mg MD starting post 24 hours
62016450|NCT00701389|EXPERIMENTAL|Sequence 3: C→B→A→D|Participants receive the following: Period 1 :single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C), Period 2: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 3: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A): Period 4: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D). Each dosing period is separated by a 5-day washout.
62016451|NCT00701389|EXPERIMENTAL|Sequence 4: D→A→B→C|Participants receive the following: Period 1: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D), Period 2: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treament A); Period 3: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 4: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C). Each dosing period is separated by a 5-day washout.
62016452|NCT05401123|EXPERIMENTAL|Comparison of Breast Milk Content in Mothers Using a Expressing Pump and Milking by Hand|"Randomization In order to ensure similarity between groups; Stratified block randomization was used to assign the women in the sample group to the experimental and control groups. According to the stratified block randomization method, the imbalances that may occur in the experimental and control groups are limited. In this method, block randomization is performed within each stratum after stratification according to risk factors (Akın \& Koçoğlu, 2017; Kanık, Taşdelen \& Erdoğan, 2011). Since the mode of delivery affects the content of breast milk, women will be divided into two layers as vaginal delivery and cesarean section in terms of delivery type (Table 1).~In order to determine the strata group of the woman who was found to meet the research criteria and accepted to participate in the study, a list of assignments was created through the website www.randomizer.org by making 6 blocks with a combination of 4 .~Experiment: A Control: B"
62016453|NCT02972697|EXPERIMENTAL|11C-acetate PET|11C-acetate and FDG PET/MRI and PET/CT will be performed.
62016454|NCT05904600|EXPERIMENTAL|Respiratory muscle training|Respiratory muscle training with the Orygen-Dual Valve (Forumed S.L. ESP) and an initial load of 30% of their maximum inspiratory and expiratory pressures.
62734941|NCT01463163|EXPERIMENTAL|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting post 12±6 hours
62205946|NCT05147571|SHAM_COMPARATOR|Sham Group (responsive stimulation OFF)|Participants are implanted with the RNS System and are not receiving treatment with responsive stimulation.
62205947|NCT02760095||Children with EED|Children are placed in this arm if they screen positive for EED using the urinary lactulose:mannitol (L:M) recovery ratio. Children will receive a one-time 3 mg standard dose of zinc sulfate with stable isotope zinc tracer and 0.5 mg standard dose of 13C10-retinyl-acetate (vitamin A isotope).
62205948|NCT02760095||Children without EED|Children are placed in this arm if they screen negative for EED using the urinary lactulose:mannitol (L:M) recovery ratio. Children will receive a one-time 3 mg standard dose of zinc sulfate with stable isotope zinc tracer and 0.5 mg standard dose of 13C10-retinyl-acetate (vitamin A isotope).
62205949|NCT03466905|ACTIVE_COMPARATOR|Intervention|Assessment of Ambulance Medical Service
62405074|NCT02014909|EXPERIMENTAL|Part II, Arm B|Combination of KTN3379 and erlotinib
62405075|NCT02014909|EXPERIMENTAL|Part II, Arm C|Combination of KTN3379 and vemurafenib
62405076|NCT02014909|EXPERIMENTAL|Part II, Arm D|Combination of KTN3379 and trastuzumab
62405077|NCT00544778|EXPERIMENTAL|Arm 1|High-dose chemotherapy with doxorubicin at 120 mg/m2 and ifosfamide at 2 g/m2 followed by a prolonged schedule of CPT-11 at 20 mg/m2.
62788386|NCT03492541|EXPERIMENTAL|SYSTANE Complete|Propylene glycol-based eye drops, 1 drop in each eye twice a day (BID) (morning and evening) for 28 days. Patients can administer additional doses in between the scheduled daily doses as needed
62405078|NCT02654561|PLACEBO_COMPARATOR|Saline|
62788387|NCT05209373|EXPERIMENTAL|Group-Delivered Self-Compassion Intervention|"A 4-week intervention pairing behaviour change and self-compassion education, aimed to increase physical activity and help women cope with their risk of cardiovascular disease. Participants in the group condition will complete Sessions 2-4 with 6-9 other participants plus a facilitator. Both conditions will be exposed to identical intervention content. All intervention sessions will be hosted on an institution-sponsored Zoom videoconferencing account.~Week 1, Session 1 (60 minutes): Participants will meet in their group to discuss CVD risk factors and set physical activity goals.~Weeks 2-4, Sessions 2-4 (60 minutes each): Participants will meet in their group to receive self-compassion education to aimed at encouraging adaptive coping with cardiovascular risk and physical activity behaviour change. Brief self-compassionate writing exercises will be assigned as home practice after Sessions 2-4."
62405079|NCT02654561|EXPERIMENTAL|Heparin|If severe sepsis with suspected DIC is diagnosed, the Heparin sodium(2ml:12500 units) will be administered intravenously continuously for 24 hours. The course of treatment will last 7 days or until the death or discharge.
62734942|NCT00292201|EXPERIMENTAL|1|Atorvastatin
62205950|NCT03466905|NO_INTERVENTION|Control|Local treatment guidelines
62205951|NCT05704738|EXPERIMENTAL|Arm A: Dose 1|"Part 1 (Initial Period); Week 0 to Week 24: Rocatinlimab Dose 1 every 4 weeks (Q4W) for 24 weeks with loading dose at Week 2 (+ topical corticosteroids (TCS)/ topical calcineurin inhibitor (TCI) if within combination therapy cohort).~Part 2 (Maintenance Period); Week 24 to Week 52: Part 1 Responders will be rerandomised at Week 24 to Rocatinlimab Dose 1 Q4W or every 8 weeks (Q8W) for 28 weeks (+ TCS/TCI if within combination therapy cohort)."
62734943|NCT00292201|PLACEBO_COMPARATOR|2|Placebo Pill
62205952|NCT05704738|EXPERIMENTAL|Arm B: Dose 2|"Part 1 (Initial Period); Week 0 to Week 24: Rocatinlimab Dose 2 Q4W for 24 weeks with loading dose at Week 2 (+TCS/TCI if within combination therapy cohort).~Part 2 (Maintenance Period); Week 24 to Week 52: Part 1 Responders will be rerandomised at Week 24 to Rocatinlimab Dose 2 Q4W or Q8W for 28 weeks (with TCS/TCI if within combination therapy cohort)."
62405080|NCT06230705|EXPERIMENTAL|Guided management|"The intervention will be comprised of four broad components (described below). The focus groups will inform these components and therefore, we propose a community-responsive and ultimately, community-driven intervention.~1. Component on reducing barriers to health care access~2. Nutritional component~3. Activity component~4. CVD risk factor education component"
62405081|NCT06230705|ACTIVE_COMPARATOR|Self-managed|Self-managed (control group): For participants randomized to the self-managed group, we will employ the standard of care that is currently used by the Strong Heart Study (SHS) and other large cohorts, which is based on a referral program for risk factor control and dissemination of educational pamphlets. Therefore, the risk factor control and education for this group will be self-managed.
62405082|NCT03755960|EXPERIMENTAL|acupuncture plus routine care|12 session of semistandardized acupuncture together with pharmacological routine care
62405083|NCT03755960|ACTIVE_COMPARATOR|routine care alone|pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
62405084|NCT02920866|EXPERIMENTAL|Functional Strength Integration (FSI)|Progressive strength training exercise, specific functional activity to improve pelvic stability and core muscle strength
62405085|NCT02920866|ACTIVE_COMPARATOR|Control Group (CON)|Usual care, continuing education on postsurgical precautions
62405086|NCT00201266||Exacerbation resistant asthma|Control group
62734944|NCT03637257|EXPERIMENTAL|Nasal cannula / Guedel|Record of capnography using a standard nasal cannula followed by use of a modified Guedel airway
62734945|NCT03637257|EXPERIMENTAL|Guedel / nasal cannula|Record of capnography using a modified Guedel airway followed by use of a standard nasal cannula
62405087|NCT00201266||Exacerbation prone asthma|Cases
62405088|NCT01955824|EXPERIMENTAL|1% lignocaine|"Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (1%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients."
62405089|NCT01955824|ACTIVE_COMPARATOR|2% lignocaine|"Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (2%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients."
62405090|NCT02057549|EXPERIMENTAL|Haloperidol plus Conventional Therapy|Intravenous dose of haloperidol 5 mg in addition to conventional therapy. Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
62405091|NCT02057549|ACTIVE_COMPARATOR|Conventional Therapy alone|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
62405092|NCT01901952|ACTIVE_COMPARATOR|Standard of care|
62405093|NCT01901952|EXPERIMENTAL|Intensive education and support|
62016455|NCT05904600|SHAM_COMPARATOR|Control group|Simulated training with the Orygen-Dual Valve (Forumed S.L. ESP), without load.
62016456|NCT05789615||200 haplo-HSCT recipients who are CMV seropositive|"The study consists 200 cases CMV-R+ adult (\>18 years) recipients of haplo-HCT. All patients will receive letermovir prophylaxis. Consider a simple interim analysis of the experimental group could be arranged after 150 patients are enrolled if necessary.~Supportive care is provided by institutional standards of care (e.g., acyclovir for herpes simplex virus and varicella zoster virus prevention).~Letermovir prophylaxis is started on day 0 or no longer than 28 days after transplantation. During the study period, letermovir 480 mg PO/IV once daily (or 240 mg per day in patients taking cyclosporine) was administered from day 0 to day +100 post-HCT.~CMV monitoring and preemptive therapy were performed according to local protocol. Plasma CMV viral load (VL) is monitored by quantitative CMV PCR, starting on day +7 and continued weekly until week 6, then every 2-4 weeks for months until week 24."
62016457|NCT05626361|EXPERIMENTAL|Specialized Dysphagia training|Power point presentation covering material related to nursing evaluation and caring of dysphagia patients. Stimulation session with nurses to practice screening skill
62016458|NCT05626361|ACTIVE_COMPARATOR|Reading material|Reading material covering information related to nursing evaluation and caring of dysphagia patient
62016459|NCT00621439|EXPERIMENTAL|I|Receives 1 dose of Pegylated Interferon
62016460|NCT00621439|PLACEBO_COMPARATOR|II|Receives placebo
62016461|NCT01282710||Pregnant, In Labor|
62016462|NCT01112995|EXPERIMENTAL|Probiotic|subjects will be given a pill formulation of a probiotic Lactobacillus rhamnosus to be taken once a day.
62016463|NCT01112995|PLACEBO_COMPARATOR|Sugar pill|placebo identical to the active product will be given
62016464|NCT04127032|EXPERIMENTAL|Tailored ICBT for PSP|Therapist-guided, Internet-delivered cognitive behavioral therapy tailored specifically for Canadian public safety personnel.
62016465|NCT00634413|EXPERIMENTAL|1|
62016466|NCT00634413|PLACEBO_COMPARATOR|2|
62016467|NCT02261818|OTHER|Meetings with peer mentors|Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.
62016468|NCT06318299|ACTIVE_COMPARATOR|Ketone 1 hour|Ketone ester drink administered one hour before elective lumbar puncture
62016469|NCT06318299|ACTIVE_COMPARATOR|Ketone 2 hours|Ketone ester drink administered two hours before elective lumbar puncture
62016470|NCT06318299|PLACEBO_COMPARATOR|Placebo 1 hour|Placebo drink administered one hour before elective lumbar puncture
62016471|NCT05422911|ACTIVE_COMPARATOR|Abiraterone Acetate|
62016472|NCT05422911|ACTIVE_COMPARATOR|Standard of Care|
62016473|NCT02270060|EXPERIMENTAL|Music Therapy Group|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
62016474|NCT02270060|ACTIVE_COMPARATOR|Music Listening Group|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
62016475|NCT02270060|NO_INTERVENTION|Control Group|Patient receives standard care and waits in treatment room/bay for twenty minutes.
62016476|NCT05482347|ACTIVE_COMPARATOR|Control (knowledge assessment before video)|The patient will complete the knowledge assessment, then they will be presented with the educational video. After watching the video, they will complete the acceptability scale questionnaire and will be asked to select a gift card preference at the end of the survey.
62016477|NCT05482347|EXPERIMENTAL|Video (video before knowledge assessment)|The patient will be presented with the educational video, then they will complete the knowledge assessment and the acceptability scale questionnaire. They will be asked to select a gift card preference at the end of the survey.
62016478|NCT05057676|EXPERIMENTAL|Intervention Autoimmune Intervention Mastery Course (AIM) online course|This arm will begin the intervention immediately after randomization
62016479|NCT05057676|OTHER|Delayed Autoimmune Intervention Mastery Course|This is the control arm.
62016480|NCT03686774|EXPERIMENTAL|Memantine group|Memantine will be given orally for four weeks starting two weeks before surgery. Memantine will be given in increasing doses: 5 mg/day for 3 days; 10 mg/day for 3 days; 15 mg/day for 3 days and 20 mg/day for 5 days.
62016481|NCT03686774|OTHER|Usual care group|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment."
62205953|NCT05704738|EXPERIMENTAL|Arm C: Placebo|"Part 1 (Initial Period); Week 0 to Week 24: Placebo Q4W for 24 weeks with loading dose at Week 2 (+TCS/TCI if within combination therapy cohort).~Part 2 (Maintenance Period); Week 24 to Week 52: Part 1 Responders will be reassigned at Week 24 with Placebo Q4W for 28 weeks (with TCS/TCI if within combination therapy cohort)."
62205954|NCT05704738|EXPERIMENTAL|Arm D: Open-Label Dose 1|Part 2; Week 24 to Week 52: Part 1 Non-Responders will be reassigned at Week 24 with Rocatinlimab Open-label Dose 1 Q4W for 28 weeks (with TCS/TCI if within combination therapy cohort). Participants in Arms A, B or C Maintenance Period will be reassigned with Rocatinlimab Open-label Dose 1 Q4W (with TCS/TCI if within combination therapy cohort) upon relapse after Week 24.
62205955|NCT00880204|EXPERIMENTAL|Trained doctors|ESS-EMCH Training will be provided to doctors working in general emergency, pediatrics and obstetrics department in district hospitals.
62205956|NCT00880204|NO_INTERVENTION|No Training|No training will be given to doctors (act as controls)
62205957|NCT02498912|EXPERIMENTAL|Cyclophosphamide followed by Autologous T Cells|Cohorts of 3-6 pts will be infused with escalating doses of modified T cells to establish the MTD of modified T cells. There are 5 planned dose levels: 3 x 10\^5, 1 x 10\^6, 3 x 10\^6, \& 1 x 10\^7 \& 3 x 10\^7 4H11-28z/fIL-12/EGFRt+ T cells/kg. Cohort I-IV \& VI will be treated escalating dose levels. Once the MTD of T cells is established, the next cohort will receive lymphodepleting cyclophosphamide dose of 750 mg/m\^2 or a regimen of cyclophosphamide dose 300 mg/m2 x 3 days concurrent with fludarabine dose 25-30 mg/m2 x 3 days 2-7 days prior to starting the T cell infusion at one dose level below the MTD. If MTD isn't established after Cohort IV, Cohort V will receive conditioning chemotherapy 2-7 days prior to starting the T cell infusion at the same dose as Cohort III. Pts in Cohort V received cyclophosphamide chemotherapy on Day 1 or cyclophosphamide concurrent with fludarabine on Day 1-3, followed 2 to 4 days later by T cell infusion. This cohort is closed to further accrual.
62205958|NCT03697551|EXPERIMENTAL|68Ga-OPS202|A single dose of Satoreotide trizoxetan will be administered as a slow intravenous (i.v.) bolus injected over 1 minute at Baseline/Day 1.
62734946|NCT02821065|EXPERIMENTAL|Home Telemonitoring|Patients will monitor their weight, blood pressure, oxygen saturation and symptoms with sensors and a tablet computer provided to them. Patients are asked to do this everyday for 60-days. A monitoring nurse receives and reviews the data electronically and will follow-up with the patient.
62205959|NCT02867215|ACTIVE_COMPARATOR|Barley bread|Two loaves, 2 x 120 g loaf/day for 3 weeks.
62205960|NCT02867215|ACTIVE_COMPARATOR|Wheat bread|Two loaves, 2 x 120 g loaf/day for 3 weeks.
62205961|NCT05912101|EXPERIMENTAL|Group 1 (PENG)|A convex USG Probe (1-5 mHz) is placed transversely on the SIAS (Spina Iliaca Anterior Superior). The probe is then rotated 45 degrees and aligned with the pubic ramus. In this position, the iliopubic eminence, ilipsoas muscle-tendon, femoral artery and pectineus muscle are observed. A 100 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is inserted in-plane from lateral to medial to the musculofascial plane with the psoas tendon in front and the pubic ramus behind and the injection is performed.
62205962|NCT05912101|EXPERIMENTAL|Group 2 (S-FICB)|A linear USG probe (7-13 mHz) is placed parasagittal to obtain an image of the SIAS. The probe is then shifted medially to identify the fascia iliaca, iliac muscle, internal oblique muscle and deep circumflex iliac artery. A 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is advanced in-plane from caudal to cephalic and injected between the fascia iliaca and iliac muscle.
62405094|NCT01973699|PLACEBO_COMPARATOR|With Epinephrine|Patients undergoing shoulder arthroscopy with epinephrine in their irrigation as standardly performed
62405095|NCT01973699|EXPERIMENTAL|Without Epinephrine|Patients undergoing shoulder arthroscopy without epinephrine in their irrigation fluid as typically done
62405096|NCT03379038|EXPERIMENTAL|Progressive Physical Therapy (PPT)|"Duration: Each child was given 40-minute session. Frequency: Two sets were performed, 5-10 active assisted sit-ups in each set at least once a day. Furthermore, the subjects were advised to use CP chair and standing frame/wall corner for sitting/standing position respectively for at least 15-30 minutes once a day. These exercises were followed by reflex inhibiting postures in sitting and lying positions.~Total 42 sessions were performed in 6 weeks (7 days/week). Intensity: The aim of the PPT was to improve the patient's level of spasticity, strength and activity level."
62734947|NCT00333411|EXPERIMENTAL|BIRT 2584 XX high dose|
62016482|NCT05257538|ACTIVE_COMPARATOR|FMT enema|FMT enema 3-5 days after standard antibiotic treatment
62405097|NCT03379038|PLACEBO_COMPARATOR|Maintenance Physical Therapy (MPT)|"Duration: Each child was given 40-minute session. Frequency: Two sets were performed, 5-10 active assisted sit-ups in each set at least once a day. Furthermore, the subjects were advised to use CP chair and standing frame/wall corner for sitting/standing position respectively for at least 15-30 minutes once a day. These exercises were followed by reflex inhibiting postures in sitting and lying positions. Total 42 sessions were performed in 6 weeks (7 days/week).~Intensity:The aim of the MPT was to maintain the patient's current level of spasticity, strength and activity level."
62405098|NCT05031975|EXPERIMENTAL|TEMIRI|"Irinotecan intravenous infusion (IV) given every 14 days in combination with oral (PO) temozolomide over days 1-5 every 28 days.~The treatment will consist of six 28-days cycles of TEMIRI."
62405099|NCT01243853|ACTIVE_COMPARATOR|Alpha-galactosidase|
62405100|NCT01243853|PLACEBO_COMPARATOR|Placebo|
62405101|NCT03224169|EXPERIMENTAL|Intervention|Directly observed hand hygiene
62405102|NCT03224169|NO_INTERVENTION|Control|No directly observed hand hygiene
62405103|NCT03367455||ARIC and JHS participants|A combined cohort of Atherosclerosis Risk in Communities (ARIC) Study and Jackson Heart Study (JHS) participants
62405104|NCT01969331|PLACEBO_COMPARATOR|Placebo|"maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171) Placebo as an addition to standard H. Pylori eradication therapy 7 days of initial therapy (2 antibiotics + PPI), followed by 21 days of PPI only therapy.~Two weeks after the end of PPI therapy subjects are seen at the follow up visit."
62405105|NCT01969331|ACTIVE_COMPARATOR|Normia|Lactobacillus rhamnosus GG, LGG® and Bifidobacterium, BB-12® Normia® probiotic as an addition to standard H. Pylori eradication therapy 7 days of initial therapy (2 antibiotics + PPI), followed by 21 days of PPI only therapy. One capsule twice per day/14 days Two weeks after the end of PPI therapy subjects are seen at the follow up visit.
62405106|NCT02777554|EXPERIMENTAL|Part 1: Apremilast 30 mg IR BID / Apremilast 75 mg XL QD|Participants received apremilast 30 mg immediate release (IR) tablet twice a day (BID) for 7 days in treatment period 1 then apremilast 75 mg extended release (XL) formulation once a day (QD) for 7 days in treatment period 2.
62405107|NCT02777554|EXPERIMENTAL|Part 1: Apremilast 75 mg XL QD / Apremilast 30 mg IR BID|Participants received apremilast 75 mg XL formulation once a day for 7 days in treatment period 1 then apremilast 30 mg IR tablet twice a day for 7 days in treatment period 2.
62405108|NCT02777554|EXPERIMENTAL|Part 2: Sequence 1|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:~Treatment period 1: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 2: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 3: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation after a standard meal."
62405109|NCT02777554|EXPERIMENTAL|Part 2: Sequence 2|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:~Treatment period 1: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 2: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a standard meal; Treatment period 4: Apremilast 75 mg XL formulation after a high-fat meal."
62405110|NCT02777554|EXPERIMENTAL|Part 2: Sequence 3|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:~Treatment period 1: Apremilast 75 mg XL formulation after a standard meal; Treatment period 2: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 4: Apremilast 30 mg IR tablet under fasted conditions."
62405111|NCT02777554|EXPERIMENTAL|Part 2: Sequence 4|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:~Treatment period 1: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 2: Apremilast 75 mg XL formulation after a standard meal; Treatment period 3: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation under fasted conditions."
62405112|NCT05198739|EXPERIMENTAL|Video Interaction Project (VIP) Group|Parent-Child dyads will participate in a Video Interaction Project to encourage parenting practices/relationships and child development by promoting positive parenting practices.
62405113|NCT04547829|EXPERIMENTAL|PEG-rhG-CSF|pegylated recombinant human granulocyte-colony stimulating factor subcutaneous injection
62405114|NCT01135147|EXPERIMENTAL|Diet|Patients treated with diet and physical therapy for the entire 6 months of the study
62405115|NCT01135147|ACTIVE_COMPARATOR|Surgery|Patients undergoing adenotonsillectomy at some point of the study period
62580952|NCT03451591|ACTIVE_COMPARATOR|ISMN XL and Cilostazol|Oral Isotard® 25 mg XL (ISMN) and oral Cilostazol 100mg tablets. Day 1-5 / ISMN - 25mg daily evening dose / Cilostazol - NIL. Day 6-10 / ISMN - 50mg daily morning dose and Cilostazol - NIL. Day 11-15 / ISMN - 50mg daily morning dose / Cilostazol - 50mg daily evening dose. Day 16-20 / ISMN - 50mg daily morning dose and Cilostazol - 50mg twice daily morning \& evening. Day 21-25 / ISMN - 50mg daily morning dose and Cilostazol - twice daily, 50mg morning \& 100mg evening dose. Day 26-30 ISMN - 50mg daily morning dose and Cilostazol 100mg - twice daily morning \& evening. Day 30 to week 52 / ISMN 50mg morning dose and Cilostazol 100mg - twice daily morning \& evening. Week 53 / ISMN 25mg daily morning dose and Cilostazol 50mg twice daily morning \& evening. Week 54 / NIL dose
62580953|NCT03451591|PLACEBO_COMPARATOR|Neither ISMN nor cilostazol|Neither isosorbide mononitrate nor Cilostazol is administered for the entire duration of the study.
62580954|NCT01034436|PLACEBO_COMPARATOR|Low intake of ALA and triacylglycerols|Sunflower oil
62580955|NCT01034436|EXPERIMENTAL|high intake of ALA and triacylglyceroles|Canola and linseed oils
62580956|NCT01034436|EXPERIMENTAL|high intake of ALA and diacylglycerols|Canola and linseed oils
62734948|NCT00333411|EXPERIMENTAL|BIRT 2584 XX medium dose|
62205963|NCT05912101|EXPERIMENTAL|Group 3 (3-1)|A linear USG probe (7-13 mHz) is placed at the level of the femoral fold and the femoral vein-arterial-nerve is visualized. The femoral nerve is located below the fascia iliaca. At this point, a 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is inserted in-plane from lateral to medial and injected lateral to the femoral nerve. After injection, pressure is applied distal to the needle entry site to spread the local anesthetic proximally in the nerve sheath.
62205964|NCT01717742|ACTIVE_COMPARATOR|tPA and placebo|
62205965|NCT01717742|EXPERIMENTAL|tPA and DNase|
62205966|NCT04061460|OTHER|non smokers|patient who never smoked
62205967|NCT04061460|OTHER|former smoker|patient who smoked in the past
62205968|NCT04061460|OTHER|smoker|patient who still smoke
62205969|NCT02906163|EXPERIMENTAL|Thymalfasin biw plus SoC (tyrosine kinase inhibitor)|Twice weekly thymalfasin
62205970|NCT02906163|EXPERIMENTAL|Thymalfasin plus SoC (tyrosine kinase inhibitor)|5 times a week thymalfasin
62205971|NCT02906163|ACTIVE_COMPARATOR|SoC (tyrosine kinase inhibitor)|12 months
62205972|NCT03369171|EXPERIMENTAL|patients with MYO armband|
62205973|NCT04180488|EXPERIMENTAL|Study A Dupilumab|dose regimens, on top of non-sedating H1-antihistamine
62205974|NCT04180488|PLACEBO_COMPARATOR|Study A Matched Placebo|placebo, on top of non-sedating H1-antihistamine
62205975|NCT04180488|EXPERIMENTAL|Study B Dupilumab|dose regimens, on top of non-sedating H1-antihistamine
62205976|NCT04180488|PLACEBO_COMPARATOR|Study B Matched Placebo|placebo, on top of non-sedating H1-antihistamine
62205977|NCT04180488|EXPERIMENTAL|Study C Dupilumab|dose regimens, on top of non-sedating H1-antihistamine
62205978|NCT04180488|PLACEBO_COMPARATOR|Study C Matched Placebo|placebo, on top of non-sedating H1-antihistamine
62405116|NCT05378568|EXPERIMENTAL|the selection scheme of peripheral venous access devices|To implement the selection scheme of peripheral venous access devices, based on the Clinical Practice Guideline on Infusion Therapy in Children. Then observe the appropriateness of peripheral venous access devices selection.
62405117|NCT05378568|ACTIVE_COMPARATOR|the existing nursing routine|Follow the existing nursing routine of intravenous infusion and the selection of peripheral venous access devices.
62580957|NCT03832517|ACTIVE_COMPARATOR|Single intravenous doses of RC-01|Single escalating doses of RC-01 from 200 mg to 1600 mg
62580958|NCT03832517|PLACEBO_COMPARATOR|Single intravenous doses of placebo|Single intravenous doses of placebo to match RC-01
62016483|NCT05257538|PLACEBO_COMPARATOR|plasebo enema|placebo
62205979|NCT06451133|EXPERIMENTAL|Mean arterial blood pressure (MAP) goal of ≥65 mmHg|
62205980|NCT06451133|EXPERIMENTAL|Mean arterial blood pressure (MAP) goal of 85-90 mmHg|
62205981|NCT06451133|EXPERIMENTAL|Spinal cord perfusion pressure (SCPP) goal of ≥65 mmHg|
62405118|NCT01983332||occupational therapists|Occupational Therapists
62405119|NCT05220774||anesthetist-administered sedation (AAS)|Patients undergoing ERCP and receiving AAS
62580959|NCT03832517|ACTIVE_COMPARATOR|Multiple intravenous doses of RC-01|Two or three times daily escalating intravenous doses of RC-01 for 10 days. Doses to be determined
62205982|NCT00222872|ACTIVE_COMPARATOR|1 - PTHrP Group|Group receiving study drug: PTHrP(1-36)
62205983|NCT00222872|PLACEBO_COMPARATOR|2 - Single Blind Placebo Group|Receives placebo injections daily via subcutaneous injection
62205984|NCT03704623|ACTIVE_COMPARATOR|Paracetamol|Patients will receive IV 1 g of Paracetamol
62205985|NCT03704623|ACTIVE_COMPARATOR|Parecoxib|Patients will receive 40 mg of Parecoxib IV
62205986|NCT01896427|ACTIVE_COMPARATOR|Dexamethazone IO|For the case group, after the inferior alveolar block injection and before starting the surgery, single dose of dexamethasone (8mg) will injected into medial pterygoid and pterygomandibular space
62205987|NCT01896427|ACTIVE_COMPARATOR|Dexamethasone IM|For the case group, after the inferior alveolar block injection and before starting the surgery, single dose of dexamethasone (8mg) will injected into medial pterygoid and pterygomandibular space
62205988|NCT04613544||Atrial Fibrillation|Atrial fibrillation diagnosed patients.
62205989|NCT02643264|EXPERIMENTAL|rTMS 10 Hz|Deep Repetitive Transcranial Magnetic Stimulation (rTMS, 10 Hz) of the insula ,15 stimulation sessions (1 daily, 5 days / week).
62205990|NCT02643264|SHAM_COMPARATOR|rTMS Sham|Sham Repetitive Transcranial Magnetic Stimulation (rTMS, Sham),15 stimulation sessions (1 daily, 5 days / week).
62205991|NCT00821587|ACTIVE_COMPARATOR|Tacrolimus|Tacrolimus
62205992|NCT00821587|ACTIVE_COMPARATOR|Cyclosporine|Cyclosporine
62205993|NCT05353205|EXPERIMENTAL|Flumatinib (400mg)|Flumatinib 400mg QD
62205994|NCT05353205|EXPERIMENTAL|Flumatinib (600mg)|Flumatinib 600mg QD
62205995|NCT06441370||women with water births|
62205996|NCT06441370||women giving birth on land|
62205997|NCT04442100|EXPERIMENTAL|bioprosthesis|"prosthetics of heart valves with dentures MedEng-Bio"
62205998|NCT05456139|ACTIVE_COMPARATOR|Treatment as Usual Only|"During 2 of the 3 six-month periods of participation, families will receive Treatment as Usual (TAU) only. Families in the TAU control condition will receive usual care and EI service in their community, which will be tracked with the BSRC Intervention History Form. Because all families join My Baby Navigator and will be screened by the SoCo CheckUp, families in both conditions will have access to the Seamless Path for Families which includes online tools about social communication developmental milestones. Families will also have access to Autism Navigator About Autism in Toddlers, the ASD Video Glossary, and the Autism Navigator How-to Guide for Families, a self-guided online course."
62205999|NCT05456139|ACTIVE_COMPARATOR|ESI-MC plus Treatment as Usual|During 1 of the 3 six-month periods of participation, families will receive 24 weekly sessions of Early Social Interaction via Mobile Coaching (ESI-MC) by a trained early intervention provider. ESI-MC is an evidence-based parent-implemented intervention for toddlers with ASD. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places. Program planning entails building consensus with families on priority targets for the child and teaching strategies and supports for the parents using manualized conversational steps, Baby Navigator social communication milestones, and ESI content for families to practice 25 hours per week. Families will be invited to participate in the online Autism Navigator How-To Guide, a self-guided web-based course and companion online group education meetings. Families will also receive Treatment as Usual (TAU).
62206000|NCT04912687|EXPERIMENTAL|All patients|"For all patients, blood sample will be collected at inclusion (liquid biopsy) for sequencing.~As per standard management, for all of these patients, EGFR gene mutation will be also analyzed on archived tumor sample."
62206001|NCT04235153||Patients with solid or hematological cancer|All the patients complete the CANUT-QVA questionnaire
62206002|NCT06224062|EXPERIMENTAL|children|reconstituted fully functional respiratory epithelium obtained from children (0 -18 years old)
62206003|NCT06224062|EXPERIMENTAL|adults|reconstituted fully functional respiratory epithelium obtained from adults (18 to 60 years old)
62206004|NCT06224062|EXPERIMENTAL|elderly|reconstituted fully functional respiratory epithelium obtained from adults (over 60 years old)
62206005|NCT06224348|EXPERIMENTAL|Amlitelimab dose 1|Subcutaneous injection as per protocol
62206006|NCT06224348|EXPERIMENTAL|Amlitelimab dose 2|Subcutaneous injection as per protocol
62206007|NCT06224348|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection as per protocol
62206008|NCT05504317|EXPERIMENTAL|AK111 regimen|
62206009|NCT05504317|PLACEBO_COMPARATOR|Placebo|
62206010|NCT06584110|EXPERIMENTAL|BUDPA program|"BUDPA program is an overall 16-week training which comprises three phases: the conditioning, consolidating and habituating phases.~i) Conditioning Phase (1st - 4th week) is the preparatory phase to introduce exercise movements in group training.~ii) Consolidating Phase (5th -12th week) is the training phase for group-based exercise. Each exercise training session will be followed by a 20-min debriefing and goal-setting session. Self-practice will be recorded on a simple logbook.~iii) Habituating phase (13th-16th week) aims at supporting the care dyad to integrate the partner exercises into their daily lifestyle. A video call meeting with the care dyad in week 13 and week 15 will be scheduled to offer the support."
62206011|NCT06584110|PLACEBO_COMPARATOR|Usual care|Usual care will be provided in the elderly centres. Usual care group will be put on a waiting list to receive the intervention (BUDPA program) after 24-weeks (T2) the second evaluation timepoint.
62405120|NCT05220774||endoscopist-directed conscious sedation (EDCS)|Patients undergoing ERCP and receiving EDCS
62405121|NCT05044182|EXPERIMENTAL|Decompression and drainage seton|Decompress the pressure in intersphincteric space,and drainage seton will be put around the external anal sphincter.
62405122|NCT05044182|EXPERIMENTAL|Cutting seton|Cutting seton will be put around the internal and external anal sphincter.
62405123|NCT02478216|NO_INTERVENTION|C group|Remote ischemic preconditioning will not be applied
62405124|NCT02478216|EXPERIMENTAL|R group|Remote ischemic preconditioning will be applied.
62405125|NCT02267616|EXPERIMENTAL|Continued Use Implant Group|Woman randomly assigned to the continued use of their Etonogestrel Implant will continue to use their Etonogestrel Implant for contraception past FDA-approved duration of 36 months.
62405126|NCT02267616|ACTIVE_COMPARATOR|New Implant Group|Woman randomly assigned to the new Etonogestrel Implant will have their existing Etonogestrel Implant removed and a new implant placed.
62580960|NCT03832517|PLACEBO_COMPARATOR|Multiple intravenous doses of placebo|Two or three times daily intravenous doses of placebo to match RC-01
62580961|NCT04415034||Pediculosis capitis|Subjects with pediculosis capitis based on the findings of eggs, larva, or an adult parasite on the scalp or in the hair
62016484|NCT05923060|EXPERIMENTAL|Standard PDT + topical aminolevulinate + red light illumination|Standard PDT using topical aminolevulinate followed by red light illumination for actinic keratosis. A region of interest (ROI) on the skin of the arms, hands, legs, or feet will be selected for monitoring. This ROI will be marked and baseline measurements will be taken. The topical drug Levulan (ALA) will be applied to the ROI and other areas being treated, and covered with plastic wrap. Prior to red light illumination, post topical measurements and baseline values will be performed to measure PpIX and sO2. Red light illumination will follow, and sO2 phosphorescence will be recorded continuously from the ROI. After, a post-PpIX measurement will be taken.
62016485|NCT05536947|ACTIVE_COMPARATOR|Standard-milled Wholegrain|Bread rolls prepared using standard-milled Wholegrain (75 g per bread roll, containing stable isotopes of Fe and Zn), with butter and strawberry jam.
62016486|NCT05536947|EXPERIMENTAL|Micro-milled Wholegrain|Bread rolls prepared using Micro-milled Wholegrain (75 g per bread roll, containing stable isotopes of Fe and Zn), with butter and strawberry jam.
62016487|NCT05536947|ACTIVE_COMPARATOR|White flour fortified with standard milled Aleurone|Bread rolls prepared using a white flour and standard-milled aleurone mix (75 g per bread roll, containing stable isotope of Fe), with butter and strawberry jam.
62016488|NCT05536947|EXPERIMENTAL|White flour fortified with micro-milled Aleurone|Bread rolls prepared using a white flour and micro-milled aleurone mix (75 g per bread roll, containing stable isotope of Fe), with butter and strawberry jam.
62016489|NCT03599427|ACTIVE_COMPARATOR|systemic lidocaine|Lidocaine 2% IV bolus: 1.5 mg/kg at induction of anesthesia and at the end of surgery.
62016490|NCT03599427|PLACEBO_COMPARATOR|Placebo|Saline 0.9% IV bolus: 0.075 ml/kg at induction of anesthesia and at the end of surgery.
62016491|NCT06534112||Regular Consumers|
62016492|NCT06534112||Nurses|
62016493|NCT05762029||Group A|Due to respiratory and circulatory failure caused by acute server poisoning, patients accepting extracorporeal membrane oxygenation for treatment.
62016494|NCT00228449|EXPERIMENTAL|Cohort 1|Conversion from epoetin alfa to peginesatide with a conversion factor (CF) of 0.033: peginesatide dose administered intravenously once every 4 weeks (Q4W) for a total of up to 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
62788388|NCT05209373|OTHER|Positive control condition: Individually-Delivered Self-Compassion Intervention|"A 4-week intervention pairing behaviour change and self-compassion education, aimed to increase physical activity and help women cope with their risk of cardiovascular disease. Participants in the individual condition will complete Sessions 2-4 individually with a facilitator. Both conditions will be exposed to identical intervention content. All intervention sessions will be hosted on an institution-sponsored Zoom videoconferencing account.~Week 1, Session 1 (60 minutes): Participants will meet individually with a facilitator to discuss CVD risk factors and set physical activity goals.~Weeks 2-4, Sessions 2-4 (60 minutes each): Participants will meet individually with a facilitator to receive self-compassion education to aimed at encouraging adaptive coping with cardiovascular risk and physical activity behaviour change. Brief self-compassionate writing exercises will be assigned as home practice after Sessions 2-4."
62206012|NCT01037556|EXPERIMENTAL|Arm 1: PR104|
62206013|NCT05180643|EXPERIMENTAL|non-fluctuating patients or with minor fluctuations (Group A)|Patient without fluctuation or with minor motor fluctuations (rated 0 or 1 on all 5 items of the UPDRS-dyskinesia and Motor Fluctuations scale)
62206014|NCT05180643|EXPERIMENTAL|patients with mild to moderate fluctuations (Group B).|Patient without fluctuation or with minor to moderate motor fluctuations (rated 2 or 3 on all 5 items of the UPDRS-dyskinesia and Motor Fluctuations scale)
62206015|NCT03331913|ACTIVE_COMPARATOR|intradermal / submucosal injection group|intradermal / submucosal injection at pain area
62206016|NCT03331913|EXPERIMENTAL|intra-masseter injection group|intra-masseter injection on the ipsilateral of pain involved
62788389|NCT00004932|EXPERIMENTAL|260 mg/m2 imatinib mesylate (ST571)|
62016495|NCT00228449|EXPERIMENTAL|Cohort 2|Conversion from epoetin alfa to peginesatide with a CF of 0.041: peginesatide dose administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
62016496|NCT00228449|EXPERIMENTAL|Cohort 3|Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
62206017|NCT04057027|EXPERIMENTAL|Delayed Cord Clamping for 30 seconds|Infants whose umbilical cord clamping will be delayed for 30 secs.
62206018|NCT04057027|EXPERIMENTAL|Delayed Cord Clamping for 60 seconds|Infants whose umbilical cord clamping will be delayed for 60 secs.
62206019|NCT04057027|EXPERIMENTAL|Umbilical Cord Milking|Infants whose umbilical cord will be clamped after milking from the distance of 20 cm from mother's side to the baby for 3-4 times.
62206020|NCT03333759|EXPERIMENTAL|Laser Treatment|"Patients will receive one laser treatment (week 0) with the Erbium YAG laser at a 2940nm wavelength (Alma - Harmony XL Laser) and parameters corresponding with their acne scar severity. They will then return to the clinic 1, 4 and 8 weeks (7, 30, and 56 days + 7 days) after the treatment for their scars to be evaluated under optical coherence tomography.~Laser parameters are as follows:~iPixelEr 2940nm Erbium:YAG Module: mild scars: 7 by 7 (7X7) mm tip, energy 1400-1600 millijoules/P (mJ), pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap moderate scars: 7X7 mm tip, energy 1600-1800 mJ/P, pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap severe scars: 7X7 mm tip, 1800-2000 mJ/P, pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap"
62405127|NCT02267616|NO_INTERVENTION|Observational Continued Use Group|Women who refuse randomization will have an option of continuing to use their existing Etonogestrel Implant beyond the FDA-approved duration (36 months).
62206021|NCT05553106||Study Group|Patients who are hospitalized in the coronary intensive care unit, who can take simple commands, and whose condition is physiologically stable.
62206022|NCT01677767||Cohort|
62206023|NCT02974439|EXPERIMENTAL|LANDI-Amlodipine Besylate Tablet 5mg|During the study session, healthy subjects will be administered a single dose of LANDI-AmlodipineTablet 5mg under fasting and FED conditions.
62206024|NCT02974439|ACTIVE_COMPARATOR|Norvasc Tablets 5mg|During the study session, healthy subjects will be administered a single dose of Norvasc Tablets 5mg under fasting and FED conditions.
62206025|NCT06310018|EXPERIMENTAL|Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis|10 patients with bilateral PE will be treated with ultrasound-facilitated, catheter-directed lower-dose fibrinolysis (total dose 8 mg tPA given as 2 mg/hour/catheter over 2 hours) followed by 50 patients (total dose 6 mg tPA given as 3 mg/hour/catheter given over 1 hour) with the EKOS+™ system
62405128|NCT02689609||Single arm|All patients will receive intensity-modulated radiation therapy (IMRT) with or without adjunct chemotherapy as standard of care. They will have baseline pre-treatment and post-IMRT serum thyroid function test at least yearly after IMRT.
62405129|NCT03752021||Laboring Subjects|Subjects with a planned cesarean delivery who labor prior to their scheduled date or those who are in labor and require an unplanned but non-emergent cesarean delivery. These subjects will be approached upon admission to the study facility by the researcher for potential enrollment to allow adequate time to consider participation, ask questions, provide consent, and prior to procedure (Myometrial Sampling).
62734949|NCT00333411|EXPERIMENTAL|BIRT 2584 XX low dose|
62734950|NCT00333411|PLACEBO_COMPARATOR|Placebo|
62734951|NCT05745337|NO_INTERVENTION|Control|Patients randomized to the control arm will continue taking their daily beta-blocker for rate control of atrial fibrillation
62788390|NCT00004932|EXPERIMENTAL|340 mg/m2 imatinib mesylate (ST571)|
62788391|NCT00004932|EXPERIMENTAL|440 mg/m2 imatinib mesylate (ST571)|
62788392|NCT00004932|EXPERIMENTAL|570 mg/m2 imatinib mesylate (ST571)|
62016497|NCT00228449|EXPERIMENTAL|Cohorts 4 and 9|Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
62206026|NCT00501280||MSF Women + their children|Blood and urine samples and interviews of Migrant or seasonal farmworker (MSF) woman + their children
62788393|NCT04035239|EXPERIMENTAL|BGS use|Use of BGS goggles for a 3-6 weeks period.
62788394|NCT00413790|EXPERIMENTAL|1|Darifenacin
62788395|NCT00413790|ACTIVE_COMPARATOR|2|Tolterodine
62788396|NCT00413790|PLACEBO_COMPARATOR|3|Placebo
62788397|NCT03875742|OTHER|"Ultraplex 360"|"This group will execute the first TAP block using Ultraplex 360 (Braun) and the second TAP block using  STIMUPLEX D SH, 30° (Braun)"
62206027|NCT00501280||Non-MSF Women + their Children|Blood and urine samples and interviews of non-MSF women (women who have never worked in agriculture) and their children
62206028|NCT02898077|EXPERIMENTAL|8 milligram/kilogram (mg/kg) Ramucirumab + 80 mg/square meter (mg/m²) Paclitaxel|"8 mg/kg ramucirumab was administered as an intravenous infusion (IV) on days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on days 1, 8, and 15 of every 28-day cycle.~Participants may continue on treatment until discontinuation criteria were met."
62206029|NCT02898077|EXPERIMENTAL|Placebo + 80 mg/m² Paclitaxel|"Placebo was administered at a volume equivalent to a dose of 8 mg/kg by IV on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on Days 1, 8, and 15 of a 28-day cycle.~Participants may continue on treatment until discontinuation criteria were met."
62206030|NCT02897362||Adolescents with ADHD|Adolescents, male or female, ages 13-17, confirmed diagnosis of Attention Deficit Hyperactivity Disorder (inattentive, hyperactive/impulsive, or combined presentations), medically healthy, no comorbid psychiatric diagnosis other than ODD, intelligence within normal limits. Participants will complete 3 nights of ambulatory polysomnography at home and a neuropsychological assessment in the lab.
62206031|NCT02897362||Healthy Control Adolescents|Adolescents, male or female, ages 13-17, medically healthy, no psychiatric diagnoses, intelligence within normal limits. Participants will complete 3 nights of ambulatory polysomnography at home and a neuropsychological assessment in the lab.
62206032|NCT05931029||The control group|The control group received Idebenone orally, at a dose of 30mg per time, three times a day, after meals for 12 consecutive weeks.
62206033|NCT05931029||The treatmen group|The treatment group received Naohuan Dan combined with Idebenone. At a dose of one per day, delivered with warm water in the morning and evening, and taken orally for 12 consecutive weeks.
62206034|NCT01665131|EXPERIMENTAL|Subcutaneous ICD group|
62206035|NCT03873753|EXPERIMENTAL|Oral cleaning|The oral cavity will be clean with gauze and mineral water three times a day.
62206036|NCT03873753|ACTIVE_COMPARATOR|No oral cleaning|The oral cavity will not be cleaned.
62405130|NCT03752021||Non Laboring Subjects|Subjects with a planned cesarean delivery will be approached by the researcher during prenatal visits or at the study facilities prior to planned procedure (Myometrial Sampling)
62405131|NCT03904602|EXPERIMENTAL|Edema Wear|Edema Wear fuzzy wale compression garment worn on lower extremities continuously for 5 days or until discharge if less than 5 days.
62405132|NCT04472910|EXPERIMENTAL|Neo-adjuvant mFFX|Neo-adjuvant mFFX up to 6 cycles, surgery, adjuvant chemotherapy for up tp 6 cycles, follow up
62405133|NCT04409327|EXPERIMENTAL|10 mg daily RTB101|TORC1 inhibitor
62016498|NCT00228449|EXPERIMENTAL|Cohort 5|Conversion from epoetin alfa to peginesatide with a CF of 0.066: peginesatide dose administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
62016499|NCT00228449|EXPERIMENTAL|Cohort 6|Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa . Doses were administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
62016500|NCT00228449|EXPERIMENTAL|Cohorts 7 and 8|Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa dose. Doses were administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
62016501|NCT00228449|EXPERIMENTAL|Cohorts 10 and 11|Conversion from epoetin alfa to peginesatide with fixed peginesatide starting doses of 4, 6, 12 or 16 mg based on total weekly doses of epoetin alfa. Doses were administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
62016502|NCT02323724||Selected Papillary carcinoma|Cases with histological diagnosis of papillary carcinoma (CP) and previous cytological diagnosis in groups III, IV and V Bethesda, collected between October 1989 and July 2014 in Corporació Parc Taulí.
62016503|NCT03626181|EXPERIMENTAL|Active TBS-DLPFC|There is only one arm. All participants will receive Theta Burst Stimulation (transcranial magnetic stimulation) of the dorsolateral prefrontal cortex.
62016504|NCT03957122|EXPERIMENTAL|individualized rTMS|Treatment with the best (highest reduction in tinnitus loudness, most reliable, superior to control condition, most tolerable) protocol as obtained in the test sessions (left vs. right temporoparietal junction, 1Hz, 10Hz, 20Hz, 0.1Hz as active control condition).
62206037|NCT03988738|EXPERIMENTAL|Intervention|Participants will receive messages regarding blood donation promotion and campaigns through social media once or twice a week for six months.
62206038|NCT03988738|SHAM_COMPARATOR|Control|Participants will receive a message regarding blood donation at the beginning of the study through social media. After four months they will receive another message including information about upcoming blood donation campaigns.
62405134|NCT04409327|PLACEBO_COMPARATOR|Placebo|Placebo
62405135|NCT06205940|EXPERIMENTAL|Audio guided nature tour|Listening to audio instructions by an app while visiting nature.
62405136|NCT06205940|ACTIVE_COMPARATOR|Non audio guided nature tour|Visiting nature without audio guided instructions (app).
62405137|NCT02195882|EXPERIMENTAL|Exercise program|
62405138|NCT01722058|EXPERIMENTAL|peptide application|
62405139|NCT06649760|EXPERIMENTAL|Gain-framed messages|"The participants will receive every 2 weeks a boosting reminder mobile text message in a gain-framed way. For example, Great breath, healthy gums only a toothbrush away flossing your teeth daily removes particles of food in the mouth, avoiding bacteria, which promotes great breath."
62405140|NCT06649760|EXPERIMENTAL|Loss-framed message|"he participants will receive every 2 weeks a boosting reminder mobile text message in a loss-framed way. For example, Brush now and avoid bad breath and gum disease, If you don't floss your teeth daily, particles of food remain in the mouth, collecting bacteria, which causes bad breath."
62405141|NCT06649760|NO_INTERVENTION|Control group|Participants allocated to this group will not receive mobile text messages. They will only receive the oral health education session given to all participants at the beginning.
62405142|NCT06487390|EXPERIMENTAL|Resident Trainees|Family medicine resident trainees who receive the PrEP Pro training intervention
62734952|NCT05745337|EXPERIMENTAL|As needed rate control|Patients randomized to the experimental arm will stop their daily beta-blocker and take as needed rate control guided by their implantable cardiac monitor
62580962|NCT06684093|ACTIVE_COMPARATOR|Back Squat Exercise without Blood Flow Restriction|In this arm of the study, participants will perform back squat exercises without any blood flow restriction. This group serves as a control to evaluate the effects of traditional resistance training alone on strength and muscle development in healthy adolescent basketball athletes.
62016505|NCT03957122|ACTIVE_COMPARATOR|standard rTMS in responders|Treatment with standard protocol: left-sided 1Hz in the group of patients who showed temporary reductions in tinnitus loudness in test sessions.
62206039|NCT04896424|OTHER|Cryoballoon-based pulmonary veins isolation cohort|Patients treated with a 28-mm second-generation cryoballoon (Arctic Front Advance, Medtronic) for paroxysmal atrial fibrillation and screened over a 2-year post-ablation period.
62206040|NCT04245553|EXPERIMENTAL|All Participants|
62206041|NCT03950700|EXPERIMENTAL|Bupivacaine solution|In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.
62405143|NCT03094923|EXPERIMENTAL|Inspiratory muscle training|Inspiratory muscle training with threshold device and workloud 30% of the peak inpiratory preassure, during two weeks prior to surgery, seven days a week, twice a day, three sets of ten repetitions with supervision.
62405144|NCT03094923|NO_INTERVENTION|Control group|Control group will receive a supportive educational component in the preoperative period.
62405145|NCT01714726|EXPERIMENTAL|1|MEDI2070 iv infusion
62405146|NCT01714726|PLACEBO_COMPARATOR|2|placebo iv infusion
62405147|NCT01714726|EXPERIMENTAL|open-label|MEDI2070 sc injection; open-label arm is available for all subjects upon completion of first placebo-controlled treatment period
62405148|NCT05044910||MAM children with TB disease|
62405149|NCT05044910||Wellnourished children with TB disease|
62405150|NCT05044910||MAM children with latent TB infection|
62580963|NCT06684093|EXPERIMENTAL|Back Squat Exercise with Blood Flow Restriction|This arm of the study involves participants performing back squat exercises while blood flow restriction is applied to the upper legs. The aim is to assess the effects of combining traditional resistance training with blood flow restriction on strength and muscle hypertrophy in healthy adolescent basketball athletes.
62788398|NCT03875742|OTHER|" STIMUPLEX D SH, 30°"|"This group will execute the first TAP block using  STIMUPLEX D SH, 30° (Braun) and the second TAP block using Ultraplex 360 (Braun)"
62788399|NCT05542758|EXPERIMENTAL|Total Body HIIT Program|This Total Body HIIT program (circuit and bike training) will involve 3 sessions per week (35-40 min on nonconsecutive days) progressed across the 12 weeks. All session will be lead by undergraduate exercise science students or doctor of physical therapy students and supervised by a physical therapist.
62788400|NCT01807299|EXPERIMENTAL|Physical Training|The training group will make physical exercise for three months (three times a week).
62405151|NCT05044910||Well-nourished children with latent TB infection|
62405152|NCT02946515|EXPERIMENTAL|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
62405153|NCT02946515|EXPERIMENTAL|Waitlist Control Group|The control group will participate in pre- and post-test assessments of their conversational skills with a trained actor. At the end of the study, the waitlist control group will be allowed to access to the simulation and the study team will provide training to participants upon request.
62405154|NCT00557986|NO_INTERVENTION|A|Standard Systemic Therapy only group (no primary surgery)
62405155|NCT00557986|OTHER|B|Surgery group
62405156|NCT01246388||Chronic Liver Disease|
62405157|NCT06651034|EXPERIMENTAL|PRP|Intralesional Platelet rich plasma
62016506|NCT03957122|ACTIVE_COMPARATOR|standard rTMS in non-responders|Treatment with standard protocol: left-sided 1Hz in the group of patients who did not show temporary reductions in tinnitus loudness in test sessions.
62016507|NCT04635046||Patients with tears to their peroneal tendons|Patients with pain over their peroneal tendons clinically, with a verified injury to either of the two tendons on MRI, where we might expect a tendon transfer of the peroneus longus, or extirpation of the peroneus longus, during surgery.
62016508|NCT02947347|EXPERIMENTAL|(Arm A) ibrutinib + rituximab|Participants will receive 560mg of ibrutinib and rituximab 375mg/m\^2 weekly x4 with maintenance.
62405158|NCT03269565|EXPERIMENTAL|Arm 1|BCD-100 1 mg/kg Q2W;
62405159|NCT03269565|EXPERIMENTAL|Arm 2|BCD-100 3 mg/kg Q3W.
62405160|NCT05716516|OTHER|Treatment Arm|Treatment Phase: Patients will be treated with 17b-estradiol until disease progression. At this point, the patient will end protocol therapy
62405161|NCT04066127|EXPERIMENTAL|Non-ischemic heart preservation (NIHP)|Non-ischemic hypothermic perfusion (NIHP): The donor heart is preserved using a portable heart-lung machine. The device perfuse the heart continuously with a a new preservation solution at a temperature of 8°C.
62405162|NCT04066127|OTHER|Standard cold storage (SCS)|Standard cold static storage (SCS): The donor heart is preserved using a standard crystalloid cardioplegia. The heart is in then storage i a transport box containing ice to keep the temperature around 4-8°C. The device does not perfuse the heart.
62405163|NCT02905695|EXPERIMENTAL|Group A|Chirocaine
62405164|NCT02905695|PLACEBO_COMPARATOR|Group B|Placebo
62405165|NCT00925795|ACTIVE_COMPARATOR|Group A (1. EVOO; 2. ROO)|
62405166|NCT00925795|ACTIVE_COMPARATOR|Group B (1. ROO; 2. EVOO)|
62405167|NCT05590182|ACTIVE_COMPARATOR|CO2 first/ iodine CM second|CO2-enhanced angiography
62405168|NCT05590182|ACTIVE_COMPARATOR|iodine CM first/ CO2 second|iodine contrast media-enhanced angiography
62580964|NCT02101736|EXPERIMENTAL|Experimental Agent XL184 (Cabozantinib)|"Cohort A (≥ 16 years - closed to accrual): Starting cabozantinib of 40 mg daily by mouth per cycle. Duration of each cycle is 28 days. Subjects will dose escalate after 2 cycles to 60 mg based on dose tolerability. Subjects who do not tolerate 40 mg will dose reduce to 20 mg. Doses will be capped at 60 mg.~Cohort B (3 - 15 years). The starting cabozantinib dose is 30 mg/m2/day by mouth per cycle. Duration of each cycle is 28 days. Subjects will dose escalate after 2 cycles to 40 mg/m2/day based on dose tolerability. Subjects who do not tolerate 30 mg/m2/day will dose reduce to 23 mg/m2/day. Doses will be capped at 60 mg/day max daily dose~Each cohort will enroll up to 24 evaluable subjects with a target minimum of 17 evaluable subjects per cohort."
62206042|NCT03950700|PLACEBO_COMPARATOR|Saline solution|In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.
62580965|NCT04403633|EXPERIMENTAL|Receiving Educational Tool|Patients in this arm will receive the educational tool after the pretest in addition to usual care.
62788401|NCT01807299|OTHER|Sedentary|The sedentary group will be oriented not to make any type of physical training for three months.
62016509|NCT02947347|PLACEBO_COMPARATOR|(Arm B) placebo + rituximab|Participants will receive placebo and rituximab 375mg/m\^2 weekly x4 with maintenance.
62206043|NCT03122691|PLACEBO_COMPARATOR|Placebo Oral Cannabis|Single acute administration of placebo cannabis baked into a brownie
62405169|NCT01595399|ACTIVE_COMPARATOR|Atropine, fentanyl and succinylcholine|20 mcg/kg atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.
62405170|NCT01595399|PLACEBO_COMPARATOR|placebo, fentanyl and succinylcholine|an equivalent volume of normal saline to atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.
62788402|NCT01807299|PLACEBO_COMPARATOR|Placebo|The omega 3 group will receive 2g per day of mineral oil during 90 days treatment
62016510|NCT00006411|ACTIVE_COMPARATOR|1|cornea assigned from donor age group \<66.0 years
62016511|NCT00006411|ACTIVE_COMPARATOR|2|cornea assigned from donor age group \>= 66.0 years
62405171|NCT01743495|OTHER|Functional Services|The program consists of up to 10 home-based functional services sessions over 4 months.
62580966|NCT04403633|NO_INTERVENTION|Receiving Usual Care|Patients in this arm will receive usual care after the pretest.
62206044|NCT03122691|EXPERIMENTAL|Low-Dose Oral Cannabis|Single acute administration of cannabis containing 10mg THC baked into a brownie
62206045|NCT03122691|EXPERIMENTAL|High-Dose Oral Cannabis|Single acute administration of cannabis containing 25mg THC baked into a brownie
62206046|NCT03122691|PLACEBO_COMPARATOR|Placebo Vaporized Cannabis|Single acute administration of placebo cannabis via commercial vaporizer
62580967|NCT03435536|EXPERIMENTAL|Circulating tumor DNA|circulating tumor DNA rate at various times of pancreatic cancer resection
62580968|NCT05481450|EXPERIMENTAL|Dietary supplement|Consume one capsule every morning after the breakfast at the same time every day for 56 days
62016512|NCT04336579||Control|Retrospective review of patients (participants) with standard analgesia post total knee arthroplasty
62405172|NCT04566965||Full-Time CCHMC Employees|All CCHMC full-time residents and fellows who have some direct contact with patients and their families as part of normal workplace duties.
62405173|NCT05207423||Participants With Advanced NSCLC With EGFR Exon-20 Mutations|Participants diagnosed with advanced NSCLC with EGFR exon 20 insertions (ex20ins) mutations who were treated according to routine clinical practice will be observed retrospectively up to 6 months or until the end of follow-up.
62405174|NCT00622752|EXPERIMENTAL|1|EVT 302, 10 mg
62405175|NCT00622752|EXPERIMENTAL|2|EVT 302, 10 mg + NRT patch, 21 mg
62405176|NCT00622752|EXPERIMENTAL|3|NRT patch, 21 mg
62405177|NCT00622752|PLACEBO_COMPARATOR|4|Placebo to match EVT 302 and placebo patch to match NRT patch
62580969|NCT05481450|PLACEBO_COMPARATOR|Placebo|Consume one capsule every morning after the breakfast at the same time every day for 56 days
62580970|NCT06197438|EXPERIMENTAL|POFI and Tislelizumab|
62580971|NCT02300038|ACTIVE_COMPARATOR|Lidocaine (Xylocaine) 0.5%|Injection of 1ml after mixing Lidocaine 10 mg/ml 1 ml +1 ml NaCl was administrated perineuromally
62788403|NCT01807299|EXPERIMENTAL|Omega 3|The omega 3 group will receive 2g per day of fish oil during 90 days treatment
62788404|NCT01427426|EXPERIMENTAL|All Greens|Subjects will consume the All Greens product daily. Product is prepared by mixing with either water, juice or in a smoothie.
62788405|NCT01427426|SHAM_COMPARATOR|Control formulation|Subjects will consume a product of similar consistency and comparable taste that does not have the same healthy ingredients as the All Greens.
62788406|NCT04084509||Healthy Controls|
62788407|NCT04084509||Idiopathic Parkinson's Disease|
62788408|NCT04084509||Symptomatic Genetic Carriers (SNCA, Parkin or PINK1)|
62788409|NCT04084509||Asymptomatic Genetic Carriers (SNCA, Parkin or PINK1)|
62788410|NCT04954924|NO_INTERVENTION|Control group - standardized physiotherapy program|The standardized physiotherapy program was designed on the basis of S. van Grinsven et al.'s (2010) rehabilitation protocol - was applied 4 weeks, 3 times per week, the duration of the procedure was 60 minutes.
62016513|NCT04336579||Diaphragmatic Breathing|Intervention: Participants will perform diaphragmatic breathing exercises postoperatively as part of their multi-modal pain regimen.
62016514|NCT01785524|EXPERIMENTAL|BR Juice (Beet-It Stamina Shot) & Supervised Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 \& 2) and at the end of the trial (between Visits 3 \& 4). It also allows for comparisons of the combination of beetroot juice and chronic training effects (between Visits 2 \& 3) to when the subject has not consumed the beverage (Visits 1 \& 4). All subjects will consume Beet-It Stamina Shot 3 hours prior to all beverage tolerance visits, Testing Visits 2 \& 3 and for all supervised exercise training visits during the 12 week intervention.
62206047|NCT03122691|EXPERIMENTAL|Low-Dose Vaporized Cannabis|Single acute administration of placebo cannabis containing 5mg THC via commercial vaporizer
62206048|NCT03122691|EXPERIMENTAL|High-Dose Vaporized Cannabis|Single acute administration of placebo cannabis containing 20mg THC via commercial vaporizer
62206049|NCT01684787|EXPERIMENTAL|1|Peginterferon alfa-2a + ribavirin in normal ALT
62206050|NCT01684787|ACTIVE_COMPARATOR|2|peginterferon alfa-2a + ribavirin in elevated ALT
62206051|NCT02184975|EXPERIMENTAL|Stitches|Cold Knife Conization with stitches
62206052|NCT02184975|ACTIVE_COMPARATOR|No stitches|Cold Knife Conization without stitches
62405178|NCT05215509|EXPERIMENTAL|RA patients TNFi Exercise|"The patients will be randomized to 12-week supervised exercise training intervention or no exercise training. The exercise training program includes three supervised sessions per week over a 12-week period.~The program consists of high intensity endurance training on ergometer bicycles. The intensity will progress throughout the 12 weeks of training. The training consists of 10 minutes of warm up at 40-60% maximum heart rate (HRmax), followed by 25 minutes of high intensity interval training (4 bouts of 4 min at \>85% HRmax interspaced by 3 minutes of low intensity training at 40-60% Hrmax) and finally a 5 min cool-down of 50% Hrmax"
62405179|NCT05215509|ACTIVE_COMPARATOR|RA patients TNFi Control|"This group will be allocated to control and therefore no supervised exercise regimen"
62405180|NCT05215509|EXPERIMENTAL|RA patients IL-6Rb Exercise|"The patients will be randomized to 12-week supervised exercise training intervention or no exercise training. The exercise training program includes three supervised sessions per week over a 12-week period.~The program consists of high intensity endurance training on ergometer bicycles. The intensity will progress throughout the 12 weeks of training. The training consists of 10 minutes of warm up at 40-60% maximum heart rate (HRmax), followed by 25 minutes of high intensity interval training (4 bouts of 4 min at \>85% HRmax interspaced by 3 minutes of low intensity training at 40-60% Hrmax) and finally a 5 min cool-down of 50% Hrmax"
62405181|NCT05215509|ACTIVE_COMPARATOR|RA patients IL-6Rb Control|"This group will be allocated to control and therefore no supervised exercise regimen"
62405182|NCT00359866|EXPERIMENTAL|Pelvic IMRT with Tomotherapy|"Helical tomotherapy will be used to plan and deliver the radiation treatment.~Treatment volume will include the upper third of the vagina and para-vaginal tissue and the common, external and internal iliac nodal regions.~External beam radiation will be delivered in 160-180 cGy daily fractions to a total dose of 4500-5120 cGY.~Receive treatment once a day for five days a week for approximately 6 weeks.~Treating physician will make determination if patient is to receive intracavitary brachytherapy.~Treating physician will make determination if patient is to receive chemotherapy (allowed but not mandated)."
62405183|NCT03356470||FLT/PET + biopsy|F-FDG and FLT PET/CT imaging will be obtained prior to anti-cancer treatment and 10-12 weeks after starting treatment with anti-PD-1 antibody.
62405184|NCT06089590||Group Anti-IL23p19|Patients treated with anti-IL23p19 (risankizumab, guselkumab, mirikizumab, brazikumab)
62580972|NCT02300038|PLACEBO_COMPARATOR|Lidocaine (Xylocaine) 10 mg/ml 0.01%|Injection of 1 ml from 10 mg/ml 1 ml lidocaine Xylocaine +10 ml Nacl was adminsitrated perineuromally
62580973|NCT05960916|EXPERIMENTAL|Densah® bur|Densah is a bur that used for drilling of the alveolar ridge that have low bone density, narrow alveolar ridge, and sinus lifting procedure in dental implant preparation technique.
62206053|NCT01581177|EXPERIMENTAL|T1|Two inhalations, one of Albuterol DPI 25 mcg/inh and one of Placebo DPI; Total Albuterol dose of 25 mcg
62206054|NCT01581177|EXPERIMENTAL|T2|Two inhalations of Albuterol DPI 25 mcg/inh; Total Albuterol dose of 50 mcg
62206055|NCT01581177|EXPERIMENTAL|T3|Two inhalations, one of Albuterol DPI 90 mcg/inh and one of Placebo DPI; Total Albuterol dose of 90 mcg
62206056|NCT01581177|EXPERIMENTAL|T4|Two inhalations of Albuterol DPI 90 mcg/inh; Total Albuterol dose of 180 mcg
62206057|NCT01581177|PLACEBO_COMPARATOR|P|Two inhalations Placebo DPI; Total Albuterol dose of 0 mcg
62206058|NCT01581177|ACTIVE_COMPARATOR|R1|One inhalation of Albuterol MDI 90 mcg/inh; Total Albuterol dose of 90 mcg
62206059|NCT01581177|ACTIVE_COMPARATOR|R2|Two inhalations of Albuterol MDI 90 mcg/inh; Total Albuterol dose of 180 mcg
62206060|NCT02878707|EXPERIMENTAL|DEX|Intraoperative intravenous infusion of dexmedetomidine
62206061|NCT02878707|PLACEBO_COMPARATOR|Control|Intraoperative intravenous infusion of 0.9% saline
62206062|NCT02580929|EXPERIMENTAL|radiation|
62206063|NCT02580929|NO_INTERVENTION|no radiation|
62405185|NCT06089590||Group Jak inhibitors|Patient treated with Jak inhibitors (tofacitinib, upadacitinib, filgotinib)
62580974|NCT05960916|ACTIVE_COMPARATOR|Conventional bur|Conventional bur is the gold standard bur that used to prepare the osteotomy for dental implant.
62580975|NCT04438733|EXPERIMENTAL|test-anastrozole tablet|1 mg anastrozole was produced and provided by Salutas Pharma GmbH
62580976|NCT04438733|EXPERIMENTAL|reference-anastrozole tablet|1 mg anastrozole was produced by AstraZeneca Pharmaceuticals LP.
62206064|NCT03083418|EXPERIMENTAL|Control group|No EDP treatment.
62206065|NCT03083418|EXPERIMENTAL|EDP therapy group|30 minutes continuous stimulation each time, two times a day, a total of one weeks of treatment .Parameters: 30min stimulation time, pacing frequency of 9 beats / min, pulse frequency is 40 hertz, the stimulus intensity (output pulse amplitude) is in the range of 0\~30 units, which should be adjusted according to the daily maximum tolerance (patients with no pain and tension).
62206066|NCT00697645|SHAM_COMPARATOR|1|Patients with stroke will be treated with usual stroke care and sham TMS will be applied
62206067|NCT00697645|EXPERIMENTAL|2|Deep TMS applied over the motor strip in patients with stroke in addition to usual stroke care.
62206068|NCT03360448|EXPERIMENTAL|Experimental|Ad5.hAC6: Intracoronary delivery of adenovirus encoding human adenylyl cyclase type 6
62206069|NCT03360448|PLACEBO_COMPARATOR|Placebo Comparator|Placebo: Intracoronary delivery of formulation buffer ( 3% sucrose)
62206070|NCT06199180|ACTIVE_COMPARATOR|Radiofrequency ablation|In this group, patients will undergo the acquisition of a 3D high-density map. If pulmonary vein (PV) reconnection is identified, radiofrequency ablation (RFA) will be employed for pulmonary vein isolation (PVI). Should PV reconnection not be detected, the operator will have the discretion to determine the necessary ablation strategies. Patients falling into this category will be included in a concurrent registry.
62206071|NCT06199180|EXPERIMENTAL|Pulsed field ablation|In this group, pulmonary vein (PV) reconnection is identified by the FARAWAVE system. If reconnection is observed, pulsed field ablation (PFA) will be employed for pulmonary vein isolation (PVI). Should PV reconnection not be detected, the operator will have the discretion to determine the necessary ablation strategies. Patients falling into this category will be included in a concurrent registry.
62206072|NCT00693940|EXPERIMENTAL|1|Participants will receive treatment with group mediated cognitive behavioral sessions.
62788411|NCT04954924|EXPERIMENTAL|Experimental group - standardized physiotherapy program and Kinesio tape|The standardized physiotherapy program was designed on the basis of S. van Grinsven et al.'s (2010) rehabilitation protocol - was applied 4 weeks, 3 times per week, the duration of the procedure was 60 minutes. The Kinesio tape (KT) technique was chosen on the basis of K. Kase et al.'s (2003) recommendations. KT (Japan) was applied to the injured leg using muscular and functional-corrective techniques on the quadriceps femoris and the hamstring muscle. There were 6 KT procedures per participant in the experimental group. The CON group received KT only during the baseline and final assessment to assess short-term effect of KT.
62788412|NCT01901627||Adalimumab|Chinese adult patients with a diagnosis of AS who meet the requirements per the local label for treatment with adalimumab.
62206073|NCT00693940|ACTIVE_COMPARATOR|2|Participants will receive treatment with health education sessions.
62788413|NCT02148055|OTHER|A group of 20 pregnant patients.|20 patients referred for intrauterine spontaneous fetal death explored by MRI and autopsy.
62788414|NCT06525129|EXPERIMENTAL|Cerebellar stimulation group (CbSG)|
62788415|NCT06525129|EXPERIMENTAL|Cerebral (M1) Stimulation group (MSG)|
62788416|NCT06525129|OTHER|Sham Stimulation group (SSG)|
62788417|NCT03053843|EXPERIMENTAL|Mediterranean diet plus extra virgin olive oil|These patients will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months.
62788418|NCT03053843|NO_INTERVENTION|no specific diet|The control group will be assigned to the usual care and patients assigned to this group will not receive any special intervention to follow a particular diet, as occurs in the current clinical practice.
62206074|NCT05679674|EXPERIMENTAL|Stereotactic Ablative Body Radiation (SABR) and Tumor Treating Fields (TTF)|50 Gy in five fractions SABR (once per day for 5 days) and use of the TTF system for 18 hours per day starting on the first day of SABR and continuing until abdominal disease progression
62206075|NCT02241590|PLACEBO_COMPARATOR|Entecavir + Placebo|Tablet with Entrcavir+ Tablet with starch
62206076|NCT02241590|EXPERIMENTAL|Entecavir + Fuzheng Huayu Tablet|Tablet with Entrcavir+ Tablet with Fuzheng Huayu
62206077|NCT02005042|NO_INTERVENTION|Accelerometer only|Wear accelerometer only to measure activity levels (steps)
62206078|NCT02005042|NO_INTERVENTION|Accelerometer plus EMA|Wear accelerometer and complete Ecological Momentary Assessment (EMA) surveys on smartphone 5 times daily
62206079|NCT02005042|EXPERIMENTAL|Feedback on smartphone|Wear accelerometer, complete EMA surveys on smartphone 5 times daily, receive intervention
62206080|NCT05447572||FIT combingning FC with colonscopy|
62788419|NCT01158781|EXPERIMENTAL|gait, balance, arm function, cognition|12 weeks of training for balance, gait, upper limb function, and cognition
62016515|NCT01785524|PLACEBO_COMPARATOR|BR Juice Placebo and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot; Placebo) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 \& 2) and at the end of the trial (between Visits 3 \& 4). It also allows for comparisons of the combination of placebo beverage and chronic training effects (between Visits 2 \& 3) to when the subject has not consumed the beverage (Visits 1 \& 4). All subjects will consume Beet-It Stamina Shot (Placebo) 3 hours prior to all beverage tolerance visits, Testing Visits 2 \& 3 and for all supervised exercise training visits during the 12 week intervention.
62206081|NCT06163573|EXPERIMENTAL|N-TEC|N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membranes for 2 weeks to allow cells to produce extracellular matrix containing cartilage specific proteins. The IMP is implanted in the knee at the patellofemoral joint.
62206082|NCT06163573|ACTIVE_COMPARATOR|Platelet Rich Plasma|Total of 3 injections of about 5 ml each of platelet rich plasma (PRP), autologous Conditioned Plasma ACP®, Arthrex, one injection per week for three consecutive weeks.
62206083|NCT06718712|EXPERIMENTAL|Single set|One set of unilateral knee-extension exercise of 8-15 RM with a 60-90 s interval.
62206084|NCT06718712|EXPERIMENTAL|Four sets|Four sets of unilateral knee-extension exercise of 8-15 RM with a 60-90 s interval between sets.
62206085|NCT05085171|EXPERIMENTAL|intervention(Enhanced package of care) Arm|The patients with advanced HIV disease that receive HIV care at the intervention clinics will receive the enhanced intervention package which will include: point of care CD4 testing with visitect, screening for TB and cryptococcal meningitis using Fujifilm LAM and semiquantitative crAg LFA respectively and pre-emptive treatment with isoniazid and rifapentine for one month. Those with a high crAg titers will receive treatment for CNS cryptococcal disease.
62206086|NCT05085171|NO_INTERVENTION|Standard of care Arm|The patients with advanced HIV disease that receive HIV care at the standard of care clinics will receive the usual routine HIV care as per the Uganda national guidelines. That is CD4 testing with flowcytometry or other CD4 testing modalities available, screening for TB and cryptococcal meningitis using Alere LAM and crAg LFA respectively and pre-emptive treatment with isoniazid and rifapentine for 3-6 month. Treatment of all asymptomatic crAG positives with fluconazole as per guidelines.
62016516|NCT03103529|EXPERIMENTAL|Early Rehab|Children will begin active rehabilitation 2 weeks post-injury
62206087|NCT01075295|EXPERIMENTAL|Lifestyle Intervention|
62206088|NCT01075295|ACTIVE_COMPARATOR|TAU|
62206089|NCT05324085|EXPERIMENTAL|Exercise intervention group|Participants will undergo supervised treadmill exercise three times each week for eight weeks, in addition to treatment as usual (TAU).
62206090|NCT05324085|OTHER|Control group|Participants will undergo TAU. The content of TAU is broadly individualized but most often includes various forms of group therapy, psychotherapy, psychoeducation and physical activity. The physical activity schedule for the patients typically includes gym-based exercises, individualized by preference of each patient, and various outdoors activities, four times per week all together.
62206091|NCT04222777|OTHER|Heatlhy volunteers.|Healthy volunteers will undergo two cinematographic recordings of the cervical spine
62206092|NCT00658216||Longitudinal|Prospective study : cohort of consecutive patients recruited over 2 years
62206093|NCT04921475||Renal regional oxygen saturation|Renal regional oxygen saturation is measured by using near infrared spectroscopy during transcatheter aortic valve implantation
62016517|NCT03103529|ACTIVE_COMPARATOR|late rehab|Children will begin active rehabilitation 4 weeks post-injury
62016518|NCT02731092|EXPERIMENTAL|Lactoferrin 100 mg/kg|100 mg/kg enteral administration daily for 30 days
62788420|NCT05720299|EXPERIMENTAL|low-dose Akkermansia muciniphila group|They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks)
62788421|NCT05720299|EXPERIMENTAL|high-dose Akkermansia muciniphila group|They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks)
62788422|NCT05720299|PLACEBO_COMPARATOR|Placebo group|They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks)
62788423|NCT00673777|EXPERIMENTAL|A|
62788424|NCT05942547|EXPERIMENTAL|diosmin group|(Diosmin group; n = 24):will receive 600 mg twice daily
62788425|NCT05942547|PLACEBO_COMPARATOR|placebo group|placebo group n=24 :will receive placebo twice daily
62788426|NCT03075358|EXPERIMENTAL|Lidocaine spray|
62788427|NCT03075358|SHAM_COMPARATOR|Normal saline spray|
62788428|NCT03075358|NO_INTERVENTION|No spray|
62788429|NCT01761019|OTHER|Taclonex topical suspension|Taclonex topical suspension will be used daily to affected areas of skin with psoriasis for 12 weeks
62788430|NCT00099658|EXPERIMENTAL|1|HIV-uninfected infants born to HIV-uninfected mothers
62788431|NCT00099658|EXPERIMENTAL|2|HIV-infected infants in CDC Disease Category 1 who were randomly assigned to the delayed therapy arm (Arm 1) of CIPRA SA-Project 2
62788432|NCT00099658|EXPERIMENTAL|3|HIV-infected infants in CDC Disease Category 1 who were randomly assigned to the first early therapy arm (Arm 2) of CIPRA SA-Project 2
62788433|NCT00099658|EXPERIMENTAL|4|HIV-infected infants in CDC Disease Category 2 or 3 who were randomly assigned to the second early therapy arm (Arm 3) of CIPRA SA-Project 2
62788434|NCT00099658|EXPERIMENTAL|5|HIV-uninfected infants born to HIV infected mothers
62788435|NCT01992835|PLACEBO_COMPARATOR|measurement of mediators in biological fluids|
62580977|NCT06412731|ACTIVE_COMPARATOR|Ceramic bur (Cerabur) C|Cera bur (Ceramic Bur) Komet, Lemgo, Germany
62788436|NCT01992835|EXPERIMENTAL|Grass pollen allergen extract|
62580978|NCT06412731|ACTIVE_COMPARATOR|Silver Diamine Fluoride (e-SDF) S|e-SDF (SDF 38%) E-kids, India
62580979|NCT06412731|ACTIVE_COMPARATOR|CMCR gel (Brix3000) B|Brix3000 (Papain based gel) S.R.L., Argentina
62016519|NCT02731092|EXPERIMENTAL|Lactoferrin 200 mg/kg|200 mg/kg enteral administration daily for 30 days
62016520|NCT02731092|EXPERIMENTAL|Lactoferrin 300 mg/kg|300 mg/kg enteral administration daily for 30 days
62580980|NCT06328387|OTHER|Sacituzumab Govitecan|Sacituzumab Govitecan (SG) is given by intervenous route, 10 mg/kg on day 1 and day 8 of 21-day treatment cycles. Patient will receive treatment until disease progression, unacceptable toxicity, or decision to withdraw its participation.
62788437|NCT05345717|EXPERIMENTAL|Patients treated with belatacept and proteasome inhibitor|Highly sensitized patients will be treated with belatacept and proteasome inhibitor and monitored for decreasing calculated Panel of Reactive Antibodies (cPRA) and suitable kidney donor base don negative crossmatch
62788438|NCT05945446||Normal Pregnancies (control group)|Healthy pregnancies with similar gestational age and body mass index with study group.
62788439|NCT05945446||Placenta accreta spectrum pregnancies (study group)|34-36 weeks of gestation. Women diagnosed with Placenta Accreta Spectrum (PAS) were invited to join the study, providing they had no known systemic diseases (e.g. chronic hypertension, diabetes, hypothyroidism, chronic renal-liver diseases, etc.), autoimmune disorders, multiple pregnancies, or the presence of fetal structural and chromosomal anomalies. They also did not have cholestasis of pregnancy, preterm delivery, or evidence of chronic and active infection.
62016521|NCT01163734|EXPERIMENTAL|Ranolazine|
62016522|NCT01163734|PLACEBO_COMPARATOR|Saline 0.9%|Saline 0.9% and placebo tablet
62016523|NCT03860389|EXPERIMENTAL|Exercise effects on anxiety|An exercise programme will be administered 3 times a week for up to an 16 week period of time in a school setting. Each exercise class will last 60 minutes. The exercise classes will involve aspects of fundamental movement skills and will be fun for the students to participate in.
62788440|NCT03331757|EXPERIMENTAL|Glucose as reference food|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from D-glucose, tested three times, in different weeks as reference food along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
62206094|NCT03477773|EXPERIMENTAL|Intervention|Perform three session of high-intensity, interval training sessions per week over the 6-week intervention
62206095|NCT03477773|NO_INTERVENTION|Control|Continue with their normal habitual lifestyle over the 6-week intervention
62206096|NCT00457652|ACTIVE_COMPARATOR|1|7 day treatment rosuvastatin
62206097|NCT00457652|PLACEBO_COMPARATOR|2|7 day treatment placebo
62206098|NCT02259660|ACTIVE_COMPARATOR|Active Group|Subjects in this arm will train their respiratory muscles at home. The training protocol will use progressively higher pressure threshold training valves to provide respiratory muscle strength training at a pressure threshold greater than 70% maximum inspiratory (MIP) and expiratory (MEP) pressures. The total daily training time should be 20 to 30 minutes in duration.
62405186|NCT06089590||Group S1P Modulators|Patient treated with S1P modulators (ozanimod, etrasimod)
62405187|NCT06089590||Group Anti TNF|Patient treated with anti-TNF (infliximab, adalimumab, golimumab) (with a maximal proportion of 25% as 1st first line biologic after conventional treatment (aminosalicylates, corticosteroids, thiopurines, methotrexate))
62405188|NCT06089590||Group Anti integrins|Patient treated with anti-integrins (vedolizumab)
62405189|NCT06089590||Group Anti IL12/23|Patient treated with anti-IL12/23 (ustekinumab)
62405190|NCT04408950||Patients with uncharacterized immune defects|Patients with uncharacterized immune defects
62206099|NCT02259660|PLACEBO_COMPARATOR|Sham Training|The intervention in the sham training arm will be identical in every way to that of the active arm with the exception of the trainer that is provided. Subjects in the sham training arm will have inspiratory and expiratory muscle strength trainers which have had the pressure threshold spring removed and are therefore unable to provide a load to the muscles being trained.
62206100|NCT05312164||Candidates for PCI|Patients undergoing diagnostic cardiac catheterization/PCI.
62405191|NCT04408950||Unaffected biological relatives|Unaffected biological relatives
62405192|NCT04440761||Troponin rise/ diagnosis of MINOCA|This study aims to assess, in a real-world setting, the safety, efficacy and feasibility of further investigations in patients diagnosed with MINOCA among all patients with coronary artery disease.
62405193|NCT05385510|EXPERIMENTAL|Group 1 - children with HIV|100 5-36 month old children with confirmed HIV infection.
62405194|NCT05385510|EXPERIMENTAL|Group 2 - children without HIV|20 5-36 month old children without HIV infection.
62206101|NCT04199559|EXPERIMENTAL|Autologous dendritic cells pulsed with antigen|peptide(WT1-H/K-HELP, Survivin-H/K-HELP,MAGE-A4-H ⁄ K-HELP and MUC1-22) . Each dose contains of 10 million activated autologous DCs. Route of Administration: Intradermal.
62206102|NCT00566605|ACTIVE_COMPARATOR|Group 1|
62405195|NCT00696891|EXPERIMENTAL|Group A|
62206103|NCT00566605|ACTIVE_COMPARATOR|Group 2|
62206104|NCT00918879|EXPERIMENTAL|1|Saxagliptin
62405196|NCT00696891|ACTIVE_COMPARATOR|Group B|
62788441|NCT03331757|EXPERIMENTAL|Fir honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from fir honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
62788442|NCT03331757|EXPERIMENTAL|Heather honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from heather honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
62405197|NCT05588765|EXPERIMENTAL|Respiratory muscle endurance training|Volume oriented incentive spirometer improves respiratory muscle endurance and chest expansion.
62405198|NCT05588765|ACTIVE_COMPARATOR|Diaphragmatic breathing exercises|Improvement in diaphragm contraction, chest wall symmetry and reduce activity of accessory muscle due to diaphragmatic breathing technique causes respiratory muscle endurance to improve.
62580981|NCT06328387|EXPERIMENTAL|Hydroxychloroquine Combined With Sacituzumab Govitecan|"The dosage of hydroxychloroquine is determined based on the dose escalation study, and the appropriate administration method will be determined based on this result.~Sacituzumab Govitecan (SG) is given by intervenous route, 10 mg/kg on day 1 and day 8 of 21-day treatment cycles. Patient will receive treatment until disease progression, unacceptable toxicity, or decision to withdraw its participation."
62788443|NCT03331757|EXPERIMENTAL|Citrus honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from citrus honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
62016524|NCT03639480|EXPERIMENTAL|Test|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
62016525|NCT03639480|ACTIVE_COMPARATOR|Reference 1|Amlodipine 10mg+Valsartan 160mg
62016526|NCT03639480|ACTIVE_COMPARATOR|Reference 2|Valsartan 160mg+Atorvastatin 40mg
62580982|NCT06328387|OTHER|Trastuzumab Deruxtecan|Patients will receive T-DXd at 5.4 mg/kg administered as an intravenous (IV) infusion every three-weeks (Q3W) until disease progression, unacceptable toxicity, death, or discontinuation from the study.
62788444|NCT03331757|EXPERIMENTAL|Pine honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from pine honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
62016527|NCT02206802||Predicted as non-responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as non-responders. 5% minoxidil topical foam will be administered to subjects in this group.
62016528|NCT02206802||Predicted as responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as responders. 5% minoxidil topical foam will be administered to subjects in this group.
62016529|NCT00320216|PLACEBO_COMPARATOR|Group I (Placebo)|Patients in the placebo group will receive placebo at Weeks 0, 1, 2, 3, and 16. At week 20, all patients will receive a single dose of ustekinumab 90 mg.
62016530|NCT00320216|EXPERIMENTAL|Group II (Ustekinumab 45 mg)|Patients will receive single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.
62206105|NCT00918879|PLACEBO_COMPARATOR|2|
62215365|NCT01814813|EXPERIMENTAL|Arm 2, HSPPC-96 with bevacizumab at progression|"HSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles). At progression: bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until further progression. (1 cycle = 14 days)~NOTE: It is possible that HSPPC-96 vaccination may end prior to evidence of progression. In this instance it is important to wait until there is confirmed evidence of progression before initiating treatment with bevacizumab.~Upon confirmation of progression the patient should initiate bevacizumab within 7-42 days from the last dose of vaccine."
62215366|NCT01814813|ACTIVE_COMPARATOR|Arm 3, Bevacizumab|Bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until progression. (1 cycle = 14 days)
62215367|NCT00484822|EXPERIMENTAL|1|Brazo 1: Bemiparina Sódica 3.500 UI/día.
62405199|NCT06651086|ACTIVE_COMPARATOR|Unstuck and On Target|Unstuck and on Target (Unstuck; Cannon et al., 2021) is a cognitive-behavioral, intervention designed to be feasibly delivered by teachers and school staff in the elementary school setting. It was adapted for and pilot-tested in outpatient mental health. Unstuck targets key executive functions, including flexibility, goal-setting, planning, and coping. Sessions include prescribed content and activities to facilitate guided practice and home extension activities to aid generalization beyond the therapeutic session. It includes both child- and caregiver-directed strategies. It has been shown effective for youth with autism and attention-deficit/hyperactivity disorder.
62405200|NCT06651086|ACTIVE_COMPARATOR|Unified Protocol for Children|Unified Protocol for Children is a transdiagnostic, cognitive-behaviorally based treatment targeting shared core dysfunctions underlying emotional disorders, including distress intolerance and emotional dysregulation. It was developed by integrating cognitive-behavioral and mindfulness strategies and includes prescribed activities, in-vivo experiments, and home-extension components to promote generalization. It includes both child- and caregiver-directed strategies. In addition to its effectiveness for youth with emotional disorders, recent work supports its efficacy for youth with additional non-emotional disorders (e.g., externalizing challenges, irritability).
62405201|NCT02808182|OTHER|A0: PET/scan with [11C] palmitate|A bolus of 180 MBq of \[11C\]-acetate at time 90min and PET acquisition
62405202|NCT02808182|OTHER|A1: PET/scan with [11C] palmitate|A bolus injection of 180 MBq of \[11C\]-acetate at time 90min, followed by PET acquisition
62788445|NCT03331757|EXPERIMENTAL|Thyme honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from thyme honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
62016531|NCT00320216|EXPERIMENTAL|Group III (Ustekinumab 90 mg)|Patients will receive 90 mg single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16 patients with PGA greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.
62016532|NCT00320216|EXPERIMENTAL|Group IV|Patients will receive 45 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.
62016533|NCT00320216|EXPERIMENTAL|Group V|Patients will receive 90 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16 patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.
62016534|NCT02252081|ACTIVE_COMPARATOR|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR \> 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =\< 45 ml/min
62016535|NCT02252081|PLACEBO_COMPARATOR|Placebo|placebo pill(s) orally per day for 16 weeks
62016536|NCT05908240|OTHER|Care Coordination|
62016537|NCT03963518||Control|chemotherapy
62215368|NCT00484822|PLACEBO_COMPARATOR|2|Brazo 2: Heparina Cálcica 10.000 UI/día.
62405203|NCT02808182|OTHER|B0: PET/scan with [18F]-FTHA|At time 0, a standard liquid meal will be drunk over 20 minutes with 70 MBq of 18FTHA . PET acquisition at time 90 min.
62405204|NCT02808182|OTHER|B1: PET/scan with [18F]-FTHA|At time 0, a standard liquid meal will be drunk over 20 minutes with 70 MBq of 18FTHA followed by a PET acquisition at time 90 min.
62405205|NCT04216134|EXPERIMENTAL|Diagnostic (68GA-PSMA-11 PET)|Patients receive gallium Ga 68-labeled PSMA-11 IV over less than 1 minute, and then undergo PET over 60 minutes.
62788446|NCT03331757|EXPERIMENTAL|Chestnut honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from chestnut honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
62405206|NCT04951895||control group|patients with normal TMJ
62788447|NCT03620084|EXPERIMENTAL|Expiratory Muscle Strength Training (EMST)|Participants will be taught how to use the EMST-150 device. The device has a one-way spring-loaded valve calibrated at different resistances that the user can select. The valve will open when expiratory pressure exceeds the threshold set by the user on the device. This threshold is set at 75% of the individual's maximum expiratory pressure for the session.
62016538|NCT03963518||Experimental|immune-checkpoint inhibitor
62016539|NCT02929576|EXPERIMENTAL|Double-blind enzalutamide with paclitaxel|
62215369|NCT03238365|ACTIVE_COMPARATOR|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes on days 3 and 17 and undergo surgery on day 31.
62215370|NCT03238365|EXPERIMENTAL|Arm II (nivolumab, tadalafil)|Patients receive nivolumab IV over 60 minutes on days 3 and 17 and tadalafil PO QD on days 3-31. Patients then undergo surgery on day 31.
62215371|NCT02508220|OTHER|Oxy-Placebo|Syntocinon first, Placebo second 2 puffs in each nostril
62016540|NCT02929576|PLACEBO_COMPARATOR|Double-blind placebo with paclitaxel|
62016541|NCT02929576|EXPERIMENTAL|Open-label enzalutamide monotherapy followed by paclitaxel|At the time of disease progression, enzalutamide treatment will be discontinued and paclitaxel will be administered if considered to be an appropriate treatment by the treating physician until second disease progression.
62016542|NCT02530619|EXPERIMENTAL|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62016543|NCT01479036|ACTIVE_COMPARATOR|docetaxel and epirubicin|DE chemotherapy alone
62016544|NCT01479036|EXPERIMENTAL|docetaxel and epirubicin plus endostatin|chemotherapy plus endostatin
62016545|NCT03705039|ACTIVE_COMPARATOR|Treatment Group|pulsed ultrasound treatment
62206106|NCT05263674|NO_INTERVENTION|"Non-sedative medical treatment"|"The patient is treated with an additional high-dose intravenous antiepileptic drug, which is selected by the treating neurologist. If NCSE continues to be detected at cEEG or clinically\> 3 hours after starting treatment, the patient should receive standard treatment (i.e. sedation in the intensive care unit or addition of additional intravenous antiepileptic drugs) in accordance with local guidelines and the assessment of the treating neurologist. The following preparations are permitted as additional treatment:~Levetiracetam (60 mg / kg as saturation dose followed by maintenance dose of 2-4 g / day), valproate (60 mg / kg as saturation dose followed by maintenance dose of 20 mg / kg / day), phosphenytoin (20 PE as saturation dose followed by maintenance dose 5 mg PE / kg / day), lacosamide (400 mg as a saturation dose followed by a maintenance dose of 200-400 mg / day), topiramate (200-400 mg per probe as a saturation dose followed by a maintenance dose of 200-400 mg / day)."
62206107|NCT05263674|EXPERIMENTAL|Fast sedation|Within a maximum of 60 minutes after the diagnosis of NCSE (EEG or clinical), the patient must be sedated with high-dose Propofol (bolus 3-5 g / kg, maintenance dose 5-10 mg / kg / hour) to - 5 on the Richmond agitation sedation scale (RASS) for 20 hours, and a single anti-epileptic drug should be added as adjunctive therapy. Addition of low-dose Midazolam (max. 0.1 mg / kg / h) is permitted if deep sedation (defined clinically by RASS -5) is not possible with Propofol alone. After 20 hours, the sedation should be completely phased out within 3 hours.
62206108|NCT03878992|OTHER|GHD|GHD patients will be studied two times - one time before initiation of GH replacement therapy and one time following three months of GH replacement therapy. The two trial days are identical
62206109|NCT02466464|ACTIVE_COMPARATOR|Microporous Polysaccharide Hemospheres (MPH)|Subjects with acute epistaxis will receive microporous polysaccharide hemospheres (Arista) powder. In the event that Arista fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the control group and will receive Merocel.
62206110|NCT02466464|ACTIVE_COMPARATOR|Merocel (Control)|Subjects with acute epistaxis will receive standard-of-care treatment, nasal tampon (Merocel). In the event that Merocel fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the MPH group and will receive Arista powder.
62206111|NCT06190964|EXPERIMENTAL|Integrative medicine|The employees are treated by a team from the system for integrative medicine, including practitioners of acupuncture; touch/movement techniques (for example, qigong, reflexology, shiatsu) or mind-body medicine (for example, relaxation and breathing exercises) and may include one or more of the above 3 treatment areas.
62206112|NCT03130881|EXPERIMENTAL|PLB1003|ALK-positive (ALK+) advanced NSCLC
62206113|NCT04164342|EXPERIMENTAL|Single ARM|This is an observational study, all patients will be followed at 3, 6 and 12 months by phone interviews to pass the Brief Pain Inventory (BPI) and the Patient Health Questionnaire-2 (PHQ-2) questionnaires (this is the intervention, since questionnaires at not usually done).
62206114|NCT05695560||Phase 1: Adult Participants|Adult participants with severe VWD (self-bleeding assessment tool \[BAT\] score ≥10) and their caregivers will be enrolled as per protocol specifications. Data will be collected from participants via questionnaire, semi-structured interviews, and focus groups using a virtual platform.
62580983|NCT06328387|EXPERIMENTAL|Hydroxychloroquine Combined With Trastuzumab Deruxtecan|"The dosage of hydroxychloroquine is determined based on the dose escalation study, and the appropriate administration method will be determined based on this result.~Patients will receive T-DXd at 5.4 mg/kg administered as an intravenous (IV) infusion every three-weeks (Q3W) until disease progression, unacceptable toxicity, death, or discontinuation from the study."
62788448|NCT05777135|EXPERIMENTAL|Group I (Preloading with Ringer Lactate)|Preloading with Ringer lactate 30ml/kg over 30 minutes prior to surgery and Propofol dose requirement for induction of anaesthesia will be noted
62788449|NCT05777135|NO_INTERVENTION|Group II (No preloading)|No preloading will be done and Propofol dose requirement for induction of anaesthesia will be noted
62016546|NCT03705039|PLACEBO_COMPARATOR|Control Group|sham ultrasound treatment
62016547|NCT06199141||VV-ECMO patients|Patients requiring VV-ECMO for acute respiratory distress syndrome (ARDS)
62016548|NCT04499157|EXPERIMENTAL|MEMOPTIC added to the usual treatment of glaucoma|MEMOPTIC added to the usual treatment of glaucoma
62016549|NCT04499157|ACTIVE_COMPARATOR|usual treatment of glaucoma|usual treatment of glaucoma
62016550|NCT04292301|EXPERIMENTAL|STrategically Acquired Gradient Echo (STAGE)|STAGE Inputs are flow compensated 3D gradient echo MR images acquired at optimal parameters which are used to calculate multiple contrasts for brain imaging. All subjects within the study are imaged using both a conventional MR protocol and STAGE protocol.
62016551|NCT03508557|EXPERIMENTAL|Advance care planning tools|Advance care planning education and structured conversation using tools
62016552|NCT00824590|EXPERIMENTAL|Severe renal impairment group|Subjects with severe renal impairment defined by creatinine clearance of less than 30 mL/min but not yet on dialysis
62016553|NCT00824590|EXPERIMENTAL|normal renal function|Subjects with normal renal function defined by creatinine clearance of greater than 80 mL/min and demographically comparable to subjects with impaired renal function
62215372|NCT02508220|OTHER|Placebo-Oxy|Placebo first, Syntocinon second 2 puffs in each nostril
62405207|NCT04951895||Study group|Patients with TMJ internal deragement
62788450|NCT01201408||Dental Caries assessment|
62788451|NCT06291831||Patients receiving Nirmatrelvir; Ritonavir (PAXLOVID)|Adult COVID-19 patients' Healthcare Resource Utilization (HRU) within the 30-day period following nirmatrelvir, ritonavir prescription.
62016554|NCT05557279|OTHER|Intervention Group|All participants will receive 500 mg NDS-446 daily for 12 weeks
62016555|NCT03129347|EXPERIMENTAL|Nalmefene (high dose)|Nalmefene (high dose) intranasal one time during the 17 day inpatient treatment period
62016556|NCT03129347|EXPERIMENTAL|Nalmefene and Intravail|Nalmefene (high dose) with Intravail intranasal one time during the 17 day inpatient treatment period
62016557|NCT03129347|EXPERIMENTAL|Nalmefene (low dose)|Nalmefene (low dose) intranasal one time during the 17 day inpatient treatment period
62016558|NCT03129347|EXPERIMENTAL|Nalmefene Intramuscular|Nalmefene intramuscular one time during the 17 day inpatient treatment period
62016559|NCT05595798||Geriatric population|patient with ages above 65-yr
62016560|NCT05595798||Pediatric population|patient with ages between 4-8 year old
62016561|NCT02375412||Pre-operative HRV group|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery.
62206115|NCT05695560||Phase 2: Pediatric Participants|Pediatric participants with severe VWD (self-pediatric bleeding questionnaire \[PBQ\] score of ≥3 for at least one symptom and caregivers will be enrolled as per protocol specifications. Data will be collected from participants via questionnaire, semi-structured interviews, and focus groups using a virtual platform. The decision to proceed with Phase 2 will be determined following completion of Phase 1.
62206116|NCT02942992|NO_INTERVENTION|Control|Usual Care Group
62405208|NCT03079648|EXPERIMENTAL|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 12 weeks.
62405209|NCT03079648|PLACEBO_COMPARATOR|Placebo|Placebo for 12 weeks
62016562|NCT01969838|EXPERIMENTAL|Momelotinib|Participants will receive momelotinib plus placebo to match ruxolitinib.
62016563|NCT01969838|ACTIVE_COMPARATOR|Ruxolitinib|Participants will receive ruxolitinib plus placebo to match momelotinib.
62016564|NCT00585897|EXPERIMENTAL|Behavioral counseling|Individual sessions which utilize motivational interviewing to assist participants to discontinue sugar sweetened beverages from their diet.
62016565|NCT00289341|PLACEBO_COMPARATOR|Placebo|12 patients in the placebo Arm for 8 weeks followed by DC/LNCAP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks.
62016566|NCT00289341|EXPERIMENTAL|DC/LNCaP|12 patients, receiving DC/LNCaP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks
62016567|NCT01642797|EXPERIMENTAL|CLE-TB|Confocal laser endomicroscopy with Targeted Biopsy
62016568|NCT01642797|EXPERIMENTAL|WLE-SB|Standard White-light endoscopy with Standard Biopsy
62016569|NCT02139644|EXPERIMENTAL|FS MDPI 100 / 12.5 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
62016570|NCT02139644|EXPERIMENTAL|FS MDPI 50 / 12.5 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg (for a total daily dose of 100 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
62016571|NCT02139644|EXPERIMENTAL|Fp MDPI 100 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg for a total daily dose of 200 mcg for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
62016572|NCT02139644|EXPERIMENTAL|Fp MDPI 50 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg for a total daily dose of 100 mcg for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
62405210|NCT00323830|EXPERIMENTAL|capecitabine/cisplatin/radiotherapy|postoperative XP/RT
62405211|NCT00323830|ACTIVE_COMPARATOR|capecitabine/cisplatin|postoperative XP
62405212|NCT05341427|EXPERIMENTAL|burn wound receiving electromagnetic therapy|There will be only one intervention group. The duration of the study will be 6 weeks divided to 18 sessions (three sessions per week). Sixty patients (male and female) will be recruited from the burn units of Cairo university hospitals
62405213|NCT01068535||Women with Metabolic Syndrome|"Pre-menopausal women with Metabolic Syndrome~Age 35-50 and any 3 of the following:~Fasting triglycerides ≥ 150 mg/dL, Waist measurement ≥ 35 inches, HDL \< 50mg/dL, Fasting glucose ≥ 100mg/dL but \<126mg/dL or Blood pressure ≥ 130/85 or taking medication to treat high blood pressure."
62405214|NCT01068535||Non-Metabolic Syndrome (healthy) women|"Non-Metabolic syndrome pre-menopausal women age 35-50~* Body Mass Index ≤ 25~* Regular menstrual cycles (occur every 24-35 days)~* Fasting glucose \< 100mg/dL~* HDL-C ≥ 50mg/dL~* Waist measurement ≤ 35 inches~* Fasting triglycerides \< 150mg/dL"
62405215|NCT00661037||1|Patients having VF induction with shock termination at implant
62206117|NCT02942992|OTHER|Intervention|Intervention Group
62206118|NCT02799641|PLACEBO_COMPARATOR|Control|Control arm receives ibuprofen, placebo pill, and placebo injection.
62206119|NCT02799641|EXPERIMENTAL|Treatment|Treatment arm receives ibuprofen, diazepam pill, and lidocaine injection.
62206120|NCT05714891|EXPERIMENTAL|Neoadjuvant therapy (JDQ443) followed by surgery. (ARM CLOSED)|"If \*MPR/cPR\* - standard of care adjuvant treatment may be followed by experimental adjuvant therapy (JDQ443)~\*Major Pathological Response (MPR)/ Complete Pathological Response (cPR)"
62405216|NCT00661037||2|Patients not having VF induction at implant or during follow-up
62405217|NCT02621528|OTHER|CeraFlex occluder|The Lifetech CeraFlex™ study is a triple-arm study.
62405218|NCT00383929|EXPERIMENTAL|1|Candesartan Cilexetil (CC) /HCT 32/12.5mg
62405219|NCT00383929|EXPERIMENTAL|2|Candesartan Cilexetil (CC) /HCT 32/25mg
62405220|NCT00383929|EXPERIMENTAL|3|Candesartan Cilexetil monotherapy
62788452|NCT06291831||Controls|Adults COVID-19 patient HRU within 30 days period following nirmatrelvir/ritonavir prescription
62580984|NCT05756816|EXPERIMENTAL|SurePulse VS and VSP devices|All enrolled participants will undergo a controlled and stepwise reduction in oxygen blood levels, with both the SurePulse VS/SurePulse VSP placed on the volunteer.
62405221|NCT06316401||Patients underwent endoscopic submucosal dissection under spinal anesthesia|"We collected data on all consecutive patients who underwent ESD for recto-sigmoid laterally spreading tumors (LSTs) \>35 mm under SA.~SA was carried out in a sitting position, following a strictly aseptic technique. After recognition of L2-L3 intervertebral space through landmark technique, a 25 Gauge needle was inserted and the correct positioning was confirmed by detecting free flow of cerebrospinal fluid. Subsequently, 10-12 mg of hyperbaric bupivacaine + sufentanil 2 mcg according to the decision of the anesthetist was administered intrathecally without barbotage.~Subsequently, the patient underwent ESD of the colorectal lesion."
62405222|NCT00495950||Questionnaire|
62405223|NCT03414099|EXPERIMENTAL|Ketum|Each participant will consume a sequence of active ketum or placebo drinks. Pain tolerance will be measured using the cold pressor task after consuming each drink.
62016573|NCT02139644|PLACEBO_COMPARATOR|Placebo MDPI|"The placebo multidose dry powder inhaler was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart).~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
62016574|NCT05031624|EXPERIMENTAL|CDX-0159|Subjects will receive a single dose of CDX-0159
62016575|NCT05031624|PLACEBO_COMPARATOR|Normal Saline|Subjects will receive a single dose of normal saline
62405224|NCT03414099|PLACEBO_COMPARATOR|Placebo|Each participant will consume a sequence of active ketum or placebo drinks. Pain tolerance will be measured using the cold pressor task after consuming each drink.
62580985|NCT05354778|PLACEBO_COMPARATOR|Placebo|Normal saline 100mL every 8 hours for 5 days or until patient dies or is discharged from the intensive care unit
62405225|NCT05129527|EXPERIMENTAL|InspirerMundi app plus usual care|Patients, in addition to usual care, will be invited to use the InspirerMundi app for 4 months to support adherence to preventive inhaled medication and their asthma self-management.
62405226|NCT05129527|ACTIVE_COMPARATOR|Usual care|Patients in the control group will maintain usual care during the study.
62580986|NCT05354778|ACTIVE_COMPARATOR|Hydrocortisone|Hydrocortisone 100mg + normal saline 100mL every 8 hours for 5 days or until patient dies or is discharged from the intensive care unit
62580987|NCT05225870|OTHER|patients with colorectal carcinoma|patients with colorectal carcinoma will undergo colectomy. their colectomy specimens will be sectioned, tissue blocks will be prepared from tumor and adjacent normal mucosa. sections will be stained immunohistochemically by antibody against cortactin.
62580988|NCT06165835|NO_INTERVENTION|Experimental|Patients who have recovered from COVID-19
62580989|NCT06165835|EXPERIMENTAL|Three months after recovering from COVID-19|Patients who have from COVID-19 in three months
62580990|NCT06165835|EXPERIMENTAL|Six months after recovering from COVID-19|Patients who have from COVID-19 in three to six months
62206121|NCT02699138|EXPERIMENTAL|Trazodone|To determine effect of trazodone on quality of sleep as measured by apnea hypopnea index in subjects with obstructive sleep apnea and PTSD on routine overnight polysomnogram.
62206122|NCT02699138|PLACEBO_COMPARATOR|Placebo|To compare placebo outcomes against administration of trazodone
62206123|NCT06365788|EXPERIMENTAL|Abemaciclib and bicalutamide|Participants receive Abemaciclib 150 mg tablet orally twice daily and Bicalutamide 150 mg orally once daily until disease progression or unacceptable toxicity.
62206124|NCT06728410|EXPERIMENTAL|Pemigatinib + Durvalumab|Pemigatinib 13.5 mg will be taken orally at the same time each day for 14 days (Day 1 through Day 14), followed by 7 days off treatment (Day 15 through Day 21) of each 21 day cycle. Durvalumab 1500 mg IV will be administered every 3 weeks on Day 1 of each 21-day cycle.
62206125|NCT02085395|EXPERIMENTAL|SR-T100 ® Gel|Topical gel containing 2.3% of solamargine in Solanum undatum extract is used once daily with occlusive dressing for 16 weeks.
62206126|NCT04961177|OTHER|EITC & ACEs Training|Trainings for frontline health workers about EITC and ACEs.
62206127|NCT04961177|OTHER|EITC Outreach and Screening|Our partners will implement EITC outreach events and EITC screening with clients.
62206128|NCT04961177|OTHER|EITC Assistance|Our partners will screen clients for EITC and refer those who qualify for free tax preparation assistance and assistance submitting their tax returns.
62206129|NCT04877353|EXPERIMENTAL|Group N|50 patients.NIV applied for approximately 30 to 45 min at 2- to 4-h intervals for 48 h following surgery
62206130|NCT04877353|NO_INTERVENTION|group C|50 patients recieved conventional oxygen therpy.
62206131|NCT05012553|NO_INTERVENTION|no education about self and peer assesment|Stoma care skills of the group who did not receive self- and peer-assessment training will be evaluated.
62206132|NCT05012553|EXPERIMENTAL|education of self and peer assesment|Stoma care skills of the group who received self and peer assessment training will be evaluated.
62405227|NCT02070367|EXPERIMENTAL|Somatosensory rehabilitation|Weekly sessions with a certified (RSDC) somatosensory therapist using distal vibro-tactile counter-stimulation to anatomically related territories of the area of allodynia. Participants will also be provided with a structured home exercise program.
62405228|NCT02070367|ACTIVE_COMPARATOR|Usual treatment|Treatment as usual for condition Physiotherapy sessions
62405229|NCT01970280|ACTIVE_COMPARATOR|Enoxaparin|Following a first AV graft thrombosis and successful thrombolysis with angioplasty, patients on chronic hemodialysis will be randomized to s.c Enoxaparin (Clexane) 0.5 mg/1kg of body weight per day or control group (not on Clexane).
62580991|NCT06165835|EXPERIMENTAL|Nine months after recovering from COVID-19|Patients who have from COVID-19 in six to nine months
62206133|NCT00559312|EXPERIMENTAL|FSC 250/50|fluticasone 250μg/salmeterol 50μg combination
62206134|NCT00559312|PLACEBO_COMPARATOR|Placebo|matched placebo inhaler
62206135|NCT01846494||Hepatitis C Virus (HCV) patients exposed to BMS-986094|Hepatitis C infected patients with previous exposure to BMS-986094
62206136|NCT01846494||HCV patients not exposed to BMS-986094|Hepatitis C patients without exposure to BMS-986094
62405230|NCT01970280|NO_INTERVENTION|Observation|
62405231|NCT04700592|EXPERIMENTAL|Gabapentin group|group which receives 600 mg of Gabapentin (two tablets) one hour prior to surgery
62580992|NCT06165835|EXPERIMENTAL|Twelve months after recovering from COVID-19|Patients who have from COVID-19 in nine to twelve months
62580993|NCT04397497|EXPERIMENTAL|Mavrilimumab|Single dose of IV Mavrilimumab
62580994|NCT04397497|PLACEBO_COMPARATOR|Placebo|Single dose of matching IV placebo
62405232|NCT04700592|EXPERIMENTAL|ketamine group|group which receives an injection of ketamine at a dosage of 0.15 mg/Kg before surgery incision
62405233|NCT04921319|EXPERIMENTAL|VExUS-Guided Arm|Will receive 24 hour fluid balance target based on daily VExUS score.
62580995|NCT05504538|EXPERIMENTAL|patient with Acute acromioclavicular joint injury|patient with Acute acromioclavicular joint injury
62580996|NCT02276560|EXPERIMENTAL|Neoadjuvant Cisplatin,nab-paclitaxel|Neoadjuvant cisplatin (75 mg/m2) D1 and nab-paclitaxel (125 mg/m2) D1, 8, 15, repeat each 28D cycle x 3 and then surgery per standard of care
62580997|NCT02276560|EXPERIMENTAL|Adjuvant Cisplatin,nab-paclitaxel|Adjuvant cisplatin (75mg/m2) D1, nab-paclitaxel (125 mg/m2)for D1, 8, 15 repeat each 28D x 2
62580998|NCT02276560|OTHER|Cisplatin+pemetrexed or gemcitabine|Adjuvant cisplatin (75mg/m2) D1, pemetrexed (500mgm2) D1 or; cisplatin (75 mg/m2),Gemcitabine (1000mg/m2) D1, 8 repeat each 21D cycle x 4
62016576|NCT00541762|OTHER|A, 3; B, 3; C, 3|A, 3: Fat with and without orlistat or placebo. B, 3: LCF vs MCF vs placebo. C, 3: LCF with and without DEXLOX or placebo.
62016577|NCT05155735||Replantation|This group will include subjects who suffered a single digit non-thumb amputation, and whose finger was replanted.
62016578|NCT05155735||Revision Amputation|This group will include subjects who suffered a single digit non-thumb amputation, and whose finger was not replanted.
62016579|NCT00927745|EXPERIMENTAL|With AutoFlow|Assist-controlled ventilation with activation of AutoFlow mode
62016580|NCT00927745|ACTIVE_COMPARATOR|Without AutoFlow|Assist-controlled ventilation without activation of AutoFlow mode
62016581|NCT03110159|EXPERIMENTAL|Levulan® Kerastick® and blue light illumination|"Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light using the standard FDA approved treatment time for the BLU-U device of 16 minutes 40 seconds.~Each subject will be randomized to undergo treatment to one side face and one dorsal forearm/hand treatment, while the other side will serve as untreated control. Treatments will be conducted at the beginning of study Day 1 (Initial Treatment), Day 30 after the initial treatment (+ 3 days), Day 180 after initial treatment (+ 30 days), 1 year after the initial treatment (+ 30 days), and every 6 months (+ 30 days) thereafter for 2 additional years."
62016582|NCT04596072|NO_INTERVENTION|control|basic treatment+ Cognitive rehabilitation training
62016583|NCT04596072|EXPERIMENTAL|treatment|basic treatment+ Cognitive rehabilitation training+Chinese traditional rehabilitation
62016584|NCT00047463|ACTIVE_COMPARATOR|CPAP active comparator|continuous positive airway pressure (CPAP)
62016585|NCT00047463|PLACEBO_COMPARATOR|CPAP Placebo|Placebo-CPAP
62405234|NCT04921319|NO_INTERVENTION|Usual Care Control Arm|Treating team will be blinded to results of daily VExUS score and will set 24 hour fluid balance target based on usual care.
62405235|NCT02457780|EXPERIMENTAL|Relaxation Response Resiliency Program|The Relaxation Response Resiliency Program (3RP) is an 8-session (90min/session) group based intervention which includes a variety of skills and techniques designed to address chronic stress. Techniques used include psychoeducation on healthy lifestyle behaviors, goal-setting, CBT skills, relaxation training and self-monitoring.
62405236|NCT02457780|ACTIVE_COMPARATOR|Health Enhancement Program|The Health Enhancement Program (HEP) is an 8-session (90min/session) group based intervention which includes psychoeducation and self-monitoring of health behaviors (e.g., sleep hygiene, nutrition, exercise, substance use etc).
62405237|NCT00128336|ACTIVE_COMPARATOR|Nurse support|
62405238|NCT00128336|EXPERIMENTAL|Intensive support|
62405239|NCT00128336|ACTIVE_COMPARATOR|High carbohydrate diet|
62206137|NCT02225132|EXPERIMENTAL|1|This is a one arm, open-label, non- randomized pilot study to evaluate the effect of algorithm- based HU dosing on the HbF response, the ability to titrate each patient to the MTD of HU, acute complications, and organ function in patients with HbSS.
62206138|NCT04589039||Participants with Ovarian Cancer|Participants diagnosed with ovarian cancer (including fallopian tube or primary peritoneal cancer) who have been prescribed with niraparib for the first time in a real-world setting, and who are in a complete or partial response to first-line platinum-based chemotherapy or who had complete or partial response to 2 or more line of platinum-based chemotherapy or who have been treated with 3 or more prior chemotherapy regimens with either breast cancer susceptibility gene (BRCA) mutation (irrespective of platinum sensitivity) or platinum-sensitive homologous recombination deficiency (HRD) positive will be observed prospectively over 24-month period, or until treatment discontinuation, or until end of study, which occurs first.
62206139|NCT02690259|EXPERIMENTAL|Sentinel node procedure|Enrolling all eligible endometrial cancer patient to the Sentinel node concept using indocyanine green.
62206140|NCT04315558|EXPERIMENTAL|Revefenacin|Revefenacin will be delivered once daily via nebulizer. In order to allow for full blinding and steady Q6 hours regimen in control arm, at hours 6, 12 and 18 after the Revefenacin dose, nebulized normal saline will be delivered.
62405240|NCT00128336|EXPERIMENTAL|High mono-unsaturated fat diet|
62405241|NCT03058159|OTHER|Subjects with a high dream recall frequency|
62405242|NCT03058159|OTHER|Subjects with a law dream recall frequency|
62405243|NCT03186287|EXPERIMENTAL|Eccentric training group|The participants in this group will actively perform eccentric phase of resistive shoulder exercises. Additionally they will receive standard physiotherapy.
62580999|NCT00708812|ACTIVE_COMPARATOR|The control group|paclitaxel-carboplatin
62581000|NCT00708812|EXPERIMENTAL|The treatment group|paclitaxel-carboplatin plus Endostar
62581001|NCT06575933|EXPERIMENTAL|Period 1: Midazolam and Digoxin|Participants will receive a single oral dose of midazolam and a single oral dose of digoxin on Day 1.
62581002|NCT06575933|EXPERIMENTAL|Period 2: MK-1084, Midazolam, and Digoxin|A washout period of at least 10 days will occur following midazolam and digoxin dosing in Period 1 and the first MK-1084 dosing in Period 2. Participants will receive MK-1084 once daily on Days 1 through Day 15 with a single oral dose of midazolam on Days 1, 6, and 14 and a single oral dose of digoxin on Days 1 and 11.
62581003|NCT05198024|PLACEBO_COMPARATOR|Usual care|"Where patients access to two exercise classes per week and all facilities as part of their cardiac rehabilitation. In addition to this, patients in this group took part in the 'Biggest loser' program in which the patients attended weekly sessions outside of their usual exercise class times. Each session follows a specific theme based on British Heart Foundation healthy eating guidelines.~Participants will undergo this approach for 6-weeks and then switch to usual care for 6-weeks."
62581004|NCT05198024|EXPERIMENTAL|Usual care plus biggest loser|"Where patients access to two exercise classes per week and all facilities as part of their cardiac rehabilitation. In addition to this, patients in this group took part in the 'Biggest loser' program in which the patients attended weekly sessions outside of their usual exercise class times. Each session follows a specific theme based on British Heart Foundation healthy eating guidelines.~Participants will undergo this approach for 6-weeks and then switch to usual care for 6-weeks."
62206141|NCT04315558|ACTIVE_COMPARATOR|Ipratropium|Nebulized ipratropium will be delivered via nebulizer Q6 hours.
62206142|NCT01108926|EXPERIMENTAL|All Subjects|All Subjects will receive the same intervention
62206143|NCT04473599|ACTIVE_COMPARATOR|Uniform Random|Participants will receive supportive text-messages for a period of 2 months. These text-messages have two categories: behavioral activation (BA) and coping skills. In this arm, participants will receive one of these types of messages daily on a random schedule in random time periods throughout the day.
62581005|NCT05198024|EXPERIMENTAL|Usual care plus new education programme|"Where patients access to two exercise classes per week and all facilities as part of their cardiac rehabilitation. In addition to this, patients in this group too part in a new education programme (anecdotally referred to as Healthy Heart Happy You) in which the same weekly topics as the biggest loser are covered yet with bespoke information regarding portion sizes and recipes provided each week and patients given a challenge each week in relation to the topic being covered e.g. include more vegetables.~Participants will undergo this approach for 6-weeks and then switch to usual care for 6-weeks."
62581006|NCT06444256|EXPERIMENTAL|SUVO|
62581007|NCT06444256|ACTIVE_COMPARATOR|TAU|
62405244|NCT03186287|EXPERIMENTAL|Concentric training group|The participants in this group will actively perform concentric phase of resistive shoulder exercises. Additionally they will receive standard physiotherapy.
62405245|NCT03186287|ACTIVE_COMPARATOR|Control group|The participants in this group will receive only standard physiotherapy.
62581008|NCT03678714|EXPERIMENTAL|Exercise Intervention|Structured exercise intervention will be undertaken for 12 weeks
62581009|NCT03678714|EXPERIMENTAL|Lifestyle Physical Activity|Increased lifestyle physical activity undertaken for 12 weeks
62206144|NCT04473599|EXPERIMENTAL|Reinforcement Learning|In this arm we will test a reinforcement learning (RL) algorithm with a learned decision mechanism for the timing and type of text-messages. The algorithm learns from previous data (which messages were sent, what was the participants' mood) to maximize an increase in participants' mood.
62206145|NCT04473599|ACTIVE_COMPARATOR|Mood ratings only|In this arm, participants will monitor their mood and receive random feedback based on mood responses.
62405246|NCT04910191|EXPERIMENTAL|Open Label|"Up to 200 patients will participate in this open study. Before each examination with the study device, data from each patient (Current medical condition, medical history and demographic data) will be inserted to a computer and added to the database of the study for further processing in conjunction with the study device results.~The study device electronic stethoscope membrane will be put on the patient's chest area in predefined anterior and posterior points. At the end of each examination the data will be transferred to a computer and stored in the patient's file. Each patient will be requested to attend the examination once."
62405247|NCT04922164|NO_INTERVENTION|Control group|Receive education-based messages about the health benefit of breastfeeding
62405248|NCT04922164|OTHER|Social normative cues|Receive social normative cues related to breastfeeding
62581010|NCT03678714|NO_INTERVENTION|Control|Resting control
62581011|NCT06390332|ACTIVE_COMPARATOR|Giving Information for Trauma Support and Safety (GIFTSS) Training|Training for college health center clinicians and staff in implementation of GIFTSS
62581012|NCT06390332|EXPERIMENTAL|GIFTSS Training and Centering gender Affirming Resources in higher Education (CARE) Learning Modules|Training for college health center clinicians and staff in implementation of GIFTSS combined with CARE's trans learning modules to support implementation with gender diverse service users.
62581013|NCT05463289|OTHER|Diabetic Retinopathy Exam at the point of care|Participants will undergo a point of care diabetic retinopathy eye exam using autonomous AI. Those that test positive will be referred to Eye Care Provider for dilated eye exam.
62016586|NCT05404022|EXPERIMENTAL|Intervention arm|12 weeks home based tailored nutrition and physical activity (PA) programme Participants will have an appointment (face-to-face if possible) with the study physiotherapist and dietitian for delivery of the PA (including breathlessness management) and nutrition intervention components. Participants will receive study equipment at these appointments (or by post) including paper-based tracking diary, resistance bands for strength exercises, a Fitbit activity monitor to track steps and aerobic activity during the study period, nutritional supplements (if prescribed), and printed study materials (if preferred over pdf emails; e.g. cooking tips, recipes). A video/telephone follow-up call (10-15 minutes) will be conducted by the research team with the participant at weeks 2,3,4,5 and 6 and then at weeks 8,10 and 12 to review and adjust their programme (with input from the physiotherapist and dietitian if required).
62206146|NCT00590252||Scheduled for an MRI|Clinically Indicated Adults
62206147|NCT01669577||severe trauma patients|analysis of blood samples and clinical features
62206148|NCT00742326|EXPERIMENTAL|Pioglitazone|pioglitazone 45 mg daily for 48 weeks
62206149|NCT00742326|PLACEBO_COMPARATOR|Placebo|one capsule daily for 48 weeks
62405249|NCT04922164|OTHER|Goal-related cues|Receive goal-related cues related to breastfeeding
62405250|NCT01457690|EXPERIMENTAL|Tocofersolan: Vitamin E water-soluble|2 months off the conventional treatment before the study. Administration of a daily dose of vitamin E for 4 months
62405251|NCT01457690|ACTIVE_COMPARATOR|Tocopherol alpha: Vitamin E conventional fat-soluble form|2 months off the conventional treatment before the study. Administration of a daily dose of vitamin E for 4 months
62405252|NCT01457690|ACTIVE_COMPARATOR|volunteers|
62581014|NCT00474981|EXPERIMENTAL|1|IMNCI
62581015|NCT00474981|NO_INTERVENTION|2|Control
62206150|NCT02143011|OTHER|orange juice|no sugar
62581016|NCT03121001|EXPERIMENTAL|Subject treatment|Patients will receive the following conditioning regimen: ATG, fludarabine (6 days before stem cell infusion), cyclophosphamide, and total body irradiation. The stem cell product will be infused according to BMT unit policy. Patients will also receive GVHD prophylaxis which will consist of cyclophosphamide, sirolimus, and mycophenolate mofetil according to the protocol. Post-transplant evaluation will be done as per standard care with study data collected at days 30, 60, 100, 180, 365, and annually thereafter.
62581017|NCT01135381|EXPERIMENTAL|CHF patients, IVR-Enhanced Care|Patients with congestive heart failure (CHF) who receive the interactive voice response (IVR) intervention.
62581018|NCT01135381|EXPERIMENTAL|COPD patients, IVR-Enhanced Care|Patients with chronic obstructive pulmonary disease (COPD) who receive the interactive voice response (IVR) intervention.
62581019|NCT01135381|NO_INTERVENTION|CHF patients, Usual Discharge Care|Patients with congestive heart failure (CHF) who receive usual discharge care (no intervention).
62581020|NCT01135381|NO_INTERVENTION|COPD patients, Usual Discharge Care|Patients with chronic obstructive pulmonary disease (COPD) who receive usual discharge care (no intervention).
62581021|NCT05422755||Arm 1|Experimental: Test Drug Recombinant Human Erythropoietin Alfa
62206151|NCT02143011|OTHER|sugar beverage|no sugar
62206152|NCT05759039|ACTIVE_COMPARATOR|MPFL-R|Medial patellofemoral ligament reconstruction
62206153|NCT05759039|ACTIVE_COMPARATOR|MPFL-R + TTO|Medial patellofemoral ligament reconstruction with concomitant tibial tubercle osteotomy
62405253|NCT02679716|OTHER|study group|MRI of the cerebral arteries ist performed
62405254|NCT04855201|EXPERIMENTAL|Bocidelpar (ASP0367)|Participants will receive Bocidelpar (ASP0367) once daily in the morning for 6 weeks.
62405255|NCT04855201|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo once daily in the morning for 6 weeks.
62581022|NCT01875757|EXPERIMENTAL|Vitamin D3 1000 IU/day|Infants will be supplemented with vitamin D and/or placebo to receive a total amount of vitamin D3 of 1.000 IU/day during the first year of life, taking into account the vitamin D received with artificial milk
62206154|NCT05315505|EXPERIMENTAL|Maintenance|"Participants will undergo an initial home-based pulmonary rehabilitation program for eight weeks.~At the end of the eight weeks, the participants will be randomly assigned into two groups, one receiving the maintenance pulmonary rehabilitation program and the other receiving the usual care.~The maintenance arm will receive home visits for supervised physical exercise and progressively alternated with phone calls to motivation and feedback"
62206155|NCT05315505|ACTIVE_COMPARATOR|control|"Participants will undergo an initial home-based pulmonary rehabilitation program for eight weeks.~At the end of the eight weeks, the participants will be randomly assigned into two groups, one receiving the maintenance pulmonary rehabilitation program and the other receiving the usual care.~The control group will have access to the usual follow."
62206156|NCT03429803|EXPERIMENTAL|DAY101 (formerly TAK-580, MLN2480) BSA </= 1.5m^2|"Phase I Part B BSA \</= 1.5m\^2~* Patients (\< 25 years) with radiographically recurrent or radiographically progressive non-hematologic malignancies (Central Nervous System (CNS) or solid tumors) associated with activation of the RAS/RAF/MEK/ERK pathway will be eligible with the exception of patients with NF1~* Study treatment cycle lasts 28 days, oral, once a week"
62206157|NCT03429803|EXPERIMENTAL|DAY101 (formerly TAK-580, MLN2480) BSA > 1.5m^2|"Phase I Part B BSA \> 1.5m\^2~* Patients (\< 25 years) with radiographically recurrent or radiographically progressive non-hematologic malignancies (Central Nervous System (CNS) or solid tumors) associated with activation of the RAS/RAF/MEK/ERK pathway will be eligible with the exception of patients with NF1~* Study treatment cycle lasts 28 days, oral, once a week"
62206158|NCT06176365|EXPERIMENTAL|Survodutide - 3.6 mg|
62206159|NCT06176365|EXPERIMENTAL|Survodutide - 6.0 mg|
62206160|NCT06176365|PLACEBO_COMPARATOR|Placebo group|
62206161|NCT03863873|ACTIVE_COMPARATOR|PRP Injection Group|PRP Preparation: 16 ml of blood was obtained from each patient using special PRP kits (GD medical pharma, Dutch company). The blood was collected on citrated tubes with a mixing ratio of 9:1 by volume. Tubes underwent 1st centrifugation at speed of 3000 rpm (704g) for 3 minutes (to separate red blood cells from plasma). Plasma was then removed by syringe and then placed into another sterile tube with no anticoagulant and then underwent 2nd centrifugation at speed of at 4000 rpm (1252g) for 15 min. The supernatant platelet-poor plasma was then removed leaving 2 ml of PRP pellets in the sediment, and suspend the PRP pellets by gentle shaking of the tube. PRP is activated by adding 200 μl of 0.025 calcium chloride(Dhurat and Sukesh, 2014).
62206162|NCT03863873|ACTIVE_COMPARATOR|Steroid injection Group|A single injection of methylprednisolone acetate 40 mg/ml using a technique similar to that described for the PRP injection
62206163|NCT05872152|NO_INTERVENTION|Standard care|Standard care are defined by routine procedures implemented in each center to prevent and control the diffusion of MDR-E bacteria in ICUs. In the first period of the study, the frequency of cross transmission will be assessed by sequencing the first ESBL-E isolate in each carrier patients (first isolate of a given species)
62206164|NCT05872152|EXPERIMENTAL|Transmission of FTIR results|In second phase of the study, the result of FTIR typing of recovered ESBL-E isolates will be weekly transmitted to participating centers.
62206165|NCT06224127|ACTIVE_COMPARATOR|Active heat and placebo c tactile stimulation|Subjects will receive an active heating device and a sham c tactile stimulation device.
62405256|NCT02203604|EXPERIMENTAL|Treatment (aldesleukin, ipilimumab)|"INDUCTION: Patients receive ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 and high-dose aldesleukin IV on days 22-26 and 43-47.~MAINTENANCE: Beginning on weeks 24, patients without disease progression or unacceptable toxicity receive ipilimumab IV over 90 minutes once every 12 weeks for up to 24 weeks in the absence of disease progression or unacceptable toxicity."
62405257|NCT06323265||Experimental|
62405258|NCT03226366||Pre-implementation (intervention site)|Adult patients age ≥18 years who received usual care after presenting to the ED of the intervention hospital with sepsis or septic shock between May 16, 2015 and April 15, 2016
62405259|NCT03226366||Post-implementation (intervention site)|"Adult patients age ≥18 years eligible to receive immediate evaluation by multidisciplinary team (swarming) after presenting to the ED of the intervention hospital with sepsis or septic shock between May 16, 2016 and February 15, 2017"
62016587|NCT05404022|NO_INTERVENTION|Usual care arm|The usual cancer care will include usual patient management and care prior, during and after cancer treatment - medication, symptom control, cancer advice and support from routine medical and nursing input with access to Allied Health Professionals (AHPs) such as physiotherapists and dietitians as clinically indicated. As part of this, it is common for older adults with cancer to be prescribed high protein supplementation. Control participants will receive a general information leaflet regarding activity and nutrition.
62016588|NCT05790343||BAPHYC|Parents of children, aged 5-12 years, who have anxiety problems.
62016589|NCT05134376|EXPERIMENTAL|Workgroup|During the repair of the mediolateral episiotomy, the pregnant women included in the study group will be shown a video accompanying the acemaşîrân office with sterile virtual reality glasses with a view of nature.
62405260|NCT03226366||Pre-implementation (control site)|Adult patients age ≥18 years who received usual care after presenting to the ED of a non-intervention study hospital with sepsis or septic shock between May 16, 2015 and April 15, 2016
62581023|NCT01875757|ACTIVE_COMPARATOR|Vitamin D3 400 IU/day|Infants will be supplemented with vitamin D and/or placebo to receive a total amount of vitamin D3 of 400 IU/day during the first year of life, taking into account the vitamin D received with artificial milk
62581024|NCT03999164|EXPERIMENTAL|Moderate to Severe Traumatic Brain Injury|All patients will undergo a \[18F\]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
62581025|NCT00850408|EXPERIMENTAL|Real rTMS|Real rTMS - subjects receiving real repetitive TMS - 1Hz over unaffected hemisphere
62016590|NCT05134376|NO_INTERVENTION|Control|Unlike the experimental group, only video and music applications will not be applied to the pregnant women included in the control group. Other applications will be done in the same way.
62206166|NCT06224127|ACTIVE_COMPARATOR|Placebo heat and active c tactile stimulation|Subjects will receive an active c tactile stimulation device and a sham heating device.
62206167|NCT06224127|ACTIVE_COMPARATOR|Active heat and active c tactile stimulation|Subjects will receive an active c tactile stimulation device and an active heating device.
62405261|NCT03226366||Post-implementation (control site)|Adult patients age ≥18 years who received usual care after presenting to the ED of a non-intervention study hospital with sepsis or septic shock between May 16, 2016 and February 15, 2017
62206168|NCT00858377|EXPERIMENTAL|Arm 1- Dose Expansion|The dose expansion part of the study will begin after completion of the dose escalation phase and will consist of 3 cohorts of 14 subjects each. One taxane-resistant tumor type will be evaluated in each cohort.
62016591|NCT06521346|EXPERIMENTAL|Active cycle breathing technique|Breathing control phase Thoracic expansion exercises Forced expiration technique (huffing)
62016592|NCT06521346|PLACEBO_COMPARATOR|Control group|Patient who receives the routine care
62405262|NCT05769348|ACTIVE_COMPARATOR|Active Unilateral Treatment|Chronic migraine patients will be randomized (Taves method) to receive UNILATERAL high-definition transcranial direct current stimulation (HD-tDCS\*) as 20 minute sessions, once daily for 20 days (M-F for 4 weeks).
62206169|NCT00858377|EXPERIMENTAL|Arm 1- Dose Escalation|The dose escalation part of the study is aimed at determining the maximum tolerated dose (MTD) of AMG 900 and if necessary, the MTD with prophylactic GCSF support (MTD-G).
62206170|NCT03101839|EXPERIMENTAL|AZD4785|This is a single-arm study in which all patients will receive AZD4785 by IV infusion. Patients will continue to receive treatment with AZD4785 until disease progression, intolerable toxicity, or discontinuation criteria are met.
62206171|NCT06144021|EXPERIMENTAL|Kefir Postbiotics Group|"* 30 healthy adult participants~* Appearance and formulation: Yellow powder/capsule with unique flavor and no off-flavor~* Period of use: 12 months~* Storage method: Store at room temperature~* Manufacturing method: The whey postbiotics derived from kefir lactic acid bacteria used in the test food are produced in the laboratory at Hanyang University, and additional ingredients are purchased from finished products. Laboratory collects the ingredients and delivers them to the manufacturer, Neo Natural, to manufacture them so that there are no differences in properties and formulations."
62206172|NCT06144021|PLACEBO_COMPARATOR|Control Group|"* 30 healthy adult participants~* Appearance and formulation: Yellow powder/capsule with unique flavor and no off-flavor~* Period of use: 12 months~* Storage method: Store at room temperature~* Manufacturing method: The same product without whey postbiotics."
62206173|NCT04562766|EXPERIMENTAL|Rilzabrutinib|Patients receive rilzabrutinib 400mg orally twice daily for up to 24 weeks followed by 28 weeks of open label period
62206174|NCT04562766|PLACEBO_COMPARATOR|Placebo|Patients receive matching placebo 400mg orally twice daily for up to 24 weeks
62206175|NCT00224887|EXPERIMENTAL|in home nutrition counseling|In-home family-based behavioral counseling using in-person and video interventions delivered by community health advisors
62206176|NCT00224887|ACTIVE_COMPARATOR|standard nutrition education curriculum|standard nutrition education curriculum consisting of video and lesson plans based on USDA Food Guide pyramid
62405263|NCT05769348|ACTIVE_COMPARATOR|Active Bilateral Treatment|Chronic migraine patients will be randomized (Taves method) to receive BILATERAL high-definition transcranial direct current stimulation (HD-tDCS\*) as 20 minute sessions, once daily for 20 days (M-F for 4 weeks).
62405264|NCT05769348|SHAM_COMPARATOR|Sham Treatment|Chronic migraine patients will be randomized (Taves method) to receive SHAM high-definition transcranial direct current stimulation (HD-tDCS\*) as 30-second administrations at the beginning and end of each 20 minute session, once daily for 20 days (M-F for 4 weeks).
62016593|NCT02543541|ACTIVE_COMPARATOR|Standard Supportive Care|
62016594|NCT02543541|EXPERIMENTAL|Structured Supportive Care|
62016595|NCT06532331|EXPERIMENTAL|ONO-7475+GnP|
62016596|NCT06532331|EXPERIMENTAL|ONO-7475＋ONO-4538＋GnP|
62016597|NCT06573515|EXPERIMENTAL|high-tone power therapy group|fifteen female patients will receive high-tone power therapy with conventional physical therapy modalities in the form of (ultrasound, massage, stretching, and strengthening exercises) 2 sessions per week for 6 weeks
62016598|NCT06573515|EXPERIMENTAL|interferential current therapy group|fifteen female patients will receive interferential current therapy with conventional physical therapy modalities in the form of (ultrasound, massage, stretching, and strengthening exercises) 2 sessions per week for 6 weeks
62016599|NCT06573515|EXPERIMENTAL|conventional physical therapy group|fifteen female patients will receive conventional physical therapy modalities only in the form of (ultrasound, massage, stretching, and strengthening exercises) 2 sessions per week for 6 weeks
62016600|NCT02012829|NO_INTERVENTION|control group|GPs from practices in the control group are asked to continue their usual care, as if they were not participating in this trial. They had to send their patients list to the research team to calculate their eligible population. They were also asked to list all the gaiac Fecal occult blood test ( gFOBT) delivered during the six months period of the study.
62016601|NCT02012829|ACTIVE_COMPARATOR|intervention|GPs communication skills and CRC screening :the intervention was a four hours educational training for GPs of the intervention group focused on communication skills with a patients' centered care approach to improve patients participation at CRC screening
62016602|NCT02520245|EXPERIMENTAL|Open-Label|
62016603|NCT04424368|EXPERIMENTAL|The remote monitoring system|A group of patients, who had myocardial infraction and who has a very high risk of developing an unfavorable prognosis, which are followed up in the local outpatient department according to existing clinical recommendations and using remote monitoring system.
62016604|NCT04424368|NO_INTERVENTION|Clinical recommendations|A group of patients, who had myocardial infraction and who has a very high risk of developing an unfavorable prognosis, which are followed up in the local outpatient department according to existing clinical recommendations.
62016605|NCT04353297|EXPERIMENTAL|BCI Group|(EEG-)BCI- assisted MI training delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
62016606|NCT04353297|ACTIVE_COMPARATOR|Control Group|MI training without BCI support delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
62016607|NCT03770572|EXPERIMENTAL|Cohort 1: AT-GTX-502 Low-Dose|No more than 5 mL of 6 x 1013 vg AT-GTX-502 administered via intrathecal injection
62016608|NCT03770572|EXPERIMENTAL|Cohort 2: AT-GTX-502 High-Dose|No more than 10 mL of 1.2 x 1014 vg of AT-GTX-502 administered via intrathecal injection
62016609|NCT04978857|EXPERIMENTAL|Virtual reality headset|
62016610|NCT06536166|EXPERIMENTAL|Experimental group|Randomization in experimental group.
62206177|NCT02527642|ACTIVE_COMPARATOR|CRM sequential media (C1/C2)|CRM sequential media, formulated according to the stages of embryo development, is used to culture the embryos from oocyte fertilization to blastocyst stage.
62206178|NCT02527642|ACTIVE_COMPARATOR|CRM single step media (C3)|CRM single step media is used to culture the embryos from oocyte fertilization to blastocyst stage.
62016611|NCT06536166|PLACEBO_COMPARATOR|Control group|Randomization in control group.
62016612|NCT00772174|EXPERIMENTAL|Pioglitazone + Metformin|
62016613|NCT00772174|ACTIVE_COMPARATOR|Metformin|
62016614|NCT05438953|EXPERIMENTAL|PEP Vaccinated|
62016615|NCT05438953|EXPERIMENTAL|PrEP Vaccinated|
62206179|NCT02527642|EXPERIMENTAL|Vitrolife media G1/2 Sequential|Vitrolife sequential media, formulated according to the stages of embryo development, is used to culture the embryos from oocyte fertilization to blastocyst stage.
62016616|NCT01398605|EXPERIMENTAL|moderate exercise training|
62016617|NCT01398605|EXPERIMENTAL|intensive exercise training|
62016618|NCT01398605|NO_INTERVENTION|Control|
62016619|NCT05235880|EXPERIMENTAL|study group|1 hour physiotherapy session for 3 times a week and 8 weeks in total.
62016620|NCT05235880|ACTIVE_COMPARATOR|control group|1 hour physiotherapy session for 3 times a week and 8 weeks in total.
62581026|NCT00850408|SHAM_COMPARATOR|Sham rTMS|Sham rTMS
62016621|NCT01311830|ACTIVE_COMPARATOR|Telephone Counseling|
62206180|NCT02527642|EXPERIMENTAL|Vitrolife G-TL Time Lapse media Single Step|G-TL Time Lapse Single step (time lapse) media is formulated for continuous culture from oocyte fertilization to blastocyst stage.
62405265|NCT05769348|NO_INTERVENTION|No Treatment|Episodic Migraine Patients will not receive study treatment. These patients will complete observational study components (Screening visit, baseline visit, MRI and PET scan only).
62016622|NCT01311830|PLACEBO_COMPARATOR|Written Materials|
62016623|NCT05859347|ACTIVE_COMPARATOR|High-Frequency (HF)|10 Hz rTMS
62016624|NCT05859347|ACTIVE_COMPARATOR|Low-Frequency (LF)|1 Hz rTMS
62016625|NCT01842828|ACTIVE_COMPARATOR|Standard care plus electronic cigarettes|Standard care for smoking cessation plus electronic cigarettes
62016626|NCT01842828|OTHER|Standard care|Standard care for smoking cessation
62016627|NCT01319006|EXPERIMENTAL|GSK1278863A 100mg (X90=13um)|single dose
62016628|NCT01319006|EXPERIMENTAL|GSK1278863A 100mg (x90=29Um)|single dose
62016629|NCT01319006|EXPERIMENTAL|GSK1278863 100mg (X90=41um)|single dose
62016630|NCT01876121||Celecox group|
62206181|NCT01516255|EXPERIMENTAL|Double-blind / liraglutide|
62581027|NCT03829826||Patients receiving IVIg|Patients are currently receiving IVIg regularly for at least every 6 weeks and exhibit a favorable response will be recruited into the study (11 patients). They will be observed for 12 weeks under their existing IVIg regimen and will undergo measurements of their impairment using the previously validated Stiffness and Sensitivity scales and quality of life questionnaire (QoL) at weeks 0, 4, 8, 12. At week 12, prior to the first SCIg infusion, blood will be drawn for humoral (immunological) studies. One week following the last dose of IVIg (at week 13), the participants will be started on SCIg at a total dose equivalent to the monthly dose of IVIg they have been receiving.
62581028|NCT03829826||de novo SCIg patients/IVIg-Naive Group|This other arm of the trial will include 11 patients naïve to IVIg who do not receive other immunotherapies while being symptomatic. These patients after a 12-week observation period will start directly on SCIg drug (HYQVIA), following the same schedule as described above for the previous group.
62581029|NCT05277051|EXPERIMENTAL|Participants receiving GSK4381562 monotherapy (Arm A)|
62581030|NCT05277051|EXPERIMENTAL|Participants receiving GSK4381562 plus dostarlimab (Arm B)|
62581031|NCT05277051|EXPERIMENTAL|Participants receiving GSK4381562 plus dostarlimab plus belrestotug (Arm C)|
62016631|NCT02569697|OTHER|HEC Placebo Gel|The placebo gel will come in pre-filled individual applicators (4mL). Placebo gel is clear in color and contains HEC as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide.
62016632|NCT02569697|OTHER|Placebo Vaginal Insert|The placebo vaginal inserts will be supplied in white plastic bottles. The placebo inserts are white to off-white in color, uncoated and bullet-shaped. The inserts are composed of ingredients generally recognized as safe including isomalt, xylitol, polyvinylpyrrolidone K 30, hydroxypropyl methylcellulose, poloxamer, and sodium stearyl fumarate. The inserts are approximately ½ to 1 inch long and approximately ¼ to ½ inch thick, similar in size to vaginal tablets that are currently available.
62016633|NCT02569697|OTHER|Placebo Vaginal Film|The placebo vaginal films will be individually wrapped. The placebo vaginal film is a thin, clear to translucent sheet with dimensions of 2 in x 2 in. The ingredients include hydroxyethyl cellulose (HEC), hydroxypropyl methyl cellulose (HPMC, E5), sodium carboxymethyl cellulose (NaCMC), and glycerin.
62016634|NCT02569697|OTHER|Placebo Intravaginal ring (IVR)|The placebo IVRs will be supplied in individual foil pouches. Each ring has a longer white to off-white segment and a shorter transparent/translucent segment, and ingredients include polyurethane, glycerin, water and modified starch.
62016635|NCT03795844|ACTIVE_COMPARATOR|Nathanson retractor|Liver retraction in group 1, a 5 mm incision was made under xiphoid during the operation, and Nathanson retractor was placed and liver left lobe retraction would be achieved.
62206182|NCT01516255|PLACEBO_COMPARATOR|Double-blind / placebo|
62206183|NCT01516255|ACTIVE_COMPARATOR|Open-label / moxifloxacin|
62206184|NCT01516255|PLACEBO_COMPARATOR|Open-label / placebo|
62016636|NCT03795844|ACTIVE_COMPARATOR|snake retractor|Liver retraction in group 2 ; 5 mm incision under the xiphoid will be used. Snake retractor was placed and liver left lobe retraction would be achieved.
62206185|NCT02420197|EXPERIMENTAL|High-intensity resistance training|Full body, progressive strength training with Theraband® Elastic bands. Three times per week for 12 weeks - 3 weeks with supervised sessions at the clinic, and 9 weeks of home training.Three guided sessions will be offered during the home training period.
62206186|NCT02420197|ACTIVE_COMPARATOR|General physical activity|12 weeks of general physical activity - 3 weeks with supervised sessions at the clinic, and 9 weeks of individually adjusted home training. This include circle-training, low-intensity resistance exercises, endurance exercises, ball playing, body awareness, stretching, and relaxation techniques, and similar activities. Neither moderate nor high-intensity resistance exercise is included for participants in this group.Three guided sessions will be offered during the home training period.
62206187|NCT01534065|EXPERIMENTAL|Barricaid|CE Marked Device
62581032|NCT05277051|EXPERIMENTAL|Participants receiving dostarlimab plus belrestotug (Arm D)|
62206188|NCT00293137||1|Patients enrolled into the trial must have left ventricular ejection fraction of \<40% by echocardiogram within 6 months of enrollment
62581033|NCT05277051|EXPERIMENTAL|Participants receiving dostarlimab plus belrestotug plus GSK4381562 (Arm E)|
62788453|NCT00765804|ACTIVE_COMPARATOR|Low Dose: DP 7.5 mA-min at 2.5 mA|Ocular Iontophoresis with EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) 7.5 mA-min at 2.5 mA
62788454|NCT00765804|ACTIVE_COMPARATOR|High Dose: DP 10.5 mA-min at 3.5 mA|Ocular Iontophoresis with EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) 10.5 mA-min at 3.5 mA
62016637|NCT03795844|ACTIVE_COMPARATOR|fan retractor|Liver retraction in group 3 ; through a 5 mm trocar entrained from the intersection of the right midclavicular line and a 4 cm superior umbilicus
62016638|NCT03795844|ACTIVE_COMPARATOR|CONTROL GROUP|Liver retraction in group 4 ; through a 5 mm trocar entrained from the intersection of the right midclavicular line and a 4 cm superior umbilicus will be provided with the aid of laparoscopic grasper without any special tools
62206189|NCT06288529||Patients with type 2 diabetes mellitus using SGLT2 inhibitor|
62206190|NCT06288529||Patients with type 2 diabetes mellitus not using SGLT2 inhibitor|
62206191|NCT06288529||Patients with chronic kidney disease mellitus using SGLT2 inhibitor|
62206192|NCT06288529||Patients with chronic kidney disease mellitus not using SGLT2 inhibitor|
62206193|NCT02232243|EXPERIMENTAL|Initial: Hydroxychloroquine 400mg HCQ|These initial 3 patients received 200mg hydroxychloroquine (HCQ) twice daily (400mg/day total) for 14 days prior to surgery.
62206194|NCT02232243|EXPERIMENTAL|Secondary: Hydroxychloroquine 800mg HCQ|Based on data analysis from the initial patients, these patients received 400mg hydroxychloroquine (HCQ) twice daily (800mg/day total) for 14 days prior to surgery.
62581034|NCT05277051|EXPERIMENTAL|Participants receiving dostarlimab plus belrestotug plus nelistotug (Arm F)|
62581035|NCT05277051|EXPERIMENTAL|China Cohort: Participants receiving dostarlimab (Arm G)|
62581036|NCT05277051|EXPERIMENTAL|China Cohort: Participants receiving dostarlimab plus belrestotug (Arm H)|
62581037|NCT05277051|EXPERIMENTAL|Participants receiving GSK5764227 plus dostarlimab (Arm I)|
62581038|NCT04410146|EXPERIMENTAL|SQUID|Embolization of the Middle Meningeal Artery (MMA)
62581039|NCT04410146|ACTIVE_COMPARATOR|No Embolization|Standard Management
62581040|NCT04638283|EXPERIMENTAL|Interventioh group|"The intervention consists of~1. Eight group sessions of two hours duration, focusing on GMT and ADHD. The Group consists of six participants and is directed by one neuropsychologist and one psychologist.~2. Four individual sessions with the neuropsychologist/psychologist directing the Group where the participant is guided through the process of formulating GAS-goals.~3. Bi-weekly Telephone follow up focusing on GAS-goal attainment the thre first months following the Group session phase."
62788455|NCT00765804|PLACEBO_COMPARATOR|Placebo: 10.5 mA-min at 3.5 mA|Ocular Iontophoresis with Placebo (sodium citrate buffer solution 100 mM at 10.5 mA-min at 3.5 mA)
62788456|NCT04871958|EXPERIMENTAL|rtCGM/MDI|Real-time CGM, insulin therapy by multiple daily injections managed according to CGM
62788457|NCT04871958|EXPERIMENTAL|rtCGM/V-Go|Real-time CGM, insulin therapy by V-Go insulin pump managed according to CGM
62581041|NCT04638283|NO_INTERVENTION|Control Group|Participants in the Control Group receive TAU. Participation in the study does not influence decisions regarding pharmacological interventions in either of the groups.
62581042|NCT04480424|EXPERIMENTAL|GAMUNEX-C + Standard Medical Treatment|Participants received 2 grams per kilogram (g/kg) of GAMUNEX-C, which was capped to a maximum of 160 g infusion intravenously (IV) for participants weighing more than 80 kg on Day 1. The 2 g/kg net total dose was divided either into infusions of 500 mg/kg body weight over 4 days or 400 mg/kg body weight over 5 days as per investigator's decision. Participants received standard of care interventions as per Principal Investigator's discretion from Day 1 up to Day 29.
62581043|NCT04480424|ACTIVE_COMPARATOR|Standard Medical Treatment|Participants received all standard of care interventions required as per Principal Investigator's discretion throughout the participant's hospitalization, from Day 1 to Day 29.
62016639|NCT02341248||A) Newly diagnosed with Crohn's disease|"Children undergoing endoscopic investigations (colonoscopy) for colonic inflammation including Crohn's disease \[children who are found not to have Crohn's disease will not participate further\].~\[Intervention - clinical, not research decision - Exclusive Enteral Nutrition for 8 weeks; usually 330ml 6 times per day\] per day"
62016640|NCT02341248||B) Existing diagnosis of Crohn's disease|"Previously diagnosed patients with Crohn's disease due to start an 8 week standard course of treatment with EEN due to disease flare up.~\[Intervention - clinical, not research decision - Exclusive Enteral Nutrition for 8 weeks; usually 330ml 6 times per day\]"
62016641|NCT02341248||c) Healthy control group|Healthy children unrelated to Crohn's disease patients No intervention
62016642|NCT05427149|ACTIVE_COMPARATOR|Group C|Patients receiving intrathecal 10 mg hyperbaric bupivacaine (Marcaine® Spinal Heavy %0.5, Sanofi, Kırklareli, Turkey) + 1 mL normal saline (Polifleks %0.9 İzotonik Sodyum Klorür, Polifarma, Ankara, Turkey)
62206195|NCT02232243|EXPERIMENTAL|Tertiary: Hydroxychloroquine 400mg HCQ|Based on data from the primary and secondary groups, patients received 200mg hydroxychloroquine (HCQ) twice daily (400mg/day total) for 14 days prior to surgery.
62206196|NCT05308797|ACTIVE_COMPARATOR|Erector Spinae Plane Block|An erector spinae plane block will be performed at the level of the 5th thoracic vertebrae with 30 mL of 0.25% bupivacaine solution under ultrasound guidance before the operation.
62206197|NCT05308797|ACTIVE_COMPARATOR|Combine Serratus Anterior Plane Block|Combine Serratus Anterior Plane block will be performed at the level of 5th costa with 30 mL of 0.25% bupivacaine (15 mL superficial serratus plane block and 15 mL deep serratus plane block) solution under ultrasound guidance before the operation.
62206198|NCT06049576|ACTIVE_COMPARATOR|Arm 1 (nivolumab and ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for cycles 1-4. Beginning cycle 5, patients receive nivolumab over 30 minutes on day 1 of each cycle. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and stool sample collection and undergo CT and/or bone scan and/or MRI on trial.
62206199|NCT06049576|EXPERIMENTAL|Arm 2 (nivolumab, ipilimumab, camu camu)|Patients receive nivolumab IV over 30 minutes on day, ipilimumab IV over 30 minutes on day 1, and camu camu PO QD continuously with each cycle. Cycles repeat every 3 weeks for cycles 1-4. Beginning cycle 5, patients receive nivolumab over 30 minutes on day 1, and camu camu PO QD of each cycle. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and stool sample collection and undergo CT and/or bone scan and/or MRI on trial.
62206200|NCT05802823|EXPERIMENTAL|Experimental Group|Resources will be distributed to the students 1 week before the application, a scenario will be given 5 minutes before the application, and informed consent will be obtained from the students. Just before the application, information about the simulation process and analysis will be given. Students will be divided into 6 groups with the random numbers table and the application will be made on different days and times. The application time is 10-15 minutes and the camera will be recorded during the interview. At the end of the application, standard patient feedback will be given for each student. At the end of the application, analysis sessions will be held with the students as a group and feedback will be given by peers and trainers about their own performances. Analysis sessions will take between 30-45 minutes.
62206201|NCT05802823|NO_INTERVENTION|Control Group|No application will be made.
62206202|NCT03795129|EXPERIMENTAL|SleepLife Application w/FitBit|"Subject receives a FitBit. Subjects receive access to the SleepLife Application. Subjects receive training and assistance setting up use and access to the SleepLife Application.~Subject physicians will receive subject sleep data. Subject and physicians have the option of messaging each other through the SleepLife application."
62206203|NCT03795129|ACTIVE_COMPARATOR|FitBit w/Minimal to No SleepLife App.|"Subjects will receive a FitBit Subjects will be told about the SleepLife Application (but not be shown how to access it).~Subjects will receive no training with regard to how to access SleepLife Application.~Subjects' physicians will receive no subject sleep data."
62206204|NCT02766101|EXPERIMENTAL|Aerobic Exergaming PE|Progressive aerobic curriculum utilizing virtual reality exergaming stationary bicycles. Classes held 2 times per week for 30-40 minutes, aerobic exercise beginning at 10 minutes at moderate to vigorous intensity and building to 20 minutes plus.
62581044|NCT05648201|EXPERIMENTAL|Doravirine|1 single dose of 100mg doravirine taken orally
62581045|NCT05648201|EXPERIMENTAL|Raltegravir|1 single dose of 1200mg raltegravir taken orally
62581046|NCT05648201|EXPERIMENTAL|Biktarvy|1 single dose of 25/200/50mg taken orally
62581047|NCT06682403|EXPERIMENTAL|Individual receives cable lock as default|Participants in this arm are either automatically assigned due to taking a cable lock at the hospital when offered AND fill out the survey OR are randomized into this group by filling out the study survey linked in study materials.
62581048|NCT06682403|EXPERIMENTAL|Individual has a choice between cable lock and lock box|Participants in this arm are randomized into it based on NOT taking a cable lock at the hospital when offered AND fill out the survey OR are randomized into this group by filling out the study survey linked in study materials.
62581049|NCT02403661|ACTIVE_COMPARATOR|Post surgical electrical stimulation|Balanced AC pulse at 20 Hz with less than 30V and 0.01 ms duration will be delivered for 1 hour.
62405266|NCT04692974|EXPERIMENTAL|Intervention Group|Participants in the intervention group will be given the wearables which they will use together with the accompanying mobile application for the period of the study (6 months). During the period of intervention, the wearable will track the physical activity of the older adults via the number of steps taken and number of hours of moderate physical work (based on heart rate). Heart rate and steps will be tracked whenever participants are wearing the watch, which is when they are awake. The watch is to be charged every night when they are sleeping. Participants will have to log down their physical activity by activating the physical activity tracker either on the watch or on the mobile application. If they did not hit the required level of physical activity, they will be sent a notification prompt through the mobile application with details of nearby workout locations as recommendation.
62206205|NCT02766101|ACTIVE_COMPARATOR|Standard PE|Traditional PE focused on gross motor skill and sports skill acquisition, and team building. Typically non-aerobic.
62206206|NCT01069653|EXPERIMENTAL|CDCA1-KIF20A-1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A\*2402-restricted CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
62206207|NCT01069653|EXPERIMENTAL|CDCA1-KIF20A-2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A\*2402-restricted CDCA1 peptide (2mg) and KIF20A peptide(2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
62206208|NCT01069653|EXPERIMENTAL|CDCA1-KIF20A-3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A\*2402-restricted CDCA1 peptide (3mg) and KIF20A peptide(3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
62206209|NCT05202392|EXPERIMENTAL|Myofascial release with Isometric Exercises|Myofascial release technique combined with isometric exercises will be given to first group. Patients in this group will be given muscle stretching along with trigger point release for following muscles. For the trapezius muscle as the patient will be in sitting and restrained friction for 30 seconds will be applied to a primary trigger point along with passive trapezius stretching on the alternative side. A chin tuck will be applied to stretch the sub-occipital muscles. Flexion and slight rotation of head will stretch the posterior rotator muscles. The extension of neck and its rotation will stretch sternocleidomastoid muscle. Combining lateral bend to alternative medial head will stretch the scalene muscles. Isometrics for this group will be neck flexion, isometric neck extension, isometric neck side flexion, Isometric neck rotation, neck extensors stretch, neck flexors and side flexors stretch, stretch for right side and lateral rotation stretch
62405267|NCT04692974|NO_INTERVENTION|Control Group|For the control group, they will wear the wearables as a tracking device for the period of the study (6 months). No prompts will be given and the mobile application will only be installed but not used for this group.
62405268|NCT00994123|EXPERIMENTAL|Phase 1: Dose-Escalation|Escalating doses of MM-121 (QOW IV) and erlotinib (daily PO)
62405269|NCT00994123|ACTIVE_COMPARATOR|Phase 2: Control|Erlotinib (daily)
62405270|NCT00994123|EXPERIMENTAL|Phase 2: Treatment|MM-121 (QOW IV) and erlotinib (daily PO)
62405271|NCT01606501||Limb Salvage patients|Patients undergoing limb salvage following severe distal tibia, ankle and/or foot injuries with major soft tissue, bone and/or ankle articular surface loss.
62405272|NCT01606501||Transtibial Amputation patients|Patients undergoing transtibial amputation following severe distal tibia, ankle and/or foot injuries with major soft tissue, bone and/or ankle articular surface loss.
62405273|NCT02483754||original MOCA|The Chinese retired military cadres were surveyed with the revised MOCA scale.
62405274|NCT02483754||revised MOCA|The random part of participants were surveyed with the revised MOCA scale.
62405275|NCT02406066|PLACEBO_COMPARATOR|Placebo|Subjects will receive capsules containing no active pharmaceutical ingredients.
62405276|NCT02406066|ACTIVE_COMPARATOR|Low Dose (Cohort 1)|270 mg metyrapone and 12 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
62581050|NCT02403661|PLACEBO_COMPARATOR|Sham stimulation|Stimulation with the same parameters delivered only for 5 s.
62405277|NCT02406066|ACTIVE_COMPARATOR|Medium Dose (Cohort 2)|540 mg metyrapone and 24 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
62405278|NCT02406066|ACTIVE_COMPARATOR|High Dose (Cohort 3)|720 mg metyrapone and 24 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
62405279|NCT05416346|EXPERIMENTAL|dCBT-i|The dCBT-i group received the whole intervention
62581051|NCT03412734|EXPERIMENTAL|Chlorhexidine group|
62581052|NCT03412734|ACTIVE_COMPARATOR|Iodine group|
62016643|NCT05427149|ACTIVE_COMPARATOR|Group M25|Patients receiving intrathecal 10 mg hyperbaric bupivacaine (Marcaine® Spinal Heavy %0.5, Sanofi, Kırklareli, Turkey) + 25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey). MgSO4 diluted to 25mg/mL with normal saline (Polifleks %0.9 İzotonik Sodyum Klorür, Polifarma, Ankara, Turkey).
62206210|NCT05202392|EXPERIMENTAL|Myofascial Release with Scapular Stabilization Exercise|These individuals will only receive same myofascial release therapy as 1st group combined with stabilization exercises. The stabilization exercises will include total 5 stages. The patient will be instructed to get into a supine position and to relax their body and will be instructed to place their feet flat on floor while bending their knees and holding this posture without and involvement of neck movements. After this, the subjects will be taught to raise their shoulder arm up to 90° combined with full scapular protraction and elbow extension and to hold this position for 10 seconds before returning to the prior positions doing this for 3 laps and 10 repetitions and with a minute break in between. For a quadruped position the individuals will alternatively lift their arms along with 120° flexion and shoulder abduction and hold this for ten seconds for ten repetitions for 3 laps and a 30 second break in between
62206211|NCT01499303|EXPERIMENTAL|Fostamatinib 200|200mg fostamatinib bid n=60
62206212|NCT01852318|EXPERIMENTAL|Pregabalin|pregabalin 75mg daily for 12 weeks
62206213|NCT01852318|ACTIVE_COMPARATOR|fexofenadine|fexofenadine 60 mg daily for 12 weeks
62206214|NCT01852318|PLACEBO_COMPARATOR|Placebo|placebo 75 mg for 12 weeks
62206215|NCT03071237||Observational group|Patients who would receive total gastrectomy or distal gastrectomy are enrolled in to the study and this group. An optional reconstruction of IPA by enhanced CT scan can be performed before surgery but not a definite require. During the operation, IPA origin location will be photo-taken or video-recorded before its transection.
62206216|NCT04782440|EXPERIMENTAL|Telerehabilitation|
62206217|NCT04782440|ACTIVE_COMPARATOR|Home exercise|
62206218|NCT03128502||healthy control|Ten healthy control subjects presented with clinically healthy periodontium. Control subjects had to meet the following criteria for inclusion: probing depth less than 3mm, no clinical attachment loss, no bleeding on probing, with Gingival and Plaque index 0-1.
62581053|NCT02701530|EXPERIMENTAL|Targeted smoking cessation|"Smoking cessation program tailored in cooperation with the target group; smokers with low education.~Peer-based anti-relapse strategy. Recruitment strategy: peer-driven, written invitations and posters."
62016644|NCT05427149|ACTIVE_COMPARATOR|Group M50|Patients receiving intrathecal 10 mg hyperbaric bupivacaine (Marcaine® Spinal Heavy %0.5, Sanofi, Kırklareli, Turkey) + 50 mg/mL MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey). MgSO4 diluted to 50mg/mL with normal saline (Polifleks %0.9 İzotonik Sodyum Klorür, Polifarma, Ankara, Turkey).
62206219|NCT03128502||plaque induced gingivitis|Ten patients who had plaque induced gingivitis characterized by the presence of any of the following clinical signs: redness and edema of the gingival tissue, bleeding upon provocation, changes in contour and consistency, presence of calculus and/or plaque, with no clinical attachment loss nor radiographic evidence of bone loss.
62405280|NCT05416346|ACTIVE_COMPARATOR|Sleep Hygiene Education (SHE)|The SHE group received sleep hygiene education delivered in text form, and the same intervention as the dCBT-i group did after four weeks.
62405281|NCT00094900|EXPERIMENTAL|IL-1 Trap|
62581054|NCT02701530|NO_INTERVENTION|Control|No smoking cessation program.
62405282|NCT05471141|EXPERIMENTAL|Group 1|To receive intervention during the phase 1 and will receive nothing during the phase 2, will complete the measure at the end of phase 2 as the follow-up
62405283|NCT05471141|NO_INTERVENTION|Group 2|To serve as the control during phase 1 and receive intervention during the phase 2
62581055|NCT04437290||Alzheimer disease|The group is composed of individuals with a consensus diagnosis of amnestic mild cognitive impairment (MCI) or amnestic multimodal MCI or dementia primarily attributed to Alzheimer's disease (AD), as determined by the UW ADRC Clinical Core. They will have age of presentation \> 55 years, sporadic onset, CDR (Clinical Dementia Rating Scale) score 0.5-1.0, and sufficient English competency to complete a standardized cognitive testing battery. All will have no contraindication to MRI and will have had an MRI scan in the UW ADRC Imaging and Biomarker Core. These participants will undergo PET scanning with the investigational tau tracer \[18F\] MK6240
62581056|NCT02714595|EXPERIMENTAL|Cefiderocol|Participants will receive cefiderocol 2 g administered intravenously over 3 hours, every 8 hours for 7-14 days. Treatment could be extended to 21 days at the discretion of the investigator.
62788458|NCT04871958|NO_INTERVENTION|blindCGM/MDI|Blind CGM, insulin therapy by multiple daily injections managed according to standard care (capillary glucose measurements)
62788459|NCT00788788|ACTIVE_COMPARATOR|1|Study subjects where breathing Heliox with a fraction of Helium of 25% followed by 50% and 75% with larger external resistor in comparison to medical air
62405284|NCT00122954|EXPERIMENTAL|Fish oil concentrate|Fish oil concentrate
62405285|NCT00122954|PLACEBO_COMPARATOR|Placebo oil|Placebo oil
62788460|NCT00788788|ACTIVE_COMPARATOR|2|Study subjects where breathing Heliox with a fraction of Helium of 50% followed by 75% and 25% with larger external resistor in comparison to medical air
62788461|NCT00788788|ACTIVE_COMPARATOR|3|Study subjects where breathing Heliox with a fraction of Helium of 25% followed by 50% and 75% with larger external resistor in comparison to medical air
62788462|NCT01711645|EXPERIMENTAL|Adacel® Tdap vaccine|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
62788463|NCT01212393||Intervention group|reminders
62788464|NCT01212393||current practice group|no intervention
62788465|NCT01528189|PLACEBO_COMPARATOR|Standard glucose management|Arterial-blood glucose levels will be checked at induction of anesthesia and every 30 - 60 min thereafter with an StatStrip Xpress® (Nova Biomedical, MA, USA) ( A blood glucose level above 10 mmol/l will be treated with a 2U bolus of IV insulin (Humulin® R regular insulin, Eli Lilly and Company, Indianapolis, IN) followed by a 1 U/hour drip infusion adjusted according to a standard sliding scale
62788466|NCT01528189|ACTIVE_COMPARATOR|Hyperinsulinemic normoglycemic clamp|The blood glucose level will be checked prior to intubation. A 2U bolus of IV insulin will be given if blood glucose level is higher than 6 mmol/l, followed by an IV infusion of 2 U/kg/min (0.12 U/kg/hour). Dextrose 20% (D20W®) will be titrated to maintain blood glucose between 4 and 6 mmol/l. Blood glucose levels will be measured at 5-30 min intervals with a to ensure normoglycemia. At the end of surgery, the insulin infusion will be stopped, and the dextrose infusion weaned off in the post anesthesia care unit.
62788467|NCT05621148||Full population|LLC patients with prior treatment with BTKi - Underlying tenet: these patients have been treated with a BTKi in at least one of two or more prior lines of therapy and progressed - FULL POPULATION
62788468|NCT05621148||Narrow population|LLC Patients who progressed BTKi and failed VEN (defined as patients who discontinued VEN due to disease progression, intolerability, or failure to achieve an objective response within 3 months of initiating therapy; small patient population) - Tenet: these patients have been treated with both BTKi and VEN in any one of the prior two lines of therapy and progressed
62788469|NCT05856266|OTHER|Efmoroctocog alfa or eftrenonacog alfa|Efmoroctocog alfa or eftrenonacog alfa is prescribed and used according to usual clinical practice.
62788470|NCT02443168|EXPERIMENTAL|100-mg AG-221 oral solution + a microtracer of [14C]-AG- 221|Subjects will receive a 100 mg AG-221 to be swallowed with 240 mL of room-temperature, non-carbonated water.
62788471|NCT02443168|EXPERIMENTAL|100-mg AG-221 tablet + 100 micrograms [14C] AG-221|Formulated tablet containing 100 mg AG-221 + IV solution containing 100 micrograms \[14C\] AG-221
62788472|NCT06272110||Post-visit survey of Patients/Caregivers (pre-implementation)|
62788473|NCT06272110||H+H EHR reports of Patients (pre-implementation)|
62788474|NCT06272110||Community survey of Community members (pre-implementation)|
62788475|NCT06272110||Key stakeholder interviews of Patients/Caregivers/Community Members (pre-implementation)|
62788476|NCT06272110||Key stakeholder interviews of NYC H+H Leadership/Providers/Staff (pre-implementation)|
62788477|NCT06272110||Key stakeholder interviews of CBO Leadership/Staff (pre-implementation)|
62788478|NCT06272110||Post-visit survey of Patients/Caregivers (post-implementation)|
62788479|NCT06272110||H+H EHR reports of Patients (post-implementation)|
62788480|NCT06272110||Community survey of Community members (post-implementation)|
62788481|NCT06272110||Key stakeholder interviews of Patients/Caregivers/Community Members (post-implementation)|
62788482|NCT06272110||Key stakeholder interviews of NYC H+H Leadership/Providers/Staff (post-implementation)|
62788483|NCT06272110||Key stakeholder interviews of CBO Leadership/Staff (post-implementation)|
62788484|NCT04248023|EXPERIMENTAL|Intervention Practices|Intervention practices will work with a practice facilitator to make practice specific changes to address unhealthy alcohol use.
62788485|NCT04248023|NO_INTERVENTION|Control Practices|Control practices will continue to screening and address unhealthy alcohol use based on their existing practice patterns.
62788486|NCT01843062|EXPERIMENTAL|Selumetinib|Selumetinib plus Radioactive Iodine Therapy
62788487|NCT01843062|PLACEBO_COMPARATOR|Placebo|Placebo plus Radioactive Iodine Therapy
62788488|NCT05132218||Ensatinib for treated patients with ALK-positive advanced non-small cell lung cancer|Ensatinib 225mg QD Until the disease progresses or intolerance
62016645|NCT05427149|ACTIVE_COMPARATOR|Group M100|Patients receiving intrathecal 10 mg hyperbaric bupivacaine (Marcaine® Spinal Heavy %0.5, Sanofi, Kırklareli, Turkey) + 100 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey). MgSO4 diluted to 100mg/mL with normal saline (Polifleks %0.9 İzotonik Sodyum Klorür, Polifarma, Ankara, Turkey)
62016646|NCT05086458|NO_INTERVENTION|No intervention|the patients in this arm will not receive probiotics.
62016647|NCT05086458|EXPERIMENTAL|Dietary Supplement|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks.
62016648|NCT01025700|EXPERIMENTAL|Cesemat|
62016649|NCT01025700|NO_INTERVENTION|Placebo|
62206220|NCT03128502||chronic periodontitis|Ten chronic moderate to severe periodontitis patients selected according to the criteria currently adopted by Armitage 1999. Moderate destruction is generally characterized by periodontal probing depths up to 6 mm with clinical attachment loss of up to 4 mm. Advanced destruction is generally characterized by periodontal probing depths greater than 6 mm with attachment loss greater than 4 mm. Radiographic evidence of bone loss is apparent, Increased tooth mobility may be present.
62206221|NCT03128502||aggressive periodontitis|Ten patients suffering generalized aggressive periodontitis, patients were less than 35 years of age and had generalized interproximal attachment loss affecting at least 3 permanent teeth other than the first molars and incisors with at least one site each with PD and CAL \>5 mm, Attachment loss occurs in pronounced episodic periods of destruction, and there is familial aggregation (subjects were asked if they had at least one other member of the family presenting or with a history of periodontal diseases).
62788489|NCT00133601|EXPERIMENTAL|1|CBT-1
62016650|NCT06123039||POSITIVE Tidal Volume Challenge|Population with positive result in the tidal volume challenge. That is, an increase in PPV greater than 2% after increasing the tidal volume from 6 ml/kg to 8 ml/kg for 1 minute.
62016651|NCT06123039||NEGATIVE Tidal Volume Challenge|Population with a negative result in the tidal volume challenge. That is, not enough increase in PPV.
62016652|NCT06435026|OTHER|Standard Dose|daily oral FTC/TDF standard dose (200mg/300mg, n=18)
62016653|NCT06435026|OTHER|150% standard dose|daily oral FTC/TDF dose (300mg/450mg, n=18),
62016654|NCT06435026|OTHER|200% standard dose|daily oral FTC/TDF (400mg/600mg, n=18)
62016655|NCT03402243|EXPERIMENTAL|Menthol ban only for cigarettes|Participants will have available to them non-menthol cigarettes, menthol and tobacco flavored versions of a cigarette-like e-cigarette, menthol and tobacco flavored versions of a tank like e-cigarette and nicotine gum and lozenge
62206222|NCT03203187|PLACEBO_COMPARATOR|No mango intake|No mango intake for two weeks
62788490|NCT00133601|NO_INTERVENTION|2|Control Group
62788491|NCT00862693|EXPERIMENTAL|1 calcitriol|calcitriol 0.5ug/BIW for 12 months
62788492|NCT00862693|NO_INTERVENTION|2|no intervention
62206223|NCT03203187|EXPERIMENTAL|330 grams of daily mango intake|330 grams (2 cups) of daily mango intake for two weeks
62206224|NCT02006251|ACTIVE_COMPARATOR|Standard Total Hip Arthroplasty|Each surgeon will use their standard methods of pre-operative planning using pre-operative x-rays, and complete the procedure using standard surgical instruments for total hip arthroplasty.
62206225|NCT02006251|EXPERIMENTAL|Real-time Instrumentation|Pre-operative planning through 3D software with design of real-time instrument intraoperatively using bone cement and surrogate bone model for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
62206226|NCT02416960|EXPERIMENTAL|Low Glycemic Index Diet Group|Patients will follow a treatment with a hypocaloric diet with low glycemic index/load for 12 weeks, immediately before the in vitro fertilization cycle.
62206227|NCT02416960|ACTIVE_COMPARATOR|Conventional Diet Group|Patients will follow a treatment with a hypocaloric diet with high glycemic index/load for 12 weeks, immediately before the in vitro fertilization cycle.
62206228|NCT02416960|NO_INTERVENTION|Control Group|Patients will follow their usual diet for 12 weeks, immediately before the in vitro fertilization cycle.
62206229|NCT01022112|EXPERIMENTAL|TA-7284-Low|
62206230|NCT01022112|EXPERIMENTAL|TA-7284-Low-middle|
62405286|NCT03683264|OTHER|Vacuum delivery|Deliveries completed using vacuum instrumentation were performed by obstetricians with a minimum of five years' experience in obstetric practice. In terms of analgesia, epidural analgesia was used for intrapartum analgesia. The vacuum was a metal vacuum (Bird's cup 50 mm, 80 kPa) was used to perform fetal extraction. Traction was carried out during contraction, along with maternal push, at a rate of 2-3 tractions per contraction, and without associating Kristeller maneuver. The procedure was abandoned if, after three cup slides or 15 min, fetal extraction had not been successful. Selective episiotomy was carried out in vacuum delivery following Valme's University Hospital clinical practice guideline for instrumental deliveries.
62405287|NCT03683264|OTHER|Forceps delivery|Deliveries completed using forceps instrumentation were performed by obstetricians with a minimum of five years' experience in obstetric practice. In terms of analgesia, epidural analgesia was used for intrapartum analgesia. The forceps used for the instrumentation was the forceps of Kielland. Traction was carried out during contraction, along with maternal push, at a rate of 2-3 tractions per contraction, and without associating Kristeller maneuver. The procedure was abandoned if, after three cup slides or 15 min, fetal extraction had not been successful. Selective episiotomy was carried out in VD following Valme's University Hospital clinical practice guideline for instrumental deliveries.
62405288|NCT01751191||Training set-chronic response to propranolol|
62405289|NCT01751191||Validation set-chronic response to propranolol|
62788493|NCT04522141|EXPERIMENTAL|Self-control treatment group|The self-control treatment group will wear a Fitbit step counter across 8 weeks. In addition, they will use the MindHike smartphone application across 8 weeks. Each day, the app sends the a reminder to wear the Fitbit as well as a short interventional input targeting self-control.
62206231|NCT01022112|EXPERIMENTAL|TA-7284-High-middle|
62206232|NCT01022112|EXPERIMENTAL|TA-7284-High|
62405290|NCT01751191||Acute response to propranolol|
62405291|NCT04888780|EXPERIMENTAL|Experiment adolescent group|The web-based Watson's Human Care Theory oriented training and support program are applied to the intervention group.
62405292|NCT04888780|NO_INTERVENTION|Control adolescent group|No intervention is applied to the control group.
62206233|NCT01022112|PLACEBO_COMPARATOR|Placebo|
62405293|NCT00308555|OTHER|Cannabis|
62206234|NCT06198348|OTHER|Aerobic Exercise (Control Group)|Group A will receive Aerobic exercise plan. The treatment will be given with the frequency of 3 times per week for 8 weeks. Treatment sessions will be of 30 minutes with short resting intervals
62206235|NCT06198348|EXPERIMENTAL|Aerobic exercise with resistance training (Experimental Group)|Group B will receive aerobic and resistance exercise plan. The frequency of treatment will be as same as that of aerobic exercise program i.e. 3 times a week for 8 weeks. Treatment sessions will be of 45 minutes with short resting intervals
62206236|NCT02360033|EXPERIMENTAL|Systemic Therapy|Systemic Therapy deals with the experience in private social systems (e.g. couples. Family, friends) and organizational systems (e.g. work teams), their appraisals and the attitude of the members towards each other within the system. It is analyzed how these systems can lead to the development and maintenance of psychological disorders.
62206237|NCT02360033|EXPERIMENTAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy deals with individual behavior as well as individual attitude, thoughts, appraisals and beliefs, which can have an influence on the development and maintenance of psychological disorders.
62206238|NCT06405100|ACTIVE_COMPARATOR|Control Group|Supportive care+Prednisolone
62206239|NCT06405100|ACTIVE_COMPARATOR|Test group 1|Supportive care+Tacrolimus+Ripertamab
62206240|NCT06405100|ACTIVE_COMPARATOR|Test group 2|Supportive care+Ripertamab
62788494|NCT04522141|ACTIVE_COMPARATOR|Control group|The control group will wear a Fitbit step counter across 8 weeks. In addition, they will use the MindHike smartphone application across 8 weeks. Each day, the app sends the a reminder to wear the Fitbit.
62788495|NCT00724984|EXPERIMENTAL|1|
62788496|NCT05973253|EXPERIMENTAL|eyes that recieved medroxy progestrone at the end of surgery|eyes that received one drop of medroxy progesterone at the end of the photorefractive keratectomy(PRK)
62016656|NCT03402243|EXPERIMENTAL|Menthol ban for cigarettes and e-cigarettes|Participants will have available to them non-menthol cigarettes, tobacco flavored version of a cigarette-like e-cigarette, tobacco flavored version of a tank like e-cigarette and nicotine gum and lozenge
62405294|NCT06542666|EXPERIMENTAL|Cognitive Functional Therapy|Cognitive Functional Therapy will be conducted once a week, in individual and in-person sessions lasting approximately 40 minutes, over eight weeks.
62405295|NCT06542666|ACTIVE_COMPARATOR|Exercises|Twelve participants will be allocated to this group. They will perform strengthening and stretching exercises twice a week for eight weeks, with each session lasting approximately 30 to 40 minutes.
62405296|NCT00294190|EXPERIMENTAL|Topotecan|
62405297|NCT06615635|EXPERIMENTAL|DaRT seeds|Diffusing Alpha emitters Radiation (DaRT) treatment to be delivered through radioactive sources inserted into malignant cutaneous squamous cell carcinoma of Immunocompromised Patients
62405298|NCT05038085|EXPERIMENTAL|experimental group application|progressive muscle relaxation exercise health education
62788497|NCT05973253|NO_INTERVENTION|eyes did not recieved moderxy progestrone|eyes that did not receive drop medroxy progesterone at the end of photorefractive keratectomy(PRK)
62788498|NCT00658463|EXPERIMENTAL|1|The study is designed with a one-month steady state period with placebo then on a cross-over design with two 6-week periods of placebo or rosuvastatin (20 mg). An in vivo kinetic study will be performed at the end of each 6-week period.
62016657|NCT03402243|OTHER|No Menthol Ban|Participants will have available to them menthol and non-menthol cigarettes, menthol and tobacco flavored versions of a cigarette-like e-cigarette, menthol and tobacco flavored versions of a tank like e-cigarette and nicotine gum and lozenge
62016658|NCT04397081||Control Group|Control group was defined as healthy patients between the ages of 30-65 without allergic complaints.Patients' height, weight, demographic features (age, marital status, income level), obstetric histories (gravida, parity, mode of delivery), contraception methods and smoking status were noted.
62405299|NCT05038085|NO_INTERVENTION|control group application|No intervention will be made in the control group.
62405300|NCT01813786|EXPERIMENTAL|755nm Alexandrite Laser with Handpiece 2|Focusing energy on skin
62405301|NCT01813786|EXPERIMENTAL|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
62405302|NCT01813786|EXPERIMENTAL|755nm Alexandrite laser with handpiece 1|Focusing energy on skin
62405303|NCT02826239||pulmonary healthy controls|patients without known pulmonary disease
62405304|NCT02826239||pulmonary disease|patients with known or suspected pulmonary disease
62206241|NCT03171662|EXPERIMENTAL|group study|Imaging and Histopathological examination for Evaluation of Pediatric Appendicitis Score
62206242|NCT05292859||Rollover subjects from Alaunos Therapeutics TCR-T cell drug product interventional studies|"This is a rollover protocol designed to provide long-term follow-up to all subjects previously enrolled in any Alaunos Therapeutics autologous, neoantigen specific TCR-T cell drug product interventional studies.~Patients will be followed for up to 15 years after dosing of Alaunos Therapeutics autologous, neoantigen specific TCR-T cell drug product."
62206243|NCT02109705||Alzheimer's Disease|
62206244|NCT02109705||other Dementia|
62206245|NCT02109705||cognitive healthy|
62206246|NCT00663702|EXPERIMENTAL|1|
62405305|NCT00625846|EXPERIMENTAL|Cohort 1 (DTC)|Patients with differentiated thyroid cancer (DTC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62405306|NCT00625846|EXPERIMENTAL|Cohort 2 (MTC)|Patients with medullary thyroid cancer (MTC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62788499|NCT00658463|PLACEBO_COMPARATOR|2|The study is designed with a one-month steady state period with placebo then on a cross-over design with two 6-week periods of placebo or rosuvastatin (20 mg). An in vivo kinetic study will be performed at the end of each 6-week period.
62206247|NCT02777476|EXPERIMENTAL|procedure with B-Lite® Light Weight Breast Implant|
62206248|NCT02410616|EXPERIMENTAL|Blended CBT|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psychoeducation, (2) behavioural activation, (3) cognitive restructuring, and (4) relapse prevention.
62206249|NCT02410616|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the secondary care system. The investigators will not interfere with treatment as usual but they will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report.
62206250|NCT04824495||Patients with acute COVID-19|
62206251|NCT01291030|EXPERIMENTAL|hypomagnesemic + magnesium supplement|The patient group of hypomagnesesemic renal transplant recipients randomized to magnesium supplementation (number = 30). The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion,which are repeated after 6 months.
62206252|NCT01291030|NO_INTERVENTION|hypomagnesemic without magnesium supplement|The patient group of hypomagnesesemic renal transplantation recipients, randomized to no magnesium supplementation (number = 30). During 6 months, no magnesium supplementation is started, provided that the serum magnesium level remains \> 1,2 milligram/deciliter. In case of cramps, intermittent supplementation is allowed, but will be recorded. The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion,which are repeated after 6 months.
62405307|NCT00625846|EXPERIMENTAL|Cohort 3 (ATC)|Patients with anaplastic thyroid cancer (ATC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62788500|NCT05858372|EXPERIMENTAL|Chios Mastiha essential oil|1 soft gel capsule containing 200 mg of CMO and 100 mg of other excipients being medium chain triglycerides, while the shell was made of bovine gelatin and glycerol
62788501|NCT05858372|PLACEBO_COMPARATOR|Placebo|1 soft gel capsule only 100 mg of other excipients being medium chain triglycerides, while the shell was made of bovine gelatin and glycerol
62206253|NCT01291030|NO_INTERVENTION|normomagnesemic without magnesium supplement|In the control group of normomagnesemic renal transplantation recipients (number = 10), only a baseline assessment will be performed. The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion.
62206254|NCT00229138|EXPERIMENTAL|reduced Tacrolimus|
62206255|NCT00229138|ACTIVE_COMPARATOR|Reference Tacrolimus|
62206256|NCT05803421|EXPERIMENTAL|Orforglipron|Participants will receive escalated doses of orforglipron orally.
62206257|NCT05803421|ACTIVE_COMPARATOR|Insulin Glargine|Participants will receive insulin glargine subcutaneously (SC). Doses will be individualized and titrated according to a treat-to-target algorithm.
62206258|NCT03257527|EXPERIMENTAL|ENHANCE group|The ENHANCE group is comprised of 12 weekly session to be completed in-person and delivered by trained group facilitators.
62206259|NCT03257527|ACTIVE_COMPARATOR|MBSR group|"The MBSR group will complete a self-help workbook entitled, A Mindfulness-Based Stress Reduction Workbook over a 12 week period."
62206260|NCT02757872|ACTIVE_COMPARATOR|Vitamin D and Omega-3 Fatty acids|"Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), one 2000 IU capsule per day.~Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])."
62206261|NCT02757872|ACTIVE_COMPARATOR|Vitamin D and Omega-3 Fatty acid Placebo|"Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), one 2000 IU capsule per day.~Dietary Supplement: Omega-3 fatty acid placebo (Fish oil placebo)"
62206262|NCT02757872|ACTIVE_COMPARATOR|Vitamin D Placebo and Omega-3 Fatty acids|"Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).~Dietary Supplement: Vitamin D placebo. One capsule per day Vitamin D3 placebo"
62405308|NCT00625846|EXPERIMENTAL|Expansion Cohort (DTC)|Patients with confirmed, differentiated thyroid cancer (DTC) who are thyroglobulin antibody negative receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62405309|NCT01250418|ACTIVE_COMPARATOR|Ketamine Group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
62405310|NCT01250418|NO_INTERVENTION|No ketamine|No ketamine added to anesthesia regimen
62788502|NCT05892328|PLACEBO_COMPARATOR|Control|Calorie-matched control beverage
62788503|NCT05892328|ACTIVE_COMPARATOR|Watermelon flesh Dose 1|1 cup watermelon flesh, \~152 g
62788504|NCT05892328|ACTIVE_COMPARATOR|Watermelon flesh Dose 2|2 cups watermelon flesh, \~304 g
62016659|NCT04397081||Study group|"Study group was defined as patients between the ages of 30-65 with allergic complaints complaints (sneezing, itching,runy nose, respiratory distress) were diagnosed atopic disease (allergic asthma, allergic rhinitis, allergic conjunctivitis, chronic urticaria and atopic dermatitis) by same clinician in Immunology and Allergy Department. Patients' height, weight, demographic features (age, marital status, income level), obstetric histories (gravida, parity, mode of delivery), contraception methods and smoking status were noted.~Subgroup atopic disease diagnoses, duration of illness, treatments regimes and treatment time of the patients in the study group were also questioned and recorded."
62206263|NCT02757872|PLACEBO_COMPARATOR|Vitamin D Placebo and Omega-3 Fatty acid Placebo|"Dietary Supplement: Vitamin D placebo. One capsule per day Vitamin D3 placebo~Dietary Supplement: Omega-3 Fatty acid Placebo (Fish oil placebo). One capsule per day"
62206264|NCT05587348|EXPERIMENTAL|1. Best Practice Advisory|Four practices receive a suite of tools intended to increase the rate of referral to DSMES classes for patients with type 2 diabetes. In these four practices, the assigned DCE specialist will have access to a list of eligible patients who have upcoming appointments with their primary care providers. The DCE specialist will message the providers about the eligible patients via the EHR. They will also place a pended order for referral to DSMES class for the eligible patients. The health care provider will be able to either approve or deny the order for the referral Additionally, when an eligible patient presents for an appointment in one of the four intervention clinics, a best practice advisory (BPA) will fire within the EHR and encourage the provider to place a referral for DSMES classes.
62788505|NCT02675608||Year 1 Group 1|They are between 18-65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; have no history of immunodeficiency or weakened immunologic function; do not have diabetes; and do not have chronic HIV or hepatitis B or C infection.
62788506|NCT02675608||Year 1 Group 2|They are ≥65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; have no history of immunodeficiency or weakened immunologic function; do not have diabetes; and do not have chronic HIV or hepatitis B or C infection.
62405311|NCT05416034|EXPERIMENTAL|Use of the ATLAS 2030 exoskeleton at home|Children with Spinal Muscular Atrophy Type II will received robot assisted gait therapy with the ATLAS 2030 exoskeleton at their homes 5 days a week during two months in 60 minutes sessions
62405312|NCT02163746|ACTIVE_COMPARATOR|CO2 (carbon dioxide) laser|Patients randomized to this group will undergo CO2 laser excision of the sinus tracts in affected axilla
62788507|NCT02675608||Year 1 Group 3|They are between 18-65 years of age, are currently diabetic, and meet the criteria listed above for not diabetic subjects in Group 1, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of \> 6.5%).
62788508|NCT02675608||Year 1 Group 4|They are ≥65 years of age, are currently diabetic, and meet the criteria listed above for non-diabetic subjects in Group 2, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of \> 6.5%).
62788509|NCT02675608||Year 1 Group 5|They are between 35-50 years of age, meet the criteria listed above for non-diabetic subjects in Group 1, with the exception of chronic HIV with or without hepatitis B or C infection, and have current medical history of CD4 T-cell counts 300-800.
62016660|NCT01686087|ACTIVE_COMPARATOR|Continuation of SRI|Patients who achieve minimal to mild OCD symptoms and are not currently depressed at end of preparatory phase will be randomized to stay on SRI. They will receive 45 minute EX/RP booster sessions once per month.
62206265|NCT05587348|PLACEBO_COMPARATOR|2. Silent Best Practice Advisory|Two practices will not receive the suite of tools, but the lists and BPA will be created and sent to the research team.
62206266|NCT05587348|EXPERIMENTAL|3. Peer Support|45 patients in the 6 clinics who are referred to DSMES classes who enroll in the study will be assigned a peer supporter who will work with the participant and encourage attendance to the DSMES classes in addition to the usual support offered by the clinic.
62206267|NCT05587348|PLACEBO_COMPARATOR|4. Usual Care|45 patients in the 6 clinics who are referred to DSMES classes who enroll in the study will receive the usual support offered by the clinic.
62206268|NCT06347328|ACTIVE_COMPARATOR|non-echo-guided infiltration|
62206269|NCT06347328|EXPERIMENTAL|echo-guided infiltration|
62206270|NCT02566057|EXPERIMENTAL|PGx testing guided treatment (PGT)|Results of the GeneceptTM Assay will be provided to their prescribers who may use the knowledge to guide medication management.
62405313|NCT02163746|ACTIVE_COMPARATOR|Surgical Deroofing|Patients randomized to this group will undergo surgical deroofing of the sinus tracts in affected axilla
62405314|NCT04143568||Control|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
62405315|NCT04143568||Periodontitis|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
62405316|NCT02300194|ACTIVE_COMPARATOR|Topic Morphine|Use of topic morphine for treatment of procedure associated pain
62788510|NCT02675608||Year 2 Group 1|They are between 18-64 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; do not have diabetes.
62206271|NCT02566057|NO_INTERVENTION|Treatment as usual condition (TAU)|Patients will also utilize the GeneceptTM Assay but the results will not be provided back to their prescribers, who will treat the patients without the knowledge of pharmacogenetic testing results.
62206272|NCT04864054|EXPERIMENTAL|Arm A|Approximately 10-15 subjects will receive ECT204 at the RP2D by intravenous infusion and preceded by cyclophosphamide and fludarabine chemotherapy for lymphodepletion.
62016661|NCT01686087|PLACEBO_COMPARATOR|Replace SRI w/placebo|Patients who achieve minimal to mild OCD symptoms and are not currently depressed at end of preparatory phase will be randomized to gradual replacement with pill placebo. They will receive 45 minute EX/RP booster sessions once per month.
62016662|NCT00903838|EXPERIMENTAL|1|
62016663|NCT00903838|ACTIVE_COMPARATOR|2|
62016664|NCT06573138|EXPERIMENTAL|Chemofree|Patients receive 3 cycles of Selinexor, anti-PD-1 antibody plus Golidocitinib.
62206273|NCT04864054|EXPERIMENTAL|Arm B|Approximately 10-15 subjects will receive ECT204 at the RP2D by intravenous infusion and preceded by cyclophosphamide and fludarabine chemotherapy for lymphodepletion. Arm B subjects will also receive pre-treatment with regorafenib (STIVARGA®) before ECT204 administration.
62206274|NCT00285662|ACTIVE_COMPARATOR|1|1 day Sulfadoxine/Pyrimethamine + 3 days Amodiaquine
62206275|NCT00285662|ACTIVE_COMPARATOR|2|1 day of Sulfadoxine/Pyrimthamine and 3 days of Artesunate
62206276|NCT00285662|PLACEBO_COMPARATOR|3|children of this gorup will receive only placebo dugs
62206277|NCT04356677|EXPERIMENTAL|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
62405317|NCT02300194|PLACEBO_COMPARATOR|Placebo|Use of topic hydrogel (placebo) for treatment of procedure associated pain
62405318|NCT05587075|ACTIVE_COMPARATOR|Control group|The control group was treated with filiform needle.
62206278|NCT04356677|EXPERIMENTAL|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
62206279|NCT05816304|ACTIVE_COMPARATOR|Intervention arm|Digital CBTi will be offered using the SleepioTM website and supporting Sleepio™ app (Big Health Ltd., London, UK) via 6 sessions training program (spanning 6 to 12 weeks), lasting an average of 20 minutes each, unlocked weekly. The participant will receive the Sleepio intervention as soon as they become assigned.
62206280|NCT05816304|NO_INTERVENTION|Attention Control arm|Participants in the control group will have access to online the sleep diary and sleep education material for 12 weeks, without the CBTi intervention by the Sleepio™ app (Big Health Ltd., London, UK). They will start the digital cognitive behavioral therapy for insomnia (dCBTi) intervention 12 weeks after the initial enrollment.
62206281|NCT06728267|EXPERIMENTAL|Experimental Group|The experimental group will receive core stabilization training in addition to the training process. This training will be given for 6 weeks, 3 days a week, with 2 sets of 10 repetitions for the first two weeks, 2 sets of 15 repetitions for the second two weeks, and 3 sets of 12 repetitions for the third two weeks.
62016665|NCT06574022|ACTIVE_COMPARATOR|1) Intraoperative Pecs Blocks (IOB) & 30 cc of 0.5% bupivacaine (PB)|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 30 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
62016666|NCT06574022|ACTIVE_COMPARATOR|2) Intraoperative Pecs Blocks (IOB) & 20 cc of Exparel mixed w/10 cc of 0.5% bupivacaine (EX)|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 20 cc of Exparel mixed with 10 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
62206282|NCT06728267|ACTIVE_COMPARATOR|Control Group|The control group will be monitored throughout the training period and will not be given any training program.
62405319|NCT05587075|EXPERIMENTAL|Observation group|The observation group was treated with long round needle.
62405320|NCT05260528|ACTIVE_COMPARATOR|Standard arm|
62405321|NCT05260528|EXPERIMENTAL|Investigational arm|
62405322|NCT01977703|ACTIVE_COMPARATOR|Traditional ICD Programming|ICD will be set to pre-LVAD settings post LVAD implant.
62016667|NCT06574022|ACTIVE_COMPARATOR|3) Intraoperative Pecs II block (IOB) & superior AT (EX or BP)|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle with superior anesthetic as determined by stage I, after mastectomy completion and prior to reconstruction, if performed, or wound closure.
62016668|NCT06574022|ACTIVE_COMPARATOR|4) Preoperative Pecs II block (POB) & superior AT (EX or BP)|Preoperative Pecs II block to be administered by 1 of 6 acute pain specialized anesthesiologists in same day surgery. Patient will be lightly sedated with midazolam, at the discretion of the anesthesiologist. The pecs II block will be performed under ultrasound guidance using a 21-gauge, 80 mm length needle to administer the superior anesthetic as determined in stage I.
62206283|NCT02768532|EXPERIMENTAL|Crohn's disease patients|The patients will receive vedolizumab in compliance with the marketing authorization regimen (300 mg at weeks 0, 2, 6 and then every 8 weeks) in Crohn's Disease patients in clinical failure or intolerant to anti-TNF (Tumor Necrosis Factor) drugs. In case of lack of clinical response at week 10 or loss of response in the follow-up, all patients will be optimized with vedolizumab 300 mg at week 10 (additional infusion) and every following 4 weeks in contrast with responder patients at week 10 who will not have vedolizumab infusion at this time-point but will receive the next vedolizumab infusion at week 14 and then every 8 weeks, as recommended.
62206284|NCT04394377|OTHER|Group 1|"The routine full anticoagulation strategy will be applied for 30 days. In this strategy, full anticoagulation therapy will be maintained for all patients randomized to group 1 and, depending on the patient's clinical condition, there will be 2 possible routes of administration (oral or parenteral):~* Oral: Rivaroxaban 20 mg 1 x daily (adjust the dose to 15 mg 1x daily if ClCr between 30 and 49ml/min and/or concomitant use of azithromycin);~* Parenteral: Enoxaparin 1 mg/kg every 12 hours subcutaneously or Unfractionated heparin (preferable option for patients progressing with disseminated intravascular coagulation)."
62206285|NCT04394377|OTHER|Group 2|Patients in this group will receive the usual standard management and currently have no indication of full anticoagulation. Venous thromboembolism (VTE) prophylaxis should be used in group 2 (usual standard of care) as recommended by guidelines.
62405323|NCT01977703|EXPERIMENTAL|Ultra Conservative ICD Programming|ICD will be set to ultra conservative settings post LVAD implant.
62016669|NCT06475131|EXPERIMENTAL|BL-B16D1|Participants receive BL-B16D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62206286|NCT05061420|EXPERIMENTAL|Cohort A1 (sub study 01) treatment- naïve|Participants with HNSCC, who are treatment-naïve for R/M disease and have a PD-L1 Combined Positive Score (CPS) ≥1, will receive pembrolizumab followed by SAR444245. Both drugs administered by intravenous (IV) infusion on Day 1 of each 21-day treatment cycle for up to 35 cycles.
62206287|NCT05061420|EXPERIMENTAL|Cohort B1: (sub study 04) PD1/PD-L1 and platinum-based treatments|Participants with HNSCC who have received treatment with a PD1/PD-L1-based regimen \& platinum-based regimen and have failed no more than 2 regimens for R/M disease, will receive pembrolizumab followed by SAR444244. Both drugs administered IV infusion on Day 1 of each 21-day treatment cycle for up to 35 cycles
62215373|NCT06609707|NO_INTERVENTION|Standard Cardiac Care|Participants assigned to the Standard Cardiac Care group will continue to participate in their child's usual cardiac care and can access any supports available to their child and family. Participants in this group will not take part in the Tuning in to Kids program as part of this study; however, once the study has ended, participants will be offered an opportunity to receive Tuning in to Kids, if they would like to.
62405324|NCT04383925|EXPERIMENTAL|BCG-Japan|Infants randomized to receive BCG-Japan at discharge from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine BCG-Japan (Tokyo BCG Laboratory) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG vaccination.
62405325|NCT04383925|ACTIVE_COMPARATOR|BCG-Russia|Infants randomized to receive BCG-Russia at discharge from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-Russia-I (Serum Institute of India) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.
62016670|NCT02554773|EXPERIMENTAL|Fitusiran|Patients will be administered subcutaneous (SC) fitusiran once monthly or every 2 months according to the dose selection rules defined in protocol.
62206288|NCT05061420|EXPERIMENTAL|Cohort B2: (sub study 05) cetuximab- naïve|Participants with R/M HNSCC, who are cetuximab-naïve, have received treatment with a platinum-based regimen, and have failed no more than 2 regimens for R/M disease, will receive treatment with cetuximab followed by SAR444245. Cetuximab IV will be given on days 1, 8, and 15 of each 21 day. SAR444245 will be administered by IV infusion on Day 1 of each 21-day treatment cycle. Dosing of both drugs is to continue until disease progression, unacceptable toxicity, or withdrawal of consent.
62206289|NCT05917470|EXPERIMENTAL|Dose Level 1: 40mg QD|40mg of single agent ONCT-534 to be administered daily in oral tablets
62206290|NCT05917470|EXPERIMENTAL|Dose Level 2: 80mg QD|80mg of single agent ONCT-534 to be administered daily in oral tablets
62206291|NCT05917470|EXPERIMENTAL|Dose Level 3: 160mg QD|160mg of single agent ONCT-534 to be administered daily in oral tablets
62405326|NCT00012766|OTHER|Arm 1|
62405327|NCT00078273|NO_INTERVENTION|Assessment Only Control|Completed Baseline and 6 month follow-up surveys only.
62405328|NCT00078273|EXPERIMENTAL|Personalized Feedback Intervention|See Intervention Description
62405329|NCT00078273|EXPERIMENTAL|Cognitive Behavioral Intervention|See Intervention Description
62206292|NCT05917470|EXPERIMENTAL|Dose Level 4: 300mg QD|300mg of single agent ONCT-534 to be administered daily in oral tablets
62206293|NCT05917470|EXPERIMENTAL|Dose Level 5: 600mg QD|600mg of single agent ONCT-534 to be administered daily in oral tablets
62405330|NCT01686607||1) parenteral micafungin users|patients who had been treated with parenteral micafungin
62405331|NCT01686607||2) other parenteral antifungal users|patients who had been treated with a parenteral antifungal agent (not micafungin)
62405332|NCT01018680|PLACEBO_COMPARATOR|Placebo|
62405333|NCT01018680|EXPERIMENTAL|Duloxetine|
62405334|NCT05245292|EXPERIMENTAL|3BNC117-LS + 10-1074-LS + N-803|3BNC117-LS dosed at 30 mg/kg IV, day 0 10-1074-LS dosed at 10 mg/kg IV, day 0 N-803 dosed at 6 mcg/kg, SC, 8 doses every 3 weeks (week 1 through week 22)
62016671|NCT03462667|EXPERIMENTAL|Stoma Boot Camp|Participants will attend the Stoma Boot Camp session prior to surgery.
62206294|NCT05917470|EXPERIMENTAL|Dose Level 6: 1200 mg QD|1200mg of single agent ONCT-534 to be administered daily in oral tablets
62206295|NCT05917470|EXPERIMENTAL|BID Dose Level 1: 160 mg BID|600mg of single agent ONCT-534 to be administered daily in oral tablets
62206296|NCT05917470|EXPERIMENTAL|BID Dose Level 2: 300 mg BID|300mg of single agent ONCT-534 to be administered twice daily in oral tablets
62206297|NCT06515821||CRC Group|Subject has positive CRC diagnosis according to colonoscopy result
62206298|NCT06515821||Control Group with risks and presence of polyps|Healthy individuals with recognized risk factors for CRC development defined by either heredity and/or obesity and/or smoking and/or excess alcohol consumption and/or hyperlipidaemia.
62405335|NCT04772456|EXPERIMENTAL|metabolic MRI|Single-arm study in patients who have Glioma Perform metabolic magnetic resonance imaging on patient have a Glioma cancer to understand if metabolic MRI can be safely performed on this population
62405336|NCT05188768|EXPERIMENTAL|Concentrated growth Factor Membrane|Autogenous platelet and leukocyte fibrin material was obtained from blood.
62405337|NCT05188768|ACTIVE_COMPARATOR|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
62405338|NCT03723460||Households|Household here means a family unit comprising of at least both parents (mother and father) and a child under 5 years of age or an adolescent child.
62405339|NCT03071809||Early stage neoplasm|Patients with stage I-III early stage non-hematologic neoplasm
62405340|NCT03071809||Healthy Control|Patients undergoing surgery for a non-malignant condition with no prior history of malignancy.
62405341|NCT02401217|EXPERIMENTAL|Phase 1-Arm 1 Infant Formula|Milk-based infant formula manufactured by an alternative method. Non-commercially available formula. To be fed ad libitum.
62016672|NCT03462667|ACTIVE_COMPARATOR|Regular Care|Participants will receive normal standard of care prior to surgery.
62016673|NCT05715645|EXPERIMENTAL|Block at the Adductor Canal + Infiltration between Popliteal Artery and Posterior Capsule|Adductor canal block analgesia associated with infiltration between the popliteal artery and the posterior capsule
62206299|NCT06515821||Control Group with risks and absence of polyps|Healthy individuals with recognized risk factors for CRC development defined by either heredity and/or obesity and/or smoking and/or excess alcohol consumption and/or hyperlipidaemia.
62405342|NCT02401217|ACTIVE_COMPARATOR|Phase 2- Arm 2 Infant Formula|Milk-based infant formula using current manufacturing and ingredients. Non-commercially available formula. To be fed ad libitum.
62405343|NCT02401217|EXPERIMENTAL|Phase 2- Arm 3 Infant Formula|Milk-based infant formula using a new protein. Non-commercially available formula. To be fed ad libitum.
62016674|NCT05715645|ACTIVE_COMPARATOR|Block at the Adductor Canal + High Volume Local Infiltration Analgesia|Adductor canal block analgesia associated with surgical periarticular infiltration
62016675|NCT00359762|EXPERIMENTAL|Exenatide|
62016676|NCT00359762|ACTIVE_COMPARATOR|Glimepiride|
62016677|NCT02563041|EXPERIMENTAL|30%TSC|After each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of 30%TSC solution exactly equivalent to the catheter internal lumen.
62206300|NCT06515821||Control Group with no risks|Healthy individuals without any recognized risk factors for CRC development defined by either heredity and/or obesity and/or smoking and/or excess alcohol consumption and/or hyperlipidemia.
62405344|NCT00320073|EXPERIMENTAL|Arm A|Pemetrexed, Vinflunine, Folate, B12, Dexamethasone, Ondansetron, Midazolam
62405345|NCT00320073|EXPERIMENTAL|Arm B|Vinflunine, Erlotinib, Ondansetron, Midazolam
62405346|NCT00869362|EXPERIMENTAL|Diabetes Management Team|Evaluation and management by diabetes management team
62405347|NCT00869362|NO_INTERVENTION|Control|Patients receive usual care for diabetes
62405348|NCT02787148|EXPERIMENTAL|Cognitive behavioral therapy|Cognitive behavioral therapy for Major Depression
62016678|NCT02563041|ACTIVE_COMPARATOR|Heparin 5000 U/mL|After each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of unfractionated sodium heparin 5000 U/mL solution exactly equivalent to the catheter internal lumen.
62016679|NCT03658720|EXPERIMENTAL|Single tablet|Ibuprofen acid ODT: 1x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.
62016680|NCT03658720|EXPERIMENTAL|Two tablets|Ibuprofen acid ODTs: 2x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.
62016681|NCT02453789|ACTIVE_COMPARATOR|Alginate oligosaccharide|Inhalation of a dry powder OligoG in the first treatment period, and placebo in the second period
62206301|NCT05956457|EXPERIMENTAL|Single Arm Cohort Receiving Digital Health Coaching|All study participants will be enrolled in a 3-month digital health coaching program. They will also receive a Fitbit device to be worn daily for the capture of physical activity data.
62016682|NCT02453789|PLACEBO_COMPARATOR|Placebo|Inhalation of placebo dry powder in the first treatment period, and OligoG in the second period
62405349|NCT02787148|NO_INTERVENTION|Waitlist group|Waitlist group to control for repeated physiological measures and fluctuations over time
62016683|NCT01061060|EXPERIMENTAL|Beraprost group|Prostaglandin I2
62016684|NCT01061060|PLACEBO_COMPARATOR|Placebo group|
62016685|NCT05211024||Aim 1: Group A|Children and adolescent who are prior GOAL participants who have a normal echocardiogram at the 2 year endpoint and are no receiving secondary antibiotic prophylaxis
62206302|NCT02960737|EXPERIMENTAL|Intervention group|Intensive training with oral neuromuscular training using an oral device (intervention group) and routine care with compensatory swallowing training under 3 months with start 12 (±3) weeks after stroke onset.
62206303|NCT02960737|NO_INTERVENTION|Control group|Routine care with compensatory swallowing training under 3 months with starting 12 (±3) weeks after stroke onset.
62206304|NCT05741138|EXPERIMENTAL|Core strengthening group|Group A were given the Standard Physical Therapy Treatment along with core strengthening exercises Core strengthening exercises were carried out in their respective standard positions (were modified according to patient's comfortability)
62206305|NCT05741138|SHAM_COMPARATOR|Conventional treatment group|Group B were given only Standard Physical Therapy treatment.
62405350|NCT03919669|EXPERIMENTAL|All Subjects|"All subjects will complete PET imaging sessions evaluating the tau PET radioligand \[18F\]MK-6240 at baseline, as well as at 6, 12 and 24 months post-baseline.~If unable to complete the 6 month, 12 month, or 24 month visit, an 18 month and/or 30 month visit may instead be scheduled, totaling a maximum of four time points."
62405351|NCT06374693|EXPERIMENTAL|Stimulation|The intervention will take place for 45 minutes twice a day for 5 days after securing the aneurysm
62788511|NCT02675608||Year 2 Group 2|They are ≥65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; do not have diabetes.
62016686|NCT05211024||Aim 1 Group B|Children and adolescent who have a normal echocardiogram at the start of the study
62016687|NCT05211024||Aim 2|Children and adolescent who are prior GOAL participants who have persistent latent RHD on echocardiogram at the 2 year endpoint.
62016688|NCT06572501|EXPERIMENTAL|Prone position|Robot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position
62016689|NCT06572501|ACTIVE_COMPARATOR|Lateral position|Robot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position
62016690|NCT02998294|EXPERIMENTAL|Respiratory monitoring group|
62016691|NCT02805192|OTHER|one Arm: size measurement by Smart phone App|
62206306|NCT04561518||Patients with ATTR amyloidosis|Patients with a diagnosis of ATTR amyloidosis, hereditary or wild type, will be eligible for the study and will follow routine clinical care.
62206307|NCT04561518||Pre-symptomatic Carriers|Pre-symptomatic carriers with a known disease-causing TTR variant will be eligible for the study and will follow routine clinical care.
62206308|NCT03697317|EXPERIMENTAL|Televideo Lifestyle Coaching|
62016692|NCT03864614|EXPERIMENTAL|SAGE-217|
62016693|NCT03223103|EXPERIMENTAL|Mutation-derived tumor vaccine|MTA-based Personalized Vaccine (peptides + Poly-ICLC with Tumor Treating Fields
62016694|NCT04962269||prostate cancer|The patient was pathologically diagnosed with prostate cancer
62016695|NCT04962269||benign prostatic hyperplasia|The patient was pathologically diagnosed with benign prostatic hyperplasia
62016696|NCT02866617|EXPERIMENTAL|Conventional|T1-T2 : VFR constructed on conventional study model T2-T3 : VFR constructed on 3D reconstructed study model
62016697|NCT02866617|EXPERIMENTAL|3D|T1-T2 : VFR constructed on 3D reconstructed study model T2-T3 :VFR constructed on conventional study model
62016698|NCT06267482|NO_INTERVENTION|Control|Standard of care medial parapetallar approach
62206309|NCT03697317|ACTIVE_COMPARATOR|Enhanced Usual Care|
62405352|NCT06374693|SHAM_COMPARATOR|Sham|The placebo group will receive the same intervention, but the device will be in 'sham' mode (i.e. attached to the earlobe).
62405353|NCT01304199||Adult Cancer Survivors|"Intervention:~Behavioural:~Questionnaires for patient/family caregiver interview"
62405354|NCT03176576|EXPERIMENTAL|Patient Navigator (PN)|Patient Navigator (PN) Intervention Group. In addition to the Baseline Questionnaire and the Follow-up Questionnaire, PN intervention participants will complete a brief Patient Navigator Satisfaction Survey.
62405355|NCT03176576|OTHER|Usual Care (UC)|Usual Care (UC) Control Group. Control sample of patients not receiving PN intervention will complete a Baseline Questionnaire and the six-week Follow-up Questionnaire. Participants under UC will have access to all services typically provided to Moffitt Cancer Center (MCC) patients. Any baseline distress score greater than three will be reported to the patient's primary oncologist and clinic nurse.
62788512|NCT02675608||Year 2 Group 3|If they are between 18-64 years of age, are currently diabetic, and meet the criteria listed above for not diabetic subjects in Group 1, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of \> 6.5%).
62016699|NCT06267482|ACTIVE_COMPARATOR|ROSA PSA Parapatellar Approach|Arm using the ROSA with PSA and medial parapetallar approach
62016700|NCT06267482|ACTIVE_COMPARATOR|ROSA PSA Subvastus Approach|Arm using the ROSA with PSA and medial subvastus approach
62206310|NCT06575790|EXPERIMENTAL|Simple Meal Bolusing|Participants will be instructed to enter a set number of carbohydrates before meals based on if they are having a small, medium, or large meal. The preset numbers for meals will be based on their average total daily dose (TDD) determined during the 2-week usual care observation period. The participants will have their insulin to carbohydrate ratios set based on the standard formula of 450/TDD for all meals initially (e.g. a child with a TDD of 50 u/day would have 450/50=9 so an I:C of 1:9). They enter a carbohydrate amount of 30 g for small meals, 60 g for regular meals, and 90 g for large meals.
62405356|NCT02689505|EXPERIMENTAL|BI 836880|
62405357|NCT04778319|ACTIVE_COMPARATOR|tubal occlusion|occlusion of tubes
62405358|NCT04778319|SHAM_COMPARATOR|non occlusion of tube|non occlusion of tubes
62405359|NCT05935449|EXPERIMENTAL|Formaderm Lidocaine|Formaderm Lidocaine was randomly administered either side of subjects' facial areas once.The injection volume was limited to 2c.c.
62405360|NCT05935449|ACTIVE_COMPARATOR|Formaderm Dermal Filler Injection|Formaderm Dermal Filler Injection was randomly administered either side of subjects' facial areas once.The injection volume was limited to 2c.c.
62405361|NCT06082427|EXPERIMENTAL|VRH|"VRH was delivered through a 3D virtual reality headpiece equipped with a head-tracking system called  IPNEO  and designed by the society Cayceo (Montpellier, France, https://cayceo.fr/). The device display an enchanted environment movie based on hypnosis induction and suggestions (relaxation, comfort, and safety)."
62788513|NCT02675608||Year 2 Group 4|If they are ≥65 years of age, are currently diabetic, and meet the criteria listed above for non-diabetic subjects in Group 2, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of \> 6.5%).
62016701|NCT05946668||Observational (vaginal sample, questionnaires, records)|Participants undergo vaginal specimen self-collection via vaginal swab collection kit, complete questionnaires, and have medical records reviewed on study.
62016702|NCT03464682|EXPERIMENTAL|HS-25 10mg|HS-25 10mg, Placebo of HS-25 1 tablet, Placebo of Aorvastatin 1 tablet, oral once daily, 12weeks
62016703|NCT03464682|EXPERIMENTAL|HS-25 20mg|HS-25 10mg 2 tablets, Placebo of Aorvastatin 1 tablet, oral once daily, 12weeks
62405362|NCT06082427|NO_INTERVENTION|Control|Usual care
62405363|NCT01281475|EXPERIMENTAL|Levodopa|Levodopa is prescribed as a combination of levodopa/carbidopa (4:1) to reduce the peripheral side effects. The dosage used was 15 mg/kg/day in 3 divided doses.
62405364|NCT01281475|PLACEBO_COMPARATOR|Placebo|The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa, so it is not expected to have any effect.
62405365|NCT05686928|EXPERIMENTAL|Healing Ointment|Petrolatum-based opaque ointment applied to surgical wound twice daily.
62016704|NCT03464682|EXPERIMENTAL|HS-25 10mg combination with Atorvastatin|HS-25 10mg, Aorvastatin 10mg, Placebo of HS-25 1 tablet, oral once daily, 12 weeks
62016705|NCT03464682|EXPERIMENTAL|HS-25 20mg combination with Atorvastatin|HS-25 20mg, Aorvastatin 10mg, oral once daily, 12 weeks
62016706|NCT03464682|ACTIVE_COMPARATOR|Aorvastatin 10mg|Aorvastatin 10mg, Placebo of HS-25 2 tablets, oral once daily, 12 weeks
62016707|NCT03464682|PLACEBO_COMPARATOR|Placebo of HS-25 and Aorvastatin|Placebo of HS-25 2 tablets, Placebo of Aorvastatin 1 tablet, oral once daily, 12 weeks
62016708|NCT02545712||Neonatal patients|Receiving 2 or more drugs at one day during their hospitalisation. For each drug, it is listed whether it is an extemporaneous, registered, the preparation, dosis, amount, interval, formulation and route of administration. It is noted if the drug contains ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propanyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerin and/or sorbitol.
62016709|NCT02545712||Pediatric patients (28 days ≤ 5 years)|Receiving 3 or more drugs at one day during their hospitalisation. For each drug, it is listed whether it is an extemporaneous, registered, the preparation, dosis, amount, interval, formulation and route of administration. It is noted if the drug contains ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propanyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerin and/or sorbitol.
62016710|NCT01942382|EXPERIMENTAL|Treatment A|Participants will receive 4 injections of paliperidone palmitate 150 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
62016711|NCT01942382|EXPERIMENTAL|Treatment B|Participants will receive 4 injections of paliperidone palmitate 75 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
62016712|NCT01942382|EXPERIMENTAL|Treatment C|Participants will receive 4 injections of paliperidone palmitate 75 milligram in the gluteal muscle on Days 1, 8, 36, and 64.
62016713|NCT02230657|ACTIVE_COMPARATOR|Same day Discharge|
62016714|NCT02230657|ACTIVE_COMPARATOR|Next day discharge|
62016715|NCT04244474|EXPERIMENTAL|vitamin D3 supplementation|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 \[18\], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) . Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code.
62016716|NCT04244474|PLACEBO_COMPARATOR|Placebo|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 \[18\], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code.
62016717|NCT03532789|EXPERIMENTAL|herbal patch group|using herbal patch as an intervention
62016718|NCT03532789|PLACEBO_COMPARATOR|placebo patch group|using placebo patch as an intervention
62016719|NCT01351129|EXPERIMENTAL|Formulation 1|
62016720|NCT01351129|EXPERIMENTAL|Formulation 2|
62016721|NCT01351129|EXPERIMENTAL|Formulation 3|
62206311|NCT06575790|ACTIVE_COMPARATOR|Precise Carbohydrate counting|Participants will be instructed to enter a precise carbohydrate count before meals to the best of their ability. Pump settings may be adjusted per provider discretion and typical clinical care during this time period.
62405366|NCT05232318|ACTIVE_COMPARATOR|leveling and alignment using fixed orthodontic appliance|leveling and alignment using fixed orthodontic appliance
62405367|NCT05232318|EXPERIMENTAL|leveling and alignment using clear aligner|leveling and alignment using clear aligner
62405368|NCT05232318|EXPERIMENTAL|leveling and alignment using clear aligner with low level laser therapy|leveling and alignment using clear aligner with low level laser therapy
62016722|NCT05036083|EXPERIMENTAL|Diagnostic (CEM, DBT, medical record)|Patient receive iodinated contrast agent IV and undergo CEM. Patients who have not undergone DBT as part of their screening or diagnostic imaging within 3 month, undergo DBT. Patients medical records are reviewed.
62016723|NCT00809289|EXPERIMENTAL|One|
62016724|NCT00809289|PLACEBO_COMPARATOR|Two|
62016725|NCT00809289|ACTIVE_COMPARATOR|Three|Administration of a single oral dse of 400mg moxifloxacin
62016726|NCT00967187|EXPERIMENTAL|MPC-4326 200 mg BID X 14 Days|
62405369|NCT04469712||SASI Bipartition|Subjects submitted to SASI Bipartition
62405370|NCT04469712||Roux-en-Y gastric bypass|Subjects submitted to gastric bypass
62405371|NCT01912469|EXPERIMENTAL|Traumeel|Traumeel tablets by mouth the total amount for 72 hours will be 26 tablets
62788514|NCT03320720|EXPERIMENTAL|Home Treatment|Patients with acute mental illness are treated at their houses by a mobile and multiprofessional care team instead of being treated as inpatients if their medical condition permits.
62788515|NCT03320720|ACTIVE_COMPARATOR|Treatment-as-usual|Patients with acute mental illness are treated as inpatients in a psychiatric clinic.
62016727|NCT00967187|EXPERIMENTAL|MPC-4326 300 mg BID X 14 Days.|
62016728|NCT04638790|EXPERIMENTAL|Early favorable HL|HL without adverse prognostic factors
62016729|NCT04638790|EXPERIMENTAL|Early unfavorable HL|Early unfavorable (stages IA-B, IIA bulky and/or extranodal lesions, age less than 50 years)
62016730|NCT04638790|EXPERIMENTAL|Advanced stages HL|(age less than 50 years)
62016731|NCT04486859|OTHER|mechanical prevention|patients were managed with IPC
62016732|NCT04486859|OTHER|mechanical plus anticoagulant drugs prevention|patients were managed with IPC, and LMWH was added 24h after surgery and followed by rivaroxaban 5 days after surgery
62206312|NCT04506645|EXPERIMENTAL|REGN5381|Single dose REGN5381 administered via IV infusion
62206313|NCT04506645|OTHER|Placebo|Placebo matching single dose REGN 5381 administered via IV infusion
62405372|NCT01912469|PLACEBO_COMPARATOR|Placebo|The Placebo tablets (300 mg lactose monohydrate and 1,5 mg magnesium stearate) by mouth the total amount for 72 hours will be 26 tablets
62405373|NCT04176068|EXPERIMENTAL|Combined microfocused ultrasound and calcium hydroxylapatite|One-time intense microfocused ultrasound with calcium hydroxylapatite injection to one anterior lower thigh with option for additional filler injection at 6 weeks, 12 weeks, and 24 weeks. Optional combined treatment of the opposite lower anterior thigh at week 24 with no further follow up.
62405374|NCT03679234|EXPERIMENTAL|Intervention|Routine infant formula
62788516|NCT06038422|EXPERIMENTAL|GTP regimen treated patients|R/R HLH patients treated with GTP regimen
62788517|NCT02632357|EXPERIMENTAL|AS group|Subjects with ULNTT asymmetry \> 10°
62788518|NCT02632357|NO_INTERVENTION|S group|Subjects with ULNTT symmetry
62788519|NCT02860104|OTHER|microwave ablation|microwave ablation
62405375|NCT05278975|EXPERIMENTAL|Phase 1 - Dose Escalation|RSO-021 administered in increasing doses as a solution for pleural infusion through an indwelling IP catheter, administered as a single dose on Day 1 of each week of a 21-day treatment cycle.
62405376|NCT05278975|EXPERIMENTAL|Ph2 - Dose Expansion - MPE from non-mesothelioma solid tumors|RSO-021 administered at the MTD/RP2D as a solution for pleural infusion through an indwelling IP catheter, administered as a single dose on Day 1 of each week of a 21-day treatment cycle in patients with MPE from non-mesothelioma solid tumors.
62405377|NCT05278975|EXPERIMENTAL|Ph2 - Dose Expansion - MPE from mesothelioma|RSO-021 administered at the MTD/RP2D as a solution for pleural infusion through an indwelling IP catheter, administered as a single dose on Day 1 of each week of a 21-day treatment cycle in patients with MPE from mesothelioma.
62405378|NCT05278975|EXPERIMENTAL|P2 - Dose Expansion - mesothelioma -First line treatment prior to Ipi/Nivo|RSO-021 administered at the MTD/RP2D as a solution for pleural infusion through an indwelling IP catheter, administered as a single dose on Day 1 of each week of a 21-day treatment cycle in patients with mesothelioma. This local treatment with RSO-021 is prior to systemic treatment of Ipi/Nivo.
62405379|NCT05278975|EXPERIMENTAL|Ph2 - Dose Expansion - MPE from non-mesothelioma solid tumors combination with Paclitaxel|RSO-021 administered at the MTD/RP2D as a solution for pleural infusion through an indwelling IP catheter, administered as a single dose on Day 1 of each week of a 21-day treatment cycle in patients with MPE from non-mesothelioma solid tumors. In combination with Paclitaxel. Paclitaxel will be administered as a systemic therapy per SoC and the approved labeling based on the tumor type being treated. Paclitaxel is commercially available in the UK
62405380|NCT06519539||Adults with overweight or obesity|Healthy adults with a BMI of 27.5 kg/sq-m or above (26 or above for those of Asian descent), who will undertake a 6 month lifestyle intervention focused on improving dieary choices, physical activity and attitudes towards weight management.
62581057|NCT02714595|ACTIVE_COMPARATOR|Best Available Therapy (BAT)|Best available therapy (BAT) will be chosen by the investigator and may include up to three antibacterial agents for carbapenem resistant Gram-negative bacteria, intravenously administered per country-specific guidelines for 7-14 days. Treatment could be extended to 21 days at the discretion of the investigator.
62581058|NCT05230706|NO_INTERVENTION|Control (CBL)|The control group was kept under normal room light conditions (CBL) 24 hours a day (level of illumination was 275.82±14 lux during the day and 145.28±14 lux at night).
62734953|NCT04810364||All HIV-positive patients with chronic coronary syndrome|The Group includes all HIV-positive patients with stable chest pain. The progression of atherosclerosis will be quantitatively characterized by the parameters of the lesions (e.g. plaque burden, cap thickness, arterial remodeling, presence of erosions or rupture, malaposition of the stent, a vessel injury score, etc.). The imaging data will be handled with expert-level post-processing software.
62734954|NCT04266392|EXPERIMENTAL|1|
62734955|NCT01575236|EXPERIMENTAL|Guardian|Guardian Laryngeal Mask
62405381|NCT01920841|EXPERIMENTAL|Left (A), Right (B)|Cream A applied to left thigh and Cream B to right thigh
62405382|NCT01920841|EXPERIMENTAL|Left (B) Right (A)|Cream B applied to left thigh and Cream A to right thigh
62405383|NCT03029754|EXPERIMENTAL|Passive leg raise|Participant's legs will be raised with a bolster prior to IV insertion.
62405384|NCT03029754|NO_INTERVENTION|No leg raise|Participants will lie flat prior to IV insertion.
62405385|NCT03681912||Implementation Block 1|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 3 months.
62206314|NCT00948116||Diabetes mellitus, renal impairment|Patients with both diabetes mellitus and eGFR \<60 ml/min
62734956|NCT01575236|EXPERIMENTAL|Supreme|Supreme Laryngeal Mask Airway
62734957|NCT02101996||Healthy|Not insulin resistant
62788520|NCT02481531|ACTIVE_COMPARATOR|Previously marketed infant formula|Cow's milk-based infant formula
62016733|NCT01319734|EXPERIMENTAL|Vitamin C supplementation plus oral hypoglycemic agents arm|This group will receive vitamin C supplementation 500mg daily for one month and then assessment will done for the patients.
62016734|NCT01319734|ACTIVE_COMPARATOR|Type 2DM patients receiving oral hypoglycemic agents alone|this group is the control group who receive oral hypoglycemic agents alone
62734958|NCT02101996||Insulin resistant|Insulin resistant by an insulin clamp
62788521|NCT02481531|EXPERIMENTAL|Previously marketed formula using a similar protein|Cow's milk-based infant formula
62788522|NCT04921228|EXPERIMENTAL|Heart rate variability biofeedback|Heart rate variability biofeedback training will be administered via a smartphone app (Optimal HRV) that reads the participants' pulse rate through a Bluetooth connected photoplethysmography (PPG) sensor attached to the finger or thumb.
62206315|NCT06379061||Adult and Pediatrics|A minimum of 244 serum samples will be collected at a minimum of two (2) US locations from enrolled pediatric and adult patients presenting signs and symptoms suggestive of acute bacterial or viral infection. The number of patients enrolled is based on total volume required to run analytical comparison studies under a future testing protocol.
62206316|NCT06194487|PLACEBO_COMPARATOR|Placebo drink|consume 1 bottle (50mL) per day
62405386|NCT03681912||Implementation Block 2|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 6 months.
62405387|NCT03681912||Implementation Block 3|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 9 months.
62405388|NCT03681912||Implementation Block 4|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 12 months.
62405389|NCT03681912||Implementation Block 5|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 15 months.
62405390|NCT03681912||Sustainment Block 1 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
62206317|NCT06194487|EXPERIMENTAL|MAXI Collagen drink|consume 1 bottle (50mL) per day
62206318|NCT06194487|ACTIVE_COMPARATOR|Normal fish collagen drink|consume 1 bottle (50mL) per day
62206319|NCT03217695|EXPERIMENTAL|Mindfulness-based Yoga Arm|"8-week period, 1x/week for 45-60 minutes/session. Sessions 1-2: Participants instructed to focus their attention on their breath, and the physical sensations in their bodies while holding the yoga postures, to develop sustained and focused attention. Sessions 3-4: exploring the sensorial qualities of physical sensation in the body whether pleasant or unpleasant and to notice thoughts and label them (e.g., planning, remembering), and to the same with emotions (e.g., worry, frustration, fear) to practice disengaging from automatic associative thinking. Session 6-8: Instructor will guide participants to allow sensations of discomfort or effort to be as they are and to bring awareness to automatic patterns of reactivity. The goal is to foster distress tolerance, provide opportunities for participants to practice self-care, and allow an opportunity to observe and respond skillfully, instead of react automatically, to unpleasant stimuli (sensations, emotions)."
62206320|NCT04101253|EXPERIMENTAL|Interventional|"Every ICD patient will undergo the standard screening process. Initial screening will be performed as usually performed by physician or Boston Scientific technical support. In case of one or more vector satisfying screening criteria, patient will be assigned in screening success group. In case of failure, a pre-determined electrode positioning protocol will be done with variation of para-sternal and axillary electrodes. Positioning variations will be left to the discretion of the operator cardiologist."
62405391|NCT03681912||Sustainment Block 2 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
62734959|NCT05145751||COVID-19 infection|Consecutive patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection
62788523|NCT06127628|EXPERIMENTAL|Ultrasound-guided scalp with ropivacaine 0.375%|Ultrasound-guided scalp block performed for supraorbital nerve, supratrochlear nerve, zygomaticotemporal nerve, auriculotemporal nerve, superficial cervical plexus, greater occipital nerve and third occipital nerve. The local anaesthetic used will be ropivacaine 0.375%.
62788524|NCT06127628|NO_INTERVENTION|Standard treatment|Standard perioperative anaesthetic and surgical treatment will be performed, with the omission of ultrasound-guided scalp block
62788525|NCT00709072|EXPERIMENTAL|1|SMS reminders
62788526|NCT00709072|NO_INTERVENTION|2|control group
62206321|NCT00353249|EXPERIMENTAL|1|Participants will receive adapted cognitive behavioral therapy treatment
62206322|NCT00353249|NO_INTERVENTION|2|Participants will receive no treatment for the course of the study; they will be offered courtesy PTSD 5 weeks after the experimental intervention.
62206323|NCT02997293||Enhanced Recovery|Those subjects who had major colorectal surgery at the University of Arkansas for Medical Sciences after Enhanced Recovery After Surgery implementation, between the dates of June 1, 2015 to November 30, 2016
62206324|NCT02997293||pre-Enhanced Recovery|Those subjects who had major colorectal surgery at the University of Arkansas for Medical Sciences prior to Enhanced Recovery After Surgery implementation between the dates of January 1, 2014 to December 31, 2014
62016735|NCT03632161|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine is added to bupivacaine the paravertebral block
62206325|NCT06696768|EXPERIMENTAL|Group A (CA-4948, bevacizumab, FOLFOX)|Patients receive CA-4948 PO BID on days 1-14 of each cycle, bevacizumab IV over 30-90 minutes on day 1 of each cycle beginning in cycle 1, and oxaliplatin IV over 120 minutes, leucovorin IV over 2 hours, and fluorouracil IV bolus followed by continuous IV infusion over 46 hours on day 1 of each cycle. Cycles repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity. After treatment for 2 years, patients may continue treatment after discussion with the study chair. Patients also undergo blood sample collection and CT, MRI, or PET/CT throughout the trial. Patients may also undergo tumor biopsy throughout the trial.
62405392|NCT03681912||Sustainment Block 3 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
62405393|NCT03681912||Sustainment Block 4 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
62405394|NCT03681912||Sustainment Block 5 Facilitated CoP|Randomized Guided Development of CoPs with an internal facilitator after one year of implementation.
62405395|NCT03681912||Sustainment Block 1 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
62734960|NCT01667497|EXPERIMENTAL|Fampridine SR|Fampridine SR 10mg BID
62734961|NCT01667497|PLACEBO_COMPARATOR|Placebo|non-drug
62734962|NCT05187897|NO_INTERVENTION|Standard Care Control|CHVs based at facilities in the control arm will continue to implement the standard of care.
62016736|NCT03632161|OTHER|Bupivacaine|Bupivacaine only in the paravertebral block
62788527|NCT06177691||Cohort A|Participants with body weight ≥30 kg (Cohort A) were randomly assigned in a factorial design during the RCT to (1) HCL plus intensive diabetes management or usual care with no HCL and (2) verapamil or placebo. No interventions were administered during the observational extension.
62788528|NCT06177691||Cohort B|Participants with body weight \<30 kg (Cohort B) were randomly assigned during the RCT 2:1 in a parallel group design to HCL plus intensive diabetes management or to usual care with no HCL. No interventions were administered during the observational extension.
62206326|NCT06696768|EXPERIMENTAL|Group B (CA-4948, bevacizumab, FOLFOX)|Patients receive CA-4948 PO BID on days 1-14 of each cycle, bevacizumab IV over 30-90 minutes on day 1 of each cycle beginning in cycle 2, and oxaliplatin IV over 120 minutes, leucovorin IV over 2 hours, and fluorouracil IV bolus followed by continuous IV infusion over 46 hours on day 1 of each cycle. Cycles repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity. After treatment for 2 years, patients may continue treatment after discussion with the study chair. Patients also undergo blood sample collection and CT, MRI, or PET/CT throughout the trial. Patients also undergo tumor biopsy throughout the trial.
62206327|NCT06565455|EXPERIMENTAL|Intervention Group|Seven healthy eating modules, delivered by Community Health Workers (CHW) in the home setting, for 14 weeks. Plus two to three cooking demonstration in the church setting.
62788529|NCT04548856|OTHER|IA-Microsurgical clipping group (ruptured aneurysms)|This subgroup includes patients who underwent microsurgical clipping of an acutely ruptured cerebral aneurysm
62788530|NCT04548856|OTHER|IB-Microsurgical clipping group (unruptured aneurysms)|This subgroup includes patients who underwent microsurgical clipping of unruptured cerebral aneurysm
62788531|NCT04548856|OTHER|IIA-Endovascular embolization group (ruptured aneurysms)|This subgroup includes patients who underwent endovascular embolization of an acutely ruptured cerebral aneurysm
62788532|NCT04548856|OTHER|IIB-Endovascular embolization group (unruptured aneurysms)|This subgroup includes patients who underwent endovascular embolization of unruptured cerebral aneurysm
62215374|NCT06609707|EXPERIMENTAL|Tuning in to Kids (Treatment Arm)|Participants will receive Standard Cardiac Care plus the Tuning in to Kids intervention.
62405396|NCT03681912||Sustainment Block 2 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
62788533|NCT02189512|OTHER|brain death organ donors|cases - blood sampling
62788534|NCT02189512|OTHER|abdominal aortic aneurysm repair|controls - blood sampling
62788535|NCT01415401|EXPERIMENTAL|AZARGA|Brinzolamide 1% / timolol 0.5% maleate fixed combination, 1 drop self-administered in study eye(s) twice daily for 8 weeks (8AM and 8PM)
62788536|NCT01018485|EXPERIMENTAL|Botulinum Toxin First Dose|Blinded and Randomized injection of 20 upper limbs with Botulinum Toxin Type A
62788537|NCT01018485|EXPERIMENTAL|Botulinum Toxin Second Dose|20 patients will receive Placebo as first dose and Botulinum Toxin as second dose injection 3 months after initiation of the study
62788538|NCT01618006|ACTIVE_COMPARATOR|Aspirin 81mg daily|Patients will receive 81mg daily during the postoperative period.
62788539|NCT01618006|ACTIVE_COMPARATOR|Aspirin 325mg daily|Patients will receive 325mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
62788540|NCT01618006|EXPERIMENTAL|Aspirin 81mg four times daily|Patients will receive ASA 81mg four times daily until postoperative day 7 or end of hospitalization
62788541|NCT04998981|EXPERIMENTAL|K-877 0.1 mg BID|K-877 0.1 mg tablet twice daily, Placebo tablet twice daily, Placebo capsule once daily
62016737|NCT04798300|OTHER|tested material|Newly Introduced Gradient Monolithic Zirconia (Intervention)
62016738|NCT04798300|ACTIVE_COMPARATOR|comparator material|Full Strength Monolithic Zirconia (Comparator)
62016739|NCT06222723|ACTIVE_COMPARATOR|Standard of care|Standard of care antiviral ribavirin therapy
62206328|NCT06565455|NO_INTERVENTION|Control/Attention Group|"Five video recordings via Facebook/WhatsApp for three months. Video topics:~* Mental Health~* Cord Blood Banking~* Dental Care~* Immunizations~* Behavioral Problems in Children"
62016740|NCT06222723|EXPERIMENTAL|Standard of care + dexamethasone|Standard of care antiviral ribavirin therapy + dexamethasone
62016741|NCT02798848|EXPERIMENTAL|Assistive technology: tablet computer|iPad tablet computers
62016742|NCT02798848|ACTIVE_COMPARATOR|Standard optical low vision devices|standard optical devices including magnifiers, telescopes, CCTV
62016743|NCT01330940|PLACEBO_COMPARATOR|Water drinking|32 ounces of water/24 hours
62016744|NCT01330940|ACTIVE_COMPARATOR|orange soda drinking|32 ounces orange soda
62016745|NCT06038682||Argatroban anticoagulation|Study subjects in this group will receive Argatroban anticoagulation.
62016746|NCT06038682||Heparin anticoagulation|Study subjects in this group will receive Heparin anticoagulation.
62016747|NCT03731494||Nickel oral hyposensitization treatment|The patients take capsules at different doses in nickel content until reaching the maximum dose of 1.5 mcg per week for a total of 12 months.
62016748|NCT01340989|EXPERIMENTAL|4% oxygen|addition of 4% oxygen to the CO2 pneumoperitoneum
62405397|NCT03681912||Sustainment Block 3 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
62405398|NCT03681912||Sustainment Block 4 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
62016749|NCT01340989|EXPERIMENTAL|full conditioning|full conditioning of the peritoneal cavity by the laparoscopic gas: 4% oxygen, 10% nitrous oxide, humidification and set temperature of 32°C
62405399|NCT03681912||Sustainment Block 5 CoP Along|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
62405400|NCT03964896|EXPERIMENTAL|Supportive Care (telephone intervention)|During standard of care chemotherapy, patients receive up to 18 telephone calls from a nurse using a standardized triage call script over 20 minutes.
62016750|NCT01340989|ACTIVE_COMPARATOR|CO2 pneumoperitoneum|standard laparoscopy with CO2 pneumoperitoneum
62016751|NCT04552873|EXPERIMENTAL|EXPERIMENTAL GROUP|the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)
62016752|NCT04552873|PLACEBO_COMPARATOR|CONTROL GROUP|the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
62206329|NCT06728020|ACTIVE_COMPARATOR|Conventional rehabilitation (Group A)|The first 140 patients who meet the inclusion criteria will be randomized between this group and group B. This group will undergo conventional therapy.
62206330|NCT06728020|EXPERIMENTAL|ROOMMATE 1st (Group B)|The 70 patients randomized to this group will undergo conventional treatment and, in addition, will have the first version of the ROOMMATE system.
62016753|NCT02742103|EXPERIMENTAL|CSL_112|CSL112 will be administered intravenously, once weekly for 4 consecutive weeks (4 infusions in total).
62016754|NCT02742103|PLACEBO_COMPARATOR|Placebo|Placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
62016755|NCT01119261|ACTIVE_COMPARATOR|Non-genotype-guided dosing algorithm|
62016756|NCT01119261|EXPERIMENTAL|Genotype-guided dosing algorithm|
62016757|NCT03843502|EXPERIMENTAL|Kava Pharmacokinetics Group|Each subject will take three 75 mg kava dietary supplement capsules in a single dose/timepoint and nine blood draws will be collected over an eight hour period following adminstration of kava.
62016758|NCT05769452|EXPERIMENTAL|BD Nexiva™|The intervention group was given a closed IV catheter system called BD Nexiva™.
62016759|NCT05769452|EXPERIMENTAL|BD Insyte™ Autoguard™|The control group received an open IV catheter called BD Insyte™ Autoguard™.
62016760|NCT05585333|EXPERIMENTAL|Photobiomodulation Group|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
62016761|NCT05585333|NO_INTERVENTION|Control Group|
62016762|NCT04741425|EXPERIMENTAL|REST intervention|There will be one session of online antenatal breastfeeding talk, 5 sessions of daily online postnatal individualized breastfeeding coaching, and 7 weekly postnatal telephone follow-ups.
62206331|NCT06728020|EXPERIMENTAL|ROOMMATE 2nd (Goup B2)|Group B2 will undergo conventional treatment and will have an extended version of the bedside multimedia monitor apparatus, integrated with an inertial sensor to enable the serious games on the experimental platform.
62405401|NCT02778295||Observation|Patients with Fabry disease or high-grade suspicion for Fabry disease
62405402|NCT03957161|EXPERIMENTAL|ACEi/ARB continuation|Intervention group will continue or start to take ACEi and/or ARBs
62405403|NCT03957161|NO_INTERVENTION|ACEi/ARB withdrawal|The control group will discontinue ACEi and/or ARBs which may be substituted with other anti-hypertensive agents (if already taking ACEi/ARB) or continue to not take ACEi/ARBs
62405404|NCT02825875||adenocarcinoma of the prostate|
62016763|NCT04741425|NO_INTERVENTION|Usual care|"Standard antenatal and postnatal care provided by midwives and lactation consultants in the hospitals through by Zoom or by online self-learning through watching videos and reading pamphlets. Participants can also attend other breastfeeding talks or breastfeeding support groups provided by the non-governmental organizations for maternal care.~After delivery, mothers will be taught about baby care at bedside. Breastfeeding skills will also be taught and assessed by the midwives and lactation consultants individually or in group-based breastfeeding talk in the postnatal ward.~Upon discharge, a breastfeeding and postnatal hotline will be provided to all women for advices, and a telephone follow-up will be arranged for all the mothers within 3 to 4 days after delivery by midwives or lactation consultants. The mother-baby dyads will be suggested to follow up in MCHCs for baby growth and breastfeeding support."
62016764|NCT03684798|EXPERIMENTAL|Mental Contrasting with Implementation Intentions (MCII)|"Mental Contrasting with Implementation Intentions (MCII) combines two methods: Mental Contrasting and Implementation Intentions.~Mental Contrasting (MC) consists of imaging a desired future and comparing it with obstacles of the present reality (Oettingen, 2000, 2014; Oettingen, Pak, \& Schnetter, 2001) in order to increase goal commitment when expectations of success are high (Gollwitzer, 2014). Implementation Intentions on the other hand specify when, where, and how to strive for a goal in form of an if-then-plan, e.g. If situation Y is encountered, then I will perform the goal-directed response Z (Gollwitzer, 2014; Wieber, Thürmer, \& Gollwitzer, 2015)."
62206332|NCT03425097|EXPERIMENTAL|Fexofenadine then Placebo|Patients in this group will get 2 weeks of fexofenadine, then 1 week of nothing, then 2 weeks of placebo.
62206333|NCT03425097|EXPERIMENTAL|Placebo then Fexofenadine|Patients in this group will get 2 weeks of placebo, then 1 week of nothing, then 2 weeks of fexofenadine.
62206334|NCT05141851|ACTIVE_COMPARATOR|Implants with 0,7mm threads|Placement of Implants with 0,7mm threads
62206335|NCT05141851|ACTIVE_COMPARATOR|Implants with 0,3mm threads|Placement of Implants with 0,3mm threads
62206336|NCT00685139|EXPERIMENTAL|Zonisamide 100 mg Capsule|A single dose of zonisamide 100 mg administered after an overnight fast.
62206337|NCT00685139|EXPERIMENTAL|Zonisamide (Zonegran® ) 100 mg Capsule|A single dose of Zonegran® 100 mg administered after an overnight fast.
62206338|NCT05768347|EXPERIMENTAL|Treatment with Adoptive Cell Therapy|TIL from bladder biopsies will be propagated and cultured with interleukin-2 (IL-2) to a target goal of \>30 million cells. These TIL then undergo rapid clonal expansion (REP) by incubation with anti-CD3 monoclonal antibody (mAb), resulting in \>500-fold expansion. After 4-6 weeks culture time intravesical TIL will be administered via intravesical infusion, consisting of up to 3.2e8 cells in 40 mL aliquot. Intravesical therapy will be administered for up to 2 hours. This treatment will occur four times (Day 0, Day 7, Day 14 and Day 21).
62206339|NCT03499470|ACTIVE_COMPARATOR|Intervention|"The intervention mainly consists of a developed protocol for education about the disease and medications AND an education of the equipment and how to use it to have the best benefit.~Actions in structured discharge and follow up protocol:~1. Patient education for disease severity and medications~2. Education of family/relatives about medications and types of equipment~3. Detailed education for LTOT and/or NIV (how to use, duration of use, solutions for possible common problems)~4. Preparation of home environment for patients needs~5. Regular telephone visits on day 7 and day 14 after discharge and telephone visits in emergency situations and early referral to the hospital when needed~6. Outpatient control for the first month"
62206340|NCT03499470|NO_INTERVENTION|Control|Control patients will receive usual care
62206341|NCT04940819|EXPERIMENTAL|Mobile Application Intervention|Participants in this arm will receive mobile application dietary intervention as well as usual CKD dietary care.
62206342|NCT04940819|NO_INTERVENTION|Care as Usual|Participants in this arm will receive usual CKD dietary care.
62206343|NCT05857189|EXPERIMENTAL|Experimental group|
62788542|NCT04998981|EXPERIMENTAL|K-877 0.2 mg BID|K-877 0.1 mg tablet x 2 twice daily, Placebo capsule once daily
62788543|NCT04998981|ACTIVE_COMPARATOR|Fenofibrate 200 mg QD|Fenofibrate 200 mg capsule once daily, Placebo tablet x 2 twice daily
62788544|NCT04998981|PLACEBO_COMPARATOR|Placebo|Placcebo tablet x 2 twice daily, Placebo capsule once daily
62206344|NCT05857189|ACTIVE_COMPARATOR|Control group|
62206345|NCT05857189|OTHER|Healthy control group|patients in this group will be observed as a normal reference group
62206346|NCT04747600||serous cystic neoplasms|
62206347|NCT04747600||mucinous cystic neoplasms|
62206348|NCT04747600||intra-papillary mucinous neoplasms|
62016765|NCT03684798|ACTIVE_COMPARATOR|Treatment as usual|The control group receive a control training, which consists of an exercise from treatment as usual. Thus, patients in the control group are supported in their intention for abstinence and in the reappraisal of risk situations and relapse, while no individual motivational strategies are planned or provided
62016766|NCT02717091|EXPERIMENTAL|FOLFIRINOX|4 course of FILFIRINOX before surgery
62016767|NCT02717091|EXPERIMENTAL|GEM + nab-PTX|2 course of GEM + nab-PTX before surgery
62016768|NCT00670124|NO_INTERVENTION|1|Standard medical treatment
62016769|NCT00670124|ACTIVE_COMPARATOR|2|Standard medical treatment plus hypothermia (33°C) maintained for 72 hours
62016770|NCT05428085||Caregivers whose children are currently receiving early treatment|Individual caregivers were interviewed through paper questionnaires to assess children's and families' digital media usage habits, children's activity levels, and parental stress. Pearson's Chi-Square test and liner regression was used for analysis.
62016771|NCT05984394||AS patients with ILD|New diagnosis of patients with AS syndrome and ILD
62206349|NCT04747600||solid pseudo-papillary neoplasms|
62206350|NCT03977857||28-day nonsurvival or transplantation|patients who died or underwent liver transplantation within 28 days since admission
62206351|NCT03977857||28-day transplantation-free survival|patients who survived without liver transplantation at 28 days since admission
62206352|NCT04698759||Stunted subject|Children with stunted status condition based on Z score criteria
62206353|NCT04698759||Normal subject|Children with normal status condition based on Z score criteria
62206354|NCT05901064|ACTIVE_COMPARATOR|Harmonic Focus|Patients that are operated with Harmonic Focus
62206355|NCT05901064|ACTIVE_COMPARATOR|Diathermy|Patients that are operated with conventional diathermy
62215375|NCT03237039|OTHER|X-ray examination, fall-risk and gait|simultaneous acquisition in upright position of two full-body radiographic images, one in the coronal plane and one in the sagittal plane. In addition, 40 out of 160 subjects will undergo fall-risk assessment and gait cycle analysis evaluation.
62405405|NCT01891136|EXPERIMENTAL|Peanut protein|Subjects to receive varying amounts of peanut protein as peanut oral immunotherapy.
62016772|NCT03531593||US Elastography|All subjects will undergo one ultrasound elastography examination after consent.
62016773|NCT02497664|OTHER|Active Breathing Control|Planning-CT will be made of patients using the Active Breathing Control Technique (in expiration and inspiration phase)
62016774|NCT01615445|ACTIVE_COMPARATOR|Resveratrol|Group A Participants will received resveratrol 500 mg twice daily for 1 week then 1000 mg twice daily for 3 weeks, according to tolerance. They will discontinue medication for 2 weeks. The will receive placebo for 4 weeks.
62016775|NCT01615445|PLACEBO_COMPARATOR|Placebo|Group B (n=6) Will receive placebo for 4 weeks, they will discontinue medication for two weeks. Then receive resveratrol for 4 weeks
62016776|NCT05977595||Deep hand burns|Adult subjects, who were hospitalized at the Pierre Colson Burn Center with a hand burn that required releasing incisions.
62016777|NCT00951067|ACTIVE_COMPARATOR|Group A|Exercise, Elevation, and Garment Compression
62016778|NCT00951067|ACTIVE_COMPARATOR|Group B|Pneumatic Compression Device (B)
62016779|NCT00951067|ACTIVE_COMPARATOR|Group C|Pneumatic Compression Device (C)
62016780|NCT00951067|ACTIVE_COMPARATOR|Group D|Pneumatic Compression Device (D)
62016781|NCT00951067|ACTIVE_COMPARATOR|Group E|Pneumatic Compression Device (E)
62405406|NCT01961778|ACTIVE_COMPARATOR|Radio-Frequency Ablation|Patients in this arm will receive treatment with radio-frequency ablation.
62405407|NCT01961778|ACTIVE_COMPARATOR|Cryothearpy|Patients in this arm will receive treatment with cryotherapy.
62405408|NCT05422105||Suspected Prostate Cancer|
62405409|NCT03063931|EXPERIMENTAL|magnesium|
62206356|NCT06306755|EXPERIMENTAL|Sequential screening group|"The enrolled participants will undergo a questionnaire investigation and receive a risk assessment for esophageal and gastric malignancies based on two questionnaire-based diagnostic models. Participants identified as high-risk (i.e., with a top 50% risk level) for esophageal and/or gastric malignancy will receive the standard upper gastrointestinal endoscopy. Standardized diagnosis and treatment recommendations will be provided to patients with screening-detected malignant lesions, and green referral channels will be established for them. For participants with screening-detected premalignant lesions, the risk of progression will be evaluated based on endoscopic characteristics, pathological diagnosis, and biomarkers. Individualized reexamination and surveillance will be implemented accordingly."
62206357|NCT06306755|ACTIVE_COMPARATOR|Universal screening group|The enrolled participants will undergo a questionnaire investigation and receive the same standard upper gastrointestinal endoscopy as those in the sequential screening group, irrespective of the results of the risk assessment. Standardized diagnosis and treatment recommendations will be provided to patients with screening-detected malignant lesions, and green referral channels will be established for them. For participants with screening-detected premalignant lesions, the reexamination and surveillance will be performed according to the current guidelines for UGIC screening and clinical treatment.
62206358|NCT05901909|NO_INTERVENTION|stroke home care patient|Before applying the education program based on the Precede-Proceed Model to 70 individuals who care for stroke home care patients, the evaluation of the patients will be made with home visits. After the training is given to the caregivers, the first evaluation will be made at the 8th week in order to determine the change in patient results after the training is completed. In the 16th week after the completion of the training, a final evaluation will be made with home visits to determine the change in patient results.
62206359|NCT05901909|EXPERIMENTAL|Individuals caring for stroke home care patients|Before the training program based on the Precede-Proceed Model is applied to the 70 individuals who care for stroke home care patients, the evaluation of the caregivers will be made in the hospital meeting room. After the training is given to the caregivers, the first evaluation will be made at the 8th week in order to determine the changes in their caregiving reactions and social support perceptions after the training is completed. In the 16th week after the completion of the training, a final evaluation will be made in the hospital meeting room in order to determine the changes in caregiver reactions and social support perceptions.
62206360|NCT00772330|EXPERIMENTAL|MIDI Arrow|Ab externo glaucoma drainage device with no reservoir
62206361|NCT06727968|EXPERIMENTAL|Conventional approach or control group|This group were provided with a pamphlet with general preventive recommendations and, in addition, their primary care physicians prescribed to the participants a gradual compression stocking, that exerted maximum pressure on the ankle that progressively decreases towards the proximal part of the extremity and their were instructed to wear it at least 6-8 hours at day.
62206362|NCT06727968|EXPERIMENTAL|Multimodal approach or experimental group|To the intervention carried out in the control group a home-based program of therapeutic exercise and self-massage presecribed by a physiotherapis was added. Home-based therapeutic exercises were based on calf strengthening, mobility and stretching of lower limbs performed in standing, sitting and laying position. Each exercise was performed 15-20 repetitions, 1 set, 3-4 days at week. In addition to these exercises, patients were instructed to walk, at least, 20 minutes at day. Self-massage techniques alterne manual lymphatic drainage maneuvers with superficial techniques that follow the path of saphenous veins, their respective cayaids and the anastomotic system.
62405410|NCT03063931|PLACEBO_COMPARATOR|placebo|
62405411|NCT04209166|EXPERIMENTAL|FAD|the first-episode major depressive disorder with atypical feature
62405412|NCT04209166|EXPERIMENTAL|RAD|the recurrent major depressive disorder with atypical feature who have been medication-free for no less than 2 weeks
62788545|NCT03411421|EXPERIMENTAL|Part 1 (AL-794 or Placebo)|Participants will receive AL-794 or placebo in 2:1 ratio in Cohorts 1 to 3. AL-794 will be administered at a 100 milligram (mg) loading dose (LD) on the morning of Day 1, followed by a 50 mg maintenance dose (MD) on the evening of Day 1 and twice-daily (BID) on Day 2 through Day 5. The duration of dosing may be extended (maximum duration 10 days), at the discretion of the Sponsor and Principal Investigator (PI).
62788546|NCT03411421|EXPERIMENTAL|Part 2 (AL-794 or Placebo)|Participants will receive AL-794 or placebo in 2:1 ratio. AL-794 will be administered as 100 mg LD on the morning of Day 1, followed by a 50 mg MD on the evening of Day 1 and BID on Day 2 through Day 5. The duration of dosing may be extended (maximum duration 10 days). Based on the results of Part 1, the duration of dosing may be modified.
62016782|NCT05056246|EXPERIMENTAL|Group 1: Japanese participants - maridebart cafraglutide low dose|Japanese participants will receive the low dose of maridebart cafraglutide administered via subcutaneous injection.
62016783|NCT05056246|EXPERIMENTAL|Group 2: Japanese participants - maridebart cafraglutide medium dose|Japanese participants will receive the medium dose of maridebart cafraglutide administered via subcutaneous injection.
62016784|NCT05056246|EXPERIMENTAL|Group 3: Japanese participants - maridebart cafraglutide high dose|Japanese participants will receive the high dose of maridebart cafraglutide administered via subcutaneous injection.
62016785|NCT05056246|EXPERIMENTAL|Group 4: Caucasian participants - maridebart cafraglutide medium dose|Caucasian participants will receive the medium dose of maridebart cafraglutide administered via subcutaneous injection.
62016786|NCT05056246|EXPERIMENTAL|Group 5: Caucasian participants - maridebart cafraglutide high dose|Japanese participants will receive the high dose of maridebart cafraglutide administered via subcutaneous injection.
62016787|NCT03274700|ACTIVE_COMPARATOR|Group 1: Patients receive tamsulosin|"Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.e foll The cases will be followed up as thowing:~In the first month: abdominal ultrasonography every week, KUB abdomen and pelvis for radiopaque stones.~At the end of the second month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones.~At the end of the third month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones, MSCT abdomen and pelvis for radiolucent stones."
62016788|NCT03274700|PLACEBO_COMPARATOR|Patients receive placebo.|"Patients who will receive placebo up to 8 weeks duration.The cases will be followed up as following:~In the first month: abdominal ultrasonography every week, KUB abdomen and pelvis for radiopaque stones.~At the end of the second month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones.~At the end of the third month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones, MSCT abdomen and pelvis for radiolucent stones."
62016789|NCT06573047|OTHER|Kinesotape|Children in group (b)will receive selected chest physical therapy exercise which including (percussion, huffing, coughing and postural drainage)three times per week for two weeks, each session will be about 20 minutesplus thoracic kinesio-tape every three days (5 times per two weeks). Children will be seated on a chair. When the children will be at the end of the expiration, it will be applied bilaterally on the fifth to sixth and ninth to tenth intercostal muscles transversally and on the anterior and posterior axillary line longitudinally with 50% tension
62016790|NCT06573047|OTHER|chest physiotherapy exercises|the children in the group(a) will receive the selected chest physiotherapy exercise three times per week for two weeks, each session will be about 20 minute which will include the following exercise ( huffing , coughing , percussion,and postural drainage)
62016791|NCT04739748||Respiratory ICU patient|patient in RICU that developed ventilator-associated pneumonia
62581059|NCT05230706|EXPERIMENTAL|Experimental (LDC)|The experimental group were allocated to alternating light/darkness conditions as follows: from 07:00 to 19:00 hours the subjects were kept under normal room light conditions; from 19:00 to 07:00 of the following day the conditions were modified by placing the patient under an acrylic cephalic helmet (length: 27 cm; width: 27 cm; height: 17.5 cm; opening: 17x12 cm). The helmet was covered with surgical cloth (green or blue) folded to 50x60cm rectangles, leaving the frontal part open in order to maintain an adequate air flow. This intervention exposed infants in the experimental group to light at 25 lux for 12 hours every day, while during daytime the cloth was removed in order for study subjects to be exposed to regular room lighting.
62016792|NCT02479984|EXPERIMENTAL|Staging laparoscopy|"Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.~Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port."
62016793|NCT01459796|EXPERIMENTAL|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 51.
62581060|NCT03756623|EXPERIMENTAL|Drug: Metformin powder|0.5g of Metformin powder administered three times a day orally before meal
62581061|NCT03756623|EXPERIMENTAL|Drug: Probiotics powder|0.5g of Probiotics powder administered three times a day orally before meal
62016794|NCT01459796|EXPERIMENTAL|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 51.
62016795|NCT06446635|EXPERIMENTAL|Patients with a perianal abscess/sinus|
62016796|NCT06446635|EXPERIMENTAL|Patients with perianal fistula|
62016797|NCT02316236|EXPERIMENTAL|dexmedetomidine loading dose|dexmedetomidine is given at load dose
62016798|NCT02316236|EXPERIMENTAL|dexmedetomidine sustaining dose|dexmedetomidine is given at sustaining dose
62016799|NCT03188640|OTHER|Surgery|Participants will be operated using laparoscopic gastric bypass surgery.
62016800|NCT06573632||Malnutrition|All malnutrition patients to received TPN for 5 days preoperatively as applicable and continued postoperatively.
62016801|NCT04629664|ACTIVE_COMPARATOR|FX-322|FX-322, 1 dose (N=24)
62581062|NCT03756623|PLACEBO_COMPARATOR|Drug: Placebo powder|0.5g of Placebo powder administered three times a day orally before meal
62016802|NCT04629664|PLACEBO_COMPARATOR|Placebo|Placebo, 1 dose (n=6)
62016803|NCT05158062|EXPERIMENTAL|pembrolizumab and bevacizumab with PBC followed by pembrolizumab, bevacizumab and olaparib|Participants will continue treatment period up to 6 cycles and enter maintenance period after treatment period. Study treatment will be continued until progressive disease (PD) based on RECIST 1.1, death, unacceptable toxicity, or participant withdrawal from the study.
62016804|NCT00612066|EXPERIMENTAL|Rosiglitazone|
62581063|NCT05074238|EXPERIMENTAL|Sunscreen Application|The study participant will be instructed to start applying the sunscreen provided to them to the randomly assigned half of the wound (A or B).
62581064|NCT05074238|EXPERIMENTAL|No Suncreen Application|The study participant will be instructed to not apply the sunscreen provided to them to the randomly assigned half of the wound (A or B).
62581065|NCT06128928|EXPERIMENTAL|REDES: Motivational interviewing training|Participants in this arm will receive training on motivational interviewing (MI) to promote vaccine acceptance and uptake with their networks. The training will be led by community health workers on how to use MI to address vaccine hesitancy using a guiding approach, open-ended questions, affirmations, reflections, and summaries.
62016805|NCT04362358|EXPERIMENTAL|7 sessions of the online CBT programme|
62405413|NCT04209166|NO_INTERVENTION|BD|the depressive episode of bipolar disorder
62734963|NCT05187897|EXPERIMENTAL|CHV-NEO Intervention|CHVs based at facilities in the Intervention arm will implement the integrated CHV-NEO two-way SMS messaging intervention with their clients.
62788547|NCT05334628|ACTIVE_COMPARATOR|Preoperative Erector Spinae Plane Block|In the preoperative period, under general anesthesia, after the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 30 ml of 0.25% bupivacaine hydrochloride will be injected into the interfacial space below the erector spinae muscle, above the transverse process.
62788548|NCT05334628|ACTIVE_COMPARATOR|Postperative Erector Spinae Plane Block|In the postoperative period, under general anesthesia, after the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 30 ml of 0.25% bupivacaine hydrochloride will be injected into the interfacial space below the erector spinae muscle, above the transverse process.
62788549|NCT01358058|EXPERIMENTAL|Proton radiation therapy|Single arm study delivering fractionated proton therapy over 6 week (54-59.4 Gy(RBE))
62788550|NCT01923662|EXPERIMENTAL|Neuroprosthesis|Eligible subjects will receive an implanted device (IRS-8 or IST-16) and surgically implanted electrodes to excite muscles that move paralyzed muscles. These electrodes are connected to the implanted stimulator that delivers electrical pulses to the nerves. These pulses cause the muscles to contract to perform functional movements or to exercise.
62788551|NCT03060200|EXPERIMENTAL|Active intervention|Self-administered online CBT plus therapist check in. Moderately depressed participants will be testing a depression app, employing a self administered plus therapist check in, online CBT intervention, for 6 weeks.
62788552|NCT03060200|NO_INTERVENTION|Waiting list|Moderately depressed participants will be put on a wait list for 6 weeks, after which access to the depression app will be given.
62788553|NCT03060200|PLACEBO_COMPARATOR|Placebo|Sham self-administered online CBT plus therapist check in. Moderately depressed participants will be using a depression app - the same platform and largely in the same format as the tested app, employing a self administered plus therapist check in, online sham intervention, for 6 weeks. The intervention will include the same sections and features as the original app, except for the complete exercises and behavioral activation sections. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense information on psychological well being.
62788554|NCT00525005|EXPERIMENTAL|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
62788555|NCT02272712|EXPERIMENTAL|Cognitive Behavioural Therapy|A 6-week online cognitive-behavioural treatment for insomnia. Each week focuses on a different topic consistent with the cognitive-behavioural theory of insomnia.
62788556|NCT02272712|NO_INTERVENTION|Control Condition|The online attention matched control arm will provide education about sleep without any focus on the active ingredients that constitute the intervention group.
62788557|NCT06210100|ACTIVE_COMPARATOR|Active stimulation|Active Intermittent theta burst stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 10 days.
62788558|NCT06210100|SHAM_COMPARATOR|Sham stimulation|Sham stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 10 days.
62788559|NCT00816192|ACTIVE_COMPARATOR|1|"The externally irrigated-tip catheter is an open system in which saline is continuously infused and empties into the blood pool. For the externally irrigated-tip catheter, RF energy delivery settings were: power ≤ 35 watts and temperature ≤ 43°C with a variable flow-rate to obtain a temperature around 40°C."
62788560|NCT00816192|EXPERIMENTAL|2|"For the internally irrigated tip catheter (reference catheter), radiofrequency (RF) energy delivery settings will be: power ≤ 35 watts, temperature ≤ 47◦C and a fixed flow rate of 0.6 ml/s.~The advantage of the Chili thermo-cooled tip system is that no saline solution leaves the catheter system and flows into the patient."
62788561|NCT04373928|EXPERIMENTAL|Drug guided by Mini-PDX/PDX|Procedure: The tumor tissue is used for drug sensitivity test by Mini-PDX, building PC PDX, and acquiring the genetic information by the second genetic sequence or RNA-sequence. PC patients will accept personalized treatment guided by the experimental results of mini-PDX and sequencing.
62788562|NCT04373928|NO_INTERVENTION|Drug according to guideline|The drugs (gemcitabine, Nab-paclitaxel, S-1) are used ccording to NCCN pancreatic cancer guideline。
62016806|NCT04362358|ACTIVE_COMPARATOR|Bibliotherapy|
62016807|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 4 IU/h|The maintenance infusion rate of oxytocin will be 4 IU/h.
62016808|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 6 IU/h|The maintenance infusion rate of oxytocin will be 6 IU/h.
62016809|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 8 IU/h|The maintenance infusion rate of oxytocin will be 8 IU/h.
62405414|NCT04209166|NO_INTERVENTION|HC|healthy control
62016810|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 10 IU/h|The maintenance infusion rate of oxytocin will be 10 IU/h.
62405415|NCT06443216|EXPERIMENTAL|Experimental Group|Patients with major depressive disorder according to ICD-10 criteria
62405416|NCT06443216|EXPERIMENTAL|Healthy Group|Healthy controls
62405417|NCT06017362|EXPERIMENTAL|Insulin|Topical insulin 1UI/ml 4 times a day
62405418|NCT06017362|PLACEBO_COMPARATOR|Placebo (artificial tears)|Artificial tears 4 times a day
62405419|NCT06425822||Left atrial mapping group in patients without atrial fibrillation|"Inclusion criteria:~* Age ≥ 18 years old.~* Absence of a prior history of atrial fibrillation or flutter.~* Patients presenting for ablation of any ventricular tachycardia related to structural heart disease or any ventricular arrhythmia with a CHA2DS2-VASc score ≥ 2.~Exclusion criteria:~* Presence of thrombus in the left atrial appendage.~* Complications related to the index procedure.~* Insufficient quality of the left atrial electroanatomical map."
62405420|NCT00775827|EXPERIMENTAL|1|fenofibrate 160 mg tablets of Ranbaxy Laboratories
62405421|NCT00775827|ACTIVE_COMPARATOR|2|Tricor 160 mg tablets
62405422|NCT01770665||Mesothelioma|
62405423|NCT01770665||all cancer types|
62405424|NCT01055184|EXPERIMENTAL|2009 H1N1 Vaccine|Participants will be stratified by age into two groups: those between 60 and 70 years old, and those older than 70 years of age. All participants will receive the 2009 H1N1 vaccine.
62016811|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 12 IU/h|The maintenance infusion rate of oxytocin will be 12 IU/h.
62206363|NCT03423576|EXPERIMENTAL|Intervention|comprehensive patient-centered outpatient health service with multiple components. These components included the addition of a case-manager, structured interventions to improve patient education and adherence to therapy, psychological counselling, social services, and exercise advice. For each Patient, relevant components were identified and a written Intervention plan was negotiated and signed.
62206364|NCT03423576|NO_INTERVENTION|Control|Standard care
62206365|NCT03612583|EXPERIMENTAL|Lower PEEP|Lung- and Diaphragm-Protective Ventilation - PEEP will be set at 8 cm H2O
62206366|NCT03612583|EXPERIMENTAL|Higher PEEP|Lung- and Diaphragm-Protective Ventilation - PEEP will be titrated to achieve end-expiratory PL = 2-3 cm H20 and at least 5 cm H2O greater than the level applied in the lower PEEP arm
62581066|NCT06128928|ACTIVE_COMPARATOR|Control: COVID-19 vaccine information|Participants in the control condition will receive a brief community health worker-led training about the safety and efficacy of the vaccine. Participants will have the opportunity to ask clarifying questions from the community health workers during the training.
62581067|NCT02933229|EXPERIMENTAL|H. pylori eradication cohort|"H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication."
62206367|NCT01546675|ACTIVE_COMPARATOR|Traditional 1, Skeletal Stabilization 2|Subjects using the Traditional Socket and socket hypothesized to increase skeletal stabilization in a case cross-over design. The intervention is the socket designed to increase skeletal stabilization.
62206368|NCT01546675|EXPERIMENTAL|Skeletal Stabilization 1, Traditional 2|Subjects using the socket hypothesized to increase skeletal stabilization and Traditional Socket and in a case cross-over design. The intervention is the socket designed to increase skeletal stabilization.
62581068|NCT01533129|ACTIVE_COMPARATOR|Daily testosterone transdermal gel|
62206369|NCT01098318|EXPERIMENTAL|Rhodiola rosea|Herbal extract
62206370|NCT01098318|ACTIVE_COMPARATOR|Sertraline|Conventional anti-depressant
62016812|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 14 IU/h|The maintenance infusion rate of oxytocin will be 14 IU/h.
62016813|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 16 IU/h|The maintenance infusion rate of oxytocin will be 16 IU/h.
62016814|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 18 IU/h|The maintenance infusion rate of oxytocin will be 18 IU/h.
62016815|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 20 IU/h|The maintenance infusion rate of oxytocin will be 20 IU/h.
62016816|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 22 IU/h|The maintenance infusion rate of oxytocin will be 22 IU/h.
62016817|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 24 IU/h|The maintenance infusion rate of oxytocin will be 24 IU/h.
62206371|NCT01098318|PLACEBO_COMPARATOR|Sugar pill|Lactose monohydrate
62016818|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 26 IU/h|The maintenance infusion rate of oxytocin will be 26 IU/h.
62206372|NCT05431374|EXPERIMENTAL|Measurement Based Care MBC|patients in the MBC group will receive treatment according to a schedule that includes individualized starting dosages, dosage adjustment, and medication changes to minimize side effects, maximize safety, and optimize the therapeutic benefit for each patient.
62206373|NCT05431374|ACTIVE_COMPARATOR|Control/Standard-care|Local medical, psychiatric and family medicine services provide routine care according to their clinical judgment and available resources. Standard-care will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of standard-care delivered to each participant. In current practice, MDD patients are not routinely referred for any psychological therapies in Pakistan. Standard-care in Pakistan largely comprises of pharmacotherapy.
62206374|NCT04074668||Type 1 Diabetes|All participants will undergo DXA scan, magnetic resonance imaging (MRI) studies of the kidneys, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
62206375|NCT04074668||Healthy Controls|All participants will undergo DXA scan, magnetic resonance imaging (MRI) studies of the kidneys, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
62206376|NCT00700700|ACTIVE_COMPARATOR|CRT-ON/CRT-OFF|Group initially randomized to CRT-ON, then cross-over to CRT-OFF
62581069|NCT01533129|ACTIVE_COMPARATOR|Injectable Testosterone esters|Testosteron 250mg injection per 3-4 weeks for 6 months
62016819|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 28 IU/h|The maintenance infusion rate of oxytocin will be 28 IU/h.
62016820|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 30 IU/h|The maintenance infusion rate of oxytocin will be 30 IU/h.
62206377|NCT00700700|ACTIVE_COMPARATOR|CRT-OFF/CRT-ON|Group initially randomized to CRT-OFF, then cross-over to CRT-ON
62206378|NCT04174391|EXPERIMENTAL|Mediterranean diet supplemented with extra-virgin olive oil|
62206379|NCT04174391|ACTIVE_COMPARATOR|Low-fat diet|
62206380|NCT02421575|EXPERIMENTAL|Group I, Arm I (lower dose hydroxychloroquine)|Patients receive hydroxychloroquine PO QD for 14 days and then undergo prostatectomy.
62016821|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 32 IU/h|The maintenance infusion rate of oxytocin will be 32 IU/h.
62016822|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 34 IU/h|The maintenance infusion rate of oxytocin will be 34 IU/h.
62788563|NCT03933228||Interscalene-Cervical Plexus Block|Ultrasound-Guided Combined Interscalene-Cervical Plexus Block
62016823|NCT05290129|EXPERIMENTAL|Oxytocin infusion rate 36 IU/h|The maintenance infusion rate of oxytocin will be 36 IU/h.
62016824|NCT01639001|EXPERIMENTAL|Crizotinib|Crizotinib
62016825|NCT01639001|ACTIVE_COMPARATOR|Chemotherapy|Chemotherapy \[Option at Investigator's Choice\]
62016826|NCT03025165|EXPERIMENTAL|Community Adherence Clubs|ART adherence support, symptom screening and dispensation of pre-packed medications by community health worker to a club meeting of 20-25 HIV+ patients every three months, with two clinic visits every year for clinical review and laboratory monitoring
62016827|NCT03025165|EXPERIMENTAL|Home-Based ART Delivery|Individuals receive ART adherence support, symptom screening and dispensation of pre-packed medications by community health worker at their household every three months, with two clinic visits every year for clinical review and laboratory monitoring
62016828|NCT03025165|OTHER|Standard of Care|Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
62016829|NCT03475641|ACTIVE_COMPARATOR|The current standard anesthesia|Standard treatment during procedure
62581070|NCT02693535|OTHER|Group 4 (CDKN2A, CDK4, CDK6)|Participants receive palbociclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation
62788564|NCT03933228||Supraclavicular-Cervical Plexus Block|Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block
62016830|NCT03475641|EXPERIMENTAL|Femoral nerve blockade|Femoral nerve blockade added to the standard treatment.
62016831|NCT01975844|EXPERIMENTAL|Individualized Anemia Mangement Protocol|"Single arm study, therefore all patients will participate in the following:~Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.~Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
62016832|NCT00141440|EXPERIMENTAL|1|COPD patients
62016833|NCT04755660|EXPERIMENTAL|Exercise behavior change group (EBCG)|Behavior Change Theory-based intervention + Resistance Exercise
62016834|NCT04755660|ACTIVE_COMPARATOR|Elastic band resistance exercise group( EBRG)|Elastic Band Resistance Exercise
62016835|NCT04755660|SHAM_COMPARATOR|Usual care (UC)|usual care: exercise education
62016836|NCT01892475|EXPERIMENTAL|Cash Only (CO)|As part of the Incentive-based physical activity program, drivers assigned to the Cash Only (CO) arm will earn incentives in the form of cash for meeting specified monthly step goals from Months 1 to 4.
62016837|NCT01892475|EXPERIMENTAL|Mental-Accounting (MA) based|As part of the Incentive-based physical activity program, drivers assigned to the Mental-Accounting (MA) based arm will receive incentives in the form of taxi rental credits for meeting specified monthly step goals from Months 1 to 4.
62016838|NCT00698529|NO_INTERVENTION|No POL Training|Participating NGOs and their staff will receive no specialized training.
62016839|NCT00698529|EXPERIMENTAL|Face-to-Face|Participating NGOs and their staff will receive training through face-to-face seminars held at the NGOs and through post-seminar consultation telephone calls.
62016840|NCT00698529|EXPERIMENTAL|Distance Learning|Participating NGOs and their staff will receive training through Web-based seminars and through post-seminar consultation telephone calls.
62016841|NCT02908568|EXPERIMENTAL|Spring device|Brisk dilatation of fhe mouth.
62016842|NCT02908568|SHAM_COMPARATOR|Mandible stimulator|Stimulation of fhe mouth.
62016843|NCT06197139|EXPERIMENTAL|[177Lu]Lu-XT117 treatment|
62016844|NCT02579291|EXPERIMENTAL|Dry needling|The experimental group will receive a single session of Bobath therapy including techniques targeting modulation of central nervous system. In addition, this group will receive a single session of dry needling into the tibialis posterior muscle with a disposable stainless steel needle (0.3mm x 50mm)
62206381|NCT02421575|EXPERIMENTAL|Group I, Arm II (higher dose hydroxychloroquine)|Patients receive hydroxychloroquine PO TID for 14 days and then undergo prostatectomy.
62788565|NCT02861898|EXPERIMENTAL|Intra-arterial Cetuximab after BBBD|Mannitol 20% 12.5ml over two minutes for Blood Brain Barrier (BBB) disruption followed by CTX administered intra-arterially for three doses at a dose of 250mg/m2
62788566|NCT00614848|EXPERIMENTAL|1|Endeavor Drug Eluting Coronary Stent
62788567|NCT00614848|ACTIVE_COMPARATOR|2|Driver bare-metal coronary stent
62788568|NCT00438165|NO_INTERVENTION|1|Control group
62788569|NCT00438165|EXPERIMENTAL|2|Nurse home visits
62788570|NCT00423449|EXPERIMENTAL|Vorinostat + Gemcitabine + Platinum-based agent|
62788571|NCT03487497||Patients|Patients who underwent lateral column lengthening osteotomy
62788572|NCT03487497||Healthy subjects|Healthy subjects without intervention
62581071|NCT02693535|OTHER|Group 5 (CSF1R,PDGFR,VEGFR)|Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations
62581072|NCT02693535|OTHER|Group 6 (mTOR, TSC)|Participants receive temsirolimus - dosage, frequency and duration per label; acceptable genomic matches include mTOR, TSC1/2, AKT1 mutations
62581073|NCT02693535|OTHER|Group 8 (ERBB2)|Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations
62016845|NCT02579291|ACTIVE_COMPARATOR|Bobath|This group will receive a single session of Bobath therapy including techniques targeting modulation of central nervous system.
62016846|NCT00541047|EXPERIMENTAL|RADICALS-RT: Early RT|
62016847|NCT00541047|EXPERIMENTAL|RADICALS-RT: Salvage RT|
62016848|NCT00541047|EXPERIMENTAL|RADICALS-HD: Radiotherapy Alone|
62206382|NCT02421575|EXPERIMENTAL|Group II (mid-dose hydroxychloroquine)|Patients receive hydroxychloroquine PO QD. Treatment continues until the beginning of local therapy or for up to 1 year.
62206383|NCT03703167|EXPERIMENTAL|ibrutinib in combination with rituximab and lenalidomide|Ibrutinib will be given day 1-28; Lenalidomide will be given day 1-21; Rituximab will be given on day 1. Rituximab is given for 6 cycles; Lenalidomide is given for 12 cycles; Ibrutinib is continued until disease progression, intolerable toxicity or death.
62206384|NCT06729229|EXPERIMENTAL|Fish and Placebo|Participants will receive 2 portions of fish (280g)
62206385|NCT06729229|EXPERIMENTAL|No fish SUPPLEMENT|Daily 1g omega-3 supplement
62206386|NCT06729229|EXPERIMENTAL|No fish PLACEBO|Placebo
62016849|NCT00541047|EXPERIMENTAL|RADICALS-HD: Radiotherapy + 6 months|
62405425|NCT03741816|ACTIVE_COMPARATOR|Biodentine|Indirect pulp capping with Biodentine in mature permanent molars with deep carious lesions and reversible pulpitis
62581074|NCT02693535|OTHER|Group 9 (BRAF V600E/D/K/R)|Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations
62016850|NCT00541047|EXPERIMENTAL|RADICALS-HD: Radiotherapy + 24 months|
62016851|NCT01771276|EXPERIMENTAL|Ultimate Anchor|Use of the g-Cath Suture Anchor Delivery Catheter and accessories in placing the ultimate number of anchors for weight loss.
62016852|NCT02595567|OTHER|ITPC|
62016853|NCT06520748|EXPERIMENTAL|Study Group|underwent a hand rehabilitation program using the computerized glove combined with the selected hand program
62206387|NCT06729229|EXPERIMENTAL|2 fish portion|Omega 3 supplement
62206388|NCT01307657|OTHER|Clopidogrel impact on platelet function|Participants will have a baseline blood sample drawn after a 12 hour fast at 8 am, then be administered a 600 mg dose of clopidogrel. At noon, another blood sample will be drawn to evaluate the extent of maximum platelet inhibition in the fasting state. Participants will then be provided a standardized high-fat meal, then an additional blood sample at 2 pm to evaluate the impact of the high-fat on platelet function assessment.
62206389|NCT02856100||Patients with CRPC, evidence of metastases, planned treatment|
62206390|NCT06045793|EXPERIMENTAL|TNX-1300|A single IV 200 mg injection of TNX-1300
62206391|NCT06045793|PLACEBO_COMPARATOR|Placebo|A single IV injection of placebo with UC
62206392|NCT03636191|EXPERIMENTAL|Probiotic|
62206393|NCT03636191|PLACEBO_COMPARATOR|Placebo|
62206394|NCT03106168|EXPERIMENTAL|With periapical granuloma|Patients presenting periapical granuloma in mandibular molar teeth, diagnosed by periapical radiography
62206395|NCT03106168|EXPERIMENTAL|Without periapical granuloma|Patients without periapical granuloma in mandibular molar teeth, diagnosed by periapical radiography
62206396|NCT01621308||IP insulin|Patients treated with continuous intraperitoneal insulin infusion using a implantable pump
62581075|NCT02693535|OTHER|Group 13 (RET,VEGFR1/2/3,KIT,PDGFRβ,RAF-1,BRAF)|Participants receive regorafenib - dosage, frequency and duration per label; acceptable genomic matches include RET, VEGFR1/2/3, KIT, PDGFRβ, RAF-1, BRAF mutations or amplifications
62016854|NCT06520748|EXPERIMENTAL|Control Group|received only the selected hand program
62016855|NCT05861115|EXPERIMENTAL|Software diagnosis|Software diagnosis with gold standard of echocardiography.
62016856|NCT01156324|PLACEBO_COMPARATOR|Control|Participants of the routine care control group will each receive a $50 gift certificate at the end of each IVF cycle for which they completed the questionnaires.
62016857|NCT01156324|EXPERIMENTAL|Online Stress Management Group (Upliv)|Personalized online stress management program consisting of weekly sessions which each include relaxation exercises, stress management strategies, and lifestyle modification advice. Participants in Upliv will also be given a set of personal care products as part of the program.
62206397|NCT01621308||SC insulin|Patients treated with subcutaneous insulin, both multiple daily injections and continuous subcutaneous insulin infusion
62206398|NCT02861235|EXPERIMENTAL|1. stress thallium-201 tomoscintigraphy|
62206399|NCT02861235|EXPERIMENTAL|2. stress technetium-99m tomoscintigraphy 1|
62206400|NCT02861235|EXPERIMENTAL|3. stress technetium-99m tomoscintigraphy 2|
62206401|NCT02861235|EXPERIMENTAL|4. stress technetium-99m tomoscintigraphy 3|
62206402|NCT02861235|EXPERIMENTAL|5. rest thallium-201 tomoscintigraphy|
62206403|NCT02861235|EXPERIMENTAL|6. rest technetium-99m tomoscintigraphy|
62206404|NCT00769652|EXPERIMENTAL|Medical nutrition therapy|Medical nutrition therapy
62206405|NCT00769652|ACTIVE_COMPARATOR|Standard care|Standard care
62405426|NCT03741816|EXPERIMENTAL|TheraCal LC|Indirect pulp capping with TheraCal LC in mature permanent molars with deep carious lesions and reversible pulpitis
62581076|NCT02693535|OTHER|Group 14 (BRCA1/2; ATM)|Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions
62206406|NCT00425464|EXPERIMENTAL|Synchrony® Dual Optic Intraocular Lens|
62206407|NCT00425464|ACTIVE_COMPARATOR|Standard Monofocal Intraocular Lens|
62206408|NCT06239389|ACTIVE_COMPARATOR|hydroxyurea|Hydroxyurea is available in oral dosage form which is capsule. frequency: once a day duration: at every 24 hours dose: 15/mg/kg/day.
62206409|NCT06239389|EXPERIMENTAL|Thalidomide|Thalidomide is available in oral dosage form which is capsule. frequency: once a day at night duration: at every 24 hours dose:50 mg / day (in patients \>10-13 years) while the adult dose was 100 mg /day (age \>13 Years)
62405427|NCT03521674|OTHER|Foley catheter|Foley catheter will be inserted through the cervical os and it will be filled with 40 ml saline. After insertion gentle traction will be applied for cervical ripening. Pregnancy termination will be achieved.
62581077|NCT02693535|OTHER|Group 15 (POLE, POLD1)|Participants receive pembrolizumab - dosage, frequency and duration per label; acceptable genomic matches include specific POLE and POLD1 mutations
62405428|NCT03521674|OTHER|Double-balloon catheter|Double-balloon catheter will be inserted through the cervical os and both baloons will be filled with 40 ml saline. No traction will be applied. Pregnancy termination will be achieved.
62405429|NCT06317701||HGNS Therapy Participants|Individuals with sleep apnea treated by HGNS therapy.
62405430|NCT05798325|OTHER|Principal|
62405431|NCT04189666|ACTIVE_COMPARATOR|Group R: patients receive Rivastigmine patch|receive a Rivastigmine patch (4.6 mg) 24 h before the operation to 3 days post-operative
62405432|NCT04189666|ACTIVE_COMPARATOR|Group M: patients receive Melatonin patch|receive Melatonin patch (7 mg) 24 h before the operation to 3 days post-operative
62016858|NCT00357305|EXPERIMENTAL|Treatment (enzyme inhibitor, chemotherapy)|Patients receive oral SAHA two or three times daily on days 1-7 and cytarabine IV over 3 hours twice daily and etoposide IV over 1 hour once daily on days 11-14. Treatment repeats approximately every 6-7 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62206410|NCT04346459|ACTIVE_COMPARATOR|Group A- Fastrach (control group)|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using intubating laryngeal mask airway Fastrach following blind intubating method through Fastrach"
62405433|NCT03371095|EXPERIMENTAL|Infliximab|Infliximab 5mg/kg intravenously at week 0, 2, 6, 12, and 18
62405434|NCT03371095|ACTIVE_COMPARATOR|Cyclophosphamide|Cyclophosphamide 0.7g/m2 up to 1.2g/m2 intravenously at week 0, 4, 8, 12, 16 and 20
62405435|NCT03986216|EXPERIMENTAL|Home based group|This group will involve 2-4 randomly selected participants who have already completed the lab based sessions. They will use the developed reliable and intuitive control of the paretic hand device (ReIn-Hand device) to assist them to practice 'reach-grasp-retrieve-release' movements at home, 1 hours per day (20 trials), 7 days per week for 12 weeks.
62581078|NCT02693535|OTHER|Group 16 (MSI-H, high mutational load and others)|Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations
62581079|NCT02693535|OTHER|Group 17 (CDKN2A, CDK4, CDK6)|Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation
62016859|NCT05176327|EXPERIMENTAL|Intervention|Subjects will receive 2 consecutive courses of exoskeleton training with twelve 45-minute sessions, each to be completed in 6 to 8 weeks. The total period of training will be 12 to 16 weeks.
62016860|NCT05176327|ACTIVE_COMPARATOR|Control|Subjects will receive twelve 45-minute sessions of usual physiotherapy treatment, consisting of maintenance exercise in the first 6 to 8 weeks, and then one course of exoskeleton training with twelve 45-minute sessions in the following 6 to 8 weeks.
62016861|NCT01100177|EXPERIMENTAL|Sunitinib plus radiothery|"* Sunitinib at doses of 37.5mg/m2/daily in a continuous dosing during 8 weeks.~* After evaluation of efficacy, they will receive Sunitinib 37.5 mg/d and treatment with Radiation therapy (total dose 60 Gy).~* After radiation therapy, Sunitinib al 37.5 mg/d will be continued until progression."
62206411|NCT04346459|ACTIVE_COMPARATOR|Group B- I-gel|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using I-gel supraglottic airway device as a conduit for tracheal intubation guided by a fiberoptic bronchoscope."
62405436|NCT02966366|EXPERIMENTAL|Cochlear implantation|Evaluation of tinnitus before and after cochlear implantation
62405437|NCT03542825|ACTIVE_COMPARATOR|Iron Sulphate|ferrous sulphate 150 mg iron capsule once daily for 3 consecutive months.
62405438|NCT03542825|ACTIVE_COMPARATOR|Amino acid Chelated|amino acid chelated iron capsule 15mg for 3 consecutive months.
62405439|NCT03542825|ACTIVE_COMPARATOR|Lactoferrin|lactoferrin 100 mg sachets once daily for 3 consecutive months.
62405440|NCT01785251|EXPERIMENTAL|NMES|Application of neuromuscular electrical stimulation to the calf muscles of the patient in order to elicit contraction of the calf muscle pump and thus, eject venous blood proximally.
62405441|NCT05769465||Patients treated with nusinersen|
62405442|NCT05769465||Patients treated with risdiplam|
62405443|NCT05769465||Patients treated with onasemnogene abeparvovec|
62405444|NCT05769465||Patients naive from disease modifying treatments|
62788573|NCT01295957|ACTIVE_COMPARATOR|reminiscence therapy, story telling|24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. Refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography. Three main variables contributed to successful reminiscing: individuality, evaluation and structure.
62206412|NCT04346459|ACTIVE_COMPARATOR|Group C- Protector|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using the Protector laryngeal mask airway as a conduit for tracheal intubation guided by a fiberoptic bronchoscope."
62788574|NCT01295957|PLACEBO_COMPARATOR|comparison|control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, but they didn't participate in reminiscence sessions to rule out the possibility that improvement in quality of life was due only to attention received and social stimulation.
62206413|NCT05667103|EXPERIMENTAL|Embotrap stent retriever|
62788575|NCT01295957|NO_INTERVENTION|control|control group was administered counseling and informal social contacts in bi-weekly sessions of one hour,
62016862|NCT02294292|EXPERIMENTAL|Carvedilol + Ivabradine|"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.~if carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"
62016863|NCT02294292|ACTIVE_COMPARATOR|Endoscopic Variceal Ligation (EVL)|
62405445|NCT05208398|EXPERIMENTAL|Apixaban|Apixaban, 5 mg oral tablets, on top of updated guidelines of acute coronary syndrome management recommendations
62405446|NCT05208398|ACTIVE_COMPARATOR|Warfarin|Warfarin, oral tablets, to achieve international normalized ratio (INR) of 2-3, on top of standards of care, as per updated guidelines of acute coronary syndrome management recommendations
62788576|NCT00559221|NO_INTERVENTION|1|
62788577|NCT04768543||Exposure|Patients with moderate to severe OSA treated with UAS (Inspire Medical Systems, Inc)
62206414|NCT05667103|ACTIVE_COMPARATOR|Other stent retriever without endochannel|
62206415|NCT05843422|EXPERIMENTAL|part 1-0.8% QY211 Gel or placebo（10%BSA）|6 subjects use 0.8% QY211 Gel，2 subject uses 0.8% QY211 placebo ，11days（Day1 QD,Day4-Day10 BID,Day11 QD ）.
62206416|NCT05843422|EXPERIMENTAL|part 1-1.5% QY211 Gel or placebo（10%BSA）|6 subjects use 0.8% QY211 Gel，2 subject uses 0.8% QY211 placebo ，11days（Day1 QD,Day4-Day10 BID,Day11 QD ）.
62206417|NCT05843422|EXPERIMENTAL|part 1-1.5% QY211 Gel or placebo（20%BSA）|6 subjects use 0.8% QY211 Gel，2 subject uses 0.8% QY211 placebo ，11days（Day1 QD,Day4-D10 BID,Day11 QD ）.
62206418|NCT05843422|EXPERIMENTAL|part 2-0.1% QY211 Gel or placebo|6 subjects use 0.1% QY211 Gel，2 subject uses 0.1% QY211 placebo ，29days（Day1-Day28 BID,Day29 QD）.
62206419|NCT05843422|EXPERIMENTAL|part 2-0.3% QY211 Gel or placebo|6 subjects use 0.3% QY211 Gel，2 subject uses 0.3% QY211 placebo ，29days（Day1-Day28 BID,Day29 QD）.
62206420|NCT05843422|EXPERIMENTAL|part 2-0.8% QY211 Gel or placebo|6 subjects use 0.3% QY211 Gel，2 subject uses 0.3% QY211 placebo ，29days（Day1-Day28 BID,Day29 QD）.
62581080|NCT02693535|OTHER|Group 19 (BRCA1/2, PALB2)|Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations
62016864|NCT01075321|EXPERIMENTAL|Arm I|Patients receive oral everolimus once daily and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
62016865|NCT04297046|ACTIVE_COMPARATOR|QLB for total abdominal hysterectomy|Quadratus lumborum block (QLB) was performed bilaterally with 0,3 ml/kg 0.25% bupivacaine (maximum dose 3 ml/kg) solution injection on each side.Combine patient-controlled intravenous analgesia(same as PCA for TAH arm).
62016866|NCT04297046|ACTIVE_COMPARATOR|TAPB for total abdominal hysterect0my|The transversus abdominis plane block (TAPB)was performed bilaterally with 0.3 ml/kg of 0.25% bupivacaine (maximum dose 3 ml/kg) solution . Combine patient-controlled intravenous analgesia(same as PCA for TAH arm).
62016867|NCT03219333|EXPERIMENTAL|Enfortumab vedotin|Enfortumab vedotin on days 1, 8 and 15 every 28 days
62581081|NCT02693535|OTHER|Group 20 (ERBB2)|Participants receive atezolizumab plus PHESGO - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression
62581082|NCT02693535|OTHER|Group 21 (BRCA1/2, PALB2, ATM, and others)|Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval
62581083|NCT02693535|OTHER|Group 22 (ROS1 fusion)|Participants receive entrectinib - dosage, frequency and duration per label; acceptable genomic matches include any ROS1 fusion
62788578|NCT05876468|EXPERIMENTAL|A description of each arm of the clinical trial that indicates its role in the clinical trial|"Arm 1 Description:~The study will consitent of recording the measurments of ventilatory settings, respiratory mechanics, flow and pressure curves, gaz exchange, haemodynamics and ventilation distribution in 5 consecutive conditions in adult patients with moderate to severe ARDS :~* After 16 hours of prone position~* In supine position 1 hour after the prone position~* 15mn after CACC with a pressure equal to the one observed in the prone position~* 15mn after CACC with a pressure set at 60 - 80 cmH20~* 15mn after taking of the CACC"
62016868|NCT04965779|EXPERIMENTAL|Intervention group (Abdominal binder)|The abdominal binder is applied after the women come to the clinic (postpartum 1st hour) following cesarean delivery and removed after the postpartum 48th hour. Postpartum nursing care in line with a follow-up protocol that was created based on the Republic of Turkey Ministry of Health's Postpartum Care Management Guide (2018) is provided together with the application of the abdominal binder.
62581084|NCT02693535|OTHER|Group 23 (NTRK amplification)|Participants receive larotrectinib - dosage, frequency and duration per label; acceptable genomic matches include NTRK1/2/3 amplification
62206421|NCT05843422|EXPERIMENTAL|part 2-1.5% QY211 Gel or placebo|6 subjects use 0.3% QY211 Gel，2 subject uses 0.3% QY211 placebo ，29days（Day1-Day28 BID,Day29 QD）.
62016869|NCT04965779|ACTIVE_COMPARATOR|Control group (No abdominal binder)|Only postpartum nursing care in line with a follow-up protocol that was created based on the Republic of Turkey Ministry of Health's Postpartum Care Management Guide (2018) is provided with no abdominal binder or similar application.
62206422|NCT04476134||patients with adverse events|patients underwent adverse events after cardiac surgery
62206423|NCT02666144||Glaucoma|
62206424|NCT02666144||Normal|
62206425|NCT06281795|ACTIVE_COMPARATOR|Active tVNS|Active stimulation will be carried out using the tVNS device with an ear clip attached to the left earlobe at a frequency of 20 Hz, 200 μs at a current slightly below the discomfort threshold. The device's operating mode is active therapeutic.
62581085|NCT02693535|OTHER|Group 24 (ERBB2)|Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations
62016870|NCT01429545|ACTIVE_COMPARATOR|Group 1 - Atosiban|Patients on single agent atosiban alone
62788579|NCT01890408|EXPERIMENTAL|ropivacaine|patients scheduled to undergo open liver resection Age \> 18 years Free from pain in preoperative period
62016871|NCT01429545|EXPERIMENTAL|Group 2|Patients on combination of atosiban and nifedipine
62016872|NCT04139811|OTHER|non-ILM peeling group|vitrectomy without ILM peeling is done to all cases
62016873|NCT04139811|OTHER|ILM peeling group|vitrectomy with ILM peeling is done to all cases
62016874|NCT06572176|EXPERIMENTAL|Experimental: With fluorescent concretization group|"Nurses were given the fluorescent lotion and asked to apply it all over their hands. The CE-certified test lotion is in gel form and is safety-approved. The lotion disperses particles the same size as bacteria on the skin. These particles settle on the skin, similar to the behavior of microorganisms, but disappear with hand washing under the influence of fluorescent light. They were then asked to wash their hands with 4 ml of soap. Two researchers marked the hand washing steps independently using the Hand Washing Skill Checklist. The duration of hand washing was recorded with a mobile stopwatch for each participant. Hand washing efficiency was evaluated using the Derma Litecheck device. UV rays were used after using the test lotion and drying the hands. Since any fluorescent material left on the hands would shine under UV light, it was possible to judge how well the hands were cleansed. The dirty spots were shown to the participants, and the reason for this was discussed."
62206426|NCT06281795|SHAM_COMPARATOR|Sham tVNS|Fictitious stimulation will be carried out using the tVNS device with an ear clip attached to the left earlobe at a frequency of 20 Hz, 200 μs at a current slightly below the discomfort threshold. The device's operating mode is research mode.
62581086|NCT02693535|OTHER|Group 25|Participants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation
62206427|NCT05786547|EXPERIMENTAL|Varenicline + Positively Smoke Free - Mobile|"Offer of varenicline per package dosing with dose escalation over week 1: 0.5 mg once daily on days 1 - 3, 0.5 mg twice daily on days 4 -7, followed by 1.0 mg twice daily on days 8 to 84.~Offer of Positively Smoke Free Mobile delivered by mobile phone including 42 days of content, tailored to individual quit date."
62206428|NCT05786547|ACTIVE_COMPARATOR|Standard Care|Brief advice to quit tobacco Offer of referral to the national tobacco quitline
62206429|NCT04168528|EXPERIMENTAL|Part I: safety, tolerability, biodistribution and dosimetry|Phase I
62581087|NCT00994461|EXPERIMENTAL|Celecoxib|
62581088|NCT00994461|ACTIVE_COMPARATOR|Loxoprofen|
62581089|NCT00994461|PLACEBO_COMPARATOR|Placebo|
62581090|NCT03763825|EXPERIMENTAL|Intervention group|Patient will receive the Mini-AFTERc intervention after completion of primary breast cancer treatment.
62581091|NCT03763825|NO_INTERVENTION|Control group|Patients will receive usual care after completion of primary breast cancer treatment.
62206430|NCT04168528|EXPERIMENTAL|Part II: tumor targeting potential and correlation to IHC|Phase II
62206431|NCT03222804|ACTIVE_COMPARATOR|Exclusively breastfed|Exclusive breastfeeding will be defined at screening as infants who have not consumed any infant formula after 7 days postnatal and have been exclusively breastfed without formula between day 7 of life through the end on the Lead-in period. ). Infants will consume B. infantis for twenty-one consecutive days.
62206432|NCT03222804|ACTIVE_COMPARATOR|Exclusively formula fed|Exclusive formula feeding is defined at screening as infants who consume only infant formula between day 7 of life through the end on the Lead-in period. Infants will consume B. infantis for twenty-one consecutive days.
62581092|NCT05450575||single arm, single group(No interventional)|Observational
62581093|NCT06413628|ACTIVE_COMPARATOR|threaded tapered screw appliance therapy|The appliance was digitally designed by solid works programs for 3rd CAD design software to obtain the STL file format. The virtual design of was approved. The printer was loaded with material of 3D-printed denture base. The appliance was printed.
62581094|NCT06413628|ACTIVE_COMPARATOR|low-level laser therapy|The laser apparatus consisted of a handpiece with two attachments: either a plastic tip was attached to the same handpiece to transfer laser energy intra-orally when it was used to irradiate the lateral pterygoid muscle, or a specially designed optic prism was attached to the tip of the prism for extraoral application on extraoral muscles.
62581095|NCT06413628|ACTIVE_COMPARATOR|low level laser therapy combined with appliance|low-level laser therapy in addition to threaded tapered screw appliance therapy as mentioned previously in group I and group II
62788580|NCT01890408|PLACEBO_COMPARATOR|placebo|patients scheduled to undergo open liver resection Age \> 18 years Free from pain in preoperative period
62788581|NCT00303485|EXPERIMENTAL|Ibandronate|Participants received Ibandronate 150 mg tablet once-monthly along with a combination dietary supplement containing vitamin D 200 international units (IU) and elemental calcium 500 mg twice daily with meals for 6 months.
62206433|NCT03222804|ACTIVE_COMPARATOR|Mixed fed|Mixed feeding is defined at screening as infants who consume a combination of infant formula and breast milk between day 7 of life through the end on the Lead-in period. Infants will consume B. infantis for twenty-one consecutive days.
62206434|NCT05192148|EXPERIMENTAL|Patients|On the day of inclusion, as part of the research, an additional blood sample will be taken (2 dry tubes of 7 ml each).
62206435|NCT04092010|EXPERIMENTAL|Stepped-care intervention (SCI) group|In the SCI group, mothers with low baseline depressive symptoms are offered the problem-solving education (PSE) prevention intervention, and mothers with greater depressive symptoms are offered Engagement Sessions.
62206436|NCT04092010|ACTIVE_COMPARATOR|Usual care control group|Families in the control group will receive usual Head Start services.
62206437|NCT04997096|EXPERIMENTAL|Exercise|"Participants randomized to one of two groups with 2:1 ratio: exercise (n=20)~- Aerobic and Resistance Exercise for 16 weeks"
62206438|NCT04997096|ACTIVE_COMPARATOR|Attention Control|"Participants randomized to one of two groups with attention control (n=10).~-Attention Control for 16 weeks home-based stretching"
62405447|NCT05110300|ACTIVE_COMPARATOR|Body weight support system control group|The Body weight support system (BWSS) active comparator control group will conduct 2 to 6, 30 minute sessions, over two-weeks. To be as pragmatic and clinically relevant as possible, treatment sessions will be incorporated directly to the participants' normal care. Furthermore, participants are allowed to complete 2 to 6 sessions as dictated by short or unexpected changes to the discharge planning timeline. During each session, participants will conduct balance exercises, including: marching, side-stepping, retro-ambulation, step-taps, and step-ups. Participants will also conduct various standard gait exercises, including: ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions.
62405448|NCT05110300|EXPERIMENTAL|Body weight support system with balance perturbations|The BWSS with balance perturbations (BWSS-P) experimental intervention group will also conduct 2 to 6, 30 minute sessions, over two-weeks. Participants in the BWSS-P group will conduct the same balance and gait exercises as the control group, including: marching, side-stepping, retro-ambulation, step-taps, step-ups, ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions. However, each sessions will include eight, resistive or assistive, balance perturbations, two in each cardinal direction (lateral, anterior, and posterior).
62405449|NCT02462564||postoperative cognitive dysfunction|Z score\>1.96
62405450|NCT02462564||non-postoperative cognitive dysfunction|Z score\<1.96
62405451|NCT03441373|EXPERIMENTAL|XC8 20 mg and Placebo (Group A)|XC8 20 mg orally. 2 tablets of XC8 10 mg +2 tablets of Placebo 100 mg (in total 4 tablets) once daily during 5 days of treatment period
62581096|NCT00680264||Operative|Diagnosis of Cerebral Palsy (standard definition of any brain injury before the age of 3) with total body involvement - any functional level Curve \>40 degrees on sitting film, A spinal fusion is being undertaken and the patient/family is proceeding with the spinal fusion (with any level of distal fusion).
62581097|NCT00680264||Non-operative|Diagnosis of Cerebral Palsy (standard definition of any brain injury before the age of 3) with total body involvement - any functional level, Curve \>40 degrees on sitting film, A spinal fusion is not being undertaken either because the family has refused surgery or because it is not recommended at this point.
62788582|NCT00303485|PLACEBO_COMPARATOR|Placebo|Participants received a matching placebo tablet to Ibandronate once-monthly along with a combination dietary supplement containing vitamin D 200 IU and elemental calcium 500 mg twice daily with meals for 6 months.
62788583|NCT01436474|EXPERIMENTAL|Varenicline|We will be comparing Varenicline to placebo in a single-blinded placebo controlled, randomized study
62206439|NCT05671627||patients with Rheumatoid arthritis and good response at 3/6/12 months|Patients with Rheumatoid arthritis that fulfill the inclusion/exclusion criteria and show a good response at 3/6 or 12 months upon recruitment according to EULAR guidelines with or without corticosteroids (corticosteroid regimens do not exceed 15 mg/day) Patients will be treated as per clinician's judgement with any kind or combination of DMARDs with or without corticosteroids (corticosteroid regimens do not exceed 15 mg/day), following EULAR recommendations for RA treatment.
62206440|NCT05671627||patients with Rheumatoid arthritis and none at 3/6/12 months|"Patients with Rheumatoid arthritis that fulfill the inclusion/exclusion criteria and show none response at 3/6 or 12 months upon recruitment according to EULAR guidelines.~Patients will be treated as per clinician's judgement with any kind or combination of DMARDs with or without corticosteroids (corticosteroid regimens do not exceed 15 mg/day), following EULAR recommendations for RA treatment."
62581098|NCT06575530|EXPERIMENTAL|remifentanil besylate group|Light sedation will started when the patient admitted to ICU after non-cardiac surgery under general anaesthesia with remifentanil besylate, which was continuously intravenously pumped at a rate of 0.2-1mg/kg/h. Depth of sedation will assessed by RASS score hourly to ensure a RASS score of 0 to -3. At the same time, use remifentanil (0.1-0.5/kg/min) as a combination analgesic drug to ensure that the CPOT is less than or equal to 2 points. When a satisfactory level of RASS score (0 to -3 points) was still not achieved within the dose range, a remedial programme of sedation will started using propofol. During the ICU stay, daily sedation interruption and spontaneous breathing test will be performed. If successful, sedation will be terminated, followed by weaning and extubation. If unsuccessful, mechanical ventilation will continue.
62788584|NCT01436474|PLACEBO_COMPARATOR|Placebo|We will be using a placebo in a randomized, controlled, single-blinded trial to look at varenicline for the indication of facilitating opioid tapering in opioid-dependent patients with chronic pain.
62206441|NCT04949243||People who use the self administered SARs-CoV-2 antigen testing kits|
62206442|NCT06078345|EXPERIMENTAL|BAT positive|Maximal activated supraclavicular BAT SUVmean \>1,5 g/ml-
62206443|NCT06078345|EXPERIMENTAL|BAT negative|Maximal activated supraclavicular BAT SUVmean \<1,5 g/ml
62788585|NCT03029923|EXPERIMENTAL|Smoking Cessation and Mood Management|Participants will receive standard smoking cessation plus Behavioral Activation based mood management. Will be offered the nicotine patch if medically cleared.
62788586|NCT03029923|ACTIVE_COMPARATOR|Smoking cessation and Health and Wellness|Participants will receive standard smoking cessation plus health and wellness education. Will be offered the nicotine patch if medically cleared.
62016875|NCT06572176|NO_INTERVENTION|Control: Without fluorescent concretization group|The same interventions were repeated without fluorescent concretization and UV-A light intervention.
62016876|NCT06463847|EXPERIMENTAL|1UC-MSCs Treatment Group|Participants will receive conventional treatment plus 1 time of UC-MSCs (5×10\^6 UC-MSCs/2.5mL, single injection into the knee cavity).
62206444|NCT06729450|EXPERIMENTAL|intra-individual Split-face comparison|Subjects will complete baseline assessments and be randomized (left face versus right face) to apply DispersinB Acne Cleanser over at 12-week treatment period, for an intra-individual, split-face comparison. Subjects will use the DispersinB Acne Cleanser on the assigned facial side for 5 minutes and then will use the provided 4% Benzoyl peroxide facial wash to wash entire face for daily (evening) use.
62206445|NCT04619797|EXPERIMENTAL|Tiragolumab+Atezolizumab+Pemetrexed+Carboplatin or Cisplatin|Induction treatment with tiragolumab in combination with atezolizumab plus pemetrexed and cisplatin or carboplatin will be administered to participants on Day 1 of each 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with tiragolumab in combination with atezolizumab and pemetrexed on Day 1 of each 21-day cycle.
62206446|NCT04619797|PLACEBO_COMPARATOR|Placebo+Pembrolizumab+Pemetrexed+Carboplatin or Cisplatin|Induction treatment with placebo in combination with pembrolizumab plus pemetrexed and cisplatin or carboplatin will be administered to participants on Day 1 of each 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with placebo in combination with pembrolizumab and pemetrexed on Day 1 of each 21-day cycle.
62206447|NCT03492125|EXPERIMENTAL|Phase I Dose Escalation Cohort A1 (MS-553 Monotherapy)|R/R CLL/SLL patients
62206448|NCT03492125|EXPERIMENTAL|Phase II Expansion Cohort A2 (MS-553 Monotherapy)|R/R CLL/SLL patients
62206449|NCT03492125|EXPERIMENTAL|Phase II Expansion Cohort A3 (MS-553 Monotherapy)|patients with aggressive lymphoma
62206450|NCT03492125|EXPERIMENTAL|Phase I Combination Dose Escalation Cohort B1|BTK inhibitor naïve CLL/SLL patients
62016877|NCT06463847|EXPERIMENTAL|2UC-MSCs Treatment Group|Participants will receive conventional treatment plus 1 time of UC-MSCs (1×10\^7 UC-MSCs/2.5mL, single injection into the knee cavity).
62206451|NCT03492125|EXPERIMENTAL|Phase II Expansion Cohort B2|BTK inhibitor naïve CLL/SLL patients
62206452|NCT03492125|EXPERIMENTAL|Phase II Expansion Cohort B3|BTK inhibitor naïve CLL/SLL patients with certain gene mutations
62016878|NCT06463847|EXPERIMENTAL|3UC-MSCs Treatment Group|Participants will receive conventional treatment plus 1 time of UC-MSCs (2×10\^7 UC-MSCs/2.5mL, single injection into the knee cavity).
62016879|NCT04468295|EXPERIMENTAL|0.018-inch slot orthodontic bracket system|En-masse retraction using frictionless mechanics with 0.018-inch slot orthodontic bracket system.
62016880|NCT04468295|ACTIVE_COMPARATOR|0.022-inch slot orthodontic bracket system|En-masse retraction using frictionless mechanics with 0.022-inch slot orthodontic bracket system.
62016881|NCT00964691|ACTIVE_COMPARATOR|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
62206453|NCT03492125|EXPERIMENTAL|Phase I Combination Dose Escalation Cohort C1|Bcl-2 inhibitor naïve CLL/SLL patients
62206454|NCT03492125|EXPERIMENTAL|Experimental: Phase II Expansion Cohort C2|Bcl-2 inhibitor naïve CLL/SLL patients
62206455|NCT05528419|EXPERIMENTAL|Sacubitril valsartan|
62206456|NCT05528419|ACTIVE_COMPARATOR|Valsartan|
62206457|NCT03454126|EXPERIMENTAL|Cohort 1: BIIB095 5 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 5 mg or placebo orally, followed by a fast of at least 4 hours post dose.
62206458|NCT03454126|EXPERIMENTAL|Cohort 2: BIIB095 25 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 25 mg or placebo orally, followed by a fast of at least 4 hours post dose.
62206459|NCT03454126|EXPERIMENTAL|Cohort 3: BIIB095 100 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 100 mg or placebo orally, followed by a fast of at least 4 hours post dose.
62016882|NCT00964691|ACTIVE_COMPARATOR|IPTp with Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
62206460|NCT03454126|EXPERIMENTAL|Cohort 4 (Fasted): BIIB095 200 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 200 mg or placebo orally, followed by a fast of at least 4 hours post dose.
62206461|NCT03454126|EXPERIMENTAL|Cohort 4 (Fed): BIIB095 200 mg|After a minimum 2 week washout period, followed by an overnight fast of at least 8 hours, participants will consume a high fat breakfast. Participants will then receive a single dose of either BIIB095 200 mg or placebo orally within 30 minutes after starting the breakfast, followed by a fast from food for at least 4 hours post dose.
62206462|NCT03454126|EXPERIMENTAL|Cohort 5: BIIB095 400 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 400 mg or placebo orally, followed by a fast of at least 4 hours post dose.
62206463|NCT03454126|EXPERIMENTAL|Cohort 6: BIIB095 600 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 600 mg or placebo orally, followed by a fast of at least 4 hours post dose.
62016883|NCT00003863||Group 1|"Tissue samples are obtained before treatment and at the time of documentation of refractory disease in patients who do not achieve complete remission after induction therapy or at the time of first relapse in patients who achieve a complete remission.~Samples are examined for rearrangements in the MYC, BCL2, BCL6, and IGH genes using fluorescent in situ hybridization. DNA is examined by comparative genomic hybridization, which allows cytogenetic detection of losses and gains of chromosomal regions in tumor cells.~Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment."
62206464|NCT03454126|EXPERIMENTAL|Cohort 7: BIIB095 50 mg BID|Participants will receive a single dose of either BIIB095 50 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
62206465|NCT03454126|EXPERIMENTAL|Cohort 8: BIIB095 100 mg BID|Participants will receive a single dose of either BIIB095 100 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
62206466|NCT03454126|EXPERIMENTAL|Cohort 9: BIIB095 200 mg BID|Participants will receive a single dose of either BIIB095 200 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
62206467|NCT03454126|EXPERIMENTAL|Cohort 10: BIIB095 300 mg BID|Participants will receive a single dose of either BIIB095 300 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
62405452|NCT03441373|EXPERIMENTAL|XC8 100 mg and Placebo (Group B)|"XC8 100 mg orally.~1 tablet of XC8 100 mg +2 tablets of Placebo 10 mg + 1 tablet of Placebo 100 mg (in total 4 tablets) once daily during 5 days of treatment period"
62788587|NCT06098248|EXPERIMENTAL|Patients already scheduled for brain tumor surgery|The biological specimens (hereafter referred to as 'tissue') and/or images to be used in this trial must be collected from patients who are male or female and ≥ 19 years of age, and the patient is suspected to have a brain tumor and has been scheduled for neurosurgery with a potential tumor resection. There will be up to three (3) tissue sample types assessed for each participant: 1- center-of-tumor, 2- normal tissue (collected from inevitable standard resection), and 3- margin tissue. Tissues will be removed as part of the standard neurosurgical procedure. Resected tissue will be cleaned, stained, and imaged ex-vivo using cCeLL. Image recordings of sample tissue using cCeLL - Ex vivo are taken and the obtained data is stored.
62206468|NCT03999801|NO_INTERVENTION|Main Observational Study|All subjects that previously received RGX-314 in a subretinal administration parent study are enrolled into this arm.
62206469|NCT03999801|EXPERIMENTAL|RGX-314 Fellow Eye Treatment Substudy|RGX-314 Fellow Eye Treatment
62206470|NCT03577015||critically ill patients at risk for DIC|patients 18 years or older with a condition potentially associated with DIC, admitted to intensive care: severe infection/sepsis, solid tumor, hematologic malignancies, trauma, obstetric complications, acute pancreatitis
62206471|NCT06715618||FMS group|Each participant will perform two FMS™, one at the beginning of the competitive season and one at the end of the competitive season. The test will take 30 minutes per player. The initial interview will last 20 minutes. Players will also be monitored throughout the season to collect all injuries sustained by the participants in the study.
62405453|NCT03441373|EXPERIMENTAL|XC8 200 mg and Placebo (Group C)|XC8 200 mg orally. 2 tablets of XC8 100 mg +2 tablets of Placebo 10 mg (in total 4 tablets) once daily during 5 days of treatment period.
62788588|NCT04070417|EXPERIMENTAL|Treatment Group|Lifestyle Medicine Group
62016884|NCT02250885|EXPERIMENTAL|Selinexor (KPT-330)|Selinexor will be taken orally at a starting dose of 50mg/m2 twice weekly on weeks 1, 2, and 3 of each 4 week cycle.
62016885|NCT05561127|EXPERIMENTAL|GIE Medical ProTractX3 TTS DCB|"The ProTractX3 Drug-coated balloon is a 0.035 guidewire compatible over-the-wire catheter."
62016886|NCT05561127|ACTIVE_COMPARATOR|Control|Standard of Care.
62016887|NCT04535037|EXPERIMENTAL|Infanrix Hexa|All subjects in this group received 3 doses (2 primary doses and 1 booster dose) of DTPa-HBV-IPV/Hib vaccine co-administered with 3 doses of pneumococcal 13 valent conjugate vaccine at 2, 4, and 12 months of age.
62788589|NCT04070417|NO_INTERVENTION|CAU Group|Care-As-Usual Group
62788590|NCT06380075|EXPERIMENTAL|Fundus autofluorescence (FAF) imaging|
62206472|NCT03891771|NO_INTERVENTION|Usual Care|Patients allocated to usual care will receive standard follow-up procedures at their primary care facility.
62206473|NCT03891771|EXPERIMENTAL|Telemonitoring sensors|Patients allocated to this arm will receive a complex sensor platform aimed at detecting falls at home, nocturia and several environmental variables, including carbon monoxide concentrations, humidity and temperature. The system also includes a panic button that can be used to request assistance in emergencies.
62405454|NCT03441373|PLACEBO_COMPARATOR|Placebo (Group D)|Placebo orally.
62405455|NCT00937859|EXPERIMENTAL|SER120|SER120
62405456|NCT00937859|PLACEBO_COMPARATOR|Placebo|
62405457|NCT02433522|EXPERIMENTAL|Rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months
62405458|NCT02433522|PLACEBO_COMPARATOR|Placebo|Placebo infusion at the randomization visit and every 6 months for 18 months
62788591|NCT02779647|EXPERIMENTAL|Study group|Consisting of 49 children who were recommended a programme of physical activity, play and nutritional advice, for both the children and their parents
62788592|NCT02779647|NO_INTERVENTION|Control group|49 children, who received only nutritional advice
62788593|NCT01683825|EXPERIMENTAL|F-18 florbetapir PET-Amyloid Subjects|Individuals with documented cardiac amyloidosis will undergo F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET).
62016888|NCT04535037|ACTIVE_COMPARATOR|Vaxelis|All subjects in this group received 3 doses (2 primary doses and 1 booster dose) of DTaP5 HBV IPV Hib vaccine co-administered with 3 doses of pneumococcal 13 valent conjugate vaccine at 2, 4, and 12 months of age.
62016889|NCT01851005|PLACEBO_COMPARATOR|Group 1|General anesthesia with sevoflurane. Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
62016890|NCT01851005|PLACEBO_COMPARATOR|Group 2|General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
62016891|NCT01851005|EXPERIMENTAL|Group 3|General anesthesia with sevoflurane. Infusion of dexmedetomidine (0.4 ug/kg/hr) during anesthesia. Administer rocuronium 0.8 mg/kg for induction.
62016892|NCT01851005|EXPERIMENTAL|Group 4|General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of dexmedetomidine (0.4 ug/kg/hr) during surgery. Administer rocuronium 0.8 mg/kg for induction.
62016893|NCT05024331||Pediatric physicians|"Assigned Interventions~1. Prediction of the first date of recovery period with given data about chemotherapy of pediatric patients who diagnosed solid tumor at Samsung medical center during 2010-2018~2. Sees the result of the prediction algorithm.~3. Change or maintain their prediction values.~4. Participate in the usability questionnaires."
62206474|NCT06681428|EXPERIMENTAL|"Amnion/Chorion/Amnion common/general allograft configuration"|Topical application of placental allograft on to surface of open chronic diabetic foot ulcer using a tri-layer dehydrated amniotic membrane allograft for the treatment of DFUs. Human amniotic membrane is a thin collagenous membrane derived from the submucosa of the placenta, the organ that connects the developing fetus to the mother's uterus. A human amniotic membrane consists of multiple layers including epithelial cells, a basement membrane, and a stromal matrix which provides a natural scaffold that allows cellular attachment or infiltration and growth factor storage.
62215376|NCT04186364|EXPERIMENTAL|Assigned Ambassador (Intervention Group)|Patients who were consented, completed the accommodations survey, and for whom a medical student was available during the time of the ED visit will serve as our intervention group. The participants will be assigned an Ambassador throughout the child's ED visit and will complete a patient satisfaction survey afterwards. The investigators hold to enroll 120 controls.
62405459|NCT04233606|PLACEBO_COMPARATOR|Control|Participants will be infused with normal (0.9% NaCL) saline for a 120 minute period.
62215377|NCT04186364|NO_INTERVENTION|Control Group|Patients who were consented, completed the accommodations survey, but for whom a medical student was not available during the time of the ED visit will serve as our control group. The controls will fill out both an accommodations survey before and a patient satisfaction survey after the ED visit, however no ambassador will be assigned during the ED visit. The investigators hope to enroll 120 controls.
62016894|NCT04986618|EXPERIMENTAL|One-way Nordic Exercise Group|
62016895|NCT04986618|EXPERIMENTAL|Two-way Nordic Exercise Group|
62016896|NCT04986618|NO_INTERVENTION|Control Group|
62016897|NCT06535581||Group 1|hypertension patients
62016898|NCT06535581||group 2|non hypertension patients
62016899|NCT04696796|EXPERIMENTAL|BasIQ-4 Surgical Knife|Following the administration of 10 ml of 1% lidocaine, mediolateral episiotomy will be preformed with BasIQ-4 Surgical Knife according to computer generated randomization.
62016900|NCT04696796|ACTIVE_COMPARATOR|Episiotomy Scissors|Following the administration of 10 ml of 1% lidocaine, mediolateral episiotomy will be preformed with episiotomy scissors according to computer generated randomization.
62215378|NCT06270706|EXPERIMENTAL|Part 1 Dose Escalation: PLN-101095 given as monotherapy and in combination with Pembrolizumab|
62215379|NCT06270706|EXPERIMENTAL|Part 2 Dose Expansion: PLN-101095 in combination with Pembrolizumab|
62215380|NCT02813876|EXPERIMENTAL|Enhanced recovery|Enhanced recovery protocol for nursing, diet and analgesic regimen
62215381|NCT02813876|NO_INTERVENTION|Standard care|Standard care arm
62215382|NCT01814852|EXPERIMENTAL|Shockwaves|4 weekly sessions of low-intensity shockwave therapy
62215383|NCT01814852|SHAM_COMPARATOR|Control Group|
62215384|NCT04445727|EXPERIMENTAL|vitamin c|daily dose of 1000 mg vitamin c in order to regenerate collagen
62215385|NCT04445727|EXPERIMENTAL|spinal manipulation|Spinal manipulation in cervical and dorsal with high speed and short amplitude techniques
62215386|NCT04445727|EXPERIMENTAL|Transcutaneous electrical nerve stimulation (TENS)|electrotherapy for an analgesic purpose
62215387|NCT04445727|EXPERIMENTAL|manual therapy|manual muscle treatment for epicondyl musculature
62788594|NCT01683825|OTHER|F-18 florbetapir PET-Healthy Controls|Individuals without documented cardiac amyloidosis will undergo F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET).
62405460|NCT04233606|EXPERIMENTAL|Hypertonic Saline|Participants will be infused with hypertonic (3% NaCL) saline for a 120 minute period.
62016901|NCT06452615|EXPERIMENTAL|Study group|They will receive Extracorporeal shockwave therapy (ESWT), two session per week for 8 weeks in addition to the routine medical treatment.
62016902|NCT06452615|NO_INTERVENTION|Control group|This group includes thirty female patients suffering from intercostobrachial neuralgia after a modified radical mastectomy. They will receive routine medical treatment.
62016903|NCT05024812|EXPERIMENTAL|Experimental|fruquintinib + toripalimab + SOX
62016904|NCT05211219|EXPERIMENTAL|Probiotics|The probiotics group was advised to consume a chewable tablet once a day in 14 days.
62016905|NCT05211219|EXPERIMENTAL|Kefir|The kefir group was advised to consume kefir as a liquid once a day in 14 days.
62016906|NCT05211219|OTHER|Control|the control group was advised without additional food supplements.
62788595|NCT01683825|EXPERIMENTAL|F-18 florbetapir PET-Amyloid Reproducibility Subjects|Some of the individuals with documented cardiac amyloidosis from arm 1 will undergo a second F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET) within 30 days to measure reproducibility
62405461|NCT00564876|EXPERIMENTAL|Treatment|Neoadjuvant dasatinib is to be administered as an oral dose of 70 mg PO twice daily on a continuous basis for 3 weeks prior to surgery. Patients will begin adjuvant dasatinib (70 mg PO twice daily) between 4-6 weeks after standard adjuvant therapy is complete or 4-8 weeks after surgery for those patients that do not receive adjuvant chemotherapy. Adjuvant dasatinib will be given on a continuous basis for up to 3 months after adjuvant chemotherapy or after surgery if no adjuvant chemotherapy is given.
62405462|NCT05359861|EXPERIMENTAL|Lead-In|A minimum of 6 patients and up to 30 patients will be enrolled in an open-label Lead-In to assess the preliminary safety and tolerability of SRF388 with atezolizumab plus bevacizumab.
62016907|NCT04333277|EXPERIMENTAL|Probiotic|Patients with major depression (both sexes) will receive capsules with 1 × 10\^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.
62405463|NCT05359861|EXPERIMENTAL|Arm A: SRF388 in Combination with atezolizumab plus bevacizumab|Patients randomized to Arm A will receive SRF388 with atezolizumab plus bevacizumab.
62788596|NCT01863329||both optic nerve sheath diameter|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
62788597|NCT00319254|EXPERIMENTAL|Advanced breast cancer|
62788598|NCT04678388|EXPERIMENTAL|Group 1|"1. Period 1: Reference drug~2. Period 2: Test drug 1~3. Period 3: Test drug 2"
62788599|NCT04678388|EXPERIMENTAL|Group 2|"1. Period 1: Test drug 2~2. Period 2: Reference drug~3. Period 3: Test drug 1"
62788600|NCT04678388|EXPERIMENTAL|Group 3|"1. Period 1: Test drug 1~2. Period 2: Test drug 2~3. Period 3: Reference drug"
62788601|NCT04678388|EXPERIMENTAL|Group 4|"1. Period 1: Test drug 2~2. Period 2: Test drug 1~3. Period 3: Reference drug"
62016908|NCT04333277|PLACEBO_COMPARATOR|Maltodextrin|Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks
62016909|NCT04962971||Cranberry extract X|373 mg per Day
62016910|NCT04962971||Cranberry extract Y|404 mg per Day
62016911|NCT04962971||Cranberry extract Z|2090 mg per Day
62016912|NCT05971212|EXPERIMENTAL|Intervention|Access to Sleep Clinic immediately
62016913|NCT05971212|EXPERIMENTAL|Control|Access to Sleep Clinic delayed
62016914|NCT01110291||Breast cancer|Twenty patients with verified high risk breast cancer will be included in the study.
62016915|NCT04704245|EXPERIMENTAL|epidermal growth factor (EGF) containing ointment group|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening. The subjects then applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment."
62215388|NCT05896423||HBH cohort|Rates of PrEP initiation among Black cis women at an FQHC, before and after the PrEP materials are used
62215389|NCT05896423||PPIL cohort|Rates of PrEP initiation among Black cis woman at a family planning clinic, before and after the PrEP materials are used
62405464|NCT05359861|EXPERIMENTAL|Arm B: Placebo in combination with atezolizumab plus bevacizumab|Patients randomized to Arm B will receive placebo with atezolizumab plus bevacizumab.
62405465|NCT02783976||Sovaldi-based regimens|Adult patients with chronic HCV infection living in Mexico who take Sovaldi as part of routine clinical care at a participating clinical site.
62788602|NCT04678388|EXPERIMENTAL|Group 5|"1. Period 1: Test drug 1~2. Period 2: Reference drug~3. Period 3: Test drug 2"
62788603|NCT04678388|EXPERIMENTAL|Group 6|"1. Period 1: Reference drug~2. Period 2: Test drug 2~3. Period 3: Test drug 1"
62788604|NCT04472455||Screen Negative Group|All women who screen negative at Visit 1.
62788605|NCT04472455||Screen Positive Group|All women who screened positive at Visit 1 and were invited to Visit 2
62788606|NCT04472455||10% Of Screen Negative Group|10% of women who screened negative at Visit 1 and were invited to Visit 2
62206475|NCT06681428|NO_INTERVENTION|Standard of Care|Standard of Care (SOC) for open chronic diabetic foot ulcer using a calcium alginate dressing and will have a silicone non-adherent dressing (MepitelTM or equivalent), a padded 3-layer dressing comprised of 4x4 gauze pads, soft roll, compressive wrap and Coban (Threeflex 3-layer or equivalent) applied. Offloading of the DFU (removable offloading boot or total contact casting \[TCC\] if the subject's foot is too large for a removable offloading boot), appropriate sharp or surgical debridement, and infection management. Graft provides a protective cover and supports the body's wound healing processes. This allograft is supplied sterile and not intended to be removed.
62016916|NCT04704245|PLACEBO_COMPARATOR|Vehicle ointment group|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening. The subjects then applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment."
62016917|NCT06502457|ACTIVE_COMPARATOR|control group|
62016918|NCT06502457|EXPERIMENTAL|hypnosis group|
62206476|NCT06681428|EXPERIMENTAL|"Amnion/Chorion common/general allograft configuration"|Topical application of placental allograft on to surface of open chronic diabetic foot ulcer using a dehydrated human amniotic membrane allograft comprised of a tri-layer membrane (amnion/intermediate layer/chorion) which provides a natural scaffold that allows cellular attachment and infiltration. Human amniotic membrane is a thin collagenous membrane derived from the submucosa of the placenta. A human amniotic membrane consists of multiple layers including epithelial cells, a basement membrane, and a stromal matrix. Graft provides a protective cover and supports the body's wound healing processes. This allograft is supplied sterile and not intended to be removed.
62215390|NCT04037618|EXPERIMENTAL|[14C]-EYP001a|\[14C\]-EYP001a dose A containing 100 μCi radioactivity
62215391|NCT03914638|EXPERIMENTAL|Active|Active intervention arm. Treatment for 8 weeks per treatment period.
62215392|NCT03914638|PLACEBO_COMPARATOR|Placebo|Placebo arm. Treatment for 8 weeks per treatment period.
62405466|NCT03818334|EXPERIMENTAL|Post Cyclophosphamide|Cyclophosphamide 50 mg/Kg on days +3 and +4 AND Calcineurin Inhibitor from day +5 AND Mycofenolate Mofetil from day +5 until day +35
62788607|NCT04890288|EXPERIMENTAL|Intervention group - High flow|High-flow nasal cannula oxygen 2L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0; enabling apneic oxygenation during laryngoscopy.
62788608|NCT04890288|EXPERIMENTAL|Intervention group - Low flow:|Low-flow oxygen (100%, 0.2 l/kg/min) via conventional neonatal nasal cannula (Intersurgical, Wokingham, Berkshire, United Kingdom) enabling apneic oxygenation during laryngoscopy.
62788609|NCT04890288|NO_INTERVENTION|Conventional|Conventionally practiced standard of care with preoxygenation with facemask with an FiO2 of 1.0, followed by bag mask ventilation after induction before oral intubation without apneic oxygenation.
62016919|NCT03808285||mandibular osteomylitis|description of mandibular osteomylitis due to denosumab
62016920|NCT06342544|EXPERIMENTAL|immediate treatment with corticosteroids addition of rituximab if recurrence|
62016921|NCT06342544|NO_INTERVENTION|based on standard practice|
62016922|NCT00861341|EXPERIMENTAL|Pioglitazone with or without Aspirin|Blood samples will be taken at time 0 to measure platelet aggregation. 30mg Pioglitazone will be ingested and another blood sample will be obtained 90-180 minutes later for platelet aggregation. After 6-9 days, subjects will ingest 81mg of aspirin. Another blood sample will be obtained 2-24 hours later for baseline determination of platelet aggregation and activation after taking aspirin. Subjects will then ingest 30mg pioglitazone and a final blood sample will be obtained 90-180 minutes later to measure platelet aggregation.
62016923|NCT01258205|EXPERIMENTAL|Part B|One dose level of AMG 139 administered as a multiple doses IV in subjects with mild-severe Crohn's disease.
62016924|NCT01258205|EXPERIMENTAL|Part A|Three dose levels of AMG 139 administered as a multiple doses IV or SC in healthy subjects.
62016925|NCT00058890|EXPERIMENTAL|Gabapentin|
62016926|NCT00058890|PLACEBO_COMPARATOR|Placebo|
62016927|NCT04748380|EXPERIMENTAL|CRC DA|Stratifying by sex, 30 participants will be randomized to receive the CRC DA pamphlet.
62405467|NCT03818334|ACTIVE_COMPARATOR|Thymoglobulin (ATG)|Thymoglobulin (ATG) total dose 5 mg/Kg from day -4 until day -1 AND Calcineurin Inhibitor from day +5 AND Methotrexate on days +1, +3, +6 and +11
62405468|NCT00773201|EXPERIMENTAL|1|Healthy subjects
62405469|NCT02430155|ACTIVE_COMPARATOR|Bakri balloon group|The women in this group will be managed by Bakri balloon
62405470|NCT02430155|ACTIVE_COMPARATOR|Condom loaded Foley's catheter group|The women in this group will be managed by condom loaded Foley's catheter
62405471|NCT04796259|NO_INTERVENTION|Negative control|Water
62788610|NCT02982421|EXPERIMENTAL|Research|Group Art Therapy
62788611|NCT02982421|SHAM_COMPARATOR|Control|Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
62788612|NCT00889525|EXPERIMENTAL|Cabergoline|
62788613|NCT05899374|EXPERIMENTAL|Experimental KindMap Group|Participants in the experimental group will register, complete the baseline assessment and have immediate access to the KindMap web app.
62016928|NCT04748380|OTHER|Home Safety Pamphlet|Stratifying by sex, 30 will be randomized to receive the home safety information at the visit.
62206477|NCT06681428|EXPERIMENTAL|"Amnion/Amnion common/general allograft configuration"|Topical application of placental allograft on to surface of open chronic diabetic foot ulcer using a dual layer dehydrated human amniotic membrane allograft. Human amniotic membrane is a thin collagenous membrane derived from the submucosa of the placenta, the organ that connects the developing fetus to the mother's uterus. A human amniotic membrane consists of multiple layers including epithelial cells, a basement membrane, and a stromal matrix which provides a natural scaffold that allows cellular attachment or infiltration and growth factor storage. This allograft provides a protective cover and supports the body's wound healing process. This allograft is supplied sterile and not intended to be removed.
62206478|NCT04491877|EXPERIMENTAL|Cohort 1 (RSV vaccine formulation 1)|1 administration of RSV vaccine formulation 1 on Day 0
62206479|NCT04491877|PLACEBO_COMPARATOR|Cohort 1 (Placebo)|1 administration of placebo on Day 0
62206480|NCT04491877|EXPERIMENTAL|Cohort 2 (RSV vaccine formulation 1)|2 administrations of RSV vaccine formulation 1 on Day 0 and Day 56
62206481|NCT04491877|PLACEBO_COMPARATOR|Cohort 2 (Placebo)|2 administrations of placebo on Day 0 and Day 56
62788614|NCT05899374|NO_INTERVENTION|Wait-list Control Group|Participants in the WL-CG will complete the baseline assessment and will be able to register and have access to the KindMap web app 10 weeks later.
62206482|NCT04491877|EXPERIMENTAL|Cohort 3 (RSV vaccine formulation 2)|1 administration of RSV vaccine formulation 2 on Day 0
62206483|NCT04491877|PLACEBO_COMPARATOR|Cohort 3 (Placebo)|1 administration of placebo on Day 0
62206484|NCT04491877|EXPERIMENTAL|Cohort 4 (RSV vaccine formulation 1)|2 administrations of RSV vaccine formulation 1 on Day 0 and Day 56
62206485|NCT04491877|EXPERIMENTAL|Cohort 4 (RSV vaccine formulation 2)|2 administrations of RSV vaccine formulation 2 on Day 0 and Day 56
62405472|NCT04796259|ACTIVE_COMPARATOR|Positive control|Non-alcoholic beer solids
62405473|NCT04796259|EXPERIMENTAL|Intervention 1|Malt ingredient I
62405474|NCT04796259|EXPERIMENTAL|Intervention 2|Malt ingredient II
62788615|NCT04979117||Participants with plantar fasciitis|"Participants with the diagnose of plantar fasciitis; typical anamnesis (exacerbating pain by the first steps in the morning or after rest and with prolonged standing).~The emerge of local point tenderness over the heel and proximal fascia due to the pressure applied by the physician.~Thickening of the plantar fascia greater than 4 mm in ultrasonographic evaluation. measurement"
62206486|NCT04491877|PLACEBO_COMPARATOR|Cohort 4 (Placebo)|2 administrations of placebo on Day 0 and Day 56
62206487|NCT06611046||Death brain donors (DBD)|Liver grafts from brain death donors suffer systemic haemodynamic, inflammatory and endocrine changes during donor maintenance due to brain-stem activity cessation.
62206488|NCT06611046||Donors after circulatory death (DCD)|Circulatory death donors do not suffer the physiologic features from brain death, almost mirroring a living donation. However, after withdrawal of life-sustaining measures these grafts suffer injury from severe ischemia.
62206489|NCT06611046||Discarded DBD (dDBD)|Liver grafts from brain death donors that were unusable due to moderate to severe steatosis. Fatty livers are vulnerable to preservation injury resulting in a higher rate of primary non-function, early allograft dysfunction and post-transplant vascular and biliary complications
62405475|NCT00219349|EXPERIMENTAL|Escitalopram|12 weeks of open label escitalopram, 10-20 mg/day (after 14 weeks of cognitive behavioral therapy
62405476|NCT06296901|EXPERIMENTAL|Perineal Wipe|Patient will use wipe before collecting mid-stream clean catch culture
62405477|NCT06296901|NO_INTERVENTION|No Wipe|Patient will not use wipe before collecting mid-stream clean catch culture
62405478|NCT01529697|ACTIVE_COMPARATOR|Active Feedback|In this arm patients will receive monthly review and education on inhaler technique and use based on a computer download of their last month of inhaler use
62788616|NCT04979117||Volunteers who has not foot complaints.|Volunteers who were not diagnosed with Plantar Fasciitis and without foot or heel pain when taking the first steps in the morning, with plantar fascia thickness less than 4 mm, painless, symptom-free and which had no additional rheumatic disease.
62016929|NCT06069154|ACTIVE_COMPARATOR|Cryoneurolysis|Active cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[1st 4 participants\] 3 minutes \[remaining participants; change based on new laboratory data\] of argon and 30 seconds of helium (Varian). For the active comparator, the gas will be deployed to the tip where a drop in temperature will result in cryoneurolysis.
62405479|NCT01529697|PLACEBO_COMPARATOR|Control|In this arm patients will be reviewed monthly, however will not have information from INCA device to tailor inhaler education.
62405480|NCT01465048|EXPERIMENTAL|Plasmodium falciparum sporozoites 2sites|2,500 sporozoites intradermally
62405481|NCT01465048|EXPERIMENTAL|Plasmodium falciparum sporozoites 1 site|2,500 sporozoites intramuscularly
62405482|NCT01465048|EXPERIMENTAL|Plasmodium falciparum sporozoites 1site|25,000 sporozoites intramuscularly
62405483|NCT01659762|EXPERIMENTAL|autologous mesenchymal stromal cells|
62405484|NCT01725100|EXPERIMENTAL|Treatment A: GSK1120212B (Standard DMSO content)|Subjects will receive Treatment A in Period 1 or 2 as single oral dose on Day 1 of Period 1 or 2 in fasting condition with water.
62405485|NCT01725100|EXPERIMENTAL|Treatment B: GSK1120212B (Lower DMSO content)|Subjects will receive Treatment B in Period 1 or 2 as single oral dose on Day 1 of Period 1 or 2 in fasting condition with water.
62405486|NCT05184491|ACTIVE_COMPARATOR|Naïve patients - ACO therapy|One hundred patients naive to H. Pylori eradication therapy will receive ACO therapy for 14 days (amoxicillin 1 g with breakfast and dinner, clarithromycin 500 mg with breakfast and dinner and lansoprazole 40 mg twice daily before meals).
62405487|NCT05184491|EXPERIMENTAL|Naïve patients - LNDL therapy|One hundred patients naive to H. Pylori eradication therapy will receive LNDL therapy for 14 days (Levofloxacin 750 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
62405488|NCT05184491|EXPERIMENTAL|Naïve patients - MNDL therapy|One hundred patients naive to H. Pylori eradication therapy will receive MNDL therapy for 14 days ( Moxifloxacin 400 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
62206490|NCT06611046||Control group|Serum samples from healthy patients who underwent elective cholecystectomy due to symptomatic gallstones were collected before incision. The patients included shared similar characteristics according to the centre living liver donor policy: 18 to 60-year-old, normal liver function and no steatosis in ultrasound.
62405489|NCT05184491|EXPERIMENTAL|Treatment-experienced patients- LNDL therapy|One hundred patients who were unresponsive to previous eradication therapy will receive LNDL therapy for 14 days (Levofloxacin 750 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
62405490|NCT05184491|EXPERIMENTAL|Treatment-experienced patients- MNDL therapy|One hundred patients who were unresponsive to previous eradication therapy will receive MNDL therapy for 14 days ( Moxifloxacin 400 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
62405491|NCT00398476|ACTIVE_COMPARATOR|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
62405492|NCT00398476|ACTIVE_COMPARATOR|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
62405493|NCT00612300|EXPERIMENTAL|A-B|Gait training by an automatic gait trainer (Lokomat) for 3 weeks followed by 3 weeks of categorized gait training by a physical therapist
62405494|NCT00612300|EXPERIMENTAL|B-A|Categorized gait training by physical therapists for 3 weeks followed by 3 weeks of lokomat training
62405495|NCT02867748|EXPERIMENTAL|1|TVT-Abbrevo
62405496|NCT02867748|EXPERIMENTAL|2|Serasis
62405497|NCT01469416|ACTIVE_COMPARATOR|Rosuvastatin|
62405498|NCT01469416|EXPERIMENTAL|Rosuvastatin + clopidogrel|
62788617|NCT04298437|EXPERIMENTAL|Parent Group Treatment|Families who meet inclusion criteria will participate in the Parent Group Treatment (ADAPT Program).
62788618|NCT04298437|NO_INTERVENTION|No Treatment|Families who do not meet inclusion criteria will not be invited to participate in the ADAPT Program.
62788619|NCT00705367|PLACEBO_COMPARATOR|Placebo|
62788620|NCT00705367|ACTIVE_COMPARATOR|Abatacept, 30 mg/kg|
62788621|NCT00705367|OTHER|Abatacept, 10 mg/kg|Open-label long-term extension phase
62788622|NCT00964652|EXPERIMENTAL|PD Group|Nine subjects with idiopathic PD, previously diagnosed by one specialist physician participated in this study.
62405499|NCT04479410||Drug resistant epilepsy patients|Patients with drug resistant epilepsy underwent epilepsy surgery
62405500|NCT01450670||Dialysis patients|
62405501|NCT05952570|EXPERIMENTAL|protein supplement|50 patients will receive oral protein nutritional supplement (Fresubin protein powder 25mg/5scoops per hemodialysis session) 1 hour before the start of the session (predialytic) for 3 months
62405502|NCT05952570|PLACEBO_COMPARATOR|control|50 patients will receive a routine nutrition regimen for 3 months. (control group)
62788623|NCT05097495|EXPERIMENTAL|Control group (Only NNS)|NNS will be started 5 minutes before diaper change. The use of NNS will continue during diaper change and up to 5 minutes after the application.
62788624|NCT05097495|EXPERIMENTAL|Experimental Group (NNS Combined with Breast Milk)|NNS combined with breast milk will be started 5 minutes before diaper change. The use of NNS combined with breast milk will continue during diaper change and up to 5 minutes after the application.
62405503|NCT06539793|EXPERIMENTAL|Study group (A)|Patients will receive exercises, and sham Non-Invasive Neuromodulation, 3 sessions per week (one hour for each session) for 4 weeks.
62405504|NCT06539793|EXPERIMENTAL|Control group (B)|Patients will receive exercises as in group (A) in addition to Non-Invasive Neuromodulation 3 sessions per week (one hour for each session) for 4 weeks.
62405505|NCT01852669|EXPERIMENTAL|Inversion, Hydration, ESWL|ESWL with hydration and inversion
62405506|NCT01852669|ACTIVE_COMPARATOR|ESWL, Hydration|ESWL with hydration
62206491|NCT03342989|EXPERIMENTAL|Speed of Processing Training|Training involves detection, localization, and discrimination of briefly displayed stimuli (17-500 milliseconds) using tasks with varying demands on visual attention. Cognitive processing speed is defined as response accuracy at a given display duration, regardless of motor speed. Training involves detection, localization, and discrimination of briefly displayed stimuli (17-500 milliseconds) using tasks with varying demands on visual attention. Speed of processing is defined as response accuracy at a given display duration, regardless of motor speed. Training consists of 10 lab-based sessions over 5 weeks, followed by home-based practice on a tablet computer for 24 months with supportive home visits.
62788625|NCT01325688|EXPERIMENTAL|Group 1|PEP005 0.05% gel applied and occluded with an aluminium disk for up to three consecutive days
62788626|NCT01325688|EXPERIMENTAL|Group 2|PEP005 0.05% Gel applied and occluded with an OpSite(TM) disk up to three consecutive days
62788627|NCT01325688|EXPERIMENTAL|Group 3|PEP005 0.05% applied with no occlusion for up to three consecutive days
62788628|NCT05489367||Pre-vaccine ovarian reserve and fertility status|Before vaccination, ovarian reserve tests and fertility status of 64 women will be examined and results will be recorded.After 2 doses of vaccination, ovarian reserve and fertility status of same 64 women will be examined and results will be recorded
62206492|NCT03342989|ACTIVE_COMPARATOR|Internet-Based Contact Control|Training involves mentally stimulating activity and consists of three levels: (1) using a computer (e.g., mouse training, pull-down menus, selecting options), (2) internet search engine training, and (3) search engine proficiency tasks. Training consists of 10 lab-based sessions over 5 weeks, followed by home-based practice on a tablet computer for 24 months with supportive home visits.
62206493|NCT05478889||Minimally invasive pancreatoduodenectomy|Whipple or pylorus preserving pancreatoduodenectomy following minimally invasive approach (laparoscopic or robotic). Hybrid (hand assisted) precedures will be included in the minimally invasive cohort.
62206494|NCT05478889||Open pancreatoduodenectomy|Whipple or pylorus preserving pancreatoduodenectomy following open (laparotomy) approach.
62206495|NCT01353651|EXPERIMENTAL|Endovascular treatment|
62581099|NCT06575530|ACTIVE_COMPARATOR|Dexmedetomidine hydrochloride group|Light sedation will started when the patient admitted to ICU after non-cardiac surgery under general anaesthesia with dexmedetomidine, which was continuously intravenously pumped at a rate of 0.2-0.7ug/kg/h. Depth of sedation will assessed by RASS score hourly to ensure a RASS score of 0 to -3. At the same time, use remifentanil (0.1-0.5/kg/min) as a combination analgesic drug to ensure that the CPOT is less than or equal to 2 points. When a satisfactory level of RASS score (0 to -3 points) was still not achieved within the dose range, a remedial programme of sedation will started using propofol.During the ICU stay, daily sedation interruption and spontaneous breathing test will be performed. If successful, sedation will be terminated, followed by weaning and extubation. If unsuccessful, mechanical ventilation will continue.
62788629|NCT00566462|EXPERIMENTAL|perampanel|
62788630|NCT00566462|PLACEBO_COMPARATOR|1|
62788631|NCT00491582|NO_INTERVENTION|Athletes, controls, patients|Sedentary controls: age, BMI, Gender and waist matched (to the growth hormone deficient patients) healthy control subjects Endurance trained athletes: minimal \>50 mlO2/KG body weight
62788632|NCT03609411||Splenectomy|Patients undergoing liver transplantation with simultaneous splenectomy
62788633|NCT03609411||Liver transplantation|Patients undergoing liver transplantation only
62206496|NCT01353651|ACTIVE_COMPARATOR|Open repair treatment|
62206497|NCT04200001||adjuvant hormonal therapy for breast cancer|women less than 51 years old, during adjuvant hormonal therapy for breast cancer
62206498|NCT05195021|EXPERIMENTAL|Group 1 (conventional irrigation)|After finishing the mechanical instrumentation, each root canal was irrigated with 5 ml of 5.25% NaOCl using a 31-gauge needle positioned 2 mm shorter than the WL. To remove the smear layer, 5 ml of 17% ethylenediaminetetraacetic acid (EDTA) was used in each canal for 1 minute, and 5 ml of saline was then administered to neutralize all the residues.
62788634|NCT05050461|ACTIVE_COMPARATOR|Cases|Patients with a history of B-NHL
62788635|NCT05050461|OTHER|Controls|Spouses of cases
62788636|NCT04423692||pregnant women with abnormal labs|Mothers who have abnormal labs during pregnancy with abnormal coagulation profile
62788637|NCT04693286|ACTIVE_COMPARATOR|Vaccine candidate arm|In this arm, participants will get nOPV2 vaccine candidate 1
62788638|NCT04693286|PLACEBO_COMPARATOR|Placebo arm|In this arm, participants will get inactive substance like sucrose in BME media and buffer.
62788639|NCT02502045|EXPERIMENTAL|Morning Simulated Sunlight|Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days. A flexible window of has been allowed to accommodate participants and care routines.
62788640|NCT02502045|PLACEBO_COMPARATOR|Non-Therapeutic Red Light|Non-therapeutic red light control at 5 lux will be used as the control condition
62788641|NCT01009606|ACTIVE_COMPARATOR|Arm 1 : Control : usual strategy|
62788642|NCT01009606|EXPERIMENTAL|Arm 2: Comparator : modified strategy|
62788643|NCT03043235||African American Females|No intervention
62788644|NCT03043235||African American Males|No intervention
62788645|NCT03043235||Caucasian Females|No intervention
62788646|NCT03043235||Caucasian Males|No intervention
62206499|NCT05195021|EXPERIMENTAL|Group 2 (EDDY)|In group 2, 1 ml of 5.25% NaOCl was agitated for 20 seconds three times with the EDDY tip positioned 2 mm shorter than the WL. The root canals were then irrigated with 2 ml of 5.25% NaOCl again. Subsequently, the EDDY tip was activated with short pumping movements, and 2 ml of 17% EDTA was activated for 30 seconds, as described above. The final irrigation followed the same procedures as in group 1.
62206500|NCT05195021|EXPERIMENTAL|Group 3 (conventional irrigation and laser irradiation)|In group 3, final irrigation followed the same procedures as in group 1 and group 2. During the laser therapy, both the operator and the patient wore eyewear for protection. Laser irradiation was performed using a 980-nm diode laser (Medency Primo 10 W Diode Laser; Vicenza, Italy), coupled with optical fibre (200 µm). The settings were as follows: average power of 1.2 W with a low frequency of 50 Hz and energy of 12 J (each cycle) in pulsed mode, irradiation for 10 seconds, followed by a 10 second pause, which constituted one cycle. This cycle was applied four times to each root canal. The optical fibre tip was located at the WL. The root canals were then slowly (at a speed of 2 mm/s) irradiated from the apical to the coronal portion using a continuous helicoidal movement, with optical fibre tip contacting the root canal walls in one cycle for each power.
62206501|NCT05195021|EXPERIMENTAL|Group 4 (EDDY and laser irradiation)|In this group, after agitation using the EDDY (VDW) system was performed using the same procedures as in group 3, final irrigation and laser irradiation were done as in group 2.
62206502|NCT04936477|EXPERIMENTAL|Assessment of alveolar surface area by functional morphometry|Non-invasive measurements of V/Q
62581100|NCT05068531||Observational|We plan to recruit up to 100 mCRC patients with baseline resectable liver-restricted metastases (mCRC-LR) without evidence of extra-hepatic metastases, with primary tumor already or to be resected (metachronous or synchronous disease), planned to receive upfront FOLFOX-based preoperative neoadjuvant systemic chemotherapy, who achieved no-evidence of disease (NED) in the abdomen by standard imaging.
62581101|NCT06683235|EXPERIMENTAL|Intervention with flaxseed|Participants in the intervention group will be given 16 g of ground flaxseed per day for 3 months.
62581102|NCT06683235|NO_INTERVENTION|Control group|control group, without intervention.
62581103|NCT05346081||Patients with underlying lung disease|
62581104|NCT05346081||Healthy subjects|
62581105|NCT06061003|OTHER|Fractured Model Group|All participants will receive 60 minutes training on anatomy and pathophysiology of theoric wrist fractures. After lecture completed, the Fractured Model Group will engage in a 2-hours hands-on practical session in the laboratory, working with wrist fracture models.
62581106|NCT06061003|OTHER|Standard Anatomic Model Group|All participants will receive 60 minutes training on anatomy and pathophysiology of theoric wrist fractures.After lecture completed, the Standard Anatomic Model Group will engage in a 2-hours hands-on practical session in the laboratory, working with standard anatomical wrist models.
62581107|NCT00792792||Tissue transfer skin flap|Modulated Imaging Spectroscopy
62581108|NCT04974138|ACTIVE_COMPARATOR|CC with amlodipine 5mg/d|For subjects with the MTHFR CC genotype, amlodipine (5mg) + amlodipine-folic acid (dummy), once daily, taken orally in the morning after waking-up.
62581109|NCT04974138|EXPERIMENTAL|CC with amlodipine folic acid 5.8mg/d|For subjects with the MTHFR CC genotype, amlodipine-folic acid (5.8mg) + amlodipine (dummy), once daily, taken orally in the morning after waking-up.
62788647|NCT02279095|EXPERIMENTAL|Palovarotene dose level 1 (completed)|Participants received 10 mg palovarotene for 14 days, followed by 5 mg palovarotene for 28 days (or weight-based equivalent) for eligible flare-ups (Part A).
62788648|NCT02279095|EXPERIMENTAL|Palovarotene dose level 2|Participants with at least 90% skeletal maturity received 5 mg palovarotene for up to 24 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
62581110|NCT04974138|ACTIVE_COMPARATOR|CT with amlodipine 5mg/d|For subjects with the MTHFR CT genotype, amlodipine (5mg) + amlodipine-folic acid (dummy), once daily, taken orally in the morning after waking-up.
62581111|NCT04974138|EXPERIMENTAL|CT with amlodipine folic acid 5.8mg/d|For subjects with the MTHFR CT genotype, amlodipine-folic acid (5.8mg) + amlodipine (dummy), once daily, taken orally in the morning after waking-up.
62581112|NCT04116970|EXPERIMENTAL|Diagnostic (bronchoscopy with EBUS-TBNA with/without vacuum)|Patients undergo bronchoscopy with EBUS-TBUA first without and then with applied vacuum.
62581113|NCT06492850|EXPERIMENTAL|FT-002 dose 1|Low dose FT-002
62581114|NCT06492850|EXPERIMENTAL|High dose FT-002|High dose FT-002
62581115|NCT04396197||COVID-19|Observations taken of standard physiotherapy practice. All patients are assessed daily and receive respiratory care and rehabilitation as deemed appropriate by the treating therapist
62581116|NCT06575036|EXPERIMENTAL|Study group|Sequential determination of dose according to previous participant's result and by chance.
62581117|NCT03176342|EXPERIMENTAL|patch test arm|Patch test by selected allergens and drawing blood for ELIspot and LTT
62581118|NCT04625881|ACTIVE_COMPARATOR|Active product|A powder containing 20 g of apple derived fiber will be consumed daily
62581119|NCT04625881|PLACEBO_COMPARATOR|Placebo|A rice derived placebo devoid of fiber and aromatized with apple fragancy will be provided
62581120|NCT00151242|ACTIVE_COMPARATOR|1|
62581121|NCT00151242|EXPERIMENTAL|2|
62206503|NCT06000033|EXPERIMENTAL|RC48+Anlotinib|Disitamab Vedotin : 2 mg/kg，ivgtt，d1-14/28day/cycle Anlotinib: 12mg once daily (taken before meals) orally, continuously for 2 weeks followed by a 1-week break. Each cycle consists of 21 days.
62206504|NCT05655273|ACTIVE_COMPARATOR|Post-liver transplant patients receiving Prograf|
62788649|NCT02279095|EXPERIMENTAL|Palovarotene dose level 3|Participants with less than 90% skeletal maturity received weight-adjusted doses of 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
62206505|NCT05655273|ACTIVE_COMPARATOR|Post-liver transplant patients receiving Envarsus|
62206506|NCT02960243|SHAM_COMPARATOR|Bilateral Thalamic Vim OFF|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
62206507|NCT02960243|EXPERIMENTAL|Left Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
62405507|NCT01935492|ACTIVE_COMPARATOR|8 cycles of Paclitaxel & bevacizumab|8 cycles of Paclitaxel: 90 mg/m2 IV on days 1, 8 and 15 every 28 days \& Bevacizumab: 10 mg/kg IV on days 1 and 15 every 28 days
62405508|NCT01935492|ACTIVE_COMPARATOR|2 x 4 cycles of Paclitaxel & bevacizumab|intermittent 2x4 cycles of Paclitaxel: 90 mg/m2 IV on days 1, 8 and 15 every 28 days \& Bevacizumab: 10 mg/kg IV on days 1 and 15 every 28 days
62788650|NCT02279095|EXPERIMENTAL|Palovarotene dose level 4|All participants will receive 5 mg palovarotene for up to 48 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part C). Skeletally immature participants will receive weight-adjusted doses.
62405509|NCT02106676||Pregnant women with PCOS and offspring|Exposures of interest: Polycystic ovary Syndrome (PCOS) according to Rotterdam
62405510|NCT02106676||Pregnant women without PCOS and offspring|Exposures of interest: Pregnant women without polycystic ovary Syndrome (PCOS) according to Rotterdam
62788651|NCT05669053|EXPERIMENTAL|Super U Story intervention|Participants in this condition will be asked to play the Roblox video game, Super U Story with the goal of reaching the end of the game (approximately 20-30 minutes)
62788652|NCT05669053|ACTIVE_COMPARATOR|Alternative Roblox game|Participants in this condition will be asked to play the Roblox video game, Rainbow Friends Story (Color Story) with the goal of reaching the end of the game (approximately 20-30 minutes)
62788653|NCT05669053|ACTIVE_COMPARATOR|Online word search|Participants in this attention control condition will be asked to complete as many online word searches on the topic of animals as they can in 20-30 minutes.
62788654|NCT02303028|EXPERIMENTAL|Topotecan and Pazopanib|Low dose Topotecan will be given metronomically in combination with Pazopanib at the dose level assigned at study entry
62405511|NCT05247606|EXPERIMENTAL|Intervention group|Mobile application
62405512|NCT05247606|NO_INTERVENTION|Control group|Usual care
62581122|NCT05674708|ACTIVE_COMPARATOR|Butter|Butter based meal
62581123|NCT05674708|ACTIVE_COMPARATOR|Coconut|Coconut based meal
62788655|NCT04840212|EXPERIMENTAL|Study Group|Patients currently hospitalized in multiple service lines (surgical intensive care unite \[SICU\], surgical progressive care unit \[SPCU\], burns, trauma, plastics, general surgery, orthopedics, surgical specialties, and inpatient rehabilitation) will be included. Lavender-Sandalwood scented aromatherapy sticker will be used throughout the patient hospital stay.
62016930|NCT06069154|SHAM_COMPARATOR|Sham Procedure|Sham cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[1st 4 participants\] 3 minutes \[remaining participants; change based on new laboratory data\] of argon and 30 seconds of helium (Varian). However, for the sham comparator, the gas will NOT be deployed to the tip, there there will NOT be a drop in temperature, and NO cryoneurolysis will occur.
62405513|NCT02854865||Echocardiography|assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
62581124|NCT05674708|ACTIVE_COMPARATOR|Corn oil|Corn oil based meal
62016931|NCT03588572|EXPERIMENTAL|Venlafaxine Group|The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation ( each containing venlafaxine 75mg), 1 capsule per day, until 4 weeks after randomization.
62016932|NCT03588572|NO_INTERVENTION|Controlled group|the patients in controlled group do not use the drug during the experiment, and the other treatments are same as the venlafaxine group.
62405514|NCT03361566|EXPERIMENTAL|low energy flux at ad libitum energy intake|physical activity: inactive energy intake: ad libitum
62405515|NCT03361566|EXPERIMENTAL|medium energy flux at ad libitum energy intake|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: ad libitum
62405516|NCT03361566|EXPERIMENTAL|high energy flux at ad libitum energy intake|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: ad libitum
62581125|NCT05674708|ACTIVE_COMPARATOR|Flax seed oil|Flax seed oil based meal
62581126|NCT04299061|EXPERIMENTAL|Study Group|
62016933|NCT02977377|ACTIVE_COMPARATOR|Whole body vibration/ Exercise|Exercise therapy and whole body vibration will be applied together for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. Whole body vibration (20-30 Hz, minimum amplitude) will be applied to cases in the form of 4 sets (1 min application and 1min rest) before exercises. After 1 week washout period, exercise program will apply for 8 weeks.
62405517|NCT03361566|EXPERIMENTAL|Low energy flux at energy balance|physical activity: inactive energy intake: individual energy balance
62581127|NCT02484417|EXPERIMENTAL|Cohort 1: RSV A2 10^5 PFU/dose|Challenge 4 subjects with low dose and proceed to larger cohort after safety review.
62581128|NCT02484417|EXPERIMENTAL|Cohort 2: RSV A2 10^5 PFU/dose|Challenge 12 subjects with the low dose and proceed to high dose after safety review.
62581129|NCT02484417|EXPERIMENTAL|Cohort 3: RSV A2 10^6.3 PFU/dose|Challenge 12 subjects with the high dose
62581130|NCT04496193|EXPERIMENTAL|Group lower dose ropivacaine with dexamethasone|Quadratus lumborum block was administered with 0.25% Ropivacaine 20 ml + dexamethasone 0.8 ml (4mg) at the end of surgery
62581131|NCT04496193|ACTIVE_COMPARATOR|Group higher dose ropivacaine with N/S|Quadratus lumborum block was administered with 0.5% Ropivacaine 20 ml + N/S 0.8 ml at the end of surgery
62581132|NCT04496193|PLACEBO_COMPARATOR|Group lower dose ropivacaine with N/S|Quadratus lumborum block was administered with 0.25% Ropivacaine 20 ml + N/S 0.8 ml at the end of surgery
62581133|NCT01416493|EXPERIMENTAL|bIAP treatment|
62788656|NCT04840212|NO_INTERVENTION|Control Group|The historical control group will be comprised of hospitalized patients in multiple service lines from the previous year with the same time period, demographic characteristics, service line, and relevant clinical information.
62581134|NCT03119675|OTHER|Photorefraction of ages 1 to 6 years|Clinical Validation of GoCheck Kids Smartphone App
62016934|NCT02977377|ACTIVE_COMPARATOR|Exercise/ Whole body vibration|Exercise therapy will be applied for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. After 1 week washout period exercise therapy and whole body vibration will be applied together for 8 weeks.
62405518|NCT03361566|EXPERIMENTAL|medium energy flux at energy balance|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: individual energy balance
62016935|NCT05758025|EXPERIMENTAL|"Resection based on thymus-vascular-inferior parathyroid complex"|
62405519|NCT03361566|EXPERIMENTAL|high energy flux at energy balance|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: individual energy balance
62581135|NCT04132804|EXPERIMENTAL|Tai Chi Treatment|All patients in the trial will receive 1-hour Tai Chi lessons once per week for a total of 8 weeks.
62581136|NCT02892110|EXPERIMENTAL|Varenicline|2 mg daily
62581137|NCT02892110|PLACEBO_COMPARATOR|Placebo|2 mg daily
62581138|NCT04275635||Children with myopia|A total of 3,000 children from Zhongshan Ophthalmic Center is required to undergo ophthalmic examinations and complete questionnaires at baseline and 1yr after wearing Ortho-K.
62581139|NCT04549389|ACTIVE_COMPARATOR|Group A|Patients will receive 6 Low-intensity shockwave therapy (LiST) sessions (1/week) by using Dornier Aries 2 shockwave machine (energy level 7)
62581140|NCT04549389|ACTIVE_COMPARATOR|Group B|Patients will receive 6 Low-intensity shockwave therapy (LiST) sessions (2/week) by using Dornier Aries 2 shockwave machine (energy level 7)
62581141|NCT03612609|OTHER|blood, urine and semen sample|15 patients, with acute dengue virus infection and a positive RNA detection in blood or/and urines
62581142|NCT02307279|EXPERIMENTAL|Gelesis100|Gelesis100 twice daily
62581143|NCT02307279|PLACEBO_COMPARATOR|Placebo|Matching placebo twice daily
62581144|NCT05985044|EXPERIMENTAL|Intervention|A patient-centered Care cO-ORDInatioN And sympTom managEment (CO-ORDINATE) intervention
62405520|NCT03361566|EXPERIMENTAL|low energy flux at caloric restriction|physical activity: inactive energy intake: caloric restriction -25%
62405521|NCT03361566|EXPERIMENTAL|medium energy flux at caloric restriction|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: caloric restriction -25%
62206508|NCT02960243|EXPERIMENTAL|Right Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
62206509|NCT02960243|EXPERIMENTAL|Bilateral Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
62206510|NCT03814148|EXPERIMENTAL|LENINGRADO 5|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Leningrado 5 association and 1 tablet Natrilix® SR placebo."
62206511|NCT03814148|ACTIVE_COMPARATOR|Natrilix® SR|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Natrilix® SR 1,5 mg and 1 tablet Leningrado 5 association placebo."
62206512|NCT05323955|EXPERIMENTAL|Experimental Group|"Trastuzumab/pertuzumab + tucatinib or T-DM1 + tucatinib~300mg of tucatinib taken orally twice a day. Taken on Days 1-21 of a 21 Day cycle (3 Weeks).~Trastuzumab/Biosimilar administered per current package insert based on site standard of care guidelines~Pertuzumab or Biosimilar administered per current package insert based on site standard of care guidelines~Trastuzumab Emtansine (T-DM1) administered per current package insert based on site standard of care guidelines"
62206513|NCT04761367|OTHER|INTERVENTION GROUP|The IG will participate in a 6-month exercise program based on the PAIR exercise protocol and will receive educational sessions and material on the importance of maintaining an active life style after THR or TKR
62206514|NCT04761367|NO_INTERVENTION|CONTROL GROUP|The CG will receive only educational sessions and material on the importance of maintaining an active life style after THR or TKR
62206515|NCT05022537|EXPERIMENTAL|Treatment (retrograde nephrostomy)|
62405522|NCT03361566|EXPERIMENTAL|high energy flux at caloric restriction|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: caloric restriction -25%
62405523|NCT03361566|EXPERIMENTAL|low energy flux at overfeeding|physical activity: inactive energy intake: overfeeding +25%
62405524|NCT03361566|EXPERIMENTAL|medium energy flux at overfeeding|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: overfeeding +25%
62405525|NCT03361566|EXPERIMENTAL|high energy flux at overfeeding|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: overfeeding +25%
62405526|NCT05463978||Females/Males treated with Sculptra Aesthetic in non-facial areas|Sculptra Aesthetic administration in non-facial areas
62405527|NCT03359499|EXPERIMENTAL|Bacillus clausii|Bacillus clausii administered orally for two weeks plus standard dietary advice for non-constipated irritable bowel syndrome
62405528|NCT03359499|OTHER|Antispasmodic|Trimebutine administered orally for two weeks plus standard dietary advice for non-constipated irritable bowel syndrome
62405529|NCT03066011||Isavuconazonium sulfate Group|Oral and Intravenous
62405530|NCT03066011||Voriconazole Group|Oral and Intravenous
62405531|NCT03066011||Posaconazole Group|Oral and Intravenous
62016936|NCT05758025|NO_INTERVENTION|Traditional thyroidectomy method|
62016937|NCT04779957|EXPERIMENTAL|Tocilizumab|Evaluation of the use of Tocilizumab after allograft nephrectomy.
62016938|NCT06572371|EXPERIMENTAL|Laparoscopic pyeloplasty|Patients underwent laparoscopic pyeloplasty.
62016939|NCT06572371|ACTIVE_COMPARATOR|Open pyeloplasty|Patients underwent open pyeloplasty.
62405532|NCT06116799|EXPERIMENTAL|Carbon fiber insole|assigned carbon fiber insole
62405533|NCT06116799|ACTIVE_COMPARATOR|Polyurethane|Assigned polyurethane insole
62405534|NCT06116799|ACTIVE_COMPARATOR|Polyethylene|assigned polyethylene insole
62405535|NCT03182972|EXPERIMENTAL|Intervention arm|"Seminar presentation will be done using the followings:~1. Power point presentation on the following topics as it relates to medication reconciliation:~   1. Communication skill (with patients and also with other members of the healthcare team)~  2. Documentation of pharmaceutical care activities~  3. Medication history taking~  4. Drug therapy problems~  5. Medication reconciliation practice~2. Case studies on medication reconciliation~3. Role plays on medication reconciliation"
62405536|NCT03182972|NO_INTERVENTION|Control arm|Control group
62405537|NCT05577975|EXPERIMENTAL|Intervention Arm|The program will consist of three face-to-face (F-T-F) horticultural activity training session for a group of 6-8 participants and then biweekly telephone follow-up for 8-week home-based horticultural intervention.
62405538|NCT01685320|ACTIVE_COMPARATOR|Direct laryngoscope|Includes cases in which the forces applied by Macintosh direct laryngoscope onto soft tissue of the pharynx during glottis visualization and intubation were measured.
62405539|NCT01685320|ACTIVE_COMPARATOR|Indirect laryngoscope|Includes cases in which the forces applied by GlideScope indirect laryngoscope onto soft tissue of the pharynx during glottis visualization and intubation were measured.
62016940|NCT01418300|ACTIVE_COMPARATOR|sequential therapy|first five day amoxicillin+PPI later five day PPI+clarithromycin+metronidazole
62016941|NCT01418300|ACTIVE_COMPARATOR|conventional triple thearpy|PPI+amoxicillin+clarithromycin
62016942|NCT02193620|PLACEBO_COMPARATOR|Placebo group|Placebo soft capsules
62016943|NCT02193620|EXPERIMENTAL|Study group|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap
62016944|NCT06173154|EXPERIMENTAL|ID prevention unit|One healthcare unit will implement the healthcare system for the prevention of iatrogenic dependency (ID) and one healthcare unit will provide standard care without any specific system in place.
62016945|NCT06173154|SHAM_COMPARATOR|Control unit|One healthcare unit will implement the healthcare system for the prevention of iatrogenic dependency (ID) and one healthcare unit will provide standard care without any specific system in place.
62206516|NCT05022537|ACTIVE_COMPARATOR|Control Group ( antegrade nephrostomy)|
62206517|NCT04185038|EXPERIMENTAL|ARM A (Tumor Cavity Infusion)|Patients with non-DIPG supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity
62206518|NCT04185038|EXPERIMENTAL|ARM B (Ventricular System Infusion)|Patients with non-DIPG either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the ventricular system
62206519|NCT04185038|EXPERIMENTAL|ARM C (DIPG)|Patients with DIPG for whom CAR T cells will be delivered into the ventricular system
62206520|NCT06466720||Prospective|"Patients with brain metastases and meningiomas that are eligible for SRS treatment will be included in the prospective arm of the trial. The patients will have neurocognitive testing in the form of the Montreal Cognitive Assessment (MoCA) and will answer two Quality of Life questionnaires (QLQs) by EORTC QLQ-C30 and BN20). The baseline visit will happen before they start their SRS treatment.~The patients will be seen an additional 4 times, at 3, 6, 9 and 12 months after radiotherapy treatment. During each visit they will complete the MoCA and the QLQs.~During the first follow up appointment they will also be asked to think back to before they had the treatment and answer the QLQs based on that."
62206521|NCT06466720||Retrospective|Patients with meningiomas that have received SRS treatment more than a year ago will be included in the retrospective arm of the trial. The patients will have neurocognitive testing in the form of the Montreal Cognitive Assessment (MoCA) and will answer two Quality of Life questionnaires (QLQs) by EORTC QLQ-C30 and BN20) once. They will also be asked to think back to before they had the treatment and answer the QLQs based on that.
62206522|NCT01077453|EXPERIMENTAL|Arm I (2.5 mg letrozole)|Patients receive 2.5 mg of letrozole PO thrice weekly for 6 months.
62206523|NCT01077453|EXPERIMENTAL|Arm II (1.0 mg letrozole)|Patients receive 1.0 mg of letrozole PO thrice weekly for 6 months.
62206524|NCT01077453|EXPERIMENTAL|Arm III (0.25 mg letrozole)|Patients receive 0.25 mg of letrozole PO thrice weekly for 6 months.
62206525|NCT01077453|EXPERIMENTAL|Arm IV (2.5 mg letrozole)|Patients receive 2.5 mg of letrozole PO once daily for 6 months.
62405540|NCT01976104|EXPERIMENTAL|Group A (avatrombopag, lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
62405541|NCT01976104|PLACEBO_COMPARATOR|Group B (placebo, lower baseline platelet count)|placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5
62405542|NCT01976104|EXPERIMENTAL|Group C (avatrombopag, higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5
62581145|NCT02751931|EXPERIMENTAL|Children (3 to < 12 Years)|Participants aged 3 to \< 12 years received initial dose of 25 milligram (mg) of mirabegron orally once daily based on weight (pediatric equivalent dose of 25 mg (milligram) \[PED25\]) on day 1. At weeks 2, 4 or 8, participant's were up-titrated to the pediatric equivalent dose of 50 mg in adults \[PED50\], orally once daily based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 end-of-study (EOS) or end-of-treatment (EOT).
62581146|NCT02751931|EXPERIMENTAL|Adolescents (12 to < 18 Years)|Participants aged 12 to \< 18 years received initial dose of 25 mg of mirabegron orally once daily based on weight \[PED25\] on day 1. At weeks 2, 4 or 8, participant's were up-titrated to the pediatric equivalent dose of 50 mg in adults \[PED50\] orally once daily based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 EOS or EOT.
62581147|NCT03816501|OTHER|music|The preference of the patients will be listened to preoperatively through the headphones.
62581148|NCT03816501|OTHER|no music|preoperative music will not be listened
62581149|NCT05072249||lay person provided with take home naloxone|Naloxone all forms
62016946|NCT02192450|ACTIVE_COMPARATOR|Insulin glargine|"Each treatment arm last for 12 months - 3 months of run-in/cross-over and 9 months of maintenance.~Patients will be randomised (1:1) to treatment with basal-bolus therapy with insulin aspart/degludec or insulin aspart/glargine in random order.~After 12 months of treatment patients will cross-over to the other basal-bolus therapy.~Insulin degludec and insulin glargine is administered once daily at the evening meal and insulin aspart is administered three times daily before the main meals."
62581150|NCT06252493||Crohn Disease|Patients with confirmed/suspected Crohn's disease scheduled for operative management/surgical intervention
62581151|NCT05097690||Case|Case (Fatal Suicide)
62206526|NCT05735600|EXPERIMENTAL|Virtual|This group will participate in weekly virtual group sessions facilitated by a culturally similar and trained health educator (Promotora). The virtual modules will be on a platform such as Zoom and will last approximately 90 minutes each. Each module will last 60 minutes with the following three components: 1) 15-minute video on behavior change-related module objective, 2) 15-minute vignette/story depicting a family implementing behavior change, and 3) 15-minute discussion on creating goals and overcoming barriers for behavior change pertaining to the module. The remaining 15-minutes will ask participants to share what worked well towards achieving goals set in the prior module
62215393|NCT01739842|ACTIVE_COMPARATOR|Kudzu extract treatment|"Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session.~During the medication week, participants will take 2 capsules three times a day for a total dose of 3 grams of kudzu."
62405543|NCT01976104|PLACEBO_COMPARATOR|Group D (placebo, higher baseline platelet count)|placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
62405544|NCT05201898|PLACEBO_COMPARATOR|usual medical management|with regular doctor visits every 3 months
62405545|NCT05201898|EXPERIMENTAL|usual medical management+individual dietary consultation|with regular doctor visits every 3 months and dietitian visits every 3 months until meeting dietary recommendation or reaching 3 years limit
62405546|NCT05201898|EXPERIMENTAL|usual medical management+individual dietary consultation+ daily tea drinking|with regular doctor visits every 3 months, dietitian visits every 3 months until meeting dietary recommendation or reaching 3 years limit, and daily tea drinking
62581152|NCT05097690||Control|Control (Non-Fatal Suicidal Behavior)
62581153|NCT05905653|EXPERIMENTAL|STN1012600 0.002%|
62206527|NCT05735600|ACTIVE_COMPARATOR|Traditional|This group will get the same educational materials in writing (slides with information from video, written story, and instructions on goal setting and overcoming barriers) and receive a phone call from one of the researchers each week (5 weeks in a row) to provide an opportunity to respond questions, comments, and provide guidance about following the recommendations of the written material
62206528|NCT01227837|SHAM_COMPARATOR|placebo|use of placebo in control group
62206529|NCT01227837|EXPERIMENTAL|omega 3|use of omega 3 2 gr/day for 6 months
62206530|NCT05826470|EXPERIMENTAL|Laser Ablation|TRANBERG® Transperineal Micro Ultrasound guided laser ablation of Prostate Cancer.
62206531|NCT05253794|EXPERIMENTAL|Colchicine|Colchicine 0.6mg PO daily for 6 months
62206532|NCT05253794|PLACEBO_COMPARATOR|Placebo|Placebo tablet daily for 6 months
62206533|NCT02499939|ACTIVE_COMPARATOR|Standard Care|Participants in this group will receive standard education about CIPN and therapeutic exercises to carry out at home.
62206534|NCT02499939|EXPERIMENTAL|Experimental: Ultrasound Therapy|Participants in this group will receive standard education about CIPN and therapeutic exercises to carry out at home. Participants in this group will also undergo 10 daily treatments of ultrasound therapy (e.g., Monday to Friday for two weeks) that is administered to their toes and fingers. The ultrasound therapy will be administered over the first two weeks of the intervention period.
62206535|NCT00798590|EXPERIMENTAL|GLP-1|
62206536|NCT00798590|PLACEBO_COMPARATOR|Saline|
62206537|NCT05716893|EXPERIMENTAL|Adaptive Aerobic Training/AT Dosing|Participants with newly diagnosed primary breast cancer initiating chemotherapy.
62206538|NCT05716893|ACTIVE_COMPARATOR|Standard (fixed) Aerobic Training/AT dosing|Participants with newly diagnosed primary breast cancer initiating chemotherapy.
62206539|NCT04239677|ACTIVE_COMPARATOR|control|Conventional crystalloid solution-based priming
62206540|NCT04239677|EXPERIMENTAL|RAP|Retrograde autologous priming
62206541|NCT04417738|ACTIVE_COMPARATOR|Active|Patients will receive the active treatment.
62206542|NCT04417738|SHAM_COMPARATOR|Sham|Patients will receive the sham treatment (the identical LED covered by aluminum foil).
62581154|NCT06530576|EXPERIMENTAL|Thalidomide|All patients first receive thalidomide 100mg monotherapy.
62788657|NCT05499468|OTHER|Popular-Opinion Leader-led workshops & conversations to encourage utilization of support resources|Physicians identified by programwide Qualtrics survey item asking housestaff who in their program they respect and trust most, personally and professionally. Identified POLs were invited to join this health promotion effort as a POL to improve the culture of wellness and psychological safety among housestaff and encourage them to utilize resources at a time when they may benefit significantly. POLs were trained to endorse the benefits of mental health promotion coaching or therapy for residents training at Stanford.
62788658|NCT05499468|NO_INTERVENTION|Standard Training Program Curriculum and Access to Existing Support Resources|All residents and fellows continued to have the same access to coaching and psychotherapy resources available through Stanford WellConnect, along with other educational activities in their usual training.
62788659|NCT02978833|EXPERIMENTAL|PRP|
62206543|NCT05435482|EXPERIMENTAL|LHE-led|Participants will receive 1) LHE outreach/support (2 small group educational sessions via Zoom and 2 individual follow-up calls), 2) COVID-19 at-home antigen test kits, and 3) a written and a video guide to using a test kit
62206544|NCT05435482|ACTIVE_COMPARATOR|Instruction only|Participants will receive 1) COVID-19 at-home antigen test kits and 2) a written and a video guide to using a test kit
62206545|NCT05651867|EXPERIMENTAL|Interventional arm|Patients treated by percutaneous CT-guided procedures in the lung with the EPIONE® device
62206546|NCT06728540|EXPERIMENTAL|Children with Lower Urinary Tract Dysfunction (Study Group)|Children included in the study will be evaluated only once. The sociodemographic and clinical characteristics of the children participating in the study will be evaluated with the evaluation form, respiratory muscle strength with the RP Check brand electronic pressure measurement device, and body composition with the Tanita MC-580 brand bioelectrical impedance analyzer. Pelvic floor muscle functions of children with LUTD will be evaluated with the 632 Myomed biofeedback device. The survey questions and the evaluation form will be filled out by the parents.
62206547|NCT06728540|OTHER|Healthy Children (Control Group)|Children included in the study will be evaluated only once. The sociodemographic and clinical characteristics of the children participating in the study will be evaluated with the evaluation form, respiratory muscle strength with the RP Check brand electronic pressure measurement device, and body composition with the Tanita MC-580 brand bioelectrical impedance analyzer. Pelvic floor muscle functions of children with LUTD will be evaluated with the 632 Myomed biofeedback device. The survey questions and the evaluation form will be filled out by the parents.
62206548|NCT04893577|EXPERIMENTAL|Study Drug (EDTA Eye Drops)|Patients will treat herpes simplex eruption with EDTA eye drops.
62206549|NCT04893577|ACTIVE_COMPARATOR|Active Comparator (Abreva)|Patients will treat herpes simplex eruption with Abreva.
62206550|NCT02228902|ACTIVE_COMPARATOR|ferrous fumarate|12 patients receive ferrous fumarate, 12 patients receive ferrous gluconate
62206551|NCT02228902|ACTIVE_COMPARATOR|ferrous gluconate|12 patients receive ferrous fumarate and 12 patients receive ferrous gluconate
62215394|NCT01739842|PLACEBO_COMPARATOR|Placebo|"Placebo will be administered as a pretreatment 2 ½ hours before a drinking session.~During the medication week, participants will take 2 capsules three times a day."
62788660|NCT02978833|ACTIVE_COMPARATOR|Whole Blood|
62788661|NCT04631848||ULTRASCORE™ Focused Force PTA Balloon|
62788662|NCT00595478|EXPERIMENTAL|1|Motivational Enhancement Therapy (MET)/CBT+CM/BPT
62581155|NCT03038685|EXPERIMENTAL|prospective, multicenter cohort|A group of 175 patients will be recruited in 4 Belgian stroke centers during the six months period. All data will be collected prospectively and patients will be treated during six months period.
62016947|NCT02192450|EXPERIMENTAL|Insulin degludec|"Each treatment arm last for 12 months - 3 months of run-in/cross-over and 9 months of maintenance.~Patients will be randomised (1:1) to treatment with basal-bolus therapy with insulin aspart/degludec or insulin aspart/glargine in random order.~After 12 months of treatment patients will cross-over to the other basal-bolus therapy.~Insulin degludec and insulin glargine is administered once daily at the evening meal and insulin aspart is administered three times daily before the main meals."
62016948|NCT01144104|EXPERIMENTAL|Public Service Announcements|Demographically targeted public service announcement
62016949|NCT01144104|EXPERIMENTAL|Interactive Multi-Media Computer Program|Personally tailored information about seeking care for depression based on respondent characteristics
62581156|NCT03038685|NO_INTERVENTION|historical, single center cohort|A historical cohort of Sint-Janhospital (2011 - Bruges, Belgium) with prospectively collected data will be used as comparator for the experimental arm. These data were published in Vanacker P, Couvreur T, Vanhooren G. Can we improve cerebrovascular risk reduction in real-life? A single centre's experience. Cerebrovasc Dis 2011;31(suppl 2):289
62581157|NCT01639820|EXPERIMENTAL|Strategy A|Only identification of sentinel nodes (without pelvic lymph-node dissection)
62581158|NCT01639820|OTHER|Strategy B|Identification of sentinel nodes + full pelvic lymph-node dissection
62581159|NCT02526420|EXPERIMENTAL|Cohort A: Somavaratan in Older Adults|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects \>= 35 years of age
62581160|NCT02526420|EXPERIMENTAL|Cohort B: Somavaratan in Younger Adults|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects \< 35 years of age
62016950|NCT01144104|ACTIVE_COMPARATOR|Attention Control Video|Two-minute video focusing on common sleep disorders.
62016951|NCT01030224|EXPERIMENTAL|AZD9742 IV Infusion|Active
62581161|NCT02526420|EXPERIMENTAL|Cohort C: Somavaratan in Women on Estrogen|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in female subjects on oral estrogen (regardless of age)
62016952|NCT01030224|PLACEBO_COMPARATOR|Placebo to AZD9742 IV Infusion|Placebo
62016953|NCT01018849|ACTIVE_COMPARATOR|Vitamin D (cholecalciferol)|Subjects receive 150,000 IU of Vitamin D3 every 2 months
62581162|NCT05621733||ruxolitinib|Patients currently receiving or going to receive Jakavi® treatment according to locally approved label
62581163|NCT01421823|EXPERIMENTAL|alpha agonist ointment|
62581164|NCT01421823|PLACEBO_COMPARATOR|Placebo|
62581165|NCT01561703|EXPERIMENTAL|Anitibiotic|Patients will receive postoperative antibiotic after surgery.
62581166|NCT01561703|NO_INTERVENTION|Control|Patients will NOT receive postoperative antibiotic
62581167|NCT06683989|EXPERIMENTAL|Pilates training|The Pilates exercise program will be conducted for eight weeks, two days per week, with each session lasting 40 minutes.
62581168|NCT00926471|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT) Program|Participants will receive a treatment program involving CBT plus adjunctive group counseling and parent training.
62581169|NCT00926471|NO_INTERVENTION|Wait list control|Participants will be placed on a 12-week wait list with no active treatment
62016954|NCT01018849|PLACEBO_COMPARATOR|Placebo|Subject will receive a placebo - an exact replica of the Vitamin D3 capsule that does not contain the active ingredient, Vitamin D3
62016955|NCT06420635|EXPERIMENTAL|Interdisciplinary intervention program on maternal self-efficacy and motor development|Interdisciplinary intervention program on maternal self-efficacy and the motor development of premature children.
62016956|NCT06420635|ACTIVE_COMPARATOR|Traditional Kangaroo Program|The control group will receive the conventional family-centered care plan, including kangaroo position, exclusive breastfeeding, and monitoring of the child's progress.
62215395|NCT03828643||Cases|Cases received secukinumab at the dose 300 mg every 4 weeks from the beginning.
62581170|NCT04971200|EXPERIMENTAL|Vitiligo Patients on Tildrakizumab|
62581171|NCT04054063|EXPERIMENTAL|HSK3486+etomidate|Cohort 1: HSK3486 0.324 mg/kg + etomidate 0.15 mg/kg Cohort 2: HSK3486 0.216 mg/kg + etomidate 0.2 mg/kg Cohort 3: HSK3486 0.432 mg/kg + etomidate 0.1 mg/kg There were an additional 2 cohorts (Cohorts 4 and 5) planned for dose escalation once the optimal ratio of the drug combination was identified from the first 3 cohorts. However, these 2 cohorts were not done as the results of Cohorts 1 to 3 suggested that dose increases would cause higher occurrence of drug-related adverse events (AEs).
62206552|NCT04589650|EXPERIMENTAL|Adult cohort (group 1)- Alpelisib|During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive alpelisib (125 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
62206553|NCT04589650|PLACEBO_COMPARATOR|Adult cohort (group 1)- Placebo|During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive placebo (125 mg, oral, once daily). After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.
62206554|NCT04589650|EXPERIMENTAL|Pediatric cohort (group 2: 6 to 17 years old) -Alpelisib|During double-blind randomized study period (from baseline up to Week 16, pediatric participants (6 to 17 years old) will be randomized to receive alpelisib (50 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
62206555|NCT04589650|PLACEBO_COMPARATOR|Pediatric cohort (group 2: 6 to 17 years old)-Placebo|During double-blind randomized study period (from baseline up to Week 16), pediatric participants (6 to 17 years old) will be randomized to receive Placebo (50mg, oral, once daily). After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.
62206556|NCT04589650|EXPERIMENTAL|Pediatric cohort (group 3: 0 to 5 years old)- Alpelisib granules|Pediatric participants (0 to 5 years old) will receive alpelisib granules formulation with an age-dependent starting dose (\<1 month: 20 mg every other day; 1 to \<6 months: 20 mg daily; 6 to \<2 years: 40 mg daily; 2 to \<6 years: 50 mg daily).
62206557|NCT04589650|EXPERIMENTAL|Pediatric cohort (group 4: 2 to 5 years old)- Alpelisib FCT|Pediatric participants (2 to 5 years old) will receive 50 mg of alpelisib film-coated tablets (FCT) once daily in an open-label setting.
62405547|NCT04785846||Single Group|Adult patients with coronary artery disease undergoing percutaneous coronary intervention on vessels with a diameter less than or equal to 2.5 mm.
62405548|NCT03155269|EXPERIMENTAL|Group 1- Protein rich beverage powder fortified with MMN|Participants will be administered orally two doses of cereal based fortified beverage (30 grams powder made up in 200 milliliter (mL) water) daily in the morning and evening for 6 months.
62405549|NCT03155269|OTHER|Group 2 -Low protein non-fortified iso-caloric beverage powder|Participants will be administered orally two doses (in morning and evening) of low protein non fortified isocaloric beverage (30 grams powder made up in 200 mL water) daily for 6 months.
62581172|NCT05165628|EXPERIMENTAL|Group 1 - CYP-006TK|Participants will receive CYP-006TK dressings
62788663|NCT00595478|ACTIVE_COMPARATOR|2|Motivational Enhancement Therapy (MET)/CBT
62788664|NCT03858374|EXPERIMENTAL|Experimental group|Patients in experimental group were transferred by air-suspending mattress.
62016957|NCT04136106||Low-dose IL-2 group|Patients in this group were treated with low-dose IL-2 combined with corticosteroid and immunosuppressor, and low-dose IL-2 is defined as 100IU subcutaneously every other day for two weeks, followed by two-week break, as one treatment cycle, and at least three cycles.
62016958|NCT04136106||Non IL-2 group|Patients in this group were only treated with corticosteroid and immunosuppressor,
62206558|NCT04589650|EXPERIMENTAL|Pediatric cohort (group 5: 6-17 years old)-Alpelisib FCT|Pediatric participants (6 to 17 year old) will receive 125 mg alpelisib film-coated (FCT) once daily, in an open-label setting.
62206559|NCT04241107|ACTIVE_COMPARATOR|Laparoscopic approach group(A)|Uterine niche will be repaired through Laparoscopic approach.
62206560|NCT04241107|ACTIVE_COMPARATOR|Transvaginal approach group(B)|Uterine niche will be repaired through Transvaginal approach.
62206561|NCT05330988|EXPERIMENTAL|Real|Randomly selected participants will receive 20 min. of anodal transcranial direct current stimulation to the the top of their heads. The current will slowly be ramped up over 30 secs.
62206562|NCT05330988|SHAM_COMPARATOR|Sham|Randomly selected participants will receive 20 min. of sham transcranial direct current stimulation to the top of their heads. Sham stimulation is accomplished by turning on the device and slowly increasing and subsequently decreasing the amount of current to zero. This occurs over 30 secs.
62581173|NCT05165628|NO_INTERVENTION|Group 2 - Standard of Care|Participants will continue to be treated as per local standard of care
62581174|NCT03749967|EXPERIMENTAL|Dose 1|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62581175|NCT03749967|EXPERIMENTAL|Dose 2|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is ten sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62581176|NCT03749967|EXPERIMENTAL|Dose 3|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is fifteen sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62788665|NCT03858374|ACTIVE_COMPARATOR|control group 1|Patients in control group 1 were transferred by slide board.
62788666|NCT03858374|ACTIVE_COMPARATOR|control group 2|Patients in control group 2 were transferred by bedsheet.
62405550|NCT03405545|EXPERIMENTAL|HIIT|This group of subjects will perform High Intensity Interval training 3x/week for 12 weeks
62405551|NCT00833391|EXPERIMENTAL|GSK1838262 arm|Each subject will participate in five dosing sessions separated by at least seven days. Subjects will receive a single dose of current formulation of GSK1838262 or one of the four new formulations of GSK1838262 at each dosing session in random sequence.
62405552|NCT02401724|ACTIVE_COMPARATOR|Action Training|Training exercise which involves patients lifting up rods of different sizes and shifting their grip if this is too far to one side
62405553|NCT02401724|EXPERIMENTAL|tDCS|A constant 1mA current will be applied to the left (undamaged) side of the scalp with an electrode covered with a damp cotton pad (25 cm2). The current will be applied for 15 minutes per day, with a total of 10 sessions over 3 weeks.
62405554|NCT02401724|EXPERIMENTAL|Action Training + tDCs|This will involve the same procedure as in action training only but with tDCS applied for 15 minutes during the rodlifting.
62016959|NCT06337929|EXPERIMENTAL|CAPOEIRA GROUP|The training program will be conducted over 12 weeks with two weekly sessions. Each session will last 60 minutes and will be divided into three parts: 1) initial part: execution of stretches and low-intensity actions with specific movements of capoeira; 2) main part: realization of the training program the schedule present in Table 1 for the learning of attacks, dodges and acrobatic movements or flourishes and; 3) Final part: in a self-selected way in the capoeira roda, the participant will develop the previously learned movements.
62016960|NCT06337929|ACTIVE_COMPARATOR|CONTROL GROUP|The CONTROL GROUP will be conducted over 12 weeks with two weekly sessions. Each session will last 60 minutes and will be divided into three parts: 1) initial part: execution of stretches and low-intensity actions with specific movements of capoeira; 2) main part: continuation with execution of stretches and low-intensity actions with specific movements of capoeira and; 3) Final part: in a self-selected way in the capoeira roda, the participant will develop the previously learned movements.
62016961|NCT02805127||Patients with COPD and Asthma .|"Patients with COPD and Asthma. Continuous capnography and spirometry measurements of the subjects will be taken form the subjects with at least two minutes recording before the first spirometry assessment.~All clinical diagnoses and treatments will be performed according to the department's protocols.~This is an observational study with no interventions"
62405555|NCT02401724|PLACEBO_COMPARATOR|Control training|For the control training, patients will be asked to simply reach for the right hand side of each rod with their right (unaffected) hand and lift it
62581177|NCT03749967|EXPERIMENTAL|Dose 4|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is twenty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62016962|NCT02880852|EXPERIMENTAL|Belimumab 10 mg/kg|In this open label study, a single dose of 10 mg/kg Belimumab will be administered intravenously in Chinese subjects with systemic lupus erythematosus.
62016963|NCT06202885||T cell engager|
62016964|NCT06202885||Standard-of-care|
62016965|NCT02703844|ACTIVE_COMPARATOR|Active|Participants will be receiving an active Caloric Vestibular Stimulation treatment for a duration of 8 weeks, 7 days a week, twice daily for 19 minutes.
62206563|NCT03723018|EXPERIMENTAL|Meditation - Headspace|Participants in this arm will be asked to meditate daily for 10 minutes for 8 weeks. Meditation instruction will be provided by the commercially available app/website Headspace (provided to participants for free). Participants in this arm will have access to the other meditation arm once they finish the study.
62206564|NCT03723018|EXPERIMENTAL|Meditation - Respite|Participants in this arm will be asked to meditate daily for 10 minutes for 8 weeks. Meditation instruction will be provided by Respite, a website created by the investigators for this study. Participants in this arm will have access to the other meditation arm once they finish the study.
62206565|NCT03723018|NO_INTERVENTION|Observational|Participants in this arm will not receive any intervention. Their only study activity will be taking online surveys. They will have access to the two meditation arms once they finish the study.
62206566|NCT02982551|EXPERIMENTAL|Hyperinsulinemic Clamp|Participants will complete two MRI scans approximately one hour apart - one under baseline conditions and the second during an insulin infusion. Each scan will include data collected during rest, and a taste task. The taste task involves receiving milkshake or a tasteless solution. After the first scan, an isoglycemic-hyperinsulinemic clamp will be implemented. An IV will be placed in the antecubital vein of of arm for infusion of insulin and dextrose. HumuLIN®-R regular insulin will be infused at 40 mU/m2/min. A second IV will be inserted in the back of the hand on the opposite arm to allow for frequent sampling of blood glucose levels. Dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline value. The study team will monitor blood glucose levels and adjust dextrose infusions as necessary. Thirty minutes after starting the insulin infusion, participants will be moved back into the bore of the MRI scanner for the repeat scans.
62405556|NCT03572348|ACTIVE_COMPARATOR|Transecting anastomotic repair (tAR)|Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.
62405557|NCT03572348|ACTIVE_COMPARATOR|Vessel-sparing anastomotic repair (vsAR)|Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
62405558|NCT02874820|EXPERIMENTAL|Patient Group|Baseline PET scan followed by a blocked PET scan
62581178|NCT03749967|EXPERIMENTAL|Dose 5|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is twenty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62405559|NCT06538376|EXPERIMENTAL|Portable Dynamic Digital Radiography (DDR) + Clinical Gold Standard Imaging|"Dynamic digital radiography (DDR) is a new version of chest radiography from Konica Minolta (KM) that provides more advanced measures of lung motion, ventilation, and perfusion compared to traditional chest radiography. DDR scans are dynamic images that have a rate of 15 frames per second (for 7-20 seconds), acting as a mini-fluorography machine with radiation that is only slightly greater than a traditional chest x-ray.~Every patient will receive both a DDR scan and a gold standard scan. Each patient's DDR images will be compared to the golden standard that is completed as part of the patient's routine standard of care. For instance, for many ICU patients this includes traditional chest x-rays, ultrasounds or VQ scans."
62405560|NCT04739202|EXPERIMENTAL|Patients with tumors positive for EBV or microsatellite instable tumors (group 1)|Atezolizumab IV (1200 mg every 3 weeks) + Ipatasertib tablet (400 mg a day continuously).
62788667|NCT04118049|EXPERIMENTAL|Vaginal Probiotic Arm|"BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) is offered over the counter. It contains a total of 5 billion lactobacilli: L. crispatus, L. gasseri, L. jensenii, and L. rhamnosus.~RestoreTM gel: moisturizing personal lubricant.~We will recommend to participants to use the probiotic supplement and vaginal lubricant as a vaginal suppository three times weekly at night for 3 months."
62016966|NCT02703844|SHAM_COMPARATOR|Placebo|"Participants will be receiving a Sham Caloric Vestibular Stimulation treatment for a duration of 8 weeks in the same manner as the active arm: 7 days a week, twice daily for 19 minutes.~Individuals allocated to this arm will be later crossed over, in unblinded fashion, to the active arm if the treatment shows evidence of efficacy and safety."
62016967|NCT06119659|EXPERIMENTAL|KL001 injection solution|Subjects will be dosed with three different dose of KL001 injection solution at 2.5x10\^12 vg/kg to 1.0x10\^13 vg/kg.
62016968|NCT06572527|EXPERIMENTAL|Intervention|"Nurse-Led Coordinated Physical Activity Program for Child Health, consisting of nurse, teacher, and family components was implemented by the researcher two days a week for six weeks. The interventions were last an average of 60 minutes each week. During this time, the nurse implemented a program, developed based on expert opinion and various guidelines, that directed students to be more active. Teachers were expected to encourage students and actively participate in the program. Families were regularly informed through the family bulletin and it was ensured that the program started at school was continued at home."
62016969|NCT06572527|NO_INTERVENTION|Control|No intervention was applied to the control group except for the regular physical activities they perform in their school life.
62016970|NCT05378867|EXPERIMENTAL|TRS003.|"Lead in Treatment Period~* Will consist of 6 cycles of Bevacizumab® + mFOLFOX6~* Each cycle length is 14 days~After completion of the Lead-in Period, patients who have not progressed or experienced intolerable side effects and remain on study will be randomized 1:1 to either the Non-Switch or Switch Arm of the study.~Switch Arm~* TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 until end of treatment due to PD, intolerability or other cause for stopping treatment. Intensive PK sampling will be performed after 7 cycles of this TRS003 switch period (to occur during Cycle 14, adequate for washout of preceding Bevacizumab®)."
62016971|NCT05378867|ACTIVE_COMPARATOR|China-approved Bevacizumab|"Lead in Treatment Period~* Will consist of 6 cycles of Bevacizumab® + mFOLFOX6~* Each cycle length is 14 days After completion of the Lead-in Period, patients who have not progressed or experienced intolerable side effects and remain on study will be randomized 1:1 to either the Non-Switch or Switch Arm of the study.~Non-Switch Arm:~* Bevacizumab®, 5 mg/kg administered IV every 14 days~* mFOLFOX6 administered as described above every 14 days"
62405561|NCT04739202|EXPERIMENTAL|Patients with genomically stable tumors (group 2)|Atezolizumab IV (1200 mg every 3 weeks) + Bevacizumab IV (15 mg/kg every 3 weeks).
62405562|NCT04739202|EXPERIMENTAL|Patients with tumors with chromosomal instability (group 3)|Atezolizumab IV (1200 mg every 3 weeks) + Bevacizumab IV (15 mg/kg every 3 weeks).
62788668|NCT04118049|OTHER|Standard Care Arm|Women will perform standard care which includes follow up at 3 months for pessary removal/care.
62206567|NCT04638920||Exacerbators|Patients with COPD exacerbation
62206568|NCT04064398|ACTIVE_COMPARATOR|Routine aspiration of gastric residuals|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
62206569|NCT04064398|NO_INTERVENTION|No aspiration of gastric residuals|Infants will not have routine aspiration of gastric contents prior to each feeding.
62206570|NCT06723171|ACTIVE_COMPARATOR|Treatment|IRX4204
62206571|NCT06723171|PLACEBO_COMPARATOR|Placebo|Placebo
62405563|NCT02020356|EXPERIMENTAL|Music therapy|"U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase."
62405564|NCT02020356|PLACEBO_COMPARATOR|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
62405565|NCT05865002|EXPERIMENTAL|AUR107, 5mg to 200mg|Currently, planned dose levels are 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD, 90 mg QD, 135 mg QD, and 200 mg QD
62206572|NCT03488693|ACTIVE_COMPARATOR|No Regional Radiotherapy|A. Whole Breast Irradiation (WBI) following BCS or; B. No Radiotherapy (RT) following mastectomy
62405566|NCT05328999||Subfertile patients|Males and females between 18 and 50 years of age with subfertility presenting at the fertility center at the Medical University of Graz.
62581179|NCT03749967|EXPERIMENTAL|Dose 6|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is thirty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62788669|NCT04386642|EXPERIMENTAL|Experiment group|Each ampule contains TXA 250 mg. TXA preparation is 2000 mg dilute in normal saline 50 ml to get the concentration of 40 mg/ml. TXA will be administered 20 mg/kg loading over 20 min before skin incision followed by a maintenance infusion of 0.025 ml/kg/h (1 mg/kg/h) until the end of operation.
62788670|NCT04386642|PLACEBO_COMPARATOR|Control group|Normal saline solution 50 ml is prepared in a clear 50 ml syringe similar to the experiment group.
62788671|NCT04993443|EXPERIMENTAL|Active Comparator: Drug :LQ036|Experimental, Single and Multiple Oral escalating dose
62788672|NCT04993443|PLACEBO_COMPARATOR|Placebo Comparator: Matching Placebo for LQ036|Matching Placebo for LQ036: Matching Placebo
62016972|NCT05298605|EXPERIMENTAL|Faith in Action!|"A train-the-trainer approach will be used to educate lay health navigators to present the culturally adapted Faith in Action! curriculum and to provide breast cancer screening navigation to Korean American women within faith-based settings"
62206573|NCT03488693|ACTIVE_COMPARATOR|Regional Radiotherapy|A. WBI plus RT to the regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following BCS or; B. RT to the chestwall and regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following mastectomy
62405567|NCT05328999||Subfertile males with elevated DNA fragmentation index and asthenozoospermia|Males between 18 and 50 years of age with elevated DNA fragmentation index and asthenozoospermia presenting at the fertility center at the Medical University of Graz.
62405568|NCT00692601|EXPERIMENTAL|1|acute oral ingestion of 3 mg capsiate
62405569|NCT00692601|EXPERIMENTAL|2|acute oral ingestion of 10 mg capsiate
62788673|NCT04091880|EXPERIMENTAL|experimental group|378 subjects from the experimental group will be simultaneously administrated with one dose of EV71 vaccine (0.5 ml) and one dose of influenza vaccine (0.25 ml). One month later, they are going to receive a second dose of EV71 vaccine and influenza vaccine, simultaneously.
62788674|NCT04091880|ACTIVE_COMPARATOR|control group A|378 subjects from the control group A will be only administrated with two doses of EV71 vaccine (0.5 ml) (1 month apart).
62788675|NCT04091880|ACTIVE_COMPARATOR|control group B|378 subjects from the control group B will be only administrated with two doses of influenza vaccine (0.25 ml) (1 month apart).
62788676|NCT02451124|EXPERIMENTAL|Screening: non-endoscopic inflatable balloon for the esophagus|Patients undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus over 30-60 minutes followed by a standard esophagogastroduodenoscopy. Questionnaire administration will provide self-reported data on patient experiences. laboratory biomarker analysis of biopsy will confirm diagnosis.
62405570|NCT00692601|PLACEBO_COMPARATOR|3|acute oral ingestion of 0 mg capsiate ( same number of capsules as two other trials and identical looking placebo capsules)
62405571|NCT01065077|EXPERIMENTAL|Arm 1|
62405572|NCT01065077|EXPERIMENTAL|Arm 2|
62581180|NCT03749967|EXPERIMENTAL|Dose 7|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is thirty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62206574|NCT06260397|EXPERIMENTAL|serratus anterior plane block|while the patients in lateral position, serratus anterior plane block will be done using high frequency linear ultrasound probe at the level of fourth rib.30 ml of 0.25% bupivacaine will be injected.
62206575|NCT06260397|EXPERIMENTAL|costotransverse plane block|while the patients in lateral position, costotransverse block will be done using 22-gauge echogenic needle. the needle is advanced in-plane lateral to the spinous process of the 4th thoracic vertebra from caudally cephalad.30 ml of 0.25% bupivacaine will be injected
62206576|NCT06260397|EXPERIMENTAL|patient controlled analgesia|After successful extubation, patients will be transferred to PACU. Patients will receive a bolus dose of 5 mg nalbuphine then PCA pump in the form of 20 mg nalbuphine HCL in 100 ml 0.9% normal saline with basal rate of infusion 5ml/hr with self-administration bolus of 0.5ml with 15 min lock-out time.
62206577|NCT06714851|EXPERIMENTAL|Chondractiv Move|8-week supplementation (12 weeks in ancillary subgroup) with 4 capsules/day
62206578|NCT06714851|PLACEBO_COMPARATOR|Placebo|8-week supplementation (12 weeks in ancillary subgroup) with 4 capsules/day
62206579|NCT03974477|EXPERIMENTAL|Intervention|"The intervention will last for 8 weeks, an individual session of presentation of SALT CONTROL H will be carried out, with explanation of how the equipment works in the culinary preparation with an adequate salt content (will be used an illustrative video and recipes with an adequate salt content); use of SALT CONTROL H at home by the participant to control the use of salt during the cooking process; supervision and enhancement of the use of equipment; daily occurrence log; and the application of a satisfaction questionnaire on the use of SALT CONTROL H. A leaflet will also be delivered about The new Food Wheel, a guide to the daily food choice!."
62206580|NCT03974477|NO_INTERVENTION|Control|"No intervention will be carried out except the provision of a leaflet on The new Food Wheel, a guide to the daily food choice! to the participants."
62581181|NCT03749967|EXPERIMENTAL|Dose 8|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is forty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62788677|NCT03084601|ACTIVE_COMPARATOR|calcium hydroxide iodoform paste|intervention administered to control group is a combination of drugs as follow: ciprofloxacin 500mg, cefixime 500 mg, metronidazole 500 mg, simvastain 40mg. all are mixed, placed in pulp chamber only one time and tooth is restored
62788678|NCT03084601|EXPERIMENTAL|3-mixtatin|intervention administered to experimental group is a ready made mixture of calcium hydroxide and iodoform, placed in pulp chamber only one time and tooth is restored
62206581|NCT00830089|EXPERIMENTAL|TAP block|40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
62206582|NCT00830089|NO_INTERVENTION|Standard care|No TAP block is given. Care is otherwise identical to arm 1
62206583|NCT03625544|EXPERIMENTAL|MagnetOs™ Granules|MagnetOs™ Granules
62206584|NCT03625544|ACTIVE_COMPARATOR|Autograft|Autologous bone graft
62016973|NCT05298605|ACTIVE_COMPARATOR|Control|A presentation of lifestyle recommendations (e.g., physical activity, nutrition) will be provided to control groups.
62016974|NCT01358981|EXPERIMENTAL|LY2881835|"One cohort of healthy participants will receive single oral doses of LY2881835 in up to 3 of the 4 periods in Part A (dose escalation: 0.5 milligram (mg), 1.5 mg, subsequent doses determined based on review of safety, tolerability, glycaemic response and available pharmacokinetic (PK) data from the first 2 dose levels). One cohort of participants with Type 2 Diabetes Mellitus (T2DM) will receive single oral doses of LY2881835 in up to 2 of the 3 periods in Part B (dose escalation: starting dose based on review of safety, tolerability, glycaemic response and available PK data from Part A).~There is a washout period of at least 5 days between periods (doses)."
62016975|NCT01358981|PLACEBO_COMPARATOR|placebo|"One cohort of healthy participants will receive a single oral dose of placebo in 1 of the 4 periods in Part A. Another cohort of participants with T2DM will receive a single oral dose of placebo in 1 of the 3 periods in Part B.~There is a washout period of at least 5 days between periods (doses)."
62405573|NCT01065077|EXPERIMENTAL|Arm 3|
62405574|NCT01065077|PLACEBO_COMPARATOR|Arm 4|
62405575|NCT02029729|EXPERIMENTAL|RTA 408 Capsules|RTA 408 capsules, beginning dose 2.5 mg once daily, 28-day cycle, up to 12 cycles. Doses will increase by 100% of previous dose (e.g., 5 mg, 10 mg, 20 mg, etc.) until such time the Protocol Safety Review Committee decreases the escalation rate to 50% of the previous dose (e.g., 20 mg, 30 mg, 45 mg, etc). Dose escalation will continue until Maximum Tolerated Dose is identified.
62405576|NCT03733301|EXPERIMENTAL|4 Milligram (mg) Baricitinib|4 mg Baricitinib administered orally once daily in combination with topical corticosteroids (TCS). Placebo administered orally once daily to match 2 mg Baricitinib.
62405577|NCT03733301|EXPERIMENTAL|2 mg Baricitinib|2 mg Baricitinib administered orally once daily in combination with TCS. Placebo administered orally once daily to match 4 mg Baricitinib.
62405578|NCT03733301|PLACEBO_COMPARATOR|Placebo|Placebo administered orally once daily in combination with TCS.
62405579|NCT05749549|EXPERIMENTAL|BR1733|25-1200 mg QD or BID
62788679|NCT06409247|ACTIVE_COMPARATOR|Standard iExposure|"iExposure. Participants will complete four intervention sessions within two weeks. The intervention will use an entirely self-guided protocol delivered via Qualtrics and Gorilla Experiment Builder:~1. During the first session, participants will receive a brief standardized psychoeducation module, presented via a 15-minute video recording. This video will explain the intervention, its rationale, and the procedure.~2. Participants will then complete 10 simulated teleconferencing interaction trials with different topics, each lasting a maximum of two minutes. During each call participants will be prompted by one of the audience members to respond to a question (described in further detail in the Materials section, below).~3. Participants will complete the Subjective Units of Distress Scale before and after each speech trial.~4. Sessions 2-4 involve the same protocol and the four intervention sessions are completed within two weeks."
62206585|NCT00881062|EXPERIMENTAL|25 mg Proellex|25 mg (100 µCi) \[14C\]-Proellex
62206586|NCT05611112|NO_INTERVENTION|Control|Patients in the control group will have unrestricted access to care as usually provided. No restrictions are imposed on the general practitioners (GPs) regarding treatment of patients with mental health problems, as we are interested in assessing the added value of PST in routine clinical practice. In both groups, GPs are recommended to follow the current guidelines.
62405580|NCT02431507|EXPERIMENTAL|Treatment Arm with Magnetic Apnea Device|The treatment arm with magnetic apnea device includes: surgical implantation of the magnetic apnea device(MAGNAP) to treat obstructive sleep apnea in each eligible enrolled subject . A custom fitted external brace will be created for wear throughout the 13 months of treatment and evaluated for improvement of symptoms..
62405581|NCT04520633||control level stable|severe asthma for which the control level is stable (variation in ACT score \<3 between M0 and M6) contributing to the test-retest
62581182|NCT03749967|EXPERIMENTAL|Dose 9|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is forty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62788680|NCT06409247|EXPERIMENTAL|iExposure + Attention Guidance Augmentation|Attention Guidance Augmentation. The attention guidance condition consists of two unique components in addition to the standard iExposure intervention: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given a target audience member to focus their gaze on during each impromptu response. They will be told that they should look at and focus on the target audience member for the whole response. In each progressive session the number of trials where the participant is directed to focus on an uninterested audience member will increase.
62788681|NCT06409247|EXPERIMENTAL|iExposure + Attention Control Augmentation|The attention control condition consists of two unique components in addition to the standard iExposure intervention (1) the intervention rationale will include information about the importance of developing attention control; (2) participants will be given a central region of the screen (non-audience member) to focus on. They will be told that they should look at and focus on the central region for the whole response.
62788682|NCT06136013|EXPERIMENTAL|Morning HIIT 30-min following breakfast between 9:00 to 10:00 am.|The exercise prescription will be standardized according to body weight and based on physical activity guidelines to achieve a weekly target of 10 kcal/kg. The duration of the exercise sessions will be based on the weekly target for energy expenditure, considering weight and individual VO2peak and will be updated at the beginning of each intervention block.
62788683|NCT06136013|EXPERIMENTAL|Afternoon HIIT 30-min following lunch between 2:00 to 3:00 pm.|The exercise prescription will be standardized according to body weight and based on physical activity guidelines to achieve a weekly target of 10 kcal/kg. The duration of the exercise sessions will be based on the weekly target for energy expenditure, considering weight and individual VO2peak and will be updated at the beginning of each intervention block.
62788684|NCT06136013|EXPERIMENTAL|Evening HIIT 30-min following dinner between 7:00 to 8:00 pm.|The exercise prescription will be standardized according to body weight and based on physical activity guidelines to achieve a weekly target of 10 kcal/kg. The duration of the exercise sessions will be based on the weekly target for energy expenditure, considering weight and individual VO2peak and will be updated at the beginning of each intervention block.
62788685|NCT02322970||Intracranial Pressure monitoring|Invasive Intracranial Pressure monitoring will be compared to non invasive intracranial monitoring ( through use of transcranial Doppler ).
62788686|NCT01098175||Control group|open surgery with exposure of the surgical wound to the air.
62206587|NCT05611112|EXPERIMENTAL|Intervention|Patients with type 2 diabetes and/or chronic ischemic heart disease are offered up to seven problem solving therapy sessions within a three-month period from inclusion. In both groups, GPs are recommended to follow the current guidelines.
62788687|NCT01098175||Full peritoneal conditioning|Full peritoneum cavity conditioning will be performed as follows. A continuous flow of less than 0.5 l/min of gas will be instilled in the lowest part of the operating wound. As gas premixed bottles with CO2+ 4% of oxygen and 10% of N2O will be used. This gas will be humidified and at 31-32 °C to be achieved by a commercial humidifier (Fisher and Paykel) programmed in order to maintain 100% relative humidity at 31-32°C upon entrance of the peritoneal cavity.
62016976|NCT04679129|EXPERIMENTAL|Single Ascending Dose-ASC42|ASC42 tablet，Dose 1，Dose 2，Dose 3，Dose 4，and Dose 5, single dose administration
62215396|NCT03828643||Controls|Controls received secukinumab at the dose 300 mg with loading dose at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing.
62405582|NCT04520633||biologic initiation|introduction or modification of biotherapy at M0
62405583|NCT05354401|ACTIVE_COMPARATOR|Obese|Obese subjects ages 10-18 years with OSA will be recruited from sleep clinic. As per standard clinic care, once a subject is diagnosed with OSA on a PSG they are reviewed in sleep clinic to discuss CPAP therapy. Families will be approached to participate in this study during the subject's regularly scheduled clinical visit. Obese subjects meeting eligibility criteria will be recruited from the sleep clinic. The patients agreeing to CPAP therapy will be invited to take part in the study.
62581183|NCT03749967|EXPERIMENTAL|Dose 10|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is fifty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62788688|NCT06478563|EXPERIMENTAL|Phase A: NNC0487-0111 (formulation D)|Participants will receive once daily dose of six different dose levels (1-6) of NNC0487-0111 (formulation D) at increasing doses (the dose will be escalated every 3 weeks).
62016977|NCT04679129|EXPERIMENTAL|Multiple Ascending Dose-ASC42|ASC42 tablet, Dose 1，Dose 2，Dose 3，q.d.×14 days
62206588|NCT03127722|EXPERIMENTAL|ESSURE (BAY1454032)|Subjects selecting hysteroscopic sterilization who are not contraindicated for the Essure procedure according to the most current approved version of the Essure IFU. Subject willing to use alternative contraception for at least 3 months post-Essure placement procedure, until a satisfactory Essure Confirmation Test is documented.
62206589|NCT03127722|ACTIVE_COMPARATOR|Laparoscopic tubal sterilization|Subjects selecting laparoscopic sterilization who are not contraindicated for laparoscopic tubal sterilization according to common clinical practice standard of care
62206590|NCT01809834|ACTIVE_COMPARATOR|Etafilcon A|Each participant was randomized to wear the test lens in one eye and the control lens in the other simultaneously
62206591|NCT01809834|EXPERIMENTAL|Stenfilcon A|Each participant was randomized to wear the test lens in one eye and the control lens in the other simultaneously
62206592|NCT00378664|EXPERIMENTAL|Intervention|All enrollees are included in the intervention - lumbar to sacral ventral nerve re-routing procedure surgical nerve re-routing procedure.
62206593|NCT04045964|EXPERIMENTAL|Motivational advice and free NRT|
62206594|NCT04045964|ACTIVE_COMPARATOR|Quitline referral|
62206595|NCT06632457|EXPERIMENTAL|Survodutide|
62206596|NCT06632457|PLACEBO_COMPARATOR|Placebo|
62206597|NCT06317467||Women with physiological pregnancies|Control group
62206598|NCT06317467||Patients diagnosed for PE|hypertension arisen suddenly after the 20th week of pregnancy with associated proteinuria, greater than or equal to 300 mg/24 hours often corresponding to 30 mg/dL (1+) on a single sample
62206599|NCT06317467||Women affected by SLE, APS, or autoimmune thyroiditis|Patients attending the medically assisted procreation department or the Department of Rheumatology, Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia
62206600|NCT01925222||PCV-vaccinated infant, 3+1 schedule|
62206601|NCT01925222||PCV-vaccinated infant, 2+1 schedule|
62206602|NCT01925222||Control-vaccinated infant|
62788689|NCT06478563|ACTIVE_COMPARATOR|Phase A: NNC0487-0111 (formulation C)|Participants will receive once daily dose of six different dose levels (1-6) of NNC0487-0111 (formulation C) at increasing doses (the dose will be escalated every 3 weeks).
62016978|NCT04679129|PLACEBO_COMPARATOR|Single Ascending Dose-Placebo|Placebo tablet，Dose 1，Dose 2，Dose 3，Dose 4，and Dose 5, single dose administration
62206603|NCT01925222||PCV-vaccinated child, catch-up schedule|
62405584|NCT05354401|ACTIVE_COMPARATOR|CMC|As per current standard clinical care, CMC diagnosed with moderate to severe OSA following a clinically indicated baseline PSG who have had a previous adenotonsillectomy or who are not considered candidates for surgery are reviewed in sleep clinic to discuss the prescription of CPAP for OSA. CMC subjects' meeting eligibility criteria will be recruited from the sleep clinic. The patients agreeing to CPAP therapy will be invited to take part in this study.
62405585|NCT02288949||Prospective cohort|Stratification of patients admitted into a network of Spanish ICUs.
62405586|NCT02515175|EXPERIMENTAL|GEN-003 60ug / Matrix-M2 50ug|GEN-003/M2 (60 ug of each antigen) with Matrix-M2 adjuvant (50ug), administered as a 0.5mL intramuscular (IM) injection
62206604|NCT01925222||Control-vaccinated child, catch-up schedule|
62206605|NCT03517813||Cohort 1|"Asymptomatic women at increased risk of breast cancer referred clinically for high risk screening breast MRI or women with newly diagnosed primary unilateral breast cancer referred for evaluation of extent of disease (EOD) in the index breast and screening of the contralateral breast.~All women enrolled on study will complete a clinical breast MRI and research contrast enhanced mammogram. Abbreviated MRI images will be extracted from the standard breast MRI exam."
62405587|NCT02515175|EXPERIMENTAL|GEN-003 60ug / Matrix-M2 75ug|GEN-003/M2 (60 ug of each antigen) with Matrix-M2 adjuvant (75ug), administered as a 0.5mL intramuscular (IM) injection
62405588|NCT02515175|PLACEBO_COMPARATOR|Placebo|0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection
62206606|NCT03517813||Cohort 2|"Women receiving MRI for any indication and for whom percutaneous biopsy with ultrasound or MRI guidance has been recommended.~All women enrolled on study will complete a standard breast MRI and research contrast enhanced mammogram. Abbreviated MRI images will be extracted from the standard breast MRI exam."
62206607|NCT04237870|ACTIVE_COMPARATOR|Active treatment|Active cTBS treatment will be delivered at an intensity that is 70% of the resting motor threshold (RMT). cTBS consist of bursts of 3 magnetic pulses at 30 Hz repeating every 200 ms for 300 pulses. cTBS repeat twice with 15 min interval. Treatment will be applied in central suleus.
62206608|NCT04237870|SHAM_COMPARATOR|Sham treatment|Sham rTMS will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
62206609|NCT06481904||TZIELD group|Patients prior to the initiation of TZIELD treatment or initiated TZIELD treatment within 6 months to study enrollment
62206610|NCT06481904||Comparator group|Patients not planned to be treated
62405589|NCT03692767|EXPERIMENTAL|Anti-CD22 CAR NK cells|Total dose of 50-600 thousand /kg Anti-CD22 CAR NK cells will be administered at day0
62788690|NCT06478563|EXPERIMENTAL|Phase B: NNC0487-0111 (formulation D)|Participants will receive once daily dose of dose level 6 of NNC0487-0111 (formulation D).
62016979|NCT04679129|PLACEBO_COMPARATOR|Multiple Ascending Dose-Placebo|Placebo tablet，Dose 1，Dose 2，Dose 3，q.d.×14 days
62016980|NCT03357042|EXPERIMENTAL|Persistent post-concussive symptoms|Participants who report post-concussive symptoms. 20 participants will receive the aerobic exercise and balance training intervention, 20 participants will receive standard of care treatment for concussions.
62016981|NCT03357042|ACTIVE_COMPARATOR|Healthy control|Persons without post-concussive symptoms. No intervention.
62206611|NCT05923749|EXPERIMENTAL|Biatain Ag|
62206612|NCT05923749|ACTIVE_COMPARATOR|Cutimed Siltec Sorbact|
62405590|NCT06132711|EXPERIMENTAL|Patients treated with CAR T cells|Peripheral blood mononuclear cells were collected and subjected to CD3+T cells were enriched, transfected with APRIL-BAFF-Bicephali lentiviral vector, expanded by in vitro culture, and pretreated with clear lymphocytes using the FC protocol before infusion of APRIL-BAFF-Bicephali CAR-T cells.
62206613|NCT00085553|EXPERIMENTAL|Treatment (erlotinib hydrochloride, tipifarnib)|Patients receive erlotinib hydrochloride PO QD on days 1-28 (days 8-28 of course 1 as of 11/4/2013) and tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. (Closed to accrual as of 2/2/06)
62206614|NCT04750564|EXPERIMENTAL|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
62206615|NCT04750564|EXPERIMENTAL|EStim|EStim is transcutaneous electrical nerve stimulation.
62206616|NCT01370590|ACTIVE_COMPARATOR|Ezetimibe and atorvastatin|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including 10 mg ezetimibe, 20 mg atorvastatin, and placebo to ezetimibe/atorvastatin.
62206617|NCT01370590|EXPERIMENTAL|Ezetimibe/atorvastatin combination|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including ezetimibe/atorvastatin 10 mg/20 mg, placebo to ezetimibe, and placebo to atorvastatin.
62405591|NCT06641245|EXPERIMENTAL|5MTHF|5MTHF
62405592|NCT06641245|ACTIVE_COMPARATOR|Synthetic folic acid|Folic acid
62405593|NCT06450509|EXPERIMENTAL|Individual intervention|Individual families will meet weekly with a pediatric speech-language pathologist for approximately 20 minutes. The speech-language pathologist will coach parents in strategies designed to boost speech and language skills, individually tailored to the child's current skillset.
62405594|NCT06450509|ACTIVE_COMPARATOR|Group intervention|Caregivers will meet in monthly 1-hour group sessions with a pediatric speech-language pathologist. The speech-language pathologist will describe strategies that families can use at home to boost their child's speech and language skills.
62405595|NCT05329012||DUL treatment group|Patients with unstable ulna fractures will be operated and treated with the Distal Ulna locking plate (I.T.S. company) according to clinical routinal indication.
62788691|NCT06478563|ACTIVE_COMPARATOR|Phase B: NNC0487-0111 (formulation C)|Participants will receive once daily dose of dose level 6 of NNC0487-0111 (formulation C).
62788692|NCT01378325|EXPERIMENTAL|Phenylephrine|PHenylephrine infusion started at 0.75 microgram per kg per mL started at spinal injection till delivery
62788693|NCT01378325|PLACEBO_COMPARATOR|Saline|Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
62788694|NCT05144711|ACTIVE_COMPARATOR|Selective excavation|Cries will be removed from the peripheries of the cavity, while only soft caries will be removed from the plural side leaving stained leathery dentine that can not be removed by hand instruments. Biodentine will be placed and the cavity will be restored.
62788695|NCT05144711|ACTIVE_COMPARATOR|Non selective excavation|Caries will be cleaned form all cavity peripheries and floor. Biodentine will be placed and the toothy will be restored.
62788696|NCT03627208||1|Retrospective chart review of children and young adults with ALL/LBL enrolled on treatment protocols in the POB
62788697|NCT00897468||breast cancer patients|
62788698|NCT03424356|EXPERIMENTAL|lma with rocuronium bromide|In study group, 2-3 mg/kg propofol, 1mcg/kg fentanyl and 0.15 mg/kg rocuronium bromide will be administered during lma insertion in cystoscopy procedure.
62788699|NCT03424356|ACTIVE_COMPARATOR|lma with saline solution|In control group, 2-3 mg/kg propofol, 1 mcg/kg fentanyl and saline(no rocuronium) will be administered during lma insertion in cystoscopy procedure.
62788700|NCT01441323|NO_INTERVENTION|Control (C)|
62016982|NCT04944823||Patients with COVID 19 infection who develop bacterial coinfection.|Follow-up for 24 months
62016983|NCT04944823||Patients with COVID 19 infection who do not develop bacterial coinfection.|Follow-up for 24 months
62016984|NCT03540342|EXPERIMENTAL|One stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
62016985|NCT03540342|NO_INTERVENTION|Staging strategy group|PCI will be performed several days after EVAR
62016986|NCT06294314||Treatment|These patients receive the surgery and are followed for two years for outcomes.
62016987|NCT06294314||Control|These patients do not need and don't receive surgery and are followed for two years to compare to the surgery treatment group
62016988|NCT02921412|NO_INTERVENTION|enfilcon A (habitual)|All participants wear enfilcon A toric lens (habitual) and then refitted with fanfilcon A toric lenses.
62016989|NCT02921412|ACTIVE_COMPARATOR|fanfilcon A|All participants wear enfilcon A toric lens (habitual) and then refitted with fanfilcon A toric lenses.
62016990|NCT04188041|NO_INTERVENTION|Qualitative|"Specific Aim 1: Explore the specific knowledge, attitudinal, and skills gaps to TB infection testing and treatment among primary care team members in RI through qualitative key informant interviews.~In Aim 1, 25 primary care team members from the Brown Family Medicine and Care New England networks will be purposively sampled to undergo key informant interviews regarding TB infection testing and treatment knowledge, attitudinal, and skill gaps. Questions will be asked to ascertain gaps throughout the entire latent TB infection care cascade. The results from Aim 1 will be used to design the survey instrument and the curriculum for an innovative, telementoring program (TB infection ECHO)."
62206618|NCT01507987||Patients with SJM leads implanted|Patient has at least one market released Riata, Riata ST, QuickSite/QuickFlex, or Durata lead implanted
62206619|NCT06433557|EXPERIMENTAL|Combination of Navepegritide and Lonapegsomatropin|
62206620|NCT05557175|EXPERIMENTAL|Active rTMS group|
62206621|NCT05557175|SHAM_COMPARATOR|Sham rTMS group|
62206622|NCT01743391|NO_INTERVENTION|Control|Standard treatment
62206623|NCT01743391|EXPERIMENTAL|Intervention|Office-hysteroscopy with endometrial biopsy before standard treatment
62206624|NCT02974777|ACTIVE_COMPARATOR|Bleeding prevention group|Patients with reduction of standard dose DAPT due to low platelet reactivity to asprin and/or P2Y12 inhibitor
62206625|NCT02974777|ACTIVE_COMPARATOR|Ischemia prevention group|Patients with intensification of standard dose DAPT due to high platelet reactivity to asprin and/or P2Y12 inhibitor
62206626|NCT03152097|PLACEBO_COMPARATOR|Placebo|This crossover design will include 4 weeks of diindolylmethane and 4 weeks of matching placebo assignment.
62206627|NCT03152097|EXPERIMENTAL|Commercially available Diindolylmethane|This crossover design will include 4 weeks of diindolylmethane and 4 weeks of matching placebo assignment.
62206628|NCT05804370|EXPERIMENTAL|Patients Receiving Gleolan|All patients in this arm will receive Gleolan and undergo intraoperative imaging
62405596|NCT06459427|EXPERIMENTAL|Robot-Assisted Minimally Invasive Surgery group|Neurosurgeons participating in the robot-assisted stereotactic brainstem hematoma puncture must be frontline doctors with independent surgical qualifications and the ability to manage common complications. They must undergo standardized training and certification by the host institution. All preoperative imaging data and path planning involved in the surgery are automatically saved and uploaded by the AI system, which supports review and evaluation by each unit.
62405597|NCT06459427|ACTIVE_COMPARATOR|Conservative non-surgical group|"Perioperative management refers to the conventional medical treatment methods in the Chinese Neurosurgery Expert Consensus on the Diagnosis and Treatment of Primary Brain Stem Hemorrhage. During the medical treatment period, the patient's condition is dynamically assessed, and surgical interventions are promptly implemented in the event of exacerbation of conditions such as brain herniation."
62405598|NCT05066776||Patients with Pulmonary Nodule|Patients at high-risk of lung cancer found to have a pulmonary nodule 6-20 mm in size.
62405599|NCT02249065|EXPERIMENTAL|Mirvaso Gel|Brimonidine topical gel, 0.33%
62405600|NCT06474780||experiment|"Patients were informed about the study and patients who signed the informed consent form were included in the study. A pretest was applied to the patients. In the pre-test, data were collected using the Patient Information Form, Adaptation to Chronic Diseases Scale and Beck Anxiety Scale. Patients in the experimental group were shown videos of nature walks, forest walks and city tours of their choice for 15 minutes through virtual reality glasses 1 3 times in 21 days. At the end of the 3rd time, final tests were applied."
62405601|NCT06474780||control|"Patients were informed about the study and patients who signed the informed consent form were included in the study. A pretest was applied to the patients. In the pre-test, data were collected using the Patient Information Form, Adaptation to Chronic Diseases Scale and Beck Anxiety Scale. No application was made to the control group for 1.3 times in 21 days. Posttests were performed at the end of treatment for the third time."
62405602|NCT02005302|EXPERIMENTAL|Vitamin D2 Treatment|
62405603|NCT02005302|ACTIVE_COMPARATOR|1,25(OH)2 Vitamin D3|
62405604|NCT02005302|EXPERIMENTAL|low protein diet|
62405605|NCT02005302|ACTIVE_COMPARATOR|normal protein diet|
62405606|NCT02384980|NO_INTERVENTION|Walk Group|This group of patients are part of the walk group. They will be encouraged to walk and will receive standard care, defined as conservative (non-surgical) management of signs and symptoms, including prescriptive medications to improve circulation and manage pain, determined by their attending physician on a case by case basis.
62581184|NCT02794610|EXPERIMENTAL|Topical tacrolimus|Ten patients will be include. Topical tacrolimus 0.05% will be instilled into the eyes of patients 15 minutes before cataract surgery. Aqueous samples will be collected at the time of cataract surgery and will be subjected to detection of presence and level of tacrolimus.
62788701|NCT01441323|EXPERIMENTAL|Nutrition (N)|
62788702|NCT01441323|EXPERIMENTAL|Strength Training & Nutrition (ST)|
62788703|NCT04526041|OTHER|Professional beatboxer singer|1 professional beatboxer singer will be asked to produced different sounds while undergoing the different procedures. Researchers wil then select the most interesting sounds to be studied.
62788704|NCT04526041|OTHER|Experimented beatboxer singer|10 experimented beatboxer singer will be asked to reproduced the sounds record by the first subject (professional singer) while undergoing the different procedures.
62788705|NCT00192413|EXPERIMENTAL|Cold-adapted influenza vaccine trivalent (CAIV-T)|A single 0.2 mL dose of 10\^7 fluorescent focus units was administered intranasally.
62016991|NCT04188041|OTHER|Quantitative|Specific Aim 2: Design and evaluate an evidence-based telementoring intervention (ECHO model) that addresses the identified TB infection gaps in Aim 1, and evaluate this model for feasibility as well as its impact on primary care team member knowledge and TB infection testing and treatment in RI. 12 primary care team members will be recruited to participate in a virtual six-month TB infection ECHO course. Participants will be asked to complete quantitative surveys before and after the course as well as post-session surveys following each session. Survey questions will assess feasibility measures related to process, resources, and management and impact measures related to learning and performance. Paired data from pre- and post-course surveys will be analyzed accordingly depending on the distribution of results.
62016992|NCT04188041|OTHER|Retrospective chart review|Pilot a retrospective electronic medical record (EMR) data review to examine RI primary care providers' testing and treatment before and after ECHO implementation and evaluate the model's reach. In Aim 3, data will be retrospectively extracted from two participants' clinics to research RI primary care providers' testing and treatment patterns before and after the ECHO course. The two clinics will be identified once Aim 2 is completed.
62206629|NCT06244992|EXPERIMENTAL|PTT-936 Dose Level 1|PTT-936 will be administered every other day (QOD)
62206630|NCT06244992|EXPERIMENTAL|PTT-936 Dose Level 2|PTT-936 will be administered every other day (QOD)
62206631|NCT06244992|EXPERIMENTAL|PTT-936 Dose Level 3|PTT-936 will be administered every other day (QOD)
62206632|NCT06244992|EXPERIMENTAL|PTT-936 Dose Level 4|PTT-936 will be administered every other day (QOD)
62206633|NCT06244992|EXPERIMENTAL|PTT-936 Dose Level 5|PTT-936 will be administered every other day (QOD)
62206634|NCT06244992|EXPERIMENTAL|PTT-936 Dose Level 6|PTT-936 will be administered every other day (QOD)
62206635|NCT06244992|EXPERIMENTAL|PTT-936 Dose Level 7|PTT-936 will be administered every other day (QOD)
62581185|NCT05788367|ACTIVE_COMPARATOR|The pericapsular nerve group|patients received Ultrasound guided The pericapsular nerve group block using 20 ml of bupivacaine 0.5%
62788706|NCT00192413|ACTIVE_COMPARATOR|Trivalent Inactivated Vaccine (TIV)|A single dose was administered by intramuscular injection.
62788707|NCT05218642|EXPERIMENTAL|Arm A|KX-826: 2.5mg twice daily
62788708|NCT05218642|EXPERIMENTAL|Arm B|KX-826: 5mg once daily
62788709|NCT05218642|EXPERIMENTAL|Arm C|KX-826: 5mg twice daily
62788710|NCT05218642|EXPERIMENTAL|Arm D|Matching placebo to KX-826
62788711|NCT02608463|OTHER|Part A - Neuropathic Pain|Subjects with a score of ≥ 13 on the painDETECT Questionnaire (PDQ) will be assigned to the Neuropathic Pain group.
62788712|NCT02608463|OTHER|Part A - Non-Neuropathic Pain|Subjects with a score of ≥ 1 or ≤ 12 on the painDETECT Questionnaire (PDQ) will be assigned to the Non-Neuropathic Pain group.
62206636|NCT06244992|EXPERIMENTAL|PTT-936 Dose Level 8|PTT-936 will be administered every other day (QOD)
62206637|NCT06244992|EXPERIMENTAL|PTT-936 Dose Level 9|PTT-936 will be administered every other day (QOD)
62206638|NCT06244992|EXPERIMENTAL|PTT-936 and anti-PD-1/L1 combination therapy|PTT-936 to be administered every other day (QOD) in combination with a standard-of-care (SOC) regimen of an anti-PD-1/L1 agent every three weeks (Q3W)
62206639|NCT05100004|ACTIVE_COMPARATOR|Left Dorsolateral Prefrontal Cortex (L-DLPFC)|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (DLPFC)
62206640|NCT05100004|SHAM_COMPARATOR|Sham Stimulation|Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region
62206641|NCT01588964|EXPERIMENTAL|HIPEC|Surgery plus HIPEC
62206642|NCT01759524|EXPERIMENTAL|Group L|40 mls of 2% lidocaine + 1.5 mcg/kg will be drawn up by an attending anaesthetist to blind the operator. Patients in this group will receive an ultra sound guided sciatic nerve block , 3 cm proximal to the nerve bifurcation, with 25 mls of the above mentioned solution and an ultra sound guided saphenous nerve block in the midthigh just lateral to the profunda femoris artery with 15 mls of the above mentioned solution.
62206643|NCT01759524|ACTIVE_COMPARATOR|Group B|40 mls of 0.5% bupivacaine will be drawn up by an attending anaesthetist to blind the operator. Patients in this group will receive an ultra sound guided sciatic nerve block , 3 cm proximal to the nerve bifurcation, with 25 mls of the above mentioned solution and an ultra sound guided saphenous nerve block in the midthigh just lateral to the profunda femoris artery with 15 mls of the above mentioned solution.
62206644|NCT05050240|EXPERIMENTAL|Cold Exposure|The cold vest procedure: The first blood draw will be taken from participants before the cooling procedure (time 0, 30mL blood). Participants will then be requested to put on hospital scrubs and the cooling vest will be placed on them. Since muscle shivering is an alternative way of heat production (skeletal thermogenesis), we will first determine individual 'shivering threshold' for each participant (coldest tolerable temperature; typically 14°C / 57.2F), based on participant-report and direct observation. The cold vest will then be kept on for 3 hours with a temp set to the coldest tolerable temperature (shivering threshold +2°C (\~16-17°C / 60.8F-62.6F) and body temperature will be monitored by a tympanic thermometer. Following 3 hours, 30mL of blood will be drawn (Time 180min). All participants will be re-warmed with blankets after cooling has been completed, and offered a warm drink and a snack.
62206645|NCT05050240|ACTIVE_COMPARATOR|Fasted procedure without cooling|"This arm has been added in order to exclude the effects of prolonged fasting on blood analytes. Previously enrolled participants will be re-invited to donate blood after 12hr fast and 3hrs later (15hr fast) without the cooling procedure. Participants will be re-consented for this lab appointment. The night prior the visit, the participants will be instructed to fast from 10:00pm. At the time of visit vital signs and anthropomorphic measurements will be taken.~Blood Draw: The first blood draw will take place in the morning. Participant will then be asked to sit in the procedure room for 3 hours at room temperature; second blood draw will take place after 3 hrs. Total of 38ml of blood will be drawn. Blood will be used for clinical labs (fasting glucose, Hba1c, TSH, TG) and research."
62206646|NCT06052137|ACTIVE_COMPARATOR|Active TBS-DLPFC|The active group will receive theta-burst TMS DLPFC stimulation.
62206647|NCT06052137|ACTIVE_COMPARATOR|Active TBS-DMPFC|The active group will receive theta-burst TMS DMPFC stimulation.
62206648|NCT02544477|EXPERIMENTAL|High-flow nasal cannula oxygen (HFNCO)|Patients will receive HFNCO treatment with a gas flow level = 50 L/min and a FiO2 set to maintain peripheral oxygen saturation (SpO2) of 92% - 98%.
62206649|NCT02544477|ACTIVE_COMPARATOR|standard oxygen therapy|Patients will receive oxygen treatment by means of a conventional face mask, with a level of fraction of inspired oxygen (FiO2) set to maintain peripheral oxygen saturation (SpO2) of 92% - 98%.
62016993|NCT05506982|EXPERIMENTAL|Supportive care (psilocybin, observation)|Patients receive psilocybin PO and undergo observation for up to 24 hours on day 14.
62788713|NCT02608463|OTHER|Part A - Control|Subjects with a score of score = 0 on the painDETECT Questionnaire (PDQ) will be assigned to the Control group.
62788714|NCT02608463|EXPERIMENTAL|Part B - rTMS|Subjects from the Neuropathic Pain group will be invited to participate in the Part B rTMS group to receive repetitive transcranial magnetic stimulation (rTMS).
62206650|NCT05047718|EXPERIMENTAL|convalescent participants PFIZER|Participants with prior history of COVID-19 in ≥3 months, virologically confirmed and vaccinated by anti-covid19 Pfizer vaccine
62206651|NCT05047718|EXPERIMENTAL|Naive participants PFIZER|Participant without past history of COVID-19 and vaccinated by anti-covid19 Pfizer vaccine
62788715|NCT00358436|EXPERIMENTAL|Aclidinium 200 μg once-daily|Aclidinium bromide 200 μg once-daily by inhalation
62788716|NCT00358436|PLACEBO_COMPARATOR|Placebo|Placebo by inhalation
62788717|NCT00465842||A - Normal Volunteers|"Normal volunteers without any history of liver disease and with normal liver functions test (LFT), including total protein/Albumin, LDH, ALT, AST, GGT, total bilirubin, direct and indirect bilirubin and do not belong to group B.~Volunteers will be screened using questionnaires. Those deemed suitable will then be asked to have the blood test done. All blood tests are done free of charge to subjects."
62788718|NCT00465842||B - Hepatitis B or C carriers with normal liver functions|
62788719|NCT00465842||C - Hepatitis B or C carriers with abnormal liver functions|
62788720|NCT00465842||D - Liver Cirrhosis|Liver cirrhosis, proven by liver biopsy or on clinical evidences, such as varices on CT scan indicative of portal hypertension.
62206652|NCT05047718|EXPERIMENTAL|convalescent participants MODERNA|Participants with prior history of COVID-19 in ≥3 months, virologically confirmed and vaccinated by anti-covid19 Moderna vaccine
62206653|NCT05047718|EXPERIMENTAL|Naive participants MODERNA|Participant without past history of COVID-19 and vaccinated by anti-covid19 Moderna vaccine
62581186|NCT05788367|ACTIVE_COMPARATOR|Interscalene group|patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5% before induction of general anesthesia.
62581187|NCT01470963|EXPERIMENTAL|Referral template|Implementation of the referral templates at the GP office
62581188|NCT01470963|NO_INTERVENTION|Control|Normal referral pattern
62788721|NCT00465842||E - Hepatocellular Carcinoma (HCC) with Resection|HCC patients with resection.
62206654|NCT05047718|EXPERIMENTAL|Boost only|Participant without past history of COVID-19 and vaccinated by anti-covid19 mRNA vaccine.
62206655|NCT03387137|EXPERIMENTAL|Group 1: RSV 6120/∆NS2/1030s Vaccine|RSV-seropositive children will receive a single dose of 10\^5.7 plaque-forming units (PFUs) of RSV 6120/∆NS2/1030s vaccine at study entry (Day 0).
62788722|NCT00465842||F - Unresectable HCC|Unresectable HCC patients with treatment
62581189|NCT06319170|EXPERIMENTAL|Olanzapine Group A|Single-dose injection
62016994|NCT02157740||Control group before telemedicine|Residents of nursing homes without telemedicine before implementation of telemedicine in nursing homes with telemedicine
62016995|NCT02157740||Control group after telemedicine|Residents of nursing homes without telemedicine after implementation of telemedicine in nursing homes with telemedicine
62206656|NCT03387137|PLACEBO_COMPARATOR|Group 1: Placebo|RSV-seropositive children will receive a single dose of placebo at study entry (Day 0).
62206657|NCT03387137|EXPERIMENTAL|Group 2: RSV 6120/∆NS2/1030s Vaccine|RSV-seronegative infants and children will receive a single dose of 10\^5.0 PFUs of RSV 6120/∆NS2/1030s vaccine at study entry (Day 0).
62206658|NCT03387137|PLACEBO_COMPARATOR|Group 2: Placebo|RSV-seronegative infants and children will receive a single dose of placebo at study entry (Day 0).
62206659|NCT03829475|EXPERIMENTAL|FMT + Bezlo|Patients in this arm will received an FMT via colonoscopy ( 250ml) as well as a single IV infusion of bezlotoxumab (10mg/kg) that will take place over 60 mins.
62206660|NCT03829475|PLACEBO_COMPARATOR|FMT + Placebo|Patients in this arm will receive a single FMT via colonoscopy (250ml) and a placebo (saline) infusion (250cc) over
62581190|NCT06319170|EXPERIMENTAL|Olanzapine Group B|Single-dose injection
62581191|NCT06319170|EXPERIMENTAL|Olanzapine Group C|Single-dose injection
62215397|NCT04120636|EXPERIMENTAL|Phase I open label study|"Drug: Episcleral Celecoxib~Other Names:~* Sequestered, Transscleral, Controlled-Release Celecoxib~* Sustained Release Transscleral Celecoxib"
62581192|NCT03995628|EXPERIMENTAL|Steroid Group|Participants will receive a one-time dose of oral dexamethasone at 0.5 mg/kg on the third post-operative day
62581193|NCT03995628|PLACEBO_COMPARATOR|No Steroid Group|Participants will receive placebo on third post-operative day
62788723|NCT00465842||G - Malignant HCC|HCC patients with active malignant disease and only palliative care are offered.
62788724|NCT03067389||History of invasive breast cancer|Subjects with a diagnosis of invasive breast cancer within the past 12 months will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.
62788725|NCT03067389||No history of invasive breast cancer|Subjects with no history of breast cancer will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.
62788726|NCT00748423|EXPERIMENTAL|1|Nitric Oxide in nitrogen
62788727|NCT00748423|PLACEBO_COMPARATOR|2|Nitrogen
62788728|NCT02150447|ACTIVE_COMPARATOR|Intervention group|Proton pump inhibitor (lansoprazole) therapy for the prevention of gastric cancer bleeding
62405607|NCT02384980|EXPERIMENTAL|FES + Walk Group|This group of patients will participate in Functional Electrical Stimulation (FES) and exercise. This group will receive functional electrical stimulation as an intervention. The FES device will stimulate (activate) the calf and shin leg muscles of both legs while the patient is walking. This group will also receive standard care, defined as conservative (non-surgical) management of signs and symptoms, including prescriptive medications to improve circulation and manage pain, determined by their attending physician on a case by case basis.
62206661|NCT01099475|EXPERIMENTAL|Pringle manoeuvre 15 minutes|When intermittent pedicle occlusion during parenchymal transection is necessary, 2 cycles of 15 minutes of hepatic inflow occlusion will be applied each followed by 5 minutes of reperfusion. During inflow occlusion, the complete portal triad was clamped using a rubber sling.
62206662|NCT01099475|EXPERIMENTAL|Pringle manoeuvre 30 minutes|When intermittent pedicle occlusion during parenchymal transection is necessary, 1 cycle of 30 minutes of hepatic inflow occlusion will be applied followed by 5 minutes of reperfusion. During inflow occlusion, the complete portal triad was clamped using a rubber sling.
62206663|NCT02317887|EXPERIMENTAL|Group 1|1e9 vg/eye
62206664|NCT02317887|EXPERIMENTAL|Group 2|1e10 vg/eye
62405608|NCT04939337|EXPERIMENTAL|TH-SC01|TH-SC01 24 mL suspension of 120 million cells as a perilesional injection, once on Day 0.
62581194|NCT05930587|EXPERIMENTAL|Cold water immersion|"The experimental group will be informed about the lower extremity cold immersion bath during the outpatient clinic controls and will be given a liquid meter digital thermometer that will allow them to check the cold water temperature at home. Patients will then be asked to do the lower extremity cold water immersion bath every day in their own home, for a total of four weeks, lasting 20 minutes in the evening before going to sleep.~It is recommended that the cold dip bath last for 20 minutes and the temperature of the water should be 15 0C for it to be effective on the symptoms.~At the end of four weeks, patients will be informed that they should come to the outpatient clinic again. When the patients come to the outpatient clinic, information about the application will be repeated and data collection forms will be applied by face-to-face interview method."
62581195|NCT05930587|NO_INTERVENTION|Control|No intervention will be made to the control group, only the data will be collected at the same time as the study group.
62581196|NCT03290261|EXPERIMENTAL|Patients with reccurent cystitis|Patient perform 3 hypnosis sessions
62581197|NCT01455532|EXPERIMENTAL|Iniparib, single agent|Iniparib will be initially administered intravenously once weekly (days 1, 8, and 15) for 3 weeks, in a 21-day cycle. Then, iniparib will be administered twice weekly (days 1, 4, 8, 11, 15, and 18) in a 21-day cycle. Cycle1 (day 1 thru day 21) will be defined as the dose limiting toxicities (DLT) observation period. Starting dose is 15 mg/kg once weekly.
62581198|NCT01455532|EXPERIMENTAL|Iniparib/Gemcitibine/Carboplatin|Gemcitabine/carboplatin (GC) : Gemcitabine will be administered at 1,000 mg/m² as a 30min IV infusion and carboplatin area under the curve (AUC) 2 as a 60min IV infusion. Patients will receive gemcitabine/carboplatin infusions once weekly (days 1 and 8). Iniparib will be administered for two weeks, followed by a 1week of rest in a 21-day cycle (weekly schedule: days 1 and 8; twice weekly schedule: days: 1, 4, 8 and 11).
62581199|NCT01455532|EXPERIMENTAL|Iniparib/Paclitaxel|Paclitaxel (P): Paclitaxel will be administered at the dose of 80 mg/m2 as a 60-minute intravenous infusion administered on days 1, 8, and 15 followed by a 1week of rest. Iniparib will be administered for three weeks, followed by 1week of rest in a 28-day cycle (weekly schedule: days 1, 8 and 15; twice weekly schedule: days 1, 4, 8, 11, 15 and 18).
62206665|NCT02317887|EXPERIMENTAL|Group 3|1e11 vg/eye
62206666|NCT02317887|EXPERIMENTAL|Group 4|1e11 vg/eye
62206667|NCT02317887|EXPERIMENTAL|Group 5|Not to exceed 3e11 vg/eye
62206668|NCT02317887|EXPERIMENTAL|Group 6|Not to exceed 6e11 vg/eye
62206669|NCT05470491|EXPERIMENTAL|1/Recipient Arm 1|RIC+alloHCT+GVHD prophylaxis per dose levels 1, 2, and
62206670|NCT05470491|EXPERIMENTAL|2/Recipient Arm 2|RIC+alloHCT+GVHD prophylaxis per RP2D
62206671|NCT05470491|NO_INTERVENTION|3/Donor Arm|Collection of research samples on hematopoietic donors
62405609|NCT04908696||TLM treatment for LC and PHC patients with early stage|TLM group: Laryngeal carcinoma (LC) (supraglottic type and glottic type) and hypopharyngeal carcinoma (HPC) (pyriform sinus and posterior pharyngeal wall) patients with T1 and T2 stages can be treated with transoral laser microsurgery (CO2 laser resection) for proper indications (NCCN 2020).
62016996|NCT02157740||Exposed group, before telemedicine|Residents of nursing homes with telemedicine prior implementation of telemedicine
62206672|NCT04910139|EXPERIMENTAL|Treatment|Treatment using acoustic energy
62215398|NCT03432260|EXPERIMENTAL|Part A (Moderate AH) DUR-928 30 mg|Lowest dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
62405610|NCT04908696||OPL treatment for LC and PHC patients with T1, T2, and T3 stages|OPL group: Open partial laryngectomy with laryngeal function preservation is performed for patients with laryngeal carcinoma (LC) (supraglottic type, glottic type, and subglottic type) and hypopharyngeal carcinoma (PHC) (pyriform sinus, postcricoid, and posterior pharyngeal wall) with proper indications (NCCN 2020).
62405611|NCT04908696||R treatment for LC and PHC patients with early stage|R group: radiotherapy is treated for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with early stage with proper indications (NCCN 2020).
62405612|NCT04908696||TORS treatment for LC and PHC patients with early stage|TORS group: transoral robotic surgery is performed for proper laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with early stage with proper indications.
62206673|NCT04020055|EXPERIMENTAL|Cohort 1: Severe Renal Impairment|All subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat) at a dose regimen based on their eGFRMDRD result at Visit 1. Subjects will take 1 migalastat capsule orally with water either every 4 or 7 days.
62405613|NCT04908696||SPA treatment for LC and PHC patients with advanced stage|SPA group: surgical treatment (S) ± postoperative adjuvant (PA) therapy is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
62405614|NCT04908696||CCR treatment for LC and PHC patients with advanced stage|CCR group: concurrent chemoradiotherapy (CCR) is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
62581200|NCT01455532|EXPERIMENTAL|Iniparib/Pegylated liposomal doxorubicin/Carboplatin|Pegylated liposomal doxorubicin (Doxil)/Carboplatin (PLD) : Doxil will be administered at 30 mg/m² as a 30min IV infusion and carboplatin AUC 4 as a 60min IV infusion on day 1 every four weeks. Iniparib will be administered for two weeks in a 28-day cycle (weekly schedule: days 1, and 8; twice weekly schedule: days 1, 4, 8, and 11).
62016997|NCT02157740||Exposed group, after telemedicine|Residents of nursing homes with telemedicine after implementation of telemedicine
62405615|NCT04908696||ARC treatment for LC and PHC patients with advanced stage|ARC group: neoadjuvant therapy (A) + radiotherapy/chemoradiotherapy (RC) is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
62405616|NCT04908696||ASRC treatment for LC and PHC patients with advanced stage|ASRC group: neoadjuvant therapy (A) + surgery (S) + radiotherapy (R) or chemoradiotherapy (C) is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
62405617|NCT02900508|EXPERIMENTAL|Exergaming training|Participants in the exergaming training group received a 4-week exergaming intervention.
62581201|NCT02982603|EXPERIMENTAL|Qinggongshoutao Bolus|Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761 .Qinggongshoutao bolus 70 pills every time (7g), 2 times per day and placebo identified to Ginkgo Biloba Extract 761, 2 pills per time, 2 times per day for 48 weeks.
62581202|NCT02982603|ACTIVE_COMPARATOR|Ginkgo Biloba Extract 761|Ginkgo Biloba Extract 761 and placebo identified to Qinggongshoutao bolus.The subjects will take Ginkgo Biloba Extract 761 2 times per day, 2 pills per time(80mg) ,and identified to Qinggongshoutao bolus 70 pills every time, 2 times per day for 48 weeks.
62581203|NCT02982603|PLACEBO_COMPARATOR|Placebos|Placebo identified to Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761.Placebo identified to Qinggongshoutao bolus 70 pills every time, 2 times per day and placebo identified to Ginkgo Biloba Extract 761, 2 pills per time, 2 times per day for 48 weeks.
62581204|NCT01661101|EXPERIMENTAL|Dabigatran|Dabigatran 110 mg capsule taken twice daily
62581205|NCT01661101|EXPERIMENTAL|Omeprazole|Omeprazole 20 mg capsule taken once daily
62581206|NCT01661101|PLACEBO_COMPARATOR|Placebo (dabigatran)|Dabigatran placebo taken twice daily
62581207|NCT01661101|PLACEBO_COMPARATOR|Placebo (omeprazole)|Omeprazole placebo taken once daily
62016998|NCT02889081||infants from birth cohort with AD|maternal biological folate level and maternal biological vitamin D level and offspring's incidence of suffering from atopic dermatitis
62016999|NCT02889081||infants from birth cohort without AD|maternal biological folate level and maternal biological vitamin D level and offspring's incidence of not suffering from atopic dermatitis
62206674|NCT04020055|EXPERIMENTAL|Cohort 2: End-Stage Renal Disease|All hemodialysis subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat). Subjects will take 1 migalastat capsule orally with water every other week.
62206675|NCT03787459|ACTIVE_COMPARATOR|oseltamivir plus placebo|
62206676|NCT03787459|EXPERIMENTAL|oseltamivir plus arbidol|
62206677|NCT00259402|EXPERIMENTAL|Oxaliplatin|
62206678|NCT01482689|EXPERIMENTAL|Fish oil capsule|
62206679|NCT01482689|EXPERIMENTAL|Multivitamin tablet|
62215399|NCT03432260|EXPERIMENTAL|Part A (Moderate AH) DUR-928 90 mg|Middle dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
62405618|NCT02900508|ACTIVE_COMPARATOR|Control training|Participants in the control training group received a 4-week conventional training.
62405619|NCT01103908||Pediatric cardiac output (CO) after CPB|Cardiac output measurements made in pediatric patients after cardiopulmonary bypass.
62405620|NCT02616458|EXPERIMENTAL|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours. The research assistant provided and reviewed proper dosing instructions for acetaminophen and ibuprofen, and provided a prescription for antipyrine/benzocaine analgesic ear drops to each family to use as pain relief if their child did develop ear pain in the subsequent 12 months.
62788729|NCT02150447|PLACEBO_COMPARATOR|Placebo group|Placebo for the prevention of gastric cancer bleeding
62405621|NCT02616458|ACTIVE_COMPARATOR|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
62788730|NCT01193114|EXPERIMENTAL|Ecologically-Based Behavioral Treatment|Ecologically-Based Treatment was provided over a period of 6 months. The treatment integrated independent housing, case management services and substance abuse counseling. Specifically, the mothers were housed in an apartment of their choice and received three months of utility and rental assistance of up to $600 per month.
62788731|NCT01193114|ACTIVE_COMPARATOR|Treatment as Usual|The Mothers were offered services provided through the family shelter.
62788732|NCT04967027|EXPERIMENTAL|TTFields group|patients with brain metastases who have been resistant to drug or radiation therapy, to be treated by continuous TTFields treatment using the ASCLU-300 TTF device.
62788733|NCT00513435|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO or by PEG tube QD on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
62788734|NCT04888169|EXPERIMENTAL|Attention Bias Modification - Word Stimuli|Attention bias modification training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threat word and one neutral word) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ABM condition, the probe replaces the neutral stimulus 100% of the time.
62788735|NCT04888169|ACTIVE_COMPARATOR|Attention Bias Modification - Face Stimuli|Attention bias modification training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threatening face and one neutral face) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ABM condition, the probe replaces the neutral stimulus 100% of the time.
62788736|NCT04888169|EXPERIMENTAL|Attention Control Training - Word Stimuli|Attention control training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (i.e. one threat word and one neutral word) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ACT condition, the probe replaces the neutral stimulus 50% of the time, and replaces the threat stimulus the other 50%.
62788737|NCT04888169|ACTIVE_COMPARATOR|Attention Control Training - Face Stimuli|Attention control training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threatening face and one neutral face) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ACT condition, the probe replaces the neutral stimulus 50% of the time, and replaces the threat stimulus the other 50%.
62206680|NCT04255199|EXPERIMENTAL|Intervention|Primary care and urgent care clinicians randomized to the intervention arm will receive two to three visits with a standardized patient instructor who will physicians how to facilitate patient acceptance of a watchful waiting strategy with regard to spinal imaging in the context of acute low back pain.
62206681|NCT04255199|PLACEBO_COMPARATOR|Control|Primary care and urgent care clinicians randomized to the control arm will receive a single visit with a standardized patient who simulates a visit with patient with acute low back pain but will deliver no instruction on patient communication or other content.
62206682|NCT02296736||Pancreatic malignancy|All patients who have undergone surgery for presumed pancreatic malignancy in Derriford Hospital between Jan 2006 and Jan 14 and had a Computerised tomography (CT) scan.
62581208|NCT01344824|OTHER|Single Arm Trial|Bevacizumab, Carboplatin, and Pemetrexed disodium, with option for second line erlotinib hydrochloride
62581209|NCT04315974||Nonvalvular atrial fibrillation patients (NVAF)|Eligible patients comprise men and women aged 18 years or older with nonvalvular atrial fibrillation diagnosis undergoing ablation procedure.
62581210|NCT03593824|EXPERIMENTAL|dense cataract group|
62206683|NCT02284217|EXPERIMENTAL|Patients with invasive ICP monitor (EVD)|Hospitalized patients who have already been implanted with an invasive ICP monitor. Eligible patients will be enrolled into the study and HS-1000 headset portion of the device will be placed in their ears.
62215400|NCT03432260|EXPERIMENTAL|Part A (Moderate AH) DUR-928 150 mg|Highest dose of dose escalation arms: 30mg, 90 mg and 150 mg
62215401|NCT03432260|EXPERIMENTAL|Part B (Severe AH) DUR-928 30 mg|Lowest dose of dose escalation arms: 30mg, 90 mg and 150 mg
62581211|NCT03593824|EXPERIMENTAL|non-dense nuclear cataract group|
62788738|NCT04888169|PLACEBO_COMPARATOR|Placebo Attention Training - Word Stimuli|Placebo attention training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (two neutral words) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen.
62788739|NCT04888169|PLACEBO_COMPARATOR|Placebo Attention Training - Face Stimuli|Placebo attention training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (two neutral faces) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen.
62788740|NCT04888169|SHAM_COMPARATOR|Control - Questions|The Control - Questions condition will only deliver a set of daily questions for participants to answer. Questions will ask about a variety of psychological factors such as mood, stress experiences, daily exercise and more.
62788741|NCT01443702|PLACEBO_COMPARATOR|Placebo|
62788742|NCT01443702|ACTIVE_COMPARATOR|Lapis judaicus|
62788743|NCT05984602|EXPERIMENTAL|Quadruplet regimen prior to resection for pancreatic cancer|Treatment of Canakinumab and Tislelizumab in Combination with Nab-Paclitaxel and Gemcitabine up to 4 cycles (4 months)
62788744|NCT02069119|EXPERIMENTAL|OPC-108459|OPC-108459 solution will be intravenously administered by 30-minute infusion in the forearm.
62788745|NCT02069119|PLACEBO_COMPARATOR|Placebo|placebo solution will be intravenously administered by 30-minute infusion in the forearm.
62788746|NCT01425125|EXPERIMENTAL|Tolvaptan in euvolemic hyponatremia|This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
62788747|NCT00320515|EXPERIMENTAL|A|
62788748|NCT05004220||Group 1|Group 1 consists of first time donors undergoing all 8 tracked plasmaphereses.
62206684|NCT06395818|EXPERIMENTAL|prefabricated CAD-CAM allogeneic bone block hydrated using hyaluronic acid|mucoperiosteal flap will be elevated to expose the atrophic ridge then the prefabricated CAD-CAM allogenic block will be fixed in its position with titanium miniscrews , The block was coated with a nonporous d-PTFE membrane
62788749|NCT05004220||Group 2|Group 2 consists of first time donors undergoing only last 4 plasmaphereses, serving as control for the first 4 donations.
62788750|NCT03450382|EXPERIMENTAL|Hans Kai Participant|Participants receiving Hans Kai intervention
62206685|NCT06395818|EXPERIMENTAL|prefabricated CAD-CAM allogeneic bone block sterilized hydrated using saline solution|mucoperiosteal flap will be elevated to expose the atrophic ridge then the prefabricated CAD-CAM allogenic block will be fixed in its position with titanium miniscrews ,The block was coated with a nonporous d-PTFE membrane
62405622|NCT00957840|OTHER|Omaya reservoir group- observational|These infants have been identified with severe enough post hemorrhagic ventricular dilation (PHVD) that they require a reservoir placed for serial cerebro-spinal fluid (CSF) removal. There is no randomization, and infants are compared to a baseline. Observational data will be collected to include NIRS and aEEg which will be done twice weekly, and CSF will be analyzed with each reservoir tap for protein biomarkers.
62405623|NCT04865536|ACTIVE_COMPARATOR|Cohort 1 TBI-223 1800 mg, fasting|1800 mg, fasting
62788751|NCT03450382|NO_INTERVENTION|Control|Participants not enrolled in Hans Kai
62788752|NCT06267534|EXPERIMENTAL|mindfulness-based mobile applications program|mindfulness-based mobile applications program. There are five audio files, listen to one audio file for two days.
62788753|NCT06267534|NO_INTERVENTION|NO intervention|The control group received no intervention, Scale exam was performed before and after the program in both groups at the same time.
62788754|NCT06415227|EXPERIMENTAL|Vericiguat (2.5 mg, 5 mg and 10 mg) first; placebo second|Treatment with Vericiguat will be uptitrated every two weeks to the highest tolerated dose, with a target maintenance dose of maximum 10 mg once daily. After a washout period of 2 weeks, matching placebo will be started and is uptitrated every two weeks to maintain double blinding.
62788755|NCT06415227|PLACEBO_COMPARATOR|Placebo first; Vericiguat (2.5 mg, 5 mg and 10 mg) second|Matching placebo is uptitrated every two weeks to maintain double blinding. After a washout period of 2 weeks, treatment with Vericiguat will be started and is uptitrated every two weeks to the highest tolerated dose, with a target maintenance dose of maximum 10 mg once daily.
62788756|NCT05109923|EXPERIMENTAL|New Mood Supplementation|The New Mood herbal supplement includes lemon balm, 5-HPT, L-Tryptophan and valerian root.
62788757|NCT05109923|PLACEBO_COMPARATOR|Placebo Supplementation|The placebo includes rice bran and maltodextrin.
62788758|NCT02776059|EXPERIMENTAL|prednisolone or pentoxifylline + pegfiltrastim|prednisolone or pentoxifylline for 28 days PO plus pegfilgrastim subcutaneous weekly shot
62788759|NCT02776059|ACTIVE_COMPARATOR|prednisolone or pentoxifylline|prednisolone or pentoxifylline for 28 days
62788760|NCT04085497|EXPERIMENTAL|Treatment|KT was applied once a week, 6 times in total. Exercises were performed for all patients for 5 weeks 5 days a week, 3 sets 15 repetitions each day.
62788761|NCT04085497|PLACEBO_COMPARATOR|Group 2|The exercise program included quadriceps set exercise, straight leg lifting, mini squat, stretching to hamstring and gastrosoleus muscle groups.
62788762|NCT03036020|EXPERIMENTAL|Contraindication anesthesiologists|Ability of anesthesiologists to detect contraindications to thrombolysis in acute stroke patients prehospital by interpretation of prehospital cerebral CT scans
62206686|NCT02223559||right heart catheterization patients|
62405624|NCT04865536|ACTIVE_COMPARATOR|Cohort 1 TBI-23 1800, fed|TBI-23 1800, fed
62405625|NCT04865536|PLACEBO_COMPARATOR|Cohort 1 Placebo, fed|Placebo, fed
62405626|NCT04865536|PLACEBO_COMPARATOR|Cohort 1 Placebo fasting|Placebo fasting
62405627|NCT04865536|ACTIVE_COMPARATOR|Cohort 2 TBI-223, 2400mg,fed|2400mg,fed
62206687|NCT05526469|ACTIVE_COMPARATOR|Group serratus anterior plane (SAP)|patients will receive ultrasound guided single shot serratus anterior plane block with 0.5 ml/kg bupivacaine 0.25%
62405628|NCT04865536|ACTIVE_COMPARATOR|Cohort 2 TBI-223, 2400 mg fasting|2400 mg fasting
62788763|NCT03833466|EXPERIMENTAL|metformin and chemotherapy|
62788764|NCT05271812||Mothers|All women delivered in the recruitment center
62788765|NCT05271812||Staff|All staff working in the labor and delivery areas of the recruiting center.
62788766|NCT02689115||Clinical activity|Patients with rheumatoid arthritis who met the criteria established by the American College of RheumatologyDisease Activity Score 28 (DAS28) \> 3.6.
62017000|NCT01057212|EXPERIMENTAL|Bevacizumab and Ixabepilone|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks. Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule to the remaining 40 patients.
62206688|NCT05526469|ACTIVE_COMPARATOR|Group erector spinae plane (ESP)|patients will receive ultrasound guided single shot erector spinae plane block with 0.5 ml/kg bupivacaine 0.25%
62581212|NCT05383040|EXPERIMENTAL|percutaneous release|Percutaneous release of A1 pulley release will be performed in the well-managed operation theater set up, using an 18 gauge hypodermic needle, after preparation of the skin and injection of 1ml 2% plain lidocaine. The proper location of the pulley will be defined using surface landmarks in each digit after waiting a few minutes to allow the anesthetic to take effect the 18 gauge needle will be longitudinally moved to keep the level of the needle parallel with the tendon grating sensation will be elucidated confirming the cut of pulley until there is no grating sensation felt and improvement of symptoms. A sterile dressing will be placed.
62788767|NCT02689115||Clinical remission|Patients with rheumatoid arthritis with Disease Activity Score 28 (DAS28) \< 2.4.
62206689|NCT06607627|EXPERIMENTAL|Gefurulimab|On Day 1, participants will receive a weight based loading dose followed by a weekly maintenance dose for up to 122 weeks.
62788768|NCT02978196|EXPERIMENTAL|Injection of 99mTc-NM-01|All patients with NSCLC who have undergone biopsy of primary tumour lesion will be administered 3-12 MBq/kg of 99mTc-NM-01 in a single injection.
62206690|NCT00841217|PLACEBO_COMPARATOR|1|placebo group
62206691|NCT00841217|ACTIVE_COMPARATOR|2|GW501516, 2.5mg
62206692|NCT03787836|NO_INTERVENTION|Controls|The primary purpose of the control participants are to provide a measure of variability. They will be used in our calculations of typical error to classify participants as responders or non-responders, and to quantify inter-individual variability.
62788769|NCT02978196|EXPERIMENTAL|Injection of 68Ga-NM-01|All patients with NSCLC who have undergone biopsy of primary tumour lesion will be administered 0.75- 4 MBq/kg of 68Ga-NM-01 in a single injection.
62788770|NCT01067144|PLACEBO_COMPARATOR|Control|Active placebo given pre-operatively, followed by inactive placebo for 10 doses post-operatively
62788771|NCT01067144|EXPERIMENTAL|Gabapentin|1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.
62788772|NCT02428569|NO_INTERVENTION|Usual Care|Participants randomized to this arm of the study will receive usual care from their physician.
62206693|NCT03787836|EXPERIMENTAL|Exercisers (Maintained)|The maintained exercise group will complete the original 16-week exercise intervention at an intensity of 4.5 metabolic equivalents (METs), and repeat the intervention for another 12-weeks following its completion.
62206694|NCT03787836|EXPERIMENTAL|Exercisers (Increased Intensity)|The increased intensity exercise group will complete the original 16-week exercise intervention, followed by an additional 12 week intervention completed at an intensity of 6.0 METs.
62206695|NCT03550391|EXPERIMENTAL|Hippocampal-avoidant (HA-WBRT) plus Memantine|WBRT 30Gy in 10 fractions + memantine
62206696|NCT03550391|EXPERIMENTAL|Stereotactic Radiosurgery (SRS)|SRS 18-20 or 22Gy in single fraction
62206697|NCT06430476|ACTIVE_COMPARATOR|EMA|Ecological momentary assessment (EMA) arm: participants will receive three ecological momentary assessment (EMA) prompts daily within three time blocks spread out throughout the day. Within each prompt, participants will answer 14 questions regarding affect, suicidality, and rumination. Afterwards, they will be shown a video clip extracted from a popular and longstanding soap opera in Chinese that lasts between three to four minutes. Each prompt would take around 8 minutes to complete. In total, participants will complete 70 EMA prompts during the intervention period.
62215402|NCT03432260|EXPERIMENTAL|Part B (Severe AH) DUR-928 90 mg|Middle dose of dose escalation arms: 30mg, 90 mg and 150 mg
62215403|NCT03432260|EXPERIMENTAL|Part B (Severe AH) DUR-928 150 mg|Highest dose of dose escalation arms: 30mg, 90 mg and 150 mg
62405629|NCT04865536|PLACEBO_COMPARATOR|Cohort 2 Placebo, fed|Placebo, fed
62405630|NCT04865536|PLACEBO_COMPARATOR|Cohort 2 Placebo, fasting|Placebo, fasting
62405631|NCT04865536|ACTIVE_COMPARATOR|Cohort 3 3000mg, fed|3000mg, fed
62405632|NCT04865536|PLACEBO_COMPARATOR|Cohort 3 placebo, fed|placebo, fed
62405633|NCT05732103|EXPERIMENTAL|Dose Escalation Cohort|Drug: CTX-712 administered at 20 mg, 40 mg, 80 mg, 100 mg, 140 mg weekly
62405634|NCT05732103|EXPERIMENTAL|Dose Expansion Cohort|Drug: CTX-712 administered at a dose to be determined from the data of dose escalation cohort
62405635|NCT05732103|EXPERIMENTAL|Phase 2|CTX-712 administered at the recommended dose by the expansion cohort
62405636|NCT00735748|EXPERIMENTAL|1|Tramadol per os (Tradonal Odis® orodispersible tablets)
62405637|NCT00735748|ACTIVE_COMPARATOR|2|Tramadol IV (Tradonal® IV)
62405638|NCT04714710|EXPERIMENTAL|Potassium canrenoate|Potassium canrenoate 200mg diluted in SODIUM CHLORIDE SOLUTION 0.9%
62017001|NCT05309512|EXPERIMENTAL|KN052 single drug group|The 8 dose groups in the dose increasing period were intravenous administration of 0.01mg/kg, 0.1mg/kg, 0.3mg/kg, 1mg/kg, 2mg/kg, 4mg/kg, 6mg/kg and 9mg/kg every two weeks, respectively. Based on the selected maximum tolerated dose of Q2W and in combination with the pharmacokinetic model, the sponsor would consider adding 1-2 Q3W treatment groups, with 6-12 patients in each dose group for DLT observation to explore the optimal dose regimen. The queue extension period is dose RP2D; Give it intravenously every two weeks or three weeks.
62206698|NCT06430476|EXPERIMENTAL|EMI|EMI arm: participants in this arm will receive two ecological momentary assessment (EMA) prompts and one econological momentary intervention (EMI) prompt daily. The EMA prompts would be identical to the ones in the EMA arm without the video clip at the end. The EMI prompt would contain an interactive task designed to counter ruminative thoughts. Examples of the interactive tasks include: mindfulness exercises (mindful walking), cognitive reappriasal, strengths recognition, etc. Each EMI prompt would last around 3-5 minutes.
62206699|NCT06729203|EXPERIMENTAL|Group A|this group receive ultrasound cavitation on abdominal muscles
62206700|NCT06729203|ACTIVE_COMPARATOR|Group B|received aerobic exercises and low caloric diet treatment.
62206701|NCT00159939|ACTIVE_COMPARATOR|prone position|prone positioning
62206702|NCT00159939|NO_INTERVENTION|supine position|
62206703|NCT05735171|ACTIVE_COMPARATOR|Conventional gross total resection surgery|Retrospective cohort of patients who underwent conventional surgery between 2018 and 2021. Confirmed gross total resection (removal of 100 % of contrast-enhancing tumor).
62206704|NCT05735171|EXPERIMENTAL|AI-guided resection|Tailored supramarginal surgery guided by AI-based recurrence probability maps. Aim of supramarginal resection, where the high-risk of recurrence areas identified by the AI-based model are subsidiary to be removed as safe locations for the patient.
62206705|NCT06715878|EXPERIMENTAL|Zero Ischemia suture-less group|Patients with T1 Stage renal cell carcinoma undergoing Zero Ischemia, Robot-Assisted Microwave Ablation assisted suture-less tumor Enucleation.
62206706|NCT06715878|ACTIVE_COMPARATOR|robotic-assisted partial nephrectomy group|Patients with T1 stage Renal Cell Carcinoma undergoing traditional robotic-assisted partial nephrectomy.
62206707|NCT03950752|EXPERIMENTAL|Bagels with optimized composition in fatty acids|Participants will consume three bagels with an optimized composition in fatty acids and without oil palm in only one day.
62206708|NCT03950752|ACTIVE_COMPARATOR|Bagels with conventional composition in fatty acids|Participants will consume three bagels with a conventional composition in fatty acids in only one day.
62206709|NCT03541200|EXPERIMENTAL|Open Label|MT-8554
62206710|NCT00589121|EXPERIMENTAL|Cohort A - Chemotherapy|Radiation therapy with neoadjuvant or adjuvant or concurrent or interdigitated chemotherapy followed by surgery followed by, for patients with positive margins, radiation therapy boost
62206711|NCT00589121|EXPERIMENTAL|Cohort B - No Chemotherapy|Radiation therapy followed by surgery followed by, for patients with positive margins, radiation therapy boost
62206712|NCT02766777|EXPERIMENTAL|Lubiprostone|Participants received lubiprostone twice daily (BID). Participants received either lubiprostone 12 mcg BID, lubiprostone 24 mcg BID (dose based on participant's weight) up to 24 weeks.
62206713|NCT06359041|EXPERIMENTAL|CABA-201|AChR Antibody-Positive Cohort AChR Antibody-Negative Cohort
62206714|NCT05113368|EXPERIMENTAL|Oral Regorafenib combined with intra-muscular injection of Fulvestrant|Oral regorafenib in a ReDOS plan (80 mg week#1, 120 mg week#2, 160 mg week#3 for cycle #1 then adjust final dose for subsequent cycles based on tolerance during cycle #1) \[3 weeks on/1 week off\] combined with intramuscular injection of fulvestrant 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
62206715|NCT06727643|OTHER|elastic tape group|Participants in this group will have their core muscles taped with flexible tape.
62581213|NCT05383040|NO_INTERVENTION|Steroid injection|The steroid injection mixed with 1 ml of methyl prednisone (40mg) with 0.5 ml of 2% plain lidocaine will be inserted into the flexor tendon sheath over the A1 pulley, which will also be performed in the operation theater for patient safety.
62017002|NCT06531330||1|Pediatric physiotherapists working in Turkey
62017003|NCT00591812|EXPERIMENTAL|1 - ComPreSs system|
62017004|NCT01528098||PEG plus bisacodyl|Those who taken PEG 4L + bisacodyl 10mg
62017005|NCT01528098||PEG 4L|Those who taken PEG 4L alone
62017006|NCT01170780|PLACEBO_COMPARATOR|Placebo|Saline
62017007|NCT01170780|ACTIVE_COMPARATOR|Dexamethasone|Corticosteroid (Fortecontin 8 mg)
62017008|NCT02277626|EXPERIMENTAL|Randomized Crossover to ElectroFlo|Experimental: ElectroFlo 5000, then VEST Patients are randomized to a sequence of ElectroFlo 5000 on one visit and during the second visit, they cross-over to the Vest system.
62206716|NCT06727643|ACTIVE_COMPARATOR|rigid tape group|Participants in this group will have their core muscles taped with rigid tape.
62206717|NCT06269705|EXPERIMENTAL|ZILRETTA|100 subjects will receive 32 mg ZILRETTA
62206718|NCT06269705|ACTIVE_COMPARATOR|TCA-IR|100 subjects will receive 40 mg TCA-IR
62206719|NCT06269705|PLACEBO_COMPARATOR|Placebo|50 subjects will receive normal saline placebo
62206720|NCT00299494|EXPERIMENTAL|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (FOLLICULAR)|Follicular
62206721|NCT00299494|EXPERIMENTAL|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (DLBCL)|Diffuse Large B-cell Lymphoma
62206722|NCT00299494|EXPERIMENTAL|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (REFRACTORY)|Refractory Aggressive NHL
62734964|NCT00652743|EXPERIMENTAL|GSK1562902A M6 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) and boosted 6 months (M6) after primary vaccination with one dose of Pandemic influenza candidate vaccine (GSK1562902A) in study 109630 (NCT00449670), administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
62581214|NCT04715074|EXPERIMENTAL|Develop and Pilot #iBeatCRC|"1. Intervention development will be informed by (1) integrating Aims 1 and 2 findings, (2) Community Action Board \[CAB\] input, and (3) the Behaviour Change Wheel,48 a step-by-step intervention development approach that identifies and addresses barriers using theory and evidence-based methods.~2. The intervention pilot may be based on a multicomponent media campaign, as endorsed by the Community Preventive Services Taskforce for promoting CRC screening among individuals ≥ age 50. #iBeatCRC may entail both outdoor mass media and online social media. #iBeatCRC will target Utah and Wisconsin hotspots and non-hotspots for comparison, with pre-post-assessment among 17 individuals in each group for both sites."
62581215|NCT05138770|EXPERIMENTAL|VC005 Tablets Dose escalation groups: 1、5、10、25、50、100mg|VC005 Tablets 1、5、10、25、50、100mg, qd
62788773|NCT02428569|EXPERIMENTAL|PREPARED Decision Support|Participants randomized to this arm of the study will receive the PREPARED educational book and video.
62206723|NCT02760498|EXPERIMENTAL|Group 1|Patients with metastatic CSCC: to distant sites or lymph nodes. Cemiplimab administered intravenously (IV) every 2 weeks (Q2W).
62405639|NCT04714710|PLACEBO_COMPARATOR|Placebo (SODIUM CHLORIDE SOLUTION 0.9%)|SODIUM CHLORIDE SOLUTION 0.9%
62405640|NCT00104858|EXPERIMENTAL|Treatment|"Patients receive a conditioning regimen comprising fludarabine IV on days -4 to -2 and rituximab IV on days -3, 10, 24, and 38.~Patients undergo single fraction low-dose TBI on day 0. After completion of TBI, patients undergo allogeneic hematopoietic stem cell transplantation on day 0. Patients then receive rituximab IV on days 10, 24, and 38.~Patients receive an immunosuppressive regimen comprising cyclosporine PO BID on days -3 to 56 followed by a taper to day 180 (related recipients) or on days -3 to 100 followed by a taper to day 180 (unrelated recipients). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related recipients) or TID on days 0-40 followed by a taper to day 96 (unrelated recipients)."
62405641|NCT01646268|EXPERIMENTAL|Rotigotine|Rotigotine, daily doses, treatment group
62581216|NCT05138770|PLACEBO_COMPARATOR|VC005 Tablets Placebo Dose escalation groups: 1、5、10、25、50、100mg|VC005 Tablets Placebo 1、5、10、25、50、100mg, qd
62581217|NCT05138770|EXPERIMENTAL|VC005 Tablets food effects group|VC005 Tablets, qd
62788774|NCT00791752|EXPERIMENTAL|1|AZD4017 in ascending doses (start dose 2mg)
62017009|NCT02277626|EXPERIMENTAL|Randomized Crossover to Vest|Experimental: VEST, then ElectroFlo 5000 Patients are randomized to a sequence of Vest system on one visit and during the second visit, they cross-over to the ElectroFlo 5000.
62405642|NCT01646268|PLACEBO_COMPARATOR|Placebo|Placebo, daily doses, placebo group
62017010|NCT02569047|ACTIVE_COMPARATOR|Atraumatic Restorative Treatment|The cavity will be prepared according to the ART (Atraumatic Restorative Treatments) steps and filled with the dental material Glass Ionomer Cement without local anesthesia.
62017011|NCT02569047|EXPERIMENTAL|Hall Technique|The cavity will not receive any preparation. A stainless crown will be placed and cemented with the dental material Glass Ionomer Cement without local anesthesia.
62017012|NCT05787769|ACTIVE_COMPARATOR|P shot arm|Drug: Autologous Platelet Rich Plasma + placebo tab Each injection session will consist of a total of 10 mL PRP infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum.
62206724|NCT02760498|EXPERIMENTAL|Group 2|Patients with unresectable locally advanced CSCC. Cemiplimab administered IV Q2 weeks.
62206725|NCT02760498|EXPERIMENTAL|Group 3|Patients with metastatic CSCC to distant sites or lymph nodes. Cemiplimab administered IV Q3 weeks.
62206726|NCT02760498|EXPERIMENTAL|Group 4|Patients with advanced CSCC \[metastatic (nodal or distal) or unresectable locally advanced\] Cemplimab administered IV Q4 weeks.
62581218|NCT06412185|EXPERIMENTAL|Group 1|CM383 injection and matched placebo, intravenous injection
62581219|NCT06412185|EXPERIMENTAL|Group 2|CM383 injection and matched placebo, intravenous injection
62581220|NCT06412185|EXPERIMENTAL|Group 3|CM383 injection and matched placebo, intravenous injection
62581221|NCT06412185|EXPERIMENTAL|Group 4|CM383 injection and matched placebo, intravenous injection
62788775|NCT00791752|PLACEBO_COMPARATOR|2|Placebo
62788776|NCT02519205||ED Nurses|ED triage nurses from Duke University Hospital (DUH) and Duke Regional Hospitals (DRH).
62788777|NCT01984502|EXPERIMENTAL|Radiation|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
62788778|NCT05490576|EXPERIMENTAL|[18F] PI-2620 PET Tau Ligand Active Agent|Participants receive dose of active agent \[18F\] PI-2620 PET Tau Ligand during dynamic PET scan acquisition
62788779|NCT04153682|ACTIVE_COMPARATOR|Antimicrobial stewardship (= AMS)|Management of HAP according to current practice, including intervention of the AMS team.
62788780|NCT04153682|EXPERIMENTAL|Antimicrobial Stewardship + Rapid Diagnostic Testing|Management of HAP including rapid diagnostic testing (FA-PP) and intervention of the AMS team.
62206727|NCT02760498|EXPERIMENTAL|Group 6|Patients with advanced CSCC (metastatic \[nodal or distant\] or locally advanced) who received cemiplimab IV Q3W for at least 27 weeks without experiencing disease progression, will have the option to receive cemiplimab by subcutaneous (SC) injection Q3W (first 12 patients) or Q6W (next ≥ 6 patients) basis.
62206728|NCT04974372||HT group|Patients have echocardiography examination before and after heart transplantation.
62206729|NCT04974372||Control group|healthy volunteers who had no history of hypertension, diabetes mellitus, renal failure or other organic diseases based on physical examinations, biochemical tests, electrocardiogram, echocardiography were enrolled as control group
62206730|NCT06244576|EXPERIMENTAL|Radically Open Dialectical Behaviour Therapy (RO-DBT)|RO-DBT consists of a 1 hour weekly individual session and a 2,5 hour weekly group skill training during 32 weeks in accordance with the published treatment manual and session guides for RO-DBT. For skills training, the 31 patients will be divided into four equal groups in terms on number.
62788781|NCT02900768|EXPERIMENTAL|Exercise Group|Patients in the intervention group will receive supervised and unsupervised exercise program after their bone marrow transplant.
62788782|NCT02900768|NO_INTERVENTION|Control Group|Patient will receive standard of care within the hospital as an inpatient and outpatient after their bone marrow transplant.
62017013|NCT05787769|ACTIVE_COMPARATOR|PDE5i arm|Drug: Tadalafil + placebo injection Patients will be treated by tadalafil 5 mg tablet daily in addition to four Tadalafil 5 mg tablet 3 hours before intercourse on demand in addition to placebo injection. Each injection session will consist of a total of 10 mL saline solution infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum.
62017014|NCT03292757|EXPERIMENTAL|Mesenteric ICG|Indocyanine green injected into the small bowel mesentery during oesophagectomy.
62017015|NCT03292757|EXPERIMENTAL|Feeding jejunostomy ICG (cream)|Indocyanine green mixed with cream infiltrated into the feeding jejunostomy.
62206731|NCT05313659|EXPERIMENTAL|group-K|At the end of surgery and immediately after the inhalational agent was discontinued, 2mL of normal saline containing 0.7 mg/kg racemic ketamine was administered intramuscularly to Group-K
62206732|NCT05313659|NO_INTERVENTION|group-S|At the end of surgery and immediately after the inhalational agent was discontinued, 2 mL of normal saline was administered intramuscularly.
62405643|NCT05429749|EXPERIMENTAL|Ferinject group|This group of hip fracture patients are treated with intravenous Ferinject between the admission and the surgery day.
62405644|NCT05429749|ACTIVE_COMPARATOR|Control group|This group of hip fracture patients are treated with normal saline as a control group.
62405645|NCT05360017|EXPERIMENTAL|Robot in lower limb motor function training of stroke patients with hemiplegia|"Test equipment: litestepper single lower limb rehabilitation training robot~Device type: Class II medical device"
62405646|NCT04325191|EXPERIMENTAL|High Salt and Melatonin|Subjects will consume sodium pills throughout the day achieving a total of 6900 mg sodium/day (4600 mg of sodium from pills and 2300 mg from diet) and will supplement with 10 mg (single dose) of melatonin at night.
62206733|NCT00673621|EXPERIMENTAL|1|
62405647|NCT04325191|PLACEBO_COMPARATOR|High Salt and Placebo|Subjects will consume sodium pills throughout the day achieving a total of 6900 mg sodium/day (4600 mg of sodium from pills and 2300 mg from diet) and will supplement with a lactose placebo (single dose) at night.
62405648|NCT03962751|EXPERIMENTAL|Sequential Post Feedback Information Delivery|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment.
62405649|NCT03962751|EXPERIMENTAL|Sequential Post Feedback Information Delivery +Text Messages|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment. Additionally, participants receive the Text Message Booster Component in the days before and during their birthday celebration(s).
62581222|NCT06412185|EXPERIMENTAL|Group 5|CM383 injection and matched placebo, intravenous injection
62581223|NCT06412185|EXPERIMENTAL|Group 6|CM383 injection and matched placebo, intravenous injection
62788783|NCT02152319|EXPERIMENTAL|KHV reporting|Clinicians will view the motor symptom severity reports and videoconference to titrate medications.
62788784|NCT02152319|ACTIVE_COMPARATOR|Standard care|Subjects in this group will still use KHV at home to minimize any placebo effects that could be attributed to using the system; however, clinicians will view the motor symptom severity reports and videoconference to titrate medications solely for the experimental subjects.
62788785|NCT05700994|EXPERIMENTAL|PEER-CM|Peer-facilitated contingency management (PEER-CM).
62788786|NCT05700994|ACTIVE_COMPARATOR|Standard of Care|Standard of care contingency management.
62788787|NCT01063647|EXPERIMENTAL|1|Treosulfan: 10 g/m² i.v. on 3 consecutive days (day -6 to -4)
62788788|NCT01063647|EXPERIMENTAL|2|Treosulfan:12 g/m² i.v. on 3 consecutive days (day -6 to -4)
62788789|NCT01063647|EXPERIMENTAL|3|Treosulfan: 14 g/m² i.v. on 3 consecutive days (day -6 to -4)
62788790|NCT03611673|EXPERIMENTAL|Group A: 15 Scents|Participants will be asked to inhale 15 different scents two times a day.
62788791|NCT03611673|ACTIVE_COMPARATOR|Group B: 4 Scents|Participants will be asked to inhale 4 different scents two times a day.
62788792|NCT04875091|EXPERIMENTAL|Intervention|
62788793|NCT02197091||Observational (communication in oncology treatment)|Patients complete questionnaires, including the FACIT-TS-G, the FACIT-Sp12, the MOS-SSS, and the DT. Doctors also complete a questionnaire. Patients' medical records may be reviewed, if necessary.
62788794|NCT04428957|EXPERIMENTAL|Telemonitoring group|3 months home-based telemonitoring
62788795|NCT04428957|NO_INTERVENTION|Control group|3 months standard care
62788796|NCT04086199||Anterior discectomy|The discectomy is made by an anterior muscle sparring approach (extraperitoneal).
62788797|NCT04086199||Posterior discectomy|The discectomy is made by a posterior approach (posterior midline incision).
62788798|NCT05083312|EXPERIMENTAL|APT-1011|APT-1011 3 mg HS
62788799|NCT05083312|PLACEBO_COMPARATOR|Placebo|HS
62206734|NCT06259578|EXPERIMENTAL|INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 μg|The study product is provided in the form of liquid in vial single dose (0.5 ml). The vaccine will be given 1 dose (0.5 ml) once.
62206735|NCT03814551||Comparison|Cohort of participants who regularly eat in cafeteria without health signage.
62206736|NCT03814551||Signage|Cohort of participants who regularly eat in cafeteria in which health signage is placed.
62206737|NCT06401746||Semaglutide|Patients undergoing Body Surface Gastric Mapping before and after administration of Semaglutide.
62206738|NCT01115127|ACTIVE_COMPARATOR|myo-inositol|30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.
62788800|NCT03523572|EXPERIMENTAL|Dose Escalation|"Part 1 will enroll participants meeting the eligibility criteria set up for any of the 4 cohorts of Part 2 specified below using a 3 + 3 + 3 design. Escalating/de-escalating doses of trastuzumab deruxtecan in combination with a flat dose of nivolumab will be administered on Day 1 of each 21-day cycle.~The recommended dose for expansion (RDE) will be calculated using data collected from this population in the first two cycles. These participants may continue to receive study treatment in subsequent cycles."
62788801|NCT03523572|EXPERIMENTAL|Dose Expansion - Cohort 1|"Cohort 1 (n=30): Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined positive HER2 expression (IHC 3+ or IHC 2+/ISH+) \[as defined by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines\]. These participants have received prior ado-trastuzumab emtansine (T-DM1).~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
62788802|NCT03523572|EXPERIMENTAL|Dose Expansion - Cohort 2|"Cohort 2 (n=15): Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined low HER2 expression (IHC 1+ or IHC 2+/ISH-), who have exhausted treatments that can confer any clinically meaningful benefit (eg, other therapies such as hormonal therapy for patients who are hormone receptor positive).~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
62788803|NCT03523572|EXPERIMENTAL|Dose Expansion - Cohort 3|"Cohort 3 (n=30): Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 2+ or 3+, who received prior platinum-based therapy with documented progression.~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
62206739|NCT01115127|ACTIVE_COMPARATOR|melatonin|30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months
62788804|NCT03523572|EXPERIMENTAL|Dose Expansion - Cohort 4|"Cohort 4 (n=15): Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 1+, who received prior platinum-based therapy with documented progression.~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
62206740|NCT01115127|ACTIVE_COMPARATOR|melatonin plus myo-inositol|30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months
62206741|NCT03856515|EXPERIMENTAL|E-Cig placebo dose followed by E-Cig nicotine dose|Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.
62788805|NCT02008227|EXPERIMENTAL|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab 1200 milligrams (mg) was administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
62788806|NCT02008227|ACTIVE_COMPARATOR|Docetaxel|Docetaxel 75 milligrams per meter square (mg/m\^2) was administered via IV infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
62788807|NCT04567394|EXPERIMENTAL|Intervention|Participants randomized to the Intervention group will complete questionnaires at baseline, 1 month, 3 months, and 6 months and will receive 4 weeks of the PNC-txt intervention.
62788808|NCT04567394|NO_INTERVENTION|Waitlist Control|Participants randomized to the waitlist control group will complete questionnaires at baseline, 1 month, 3 months, and 6 months.
62017016|NCT03025620|PLACEBO_COMPARATOR|Sunflower arm|Participants were supplied with the usual diet of the hospital, daily enriched with 17.5g fat as follows during 42 days: 10 g of sunflower oil (with a high content in linoleic acid) were added into the dinner soup and 7.5g delivered through a 12.5g portion of margarine made with sunflower oil (60% fat) that replaced butter on the breakfast toasts.
62206742|NCT03856515|EXPERIMENTAL|E-Cig nicotine dose followed by E-Cig placebo dose|Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.
62206743|NCT06729489|EXPERIMENTAL|Children with referactory iron deficiency anemia|
62405650|NCT03962751|EXPERIMENTAL|Simultaneous Post Feedback Information Delivery|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content.
62405651|NCT03962751|EXPERIMENTAL|Simultaneous Post Feedback Information Delivery +Text Messages|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content. Additionally, participants receive the Text Message Booster Component in the days before and during their birthday celebration(s).
62405652|NCT03962751|NO_INTERVENTION|Baseline Assessment Only|Participants complete baseline survey and conclude participation.
62405653|NCT03512106|EXPERIMENTAL|Acupuncture group|Chinese traditional acupuncture
62581224|NCT05721742|ACTIVE_COMPARATOR|pre-existing online group education program for IBS|This arm will be enrolled in the online course run by Happy Bellies Nutrition https://www.happybelliesnutrition.com/ibs-gentle-group-program. The Happy Bellies nutrition course has 5.5 hours of total video content and optional biweekly group calls via Zoom (45-minutes per session). This course is designed to take 12 weeks to complete. The participants would have access to the content for one year.
62581225|NCT05721742|EXPERIMENTAL|virtual dietitian consults for IBS patients|This arm will receive consults with a virtual dietitian (60 minutes initial + 4 x30-minute follow-up appointment) by a dietitian who has had additional training in the dietary management of IBS.
62581226|NCT05686135|EXPERIMENTAL|90Second IBD|Participants will receive 90SecondIBD weekly at no charge via text message or email linked to a website.
62788809|NCT05967650|ACTIVE_COMPARATOR|HBV vaccination of Inflammatory bowel disease patients with stander regemin|"inflammatory bowel disease patient with negative HBVs AB will be vaccinated with standerd regemin HBV vaccination~1. st dose zero~2. nd dose after 2 months~3. rd dose after 6 months"
62788810|NCT05967650|ACTIVE_COMPARATOR|HBV vaccination of Inflammatory bowel disease patients with accelearetd regemin|"inflammatory bowel disease patient with negative HBVs AB will be vaccinated with standerd regemin HBV vaccination~1. st dose zero~2. nd dose after 1months~3. rd dose after 3 months"
62788811|NCT00108316|OTHER|Arm 1|
62788812|NCT04803227|ACTIVE_COMPARATOR|Emricasan|Emricasan
62788813|NCT04803227|PLACEBO_COMPARATOR|Placebo|Placebo
62788814|NCT03369977|EXPERIMENTAL|BioGlue Surgical Adhesive|Subjects in the BioGlue group will receive BioGlue as an adjunct for traditional surgical repair of the sinus of Valsalva.
62788815|NCT03369977|OTHER|Traditional Surgical Repair|Subjects in the control group will receive traditional surgical repair of the sinus of Valsalva.
62017017|NCT03025620|ACTIVE_COMPARATOR|Rapeseed arm|Participants were supplied with the usual diet of the hospital, daily enriched with 17.5g fat as follows during 42 days: 10 g of rapeseed oil (with a high content in alpha-linolenic acid) were added into the dinner soup and 7.5g delivered through a 12.5g portion of margarine made with rapeseed oil (60% fat) that replaced butter on the breakfast toasts.
62405654|NCT03512106|PLACEBO_COMPARATOR|Sham group|Sham
62405655|NCT06261827|ACTIVE_COMPARATOR|Control group|Oxygen-air mixture without NO after extubation within 5 days after surgery 2 times a day for 30 min
62581227|NCT06202092|EXPERIMENTAL|Honey Group|will receive phonophoresis with honey and conventional physical therapy treatment in the form of transcutaneous electrical nerve stimulation (TENS) current and exercise . The parameters of the application of phonophoresis will be the continuous modality, 1 MHz frequency, intensity of 1 or 1.5 W/cm2, and an application time of 10 minutes
62581228|NCT06202092|OTHER|Control Group|will receive ultrasound therapy with gel media and the same conventional physical therapy treatment (control group)
62581229|NCT04290208|ACTIVE_COMPARATOR|Intravenous Administration of Acetaminophen|A single peri-operative dose of acetaminophen 1000 mg IV over 15 minutes after skin is closed.
62581230|NCT04290208|ACTIVE_COMPARATOR|Per Oral Administration of Acetaminophen|A pre-operative liquid dose of acetaminophen 1000mg orally in the on-call to Operative Room.
62581231|NCT01551264|OTHER|4-Year Bracing Arm|This group has been randomized to 4 years of bracing after correction of clubfoot using the Ponseti Method.
62788816|NCT05799768|EXPERIMENTAL|Ketogenic diet plan|Subjects will be provided extensive educational and ongoing support on the KD, including personalized coaching with the ability to text a dietitian at any time and expect a response within 12 hours. Diet adherence and progress will be assessed daily using at-home whole capillary blood ketone/glucose monitors, along with diet records. We will assess adherence based on days in ketosis following these parameters: (BHB ≥ 0.5mM). Adherence will be defined as \> 80% of days in ketosis.
62581232|NCT01551264|OTHER|2-Year Bracing Arm|This group has been randomized to 2 years of bracing after correction of clubfoot using the Ponseti Method.
62581233|NCT06247527|EXPERIMENTAL|PROACT group|Participants in intervention clinics with at least mild psychological distress (having depressive, anxiety or trauma symptoms) will receive a brief, modular, transdiagnostic psychological intervention (PROACT) delivered by non-specialist health providers at the HIV clinic.
62788817|NCT04357483|EXPERIMENTAL|Collastat|Patients who were applied flowable thrombin containing collagen hemostat matrix after pancreatectomy
62788818|NCT04357483|ACTIVE_COMPARATOR|Collaseal|Patients who were applied thrombin coated L-dopa contained collagen patch after pancreatectomy
62788819|NCT01625000|EXPERIMENTAL|MP-214 3mg|
62788820|NCT01625000|EXPERIMENTAL|MP-214 6mg|
62788821|NCT01625000|EXPERIMENTAL|MP-214 9mg|
62788822|NCT01625000|ACTIVE_COMPARATOR|Risperidone 4mg|
62788823|NCT01625000|PLACEBO_COMPARATOR|Placebo|
62017018|NCT02127008|EXPERIMENTAL|Resection of epidural fat|During surgical procedure, epidural fat was resected fully.
62017019|NCT02127008|ACTIVE_COMPARATOR|No resection of epidural fat|During surgical procedure, the epidural fat was not resected.
62017020|NCT02715765|SHAM_COMPARATOR|Sham|The sham procedure involves only 40 sec direct current stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec.
62215404|NCT06186661|EXPERIMENTAL|Experimental Group|The Experimental group was applied a total of 2 hours-exercise programs consisting of 1-hour-neurophysiological exercise and 1-hour cognitive rehabilitation
62215405|NCT06186661|ACTIVE_COMPARATOR|Control Group|The Control Group was implemented only 1-hour neuropsychological exercise program.
62405656|NCT06261827|EXPERIMENTAL|200 ppm|NO will be supplemented at 200-ppm concentration after extubation within 5 days after surgery 2 times a day for 30 min
62405657|NCT03093558|EXPERIMENTAL|Intervention arm|Receive the ECA/Kardia for 30-day use.
62405658|NCT03093558|NO_INTERVENTION|Usual care arm|Receive a journal for observation of adherence and symptoms.
62788824|NCT01033916|NO_INTERVENTION|STRICT Glucose Control (80-120 mg/dL)|The STRICT arm of the study will have a target Blood Glucose level ranging from 80-120 mg/dL. This is currently the standard of care for post CABG patients.
62788825|NCT01033916|ACTIVE_COMPARATOR|LIBERAL (Target Glucose:121-180 mg/dL)|
62788826|NCT02809339||Epithelial ovarian cancer|
62788827|NCT05342272|EXPERIMENTAL|GUM Hydral Moisturizing Gel|One group of 20 patients receiving GUM® Hydral® Moisturizing Gel (test group): they were be instructed to apply during a 28 days treatment period 1 to 2 cm of gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary.
62788828|NCT05342272|ACTIVE_COMPARATOR|Biotene Oral Balance Gel|One group of 20 patients receiving Biotene® Oral Balance Gel (control group): they were be instructed to apply during a 28 days treatment period 1 to 2 cm of gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary.
62405659|NCT06142448|EXPERIMENTAL|Responders|
62788829|NCT03089541|EXPERIMENTAL|Survey Arm|Will receive incentives for completing surveys and evidence of tobacco use status daily for 1 week
62788830|NCT03804853|EXPERIMENTAL|Immediate Active Shoulder Rehabilitation|
62405660|NCT06142448|NO_INTERVENTION|Non-responders|
62405661|NCT03403010|NO_INTERVENTION|Control period|In this group conventional physiotherapy of the child will be continued and the therapist will be asked not to use any gaming activities. Also during the control period, the frequency and duration of the therapy sessions will not be influenced by the researchers.
62788831|NCT03804853|ACTIVE_COMPARATOR|Traditional Should Rehabilitation|
62788832|NCT02602119|EXPERIMENTAL|OTL38|Dosage calculated by weight of individual
62788833|NCT04647123||Hopeless teeth|The teeth that can not be treated periodontally and who are desperate for extraction will be included in this group.
62788834|NCT04647123||Periodontitis|Teeth diagnosed with periodontitis will be included in this group.
62788835|NCT04647123||Gingivitis|Teeth diagnosed with gingivitis will be included in this group.
62788836|NCT04647123||Healthy|Teeth diagnosed with helthy will be included in this group.
62788837|NCT05868837|EXPERIMENTAL|Rituximab|Rituximab will be provided in 500mg/50ml vials; excipients include sodium chloride, tri-sodium citrate dihydrate, polysorbate 80, water for injections. Two vials will be diluted in 500 ml of sodium chloride 0,9% to reach a concentration of 2mg/ml. Rituximab will be administered intravenously in two 1000 mg infusions, with two weeks distance between the first and the second infusion.
62788838|NCT05868837|PLACEBO_COMPARATOR|Placebo|Placebo will consist of 500 ml flacons of sodium chloride 0,9%.
62788839|NCT05018650|EXPERIMENTAL|Route 92 Medical Monopoint Reperfusion System|Aspiration thrombectomy with the Route 92 Medical HiPoint 88 and HiPoint 70 Reperfusion Catheters as part of the Monopoint Reperfusion System to treat acute ischemic stroke
62788840|NCT05018650|ACTIVE_COMPARATOR|Aspiration Predicate|Aspiration thrombectomy with a predicate aspiration device to treat acute ischemic stroke
62017021|NCT02715765|EXPERIMENTAL|Active tDCS|Current (2mA) is initiated in a ramp-like fashion over 10s from 0mA to 2mA using (SPONSTIM-25 25cm2 electrodes). The current is held constant for 20 min. Then the current is decreased in a ramp-like fashion over 10s from 2mA to 0mA.
62581234|NCT06247527|ACTIVE_COMPARATOR|Control group|Participants in control clinics with at least mild psychological distress (having depressive, anxiety or trauma symptoms) will be enrolled in the study, and will receive the standard of care interventions available in the HIV clinic.
62206744|NCT06316310|ACTIVE_COMPARATOR|Acupoint Thread Embedding group+health education|Acupuncture thread embedding (ATE), extension and development of acupuncture therapy, which emerged in mid 1950s, is an acupoint stimulation technique which sterile biodegradable threads (such as polydioxanone (PDO) threads) are inserted into acupuncture points, by using hollow core embedding needles. The aim of this therapy is provide long term stimulation of acupoints, making this technique one of the most commonly used methods for treating obesity.
62788841|NCT01629459|EXPERIMENTAL|Resistance exercise training|Participants will undergo resistance exercise training 3x/wk for 12 weeks at a physical therapy or cardiac rehabilitation facility near the participant's home.
62788842|NCT05426070|EXPERIMENTAL|Strength training-based exercise|The strength training-based exercise intervention will be delivered via group-based Zoom sessions, motivational text messages, and a website. Participants will take part in two group-based Zoom exercise sessions (40-minute exercise sessions and 20 minutes of motivational counseling) and two individual exercise sessions per week for three months. Exercise sessions will include a combination of various aerobic and muscle strengthening exercises designed to keep heart rate in the 60-85% range of maximum heart rate. Motivational counseling will be focused on increasing motivation to exercise and habit formation. Strength training-based participants will also receive access to a mobile phone-friendly study website and will receive email messages. Both the website and email messages will contain motivational content to complete the exercise sessions.
62788843|NCT05426070|NO_INTERVENTION|No contact, wait-list control|Participants in the no contact, wait-list control intervention will participate in assessments at baseline and three months. Following the six month assessment, participants will have the option of receiving the strength training-based intervention as described above.
62788844|NCT03954821||control group|control group in which all of them present pronated foot without tratment
62788845|NCT03954821||experimental group|Group in which they have been treated with prefabricated plantar insoles to stop pronation
62788846|NCT03603483|ACTIVE_COMPARATOR|Patients with sever aortic stenosis 1|Procedure: the patients will undergo aortic valve replacement with aortic root enlargement.
62017022|NCT02715765|EXPERIMENTAL|Active tRNS|Current (2mA) is initiated in a ramp-like fashion over 10s from 0mA to 2mA using (SPONSTIM-25 25cm2 electrodes). Once at 2mA, an alternating current of 2mA with a 0mA offset is applied at random frequencies over a range of 0.1 to 100 Hz. This is performed for 20 minutes. Then the current is decreased in a ramp-like fashion over 10s from 2mA to 0mA.
62788847|NCT03603483|ACTIVE_COMPARATOR|Patients with sever aortic stenosis 2|Procedure: the patients will undergo conventional aortic valve replacement
62788848|NCT06108206|EXPERIMENTAL|Adaptive Radiotherapy|Subjects will receive radiotherapy per standard of care over 30-33 once-daily fractions in addition to 7 brain MRIs each in every week of treatment. Subjects receiving hypofractionated radiotherapy will receive radiotherapy per standard of care over 15 once-daily fractions in addition to 4 brain MRIs each in every week of treatment.
62017023|NCT01702792|EXPERIMENTAL|Tumor Vaccine|1 x 107 TCE tumor lysate in 0.5 ml Lactated Ringers Solution (approximately 1 mg of tumor lysate protein) and equivalent volume of adjuvant will be injected 2 weeks and 3 weeks (2 vaccinations) after surgery in the intradermal skin of the upper thigh. There will be 2 vaccine administrations and patients will be followed for 2 months after inguinal node removal for any possible vaccine/study-related toxicity.
62215406|NCT04820218|OTHER|Without Try-on glasses|Subjects will be asked to measure their visual acuity without their try-on glasses
62215407|NCT02307461|EXPERIMENTAL|Part 1 Cohort 1|IPI-145 test formulation (capsule) high single dose and IPI-145 reference formulation (capsule) high single dose
62581235|NCT03750149|EXPERIMENTAL|Ophthalmologic Disease|Patients with glaucoma, AMD, diabetic maculopathy, epiretinal membranes, and healthy patients will undergo a reading analysis using the EyeTracker
62017024|NCT02974361|ACTIVE_COMPARATOR|Part A Ibuprofen control|
62017025|NCT02974361|EXPERIMENTAL|Part A Ibuprofen-LDH|
62581236|NCT01597414|ACTIVE_COMPARATOR|Pertuzumab + trastuzumab (PH)|Pertuzumab + trastuzumab. After progression,patients will be given the option of receiving T-DM1
62788849|NCT03634930||EBF exclusive breast fed children at 16 weeks|observation of 24 hours drinking volume, weight, length, body composition, biomarker and satiety cues, as well as eating- and feeding behaviour and nutritional status of exklusiv breastfed children at the age of 8 and 16 weeks, and at 1 and 2 Years
62017026|NCT02974361|EXPERIMENTAL|Part A Ibuprofen-LDH Excipient Combo 1|
62017027|NCT02974361|EXPERIMENTAL|Part A Ibuprofen-LDH Excipient Combo 2|
62405662|NCT03403010|ACTIVE_COMPARATOR|Intervention period|In this group the usual individual physiotherapy program of the child will be continued as performed before the study and will be executed by the child's usual, familiar physiotherapist. The therapist will be asked to use the rehabilitation-specific gaming software every therapy session, for at least 15 to 20 minutes. The therapist will receive an extensive introduction and demonstration of the software and the researchers will participate in at least one therapy session.
62405663|NCT03403010|NO_INTERVENTION|Wash-out period|The wash-out period is considered after each intervention period. As during the control period, therapy will be continued as usual during the washout-period but no gaming is allowed during therapy.
62581237|NCT01597414|EXPERIMENTAL|PH + metronomic chemotherapy (PHM)|Pertuzumab + trastuzumab + metronomic chemotherapy. After progression,patients will be given the option of receiving T-DM1
62788850|NCT03634930||EFF exclusive formula fed children at 16 week|observation of 24 hours drinking volume, weight, length, body composition, biomarker and satiety cues, as well as eating- and feeding behaviour and nutritional status of exklusiv formula fed children at the age of 8 and 16 weeks, and at 1 and 2 Years
62788851|NCT00741013|PLACEBO_COMPARATOR|Placebo pill and placebo IV|
62788852|NCT00741013|EXPERIMENTAL|Lovastatin pill and placebo IV|
62788853|NCT00741013|EXPERIMENTAL|Placebo pill and rhAPC IV|
62788854|NCT05541575|EXPERIMENTAL|Intervention|Experimental: offered 3 films of VR course of BPSD for 30 mins to each participants.
62788855|NCT05541575|NO_INTERVENTION|No intervention|NO films of VR course of BPSD to any participants.
62788856|NCT03781505|EXPERIMENTAL|Intravenous paracetamol with Caudal Ropivacaine|"Paracetamol is widely accepted and most commonly used as an adjuvant for postoperative analgesia. It also improves the quality of recovery by attenuating the pain associated with the surgical position. Adverse effects associated with the paracetamol are rare \<1/10000, which includes malaise, increased level of hepatic transaminases and hypersensitivity reaction. It has been studied in combination with caudal analgesia with bupivacaine through the rectal route 7,8 with variable results.~Caudal anaesthesia is effective in alleviating pain below the umbilicus. Also if the caudal block is administered at the beginning of surgery, the effect will start wearing off 2 to 3 hours post surgery. Administration of paracetamol towards end of surgery may help with both these issues. In this study we aim to investigate the effect of adding intravenous paracetamol in combination with caudal analgesia with ropivacaine, hoping that it may improve quality of postoperative analgesia and recovery."
62788857|NCT03781505|PLACEBO_COMPARATOR|Placebo|Intravenous Normal Saline with Caudal Ropivacaine
62788858|NCT01825967||Acute Diverticulitis|We measured C-reactive protein in all the patients diagnosed with acute diverticulitis
62788859|NCT04301544|EXPERIMENTAL|INDAK & Standardized Vascular Care Group|The experimental arm will receive training on the ballroom dance modules called INDAK (Improving Neurocognition through Dance and Kinesthetics), nutrition counseling and vascular risk management
62206745|NCT06316310|SHAM_COMPARATOR|Sham Acupoint Thread Embedding group+health education|"Sham acupoint thread embedding method in this study is set as the Sham acupoint thread embedding manipulated at the same main acupoints won't be put into trocar and de qi sensation will not be obtained.~The aim of the sham acupoint thread embedding is to eliminate the possible placebo effect of ATE treatment."
62206746|NCT04965675|EXPERIMENTAL|Eptinezumab 300 mg|Participants will receive a single IV infusion of eptinezumab 300 mg (weight adjusted).
62206747|NCT04965675|EXPERIMENTAL|Eptinezumab 100 mg|Participants will receive a single IV infusion of eptinezumab 100 mg (weight adjusted).
62206748|NCT04965675|PLACEBO_COMPARATOR|Placebo|Participants will receive a single IV infusion of placebo matching to eptinezumab.
62405664|NCT03866811|EXPERIMENTAL|Intervention arm|The intervention consists of a brief contraception educational video and then the 10-week texting intervention which consists of 30 automated, personalized and interactive texting algorithms (3 texts per week).
62405665|NCT03866811|NO_INTERVENTION|Control arm|Patients randomized to the control arm will receive the current standard discharge instructions provided in the investigator's ED.
62788860|NCT04301544|ACTIVE_COMPARATOR|Standardized Vascular Care Group|The control group will receive nutrition counseling and vascular risk management
62788861|NCT02470325|ACTIVE_COMPARATOR|1 Avidekel|Patients with spasticity and dystonia related to genetic neurodegenerative disease will consume Avidekel oil (6-to-1 ratio of CBD to THC)
62788862|NCT02470325|ACTIVE_COMPARATOR|2 Enriched Avidekel|Patients with spasticity and dystonia related to genetic neurodegenerative disease will consume Enriched Avidekel oil (20-to-1 ratio of CBD to THC)
62788863|NCT02470325|ACTIVE_COMPARATOR|3 Avidekel|Patients with spasticity and dystonia due to cerebral palsy will consume Avidekel oil (6-to-1 ratio of CBD to THC)
62788864|NCT02470325|ACTIVE_COMPARATOR|4 Enriched Avidekel|Patients with spasticity and dystonia due to cerebral palsy will consume Enriched Avidekel oil (20-to-1 ratio of CBD to THC)
62405666|NCT05132543|EXPERIMENTAL|Wireless µECoG Prosthesis for Speech|
62405667|NCT05033795|EXPERIMENTAL|Water A|2 L of water A per day
62788865|NCT06583863|ACTIVE_COMPARATOR|Control Group|
62405668|NCT05033795|OTHER|Water B|2 L of water B per day
62581238|NCT00160732|EXPERIMENTAL|Transplant|
62788866|NCT06583863|ACTIVE_COMPARATOR|Group I|
62788867|NCT06583863|ACTIVE_COMPARATOR|Group II|
62788868|NCT03628976|SHAM_COMPARATOR|Sham-tVNS to ear lobe|Sham-tVNS will be applied to the ear lobe.
62581239|NCT04002245|EXPERIMENTAL|Go back|Application of a compress impregnated with alcoholic Betadine® by movement of return
62788869|NCT03628976|ACTIVE_COMPARATOR|tVNS to tragus|tVNS will be applied to the tragus.
62788870|NCT02376868||Normal Eyes|Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
62017028|NCT02974361|EXPERIMENTAL|Part A Ibuprofen-LDH Excipient Combo 3|
62206749|NCT01422642|EXPERIMENTAL|legacy posterior stabilized high-flexion|NexGen LPS-Flex total knee system
62206750|NCT01422642|EXPERIMENTAL|legacy posterior stabilized standard|standard NexGen LPS prosthesis
62405669|NCT04882085|EXPERIMENTAL|CAZ-AVI|ceftazidime 2g plus avibactam 0.5g
62788871|NCT02376868||Glaucomatous Eyes|Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
62788872|NCT02376868||Eyes with Retinal Diseases|Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
62788873|NCT04123145|EXPERIMENTAL|CDK-ND|
62788874|NCT04909203|EXPERIMENTAL|iKinnect2.0|Parent-Youth dyads assigned to the iKinnect2.0 condition will be given access to the iKinnect2.0 app that has been developed for this study. Parent and youth will be asked to download the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 16 week trial. The app is designed to be used several times throughout each day.
62788875|NCT04909203|PLACEBO_COMPARATOR|Attention-Control Placebo App & Supporting Materials|Parent-Youth dyads assigned to the control condition will be asked to download the free Life360 app to their phone during the baseline assessment process and will also be given access to an online suicide resources brochure. Participants will be asked to use the control-condition app and associated materials as often as they would like throughout the duration of the 16 week trial.
62788876|NCT03162419|ACTIVE_COMPARATOR|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
62788877|NCT03162419|EXPERIMENTAL|Standard Medical Therapy + Plasma exchange + GCSF|The patients in group B shall be given GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28 along with alternate day high volume plasma exchange sessions till a maximum of ten sessions.
62788878|NCT03162419|EXPERIMENTAL|Standard Medical Therapy + GCSF|"The patients in this will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.~The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28"
62788879|NCT05370872|NO_INTERVENTION|Care-as-usual|Clients in this group will complete functional testing in the clinic using the care-as-usual approach.
62788880|NCT05370872|EXPERIMENTAL|Remote functional testing|Clients in this group will complete functional testing using the remote functional testing approach.
62788881|NCT04087577|EXPERIMENTAL|experimental group|conventional physical therapy with mirror therapy
62788882|NCT04087577|ACTIVE_COMPARATOR|control group|conventional physical therapy
62788883|NCT04983355|EXPERIMENTAL|Peptidyss|"Dietary supplement : fish hydrolysate~The experimental product is a dietary supplement composed of a hydrolysate of fish containing low molecular weight peptides (4 capsules/day providing 1,4 g of fish hydrolysate)"
62405670|NCT04882085|ACTIVE_COMPARATOR|Best Available Treatment|Based on investigative site practice and local epidemiology and guideline
62788884|NCT04983355|PLACEBO_COMPARATOR|Placebo|The placebo product containing mainly silica is presented in the same form as the active product, so that people handling the product cannot distinguish both formula (4 capsules/day)
62788885|NCT03579043|EXPERIMENTAL|Nutritive Sweetener|Participants will consume 36 ounces of Coke daily for three consecutive days.
62788886|NCT03579043|EXPERIMENTAL|Non-Nutritive Sweetener|Participants will consume 36 ounces of Diet Coke daily for three consecutive days.
62788887|NCT03579043|EXPERIMENTAL|Carbonated Water|Participants will consume 36 ounces of carbonated water daily for three consecutive days.
62788888|NCT05365126|EXPERIMENTAL|Complete Vocal Technique Voice Therapy|Up to six 45 minute sessions delivered by a CVT Practitioner using a video link within an eight week therapy period
62405671|NCT01002417|PLACEBO_COMPARATOR|Placebo|Both the phase 2b and phase 3 parts of the study have the placebo arm.
62788889|NCT03302247|EXPERIMENTAL|Nivolumab+Gemcitabine|Nivolumab infusion on day 1 and 15 with the addition of gencitabine on day 1, 8 and 15 of 28 day cycle
62788890|NCT04820413|EXPERIMENTAL|FMT|
62788891|NCT01963845|PLACEBO_COMPARATOR|Placebo|Placebo
62788892|NCT01963845|EXPERIMENTAL|Active drug|Sitagliptin 100 mg
62788893|NCT02865655||CSD-TVU|Cesarean Section Scar Evaluation by TVU
62788894|NCT02865655||CSD-MRI|Cesarean Section Scar Evaluation by MRI
62788895|NCT02865655||CSD-MRI with saline|Cesarean Section Scar Evaluation by MRI with saline
62405672|NCT01002417|ACTIVE_COMPARATOR|MCS-2 15 mg/day|For the phase 2b part of the study. It can also be used in the phase 3 part of the study if MCS-2 15 mg/day is selected as the optimal dosage.
62405673|NCT01002417|ACTIVE_COMPARATOR|MCS-2 30 mg/day|For the phase 2b part of the study. It can also be used in the phase 3 part of the study if MCS-2 30 mg/day is selected as the optimal dosage.
62405674|NCT04121468|OTHER|Group A|"Placebo for 3 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day.~Metformin for 9 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day."
62581240|NCT04002245|EXPERIMENTAL|Technique of snail|Application of a compress impregnated with alcoholic Betadine into a single movement from the center towards the periphery and covering the end surface of followed by spontaneous drying time 30 seconds.
62788896|NCT02865655||CSD-Hysteroscopic|Cesarean Section Scar Evaluation by Saline Contrast Sonohysterography During Hysteroscopy
62788897|NCT00662168||observation|Individuals with a diagnosis of carcinoid carcinoma
62788898|NCT03593044|EXPERIMENTAL|One Week Atropine|0.01% concentration atropine drops
62788899|NCT04063592|EXPERIMENTAL|Intervention|Subjects undergoing the proposed operative intervention. Intervention patients will serve as their own control for all outcome measures
62788900|NCT00748371|EXPERIMENTAL|1|ASA 40mg daily for 8 weeks followed by 3 weeks of observation
62017029|NCT02974361|EXPERIMENTAL|Part A Ibuprofen-LDH Excipient Combo 4|
62788901|NCT00748371|EXPERIMENTAL|2|ASA 1300mg daily for 8 weeks followed by 3 weeks of observation
62017030|NCT02974361|ACTIVE_COMPARATOR|Part A Ibuprofen Lysine|
62788902|NCT00748371|PLACEBO_COMPARATOR|3|Placebo: one Avicel (cellulose) capsule by mouth twice daily
62206751|NCT06050616||binge eating disorder|Participants with a current binge eating disorder, as assessed by the Eating Disorder Diagnostic Screen (DSM-5 version). These participants have been recruited as part of the STRATIFY study. An additional 30 participants will be recruited in this study to enlarge the sample size, using the same study procedure and assessments in the STRATIFY study.
62206752|NCT06050616||anorexia nervosa|Participants with current anorexia nervosa, as assessed by the Eating Disorder Diagnostic Screen (DSM-5 version).. These participants have been recruited as part of the STRATIFY study. Their data will be used in this study.
62206753|NCT06050616||bulimia nervosa|Participants with current bulimia nervosa, as assessed by the Eating Disorder Diagnostic Screen (DSM-5 version). These participants have been recruited as part of the STRATIFY study. Their data will be used in this study.
62206754|NCT06050616||healthy controls|Healthy controls are selected from the IMAGEN study at the third follow-up (\~age 22 years) who do not exhibit any psychiatric disorder. Their data will be used in this study. IMAGEN and STRATIFY are sister studies that employ matched study protocols.
62206755|NCT06147297|EXPERIMENTAL|Intervention group|Receive the music-based program once a week for 4 weeks, each session is 60 to 90 minutes, and participants will complete the survey before- and after- the program.
62206756|NCT06147297|NO_INTERVENTION|Wait-list group|Complete the survey before- and after the 4-week waiting period. Then the waitlist group will also be offered the program, and invited to complete an optional post-program survey
62405675|NCT04121468|OTHER|Group B|"Placebo for 6 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day.~Metformin for 6 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day."
62405676|NCT04121468|OTHER|Group C|"Placebo for 9 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day.~Metformin for 3 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day."
62788903|NCT01848119|ACTIVE_COMPARATOR|Gabapentin|Gabapentin 600mg, 1 dose preoperatively, followed by Gabapentin 200mg tid for 5 doses.
62788904|NCT01848119|PLACEBO_COMPARATOR|Placebo|lactose capsules
62788905|NCT03257683||Selected group with cardiac ischemia|This selected study group will have a specific echocardiographic imaging protocol performed, which includes the known ischemic regions. All segments will be collected and analyzed as a pre-therapeutic baseline using specialized STE software to derive strain values. Following eight (8) weeks of ranolazine therapy, each subject will be re-interrogated with the same echocardiographic imaging protocol and have identical measurements of regional strain performed. Ranolazine will be added to the patients' usual medical therapy. Each patient will serve as their own control, from baseline to post therapeutic state.
62788906|NCT00691184|EXPERIMENTAL|Group 1|0% Terbinafine HCl Nail Lacquer for 28 days.
62788907|NCT00691184|EXPERIMENTAL|Group 2|10% Terbinafine HCl Nail Lacquer.
62017031|NCT02974361|ACTIVE_COMPARATOR|Part B Ibuprofen|
62581241|NCT02173522|EXPERIMENTAL|Prostate artery embolization (PAE)|10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
62581242|NCT02173522|NO_INTERVENTION|Control|10 patients, matched to PAE patients by risk score, will receive RALRP without PAE. RALRP without PAE is the current standard of care treatment for prostate cancer at the Sylvester Comprehensive Cancer Center.
62581243|NCT02766803|ACTIVE_COMPARATOR|Simvastatin + resveratrol|simvastatin 20 mg daily micronized trans-resveratrol 500 mg daily
62788908|NCT00691184|ACTIVE_COMPARATOR|Group 3|1% Lamisil® Cream
62788909|NCT00691184|ACTIVE_COMPARATOR|Group 4|Dose of 250 mg Lamisil® Tablets (Groups 1,2,3) at end of study.
62788910|NCT03469713|EXPERIMENTAL|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
62017032|NCT02974361|EXPERIMENTAL|Part B Ibuprofen LDH Excipient Combo 1|
62017033|NCT02974361|EXPERIMENTAL|Part B Ibuprofen LDH Excipient Combo 2|
62206757|NCT05000931|EXPERIMENTAL|To demonstrate the safety of the Osia 2 System in a pediatric population aged 5 - 11 years.|
62206758|NCT06728904|EXPERIMENTAL|intervention group|The experimental group needs to complete high-intensity Tai Chi intervention for about 4-8 weeks according to the intervention requirements, 3-5 times/week, 45-90 minutes/time. Except for this, participants are required to participate in theoretical knowledge learning such as health lectures and online courses, as well as home autonomy exercises. This study will monitor the training status of participants through enterprise WeChat, mini programs, or app check-in to ensure high compliance. In addition, as the research subjects belong to a special population, this study expects to use the Subjective Fatigue Scale (RPE) to monitor the fatigue level of the subjects in real time to ensure safety.
62215408|NCT02307461|EXPERIMENTAL|Part 1 Cohort 2|IPI-145 test formulation (capsule) low single dose and IPI-145 reference formulation (capsule) low single dose
62215409|NCT02307461|EXPERIMENTAL|Part 2 Cohort 3|IPI-145 test formulation (capsule) high single dose administered under fasted and fed conditions
62581244|NCT02766803|PLACEBO_COMPARATOR|simvastatin+ placebo|simvastatin 20 mg daily Placebo
62017034|NCT02974361|EXPERIMENTAL|Part B Ibuprofen LDH Excipient Combo 3|
62017035|NCT02974361|EXPERIMENTAL|Part B Ibuprofen LDH Excipient Combo 4|
62017036|NCT02974361|ACTIVE_COMPARATOR|Part C Ibuprofen|
62017037|NCT02974361|EXPERIMENTAL|Part C Ibuprofen LDH Excipient Combo 1|
62206759|NCT06728904|NO_INTERVENTION|control group|This study provides health education and stretching courses for the control group. Various health education professionals will provide educational courses on asthma treatment topics, covering self-assessment, coping strategies, solutions, dietary nutrition, and disease management. At the same time, the participants in this group are required to participate in stretching courses (such as 40 minutes/time, 3 times/week), as well as home self stretching (expected to be 20 minutes/day).
62206760|NCT00706290|EXPERIMENTAL|Intervention - CBT|Participants randomized to the intervention group received cognitive behavioral therapy (CBT) for anxiety after completing a baseline assessment consisting of clinician administered psychiatric evaluations and a psychosocial self-report battery. After completing the CBT intervention, consisting of 6-7 sessions over the course of 2-3 months, participants completed a post-intervention assessment identical to the baseline.
62206761|NCT00706290|NO_INTERVENTION|Routine Care Control|Participants randomized to the control condition completed a baseline assessment consisting of clinician administered psychiatric evaluations and a psychosocial self-report battery. They then received routine medical care. After 2 months and after completing the post clinical assessment identical to the baseline, they were offered the opportunity to receive the CBT intervention for free. This ensured that all participants ultimately received cognitive-behavioral therapy if desired, while permitting an examination of the effect size for the intervention compared to routine care.
62206762|NCT05672901|EXPERIMENTAL|StrataMGT|Participants will apply StrataMGT (silicone gel) 2-5 times daily (no limit in application times) to treat GSM for 3 months.
62788911|NCT05179525|EXPERIMENTAL|Risperidone ISM® 100 mg|Subjects will receive 4 mg oral risperidone once daily for 7 days. After the 1 week oral risperidone regimen subjects will be administered 100 mg risperidone ISM as an injectable into the gluteal muscle. A total of 4 doses of intramuscular (IM) 100 mg risperidone ISM® will be administered deeply into the gluteal muscle. Each dose will be separated by 4 weeks.
62788912|NCT03833219|NO_INTERVENTION|Control (monitor only)|Continue in monitoring only mode
62788913|NCT03833219|EXPERIMENTAL|Social comparison feedback|Report user's handheld phone use/ hour of driving for week. Compare this week's performance to distribution for driver cohort.
62788914|NCT03833219|EXPERIMENTAL|End of rating period incentive|Monitor throughout intervention period and compare overall use to distribution for cohort. Notify participant at end of intervention period regarding the amount they have earned.
62788915|NCT03833219|EXPERIMENTAL|End of rating period incentive + social comparison feedback|Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant at end of intervention period regarding the amount they have earned.
62788916|NCT03833219|EXPERIMENTAL|Weekly loss-framed incentive + social comparison feedback|Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant weekly regarding the amount they have earned.
62788917|NCT03833219|EXPERIMENTAL|Larger weekly loss-framed incentive+social comparison feedback|"Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant weekly regarding the amount they have earned. Incentive amount is higher than Weekly loss-framed incentive + social comparison feedback Arm."
62788918|NCT01746225|EXPERIMENTAL|A: nab-Paclitaxel 150 mg/m2 days 1,15|"Arm A: Induction\* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 150 mg/m2 administered on days 1, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.~\*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m²."
62788919|NCT01746225|EXPERIMENTAL|B: nab-Paclitaxel 100 mg/m2 days 1,8,15|"Arm B: Induction\* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 100 mg/m2 administered on days 1, 8, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.~\*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m²."
62788920|NCT01746225|EXPERIMENTAL|C: nab-Paclitaxel 75 mg/m2 days 1,8,15,22|"Arm C: Induction\* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 75 mg/m2 administered on days 1, 8, 15, 22 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.~\*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m²."
62788921|NCT05706441||ultrasound|Pulmonary and diaphragm ultrasound was evaluated within one hour before withdrawal
62206763|NCT05672901|ACTIVE_COMPARATOR|Estrace|Participants will receive Estrace vaginal cream (estrogen) to treat GSM for 3 months. Application will be 1 g daily for the first two weeks. Afterwards, a maintenance dosage of 1 g three times a week is applied.
62206764|NCT04806373|PLACEBO_COMPARATOR|Talc Slurry Pleurodesis (TSP) plus placebo|Patients who sign informed consent may be randomized to receive TSP alone (talc, 5 gm in 50 ml NS) with placebo (50 ml Normal saline (NS)) through the chest pleural catheter.
62017038|NCT02974361|EXPERIMENTAL|Part C Ibuprofen LDH Excipient Combo 2|
62017039|NCT02974361|EXPERIMENTAL|Part C Ibuprofen LDH Excipient Combo 3|
62405677|NCT02329951||Epidural steroid injections|Patients will receive a single interlaminar epidural steroid injection with 60 mg depomethylprednisolone, 1.5 ml of 0.25% bupivacaine and 1.5 ml of saline or a transforaminal epidural steroid injection with 60 mg depomethylprednisolone, 1.5 ml of 0.25% bupivacaine and 0.5 ml of saline.
62405678|NCT02329951||Facet interventions|Patients will receive diagnostic medial branch (facet joint nerve) blocks with 0.5 ml of 0.5% bupivacaine. If they experience a positive block (\> 50% pain relief lasting more than 3 hours), they will then receive radiofrequency denervation.
62405679|NCT02329951||Sacroiliac joint injections|Patients will receive a single SI joint injection on the affected side(s) with 40 mg depomethylprednisolone and 2 ml of 0.5% bupivacaine.
62405680|NCT03503565||Moderate block group|maintaining moderate intraoperative neuromuscular blockade (TOF count 1 or 2) during surgery and reversal using sugammadex 2 mg/kg after surgery
62017040|NCT02974361|EXPERIMENTAL|Part B Ibuprofen LDH Excipient Combo 5|
62017041|NCT00652457|EXPERIMENTAL|Memantine|Memantine 10 mg BID for three months
62405681|NCT03503565||Deep block group|maintaining deep intraoperative neuromuscular blockade (PTC 1 or 2) during surgery and reversal using sugammadex 4 mg/kg after surgery
62405682|NCT03436940|ACTIVE_COMPARATOR|On Demand Discharge Planning (DDP)|Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team only in case of a specific request by the unit of hospitalization.
62788922|NCT03124836|EXPERIMENTAL|R2-25 Sensor|All subjects will be enrolled in the test group and will receive R2-25 Pulse Oximeter Sensor
62017042|NCT00652457|PLACEBO_COMPARATOR|Placebo|Placebo 10 mg BID for three months
62206765|NCT04806373|EXPERIMENTAL|Talc Slurry Pleurodesis (TSP) plus Cathflo Activase|Patients who sign informed consent may be randomized to receive TSP (Talc, 5mg in 50ml Normal saline (NS)) with cathflo activase (4 mg in 50 ml NS) through the chest pleural catheter
62405683|NCT03436940|EXPERIMENTAL|Routine Discharge Planning (RDP)|All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
62788923|NCT06530966|EXPERIMENTAL|ICP-332|
62788924|NCT06530966|PLACEBO_COMPARATOR|Placebo|
62788925|NCT01177189|OTHER|Arm 1|Young healthy men and women aged 18-30
62788926|NCT01177189|OTHER|Arm 2|Older healthy men and women aged \>70.
62017043|NCT02418260|ACTIVE_COMPARATOR|Open reduction and plate osteosynthesis|Open reduction and internal fixation with DCP 4.5mm plate.
62017044|NCT02418260|EXPERIMENTAL|Bridge Plate|Patients will be submitted to closed reduction and anterior bridge plate osteosynthesis (narrow 4.5mm DCP plate will be used)
62017045|NCT02418260|EXPERIMENTAL|Intramedullary nail|Patients will be submitted to closed reduction and locked intramedullary nail osteosynthesis.
62788927|NCT01558453|EXPERIMENTAL|Eloxatin|Oxaliplatin
62788928|NCT01037686|OTHER|PD, DBS, healthy controls|Patients with idiopathic PD before or after DBS surgery (during on or off-stimulation) and healthy controls.
62788929|NCT05728398|ACTIVE_COMPARATOR|Music Intervention Group|Participants randomized to receive music intervention during interventional radiology procedure.
62788930|NCT05728398|SHAM_COMPARATOR|No Music Comparator Group|Participants randomized to have no music played during interventional radiology procedure.
62788931|NCT00571038|EXPERIMENTAL|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
62788932|NCT00571038|ACTIVE_COMPARATOR|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
62788933|NCT05267951|EXPERIMENTAL|Open-loop Stimulation|Continuous stimulation
62788934|NCT05267951|EXPERIMENTAL|Close-loop Stimulation|Intended movement-based stimulation.
62788935|NCT01248949|EXPERIMENTAL|MEDI3617 SINGLE AGENT TOTAL|Participants will receive MEDI3617 via intravenous (IV) infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
62788936|NCT01248949|EXPERIMENTAL|MEDI3617 + BEVACIZUMAB Q3W ESCALATION|Participants will receive MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
62206766|NCT06145438|ACTIVE_COMPARATOR|Leuprolide Acetate|Leuprolide Acetate, brand name Tapros 3.75 mg, injected intramuscularly every month for 3 months
62206767|NCT06145438|EXPERIMENTAL|Dienogest|Dienogest 2 mg, brand name Nelandoz 2mg, administered orally, every day for 3 months
62206768|NCT06145438|EXPERIMENTAL|Depot medroxyprogesterone acetate|Depot medroxyprogesterone acetate, brand name Depo Provera 150mg/ml, injected intramuscularly, every month for 3 months
62206769|NCT06145438|EXPERIMENTAL|Combined Oral Contraceptive|Levonogestrel 150 mcg + etinilestradiol 30 mcg, brand name Mycrogynon, administered orally, every day for 3 months
62206770|NCT04446728|ACTIVE_COMPARATOR|Strategy I.Training|Sites randomized to Strategy I will receive a three hour training webinar in preparing for implementation of the PAT in their center.
62206771|NCT04446728|ACTIVE_COMPARATOR|Strategy II.Training+Implementation Enhanced Resources (TIER)|Sites randomized to Strategy II will identify a Champion for screening and will participate in a monthly consultation call in addition to completing the three hour training webinar for implementing the PAT in their center.
62206772|NCT06064968|EXPERIMENTAL|intervention group|"In intervention group, researcher will explain the patient about the intermittent catheterization technique and give the practical demonstration for better patient understanding and make correction in patient's technique of intermittent bladder catheterization.~Patient will be followed from the day of recruitment in the study after every 02 weeks by the researcher for 2 successive months.~In every follow up session, assessment of the urinary complaints via AUA scoring, review of patient's technique of urethral catheterization in intervention group, and each patient's adherence to the intermittent bladder catheterization (IBC) will be noted"
62206773|NCT06064968|ACTIVE_COMPARATOR|Control group|In control group already diagnosed cases of urethral stenosis who have undergone urethral dilatation will be followed fortnightly for AUA symptoms scoring for urinary complaints and urethral catheterization with nelton 14 Fr to exclude urethral stricture recurrence.
62206774|NCT06184126|EXPERIMENTAL|Active Immersive Virtual Reality|Patient with sickle cell disease experiencing acute vaso-occlusive crisis randomized to this arm will participate in an active immersive application on the virtual reality headset with hand-held controllers. The active immersive application will allow the user to interact directly with the application and move through the virtual environment .The patient will be able to use the active immersive application on the device for a maximum of two hours.
62017046|NCT00945516|ACTIVE_COMPARATOR|Flared end FCSEMS|Flared end FCSEMS will be inserted for the benign bile duct stricture.
62206775|NCT06184126|EXPERIMENTAL|Passive Immersive Virtual Reality|Patient with sickle cell disease experiencing acute vaso-occlusive crisis randomized to this arm will participate in a passive immersive application on the virtual reality headset with hand-held controllers. The passive immersive application will not allow the user to interact directly with the application or move through the virtual environment .The patient will be able to use the passive immersive application on the device for a maximum of two hours.
62405684|NCT05353920|EXPERIMENTAL|Cognitive traiinig|
62405685|NCT05353920|ACTIVE_COMPARATOR|Active control|
62405686|NCT03323021|EXPERIMENTAL|Treatment with DHACM|Partial nephrectomy patched with DHACM
62405687|NCT03323021|ACTIVE_COMPARATOR|Control without DHACM|Partial nephrectomy without DHACM.
62405688|NCT05173025|EXPERIMENTAL|Fimasartan|- Fimasartan group: Fimasartan, 60 mg once a day, oral administration
62206776|NCT06184126|PLACEBO_COMPARATOR|Blindfold and Ear Plugs|Patient with sickle cell disease experiencing acute vaso-occlusive crisis randomized to this arm will wear a blindfold and ear plugs. The patient will be able to remain blindfolded and earplugs for a maximum of two hours.
62206777|NCT02550938|EXPERIMENTAL|7 Aligner Cohort weartime 1|Seven Aligner cohort will change aligners at a designated interval Invisalign is the intervention.
62206778|NCT02550938|EXPERIMENTAL|7 Aligner Cohort weartime 2|Seven Aligner cohort will change aligners at a modified interval Invisalign is the intervention.
62206779|NCT02550938|EXPERIMENTAL|12 aligner cohort weartime 1|Twelve Aligner cohort will change aligners at a designated interval Invisalign is the intervention.
62206780|NCT02550938|EXPERIMENTAL|12 aligner cohort weartime 2|Twelve Aligner cohort will change aligners at a modified interval Invisalign is the intervention.
62206781|NCT03211234|EXPERIMENTAL|2.0 mg DE-122|2.0 mg DE-122 and Lucentis ® 0.5 mg
62206782|NCT03211234|EXPERIMENTAL|4.0 mg DE-122|4.0 mg DE-122 and Lucentis ® 0.5 mg
62206783|NCT03211234|SHAM_COMPARATOR|Sham|Sham and Lucentis ® 0.5 mg
62206784|NCT02842151|OTHER|Manifest refraction|Manifest refraction performed by autorefraction (automated) and manual procedures (standard). Subject implanted with ACRYSOF® IQ Monofocal IOL Model SN60WF. Autorefraction performed by Topcon® KR-1W Wave-Front Analyzer.
62405689|NCT05173025|ACTIVE_COMPARATOR|Amlodipine|- Comparator group: Amlodipine, 5 mg once a day, oral administration
62405690|NCT02413749||Stable PsA response to treatment|Individuals with psoriatic arthritis who are being treated standard of care with a stable DMARD or a biologic
62405691|NCT02413749||PsA inadequate response to DMARD|Individuals with psoriatic arthritis who have had an inadequate response to a DMARD and are being treated standard of care with a biologic.
62206785|NCT03556956|EXPERIMENTAL|Masitinib plus FOLFIRI|"Masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid).~Masitinib will be prescribed until disease progression (or treatment switch to next line of treatment), death, limiting toxicity or patient consent withdrawal."
62206786|NCT03556956|NO_INTERVENTION|Best Supportive Care|Best Supportive Care (BSC) includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
62206787|NCT02506075|EXPERIMENTAL|Pre-tDCS group|"In Pre-tDCS group, total sessions of the transcranical direct current stimulator stimulation(tDCS) was done for each three subgroups and visual inattention training was followed after that.~Patient had 2 times of tDCS for 13 minutes with 20minutes of resting interval. After that, additional 2 times of Visual inattention training was done with same protocol."
62206788|NCT02506075|EXPERIMENTAL|Simultaneous tDCS group|In Simultaneous transcranical direct current stimulator(tDCS) group, tDCS and visual inattention training was done simultaneously.
62206789|NCT02506075|NO_INTERVENTION|Sham control group|without transcranical direct current stimulator(tDCS) or without visual training
62206790|NCT00830505|EXPERIMENTAL|1: fluticasone/salmeterol|2 puffs twice a day for 2 weeks
62206791|NCT00830505|ACTIVE_COMPARATOR|2: fluticasone|2 puffs twice a day for 2 weeks
62206792|NCT01720160|EXPERIMENTAL|Device|1) BAROSTIM NEO System and 2) standard of care medical management therapy for heart failure (American Heart Association \[AHA\] / American College of Cardiology \[ACC\] guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
62788937|NCT01248949|EXPERIMENTAL|MEDI3617 + BEVACIZUMAB Q2W TOTAL|Participants will receive MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.
62788938|NCT01248949|EXPERIMENTAL|MEDI3617 + PACLITAXEL TOTAL|Participants will receive MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.
62788939|NCT01248949|EXPERIMENTAL|MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL|Participants will receive MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
62788940|NCT06040762|EXPERIMENTAL|Arm A ([P]REHAB intervention)|Patients use the ExerciseRx app to follow the (P)REHAB exercise program, which consists of four 20-30 minute home exercise sessions per week and personalized step count goal setting and tracking, prior to SOC surgery and for 90 days following surgery (total \~4-7 months). Patients also download the FitBit app and wear a FitBit throughout the study.
62017047|NCT00945516|ACTIVE_COMPARATOR|Anchoring FCSEMS|Anchoring FCSEMS will be inserted for benign bile duct stricture
62017048|NCT04304690|OTHER|caregiver|caregivers from emergency, ICU, virology and infectious disease services
62017049|NCT03096548|EXPERIMENTAL|Sun Safety Ink! Program|A program to (1) increase full-body sun comprehensive sun protection practices, (2) decrease sunburning and tanning and (3) decrease positive attitudes regarding tanning and tanning attractiveness of tattoo studio clients. The program is comprised of a video based communication strategy training presented by research staff to artists of tattoo studios.
62017050|NCT03096548|ACTIVE_COMPARATOR|Attention Control|The attention control group will provide standard tattoo aftercare instructions to their clients.
62017051|NCT05953194|ACTIVE_COMPARATOR|Control (neutral) messages|Participants will view control messages approximately matched to the intervention messages on length, but discussing a neutral topic unrelated to sugary drinks (safe driving). Participants will view a total of 4 messages developed for this arm.
62206793|NCT01720160|ACTIVE_COMPARATOR|Medical Management|Standard of care medical management therapy for heart failure (American Heart Association \[AHA\] / American College of Cardiology \[ACC\] guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
62206794|NCT06718335|EXPERIMENTAL|Pyrotinib|Patients who meet the screening criteria will receive pyrotinib (400mg, qd) + trastuzumab injection (first dose 8mg/kg, subsequent 6mg/kg, d1) + albumin purpurenin (125mg/m2, d1, d8) + carboplatin (AUC=6, d1) for 21 days/cycle for a total of 6 cycles of neoadjuvant therapy. One month after the end of neoadjuvant therapy, patients should receive radical mastectomy (breast-conserving surgery or total mastectomy), if the postoperative pathological complete response patients receive pyrotinib (400mg, qd) for one year,. If patients were hormone receptor positive patients at the adjuvant treatment stage, the endocrine treatment regimen was selected by the investigators.
62206795|NCT06718335|EXPERIMENTAL|T-DM1|Patients who meet the screening criteria will receive pyrotinib (400mg, qd) + trastuzumab injection (first dose 8mg/kg, subsequent 6mg/kg, d1) + albumin purpurenin (125mg/m2, d1, d8) + carboplatin (AUC=6, d1) for 21 days/cycle for a total of 6 cycles of neoadjuvant therapy. One month after the end of neoadjuvant therapy, patients should receive radical mastectomy (breast-conserving surgery or total mastectomy), if the postoperative non-pathological complete response patients with RCB-1 receive Trastuzumab Emtansine (3.6 mg/kg, iv) for one year. If patients were hormone receptor positive patients at the adjuvant treatment stage, the endocrine treatment regimen was selected by the investigators.
62405692|NCT04766346|EXPERIMENTAL|Nutritional Supplement|The NS is a fortified cow's milk-based product provided in powdered form.
62405693|NCT05144724|EXPERIMENTAL|Volume Targeted Ventilation|Positive pressure ventilation will be provided using a set tidal volume
62788941|NCT06040762|ACTIVE_COMPARATOR|Arm B (standard of care)|Patients receive SOC educational materials and wear a FitBit and use the FitBit app prior to SOC surgery and for 90 days following surgery (total \~4-7 months).
62215410|NCT06599671|EXPERIMENTAL|Transvaginal niche resection|The patients assigned to the intervention group will undergo a procedure under general anaesthesia in lithotomy position.
62206796|NCT06718335|EXPERIMENTAL|T-DM1 and pertuzumab|Patients who meet the screening criteria will receive pyrotinib (400mg, qd) + trastuzumab injection (first dose 8mg/kg, subsequent 6mg/kg, d1) + albumin purpurenin (125mg/m2, d1, d8) + carboplatin (AUC=6, d1) for 21 days/cycle for a total of 6 cycles of neoadjuvant therapy. One month after the end of neoadjuvant therapy, patients should receive radical mastectomy (breast-conserving surgery or total mastectomy), if the postoperative non-pathological complete response patients with RCB≥2 were treated with Trastuzumab Emtansine (3.6 mg/kg, iv) combined with pertuzumab for one year. If patients were hormone receptor positive patients at the adjuvant treatment stage, the endocrine treatment regimen was selected by the investigators.
62206797|NCT06729216||Antifungal susceptibility testing (AFST)|
62206798|NCT04739943|EXPERIMENTAL|Mobile Monitoring|Participants will be asked to use a smartphone or tablet application for remote monitoring or respiratory health. They will be followed over time with surveys as well as chart review to assess effects of adding these mobile monitoring elements to their standard care.
62206799|NCT06333028||enVista Aspire intraocular lens (IOL)|Subjects bilaterally implanted with enVista Aspire EA IOLs.
62206800|NCT04351958|EXPERIMENTAL|"Augmented Reality (No Time Wasted)"|
62206801|NCT06728514|EXPERIMENTAL|GROUP-ESPB|Erector spinae plane block
62206802|NCT06728514|EXPERIMENTAL|GROUP-PVB|Para vertebral block
62405694|NCT05144724|ACTIVE_COMPARATOR|Pressure guided Ventilation|Positive pressure ventilation will be provided using a set peak inflation pressure
62405695|NCT00978640|EXPERIMENTAL|fasting and exercise|36 h fast and 1 h ergometer cycling 50% VO2max
62405696|NCT00978640|EXPERIMENTAL|exercise|1 h ergometer cycling 50% VO2max
62405697|NCT01283009|PLACEBO_COMPARATOR|Arm 1: Inactive substance|Inactive substance
62206803|NCT04656496|EXPERIMENTAL|NOURISH-T+|NOURISH-T+ targets parents as agents of change by providing intensive parent skills training emphasizing role modeling of positive health behaviors to foster the development of healthy eating and physical activity in pediatric cancer survivors. The NOURISH-T+ group will have 6 weekly, 1-1.5 hour, manualized sessions delivered using video-conferencing. There will be 2 additional brief sessions where the child will participate along with their parent to promote child engagement. Additionally, there will be one session with a pediatric oncology dietician based out of Nicklaus Children's Hospital who will discuss personalized nutritional strategies. Brief booster sessions at 2-, 4-, 8-, and 10- months will maximize retention and follow-up participation. NOURISH-T+ content is theory-based, manualized, and builds upon strengths of our prior work with NOURISH-T (our pilot) and NOURISH (our work with otherwise healthy overweight and obese children).
62206804|NCT04656496|ACTIVE_COMPARATOR|EUC - Brief NOURISH-T+|The EUC condition (Brief NOURISH-T+) engages parents in one information session moderated by a USF-based interventionist using videoconferencing. Session content is taken from the publicly available We Can! Manual. Parents in this group will receive nationally available web-based brochures on pediatric overweight/obesity on two occasions during the 6 weeks that NOURISH-T+ families participate in the study. Check-ins will take place at 2-, 4-, 8-, and 10- months post-intervention.
62206805|NCT02580721|ACTIVE_COMPARATOR|Thick mucosal tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted.
62206806|NCT02580721|EXPERIMENTAL|Thin mucosal tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted.
62206807|NCT02580721|EXPERIMENTAL|Thickened mucosa with connective tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted. Soft tissue augmentation will be performed with sub epithelial connective tissue graft.
62206808|NCT02580721|EXPERIMENTAL|Thickened mucosa with ADM|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted. Acellular dermal matrix, thick 1 x 4 cm will be used for vertical soft tissue augmentation.
62788942|NCT04529343|EXPERIMENTAL|Virtual Reality Group|To the virtual reality group; In addition to upper extremity exercises applied 2 days a week, upper extremity rehabilitation via virtual reality glasses will be performed 3 days a week for 6 weeks and each session will be 45 minutes.
62788943|NCT04529343|ACTIVE_COMPARATOR|Control Group|Upper extremity exercises will be applied to the participants in the control group 2 days a week for 6 weeks.
62206809|NCT05299697|EXPERIMENTAL|TG103 15 mg|Administered subcutaneously (s.c., under the skin) once every week for 24 weeks. Doses gradually increased to 15 mg.
62206810|NCT05299697|EXPERIMENTAL|TG103 22.5 mg|Administered subcutaneously (s.c., under the skin) once every week for 24 weeks. Doses gradually increased to 22.5 mg.
62206811|NCT05299697|PLACEBO_COMPARATOR|Placebo|Administered subcutaneously (s.c., under the skin) once every week for 24 weeks.
62405698|NCT01283009|ACTIVE_COMPARATOR|Arm 2: Methylprednisolone|Methylprednisolone
62405699|NCT05069376|EXPERIMENTAL|The intraureteral placement of distal end of ureteral stent|Patients randomized to this group received 5-16/5-18 D-J stent with intraureteral placement of the distal end
62405700|NCT05069376|ACTIVE_COMPARATOR|The conventional placement of the distal end of ureteral stent|Patients randomized to this group received 5-22/5-24 D-J stent with bladder placement of the distal end
62405701|NCT02223637||Exposure group|"Pregnant women who were exposed to~≥1 dose of Menveo vaccine within 28 days prior to conception or at any time during pregnancy were included."
62405702|NCT06096909|EXPERIMENTAL|experimental group|intensive lipid lowering therapy
62405703|NCT06096909|ACTIVE_COMPARATOR|control group|conventional lipid lowering therapy
62405704|NCT04698018|EXPERIMENTAL|Faster aspart|Subjects will receive 2 injections of a single dose of faster aspart at a predefined fixed dose level (0.2 U/kg body weight) for type 1 diabetes and (0.3 U/kg body weight) if subject has type 2 diabetes.
62581245|NCT06682026|NO_INTERVENTION|No Intervention|Written informed consent will be obtained from the patients immediately before they enter the procedure, and Personal Information Forms and the State Anxiety Inventory (STAI) will be administered to all participants. No intervention will be made to women in the control group. At the end of the procedure, the Visual Analog Scale (VAS) pain scale and the State Anxiety Inventory (STAI) will be applied to both groups.
62581246|NCT06682026|EXPERIMENTAL|listening to music or chatting|"Written consent will be obtained from the patients just before they enter the procedure, and Personal Information Forms and the State Anxiety Inventory (STAI) will be applied to all participants.~Women in the experimental group will be asked to listen to a lively music of their own choosing during the mammography, or for those who do not want music, their attention will be drawn in a different direction by chatting.~At the end of the procedure, the Visual Acuity Scale (VAS) pain scale and the State Anxiety Inventory (STAI) will be applied to both groups."
62581247|NCT06455293|EXPERIMENTAL|Psilocybin Administration Session 1|"Participants will receive one dose of psilocybin ranging from low (microdose) to high in a monitored setting with preparation sessions before and integration sessions after."
62581248|NCT06455293|EXPERIMENTAL|Psilocybin Administration Session 2|"Participants will receive one dose of psilocybin ranging from low (microdose) to high in a monitored setting with preparation sessions before and integration sessions after."
62581249|NCT06683274||Control cohort|Current practice cohort
62581250|NCT06683274||Interventional cohort|Best practice care pathway with standardized Bascom cleft lift
62581251|NCT06585982|ACTIVE_COMPARATOR|RILLUS|Treatment group receive RILLUS, a synbiotic that each tablet contains Viable cells 1.0 x 109 CFU containing three types of prebiotic species (Lactobacillus plantarum 8.55mg, Streptococcus thermophilus 8.55mg, and Bifidobacterium bifidum 2.55 mg) and Fructooligosaccharide (FOS) 480 mg as prebiotic.
62581252|NCT06585982|PLACEBO_COMPARATOR|Placebo|Control group receive what appeared to be RILLUS, but only placebo containing Fructooligosaccharide, Xylitol DC, Isomalt, Microcrystalline cellulose, Corn starch, Milk flavor powder, Hydroxypropyl methylcellulose, Vanilla flavor powder, Magnesium stearate
62581253|NCT02624414|OTHER|Anti TNF induction therapy 6-12 months|All subjects will be identified through The Royal Melbourne Hospital's IBD clinic, associated specialty clinics and the colonoscopy waiting list of The Royal Melbourne Hospital. The potential participants who have been commenced on Anti TNF induction therapy 6-12 months prior to commencement of the study will be identified. The potential participants identified in this way will be informed of the project at the time of contact and assessment; in some instances the potential participant will be informed of the project via telephone where subjects are remote. The potential participants will be provided an Ethically-approved information sheet at this time. Consent will be gained at the time of assessment.
62017052|NCT05953194|EXPERIMENTAL|Traditional health messages|Participants will view traditional health messages focused on the health consequences of sugar-sweetened beverage consumption, using text adapted from prior sugary drink campaigns. Participants will view a total of 4 messages developed for this arm.
62017053|NCT05953194|EXPERIMENTAL|Counter-marketing messages|Participants will view counter-marketing messages about sugary drinks that incorporate principles of effective counter-marketing campaigns, including describing industry manipulation of consumers, appealing to emotions (especially anger), describing health consequences, and criticizing the industry for demographic targeting. Messages include text adapted from prior counter-marketing campaigns. Participants will view a total of 4 messages developed for this arm.
62581254|NCT04411056|EXPERIMENTAL|Barrier box|Participants will have a barrier box placed during intubation
62581255|NCT04411056|NO_INTERVENTION|No Barrier box|Participants will have routine intubation with no barrier box
62581256|NCT00443079|EXPERIMENTAL|Siliphos/Placebo|Received study medication first followed by placebo
62581257|NCT00443079|EXPERIMENTAL|Placebo/Siliphos|Received placebo first followed by study medicaiton
62017054|NCT03360500|EXPERIMENTAL|EXERCISE PROTOCOL + CRYOTHERAPY|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
62017055|NCT03360500|EXPERIMENTAL|EXERCISE PROTOCOL|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
62017056|NCT03360500|PLACEBO_COMPARATOR|EXERCISE PROTOCOL + PLACEBO|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
62017057|NCT05558410|EXPERIMENTAL|VX-548|Participants will receive VX-548.
62405705|NCT04698018|ACTIVE_COMPARATOR|NovoRapid®|Subjects will receive 2 injections of a single dose of NovoRapid® at a predefined fixed dose level (0.2 U/kg body weight) for type 1 diabetes and (0.3 U/kg body weight) if subject has type 2 diabetes.
62405706|NCT05629260||G-CSF/ATG group|Patients in the G-CSF/ATG group received a modified Bu/Cy plus ATG conditioning regimen as follows: cytarabine (4/g m2 per day IV.) on days -10 to -9; Bu (3.2 mg/kg per day IV.) on days -8 to -6; Cy (1.8 g/m2 per day IV.) on days -5 to -4; methyl chloride hexamethylene urea nitrate (Me-CCNU) (250 mg/m2 per day orally) once on day -3; and ATG (2.5 mg/kg per day IV; rabbit, Sang Stat, Lyon, France) on days -5 to -2.
62017058|NCT05558410|ACTIVE_COMPARATOR|Hydrocodone bitartrate/acetaminophen (HB/APAP)|Participants will receive HB/APAP.
62017059|NCT05558410|PLACEBO_COMPARATOR|Placebo|Participants will receive placebos matched to VX-548 and HB/APAP.
62215411|NCT06599671|NO_INTERVENTION|Standard of care|The patients assigned to the control group will receive usual care at least 9 months which means no additional surgical intervention during this period.
62405707|NCT05629260||PT-Cy group|Patients in PT-Cy group received a Bu/Flu/Cy-based conditioning regimen as follows: Flu (40 mg/m2 or 1 mg/kg IV) on days -8 to -4; Bu (3.2 mg kg/ d-1 IV) on days -7 to -4; Cy (14.5-40 mg/kg IV) on days -3 to -2;±cytarabine (3 g/m2/d IV) on days -9 to -8; and ± IDA (15 mg/m2/d IV) on days -9 to -8. The addition of IDA and/or cytarabine depended on the performance status of the patients and whether the patients were in relapse status. High-dose PTCy (50 mg/kg/d IV) was administered on days +3 and +4.
62405708|NCT03648073|EXPERIMENTAL|Patients with Radiographic Evidence of HCC on CT or MRI|\[68Ga\]DOTATATE-PET/MRI in Hepatocellular Carcinoma
62581258|NCT02241083|ACTIVE_COMPARATOR|dopamine group|vasopressor dosage individually titred according to the mean arterial pressure
62405709|NCT01035021|ACTIVE_COMPARATOR|group N|Anesthesia is induced with propofol and remifentanil and LMA is inserted by the standard technique according to eht manufacturer's instruction. Rocuronium is administered for the operation.
62405710|NCT01035021|ACTIVE_COMPARATOR|group R|Anesthesia is induced with a propofol and remifentanil and rocuronium 0.06 mg/kg is injected. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction.
62581259|NCT02241083|ACTIVE_COMPARATOR|norepinephrine group|vasopressor dosage individually titred according to the mean arterial pressure
62581260|NCT02241083|ACTIVE_COMPARATOR|control group|no medication
62581261|NCT03599011||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
62581262|NCT03599011||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
62581263|NCT03599011||Non exposure|Non-pharmacological treatment (psychotherapy)
62206812|NCT02074189|ACTIVE_COMPARATOR|Adjuvant Chemotherapy|Adjuvant Chemotherapy(Gemcitabine, Cisplatin):Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)
62206813|NCT02074189|NO_INTERVENTION|Control|No immediate post-surgery treatment. Patients undergo observation followed by cisplatin and gemcitabine as in arm I at local relapse, or receive intravenously chemotherapy with cisplatin and gemcitabine at multiple metastases
62206814|NCT00964886|EXPERIMENTAL|Arm 1|desipramine hydrochloride
62581264|NCT06193811|EXPERIMENTAL|R-T1-T2-T3|Reference (R): Avenciguat (BI 685509) (TF2), fasted Test 1 (T1): Avenciguat (BI 685509) (iCF), fasted Test 2 (T2): Avenciguat (BI 685509) (iCF), fed Test 3 (T3) Nexium mups from Day -4 to 1; on Day 1 intake of Nexium mups is followed by the intake of Avenciguat (BI 685509) (iCF), fasted There will be a washout period of at least 6 days between Avenciguat (BI 685509) administrations.
62581265|NCT06193811|EXPERIMENTAL|T1-T3-R-T2|
62581266|NCT06193811|EXPERIMENTAL|T2-R-T3-T1|
62581267|NCT06193811|EXPERIMENTAL|T3-T2-T1-R|
62581268|NCT05305105|EXPERIMENTAL|Psilocybin|Participants will complete an 8-week course of study treatment including two doses of psilocybin with psychological support administered approximately 2 weeks apart.
62581269|NCT01909362||Early recurrence (≤ 12 months)|Biospecimens from 25 patients who have had early recurrence (≤ 12 months) of their metastatic colorectal cancer
62206815|NCT00964886|EXPERIMENTAL|Arm 2|cognitive behavioral therapy
62206816|NCT00964886|EXPERIMENTAL|Arm 3|desipramine hydrochloride and cognitive behavioral therapy
62206817|NCT00964886|PLACEBO_COMPARATOR|Arm 4|anticholinergic medication; active placebo
62405711|NCT04543747||Patients implanted with HVAD System|Patients who require treatment with HVAD for use as bridge to cardiac transplantation (BTT) or destination therapy (DT) within the re-examination period are eligible for enrollment into the MCS Korea PMS. Patient consent may be obtained prior to HVAD implant or after receiving HVAD implant. Waiver of consent may be allowed if allowed by site's Institutional Review Board (IRB) or Ethics Committee (EC).
62405712|NCT03726242|ACTIVE_COMPARATOR|Levcromakalim|"To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.~To give 0,05 ml intradermal and 0.2 intramuscular of 150 ug/ml levcromakalim after baseline time 0."
62405713|NCT03726242|PLACEBO_COMPARATOR|Saline|"To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.~To give 0,05 ml intradermal and 0.2 intramuscular of saline after baseline time 0."
62405714|NCT06207045|EXPERIMENTAL|limb elevation group|limb elevation plus standard medication
62206818|NCT01978327|EXPERIMENTAL|GSK2647544|The planned repeat doses of GSK2647544 are 80 mg bid, 200 mg bid, and 350 mg bid
62206819|NCT01978327|PLACEBO_COMPARATOR|Placebo|Matching placebo
62206820|NCT01978327|EXPERIMENTAL|simvastatin|for drug-drug interaction
62206821|NCT01978327|EXPERIMENTAL|simvastatin co-dosed with GSK2647544|for drug-drug interaction
62206822|NCT04629833|EXPERIMENTAL|MC0518|Participants will receive MC0518 1-2 million cells/ kilogram infusions (based on body weight at the Screening Visit) once a week for 4 weeks (Visit Day 1, 8, 15, and 22). Participants with partial response (PR) on Day 28 will have 2 additional MC0518 infusions administered on Day 29 and 36.
62215412|NCT01563159||Group A|All children ≤ 5 years old with a rotavirus detection test (inpatient and ambulatory tests) performed during the period of June the 1st 2010 and May the 31st 2011.
62581270|NCT01909362||Late recurrence (> 12 months)|Biospecimens from 25 patients who have had late recurrence (\> 12 months) of their metastatic colorectal cancer
62581271|NCT05950893|EXPERIMENTAL|Experimental|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
62581272|NCT05606874|EXPERIMENTAL|Pre-heating of flowable resin composite .|(Filtek™ Z350Xt Flowable Restorative, 3M ESPSE, USA)
62581273|NCT05606874|ACTIVE_COMPARATOR|Conventional resin fissure sealant|(total etch), (UltraSeal XT®, Ultradent, USA)
62581274|NCT06684275|EXPERIMENTAL|Pulsed Radiofrequency (PRF)|Participants in this group will receive pulsed radiofrequency (PRF) treatment targeted to the trigeminal nerve. The procedure will involve a standard PRF protocol.
62017060|NCT01198184|EXPERIMENTAL|Treatment (temsirolimus and RO4929097)|Patients receive temsirolimus IV over 30 minutes on day -6 (course 1 only). Patients then receive temsirolimus IV or PO on days 1, 8, and 15 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62788944|NCT03355066|EXPERIMENTAL|Part 1A: Dose Escalation|Cohorts of subjects with advanced solid tumors will receive increasing doses (10, 20, 40, 60, 80, 120, 160, or 200 mg) of SM08502, administered orally, once daily, following 28-day treatment cycles. If the maximum tolerated dose (MTD) is not determined at the 200 mg dose, dosing will continue at 50 mg/dose increments until an MTD is determined. Cohorts will include approximately 1 to 6 subjects according to an accelerated escalation design and safety requirements for expansion of subject numbers. For the purpose of dose escalation and de-escalation, the dose of SM08502 and regimen may be modified based on the type of dose limiting toxicities (DLTs) observed and following data review and discussions between the Sponsor and Investigators.
62788945|NCT03355066|EXPERIMENTAL|Part 1B: Dose Finding|Indications eligible for Part 1B include castration-resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), endometrial cancer, or ovarian cancer for which histologic or cytologic confirmation of malignancy was obtained at diagnosis. Initially, two cohorts of 6-24 subjects will be evaluated comparing 2 different doses and schedules of SM08502 (30 mg daily and 40 mg 5 days on and 2 days off), administered orally following 28-day treatment cycles. If appropriate, alternative doses and schedules may be evaluated depending on the results.
62788946|NCT03355066|EXPERIMENTAL|Part 2: Expansion|"Part 2 will evaluate the recommended Part 2 dose and schedule of SM08502, as determined in Part 1B, in 3 cohorts of subjects. The indications to be evaluated include subjects with advanced and/or metastatic CRPC (two biomarker selection cohorts) and NSCLC for which histologic or cytologic confirmation of malignancy was obtained at diagnosis. Each cohort will enroll up to 20 subjects.~Approximately 10 subjects of the total enrolled in Part 2, irrespective of cohort, will be included in a food-effect substudy to assess the preliminary effect of a high-fat, high-calorie meal on the PK of SM08502."
62788947|NCT00640497|EXPERIMENTAL|1|Treatment arm
62017061|NCT05660109|EXPERIMENTAL|TPM502|
62017062|NCT05660109|PLACEBO_COMPARATOR|placebo|
62017063|NCT03590977|EXPERIMENTAL|licorice extract mouthwash|administration of a mouthwash containing licorice as a preventive measure to high caries risk patients (faculty of pharmacy, cairo university)
62017064|NCT03590977|PLACEBO_COMPARATOR|chlorohexidine mouthwash|administration of chlorohexidine 0.2% in 1:1 diluation mouthwash that is broad spectrum antimicrobial activity to high caries risk patients
62017065|NCT00165282|NO_INTERVENTION|Usual Care|Normal standard of care
62788948|NCT04405973||COVID-19 ARDS, vv-ECMO|All patients in the study centers with diagnosed COVID-19 infection (PCR proven) and treatment with vv-ECMO
62017066|NCT00165282|ACTIVE_COMPARATOR|Nurse education|Meets with oncology nurse
62017067|NCT00165282|EXPERIMENTAL|Mindfulness training|Taught Mindfulness meditation
62017068|NCT01826825||Clock in the box|Those patients with and without probable cognitive impairment based on the Clock-in-the-box assessment.
62581275|NCT06684275|ACTIVE_COMPARATOR|Pulsed and Thermal Radiofrequency (PRF + TRF)|Participants in this group will receive a combination of pulsed radiofrequency (PRF) and thermal radiofrequency (TRF). The TRF procedure will involve creating a thermal lesion at a target temperature in addition to the standard PRF treatment protocol.
62581276|NCT04033822|NO_INTERVENTION|Standard of Care|Patients randomized to the standard of care arm of the trial will not receive accelerated cholecystectomy surgery to correct cholecystitis. No services will be taken away but patients will continue with care as originally provided by the healthcare system.
62581277|NCT04033822|EXPERIMENTAL|FAST Intervention|Patients diagnosed with cholecystitis and randomized to the FAST intervention arm of the study will undergo surgery as soon as possible with a goal of surgery within 6 hours of diagnosis.
62206823|NCT04629833|ACTIVE_COMPARATOR|Best Available Therapy (BAT)|Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), everolimus, and ruxolitinib (RUX).
62206824|NCT01506973|EXPERIMENTAL|Gemcitabine/Abraxane/Hydroxychloroquine|Abraxane: 125mg/m2 IV infusion over 30 minutes on Days 1, 8, 15 Gemcitabine: 1000mg/m2 IV infusion over 30-100 minutes on Days 1, 8, 15 Hydroxychloroquine: 1200 mg/day PO daily (600mg BID) Daily from D1
62206825|NCT01506973|EXPERIMENTAL|Gemcitabine/Abraxane|Abraxane: 125mg/m2 IV infusion over 30 minutes on Days 1, 8, 15 Gemcitabine: 1000mg/m2 IV infusion over 30-100 minutes on Days 1, 8, 15
62206826|NCT02255253|EXPERIMENTAL|Telmisartan|capsule,40mg per day,2 months
62206827|NCT02255253|EXPERIMENTAL|Hydrochlorothiazide|tablet, 25mg per day, 2 months
62206828|NCT06168539|ACTIVE_COMPARATOR|Standard|A regular standard dialysis is performed and held as active comparator for analysis
62206829|NCT06168539|EXPERIMENTAL|Emboless|"Emboless tubing set is part of the extracorporeal venous bloodline instead of the venous chamber by Fresenius (see standard above).~For more information see reference Jonsson et al 2023- mentioned in references."
62206830|NCT03865927|EXPERIMENTAL|GKT137831|GKT137831 will be administered orally, at a dose of 400 mg twice daily, for a total of 24 weeks.
62206831|NCT03865927|PLACEBO_COMPARATOR|Placebo Oral Tablet|Identically-appearing placebo oral tablets will be administered orally, twice daily, for a total of 24 weeks.
62206832|NCT05401877||short term rehabilitation|breast cancer survivors that recieved post-OP rehabilitation for equal or less than 300 minutes totally.
62206833|NCT05401877||long term rehabilitation|breast cancer survivors that recieved post-OP rehabilitation for more than 300 minutes totally.
62206834|NCT06075316|OTHER|ePRO monitoring|Thoracic surgery patients will be enrolled in ePRO monitoring using web-based or telephone surveys.
62206835|NCT06554340|EXPERIMENTAL|Home-based aerobic training|A 3-month home-based exercise training intervention comprising cycle ergometry as an aerobic mode of training coupled with behavioral coaching. The regimen will be delivered 3-4 days per week.
62405715|NCT06207045|NO_INTERVENTION|control group|standard medication only
62581278|NCT02863445|ACTIVE_COMPARATOR|LNG-ECx1|Levonorgestrel 1.5 mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
62581279|NCT02863445|EXPERIMENTAL|LNG-ECx2|Levonorgestrel 3mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
62581280|NCT02102620|EXPERIMENTAL|IAI triamcinolone hexacetonide|"Intra-articular injection with corticosteroid . The study group was called triamcinolone hexacetonide / lidocaine (TH / LD) and a control group, called lidocaine (LD).~Patients in TH / LD group underwent corticosteroid IAI scheme in its most symptomatic interphalangeal (IP) joint composed with triamcinolone hexacetonide(TH) (20mg/ml) and 2% lidocaine without vasoconstrictor. The IAI was realized in the 0.3 ml dose (6mg) of TH for PIP and 0.2 ml (4 mg) of HT for DIP, always associated with 0.1 mL of 2% lidocaine. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day)."
62581281|NCT02102620|PLACEBO_COMPARATOR|IAI lidocaine|Intra-articular injection with lidocaine. The LD group patients underwent IAI with only 2% lidocaine without vasoconstrictor in its most symptomatic IP joint. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day) . Both groups of patients underwent only one IAI in the most symptomatic joint and on a single occasion.
62581282|NCT01760915||Severe asthma|Subjects with severe asthma (SARP protocol definition)
62017069|NCT01826825||Mini-Cog|Those patients with and without probable cognitive impairment based on the Mini-Cog assessment.
62017070|NCT03378596|EXPERIMENTAL|L-citrulline & L-arginine|L-citrulline (6 grams) L-arginine (8 grams)
62017071|NCT03378596|ACTIVE_COMPARATOR|L-citrulline & Placebo|L-citrulline (6 grams) Placebo (6 grams)
62017072|NCT03378596|ACTIVE_COMPARATOR|L-arginine & Placebo|L-arginine (8 grams) Placebo (6 grams)
62017073|NCT03378596|ACTIVE_COMPARATOR|Placebo|Placebo (6 grams)
62017074|NCT04260191|EXPERIMENTAL|Cohort 1: AMG 910 6.5 μg|For Cycles 1 and 2, participants received AMG 910 as a short-term intravenous (IV) infusion (approximately 60 minutes) at a dose of 6.5 μg twice a week on Days 1 and 3 of each week in a 28-day cycle. For Cycles 3 to 6, participants received AMG 910 as a short-term IV infusion (approximately 60 minutes) at a dose of 6.5 μg weekly, ie, Days 1, 8, 15 and 22 in a 28-day cycle.
62017075|NCT04260191|EXPERIMENTAL|Cohort 1b: AMG 910 6.5 μg|For Cycle 1 Week 1, participants received AMG 910 as an extended IV (eIV) infusion (approximately 96 hours) at a dose of 6.5 μg. For the remainder of Cycles 1 and 2, participants received AMG 910 as a short-term IV infusion (approximately 60 minutes) at a dose of 6.5 μg twice a week on Days 1 and 3 of each week in a 28-day cycle. For Cycles 3 to 6, participants received AMG 910 as a short-term IV infusion (approximately 60 minutes) at a dose of 6.5 μg weekly, ie, Days 1, 8, 15 and 22 in a 28-day cycle.
62017076|NCT04260191|EXPERIMENTAL|Cohort 2b: AMG 910 15 μg|For Cycle 1 Week 1, participants received AMG 910 as an eIV infusion (approximately 96 hours) at a dose of 15 μg. For the remainder of Cycles 1 and 2, participants received AMG 910 as a short-term IV infusion (approximately 60 minutes) at a dose of 15 μg twice a week on Days 1 and 3 of each week in a 28-day cycle. For Cycles 3 to 6, participants received AMG 910 as a short-term IV infusion (approximately 60 minutes) at a dose of 15 μg weekly, ie, Days 1, 8, 15 and 22 in a 28-day cycle.
62206836|NCT06554340|NO_INTERVENTION|Attention control|The alternative treatment condition comprises a stretching program with minimal exercise and attention control. This program will be delivered using the same frequency and duration as the intervention. The first session will be conducted under the supervision of visiting study personnel as described above. The stretching exercises will follow the manual provided by the National Multiple Sclerosis Society and the investigators will progressively include more exercises and sets over the 3 months, this too has been standardized and manualized for reproducibility. The investigators will provide the same materials and Internet coaching for the attention control group as for the intervention group but focused on stretching and not on increasing aerobic exercise. The investigators will ask that participants not undertake additional exercise during the study duration and this will be documented through an exercise history, the Godin Leisure-Time Exercise Questionnaire.
62206837|NCT03397875|ACTIVE_COMPARATOR|Zinc oxide based sealer|After root canal treatment obturation with gutta percha will be done using zinc oxide based sealer.
62206838|NCT03397875|EXPERIMENTAL|Epoxy resin based sealer|After root canal treatment obturation with gutta percha will be done using epoxy resin based sealer.
62206839|NCT03397875|EXPERIMENTAL|Bioactive silicone based sealer|After root canal treatment obturation with gutta percha will be done using bioactive silicone based sealer.
62405716|NCT02729597||Myotonic dystrophy type 1 patients|"Patients with myotonic dystrophy type 1 (diagnosis confirmed by genetic testing) who meet all inclusion and exclusion criteria for patients.~To be assessed at baseline and follow-up:~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
62405717|NCT02729597||Myotonic dystrophy type 2 patients|"Patients with myotonic dystrophy type 2 (diagnosis confirmed by genetic testing) who meet all inclusion and exclusion criteria for patients.~To be assessed at baseline and follow-up:~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
62581283|NCT01760915||Well controlled asthma|Subjects with well controlled asthma
62581284|NCT01760915||Normal control|Subjects that are healthy normals
62581285|NCT01256164|EXPERIMENTAL|Fibrocaps + Gelfoam|After identification of a Target Bleeding Site (TBS), topical Fibrocaps should be applied using the Fibrospray device for general surgeries; and either the Fibrospray device or direct application for spinal and vascular surgeries, followed by application of Gelfoam and manual pressure with sterile gauze.
62017077|NCT02323191|EXPERIMENTAL|Part 1 (Dose-finding): Emactuzumab + Atezolizumab|Participants will receive escalating doses of emactuzumab along with atezolizumab every 3 weeks (q3w).
62017078|NCT02323191|EXPERIMENTAL|Part 2 (Expansion): Emactuzumab + Atezolizumab|Participants will receive emactuzumab at or below the MTDs for the combination treatments that are determined during Part 1 along with atezolizumab.
62206840|NCT01846377|EXPERIMENTAL|G4H-Diab-Nano|Intervention - play two videogames Diab and Nanoswarm (9 sessions each, 18 total sessions) over a 12-week time period.
62206841|NCT01846377|NO_INTERVENTION|Wait List Control|5-months after baseline assessment they will receive the two video games: 1) Diab and 2) Nanoswarm.
62206842|NCT06010927|ACTIVE_COMPARATOR|Group-A; ketamine/midazolam premedication|
62206843|NCT06010927|ACTIVE_COMPARATOR|Group-B: Ketofol pre-extubation|
62405718|NCT02729597||Controls|"Healthy control subjects who meet all inclusion and exclusion criteria for healthy controls.~To be assessed at baseline and follow-up:~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
62405719|NCT04876482|SHAM_COMPARATOR|Control|Without the willingness of surgery, those participants waiting for oral appliance (Device), losing weights and using continuous positive airway pressure (Device) were distribute to control group.
62581286|NCT01256164|ACTIVE_COMPARATOR|Gelfoam|Treatment is Gelfoam followed by manual pressure with sterile gauze. If hemostasis is not achieved within 10 minutes of the Start Time,the subject should be considered a treatment failure and the surgeon should implement additional hemostatic measures.
62581287|NCT04610567|EXPERIMENTAL|MTX-LDE phase 1|Methotrexate carried by a lipid nanoparticle (MTX-LDE)
62581288|NCT04610567|EXPERIMENTAL|MTX-LDE phase 2|Methotrexate carried by a lipid nanoparticle (MTX-LDE)
62581289|NCT04610567|PLACEBO_COMPARATOR|Placebo-LDE phase 2|Lipid nanoparticle (LDE)
62788949|NCT05594628|EXPERIMENTAL|Neuromuscular Training+Basketball training|After all participiants are evaluated, they will be divided randomly to two groups, which one group will be taking neuromuscular training+usual basketball training
62206844|NCT02844218||Intensive chemotherapy group|Group 1: Patients' age ≥ 70 years treated from 1985 to 1999 with intensive induction chemotherapy.
62206845|NCT02844218||Lower intensity treatment group|Group 2: patients treated from 2000 to 2006 with intensive chemotherapy plus improved supportive care and a follow-up protocol systematically performed at the university hospital.
62206846|NCT02844218||personalized treatment group|"Group 3: patients who had received, starting in 2007, more personalized treatment with either intensive chemotherapy or lower-intensity therapy determined by the clinical judgment of the treating physician."
62788950|NCT05594628|NO_INTERVENTION|Control group(Basketball training)|After all participiants are evaluated, they will be divided randomly to two groups, which one group will be taking just the usual basketball training and not any extra interventions.
62788951|NCT02606331|EXPERIMENTAL|Piezosurgery|In one half of the dental arch, piezosurgery will be performed for canine retraction, whereas in the other half ordinary canine retraction procedure will be followed.
62788952|NCT02606331|EXPERIMENTAL|ER:YAG Laser|In one half of the dental arch, ER:YAG laser irradiation will be performed for canine retraction, whereas in the other half ordinary canine retraction procedure will be followed.
62405720|NCT04876482|EXPERIMENTAL|Transoral robotic surgery (TORS)|The participants underwent TORS. TORS is a kind of surgery that the surgeons would remove the tonsils and the fat tissue of tongue base and suspend the soft palate.
62788953|NCT04314674|ACTIVE_COMPARATOR|%3 HS bolus 3 mL.kg-1|After the head fixation 3 mL.kg-1 %3 hypertonic saline will be administered over the 20 min intravenously.
62788954|NCT04314674|ACTIVE_COMPARATOR|%3 HS infusion 20 ml/h|After the head fixation 3% hypertonic saline at 20 ml/h infusion rate will be administered during the operation
62788955|NCT04314674|ACTIVE_COMPARATOR|%20 mannitol 0,6 gr.kg-1|After the head fixation %20 mannitol 0,6 gr.kg-1 will be administered over the 20 min intravenously.
62788956|NCT06583759|ACTIVE_COMPARATOR|Stainless Steel Crowns|
62788957|NCT06583759|EXPERIMENTAL|PEEK Crowns|
62788958|NCT01080846|EXPERIMENTAL|600 mcg of sublingual misoprostol|
62788959|NCT01957371|EXPERIMENTAL|Mindful Yoga Therapy|12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
62788960|NCT01777776|EXPERIMENTAL|Phase Ib|Phase Ib will randomize 18 patients with BRAF mutant melanoma, who are naïve or who have progressed on prior therapy to evaluate the safety and tolerability of the combination of LEE011 and LGX818.
62788961|NCT01777776|EXPERIMENTAL|Phase II arm 1a|Phase II arm 1a will randomize 60 patients that are naïve to prior BRAF inhibitor therapy to LGX818+LEE011 to evaluate the effect of adding LEE011 to a BRAFi in this population.
62788962|NCT01777776|EXPERIMENTAL|Phase II arm 1b|Phase II arm 1b will randomize 30 patients to LGX818. Single agent anti-tumor activity of LGX818 is comparable to other BRAFi that are either approved or in clinical trials. This single agent anti-tumor activity will be compared to that of the combination (LEE011 + LGX818) in the BRAFi naïve patient population.
62788963|NCT01777776|EXPERIMENTAL|Phase II arm 2|Phase II arm 2 will evaluate a single arm LEE011+LGX818 in 40 patients resistant to prior BRAF inhibitor therapy. Single agent LGX818 has shown limited activity in patients with melanoma who have failed prior BRAF inhibitor treatment; the contribution of LEE011 in this combination will be evaluated.
62788964|NCT01260597|EXPERIMENTAL|Life Style Counseling|For individuals who report being quit, a brief congratulatory message will be delivered, independent of each arm of the study they were randomized to. For individuals who report not being quit and are randomized to the intervention condition, tailored messages are delivered via the IVR system. The automated calls would include an assessment of the individual's interest in another quit attempt and deliver brief, tailored messages to perceived barriers for re-engaging into treatment. The system is programmed to transfer the caller to a live quit line counselor if the individual is willing to re-engage in cessation treatment.
62788965|NCT01260597|ACTIVE_COMPARATOR|Life Counseling|For individuals who report being quit, a brief congratulatory message will be delivered, independent of each arm of the study they were randomized to. For individuals who report still smoking the IVR will thank them for their time and the call will end.
62788966|NCT02564978|EXPERIMENTAL|Minocycline|Oral administration of minocycline.
62017079|NCT04901559||BQT|Patients treated with the Bone Quadriceps Tendon (BQT) autograft
62017080|NCT04901559||STG|Patients treated with the Semitendinosus-Gracilis (STG) autograft
62017081|NCT04901559||BPTB|Patients treated with the Bone-Patellar Tendon-Bone (BPTB) autograft
62017082|NCT02733497|ACTIVE_COMPARATOR|Sympathectomy Group|Excision of ganglia at T3 level
62206847|NCT04986839|ACTIVE_COMPARATOR|Ibuprofen|Standard treatment arm which will provide the comparator arm to the proposed new treatment. This is routine standard of practice
62017083|NCT02733497|ACTIVE_COMPARATOR|Sympathicotomy Group|Resection of sympathetic chain at T3 level
62206848|NCT04986839|EXPERIMENTAL|Paracetamol|To study the efficacy of Paracetamol (proposed new treatment) in treating hsPDA in comparison to Ibuprofen (current standard treatment) in preterm infants
62206849|NCT06419998|ACTIVE_COMPARATOR|Group A|Pediatric patients presented with Hirschsprung's disease treated by pure transanal endorectal pull-through (TAERPT)
62206850|NCT06419998|ACTIVE_COMPARATOR|Group B|Pediatric patients presented with Hirschsprung's disease treated by laparoscopic-assistance endorectal pull-through (LAERPT)
62405721|NCT04876482|EXPERIMENTAL|TORS+OPR|The participants started OPR 6 weeks after TORS. Each exercise was repeated 10 times, 1-3 cycles per day, 3-5 sessions per week at their home and performed for 3 months. Patients were supervised by physical therapist once a week for 30 minutes.
62405722|NCT06231901|EXPERIMENTAL|coop plus traditional occupational therapy|This group received the traditional occupational therapy plus CO-OP approach.
62405723|NCT06231901|EXPERIMENTAL|GDT plus traditional occupational therapy|This group received the traditional occupational therapy plus Goal directed training.
62788967|NCT00907504|EXPERIMENTAL|CP-751,871 + Gemcitabine + Cisplatin|investigational arm
62788968|NCT00907504|ACTIVE_COMPARATOR|Gemcitabine + Cisplatin|standard of care
62788969|NCT00587704|OTHER|Nerve Stimulation|Use of nerve stimulator for placement of PVB nerve block
62788970|NCT00587704|OTHER|Anatomic landmarks|Use of anatomic landmarks for placement of PVB block
62206851|NCT06644170|EXPERIMENTAL|Treatment (psilocybin, group therapy)|Patients receive psilocybin PO with optional booster dose on day 0. Patients attend an individual prep visit on day -1 and an individual integration visit on day 1. Patients also attend group preparation visits on days -14, -7 and -1 and group integration visits on days 1, 8, 22 and 36.
62581290|NCT02002455|EXPERIMENTAL|Multimodality imaging|PET/CT, PET/MRI, mpMRI
62206852|NCT05746559|PLACEBO_COMPARATOR|Placebo|Participants will receive a single weight-based dose of placebo via intravenous infusion, 1 to 7 days prior to surgery.
62788971|NCT01451385|EXPERIMENTAL|COV795|Participants receive 2 tablets of COV795 every 12 hours for up to 35 days
62788972|NCT05822622||HFpEF(heart failure with preserved ejection fraction)|chronic heart failure with echocardiographic finding of LVEF (left ventricular ejection fraction) equal or more than 50% , diagnostic test :Abdominal ultrasound and transient elastography for detecting non alcoholic fatty liver disease .
62788973|NCT05822622||NAFLD(non alcoholic fatty liver disease)|ultrasound and transient elastographic finding of fatty liver disease, diagnostic test :echocardiography to determine heart failure with preserved ejection fraction .
62788974|NCT01974011|EXPERIMENTAL|Dorsal penile nerve block according to Dalens' technique|Two injections at the dorsum penis according to Dalens' technique.
62788975|NCT01974011|ACTIVE_COMPARATOR|DPNB with additional infiltration of the ventromedial penis|"Modified procedure:~Two injections at the dorsum penis according to Dalens' technique plus on subcutaneous injection in the ventral midline of the penis at the transition between the penis and the scrotum."
62788976|NCT03326700|ACTIVE_COMPARATOR|Laparoscopic hernia repair.|Intervention: inguinal hernia repair.
62788977|NCT03326700|ACTIVE_COMPARATOR|Open hernia repair.|Intervention: inguinal hernia repair.
62788978|NCT01286077|EXPERIMENTAL|bortezomib|bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles
62206853|NCT05746559|EXPERIMENTAL|Ravulizumab|Participants will receive a single weight-based dose of ravulizumab, via intravenous infusion, 1 to 7 days prior to surgery.
62788979|NCT01286077|NO_INTERVENTION|Non-treated control|no treatment, observation only
62788980|NCT02059304|OTHER|Preterm Delivery|Preterm Delivery: Births before the completion of 37 weeks' of gestation.
62788981|NCT02059304|OTHER|Term Delivery|Term Delivery: Births after the completion of 37 weeks' of gestation.
62017084|NCT05244525|EXPERIMENTAL|Treatment|
62017085|NCT05244525|ACTIVE_COMPARATOR|Control Group|
62206854|NCT05532735|EXPERIMENTAL|2 mg ANXV|ANXV (human recombinant Annexin A5), infusion, 2 mg daily during five days.
62206855|NCT05532735|EXPERIMENTAL|4 mg ANXV|ANXV (human recombinant Annexin A5), infusion, 4 mg daily during five days.
62581291|NCT00863343||All|Anyone presenting with influenza-like-illness
62017086|NCT02182284|EXPERIMENTAL|BI 201335 NA - low dose|
62017087|NCT02182284|EXPERIMENTAL|BI 201335 NA - high dose|
62206856|NCT05532735|EXPERIMENTAL|1 mg ANXV|ANXV (human recombinant Annexin A5), infusion, 1 mg daily during five days.
62206857|NCT05532735|EXPERIMENTAL|6 mg ANXV|ANXV (human recombinant Annexin A5), infusion, 6 mg daily during five days.
62581292|NCT06127693||Mild childhood adversity (control)|Score of 25-36 on the Childhood Trauma Questionnaire-short form.
62788982|NCT01055314|EXPERIMENTAL|Group 1 (chemotherapy, radiation therapy, cixutumumab)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-5, 7, 8, 11, 12, 15, 16, 20-24, 28, 29, 32, 33, 35, 38, 41-44, 47, 48, 50, and 51; irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 1, 4, 20, 23, 47, and 50; ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 of weeks 9, 13, 17, 26, and 30; doxorubicin hydrochloride IV over 1-15 minutes on days 1 and 2 of weeks 7, 11, 15, 28, and 32; cyclophosphamide IV over 30-60 minutes on day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41, and 44; dactinomycin IV over 1-5 minutes on day 1 of weeks 35, 38, 41, and 44; and cixutumumab IV over 1 hour on day 1 of weeks 1-51. Patients also undergo radiation therapy on days 1-5 of weeks 20-24.
62017088|NCT01061294|OTHER|Advanced CustomVue™ iLASIK procedure|
62017089|NCT00399438|OTHER|1|0 mg
62017090|NCT00399438|OTHER|2|25 mg
62017091|NCT00399438|OTHER|3|100 mg
62017092|NCT00789217|ACTIVE_COMPARATOR|In-house penicillin testing preparation|In-house penicillin testing prepared from alkali-treated penicillin G
62206858|NCT05532735|EXPERIMENTAL|8 mg ANXV|ANXV (human recombinant Annexin A5), infusion, 8 mg daily during five days.
62581293|NCT06127693||Moderate childhood adversity|Score of 37-67 on the Childhood Trauma Questionnaire-short form.
62581294|NCT06127693||Severe childhood adversity|Score of \>67 on the Childhood Trauma Questionnaire-short form.
62581295|NCT00003118|EXPERIMENTAL|Chemotherapy + Radiation + Surgery|
62581296|NCT00003118|ACTIVE_COMPARATOR|Surgery|
62788983|NCT01055314|EXPERIMENTAL|Group 2 (chemotherapy, radiation therapy, temozolomide)|Patients receive vincristine sulfate, irinotecan hydrochloride, ifosfamide, etoposide, doxorubicin hydrochloride, cyclophosphamide, and dactinomycin and undergo radiation therapy as in group 1. Patients also receive temozolomide PO on days 1-5 of weeks 1, 4, 20, 23, 47, and 50.
62405724|NCT06231901|OTHER|traditional occupational therapy|This group only received the traditional occupational therapy .
62405725|NCT06455670|EXPERIMENTAL|Chinese medicine granules plus western medicine treatment|On the basis of conventional western medicine treatment, the experimental group will be given Sanhan Huayin granule , Qingre Huatan granule or Zaoshi Huatan granule based on CM syndrome differentiation.Take 1 dose daily for 10 days.
62581297|NCT05588219|EXPERIMENTAL|Experimental arm|The therapeutic schedule of the experimental arm: External irradiation 45\~50Gy/25f+ Brachytherapy 28\~30Gy/4\~5f; Chemotherapy: DDP 40mg/m2/W, synchronous with radiotherapy, complete at least 4 cycles; Tislelizumab injection\[10ml:100mg\]: 200mg/3W for 1 year or disease progression or intolerable toxicity, whichever occurs first.
62581298|NCT06638606||A: Normal couples (have normal sleep pattern), B: Insomniac and C: hypersomniac couples|Group A: Couples with normal sleep pattern. Group B: One spouse suffers from insomnia. Group C: Once spouse suffers from hypersomnia.
62405726|NCT06455670|PLACEBO_COMPARATOR|Chinese medicine granules placebo plus western medicine treatment|On the basis of conventional treatment of western medicine, in the experimental group 5% of the placebo drug, color, smell, taste, appearance, weight, similar to the experimental drug, drug packaging and test group. One dose was given daily for 10 days.
62206859|NCT05216159|EXPERIMENTAL|mHealth HAPA Intervention Group|This intervention group will receive a single one-on-one behavioural counselling session and weekly action and coping planning worksheets delivered through a downloaded smartphone application with the aim of increasing the breaking of consecutive work related sedentary behaviour. Counselling strategies will be grounded in the HAPA model, specifically focusing on the creation of action plans and the development of coping strategies to increase sedentary behaviour breaks. The weekly HAPA based worksheets will be sent out to participants at the beginning of their work week so that they can formulate their own personal action plans and coping strategies for the week to come. They will be prompted to refer back to the information conveyed in one-on-one counselling session where they should try to create action plans that are specific and meaningful to them. The intervention will last for a total of four weeks with the outcomes being measured through questionnaires.
62206860|NCT05216159|NO_INTERVENTION|Control Group|The control group will receive no intervention or further instruction past the letter of information.
62215413|NCT01269515|ACTIVE_COMPARATOR|Etoricoxib 90 mg qd for 25 weeks ART-|Etoricoxib for 25 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 5 weeks.
62215414|NCT01269515|ACTIVE_COMPARATOR|Etoricoxib 90 mg qd for 2 weeks ART-|Etoricoxib for 2 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
62405727|NCT00905437|PLACEBO_COMPARATOR|Placebo|Placebo as an adjunct to standard of care
62405728|NCT00905437|ACTIVE_COMPARATOR|Pregabalin|Pregabalin as an adjunct to standard of care
62405729|NCT05198414||Healthcare workers|Healthcare workers at the first line and healthcare directives.
62581299|NCT02595463|EXPERIMENTAL|Lidocaine|Following intraoperative IV placement, a 1.5 mg/kg bolus does of lidocaine hydrochloride is given and is followed by a continuous infusion of 2 mg/kg/hr until discharge from the Phase 1 recovery period.
62017093|NCT00789217|ACTIVE_COMPARATOR|Commercial penicillin test kit|Commercial penicillin test kit order from Diater company
62215415|NCT01269515|NO_INTERVENTION|Control ART-|No Etoricoxib. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
62215416|NCT01269515|ACTIVE_COMPARATOR|Etoricoxib 90 mg qd for 25 weeks ART+|Etoricoxib for 25 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 5 weeks.
62215417|NCT01269515|ACTIVE_COMPARATOR|Etoricoxib 90 mg qd for 2 weeks ART+|Etoricoxib for 2 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
62215418|NCT01269515|NO_INTERVENTION|Control ART+|No Etoricoxib. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
62405730|NCT06370884|EXPERIMENTAL|IMT group|individuals of the ages of 18-75 with a history of diverticulitis or sigmoid colon cancer will be enrolled to have a feeding tube placed at the time of surgery and receive either IMT solution
62581300|NCT02595463|PLACEBO_COMPARATOR|Placebo|Following intraoperative IV placement, a bolus of saline is given and is followed by a continuous infusion until discharge from the Phase 1 recovery period. The volume of the bolus and rate of infusion are equivalent to that which would have been given in the experimental arm.
62581301|NCT03825003||Basketball Players|Outcome assessments were done.
62017094|NCT00789217|ACTIVE_COMPARATOR|Penicillin G Sodium|Penicillin G Sodium from routine clinical use
62215419|NCT04764461|NO_INTERVENTION|Control Group|The control group will continue with the standard practice of antenatal care using Mc Donald's rule for fundal heights measurements.
62215420|NCT04764461|EXPERIMENTAL|Intervention Group|Intervention group will follow the same antenatal visit plan as the control group with the use of customised GROW Charts for fundal height measurements.
62017095|NCT02658851|EXPERIMENTAL|J-Plasma|Enrolled participants will have their PLND performed using J-Plasma® for dissection and sealing of lymphatic channels.
62206861|NCT05902949|ACTIVE_COMPARATOR|Stretching Group|The pattern will be performed 3 times per day (10 repetitions, 30 seconds each repetition). A daily control diary will be filled in when performing the exercise.
62206862|NCT05902949|ACTIVE_COMPARATOR|Heel Cup Group|The heel cup will be 5mm high (Eva Shore 65)
62206863|NCT04465799|EXPERIMENTAL|ENTREN Programme|This intervention consists in a total of 12 biweekly sessions: 9 sessions of 2-hr only for children, with a further three 3-hr sessions attended by both families and children together: nutrition, physical activity sessions, and a closing event session. Children content was developed based a cognitive-behavioural perspective, and included motivational interviewing tools. The aim of the children's programme is, to promote healthy eating habits, problem awareness, motivation to change unhealthy behaviours, health commitment, emotional regulation, social skills and self-esteem. One 2-hr session at 6, 12 and 18-month follow-up was provided to refresh skills, their physical activity, and nutritional behaviours.
62206864|NCT04465799|EXPERIMENTAL|ENTREN-F Programme|ENTREN-F has the same children's intervention than ENTREN. It has extra 6 2-hr sessions to work on family environment and communication, plus three 2-hr sessions attended by both families and children together. One 2-hr session at 6, 12 and 18-month follow-up was provided to refresh skills, their physical activity, and nutritional behaviours.
62405731|NCT02892916|EXPERIMENTAL|Ketamine|Patients in this experimental group will receive a bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
62405732|NCT02892916|PLACEBO_COMPARATOR|Placebo|Patients in this control group will receive a bolus of an intravenous normal saline solution following induction of anaesthesia.
62581302|NCT03825003||Sedentary Peers|Outcome assessments were done.
62581303|NCT01896999|EXPERIMENTAL|Phase I Arm I (brentuximab vedotin, ipilimumab)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 of cycles 1-16 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4, 8, 12, and 16. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.
62405733|NCT01528839|PLACEBO_COMPARATOR|Pill|
62405734|NCT01528839|EXPERIMENTAL|L-Thyroxine as addon|
62581304|NCT01896999|EXPERIMENTAL|Phase I Arm II (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-46. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.
62017096|NCT06385444||The female spouse of a couple|Women in couples with IVF pregnancy loss and IVF failure
62017097|NCT06385444||The male spouse of a couple|Men in couples with IVF pregnancy loss and IVF failure
62017098|NCT05160805|EXPERIMENTAL|Treatment Group A|ONL1204 Ophthalmic solution (Dose A) administered by intravitreal injection
62017099|NCT05160805|EXPERIMENTAL|Treatment Group B|ONL1204 Ophthalmic solution (Dose B) administered by intravitreal injection
62017100|NCT05160805|SHAM_COMPARATOR|Treatment Group C|Sham procedure without penetrating the eye
62206865|NCT04465799|OTHER|Control group|The intervention of this group consists in usual treatment in Primary Care provided by Endocrinology Services. 3 monthly face-to-face consultations and continuous online monitoring are provided to these families, oriented to promote healthy habits of nutrition and physical activity for 6 months. It works from an exclusively behavioural perspective. A token economy is used with the families as a system of contingency management based on the systematic reinforcement of target behaviour.
62206866|NCT06133153|EXPERIMENTAL|Arm THIODERM ELATE|Subjects randomized to Arm A (approx. 66.7% of subjects) will receive THIODERM ELATE injected into both lips (Experimental Device) at the initial treatment and a potential touchup treatment.
62405735|NCT04135248||IDF-DAR arm|Insulin management according to IDF-DAR guidelines (IDF-DAR arm) during the fasting period.
62405736|NCT04135248||DAFNE arm|Insulin management according to local experience (DAFNE arm) during the fasting period.
62405737|NCT06652581|EXPERIMENTAL|Modified Thorachoabdominal Nerve Block Perichondrial Approach(M-TAPA)|USG Guided Bilateral Modified Thorachoabdominal Nerve Block Perichondrial Approach (M-TAPA) using 20 ml Bupivacaine 0,25%.
62405738|NCT06652581|ACTIVE_COMPARATOR|Opioid Intravena|This Group receive opioid intravena post surgery without M-TAPA Block
62405739|NCT01164280|EXPERIMENTAL|Pulse Rate Change|Patients are subjected to different pulse rate settings of their neurostimulator. The effect of pulse rate changes on clinical outcome is measured.
62405740|NCT04999904|EXPERIMENTAL|Uneven Treadmill Arm|Uneven Treadmill Intervention with up to twelve sessions over approximately six weeks and Standard of Care Physical Therapy with an 18 month follow-up period
62581305|NCT01896999|EXPERIMENTAL|Phase I Arm III (brentuximab vedotin, nivolumab, ipilimumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-46, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.
62734965|NCT00652743|EXPERIMENTAL|GSK1562902A M12 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) in study 109630 (NCT00449670) receiving one dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, at 12 Months (M12) after the primary vaccination, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
62405741|NCT04999904|ACTIVE_COMPARATOR|Control Arm|Standard of Care Physical Therapy over approximately six weeks with an 18 month follow-up period
62017101|NCT03370341|EXPERIMENTAL|Active anodal tDCS first, then Sham tDCS|Active anodal tDCS (20 minutes) followed by behavioral testing; Washout (1 week); sham stimulation (20 minutes) followed by behavioral testing Intervention: Device: active anodal tDCS and sham tDCS
62017102|NCT03370341|SHAM_COMPARATOR|Sham tDCS first, then Active anodal tDCS|Sham tDCS (20 minutes) followed by behavioral testing; Washout (1 week); Active anodal tDCS (20 minutes) followed by behavioral testing Intervention: Device: sham tDCS and sham tDCS
62017103|NCT03120104|ACTIVE_COMPARATOR|Pre-intervention group|Pre-intervention group interventions:pelvic floor muscle training for one month (2\~3 times a week, for 4 weeks) just one month before the stoma closure
62405742|NCT04877405||Intracerebral hemorraghe|Patients that suffered an intracerebral hemorraghe and that have been subjected to CT and MRI scans
62405743|NCT01251510||Healthy adults|
62405744|NCT01251510||Type 2 diabetes|
62017104|NCT03120104|ACTIVE_COMPARATOR|Post-intervention group|Post-intervention group: pelvic floor muscle training for one month (2\~3 times a week, for 4 weeks) two weeks after the stoma closure
62206867|NCT06133153|ACTIVE_COMPARATOR|Arm JUVÉDERM ULTRA|Subjects randomized to Arm A (approx. 33.3% of subjects) will receive Juvéderm(R) Ultra injected into both lips (Comparator Device) at the initial treatment and a potential touchup treatment. .
62405745|NCT02145949|EXPERIMENTAL|Essential Amino Acids (EAA)|"Aim 1: Twice-daily ingestion of 20 g of EAA for 1 wk before through 6 wk after TKA.~Supplement composition for the EAAs: histidine, 2.2 g (11% of total); isoleucine, 2.0 g (10%); leucine, 3.6 g (18%); lysine, 3.2 g (16%); methionine, 0.6 g (3%); phenylalanine, 3.2 g (16%); threonine, 2.8 g (14%); and valine, 2.4 g (12%).~Aim 2: Twice-daily ingestion of 23 g of EAA for 1 wk before through 6 wk after TKA.~Supplement composition for the EAAs: histidine, 1.28 g (5% of total); isoleucine, 1.8 g (8%); leucine, 7.4 g (32%); lysine, 3.6 g (15%); methionine, 1.76 g (8%); phenylalanine, 3.1 g (13%); threonine, 1.9 g (8%); valine, 2.08 g (9%); and tryptophan, 0.5 g (2%)."
62206868|NCT05071820|EXPERIMENTAL|Mobile application program|
62788984|NCT06166199|EXPERIMENTAL|High-intensity interval training (HIIT) combined with resistance training|"Patients with SLE will undergo supervised HIIT on an ergometercycle 4 x 4 minutes interval (85-90% of maximal heart rate in 4 minutes and lower intensity for another 4 minutes etc). The HIIT is combined with resistance exercises for upper and lower extremity. In total the supervised training takes around 50 minutes per occasion and will be performed 2 times/week, for 3 months. In addition, the patients will exercise, according to the program, by themselves once a week.~Between months 3 and 6 the patients exercise by themselves, 3 times/week, with video-call/telephone support from a physiotherapist once a week."
62206869|NCT05071820|ACTIVE_COMPARATOR|Traditional program|
62206870|NCT06717971|EXPERIMENTAL|Intervention group|The intervention in this group is exergame-based multicomponent training program.
62206871|NCT06717971|SHAM_COMPARATOR|Control group|The control group received routine care in a long-term care center.
62206872|NCT03356392||stroke patients|acute stroke patients treated with endovascular treatment combined with or without
62206873|NCT04157725|EXPERIMENTAL|Group A (mild stimulation protocol)|
62206874|NCT04157725|ACTIVE_COMPARATOR|Group B (conventional stimulation protocol)|
62206875|NCT06715852|EXPERIMENTAL|PHYSBI: 12-week physical exercise program|An individualized 12-week training program including 3 occasions/week of moderate-high intensity. It may also contain elements of high intensity, corresponding to 3.0-8.9 metabolic equivalents (METs), Borg Rating of Perceived Exertion (RPE) 12-17 and 60-94% of maximal heart rate. The intervention includes cardiorespiratory and resistance training where two sessions per week are group-sessions and one session per week is performed individually. A study physiotherapists will design individualized exercise programs during a single one-to-one session with the patients.
62405746|NCT02145949|PLACEBO_COMPARATOR|Placebo (Alanine)|"Aim 1: Twice-daily ingestion of 20 g of Alanine (Non-essential amino acid) for 1 wk before through 6 wk after TKA.~The placebo supplement consists of 20 g (100%) alanine.~Aim 2: Twice-daily ingestion of 23 g of Alanine (Non-essential amino acid) for 1 wk before through 6 wk after TKA.~The placebo supplement consists of 23 g (100%) alanine."
62405747|NCT03279120|EXPERIMENTAL|TFV/LNG IVR (8-10mg/20μg) (Continuous)|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (continuous).
62405748|NCT03279120|EXPERIMENTAL|TFV/LNG IVR (8-10mg/20μg) (Interrupted)|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (3x28 days interrupted).
62405749|NCT03279120|PLACEBO_COMPARATOR|Placebo (Continuous)|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (continuous).
62405750|NCT03279120|PLACEBO_COMPARATOR|Placebo (Interrupted)|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (3x28 days interrupted).
62405751|NCT02435082||Concussion with TCD|Any patient (adolescent/adult) receiving a Transcranial Doppler (TCD) for a head injury, suspected concussion, or suspected mild traumatic brain injury (sports related or not).
62405752|NCT00621309|ACTIVE_COMPARATOR|1|Subjects are given 300 mg / 7 days of rifampicin to induce CYP3A4. Midazolam clearance is measured on the 8th day.
62405753|NCT00621309|ACTIVE_COMPARATOR|2|Sulforaphane (SFN), a natural product derived from broccoli sprouts, is utilized as a putative inhibitor of ligand (Rifampin) activation of the Pregnane X-receptor. In this arm, both SFN (putative inhibitor of ligand binding to PXR) and Rifampin (strong activating ligand of PXR) are given together.
62788985|NCT06166199|NO_INTERVENTION|Control group|Both the control group and the HIIT combined with resistance training group receive standard care.
62788986|NCT03694834|EXPERIMENTAL|Single Arm - Pembrolizumab|Single dose of Pembrolizumab 200mg IV administered prior to hysterectomy and surgical staging.
62788987|NCT01984918|ACTIVE_COMPARATOR|SMS reminder|A text message reminder via Short Message Service (SMS) will be sent to remind subjects 7-10 days before his colonoscopy appointment
62788988|NCT01984918|NO_INTERVENTION|Non-SMS reminder|No text message reminder via Short Message Service (SMS) will be sent
62206876|NCT06715852|EXPERIMENTAL|Modified eHealth Lift: a digital, evidence based lifestyle-intervention for health promotion.|A modified and digital development of the Health Lift, an evidence based lifestyle-intervention for health promotion and prevention in primary health care. This intervention will be executed together with care manager contact according to medical guidelines. The patient receives a material consisting of separate questionnaires dealing with dietary habits, smoking, alcohol habits, physical activity, stress, living conditions, waist-hip-ratio and well-being expressed as a life ladder, present and future. Results are then converted into a health profile and a counsellor indicated what could be offered individually or in groups depending on the participant's wishes. This person-centered method ia based on strengthening the individual's own chosen health promoting activities and support for participation in municipal facilities.
62017105|NCT05916755||Cohort A|Pembrolizumab + neoadjuvant chemotherapy
62206877|NCT06715852|NO_INTERVENTION|Care as usual|Care as usual for anxiety disorders at the primary care centers.
62206878|NCT05332236||Community sample|Adolescents (10-18 years) and their parents, recruited via online sampling, from the general population
62206879|NCT05332236||At-risk sample|Parents seeking parenting advice in information centres/helplines.
62206880|NCT05332236||Clinical sample|Children and parents are recruited among in- and outpatients at the Clinic for Child and Adolescent Psychiatry of the University Medical Center Hamburg-Eppendorf
62206881|NCT00522405|ACTIVE_COMPARATOR|1|Transarterial Chemoembolisation
62206882|NCT00522405|ACTIVE_COMPARATOR|2|TACE Plus oral chemotherapy
62206883|NCT05714969|EXPERIMENTAL|TAK-755 Dose 1 in Acute Phase and Dose 2 in Post-acute Phase|TAK-755 Dose 1, IV infusion, in the acute phase until clinical response is achieved. All participants achieving clinical response will receive TAK-755 at Dose 2, for up to 6 weeks during the post-acute phase.
62017106|NCT05916755||Cohort B|Neoadjuvant chemotherapy
62206884|NCT05714969|EXPERIMENTAL|TAK-755 Dose 2 in Both Acute and Post-Acute Phase|TAK-755 Dose 2, IV infusion, in the acute phase until clinical response is achieved. All participants achieving clinical response will receive TAK-755 at Dose 2, for up to 6 weeks during the post-acute phase.
62206885|NCT06000059|EXPERIMENTAL|Radio Drama|Participants in this group will participate in three listening sessions. The first and third listening sessions will consist of information unrelated to mental illness. The second listening session will be the radio theater intervention that is being developed.
62206886|NCT06000059|NO_INTERVENTION|Control|Participants in this group will participate in three listening sessions all unrelated to mental illness.
62206887|NCT06000059|NO_INTERVENTION|Randomly selected community members|randomly selected members of the community that have not had exposure to the intervention over the course
62206888|NCT01208389|EXPERIMENTAL|voretigene neparvovec-rzyl (AAV2-hRPE65v2)|Administration of study agent (AAV2-hRPE65v2) to the previously, uninjected contralateral eye:
62017107|NCT00578370|EXPERIMENTAL|1|
62017108|NCT00578370|EXPERIMENTAL|2|
62017109|NCT00578370|ACTIVE_COMPARATOR|3|
62017110|NCT00578370|ACTIVE_COMPARATOR|4|
62017111|NCT00578370|PLACEBO_COMPARATOR|5|
62017112|NCT01044810||Simultaneous interruption (Exposure gr)|stopped all drugs in NNRTI-based regimens simultaneously after allergic reactions to NVP-based regimens, and later started EFV-based regimens
62017113|NCT01044810||Naive (Control group)|HIV-1-infected patients who started EFV-based regimens as their initial ARV regimens.
62017114|NCT01044810||staggered interruption (exposure group)|"after having allergic reactions to NVP-based regimens, stopped NNRTIs first, continued the other NRTIs for a period of time, i.e. staggered interruption, and later started EFV-based regimens"
62206889|NCT04869358|EXPERIMENTAL|Cohort 1a|Patients received first SARS-CoV-2 vaccination within the study prior to starting ofatumumab treatment.
62206890|NCT04869358|EXPERIMENTAL|Cohort 1b|Patients had already completed initial vaccination cycle and received a booster vaccine within the study prior to starting ofatumumab treatment.
62206891|NCT04869358|EXPERIMENTAL|Cohort 2a|Patients who received their first SARS-CoV-2 vaccination within the study while already stable on ofatumumab treatment for at least 4 weeks (since the first dose).
62206892|NCT04869358|EXPERIMENTAL|Cohort 2b|Patients who had already completed their initial vaccination cycle and received a booster vaccine within the study while already stable on ofatumumab treatment for at least 4 weeks (since the first dose).
62206893|NCT05862129||observation group|This group will collect rectal secretions and stool samples and pus samples from patients with perianal abscess before treatment, and collect rectal secretions and stool samples from patients again 2 months after treatment according to the diagnosis and treatment guidelines.
62206894|NCT05862129||control group|This group collected rectal secretions and stool specimens from a healthy population.
62581306|NCT01896999|EXPERIMENTAL|Phase II Arm I (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-34. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.
62581307|NCT01896999|EXPERIMENTAL|Phase II Arm II (brentuximab vedotin, nivolumab, ipilimumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-34, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.
62206895|NCT03907644|EXPERIMENTAL|Active FPS|We use Starstim AC (alternative current) -Stimulator R32. FPS protocol will be used with 20 minutes 2mAmp 6 Hz tACS to the middle frontal gyrus (DLPFC, F4 in EEG electrodes with 10-20 system measurement) and inferior parietal cortex (IPC, P4), as the main nodes of the frontoparietal network, in synchronous oscillation. The 4 return electrodes will receive 0.5 mAmp each around each active electrode (High Definition Montage). The electrodes are silver/silver chloride that are wet with conductive gel. We will use surface landmarks and EEG caps on the head to place the electrodes, which are held in place by head caps with holes indicating places for electrode positioning.
62405754|NCT00621309|ACTIVE_COMPARATOR|3|This arm involves the administration of Sulforaphane (SFN) alone, in the absence of the PXR ligand, rifampicin. The hypothesis is that SFN will have no effect on the expression of PXR-regulated genes. Alternatively, it is possible that SFN could inhibit as yet unidentified endogenous ligands to the PXR receptor, thereby causing down-regulations of genes regulated wholely or in part by PXR. SFN is administered as a broccoli sprout extract at a dose rate of 75 mg (\~420 umoles) per day for 7 days.
62405755|NCT00261859|NO_INTERVENTION|SCA|Standard Care with Assessment
62405756|NCT00261859|NO_INTERVENTION|SCNA|Standard Care No Assessment
62405757|NCT00261859|EXPERIMENTAL|BNI|Brief Negotiated Interview
62405758|NCT00261859|EXPERIMENTAL|EBNI|Enhanced Brief Negotiated Interview
62788989|NCT05003596|EXPERIMENTAL|Steroid Group|Patients receive 21 tablets of 4 mg methylprednisolone to be taken by mouth over a 6 week taper. Patients will be advised to not take other anti-inflammatory medications like NSAIDs.
62405759|NCT02089022|EXPERIMENTAL|Physiotherapy resources|The goal of applying ice and shortwave diathermy to the calf, ankle and sole of the foot was to verify the effect of this resources at the neuromuscular response of the lower limb and postural balance
62405760|NCT03577665|EXPERIMENTAL|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
62581308|NCT02953847|OTHER|sequence 1|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
62788990|NCT05003596|ACTIVE_COMPARATOR|Control Group|Patients will recieve standard treatment that focuses on mobilization and stabilization using common techniques like buddy taping and splinting. Pain control will be managed using non-NSAID medications like Tylenol or opioid narcotics when deemed medically necessary.
62206896|NCT03907644|SHAM_COMPARATOR|Sham FPS|In the sham stimulation mode, the device shows pseudorandom numbers on the screen that look like real stimulation is being delivered. The device gives a low level of stimulation at the very beginning and at the very end of the stimulation session (30 seconds ramp up and 30 seconds ramp down) in order to recreate the feeling of tingling that subjects perceive at the beginning and end of real stimulation.
62206897|NCT04129164|EXPERIMENTAL|VIB4920 Dose 1 in Population 1|Participants in population 1 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
62206898|NCT04129164|PLACEBO_COMPARATOR|Placebo in Population 1|Participants in population 1 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
62206899|NCT04129164|EXPERIMENTAL|VIB4920 Dose 1 in Population 2|Participants in population 2 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
62206900|NCT04129164|PLACEBO_COMPARATOR|Placebo in Population 2|Participants in population 2 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
62206901|NCT01996553||Transradial cardiac catheterization|Patients undergoing cardiac catheterization through the radial artery.
62206902|NCT06718296||Study group|All individuals participating in the study will sign an 'Informed Consent Form', and they will be informed about what they need to do as part of the study, what situations may arise, and any questions they have will be addressed. In the research methodology, a Patient Information Form will be used to evaluate demographic and clinical information. The ASES Scale will be used to assess shoulder pain and function, the Quick DASH will be used to measure the level of disability and functional limitations, and the SF-12 Scale will be used to assess quality of life. All scales applied to the patients will be completed within one day. The re-test of the Photographic Shoulder Scale will be conducted 7 days later. Individuals who are being followed at the Orthopedics and Traumatology Department of Başakşehir Çam and Sakura City Hospital and meet the inclusion criteria will be included in the study.
62206903|NCT05385315||Parkinson's Disease, de novo|patients with de novo PD, without dopaminergic treatment
62206904|NCT05385315||Parkinson's Disease, advanced stage|PD patients with diagnosis \>5years, with dopaminergic treatment and motor fluctuations.
62206905|NCT05385315||Multiple system atrophy|patients with multiple system atrophy
62206906|NCT04555785|EXPERIMENTAL|Platelet transfusion with Wilate ®|
62206907|NCT04555785|PLACEBO_COMPARATOR|Platelet transfusion with Placebo|
62206908|NCT05751785|ACTIVE_COMPARATOR|Physical Therapy (PT) Only|"Participants in the PT only arm will follow the PT program outlined above. Twice a week for three weeks, a team member will check-in with the participants to ensure physical therapy exercise adherence, and response to treatment. During the second check-in of the week, the study team member will also ensure the participant is keeping their activity/medication/pain log; the study team member will also deliver the DVPRS with supplemental questions. (See Appendix F for Check-in Data Collection CRF). These check-ins may occur virtually or in person.~In Part 1, the physical therapy only arm requires 8 visits. The participants will complete 2 check-in visits each week (remote or in person), for three weeks. Follow-up data will be collected at 6 weeks (virtual or in-person) and at 3 months (in-person)."
62206909|NCT05751785|ACTIVE_COMPARATOR|PT + Photobiomodulation Therapy (PBMT)|"The physical therapy + photobiomodulation therapy arm will receive PBMT twice a week, for three weeks, in addition to the PT treatment described above.~A member of the study team will measure the treatment area according to a standard protocol (Appendix N PBM Dose Calculations), to calculate and determine the treatment time, approximately 5-20 minutes. PBMT will be delivered at 25W."
62206910|NCT05751785|ACTIVE_COMPARATOR|PT + Shockwave Therapy (SWT)|"The physical therapy + shockwave therapy arm will receive SWT once a week for three weeks in addition to the PT treatment described above. Twice a week, for three weeks, a team member will check-in with the participants to ensure physical therapy exercise adherence, and response to treatment. During the second check-in of the week, the study team member will also ensure the participant is keeping their activity/medication/pain log; the study team member will also deliver the DVPRS with supplemental questions. (See Appendix F for Check- in Data Collection CRF). The first check-in of the week will occur in-person after the SWT, if, however, this is not feasible, it may be conducted virtually; the second check-in of the week may occur virtually or in-person.~In total, participants will receive one SWT treatment each week (in person) and complete two check-ins each week (remote or in person), for three weeks. The SWT will take approximately 5-20 minutes."
62215421|NCT00355485|EXPERIMENTAL|Microdermabrasion Treatment|Bilateral, split-face comparison in which one half of the face will be randomly assigned to receive the microdermabrasion treatment(s) while the other half of the face will not. Subjects will receive a series of microdermabrasion treatment sessions (up to 6) spaced one to two weeks apart. In all cases, microdermabrasion treatment parameters will be within those accepted in cosmetic work.
62581309|NCT02953847|OTHER|sequence 2|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
62215422|NCT04147520|ACTIVE_COMPARATOR|Brief Motivational Interview|Single-session in person conversation focusing on risks associated with alcohol use.
62215423|NCT04147520|NO_INTERVENTION|Natural History Control|No contact.
62215424|NCT04999124|OTHER|Type 2 Diabetes Mellitus patients|
62788991|NCT05629130|EXPERIMENTAL|Embolization|embolization procedure (superselective embolization of target arteries with spherical microparticles Embosphere 100-300 micrometers (Biosphere Medical, Roissy, France) of the affected joint, until partial vascular stasis and decharacterization of pathological synovial enhancement.
62788992|NCT05725980||Skeletal Class I patients|Patients from this group present 0° \< ANB \< 4° on the cephalometric tracing.
62788993|NCT05725980||Skeletal Class II patients|Patients from this group present ANB \> 4° on the cephalometric tracing.
62788994|NCT05725980||Skeletal Class III patients|Patients from this group present ANB \< 0° on the cephalometric tracing.
62017115|NCT06529497|EXPERIMENTAL|treatment group receiving (racecadotril+ORS+Zinc)|The intervention group will receive racecadotril+ORS+Zinc while the reference group will receive ORS+Zinc alone
62405761|NCT05075551|EXPERIMENTAL|Acupuncture|Before participants accept the treatment, they are acquired to finish the clinical scales (including NIH-CPSI scale, HADS, VAS, SSRS, SES, IPSS and QoL) and then get the fMRI scan. Hwato brand disposable acupuncture needles will be used. Sanyinjiao (SP6), Zhibian (BL54), Shenshu (BL23), and Huiyang (BL35) are selected as acupoints. The course of treatment is 2 times a week in three months (totally 24 times). At the ending of the treatment, all the volunteers will be asked to finish the clinical scales and get the fMRI scan again. As the step of following up, all the patients will be asked to finish the clinical scales and get the fMRI scan again to evaluate the efficacy of avoiding the recurrence of acupuncture.
62405762|NCT05075551|SHAM_COMPARATOR|Sham Acupuncture|In the sham acupuncture group, these volunteers will receive relatively shallow needling at bilateral sham SP6, BL54, BL23, and BL35. This treatment gets involved in the same duration and frequency of sessions, but the treatment was delivered superficially at non-acupuncture points 10 mm to the lateral of corresponding acupuncture and not above a meridian line (10mm to SP6, BL54, BL23 and BL35). The Hwato brand disposable acupuncture needles will be inserted with a depth of 2-3 mm without any manipulation.The procedure of finishing scales and get fMRI scanning will be the same as the group of acupuncture.
62788995|NCT01331980||cystic fibrosis|children aged 6-12 years of age and Tanner stage 1 with a diagnosis of cystic fibrosis
62788996|NCT01331980||healthy controls|children ages 6-12 years and Tanner stage 1 without cystic fibrosis or other chronic disease that affects bone health
62788997|NCT04280796|EXPERIMENTAL|Substudy 1|"All participants will perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other. No arms will perform. In addition, in Substudy 1 an operant learning paradigm will be implemented to dissociate these responses, increasing the sensory-discriminative pain responses compared to emotional-motivational pain responses by contingent monetary reinforcement and vice versa.~Primary objectives:~1. To develop psychophysical methods that allow the independent assessment of sensory-discriminative and emotional-motivational pain responses and~2. to show that emotional-motivational and sensory-discriminative pain components can be dissociated~Secondary objective:~To assess whether fear of pain, fear-avoidance beliefs, pain catastrophizing, and sensation seeking as personality traits can explain variations in how strongly sensory-discriminative and emotional-motivational pain responses can be dissociated"
62405763|NCT01081431|EXPERIMENTAL|Lenalidomide|
62405764|NCT03486015|EXPERIMENTAL|30% glucose|This group will be given 2 ml of 30% glucose in the mouth before the physical examination of the infant.
62405765|NCT03486015|PLACEBO_COMPARATOR|Sterile water|This group will be given 2 ml of sterile water in the mouth before the physical examination of the infant.
62405766|NCT03448380||SMBG and FreeStyle Libre|During the intervention phase, subjects will use FreeStyle Libre Flash Glucose Monitoring System for 6 months to managed their diabetes.
62405767|NCT02026986|EXPERIMENTAL|sleep deprivation|Ten subjects in the SD group were examined after a SD experiment in which they did not sleep for 24 h.
62405768|NCT02026986|NO_INTERVENTION|control|The 10 subjects in the control group were not sleep deprived (had 8 h of sleep).
62405769|NCT01275170|EXPERIMENTAL|Panel A Mild Renal Impairment|Participants with an eGFR of \>50 to \<80 mL/min/1.73 m\^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
62405770|NCT01275170|EXPERIMENTAL|Panel B Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel A and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
62405771|NCT01275170|EXPERIMENTAL|Panel C Moderate Renal Impairment|Participants with an eGFR of 30 to 50 mL/min/1.73 m\^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
62405772|NCT01275170|EXPERIMENTAL|Panel D Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel C and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
62405773|NCT01275170|EXPERIMENTAL|Panel E Severe Renal Impairment|Participants with an eGFR \<30 mL/min/1.73 m\^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
62405774|NCT01275170|EXPERIMENTAL|Panel F Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel E and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
62405775|NCT01275170|EXPERIMENTAL|Panel G End Stage Renal Disease with Hemodialysis (ESRD/HD)|Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2). In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg predialysis (Part 2, Period 1) and postdialysis (Part 2, Period 2).
62405776|NCT01275170|EXPERIMENTAL|Panel H Healthy Volunteers|A subset of healthy control participants were matched specifically to participants in Panel G and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
62405777|NCT02764606||Patients with a non-small cell lung cancer|Serum and plasma samples (at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases).
62405778|NCT01985776|ACTIVE_COMPARATOR|Exercise intervention|Patients will functional stabilisation exercise for the trunk.
62405779|NCT01985776|ACTIVE_COMPARATOR|Exercise and e-stim|Patients will receive exercise intervention and electrical stimulation simultaneously.
62405780|NCT01985776|NO_INTERVENTION|Patients control|Patients will not receive any treatment but could use compression belt as per usual.
62405781|NCT01985776|NO_INTERVENTION|Healthy control|Healthy asymptomatic participants who will not receive any treatment.
62206911|NCT05751785|ACTIVE_COMPARATOR|PT + SWT and PBMT|"The PT + SWT + PBMT arm will receive both SWT and PBMT treatments in addition to PT treatment described above. Participants will receive PBMT twice a week and SWT once a week, for three weeks. The SWT visit may be combined with a PBMT visit in the same week. Up to two times each week after a treatment visit (for three weeks), a team member will check-in with the participants to ensure physical therapy exercise adherence, and response to treatment. During the second check-in of the week, the team member will also ensure the participant is keeping their activity/medication/pain log; the team member will also deliver the DVPRS with supplemental questions. When/if needed, these check-ins may occur virtually. (See Appendix F for check-in data collection CRF).~In Part 1, the PT+ SWT + PBMT treatment arm requires 8 visits: 3 for PBMT alone with check- ins (in person), 3 for PBMT \& SWT with check-ins (in person), 6-week follow-up (virtual or in-person), and 3-month follow-up (in person)."
62206912|NCT01456572|ACTIVE_COMPARATOR|satiation_obese weight|Obese subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.
62206913|NCT01456572|ACTIVE_COMPARATOR|gastric emptying_obese weight|Obese subjects will receive a standardized meal, consisting of two scrambled eggs (cooked with 10 g butter), placed on two slices of whole wheat bread and 200 mL of milk (in total: 468 kcal). The test meal will be labeled with 100 mg of 13C-octanoic acid for determination of gastric emptying.
62206914|NCT01456572|PLACEBO_COMPARATOR|gastric emptying_normal weight|Normal weight subjects will receive a standardized meal, consisting of two scrambled eggs (cooked with 10 g butter), placed on two slices of whole wheat bread and 200 mL of milk (in total: 468 kcal). The test meal will be labeled with 100 mg of 13C-octanoic acid for determination of gastric emptying.
62206915|NCT01456572|PLACEBO_COMPARATOR|satiation_normal weight|Normal weight subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.
62206916|NCT01456572|ACTIVE_COMPARATOR|hormone profiles_obese weight|Obese subjects will receive 500 mL of a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate). At regular time intervals fasting and post-prandial blood samples will be collected.
62206917|NCT01456572|PLACEBO_COMPARATOR|hormone profiles_normal weight|Normal weight subjects will receive 500 mL of a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate). At regular time intervals fasting and post-prandial blood samples will be collected.
62206918|NCT03912363|ACTIVE_COMPARATOR|Rotating fluids|Rotating fluids protocol will be initiated at the time of admission to Labor and Delivery.
62206919|NCT03912363|ACTIVE_COMPARATOR|Insulin infusion|Insulin infusion protocol will be initiated at the time of admission to Labor and Delivery.
62206920|NCT06532617|EXPERIMENTAL|Cadonilimab+S-1or Capecitabine|
62206921|NCT06365619|EXPERIMENTAL|Treatment: All Patients|Neoadjuvant Ipilimumab and Nivolumab
62206922|NCT04889209|EXPERIMENTAL|Cohort 1 Group 10E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV2-S 5x10\^10 vp stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273.211 (boost dose). N = 50
62206923|NCT04889209|EXPERIMENTAL|Cohort 1 Group 11E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273.211 (boost dose). N = 50
62206924|NCT04889209|EXPERIMENTAL|Cohort 1 Group 12E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV.2.S at 5x10\^10 vp stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 50-mcg dose of mRNA- 1273 N = 50
62206925|NCT04889209|EXPERIMENTAL|Cohort 1 Group 13E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Moderna-mRNA-1273 at 100mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 50-mcg dose of mRNA-1273. N = 50
62206926|NCT04889209|EXPERIMENTAL|Cohort 1 Group 14E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 50-mcg dose of mRNA-1273. N = 50
62206927|NCT04889209|EXPERIMENTAL|Cohort 1 Group 15E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV.2.S 5x10\^10 vp for one or two doses stratified with two age ranges of 18-55 years (n= 30) and 56 or older (n = 30) randomized to receive a single intramuscular (IM) injection of a 5-mcg dose of NVX-CoV2373 (SARS-COV-2). N =60
62206928|NCT04889209|EXPERIMENTAL|Cohort 1 Group 16E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses stratified with two age ranges of 18-55 years (n = 30) and 56 or older (n = 30) randomized to receive a single intramuscular (IM) injection of a 5-mcg dose of NVX-CoV2373 (SARS-COV-2). N =60
62206929|NCT04889209|EXPERIMENTAL|Cohort 1 Group 17E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 30) and 56 or older (n = 30) randomized to receive a single intramuscular (IM) injection of a 5-mcg dose of NVX-CoV2373 (SARS-COV-2). N =60
62405782|NCT04366115|ACTIVE_COMPARATOR|AVM0703 COVID-19 ARDS - active|Supra-pharmacologic dexamethasone sodium phosphate
62405783|NCT04366115|PLACEBO_COMPARATOR|Placebo COVID-19 ARDS - placebo|Matching placebo
62405784|NCT04366115|ACTIVE_COMPARATOR|AVM0703 Influenza ARDS - active|Supra-pharmacologic dexamethasone sodium phosphate
62405785|NCT04366115|PLACEBO_COMPARATOR|AVM0703 Influenza ARDS - placebo|Matching placebo
62206930|NCT04889209|EXPERIMENTAL|Cohort 1 Group 1E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV.2.S at 5x10\^10 vp stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of 100-mcg dose of mRNA-1273 (boost dose). N = 50
62206931|NCT04889209|EXPERIMENTAL|Cohort 1 Group 2E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA) -dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273 (boost dose). N = 50
62206932|NCT04889209|EXPERIMENTAL|Cohort 1 Group 3E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA) -dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n ˜ 25) randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273 (boost dose). N = 50
62206933|NCT04889209|EXPERIMENTAL|Cohort 1 Group 4E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV2-S at 5x10\^10 vp stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of Ad26.COV2.S 5x10\^10 vp (boost dose). N = 50
62206934|NCT04889209|EXPERIMENTAL|Cohort 1 Group 5E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of Ad26.COV2.S 5x10\^10 vp (boost dose). N = 50
62206935|NCT04889209|EXPERIMENTAL|Cohort 1 Group 6E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of Ad26.COV2.S 5x10\^10 vp (boost dose). N = 50
62206936|NCT04889209|EXPERIMENTAL|Cohort 1 Group 7E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV.2.S 5x10\^10 vp stratified with two age ranges of 18-55 years (n=˜ 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 30-mcg dose of BNT162b2 (boost dose). N = 50
62206937|NCT04889209|EXPERIMENTAL|Cohort 1 Group 8E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 30-mcg dose of BNT162b2 (boost dose). N = 50
62206938|NCT04889209|EXPERIMENTAL|Cohort 1 Group 9E|Adaptive design cohort with participants that previously (\>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 30-mcg dose of BNT162b2 (boost dose). N = 50
62206939|NCT04889209|EXPERIMENTAL|Cohort 2|A prospective design cohort with naïve to COVID-19 vaccine and infection participants of \> / = 18 years of age to receive COVID-19 vaccine intramuscularly under Emergency Use Authorization dosing (EUA) (two vaccinations of mRNA-1273 at the 100mcg dose at a 28 days of interval) followed by a delayed vaccination (50 mcg mRNA-1273) after a minimum of 12 weeks. A second booster (fourth dose) will be administered intramuscular using Moderna mRNA-1273.222 at 50 mcg at a 4-12 month interval N=250
62206940|NCT03374449|EXPERIMENTAL|continuation of the RAS-inhibitors|in the continuation of the RAS-inhibitors arm the treatment will be continued until the morning the day of surgery.
62206941|NCT03374449|ACTIVE_COMPARATOR|discontinuation of the RAS-inhibitors|In this arm : discontinuation of the RAS-inhibitors 48 hours before surgery Patients won't receive the drug on the morning of the day of the surgery.
62206942|NCT00044798|EXPERIMENTAL|1|Participants will receive treatment with repetitive transcranial magnetic stimulation and citalopram.
62206943|NCT00044798|ACTIVE_COMPARATOR|2|Participants will receive treatment with sham repetitive transcranial magnetic stimulation and citalopram.
62206944|NCT06079554||the gastric cancer group|16 cases of intestinal type of gastric cancer under the background of atrophic gastritis
62206945|NCT06079554||the atrophic gastritis group|16 cases of atrophic gastritis without gastric cancer matched according to gender, age, and degree of gastric atrophy
62206946|NCT03139604|EXPERIMENTAL|Itacitinib|Itacitinib plus corticosteroids
62206947|NCT03139604|PLACEBO_COMPARATOR|Placebo|Matching placebo plus corticosteroids
62206948|NCT06280040||Uveal Melanoma|Patients with newly diagnosed uveal melanoma, which will be treated with hypofractionated stereotactic photon radiotherapy as clinical routine.
62215425|NCT05949073|ACTIVE_COMPARATOR|Non impregnated gingival retraction cord - less than 10 minutes|Non impregnated gingival retraction cord will be placed around the prepared tooth and left for less than 10 minutes.
62206949|NCT03816761|EXPERIMENTAL|Fast-acting insulin aspart, default tmax setting|Participants will receive fast-acting insulin aspart using the iLet™ with default tmax setting (t65 = 65 minutes) in two different treatment periods in a cross-over manner. There will be 3 different cohorts with 2 treatment periods in each cohort.
62206950|NCT03816761|EXPERIMENTAL|Fast-acting insulin aspart, non-default tmax setting|Participants will receive fast-acting insulin aspart using the iLet™ with non-default tmax setting (t50 = 50 minutes, t40 = 40 minutes or t30 = 30 minutes) in two different treatment periods in a cross-over manner. There will be 3 different cohorts with 2 treatment periods in each cohort.
62206951|NCT01056497|EXPERIMENTAL|alpha lipoic acid|
62206952|NCT00230880|EXPERIMENTAL|Treatment|follow-up phone counseling
62206953|NCT00230880|NO_INTERVENTION|Control|Usual care
62405786|NCT01832896|EXPERIMENTAL|Ecallantide|"Study Medication, Dose, and Mode of Administration:~Single dose of ecallantide subcutaneous dosing:~* Age less than 10: Weight \<25 Kg: 10mg subcutaneously at one site; 25-50kg: 20mg subcutaneously, 10mg per site for 2 separate sites; \>50 kg 30mg subcutaneously, 10mg per site for 3 separate sites. Dosing will not exceed 30mg.~* Age greater than 10: 10mg per site for 3 separate sites. Dosing will not exceed 30mg."
62206954|NCT06705348||Transdiagnostic|Participants will be a transdiagnostic sample of older individuals (age 55+ years) with stress disorders without psychosis including individuals with MDD, bipolar disorder, post-traumatic stress disorder (PTSD), dysthymia, and non-psychiatric individuals.
62206955|NCT03545802|EXPERIMENTAL|Training|6 weeks of home-based high intensity interval training
62206956|NCT02013921||Physical Activity|Patients with a breast cancer and are completing treatment
62206957|NCT05336214|EXPERIMENTAL|Refer|Practice referral of patients to a virtual CGM initiation service
62405787|NCT00363272|EXPERIMENTAL|Arm I|Patients receive ispinesib IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
62405788|NCT01826006|ACTIVE_COMPARATOR|Excimer laser|After wire crossing, Excimer Laser will be performed. Consequently, intracoronary adenosine will be selectively administered through the guiding catheter.
62017116|NCT06529497|ACTIVE_COMPARATOR|the control group (receiving ORS + Zinc or standard treatment)|The intervention group will receive racecadotril+ORS+Zinc while the reference group will receive ORS+Zinc alone
62017117|NCT04498884|EXPERIMENTAL|Rinsulin® mix 30/70|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
62206958|NCT05336214|EXPERIMENTAL|Learn|Practice completion of online educational module, American Academy of Family Physicians (AAFP) Transformation in Practice Series (TIPS) on continuous glucose monitoring in primary care
62206959|NCT05336214|EXPERIMENTAL|Learn + Practice Facilitation|Practice completion of online educational module, American Academy of Family Physicians (AAFP) Transformation in Practice Series (TIPS) on continuous glucose monitoring in primary care plus practice facilitation
62206960|NCT06092424|ACTIVE_COMPARATOR|Investigations at High altitude (HA, 2840m)|PAP and other hemodynamics assessed by echocardiography and blood gases near their living altitude in Quito at 2840m
62017118|NCT04498884|ACTIVE_COMPARATOR|Humulin® M3|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
62017119|NCT00919386||1 Direct ureteric measurement|This is determined by using a 5 French Pollack Open-Ended Flexi-Tip Ureteral catheter (Cook, Spencer, Indiana) to cannulate the ureteral orifice. A retrograde pyelogram will be done at the conclusion of the procedure and the Pollack will be advanced to the pyeloureteral junction (PUJ) under fluoroscopy. At this point the length of the distance between the PUJ and vesicoureteral junction (VUJ) will be recorded and stent length determined based on this measurement.
62017120|NCT00919386||2 Based on patient height|"We will use the height measurement criteria used by Lee et al in their study. Patients less than 5'2 will receive a 22 cm stent, 5'3-5'7 will get a 24 cm stent, 5'8-5'10 will get a 26 cm stent, 5'11 to 6'1 will get a 28 cm stent, and all patients greater than 6'2 will receive a 30 cm stent."
62017121|NCT00919386||3 Based on a predetermined formula|We will use the formula described by Wieder. Stent length in cm= patients height in inches - 42.
62017122|NCT00322062|EXPERIMENTAL|1|"1 pack (contains 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets)= 2L NRL994 . 2 sachets (one of each) will be dissolved in 1L of water. Each litre will be drunk within 1 hour. Furthermore, at least 1000ml (or more) of any additional clear fluid (except milk) has to be drunk after the 2L of NRL994."
62017123|NCT00322062|ACTIVE_COMPARATOR|2|1 pack consists of 2 flasks of 45ml. Each flask has to be dissolved within 125ml of water. Each intake of NaP solution has to be preceded and followed by 250ml (or more if necessary)of clear liquids(excluding milk)and a delay of at least 12 hours between the intake of the 2 x 45ml of NaP solution has to be completed. In addition, 750ml more of clear liquids (excluding milk)or more if needed must be drunk between the 2 intakes.
62017124|NCT01767116|EXPERIMENTAL|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62017125|NCT01767116|EXPERIMENTAL|ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks plus placebo RBV (twice daily) for 12 weeks
62017126|NCT05051644|EXPERIMENTAL|Steps 2 Change (S2C)|Participants randomized to S2C will be scheduled for 60-minute weekly treatment sessions held over four consecutive weeks in the outpatient OAT clinic. Veterans will be expected to increase their average step counts by 10% over their prior week's average starting after Session 1. Session 1 will provide pain education including a discussion the biopsychosocial treatment model for chronic pain and benefits of activity. Session 2 and 3 will emphasize benefits of low impact physical activity and introduce activity pacing to address pain flare ups caused by cycles of over activity and subsequent sedentary behavior. Session 4 will help develop a treatment plan to continue walking and identify possible barriers to meeting goals.
62206961|NCT06092424|EXPERIMENTAL|Investigations at Low altitude (LA, sea level)|PAP and other hemodynamics assessed by echocardiography and blood gases after the first and second night at LA (sea level)
62206962|NCT06264128|EXPERIMENTAL|CPAP v TPAP|Participants will compare CPAP to 2 different levels of TPAP, then will compare 2 levels of TPAP against each other by breathing on each pair of therapies for a minute or so, then deciding which is more comfortable or if they are equivalent.
62206963|NCT03735667|EXPERIMENTAL|ACURATE Valve - Main Randomized|"Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System.~\*A subset of subjects will also be enrolled in the 4D CT Imaging Substudy."
62206964|NCT03735667|EXPERIMENTAL|ACURATE Valve - Single-arm Roll-in|Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System.
62206965|NCT03735667|ACTIVE_COMPARATOR|Commercial Valve - Main Randomized|"Medtronic CoreValve TAVR System OR, Edwards SAPIEN 3 TAVR System~Patients assigned to this group will be implanted with commercially available balloon-expandable SAPIEN 3™ Transcatheter Heart Valve or future iteration (SAPIEN 3; Edwards Lifesciences LLC, Irvine, CA, USA) or a commercially available self-expanding CoreValve® Transcatheter Aortic Valve Replacement System, CoreValve® Evolut™ R Recapturable TAVR System, EVOLUT™ PRO System, or future iteration (CoreValve; Medtronic, Inc., Dublin, Ireland) TAVR device.~\*A minimum of 200 subjects will also be enrolled in the 4D CT Imaging Substudy."
62206966|NCT03735667|EXPERIMENTAL|ACURATE Valve - Single-arm Prime XL|"Patients assigned to this group will be implanted with ACURATE Prime™ transfemoral TAVR System XL.~\*50 subjects will be enrolled in the Prime™ XL Nested Registry"
62206967|NCT03735667|EXPERIMENTAL|ACURATE Valve - Extended Durability Randomized|Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System (S, M, L) or ACURATE Prime™ transfemoral TAVR System XL. Only low risk patients are enrolled in this group.
62206968|NCT03735667|ACTIVE_COMPARATOR|Commercial Valve - Extended Durability Randomized|"Medtronic CoreValve TAVR System OR, Edwards SAPIEN 3 TAVR System~Patients assigned to this group will be implanted with commercially available balloon-expandable SAPIEN 3™ Transcatheter Heart Valve or future iteration (SAPIEN 3; Edwards Lifesciences LLC, Irvine, CA, USA) or a commercially available self-expanding CoreValve® Transcatheter Aortic Valve Replacement System, CoreValve® Evolut™ R Recapturable TAVR System, EVOLUT™ PRO System, or future iteration (CoreValve; Medtronic, Inc., Dublin, Ireland) TAVR device. Only low risk patients are enrolled in this group."
62206969|NCT03735667|EXPERIMENTAL|ACURATE Valve - Continued Access Study|Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System (S, M, L) or ACURATE Prime™ transfemoral TAVR System XL.
62788998|NCT04280796|EXPERIMENTAL|Substudy 2|"All participants will perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other. No arms will perform. In addition, in Substudy 2, responses of chronic pain patients will be compared to those of healthy participants to characterize possible alterations in the patients and operant learning will be operationalized to decrease emotional-motivational pain responses, which are assumed to be already increased in the patients.~Primary objective:~To demonstrate that in chronic pain patients, emotional-motivational pain responses are increased relative to sensory-discriminative pain responses~Secondary objective:~To assess whether fear of pain, fear-avoidance beliefs, pain catastrophizing, and sensation seeking as personality traits can explain variations in the present dissociation of sensory-discriminative and emotional-motivational pain responses in chronic pain patients"
62206970|NCT01763515|EXPERIMENTAL|Laterally wedged insoles|Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
62206971|NCT02084563|OTHER|AML-Intensive Chemotherapy|"Patients with Acute Myeloid Leukemia fit for intensive chemotherapy Patients will receive Induction Chemotherapy, and CR will be evaluated after 28 days.~Patients who achieve CR post-induction chemotherapy will receive post-remission therapy according to risk:~* Low risk patients: Consolidation chemotherapy or Autologous stem cell transplantation~* Intermediate and high-risk patients: Allogeneic stem cell transplantation Patients who do not achieve CR may receive one second induction cycle, and if CR is achieved may proceed to post-remission therapy as per above. Patients who do not achieve CR after two cycles of induction will be deemed refractory and removed from the study."
62206972|NCT02084563|OTHER|AML-Non-intensive chemotherapy|"Patients with acute myeloid leukemia not fit for intensive chemotherapy Patients will receive induction chemotherapy with either low dose cytarabine or decitabine. Assignment to each drug will depend on drug availability and physician discretion. No randomization will be done between the drugs.~Cycles will be repeated every 28 days. Patients who achieve CR will continue to post-consolidation therapy with either cytarabine or decitabine, based on the induction therapy received. Patients will receive a maximum of 4 cycles until achieving CR, if no response is seen after 4 cycles patients will be deemed refractory."
62206973|NCT02084563|NO_INTERVENTION|Chronic Myeloid Disorders|"Patients with Chronic Myeloid Disorders:~* Myeloproliferative Neoplasms~* Myelodysplastic Syndromes~* Myeloproliferative/Myelodysplastic Neoplasms"
62206974|NCT06437782||type 1 diabetes closed loop|
62206975|NCT06437782||type 2 diabetes|
62206976|NCT06437782||Gestational diabetes|
62206977|NCT01891175|EXPERIMENTAL|Intermittent pneumatic compression|With intermittent pneumatic compression of the lower extremities (Covidien / Kendall SCD ™ sequential compression systems) plus phenylephrine perfusion (usual treatment)in elective caesarean section under spinal anaesthesia.
62206978|NCT01891175|ACTIVE_COMPARATOR|Only pheniyephrine perfussion|No intermittent pneumatic compression of the lower extremities in elective caesarean section under spinal anaesthesia.
62206979|NCT02918305|SHAM_COMPARATOR|PRDS-001 Renal Denervation Ultrasound System|Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using PRDS-001 System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
62206980|NCT02918305|SHAM_COMPARATOR|Sham Procedure|Randomization will occur following the diagnostic renal angiography. For blinded patients randomized to control, the diagnostic renal angiography will be considered the sham procedure.
62206981|NCT05596253||Patients with cirrhosis who underwent TIPS|Patients with cirrhosis who underwent TIPS due to complications of portal hypertension were inclueded for observation.
62206982|NCT06148623|EXPERIMENTAL|Test Subject|All subjects who are enrolled into the test group and participate in data collection have the Philips FAST SpO2 with Masimo Pulse Oximetry Sensors
62206983|NCT06324695|EXPERIMENTAL|HautKompass intervention|Participants in the intervention group will attend the self-guided 8-session online psychosocial intervention HautKompass.
62206984|NCT06324695|NO_INTERVENTION|Waiting list|Participants in the control group will not attend any psychosocial intervention during the course of the RCT (waiting list). They will be offered the opportunity to attend the HautKompass program after the follow-up phase.
62206985|NCT04573348||Groups 1-4|no intervention will be performed in this study, only blood drawn
62206986|NCT05797168|EXPERIMENTAL|Module 1: AZD5335 Monotherapy|AZD5335 Monotherapy
62788999|NCT04280796|EXPERIMENTAL|Substudy 3|"All participants will perform a psychophysical task to assess metacognition in pain perception as an indicator of the cognitive-evaluative pain component. No arms will perform.~Primary objective:~To assess whether metacognition on pain perception are involved and subjective ratings of perceived pain and how metacognition relates to pain intensity.~Secondary objective:~To assess whether confidentiality as a personality trait , pain catastrophizing, and skin conductance responses are related to metacognition in pain."
62206987|NCT05797168|EXPERIMENTAL|Module 2: AZD5335 + Saruparib|AZD5335 + Saruparib
62206988|NCT05797168|EXPERIMENTAL|Module 3: AZD5335 + Bevacizumab|AZD5335 + Bevacizumab
62206989|NCT05797168|EXPERIMENTAL|Module 4: AZD5335 + Carboplatin +/- Bevacizumab|AZD5335 + Carboplatin +/- Bevacizumab
62206990|NCT06729723|EXPERIMENTAL|SAT-001 Treatment Group|Using SAT-001 for 30 minutes
62206991|NCT06729723|ACTIVE_COMPARATOR|Modified SAT-001 Treatment Group|using modified SAT-001, which excludes rest session from SAT-001, for 15 minutes
62789000|NCT05330767||Wound on either the upper or lower extremity with DermaClose and/or DermaClose XL|Non-fasciotomy
62206992|NCT01857089|EXPERIMENTAL|Pressure Measurement|
62206993|NCT06659861|EXPERIMENTAL|Test Group|This group will apply the RV3278B-OS0386 cosmetic product for acne prone skin.
62206994|NCT06659861|OTHER|Control Group|This group will receive the associated cosmetic product RV4632A-RY1845 (emollient cream), to be applied in the event of facial skin discomfort only.
62789001|NCT05330767||Wound undergoing fasciotomy with DermaClose and/or DermaClose XL|
62789002|NCT05330767||Wound undergoing fasciotomy with conventional wound dressings|
62789003|NCT00853151|EXPERIMENTAL|LY2428757 plus TT223 3 milligrams (mg)|Weekly LY2428757 plus 3 milligrams (mg) daily TT223
62789004|NCT00853151|EXPERIMENTAL|LY2428757 plus TT223 2mg|Weekly LY2428757 plus 2 mg daily TT223
62789005|NCT00853151|EXPERIMENTAL|LY2428757 plus placebo|Weekly LY2428757 plus daily TT223 placebo
62789006|NCT00853151|PLACEBO_COMPARATOR|Placebo plus Placebo|Weekly LY2428757 placebo plus daily TT223 placebo
62789007|NCT02336672|NO_INTERVENTION|Group A Chemotherapy|Patients receiving chemotherapy alone. These patients start standard chemotherapy right after the oncologist's evaluation according to accepted Guidelines of the Italian Association of Medical Oncologists (AIOM). Restaging is performed 2, 4 and 6 months after chemotherapy onset, with MDCT scan and DW-MRI.
62789008|NCT02336672|EXPERIMENTAL|Group B Chemotherapy + HybridTherm|Patients receiving chemotherapy plus EUS-guided Cryothermal Ablation with HybridTherm probe. These patients are first treated by cryothermal ablation and one week after they start with chemotherapy. Cryothermal ablation can be performed up to three times, with interval of 4 +/- 1 weeks. Restaging is performed 2, 4 and 6 months after chemotherapy onset, with MDCT scan and DW-MRI.
62206995|NCT02685098|EXPERIMENTAL|Active/Treatment Group|Amputation performed at 7 days post allogeneic bone marrow derived mesenchymal stem cell injections.
62206996|NCT02685098|NO_INTERVENTION|Observation Group 1|Amputation performed with no MSC administration. Subjects will be followed for incidence of infection and wound healing status to week 24 as a comparator to the Active/Treatment group.
62206997|NCT02685098|NO_INTERVENTION|Observation Group 2|"Tissue Collection Group:~Amputation performed with no MSC administration. Subjects will not be followed after amputation is performed. Tissue collection will occur at time of amputation."
62206998|NCT02685098|NO_INTERVENTION|Observation Group 3|Patients undergoing lower extremity bypass grafting procedure. Skeletal muscle samples of the sartorius and anterior tibial muscle will be collected for comparison to treatment group. No study testing, nor follow up visits will occur.
62206999|NCT02685098|NO_INTERVENTION|Control Group 4|Patients undergoing a standard of care surgical procedure under anesthesia. Core needle biopsies will be collected from the anterior tibial muscle at the time of surgical procedure. No study testing, nor follow up visits will occur.
62207000|NCT06464653|EXPERIMENTAL|Forel's Field H-DBS group|participants will undergo Forel's Field H-DBS ON with the individual stimulation parameters determined in the parameter determination period, then continue to receive stimulation for the remainder of the study.
62207001|NCT01233362|ACTIVE_COMPARATOR|Arm 1: Adults; 14 days interval|89 Adults (=\> 18 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
62207002|NCT01233362|ACTIVE_COMPARATOR|Arm 2: Adults; 28 days interval|89 Adults (=\> 18 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
62207003|NCT01233362|ACTIVE_COMPARATOR|Arm 3: children; 14 days interval|89 children (1-17 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
62207004|NCT01233362|ACTIVE_COMPARATOR|Arm 4: children; 28 days interval|89 children (1-17 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
62207005|NCT01233362|ACTIVE_COMPARATOR|Arm 5: Adults; 14 days Interval|15 Adults (=\> 18 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
62207006|NCT01233362|ACTIVE_COMPARATOR|Arm 6: Adults; 28 days interval|15 Adults (=\> 18 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
62207007|NCT04310930|ACTIVE_COMPARATOR|Intensive Therapy A|Following Randomisation 1, Participants will receive intensive drug therapy in the form of IV amikacin, IV tigecycline, IV cefoxitin/imipenem + oral azithromycin AND clofazimine.
62207008|NCT04310930|EXPERIMENTAL|Intensive Therapy B|Following Randomisation 1, Participants will receive inhaled amikacin (IA), IV tigecycline, IV cefoxitin/imipenem + oral azithromycin/oral clarithromycin AND clofazimine.
62207009|NCT04310930|EXPERIMENTAL|Intensive Therapy C|Following Randomisation 1, Participants will receive intensive drug therapy in the form of IV amikacin, IV tigecycline, IV cefoxitin/imipenem + oral azithromycin/oral clarithromycin.
62207010|NCT04310930|ACTIVE_COMPARATOR|Consolidation A|Oral clofazimine + oral azithromycin/oral clarithromycin in combination with one to three of the following oral antibiotics: oral linezolid, oral co-trimoxazole, oral doxycycline, oral moxifloxacin, oral bedaquiline (adults only), oral rifabutin.
62789009|NCT02393937|EXPERIMENTAL|Test: Metronidazole Gel 1%|Metronidazole Gel 1% once daily for 70 days.
62789010|NCT02393937|ACTIVE_COMPARATOR|Reference: Metronidazole Gel 1%|Metronidazole Gel, 1% (MetroGel) Galderma S.A. once daily for 70 days.
62017127|NCT05051644|ACTIVE_COMPARATOR|Control|Participants randomized to control will be scheduled for 60-minute weekly treatment sessions held over four consecutive weeks focused on problems associated with MOUD, substance use, and general self-management strategies. Importantly, group will explicitly avoid talking about pain coping skills and setting goals for daily step targets.
62017128|NCT03058731||Matristem|Hernia repair with MatriStem Surgical Matrix
62017129|NCT03058731||Control|Other biological mesh
62017130|NCT00259753|EXPERIMENTAL|1|0.2 mg/eye
62017131|NCT00259753|EXPERIMENTAL|2|1.5 mg/eye
62017132|NCT00259753|EXPERIMENTAL|3|3.0 mg/eye
62789011|NCT02393937|PLACEBO_COMPARATOR|Placebo|Placebo Gel once daily for 70 days.
62789012|NCT05205174|OTHER|Feasibility|This is a preliminary, prospective interventional study to investigate the feasibility of using depth electrodes in conjunction with novel analytical algorithms to detect CSDs in TBI patients.
62789013|NCT05808140|NO_INTERVENTION|Control group|Standard endoscopic spinal surgery
62789014|NCT05808140|EXPERIMENTAL|0.5mg/kg ICG group|The patients receive 0.5mg/kg ICG intravenous injection before surgery. The search for lumbar nerve roots is performed with the assistance of fluoroscopic endoscopic imaging equipment. And the procedure follows standard endoscopic spinal surgery procedures.
62789015|NCT05808140|EXPERIMENTAL|1mg/kg ICG group|The patients receive 1mg/kg ICG intravenous injection before surgery. The search for lumbar nerve roots is performed with the assistance of fluoroscopic endoscopic imaging equipment. And the procedure follows standard endoscopic spinal surgery procedures.
62017133|NCT02096835|EXPERIMENTAL|Acustimulation|Transcutaneous electrical acupoint stimulation (TEAS) starts 30 min before surgery and lasts until patient leaves the postanesthetic care unit.Dexamethasone 10mg i.v. after induction.
62017134|NCT02096835|ACTIVE_COMPARATOR|Tropisetron|Tropisetron 5mg iv. at the start of skin closure.Sham transcutaneous electrical acupoint stimulation.Dexamethasone 10mg i.v.after induction.
62017135|NCT02096835|SHAM_COMPARATOR|Control|Sham transcutaneous electrical acupoint stimulation. Dexamethasone 10mg i.v.after induction.
62017136|NCT05339685|EXPERIMENTAL|Study treatment|Participants receive BL-M02D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62017137|NCT04702074|EXPERIMENTAL|Traditional Chinese medicine granules|The experimental group will be given Bu Fei Jian Pi Hua Tan granule or Yi Qi Yang Yin Qing Fei granule based on TCM syndrome differentiation.
62017138|NCT04702074|PLACEBO_COMPARATOR|Traditional Chinese medicine granules placebo|The control group will be given Bu Fei Jian Pi Hua Tan granule placebo or Yi Qi Yang Yin Qing Fei granule placebo based on TCM syndrome differentiation.
62017139|NCT06052384|EXPERIMENTAL|Reinforced sleep program|standard pain management + sleep disorders management
62017140|NCT06052384|NO_INTERVENTION|Standard care|Control group: standard pain management
62017141|NCT03947645|EXPERIMENTAL|Ipsilesional stimulation|Ipsilesional stimulation
62017142|NCT03947645|EXPERIMENTAL|Contralesional stimulation|Contralesional stimulation
62017143|NCT06068816|EXPERIMENTAL|Nutrient Dense Drink|"Experimental: Nutrient-dense drink Nutrient-dense drink on top of standard care~* 200 kcal~* 15 grams of (whey) protein, 8 grams of fat, and 17 grams of carbohydrates including only 0.2 g lactose~* 400 IU vitamin D, 250 mg Ca, 10-20 % of the other vitamins/minerals~Servings :~• 100 ml water for dissolving 46 g of the served powder"
62207011|NCT04310930|EXPERIMENTAL|Consolidation B|Inhaled amikacin (IA), oral clofazimine + oral azithromycin/oral clarithromycin in combination with one to three of the following oral antibiotics: oral linezolid, oral co-trimoxazole, oral doxycycline, oral moxifloxacin, oral bedaquiline (adults only), oral rifabutin.
62789016|NCT05808140|EXPERIMENTAL|2mg/kg ICG group|The patients receive 2mg/kg ICG intravenous injection before surgery. The search for lumbar nerve roots is performed with the assistance of fluoroscopic endoscopic imaging equipment. And the procedure follows standard endoscopic spinal surgery procedures.
62207012|NCT05061472||Combined Oral Contraceptives|Pre-menopausal women with overweight or obesity who are newly initiating the combined oral contraceptive pill, Sprintec (norgestimate/ethinyl estradiol 0.25mg/35mcg)
62017144|NCT06068816|NO_INTERVENTION|Standard Care|"Standard care comprising:~Standard care only will be provided nutritional counseling to achieve a better nutritional state"
62207013|NCT05061472||Nonhormonal Contraceptives (Control)|Pre-menopausal women with overweight or obesity who are using non-hormonal methods of birth control
62405789|NCT01826006|ACTIVE_COMPARATOR|Manual Thrombus Aspiration|After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary adenosine will be selectively administered.
62405790|NCT02999516|EXPERIMENTAL|Motor imaginary|Intervention with Motor imaginary with video
62405791|NCT02999516|EXPERIMENTAL|Non Motor imaginary|Intervention with Rest without motor imaginary
62581310|NCT02953847|OTHER|sequence 3|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
62581311|NCT02953847|OTHER|sequence 4|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
62789017|NCT00572013|EXPERIMENTAL|Arm I Rituxan and BEAM post-autologous stem cell transplant|Rituxan and BEAM \[Carmustine (BCNU), Etoposide, Cytarabine (Ara-C, cytosine arabinoside), Melphalan\] will be a pre- and post-transplant agent to aid in the chemotherapy sensitization post-autologous stem cell transplant.
62789018|NCT00248807|PLACEBO_COMPARATOR|ARM 1|Head-up tilt maneuver without drug in subjects with spinal cord injury
62789019|NCT00248807|PLACEBO_COMPARATOR|ARM 3|Head-up tilt maneuver without drug in able-bodied controls
62789020|NCT00248807|ACTIVE_COMPARATOR|ARM 2|Head-up tilt maneuver with an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat) in subjects with spinal cord injury
62017145|NCT06663306|EXPERIMENTAL|Arm A|Enrolled patients were treated with pemetrexed intrathecal injection
62017146|NCT06663306|EXPERIMENTAL|Arm B|Enrolled patients were treated with pemetrexed combined with bevacizumab intrathecal injection
62207014|NCT01413087|EXPERIMENTAL|8 mg BC-819 and Gemcitabine|gemcitabine dose of 1000mg/m2 + 8 mg of BC-819
62207015|NCT01413087|EXPERIMENTAL|12 mg BC-819 and Gemcitabine|gemcitabine dose of 1000mg/m2 + 12 mg of BC-819
62207016|NCT05849337|EXPERIMENTAL|Brief imagery-competing task|Access to a brief imagery-competing task for 24 weeks (with optional researcher support during the study)
62207017|NCT05849337|EXPERIMENTAL|Brief psychoeducation and signposting task|Access to psychoeducation and signposting regarding resources for psychological trauma in Iceland for 24 weeks (with optional researcher support during the study)
62207018|NCT05849337|OTHER|Treatment as usual (TAU)|Routine care that participants would otherwise receive if having intrusive memories of traumatic events.
62207019|NCT02092623|OTHER|Transvaginal posterior mesh surgery|All study patients undergo transvaginal mesh operation.
62207020|NCT01142115|EXPERIMENTAL|Monza|nonCE marked intermittent catheter
62207021|NCT01142115|ACTIVE_COMPARATOR|control|SpeediCath coated catheter
62215426|NCT05949073|ACTIVE_COMPARATOR|Non impregnated gingival retraction cord - more than 10 minutes|Non impregnated gingival retraction cord will be placed around the prepared tooth and left for more than 10 minutes.
62215427|NCT05949073|ACTIVE_COMPARATOR|impregnated gingival retraction cord - less than 10 minutes|Impregnated gingival retraction cord will be placed around the prepared tooth and left for less than 10 minutes.
62215428|NCT05949073|ACTIVE_COMPARATOR|impregnated gingival retraction cord - more than 10 minutes|Impregnated gingival retraction cord will be placed around the prepared tooth and left for more than 10 minutes.
62581312|NCT02953847|OTHER|sequence 5|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
62789021|NCT00248807|ACTIVE_COMPARATOR|ARM 4|Head-up tilt maneuver with an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat) in able-bodied controls.
62789022|NCT02848807|ACTIVE_COMPARATOR|NUTRIDRINK Compact Protein|NUTRIDRINK Compact Protein Oral nutritional supplement Dietary advice
62789023|NCT02848807|NO_INTERVENTION|without oral nutritional supplements|Dietary advice alone
62789024|NCT05355792|EXPERIMENTAL|Single tooth restorations|A single, open-label group with patients in need of single tooth restorations will receive an OmniTaper EV implant system available in the following sizes: diameter 3.4, 3.8, 4.5 and 5.5 mm and lengths 8, 9.5, 11, 13, 15 and 18 mm.
62789025|NCT02055378|EXPERIMENTAL|auricular acupoint stimulation|Five auricular acupoints were selected for taping stimulation by using a 1-mm alloy ball by fingers three times a day, each time for five minutes over the five selected acupoints. Topical 0.125% atropine was given nightly.
62789026|NCT02055378|ACTIVE_COMPARATOR|Atropine|topical 0.125% atropine was given nightly during the study period.
62789027|NCT03222297||test group|Patients with craniocerebral injury were randomized into test group (n = 40) with early skull repair using titanium mesh within 1-3 months after decompression.
62789028|NCT03222297||control group|Patients with craniocerebral injury were randomized into control group (n = 46) with late-stage skull repair using titanium mesh within 6-12 months after decompression.
62789029|NCT02732782|EXPERIMENTAL|Isometric exercise|Isometric exercise (90% maximum voluntary contraction (MVC), 12 weeks, 4 times a week, 5 sets of 4 repetitions a 3 seconds)
62789030|NCT02732782|ACTIVE_COMPARATOR|Eccentric exercise|"Eccentric training (Alfredson approach, 12 weeks, 2 sets per day with extended and two sets per day with bended knee, 15 repetitions per set)"
62789031|NCT02732782|NO_INTERVENTION|Control|Control, no intervention
62789032|NCT00630435|EXPERIMENTAL|1|
62789033|NCT00630435|EXPERIMENTAL|2|
62215429|NCT05525689|EXPERIMENTAL|Technology Enabled Service|Access to the Intellicare suite of digital mental health self-management tools and coaching
62405792|NCT02999516|EXPERIMENTAL|tDCS|tDCS stimulation during 20 minutes in the motor cortex.
62215430|NCT05525689|ACTIVE_COMPARATOR|eTreatment as Usual|Current care plus access to a website that will provide content specific to perinatal depression
62215431|NCT04081623||Clinic|This group is undergoing their scheduled visit for Non-Stress Test (NST) or Biophysical Profile (BPP)
62405793|NCT02999516|SHAM_COMPARATOR|tDCS sham|tDCS stimulation during 30 seconds in the motor cortex and then 19 minutes and 30 seconds without any stimulation.
62405794|NCT02999516|EXPERIMENTAL|Neurofeedback|EEG monitoring in real time with positive feedback in the computer screen when participants motor cortex is activated.
62789034|NCT00630435|EXPERIMENTAL|3|
62405795|NCT02999516|SHAM_COMPARATOR|Neurofeedback sham|EEG monitoring in real time with randomized feedback in the computer screen despite the motor cortex activation.
62789035|NCT00630435|ACTIVE_COMPARATOR|4|
62789036|NCT00122174|OTHER|Arm 1|
62789037|NCT04473248|EXPERIMENTAL|Method 1- Nasopharyngeal Swab in transfer liquid|A nasopharyngeal swab will inoculate a proprietary solution which will be transferred to the Spartan COVID-19 System for analysis
62789038|NCT04473248|EXPERIMENTAL|Method 2- Dipping of specialized swab in VTM|A nasopharyngeal swab will inoculate VTM solution. A modified traditional Spartan Swab will be dipped into the inoculated VTM solution and then transferred to the Spartan COVID-19 System for analysis.
62215432|NCT04081623||Labor and Delivery|This group is in active labor.
62215433|NCT01427751|ACTIVE_COMPARATOR|Ozurdex®|Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
62789039|NCT04473248|EXPERIMENTAL|Method 3: Direct input of VTM|Using the VTM from Method 2, pipette 10uL of VTM, inoculated with sample, into the Spartan COVID-19 System for analysis.
62789040|NCT04473248|EXPERIMENTAL|Method 4: Collection of nasal sample.|Using a modified tip of the Spartan swab, a nasal sample will be taken from the patient and directly placed into the Spartan COVID-19 System for analysis.
62789041|NCT02435420||EMPERION Modular Primary Stem subjects|All subjects have previously been implanted with the EMPERION Modular Primary Stem for primary total hip arthroplasty.
62789042|NCT00966251|EXPERIMENTAL|CT-011|
62405796|NCT00548340|EXPERIMENTAL|VEC-162 20 mg|VEC-162 (tasimelteon) 20 mg capsules PO daily for five weeks
62405797|NCT00548340|EXPERIMENTAL|VEC-162 50 mg|VEC-162 (tasimelteon) 50 mg capsules PO daily for five weeks
62405798|NCT00548340|PLACEBO_COMPARATOR|Placebo|Placebo capsules PO daily five weeks
62405799|NCT03881748|EXPERIMENTAL|Manual acupuncture|Insertion of very thin, solid, sterile, stainless steel needles into the skin at specific points.
62405800|NCT03881748|EXPERIMENTAL|Electro-acupuncture|Insertion of very thin, solid, sterile, stainless steel needles into the skin at specific points with additional application of weak electrical stimulation
62405801|NCT04330066||Exogenous hormone replacement thaw cycle|Participants in this group will follow Boston IVF's standard exogenous hormone replacement protocol. Participants will take Estrace 3mg twice daily by mouth for endometrial preparation. After 16-18 days of Estrace, endometrial thickness will be measured by transvaginal ultrasound but medication and ultrasounds will be continued until the endometrial lining is ≥ 7 mm. Once the final endometrial lining is ≥ 7 mm (T1), the doctor of record will start the participant the following day with intramuscular progesterone daily or intramuscular progesterone every 3 days with daily vaginal progesterone. Frozen embryo transfers would occur on the sixth day of progesterone.
62405802|NCT04330066||Natural thaw cycle|Participants in this group will follow Boston IVF's standard natural thaw cycle protocol. Participants will be coming for blood and transvaginal ultrasound monitoring around day 11 of the participants cycle. Once the participant has a final measurement of the endometrial lining ≥ 7 mm (T1), a 17mm ovarian follicle, and a progesterone \< 1.2 ng/mL, the doctor of record will schedule the patient to receive a trigger injection to induce ovulation followed by an embryo transfer 6-7 days later. Participants may be started on vaginal progesterone 4 days after the trigger injection for added supplementation per the doctor of record.
62405803|NCT06578078|EXPERIMENTAL|SZC group|Sodium zirconium cyclosilicate with standard of care treatment (RAASi therapy)
62405804|NCT06578078|ACTIVE_COMPARATOR|Control group|Standard of care treatment (RAASi therapy) without Sodium zirconium cyclosilicate
62405805|NCT00698009|EXPERIMENTAL|Fludarabine + Cyclophosphamide + NK Cell Infusion|Fludarabine 25 mg/m\^2 intravenous (IV) Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2. Cyclophosphamide 60 mg/kg IV Daily Over 2 Hours On Days -5 and -4. Natural Killer Cell Infusion on Day 0. Mesna 12 mg/kg By Vein, Over about 15 minutes, 5 Times Per Day on Days -5 and -4. Interleukin-2 subcutaneously three times weekly for 9 total doses following NK Cell Infusion.
62405806|NCT05880069||Drug-resistant pathogen|"Individuals of all ages with the target pathogen, resistance phenotype, and infection site combinations as follows:~1. P. aeruginosa, carbapenems resistant: BSI~2. A. baumannii, carbapenems resistant: BSI~3. E. coli, 3rd generation cephalosporins resistant: BSI and UTI~4. K. pneumoniae, 3rd generation cephalosporins resistant: BSI~5. K. pneumoniae, carbapenems resistant: BSI~6. S. aureus, methicillin resistant: BSI, pneumonia, SSI and SSTI~7. E faecium, vancomycin resistant: BSI~8. Enterobacterales, 3rd generation cephalosporins resistant: BSI"
62405807|NCT05880069||Drug-susceptible pathogen|"Individuals of all ages with the target pathogen, susceptible phenotype, and infection site combinations as follows:~1. P. aeruginosa, carbapenems susceptible: BSI~2. A. baumannii, carbapenems susceptible: BSI~3. E. coli, 3rd generation cephalosporins susceptible: BSI and UTI~4. K. pneumoniae, 3rd generation cephalosporins susceptible: BSI~5. K. pneumoniae, carbapenems susceptible: BSI~6. S. aureus, methicillin susceptible: BSI, pneumonia, SSI and SSTI~7. E faecium, vancomycin susceptible: BSI~8. Enterobacterales, 3rd generation cephalosporins susceptible: BSI"
62405808|NCT05880069||No infection|Individuals of all ages without the infection under study
62405809|NCT00908362|ACTIVE_COMPARATOR|A|Inhalation of Fluticasone (via discus) twice daily for 28 days
62405810|NCT00908362|ACTIVE_COMPARATOR|B|Inhalation of Fluticasone and Salmeterol (via discus) twice daily for 28 days
62581313|NCT02953847|OTHER|sequence 6|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
62405811|NCT00908362|PLACEBO_COMPARATOR|C|Inhalation of Placebo (via discus) twice daily for 28 days.
62215434|NCT01427751|ACTIVE_COMPARATOR|Lucentis®|Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
62215435|NCT06277544||rupture group|rupture of lateral ankle ligament
62215436|NCT06277544||fracture group|avulsion fracture of lateral ankle ligament
62405812|NCT00341627||1|Population-based sampling of individuals affected with Chordoma
62405813|NCT02800317|EXPERIMENTAL|RISAS|All patients will undergo RISAS procedure, followed by axillary lymph node dissection in a one-step surgical procedure.
62405814|NCT05803876||General anesthesia|Patients undergoing surgery under general anesthesia with an intravenous anesthesia protocol with a concentration target (Orchestra® Base Primea - Fresenius Kabi France), a vasopressor support by norepinephrine and blood pressure optimisation.
62581314|NCT04447391|EXPERIMENTAL|Exercise group|Exercise group who performed a combined exercise and 300 kcal/day deficit diet during 12 weeks.
62581315|NCT04447391|PLACEBO_COMPARATOR|Control group|Control group who performed 300 kcal/day deficit diet during 12 weeks.
62581316|NCT04519801|OTHER|REHAB|Standard post-operative rehabilitation regimen (REHAB) (Control)
62207022|NCT06137274|EXPERIMENTAL|Adaptive Radiotherapy treatment|Patients will undergo adaptive radiotherapy boost for head/neck squamous cell carcinomas. A base conventional IMRT plan of 46-50Gy in 2 Gy to gross disease in the primary/nodes and 41.4-45 Gy in 1.8 Gy to the elective nodes per fraction will be utilized. The MR simulation will be utilized for boost treatment planning. Patients will receive their 6th fraction of the week on the adaptive platform treating the gross disease until completion of the base plan to 20 Gy in 2Gy daily fractions (10 fractions). Each ART treatment will be recontoured/replanned by the treating head/neck radiation oncologist as deemed clinically or dosimetrically necessary.
62207023|NCT06423690|EXPERIMENTAL|Treatment Arm - Ablation with EAS1 System|Ablation of the lung tumor via Irreversible Electroporation (IRE) method, followed by resection of the tumor up to 14 days after the ablation
62207024|NCT03561298|EXPERIMENTAL|Single Arm: BGB-3111 + Drug Cocktail|BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)
62207025|NCT04035902|EXPERIMENTAL|ferric carboxymaltose 1000 mg|Ferric carboxymaltose is administered during surgery
62017147|NCT05520216||asymptomatic individuals|The demographic information of the participants (gender, age, height, body weight, body mass index, occupation, dominant extremity, education level, marital status) will be questioned with the Demographic Data Form to be created by the researchers. Except for the demographic data form, the breath-holding capacity of the participants will be evaluated by measuring the breath-holding times, and the thoracic cage mobility will be evaluated by measuring the chest circumference during normal respiration, maximal inspiration and maximal expiration. The curvature of the spine, the presence of kyphosis and lordosis will be measured using the Spinal Mouse (IDIAG m360) device, which is an objective measurement method. The flexibility of the spine and indirectly the mobility of the rib cage will be checked with the sit and lie test. The results of the evaluations will be recorded.
62017148|NCT02678611|EXPERIMENTAL|Basis 250|
62017149|NCT02678611|EXPERIMENTAL|Basis 500|
62017150|NCT02678611|PLACEBO_COMPARATOR|Placebo|
62017151|NCT04596878|EXPERIMENTAL|GBS-NN/NN2 in pregnant women living with HIV|2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV
62017152|NCT04596878|PLACEBO_COMPARATOR|Placebo Comparator in pregnant women living with HIV|2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV
62017153|NCT04596878|EXPERIMENTAL|GBS-NN/NN2 in pregnant women who do not have HIV|2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV
62017154|NCT04596878|PLACEBO_COMPARATOR|Placebo Comparator in pregnant women who do not have HIV|2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV
62017155|NCT04419636|EXPERIMENTAL|Part A Single doses|Lu AG06466 in fast and fed state
62017156|NCT04419636|EXPERIMENTAL|Part B Repeated doses|Lu AG06466 after light meal
62017157|NCT03617809||Prewarming|Active Prewarming will be performed using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be warmed using a surgical blanket during the intraoperative period. Esophageal thermometer will be used to measure the temperature throughout the intraoperative period.
62017158|NCT03617809||Control|Non-active prewarming. Patients will be warmed using a surgical blanket during the intraoperative period. Esophageal thermometer will be used to measure the temperature throughout the intraoperative period.
62017159|NCT00022776|EXPERIMENTAL|1|Participants will undergo surgery for spinal stenosis. Participants in this group will undergo surgical decompression as described by Rothman and Simeone.
62017160|NCT00022776|EXPERIMENTAL|2|Participants will undergo physical therapy for spinal stenosis. These participants will undergo a physical therapy program emphasizing lumbar flexion exercises, general conditioning exercises, and patient education for six weeks, with a frequency of 1-2 visits per week. Each patient will receive instruction in a home exercise program.
62017161|NCT02256111|EXPERIMENTAL|ENZ+ADT+Usual care|The usual care arm will receive treatment with enzalutamide with androgen deprivation therapy, with no supervised exercise training.
62017162|NCT02256111|EXPERIMENTAL|ENZ+ADT+Exercise|The ENZ+ADT+Exercise arm will receive treatment with enzalutamide plus androgen deprivation therapy along with supervised exercise training.
62207026|NCT04035902|ACTIVE_COMPARATOR|control|Ferric carboxymaltose is not administered
62207027|NCT06500468|EXPERIMENTAL|PillSense group|Participants in the PillSense arm will swallow one PillSense capsule. Participants who have blood detected will be admitted with a scheduled oesophagogastroduodenoscopy within 72 hours. Participants with no blood detected will be discharged with medications and a scheduled OGD within 96 hours.
62581317|NCT04519801|EXPERIMENTAL|REHAB + BFR|Standard rehabilitation regimen with BFR therapy (REHAB + BFR) (Experimental)
62017163|NCT06067074|EXPERIMENTAL|Volar Locking Plate|Surgery with a Volar Locking Plate due to displaced distal radius fracture
62207028|NCT06500468|NO_INTERVENTION|Standard group|Participants randomized to the standard arm will follow standard of care and will either be admitted or discharged with medications and to undergo an oesophagogastroduodenoscopy (OGD) within 72 hours if admitted or 96 hours if discharged.
62207029|NCT03578653|EXPERIMENTAL|Merging Yoga and Occupational Therapy for Parkinson disease|The group participates in three assessment periods: August, October, and December. Then in October-December the group will receive group occupational therapy and recommended community adaptive yoga programming 2x/week for 8 weeks.
62215437|NCT01038739|EXPERIMENTAL|A|
62017164|NCT06067074|EXPERIMENTAL|Non-operative treatment group|Patients allocated to non-operative treatment received a plaster cast for 4-5 weeks.
62215438|NCT01038739|EXPERIMENTAL|B|
62215439|NCT01038739|PLACEBO_COMPARATOR|C|
62405815|NCT00852267|ACTIVE_COMPARATOR|High CHO, High SatFat Diet|
62405816|NCT00852267|EXPERIMENTAL|Low CHO, High SatFat Diet|
62405817|NCT00852267|EXPERIMENTAL|Low CHO, Low SatFat Diet|
62581318|NCT05027906|EXPERIMENTAL|AT-1501 Single Arm|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
62581319|NCT00060203|EXPERIMENTAL|Brostallicin|
62581320|NCT02129777|EXPERIMENTAL|Blinded period: Namilumab 300 mg + namilumab 150 mg|Namilumab 300 mg (2 separate injections of 150 mg), subcutaneous injection, on Day 1, followed by namilumab 150 mg subcutaneous injection, on Days 15, 43 and 71.
62017165|NCT03511521|EXPERIMENTAL|NPH Insulin|"NPH will be given at the time of steroid administration to the patient in addition to standard basal/bolus insulin the patient may be receiving in the following doses:~Prednisone Dose (mg/day) - NPH dose (U=Units): 10-20 mg/day - 1.2U (units)/mg; 21-40 mg/day - 0.6U/mg; 41-60 mg/day - 0.45U/mg; 61-80 mg/day - 0.3U/mg; \>80 mg/day - no additional NPH. Note that the amounts of NPH are added to each other for the various prednisone doses. For example, a dose of 75 mg/day of prednisone would come out to be (1.2U x 20mg = 24U) + (0.6U x 20mg = 12U) + (0.45U x 20mg = 9U) + 0.3U x 15 mg = 4.5U) for a total of 24 + 12 + 9 + 4.5 = 49.5U of NPH for 75 mg of prednisone."
62017166|NCT03511521|ACTIVE_COMPARATOR|Basal/Bolus Insulin|"Basal insulin (glargine) and Bolus insulin (insulin aspart) will be increased (doses given in U \[units\]/kg) according to the Prednisone dose (mg/day) as follows:~Prednisone Dose (mg/day) - doses of insulin (U/kg): Prednisone 0 mg - Glargine 0.25U/kg, Bkfst Aspart 0.08U/kg, Lunch Aspart 0.08U/kg, Dinner Aspart - 0.08U/kg; Prednisone 10-20 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.15U/kg, Dinner Aspart - 0.2U/kg; Prednisone 21-40 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.2U/kg, Dinner Aspart - 0.25U/kg; Prednisone 41-60 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.25U/kg, Dinner Aspart - 0.30U/kg; Prednisone 61-80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.30U/kg, Dinner Aspart - 0.35U/kg; Prednisone \>80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.35U/kg, Dinner Aspart - 0.40U/kg."
62207030|NCT05922501|EXPERIMENTAL|Isatuximab + Belantamab mafodotin + Pomalidomide + Dexamethasone|"Isatuximab will be given once daily into your vein (by intravenous infusion) over about 30-60 minutes. This will occur during cycle 1 (cycle equals 28 days) on days 1, 8, 15, and 22 and cycle 2 and onwards days 1 and 15.~Belantamab mafodotin will be given once every 8 weeks into your vein (by intravenous infusion) over about 60 minutes after completion of isatuximab infusion.~Pomalidomide will be taken orally once daily during days 1-21 of each cycle.~Dexamethasone will be taken orally once daily during days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle.~Drug diaries will be provided to participants to document information about taking pomalidomide and dexamethasone."
62405818|NCT05292248|EXPERIMENTAL|CONFIDENCE Education Intervention|Participants will attend the 5-week CONFIDENCEProgram. This program will include attending 5 group-based sessions delivered by videoconference. Each session will last approximately 1.5 hours each and will cover topics such as how to budget, accessing community resources to displace the out-of-pocket costs of caregiving, asking for help, balancing employment and caregiving, and more.
62405819|NCT05557526|NO_INTERVENTION|Standard Medical Care Control Group|Patients with atrial fibrillation receiving catheter ablation of atrial fibrillation without additional intervention.
62789043|NCT04981652|EXPERIMENTAL|Whole Milk|Participants randomly assigned to the whole milk condition will undergo three sequential study phases, each lasting three days in length. During phase 1, these participants will participate in habitual physical activity and consume a standardized diet, delivering 0.8 g/kg/body mass per day of protein. During the second phase, participants in this group will continue to perform habitual activity, but will have two whole milk experimental beverages (250 mL each serving, 3% milk fat) added to their standardized diet each day for the three day period. Finally, during the last three days of the study, participants will continue to consume the their intervention diet, but their physical activity levels (monitored via daily step count) will be increased to \~150% of their habitual levels.
62207031|NCT01068275|ACTIVE_COMPARATOR|Lumbar plexus catheter|
62581321|NCT02129777|EXPERIMENTAL|Blinded period: Namilumab 160 mg + namilumab 80 mg|Namilumab 160 mg (2 separate injections of 80 mg), subcutaneous injection, on Day 1, followed by namilumab 80 mg subcutaneous injection, on Days 15, 43 and 71.
62581322|NCT02129777|EXPERIMENTAL|Blinded period: Namilumab 100 mg + namilumab 50 mg|Namilumab 100 mg (2 separate injections of 50 mg), subcutaneous injection, on Day 1, followed by namilumab 50 mg subcutaneous injection, on Days 15, 43 and 71.
62789044|NCT04981652|EXPERIMENTAL|Skim Milk|Participants randomly assigned to the skim milk condition will undergo three sequential study phases, each lasting three days in length. During phase 1, these participants will participate in habitual physical activity and consume a standardized diet, delivering 0.8 g/kg/body mass per day of protein. During the second phase, participants in this group will continue to perform habitual activity, but will have two skim milk experimental beverages (250 mL each serving, 0% milk fat) added to their standardized diet each day for the three day period. Finally, during the last three days of the study, participants will continue to consume the their intervention diet, but their physical activity levels (monitored via daily step count) will be increased to \~150% of their habitual levels.
62789045|NCT04981652|EXPERIMENTAL|Almond Beverage|Participants randomly assigned to the almond beverage condition will undergo three sequential study phases, each lasting three days in length. During phase 1, these participants will participate in habitual physical activity and consume a standardized diet, delivering 0.8 g/kg/body mass per day of protein. During the second phase, participants in this group will continue to perform habitual activity, but will have two almond experimental beverages (250 mL each serving) added to their standardized diet each day for the three day period. Finally, during the last three days of the study, participants will continue to consume the their intervention diet, but their physical activity levels (monitored via daily step count) will be increased to \~150% of their habitual levels.
62789046|NCT03831035||15 patients and both parents.|The patients are aged 12 months or under hospitalized in the ICU suffering from multiple congenital malformations and/or neurologic symptoms.
62789047|NCT03896945|PLACEBO_COMPARATOR|Placebo|Placebo capsules will be administered orally twice a day over a 15-week period.
62789048|NCT03896945|EXPERIMENTAL|AVP-786|AVP-786 capsules will be administered orally twice a day over a 15-week period.
62789049|NCT05041270|PLACEBO_COMPARATOR|control group|patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline).
62789050|NCT05041270|ACTIVE_COMPARATOR|dexmedetomidine group|patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume)
62789051|NCT05041270|ACTIVE_COMPARATOR|nalbuphine group|patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume)
62207032|NCT01068275|ACTIVE_COMPARATOR|femoral nerve catheter|
62207033|NCT01068275|ACTIVE_COMPARATOR|single-shot femoral block|
62207034|NCT06150170|EXPERIMENTAL|Group 1|This group includes patients with grade 1 and grade 2 knee osteoarthritis.
62207035|NCT06150170|EXPERIMENTAL|Group 2|This group includes patients with grade 3 and grade 4 osteoarthritis.
62207036|NCT06166875||Derivation Sample|80 patients will be recruited as a derivation sample to calculate the regression equation
62207037|NCT06166875||Validation Sample|80 patients will be recruited as a validation sample to test the performance of the equation
62207038|NCT06729008|EXPERIMENTAL|DSNF + MNT|
62207039|NCT06729008|ACTIVE_COMPARATOR|MNT|
62207040|NCT06122675|ACTIVE_COMPARATOR|Effective stimulation|All participants will receive deep brain stimulation (DBS) in the cerebellum. For the first 20 weeks, every participant undergoes an open label phase to titrate stimulation and determine optimal stimulation settings. Following that phase, each participant starts three cycles of randomized, paired 8-week exposure periods, each pair including effective stimulation followed by sham stimulation, or vice versa. Effective stimulation will be the optimal stimulation settings determined during the open label phase.
62207041|NCT06122675|SHAM_COMPARATOR|Sham stimulation|Sham stimulation will be settings at low amplitude (0.1mA) known to be ineffective.
62207042|NCT06266624|EXPERIMENTAL|Tourniquet Test|Patients with HHT patients who undergo the Tourniquet Test
62207043|NCT03712059||Screening group|All patients receive FIT test and colonoscopy, whose age, sex, family history, smoking history, body mass index (BMI), diabetes and other risk factors are collected by researchers through pad, equipped with a specially designed database and app. Using colonoscopy results as the gold standard, the diagnostic value of risk prediction model for the Chinese population is explored, and the optimal strategy of colonoscopy practice for the Chinese established initially.
62207044|NCT03712059||Adenoma resection group|During the polypectomy of 2000 patients, for all pathologically confirmed or NBI-predicted adenomas with size\<10mm, 1-2 biopsies were randomly performed on the edge after resection to determine the completion rate of the polypectomy.
62207045|NCT03712059||Identification and classification group|For 12000 patients regardless of cancer diagnosis or polypectomy, if there is polyp, NBI (magnification) observation is required, with 4 white light and NBI images collected and reserved, respectively. If there is magnifying endoscopy, another 4 endoscopic images of magnification are also required. Endoscopists are invited to predict the pathology of polyps according to the NICE classification principle and endoscopic images, and upload the pathological results and endoscopic images within 2-4 week after colonoscopy.
62581323|NCT02129777|EXPERIMENTAL|Blinded period: Namilumab 40 mg + namilumab 20 mg|Namilumab 40 mg (2 separate injections of 20 mg), subcutaneous injection, on Day 1, followed by namilumab 20 mg subcutaneous injection, on Days 15, 43 and 71.
62581324|NCT02129777|PLACEBO_COMPARATOR|Blinded period: Placebo|Placebo (2 separate injections), subcutaneous injection, on Day 1, followed by placebo, subcutaneous injection, on Days 15, 43 and 71.
62581325|NCT02129777|EXPERIMENTAL|Open label: Namilumab 80 mg|Namilumab 80 mg subcutaneous injection, at Week 0 and every 4 weeks thereafter up to 52 weeks (active extension period) - if appropriate on the basis of treatment response.
62581326|NCT02129777|EXPERIMENTAL|Open label: Namilumab 150 mg|Namilumab 150 mg, subcutaneous injection, from Week 8 and then every 4 weeks thereafter up to 52 weeks (active extension period) - if appropriate on the basis of treatment response.
62581327|NCT05655819|ACTIVE_COMPARATOR|Glutamine Group|Subjects will receive glutamine for 28 days.
62581328|NCT05655819|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive placebo for 28 days.
62581329|NCT04236141|EXPERIMENTAL|Polatuzumab Vedotin plus BR|
62581330|NCT04236141|ACTIVE_COMPARATOR|Placebo plus BR|
62581331|NCT04936802|EXPERIMENTAL|Transcatheter tricuspid valve repair system (Trialign)|Subjects who received transcatheter tricuspid valve repair with Trialign will be included in this arm.
62207046|NCT03791086||Patients with bronchiectasis|Adult patients with bronchiectasis meeting the inclusion criteria.
62207047|NCT05162274|EXPERIMENTAL|Group 1|Participants first received lazertinib(G001) 240mg tablet morning in a fasting state for 1 day. After a washout period of 14\~21days, they then received lazertinib(G002) 240mg in a fasting state morning for 1 day.
62207048|NCT05162274|EXPERIMENTAL|Group 2|Participants first received lazertinib(G002) 240mg tablet morning in a fasting state for 1 day. After a washout period of 14\~21days, they then received lazertinib(G001) 240mg in a fasting state morning for 1 day.
62581332|NCT00972933|EXPERIMENTAL|Ipilimumab|Induction ipilimumab 10 mg/kg IV day 0, 21 (baseline, week 3) Maintenance Ipilimumab 10 mg/kg IV days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
62581333|NCT06093048|ACTIVE_COMPARATOR|group A|patients with obstructive jaundice equal or older than 65 years old
62581334|NCT06093048|ACTIVE_COMPARATOR|group B|patients with obstructive jaundice younger than 65 years old
62581335|NCT00558350||1|lobectomy / segmentectomy in patients with lung cancer
62581336|NCT05287126|EXPERIMENTAL|Etrasimod|
62581337|NCT01676935|EXPERIMENTAL|ABT-126|ABT-126 Open-label dose
62581338|NCT05182814|PLACEBO_COMPARATOR|Placebo drink|
62581339|NCT05182814|EXPERIMENTAL|Collagen drink|
62207049|NCT01803282|EXPERIMENTAL|Part A: ADX 200 mg|Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 200 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
62207050|NCT01803282|EXPERIMENTAL|Part A: ADX 600 mg|Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 600 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
62207051|NCT01803282|EXPERIMENTAL|Part A: ADX 1800 mg|Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 1800 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug
62405820|NCT05557526|EXPERIMENTAL|Optimize Expectation Group|Patients with atrial fibrillation receiving catheter ablation of atrial fibrillation and an additional verbal intervention to optimize the expectation of the patient towards the procedure.
62405821|NCT03856502|EXPERIMENTAL|group that received dexamethasone (DLSA)|The study group of 30 patients ASA status 2 or 3 received 8 mg of dexamethasone with 12,5 mg of 0,5% of levobupivacaine intrathecally for surgical reconstruction of proximal femoral fracture. Spinal anaesthesia was performed in sitting position using middle approach in intervertebral space L2-L3 or L3-L4 with spinal needles 22-27 GA.
62405822|NCT03856502|ACTIVE_COMPARATOR|group without dexamethasone (LSA)|The control group of 30 patients ASA status 2 or 3 received 12,5 mg of 0,5% of levobupivacaine intrathecally for surgical reconstruction of proximal femoral fracture. Spinal anaesthesia was performed in sitting position using middle approach in intervertebral space L2-L3 or L3-L4 with spinal needles 22-27 GA.
62581340|NCT06197646|EXPERIMENTAL|Inhaler mask with cartoon characters|Inhalation therapy with cartoon characters inhaler mask and Inhaler therapy training
62017167|NCT00002912|EXPERIMENTAL|Arm I|Patients undergo induction therapy consisting of etoposide IV and mitoxantrone IV on days 1-5. Patients then receive PSC-833 IV over 124 hours beginning on day 2. A second course is administered no sooner than 21 days from the start of the first course if the marrow is hypocellular after the first course. Patients with persistent disease after 2 induction courses are removed from the study. Patients receive a total of 3 courses of etoposide/mitoxantrone. Patients who achieve complete remission after 1 induction course receive 2 courses of etoposide/mitoxantrone with PSC-833 as consolidation, beginning within 4 weeks of attainment of complete remission. Patients who achieve complete remission after 2 induction courses receive 1 course of etoposide/mitoxantrone with PSC-833 as consolidation. Cohorts of 3-6 patients receive escalating doses of PSC-833 until the maximum tolerated dose is determined. Patients are followed every 6 months.
62581341|NCT06197646|NO_INTERVENTION|Inhaler mask|Inhalation therapy with the inhaler mask routinely used by the clinic and Inhaler therapy training
62789052|NCT05194800|EXPERIMENTAL|Unilateral upper extremity amputees|Unilateral upper extremity amputees suffering from chronic phantom limb pain \> 1 yr will be recruited from a hospital based outpatient Physical Medicine and Rehabilitation Amputee Clinic at UAB.
62581342|NCT00214786|EXPERIMENTAL|Islet Cell Transplantation|Allogenic islet cell transplantation
62017168|NCT03169140|ACTIVE_COMPARATOR|Group 1|Receive a combination of products (TheraBand Kinesiology Tape and Biofreeze) to use for one week for at home pain management.
62581343|NCT06684158|EXPERIMENTAL|Arm A: Mecapegfilgrastim plus Adebrelimab and FLOT|Mecapegfilgrastim：（6 mg, HD, d3） Adebrelimab （1200 mg，iv d1） Docetaxel（50 mg/m2 iv gtt d1） Oxaliplatin （85 mg/m2 iv gtt d1） 5- fluorouracil, leucovorin （200 mg/m2 iv gtt d1） for 4 cycles (every 2 weeks) before surgery.
62789053|NCT01885624|EXPERIMENTAL|TAB08|Single TAB08 i.v. infusion
62789054|NCT02356718|EXPERIMENTAL|Experimental|Computerized cognitive training activities
62017169|NCT03169140|ACTIVE_COMPARATOR|Group 2|Receive TheraBand Kinesiology Tape product to use for one week for at home pain management.
62017170|NCT03169140|ACTIVE_COMPARATOR|Group 3|Receive a topical product, Biofreeze, to use for one week for at home pain management
62017171|NCT03169140|ACTIVE_COMPARATOR|Group 4|Receive advice sheet outlining at home pain management strategies to use for one week.
62017172|NCT03748745|EXPERIMENTAL|Cohort A|SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
62789055|NCT02356718|ACTIVE_COMPARATOR|Control|Non-adaptive computerized cognitive training activities
62789056|NCT05154526|EXPERIMENTAL|Exercise Group|Exercise Program only
62017173|NCT03748745|EXPERIMENTAL|Cohort B|SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
62207052|NCT01803282|EXPERIMENTAL|Part B: PAC, ADX 800 mg|Participants with PAC will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (gemcitabine and nab paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
62207053|NCT01803282|EXPERIMENTAL|Part B: LAC, ADX 1200 mg|Participants with lung adenocarcinoma (LAC) will receive ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and pemetrexed, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
62207054|NCT01803282|EXPERIMENTAL|Part B: LSC, ADX 1200 mg|Participants with lung squamous cell carcinoma (LSC) will receive ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and paclitaxel, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
62207055|NCT01803282|EXPERIMENTAL|Part B: EGC, ADX 800 mg|Participants with esophagogastric adenocarcinoma (EGC) will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+oxaliplatin+5-fluorouracil {5-FU} \[mFOLFOX6\], on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
62207056|NCT01803282|EXPERIMENTAL|Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg|Participants with colorectal cancer (CRC) will receive first-line (FL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
62207057|NCT01803282|EXPERIMENTAL|Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg|Participants with CRC will receive FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
62207058|NCT01803282|EXPERIMENTAL|Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg|Participants with CRC will receive second-line (SL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+irinotecan+5-FU \[FOLFIRI\] and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
62207059|NCT01803282|EXPERIMENTAL|Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg|Participants with CRC will receive SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
62207060|NCT01803282|EXPERIMENTAL|Part B: BRCA, ADX 800 mg|Participants with breast cancer (BRCA) will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
62207061|NCT06569394|ACTIVE_COMPARATOR|Broad Spectrum Cannabidiol (bsCBD) 400 mg|bsCBD in a 400 mg dose will be used as described in the study arms.
62207062|NCT06569394|PLACEBO_COMPARATOR|Placebo|A medically inert placebo medication will be used as described in the study arms.
62207063|NCT06645366|EXPERIMENTAL|Treatment with BTL-785F|Three (3) treatment sessions will be applied to the subjects' face and neck using the BTL-785F system.
62207064|NCT04672811|EXPERIMENTAL|App/Sensor Intervention|All subjects will be enrolled into the same experimental group for the duration of the study
62207065|NCT02437201|EXPERIMENTAL|Liberty Group|Weekly intensive support group for women with children who have suffered or are still suffering from domestic abuse (DA).
62207066|NCT02437201|NO_INTERVENTION|Control group|
62581344|NCT06684158|EXPERIMENTAL|Arm B: Adebrelimab plus FLOT|Adebrelimab （1200 mg，iv d1） Docetaxel（50 mg/m2 iv gtt d1） Oxaliplatin （85 mg/m2 iv gtt d1） 5- fluorouracil, leucovorin （200 mg/m2 iv gtt d1） for 4 cycles (every 2 weeks) before surgery.
62581345|NCT06070181|OTHER|Control- no adjunctive treatment|One arm is the control: two quadrants per each patient treated with non-surgical periodontal treatment alone. NO adjunctive treatment with emdogain. The two quadrants are randomized.
62207067|NCT04939363|EXPERIMENTAL|combination of Ibrutinib, Venetoclax and Obinutuzumab|"1. Obinutuzumab intravenous infusion:~   Cycles 1: Day 1: Obinutuzumab 100 mg Day 1 (or 2): Obinutuzumab 900 mg Day 8: Obinutuzumab 1000 mg Day 15: Obinutuzumab 1000 mg Cycles 2-6: Day 1: Obinutuzumab 1000 mg The first infusion of Obinutuzumab may be administered at the full dose (1000 mg) on day 1 of cycle 1, if the infusion of a test-dosage of 100 mg is well tolerated by the patient. Alternatively, if the first 100 mg infusion on day 1 is not well tolerated, the remaining 900 mg of the first dose should be administered on day 2.~2. Ibrutinib PO 560mg daily starting on cycle 1 day 1 for 12 cycles.~3. Venetoclax with an accelerated ramp-up and close inpatient TLS monitoring starts on cycle 1 day 15 to the target dose of 400mg daily for a total of 12 cycles:~Cycle 1: Day 15: Venetoclax 20 mg Days 16-17: Venetoclax 50 mg Days 18-21: Venetoclax 100 mg Days: 22-28: Venetoclax 200 mg Cycles 2-12: Days 1-28: Venetoclax 400 mg"
62207068|NCT03169790|EXPERIMENTAL|Nant NHL Vaccine|avelumab, bevacizumab, capecitabine, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, lovaza, oxaliplatin, rituximab, stereotactic body radiation therapy, ALT-803,ETBX-061, and haNK.
62581346|NCT06070181|EXPERIMENTAL|Test-adjunctive treatment with Emdogain|The experimental arm is the two quadrants per patient assigned to be treated vid adjunctive Emdogain.
62581347|NCT04050410|EXPERIMENTAL|Moxonidine|Patients will receive a single oral dose of moxonidine 0.4 mg.
62581348|NCT04050410|PLACEBO_COMPARATOR|Placebo|Patients will receive a single oral dose of placebo.
62581349|NCT04607694|EXPERIMENTAL|Proton radiotherapy|Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
62581350|NCT04607694|ACTIVE_COMPARATOR|Photon radiotherapy|Photon radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
62017174|NCT06533202|ACTIVE_COMPARATOR|Education Programme|"Why: At the end of the baseline assessment, participants will receive instructions and recommendations to facilitate a positive and healthy transition to retirement, as part of an education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow.~What (materials): Instructions and recommendations for an education programme.~What (procedures): Participants will receive instructions and recommendations on how to facilitate a positive and healthy transition to retirement as part of an education programme.~How: The participants will receive the material individually at the commencement of the programme.~When and for how long: The intervention consists of a single session and details of the time and duration will be provided to participants."
62207069|NCT05606510|EXPERIMENTAL|Intervention|A 12-week, group-based mindful exercise program which will be conducted 5 times per week, 30 minutes per session.
62207070|NCT05606510|OTHER|Control|Routine medicine, nursing care, and hospital-recommended exercise.
62017175|NCT06533202|EXPERIMENTAL|Psychoeducational Programme|"Why: The programme is based on a psychoeducational intervention that aims to facilitate a positive and healthy transition into retirement.~What (materials): projector, computer, screen, presentation of content, stationery, chairs, tables and self-recording of home tasks.~What (procedures): Patients assigned to the experimental group will follow a psychoeducational programme structured and supervised at the University of Salamanca, consisting of a education programme combined with a psychoeducational programme.~Who will carry out the interventions: The content is divided into six modules: (I) Introduction to retirement from a psychosocial approach, (II) Health and retirement, (III) Financial security and the process of successful retirement, (IV) Status and retirement, (V) Leisure and retirement, and (VI) My personal project (Table 1).~When and for how long: Each participant will receive 4 sessions per month for 3 months, for a total of 12 sessions."
62017176|NCT03029208|EXPERIMENTAL|Daprodustat treated anemic subjects|Subjects will receive oral daprodustat once daily.
62017177|NCT03029208|ACTIVE_COMPARATOR|Darbepoetin alfa treated anemic subjects|Subjects will receive darbepoetin alfa subcutaneously or intravenously.
62017178|NCT05253703|OTHER|Virtual Reality Bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session. Exercise intensity and enjoyment are measured while participants bicycle in a virtual reality environment (wearing virtual reality goggles) in three different conditions lasting approximately 5 minutes each.
62017179|NCT04267172|EXPERIMENTAL|Surgical Residents with additional simulation training|Surgeon participant Group 1a: Interventional group ('StR's'): Trauma \& Orthopaedic Specialty Registrars (Surgical Residents) on Arthroplasty clinical placements (n=6-8) receiving additional simulation training.
62017180|NCT04267172|ACTIVE_COMPARATOR|Surgical Residents with routine training|Surgeon participant Group 1b: control group (StR's): Trauma \& Orthopaedic Specialty Registrars (Surgical Residents) on Arthroplasty clinical placements (n=6-8) receiving routine and normal training.
62207071|NCT05734105|EXPERIMENTAL|Ripretinib|150 mg QD of ripretinib (3×50 mg tablets) will be dosed continuously in repeated 42-day cycles.
62207072|NCT05734105|ACTIVE_COMPARATOR|Sunitinib|50 mg QD of sunitinib (4×12.5 mg capsules) will be dosed in 42-day cycles. Sunitinib will be given continuously for 4 weeks with a 2-week break.
62207073|NCT02535975|EXPERIMENTAL|Metformin|Metformin 500mg PO three times a day for 24 weeks
62207074|NCT02535975|PLACEBO_COMPARATOR|Placebo|Placebo tab. PO three times a day for 24 weeks
62207075|NCT04687462|EXPERIMENTAL|Experimental|TKRA operation undergoing 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
62207076|NCT04687462|ACTIVE_COMPARATOR|Control|TKRA operation undergoing 2-mm thickness variance polyethylene insert total knee arthroplasty system (Lospa, Corentec)
62207077|NCT06560957|OTHER|Group 1: Eating ad libitum, nutritional counselling plus treatment as usual|Participants randomized to this group will be offered nutritional counselling from a registered dietician. They will also receive a check-in from the registered dietician at week 4. They will also continue to receive treatment as usual. Treatment as usual includes pharmacological treatment options such as mood stabilizers and/or atypical antipsychotics, and psychological treatments such as psychotherapy. No current treatments will be stopped to participate in the study. We will record changes made to the doses of medications during the trial. No new treatments will be started for the duration of the trial, including pharmacological and psychological treatments
62405823|NCT03057769|EXPERIMENTAL|PES group|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
62581351|NCT04481789|EXPERIMENTAL|Rosuvastatin, Sildenafil, and MT-1186|"Group 1 of Cohort 1:~A single-sequence study in which healthy male subjects receive a single dose of rosuvastatin on Day 1 followed by a single dose of sildenafil on Day 4. MT-1186 will be administered from Day 6 to 13 with co-administration of rosuvastatin and sildenafil on Day 9 and 12, respectively."
62405824|NCT03057769|PLACEBO_COMPARATOR|Control group|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
62581352|NCT04481789|EXPERIMENTAL|Furosemide and MT-1186|"Group 2 of Cohort 1:~A single-sequence study in which healthy male subjects receive a single dose of furosemide on Day 1. MT-1186 will be administered from Day 3 to 7 with co-administration of furosemide on Day 6."
62789057|NCT05154526|ACTIVE_COMPARATOR|Manual Therapy Group|Manual Therapy only
62581353|NCT04481789|EXPERIMENTAL|MT-1186|"Cohort 2:~A three-way crossover study in which Japanese healthy male subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 4, and 7 according to their treatment sequence with 3-day wash out between doses. Caucasian healthy male subjects receive a single dose of MT-1186 at the same period with Japanese subjects under the corresponding condition on Day 1, 4, or 7 according to their treatment schedule."
62581354|NCT05019976|EXPERIMENTAL|Dose-Finding Group 0 - Dose Level 0|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
62405825|NCT00186173|EXPERIMENTAL|After school sports|After school team sports intervention designed specifically for overweight and obese children
62405826|NCT00186173|ACTIVE_COMPARATOR|After school health education|After school heath and nutrition education program
62789058|NCT05154526|ACTIVE_COMPARATOR|Manual Therapy and Exercise Group|Manual Therapy + exercise program
62405827|NCT04300049|EXPERIMENTAL|Change in Glycerol Ra|The difference in rate of lipolysis (glycerol Ra) during the basal state (-120 -0 minute) between subjects receiving glucagon and saline represents the change in whole body lipolysis caused by glucagon.
62789059|NCT05020080|EXPERIMENTAL|ECR MEP conditioning - Stroke|MEP operant conditioning of ECR in stroke survivors
62789060|NCT01695356|ACTIVE_COMPARATOR|290-400 nm sunscreen|"Sunscreen containing Mexoryl SX, Mexoryl XL, Titanium Dioxide, Octocrylene, Tinosorb S, Avobenzone, and Ethylhexyl triazone.~Fluid vehicle administered daily, from 8AM to 5PM every 3 hr, for 12 weeks."
62789061|NCT01695356|EXPERIMENTAL|290-800 nm sunscreen|"Sunscreen containing Benzophenone-3, Octinoxate, Octocrylene, Titanium Dioxide, Zinc Oxide, and iron oxide.~Fluid vehicle administered daily, from 8AM to 5PM every 3 hr, for 12 weeks."
62789062|NCT05905367|EXPERIMENTAL|Symptom-inhibited IV fentanyl induction|Symptom-inhibited IV fentanyl induction followed by opioid agonist therapy (OAT) with either oral methadone or slow-release oral morphine (SROM)
62789063|NCT02904733|EXPERIMENTAL|mHealth platform|Stable HIV-1 infected subjects will be followed-up using an mHealth platform. The platform will provide users with web based and mobile device applications which interface securely with relevant medical data and facilitate remote access to healthcare providers. The minimum length of follow-up will be 12 months and the maximum 35 months.
62017181|NCT04267172|ACTIVE_COMPARATOR|Orthopaedic Surgeon 'Experts & Fellows'|Consultant Orthopaedic Surgeons (n=5), and nationally appointed Arthroplasty Fellows (n=8). Surgeon participants within this group will not undergo any interventions.
62017182|NCT01339650|EXPERIMENTAL|ABT-767|ABT-767 monotherapy
62017183|NCT05474417||Cystic Fibrosis Carrier Group|Participants who have been identified as Cystic Fibrosis Carriers via previous genetic testing.
62017184|NCT05474417||Control Group|Participants who have been identified as not being Cystic Fibrosis Carriers via previous genetic testing.
62207078|NCT06560957|OTHER|Group 2:Time-restricted eating plus treatment as usual|In addition to the nutritional counselling and continuing treatment as usual outlined in Group 1, this group will be provided time restricted eating instruction. The experimental group will be instructed to select a consistent 10-h eating window between 06:00 and 19:00 for all days of the week to consume all food and beverages (except water) for the duration of the 8-week intervention. Adherence to the intervention will be monitored weekly through phone check-ins with the research assistant. At 4-weeks, the study dietician will have a 1-hour check in with participants to review progress and adherence to TRE and to address any difficulties the participants may be facing.
62207079|NCT06499298||Participants receiving adjuvant nivolumab|
62207080|NCT01769326|EXPERIMENTAL|MusicGlove Group|Subject participates in 3 weeks of exercising with the experimental device: MusicGlove at a minimum of 3 days per week, 1 hour per day with the exercise program
62207081|NCT01769326|ACTIVE_COMPARATOR|Control Group for Music Glove|Subject participates in 3 weeks of conventional hand exercise program, at a minimum of 3 days per week, 1 hour per day with the exercise program.
62405828|NCT06391047|EXPERIMENTAL|Group A|Group A was given hot pack at knee joint for 10-15min. Then the Mulligan's Squeeze Technique was applied. The patient in supine lying. The therapist placed thumb on joint line tenderness of knee. With the other thumb, the therapist reinforced the first thumb. The patient was asked to slowly flex knee. The therapist maintaining the thumb contact, applied the force centrally. The force was increased progressively as the knee moved towards full range of available flexion. At the end range, the therapist assisted the tibia to move towards more flexion with ulnar border of their hand. This position was maintained for a few seconds and the overpressure was applied. Then patient was asked to perform knee extension. As the knee moved towards extension the force applied from both thumbs was progressively reduced. At maximal extension, no force was applied. This was repeated 10 times in each set with total 3 sets. After this stretching and strengthening exercises were performed by patient.
62405829|NCT06391047|ACTIVE_COMPARATOR|Group B|Group B was given hot pack at knee joint for 10-15min. Then they were asked to perform stretching and strengthening exercises of the knee with at least 10 repetitions in each set and a total two sets in a day.
62405830|NCT02557191||Group 1|Preterm infants \<32 weeks gestational age
62405831|NCT03372265|EXPERIMENTAL|API+PCA|Infusion of ropivacaine 0.2 %, 15 mL, every 10th hour. Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
62405832|NCT03372265|ACTIVE_COMPARATOR|CI+PCA|Continuous infusion of ropivacaine 0.2 %, 6 mL/hour. Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
62405833|NCT03372265|ACTIVE_COMPARATOR|PCA only|Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
62405834|NCT06041100|EXPERIMENTAL|Intervention|30 minutes of daily wearing an exoskeleton for 12-weeks
62405835|NCT02253849|EXPERIMENTAL|CBZ - TPB/r+CBZ|"Days 1-14: carbamazepine (CBZ) twice daily~Days 15-22: CBZ twice daily plus TPV/r twice daily"
62405836|NCT03588312||simple heart defects|Newborns with hypoplastic aortic arch in simple congenital heart defects requiring aortoplasty
62405837|NCT03588312||complex heart defects.|Newborns with hypoplastic aortic arch in complex congenital heart defects requiring aortoplasty
62405838|NCT03903575|EXPERIMENTAL|En Masse Retraction|Group treated by retracting the six anterior teeth simultaneously.
62017185|NCT06396897||Decompensated Cirrhotics|"Phase 1:~* two questionnaires to assess patient reported outcomes~* an open-ended patient interview using a variety of patient-engagement methods to assess program expectations~Phase 2:~• completion of the Hospital at Home (H@H) program as part of clinical care. In brief, the Hospital at Home program (H@H) is an innovative care delivery method that aims to provide hospital-level care at home and facilitate the transition care from the hospital to the home.~Phase 3:~* researchers engage virtually to discuss actual experience, outcomes, and challenges. These will be semi-structured interviews about their perspectives on the program, including desired outcomes and expectations and perceived barriers and drivers and will last about two hours.~* complete four questionnaires relating to quality of life."
62017186|NCT06396897||Caregivers|Caregivers who self-identify as one who provides care for the afflicted person will be asked to participate in the study and will sign a separate informed consent statement. Caregivers will provide basic demographic information including prior involvement in the patient participant's care. At two time points, caregivers will complete two questionnaires to assess caregiver burden and quality of life. After participant completion of the H@H program, the caregiver will be asked to complete a brief questionnaire to assess the program.
62017187|NCT06346093|PLACEBO_COMPARATOR|Placebo capsules|Placebo capsules will be administered orally three days and then every three weeks for 24 weeks. SOX and anti-PD-L1 will be intravenously infused every three weeks for 24 weeks.
62405839|NCT03903575|ACTIVE_COMPARATOR|Two-Step Retraction|Group treated by retracting the canines incisors in two different steps.
62405840|NCT02665858|ACTIVE_COMPARATOR|IIH Patients|Patients diagnosed with Idiopathic Intracranial Hypertension who undergo OCT imaging
62789064|NCT04870125|EXPERIMENTAL|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%) for up to 90 minutes daily for 3 days.
62789065|NCT04870125|PLACEBO_COMPARATOR|Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
62789066|NCT03094533|ACTIVE_COMPARATOR|Total intravenous anesthesia|In the total intravenous anesthesia(TIVA) group, target controlled infusion (TCI) I was performed with propofol 4 mcg / ml. When the consciousness of the patient is lost, Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
62207082|NCT01769326|EXPERIMENTAL|Resonating Arm Exerciser (RAE)|Subject participates in 3 weeks of exercising with the experimental device: RAE at a minimum of 3 days per week, 1 hour per day with the exercise program
62207083|NCT01769326|ACTIVE_COMPARATOR|Control Group for RAE|Subject participates in 3 weeks of conventional arm exercise program, at a minimum of 3 days per week, 1 hour per day with the exercise program.
62405841|NCT02665858|ACTIVE_COMPARATOR|Control Group|Patients diagnosed with headache with ruled out Idiopathic Intracranial Hypertension who undergo OCT imaging
62405842|NCT01321528||IBSR Intervention group|30 nurses in the geriatric departments in TASMC
62405843|NCT05500729||Female CrossFitters|Crossfit practitioners born as female
62405844|NCT05500729||Male CrossFitters|Crossfit practitioners born as male
62207084|NCT06136741|EXPERIMENTAL|Arm A|Rezpegaldesleukin Dose Regimen A every 2 weeks during the induction period
62207085|NCT06136741|EXPERIMENTAL|Arm A1|Rezpegaldesleukin Dose Regimen A every 4 weeks during the maintenance period
62405845|NCT06647862|EXPERIMENTAL|IMM01 in combination with azacitidine|One treatment cycle consists of 4 weeks (28 days). IMM01(timdarpacept) will be administered once weekly, and azacitidine will be administered from Day 1 to Day 7 of each cycle.
62405846|NCT06647862|PLACEBO_COMPARATOR|placebo in combination with azacitidine|One treatment cycle consists of 4 weeks (28 days). Placebo will be administered once weekly, and azacitidine will be administered on days 1-7 of each cycle.
62017188|NCT06346093|EXPERIMENTAL|FMT capsules|FMT capsules will be administered orally three days and then every three weeks for 24 weeks. SOX and anti-PD-L1 will be intravenously infused every three weeks for 24 weeks.
62017189|NCT03042806|OTHER|experimental group|COPD patients will be asked to fill in the Maugeri Physical Activity Questionnaire (MaPAct) to assess self perceived physical activity.
62405847|NCT01001286|ACTIVE_COMPARATOR|Youth Club|The intervention will be compared to a waitlist comparison group. The group will enter NFE after the four-month posttest. During the four months, the youth will be offered a biweekly recreational youth club. The club will be led by Jordanian university student volunteers out of community-based organizations. Club activities will take place approximately every two weeks, including games, sports, arts and crafts, cultural activities, and trips. The Club will not include any significant education components or youth empowerment methodology--the hypothesized active ingredients of QS NFE.
62405848|NCT01001286|EXPERIMENTAL|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
62405849|NCT04209426||HMB-DMR-HA|Total hip arthroplasty with hemispherical metal-back dual-mobility acetabular cup with tripod fixation consisting of a hydroxyapatite-coated outer surface as well as two pegs and one screw.
62405850|NCT04209426||HMB-DM-CEM|Total hip arthroplasty with hemispherical metal-back dual-mobility acetabular cup with tripod fixation consisting of a bare metal outer surface to be covered with bone-compatible cement.
62405851|NCT04144309|ACTIVE_COMPARATOR|True acupuncture group|12 sessions of acupuncture treatment (EA+AA) will be given twice a week for 6 weeks after randomization, followed by once a month for 3 months, for a total of 15 sessions of treatments.
62405852|NCT04144309|PLACEBO_COMPARATOR|Sham acupuncture group|12 sessions of sham acupuncture treatment (SE+SA) will be given twice a week for 6 weeks after randomization, followed by once a month for 3 months, for a total of 15 sessions of treatments.
62405853|NCT01872663|EXPERIMENTAL|Incentive spirometry (Voldyne®)|Individuals will be treated with incentive spirometry, Voldyne Model 5000® in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
62789067|NCT03094533|ACTIVE_COMPARATOR|volatileinduction maintenance anesthesia|In the volatile induction and maintenance anesthesia(VIMA) group, when 8% sevoflurane is inhaled with 100% oxygen at 6 L / min and the consciousness is lost, the concentration of sevoflurane is reduced to 2-3% and then the mask is ventilated.Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
62789068|NCT02742376|OTHER|Soft surface|A soft sponge used for physiotherapy is placed on the floor along a path,
62789069|NCT02742376|OTHER|Floor|The subject will walk on the floor.
62789070|NCT02742376|OTHER|Shoes|Special shoes (Kyboot) with air cushions that are meant to relieve pressure will be used.
62789071|NCT03016091|EXPERIMENTAL|Arm 1|IV Pembrolizumab 200mg, given every 3 weeks until disease progression or intolerable toxicity
62789072|NCT05572164|ACTIVE_COMPARATOR|TRADITIONAL EPIDURAL|standard epidural technique used for intraoperative analgesia (the EPL group; local anesthetics will be delivered via epidural catheter guided by SPI to provide intraoperative analgesia
62789073|NCT05572164|ACTIVE_COMPARATOR|DURAL PUNCTURE EPIDURAL|group on whom dural puncture epidural technique used for intraoperative analgesia ( the DPL group; local anesthetics will be delivered via an epidural catheter placed after a dural pucture performed with the SPI guidance to provide intraoperative analgesia)
62789074|NCT03808012|EXPERIMENTAL|Braking after inguinal hernia surgery|Cohort testing of driving performance in a brake simulator in patients before and after scheduled inguinal hernia surgery
62789075|NCT01983085|OTHER|SPT Burn Wound|Each wound will be divided into 2 with half the wound being treated with the NOx dressing and the other half with standard of care
62017190|NCT01365975||Community Intervention Program Population: The Chinese Childre|Community sample of mothers, fathers and offspring from 2 provinces in China who participated in a community public health study in 1994-1996.
62017191|NCT06487039|EXPERIMENTAL|Group A|EB-203 2% QID
62789076|NCT01983085|OTHER|SPT graft donor site|Each wound will be divided into 2 with half the wound being treated with the NOx dressing and the other half with standard of care
62789077|NCT04177979|EXPERIMENTAL|Near assisted learning group|Participants in this arm were supervised by the trained peer-instructors.
62789078|NCT04177979|NO_INTERVENTION|Self directed learning group|Participants in this arm were practicing independently. They were not supervised by any instructors.
62017192|NCT06487039|EXPERIMENTAL|Group B|EB-203 4% QID
62017193|NCT05234346|EXPERIMENTAL|150 mg 5-ALAPhosphate + SFC|2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.
62017194|NCT05234346|PLACEBO_COMPARATOR|Placebo|
62017195|NCT03779529|ACTIVE_COMPARATOR|Arm label extra-vergin olive oil (EVOO)|Participants will ingest two tablespoons of extra-vergin olive oil (EVOO) Coratina during the day: one spoon containing 10g of olive oil (\>5mg of total biophenols/kg of olive oil) at lunch and one at dinner. The total biophenols ingested per day will be \>10mg.
62207086|NCT06136741|EXPERIMENTAL|Arm A2|Rezpegaldesleukin Dose Regimen A every 12 weeks during the maintenance period
62207087|NCT06136741|EXPERIMENTAL|Arm B|Rezpegaldesleukin Dose Regimen B every 4 weeks during the induction period
62017196|NCT03779529|ACTIVE_COMPARATOR|Arm label refined olive oil (ROO)|Participants will ingest two tablespoons of refined olive oil during the day: one spoon containing 10 g of refined olive oil at lunch and one at dinner.
62017197|NCT03893227||Patients|Patients with chronic upper airway inflammation
62017198|NCT03893227||Healthy control|Healthy controls without chronic upper airway inflammation
62017199|NCT05821010|EXPERIMENTAL|LFMT-capsules|LFMT-capsules. 3 times bulk, and further continuous administration. This arm is also treated pre- and probiotics.
62017200|NCT05821010|PLACEBO_COMPARATOR|Placebo|Placebo-capsules. 3 times bulk, and further continuous administration. This arm is also treated pre- and probiotics.
62017201|NCT01334931|EXPERIMENTAL|Large field of view|Patients will have coronary angiography performed with large field of view lens
62017202|NCT01334931|ACTIVE_COMPARATOR|Medium field of view|Patients will have coronary angiography performed with medium field of view lens
62017203|NCT04960813|EXPERIMENTAL|Kidpower - Structured Games|Structured Games Camp.
62017204|NCT04960813|ACTIVE_COMPARATOR|Kidpower - Playgroup|Playgroup camp
62017205|NCT03872050||Rosacea|Patients who have been diagnosed with rosacea
62017206|NCT03872050||Migraine|Patients who have been diagnosed with migraine
62207088|NCT06136741|EXPERIMENTAL|Arm B1|Rezpegaldesleukin Dose Regimen B every 4 weeks during the maintenance period
62207089|NCT06136741|EXPERIMENTAL|Arm B2|Rezpegaldesleukin Dose Regimen B every 12 weeks during the maintenance period
62207090|NCT06136741|EXPERIMENTAL|Arm C|Rezpegaldesleukin Dose Regimen C every 2 weeks during the induction period
62207091|NCT06136741|EXPERIMENTAL|Arm C1|Rezpegaldesleukin Dose Regimen C every 4 weeks during the maintenance period
62207092|NCT06136741|EXPERIMENTAL|Arm C2|Rezpegaldesleukin Dose Regimen C every 12 weeks during the maintenance period
62207093|NCT06136741|PLACEBO_COMPARATOR|Arm D|Placebo every 2 weeks during the induction period
62207094|NCT06136741|PLACEBO_COMPARATOR|Arm D1|Placebo every 4 weeks during the maintenance period
62207095|NCT06136741|EXPERIMENTAL|Escape Therapy (open-label)|Rezpegaldesleukin Dose Regimen A every 2 weeks during the maintenance period
62207096|NCT04419870||Group 1a|Patients with mitochondrial disease who are ill with suspected or confirmed COVID19
62789079|NCT03383510|EXPERIMENTAL|Climate friendly group|The climate friendly group will receive instructions to eat according to a climate friendly diet, i.e., to replace the majority of their intake of animal based products with plant based food.
62207097|NCT04419870||Group 1b|Patients with mitochondrial disease who are NOT ill with acute infection
62207098|NCT04419870||Group 2|Family members of patients with mitochondrial disease in Group 1
62789080|NCT03383510|EXPERIMENTAL|Organic group|The organic group will receive instructions to eat an organic diet, i.e., to replace at least 50% of their normally consumed food with organic equivalents.
62789081|NCT03383510|EXPERIMENTAL|Climate friendly and organic group|The climate friendly and organic group will receive instructions to consume a climate friendly and organic diet, i.e, to replace the majority of their intake of animal based products with plant based food AND to consume at least 50% organic food products.
62789082|NCT03383510|PLACEBO_COMPARATOR|Control group|The control group will receive instructions to eat according to the Nordic Nutrition Recommendations.
62017207|NCT02406144|ACTIVE_COMPARATOR|Lenalidomide|Oral administration of 15 mg/day of oral lenalidomide on days 1-21, and 20 mg/day of dexamethasone administered orally on days 1-4 and 9-12 for a period of two years
62017208|NCT02406144|EXPERIMENTAL|MLN9708 plus Lenalidomide|MLN9708 during the two year maintenance period, at a dose of 4 mg/day on days 1, 8 and 15 of the cycle.
62017209|NCT01994486|EXPERIMENTAL|Telaprevir and Sofosbuvir|All subjects will receive Telaprevir twice a day, 1125mg capsule and Sofosbuvir 400 mg capsule once daily. Both will be given for 12 weeks.
62017210|NCT00127673|ACTIVE_COMPARATOR|CBT no choice|Participants will receive no choice cognitive behavioral therapy (CBT no choice)
62207099|NCT03952091|EXPERIMENTAL|TJ202, Lenalidomide and Dexamethasone|
62207100|NCT03952091|ACTIVE_COMPARATOR|Lenalidomide and Dexamethasone|
62207101|NCT05492942|NO_INTERVENTION|Clinician prompting and Decision Support, Best Practice Advisory (BPA)|Access to an existing BPA for risky alcohol use and alcohol use disorder.
62207102|NCT05492942|EXPERIMENTAL|BPA plus Population Health Management (BPA+PHM)|Access to the existing Epic BPA for risky alcohol use and alcohol use disorder + targeted support by a population health manager (PHM).
62207103|NCT05492942|EXPERIMENTAL|BPA plus Clinical Care Management (BPA+CCM)|Access to the existing Epic BPA for risky alcohol use and alcohol use disorder + targeted support by a clinician care manager (CCM).
62207104|NCT05492942|EXPERIMENTAL|BPA plus Population Health Management plus Clinical Care Management (BPA+PHM+CCM)|Access to the existing Epic BPA risky alcohol use and alcohol use disorder + targeted support by a population health manager (PHM) and clinician care manager (CCM)
62017211|NCT00127673|ACTIVE_COMPARATOR|CBT choice|Participants will receive choice cognitive behavioral therapy (CBT choice)
62017212|NCT00127673|ACTIVE_COMPARATOR|sertraline no choice|Participants will receive no choice sertraline (sertraline no choice)
62017213|NCT00127673|ACTIVE_COMPARATOR|sertraline choice|Participants will receive choice sertraline (sertraline choice)
62207105|NCT03529682|EXPERIMENTAL|Circuit Training Group|Circuit exercise training will be given to the experimental group participants during 10 weeks, 60 minutes in a day and 3 times a week.
62207106|NCT03529682|OTHER|Control Group|The control group participants will continue to their own previous physiotherapy approaches as the same as minimum 3 times a week and total 3 hours.
62207107|NCT05916313|EXPERIMENTAL|BI 764532: Part A - Dose escalation cohort|
62207108|NCT05916313|EXPERIMENTAL|BI 764532: Part B - Dose expansion cohort|
62207109|NCT06036706|OTHER|"Cohort IMRT:"|Patients receiving normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning (IMRT, VMAT, Tomotherapy...)
62207110|NCT06036706|OTHER|"Cohort SRT"|Patients receiving hypo-fractionated stereotactic brain irradiation
62207111|NCT06036706|OTHER|"Cohort PRT"|Patients receiving normo-fractionated proton therapy brain irradiation
62207112|NCT06036706|OTHER|Control cohort|Participants without any meningioma, cancer history or neurological comorbidities
62789083|NCT05792189|ACTIVE_COMPARATOR|Open reduction and internal fixation (ORIF) of distal femur fracture|Su Type 2 or 3 periprosthetic distal femur fractures about a total knee after undergoing ORIF for a minimum of 2 years
62789084|NCT05792189|ACTIVE_COMPARATOR|Distal femur replacement total knee arthroplasty (DFR) of distal femur fracture|Su Type 2 or 3 periprosthetic distal femur fractures about a total knee after undergoing DFR for a minimum of 2 years
62789085|NCT03682692|EXPERIMENTAL|ACEI/CCB|
62789086|NCT03682692|EXPERIMENTAL|ACEI/DIU|
62789087|NCT00005773|EXPERIMENTAL|Early iNO Management|Initiation of iNO in use for term and near-term infants in respiratory failure with an oxygenation index between 15-25.
62789088|NCT00005773|ACTIVE_COMPARATOR|Standard iNO management|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI \>=25).
62017214|NCT01410981||Multiple Myeloma subjects with bone marrow aspirate/biopsy|All patients seen at MUSC with a diagnosis of multiple myeloma or possible multiple myeloma who undergo bone marrow aspirate and biopsy will be approached for participation in this study.
62207113|NCT05432232|EXPERIMENTAL|HistoSonics Investigational System|
62789089|NCT02523378|EXPERIMENTAL|ESAS Self-Administration - Group A|Participants complete the symptom questionnaire alone. It is then counterchecked by health care professional (HCP).
62207114|NCT02541370|EXPERIMENTAL|anti-CD133 CAR T cells|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Patients receive anti-CD133-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity."
62207115|NCT05819385||All participants|All participants must be diagnosed with rheumatic disease (connective tissue disease (CTD)) and intestinal lung disease (ILD) and fulfil all inclusion and no exclusion criteria. Information about participants will be obtained from electronic and physical medical records for existing data collection (over the past ten years, from 2012 to 2022) and/or from medical consultations for newly collected data (for the next three years, from 2023 to 2026). The participants' observation time varies and can be over the whole study duration (from 2012 to 2023), over the past ten years only (existing data) or over the next three years (new data).
62207116|NCT02776995|OTHER|Patients undergoing radiation|In this study, patients undergoing radiation treatment will undergo thermography imaging during radiation treatment course. Patients will be evaluated with thermography imaging every 5 fraction of radiation, starting prior to the first radiation treatment, periodically, until the end of radiation therapy (a period of several weeks).
62207117|NCT06654102|EXPERIMENTAL|Regimen 1: Deep UVA|Deep UVA, 380-400nm, will be used for subsites 2 to 7 of Test Sites 1 and 2.
62789090|NCT02523378|EXPERIMENTAL|ESAS Assisted-Completion - Group B|Participants complete the symptom questionnaire with the help of the research nurse or assistant.
62789091|NCT01461707|EXPERIMENTAL|Mobile app plus activity monitor group|Participants in the group will receive the mobile phone-based physical activity program and an activity monitor
62789092|NCT01461707|ACTIVE_COMPARATOR|Activity monitor group|Participants in the group will receive an activity monitor
62789093|NCT04590573|EXPERIMENTAL|CBCT|Cognitive behavioural couple therapy (CBCT), 5-session
62789094|NCT04590573|EXPERIMENTAL|EFCT|Emotion focused couple therapy (EFCT), 5-session
62789095|NCT04590573|ACTIVE_COMPARATOR|Control|Social activity wait-list groups (Control), 5-session
62789096|NCT03778996|EXPERIMENTAL|Maintenance Treatment: Ewing's Sarcoma|Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus
62789097|NCT03778996|EXPERIMENTAL|Salvage Treatment: Sarcoma|Combination metyrosine-derivative, low-dose methoxasalen, phenytoin and sirolimus
62789098|NCT02606799|NO_INTERVENTION|Standard Care|intensive care therapy according to international standards and following local SOPs, including fluid therapy, mechanical ventilation, catecholamine therapy and other pharmacotherapy as required
62789099|NCT02606799|EXPERIMENTAL|CytoSorb|all of the above, plus extracorporeal hemadsorption therapy (CytoSorbents Adsorber cartridge) using continuous veno-venous hemofiltration (citrate anticoagulation) CytoSorb cytokine elimination
62017215|NCT01040611|EXPERIMENTAL|Music therapy|This study examined the effectiveness of music therapy on anxiety, depression and physiological responses for patients with tuberculosis.
62017216|NCT01040611|NO_INTERVENTION|Placebo|No music therapy apply to this arm
62017217|NCT03185624|EXPERIMENTAL|Rifaximin|Prescribed Rifaximin (600mg, twice daily) for 3 months after surgery
62017218|NCT03185624|NO_INTERVENTION|Blank control|No intervention after surgery
62207118|NCT06654102|EXPERIMENTAL|Regimen 2: Deep UVA + HEV Blue Light|Deep UVA + HEV Blue Light, 380-420 nm, will be used for subsites 2 to 7 of Test Sites 3 and 4
62789100|NCT02454257||Admission to ICU|Patients admitted to an adult critical care unit or cardiothoracic critical care unit
62207119|NCT06654102|NO_INTERVENTION|Non-irradiated control|Subsite 1 in each test site (Test Sites 1-4) will be a non-irradiated control
62405854|NCT01872663|EXPERIMENTAL|Continuous positive airway pressure|Individuals will be treated with flow generator(Whisperflow, Caradyne, Ireland)and valve PEEP type spring-loaded which remain 10 cmH2O, in the immediate and the first postoperative day, twice a day, in sessions 30 minutes each, with an interval of four hours between them.
62789101|NCT02454257||In-hospital cardiac arrest|Patients experiencing an in-hospital cardiac arrest
62789102|NCT01597713|EXPERIMENTAL|Part 1, level 1-7 escalating doses|
62789103|NCT01597713|EXPERIMENTAL|Part 2, cross-over|
62789104|NCT05243082|OTHER|Historical controls|Historical controls
62789105|NCT00163020|ACTIVE_COMPARATOR|1 Test Group (170HP)|Test Group will receive weekly doses of 170HP via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
62789106|NCT00163020|PLACEBO_COMPARATOR|2 - Control (Normal Saline)|Control Group will receive weekly doses of placebo (NS) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
62789107|NCT00166439|EXPERIMENTAL|Treatment (ROAD)|The treatment regimen included oxaliplatin with rituximab, cytarabine, and dexamethasone (ROAD); specifically, rituximab 375 mg/m\^2 IV on days 1, 8,15, and 22 (cycle 1 only); dexamethasone 40 mg PO/IV days 2-5; oxaliplatin 130 mg/m\^2 IV over 2 hours on day 2; cytarabine 2000 mg/m\^2 IV in 250 mL of D5W over three hours x two doses on days 2-3. The second dose of cytarabine was to be given no sooner than 12 hours after the first dose and no later than 24 hours after the conclusion of the first dose. This permitted outpatient administration if desired. Patients were provided pegfilgrastim 6 mg SC on day 4. A cycle was 21 days.
62789108|NCT02947737|EXPERIMENTAL|Amniotic membrane dressing|One donor site per study participant will be covered with an amniotic membrane dressing.
62789109|NCT02947737|ACTIVE_COMPARATOR|Gentamicin and xeroform dressing|One donor site per study participant will be covered with a gentamicin and xeroform dressing.
62017219|NCT05873192|EXPERIMENTAL|ADT plus Enzalutamide plus Talazoparib|Participant will recive ADT plus Enzalutamide for a total of 8 weeks. After about 8 weeks of ADT and Enzalutamide treatment, participant will begin taking Talazoparib
62017220|NCT01260922|EXPERIMENTAL|Investigational Test Product|Donepezil Hydrochloride 10 mg Orally Disintegrating Tablets
62017221|NCT01260922|ACTIVE_COMPARATOR|Reference Listed Drug|Aricept® 10 mg Orally Disintegrating Tablets
62789110|NCT03594136|EXPERIMENTAL|Telemetric intracranial pressure implant|A telemetric intracranial pressure monitoring sensor is inserted into the brain parenchyma at the end of an uncomplicated surgery for an unruptured aneurysm
62789111|NCT02457676|EXPERIMENTAL|Alert Program for Self-Regulation|Participants with FASD who received the Alert Program for Self-Regulation therapy between the two testing periods.
62017222|NCT01164059|EXPERIMENTAL|atypical antipsychotics|Olanzapine, Quetiapine, or Aripiprazole
62789112|NCT02457676|NO_INTERVENTION|FASD Alert Waitlist|Participants with FASD who did not receive therapy between the two testing periods but were provided intervention on study completion.
62017223|NCT01164059|ACTIVE_COMPARATOR|typical antipsychotics|Haloperidol or Flupentixol
62789113|NCT02457676|NO_INTERVENTION|Typically Developing Control|Normally developing controls not exposed to alcohol in utero who were not treated between the two testing periods.
62789114|NCT01576497|ACTIVE_COMPARATOR|EUS-FNA with suction|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA with suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
62017224|NCT03681301|EXPERIMENTAL|Interventional|Additional self-directed learning and practice using virtual reality simulator, after conventional training session
62789115|NCT01576497|ACTIVE_COMPARATOR|EUS-FNA without suction|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
62789116|NCT00348673|EXPERIMENTAL|Stage 1|
62789117|NCT00348673|EXPERIMENTAL|Stage 2|
62789118|NCT06364462||Observational group of NASH-related liver fibrosis|
62789119|NCT06499831|EXPERIMENTAL|High Grade Glioma|0-(2-18F-Fluoroethyl)-L-Tyrosine (FET) PET/MRI for planning of radiation therapy of post-operative grade III/IV glioma patients
62789120|NCT06174610||Acute Kidney Injury + CRRT|"Critically ill patients admitted to the intensive care unit (ICU), undergoing continuous renal replacement therapy due to Acute Kidney Injury.~Diagnostic Test: Daily Doppler measurement of Renal Resistive Index"
62789121|NCT00532298|EXPERIMENTAL|GSK576389A- 2006/2007 Season - 1 container Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.
62017225|NCT03681301|NO_INTERVENTION|Control|Conventional training session which includes didactic teaching and low-fidelity simulation session involving trainer's demonstration, followed by hands-on practice
62789122|NCT00532298|EXPERIMENTAL|GSK576389A - 2006/2007 Season - 2 containers Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.
62789123|NCT00532298|ACTIVE_COMPARATOR|Fluarix 2006/2007 Season Group|Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
62789124|NCT00532298|EXPERIMENTAL|GSK576389A - 2007/2008 Season - 1 container Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.
62789125|NCT00532298|EXPERIMENTAL|GSK576389A - 2007/2008 Season - 2 containers Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.
62789126|NCT00532298|ACTIVE_COMPARATOR|Fluarix 2007/2008 Season Group|Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
62789127|NCT03100591|EXPERIMENTAL|14C-radiolabelled ACT-132577|On Day 1, subjects will receive a single oral dose of 25 mg 14C-radiolabeled ACT-132577, administered as an oral formulation in the fasted state
62789128|NCT02828436|EXPERIMENTAL|Spinal Cord Stimulation|Boston Scientific Precision Spectra System
62017226|NCT02693444|ACTIVE_COMPARATOR|Subacromial Lidocaine Injection|Both of your shoulders will be examined and evaluated (shoulder survey). Following the exam, you will be randomized (assigned by chance, similar to a coin toss) to receive a 10cc (2 teaspoon) subacromial injection of lidocaine, will be given under ultrasound (using sound waves) guidance to your affected shoulder. A repeat shoulder exam will be performed and recorded
62017227|NCT02693444|PLACEBO_COMPARATOR|Subacromial Saline Injection|Both of your shoulders will be examined and evaluated (shoulder survey). Following the exam, you will be randomized (assigned by chance, similar to a coin toss) to receive a 10cc (2 teaspoon) subacromial injection of saline, will be given under ultrasound (using sound waves) guidance to your affected shoulder. A repeat shoulder exam will be performed and recorded
62017228|NCT05711550|EXPERIMENTAL|Healthy Subjects: Study 1|This arm corresponds to study 1 (Real Neurofeedback uses only normal frequency band signals ranging from 1 to 35 Hz from the EEG-signal). All included participants participate at 2 experimental conditions (Real Neurofeedback, Sham Neurofeedback) at 2 different days in a randomized order. Both, the investigators and the participants are blinded in regard to the intervention they receive at the two experimental visits.
62017229|NCT05711550|EXPERIMENTAL|Healthy Subjects: Study 2|This arm corresponds to study 2 (Real Neurofeedback uses only infra-low frequencies below 0.1Hz from the EEG-signal). All included participants participate at 2 experimental conditions (Real Neurofeedback, Sham Neurofeedback) at 2 different days in a randomized order. Both, the investigators and the participants are blinded in regard to the intervention they receive at the two experimental visits.
62789129|NCT02828436|OTHER|Exercise Intervention|If subject cannot tolerate Spinal Cord stimulation they will be assigned this arm
62789130|NCT05725083|EXPERIMENTAL|Lower thoracic epiduarl|before induction of anesthesia,first the investigators identify the correct targeted thoracic level. All epidural block will be performed under all aseptic precautions with a 17-gauge Tuohy needle and 19 G flex-tip catheters. Using the loss of resistance to saline technique, catheter will be inserted 4 cm into the epidural space and a suitable test dose will be administered to exclude intravascular or sub-arachnoid injection. Bupivacaine 0.25% of 7.5-12 ml volume will be given bolus through the epidural catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15ml/h .for breakthrough pain patient controlled analgesia (PCA) using nalbuphine 1 mg bolus , 10 min lockout period . The catheter will be removed under complete aseptic precautions after 48 hrs.
62017230|NCT05711550|EXPERIMENTAL|Healthy Subjects: Study 3|This arm corresponds to study 3 (normal frequency band \& infra-low frequencies are used in Real Neurofeedback). All included participants participate at 2 experimental conditions (Real Neurofeedback, Sham Neurofeedback) at 2 different days in a randomized order. Both, the investigators and the participants are blinded in regard to the intervention they receive at the two experimental visits.
62207120|NCT04604561||Participants receiving SmartClip|Participants will undergo a preoperative physical exam and at least one preoperative ultrasound demonstrating the mass for resection. The SmartClip will be placed under ultrasound guidance. Post-placement mammogram will be obtained after placement of the clip. The SmartClip can be placed up to 30 days prior to the planned surgical resection. At the time of definitive surgery, the Envisio system will be used to identify the clip and the targeted lesion for resection. Intraoperatively, a specimen radiograph will be performed to confirm the presence of the SmartClip and the targeted lesion in the surgical specimen. The breast surgical specimen will be sent for gross examination, including measurements of the tumor in 3 axes. Immediately post-procedure, the performing surgeon will fill out a questionnaire to determine the ability of localizing in-breast lesions using the Envisio Navigation and SmartClip system in surgery.
62207121|NCT04604561||Radiologist Placing SmartClip|Radiologist will place SmartClip under ultrasound guidance. A Post-placement mammogram will be obtained after placement of the SmartClip. Immediately post-procedure, the performing radiologist will fill out a questionnaire.
62207122|NCT04604561||Surgeon|The surgeon will use the EnVisio™ Navigation System to identify the SmartClip and the targeted lesion for resection. Immediately post-procedure, the performing surgeon will fill out a questionnaire
62207123|NCT05133349|EXPERIMENTAL|Anlotinib|Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
62207124|NCT06360289||Asymptomatic Carriers|Participants who are asymptomatic carriers of a pathogenic TTR variant, and not diagnosed with hATTR amyloidosis with polyneuropathy will be enrolled in this cohort.
62207125|NCT06360289||Participants with hATTR Amyloidosis with Polyneuropathy|Participants with a confirmed diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR variant will be enrolled in this cohort.
62405855|NCT01872663|EXPERIMENTAL|Expiratory Positive Airway Pressure|Subjects will be treated with oronasal mask affixed to the face, with the PEEP valve set at 10 cmH2O, in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
62405856|NCT01872663|EXPERIMENTAL|Intermittent positive pressure breathing|Subjects will be treated with application of Müller Resuscitator (Engesp®) through a nozzle, using a pressure endotracheal 20-30 cmH2O, refering to 2-3 kgf/cm², adjusted throttle valve oxygen, according to the patient's comfort and the micronebulizer coupled only saline as the diluent. The procedure will be performed in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
62405857|NCT01872663|EXPERIMENTAL|Bi-level positive airway pressure|Individuals will be treated with positive pressure in the BiPAP mode (Bi-level positive airway pressure) in the immediate and the first postoperative day, twice a day, in sessions 30 minutes each, with an interval of four hours between them.
62405858|NCT01872663|EXPERIMENTAL|Breath Stacking|Subjects will be treated with a siliconized mask connected to a unidirectional valve and adapted to the patient's face, allowing only the inspiration and the expiratory limb remains occluded, while the volunteer is instructed to perform successives inspiratory efforts, in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
62405859|NCT01872663|NO_INTERVENTION|Control|Individuals will be treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
62405860|NCT00062075|EXPERIMENTAL|Treatment|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62017231|NCT02143622|EXPERIMENTAL|LJM716+cetuximab|
62017232|NCT05234099|EXPERIMENTAL|Control subjects|"Visit 1 (V1) (Duration: 2.5h)~* Information, verification of inclusion and exclusion criteria, information note.~* Consent form.~* Location of the diaphragm and parasternal intercostal muscle using ultrasound.~* Measurements at rest (mouth pressures, sEMG, ultrasound imaging).~* Injection of 3 MBq/kg of 18F-FDG.~* 1h resting period.~* 18F-FDG PET-MRI scan.~Visit 2 (V2) 3-10 days after V1 (Duration: 3h)~* Location of the diaphragm and parasternal intercostal muscle.~* Measurements at rest (mouth pressures, sEMG, ultrasound imaging)~* Magnetic stimulation of the phrenic nerves~* Ventilation against inspiratory loading~* Magnetic stimulation of the phrenic nerves~* Injection of 3 MBq/kg of 18F-FDG~* 1h resting period~* 18F-FDG PET-MRI scan~Visit 3 (V3) 3-10 days after V2 (Duration: 3h)~- Identical to visit 2"
62017233|NCT06458010|EXPERIMENTAL|Single Arm|dosage group: 0.2mg/kg, 0.4mg/kg, 0.6mg/kg; dosage form: injection; frequency of administration: once.
62017234|NCT03095989|EXPERIMENTAL|Mindfulness|Subjects in the intervention group will participate in an online mindfulness program developed in the first phase of the study, in addition to standard clinical care.
62017235|NCT03095989|NO_INTERVENTION|Waiting list|Participants from the control group will be placed on a waiting list and will receive the standard care, that they would receive if not in the study. They will be assessed according to the assessment schedule, exactly as subjects in the intervention group. After the last assessment (six months after recruitment), they will receive the option to enter the mindfulness program.
62207126|NCT03711032|EXPERIMENTAL|BCG plus Pembrolizumab: Post-induction Cohort A (Arm A-1)|Participants receive BCG (Induction and Maintenance) in combination with 200 mg pembrolizumab administered intravenously (IV) every 3 weeks (Q3W) for 35 doses (\~2 years).
62207127|NCT03711032|EXPERIMENTAL|BCG Monotherapy: Post-induction Cohort A (Arm A-2)|Participants receive BCG monotherapy (Induction and Maintenance).
62207128|NCT03711032|EXPERIMENTAL|BCG plus Pembrolizumab: BCG Naïve Cohort B-Reduced Maintenance (Arm B-1)|Participants receive BCG (Induction and reduced Maintenance) in combination with 400 mg pembrolizumab administered IV every 6 weeks (Q6W) for 9 doses (\~1 year).
62207129|NCT03711032|EXPERIMENTAL|BCG plus Pembrolizumab: BCG Naïve Cohort B-Full Maintenance (Arm B-2)|Participants receive BCG (Induction and full Maintenance) in combination with 400 mg pembrolizumab administered IV Q6W for 9 doses (\~1 year).
62207130|NCT03711032|EXPERIMENTAL|BCG Monotherapy: BCG Naïve Cohort B (Arm B-3)|Participants receive BCG monotherapy (Induction and Maintenance).
62207131|NCT06084767|EXPERIMENTAL|Malignant tumors|This arm investigated the clinical value of 68Ga-TCR-FAPI PET/CT in suspected malignant tumors.
62207132|NCT04870255|ACTIVE_COMPARATOR|Left Dorsolateral Prefrontal Cortex (L-DLPFC)|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (L-DLPFC)
62207133|NCT04870255|ACTIVE_COMPARATOR|Dorsomedial Prefrontal Cortex (DMPFC)|The accelerated theta burst stimulation protocol will be applied to the dorsomedial prefrontal cortex (DMPFC)
62207134|NCT04870255|SHAM_COMPARATOR|Sham stimulation|Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region
62207135|NCT01223352|EXPERIMENTAL|Bosentan 2 mg/Kg t.i.d.|2 mg/kg bosentan administered three times a day (morning, afternoon, evening) for a planned duration of 24 weeks
62405861|NCT03051152|EXPERIMENTAL|Elderly with CCS>5 - D1 gastrectomy|Patients aged \>75 years with Charlson Comorbidity Score \> 5 undergoing gastrectomy with limited lymphadenectomy
62405862|NCT03051152|EXPERIMENTAL|Elderly with CCS>5 - D2 gastrectomy|Patients aged \>75 years with Charlson Comorbidity Score \> 5 undergoing gastrectomy with extended lymphadenectomy
62405863|NCT05081115||ABCDE-Stress Echo in Coronary Artery Disease (SECAD project)|All patients with known or suspected CAD will be evaluated with ABCDE-SE. Patients will be referred according to existing 2020 guidelines indication; status post heart transplant; pediatric patients and congenital heart disease ; peri-partum cardiomyopathy. Information on demographics, lifestyle and other risk factors and ongoing therapy will be collected. Data related to carotid disease and cardiac calcification will be collected. All patients will enter a regular clinical follow-up program with annotation of cardiovascular and non-cardiovascular endpoints, such as cancer or neurodegenerative disease, characterized by endothelial dysfunction (step D positivity) and autonomic dysfunction (step E positivity). A sample size of about 2 430 patients with a 5-year follow-up is required to provide 90% power with an alpha error of 5% to detect a difference for the primary endpoint of all-cause mortality among those with positive versus negative SE also considering a 20% drop-out.
62207136|NCT01223352|EXPERIMENTAL|Bosentan 2 mg/Kg b.i.d.|2 mg/kg bosentan administered twice daily (morning and evening) for a planned duration of 24 weeks
62207137|NCT04238949|NO_INTERVENTION|Standard Diabetes Care Group|Patients receive standard diabetes care.
62207138|NCT04238949|EXPERIMENTAL|Community Health Worker Group|Patients are assigned a community health worker for the first year in addition to standard diabetes care. They do not receive a community health worker for the second year of the study.
62207139|NCT05669014|EXPERIMENTAL|Daxdilimab|"Daxdilimab will be administered by subcutaneous (SC) injection during the 24-week treatment period followed by an 8-week safety follow up.~Prior to amendment 2 participants could enter an open-label extension period from weeks 24-48. For those participants already in the open-label extension, they will stop dosing and enter the safety follow up."
62207140|NCT05669014|PLACEBO_COMPARATOR|Placebo|"Matching placebo will be administered by SC injection during the 24-week treatment period followed by an 8-week safety follow up.~Prior to amendment 2 participants could enter an open-label extension period from weeks 24-48 and receive daxdilimab. For those participants already in the open-label extension, they will stop dosing and enter the safety follow up."
62734966|NCT00652743|EXPERIMENTAL|GSK1562902A M36 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) in study 109630 (NCT00449670) receiving one dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, at 36 Months (M36) after the primary vaccination, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
62734967|NCT03337802|NO_INTERVENTION|Pregnant women at standard diet|obstetrical and gynecological follow-up
62207141|NCT06194552|EXPERIMENTAL|NTRX-07 Low Dose Normal Volunteers|NTRX-07 administered orally once per day for 7 days
62207142|NCT06194552|EXPERIMENTAL|NTRX-07 Mid Dose Normal Volunteers|NTRX-07 administered orally once per day for 7 days
62207143|NCT06194552|EXPERIMENTAL|NTRX-07 High Dose Normal Volunteers|NTRX-07 administered orally once per day for 7 days
62207144|NCT06194552|EXPERIMENTAL|NTRX-07 High Dose Alzheimer's Participants|NTRX-07 administered orally once per day for 7 days
62207145|NCT06194552|PLACEBO_COMPARATOR|Placebo Control|Placebo administered orally once per day for 7 days
62207146|NCT06194552|EXPERIMENTAL|Mid Dose Fed|NTRX-07 administered orally once with high fat meal
62207147|NCT02673346||employees|YKHC employees
62207148|NCT02716259|EXPERIMENTAL|Scaling and root planing|Two sessions of scaling and root planing under local anesthesia and oral antiseptics (clorhexidine 0.12% rinse),
62207149|NCT02716259|PLACEBO_COMPARATOR|Supragingival prophylaxis|Two sessions of supragingival prophylaxis under local anesthesia and an oral rinse with no antiseptic properties.
62017236|NCT04494919||Ultrafine Endoscope Assisted|The self-expanding metal stent (SEMS) implantation was conducted using an ultrafine endoscope (UFE) (GIF-XP260NS; Olympus, Tokyo, Japan). The UFE researched the stricture, and a guidewire was inserted into the endoscopic working channel. The guidewire was left. And the endoscope was withdrawn. The normal colonoscope was exchanged under the reverse guidance of the guidewire. Finally, a metal, uncovered SEMS was placed along the guidewire.
62017237|NCT00761059|ACTIVE_COMPARATOR|Glucose 20%|
62017238|NCT00761059|PLACEBO_COMPARATOR|placebo|
62017239|NCT01488812||Hip-fracture patients|All the hip-fracture patients admitted to the Orthopaedic Depart of Danderyd Hospital between 1st June 2007- 1st June 2008 who fulfilled the inclusion criteria of the study.
62017240|NCT04051892|EXPERIMENTAL|Implantation of FixNip™ NRI|Female Patients Seeking Reconstructive Surgery of the Nipple
62017241|NCT03542643|ACTIVE_COMPARATOR|N-3 polyunsaturated fatty acids|n-3 polyunsaturated fatty acids dosage of 1g of Eicosapentaenoic acid(EPA)
62017242|NCT03542643|PLACEBO_COMPARATOR|Placebo|olive oil ethyl esters
62017243|NCT00509197|ACTIVE_COMPARATOR|Active treatment group (A)|Intervention : treatment with inhaled corticosteroids (Fluticasone) will be administered to this group
62017244|NCT00509197|PLACEBO_COMPARATOR|Control group treated with placebo (B)|treatment with placebo
62017245|NCT02268773|EXPERIMENTAL|Acetylsalicylic acid low dose with Asasantin®|
62017246|NCT02268773|ACTIVE_COMPARATOR|Acetylsalicylic acid high dose|
62207150|NCT00586612|EXPERIMENTAL|Preterm group|Subjects born after a gestation period of less than or equal to 36 weeks and who received 3 doses (at 2, 4 and 6 months of age) of Menitorix™, Infanrix™ penta and Prevenar™ and a booster dose of Menitorix™, Infanrix™ IPV and Prevenar™ at 16-18 months of age.
62207151|NCT00586612|ACTIVE_COMPARATOR|Full-term group|Subjects born after a gestation period of more than 36 weeks and who received 3 doses (at 2, 4 and 6 months of age) of Menitorix™, Infanrix™ penta and Prevenar™ and a booster dose of Menitorix™, Infanrix™ IPV and Prevenar™ at 16-18 months of age.
62207152|NCT02290080|EXPERIMENTAL|Oxygen|"For patients randomized to oxygen therapy:~* 6 L/min of oxygen delivered by oxymask® started immediately after inclusion of the ambulance service or in the emergency department given continuously for 6-12 hours (at least 6 hours)~* all patients receive standard acute coronary syndrome treatment including reperfusion strategies"
62207153|NCT02290080|NO_INTERVENTION|No oxygen|"For patients randomized to withholding oxygen treatment~* no oxygen is administered at any time as long as the oxygen saturation is ≥90% on pulse oximeter (repetitive checks are performed)~* all patients receive standard acute coronary syndrome treatment including reperfusion strategies~* observation duration 12 hours"
62207154|NCT04113642||single group|healthy subjects
62207155|NCT02106962|EXPERIMENTAL|Clotting time Using Tranexamic Acid 5%|Measure Native AV Fistula clotting time after dialysis using 5% Tranexamic Acid compared to normal Clotting time of Native AV Fistula after dialysis
62207156|NCT02106962|EXPERIMENTAL|Clotting Time Using Tranexamic Acid 25%|Measure Native AV Fistula clotting time after dialysis using 25% Tranxemic Acid compared to normal clotting time of native AV Fistula after dialysis
62017247|NCT04382794||DMT2 COVID19 positive patients treated with Sitagliptin|The anonymous data relating to the clinical, laboratory and instrumental parameters of patients hospitalized for COVID-19 and suffering from type 2 diabetes treated with Sitagliptin will be extracted from the medical records currently in use in the centers participating in the study. The data will be anonymous and not attributable to individual subjects
62017248|NCT04382794||DMT2 COVID19 positive patients not treated with Sitagliptin|The anonymous data relating to the clinical, laboratory and instrumental parameters of patients hospitalized for COVID-19 and suffering from type 2 diabetes not treated with Sitagliptin will be extracted from the medical records currently in use in the centers participating in the study. The data will be anonymous and not attributable to individual subjects
62017249|NCT01924936|PLACEBO_COMPARATOR|Email|Caring email (based on the caring letters literature) sent via secure email messaging. Of the interventions, it is by far the most minimal in clinical intensity and human resources needs for delivery.
62017250|NCT01924936|EXPERIMENTAL|DBT program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
62017251|NCT01924936|EXPERIMENTAL|Email + DBT program & Coach|"Caring Email + DBT online program \& Coach: in addition to the DBT online program, will include personalized outreach and support for use of the program. An intervention coach will deliver this support exclusively via secure email messaging. The intervention coach will not provide psychotherapy, but instead provide reinforcement and contingency management surrounding completion of the three lessons. This intervention will utilize significantly greater ongoing clinical resources for its maintenance and offer greater clinical intensity for patients."
62017252|NCT00435123|ACTIVE_COMPARATOR|A|Patients are randomly assigned to receive either Active Comparator (ProStat 64) or placebo for the first 3 months. At the end of this, all patients receive open label ProStat64.
62017253|NCT00435123|PLACEBO_COMPARATOR|B|Patients are randomly assigned to Placebo Comparator or Active Comparator (ProStat 64). At the end of 3 months, all patients receive active ProStat 64
62017254|NCT06402500|EXPERIMENTAL|ICON resin group|Clean the white spot with prophylactic paste and then infiltrate the lesion with ICON resin.
62017255|NCT06402500|EXPERIMENTAL|Bioactive resin group|Clean the white spot with prophylactic paste and then infiltrate the lesion with bioactive resin.
62207157|NCT06463340|EXPERIMENTAL|Dose Escalation|28-day treatment cycle.
62207158|NCT03820752||Pediatric chronically ill patients|"Through a questionnaire parents of chronically ill patients will be asked about the vaccination status of all recommended vaccines of their child. Also questions on disease, therapy and sociodemographic factors that can influence vaccination coverage will be asked.~A blood sample to determine antibodies against measles, mumps, rubella and pertussis will be drawn from children who consent to sampling.~The following groups of patients will be questioned: diabetes, allergy, congenital heart disease, cystic fibrosis, immunodeficiency and transplant patients, cancer patients."
62405864|NCT05081115||ABCDE-Stress Echo in Diastolic Heart failure (SEDIA project)|Patients with dyspnea and known or suspected heart failure with preserved ejection fraction by 2019 European Society of Cardiology criteria will be enrolled and studied with cycle-ergometer in semi-supine SE (or treadmill). A score of at least 1 according to the criteria proposed by Pieske et al. is required for inclusion. In patients unable to exercise or did not allow sampling of CFVR, pharmacological test (vasodilator or dobutamine) is recommended. Assuming that the hypothesis of proportionality of hazard holds, as required for Cox proportional hazards regression, with a power of 90%, an attrition rate of 10% and a 5-year follow-up period of a sample size of 181 patients is required.
62789131|NCT05725083|EXPERIMENTAL|Erector spinae block|before induction of anasthesia ,highfrequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle.confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging.Then the catheter placement 5cm into the space under the erector spinae muscle and suitable test dose will be administered . Bupivacaine 0.25% of 7.5-12 ml volume will be given bolus through the catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15 ml/h , for breakthrough pain patient controlled analgesia (PCA) using nalbuphine 1mg bolus,10 min lockout period.The catheter will be removed under complete aseptic precautions after 48 hrs.
62789132|NCT04168671|OTHER|Asthma|Asthma and symptomatic during exercise
62789133|NCT04168671|OTHER|Severe asthma|Severe asthma and symptomatic during exercise
62789134|NCT04027751|EXPERIMENTAL|Tropisetron|Patients allocated to this arm will receive single dose of intravenous Tropisetron (5mg) before anesthesia induction.
62017256|NCT01795001||late-onset FECD|tissue samples from patients with late-onset Fuchs' endothelial corneal dystrophy (FECD)
62789135|NCT04027751|PLACEBO_COMPARATOR|Placebo|Patients allocated to this arm will receive an identical volume of saline solution before anesthesia induction.
62789136|NCT01078363|ACTIVE_COMPARATOR|ramipril|ramipril, 5mg starting dose to maximum dose of 20mg daily dose for one year.
62017257|NCT01795001||normal control|tissue samples from patients with normal corneas
62405865|NCT05081115||ABCDE-Stress Echo in Hypertrophic Cardiomyopathy (SEHCA project)|The primary aim is to evaluate the feasibility of comprehensive ABCDEFG-SE in the evaluation of HCM. The secondary aim is to assess the value of each of obtaained parameters in predicting response to specific therapy and other interventions. The tertiary aim is to assess the prognostic value of SE indices for prognostic stratification in the medium-long-term. HCM diagnosis will be based on existing guidelines. All patients will be followed-up. In patients and first-degree relatives with genetic characterization different phenotypes will be correlated with specific genotypes. Non-imaging or routine imaging non-ultrasound exams will be collected and analyzed with neural network analysis developed in project 5. We assume that a sample size of 338 patients is required.
62734968|NCT03337802|EXPERIMENTAL|Pregnant women at mediterranean diet|obstetrical and gynecological follow-up + nutritional counseling
62789137|NCT01078363|PLACEBO_COMPARATOR|Placebo|Sugar pill manufactured to mimic ramipril 5mg starting dose , increasing to 20mg daily for one year.
62017258|NCT01795001||non-FECD edematous control|tissue samples from patients with corneal edema but without FECD
62017259|NCT06259344|ACTIVE_COMPARATOR|Fractioned Pain Science Education + Manual Therapy + Orofacial and Neck Exercises|All participants in this arm will initially receive six sessions in which a workshop on PSE will be administered and discussed. A power-point presentation with metaphors and animated videos will be employed. The PSE program will be held in 6 sessions of 15 minutes each. Two protocols of Orofacial Exercises and Manual Therapy and of Neck Motor Control will be adopted in the present study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will consist of orofacial therapy and exercises and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
62734969|NCT01956747||standard anticancer treatment|Patients older than 70 years of age with advanced malignancies of colorectum, breast or prostate, who will start with full standard anticancer treatment as decided by their oncologist.
62734970|NCT02181946|EXPERIMENTAL|Fluconazole with and without Nevirapine|
62734971|NCT05964348||Patient with infrarenal abdominal aortic aneurysms|Patient with infrarenal abdominal aortic aneurysms treated with EVAR
62734972|NCT03838614|EXPERIMENTAL|RAS-MPT group|Rhythmical auditory stimulation gait training and muscle power training group
62789138|NCT03009799|ACTIVE_COMPARATOR|Eye drops containing Iota-Carrageenan|Eye drops 3.2mg/ml
62789139|NCT03009799|PLACEBO_COMPARATOR|Ocular Lubricant Eye Drops|Carmellose 0.5% sterile solution
62789140|NCT01618695|EXPERIMENTAL|Perampanel|
62789141|NCT01618695|PLACEBO_COMPARATOR|Placebo|
62789142|NCT02154256|EXPERIMENTAL|Increasing incentives|The investigators will offer incentives to users that begin low, and get higher over time.
62207159|NCT03820752||Adult chronically ill patients|"Through a questionnaire chronically ill patients will be asked about their vaccination status of diphtheria, tetanus,pertussis, flu, pneumococcal and hepatitis B vaccine(s). Also questions on disease, therapy and sociodemographic factors that can influence vaccination coverage will be asked.~A blood sample to determine antibodies against diphtheria, tetanus and pertussis will be drawn.~The following groups of patients will be questioned: diabetes, chronic kidney disease, heart failure, COPD, immunodeficiency and transplant patients, HSCT patients."
62207160|NCT05689775||Patients|Patients over 18 years of age operated for locally advanced anal or rectal cancer with robot-assisted abdomino-perinal resection and robot-assisted reconstruction of pelvic floor and/or vagina with vertical rectus abdomínis muscle flap.
62207161|NCT00831753|EXPERIMENTAL|Group 1|DTaP-IPV-Hep B-PRP\~T vaccine group
62207162|NCT00831753|ACTIVE_COMPARATOR|Group 2|Infanrix® Hexa vaccine group
62207163|NCT04409171||PD|pancreaticoduodenectomy
62207164|NCT04409171||DP|distal pancreatectomy
62207165|NCT02683785|EXPERIMENTAL|GSK3196165|Subjects will receive a total of 8 doses of GSK3196165 over a 12-week treatment period.
62207166|NCT02683785|PLACEBO_COMPARATOR|Placebo|Subjects will receive a total of 8 doses of placebo over a 12-week treatment period.
62207167|NCT00856440||1|SCI
62207168|NCT00856440||2|Able-bodied
62207169|NCT04571788||FCB group|FCB group received FCB implantation
62207170|NCT04571788||Control group|Control group undergoes silicone scleral pad surgery
62207171|NCT01519505|EXPERIMENTAL|Lifestyle counseling|"Complete lifestyle counseling including~1. Individual intervention, OR~2. Group intervention"
62207172|NCT01519505|NO_INTERVENTION|Usual health care|Usual health care, including self-administered information by leaflets
62207173|NCT02961439||Patient Participants|Patient participants are adult patients in the Epworth Richmond Intensive care Unit. They are not the focus of the research but rather represent a general population of ICU patients that require echocardiography in the management of their critical illness. They will be a mix of medical and surgical patients some of whom are receiving mechanical ventilation, have movement restrictions, high BMI or other impediments to performing echocardiography.
62207174|NCT02961439||Registrar Participants|Registrar participants are doctors in training in ICU. They have completed a formal echo teaching program and completed a logbook of 30 supervised scans. They are the focus of the research and are being assessed on their diagnostic accuracy with echocardiography.
62405866|NCT05081115||ABCDE-Stress Echo post-Radiotherapy (SERA project)|Radiation-induced heart disease is associated with a significantly higher morbidity and mortality in cancer patients. The most frequent forms treated with chest radiation therapy are breast, lung, and esophageal cancers or lymphoma. The chances of developing radiation-induced heart disease increase with higher cumulative doses (\>30 Gray) in anterior or left sided irradiation, concomitant chemotherapy, presence of cardiovascular risk factors, and increased distance from time of irradiation. The estimated incidence of major cardiac events related to ischemic heart disease is 30% at 10 years post-treatment in female patients with radiotherapy post-breast cancer. The resulting epicardial artery stenosis, low grade inflammation , myocardial fibrosis, microvascular injury , alterations in autonomic balance, valve leaflets, and accelerated calcification can lead to significant alteration of all SE steps. A sample size of 507 patients is required and will be enrolled.
62734973|NCT03838614|EXPERIMENTAL|RAS group|Rhythmical auditory stimulation gait training group
62207175|NCT05930483|EXPERIMENTAL|Baseline (instructions, video, tape, scale, accelerometer)|Participants receive written instructions and website link to an instructional video along with supportive materials including measuring tape, Aria WiFi-enabled scale, and Actigraph accelerometer to be worn for 7 days at baseline. Patients also undergo blood sample collection at baseline.
62207176|NCT05930483|EXPERIMENTAL|Stage I, Arm I (¡Vida!)|Participants participate in the online ¡Vida! program consisting of 26 health education online sessions, dietary modifications, and home-based exercise sessions on study. Participants receive supportive materials consisting of a Fitbit Aria scale, a Fitbit Luxe (or latest device), the Fitbit app, and access to the Cook for Your Life website on study. Patients also undergo blood sample collection on study.
62207177|NCT05930483|EXPERIMENTAL|Stage I, Arm II (¡Vida!, lifestyle sessions)|Participants participate in the online ¡Vida! program consisting of 26 health education online sessions, dietary modifications, and home-based exercise sessions on study. Participants receive supportive materials consisting of a Fitbit Aria scale, a Fitbit Luxe (or latest device), the Fitbit app, and access to the Cook for Your Life website on study. Participants also attend remote lifestyle health education sessions on study. Patients also undergo blood sample collection on study.
62207178|NCT05930483|EXPERIMENTAL|Stage II, Arm III (¡Vida!, lifestyle sessions)|Participants receive interventions as in arm II.
62207179|NCT05930483|EXPERIMENTAL|Stage II, Arm IV (¡Vida!, lifestyle sessions, coaching)|Participants participate in the online ¡Vida! program consisting of 26 health education online sessions, dietary modifications, and home-based exercise sessions on study. Participants receive supportive materials consisting of a Fitbit Aria scale, a Fitbit Luxe (or latest device), the Fitbit app, and access to the Cook for Your Life website on study. Participants also attend remote lifestyle health education sessions and receive 14 30-minute individualized telephone health coaching sessions. Patients also undergo blood sample collection on study.
62207180|NCT05930483|EXPERIMENTAL|Stage II, Arm V (¡Vida!, lifestyle sessions, coaching)|Participants receive interventions as in arm IV.
62207181|NCT05930483|EXPERIMENTAL|Stage II, Arm VI (¡Vida!, lifestyle sessions, coaching, food))|Participants participate in the online ¡Vida! program consisting of 26 health education online sessions, dietary modifications, and home-based exercise sessions on study. Participants receive supportive materials consisting of a Fitbit Aria scale, a Fitbit Luxe (or latest device), the Fitbit app, and access to the Cook for Your Life website on study. Participants also attend remote lifestyle health education sessions and receive 14 30-minute individualized telephone health coaching sessions and receive a bag of groceries each month on study. Patients also undergo blood sample collection on study.
62734974|NCT03838614|EXPERIMENTAL|MPT group|Muscle power training group
62207182|NCT01498757||Patients treated with Taxane/5-FU/platinum based chemo.|
62207183|NCT02729064|EXPERIMENTAL|Intranasal 40|Patients will receive 40 IU of intranasal insulin (Humulin R) via a metered nasal dispenser
62734975|NCT03838614|OTHER|Control group|Usual care group
62734976|NCT03263988||PIEZO-Group|All patients in this study receive IBP by PICCO and piezocapacitative-interlayer-technology measurement.
62789143|NCT02154256|EXPERIMENTAL|Decreasing incentives|The investigators will offer incentives to users that start high, and decrease over time.
62789144|NCT02154256|EXPERIMENTAL|Stable incentives|The investigators will offer incentives that stay stable over time.
62789145|NCT02154256|NO_INTERVENTION|Usual care control|The investigators will offer incentives that are identical to the incentives normally offered by the investigators' partner company.
62789146|NCT05929625|EXPERIMENTAL|RF+US group|Subjects will be treated with the subject device using both, radiofrequency and ultrasound energies simultaneously with regular treatment settings.
62789147|NCT05929625|EXPERIMENTAL|RF only group|Subjects will be treated with the subject device using only radiofrequency energy with regular treatment settings.
62789148|NCT01939184|EXPERIMENTAL|WC3055-01F|WC3055 12.5 mg tablet once daily for 12 weeks
62207184|NCT02729064|EXPERIMENTAL|Intranasal 80|Patients will receive 80 IU of intranasal insulin (Humulin R) via a metered nasal dispenser
62207185|NCT02729064|PLACEBO_COMPARATOR|Placebo|Patients will receive intranasal normal saline via a metered nasal dispenser
62207186|NCT03921385||Single cohort - navigated cranial and spine surgery|
62734977|NCT05891535|EXPERIMENTAL|Stentless FloRIN|Florence robotic Intra Corporeal Neobladder configuration was performed without the employement of Mono J ureteral catheters
62734978|NCT05891535|ACTIVE_COMPARATOR|Stented FloRIN|Florence robotic Intra Corporeal Neobladder configuration was performed with the employement of Mono J ureteral catheters
62734979|NCT03951766|OTHER|Smiling Instead of Smoking App|This is a pilot study; all participants will use the app in the same manner/time period.
62734980|NCT02231528|EXPERIMENTAL|Use of ultrasound with active GPS|
62734981|NCT02231528|ACTIVE_COMPARATOR|Use of ultrasound with inactive GPS|
62734982|NCT03998514|EXPERIMENTAL|Group A1 single ascending dose (SAD)|CB4211 Dose 1 (N=6) Placebo (N=2) Subcutaneous injection
62734983|NCT03998514|EXPERIMENTAL|Group A2 SAD|CB4211 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection
62734984|NCT03998514|EXPERIMENTAL|Group A3 SAD|CB4211 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection
62734985|NCT03998514|EXPERIMENTAL|Group A4 SAD|CB4211 Dose 4 (N=1) Placebo (N=1) Subcutaneous injection
62734986|NCT03998514|EXPERIMENTAL|Group A5 SAD|CB4211 Dose 5 (N=6) Placebo (N=2) Subcutaneous injection
62734987|NCT03998514|EXPERIMENTAL|Group A6 SAD|CB4211 Dose 6 (N=6) Placebo (N=2) Subcutaneous injection
62734988|NCT03998514|EXPERIMENTAL|Group B1 multiple ascending dose (MAD)|CB4211 Dose to be determined (TBD) (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
62734989|NCT03998514|EXPERIMENTAL|Group B2 MAD|CB4211 Dose TBD (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
62734990|NCT03998514|EXPERIMENTAL|Group B3 MAD|CB4211 Dose TBD (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
62734991|NCT03998514|EXPERIMENTAL|Part C|CB4211 Dose TBD (N=10) Placebo (N=10) Subcutaneous injection once daily for 28 days
62734992|NCT04558541|EXPERIMENTAL|Sensitivity to phonological rules: Children|Arm 1: Single Feature Pattern; Arm 2: OR/Disjunction Pattern; Arm 3: Family Resemblance/Prototype Pattern
62734993|NCT04558541|EXPERIMENTAL|Sensitivity to semantic category cues: Children|Arm 1.Referential cue during OR learning.
62734994|NCT00263432|EXPERIMENTAL|1|Implantation of fresh human allogenic chondrocytes
62734995|NCT03747796|ACTIVE_COMPARATOR|supine position|The children will be in the supine position after ingestion of a standard volume of clear fluid.
62734996|NCT03747796|EXPERIMENTAL|Semi-sitting position|The children will be in the semi-sitting position after ingestion of a standard volume of clear fluid.
62734997|NCT04249297||IVF/Dydrogesteron|Females aged ≥ 18 years, underwent In-Vitro Fertilization with Elective single embryo transfer in fresh cycle, for whom were prescribed treatment with Duphaston® for luteal phase support as part of an Assisted Reproductive Technology
62734998|NCT03958864|EXPERIMENTAL|CC-90001 100 mg|100 mg of CC-90001 (once daily \[QD\] x 7 days) will be given orally
62734999|NCT03958864|EXPERIMENTAL|CC-90001 200 mg|200 mg of CC-90001 (once daily \[QD\] x 7 days) will be given orally
62735000|NCT03958864|EXPERIMENTAL|CC-90001 400 mg|400 mg of CC-90001 (once daily \[QD\] x 7 days) will be given orally
62735001|NCT01858441|OTHER|Abiraterone Acetate|
62735002|NCT05474287|EXPERIMENTAL|Supraglottic jet oxygenation and ventilation|Supraglottic jet oxygenation and ventilation is conducted for the participants during sedation.
62735003|NCT05474287|ACTIVE_COMPARATOR|High-flow nasal oxygen therapy|High-flow nasal oxygen therapy is conducted for the participants during sedation.
62735004|NCT02243371|EXPERIMENTAL|Arm A: CY/ GVAX/ CRS-207/ nivolumab|
62735005|NCT02243371|EXPERIMENTAL|Arm B: CY/ GVAX/ CRS-207|
62735006|NCT04925219|EXPERIMENTAL|Remotely supervised exercise|"Best medical therapy including aspirin 75mg od + rivaroxaban 2.5mg bd (if not tolerated clopidogrel 75mg od), atorvastatin 80mg and smoking cessation referral as per NICE guideline for PAD.~Intervention = electronic walking log and fortnightly video/telephone call with physiotherapist for 3 months."
62789149|NCT01939184|EXPERIMENTAL|WC3055-02F|WC3055 25 mg tablet once daily for 12 weeks
62789150|NCT01939184|EXPERIMENTAL|WC3055-03F|WC3055 50 mg tablet once daily for 12 weeks
62789151|NCT01939184|EXPERIMENTAL|WC3055-04F|WC3055 75 mg tablet once daily for 12 weeks
62789152|NCT01939184|PLACEBO_COMPARATOR|WC3055-07P|Placebo tablet once daily for 12 weeks
62789153|NCT02401503|EXPERIMENTAL|Bendamustine + GA101 + ABT-199|"Bendamustine: 70mg/m² i.v. GA101: 1000 mg i.v. ABT-199: 20 - 400 mg p.o.~Possible Re-treatment of the included patients with GA101: 1000 mg i.v. and ABT-199: 20 - 400 mg p.o."
62789154|NCT03878849|EXPERIMENTAL|2X-121|Oral administration of 2X-121 twice daily as 600 mg hard gelatin capsules in a 28 days cycle.
62735007|NCT04925219|ACTIVE_COMPARATOR|Self-directed exercise|"Best medical therapy including aspirin 75mg od + rivaroxaban 2.5mg bd (if not tolerated clopidogrel 75mg od), atorvastatin 80mg and smoking cessation referral as per NICE guideline for PAD.~Control = electronic walking log and instructions to exercise 4 times per week for 3 months"
62789155|NCT03461640|EXPERIMENTAL|Community-based doula support for labour|"Women will receive support from a Community-based doula (CBD) plus standard labour support. Women will meet twice with the CBD prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. The CBD will then stay with her throughout her labour and birth and support her with interpretation/Communication with the staff and emotional and instrumental support. The CBD-support will be in addition to any other support people she may have, such as her partner.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation.~CBDs will be recruited, trained and employed by non-profit organization MIRA, using well-tested processes."
62789156|NCT03461640|ACTIVE_COMPARATOR|Standard labour support|"Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation."
62789157|NCT00752479|EXPERIMENTAL|1|
62789158|NCT00752479|ACTIVE_COMPARATOR|2|
62789159|NCT00103740|EXPERIMENTAL|Zoledronic acid and placebo to risedronate|Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
62789160|NCT00103740|ACTIVE_COMPARATOR|Risedronate and placebo to zoledronic acid|Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
62789161|NCT02445326|EXPERIMENTAL|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
62789162|NCT02445326|PLACEBO_COMPARATOR|PV|PV (placebo drug delivery vehicle)
62789163|NCT05820854||Non-valvular atrial fibrillation (NVAF) patients treated with oral anticoagulants|Adult outpatients (≥ 18 years) with NVAF and treated with OAC for at least three months.
62789164|NCT05343377|EXPERIMENTAL|circulate free methylated EBV DNA predicts PFS rate in ENKTCL|
62789165|NCT01272635|EXPERIMENTAL|Azythromycin (APRIL) and Prednisolone (OCELOT)|
62789166|NCT01272635|EXPERIMENTAL|Azythromycin (APRIL) and Placebo (OCELOT)|
62789167|NCT01272635|EXPERIMENTAL|Placebo (APRIL) and Prednisolone (OCELOT)|
62789168|NCT01272635|PLACEBO_COMPARATOR|Placebo (APRIL) and Placebo (OCELOT)|
62789169|NCT01031979|EXPERIMENTAL|Yohimbime Group|Patients will take one 21.6 mg. dose of yohimbine one hour before first imaginal exposure in PE.
62581355|NCT05019976|EXPERIMENTAL|Dose-Finding Group 1 - Dose Level 1|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
62581356|NCT05019976|EXPERIMENTAL|Dose-Finding Group 2 - Dose Level 2|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
62581357|NCT05019976|EXPERIMENTAL|Dose-Finding Group 3 - Dose Level 3|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
62735008|NCT05877937|EXPERIMENTAL|Interventions group|The intervention group watched a comedy movie during routine IV biologic treatment in the chemotherapy day unit.
62735009|NCT05877937|NO_INTERVENTION|Control group|The control group received only routine IV biologic treatment as a usual care.
62789170|NCT01031979|PLACEBO_COMPARATOR|Placebo Group|Patients will take a placebo one hour before first imaginal exposure in PE.
62789171|NCT06413979|EXPERIMENTAL|Fam-Aid|
62789172|NCT01612130|EXPERIMENTAL|Valeriana officinalis L (100mg)|100 mg of Valeriana officinalis L. (Valerian)
62789173|NCT01612130|PLACEBO_COMPARATOR|Placebo (100 mg)|Placebo 100mg
62789174|NCT01736371|SHAM_COMPARATOR|Total Intravenous Anesthesia|Only propofol infusion is used for maintenance of anesthesia keeping Bispectral Index (BIS) between 45-55.
62789175|NCT01736371|ACTIVE_COMPARATOR|1% Sevoflurane|1% Sevoflurane with propofol infusion is used for maintenance. BIS is kept between 45-55 by adjusting propofol infusion.
62789176|NCT01736371|ACTIVE_COMPARATOR|Sevoflurane|Only Sevoflurane is used for maintenance keeping BIS between 45-55
62789177|NCT06335316|EXPERIMENTAL|Stellate Nerve Block+ routine rehabilitation treatment|The patients were given Nerve block and routine rehabilitation treatment for 10 days.
62207187|NCT00890695|ACTIVE_COMPARATOR|Ready to use supplementary food (RUSF)|The RUSF intervention consists of a food paste made of maize, soya, sorghum, vegetable oil, sugar, dried skim milk and vitamin/mineral premix, prepared by VALID Nutrition in collaboration with Insta Products, Kenya in accordance with composition specified by the latest WHO expert consultation in 2008. Children in the intervention arm receive 4 weeks supply of RUSF. The amount supplied is based on the child's weight to give energy supplement of 100kcal per kg per day, equivalent to 25g RUSF per kg per day.
62789178|NCT06335316|PLACEBO_COMPARATOR|placebo+routine rehabilitation treatment|The patients were given placebo block and routine rehabilitation treatment for 10 days.
62207188|NCT00890695|NO_INTERVENTION|Normal diet (standard of care)|For equity, parents or guardians of children in the usual diet arm will be given 2 bags of maize meal(4Kg) for family consumption instead of RUSF. All parents and carers in both arms will also receive standard nutritional advice as specified in the current WHO IMCI handbook.
62207189|NCT05751954|OTHER|Arm Label|All patients who undergo total knee arthroplasty and met inclusion and exclusion criteria
62207190|NCT04474444||Hear and treat|phone call, treatment, not attended
62207191|NCT04474444||See and treat|Ambulance crew attended
62207192|NCT04116892|ACTIVE_COMPARATOR|the peeling group|the internal limiting membrane was discarded
62789179|NCT04780412|ACTIVE_COMPARATOR|Misoprostol Group|
62789180|NCT04780412|PLACEBO_COMPARATOR|Placebo Group|
62789181|NCT00132808|EXPERIMENTAL|Zoledronic Acid 2x5 mg|Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12
62789182|NCT00132808|EXPERIMENTAL|Zoledronic Acid 1x5 mg|Zoledronic acid 5 mg intravenous (i.v.) given at randomization and placebo at Month 12
62207193|NCT04116892|EXPERIMENTAL|the Cover group|the internal limiting membrane was peeled centripetally all the way up to the MH rim and the hinged ILM flap folded upside-down on top of the MH in order to bridge the entire retinal defect with a single layer.
62207194|NCT04116892|EXPERIMENTAL|the Fill group|"the internal limiting membrane was folded in multiple layers and deliberately stuffed or packed within the MH defect using a forceps."
62405867|NCT05081115||ABCDE- Artificial Intelligence Stress echo (AI-SEE)|The project have 2 separate aims: AI-SEE images: To make SE reading operator-independent for each of the essential reading steps (from A to E). AI-SEE data: To identify the links between clinical imaging and stress variables and develop a tailored personalized model for risk prediction. For each parameter assessment (positivity versus negativity), the area under the receiver-operating characteristic curve produced by the deep learning algorithm will be compared to that produced by the experienced cardiologist (cross-sectional analysis). AI-SEE images: a set of images from 1 250 patients from at least 10 laboratories will be sufficient to develop the algorithm (modeling set) subsequently prospectively tested on a different set of 1250 patients (validation set). AI-SEE data: a set of data from 2 500 patients from at least 10 laboratories will be sufficient to develop the algorithm (modeling set) subsequently tested on a different set of 2 500 patients (validation set).
62789183|NCT00132808|PLACEBO_COMPARATOR|Placebo|Placebo given at randomization and Month 12
62789184|NCT06262724|OTHER|Surgery|Surgical intervention for breast reshaping utilizing chest wall perforators for auto-augmentation.
62789185|NCT04099615||Endovascular urgent stroke treatment group|Patients between 18 and 85 years old who have and acute cerebral stroke due to a demonstrated occlusion in the anterior circulation (M1 or M2 segment of middle cerebral artery with or without ipsilateral internal carotid artery (ICA), that undergo endovascular acute therapy fulfilling all inclusion criteria and with non exclusion criteria for that treatment. We also exclude patient with well-documented history of neuromuscular disorders, stroke or central nervous system tumors that could interfere in the SEPs assessment.
62789186|NCT01286883||Blood draws|Laboratory studies will be performed at baseline; Cycle 1, Day 1; Cycle 1, Day 7; Cycle 2, Day 1; Cycle 3, Day 1; Cycle 4, Day 1; Cycle 6, Day 1; Cycle 12, Day 1.
62789187|NCT02324816|EXPERIMENTAL|Lateral Thigh Treatment Group|CoolSculpting treatment in the lateral thighs for non-invasive subcutaneous fat reduction.
62789188|NCT01166425|ACTIVE_COMPARATOR|Lithium Carbonate|Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID (three times a day) at visit 1 (total dose 900 mg). Participants weighing \< 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID (two times a day) the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose.
62789189|NCT01166425|PLACEBO_COMPARATOR|placebo|Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
62789190|NCT05225363|EXPERIMENTAL|Treatment (TAG72-CAR T cells)|Patients receive fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients receive TAG72-CAR T cells IP on day 0.
62789191|NCT00434642|EXPERIMENTAL|Carboplatin and gemcitabine + bevacizumab|Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m\^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.
62789192|NCT00434642|ACTIVE_COMPARATOR|Carboplatin and gemcitabine + placebo|Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m\^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.
62789193|NCT05039944|EXPERIMENTAL|SI-B001_A|Patients with unresectable or metastatic gastric cancer, HER2-negative and without standard treatment were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).
62207195|NCT05920720|EXPERIMENTAL|Self-guided Personalized Treatment|Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
62207196|NCT04891562|EXPERIMENTAL|pDCD (hildren with (probably) Developmental Coordination Disorder)|children with (probably) Developmental Coordination Disorder (pDCD)
62207197|NCT04891562|ACTIVE_COMPARATOR|TDC (Typically Developing Children)|Typically Developing Children
62207198|NCT03523611||lung resection|Patients with suspected lung cancer undergoing lung resection by anatomic lobectomy
62207199|NCT04912453|EXPERIMENTAL|Primary anastomosis group|
62735010|NCT04743219|ACTIVE_COMPARATOR|Biodentine Group|Biodentine group: patients with mature permanent posterior teeth with deep caries lesions treated with the selective removal technique to soft dentin with Biodentine as indirect pulp capping material before placement of a definitive direct composite resin restoration.
62735011|NCT04743219|EXPERIMENTAL|No base Group|The experimental group or No Base group: patients with mature permanent posterior teeth with deep caries lesions treated with the selective removal technique to soft dentin without the placement of a bioactive material as a base and restored directly with a definitive direct composite resin restoration.
62789194|NCT05039944|EXPERIMENTAL|SI-B001_B|Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed conventional chemotherapy combined with EGFR mab were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).
62789195|NCT05039944|EXPERIMENTAL|SI-B001_C|Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed multiple lines of conventional chemotherapy (excluding EGFR monoclonal antibody) were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).
62207200|NCT04912453|EXPERIMENTAL|Enterostomy group|
62207201|NCT03993262|EXPERIMENTAL|Interventional|1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
62207202|NCT03993262|PLACEBO_COMPARATOR|Placebo|1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
62207203|NCT05702697|EXPERIMENTAL|F-ESWT|F-EWST with 0.15 mJ/mm2 intensity and 6 Hz frequency for 3 weeks. The shocking head was placed at the muscle positions of the long head of the bicep femoris, semitendinosus, and semimembranosus for 1,000, 500, and 500 shocks, respectively, accounting for 2,000 shocks in total/ session/week.
62405868|NCT05081115||ABCDE- Environmental Stress Echocardiography, air pollution and medical radiation (ESTER project)|The primary aim is to assess the inter-patient correlation between SE results and outdoor air pollution levels in patients matched for clinical, coronary anatomy (if available) and resting functional features. Secondary aim is to assess the effects of air quality and cumulative medical radiation exposure in prognostic modeling using traditional risk factors and SE results. All patients enrolled in projects 1 to 4 have information on house residency and work place in the data bank. The air epidemiology unit will obtain same day local air quality data from publicly available data sets from regional authority of environmental protection. For each patient and each test of the same patient, the values of 2 particulate and 4 gaseous pollutants will be collected when available. Data on medical radiation exposure will also be systematically collected. Of the 2 430 tests recruited in protocol 1, at least 600 will have access to geo-referenced air quality data.
62405869|NCT05081115||SETOF Stress Echo in operated Tetralogy of Fallot.|The primary aim is to evaluate the feasibility of right ventricular SE in patients with repaired Tetralogy of Fallot. The secondary aim is to assess the presence and amount of right ventricular contractile reserve and its correlation with indices of functional severity (NYHA class, cardiac natriuretic peptides, peak VO2, 6-min walking test, etc.). The tertiary aim is to assess the prognostic value of SE indices for prognostic stratification in the medium and long-term. Patients with repaired Tetralogy of Fallot or Fallot-like pathology evaluated at least 1 year after the last surgical or percutaneous procedure, will be recruited by regional reference centers for congenital heart disease. Additional inclusion criteria are age\>10 years, height\>140 cm, NYHA class I or II. Data on medical radiation exposure will also be systematically collected. A sample size of about 250 patients is required to detect a significant stress-induced increase in tricuspid annular plane systolic excursion.
62735012|NCT06379503|EXPERIMENTAL|intervention|Heart yoga practice for 12 weeks on 30 patients who underwent heart surgery
62789196|NCT05039944|EXPERIMENTAL|SI-B001 combined with irinetecan_D|Patients with MSI-H KRASwt BRAFwt unresectable or metastatic colorectal cancer who had previously failed to receive anti-PD-1 (L1) mab (excluding EGFR mab) in the first or second line were treated with SI-B001 in combination with irinetecan in the third line.SI-B001 is administered by intravenous drip twice weekly (Q2W).
62207204|NCT05702697|SHAM_COMPARATOR|Sham-ESWT|sham ESWT by using the focused shockwave device and placing the shocking head in the same muscle positions as performed in the intervention group with 0.01 mJ/mm2 intensity and 6 Hz frequency in 2,000 shocks/session/week for 3 weeks.
62789197|NCT05039944|EXPERIMENTAL|SI-B001 combined with FOLFIRI or FOLFOX_E|Patients with MSI-H KRASwt BRAFwt unresectable or metastatic colorectal cancer who had previously failed first-line anti-PD-1 (L1) mab were treated with SI-B001 in combination with FOLFIRI or FOLFOX for second-line treatment.SI-B001 is administered by intravenous drip twice weekly (Q2W).
62789198|NCT05039944|EXPERIMENTAL|SI-B001 combined with irinetecan_F|Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed standard first-line treatment containing oxaliplatin or irinotecan plus fluorouracil plus or minus bevacizumab were treated with SI-B001 plus irinotecan in the second-line.SI-B001 is administered by intravenous drip twice weekly (Q2W).
62207205|NCT02247453|EXPERIMENTAL|Screening|Healthy heavy smokers aged 50-75 years
62207206|NCT01518153|EXPERIMENTAL|Low Dose Donor T-Cells|Fludarabine 40 mg/m\^2 by vein on Day -6 to -3. Melphalan 140 mg/m\^2 by vein on Day -2. Alemtuzumab 50 mg by vein on Day -1. Reduced intensity stem cell transplant on Day 0. Planned Donor Lymphocyte Infusion CD3+ cells: 3 \* 106 CD3+ cells/kg between Day +56 and +64. Tacrolimus 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35. Methotrexate 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
62207207|NCT01518153|EXPERIMENTAL|High Dose Donor T-Cells|Fludarabine 40 mg/m\^2 by vein on Day -6 to -3. Melphalan 140 mg/m\^2 by vein on Day -2. Alemtuzumab 50 mg by vein on Day -1. Reduced intensity stem cell transplant on Day 0. High Dose Donor T-Cells Planned Donor Lymphocyte Infusion CD3+ cells: 1 \* 107 CD3+ cells/kg between Day +56 and +64. Tacrolimus 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35. Methotrexate 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
62207208|NCT05751278|EXPERIMENTAL|Cryoprobe|Participants in this arm will undergo a standard of care bronchoscopy with a transbronchial biopsy using the 1.1mm sheath cryoprobe
62207209|NCT05751278|ACTIVE_COMPARATOR|Forceps|Participants in this arm will undergo a standard of care bronchoscopy with a transbronchial biopsy using forceps
62207210|NCT06424470|EXPERIMENTAL|Stapokibart|Stapokibart Injection, subcutaneous injection (SC)
62735013|NCT06379503|ACTIVE_COMPARATOR|control|routine nursing care
62789199|NCT00992459|EXPERIMENTAL|Buphenyl (NaPBA) /HPN 100 Placebo|Subjects in Arm A were randomly assigned to receive NaPBA + HPN 100 placebo for 2 weeks and then crossed over to receive HPN 100 + NaPBA Placebo for 2 weeks.
62789200|NCT00992459|EXPERIMENTAL|HPN-100/NaPBA Placebo|Subjects in Arm B were randomly assigned to receive HPN-100 + NaPBA placebo for 2 weeks and then crossed over to receive NaPBA + HPN 100 placebo for 2 weeks.
62207211|NCT06424470|PLACEBO_COMPARATOR|Placebo|subcutaneous injection (SC)
62017260|NCT06259344|EXPERIMENTAL|Full Dosage Pain Science Education + Manual Therapy + Orofacial and Neck Exercises|All participants in this arm will initially receive two sessions in which a workshop on PSE will be administered and discussed. A power-point presentation with metaphors and animated videos will be employed. The PSE program will be held in 2 sessions of 45 minutes each one. Two protocols of Orofacial Exercises and Manual Therapy and of Neck Motor Control will be adopted in the present study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will consist of orofacial therapy and exercises and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
62017261|NCT02015377|EXPERIMENTAL|High Sugar/Low Fiber (HSLF) meals|Comparing the impact of High sugar/Low fiber (HSLF) meal versus Low Sugar/High Fiber meals (LSHF) on insulin and glucose profiles, gut hormones (ghrelin, amylin, leptin) free fatty acids, cortisol, mood (MOOD), meaning of physical activity (MEANPA), and physical activity engagement (PA) in overweight African American and Hispanic youth
62017262|NCT02015377|EXPERIMENTAL|Low Sugar/High Fiber (LSHF) meals|Comparing the impact of High sugar/Low fiber (HSLF) meal versus Low Sugar/High Fiber meals (LSHF) on insulin and glucose profiles, gut hormones (ghrelin, amylin, leptin) free fatty acids, cortisol, mood (MOOD), meaning of physical activity (MEANPA), and physical activity engagement (PA) in overweight African American and Hispanic youth
62017263|NCT05423262|EXPERIMENTAL|Part 1 : TRK-950|"* Solid Tumor~* TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. Two dose levels will be explored during this Arm."
62017264|NCT05423262|EXPERIMENTAL|Part 2 Cohort 1: TRK-950+Nivolumab|"* Nivolumab-eligible solid tumor~* Nivolumab will be administered intravenously on days 1 and 15 of a 28-day cycle. TRK-950 will be administered as an intravenously infusion on days 1, 8, 15 and 22. After the administration of Nivolumab on days 1 and 15, TRK-950 will be administered as an intravenously infusion."
62017265|NCT05423262|EXPERIMENTAL|Part 2 Cohort 2: TRK-950+Nivolumab|"* Nivolumab-eligible solid tumor~* Nivolumab will be administered intravenously on days 1 and 15 of a 28-day cycle. TRK-950 will be administered as an intravenously infusion on days 1 and 15. After the administration of Nivolumab on days 1 and 15, TRK-950 will be administered as an intravenously infusion."
62017266|NCT02282449|EXPERIMENTAL|Power Injectable Port|The subjects randomized to this group will receive the newer, power injectable port.
62207212|NCT03288207|OTHER|Group 2 Label: PA monitor with standard remote coaching (SRC)|African American women who are at risk for cardiovascular outcomes in resource-limited communities in the Washington D.C. area.
62581358|NCT05019976|EXPERIMENTAL|Dose-Finding Group 4 - Dose Level 4|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
62789201|NCT05987163|EXPERIMENTAL|GP0116|
62207213|NCT03288207|OTHER|Group 1 Label: PA monitor with remote coaching tailored to place|African American women who are at risk for cardiovascular outcomes in resource-limited communities in the Washington D.C. area.
62017267|NCT02282449|ACTIVE_COMPARATOR|Non-Power Injectable Port|The subjects randomized to this group will receive the older, non-power injectable port.
62017268|NCT02311595|EXPERIMENTAL|reduced port|gastric cancer patients go through reduced port laparoscopic distal gastrectomy with D2 lymph node dissection
62017269|NCT05095480|EXPERIMENTAL|Lesstat|Those who received Lesstat
62017270|NCT05095480|PLACEBO_COMPARATOR|Placebo|Those who received Lesstat
62207214|NCT01367288|EXPERIMENTAL|A (Neoadjuvant therapy + Zometa)|Patients will be treated every 3 weeks (+/- 2 days ) for 8 cycles in total. The 4 first cycles : Zometa 4 mg (in a 15 min. infusion) + doxorubicin (60 mg/m²) + cyclophosphamide (600 mg/m²). The 4 last cycles with Zometa 4 mg (in a 15 min. infusion) + docetaxel (100 mg/m²)
62207215|NCT01367288|ACTIVE_COMPARATOR|B (Neoadjuvant therapy)|Patients will be treated every 3 weeks (+/- 2 days) for 8 cycles in total. The 4 first cycles : doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²). The 4 last cycles with docetaxel (100 mg/m²)
62207216|NCT00668265|EXPERIMENTAL|Seroquel|
62207217|NCT03725657||Pediatric|Pediatric Type1 Diabetes Mellitus patients
62207218|NCT04094441|EXPERIMENTAL|additional pulmonary function tests|additional pulmonary function tests
62207219|NCT04803721||Patient with a myelodysplastic syndrome|Patient over 18 years of age with a myelodysplastic syndrome (WHO 2016 classification) of low risk (LR= International Prognostic Scoring System (IPSS)-R\<4.5) or high risk (HR=Revised International Prognostic Scoring System\>4.5)
62207220|NCT04803721||Control patient|Healthy blood donor (regardless of age) Or Patient \>60 years old, see at the geriatrics platform of the hospital la Grave (CHU of Toulouse), having expressed his non opposition to participate in the study
62581359|NCT03389230|EXPERIMENTAL|Arm I (intratumoral/intracavitary delivery)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tcm cells via intratumoral/intracavitary catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to alternative delivery routes for the optional infusions.
62789202|NCT05987163|ACTIVE_COMPARATOR|FDA Approved Device|
62207221|NCT01291459|EXPERIMENTAL|single arm|Maraviroc/raltegravir/emtricitabine/tenofovir 24 weeks followed by Maraviroc/Raltegravir 24 weeks
62789203|NCT02583295|ACTIVE_COMPARATOR|Music group|Music sound
62789204|NCT02583295|ACTIVE_COMPARATOR|Maternal sound group|Maternal sound
62789205|NCT01945203||PD-ABI|"1. Patients at National Taiwan University Hospital (NTUH)~2. Patients who have received PD more than 3 months~3. Patients who sign the informed consents~4. Patients who aged between 20-90 years."
62207222|NCT02473705|ACTIVE_COMPARATOR|Fish Oil and Bicarbonate placebo|1280mg of fish oil per day and bicarbonate placebo
62207223|NCT02473705|ACTIVE_COMPARATOR|Fish Oil Placebo and Bicarbonate|fish oil placebo and 1mg of bicarbonate per Kg of body weight per day
62207224|NCT02473705|EXPERIMENTAL|Fish Oil and Bicarbonate|1280mg of fish oil per day and 1mg of bicarbonate per Kg of body weight per day
62207225|NCT02473705|PLACEBO_COMPARATOR|Fish Oil placebo and Bicarbonate placebo|Fish oil placebo and Bicarbonate placebo
62207226|NCT06634823|PLACEBO_COMPARATOR|Placebo|Placebo injection into deltoid (arm)
62017271|NCT04400552|ACTIVE_COMPARATOR|ONS Pre-op + ONS Post-op|Oral nutrition supplementation (ONS) pre-operatively and post-operatively up to being discharged from hospital
62207227|NCT06634823|EXPERIMENTAL|Steroid|Triamcinolone injection into deltoid (arm)
62207228|NCT06091293|EXPERIMENTAL|NICO|The NICO intervention includes components of narrative-informed interventions, brief solution-focused therapy, and medical social work case management to examine adjustment to illness for people living with Long COVID.
62207229|NCT06619756|EXPERIMENTAL|PMT|Phonomotor Treatment (PMT) will be administered. This treatment improves anomia by training the sound sequences of words. This is a multimodal treatment approach that includes listening, producing, visualizing, and describing sounds and sound sequences. The participant practices the sound sequence tasks with the clinician.
62207230|NCT06619756|EXPERIMENTAL|PCA|Phonological Components Analysis (PCA) will be administered. This treatment improves anomia by identifying phonological features of words. A picture is presented. The participant provides features of the picture name: the first sound of the word, the final sound of the word, the number of syllables of the word, another word that starts with the same sound, and another words that rhymes with the word. The participant attempts to produce the word independently and by repeating after the clinician.
62207231|NCT06552767||Affected Participants and Relatives|Participants with relevant immune, inflammation, thrombotic and/or vascular diseases and their relatives
62207232|NCT06552767||Healthy Volunteers|Healthy volunteers
62207233|NCT02060370|EXPERIMENTAL|Sunitinib|"Sunitinib starting dose 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks."
62207234|NCT05774197|EXPERIMENTAL|STAMP+CBT app|"This app will allow the patient to access daily surveys designed to assess pain, stress, mood, and related symptoms.~Based on patient-reported symptoms, this app will disseminate tailored education to manage the symptoms."
62207235|NCT04225689|EXPERIMENTAL|CD-TREAT diet|"Solid food-based dietary intervention replicating composition of exclusive enteral nutrition (EEN).~Daily for a maximum of 21 days. Individualised diet based on energy requirements and physical activity levels."
62207236|NCT04225689|NO_INTERVENTION|Unrestricted diet|Free, unrestricted diet. Daily for a maximum of 21 days.
62207237|NCT02619903|NO_INTERVENTION|COPD Control|Subjects with COPD recieve no treatment. When exiting the trial after 12 months, they do however receive the intervention.
62207238|NCT02619903|ACTIVE_COMPARATOR|COPD Test|Subjects with COPD that do get the additional dental cleaning, as well as dental examination.
62207239|NCT02238821||resectable colorectal cancer|
62017272|NCT04400552|ACTIVE_COMPARATOR|ONS Pre-op + ONS Post-op + ONS Post-op 3 months|Oral nutrition supplementation (ONS) pre-operatively, post-operatively up to being discharged from hospital and an extended oral nutrition supplementation post-operatively up to 3 months
62017273|NCT04400552|ACTIVE_COMPARATOR|Usual intake Pre-op + ONS Post-op|Follow a meal plan of 2000 kcal / day using conventional foods and oral nutrition supplementation (ONS) post-operatively up to being discharged from hospital
62017274|NCT06065696||Early mobilization|Patients who achieved early mobilization after colorectal surgery
62017275|NCT06065696||No early mobilization|Patients who did not achieve early mobilization after colorectal surgery
62017276|NCT02426671|EXPERIMENTAL|MuteButton sensory stimulation device|"Participants will be asked to use the Mutebutton, neuro-modulation device every day for 60 minutes for 12 weeks. Use of the device involves placing a 'lollipop' type sensor on the tongue and wearing earphones. The participant will hear pink noise through the earphones and will receive neuro-stimulation through the sensor. The participant will not feel any discomfort whilst using the MuteButton device."
62207240|NCT04844073|EXPERIMENTAL|Dose Escalation Phase|TAK-186 initial 60 minutes infusion and 30 minutes subsequent infusions on Day 1 of every week in Dose Escalation Phase. Participants may receive additional treatment with TAK-186. Dose escalation will be carried out in sequential cohorts of escalating doses.
62207241|NCT04844073|EXPERIMENTAL|Cohort Expansion Phase: NSCLC|Participants with non-small cell lung cancer (NSCLC) will be randomized to receive low dose or high dose of RDE of TAK-186 infusion on Day 1 of every week during Dose Expansion Phase of the study. Participants may receive additional treatment with TAK-186. Based on the results for this cohort additional cohorts for HNSCC and CRC, may be enrolled.
62207242|NCT01357291|EXPERIMENTAL|Recidivism Reduction Program|Inmates who were assigned to the RRP intervention.
62207243|NCT01357291|ACTIVE_COMPARATOR|Business-as-usual|Business-as-usual are those inmates not assigned to RRP and who receive standard inmate programming.
62207244|NCT03218748|EXPERIMENTAL|Honest, Open, Proud|"The group program is about disclosure versus secrecy of one's mental illness. The groups are facilitated by two peers (soldiers with lived experience of mental illness). Each group runs for three weeks, one meeting per week, and two hours per meeting. There is one 2-hour booster session in week 6.~Fidelity to manual: rated by a research assistant who is present during the group session"
62207245|NCT03218748|NO_INTERVENTION|Control group|Treatment as usual (TAU)
62789206|NCT01702246|EXPERIMENTAL|simvastatin|Simvastatin (Zocor), 40mg tablet, 40mg orally once daily, for 3 months
62017277|NCT05937035|OTHER|Customized allogenic bone block|1 group to study
62017278|NCT04223856|EXPERIMENTAL|Arm A|Enfortumab vedotin + pembrolizumab
62017279|NCT04223856|ACTIVE_COMPARATOR|Arm B|Gemcitabine + cisplatin or carboplatin
62789207|NCT00887510|ACTIVE_COMPARATOR|Thiazide First|Participants will receive 25 mg of hydrochlorothiazide (HCTZ) each day for 6 weeks, followed by 25 mg of HCTZ every day plus 4 mg of trandolapril each day for 6 weeks, followed by 4 mg trandolapril each day for 6 weeks.
62017280|NCT06039332|EXPERIMENTAL|Fittig with DSL-BCD|The new way of fitting the audioprocessor
62017281|NCT06039332|ACTIVE_COMPARATOR|Fitting with DSL v5|The way of fitting the audioprocessor until now
62017282|NCT05171569|EXPERIMENTAL|Virtual Care with Remote Automated Monitoring|Patients randomized to the PVC-RAM-3 intervention will take biophysical measurements with the RAM technology, complete a daily recovery survey, complete video visits with a virtual care clinical team, and take wound photos during the 14 days after discharge. If the patient's RAM measurements exceed predetermined thresholds, the patient reports specific symptoms (e.g., shortness of breath), a drug error is identified, or the virtual nurse has concerns about the patient's health that they cannot resolve, the virtual nurse will escalate care to a pre-assigned and available physician.
62017283|NCT05171569|NO_INTERVENTION|Standard Care|Standard post surgical care per treating institution.
62017284|NCT04932265|ACTIVE_COMPARATOR|Red ginseng HRG80|16 subjects will receive 200 mg of red ginseng preparation HRG80 in one capsule
62017285|NCT04932265|EXPERIMENTAL|Red ginseng HRG80 incorporated in gamma-cyclodextrin|16 subjects will receive 200 mg of red ginseng preparation HRG80 incorporated in gamma-cyclodextrin in two chewable tablets
62017286|NCT04120896|EXPERIMENTAL|Karate group|
62017287|NCT04120896|ACTIVE_COMPARATOR|Kung Fu group|
62017288|NCT06396728|EXPERIMENTAL|Consumption of GI BIOTICS 100B UFC|Participants will consume one GI BIOTICS 100B UFC capsule daily for a period of 8 weeks; n=22.
62017289|NCT06396728|PLACEBO_COMPARATOR|Placebo Consumption|Participants will consume one placebo capsule daily for a period of 8 weeks; n=22.
62017290|NCT02766608|EXPERIMENTAL|BFF MDI 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
62017291|NCT02766608|EXPERIMENTAL|BFF MDI 160/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol-80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
62017292|NCT02766608|EXPERIMENTAL|FF MDI 9.6 μg|Formoterol Fumarate Inhalation Aerosol-4.8 μg per actuation MDI/ 120 inhalations Taken as 2 inhalations BID
62207246|NCT01450384|EXPERIMENTAL|Treatment (enzyme inhibitor therapy, antiangiogenesis)|Patients receive pemetrexed disodium IV on day 1 every 2 weeks and sorafenib tosylate PO BID for 4 weeks on days 1-5. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62207247|NCT06728995||Study Population|All participants included in the retrospective study who underwent living-donor kidney transplantation. No interventions were applied as this is an observational study.
62735014|NCT05245682|EXPERIMENTAL|Treatment (tolinapant, radiation therapy)|Patients undergo standard of care radiation therapy for a total of 35 fractions over 7 weeks and receive tolinapant PO daily for 7 days during weeks 1, 3, 5, and 7 of radiation therapy in the absence of disease progression or unacceptable toxicity.
62017293|NCT02766608|EXPERIMENTAL|BD MDI 320 μg|Budesonide inhalation Aerosol 160 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
62017294|NCT02766608|OTHER|Symbicort® TBH 400/12 μg|Symbicort Turbuhaler 400/12 μg Taken as 2 inhalations BID
62017295|NCT05107986||Patients diagnosed with complicated groin hernia|
62017296|NCT04315311|EXPERIMENTAL|CREON|Participants will receive daily dose of CREON.
62207248|NCT03309540|EXPERIMENTAL|experimental group (EGR)|"Physical therapy intervention.~In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises)."
62207249|NCT03309540|SHAM_COMPARATOR|Sham group (SGR)|"Physical therapy intervention.~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze and Evidence Based Practice Therapy. The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
62207250|NCT02782312|EXPERIMENTAL|ICS+LABA Group|Seretide 250，inhalation，twice daily，one year
62207251|NCT02782312|ACTIVE_COMPARATOR|Control Group|routine therapy for one year
62207252|NCT04641676|OTHER|Foundation medicine NGS in parallel with local NGS|The patient will have in parallel FMI NGS test and Local reimbursed NGS test.
62207253|NCT04641676|OTHER|Foundation Medicine NGS|The patient will have only FMI NGS test.
62207254|NCT04641676|EXPERIMENTAL|LB Foundation Medicine NGS test|The patient do not have enough biopsy material or have tumor not accessible for a biopsy will have a liquid biopsy Foundation Medicine test.
62207255|NCT05190783|EXPERIMENTAL|formocresol pulpotomy|gold standard arm which pulpotomy will be done with formocresol
62207256|NCT05190783|ACTIVE_COMPARATOR|formocresol partial pulpotomy|partial pulpotomy will be done with formocresol
62207257|NCT05190783|ACTIVE_COMPARATOR|MTA pulpotomy|in this group complete pulpotomy will be done with MTA
62405870|NCT05081115||Stress Echo for surveillance post-COVID-19 (SECOV).|Cardiovascular abnormalities are observed in half of all COVID-19 patients and may range from RWMA to interstitial lung disease with alveolar capillary distress, global contractile dysfunction, coronary microvascular abnormalities and cardiac autonomic dysfunction. In addition, pulmonary hypertension and valves abnormalities are a possible consequence. The primary aim is to assess the feasibility of an integrated ABCDEFG approach in post-COVID 19 patients. Secondary aim is to prevalence of abnormalities of different SE parameters in populations stratified according to severity of COVID-19. Tertiary aim is to assess the prognostic value of individually considered or combined SE indices in prognostic modeling using traditional risk factors and COVID-19 variables. The relevant parameters related to COVID-19 infection will be collected .SE will be performed from 3 months to 3 years after infection. A sample size of 406 patients is required.
62581360|NCT03389230|EXPERIMENTAL|Arm II (dual delivery Tcm enriched)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tcm cells via intratumoral/intracavitary catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
62789208|NCT00887510|ACTIVE_COMPARATOR|Trandolapril First|Participants will receive 4 mg of trandolapril each day for 6 weeks, followed by 4 mg of trandolapril for 6 weeks plus 25 mg of HCTZ each day for 6 weeks, followed by 25 mg of HCTZ each day for 6 weeks.
62789209|NCT03250182|EXPERIMENTAL|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol per protocol. Administered as 2 inhalations per use as instructed in the protocol.
62789210|NCT00881348|EXPERIMENTAL|Dermacyd infantile (Lactic Acid)|5 weeks treatment
62789211|NCT05512780|EXPERIMENTAL|Dalpiciclib+ letrozole|"Dalpiciclib combined with Letrozole,28 days as one cycle.~1. Dalpiciclib: 150 mg (p.o.) was given once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~2. Letrozole: 2.5mg, p.o., once a day, continuous administration."
62789212|NCT01317901|EXPERIMENTAL|TRU-016+bendamustine+rituximab|Two dose levels (10 and 20 mg/kg) of TRU 016 combined with rituximab 375 mg/m2 and bendamustine 90 mg/m2 were evaluated during up to 6 cycles (28 days each). TRU-016 was administered by intravenous (IV) infusion on Days 1 and 15 of each cycle. Rituximab was administered by IV infusion on Day 2 of each cycle. Bendamustine was administered by IV infusion on Days 1 and 2 of each cycle. Subjects received study treatment for up to 6 cycles.
62207258|NCT05190783|ACTIVE_COMPARATOR|MTA partial pulpotomy|in this study group partial pulpotomy will be done with MTA
62207259|NCT05190783|ACTIVE_COMPARATOR|pulpotomy with Theracal LC|in this study group complete pulpotomy will be done with Theracal LC
62207260|NCT05190783|ACTIVE_COMPARATOR|partial pulpotomy with Theracal LC|in this study group partial pulpotomy technique will be done with Theracal LC
62207261|NCT03764176|ACTIVE_COMPARATOR|Conventional impression|"The intervention of this arm will be conventional impression: polyether impression will be taken with a customized tray."
62207262|NCT03764176|EXPERIMENTAL|Digital impression|"The intervention of this arm will be digital impression: digital impression will be taken using a CS 3600 intraoral scanner ."
62207263|NCT05551325|NO_INTERVENTION|Control|Usual ICU care.
62207264|NCT05551325|EXPERIMENTAL|Chronobundle|The chronobundle will include bright daytime light, time-restricted intermittent feeding, enhanced exercise/mobility, and overnight sleep promotion.
62207265|NCT05692596||All participants|Participants include patients scheduled to see the clinical team in the Pancreas Interception Center (PIC) which will be housed in the Moffitt GI Clinic.
62207266|NCT05060549|EXPERIMENTAL|Cariprazine 1.5 mg|Participants will receive 1.5 mg daily of cariprazine (Vraylar) for six weeks
62207267|NCT05060549|EXPERIMENTAL|Cariprazine 3 mg|Participants will receive 3 mg daily of cariprazine (Vraylar) for six weeks
62405871|NCT05081115||RESURGE: Recovery by stress echo of conventionally unfit donor good hearts.|The primary aim is to recruit hearts from donation which are currently excluded by conventional criteria as aged hearts in patients \> 55 years and ≤ 55 years with multiple risk factors. Secondary aim is to assess outcome in SE-driven transplantation compared to hearts transplanted in the same cardiac surgery centers on the basis of conventional criteria. Tertiary aim is to assess the additional prognostic value of other signs not used for decision-making. These aspects may include diastolic function, preload reserve, coronary microvascular function, and residual innervation of the intrinsic cardiac autonomic system through assessment of HRR in donor heart. In case of donor with age \>55 years o ≤ 55 years but with concomitant ≥ 3 risk factors (diabetes, hypertension, smoking, obesity, hypercholesterolemia) or history of cardiac arrest, the protocol will be applied.
62405872|NCT05081115||SEMIR- Stress echo in ischemic mitral regurgitation|The value of SE testing as an indicator of outcome will be assessed in patients with resting moderate mitral regurgitation (effective regurgitant orifice 0.2-0.39 cm2, and regurgitant volume 30-59 ml) of ischemic origin and angiographically documented CAD, and will enter a regular clinical follow-up program with annotation of cardiovascular and non-cardiovascular endpoints. Patients undergoing CABG with or without mitral repair or PCI with or without mitral valve intervention will be separately analyzed. A sample size of 173 patients per arm (CABG or PCI) is required. The primary hypothesis is that patients with moderate mitral regurgitation worsening of ≥ 1 grade during exercise have worse outcome on medical therapy and greater benefit from valve correction. The secondary hypothesis is that patients with worse SE pre-surgery parameters will have worse prognosis independent of regurgitation severity and treatment (medical therapy or valve repair).
62581361|NCT03389230|EXPERIMENTAL|ARM III (dual delivery Tn/mem enriched)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tn/mem cells via intratumoral/intracavitary catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
62581362|NCT02154503|EXPERIMENTAL|Microneedling|"By randomization, the side for treatment will be determined. Topical anaesthetic will be then placed onto the treatment area under occlusion for thirty minutes to one hour. This will then be removed with 70% alcohol. The area will be rolled with microneedles in two planes: coronally and sagitally. In each plane, five passes will be made. Patients will restart application of Minoxidil the following day to both sides of the lesion.~The same half of the scalp will be treated for the rest of the sessions, with topical anaesthetic applied by patient 30 minutes to an hour prior to start of treatment session. Patients will undergo microneedling on alternate weeks for a total of six treatments in 12 weeks. If there is \>30% growth seen after six weeks, then the entire area will be treated."
62789213|NCT02756117|EXPERIMENTAL|Healthy|"10 Healthy subjects will be enrolled and each will undergo study procedures at one study visit. After screening and consent have been conducted over the phone, subjects will participate in the study procedures. Subjects will arrive in a fasting state (no eat or drink for 8 hours, excluding water). Following collection of blood pressure, height, weight, and a urine and blood sample, subjects will be given an oral bolus of L-lysine (10 g) in 100 ml water. This amount of lysine is equivalent to that which is found in a 10oz. serving of beef. Subjects will provide additional urine and blood samples serially post-ingestion. Because blood draws will be collected through an IV, Normal (0.9%) Saline (NS) will be infused at a rate of 10 ml/hr to flush the canula prior to each blood draw.~All subjects will undergo the same procedures and interventions."
62789214|NCT01898039|EXPERIMENTAL|A2/4-1BBL melanoma vaccine|"On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm.~On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered at the day care unit. On day 14 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed. Four additional doses of the vaccine will be administered at intervals of 21 days."
62207268|NCT04900675|EXPERIMENTAL|bright white light intervention|exposure to 5,000 lux with polychromatic white light with 5,300 Kelvin at eye level; light exposure starts immediately after awakening; light exposure takes place on weekdays (Monday till Friday) over a period of 3 weeks
62581363|NCT06433362|EXPERIMENTAL|CMOEP|Mitoxantrone Hydrochloride Liposome with Cyclophosphamide, Vincristine, Etoposide and Prednisone
62207269|NCT04900675|PLACEBO_COMPARATOR|dim reddish light intervention|exposure to 50 lux with polychromatic reddish light with 2,200 Kelvin at eye level; light exposure starts immediately after awakening; light exposure takes place on weekdays (Monday till Friday) over a period of 3 weeks
62207270|NCT04900675|NO_INTERVENTION|no light intervention|no light intervention takes place in the morning; the study participants follow their natural rhythm of life
62207271|NCT02767336|EXPERIMENTAL|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
62207272|NCT05049135||Sleep apnea group|Patients with undiagnosed suspected sleep apnea who are referred to Levanger Hospital for respiratory polygraphy
62405873|NCT05081115||SEVA: Stress Echocardiography in Valvular Heart Disease|SE is recommended in valvular heart disease in patients characterized by a mismatch between resting transthoracic echocardiography findings and symptoms during exercise or activities of daily living: 1. Severe valve disease without symptoms; 2. Non-severe single- or multi-valve disease with symptoms; and 3. Symptomatic valve disease of indeterminate severity in context of low flow. The primary aim is to evaluate the feasibility of ABCDEFG-SE plus L (left atrium), P (pulmonary vascular reserve) and R (right ventricular function) in these patients. The secondary aim is to assess the correlation of each SE parameter with indices of functional severity (NYHA, cardiac natriuretic peptides, peak oxygen consumption, etc.). The tertiary aim is to assess the prognostic value of SE for prognostic stratification in the long-term. A sample size of about 217 patients per sub-group is required to evaluate the tertiary endpoint with 90% power and an alpha error of 5% .
62405874|NCT05081115||SESPASM - SE for coronary vasospasm|The primary aim is to evaluate the feasibility and safety of hyperventilation and exercise ABCDE-SE in patients with angiographically normal coronary arteries and an intermediate-to-high pre-test probability of coronary vasospasm of epicardial arteries or microvasculature. The secondary aim is to assess the positivity rate of A and D criteria in these patients, compared to standard ECG criteria. The tertiary aim is to assess the prognostic value of the different responses of SE leading to SE-driven therapies. Only patients with strong (Class 1) indication to vasospasm testing according to the recent guidelines will be initially considered. Patients prepared for exercise testing will undergo vasospasm testing in the morning with hyperventilation. If negative or equivocal at 5 minutes after the end of hyperventilation, the patient will start exercise with the usual protocol. A sample size of 513 patients is required with a 5-year follow-up for the composite endpoint.
62405875|NCT01620749|EXPERIMENTAL|MEL050|
62405876|NCT02209220|ACTIVE_COMPARATOR|Automatic positive airway pressure|Automatic positive airway pressure treatment of obstructive sleep apnea
62405877|NCT02209220|ACTIVE_COMPARATOR|Continuous positive airway pressure|Continuous positive airway pressure for the treatment of obstructive sleep apnea
62789215|NCT06233565|PLACEBO_COMPARATOR|Placebo|0.2% ropivacaine for popliteal nerve block
62207273|NCT05049135||Control group|partners of patients with undiagnosed suspected sleep apnea who are referred to Levanger Hospital for respiratory polygraphy
62207274|NCT06533059|EXPERIMENTAL|ALTA2618|ALTA2618 will be administered continuously at a protocol-defined dose based on cohort assignment
62207275|NCT06644924|EXPERIMENTAL|Treatment Sequence 1|Participants will be randomized to 1 of the 6 different treatment sequences. Each treatment sequence consist of Treatment A (Ventolin Evohaler) , Treatment B (Placebo MDI), and Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007).
62207276|NCT06644924|EXPERIMENTAL|Treatment Sequence 2|Participants will be randomized to 1 of the 6 different treatment sequences. Each treatment sequence consist of Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007), Treatment A (Ventolin Evohaler) and Treatment B (Placebo MDI).
62405878|NCT05517291|EXPERIMENTAL|DCB|participants in this group will be received drug-coated balloon angioplasty
62405879|NCT05517291|ACTIVE_COMPARATOR|stenting|participants in this group will be received primary selective stenting
62405880|NCT05749900|EXPERIMENTAL|Trastuzumab+Nivolumab+Gemcitabine+Cisplatin|Trastuzumab+Nivolumab+Gemcitabine+Cisplatin
62789216|NCT06233565|ACTIVE_COMPARATOR|Dexamethasone|0.2% ropivacaine + 0.1mg/kg Dexamethasone for popliteal nerve block
62207277|NCT06644924|EXPERIMENTAL|Treatment Sequence 3|Participants will be randomized to 1 of the 6 different treatment sequences. Each treatment sequence consist of Treatment B (Placebo MDI), Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007), Treatment A (Ventolin Evohaler).
62207278|NCT06644924|EXPERIMENTAL|Treatment Sequence 4|Participants will be randomized to 1 of the 6 different treatment sequences. Each treatment sequence consist of Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007), Treatment B (Placebo MDI), Treatment A (Ventolin Evohaler).
62207279|NCT06644924|EXPERIMENTAL|Treatment Sequence 5|Participants will be randomized to 1 of the 6 different treatment sequences. Each treatment sequence consist of Treatment B (Placebo MDI), Treatment A (Ventolin Evohaler), and Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007).
62207280|NCT06644924|EXPERIMENTAL|Treatment Sequence 6|Participants will be randomized to 1 of the 6 different treatment sequences. Each treatment sequence consist of Treatment A (Ventolin Evohaler), Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007) and Treatment B (Placebo MDI).
62207281|NCT03377699|EXPERIMENTAL|Insulin Degludec|Insulin Degludec once daily and Insulin Aspart 2-4 times daily
62405881|NCT04423289|EXPERIMENTAL|Farmalarm|Farmalarm app for the follow-up
62405882|NCT04423289|NO_INTERVENTION|Control|Regular primary care follow-up
62405883|NCT01678586|ACTIVE_COMPARATOR|True Acupuncture|Pain subjects with radicular pain receiving 6, 30 minute acupuncture treatments.
62405884|NCT01678586|SHAM_COMPARATOR|Sham Acupuncture|Pain subjects with radicular pain receiving 6, 30 minute sham acupuncture treatments.
62405885|NCT01678586|ACTIVE_COMPARATOR|Gabapentin|Pain subjects with radicular pain receiving gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.
62581364|NCT00434616|PLACEBO_COMPARATOR|1|saline injections
62789217|NCT06233565|ACTIVE_COMPARATOR|Dexmedetomidine|0.2% ropivacaine + 0.1ug/kg Dexmedetomidine for popliteal nerve block
62789218|NCT02954393|PLACEBO_COMPARATOR|Control|Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Placebos healing phase TID for 14 days.
62789219|NCT02954393|ACTIVE_COMPARATOR|Active phase|Scaling and root planing + Metronidazole active phase (400 mg/thrice a day,TID) + Amoxicillin active phase (500 mg/ TID) for 14 days and Placebos healing phase TID for 14 days.
62789220|NCT02954393|ACTIVE_COMPARATOR|Healing phase|Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Metronidazole healing phase (400 mg/TID) + Amoxicillin healing phase (500 mg/TID) for 14 days.
62789221|NCT04350996||Continuous alcohol monitoring|Wearable BACtrack Skyn device
62207282|NCT03377699|ACTIVE_COMPARATOR|Insulin Determir|Insulin Determir once daily or twice daily and Insulin Aspart 2-4 times daily
62405886|NCT01678586|SHAM_COMPARATOR|Sham Gabapentin|Pain subjects with radicular pain receiving sham gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.
62405887|NCT03252236|EXPERIMENTAL|Tai Chi|Subjects in this group were trained with Tai Chi exercise. The training lasted for 12 weeks, one hour per session and twice a week. Subjects were asked to practice outside of the class 30 minutes at least once a week.
62405888|NCT03252236|ACTIVE_COMPARATOR|Conventional exercise|Subjects in this group were trained with conventional exercises. Subjects were also asked to practice the exercises outside of the class 30 minutes at least once a week
62405889|NCT03252236|NO_INTERVENTION|Control|No training was given to the subjects in this group
62405890|NCT06549439|EXPERIMENTAL|Intervention|A nominal electron energy of 9 MeV will be used for both Flash-RT and Conv-RT, which guarantees ≥ 90% dose coverage up to a depth of 2.8 cm. Shallower lesions will be treated with the same electron energy and with a bolus. In order to treat these patients, field sizes between 2x2cm2 and 10x10cm2 will be used, which can be delivered with sufficient flatness (\<5%) and symmetry (\<2%) by the FlashTrueBeam v2.7.5.
62405891|NCT04416412||Open Fracture Cohort|"Patients 18 years of age or older. Open extremity fracture. Planned definitive fracture management with external fixation, internal fixation, or joint fusion.~Open fracture wound management that includes formal surgical debridement within 72 hours of their injury.~Will have all planned fracture care surgeries performed by a participating surgeon or delegate.~Provision of informed consent."
62405892|NCT03226782|ACTIVE_COMPARATOR|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
62207283|NCT01555840|OTHER|patients requiring upper GI endoscopy|patients with upper abdominal complaints requiring upper GI endoscopy
62405893|NCT03226782|ACTIVE_COMPARATOR|Long Intervention protocol|"Consisting of 29 exercises to be performed at home. The guideline is to perform each exercise 6 to 8 times in a gentle manner keeping your attention on movement.~This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect."
62405894|NCT01012609|EXPERIMENTAL|pts with high-grade astrocytoma|This is a 2-group parallel (high-grade astrocytoma, diffuse pontine tumor), single stage study investigating cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan in pediatric and young adult patients. Optional exploratory components of the study include (1) correlation of tumor molecular markers with outcome, (2) CSF proteomics, and (3) assay of serum cytokine levels in patients who develop a cetuximab-associated rash.
62405895|NCT01012609|EXPERIMENTAL|pts with diffuse pontine tumor|This is a 2-group parallel (high-grade astrocytoma, diffuse pontine tumor), single stage study investigating cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan in pediatric and young adult patients. Optional exploratory components of the study include (1) correlation of tumor molecular markers with outcome, (2) CSF proteomics, and (3) assay of serum cytokine levels in patients who develop a cetuximab-associated rash.
62405896|NCT03445663|EXPERIMENTAL|AMG 424|Comparison of different dosages of AMG 424
62405897|NCT06522828|EXPERIMENTAL|SSGJ-707(dose 1)+ carboplatin + paclitaxel|
62405898|NCT06522828|EXPERIMENTAL|SSGJ-707(dose 2)+ carboplatin + paclitaxel|
62207284|NCT04548323||Motor Imagery in Sedentary subjects|
62207285|NCT04548323||Motor Imagery active subjects|
62207286|NCT00954187|EXPERIMENTAL|Gabapentin|Neurontin
62207287|NCT00954187|EXPERIMENTAL|Pregabalin|Lyrica
62207288|NCT06727695|ACTIVE_COMPARATOR|Control Group (No BioStrength Training)|Participants in the Active Comparator group will undergo a conventional strength training program using standard gym machines. Training sessions will occur 3 times per week for 12 weeks. The goal is to compare the outcomes of BioStrength training with traditional strength training.
62207289|NCT06727695|EXPERIMENTAL|BioStrength training|Participants in the Intervention Group will undergo BioStrength training using Technogym equipment. The intervention will last for 12 weeks, with sessions conducted 3 times per week
62207290|NCT03745742|OTHER|control|standard rehabilitation protocol according to the personal functional capacities (measured by a cardiopulmonary test on the beginning of the cardiac reeducation.
62017297|NCT05456035|EXPERIMENTAL|Cognitive behavioral therapy plus social cognitive training (CBTSCT)|The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. We will conduct individual therapy with depressed adolescents using modules from the Coping with Stress manual used in other depression treatment studies with adolescents. In addition, therapists will teach teens explicitly about theory of mind and social perspective taking during each session and will use examples from the teen's own life to help them learn the skills.
62207291|NCT03745742|EXPERIMENTAL|study strategy|individualization of the rehabilitation program according to the daily HRV measure and the personal functional capacity (measured by a cardiopulmonary test on the program beginning).
62789222|NCT02611843|EXPERIMENTAL|Peer-Supported Web CBT|Semi-structured brief sessions conducted weekly for the 12 weeks of study treatment by a certified peer support specialist. Sessions focus on helping participants use the skills they are learning in the Web CBT treatment in their daily lives. Web CBT consists of 24 brief (i.e., 20-minute) modules. Participants will be asked to complete two modules per week. Module topics include The Connection Between PTSD and Substance Use, Motivational Enhancement, Relaxation, Identifying, Evaluating and Challenging Automatic Thoughts, Functional Analyses of Substance Use, Substance Use Refusal Skills, Communication, Anger Management, Pain Management, and Insomnia.
62789223|NCT02611843|EXPERIMENTAL|Self-Managed Web CBT|Self-managed Web CBT consists of 24 brief (i.e., 20-minute) modules. Participants will be asked to complete two modules per week. Module topics include The Connection Between PTSD and Substance Use, Motivational Enhancement, Relaxation, Identifying, Evaluating and Challenging Automatic Thoughts, Functional Analyses of Substance Use, Substance Use Refusal Skills, Communication, Anger Management, Pain Management, and Insomnia.
62789224|NCT01178099|EXPERIMENTAL|Prasugrel|Participants received a single 10 milligram (mg) dose on Day 1 (single dose \[SD\]), followed by either 5 mg/day (for participants\<60 kilograms \[kg\]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose \[MD\]).
62789225|NCT04063163|EXPERIMENTAL|A|HLX 10+chemotherapy (Carboplatin-Etoposide)
62789226|NCT04063163|PLACEBO_COMPARATOR|B|Placebo+chemotherapy (Carboplatin-Etoposide)
62789227|NCT00432341|EXPERIMENTAL|BOTOX®|Botulinum toxin type A (BOTOX®)
62789228|NCT00432341|ACTIVE_COMPARATOR|Dysport®|Botulinum toxin type A (Dysport®)
62789229|NCT01858766|EXPERIMENTAL|SOF+VEL 25 mg 12 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
62789230|NCT01858766|EXPERIMENTAL|SOF+VEL 100 mg 12 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
62789231|NCT01858766|EXPERIMENTAL|SOF+VEL 25 mg 12 Weeks (GT2/4/5/6)|Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
62017298|NCT05456035|ACTIVE_COMPARATOR|Cognitive behavioral therapy (CBT)|The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. Therapists will conduct individual therapy sessions with depressed adolescents using modules from the Coping with Stress manual. Social cognitive training will not be provided to teens in this condition.
62207292|NCT06307106|EXPERIMENTAL|group A: ketorolac and light marcaine injection|
62207293|NCT06307106|EXPERIMENTAL|group B: light marcaine injection|
62207294|NCT06307106|EXPERIMENTAL|group C: corticosteroids injection|
62207295|NCT06307106|EXPERIMENTAL|group D: topical diclofenac sodium|
62207296|NCT06331468|EXPERIMENTAL|Cisplatin with concurrent Intensity Modulated Radiotherapy and Brachytherapy|"Cisplatin two (2) one-time weekly intravenous infusions at 40 mg/m2 (70mg maximum)~IMRT once daily, four fractions per week for 2 weeks 4.56 Gy x 8 fractions~High dose rate Brachytherapy twice per week with a 2-day break in between sessions for a total of four brachytherapy treatments. The dose is 7 Gy x 4 fractions"
62207297|NCT06633926|EXPERIMENTAL|Ayurveda and Usual Care (AVI)|Participants receive usual care on study. Participants also receive nutrition education, lifestyle recommendations, and participate in yoga, as well as marma therapeutic touch during one-on-one AVI visits over 1-2 hours for up to 14 visits over 6 months. After 6 months, participants may also complete a videoconference visit over 30 minutes once monthly for 6 months.
62207298|NCT06633926|EXPERIMENTAL|Health Education and Usual Care (HEI)|Participants receive usual care on study. Participants also attend online HEI sessions over 1 hour each for up to 15 sessions over 6 months.
62207299|NCT02555839||Pomalidomide and Dexamethasone|Pomalidomide 4mg capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (\>75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity
62405899|NCT06522828|EXPERIMENTAL|SSGJ-707(dose 3)+ carboplatin + paclitaxel|
62789232|NCT01858766|EXPERIMENTAL|SOF+VEL 100 mg 12 Weeks (GT2/4/5/6)|Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
62789233|NCT01858766|EXPERIMENTAL|SOF+VEL 25 mg 12 Weeks (GT3)|Participants with genotype 3 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
62789234|NCT01858766|EXPERIMENTAL|SOF+VEL 100 mg 12 Weeks (GT3)|Participants with genotype 3 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
62789235|NCT01858766|EXPERIMENTAL|SOF+VEL 25 mg 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 8 weeks.
62789236|NCT01858766|EXPERIMENTAL|SOF+VEL 25 mg + RBV 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.
62017299|NCT03855215|EXPERIMENTAL|Intervention|"The ACTIM CRP Rapid Test (Medix, Biochemica) will be made available to the healthcare workers at the CHCs for use in patients in the target population.~Printed guidance will be issued for the performance and interpretation of the CRP test results in terms of antibiotic guided treatment. The treating healthcare worker will decide based on their clinical evaluation whether or not to comply with this guideline. This guidance will also be discussed during the training sessions.~The healthcare workers are recommended to use the CRP tests in all patients meeting the target population. The CRP cut-offs will be recommended below in the absence of warning signs of severity:~CRP level \< 10 mg/L: no antibiotics are recommended CRP level from 10 mg/L to 40 mg/L: antibiotics are unlikely to be needed but should be considered in cases of high clinical concern CRP level \> 40 mg/L: antibiotics are recommended."
62017300|NCT03855215|NO_INTERVENTION|Control|Working as routine
62207300|NCT02555839||Pomalidomide, Bortezomib and Dexamethasone|Cycle 1-8: Pomalidomide 4mg capsules by mouth (PO) on days 1 through 14 of a 21 day cycle, Bortezomib (1,3mg/m2) s.c. on day 1, 4, 8, 11 of a 21 day cycle, and Dexamethasone 20mg PO (≤75 years) or 10mg (\>75years) on Days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle until progression or unacceptable toxicity; from cycle 9 onwards: Pomalidomide 4mg capsules by mouth (PO) on days 1 through 14 of a 21 day cycle, Bortezomib (1,3mg/m2) s.c. on day 1 and 8 of a 21 day cycle, and Dexamethasone 20mg PO (≤75 years) or 10mg (\>75years) on Days 1, 2, 8, 9 of a 21 day cycle until progression or unacceptable toxicity
62207301|NCT06729567||Parturients given spinal block with conventional dose of bupivacaine for cesarean delivery|Using electronic hospital database we will identify cases of cesarean section. Initially, all cases of cesarian delivery under spinal anesthesia will be identified. After that, manual review of the anesthetic charts will follow. Detailed data on anesthetic technique will be retrieved and cases where conventional dose of hyperbaric bupivacaine was used will be included in further analysis. Further review of the charts will provide demographic data of the parturients, data on vital signs during anesthesia and dynamic of sensory block level. Attention will be paid to assure that identification of the patient would not be possible with data used in this study. All identifiable data used in data retrieval process and analysis will be accessible only for investigators.
62207302|NCT02810704|EXPERIMENTAL|Arm 1: Enteric Coated Aspirin|Enteric coated aspirin (162 mg po) will be administered on the day of operation, prior to surgery, with a sip of water. Thereafter, starting on postoperative day #1, all patients in the aspirin group will receive 81 mg po bid to complete the treatment period of 30 days. Patients on preoperative cardiac dose aspirin may continue their usual dosing regimen prior to the morning of surgery, and then commence the PEPPER trial aspirin dose of 81 mg po bid on the day after operation.
62405900|NCT06522828|EXPERIMENTAL|SSGJ-707(dose 4)+ paclitaxel|
62405901|NCT04635956|EXPERIMENTAL|Study group|Patients will accept therapy consisting of platinum/etoposide/bevacizumab/camrelizumab
62405902|NCT03602846||Good Outcome|Good outcome is defined as the safe delivery of the newborn.
62405903|NCT03602846||Poor Outcome|Poor outcome is defined as the incidence of fetal demise during pregnancy.
62405904|NCT04536818||Time to surgery ≤12 hours|Waiting time to surgery ≤12 hours from hospital presentation.
62405905|NCT04536818||Time to surgery >12 hours|Waiting time to surgery \>12 hours from hospital presentation.
62789237|NCT01858766|EXPERIMENTAL|SOF+VEL 100 mg 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 8 weeks.
62789238|NCT01858766|EXPERIMENTAL|SOF+VEL 100 mg + RBV 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.
62789239|NCT01858766|EXPERIMENTAL|SOF+VEL 25 mg 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg for 8 weeks.
62405906|NCT04898946||BNT162b2|Subjects who receive mRNA vaccine BNT162b2.
62789240|NCT01858766|EXPERIMENTAL|SOF+VEL 25 mg + RBV 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.
62405907|NCT04898946||CoronaVac|Subjects who receive inactivated vaccine, CoronaVac.
62405908|NCT04588740|ACTIVE_COMPARATOR|Dietary nitrate|The active treatment, beetroot juice (BEET IT, James White Drinks, Ipswich, UK), contains 6.2mmol of inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
62789241|NCT01858766|EXPERIMENTAL|SOF+VEL 100 mg 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg for 8 weeks.
62789242|NCT01858766|EXPERIMENTAL|SOF+VEL 100 mg + RBV 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.
62789243|NCT01578655|EXPERIMENTAL|Cabazitaxel plus Custirsen|cabazitaxel, prednisone, and custirsen sodium
62789244|NCT01578655|ACTIVE_COMPARATOR|Cabazitaxel|cabazitaxel and prednisone
62405909|NCT04588740|PLACEBO_COMPARATOR|Placebo|The placebo beet root juice is made by the same company (BEET IT, James White Drinks, Ipswich, UK) and contains no inorganic nitrate.
62581365|NCT00434616|ACTIVE_COMPARATOR|2|autologous bone marrow transplantation into the ischemic leg
62581366|NCT02531776|EXPERIMENTAL|Subcutaneous insertions of needles|36 subcutaneous needle insertions per participant with 18 differently designed needles. 30test participants in total. No fluid will be injected. Pain perception will be rated by the subjects, penetration force and skin blood perfusion will be measured, and any skin reactions will be assessed.
62405910|NCT03740126|EXPERIMENTAL|Arm A, PET/CT|18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) replacing computed tomography (CT) at months 6, 12, 18 and 24, otherwise as B with CT scan months 9, 15 and 21. Quality of life assessment and liquid biopsy every 3 months for later analysis.
62405911|NCT03740126|NO_INTERVENTION|Control arm B|CT-scan and clinical evaluation every 3 months. Quality of life assessment and liquid biopsy at every 3 months for later analysis.
62405912|NCT05428306|EXPERIMENTAL|Group A: Ibuprofen/ Acetaminophen in fixed dose|Pharmaceutical Form: Tablet Formula: Ibuprofen 200 mg/ Acetaminophen 500 mg Dosage: 400 mg / 1000 mg (2 tablets) Administration way: oral
62405913|NCT05428306|ACTIVE_COMPARATOR|Group B: Ibuprofen|Pharmaceutical Form: tablets Dosage: 400 mg (1 tablet) Administration way: oral
62405914|NCT05428306|ACTIVE_COMPARATOR|Group C: Acetaminophen|Pharmaceutical Form: Tablet Formula: Acetaminophen 500 mg Dosage: 1000 mg (2 tablets) Administration way: oral
62405915|NCT05458791||Standard Dose Intra-arterial Perfusion|All patients will undergo standard of care interventional treatment for liver cancer. The procedure will take place utilizing fluoroscopic and CT guidance. During their procedure, patients will have intra-arterial CT perfusion maps derived of the liver including the region of the tumor. (n=10)
62405916|NCT05458791||Low Dose Intra-arterial Perfusion|Investigate the impacts on contrast and radiation doses and the robustness of reconstruction algorithms on intra-arterial CT perfusion using a lower radiation dose technique. (N=10)
62405917|NCT02008955|EXPERIMENTAL|lysine intake at different levels of intake|all subjects will receive all 7 of the lysine test levels, assigned in random order.
62405918|NCT02900157|EXPERIMENTAL|MEDI9090|
62405919|NCT05549271||Obese patients who underwent a Laparoscopic One Anastomosis Gastric Bypass (OAGB) 5 years ago|Patients (BMI \> or = 35kg/m2 +/- co-morbidities) who have been operated on using the Gastric bypass procedure built with an Omega loop of 200 cm and a unique gastro-jejunal anastomosis
62405920|NCT05549271||Obese patients who underwent a Laparoscopic Roux-en-Y Gastric ByPass (RYGBP) 5 years ago|Patients (BMI \> or = 35kg/m2 +/- co-morbidities) who have been operated on using the Roux-en-Y gastric bypass which consists in a small gastric pouch (30cc), a 150cm alimentary limb and a 50cm biliary limb. Mesenteric defects were closed.
62581367|NCT05731856|EXPERIMENTAL|Apollo Intervention Arm|Eligible UPMC Physicians and Residents who consent to be part of this study will use an Apollo Device TVS (10-200 Hz) attached to the subject's wrist or ankle via a commercially available wearable vibration technology that can deliver TVS (Transcutaneous Vibratory Stimulation). The intensity will be targeted for the sensory threshold (the level at which the vibration is just noticeable), as this is where the TVS seems most effective from prior studies. Similar vibratory stimuli have been demonstrated to be safe in the literature. The intensity of the vibration will be adjusted to the subjects' comfort and can be controlled by the subject at any time.
62405921|NCT01151501|EXPERIMENTAL|noninvasive positive pressure ventilation|
62581368|NCT06683196|EXPERIMENTAL|Study Group|All interventions applied to all of the participants.
62581369|NCT02700373|EXPERIMENTAL|PDC-APB|"PDC-APB Intra-Muscular (IM)~One single dose will be administered with an inpatient direct observational period of 24 hours following the dose, followed by outpatient follow-up for a total of 28 days. After Day 28, the subject will continue to be followed up for study related AE assessments thru Week 24."
62581370|NCT02700373|PLACEBO_COMPARATOR|Placebo|"Placebo~One single dose will be administered with an inpatient direct observational period of 24 hours following the dose, followed by outpatient follow-up for a total of 28 days. After Day 28, the subject will continue to be followed up for study related AE assessments thru Week 24."
62735015|NCT05792982||Fasting Adult Males|A questionnaire was administered in order to determine individuals' general characteristics, nutrition habits, and smoking and alcohol habits. Anthropometric measurements, 24 hours dietary recall and physical activities were recorded and blood samples were taken four times in following periods; before Ramadan, first week of Ramadan, third week of Ramadan and two weeks after Ramadan.
62735016|NCT00496678|EXPERIMENTAL|Navigation|Navigation through the cancer care system is the intervention
62735017|NCT00496678|ACTIVE_COMPARATOR|Standard of Care|Cancer patient receives standard of care.
62017301|NCT01778465|EXPERIMENTAL|Low salicylate diet, then Normal Diet|Patients followed a low salicylate diet for one week, then they followed a Normal diet for another week.
62405922|NCT02675881|ACTIVE_COMPARATOR|RFA DSM|Eligible patients who undergo RFA using DSM and separable clustered electrodes.
62789245|NCT00262899|EXPERIMENTAL|Rapid genetic counseling|Following randomization, participants will be informed about whether they are assigned to Usual Care (UC) or Rapid Genetic Counseling (RGC). Participants in the UC arm can schedule a genetic counseling appointment at any time during the study if they wish. Participants in the RGC agree to obtain genetic counseling as soon as possible, before they make a definitive surgery decision. RGC can be accomplished by telephone or in-person. The RGC intervention is delivered by highly experienced genetic counselors at each site. This counseling is identical to our standard genetic counseling procedure for newly diagnosed patients. Immediate DNA collection via blood or buccal cell collection is available following counseling. Phone counseling participants will be been mailed a kit for DNA collection or have the option of having the sample collected at at LCCC.
62207303|NCT02810704|EXPERIMENTAL|Arm 2: Warfarin Other Names: Coumadin|Warfarin will be administered starting on the day of operation, prior to surgery, with a sip of water. The initial dose will be empirically determined by body weight: less than 125 lbs (56.7 kg) - 2.5 mg; 125-250 lbs (56.7-113.4 kg) - 5 mg; greater than 250 lbs (113.4 kg) - 7.5mg. The initial dose will be repeated on the evening of surgery if the preoperative dose was administered prior to noon on the day of operation; no warfarin will be given on the evening of surgery if the preoperative dose was received after noon on the day of operation. Thereafter, starting on postoperative day #1, warfarin will be given each evening based on INR values to achieve a target of 2.0 (range 1.7-2.2).
62405923|NCT02675881|NO_INTERVENTION|RFA SSM|Historical control group consisted of patients underwent RFA in our institution with single switching mode (SSM) and single/ or multiple clustered electrodes.
62405924|NCT01096017|EXPERIMENTAL|1|Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI ⇒salbutamol pMDI 200 μg +placebo Turbuhaler®
62405925|NCT01096017|EXPERIMENTAL|2|salbutamol pMDI 200 μg +placebo Turbuhaler® ⇒Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI
62405926|NCT05102162|ACTIVE_COMPARATOR|Continuous Antibiotic Dose Over 24 hours Arm|Subjects will be receiving a continuous dose of antibiotic prescribed by their doctor for the duration they choose.
62405927|NCT05102162|ACTIVE_COMPARATOR|Intermittent Antibiotic Dose Over 30 minutes|Subjects will be receiving an intermittent dose of antibiotic prescribed by their doctor for the duration they choose.
62789246|NCT00262899|NO_INTERVENTION|Usual Care|Usual Care (UC) for newly diagnosed breast cancer patients does not typically include a pre-surgical genetic referral. These patients may obtain genetic counseling at their own discretion.
62017302|NCT01778465|EXPERIMENTAL|Normal diet, then Low Salicylate diet|Patients followed a Normal diet for one week, then they followed a Low Salicylate diet for another week.
62017303|NCT02349711|PLACEBO_COMPARATOR|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
62017304|NCT02349711|EXPERIMENTAL|Probiotic mixture|A commercially available probiotic mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
62017305|NCT03077282|EXPERIMENTAL|group1|Group1 will take Prasaprohyai 95% ethanolic extract capsules at a dose of 100 mg three times a day before meals (for 6 weeks)
62017306|NCT03077282|EXPERIMENTAL|group2|Group2 will take Prasaprohyai 95% ethanolic extract capsules at a dose of 200 mg three times a day before meals (for 6 weeks)
62017307|NCT01469676|NO_INTERVENTION|Control group|In the Control group, a standard arterial line filter was inserted on CPB circuit.
62017308|NCT01469676|EXPERIMENTAL|Filtering Group|In the Filtering group, a leukocyte filter was inserted in the arterial line circuit.
62017309|NCT02207868||no treatment|
62789247|NCT03877302|EXPERIMENTAL|reflexology group|In addition to providing routine nursing/midwifery care, foot reflexology was applied by the researcher to the pregnant women in the experimental group in the active phase of labor (dilatation 4 cm). By giving appropriate position to the pregnant women, the massage was done to both feet for totally 10 minutes including 5 minutes for each foot starting from right foot under the supervision of a doctor. Whereupon, the reflexology technique was applied by stimulating the nerve points by applying pressure to reflex regions of each foot for 20 minutes as totally 40 minutes for both feet. As reflex points of the feet for manual pressure in labor pain; 1: Solar Plexus, 2: Hypothalamus, 3: Pituitary, 4: Spleen, 5: Thyroid Gland, 6: Adrenal, 7: Intestine, 8: Spinal Cord 9: Uterus, Vagina, Ovaries and Fallopian Tubes were studied.
62789248|NCT03877302|NO_INTERVENTION|Control Group|The control group received only routine treatment, care, and practices of the hospital. Visual Analog Scale (VAS) and State-Trait Anxiety Inventory (STAI FORM TX-I) were evaluated 2 times as in active (4-7 cm) and transition (8-10 cm) phases in the pregnant women in the control group. After the delivery, the Birth Satisfaction Scale was applied to the women by the researcher.
62789249|NCT04298957|OTHER|See and treat|Cone biopsi is offered to women age ≥ 45 years referred to Department of Obstetrics and Gynecology due to a positive cervical screening test and partly or invisible transformation zone.
62789250|NCT04368780|NO_INTERVENTION|Control group|Individuals who provide home care to an elderly person who is dependent on the bed
62789251|NCT04368780|EXPERIMENTAL|Experimental group|Individuals who provide home care to an elderly person who is dependent on the bed. It is planned that the exercises will be conducted two days a week with the researcher and on the other days by the caregiver herself for a total of eight weeks.
62789252|NCT04869969|EXPERIMENTAL|supine percutaneous nephrolithotomy|percutaneous nephrolithotomy to be done in the supine position
62017310|NCT01184352||PCI patients treated with Glider Device|
62207304|NCT02810704|EXPERIMENTAL|Arm 3: Rivaroxaban Other Names: Xarelto|Rivaroxaban 10 mg will be first administered approximately 24 hours after completion of the index operation. Medication will then be administered in the evening on postoperative day #2 and thereafter each evening until completion.
62735018|NCT04142138|EXPERIMENTAL|nutrition implementation|Volunteers with prehypertension, but otherwise healthy, will complete a screening visit, then be admitted to the In-Patient Unit for fourteen (14) days. Participants will be admitted for 5 days during the week and then go on pass for 2 weekend days each week with packed DASH diet meals. During hospitalization we will: 1) collect samples of blood and urine daily 2) monitor blood pressure, weight and pulse twice daily 3) collect 24-hour urine, twice during the period of two weeks 4) serve participants a menu based on DASH principles, namely low in sodium and high in potassium.
62735019|NCT00005289||1988-1991|
62789253|NCT04869969|ACTIVE_COMPARATOR|prone percutaneous nephrolithotomy|percutaneous nephrolithotomy to be done in the prone position
62789254|NCT04139850||Korean chronic hepatitis B patients cohort|Korean patients with chronic hepatitis B with or without antiviral therapy on a regular follow-up in tertially medical institution
62789255|NCT03069157|NO_INTERVENTION|Without lung recruitment maneuver|patient ventilation will be maintained After induction of anesthesia all patients will be ventilated using pressure controlled mode targeting tidal volume 6-8 ml/kg with inspiratory to expiratory ( I: E) ratio 1:1.5 without recruitment but with PEEP 5cm H2O.
62789256|NCT03069157|ACTIVE_COMPARATOR|recruitment group|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O.
62789257|NCT04967404|EXPERIMENTAL|Phosphatidylserine, 800 mg per day, 10 days|
62789258|NCT04967404|PLACEBO_COMPARATOR|Maltodextrin, 800 mg per day, 10 days|
62017311|NCT03551652||Young patients|Patients aged 18 - 50 years
62017312|NCT03551652||Geriatric patients|Patients aged ≥ 80 years
62017313|NCT02211833|EXPERIMENTAL|BI 2536 with pemetrexed|combination therapy phase may be followed by BI 2536 monotherapy for eligible patients
62017314|NCT03460340|EXPERIMENTAL|FM group|patients diagnosed with Fibromyalgia receiving dTMS treatment.
62017315|NCT03460340|SHAM_COMPARATOR|placebo group|patients diagnosed with Fibromyalgia receiving sham- treatment.
62207305|NCT04108143|EXPERIMENTAL|Intervention|MonitorMe device
62207306|NCT00198276|EXPERIMENTAL|Bleomycin|Bleomycin 4.0 U/mL at dose of 1 U/cm\^3 of treatment area; Medpulser EP
62207307|NCT04981795||1|Group 1: Racial and ethnic minority patients (at least 50 patients)
62207308|NCT04981795||2|Group 2: Non Hispanic White (NHM) patients (at least 50 patients)
62405928|NCT06533410||chronic widespread pain|
62405929|NCT06533410||Fibromyalgia|
62405930|NCT00031096|EXPERIMENTAL|Arm 1|
62405931|NCT00031096|PLACEBO_COMPARATOR|Arm 2|
62735020|NCT00005289||2003-2004|
62789259|NCT01884272|EXPERIMENTAL|Lesinurad 400 mg and naproxen 250 mg|Lesinurad once daily (qd) Day 1, naproxen twice daily (bid) Day 2-6, lesinurad qd with naproxen bid Day 7-14.
62789260|NCT01884272|ACTIVE_COMPARATOR|Lesinurad 400 mg and indomethacin 25 mg|Lesinurad qd Day 1, indomethacin bid Day 2-6, lesinurad qd with indomethacin bid Day 7-14.
62789261|NCT03623568|EXPERIMENTAL|Treatment with Mavyret (glecaprevir/pibrentasvir) for HCV|12 weeks of treatment with Mavyret
62581371|NCT00619892|ACTIVE_COMPARATOR|Quetiapine XR|Our target daily dose for quetiapine XR was 200 mg/day. The detailed quetiapine XR dosing guidelines were as follows: 50 mg 1 tab po at HS × 3 days, then, if 50 mg tolerated, increase to 50 mg 2 tabs at HS × 4 days; at the beginning of week 2, if the last dose was tolerated increase to 50 mg 3 tabs at HS × 3 days, then, if 150 mg tolerated, increase to 4 tabs at HS; at the beginning of week 3, if no efficacy \& the 200 mg dose was well tolerated, increase to one 300 mg tab at HS-otherwise remain at 200 mg one tab at HS; at week 4 if still no improvement, \& 300 mg was tolerable, increase to 200 mg tablet 2 at HS. From the beginning of week 5 to the end of the trial, quetiapine XR doses were held. We used quetiapine XR tablets provided by Astra Zeneca (50, 200, and 300 mg designations).
62581372|NCT00619892|PLACEBO_COMPARATOR|Placebo|Subjects received identical-appearing placebo tablets provided by Astra Zeneca (50, 200, and 300 mg designations).
62581373|NCT05231746|EXPERIMENTAL|hSTC810|6 escalating doses of hSTC810 will be administered to participants
62581374|NCT01259622|PLACEBO_COMPARATOR|placebo|
62581375|NCT01259622|EXPERIMENTAL|K201|intravenous K201
62789262|NCT06125782|ACTIVE_COMPARATOR|Omega-3 fatty acid|One Omega-3 fatty acid softgel capsule 1 gm for children at or below 25 kg and two Omega-3 fatty acid softgel capsule above 25 kg. In this intervention arm having 32 participants, half will have plasma Omega 3 fatty acid level within reference value and rest half below reference value.
62789263|NCT06125782|PLACEBO_COMPARATOR|Placebo|Placebo softgels having almost same color and shape, one softgel for children at or above 25 kg and two softgels for children above 25 kg. In this placebo arm having 32 participants, half will have plasma Omega 3 fatty acid fatty acid level within reference value and rest half below reference value.
62017316|NCT03550963|OTHER|rice-richen meal|All participants included in the study will be randomized assigned into one of two groups in parallel, the rice-richen meal group and wheaten-richen meal group. The intervention of group one is that participants will be provided with rice-richen meal, meaning most of the calculated carbohydrates are from rice.
62207309|NCT05452174|EXPERIMENTAL|Mirtazapine Treatment Arm|Subjects will be administered the initial dose of mirtazapine, with dosage progressively increased over the course of the study. The initial dose of mirtazapine is 15 mg tablet, once per day. The dose will be increased weekly as tolerated up to 45 mg per day. The dose will be increased by 15 mg each week if the lower dose is tolerated without significant side effects. That is to say, the subject will take 15 mg/day every day for the first week, 30 mg/day every day for the second week, and 45 mg/day every day for the third week, with the option of the subject continuing the medication for the remainder of the pregnancy. If subjects choose to discontinue the mirtazapine, there will be a tapering regimen: if a patient is taking 45 mg at the end of week 3, they will begin a taper (by week) of 30 to 15 to 7.5 to 0 mg. If they relapse or has discontinuation symptoms, the previous effective dose will be given. They may attempt to taper again with the same approach.
62581376|NCT06186700|ACTIVE_COMPARATOR|Pentoxifylline group|the patient will take 400 mg orally Pentoxifylline 3 tablets per day starting from the first day of the first cycle of doxorubicin/cyclophosphamide till finishing the fourth cycle
62017317|NCT03550963|OTHER|wheaten-richen meal|All participants included in the study will be randomized assigned into one of two groups in parallel, the rice-richen meal group and wheaten-richen meal group.The intervention of group two is that participants will be provided with wheaten-richen meal, meaning most of the calculated carbohydrates are from wheaten.
62581377|NCT06186700|PLACEBO_COMPARATOR|Control group|the patient will take placebo tablets three times per day, starting from the first day of the first cycle of doxorubicin/cyclophosphamide till finishing the fourth cycle
62581378|NCT05313568|ACTIVE_COMPARATOR|static stretching group|The stretch will be done by placing both feet on a raised platform, lowering the heel off the platform without touching the ground, and held in this position to perform a static stretch. They will perform 5 repetitions, 15 seconds of rest and 1 minute of stretching.
62581379|NCT05313568|EXPERIMENTAL|self massage group|In addition to the self-stretching application, plantar self-massage will be applied. Plantar self massage will be shown to the participants by the physiotherapist with a 7 cm spiky massage ball. Then, participants will be asked to self-massage the plantar sole of the foot for 5 minutes with a 7 cm spiky massage ball.
62581380|NCT05313568|EXPERIMENTAL|Manual Stimulation Group|"In addition to the self-stretching application, manual stimulation will be applied.~Manual protocol:~A) Pressure will be applied in each interdigital space and on the longitudinal arch with shear in the longitudinal direction (5 repetitions of 10 seconds each).~B) Pressure with transverse shear on the metatarsal heads (5 repetitions of 5 seconds each) C) Static pressure will be applied to the first and fifth metatarsal head, center of the midfoot, and heel (5 repetitions per 10-second period each)."
62581381|NCT06414395|EXPERIMENTAL|The Dexmedetomidine Group D1|D1 group will receive 1µg.kg as a loading dose over 10 minutes, followed by maintenance 0.5 µg.kg.
62581382|NCT06414395|EXPERIMENTAL|The Dexmedetomidine Group D 0.5|D 0.5 group will receive 0.5 µg.kg as a loading dose over 10 minutes, followed by maintenance 0.5 µg.kg
62581383|NCT06414395|EXPERIMENTAL|The Dexmedetomidine Group D0.25|D 0.25 group will receive 0.25 µg.kg as a loading dose over 10 minutes, followed by maintenance 0.5 µg.kg
62581384|NCT06414395|PLACEBO_COMPARATOR|The Dexmedetomidine Group D 0|D 0 group will receive a placebo saline infusion over 10 minutes and then will receive 50 ml of normal saline as a placebo
62207310|NCT00383110||Group 1|Adults (age 18 or older) with type 2 diabetes.
62207311|NCT05467293|ACTIVE_COMPARATOR|0.3% YP-P10 Ophthalmic Solution|
62207312|NCT05467293|ACTIVE_COMPARATOR|1% YP-P10 Ophthalmic Solution|
62207313|NCT05467293|PLACEBO_COMPARATOR|YP-P10 Placebo Ophthalmic Solution (vehicle)|
62207314|NCT03588559|EXPERIMENTAL|BPM, TMB-1591-A-002 and Reference Device|DUT: Transtek Blood Pressure Monitor TMB-1591-A-002 Reference Device: Baumanometer Desk Mercury Sphygmomanometer. Blood Pressure Measurement with the Transtek BPM TMB-1591-A-002 and with reference device.
62207315|NCT05877898|NO_INTERVENTION|No strategy|Individuals assigned to this arm with receive a publicly available color copy of the NIH's Healthy Blood Pressure for Healthy Hearts: Small Steps to Take Control Flyer available
62207316|NCT05877898|EXPERIMENTAL|Community health worker provided education|Participants will be invited to meet with the CHW to learn about eating healthier to reduce blood pressure and enhance quantity and quality of life. The CHW will register individuals for SNAP benefits and educate them on how to use their benefits locally. As other resources exist, including food pantries, food distribution events, and Fresh Access Bucks (a federal program to double SNAP if spent on local produce at eligible farmers markets), the CHW will provide information on these services. The CHW will also provide a brief motivational educational session about eating healthier to reduce BP and enhance quality and quantity of life. The CHW will meet once for up to one hour with each participant.
62405932|NCT03938454|EXPERIMENTAL|Crizanlizumab|5 mg/kg by intravenous infusion at Week 1 Day 1, Week 3 Day 1 and Day 1 of every 4-week cycle until Week 51
62405933|NCT04434612|EXPERIMENTAL|OXSIGHT smart glasses|Wearing OXSIGHT smart glasses
62405934|NCT01286896|EXPERIMENTAL|Sunitinib|Sunitinib is administered in oral capsules of 12.5 mg. Patients will start with a continuous once-daily dose of 37.5 mg.
62581385|NCT05162287||Patients who are treated in the acute ward of the child and adolescent psychiatry|All children and adolescents aged 12 to 18 years who are treated in the acute ward of the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics at the University Medical Center Hamburg-Eppendorf are recruited.
62581386|NCT06575335|EXPERIMENTAL|Triphala Tooth Wipe|The three fruits of triphala (Terminalia chebula, Emblica officinalis and Terminalia bellerica) will be bought in powder form from an herbal drug vendor. A mixture will be made by combining equal proportion of all these three powders in distilled water. This will then be boiled till the volume reduces to 1/8th part of the initial volume. A sweetener will be added to the decoction followed by filtering using a white muslin cloth and then storing in a sterile amber-coloured glass bottle in a refrigerator. The decoction obtained will be subjected to dilution to obtain 0.6% concentration. This will then be used to impregnate the marketed tooth wipes fabric. The triphala tooth wipes will be cut, folded individually, and then packed. Each pack will contain 16 wipes.
62789264|NCT06468189|EXPERIMENTAL|tDCS|tDCS Interictal application will be performed during the attack-free period. Experimental group, 3 consecutive sessions, cathodal to occipital cortex (O1 or O2, ipsilateral); anodal to M1 (left)
62789265|NCT06468189|SHAM_COMPARATOR|Sham|Control group, 3 consecutive sessions of sham stimulation to the same locations.
62405935|NCT02788890|ACTIVE_COMPARATOR|Control Group (T0)|The supragingival scaling without LA
62789266|NCT05990361||women with pelvic girdle pain|The subjects who have at least one positive result from Active Straight Leg Raise, and Posterior Pelvic Pain Provocation Tests; and at least two positive results from the Pelvic Compression and Distraction, Patrick Faber, Gaenslen and Long Dorsal Sacroiliac Ligament Palpation tests are classified as with PGP group.
62405936|NCT02788890|EXPERIMENTAL|Test Group 1 (T1)|The simple restoration under LA
62405937|NCT02788890|EXPERIMENTAL|Test Group 2 (T2)|The simple exodontia under LA
62405938|NCT02183168|EXPERIMENTAL|Meloxicam suppository|
62405939|NCT02183168|EXPERIMENTAL|Meloxicam tablet|
62405940|NCT02183168|ACTIVE_COMPARATOR|Indomethacin suppository|
62405941|NCT03959748||PAH adults|Patients with pulmonary arterial hypertension who are at least 18 years old at study entry
62405942|NCT03959748||PAH children|Patients with pulmonary arterial hypertension who are at least 3 months old and are less than 18 years old at study entry
62405943|NCT03959748||CTEPH|Patients with chronic thromboembolic pulmonary hypertension who are at least 18 years old at study entry
62017318|NCT04049994|EXPERIMENTAL|Immunomodulation|Lyophilized lysate of 18 E. coli strains (6 mg) for oral application. A treatment lasts 90 days (one capsule daily).
62017319|NCT04049994|PLACEBO_COMPARATOR|Placebo|Oral placebo tablet once daily for 90 days.
62017320|NCT03142074||Ascending thoracic aortic aneurysm|"Biomechanical and microstructural analysis of ATAA~ECG-gated CT"
62017321|NCT04150575|EXPERIMENTAL|HLX10|HLX10+albumin-bound paclitaxel
62017322|NCT01775137|EXPERIMENTAL|TBM100|TIP 112 mg/b.i.d
62017323|NCT00812929|PLACEBO_COMPARATOR|Placebo|
62017324|NCT00812929|EXPERIMENTAL|GSK2190915 10 mg|
62017325|NCT00812929|EXPERIMENTAL|GSK2190915 50 mg|
62017326|NCT00812929|EXPERIMENTAL|GSK2190915 100 mg|
62017327|NCT00812929|EXPERIMENTAL|GSK2190915 200 mg|
62017328|NCT05177471||SSc-ILD patients with JAK inhibitors|
62017329|NCT01856140|EXPERIMENTAL|1 million cells/ml of ALLO-ASC|1 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.
62017330|NCT01856140|ACTIVE_COMPARATOR|10 million cells/ml of ALLO-ASC|10 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.
62017331|NCT02006030|EXPERIMENTAL|ADI-PEG 20 + TACE|ADI-PEG 20 plus concurrent transarterial chemoembolization
62017332|NCT02006030|ACTIVE_COMPARATOR|Transarterial chemoembolization (TACE)|transarterial chemoembolization alone
62017333|NCT01438411|OTHER|Cholic Acid|Active drug
62017334|NCT04274517|EXPERIMENTAL|Sterile Water|
62017335|NCT04274517|EXPERIMENTAL|3.5% betadine|
62017336|NCT04274517|EXPERIMENTAL|0.05% chlorhexidine gluconate|
62017337|NCT04519632||Parents|Qualitative interviews
62017338|NCT04519632||Healthcare Professionals|Qualitative interviews
62207317|NCT05877898|EXPERIMENTAL|Community health worker provided education and Navigation|Participants will be invited to complete all the CHW education arm material and be offered a menu of optional services for personalization including: (1) transportation to the grocery store (weekly for 4 weeks), (2) culturally adapted hypertension-tailored cooking recipes, (3) a virtual cooking class with food delivered to their door led by community partner, (4) access to UF IFAS's online library of healthy food cooking videos, and (5) in-store education on food labels, grocery shopping, and food resource management skills through the Cooking Matters at the Store curricula.
62207318|NCT05334316|NO_INTERVENTION|Usual Care Group|Usual care as determined by the patient's primary team. Initiation and daily dosing of corticosteroid treatment will be based on clinicians' preference and clinicians.
62207319|NCT05334316|EXPERIMENTAL|Individualized dosing strategy|Biomarker guided corticosteroid use. Initiation of corticosteroid will be recommended based on the an individual treatment rule (ITR) and subsequent dosing of corticosteroid will be recommended based on daily CRP values till CRP \<50 mg/L.
62207320|NCT06484920|EXPERIMENTAL|ATRA and Pembrolizumab|Patients will receive 200mg Q3W pembrolizumab treatment plus the supplemental treatment of 150 mg/m2 ATRA orally for 3 days surrounding each of the first four infusions of pembrolizumab (day -1, day 0, day +1).
62207321|NCT04743791|ACTIVE_COMPARATOR|Dupilumab|Two injections of Dupilumab will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of Dupilumab will be given every 2 weeks ± 3 days at home by the patient. The doses of investigational product must be separated by ≥11 days to avoid an overdose.
62581387|NCT06575335|ACTIVE_COMPARATOR|Chlorhexidine Tooth Wipe|The commercially available mouthwash containing 0.2% chlorhexidine will be purchased from the market and will then be used to impregnate the marketed tooth wipes fabric. The chlorhexidine tooth wipes will be cut, folded individually, and then packed. Each pack will contain 16 wipes.
62207322|NCT04743791|PLACEBO_COMPARATOR|Placebo|Two injections of placebo will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of placebo will be given every 2 weeks ± 3 days at home by the patient. The doses must be separated by ≥11 day.
62581388|NCT01419262|EXPERIMENTAL|2000 IU per day vitamin D|
62581389|NCT01419262|ACTIVE_COMPARATOR|400 IU per day vitamin D|
62789267|NCT05990361||women without pelvic girdle pain|The subjects who have not at least one positive result from Active Straight Leg Raise, and Posterior Pelvic Pain Provocation Tests; and at least two positive results from the Pelvic Compression and Distraction, Patrick Faber, Gaenslen and Long Dorsal Sacroiliac Ligament Palpation tests are classified as without PGP group.
62789268|NCT01494077||EUS-FNA of Pancreatic Cyst|Patients who have a pancreatic cyst requiring standard of care EUS-FNA that yields 2.25 ML (or greater) of fluid will be included in the study.
62789269|NCT00958061||Vietnam-Era Women Veterans|For this study we will use a cohort of women who are on a roster of Vietnam Era women veterans (4,644 Vietnam, 1,213 near Vietnam, 5,465 non-Vietnam) previously identified and characterized by a review of their military personnel records and link it to a list of 8,061 women who presumably served in Southeast Asia. This final cohort could potentially contain approximately 14,000 women. After deceased individuals are removed from the active cohort and contact information is updated, we estimate that there could be approximately 10,000 women to whom the informed consent and mailed survey will be initially mailed.
62789270|NCT05731479|EXPERIMENTAL|Diathermy + exercise group|Application of diathermy and a therapeutic exercise protocol.
62789271|NCT05731479|PLACEBO_COMPARATOR|Diathermy placebo + exercise group|Application of the diathermy device without energy emission and a therapeutic exercise protocol.
62207323|NCT06401070|PLACEBO_COMPARATOR|Control group|The control group was given a placebo press needle acupuncture (using plaster)
62207324|NCT06401070|EXPERIMENTAL|Intervention Group|The intervention group was given press needle acupuncture
62207325|NCT06151899|EXPERIMENTAL|Kinesio tape applying group|To the mothers in the experimental group; Kinesio tape application will be performed by two experienced physiotherapists, one of whom is an expert and the other has a doctorate degree, with a kinesio tape certificate.
62207326|NCT06151899|NO_INTERVENTION|Control group|The control group will receive placebo kinesio taping.
62207327|NCT00691795|EXPERIMENTAL|CLONIDINE|Participants randomized to this arm of the study receive 75 micrograms clonidine with the bupivacaine in their epidural when requesting pain relief in advanced labor
62207328|NCT00691795|EXPERIMENTAL|FENTANYL|Participants randomized to this arm of the study receive 75 micrograms fentanyl with the bupivacaine in their epidural when requesting pain relief in advanced labor
62581390|NCT01082263|OTHER|Midazolam/Lurasidone|Schizophrenia patient
62581391|NCT01508130||Cohort|
62581392|NCT00921466||Hospital Patients/Hospital Employees|
62581393|NCT00921466||Hospital employees|A group of 10 hospital employees used as baseline
62581394|NCT04178174|EXPERIMENTAL|SABR boost and de-escalated chemoradiation|SABR boost of 14 Gy in 2 fractions to the GTV, immediately followed by de-escalated chemoradiation. De-escalated chemoradiation will consist in 40 Gy in 20 fractions with concurrent high dose Cisplatin (3-weekly, 100 mg/m2) for 2 cycles, aiming for a cumulative dose of 200 mg/m2.
62581395|NCT04178174|ACTIVE_COMPARATOR|Standard chemoradiation|The standard arm will consist of conventionally radiation to a dose of 70 Gy in 33 fractions concurrently with high dose Cisplatin (3-weekly, 100 mg/m2) for 2-3 cycles, aiming for a cumulative dose of ≥ 200 mg/m2.
62207329|NCT02135081||Single Ventricle|"Subjects will be single ventricle patients who will be prospectively recruited when they are at the first stage of Fontan reconstruction; they will be followed throughout all 3 stages with cerebral blood flow measurements and brain MRIs.~Additional single ventricle patients who will not participate in the study for all 3 stages but who may participate for one of two. For example, patients who completed their Stage I and hemi Fontan/bidirectional Glenn operations before this study began will be recruited before Fontan stage completion. Also, patients whose Stage I and hemi Fontan/bidirectional Glenn surgeries will be completed during the study, but who will not complete all 3 surgical stages before this project ends. Cerebral blood flow measurements and brain MRIs will be completed after each surgical stage which occurs during study participation."
62207330|NCT02135081||Normal Control Group|Children likely to have a normal brain MRI will be asked to participate. After the brain MRI is obtained as part of routine clinical care, and a normal brain scan is confirmed, measurement of cerebral blood flow using velocity mapping in the jugular veins and the aorta will be performed. This will add approximately 10 minutes to the scan but no extra sedation medications will be administered to obtain this data.
62207331|NCT02154464|ACTIVE_COMPARATOR|Paracetamol|
62207332|NCT02154464|PLACEBO_COMPARATOR|Placebo|
62207333|NCT00012831||Group 1|
62581396|NCT03023631|EXPERIMENTAL|Prevention (Gardasil 9 vaccine)|Patients undergo standard of care allogeneic stem cell transplant. 6-12 months following transplant, patients receive recombinant human papillomavirus nonavalent vaccine IM on day 0 and at 2 and 6 months in the absence of disease progression or unacceptable toxicity.
62581397|NCT04029155|ACTIVE_COMPARATOR|TBNA with Conventional bronchoscope|patients in this arm will undergo bronchoscopy by a conventional probe
62581398|NCT04029155|EXPERIMENTAL|TBNA with a Ultrathin bronchoscope|Patients in this arm will undergo bronchoscopy by a ultra thin probe
62789272|NCT05971537|ACTIVE_COMPARATOR|intervention arm|"in addition to the appropriate IP antibiotics, an antibiotic-lock will be prepared by the same antibiotics. We will follow the suggested data used in hemodialysis catheter for the concentration of different antibiotics to prepare the locking solution The resulting locking solution will be instilled precisely to fill up the Tenckhoff catheter and the transfer set once a day. Prior to that, the existing PD solution is drained out first. As such, a dry abdomen is maintained during antibiotic-lock dwelling in the Tenckhoff catheter. This is to ensure the antibiotic-lock solution can be maintained within the catheter lumen for a prolonged period of time After a 6-hour dwell, the antibiotic-lock is drained out and usual PD schedule is resumed. Such a daily application of antibiotic lock shall last until the course of IP antibiotics is completed."
62207334|NCT05661916|EXPERIMENTAL|ALN-TTRSC04|Participants will be administered a single dose of ALN-TTRSC04.
62207335|NCT05661916|PLACEBO_COMPARATOR|Placebo|Participants will be administered a single dose of placebo.
62207336|NCT03633292|ACTIVE_COMPARATOR|Clorhexidine|- Clorhexidine Gel (LACER®, Barcelona, Spain) 0.12%, application 2 times / days for 1 month. The gel will be applied two times/day each 12 hours to the gingiva and mucosa.
62207337|NCT03633292|EXPERIMENTAL|Aloe Vera|"- 80% Aloe vera gel, application 2 times / day for 1 month~Master formula of 80% aloe vera gel Aloe Vera extract, obtained from the central part of the caudal leaves of plants with more than 8 years of life, eliminating its bark. Formulated with carbopol, hydrophilic crosslinked polymer of acrylic acid and vitamin C. The mixture is presented in containers that serve as a container for preparation and will be dispensed in the canister format with applicator tube."
62405944|NCT04113746|EXPERIMENTAL|Asthma and Exercise Lifestyle Change|Participants receive asthma and lifestyle change education related to exercise
62405945|NCT04113746|PLACEBO_COMPARATOR|Asthma Education|No lifestyle change education
62735021|NCT02142335|EXPERIMENTAL|Rituxan/Abraxane|This is a single arm study. All patients recieve treatment.
62017339|NCT04519632||Children|Children and young people aged 6-18 years, Qualitative interviews
62017340|NCT00815126|ACTIVE_COMPARATOR|Mucocutaneous symptoms from NSAIDs|
62017341|NCT00815126|ACTIVE_COMPARATOR|Respiratory symptoms from NSAIDs|
62017342|NCT00815126|ACTIVE_COMPARATOR|NSAIDs tolerant individuals|
62017343|NCT04112849||Heart failure subjects|Subjects who have heart failure, and meet inclusion/exclusion criteria, who will be enrolled in this study and will have their heart sounds measured with Nanowear vest (NCHFMS).
62405946|NCT04353115||Training with Serious Game|Trained group, 5 weeks training with the serious game; patients have a vestibular impairment.
62405947|NCT00554268|EXPERIMENTAL|PBI-05204|PBI-05204 starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle.
62405948|NCT05711459|EXPERIMENTAL|Liver Injury Group|The patients have liver injuries caused by antitumor drugs.
62405949|NCT01713075||Symbicort|
62017344|NCT05560867|OTHER|Patient Robot-Assisted Training Group|Patients will undergo robot-assisted physical therapy three times a week, for a total of 9 sessions, while functional near-infrared spectroscopy data is collected.
62017345|NCT03055234|EXPERIMENTAL|Oral Treprostinil|Extended-release oral tablet for three times daily (TID) administration
62017346|NCT03055234|PLACEBO_COMPARATOR|Placebo|Placebo (sugar pill) for TID administration
62017347|NCT03702829|EXPERIMENTAL|Experimental Drug|Inotersen, a transthyretin (TTR) antisense oligonucleotide. Administered subcutaneously weekly. Each dose shall contain 300 mg of active drug. Subsequent visits will occur at 3, 6, 12, 18 and 24 months. Every 2 weeks, blood will be monitored for renal function and platelet count and urine will be tested by dipstick for proteinuria.
62207338|NCT04153149|EXPERIMENTAL|Vutrisiran 25 mg|Participants will receive vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) during the double-blind (DB) period. After the DB period, participants enter the open-label randomized treatment extension (RTE) period to receive vutrisiran 25 mg SC q3M or vutrisiran 50 mg SC every 6 months (q6M). After implementation of Amendment 4, participants from the DB period will enter the open-label treatment extension (OLE) period to receive vutrisiran 25 mg SC q3M and participants who were previously receiving vutrisiran 50 mg q6M in the RTE period, will be transitioned to vutrisiran 25 mg q3M in the OLE period.
62405950|NCT03770806|EXPERIMENTAL|Femoral Nerve Block|Standard Ultrasound-guided femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg. These subjects will also receive the standard multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg.
62405951|NCT03770806|EXPERIMENTAL|Adductor Canal Nerve Block|Standard Ultrasound-guided adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg. These subjects will also receive the standard multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg.
62405952|NCT03770806|EXPERIMENTAL|No Block|For subjects who choose to have medication alone with no block for their routine care, there will be no changes to their care, which includes receiving the multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg. They will be in an observational group only with no randomization.
62581399|NCT01894100|OTHER|Delayed Intervention Group|This group will not receive shoe lifts during the first 3 months after baseline. At 3 months, they will begin the shoe lift correction for leg length inequality.
62789273|NCT05971537|OTHER|control arm|"In the control arm, appropriate IP antibiotics are to be continued. The dosage and duration of antibiotics will fully follow the recommendation from the latest International Society for Peritoneal Dialysis (ISPD) peritonitis guidelines~\*For the subjects in the control arm who reach the defined primary end-point, they will automatically undergo crossover to the intervention arm to receive standard IP antibiotics together with the intra-catheter antibiotic-lock. They will be followed for another 6 months subsequently."
62789274|NCT04120272||Delirium group|Group of patients with postoperative delirium
62405953|NCT06481397|EXPERIMENTAL|ONCObind (Onco-Seraph) 100 Filter is a single use|The Onco-Seraph 100 Filter is a single use, disposable column packed with ultra-high molecular weight polyethylene beads which have been modified to contain endpoint attached heparin on the surface. The devices are sterilized using a standard ethylene oxide cycle, following ISO 11135:2014/A1:2018. Chemical Indicator labels are located near the product label. A green label indicates that the device has been exposed to ethylene oxide gas. Onco-Seraph 100 is part of the Seraph platform technology that was also developed as an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens from the bloodstream.
62405954|NCT06032260|EXPERIMENTAL|Enriched panettone|100 grams of panettone enriched with fiber. The added fiber is JAX Plus® (Heallo srl, Milano, Italy), a soluble fiber with Arabinoxylans from wheat and barley
62405955|NCT06032260|ACTIVE_COMPARATOR|Panettone standard|100 grams of panettone without fiber enrichment
62789275|NCT04120272||Non delirium group|Group of patients without postoperative delirium
62789276|NCT02156778|ACTIVE_COMPARATOR|Extended Standard Care (Stroke Card)|
62789277|NCT02156778|ACTIVE_COMPARATOR|Standard Care|
62789278|NCT00582777|ACTIVE_COMPARATOR|USUAL|USUAL treatment - The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
62207339|NCT04153149|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo during the double-blind period. After the DB period, participants enter the RTE period to receive vutrisiran 25 mg SC q3M or vutrisiran 50 mg SC q6M. After implementation of Amendment 4, participants from the DB period will enter the OLE period to receive vutrisiran 25 mg SC q3M and participants who were previously receiving vutrisiran 50 mg q6M in the RTE period, will be transitioned to vutrisiran 25 mg q3M in the OLE period.
62207340|NCT02951520|EXPERIMENTAL|SOFT block|Fifty patients will form the study group (one group). All the patients will receive supine ultrasound guided (US) sciatic, obturator, femoral nerve block technique using a single skin puncture (SOFT block).
62405956|NCT05828030|EXPERIMENTAL|high flow nasal cannula group|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%. The flow rate will be set at titrated from 60 L/min.
62581400|NCT01894100|EXPERIMENTAL|Immediate Intervention Group|At baseline, participants in this group will begin shoe lift correction for leg length inequality.
62789279|NCT00582777|EXPERIMENTAL|HS Dosing|"HS DOSING - In this period, the patient's antihypertensive regimen at the baseline visit will be standardized for the once/day medications to be given at bedtime.~* For those on monotherapy with a once/day antihypertensive regimen, the time of administration will be changed to bed time.~* For those on multi-drug therapy, the time of administration of all once a day antihypertensive drugs will be changed to bed time."
62789280|NCT00582777|EXPERIMENTAL|ADD-ON DOSING|ADD-ON DOSING - This regimen will start with the USUAL regimen to which an additional agent will be added at bed time. An additional dose of ramipril, diltiazem, or hydralazine are three possible options for the add on medication. The intent of the ADD ON therapy is to lower nocturnal BP with minimal impact on daytime BP. Thus, agents with \< 24 hr duration of action are preferred. The specific choice and dose of add-on therapy (of the three agents) will be up to the site investigator considering the clinical situation of each participant based on the guidelines below.
62405957|NCT05828030|ACTIVE_COMPARATOR|Oxygen Mask group|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
62789281|NCT02769221|EXPERIMENTAL|Optiscope|Endotracheal intubation by rigid video stylet, manufactural named Optiscope.
62789282|NCT02769221|ACTIVE_COMPARATOR|McGrath|Endotracheal intubation by video laryngoscope, manufactural named McGrath.
62789283|NCT02994875|PLACEBO_COMPARATOR|Placebo First|Placebo - Participants will receive placebo for one week. Following a two-week washout period, they will receive NAC for one week. NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications
62789284|NCT02994875|ACTIVE_COMPARATOR|NAC First|N-acetylcysteine - Participants will receive NAC for one week. Following a two-week washout period, they will receive placebo for one week. NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications
62789285|NCT02524002|PLACEBO_COMPARATOR|Usual Clear Diet|This intervention consists of soup broth, variety of juices (apple, cranberry, grape), ginger ale, water, and ice.
62789286|NCT02524002|EXPERIMENTAL|Accel Gel|"This intervention is an enhanced clear liquid gel is Accel Gel, produced by PacificHealth Labs of Matawan, NJ. This gel has 4:1 carb to protein ratio formula, and ingredients that are not contraindicated in pregnancy (only the flavors with minimal caffeine are used).~http://www.pacifichealthlabs.com/accel-gel-all-natural-rapid-energy-gel-product.html"
62789287|NCT01433562|EXPERIMENTAL|DLBS1425|
62789288|NCT01433562|PLACEBO_COMPARATOR|Placebo|
62789289|NCT06189131|EXPERIMENTAL|Group 1: Acutely admitted surgical patients with no planned surgery|This cohort of individuals will be those admitted to the EGS department with a surgical pathology but who have not undergone surgery during the admission and by the end of data collection (7 days) (e.g. pancreatitis, conservative management intra-abdominal pathology). The rationale behind recruiting this cohort of patients is to assess the admission V02Max and how unwell patients are during their admission by correlating this result to their NEWS score, blood results and any evidence of clinical deterioration. This cohort of patients will help us understand whether V02Max correlates with patient's clinical conditions and outcomes.
62789290|NCT06189131|EXPERIMENTAL|Group 2: Acutely admitted surgical patients who have undergone an emergency procedure|Pre and post-operative Ventriject V02Max values will be taken in this group of patients to assess whether pre-operative V02Max correlates with pre-operative PPOSSUM, NELA scores and post-operative outcomes. This group of participants will answer whether acute V02Max is reflective of operative outcomes and whether it correlates with current methods of risk stratification (PPOSSUM, NELA, ASA) and post-operative outcome scores (Clavien-Dindo classification). This group is important as it will help establish whether V02Max measurements in the acute setting for operative risk stratification is feasible.
62207341|NCT03350932|NO_INTERVENTION|Control|This group of children, will have to perform a sensory imagination task about neutral facts before choosing the portion size of a food.
62405958|NCT05724615|NO_INTERVENTION|Usual care|Participants will receive usual care only, and no additional intervention from this study.
62207342|NCT03350932|EXPERIMENTAL|Food sensory imagination|"This group, the food sensory imagination group, will have to perform a sensory imagination task foods (being the intervention) before choosing the portion size of a food."
62207343|NCT06345651|EXPERIMENTAL|Theta negative peak triggered TMS of left dmPFC|Repetitive TMS (100 Hz triple pulses) of the dmPFC will be applied daily for four weeks (5 sessions per week on working days, 20 sessions in total). Stimulation triggers will be brain oscillation-synchronized based on EEG extracted over left dmPFC, synchronized with the negative peak of endogenous theta oscillations in left dmPFC.
62207344|NCT06345651|ACTIVE_COMPARATOR|iTBS TMS of left dlPFC|Standard intermittent Theta Burst Stimulation of the dlPFC will be applied daily for four weeks (5 sessions per week on working days, 20 sessions in total). Stimulation triggers will be applied independently of the EEG signal.
62207345|NCT06116890|EXPERIMENTAL|Arm A|KHK4951 High dose
62207346|NCT06116890|EXPERIMENTAL|Arm B|KHK4951 Middle dose
62207347|NCT06116890|EXPERIMENTAL|Arm C|KHK4951 Low dose
62581401|NCT04424706||Normal people|No diabetes and atherosclerosis
62581402|NCT04424706||type 2 diabetes mellitus without atherosclerosis|Newly diagnosed type 2 diabetes without atherosclerosis
62581403|NCT04424706||type 2 diabetes mellitus with atherosclerosis|Newly diagnosed type 2 diabetes with atherosclerosis
62581404|NCT02528006|OTHER|Titanium Bridges|Surgery
62581405|NCT01864226|PLACEBO_COMPARATOR|Placebo|
62789291|NCT03536832|ACTIVE_COMPARATOR|cesarean section with Vicryl|Women undergoing cesarean section with low transverse skin incisions will be closed with 3-0 Vicryl.
62789292|NCT03536832|ACTIVE_COMPARATOR|cesarean section with prolene|Women undergoing cesarean section with low transverse skin incisions will be closed with 3-0 Prolen.
62789293|NCT02357121|EXPERIMENTAL|Laser ablation|All patient will undergo focal ablation of prostate tissue utilizing laser energy.
62789294|NCT04370106|NO_INTERVENTION|Control|Usual care for participants with existing VLU in the CG is defined as visiting the outpatient wound clinic/visits by the community care nurse as prescribed by the physician. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses.
62789295|NCT04370106|OTHER|Social leg Program|Usual care as described for the CG will also be provided to the IG. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by frequenting a social leg program.
62789296|NCT00607867|ACTIVE_COMPARATOR|Arm 1|A LoBAG30, weight maintenance diet will be given to subjects on metformin. All food will be provided for 5 weeks.
62789297|NCT00607867|PLACEBO_COMPARATOR|Arm 2|A weight maintenance, control diet consisting of 55% carbohydrate, 15% protein, 30% fat will be given to subjects on metformin. All food will be provided for 5 weeks.
62789298|NCT05472922|EXPERIMENTAL|Banded Mini Gastric Bypass|Patients are treated for morbid obesity with a Mini gastric bypass (MGB-OAGB) with addition of the implantation of a MiniMizer Gastric Ring (Bariatric Solutions GmbH, Stein am Rhein Switzerland)
62789299|NCT05472922|ACTIVE_COMPARATOR|non-Banded Mini Gastric Bypass|Patients are treated for morbid obesity with a Mini gastric bypass (MGB-OAGB)
62789300|NCT04499625|OTHER|Control - Lateral window|Standard surgical technique to access maxillary sinus for sinus floor augmentation procedure.
62207348|NCT06295354||20-30 years old|The target population consists of 1000 participants, equally distributed over different age groups (20-30, 30-40, 40-50, and 50-60 years old) and sex. Main exclusion criteria are any systemic condition or medication apart from cardiometabolic disorders, pregnancy at inclusion or recent vaccinations. Individuals will be compared over time, and age groups will be compared over time and per time point. None of the age groups will get an intervention, the goal is to observationally study them.
62405959|NCT05724615|EXPERIMENTAL|Outreach + Bulk ordering|Participants will receive a standard mailed letter about lipid panel screening signed by Penn Primary Care, similar to birthday letters that are currently sent to some practices. These letters or messages will describe the importance of getting a lipid panel, their eligibility for a lipid panel, and information about fasting implications of getting the test. This letter will be complemented by a lipid panel order on behalf of their primary care provider, with a signed laboratory slip/order for lipid panel screening. Laboratory orders will be generated through bulk ordering in the electronic health records for all patients by a designated practice representative and the primary care provider as the authorizing clinician. Participants in Arm 2 will be asked to take the laboratory order to the laboratory of their choice to complete their test within the next 6 weeks.
62405960|NCT05724615|EXPERIMENTAL|Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance|Participants will receive a standard mailed letter, a signed laboratory slip/order, and text-based outreach. It will provide the patient information on walk-in hours in a partnering lab / or ask the patient to schedule an appointment with one of the listed Penn Labs with instructions on how to do so. Patients with an active MyPennMedicine account will be asked to schedule an appointment via MPM. Other patients will be sent a list with the contact of nearby available labs and opening hours and asked to call to schedule an appointment. Up to 2 reminder text messages with the deadline for the lab order will be sent to patients for which no appointment has been scheduled on MyPennMedicine at 2 weeks intervals. Enrollment in the text messaging platform will be opt-out. All results for lipid panel testing will be routed to the patients' primary care provider
62405961|NCT04592666|EXPERIMENTAL|Combinational therapy|
62789301|NCT04499625|EXPERIMENTAL|Test - Hydrodynamic transalveolar approach|Novel transalveolar approach (using an ultrasonic device) to access maxillary sinus for sinus floor augmentation procedure.
62207349|NCT06295354||3-40 years old|The target population consists of 1000 participants, equally distributed over different age groups (20-30, 30-40, 40-50, and 50-60 years old) and sex. Main exclusion criteria are any systemic condition or medication apart from cardiometabolic disorders, pregnancy at inclusion or recent vaccinations. Individuals will be compared over time, and age groups will be compared over time and per time point. None of the age groups will get an intervention, the goal is to observationally study them.
62207350|NCT06295354||40-50 years old|The target population consists of 1000 participants, equally distributed over different age groups (20-30, 30-40, 40-50, and 50-60 years old) and sex. Main exclusion criteria are any systemic condition or medication apart from cardiometabolic disorders, pregnancy at inclusion or recent vaccinations. Individuals will be compared over time, and age groups will be compared over time and per time point. None of the age groups will get an intervention, the goal is to observationally study them.
62789302|NCT05178602|EXPERIMENTAL|The experimental group|Routine treatment, and tai Chi exercise,5 times a week
62789303|NCT05178602|NO_INTERVENTION|The control group|Routine treatment, and cardiac rehabilitation is not mandatory
62789304|NCT03359252|ACTIVE_COMPARATOR|non-stent assisted coiling|patients treated with non-stent assisted coiling of unruptured intracranial aneurysms
62789305|NCT03359252|EXPERIMENTAL|stent assisted coiling|patients treated with stent assisted coiling of unruptured intracranial aneurysm
62207351|NCT06295354||50-60 years old|The target population consists of 1000 participants, equally distributed over different age groups (20-30, 30-40, 40-50, and 50-60 years old) and sex. Main exclusion criteria are any systemic condition or medication apart from cardiometabolic disorders, pregnancy at inclusion or recent vaccinations. Individuals will be compared over time, and age groups will be compared over time and per time point. None of the age groups will get an intervention, the goal is to observationally study them.
62207352|NCT03336359|ACTIVE_COMPARATOR|LCI|Tandem colonoscopy with Linked Color Imaging system
62207353|NCT03336359|ACTIVE_COMPARATOR|NBI|Tandem colonoscopy with Narrow band imaging system
62207354|NCT06191055|EXPERIMENTAL|Beta Alanine high dose|Consumption for 28 days.
62207355|NCT06191055|EXPERIMENTAL|Beta Alanine low dose|Consumption for 28 days.
62207356|NCT06191055|PLACEBO_COMPARATOR|Control group|Consumption for 28 days.
62207357|NCT06480344||Case|Patients who developed surgical site infection.
62207358|NCT06480344||Controls|Patients who did not developed surgical site infection.
62207359|NCT06374108|ACTIVE_COMPARATOR|High dose resistance training|10 weeks intervention with 2.5 weekly supervised resistance training sessions (2 or 3 sessions/week for high dose resistance training; 25 sessions in total).
62207360|NCT06374108|ACTIVE_COMPARATOR|Low dose resistance training|10 weeks intervention with 1 weekly supervised resistance training session (low dose resistance training; 10 sessions in total).
62207361|NCT06374108|NO_INTERVENTION|Waitlist control.|The waitlist control group will initially be instructed to maintain their normal daily activity during the 10 week intervention period. Hereafter, they will be offered a 10 week high dose resistance training intervention that combines supervised and home based exercise sessions .
62405962|NCT04592666|ACTIVE_COMPARATOR|Single TKI|
62207362|NCT06242808|ACTIVE_COMPARATOR|Usual free community food market services|Usual free community food market services, no tailoring of food received.
62207363|NCT06242808|EXPERIMENTAL|Medically tailored groceries and food resource coaching|Medically tailored groceries and food resource coaching.
62581406|NCT01864226|EXPERIMENTAL|RO5545965|
62207364|NCT06242808|EXPERIMENTAL|Medically tailored groceries|Medically tailored groceries only, no coaching.
62207365|NCT01905150|EXPERIMENTAL|G-FLIP+VitaminC, then G-FLIP-DM+VitaminC|G-FLIP in combination with Vitamin C, then G-FLIP-DM in combination with Vitamin C
62207366|NCT01905150|ACTIVE_COMPARATOR|G-FLIP, then G-FLIP-DM|G-FLIP alone, then G-GLIP-DM alone
62207367|NCT04206657|EXPERIMENTAL|Single dose administration of 1mg KHK7580|
62207368|NCT04206657|EXPERIMENTAL|Single dose administration of 3mg KHK7580|
62207369|NCT04206657|EXPERIMENTAL|Single dose administration of 6mg KHK7580|
62207370|NCT04206657|EXPERIMENTAL|Single dose administration of 12mg KHK7580|
62207371|NCT04206657|EXPERIMENTAL|Multiple dose administration of 6mg KHK7580 for 8days|
62207372|NCT06718361||O2 mask|Delivering oxygen via face mask with different oxygen flow (5, 10, 15 l/min).
62207373|NCT06718361||Bag mask ventilation|Delivering oxygen via bag mask ventilation
62207374|NCT06718361||Supraglotic airway|Delivering oxygen via laryngeal mask with bag or mechanical ventilation
62207375|NCT06718361||Orotracheal intubation|Delivering oxygen via orotracheal tube with bag or mechanical ventilation
62207376|NCT06718361||High-Flow Nasal Oxygenation|Oxygen delivery via high-flow nasal oxygenation
62207377|NCT05243563|EXPERIMENTAL|Fractionated CO2 laser plus topical steroids|3 laser treatments at 6 week intervals for 6 months by a single trained operator
62207378|NCT05243563|ACTIVE_COMPARATOR|topical steroids alone|self-applied topical steroid therapy using clobetasol propionate 0.05%
62207379|NCT06328439|EXPERIMENTAL|ANS014004|"Dosage: 1. Dose-escalation participants receive ANS014004 single dose on Day 1, if DLT does not occur within the 7-day elution period, subjects will begin multiple doses on Day 8 and receive ANS014004 QD (once daily) for a 28-day cycle. 2, Backfill, Dose Extension Subjects, who go directly to multiple dosing, will receive ANS014004 QD (once daily) for 28 days as a cycle.~Dosing Schedule: 1. Dose-escalation subjects, single dosing + multiple dosing, 35-day cycle. 2, Backfill, dose-expansion subjects, direct access to multiple dosing, 28 days to a cycle."
62405963|NCT02046720|EXPERIMENTAL|propofol induced sedation|Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.
62405964|NCT03976674|EXPERIMENTAL|Patients in preparation for bariatric surgery|Patients in preparation for bariatric surgery in the endocrinology department will follow a cognitive behavioural therapy
62405965|NCT03976674|NO_INTERVENTION|Control group|Standard practice
62405966|NCT04424186|EXPERIMENTAL|'Rehabilitation for Life'|Vital sign measurement and rehabilitation
62405967|NCT04424186|ACTIVE_COMPARATOR|Usual care and rehabilitation|Usual care and rehabilitation provided in primary and secondary sectors
62405968|NCT03014570|ACTIVE_COMPARATOR|Education-Only Control|This arm includes the education provided to all sites (this is Step 2 of the EIT-4-BPSD intervention). The sites are given the opportunity to decide how they want the education around management of behavioral symptoms to occur-face-to-face by a research staff member, via a powerpoint they can use on their own or via a webinar.
62405969|NCT03014570|EXPERIMENTAL|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
62405970|NCT05978375||Irreducible Atlantoaxial Dislocation|Atlantoaxial dislocation which could not be reducted under anesthesia traction with 1/6 weight.
62405971|NCT01667016||Orsiro DES|
62405972|NCT05046145|EXPERIMENTAL|tDCS + speech therapy+ sham|Participants will receive real tDCS and tDCS sham for 5 sessions during each treatment period. The interstice period of the total intervention will be 25 days, with 15 days of wash out between the two interventions. The probabilistic, simple randomized sample will consist of participants with food cravings randomized into two groups, according to the presence or absence of changes in eating behavior and within each group there will be subdivision to receive or not neuromodulation, according to the flowchart
62207380|NCT06601075||Patients diagnosis of advanced colorectal cancer|Patients diagnosis of advanced colorectal cancer (peritoneal metastasis with/without other metastases)
62207381|NCT06729398|EXPERIMENTAL|NIRS and SafeboosC group|NIRS is placed on the frontoparietal once the neonates born in the delivery room until 72 hours. SafeboosC treatment guideline is used to maintain normal value of cerebral rStO2.
62207382|NCT06729398|NO_INTERVENTION|Control group|Standard procedure and monitoring device are used for every participant in the control group.
62207383|NCT06145477||Parents enroll in Parenting for Tomorrow using Chicago Parent Program - individualized for families|Parents enroll in Parenting for Tomorrow using Chicago Parent Program - individualized for families (CPPi) implemented through a telehealth approach.
62207384|NCT05444231|EXPERIMENTAL|Brain Training A|This group will access one type of online brain-health oriented training.
62207385|NCT05444231|ACTIVE_COMPARATOR|Brain Training B|This group will access a distinct type of online brain-health oriented training.
62207386|NCT05444231|ACTIVE_COMPARATOR|Brain Training C|This group will access a distinct type of online brain-health oriented training.
62207387|NCT06182774|EXPERIMENTAL|Lenalidomide & Dexamethasone|
62207388|NCT06182774|ACTIVE_COMPARATOR|Daratumumab, Lenalidomide & Dexamethasone|Standard of Care
62207389|NCT05623059|OTHER|50mg dose|This arm will start with a one-time dose and progress to twice daily dosing for 3 days, every 12 hours. Study cohort will be 9 subjects with asthma. DHEA dose will be 50 mg via slow release capsules. Endpoints will be serum DHEA and DHEA-S levels at 10, 20, 30, 60 min \& 2, 4, 6, 8, 12h after administration. After a one-week washout period, the protocol will be repeated using 100 mg of SR-DHEA.
62207390|NCT05623059|OTHER|100mg dose|This arm will start with a one-time 100mg dose and progress to twice daily dosing for 3 days, every 12 hours. Study cohort will be same 9 subjects with asthma. DHEA dose will be 100mg via slow release capsules. Endpoints will be serum DHEA and DHEA-S levels at 10, 20, 30, 60 min \& 2, 4, 6, 8, 12h after administration.
62207391|NCT01334424|PLACEBO_COMPARATOR|no propofol|induction anesthesia with midazolam 0.2 - 0.3 mg/kg
62207392|NCT01334424|EXPERIMENTAL|propofol induction|induction anesthesia with propofol 2 - 2.5 mg/kg
62207393|NCT01334424|EXPERIMENTAL|propofol maintenance|induction anesthesia with midazolam 0.2 - 0.3 mg/kg and maintain anesthesia with propofol 2 mg/kg.h (maintenance dose)
62207394|NCT01334424|EXPERIMENTAL|propofol induction and maintenance|induction anesthesia with propofol 2 - 2.5 mg/ kg and maintain anesthesia with propofol 2 mg/kg.h (maintenance dose)
62207395|NCT06584357||Cognitively Normal|No reported memory loss or concerns as reported by participant and study partner.
62207396|NCT06584357||Mild Cognitive Impairment|A diagnosis of Mild Cognitive Impairment (MCI) based on the National Institute of Aging (NIA) criteria and verified through medical records.
62207397|NCT06584357||Mild-to-Moderate AD Dementia|A diagnosis of Mild-to-Moderate AD Dementia based on the National Institute of Aging (NIA) criteria and verified through medical records.
62207398|NCT06446687|EXPERIMENTAL|Sinus Lifting by Using Crestal approach with membrane control technique.|Sinus Lifting with simultaneously implant placement.
62207399|NCT04427943||RIKA cohort|patients with periprosthetic knee joint infection scheduled for revision knee arthroplasty surgery
62405973|NCT05046145|EXPERIMENTAL|sham + tDCS + speech therapy|Participants will receive real tDCS and tDCS sham for 5 sessions during each treatment period. The interstice period of the total intervention will be 25 days, with 15 days of wash out between the two interventions. The probabilistic, simple randomized sample will consist of participants with food cravings randomized into two groups, according to the presence or absence of changes in eating behavior and within each group there will be subdivision to receive or not neuromodulation, according to the flowchart
62207400|NCT05860582|EXPERIMENTAL|[14C]GB491|
62207401|NCT00656708|EXPERIMENTAL|PB|All patients admitted to the burn unit during the prospective portion (interventional portion) of the study who have open wounds will have Kerlix AMD applied to their wounds; only those patients consenting to the study will have data abstracted.
62207402|NCT03368742|EXPERIMENTAL|SGT-001 - Dose Level 1|Single IV infusion of SGT-001 at starting dose
62207403|NCT03368742|EXPERIMENTAL|SGT-001 - Dose Level 2|Single IV infusion of SGT-001 at next ascending dose
62207404|NCT03368742|NO_INTERVENTION|Untreated Control|Untreated control group. After 1 year, treatment-eligible control patients will receive SGT-001 at the selected dose.
62207405|NCT05157243|EXPERIMENTAL|Nitazoxanide|Nitazoxanide 300 mg extended release tablets
62207406|NCT05157243|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62207407|NCT04885985|EXPERIMENTAL|DEB catheter|Use DEB catheter to treat the stenosis or occlusion in below popliteal artery of experimental arm
62207408|NCT02179567|EXPERIMENTAL|Doc/Bev|Docetaxel/Bevacizumab
62207409|NCT06704334|EXPERIMENTAL|Median nerve electrical stimulation group|The optimal median nerve electrical stimulation treatment was given
62207410|NCT06704334|EXPERIMENTAL|Huperzine A injection + median nerve electrical stimulation group|"Huperzine A injection can be administered before median nerve electrical stimulation to improve the therapeutic effect of electrical stimulation.~Huperzine A injection: intramuscular injection, 1ml,0.2mg once a day, the course of treatment was 7 days."
62207411|NCT06704334|EXPERIMENTAL|Huperzine A injection + median nerve electrical stimulation + Ginkgo leaf dropping pill group|"Huperzine A injection can be administered before median nerve electrical stimulation to improve the therapeutic effect of electrical stimulation. After the end of the electrical stimulation treatment, ginkgo biloba dropping pills were given as long-term administration to maintain the therapeutic effect.~Huperzine A injection: intramuscular injection, 1ml,0.2mg once a day, the course of treatment was 7 days.~Ginkgo leaf dropping pills: Oral, each pill weighs 63mg, 5 pills/time, 3 times/day, the course of treatment is 3 months."
62207412|NCT06204809|EXPERIMENTAL|PGN-EDODM1|PGN-EDODM1 for infusion
62207413|NCT06204809|PLACEBO_COMPARATOR|Placebo|0.9% NaCl
62207414|NCT06223360|EXPERIMENTAL|Low Dose Benfotiamine|Participants will take 300mg benfotiamine capsules twice a day (BID; once in the morning and once in the evening).
62207415|NCT06223360|EXPERIMENTAL|High Dose Benfotiamine|Participants will take 600mg benfotiamine capsules twice a day (BID; once in the morning and once in the evening).
62207416|NCT06223360|PLACEBO_COMPARATOR|Placebo|Participants will take placebo capsules twice a day (BID; once in the morning and once in the evening). In the placebo group, capsules will be filled with inactive microcrystalline cellulose. The other capsule components, shape and color are identical between benfotiamine and placebo arms.
62207417|NCT04566562||Study Group|Brain scans, cognitive tests, blood biomarkers
62207418|NCT04975308|EXPERIMENTAL|Imlunestrant|Imlunestrant administered orally.
62207419|NCT04975308|ACTIVE_COMPARATOR|Investigator's Choice of Endocrine Therapy|Investigator's choice of exemestane administered orally or fulvestrant administered intramuscularly (IM). See local approved label for additional instructions.
62207420|NCT04975308|EXPERIMENTAL|Imlunestrant plus Abemaciclib|Imlunestrant plus abemaciclib administered orally.
62207421|NCT05420233|OTHER|Patients diagnosed with Crohn´s disease within the past 12 months|All patients will undergo MRE in year 1, and this test may not be recommended in all patients. Year 1 MRE is the only procedure that may be performed outside of clinical practice.
62207422|NCT05316116|EXPERIMENTAL|Siltuximab|Siltuximab will be given every 3 weeks, for between 18 and 36 weeks
62207423|NCT04734652|EXPERIMENTAL|BIC arm|The Intervention Arm ART regimen is a fixed-drug combination of a single tablet co-formulated regimen containing Bictegravir 50mg Emtricitabine 200mg and tenofovir alafenamide 25mg (BIC/FTC/TAF; Biktarvy®) that will be taken twice a day during rifampicin-containing TB treatment and 2 weeks after stopping TB treatment, thereafter the BIC/FTC/TAF single tablet co-formulation will be taken once daily.
62207424|NCT04734652|ACTIVE_COMPARATOR|DTG Arm|Dolutegravir 50mg /Lamivudine 300mg/ Tenofovir 300mg (TLD- fixed-drug combination single tablet) plus Dolutegravir 50mg evening dose during TB treatment and for two weeks after completion of TB treatment, then TLD once daily thereafter- as per Standard of Care (SOC)
62207425|NCT05329194|EXPERIMENTAL|Tezepelumab|Participants will be receiving 210 mg of tezepelumab every 4 weeks (Q4W) from Week 0 until Week 48.
62207426|NCT04050657|EXPERIMENTAL|Two-week appointment interval group|Orthodontic patients who come to tighten their braces every 2-weeks.
62207427|NCT04050657|OTHER|Eight-week appointment interval group|Orthodontic patients who come to tighten their braces every every 8-weeks.
62207428|NCT00468559|EXPERIMENTAL|Open Label Esomeprazole|This is an open label, run-in phase. All patients received Esomeprazole.
62207429|NCT00468559|EXPERIMENTAL|Double Blind Esomeprazole|This is the double blind withdrawal phase. Patients are randomized to active drug or placebo.
62207430|NCT00468559|PLACEBO_COMPARATOR|Double Blind Placebo|This is the double blind withdrawal phase. Patients are randomized to active drug or placebo.
62207431|NCT06710886|EXPERIMENTAL|Music|Participants will be asked to listen to the brief music demo and the 15-minute music session. The pre- and post-assessments will require participants to complete a 5-10-minute online survey.
62207432|NCT01661608|EXPERIMENTAL|EOS|Collecting data on the use of the EOS for gastric tissue approximation during primary gastric restrictive procedures
62207433|NCT03878277|EXPERIMENTAL|Cold Brew Coffee|6 days of drinking 1 bottle of Starbucks® Cold brew 325ml \[205 mg caffeine\] every morning between 6am-9am.
62207434|NCT01333813|EXPERIMENTAL|Engerix-B Kinder Group|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 7-8 years of age.
62207435|NCT05755906|EXPERIMENTAL|BFF MDI 160/9.6 μg BID (320/19.2μg/day)|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), BDI (320/19.2μg/day)
62207436|NCT05755906|ACTIVE_COMPARATOR|BD MDI 160 μg BID (320 μg/day)|Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)
62207437|NCT03106454|ACTIVE_COMPARATOR|Combination oral contraceptive pill|Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg Taken cyclically as 24 tablets containing EE 10mcg/NET acetate 1mg 2 tablets of EE 10mcg only 2 tablets of ferrous fumarate 75mg
62207438|NCT03106454|EXPERIMENTAL|Progestin only pill|Norethindrone 0.35mg Marketed use for 1 tablet per day. For study dosing, patients will take 3 tablets daily for a total of 1.05mg daily.
62207439|NCT00776477|EXPERIMENTAL|1|
62207440|NCT00776477|ACTIVE_COMPARATOR|2|
62207441|NCT02566200||IM group|Patients admitted in intensive care for a myocardial infarction
62017348|NCT04823338|EXPERIMENTAL|Conectar Jugando Online Program|The program consisted of 12 one-hour intervention sessions. The sessions were biweekly with a total duration of 6 weeks. The modern board and card games used in the program were Bee Alert (Knizia, 2012), Monster Match (Gruhl \& Weir, 2018), Sherlock Express (Kermarrec, 2019), Streams (Itsubaki, 2011) and Blurble (Bernard, 2013). The play sessions were carried out in groups of between 2 and 4 boys and girls of similar ages (same school stage) formed according to the availability of the participants. In the sessions, the physical games were projected on the videoconference tool by the researcher and the participating boys and girls carried out their actions using their voice and the platform tools. The program was gamified though a narrative about a space travel to different planets in discovering new games and get different mission badges and super team badges in their logbook.
62017349|NCT04823338|NO_INTERVENTION|Wait-list group|Wait-list
62017350|NCT05531214|EXPERIMENTAL|Intervention|Patients randomized based on their primary care clinician to a co-localized care with a telemedicine-based cardiorenal multidisciplinary team (cardiologist, nephrologist, and research coordinators) providing guidance and recommendations to the primary care clinician.
62207442|NCT00569842||observational|
62207443|NCT03793036|NO_INTERVENTION|FAST group|preoperative fasting
62017351|NCT05531214|NO_INTERVENTION|Control|"Patients randomized to the control group will proceed with usual care with a primary care clinician making referrals to a cardiologist or nephrologist for-cause as determined by the primary care clinician, to ultimately assess the rates of improvement in the implementation of GDMT."
62017352|NCT02841423|EXPERIMENTAL|INTRAVENOUS ANESTHESIA|neuropsychological test battery
62017353|NCT02841423|EXPERIMENTAL|CLOSED LOOP ANESTHESIA|neuropsychological test battery
62017354|NCT03128749|EXPERIMENTAL|Mindfulness Based Intervention|"Mindfulness-based cognitive therapy (MBCT), adjusted to OCD patients, will be applied in 10 weekly sessions of 2 hours followed by an extra session 4 weeks later. The treatment will be applied in a group format of 10 to 12 patients.~These patients will be also attending to their regular psychiatric visits for medication control."
62017355|NCT03128749|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Patients will be attending to their regular psychiatric visits during the whole trial period.
62207444|NCT03793036|EXPERIMENTAL|CHO group|preoperative nutrition The participants of experimental group received 400 mil of a clear carbohydrate drink (12,5 gr/100 mil carbohydrate, 50 kcal/100ml, pH 5.0) at 10:00 pm the evening before surgery and another 200 mil of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
62581407|NCT00082446|EXPERIMENTAL|E|Subject will receive an SC dose of MVA 1x10\^8 on day 0 and day 28. On day 112 subjects will receive a dose of placebo by scarification.
62207445|NCT00650884|NO_INTERVENTION|1|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). CONTROL PATIENTS will only be treated with Standard of Care during this 12 week trial, but will also be treated with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch after completion of this study.
62207446|NCT00650884|EXPERIMENTAL|2|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). EXPERIMENTAL PATIENTS will also be treated with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch while sleeping.
62207447|NCT00650884|OTHER|3|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). CROSS-OVER patients will be initially treated only with Standard of Care, and after six weeks, they will be Crossed-Over and fit with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch while sleeping.
62207448|NCT01141153|EXPERIMENTAL|Oral anticoagulation plus dual antiplatelet therapy|
62789306|NCT01104727|ACTIVE_COMPARATOR|Multi port|4-Ports Cholecystectomy (4PC): a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.
62207449|NCT01141153|ACTIVE_COMPARATOR|Dual antiplatelet therapy|
62405974|NCT03583931|ACTIVE_COMPARATOR|Operative VATS decortication|Operative group that will undergo early VATS decortication of complicated parapneumonic effusion/empyema
62405975|NCT03583931|ACTIVE_COMPARATOR|Non-operative Fibrinolytic Therapy|Non-operative group that will undergo instillation of the drugs DNAse and tPA (tissue plasminogen activator) together i.e. 5mg DNAse and 10mg tPA twice a day for up to six doses, through chest tube as treatment of the patient's complicated parapneumonic effusion/empyema. Fibrinolytic therapy = DNAse + tPA; these medications are not mutually exclusive.
62581408|NCT00082446|ACTIVE_COMPARATOR|D|Subject will receive a SC dose of placebo on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
62581409|NCT00082446|EXPERIMENTAL|C|Subject will receive a SC dose of MVA 1x10\^8 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
62207450|NCT05163769|EXPERIMENTAL|Multimodal Training|The participants in the Multimodal training arm (mBCI) will undergo 48 physical and cognitive training sessions over 24 weeks on the NeeuroCycle BCI Physical and Cognitive training system. Sessions are scheduled three times a week for the first 12 weeks and then once a week for the subsequent 12 weeks. Sessions are spaced at least one day apart and will take about one hour per session.The mBCI training program will deliver cognitive training modules in tandem with a stationary cycling regime. The cognitive training program consists of six different gamified tasks that target attention, immediate/working and delayed memory, decision-making, and visuospatial abilities delivered on an electronic tablet. The cycling regime is divided into seven non-consecutive sections. The participant will be tasked to complete a cognitive training activity that will last about 2-3 minutes between each cycling session.
62405976|NCT02938819|EXPERIMENTAL|Experimental group|Patients in the experimental group received a Goal-oriented upper limb intervention.
62405977|NCT02938819|ACTIVE_COMPARATOR|Control group|Patients in the control group received a standard upper limb intervention
62581410|NCT00082446|EXPERIMENTAL|B|Subjects will receive a SC dose of MVA 5x10\^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
62789307|NCT01104727|ACTIVE_COMPARATOR|Single port|"Single-Port Cholecystectomy (SPC): a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.~In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones."
62789308|NCT06346015|EXPERIMENTAL|Gamma Entrainment Stimulation + Standard Care|Gamma Entrainment Stimulation
62789309|NCT06346015|NO_INTERVENTION|Standard Care|
62789310|NCT06205238|EXPERIMENTAL|Domiciliary CGA|The intervention will consist of domiciliary CGA including nursing, medical and allied health assessment and intervention for frail older adults over age 75 who are discharged the ED or referred urgently from their GP and referred to the CST in Limerick. The bulk of this intervention will be delivered in the patient's own home. Each participant will be required to attend the hub for their medical review where they will access specialist geriatric medical expertise. A domiciliary visit to the older person within 24-48 hours of referral from the ED or within 24-48 hours of triage of GP referral by a member of the multidisciplinary team. This person will act as the case coordinator. During this visit, there will be a detailed assessment of the older adult. Referrals will be made for domiciliary care to the appropriate healthcare professionals based on patient. The template proposed by Ellis et al. (2017) will be used to characterise the components of the CGA intervention.
62789311|NCT06205238|ACTIVE_COMPARATOR|Hub-based CGA|The intervention will consist of CGA as defined above, including nursing, medical and allied health assessment and intervention for frail older adults over age 75 who are discharged the ED or referred urgently from their General Practitioner and referred to the CST in Limerick and will be seen in the Out-patient CST setting.
62789312|NCT03226496|EXPERIMENTAL|Intervention Group|This group receives a brief motivational interviewing session about PrEP
62789313|NCT03226496|NO_INTERVENTION|Control Group|This group receives standard of care clinic based counseling about PrEP
62789314|NCT04518540|EXPERIMENTAL|lipoic acid group|The patients will take lipoic acid by intravenous. At the same time, the patients will take take riluzole tablets orally everyday.
62207451|NCT05163769|EXPERIMENTAL|Neurocognitive-Training only|The participants in the Neurocognitive training-only arm (nBCI) will undergo 48 cognitive training sessions over 24 weeks on the NeeuroCycle BCI Cognitive training system. The sessions are scheduled three times a week for the first 12 weeks and then once a week for the subsequent 12 weeks. Sessions are spaced at least one day apart and will take about one hour per session. The nBCI training protocol will deliver cognitive training modules that consists of six different gamified tasks that target attention, immediate/working and delayed memory, decision-making, and visuospatial abilities delivered on an electronic tablet. Participants will navigate the virtual space of the cognitive training program by using arrow keys on the tablet.
62789315|NCT04518540|EXPERIMENTAL|control group|The patients will take riluzole tablets orally everyday.
62789316|NCT06524193|EXPERIMENTAL|Telepractice group voice therapy|Voice therapy delivered in group basis via telepractice.
62405978|NCT01574976|ACTIVE_COMPARATOR|control, no feeback|subjects without ADHD, probabilistic choices without feedback
62405979|NCT01574976|ACTIVE_COMPARATOR|control, feedback|subjects without ADHD, probabilistic choices with feedback
62405980|NCT01574976|EXPERIMENTAL|ADHD, no feedback|subjects with ADHD, probabilistic choices without feedback
62405981|NCT01574976|EXPERIMENTAL|adhd, feedback|subjects with ADHD, probabilistic choices with feedback
62405982|NCT04514224||Healthy Start Program 1|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
62789317|NCT06524193|ACTIVE_COMPARATOR|Face-to-face group voice therapy|Voice therapy that will be delivered in group basis in-person with patients.
62581411|NCT00082446|EXPERIMENTAL|A|Subjects will receive a SC dose of MVA 2x10\^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
62581412|NCT00082446|EXPERIMENTAL|F|Subject will receive an IM dose of MVA 1x10\^8 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
62581413|NCT05349110||Gastroenterology patients|"Patient receiving a colonoscopy because of regular care will be considered eligible for inclusion if at least one diminutive colorectal polyp is encountered during the colonoscopy. Patients receive an endoscopic procedure in the context of the Dutch national screening program, because of gastrointestinal symptoms, or because of follow-up of previously diagnosed bowel diseases.~Colonoscopies will be executed using Fujifilm endoscopy systems (Fujifilm® Corporation, Tokyo, Japan), using Pentax endoscopy systems (Pentax Medical®, Hamburg, Germany), and using Olympus endoscopy systems (Olympus®, Tokyo, Japan)."
62789318|NCT00897221|EXPERIMENTAL|Dose 1|Deferiprone oral solution 20 mg/kg/day
62789319|NCT00897221|EXPERIMENTAL|Dose 2|Deferiprone oral solution 40 mg/kg/day
62207452|NCT05163769|NO_INTERVENTION|Active Control|The participants in the Active Control arm (AC) will undergo 48 sessions over 24 weeks. The sessions are scheduled three times a week for the first 12 weeks and then once a week for the subsequent 12 weeks. Sessions are spaced at least one day apart and will take about one hour per session. Participants in this arm will view informative documentaries on an electronic tablet and answer three general questions about documentary.
62405983|NCT04514224||Community Health Center 1|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
62581414|NCT01661088|EXPERIMENTAL|Study Treatment|"Patients will receive FOLFIRINOX x 6 followed by IMRT concurrent with fixed dose rate (FDR)-gemcitabine (1g/m\^2) on days 1, 8, 22, 29.~Intensity-modulated radiotherapy (IMRT): The prescribed dose was 50.0Gy in 2.0Gy per fraction.~Patients without metastatic disease will be offered surgical exploration."
62581415|NCT03852264|EXPERIMENTAL|Pet Dog Interaction first, then Nonsocial Control, then Unfamiliar Dog Interaction|Participant's first study visit involved 25 minutes of interaction with the participant's pet dog. The second study visit involved 25 minutes of individual play with toys. The third study visit involved 25 minutes of interaction with an unfamiliar dog.
62789320|NCT00003199|EXPERIMENTAL|Arm I|See Detailed Description.
62789321|NCT00002913|EXPERIMENTAL|Treatment (paclitaxel, cisplatin, topotecan hydrochloride)|"Patients receive paclitaxel IV over 3 hours and cisplatin IV on day 1, followed by topotecan IV over 30 minutes on days 1-3. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 4 and continuing until blood counts recover. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 4-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicities."
62405984|NCT04514224||Healthy Start Program 2|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
62789322|NCT02663830|EXPERIMENTAL|(Sildenafil & clomiphene citrate group)|105 Patients will receive 25 mg sildenafil citrate 6 hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
62581416|NCT03852264|EXPERIMENTAL|Unfamiliar Dog Interaction first, then Nonsocial Control, then Pet Dog Interaction|Participant's first study visit involved 25 minutes of interaction with an unfamiliar dog. The second study visit involved 25 minutes of individual play with toys. The third study visit involved 25 minutes of interaction with the participant's pet dog.
62017356|NCT03765957|EXPERIMENTAL|Mesenchymal Stem Cells|The mesenchymal stem cells will be derived from human umbilical cord. After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjects of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment.
62581417|NCT06148038|EXPERIMENTAL|CBD Oral|CBD Oral 350mg twice daily for 28 days
62207453|NCT06208449|EXPERIMENTAL|Robotic repair group|"1. the patients were lying in a left decubitus position (45° prone).~2. An 8-mm trocar was inserted into the thoracic cavity at the fifth intercostal space of the right midaxillary line and used as a camera port, Another two 8-mm trocars were placed at the third intercostal space of the right midaxillary line and the eighth intercostal space of the posterior axillary line. Insufflation of the CO2 was at a flow rate of 1 L/min and a pressure of 6 mm Hg.~3. The fistula was ligated and sutured by figure-of-eight suture ligation. The proximal blind end was fully mobilized and the distal blind end was properly mobilized to prepare for anastomosis.~4. Next, the 5-0 absorbable sutures were used to perform the anastomosis posteriorly and anteriorly in an interrupted way.. Thereafter, the nasogastric tube was inserted into the stomach. followed by another 6 sutures to complete the anterior wall anastomosis.~5. A chest drain was placed alongside the anastomosis."
62581418|NCT06148038|PLACEBO_COMPARATOR|Placebo control|Placebo control Oral twice daily for 28 days
62789323|NCT02663830|ACTIVE_COMPARATOR|clomiphene only|105 patients will receive only clomiphene citrate 100mg/day (day 2 to 6) orally (2 tablets at same time daily).
62017357|NCT03540901|ACTIVE_COMPARATOR|ACETAZOLAMIDE oral capsule|375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3100m until the morning after the second night at 3100m
62581419|NCT04905472|EXPERIMENTAL|Vestibular & Cochlear Implant Patients|"* scheduled for CI surgery because of deafness~* a minimum of five year history of documented absence of auditory and vestibular function, based on review of their audiograms and vestibular tests.~* Specific vestibular criteria are: peak ice water caloric response of less than 3 deg/s for each ear; yaw VOR time constant \< 3.0 sec and gain \< 0.25; and reduced head impulse gain (\<0.25) for all canal planes.~* Specific audiographic criteria: 80dB or greater sensorineural hearing loss in both ears"
62581420|NCT00579579||1|Patients Undergoing Surgery for Rectal Cancer
62581421|NCT02446210|ACTIVE_COMPARATOR|Healthy Controls Group|Magstim 200 magnetic stimulator for Transcranial Magnetic Stimulation and Peripheral Nerve Stimulation
62581422|NCT02446210|ACTIVE_COMPARATOR|Spinal Cord Injury Group|Magstim 200 magnetic stimulator for Transcranial Magnetic Stimulation and Peripheral Nerve Stimulation
62017358|NCT03540901|PLACEBO_COMPARATOR|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3100m until the morning after the second night at 3100m.
62405985|NCT04514224||Community Health Center 2|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
62581423|NCT05779033|PLACEBO_COMPARATOR|control group|will receive scapular stabilization exercises 3 times per week for 4 weeks.
62581424|NCT05779033|ACTIVE_COMPARATOR|study group (A)|will receive scapular stabilization exercises and Kinesiotape 3 times per week for 4 weeks
62581425|NCT05779033|ACTIVE_COMPARATOR|study group (B)|will receive scapular stabilization exercises and Ultrasound 3 times per week for 4 weeks.
62581426|NCT04717531|EXPERIMENTAL|Cohort A|"2 cycles of pyrotinib and trastuzumab with docetaxel followed by 4 cycles of pyrotinib, epirubicin, and cyclophosphamide (THB\*2-ECB\*4). The cycles repeated every 21 days.~Pyrotinib: 400mg, qd, po, day 1-21; Trastuzumab: 6 mg/kg, day 1; Docetaxel: 100 mg/m2, day 1; Epirubicin: 90 mg/m2, day 1; Cyclophosphamide: 600 mg/m2, day 1."
62789324|NCT03261791|EXPERIMENTAL|Apatinib|Apatinib mesylate tablets 500 mg po qd.
62789325|NCT01020656||group 1|patients with no anticoagulants used as the control group
62735022|NCT03302689|EXPERIMENTAL|Ropivacaine|TAP-block with Ropivacaine Solution
62017359|NCT02787616||Rosacea Group|
62789326|NCT01020656||group 2|patients treated with anticoagulant therapy (warfarin, fluindone, acenocoumarol)
62789327|NCT01020656||group 3|patients treated with aspirin
62789328|NCT01020656||group 4|patients treated with clopidogrel therapy
62789329|NCT01020656||group 5|patients treated with both anticoagulant and aspirin medications
62789330|NCT01020656||group 6|patients treated with both anticoagulant and clopidogrel medications
62405986|NCT04514224||Healthy Start Program 3|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
62405987|NCT04514224||Community Health Center 3|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
62789331|NCT01020656||group 7|patients treated with both aspirin and clopidogrel medications
62789332|NCT03807414||Critically ill patients|In centres that obtained IRB approval for this prospective study, all critically ill adult patients (\>18yrs) undergoing treatment with oXiris will be prospectively observed.
62017360|NCT02787616||Non-Rosacea Group|
62405988|NCT04514224||Healthy Start Program 4|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
62789333|NCT00976833|ACTIVE_COMPARATOR|Usual Care|Usual Care
62789334|NCT00976833|OTHER|Standardized Rehabilitation|Intervention arm to receive Standardized Rehabilitation Therapy
62789335|NCT01616680|EXPERIMENTAL|Supportive care (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15.
62789336|NCT05185050||AIS with MPS|the participants who has Cobb angle above 10 degrees and diagnosed with myofascial pain syndrome
62789337|NCT05185050||AIS with no pain|the participants who has Cobb angle above 10 degrees and without pain
62789338|NCT01196351|EXPERIMENTAL|Sedentary activity, noncaloric beverage|
62789339|NCT01196351|EXPERIMENTAL|Sedentary activity, glucose beverage|
62789340|NCT01196351|EXPERIMENTAL|Exercise activity, noncaloric beverage|
62789341|NCT01196351|EXPERIMENTAL|Exercise activity, glucose beverage|
62789342|NCT02061514|EXPERIMENTAL|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
62789343|NCT02061514|ACTIVE_COMPARATOR|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
62405989|NCT04514224||Community Health Center 4|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
62581427|NCT04717531|ACTIVE_COMPARATOR|Cohort B|"2 cycles of trastuzumab and pertuzumab with docetaxel followed by 4 cycles of epirubicin and cyclophosphamide (THP\*2-EC\*4). The cycles repeated every 21 days.~Trastuzumab: 6 mg/kg, day 1; Pertuzumab: 420 mg, day 1; Docetaxel: 100 mg/m2, day 1; Epirubicin: 90mg/m2, day 1; Cyclophosphamide: 600 mg/m2, day 1."
62581428|NCT02471378||Pregnant Women 15-25 years old|Malaria-infected pregnant Women
62789344|NCT00932581||Full Exam|The first group will receive the full motor examination section in its original order.
62789345|NCT00932581||Subscale|The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
62405990|NCT04514224||Healthy Start Program 5|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
62581429|NCT05394259|EXPERIMENTAL|Piflufolastat F18|Piflufolastat F18 will first be given by vein over about 5 seconds.
62735023|NCT03302689|EXPERIMENTAL|Levobupivacaine|TAP-block with Levobupivacaine Solution
62789346|NCT01776034|EXPERIMENTAL|SystemCHANGE Group Lifestyle counseling|"The SystemCHANGE™ intervention will be delivered over a six-month period involving 12 face-to-face group sessions (1.5 to 2 hours each) held weekly for three months, followed by three monthly booster calls. Intervention groups include \~10 to 15 patients, and friends and family members are encouraged to attend. Intervention sessions consist of 30-min to 60-min of behavior change activities and 60-min focused on healthy behaviors."
62789347|NCT01776034|ACTIVE_COMPARATOR|Phone Lifestyle Counseling|Participants will receive pamphlets that contain information on healthy eating, physical activity, sleep, and symptom management, and will be followed-up with telephone calls.
62789348|NCT02163109||Critically-ill patients|Adult patients requiring intubation and mechanical ventilation on an intensive care unit, predicted to require a further 48 hours of artificial ventilation
62789349|NCT01336413|ACTIVE_COMPARATOR|Arm 1|Pregnenolone
62405991|NCT04514224||Healthy Start Program 6|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
62405992|NCT03304132||Upper aerodigestive squamous cell cancers (UADSCC) cases|From PLCO and ACS CPS II, identified 140 UADSCC cases. These cases are frequency matched 3:1 (420 controls) by incidence density sampling for study (ACS. PLCO),
62789350|NCT01336413|PLACEBO_COMPARATOR|Arm 2|Placebo
62789351|NCT02547558|EXPERIMENTAL|Indacaterol|"Drug:~-Indacaterol, inhaled, single dose, 300 mcg~Diagnostic Interventions:~* Arterial blood gases~* Cardiac output~* Vital signs~* Exhaled breath~* Spirometry"
62789352|NCT01112878|PLACEBO_COMPARATOR|Sugar Pill|"Frequency and Dosage:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
62789353|NCT01112878|ACTIVE_COMPARATOR|Clonidine|"Dosage: 0.2 mg~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
62789354|NCT01112878|ACTIVE_COMPARATOR|Gabapentin|"Dosage: 600 mg~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
62789355|NCT01685697|ACTIVE_COMPARATOR|Laerdal Mask|Mask ventilation with a Laerdal face mask
62789356|NCT01685697|EXPERIMENTAL|F&P Mask|Mask ventilation with a F\&P face mask
62789357|NCT00117299|EXPERIMENTAL|A|PTK/ZK o.d. 1250 mg p.o.
62789358|NCT05240365|EXPERIMENTAL|SDF modified Hall technique|"When Hall technique is used an accurate size of PMC is placed without local anesthesia, caries removal, or tooth preparation.~SDF is applied directly to carious lesions to arrest caries, the technique is noninvasive and relatively painless that could be a good option for treating dental caries in children"
62789359|NCT05240365|ACTIVE_COMPARATOR|Conventional pulpotomy and stainless steel crown|Amputation of the coronal pulp and treatment of the remaining vital radicular portion with a long term clinically successful medicament. Then using an accurate size of stainless steel crown.
62789360|NCT03489889|EXPERIMENTAL|capsule|pharmaceutical form: capsule ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months
62789361|NCT03489889|EXPERIMENTAL|tablet|pharmaceutical form: tablet ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months
62405993|NCT03304132||Controls|From PLCO and ACS CPS II, we have identified 140 UADSCC cases. These cases are frequency matched 3:1 (420 controls) by incidence density sampling for study (ACS. PLCO),
62789362|NCT05658705|EXPERIMENTAL|experimental group(15-min supine group)|Participants in the experimental group will keep supine position for 15 minutes before AVS.
62789363|NCT05658705|ACTIVE_COMPARATOR|control group(2-hour supine group)|Participants in the control group will keep supine position for 2 hours before AVS.
62789364|NCT04239651|ACTIVE_COMPARATOR|Enrolment in rTMS sessions alone|All patients will be scheduled to receive 30 sessions of rTMS treatments over a six-week period as pre-determined by Alberta Health Services' Strategic Clinical Network for Addiction and Mental Health.
62789365|NCT04239651|ACTIVE_COMPARATOR|Enrolment in iCBT Plus rTMS|Patients in the rTMS plus iCBT arm of the study, would be assisted to register on the iCBT program (Moodgym) to receive unique login information. They would be assisted to participate in 12 one-hour sessions of iCBT at the clinic prior to receiving rTMS treatments. These in-clinic iCBT sessions would be scheduled in about three days intervals (ideally Tuesdays and Thursdays) so that patients receive two iCBT sessions each week. Patients would also be encouraged to continue with iCBT treatments on their own at home outside the sessions delivered in the clinic.
62789366|NCT02586948|EXPERIMENTAL|extracorporeal CO2 removal|extracorporeal CO2 removal initiated shortly after intubation, using the veno-venous Hemolung device
62789367|NCT05508919|EXPERIMENTAL|Biofeedback Group|"* The training consists of a total of 8 sessions for every individual with 2 sessions per week over the duration of 4 weeks. Each session will be approximately of 1 to 1.30 hour.~* Subjects will be given clear instructions to not to use chocolate, coffee, tea and cocoa drinks at least 3 hours before the training session.~* Since it is suggested that Anxiety tends to change with time so we might consider a one-month pretreatment measure as well as a just before treatment measure. That way we can be sure if our baseline is stable or not.~* Baseline session: Subject will be asked to sit quietly for 15 minutes and their breathing rate, skin temperature and muscle tension using EMG will be measure without giving any intervention.~* Subjects will then be given biofeedback training gradually to control their breathing rate, relaxed their muscle activity and temperature through RESP biofeedback, assisted EMG biofeedback and TEMP biofeedback, from the 1st session till their 8th Session."
62789368|NCT05508919|ACTIVE_COMPARATOR|Active Control Group|Active Control: Writing Sessions The subjects will be asked to take three 20-minute writing sessions and write about the given control topic about their daily events of the past week. For example, in Session 1, we may ask the Subjects to write about how they will use their time. Similarly, we will ask the subject to give more detail and write briefly about the given control condition in session 2 and session 3. At the end of three writing session, we will measure their EMG, RESP and TEMP to compare with the Biofeedback training group.
62405994|NCT03495167|EXPERIMENTAL|SyB C-1101|
62405995|NCT03546270|EXPERIMENTAL|Swimming|Participants performed SWM training (combination of free style, breast stroke, and backstroke) for 20 weeks. For the first 5 weeks subjects swam 25-30 minutes/day, 3-4 days/week at \~60% of maximal heart rate. As their overall level of fitness and exercise skill improved, the intensity and duration of exercise increased to 40-45 minutes/day, 3-4 days/week at an intensity of 70-75% of the HRmax. Target HR was adjusted based on the observation that maximal heart rate during SWM is approximately 12 beats/min lower than that during running. Each subject was instructed to swim continuously except during the time needed for checking a target heart rate
62405996|NCT03546270|NO_INTERVENTION|Control|Participants in the non-exercising control group did not participate in a supervised exercise program and visited the laboratory at the same frequency as participants in the swim intervention and underwent recreational activities such as board games
62405997|NCT02853825|NO_INTERVENTION|Wait List Control Group|No interventions given, this is a wait list control group.
62789369|NCT05767359|EXPERIMENTAL|Safety Run-In|"Participants will be enrolled into each of the 2 safety run-in phases in a standard 3 + 3 design.~- Participants will undergo study procedures as outlined:~* Apheresis for collection of peripheral blood mononuclear cells (PBMC) will occur on-site~* Stem cell collection on-site post-apheresis per standard care.~* Administration of Cyclophosphamide and fludarabine in pre-determined doses 1 x daily for 3 consecutive days.~* Hospitalization to receive Cilta-cel in per-determined dose per protocol 1 x daily for 3 consecutive days and will remain in the hospital for 2 weeks post cilta-cell infusion.~* Follow-up for 3 years post-treatment and up to 15 years."
62017361|NCT02279303|EXPERIMENTAL|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
62017362|NCT02279303|ACTIVE_COMPARATOR|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
62017363|NCT02711657|EXPERIMENTAL|Fibrocyte measurement and lung function test|All participants has a peripheral blood sample taken, where fibrocytes are measured using flowcytometry. Further peripheral blood mononuclear cells (PBMC) are isolated and cultured. All, except healthy controls, have their lung function measured.
62017364|NCT04793321|OTHER|healty nulliparous females|"each participant did three conditions:~1. holding nothing (unloaded).~2. holding an infant mannequin in arms(arms).~3. holding an infant mannequin in the baby carrier(carriers)."
62017365|NCT05615311|EXPERIMENTAL|Vitamin D group|
62017366|NCT05615311|PLACEBO_COMPARATOR|Control group|
62017367|NCT02086591|EXPERIMENTAL|Doxycycline|Doxycycline 200 mg twice daily
62405998|NCT02853825|EXPERIMENTAL|Intervention Group|Receive relationship skill enhancement classes with access to parenting, employment services, and financial services.
62017368|NCT02188823|EXPERIMENTAL|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate, ketogenic diet: carbohydrate intake 20-35 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.~Participants will also be taught information about exercise, sleep, mindfulness, and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
62017369|NCT04411290||Total Thyroidectomy (TT)-indicated patients|Patients with presumably benign thyroid disease (multinodular goitre, solitary thyroid nodule, toxic goitre, etc.) Patients with thyroid carcinoma (biopsy-proved) Total thyroidectomy preference by the primary surgeon
62017370|NCT03397511|EXPERIMENTAL|Usual Care+Financial Incentive|Smoking cessation counseling couples with financial incentives
62017371|NCT00113516|EXPERIMENTAL|1|
62017372|NCT02843789|EXPERIMENTAL|Adiponectin evaluation|Patients evaluated for serum adiponectin level and for body composition before each infusion of Tocilizumab
62017373|NCT01962974|EXPERIMENTAL|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
62017374|NCT02120924|ACTIVE_COMPARATOR|Finacea|Finacea® (azelaic acid) Gel, 15% (Intendis)
62017375|NCT02120924|EXPERIMENTAL|Azelaic Acid|Azelaic Acid, 15% topical gel (Watson Laboratories, Inc.)
62017376|NCT02120924|PLACEBO_COMPARATOR|Vehicle Gel|Gel Vehicle of the test product (Watson Laboratories, Inc.)
62017377|NCT06043362|EXPERIMENTAL|0 mg + Smooth flavor|Participants are provided with zero strength (0 mg) nicotine pouches with smooth flavor.
62207454|NCT06208449|EXPERIMENTAL|Thoracoscopic repair group|"1. All procedures were performed through three ports~2. Insufflation of the CO2 was at a flow rate of 1 L/min and a pressure of 4-6 mm Hg.~3. The azygos vein was ligated and cut, or divided by electrocoagulation.~4. The fistula was then dissociated, ligated with 4-0 absorbable sutures, and divided.~5. After identifying the proximal esophageal pouch with a nasogastatic tube, the proximal and distal blind ends were mobilized to prepare for anastomosis.~6. Next, the tip of the blind ends was excised, and the anastomosis was completed with 5-0 absorbable sutures in an interrupted manner.~7. A chest drain was placed alongside the anastomosis."
62581430|NCT04539899|EXPERIMENTAL|VR+|For patients in the experimental group, using the virtual reality helmet, the caregiver will position the helmet on the patient when she is placed on the gynecological examination table. He or she will make sure that the patient can see and hear the current sequence. The caregiver can then proceed with the different steps of the IUD insertion. Once the procedure is completed, the caregiver will indicate to the patient that she can remove the headphones.
62581431|NCT04539899|NO_INTERVENTION|VR-|For patients in the control group, without a helmet, the course of the consultation will not be modified.
62017378|NCT06043362|EXPERIMENTAL|3 mg + Smooth flavor|Participants are provided with medium strength (3 mg) nicotine pouches with smooth flavor.
62017379|NCT06043362|EXPERIMENTAL|6 mg + Smooth flavor|Participants are provided with high strength (6 mg) nicotine pouches with smooth flavor.
62017380|NCT06043362|EXPERIMENTAL|0 mg + Wintergreen flavor|Participants are provided with zero strength (0 mg) nicotine pouches with wintergreen flavor.
62017381|NCT06043362|EXPERIMENTAL|3 mg + Wintergreen flavor|Participants are provided with medium strength (3 mg) nicotine pouches with wintergreen flavor.
62017382|NCT06043362|EXPERIMENTAL|6 mg + Wintergreen flavor|Participants are provided with high strength (6 mg) nicotine pouches with wintergreen flavor.
62017383|NCT04233814|SHAM_COMPARATOR|Placebo|Matching placebo is a micronized lactose powder administered by inhalation through a dry powder inhaler (DPI)
62017384|NCT04233814|EXPERIMENTAL|SAD Cohort 1|LTI-03 20 mg delivered qd x 1 day via DPI
62017385|NCT04233814|EXPERIMENTAL|SAD Cohort 2|LTI-03 40 mg delivered qd x 1 day via DPI
62581432|NCT00657904|EXPERIMENTAL|1|
62017386|NCT04233814|EXPERIMENTAL|SAD Cohort 3|LTI-03 80 mg delivered qd x 1 day via DPI
62017387|NCT04233814|EXPERIMENTAL|MAD Cohort 1|LTI-03 dose at 20mg once daily x 14 days via DPI
62017388|NCT04233814|EXPERIMENTAL|MAD Cohort 2|LTI-03 dose at 40mg once daily x 14 days via DPI
62017389|NCT04233814|EXPERIMENTAL|MAD Cohort 3|LTI-03 dose at 2.5 mg once daily x 14 days via DPI
62017390|NCT04233814|EXPERIMENTAL|MAD Cohort 4|LTI-03 dose at 5 mg once daily x 14 days via DPI
62017391|NCT04233814|EXPERIMENTAL|MAD Cohort 5|LTI-03 dose at 5 mg twice daily x 14 days via DPI
62017392|NCT04832204|EXPERIMENTAL|solid tumor with only liver metastases after first line treatment|Apatinib 250mg, Qd, oral administration,SHR-1210 200mg, q3w one week later, intravenous administration, continuous administration until the disease progresses or an intolerable adverse reaction occurs.
62581433|NCT00657904|PLACEBO_COMPARATOR|2|
62789370|NCT05767359|EXPERIMENTAL|Cilta-Cel Dose Expansion Cohort|"Expansion cohort of 14 participants will be enrolled after safety run-in phases, and participants will undergo study procedures as outlined:~* Apheresis for collection of peripheral blood mononuclear cells (PBMC) will occur on-site~* Stem cell collection on-site post-apheresis per standard care.~* Administration of Cyclophosphamide and fludarabine in pre-determined doses 1 x daily for 3 consecutive days.~* Hospitalization to receive Cilta-cel in per-determined dose per protocol 1 x daily for 3 consecutive days and will remain in the hospital for 2 weeks post cilta-cell infusion.~* Follow-up for 3 years post-treatment and up to 15 years."
62789371|NCT00121186|EXPERIMENTAL|Nonmyeloablative allogeneic stem cell transplant|Patients are given fludarabine 30 mg/m\^2 on days -6 to -2 and melphalan 70 mg/m\^2 on days -3 and -2, then transplanted with donor peripheral blood stem cells or harvested bone marrow stem cells on day 0. Patients are then given post-transplant immunosuppression consisting of tacrolimus 0.06 mg/kg/day on days -3 to 100 and methotrexate 5 mg/m\^2 on days 1, 3, and 7.
62207455|NCT06208449|ACTIVE_COMPARATOR|Thoracotomy repair|Usually, the fifth intercostal space was applied using the muscular-sparing technique. Fistula ligation, proximal pouch isolation and anastomosis were performed in turn.The fistula was then dissociated, ligated with 4-0 absorbable sutures, and divided. After identifying the proximal esophageal pouch with a nasogastatic tube, the proximal and distal blind ends were mobilized to prepare for anastomosis. Next, the tip of the blind ends was excised, and the anastomosis was completed with 5-0 absorbable sutures in an interrupted manner. A chest drain was placed alongside the anastomosis.
62789372|NCT04548804|EXPERIMENTAL|Control|Control subjects receiving body-surface potential mapping (BSPM) and either a CT-scan or a CMR scan
62789373|NCT04548804|EXPERIMENTAL|Diseased|Diseased subjects receiving body-surface potential mapping (BSPM) and either a CT-scan or a CMR scan. Outcome measures from these procedures will be compared to controls.
62789374|NCT02265250||Asymptomatic, CACS <300|"5 asymptomatic subjects with low CVD risk, defined as recent coronary artery calcium score (CACS) \<300~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers)"
62581434|NCT03231202|EXPERIMENTAL|Embolization|"The intervention arm will perform SAE as a central embolization of the splenic artery.~Additional peripheral embolization is left to the discretion of the interventional radiologist.~The study does not interfere with local diagnostic work-up and treatment protocols."
62789375|NCT02265250||Asymptomatic, CACS ≥300|"5 asymptomatic subjects with increased CVD risk, defined as a recent coronary artery calcium score (CACS) ≥300~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
62207456|NCT06380296|ACTIVE_COMPARATOR|NeoMTA|Trained dentists will perform the primary molar pulpotomy following a standardized protocol. After amputation of the coronal pulp, the pulp chamber will be filled with NeoMTA 2. Tooth will be then restored with an appropriately sized stainless steel crown cemented with a glass ionomer cement at the same visit. Follow-up visits will be scheduled at 1, 6, 12 and 24 months after the procedure to assess the success rate of primary molars pulpotomy.
62207457|NCT06380296|EXPERIMENTAL|NeoPUTTY|Trained dentists will perform the primary molar pulpotomy following a standardized protocol. After amputation of the coronal pulp, the pulp chamber will be filled with NeoPUTTY. Tooth will be then restored with an appropriately sized stainless steel crown cemented with a glass ionomer cement at the same visit. Follow-up visits will be scheduled at 1, 6, 12 and 24 months after the procedure to assess the success rate of primary molars pulpotomy.
62405999|NCT02395393|OTHER|Lung transplant recipients|In patients scheduled for bronchoscopy as part of regular clinical care/diagnostic workup, the investigators will offer the patient concurrent confocal microscopy imaging to be performed during the bronchoscopic procedure. A 1.4mm or 1.9mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli.
62406000|NCT02224794||Fast-Track Group|includes subjects who complete the Fast-Track EVAR protocol
62406001|NCT02224794||Standard P-EVAR Group|includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are completed with bilateral percutaneous access
62581435|NCT03231202|NO_INTERVENTION|Observation|The control arm in this randomized controlled trial will include only NOM patients diagnosed with splenic injuries OIS grade 4 or 5 and suitable for observation alone, and will comprise clinical observation according to local routines and protocols.
62581436|NCT00458536|EXPERIMENTAL|Cohort 1|Patients treated with DC/RCC vaccine to evaluate for treatment-limiting toxicity
62581437|NCT00458536|EXPERIMENTAL|Cohort 2|Patients treated with DC/RCC vaccine to evaluate response
62581438|NCT00723008|EXPERIMENTAL|A|Upon randomization, a double blinded Alpha Stim 100 device preset to the lowest effective setting (1/6) will be applied to the earlobes of the subject for one hour per day for 5 days per week for 4 weeks; after the blinded period is completed the patient will wear a different Alpha Stim device that has not been blinded for one hour per day for 5 days per week for 4 weeks, with settings at the patient's preference (1 to 6/6). Report of pain, anxiety will be assessed before and after each daily session during the 8 week period.
62581439|NCT00723008|EXPERIMENTAL|B|Upon randomization, a double blinded Alpha Stim 100 device preset to no stimulation (0/6)will be applied to the earlobes of the subject for one hour per day for 5 days per week for 4 weeks; after the blinded period is completed the patient will wear a different Alpha Stim device that has not been blinded for one hour per day for 5 days per week for 4 weeks, with settings at the patient's preference (1 to 6/6). Report of pain, anxiety will be assessed before and after each daily session during the 8 week period.
62581440|NCT02849145|EXPERIMENTAL|Biological/Vaccine|
62017393|NCT02464969|EXPERIMENTAL|Apixaban|Subjects between birth to \<18 years will be dosed on a body weight tiered regimen. Subjects ≥35kg will receive 10mg twice daily(BID) for 7 days followed by 5mg BID thereafter;\<35kg to 25kg will receive 8mg BID for 7 days followed by 4mg BID thereafter;\<25 to 18kg will receive 6mg BID for 7 days and then 3mg BID thereafter;\<18 to 12kg will receive 4mg BID for 7 days and then 2mg BID thereafter;\<12 to 9kg will receive 3mg BID for 7 days and then 1.5mg BID thereafter;\< 9kg to 6kg will receive 2 mg BID for 7 days and 1mg BID thereafter;\<6kg to 5kg will receive 1mg BID for 7 days and 0.5mg BID thereafter;\<5kg to 4kg will receive 0.6mg twice daily for 7 days and 0.3mg BID thereafter;PK cohort neonates ≥ 2.6kg will receive 0.1mg BID. Dose will be adjusted as determined by PK measurements (ie, to 0.2mg BID, 0.1mg daily or dose will stay the same).For the post PK cohort Neonates ˂4kg to 2.6kg, if confirmed by PK sub analysis,subjects will receive 0.2mg BID for 7 days and 0.1mg BID thereafter.
62207458|NCT06254612|EXPERIMENTAL|SP-624|Participants to receive two 10 mg capsules of SP-624 once daily for a total daily dose of 20 mg
62207459|NCT06254612|PLACEBO_COMPARATOR|Placebo|Participant to receive 2 matching placebo capsules once daily
62207460|NCT05152953||Persons with HIV|Persons with HIV who are currently taking antiretroviral therapy who reside in the study's target geographical areas.
62207461|NCT05152953||Pharmacy staff members|Pharmacists, pharmacy technicians, pharmacy managers, or clerks employed at a community pharmacy who would potentially be involved in program development, scheduling, financial aspects, planning or administration of long-acting injectable antiretroviral therapy in the pharmacy.
62207462|NCT05152953||Clinic staff members|Physicians, clinic managers, nurses, medical assistants, social work staff or case managers, therapists, and other clinic personnel who are involved or would potentially be involved in any aspect of long-acting antiretrovirals in the clinic facility including financial aspects, planning, scheduling patients, educating patients, ordering medication, or administering medications.
62207463|NCT00734357|EXPERIMENTAL|Isovue Arm|Subjects with a clinically scheduled CT examination will be given the contrast Isovue. The investigators of this study will determine which contrast medication subjects will receive using randomization.
62207464|NCT00734357|EXPERIMENTAL|Omnipaque Arm|Subjects with a clinically scheduled CT examination will be given the contrast Omnipaque. The investigators of this study will determine which contrast medication subjects will receive using randomization
62207465|NCT06419374|EXPERIMENTAL|Pegozafermin|
62207466|NCT06419374|PLACEBO_COMPARATOR|Placebo|Matched placebo
62207467|NCT02604888|OTHER|Volunteers|20 volunteers both men and women with an age between 18 and 70 years suffering from Alopecia Areata in several types apply on the scalp drops of the MEXIS/M6S PATENT - lotion against Alopecia
62581441|NCT01533324|EXPERIMENTAL|S-1 combined with LV|S-1 combined with LV
62406002|NCT02224794||Standard EVAR Group|includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are not completed with bilateral percutaneous access (i.e. converted to femoral cutdown or open surgical repair)
62406003|NCT00124709|EXPERIMENTAL|1|Pimecrolimus
62406004|NCT00124709|ACTIVE_COMPARATOR|2|Corticosteroid
62406005|NCT02726516|EXPERIMENTAL|Treated|Treated volunteers will be administered one dose of PRJ-205 1,5 hours before the exercise task for the acute testing and will be taking one dose per day of PRJ-205 for 4 days for the chronic testing.
62406006|NCT02726516|PLACEBO_COMPARATOR|Placebo|Placebo volunteers will be administered one dose of placebo 1,5 hours before the exercise task for the acute testing and will be taking one dose per day of placebo for 4 days for the chronic testing.
62406007|NCT02713724|ACTIVE_COMPARATOR|DAPS-group|Physical exercise
62406008|NCT02713724|ACTIVE_COMPARATOR|Standard-group|Limited physical exercise
62406009|NCT00346970|EXPERIMENTAL|1|Extended-release Niacin
62406010|NCT00346970|PLACEBO_COMPARATOR|2|Placebo
62581442|NCT04961450||Patients|"Inclusion Criteria:~1. Patients aged 18-80 years who visit Peking University Third Hospital, Beijing, China from December 2020.~   Patients who diagnosis MND/FTD spectrum disease (including ALS, FAS, FLS, PLS, PBP, PMA, FTD, MND-FTD) by an experienced neurologist strictly according to a list of diagnosis criteria and clinical guidelines~2. Informed consent signed~Exclusion Criteria~1. Patients who receive alternative diagnoses during the follow-up.~2. Patients who refuse to sign informed consent."
62789376|NCT02265250||Stable angina|"5 subjects with stable angina and evidence of coronary atherosclerosis based on a recent invasive or CT coronary angiogram~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
62017394|NCT05163860||Youth|TGGD youth age 12-17 will answer a survey regarding demographics (gender identity, sex assigned at birth, age, religion, degree of religiosity, degree of family religiosity, degree of conservatism/liberalism, degree of family conservatism/liberalism, ethnicity), age at which they revealed their gender identity, family gender environment (FGE), eating disorder risk (ADO-BED, previous Eating Disorder diagnosis), food insecurity (HVS), perceived support of healthy eating and physical activity (SheL), risk taking behavior (ARQ), adequacy of physical activity (PACE+), bodyweight (BMI, BMI%ile, %mBMI), and previously diagnosed psychiatric and neurodevelopmental disorders
62017395|NCT05163860||Young Adults|TGGD young adults age 18-25 will answer a survey regarding demographics (gender identity, sex assigned at birth, country of residence, ethnicity, age, religion, degree of religiosity, degree of family religiosity, degree of conservatism/liberalism), age at which they revealed their gender identity, family gender environment (FGE), eating disorder risk (SCOFF, ADO-BED, previous ED diagnosis), food insecurity (HVS), perceived support of healthy eating and physical activity (SheL), risk taking behavior (RRBQ), bodyweight (BMI), malnutrition risk (MST), and previously diagnosed psychiatric and neurodevelopmental disorders.
62207468|NCT01805752|EXPERIMENTAL|Integrated family-focused PMTCT arm|"Intervention package includes: 1) task-shifting to lower-cadre providers at PMTCT sites; 2) POC CD4+ cell count testing; (3) integrated mother-infant care; and (4) a prominent role for influential family members (male partners), working in close partnership with community-based health workers/volunteers.~Patients attending sites randomized to this arm will also receive group health education; opt-out HIV testing, same-day HIV test results; infant feeding counseling; HBC services; infant prophylaxis, early infant diagnosis, and linkage to family spacing services, if desired."
62207469|NCT01805752|NO_INTERVENTION|Standard of care|Arm will receive standard of care activities, namely: group health education; opt-out HIV testing, same-day HIV test results; infant feeding counseling; HBC services; infant prophylaxis, early infant diagnosis, linkage to family spacing services, if desired.
62207470|NCT05169333||Group 1|Participants attending cardiology department, hypertension or outpatient clinics.
62207471|NCT05169333||Group 2|Participants who are recruited prospectively, during their clinically indicated CT scan, and they are followed-up prospectively for clinical endpoints; A follow-up CCTA at least 6 months later will be offered to a subgroup of these patients, to assess disease progression.
62207472|NCT05169333||Group 3|Individuals where at least 6 months have elapsed from previous CCTA will undergo repeat CCTA scan and enter prospective follow up for clinical endpoints.
62207473|NCT05169333||Group 4|Cohort of consecutive patients who have undergone clinical CTAs or unenhanced CT chest, abdomen and pelvis in the past, linking the index CT scan with prospective outcomes collection already accumulated.
62207474|NCT00655525|ACTIVE_COMPARATOR|1|
62207475|NCT00655525|PLACEBO_COMPARATOR|2|
62207476|NCT06417775|EXPERIMENTAL|Double-Blind Period: Ubrogepant|Participants will receive ubrogepant during the double-blind period.
62406011|NCT03359278||open reduction and internal fixation|The volar approach was used for open reduction and internal fixation of distal radius fractures
62207477|NCT06417775|EXPERIMENTAL|Double-Blind Period: Placebo for Ubrogepant|Participants will receive placebo during the double-blind period.
62406012|NCT01583465|EXPERIMENTAL|Aquamantys Malleable Bipolar Sealer|In 100 patients randomly assigned, primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of the Aquamantys Malleable Bipolar Sealer with Light.
62207478|NCT06417775|EXPERIMENTAL|Open-Label Extension Period: Ubrogepant|Eligible participants from Double-Blind period may continue to receive ubrogepant during the open-label extension period.
62406013|NCT01583465|ACTIVE_COMPARATOR|Standard Treatment|100 patients randomly assigned will undergo primary total hip arthroplasty via the anterior supine intermuscular approach performed with the assistance of standard electrocautery.
62406014|NCT01969201|EXPERIMENTAL|Fostimon®|75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
62406015|NCT01969201|ACTIVE_COMPARATOR|Gonal-F®|75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
62735024|NCT03281031|OTHER|Additional MRI Examination|Single arm, all patient will undergo CT followed by additional MRI examination
62789377|NCT02265250||Recent acute MI|"5 subjects with a recent acute myocardial infarction (within 1 month) and evidence of coronary atherosclerosis based on invasive or CT coronary angiogram~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
62581443|NCT04961450||Control|"Control group consists of individuals matched for gender and age with the patients who are mainly the caregivers of the patients, including but not limited to the patients' spouses and their long-term nurses.~Exclusion criteria:~1. Suffering from neurological disease, including but not limited to motor neuron disease/frontotemporal dementia spectrum disease, dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, neuromyelitis and so on.~2. Individuals who refuse to sign informed consent."
62017396|NCT05163860||Parents|Parents of TGGD youth will answer a survey with information regarding demographics (religion, degree of religiosity, degree of conservatism/liberalism, country of residence, ethnicity, gender identity, sex assigned at birth, sexual orientation, education, marital status, household size, income), anxiety (GAD-7), depression (PHQ-9), family gender environment (FGE), food insecurity (HVS), height and bodyweight (BMI).
62017397|NCT00614939|EXPERIMENTAL|Saxa|Saxagliptin
62017398|NCT00614939|NO_INTERVENTION|Placebo|Placebo to match
62017399|NCT06398704||Sarcopenia Group|Individuals with sarcopenia according to the ISarcoPRM algorithm using the STAR method and Hand-grip
62017400|NCT06398704||Dinapenia Group|Individuals with dynapenia according to the ISarcoPRM algorithm using the STAR method and Hand-grip
62017401|NCT06398704||Non-sarcopenia Group|Individuals with non-sarcopenia according to the ISarcoPRM algorithm using the STAR method and Hand-grip
62017402|NCT04888286||patients who underwent mismatched allogeneic transplantation|Pediatric and adult patients who underwent mismatched allogeneic transplantation, from January 2014 to June 2017.
62017403|NCT03845257||Patients with COPD|"The following parameters are to be evaluated:~* Blood eosinophils~* FeNO~* Eosinophils in bronchoalveolar lavage~* Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)"
62017404|NCT03845257||Patients with asthma|"The following parameters are to be evaluated:~* Blood eosinophils~* FeNO~* Eosinophils in bronchoalveolar lavage~* Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)"
62207479|NCT01269723|ACTIVE_COMPARATOR|Broccoli sprout homogenate|"The broccoli sprouts and water are chopped in a blender until a uniform mix is obtained. Salt or sugar may be added to the shake."
62207480|NCT01269723|PLACEBO_COMPARATOR|alfalfa sprout homogenate|"Alfalfa sprouts and water are chopped in a blender until a uniform mix is obtained. Salt or sugar may be added to the shake."
62406016|NCT04166188|EXPERIMENTAL|Cadavers|"20ml of 0.01% methylene blue solution (50mg of methylene blue diluted in 0.9% saline 500ml) will be injected, simulating the LESP block technique: injection between the transverse process of the fourth lumbar vertebra (L4) and the erector muscle of the underlying spine.~The injection will be performed with a Quincke 20G 100-150mm ultrasound-guided needle with a low-frequency curvilinear transducer (4-8 MHz - SonoSite) in the plane between the transverse process of L4 and the spinal erector muscle, bilaterally in each cadaver. by the same operator.~After injection of the solution the cadavers will be submitted to posterior lumbar region dissection by an anatomist and analyzed the dispersion and impregnation of the blue solution. The anatomical structures with the dye dispersion will be photographed and stored."
62406017|NCT02835794|EXPERIMENTAL|Arm 1|Omacetaxine - escalating doses subcutaneous twice daily on Days 1-5 and 8-12 Azacitidine 50 mg/m2 subcutaneous/intravenous daily on Days 8-12 G-CSF 5mcg/kg subcutaneous daily on Days 15-19 and 22-26
62406018|NCT02058459|ACTIVE_COMPARATOR|Targeted Lung Denervation|active targeted lung denervation
62406019|NCT02058459|SHAM_COMPARATOR|Sham-Control|non-active targeted lung denervation
62406020|NCT00882804|EXPERIMENTAL|Hemin|
62406021|NCT00882804|PLACEBO_COMPARATOR|placebo|
62406022|NCT00658203|ACTIVE_COMPARATOR|1|PEA optimized CRT
62406023|NCT00658203|OTHER|2|Standard optimized CRT
62581444|NCT05708157||Active group|Patients with perennial allergic rhinitis who receive concomitant intranasal antihistamine and corticosteroid.
62581445|NCT01163968|EXPERIMENTAL|Weight reduction program|MOMENTUM intervention
62581446|NCT01016899||Non-melanoma skin cancer|Early stage squamous or basal cell carcinoma
62017405|NCT05333445|EXPERIMENTAL|Nursing intervention|The NI will be performed at 3 times: face to face between 21 and 7 days before admission, between 7 and 15 days after the date of ablation, and 6 months after the ablation procedure.
62207481|NCT04702321||Patient cohort|Patients with clinical data and biospecimens
62207482|NCT04181372|EXPERIMENTAL|Anlotinib plus Platinum-based chemotherapy|"1. Take anlotinib hydrochloride 12mg once daily for two weeks, stop for one week, the program repeats every 21 days for 2 cycles.~2. Platinum-based chemotherapy regimens for neoadjuvant:(1)Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m\^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m\^2 ,i.v. on day 1, pemetrexed was given 500 mg/m\^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m\^2 i.v. on day 1; docetaxel was given 75 mg/m\^2 i.v. on day 1 ,each 21-day cycle for 2 cycles."
62406024|NCT01256229|EXPERIMENTAL|Developmentally delayed - Hearing aids|This arm contains deaf children that have developmental delays and are randomized to be treated with the conventional therapy, hearing aids.
62406025|NCT01256229|EXPERIMENTAL|Developmentally Delayed - Cochlear implant|This arm contains deaf children that have developmental delays and are randomized to be treated with cochlear implantation.
62406026|NCT01256229|ACTIVE_COMPARATOR|Not developmentally delayed|This control arm contains deaf children that do not have developmental delays and will be treated with cochlear implantation.
62406027|NCT01429142|EXPERIMENTAL|AIMS intervention|see http://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-13-274
62406028|NCT01429142|ACTIVE_COMPARATOR|Treatment as usual|see http://www.tandfonline.com/doi/abs/10.1080/08870446.2014.1001392
62406029|NCT01471600|NO_INTERVENTION|No intervention|Group overnight fasting
62017406|NCT05333445|ACTIVE_COMPARATOR|control group|"After hospital discharge, all patients will be referred to their primary care physician or cardiologist for follow-up.~Patients will receive standard follow-up checks by the medical team will not receive structured education from the nurse."
62017407|NCT03809845|ACTIVE_COMPARATOR|Motor neuron disease|
62017408|NCT03809845|ACTIVE_COMPARATOR|Benign fasciculation syndrome|
62017409|NCT02793492|EXPERIMENTAL|Misago® RX Self-expanding Stent|Eligible participants will undergo stent implantation with the Misago® RX Self-expanding Stent
62789378|NCT03240094|EXPERIMENTAL|Nutritional telemonitoring|Participants in the intervention group receive a telemonitoring intervention, including self-measurements of body weight, nutritional status, appetite, diet quality, and physical activity. Additionally, participants receive guidance on nutrition and physical activity by means of customized and general television messages and/or if necessary personal guidance by a nurse.
62789379|NCT03240094|NO_INTERVENTION|Usual care|Participants in the control group receive usual care.
62207483|NCT04181372|ACTIVE_COMPARATOR|platinum-based chemotherapy|Platinum-based chemotherapy regimens for neoadjuvant:(1)Carboplatin was given dosed to an AUC of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m\^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m\^2 ,i.v. on day 1, pemetrexed was given 500 mg/m\^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m\^2 i.v. on day 1; docetaxel was given 75 mg/m\^2 i.v. on day 1 ,each 21-day cycle for 2 cycles.
62207484|NCT03477487|EXPERIMENTAL|Lowest dose|The lowest dose of XT-150 in the escalation schedule
62207485|NCT03477487|EXPERIMENTAL|Second dose|The 2nd dose of XT-150 in the escalation sequence
62207486|NCT03477487|EXPERIMENTAL|Third dose|The 3rd dose of XT-150 in the escalation sequence
62207487|NCT03477487|EXPERIMENTAL|Highest dose|The highest dose of XT-150 in the escalation sequence
62207488|NCT05556096|EXPERIMENTAL|ALXN1720|Participants will receive a weight-based initial (loading) dose of ALXN1720 on Day 1, followed by weight-based maintenance treatment with ALXN1720 on Day 8 and once every week (Q1W) thereafter for a total of 26 weeks. Following this randomized controlled treatment (RCT) period, all participants will receive ALXN1720 in an open-label extension (OLE) period of 105 weeks.
62207489|NCT05556096|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo during the 26-week RCT period, after which they will enter the OLE period of the study and receive ALXN1720.
62207490|NCT03073252|EXPERIMENTAL|Normal Protein|Consumption of normal protein (NP) meal
62207491|NCT03073252|EXPERIMENTAL|High Protein|Consumption of high protein (HP) meal
62207492|NCT03652727|EXPERIMENTAL|ECG-EM Guidance|PICC insertion using electrocardiographic and electromagnetic guidance \[Site\~Rite® 8 Ultrasound System with integrated SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS)\]
62207493|NCT03652727|ACTIVE_COMPARATOR|FX Guidance|PICC insertion using fluoroscopic guidance
62207494|NCT05898841|EXPERIMENTAL|Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day|Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day. They may be administered in combination as 50/25 mg/day tablets (Juluca 50/25) or separately as Dolutegravir 50 mg/d tablets together with Rilpivirine 25 mg/d tablets (Tivicay 50 + Edurant 25)
62207495|NCT05898841|EXPERIMENTAL|TDF 245 mg /day or TAF 25 mg /day + FTC 200 mg /day + RPV 25 mg / day|Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabina (FTC) 200 mg/d + Rilpivirina (RPV) 25 mg/d. They may be administered as single tablets (EVIPLERA 200 mg/25 mg/245 mg) or in combination forms where one tablet contains TDF/TAF and FTC and another RPV tablet (TDF/FTC + Edurant 25 or Descovy 25/200 + Edurant 25)
62789380|NCT04364295||Implanted with SeaSpine spinal or orthobiologics product|Standard of Care Registry- Patients must have been implanted with at least one SeaSpine product
62789381|NCT06238284||Cervical Cancer Group|
62207496|NCT05898841|ACTIVE_COMPARATOR|Continue with their previous treatment. Any previous HAART does not contain RILPIVIRINE.|Patients who are randomised to this treatment arm will continue with the HAART they were receiving prior to signing the informed consent. As in arms 1 and 2, a change in the form of HAART administration (from a combined to a separate form and vice versa) will be allowed as long as the HAART components are respected.
62207497|NCT03685175|EXPERIMENTAL|Formal Study|Hyperpolarized 13C-pyruvate, is injected into patients before receiving cardiotoxic therapy and immediately after, for a cardiac MRI scan
62406030|NCT01471600|ACTIVE_COMPARATOR|Group drink|Glucose drink (200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia)
62406031|NCT05392699|EXPERIMENTAL|Human single chain IL-12 mRNA-single dose|Human single chain IL-12 mRNA-single dose
62406032|NCT05392699|EXPERIMENTAL|Human single chain IL-12 mRNA-multiple dose|Human single chain IL-12 mRNA-multiple dose
62735025|NCT05435131|EXPERIMENTAL|Periodontal Health|Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.
62789382|NCT06238284||Endometrial Cancer Group|
62789383|NCT06238284||Ovarian Cancer Group|
62789384|NCT05388617|EXPERIMENTAL|Group A|Subjects in Group A will receive up to 8 treatments with the Brera/Med 400 device on their abdomen or flanks. Subjects may receive a phone call 1 week (1-7 days) after each treatment to record side effects. Subjects will return for follow up visits at 30 and 90 days post last treatment for efficacy and side effects assessments.
62207498|NCT03685175|EXPERIMENTAL|Feasibility Study|Hyperpolarized 13C-pyruvate injection, is given to patients after completing cardiotoxic therapy, and again at 1 to 6 six months after the first cardiac MRI scan
62207499|NCT06438120|EXPERIMENTAL|Chatbot group|In this group, participants will receive chatbot-based positive psychology intervention.
62207500|NCT01674829|EXPERIMENTAL|Cohort 1|Biological: MA09-hRPE Cellular therapy Cohort 1 Dose 1
62207501|NCT01674829|EXPERIMENTAL|Cohort 2|Biological: MA09-hRPE Cellular therapy Cohort 2 Dose 2
62406033|NCT06367751|EXPERIMENTAL|Active Comparator|"Patients included in the ongoing registry AO_2023-00091.~Patients will have ctDNA measurements being performed on blood samples collected as part of clinical routine."
62789385|NCT05388617|EXPERIMENTAL|Group B|Subjects in Group B may receive up to 8 treatments with the Brera/Med 400 device on their abdomen and/or flanks. Subjects may receive a phone call 1 week (1-7 days) after each treatment to record side effects. Subjects may be asked return for follow up visits at 30 and 90 days post last treatment for efficacy and side effects assessments. Outcome measures will not be taken for subjects enrolled in this group.
62207502|NCT01674829|EXPERIMENTAL|Cohort 3|Biological: MA09-hRPE Cellular therapy Cohort 3 Dose 3
62406034|NCT01340794|EXPERIMENTAL|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28 (days 1-14 of courses 1 and 2). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62406035|NCT00604175|EXPERIMENTAL|Stratum A|Participants with screening CD4 count \>350 cells/mm\^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
62017410|NCT06171152|EXPERIMENTAL|Study Group 1 (Drug Regimen A)|"During the study, liraglutide will be given in cycles. A cycle is a scheduled period of time for taking study drugs. For this study, each cycle length as well as the dose of liraglutide participants take will be based on the drug regimen (or schedule) they receive. The drug regimen receive each participant receives will be selected using a random assignment process, similar to flipping a coin.~Participants in this study group will receive Drug Regimen A, which means they will take liraglutide at the below doses and times:~Dose Schedule Cycle Length 0.6mg Daily 1 week 1.2mg Daily 1 week 1.8mg Daily 1 week 2.4mg Daily 1 week 3.0mg Daily 8 weeks"
62207503|NCT01674829|EXPERIMENTAL|Cohort 4|Biological: MA09-hRPE Cellular therapy Cohort 4 Dose 4
62207504|NCT06618794|EXPERIMENTAL|HVIP-MLP|This arm includes patients receiving usual care and also support from Recovery Legal Care (HVIP+MLP)
62207505|NCT06618794|ACTIVE_COMPARATOR|HVIP|This arm includes patients receiving usual care (HVIP only).
62207506|NCT03442153|EXPERIMENTAL|Solgar No7|Aflapin 100 mg and Collagen UC2 40 mg by mouth every 24 hours for 90 days
62207507|NCT03442153|PLACEBO_COMPARATOR|Placebo for Solgar No7|Placebo 1 Capsule by mouth, every 24 hours for 90 days
62207508|NCT04224857|EXPERIMENTAL|AMT-101|AMT-101
62207509|NCT04224857|PLACEBO_COMPARATOR|Placebo|Placebo
62207510|NCT00005927||Hyperaldosteronism and cushing participants|Subjects with Hyperaldosteronism and cushing. Adults, pediatric subjects and family members (DNA collection only for family members).
62207511|NCT04891705||Pleural Effusion|Adult and pediatric subjects with suspicion of pleural effusion
62207512|NCT04891705||Lung Consolidation|Adult and pediatric subjects with suspicion of lung consolidation
62207513|NCT06211322|EXPERIMENTAL|To determine the feasibility of a patient self-management application (Urika) in patients with gout.|The intended purpose of the app is to support self-management for patients with gout that initiate urate lowering therapy.
62207514|NCT04672785||Patients who underwent a posterior fossa craniectomy for a cerebellar hematoma|
62207515|NCT00095056|EXPERIMENTAL|Sitagliptin|Participants in the Sitagliptin treatment sequence will receive sitagliptin in Phase A and placebo to glipizide in Phase B.
62207516|NCT00095056|PLACEBO_COMPARATOR|Placebo|Participants in the Placebo treatment sequence will receive placebo to sitagliptin in Phase A and glipizide in Phase B.
62207517|NCT03014479|EXPERIMENTAL|Trelagliptin|Trelagliptin 100 mg, orally, once weekly for up to 12 weeks. Trelagliptin 50 mg, orally, once weekly for up to 12 weeks in patients with moderate renal impairment.
62207518|NCT03014479|ACTIVE_COMPARATOR|Daily DPP-4 inhibitors|An inhibitor orally administered at the dosage and administration in the package inserts for each drug, for up to 12 weeks.
62789386|NCT04040829|ACTIVE_COMPARATOR|SE + TAU|"Supported education (SE) includes a variety of services ranging from orientation, study strategies or homework help. This intervention is personalized to the need of each patient in terms of services and frequency. Previous to this randomized controlled trial, we conducted interviews with each site that will provide SE. In these interviews, we explored the fidelity of their services to the Individual Placement and Support adapted to education. Information regarding the dosage of SE (frequency, length of session, type of support) will be collected and used as covariates for each participant since intensity treatment can impact outcomes.~Treatment as usual (TAU) consists of medication and routine contact with the clinical team. Patients will continue to receive their standard treatment, but we will collect information regarding the type of medication, the dosage, and all other relevant information and use it as covariate in our analyses."
62207519|NCT02442089|NO_INTERVENTION|No Intervention|The intervention arm subjects will not receive the automated interactive voice reminder before their appointment.
62017411|NCT06171152|EXPERIMENTAL|Study Group 2 (Drug Regimen B)|"During the study, liraglutide will be given in cycles. A cycle is a scheduled period of time for taking study drugs. For this study, each cycle length as well as the dose of liraglutide participants take will be based on the drug regimen (or schedule) they receive. The drug regimen receive each participant receives will be selected using a random assignment process, similar to flipping a coin.~Participants in this study group will receive Drug Regimen B, which means they will take liraglutide at the below doses and times:~Dose Schedule Cycle Length 0.6mg Daily 5 weeks 1.2mg Daily 1 week 1.8mg Daily 1 week 2.4mg Daily 1 week 3.0mg Daily 4 weeks"
62207520|NCT02442089|EXPERIMENTAL|Intervention|The intervention arm subjects will receive the automated interactive voice reminder before their appointment.
62207521|NCT04811014|EXPERIMENTAL|MOUD induction and behavioral interventions among opioid-dependent youths|Induction into medication for opioid use disorder (MOUD) treatment and behavioral interventions
62207522|NCT06675825|EXPERIMENTAL|Study Group 1: BougieCap|Patients randomized into this group will undergo the dilation using the BougieCap.
62207523|NCT06675825|ACTIVE_COMPARATOR|Study Group 2: Standard treatment|Patients randomized to the standard treatment arm will be provided one of the two standard dilation techniques, Savary- Bougie dilation or balloon dilation. This procedure could take place under endoscopic or radiological control.
62207524|NCT05350280|EXPERIMENTAL|Low-intensity electrical current (LIEC)|A removable device containing a small electrical circuit will supply the required electric current for five hours a day until the completion the retraction of the upper anterior teeth.
62207525|NCT05350280|ACTIVE_COMPARATOR|Traditional fixed orthodontic appliance|The maxillary arch will be levelled and aligned. (250-300) g force will be applied on each side using two NiTi springs attached between the mini-implants and the soldered hooks in a direction approximately parallel to the occlusal plane for conducting an en-masse retraction.
62207526|NCT03464851||Unknown/Normal/Mild Disease|No prior carotid duplex study or known normal or mild disease in the ICAs (PSV \<= 125 cm/sec)
62207527|NCT03464851||Known moderate or severe ICA Stenosis (PSV>125 cm/sec)|
62207528|NCT03464851||Known ICA Fibromuscular Dysplasia|
62207529|NCT04337541|NO_INTERVENTION|Normal recommendations, no mask|Normal behavior according to the authority's recommendations or
62207530|NCT04337541|EXPERIMENTAL|Normal recommendations AND mask|Normal behavior according to the authority's recommendations AND use of facial masks
62207531|NCT02654353|OTHER|Group A: stepwise ablation|Stepwise ablation of persistent atrial fibrillation (conventional treatment arm) In this arm, patients will be treated with the conventional stepwiese ablation approach
62406036|NCT00604175|EXPERIMENTAL|Stratum B|Participants with screening CD4 count \>200 to \<=350 cells/mm\^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
62735026|NCT05435131|EXPERIMENTAL|Gingivitis|Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.
62017412|NCT01592630|EXPERIMENTAL|Ropivacaine|Subjects with TAP catheters attached to the On-Q pump with 0.2% ropivacaine
62017413|NCT01592630|PLACEBO_COMPARATOR|Saline|Subjects with TAP catheters attached to the On-Q pump with saline
62207532|NCT02654353|ACTIVE_COMPARATOR|Group B: sequential substrate ablation|Sequential substrate ablation of persistent atrial fibrillation (novel procedure) In this arm, patients will undergo an ablation procedure that consist of PVI, cardioversion, linear ablation and atrial fibrillation re-induction after blocked lines, followed by electrogram-guided ablation
62207533|NCT06252753||unresectable hepatocellular carcinoma (uHCC)|unresectable hepatocellular carcinoma (uHCC)
62207534|NCT06252753||advanced biliary tract cancer (aBTC)|advanced biliary tract cancer (aBTC)
62207535|NCT06729710|ACTIVE_COMPARATOR|1 hour prism adaptation|Patients who receive one hour of prism adaptation.
62207536|NCT06729710|ACTIVE_COMPARATOR|4 hours of prism adaptation|Patients who receive four hour of prism adaptation.
62207537|NCT04579783|ACTIVE_COMPARATOR|Ultrasound intracarpal corticosteroid injection|"Twice ultrasound-guided hydro-dissection of median nerve at carpal tunnel level.~1st injection (0 week): 40mg triamcinolone acetonide (40mg/mL ) with 4mL normal saline, 2nd injection (6 week): 5 mL normal saline"
62207538|NCT04579783|ACTIVE_COMPARATOR|Ultrasound guided intracarpal dextrose hydro-dissection|"Twice ultrasound-guided hydro-dissection of median nerve at carpal tunnel level.~Group B: 1st injection (0 week): 5 mL 5% dextrose, 2nd injection (6 week): 5 mL 5% dextrose"
62207539|NCT04730141|EXPERIMENTAL|mobilization protocol|The early mobilization protocol developed by using up-to-date guidelines and expert opinions were applied to the patients in the intervention group.
62207540|NCT04730141|NO_INTERVENTION|routine care|The routine mobilization follow-up approach of the intensive care unit was applied to the patients in the control group .
62017414|NCT06071000|EXPERIMENTAL|Experimental group|
62017415|NCT06071000|NO_INTERVENTION|Control group|
62207541|NCT05896384|EXPERIMENTAL|Microgynon® (Reference treatment (R)) followed by BI 456906 and Microgynon® (Test treatment (T))|
62207542|NCT01562041|EXPERIMENTAL|Ranolazine 500 mg|Participants received ranolazine 500 milligrams (mg), orally, twice daily (b.i.d.) up to 14 days.
62207543|NCT03714087|EXPERIMENTAL|T1 Conventional treatment before aligner|T1 before aligner: Conventional orthodontic treatment patients before the essix aligner
62207544|NCT03714087|EXPERIMENTAL|T2 After essix aligner|T2 after the aligner: Essix aligner appliance with setup for 3 weeks full time
62207545|NCT03714087|ACTIVE_COMPARATOR|Historic control group|Conventional orthodontic treatment without finishing protocol UdeA2
62207546|NCT04048902|PLACEBO_COMPARATOR|Pilates and Shortwave placebo|In this group the patients will receive 20 minutes of short wave placebo application. The equipment will keep the timer on and the intensity will remain at zero. The patient will be informed that the dose is subsensory and therefore there will be no perception of the passage of the short waves through the body.The application will be performed with two coplanar plates in parallel, arranged on the right and left side of the lumbar region, maintaining a distance of 5 to 10 cm between them, with the patient lying in the dorsal decubitus position
62207547|NCT04048902|ACTIVE_COMPARATOR|Pilates and Shortwave active|In this group the patients will receive 20 minutes of application of the Shortwave Active continuous mode (thermal effect), with vigorous local thermal sensation.The application will be performed with two coplanar plates in parallel, arranged on the right and left side of the lumbar region, maintaining a distance of 5 to 10 cm between them, with the patient lying in the dorsal decubitus position
62207548|NCT03952598|EXPERIMENTAL|1/Arm 1|Monitoring of quantitative levels of 2-hydroxyglutarate (2-HG) via proton magnetic resonance spectroscopy (1H-MRS) -- THIS ARM IS NOW CLOSED
62207549|NCT03952598|EXPERIMENTAL|2/Arm 2|Monitoring of quantitative levels of 2-hydroxyglutarate (2-HG) via proton magnetic resonance spectroscopy (1H-MRS) and HP 13C pyruvate MRSI
62017416|NCT04352335||Cohort 1：ICI treatment with immunomodulator|Lung cancer patients received immunological checkpoint inhibitors (ICIs) and any immunomodulatory drugs.
62017417|NCT04352335||Cohort 2：ICI treatment without immunomodulator|Lung cancer patients received immunological checkpoint inhibitors (ICIs).
62017418|NCT03949725|EXPERIMENTAL|Hans Kai program|The Hans Kai program is a peer-led, preventative, self-sustaining, community-based health promotion program for adults of all ages, genders, and socioeconomic circumstances who wish to maintain or improve their health. Hans Kai empowers individuals to take control of their own health and provides a unique opportunity for participants to have an active role in improving or maintaining their health and wellbeing.
62207550|NCT03952598|EXPERIMENTAL|3/Arms 3|Monitoring of quantitative levels of 2-hydroxyglutarate (2-HG) via proton magnetic resonance spectroscopy (1H-MRS)
62207551|NCT05202873||Cases|Patients with distal femoral megaprosthesis due to musculoskeletal tumor
62207552|NCT05202873||Control|Healthy subjects
62207553|NCT04828837|EXPERIMENTAL|Bubble positive expiratory pressure training|The experimental group receives the Bubble PEP training.
62207554|NCT04828837|NO_INTERVENTION|general care|The control group receives the division of chest ward routine care.
62207555|NCT04246021|EXPERIMENTAL|Ferric carboxymaltose (ferrinject)|"Patients will receive one or two doses of Ferric carboxymaltose (ferrinject), based on the body weight and Hb level.~* Ferric carboxymaltose will be administered as a single infusion if the needed dose is 1000 mg as a short IV infusion~* If the needed Ferric carboxymaltose dose is \> 1000 mg, an initial dose of 1000 mg will be given as a short IV infusion and the remaining dose will be given the week after in a similar fashion"
62789387|NCT04040829|EXPERIMENTAL|CR + SE + TAU|"Cognitive remediation therapy (CR) will be conducted using CIRCuiTS, a computerized program designed to improve cognition (attention, memory, executive functioning) and metacognitive skills. CIRCuiTS has an integrated focus on the transfer of cognitive skills to daily living, using real-world goals and homework to facilitate in vivo use of new strategies, as well as a formulation-based approach, which takes into account the impact of cognitive strengths and difficulties with daily living skills. Each session includes about 4-8 tasks targeting a range of cognitive problems, which become more ecologically valid as the program progresses. The rate of delivery for CIRCuiTS will be two to three sessions per week, for a maximum of 40 sessions. The therapy will be provided entirely online with a therapist, using the platform Zoom.~This arm will include our active control condition : supported education (SE) as well as Treatment as usual (TAU) as previously described."
62789388|NCT01854034|EXPERIMENTAL|AUY922 Treatment Arm|AUY922 administered once weekly via intravenous, 70 mg/m2
62789389|NCT06141265|EXPERIMENTAL|Niraparib|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
62789390|NCT02817243|OTHER|SP2086 and Simvastatin|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
62789391|NCT00550966|ACTIVE_COMPARATOR|1|"Randomized controlled trial with a 12-month follow-up involving two groups, one of which is the intervention group that includes patients receiving a psychoeducative program and the other is the control group formed by patients treated for FM in the usual way.~Setting. Three urban PC centers in the province of Barcelona (Spain) Sample. The total sample comprises 218 patients (over 18 years of age) suffering FM, selected from a database (Rheumatology service-Viladecans hospital) of patients with this illness. Only those patients introduced in the database between the years 2005 and 2007 are included in the selection. Selected patients are asked for written informed consent to participate in the study."
62789392|NCT05373849|EXPERIMENTAL|Aromatherapy first then no intervention|The participant will receive the study treatment (essential oils mixture in inhaler sticks for 2 months) and the control (no intervention for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed
62207556|NCT04734743|OTHER|Cystic fibrosis|
62207557|NCT03055429|EXPERIMENTAL|Full Scale Unit|Testing of 6 modules
62207558|NCT06728384||CTO patients undergoing FFR collateral, Absolute flow and OCT measurements|"FFR collateral will be measured by measuring the wedge pressure distal from the occlusion, and after stent implantation by creating a balloon-over-the-wire occlusion.~MLD will be measured with quantitative coronary analysis (QCA)~Absolute flow will be measured by using a rayflow catheter with a pressure wire, and by using the Coroventis system.~OCT will be performed during follow-up, using an OCT catheter and perform a pullback through the entire stent trajectory."
62207559|NCT05155332|EXPERIMENTAL|Part 1 (Monotherapy): Arm A|
62207560|NCT05155332|EXPERIMENTAL|Part 1 (Monotherapy): Arm B|
62207561|NCT05155332|EXPERIMENTAL|Part 1 (Monotherapy): Arm C|
62207562|NCT05155332|EXPERIMENTAL|Part 2 (Combination therapy): Arm D|
62207563|NCT05155332|EXPERIMENTAL|Part 2 (Combination therapy): Arm E|
62207564|NCT05155332|EXPERIMENTAL|Part 2 (Combination therapy): Arm F|
62207565|NCT05155332|EXPERIMENTAL|Part 2 (Combination therapy): Arm G|
62406037|NCT00604175|EXPERIMENTAL|Stratum C|Participants with screening CD4 count \<=200 cells/mm\^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
62406038|NCT02160054||Group 1|patients with kidney transplantation who converted the immunosuppressant from cyclosporine to Graceptor ®
62581447|NCT04155229|EXPERIMENTAL|Null setting, forced entry|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.~This arm has a default setting for opioid quantity set at -blank-. This setting required the prescriber to enter a quantity in order to write a prescription."
62207566|NCT06727942|EXPERIMENTAL|V-TARGET intervention group|"All participants in the V-TARGET intervention group will exercise on the Virtuix Omni 360-degree self-paced, non-powered treadmill-simulator in the lab for 5-weeks (2 days/week, 30 minutes/session, 10 sessions total. The treadmill-simulator is a first-of-its-kind motion platform on which an individual can walk and run at a self-paced speed in 360 degrees (i.e., forwards, sideways and backwards) without risk of falling or colliding with other people.~The V-TARGET intervention group will self-pace their locomotor action (walking/running) on the Omni treadmill-simulator while they wear the Pico Neo 2 head-mounted display (HMD) headset and use the Neuro Rehab VR XR Therapy system to experience daily activity exercises/games, including Retail Therapy, Explore (gait training), Lunchtime Adventure, and Nature Walk."
62207567|NCT06727942|NO_INTERVENTION|The waitlist control group|The control group will not do any VR exercise but will only complete the pre-post and 1-month follow-up assessment upon signing up the study.
62581448|NCT04155229|EXPERIMENTAL|5 tablet default|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.~This arm has a default setting for opioid quantity set at 5."
62207568|NCT00619749|EXPERIMENTAL|1|
62207569|NCT00619749|PLACEBO_COMPARATOR|2|
62207570|NCT05936151|EXPERIMENTAL|Retatrutide|Participants will receive multiple doses of retatrutide subcutaneously (SC)
62406039|NCT03741543|OTHER|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material
62207571|NCT05936151|PLACEBO_COMPARATOR|Placebo|Participants will receive LY3437943
62207572|NCT05527262|EXPERIMENTAL|Queen Square Upper limb training programme|Patients will undergo 45-60 hours of conventional physiotherapy and occupational therapy over 3 weeks as part of the Queen Square Upper Limb Neurorehabilitation Programme (QSUL) (Ward et al., 2019).
62207573|NCT05527262|EXPERIMENTAL|Mindpod Dolphin|Patients will undergo 45-60 hours of arm, hand and finger training using immersive gaming technology (e.g. MindPod Dolphin) over 3 weeks.
62207574|NCT05527262|NO_INTERVENTION|Wait-list Control|Patients will receive no planned treatment but will be on a waiting list for QSUL Programme after their follow up period if over.
62207575|NCT05702814||Group A: GD1 with Low-normal Bone Disease|Participants with GD1 with low-normal bone disease whose samples are available for analysis in BSSA will be collected retrospectively up to approximately 5 years from diagnosis.
62207576|NCT05702814||Group B: GD1 with Mild Bone Disease|Participants with GD1 with mild bone disease whose samples are available for analysis in BSSA will be collected retrospectively up to approximately 5 years from diagnosis.
62207577|NCT05702814||Group C: GD1 with Severe Bone Disease|Participants with GD1 with severe bone disease whose samples are available for analysis in BSSA will be collected retrospectively up to approximately 5 years from diagnosis.
62406040|NCT01920269|ACTIVE_COMPARATOR|Transurethral resection alone|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra-ie, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Response to treatment will be assessed with cystoscopy, biopsy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
62581449|NCT04155229|EXPERIMENTAL|10 tablet default|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.~This arm has a default setting for opioid quantity set at 10."
62207578|NCT05702814||Group D: Healthy Participants|Healthy Participants whose samples are available for analysis in BSSA will be collected retrospectively up to approximately 5 years.
62207579|NCT01280357|ACTIVE_COMPARATOR|Monitor Philips 50XM (K954351)|CTG Fetal Monitor If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
62207580|NCT01280357|EXPERIMENTAL|Monica AN24 (K101801)|EHG Fetal Monitor
62581450|NCT04155229|EXPERIMENTAL|15 tablet default|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.~This arm has a default setting for opioid quantity set at 15."
62207581|NCT06027671|NO_INTERVENTION|Care-as-usual (CAU) arm|Per DCS routine, at release, participants will receive a referral letter form the DCS health services and, in most cases, will be provided with a 28-day supply of ART.
62207582|NCT06027671|EXPERIMENTAL|Group-SPARCS intervention arm|The Group-SPARCS component comprises one individual pre-release session, one individual post-release session, and 12 every-other-week (every two weeks) post-release group sessions extending six months post-release. Each session will be led by two trained individuals: a peer (history of criminal justice involvement and living with HIV) and a social worker.30 Within 14 days of release, participants will have one-on-one contact with a facilitator to update locator information, continue rapport building, review disclosure plans, provide a reminder of SPARCS logistics, and assign or remind the participant to a SPARCS group based on the location of residence and timing of release (depending on whether this occurred pre-release). Each Group-SPARCS meeting lasts approximately 2 hours, and the sessions occur in a private space in a community venue (e.g., community centre or church).
62406041|NCT01920269|ACTIVE_COMPARATOR|Intravesical passive diffusion mitomycin|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Patients are scheduled to receive an initial 6 intravesical mitomycin treatments at weekly intervals commencing 2 weeks after endoscopic procedures. Patients are placed on fluid restriction and oral sodium bicarbonate before intravesical mitomycin treatments. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations. Response to treatment will be assessed with cystoscopy, biopsy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
62406042|NCT01920269|ACTIVE_COMPARATOR|Intravesical electromotive mitomycin|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Patients are scheduled to receive an initial 6 intravesical mitomycin treatments at weekly intervals commencing 2 weeks after endoscopic procedures. Patients are placed on fluid restriction and oral sodium bicarbonate before intravesical mitomycin. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations. Response to treatment will be assessed with cystoscopy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
62406043|NCT01381068|EXPERIMENTAL|Monitored Arm|The end tidal CO2 sensor is placed in the respiratory circuit and the monitor is visible to the resuscitation team. The resuscitation team is instructed to adjust ventilation to keep EtCO2 levels between 40-55.
62735027|NCT05435131|EXPERIMENTAL|Stage II grade B Periodontitis|Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.
62207583|NCT06027671|EXPERIMENTAL|ART-SPARCS intervention arm|"ART delivery will follow Department of Health (DoH) procedures for differentiated models of care, in particular the Community Adherence Club model. Similar to community adherence clubs, the ART provision in SPARCS will be affiliated with a 'home clinic that will provide ART supplies for the participants. Routine community adherence club activities include:~ART will be provided every two months from correctional facility release to 6 months post-release (months 2, 4, and 6). Participants with less than two months of ART at release will receive a top-off to reach two months. ART will be pre-packaged by the DoH home clinic, collected by the facilitators, and distributed to the participants. At the time of distribution, the facilitators will conduct a standard DoH differentiated care symptom screen. Participants who report specific symptoms will be referred to the home clinic for further assessment per routine with Community Adherence Clubs."
62207584|NCT06027671|EXPERIMENTAL|Full-SPARCS arm|Full-SPARCS combines Group-SPARCS and ART-SPARCS with ART delivery during SPARCS group meetings.
62207585|NCT03231241||Episodic Headache|Participants experiencing headache of any type more than twice per year but less than 15 days per month. No interventions
62207586|NCT03231241||Chronic Headache|Participants experiencing headache more than 15 days per month for at least three consecutive months. No interventions
62207587|NCT03231241||Control|Participants reporting fewer than two headaches per year. No interventions
62406044|NCT01381068|PLACEBO_COMPARATOR|Control Arm|The end tidal CO2 sensor is placed in th respiratory circuit. The monitor is covered so the resuscitation team can not see the display. The resuscitation team is instructed to provide ventilation according to clinical judgment.
62581451|NCT04155229|ACTIVE_COMPARATOR|Status quo default setting|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.~This arm has a default setting for opioid quantity set at the status quo value for each site (20 for site 1, 12 for site 2)."
62207588|NCT05654142|ACTIVE_COMPARATOR|Group A: Waitlist-Base Intervention|Participants in Group A will be in the waitlist control condition initially and transition to receive the base intervention at Week 12, which includes 12 GLB video sessions from Week 13-24 and digital messages from Week 25-52.
62406045|NCT02901184|ACTIVE_COMPARATOR|Spironolactone treatment|Spironolactone will be prescribed by the Investigator and filled by patient at conventional pharmacies as 25 mg tablets. The treatment will be on top of standard care. Initial dose is 25 mg/day, which will be increased to target dose 50 mg/day if tolerated. Eplerenone can be prescribed if spironolactone is not tolerated.
62581452|NCT00839813|EXPERIMENTAL|Yoga|10 week trauma-sensitive yoga classes
62207589|NCT05654142|ACTIVE_COMPARATOR|Group B: Waitlist-Augmented Intervention|Participants in Group B will be in the waitlist control condition initially and transition to receive the augmented intervention at Week 12, which includes 12 GLB video sessions plus one-on-one PST from Week 13-24 and digital messages plus group-based PST from Week 25-52. Trained coaches will deliver the PST via videoconference (preferred) or phone.
62581453|NCT00839813|NO_INTERVENTION|Women's Health Education|10 weeks of women's health education classes as an attentional control group
62581454|NCT02366637|PLACEBO_COMPARATOR|Placebo|Double blind placebo for PF-03715455
62207590|NCT05654142|EXPERIMENTAL|Group C: Base Intervention (Responders)|Participants in Group C will be the individuals initially randomized to receive the base intervention who achieve 3% weight loss or more by Week 6 after completing the first 6 GLB videos. They will continue the base intervention without re-randomization and complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52.
62581455|NCT02366637|EXPERIMENTAL|PF-03715455|
62017419|NCT03949725|NO_INTERVENTION|Wait list control|Participants in the waitlist control group will remain as close to a 'typical' community member as possible as they will be able to receive any health programming normally available to them in Winnipeg, except the Hans Kai program. Standard of care is made available to all members of the control group as related to the healthcare rights of Canadians and Manitobans holding a Manitoba health card. NorWest staff will provide support to the community members without a Manitoba health card in obtaining one. The only deviation from standard care in the waitlist control group will be the pre- and post-intervention visits during which the control participants will fill out self-report questionnaires and undergo physical assessments.
62207591|NCT05654142|EXPERIMENTAL|Group D: Base Intervention (Non-responders)|Participants in Group D will be the individuals initially randomized to receive the base intervention who do not achieve 3% weight loss by Week 6 after completing the first 6 GLB videos, and who are re-randomized to continue the base intervention. They will complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52.
62207592|NCT05654142|EXPERIMENTAL|Group E: Augmented Intervention (Non-responders)|Participants in Group E will be the individuals initially randomized to receive the base intervention who do not achieve 3% weight loss by Week 6 after completing the first 6 GLB videos, and who are re-randomized to receive the augmented intervention. They will complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52. They will also work with a trained coach via videoconference (preferred) or phone to receive one-on-one PST from Week 7-24 and group-based PST from Week 25-52.
62207593|NCT06728202|ACTIVE_COMPARATOR|Alveolar ridge split group:|"* a crestal incision and two vertical releasing incisions will be formed, followed by a full-thickness mucoperiosteal flap.~* the flap will be raised to expose the whole length facial cortical bone.~* The palatal mucoperiosteum will also be slightly reflected for better exposure of the crest of the alveolar ridge and free placement of the surgical guides.~* the patient specific guides will be placed and fixed by monocortical osteosynthesis screws at the pre-planned positions at the labial cortical plate of bone , precisely locate the mid-crestal and two vertical stop cuts to improve the accuracy of the procedure, preventing bad splits with the aim of reducing the final marginal bone loss associated with this technique.~* bony cut will be performed using a piezoelectric device on the facial aspect of alveolar ridge 1.5 mm away from the adjacent teeth or implants, extending 7 mm apically from the crest of the ridge.implants will be inserted in the osteotomy sites using torque-wrench"
62207594|NCT06728202|ACTIVE_COMPARATOR|Implant placement in pristine bone with Osseodensification burs group:|"* A crestal incision and two vertical releasing incisions will be formed, followed by a full-thickness mucoperiosteal flap~* Implant osteotomies are being performed with the assistance of saline irrigation. The osteotomies will be performed at 800-1500 rpm in a counterclockwise direction (Densifying Mode) with the use of sequential burs of similar diameter (OD drilling burs) used with copious irrigation in a Bouncing-Pumping motion (minor vertical pressure to advance the drill into the osteotomy, then pull out for pressure relief, then advance with vertical pressure again and so on in an in/out fashion). the instrumentation will be performed according to the recommended drilling protocols for Densah® Burs implant system; either by standard drilling, as recommended by implant company protocols.~* The insertion of the implants will be initiated with the motor handpiece, without irrigation at 20-50 rpm, and installation will be completed with a manual surgical torque wrench"
62581456|NCT06296979|ACTIVE_COMPARATOR|USUAL PHYSIOTHERAPY|the usual treatment of the center consisting of manual therapy, exercise and thermotherapy will be performed.
62735028|NCT05435131|EXPERIMENTAL|Stage III grade B Periodontitis|Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.
62207595|NCT02533024|EXPERIMENTAL|Group Cohort|All subjects will have nerve conduction studies (Electromyography/EMG) pre-operatively, monitored intra-operatively and immediately post-operative.
62207596|NCT03934372|EXPERIMENTAL|Ponatinib|Phase 1: Ponatinib administered according to age-based cohort doses and formulations to determine the maximum tolerated dose and recommended Phase 2 dose. Phase 2: Ponatinib administered at the recommended Phase 2 dose.
62207597|NCT05890859|OTHER|DXA scans and physical tests|All patients are allocated to this arm and will undergod DXA scans and physical testing in addition to usual care/treatment
62207598|NCT04531826|ACTIVE_COMPARATOR|Group A|Five-strand hamstring autograft group
62207599|NCT04531826|PLACEBO_COMPARATOR|Group B|Quadripled hamstring autograft group
62207600|NCT02491476|EXPERIMENTAL|micro-macroelectrodes|All patients will be implanted with usually 4 intracerebral micro-macroelectrodes(replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
62406046|NCT02901184|PLACEBO_COMPARATOR|Standard care alone|Patients in the control arm will get the standard care alone
62406047|NCT02064231|EXPERIMENTAL|Coloplast Test A, Coloplast Test B, Own product|The subjects first test Coloplast Test A and thereafter Coloplast Test B and finally their own product for 14 days
62406048|NCT02064231|EXPERIMENTAL|Coloplast Test C , Coloplast Test D, Own product|The subjects first test Coloplast Test C and thereafter Coloplast Test D and finally their own product for 14 days
62406049|NCT06242262|EXPERIMENTAL|Deep neuromuscular block|Patients will receive deep neuromuscular block by using cis-atracurium
62406050|NCT06242262|OTHER|Moderate neuromuscular block|Patients will receive moderate neuromuscular block by using cis-atracurium.
62406051|NCT02466191|EXPERIMENTAL|memantine first|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
62406052|NCT02466191|EXPERIMENTAL|gabapentin first|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
62406053|NCT01667523|EXPERIMENTAL|Capsaicin|
62406054|NCT01667523|EXPERIMENTAL|Cinnamaldehyde|
62017420|NCT06280300|ACTIVE_COMPARATOR|Standard of Care|
62017421|NCT06280300|EXPERIMENTAL|Multidisciplinary Care|
62207601|NCT06350760|EXPERIMENTAL|PROCARE-I (UP-A for indicated purposes)|To ensure cost-effectiveness, PROCARE-I intervention will be designed as a brief 8-session child-focused programme by adapting the core modules from UP-A, along with one individual session with adolescent and parents. Sessions will be delivered in reduced groups, using a typical indicated preventive intervention format focused on cost-effectiveness.
62406055|NCT01667523|PLACEBO_COMPARATOR|Placebo|Physiological saline
62406056|NCT05917080|EXPERIMENTAL|Group A (Experimental Group)|Manual Therapy Technique Anti-Pronation Low- Dye Taping Technique Intrinsic Foot Muscles Exercises Calf Muscle \& Plantar Fascia Stretching VMO Strengthening
62406057|NCT05917080|EXPERIMENTAL|Group B (Experimental Group)|Neuromuscular Training Anti-Pronation Low- Dye Taping Technique Intrinsic Foot Muscles Exercises Calf Muscle \& Plantar Fascia Stretching VMO Strengthening
62406058|NCT05917080|OTHER|Group C (Control Group)|Intrinsic Foot Muscles Exercises Calf Muscle \& Plantar Fascia Stretching VMO Strengthening
62406059|NCT04557293|EXPERIMENTAL|CPAP Treatment|Patients with OSA will undergo cognitive assessment before starting CPAP treatment and after six months of CPAP use.
62017422|NCT03394924|EXPERIMENTAL|EDP-305 1 mg|Subjects will take 2 tablets once a day orally for 12 weeks
62207602|NCT06350760|EXPERIMENTAL|PROCARE-I+ 8-session (for indicated purposes)|PROCARE-I+ intervention will be designed as a brief 8-session with 4 additonal sessions (add-on modules) child-focused programme by adapting the core modules from UP-A. Sessions will be delivered in reduced groups, using a typical indicated preventive intervention format focused on cost-effectiveness.
62207603|NCT00359983|EXPERIMENTAL|MenHibrix 4-dose group|Subjects received in the primary study (NCT00129129) 3 doses of MenHibrix co-administered with Pediarix and Prevnar and a 4th dose of MenHibrix co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
62406060|NCT04557293|NO_INTERVENTION|Control Group|We will enrol a control group of subjects without sleep disorders and comparable to OSA patients for age and schooling. Control group will undergo cognitive assessment.
62406061|NCT04088617|EXPERIMENTAL|Ketone monoester|Acute morning dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.45 ml/kg body weight)
62406062|NCT04088617|PLACEBO_COMPARATOR|Placebo|Acute morning dose of flavour-matched placebo.
62735029|NCT05435131|EXPERIMENTAL|Stage III grade C Periodontitis|Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.
62017423|NCT03394924|EXPERIMENTAL|EDP-305 2.5 mg|Subjects will take 2 tablets once a day orally for 12 weeks
62017424|NCT03394924|PLACEBO_COMPARATOR|Placebo|Subjects will take two tablets once a day orally for 12 weeks
62017425|NCT06535113||acute myeloid leukemia (AML) patients treated in the clinical units|acute myeloid leukemia (AML) patients treated in the clinical units
62207604|NCT00359983|ACTIVE_COMPARATOR|ActHIB 4-dose group|Subjects received in the primary study (NCT00129129) 3 doses of ActHIB co-administered with Pediarix and Prevnar and a 4th dose of ActHIB co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
62406063|NCT00707252|EXPERIMENTAL|Phase I/II|Phase I: Polyphenon E + Erlotinib - Polyphenon E 200, 400 and 800 mg/day dose levels evaluated in a step-wise manner with Erlotinib 150 mg/day to establish Maximum Tolerated Dose (MTD) of Polyphenon E. Phase II consists of MTD of Polyphenon E established in Phase I, administered alone for two weeks and thereafter together with Erlotinib 150 mg/day.
62789393|NCT05373849|EXPERIMENTAL|No intervention first then Aromatherapy|The participant will receive the control (no intervention for 2 months) and the study treatment (essential oils mixture in inhaler sticks for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed.
62789394|NCT00544219|OTHER|R-Chop 14|Standard treatment
62789395|NCT01811134|EXPERIMENTAL|PIPELINE flow diverter stent|flow diverter stent
62207605|NCT00359983|EXPERIMENTAL|ActHIB 3-dose + MenHibrix 4th-dose group|Subjects received in the primary study (NCT00129129) 3 doses of ActHIB co-administered with Pediarix and Prevnar and a dose of MenHibrix co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
62789396|NCT01811134|ACTIVE_COMPARATOR|Coils, with or without expendable stent|Coils
62789397|NCT03478800|EXPERIMENTAL|High school football players and acupuncture|50 healthy high school football players without active musculoskeletal injury
62789398|NCT04153916|OTHER|Single use and continuous use|"Patients with a continuous unilateral facial paralysis that underwent an operation for facial reanimation will be enrolled at least one year after the operation according to review of medical records of the Department of plastic surgery.~Patients with temporary unilateral facial paralysis secondary to Bell's palsy as was identified in the admission to the Hospital Department of Plastic Surgery or to the Department of Ear, Nose and Throat."
62789399|NCT04124705|EXPERIMENTAL|Armour® Thyroid|Participants were randomized to receive Armour Thyroid at a dose corresponding to their pre-randomized dose of synthetic T4. During the first 18 to 36 weeks (titration period) the dose of Armour Thyroid could be titrated based on levels of thyroid stimulating hormone (TSH), in order to achieve TSH levels within the normal reference range (0.45 - 4.12 mIU/L, inclusive). Once TSH levels were within the normal reference range, participants continued to receive a stable dose of Armour Thyroid for an additional 12 weeks (stabilization period).
62789400|NCT04124705|ACTIVE_COMPARATOR|Levothyroxine|Participants were randomized to receive levothyroxine at their pre-randomized dose. During the first 18 to 36 weeks (titration period) the dose of levothyroxine could be titrated based on levels of TSH in order to achieve TSH levels within the normal reference range (0.45-4.12 mIU/L, inclusive). Once TSH levels were within the normal reference range, participants continued to receive a stable dose of levothyroxine for an additional 12 weeks (stabilization period).
62789401|NCT00510744|EXPERIMENTAL|pancreatic enzyme supplementation|3 month supplementation in those gastric bypass patients shown to have a fat absorption less than 80%
62789402|NCT02156414||Clinically Localized Prostatic Neoplasm|Radical Prostatectomy Extended Lymphadenectomy
62789403|NCT02048085|EXPERIMENTAL|Ticagrelor|Ticagrelor Arm will be dosed with a loading dose of 180 mg followed by maintenance dose of 90 mg BID until discharge or up to 8 days.
62789404|NCT02048085|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel arm will be dose with a loading dose of 300 mg followed by maintenance dose of 75 mg everyday until discharge or up to 8 days.
62789405|NCT02858947|ACTIVE_COMPARATOR|Aelite Flo|Microhybrid flowable composite
62789406|NCT02858947|ACTIVE_COMPARATOR|x-tra base|Bulk-fill flowable composite
62789407|NCT04036526|EXPERIMENTAL|Group 1 Drop method|Group 1 will receive vaccine/placebo by drop method.
62789408|NCT04036526|EXPERIMENTAL|Group 2 Nasal actuator|Group 2 will receive vaccine/placebo with nasal actuator.
62789409|NCT05138627|EXPERIMENTAL|intervention|"1. Teaching of oral cryotherapy by the investigator in the hospital,~2. Implementation of oral cryotherapy accompanied by the investigator in the hospital~3. Individual application of oral cryotherapy at home by patients"
62789410|NCT05138627|NO_INTERVENTION|control|Routine procedures in the clinic were performed on the first course (day 0) when the patients came to receive adjuvant chemotherapy and every 21 days thereafter, and oral cryotherapy was not applied to the patients. Before applying the first adjuvant chemotherapy, Nausea Vomiting Training and Guide was given to have equal conditions with the patients in the intervention groups.
62789411|NCT03481699|EXPERIMENTAL|Incremental theory of personality|1 hour behavioral intervention (based on ITP) consisting on several tasks to be completed on paper individually.
62789412|NCT03481699|OTHER|Educational intervention|1 hour educational intervention (about the human brain) consisting on several tasks to be completed on paper individually.
62789413|NCT05238545|EXPERIMENTAL|PD gluten-free diet group|Subjects with PD on gluten-free diet, ie. excluding all gluten-containing food during the day.
62789414|NCT05238545|NO_INTERVENTION|PD gluten-containing diet group|Subjects with PD on regular, gluten-containing diet, i.e. no restrictions during eating.
62789415|NCT05238545|EXPERIMENTAL|MSA gluten-free diet group|Subjects with PD on gluten-free diet, ie. excluding all gluten-containing food during the day.
62406064|NCT03585166||laparoscopic hepatectomy|laparoscopic hepatectomy for primary liver cancer
62789416|NCT05238545|NO_INTERVENTION|MSA gluten-containing diet group|Subjects with MSA on regular gluten-containing diet, i.e. no restrictions during eating.
62017426|NCT00779246|ACTIVE_COMPARATOR|1|Active surveillance cultures (ASC) (via nasal swabs) will be performed for all patients admitted to the medical intensive care unit (ICU) during the designated study period. All patients will be placed in contact isolation until nasal swabs return negative; otherwise will remain in isolation.
62017427|NCT00779246|ACTIVE_COMPARATOR|2|Chlorhexidine gluconate (CHG) cloths will be used to bathe patients daily instead of standard soap and water. Active surveillance cultures (ASC) will also be used in this arm, but results will be blinded and not used to determine whether patients should be in contact isolation.
62017428|NCT03503968|EXPERIMENTAL|Phase I - 3 disease entities|MDG1011 administration of escalating doses
62017429|NCT03503968|EXPERIMENTAL|Phase II - HLA*02:01 - disease entity 1|MDG1011 administration of Phase II recommended dose
62017430|NCT03503968|ACTIVE_COMPARATOR|Phase II - HLA*other - disease entity 1|Investigator Choice therapy
62017431|NCT03503968|EXPERIMENTAL|Phase II - HLA*02:01 - disease entity 2|MDG1011 administration of Phase II recommended dose
62017432|NCT03503968|ACTIVE_COMPARATOR|Phase II - HLA*other - disease entity 2|Investigator Choice therapy
62017433|NCT01038921|EXPERIMENTAL|Melatonin|Melatonin 8mg one hour before bedtime for 10 weeks
62017434|NCT01038921|PLACEBO_COMPARATOR|Placebo|Placebo administered 1 hour before bedtime for 10 weeks
62207606|NCT04642534||Postpartum women who had gestational diabetes mellitus|Inclusion at 4-8 weeks postpartum Follow-up for 6 months
62207607|NCT04642534||Postpartum women after an uneventful pregnancy|Inclusion at 4-8 weeks postpartum Follow-up for 6 months
62207608|NCT02893787||Patients treated with anthracyclines in childhood|
62207609|NCT02893787||Healthy volunteers|
62789417|NCT03301610|EXPERIMENTAL|Mobile Education Delivery|The participants in the study arm will receive comprehensive pain management education delivered using mobile iPads at the point of care. The mobile based education modules will be inclusive of the use of the pain rating scale and assessment of pain; communication with healthcare providers; daily expectations for pain and pain management; pharmacologic and non-pharmacologic treatment options; medication side effects and safety; and discharge instructions including safe handling of opioids, disposal, tapering, and when to call the provider. It will also include an interactive pain and discomfort menu, knowledge based questions, and medication tracking log.
62581457|NCT06296979|EXPERIMENTAL|Transcutaneous electrical nerve stimulation|The intervention group will receive the usual physiotherapy treatment at the health center and will also receive neuromodulation on the phrenic nerve at its exit through the anterior cervical region. The neuromodulation technique will be applied for 10 minutes.
62017435|NCT00777517|OTHER|Reference|Commercial 10 mg Lipitor formulation tablet
62017436|NCT00777517|OTHER|Test|Atorvastatin pediatric formulation
62017437|NCT05804058||Orthopaedic Patients|Patients due to undergo prosthetic hip revision surgery
62017438|NCT01679119|EXPERIMENTAL|IO-R-CVP|Inotuzumab Ozogamicin plus Rituximab and CVP (Cyclophosphamide, vincristine \& prednisolone).
62017439|NCT01679119|ACTIVE_COMPARATOR|Gem-R-CVP|Gemcitabine plus Rituximab and CVP (Cyclophosphamide, Vincristine and Prednisolone).
62017440|NCT05561998|EXPERIMENTAL|TalkingMats intervention group|Participants will use TalkingMats as a decision aid for the needs-assessment conversation as well as in conversations planning the provision of social care.
62017441|NCT05561998|ACTIVE_COMPARATOR|Usual conversation methods control group|Participants will use usual conversation methods in both the needs-assessment conversation and the provision planning conversations.
62017442|NCT01379963||Cohort|
62017443|NCT06573489|EXPERIMENTAL|Fospropofol group|patients in the fospropofol group received propofol phosphate, sufentanil, and rocuronium.
62017444|NCT06573489|ACTIVE_COMPARATOR|Propofol group|patients in the propofol group received propofol, sufentanil, and rocuronium.
62017445|NCT01918345|NO_INTERVENTION|Standard Care (Control)|This group will receive a one-on-one counseling session during one visit with a Certified Diabetes Educator (CDE), who will provide standard advice on diabetes prevention and healthy lifestyle. They will receive a booklet on exercise and healthy diet as per current Canadian guidelines for healthy eating. This group will also receive a check-in telephone call from the Study Coordinator, half-way through the study. This group will not receive motivational interviewing, health coaching on low GI diet and/or exercise, or additional telephone follow-up.
62207610|NCT06224283||Performed cryotherapy|Patients who received cryoablation for desmoid tumor and no chemotherapy
62207611|NCT06728306|EXPERIMENTAL|Immersive Virtual Reality Based Relaxation|
62207612|NCT06728306|EXPERIMENTAL|Non-Immersive Virtual Reality Based Exergaming|
62207613|NCT06728306|ACTIVE_COMPARATOR|Traditional Jacobson's Relaxation|
62406065|NCT03585166||open hepatectomy|open hepatectomy for primary liver cancer
62406066|NCT04892875|EXPERIMENTAL|Concurrent Cisplatin/Radiation Therapy + Zimberelimab (Cohort 1)|Concurrent weekly cisplatin with radiation and zimberelimab therapy followed by adjuvant zimberelimab
62017446|NCT01918345|EXPERIMENTAL|Diet & Physical Activity Program with Health Coach|Participants assigned to this arm will receive a combination of the home-based physical activity program with health coach and the home-based low-GI diet program with health coach, as described in the respective individual arms. The Health Coach for this group will be a CDE.
62017447|NCT01918345|EXPERIMENTAL|Physical Activity Program with Health Coach|Participants will be counseled to follow physical activity recommendations for Canadians, which is at least 150 minutes of moderate physical activity per week. Participants will be asked to participate in aerobic, strength training and stretching activities. Health Coaches will use motivational interviewing, goal-setting and problem solving to assist participants in meeting their physical activity goals. More participants will be randomized to this group and the participants will either have CDE or a Registered Kinesiologist (R. Kin) as their health coach.
62207614|NCT02277184|EXPERIMENTAL|Ficlatuzumab, Cisplatin and IMRT|"Ficlatuzumab will be administered as an IV infusion over 30-60 minutes, once every two weeks beginning the week prior to cisplatin-IMRT (week -1), for a total of 4 doses.~Cisplatin will be administered as an IV infusion over 60 minutes on Monday, Tuesday, or Wednesday of each treatment week beginning concurrent with IMRT during week 1 of study treatment (and one week following the first dose of ficlatuzumab) for a total of 7 doses.~IMRT: Treatment will be delivered once daily, 5 fractions per week, 35 - 37 fractions, no weekends or holidays over 7 - 8 weeks. All targets will be treated sequentially."
62207615|NCT02879526|EXPERIMENTAL|C-CPT|
62207616|NCT06140836|EXPERIMENTAL|Arm A|
62207617|NCT06140836|ACTIVE_COMPARATOR|Arm B|
62207618|NCT04480736|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo of JNJ-64281802 orally.
62207619|NCT04480736|EXPERIMENTAL|JNJ-64281802 High dose|Participants will receive high dose of JNJ-64281802 orally.
62207620|NCT04480736|EXPERIMENTAL|JNJ-64281802 Medium dose|Participants will receive medium dose of JNJ-64281802 orally.
62207621|NCT04480736|EXPERIMENTAL|JNJ-64281802 Low dose|Participants will receive low dose of JNJ-64281802 orally.
62207622|NCT04480736|EXPERIMENTAL|JNJ-64281802 Dosing Regimen X|Participants will receive dosing regimen X of JNJ-64281802 orally.
62207623|NCT04480736|EXPERIMENTAL|JNJ-64281802 Dosing Regimen Y|Participants will receive dosing regimen Y of JNJ-64281802 orally.
62207624|NCT04480736|EXPERIMENTAL|JNJ-64281802 Dosing Regimen Z|Participants will receive dosing regimen Z of JNJ-64281802 orally.
62017448|NCT01918345|EXPERIMENTAL|Diet Program with Health Coach|Participants will be counseled to follow recommendations for Canadians on healthy eating (Canada's Food Guide and Space on Your Plate. Low GI education will be layered on top of Canada's Food Guide recommendations. The goal for participants in the diet group is to lower their dietary GI by 8-10 units. Health Coaches will use motivational interviewing, goal-setting and problem solving to assist participants in meeting their dietary and low GI goals. The health coach for this group will be a CDE.
62017449|NCT05515432|EXPERIMENTAL|Mildly impaired renal funtion: eGFR (mL/min/1.73 m^2) ≥60 - <90|Participants with renal impairment
62207625|NCT05849480|EXPERIMENTAL|Phase I|Keytruda, oxaliplatin, capecitabine and escalating doses of CDX-1140
62207626|NCT05849480|EXPERIMENTAL|Phase II|Keytruda, oxaliplatin, capecitabine and estimated safe dose of CDX-1140
62207627|NCT02771821|EXPERIMENTAL|Group Intervention|Individual routine consultation with the Family Health Unit team and participation in operative groups based on methodology of problematization
62207628|NCT02771821|NO_INTERVENTION|Control Group|Individual routine consultation with the Family Health Unit team
62207629|NCT05877716|ACTIVE_COMPARATOR|Treatment as Usual|Participants will be treated as usual in their early psychosis CSC program and will not complete cognitive training or use the Personalized Real-Time Motivational Enhancement App.
62207630|NCT05877716|EXPERIMENTAL|Cognitive Training plus Personalized Real-Time Intervention for Motivational Enhancement|The Mobile Intervention. 20 hours of training consisting of 10 hours of cognitive training exercises plus 10 hours of social cognitive training exercises will be delivered over the course of 12 weeks. Participants will also engage in the PRIME app on a smart phone and will receive personalized support from a motivation enhancement coach.
62207631|NCT05543707|EXPERIMENTAL|PBI-0451 (Pomotrelvir)|PBI-0451(Pomotrelvir): 2 x 350 mg tablets administered orally twice daily (BID) (1400 mg/day) with food for 5 days (10 total doses)
62207632|NCT05543707|PLACEBO_COMPARATOR|Placebo|PBI-0451(Pomotrelvir): 2 x placebo to match PBI-0451(Pomotrelvir) tablets administered orally twice daily (BID) with food for 5 days (10 total doses)
62017450|NCT05515432|EXPERIMENTAL|Moderately impaired renal funtion: eGFR (mL/min/1.73 m^2) ≥30 - <60|Participants with renal impairment
62017451|NCT05515432|EXPERIMENTAL|Severely impaired renal funtion: eGFR (mL/min/1.73 m^2) <30|Participants with renal impairment
62017452|NCT05515432|EXPERIMENTAL|ESRD (end stage renal disease) on dialysis|Participants with renal impairment
62017453|NCT05515432|EXPERIMENTAL|Normal renal function (control group): eGFR (mL/min/1.73 m^2) ≥90|Age-, weight-, and gender-matched participants with normal renal function as control group
62017454|NCT05042622|EXPERIMENTAL|Cytokine adsorber patients on ECMO|Cytokine adsorber filter will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients on ECMO)
62207633|NCT02299089|EXPERIMENTAL|CAM2029 10 mg (NET)|CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
62207634|NCT02299089|EXPERIMENTAL|CAM2029 20 mg (NET)|CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly
62207635|NCT02299089|EXPERIMENTAL|CAM2029 10 mg (Acromegaly)|CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
62207636|NCT02299089|EXPERIMENTAL|CAM2029 20 mg (Acromegaly)|CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly
62207637|NCT06727474||Follow up cohort|Discharged alive from the ICU and admitted to the follow-up program. Programed scheduled visits, which included an evaluation at one month, six months, and one year after hospital discharge
62207638|NCT01955408||Overactive bladder after Synergo|
62581458|NCT03449329|PLACEBO_COMPARATOR|placebo SIP block|This group will receive a placebo SIP block injection with 60mL NaCl 0.9%
62789418|NCT03301610|PLACEBO_COMPARATOR|Standard verbal and written education|The control group will receive the current standard of care which consists of verbal instruction and pain management educational pamphlets. At a minimum, the patients will receive two educational pamphlets titled Your Pain and Discomfort Management Menu and Communicating About Your Pain. Verbal instruction is nurse dependent. At a minimum the nurse will provide the two pamphlets to the patient and follow-up with the patient to address any questions.
62207639|NCT06506422|EXPERIMENTAL|Empagliflozin|10mg Empagliflozin daily for 12 weeks
62207640|NCT06506422|PLACEBO_COMPARATOR|Placebo|10mg Placebo daily for 12 weeks
62207641|NCT01427725||Lipacreon|"In general, pancrelipase 600 mg/dose was orally administered immediately after a meal, 3 times a day.~Also, the dose was adjusted appropriately according to the patient's condition."
62207642|NCT01205854|NO_INTERVENTION|Conventional clinical and laboratory assessment|
62207643|NCT01205854|EXPERIMENTAL|Conventional assessment plus ultrasonography|
62406067|NCT04892875|EXPERIMENTAL|Concurrent Cisplatin/Radiation Therapy + Zimberelimab + Etrumadenant (Cohort 2)|Concurrent weekly cisplatin with radiation + etrumadenant + zimberelimab with adjuvant combined etrumadenant + zimberelimab
62406068|NCT04892875|ACTIVE_COMPARATOR|Concurrent Cisplatin/Radiation Therapy|Concurrent weekly cisplatin with radiation therapy control arm
62406069|NCT05700526|SHAM_COMPARATOR|Standard Group|The main measures of the designed graft are extrapolated from VSP. The dimensioned drawings of the graft are delivered to the bone bank that prepares the graft according to standard procedures.
62406070|NCT05700526|ACTIVE_COMPARATOR|GSI Group|The main measures of the designed graft are extrapolated from VSP. The bone bank provides a series of CTs of bone segments from those available for processing. These bone segments are reconstructed and compared with the planning to find the best match. Once defined which bone segment will be used, if necessary, the planning is adapted to it.
62406071|NCT04684979|EXPERIMENTAL|HLA-compatible Related Donor|This is a phase 2 study to evaluate NMA PBSCT incorporating peri-transplant rituximab and utilizing PBSC to augment graft cell dose in patients with selected B lymphoid malignancies. Salvage chemotherapy will be required as part of transplant eligibility, both to achieve debulking of disease to allow sufficient time for the development of a post-transplant GVL effect, and to contribute to recipient immune suppression and thus facilitate donor engraftment.
62789419|NCT01286740|EXPERIMENTAL|FTC/RPV/TDF|Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.
62789420|NCT01207752|EXPERIMENTAL|Systane Balance|Artificial tear emulsion
62789421|NCT01207752|ACTIVE_COMPARATOR|Optive Lubricant Eye Drops|Artificial tear
62789422|NCT03451123|EXPERIMENTAL|FET-PET/MRI|O-(2-\[F-18\]FET)-L-tyrosine (FET) for brain PET/MRI
62789423|NCT05698602|EXPERIMENTAL|NivolisMonitor and NivolisAnton Arm|"For each patient enrolled in the study, a NivolisMonitor device is added to the usual ventilatory device for 3 days. NivolisMonitor is connected to the patient circuit, between the ventilatory device and the patient interface, ideally at the patient end of the circuit or possibly at the end of the breathing support device of the circuit (NIV or HDN).~NivolisMonitor continuously measures pressure (P in cm H20) and flow (F in L.min-1) as well as temperature (T in degree Celsisus), relative humidity (RH in percent RH) and, optionally, the Fi02 (in percent).~In addition, an overnight transcutaneous capnia recording will be performed using a Sentec SDM monitor to which a NivolisAnton device will be connected and will be able to collect data and transmit it via remote monitoring."
62207644|NCT01969682|EXPERIMENTAL|Arm A (ABT-199 and rifampin)|
62207645|NCT01460862||Omalizumab Cohort|
62207646|NCT02260713|NO_INTERVENTION|Control|control subjects with acute complete spinal cord injury who would not receive any bone marrow transplantation.
62207647|NCT02260713|EXPERIMENTAL|Transplantation via intrathecal route|Subjects with acute complete spinal cord injury who receive autologous bone marrow cell transplantation via lumber puncture
62406072|NCT04684979|EXPERIMENTAL|Unrelated Donor|This is a phase 2 study to evaluate NMA PBSCT incorporating peri-transplant rituximab and utilizing PBSC to augment graft cell dose in patients with selected B lymphoid malignancies. Salvage chemotherapy will be required as part of transplant eligibility, both to achieve debulking of disease to allow sufficient time for the development of a post-transplant GVL effect, and to contribute to recipient immune suppression and thus facilitate donor engraftment.
62406073|NCT02583594|EXPERIMENTAL|alemtuzumab (subcutaneous injection)|Dose 1 (initial course) of alemtuzumab will be administered subcutaneously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine \[loratadine, cetirizine, dexchlorpheniramine\], paracetamol, acyclovir) will be administered prior alemtuzumab administration.
62581459|NCT03449329|ACTIVE_COMPARATOR|Locoregional SIP block|"This group will receive a SIP block using:~3mg/kg Ropivacain 1%~1mcg/kg dexmedetomidine (Dexdor®) 100mcg/ml Addition of NaCl 0.9% up to 60ml"
62581460|NCT03004573|EXPERIMENTAL|Deep brain stimulation|
62789424|NCT03592485|EXPERIMENTAL|ESP|Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
62207648|NCT02260713|EXPERIMENTAL|Transplantation via intralesional route|Subjects with acute complete spinal cord injury who receive autologous bone marrow cell transplantation via durotomy and injection at the lesional site .
62207649|NCT02361268|EXPERIMENTAL|Intra-dialysis yoga|The experimental intervention in this study is intra-dialysis yoga.
62207650|NCT02361268|ACTIVE_COMPARATOR|Educational program|The active comparator for the study is an educational program.
62207651|NCT06347796|EXPERIMENTAL|Middle Menningeal Artery Embolization (MMAE)|
62207652|NCT06347796|ACTIVE_COMPARATOR|Conventional Surgery (Craniotomy or Burr Holes)|
62581461|NCT04252521|ACTIVE_COMPARATOR|metoclopramide+ dexketoprofen trometamol|10 mg metoclopramide+ 50 mg dexketoprofen trometamol
62581462|NCT04252521|EXPERIMENTAL|metoclopramide|10 mg metoclopramide
62017455|NCT05042622|EXPERIMENTAL|Cytokine adsorber patients with sepsis|Cytokine adsorber filter will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients with sepsis)
62017456|NCT05042622|EXPERIMENTAL|Extracorporeal hemoperfusion cartridge patients on ECMO|Extracorporeal hemoperfusion cartridge will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients on ECMO)
62207653|NCT05982795||CFTR-MT Group|"The cohort of adult cystic fibrosis patients that are currently on Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy (CFTR-MT) will be asked to complete the following research activities at baseline and every six months following for a two-year period.~1. Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge~2. The Sniffin' Sticks extended test kit and/or the University of Pennsylvania Smell Identification Test (UPSIT)~3. 4 validated quality of life questionnaires:~   1. Cystic Fibrosis Questionnaire Revised (CFQ-R)~  2. Sino-Nasal Outcome Test-22 (SNOT-22)~  3. Sinus Control Test (SCT)~  4. Questionnaire of Olfactory Disorders"
62207654|NCT05982795||Non-CFTR-MT Group|"The cohort of adult cystic fibrosis patients that are not currently on Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy (CFTR-MT) will be asked to complete the following research activities at baseline and every six months following for a two-year period.~1. Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge~2. The Sniffin' Sticks extended test kit and/or the University of Pennsylvania Smell Identification Test (UPSIT)~3. 4 validated quality of life questionnaires:~   1. Cystic Fibrosis Questionnaire Revised (CFQ-R)~  2. Sino-Nasal Outcome Test-22 (SNOT-22)~  3. Sinus Control Test (SCT)~  4. Questionnaire of Olfactory Disorders"
62207655|NCT06679621|NO_INTERVENTION|Routine Preoperative Counseling|Participants scheduled to undergo urogynecologic surgery will receive routine preoperative counseling.
62406074|NCT02583594|EXPERIMENTAL|alemtuzumab (intravenous infusion)|Dose 1 (initial course) of alemtuzumab will be administered intravenously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine \[loratadine, cetirizine, dexchlorpheniramine\], paracetamol, acyclovir) will be administered prior alemtuzumab administration.
62406075|NCT03148912|EXPERIMENTAL|diagnostic algorithm|Optimizing the interpretation of the more readily available anti-PF4 assay would reduce the reliance on functional testing/ confirmatory testing (Serotonin Release Assay, SRA) and the number of patients exposed to unnecessary changes in anticoagulation therapy while awaiting the timely functional test results
62581463|NCT04252521|EXPERIMENTAL|dexketoprofen trometamol|50 mg dexketoprofen trometamol
62581464|NCT04877925|ACTIVE_COMPARATOR|Standard Group|Patients with 2 standard chest tubes
62581465|NCT04877925|EXPERIMENTAL|Coaxial Group|Patients with 1 coaxial tube
62581466|NCT00005807|EXPERIMENTAL|Treated Participants|dose escalation treatment
62581467|NCT03960450|EXPERIMENTAL|Part A: BOS-475|Daily application of BOS-475 0.5%, 1%, or 2%
62789425|NCT03592485|EXPERIMENTAL|PECS|Before the induction of general anesthesia, Erector Spinae Plane (ESP) block and Pectoral fascia type I and II will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
62207656|NCT06679621|EXPERIMENTAL|Telehealth intervention|Patient scheduled to undergo urogynecologic surgery will receive routine preoperative counseling in addition to the modified telehealth intervention.
62207657|NCT01844960|ACTIVE_COMPARATOR|Multiple Incision Gastric Band Insertion|Current standard surgical approach for laparoscopic gastric band insertion
62789426|NCT03282929|EXPERIMENTAL|Part 1 Group 1|A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order.
62789427|NCT03282929|EXPERIMENTAL|Part 2 group 1|300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
62789428|NCT03282929|EXPERIMENTAL|Part 2 Group 2|500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
62789429|NCT03282929|EXPERIMENTAL|Part 2 Group 3|300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
62017457|NCT05042622|EXPERIMENTAL|Extracorporeal hemoperfusion cartridge patients with sepsis|Extracorporeal hemoperfusion cartridge will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients with sepsis)
62017458|NCT05042622|NO_INTERVENTION|Control (subgroups)1|No filter will be installed into the ECMO in this study group (15 patients)
62017459|NCT05042622|NO_INTERVENTION|Control (subgroups) 2|No filter will be installed into the patient with sepsis (15 patients)
62017460|NCT00147095||HEALTHY NON-SMOKER|Healthy non-smoker participants
62207658|NCT01844960|EXPERIMENTAL|Single Incision Gastric Band Insertion|New surgical approach for gastric band insertion
62406076|NCT04766658|OTHER|Water Swallow Intervention First|Subjects will complete voice recordings after water swallows and then perform voice recordings after gargle phonation.
62789430|NCT03282929|EXPERIMENTAL|Part 2 Group 4|300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
62789431|NCT00719355|EXPERIMENTAL|Walking with Poles|Patients were assigned to a 24 week walking with poles program of rehabilitation. The intervention was the additional of poles to the walking program.
62789432|NCT00719355|ACTIVE_COMPARATOR|Traditional walking program|Patients were assigned to a 24 week traditional walking program.
62789433|NCT02720692|EXPERIMENTAL|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 7 doses.
62789434|NCT02720692|PLACEBO_COMPARATOR|IV Placebo|IV Placebo every 24 hours for up to 7 doses.
62789435|NCT04071158|EXPERIMENTAL|Lower RSV vaccine dose and Tdap|Lower RSV vaccine dose and Tdap
62789436|NCT04071158|EXPERIMENTAL|Lower RSV vaccine dose and Placebo|Lower RSV vaccine dose and Placebo
62017461|NCT00147095||HEALTHY SMOKER|Healthy smoker participants
62406077|NCT04766658|OTHER|Gargle Phonation Intervention First|Subjects will complete voice recordings after gargle phonation and then perform voice recordings after gargle phonation.
62406078|NCT02798302|ACTIVE_COMPARATOR|Non rebreather|
62207659|NCT05850728|EXPERIMENTAL|TLC-ART 101 Initial Dosage|"The arms will all receive the nanoparticle suspension of lopinavir, ritonavir, and tenofovir (TLC-ART 101). The arms are also called cohorts. The dose a participant receives will vary, depending upon the study results and the time of when they enroll in the study.~The initial dosage administered to 4 participants will contain:~lopinavir 15.6 mg, ritonavir 4.2 mg, and tenofovir 9.15 mg in 1.5mL of the formulation~If the initial dose is appropriate, an additional 8 participants will be enrolled in Arm 1, for a total study size of 12 participants."
62789437|NCT04071158|EXPERIMENTAL|Higher RSV vaccine dose with Aluminum Hydroxide and Tdap|Higher RSV vaccine dose with Aluminum Hydroxide and Tdap
62789438|NCT04071158|EXPERIMENTAL|Higher RSV vaccine dose with Aluminum Hydroxide and Placebo|Higher RSV vaccine dose with Aluminum Hydroxide and Placebo
62207660|NCT05850728|EXPERIMENTAL|TLC-ART 101 Dosage 2A|"In the scenario in which the dosage in Arm 1 produces insufficient pharmacokinetics (PK), the dosage will be increased 2 fold in Arm 2A and administered to 4 participants.~If Arm 2A shows ideal PK parameters, and additional 8 participants will be enrolled in this arm, for a total study size of 16 participants."
62207661|NCT05850728|EXPERIMENTAL|TLC-ART 101 Dosage 2B|"In the scenario in which the dosage in Arm 1 produces excessive drug levels, the dosage will be decreased by up to 2-5 fold (2-5x descending dose) and administered to 4 participants.~If Arm 2B shows ideal PK parameters, and additional 8 participants will be enrolled in this arm, for a total study size of 16 participants."
62207662|NCT05850728|EXPERIMENTAL|TLC-ART 101 Dosage 3A|"In the scenario in which the dosage in Arm 2A produces insufficient drug levels, the dosage may be further increased by 2-fold from Arm 2A dosage (4x total dosage increase) and administered to an additional 4 participants.~If Arm 3A shows ideal PK parameters, and additional 4 participants will be enrolled in this arm, for a total study size of 16 participants"
62017462|NCT00147095||COPD and smoking|Smoking participants with COPD
62406079|NCT02798302|ACTIVE_COMPARATOR|Bag valve mask without leak|
62406080|NCT02798302|ACTIVE_COMPARATOR|Bag valve mask with simulated mask leak|
62789439|NCT04071158|PLACEBO_COMPARATOR|Placebo and Tdap|Normal saline solution for injection (0.9% sodium chloride injection) and Tdap
62406081|NCT05478356|EXPERIMENTAL|orthokeratology group|
62406082|NCT05478356|ACTIVE_COMPARATOR|low-dose atropine group|
62406083|NCT01042288|EXPERIMENTAL|Carboplatin/Pemetrexed/Panitumumab|Systemic Therapy
62789440|NCT03854513||-Group 1 (anuric)|patients on maintenance hemodialysis after 6 months to 1 year or more and urinary output less than 100ml / day
62406084|NCT02553291|EXPERIMENTAL|SystemCHANGE|Subjects will participate in SystemCHANGE behavioral intervention focusing on diet and exercise. This six-session intervention focuses on system redesign of an individual's interpersonal environment and daily routines using small self-designed experiments to increase healthy behavior.
62789441|NCT03854513||Group 2 (good UOP)|patients on maintenance hemodialysis after 6 months to 1 year or more and urinary output 400ml / day or more
62789442|NCT03659071|EXPERIMENTAL|DONORS|donors from the siblings of survivors of acute childhood leukemia who have received hematopoietic stem cell transplantation questionnaire VSP-A will be performed
62789443|NCT03659071|OTHER|NON DONORS|non-donor siblings. questionnaire VSP-A will be performed
62789444|NCT05269108|EXPERIMENTAL|Fluoroscopy-free RIRS|Patients will be treated by RIRS without fluoroscopy
62789445|NCT05269108|ACTIVE_COMPARATOR|Standard RIRS|Standard RIRS under fluoroscopy-guidance will be performed
62207663|NCT05850728|EXPERIMENTAL|TLC-ART 101 Dosage 3B|"In the scenario in which the dosage in Arm 2B produces excessive drug levels, the dosage may be further decreased further by up to 2-5-fold from Arm 2B dosage (4-10x dose decrease) and administered to 4 participants.~If Arm 3B shows ideal PK parameters, and additional 4 participants will be enrolled in this arm, for a total study size of 16 participants"
62017463|NCT02348138|EXPERIMENTAL|Home-based isometric handgrip training|All participants that will be assigned to home-based isometric handgrip training (HBT) will train three times per week for a total of 12 weeks, will perform a bout of isometric handgrip exercise: four sets of 2-min isometric contractions (using alternate hands) at 30% of maximal voluntary contraction; however, the training will be performed without daily supervision. Therefore, the subjects will receive a logbook to record the exercise sessions. In addition, visits will be scheduled at weeks 1, 3, 6, 9 and 11 to provide feedback to individuals and discuss potential problems in conducting training.
62017464|NCT02348138|EXPERIMENTAL|Supervised isometric handgrip training|All participants that will be assigned to supervised isometric handgrip training (ST) will train three times per week for a total of 12 weeks, will perform a bout of isometric handgrip exercise: four sets of 2-min isometric contractions (using alternate hands) at 30% of maximal voluntary contraction with. The training will be performed with daily supervision.
62207664|NCT06151093|EXPERIMENTAL|Video-based balance games group|
62207665|NCT06151093|EXPERIMENTAL|Balance exercises group|
62406085|NCT02553291|ACTIVE_COMPARATOR|Control|Subjects randomized to the control group will receive an usual care condition and pamphlets on diet and exercise from the U.S. Department of Agriculture and the American Heart Association (AHA)
62406086|NCT03652129|EXPERIMENTAL|Laser Group|Disinfection using biostimulating LASER
62406087|NCT03652129|EXPERIMENTAL|Nano irrigant Group|Disinfection using Nano irrigant
62406088|NCT03652129|ACTIVE_COMPARATOR|Conventional irrigation protocol group|disinfection using normal irrigation protocols
62789446|NCT00913939|ACTIVE_COMPARATOR|1: Salvage After EBRT|Patients with locally recurrent prostate cancer after radiotherapy will receive tumor-targeted salvage HDR brachytherapy. Arm 1 of the study will be coordinated and closely integrated with a separate concurrent study of MRI-guided prostate biopsy, which will be performed prior to accrual to Arm 1 of this trial (UHN 05-0641-C).
62789447|NCT00913939|ACTIVE_COMPARATOR|2: Boost to EBRT|Patients with locally advanced prostate cancer will receive a boost of prostate-targeted HDR brachytherapy during external beam radiotherapy.
62017465|NCT02348138|NO_INTERVENTION|Control group|Subjects randomized to the control group (CG) will be encouraged to increase the level of physical activity and make healthy eating, without, however, receive specific recommendations
62207666|NCT06003842|ACTIVE_COMPARATOR|control group|The exercise program to be given to the participants consists of stretching, strengthening and postural exercises for the muscles in the neck-back region. While doing the posture exercises, the participants will be asked to do the exercises in front of the mirror in order to correct the wrong postural posture and to provide relaxation.
62207667|NCT06003842|EXPERIMENTAL|taping group|In addition to the exercises, the Kinesio® Tex taping application will remain on the body for 4 days, and then it will be applied 6 times in total, with a 3-day break.
62207668|NCT06648928|EXPERIMENTAL|Clinician Supported PTSD Coach|PTSD Coach application combined with remotely delivered clinician support, focusing on app use, symptom monitoring, and management strategies.
62207669|NCT06648928|ACTIVE_COMPARATOR|Self Managed PTSD Coach application|Participant remotely receives basic instructions on using the PTSD Coach application but receives no further clinician support
62207670|NCT06648928|NO_INTERVENTION|Wait list control|No intervention until after the follow-up assessment when they have a choice of receiving either CS PTSD Coach or SM PTSD Coach.
62207671|NCT06673966||Individuals with schizophrenia|"Inclusion Criteria:~1. Age, 16-50years.~2. Clinical diagnosis that meets ICD-11 criteria for schizophrenia.~3. Confirmation of the diagnosis of schizophrenia using the SCID-5-RV (DSM-5 Structured Clinical Interview for DSM-5 Disorders - Research Version).~4. Disease duration \< 10 years.~Exclusion criteria:~1. Clinical diagnosis or SCID-5-RV assessment confirming neurodevelopmental disorders, bipolar and related disorders, substance use disorders (excluding alcohol and tobacco).~2. Presence of severe or acute physical illnesses, including traumatic brain injury, intracranial space-occupying or infectious diseases, acute cardiovascular diseases, acute respiratory system diseases, acute hematological disorders, autoimmune disease, etc.~3. Presence of clearly defined genetic diseases, including tuberous sclerosis, multiple sclerosis, Kleefstra syndrome, 22q11.2 deletion syndrome, Prader-Willi syndrome, Klinefelter syndrome (47, XXY), etc."
62406089|NCT02619565|OTHER|Blood samples if evolution of the disease|blood samples at Day 0 and also if there is an evolution of the disease
62406090|NCT05437731|EXPERIMENTAL|Study group|
62406091|NCT05437731|ACTIVE_COMPARATOR|Control group|
62406092|NCT05028985||early COPD patients|younger than 50 years with 10 or more pack-years smoking history and any of these abnormalities: 1) early airflow limitation (post-bronchodilator forced expiratory volume in the first second(FEV1)/forced vital capacity(FVC) \< lower limit of normal), 2) compatible CT abnormalities, 3) rapid decline in FEV1 (≥60 ml/yr).
62406093|NCT05028985||Healthy people|healthy without any disabling, physical, neurological, or mental disease and were excluded living in a nursing home.
62406094|NCT05966142|EXPERIMENTAL|Chronic Pain - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
62406095|NCT05966142|OTHER|Chronic Pain - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period
62406096|NCT06015061||Pheochromocytoma or Paraganglioma Patients with Anlotinib Treatment|to evaluate the efficiency of contrast enhanced ultrasound in assessing effectiveness of anlotinib in patients with locally advanced, metastatic, or unresectable pheochromocytoma or paraganglioma(PPGL).
62406097|NCT00701012|EXPERIMENTAL|1|low ligation, which the IMA is ligated below the origin of the left colic artery
62406098|NCT00701012|ACTIVE_COMPARATOR|2|high ligation, which the IMA is ligated at its origin from the aorta
62406099|NCT02459756|ACTIVE_COMPARATOR|Intervention|Spray dried blackcurrant powder dissolved in water
62406100|NCT02459756|PLACEBO_COMPARATOR|Placebo|(sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)
62406101|NCT02768506||Gastric bypass|Subjects submitted to gastric bypass
62017466|NCT04696159|EXPERIMENTAL|Endoscopic Per-Oral Pyloromyotomy (POP)|The study cohort will include 40 patients with a HbA1c \>7.5% with medically refractory gastroparesis who are scheduled to undergo POP. Each patient will undergo two 10-day periods of CGM at an interval of approximately seven months, one month prior to the procedure and six months after. Symptoms and diabetes management improvement will be measured by the Gastroparesis Cardinal Symptom Index (GCSI) scores and the Diabetes Self-Management Questionnaire (DSMQ).
62017467|NCT03038373||Group I|Morbid Obese Type 2 Diabetics, undergo Laparoscopic Sleeve Gastrectomy
62406102|NCT02768506||SADI-S|Subjects submitted to SADI-S
62581468|NCT03960450|PLACEBO_COMPARATOR|Part A: Vehicle cream|Daily application of vehicle cream
62581469|NCT03960450|EXPERIMENTAL|Part B: BOS-475|Daily application of BOS-475 0.5%, 1%, or 2%
62581470|NCT03960450|PLACEBO_COMPARATOR|Part B: Vehicle cream|Daily application of vehicle cream
62017468|NCT03038373||Group II|Morbid Obese Non Diabetics, undergo Laparoscopic Sleeve Gastrectomy
62017469|NCT03038373||Group III|Lean Diabetics, No surgery
62017470|NCT03038373||Group IV|Lean Non Diabetics, No surgery
62017471|NCT05041166|EXPERIMENTAL|Protocol optimization cohort|Following the \[13C\]pyruvate injection, dynamic imaging and 3D volumetric imaging of volunteers in the first cohort (HP MRI protocol optimization, Aim 1) will be performed on the 3-T MRI scanner, using different \[13C\] RF excitation/detection coils.
62017472|NCT05041166|EXPERIMENTAL|Tissue reference cohort|The optimal setup will then be used for HP MRI of the second cohort.
62017473|NCT01702129|EXPERIMENTAL|anti-EGFR Immunoliposomes|anti-EGFR immunoliposomes loaded with doxorubicin. Dose escalating study. 3 patients per dose level. Dose levels: 5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2.
62017474|NCT05395624|EXPERIMENTAL|Healthy Volunteer participants|Intravenous Administration of 18F-OP-801 (18F Hydroxyl Dendrimer)
62017475|NCT05395624|EXPERIMENTAL|Amyotrophic Lateral Sclerosis participants|Intravenous Administration of 18F-OP-801 (18F Hydroxyl Dendrimer)
62017476|NCT05395624|EXPERIMENTAL|Alzheimer's Disease participants|Intravenous Administration of 18F-OP-801 (18F Hydroxyl Dendrimer)
62017477|NCT05395624|EXPERIMENTAL|Multiple Sclerosis participants|Intravenous Administration of 18F-OP-801 (18F Hydroxyl Dendrimer)
62406103|NCT06126107|ACTIVE_COMPARATOR|Loss-framed Messaging|"Daily text messages on the consequences of hazardous drinking (e.g., Think of all you have lost as a result of drinking too much. Make today a day that sets the stage for change.)"
62017478|NCT05395624|EXPERIMENTAL|Parkinson's Disease participants|Intravenous Administration of 18F-OP-801 (18F Hydroxyl Dendrimer)
62017479|NCT04623801|EXPERIMENTAL|Participants with papillary microcarcinoma (PTMC)|Participants with papillary microcarcinoma (PTMC) who have elected to proceed with thyroidectomy rather than an observational management approach will be considered as potential candidates for this trial.
62406104|NCT06126107|ACTIVE_COMPARATOR|Gain-framed Messaging|"Daily text messages on the benefits of reducing drinking to safe guidelines (e.g., Think of all you can achieve if you can control your drinking. Make today a day that sets the stage for change.)"
62406105|NCT06126107|ACTIVE_COMPARATOR|Gain-framed and Loss-framed Messaging|"Daily text messages that alternate between loss-framed (e.g., Think of all you have lost as a result of drinking too much. Make today a day that sets the stage for change.) and gain-framed messaging (e.g., Think of all you can achieve if you can control your drinking. Make today a day that sets the stage for change.)"
62581471|NCT03681288|EXPERIMENTAL|Mindful Self-Compassion|Mindful Self-Compassion Intervention
62581472|NCT05105542|EXPERIMENTAL|Schizophrenia or schizoaffective disorder|Participants will undergo a single PET scan with \[11C\]EMO ≤ 20 mCi
62581473|NCT05105542|EXPERIMENTAL|Healthy Controls|Participants will undergo a single PET scan with \[11C\]EMO ≤ 20 mCi
62581474|NCT06684041|EXPERIMENTAL|Dose 1|
62581475|NCT06684041|EXPERIMENTAL|Dose 2|
62581476|NCT06684041|EXPERIMENTAL|Dose 3|
62581477|NCT06406153|EXPERIMENTAL|YW17 (laronidase biosimilar)|YW17 (2.9 mg/5 mL) produced by CinnaGen Company, is administered 0.58 mg/kg weekly.
62017480|NCT06572254|NO_INTERVENTION|Self-study Pictorial Module|The control group will only be provided with a self-study pictorial module, and they will be tracked and requested to visit the center at the 6 months (child age) post-delivery. At 6 months, their data on responsive interactions, parenting confidence, and patient experience will be collected.
62017481|NCT06572254|EXPERIMENTAL|Monthly Sessions and Self-study handouts|The intervention will undergo a 6-month intervention consisting of 1 session at birth with a self-study manual, and 5 monthly sessions (once a month till the infant turns 6 months). At 6 months, they will also be assessed on the measures mentioned above.
62581478|NCT06406153|ACTIVE_COMPARATOR|Aldurazyme®|Aldurazyme® (2.9 mg/5 mL), is administered 0.58 mg/kg weekly.
62581479|NCT05890989||INCREASED EPICARDIAL ADIPOSIS TISSUE|
62017482|NCT06431750||Secukinumab|pediatric patients with active ERA/jPsA for whom routine treatment with secukinumab according to the approved national label is initiated during 4 to 8 weeks prior to enrollment
62017483|NCT02723617|OTHER|MED 0.5|
62017484|NCT02723617|OTHER|MED 2.5|
62017485|NCT02723617|OTHER|MED 5.5|
62581480|NCT02391805|PLACEBO_COMPARATOR|Placebo, Every Other Day (QOD)|Placebo orally (PO) QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
62017486|NCT02723617|OTHER|AAD 2.5|
62017487|NCT06532045|EXPERIMENTAL|TENS arm|This arm who was experimental group who received transcutaneous electrical nerve stimulation and breathing exercises
62017488|NCT06532045|SHAM_COMPARATOR|Breathing arm|This arm was sham and not received official treatment
62017489|NCT01889589||NYC adults|
62017490|NCT01903278|EXPERIMENTAL|PEG-IFN-SA /RBV T1(Genotype2,3)|PEG-IFN-SA/RBV, 1.5μg/kg/week im and RBV 1000mg-1200mg/d po bid（BW\<75kg,1000mg/d; BW≥75kg, 1200mg/d）,24 weeks
62581481|NCT02391805|PLACEBO_COMPARATOR|Placebo, Once a Week (QWk)|Placebo PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
62581482|NCT02391805|EXPERIMENTAL|RO6864018, 1200 milligrams (mg) QOD|RO6864018 1200 mg PO QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
62581483|NCT02391805|EXPERIMENTAL|RO6864018, 1200 mg QWk|RO6864018 1200 mg PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
62789448|NCT03999060|EXPERIMENTAL|Electric Stimulation|
62017491|NCT01903278|ACTIVE_COMPARATOR|Pegasys /RBV C1(Genotype 2,3)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW\<75kg，1000mg/d；BW≥75kg，1200mg/d）for 24 weeks
62017492|NCT01903278|EXPERIMENTAL|PEG-IFN-SA /RBV T2(Non-genotype 2,3)|PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW\<75kg，1000mg/d；BW≥75kg，1200mg/d）for 48 weeks
62017493|NCT01903278|ACTIVE_COMPARATOR|Pegasys /RBV C2(Non-genotype 2,3)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW\<75kg，1000mg/d；BW≥75kg，1200mg/d）for 48 weeks
62207672|NCT06673966||Healthy volunteers|"1. Age, 16-50 years;~2. Clinical diagnosis not meeting ICD-11 criteria for schizophrenia.~3. Diagnosis not meeting schizophrenia criteria confirmed using SCID-5-RV (DSM-5 Structured Clinical Interview for DSM-5 Disorders - Research Version).~Exclusion criteria are the same as for the schizophrenia patient group."
62207673|NCT04875299||adalimumab TDM|Patients with active ankylosing spondylitis receiving adalimumab treatment.
62207674|NCT01514708|EXPERIMENTAL|AdimFlu-S Influenza Vaccine, 0.5mL/dose, receive 1 dose|
62406106|NCT02986048||Proton Beam Therapy|All patients treated with proton beam therapy at the UH Proton Therapy Center who consent to have their health information recorded, including whether the cancer was cured and if any complications occur ed due to treatment
62581484|NCT02391805|EXPERIMENTAL|RO6864018, 800 mg QOD|RO6864018 800 mg PO QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
62581485|NCT02391805|EXPERIMENTAL|RO6864018, 800 mg QWk|RO6864018 800 mg PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
62017494|NCT01911364|EXPERIMENTAL|BDP/FF/GB|CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations b.i.d
62017495|NCT01911364|ACTIVE_COMPARATOR|Tiotropium|Tiotropium bromide 18 mcg
62207675|NCT06297226|EXPERIMENTAL|BMS-986393|
62581486|NCT00030394|EXPERIMENTAL|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve a complete hematologic response after 3 courses or a partial or complete cytogenic response after 6 courses are removed from the study.
62735030|NCT00086983|EXPERIMENTAL|Treatment (becatacarin, oxaliplatin)|"Patients receive rebeccamycin analogue IV over 1 hour on days 1-5 and oxaliplatin IV over 2 hours on day 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue and oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD."
62789449|NCT01600079||Vaccinated Cohort|Participants vaccinated with at least one dose of ZOSTAVAX™
62789450|NCT01600079||Unvaccinated Comparison Cohort|Participants who are not yet vaccinated with any zoster vaccine
62207676|NCT00649636|EXPERIMENTAL|1|Fluoxetine Capsules 40 mg
62207677|NCT00649636|ACTIVE_COMPARATOR|2|Prozac Pulvules 40 mg
62789451|NCT01020370||Alemtuzumab Group|
62017496|NCT01911364|ACTIVE_COMPARATOR|BDP/FF + Tiotropium|"BDP/FF pMDI 100/6/12.5 mcg 2 inhalations b.i.d and Tiotropium 18 mcg daily~BDP/FF/GB versus BDP/FF + Tiotropium"
62017497|NCT01381055|EXPERIMENTAL|Pentoxifylline plus antimony|
62017498|NCT01381055|PLACEBO_COMPARATOR|Placebo plus antimony|
62017499|NCT04971382|EXPERIMENTAL|curcumin combined with particulate xenograft.|"Curcumin will be used in combination with xenograft after ridge splitting surgery~Curcumin is widely used in medicine due to medicinal properties, cost-effectiveness, and simple extraction from a turmeric plant that grows in different regions in the world. Recent evidences have shown that curcumin possesses multiple biological activities and pharmacological properties including anti-inflammation , antioxidation , anticancer , antimicrobial , and free radical scavenger effects"
62017500|NCT04971382|ACTIVE_COMPARATOR|alveolar ridge splitting with use of particulate xenograft alone.|xenograft will be used alone after ridge splitting
62017501|NCT03749226|ACTIVE_COMPARATOR|AZLI group|Patients assigned to study group will receive nebulized Aztreonam lysine (AZLI 75 mg-dose) three times /day during 5 days by mean of the ultrasonic nebulizer (Aeroneb solo®) plus Combihaler® spacer adapted of the ventilator
62207678|NCT06432972|EXPERIMENTAL|Prehab|
62207679|NCT05986643|ACTIVE_COMPARATOR|Exergame & Neurofeedback|Six 5 minutes sets of participants standing on a balance board within virtual environment playing the exergame and receiving real neurofeedback with 1 minute rest between each set.
62207680|NCT05986643|SHAM_COMPARATOR|Exergame & SHAM Feedback|Six 5 minutes sets of participants standing on a balance board within virtual environment playing the exergame and receiving SHAM neurofeedback with 1 minute rest between each set.
62207681|NCT00932542|EXPERIMENTAL|Eutectic mixture|
62207682|NCT00932542|PLACEBO_COMPARATOR|placebo|
62207683|NCT00932542|ACTIVE_COMPARATOR|Medicaina|
62207684|NCT01249027||Observational|Single arm prospective, observational, single-arm, open-label, multicenter, postapproval registry study using XIENCE V® Everolimus Eluting Coronary Stent System (EECSS).
62207685|NCT06398301|EXPERIMENTAL|Prehabilitation|Prehabilitation arm groups will receive preoperative intervention which includes exercise training, nutritional therapy and anxiety reducing techniques, aimed at preventing or attenuating surgery-driven functional decline.
62207686|NCT06398301|NO_INTERVENTION|Control group|Standard care treatment. Application of ERAS pathways (Enhanced Recovery After Surgery)
62207687|NCT00538317|EXPERIMENTAL|1|tirofiban bolus + perfusion started at the site of caring
62406107|NCT05719701|EXPERIMENTAL|ICP-490|
62406108|NCT05719701|EXPERIMENTAL|ICP-490 in combination with Dexamethasone|
62406109|NCT06493110||diabetic term pregnant|"1. Patients with good mental status~2. Pregnant patients aged ≥18 years~3. Patients in ASA II-III group~4. Patients complying with preoperative fasting instructions (at least 6 hours for solids, at least 2 hours for clear liquids)~5. Term pregnant women (gestational age ≥ 36 weeks)~6. 50-120kg weight~7. 150cm height or taller~8. Have written informed consent"
62406110|NCT06493110||non-diabetic term pregnant|"1. Patients with good mental status~2. Pregnant patients aged ≥18 years~3. Patients in ASA II-III group~4. Patients complying with preoperative fasting instructions (at least 6 hours for solids, at least 2 hours for clear liquids)~5. Term pregnant women (gestational age ≥ 36 weeks)~6. 50-120kg weight~7. 150cm height or taller~8. Have written informed consent"
62406111|NCT00902759|NO_INTERVENTION|Usual Care Group|"Participants randomized to the usual care group will be encouraged to return to their usual or pre-surgical levels of activity. Usual care of post-surgical PC and peri-ampullary patients typically includes encouragement to walk and be active as they can be by the surgeons, surgical nurses and the nurse practitioners. Participants in the usual care group will not receive an individual Exercise Prescription at the time of entry. The usual care group will perform a baseline walk. Participants in the usual care group will not receive an individual Exercise Prescription at the time of entry nor will they will a telephone call every month. Repeat questionnaires will be performed at 6 months."
62207688|NCT00538317|ACTIVE_COMPARATOR|2|tirofiban bolus + perfusion started at the beginning of coronarography (usual use of tirofiban)
62406112|NCT00902759|EXPERIMENTAL|Walking Program|Participants in the intervention arm will participate in a walking program consisting of a 6 week graduated walking program. There are three phases to the walking program, Phase 1 is Warm-up, Phase 2 is Brisk Walking and Phase 3 is Cool Down. Phase 1 is the same for all 6 weeks, and consists of a slow 5 minute walk. In Months 1 and 2, Phase 2 is a 10 minute brisk walk. In Months 3 and 4, Phase 2 is a 20 minute brisk walk. In Months 5 and 6, Phase 2 is a 25 - 30 minute brisk walk. Phase 3 is the same for all 6 weeks and consists of a 5 minute rest/cool down period.
62406113|NCT05346458|EXPERIMENTAL|Intra coronary rapid-exchange iKOs microcatheter intervention|Patients with coronary heart disease and undergoing coronary physiology investigations (pressure wire measurements) will have additional coronary pressure and flow measurements using the iKOs rapid-exchange microcatheter and iKOr console.
62207689|NCT02108964|EXPERIMENTAL|Phase I part|Participants with locally advanced or metastatic NSCLC harboring specific EGFR mutations will be administered escalated doses of EGF816 orally once a day as continuous daily dosing in each cycle (of 28 days) during Phase I part of the study. The starting dose for the Phase I part first cohort of patients will be 75 mg once per day capsule.
62207690|NCT02108964|EXPERIMENTAL|Phase II part|Treatment naïve participants with locally advanced or metastatic NSCLC harboring EGFR mutations will be administered with EGF816 at RP2D during Phase II part of the study.
62789452|NCT01020370||Interferon Beta-1a SC Group|
62789453|NCT00465088|EXPERIMENTAL|1|
62207691|NCT04606186|ACTIVE_COMPARATOR|Lactobacillus reuteri Prodentis®-lozenges|
62207692|NCT04606186|PLACEBO_COMPARATOR|Placebo-lozenges (BioGaia)|
62207693|NCT05914870|EXPERIMENTAL|Multi-component training|"The Multicomponent Training programme will apply two main training units per session per day.~This experimental group will perform 2 intervention sessions per week with a duration of 60 minutes each; 10 minutes for the preparatory phase to exercise in which they will perform joint mobility exercises and dynamic stretching; 40 minutes will be dedicated to the main phase of the training, 20 minutes for strength work, with two exercises, one for the upper body and one for the lower body, and 20 minutes for cardiovascular work; finally, 10 minutes for the post-exercise phase in which they will perform a return to calm and static stretching.~The duration of the programme will be 12 weeks (3 months)."
62207694|NCT05914870|EXPERIMENTAL|Continuous Cardiovascular Training|"The Continuous Cardiovascular Training programme will apply a single main training unit per session per day.~This experimental group will perform 2 intervention sessions per week with a duration of 60 minutes each; 10 minutes for the preparatory phase to exercise in which they will perform joint mobility exercises and dynamic stretching; 40 minutes for the main phase of the training where they will perform continuous aerobic work without changes in intensity during the session; finally, 10 minutes for the post-exercise phase in which they will perform a return to calm and static stretching.~The duration of the programme is 12 weeks (3 months)."
62207695|NCT05914870|NO_INTERVENTION|Control Group|The control group will not perform any physical exercise programme and will continue with their daily tasks.
62207696|NCT03940703|EXPERIMENTAL|Tepotinib and Osimertinib|Participants received a single oral dose of Tepotinib 500 milligrams (mg) followed by Omisertinib 80 mg once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal.
62207697|NCT03940703|EXPERIMENTAL|Tepotinib Mono-therapy|Participants received a single oral dose of Tepotinib 500 mg until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal.
62207698|NCT03099564|EXPERIMENTAL|pembrolizumab + Y90 radioembolization|Pembrolizumab 200mg IV every 3 weeks in conjunction with Y90 radioembolization (performed one week after the first dose of pembrolizumab)
62207699|NCT01949389|EXPERIMENTAL|Internet-based Cognitive Behavioral Therapy for Insomnia|This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
62789454|NCT00465088|EXPERIMENTAL|2|
62789455|NCT06527924||Health Group|Non-osteoarthritis (OA) patients who underwent sagittal plane EOS examinations at the Chinese PLA General Hospital between September 2024 and September 2026.
62789456|NCT06527924||OA group|OA patients who underwent sagittal plane EOS examinations at the Chinese PLA General Hospital from September 2024 to September 2026. The sagittal alignment angles on the EOS radiographs of the subjects were measured to establish a classification system for extension or non-extension.
62207700|NCT06651359|OTHER|Control group|Participants in this arm will be eligible Black men who have prostate cancer and are either currently undergoing treatment or are cancer survivors.
62207701|NCT06651359|EXPERIMENTAL|Intervention group|Participants in this arm will be eligible Black men who have prostate cancer and are either currently undergoing treatment or are cancer survivors, who are given access to the mHealth app for this study.
62789457|NCT06268938|EXPERIMENTAL|Muscle obliteration|Mastoid cavity obliteration by muscle
62789458|NCT06268938|ACTIVE_COMPARATOR|Bone obliteration|Mastoid cavity obliteration by bone
62789459|NCT02696213|EXPERIMENTAL|SCOOT Immediate|This group will receive SCOOT immediately
62207702|NCT06042413|EXPERIMENTAL|Group A/C (intervention)|"Participants randomized to this intervention group will receive the following interventions:~* Personalized CPC Prehabilitation~* Cognitive Training~* Meditation~* Daily Exercise~* Enhanced Social Support~Additionally, they will undergo standard of care routine intraoperative SSEP and EEG monitoring during the scheduled surgery."
62207703|NCT06042413|ACTIVE_COMPARATOR|Group B/C (SOC control)|Participants randomized to the control group will receive standard of care pre-operative treatment, which may or may not include a visit to the CPC. Participants will receive standard of care routine intraoperative SSEP and EEG monitoring during the scheduled surgery.
62207704|NCT06042413|EXPERIMENTAL|Group A/D (intervention + SOC)|"Participants randomized to this intervention group will receive the following interventions for study Part I:~* Personalized CPC Prehabilitation~* Cognitive Training~* Meditation~* Daily Exercise~* Enhanced Social Support~If eligible to continue to Study Part 2, participants who received the Part I intervention will receive standard of care monitoring that includes: Routine intraoperative SSEP and EEG monitoring."
62207705|NCT06042413|EXPERIMENTAL|Group B/D (SOC + proactive bundle interventions)|"Participants randomized to the control group in study Part I will receive standard of care pre-operative treatment, which may or may not include a visit to the CPC.~If eligible to continue to Study Part 2, participants who received standard of care pre-operatively, will receive Proactive Bundle Interventions during surgery that includes: Participants randomized to the proactive bundled intervention group (Group D) will receive a routine intraoperative SSEP and EEG monitoring as well as optimization of intraoperative physiology by maintaining normal blood pressure, oxygen levels, opioid sparing analgesia, avoiding deep anesthesia and benzodiazepines."
62406114|NCT01424631|ACTIVE_COMPARATOR|single incision laparoscopic appendectomy|
62406115|NCT01424631|PLACEBO_COMPARATOR|conventional laparoscopic appendectomy|
62406116|NCT00186082|ACTIVE_COMPARATOR|Cefotetan, Cefoxitin or Clindamycin|
62406117|NCT00186082|PLACEBO_COMPARATOR|Normal Saline|
62406118|NCT06251765||Patients|Patients who underwent Judet arthromyilisis for treatment of post-traumatic knee stiffness
62406119|NCT00790972|PLACEBO_COMPARATOR|2|Identical-appearing placebo
62406120|NCT00790972|ACTIVE_COMPARATOR|1|two sprays in each nostril three times daily for one week
62406121|NCT05897411|EXPERIMENTAL|Deconditioning|
62406122|NCT05897411|SHAM_COMPARATOR|Sham deconditioning|
62406123|NCT05890235|EXPERIMENTAL|Ningmitai Capsule group|Patients take Ningmitai capsule, 0.38 g/capsule, tid, 4 capsules each time, after meals, for 8 weeks.
62789460|NCT02696213|OTHER|SCOOT Delayed|This group will receive SCOOT after 6 weeks
62789461|NCT03257839||Asymptomatic women with dense breast tissue|Healthy women presenting to enrollment sites for routine annual mammographic examinations, confirmed to have BI-RADS category c or d breast composition (density).
62789462|NCT04949022|EXPERIMENTAL|Hybrid closed loop system|Initiation of 780G insulin pump. First two weeks run-in-phase in open loop Manual mode, followed by a12 month study phase with advanced hybrid closed loop Auto mode.
62789463|NCT05950698||Obese patients submitted to bariatric surgery|"50 patients, both females and males, aged between 18 and 60 years, who will be submitted to bariatric surgery with Roux-en-Y reconstruction reduction gastroplasty technique.~Patients will be evaluated for five times: before the bariatric surgery and 3-6-12-24 months after the bariatric surgery."
62207706|NCT05905159|EXPERIMENTAL|ABM|"ABM training will consist of five sessions over five consecutive days during which patients performed a modified version of the visual dot-probe task. The whole ABM program will include a total of 1000 trials that will be distributed in 200 trials per session (twenty minutes per session).~Participants assigned to ABM training condition will be trained implicitly to attend away from pain-related stimuli (i.e., facial expressions). They will be presented with a modified dot-probe task with trials including targets that often replaced neutral faces. Thus, 80% of trials (i.e., 160 trials) included targets that replaced neutral cue faces (pain incongruent trials: target appeared in the opposite side of pain-related faces). The rest of trials (i.e., 40 trials) belonged to pain congruent trials (i.e., target will occur in the same location of the pain-related facial expression)."
62406124|NCT05890235|ACTIVE_COMPARATOR|Tamsulosin Hydrochloride Sustained-release Capsules group|Patients take Tamsulosin Hydrochloride Sustained-release Capsules ,0.2 mg/capsule, once daily, 1 capsule each time, for 8 weeks.
62789464|NCT06584045|EXPERIMENTAL|CBS therapy, CBS dosage: 100mg per day from day 1 to day 84, in encephalitis cohort|Subjects in encephalitis cohort of this arm will receive general therapy plus CBS.
62789465|NCT06584045|NO_INTERVENTION|Control therapy: no intervention, in encephalitis cohort|Subjects in encephalitis cohort of this arm will only receive general therapy.
62017502|NCT03749226|NO_INTERVENTION|Control group|Patients assigned to control group will no receive any intervention for heavy Gram negative colonization
62017503|NCT05882851||grup 1|Those who recover after vaginitis treatment
62207707|NCT05905159|PLACEBO_COMPARATOR|Control|By contrast, patients assigned to control condition were exposed to a standard visual dot-probe task in which targets were equally likely to replace pain or neutral cues (i.e., facial expressions) during pain trials (i.e., 50% pain-incongruent trials and 50% pain-congruent tri-als). The whole Control program will include a total of 1000 trials that will be distributed in 200 trials per session (twenty minutes per session).
62207708|NCT02770417|ACTIVE_COMPARATOR|COPD (beta-alanine)|
62207709|NCT02770417|PLACEBO_COMPARATOR|COPD (placebo)|
62207710|NCT02770417|OTHER|Healthy controls|
62207711|NCT02589275|EXPERIMENTAL|TNX-102 SL Tablet 2.8 mg|1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 3 months
62207712|NCT00754364|EXPERIMENTAL|Pemetrexed/Carboplatin|Pemetrexed (500 mg/m2 infusion) plus Carboplatin (AUC5 infusion)
62207713|NCT00754364|ACTIVE_COMPARATOR|Gemcitabine|Gemcitabine 1250 mg/mq
62207714|NCT05419024|EXPERIMENTAL|ATI|Participants randomized to ATI will halt their ART medications starting 2 weeks (more or less 3 days) after the first imaging visit. This plan will be discussed with participants during the baseline visit. Patients will be contacted 1-3 days prior to ATI initiation. ATI may be delayed or cancelled if there are new safety concerns. HIV plasma viral levels and CD4 counts will be monitored every week during the ATI phase. If a participant meets any of the ART restart criteria during the ATI phase, then they will discontinue ATI and restart ART. Participants who do not meet restart criteria will remain off ART and continue to be monitored weekly until they have been on ATI for 90 days, and then will restart ART.
62207715|NCT05419024|NO_INTERVENTION|Continue ART|Participants will continue on their pre-study ART throughout the trial.
62207716|NCT03882177|EXPERIMENTAL|Arm 1: Pravastatin (40 mg) and Rifafour|"Participants will receive pravastatin (40 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.~Vitamin B6 will be added to each of the regimens."
62406125|NCT05890235|ACTIVE_COMPARATOR|Combined group|Patients take Ningmitai capsule, 0.38 g/capsule, tid, 4 capsules each time, after meals, for 8 weeks and Tamsulosin Hydrochloride Sustained-release Capsules ,0.2 mg/capsule, once daily, 1 capsule each time, for 8 weeks.
62406126|NCT00709449|EXPERIMENTAL|1|20 patients with age related macular degeneration
62406127|NCT00709449|EXPERIMENTAL|2|20 patients with primary open angle glaucoma
62017504|NCT05882851||grup 2|those who were resistant to treatment
62207717|NCT03882177|EXPERIMENTAL|Arm 2: Pravastatin (80 mg) and Rifafour|"Participants will receive pravastatin (80 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.~Vitamin B6 will be added to each of the regimens."
62581487|NCT02977572|EXPERIMENTAL|Non-Invasive ventilation (NIV group)|For the NIV group, a BiPAP Vision was used, by setting the Inspiratory Positive Airway Pressure (IPAP) at a level that was required to achieve a tidal volume of approximately 8-10 ml/kg. Also an Expiratory Positive Airway Pressure (EPAP) was set at a minimum of 5 cmH20 during the first hour, gradually increasing until there was a clinical improvement. Fraction inspiratory of oxygen (FiO2) was applied to maintain a transcutaneous arterial oxygen saturation (SaO2) of 92%-94%. NIV was continuously applied until there was a clinical and/or a gasometrical improvement, at which time they were replaced by a Venturi mask with FiO2 of 0.4.
62207718|NCT03882177|EXPERIMENTAL|Arm 3: Pravastatin (120 mg) and Rifafour|"Participants will receive pravastatin (120 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.~Vitamin B6 will be added to each of the regimens.~(Arm 3 will only be recruited if pravastatin 80 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.)"
62207719|NCT03882177|EXPERIMENTAL|Arm 4: Pravastatin (160 mg) and Rifafour|"Participants will receive pravastatin (160 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.~Vitamin B6 will be added to each of the regimens.~(Arm 4 will only be recruited if pravastatin 120 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.)"
62207720|NCT06718647||Low Dose of Enzalutamide|Low Dose of Enzalutamide: ≤ 50% of the standard dose
62207721|NCT06718647||Intermediate Dose of Enzalutamide|Intermediate Dose of Enzalutamide: \> 50% and ≤ 80% of the standard dose
62207722|NCT06718647||High Dose of Enzalutamide|High Dose of Enzalutamide: \> 80% of the standard dose
62207723|NCT01228331|ACTIVE_COMPARATOR|Arm I intensification (cytarabine)|"LR-S patients receive HD cytarabine IV 4 x 3 g over 12 hours daily on days 29-31 and pegaspargase IV over 2 hours on days 31, 52, and 80.~LR-I and precursor B-cell ALL HR-S and HR-I patients receive HD cytarabine IV 2.500 over 3 hours twice daily on days 29-31 and 106-108 and pegaspargase IV over 2 hours on days 31, 53, 67, and 108.~Followed by standard consolidation therapy regarding to stratification containing:~methotrexate, cyclophosphamide, thioguanin, mercaptopurine, etoposide phosphate, amsacrine, cytarabine, methylprednisolone, dexamethasone, vincristine sulfate; whole-brain radiation therapy only if indicated in patients with cns involvement or T-cell ALL"
62789466|NCT06584045|EXPERIMENTAL|CBS therapy, CBS dosage: 100mg per day from day 1 to day 84, in healthy cohort|Subjects in healthy cohort of this arm will only receive CBS.
62789467|NCT05575193|EXPERIMENTAL|Acupressure Group|The patients receiving the intervention of acupressure are in the experimental group.The experimental group will receive the acupressure at the hemodialysis center for a total of 12 weeks, three times a week. The patients will receive 4 acupuncture points, including Quchi acupoint, Xuehai acupoint, Sanyinjiao acupoint, and Zusanli acupoint. Each acupoint will be pressed for 3 minutes, and totally 4 acupuncture points are 12 minutes. The effectiveness will be evaluated at the fourth week, eighth week and twelfth week.
62789468|NCT05575193|NO_INTERVENTION|Non-Acupressure Group|"Acupressure is not provided, only general routines are performed. Pre-test and 3 post-tests of Visual Analog Scale (VAS), 5D Tickling Scale, and Pittsburgh Sleep Quality Scale are also required (week 4, week 8 and week 12)."
62017505|NCT06068205||Type 1 diabetes with microvascular complications|
62406128|NCT00709449|EXPERIMENTAL|3|20 age and sex matched control subjects
62406129|NCT03367676|EXPERIMENTAL|Experimental Arm|12 weeks adjuvant docetaxel plus trastuzumab
62406130|NCT05450900|ACTIVE_COMPARATOR|Cohort 1|hCG plus biotin supplement
62406131|NCT05450900|PLACEBO_COMPARATOR|Cohort 2|hCG plus placebo supplement
62406132|NCT01694927|EXPERIMENTAL|Mesenchymal Stem cells|
62406133|NCT03459066||Institution-Group 8 district|Group of patients belonging to institutions of district 8. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
62406134|NCT03459066||Institution-Group 9 district|Group of patients belonging to institutions of district 9. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
62735031|NCT04736290||Noncardiac surgery|Calculation of the NLR and PLR in patients undergoing noncardiac surgery under general anesthesia
62017506|NCT06068205||Type 1 diabetes without microvascular complications|
62017507|NCT02687880||All Subjects|"All subjects will undergo a surgical procedure (Testicular biopsy) to harvest their testicular tissue. In most cases, this will be done as part of their routine care but it is possible the subject may elect to have the procedure as part of a research only biopsy."
62017508|NCT03221257|PLACEBO_COMPARATOR|Placebo (Plac) + Mycophenolate (MMF)|Participants will receive Placebo (Plac) as add-on to a background therapy of Mycophenolate Mofetil (MMF).
62789469|NCT02462720|EXPERIMENTAL|Varithena®, then Radiofrequency Ablation|Varithena (polidocanol injectable foam) supplied as polidocanol solution 180 mg/18 mL (10 mg/mL) to be activated before use. Once activated, Varithena is a white injectable foam delivering a 1% polidocanol solution. Each milliliter of Varithena injectable foam contains 1.3 mg of polidocanol. Up to 5 mL per injection or 15 mL per treatment session could be used. This was followed by RFA treatment.
62017509|NCT03221257|EXPERIMENTAL|Pirfenidone (PFD) + Mycophenolate (MMF)|Participants will receive Pirfenidone (PFD) as add-on to a background therapy of Mycophenolate Mofetil (MMF).
62017510|NCT02533843|ACTIVE_COMPARATOR|Arm I|ablation at sources guided by FIRMap (using RhythmView™ Workstation from TOPERA) Intervention: AF ablation
62017511|NCT02533843|ACTIVE_COMPARATOR|Arm II|ablation at sources guided by FIRMap (using RhythmView™ Workstation from TOPERA) + conventional pulmonary vein antrum isolation (PVAI) Intervention: AF ablation
62017512|NCT02533843|ACTIVE_COMPARATOR|Arm III|Extended PVAI plus ablation of non-PV triggers and complex fractionated atrial electrograms (CFAE) Intervention: AF ablation
62017513|NCT05477823|EXPERIMENTAL|EBRT + BTX + ADT, PET and MRI|Standard of care EBRT + BTX + ADT, with mid-treatment PET and MRI (or PET and CT) scans for research.
62017514|NCT03063229|ACTIVE_COMPARATOR|Islet Transplant Patients|Patients with Type 1 Diabetes who are on the waiting list to undergo an islet transplant.
62789470|NCT02462720|ACTIVE_COMPARATOR|Radiofrequency ablation then Varithena|RFA procedures were conducted in accordance with the physician's standard of care and according to the manufacturer's instructions for use. This was followed by treatment with Varithena.
62789471|NCT01331109|EXPERIMENTAL|Milnacipran|oral administration, twice daily dosing
62017515|NCT03063229|ACTIVE_COMPARATOR|Insulin Pump Therapy Patients|Patients with Type 1 Diabetes waiting to start on an Insulin Pump.
62017516|NCT03063229|OTHER|Healthy Volunteers|Participants with no Diabetes.
62017517|NCT00909259|EXPERIMENTAL|Phrenic Stimulation|
62017518|NCT03732092||patients with disorders of consciousness|Patients with disorders of consciousness from several brain injury, assessed by Coma Recovery Scale-Revised (CRS-R), have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state.
62017519|NCT03084328||Patients with Vitamin D level of <30ng/dL|This is a cohort of patients with fatty liver disease and also have low levels of vitamin D
62017520|NCT03084328||Patients with Vitamin D level of >30ng/dL|This is a cohort of patients with fatty liver disease and have normal levels of vitamin D
62017521|NCT00210652|EXPERIMENTAL|001|RWJ 333369: Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
62017522|NCT01081587|EXPERIMENTAL|Nutritional Support Team|
62017523|NCT01081587|ACTIVE_COMPARATOR|Usual care|
62017524|NCT04611997|EXPERIMENTAL|Group A|Laparoscopic gastrectomy group with the use of near-infrared imaging (ICG group)
62017525|NCT04611997|PLACEBO_COMPARATOR|Group B|Laparoscopic gastrectomy group without the use of near-infrared imaging (Non-ICG group)
62017526|NCT01675180|OTHER|Information|Women randomized to the intervention will recieve information and counseling on oral health care during pregnancy
62017527|NCT01675180|NO_INTERVENTION|Control|
62017528|NCT01668095||Ancillary-Correlative (biomarker analysis)|Immunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis.
62017529|NCT04335877|EXPERIMENTAL|Private sector component + modified BCC|Private sector component + modified BCC + current standard of care
62017530|NCT04335877|NO_INTERVENTION|Control|Current standard of care + standard BCC
62017531|NCT06037889|EXPERIMENTAL|Tirofiban group|Intravenous tirofiban will be administered immediately after randomization for a total duration of 48h with a loading dose of 0.4ug/kg/min\*30min, followed by a maintenance dose of 0.1ug/kg/min\*47.5h.
62789472|NCT04267406||Cirrhosis|Patients who diagnosed as cirrhosis. 2 ml EDTA blood sample was taken from patients during their routine controls or at the time of diagnosis. Samples will be tested for ADAMTS-13 and vWF levels and activity at the end of study.
62789473|NCT04267406||Non-cirrhotic portal hypertension|Patients who diagnosed as extrahepatic portal hypertension (due to portal vein thrombosis). 2 ml EDTA blood sample was taken from patients during their routine controls or at the time of diagnosis. Samples will be tested for ADAMTS-13 and vWF levels and activity at the end of study.
62207724|NCT01228331|ACTIVE_COMPARATOR|Arm II intensification (clofarabine)|"LR-S patients receive clofarabine\* IV 5 x 40 mg over 2 hours every day on days 29-33 and pegaspargase IV over 2 hours on days 33, 52, and 80.~LR-I and precursor B-cell ALL HR-S and HR-I patients receive clofarabine\* IV over 2 hours on days 29-33 and pegaspargase IV over 2 hours on days 33, 53, 67, and 108.~Followed by standard consolidation therapy regarding to stratification containing:~methotrexate, cyclophosphamide, thioguanin, mercaptopurine, etoposide phosphate, amsacrine, cytarabine, methylprednisolone, dexamethasone, vincristine sulfate; whole-brain radiation therapy only if indicated in patients with cns involvement or T-cell ALL"
62207725|NCT01228331|ACTIVE_COMPARATOR|Arm III reinduct.(doxorubicin hydrochl.)|"LR-S patients receive doxorubicin hydrochloride IV 30 mg/m2 over 24 hours on days 1 and 8.~LR-I, HR-S and HR-I Patients receive doxorubicin hydrochloride IV 30 mg/m2 over 24 hours on days 1, 8, 22, and 29.~Followed by standard reinduction and maintenance therapy containing:~cyclophophamide, cytarabine, thioguanine, mercaptopurine, methotrexate and pegaspargase, dexamethasone, vincristine sulfate"
62406135|NCT03459066||Institution-Group 10 district|Group of patients belonging to institutions of district 10. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
62406136|NCT04145739|EXPERIMENTAL|Mastectomy group|Patients undergoing mastectomy
62581488|NCT02977572|PLACEBO_COMPARATOR|Continuous Positive AirwayPressure CPAP|The CPAP was applied by using a flow generator with adjustable fractional inspired oxygen (FiO2). This was connected to the Positive End-Expiratory Pressure (PEEP) valve that was placed in the face mask. In the second instance, the CPAP system that was used was a Boussignac CPAP System Flow Jet. The Boussignac valve takes gas from a single source and splits it in order to create four high flow jets. These jets converge in the chamber creating a virtual valve. A initial level of 5cmH20 of PEEP was recommended for the first hour of ventilation, with subsequent increments (up to 15cmH20) until a clinical improvement was obtained. CPAP was continuously applied until there was a clinical and/or a gasometrical improvement, at which time it was replaced by a Venturi mask.
62017532|NCT06037889|ACTIVE_COMPARATOR|Standard antiplatelet therapy group|Standard antiplatelet therapy based on Chinese stroke guideline will be administered after randomization for a total duration of 48h, as the two following types: 1) aspirin 150-300 mg qd, or 2) aspirin 100 mg qd plus clopidogrel 75 mg qd. The time for administration of antiplatelet drugs will be determined by the doctor in conjunction with the participants' use of antiplatelet or anticoagulant medication in the 24h prior to randomization, but the drug should be given as soon as possible after randomization.
62406137|NCT04145739|EXPERIMENTAL|Quadrantectomy group|Patients undergoing quadrantectomy
62406138|NCT05352607|EXPERIMENTAL|TENS group|"TENS group will receive the conventional physiotherapy treatment plus TENS. TENS is most commonly used directly on affected muscles in patients with CP. The device will be used from Cosmogamma company (MIXING 2 (EVO): COMBINED THERAPY). It consists of 3 parts: the stimulator part, electrode and connected wires. Strap or plaster for electrodes adhesive with gel. Electrode diameter (6×4.5 cm). The program will be (Pain therapy - TENS - Free program - Modify -Parameter's setup).~Parameter setup (pulse frequency= 100 Hz, pulse duration= 250 μs, time=30 minutes and the intensity according to patient to feel tingling sensation only and no muscle contraction)."
62406139|NCT05352607|ACTIVE_COMPARATOR|Control group|The Control group will receive the conventional physiotherapy treatment for upper limb spasticity only.
62581489|NCT06683131|EXPERIMENTAL|PCSK9 inhibitor (PCSK9i) group|Participants receive PCSK9i tafolecimab and standard of care (SoC) of acute myocardial infarction
62581490|NCT06683131|NO_INTERVENTION|Control group|Participants receive SoC of acute myocardial infarction
62789474|NCT04267406||Control|Healthy volunteers, who admitted to our hospital for any complaints, but was not determined any organic disease. 2 ml EDTA blood sample was taken from healthy volunteers, during their hospital admition. Samples will be tested for ADAMTS-13 and vWF levels and activity at the end of study.
62789475|NCT03101501|EXPERIMENTAL|MMC for fibrosis prevention|no intervention is required after procedure is performed
62789476|NCT02745808|EXPERIMENTAL|HUC-MSCs|Intracavernous injection of 15 million HUC-MSCs.
62789477|NCT02745808|EXPERIMENTAL|Injectable Collagen Scaffold + HUC-MSCs|Intracavernous injection of injectable collagen scaffold combined with 15 million HUC-MSCs.
62789478|NCT05789563|EXPERIMENTAL|First smartwatch model|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, SpO2 measurements will be taken by hand from the watch and the pulse oximeter simultaneously.
62789479|NCT05789563|EXPERIMENTAL|Second smartwatch model|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, SpO2 measurements will be taken by hand from the watch and the pulse oximeter simultaneously.
62789480|NCT05789563|EXPERIMENTAL|Third smartwatch model|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, SpO2 measurements will be taken by hand from the watch and the pulse oximeter simultaneously.
62789481|NCT05383716|EXPERIMENTAL|chemotherapy plus pembrolizumab|Two to four cycles of neoadjuvant chemotherapy in combination with pembrolizumab will be administered before surgery, followed by another one to two cycles of chemotherapy plus pembrolizumab after surgery (4 cycles neoadjuvant/adjuvant chemotherapy in total ) then use pembrolizumab monotherapy for up to 1 year
62789482|NCT03062293|EXPERIMENTAL|Functional Re-adaptive Exercise Device|Single arm for within subject repeated measures design.
62789483|NCT04203004|EXPERIMENTAL|HOPE-CytoSorb|Patients transplanted with livers preserved by HOPE with cytokine filtration by CytoSorb, a CE approved medical device for extracorporeal cytokine removal
62789484|NCT04203004|NO_INTERVENTION|HOPE-standard|Patients transplanted with livers preserved by HOPE without cytokine filtration
62789485|NCT02358421||Initial cohort|Patients at risk of developing OHSS according to the inclusion criteria
62789486|NCT05695274|EXPERIMENTAL|Experimental group|To examine the effects of progressive muscle relaxation exercises on pain, kinesiophobia and functional status in fibromyalgia patients.
62789487|NCT05695274|NO_INTERVENTION|Control group|Control group; routine care and treatment will be applied.
62017533|NCT05284045|NO_INTERVENTION|Usual information|Subjects allocated to this arm will receive the usual information about OSA and CPAP treatment given in clinical practise
62017534|NCT05284045|ACTIVE_COMPARATOR|Detailed information|Subjects allocated to this arm will also receive the usual information about OSA and CPAP treatment and they will also receive information related to the possible adverse side effects of CPAP treatment. The healthcare professional will enumerate the possible side effects and indicate which are more and less common.
62207726|NCT01228331|ACTIVE_COMPARATOR|Arm IV reinduct.(daunorubicin hydrochl.)|"LR-S patients receive daunorubicin hydrochloride IV 36 mg/m2 over 24 hours on days 1 and 8.~LR-I, HR-S and HR-I Patients receive daunorubicin hydrochloride IV 36 mg/m2 over 24 hours on days 1, 8, 22, and 29.~Followed by standard reinduction and maintenance therapy containing:~cyclophophamide, cytarabine, thioguanine, mercaptopurine, methotrexate and pegaspargase, dexamethasone, vincristine sulfate"
62017535|NCT06573957|ACTIVE_COMPARATOR|Dexmedetomidine|Twenty-one patients are administered dexmedetomidine at a dose of 0.5 µg/kg body weight 10 minutes before induction, then receive general anesthesia induction with intravenous propofol 2 mg/kg body weight and intravenous atracurium 0.5 mg/kg body weight. Positive pressure ventilation is then applied for 3 minutes using a ventilator in volume control mode with a tidal volume of 6-8 mL/kg body weight, a respiratory rate of 12 breaths per minute, and PEEP 5. Oxygen at 3 liters, air at 3 liters, and sevoflurane at 2 vol% are set.
62017536|NCT06573957|ACTIVE_COMPARATOR|Lidocaine|Twenty-one patients receive general anesthesia induction with intravenous propofol 2 mg/kg body weight and intravenous atracurium 0.5 mg/kg body weight. Positive pressure ventilation is then applied for 3 minutes using a ventilator in volume control mode with a tidal volume of 6-8 mL/kg body weight, a respiratory rate of 12 breaths per minute, and PEEP 5. Oxygen at 3 liters, air at 3 liters, and sevoflurane at 2 vol% are set, followed by lidocaine at 1.5 mg/kg body weight in a 5cc syringe 90 seconds before intubation.
62207727|NCT04939701|EXPERIMENTAL|Dose Escalation (Phase 1): ASP0739 1x10^7 cells/mL|Participants with Relapsed/Refractory (R/R) solid tumors known to express New York esophageal squamous cell carcinoma 1 (NY-ESO-1) received intravenous (IV) infusion of ASP0739 (human embryonic kidney cell \[HEK293\] transfected with a lentiviral vector that is encoding the target antigen NY-ESO-1) at a dose of 1x10\^7 cells/milliliters (mL) at 4 to 6 mL/minute infusion rate on day 1 of each cycle for a total of 4 doses; an additional 2 doses was administered in participants with a partial response (PR) or stable disease (SD) (1 cycle= 28 days). .
62207728|NCT04939701|EXPERIMENTAL|Dose Escalation (Phase 1): ASP0739 1x10^8 cells/mL|Participants with R/R solid tumors known to express NY-ESO-1 received IV infusion of ASP0739 (HEK293 transfected with a lentiviral vector that is encoding the target antigen NY-ESO-1) at a dose of 1x10\^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for a total of 4 doses; an additional 2 doses was administered in participants with a PR or SD (1 cycle= 28 days).
62207729|NCT04939701|EXPERIMENTAL|Dose Expansion (Phase 2): ASP0739 1x10^8 cells/mL|Participants with synovial sarcoma (SS), myxoid/round cell liposarcoma (MRCL), ovarian cancer and other solid tumors known to express NY-ESO-1 (melanoma, non-small cell lung cancer \[NSCLC\] adenocarcinoma and squamous cell and esophageal squamous cell carcinoma \[ESCC\]) received IV infusion of ASP0739 (HEK293 transfected with a lentiviral vector that is encoding the target antigen NY-ESO-1) at a dose of 1x10\^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for a total of 4 doses; an additional 2 doses was administered in participants with a PR or SD (1 cycle= 28 days).
62207730|NCT02992691|EXPERIMENTAL|Test Product 1|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
62207731|NCT02992691|EXPERIMENTAL|Test Product 2|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
62207732|NCT02992691|EXPERIMENTAL|Test Product 3|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
62207733|NCT02992691|ACTIVE_COMPARATOR|Positive Control|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
62207734|NCT02992691|OTHER|Negative Control|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
62207735|NCT06727708|EXPERIMENTAL|Tone Your Body Group|Participants in the Tone Your Body group follow a 12-week BioCircuit training programme designed to improve body composition and muscle toning. The programme consists of six total-body strength exercises and two cardio exercises in a circuit format. Each exercise is performed for 45 seconds, followed by a 40-second rest between machines. The endurance exercises are performed for 3 minutes and 35 seconds each. The eccentric phase of each strength exercise is overloaded by 20% to maximise muscle development.
62207736|NCT06727708|EXPERIMENTAL|Boost Performance Group|Participants in the Boost Performance group follow a 12-week BioCircuit training programme designed to increase strength and endurance. The programme consists of six strength exercises and two cardio exercises, also in a circuit format. Each exercise is performed for 45 seconds, with 40 seconds rest between machines, and the endurance exercises are performed for 3 minutes and 35 seconds. The strength exercises use a viscous resistance mechanism to increase strength and endurance. Participants also undergo performance tests including the jump and reach test, one minute squats and one minute push-ups.
62207737|NCT02731144|EXPERIMENTAL|Study group|Individualization of caloric administration with indirect calorimetry and 2.0 to 2.2 g/kg/day of protein. Early initiation of nutritional support (24 hours of admission)
62789488|NCT00582998|ACTIVE_COMPARATOR|Standard Wound Dressing|Standard post-operative wound dressing
62789489|NCT00582998|ACTIVE_COMPARATOR|Vacuum Assisted Closure Device|Vacuum Assisted Closure (VAC) device
62789490|NCT02278861|ACTIVE_COMPARATOR|Oral isotretinoin 10mg/day|Oral isotretinoin 10mg/day for 6 months The dose could be reduced if there were any significant laboratory alterations or clinical adverse events, along with sunscreen FPS 60 every 3 hours during the day.
62017537|NCT00522210|EXPERIMENTAL|BID insulin with LA analogue|Treatment Group: BID Insulin Regimen with Long Acting Insulin Analogue (Detemir)
62017538|NCT00522210|ACTIVE_COMPARATOR|Standard TID insulin|Active Control Group: Usual TID Insulin Regimen (intermediate insulin- Humulin N or Novolin NPH)
62789491|NCT02278861|ACTIVE_COMPARATOR|Tretinoin 0,05% cream|"An every other night application of tretinoin 0,05% cream in the face and forearms for 6 months, along with sunscreen FPS 60 every 3 hours during the day.~If there were any clinical adverse events the drug could be reduced to twice a week."
62207738|NCT02731144|ACTIVE_COMPARATOR|Control group|Nutritional support initiated in the first 24 hours of admission. Protein and caloric goals calculated as 25 Kcal/kg/day and 1.4 to 1.5 g/kg/day of protein.
62207739|NCT02260323|EXPERIMENTAL|patient-tailored anti-arthritis herbs|patient use tailored anti-arthritis herbs
62207740|NCT02260323|ACTIVE_COMPARATOR|patient-tailored DMARDs|Patients use tailored DMARDs
62207741|NCT05850598|SHAM_COMPARATOR|sham stimulation targeting the cerebellum|Patients will be randomly allocated into this group, and they will receive sham stimulation.
62207742|NCT05850598|ACTIVE_COMPARATOR|real rTMS targeting the cerebellum|Patients will be randomly allocated into this group, and they will receive real stimulation.
62207743|NCT06405568|EXPERIMENTAL|Physical activity recommendations plus motivation package (Intervention Arm)|Participants randomized to the intervention arm will receive a package consisting of two components: (1) a copy of age-appropriate physical activity (PA) recommendations matching the Canadian Society of Exercise Physiology (CSEP) recommendations and spotlighting PA benefits, and (2) a PA motivation package including: (a) a link to a website to view three 20-minute webinars covering PA benefits (for cancer risk reduction, quality of life, and weight management) and how to get started using the digitized PA materials and logbook, (b) digitized PA materials containing information explaining and supporting PA recommendations, examples of easy and safe PA participation for all, and activity sheets on behaviour change tools for sustaining PA, and (c) a PA logbook with instructions on how to track PA and tips for increasing PA.
62207744|NCT06405568|NO_INTERVENTION|Standard care and physical activity recommendations (Control Arm)|Participants randomized to the control arm will receive standard care (medical consultations/monitoring at the discretion of each patient's care team) and be advised to continue regular daily living activities; physical activity (PA) restrictions will not be imposed. To facilitate trial retention and because contamination could occur as control arm participants' care team may recommend PA as part of their practice, participants will receive a copy of age-appropriate PA recommendations matching the Canadian Society of Exercise Physiology (CSEP) recommendations and spotlighting PA benefits. This further helps to mitigate the risk that knowledge of which arm a participant has been allocated to leads to moral demoralization in control arm participants. The control arm participants will receive the PA motivation package post-study completion to encourage study completion.
62207745|NCT02330289|EXPERIMENTAL|Report card arm|The intervention arm will receive an email report card describing their lab use compared to their peers as well as a link to a website visually tracking the team's daily ordering of common lab tests compared to the peer teams.
62207746|NCT02330289|NO_INTERVENTION|Control arm|Physicians in the control arm will not receive the email or website link.
62207747|NCT04127500|EXPERIMENTAL|DEX group|use DEX
62207748|NCT04127500|NO_INTERVENTION|control group|use placebo
62207749|NCT03892252||before surgery|no intervention(s)
62207750|NCT03892252||after surgery|no intervention(s)
62207751|NCT03892252||Normal colonoscopy|People who were diagnosed by colonoscopy without colorectal cancer.
62207752|NCT05855135|EXPERIMENTAL|CCM-D Implant|The subject is implanted with the CCM-D device.
62207753|NCT03215862|ACTIVE_COMPARATOR|Control|
62207754|NCT03215862|EXPERIMENTAL|Experimental|
62406140|NCT06344676|ACTIVE_COMPARATOR|Usual Care|This group will do the usual therapies and activities that were doing before the enrolment in the study
62207755|NCT06352099|EXPERIMENTAL|G-Alt12|G-Alt12 patients, without making any changes to their current drug routine, will take 1 stick per day of Altemor® for 8 weeks, go for a period of 4 weeks without taking the food supplement, and then take 2 sticks per day of Altemor® for another 8 weeks.
62207756|NCT06352099|EXPERIMENTAL|G-Alt21|G-Alt21 patients, without making any changes to their current medication routine, will take 2 sticks per day of Altemor® for 8 weeks, do a 4-week period without taking the dietary supplement, and then take 1 stick per day of Altemor® for another 8 weeks.
62207757|NCT06352099|NO_INTERVENTION|G-Con|G-Con patients will undergo clinical and instrumental evaluations at the study endpoints
62406141|NCT06344676|EXPERIMENTAL|Robot|"This group will do the usual therapies and activities that were doing before the enrolment in the study plus:~* 3 weekly individual cognitive stimulation sessions of 10 minutes.~* 2 weekly group mobility sessions of 30 minutes.~* 1 monthly group social session of 60 minutes"
62406142|NCT06311981|EXPERIMENTAL|Study arm|The patient will receive carbon ion radiotherapy with 70Gy per 20 fractions. Patients with genetic mutations (including but not limited to EGFR, ALK, etc.) should receive targeted therapy as their systemic therapy. For patients who are not suitable for targeted therapy, we recommend single regimen chemotherapy in sequence with radiotherapy. The drugs include etoposide, platinum (carboplatin, cisplatin, nedaplatin or loplatin), vinorelbine, paclitaxel (including liposome paclitaxel and albumin paclitaxel), docetaxel, pemetrexel, gemcitabine, etc. If there is no contraindication to PD-1/PD-L1 immunotherapy, it can be combined with immunotherapy, such as Pembrolizumab. For patients who cannot tolerate chemotherapy, PD-1/PD-L1 immunotherapy is recommended. The progression-free survival rate, toxicity, local control rate, cause-specific survival rate and overall survival rate were observed with regular follow-up after treatment.
62789492|NCT05062408||cases|Patients treated with direct-acting antivirals.
62789493|NCT02903498|EXPERIMENTAL|UFT treatment|Uracil and Tegafur
62789494|NCT02903498|NO_INTERVENTION|comparator|no treatment, follow-up at regular time
62789495|NCT01907763|EXPERIMENTAL|SOTB07 200mg|One tablet of SOTB07 200mg and One tablet of SOTB 400mg Placebo are administered twice a day.
62789496|NCT01907763|EXPERIMENTAL|SOTB07 400mg|One tablet of SOTB07 400mg and One tablet of SOTB 200mg Placebo are administered twice a day.
62789497|NCT01907763|PLACEBO_COMPARATOR|Placebo|One tablet of SOTB 200mg Placebo and One tablet of SOTB 400mg Placebo are administered twice a day.
62789498|NCT00939562|EXPERIMENTAL|doxycycline monohydrate tablet|
62789499|NCT00939562|ACTIVE_COMPARATOR|doxycycline carragenate tablet|
62017539|NCT04895397|ACTIVE_COMPARATOR|Group A: (30 patients)|modified pectoral nerve block will be done.
62406143|NCT06426901|EXPERIMENTAL|Experimental Group: the group A will be received Tan Tui exercies|"Experimental Group A Springing Leg Forms. var-arranged sequences of movements that incorporate kicks, strikes, and blocks.~Pattern Drills: Pattern drills involve repeating specific combinations of kicks, strikes, and blocks in a repetitive manner.~Basic Kicking Drills: which involve ious types of kicks such as front kicks, sidekicks, roundhouse kicks, and crescent kicks.~Stance Work: Practitioners work on a variety of stances, including horse stance (ma bu), bow stance (gong bu), and cat stance (mao bu).~Forms (Taolu): These forms consist of predrills enhance muscle memory and the ability to execute techniques quickly and accurately.~Conditioning: includes rigorous conditioning exercises to strengthen the legs and develop endurance.~Sparring (San Shou):~bouncing leg exercise intervention cycle lasted 6 weeks, 3 times a week for 30 minutes each. The intervention was split into two parts: motor learning in the first week and motor improvement in the last five weeks.~."
62406144|NCT06426901|NO_INTERVENTION|Controlled|"Conventional exercises Squats: Squats are a foundational lower-body exercise that targets the quadriceps, hamstrings, glutes, and lower back.~Bench Press: The bench press is a classic upper-body exercise that targets the chest, shoulders, and triceps.~Power Cleans: Similar to the clean and jerk, power cleans are used to develop explosive power, especially in the legs and hips.~Pull-Ups/Chin-Ups: Pull-ups and chin-ups strengthen the muscles of the upper back, shoulders, and arms.~Push-Ups: Push-ups are a versatile exercise that works the chest, shoulders, triceps, and core.~Lunges: Lunges are excellent for targeting the quadriceps, hamstrings, and glutes while also improving balance and stability.~Core Exercises: Core strength is vital for stability and balance in football. Exercises like planks, Russian twists, and medicine ball throws target the core muscles."
62406145|NCT01821508|ACTIVE_COMPARATOR|Clinical treatment|Best and most modern clinical treatment of type 2 diabetes mellitus.
62789500|NCT02134470|EXPERIMENTAL|Testosterone|Chemical testing of saliva is an objective method to quantify steroid hormones. Recent studies indicate that salivary testosterone is significantly higher than in other body fluids. Therefore, saliva may serve as pre-screening parameter to select suspicious cases for further target evaluation. The aim of the present project is to detect administered testosterone in saliva and compare these levels to those in blood and urine. Therefore, each participant represents its own control.
62789501|NCT03492606||multiple sclerosis patients|
62789502|NCT02255084|EXPERIMENTAL|Group 1|"Group 1 remove self sample kit at gp consulting room or perform pap smear :~Study coordinators send mail inviting women to remove a kit for vaginal self-sampling at their general practitioner s consulting room.~Either a pap smear is perform or, at home, women perform vaginal self sampling. Then women send it to a central laboratory for HPV test (Human papillomaVirus)."
62789503|NCT02255084|EXPERIMENTAL|Group 2|"Group 2 perform self sample at home or pap smear :~Kit for vaginal self-sampling sent at women home. Women perform vaginal self sampling. Then women send it to a central laboratory for HPV test (Human papillomaVirus)."
62789504|NCT02813291|EXPERIMENTAL|Stimulation group (Young Stim)|Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex.
62789505|NCT02813291|EXPERIMENTAL|Stimulation group (Elderly Stim)|Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex.
62789506|NCT02813291|SHAM_COMPARATOR|Sham group (Young Sham)|Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex.
62017540|NCT04895397|ACTIVE_COMPARATOR|Group B: (30 patients)|serratus plane block will be done.
62017541|NCT04293887|EXPERIMENTAL|Standard therapy + interferon therapy|Standard treatment + recombinant human interferon α1β 10ug Bid was administered by nebulization for 10 days.
62017542|NCT04293887|NO_INTERVENTION|Standard therapy + blank therapy|Standard therapy
62017543|NCT03783559|EXPERIMENTAL|Arm A|TACE plus chemotherapy ± target therapy
62017544|NCT03783559|ACTIVE_COMPARATOR|Arm B|chemotherapy ± target therapy
62017545|NCT01923181|EXPERIMENTAL|1:Semaglutide tablets : 2.5 mg|2.5 mg for 26 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
62017546|NCT01923181|EXPERIMENTAL|2:Semaglutide tablets: 2.5 mg/5 mg|2.5 mg for 4 weeks, then 5.0 mg for 22 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
62017547|NCT01923181|EXPERIMENTAL|3:Semaglutide tablets: 5.0 mg/10 mg|5.0 mg for 4 weeks, then 10 mg for 22 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
62017548|NCT01923181|EXPERIMENTAL|4:Semaglutide tablets:5.0 mg/10 mg/20 mg|5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 18 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
62017549|NCT01923181|EXPERIMENTAL|5:Semaglutide tablets:5.0 mg/10 mg/20 mg/40 mg|"5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 4 weeks, then 40 mg for 14 weeks.~All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone."
62017550|NCT01923181|EXPERIMENTAL|6:Semaglutide tablets:5.0 mg/10 mg/20 mg/40 mg|5.0 mg for 8 weeks, then 10 mg for 8 weeks, then 20 mg for 8 weeks, then 40 mg for 2 weeks All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
62017551|NCT01923181|EXPERIMENTAL|7:Semaglutide tablets: 5.0 mg/10 mg/20 mg/40 mg|"5.0 mg for 2 weeks, then 10 mg for 2 weeks, then 20 mg for 2 weeks, then 40 mg for 20 weeks.~All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone."
62017552|NCT01923181|PLACEBO_COMPARATOR|8:Placebo tablets|All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
62017553|NCT01923181|ACTIVE_COMPARATOR|9:Semaglutide injections :0.25 mg/0.50 mg/1.0 mg|0.25 mg for 4 weeks, then 0.50 mg for 4 weeks, then 1.0 mg for 18 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
62207758|NCT00596700|EXPERIMENTAL|Device|"Patient preparation procedure will be done according to chapter 4 in the Given Diagnostic System user manual. In brief: to drink only clear liquids beginning 12:00 noon the day before.at least 8 hours (since 12:00 PM) fast prior to the procedure. Patient will undergo a standard capsule endoscopy. Patients will be allowed to drink clear liquids 2 hours post ingestion, and eat 4 hours post ingestion.~Eight hours post ingestion, data recorder will be removed and the patient will be dismissed.~A local experienced reader will review the RAPID video to determine the diagnosis blinded to the results of the standard workup procedures, and to each other results. Results will be recorded in the case report forms. A decoded video will be transferred to the principal investigator for reevaluation"
62207759|NCT04193436|EXPERIMENTAL|PF-06835919 with severe hepatic impairement|This arm includes participants with severe hepatic impairment who will receive a 25mg oral dose of PF-06835919
62207760|NCT04193436|EXPERIMENTAL|PF-06835919 with moderate hepatic impairement|This arm includes participants with moderate hepatic impairment who will receive a 25mg oral dose of PF-06835919
62207761|NCT04193436|EXPERIMENTAL|PF-06835919 with mild hepatic impairement|This arm includes participants with mild hepatic impairment who will receive a 25mg oral dose of PF-06835919
62017554|NCT05734859|EXPERIMENTAL|EHARW Treatment group|The experimental group will drink a total amount of 20 mL/ kg body weight/day of EHARW for 4 weeks on an empty stomach according to the researcher's instruction.
62207762|NCT04193436|EXPERIMENTAL|PF-06835919 without hepatic impairment|This arm includes participants without hepatic impairment who will receive a 25mg oral dose of PF-06835919
62207763|NCT04215484||P|P (previa) : pregnant women with placenta previa on ultrasound and no suggestive signs of placenta accreta
62207764|NCT04215484||I|I (abnormal placental Invasion) : pregnant women with placenta previa on ultrasound,and suggestive signs of placenta accreta on ultrasound with or without MRI
62207765|NCT04215484||N|N (placenta normally located) : pregnant women without suggestive signs of placenta previa or accreta on ultrasound
62207766|NCT01541098|ACTIVE_COMPARATOR|Licensed Plasma|
62207767|NCT01541098|EXPERIMENTAL|Lyophilized Plasma|
62207768|NCT05316272|EXPERIMENTAL|Exercise and placebo|supervised bone-loading exercise 3 days per week and one placebo pill per day for 36 weeks
62207769|NCT05316272|EXPERIMENTAL|Exercise and DHEA|supervised bone-loading exercise 3 days per week and one dose of DHEA (50 milligrams) per day for 36 weeks
62581491|NCT04335409|EXPERIMENTAL|Participants irradiated for lung cancer|Participants who receive radiotherapy for lung cancer and have risk factors for developing radiation pneumonitis. Risk factors include mean dose to the ipsilateral lung \>13 Gy plus at least one other factor (significant cardiovascular disease, history of heavy smoking (≥40 pack years), previous/concurrent chemotherapy or previous/adjuvant immunotherapy) or mean dose to the ipsilateral lung \>20 Gy without other factors.
62207770|NCT05316272|EXPERIMENTAL|no exercise and DHEA|no supervised bone exercise and one dose of DHEA (50 milligrams) per day for 36 weeks
62207771|NCT05316272|EXPERIMENTAL|no exercise and placebo|no supervised bone-loading exercise and one placebo pill per day for 36 weeks
62207772|NCT06153355|EXPERIMENTAL|LY3839840 (Part A)|Single ascending dose of LY3839840 administered orally.
62207773|NCT06153355|EXPERIMENTAL|LY3839840 (Part B) Cohort 1-3|Multiple ascending dose of LY3839840 administered orally.
62207774|NCT06153355|EXPERIMENTAL|LY3839840 (Part B) Cohort 4|Multiple ascending dose of LY3839840 administered orally.
62207775|NCT06153355|EXPERIMENTAL|LY3839840 (Part B) Optional Cohort 5|Multiple ascending dose of LY3839840 administered orally pending data from Cohort 4
62207776|NCT06153355|EXPERIMENTAL|LY3839840 (Part C)|Single and multiple dose of LY3839840 administered orally in Chinese participants.
62207777|NCT06153355|EXPERIMENTAL|LY3839840 (Part D)|Multiple ascending dose of LY3839840 administered orally in Japanese participants.
62207778|NCT06153355|PLACEBO_COMPARATOR|Placebo|Placebo administered orally.
62581492|NCT02931084||ACL injury|Patients with an acute (not more than 6 weeks old) anterior cruciate ligament (ACL) injury
62789507|NCT02813291|SHAM_COMPARATOR|Sham group (Elderly Sham)|Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex.
62406146|NCT01821508|ACTIVE_COMPARATOR|Roux-En-Y gastric bypass surgery|"A metabolic surgery consists of any surgical procedure in which there is any anatomical alteration in the gastrointestinal tract by means of a diversion of food passage, resulting in improved metabolic control in patients with type 2 diabetes mellitus \[SCHULMAN, 2009\]."
62406147|NCT06496984|EXPERIMENTAL|Nutritional Intervention|All patients with MUST 1 and 2 will be sent to the dietitian. The clinician will act on the patient's characteristics by providing different dietary therapies, such as oral nutritional supports (ONS), extra nutritional cares, diet changes without supplements and artificial nutrition.
62406148|NCT02866201|EXPERIMENTAL|Patient suffering from traveler's diarrhoea|Patient suffering form traveler's diarrhoea during a stay (up to 3 months) outside metropolitan France
62406149|NCT01654211|EXPERIMENTAL|Part 1: iv danoprevir|
62406150|NCT01654211|PLACEBO_COMPARATOR|Part 1: placebo|
62207779|NCT06071897|EXPERIMENTAL|intervention/treatment|"\* days of 21 days schedule N5~* Vincristine 1,5 mg/m2 i.v., day 1\*~* Etoposide 100 mg/m2 i.v. , days 1-4\*~* Cisplatin 100 mg/m2 i.v., days 1-4\* N6~* Vincristine 1,5 mg/m2 i.v. on days 1, 8\*~* Dacarbasine 200 mg/m2 i.v., days 1-5\*~* Ifosphamide 1500 mg/m2 i.v, days 1-5\*~* Doxorubicin 30 mg/m2 i.v, days 6, 7\*~N5Q~* N5 (see above)~* Dinutuximab beta 10 mg/m2 i.v., days 5-9\*~G-CSF (granulocyte colony-stimulating factor) 5 mcg/kg s.c. on day 9 until the ANC is more than 2000 /ml or until counts have recovered for the next cycle of therapy~N6Q~* N6 (see above)~* Dinutuximab beta 10 mg/m2 i.v., days 6-10\*~G-CSF (granulocyte colony- stimulating factor) 5 mcg/kg s.c. on day 10 until the ANC is more than 2000 /ml or until counts have recovered for the next cycle of therapy~Delayed surgery (if needed) will be done after the 4th or 6th course of induction therapy and stem cells apheresis after the 2nd-5th course of induction therapy."
62406151|NCT01654211|EXPERIMENTAL|Part 2 A: iv danoprevir|
62406152|NCT01654211|ACTIVE_COMPARATOR|Part 2 B: oral danoprevir|
62789508|NCT03291405||Body Mass Index less than 30|
62406153|NCT01654211|ACTIVE_COMPARATOR|Part 2 C: ritonavir|
62406154|NCT01654211|EXPERIMENTAL|Part 3 D: iv danoprevir|
62789509|NCT03291405||Body Mass Index more than 30|
62789510|NCT00513942|NO_INTERVENTION|A|These women will follow standard antenatal care according to the Norwegian Guidelines
62207780|NCT04851639|EXPERIMENTAL|Proof of principle|Proof of principle of the efficacy and utility of the WATapp
62406155|NCT01654211|EXPERIMENTAL|Part 3 E: iv danoprevir + cyclosporine|
62406156|NCT01056458|ACTIVE_COMPARATOR|Acupressure acupressure|
62406157|NCT01056458|SHAM_COMPARATOR|sham acupressure|
62406158|NCT02226575|EXPERIMENTAL|Distress management|The distress management program (cognitive behavioral therapy) alongside standard care
62406159|NCT02226575|NO_INTERVENTION|Control|Controls only dilivery standard care
62789511|NCT00513942|ACTIVE_COMPARATOR|B|Intervention group for Fetal Movement Counting
62789512|NCT01698723|ACTIVE_COMPARATOR|Ribavirin|1000 mg (5 capsules)
62406160|NCT01277172|EXPERIMENTAL|Group 1 / PBO-326|This group will be treated three cycles with PBO-326, after the third cycle the patients will receive Mabthera for another three cycles.
62406161|NCT01277172|ACTIVE_COMPARATOR|Group 2 / Mabthera|This group will be treated three cycles with Mabthera, after the third cycle the patients will receive PBO-326 for another three cycles.
62406162|NCT01277172|EXPERIMENTAL|Group 3 / PBO-326|This group will be treated six cycles with PBO-326
62406163|NCT01277172|ACTIVE_COMPARATOR|Group 4 / Mabthera|This group will be treated six cycles with Mabthera
62406164|NCT06202950|EXPERIMENTAL|Yoga|Applying yoga for one hour a week for eight weeks to with type 1 diabetes
62406165|NCT06202950|ACTIVE_COMPARATOR|Mindfulness|Applying mindfulness to youth with type 1 diabetes one hour a week for eight weeks
62406166|NCT06202950|NO_INTERVENTION|control|the control group received the usual care
62406167|NCT03632057|ACTIVE_COMPARATOR|Fixed Tilt (65%)|This is the control group, so device programming for shock energy is the default setting
62406168|NCT03632057|ACTIVE_COMPARATOR|Fixed Pulse Width|This is the Study group.
62406169|NCT04216953|EXPERIMENTAL|Atezolizumab + Cobimetinib|"Atezolimumab :~* Adult Patient and patients ≥12 years-old with a BW ≥60kg: 840mg, Q2W~* Pediatric Patient including patients ≥12 years-old with a BW \<60kg: 15mg/kg, Q2W with a maximum of 840mg.~Cobimetinib :~* Pediatric patients ≥ 12 and a BW \< 60kg:1mg/kg. Pediatric patients ≥ 12 and with a BW ≥ 60kg: 60mg/d.~* Adult Patients: 60mg/d D1 to D21 over a 28-day cycle."
62406170|NCT01998165|EXPERIMENTAL|Remifentanil (0.25 µg/kg/min)|
62406171|NCT02484209|EXPERIMENTAL|Glimepiride + metformin|Glimepiride (2-4mg twice daily) + metformin (1500 mg daily) (n = 10 in total) Older subjects with moderate frailty will be assigned for 16 weeks to this arm. A subgroup (n=5) will undergo 3 x 72h periods of CBGM
62406172|NCT02484209|ACTIVE_COMPARATOR|Metformin|Metformin (1500 mg daily) (n = 10 in total) Older subjects with moderate frailty will be assigned for 16 weeks to this arm. A subgroup (n=5) will undergo 3 x 72h periods of CBGM
62581493|NCT02931084||ACL reconstruction|Some of the patients with ACL injury will have reconstruction of the ACL. These will be followed as a new group.
62581494|NCT00970541|ACTIVE_COMPARATOR|Cinnamon Supplementation|A 500mg (consumed as two, 250mg capsules) of cinnamon extract (Cinnamon Bark P.E\> 20:1) will be consumed before meals, three times per day.
62789513|NCT01698723|PLACEBO_COMPARATOR|Placebo|5 capsules of placebo
62789514|NCT02630914|EXPERIMENTAL|Intervention|All patients will have the hybrid procedure of ablation of atrial fibrillation.
62789515|NCT05505006|EXPERIMENTAL|Cancer patients with anemia (i.e. Hb <12 g/dl if females, <13 g/dL if males)|"Cancer patients eligible for surgery with anemia will be managed as follows:~* s-ferritin \<100 mcg/l or s-ferritin \<500 mcg/l + TSAT\<20% = i.v. iron (ferric carboxymaltose, dosage according to body weight and Hb level)~* folate \< 5 ng/ml = folate 5 mg per day for 1 month~* B12 \< 200 pg/ml = B vitamin complex 1 tablet per day for 1 month~Patients will receive combined treatment if they have multiple deficiencies simultaneously.~Patients without correctable deficiencies will not receive any treatment."
62789516|NCT03288636|EXPERIMENTAL|Experimental|"PKGroup:~Ravidasvir + Danoprevir/ Ritonavir"
62789517|NCT03288636|PLACEBO_COMPARATOR|Placebo|"Placebo Group:~Placebo"
62207781|NCT06728592|EXPERIMENTAL|Acute ischemic stroke patients with NIHSS ≥5, potentially eligible for IVT and/or EVT|Acute ischemic stroke patients with NIHSS ≥5, who are potentially eligible for IVT and/or EVT therapies and can be treated within 6 hours of symptom onset, will be triaged for intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT) in Emergency Stroke Unit (ESU) based on lfMRI for diagnosis of ischemic stroke, differentiation of intracerebral hemorrhage (ICH) and identification of large vessel occlusion (LVO). Other screening and assessment procedures for IVT/EVT, and clinical management of the patients, are the same with standard practice as recommended by contemporary guidelines. In the historical control group, patients were triaged for IVT and/or EVT by standard practice, using plain CT and CTA for imaging triage.
62207782|NCT03729401|ACTIVE_COMPARATOR|DAPT - Aspirin and Ticagrelor|As per results of the PEGASUS trial, patients will be treated with aspirin 81mg daily and ticagrelor 60mg twice daily
62207783|NCT03729401|EXPERIMENTAL|Ticagrelor Monotherapy|Patients will only receive ticagrelor 60mg twice daily.
62406173|NCT06050382|EXPERIMENTAL|WOMEN WITH TENSION-TYPE HEADACHE|"The tension headache group consists of 22 women aged 20-45 years.The inclusion criteria were determined as follows being between the ages of 20 and 45, having a diagnosis of TTH or migraine according to the International Classification of Headache Disorders (ICHD-II)(1), and expressing voluntary willingness to participate in this study.~The exclusion criteria for the study included having any pathology involving the cervical region such as disc herniation, radiculopathy, a history of surgery, tumor, or cyst, having received any form of physical therapy targeting the cervical region within the past 3 months, being pregnant or in the menopausal phase; not participating in at least 15% of the training sessions, having a mental disorder (being diagnosed with depression or using antidepressant medication), having a chronic, neurological, or rheumatic disorder; suffering from sinusitis, and being on continuous prophylactic medication for migraines"
62406174|NCT06050382|EXPERIMENTAL|WOMEN WITH MIGRAINE|"The Migraine group consists of 22 women aged 20-45 years.The inclusion criteria were determined as follows being between the ages of 20 and 45, having a diagnosis of TTH or migraine according to the International Classification of Headache Disorders (ICHD-II)(1), and expressing voluntary willingness to participate in this study.~The exclusion criteria for the study included having any pathology involving the cervical region such as disc herniation, radiculopathy, a history of surgery, tumor, or cyst, having received any form of physical therapy targeting the cervical region within the past 3 months, being pregnant or in the menopausal phase; not participating in at least 15% of the training sessions, having a mental disorder (being diagnosed with depression or using antidepressant medication), having a chronic, neurological, or rheumatic disorder; suffering from sinusitis, and being on continuous prophylactic medication for migraines"
62406175|NCT05809440|EXPERIMENTAL|Intervention Group|A 20-minute mindful breathing session guided by a trained medical doctor. The session consisted of four 5-minute breathing exercises done consecutively. Participants were instructed to close their eyes and bring their attention to their breathing, and re-direct their attention back to their breathing once they were distracted.
62406176|NCT05809440|NO_INTERVENTION|Control Group|No intervention was provided for control group.
62406177|NCT06355180|EXPERIMENTAL|Subanesthetic dose intravenous Esketamine|The dosage for intravenous infusion of esketamine is 0.2mg/kg, infused over at least 40 minutes, with treatments administered three times a week for two consecutive weeks, totaling six sessions.
62406178|NCT06355180|ACTIVE_COMPARATOR|Modified electroconvulsive therapy|MECT will be given in a standard manner 3 times a week for 2 weeks.
62581495|NCT00970541|PLACEBO_COMPARATOR|Placebo|A 500 mg placebo (wheat flour) will be consumed before meals, three times per day.
62735032|NCT03712176||Cohort 1 : chemotherapy and radiotherapy|50 women aged between 18 and 65 with first non-metastatic breast cancer treated by surgery and adjuvant therapy (chemotherapy and radiotherapy)
62735033|NCT03712176||Cohort 2 : radiotherapy only|150 women aged between 18 and 65 with first non-metastatic breast cancer treated with surgery and adjuvant therapy (radiotherapy only).
62789518|NCT05796492|SHAM_COMPARATOR|LOGIQ E10 Sham|The sham condition will consist of the ultrasound probe placed over the spleen with no energy applied.
62207784|NCT03729401|EXPERIMENTAL|Personalized Therapy Arm|Patients allocated to the personalized arm (PA) will have a DAPT score calculated. For those with a score of \< 2, only aspirin at 81 mg daily will be prescribed. For those with a score of ≥ 2, P2Y12 inhibitor choice will be dependent on carrier status of CYP2C19 LOF alleles. Heterozygous or homozygous carriers will receive be prescribed ticagrelor 60mg twice daily and non-carriers with will be prescribed clopidogrel 75mg daily.
62207785|NCT00733928|OTHER|1 - All Polyethylene Tibia|Total knee replacement with an all polyethylene tibial tray
62789519|NCT05796492|ACTIVE_COMPARATOR|LOGIQ E10 ultrasound Active|The intervention condition will receive 10 minutes of splenic ultrasound daily.
62789520|NCT02602158|ACTIVE_COMPARATOR|Octanoic acid (1-13C, 99%)|100 µL 13C Octanoic acid (Cambridge isotope laboratories)
62789521|NCT02602158|ACTIVE_COMPARATOR|TRIOCTANOIN (1,1,1-13C3, 99%)|100 µL 13C Trioctanoin (Cambridge isotope laboratories)
62789522|NCT04347629|NO_INTERVENTION|Usual Care|Usual clinical care
62207786|NCT00733928|ACTIVE_COMPARATOR|2 - Poly & Metal Tibia|Total knee replacement with a metal-backed tibial component
62207787|NCT05242952|EXPERIMENTAL|Immediate Intervention Group|Participants will enter an online game and learn about how to prevent cardiovascular and metabolic conditions.
62207788|NCT05242952|OTHER|Waitlist Control Group|Participants will enter an online game at a later date after the immediate intervention group and learn about how to prevent cardiovascular and metabolic conditions.
62789523|NCT04347629|EXPERIMENTAL|Video Decision Aid|The video intervention consists of a video decision aid along with a video declaration (ViDec), which is recorded by the patient. The video decision aid explores ACP options for medical care for end-stage renal disease (ESRD) and reviews hemodialysis, peritoneal dialysis, as well as medical management without dialysis; it also reviews cardiopulmonary resuscitation (CPR). Patients will also audio- or video-record their preferences using a tablet.
62017555|NCT03269591|ACTIVE_COMPARATOR|Pulsed electromagnetic field|magnetic therapy device which generate frequency from 5-100 Hz and intensity from 1 to 60 Gauss. Group (A) received 20 min 3 times per week for three month with strength 60 gauss and frequency 50 Hz
62207789|NCT06371638|EXPERIMENTAL|Patients with POCD|MMSE was assessed 24h before surgery, 3 days after surgery, and 30 days before surgery. Subjects is considered to have POCD if the postoperative MMSE score was lower by at least 2 points compared to the preoperative score.
62207790|NCT06371638|ACTIVE_COMPARATOR|Patients without POCD|MMSE was assessed 24h before surgery, 3 days after surgery, and 30 days before surgery. Subjects is considered to have POCD if the postoperative MMSE score was lower by at least 2 points compared to the preoperative score.
62207791|NCT05211947|EXPERIMENTAL|Patients with cognitive impairment due to schizophrenia|
62207792|NCT06336356|EXPERIMENTAL|Arm 1: Baxdrostat 2 mg|Participants will receive baxdrostat 2 mg tablet orally once daily.
62207793|NCT06336356|PLACEBO_COMPARATOR|Arm 2: Placebo|Participants will receive placebo tablet orally once daily.
62207794|NCT01638429|EXPERIMENTAL|Obese/overweight, prediabetic methane positive|Neomycin Rifaximin
62789524|NCT03419988|EXPERIMENTAL|Exercise Intervention|8-weeks exercise intervention: 3-days per week for 45-55 minutes per session
62789525|NCT03419988|NO_INTERVENTION|Control|8-weeks control: asked not to change anything or start exercising.
62789526|NCT01966913|EXPERIMENTAL|bevacizumab|"Two intensified treatments at 6-week intervals will start on D69 (max D76) and D111 (max J118) respectively, combining:~* A bevacizumab treatment: 7.5 mg/kg every 3 weeks from D1 to the first intensified treatment for a total of 4 injections.~* The ICE chemotherapy regimen:~  1. Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals,~ 2. Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance,~ 3. Ifosfamide, 2400 mg/m²/d,~ 4. For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle"
62789527|NCT00317304|EXPERIMENTAL|MBSR|
62789528|NCT03081871|EXPERIMENTAL|Web and mobile app access|Subjects will have access to both the mobile and web-app versions of the study Personal Health Record to communicate with the study pharmacist and enter and track their health data.
62789529|NCT03081871|ACTIVE_COMPARATOR|Web app only access|Subjects will have access to the web-app version of the study Personal Health Record (and not the mobile app version) to communicate with the study pharmacist and enter and track their health data.
62789530|NCT03456232|EXPERIMENTAL|High-flux hemodialysis|High-flux hemodialysis lasting for 4 hours
62789531|NCT03456232|ACTIVE_COMPARATOR|Hemodiafiltration|Hemodiafiltration lasting for 4 hours
62207795|NCT05474430||Cystic Fibrosis Carrier Group|Participants have been identified as Cystic Fibrosis Carriers via previous genetic testing.
62207796|NCT05474430||Control Group|Participants have been identified as not being Cystic Fibrosis Carriers via previous genetic testing.
62207797|NCT05465083|EXPERIMENTAL|Lungpacer AeroPace Protect System|"The PNS device used for this study will be the most recent AeroPace central venous catheter from Lungpacer Medical Inc (Vancouver, BC). It is an 8.5F 23cm triple lumen central venous catheter with 30 electrodes arranged in two arrays (distal 9 electrodes intended to capture the right phrenic nerve and the 21 proximal to capture the left phrenic nerve). It is inserted via the left internal jugular or left subclavian vein where it is placed in the proximal superior vena cava (SVC) at or above the cavo-atrial junction.~The AeroPace system monitors airway pressure to detect ventilator-triggered controlled mechanical breaths and patient-triggered assisted mechanical breaths. In response to detection of native respiratory efforts the PNS lies quiescent."
62207798|NCT06703229|ACTIVE_COMPARATOR|group, D1|group, D1, had a TAP block that included 0.5 µg/kg of dexmedetomidine and bupivacaine
62789532|NCT03865641|EXPERIMENTAL|Virtual reality intervention|Experimental group : virtual reality intervention
62789533|NCT03865641|NO_INTERVENTION|Control group|conventional rehabilitation without virtual reality intervention
62789534|NCT00656864|ACTIVE_COMPARATOR|1|Pioglitazone arm
62789535|NCT00656864|PLACEBO_COMPARATOR|2|Placebo arm
62789536|NCT04500886|EXPERIMENTAL|PEG-rhG-CSF group|Patients received subcutaneous injection of PEG-rhG-CSF(Jinyouli®)24 hours after the end of chemotherapy, 6mg for patients with body weight ≥ 45kg and 3mg for patients with body weight less than 45kg, once per chemotherapy cycle
62207799|NCT06703229|ACTIVE_COMPARATOR|group, D2|group, D2, received the same block but with 1 µg/kg of dexmedetomidine.
62207800|NCT05798793|NO_INTERVENTION|Surgery followed by postoperative RT|The participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.
62207801|NCT05798793|EXPERIMENTAL|Neoadjuvant TP chemotherapy|The participants will receive 2 courses of TP chemotherapy. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.
62406179|NCT03160092|EXPERIMENTAL|Intervention|"Clinical Participants will receive a 4 session individual intervention, which will be delivered by Assistant Practitioners and Assistant Psychologists (who will have received specific training in the delivering of the intervention).~The intervention will target the participant's attenuated positive psychotic symptoms, which will be referred to as: 'unusual' experiences (unless the participant prefers an alternative).~The therapist will focus on creating a therapeutic relationship in which the participant experiences them as warm, accepting and empathic. The aim is for the participant to feel listened to and understood.~The intervention will focus on taking a normalising and non-catastrophising approach to the individual's unusual experiences. The participants will be provided with psychoeducation to support this aim."
62207802|NCT05798793|EXPERIMENTAL|Neoadjuvant anti-PD-1 immunotherapy plus TP chemotherapy|The participants will receive 3 doses of PD-1 blockade and 2 courses of TP chemotherapy. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.
62207803|NCT03329859|EXPERIMENTAL|Interventional arm|"High resolution standardized laparoscopic cholecystectomy Patients in which laparoscopic cholecystectomy was performed after high Resolution standardization and Training of the OR Team according to the Standard."
62207804|NCT03329859|ACTIVE_COMPARATOR|Control arm|No 'High resolution standardized laparoscopic cholecystectomy' Patients in which laparoscopic cholecystectomy was performed in the conventional way without prior standardization
62406180|NCT05588401|EXPERIMENTAL|GenPHSat safety injection and GenPHSat efficacy injection|Initial intervention with six injections into the left biceps. A second intervention with 36 injections into the right biceps.
62406181|NCT00627094|EXPERIMENTAL|Biatain Ibu|Biatain Ibu
62406182|NCT00627094|ACTIVE_COMPARATOR|Biatain|Biatain
62406183|NCT06497595|EXPERIMENTAL|multi-disciplinary intervention group (MDIG)|Participants in this group will receive Semaglutide 2.4 mg SC QW and take part in a multi-disciplinary intervention comprised of home-based exercise and nutritional counselling for the 26-week trial duration.
62207805|NCT02449369|ACTIVE_COMPARATOR|Control|Preop acetaminophen IV 1000 mg, Postop oral oxycodone \& acetaminophen (5/325 mg) 1 to 2 tabs every 4 hours PRN, and Postop hydromorphone IV 0.5 mg every 4 hours PRN
62207806|NCT02449369|ACTIVE_COMPARATOR|Standard|Preop acetaminophen IV 1000 mg, Preop orphenadrine IV 60 mg, Postop oral orphenadrine 100 mg every 12 hours for 3 doses, Postop oral oxycodone \& acetaminophen (5/325 mg) 1 to 2 tabs every 4 hours PRN, Postop hydromorphone IV 0.5 mg every 4 hours PRN
62406184|NCT06497595|ACTIVE_COMPARATOR|general health recommendations control group (GHRG)|Participants in this group will receive Semaglutide 2.4 mg SC QW and general health recommendations for the 26-week trial duration.
62406185|NCT04711642|NO_INTERVENTION|No intervention|Control group.
62406186|NCT04711642|EXPERIMENTAL|Treatment 1|Sodium hyaluronate 0.1% eyedrops (Systane ultra plus), q.i.d from day 7 to day 30 after cataract surgery.
62406187|NCT04711642|EXPERIMENTAL|Treatment 2|Sodium hyaluronate 0.1% eyedrops (Hylo-comod), q.i.d from day 7 to day 30 after cataract surgery.
62406188|NCT01428388|ACTIVE_COMPARATOR|Bevacizumab|
62406189|NCT01428388|ACTIVE_COMPARATOR|Ranibizumab|
62581496|NCT03518762|EXPERIMENTAL|Sustained lung inflation|"Participants in this arm (n=80) received:~1. Sustained lung inflation (SLI) manoeuvre(s) was applied once or twice, based on the protocol algorithm.~   Within the first 60 seconds of life, assessment for the need of advanced resuscitation (defined as the need for more than oxygen and tactile stimulation during resuscitation) was done;~  * Infants who needed advanced resuscitation were considered to receive SLI as a rescue approach.~  * Infants who needed only oxygen and tactile stimulation were considered to receive SLI as a prophylactic approach.~2. Then Continuous positive airway pressure (CPAP). Intermittent positive pressure ventilation (IPPV) was given through an ETT, if intubation was needed."
62789537|NCT04500886|ACTIVE_COMPARATOR|rhG-CSF group|Patients received subcutaneous injection of rhG-CSF 24 hours after the end of chemotherapy, 300ug for patients with body weight ≥45kg and 150ug for patients with body weight less than 45kg, Once a day for 3-5 days until the absolute count of neutrophils ≥2×109/L.
62789538|NCT04332718|NO_INTERVENTION|24 Hour Holter|Patients who are randomised to the 24 Hour Holter monitoring will be contacted within one month from randomisation. The repeat 24 Hour Holter result will be explained to the patient at the end of 30-day follow-up.
62789539|NCT04332718|ACTIVE_COMPARATOR|Smartphone ECG|Patients who are randomised to the 30-day smartphone ECG monitoring will be contacted within one month from randomisation. Patients will be taught on how to use the smartphone ECG monitoring. Patients are required to monitor their ECG 3 times a day for 30 days. Patients will be contacted during the monitoring period to assess for compliance and to ensure that the recording is done correctly.
62789540|NCT01303601|EXPERIMENTAL|olanzapine|
62789541|NCT01303601|PLACEBO_COMPARATOR|placebo|
62789542|NCT02272374|EXPERIMENTAL|e-AVF group|120 elderly with end stage renal disease will undergo AVF creation.
62789543|NCT02272374|EXPERIMENTAL|e-TCC group|120 elderly with end stage renal disease will undergo TCC placement.
62789544|NCT02272374|EXPERIMENTAL|e-AVG group|60 elderly with end stage renal disease will undergo AVG creation.
62789545|NCT02272374|EXPERIMENTAL|ve-AVF group|80 very elderly with end stage renal disease will undergo AVF creation.
62789546|NCT02272374|EXPERIMENTAL|ve-TCC group|80 very elderly with end stage renal disease will undergo TCC placement.
62789547|NCT02272374|EXPERIMENTAL|ve-AVG group|40 very elderly with end stage renal disease will undergo AVG creation.
62789548|NCT01838915|EXPERIMENTAL|Dietary Supplement: Prebiotics+Glutamine|
62789549|NCT01838915|PLACEBO_COMPARATOR|Placebo|
62789550|NCT04003740|EXPERIMENTAL|Active tDCS|The anode will be placed over the right dorsolateral prefrontal cortex (DLPFC) and the cathode over the left DLPFC. Stimulation will be performed for 30 minutes with a current intensity of 2 mA. A ramp-up time of 20 s for the current to go from zero to 2 mA and a ramp-down time that also takes 20 s for the current to go from 2 mA to zero will be used.
62207807|NCT02449369|EXPERIMENTAL|IVAM|Preop acetaminophen IV 1000 mg, Preop orphenadrine IV 60 mg, Postop acetaminophen IV 1000 mg every 6 hours for 7 doses, Postop orphenadrine IV 60 mg every 12 hours for 3 doses, Postop oral oxycodone 5 mg 1 to 2 tabs every 4 hours PRN, Postop hydromorphone IV 0.5 mg every 4 hours PRN
62207808|NCT05846646|EXPERIMENTAL|Experimental Arm|PULSAR-ICI + IMSA101
62207809|NCT05846646|ACTIVE_COMPARATOR|Control Arm|PULSAR-ICI
62207810|NCT04602559|EXPERIMENTAL|MOBIDERM Panty group|"MOBIDERM Panty group :~All patients will wear the Panty MOBIDERM device for 12 weeks, day and night recommended. A removable pad is also recommended to be worn additionnaly to the panty."
62207811|NCT06144970|ACTIVE_COMPARATOR|Active Treatment 1|Low dose TG-C 1.5 x 10e6 cells
62789551|NCT04003740|SHAM_COMPARATOR|Sham tDCS|The same montage will be used. Sham stimulation will have the same ramp-up and ramp-down time in three different moments (beginning, middle and at the end of the session).
62017556|NCT03269591|EXPERIMENTAL|diclofenac tablets|(50 mg) few hours at the onset of menstruation for 3 months
62017557|NCT03269591|OTHER|Visual analogue scale|was used to determine the pain intensity level. Pain assessed before and after treatment procedure (3 month)
62789552|NCT06271889|NO_INTERVENTION|Control|Control group pregnant women will be selected using randomization. their babies' fetal voice will not be listened.
62017558|NCT03269591|OTHER|Progesterone blood level|Sample of blood was taken to detect the level of progesterone.
62017559|NCT03269591|OTHER|Menstrual symptom questionnaire|to assess symptoms of dysmenorrhea.
62017560|NCT05069662||Patients treated with oral anticancer drugs|Patients treated with oral anticancer drugs followed in the Oncoral program
62017561|NCT02540239|PLACEBO_COMPARATOR|2L PEG|only used 2L PEG
62017562|NCT02540239|EXPERIMENTAL|Simethione+2L PEG|used 2L PEG+Simethione
62207812|NCT06144970|ACTIVE_COMPARATOR|Active Treatment 2|Middle dose TG-C 5.0 x 10e6 cells
62789553|NCT06271889|ACTIVE_COMPARATOR|Intervention|Pregnant women in the intervention group will be selected using randomization. the fetal voice of their babies will be listened to for about 3-5 minutes with a Non-stress Tester.
62789554|NCT01910415|EXPERIMENTAL|Part A|"Will consist of up to 4 cohorts with subjects receiving lumacaftor or placebo for 7 days.~Cohort 1: 600 mg lumacaftor once a day Cohort 2: 1000 mg lumacaftor once a day Cohort 3: 1200 mg lumacaftor once a day"
62789555|NCT01910415|EXPERIMENTAL|Part B|"Will consist of 3 cohorts. All cohorts will be dosed in parallel. Cohort A will receive 600 mg Lumacaftor once a day plus 250 mg Ivacaftor twice a day for 7 days. From day 8-14 subjects will receive a supratherapeutic dose of Lumacaftor (TBD) plus 450 mg Ivacaftor twice a day.~Cohort B will receive lumacaftor and ivacaftor matching placebo for 14 days Cohort C will receive a single dose of 400 mg moxifloxacin on day 14"
62207813|NCT06144970|ACTIVE_COMPARATOR|Active Treatment 3|High dose TG-C 1.5 x 10e7 cells
62207814|NCT06144970|SHAM_COMPARATOR|Sham Control|single subcutaneous injection of normal saline
62207815|NCT00818779|EXPERIMENTAL|Aliskiren|Aliskiren 150-300 mg once daily
62207816|NCT00818779|ACTIVE_COMPARATOR|Amlodipine|5-10 mg amlodipine once daily
62017563|NCT01151241|EXPERIMENTAL|Early discharge|Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.
62017564|NCT01151241|ACTIVE_COMPARATOR|Normal Discharge|Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
62017565|NCT04471259||Patients' injured side|The Biodex, AOFAS, VAS were tested on the patients' injured side
62017566|NCT04471259||Patients' uninjured side|The Biodex, AOFAS, VAS were tested on the patients' uninjured side
62017567|NCT02217306||Contrast Sensitivity|Determine changes in contrast sensitivity frequences and visual function (visual acuity) after one month of treatment photocoagulation in macular edema
62581497|NCT03518762|OTHER|Control|"Participants in this arm (n=80) received:~1. Resuscitation according to the American academy of pediatrics guidelines.~2. Then Continuous positive airway pressure (CPAP). Intermittent positive pressure ventilation (IPPV) was given through an ETT, if intubation was needed."
62789556|NCT03840954|EXPERIMENTAL|Neuromuscular Electrical Stimulation|The experimental group will receive the application of NMES associated with conventional physiotherapy. After the NMES application, conventional physiotherapy will be performed. The exercises performed will be according to the patient's physical condition, and the conducts will always be performed seeking the maximum possible functional performance for the patient. The conducts adopted according to the standard routine of the HCPA stroke unit are: passive, active, assisted and / or active exercises; muscle stretching; selective hip extension; trunk stabilization training in sedestation; orthostasis training and walking training.
62789557|NCT03840954|NO_INTERVENTION|Group Control|The control group will only receive conventional physiotherapy, composed of the same exercises performed in the experimental group.
62789558|NCT01822262|EXPERIMENTAL|gallbladder reservation|Patients in trial group all took minimally invasive cholecystolithotomy with gallbladder reservation
62789559|NCT01822262|EXPERIMENTAL|laparoscopiccholecystectomy|Patients in control group all received LC.
62789560|NCT01916434|EXPERIMENTAL|High Pufa Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (\~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
62789561|NCT01916434|EXPERIMENTAL|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (\~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption
62017568|NCT01324024|EXPERIMENTAL|Lisdexamfetamine, then placebo|Participants first received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks followed by a 2-week washout, then they received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks.
62017569|NCT01324024|EXPERIMENTAL|Placebo, then Lisdexamfetamine|Participants first received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks followed by a 2-week washout, then they received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks.
62017570|NCT05191706|EXPERIMENTAL|DEXYCU (dexamethasoneintraocular suspension) 9%|A single 0.005-mL anterior chamber injection of DEXYCU (dexamethasoneintraocular suspension) 9%, equivalent to 517mcg dexamethasone.
62017571|NCT05191706|ACTIVE_COMPARATOR|Prednisolone acetate ophthalmic suspension (USP) 1%|Active treatment control, prednisolone acetate ophthalmic suspension (USP) 1%, four times daily (QID) for 28days, followed by a treatment taper at the investigator's discretion.
62017572|NCT02782481|EXPERIMENTAL|ND0612 High dose (Levodopa/Carbidopa solution)|High dose ND0612 SC infusion over 24 h
62017573|NCT02782481|EXPERIMENTAL|ND0612 Low dose (Levodopa/Carbidopa solution)|Low dose ND0612 SC infusion over 24 h
62017574|NCT02782481|PLACEBO_COMPARATOR|Placebo|Placebo SC infusion over 24 h
62017575|NCT02423382|OTHER|3-6 months group|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for 3-6 months.
62789562|NCT01916434|PLACEBO_COMPARATOR|No salmon|The placebo group will continue to consume their habitual diet
62017576|NCT02423382|OTHER|6-9 months|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for 6-9 months.
62017577|NCT02423382|OTHER|>9 months|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for more than 9 months.
62207817|NCT02218606|EXPERIMENTAL|Abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID|Arm 1: Abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID
62207818|NCT02218606|EXPERIMENTAL|Cabazitaxel 25 mg/m2 IV + abiraterone acetate 1000 mg po daily|Arm 2: Cabazitaxel 25 mg/m2 IV + abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID
62207819|NCT05457725|EXPERIMENTAL|Contingent rtfMRI neurofeedback training|Contingent rtfMRI neurofeedback training will follow an alternating up-regulation/rest block design with screen-color cues. Visual feedback about real-time brain activity in the ROI will be provided (e.g., via a thermometer bar). During resting blocks, the thermometer bar remains static.
62581498|NCT03125538|EXPERIMENTAL|Motor Imagery|Participants from the experimental group will perform MIP concomitantly with usual physical rehabilitation program.
62581499|NCT03125538|ACTIVE_COMPARATOR|Control task|Concomitantly with usual physical rehabilitation program, participants from the control group will perform a cognitive task that has no impact on motor rehabilitation (word scramble game).
62581500|NCT03500783|EXPERIMENTAL|Nitric Oxide|Patients of this group receive treatment with exogenous gaseous nitric oxide supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting for coronary artery disease.
62017578|NCT00956150|ACTIVE_COMPARATOR|60 GWS Rifaximin|
62017579|NCT00956150|PLACEBO_COMPARATOR|60 GWS Placebo|
62017580|NCT00956150|EXPERIMENTAL|Healthy Control|Patient is a healthy control and will not be on study intervention. Asked to perform Lactulose Breath Test to compare results with GWS patients.
62017581|NCT00672477|EXPERIMENTAL|Methylnaltrexone|Methylnaltrexone subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; or 0.4 mL (8 mg) every other day if weight between 38 and \<62 kg. Subjects with impaired kidney function received reduced doses according to instructions in the Relistor prescribing information.
62207820|NCT05457725|SHAM_COMPARATOR|Non-contingent/sham rtfMRI neurofeedback training|Non-contingent/sham rtfMRI neurofeedback training will follow an alternating up-regulation/rest block design with screen-color cues. Visual feedback about non-contingent/sham brain activity in the ROI will be provided (e.g., via a thermometer bar). During resting blocks, the thermometer bar remains static.
62207821|NCT04629573|ACTIVE_COMPARATOR|Group 1|Epidural Anesthesia
62789563|NCT05077332|EXPERIMENTAL|Group 1 (Study Product)|Participants will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, participants will continue their famotidine treatment for an additional 9 days.
62406190|NCT04726631|OTHER|Basal insulin analogue and premeal rapid acting insulin|
62406191|NCT04726631|OTHER|Neutral Protamine Hagedorn with regular insulin|
62406192|NCT04494334||Healthy Volunteers|These will be age matched healthy volunteers (n=15) who will not undergo bronchoscopy
62406193|NCT04494334||Probable Idiopathic Pulmonary Fibrosis|Patients with probable IPF, who will be having bronchoscopy as part of their clinical diagnostic work up
62406194|NCT04494334||Sarcoidosis,|Patients with sarcoidosis who will be having bronchoscopy as part of their clinical diagnostic work up
62406195|NCT02350114|EXPERIMENTAL|Functional Capacity|6 Minute Walk Test
62406196|NCT01734109|PLACEBO_COMPARATOR|Standard of Care - Wound Care|Standard, acceptable local wound care management, consisting of topical treatments, chemical debriders, or light bedside debridement.
62406197|NCT01734109|ACTIVE_COMPARATOR|Quantum NPWT|Intervention with Quantum NPWT to Standard III/IV pressure ulcers for 12 weeks.
62406198|NCT01734109|ACTIVE_COMPARATOR|Quantum NPWT with Irrigation|NPWT with the Quantum device, with the addition of simultaneous irrigation using 0.25% acetic acid.
62406199|NCT02530086|ACTIVE_COMPARATOR|Placement of a Nasogastric tube|Placement of a Nasogastric tube
62789564|NCT05077332|PLACEBO_COMPARATOR|Group 2 (Reference Therapy)|Participants will receive matching placebos QID and BID, for 5 days. Following this 5-day period, subjects will continue to receive matching famotidine placebo, QID, for an additional 9 days.
62207822|NCT04629573|ACTIVE_COMPARATOR|Group 2|General Anesthesia
62207823|NCT06502691|EXPERIMENTAL|Arm I ([18F]FTT PET, FDG PET/CT, PARP inhibitor, ICI)|Patients receive \[18F\]FTT IV and undergo PET scan 60-75 minutes later on day 1 of initiating SOC PARP inhibitor ± ICI therapy and again at 12 weeks. At least 1-7 days later, patients undergo SOC FDG PET/CT and follow up scans at 12 weeks and 6 months. Patients may also undergo tissue biopsy during screening and during follow up.
62406200|NCT02530086|EXPERIMENTAL|No placement of a Nasogastric tube|No placement of a Nasogastric tube
62406201|NCT04507282||COVID 19 positive patients|
62406202|NCT04822467|ACTIVE_COMPARATOR|Standard Wipe|Participants will receive a supply of ethanol-based wipes for daily use
62406203|NCT04822467|EXPERIMENTAL|SQ53 Wipe|Participants will receive a supply of SQ53 wipes for daily use.
62406204|NCT05584241|ACTIVE_COMPARATOR|Diagnostic Disclosure|"Personalized disclosure on cognitive test results and research diagnosis, plus post-disclosure dementia risk reduction counseling.~For reporting purposes those participants randomized to this condition are analyzed by biomarker status (positive/+ or negative/-)."
62406205|NCT05584241|EXPERIMENTAL|Biomarker and Diagnostic Disclosure|"Participants receive information about their cognitive test results and research diagnosis. In addition, participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging. PET is a type of imaging biomarker (Aß-PET and tau PET) for clinical diagnosis of Alzheimer's disease. These actions are followed by post-disclosure dementia risk reduction counseling.~For reporting purposes those participants randomized to this condition are analyzed by biomarker status (positive/+ or negative/-)."
62406206|NCT03826446|OTHER|Open Surgery|Patients diagnosed as operable right sided colon cancer were enrolled in this study and did open complete mesocolic excision procedures
62406207|NCT03826446|OTHER|Laparoscopic Surgery|Patients diagnosed as operable right sided colon cancer were enrolled in this study and did laparoscopic complete mesocolic excision procedures
62406208|NCT04380662||COVID+ patients WITH worsening of the disease|COVID+ patients WITH worsening of the disease (case group)
62406209|NCT04380662||COVID+ patients WITHOUT worsening of the disease|COVID+ patients WITHOUT worsening of the disease (control group)
62406210|NCT00778193|PLACEBO_COMPARATOR|Placebo|
62406211|NCT00778193|ACTIVE_COMPARATOR|Naproxen|
62406212|NCT00778193|EXPERIMENTAL|Aspirin|
62406213|NCT00778193|EXPERIMENTAL|Clopidogrel|
62406214|NCT00778193|EXPERIMENTAL|Celecoxib|
62406215|NCT01440608|EXPERIMENTAL|Zinc therapy|High-dose zinc, equivalent 20 mg elemental zinc, to be given once per day for 14 days
62406216|NCT01440608|EXPERIMENTAL|Albendazole|Albendazole to be given once on the day of enrollment. Placebo will then be given for 13 days following.
62581501|NCT03500783|PLACEBO_COMPARATOR|Standard CPB|Patients of this group receive sham-treatment without supplying nitric oxide to the cardiopulmonary bypass circuit during coronary artery bypass grafting for coronary artery disease. Considering dilution of nitric oxide at a high ratio of 1 to 25,000 in the gas mixture of the cardiopulmonary bypass circuit (CPB), no addition of any inert gas to the CPB circuit is required in sham-treatment group.
62581502|NCT05863507|EXPERIMENTAL|grape group|The participant of this group will received a lyophilized grape powder
62581503|NCT05863507|PLACEBO_COMPARATOR|placebo group|The participant of this group will received a lyophilized powder similar to the grape one
62207824|NCT06502691|ACTIVE_COMPARATOR|Arm II ([18F]FTT PET, FDG PET/CT, PARP inhibitor, ICI)|Patients receive \[18F\]FTT IV and undergo PET scan 60-75 minutes later on day 1 of initiating SOC PARP inhibitor ± ICI therapy. At least 1-7 days later, patients undergo SOC FDG PET/CT and follow up scans at 12 weeks and 6 months. Patients may also undergo tissue biopsy during screening.
62207825|NCT02892695|EXPERIMENTAL|CAR-NK Cell immunotherapy|Enrolled patients will receive CAR-NK cell immunotherapy with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
62207826|NCT04490759||Healthy volunteers|Blood samples from healthy volunteers analyzed on the Quantra System
62581504|NCT04611672||Patients with stroke|Patients with stroke of all subtypes, with and without different Kind of Lysis therapy
62207827|NCT03054051|EXPERIMENTAL|Tumaini Mobile Phone Game|Participants randomized to this arm will be invited to play the Tumaini game.
62207828|NCT03054051|NO_INTERVENTION|Standard of Care|Participants randomized to this arm will receive no intervention beyond the current standard of care for sexual education.
62207829|NCT02163005|EXPERIMENTAL|Gadolinium enhancement|Gadolinium enhancement will be performed using intravenous Dotarem\[recommended dose of 0.2 mL/kg (0.1 mmol Gd/kg )\]
62789565|NCT00586053||1|485 patients,who have an average risk (asymptomatic and without colon screening in the last 5 years) or those who have a high risk for colon cancer (strong family history of colon cancer or polyps and/or personal history of colon cancer or polyps).
62207830|NCT05518617||SNCA (Alpha-synuclein gene)|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology.
62207831|NCT05518617||Parkin (Parkin gene)|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
62406217|NCT01440608|PLACEBO_COMPARATOR|Placebo|Placebo will be given for 14 days
62581505|NCT04611672||Controls|Healthy controls of all Ages above 18 years
62207832|NCT05518617||PINK1 (Phosphatase and Tensin Homolog (PTEN)-Induced Kinase 1 gene)|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
62207833|NCT06347874|EXPERIMENTAL|Cryoablation|Participants with rib fracture randomized to Cryoablation.
62581506|NCT05163496|EXPERIMENTAL|Psilocybin arm|psychedelic assisted psychotherapy + 25mg psilocybin
62017582|NCT00672477|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL every other day if weight ≥ 62kg; or 0.4 mL every other day if weight between 38 and \< 62 kg. Subjects with impaired kidney function received reduced volumes of placebo solution to match the volumes used in the experimental group.
62207834|NCT06347874|ACTIVE_COMPARATOR|ESP catheter|Participants with rib fracture randomized to ESP Catheter.
62207835|NCT03303768||Pregnant women|Pregnant woman with suspected coarctation of isolated aorta or woman followed in the last 12 for suspected coarctation of the aorta isolated during pregnancy
62406218|NCT04219046|EXPERIMENTAL|Experimental Treatment|ERAS program with administration of experimental treatment: Naloxegol 25mg administrated once daily from surgery for up to 7 days
62406219|NCT04219046|PLACEBO_COMPARATOR|Placebo|ERAS program with administration of placebo: Placebo administrated once daily from surgery for up to 7 days
62406220|NCT06372392|EXPERIMENTAL|Universal coefficient|With fixed meal bolus coefficients (TDD/300 breakfast and TDD/400 other meals)
62406221|NCT06372392|ACTIVE_COMPARATOR|Individualized coefficient|With meal bolus coefficient individualized according to physician judgment's
62789566|NCT00586053||2|160 patients, with a known colorectal lesion at or greater than 1 cm.
62207836|NCT04389203|EXPERIMENTAL|Study group|Unilateral tubal disconnection and waiting for pregnancy for 2 years after laparoscopy
62207837|NCT04389203|EXPERIMENTAL|Control group|Unilateral tubal disconnection and ICSI
62207838|NCT06723158|EXPERIMENTAL|Virtual Reality (VR) Intervention Group|Participants randomized to this group will receive VR glasses with a relaxation module (audio, visual) to wear during IV placement, induction of anesthesia, and during the procedure.
62406222|NCT03908840|EXPERIMENTAL|TBI 302 Safety, Tolerability|5 Cohorts, Dose escalation TBI 302 will be formulated in 0.9% saline. TBI 302 in a syringe will be administered over approximately 1 hour under constant observation once per week for 4 weeks (on Days 1, 8, 15 and 22).
62406223|NCT01761123|EXPERIMENTAL|VXA-A1.1|Intestinal Delivery
62581507|NCT05163496|ACTIVE_COMPARATOR|Placebo|Psychedelic assisted psychotherapy + 250mg niacin
62581508|NCT02086149|EXPERIMENTAL|Exercise|12-week moderate-intensity behavioral exercise intervention (AE)
62581509|NCT02086149|ACTIVE_COMPARATOR|Health Education|12-week health education control
62581510|NCT00264745|EXPERIMENTAL|1|
62581511|NCT00264745|ACTIVE_COMPARATOR|2|
62789567|NCT00586053||3|610 patients, who are of average risk for colon cancer (asymptomatic and no colon cancer screening in the last 5 years).
62207839|NCT06723158|NO_INTERVENTION|Virtual Reality (VR) Control Group|Participants randomized to this group will receive VR glasses without a relaxation module to be worn only as safety glasses, during IV placement, induction of anesthesia, and during the procedure.
62406224|NCT01591109||Bevacizumab including chemotherapy|Patients treated with bevacizumab including chemotherapy for metastatic liver tumor derived from colorectal cancer before metastasectomy.
62406225|NCT01591109||no adjuvant chemotherapy|Patients with no adjuvant chemotherapy including bevacizumab
62406226|NCT00457795|EXPERIMENTAL|brimonidine 0.1%|brimonidine 0.1%
62789568|NCT02675010|OTHER|ENDOSCOPIC GASTRIC BIOPSIES|ENDOSCOPIC BIOPSEIS TAKEN FROM BOTH ANTRUM AND CORPUS FOR H PYLORI DETECTION
62789569|NCT01764555|EXPERIMENTAL|normal weight patients|normal weight patients receiving acetaminophen 2 g instead of 1 g
62017583|NCT02533882|EXPERIMENTAL|Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors.
62017584|NCT02533882|ACTIVE_COMPARATOR|Adapted Yoga|Yoga classes will consist of postures adapted by qualified yoga instructors who have extensive experience in disability.
62207840|NCT04431167|EXPERIMENTAL|Living well with Lupus Group|A newly developed intervention focused on promoting lifestyle change through recommendations for structured and unstructured physical activity and healthy eating.
62406227|NCT03147209|EXPERIMENTAL|Health Coaching|This group will undergo coaching and activities to improve strength and balance.
62789570|NCT01764555|EXPERIMENTAL|mobidly obese patients|morbidly obese patients receiving acetaminophen 2 g instead of 1 g
62789571|NCT02816489|EXPERIMENTAL|Group I|"will be treated using passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner (3M Unitek - USA).~Intervention: Device: passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner (3M Unitek - USA)."
62789572|NCT02816489|EXPERIMENTAL|Group II|"will be treated using conventional stainless steel orthodontic brackets ligated with elastomeric ligature (3M Unitek - USA).~Intervention: Device: conventional stainless steel orthodontic brackets ligated with elastomeric ligature (3M Unitek - USA)."
62789573|NCT00614146|EXPERIMENTAL|1|
62789574|NCT00614146|ACTIVE_COMPARATOR|2|
62789575|NCT02444325|NO_INTERVENTION|Routine Prenatal Care|Subjects randomized to routine care will receive their care in the usual diabetic clinic attended by residents and faculty. They will receive consultation with the diabetes educator at diagnosis and as needed. Patients are seen every 2 weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits are 10-15 minutes and focus on routine screening tests and review of blood sugar logs/medication titration. Each subject's medical chart will be reviewed for demographics, antenatal management, maternal and neonatal outcomes.
62789576|NCT02444325|EXPERIMENTAL|Group prenatal care|Group visits will be held every 2 weeks in a continuous cycle through a four session curriculum. Women will have weekly visits beginning at 37 weeks with traditional prenatal visits on the weeks when the group does not meet. Groups of 4-12 women will meet for two hour visits and much of that time will be spent on pregnancy, behavioral health, diabetes and nutrition education. Groups will be co-facilitated by 2 CenteringPregnancy trained providers at each site and an obstetric provider. Women may be instructed to have additional visits in the traditional clinic at the discretion of the obstetric provider.
62789577|NCT05747183|EXPERIMENTAL|ProTaper Ultimate|Root canal preparation using ProTaper Ultimate files.
62789578|NCT05747183|ACTIVE_COMPARATOR|ProTaper Gold files|Root canal preparation using ProTaper Gold files.
62789579|NCT05795192|EXPERIMENTAL|SB17170 of 50mg, Single dose|Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 50mg capsule, QD for 1 day(single).
62789580|NCT05795192|PLACEBO_COMPARATOR|Placebo of 50mg, Single dose|Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 50mg, QD for 1 day(single).
62789581|NCT05795192|EXPERIMENTAL|SB17170 of 150mg, Single dose|Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 100mg and 50mg capsules, QD for 1 day(single).
62789582|NCT05795192|PLACEBO_COMPARATOR|Placebo of 150mg, Single dose|Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 100mg and 50mg capsules, QD for 1 day(single).
62207841|NCT04431167|NO_INTERVENTION|Usual Care Group|This group will receive all regular medical care and advice healthy
62207842|NCT06073002|EXPERIMENTAL|Home-based concurrent training|Combination of resistance training (5 exercises with bodyweight and/or resistance bands; 3 sets per exercise, 15-20 repetitions) and endurance training (mode of choice, light to moderate intensities which are monitored via heartrate zones, 20-40min per sessions); 3 weekly sessions on non-consecutive days
62406228|NCT06561620|ACTIVE_COMPARATOR|Treatment|
62406229|NCT06561620|NO_INTERVENTION|Observation|
62406230|NCT04246411|ACTIVE_COMPARATOR|Ultrasound|Ultrasound-guided detection of endobronchial intubation depth by loss of lung sliding sign in the left lung field
62789583|NCT05795192|EXPERIMENTAL|SB17170 of 250mg, Single dose|Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg capsule, QD for 1 day(single).
62789584|NCT05795192|PLACEBO_COMPARATOR|Placebo of 250mg, Single dose|Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg capsule, QD for 1 day(single).
62789585|NCT05795192|EXPERIMENTAL|SB17170 of 500mg, Single dose, Food-effect|"Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg 2 capsules, QD for 1 day(single).~Food-effect test for the expected efficacy dose~* 1st period without a meal~* Wash out period more than 7 days~* 2nd period with a high-fat meal"
62789586|NCT05795192|PLACEBO_COMPARATOR|Placebo of 500mg, Single dose, Food-effect|"Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 2 250mg 2 capsules, QD for 1 day(single).~Food-effect test for the expected efficacy dose~* 1st period without a meal~* Wash out period more than 7 days~* 2nd period with a high-fat meal"
62789587|NCT05795192|EXPERIMENTAL|SB17170 of 1000mg, Single dose|Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg 4capsules, QD for 1 day(single).
62207843|NCT05170633|NO_INTERVENTION|Standard care|"Standard care/Control group: The nurse will receive the PRBC transfusion from the Blood~Bank. As standard care, there are no deliberate procedures for warming PRBC transfusions in this NICU. The syringe of blood may sit outside the incubator for some time and as such, will warm to the environmental ambient temperature while transfusing into the infant using a standard pump. The transfusion will be given over 4 hours, per the clinician's orders. The bedside nurse will document transfusion start and stop times, and route, on the study document at the bedside. The infant will end study participation 24 hours after the PRBC transfusion is complete to verify that all temperature data have been received and are valid."
62207844|NCT05170633|ACTIVE_COMPARATOR|Intervention|"Intervention group: Once a nurse receives the PRBC from the Blood Bank, the nurse will~obtain a specialized tubing and use a commercial PRBC warming device, the Ranger blood warmer (3M Healthcare, Oakdale, Minnesota) to deliver the PRBC transfusion to the infant. The unit contains highly responsive aluminum heating plates that distribute heat quickly, which~responds to flow changes with even and consistent heat. The plate temperature is monitored 4 times per second and is accurate within 1°C (3M Healthcare, Oakdale, Minnesota). The Ranger blood warmer meets the American Association of Blood Bank (AABB) guidelines for warming blood. All times and information associated with the PRBC transfusion will be recorded on the bedside study document. The transfusion will be given over 4 hours, per the clinician's orders. The infant will end study participation 24 hours after the PRBC transfusion is complete to verify that all temperature data have been received and are valid."
62207845|NCT05194332|EXPERIMENTAL|LIFUP sonication to the amygdala|
62207846|NCT03002220|EXPERIMENTAL|open-label|Patient will be treated with radium-223 at a dose of 55 kilobecquerel (kBq) (after 2015 National Institute of Standards and Technology's (NIST) implementation) per kilogram body weight, given at four-week intervals for six intravenous injections.
62207847|NCT06550089|EXPERIMENTAL|High-dose oxytocin|900 mL/hr (54 units/hr) intravenously for the duration of the cesarean delivery
62789588|NCT05795192|PLACEBO_COMPARATOR|Placebo of 1000mg, Single dose|Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 2 250mg 4 capsules, QD for 1 day(single).
62789589|NCT05795192|EXPERIMENTAL|SB17170 of 1500mg, Single dose|Optional dose Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg 6 capsules, QD for 1 day(single).
62789590|NCT05795192|PLACEBO_COMPARATOR|Placebo of 1500mg, Single dose|Optional dose Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg 6 capsules, QD for 1 day(single).
62207848|NCT06550089|ACTIVE_COMPARATOR|Low-dose oxytocin|"For unlabored cesarean births: 300 mL/hr (18 IU/hr), with a maximum rate of 900 mL/hr (54 units/hr) intravenously for the duration of the cesarean delivery~For laboring cesarean births: 600 mL/hr (36 IU/hr), with a maximum rate of 900 mL/hr (54 units/hr) intravenously for the duration of the cesarean delivery"
62207849|NCT00712140|ACTIVE_COMPARATOR|Arm I|Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity. All patients also receive standard chemotherapy regimens as per local institutional protocols either concurrently with or sequentially to trastuzumab.
62207850|NCT00712140|EXPERIMENTAL|Arm II|Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. All patients also receive standard chemotherapy regimens as per local institutional protocols either concurrently with or sequentially to trastuzumab.
62789591|NCT05795192|EXPERIMENTAL|SB17170 of 250mg, Multiple dose for 7days|Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg, 1 capsule, QD for 7 days(multiple).
62789592|NCT05795192|PLACEBO_COMPARATOR|Placebo of 250mg, Multiple dose for 7days|Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg, 1 capsule, QD for 7 days(multiple).
62207851|NCT06715150|ACTIVE_COMPARATOR|Azithromycin 500 mg|Systemic antibiotic: Azithromycin 500 mg every 24 hours for 3 days
62017585|NCT02533882|NO_INTERVENTION|Waitlist Control|This group will receive biweekly newsletters on a variety of topics. At the end of this trial, they will receive a home based intervention.
62207852|NCT06715150|PLACEBO_COMPARATOR|Placebo|Same shape, size and dosage as test
62789593|NCT05795192|EXPERIMENTAL|SB17170 of 500mg, Multiple dose for 7days|Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg, 2 capsules, QD for 7 days(multiple).
62789594|NCT05795192|PLACEBO_COMPARATOR|Placebo of 500mg, Multiple dose for 7days|Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg, 2 capsules, QD for 7 days(multiple).
62789595|NCT05795192|EXPERIMENTAL|SB17170 of 1000mg, Multiple dose for 7days|Optional dose Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg, 4 capsules, QD for 7 days(multiple).
62789596|NCT05795192|PLACEBO_COMPARATOR|Placebo of 1000mg, Multiple dose for 7days|Optional dose Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg, 4 capsules, QD for 7 days(multiple).
62789597|NCT05848427||LUSZ WOSS-3|hospitalized COVID-19 patients classified as WOSS-3 (as per the WHO Ordinal Severity Scale) who didn't need oxygen therapy
62789598|NCT05848427||LUSZ WOSS-4|hospitalized COVID-19 patients classified as WOSS-4 (as per the WHO Ordinal Severity Scale) who needed oxygen therapy by mask or traditional nasal cannula
62789599|NCT05848427||LUSZ WOSS-5|hospitalized COVID-19 patients classified as WOSS-5 (as per the WHO Ordinal Severity Scale) who needed oxygen therapy NIMV or HFNC
62789600|NCT05848427||LUSZ WOSS-6|hospitalized COVID-19 patients classified as WOSS-6 (as per the WHO Ordinal Severity Scale) who needed oxygen therapy IMV \& intubation
62207853|NCT04245059|EXPERIMENTAL|Transcranial Direct Current Stimulation|Each subject will receive transcranial electrical stimulation at primary motor cortex in both hemispheres. The pilot program will include 12 sessions with a frequency of 3 times per week during 4 weeks. Therefore, during tDCS sessions, subjects will receive stimulation for 20 minutes with a current of 2.0 milliamp using 6x4 cm electrodes. The participants will also complete a set of manual dexterity, grip and pinch tests bilaterally at baseline and post-intervention to determine if the subject responds to tDCS. Thus, each session will be monitored on safety aspects of the subjects with emphasis on skin disorders and other possible side effects of tDCS.
62207854|NCT06729138|ACTIVE_COMPARATOR|Sprint training|
62207855|NCT06729138|EXPERIMENTAL|Resisted Sprint|
62207856|NCT03370744||Subjective cognitive decline, SCD|The inclusion criteria for SCD are as following: (1) presence of self-perceived continuous cognitive decline compared to previous normal status and unrelated to an acute event; and (2) failure to meet the following criteria for MCI.
62207857|NCT03370744||Normal control, NC|NC are individuals who have no self-report persistent decline in cognitive capacity, and with neither worry nor concern about their cognition. Without measurable cognitive impairment according to results of standard assessments.
62207858|NCT03370744||Mild cognitive impairment, MCI|MCI are defined by an actuarial neuropsychological method proposed by Jak and Bondi. Participants are considered to have MCI if any one of the following three criteria are met with a total Clinical Dementia Rating (CDR) score of 0.5 as well as failure to meet the criteria for dementia: (1) having impaired scores (defined as \>1 SD below the age-corrected normative mean) on both measures within at least one cognitive domain (i.e., memory, language, or speed/executive function); (2) having impaired scores in each of the three cognitive domains sampled; (3) the Functional Activities Questionnaire (FAQ) ≥9.
62789601|NCT02060136||Study group|Men presenting to the urology clinic with lower urinary tract symptoms
62789602|NCT05728268|EXPERIMENTAL|dose-dense arm|
62017586|NCT05235529||Aortic valve replacement with surgery (SVAo)|This group of patients with severe aortic stenosis will be treated with aortic valve replacement with surgery.
62017587|NCT05235529||Transcatheter aortic valve implant (TAVI)|This group of patients with severe aortic stenosis will be treated with transcatheter aortic valve implant (TAVI).
62207859|NCT03370744||Alzheimer's disease, AD|The diagnosis of AD syndrome is based on the diagnostic guidelines for dementia due to AD delivered by the National Institute on Aging-Alzheimer's Association workgroups (NIA-AA) with a total CDR score of 1.
62406231|NCT04246411|PLACEBO_COMPARATOR|Auscultation|Auscultation-guided detection of endobronchial intubation depth by loss of breathing sound in the left lung field
62789603|NCT01865448|ACTIVE_COMPARATOR|omega-3 DHA|Patients in this group will receive 500 mg/day supplement of DHA omega-3 fatty acid in capsule form, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme.
62789604|NCT01865448|PLACEBO_COMPARATOR|Control|Patients in control group will receive an placebo capsule, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme
62017588|NCT03049059|EXPERIMENTAL|Fractional Picosecond 1,064 nm laser and 4% hydroquinone cream|
62017589|NCT03049059|ACTIVE_COMPARATOR|4% hydroquinone cream alone|
62017590|NCT06208527|PLACEBO_COMPARATOR|Placebo group|Placebo, no active ingredients. Administered in tablet form twice daily for the duration of the trial (1 year).
62017591|NCT06208527|EXPERIMENTAL|NR group|Nicotinamide Riboside (NR) administered in doses of 1000 mg twice daily for the duration of the trial (1 year).
62017592|NCT06663137|EXPERIMENTAL|NDV01|"1. Treatment phase: 6 biweekly instillations~2. Maintenance phase: monthly administration"
62017593|NCT01713803|PLACEBO_COMPARATOR|Sugar pill|
62017594|NCT01713803|EXPERIMENTAL|buprenorphine and nalaxone|
62017595|NCT00403546|EXPERIMENTAL|High-Dose Ziprasidone|Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take ziprasidone oral capsule twice daily added to their regular open-label ziprasidone dose (total of 240 mg/d). After the first week, the study drug will be increased to a total ziprasidone dose of 320 mg/d for 7 weeks.
62789605|NCT02898896|OTHER|HIV-infected patients|HIV-infected patients \>= 45 years with 2 or more CV risk factors currently on ART and HIV-RNA \< 50 copies \>= 12 months (one blip allowed) As part of this research, three additional tubes of blood (EDTA) will be taken from patients (21 mL) during blood tests performed as part of a scheduled consultation for the management of their pathology
62207860|NCT03370744||Subjective Cognitive Decline plus, SCD-plus|The inclusion criteria for SCD-plus are as following: (1) presence of self-perceived continuous cognitive decline compared to previous normal status and unrelated to an acute event; and (2) concerns (worries) associated with memory complaint; and (3) failure to meet the following criteria for MCI.
62017596|NCT00403546|PLACEBO_COMPARATOR|Placebo, Standard Treatment Ziprasidone|Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take matching placebo oral capsule twice daily added to their regular open-label ziprasidone dose of 160 mg/d. After the first week, the matching placebo will be increased to two capsules twice daily and their regular open-label ziprasidone will remain the same (160 mg/d) for 7 weeks.
62207861|NCT02797080|EXPERIMENTAL|interferon γ-1b|ACTIMMUNE® will be administered 3 times per week (TIW) by subcutaneous (SC) injection.
62207862|NCT06402565|EXPERIMENTAL|NOX1416 and SOC|"NOX1416 is a foam based gaseous nitric oxide (NO) product that will be topically applied directly onto the wound bed and left on the wound bed for a 5-minute period. Subjects randomized to the NOX1416 treatment group will receive once a day application, for a total of 12 weeks with a double treatment, 10 minutes apart, on the first day.~Standard of care will include evaluation to document, offloading, adequate arterial flow, wound cleansing, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of a moist wound environment, and management of infection."
62406232|NCT05299359|EXPERIMENTAL|TAK-019 Main Part|TAK-019 0.5 mL, intramuscular injection in the mid deltoid, preferable in the non-dominant upper arm
62406233|NCT05299359|EXPERIMENTAL|TAK-019 Extension Part|TAK-019 0 .5 mL, intramuscular injection in the mid deltoid, preferable in the non-dominant upper arm. The participants who received the first single booster vaccination of TAK-019 in the main part and remained in study follow-up at least 5 months will receive a second single booster vaccination of TAK-019 by intramuscular injection.
62406234|NCT02402556|EXPERIMENTAL|MOCEP|MOCEP is implemented over a period of 25 weeks, through weekly group meetings that last approximately three hours.
62581512|NCT02656004|EXPERIMENTAL|Essential Eucalyptus Oil|Using a disposable face mask was inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus.
62789606|NCT02363959|EXPERIMENTAL|Hyperbaric Oxygen, Airway Biopsy|"The hyperbaric oxygen therapy (HBOT) will be performed with the standard HBOT protocol used at Duke for the treatment of compromised grafts and flaps. This is 2 hours of breathing \>99% medical grade oxygen inside an air-pressurized chamber at atmospheric pressure of 2 (2 ATA) once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.~During standard bronchoscopies, an endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure."
62789607|NCT02363959|OTHER|No Hyperbaric Oxygen, Airway Biopsy|No hyperbaric oxygen therapy administered, but lung biopsy still completed during standard post-lung transplant bronchoscopies. An endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure.
62789608|NCT00839644|ACTIVE_COMPARATOR|2|
62789609|NCT00839644|ACTIVE_COMPARATOR|3|
62789610|NCT00839644|ACTIVE_COMPARATOR|1|
62789611|NCT06371846||Cohort one|This was a non-randomized, prospective multicentric study. From july 2023 to may 2024 consecutive patients over 18 years of age who underwent a LBBAP system as first intention, were enrolled from five participating hospitals. Baseline characteristics including demography, pacing indication, basal QRS and left ventricular ejection fraction were collected. For the implantation procedure analysis, total procedural time, total fluoroscopy time, total radiation dosage, pacing electrocardiogram parameters including the paced QRS morphology and duration, V6 R wave peak time (V6-RWPT), and changes between selective and non-selective LBBP were recorded, as well as the pacing lead parameters including R-wave amplitude, threshold and impedance with unipolar and bipolar configurations. First 24hs complications were all documented.
62017597|NCT05567991|EXPERIMENTAL|Treatment group|The individuals assigned to the treatment group attend the training sessions and were asked to complete all the questionnaires at both time points
62017598|NCT05567991|NO_INTERVENTION|Passive Control Group|The individuals assigned to the passive control group did not attend any training session and were only asked to complete the same questionnaires as the treatment group at both time points. Participants in the control group were asked not to practice meditation during the period of the study for an unbiased comparison with the intervention group.
62017599|NCT06420284||MRONJ Stage 0|Participants in this group are receiving antiresorptive/antiangiogenic therapy and exhibit nonspecific symptoms but no exposed bone. This stage is considered a precursor stage, where the risk of developing MRONJ is present but not yet visible through exposed bone.
62017600|NCT06420284||MRONJ Stage I|Individuals in this group are on antiresorptive/antiangiogenic therapy and show exposed bone without any symptoms. This stage represents the early manifestation of MRONJ, characterized by visible bone changes without associated pain or infection.
62017601|NCT06420284||MRONJ Stage II|This group includes patients treated with antiresorptive/antiangiogenic agents, who have exposed bone accompanied by symptoms such as pain or infection but without extensive bone involvement. This stage indicates a progression in the severity of MRONJ.
62017602|NCT06420284||MRONJ Stage III|Participants are undergoing antiresorptive/antiangiogenic treatment and exhibit exposed bone with symptoms, where the exposed bone extends beyond the alveolar bone, indicating advanced disease with significant bone and surrounding tissue involvement.
62017603|NCT06420284||At-Risk Group|This group consists of individuals receiving antiresorptive/antiangiogenic therapy who do not yet show any exposed bone or symptoms. They are considered at risk for developing MRONJ and are monitored for any potential progression.
62406235|NCT02402556|ACTIVE_COMPARATOR|Waitlist Control Group|For ethical reasons, no one recruited will be excluded from the opportunity to benefit from the intervention. MOCEP group will be the primary intervention group and the second group will act as the wait-listed control group. Although the families in the wait-listed control group will start out as a control group (not receiving the intervention), they will have the opportunity to participate in the intervention in a later round of implementation, after the intervention group has completed the program.
62406236|NCT03229902|EXPERIMENTAL|mantra meditation|Each session of mantra meditation lasts for 30 minutes. The participants in each session comprise 1 subject and the PI. In each session, the subject and the PI co-participate in repetitive intonation of a pre-specified mantra. Intervention is comprised of 9 sessions, each of which occurs on a separate weekday at approximately equal intervals over a total intervention period of 3 weeks.
62406237|NCT05513807|EXPERIMENTAL|Nicotinamide|
62789612|NCT00630344|EXPERIMENTAL|RAD001 + Bicalutamide|"RAD001: once daily dose of 10 mg (5 mg tablets)~Bicalutamide: once daily dose of 50 mg (50 mg tablets)~1 cycle=28 days~Both agents are administered continuously until progression of disease or unacceptable toxicity."
62017604|NCT06420284||Healthy Control Group|This control group comprises individuals who have not received antiresorptive/antiangiogenic therapy and show no signs of exposed bone or symptoms. This group serves to provide baseline data for comparing immunological parameters against those receiving treatment.
62017605|NCT00097591|EXPERIMENTAL|Prasugrel|Oral loading dose of six 10 mg prasugrel tablets and four placebo tablets matched to clopidogrel, followed by an oral maintenance dose of prasugrel one 10 mg tablet and one placebo tablet matched to clopidogrel once daily
62406238|NCT05513807|PLACEBO_COMPARATOR|Placebo|
62406239|NCT05480904||On campus|SJLIFE Study Campus Visit
62406240|NCT05480904||Remote|SJLIFE cohort: ALL, CNS tumors, and non-CNS solid tumors
62581513|NCT02656004|EXPERIMENTAL|Control|In the control session the procedure was the same. Using a disposable face mask was inhale for ten minutes fresh air. Inhalation of the fresh air occurred immediately after the 20 minute rest period in the session Control.
62581514|NCT03933618|OTHER|anastrazole-clomiphene-placebo|anastrozole for eight weeks then clomiphene for eight weeks then placebo for eight weeks
62789613|NCT01122693|ACTIVE_COMPARATOR|standard 2D ultrasound images|
62581515|NCT03933618|OTHER|anastrazole-placebo-clomiphene|anastrozole for eight weeks then placebo for eight weeks then clomiphene for eight weeks
62581516|NCT03933618|OTHER|clomiphene-anastrazole-placebo|clomiphene for eight weeks then anastrozole for eight weeks then placebo for eight weeks
62581517|NCT03933618|OTHER|clomiphene-placebo-anastrazole|clomiphene for eight weeks then placebo for eight weeks then anastrozole for eight weeks
62789614|NCT01122693|EXPERIMENTAL|high-quality 2D ultrasound images|
62789615|NCT01122693|ACTIVE_COMPARATOR|nerve stimulation techniques|
62406241|NCT05852106|EXPERIMENTAL|Experimental|"Preoperative:Once the surgery date is set, appointments will be made with the surgeon for surgical simulation and with the family for education one week prior to surgery. The surgeon will be asked to complete the Surgical Simulation Evaluation Form-Part I. At the same time, another researcher will complete the family sociodemographic information form and PedsQL questions in the examination room. After completion of the pre-test and the surgical simulation, the families are given a 30-minute preoperative education with the Congenital Heart Disease Parent Education Booklet, together with a life-size 3D heart model obtained from their child's own heart, and drawings on paper where they are not understood.~Postoperative: After surgery, the patient will be followed until discharge, and only Part II of the Surgical Simulation Evaluation Form will be completed. On the 15th postoperative day, the Surgical Simulation Evaluation Form Part II and the PedsQL will be given again as a posttest."
62406242|NCT05852106|NO_INTERVENTION|Control Group|"Preoperative:When the operation date is determined, one week before the operation, the patients included in the study's control group will be asked the Sociodemographic Information Form and Pediatric Quality of Life Inventory Family Module (PedQL) questions in the examination room. After the pretest, standardized education will be given to the families. The disease process will be explained to the patients with the same 'Congenital Heart Diseases Parent Education Booklet', and the disease process will be presented with the heart model used in standard medical faculty anatomy courses and the ununderstood parts will be detailed by drawing on paper. The remaining 15 minutes of the education will be conducted as a question and answer with the parents.~Postoperative:After the operation, the Surgical Simulation Evaluation Form Part II and PedsQL will be filled out again as post-tests for this group."
62406243|NCT04518800|EXPERIMENTAL|Jin Youli(PEG-rhG-CSF)|PEG-rhG-CSF Secondary Prevention：patients with pancreatic cancer who met the eligibility criteria were given secondary prophylactic administration of the Jin Youli(PEG-rhG-CSF).
62581518|NCT03933618|OTHER|placebo-clomiphene-anastrazole|placebo for eight weeks then clomiphene for eight weeks then anastrozole for eight weeks
62581519|NCT03933618|OTHER|placebo-anastrazole-clomiphene|placebo for eight weeks then anastrozole for eight weeks then clomiphene for eight weeks
62735034|NCT02353013|ACTIVE_COMPARATOR|Standard Protein Group|For infants in this group, the target protein-energy ratio (PER) will be \~3 g/100 kcal. This will be achieved by providing standard fortification by adding a commercially available human milk fortifier to human milk or by providing a preterm formula.
62789616|NCT03221842|EXPERIMENTAL|C1-INH|C1-esterase inhibitor
62789617|NCT03221842|PLACEBO_COMPARATOR|Placebo|Excipients of C1-INH plus albumin
62207863|NCT06402565|PLACEBO_COMPARATOR|Placebo and SOC|"Placebo is topically applied directly onto the wound bed and left on the wound bed for a 5-minute period. Subjects randomized to the control group will receive once a day application, fora total of 12 weeks with a double treatment, 10 minutes apart, on the first day.~Standard of care will include evaluation to document, offloading, adequate arterial flow, wound cleansing, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of a moist wound environment, and management of infection."
62207864|NCT06303505|EXPERIMENTAL|Platinum resistant ovarian cancer|
62207865|NCT06303505|EXPERIMENTAL|Non small cell lung cancer-adenocarcinoma|
62789618|NCT05962892||No Intervention|
62789619|NCT05615207|ACTIVE_COMPARATOR|Standard of Care (physical practice)|Participants will be given a single one on one in person instruction session and a home exercise program corresponding to their assigned group with instructions on physical practice. The Standard of Care / Physical practice will include physically performing movements that closely or entirely mimic elements of the BBS. For example, if a subject struggles with the sit to stand portion of the BBS, they will physically practice sit to stand based on the treating physical therapist's clinical decision of appropriate task parameters and dosage. The individual subject's MS fatigue and their performance of the task will be taken into account when deciding dosage.
62207866|NCT05640999|EXPERIMENTAL|Sub-study A: RAINBO BLUE Cohort A1|Observation
62207867|NCT05640999|EXPERIMENTAL|Sub-Study A: RAINBO BLUE Cohort A2 Exploratory|Observation or Adjuvant Radiotherapy
62207868|NCT05640999|EXPERIMENTAL|Sub-Study B: TAPER|Observation or Vaginal Brachytherapy
62207869|NCT05447650|EXPERIMENTAL|i-Lumen AMD Active|Active transpalpebral microcurrent stimulation therapy
62207870|NCT05447650|SHAM_COMPARATOR|i-Lumen AMD Sham|Sham transpalpebral microcurrent stimulation therapy
62207871|NCT00555269||MB|
62207872|NCT00555269||IFCG|
62207873|NCT01189175|EXPERIMENTAL|BI 113823|single oral dose per subject
62207874|NCT01189175|EXPERIMENTAL|BI 113823 + Ketokonazole|after wash-out 5 days ketokonazole with BI 113823 on day 3
62207875|NCT06487624|EXPERIMENTAL|Experimental: 0.3 mg/kg HCB301|0.3 mg/kg HCB301 in subjects with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas.
62207876|NCT06487624|EXPERIMENTAL|Experimental: 0.6 mg/kg HCB301|0.6 mg/kg HCB301 in subjects with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas.
62017606|NCT00097591|ACTIVE_COMPARATOR|Clopidogrel|Oral loading dose of four 75 mg clopidogrel tablets and six placebo tablets matched to prasugrel, followed by an oral maintenance dose of one 75 mg clopidogrel tablet and one placebo tablet matched to prasugrel once daily
62017607|NCT06573333|EXPERIMENTAL|15 seconds|Umbilical Cord will be clamped after 15s of birth and Serum calcium levels will be measured at 6 hours of life
62017608|NCT06573333|EXPERIMENTAL|30seconds|Umbilical Cord will be clamped after 30s of birth and Serum calcium levels will be measured at 6 hours of life
62017609|NCT06573333|EXPERIMENTAL|60seconds|Umbilical Cord will be clamped after 60s of birth and Serum calcium levels will be measured at 6 hours of life
62017610|NCT06573333|EXPERIMENTAL|120 seconds|Umbilical Cord will be clamped after 120s of birth and Serum calcium levels will be measured at 6 hours of life
62017611|NCT03226652||Patients with clinically suspected sleep disordered breathing (SDB)|Patients referred for Sleep disordered breathing assessment.
62017612|NCT01474135|EXPERIMENTAL|0.25% AR-12286/ 0.004% travoprost|Fixed dose combination of 0.25% AR-12286 and 0.004% travoprost
62017613|NCT01474135|EXPERIMENTAL|0.5% AR-12286/ 0.004% travoprost|Fixed dose combination of 0.5% AR-12286/ 0.004% travoprost
62017614|NCT01474135|ACTIVE_COMPARATOR|0.004%Travoprost|Travatan(R) Z(travoprost ophthalmic solution)
62207877|NCT06487624|EXPERIMENTAL|Experimental: 1.2 mg/kg HCB301|1.2 mg/kg HCB301 in subjects with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas.
62207878|NCT06487624|EXPERIMENTAL|Experimental: 2.4 mg/kg HCB301|2.4 mg/kg HCB301 in subjects with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas.
62207879|NCT06487624|EXPERIMENTAL|Experimental: 4.8 mg/kg HCB301|4.8 mg/kg HCB301 in subjects with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas.
62406244|NCT01203982|ACTIVE_COMPARATOR|Rosuvastatin 5mg|Rosuvastatin 5mg/day
62406245|NCT01203982|ACTIVE_COMPARATOR|Rosuvastatin 40mg|Rosuvastatin 40mg/day
62207880|NCT06487624|EXPERIMENTAL|Experimental: 9.6 mg/kg HCB301|9.6 mg/kg HCB301 in subjects with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas.
62207881|NCT06487624|EXPERIMENTAL|Experimental: 15.0 mg/kg HCB301|15.0 mg/kg HCB301 in subjects with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas.
62207882|NCT04623177||Anticoagulation|Patients receiving an anticoagulant dose (equal or higher than 150 IU/kg/24 h) of LMWH within the first 48 hours after the ICU admission
62406246|NCT02705534|EXPERIMENTAL|Treatment|Subjects will receive sofosbuvir, ledipasvir and ribavirin
62406247|NCT01587807|EXPERIMENTAL|Cohort 1|single inhaled dose of GSK1995057 (dose 1) or placebo
62406248|NCT01587807|EXPERIMENTAL|Cohort 2|single inhaled dose of GSK1995057 (dose 2) or placebo
62406249|NCT01587807|EXPERIMENTAL|Cohort 3|single inhaled dose of GSK1995057 (dose 3) or placebo
62406250|NCT01587807|EXPERIMENTAL|Cohort 4|single inhaled dose of GSK1995057 (dose 4) or placebo
62406251|NCT01587807|EXPERIMENTAL|Cohort 5|single inhaled dose GSK1995057 (dose 4) with bronchoalveolar lavage (BAL)sampling procedure conducted approximately 30 minutes post GSK1995057 dose
62789620|NCT05615207|EXPERIMENTAL|Motor Imagery|Participants will be given a single one on one in person instruction session and a home exercise program corresponding to their assigned group with instructions on using motor imagery to imagine themselves performing the balance task with which they struggled on the BBS. Motor imagery practice involves having the participant imagine themselves performing elements of the BBS without physically moving. The participants in this group will be guided through 1 session of motor imagery that will be recorded on their person phone for them to use as a home exercise program.
62789621|NCT02219373|EXPERIMENTAL|Gabapentin|
62789622|NCT02219373|EXPERIMENTAL|Oxcarbazepine|
62789623|NCT02219373|PLACEBO_COMPARATOR|Placebo|Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
62207883|NCT04623177||Thromboprophylaxis|Patients receiving a prophylactic dose (lower than 150 IU/kg/24 h) of LMWH within the first 48 hours after the ICU admission
62207884|NCT04623177||No heparin|Patients receiving no anticoagulant drug within the first 48 hours after the ICU admission
62789624|NCT04248543|EXPERIMENTAL|quantitative MRI at 4 weeks|
62789625|NCT01351116|EXPERIMENTAL|EBR plus HDRIB|External Beam Radiation (EBR) plus High Dose Rate Intraluminal Brachytherapy (HDRIB)
62581520|NCT03433469|EXPERIMENTAL|Treatment (osimertinib)|Participants receive 80mg osimertinib orally, once a day (PO QD) on days 1-28. Treatment repeats every 28 days for a minimum of 1 cycle prior to surgery in the absence of disease progression or unacceptable toxicity. Investigators will have the option to give a second cycle of study drug prior to surgery if clinically indicated. Depending on the timing of the final scans, patients may ultimately receive up to two weeks additional therapy with study drug beyond end of cycle 1 (or cycle 2) while awaiting surgery. Patients then undergo surgical resection of their cancer. No treatment with the study drug will be given after surgery.
62735035|NCT02353013|EXPERIMENTAL|Enhanced Protein Group|For infants in this group, the target protein-energy ratio (PER) will be \~4 g/100 kcal. This will be achieved by providing standard fortification by adding a commercially available human milk fortifier to human milk or by providing a preterm formula. In addition, liquid protein will be added to provide protein supplementation and increase the PER.
62789626|NCT01351116|ACTIVE_COMPARATOR|EBR|External Beam Radiation (EBR)
62207885|NCT06438263|EXPERIMENTAL|Treatment A|Participants will be randomized to receive a single dose of rocatinlimab vial solution for SC injection.
62789627|NCT05204030|EXPERIMENTAL|Narrative|The intervention condition will present narrative-focused messages about HPV and the HPV vaccine that includes important parent focused exemplar language and cultural norms on Twitter told through stories and characters (i.e., pseudo-parents).
62789628|NCT05204030|ACTIVE_COMPARATOR|Non-Narrative|The non-narrative condition will present scientific-focused messages about HPV and the HPV vaccine that includes important information relayed with numbers and facts.
62789629|NCT02235636||Laparoscopic group|
62789630|NCT02235636||Robotic group|
62789631|NCT05280353|EXPERIMENTAL|lymphadenectomy without drainage and with Glubran|Application of Glubran 2 in axillary dissection with the objective of seroma reduction. No drain
62207886|NCT06438263|EXPERIMENTAL|Treatment B|Participants will be randomized to receive a single dose of rocatinlimab autoinjector for SC injection.
62207887|NCT06240598|EXPERIMENTAL|Second Look Laparoscopy (SLL)|Patients will be treated with standard of care observation or maintenance therapy as per investigator decision.The only investigational intervention performed through this study is the SLL.
62207888|NCT06723197|ACTIVE_COMPARATOR|14-day dual regimen|
62207889|NCT06723197|EXPERIMENTAL|10-day dual regimen|
62207890|NCT06723197|EXPERIMENTAL|7-day quadruple regimen|
62207891|NCT01072630|PLACEBO_COMPARATOR|Placebo|Participants were administered placebo and titrated to match the armodafinil treatment arms. Total treatment was 8 weeks.
62789632|NCT05280353|NO_INTERVENTION|Lymphadenectomy without drainage|No intervention required, only axillary dissection without drain
62789633|NCT03260296||University students|university students who use smartphones
62207892|NCT01072630|EXPERIMENTAL|Armodafinil 150 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 150 mg/day. The 150 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment.
62207893|NCT01072630|EXPERIMENTAL|Armodafinil 200 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 200 mg/day. The 200 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment. This treatment arm was discontinued via a protocol amendment.
62789634|NCT00548145|EXPERIMENTAL|1|
62789635|NCT00548145|ACTIVE_COMPARATOR|2|
62789636|NCT04057430|ACTIVE_COMPARATOR|String floss|
62789637|NCT04057430|EXPERIMENTAL|Gumchucks floss|
62789638|NCT03747679|EXPERIMENTAL|A- Bosutinib in water|200 Mg of bosutinib (50 mg capsule x4) in Water solution
62789639|NCT03747679|EXPERIMENTAL|B- bosutinib in sorbitol|200 Mg of bosutinib sorbitol base in water solution
62789640|NCT03747679|EXPERIMENTAL|C- - bosutinib mannitol|200 Mg of bosutinib powder mannitol base in water solution
62789641|NCT03747679|EXPERIMENTAL|D - bosutinib in mannitol low sweet|200 Mg of bosutinib mannitol low sweet solution
62789642|NCT03747679|EXPERIMENTAL|E- - bosutinib in mannitol high sweet|200 Mg of bosutinib High % sweet mannitol solution
62789643|NCT03747679|EXPERIMENTAL|F- - bosutinib low flavour|Taste assessment of 200 Mg of bosutinib low % Flavour
62581521|NCT03983148|EXPERIMENTAL|Motivational interviewing|Other than usual medical care received by children, their parents in this group will receive three individual, face-to-face interventions on motivational interviewing by a trained registered nurse at baseline, 3-month and 6-month, with each session is about 60 minutes. All sessions of motivational interviewing will be scheduled based on the treatment schedule of the children and conducted in an interview room inside the pediatric oncology unit. A 25-30 minutes semi -structured interview will be conducted for process evaluation at 6-month.
62789644|NCT03747679|EXPERIMENTAL|G- bosutinib high flavour|Taste assessment of 200 Mg of bosutinib high percentage of flavor in water
62017615|NCT05387759|EXPERIMENTAL|Treatment Sequence 1|Healthy participants will receive single oral dose of Aticaprant (Dose 1) (Treatment A) in Treatment Period 1, followed by Moxifloxacin (Dose 2) (Treatment D) in Treatment Period 2, followed by Aticaprant (Dose 3) (Treatment B) in Treatment Period 3 and then placebo (Treatment C) in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7-15 days between each treatment period.
62207894|NCT05248126|ACTIVE_COMPARATOR|Comparator arm|All patients randomized to this arm will participate in a standard patient education program.
62406252|NCT01587807|EXPERIMENTAL|Cohort 6|high dose of GSK1995057 or placebo followed by an inhaled LPS challenge and BAL sampling procedure.
62789645|NCT03747679|EXPERIMENTAL|H- - bosutinib capsules in low sweet|Taste assessment of 200 Mg of bosutinib (50 mg x4 capsules) low % sweet
62017616|NCT05387759|EXPERIMENTAL|Treatment Sequence 2|Healthy participants will receive single oral dose of Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3 and then Treatment D in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7-15 days between each treatment period.
62017617|NCT05387759|EXPERIMENTAL|Treatment Sequence 3|Healthy participants will receive single oral dose of Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment D in Treatment Period 3 and then Treatment A in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7-15 days between each treatment period.
62017618|NCT05387759|EXPERIMENTAL|Treatment Sequence 4|Healthy participants will receive single oral dose of Treatment D in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3 and then Treatment B in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7 to 15 days between each treatment period.
62207895|NCT05248126|EXPERIMENTAL|Experimental arm|All patients randomised to this arm have the opportunity to participate in a patient education programme via a chatbot.
62406253|NCT04156009|EXPERIMENTAL|Treatment (+aromatherapy) group|
62406254|NCT04156009|SHAM_COMPARATOR|Control (-aromatherapy) group|
62406255|NCT01713374|ACTIVE_COMPARATOR|Myogenic activation|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of myogenic activation
62789646|NCT03747679|EXPERIMENTAL|I - bosutinib capsules high sweet|200 Mg of bosutinib (4 X 50 mg capsules)in high % sweetener
62789647|NCT03747679|EXPERIMENTAL|J- - bosutinib capsules low flavour|Taste assessment of 200 Mg of bosutinib (50 mg X4 capsules) in Low % flavour Water solution
62789648|NCT03747679|EXPERIMENTAL|K - bosutinib capsules high flavour|Taste assessment of 200 Mg of bosutinib (50 mg X 4 capsules) in high % flavour
62789649|NCT03747679|EXPERIMENTAL|L - bosutinib capsules applesauce|200 Mg of bosutinib (50 mg x 4 capsules) in applesauce
62017619|NCT02170727|EXPERIMENTAL|Arm 1 : DCV/ASV/BMS-791325|DCV 30 mg (as the free base) / Asunaprevir (ASV) 200 mg / BMS-791325 75 mg FDC tablet orally twice daily for 12 weeks
62789650|NCT03747679|EXPERIMENTAL|M - bosutinib capsules full fat yougurt|200 Mg of bosutinib (50 mg x 4 capsules) in full fat yogurt
62789651|NCT03747679|EXPERIMENTAL|N - bosutinib capsules in water (retest)|200 Mg of bosutinib (50 mg x 4 capsules) in Water (retest)
62789652|NCT04231604|EXPERIMENTAL|A Lust for Life programme group|A Lust for Life programme will be delivered to adolescents by their school teachers in six weekly lessons. Well-being and resilience will be promoted in each lesson through classroom discussions, videos, classroom activities and homework assignments.
62017620|NCT04749264||Mindfulness Meditation Retreat|6 to 7-days mindfulness meditation retreat
62207896|NCT05083390|EXPERIMENTAL|norUrsodeoxycholic acid 1500 mg/day|3 film-coated tablets once daily for 72 weeks containing in total norUrsodeoxycholic acid 1500 mg
62406256|NCT01713374|ACTIVE_COMPARATOR|Cold pressure test|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of cold pressure test
62406257|NCT01713374|ACTIVE_COMPARATOR|mental stress|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of mental stress
62406258|NCT01713374|ACTIVE_COMPARATOR|Control|Control visit - no intervention performed - subjects will undergo endothelial function measurement twice at a distance of 45 minutes
62406259|NCT03911700|EXPERIMENTAL|Phasix™ Mesh|Prophylactic onlay placement of mesh.
62406260|NCT03911700|NO_INTERVENTION|Primary Suture Closure|Standard Fascial closure.
62406261|NCT06389708||Group 1|heart failure patients
62406262|NCT05818046|EXPERIMENTAL|Single Group Assignment|intervention consiste to non-invasive arterial assessment by doppler (arterial waveform) and external oxygen probe (Transcutaneous oxygen pressure) at 3,6 and 9 weeks of supervised exercise therapy
62406263|NCT04745572|EXPERIMENTAL|High Carbohydrate Diet|Enrollment in a group-based behavioral weight loss intervention based on the Diabetes Prevention Program curriculum with high carbohydrate diet plan.
62406264|NCT04745572|EXPERIMENTAL|Reduced Carbohydrate Diet|Enrollment in a group-based behavioral weight loss intervention based on the Diabetes Prevention Program curriculum with reduced carbohydrate diet plan.
62789653|NCT04231604|OTHER|Waiting list control group|Participants will be placed on a twelve-week waiting list for the programme.
62789654|NCT04800237|EXPERIMENTAL|VQW-765|
62789655|NCT04800237|PLACEBO_COMPARATOR|Placebo|
62789656|NCT00386243|NO_INTERVENTION|Usual Care|Study subjects randomized to this arm would receive usual care from their provider(s). No study intervention is undertaken on subjects in this arm. Participants in Usual Care would complete the same four outcome assessments (surveys) throughout the course of the study that members of the intervention complete.
62017621|NCT04749264||No intervention, Matched control|Adults participants will be recruited from social media and local community of meditation practitioners, and will be matched to the retreat group by gender, age and level of experience in meditation.
62207897|NCT05083390|EXPERIMENTAL|norUrsodeoxycholic acid 1000 mg/day|3 film-coated tablets once daily for 72 weeks containing in total norUrsodeoxycholic acid 1000 mg
62207898|NCT05083390|PLACEBO_COMPARATOR|Placebo to norUrsodeoxycholic acid|3 film-coated tablets once daily for 72 weeks containing placebo to norUrsodeoxycholic acid
62207899|NCT04419298||Acute CO poisoning with myocardial injury|"A diagnosis of CO poisoning was made according to medical history and carboxyhaemoglobin \>5% (\>10% in smokers).~Myocardial injury was defined as elevated high-sensitivity TnI level above the upper limit (\> 0.046 ng/mL) when measured in the emergency department (ED) or repeatedly within 24 hours after ED arrival."
62406265|NCT06649916|EXPERIMENTAL|Parentese|All participants will learn novel words in two conditions (parentese vs adult register) in each of the experiment (video and live word learning). In the Parentese condition, participants will listen to sentences that contain novel words in parentese.
62789657|NCT00386243|EXPERIMENTAL|Stepped Care|Study subjects randomized to this arm would receive stepped care for their pain. Stepped care involves FDA-approved analgesic therapy, a 12-week pain self-management program, and if pain does not improve, a 12-week cognitive behavioral therapy program.
62789658|NCT00851279|EXPERIMENTAL|Magnetic irrigated ablation catheter|Patients with documented VT and prior MI, in whom an ICD was implanted either for primary or secondary prevention, were recruited for endocardial mapping/ablation during VT (entrainment mapping, activation mapping) and/or substrate mapping in sinus rhythm (elimination of fractionated/late potentials, endocardial scar homogenization) with remote magnetic navigation (Niobe, Stereotaxis Inc.,St Louis, USA) and irrigated RF ablation (NaviStar RMT ThermoCool, Biosense Webster,California, USA).
62789659|NCT06363539|EXPERIMENTAL|topical steroid|topical steroid used for treatment of granuloma
62789660|NCT06363539|EXPERIMENTAL|silver nitrate|silver nitrate used for umblical granuloma treatment
62789661|NCT05747703|EXPERIMENTAL|Ria Treatment Platfrom|The Ria Treatment Platform is a telehealth approach that includes medical assessment, prescription of clinically appropriate medications for alcohol use disorder, individual and group coaching, educational video modules, and monitoring of breath alcohol concentrations through a Bluetooth-enabled breathalyzer.
62789662|NCT05747703|NO_INTERVENTION|waitlist control|Patients in this arm will not be provided treatment during the study period.
62406266|NCT06649916|ACTIVE_COMPARATOR|Adult Register|All participants will learn novel words in two conditions (parentese vs adult register) in each of the experiment (video and live word learning). In the Adult Register condition, participants will listen to sentences that contain novel words in adult register speech.
62406267|NCT04801017|EXPERIMENTAL|OT-101 + Artemisinin + Standard of Care|"OT-101 - Days 1 to 7: 140 mg/m2 daily intravenous (i.v.) infusion for 7 continuous days.~Artemisinin: Days 1 to 5: 500 mg per day for 5 days by oral"
62406268|NCT04801017|PLACEBO_COMPARATOR|Placebo + Artemisinin + Standard of Care|Artemisinin: Days 1 to 5: 500 mg per day for 5 days by oral
62406269|NCT00011037|EXPERIMENTAL|1|Participants will receive ALVAC-HIV vCP1452 at 0, 1, 3, and 6 months and MN rgp120 and Months 3 and 6
62581522|NCT03983148|PLACEBO_COMPARATOR|Placebo control|"Other than usual medical care received by children, parents in this group will receive an individual, face-to-face intervention which mimics the time and attention received by those in the experimental group. The intervention includes three sessions of educational talk to parents of children with cancer on healthy diet for cancer patients, adverse effects of cancer treatment, methods to minimize adverse effects.~Subjects in both groups will receive a booklet developed by the advisory committee, which contains a various kind of physical activities specially designed for children with cancer."
62789663|NCT03063281||SLE patient|165 SLE patients. Subgroup : 77 with active lupus and 88 in disease remission. in the active subgroup : 36 with lupus nephritis and 41 without. Biological analysis were performed.
62789664|NCT03063281||healthy patients|48 healthy patients. Biological analysis were performed.
62017622|NCT02866578|EXPERIMENTAL|Open lung protective ventilation|"* Recruitment maneuvers (30 cmH2O during 30 seconds) after intubation, after CPB initiation, before aortic declamping and at ICU arrival.~* PEEP at 8 cmH2O.~* Ultraprotective ventilation during CPB: PEEP 8 cmH2O, Tidal volume 3mL/kg, Respiratory rate 12 cycles per minute, FiO2 40%.~* Assigned intervention - Procedure: patients are randomized and ventilated with the open lung strategy from intubation to detubation."
62017623|NCT02866578|NO_INTERVENTION|Conventional strategy|No recruitment maneuvers. PEEP at 2 cmH2O. During CPB: continuous positive pressure at 2 cmH2O.
62017624|NCT05233891||Breast reconstruction after breast cancer|Women who have had/have breast cancer and will have/have had a breast reconstruction.
62017625|NCT05233891||Breast reduction|Women who have had/will have a breast reduction due to breast hypertrophy.
62017626|NCT05027191||Sevoflurane|This group will receive sevoflurane as the maintenance inhalational anesthetic.
62017627|NCT05027191||Desflurane|This group will receive desflurane as the maintenance inhalational anesthetic.
62017628|NCT05494112|EXPERIMENTAL|Amount of Celastrol Administered|Chronic evaluation of the same doses of Celastrol to each subject over 90-day period
62406270|NCT00011037|EXPERIMENTAL|2|Participants will receive ALVAC-HIV vCP1452 at 0, 1, 3, and 6 months and MN rgp120 placebo and Months 3 and 6
62581523|NCT05233748|EXPERIMENTAL|Stochastic Resonance (SR)|During this condition, participants will walk on the treadmill while receiving SR stimulation at their individual optimal intensity (SR) with and without visual perturbations.
62581524|NCT05233748|NO_INTERVENTION|No Stochastic Resonance (noSR)|During this condition, participants will walk on the treadmill while receiving no SR stimulation (noSR) with and without visual perturbations.
62789665|NCT03647644||Acute Normovolemic Hemodilution Group|All patients enrolled in the study will undergo a perioperative cardiac surgical anesthetic care plan standardized to the current institutional protocol utilized for intraoperative medication administration. If clinically indicated and appropriate per the discretion of the anesthesiologist, Acute Normovolemic Hemodilution (ANH) blood, about 2 units, will be withdrawn from the patients and stored carefully at room temperature per standard protocol. At the conclusion of cardiopulmonary bypass and after protamine administration, Coagulation Laboratory Testing will be drawn from the patients prior to re-infusing the ANH blood and after the blood has been infused per standard institutional protocol.
62789666|NCT03647644||Control Group|All patients enrolled in the study will undergo a perioperative cardiac surgical anesthetic care plan standardized to the current institutional protocol utilized for intraoperative medication administration. In this arm, ANH would be clinically appropriate, however, the anesthesiologist determined they would not have ANH preformed. At the conclusion of cardiopulmonary bypass and after protamine administration, Coagulation Laboratory Testing will be drawn from the patients and again 30 minutes later to mirror the time lapse in the ANH group.
62017629|NCT03813303|ACTIVE_COMPARATOR|Midazolam group|Midazolam and Propofol administered for sedation in colonoscopy elective patients by anesthesiologist . Complications and procedure and recovery times were recorded for comparison with the Fentanyl group.
62017630|NCT03813303|ACTIVE_COMPARATOR|Fentanyl group|Fentanyl and Propofol administered for sedation in colonoscopy elective patients by anesthesiologist .Complications and procedure and recovery times have were recorded for comparison with the Midazolam group.
62207900|NCT05665504||High-Risk for Recurrence That Accept Adjuvant Chemotherapy|Participants whose gene assay show that they are at a higher risk of recurrence will be offered to receive postoperative chemotherapy. If participants also have a special mutation on the tumor (EGFR), investigators will recommend that the participant also receive the oral anti-EGFR pill (TagrissoTM) daily for 3 years after completing the chemotherapy. The administration of standard postoperative chemotherapy is not considered part of the study. Only the results of the DetermaRx test is a part of this study.
62406271|NCT00011037|PLACEBO_COMPARATOR|3|Participants will receive ALVAC-HIV vCP1452 placebo at 0, 1, 3, and 6 months and MN rgp120 placebo and Months 3 and 6
62207901|NCT05665504||High-Risk for Recurrence That Decline Adjuvant Chemotherapy|Participants whose gene assay show that they are at a higher risk of recurrence will be offered to receive postoperative chemotherapy. If participant declines, investigators will followup with participants periodically every 6-12 months over 5 years.
62406272|NCT04217239|EXPERIMENTAL|Ivor-Lewis group|minimally invasive esophagectomy (MIE) with intrathoracic anastomosis
62406273|NCT04217239|ACTIVE_COMPARATOR|McKeown group|minimally invasive esophagectomy (MIE) with cervical anastomosis
62406274|NCT00744068|EXPERIMENTAL|1|Structured Directive Telephone Support Calls
62789667|NCT04811495|EXPERIMENTAL|patient with temporomandibular joint disorders|
62789668|NCT06327828|EXPERIMENTAL|Semi-automated computer-aided treatment|Treatment based on the dosing suggestions by a mathematical algorithm and cross-checked by the treating physician
62207902|NCT05665504||Low-Risk for Recurrence|Participants whose gene assay show that they are at a lower risk of recurrence will not be offered additional treatment after resection. Investigators will followup with participants periodically every 6-12 months over 5 years.
62406275|NCT00744068|EXPERIMENTAL|2|Structured Non-Directive Telephone Continuing Care Support
62789669|NCT06327828|ACTIVE_COMPARATOR|Usual care|Treatment based on the dosing suggestions by the treating physician
62789670|NCT00714805||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
62207903|NCT06727812|EXPERIMENTAL|Experimental arm|
62406276|NCT00744068|EXPERIMENTAL|3|Unstructured Directive Telephone Support
62406277|NCT00744068|EXPERIMENTAL|4|Unstructured Non-Directive Telephone Support
62406278|NCT00744068|NO_INTERVENTION|5|
62406279|NCT04833816|EXPERIMENTAL|Ketamin|Patient will get a bolus of ketamine at 0.1 mg / kg followed by a continuous infusion of ketamine at a dose of 0.15 mg / kg / hour
62406280|NCT04833816|PLACEBO_COMPARATOR|Placebo|Patient will get a bolus of NaCL at 0.1 mg / kg followed by a continuous infusion of NaCl at a dose of 0.15 mg / kg / hour
62406281|NCT02378870|EXPERIMENTAL|A:Osteodex|3.0 mg/kg bodyweight solution for infusion
62406282|NCT02378870|PLACEBO_COMPARATOR|B: Placebo|NaCl 0.9% solution for infusion
62406283|NCT06653556|EXPERIMENTAL|LCAR-AIO T Cells|"Experimental: Chimeric antigen receptor T cells (LCAR-AIO)~Each subject will be given a single-dose LCAR-AIO cells infusion at each dose level"
62406284|NCT03205839|EXPERIMENTAL|Acceptance-based self-help|"Participants in this group will receive the self-help booklet.~Surviving to Thriving: ACT self-help for living well with a visible difference in appearance"
62406285|NCT03205839|NO_INTERVENTION|Waitlist control group|Participants in this group will be placed onto a waitlist for the four-week intervention period.
62406286|NCT06178276||A2 level|Level of oral comprehension in italian language
62406287|NCT06178276||B2 level|Level of oral comprehension in italian language
62406288|NCT05254041|OTHER|Mentrual Cup Removal|Menstrual Cup Removal.
62789671|NCT00714805||Healthy Control|Subjects having no known ailment.
62581525|NCT06065020|EXPERIMENTAL|Intervention group|VIDACTIVA program
62581526|NCT06065020|ACTIVE_COMPARATOR|Control group|Standard Care
62581527|NCT04836325|EXPERIMENTAL|Experimental: transcranial static magnetic field stimulation (tSMS)|The intervention group will receive a treatment of Transcranial Static Magnetic Field Stimulation (tSMS) in the primary motor cortex with a duration of 30 minutes, 5 times a week, during 4 weeks, for a total of 20 sessions.
62581528|NCT04836325|SHAM_COMPARATOR|Sham transcranial static magnetic field stimulation|The placebo group will receive a dummy treatment with a duration of 30 minutes, 5 times a week, during 4 weeks, for a total of 20 sessions.
62207904|NCT01952067|EXPERIMENTAL|line-to-line reaming|Corail cemented femoral stem using line-to-line reaming and cementing technique, 28mm Alumine Biolox forte femoral head, Marathon cup
62581529|NCT02001844|PLACEBO_COMPARATOR|Control|"The control FOs, or placebo FOs was supplied to patients who were randomly included in the control group. The control FOs was made of leather board (1mm), grey Poron (1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any sort of biomechanical support, nor had it any effect on the distribution of pressure, as it was completely flat. In addition, the placebo FOs did not present with any intrinsic or extrinsic correction underneath the sub-talar-joint (STJ).~The use of black EVA as the covering material and the leather-board as a base, allowed for gathering of a dynamic impression over the 6 months of the trial."
62207905|NCT01952067|ACTIVE_COMPARATOR|standard over-reaming|Corail cemented femoral stem using standard over-reaming with 2 broach sizes, 28mm Alumine Biolox forte femoral head, Marathon cup
62581530|NCT02001844|EXPERIMENTAL|Trial Group|"Trial Group:~children who were randomly introduced into this group received the pre-formed semi-rigid FOs. The FOs were used as an off the-shelf device and subsequently customised with chair side modifications. In order to reproduce the exact same aesthetical appearance as the control FOs, grey poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs.~Furthermore, depending on the type of correction applied to the trial patient, the black EVA also allowed the correction applied on the surface of the device to be masked."
62581531|NCT00824902|EXPERIMENTAL|Tissue Elastography Imaging|Using special elastography software, probe pressed gently against prostate during routine ultrasound before prostate surgery, 10-15 minutes process.
62581532|NCT01561326|EXPERIMENTAL|Cognitive-affective barriers counseling delivered by phone|Standard care plus cognitive-affective barriers counseling delivered by phone , i.e., culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence
62581533|NCT01561326|EXPERIMENTAL|cognitive-affective barriers counseling via brochure|Standard care plus cognitive-affective barriers counseling delivered via mail-home print material
62581534|NCT01561326|ACTIVE_COMPARATOR|standard care|Cognitive-affective barriers (CAB) assessment delivered via phone; receipt of a notification letter from physician regarding abnormal Pap test result, need to undergo colposcopy, appointment date and clinic contact numbers; telephone confirmation and post-card appointment reminder
62581535|NCT04049162|EXPERIMENTAL|Blueberry Plus Exercise (BB-EX)|BB-Ex participants will consume lyophilized blueberry powder, mixed with water (18 grams, equivalent to 3/4ths cup of blueberries) with 2 daily meals (36 g/d blueberry powder total; approx. 1.5 servings/d)
62581536|NCT04049162|PLACEBO_COMPARATOR|Blueberry Placebo Plus Exercise (P-EX)|Participants randomized to P-EX treatment will consume an indistinguishable placebo powder, matched for color, flavor, consistency, and caloric content, in the same manner.
62581537|NCT01496378|EXPERIMENTAL|Problem-Solving Skills Training|In addition to standard medical care, parents in the problem-solving skills training group will receive 8 sessions (1 hour each) of individual problem-solving therapy over 8 weeks. Caregivers will be asked to complete the first training session and at least 3 subsequent sessions in person at their local treatment facility (Seattle Children's Hospital or Oregon Health and Science University). Remaining sessions will be completed via telephone.
62581538|NCT01496378|NO_INTERVENTION|Standard Care|Parents and children in the Standard Care group will continue with the care that has been prescribed for their child's pain problem by their treating physician, which may include medications, physical therapy, and mental health intervention.
62581539|NCT02754687|PLACEBO_COMPARATOR|Placebo|Placebo
62581540|NCT02754687|EXPERIMENTAL|11βmethyl nortestosterone dodecylcarbonate|11β-MNTDC in doses of 100 mg, 200 mg, 400 mg, and 800 mg
62581541|NCT03775902|EXPERIMENTAL|Healthy subjects|Two experimental day where the effect of Nicorandil (20mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.
62581542|NCT03775902|EXPERIMENTAL|Insulin resistant|Two experimental day where the effect of Nicorandil (20mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.
62735036|NCT05679661|EXPERIMENTAL|Group A (immunonutrition and oral chlorhexidine decontamination, IN&CD)|Patients will receive immunonutrition supplement of ORAL IMPACT™ 2 servings per day from the day of allocation at the preoperative anesthesia clinic until the day before surgery and oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
62207906|NCT00954980||Endovenous Sclerotherapy|For those who have been diagnosed with varicose veins of the leg and have been scheduled to undergo an endovenous sclerotherapy procedure
62207907|NCT06250244|EXPERIMENTAL|LNC1011 Dose escalation|Patients received a single dose of 1.85 GBq (50 mCi) of 177Lu-LNC1011 via intravenous injection, followed by monitoring at 3, 24, 48, 72, and 168 hours post-injection. Subsequent cohorts received a dose escalation of 0.925 GBq from the previous cohort.
62207908|NCT04425304|ACTIVE_COMPARATOR|Group counseling|
62207909|NCT04425304|EXPERIMENTAL|Group counseling + persuasive ICT support|
62207910|NCT04425304|ACTIVE_COMPARATOR|Intensive group counseling|
62207911|NCT04425304|EXPERIMENTAL|Intensive group counseling + persuasive ICT support|
62207912|NCT00667147|EXPERIMENTAL|A|
62207913|NCT00667147|EXPERIMENTAL|B|
62207914|NCT05349227|EXPERIMENTAL|Intervention Group|In addition to standard of care services at the participant's respective health system, and study specific collection of clinical, PRO, and wearable data, as well as microbiome specimens, individuals randomized to the intervention group will receive immediate enrollment to a 6-month digital health coaching program followed by 6 months monitoring via PRO, wearable, and clinical data collection. They will collect fecal microbiome samples at baseline (study enrollment) and month 6 following enrollment.
62017631|NCT04378075|EXPERIMENTAL|Vatiquinone|15 milligrams/kilogram (mg/kg) if body weight \<13 kg, and 200 mg if body weight ≥13 kg, administered orally, 3 times per day (TID) or up to 72 weeks
62017632|NCT04378075|PLACEBO_COMPARATOR|Placebo|Vatiquinone-matching placebo, administered orally, TID for up to 24 weeks followed by vatiquinone 15 mg/kg if body weight \<13 kg, and 200 mg if body weight ≥13 kg, administered orally, TID for up to 48 weeks.
62017633|NCT03886038|ACTIVE_COMPARATOR|RA patients on JAK inhibitors|RA patients treated with JAK inhibitors as a monotherapy or in combination with methotrexate/other DMARDs/prednisone for at least 3 months will receive two doses of Shingrix vaccine administrated with at least 2 months apart
62017634|NCT03886038|ACTIVE_COMPARATOR|healthy controls|healthy individuals without any rheumatic disease or not treated with any immunosupressive drug for any other condition will receive two doses of Shingrix vaccine administrated with at least 2 months apart
62017635|NCT03113539|EXPERIMENTAL|Subjects awaiting for an aortic evaluation|"Subjects already waiting for an aortic evaluation, either a first diagnostic scan or follow-up of a known aneurysm.~Each subjects will have the two CT-scans on the same day."
62017636|NCT06460623|EXPERIMENTAL|(external coccygeal mobilization+ stretching|Patients lying prone received external mobilization as part of the study. Contact was made with the sacrospinous ligament and all soft tissue on the opposite side (e.g., if the coccyx was bent to the right, contact was made on the left). If the coccyx was bent to one side, the slack was taken up and stretched for five minutes. The manipulation group underwent two 5-minute sessions of external manipulation per week over a 5-week period.Burst TENS, which administers bursts of high-frequency pulses at a low frequency (less than 10 Hz), accompanied by a 10-minute application of a hot pack. Furthermore, muscle stretching, targeting the iliopsoas and piriformis, was conducted with a 30-second hold, comprising three sets of five repetitions per set.
62017637|NCT06460623|ACTIVE_COMPARATOR|internal coccygeal mobilization+ stretching|. The investigator inserted the gloved and lubricated index finger of their right hand into the anal passage. The thumb of the investigator's other hand, also gloved but not lubricated, was placed on the dorsum of the coccyx to establish a good grasp between the two fingers. The technique involved distracting the coccyx along its long axis during the initial treatments,to correct alignment using controlled force in the coronal plane. The treatment consisted of two 5-minute sessions of external manipulation per week over a 5-week period.Burst TENS,less than 10 Hz accompanied by a 10-minute application of a hot pack. Furthermore, muscle stretching, targeting the iliopsoas and piriformis, was conducted with a 30-second hold, comprising three sets of five repetitions per set.
62207915|NCT05349227|OTHER|Wait List Control Group|In addition to standard of care services, individuals in the wait list control will be monitored via the collection of PRO, clinical, and wearable data for the first 6 months, along with fecal microbiome collection at study enrollment baseline (study enrollment) and month 6. At month 6 these individuals will be enrolled into the 6-month digital health coaching program, during which clinical, PRO and wearable data will continue to be collected. At the completion of the 6-month coaching these individuals will come off study and will not receive additional follow-up.
62017638|NCT05313243|EXPERIMENTAL|Brentuximab vedotin (brentuximab) and pembrolizumab|"All subjects are scheduled to receive up to 16 cycles of combinatorial treatment with brentuximab + pembrolizumab, followed by up to 19 additional cycles of pembrolizumab monotherapy.~After receiving 35 total doses of pembrolizumab (i.e. scheduled for 16 doses in the combinatorial setting and 8 doses as monotherapy), a subject's pembrolizumab treatment will be complete."
62017639|NCT05187962||Women receiving epidural analgesia for labor|Sensory block level check Patients will have their sensory block level checked using 3 modalities: ice, pin prick and soft touch (cotton ball).
62017640|NCT02376452|EXPERIMENTAL|RALIRI|Raltitrexed combined with irinotecan
62017641|NCT02376452|PLACEBO_COMPARATOR|FOLFIRI|5-fluorouracil,folinate combined with irinotecan
62207916|NCT05349227|NO_INTERVENTION|Household Healthy Participants|A cohort of consisting of adults without a cancer diagnosis residing in the same residence as participants, will be consented to collect fecal microbiome specimens to serve as a control for potential regional variation in microbiome dysbiosis. Up to 25 healthy controls will be enrolled per 100 participants at each study site. At sites enrolling fewer than 100 participants, an n up to 25% of the total patient enrollment sample will be approached for enrollment.
62017642|NCT02466945|OTHER|V063B-DP3003|all patients will received the study product (V063B-DP3003)
62017643|NCT04849234||New born|New born population aged 37 Weeks of Amenorrhea (SA) to 42 Weeks of Amenorrhea (SA) will be included. Their cries will be longitudinally registered.
62017644|NCT05855629|OTHER|Topical Adapalene, Benzoyl Peroxide Gel|
62207917|NCT06151574|EXPERIMENTAL|Experimental treatment arm|zongertinib only
62207918|NCT06151574|ACTIVE_COMPARATOR|Comparator arm|pembrolizumab plus platinum-pemetrexed chemotherapy
62207919|NCT04831073||Acute type A aortic dissection|Patients who underwent surgery for acute type A aortic dissection
62207920|NCT00993005|EXPERIMENTAL|A|Cicatrix
62207921|NCT00993005|PLACEBO_COMPARATOR|B|Placebo
62207922|NCT06104813||URASSM volunteer deaf men|Volunteer deaf men recruited at Nancy's URASSM Deaf Care Unit (Unité régionale d'accueil et de soins des sourds et malentendants), for individual interviews.
62207923|NCT04958239|EXPERIMENTAL|Phase 1 Arm A: BI 765179|
62207924|NCT04958239|EXPERIMENTAL|Phase 1a Arm B: BI 765179 + ezabenlimab|
62207925|NCT04958239|EXPERIMENTAL|Phase 1b Cohort 1: pembrolizumab + low dose of BI 765179|
62207926|NCT04958239|EXPERIMENTAL|Phase 1b Cohort 2: pembrolizumab + high dose of BI 765179|
62207927|NCT06511453|EXPERIMENTAL|Usual Care + Acupressure|Participants will continue ongoing usual care and administer self-acupressure treatment.
62207928|NCT06511453|NO_INTERVENTION|Usual Care Only|
62207929|NCT03621462|EXPERIMENTAL|Acquisition of Lesion Images with AIDA|Subjects presenting with atypical skin lesions referred for biopsy will have their lesion imaged using the Artificial Intelligence Dermatology Assistant (AIDA™) study device
62735037|NCT05679661|EXPERIMENTAL|Group B (immunonutrition and routine oral care, IN&RC)|Patients will receive immunonutrition supplement of ORAL IMPACT™ 2 servings per day from the day of allocation at the preoperative anesthesia clinic until the day before surgery and routine oral care.
62017645|NCT05855629|OTHER|Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule|
62017646|NCT05855629|OTHER|Topical Adapalene,Benzoyl Peroxide Gel,Oral Lactobacillus Rhamnosus,D-chiro-inositol,Inulin Capsule|
62017647|NCT00286143|ACTIVE_COMPARATOR|A|Fentanyl added to Bupivacaine via epidural catheter.
62017648|NCT06428201|ACTIVE_COMPARATOR|Control Group|
62207930|NCT00673036||1|Adults (female and male) with a acute coronary syndrome
62207931|NCT02051959|ACTIVE_COMPARATOR|Crossover 1a: anodal stimulation of M1 + sham|"6 amputees will undergo 8 active treatments of 20 min 2mA anodal stimulation of M1 localized to the contralateral amputation area followed by 8 sham treatments.~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.~Each session will last approximately one hour which will consist of:~* EEG and pain measurements~* 20 minutes of stimulation~* EEG and pain measurements after completion of stimulation"
62207932|NCT02051959|ACTIVE_COMPARATOR|Crossover 1b: sham + anodal stimulation of M1|"6 amputees will undergo 8 sham treatments followed by 8 active treatments of 20 min 2mA anodal stimulation of M1 localized to the contralateral amputation area.~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.~Each session will last approximately one hour which will consist of:~* EEG and pain measurements~* 20 minutes of stimulation~* EEG and pain measurements after completion of stimulation"
62207933|NCT02051959|ACTIVE_COMPARATOR|Crossover 2a: cathodal stimulation of M1 + sham|"6 amputees will undergo 8 active treatments of 20 min 2mA cathodal stimulation of M1 localized to the contralateral amputation area followed by 8 sham treatments.~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.~Each session will last approximately one hour which will consist of:~* EEG and pain measurements~* 20 minutes of stimulation~* EEG and pain measurements after completion of stimulation"
62017649|NCT06428201|EXPERIMENTAL|EXP group|
62017650|NCT03901248||Normoglycemia|Participant with normal blood glucose level with No Intervention
62017651|NCT03901248||Impaired Glucose Tolerance|Participants with Impaired Glucose Tolerance blood glucose level with No Intervention
62017652|NCT03901248||Type 2 Diabetes|Newly diagnosed type 2 diabetes patients with No Intervention
62406289|NCT03158857||Hepatitis C monoinfection|"Sofosbuvir 400 mg tablet once a day + Daclatasvir 60mg tablet once a day~Patients with evidence of cirrhosis will be offered treatment for 24 weeks, those who are not cirrhotic will be offered 12 weeks of treatment."
62406290|NCT03158857||Hepatitis C and HIV co-infection|"Sofosbuvir tablet 400 mg once a day + Daclatasvir tablet 90 mg once a day (increased dose in patients receiving efavirenz. Patients on an alternative HIV drug regimen will receive standard dose i.e. 60 mg)~Patients with evidence of cirrhosis will be offered treatment for 24 weeks, those who are not cirrhotic will be offered 12 weeks of treatment."
62581543|NCT05076591|EXPERIMENTAL|IMM2902|"IMM2902 Phase 1a Dose escalation: 0.03, 0.1, 0.25, 0.5, 1.0, 1.5, and 2.0 mg/kg through intravenous administration weekly up to 48 weeks.~Phase 1b Dose expansion: A disease-specific dose expansion study in patients with locally advanced (unresectable) and/or metastatic breast with HER2-overexpression (Cohort 1) or HER2-low (Cohort 2), gastric/esophageal/gastroesophageal junction (GEJ) cancer with HER2-overexpression (Cohort 3) or HER2-low (Cohort 4) and other solid tumors with HER2-overexpression (Cohort 5) is aimed at further defining safety and characterizing efficacy. Dose expansion is through intravenous administration weekly up to 48 weeks."
62017653|NCT06659523|EXPERIMENTAL|Supplement Intervention Group|31 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the intervention group, and were given for 12 weeks of one daily dose of 1.5 g powdered capsules of EPS.
62017654|NCT06659523|PLACEBO_COMPARATOR|Placebo Group|29 individuals with pre-diabetes, male and female, were recruted at one family health unit, and randomly assigned to the intervention group, and were given for 12 weeks of one daily dose of placebo supplement (cellulose).
62017655|NCT05346510|EXPERIMENTAL|ALND Group|ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS.
62017656|NCT05346510|EXPERIMENTAL|pALND Group|pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.
62017657|NCT05346510|EXPERIMENTAL|SLNB Group|SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.
62406291|NCT04281030|EXPERIMENTAL|Progressive Muscle Relaxation (PMR) Therapy|After the PMR APP is loaded onto the subject's smartphone, the subject will perform PMR in the ED and discuss the optimal time and place to practice PMR at home. All subjects will be asked to keep records of headache occurrence, side effects, compliance, and medication changes on the APP.
62581544|NCT06683859||Paranasal sinus of patients with no obvious pathology|
62581545|NCT00449137|EXPERIMENTAL|Single Arm|
62581546|NCT06489470|EXPERIMENTAL|Necrosectomy/Strokectomy|
62017658|NCT01259193|EXPERIMENTAL|Sorafenib and Zoledronic Acid|
62017659|NCT05747118||Intervention|People with type 2 diabetes or MODY in the training group
62017660|NCT05747118||Control|People with type 2 diabetes or MODY in the control group
62207934|NCT02051959|ACTIVE_COMPARATOR|Crossover 2b: sham + cathodal stimulation of M1|"6 amputees will undergo 8 sham treatments followed by 8 active treatments of 20 min 2mA cathodal stimulation of M1 localized to the contralateral amputation area.~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.~Each session will last approximately one hour which will consist of:~* EEG and pain measurements~* 20 minutes of stimulation~* EEG and pain measurements after completion of stimulation"
62207935|NCT06708572|NO_INTERVENTION|biliary atresia without GCSF|20 infants with the final diagnosis of biliary atresia type 3 (supported by the liver histology and intra-operative finding) for GCSF after Kasai operation will not receive GCSF.
62789672|NCT05326867|ACTIVE_COMPARATOR|Infiltration of 2% Lidocaine with Needle|Free needle infiltration of lidocaine can be an alternative to reduce epidural needle insertion pain. The study of Gozdemir et al. found that 10% lidocaine infiltration without needle was less painful than 2% lidocaine infiltration with a 27G needle with no significant difference in analgesia effect during epidural needle insertion. This study aimed to compare infiltration of lidocaine with and without needle for epidural needle insertion
62789673|NCT05326867|ACTIVE_COMPARATOR|Infiltration of 2% Lidocaine without Needle|Free needle infiltration of lidocaine can be an alternative to reduce epidural needle insertion pain. The study of Gozdemir et al. found that 10% lidocaine infiltration without needle was less painful than 2% lidocaine infiltration with a 27G needle with no significant difference in analgesia effect during epidural needle insertion. This study aimed to compare infiltration of lidocaine with and without needle for epidural needle insertion
62789674|NCT04367246||Affected Patients|Eligible subjects have a confirmed germline TP53 mutation or variant, OR have a family history of LFS and clinically managed as a LFS patient, OR meet LFS diagnostic criteria including Classic, Chompret, and LFL (Birch and Eeles) criteria. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time DNA sample, a blood sample for plasma and a stool sample every six months, as well as access to their residual clinical tissues.
62207936|NCT06708572|EXPERIMENTAL|biliary atresia with GCSF|20 infants with the final diagnosis of biliary atresia type 3 (supported by the liver histology and intra-operative finding) for GCSF after Kasai operation will receive GCSF.
62207937|NCT00704899|EXPERIMENTAL|2|anti-depressants
62207938|NCT00704899|EXPERIMENTAL|1|physiotherapy
62207939|NCT05172960|EXPERIMENTAL|TAVR - Main Cohort|Subjects will undergo transcatheter aortic valve replacement (TAVR)
62207940|NCT05172960|EXPERIMENTAL|TAVR - Bicuspid Registry|Subjects with bicuspid aortic valve morphology will undergo TAVR
62207941|NCT06502327|EXPERIMENTAL|Instructions A|"The Instructions A is a four-step, coloured illustrated brochure with images of newborn mannequins and supplies for laryngeal mask insertion."
62207942|NCT06502327|ACTIVE_COMPARATOR|Instructions B|"The Instructions B is a six-step, black-and-white illustrated brochure with images of adults and supplies for laryngeal mask airway insertion."
62207943|NCT01575600|ACTIVE_COMPARATOR|10 mL/kg/h lactated Ringer's solution|Group 1, 10 mL/kg/h lactated Ringer's solution
62207944|NCT01575600|EXPERIMENTAL|30 mL/kg/h lactated Ringer's solution|Group 2, 30 mL/kg/h lactated Ringer's solution
62207945|NCT06164587|EXPERIMENTAL|Patients with geographic atrophy associated with age-related macular degeneration|Kamuvudine-8 treatment (0.3 mg) at baseline visit and week 13 visit, in one eye of each subject, for a total of 5 subjects. Patients will be followed for 26 weeks after baseline visit injection.
62207946|NCT04757662|EXPERIMENTAL|Tadalafil|"* Tadalafil will be given orally once daily for a total of 60 days at a weight-normalized dose as follows:~  * 10 mg/day if weight ≤63.5 kg~ * 15 mg/day if weight \>63.5 kg and ≤104.3 kg~ * 20 mg/day for weight \>104.3 kg~* Standard of care fractionated radiation therapy (RT) to 60 Gy in 30 daily fractions will be administered in this study.~* Concurrent temozolomide (TMZ) will be administered as per standard of care, i.e., continuously (Monday through Sunday) from Day 1 of RT to the last day of RT at a daily oral dose of 75 mg/m\^2 at the discretion of treating medical oncologist.~* Adjuvant therapy will administered as per standard of care. Typically, this consists of adjuvant TMZ initiated 4 to 6 weeks after completion of RT for 6 cycles at 150-200 mg/m\^2 PO per day on Days 1-5 of every 28-day cycle. Tumor-treating fields or Optune device (Novocure) as per routine clinical care during adjuvant TMZ is permitted at the discretion of the treating physician."
62207947|NCT02837003||Experimental: Aspirin|Aspirin treatment for 3 months after the Ultimaster sirolimus-eluting stent implantation.
62207948|NCT02837003||Experimental: Thienopyridine|Thienopyridine treatment for 3 months after the Ultimaster sirolimus-eluting Stent implantation.
62207949|NCT06251284|EXPERIMENTAL|Placebo - Control|Participants in this group receive sham oxytocin on the first study day.
62207950|NCT06251284|EXPERIMENTAL|Control - Placebo|Participants in this group receive sham oxytocin on the second study day
62207951|NCT06709404|EXPERIMENTAL|Group 1 (Telehealth intervention)|Participants receive telehealth navigation intervention which may consist of referral to specific resources for caregiving experience over 1 hour 1-4 weeks prior to patient's surgery.
62207952|NCT06709404|ACTIVE_COMPARATOR|Group 2 (Usual Care)|Participants receive standard caregiving experience on study.
62789675|NCT04367246||Family Members|Biological relative of subjects with germline TP53 mutation or variant (LFS), including first degree (siblings, parents) and second degree (grandparents, aunts, uncles) relatives. Negative for germline TP53 mutation or variant. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time DNA sample, a stool sample, as well as access to their residual clinical tissues.
62207953|NCT02005770|EXPERIMENTAL|Sevoflurane|General anesthesia using Sevoflurane
62207954|NCT02005770|ACTIVE_COMPARATOR|Propofol|General anesthesia using propofol TCI
62207955|NCT00669279|EXPERIMENTAL|Carvedilol CR|
62207956|NCT00669279|EXPERIMENTAL|Atenolol|
62207957|NCT01341054|EXPERIMENTAL|mouthwash with Chamomilla extract 1%|The Chamomile recutita mouthwash 1% was administered two times daily for 30 days.
62207958|NCT01341054|EXPERIMENTAL|mouthwash with Chamomilla extract 2%|The Chamomile recutita mouthwash 2% was administered two times daily for 30 days.
62207959|NCT01341054|ACTIVE_COMPARATOR|standard oral care protocol|The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12%; oral hygiene teaching. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.
62207960|NCT01341054|EXPERIMENTAL|mouthwash with Chamomilla extract 0.5%|The Chamomile recutita mouthwash 0.5% was administered two times daily for 30 days, starting on the first day of chemotherapy.
62017661|NCT02717793|EXPERIMENTAL|isometric muscle strength|"isometric muscle strength was measured with a digital hand-held dynamometer. The digital hand-held dynamometer was held by the therapist against the flexor aspect of the distal forearm of the subject, on the wrist joint. Subject was asked to maintain the position and a break test was done with progressive loading of 5 seconds given by the tester. The peak isometric strength was recorded by a second tester at the end of 5 seconds. A standardised instructions and verbal encouragement was given to the subject for motivation. Subject as well as the tester was blinded to the values recorded on the digital hand-held dynamometer. An average of three measurements (with a rest period of 4 minutes in between each trial session) was recorded for the analysis. After each trial session, the rate of perceived exertion (RPE) was asked to the subject using the 1-10 Borg rating of perceived exertion scale"
62017662|NCT02717793|EXPERIMENTAL|1RM measurement of muscle strength|1RM measurement was done using the Brzycki 1RM prediction equation. In first testing session, subject was instructed to perform a general warm up for 5 minutes. Thereafter, the subject was asked to perform 10 repetitions of the movement using the amount of resistance that the subject felt she will be able to lift for only less than 10 times. The selection of the weight is made based on a list of weights provided (1kg to 10kg). When the subject performed the movement for 10 times or more, then the resistance was increased 1kg at a time, until the subject can perform only 9 or fewer repetitions of the movement correctly throughout the range of motion. A 3 minutes rest period was given to the subject before the new attempt was done with the increased weight. A standardized verbal encouragement was provided for motivation
62017663|NCT02710630|ACTIVE_COMPARATOR|Dabigatran etexilate capsule|
62207961|NCT03397043|EXPERIMENTAL|Healthy females|All participants receive the intervention: Protein intake (dose). This consists of varying levels of dietary protein intakes, in the form of crystalline amino acids, ranging from 0.2-3.0 g/kg/d
62207962|NCT05421663|EXPERIMENTAL|JNJ-90014496|Participants will receive intravenous (IV) infusion of autologous JNJ-90014496 on Day 1.
62207963|NCT04224012|NO_INTERVENTION|Conventional therapy group (control group)|patients of the control Group receive usual care
62207964|NCT04224012|EXPERIMENTAL|Interventional group (training group)|Specialized exercise and respiratory therapy for patients with pulmonary hypertension
62207965|NCT03047395|EXPERIMENTAL|Risankizumab|Participants will receive risankizumab administered by subcutaneous injection.
62207966|NCT04120571|EXPERIMENTAL|experimental|Sleep Audiological Intervention Device (SleepAID)
62581547|NCT06601101|ACTIVE_COMPARATOR|Group A|Insulin eye drops 50 IU/ml (1 drop every 6 hours)
62789676|NCT04367246||Household Members|Household member of subjects with germline TP53 mutation or variant (LFS), sharing a living space (apartment or free-standing home) for at least 6 months prior to study enrollment. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time stool sample.
62017664|NCT02710630|EXPERIMENTAL|Dabigatran etexilate tablet A1|
62017665|NCT02710630|EXPERIMENTAL|Dabigatran etexilate tablet B1|
62207967|NCT04120571|SHAM_COMPARATOR|control|no sound
62017666|NCT02710630|EXPERIMENTAL|Dabigatran etexilate tablet C1|
62017667|NCT02710630|EXPERIMENTAL|Dabigatran etexilate tablet D1|
62207968|NCT06727591|EXPERIMENTAL|Horizontal Ridge Augmentation with Split Bone Block|
62789677|NCT01347242|EXPERIMENTAL|study treatment|autologous CD34 positive cells transduced with a lentiviral vector containing the human WAS gene
62207969|NCT03596762|EXPERIMENTAL|160 mg Elinzanetant (BAY3427080)|Participants received 4x40 mg elinzanetant capsules.
62207970|NCT03596762|EXPERIMENTAL|120 mg Elinzanetant (BAY3427080)|Participants received 3x40 mg elinzanetant capsules and 1 placebo capsule.
62789678|NCT02117180|OTHER|FODMAP's diet|A diet low in Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols (FODMAPs)
62789679|NCT02558777|EXPERIMENTAL|Intervention Group|Multicomponent nurse-led intervention (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain)
62207971|NCT03596762|EXPERIMENTAL|80 mg Elinzanetant (BAY3427080)|Participants received 2x40 mg elinzanetant capsules and 2 placebo capsules.
62207972|NCT03596762|EXPERIMENTAL|40 mg Elinzanetant (BAY3427080)|Participants received one 40 mg elinzanetant capsule and 3 placebo capsules.
62207973|NCT03596762|PLACEBO_COMPARATOR|Placebo|Participants received four placebo capsules orally once daily in the evening before bedtime.
62207974|NCT06622655|EXPERIMENTAL|Intervention Arm|Home rehabilitation
62207975|NCT06622655|NO_INTERVENTION|Control Group|
62207976|NCT02234791||gene mutation|
62207977|NCT00418769|EXPERIMENTAL|Nilotinib Tablet Formulations|
62581548|NCT06601101|PLACEBO_COMPARATOR|Group B|Placebo eye drops of 0.5% Methylcellulose (1 drop every 6 hours)
62789680|NCT02558777|NO_INTERVENTION|Control Group|Usual care
62789681|NCT05303818|EXPERIMENTAL|post-operative patients with colonic cancer|Patients will receive Rivaroxaban 10mg/daily for 28 days after surgery. Only one arm.
62789682|NCT03095729||Healthy|40 healthy subjects, during quiet breathing and under an inspiratory load (inspiratory threshold loading)
62207978|NCT00418769|ACTIVE_COMPARATOR|Established Nilotinib Capsule Formulation|
62207979|NCT04138108|EXPERIMENTAL|Experimental Group|Two sessions of psychoeducation were given to the parents in the experimental group.
62207980|NCT04138108|NO_INTERVENTION|Control Group|The parents in the control group did not undergo any intervention and the children of the parents in this group continued their current treatment plans.
62207981|NCT04224974|EXPERIMENTAL|Other: Usual Care|
62789683|NCT03095729||Ondine syndrome|12 patients presenting with central hypoventilation syndrome or Ondine's curse syndrome, during spontaneous breathing and with Non Invasive Ventilation
62207982|NCT04224974|EXPERIMENTAL|Behavioral: Usual Care + EASE Intervention-psy|EASE Intervention = EASE-psy + EASE-phys
62406292|NCT04281030|ACTIVE_COMPARATOR|Monitored Usual Care (MUC)|Subjects will be given general educational information consisting of basic migraine information such as evidence-based ways to treat migraine: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently. Any migraine treatment decisions on discharge will be left up to the ED attending. The research coordinator (RC) will load the APP onto the subjects' smart phones but the PMR component will be blocked on the version of the APP that the MUC subjects receive. All subjects will be asked to keep records of headache occurrence, side effects, compliance, and medication changes on the APP.
62207983|NCT03553199|EXPERIMENTAL|TRS|TRS, Tissue resection system
62406293|NCT00673712|EXPERIMENTAL|Continuous Sternal Block|Continuous Sternal block with infusion of local anesthetic via ON-Q Painbuster Silver Soaker system
62406294|NCT00673712|ACTIVE_COMPARATOR|Opioid based analgesia|Opioid based analgesia including Patient controlled analgesia plus IM, Oral narcotics and other analgesics
62406295|NCT04688034|EXPERIMENTAL|OP-724 400 mg / 20 mL / vial (20 mg / mL)|"Dose: \[Cohort 1\] 140 mg/m2/4 hours (starting dose) , \[Cohort 2\] 280 mg/m2/4 hours~Administration method: In the single administration, the safety of concomitant use with the investigational drug and antiretroviral drug will be confirmed and then the cycle administration will be started. For the single administration, at 14 days before the first cycle of administration, the dose planned for the first cycle with continuous intravenous administration for 4 hours will be administrated once. When an integrase inhibitor is used in combination as a key drug for antiretroviral drugs, it should be administered at the same time as the start of investigational drug administration only after the single administration. For the cycle administration, the continuous intravenous administration for 4 hours twice a week is defined as one cycle, and 12 cycles (12 weeks in total) will be performed."
62207984|NCT05677919|EXPERIMENTAL|Treatment (pirtobrutinib and venetoclax)|Patients receive pirtobrutinib and venetoclax PO on study. Patients also undergo CT, MRI, and PET scans during screening and on study. Patients also undergo bone marrow aspiration and bone marrow biopsy, and collection of blood, tissue, stool, and saliva samples on study.
62207985|NCT00835744|PLACEBO_COMPARATOR|A|Patients undergo a standard treatment with clomiphene citrate from day 3 until day 7 of the cycle at a dose of 50 mg daily. If no reaction on day 13 of the cycle, an increased dose of 100 mg of clomiphene citrate is administered from day 13 until day 17 of the cycle.
62207986|NCT00835744|ACTIVE_COMPARATOR|B|Patients undergo a standard treatment with clomiphene citrate from day 3 until day 7 of the cycle at a dose of 50 mg daily. If no reaction on day 13 of the cycle, gonadotropins (75IU) are administered from day 13 until day 17 of the cycle.
62207987|NCT00814177|EXPERIMENTAL|No change|Intervention Drug warfarin no change in the dose is performed
62581549|NCT02484781|ACTIVE_COMPARATOR|Total Hip Arthroplasty|Gait analysis on a trendmill of patients with a well functioning total hip arthroplasty on a trendmill
62581550|NCT02484781|ACTIVE_COMPARATOR|Resurfacing Hip Arthroplasty|Gait analysis on a trendmill of patients with a well functioning resurfacing hip arthroplasty on a trendmill
62789684|NCT03095729||Amyotrophic Lateral Sclerosis|30 patients presenting with Amyotrophic Lateral Sclerosis during spontaneous breathing and with Non Invasive Ventilation
62789685|NCT02697318|OTHER|Professional Administration|Instillation of Timolol maleate 0.5% ophthalmic solution (or participant's own glaucoma medication) administered by a professional, using the standard clinical method.
62207988|NCT00814177|ACTIVE_COMPARATOR|Change|Intervention Drug Warfarin One dose increased if subtherapeutic level; one dose deleted or reduced if supratherapeutic level
62789686|NCT02697318|OTHER|Self-Administration (new method)|Instillation of Timolol maleate 0.5% ophthalmic solution (or participant's own glaucoma medication) self-administered by the participant, using the new proposed method.
62789687|NCT03779048|ACTIVE_COMPARATOR|Behavioral Treatment + Placebo|"All participants will complete an initial 4-week behavioral treatment (BT) run-in. Participants with suboptimal early weight loss in the BT run-in will then be randomly assigned to 24 additional weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg) in a double-blinded fashion. Both treatment groups will continue to attend individual BT sessions and will take a once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period.~Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial."
62789688|NCT03779048|ACTIVE_COMPARATOR|Behavioral Treatment + Medication|"All participants will complete an initial 4-week behavioral treatment (BT) run-in. Participants with suboptimal early weight loss in the BT run-in will then be randomly assigned to 24 additional weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg) in a double-blinded fashion. Both treatment groups will continue to attend individual BT sessions and will take a once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period.~Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial."
62789689|NCT02799498|ACTIVE_COMPARATOR|A-etanercept (ENBREL®) by auto-injector|Single dose of etanercept (ENBREL®) in a pre-filled syringe administered with an auto-injector device manufactured by Scandinavian Health Limited (SHL)
62789690|NCT02799498|OTHER|B-etanercept (ENBREL®) by Manual injection|Single dose of etanercept (ENBREL®) in a syringe given by manual injection (reference treatment)
62207989|NCT02753543|EXPERIMENTAL|Chidamide plus previous chemotherapy|Chidamide 20mg/d Biw p.o. on d1,4,8,11 for of each cycle for 3 cycles
62207990|NCT05440851|OTHER|Ultra-protective ventilation facilitated by extracorporeal carbon dioxide removal (ULTIMATE) domain|Patients with acute hypoxemic respiratory failure in the high elastance state will be randomized to ultra-protective ventilation facilitated by extracorporeal carbon dioxide removal or to conventional lung-protective ventilation.
62207991|NCT05440851|OTHER|Invasive Mechanical Ventilation (IMV) Strategies domain|Patients on invasive mechanical ventilation in the low elastance, high elastance, and ECLS states will be randomized to one of two or three mechanical ventilation interventions (including conventional lung-protective ventilation as a control group). Most sites will randomize patients to two arms (one of which is the control group, LPV). A subset of sites will randomize patients to all three arms.
62017668|NCT02710630|EXPERIMENTAL|Dabigatran etexilate tablet E1|
62207992|NCT05440851|OTHER|The Corticosteroid Early and Extended (CORT-E2) Randomized Controlled Trial domain|Patients with acute hypoxemic respiratory failure (AHRF) requiring invasive or non-invasive respiratory support will be randomized in the Early Cohort to receive corticosteroid or usual care without corticosteroids. Patients treated with corticosteroids who still require invasive or non-invasive respiratory support after 10 days will be randomized in the Extended Cohort to extending corticosteroid use or stopping corticosteroids after 10 days.
62017669|NCT05929014|ACTIVE_COMPARATOR|Active bilateral-tDCS|Participants will be received different intensities which are 1 mA, 1.5 mA and 2 mA for 20 minutes during performed serial reaction time task. The tDCS will be set with bilateral montage which applied anodal electrode over left hemisphere and cathodal electrode over right hemisphere.
62207993|NCT06723886|EXPERIMENTAL|Olive pomace oil|Consumption of olive pomace oil as the only dietary fat.
62207994|NCT06723886|ACTIVE_COMPARATOR|High-sunflower olive oil|Consumption of high-oleic acid sunflower oil as the only dietary fat.
62207995|NCT04141059|EXPERIMENTAL|Oligopin|Intervention group that will intake 100 mg of Oligopin® for 6 weeks
62207996|NCT04141059|PLACEBO_COMPARATOR|Placebo|Placebo group that will intake 250 mg of Maltodextrin
62207997|NCT02149953|EXPERIMENTAL|Glycine intake|Dietary supplement: Glycine intake
62207998|NCT01483547||Neurosurgical|
62207999|NCT01483547||Non-neurosurgical|
62208000|NCT05017103|EXPERIMENTAL|Treatment (sintilimab)|Patients receive sintilimab IV over 30-60 minutes on day 1. Cycles repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
62208001|NCT05750498||Children and adolescents with Autoimmune Liver Disease|Pediatric patients with a diagnosis of autoimmune hepatitis, or primary sclerosing cholangitis.
62208002|NCT03837977|ACTIVE_COMPARATOR|nal-IRI, 5-FU and racemic folinic acid|liposomal Irinotecan (naI-IRI) (80mg/m\*2 intravenously over 90 minutes (± 10 minutes) prior to Fluorouracil (5-FU) 5-FU 2400 mg /m\*2 BSA infusor over 46 hours racemic folinic acid (as per local standard practice) every 14 days
62208003|NCT03837977|ACTIVE_COMPARATOR|docetaxel|75mg/m\*2 intravenously over 60 minutes) every 21 days\]
62208004|NCT04853641||Living Donor Liver Transplant Recipient|Patients who have received a living donor liver transplant.
62208005|NCT04853641||Deceased Donor Liver Transplant Recipient|Patients who have received either a Deceased by Circulatory Death or Deceased by Brain Death Liver Transplant
62208006|NCT04417595|EXPERIMENTAL|Fish Oil|Participants allocated to n-3 LCPUFA supplementation will be instructed to take four 1000 mg n-3 LCPUFA capsules (Metagenics™) daily. This will provide a total daily dose of 4000 mg n-3 LCPUFAs (2840 EPA and 1160 DHA).
62208007|NCT04417595|PLACEBO_COMPARATOR|Olive Oil|Oleic acid (olive oil) capsules have a similar texture, size, color, and consistency to EPA capsules. Participant will be instructed to take four 100mg olive oil capsules
62208008|NCT06310356|EXPERIMENTAL|continuous glucose monitoring|continuous use of realtime-continuous glucose monitoring with Freestyle Libre 3
62208009|NCT06310356|ACTIVE_COMPARATOR|self monitoring of blood glucose with glucometer|self monitoring of blood glucose with glucometer, at least 2 days per week if treated with lifestyle and daily if additional treatment with insulin is started
62208010|NCT01608126|ACTIVE_COMPARATOR|Combined Cervical Block|
62017670|NCT05929014|SHAM_COMPARATOR|Sham bilateral-tDCS|Participants will be received sham of bilateral tDCS during performed serial reaction time task.
62017671|NCT05929014|ACTIVE_COMPARATOR|Active cathodal-tDCS|Participants will be received different intensities which are 1 mA, 1.5 mA and 2 mA for 20 minutes during performed serial reaction time task. The tDCS will be set with cathodal montage which applied cathodal electrode over left hemisphere and anodal over right orbit.
62208011|NCT01608126|ACTIVE_COMPARATOR|Median Cervical Block US guided|
62208012|NCT06287203|ACTIVE_COMPARATOR|Risk estimates + Psychoeducation|Participants in this condition will complete the prevention program in which individuals receive their personalized risk estimates, followed by psychoeducation about ways to reduce substance use and associated harm.
62789691|NCT01258023|EXPERIMENTAL|transplant recipients|Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation
62208013|NCT06287203|ACTIVE_COMPARATOR|Risk estimates + Online CBT Modules|Participants in this condition will complete the prevention program in which individuals receive their personalized risk estimates, followed by on-line cognitive behavioral therapy (CBT)-based modules to assist with controlling substance use.
62208014|NCT06287203|ACTIVE_COMPARATOR|Risk estimates + Genetic Counselor|Participants in this condition will complete the prevention program in which individuals receive their personalized risk estimates, followed by a follow-up appointment with a genetic counselor.
62208015|NCT06287203|OTHER|Waitlist Control - Psychoeducation Only|Participants in this condition will not receive their personalized risk estimates until the end of the study. They will receive psychoeducation about ways to reduce substance use and associated harm at the time that the active conditions receive their estimates and associated follow-up content.
62208016|NCT05816772|EXPERIMENTAL|Endosequence Bio ceramic based Sealer|Sealer was introduced into the canal by coating the master gutta-percha point (Endosequence, Brasseler USA, Gutta Percha ) with sealer, followed by cold lateral compaction using a finger spreader # 30 and # 35 (Saybron Endo) with decreasing working length by 1-2 mm. A heated plugger was used to sear off GuttaPercha coronal to canal orifice.Recordings of postoperative pain was obtained at 24 hours, 48 hours, 72 hours and 7 days after obturation with aid of the Visual Analogue Scale.
62208017|NCT05816772|ACTIVE_COMPARATOR|Sealapex calcium hydroxide based sealer|Sealer was introduced into the canal by coating the master gutta-percha point (Dentsply Sirona, GuttaPercha Conform fit) with sealer, followed by cold lateral compaction using a finger spreader # 30 and # 35 (Saybron Endo) with decreasing working length by 1-2 mm. A heated plugger was used to sear off GuttaPercha coronal to canal orifice.Recordings of postoperative pain was obtained at 24 hours, 48 hours, 72 hours and 7 days after obturation with aid of the Visual Analogue Scale.
62208018|NCT02958046|EXPERIMENTAL|Lansoprazole/Domperidone|DUOLANS 30/30 mg SR tablet per oral, one tablet daily
62208019|NCT00616902|ACTIVE_COMPARATOR|Paricalcitol Injection 4 mcg/mL|Paricalcitol Injection 4 mcg/mL given intravenously 3 times per week during dialysis
62208020|NCT00616902|PLACEBO_COMPARATOR|Placebo Injection 4 mcg/mL|Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
62789692|NCT06422013|ACTIVE_COMPARATOR|GTB1|Once-daily, once a packet, for 12 week
62017672|NCT05929014|SHAM_COMPARATOR|Sham cathodal-tDCS|Participants will be received sham of cathodal tDCS during performed serial reaction time task.
62017673|NCT05087940||Resistant hypertension|The adult patients with resistant hypertension which is defined as casual blood pressure during clinical examination of more than 140/90 mmHg despite treatment with optimal or best-tolerated doses of three or more drugs, which should include a diuretic, typically an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB), and a calcium channel blocker (CCB). All reference blood pressures will be taken as a mean of the 2nd and 3rd measurements in physician's office during a single examination, measured at least 3 min apart. The following add-on therapy is available in Serbia, where the study is conducted: an aldosterone receptor blocker (e.g. spironolactone), a loop diuretic (e.g. furosemide), a thiazide in large daily dose, an alpha 1 selective blocker and a beta 1 selective blocker.
62017674|NCT03430466|EXPERIMENTAL|Durvalmab&Tremelimumab&Fulvestrant|Durvalmab\&Tremelimumab\&Fulvestrant
62208021|NCT05138744|EXPERIMENTAL|Virtual reality treatment|Use of google maps with virtual reality to virtually situate the participants into scenarios that are motivating for them (i.e., the beach, a mountain, a park, etc.) at their choice.
62208022|NCT01486290|EXPERIMENTAL|Geriatric Diabetes Team Intervention|The subjects in this group underwent evaluation for barriers to self care by a diabetes educator well versed with age specific barriers. After consideration of patient clinical, function, and psychosocial background, a geriatric diabetes team devised strategy to help patients cope with respective barriers. An office based diabetes diabetes educator conveyed the strategy to patient and caregivers viz phone calls. the educator called study participants up wot eleven times over a sex month period.
62789693|NCT06422013|PLACEBO_COMPARATOR|Placebo|Once-daily, once a packet, for 12 week
62208023|NCT01486290|NO_INTERVENTION|Atention Control Arm|The subjects in the group received similar, in person contact, as the intervention group. an educator, separate from the one involved in the intervention team, called patients in this group for a total of eleven times within the first six months. The Phone calls were focused toward general discussion without any diabetes related advice.
62789694|NCT05003258|OTHER|Patients with RVO|Dexamethasone Intravitreal Implant is used in patients with Macular ar edema due to retinal vein occlusion either from the start or after unsatisfactory response to anti - VEGF
62789695|NCT02434419|EXPERIMENTAL|PENS with training|Patients undergoing percutaneous electrostimulation (PENS) of the pectoral muscle combined with specific training during 12 weeks postoperatively
62208024|NCT04484116||Succesful surgery|PTH 24 hours after surgery \<150pg/mL
62208025|NCT04484116||Unsuccessful surgery|PTH 24 hours after surgery \>150pg/mL
62208026|NCT02334475|EXPERIMENTAL|GROUP (P)|Ultrasound guided sacroiliac joint injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml) per course. Single injection per course is being given.
62789696|NCT02434419|ACTIVE_COMPARATOR|Specific training|Patients undergoing specific training during 12 weeks postoperatively
62789697|NCT02434419|NO_INTERVENTION|No intervention|No specific treatment was assigned to these patients postoperatively
62789698|NCT03083301||Cardiac insufficiency|Patients with cardiac insufficiency (i.e in NYHA class III or IV) or refractory to optimal medical treatment (155 patients since 2003) in the Brugmann University Hospital, in the cardiac surgery department
62789699|NCT05613829||patients with burn injury|
62789700|NCT02638649||subjects who call 911 for dyspnea|All subjects who call 9-1-1 for difficulty breathing will have the potential to be enrolled in the study.
62208027|NCT02334475|ACTIVE_COMPARATOR|GROUP (S)|Ultrasound guided sacroiliac joint injection of 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml). Single injection per course is being given.
62017675|NCT06497517|EXPERIMENTAL|Sequence 1|In sequence 1, eligible participants will be randomly assigned to 1 of 2 sequences to receive single dose of GSK5464714- Camlipixant on Day 1 under fasting condition (Treatment A), followed by single dose of GSK5464714 in fed condition (Treatment B). There will be a washout period of minimum 7 days between each period.
62017676|NCT06497517|EXPERIMENTAL|Sequence 2|In sequence 2, eligible participants will be randomly assigned to 1 of 2 sequences to receive single dose of GSK5464714- Camlipixant on Day 1 in fed condition (Treatment B), followed by single dose of GSK5464714 under fasting condition (Treatment A). There will be a washout period of minimum 7 days between each period.
62208028|NCT06085495|OTHER|Improved approach mechanical thrombectomy (PMT) group|
62208029|NCT06085495|NO_INTERVENTION|Traditional simple anticoagulant group|
62208030|NCT06013696|ACTIVE_COMPARATOR|Pediatric UC subjects treated with 5ASA compunds|Each subject will provide a fresh urine sample in an empty sterile plastic cup. Urinalysis will be performed to check for macro- or micro-hematuria or signs of infection. We will take 10mL of the urine sample and add 1mL of transparent (colorless) household bleach (≤5% sodium hypochlorite). The color of the urine before and 5 minutes after adding the bleach will be recorded.
62208031|NCT06013696|PLACEBO_COMPARATOR|Pediatric UC subjects not treated with 5ASA compunds (any other treatments is allowed)|Each subject will provide a fresh urine sample in an empty sterile plastic cup. Urinalysis will be performed to check for macro- or micro-hematuria or signs of infection. We will take 10mL of the urine sample and add 1mL of transparent (colorless) household bleach (≤5% sodium hypochlorite). The color of the urine before and 5 minutes after adding the bleach will be recorded.
62208032|NCT02437461|ACTIVE_COMPARATOR|single dose 20 mg|Intraarticular injection of triamcinolone hexacetonide
62208033|NCT02437461|EXPERIMENTAL|single dose 40 mg|Intraarticular injection of triamcinolone hexacetonide
62208034|NCT02951689|EXPERIMENTAL|Probiotic|Multi-strain probiotic
62208035|NCT02951689|PLACEBO_COMPARATOR|Placebo|Maltodextrin placebo
62208036|NCT06267092|OTHER|Part A|Participants will not get any medicine during this study.
62208037|NCT06267092|EXPERIMENTAL|Part B|Participants will receive CagriSema or placebo (Dose 1,2,3,4) for 16-weeks dose-escalation period followed by 37-weeks intervention period on CagriSema or placebo (Dose 5) that includes a 12-day standardised energy intake period.
62208038|NCT03064217|EXPERIMENTAL|Making impression at surgery|Making impression at surgery
62208039|NCT03064217|NO_INTERVENTION|Making impression 8 weeks after surgery|
62406296|NCT03331952||Invasive pneumococcal disease study (PCV-D)|"Prospective study of children with invasive pneumococcal disease / probable bacterial meningitis (PCV-D)~Clinical procedures~At study enrolment:~* Admission clinical findings / laboratory results will be recorded.~* A questionnaire will be administered to the parent / guardian or caretaker to assess the child's immunisation status, household structure, environmental exposures, and recent antimicrobial use.~Radiology procedures As part of routine clinical management at AHC, a digital chest radiograph (CXR) may be performed as part of a child's diagnostic work up. CXRs will be read and interpreted primarily by the AHC radiologists. All CXR will subsequently be re-read by two study clinicians and interpreted according to the WHO paediatric radiologic pneumonia criteria.~Laboratory procedures~• Residual routine clinical specimens further analysed as part of the study protocol:~* Blood and cerebrospinal fluid culture specimens.~* EDTA / serum specimens.~* Urine."
62017677|NCT00828646|EXPERIMENTAL|BMS-708163 - Panel 1|(Age 20-45 years)
62017678|NCT00828646|EXPERIMENTAL|BMS-708163 - Panel 2|(Age 20-45 years)
62017679|NCT00828646|EXPERIMENTAL|BMS-708163 - Panel 3|(age 65 or above)
62017680|NCT00828646|EXPERIMENTAL|BMS-708163 - Panel 4|(age 65 or above)
62017681|NCT01010581|EXPERIMENTAL|SC12267 (4SC-101) + Methotrexate|
62017682|NCT01010581|PLACEBO_COMPARATOR|Placebo + Methotrexate|
62208040|NCT03283540||TaTME|Trans-anal Total Mesorectal Excision (TaTME) is the visualization and dissection of the rectum located deep in the pelvis. In it, a trans-anal port is inserted for the duration of the surgery. Multiple surgical tools are then introduced through the port and the rectum is resected from down-to-up under direct visualization.
62208041|NCT03283540||abdominal TME|"Total Mesorectal Excision involves resecting the rectum along with its surrounding Mesorectal plane. If the anal sphincter is spared, this surgery is named Low Anterior resection (LAR) for rectal cancer. Traditionally, TME dissection in LAR is performed through open or laparoscopic incisions(s) made in the abdominal wall. Mobilization of the splenic flexure along with sigmoid dissection follows. Lastly, the rectum is dissected in accordance with TME principles from above. This up-to-down approach is known as abdominal TME."
62208042|NCT01351467||Parkinson's disease patients|People diagnosed with Parkinson's disease by a physician
62208043|NCT03887780||Treatment|Rivaroxaban treatment-naïve patients, at least 18 years of age and presenting with NVAF will be considered eligible for participation in this study only after the decision to treat with rivaroxaban has been made by the treating physician.
62208044|NCT05465447||Toric IOL|This study included the patients who underwent cataract surgery with the toric IOL(SN6ATX) implantation. Preoperative and postoperative corneal astigmatism, short-term and long-term postoperative total astigmatism were the main outcome indicators. Preoperative corneal astigmatism (Pentacam and IOLMaster) would be obtained from outpatient and inpatient medical records, and the IOL axis should be calculated before surgery. Short-term postoperative (1-3 months) subjective optometry results; Long-term postoperative (3-5 years) corneal astigmatism (Pentacam and IOLMaster), subjective optometry results, and axial lens would be observed using SSOCT after pupil dilation.
62208045|NCT00682981|EXPERIMENTAL|Phase I A|Obatoclax for 3 hours for 3 days with carboplatin/etoposide.
62208046|NCT00682981|EXPERIMENTAL|Phase I B|Obatoclax for 24 hours for 3 days with carboplatin/etoposide.
62208047|NCT00682981|EXPERIMENTAL|Phase II A|Obatoclax for 3 hours for 3 days with carboplatin/etoposide.
62208048|NCT00682981|ACTIVE_COMPARATOR|Phase II B|Carboplatin/etoposide without continued study treatment
62208049|NCT03651778||Suspected spiked drink exposure, no assault|
62208050|NCT03651778||Suspected spiked drink exposure, sexual assault|
62208051|NCT03651778||Suspected GHB exposure|
62208052|NCT02636725|EXPERIMENTAL|Axitinib Plus Pembrolizumab Group|Participants in this group will receive combination treatment of Axitinib plus Pembrolizumab for up to 2 years followed by monotherapy of Axitinib until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
62208053|NCT02636725|EXPERIMENTAL|Axitinib Plus Pembrolizumab Expansion Cohort|Expansion cohort for up to 10 additional patients with alveolar soft part sarcoma. Participants in this group will receive combination treatment of Axitinib plus Pembrolizumab for up to 2 years followed by monotherapy of Axitinib until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
62208054|NCT04773743|EXPERIMENTAL|chronic nonspecific low back pain|Remotely delivered yoga intervention
62208055|NCT06390839|EXPERIMENTAL|Treatment (palbociclib)|Patients receive palbociclib 125mg PO QD on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI and blood sample collection throughout the trial. Patients may also undergo a biopsy on study.
62208056|NCT06117852||Group A|Participants with CKD and High Proteinuria
62208057|NCT06117852||Group B|Participants with CKD and Hypertension
62208058|NCT05512143|EXPERIMENTAL|TMS|Participants will receive 30 sessions (5 days/week, 6 consecutive weeks) of active TMS to the left dorsolateral prefrontal cortex (DLPFC). Right DLPFC will be targeted using a modification of the Beam method. TMS will be administered at 10Hz, 120% of motor threshold, 3000 pulses per session
62581551|NCT04939935|EXPERIMENTAL|Intervention|"Participants randomised to the intervention group receive Metformin XR plus standard of care for 104 weeks.~Dosage will depend on individual participant's level of tolerance to Metformin XR as well as their estimated glomerular filtration rate (eGFR). The dosage will be between 500-2000mg/day."
62581552|NCT04939935|PLACEBO_COMPARATOR|Control|Participants randomised to the control group receive placebo plus standard of care for 104 weeks.
62581553|NCT03922217|EXPERIMENTAL|Mindfulness|This group will be given the Mindfulness mobile intervention, Mindful My Way (MMW)
62581554|NCT03485807|EXPERIMENTAL|Mindfulness Training (MT)|
62581555|NCT03485807|EXPERIMENTAL|Active Coping Training (CT)|
62017683|NCT03037944|EXPERIMENTAL|Group A-LNG|"The Levonorgestrel releasing intrauterine device - IUD- will be Metraplant-E, which is used in this study for group A, is a modified Levonorgestrel-releasing intrauterine system from the old IUD Metraplant, Metraplant-E design has a T-shaped frame containing Levonorgestrel and Ethylene Vinyl Acetate as well as Barium Sulphate to make it radio-opaque, All the T frame, the bulb of 20 mm length and sleeves contain: Ethylene Vinyl Acetate, Levonorgestrel and Barium Sulphate, ensure more exposure of the endometrial surface to the system and hence expect more endometrial suppression."
62017684|NCT03037944|EXPERIMENTAL|Group B-COCs|Group B will receive combined oral contraceptive pills (Yasmin) COCs which will be Monophasic pills that have a constant dose of both estrogen and progestins in each of the hormonal active pills throughout the entire cycle . Yasmin (ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets, provides an oral contraceptive regimen, it will be used continuously for 6 months with stoppage after 3 months for withdrawal bleeding.
62017685|NCT02681926||Average force group|A recent tool, called VISITAG, has been developed (and approved by EMEA) for Biosense Webster Navistar Smart Touch catheter in order to allow collection of ablation points with pre-determined characteristics, such as stability of catheter during ablation, mean contact force, drop in impedance. In the Average Force group, the operators decided to use the mean contact force as target parameter indicating a good lesion.
62017686|NCT02681926||Force Time Integral group|In the Force Time Integral (FTI) group, the operators decided to use the FTI as target parameter indicating a good lesion.
62208059|NCT05776043|ACTIVE_COMPARATOR|SGLT 2 Inhibitor|Empagliflozin (n=341) or Dapagliflozin (n=341): 9 months of treatment
62581556|NCT03907488|EXPERIMENTAL|Arm I (chemotherapy, nivolumab, radiation)|Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and nivolumab IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.
62581557|NCT03907488|EXPERIMENTAL|Arm II (chemotherapy, brentuximab vedotin, radiation)|Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.
62581558|NCT05502536|EXPERIMENTAL|Intervention group|traditional rehabilitation programs with additional individualized fairytales class
62581559|NCT05502536|NO_INTERVENTION|Control group|traditional rehabilitation programs without additional individualized fairytales class
62581560|NCT06684886||diabetic foot group|diabetic nephropathy patients with diabetic foot
62581561|NCT06684886||non diabetic foot group|diabetic nephropathy patients without diabetic foot
62017687|NCT03395535|EXPERIMENTAL|'Laser-1st'|"Initial Selective Laser Trabeculoplasty (SLT) \[PROCEDURE\] followed by conventional medical therapy (eye-drops) as required.~All participants in this arm start their treatment pathway with SLT. If this does not reach the predefined, patient-specific target IOP then repeat laser (once only) is given. If the IOP target is then not reached additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy with mitomycin C) as needed."
62017688|NCT03395535|ACTIVE_COMPARATOR|Medicine-1st|"Conventional medical therapy \[DRUG\] without laser. All participants in this arm start their treatment pathway medical treatment. If the IOP target is then not reached, additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy with mitomycin C) as needed.~During this pathway of treatment all commercially available medical treatments (eye-drops) are permitted according to a pre-specified step-wise intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
62017689|NCT03136601|ACTIVE_COMPARATOR|PTNS monthly|Patients return for PTNS maintenance monthly.
62581562|NCT05231733|EXPERIMENTAL|SPX-101|A total of up to 27 patients will be enrolled in this study. Subjects will receive SPX-101 by IV infusion in 60-minutes（±15 minutes）on Day 1 of the first cycle (3 weeks), and will be evaluated for DLTs in 3 weeks (DLT window). After the first cycle, subjects will continue the treatment at the assigned dose level.
62581563|NCT06491329|EXPERIMENTAL|High-intensity interval training|For non-permanent atrial fibrillation patients, a 12-week high-intensity interval training will be administered. The primary objective is to assess alterations in atrial fibrillation burden, with secondary endpoints encompassing changes in cardiorespiratory fitness, quality of life metrics, psychological profiling, atrial strain, ventricular diastolic function, as well as the incidence rates of exercise-related adverse events and adverse cardiovascular events.
62017690|NCT03136601|EXPERIMENTAL|PTNS as needed|Patients return for PTNS as needed (2-12 weeks).
62017691|NCT01886547||New patient presented with prostate disease|prostate disease identified
62017692|NCT00672880|EXPERIMENTAL|1|Psychotherapy
62017693|NCT00672880|ACTIVE_COMPARATOR|2|Spine Education
62017694|NCT00672880|PLACEBO_COMPARATOR|3|Standard Care
62017695|NCT06574282||Persistant hypophosphatasemia|
62581564|NCT06491329|EXPERIMENTAL|moderate-intensity interval training|For non-permanent atrial fibrillation patients, a 12-week moderate-intensity interval training will be administered. The primary objective is to assess alterations in atrial fibrillation burden, with secondary endpoints encompassing changes in cardiorespiratory fitness, quality of life metrics, psychological profiling, atrial strain, ventricular diastolic function, as well as the incidence rates of exercise-related adverse events and adverse cardiovascular events.
62208060|NCT05776043|PLACEBO_COMPARATOR|Placebo with a switch to SGLT 2 Inhibitor|Placebo (n=682) for 3 months of treatment with a subsequent switch to Empagliflozin (n=341) or Dapagliflozin (n=341): 6 months of treatment
62017696|NCT06574282||Transient hypophosphatasemia (Control group without hypophosphatasia)|
62017697|NCT01591681|ACTIVE_COMPARATOR|Pump suspension algorithm|The study laptop will be running actively during the night and suspending the patient's pump if the algorithm predicts hypoglycemia based on the patient's continuous glucose sensor trend.
62017698|NCT01591681|NO_INTERVENTION|Standard of Care|The control algorithm will run passively and not recommend control the patient's pump.
62017699|NCT01392352|EXPERIMENTAL|Pazopanib|Patients will receive 800mg (2 X 400mg tablets) of pazopanib, to be administered once daily orally for 12 weeks or until development of hypertension (defined as VHyp), whichever occurs first.
62208061|NCT06728618|EXPERIMENTAL|Experimental: Neoadjuvant Treatment + Salvage Surgery + Adjuvant Treatment|"Neoadjuvant treatment: The participants will receive 2 cycles of combination therapy (Tislelizumab, Cetuximab, Cisplatin and Nab-paclitaxel).~Salvage surgery: Primary tumor resection and/or lymph node dissection surgery 3-6 weeks from cycle 2 day 1.~Adjuvant treatment: 3-8 weeks post-surgery and upto a total of half a year. The participants will receive Tislelizumab (q3w) and Cetuximab (q2w) therapy.~Interventions:~Drug: Tislelizumab, Cetuximab, Cisplatin and Nab-paclitaxel"
62208062|NCT05527652|EXPERIMENTAL|Self-Supporting Nasopharyngeal Airway (ssNPA)|
62208063|NCT05527652|NO_INTERVENTION|Standard of Care|Waitlist control group: While waiting, participants will continue to receive the treatment they would have had before which will likely include being placed on the waiting list for positive airway pressure (PAP). After a period of being on the waitlist (8 weeks) there is an option to cross-over to the device arm.
62208064|NCT00870077|EXPERIMENTAL|1|
62208065|NCT02613377||Transfused critically ill children|Any infusion of RBC, plasma or platelets will be considered a transfusion.
62208066|NCT02613377||Non-transfused critically ill children|For each transfused patient (index patient), one matched non-transfused control will be identified and included in the control group. The matching will be conducted using four criteria in hierarchical order: gender; age ± 10%; baseline Hemoglobin level (± 15 g/L); and Pediatric Risk of Mortality III score (PRISM III score ± 10%).
62208067|NCT04631900|EXPERIMENTAL|Spiritual Intervention Programme|"The intervention is a 8 weeks' programme. The Christianity approach as the framework for spiritual intervention includes use of Bible verses, prayer, hymns singing, sharing and caring for others (mutual support) within the group.~Through these activities, participants have opportunities to re-build and further develop their connectedness to themselves, to others, to their living, their environment, and to larger meaning and purpose."
62208068|NCT04631900|NO_INTERVENTION|Wait-list Control group|Participants recruited in the waitlist control will be initially tested to generate pre-test scores and will then tested six weeks later which is equivalent to the timespan between the pre-test and post-test for the experimental spiritual programme. In between these two testing sessions, the waitlist control group will not receive any type of spiritual intervention. For ethical reasons, following the second testing session, the participants in the waitlist group will be given the opportunity to participant in the spiritual intervention programme.
62789701|NCT02249611|EXPERIMENTAL|MT and life counseling|To improve physical activity, body composition, physiological parameters and quality of life by using MT (mobile physical activity promotion tool) and lifestyle counseling in diet control, increased physical activity, less smoking and drinking, deal with pressure, and regular health examination will be conducted for 3 months in intervention periods.
62208069|NCT00859222|EXPERIMENTAL|Phase I Cohort 1: Bevacizumab +LBH589 20 mg every week|Phase I Cohort 1 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the original starting LBH589 dose of 20 mg/day orally, 3x per week, every week (days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26). Participants were treated until disease progression or unacceptable toxicity.
62208070|NCT00859222|EXPERIMENTAL|Phase I Cohort 2: Bevacizumab + LBH589 20 mg every other week|Phase I Cohort 2 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the amended starting LBH589 dose of 20 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
62208071|NCT00859222|EXPERIMENTAL|Phase I Cohort 3: Bevacizumab + LBH589 30 mg every other week|Phase I Cohort 3 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
62208072|NCT00859222|EXPERIMENTAL|All Phase I Participants|All phase I participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 according to the established dose escalation schedule. Participants were treated until disease progression or unacceptable toxicity.
62208073|NCT00859222|EXPERIMENTAL|Phase II GBM: Bevacizumab + LBH589 30 mg every other week|Phase II glioblastoma (GBM) participants received the regimen established in the Phase I study (Feb 2011). Phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
62581565|NCT06491329|NO_INTERVENTION|Maintain previous exercise habits group|Not undergoing exercise rehabilitation, maintaining previous exercise habits
62581566|NCT01435018|EXPERIMENTAL|ET+ART|Etoposide (ET) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
62581567|NCT01435018|EXPERIMENTAL|BV+ART|Bleomycin and Vincristine (BV) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
62581568|NCT01435018|ACTIVE_COMPARATOR|PTX+ART|Paclitaxel (PTX) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
62581569|NCT00943956|EXPERIMENTAL|Everolimus|Everolimus + radiation
62789702|NCT02249611|ACTIVE_COMPARATOR|Standard care|Lifestyle counseling in diet control, increased physical activity, less smoking and drinking, deal with pressure, and regular health examination based on the booklet of metabolic syndrome prevention which is edited by Health Promotion Administration, Ministry of Health and Welfare in Taiwan only once in this period (3 months).
62581570|NCT02660957|EXPERIMENTAL|self-determination smoking cessation|Subjects in the intervention group will be allowed to select their own schedules of quitting after discussing their situation with the counsellor (quit immediately (QI), or quit progressively (QP) with the ultimate goal of completing cessation over an acceptable period). Subjects in the intervention group will receive a self-help quitting leaflet published by the Hong Kong Council on Smoking and Health plus a series of brief interventions using the AWARD model.
62017700|NCT05820022||Physical Medicine and Rehabilitation Specialists|Physical medicine and rehabilitation specialists
62017701|NCT06534060|OTHER|Single arm|This is a single arm, two-stage, Phase 2, open-label, multicenter study.
62406297|NCT03331952||Pneumonia study (PCV-P)|"Prospective study of children hospitalised with clinical and/or radiologic pneumonia (PCV-P)~Clinical procedures As described for PCV-D.~Radiology procedures As part of routine clinical management at AHC, a digital chest radiograph (CXR) is performed on all children with an admission diagnosis of pneumonia. CXRs will be handled as described for PCV-D.~Laboratory procedures~* Study specific specimens:~  o Nasopharyngeal swab at enrolment.~* Residual routine clinical specimens further analysed as part of the study protocol:~  * As described for PCV-D."
62017702|NCT02322606|OTHER|Cohort 1: TAK-137 5 mg, TAK-137 placebo|Single-dose administration in a fasting state
62017703|NCT02322606|OTHER|Cohort 2: TAK-137 10 mg, TAK-137 placebo tablet|Single-dose administration in a fasting state
62017704|NCT02322606|OTHER|Cohort 3: TAK-137 20 mg or TAK-137 2 mg + TAK-137 placebo|Single-dose administration in a fasting state
62208074|NCT00859222|EXPERIMENTAL|Phase II AG: Bevacizumab + LBH589 30 mg every other week|Phase II Anaplastic Glioma (AG) participants received the regimen established in the Phase I study (Feb 2011). Phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
62406298|NCT03331952||Pneumococcal colonisation study (PCV-C)|"Cross-sectional pneumococcal colonisation surveys in children attending the AHC out-patient department (PCV-C)~Three annual surveys, enrolling 450 children each year, will be done to identify and characterise pneumococcal nasopharyngeal colonisation in AHC out-patient department (OPD) attendees.~Clinical procedures~• Subjects will be recruited from the OPD waiting area after nurse triage. A questionnaire will be administered to the parent / guardian or caretaker to assess the child's immunisation status (by review of the handheld immunisation card where possible), household structure, environmental exposures, and recent antimicrobial use.~Laboratory procedures • Study specific specimens:~o Nasopharyngeal swab at enrolment. A nasopharyngeal swab will be collected from each participant and these will be processed as described for PCV-P."
62406299|NCT00207116|EXPERIMENTAL|A|
62581571|NCT02660957|PLACEBO_COMPARATOR|health life|Subjects in the placebo control group will receive a smoking cessation leaflet published by the Hong Kong Council on Smoking and Health (COSH), as will the intervention group. Moreover, subjects in the placebo control group will undergo a similar schedule of telephone follow-up as those in the intervention group. They will receive a 'placebo' intervention with a 'placebo booster' of the same duration on increasing physical activity and fruit and vegetable intake.
62789703|NCT02774148|ACTIVE_COMPARATOR|PO Acetaminophen|1,000mg Acetaminophen po every 8 hours until discharge.
62017705|NCT02322606|OTHER|Cohort 4: TAK-137 5mg, TAK-137 placebo|Once daily for 7 days in a fasting state
62017706|NCT02322606|OTHER|Cohort 5: TAK-137 10 mg, TAK-137 placebo|Once daily for 7 days in a fasting state
62017707|NCT02322606|OTHER|Cohort 6: TAK-137 15 mg, TAK-137 placebo|Once daily for 7 days in a fasting state
62017708|NCT03857438||Bipolar Mania|Diagnosis of BD type I, manic episode according to DSM-5 given by the following doctor
62017709|NCT03857438||Healthy Control|showing normal mental capacity during interview, have more than five years of public education, no diagnosis of substance or alcohol abuse in the last three months (except nicotine and caffeine, no presence of family history of mood or psychotic disorder, and no presence of psychiatric disorder during interview or in the past, no presence of severe organic disease.
62017710|NCT03108534|EXPERIMENTAL|CHF1535 NEXThaler|CHF1535 100/6 NEXThaler (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)
62017711|NCT03108534|ACTIVE_COMPARATOR|CHF1535 pMDI|CHF1535 100/6 pMDI (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)
62017712|NCT03108534|PLACEBO_COMPARATOR|Placebo|Double dummy study: placebo is for both CHF1535 pMDI and CHF1535 NEXThaler
62017713|NCT01787604|ACTIVE_COMPARATOR|Aortic Root Reimplantation Procedure|Aortic Root Reimplantation Procedure
62581572|NCT04639102|EXPERIMENTAL|PATH Intervention|Patients in the treatment arm will receive a personalized plan of care upon discharge from the emergency department.
62017714|NCT01787604|ACTIVE_COMPARATOR|Aortic Valve Reimplantation Procedure|Aortic Valve Reimplantation Procedure
62017715|NCT02201602|EXPERIMENTAL|Gliclazide|Gliclazide, 80 mg tablet, half to maximal dose, 3 weeks
62017716|NCT02201602|ACTIVE_COMPARATOR|Glibenclamide|Glibenclamide, 5 mg tablet, half to maximal dose, 3 weeks
62017717|NCT02207829|EXPERIMENTAL|Umeclidinium 62.5 mcg + placebo|Subjects will receive UMEC Inhalation Powder 62.5 mcg once daily via nDPI plus placebo once daily via HANDIHALER inhaler for 12 weeks (24 weeks in Germany). Subjects will be instructed to take one inhalation each morning from both the nDPI and the HANDIHALER inhaler
62789704|NCT02774148|EXPERIMENTAL|IV Acetaminophen|1,000mg Acetaminophen IV every 8 hours until the patient has received 3 doses post-operatively. Then 1,000mg Acetaminophen po every 8 hours until discharge.
62789705|NCT01402713|EXPERIMENTAL|GC1107-T5.0|Dosage: 0.5ml
62789706|NCT01402713|EXPERIMENTAL|GC1107-T7.5|Dosage: 0.5ml
62789707|NCT01402713|ACTIVE_COMPARATOR|TD_PUR INJ /SK Td vaccine|The name: step 1(phase 2)-SK Td vaccine step 2(phase 3)-TD_PUR INJ Dosage: 0.5ml
62017718|NCT02207829|ACTIVE_COMPARATOR|Tiotropium 18mcg + placebo|Subjects will receive Tiotropium 18 mcg once daily via HANDIHALER inhaler plus placebo once daily via nDPI for 12 weeks (24 weeks in Germany). Subjects will be instructed to take one inhalation each morning from both the nDPI and the HANDIHALER inhaler
62017719|NCT05927441|EXPERIMENTAL|DragonFly Transcatheter Mitral Valve Repair System-DMR|Transcatheter mitral valve repair with the DragonFly System in patients with degenerative mitral regurgitation
62017720|NCT05927441|EXPERIMENTAL|DragonFly Transcatheter Mitral Valve Repair System-FMR|Transcatheter mitral valve repair with the DragonFly System in patients with functional mitral regurgitation
62208075|NCT00859222|EXPERIMENTAL|All Phase II Participants|All phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
62208076|NCT05954910||Cohort 1|Unfit/frail participants with DLBCL who are untreated before the administration of polatuzumab and who have started receiving polatuzumab at physician's discretion in accordance with local clinical practice and/or labeling will be observed for safety and efficacy until death, withdrawal of consent, loss to follow-up or end of study whichever occurs first (up to approximately 3 years).
62208077|NCT05954910||Cohort 2|Participants with DLBCL who can not be classified into unfit/frail but are untreated before the administration of polatuzumab and who have started receiving polatuzumab at physician's discretion in accordance with local clinical practice and/or labeling will be observed for safety and efficacy until death, withdrawal of consent, loss to follow-up or end of study whichever occurs first (up to approximately 3 years).
62406300|NCT03526549|EXPERIMENTAL|CCH-aaes Treatment in Parent Studies (EN3835-302/303)|Participants who received CCH-aaes treatment in EN3835-302/303 were followed for 180 days of observation with no treatment. Participants who were identified as received CCH-aaes in the parent studies following the 180-day Observation Phase and entered the Open-label Phase of the study. Participants in the Open-label Phase who qualified for, and opted for, retreatment were administered CCH-aaes up to 1.68 mg at 3 treatment sessions, at 21-day intervals.
62406301|NCT03526549|OTHER|Placebo Treatment in Parent Studies (EN3835-302/303)|Participants who received placebo in the parent studies, were followed for 180 days of observation with no treatment. After Day 180, all participants who received placebo during the double-blind parent studies were discontinued. No treatment was administered.
62581573|NCT04639102|NO_INTERVENTION|Routine Care|Patients in the control arm will receive standard-of-care services (the care plan that the emergency physician would normally offer if PATH were not available) without PATH enrollment.
62789708|NCT05512416|EXPERIMENTAL|cohort 1|patients with stage IIB-III HR+/HER2- breast cancer
62208078|NCT05954910||Cohort 3|Participants with relapsed or refractory (R/R) DLBCL who have started receiving polatuzumab at physician's discretion in accordance with local clinical practice and/or labeling will be observed for safety and efficacy until death, withdrawal of consent, loss to follow-up or end of study whichever occurs first (up to approximately 3 years).
62208079|NCT00385177|EXPERIMENTAL|A|SN2310 Injectable Emulsion
62789709|NCT05854979||Diabetics taking a GLP-1 receptor agonist|
62789710|NCT05854979||Diabetics not taking a GLP-1 receptor agonist (control)|
62017721|NCT04574895|OTHER|VTE risk prediction scores|Patients in the intervention arm will have their VTE risk prediction scores presented to the study team daily on weekdays via an automated report, which will list patients in descending order of risk severity for review by the VTE research team each weekday. Starting with the highest risk patients, the VTE research team will review each patient and clinical situation, and then the VTE research team will directly discuss risks/benefits of prophylactic anticoagulation with the admitting team. Patients with a risk score \<2.5% will not be reviewed, and the investigators anticipate most of the intervention arm patients will fall into this category (based on our previous data, the investigators anticipate \>90% of all patients will score \<2.5%). The VTE risk report will be re-calculated based on updated EHR data every day at midnight.
62208080|NCT02940587|EXPERIMENTAL|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
62208081|NCT02940587|NO_INTERVENTION|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
62208082|NCT06716658|EXPERIMENTAL|JAK1 inhibitor|Golidocitnib 150mg QD orally
62208083|NCT00565851|ACTIVE_COMPARATOR|Arm I (paclitaxel, docetaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours or docetaxel IV over 1 hour and carboplatin over 30 minutes on day 1. Treatment repeats every 21 days.
62208084|NCT00565851|EXPERIMENTAL|Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab)|Patients receive chemotherapy as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days.
62208085|NCT00565851|EXPERIMENTAL|Arm III (gemcitabine hydrochloride, carboplatin)|Patients receive gemcitabine hydrochloride IV over 60 minutes on days 1 and 8 and carboplatin as in Arm I.
62208086|NCT00565851|EXPERIMENTAL|Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin)|Patients receive gemcitabine hydrochloride IV as in Arm III, bevacizumab IV and carboplatin IV as in Arm II.
62208087|NCT06723340|EXPERIMENTAL|Experimental|Scar gel
62208088|NCT03547973|EXPERIMENTAL|Cohort 1: Sacituzumab Govitecan-hziy (SG)|Participants with urothelial cancer (UC) previously treated with platinum-based and/or checkpoint inhibitors (CPIs) will receive SG 10 mg/kg intravenously (IV) on Days 1 and 8 of a 21-day cycle.
62208089|NCT03547973|EXPERIMENTAL|Cohort 2: SG|Participants with UC who are ineligible for platinum-based therapy and failed therapy with previous immune CPI therapy will receive SG 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle.
62406302|NCT05344391|EXPERIMENTAL|BFR cycling|This group will perform cycling with BFR applied bilaterally at 80% LOP for 10 min and cycling at 40% HRR. Next they will perform 3x15 of the scaption and sidelying external rotation exercises. These will initially be performed at 30% 1RM; every 2 weeks load increased by 1lbs.
62406303|NCT05344391|ACTIVE_COMPARATOR|Cycling without BFR|This group will perform cycling and the same shoulder exercises using the same training parameters; however, BFR will not be applied.
62406304|NCT02399046|EXPERIMENTAL|Total Knee System made in China|Patinet in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured in China
62406305|NCT02399046|ACTIVE_COMPARATOR|Total Knee System made outside of China|Patient in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured Outside of China
62406306|NCT00470249|EXPERIMENTAL|Patients with (HER-2)-negative and anthracycline- and taxane-resistant|Patients with human epidermal growth factor 2 (HER-2)-negative locally advanced or metastatic breast cancer that was anthracycline- and taxane-resistant
62581574|NCT01668173|EXPERIMENTAL|AUY922|This is an open-label phase II trial to assess the efficacy of the HSP90 inhibitor, AUY922, in patients with PMF, post-PV MF, post-ET MF, and with PV/ET who are refractory to hydroxyurea, phlebotomy or anagrelide.
62789711|NCT04483609||pre-test Group|10 people with multiple sclerosis. The eligibility criteria were: (1) age 18-65; (2) definitive diagnosis of MS according to McDonald criteria; (3) ability to read and write in Turkish. The exclusion criteria are: (1) acute attacks of MS (within 3 months); (2) cognitive impairment (Mini Mental test result 24 points and below); (3) any chronic disease other than MS; (4) active malignant tumors; (5) symptomatic urinary tract infections; (6) patients who changed treatment within the test-retest period.
62406307|NCT00270205|EXPERIMENTAL|A: 0.1 mg DNA/participant vaccination at weeks 1,7,13|Participants receiving three separate low-dose vaccinations of LC002 (0.1 mg DNA/participant, 0.8 ml total, administered over two skin sites \[on the left and right upper back\] of 80 cm\^2 each, 0.4 ml/site) at weeks 1, 7, and 13.
62208090|NCT03547973|EXPERIMENTAL|Cohort 3: SG + Pembrolizumab|Participants who have had progression or recurrence of UC following a platinum-containing regimen in the metastatic setting, or progression or recurrence of UC within 12 months of completion of platinum-based therapy as neoadjuvant or adjuvant therapy will receive SG 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle and pembrolizumab at the standard approved dose (200 mg) only on Day 1 of a 21-day cycle. Lower doses of SG may be tested based on dose-limiting toxicities (DLTs) observed to determine the Recommended Phase 2 Dose (RP2D) of SG in combination with pembrolizumab.
62208091|NCT03547973|EXPERIMENTAL|Cohort 4: SG + Cisplatin + Avelumab (Dose Escalation Phase)|Participants with UC who have never received therapy with platinum in the metastatic setting or for unresectable locally advanced disease will first receive cisplatin (either at 70 mg/m\^2 on Day 1 of a 21-day cycle or at a split dose of 35 mg/m\^2 on Days 1 and 8 of a 21-day cycle with a maximum body surface area of 2) and sacituzumab govitecan-hziy with maximum dose of 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle for up to 6 cycles. Based on DLTs observed, two additional lower doses may be tested to determine RP2D of sacituzumab govitecan-hziy in combination with cisplatin. If premature termination of 1 agent occurs due to toxicity, the other agent may be continued to complete up to 6 cycles of therapy. For participants who have not progressed, maintenance therapy will begin with infusions of avelumab 800 mg every 2 weeks beginning on Cycle 1, Day 1 and every 2 weeks thereafter and sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8 every 21 days.
62208092|NCT03547973|EXPERIMENTAL|Cohort 4: SG + Cisplatin + Zimberelimab (ZIM) (Dose Expansion Phase)|Participants with UC who have never received therapy with platinum in the metastatic setting or for unresectable locally advanced disease will first receive cisplatin (either at 70 mg/m\^2 on Day 1 of a 21-day cycle or at a split dose of 35 mg/m\^2 on Days 1 and 8 of a 21-day cycle with a maximum body surface area of 2) and sacituzumab govitecan-hziy with maximum dose of 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle for up to 6 cycles. If premature termination of 1 agent occurs due to toxicity, the other agent may be continued to complete up to 6 cycles of therapy. For participants who have not progressed, maintenance therapy will begin with infusions of sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8 every 21 days and zimberelimab 360 mg every 3 weeks (Day 1 of a 21-day cycle).
62406308|NCT00270205|EXPERIMENTAL|B|Participants receiving three separate vaccinations of LC002 placebo (0.8 ml total, administered over two skin sites \[on the left and right upper back\] of 80 cm\^2 each, 0.4 ml/site) at weeks 1, 7, and 13.
62406309|NCT00270205|EXPERIMENTAL|C: 0.4 mg DNA/participant vaccination at weeks 1, 7, 13|Participants receiving three separate high-dose vaccinations of LC002 (0.4 mg DNA/participant, 3.2 ml total, administered over four skin sites \[on the left and right upper back and left and right upper ventral thigh\] of 80 cm\^2 each, 0.8 ml/site) at weeks 1, 7, and 13.
62406310|NCT00270205|EXPERIMENTAL|D|Participants receiving three separate vaccinations of LC002 placebo (3.2 ml total, administered over four skin sites \[on the left and right upper back and left and right upper ventral thigh\] of 80 cm\^2 each, 0.8 ml/site) at weeks 1, 7, and 13.
62406311|NCT00270205|EXPERIMENTAL|E: 0.4 mg DNA/participant vaccination at weeks 0,1,6,7,12,13|Participants receiving six separate high-dose vaccinations of LC002 (0.4 mg DNA/participant, 3.2 ml total, administered over four skin sites \[on the left and right upper back and left and right upper ventral thigh\] of 80 cm\^2 each, 0.8 ml/site) at study entry and weeks 1, 6, 7, 12, and 13.
62406312|NCT00270205|EXPERIMENTAL|F|Participants receiving six separate vaccinations of LC002 placebo (3.2 ml total, administered over four skin sites \[on the left and right upper back and left and right upper ventral thigh\] of 80 cm\^2 each, 0.8 ml/site) at study entry and weeks 1, 6, 7, 12, and 13.
62406313|NCT02333175|ACTIVE_COMPARATOR|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
62406314|NCT02333175|NO_INTERVENTION|Care as usual|Care as usual
62406315|NCT06514365|EXPERIMENTAL|Echo-guided IPACK block|IPACK block using 0.25% bupivacaine 15mL with adrenaline once.
62581575|NCT00454688|PLACEBO_COMPARATOR|Placebo|
62581576|NCT00454688|EXPERIMENTAL|Asimadoline 0.15 mg|
62581577|NCT00454688|EXPERIMENTAL|Asimadoline 0.5 mg|
62581578|NCT00454688|EXPERIMENTAL|Asimadoline 1.0 mg|
62581579|NCT03460405|EXPERIMENTAL|VI-DT vaccine (adults,adolescent)|1 dose of 0.5 ml Vi-DT vaccine
62581580|NCT03460405|ACTIVE_COMPARATOR|Vi polysaccharide (adults,adolescent)|1 dose of 0.5 ml Vi polysaccharide vaccine
62581581|NCT03460405|EXPERIMENTAL|VI-DT vaccine (children)|1 dose of 0.5 ml Vi-DT vaccine
62406316|NCT06514365|ACTIVE_COMPARATOR|Echo-guided sciatic block|Sciatic nerve block using 0.25% bupivacaine 15mL with adrenaline once.
62581582|NCT03460405|ACTIVE_COMPARATOR|Vi polysaccharide vaccine (children)|1 dose of 0.5 ml Vi polysaccharide vaccine
62581583|NCT03460405|EXPERIMENTAL|VI-DT vaccine (infants)|1 dose of 0.5 ml Vi-DT vaccine
62581584|NCT03460405|ACTIVE_COMPARATOR|IPV Vaccine (infants)|1 dose of 0.5 ml IPV vaccine
62581585|NCT04242290||Cervicogenic headache|The group with cervicogenic headaches
62581586|NCT04242290||Neck pain|The group with isolated neck pain
62581587|NCT00950339|EXPERIMENTAL|4 weeks of omeprazole, 20mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
62208093|NCT03547973|EXPERIMENTAL|Cohort 5 (Arm 1): SG + ZIM|Participants in Cohort 5 will have completed 4 to 6 cycles of gemcitabine (GEM) + cisplatin therapy without PD prior to study entry. The safety lead-in will be conducted, in 6 to 8 participants (treated with SG 10 mg/kg IV on Day 1 and Day 8 of a 21-day cycle + ZIM 360 mg IV every 3 weeks on a 21-day cycle). Upon completion of the safety lead-in, participants will receive SG 10 mg/kg IV on Days 1 and 8 of a 21-day cycle followed by ZIM 360 mg IV, every 3 weeks (Q3W) (Day 1 of a 21-day cycle) until PD, unacceptable toxicity, or loss of clinical benefit. participants who must discontinue 1 agent may continue the other until PD, unacceptable toxicity, or loss of clinical benefit.
62208094|NCT03547973|EXPERIMENTAL|Cohort 5 (Arm 2): Avelumab|Participants in Cohort 5 will have completed 4 to 6 cycles of gemcitabine (GEM) + cisplatin therapy without PD prior to study entry. The safety lead-in will be conducted, in 6 to 8 participants (treated with SG 10 mg/kg IV on Day 1 and Day 8 of a 21-day cycle + ZIM 360 mg IV every 3 weeks on a 21-day cycle). Upon completion of the safety lead-in, participants will be randomized to receive avelumab 800 mg IV every 2 weeks (Q2W) until PD, unacceptable toxicity, or loss of clinical benefit.
62406317|NCT03290131|ACTIVE_COMPARATOR|AERT 40 mg|40 mg Arbaclofen Extended-Release Tablets
62406318|NCT03290131|ACTIVE_COMPARATOR|AERT 80 mg|80 mg Arbaclofen Extended-Release Tablets
62406319|NCT03290131|PLACEBO_COMPARATOR|Placebo|Placebo
62581588|NCT00950339|EXPERIMENTAL|4 weeks of famotidine 40mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
62581589|NCT00950339|EXPERIMENTAL|4 weeks of pantoprazole 40mg once daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
62581590|NCT06161974|EXPERIMENTAL|Stratum A|Patients with localized, intracranial, non-pontine, and non-thalamic IDH 1 mutant Astrocytoma, CNS WHO Grade 3.
62581591|NCT06161974|EXPERIMENTAL|Stratum B|Patients with localized, intracranial, non-pontine, and non-thalamic IDH 1 mutant Astrocytoma, CNS WHO Grade 4.
62581592|NCT06161974|EXPERIMENTAL|Stratum C|Patients with IDH-1 mutant DIPG, primary thalamic and spinal cord IDH-1 mutant HGG.
62789712|NCT04483609||Validation and Reliability Group|80 people with multiple sclerosis. The eligibility criteria were: (1) age 18-65; (2) definitive diagnosis of MS according to McDonald criteria; (3) ability to read and write in Turkish. The exclusion criteria are: (1) acute attacks of MS (within 3 months); (2) cognitive impairment (Mini Mental test result 24 points and below); (3) any chronic disease other than MS; (4) active malignant tumors; (5) symptomatic urinary tract infections; (6) patients who changed treatment within the test-retest period.
62789713|NCT02231684|EXPERIMENTAL|s.c. 0.5 mg (1 mg/ml) followed by s.c. 0.5 mg (3 mg/ml)|
62789714|NCT02231684|EXPERIMENTAL|s.c. 0.5 mg (3 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
62789715|NCT02231684|EXPERIMENTAL|s.c. 0.5 mg (3 mg/ml) followed by s.c. 0.5 mg (10 mg/ml)|
62789716|NCT02231684|EXPERIMENTAL|s.c. 0.5 mg (10 mg/ml) followed by s.c. 0.5 mg (3 mg/ml)|
62789717|NCT02231684|EXPERIMENTAL|s.c. 0.5 mg (1 mg/ml) followed by s.c. 0.5 mg (10 mg/ml)|
62789718|NCT02231684|EXPERIMENTAL|s.c. 0.5 mg (10 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
62789719|NCT02231684|EXPERIMENTAL|i.v. 0.25 mg (1 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
62789720|NCT02231684|EXPERIMENTAL|s.c. 0.5 mg (1 mg/ml) followed by i.v. 0.25 mg (1 mg/ml)|
62789721|NCT05377619|EXPERIMENTAL|prucalopride|prucalopride 2 mg 1 capsule orally 1 hour before the wine challenging (during a dinner), in five dinners (2 dinners per week)
62789722|NCT05377619|EXPERIMENTAL|buspirone|buspirone 10 mg 1 capsule orally 1 hour before the wine challenging (during a dinner), in five dinners (2 dinners per week)
62789723|NCT05377619|PLACEBO_COMPARATOR|placebo|placebo 1 capsule orally 1 hour before the wine challenging (during a dinner), in five dinners (2 dinners per week)
62789724|NCT02309008|PLACEBO_COMPARATOR|placebo|vehicle cream, dermal administration, multiple dosing
62789725|NCT02309008|EXPERIMENTAL|drug|PAC-14028 cream, dermal administration, multiple dosing, dose escalation
62789726|NCT04742114|SHAM_COMPARATOR|the face mask without EPAP|Will be collected clinical and anthropometric data of the participant. Will have the pulmonary function test every two months. Will be collected CT scan data. Patients will conduct 6MWT every two months. Borg scale data will be collected.The face mask without the application of EPAP will be used.
62789727|NCT04742114|EXPERIMENTAL|the face mask with EPAP|Will be collected clinical and anthropometric data of the participant. Will have the pulmonary function test every two months. Will be collected CT scan data. Patients will conduct 6MWT every two months. Borg scale data will be collected.The application of EPAP (15cmH2O) via face mask will be used.
62789728|NCT05253885||Smartphone addiction group|
62789729|NCT04852198|ACTIVE_COMPARATOR|OAGB|149 patients receiving one anastomosis gastric bypass (OAGB) with a Biliopancreatic-limb of 150cm
62406320|NCT06540131||group of 15 seconds ethanol|Group of eyes with ethanol applied on the corneal surface for 15 seconds
62406321|NCT06540131||group of 30 seconds ethanol|Group of eyes with ethanol applied on the corneal surface for 30 seconds
62406322|NCT04165824|EXPERIMENTAL|MT-1186|
62406323|NCT02384031|ACTIVE_COMPARATOR|Traumatic group|Traumatic needle
62406324|NCT02384031|ACTIVE_COMPARATOR|Atraumatic group|Atraumatic needle
62406325|NCT05814224|EXPERIMENTAL|Hormone-receptor positive MBC|Women with hormone receptor-positive MBC, that will be eligible for endocrine therapy as first line treatment
62406326|NCT00357734|EXPERIMENTAL|Gefitinib (ZD1839)|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
62406327|NCT04962191||Lung Cancer|The Idylla EGFR Mutation Test, performed on the BioCartis Idylla System, is an in vitro diagnostic test for the qualitative detection of exon mutations. One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. This study can help test the BioCartis Idylla System against standard of care (SoC) pathology results from tissue biopsies in the same setting, ultimately being able to diagnose with a fraction of the tissue previously needed.
62789730|NCT04852198|ACTIVE_COMPARATOR|RYGB|149 patients receiving Roux-en-Y gastric bypass (RYGB) with a Biliopancreatic-limb of 150cm
62406328|NCT02991911|EXPERIMENTAL|Arm A|MEDI3726 Post-Chemo
62406329|NCT02991911|EXPERIMENTAL|Arm B|MEDI3726 Pre-Chemo
62208095|NCT03547973|EXPERIMENTAL|Cohort 5 (Arm 3): ZIM|"Participants in Cohort 5 will have completed 4 to 6 cycles of gemcitabine (GEM) + cisplatin therapy without PD prior to study entry. The safety lead-in will be conducted, in 6 to 8 participants (treated with SG 10 mg/kg IV on Day 1 and Day 8 of a 21-day cycle + ZIM 360 mg IV every 3 weeks on a 21-day cycle).~Upon completion of the safety lead-in, participants will be randomized to receive ZIM 360 mg IV Q3W (Day~1 of a 21-day cycle) until PD, unacceptable toxicity, or loss of clinical benefit."
62406330|NCT02991911|EXPERIMENTAL|Arm C|MEDI3726 \& Enzalutamide Combo
62406331|NCT01238861|PLACEBO_COMPARATOR|Eosinophilic phenotype (EOS+) Placebo|EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo injections subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
62789731|NCT04119674|EXPERIMENTAL|single-arm|single-arm Drug: Anlotinib Drug: Temozolomide Radiotherapy:Radiotherapy was initiated 4 to 6 weeks postoperatively at a dose of 1.8-2.0 Grays (Gy) per fraction for 5 days per week for 6 weeks with a total dose of 54-60 Gy.
62789732|NCT04150094|ACTIVE_COMPARATOR|Pelvic floor muscle training (PFMT)|Pelvic floor muscle training without stimulus.
62406332|NCT01238861|EXPERIMENTAL|EOS+ Benralizumab (2 mg)|EOS+ participants received single benralizumab 2 milligram (mg) injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
62406333|NCT01238861|EXPERIMENTAL|EOS+ Benralizumab (20 mg)|EOS+ participants received single benralizumab 20 mg injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
62789733|NCT04150094|EXPERIMENTAL|Pelvic floor muscle training + intravaginal vibratory stimulus|Pelvic floor muscle training with intravaginal vibratory stimulation.
62406334|NCT01238861|EXPERIMENTAL|EOS+ Benralizumab (100 mg)|EOS+ participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
62406335|NCT01238861|PLACEBO_COMPARATOR|Non-eosinophil phenotype (EOS-) Placebo|EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
62406336|NCT01238861|EXPERIMENTAL|EOS- Benralizumab (100 mg)|EOS- participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
62581593|NCT05206955|EXPERIMENTAL|Tadalafil Group|Study participants will receive 10 mg of Tadalafil daily for 1 week, then 20 mg daily for 1 week, and finally 40 mg daily for 50 weeks for a total therapy time of 52 weeks. Tadalafil will be taken orally in capsule form once daily.
62789734|NCT02545764|EXPERIMENTAL|Intervention|Strength and neuromuscular exercise programme
62789735|NCT02545764|NO_INTERVENTION|Control|Control group will receive opportunity for the training programme after data capturing is finished
62789736|NCT05932472|EXPERIMENTAL|Aspirin at bedtime|Participants randomized to aspirin administration at bedtime will be instructed to take their aspirin at approx. 8PM-12AM.
62789737|NCT05932472|ACTIVE_COMPARATOR|Aspirin in the morning|Participants randomized to aspirin administration in the morning will be instructed to take their aspirin upon awakening or with their breakfast (approx. 6-10AM).
62789738|NCT00189605|ACTIVE_COMPARATOR|1|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)
62789739|NCT00189605|EXPERIMENTAL|2|Percutaneous Disc Decompression of the lumbar level which is secondary to radicular pain
62789740|NCT03071393|EXPERIMENTAL|Acute Intermittent Hypoxia, then Sham Intermittent Hypoxia|Subjects with chronic spinal cord injury first received an acute intermittent hypoxia protocol with low oxygen air (9-15% inspired oxygen). After a washout period of at least one week, they then received sham intermittent hypoxia with normal oxygen air (21% inspired oxygen).
62789741|NCT03071393|EXPERIMENTAL|Sham Intermittent Hypoxia, then Acute Intermittent Hypoxia|Subjects with chronic spinal cord injury first received a sham (placebo) intermittent hypoxia protocol with normal oxygen air (21% inspired oxygen). After a washout period of at least one week, they then received an acute intermittent hypoxia protocol with low oxygen air (9-15% inspired oxygen).
62789742|NCT01444885|EXPERIMENTAL|Cilostazol|To investigate the efficacy and safety of Pletaal(Cilostazol) in comparison with placebo for 4 weeks in vasospastic angina patients who have an insufficient response to Amlodipine (Calcium channel blocker).
62789743|NCT01928901|EXPERIMENTAL|administration of Bronchipret|7 days of administration of Bronchipret, 2 FCT t.i.d
62789744|NCT01928901|EXPERIMENTAL|administration of Sinupret|7 days of administration of Sinupret, 2 CT t.i.d
62406337|NCT01484691|NO_INTERVENTION|Healthy non-asthmatic controls|Healthy non-asthmatic controls who will be studied at one point in time and serve as a control group for the baseline bronchoscopy and evaluation of T-cell miRNA expression.
62406338|NCT01484691|ACTIVE_COMPARATOR|Asthmatics (treatment)|Steroid-naïve asthma (randomized to 8 weeks of treatment with inhaled corticosteroids). Asthmatics not on inhaled corticosteroids, randomized to inhaled budesonide, 1 puff (180mcg) twice a day for 8-10 weeks. These subjects will undergo bronchoscopy and T-cell miRNA measurement at baseline (before corticosteroids) and again after treatment with inhaled corticosteroids.
62406339|NCT01484691|NO_INTERVENTION|Asthmatics (no treatment)|Steroid-naïve asthma (randomized to 8 weeks of no inhaled corticosteroid treatment). Asthmatics not on inhaled corticosteroids, randomized to no change in treatment for 8-10 weeks. These subjects will undergo bronchoscopy and T-cell miRNA measurement at baseline and again after 8 weeks without treatment with inhaled corticosteroids.
62406340|NCT04642040|EXPERIMENTAL|Pulmonary Rehabilitation|Patients are included in a personalized pulmonary telerehabilitation program consisting of patient education, respiratory and peripheral muscle training, and breathing strategies for 4 weeks. In the telerehabilitation program, exercises will be supervised by a physiotherapist two days a week, and patients will be asked to do the exercises themselves for the other 3 days. Patients will also receive instructional exercise videos for these 3 days.
62789745|NCT01928901|PLACEBO_COMPARATOR|administration of Bronchipret Placebo|7 days of administration of Bronchipret Placebo, 2 FCT t.i.d
62789746|NCT01928901|PLACEBO_COMPARATOR|administration of Sinupret Placebo|7 days of administration of Sinupret Placebo, 2 CT t.i.d
62017722|NCT04574895|NO_INTERVENTION|Standard of care|Patients randomized to the control arm will continue to receive current standard of care anticoagulation practice, which is at the discretion of the admitting team. In general, nearly no pediatric patients are offered prophylactic anticoagulation unless a previous VTE has been identified. This currently is at the discretion of the provider and no risk scoring is used. VTE risk prediction scores will be calculated and stored for analysis, these will not be visible to the study team in real time.
62208096|NCT03547973|EXPERIMENTAL|Cohort 6 (Arm 1): SG|Upon completion of the safety lead-in, participants in Cohort 6 will be randomized and SG will be administered in cisplatin-ineligible participants who have never received therapy in the metastatic setting or for unresectable locally advanced disease. Treatment may be discontinued at any time, but participants will continue to be followed for tumor response until progression is documented, and alternate therapy is initiated. If participants discontinue therapy before evidence of radiologic progression, imaging should continue until radiologic progression is documented, if feasible.
62208097|NCT03547973|EXPERIMENTAL|Cohort 6 (Arm 2): SG + ZIM|Upon completion of the safety lead-in, participants in Cohort 6 will be randomized and SG in combination with ZIM will be administered in cisplatin-ineligible participants who have never received therapy in the metastatic setting or for unresectable locally advanced disease. The standard approved dose of SG will be used in combination with ZIM. Treatment may be discontinued at any time, but participants will continue to be followed for tumor response until progression is documented or alternate therapy is initiated. If participants discontinue therapy before evidence of radiologic progression, imaging should continue until radiologic progression is documented, if feasible.
62208098|NCT03547973|EXPERIMENTAL|Cohort 6 (Arm 3): SG + ZIM + Domvanalimab (DOM)|Upon completion of the safety lead-in, participants in Cohort 6 will be randomized and SG in combination with ZIM and DOM will be administered in cisplatin-ineligible participants who have never received therapy in the metastatic setting or for unresectable locally advanced disease.
62406341|NCT03581500|EXPERIMENTAL|Diagnostic (hyperpolarized carbon C 13 pyruvate MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over 10-20 seconds and undergo MRSI over 2-3 minutes at 6 and 8 weeks.
62406342|NCT04787575|EXPERIMENTAL|Arm A|Oxygen-ozone therapy plus antibiotic therapy
62406343|NCT04787575|OTHER|Arm B|Antibiotic therapy
62581594|NCT05206955|PLACEBO_COMPARATOR|Placebo Group|Study participants will receive a placebo capsule that looks identical to the Tadalafil capsule. The placebo will be taken orally once daily for 52 weeks.
62406344|NCT01947010|ACTIVE_COMPARATOR|Crohn's patients treated with Azathioprine|Vaccination with PPV23 or Vaccination with PCV 13
62406345|NCT01947010|ACTIVE_COMPARATOR|Crohn's patients treated with Azathioprine and TNFa inhibitors|Vaccination with PPV23 or Vaccination with PCV 13
62406346|NCT01947010|ACTIVE_COMPARATOR|Crohn's disease patients without treatment|Vaccination with PPV23 or Vaccination with PCV 13
62406347|NCT01756586|ACTIVE_COMPARATOR|Control|Plain bupivacaine
62406348|NCT01756586|EXPERIMENTAL|Experimental|Bupivacaine with Dexamethasone
62406349|NCT00062829|OTHER|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
62406350|NCT06182410|EXPERIMENTAL|Supportive Care (defibrotide)|Participants receive defibrotide IV over 2 hours every six hours on days -8 to +21 during the first and second rounds of Hematopoietic stem-cell transplantation (HSCT).
62406351|NCT06653530|EXPERIMENTAL|Thread embedding acupuncture|The participants in the thread embedding acupuncture therapy group will receive treatment that consists of 18 thread embedding acupuncture sessions over a 24-week period after baseline (once a week for the first 12 weeks and every two weeks for the next 12 weeks).
62789747|NCT04829916|EXPERIMENTAL|RMC-035|Participants will receive RMC-035 intravenously
62789748|NCT04829916|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo solution intravenously
62789749|NCT05332132|EXPERIMENTAL|Intrauterine Morcellation of Uteri Post-Surgery|Intrauterine Morcellation of Uteri Post-Surgery (Ex Vivo Study)
62017723|NCT05944900|EXPERIMENTAL|PICC placement according to standard practice + cyanoacrylate glue|"PICC placement will be performed according to standard practice (Safe Insertion of PICC protocol (SIP2) steps).~The catheter will be secured by the Statlock system. Cyanoacrylate glue will be applied on the catheter exit point in accordance with the instructions for use.~A transparent dressing will be applied, with a compress in the event of bleeding."
62017724|NCT05944900|NO_INTERVENTION|PICC placement according to standard practice|"PICC placement will be performed according to standard practice (Safe Insertion of PICC protocol (SIP2) steps).~The catheter will be secured by the Statlock system. A transparent dressing will be applied, with a compress in the event of bleeding."
62017725|NCT02011841|EXPERIMENTAL|Rifaximin group|Rifaximin 1200 mg/day orally for 6 months
62017726|NCT02011841|ACTIVE_COMPARATOR|Control group|Ciprofloxacin 500 mg/day orally for 6 months
62017727|NCT05754320|EXPERIMENTAL|Tension Band Wire fixation|patients suffering simple olecranon fracture, randomized for treatment of tension band wire fixation
62789750|NCT01818102|EXPERIMENTAL|Width 1000 HU/Level -450 HU|
62789751|NCT01818102|ACTIVE_COMPARATOR|Width 400 HU/Level 25 HU|
62789752|NCT06169813|ACTIVE_COMPARATOR|Control (Quit-Line Referral)|Participants will receive referral to the existing South African Quitline. Participants will receive information to contact the Quitline if participants so choose, in addition to ecological momentary assessment (EMA) texting orientation.
62789753|NCT06169813|EXPERIMENTAL|Nicotine Replacement Therapy (NRT)|In addition to phone counseling + ecological momentary intervention (EMI) texting, participants will receive combination NRT (daily patches and lozenges).
62017728|NCT05754320|EXPERIMENTAL|Plate fixation|patients suffering simple olecranon fracture, randomized for treatment of plate fixation
62017729|NCT04104035||BCR-ABL-positive hematopoiesis|Patients with BCR-ABL-positive hematopoiesis (newly diagnosed CML patients, CML patients with leukocytosis, CML patients without a hematological and/or cytogenetic and/or molecular response, CML patients whose BCR-ABL status becomes negative and then positive) will be included.
62017730|NCT04104035||BCR-ABL activity inhibition under TKI|Patients with CML with BCR-ABL activity inhibition under TKI therapy (patients with MMR and/or deeper response) will be included.
62017731|NCT04946240|EXPERIMENTAL|Supervised (BRACE) Group|the self-developed protocol (BRACE) is used in the experiment with a combination of balance, resistance, aerobic and cognitive exercises for 12 weeks with repetition of different tasks
62581595|NCT04349345||sperm count over time|observation
62789754|NCT06169813|EXPERIMENTAL|Electronic Cigarette (EC)|"In conjunction with phone counseling + EMI texting, participants will receive the VUSE Solo EC."
62789755|NCT06393166|EXPERIMENTAL|Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection|Nab-paclitaxel:125 mg/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle Gemcitabine hydrochloride: 1g/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle 5-FU: 2400 mg/m2 ,ivgtt over 46h, D29-30, every 6 weeks for a treatment cycle Oxaliplatin: 85 mg/m2 ,ivgtt, D29, every 6 weeks for a treatment cycle LV: 400 mg/m2 ,ivgtt over 2h, D29, every 6 weeks for a treatment cycle Serplulimab Injection: 3mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle. Bevacizumab Injection: 5mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle.
62789756|NCT03637478|EXPERIMENTAL|Enhanced Systems of Care Team|The four intervention sites have been selected based on their size: taken together, their pediatric populations comprise over 80% of the total number of children receiving care at Cambridge Health Alliance. At the four intervention sites, the study will involve: 1) an integrated child mental health assessment done by the E-SOC team within primary care, 2) active follow-up, collaboration with specialty providers and support to families, 3) School, child welfare and other community linkages as appropriate.
62789757|NCT01035281|EXPERIMENTAL|Nabilone|A one-week screening period will occur, during which pain scores and sleep scores will be tabulated. Following screening, a 4-week period of single blind treatment with flexible dosing of nabilone at 0.5 - 4 mg/day will initiate.
62789758|NCT01035281|PLACEBO_COMPARATOR|Placebo|All subjects who experience at least a 30% reduction in their weekly mean pain score during the single blind flexible dosing phase will be considered a responder, and will be further continued in the study. During the double-blind portion of the study, subjects randomized to nabilone will continue on the dose of nabilone achieved at the completion of the single-blind phase, and this dose will be maintained throughout the double-blind phase. Subjects randomized to placebo will receive 1 mg of nabilone daily for one week, followed by 4 consecutive weeks of placebo. This dose of nabilone will permit a tapering for those subjects achieving a higher daily dose of nabilone during the single-blind phase, or will maintain those who were taking only 1 mg per day in the single-blind phase, preventing an abrupt termination of treatment in subjects who are randomized into the placebo portion.
62017732|NCT04946240|ACTIVE_COMPARATOR|Conventional Balance Exercises Group|The unsupervised home plan included balance and resistance exercise was guided to conventional group
62017733|NCT00466323|EXPERIMENTAL|FMPO Condition|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
62017734|NCT00466323|ACTIVE_COMPARATOR|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
62208099|NCT03547973|EXPERIMENTAL|Cohort 6 (Arm 4): Carboplatin (CARBO) + Gemcitabine (GEM)|Upon completion of the safety lead-in, participants in Cohort 6 will be randomized and CARBO in combination with GEM will be administered in cisplatin-ineligible participants who have never received therapy in the metastatic setting or for unresectable locally advanced disease. Participants without disease progression as assessed by the investigator after completion of 4 to 6 cycles of therapy may continue with maintenance therapy (avelumab 800 mg every 2 weeks) until loss of clinical benefit.
62208100|NCT03547973|EXPERIMENTAL|Cohort 7 (Phase 1: Safety Lad-in and Dose Expansion): SG + Enfortumab Vedotin (EV) + ZIM|"In the safety lead-in phase, participants will receive a starting dose level of SG 7.5 mg/kg IV and starting dose level of EV 1.25 mg/kg IV will be administered on Days 1 and 8 of each 21-day cycle and ZIM 360 mg IV will be administered on Day 1 of each 21-day cycle.~In dose-expansion, participants will receive SG IV and EV IV at the RP2Ds on Days 1 and 8 of each 21-day cycle and ZIM 360 mg IV on Day 1 of each 21-day cycle."
62208101|NCT03547973|EXPERIMENTAL|Cohort 7 (Phase 2: Arm 1): SG + EV + ZIM|Upon completion of the Cohort 7 dose-expansion phase, participants will receive SG IV at the RP2D in combination with EV IV at the RP2D, and ZIM 360 mg IV until PD, unacceptable toxicity, or loss of clinical benefit.
62208102|NCT03547973|EXPERIMENTAL|Cohort 7 (Phase 2: Arm 2): EV + ZIM|Upon completion of the Cohort 7 dose-expansion phase, participants will receive EV 1.25 mg/kg IV and ZIM 360 mg IV.
62208103|NCT03547973|EXPERIMENTAL|Cohort 7 (Phase 2: Arm 3): Optional Dose Optimization SG + EV + ZIM|Upon completion of the Cohort 7 dose-expansion phase, participants will receive SG IV at 1 dose level below the RP2D in combination with EV 1.25 mg/kg IV and ZIM 360 mg IV.
62208104|NCT06617923|EXPERIMENTAL|Treatment|Senaparib 80mg Temozolomide 20mg
62208105|NCT06729593|EXPERIMENTAL|Remdesivir + SOC|
62208106|NCT06729593|PLACEBO_COMPARATOR|Placebo + SOC|
62208107|NCT06295393||Pediatric Septic|1 day -18 year olds admitted to the ICU meeting criteria for sepsis define as pSOFA \>/= 2 and/or Phoenix score.
62406352|NCT06653530|SHAM_COMPARATOR|Sham thread embedding acupuncture|The participants in the sham thread embedding acupuncture therapy group will receive treatment that consists of 18 sham thread embedding acupuncture sessions over a 24-week period after baseline (once a week for the first 12 weeks and every two weeks for the next 12 weeks).
62208108|NCT06295393||Healthy|1 day - 18 year old; healthy outpatient
62208109|NCT03486860|EXPERIMENTAL|Turtle Program|The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
62208110|NCT03486860|OTHER|Waitlist Control|Untreated comparison group during the study, received parent psychoeducation intervention after the active treatment group.
62208111|NCT06597539||Diagnosis of advanced hepatobiliary malignancies|Patients diagnosis of advanced hepatobiliary malignancies require immunotherapy or combination immunotherapy after evaluation according to clinical guidelines
62208112|NCT04969419||Cases|Patients with a confirmed diagnosis of Vitiligo within the study period will be included as cases for analysis.
62208113|NCT04969419||Controls|The controls will be defined by matching cases with people who have never been diagnosed with vitiligo either prior to or during the study period, by age and sex, at General Practice level.
62208114|NCT03884946|ACTIVE_COMPARATOR|Immediate Delivery|Participants randomized into the Immediate Delivery arm (n = 150) receive access to the app immediately upon enrollment, and are given a pre- (baseline) and post- (one month post-baseline) test.
62208115|NCT03884946|PLACEBO_COMPARATOR|Delayed Delivery|Participants randomized into the Delayed Delivery arm (n = 150) don't receive access to the app until one month post-baseline. For the RCT portion of the analysis, they will also be assessed at baseline and one month post-baseline (i.e., a pre- and post- prior to app exposure, making them the placebo comparator).
62208116|NCT04396574|EXPERIMENTAL|Lasmiditan Dose 1|Lasmiditan administered orally.
62208117|NCT04396574|EXPERIMENTAL|Lasmiditan Dose 2|Lasmiditan administered orally.
62406353|NCT01118949|EXPERIMENTAL|Lacosamide|
62581596|NCT05322577|EXPERIMENTAL|Part 1 Cohort A: Bemarituzumab with CAPOX|
62017735|NCT05145231||grup 1|GMFCS PEDİ ABİLOCO-KİDS FMS
62017736|NCT04715594||CONNECT DES Registrty|
62017737|NCT06534333||Group 1|Patellofemoral pain syndrome group
62406354|NCT03296397|ACTIVE_COMPARATOR|HPV Quadrivalent vaccine (QHV)|Gardasil
62406355|NCT03296397|PLACEBO_COMPARATOR|Placebo|Normal Saline
62017738|NCT06534333||Group 2|Control group
62017739|NCT05779657|EXPERIMENTAL|Study group (Ket-Mid)|Children receiving ketamine + midazolam
62017740|NCT05779657|PLACEBO_COMPARATOR|Control group (Pla-Mid)|Children receiving placebo + midazolam
62017741|NCT02642913|EXPERIMENTAL|Enzalutamide without Sorafenib|Will get enzalutamide, at the dose approved by the FDA for prostate cancer. If this dose has serious side effects, a lower dose will be given to new patients as they take part in the study. At the end of this part of the study, the recommended dose of enzalutamide will be set for all patients on this study. More patients will then be treated with this dose.
62208118|NCT05434052||stroke patients|The aim of this study is to adapt the Community Integration Questionnaire-Revised (CIQ-R)scale to Turkish society in stroke patients and to make its validity and reliability in Turkish.
62406356|NCT06650007|EXPERIMENTAL|Group A|
62406357|NCT06650007|PLACEBO_COMPARATOR|Group B|
62406358|NCT06650007|EXPERIMENTAL|Group C|
62406359|NCT06650007|PLACEBO_COMPARATOR|Group D|
62406360|NCT01577082|EXPERIMENTAL|CHF 1535 200/6µg|
62581597|NCT05322577|EXPERIMENTAL|Part 1 Cohort C: Bemarituzumab with CAPOX and Nivolumab|
62581598|NCT05322577|EXPERIMENTAL|Part 1 Cohort D: Bemarituzumab with SOX and Nivolumab|
62581599|NCT05322577|EXPERIMENTAL|Part 2: Bemarituzumab with SOX and Nivolumab.|
62406361|NCT01577082|ACTIVE_COMPARATOR|BDP 100µg|
62406362|NCT00845559|EXPERIMENTAL|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide.
62406363|NCT00845559|NO_INTERVENTION|No Treatment|
62208119|NCT04733027|EXPERIMENTAL|Part 2 cohort 1 : PEP010 in combination with paclitaxel|Fort part 2 the Cohort 1 will include patients with PDAC treated with the combination of PEP-010 at the dose of 2.5 mg/kg and weekly paclitaxel 80 mg/m².
62208120|NCT04733027|EXPERIMENTAL|Part 2 cohort 2 : PEP010 in combination with gemcitabine|"In arm B, the dose escalation phase will begin with DL4 (1.2 mg/kg) and will follow a 3+3 design For part 2 Cohort 2 will include patients with PDAC or OC treated with the combination of PEP-010 in ascending doses, and gemcitabine at 1000 mg/m2.~Four doses of PEP-010 will be tested: 1.2 mg/kg, 2.5 mg/kg, 5 mg/kg and 10 mg/kg, according to a 3+3 dose escalation design.~Once a MTD is achieved, and in light of safety, PK, and PD data, two dosing schedules will be further explored based on TSC recommendations. Each dosing schedule will be evaluated in a separate cohort to generate more data and inform on the choice of the RP2D, as per the recommendations of the FDA (Project Optimus). Patients will be randomized simultaneously in the two dose cohorts, each would include approximately 6 - 10 patients."
62208121|NCT06421155|OTHER|MRF +/-Neurocognitive Testing|Once the participants meeting the inclusion criteria are identified and formally consent to participate in the study, each participant will undergo a baseline MRF imaging exam along with the neurocognative testing, preferably prior to starting induction chemotherapy. The total treatment duration for an individual participant can vary anywhere between 6 months - 3 years depending on the type of acute leukemia, so investigator plans to obtain MRF scans every 6 months during the therapy as well as during the first year of the off -therapy period
62208122|NCT02458222|EXPERIMENTAL|game therapy then standard therapy|participants will take part in language game therapy followed by standard aphasia therapy
62406364|NCT06282185|EXPERIMENTAL|intervention|supervised training program for twelve weeks + usual care + advice about exercise
62581600|NCT05997069|EXPERIMENTAL|Posterior-anterior vertebral mobilizations followed by Prone press-up exercise|In experimental group the application of posterior-anterior vertebral mobilizations (three bouts of 40 seconds oscillations will be applied at the rate of approximately 3 oscillations per second and at the highest amplitude when tolerated without the reproduction of symptoms) followed by Prone press-up exercise (Ten repetitions will be performed with 5 second hold. on successful completion of 10 repetitions without increase in discomfort, second and third sets will be performed) will given.
62735038|NCT05679661|EXPERIMENTAL|Group C (routine nutrition advice and oral chlorhexidine decontamination, RN&CD)|Patients will be advised to follow a standard nutrition advice with a total intake of 30kcal/kg/d and protein intake of 1.2g/kg/d. Patients will also receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
62208123|NCT02458222|EXPERIMENTAL|standard therapy then game therapy|participants will have standard aphasia therapy first then will take part in language game therapy
62208124|NCT05474339|EXPERIMENTAL|Cardiac rehabilitation group|
62208125|NCT05474339|NO_INTERVENTION|Control group|
62406365|NCT06282185|NO_INTERVENTION|usual care|usual care + advice about exercise
62406366|NCT06382324|EXPERIMENTAL|intervention arem|The patient randomized in the intervention arm will listen to the records of body scan for 40 minutes with polysomnography evaluation
62406367|NCT06382324|PLACEBO_COMPARATOR|control arm|listening to light music for 40 minutes with polysomnography evaluation
62406368|NCT04866602|EXPERIMENTAL|Atoguanil|Atovaquone 500 mg + Proguanil 348 mg
62406369|NCT04866602|ACTIVE_COMPARATOR|Malarone®|Atovaquone 1000 mg + Proguanil HCl 400 mg
62406370|NCT00998166|EXPERIMENTAL|Pemetrexed, Cisplatin, Bevacizumab|Chemotherapy infusion on Day 1 of a 3-week cycle
62406371|NCT03022526|EXPERIMENTAL|CSE|intrathecal bupivacaine 2.5mg + fentanyl 15mcg followed by infusion (PCEA): bupivacaine 0.083% with fentanyl 2mcg/mL: basal 8mL/hr, demand 8mL, 2 boluses per hour allowed, total maximum hourly allowance 24mL
62406372|NCT03022526|ACTIVE_COMPARATOR|Epidural|epidural bupivacaine 0.083% + fentanyl 2mcg/mL (8mL) followed by fentanyl 100mcg (2mL); follwed by infusion (PCEA): bupivacaine 0.083% with fentanyl 2mcg/mL: basal 8mL/hr, demand 8mL, 2 boluses per hour allowed, total maximum hourly allowance 24mL
62406373|NCT01383759|EXPERIMENTAL|Bortezomib/Dexamethasone (BD) , STC & Maintenance BD|This is a pilot study to gain information and estimate the toxicity/tolerability of 1-3 cycles of BD, followed by HDM/ASCT, and maintenance therapy with BD in patients with MIDD associated with multiple myeloma and AL amyloidosis.
62406374|NCT04392791|ACTIVE_COMPARATOR|Treated group|The participants received thermal water therapy
62789759|NCT05496296|ACTIVE_COMPARATOR|Standard of Care Dressing for Pressure Injury|Standard wound dressings recommended by the National Pressure Injury Advisory Panel (NPIAP), according to the wound stage, will be utilized to treat pressure injuries. These include hydrocolloid, hydrogel, polymeric membranes, foam, collagen dressings, and negative pressure wound therapy. Dressings will be changed according to wound conditions, and type of dressing selected.
62406375|NCT04392791|NO_INTERVENTION|Control group|The participants haven't received thermal water therapy
62406376|NCT02569502|EXPERIMENTAL|Enfuvirtide|Participants will receive 180 milligrams (mg) of enfuvirtide adminstered twice daily as subcutaneous injections
62406377|NCT05321342|EXPERIMENTAL|Intervention group|This group will receive Professional Development and Coaching (CCU)
62406378|NCT05321342|NO_INTERVENTION|Control group|Business as usual
62406379|NCT05843253|EXPERIMENTAL|Stratum A (n=40)|Patients with localized, intracranial, non-pontine, and non-thalamic HGG (who do not meet criteria for strata B, C, or D).
62789760|NCT05496296|ACTIVE_COMPARATOR|Altrazeal® Transforming Powder Dressing|Altrazeal® Transforming Powder Dressing will be applied during the Baseline visit. It should be left in place for up to 30 days, and topped off (additional powder applied if needed) at each subsequent visit. Secondary dressing, including a contact layer over the Altrazeal® and a secondary dressing (like gauze or foam) may be applied over the contact layer.
62406380|NCT05843253|EXPERIMENTAL|Stratum B (n=40)|Patients with DIPG, defined as a tumor with pontine epicenter and diffuse involvement of at least 2/3 of the pons, with histopathology consistent with diffuse WHO grade 2-4 glioma (e.g., diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, H3K27-altered diffuse midline glioma).
62406381|NCT05843253|EXPERIMENTAL|Stratum C (n=6-12)|Patients with primary thalamic, spinal cord, and/or secondary (radiation-related) HGG.
62406382|NCT05843253|EXPERIMENTAL|Stratum D (n=6-12)|Patients with metastatic/disseminated HGG, multifocal HGG, and/or gliomatosis cerebri who received craniospinal irradiation.
62406383|NCT04681859|ACTIVE_COMPARATOR|High Flow Nasal Oxygen (HFNO) treatment|
62406384|NCT04681859|EXPERIMENTAL|Continuous positive airway pressure (CPAP) therapy using OxyJet|
62581601|NCT05997069|ACTIVE_COMPARATOR|Conventional physiotherapy|In conventional physiotherapy, the application of thermotherapy on lower back region (continuous with duration of 10 minutes) by means of hot pack followed by general stretching exercises (Lower Back, Hamstring, Tensor Fasciae Latae Stretching with two sets and ten repetitions) will given.Thirty second rests will be taken every five minutes during the stretching session.
62581602|NCT03820635||Calcified|those with evidence of vascular calcification
62581603|NCT03820635||Non-calcified|those with no evidence of vascular calcification
62581604|NCT06683456|EXPERIMENTAL|eMOTE|Participants will have access to eMOTE for eight weeks.
62581605|NCT06683456|NO_INTERVENTION|Waiting List|Participants will be on a waiting list group for eight weeks. After that period, the participants will have access to eMOTE.
62581606|NCT04106219|EXPERIMENTAL|LY3295668 Erbumine Escalation|LY3295668 Erbumine given orally.
62789761|NCT04117529|EXPERIMENTAL|Experimental Arm|Pemphigus or other autoimmune diseases.
62789762|NCT05836883|PLACEBO_COMPARATOR|Cohort 1: Placebo|Local injection 15 mL of normal saline on Day 0
62789763|NCT05836883|PLACEBO_COMPARATOR|Cohort 2: Placebo|Local injection 30 mL of normal saline on Day 0
62406385|NCT04505592|EXPERIMENTAL|Tenecteplase|First 20 patients randomized to treatment will receive tenecteplase 0.25 mg/kg (maximum 25 mg). Last 20 patients randomized to treatment will receive tenecteplase 0.50 mg/kg (maximum 40 mg).
62581607|NCT04106219|EXPERIMENTAL|LY3295668 Erbumine + Topotecan + Cyclophosphamide Escalation|LY3295668 Erbumine given orally and topotecan and cyclophosphamide given intravenously (IV).
62581608|NCT04106219|EXPERIMENTAL|LY3295668 Erbumine Expansion|LY3295668 Erbumine given orally.
62581609|NCT04106219|EXPERIMENTAL|LY3295668 Erbumine + Topotecan + Cyclophosphamide Expansion|LY3295668 Erbumine given orally and topotecan and cyclophosphamide given IV.
62581610|NCT01122394|EXPERIMENTAL|Tailored Intervention (TI)|Tailored intervention based on the transtheoretical model
62581611|NCT01122394|PLACEBO_COMPARATOR|Attention Placebo (AP)|Attention Placebo
62581612|NCT00887848|EXPERIMENTAL|Lokomat training|Lokomat training
62581613|NCT00887848|OTHER|Waiting list|Lokomat training after waiting phase of 5 weeks
62406386|NCT04505592|PLACEBO_COMPARATOR|Placebo|Placebo control
62406387|NCT02267343|EXPERIMENTAL|ONO-4538 Arm|ONO-4538 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
62406388|NCT02267343|PLACEBO_COMPARATOR|Placebo Arm|Placebo intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
62406389|NCT04887922|NO_INTERVENTION|Pre-Surgery: No Incentive Spirometry (IS)|-Will not receive a incentive spirometer prior to surgery
62406390|NCT04887922|EXPERIMENTAL|Pre-Surgery: Standard Incentive Spirometry (IS)|"* Will receive a conventional spirometer prior to surgery~* Will be asked to perform spirometry 30 times per day."
62581614|NCT03055897|EXPERIMENTAL|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
62581615|NCT06684873|EXPERIMENTAL|AK112 combined with chemotherapy|AK112 combined with chemotherapy
62581616|NCT00836381|EXPERIMENTAL|Tolterodine ER|Tolterodine ER 4mg once daily
62581617|NCT00836381|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62581618|NCT01250574||Postoperative infections|
62789764|NCT05836883|PLACEBO_COMPARATOR|Cohort 3: Placebo|Local injection 30 mL of normal saline on Day 0 and Month 3
62789765|NCT05836883|EXPERIMENTAL|Cohort 1: Treatment|Local injection of 15 mL of ExoFlo on Day 0
62789766|NCT05836883|EXPERIMENTAL|Cohort 2: Treatment|Local injection of 30 mL of ExoFlo on Day 0
62789767|NCT05836883|EXPERIMENTAL|Cohort 3: Treatment|Local injection of 30 mL of ExoFlo on Day 0 and Month 3
62789768|NCT05994027|OTHER|ATTACH™ Online Platform Parenting Program|"A quasi-experimental design was selected to more closely approximate service delivery models in agencies that do not typically employ control groups.~Given promising findings (from seven ATTACH™ pilot studies), a randomized controlled trial design, even employing wait-list controls, was deemed unacceptable and even unethical by patients, healthcare professionals, and health system administrators in engagement activities surrounding the preparation of this proposal."
62406391|NCT04887922|EXPERIMENTAL|Pre-Surgery: Digital Incentive Spirometry (IS) + Text Message|"* Will receive the digital incentive spirometer (Spirobank G) that is compatible with health monitoring software developed by ZEPHYRx®. The digital spirometer couples with a HIPAA-compliant mobile application that calculates and stores pulmonary function test (PFT) results.~* Will be asked to perform spirometry 10 times per hour, every hour while awake, every day for at least 7 days prior to surgery. Absence of spirometry for 24 hours will trigger a text message reminder to encourage compliance with IS."
62406392|NCT04887922|ACTIVE_COMPARATOR|Post-Surgery: Standard Incentive Spirometry (IS)|"* After surgery, the participants will receive a conventional spirometer.~* Will be instructed to perform spirometry 10 times per hour, every hour while awake through postoperative Day 3~* The conventional spirometer will be equipped with an accelerometer that will allow the research team to determine whether the spirometer moves throughout the patients' postoperative stay (as a proxy for IS use)"
62017742|NCT02642913|EXPERIMENTAL|Enzalutamide with Sorafenib|Will get enzalutamide and sorafenib. The first group of patients will get the recommended dose of enzalutamide with sorafenib by mouth either once or twice daily. The dose of sorafenib you receive will depend on when the patient starts the study. At the beginning of the study, patients will be treated with a lower dose of sorafenib. If this dose does not have serious side effects, a higher dose will be given to new patients as they take part in the study.
62017743|NCT06535269|ACTIVE_COMPARATOR|Control|Conventional hemorrhoidectomy with monopolar diathermy + intravenous analgesia with elastomeric pump + discharge with home hospitalization.
62406393|NCT04887922|EXPERIMENTAL|Post-Surgery: Digital Incentive Spirometry (IS) + Text Message|"* After surgery, the participants will receive the digital incentive spirometer (Spirobank G) that is compatible with health monitoring software developed by ZEPHYRx®. The digital spirometer couples with a HIPAA-compliant mobile application that calculates and stores pulmonary function test (PFT) results.~* Will be instructed to perform spirometry 10 times per hour, every hour while awake through postoperative Day 3~* Will receive text reminders to perform spirometry if they do not perform spirometry in a 24-hour period."
62406394|NCT02921646|OTHER|energetic expenditure measure|To a standard treatment by chemotherapy, energetic expenditure will be measured 5 times during the study.
62406395|NCT00620191|PLACEBO_COMPARATOR|Matching Placebo|Placebo identical to metformin
62406396|NCT00620191|EXPERIMENTAL|Metformin|Metformin 1000 mg twice a day
62581619|NCT01250574||Bacterial infections in the GI tract|
62581620|NCT06419842|EXPERIMENTAL|hypnosis|In group 1, the patient benefits from a dedicated nurse consultation. During this consultation, the nurse will explain the highlights of the hospitalization, the procedure and anticipate the hypnosis technique to be used. The technique chosen during the consultation will be applied during the test. The nurse is positioned at the head of the patient and with physical contact.
62735039|NCT05679661|NO_INTERVENTION|Group D (routine nutrition advice and routine oral care, RN&RC)|Patients will be advised to follow a standard nutrition advice and routine oral care.
62789769|NCT00637416|ACTIVE_COMPARATOR|Lansoprazole and dietary control|Lansoprazole and dietary control
62789770|NCT00637416|PLACEBO_COMPARATOR|Placebo and dietary control|Dietary control and placebo
62789771|NCT04306263|EXPERIMENTAL|Enriched infant formula|Infant formula enriched with dairy ingredients: osteopontin, prebiotics (Human milk oligosaccharide, Glucooligosaccharides) and probiotics.
62017744|NCT06535269|EXPERIMENTAL|Experimental|conventional haemorrhoidectomy with Caiman® bipolar energy (AESCULAP®) + oral conventional analgesia + conventional home discharge.
62017745|NCT05014009|EXPERIMENTAL|FIFA11+ and multidirectional training (MD)|Participants in the MD group will take part in an 8-week NMT intervention known to reduce the risk of sports injury and expected to improve COD movement strategies.
62017746|NCT05014009|ACTIVE_COMPARATOR|FIFA11+ and linear sprint training (LS)|Participants in the LS group will take part in an 8-week NMT intervention, which is known to reduce the risk of sports injury but is unlikely to improve COD movement strategies and is expected to improve linear sprint performance.
62017747|NCT05447169||High risk population of nasopharyngeal carcinoma|first-degree relatives of nasopharyngeal carcinoma patients, aged 30-62 male
62017748|NCT05884034|EXPERIMENTAL|Telerehabilitation group|Self-care educational program via telerehabilitation
62017749|NCT05884034|ACTIVE_COMPARATOR|Education group|Self-care educational program via informative booklet
62789772|NCT04306263|ACTIVE_COMPARATOR|Standard formula|Infants receiving a standard infant formula.
62789773|NCT04306263|ACTIVE_COMPARATOR|Breastfeeding arm|Infants exclusively or predominantly breastfed (\>75%).
62789774|NCT05210387|EXPERIMENTAL|7-day adequate antibiotic therapy|Adequate antibiotic therapy is defined as antimicrobial treatment with at least one agent with in vitro susceptibility.
62789775|NCT05210387|ACTIVE_COMPARATOR|14-day adequate antibiotic therapy|Adequate antibiotic therapy is defined as antimicrobial treatment with at least one agent with in vitro susceptibility.
62789776|NCT05076890|EXPERIMENTAL|15 mg/g Full Spectrum Hemp Extract|A single capsule of 15 mg/g Full Spectrum Hemp Extract will be delivered.
62789777|NCT05076890|EXPERIMENTAL|50 mg/g Full Spectrum Hemp Extract|A single capsule of 50 mg/g Full Spectrum Hemp Extract will be delivered.
62789778|NCT02034838|EXPERIMENTAL|atazanavir 300mg boosted with ritonavir 100mg|"Two period drug interaction. Period one: atazanavir 300mg boosted with ritonavir 100 mg once daily as part of current treatment standard of care.~Period two: atazanavir 300 mg boosted with ritonavir 50 mg once daily for study days 2-8 inclusive"
62789779|NCT03614325|NO_INTERVENTION|Usual Anesthesia Care|Patients in the usual care arm will undergo the current standard of care for hand/wrist surgery and postoperative recovery. They will be asked to refrain from using a virtual reality headset during their surgery.
62208126|NCT03691272|EXPERIMENTAL|rTMS- Real Air Film Coil|Patient MR brain scans will be loaded and processed using the Brainsight TMS neuronavigation software and stereotaxic data for localization of the TMS stimulation site will be determined through a co-registration method between the TMS coil position and the projected site on the MR brain scan. The DLPFC will be located through MNI coordinates (-48, 20, 34). Electromyography (EMG) electrodes will be attached to the right abductor digiti minimi (ADM) muscle. The resting motor threshold (RMT) is determined as the minimal stimulation intensity required to elicit motor-evoked response of 50 microvolts peak-to-peak amplitude in at least 5 out of 10 consecutive trials of the ADM (contralateral to stimulation).
62581621|NCT06419842|SHAM_COMPARATOR|comfort|In group 2, the patient benefits from a nurse consultation. Non-medicinal techniques are not offered. During the infusion test, the nurse will be positioned at the patient's head allowing proximity but without oral or physical intervention.
62017750|NCT05885347|PLACEBO_COMPARATOR|Control group|This caregivers group will not receive any intervention different to the routinely practice.
62017751|NCT05885347|EXPERIMENTAL|Video Intervention|Caregivers will be taught by a video intervention about how to develop their home tasks during an hour.
62017752|NCT05885347|EXPERIMENTAL|Virtual reality|Caregivers will be taught by a VR intervention during 20minutes about how to develop their home tasks.
62017753|NCT05885347|EXPERIMENTAL|Augmented reality|Caregivers will be taught by a AR intervention during 20minutes about how to develop their home tasks.
62017754|NCT03933293|EXPERIMENTAL|AK102|450mg AK102, Q4W, subcutaneous injection
62017755|NCT03933293|PLACEBO_COMPARATOR|placebo|Placebo, Q4W, subcutaneous injection
62017756|NCT03957174|EXPERIMENTAL|Reboxetine|Single dose of 4mg
62017757|NCT03957174|EXPERIMENTAL|Rivastigmine|Single dose of 3mg
62017758|NCT03957174|PLACEBO_COMPARATOR|Placebo|Single dose of placebo
62208127|NCT03691272|SHAM_COMPARATOR|rTMS- Sham coil|The same procedure for determining RMT as described above will be employed for the Sham Arm. However, a sham coil will be used when the treatment over the left DLPFC is applied.
62208128|NCT06729840|ACTIVE_COMPARATOR|Group 1|Will include 15 patients will injected with vitamin D
62208129|NCT06729840|ACTIVE_COMPARATOR|Group 2|Will include 15 patients will injected with botulinum toxin type A
62208130|NCT06729840|ACTIVE_COMPARATOR|Group 3|Will include 15 patients will injected with triamcinolone acetonide
62208131|NCT05027633|OTHER|pembrolizumab, docetaxel, and cisplatin or carboplatin|IV
62789780|NCT03614325|EXPERIMENTAL|Virtual Reality Immersive Relaxation|"Patients in the experimental group will wear a headset and be immersed in a virtual reality environment during their surgery. There are various short videos and environments such as sitting on a beach that are designed to promote relaxation and calmness.~Throughout their surgery patients will be monitored according to current anesthesia standards. The relaxation programming will run for the duration of the operative procedure. At the end of the procedure the headset will be removed and standard postoperative care will commence."
62017759|NCT05367453|ACTIVE_COMPARATOR|Lactase|Volunteers will consume once a day for 1 month a tropical juice (orange, mango, pineapple and turmeric) and a lactase tablet
62208132|NCT05789069|EXPERIMENTAL|Dose Escalation - HFB200603 monotherapy|Participants will be administered HFB200603 at dose levels 1-4 as an intravenous infusion to determine the Recommended Dose for Expansion (RDE).
62208133|NCT05789069|EXPERIMENTAL|Dose Escalation - HFB200603 in combination with tislelizumab|Participants will be administered HFB200603 at dose levels 1-3 in combination with one dose level of tislelizumab as an intravenous infusion to determine the combination Recommended Doses for Expansion (RDEs).
62208134|NCT05789069|EXPERIMENTAL|Dose Expansion - HFB200603 monotherapy (optional)|Participants will be administered HFB200603 at monotherapy RDE as an intravenous infusion.
62208135|NCT05789069|EXPERIMENTAL|Dose Expansion - HFB200603 in combination with tislelizumab|Participants will be administered HFB200603 in combination with tislelizumab at combination RDEs as an intravenous infusion. Based on the cancer type, participants will be randomized to combination HFB200603 RDE 1 or RDE 2.
62208136|NCT05963347|EXPERIMENTAL|Go-CHOP|Golidocitinib in combination with CHOP
62208137|NCT04133909|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo subcutaneously once every 4 weeks over a treatment period of at least 52 weeks up to a maximum of 104 weeks.
62581622|NCT06419842|NO_INTERVENTION|standard|In group 3, the IDE consultation is performed according to the same modalities as in group 2. During the procedure, the nurse will be out of the patient's field of vision and will assist the surgeon in the installation behind the patient. Only the surgeon will interact with the patient.
62581623|NCT06137859|EXPERIMENTAL|Intervention|Participants will receive PLBI intervention treatment including weekly-based functional fitness training, mastering physical literacy class, daily based reflective writing, buddy peers support group.
62789781|NCT06583629|EXPERIMENTAL|Enrolled participants|
62017760|NCT05367453|EXPERIMENTAL|Probiotic|Volunteers will consume once a day for 1 month the probiotic added to a liquid matrix (tropical juice) and and a placebo tablet (cornstarch)
62017761|NCT06535308|EXPERIMENTAL|BnH-015B 5 mg|Cohort 1 / Single-dose
62017762|NCT06535308|EXPERIMENTAL|BnH-015B 10 mg|Cohort 2 / Single-dose
62017763|NCT06535308|EXPERIMENTAL|BnH-015B 20 mg|Cohort 3 / Single-dose
62017764|NCT06535308|EXPERIMENTAL|BnH-015B 40 mg (Dietary impact)|Cohort 4 / Single-dose
62017765|NCT06535308|EXPERIMENTAL|BnH-015B 40 mg|Cohort 4-1 / Single-dose
62017766|NCT06535308|EXPERIMENTAL|BnH-015B 80 mg|Cohort 5 / Single-dose
62017767|NCT06535308|EXPERIMENTAL|BnH-015B 160 mg|Cohort 6 / Single-dose
62017768|NCT06535308|EXPERIMENTAL|BnH-015B 40 mg (MAD)|Cohort 7 / Multiple-dose
62017769|NCT06535308|EXPERIMENTAL|BnH-015B 80 mg (MAD)|Cohort 8 / Multiple-dose
62017770|NCT06535308|EXPERIMENTAL|BnH-015B 40 mg (Part II)|Experimental group 1
62017771|NCT06535308|EXPERIMENTAL|BnH-015B 80 mg (Part II)|Experimental group 2
62017772|NCT06535308|PLACEBO_COMPARATOR|BnH-015B Placebo (Part II)|Placebo group
62208138|NCT04133909|EXPERIMENTAL|Mepolizumab|Participants will receive mepolizumab subcutaneously once every 4 weeks over a treatment period of at least 52 weeks up to a maximum of 104 weeks.
62208139|NCT06338930|EXPERIMENTAL|Remote monitoring group|This group will follow the remote monitoring programme.
62208140|NCT06338930|NO_INTERVENTION|Control group|This group will be monitored following the standard of care.
62208141|NCT03812302|EXPERIMENTAL|DOTATATE|All 15 GCA patients will undergo 68-Ga HA-DOTATATE PET/CT imaging at baseline, in addition to FDG PET/CTA (as part of standard of care). DOTATATE PET/CT imaging will be repeated at 6 months follow-up.
62017773|NCT02129686|EXPERIMENTAL|Immediate Acupuncture Group|"Immediate acupuncture arm will receive acupuncture 3 times per week during week 1 and week 2, then 2 times per week from week 2 to week 8 for a total of 18 sessions. The crossover will take place after 8th week.~The immediate acupuncture arm will enter a follow-up phase without acupuncture for 8 weeks from week 9 to week 16, while the standard usual care will be provided."
62017774|NCT02129686|ACTIVE_COMPARATOR|Delayed Acupuncture Group|The patients on the usual care/delayed acupuncture arm will continue their standard usual care with their physicians and care team. The crossover will take place after 8th week. After crossover, the patients initially on the usual care/delayed acupuncture arm will receive the identical acupuncture protocol but a less frequent schedule from week 9 to week 16: 2 times per week at week 9, then 1 time per week from week 10 to week 16 for a total of 9 sessions
62017775|NCT03209908||control group|In this group, pregnant women with HBsAg/HBeAg positive and HBV DNA \> 106 copies/ml don not use any antiviral drugs during pregnancy.
62208142|NCT00964275|EXPERIMENTAL|Arm I|Patients undergo diagnostic fludeoxyglucose F 18 PET in addition to standard methods.
62208143|NCT00964275|ACTIVE_COMPARATOR|Arm II|Patients only undergo standard diagnostic methods.
62789782|NCT04371965|EXPERIMENTAL|Decolonization|1% Povidone iodine mouthwash (95 mL), gargle, and nasal spray (2,5 mL by nostril), and 10% nasal gel (one drop). All four time a day for five days.
62789783|NCT04371965|NO_INTERVENTION|Control|Absence of local decolonization
62017776|NCT03209908||experimental group|pregnant women with HBsAg/HBeAg positive and HBV DNA \> 106 copies/ml start to use Tenofovir Disoproxil Fumarate(TDF) antiviral treatment from the 32 weeks of gestation to block mother-to-child transmission of hepatitis B virus.
62017777|NCT06535178|EXPERIMENTAL|Sleep Regularity Group|Individuals in the lowest SRI tertile will begin the 12-week intervention to improve sleep regularity. Participants will be instructed to maintain a consistent sleep onset time (±30 min self-selected sleep time).
62017778|NCT06535178|NO_INTERVENTION|Control Group|All other participants will be instructed to maintain their habitual sleep patterns.
62208144|NCT00037830|ACTIVE_COMPARATOR|Early-Start Group|Subjects were randomized to receive GM1 ganglioside for 24 weeks.
62789784|NCT01991522|EXPERIMENTAL|Curriculum Group|The curriculum group will undergo a comprehensive curriculum in colonoscopy utilizing a virtual reality (VR) colonoscopic simulator. This curriculum involves 6 hours of interactive, small-group didactic teaching on colonoscopy interlaced with 8 hours of supervised one-on-one endoscopy VR simulation training with experienced endoscopists.
62789785|NCT01991522|ACTIVE_COMPARATOR|Self-directed learning group|The self-directed group will receive 8 hours of colonoscopic virtual reality (VR) simulation practice with an experienced endoscopist present, but without structured training.
62208145|NCT00037830|PLACEBO_COMPARATOR|Delayed-Start Group|Subjects were randomized to receive placebo for 24 weeks.
62208146|NCT00037830|NO_INTERVENTION|Comparison Group|A separate group of Parkinson's disease patients who received standard of care were followed for one to two years to provide comparative information about natural disease progression. This comparison group was not compared statistically to the treatment groups since they were not randomized.
62208147|NCT06573294|EXPERIMENTAL|GEN1057 Monotherapy|
62208148|NCT01162863|ACTIVE_COMPARATOR|Lubiprostone 8 mcg BID|
62208149|NCT01162863|ACTIVE_COMPARATOR|Lubiprostone 24 mcg QD|
62208150|NCT01162863|PLACEBO_COMPARATOR|Placebo|
62208151|NCT06034743|EXPERIMENTAL|2 mg baxdrostat|2 mg baxdrostat administered orally, once daily (QD).
62208152|NCT06034743|EXPERIMENTAL|1 mg baxdrostat|1 mg baxdrostat administered orally, once daily (QD).
62208153|NCT06034743|PLACEBO_COMPARATOR|Placebo|Placebo administered orally, once daily (QD).
62789786|NCT06279832|EXPERIMENTAL|Transcriptomic analyses|
62789787|NCT00196144|EXPERIMENTAL|1|Optimization of the postventricular atrial blanking period to avoid far-field R-wave sensing.
62789788|NCT00196144|EXPERIMENTAL|2|Programming of the nominal setting for the post-ventricular atrial blanking period (100 ms)
62208154|NCT03401008||Acromegalic patients|patients with a proven diagnosis of acromegaly achieved by an IGFA assay and a GH measure.
62208155|NCT05127187||Detainees in an Administrative Detention Center|
62017779|NCT03200522|ACTIVE_COMPARATOR|Prudent diet then Western diet|Participants randomized to this arm will received 6 days of meals consistent with a Prudent diet, followed by a washout period, and then 6 days of meals consistent with a Western diet.
62017780|NCT03200522|ACTIVE_COMPARATOR|Western diet then Prudent diet|Participants randomized to this arm will received 6 days of meals consistent with a Western diet, followed by a washout period, and then 6 days of meals consistent with a Prudent diet.
62017781|NCT03335657|EXPERIMENTAL|CBPT Treatment|The CBPT intervention delivers a patient-oriented cognitive-behavioral self-management program to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy. The program consists of six weekly telephone sessions with a trained physical therapist. Sessions cover an introduction and rationale for treatment in addition to techniques such as deep breathing, graded activity plan and goal-setting, distraction techniques, automatic thoughts, coping self-statements, being present-minded, and relapse prevention and symptom management plans. At the end of the 6th week, patients will build individualized recovery plans with selected strategies and details on frequency of practice.
62017782|NCT03335657|PLACEBO_COMPARATOR|Education Treatment|The education program provides a postoperative recovery and is based on education that would typically be provided by a treating physician or a physical therapist in an outpatient setting. The education program is matched to the CBPT treatment in terms of session frequency and contact with the study therapist. The therapist will call weekly to check in with the patient and encourage him/her to read the manual. Manuals contain educational information on injury patterns and symptoms, stress and recovery, benefits of physical therapy, and importance of daily exercise, and ways to promote healing. Education on sleep hygiene, energy management, healthy eating, and preventing future injury are also provided.
62017783|NCT03282084||Unproven GERD|Subjects with no prior testing, normal prior EGD or prior LA Grade A esophagitis
62208156|NCT01208649|ACTIVE_COMPARATOR|Exenatide|Drug (including placebo)
62208157|NCT01208649|PLACEBO_COMPARATOR|Placebo|
62581624|NCT06137859|NO_INTERVENTION|Control|Participants will not receive PLBI intervention treatment. However, participants in the control group will be given the same treatment (program and activities) after all data has been collected.
62581625|NCT04576377|EXPERIMENTAL|Influenza vaccination|
62581626|NCT04576377|PLACEBO_COMPARATOR|Placebo|
62581627|NCT05280626|EXPERIMENTAL|A: PD-1+R-CHOP|After one cycle of standard R-CHOP chemotherapy, Group A uses Sindilizumab + R-CHOP, with Sindilizumab administered on day 10 post-chemotherapy, scheduled for 5 cycles. After 5 cycles, CR patients in group A continue Sindilizumab treatment for 8 times, once every 21 days.
62581628|NCT05280626|ACTIVE_COMPARATOR|B: R-CHOP|After one cycle of standard R-CHOP chemotherapy, Group B uses R-CHOP and plans for 5 cycles. CR patients in group B are followed up for observation.
62581629|NCT03850912|NO_INTERVENTION|Activity 1: Stakeholder Feedback|"Obtain stakeholder feedback to inform eSyM finalization and implementation from:~* patient advisory councils~* health system leaders~* clinicians~* clinic support staff/administration~* IT/Informatics"
62017784|NCT03282084||Proven GERD|LA Grade B-D esophagitis, long-segment Barrett's, prior positive pH study
62017785|NCT05158946|EXPERIMENTAL|Intervention Group|Participants in the intervention group received Future Oriented Group Training in addition to their treatment as usual.
62017786|NCT05158946|NO_INTERVENTION|Control Group|Participants in the control group received their treatment as usual.
62017787|NCT04523129|EXPERIMENTAL|CyclASol Ophthalmic Solution|Cyclosporine A solution in vehicle
62017788|NCT04523129|PLACEBO_COMPARATOR|Vehicle Ophthalmic solution|Vehicle only
62017789|NCT02067013|ACTIVE_COMPARATOR|Ranibizumab|Subjects undergoing surgery for neovascular glaucoma, diabetic retinopathy, or tractional Retinal Detachment due to AMD will receive one intravitreal injection of ranibizumab within 2 weeks of their surgery. Vitreous and aqueous humor samples will be collected during the surgery. Serum samples may be collected before, during, or after surgery.
62017790|NCT02067013|PLACEBO_COMPARATOR|Control|Subjects undergoing surgery for ERM or macular hole will NOT receive an injection of ranibizumab, but will have vitreous, and aqueous humor samples collected during surgery (no serum collection).
62208158|NCT01915225||1/ Cohort 1|Subjects with or without solid tumors in whom diagnostic, preventative, or therapeutic intervention is being performed
62208159|NCT06598436|EXPERIMENTAL|Patient Intervention + Clinic Intervention|Digital coach navigator + Clinic Intervention
62208160|NCT06598436|NO_INTERVENTION|Patient Usual Care + Clinic Usual Care|Usual Care (Patient-Level) + Clinic Usual Care
62017791|NCT01348529|EXPERIMENTAL|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
62017792|NCT01095744||EOAD typical AD|this cohort is constituted with early onset typical AD.
62208161|NCT06598436|EXPERIMENTAL|Patient Intervention + Clinic Usual Care|Digital coach navigator + Clinic Usual Care
62208162|NCT06598436|EXPERIMENTAL|Patient Usual Care + Clinic Intervention|Usual Care (Patient-Level) + Clinic Intervention
62581630|NCT03850912|NO_INTERVENTION|Activity 2: eSym Build|"* Build and deploy eSyM~* Finalize training materials based on findings from stakeholder engagement"
62581631|NCT03850912|EXPERIMENTAL|Activity 3: Pilot Test eSyM App|"Pilot testing of the eSyM app will include:~* Activity 3a (eSyM app usage by patients)~* Activity 3b (User acceptability testing)~* Activity 3c (Medical record abstraction)"
62208163|NCT06728670|ACTIVE_COMPARATOR|Intravenous infusion of TXA|Slowly infuse 1g TXA at a rate of approximately 1 ml/min.
62208164|NCT06728670|EXPERIMENTAL|Intramuscular injection of TXA|1g TXA is administered with twice intramuscular injections, and each injection takes no more than 30 seconds. The injection site is chosen as the deltoid or lateral thigh muscle.
62208165|NCT02787044|EXPERIMENTAL|High Dose Influenza Vaccine|High Dose Influenza Vaccine
62208166|NCT02787044|ACTIVE_COMPARATOR|Standard Dose Influenza Vaccine|Standard Dose Influenza Vaccine
62208167|NCT04061044|EXPERIMENTAL|Treatment|
62208168|NCT03593226|EXPERIMENTAL|AGI-134|AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
62208169|NCT06685848|EXPERIMENTAL|A - Hemanext ONE system|Hypoxic RBCs
62208170|NCT06685848|ACTIVE_COMPARATOR|B - Conventional RBCs|Conventional RBCs
62208171|NCT00468143|EXPERIMENTAL|Adderall Extended Release First|This group was treated with Adderall extended release, either during phase 2 of the trial, or during phase 3 (this subset received Adderall immediate release during phase 2 and then underwent a washout period). This was a counterbalanced crossover study, with a washout period in between treatment periods. Participants were randomized in a 1:1 ratio to one of two schedules Adderall IR followed by Adderall XR, or Adderall XR followed by Adderall IR.
62581632|NCT03850912|EXPERIMENTAL|Activity 4: eSyM+ Participants|"* These patients (and/or proxy) will report their symptoms in eSyM~* A subset of these patients will be asked to complete a research questionnaire called the SASS (Self-Efficacy, Attainment of informational needs, Symptom Burden, and Satisfaction with care) Questionnaire (eSyM+ version or eSyM-Non-Responder version)~* A subset of these patients will be invited to take part in follow-up qualitative interviews.~* A medical record abstraction will be completed for all eSyM+ patients"
62406397|NCT03148834|EXPERIMENTAL|Control Reperfusion Primary Angioplasty|Patients admitted with acute myocardial infarction and TIMI flow 0/1, will be treated with the use of an intracoronary venous blood solution and dextran to protect the myocardium during reperfusion.
62406398|NCT03148834|NO_INTERVENTION|Standard Primary Coronary Angioplasty|Patients admitted with an acute myocardial infarction and TIMI flow 0/1, will be treated with primary angioplasty according to norms described in the international guidelines of treatment.
62406399|NCT01613066|EXPERIMENTAL|Treatment|Patients with high risk haematological malignancies
62406400|NCT03202329|OTHER|standard care|responsible surgeon has actively to ask for cardiology support (he decides whether a heart failure specialist should see the patient post-operatively)
62406401|NCT03202329|OTHER|nurse-based care|heart failure nurses visit postoperatively every (working-) day to check fluid balance, medication, rhythm and general condition
62406402|NCT06021873|ACTIVE_COMPARATOR|Laparoscopic SADI-S|Patients with indication to laparoscopic Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy
62581633|NCT03850912|EXPERIMENTAL|Activity 4: eSyM- Participants|"* These patients (and/or proxy) will NOT report their symptoms in eSyM~* A subset of these patients will be asked to complete a research questionnaire called the SASS Questionnaire (eSyM- version)~* A subset of these patients will be invited to take part in follow-up qualitative interviews.~* A medical record abstraction will be completed for all eSyM- patients"
62789789|NCT03235947|EXPERIMENTAL|Fosfomycin disodium|"* Fosfomycin disodium 4 g intravenously: 3 hours before kidney transplant surgery, 3 hours before urinary catheter removal and 3 hours prior to ureteral catheter removal.~* Trimethoprim / Sulfamethoxazole (160/800 mg) 1 tablet orally every 24 hours."
62406403|NCT06021873|ACTIVE_COMPARATOR|Robotic SADI-S|Patients with indication to robotic Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy
62406404|NCT01278381||Pancreaticoduodenectomy (PD)|Patients undergoing PD from 2002 to 2010
62406405|NCT03056456|EXPERIMENTAL|LY900014|LY900014 (Treatment B) delivered via an insulin pump as a continuous infusion under the skin, with various intermittent bolus doses immediately before meals over 3-days per period.
62406406|NCT03056456|ACTIVE_COMPARATOR|Insulin Lispro (Humalog)|Insulin lispro (Treatment A) delivered via an insulin pump as a continuous infusion under the skin, with various intermittent bolus doses immediately before meals over 3-days per period.
62406407|NCT05859594|EXPERIMENTAL|Experimental (laughter yoga) group|The intervention group will receive eight online laughter yoga sessions, two sessions per week for four weeks. In this study, the number of laughter yoga sessions was determined in line with the studies in the literature. Each laughter yoga session is planned to last approximately 40-45 minutes. Each session of laughter yoga consists of clapping and warm-up exercises, deep breathing exercises, childlike play and laughter.
62581634|NCT05025228||Paracetamol IV|Patients with femur fracture that received an initial analgesic treatment with paracetamol intravenously (IV).
62581635|NCT05025228||Paracetamol OR|Patients with femur fracture that received an initial analgesic treatment with paracetamol orally (OR).
62735040|NCT04520152|EXPERIMENTAL|Treatment group|Bronchoscopic LTD placement
62789790|NCT03235947|ACTIVE_COMPARATOR|Trimethoprim / Sulfamethoxazole|"* Trimethoprim / Sulfamethoxazole (160/800 mg) 1 tablet orally every 24 hours.~* Intravenous placebo solution at the same time of application of fosfomycin disodium in the experimental arm."
62789791|NCT02289794|ACTIVE_COMPARATOR|E.coli bioconjugate vaccine|E.coli bioconjugate vaccine in saline buffer
62789792|NCT02289794|PLACEBO_COMPARATOR|Placebo|Saline buffer
62789793|NCT03887234|ACTIVE_COMPARATOR|Through the coracoid|The semitendinosus tendon graft goes through the 4.5 mm coracoid drill hole.
62789794|NCT03887234|EXPERIMENTAL|Around the coracoid|The semitendinosus tendon graft goes around the coracoid.
62017793|NCT01095744||LOAD typical|this group is constituted with late onset typical AD
62789795|NCT04712708|ACTIVE_COMPARATOR|Control Group|Eighteen children with spastic CP will receive especially designed physical therapy program based on Neuro-Developmental treatment (NDT) approach with emphasis on exercise encourage independent standing, stretches exercises, strengthening exercises, approximation, enhancement and facilitation of gait patterning and ankle ROM exercises for one hour for 24 sessions
62017794|NCT01095744||atypical AD|this group is constituted with atypical form of focal cortical atrophy, like posterior cortical atrophy and logopenic progressive aphasia.
62017795|NCT01095744||young controls|under 65
62581636|NCT05016180|PLACEBO_COMPARATOR|Normal Saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
62581637|NCT05016180|EXPERIMENTAL|Ropivacaine|Before the induction of anesthesia, Ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
62581638|NCT05175391|ACTIVE_COMPARATOR|Meat based protein, no spice|Test meal will be a chicken salad entree consisting of shredded skinless chicken breast, mayonnaise, lemon juice, celery, salt and pepper, with whole wheat crackers and grapes as side items.
62017796|NCT01095744||old controls|over 65
62017797|NCT05430386|EXPERIMENTAL|Dose escalation and dose expansion|HS-10241 in combination with Almonertinib
62406408|NCT05859594|NO_INTERVENTION|Control group|The control group will receive no intervention for 4 weeks.
62017798|NCT03762226||Patient with Macular edema|Patients with clinically significant macular edema due to diabetes or retinal vein occlusion, undergoing at least 4 monthly intravitreal anti-VEGF injections.
62017799|NCT01714024|EXPERIMENTAL|Healthy Volunteers|Subjects who are non-diabetic, with no history of smoking within the past two years and no metabolic bone disease diagnosis.
62017800|NCT01714024|EXPERIMENTAL|Diabetic Subjects|Subjects must have Type 2 diabetes mellitus as diagnosed by a physician or in medication history. The condition must be currently diagnosed and treated by medications and/or insulin.
62581639|NCT05175391|EXPERIMENTAL|Meat based protein, spice added|Test meal will be a chicken salad entree consisting of shredded skinless chicken breast, mayonnaise, lemon juice, celery, salt and pepper, onion powder, garlic powder, dill and ground mustard seed, served with whole wheat crackers and grapes as side items.
62581640|NCT05175391|ACTIVE_COMPARATOR|Plant based protein, no spice|Test meal will be a chick pea and rice salad entree consisting of chick peas, brown rice, mayonnaise, yogurt, lemon juice, celery, soy protein powder, salt and pepper, served with whole wheat crackers and grapes as side items.
62017801|NCT01714024|EXPERIMENTAL|Osteopenic Subjects|Subjects must be diagnosed with osteoporosis or osteopenia and must be currently under the care of a physician and treatment with oral bisphosphonates
62017802|NCT05836038|EXPERIMENTAL|Visio-tactile stimulation (VTS) during Virtual Reality|Participants in this group will receive visio-tactile stimulation prior to engaging with the VR program. They will see their virtual hand touched while simultaneously feel their opposite real hand touched in the same pattern.
62017803|NCT05836038|NO_INTERVENTION|No Visio-Tactile Stimulation (NoVTS) during Virtual Reality|Participants in this group will not receive visio-tactile stimulation prior to engaging with the VR program. They will be asked to look at their virtual hands for approximately the same amount of time as the VST group receive their stimulation
62017804|NCT04286347|EXPERIMENTAL|HCV, HBV, HIV testing|All patient ≥ 18 years-old with a next planned surgery in Lariboisiere Hospital, Paris, France, able to give written informed consent for testing will be proposed to be tested for HIV and HCV if no previous testing found in the medical record and will be proposed to be tested for HBV if the patient belong to a high-risk group: high prevalence area (Asia, sub-Saharan Africa, French Indies, East and South Europe, North-Africa, Middle-East, India, Pakistan, South-America), IVDU, prisoners, unprotected sexual intercourses.
62017805|NCT05745740|EXPERIMENTAL|RC48-ADC + Pyrotinib|
62017806|NCT01116960||Faculty; MD|Full time Faculty members working with the Department
62017807|NCT01116960||CRNAs|Full time CRNAs working within the department
62406409|NCT03962426|ACTIVE_COMPARATOR|Social Cognitive Training (SCT)|10 hours of computerized SCT using tablet with 30-minute sessions, 4-5 times per week
62406410|NCT03962426|NO_INTERVENTION|Treatment as usual (TAU)|This arm is getting treatment as usual, meaning antipsychotic medication (any needed medication in general) and psychotherapy/occupational therapy
62406411|NCT05071846|EXPERIMENTAL|MVX-ONCO-2|Implantation of 2 capsules containing MVX-2 cells and 1 injection of 4 × 10\^6 lethally irradiated autologous tumor cells
62581641|NCT05175391|EXPERIMENTAL|Plant based protein, spice added|Test meal will be a chick pea and rice salad entree consisting of chick peas, brown rice, mayonnaise, yogurt, lemon juice, celery, soy protein powder, salt and pepper, onion powder, garlic powder, cumin, parsley, dill, oregano, ground rosemary and ground mustard seed, served with whole wheat crackers and grapes as side items.
62789796|NCT04712708|EXPERIMENTAL|Study Group|ighteen children with spastic CP will receive the same program that the control group received in addition to especially designed exercises using rebound therapy (Mini Trampoline) that include push up exercise, standing, squatting, single limb squatting, kneeling position, catching and throwing a ball over head in kneeling position, catching and throwing a ball over head in standing position, kicking the ball, broad jumping with assistance, jumping in place, for 1 hour three times per week for three successive months.
62789797|NCT05950984||Critically Ill Adults and Children|Adults and children from 1-day old admitted to a critical care unit.
62789798|NCT04383327|EXPERIMENTAL|ParentCorps-Professional Development (PD)|"n = 6 Schools in Kampala, Uganda (Urban) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs~+ n = 6 Schools in Hoima, Uganda (Rural) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs"
62789799|NCT04383327|EXPERIMENTAL|ParentCorps-Professional Development (PD) + T-Wellness|"n = 6 Schools in Kampala, Uganda (Urban) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs~+ n = 6 Schools in Hoima, Uganda (Rural) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs"
62789800|NCT04383327|NO_INTERVENTION|Control|"n = 6 Schools in Kampala, Uganda (Urban) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs~+ n = 6 Schools in Hoima, Uganda (Rural) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs"
62789801|NCT01771796|EXPERIMENTAL|Aerobic and muscle resistance training|
62789802|NCT01771796|NO_INTERVENTION|Usual care group|All patients (intervention and usual care group) are patients with lung cancer who underwent a resection surgery.
62789803|NCT02277925|ACTIVE_COMPARATOR|Gore-Tex permanent suture|Participants in this arm will receive Gore-Tex permanent suture
62406412|NCT02046655|EXPERIMENTAL|Corifollitropin alfa group|"On day 2 of the cycle, a single subcutaneous (SC) dose of 150 μg Corifollitropin alfa (Elonva) will be administered.~GnRH antagonist (Orgalutran) 0.25 mg/day flexible initiation by a follicle of 14mm.~A daily dose of recFSH (450 IU/day) will be used from day 8 of stimulation until the day of hCG, if necessary.~Triggering of final oocyte maturation will be performed using 250 μg of rechCG."
62406413|NCT02046655|ACTIVE_COMPARATOR|rec FSH group|"On day 2 of the cycle, daily SC dose of min 450 IU recFSH (Puregon) will be administered.~GnRH antagonist (Orgalutran) 0.25 mg/day , flexible initiation by a follicle of 14mm.~Triggering of final oocyte maturation will be performed using 250 μg of rechCG."
62406414|NCT06175468|PLACEBO_COMPARATOR|Placebo control group|take the placebo drug 5g/bag、three times a day, treatment for 5 days
62017808|NCT01116960||Residents|Residents working within the department
62406415|NCT06175468|ACTIVE_COMPARATOR|Treatment group|take the Formosa 1-Breath Free (NRICM101) 5g/bag、three times a day, treatment for 5 days
62406416|NCT00714025|EXPERIMENTAL|I|40 patients with metastatic or locally advanced transitional bladder cancer with failed platinum-based chemotherapy receiving RAD001 10mg daily PO.
62406417|NCT06567067||Video guided|Participants will perform a scan using Pulsenmore ES device in the video mode independently following video tutorial. Participants will be remotely observed during the scan and interviewed by a human factoring researcher right after
62789804|NCT02277925|EXPERIMENTAL|PDS delayed absorbable suture|Participants in this arm will receive 2-0 PDS delayed absorbable suture
62208172|NCT00468143|EXPERIMENTAL|Adderall Immediate Release First|This group was treated with Adderall immediate release, either during phase 2 of the trial, or during phase 3 (this subset received Adderall extended release during phase 2 and then underwent a washout period). This was a counterbalanced crossover study, with a washout period in between treatment periods. Participants were randomized in a 1:1 ratio to one of two schedules Adderall IR followed by Adderall XR, or Adderall XR followed by Adderall IR.
62208173|NCT06717152|EXPERIMENTAL|SJP-0132|The participants receive placebo for 2 weeks in run-in period, then SJP-0132 for 8 weeks in treatment period.
62208174|NCT06717152|PLACEBO_COMPARATOR|Placebo|The participants receive placebo for 2 weeks in run-in period, then placebo for 8 weeks in treatment period.
62208175|NCT04720872|EXPERIMENTAL|Experimental group|"* Manual therapy: 4 sessions, 1 session per week (20 minutes approximately).~* Physical therapist-directed vestibular rehabilitation: 4 weeks, 1 session per week with the physical therapist (30 minutes approximately), after manual therapy.~* Home based vestibular rehabilitation: 4 weeks (2 sessions per day)."
62208176|NCT04720872|NO_INTERVENTION|Control group|Home based vestibular rehabilitation: 4 weeks (2 sessions per day). The participants attended the center once a week to check correct execution of the exercises.
62581642|NCT02975986|OTHER|Controlled metabolic diet|All study patients will be placed on an instructed controlled metabolic diet. Intervention: Uptake of radioactive isotope by the kidney Radiotracer: 123I-BMIPP, 99mTc-MAG3
62789805|NCT01411956|EXPERIMENTAL|Treatment Group|"This group viewed the intervention video, a 24-minute episode of the sitcom White Coats, deliberately scripted with the five health behavior theory constructs we are testing."
62789806|NCT01411956|PLACEBO_COMPARATOR|Control Group|The control group viewed a 25-minute video on an unrelated subject (depression).
62789807|NCT03325842||Cerebral palsy|ASKp will be submitted to children of 5 to 15 years with hemiplegia or diplegia due to Cerebral Palsy, with normal or slightly impaired cognitive level.
62789808|NCT03325842||Healthy individuals|ASKp will be submitted to children of 5 to 15 years with typical development
62789809|NCT02596230||Patients with acute VTE|Patients will be enrolled for cross sectional characterization of baseline characteristics
62789810|NCT02596230||Dabigatran|Patients treated with dabigatran for acute VTE will be followed for one year
62789811|NCT02596230||vitamin K antagonist|Patients treated with VKA for acute VTE will be followed for one year
62789812|NCT05643950|ACTIVE_COMPARATOR|Control arm (Foley catheter)|When randomly allocated to this arm, a conventional Foley-type catheter will be inserted during all the study period (2 weeks). At day 14 after inclusion, the patient will be called for a follow-up visit to remove the catheter.
62789813|NCT05643950|EXPERIMENTAL|T-Control arm|When randomly allocated to this arm, the T-Control catheter will be inserted during all the study period (2 weeks). At day 14 after inclusion, the patient will be called for a follow-up visit to remove the catheter.
62789814|NCT05137769|EXPERIMENTAL|Body Scan|Participants will listen to a 20-minute, audio-guided mindfulness-based body scan exercise.
62789815|NCT04680429|EXPERIMENTAL|RP7214, Single and multiple doses|"In Part 1 up to 3 cohorts with single ascending doses of RP7214 at 100 mg QD, 200 mg QD and 400 mg QD.~In Part 2 up to 2 cohorts with multiple ascending doses of RP7214 at 200 mg BID, 400 mg BID."
62208177|NCT06581588|ACTIVE_COMPARATOR|oxygenation using THRIVE technique|oxygenation delivered via nasal high flow humidified oxygen (Optiflow) . 70 litres/minute
62208178|NCT06581588|EXPERIMENTAL|THRIVE combined nasopharyngeal airway|oxygenation delivered via nasopharyngeal airway and THRIVE technique. 70 litres/minute
62208179|NCT05961787|EXPERIMENTAL|DCB ARM|patients with large primary coronary artery lesions (3.0mm≤ vessel diameter ≤4.0mm, lesion length ≤35mm).
62208180|NCT05961787|ACTIVE_COMPARATOR|DES ARM|patients with large primary coronary artery lesions (3.0mm≤ vessel diameter ≤4.0mm, lesion length ≤35mm).
62208181|NCT05460832|PLACEBO_COMPARATOR|Placebo|
62208182|NCT05460832|EXPERIMENTAL|MBS2320 5 mg|
62208183|NCT05460832|EXPERIMENTAL|MBS2320 20 mg|
62017809|NCT05040217|EXPERIMENTAL|Gene transfer of AAV2-BDNF|Up to 12 subjects will receive open-label AAV2-BDNF
62208184|NCT05460832|EXPERIMENTAL|MBS2320 40 mg|
62208185|NCT04229264|ACTIVE_COMPARATOR|Control group|Aspirin 100 mg (oral, once-daily) for 1 year plus Clopidogrel 75 mg (oral, once-daily) for 3 months.
62789816|NCT04680429|PLACEBO_COMPARATOR|Placebo, Single and multiple doses|In Part 1 up to 3 cohorts and in Part 2 up to 2 cohorts with matching placebo to RP7214 tablet
62789817|NCT02569684|ACTIVE_COMPARATOR|Arm A|Prebiotic fibers: Oligofructose and inulin
62789818|NCT02569684|PLACEBO_COMPARATOR|Arm B|Maltodextrin
62789819|NCT00244101|ACTIVE_COMPARATOR|PS Group|Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
62789820|NCT00244101|EXPERIMENTAL|NCPAP Group|Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
62789821|NCT00244101|EXPERIMENTAL|ISX Group|Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
62789822|NCT01663012|EXPERIMENTAL|Drug: Etirinotecan pegol|145 mg/m2 dose
62789823|NCT00479856|EXPERIMENTAL|Lapatinib plus Chemotherapy|Lapatinib is administered in combination with one of the following chemotherapies based on the discretion of the investigator : capecitabine, docetaxel or nab-paclitaxel.
62017810|NCT03231371|EXPERIMENTAL|Study Arm|
62017811|NCT05502016|EXPERIMENTAL|Intervention|Family model diabetes self-management education and support
62208186|NCT04229264|EXPERIMENTAL|Apixaban group|Apixaban 2.5 mg (oral, twice daily) for 1 year plus Aspirin 100 mg (oral, once-daily) for 1 year.
62208187|NCT06729047|PLACEBO_COMPARATOR|Group C|patients will receive placebo (normal saline)
62208188|NCT06729047|ACTIVE_COMPARATOR|Group N|patients will receive neostigmine (40 μg/kg) plus atropine (20 μg/kg)
62208189|NCT06729047|ACTIVE_COMPARATOR|Group K|patients will receive ketorolac (0.5 mg/kg)
62208190|NCT00316602|EXPERIMENTAL|Healthy Participants|Healthy, vaccinia naive subjects without Atopic Dermatitis, receiving two doses of MVA-BN (IMVAMUNE)
62208191|NCT00316602|EXPERIMENTAL|Atopic Dermatitis Participants|"Vaccinia naive subjects with diagnosed Atopic Dermatitis. Diagnosed AD included subjects with either history of or subjects with currently active AD (defined as scoring AD \[SCORAD\] \<= 30), receiving two doses of MVA-BN (IMVAMUNE)"
62208192|NCT04538911|EXPERIMENTAL|Experimental group|30 tuberculosis patient were randomly assigned to the experimental group and the control group. The experimental group was injected with BCG-PPD drug once, while the control group was injected with BCG-PPD drug once
62208193|NCT04538911|OTHER|control group|30 tuberculosis patient were randomly assigned to the experimental group and the control group. The experimental group was injected with BCG-PPD drug once, while the control group was injected with BCG-PPD drug once
62208194|NCT04959188||Bereaved family caregivers|Bereaved family caregivers (parents or spouses/partners) of individuals who died from complications associated with dyskeratosis congenita or a related telomere biology disorder.
62208195|NCT04959188||Caregivers|Family and/or caregivers of individuals with dyskeratosis congenita or a related telomere biology disorder.
62208196|NCT04959188||Patients|Individuals with dyskeratosis congenita or a related telomere biology disorder.
62017812|NCT05502016|ACTIVE_COMPARATOR|Wait-list Control|Family model diabetes self-management education and support
62017813|NCT05407545|EXPERIMENTAL|Prosthesis|A unilateral transfemoral amputee will conduct experiments with the active prosthesis and with the current prosthesis.
62017814|NCT02443389||Neonates admitted to NICU|Retrospective cohort of neonates admitted to NICU with stated inclusion and exclusion criteria
62017815|NCT00607841|EXPERIMENTAL|Dose Escalation Cohort 1|Ispinesib given on days 1 and 15 of a 28 day cycle.
62017816|NCT00607841|EXPERIMENTAL|Dose Escalation Cohort 2|Ispinesib given on days 1 and 15 of a 28 day cycle.
62017817|NCT00607841|EXPERIMENTAL|Dose Escalation Cohort 3|Ispinesib given on days 1 and 15 of a 28 day cycle.
62017818|NCT02670590|EXPERIMENTAL|NAFLD|diet
62017819|NCT01866436|EXPERIMENTAL|Multimedia group|The multimedia group is the interventional arm of the study
62017820|NCT01866436|EXPERIMENTAL|Study Day Group|The study day group are the control arm of the study
62017821|NCT01794949|EXPERIMENTAL|Non-diabetic patients receiving the Resolute stent|Non-diabetic patients presenting with Acute Coronary Syndrome (ACS), receiving the Resolute stent.
62208197|NCT05785546||development cohort|Neuromuscular diseases
62208198|NCT05785546||validation cohort|Neuromuscular diseases
62017822|NCT01794949|EXPERIMENTAL|Diabetic patients receiving the Resolute stent|Non-insulin dependent diabetes mellitus (NIDDM) patients presenting with Acute Coronary Syndrome (ACS), receiving the Resolute stent.
62017823|NCT05035979|EXPERIMENTAL|TCM comprehensive treatment group|Participants in the TCM treatment group will receive BaiDi Quzhi granule two times daily after meals, Ju Yin cream therapy three times per week for 8 weeks.
62017824|NCT05035979|ACTIVE_COMPARATOR|TCM internal treatment group|Participants in the TCM internal treatment group will receive Baidi Quzhi granule two times daily after meals and Ju Yin placebo therapy three times per week for 8 weeks.
62017825|NCT05035979|ACTIVE_COMPARATOR|TCM external treatment group|Participants in the TCM external treatment group will receive Baidi Quzhi placebo granule two times daily after meals and Ju Yin cream therapy three times per week for 8 weeks.
62017826|NCT05035979|PLACEBO_COMPARATOR|Placebo group|Participants in the placebo group will receive Baidi Quzhi placebo granule two times daily after meals, Ju Yin placebo therapy three times per week for 8 weeks.
62017827|NCT02509741|EXPERIMENTAL|Educational intervention|High-protein and low-GI diet education
62017828|NCT02509741|EXPERIMENTAL|Dietary intervention|High-protein and low-GI diet plus education
62017829|NCT02509741|EXPERIMENTAL|Internet-of-things (IOT) monitoring intervention|Dietary intervention plus IOT monitoring
62017830|NCT02509741|NO_INTERVENTION|control|Routine diet recommendation
62017831|NCT03144726|EXPERIMENTAL|Negative pressure wound therapy|A vacuum assisted closure device will be applied in this arm
62017832|NCT03144726|OTHER|Standard dressing|Standard dressing will be applied to this arm
62017833|NCT06026566|EXPERIMENTAL|Dos of R 0.1|The dosage of Remimazolam Besylate is 0.1 mg/kg
62017834|NCT06026566|EXPERIMENTAL|Dos of R 0.15|The dosage of Remimazolam Besylate is 0.15 mg/kg
62017835|NCT06026566|EXPERIMENTAL|Dos of R 0.2|The dosage of Remimazolam Besylate is 0.2 mg/kg
62208199|NCT05845710|EXPERIMENTAL|Neuroguard IEP Direct System|The Neuroguard IEP® 3-in-1 Direct Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP Direct System) is a combination self-expanding carotid artery stent, nitinol embolic protection filter, and post-dilation balloon. Neuroguard IEP Direct System is used with the Neuroguard Direct Access Kit which includes the Flow Redirection System.
62017836|NCT06026566|EXPERIMENTAL|Dos of R 0.25|The dosage of Remimazolam Besylate is 0.25 mg/kg
62017837|NCT06026566|EXPERIMENTAL|Dos of R 0.3|The dosage of Remimazolam Besylate is 0.3 mg/kg
62017838|NCT06026566|EXPERIMENTAL|Dos of R 0.35|The dosage of Remimazolam Besylate is 0.25 mg/kg
62208200|NCT06108011|EXPERIMENTAL|Lollipop|Given lollipop 6 hours after operation, sucking of lollipop at least 20mins every 4 hours after operation until feeding is resumed.
62208201|NCT06108011|NO_INTERVENTION|No Lollipop|No placebo would be given
62017839|NCT02647359|EXPERIMENTAL|Ataluren|Participants will receive ataluren orally 3 times a day (TID) at a dose of 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 48 weeks in Stage 1 (double-masked period) and for additional 96 weeks in Stage 2 (open-label extension period). Participants, who complete Stage 2 and agree to continue in open-label sub-study, will continue to receive ataluren treatment at same dose as mentioned above, for 96 weeks or until commercial availability of ataluren for this indication, whichever is first, or until a positive risk-benefit assessment in this indication is not demonstrated.
62017840|NCT02647359|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to ataluren TID orally in the morning, at midday, and in the evening for 48 weeks in Stage 1 (double-masked period) and ataluren orally TID at a dose of 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for additional 96 weeks in Stage 2 (open-label extension period). Participants, who complete Stage 2 and agree to continue in open-label sub-study, will continue to receive ataluren treatment at same dose as mentioned above, for 96 weeks or until commercial availability of ataluren for this indication, whichever is first, or until a positive risk-benefit assessment in this indication is not demonstrated.
62017841|NCT06662916||220 ASD cases regularly followed our specific diet|220 individuals who regularly followed our specific diet program for at least 12 months were identified as a study group.
62017842|NCT06662916||100 ASD cases who did not have diet compliance|100 children with ASD who did not have diet compliance were identified as control group.
62017843|NCT00991601|EXPERIMENTAL|biopsy arm|patients with tumors in liver and/or pancreas
62208202|NCT05880004|EXPERIMENTAL|Food Pantries receiving SAFPAS intervention|Food Pantries in this arm will receive access to all functions of the SAFPAS application
62208203|NCT05880004|NO_INTERVENTION|Food Pantries not receiving SAFPAS intervention|Food Pantries in the arm will not receive access to the SAFPAS application
62208204|NCT06189885|EXPERIMENTAL|Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty|
62017844|NCT05712226|OTHER|Sleepiz One+ vs. gold standard|Each enrolled participant will undergo a simultaneous recording with the Sleepiz One+, Capnography device and cardiorespiratory polygraphy with reduced number of channels (ECG and REB only) to measure respiration rate at and heart rate at rest, while sitting and lying down on a bed.
62017845|NCT04295941||Trazodone once-a-day treated patients|Major Depressive Disorder outpatients who, following an initial positive response to the acute treatment with Trazodone once-a-day monotherapy, will be eligible to enter the continuation therapy and will be observed up to 24 weeks.
62017846|NCT02305940|ACTIVE_COMPARATOR|Doxycycline|Doxycycline: oral dose of 100 mg once daily, for a total duration of 52 weeks.
62017847|NCT02305940|PLACEBO_COMPARATOR|Placebo|Placebo: an oral dose of one capsule once daily, for a total duration of 52 weeks.
62017848|NCT05584449|EXPERIMENTAL|Supportive Care (group curriculum)|Participants attend an online group facilitated by two oncology social workers and receive information regarding coping with cancer survivorship as a young adult, as well as discuss survivorship issues/concerns with peers.
62017849|NCT01911052|EXPERIMENTAL|Intervention|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
62017850|NCT01911052|NO_INTERVENTION|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care at Keimyung University Dongsan Medical Center
62017851|NCT01911052|EXPERIMENTAL|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
62017852|NCT03435094||Fosamax®|1 group will be treated with alendronate 70 mg tablets (Fosamax®)
62017853|NCT03435094||Binosto®|1 group will be treated with alendronate 70 mg effervescent tablets for buffered solution (Binosto®)
62017854|NCT00633035|ACTIVE_COMPARATOR|1|oral esomeprazole tablet dissolved in water given through NG tube
62017855|NCT00633035|ACTIVE_COMPARATOR|2|intravenous famotidine injection
62017856|NCT01602315|EXPERIMENTAL|Phase Ib: A-BYL719 FC whole tab+cetux|Oral film-coated tablets without swallowing dysfunction.
62017857|NCT01602315|EXPERIMENTAL|Phase II: 2-Cetuximab|Cetuximab in patients naive to cetuximab (phase ll)
62017858|NCT01602315|EXPERIMENTAL|Phase Ib: B-BYL719 FC drink sus+cetux|Crushed film-coated (FC) tablets as an oral suspension with swallowing dysfunction.
62017859|NCT01602315|EXPERIMENTAL|Phase II: 3-BYL719 + Cetuximab|BYL719 + cetuximab in patients resistant to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
62017860|NCT01602315|EXPERIMENTAL|Phase II: 1-BYL719 + Cetuximab|BYL719 + Cetuximab in Patients naive to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
62017861|NCT01602315|EXPERIMENTAL|Phase Ib: C-BYL719 DT+cetux|Dispersible tablet with swallowing dysfunction administered via a gastrostomy tube (G-tube)
62017862|NCT01602315|EXPERIMENTAL|Phase II: Cross over|patients received BYL719 at RP2D in combination with cetuximab.
62017863|NCT04542993|ACTIVE_COMPARATOR|Resveratrol and Zinc Picolinate combination therapy|Resveratrol and Zinc Picolinate combination therapy
62735041|NCT01304615|ACTIVE_COMPARATOR|Web-Based|Participants will receive a web-based behavioral intervention that decreases dietary energy density and increases physical activity combined with a life skills training program. Life skills training topics include stress management, coping with change, time management, and thoughts and emotions in weight control.
62017864|NCT04542993|PLACEBO_COMPARATOR|Resveratrol Placebo and Zinc Placebo combination therapy|Placebo Resveratrol and Placebo Zinc combination therapy
62017865|NCT02784418|ACTIVE_COMPARATOR|PCI of CTO|Intervention: PCI of CTO (Chronic Total Occlusion Percutaneous Coronary Intervention) Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice. Hospitalized overnight after the procedure, with post procedure monitoring practices as per standard of care for PCI. CTO PCI patients will receive blinded clopidogrel 75 mg daily for 6 months.
62017866|NCT02784418|SHAM_COMPARATOR|Sham Procedure|"Intervention: Sham procedure Subjects will be blinded to randomization assignment using a combination of conscious sedation and sensory isolation (e.g., blindfold and noise isolation). Control subjects will only undergo a Sham procedure, wherein they will undergo bilateral arterial access, without angiography or PCI being performed. Hospitalized overnight after the procedure, with post procedure monitoring practices as per standard of care for PCI. Sham group will receive blinded placebo clopidogrel for 6 months."
62017867|NCT02418546|ACTIVE_COMPARATOR|In-Person Nutritional Counseling|Participants in the in-person nutritional counseling arm will meet with a Registered Dietitian at every clinic visit and will also receive regular phone calls to monitor weight and food intake. Participants' individual dietary needs will be calculated using baseline calorie consumption, weight history, disease status and current activity level.
62208205|NCT06189885|EXPERIMENTAL|Preoperative Vancomycin Prophylaxis in Two-Stage Exchange Arthroplasty|
62208206|NCT00867308|EXPERIMENTAL|Lenalidomide 15 mg|"Patients diagnosed with high risk Myelodysplastic syndrome (MDS), regardless of 5q deletion status, will receive lenalidomide 15 mg per day orally, on days 1-28 of a 42 day cycle for 2 cycles. At this point, patients meeting protocol specified response criteria will proceed to Continuing Therapy on a reduced dose of lenalidomide until progression.~Patients not achieving response will receive 2 additional cycles of treatment, whereupon response will again be assessed. Patients achieving response at this point will proceed to Continuing Therapy as described.~Patients without evidence of response after 4 cycles will be taken off-study."
62208207|NCT00867308|EXPERIMENTAL|Lenalidomide 50 mg|"Patients diagnosed with high risk Myelodysplastic syndrome (MDS), regardless of 5q deletion status, will receive lenalidomide 50 mg per day orally, on days 1-28 of a 42 day cycle for 2 cycles. At this point, patients meeting protocol specified response criteria will proceed to Continuing Therapy on a reduced dose of lenalidomide until progression.~Patients not achieving response will receive 2 additional cycles of treatment, whereupon response will again be assessed. Patients achieving response at this point will proceed to Continuing Therapy as described.~Patients without evidence of response after 4 cycles will be taken off-study."
62208208|NCT06589310||Multicancer Early Detection (MCED) cohort|
62208209|NCT00969826|EXPERIMENTAL|GCPGC 30 μg/kg|Ten volunteers were administered GCPGC 30 μg/kg or placebo (active:placebo=8:2)
62208210|NCT00969826|EXPERIMENTAL|GCPGC 100 μg/kg|Ten volunteers were administered GCPGC 100 μg/kg or placebo (active:placebo=8:2)
62208211|NCT00969826|EXPERIMENTAL|GCPGC 300 μg/kg|Ten volunteers would be administered GCPGC 300 μg/kg or placebo (active:placebo=8:2)
62581643|NCT01775072||Pts with solid tumors|Patients must have solid or hematologic cancer. for treatment on a . Patients must have undergone pathologic confirmation of their tumor at MSKCC and have either: 1) archival tissue available for analysis, 2) have fresh tissue collection planned as routine standard of care biopsy or part of a research biopsy under another clinical trial(or peripheral blood / bone marrow collection in the case of hematologic cancers) outside of the context of this protocol, or 3)archival tissue .available at an outside facility. For prospective genotyping tissue specimens from the primary site, a metastasis or recurrence will be used based upon the availability and quality of tissue.
62017868|NCT02418546|EXPERIMENTAL|E-Health App for Nutritional Counseling|Participants randomized to the e-Health App arm with receive nutritional counseling using the e-Health Application. Participants will enter weights at home and complete electronic food records using the App. Participants' individual dietary needs will be calculated using baseline calorie consumption, weight history, disease status and current activity level. Participants will receive these calorie recommendations through the Application.
62581644|NCT00950443|EXPERIMENTAL|1|Children with upper airway obstruction
62017869|NCT02418546|NO_INTERVENTION|Standard Care|Participants are allowed to receive all usual treatments and medications. Participation in other research studies is allowed.
62208212|NCT00969826|EXPERIMENTAL|Neulasta 100 μg/kg|Eight volunteers were administered Neulasta 100 μg/kg
62208213|NCT05053607|OTHER|1. Single Arm Cohort Receiving Digital Health Coaching|"All study participants will be enrolled in a 3-month digital health coaching program. They will also receive a Fitbit device to be worn daily for the capture of physical activity data.~Participants have the option to participate in a one time interview about their treatment experience."
62208214|NCT05215275|EXPERIMENTAL|MICT to HIIT|participants will receive moderate-intensity continuous training lasting 8 weeks, and then exchange to high-intensity interval training lasting 8 weeks, with 8 weeks rest insert to two different modalities of exercise.
62208215|NCT05215275|EXPERIMENTAL|HIIT to MICT|participants will receive high-intensity interval training lasting 8 weeks, and then exchange to moderate-intensity continuous training lasting 8 weeks, with 8 weeks rest insert to two different modalities of exercise.
62581645|NCT00950443|ACTIVE_COMPARATOR|2|Children without upper airway obstruction
62581646|NCT04839523|EXPERIMENTAL|Exufiber|Treatment with Exufiber gelling fiber dressing
62581647|NCT04839523|EXPERIMENTAL|Exufiber Ag+|Treatment with Exufiber Ag+ silver-coated, gelling fiber dressing
62581648|NCT00526812|EXPERIMENTAL|Group A (RTA 744)|Receive study drug for three consecutive days, Cycle repeated every 21 days.
62581649|NCT00526812|EXPERIMENTAL|Group C (RTA 744 Injection)|Receive study drug once a week for four consecutive weeks. Repeat cycle every 5 weeks.
62581650|NCT03668847|EXPERIMENTAL|DM-CHOC-PEN|4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) - 75 or 98.7 mg/m2 emulsion will be administered IV once every 21-days until relapse
62017870|NCT02149589|EXPERIMENTAL|Focal ARDS|In Focal ARDS prone position will be promote early, with low PEEP and moderate Vt.
62017871|NCT02149589|OTHER|non focal ARDS|In non-Focal ARDS, Recruitment maneuvers, high PEEP and low V twill be used
62017872|NCT05344105|ACTIVE_COMPARATOR|Transversalis fascia plan block (Group T)|After local cleaning of the skin area, the transducer will be placed on the iliac crest in the transverse plane with a low-frequency convex probe, and the skin, subcutaneous tissue, external oblique muscle will be placed with a 20 G, 100 mm needle. After visualization of the internal oblique muscle and transversus abdominis muscles and finally the deep fascia of the transversus abdominis, local anesthetic will be given unilaterally between the last part of the transversus abdominis muscle and the transversalis fascia with the out-off plan technique.
62406418|NCT06567067||Clinician guided|Participants will perform a scan using Pulsenmore ES device either in the clinician guided mode, guided by a health care professional via a telehealth visit. Participants and healthcare professionals will be remotely observed during the scan and interviewed by a human factoring researcher right after
62406419|NCT03814824|ACTIVE_COMPARATOR|VLE without IRIS, followed by VLE with IRIS|VLE (Volumetric laser endomicroscopy) performed alone, followed by IRIS (Intelligent real-time image segmentation) imaging.
62406420|NCT03814824|ACTIVE_COMPARATOR|VLE with IRIS, followed by VLE without IRIS|VLE (Volumetric laser endomicroscopy) performed with IRIS (Intelligent real-time image segmentation) imaging, followed by VLE alone.
62406421|NCT02974270|EXPERIMENTAL|Leuprolide acetate|
62406422|NCT03882567|EXPERIMENTAL|Electro Neuro adaptative Regulator|8 SCENAR sessions (twice a week) (30 min of duration) following the protocols for treatment several points in the body
62406423|NCT03882567|SHAM_COMPARATOR|Sham Electro Neuro adaptative Regulator|8 Sham SCENAR sessions (twice a week) (30 min of duration), following the same protocol tan experimental group but the machine will be turn off 30 seconds after starting on the treatment.
62208216|NCT04489134|EXPERIMENTAL|A D B C|Period n°01: Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°02:Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®) Period n°03:Administration of a 2 mg dose of LCP-tacro (Envarsus®) Period n°04:Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
62208217|NCT04489134|EXPERIMENTAL|B A C D|Period n°01: Administration of a 2 mg dose of LCP-tacro (Envarsus®) Period n°02:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°03:Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°04:Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®)
62208218|NCT04489134|EXPERIMENTAL|C B D A|Period n°01: Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°02:Administration of a 2 mg dose of LCP-tacro (Envarsus®) Period n°03:Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®) Period n°04:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
62208219|NCT04489134|EXPERIMENTAL|D C A B|Period n°01:Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®) Period n°02:Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°03:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°04:Administration of a 2 mg dose of LCP-tacro (Envarsus®)
62208220|NCT06426212||patients with deep infections (deep seated infections - DSIs)|
62208221|NCT06426212||patients with superficial infections (non deep seated infections - NDSIs).|
62208222|NCT06476847|EXPERIMENTAL|Intervention group|Participants randomized into this group will receive a behavioral economics informed intervention to improve persistence among amongst high risk men newly initiating PrEP in South Africa.
62208223|NCT06476847|NO_INTERVENTION|Control group|Usual care for high risk men newly initiating PrEP in South Africa.
62208224|NCT03753698|EXPERIMENTAL|eCoin|Neuromodulation of posterior tibial nerve
62208225|NCT06470828|EXPERIMENTAL|TAK-861 Dose 1|Participants will receive TAK-861 tablets at dose 1, orally, for 12 weeks.
62208226|NCT06470828|EXPERIMENTAL|TAK-861 Dose 2|Participants will receive TAK-861 tablets at dose 2, orally, for 12 weeks.
62581651|NCT06682754|EXPERIMENTAL|Experimental|All participants will perform a baseline and an experimental test. There will be a group of young people and a group of older people, but all participants will perform the same intervention
62208227|NCT06470828|PLACEBO_COMPARATOR|Placebo|Participants will receive TAK-861-matching placebo tablets, orally, for 12 weeks.
62208228|NCT05557513|ACTIVE_COMPARATOR|Ag-RDT (arm 1)|Symptomatic /suspected COVID-19 participant or close contact/family members of COVID-19 patient will be tested with Ag RDT and also involve in awareness-raising campaign with mask distribution.
62208229|NCT05557513|NO_INTERVENTION|No Ag-RDT (arm 2)|No community based Ag RDT testing but there has routine ATK or RT-PCR test by Thai health authorities if local health volunteer finds symptomatic or suspected COVID-19 or close contact with positive cases in their villages. The participant also involves in awareness-raising campaign with mask distribution.
62208230|NCT03856489||Patients|This study group will consist of patients hospitalized at ICU, who will be given the Richards-Campbell Sleeping Questionnaire (RCSQ) to fill in every morning between 7 am and 10 am.
62208231|NCT03856489||Nurses|This study group will consist of patients hospitalized at ICU, who will be given the Richards-Campbell Sleeping Questionnaire (RCSQ) to fill in every morning between 7 am and 7:30 am.
62208232|NCT05215665|EXPERIMENTAL|group 1|GEMOX+Lenvatinib+Toripalimab
62208233|NCT05215665|EXPERIMENTAL|group 2|GEMOX+Toripalimab
62581652|NCT05839951||Cohort R-T|Patients with mCRC who started with regorafenib first, followed by TAS+/-Bev (Bevacizumab) without other therapies in between.
62581653|NCT05839951||Cohort T-R|Patients with mCRC who started with TAS+/-Bev first, followed by regorafenib, without other therapies in between.
62208234|NCT02997228|ACTIVE_COMPARATOR|Arm I (bevacizumab, mFOLFOX6)|Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. (CLOSED TO ACCRUAL)
62208235|NCT02997228|EXPERIMENTAL|Arm II (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
62406424|NCT06417853|ACTIVE_COMPARATOR|Arm 1: Influenza A (H7N9) Vaccine Intramuscular Injection|7.5 mcg HA unadjuvanted IM injection (n=30)
62581654|NCT05839951||Cohort TAS+BEV|Patients with mCRC who received combo use of TAS+BEV.
62581655|NCT04300309|EXPERIMENTAL|artemether lumefantrine (2.5 mg:30 mg)|Artemether-lumefantrine (5 mg:60 mg) twice daily for 3 days
62581656|NCT02895113|EXPERIMENTAL|Aspirin|Patients will be treated with aspirin 100 mg/day for one year
62581657|NCT02895113|PLACEBO_COMPARATOR|Placebo|Patients will be treated with placebo for one year
62581658|NCT04436562|EXPERIMENTAL|Poziotinib|A single oral dose of 8 mg poziotinib as a capsule formulation (as the hydrochloride salt) containing approximately 100 μCi of \[14C\]-poziotinib
62789824|NCT02524158|EXPERIMENTAL|Yoga|The yoga intervention will consist of 2x weekly, 60-minute Hatha Yoga classes for 12 weeks, geared toward a CLBP population. Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
62406425|NCT06417853|EXPERIMENTAL|Arm 2: Unadjuvanted Influenza A (H7N9) Vaccine Microarray Patch|VXS-1219 12 mcg HA (n=30) and VXS-1219U (n =3)
62406426|NCT06417853|EXPERIMENTAL|Arm 3: Adjuvanted Influenza A (H7N9) Vaccine Microarray Patch|VXS-1219 25 mcg HA (n=30) and VXS-1219U (n =3)
62406427|NCT06417853|ACTIVE_COMPARATOR|Arm 4: Adjuvanted Influenza A (H7N9) Vaccine Intramuscular Injection|7.5 mcg HA with MF59® adjuvant 7.5 IM injection (n=30)
62406428|NCT06417853|EXPERIMENTAL|Arm 5: Adjuvanted Influenza A (H7N9) Vaccine Microarray Patch|VXS-1219A 12 mcg HA + QS21 4 mcg (n=30) and VXS-1219U (n =3)
62581659|NCT04885439|EXPERIMENTAL|NextSteps Intervention|Patients and caregivers will each receive their own tailored manual and six weekly 45-minute telephone calls that correspond to the manual, delivered by a Masters level trained interventionist.
62789825|NCT02524158|NO_INTERVENTION|Delayed Treatment Control - Usual Care|Participants randomly assigned to this arm are allowed to continue all existing treatments. Participants and their primary care physician are asked to not change treatments unless medically necessary. participants are asked to not do yoga for 6 months. They are given free yoga and a yoga mat after 6 months.
62789826|NCT06356051||Type1 diabetes mellitus|
62789827|NCT06356051||Healthy children|
62406429|NCT06417853|EXPERIMENTAL|Arm 6: Adjuvanted Influenza A (H7N9) Vaccine Microarray Patch|VXS-1219A 12 mcg HA + QS21 8 mcg (n=30) and VXS-1219 (n = 3)
62581660|NCT04885439|NO_INTERVENTION|Usual Medical Care|UMC consists of standard oncologic care for the patient from the point of diagnosis of advanced cancer.
62581661|NCT00794040|ACTIVE_COMPARATOR|Add-on citalopram following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
62581662|NCT00794040|PLACEBO_COMPARATOR|Add-on placebo after optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
62581663|NCT05485077||Positive group|All the subjects who completed colorectal cancer polygene methylation test at baseline completed colonoscopy within 3 months. Colorectal cancer diagnosed by colonoscopy, adenoma or polyp lesions found after treatment will reach the end of the study. The tumor history of family members was tracked for patients who met the end point of the study. The positive subjects who did not reach the end point of the study underwent three center visits at 12, 36 and 60 months after enrollment respectively, including history taking, colonoscopy, FIT test and blood CEA test. Another telephone follow-up was conducted at 24 and 48 months, respectively.
62017873|NCT05344105|ACTIVE_COMPARATOR|Erector spina plan block (Group E)|After local cleaning of the skin area, a convex probe is determined to be placed longitudinally 3 cm lateral to the spinous process of the T11 vertebra, after determining the erector spina muscle, with a 20 G, 100 mm needle inplane method in the craniocaudal direction will be advanced and a local anesthetic will be administered between the erector spinae muscle and the transverse process.
62017874|NCT04930029||OAGB150|One anastomosis gastric bypass with 150cm biliary limb
62017875|NCT04930029||OAGB200|One anastomosis gastric bypass with 200cm biliary limb
62017876|NCT06280352|EXPERIMENTAL|Custom made Total Knee Arthroplasty|Implant used is a patient specific custom made total knee Origin (Symbios, Symbios Orthopédie SA, Avenue des Sciences 1, 1400 Yverdon-les-Bains, Switzerland)
62406430|NCT06417853|EXPERIMENTAL|Arm 7: Adjuvanted Influenza A (H7N9) Vaccine Microarray Patch|VXS-1219A 20 mcg HA + QS21 3.3 mcg (n=30) and VXS-1219U (n=3)
62406431|NCT06417853|EXPERIMENTAL|Arm 8: Adjuvanted Influenza A (H7N9) Vaccine Microarray Patch|VXS-1219A 20 mcg HA + QS21 6.7 mcg (n=30) and VXS 1219U (n=3)
62406432|NCT02511587|ACTIVE_COMPARATOR|intra muscular application|intra muscular application of FSME-Immune vaccination
62581664|NCT05485077||Negative group|The subjects who completed colorectal cancer polygene methylation test at baseline, and those with negative test results (n= 500, direct extraction method) completed colonoscopy within 3 months. The end points and follow-up were the same as those in the positive group. The negative group was compared with the positive group to observe the difference of negative predictive value and survival outcome.
62581665|NCT05416684||PEEK Group|
62581666|NCT05416684||Titanium Mesh Group|
62789828|NCT00695526|ACTIVE_COMPARATOR|A|
62406433|NCT02511587|EXPERIMENTAL|subcutaneous application|subcutaneous application of FSME-Immune vaccination
62406434|NCT03651440|EXPERIMENTAL|lumbar stabilization training|lumbar stabilization training exercises
62581667|NCT03364374||Stroke survivors|Individuals that experienced uni-hemispheric ischemic or hemorrhagic stroke
62581668|NCT03364374||Controls|Healthy controls with no history of stroke
62581669|NCT04931823|EXPERIMENTAL|Part A-1: Dose Escalation|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks).
62581670|NCT04931823|EXPERIMENTAL|Part A-2: Dose escalation|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) with the option to administer G-CSF in cycle one. Starting dose will be 45 mg/m2.
62581671|NCT04931823|EXPERIMENTAL|Part B: Cohort 1|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) at the recommended Phase 2 dose (X mg/m2) in 15 patients with taxane naïve advanced solid tumors of gastric, head and neck, lung, and ovarian.
62789829|NCT04610398|ACTIVE_COMPARATOR|Dexamethasone group|The patients in the dexamethasone group will receive 12mg dexamethasone (Fortecortin ®) intravenously 15-60 minutes prior to surgery while in general anasthesia as well as 12mg dexamethasone intravenously (Fortecortin®) on the first postoperative day at approx. 8.00a.m. by the investigators.
62789830|NCT04610398|PLACEBO_COMPARATOR|Placebo/ Control group|The patients will not receive any additional drugs preoperatively. A 0.9% NaCl Solution (NaCl B. Braun Inf Lös 0.9 % 250ml Ecoflac plus®) will be administered at approx. 8.00 a.m. on the first postoperative day by the investigators.
62789831|NCT03020706|EXPERIMENTAL|Magnesium|magnesium sulfate, injectable intravenous administration (50mg/kg diluted in 100ml normal saline) during general anesthesia
62789832|NCT03020706|NO_INTERVENTION|Control|No intervention
62789833|NCT01359943|EXPERIMENTAL|secukinumab 10 mg/kg i.v. loading|secukinumab 10mg/kg i.v. loading at Weeks 0, 2 and 4, and placebo s.c. at weeks 0, 1, 2, 3 and 4, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 8
62789834|NCT01359943|EXPERIMENTAL|secukinumab 150 mg s.c. loading|secukinumab 150mg s.c. loading at Weeks 0, 1, 2, 3 and 4, and placebo i.v. at weeks 0, 2 and 4, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 8
62789835|NCT01359943|PLACEBO_COMPARATOR|placebo|placebo at Weeks 0, 1, 2, 3, 4, 8 \& 12, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 16
62017877|NCT06280352|ACTIVE_COMPARATOR|Functionally aligned robotically assisted total knee arthroplasty|Total Knee Implant Triathlon (Stryker, Kalamazoo, Michigan, U.S.) implanted using MAKO Rio Robotic Arm (Stryker)
62017878|NCT04345146|EXPERIMENTAL|FSRT & Bevacizumab|Patients will receive Bevacizumab before and after FSRT: daily FSRT(40Gy in 10 fractions or 30Gy in 5 fractions) to the brain metastases with Bevacizumab(7.5mg/kg, q3w, IV)
62017879|NCT01485952|EXPERIMENTAL|SEN0014196 (Low Dose)|10 mg, once daily administration (immediate release capsule)
62017880|NCT01485952|EXPERIMENTAL|SEN0014196 (High dose)|100 mg, once daily administration (immediate release capsule)
62017881|NCT01485952|PLACEBO_COMPARATOR|Placebo|Once daily (immediate release capsule)
62017882|NCT02044887|EXPERIMENTAL|INTERVENTION|Participants will receive instructions to do physical activity with an adapted physical activity program. This program will be designed and applied by Primary Health Care professionals in patients with dementia and caregivers.
62017883|NCT02044887|NO_INTERVENTION|Control|The control group will receive regular care.
62017884|NCT06572280|EXPERIMENTAL|PNS group|Electrical stimulation of the phrenic nerve in ARDS patients.
62017885|NCT04833257|EXPERIMENTAL|GP combine with Tislelizumab neoadjuvant therapy+CCRT|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) and tislelizumab(200mg) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) .
62017886|NCT01422759|EXPERIMENTAL|spironolactone|12 weeks spironolactone with pre- and post-intervention dexamethasone, and ACTH to perform standardized adrenal stimulation testing; dexamethasone and rhCG to perform standardized ovarian stimulation testing
62406435|NCT03651440|EXPERIMENTAL|PNF training|PNF training exercises
62406436|NCT03651440|EXPERIMENTAL|physical therapy|HP,TENS US
62406437|NCT03651440|SHAM_COMPARATOR|control|NO APPLİCATİON
62789836|NCT05345275||pain assessments|In the study, primarily the pain assessment data of children were collected. In these pain assessments, assessments of the child, mother, nurse and an independent observer were taken. Simultaneously, a video recording of the child's facial expressions was made.
62789837|NCT02287467|EXPERIMENTAL|Arm A: hIVIG|Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (hIVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
62789838|NCT02287467|PLACEBO_COMPARATOR|Arm B: Placebo|Participants will receive a single infusion of placebo for hIVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
62406438|NCT05026424|PLACEBO_COMPARATOR|Active Comparator: Oral Nutrition Supplement Control|The control study intervention is an oral drink that contain protein, carbohydrate and fat and are intended for use as supplemental nutrition.
62406439|NCT05026424|ACTIVE_COMPARATOR|Active Comparator: Oral Nutrition Supplement Test|The test study intervention is an oral drink that contain protein, carbohydrate and fat and are intended for use as supplemental nutrition for people living with diabetes.
62581672|NCT04931823|EXPERIMENTAL|Part B: Cohort 2|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) at the recommended Phase 2 dose (X mg/m2) in 15 patients with taxane naïve advanced breast cancer.
62581673|NCT04931823|EXPERIMENTAL|Part B: Cohort 3|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) at the recommended Phase 2 dose (X mg/m2) in 15 patients with taxane naïve advanced prostate cancer.
62581674|NCT04931823|EXPERIMENTAL|Part B: Cohort 4|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) at the recommended Phase 2 dose (X mg/m2) in 15 patients with either ovarian or/and breast cancer who have failed prior taxane treatment (ie, either progressed on a taxane regimen or within 6 months of receiving a taxane regimen).
62581675|NCT03762863|EXPERIMENTAL|Appropriate application of a CAT tourniquet|All study subjects attended an American College of Surgeons Stop the Bleed Basic course with live training by approved instructors. 6 months after participation in the Stop the Bleed class volunteers study subjects are randomly solicited to return for a refresher session. During this refresher session the volunteer study subjects are observed to determine if they have retained tourniquet application skills and to what degree they have retained them. A 10 point check list will be used to evaluated tourniquet application skill retention.
62581676|NCT02298062|EXPERIMENTAL|Infliximab|For one group of patients with resistance to intravenous immunoglobulin in Kawasaki disease , we will give them infliximab (5mg/kg) once.
62581677|NCT02298062|ACTIVE_COMPARATOR|IVIG|For the other group of patients with resistance to intravenous immunoglobulin in Kawasaki disease , we will give them IVIG (2g/kg) once.
62581678|NCT03205956|EXPERIMENTAL|PD Group|A broad range of Parkinson's disease severity and disease duration. Some subjects will not be treated currently with levodopa, and thus likely will be early in the disease process.
62581679|NCT02880865|EXPERIMENTAL|Group 1 - MMR and CD-JEV|Participants receiving one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0; Group 1 will also receive a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).
62581680|NCT02880865|EXPERIMENTAL|Group 2 - MMR then CD-JEV|Participants receiving one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Group 2 will receive a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).
62581681|NCT02055365|EXPERIMENTAL|Hepatitis B vaccination|All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).
62581682|NCT00049166|EXPERIMENTAL|Regimen A (erlotinib hydrochloride, IMRT)|"Patients receive oral erlotinib once daily. Beginning on day 15, patients also undergo IMRT once daily 5 days a week for 7 weeks.~Patients in both regimens continue to receive erlotinib until the last day of IMRT (patients already in the maintenance phase of this study as of 5/11/04 continue to receive erlotinib once daily for up to 2 years) in the absence of disease progression or unacceptable toxicity.~In both regimens, cohorts of 3-6 patients receive escalating doses of erlotinib until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
62789839|NCT05921175|ACTIVE_COMPARATOR|RGT+ conventional physiotherapy|16 sessions of robotic gait training (RGT) + conventional physiotherapy in 8-10 weeks
62789840|NCT05921175|EXPERIMENTAL|RGT+ tSCS + conventional physiotherapy|Phase 2: 16 sessions of RGT training + transcutaneous electrical stimulation (tSCS) + functional training in 8-10 weeks.
62789841|NCT05921838||ET patients|patients suffer from primary thrombocytosis
62789842|NCT05921838||healthy doner|Healthy individuals without blood system diseases
62789843|NCT03112655|EXPERIMENTAL|Human african trypanosomiasis patient|RNA, neopterin and 5-hydroxytryptophan detection
62789844|NCT02465372|EXPERIMENTAL|CSPAP|Schools in this arm will receive the Comprehensive School Physical Activity Program training.
62789845|NCT02465372|NO_INTERVENTION|Control|Standard practice.
62789846|NCT01406977|EXPERIMENTAL|BPS804 dose escalation|BPS804 IV Setrusumab given in escalating doses from 5mg/Kg to 20mg/Kg
62789847|NCT03019094|EXPERIMENTAL|Treatment|Implantation of the RENOVA tibial nerve stimulation system
62017887|NCT00911365|PLACEBO_COMPARATOR|normal saline|
62017888|NCT00911365|EXPERIMENTAL|autologous mesenchymal stem cells|
62017889|NCT03843359|EXPERIMENTAL|Part 1A: Participants receiving GSK3745417, Dose-escalation Cohort|
62017890|NCT03843359|EXPERIMENTAL|Part 2A: Participants receiving GSK3745417 + dostarlimab, Dose escalation Cohort|
62017891|NCT04479891|EXPERIMENTAL|pyrotinib alone, pyrotinib + itraconazole|Sequential treatments of pyrotinib alone followed by pyrotinib + itraconazole, with a washout period in between.
62017892|NCT06572813|EXPERIMENTAL|Phase 1 (Drug Tolerance Evaluation)|Using a 3 + 3 trial design, bortezomib dose exploration was performed to determine the stage 2 bortezomib dose. The number of participants at this stage is 6-9.
62017893|NCT06572813|EXPERIMENTAL|Phase 2 (Dose extension)|Phase 2: This phase will adopt competitive enrollment, and the Bayesian prediction probability method will be used to monitor the main efficacy index of the trial ORR in real time to determine the early termination or continue the trial. A maximum number of 57 patients were enrolled in this stage.
62017894|NCT04409964|EXPERIMENTAL|opioid-free anesthesia|The study group receives the dexmedetomidine and lidocaine infusion with general anesthesia for gynecological laparoscopy.
62017895|NCT04409964|ACTIVE_COMPARATOR|opioid anesthesia|The control group receives the remifentanil infusion with general anesthesia for gynecological laparoscopy.
62017896|NCT00767000|EXPERIMENTAL|MK-0941 10 mg|
62017897|NCT00767000|EXPERIMENTAL|MK-0941 20 mg|
62017898|NCT00767000|EXPERIMENTAL|MK-0941 30 mg|
62017899|NCT00767000|EXPERIMENTAL|MK-0941 40 mg|
62017900|NCT00767000|PLACEBO_COMPARATOR|Placebo|
62581683|NCT00049166|EXPERIMENTAL|Regimen B (erlotinib hydrochloride, cisplatin, IMRT)|"Patients receive oral erlotinib and undergo IMRT as in regimen A. Patients also receive cisplatin IV over 20 minutes on each day of radiotherapy.~Patients in both regimens continue to receive erlotinib until the last day of IMRT (patients already in the maintenance phase of this study as of 5/11/04 continue to receive erlotinib once daily for up to 2 years) in the absence of disease progression or unacceptable toxicity.~In both regimens, cohorts of 3-6 patients receive escalating doses of erlotinib until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
62017901|NCT04880941|EXPERIMENTAL|Progressive Relaxation Exercise|The Progressive Relaxation Exercise will be held 7 days for 4 weeks, a total of twenty eight sessions. Each session is set as fifty minutes
62017902|NCT04880941|NO_INTERVENTION|Control group|Routine maintenance will be applied
62017903|NCT01312545|EXPERIMENTAL|local made implant (3DP)|Enucleation and local made implant (3DP) insertion
62017904|NCT01312545|EXPERIMENTAL|imported implant (Medpor)|Enucleation and imported implant (Medpor) insertion
62208236|NCT02997228|EXPERIMENTAL|Arm III (atezolizumab, bevacizumab, mFOLFOX6)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
62208237|NCT04210167|EXPERIMENTAL|web-based training and telephone monitoring|The heart failure patients in the intervention group were given web-based training for three months after discharge and followed up by telephone at the first, fourth, eighth and 12th weeks. At the same time, a text message was sent once a week. Scale data were collected before the patient was discharged from the hospital and at the third month of discharge.
62581684|NCT00003620|EXPERIMENTAL|Treatment (flavopiridol)|"Patients registered before 9/15/2000 receive flavopiridol IV continuously on days 1-3. Treatment repeats every 14 days for a total of 12 courses in the absence of disease progression or unacceptable toxicity.~Patients registered after 9/15/2000 receive flavopiridol IV over 1 hour daily on days 1-3. Treatment repeats every 3 weeks for a total of 8 courses in the absence of disease progression or unacceptable toxicity."
62581685|NCT04449302|EXPERIMENTAL|Immediate molar implant with customized healing abutment|Patients will receive an immediate mandibular molar implant with customized healing abutment
62581686|NCT04449302|ACTIVE_COMPARATOR|Immediate molar implant with submerged healing|Patients will receive an immediate mandibular molar implant with submerged healing
62017905|NCT03751904|OTHER|AcoustiCare|Single Arm
62017906|NCT05660525|EXPERIMENTAL|QuitAid, 4 weeks, Patch + Lozenge|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist and 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and the nicotine lozenge.
62581687|NCT00925938|EXPERIMENTAL|Misoprostol vaginal priming insert (MVPI)|One vaginal insert administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit. The initial dose is 400 mcg and dose will be adjusted between 100 - 1600 mcg after each study cohort based on safety and efficacy criteria as assessed by the Data and Safety Monitoring Board (DSMB).
62581688|NCT00925938|PLACEBO_COMPARATOR|MVPI Placebo|One vaginal insert of placebo administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit.
62581689|NCT06483438||Group 1: subjects with dementia Group 2: subjects without dementia o Group/Cohort Description [*]|"Group 1: subjects over the age of 50, with a diagnosis of dementia according to DSM-5 criteria and proven by neuropsychological assessment.~Group 2: subjects over the age of 50, with no cognitive impairment on the neuropsychological assessment and with no previous neurological and/or psychiatric history or other illnesses that could interfere with the collection of writing data."
62581690|NCT04266587|EXPERIMENTAL|Healthy volunteers|blood sampling is done on healthy volunteers
62581691|NCT02704065||Recurrent AA amyloidosis|Renal transplant recipients with biopsy-confirmed AA amyloidosis in the renal allograft
62581692|NCT02704065||Control group 1|Renal transplant recipients whose primary diseases are amyloidosis with no clinical or laboratory signs of recurrence in the renal allograft
62581693|NCT02704065||Control group 2|Renal transplant recipients whose primary diseases are other than amyloidosis
62581694|NCT05594836|EXPERIMENTAL|Training|Perception of Maternal Role, Maternal Attachment and Breastfeeding Self-Efficacy
62789848|NCT02474602|EXPERIMENTAL|Group A - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group A, received program 1 before strength training, and the same program 1 after training."
62789849|NCT02474602|EXPERIMENTAL|Group B - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 1 before strength training, and program 2 after training."
62789850|NCT02474602|EXPERIMENTAL|Group C - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group C, received program 2 before strength training, and program 1 after training."
62789851|NCT02474602|EXPERIMENTAL|Group D - Active or Placebo Phototherapy'|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 2 before strength training, and the same program 2 after training."
62017907|NCT05660525|EXPERIMENTAL|QuitAid, 8 weeks, Patch + Lozenge|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist and 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and the nicotine lozenge.
62406440|NCT05538039|EXPERIMENTAL|Distract with play dough|The intervention will begin approximately 30 minutes before premedication. The initiative will be applied to both the child and the parent participating in the research. Attempts to distract with play dough will be conducted under investigative coaching for at least 10 minutes. If after 10 minutes the child or parent wants to continue playing, they will be told that they can play as long as they want. Each family will be given 4 boxes of play dough. After the play is played, the play dough will not be put back in the package, and the child and parents will be told that they can keep the shapes they have made if they wish. The play dough used will be provided by the researchers and will be given to the participants after the intervention.
62581695|NCT05594836|NO_INTERVENTION|control|not Perception of Maternal Role, Maternal Attachment and Breastfeeding Self-Efficacy
62581696|NCT04000438|EXPERIMENTAL|Experimental DF01 high dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
62581697|NCT04000438|EXPERIMENTAL|Experimental: DF01 medium dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
62581698|NCT04000438|EXPERIMENTAL|Experimental: DF01 low dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
62581699|NCT04000438|PLACEBO_COMPARATOR|Placebo comparator: PL1|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
62581700|NCT04074681|EXPERIMENTAL|Gambling Internet-based Protocol|Intervention group that carries out the Gambling Internet-based Protocol based on Cognitive and Behavioral Therapy (CBT) and receives support by the therapist (a weekly 10-minute phone call without clinical content). In addition, they will receive one notification per day to respond to the EMI questions at 8 PM. The EMI includes immediate automatic feedback depending on the participant's responses.
62789852|NCT03963843|EXPERIMENTAL|SCI internet delivered cognitive behavioural therapy|An 8-week internet- delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a health educator with experience delivering ICBT will provide support by email once a week. The health educator will spend approximately 15 minutes per week/per client.
62581701|NCT04074681|NO_INTERVENTION|Waiting List Control Group|Participants in a 12-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
62581702|NCT02295046|EXPERIMENTAL|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg of Dr. Reddys Laboratories Limited
62581703|NCT02295046|ACTIVE_COMPARATOR|Caduet|Caduet® 10/80 mg tablets of Pfizer, Ireland
62581704|NCT01387711|EXPERIMENTAL|ingenol mebutate|PEP gel 0.05% once daily exposure
62581705|NCT06683885|EXPERIMENTAL|Elderly patients with newly diagnosed DLBCL|Obutinib or Decitabine with Rituximab, Compound Cyclophosphamide Tablets and Prednisone
62581706|NCT05473299|EXPERIMENTAL|aXess graft|
62017908|NCT05660525|EXPERIMENTAL|QuitAid, 4 weeks, Patch + Lozenge, QuitLine|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and the nicotine lozenge, and a Quitline intervention
62208238|NCT00474526|EXPERIMENTAL|US1A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
62208239|NCT00474526|EXPERIMENTAL|US1B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 13 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
62789853|NCT03963843|ACTIVE_COMPARATOR|SCI rehabilitation mental health education|Participants will receive information provided to SCI patients in usual care at specialized SCI rehabilitation units (the Spinal Cord Injury Rehabilitation Evidence (SCIRE) Community handouts available at: https://scireproject.com/community/handouts/). The lessons will include information on spinal cord injury rehabilitation: 1)spinal cord injury basics, 2)mental health after SCI, 3)pain after SCI, 4)understanding rehabilitation 5)summary of lessons through an online platform over 8 weeks. A health educator will check in with participants once a week to answer any content related questions. The health educator will spend approximately 15 minutes per week/per client.
62208240|NCT00474526|EXPERIMENTAL|US2 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
62789854|NCT04717817|EXPERIMENTAL|Group 1: experimental|Daily inspiratory muscle training (IMT) using an IMT Threshold device (Philips) prior to surgery
62789855|NCT04717817|ACTIVE_COMPARATOR|Group 2: comparator|Standard physiotherapy prior to surgery
62208241|NCT00474526|EXPERIMENTAL|US3 (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
62406441|NCT05538039|EXPERIMENTAL|Distract with play kaleidoscope|The intervention will begin approximately 30 minutes before premedication. The initiative will be applied to both the child and the parent participating in the research. Attempts to distract with the kaleidoscope will be conducted under investigative coaching for at least 10 minutes. It is a game tool that reproduces the outside image when viewed from inside the kaleidoscope. This image is obtained thanks to the glasses placed inside the kaleidoscope at different angles, and the images change as the kaleidoscope is rotated. If after 10 minutes the child or parent wants to continue playing, they will be told that they can play as long as they want. Each child and parent will be given a separate kaleidoscope.
62789856|NCT00812773|EXPERIMENTAL|3 day repeat dose|
62789857|NCT05377138|EXPERIMENTAL|MYDAWA clients|MYDAWA clients determined to be eligible for PrEP or PEP can order them online and have them delivered a small fee. This is not currently the standard of care in Kenya. Those who are not in the study can only receive PrEP or PEP at healthcare facilities in Kenya.
62789858|NCT01900587|EXPERIMENTAL|Tapentadol Extended release (ER) TRF then tapentadol ER PR2|Single dose of tapentadol ER 50 milligram (mg), tamper-resistant formulation (TRF) tablet will be administered under fasted condition in first treatment period; after that in second treatment period, single-dose of tapentadol ER 50 mg, prolonged released (PR2) tablet will be administered under fasted condition. A washout period of 7 to 14 days will be maintained between each treatment period.
62789859|NCT01900587|EXPERIMENTAL|Tapentadol ER PR2 then tapentadol ER TRF|Single dose of tapentadol ER 50 milligram (mg), PR2 tablet will be administered under fasted condition in first treatment period; after that in second treatment period, single-dose of tapentadol ER 50 mg, TRF tablet will be administered under fasted condition. A washout period of 7 to 14 days will be maintained between each treatment period.
62017909|NCT05660525|EXPERIMENTAL|QuitAid, 8 weeks, Patch + Lozenge, QuitLine|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and the nicotine lozenge, and a Quitline intervention
62017910|NCT05660525|EXPERIMENTAL|QuitAid, 4 weeks, Patch|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist and 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch.
62017911|NCT05660525|EXPERIMENTAL|QuitAid, 8 weeks, Patch|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist and 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch.
62017912|NCT05660525|EXPERIMENTAL|QuitAid, 8 weeks, Patch, QuitLine|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a Quitline intervention
62017913|NCT05660525|EXPERIMENTAL|QuitAid, 4 weeks, Patch, QuitLine|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a Quitline intervention
62208242|NCT00474526|EXPERIMENTAL|US4A (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
62406442|NCT05538039|OTHER|Control Group|The participants in the control group will be given routine nursing care.
62581707|NCT06238908|EXPERIMENTAL|Experimental|3 doses of NGGT003 will be administered according to the principle of dose escalation
62208243|NCT00474526|EXPERIMENTAL|US4B (Infant Vaccines Only)|"Received vaccines:~MenACWY: 13 and 15 months DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
62406443|NCT00785252|EXPERIMENTAL|1|EZIO
62581708|NCT06530251|EXPERIMENTAL|AK112 in combination with AK130|
62581709|NCT06530251|EXPERIMENTAL|AK112 in combination with AK127|
62406444|NCT00785252|EXPERIMENTAL|2|Central line
62406445|NCT01458535|EXPERIMENTAL|ABT-450/r and ABT-267 plus RBV in genotype 1 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided twice daily (BID) in treatment-naïve participants with HCV genotype 1 infection.
62406446|NCT01458535|EXPERIMENTAL|ABT-450/r and ABT-267 plus RBV in genotype 2 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided BID in treatment-naïve participants with HCV genotype 2 infection.
62406447|NCT01458535|EXPERIMENTAL|ABT-450/r and ABT-267 plus RBV in genotype 3 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided BID in treatment-naïve participants with HCV genotype 3 infection.
62406448|NCT01458535|EXPERIMENTAL|ABT-450/r and ABT-267 in genotype 1 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 1 infection.
62406449|NCT01458535|EXPERIMENTAL|ABT-450/r and ABT-267 in genotype 2 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 2 infection.
62406450|NCT01458535|EXPERIMENTAL|ABT-450/r and ABT-267 in genotype 3 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 3 infection.
62406451|NCT00552422|EXPERIMENTAL|Domperidone Arm|Study subjects will self-administer oral domperidone 10mg four times a day. If symptoms persist for more than 7 days, the investigator may increase the dose to 20mg four times a day. 20mg four times a day will be the maximal dose. Subjects with signiﬁcant renal impairment will received a starting dose of 10mg twice a day. The maximal dose in subjects with signiﬁcant renal impairment will be 20mg twice a day.
62406452|NCT03291249|PLACEBO_COMPARATOR|Group A|Group A will receive placebo solution for 30 consecutive days
62406453|NCT03291249|EXPERIMENTAL|Group B|Group B will receive 0.5 mg Foralumab Solution daily for 30 consecutive days
62406454|NCT03291249|EXPERIMENTAL|Group C|Group B will receive 2.5 mg Foralumab Solution daily for 30 consecutive days
62581710|NCT06530251|EXPERIMENTAL|AK112 in combination with Cadonilimab|
62017914|NCT05660525|EXPERIMENTAL|QuitAid, 4 weeks, Patch, SmokeFree Txt|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a texting intervention to help quit smoking.
62017915|NCT05660525|EXPERIMENTAL|QuitAid, 8 weeks, Patch, SmokeFree Txt|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a texting intervention to help quit smoking.
62017916|NCT05660525|EXPERIMENTAL|QuitAid, 8 weeks, Patch + Lozenge, SmokeFree Txt|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, and a texting intervention to help quit smoking.
62017917|NCT05660525|EXPERIMENTAL|QuitAid, 4 weeks, Patch + Lozenge, SmokeFree Txt|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, and a texting intervention to help quit smoking.
62017918|NCT05660525|EXPERIMENTAL|QuitAid, 8 weeks, Patch + Lozenge, SmokeFree Txt, QuitLine|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, a texting intervention to help quit smoking, and a Quitline Intervention.
62017919|NCT05660525|EXPERIMENTAL|QuitAid, 8 weeks, Patch, SmokeFree Txt, QuitLine|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, a texting intervention to help quit smoking, and a Quitline Intervention.
62017920|NCT05660525|EXPERIMENTAL|QuitAid, 4 weeks, Patch + Lozenge, SmokeFree Txt, QuitLine|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, a texting intervention to help quit smoking, and a Quitline Intervention.
62017921|NCT05660525|EXPERIMENTAL|QuitAid, 4 weeks, Patch, SmokeFree Txt, QuitLine|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, a texting intervention to help quit smoking, and a Quitline Intervention.
62017922|NCT05660525|EXPERIMENTAL|8 weeks, Patch + Lozenge, SmokeFree Txt, QuitLine|Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, a texting intervention to help quit smoking, and a Quitline Intervention.
62017923|NCT05660525|EXPERIMENTAL|8 weeks, Patch, SmokeFree Txt, QuitLine|Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, a texting intervention to help quit smoking, and a Quitline Intervention.
62017924|NCT05660525|EXPERIMENTAL|4 weeks, Patch + Lozenge, SmokeFree Txt, QuitLine|Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, a texting intervention to help quit smoking, and a Quitline Intervention.
62017925|NCT05660525|EXPERIMENTAL|4 weeks, Patch, SmokeFree Txt, QuitLine|Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, a texting intervention to help quit smoking, and a Quitline Intervention.
62017926|NCT05660525|EXPERIMENTAL|8 weeks, Patch + Lozenge, QuitLine|Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, and a Quitline Intervention.
62017927|NCT05660525|EXPERIMENTAL|8 weeks, Patch, QuitLine|Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a Quitline Intervention.
62017928|NCT05660525|EXPERIMENTAL|4 weeks, Patch + Lozenge, QuitLine|Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, and a Quitline Intervention.
62017929|NCT05660525|EXPERIMENTAL|4 weeks, Patch, QuitLine|Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a Quitline Intervention.
62017930|NCT05660525|EXPERIMENTAL|8 weeks, Patch + Lozenge, SmokeFree Txt|Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge and a texting intervention to help quit smoking.
62208244|NCT00474526|EXPERIMENTAL|US4C (Infant Vaccines Only)|"Received vaccines:~MenACWY: 18 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
62208245|NCT00474526|EXPERIMENTAL|LA1A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months Pneumococcal, HAV, and MMR-V: 12 months"
62406455|NCT03291249|EXPERIMENTAL|Group D|Group B will receive 5.0 mg Foralumab Solution daily for 30 consecutive days
62406456|NCT02037594|EXPERIMENTAL|Counseling + SOC Adherence|Sexual Health Counseling followed by Standard of Care Adherence Support
62406457|NCT02037594|EXPERIMENTAL|Counseling + Enhanced Adherence|Sexual Health Counseling followed by Enhanced Adherence Intervention
62406458|NCT02037594|EXPERIMENTAL|Information + SOC Adherence|PrEP Information followed by Standard of Care Adherence Support
62406459|NCT02037594|EXPERIMENTAL|Information + Enhanced Adherence|PrEP Information followed by Enhanced Adherence Intervention
62406460|NCT03128801|EXPERIMENTAL|Global Stretching Program (GSP)|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active).
62406461|NCT03128801|ACTIVE_COMPARATOR|Stabilization Exercises|A exercise protocol will be administered and the criteria to increase exercise progression was previously described by Hicks et al (2005).
62406462|NCT00678652|EXPERIMENTAL|10 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 10 μg with Adjuvant
62581711|NCT06530251|EXPERIMENTAL|AK112|
62581712|NCT06530251|ACTIVE_COMPARATOR|Sintilimab in combination with Bevacizumab biosimilar|
62017931|NCT05660525|EXPERIMENTAL|8 weeks, Patch, SmokeFree Txt|Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and a texting intervention to help quit smoking.
62017932|NCT05660525|EXPERIMENTAL|4 weeks, Patch + Lozenge, SmokeFree Txt|Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge and a texting intervention to help quit smoking.
62017933|NCT05660525|EXPERIMENTAL|4 weeks, Patch, SmokeFree Txt|Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and a texting intervention to help quit smoking.
62017934|NCT05660525|EXPERIMENTAL|8 weeks, Patch + Lozenge|Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge.
62017935|NCT05660525|EXPERIMENTAL|8 weeks, Patch|Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch.
62017936|NCT05660525|EXPERIMENTAL|4 weeks, Patch + Lozenge|Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge.
62017937|NCT05660525|EXPERIMENTAL|4 weeks, Patch|Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch.
62017938|NCT06311500|EXPERIMENTAL|Sleep Health Enhancement Intervention|4 weekly visits using Zoom video conferencing consisting of education and strategies to enhance sleep health with each visit lasting about 60 minutes.
62017939|NCT06311500|NO_INTERVENTION|Wait-List Control Group|People in the wait-list group will continue with their usual activities for 4 weeks and then start the sleep health enhancement intervention.
62017940|NCT04359836||General Population|The general population will have their microbiome sequenced from stool samples provided.
62017941|NCT03738150|EXPERIMENTAL|Sotatercept|Each participant will receive SOC plus sotatercept at a dose of 0.3 mg/kg SC for Cycle 1. (Each cycle will be 21 days.) From Cycle 2 through Cycle 9, the dose will be escalated to 0.7 mg/kg SC. Dosing will be every three weeks during the 24-week treatment period and 18-month extension period.
62017942|NCT01927445|NO_INTERVENTION|Usual care|No standardized intervention for management of patients with atrial fibrillation. Instead participants receive interventions for management of chronic kidney disease.
62017943|NCT01927445|EXPERIMENTAL|quality improvement toolkit|The toolkit includes provider-focused strategies (education, audit and feedback, electronic decision support and reminders) plus patient-directed strategies (educational letters and reminders).
62017944|NCT02838602|EXPERIMENTAL|Carbon ions therapy|Radical and exclusive carbon ions radiotherapy
62017945|NCT02838602|ACTIVE_COMPARATOR|Conventional radiotherapy|Radical radiotherapy by Xrays and / or protons
62208246|NCT00474526|EXPERIMENTAL|LA1B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 6, and 13 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
62406463|NCT00678652|EXPERIMENTAL|25 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 25 μg with Adjuvant
62406464|NCT00678652|EXPERIMENTAL|50 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 50 μg with Adjuvant
62406465|NCT00678652|EXPERIMENTAL|75 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 75 μg with Adjuvant
62406466|NCT01880580||Normal Group|In Group I, up to 100 women, at least 40 years of age, who have had a routine standard mammogram read as BI-RADS® 0, 1, 2, or 3 will also undergo 3D breast imaging using a cone beam CT scanner specifically designed to image the breast. Of these 100, we hope to enroll at least 30 subjects with mammograms read as BI-RADS® 0 and at least 30 read as BI-RADS® 3. The BI-RADS® 0 category refers to patients for whom additional imaging is required after a screening mammogram provided incomplete diagnostic information.
62406467|NCT01880580||Diagnostic Group|The goals of Group II will be to compare the CBCT study with standard imaging for the diagnosis of breast disease in palpable or non-palpable breast lesions (having a BI-RADS® score of 4 or 5). Forty (40) women, who have had abnormalities detected by physical exam or an imaging modality and are also scheduled for breast biopsy of the index lesion, will also undergo a CBCT of the breast(s), prior to biopsy.
62406468|NCT05041218||Patients undergoing coronary artery angiography and/or percutaneous coronary intervention|Consecutive patients with indication to perform coronary artery angiography and/or percutaneous coronary intervention at Ferrara University Hospital
62406469|NCT06651073||ATTR-CM patients in Taiwan, Hong Kong, and Malaysia|case-only
62406470|NCT00731640|ACTIVE_COMPARATOR|Monofocal|Patients unilaterally implanted with ReSTOR lens in one eye and previously implanted with monofocal Intraocular lens (IOL) (unspecified) in other eye
62406471|NCT00731640|ACTIVE_COMPARATOR|Phakic|Patients unilaterally implanted with ReSTOR lens in one eye and phakic in the other eye with no necessary cataract removal impending
62208247|NCT00474526|EXPERIMENTAL|LA2 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
62406472|NCT00709904|EXPERIMENTAL|Semuloparin extension treatment|Extension treatment with Semuloparin sodium 20 mg (10 mg if SRI) for 19-23 days following initial treatment with open-label Semuloparin 20 mg (10 mg if SRI) for 7-10 days.
62208248|NCT00474526|EXPERIMENTAL|LA3A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 16 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 16 months~Pneumococcal, HAV, and MMR-V: 12 months"
62406473|NCT00709904|PLACEBO_COMPARATOR|Placebo extension treatment|Extension treatment with placebo (for Semuloparin sodium) for 19-23 days following initial treatment with open-label Semuloparin 20 mg (10 mg if SRI) for 7-10 days
62406474|NCT03239548||Doctor|It refers to the doctors with minimum qualification as M.B.B.S and B.A.M.S; working on various posts in the clinical areas of all the departments of selected hospitals.
62406475|NCT03239548||Nurses|It refers to the Registered Nurses working on various posts in the clinical areas of all the departments of selected hospitals and Principals, Vice Principals of selected colleges.
62406476|NCT03239548||Key informants|It refers to the general public including patients admitted and attending O.P.D and their attendants with minimum qualification as graduation.
62406477|NCT03384576|EXPERIMENTAL|Music intervention|Participants listen to music in the waiting room
62789860|NCT02540070|ACTIVE_COMPARATOR|Periarticular|Patients in group 1 will receive periarticular infiltration of LA mixture (100 ml) consisting of 0.3% ropivacaine, 2.5 µg/mL of epinephrine, 10 mg of morphine and 30 mg of ketorolac at the end of surgery and sham injections of saline into the motor sparing knee blocks preoperatively.
62017946|NCT05351216||Cases|Individuals diagnosed with KHE and treated with sirolimus. After immunoglobulin and flow cytometry assays, as well as outpatient evaluation and assessment, those participants will be vaccinated with live attenuated vaccines or inactivated vaccines in a timely order according to the advice. （Sirolimus Rapamycin 0.8mg/m2 bid po）
62017947|NCT05351216||Controls|Healthy children with no immunodeficiency disease, vaccinated according to the National Immunization Program. Particpants should be age-matched with the case group.
62208249|NCT00474526|EXPERIMENTAL|LA3B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 17 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 16 months~Pneumococcal, HAV, and MMR-V: 12 months"
62208250|NCT00474526|EXPERIMENTAL|LA4 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 15 months~Pneumococcal, HAV, and MMR-V: 12 months"
62208251|NCT00474526|EXPERIMENTAL|LA5 (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
62208252|NCT00474526|EXPERIMENTAL|LA6A (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12, and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
62406478|NCT03384576|ACTIVE_COMPARATOR|No music|Participants will not have music in the waiting room
62581713|NCT05704101||Asthma patients (n=20) out of them 10 with mild, controlled and 10 with severe, uncontrolled asthma|"* Assessments of the SNA-axis. For this, HRV and dBPV will be analyzed using a 3-lead ECG and a continuous non-invasive arterial blood pressure signal. HRV and dBPV will be computed and presented as the high frequency , low frequency , their relative ratio (LF/HF), and the very low frequency component for both.~* MSNA will be recorded via a tungsten microelectrode placed in the peroneal nerve.~* NHFT at a flow rate of 20/30/40 liters/minute for 30 minutes respectively, with breaks of 15 minutes for all physiological variables to return to baseline.~* OSA severity: defined as apnoea-hypopnoea index \[AHI\] \>15/h and obstructive apnoea index \[OAI\] \>5/h~* Determination of PH and right HF severity (TAPSE ≤14 mm) and pulmonary arterial pressure (PAsys) using TTE.~* Comprehensive lung function and inspiratory muscle strength and function testing as described previously by our group.~* Assessment of systemic inflammation in blood samples."
62017948|NCT03296189|ACTIVE_COMPARATOR|Local anaesthetic|Post-ureteroscopy intraluminal injection of alkalinised high concentration levo-bupivicaine in the renal pelvis
62017949|NCT03296189|ACTIVE_COMPARATOR|Local anaesthetic + steroid|Post-ureteroscopy intraluminal injection of 10 mls alkalinised high concentration levo-bupivicaine with l dexamethasone in the renal pelvis
62017950|NCT03296189|PLACEBO_COMPARATOR|Placebo|Post-ureteroscopy intraluminal injection of 10 mls normal saline (placebo) in the renal pelvis
62017951|NCT05875584||advanced adenomas (AA) group|Prospective enrollment of subjects with advanced adenomas
62017952|NCT05875584||CRC group|Retrospective enrollment of subjects with confirmed colorectal cancer
62017953|NCT03713567|PLACEBO_COMPARATOR|Experimentally induced plaque|Induced inflammation by suspension of oral hygiene
62017954|NCT03713567|EXPERIMENTAL|Experimentally induced plaque GAP|Induced inflammation by suspension of oral hygiene in patients with history of Generalized Aggressive periodontitis
62017955|NCT05410912||The younger group|Patients who were under the age of 40
62017956|NCT05410912||The older group|Patients who were more than 40 years old
62017957|NCT02973659|EXPERIMENTAL|patients with palmar hyperhidrosis|oxybutynin Vs placebo
62017958|NCT02973659|EXPERIMENTAL|patients with plantar hyperhidrosis|oxybutynin Vs placebo
62017959|NCT02973659|EXPERIMENTAL|patients with axillary hyperhidrosis|oxybutynin Vs placebo
62208253|NCT00474526|EXPERIMENTAL|LA6B (Infant Vaccines Only)|"Received vaccines:~MenACWY: 13 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
62208254|NCT00474526|EXPERIMENTAL|LA6C (Infant Vaccines Only)|"Received vaccines:~MenACWY: 18 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
62208255|NCT05427084|ACTIVE_COMPARATOR|Active|Canagliflozin 300mg PO daily
62208256|NCT05427084|PLACEBO_COMPARATOR|Placebo|Placebo PO daily
62208257|NCT00003489|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62406479|NCT03361709|ACTIVE_COMPARATOR|Dexamethasone group|Dexamethasone injected at conclusion of Phacoemulsification
62406480|NCT03361709|PLACEBO_COMPARATOR|Non-dexamethasone group|No dexamethasone will be injected at the conclusion of Phacoemulsification
62406481|NCT01890876|ACTIVE_COMPARATOR|Low altitude|Walking uphill Walking downhill
62406482|NCT01890876|ACTIVE_COMPARATOR|High altitude|Walking uphill Walking downhill
62406483|NCT04683874|EXPERIMENTAL|3D printed tray|3D printed tray
62017960|NCT04257903||Occlusal Splint Therapy|The data of patients who previously received occlusal splint therapy were evaluated. Participants in the study received occlusal splint therapy, but the investigator did not assign this intervention specifically to the study participants. Participants received occlusal splint therapy as part of routine medical care, and a researcher studied the effect of occlusal splint therapy.
62017961|NCT04257903||Low-Level Laser Therapy|The data of patients who previously received Low-Level Laser Therapy were evaluated. Participants in the study received Low-Level Laser Therapy, but the investigator did not assign this intervention specifically to the study participants. Participants received Low-Level Laser Therapy as part of routine medical care, and a researcher studied the effect of Low-Level Laser Therapy.
62017962|NCT01307501|OTHER|Cryoablation|Participants will undergo a cryoablation procedure with the Galil Medical Cryoablation System according to the manufacturer's guidelines. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators. No more than 3 tumors in 1 lung can be treated in a single session, and no more than 5 total lung tumors (across both lungs) can be treated during the study.
62017963|NCT05740930|EXPERIMENTAL|Intervention group|The participants wear the partition defocus myopia management spectacle lens.
62017964|NCT05740930|ACTIVE_COMPARATOR|Control group|spectacle lenses with aspherical lenslets
62017965|NCT03505658|EXPERIMENTAL|Intervention|The Intervention is educational with 6 workshops for 2 hrs a week. Data/ assessments are collected, pre and post the 6 weeks intervention and 6 months post follow-up.
62017966|NCT03505658|NO_INTERVENTION|Control|One or two non-intervention related workshop talks are given; 1 hr each during the same 6 weeks as the intervention arm. Pre and post assessment/ data collection and 6 months follow-up are completed.
62017967|NCT00665119|EXPERIMENTAL|treatment|Any patient alternatively receive both remifentanil and isotonic saline (placebo)infusion. The order of infusion is randomized. An interval of 30 minutes is planned between the two infusions.
62017968|NCT01273272|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT)|Comprehensive, CBT-based, multi-component treatment. Comprehensive CBT intervention in addition to standard treatment
62017969|NCT01273272|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Standard Treatment (medical and psychosocial)
62017970|NCT04894474|EXPERIMENTAL|BI 767551 inhalation and placebo intravenous infusion|
62208258|NCT02412371|EXPERIMENTAL|Phase 1: Veliparib + Carboplatin + Paclitaxel + Radiotherapy|"Participants in Phase 1 will be sequentially assigned to ascending dose levels of 60 mg, 80 mg, 120 mg, 200 mg, and 240 mg of twice daily (BID) veliparib in combination with carboplatin at an area under the concentration-time curve (AUC) 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of veliparib 120 mg or 240 mg BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
62208259|NCT02412371|EXPERIMENTAL|Phase 2: Veliparib + CRT -> Paclitaxel/Carboplatin/Veliparib|"Participants will receive veliparib at the recommended phase 2 dose determined in Phase 1 in combination with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of veliparib 120 mg or 240 mg BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
62208260|NCT02412371|EXPERIMENTAL|Phase 2: Veliparib + CRT -> Paclitaxel/Carboplatin/Placebo|"Participants will receive veliparib at the recommended phase 2 dose determined in Phase 1 in combination with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of placebo to veliparib BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
62208261|NCT02412371|ACTIVE_COMPARATOR|Phase 2: Placebo + CRT -> Paclitaxel/Carboplatin/Placebo|"Participants will receive placebo to veliparib with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of placebo to veliparib BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
62208262|NCT02423148|EXPERIMENTAL|FluoSCOPE device|"All study interventions will occur intraoperatively during the subject's planned surgery. No deviation from standard of care will be performed with the exception of the following specific interventions:-~* Intraoperative injection of indocyanine green (ICG) around tumor and imaging with the FluoSCOPE NIR endoscopic imaging system~* Treatment will be administered on an inpatient basis"
62208263|NCT06430905|EXPERIMENTAL|HB-502 and HB-501 alternating 2-vector therapy (Dose Level 1) OR placebo|Intramuscular injection of HB-502 and HB-501 alternating 2-vector therapy at Dose Level 1 OR placebo every 8 weeks for 24 weeks (injections at Weeks 0, 8, 16, and 24).
62208264|NCT06430905|EXPERIMENTAL|HB-502 and HB-501 alternating 2-vector therapy (Dose Level 2) OR placebo|Intramuscular injection of HB-502 and HB-501 alternating 2-vector therapy at Dose Level 2 OR placebo every 8 weeks for 24 weeks (injections at Weeks 0, 8, 16, and 24).
62208265|NCT01994967|EXPERIMENTAL|Levobupivacaine|"Presentation: injectable solution - ampoule of Levobupivacaine Hydrochloride~Indication: production of subarachnoid block (spinal/ spinal anesthesia)."
62208266|NCT01994967|ACTIVE_COMPARATOR|Bupivacaine|"Presentation: injectable solution - ampoule of Bupivacaine Hydrochloride~Indication: production of subarachnoid block (spinal/ spinal anesthesia)."
62208267|NCT06527599|EXPERIMENTAL|PCST-Lite + eTCC re-randomized to eTCC + PCST-Plus|Participants initially randomized to Pain Coping Skills Training-Lite (PCST-Lite) plus enhanced Trauma Care Coordination (eTCC) who are identified to be at elevated risk for opioid misuse at week 4 may be re-randomized to receive eTCC and Enhanced Pain Coping Skills Training (PCST-Plus).
62789861|NCT02540070|EXPERIMENTAL|Motor free|Patients in group 2 will receive motor sparing knee blocks with 0.5% ropivacaine with 2.5 µg/mL of epinephrine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Sham injections of saline (100 ml) will be injected periarticularly at the end of surgery.
62208268|NCT06527599|EXPERIMENTAL|PCST-Lite + eTCC re-randomized to eTCC + PCST-M|Participants initially randomized to PCST-Lite plus eTCC who are identified to be at elevated risk for opioid misuse at week 4 may be re-randomized to receive eTCC and Pain Coping Skills Training-Maintenance (PCST-M) at 4 weeks.
62208269|NCT06527599|EXPERIMENTAL|PCST-Lite + eTCC Low Risk eTCC + PCST-M|Participants initially randomized to PCST-Lite plus eTCC who are identified to be at low risk for opioid misuse at week 4 will then receive eTCC and PCST-M.
62208270|NCT06527599|EXPERIMENTAL|eTCC re-randomized to PCST-LITE|Participants initially randomized to eTCC who are identified to be at elevated risk for opioid misuse at week 4 may be re-randomized to PCST-LITE at 4 weeks.
62208271|NCT06527599|EXPERIMENTAL|eTCC re-randomized to eTCC|Participants initially randomized to eTCC who are identified to be at elevated risk for opioid misuse at week 4 may be re-randomized to receive the same intervention at 4 weeks.
62208272|NCT06527599|EXPERIMENTAL|eTCC Low Risk eTCC|Participants initially randomized to eTCC who are identified to be at low risk for opioid misuse at week 4 will continue eTCC.
62208273|NCT06527599|EXPERIMENTAL|PSCT-LITE re-randomized to PCST+|Participants initially randomized to PCST-LITE who are identified to be at elevated risk for opioid misuse at week 4 re-randomized to PCST+.
62208274|NCT06527599|EXPERIMENTAL|PCST-LITE re-randomized to PCST-Maintenance|Participants initially randomized to PCST-LITE and are not re-randomized to an augmented form of PCST will instead receive PCST-Maintenance (PCST-M).
62208275|NCT06527599|EXPERIMENTAL|PCST-Lite Low Risk PCST-M|Participants initially randomized to PCST-Lite who are identified to be at low risk for opioid misuse at week 4 will be assigned to PCST-M.
62789862|NCT02540070|EXPERIMENTAL|Motor free with Dex|Patients in group 3 will receive motor sparing knee blocks with 0.5% ropivacaine with 1 µg/Kg of dexmedetomidine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Patients in group 3 will receive sham injections of saline (100 ml) periarticularly at the end of surgery.
62017971|NCT04894474|EXPERIMENTAL|BI 767551 intravenous infusion and placebo inhalation|
62017972|NCT04894474|PLACEBO_COMPARATOR|Placebo inhalation and placebo intravenous infusion|
62017973|NCT03598504|ACTIVE_COMPARATOR|Healthy Controls Group|1. A focus group to gather information about the perceptions, opinions, beliefs, and attitudes towards management of muscle spasms by vibration using our portable device, information that will drive design improvement (size, fit, weight).
62208276|NCT06527599|EXPERIMENTAL|sTCC re-randomized to PCST-LITE|Participants initially randomized to Standard Trauma Care Coordination (sTCC) who are identified to be at elevated risk for opioid misuse at week 4 will be re-randomized to either PCST-LITE or continued sTCC.
62208277|NCT06527599|EXPERIMENTAL|sTCC re-randomized to sTCC|Participants initially randomized to sTCC who are identified to be at elevated risk for opioid misuse at week 4 will be re-randomized to either PCST-LITE or continued sTCC.
62208278|NCT06527599|ACTIVE_COMPARATOR|sTCC Low Risk sTCC|Participants initially randomized to sTCC who are identified to be at low risk for opioid misuse at week 4 will continued sTCC.
62208279|NCT01966172|EXPERIMENTAL|Multimodal|oral Ibuprofen 400mg 4 times daily oral Gabapentin 300mg twice daily oral Paracetamol 1000mg 4 times daily
62406484|NCT02439593|ACTIVE_COMPARATOR|Chemoradiotherapy (CTRT) (Control Group)|"Intervention type:~Drug and Radiation~Intervention name:~Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT)~Intervention description:~Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2"
62406485|NCT02439593|EXPERIMENTAL|Thermochemoradiotherapy (CTRTHT)|"Intervention type:~Drug, Radiation and Hyperthermia~Intervention name:~Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT) Hyperthermia (Loco-regional hyperthermia),~Intervention description:~Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2 Hyperthermia: Weekly Local hyperthermia before radiotherapy on D1 of every week, 41-43°C for 60 mins, once every week"
62406486|NCT05925036|EXPERIMENTAL|Experimental Cohort|MSC
62406487|NCT05925036|PLACEBO_COMPARATOR|Validation Cohort|Placebo
62406488|NCT06121986|EXPERIMENTAL|MKN Adherence Program + Maintenance Opt 1|The M-KN adherence program will consist of 10, 1-hour weekly group meetings, which will take place via HIPAA-compliant Zoom. Sessions will be devoted to providing nutrition information, building group support, identifying participant goals, and working as a group to overcome barriers. Participants will be provided with access to ongoing monthly support groups after the 10-week program ends and/or continued use of an online forum after the program.
62406489|NCT06121986|ACTIVE_COMPARATOR|Mediterranean Adherence Program + Maintenance Opt 1|The Mediterranean adherence program will consist of 10, 1-hour weekly group meetings, which will take place via HIPAA-compliant Zoom. Sessions will be devoted to providing nutrition information, building group support, identifying participant goals, and working as a group to overcome barriers. Participants will be provided with access to ongoing monthly support groups after the 10-week program ends and/or continued use of an online forum after the program.
62406490|NCT06121986|EXPERIMENTAL|MKN Adherence Program + Maintenance Opt 2|The M-KN adherence program will consist of 10, 1-hour weekly group meetings, which will take place via HIPAA-compliant Zoom. Sessions will be devoted to providing nutrition information, building group support, identifying participant goals, and working as a group to overcome barriers. Participants will be provided with access to an online forum after the program.
62735042|NCT01304615|EXPERIMENTAL|Web-Based plus Culinary Training|Participants will receive a web-based behavioral intervention that decreases dietary energy density and increases physical activity combined with a hands-on culinary skills training program designed to increase food purchasing and meal self-preparation and consumption of meals low in energy density.
62735043|NCT01648244|EXPERIMENTAL|Computer-Assisted Decision Support|These providers will use the CADS program to treat their enrolled patients.
62208280|NCT01966172|ACTIVE_COMPARATOR|Morphine|oral Morphine 10mg 4 times daily oral paracetamol 1000mg 4 times daily
62208281|NCT06682039|EXPERIMENTAL|Arm I (ABM, gratitude/savoring)|Patients engage in ABM over 10 minutes BIW and respond daily to text messaging prompts to complete gratitude/savoring activity for 4 weeks.
62406491|NCT06121986|ACTIVE_COMPARATOR|Mediterranean Adherence Program + Maintenance Opt 2|The Mediterranean adherence program will consist of 10, 1-hour weekly group meetings, which will take place via HIPAA-compliant Zoom. Sessions will be devoted to providing nutrition information, building group support, identifying participant goals, and working as a group to overcome barriers. Participants will be provided with access to an online forum after the program.
62406492|NCT00615927|EXPERIMENTAL|Astrocytoma|Grade II Astrocytoma
62208282|NCT06682039|ACTIVE_COMPARATOR|Arm II (inert attention task)|Patients engage in inert attention task sessions over 10 minutes BIW for 4 weeks. Patients also receive and respond to text messaging prompts about their mood QD for 4 weeks. After completion of the 4 week follow up survey, patients are given access to all components of ABM + gratitude/savoring sessions and texts on study.
62208283|NCT01695252|NO_INTERVENTION|S-Sup|Standard supervision
62208284|NCT01695252|EXPERIMENTAL|MEMOS|Patient informed clinical outcomes supervision
62208285|NCT06729125|EXPERIMENTAL|study group|
62208286|NCT06729125|ACTIVE_COMPARATOR|control group|
62208287|NCT06617897|EXPERIMENTAL|CSL511|
62208288|NCT06617897|ACTIVE_COMPARATOR|Cryoprecipitate|
62208289|NCT01528345|EXPERIMENTAL|Fulvestrant + Dovitinib active|Fulvestrant in combination with the study drug Dovitinib.
62208290|NCT01528345|PLACEBO_COMPARATOR|Fulvestrant + Dovitinib placebo|Fulvestrant in combination with a placebo matching Dovitinib.
62208291|NCT03656172||Haemoglobin measure|Anaemic adult Patients eligible to iron Treatment supported within the ICO for a solid tumor, untreated or treated by chemotherapy and/or radiotherapy and/or surgery, having benefited of a blood test (NFS, reticulocytes with RET-He , a martial blood test (iron, transferrin and Ferritin), a CRP, vitamins B12 and B9, a creatinine, a haptoglobin, a TSH) before and after iron treatment.
62208292|NCT05027035|ACTIVE_COMPARATOR|Surgical plication|Surgical plication of the diaphragm
62208293|NCT05027035|ACTIVE_COMPARATOR|Mechanical ventilation|Non-invasive ventiatilatory support while on the waiting list for surgical plication
62789863|NCT04373005||Nasopharyngeal (NP) swabs|"NP swabs:~* At the time of consent~* 3-6 weeks after starting cancer treatment (for patients whose treatment has yet not started) or 3-6 weeks after first swab (for patients already on treatment)~* 3 months after second swab~* 6 months after second swab~* 12 months after second swab"
62789864|NCT01949090|EXPERIMENTAL|GSK2789869A F1 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
62789865|NCT01949090|EXPERIMENTAL|GSK2789869A F2 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
62208294|NCT01602029|ACTIVE_COMPARATOR|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
62208295|NCT01602029|ACTIVE_COMPARATOR|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
62208296|NCT01602029|PLACEBO_COMPARATOR|Placebo|Placebo added to TAU
62208297|NCT01602029|ACTIVE_COMPARATOR|Odansetron Plus Simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
62208298|NCT05857761|SHAM_COMPARATOR|Sham group|participants (n=31) will receive sham rTMS.
62208299|NCT05857761|ACTIVE_COMPARATOR|Active rTMS treatment|Participants (n=31) will receive active rTMS treatment.
62789866|NCT01949090|EXPERIMENTAL|GSK2789869A F3 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
62789867|NCT01949090|EXPERIMENTAL|GSK2789869A F4 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
62789868|NCT01949090|PLACEBO_COMPARATOR|Placebo Group|Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
62789869|NCT02035917|EXPERIMENTAL|Locking plate|
62208300|NCT00480935|EXPERIMENTAL|Sunitinib Malate (Sutent)|Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 2 week rest period to comprise a complete cycle of 6 weeks. Patients will then continue on Sutent for another cycle of 4 consecutive weeks
62208301|NCT05397691|EXPERIMENTAL|Intervention refinement arm|20 parent-youth \[12-18 years old\] dyads will be randomized to this arm and receive the Modified Family Talk intervention.
62208302|NCT05397691|EXPERIMENTAL|Parameter estimation arm|20 parent-youth dyads randomized to this control-like arm will receive current best practice care in the patient-centered medical home
62208303|NCT03262259|EXPERIMENTAL|GSDG Intervention|Cities receiving a multi-component intervention, including screening and brief intervention, other evidence-based interventions (e.g., enforcement of drink-driving or underage drinking laws), and novel or partially tested interventions that warrant further evaluation.
62208304|NCT03262259|NO_INTERVENTION|Comparison|Comparison cities receiving no evidence-based interventions.
62208305|NCT04711733||Patients 6-14 years old|Individual interview + Self-report questionnaire + long-term follow-up medical consultation + At 1 year : Assessment of prescription's adherence
62208306|NCT04711733||Parents of 6-14 years old patients|Individual interview + Self-report questionnaire
62208307|NCT04711733||Patients 15-25 years old|Individual interview + Self-report questionnaire + long-term follow-up medical consultation + At 1 year : Assessment of prescription's adherence
62208308|NCT04711733||Parents of 15-25 years old patients|Individual interview + Self-report questionnaire
62208309|NCT04711733||Patients > 25 years old|Individual interview + Self-report questionnaire + long-term follow-up medical consultation + At 1 year : Assessment of prescription's adherence
62208310|NCT04711733||Parents of > 25 years old patients|Individual interview + Self-report questionnaire
62208311|NCT01600898||Asymptomatic BMPR2 mutation carriers|Asymptomatic BMPR2 mutation carriers
62208312|NCT02167009|EXPERIMENTAL|Prostate Artery Embolization|Embospheres microspheres
62208313|NCT02904070|EXPERIMENTAL|Threat of premature delivery|"* Perform detection test of Placental Alpha-Microglobulin-1, fetal Fibronectin and phosphorylated Insulin-like Growth Factor Binding Protein-1ph by vaginal swabbing;~* Collection of clinical data, laboratory data and treatment of obstetric care in the delivery room during childbirth for all included subjects"
62789870|NCT02035917|ACTIVE_COMPARATOR|Non-Locking plate|
62789871|NCT01817439|EXPERIMENTAL|oral amiodarone, group A|oral amiodarone 400 mg three times a day for 2 days
62734444|NCT05640050|EXPERIMENTAL|Audit Implementation with Community Engagement|This feasibility and implementation research implementing in secondary level care hospitals (Tehsil Head Quarters THQ) at Matiari district of Sindh Province, Pakistan. The audit committees will be established in three THQs including management, specialist, medical officer, and community representatives from catchment area.The implementation phases follow the standard World Health Organization (WHO) audit system. The initial step includes identifying death cases for review and subsequently collecting the detailed information on the near miss and adverse event history. A mixed methods data analysis will include both quantitative components, such as identification of trends in rates and causes of death and geographic location, and qualitative components, such as analysis of modifiable factors. A monthly monitoring cycle will be set up within the implementing facilities to ensure effective implementation of the audit systems.
62208314|NCT00700778|EXPERIMENTAL|Recombinant human chorionic gonadotropin|Patients receive recombinant human chorionic gonadotropin subcutaneously three times weekly. Treatment continues weekly for 90 days in the absence of unacceptable toxicity.
62208315|NCT04827901|ACTIVE_COMPARATOR|XEN1101|Subjects will take two 10 mg capsules of XEN1101 daily for 8 weeks for a total daily dose of 20 mg.
62208316|NCT04827901|PLACEBO_COMPARATOR|Placebo|Subjects will take a matching placebo daily for eight weeks.
62208317|NCT02126761|ACTIVE_COMPARATOR|Group 1|aTIV
62406493|NCT00615927|EXPERIMENTAL|Oligodendroglioma|Grade II Oligodendroglioma or oligoastrocytomas
62406494|NCT04481087|EXPERIMENTAL|Clearfil Universal Bond Quick, self-etch mode (CU-SE)|
62406495|NCT04481087|EXPERIMENTAL|Clearfil Universal Bond Quick, selective etch mode (CU-SLE)|
62406496|NCT04481087|EXPERIMENTAL|Clearfil Universal Bond Quick, etch&rinse mode (CU-ER)|
62406497|NCT04481087|EXPERIMENTAL|Clearfil SE Bond (CSE)|
62406498|NCT04481087|EXPERIMENTAL|Tetric N-Bond (TB)|
62406499|NCT01808508|ACTIVE_COMPARATOR|Group 1- Continuous positive airway pressure (CPAP)|Group 1 will receive therapeutic CPAP for 4 months.
62789872|NCT01817439|EXPERIMENTAL|IV amiodarone, Group B|"Amiodarone:~IV loading of 300 mg for 30 min in 100cc glucose 5% IV infusion with 900 mg/24h in 1000cc glucose 5%"
62208318|NCT02126761|EXPERIMENTAL|Group 2|aTIV + 1X MF59
62208319|NCT02126761|EXPERIMENTAL|Group 3|aTIV + TIV
62208320|NCT02126761|EXPERIMENTAL|Group 4|aTIV + aTIV
62208321|NCT02126761|ACTIVE_COMPARATOR|Group 5|aTIV (Left deltoid) Saline (Right deltoid)
62208322|NCT02126761|EXPERIMENTAL|Group 6|aTIV+2X MF59 (Left deltoid) Saline (Right deltoid)
62208323|NCT02126761|EXPERIMENTAL|Group 7|aTIV (Left deltoid) aTIV (Right deltoid)
62208324|NCT05677997|NO_INTERVENTION|Control|Receiving monthly resources only
62406500|NCT01808508|PLACEBO_COMPARATOR|Group 2-Sham Continuous positive airway pressure (CPAP)|Group 2 are individuals with OSAS who will receive sham or placebo continuous positive airway pressure (CPAP) for 4 months.
62406501|NCT01808508|NO_INTERVENTION|Group 3- No Intervention|Group 3 are individuals with normal breathing during sleep who will not receive any intervention and will be used as a control group.
62406502|NCT04045041|EXPERIMENTAL|Treatment group|10 week internet-based acceptance and commitment therapy
62789873|NCT04916236|EXPERIMENTAL|Phase I - Dose-escalation|This is a single-center open-label phase I dose-finding study (3+3 classical design) evaluating the RP2D of RMC-4630 in combination with LY3214996. Based on the safety, tolerability, and PK and PD data from the dose-finding stage of the study, a RP2D will be defined for the expansion phase.
62208325|NCT05677997|EXPERIMENTAL|Intervention Group|Receiving sessions with a resource navigator 2x a month, and monthly resources.
62208326|NCT05684718|EXPERIMENTAL|BV100 Plus Itraconazole|A total 2 doses of BV100 and 14 doses of itraconazole will be administered to each participant per specified dosing schedule
62208327|NCT04222361|EXPERIMENTAL|KDIGO guide recommendations|Preventive recommendations the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for AKI
62208328|NCT04222361|NO_INTERVENTION|Standard care|The patients assigned to the control group will receive the current standard care of the septic patients of the Unit according to our protocols
62208329|NCT05797610|EXPERIMENTAL|RO7434656|Participants will receive subcutaneous (SC) doses of RO7434656 on Days 1, 15, and 29 followed by once every 4 weeks until Week 105. After Week 105, participants may continue blinded treatment or enter open-label treatment until up to 1 year after the date at which the last participant completes the Week 105 assessment, withdraws, or is discontinued from the study.
62406503|NCT04045041|NO_INTERVENTION|Control group|Waiting-list control.
62406504|NCT01042379|ACTIVE_COMPARATOR|Standard Therapy|Paclitaxel, Herceptin followed by Doxorubicin and Cyclophosphamide treatment depending on HR/HER-2 status.
62406505|NCT01042379|EXPERIMENTAL|AMG 386 with or without Trastuzumab|Arm is closed.
62406506|NCT01042379|OTHER|AMG 479 plus Metformin|Arm is closed.
62406507|NCT01042379|EXPERIMENTAL|MK-2206 with or without Trastuzumab|Arm is closed.
62406508|NCT01042379|EXPERIMENTAL|T-DM1 and Pertuzumab|Arm is closed.
62406509|NCT01042379|ACTIVE_COMPARATOR|Pertuzumab and Trastuzumab|Novel Control Investigational Agent. Arm is closed.
62406510|NCT01042379|EXPERIMENTAL|Ganetespib|Arm is closed.
62406511|NCT01042379|OTHER|ABT-888|Arm is closed.
62406512|NCT01042379|OTHER|Neratinib|Arm is closed.
62406513|NCT01042379|EXPERIMENTAL|PLX3397|Arm is closed.
62406514|NCT01042379|EXPERIMENTAL|Pembrolizumab 4 cycle|Arm is closed.
62406515|NCT01042379|EXPERIMENTAL|Talazoparib plus Irinotecan|Arm is closed.
62406516|NCT01042379|EXPERIMENTAL|Patritumab with or without Trastuzumab|Arm is closed.
62406517|NCT01042379|EXPERIMENTAL|Pembrolizumab 8 cycle|Arm is closed.
62017974|NCT03598504|ACTIVE_COMPARATOR|Spinal Cord Injury Group|"1a. A focus group to gather information about the perceptions, opinions, beliefs, and attitudes towards management of muscle spasms by vibration using our portable device, information that will drive design improvement (size, fit, weight).~1b. In the lab, we will trigger spasms in paralyzed leg muscles in one of two common postures (seated, reclined), detect the contractions using electromyography (EMG), and condition alternate spasms with vibration using our custom device. We will examine the vibration parameters that reduce muscle spasms best.~2. Participants will complete 1 or 2 multi-day experiments. EMG (24-hour) data will be collected at baseline (day 1), during the vibration intervention (day 2), and post intervention (day 3) to examine the acute effects of vibration on muscle spasms"
62017975|NCT00968617|EXPERIMENTAL|MK2578 1.0 mcg/kg|MK2578
62208330|NCT05797610|PLACEBO_COMPARATOR|Placebo|Participants will receive SC doses of RO7434656 matching placebo on Days 1, 15, and 29 followed by once every 4 weeks until Week 105. After Week 105, participants may continue blinded treatment or enter open-label treatment until up to 1 year after the date at which the last participant completes the Week 105 assessment, withdraws, or is discontinued from the study.
62017976|NCT00968617|EXPERIMENTAL|MK2578 2.0 mcg/kg|MK2578
62017977|NCT00968617|EXPERIMENTAL|MK2578 3.6 mcg/kg|MK2578
62208331|NCT04613583||SAFeR Fetuses|Different maternal lifestyle factors: smoking, BMI, social deprivation, alcohol use, medicines. Depends on specific subproject analyses.
62208332|NCT06162572|EXPERIMENTAL|S095018 (anti-TIM3 antibody) in combination with cemiplimab|Part A: Combination-therapy safety lead-in
62208333|NCT06162572|EXPERIMENTAL|S095024 (anti-CD73 antibody) in combination with cemiplimab|Part A: Combination-therapy safety lead-in
62208334|NCT06162572|EXPERIMENTAL|S095029 (anti-NKG2A antibody) in combination with cemiplimab|Part A: Combination-therapy safety lead-in
62208335|NCT06162572|EXPERIMENTAL|S095018 (anti-TIM3 antibody) RDE in combination with cemiplimab|Part B: Randomized dose expansion
62208336|NCT06162572|EXPERIMENTAL|S095024 (anti-CD73 antibody) RDE in combination with cemiplimab|Part B: Randomized dose expansion
62208337|NCT06162572|EXPERIMENTAL|S095029 (anti-NKG2A antibody) RDE in combination with cemiplimab|Part B: Randomized dose expansion
62208338|NCT06162572|ACTIVE_COMPARATOR|Cemiplimab (control arm)|Part B: Randomized dose expansion
62208339|NCT06564701|EXPERIMENTAL|Lab and Home Trial|Participants who complete the lab testing, and who are able to use both devices during a field trial period in school
62208340|NCT06564701|EXPERIMENTAL|Experimental No Field Trial|Participants who are only able to complete the lab testing
62208341|NCT01582841|EXPERIMENTAL|MSI testing|All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI following surgery. Those with MSI-H results will receive a genetic counseling informational call.
62208342|NCT01582841|NO_INTERVENTION|Usual care|These patients will be treated as usual by their oncologist and medical team. These patients receive a follow up letter a year after randomization, alerting them to the availability of clinical Lynch Syndrome screening.
62208343|NCT00412412|EXPERIMENTAL|A|Patients with HER2- Breast Cancer
62208344|NCT00412412|EXPERIMENTAL|B|Patients with HER2+ Breast Cancer
62208345|NCT03775486|EXPERIMENTAL|Durvalumab/Olaparib Combination Therapy|"Durvalumab/Olaparib Combination Therapy:~Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/Olaparib (maintenance phase)"
62208346|NCT03775486|EXPERIMENTAL|Durvalumab Monotherapy|Durvalumab Monotherapy: Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/placebo (maintenance phase)
62208347|NCT05910944||Group 1 - prodromal iNPH|Individuals with typical imaging findings consistent with iNPH but none or too mild symptoms to motivate shunt surgery.
62208348|NCT05910944||Group 2 - Healthy controls|Age matched healthy controls
62208349|NCT05910944||Group 3 - symptomatic iNPH|Patients with symptomatic iNPH
62208350|NCT05597787|ACTIVE_COMPARATOR|HIV Connect|Participants randomized to this condition will complete HIV Connect, which is an online course developed by the Malaysian Society of HIV Medicine designed to educate primary care physicians in Malaysia about HIV. It consists of a series of modules featuring HIV infectious disease experts who instruct on topics including epidemiology and natural history of HIV, pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), sexual history taking and STI testing, and others.
62208351|NCT05597787|ACTIVE_COMPARATOR|Project ECHO for HIV Prevention|Participants randomized to this condition will receive Project ECHO for HIV Prevention, without added evidence-based stigma reduction tools. Participants will meet with the Project ECHO Hub specialists and their learning community on a bi-weekly basis for 60 minutes over the course of 9 months. Each session will feature a didactic training incorporating standardized procedures for HIV testing, prevention, and/or linkage to care, and patient-case presentation and discussion.
62208352|NCT05597787|EXPERIMENTAL|Project ECHO for HIV Prevention + Stigma Reduction|Participants randomized to this condition will receive the Project ECHO for HIV Prevention intervention with added evidence-based stigma reduction tools. Participants will meet with the Project ECHO Hub specialists and their learning community on a bi-weekly basis for 60 minutes over the course of 9 months. Each session will feature a didactic training incorporating standardized procedures for HIV testing, prevention, and/or linkage to care, and patient-case presentation and discussion.
62208353|NCT03553576|EXPERIMENTAL|Low volume bolus|6.25 mL administration at 250 ml per hour of a greater density solution (0.1% bupivacaine with fentanyl 2.0 mcg/mL)
62208354|NCT03553576|EXPERIMENTAL|High volume bolus|10 mL administration of a lower density local anesthetic (0.0625% bupivacaine with fentanyl 2.0 mcg/mL).
62406518|NCT01042379|EXPERIMENTAL|SGN-LIV1A|Arm is closed.
62406519|NCT01042379|EXPERIMENTAL|Durvalumab plus Olaparib|Arm is closed.
62017978|NCT00968617|ACTIVE_COMPARATOR|Darbepoetin alfa|darbepoetin alfa
62017979|NCT00486343|EXPERIMENTAL|1|Zileuton CR
62017980|NCT00486343|PLACEBO_COMPARATOR|2|Placebo
62017981|NCT02258633|EXPERIMENTAL|Intervener Brief Intervention (IBI)|Subjects and parents will complete a Brief Motivational Interview (BMI) incorporating personalized feedback, discussion of choices and changes, and therapist led intervention message relating behavioral change and future goals.
62017982|NCT02258633|NO_INTERVENTION|Enhanced Usual Care|Subjects and parents will receive standard trauma care, plus complete brief questionnaires and receive general safety information.
62208355|NCT02843061|EXPERIMENTAL|Rituximab and NK immunotherapy|In this group, the patients will receive regular Rituximab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62789874|NCT04916236|EXPERIMENTAL|Phase Ib|The phase Ib expansion cohort study is intended to further characterize the safety, tolerability and PK/PD of the selected dose of RMC-4630 in combination with LY3214996 in patients with advanced KRASm PDAC. Furthermore, it will explore the clinical activity of RMC-4630 in combination with LY3214996 in patients with advanced KRASm PDAC.
62017983|NCT01583725|EXPERIMENTAL|Roux-en-Y Gastric Bypass|30 subjects who plan to undergo Roux-en-Y Gastric Bypass bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
62208356|NCT02843061|ACTIVE_COMPARATOR|Rituximab|In this group, the patients will receive regular Rituximab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62208357|NCT04571450|EXPERIMENTAL|Experimental group|All participants will receive access to the same web-based lifestyle intervention (exercise and nutritional education)
62208358|NCT05619653|ACTIVE_COMPARATOR|Verum|Prednisolone and Losartan
62208359|NCT05619653|PLACEBO_COMPARATOR|Placebo|Placebo 1 and Placebo 2
62208360|NCT05179213|EXPERIMENTAL|Azacytidine combined with chidamide|Patients in the experimental arm will received azacytidine plus chidamide treatment. This regimen was repeated every 28 days.
62208361|NCT00847080|EXPERIMENTAL|Sitagliptin|
62208362|NCT00847080|PLACEBO_COMPARATOR|Placebo|
62208363|NCT06728644|EXPERIMENTAL|L-arginine intervention with 3g daily treatment for three months|L-arginine therapy
62208364|NCT00588692|ACTIVE_COMPARATOR|SphygmoCor Unblinded|The use of the sphygmocor values will determine medication adjustments to optimize HF treatment.
62208365|NCT00588692|PLACEBO_COMPARATOR|SphygmoCor Blinded|Sphygmocor values will be blinded to the investigator.
62789875|NCT00615004||1-SSA|All patients receiving first-line depot SSA treatment, with either octreotide-LAR or lanreotide, achieving control of the disease, and with available follow-up after 12 months of treatment.
62789876|NCT00615004||2-Surgery|All patients treated with first-line surgery via trans-sphenoidal route by microscopic and/or endoscopic approach, who did not require any additional therapy for acromegaly and with available follow-up after 12 months of treatment
62208366|NCT04514510|EXPERIMENTAL|Participants with Sickle Cell Disease Receiving Isoquercetin|Isoquercetin 1000 mg, once daily by mouth for 28 days in participants with Sickle Cell Disease.
62208367|NCT04514510|PLACEBO_COMPARATOR|Participants with Sickle Cell Disease Receiving Placebo|Placebo once daily, by mouth for 28 days in participants with Sickle Cell Disease.
62208368|NCT04476251|EXPERIMENTAL|Arm 1/E7 T-Cell Receptor (TCR) T Cell Therapy|E7 TCR T Cell Therapy
62208369|NCT03440060|NO_INTERVENTION|standard group|participants receive systematically empiric antibiotic therapy on admission with amoxicillin- acid clavulanic or levofloxacin in case of allergy
62208370|NCT03440060|ACTIVE_COMPARATOR|Procalcitonin group|participants receive antibiotics only if the procalcitonin value is at or greater than 0.25 ng/ml
62789877|NCT00764062|EXPERIMENTAL|1|7-day amoxicillin treatment (1g per os twice daily)
62789878|NCT00764062|ACTIVE_COMPARATOR|2|3-day amoxicillin (1g per os twice daily) + 4-day placebo treatment (1g per os twice daily)
62789879|NCT04269356|EXPERIMENTAL|BMS-986256|
62017984|NCT01583725|EXPERIMENTAL|Gastric Banding (Lap-band)|30 subjects who plan to undergo Gastric Banding bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
62017985|NCT01583725|EXPERIMENTAL|Formula Diet Weight Loss|30 subjects who plan to begin a formula diet to lose weight. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before subjects undertake a 12-week weight loss intervention (T1), at the end of the weight loss intervention (T2) and 18 months after they completed the weight loss intervention(T3).
62208371|NCT05595252||Patients with CIN lésions during pregnancy|
62208372|NCT02826928|EXPERIMENTAL|patients with small-intestine neuroendocrine tumors|
62208373|NCT02826928|EXPERIMENTAL|control subjects with irritable bowel syndrome|
62208374|NCT06077500|EXPERIMENTAL|Part A - Dose escalation: BI 764532 very low dose + carboplatin + etoposide + atezolizumab|
62208375|NCT06077500|EXPERIMENTAL|Part A - Dose escalation: BI 764532 low dose + carboplatin + etoposide + atezolizumab|
62789880|NCT02692755|EXPERIMENTAL|Palbociclib + Letrozole or Fulvestrant|
62789881|NCT00730080||Sapropterin (Kuvan)|Individuals with phenylketonuria (PKU) who are beginning treatment with sapropterin.
62789882|NCT00730080||Control|Healthy individuals without phenylketonuria (PKU).
62789883|NCT01103570|EXPERIMENTAL|group 1 cholecystocholangiography|cholangiography via gall bladder
62789884|NCT01103570|EXPERIMENTAL|group2 cystic duct cholangiography|cystic duct cholangiography
62789885|NCT05370053|EXPERIMENTAL|ELF-test|Patients receive ELF testing (a blood draw) and their hepatologist receives the result within a week.
62208376|NCT06077500|EXPERIMENTAL|Part A - Dose escalation: BI 764532 medium dose + carboplatin + etoposide + atezolizumab|
62208377|NCT06077500|EXPERIMENTAL|Part A - Dose escalation: BI 764532 high dose + carboplatin + etoposide + atezolizumab|
62208378|NCT06077500|EXPERIMENTAL|Part B - Dose expansion: BI 764532 + carboplatin + etoposide + atezolizumab|
62208379|NCT06077500|EXPERIMENTAL|Part B - Dose expansion: BI 764532 + carboplatin + etoposide + durvalumab|
62208380|NCT06077500|EXPERIMENTAL|Part B - Dose expansion: BI 764532 + cisplatin + etoposide + durvalumab|
62208381|NCT05478759|EXPERIMENTAL|MMART and attention training|Training to recognize affect and prosodic expressions of emotions combined with attention training.
62208382|NCT05478759|PLACEBO_COMPARATOR|Brain Health Workshop and National Geographic Movies|an inactive arm that matches sessions of intervention. BHW is education about the brain and cognition. National Geographic movies are viewed with the clinician and the participant answers questions about the movies.
62208383|NCT01161381||Normal|Subjects that underwent night polysomnography with an observed Apnea-Hypopnea Index (AHI) \< 5.
62208384|NCT01161381||OSAHS patients|Subjects that underwent night polysomnography with an observed Apnea-Hypopnea Index (AHI) \> 5.
62208385|NCT05418751|EXPERIMENTAL|Manual therapy group|Patients in this group (n=20) will receive a manual therapy protocol.
62208386|NCT05418751|PLACEBO_COMPARATOR|Placebo group|Patients in this group (n=20) will receive a placebo treatment.
62208387|NCT06727890|EXPERIMENTAL|Compound Danshen Dripping Pill|
62406520|NCT01042379|EXPERIMENTAL|SD-101 + Pembrolizumab|Arm is closed.
62208388|NCT06727890|PLACEBO_COMPARATOR|Placebo|
62208389|NCT06729242|EXPERIMENTAL|Aerobic session in luteal phase first menstruation|The aerobic exercise session will begin with a 3 min resting period (sitting quietly on the cycle ergometer (0 W), followed by a 3 min warm-up at 40 W and a stepwise intensity increase by 20 W / min (to control for day-to-day variations in exercise response) until the 5% of Pmax from IET above PLTP1 is achieved (i.e. moderate steady state walking or low-intensity running or cycling). This target workload will be maintained for 30 min. Active and passive recovery periods of 3 min each will be the same as the incremental test. This session will be held on day 21 of first menstruation.
62208390|NCT06729242|EXPERIMENTAL|Aerobic session in follicular phase first menstruation|The aerobic exercise session will begin with a 3 min resting period (sitting quietly on the cycle ergometer (0 W), followed by a 3 min warm-up at 40 W and a stepwise intensity increase by 20 W / min (to control for day-to-day variations in exercise response) until the 5% of Pmax from IET above PLTP1 is achieved (i.e. moderate steady state walking or low-intensity running or cycling). This target workload will be maintained for 30 min. Active and passive recovery periods of 3 min each will be the same as the incremental test. This session will be held on day 3 of menstruation.
62208391|NCT06729242|EXPERIMENTAL|Aerobic session in luteal phase second menstruation|The aerobic exercise session will begin with a 3 min resting period (sitting quietly on the cycle ergometer (0 W), followed by a 3 min warm-up at 40 W and a stepwise intensity increase by 20 W / min (to control for day-to-day variations in exercise response) until the 5% of Pmax from IET above PLTP1 is achieved (i.e. moderate steady state walking or low-intensity running or cycling). This target workload will be maintained for 30 min. Active and passive recovery periods of 3 min each will be the same as the incremental test. This session will be held on day 21 of second menstruation.
62208392|NCT06729242|EXPERIMENTAL|HIIT session in luteal phase first menstruation|The HIIT exercise will consist of strength exercises with elastic bands. The session consists of two sets of exercise intervals of 20 s separated by 10 s of rest (i.e. 4 min in total) with a rest of 3 minutes between each set, performing in each interval a different exercise resisted by the elastic band. This session will be held on day 21 of first menstruation.
62208393|NCT06729242|EXPERIMENTAL|HIIT session in follicular phase first menstruation|The HIIT exercise will consist of strength exercises with elastic bands. The session consists of two sets of exercise intervals of 20 s separated by 10 s of rest (i.e. 4 min in total) with a rest of 3 minutes between each set, performing in each interval a different exercise resisted by the elastic band. This session will be held on day 3 of first menstruation.
62208394|NCT06729242|EXPERIMENTAL|HIIT session in luteal phase second menstruation|The HIIT exercise will consist of strength exercises with elastic bands. The session consists of two sets of exercise intervals of 20 s separated by 10 s of rest (i.e. 4 min in total) with a rest of 3 minutes between each set, performing in each interval a different exercise resisted by the elastic band. This session will be held on day 21 of second menstruation.
62406521|NCT01042379|EXPERIMENTAL|Tucatinib|Arm is closed.
62406522|NCT01042379|EXPERIMENTAL|Cemiplimab|Novel Investigational Agent. Arm is closed.
62789886|NCT05370053|NO_INTERVENTION|Control|No intervention.
62789887|NCT01431053|EXPERIMENTAL|Exemestane + Aspirin|
62406523|NCT01042379|EXPERIMENTAL|Cemiplimab plus REGN3767|Novel Investigational Agent. Arm is closed.
62406524|NCT01042379|EXPERIMENTAL|Trilaciclib with or without trastuzumab + pertuzumab|Novel Investigational Agent. Arm is closed.
62789888|NCT01431053|ACTIVE_COMPARATOR|Exemestane|
62789889|NCT04270539|EXPERIMENTAL|Experimental Group (nap)|The experimental group will be allowed to take a brief nap daily on school days during the study period.
62406525|NCT01042379|EXPERIMENTAL|SYD985 ([vic-]trastuzumab duocarmazine)|Novel Investigational Agent. Arm is closed.
62406526|NCT01042379|EXPERIMENTAL|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab|Novel Investigational Agent. Arm is closed.
62789890|NCT04270539|NO_INTERVENTION|Control Group (no nap)|The control group will not be allowed to take daily nap on school days during the study period.
62789891|NCT02095080|EXPERIMENTAL|Leucine intake|Dietary supplement: Leucine intake
62789892|NCT04308629|EXPERIMENTAL|tDCS over PMAs|One session of transcranial direct current stimulation (tDCS) over premotor areas (PMAs)
62789893|NCT04308629|ACTIVE_COMPARATOR|tDCS over M1|One session of transcranial direct current stimulation (tDCS) over primary motor area (M1)
62789894|NCT02416154||Follicular phase|Normally cycling women in the follicular phase of menses
62789895|NCT02416154||Luteal phase|Normally cycling women in the luteal phase of menses
62017986|NCT01583725|EXPERIMENTAL|No Treatment|30 subjects who do not undergo any treatment for weight loss. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed at baseline (T1) and at 3 months (T2) and 18 months (T3) later.
62017987|NCT01583725|EXPERIMENTAL|Sleeve Gastrectomy Surgery|30 subjects who plan to undergo Sleeve Gastrectomy bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
62017988|NCT00289796|ACTIVE_COMPARATOR|Infanrix hexa Group|Subjects received a dose of hepatitis B vaccine at birth followed by immunization with 3 doses of Infanrix hexa™ (2, 4 and 6 months of age) and one booster dose of Infanrix hexa™ between 12 and 23 months of age. All vaccines were administered by deep intramuscular injection into the left anterolateral thigh.
62017989|NCT00426023|EXPERIMENTAL|1|this group of patients is treated with the experimental drug (Cyclosporine A 0,05% eye drops) 2 times daily
62017990|NCT00426023|ACTIVE_COMPARATOR|2|
62406527|NCT01042379|EXPERIMENTAL|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab|Novel Investigational Agent. Arm is closed.
62406528|NCT01042379|EXPERIMENTAL|Endocrine Optimization Pilot: Amcenestrant Monotherapy|Novel Investigational Agent. Arm is closed.
62789896|NCT04876352|EXPERIMENTAL|VR-training|Upper limb/handwriting exercises in an immersive virtual reality setting
62789897|NCT04876352|ACTIVE_COMPARATOR|RS-training|The same upper limb/handwriting exercises in a real setting
62789898|NCT04876352|OTHER|Healthy subjects|Age- and sex-matched healthy subjects recruited to compare clinical and fMRI characteristics at baseline.
62789899|NCT02779413||Insulin degludec|
62017991|NCT06111092|OTHER|Design Thinking Group|A group of randomized participants (autistic adults, parents/caregivers, OT practitioners, teachers, and cultural experts) will participate in the Design Thinking (DT) process.
62017992|NCT06111092|OTHER|Focus Group|A group of randomized participants (autistic adults, parents/caregivers, OT practitioners, teachers, and cultural experts) will participate in the Focus Group (FG) process.
62017993|NCT02148562||Chronic Hepatitis B|Diagnosis of Hepatitis B related liver disease in a pre-advanced stage
62017994|NCT02148562||End stage liver disease|Diagnosis of advanced liver disease related to Hepatitis B
62406529|NCT01042379|EXPERIMENTAL|Endocrine Optimization Pilot: Amcenestrant + Abemaciclib|Novel Investigational Agent. Arm is closed.
62406530|NCT01042379|EXPERIMENTAL|Endocrine Optimization Pilot: Amcenestrant + Letrozole|Novel Investigational Agent. Arm is closed.
62406531|NCT01042379|EXPERIMENTAL|ARX788 in Block A and followed by SOC in Block B|Novel investigational Agent followed by SOC
62406532|NCT01042379|EXPERIMENTAL|ARX788 + Cemiplimab in Block A and followed by SOC in Block B|Novel investigational Agent followed by SOC. Arm is closed.
62406533|NCT01042379|EXPERIMENTAL|VSV-IFNβ-NIS (VOYAGER V1™; VV1) + Cemiplimab in Block A and followed by SOC in block B|Novel investigational Agent followed by SOC
62789900|NCT00772265|EXPERIMENTAL|Wosulin N|Wosulin N, Isophane insulin for injection (Recombinant Human Insulin)(100 IU/mL), cartridges 3.0 mL
62789901|NCT00772265|ACTIVE_COMPARATOR|Novolin N|Novolin N, Isophane insulin for injection (Recominant Human Insulin)(100IU/ml),cartridges 3.0ml.
62789902|NCT00079716|EXPERIMENTAL|1|
62017995|NCT01420406|PLACEBO_COMPARATOR|0 mg retinol|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
62017996|NCT01420406|EXPERIMENTAL|12 mg BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule.
62017997|NCT01420406|EXPERIMENTAL|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
62017998|NCT01420406|EXPERIMENTAL|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
62017999|NCT01047683|PLACEBO_COMPARATOR|Placebo|
62018000|NCT01047683|EXPERIMENTAL|AMR101 (ethyl icosapentate) - 2 g/day|
62018001|NCT01047683|EXPERIMENTAL|AMR101 (ethyl icosapentate) - 4 g/day|
62018002|NCT02297152|OTHER|FLIP HOLE|The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation
62406534|NCT01042379|EXPERIMENTAL|Datopotamab Deruxtecan in Block A and followed by SOC in block B|Novel investigational Agent followed by SOC
62406535|NCT01042379|EXPERIMENTAL|Datopotamab Deruxtecan + Durvalumab in Block A and followed by SOC in block B|Novel investigational Agent followed by SOC
62789903|NCT02338050|EXPERIMENTAL|Moxetumomab Pasudotox|Moxetumomab pasudotox 32 mcg/kg/dose IV every other day for a total of 6 doses. Dexamethasone 2.5 mg/m2/dose (or corticosteroid equivalent) will be administered before and after each dose of moxetumomab pasudotox.
62789904|NCT04270084|OTHER|Treatment|Participants will be asked use a mobile health (m-health) app for 2 months. The app is designed to provide weekly education and motivation about healthful diet and physical activity behaviors in adolescents and their parent/adult caretaker. Both adolescent and parent/adult caretaker participants will use the app to enter weekly self-report data, set healthy eating and exercise goals, and receive educational and motivational content. Participants will conduct a weekly self-assessment of waist circumference, diet, and physical activity during the 2 month trial.
62789905|NCT04607746|EXPERIMENTAL|Capsule|Participants will swallow the capsule for imaging prior to completing colonoscopy. Capsule swallow may be 1 day prior or 3-6 weeks prior to colonoscopy.
62789906|NCT05746156|EXPERIMENTAL|lymphatic map|Lymphatic mapping will be performed
62789907|NCT03371784|ACTIVE_COMPARATOR|Hydrocortisone|Patients who meet the inclusion criteria, with a CWP above the derived cutoff, with continuous elevation of the pressure line, who are randomized to i.v hydrocortisone administration.
62789908|NCT03371784|PLACEBO_COMPARATOR|Placebo|Patients who meet the inclusion criteria, with a CWP above the derived cutoff, with continuous elevation of the pressure line, who are randomized to placebo (sodium chloride 0.9%).
62789909|NCT01824355|EXPERIMENTAL|Intended Users of the Monitoring System|"Untrained subjects with diabetes used the Ninja 3 PLUS Investigational BG Monitoring System. General enrollment criteria for the 'Intended Users' population:~1. At least 60% of subjects were younger than 65 years of age.~2. At least 20% had type 1 diabetes.~3. At least 50% with type 2 diabetes were insulin users."
62018003|NCT04159831|EXPERIMENTAL|400,000 U LTI-01|400,000 U LTI-01 once a day (qd) x 3 days administered intrapleurally
62208395|NCT04080453||Septic shock|Plasma of 100 patients presenting a septic shock will be analysed including plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha and HMGB-1
62208396|NCT04080453||Systemic Inflammatory Response Syndrome|Plasma of 100 patient presenting a systemic inflammatory response syndrome = SIRS will be analysed including plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha and HMGB-1
62208397|NCT06728059|ACTIVE_COMPARATOR|AIDANET→AIDANET+ BPS_RL|Group A: AIDANET followed by AIDANET+ BPS_RL during the hotel session
62208398|NCT06728059|ACTIVE_COMPARATOR|AIDANET+ BPS_RL→AIDANET|Group B: AIDANET+BPS_RL followed by AIDANET during the hotel session
62208399|NCT03165747|EXPERIMENTAL|VSL#3|VSL#3 two active sachets \[containing 450x109 colony-forming units (CFU)/sachet\], taken daily in a single administration.
62208400|NCT03165747|PLACEBO_COMPARATOR|Control|Placebo, no supplemental probiotics.
62208401|NCT02828813||Normal|healthy subjects
62208402|NCT02828813||CogImpair|persons with cognitive impairments
62208403|NCT02828813||MotorDeficits|persons with motor deficits
62208404|NCT05816226|EXPERIMENTAL|Hydrocortisone topical|2.5% hydrocortisone cream
62734445|NCT04706780||ESP block group|Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
62789910|NCT01458418|EXPERIMENTAL|Montelukast 10 mg/day|Subjects will receive two 5mg tablets of Montelukast/day.
62789911|NCT01458418|EXPERIMENTAL|Montelukast 5mg/day|Subjects will receive one 5mg tablet of montelukast and 1 placebo tablet per day.
62208405|NCT05816226|ACTIVE_COMPARATOR|Diclofenac topical|1% diclofenac cream
62208406|NCT06728722||critically ill obstetrics patients , admitted to ICU|
62406536|NCT01042379|EXPERIMENTAL|Zanidatamab in Block A and followed by SOC in block B|Novel investigational Agent followed by SOC
62789912|NCT01458418|PLACEBO_COMPARATOR|placebo|Subjects will receive two placebo tablets per day.
62018004|NCT04159831|EXPERIMENTAL|800,000 U LTI-01|800,000 U LTI-01 qd x 3 days administered intrapleurally
62018005|NCT04159831|EXPERIMENTAL|1,200,000 U LTI-01|1,200,000 U LTI-01 qd x 3 days administered intrapleurally
62208407|NCT06728722||critically ill gynecological cases, admitted to ICU|
62208408|NCT06024434|EXPERIMENTAL|Experimental interventional group A|Exercises for core, gluts, upper body and lower body
62208409|NCT06024434|ACTIVE_COMPARATOR|Control group B|Walking for 30 min 5 days a week
62208410|NCT05602792|EXPERIMENTAL|T3011 Herpes Virus Injection|
62208411|NCT03856190|ACTIVE_COMPARATOR|"Fasting and best practice nutrition"|Initial fasting followed by 11 weeks plant-based diet
62208412|NCT03856190|ACTIVE_COMPARATOR|Standard Nutrition Counselling|12 weeks standard antiinflammatory diet
62208413|NCT02015208|EXPERIMENTAL|Ruxolitinib|Ruxolitinib will be administered over a 28-day cycle, which will be repeated 6 more times in the absence of intolerable toxicity, disease progression, patient withdrawal of consent, or investigator decision to end therapy. The dose and schedule have been adapted from the product monograph for myelofibrosis. The starting dose will be 20 mg orally twice a day with normal .platelet and absolute neutrophil counts and no hepatic and renal impairment.
62406537|NCT01042379|EXPERIMENTAL|Endocrine Optimization Pilot: Lasofoxifene|Novel investigational Agent
62406538|NCT01042379|EXPERIMENTAL|Endocrine Optimization Pilot: (Z)-Endoxifen|Novel investigational Agent
62406539|NCT01042379|EXPERIMENTAL|Endocrine Optimization Pilot: ARV-471|Novel investigational Agent
62406540|NCT01042379|EXPERIMENTAL|Endocrine Optimization Pilot: ARV-471 + Letrozole|Novel investigational Agent
62406541|NCT01042379|EXPERIMENTAL|Endocrine Optimization Pilot: ARV-471 + Abemaciclib|Novel investigational Agent
62208414|NCT06395090|EXPERIMENTAL|Favezelimab + Pembrolizumab|Participants will receive pembrolizumab and favezelimab via an intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 cycles. Each cycle is 21 days.
62208415|NCT06395090|EXPERIMENTAL|Favezelimab/Pembrolizumab|Participants will receive coformulated favezelimab/pembrolizumab via an IV infusion Q3W for up to 35 cycles. Each cycle is 21 days.
62208416|NCT06395090|EXPERIMENTAL|Pembrolizumab + Vibostolimab|Participants will receive pembrolizumab and vibostolimab via an IV infusion Q3W for up to 35 cycles. Each cycle is 21 days.
62406542|NCT01042379|EXPERIMENTAL|Endocrine Optimization Pilot: (Z)-Endoxifen + Abemaciclib|Novel investigational Agent
62208417|NCT06395090|EXPERIMENTAL|Pembrolizumab/Vibostolimab|Participants will receive coformulated pembrolizumab/vibostolimab via an IV infusion Q3W for up to 35 cycles. Each cycle is 21 days.
62208418|NCT03100487|EXPERIMENTAL|Audio Record Guided Imagery (ARGI)|The audio recorded guided imagery sessions (treatment) will be delivered through a digital audio player (Apple iPod Shuffle).
62406543|NCT01042379|EXPERIMENTAL|Rilvegostomig + TDXd in Block A and followed by SOC in Block B|Novel investigational Agent
62406544|NCT01042379|EXPERIMENTAL|DAN222 + Niraparib in Block A and followed by SOC in Block B|Novel investigational Agent
62734446|NCT05698615|EXPERIMENTAL|Chess training group|group receiving additional chess training
62734447|NCT05698615|NO_INTERVENTION|control group|group receiving standard therapy only
62734448|NCT01735734||Capillary malformation|
62734449|NCT01564212|ACTIVE_COMPARATOR|standard airflow and forced air warming|Subjects will lie on operating room bed with standard airflow and forced air warming.
62789913|NCT05844241|EXPERIMENTAL|Music and Theta Auditory Beat Stimulation (ABS)|Participants listen to 30 minutes of personalized music with theta auditory beat stimulation (ABS).
62789914|NCT05844241|ACTIVE_COMPARATOR|Audiobooks|Participants listen to a 30-minute audiobook.
62789915|NCT00546000|EXPERIMENTAL|1|Receive between 22 and 29 days of Cutivate lotion treatment
62789916|NCT01651325|EXPERIMENTAL|Isavuconazole and dextromethorphan|Dextromethorphan on Day 1and Day 10, Isavuconazole three times per day (TID) on Days 6 and 7, and once daily (QD) on Days 8 thru 12.
62789917|NCT03325595|ACTIVE_COMPARATOR|Experimental: AEF0117|Subjects in Cohorts 1 through 4 receive active treatments. Subjects in Cohorts 1 through 4 will receive a single dose of 0.2, 0.6, 2 and 6mg respectively of AEF0117 on Day1.
62208419|NCT03100487|EXPERIMENTAL|Deep Breathing Exercises|The deep breathing exercises (control) will be delivered through a digital audio player (Apple iPod Shuffle).
62208420|NCT03614949|EXPERIMENTAL|Combination Therapy|Stereotactic body radiation therapy (SBRT) followed by atezolizumab, 1 week later.
62208421|NCT03563157|EXPERIMENTAL|NANT Colorectal Cancer (CRC) Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCI, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT.
62208422|NCT03563157|ACTIVE_COMPARATOR|Regorafenib|Regorafenib will be administered to subjects in this study.
62208423|NCT06723184|EXPERIMENTAL|Experimental grup|Experimental grup
62208424|NCT06723184|NO_INTERVENTION|Control group|No intervention grup
62208425|NCT04451967||Transfer after thrombolysis|
62208426|NCT04451967||Transfer after DAPT|
62208427|NCT04451967||Direct transfer|
62208428|NCT02925598|EXPERIMENTAL|I-gel LMA|I-gel LMA insertion: I-gel insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
62208429|NCT02925598|EXPERIMENTAL|AuraGain LMA|AuraGain insertion:AuraGain LMA insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
62208430|NCT02925598|EXPERIMENTAL|Endotracheal tube (ETT)|Endotracheal tube insertion: Endotracheal tube (ETT) insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
62208431|NCT03896152|EXPERIMENTAL|LNP023 25 mg bid/100 mg bid|Four weeks of treatment with iptacopan 25 mg bid in Period 1 followed by treatment with 100 mg bid in Period 2 and Period 3.
62208432|NCT03896152|EXPERIMENTAL|LNP023 50 mg bid/200 mg bid|Four weeks of treatment with iptacopan 50 mg bid in Period 1 followed by treatment with 200 mg bid in Period 2 and Period 3.
62208433|NCT03767829|EXPERIMENTAL|Part A: SAD: ALN-AAT02|Participants will be administered a single dose of ALN-AAT02.
62406545|NCT01042379|EXPERIMENTAL|Sarilumab + Cemiplimab + Paclitaxel in Block B followed by SOC Block C|Novel investigational Agent
62406546|NCT03525769||Type 2 Diabetes Mellitus|
62406547|NCT00453336|EXPERIMENTAL|Single Arm|
62789918|NCT03325595|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Subjects in Cohorts 1 through 4 will be randomly assigned in an 6:2 allocation to receive active or placebo treatments.
62018006|NCT04159831|PLACEBO_COMPARATOR|Placebo|placebo (normal saline) 6ml qd x 3 days administered intrapleurally
62018007|NCT02741947|ACTIVE_COMPARATOR|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
62208434|NCT03767829|PLACEBO_COMPARATOR|Part A: SAD: Placebo|Participants will be administered a single dose of matching placebo.
62208435|NCT03767829|EXPERIMENTAL|Part B: MAD: ALN-AAT02|Participants will be administered multiple doses of ALN-AAT02.
62208436|NCT03767829|PLACEBO_COMPARATOR|Part B: MAD: Placebo|Participants will be administered multiple doses of matching placebo.
62208437|NCT06161519|EXPERIMENTAL|Phase I|Escalating and de-escalating doses of PLX038
62208438|NCT06161519|EXPERIMENTAL|Phase II|RP2D of PLX038
62208439|NCT03995966|ACTIVE_COMPARATOR|Subtype 2 Automatically Maintained SIB|
62208440|NCT03995966|ACTIVE_COMPARATOR|Subtype 3 Automatically Maintained SIB|
62208441|NCT06308887|ACTIVE_COMPARATOR|Group 1|patients who had perimeniscal 5 % dextrose injection
62208442|NCT06308887|ACTIVE_COMPARATOR|Group 2|patients who had perimeniscal triamcinolone injection
62406548|NCT02206984|ACTIVE_COMPARATOR|tamoxifen|Tamoxifen is administered orally, at a dose of 20 mg,daily, for 21 days
62406549|NCT02206984|ACTIVE_COMPARATOR|Anastrozole|1mg given orally daily for 21 days
62018008|NCT02741947|EXPERIMENTAL|Levodopa Benserazide Teva Italia|Levodopa Benserazide Teva Italia100+25mg and 200+50mg, tablet, tid e qid, for four weeks
62018009|NCT02809495||Patients who will use the clinical application|
62018010|NCT02809495||Patients who do not make use of clinical application|
62208443|NCT03843762||Adolescents|Adolescents, male or female, ages 11 - 17. Participants will complete 7 days/nights of actigraphy and sleep-based EEG and questionnaires.
62208444|NCT01073644||Sunitinb malate|
62208445|NCT06603987|EXPERIMENTAL|Boron Neutron Capture Therapy (BNCT)|
62208446|NCT06165302|EXPERIMENTAL|Exercise Intervention|Participants will be prescribed an exercise program after completing assessments at baseline. Participants will adhere to the prescribed exercise intervention for 12 weeks and log activity in a physical activity diary. Participants will return to clinic on Week 5 and Week 9 for assessments and adjustment to their exercise prescription as needed.
62208447|NCT05246527|EXPERIMENTAL|Exercise|"30 min of cycling on a stationary ergometer, guided by a video of a professional cycling instructor.~* Half of the patients (n=30) and their respective matched healthy controls (n=30) will perform moderate-intensity exercise: continuous cycling at 64-76% of the individual HRmax).~* The other half will perform a high-intensity interval training (HIIT) protocol: 5 min warm-up phase, followed by bursts of high-intensity cycling interspersed with varied recovery times (21 min in total), 4 min cool-down. Excluding warm-up and cool-down, intensities will remain \>77% of individual HRmax during the whole routine.~Heart rate will be continuously recorded using a chest strap heart rate monitor and monitored by the patients themselves and the experimenter."
62208448|NCT05246527|ACTIVE_COMPARATOR|Control condition|30 min of watching a documentary about the benefits of physical activity on health. Heart rate will be recorded also during the control condition.
62406550|NCT02206984|ACTIVE_COMPARATOR|fulvestrant|500 mg, administered as two 250 mg IM injections, given on days 1 and 14
62734450|NCT01564212|ACTIVE_COMPARATOR|laminar airflow with surgical drapes|Subjects will lie on operating room bed with laminar airflow device on and surgical drapes surrounding bed.
62734451|NCT01564212|ACTIVE_COMPARATOR|laminar aiflow with forced air warming|Subjects will lie on operating room bed with laminar airflow on and warming forced air.
62734452|NCT01564212|ACTIVE_COMPARATOR|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow and surgical drapes surrounding bed.
62018011|NCT01699399|EXPERIMENTAL|water immersion|infuse water during insertion phase of colonoscopy instead of air insufflation; remove the water during withdrawal phase.
62018012|NCT01699399|EXPERIMENTAL|water exchange|infuse and remove water during the insertion phase of colonoscopy. Air insufflation is used only in the withdrawal phase
62208449|NCT03668223|EXPERIMENTAL|Promoting Resilience in Stress Management (PRISM)|Resilience Skills Training
62208450|NCT03668223|NO_INTERVENTION|Usual Care|Standard psychosocial care
62208451|NCT06659640|EXPERIMENTAL|ALN-6400|Participants will be administered a single dose of ALN-6400.
62208452|NCT06659640|PLACEBO_COMPARATOR|Placebo|Participants will be administered a single dose of placebo.
62734453|NCT04501601|EXPERIMENTAL|Experimental: weight loss program kit|weight loss program kit
62789919|NCT06418490||3D-group|After adequate general anesthesia, the non-3D group underwent conventional choledochal cyst excision surgery, while the 3D group underwent choledochal cyst excision surgery guided by three-dimensional visualization technology or enhanced reality navigation.
62789920|NCT06418490||Non-3D Group|After adequate general anesthesia, the non-3D group underwent conventional choledochal cyst excision surgery, while the 3D group underwent choledochal cyst excision surgery guided by three-dimensional visualization technology or enhanced reality navigation.
62789921|NCT04345679|EXPERIMENTAL|Hospitalized patients with SARS CoV-2 infection|
62789922|NCT02889211|ACTIVE_COMPARATOR|Metabolically Healthy - Non-depressed|Overweight individuals without metabolic syndrome and free of psychiatric illness
62789923|NCT02889211|EXPERIMENTAL|Metabolically Healthy - Depressed|Overweight individuals without metabolic syndrome and with active major depression
62789924|NCT02889211|EXPERIMENTAL|Insulin Resistant - Depressed|Overweight individuals with metabolic syndrome and active major depression
62789925|NCT02889211|EXPERIMENTAL|Insulin Resistant - Non-depressed|Overweight individuals with metabolic syndrome and free of psychiatric illness
62789926|NCT01996280|PLACEBO_COMPARATOR|Motivational Interviewing|The MI is a single brief motivational intervention lasting 1.5 hours that includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan. The MI is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.
62789927|NCT01996280|EXPERIMENTAL|Culturally Tailored MI|The CTMI is a single brief motivational interview lasting 1.5 hours. It follows the same sequence of structured strategies as the MI, but the focus of the components is different. CTMI has augmented some of the components with culturally relevant material, including discussion about acculturation stress. The CTMI components are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback elements in the CTMI, such as ethnic normative feedback about drinking. To control for time across conditions, interventionists are instructed to select CTMI components based on participant interests, not the entire array of components.
62789928|NCT01770236|EXPERIMENTAL|IV acetaminophen|Patients in this group will receive intraoperative intercostal block + IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)
62789929|NCT01770236|NO_INTERVENTION|On-Q Pain Pump catheter|Patients in this group will receive the current standard care which includes an intraoperative intercostal block + On-Q Pain Pump catheter (continuous dosing).
62789930|NCT04787978|EXPERIMENTAL|AAMWI-OSU Intervention|In this single-arm pilot program, 100 African American male participants will be enrolled who have poor or average cardiovascular health (\< 4 life's simple 7 metrics in the ideal range) to a physical activity, education and patient activation intervention.
62789931|NCT03084835|ACTIVE_COMPARATOR|UC|Usual Care
62789932|NCT03084835|ACTIVE_COMPARATOR|WEB+TXT|Digital Intervention
62789933|NCT03084835|ACTIVE_COMPARATOR|WEB+TXT+TTS|Digital plus Counseling Intervention
62789934|NCT00048347|EXPERIMENTAL|Avonex|Interferon-beta1a (Avonex) 30 µg IM every week for 12 weeks
62789935|NCT00904904|EXPERIMENTAL|Indomethacin|Indomethacin ophthalmic solution 0.1% for post-surgical inflammation
62789936|NCT00904904|ACTIVE_COMPARATOR|Ketorolac|Ketorolac ophthalmic solution 0.5% for post-surgical inflammation
62789937|NCT00055692|EXPERIMENTAL|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment continues every 2 weeks in the absence of disease progression or unacceptable toxicity.
62789938|NCT02454478|EXPERIMENTAL|Lenvatinib plus Everolimus|
62018013|NCT01699399|ACTIVE_COMPARATOR|air insufflation|standard colonoscopy using traditional air insufflation during insertion
62018014|NCT00171977|EXPERIMENTAL|Imatinib Mesylate|400 mg once per day
62018015|NCT06574256|EXPERIMENTAL|intervention group|Patients in the intervention group will receive online nursing education and their quality of life and symptom complaints will be monitored by the nurse who provides education during three cycles of chemotherapy. At the end of the third cycle, patients' satisfaction with this education will be determined.
62018016|NCT06574256|NO_INTERVENTION|control group|Patients in the control group will receive routine nursing care. Patients in the control group will be monitored for quality of life and symptom complaints during three cycles of chemotherapy.
62018017|NCT05548075||Fibromyalgia Cohort|\*As diagnosed by an appropriate medical professional according to the American College of Rheumatology(ACR) diagnostic criteria
62018018|NCT03769441|ACTIVE_COMPARATOR|Ferric(III) carboxymaltose|The intervention group will be treated with four dosages of 500 mg iron in the form of 10 mL ferric(III) carboxymaltose dissolved in 240 mL of NaCl 0.9%, with interval periods of six weeks.
62208453|NCT04207151|NO_INTERVENTION|Standard of Care|Participants will receive HIV and STI testing, clinical monitoring, client centered counseling and PrEP prescriptions as standard of care, this includes scheduled visits every three months.
62406551|NCT05287581|EXPERIMENTAL|Experimental|The experimental intervention is a 16-week progressive home-based exercise program in which participants are supported through seven coaching calls based on social cognitive theory and motivational interviewing principles. The individual sessions will provide tailored support for increasing physical activity behavior towards the recommended guidelines of at least 150 minutes of moderate aerobic activity and two strength-training sessions per week. There are no drugs involved in the intervention.
62406552|NCT05287581|NO_INTERVENTION|Waitlist Control|24-week waitlist control condition
62406553|NCT01335620|OTHER|Tenofovir/Emtricitabine and Raltegravir|"Single arm study~tenofovir/emtricitabine 245/200 mg once daily and raltegravir 400 mg twice daily"
62406554|NCT04966702|ACTIVE_COMPARATOR|Albendazole|The albendazole group will receive a single dose of 400 mg, given once a month for three months. Generic products will be used in both countries, the final product will be GMP certified and fully bioequivalent with GSK's Albenza®. Bendex (CIPLA) in Mozambique and G-Abzole (Guilin) in Kenya.
62581714|NCT05704101||Controls (n=10) (and in a group of healthy controls [2:1] matched for age, sex and BMI).|"* Assessments of the SNA-axis. For this, HRV and dBPV will be analyzed using a 3-lead ECG and a continuous non-invasive arterial blood pressure signal. HRV and dBPV will be computed and presented as the high frequency , low frequency , their relative ratio (LF/HF), and the very low frequency component for both.~* MSNA will be recorded via a tungsten microelectrode placed in the peroneal nerve.~* NHFT at a flow rate of 20/30/40 liters/minute for 30 minutes respectively, with breaks of 15 minutes for all physiological variables to return to baseline.~* OSA severity: defined as apnoea-hypopnoea index \[AHI\] \>15/h and obstructive apnoea index \[OAI\] \>5/h~* Determination of PH and right HF severity (TAPSE ≤14 mm) and pulmonary arterial pressure (PAsys) using TTE.~* Comprehensive lung function and inspiratory muscle strength and function testing as described previously by our group.~* Assessment of systemic inflammation in blood samples."
62789939|NCT04382885|EXPERIMENTAL|Cohort 1 (10-17 years)|10 to 12 years: 0.75 mg/day cariprazine oral solution 13 to 17 years: 1.5 mg/day cariprazine oral solution
62018019|NCT03769441|PLACEBO_COMPARATOR|Placebo|The placebo-controlled group will receive four dosages of 250 mL of NaCl 0.9% solution with interval periods of six weeks.
62018020|NCT00975975|EXPERIMENTAL|Basiliximab|Basiliximab will be given by IV on Day +7 post transplant for recipients of matched unrelated cells. Basiliximab will be given by IV on Day +9 post transplant for recipients of matched related cells.
62208454|NCT04207151|EXPERIMENTAL|Pre- and Post- SNAPS intervention|In addition to the standard of care treatment, approximately twenty subjects will be selected for interview pre- and post-SNAPS intervention to assess PrEP facilitators and barriers for uptake. Participants of interest include cis- and trans-women, for which there is limited data regarding PrEP and HIV prevention.
62406555|NCT04966702|EXPERIMENTAL|Ivermectin human|The ivermectin group will receive a single dose of 400 mcg/kg, given once a month for three months. Product to be used is Stromectol (Merck) in Mozambique and Ivermectin 3mg USP (Edenbridge) in Kenya.
62406556|NCT04966702|EXPERIMENTAL|Ivermectin human and livestock (Mozambique only)|The ivermectin group will receive a single dose of 400 mcg/kg, given once a month for three months. Product to be used is Stromectol (Merck). For livestock, locally registered veterinary injectable ivermectin at 1% will be used.
62406557|NCT03223506|EXPERIMENTAL|Paracetamol arm|Administration of 10 mg/ml of paracetamol
62406558|NCT04079972|EXPERIMENTAL|personalized lifestyle intervention|to provide personalized lifestyle guidance for weight loss through SNP testing
62406559|NCT04079972|ACTIVE_COMPARATOR|general lifestyle intervention|to provide general lifestyle guidance for weight loss
62581715|NCT01511354||Standard clinical care|Standard nutritional therapy and treatment
62789940|NCT04382885|EXPERIMENTAL|Cohort 2 (10-17 years)|10 to 12 years: 1.5 mg/day cariprazine oral solution 13 to 17 years: 3.0 mg/day cariprazine oral solution
62406560|NCT03971422|EXPERIMENTAL|Dosage Regimen 1|Study participants randomized to dosage regimen 1 will receive assigned dosage of rozanolixizumab at pre-specified time points during Treatment Period.
62406561|NCT03971422|EXPERIMENTAL|Dosage Regimen 2|Study participants randomized to dosage regimen 2 will receive assigned dosage of rozanolixizumab at pre-specified time points during Treatment Period.
62406562|NCT03971422|PLACEBO_COMPARATOR|Placebo|Study participants randomized to this arm will receive placebo.
62734454|NCT03752996|EXPERIMENTAL|ACURATE TF™ Aortic Valve System|ACURATE TF™ Aortic Valve System is intended for subjects with severe symptomatic Aortic Stenosis and considered high risk for surgical conventional Aortic Valve Replacement .
62018021|NCT03032692|EXPERIMENTAL|SWORD and exercise with biofeedback|The patient will perform one repetition of the exercise shoulder flexion with elbow flexion at 90 degrees under monitoring from SWORD. The recorded parameters will be used to define: baseline and target angle; execution time; maximum postural sway. Two additional repetitions will be performed to ensure reproducibility. During the session, SWORD will be providing real-time audiovisual feedback. The patient has to start in the baseline position and fill the progress bar without violating movement or posture constraints. If the patient does not reach the goal or violates constraints he will receive a negative audio feedback, the progress bar will turn red and be reset. The patient has to return to the baseline position to restart the movement.
62018022|NCT03032692|ACTIVE_COMPARATOR|SWORD and exercise without biofeedback|The patient will perform one repetition of the exercise shoulder flexion with elbow flexion at 90 degrees under monitoring from SWORD. The recorded parameters will be used to define: baseline and target angle; execution time; maximum postural sway. Two additional repetitions will be performed to ensure reproducibility. The patient will then be instructed to perform as many movements as possible during the allocated time (4 minutes), at a comfortable pace, starting at or below the baseline and trying to reach maximum flexion without significant pain or discomfort. During the session, the SWORD system will be recording the patient´s movement without providing feedback to the patient.
62208455|NCT02236988|EXPERIMENTAL|Group 1|"Participants received the following 4 treatments, given in 4 possible sequences (ADBC, BACD, CBDA, and DCAB) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) B) A single oral dose 75 mg apremilast tablet prototype MR 1 C) A single oral dose 75 mg apremilast tablet prototype MR 2 D) A single oral dose 75 mg apremilast capsule prototype MR 3"
62208456|NCT02236988|EXPERIMENTAL|Group 2|"Participants received the following 4 treatments, given in 4 possible sequences (AGEF, EAFG, FEGA, and GFAE) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) E) A single oral dose 75 mg apremilast capsule prototype MR 4 F) A single oral dose 75 mg apremilast capsule prototype MR 5 G) A single oral dose 75 mg apremilast capsule prototype MR 6"
62208457|NCT02236988|EXPERIMENTAL|Group 3|"Participants received the following 3 treatments, given in 6 possible sequences (AIJ, IJA, JAI, AJI, IAJ, or JIA) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) I) A single oral dose 80 mg apremilast capsule prototype MR 8 J) A single oral dose 80 mg apremilast capsule prototype MR 9"
62789941|NCT04382885|EXPERIMENTAL|Cohort 3 (5-9 years)|0.5 mg/day cariprazine oral solution
62208458|NCT02236988|EXPERIMENTAL|Group 4|"Participants received the following 5 treatments, given in 10 possible sequences (ALOMN, LMANO, MNLOA, NOMAL, OANLM, NMOLA, ONAML, AOLNM, LAMON, or MLNAO) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) L) A single oral dose 80 mg apremilast capsule prototype MR 11 M) A single oral dose 80 mg apremilast capsule prototype MR 12 N) A single oral dose 80 mg apremilast capsule prototype MR 13 O) A single oral dose 80 mg apremilast capsule prototype MR 14"
62018023|NCT06312098||no-remote ischemic preconditioning group|patients who did not receive remote ischemic preconditioning
62018024|NCT06312098||paired remote ischemic preconditioning group|patients who receive remote ischemic preconditioning
62018025|NCT06107218|ACTIVE_COMPARATOR|Diamond Stone group (Comparator)|Class I cavities will be finished using 20-30 μm grit extra fine (EF) yellow coded diamond stone with maximum rotational speed 300,000 min -1.
62208459|NCT06728358|EXPERIMENTAL|Patients undergoing molecular analysis|Patients undergoing molecular analysis
62208460|NCT05269966|EXPERIMENTAL|Brolucizumab|"Brolucizumab, formerly known as ESBA1008, is a humanized single-chain Fv (scFv) antibody fragment.~Brolucizumab 6 mg was administered by Intravitreal (IVT) injections as per the Prescribing information (PI) and in line with the treating physician's clinical judgement. Patients received loading doses of brolucizumab at Day 0/Visit 1, Week 4/Visit 2 and Week 8/Visit 3. After the loading doses, at Week 16, disease activity assessment (DAA) was performed based on Best Corrected Visual Acuity (BCVA) and Optical Coherence Tomography (OCT) to assess whether the patient required q8w or q12w dosing."
62208461|NCT00684723|EXPERIMENTAL|Lovastatin 40 mg Tablet|A single dose of Lovastatin 40 mg administered under fed conditions.
62208462|NCT00684723|EXPERIMENTAL|Lovastatin (Mevacor®) 40 mg Tablet|A single dose of Lovastatin (Mevacor®) 40 mg administered under fed conditions.
62208463|NCT06393439|EXPERIMENTAL|Functional Movement Disorder|
62406563|NCT03749434||Adults with HAIs after VAD therapy|Adult patients who have received a ventricular assist device implant.
62789942|NCT04382885|EXPERIMENTAL|Cohort 4 (5-9 years)|1.5 mg/day cariprazine oral solution
62789943|NCT01670721|EXPERIMENTAL|Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)|Aflibercept 4 mg/kg intravenous (IV) infusion over 60 minutes followed by Irinotecan 180 mg/m\^2 IV infusion over 90 minutes and Leucovorin 400 mg/m\^2 IV infusion over 120 minutes at the same time followed by 5-FU 400 mg/m\^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m\^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until DP, unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.
62208464|NCT06393439|EXPERIMENTAL|Essential Tremor|
62208465|NCT06393439|EXPERIMENTAL|Healthy Control|
62406564|NCT03563729|EXPERIMENTAL|B: Pembrolizumab (Prednisolone >10 mg)|Intravenous infusion of pembrolizumab 2 mg/kg every third week for up to two years.
62018026|NCT06107218|ACTIVE_COMPARATOR|Bioactive Glass Air Abrasion group (Intervention)|Class I cavities will be finished by AquaCare Air Abrasion Device using bioactive glass air-abrasion particles (a mix of 30-60-90 μm particles). The nozzle of the air abrasion device will be 0.6 in diameter and angulated at 90° to the occlusal surface with a distance away from the tooth about 2-3 mm. The device will be used in a dynamic motion with 60 psi (4 Bar) adjusted pressure for 3 seconds.
62581716|NCT06622850|EXPERIMENTAL|Acupressure group|"In acupressure, cun is used as the unit of measurement to determine the points to be applied. In order to find the acupressure points correctly, measurements should be made using the individual's own fingers. The thumb widths of the individuals participating in the study will be measured and converted as centimeter 1 cun unit. The points to be used in acupressure will be Shen Men (HT7) located in the transverse wrist crease, in the small depression between the pisiform and ulna bones, (LI11) located at the end of the crease when the elbow is bent, and Hegu (LI4) located in the space between the thumb and index finger will be marked by the certified researcher (GB) with an acetate pen in the patients in the study group. And the application will be performed by the certified researcher (GB)."
62581717|NCT06622850|NO_INTERVENTION|Control group|The control group will receive routine care.
62789944|NCT02681471|ACTIVE_COMPARATOR|Monopolar TURP|Patients in Group M (Monopolar) were used monopolar resectoscope (Karl Storz, Tottling, Germany) and 5% Mannitol as an irrigation fluid.
62789945|NCT02681471|ACTIVE_COMPARATOR|Bipolar TURP|Patients in Group B (Bipolar) were used bipolar resectoscope TURis (OLYMPUS, Tokyo, Japan) and 0,9% Sodium chloride as an irrigation fluid.
62789946|NCT03529981|ACTIVE_COMPARATOR|Stress incidents without TVS|a fraction of physiological detected stress incidents will not trigger TVS
62789947|NCT03529981|EXPERIMENTAL|TVS in response to participant initiation or stress detection|The majority of detected stress incidents will trigger TVS. Participants can also trigger TVS voluntarily
62789948|NCT05798221|EXPERIMENTAL|Complementary self-help strategies in addition to treatment as usual|The experimental group consists of 10 weeks of group treatments with educative and actively practicing elements. The patients will also receive a booklet with self-help basics and descriptions of the techniques, which should facilitate the correct practice at home. Parallel treatment as usual is allowed.
62789949|NCT05798221|ACTIVE_COMPARATOR|Treatment as usual|The active control group consists a 16-week waiting period, where treatment as usual is allowed. In case of acute worsening/progression of the symptoms, consultations with the study physician are offered anytime. After the waiting period, the control group will be offered the same units as in the experimental group.
62789950|NCT06122038|PLACEBO_COMPARATOR|Placebo|Rice Flour. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
62789951|NCT06122038|EXPERIMENTAL|Tart Cherry Extract Powder|Tart Cherry Extract Powder (NordicCherry, SpecNova, LLC). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
62789952|NCT04322617|EXPERIMENTAL|Cohort A: Anlotinib with the same Immune Checkpoint Inhibitors.|Anlotinib plus Immune Checkpoint Inhibitors which has been used in first line treatment.
62789953|NCT04322617|EXPERIMENTAL|Cohort B: Anlotinib with the new Immune Checkpoint Inhibitors.|Anlotinib plus Immune Checkpoint Inhibitors which has not been used in first line treatment.
62789954|NCT04322617|EXPERIMENTAL|Cohort C: Anlotinib Monotherapy.|Anlotinib Monotherapy.
62789955|NCT02240511|ACTIVE_COMPARATOR|Resistance Exercise|"Resistance Exercise (RE) therapy was divided in four parts: stretching: arms, hands, wrists, legs, knees and ankles, each one for 10 - 20 seconds with resting intervals of 5 seconds (4 series), warming and flexion: the same muscle groups, making small circles forward and backward for 5 - 10 seconds with resting intervals of 5 seconds (4 series), resistance exercises: flexion, contractions and twisting of the same muscle groups worked in the two previous sections. In this part resistance was increased with the aid of dumbbells (500 g - 1500 g), barbells and bands, and patients performed the same exercises with 15 - 20 repetitions with resting intervals of 10 seconds. (4 series), relaxation: involved the same exercises as stretching to rest all muscle groups worked."
62789956|NCT02240511|EXPERIMENTAL|RE and BCAA Supplementation|"RE: Resistance Exercise Resistance Exercise therapy was the same as in the Active Comparator~Branched Chain Aminoacids Amino 2000 BCAA (PRONAT® laboratory) supplementation group received 180 packets of 5 grams (g)and ingested 10 g/day (5 g after breakfast and 5 g before RE)"
62789957|NCT01803256||Scoliosis patients:|15 patients with adolescent idiopathic scoliosis.
62789958|NCT01803256||Control subjects:|15 adolescent healthy control subjects
62789959|NCT02770989|EXPERIMENTAL|Vimecon Laser CAI Cardiac Ablation|Ablation of the cardiac tissue by the use of the Vimecon Laser CAI (Cardiac Ablation Instrument).
62734455|NCT01374321|PLACEBO_COMPARATOR|Placebo|
62018027|NCT01405157|EXPERIMENTAL|methylprednisolone suspension|
62018028|NCT01405157|ACTIVE_COMPARATOR|methylprednisolone tablets|
62018029|NCT04077008|OTHER|Bilaterally Obstructed Kidneys by benign cause|
62018030|NCT04077008|OTHER|Bilaterally Obstructed Kidneys by malignant cause|
62581718|NCT05865496|EXPERIMENTAL|611 Dose A|611 300 mg Q2W, subcutaneous (SC) injection.
62208466|NCT03164694|EXPERIMENTAL|Apatinib|Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5) plus apatinib. Apatinib was given 850 mg per day orally at day one of chemotherapy.
62208467|NCT03164694|ACTIVE_COMPARATOR|Control|Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5).
62208468|NCT00682747|EXPERIMENTAL|HBO|40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen)
62208469|NCT00682747|NO_INTERVENTION|non HBO|
62208470|NCT06142773|EXPERIMENTAL|Group 1: tidal volume delivered at 6 ml/kg for 3-5 minutes, followed by 12ml/kg for 3-5 minutes|"The clinical MRI examination will be obtained before commencing with the study protocol. The study protocol will commence once the scheduled MRI scan is finished. The study-related procedures will add 10 minutes after the scheduled MRI scans are finished with two different tidal volumes with maintaining isocapnia and isooxia.~Study procedure: tidal volume delivered at 6 ml/kg for 5 minutes, followed by 12ml/kg for 5 minutes"
62208471|NCT06142773|ACTIVE_COMPARATOR|Group 2: tidal volume delivered at 12 ml/kg for 3-5 minutes, followed by 6ml/kg for 3-5 minutes|"The clinical MRI examination will be obtained before commencing with the study protocol. The study protocol will commence once the scheduled MRI scan is finished. The study-related procedures will add 10 minutes after the scheduled MRI scans are finished with two different tidal volumes with maintaining isocapnia and isooxia.~Study procedure: tidal volume delivered at 12 ml/kg for 5 minutes, followed by 6ml/kg for 5 minutes"
62208472|NCT03773575|EXPERIMENTAL|Prevena|PREVENA™ PEEL \& PLACE™ Dressing Kit
62208473|NCT03773575|NO_INTERVENTION|Standard Care|sterile gauze dressing supplemented with an Ace wrap
62208474|NCT05020587|OTHER|Open Pilot Trial|Open pilot trial of a group therapy manual.
62208475|NCT04224376|NO_INTERVENTION|Conventional rehabilitation|Normal postoperative treatment protocol with physiotherapy after ACL surgery
62208476|NCT04224376|EXPERIMENTAL|Serious Gaming|In the training group each patient was additionally provided with a GenuSport knee trainer device (prototype plus tablet with software application) with the active knee extension training program for 6 weeks. Other postoperative treatment was identical.
62208477|NCT00848588||1|Full and part-time 9-1-1 call takers employed at Ambulance Communication Centres in the Canadian provinces of Ontario, Nova Scotia, New Brunswick, as well as the city of Montreal, Quebec, Canada.
62581719|NCT05865496|EXPERIMENTAL|611 Dose B|611 450 mg Q4W, subcutaneous (SC) injection.
62581720|NCT05865496|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous (SC) injection.
62789960|NCT01361893|OTHER|Lifestyle Counseling|Parents who qualify for the study will be asked to participate in the survey portion of the study. informed consent will be obtained. After completing the survey each parent will be asked if they would be willing to participate in and additional interview (focus group or semi-structured in-debth interview) at a later date.
62018031|NCT02731131|EXPERIMENTAL|Group A: Monotherapy with Peginterferon alfa-2a|Participants will receive peginterferon alfa-2a alone, administered over 48 weeks.
62018032|NCT02731131|EXPERIMENTAL|Group B: Combination with Peginterferon alfa-2a + Ribavirin|Participants will receive combination therapy with peginterferon alfa-2a plus ribavirin, administered over 48 weeks.
62208478|NCT06601010||Diagnosis of pancreatic cancer|Patients diagnosis of pancreatic cancer require immunotherapy or combination immunotherapy after evaluation according to clinical guidelines
62208479|NCT00706953|ACTIVE_COMPARATOR|001|
62208480|NCT04447105|EXPERIMENTAL|TIVA group|Patients receiving total intravenous anesthesia with propofol.
62208481|NCT04447105|ACTIVE_COMPARATOR|Desflurane group|Patients receiving inhalation anesthesia with desflurane.
62208482|NCT00564746|EXPERIMENTAL|6 subjects in a single cohort|Each subject will be administered a single 10 milligrams (50 microcurie) oral dose of \[14C\]SB-681323.
62208483|NCT01696552|ACTIVE_COMPARATOR|TKR with Positioning Guides (PSPG)|Use of PSPG (Signature, Materialise) in TKR (Vanguard Total Knee System, Biomet)
62208484|NCT01696552|ACTIVE_COMPARATOR|TKR with Conventional Technique|TKR (Vanguard Total Knee System, Biomet), Conventional Technique
62208485|NCT04671966|EXPERIMENTAL|Fasting only|To acutely elevate myocardial triglyceride content, subjects will be asked to abstain from eating for 2 days (reproducibly causes a significant and physiological increase in myocardial fat deposition, transiently). Subjects will be allowed water and/or an isotonic saline solution in order to maintain hydration status.
62208486|NCT04671966|EXPERIMENTAL|LBNP Only|Subjects undergo lower body negative pressure at 40 mmHg.
62208487|NCT04671966|EXPERIMENTAL|Estrogen add back with GnRHant|Subjects are given estradiol patch.
62208488|NCT04671966|EXPERIMENTAL|Placebo add back with GnRHant|Subjects are given placebo patch.
62406565|NCT03563729|EXPERIMENTAL|C: Ipilimumab/nivolumab (Prednisolone 11-25 mg)|Intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
62406566|NCT03563729|EXPERIMENTAL|D: Ipilimumab/nivolumab (Prednisolone >25 mg)|Intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
62406567|NCT03563729|EXPERIMENTAL|E: BRAF/MEK -> ipi/nivo (prednisolone >10 mg)|Induction treatment with BRAF/MEK inhibitors (either the combination of encorafenib/binimetinib or dabrafenib/trametinib) orally for 28 days followed by intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
62406568|NCT03204006|ACTIVE_COMPARATOR|Dexmedetomidine group|35 patients will receive dexmedetomidine 0.5 µg/kg was administered intravenously using a syringe pump over 10 min sterile saline pre-induction of anesthesia.
62406569|NCT03204006|PLACEBO_COMPARATOR|Control group|35 patients will receive sterile saline 0.5 µg/kg was administered intravenously using a syringe pump over 10 min pre-induction of anesthesia.
62406570|NCT05924009|EXPERIMENTAL|All participants|All participants
62581721|NCT03006978|EXPERIMENTAL|TearCare|Subjects will receive a 12-minute treatment session with the TearCare System followed by manual expression of the meibomian glands.
62208489|NCT02265289|EXPERIMENTAL|Lefradafiban with clopidogrel|"All patients received the same treatment:~* Lefradafiban only (day 1-4)~* Lefradafiban in combination with Clopidogrel (day 5-8)~* Clopidogrel only (day 9-12)"
62208490|NCT04002843|EXPERIMENTAL|- Virgin patients with Botulinum Toxin, first injection|"Experimental: - Virgin patients with Botulinum Toxin, first injection~* A clinical evaluation of spasticity with the Modified Ashworth Scale by the referent practitioner.~* Pain management: according to the patient's wishes, local anaesthetic can be provided on the target area (EMLA patch type)~* Single fiber electrophysiological evaluation by the principal investigator: comfortable installation of the patient in decubitus, with the upper limb in the optimal relaxation position, supported by the examiner to achieve minimal tone. Arrangement of the needle electrode at the level of the elbow flexor muscle chosen (biceps brachialis, anterior brachialis), located ultrasonographically.~Repeated measurements at D0, week 4 to 6 and week 12 for the stroke patients. Only one measure for controls subjects"
62208491|NCT04002843|EXPERIMENTAL|- Injected group: Patients already injected|"- Injected group: Patients already injected~* A clinical evaluation of spasticity with the Modified Ashworth Scale by the referent practitioner.~* Pain management: according to the patient's wishes, local anaesthetic can be provided on the target area (EMLA patch type)~* Single fiber electrophysiological evaluation by the principal investigator: comfortable installation of the patient in decubitus, with the upper limb in the optimal relaxation position, supported by the examiner to achieve minimal tone. Arrangement of the needle electrode at the level of in one elbow flexor muscle (biceps brachialis, anterior brachialis), located ultrasonographically.~Repeated measurements at D0, week 4 to 6 and week 12 for the stroke patients. Only one measure for controls subjects"
62208492|NCT04002843|OTHER|Control|healthy patient matched in age and sex to included patients
62208493|NCT02271438|EXPERIMENTAL|Part 1: Ibrutinib 840 milligram (mg)|Participants will receive ibrutinib 840 mg (6\*140 mg capsules) + 6 placebo capsules on Day 1 of Part 1, Period 1.
62208494|NCT02271438|EXPERIMENTAL|Part 1: Ibrutinib 1680 mg|Participants will receive ibrutinib 1680 mg (12\*140 mg capsules) on Day 1 of Part 1, Period 2.
62208495|NCT02271438|EXPERIMENTAL|Part 2: Treatment A|Participants will receive ibrutinib, 1680 mg (12\*140 mg capsules) + 1 moxifloxacin-matching placebo capsule Day 1of Part 2.
62208496|NCT02271438|EXPERIMENTAL|Part 2: Treatment B|Participants will receive ibrutinib, 840 mg (6\*140 mg capsules) + 6 ibrutinib-matching placebo capsules + 1 moxifloxacin-matching placebo capsule.
62208497|NCT02271438|EXPERIMENTAL|Part 2: Treatment C|Participants will receive placebo (12 ibrutinib-matching placebo capsules + 1 moxifloxacin-matching placebo capsule) Day 1 of Part 2.
62208498|NCT02271438|EXPERIMENTAL|Part 2: Treatment D|Participants will receive moxifloxacin 400 mg (1 capsule) + 12 ibrutinib-matching placebo capsules Day 1 of Part 2.
62208499|NCT04523675|EXPERIMENTAL|EXP-NAC|Participated in daily training sessions and three games, and supplemented daily with N-acetylcysteine, orally in three daily dosages (morning-midday-evening),for seven consecutive days.
62208500|NCT04523675|EXPERIMENTAL|EXP-Pla|Participated in daily training sessions and three games, and supplemented daily with Placebo, orally in three daily dosages (morning-midday-evening), for seven consecutive days.
62208501|NCT04523675|ACTIVE_COMPARATOR|CON-NAC|Participated in daily training sessions only and supplemented daily with N-acetylcysteine, orally in three daily dosages (morning-midday-evening),for seven consecutive days.
62208502|NCT04523675|ACTIVE_COMPARATOR|CON-Pla|Participated in daily training sessions only and supplemented daily with Placebo, orally in three daily dosages (morning-midday-evening), for seven consecutive days.
62208503|NCT05937893|OTHER|Alcohol consumer (AC) participants|Adult volunteers who are alcohol consumers drawn from both an outpatient population and recruited heavy drinkers from the community.
62208504|NCT05937893|OTHER|Healthy participants|Healthy adult volunteers who are not dependent on alcohol.
62208505|NCT01500811|EXPERIMENTAL|chondrocyte|Patients with sever hip osteoarthritis who underwent intra articular cell injection.
62018033|NCT01496651|ACTIVE_COMPARATOR|Percutaneous coronary intervention|Coronary Artery Bypass Grafting Versus Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis
62208506|NCT03475654|EXPERIMENTAL|technology-assisted rehabilitation|The experimental group will receive treatment as usual, in addition to training with the Jintronix platform. Participants will undergo their prescribed therapy regimen for 3 months, with outcomes follow-up to 12 months post-discharge.
62208507|NCT03475654|ACTIVE_COMPARATOR|Usual care|The control group will receive treatment as usual, which includes a personalized home exercise program prescribed by a burn therapist, prior to hospital discharge. Participants will undergo their prescribed therapy regimen for 3 months, with outcomes follow-up to 12 months post-discharge.
62208508|NCT05499273|ACTIVE_COMPARATOR|scalpel-bougie tracheostomy (SBT)|SBT technique described in Interventions
62208509|NCT05499273|ACTIVE_COMPARATOR|rapid sequence tracheotomy (RST|RST technique described in Interventions
62208510|NCT05007925|EXPERIMENTAL|Single-arm|
62208511|NCT06226272||S-S-102-A: Cervical Sub-Protocol|The study population includes subjects who are surgically treated with a Stryker device for a cervical condition per the specific device cleared IFUs and Surgical Technique Guides (STGs), by a participating investigator and are willing to complete patient-reported questionnaires at the study-specific time points.
62208512|NCT06226272||S-S-102-B: Thoracolumbar Sub-Protocol|The study population includes subjects who are surgically treated with a Stryker device for a thoracic/lumbar condition per the specific device cleared IFUs and STGs, by a participating investigator and are willing to complete patient-reported questionnaires at the study-specific time points.
62581722|NCT03006978|ACTIVE_COMPARATOR|Warm Compress|Subjects will apply a warm compress to the eyelids for 5 minutes daily for 4 weeks.
62581723|NCT01490879|EXPERIMENTAL|Nexagon® Low Dose|Twice weekly applications of Nexagon® low dose in addition to off-loading using a Removable Cast Walker
62734456|NCT01374321|EXPERIMENTAL|TRO40303|
62018034|NCT01496651|ACTIVE_COMPARATOR|Coronary artery bypass graft operation|Coronary Artery Bypass Grafting Versus Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis
62018035|NCT06263777|EXPERIMENTAL|Nurses group|Nurse training program on early detection of disability. It included four main elements, which are: a booklet defining different disabilities; a list of the guidelines for early detection; a guide for family guidance for families of children with disabilities; and a monitoring and follow-up form for cases of children with disabilities.
62018036|NCT04182776||Pelvis fracture type II to IV|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics. The registry does not dictate any specific treatment.
62018037|NCT02358486|EXPERIMENTAL|Acupuncture|Participants in this group are given 10 times of real acupuncture treatment for 4 weeks.
62018038|NCT02358486|SHAM_COMPARATOR|Sham acupuncture|Participants in this group are given 10 times of sham acupuncture treatment for 4 weeks.
62018039|NCT00853450|EXPERIMENTAL|1|AZD6482 on top of ASA
62018040|NCT00853450|ACTIVE_COMPARATOR|2|Clopidogrel on top of ASA
62018041|NCT01455649|EXPERIMENTAL|Everolimus|
62018042|NCT01455649|ACTIVE_COMPARATOR|calcineurin inhibitor|
62018043|NCT01355744||Spider bite patients|All patients treated for an actual spider bite by a Swiss physician during study period.
62018044|NCT05324475|PLACEBO_COMPARATOR|Standard treatment (SC)|nutritional counselling (SC) + Placebo: These patients will receive Oral Nutrient Supplementation (ONS) and maltodextrin 4 g
62018045|NCT05324475|EXPERIMENTAL|Branch-chained aminoacids|In addition to the ONS these patients will receive 4 gram per day of BCAAs mixture. Ratio between the BCAAs will be Leucine/Isoleucine/Valine=2:1:1.
62018046|NCT05324475|EXPERIMENTAL|Micronutrients|In addition to the ONS the patients will receive a combination of micronutrients
62581724|NCT01490879|EXPERIMENTAL|Nexagon® Medium Dose|Twice weekly applications of Nexagon® medium dose in addition to off-loading using a Removable Cast Walker
62018047|NCT03294434||High Grade Glioma|Diffusion tensor Imaging (DTI-MRI) scan to be performed pre-operatively and pre-radiotherapy
62018048|NCT01200381|ACTIVE_COMPARATOR|Group A|Automatic anonymous ICD/CRTD follow up (quarterly remote follow ups)
62018049|NCT01200381|ACTIVE_COMPARATOR|Group B1|Personal ICD/CRTD follow up (phone calls + quarterly remote follow ups)
62018050|NCT01200381|ACTIVE_COMPARATOR|Group B2|Personal ICD/CRTD follow up (Quarterly visits)
62018051|NCT00557115|NO_INTERVENTION|Usual Care|Usual Care (UC): usual follow up care post acute COPD exacerbation
62018052|NCT00557115|EXPERIMENTAL|EPR|Early pulmonary rehabilitation (EPR): pulmonary rehabilitation commenced within 1-week of hospital discharge from an acute COPD exacerbation
62018053|NCT05611528|EXPERIMENTAL|Evinacumab-treated patients|
62018054|NCT02412267|EXPERIMENTAL|O-ICE|"O-ICE:~Ofatumumab 1000mg intravenous (IV) infusion on Day 1 and Day 8 of cycle 1 of the salvage chemotherapy, and thereafter on Day 1 of each cycle; Ifosfamide 1667 mg/m2 IV infusion over 2 hours on days 1,2,3 of each cycle; Carboplatin 5 x ((25 + Creatinine clearance (CrCl)) IV in 250 ml Normal Saline over 1 hour on day 1 of each cycle; Etoposide 100mg/m2/day IV infusion day 1,2,3 over 45 to 60 minutes of each cycle."
62018055|NCT06326372||Control group|In the control group, observation will be conducted solely by another anesthesia doctor or assistant participating in the study, and the data will be recorded blindly without being reported to the anesthesia doctor responsible for the surgery. The oxygen therapy administered by the anesthesia doctor in charge and the FiO2 values will be recorded independently and blindly, based solely on the clinician's own assessment, rather than according to the information obtained from ORi. Subsequently, for two days following the surgery, evaluations will be conducted twice daily at the same hours for ward patients using CAM, and for ICU patients using CAM-ICU. If delirium is detected, delirium subtyping will be performed using the Richmond Agitation-Sedation Scale (RASS).
62018056|NCT06326372||ORi+SpO2 group|"In the SpO2+ORi group; It is aimed to maintain SpO2 between %95 and %98, and ORi at 0.00.~Data will be recorded every 10 minutes. After extubation, patients will first be evaluated in the postoperative recovery room. Subsequently, for two days following the surgery, evaluations will be conducted twice daily at the same hours for ward patients using CAM, and for ICU patients using CAM-ICU. If delirium is detected, delirium subtyping will be performed using the Richmond Agitation-Sedation Scale (RASS)."
62018057|NCT06240026|EXPERIMENTAL|transauricular Vagal Nerve Stimulation|NEMOS taVNS electrodes will be placed in the left concha cymba of participants (CerboMed GmbH, Erlangen, Germany). When appropriate, these electrodes will be plugged into a digitimer. Whilst pulse width, frequency, stimulation burst and total duration will be respectively standardized to 200microseconds, 20Hz, 30seconds on and 30seconds off and 20minutes, the stimulation will be person specific. To acquire this intensity, participants will perform a thresholding protocol. Based on an elegant stair-case algorithm, the perception and pain (described as a 7/10 pain level, where 10 is the most amount of pain imaginable) thresholds will be obtained. Stimulation intensity will then be defined as 2/3 the range between these thresholds. For example, if the perception and pain thresholds are respectively at 2mA and 8mA, the stimulation intensity would be 6mA.
62581725|NCT01490879|EXPERIMENTAL|Nexagon® High Dose|Twice weekly applications of Nexagon® high dose in addition to off-loading using a Removable Cast Walker
62581726|NCT01490879|PLACEBO_COMPARATOR|Nexagon® vehicle|Twice weekly applications of Nexagon® vehicle in addition to off-loading using a Removable Cast Walker
62581727|NCT05434338|OTHER|Major women with HPV-related high-grade intraepithelial lesions|
62581728|NCT02429778|EXPERIMENTAL|BREATHE|4 weeks DVD-delivered relaxation intervention program called breathe. The experimental intervention includes progressive muscle relaxation, diaphragmatic breathing, and home practice of the skills. Following the 4 weeks of treatment, participants will be asked to continue to practice at home for 4 weeks.
62208513|NCT06226272||S-S-102-C: Adult Spinal Deformities|The study population includes subjects who are surgically treated with a Stryker device for a spinal deformity condition per the specific device cleared IFUs and STGs, by a participating investigator and are willing to complete patient-reported questionnaires at the study-specific time points.
62208514|NCT04519905|EXPERIMENTAL|chemoradiotherapy|50.4Gy/28Fx; Paclitaxel plus carboplatin
62018058|NCT06240026|ACTIVE_COMPARATOR|Earlobe Stimulation|A 0.5cm and a 1cm diameter round electrode (Ambu, Neuroline, Bordeaux, France) will respectively be placed on the front and back of the earlobe. When appropriate, these electrodes will be plugged into a digitimer . Whilst pulse width, frequency, stimulation burst and total duration will be respectively standardized to 200microseconds, 20Hz, 30seconds on and 30seconds off and 20minutes, the stimulation will be person specific. To acquire this intensity, participants will perform a thresholding protocol. Based on an elegant stair-case algorithm, the perception and pain (described as a 7/10 pain level, where 10 is the most amount of pain imaginable) thresholds will be obtained. Stimulation intensity will then be defined as 2/3 the range between these thresholds. For example, if the perception and pain thresholds are respectively at 2mA and 8mA, the stimulation intensity would be 6mA.
62018059|NCT01513772|PLACEBO_COMPARATOR|Control|
62018060|NCT01513772|ACTIVE_COMPARATOR|Dexmedetomidine|
62581729|NCT02429778|NO_INTERVENTION|Wait List|8 week wait list period. Participants assigned to wait list will have the opportunity to receive BREATHE arm after 8 weeks if interested.
62581730|NCT01470625|OTHER|LCP Program|The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
62018061|NCT00746603|EXPERIMENTAL|A Intervention Arm|Escalating dose of simvastatin in subjects who are survivors of Hodgkin Lymphoma
62208515|NCT04519905|ACTIVE_COMPARATOR|radiotherapy|61.2Gy/34Fx
62581731|NCT04126902||late-onset preeclampsia|The diagnosis of L-PrE, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), is established based on the presence of proteinuria (urinary excretion of protein ≥300 mg in a 24-h urine specimen, or proteinüria ≥1+ in dipstick) and a blood pressure level of ≥90/140 mmHg (two blood pressure measurements 6 h apart) that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure \<110/160 mm Hg, it was accepted as mild; and in case these values exceeded this level, it was accepted as severe. The study population consisted of 50 late-onset preeclampsia patients as study group and 50 patients with normal pregnancies as control group.
62734457|NCT02943317|EXPERIMENTAL|Part A: VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
62789961|NCT05156957|EXPERIMENTAL|intervention group|The study intervention is a brief physiotherapeutic assessment, a brief information on the expected course of the condition, and a brief instruction on self-management, including three exercises for daily self-guided therapy.
62789962|NCT05156957|NO_INTERVENTION|control group|The control group will receive written information on the expected course of the condition, written instructions on self-management and written instructions on exercises for daily self-guided therapy.
62018062|NCT06572553|EXPERIMENTAL|Injection of faricimab|Intervention: Intravitreal Injections Generic name: faricimab Dosage: 0.05ml (6mg) Frequency: every month Duration: 3 months
62018063|NCT01979926|EXPERIMENTAL|N02RS1 200mg|Combination of Broussonetia spp and Lonicera spp
62581732|NCT04126902||Control|The control groups' samples obtained during the routine obstetrical care examination in the third trimester of pregnancy. Then these pregnant women followed-up until the delivery.
62581733|NCT03980951|ACTIVE_COMPARATOR|combined spinal epidural group|Bupivacaine 2.5 mg
62208516|NCT05056857||Observational (biospecimen collection, medical chart review)|Patients undergo collection of blood samples and their medical charts are reviewed.
62208517|NCT06644274||Diagnosis of gastrointestinal malignancies|Patients diagnosis of gastrointestinal malignancies require immunotherapy or combination immunotherapy after evaluation according to clinical guidelines
62208518|NCT06727487|ACTIVE_COMPARATOR|Group 1, control|Group 1/Control: patients will receive the basic recommendations on healthy lifestyle habits indicated by the World Health Organization (WHO) through audiovisual material that they will receive via email. An explanatory video and a document with WHO guidelines will be included (https://apps.who.int/iris/bitstream/handle/10665/337004/9789240014817-spa.pdf).
62581734|NCT03980951|ACTIVE_COMPARATOR|dura puncture epidural group|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 20 mL load over 5 min
62018064|NCT01979926|EXPERIMENTAL|N02RS1 400mg|Combination of Broussonetia spp and Lonicera spp
62208519|NCT06727487|EXPERIMENTAL|Group 2, experimental|Group 2/ Exercise, nutrition, and psycho-oncological support: patients will carry out a cardiovascular and strength exercise program of moderate-high intensity at the facilities of the Exercise and Cancer Center organized in sessions of 60 to 75 minutes in duration, with a frequency of 2 days/week for 12 weeks; In addition, 3 sessions of nutritional counseling and 3 sessions of psycho-oncological intervention will be developed.
62208520|NCT04716062||subjects who underwent open-air surgery|Fifty-one (37%) out of 138 subjects underwent open-air surgery.
62581735|NCT03980951|ACTIVE_COMPARATOR|epidural|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 20 mL load over 5 min
62581736|NCT01479855||Patients|Patients referred to a memory clinic due to memory problems and their healthy spouse
62581737|NCT05786469|EXPERIMENTAL|Participants randomized to receive one 8.4 g packet of patiromer per day|Patiromer is an organic, non-absorbed, sodium-free, potassium-binding polymer that exchanges potassium for calcium in the gastrointestinal tract.
62581738|NCT05786469|PLACEBO_COMPARATOR|Participants randomized to receive one identical packet containing placebo|Active study treatment and placebo will be provided by Vifor Pharma and will be indistinguishable from one another in terms of labelling and instructions
62581739|NCT05375994|EXPERIMENTAL|avutometinib(VS-6766)+adagrasib|To determine the recommended phase 2 dose (RP2D) for VS-6766 in combination with adagrasib in G12C inhibitor exposed patients
62018065|NCT01979926|PLACEBO_COMPARATOR|Placebo|Sugar pill
62018066|NCT04876508|EXPERIMENTAL|Acupressure group|Patients in the acupressure group will be given acupressure once a day for 7 consecutive days. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the patients are in supine position, pressure will be applied to each acupressure point around the navel, respectively, Zhongwan (CV12), Guanyuan (CV4) and Tianshu (ST25) for 2 minutes for a total of 6 minutes.
62406571|NCT04527406|EXPERIMENTAL|Early surgical group|The subjects in this group received early surgical treatment, and they are arranged to be admitted to the hospital for surgical treatment after admission. The operation choice is posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction.
62406572|NCT04527406|ACTIVE_COMPARATOR|Traditional surgical treatment|This group of subjects received conservative treatment with custom-made braces to delay the progression of scoliosis. It is planned to use the classic posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction to complete the correction around the age of 5.
62406573|NCT00625313|EXPERIMENTAL|HMY Model YA-60BB IOL|Patients receiving a Hoya HMY Acrylic Foldable Intraocular Lens.
62406574|NCT02279888||CardioMEMS HF System Group|Patients implanted with a CardioMEMS HF System.
62406575|NCT05152498|EXPERIMENTAL|Fu Zheng Jie Du Hua Yu therapy|
62208521|NCT04716062||subjects underwent laparoscopic-assisted surgery|A total of 87 (63%) out of 138 subjects underwent laparoscopic-assisted surgery.
62208522|NCT01035645|EXPERIMENTAL|GSK1070806 or placebo|This is a single dose escalating study. On enrolment into the study, each subject will be assigned to a group. These groups will be aligned to specific dose levels of GSK1070806. All subjects will be randomised to receive either a single intravenously administered dose of GSK1070806 or matching placebo (saline). The randomisation is generated by GSK prior to study start.
62208523|NCT04449328|EXPERIMENTAL|Patient with first stroke causing hemiplegic|"Patient with first stroke causing hemiplegic will be included.~They will have Computerized Mirror Therapy (CMT) associated at tendon vibration:~* Visit 1: wrist flexion (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of extension+vibration(incongruence))~* Visit 2 (1 week later): wrist extension (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of flexion+vibration (incongruence)) These conditions will be recording by the Kinovea software, which allows the measurement of angles and amplitudes."
62208524|NCT04449328|SHAM_COMPARATOR|healthy subjects|"Healthy subjects will be included.~They will have Computerized Mirror Therapy (CMT) associated at tendon vibration:~* Visit 1: wrist flexion (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of extension+vibration(incongruence))~* Visit 2 (1 week later): wrist extension (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of flexion+vibration (incongruence)) These conditions will be recording by the Kinovea software, which allows the measurement of angles and amplitudes."
62406576|NCT05152498|EXPERIMENTAL|Routine medical care|
62406577|NCT05284227|ACTIVE_COMPARATOR|Clinical Decision Support Application guided Anaesthesiological Assessment|Preoperative anaesthesiological assessment and risk evaluation using a clinical decision support application.
62406578|NCT05284227|SHAM_COMPARATOR|Standard Anaesthesiological Assessment|Preoperative anaesthesiological assessment using standard procedures of the hospital and a sham clinical decision support application.
62406579|NCT01269346|EXPERIMENTAL|1|
62581740|NCT05375994|EXPERIMENTAL|avutometinib (VS-6766)+adagrasib RP2D|To determine the efficacy of the RP2D identified from Part A in G12C inhibitor exposed patients
62581741|NCT06506474||Children admitted to CHU Sainte-Justine|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62581742|NCT06506474||Children admitted to McMaster Children's Hospital|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62208525|NCT06470620||research group|women with hip-related pain
62208526|NCT06470620||control group|healthy women without hip pain
62406580|NCT00230113|ACTIVE_COMPARATOR|1|
62406581|NCT00230113|PLACEBO_COMPARATOR|2|
62581743|NCT06506474||Children admitted to British Columbia Children's Hospital|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62581744|NCT06506474||Children admitted to IWK Children's Hospital|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62406582|NCT03541408|PLACEBO_COMPARATOR|Control|Subjects will receive anesthesia
62406583|NCT03541408|EXPERIMENTAL|Preventative Delirium Protocol|"* Consider regional block if applicable~* Minimized fentanyl usage intraoperatively~  * Intubation + GA adjunct total: 1-2 mcg/kg~ * Sedation: 0-0.25 mcg/kg~ * Post-op: 0.5-1 mcg/kg~* Avoid morphine~* Avoid ketamine~* Avoid diphenhydramine, dexamethasone, scopolamine, metoclopramide, and promethazine~* Avoid H2-blockers (cimetidine, ranitidine, famotidine)~* Avoid polypharmacy intraoperatively if possible (i.e. \>5 new medications)~* Fluid repletion based on maintenance and losses"
62406584|NCT02696837|ACTIVE_COMPARATOR|ETT & Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Endotracheal Intubation and Muscle Relaxant
62581745|NCT06506474||Children admitted to CHU de Quebec University Laval Hospital|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62406585|NCT02696837|ACTIVE_COMPARATOR|ETT & No Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Endotracheal Intubation and No Muscle Relaxant
62406586|NCT02696837|ACTIVE_COMPARATOR|Proseal LMA & No Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Proseal Laryngeal Mask Airway and NO Muscle Relaxant
62406587|NCT02696837|ACTIVE_COMPARATOR|Proseal LMA & Subparalytic Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Proseal Laryngeal Mask Airway and subparalytic dose Muscle Relaxant
62406588|NCT03628781|EXPERIMENTAL|mehealth portal with integrated behavioral tools|Patients in this arm will continue to use the mehealth for ADHD web-based software for ADHD care but will also have access to a module that allows parents and teachers to develop and implement behavioral interventions such as daily report cards online.
62406589|NCT03628781|OTHER|mehealth portal with no integrated behavioral tools|Patients in this arm will continue to use the mehealth for ADHD web-based software for ADHD care but will wait one year before getting access to the behavioral intervention features.
62208527|NCT05310422|EXPERIMENTAL|Tivanisiran sodium ophthalmic solution|
62208528|NCT05310422|PLACEBO_COMPARATOR|Vehicle ophthalmic solution|
62406590|NCT00958659||Ancillary-Correlative (gene expression profiling)|Previously collected samples are analyzed for 59 prognostic genes by real-time quantitative PCR-based gene expression profiling.
62406591|NCT05663333||DOCTA cohort|Patients \> 50 years of age with suspected giant cell arteritis requiring temporal artery biopsy in the dermatology department
62406592|NCT02058264|EXPERIMENTAL|Low Strength BBI-4000 and Vehicle|
62406593|NCT02058264|EXPERIMENTAL|High Strength BBI-4000 and Vehicle|
62406594|NCT06650358||LAL+|Bilateral pesudophakic adults implanted with the LAL+ in at least one eye
62406595|NCT01979549||Sedation|patients underwent upper gastrointestinal endoscopy with sedation
62581746|NCT06506474||Children admitted to Montreal Children's Hospital|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62406596|NCT01979549||non-sedation|patients underwent upper gastrointestinal endoscopy without sedation
62406597|NCT00738140|EXPERIMENTAL|A|Intensive lifestyle intervention based on the Diabetes Prevention Program
62406598|NCT00738140|NO_INTERVENTION|B|Will follow the guidelines for healthy living established by the Food Guide Pyramid and the National Cholesterol Education Program
62406599|NCT01114126|EXPERIMENTAL|Neu-P11 2mg|
62208529|NCT03714698|ACTIVE_COMPARATOR|Pilates Exercise Group|Pilates exercise group participated in supervised Pilates-based group training twice per week for six weeks
62208530|NCT03714698|PLACEBO_COMPARATOR|Control Group|the control group participated in a routine non-specific activity program twice a week in Community Mental Health Center during study
62208531|NCT05695586|EXPERIMENTAL|Mindful Self-Compassion (MSC) training|Participants in the MSC group will be trained in the standard 8-week Mindfulness Self-Compassion (MSC) protocol (Germer and Neff, 2013a, b; Germer and Neff, 2019). Once participants have completed the 8-week MSC training they will enter a 12-month phase of regular supervised practice, in which they will continue to perform MSC exercises on a guided basis. Supervised practice will be provided on a weekly basis.
62208532|NCT05695586|EXPERIMENTAL|Mindfulness Based Stress Reduction (MBSR) training|Participants in the MBSR group will receive the standard 8-week Mindfulness-Based Stress Reduction (Stahl \& Goldstein, 2010). Once participants have completed the 8-week MBSR training they will enter a 12-month phase of regular supervised practice, in which they will continue to perform MBSR exercises on a guided basis. Supervised practice will be provided on a weekly basis.
62406600|NCT01114126|EXPERIMENTAL|Neu-P11 5 mg|
62406601|NCT01114126|EXPERIMENTAL|Neu-p11 20 mg|
62406602|NCT01114126|EXPERIMENTAL|Neu-P11 50 mg|
62406603|NCT01114126|PLACEBO_COMPARATOR|Placebo|
62406604|NCT04552158|NO_INTERVENTION|controlled group|patients with IBD who will be assessed for their nutritional status at day 0 and after 3 months of medical management only
62406605|NCT04552158|EXPERIMENTAL|experimental group|patients with IBD who will be assessed for their nutritional status at day 0 and after 3 months of medical management and nutritional management in the form of the Mediterranean diet
62581747|NCT06506474||Children admitted to Children's Hospital of Eastern Ontario|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62581748|NCT06506474||Children admitted to Kingston Health Sciences Centre|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62018067|NCT04876508|NO_INTERVENTION|Control group|No intervention will be applied
62018068|NCT05464147|EXPERIMENTAL|DynamX Drug-Eluting Coronary Bioadaptor System|
62018069|NCT05403047|OTHER|pregnant woman - tenofovir|Participants will be started on tenofovir disoproxil fumarate (TDF) 245 mg one tablet per day from week 28 of pregnancy until 6 weeks postpartum.
62406606|NCT06153758|EXPERIMENTAL|Part A|Participants will receive a single oral dose of danuglipron on Day 1 of each period
62406607|NCT06153758|EXPERIMENTAL|Part B|Participants will receive a single oral dose of danuglipron on Day 1 of each period
62406608|NCT06153758|EXPERIMENTAL|Part C|Participants will receive a single oral dose of danuglipron on Day 1 of each period
62406609|NCT06153758|EXPERIMENTAL|Part D|Participants will receive a single oral dose of danuglipron on Day 1 of each period
62406610|NCT02006810|EXPERIMENTAL|lipids|The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome).
62406611|NCT02006810|OTHER|flavonoids|The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome).
62406612|NCT02701660|EXPERIMENTAL|electronic medication dispenser|An Automatic Tablet Dispensing and Packaging System is used to repack all solid oral prescription medications for each participant into unit-of-dose pouches. Every participant receives a roll with pouches for 14-28 days loaded into a dispenser installed at their homes. The electronic medication dispenser is a remote controlled, electronic medication management aid reminding the patients with acoustic alerts to take their medication.
62406613|NCT04342130|EXPERIMENTAL|All Participants|People with low back pain who were given and oral dose of 30 mg morphine.
62734458|NCT02943317|EXPERIMENTAL|Part A: Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
62208533|NCT05695586|NO_INTERVENTION|Control group|The waitlist CG will comprise subjects with no MBSR/MSC related practice, who will not receive the MSC or MBSR training. However, subjects in the CG will be waitlisted to receive a MBSR or MSC training once the present project will be finished.
62208534|NCT06441266|EXPERIMENTAL|M-PART Assessment via MyCap|Assessment through the MyCap app to assess radiation dermatitis with the use of Kerastat cream.
62208535|NCT03231800|EXPERIMENTAL|Dasotraline|Dasotraline capsule 2mg/day
62208536|NCT03231800|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62208537|NCT06352814||ABLT vs traditional PT|Activities-based locomotor training is implemented through a combination of partial body weight supported treadmill training, overground walking, and play-based activities.
62208538|NCT03932305|PLACEBO_COMPARATOR|Control|Patients taking inactive placebo tablets
62208539|NCT03932305|EXPERIMENTAL|Lutein|Patients taking lutein supplement
62208540|NCT06332560|NO_INTERVENTION|Standard care (control group)|
62208541|NCT06332560|EXPERIMENTAL|Standard care and an anti-inflammatory diet (DI group)|
62208542|NCT06332560|EXPERIMENTAL|Standard care, anti-inflammatory diet and cognitive behavioral therapy (DI + CBT group)|
62208543|NCT06332560|EXPERIMENTAL|Standard care and cognitive behavioral therapy (CBT group)|
62208544|NCT05305729||Subjects with a genetic disease|
62406614|NCT01006031|EXPERIMENTAL|PegIFN alfa-2a and Ribavirin|HIV-coinfected patients with compensated cirrhosis by hepatitis C virus, genotype 1 or 4.
62406615|NCT00103376|EXPERIMENTAL|Part A: Velcade|Patient will complete Part A (Velcade only). If the patient has a complete response, he will come off study. If the patient has progressive disease, he will start Part B (Velcade + antiandrogen). If the patient has a partial response or stable disease, he will start Part B after at least a 7-day break.
62406616|NCT00103376|EXPERIMENTAL|Part B: Velcade+LH-RH antagonist+Androgen receptor antagonist|Patient will start Part B after completing Part A or may be enrolled to part B only.
62406617|NCT05665556||Pulmonary Arterial Hypertension (Group I)|Group I Pulmonary Arterial Hypertension associated with Connective Tissue Diseases
62406618|NCT05665556||Pulmonary Arterial Hypertension (Group IV)|Group IV Pulmonary Arterial Hypertension associated with Connective Tissue Diseases
62406619|NCT00536991|EXPERIMENTAL|Treatment (calcitriol, ketoconazole, hydrocortisone)|"PHASE I: Patients receive calcitriol PO QD on days 1-3, 8-10, 15-17, and 22-24. Patients also receive ketoconazole PO TID on days 1-24 and therapeutic hydrocortisone PO BID on days -1 to 24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive calcitriol and therapeutic hydrocortisone as in phase I. Patients also receive ketoconazole PO TID on days 4-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62406620|NCT03206307||Group 1|Group 1 will be questioned 36 months (in 2017) after their medical rehabilitation which was in 2013/2014.
62406621|NCT03206307||Group 2|Group 2 has the medical rehabilitation in 2017 and will be questioned at the end of the medical rehabilitation and 6, 12 and 18 months after that
62406622|NCT03930524|NO_INTERVENTION|Assessment Only|Control
62406623|NCT03930524|EXPERIMENTAL|Early-college Universal|Prior to beginning their first semester of college, incoming students will receive personalized normative feedback (PNF) comparing their experiences to other college students their age, as well as up to 4 self-monitoring surveys over the course of the semester.
62406624|NCT03930524|EXPERIMENTAL|Early-college No Coach (automated email)|Students from the early-college universal arm, who flag on one of the self-monitoring surveys are invited to engage in a web-based resource or in-person consultation to improve well-being, with a particular emphasis on alcohol use.
62406625|NCT03930524|EXPERIMENTAL|Early-college Coach|Students from the early-college universal arm, who flag on one of the self-monitoring surveys are invited to correspond with an online health coach who will use motivational interviewing strategies to encourage engagement in a web-based resource or in-person consultation to improve wellbeing, with a particular emphasis on alcohol use.
62208545|NCT05618912|EXPERIMENTAL|hydrocolloid dressing arm|After informed consent and closing the wound with the sutures, the scar will be covered by a hydrocolloid dressing, which will be left in place for 7 days (Experimental)
62208546|NCT05618912|ACTIVE_COMPARATOR|Petrolatum jelly dressing arm|and the other group of patients (control), after closing the wound with the sutures, the scar will be covered with petrolatum jelly during this time period, which has to be re-applied daily.
62208547|NCT02185222|EXPERIMENTAL|Cholecalciferol 100 000 UI (Unité Internationale)|Oral solution in single-dose : 100 000 UI per month
62208548|NCT02185222|PLACEBO_COMPARATOR|Placebo|Oral solution in single-dose per month
62208549|NCT05846802||Gastroparesis|Gastroparesis symptoms with delayed emptying
62208550|NCT05846802||Functional Dyspepsia|Gastroparesis symptoms without delayed emptying
62406626|NCT03930524|EXPERIMENTAL|Later-college Universal|After beginning their first semester of college, students will receive personalized normative feedback (PNF) comparing their experiences to other college students their age, as well as up to 4 self-monitoring surveys over the course of the semester.
62018070|NCT01190241|EXPERIMENTAL|Targeted treatment|Targeted treatment with desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib
62208551|NCT06288594|EXPERIMENTAL|Application Plus Online Therapist Support Group|"Participants in this arm will engage with the TraumaRelief mobile application while also receiving weekly online therapy sessions lasting 20 to 30 minutes for the duration of five weeks."
62208552|NCT06288594|EXPERIMENTAL|Application Only Group|"Participants in this arm will utilize the TraumaRelief mobile application as the sole intervention over a period of five weeks. This group will not receive any therapist-led sessions or additional support outside of the application's features."
62208553|NCT06288594|NO_INTERVENTION|Waitlist Control Group|"Participants in this control group are placed on a waitlist and will not receive any intervention during the initial five-week active phase of the trial. They serve as a comparative benchmark against the experimental groups to assess the effectiveness of the interventions. Following the three-month follow-up period, participants in this group will be granted access to the TraumaRelief mobile application, allowing them to benefit from the application."
62208554|NCT04042376|EXPERIMENTAL|Ibrutinib 420 milligram (mg)|Participants will receive ibrutinib 420 mg once daily, continuously starting at Day 1 of Week 1 until disease progression or unacceptable toxicity, whichever occurs first.
62208555|NCT04500769|EXPERIMENTAL|Acute Resistance Exercise|Participants will perform four exercises: squat, knee extension, leg press, and lat pulldown at 80% of 1-RM determined during a previous visit.
62208556|NCT05183789||Cases|Malnourished children with acute diarrhea
62208557|NCT05183789||Control|Non-malnourished children with acute diarrhea
62208558|NCT06728345||female migraine patients who recevie Rimegepant as prophylactic treatment|
62208559|NCT02302378|ACTIVE_COMPARATOR|Taylor's approach|This arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
62208560|NCT02302378|ACTIVE_COMPARATOR|Lumbar approach|This arm will have the procedure of spinal anesthetic performed via a paramedian 'Lumbar approach' at interspace L3-L4. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
62208561|NCT05052788||Case group|40 patients according to inclusion criteria .
62208562|NCT05052788||Control group|20 normal people with no history of previous brain insult and with free neurological examination .
62208563|NCT02984722|EXPERIMENTAL|1|PCOS women treated with 1500 mg/die of extended-release metformin
62208564|NCT02984722|EXPERIMENTAL|2|PCOS women treated with 1500 mg/die of immediate-release metformin
62208565|NCT06081153|EXPERIMENTAL|Evolocumab|Evolocumab is the drug that will be administered in this study. It will be administered as a 140mg subcutaneous injection every 14 days for 5 weeks (for a total of 3 doses).
62208566|NCT06081153|PLACEBO_COMPARATOR|Placebo|This arm is a matching placebo that will be administered in the same fashion as the study drug if the patient is randomized to placebo.
62581749|NCT06506474||Children admitted to The Hospital for Sick Kids|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62789963|NCT04220944|EXPERIMENTAL|Locoregional therapies combined with Anti-PD-1 antibody|Percutaneous microwave ablation combined with simultaneous TACE was performed. Sintilimab will be initiated on day 3-7 after the first locoregional therapies. Sintilimab will be administered every three weeks (200mg fixed dose IV) until disease progression for up to one year.The second locoregional procedure will be repeated according to the enhanced CT images.
62208567|NCT00440440|ACTIVE_COMPARATOR|1|testosterone gel
62208568|NCT00440440|PLACEBO_COMPARATOR|2|placebo gel
62208569|NCT06729619||Patients with central infection|
62208570|NCT06095271|EXPERIMENTAL|sNfL monitoring|6-monthly blood draw to measure sNfL
62208571|NCT06095271|NO_INTERVENTION|Usual care|SMSC usual care
62208572|NCT02304705|PLACEBO_COMPARATOR|Placebo|Placebo three times per day, orally
62208573|NCT02304705|ACTIVE_COMPARATOR|Sildenafil|Sildenafil 20 mg three times per day, orally
62208574|NCT00080678|EXPERIMENTAL|Docetaxel + Imatinib Mesylate|Docetaxel 30 mg/m\^2 intravenous over 60 minutes on days 1, 8, 15, and 22 in 42-day cycles, with daily oral 600 mg imatinib mesylate.
62208575|NCT00080678|PLACEBO_COMPARATOR|Docetaxel + Placebo|Docetaxel 30 mg/m\^2 intravenous (IV) over 60 minutes on days 1, 8, 15, and 22 in 42-day cycles, with daily oral placebo.
62208576|NCT03775928|EXPERIMENTAL|Apatinib + Capecitabine|Apatinib 425mg d1-21+ capecitabine 1000mg/m2 bid d1-14, q21d
62208577|NCT03775928|ACTIVE_COMPARATOR|Capecitabine|capecitabine 1000mg/m2 bid d1-14, q21d
62208578|NCT04855838|EXPERIMENTAL|Intervention group|Intensive training with oral neuromuscular device (intervention group) and traditional compensatory swallowing training under 8 weeks with start 4 (±1) weeks post-operation.
62581750|NCT06506474||Children admitted to Children's Hospital of Western Ontario|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62734459|NCT04359862|EXPERIMENTAL|SEVOFLURANE Group|
62734460|NCT04359862|ACTIVE_COMPARATOR|PROPOFOL Group|
62208579|NCT04855838|NO_INTERVENTION|Control group|Traditional compensatory swallowing training under 8 weeks with start 4 (±1) weeks post-operation.
62208580|NCT05436197|EXPERIMENTAL|PLAYshop Intervention|Participants will receive a 60 minute virtual/hybrid physical literacy workshop, an equipment goody-bag with basic play equipment and printed resources, and access to a digital app with an online toolkit and four bi-weekly boosters lessons.
62406627|NCT03930524|EXPERIMENTAL|Later-college No Coach (automated email)|Students from the later-college universal arm, who flag on one of the self-monitoring surveys are invited to engage in a web-based resource or in-person consultation to improve wellbeing, with a particular emphasis on alcohol use.
62208581|NCT05436197|NO_INTERVENTION|Control|Participants will receive the 60 minute virtual/hybrid physical literacy workshop, equipment goody-bag, and access to the digital app after completing the follow-up measures.
62406628|NCT03930524|EXPERIMENTAL|Later-college Coach|Students from the later-college universal arm, who flag on one of the self-monitoring surveys are invited to correspond with an online health coach who will use motivational interviewing strategies to encourage engagement in a web-based resource or in-person consultation to improve wellbeing, with a particular emphasis on alcohol use.
62208582|NCT04217603|EXPERIMENTAL|Group 1|This group will perform a 6MWT with CPAP
62208583|NCT04217603|SHAM_COMPARATOR|Group 2|This group will perform a 6MWT with a sham-CPAP
62208584|NCT06332807|EXPERIMENTAL|NGGT002|"Low dose and high dose group:~Six to twelve patients will be enrolled into two cohorts at two dose levels. The safety of this study can be ensured by selecting the highest dose under the No Observed Adverse Effect Level (NOAEL) doses observed in preclinical toxicology studies."
62406629|NCT04801069|EXPERIMENTAL|Auto-Adaptative Servo-Ventilation|
62208585|NCT01725373||Angioplasty of left main|"Patients with:~* stable or unstable angina and/or documented ischemia~* de novo ≥50% stenosis in the left main stem referred for angioplasty"
62208586|NCT05336630|EXPERIMENTAL|Forceps Assisted Cannulation|Patients will have a forceps assisted cannulation during their ERCPs.
62208587|NCT05336630|NO_INTERVENTION|No Forceps Assisted Cannulation|Patients will not have a forceps assisted cannulation during their ERCPs.
62208588|NCT05271721|OTHER|control group|Dexamethasone 4 mg (1ml) plus 40 mg ( 2ml) lidocaine 2% plus 1ml sterile saline
62208589|NCT05271721|ACTIVE_COMPARATOR|Magnesuim group|. 200 mg Mg sulfate (1ml) plus 4 mg dexamethasone(1ml) plus 40mg lidocaine 2% (2ml)
62406630|NCT04801069|NO_INTERVENTION|Control|
62406631|NCT03784755|ACTIVE_COMPARATOR|Arm 1 (standard of care)|"Standard systemic therapy~+ Ablative therapy to untreated prostate primary for patients with low volume metastatic disease burden"
62406632|NCT03784755|EXPERIMENTAL|Arm 2 (standard systemic therapy + ablative therapy))|"Local Ablative therapy to all sites of disease (including untreated prostate primary)~+ Standard systemic therapy"
62208590|NCT05271721|ACTIVE_COMPARATOR|Dexmedetomidine group|Dexmedetmodine 50mic (0.5ml) ,4 mg dexamethasone (1ml), 40 mg lidocaine 2% (2ml) added to 4ml total volume with sterile saline .
62208591|NCT05523947|EXPERIMENTAL|YH32367|"Dose Escalation Part: 8 Cohorts. In Dose Escalation part, patients are assigned to receive YH32367 at a starting dose and the dose being escalated/de-escalated in adjacent dose cohorts.~Dose Expansion Part: 2 Cohorts (Cohort 1: Biliary tract cancer, Cohort 2: Solid tumors). Dose Expansion part will consist of multiple cohorts in patients who were treated with at least 1 prior gemcitabine- and/or cisplatin-based therapy, HER2 positive biliary tract cancer(Cohort 1); in patients who were treated with all available standard therapies and have no available options, HER2 positive solid tumor malignancies other than breast and gastric or gastroesophageal junction adenocarcinoma and biliary tract cancer(Cohort 2)."
62406633|NCT04381793|EXPERIMENTAL|Assessing clinical efficacy|Subjects will receive four tablets twice a day (three times a day for five day loading dose), taking the treatment for 5 - 6 weeks. The treatment is a unique nutritional peptide mix derived from porcine serum. Pre-and post FIQ-R and VA symptom score will be assessed as well as overall well-being. In a subgroup, pre-and post antibody levels will also be checked. Phase 1 will be a group of 60 subjects
62406634|NCT05200975|OTHER|Adequate renal function|Patients with adequate renal function (egfr\>30ml/min) receiving a regular cefuroxime dose
62406635|NCT05200975|OTHER|Impaired renal function|Patients with impaired renal function (egfr\<30ml/min) receiving a guideline recommended reduced dose
62581751|NCT06506474||Children admitted to Alberta Children's Hospital|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62208592|NCT04211662|EXPERIMENTAL|Intervention Group|Tailored Multidimensional Intervention
62208593|NCT04211662|NO_INTERVENTION|Control Group|Regarding the control group, the participants will receive a simple educational booklet through one home visit.
62208594|NCT05859451|NO_INTERVENTION|Smokers|Participants subject to an orthopedic surgery (does not want to quit smoking conventional cigarettes) will continue smoking conventional cigarettes ad libitum for a period of 6 month post surgery
62208595|NCT05859451|EXPERIMENTAL|Smokers willing to switch to THS|Participants subject to an orthopedic surgery (currently smoking conventional cigarettes) will start to used THS ad libitum for a period of 6 month post surgery
62581752|NCT06506474||Children admitted to Stollery Children's Hospital|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62581753|NCT06506474||Children Admitted to Hôpital Maisonneuve-Rosemont|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62789964|NCT02240771|ACTIVE_COMPARATOR|Transarterial chemotherapy|Doxorubicin 50mg, Cisplatin 100mg
62208596|NCT05859451|ACTIVE_COMPARATOR|Ex Smokers|Participants subject to an orthopedic surgery will not smoke cigarettes or use electronic nicotine deliver systems for a period of 6 month post surgery
62208597|NCT00488475||Patients with Rheumatoid Arthritis|
62208598|NCT02166996|ACTIVE_COMPARATOR|A|Suture removal time 7 days.
62208599|NCT02166996|EXPERIMENTAL|B|Suture removal time 14 days.
62208600|NCT01149577|EXPERIMENTAL|Schizophrenia patients|The study population of 25 schizophrenia patients constituted the active arm of the study.
62208601|NCT03293160||Treatment group|The set of patients in the sample who are offered enrollment in care management services.
62208602|NCT03293160||Control group|The set of patients in the sample who are not initially offered enrollment in care management services (will be offered enrollment after six months).
62208603|NCT04807673|EXPERIMENTAL|Pembrolizumab+ Paclitaxel+Cisplatin+ Surgery+Pembrolizumab (228)|"Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W), paclitaxel 135mg/m\^2 IV on Day 2 Q3W, and cisplatin 80 mg/m\^2 IV on Day 2 Q3W, a total of three cycles. All treatments will be beginning on Day 1 of each 3-week dosing cycle. Surgery should be done within 4-6 weeks after the last neoadjuvant treatment. After surgery, pembrolizumab 200 mg IV on Day 1 Q3W lasting one year.~Surgery: McKeown esophagectomy"
62208604|NCT04807673|EXPERIMENTAL|neoadjuvant chemoradiotherapy+ Surgery (114)|"neoadjuvant chemoradiotherapy 41.4Gy(1.8Gy×23 fractions) with five cycles of TP(Paclitaxel 50mg/m\^2 on D1 and Cisplatin 25mg/m\^2 D1, repeated every week. Surgery should be done within 4-6 weeks after the last neoadjuvant treatment.~Surgery: McKeown esophagectomy"
62208605|NCT02539745||primary open-angle glaucoma patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in primary open-angle glaucoma patients.
62208606|NCT02539745||randomly age-matched people|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in randomly age-matched people.
62208607|NCT02309151|EXPERIMENTAL|Immediate coronary angiography|Immediate coronary angiography for out of hospital cardiac arrest patients with no signs of ST elevation on their first ECG after ROSC
62208608|NCT02309151|NO_INTERVENTION|Not immediate coronary angiography|Coronary angiography with possible coronary intervention may be performed at the discretion of the interventional cardiologist and should preferably not be performed until three days after the cardiac arrest. This strategy is in accordance with standard practice.
62208609|NCT06076395|EXPERIMENTAL|Group A pressure control ventilation|Inspiratory pressure was adjusted to achieve an expired tidal volume of 7 ml/Kg, respiratory rate was adjusted to achieve an end ETCO2 at 32-35 mmHg, inspiratory to expiratory ratio at 1:2, PEEP at 4 cm H2O and FiO2 at 0.5 providing that the maximum airway pressure was limited to 25 cmH2O.
62208610|NCT06076395|EXPERIMENTAL|Group B volume control ventilation|VT adjacent to 7 ml/Kg, respiratory rate was adjusted to achieve an end ETCO2 at 32-35 mmHg and I/E at: 1:2 and PEEP at 4 cm H2O and FiO2 at 0.5.
62208611|NCT00631839||1|There is only one group in this study. The patients of this group will go through procedures as follow: basic pre-treatment information collected,treatment include platinum-based chemotherapy and 3-D conformal radiotherapy, blood test during RT 6am every Monday and follow-up visits with treatment-induced injury assessed.
62208612|NCT06290128|EXPERIMENTAL|Riliprubart Arm|Riliprubart for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks
62208613|NCT06290128|PLACEBO_COMPARATOR|Placebo Arm|Placebo for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks
62208614|NCT06643039|OTHER|Patients hospitalized in participating services for more than 24h|Patients hospitalized for more than 24 hours in the participating services (geriatric, internal medicine, transplantation) and who presents an influenza like illness (ILI) on admission or during hospital stay are eligible to participate. Following the signature of the consent, nasopharyngeal sample will be collected. Socio-demographic (questionnaire) and clinical information will be obtained using the study e-CRF.
62208615|NCT06643039|OTHER|Volunteered health care professionals|Volunteered health care professionals in the participating services (geriatric, internal medicine, transplantation) and who presents an influenza like illness (ILI) are eligible to participate. Following the signature of the consent, nasopharyngeal sample will be collected. Socio-demographic (questionnaire) and clinical information will be obtained using the study e-CRF
62208616|NCT04300751|EXPERIMENTAL|Alcohol|Participants will receive experimental doses of active or placebo alcohol, p.o. Alcohol/placebo will be administered once per session.
62208617|NCT04300751|EXPERIMENTAL|Opioid Agonist|Participants will receive non-therapeutic, experimental doses of an active opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered orally
62406636|NCT00726440|ACTIVE_COMPARATOR|Group1-patient|The patient will be encouraged to use the Navigator® all the time and to modify his treatment according to the continous blood glucose measurements. The patients will follow an educational process in order to adapt insulin doses according to each sensor data.
62406637|NCT00726440|ACTIVE_COMPARATOR|Group2-diabetologist|"The patient will follow the same educational process as group 1 concerning insulin dose adaptation. They will use the continous glucose monitoring device according to the diabetologist's prescription and they will receive precise instructions to make considering results. The duration of the use of the Navigator® will be increased if one of the following criteria is observed at the consultation each 3 months:~* HbA1c\>=7.5%~* 1 severe hypoglycaemia or more~* More than 4 benign hypoglycaemia per week~According to these criteria, every 3 months, the duration of the use of the monitoring system will be increased as following:~* step 1: 3 sensors per month~* step 2: 4 sensors per month~* step 3: 5 sensors per month~* step 4: continuous use"
62406638|NCT00726440|PLACEBO_COMPARATOR|Group3-Control|Usual follow up with self-monitoring blood glucose.
62406639|NCT02872584||Prednisone|Patients with dermatological conditions requiring high dose long term glucocorticoid treatment
62406640|NCT06652022|ACTIVE_COMPARATOR|Systemic treatment group|The choice of first-line treatment is based on the guidelines, and may include chemotherapy or immune checkpoint inhibitors, or a combination of therapies. For patients who can tolerate cisplatin, chemotherapy is given with the gemcitabine-cisplatin regimen, as follows: gemcitabine 1000mg/m2 d1,8; cisplatin 70 mg/m2, avoiding light, intravenous drip d2; 3 weeks for 1 cycle. For intolerant patients, the gemcitabine-carboplatin regimen is given as follows: gemcitabine 1000 mg/m2 d1,8, IV, carboplatin (4.5×\[GFR+25\]) mg, IV, d1; 3 weeks as 1 cycle. Immune checkpoint inhibitors and targeted agents may be administered if the patient does not tolerate chemotherapy; either in combination with chemotherapy or directly as first line.
62581754|NCT06506474||Children admitted to Hôpital St-Jérôme|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62581755|NCT06506474||Children admitted to Hôpital Saint-Eustache|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62208618|NCT04300751|EXPERIMENTAL|Opioid Agonist/Alcohol Combination|Participants will receive non-therapeutic, experimental doses of active opioid/placebo in combination with experimental doses of active alcohol placebo. Opioid/placebo and alcohol/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Both opioid and alcohol doses will be administered orally.
62208619|NCT00464984|ACTIVE_COMPARATOR|ILI-group|Intensive lifestyle intervention at a tertiary care rehabilitation center. Treatment included changes in both dietary habits (calori restriction) and physical activity with particularly high intensity the first 3 months.
62208620|NCT00464984|ACTIVE_COMPARATOR|MLI|Moderate lifestyle intervention at a secondary care outpatient center. Treatment included moderate changes in dietary habits (calori restriction) and physical activity.
62208621|NCT00540865|EXPERIMENTAL|A|Participants will receive problem-solving therapy and case management
62208622|NCT00540865|ACTIVE_COMPARATOR|B|Participants will receive case management
62208623|NCT05119179|EXPERIMENTAL|Semaglutide|Semaglutide 0.25 mg subcutaneously weekly for 4 weeks, followed by semaglutide 0.5 mg subcutaneously weekly for 8 weeks.
62789965|NCT02240771|PLACEBO_COMPARATOR|Oral chemotherapy|Thalidomide---50-300mg once a day Capecitabine---- 500-1500mg once a day
62208624|NCT05223530||Prevention of Pre-eclampsia and Intrauterine Growth Restriction (PREDO)|"The PREDO study is a cohort study that was started in 2005 in the Helsinki metropolitan area and Northern Karelia. In 2005-2009, it recruited a total of 4,777 women in the early pregnancy. Almost all subjects participated in stress monitoring during pregnancy. In addition, some mothers participated in either genetic, ultrasound, or drug research to develop methods for predicting and preventing pre-eclampsia and fetal growth retardation, and for identifying related factors.~Some key objectives have been to determine whether the physical and mental well-being of the pregnant women could be relevant with hereditary factors for the course of pregnancy and the subsequent physical and mental development and health of the child.~The previous follow-up phases have been performed 2 weeks and 6 months after the birth in 2006-2011 and at the age of approximately 2-6 and 7-12 years. More than 2,500 families participated in the most recent follow-up phase. Now it is 11-17 years of follow-up."
62789966|NCT03917095|ACTIVE_COMPARATOR|Mesalazine conventional enema|Participants undergo the conventional enema of Mesalazine Enemas (4g) for one week.
62789967|NCT03917095|EXPERIMENTAL|Mesalazine TET enema|Participants undergo the TET enema of Mesalazine Enemas (4g) for one week.
62018071|NCT04534829|EXPERIMENTAL|Ultrasound-Guided SIJ RFA|"Utilizing short axis views, the S1, S2 and S3 foramen and tubercles would be localized and marked by a surgical skin marker. Then, the ultrasound transducer will be moved laterally to achieve a long axis view between the S1 and S2 tubercle. Local skin and subcutaneous tissue freezing would be performed with Lidocaine 1% utilizing a 30-gauge needle. An 18-gauge radiofrequency (RF) cannula will be directed utilizing an in-plane approach toward the S2 and S3 lateral branches between the S2 and S3 tubercles. A small amount of 1% lidocaine will be injected in order to provide comfort.~The RF generator will be set to continuous monopolar RF ablation and the needle will be heated to 80 degrees Celsius for 90 seconds. The needle will then be repositioned proximally to obtain a slightly larger burn in a similar fashion previously described. A similar approach will be utilized for the S1 lateral branch RF ablation between the S1 and S2 tubercles."
62208625|NCT05223530||Finnish Gestational Diabetes Prevention (RADIEL)|"The RADIEL study is a randomized multicenter study that was launched in 2008 in Helsinki, Espoo, Vantaa and Lappeenranta. Between 2008 and 2011, we recruited a total of 729 women for gestational diabetes prevention research. Subjects either planned to become pregnant or were in early pregnancy at the time of the study. Subjects were randomized to either receive diet and exercise intervention (active group) or to continue with normal counseling follow-up (control group). Study visits occurred every three months before pregnancy (if recruited before pregnancy), once in each trimester of pregnancy, and at 6 weeks, 6 months, and 12 months after delivery. The effectiveness of the intervention was measured with a variety of metrics.~In 2013-2017, we invited mothers and children who participated in the RADIEL study to a 5-year follow-up of the project, and nearly 350 mother-child pairs participated. Now it is 11-17 years of follow-up."
62208626|NCT00666692|EXPERIMENTAL|1|Escalating doses of volociximab at 10, 20, and 30 mg/kg with carboplatin, paclitaxel, and bevacizumab
62208627|NCT01843790|PLACEBO_COMPARATOR|Placebo, saline|Saline, dosed weekly for 8 weeks
62208628|NCT01843790|EXPERIMENTAL|GCS-100 low dose|Low dose of GCS-100 given IV once per week for 8 weeks
62208629|NCT01843790|EXPERIMENTAL|GCS-100 high dose|High dose of GCS-100 given IV once per week for 8 weeks
62208630|NCT06358729|EXPERIMENTAL|Nipple order 1|First the typical nipple and then challenging nipple
62208631|NCT06358729|EXPERIMENTAL|Nipple order 2|First the challenging nipple and then the typical nipple
62208632|NCT06007222|ACTIVE_COMPARATOR|Aspirin group|Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.
62208633|NCT06007222|EXPERIMENTAL|Non-antithrombotic group|No antithrombotic agents will be administered after randomization until the end of the study period.
62208634|NCT02627404|OTHER|Main module|Blood sample
62581756|NCT06506474||Children admitted to Cité-de-la-Santé|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62208635|NCT04508582||Women with Pre-eclampsia|De novo hypertension after 20 weeks gestation with evidence of end organ dysfunction.
62208636|NCT04508582||Women with Pregnancy-induced hypertension|De novo hypertension after 20 weeks gestation without evidence of end organ dysfunction.
62208637|NCT04508582||Healthy pregnant controls|Low risk women at booking as per NICE guidelines without any medical condition throughout pregnancy
62208638|NCT01906970|EXPERIMENTAL|ClampArt|ClampArt
62208639|NCT05045820|EXPERIMENTAL|Needling Acupuncture - 5 weeks|Needling acupuncture treatment will last 30 minutes per session and will be administered two times per week for 5 weeks. Each subject will receive one course of treatment which contains 10 treatment sessions.
62208640|NCT05045820|EXPERIMENTAL|Laser Acupuncture - 5 weeks|Laser acupuncture treatment will also last 30 minutes per session and will be administered two times per week for 5 weeks. Each subject will receive one course of laser acupuncture treatment which contains 10 treatment sessions.
62208641|NCT05045820|EXPERIMENTAL|Needling Acupuncture - 12 weeks|Needling acupuncture treatment will last 30 minutes per session and will be administered once per week for 12 weeks. Each subject will receive one course of treatment which contains 12 treatment sessions.
62208642|NCT05045820|EXPERIMENTAL|Laser Acupuncture - 12 weeks|Laser acupuncture treatment will also last 30 minutes per session and will be administered once per week for 12 weeks. Each subject will receive one course of laser acupuncture treatment which contains 12 treatment sessions.
62208643|NCT05272943||Preanesthesia visit measurement|Oxygen saturation will be measured by validated pulse oxymetry and smart electronics in pediatric patients during preanesthesia visit
62208644|NCT05272943||General anesthesia measurement|Oxygen saturation will be measured by validated pulse oxymetry and smart electronics in pediatric patients during general anesthesia
62208645|NCT05272943||PACU measurement|Oxygen saturation will be measured by validated pulse oxymetry and smart electronics in pediatric patients during PACU stay
62581757|NCT06506474||Children Admitted to Trillium Health Partners|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62208646|NCT05272943||PICU measurement|Oxygen saturation will be measured by validated pulse oxymetry and smart electronics in pediatric patients during PICU stay
62208647|NCT02065687|EXPERIMENTAL|Arm I (paclitaxel, carboplatin, metformin hydrochloride)|"Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator."
62018072|NCT04534829|ACTIVE_COMPARATOR|Fluoroscopic-Guided SIJ RFA|An anterior-posterior approach is used to identify the S1-S3 foramen. A 3-inch spinal needle would be used for marking. Local tissue freezing would be accomplished with Lidocaine 1% and a 30-G needle. An 18-G RF cannula will be positioned over the 12 o'clock position of the S1 foramen and a second cannula placed in the 2 o'clock or 10 o'clock position for the right and left respectively (4-5 mm distance between the cannula). A small amount of 1% lidocaine will be injected for comfort. A lateral projection is taken to ensure the needles are not placed into the foramen. The RF generator will be set to continuous bipolar RF ablation and heated to 80 degrees Celsius for 90 seconds. Then another 18-G RF cannula will be positioned at the 4 o'clock or 8 o'clock position (4-5 mm distance between the cannula) to achieve the second RF ablation. The third RF ablation will be performed with the RF cannula at the 6 o'clock position. An identical fashion is utilized at the S2 and S3 foramen.
62018073|NCT01169324|EXPERIMENTAL|DBS on|baseline settings
62018074|NCT01169324|NO_INTERVENTION|DBS off|DBS off
62018075|NCT00215293|EXPERIMENTAL|Cervical Cage|Cervical I/F Cage
62018076|NCT00215293|ACTIVE_COMPARATOR|Graft Spacer|Autograft or allograft with a plate, or autograft alone.
62018077|NCT02268591|ACTIVE_COMPARATOR|Transcranial Stimulator|We will apply oscillating current at a slow frequency of 0.5-1.5 Hz during early sleep, which is rich in slow waves \[ie non-REM sleep\]. The peak intensity of stimulation which allows for optimal phase entrainment will be determined in pilot studies. However, peak stimulation intensities will not exceed 2 mA (as discussed above). The current will be applied over the left and right prefrontal cortex (F3, F4), corresponding to the predominant region of slow oscillations, during the onset of deep sleep to the first REM episode (early non-REM-rich sleep).
62581758|NCT06506474||Children admitted to Lakeridge Health|Children aged \>28 days to \<12 months with an admission diagnosis of bronchiolitis, admitted to a general pediatric inpatient unit, not previously recruited for the study.
62018078|NCT02268591|NO_INTERVENTION|Sham Stimulation|The EEG and stimulation electrodes will be placed as in the stimulation sessions, but stimulation will not be administered.
62018079|NCT04237298|ACTIVE_COMPARATOR|Hawley retainer|Standard retention regime for patients with arch expansion. Patients will be instructed to wear the retainer 24 hours during the study period.
62018080|NCT04237298|EXPERIMENTAL|Modified vacuum-formed retainer covering the palate|The modified vacuum-formed retainer is designed to cover the palate. It is cheaper, easier to fabricate and more esthetic. Patients will be instructed to wear the retainer 24 hours during the study period.
62018081|NCT01049555|OTHER|Alzheimer and apathy|Alzheimer's disease patients with apathy
62018082|NCT01049555|OTHER|alzheimer without disease|Alzheimer's disease patients without apathy
62018083|NCT01049555|OTHER|Case control|subject without apathy neither Alzheimer's disease
62734461|NCT03046927|EXPERIMENTAL|Ergocalciferol|Oral administration of 50,000 IU of ergocalciferol one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
62018084|NCT06057896||inositol, phytoestrogens, cocoa polyphenols|
62018085|NCT03239652|EXPERIMENTAL|Taiwan ACE Beads microspheres|The maximum use of dosage will not exceed 100 milligrams. The embolization procedure usually lasts less than an hour.
62018086|NCT01739322|EXPERIMENTAL|1|"Four concentrations of Platanus acerifolia allergen extract (10, 1, 0.1, 0.01 mg/ml)~Positive control (10 mg/ml histamine dihydrochloride)~Negative control (glycerinated phenol saline solution)"
62018087|NCT04227483|ACTIVE_COMPARATOR|Prednisolone|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. All doses will be rounded off to the nearest 5 mg (maximum duration of therapy, 4 months)
62018088|NCT04227483|EXPERIMENTAL|Deflazacort|Deflazacort 0.75 mg/kg/day for 4 weeks; 0.375 mg/kg/day for 4 weeks; 0.1875 mg/kg/day for 4 weeks. Then taper by 6 mg every 2 weeks and discontinue. All doses will be rounded off to the nearest 6 mg (maximum duration of therapy, 4 months)
62406641|NCT06652022|EXPERIMENTAL|Systemic treatment combined with radiotherapy group|"For patients with oligometastases, the radiotherapy protocol adopts a full-coverage radiotherapy protocol for metastatic foci, which is used as early as possible during the 2 cycles of systemic treatment for the patients. For retroperitoneal lymph node metastases, the conventional segmental radiotherapy protocol is used, and for isolated metastatic foci, the SBRT radiotherapy is used as much as possible.~PETCT was used to determine the location and number of metastatic foci before radiotherapy, and for some patients who could not undergo PETCT, chest, abdominal and pelvic CT, ultrasound of superficial lymph nodes, bone scanning and cranial MRI were used to define the scope of the patient's foci."
62406642|NCT03309072|EXPERIMENTAL|active tDCS|active tDCS with Face Name associate Memory task
62406643|NCT03309072|SHAM_COMPARATOR|sham tDCS|sham tDCS with Face Name associate Memory task
62406644|NCT06650904|OTHER|Simulation-Based Child and Family Communication Application|pre-test post-test design quasi-experimental study without control group
62406645|NCT01112969|EXPERIMENTAL|Internet-based supportive coaching OSCAR|Arm 1: Internet-based supportive coaching OSCAR
62406646|NCT01112969|OTHER|Waiting list control group (treatment as usual, TAU)|
62406647|NCT04912973|ACTIVE_COMPARATOR|inverse Kinematic Alignment|
62406648|NCT04912973|ACTIVE_COMPARATOR|adjusted Mechanical Alignment|
62406649|NCT05862870|EXPERIMENTAL|painTRAINER pain management web application|This is a patient-administered pain management training program delivered in 10 sessions over 8 weeks. Each session is composed of different skills useful for managing chronic pain. Each session is also accompanied by recommendations for skills practice to be done between sessions.
62406650|NCT01102881|PLACEBO_COMPARATOR|No fiber|No fiber added to muffins or cereal
62406651|NCT01102881|EXPERIMENTAL|Fiber made from corn starch|Muffins and cereal made with novel corn fiber
62406652|NCT01102881|EXPERIMENTAL|Glucose polymer fiber|Muffins and cereal made from glucose polymer fiber
62406653|NCT06538194|ACTIVE_COMPARATOR|Mesotherapy|The first group received mesotherapy: For this group, a solution containing 1 cc each of lidocaine, pentoxifylline, vitamin B complex diluted 1/10 with saline, thiocolchicoside, and meloxicam diluted 1/5 with saline will be made. A 30 gauge, 4 mm mesotherapy injector will be used for the application. The lateral epicondyle will be the site of an intradermal injection. Of that amount, 2.5 cc will be applied point-by-point at intervals of 1-2 cm, and the remaining 2.5 cc will be applied using the napage method, 0.1 cc of solution were given with each injection.
62406654|NCT06538194|ACTIVE_COMPARATOR|Prolotherapy|Group 2 received dextrose prolotherapy: A 22 gauge syringe was used to apply a total of 5 cc of 15% dextrose solution (a combination of 3.75 ml 20% dextrose and 1.25 mg 2% lidocaine) to at least 5 most sensitive points of the lateral epicondyle. It was injected 3 times with 3 weeks intervals.
62406655|NCT06538194|ACTIVE_COMPARATOR|Control|Only exercise and resting wrist splints will be administered to the third group, which is the control group.
62406656|NCT02300272||Typically healthy older adults|Adults 65 years and older with only common late-life medical conditions who will complete a screening that includes a Polysomnograph and assessment that includes Actiwatch.
62406657|NCT02865616|EXPERIMENTAL|MET-2 Capsules|"Patients will be on vancomycin to control symptoms up until the time of the treatment.~Initial Loading Dose: Patients will be given an initial daily loading dose of 5 g MET-2 over 2 days followed by a maintenance dose of 1.5 g over 8 days. Patients who do not experience treatment failure between Day 14 and Day 40 will be monitored until Day 130.~Second Loading Dose: Patients experiencing treatment failure after the first dose may be offered a second, higher loading dose 10 g of MET-2 in the form of 20 MET-2 capsules per day for two days, there will not be additional daily dosing beyond the first 10 days.~Colonoscopy: Patients failing the second loading dose of MET-2 may be offered 15 g of MET-2, equivalent to a 30 MET-2 capsule loading dose by weight, via colonoscopy..~All patients will be followed up for 120 days after the last treatment has been received."
62406658|NCT03441620|PLACEBO_COMPARATOR|Control|Calorie and fiber-matched control powder
62406659|NCT03441620|EXPERIMENTAL|Strawberry one serving|Freeze-dried powder equivalent to one serving fresh strawberries per day.
62406660|NCT03441620|EXPERIMENTAL|Strawberry two-half servings|Freeze-dried powder equivalent to 2.5 serving fresh strawberries per day.
62406661|NCT02365701|EXPERIMENTAL|Motilitone 30mg|Motilitone will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 4 weeks.
62406662|NCT02365701|PLACEBO_COMPARATOR|Placebo|Placebo (same formulation as Motilitone but without the active ingredients) will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this tablet for 4 weeks.
62406663|NCT05316376|EXPERIMENTAL|dd-nabTC|albumin-bound paclitaxel (100 mg/m2, days 1, 8, and 15, every 4 weeks) combined with carboplatin (AUC = 5, day 1, every 4 weeks)
62406664|NCT05316376|ACTIVE_COMPARATOR|CONTROL|paclitaxel (175 mg/m2, day 1, every 4 weeks) combined with carboplatin (AUC=6, day1, every 4 weeks)
62406665|NCT05598502|EXPERIMENTAL|REBOA|Addition of REBOA (Resuscitative Endovascular Occlusion of the Aorta)
62406666|NCT05598502|ACTIVE_COMPARATOR|National guidelines|Treatment according to Uganda national guidelines for post-partum hemorrhage.
62406667|NCT00437294|EXPERIMENTAL|Capecitabine + Enzastaurin|
62406668|NCT00437294|PLACEBO_COMPARATOR|Capecitabine + Placebo|
62406669|NCT05143489|ACTIVE_COMPARATOR|Preservative Free Lidocaine Group|The patient will receive a 1mg/kg IV dose of preservative free lidocaine with a max dose of 40mg
62208648|NCT02065687|ACTIVE_COMPARATOR|Arm II (paclitaxel, carboplatin, placebo)|"Patients receive paclitaxel IV and carboplatin IV as in Arm I. Patients also receive placebo PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator."
62208649|NCT00920322|ACTIVE_COMPARATOR|five times weekly|Patients will receive rTMS on each weekday for 4 weeks (5 x weekly)
62208650|NCT00920322|EXPERIMENTAL|three times weekly|Patients will receive rTMS three times weekly for four weeks
62208651|NCT03847792|ACTIVE_COMPARATOR|Group DB/Dexamethasone-Bupivacaine|Patients were received an intra-articular injection of 8mg dexamethasone added to18mL of 0.25% bupivacaine
62208652|NCT03847792|ACTIVE_COMPARATOR|Group FB /Fentanyl-Bupivacaine|Patients were received an intra-articular injection of 1 ug/kg fentanyl added to 18 mL of 0.25% bupivacaine
62208653|NCT03847792|PLACEBO_COMPARATOR|Group PB/Placebo-Bupivacaine|Patients were received an intra-articular injection of 2 mL isotonic saline added to 18 mL of 0.25% bupivacaine
62208654|NCT03053687|EXPERIMENTAL|Nutritional Standardized Supplementation Formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
62208655|NCT03053687|PLACEBO_COMPARATOR|Placebo|Low caloric formula (Powder added to water) without added vitamins and mineral
62581759|NCT02915120|ACTIVE_COMPARATOR|Real Pulsed Radiofrequency|Before needle insertion, the patient's inferomedial (IM), superomedial (SM), and superolateral (SL) GN branches will be identified under ultrasound guidance. RF needles and probes will be advanced to each of the target nerves under ultrasound guidance. A 50 Hz-frequency sensorial stimulation will be applied with a threshold of \< 0.5 mA to identify the nerve position, the current intensity (mA) will be reduced at \< 0,2 mA. During the sensorial stimulation, the patients will be asked if they feel tingling, pain, or discomfort inside the knee. The RF probe will be maintained in place until one of those feelings is elicited. In order to avoid inactivating motor nerves, the nerve will be tested for the absence of fasciculation in the the lower extremity on stimulation of 0,5 mA at 2 Hz.
62208656|NCT06729476|ACTIVE_COMPARATOR|Active device study arm|Study Procedure: In this study, half of the recruited patients were connected to the UROSHIELD device (study group), while the other half was connected to a similar but inactive sham device (control group). The medical treating team, research team, and the patients themselves were unaware of who received the active device and who was connected to the inactive, sham device. As mentioned, randomization and allocation of devices was performed by a physician not otherwise involved in the conduct of the study or with data processing.
62208657|NCT06729476|PLACEBO_COMPARATOR|Sham device control arm|Study Procedure: In this study, half of the recruited patients were connected to the UROSHIELD device (study group), while the other half was connected to a similar but inactive sham device (control group). The medical treating team, research team, and the patients themselves were unaware of who received the active device and who was connected to the inactive, sham device. As mentioned, randomization and allocation of devices was performed by a physician not otherwise involved in the conduct of the study or with data processing.
62208658|NCT06515145|EXPERIMENTAL|High Volume Therapeutic plasma Exchange|The high - volume strategy would be performed by centrifugation technique \~ 8 - 9 litres of plasma would be exchanged in each patient over 6 - 8 hours along with Standard Medical Treatment
62406670|NCT05143489|ACTIVE_COMPARATOR|Placebo Group|The patient will receive IV normal saline of 1mg/kg with a max of 40mg
62406671|NCT01418365|EXPERIMENTAL|Metronidazole + MMX placebo|
62406672|NCT01418365|EXPERIMENTAL|Metronidazole + MMX Mesalazine/mesalamine|
62406673|NCT00740129|EXPERIMENTAL|Zoledronic Acid 5 mg|Participants received single re-treatment dose of zoledronic acid 5 mg intravenous (IV) infusion.
62406674|NCT02116309|ACTIVE_COMPARATOR|Rectal Indomethacin only|Patients in this group will receive 20 ml of normal saline sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin.
62406675|NCT02116309|ACTIVE_COMPARATOR|Rectal Indomethacin plus papillary spray of Epinephrine|Patients in this group will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin.
62406676|NCT06327048|NO_INTERVENTION|Control group|Routine rehabilitation nursing
62581760|NCT02915120|SHAM_COMPARATOR|Sham Pulsed Radiofrequency|Control patients will undergo the same procedure. The sensorial and motor stimulations will be applied too. The RF electrode will be then inserted through the cannula, and RF lesions will be simulated without applying pulsed RF treatment to the IM, SM and SL, GN branches for 8 minutes each GN branch and the temperature of the electrode tip was not raised.
62406677|NCT06327048|EXPERIMENTAL|Intervention group|On the basis of routine rehabilitation nursing, individual cognitive rehabilitation training based on Remind strategy was given
62406678|NCT06026969||Lyme disease|"Pregnant participants in the Lyme disease cohort will meet CDC criteria for clinical and/or laboratory diagnosis of Lyme disease during pregnancy based on stage of disease. Participants will be enrolled following confirmation that they have been diagnosed by a medical professional per CDC guidelines.~Participants in this cohort may be enrolled during any trimester of pregnancy. Live-born infants will be included in the cohort and followed through age 18 months."
62406679|NCT06026969||Post-treatment Lyme Disease Syndrome (PTLDS) or Chronic Lyme|"Pregnant participants in the PTLDS/Chronic Lyme cohort will have been diagnosed with PTLDS/Chronic Lyme by a health care provider no less than 6 months, but no greater than 3 years, prior to enrollment. Participants will be enrolled following confirmation that they have been diagnosed by a medical professional per CDC guidelines.~Participants in this cohort may be enrolled during any trimester of pregnancy. Live-born infants will be included in the cohort and followed through age 18 months."
62018089|NCT01690403|EXPERIMENTAL|cohort 1|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 1).
62018090|NCT01690403|EXPERIMENTAL|cohort 2|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 2).
62208659|NCT06515145|ACTIVE_COMPARATOR|Standard volume Therapeutic Plasma Exchange|The standard volume strategy would be performed centrifugation technique with Plasma volume varying from 1.5 - 2.5 times the plasma - volume along with Standard Medical Treatment.
62208660|NCT02428764|EXPERIMENTAL|Intervention group|Patients were assigned to receive neoadjuvant nimotuzumab plus gemcitabine and carboplatin followed by surgery.
62789968|NCT03917095|ACTIVE_COMPARATOR|Compound Glutamine conventional enema|Participants undergo the conventional enema of Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.
62789969|NCT03917095|EXPERIMENTAL|Compound Glutamine TET enema|Participants undergo the TET enema of Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.
62018091|NCT01690403|EXPERIMENTAL|cohort 3 (optional)|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 3).
62018092|NCT02621762|EXPERIMENTAL|Mg first|Receives MgCl2 first, MgCl2 and Bicarbonate in second phase
62208661|NCT06457451|EXPERIMENTAL|DIAPASOM program|"Program of adapted physical activity carried out remotely by a specialized instructor for one year:~* Phase 1 (3 months): 2 supervised weekly sessions.~* Phase 2 (3months): 1 supervised weekly session and 1 independent weekly session.~* Phase 3 (6months): 2 independent weekly sessions with monthly telephone follow-up.~Combined with personalized dietetic care by a dietician for one year too:~In person dietetic consultation every 3 months to monitor personalized objectives, with telephone follow-up between each face-to-face consultation to improve compliance."
62208662|NCT06457451|NO_INTERVENTION|Management as usual|Management of nutrition and physical activity as usual
62208663|NCT02549456|EXPERIMENTAL|Natural orifice specimen extraction|Conventional laparoscopic resection of colorectal cancer with natural orifice specimen extraction
62208664|NCT02549456|EXPERIMENTAL|Laparoendoscopic resection|Laparoscopic assisted transanal endoscopic resection of rectal cancer
62208665|NCT06728631|EXPERIMENTAL|Intervention with Candonilimab and ATRA|Candonilimab at a dose of 6mg/kg IV Q3W will be administered until a maximum treatment duration of 1 year. All-trans retinoic acid will be administered at a dose of 25mg/m² twice daily on days 1-14, with a treatment cycle of 21 days, until a maximum treatment duration of 6 months, or until the occurrence of oral cancer or other malignancies, death, intolerable toxicity, withdrawal of informed consent, or any other reasons specified in the protocol.
62789970|NCT03917095|EXPERIMENTAL|Compound Glutamine and Mesalazine TET enema|Participants undergo the TET enema of Mesalazine(4g) and Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.
62789971|NCT02381015|EXPERIMENTAL|Genetic Risk Score: Number Format|Genetic Risk Score: Number Format Subjects receive genetic risk scores in a number format.
62208666|NCT06728631|OTHER|mixed arm|Routine follow-up or treatment methods other than those in the intervention group of this study
62208667|NCT05343260|ACTIVE_COMPARATOR|Sevoflurane group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol, and rocuronium.~Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
62208668|NCT05343260|EXPERIMENTAL|Propofol group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol, and rocuronium.~Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
62208669|NCT06729060|NO_INTERVENTION|Control Group|
62208670|NCT06729060|ACTIVE_COMPARATOR|Combination of Motor Imagery and Physical Performance Group|"For 15 minutes you will physically eliminate targets by clicking on them in the Aim Lab Trainer (Physical Performance Part).~Then, on a screen divided into 60 squares, the target will appear and disappear in a random square for 5 seconds. At the same time, the metronome will give a warning sound at each new target. The stimulus will come every five seconds and each time the stimulus comes, the target will imagine that it has disappeared. In the next 5 seconds, the stimulus will come again in a different place and he will imagine that he has destroyed it again. In the first two weeks, this will happen for 60 stimuli with 5 second intervals.~(60target\*5sec=300sec \*3=900sec/60 =15 min). In the next 2 weeks, the interval will be reduced by 1 second and in the last two weeks it will not be reduced. But the duration will always be 15 minutes (Motor Imagery Part)."
62208671|NCT06729060|ACTIVE_COMPARATOR|Physical Performance Group|For 30 minutes, they will eliminate the Aim Lab Trainer test by clicking quickly and accurately with their dominant hands. The physical performance application to be applied both in this group and in the Motor Imagery and Physical Performance Combination Group is the same and will be applied in the same way for 8 weeks.
62208672|NCT04642807|ACTIVE_COMPARATOR|"Group 1 Long-arm full cast and routine follow-up"|Patients assigned to Group 1 will be placed in a long arm cast, at 90-100 degrees in neutral rotation. A referral will then be made to the orthopedic department and the patient reviewed at week 3 with cast removal, clinical assessment and radiographic assessment as determined by the normal practice at the local center.
62208673|NCT04642807|EXPERIMENTAL|"Group 2 Long-arm soft cast and no clinical or radiographic follow-up"|"Patients assigned to group 2 will be placed in a long arm cast at 90-100 degrees in neutral rotation. They will be given verbal and written information on the injury, when and how to remove the cast and contact details if there are any concerns.~Since they will not be attending clinical follow-up, an email or telephone survey will be undertaken at 3 weeks and after 6 months. The survey will inquire initially about pain, unplanned returns to the Family Physician and hospital, complications, parent/patient satisfaction and a standardized patient reported outcome score will be taken. Please see attached documentation for the itemized survey questions. The 6 month follow-up will include photographs and an illustrated guide will be given to the families on how to obtain pictures of maximal flexion, extension and the child's carrying angle (attached). Measurements of range of motion from photographs are considered comparable to clinical assessment of range of motion"
62208674|NCT06470997||CHILI : hepatitis induced by immune checkpoint inhibitors|Patient with immunotherapy-induced hepatitis
62208675|NCT06470997||Control group: idiopathic autoimmune hepatitis|Patient with idiopathic autoimmune hepatitis
62208676|NCT04549896|EXPERIMENTAL|CT scan|CT scan with a last generation 256 slice machine of occluded coronary artery before CTO PCI
62208677|NCT04549896|ACTIVE_COMPARATOR|Control|No CT scan before CTO PCI
62208678|NCT03838120|OTHER|Bupivacaine 0,5% Single arm study|Bupivacaine 0,5% Single arm study
62406680|NCT02325206|EXPERIMENTAL|dapafliflozin|one administration of 10mg dapagliflozin as tablet
62406681|NCT02325206|PLACEBO_COMPARATOR|placebo|one administration as tablet identical to the experimental drug
62406682|NCT05170217|EXPERIMENTAL|CBD:THC 0:1|Inhalation of cannabis containing only THC
62406683|NCT05170217|EXPERIMENTAL|CBD:THC 1:1|Inhalation of cannabis containing THC and CBD
62406684|NCT05170217|EXPERIMENTAL|CBD:THC 2:1|Inhalation of cannabis containing THC and CBD
62581761|NCT01102257|EXPERIMENTAL|Omega-3 EFA Supplement|"The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 esssential fatty acid i.e Omega-3 EFA supplement comprised of:~2000 mg EPA 1000 mg DHA"
62789972|NCT02381015|EXPERIMENTAL|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Subjects receive genetic risk scores in a number and pictograph format.
62406685|NCT05170217|EXPERIMENTAL|CBD:THC 3:1|Inhalation of cannabis containing THC and CBD
62406686|NCT03673111|EXPERIMENTAL|1.0 mg|Y14 single dose, subcutaneous
62406687|NCT03673111|EXPERIMENTAL|2.0 mg|Y14 single dose, subcutaneous
62406688|NCT03673111|EXPERIMENTAL|6.0 mg|Y14 single dose, subcutaneous
62406689|NCT03673111|EXPERIMENTAL|9.0 mg|Y14 single dose, subcutaneous
62406690|NCT03673111|EXPERIMENTAL|18.0 mg|Y14 single dose, subcutaneous
62406691|NCT03673111|EXPERIMENTAL|36.0 mg|Y14 single dose, subcutaneous
62406692|NCT03673111|PLACEBO_COMPARATOR|Placebo|0.9% saline
62406693|NCT03673111|EXPERIMENTAL|26.0 mg (B1)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 9mg on day 1, 12mg on day 8, 16mg on day 15, 20mg on day 22 and 26mg on day 29.
62406694|NCT03673111|EXPERIMENTAL|36mg (B2)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 9mg on day 1, 24mg on day 8, 36mg on day 15, no dose on day 22 and 36mg on day 29.
62581762|NCT01102257|PLACEBO_COMPARATOR|Olive Oil|Gel Capsule
62789973|NCT02381015|EXPERIMENTAL|Family History: Number Format|Family History: Number Format Subjects receive family history risk in a number format.
62581763|NCT03880682||Study Group|Kidney transplant recipients with chronic HCV infection who were treated using direct acting antivirals.
62581764|NCT01180751|OTHER|[18F]-Fluorodeoxyglucose|Scanning Procedure: Non-diagnostic Computed Tomography (CT) scan followed by a Diagnostic Positron Emission Tomography (PET) scan.
62406695|NCT03673111|EXPERIMENTAL|36mg (B3)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 12mg on day 1, 24mg on day 8, 36mg on day 15, no dose on day 22 and 36mg on day 29.
62581765|NCT06178029|ACTIVE_COMPARATOR|conventional rehabilitation|20 multiple sclerosis patients will receive conventional rehabilitation
62406696|NCT03042338|EXPERIMENTAL|Central Executive Training1|Training tasks targeting working memory
62406697|NCT03042338|ACTIVE_COMPARATOR|Central Executive Training2|Training tasks targeting inhibitory control and response speed
62581766|NCT06178029|ACTIVE_COMPARATOR|conventional rehabilitation and acupuncture|20 multiple sclerosis patients will receive conventional rehabilitation and acupuncture treatment.
62018093|NCT02621762|EXPERIMENTAL|Bicarbonate first|Receives Bicarbonate first, MgCl2 and Bicarbonate in second phase
62406698|NCT05156060|EXPERIMENTAL|Gabapentin plus Ketamine|Gabapentin and Ketamine will be taken 3 times per day.
62581767|NCT05329363|EXPERIMENTAL|PEPITS programme|
62581768|NCT05329363|ACTIVE_COMPARATOR|Usual care|
62581769|NCT03069261||Intervention - ICG angiography|ICG-angiography was used intraoperatively after placement of the flap at the recipient cite, evaluating the viability and perfusion of the flap. Poor perfused areas were excised
62581770|NCT03069261||Control - clinical assessment|A control group receiving identical operations but without ICG-angiography evaluation.
62734462|NCT03046927|PLACEBO_COMPARATOR|Placebo|Oral administration of placebo one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
62734463|NCT04492748|EXPERIMENTAL|Collagen and PRP injections|Ultrasound guided injections
62208679|NCT05812820|PLACEBO_COMPARATOR|Control|"Control group receives the routine treatment and uses distilled water (RO) water~Routine treatment at Department of Gastroenterology, Vietnam National Children's Hospital is as follows:~* Antibiotics: oral (e.g. Zithromax® or Ciprofloxacin®) or intervention (ceftriaxone®, Ciprofloxacin®, Metronidazole®, Vancomycin®) drugs.~* Oral rehydration Solution: Oremute~* Zinc gluconate"
62208680|NCT05812820|EXPERIMENTAL|DIA30|"DIA 30 group receives the routine treatment and uses distilled water plus B. subtilis, B. clausii and B. coagulans at 5 billion CFU/5 mL (LiveSpo® DIA 30)~Routine treatment at Department of Gastroenterology, Vietnam National Children's Hospital is as follows:~* Antibiotics: oral (e.g. Zithromax® or Ciprofloxacin®) or intervention (ceftriaxone®, Ciprofloxacin®, Metronidazole®, Vancomycin®) drugs.~* Oral rehydration Solution: Oremute~* Zinc gluconate"
62581771|NCT04447027|EXPERIMENTAL|1- Experimental Treatment: Dose Escalation|Lenalidomide by oral intake at escalating doses of 5, 10, 15, or 20 mg/day on days -7 to 10 of each 21-day cycle (max 6 cycles) with CC-486 (5-azacitidine) at 300mg/day by oral intake on days 1-10, romidepsin at 12mg/m2 by IV infusion on Day 1 and 10 and dexamethasone at 40mg by oral intake on days 1 and 10 of each cycle, to determine MTD
62734464|NCT04492748|ACTIVE_COMPARATOR|Collagen injections|Ultrasound guided injections
62734465|NCT04492748|ACTIVE_COMPARATOR|PRP injections|Ultrasound guided injections
62734466|NCT01178476|EXPERIMENTAL|Hyposafe Hypoglycemia alarm device|EEG based hypoglycemia detection
62018094|NCT00066092|EXPERIMENTAL|Pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
62018095|NCT00066092|EXPERIMENTAL|Pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
62018096|NCT00066092|ACTIVE_COMPARATOR|filgrastim|Filgrastim given daily for PBPC mobilization
62018097|NCT01033747|EXPERIMENTAL|Deferasirox|Deferasirox group consists of all participants who were initially randomized to 10 and 20 mg/kg/day deferasirox orally daily in the main study and remained on the same treatment during the comparative prolongation study (NCT00379483) and at the beginning of the 5-year non-comparative study
62018098|NCT01033747|EXPERIMENTAL|Deferasirox Crossover|Deferasirox Crossover group consists of participants who were initially randomized to 40 mg/kg/day deferoxamine (DFO)subcutaneously in the main study and comparative prolongation study and crossed over to 5mg/kg/day to 30 mg/kg/day deferasirox orally daily at the beginning of the 5-year non-comparative extension study
62018099|NCT02080091||Chronic DME|Patients with vision impairment associated with chronic diabetic macular edema (DME)
62018100|NCT02664428|ACTIVE_COMPARATOR|PREBIOIL TEST|Product tests prepared with olives flour, buckwheat flour, pea flour, chestnut flour, oil chemical leavening agents, salt, sucrose. Baked
62018101|NCT02664428|PLACEBO_COMPARATOR|CONTROL|Product control prepared with wheat flour, oil, chemical leavening agents, salt, sucrose. Baked
62018102|NCT05089396|ACTIVE_COMPARATOR|conventional dentally anchored maxillary protraction|A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch). a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
62018103|NCT05089396|EXPERIMENTAL|skeletally anchored maxillary protraction|A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch) in addition, two miniscrews will be inserted in the anterior region of the palate one on each side of the midline to provide skeletal anchorage for the facemask splint. a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
62018104|NCT03041272||Nurses and nursing personnel|All registered nurses and assistive nursing personnel, including patient care associates (PCAs) , patient care technicians (PCTs), clinical technicians (CTs), primary employment on the study unit, minimum of 24 hours per week of employment on study unit.
62018105|NCT01554046|EXPERIMENTAL|couples of first-degree family members|
62018106|NCT06572709||Stroke patients|Ultrasonographic measurements were performed of the bilateral parasternal intercostal muscle thickness. Spirometry evaluation was performed by another investigator.
62018107|NCT06572709||Healthy individuals|Ultrasonographic measurements were performed of the dominant side parasternal intercostal muscle thickness. Spirometry evaluation was performed by another investigator.
62018108|NCT01427712||LipaCreon|"In general, pancrelipase 600 mg/dose was orally administered immediately after a meal, 3 times a day.~Also, the dose was adjusted appropriately according to the patient's condition."
62018109|NCT05853094|EXPERIMENTAL|Ileostomy|Protective ileostomy as a defunction mean after low anterior resection
62018110|NCT05853094|EXPERIMENTAL|Transverse colostomy|Protective transverse colostomy as a defunction mean after low anterior resection
62018111|NCT04980638|EXPERIMENTAL|ER004|Human immunoglobulin G1 constant region - human ectodysplasin-A1 receptor binding domain fusion protein.
62018112|NCT05148494|ACTIVE_COMPARATOR|Fleet Enema|Patient is to administer one sodium bisphosphate (Fleet) enema at home 2 hours prior to arrival for surgery and a second enema one hour prior to arrival for surgery. Each 120 mL application of rectally administered enema contains 19g of monobasic sodium phosphate and 9 g of dibasic sodium phosphate. Patient is to follow standard packaging instructions from the manufacturer.
62208681|NCT05812820|EXPERIMENTAL|CLAUSY|"CLAUSY group receives the routine treatment and uses distilled water plus B. clausii at 2 billion CFU/5 mL (LiveSpo® CLAUSY)~Routine treatment at Department of Gastroenterology, Vietnam National Children's Hospital is as follows:~* Antibiotics: oral (e.g. Zithromax® or Ciprofloxacin®) or intervention (ceftriaxone®, Ciprofloxacin®, Metronidazole®, Vancomycin®) drugs.~* Oral rehydration Solution: Oremute~* Zinc gluconate"
62208682|NCT02215525|EXPERIMENTAL|UVA and Herbal|Twenty four daily one hour sessions using Extra-corporeal electro-magnetic irradiation device combined with Herbal Food Supplement Selenium containing tables as an Anti Oxidant (Tablet A) starting 10 days before the radiation sessions and to continue for 24 weeks
62208683|NCT02215525|EXPERIMENTAL|Herbal|Chronic HCV patients, non complicated will be treated by Herbal tablets only . 500 mg twice tablets every 6 hours daily for 6 months.
62208684|NCT03363854|EXPERIMENTAL|Tralokinumab(initial)responders-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
62208685|NCT03363854|EXPERIMENTAL|Tralokinumab(initial)responders-> Tralokinumab(continuation B)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen B."
62208686|NCT03363854|EXPERIMENTAL|Tralokinumab(initial)non-respon-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
62406699|NCT01959217|EXPERIMENTAL|PM Component Text Reminders|There will be a a single face-to-face intervention followed by tailored text reminders. The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text message reminders will be determined by Phase 1.
62406700|NCT02290652||Prospective|Prospective - Factors affecting sexual function pre-THR
62018113|NCT05148494|ACTIVE_COMPARATOR|Pico Salax|Patient is to take Pico Salax oral bowel preparation which is a combination product consisting of 10 mg picosulfate sodium, 3.5 g magnesium oxide, and 12 g citric acid per sachet the day prior to surgery. Patient is to take 2 doses of this product, as per standard packaging instructions from the manufacturer. Specifically patient is to take the first packet contents dissolved in 150 mL water at 3pm the day before surgery. Patient is to take the second packet dissolved in 150 mL water at 8pm the day before surgery. Patient should drink 2-3L of clear liquids after each dose, for a total of 4-6L.
62208687|NCT03363854|EXPERIMENTAL|Placebo (initial)non-respon-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
62406701|NCT02290652||Retrospective|Retrospective- Factors affecting sexual function post-THR
62406702|NCT03597126|ACTIVE_COMPARATOR|robot-assisted ISR|Patients with low rectal cancer undergo intersphincteric resection assisted by Robotic
62406703|NCT03597126|ACTIVE_COMPARATOR|laparoscopic ISR|Patients with low rectal cancer undergo laparosocopic intersphincteric resection
62406704|NCT04054323|EXPERIMENTAL|Patient Physical Activity Arm|Patients only receive physical activity intervention.
62406705|NCT04054323|EXPERIMENTAL|Dyadic Physical Activity Arm|Patients and caregivers both receive physical activity intervention.
62406706|NCT06421662|EXPERIMENTAL|Study Group|Thirty pregnant women between 28th and 38th gestational weeks who applied to the outpatient clinic of a training and research hospital were included in the study group. During the training, 7 participants were excluded due to premature birth.
62406707|NCT06421662|NO_INTERVENTION|Control Group|"Thirty-one pregnant women between 28th and 38th gestational weeks who applied to the outpatient clinic of a training and research hospital were included in the control group. The control group was administered only the Maternal Attachment Inventory  developed by Mary Muller in 1994 and the Turkish validity and reliability study was conducted by Şirin and Kavlak at the 8th week after birth."
62406708|NCT05163249|ACTIVE_COMPARATOR|Cohort 1: osimertinib, 80mg, daily, P.O.|"Patients will continue to receive study medication in 28 day cycles until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criterion is met.~Patients who progress on first-line treatment of osimertinib monotherapy will have the opportunity to receive second-line treatment of osimertinib plus savolitinib after confirmation of MET status at disease progression."
62581772|NCT04447027|EXPERIMENTAL|2 - Experimental Treatment: Dose Expansion|Lenalidomide by oral intake at MTD on days -7 to 10 of each 21-day cycle (max 6 cycles) with CC-486 (5-azacitidine) at 300mg/day by oral intake on days 1-10, romidepsin at 12mg/m2 by IV infusion on Day 1 and 10 and dexamethasone at 40mg by oral intake on days 1 and 10 of each cycle
62734467|NCT01178476|ACTIVE_COMPARATOR|Regular glucose control|Regular glucose control group
62406709|NCT05163249|EXPERIMENTAL|Cohort 2: osimertinib 80mg daily, P.O. and savolitinib 300mg BID, P.O.|"All eligible patients will be randomized to receive treatment with osimertinib (80 mg daily) or osimertinib (80 mg daily) in combination with savolitinib (300 mg BID) in this study. Treatment will continue until either objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criterion is met.~Patients in Cohort 2 can continue on savolitinib monotherapy (if osimertinib was stopped earlier) or osimertinib monotherapy (if savolitinib was stopped earlier) until objective disease progression or meet any of the discontinuation criteria."
62734468|NCT03275246|EXPERIMENTAL|Total knee arthroplasty|Patients undergoing total knee arthroplasty
62018114|NCT05655182|EXPERIMENTAL|Group 1, infants (age 18-59 months), RSV+, BLB201 10^6 PFU|6 RSV seropositive participants will be administered 10\^6 PFU BLB-201 by intranasal route on Day 1
62018115|NCT05655182|PLACEBO_COMPARATOR|Group 1, infants (age 18-59 months), RSV+, Placebo|4 RSV seropositive participants will be administered placebo by intranasal route on Day 1
62208688|NCT03363854|PLACEBO_COMPARATOR|Placebo(initial)responders-> Placebo(continuation A)|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 32 (continuation period):~Placebo continuation SC injection regimen A."
62208689|NCT01540864|EXPERIMENTAL|HPP404 35 mg|
62406710|NCT04985825|EXPERIMENTAL|Imgatuzumab monotherapy|
62018116|NCT05655182|EXPERIMENTAL|Group 2, infants (age 18-59 months), RSV+, BLB201 10^7 PFU|6 RSV seropositive participants will be administered 10\^7 PFU BLB-201 by intranasal route on Day 1
62208690|NCT01540864|EXPERIMENTAL|HPP404 50 mg|
62208691|NCT01540864|PLACEBO_COMPARATOR|Placebo|
62406711|NCT01752608|EXPERIMENTAL|eCBT Mood|Electronic cognitive behavioral therapy application running on the iPhone and iPod Touch.
62406712|NCT01752608|NO_INTERVENTION|Mood Tracker|Mood monitoring application running on the iPhone and iPod Touch
62406713|NCT04899362|EXPERIMENTAL|RIC group|RIC was induced by 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation).All subjects will take 14 RIC intervention, blood collection and 10 dCA measurements.
62406714|NCT00572910|EXPERIMENTAL|V710 - Group 1|V710 (60 mcg without MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
62406715|NCT00572910|EXPERIMENTAL|V710 - Group 2|V710 (60 mcg without MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
62734469|NCT02125838|ACTIVE_COMPARATOR|Group ETT|Group endotracheal tube In the endotracheal tube group for women no. 7-7.5 tube will use. ETT:Rüschelit, Teleflex Medical Sdn. Bhd. Malaysia. Ref:112482
62789974|NCT02381015|EXPERIMENTAL|Family History: Number + Pictograph|Family History: Number + Pictograph Subjects receive family history risk in a number and pictograph format.
62018117|NCT05655182|PLACEBO_COMPARATOR|Group 2, infants (age 18-59 months), RSV+, Placebo|4 RSV seropositive participants will be administered placebo by intranasal route on Day 1
62406716|NCT00572910|EXPERIMENTAL|V710 - Group 3|V710 (60 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
62406717|NCT00572910|EXPERIMENTAL|V710 - Group 4|V710 (60 mcg with MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
62406718|NCT00572910|EXPERIMENTAL|V710 - Group 5|V710 (90 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
62406719|NCT00572910|PLACEBO_COMPARATOR|Group 6|Placebo on Day 1, 28 and 180.
62406720|NCT03143075|ACTIVE_COMPARATOR|Inflammation group|Subjects with CRP≥3, will receive eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, for 8 weeks, added to their pre-stabilized antidepressant medication
62406721|NCT03143075|ACTIVE_COMPARATOR|Non-inflammation group|Subjects with CRP\<3, will receive eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, for 8 weeks, added to their pre-stabilized antidepressant medication
62018118|NCT05655182|EXPERIMENTAL|Group 3, children (age 8-24 months), RSV+ or RSV-, BLB201 10^6 PFU|16 participants will be administered BLB201 10\^6 PFU by intranasal route on Day 1
62018119|NCT05655182|PLACEBO_COMPARATOR|Group 3, children (age 8-24 months), RSV+ or RSV-, Placebo|8 participants will be administered placebo by intranasal route on Day 1
62018120|NCT05655182|EXPERIMENTAL|Group 4, children (age 6-24 months), RSV+ or RSV-, BLB201 10^7 PFU|32 participants will be administered BLB201 10\^7 PFU by intranasal route on Day 1
62406722|NCT04205864|ACTIVE_COMPARATOR|Conventional pelvic lymphadenectomy|Conventional pelvic lymphadenectomy
62406723|NCT04205864|EXPERIMENTAL|Thrombin gel matrix pelvic lymphadenectomy|Thrombin gel matrix applicated after conventional pelvic lymphadenectomy
62406724|NCT02332044|EXPERIMENTAL|Erdosteine 300mg|
62406725|NCT02332044|EXPERIMENTAL|Bepotastine besilate 10mg|
62734470|NCT02125838|EXPERIMENTAL|Group LMS|Laryngeal mask airway-supreme Group In the LMS group for \<50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) will insert.
62789975|NCT03030469|EXPERIMENTAL|10-pill default|"The intervention condition consists of a change to the electronic health record so that new opioid analgesic prescriptions automatically default to 10 pills (i.e., the quantity dispensed field is pre-populated). This value is modifiable by providers who can tailor the prescription based on clinical factors."
62789976|NCT03030469|EXPERIMENTAL|5-pill default|New opioid analgesic prescriptions will automatically default to 5 pills.
62789977|NCT03030469|NO_INTERVENTION|Standard of care|The control condition will be the usual electronic health record interface. The default number of pills varies by medication, most medications currently have either a blank default or a default of 30 pills.
62789978|NCT04859426|EXPERIMENTAL|Mild Hepatic Impairment|Subjects will receive a single dose of 100 mg DBPR108.
62018121|NCT05655182|ACTIVE_COMPARATOR|Group 4, children (age 8-24 months), RSV+ or RSV-, Placebo|16 participants will be administered placebo by intranasal route on Day 1
62208692|NCT00452777|EXPERIMENTAL|BVT.115959|Capsules containing 7 mg BVT.115959 administered orally three times daily
62208693|NCT00452777|PLACEBO_COMPARATOR|Placebo|Placebo capsules administered orally three times daily
62208694|NCT03539588|ACTIVE_COMPARATOR|Treatment group 1|In this group participants will receive trigger point dry needling with electrical stimulation first and receive trigger point needling by itself second. Only MYOTECH dry needles will be used in this study. However we are not studying the equipment.
62208695|NCT03539588|ACTIVE_COMPARATOR|Treatment Group 2|In this group the participants will receive trigger point dry needling first and receive trigger point dry needling with electrical stimulation second. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
62208696|NCT03227406|NO_INTERVENTION|Daytime Wake|Subjects are trained and retested during a single period of daytime wake
62018122|NCT05655182|EXPERIMENTAL|Group 6, children (age 8-24 months), RSV+ or RSV-, BLB201 10^7 PFU|30 participants will be administered BLB201 10\^7 PFU by intranasal route on Day 1 and Day 57
62406726|NCT02332044|EXPERIMENTAL|Erdosteine 300mg + Bepotastine besilate 10mg|
62018123|NCT05655182|PLACEBO_COMPARATOR|Group 6, children (age 8-24 months), RSV+ or RSV-, Placebo|15 participants will be administered Placebo by intranasal route on Day 1 and Day 57
62208697|NCT03227406|NO_INTERVENTION|Overnight sleep|Subjects are trained on one day and tested the next day, after a night of normal sleep
62208698|NCT03227406|EXPERIMENTAL|Sleep deprivation|Subjects are trained on one day and tested the next day, after a night of sleep deprivation
62208699|NCT03227406|EXPERIMENTAL|Daytime Nap|Subjects are trained and then retested after a daytime nap
62018124|NCT02516059|ACTIVE_COMPARATOR|Oxycodone and naloxone (Targin®)|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
62208700|NCT00704405|EXPERIMENTAL|24-wk Vaniprevir 600 mg + Peg-IFN/RBV|Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 24 weeks.
62208701|NCT00704405|EXPERIMENTAL|24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV|Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for an additional 24 weeks.
62018125|NCT02516059|ACTIVE_COMPARATOR|Oxycodone (Oxycontin®)|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
62208702|NCT00704405|EXPERIMENTAL|48-wk Vaniprevir 300 mg + Peg-IFN/RBV|Vaniprevir 300 mg (total daily dose, taken once daily \[q.d.\]) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
62208703|NCT00704405|EXPERIMENTAL|48-wk Vaniprevir 600 mg + Peg-IFN/RBV|Vaniprevir 600 mg and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
62208704|NCT00704405|PLACEBO_COMPARATOR|48-wk PBO + Peg-IFN/RBV|PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
62406727|NCT02333110|EXPERIMENTAL|GRID radiation therapy|A single dose of 15-20Gys of spatially fractionated radiation therapy
62406728|NCT04897724|OTHER|patients have carious lesions in one or more surface of molars and premolars|patients received direct composite restorations using a nanohybrid and a nonofil composite restorations
62789979|NCT04859426|EXPERIMENTAL|Moderate Hepatic Impairment|Subjects will receive a single dose of 100 mg DBPR108.
62789980|NCT04859426|EXPERIMENTAL|Normal hepatic function|Subjects will receive a single dose of 100 mg DBPR108.
62789981|NCT01426022|PLACEBO_COMPARATOR|Alcohol|"1. 3 glasses of sparkling white wine (30g alcohol) with dinner~2. 3 glasses of alcohol free sparkling white wine (\<2g alcohol) with dinner"
62789982|NCT01426022|EXPERIMENTAL|Ambiance|"1. Pleasant ambiance~2. Unpleasant ambiance"
62789983|NCT02542826|EXPERIMENTAL|Pulmonary Rehabilitation|
62789984|NCT04395690|ACTIVE_COMPARATOR|Inferior Alveolar Block Nerve (IABN)|Inferior Alveolar Block Nerve (IABN) anesthesia technique before posterior mandibular implant placement.
62789985|NCT04395690|EXPERIMENTAL|Infiltration (INF)|Infiltration (INF) anesthesia technique before posterior mandibular implant placement.
62789986|NCT04521985||thoracolumbar kyphosis|patients undergoing thoracolumbar kyphosis surgery
62789987|NCT05017467|EXPERIMENTAL|vss|Vancouver Scar Scale (VSS) at the one, three and 6 months after surgery
62789988|NCT05017467|EXPERIMENTAL|QuickDASH , VAS|, Quick Disabilities of Arm Shoulder and Hand functional score (QuickDASH) and Visual Analogue Scale (VAS) test was used to determine overall hand function, activities of daily living, work performance, pain, aesthetics, and satisfaction with hand function
62018126|NCT02516059|PLACEBO_COMPARATOR|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
62018127|NCT02588118||male group|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
62406729|NCT01959282|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive placebo through Week 32. Participants not in clinical response at Week 8 will receive treatment with 150 mg JNJ-54781532 orally once daily from Week 8 to Week 16. Participants who achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) at Week 16 can continue receiving 150 mg JNJ-54781532 orally once daily through Week 32
62789989|NCT02618161|EXPERIMENTAL|Arm A|HDR Brachytherapy single dose of 15 Gy followed by EBRT of 46 Gy in 23 fractions and Androgen deprivation therapy 6 months to 3 years, (sequencing of HDR followed by EBRT)
62789990|NCT02618161|ACTIVE_COMPARATOR|ARM B|External Beam Radiotherapy (EBRT) of 46 Gy in 23 fractions, followed by single dose of HDR brachytherapy of 15 Gy boost and Androgen deprivation therapy 6 months to 3 years (timing of HDR Brachytherapy Treatment is changed compared to ARM A)
62018128|NCT02588118||female group|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
62208705|NCT04620343|ACTIVE_COMPARATOR|Phase 1, Group 1|"Patients are provided with basic information and breathing advice with biofeedback (IBA).~This is the reference treatment against which the other methods will be measured."
62406730|NCT01959282|EXPERIMENTAL|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 25 mg once daily through Week 32
62406731|NCT01959282|EXPERIMENTAL|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg once daily through Week 32
62789991|NCT04499560|EXPERIMENTAL|Intervention|Participants consume 2 ounces of the supplement each morning for 60 days.
62789992|NCT04499560|NO_INTERVENTION|Control|Participants do not make any changes to their health related routines
62018129|NCT05442411|EXPERIMENTAL|post operative pain score|post operative pain score at 1hour, 2 hour, 4 hour, 6 hour, and 12 hour
62789993|NCT00275067|EXPERIMENTAL|Radiation + temozolomide and arsenic trioxide|Radiation therapy followed by the combination of temozolomide and arsenic trioxide at the maximum tolerated dose determined in phase 1
62789994|NCT01096693|PLACEBO_COMPARATOR|Saline Placebo|In this arm, the response in forearm blood flow to incremental doses of Urocortins 2, 3 and Substance P will be studied co infused with saline placebo.
62789995|NCT01096693|ACTIVE_COMPARATOR|Response to Urocortin infusion in presence of Astressin 2B|This arm studies the response to intra arterial infusion of incremental doses of Urocortins 2, 3 and Substance P in the presence or absence of a selective antagonist - Astressin 2B.
62789996|NCT03127176||BD with cognitive impairment|"This group will include euthymic patients with bipolar disorder type I or II (YMRS\<6 and HMDRS\<8) and cognitive impairment.~Intervention: Genome sequencing of fecal samples"
62789997|NCT03127176||BD without cognitive impairment|"This group will include euthymic patients with bipolar disorder type I or II (YMRS\<6 and HMDRS\<8) without cognitive impairment.~Intervention: Genome sequencing of fecal samples"
62789998|NCT03127176||Control group|This group will include healthy volunteers. Intervention: Genome sequencing of fecal samples
62789999|NCT01687101|EXPERIMENTAL|STOPAIN topical gel|STOPAIN gel which is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
62018130|NCT05442411|EXPERIMENTAL|morphine requirement|post operative PCA morphine requirement
62018131|NCT06531525|EXPERIMENTAL|The combination group|Subjects randomized to the combination group will receive daily injections of enoxaparin at a dose of 4000 IU and aspirin 75mg per day orally until delivery.
62208706|NCT04620343|EXPERIMENTAL|Phase 1, Group 2|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with inspiratory muscle training (IMT)
62208707|NCT04620343|EXPERIMENTAL|Phase 1, Group 3|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with speech therapy
62208708|NCT04620343|EXPERIMENTAL|Phase 1, Group 4|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with inspiratory muscle training (IMT) and speech therapy
62208709|NCT04620343|NO_INTERVENTION|Phase 2, Group 1|Groups 2,3,4 in Phase 1 Wait for therapy effect
62208710|NCT04620343|EXPERIMENTAL|Phase 2, Group 2|If patients from Phase 1, Group 1 (reference treatment) have unchanged CLE-scoring, they are treated with inspiratory muscle training (IMT) and speech therapy.
62208711|NCT04620343|EXPERIMENTAL|Phase 3, Group 1|Treated with Surgery, supraglottoplasty - full procedure
62208712|NCT04620343|EXPERIMENTAL|Phase 3, Group 2|Treated with Surgery, supraglottoplasty mini-invasive procedure
62208713|NCT04620343|NO_INTERVENTION|Phase3, Group 3|Non-surgery control group
62208714|NCT03476759|ACTIVE_COMPARATOR|Tubal adhesiolysis|laparoscopic tubal adhesiolysis and\\or tuboplasty
62208715|NCT03476759|ACTIVE_COMPARATOR|IVF/ICSI|These patients will undergo IVF/ICSI
62208716|NCT04445532||hepatobiliary tumor patients|benign or malignant hepatobiliary tumors patients
62208717|NCT04445532||Benign Hepatobiliary Disease|chronic hepatitis, cirrhosis, and healthy control
62018132|NCT06531525|ACTIVE_COMPARATOR|The Aspirin group|Aspirin will be given at a dose of 75mg, orally, each day until delivery.
62018133|NCT06531525|NO_INTERVENTION|No intervention|No intervention
62018134|NCT06531525|OTHER|All groups|Participants in all groups will receive daily injections of enoxaparin at a dose of 4000 IU within 6 weeks at postpartum.
62018135|NCT03884972|EXPERIMENTAL|Cohort I (BTK-refractory)|Patients receive venetoclax PO QD beginning on day 1 for 5 weeks (cycle 1). Beginning in cycle 2, patients receive venetoclax PO QD and trabectedin IV over 3 hours on day 1. Cycles 2+ repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62406732|NCT01959282|EXPERIMENTAL|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 150 mg once daily through Week 32
62406733|NCT01959282|EXPERIMENTAL|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg twice daily through Week 32
62406734|NCT06651333||Methadone|Participants initiated into methadone within the past 6 months will receive fMRI and cognitive assessment battery.
62406735|NCT06651333||Buprenorphrine|Participants initiated into buprenorphine within the past 6 months will receive fMRI and cognitive assessment battery.
62790000|NCT03658733|EXPERIMENTAL|Esomeprazole-containing therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole,amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.~Drugs: 1. esomeprazole 40mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the first 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
62790001|NCT03658733|ACTIVE_COMPARATOR|Rabeprazole-containing therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.~Drugs: 1. rabeprazole 20mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the first 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
62790002|NCT05081206|EXPERIMENTAL|Manually controlled|
62790003|NCT05081206|EXPERIMENTAL|Target controlled|
62790004|NCT04137185|EXPERIMENTAL|rhTSH|Phase 1: 0.9mgx1d、0.9mgx2d、1.8mgx1d、1.8mgx2d, intramuscularly (IM) ; Phase 2: patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the Phase 1.
62790005|NCT04895826||Back pain and no back pain|Participants with and without back pain will be included in the study and they will be asked to perform standard functional movements that would be used for a physiotherapy assessment for a back condition. The participants will also perform these movements in front of a camera for video recordings to be analysed by the CV system. The measurements by the CV system will be compared to the measurements by the physiotherapist. Additionally, participants will perform and record videos of the same set of movements at home to test the feasibility of the CV system in a home environment.
62406736|NCT04478994|ACTIVE_COMPARATOR|TEPEZZA 20mg/kg|Approximately 15 participants will receive 8 infusions of TEPEZZA q3W for a total of 21 weeks. TEPEZZA 10mg/kg will be administered on Day 1 and TEPEZZA 20mg/kg will be administered q3W for the remaining 7 infusions.
62018136|NCT03884972|EXPERIMENTAL|Cohort II (BTK-intolerant)|Patients receive trabectedin IV over 3 hours on day 1 of a 3-week cycle (cycle 1), then receive venetoclax PO QD beginning on day 1 of a 5-week cycle (cycle 2). Beginning in cycle 3, patients receive trabectedin IV over 3 hours on day 1 and venetoclax PO QD every 3 weeks in the absence of disease progression or unacceptable toxicity.
62018137|NCT06368128|NO_INTERVENTION|Control|Participants in the control arm will be asked to maintain their current lifestyle behaviors.
62581773|NCT06684392|NO_INTERVENTION|Control group|The control group will follow the current protocol at HRLBO. This involves a weaning protocol from mechanical ventilation 24 hours after tracheostomy placement. Initial disconnection windows are 2 hours in the morning and 2 hours in the afternoon. If tolerated, the next day's windows are extended to 4 hours each. On the third day, the windows are extended to 6 hours each. On the fourth day, a continuous 12-hour disconnection is attempted, progressing to 24 hours if successful. Additionally, subjects will train at 50% of their maximum inspiratory pressure (MIP) in 5 sets of 6 breaths once weaned from mechanical ventilation. If tracheostomy tube occlusion (defined as temporary closure of airflow through the tracheostomy tube, using physiological ventilation) is achieved for 24 hours and the decannulation criteria are met, the tracheostomy tube will be removed.
62018138|NCT06368128|EXPERIMENTAL|Intervention|Participants in the intervention arm will be asked to partake in a 12-week progressive, supervised, indoor rock climbing training program.
62018139|NCT03345563|EXPERIMENTAL|Body Mind Training (BMT)|Body mind training
62018140|NCT03345563|ACTIVE_COMPARATOR|Body Training (BT)|Body training only
62018141|NCT03345563|OTHER|Usual care (UC):|Control
62018142|NCT02526134|EXPERIMENTAL|Laying of medical devices|radio opaque markers
62018143|NCT05924828||Healthy|participants without periodontitis
62018144|NCT05924828||periodontitis|participants with stage-3 periodontitis
62018145|NCT04327284|EXPERIMENTAL|test group|The test group will receive immediate molar implant placement in fresh extraction socket with nonocclusal loading immediate provisionalization (Straumann BLX 6.5mm).
62018146|NCT04327284|ACTIVE_COMPARATOR|Control group|The control group will receive delayed molar implant placement at least 12 weeks post molar extraction with nonocclusal loading immediate provisionalization (Straumann BLX 5.0mm).
62018147|NCT05297045|EXPERIMENTAL|Dose Group A|
62018148|NCT05297045|EXPERIMENTAL|Dose Group B|
62018149|NCT05297045|EXPERIMENTAL|Dose Group C|
62018150|NCT05297045|EXPERIMENTAL|Dose Group D|
62208718|NCT04731519|ACTIVE_COMPARATOR|General Health Education Active Control Group|The control condition will receive General Health Education a structured manualized group health education intervention previously developed by VISN 2 MIRECC investigators as a control condition for group psychotherapy RCTs. It has 12 1.5-hour weekly group sessions focusing on health and wellness topics such as Sleep, Physical Activity, Impact of Stress, Relaxation Techniques, Substance Use, Nutrition, Managing Daily Activities, Medication Benefits and Side Effects. GHE was chosen for the AC because it aligns in many respects with CI-CT (e.g., group format, length of sessions, similar expectations) while diverging in specific topics and skills targeted allowing for control of common factors like attention without causing confounding due to overlap in concepts
62208719|NCT04731519|EXPERIMENTAL|CI-CT Group|The experimental group will receive CI-CT (Continuous Identity Cognitive Therapy). CI-CT is planned to be a weekly, 90-minute, 12-session group treatment and to be run by two clinicians using the final version manual and workbook. CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The CI-CT includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
62018151|NCT05297045|EXPERIMENTAL|Dose Group E|
62018152|NCT05297045|EXPERIMENTAL|Dose Group F|
62406737|NCT04478994|PLACEBO_COMPARATOR|Placebo|Approximately 10 participants will receive 8 infusions of placebo q3W for a total of 21 weeks.
62406738|NCT01079000|ACTIVE_COMPARATOR|Control - usual care (UC)|Usual care after an ED visit for asthma will include the provision of discharge instructions/plan, and action plan, and verbal instructions for follow-up with their PCP, and a faxed copy of the ED chart to the patient's PCP.
62018153|NCT05297045|PLACEBO_COMPARATOR|Placebo Group|
62018154|NCT05296616|EXPERIMENTAL|MSQSLHRV|The group in which the mindfulness-based stress reduction intervention will be implemented.
62018155|NCT05296616|NO_INTERVENTION|Control|The group to which mindfulness-based stress reduction intervention will not be applied
62018156|NCT03757559|EXPERIMENTAL|Cebranopadol 200 micrograms (Treatment A)|"Cebranopadol 200 micrograms (low dose): Participants took 2 tablets (cebranopadol 100 micrograms) as a single dose.~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
62018157|NCT03757559|EXPERIMENTAL|Cebranopadol 400 micrograms (Treatment B)|"Cebranopadol 400 micrograms (medium dose): Participants took 2 tablets (cebranopadol 400 micrograms plus matching placebo) as a single dose.~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
62018158|NCT03757559|EXPERIMENTAL|Cebranopadol 800 micrograms (Treatment C)|"Cebranopadol 800 micrograms (high dose): Participants took 2 tablets containing cebranopadol 400 micrograms as a single dose.~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
62018159|NCT03757559|ACTIVE_COMPARATOR|Hydromorphone IR 8 milligrams (Treatment D)|"Hydromorphone immediate-release (IR) 8 milligrams: Participants took 4 capsules (2 capsules of hydromorphone hydrochloride 4 mg plus 2 placebo capsules) as a single dose.~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
62406739|NCT01079000|EXPERIMENTAL|Opinion leader (OL) guidance to patients' PCPs|In addition to UC, OL guidance will be provided to the patients' PCP. A letter signed by an influential, respected, and local clinical leader (Respirologist) will encourage follow-up within two weeks and provide management suggestions.
62406740|NCT01079000|EXPERIMENTAL|Care manager education to patients|In addition to UC and OL guidance provided to the patients' PCP, care manager self-management education will be provided to patients. A care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged.
62018160|NCT03757559|ACTIVE_COMPARATOR|Hydromorphone IR 16 milligrams (Treatment E)|"Hydromorphone immediate-release (IR) 16 milligrams: Participants took 4 capsules of hydromorphone hydrochloride 4 mg as a single dose.~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
62406741|NCT04666935|EXPERIMENTAL|Intervention group|The intervention group will be instructed to include the Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program as a warm up before training session (3 times per week) during one season (6 months).
62734471|NCT02290496|EXPERIMENTAL|CBT for Insomnia (CBT-I)|Cognitive behavior therapy to improve sleep and depression.
62018161|NCT03757559|PLACEBO_COMPARATOR|Placebo (Treatment F)|"Placebo: Participants took 4 placebo capsules matching hydromorphone capsules as a single dose.~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
62208720|NCT04731519|OTHER|CI-CT Treatment Development Group|The 3 treatment development groups will receive CI-CT (Continuous Identity Cognitive Therapy). CI-CT is planned to be a weekly, 90-minute, 12-session group treatment and to be run by two clinicians using the final version manual and workbook. CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The CI-CT includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
62018162|NCT03757559|PLACEBO_COMPARATOR|Placebo (Treatment G)|"Placebo (following Treatment C): Participants took 2 placebo tablets matching cebranopadol tablets as a single dose.~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
62208721|NCT02207504|EXPERIMENTAL|crizotinib and enzalutamide|"A traditional 3+3 dose escalation scheme will be used to identify the recommended phase 2 dose (RP2D) of crizotinib when used in combination with standard fixed dose enzalutamide.~* Crizotinib- given orally daily-28 day cycle~* Enzalutamide- given orally daily-28 day cycle"
62208722|NCT03423628|EXPERIMENTAL|AZD1390 + Radiation Therapy|AZD1390 + Radiation Therapy
62406742|NCT04666935|ACTIVE_COMPARATOR|Control group|The control group will practice their usual warm up. Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
62406743|NCT03804060|EXPERIMENTAL|Cooling + Recanalization|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Thermogard XP3 IVTM System before and after recanalization.
62406744|NCT03804060|ACTIVE_COMPARATOR|Recanalization only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow recanalization only.
62406745|NCT01294865||septic|Infants having clinical suspected late-onset neonatal sepsis enrolled in the study. Blood samples for suPAR were obtained before initiating antibiotic treatment and at the end of the treatment with other laboratory tests.
62406746|NCT01294865||non-septic|Infants without any clinical or hematological septic signs. Blood samples will be taken only once.
62406747|NCT05208710|EXPERIMENTAL|PANHPVAX 10µg|PANHPVAX 10µg plus c-di AMP in escalating doses
62406748|NCT05208710|EXPERIMENTAL|PANHPVAX 40µg|PANHPVAX 40µg plus c-di AMP in escalating doses
62406749|NCT05208710|EXPERIMENTAL|PANHPVAX 100µg|PANHPVAX 100µg plus c-di AMP in escalating doses
62406750|NCT03055273|EXPERIMENTAL|SOCIABLE IMMEDIATE|Receive services now
62406751|NCT03055273|ACTIVE_COMPARATOR|SOCIABLE wait list|Receive services four months post-enrollment
62581774|NCT06684392|EXPERIMENTAL|Experimental Group|The intervention group will follow the current HRLBO protocol, with the addition of an Inspiratory Muscle Training (IMT) regimen. Subjects will train only inspiratory muscle strength if they do not achieve weaning or complete disconnection from mechanical ventilation. Once they achieve weaning or disconnection, the new IMT regimen, combining strength and endurance training, will begin. On days when MIP evaluation is scheduled according to the IMT protocol, training time will be replaced by evaluation to avoid excessive ventilatory workload, limiting training to once a day. If a patient exhibits two or more clinical criteria for respiratory failure, IMT will be suspended for that day. These criteria include: RR \> 35 bpm; SpO2 \< 88%; HR \> 130 bpm; SBP \> 180 mmHg or \< 90 mmHg; Modified Borg score \> 6, signs of agitation, sweating, or altered consciousness.
62581775|NCT01925066|EXPERIMENTAL|Aerosolized Vancomycin|
62581776|NCT05164484|OTHER|Transpulmonary thermodilution in patients implanted with VV-ECMO during standard care for ARDS|Standard of care procedure for patient with severe ARDS
62018163|NCT05940285|EXPERIMENTAL|Single arm study|Patients included in the study will undergo subsequently at 1-month after acute coronary syndrome Dynamic 99mTc-Tetrofosmin CZT-SPECT followed by FFR and IMR assessment
62018164|NCT01266239|ACTIVE_COMPARATOR|SES-KB|Sirolimus-eluting stent (SES) is deployed in the main vessel (MV)and subsequent kissing balloon inflation is performed in the bifurcation.
62018165|NCT01266239|ACTIVE_COMPARATOR|SES-NK|SES is deployed in the MV without kissing balloon inflation.
62018166|NCT01266239|ACTIVE_COMPARATOR|EES-KB|Everolimus-eluting stent (EES) is deployed in the MV and subsequent kissing balloon inflation is performed in the bifurcation.
62018167|NCT01266239|ACTIVE_COMPARATOR|EES-NK|EES is deployed in the MV without kissing balloon inflation.
62018168|NCT03109834|ACTIVE_COMPARATOR|Meal replacement (MR) group|"Energy-restricted modified diet with MR for weight control dietary supplement: MR shakes, soups or bars. Duration: 3-month weight loss phase (phase 1)~During weight stabilization phase (phase 2) MR counted to food choice option."
62018169|NCT03109834|OTHER|Control (C) group|"Energy-restricted modified diet without MR for weight control. Duration: 3-month weight loss phase (phase 1)~During 3-month weight stabilization phase (phase 2) MR counted to food choice option."
62406752|NCT00592137|PLACEBO_COMPARATOR|C|During one three week session of a controlled diet subjects will receive a smoothie based on soy protein two times per day that does not contain any additional calcium
62406753|NCT00592137|ACTIVE_COMPARATOR|B|During one three week period half of the participants will receive two smoothies per day based on soy protein that contain 650 mg Ca as calcium carbonate
62406754|NCT00592137|ACTIVE_COMPARATOR|A|During one three week session subjects will receive two smoothies per day based on dairy protein containing 650 mg calcium
62018170|NCT03109834|ACTIVE_COMPARATOR|Verum group|"Specific micronutrient composition with omega-3 fatty acids (capsules)~Duration: 6-month weight maintenance phase (phase 3)"
62018171|NCT03109834|PLACEBO_COMPARATOR|Placebo group|"Placebo capsules~Duration: 6-month weight maintenance phase (phase 3)"
62018172|NCT00710333|PLACEBO_COMPARATOR|1|500ng dose
62018173|NCT00710333|EXPERIMENTAL|2|
62018174|NCT06377735|EXPERIMENTAL|BAI-BACE|Bronchial arterial infusion, bronchial arterial chemoembolization (BACE-BAI)
62018175|NCT04167397|EXPERIMENTAL|Single training|Initial training individually
62018176|NCT04167397|EXPERIMENTAL|Dyad training|Initial training in groups of 2
62018177|NCT04167397|EXPERIMENTAL|Triad training|Initial training in groups of 3
62018178|NCT04167397|EXPERIMENTAL|Tetrad training|Initial training in groups of 4
62018179|NCT02682654|EXPERIMENTAL|Ankle/Knee brace|Dr. Scholl's Prototype Ankle or Knee Brace
62018180|NCT01183091||First AF ablation|Description of the patients experiencing an AF ablation
62018181|NCT03424746|EXPERIMENTAL|Open label EDTA chelation|EDTA-based chelation therapy plus vitamins in diabetic patients with severe peripheral artery disease presenting with impending amputation and determine if there is an improvement in outcomes and a delay or reduction of amputations.
62018182|NCT02829034|ACTIVE_COMPARATOR|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increase to 1000mg by mouth twice per day
62018183|NCT02829034|PLACEBO_COMPARATOR|Placebo|Placebo by mouth twice per day
62018184|NCT06572189|EXPERIMENTAL|CD-801, a lipid nanoparticle-encapsulated self-replicating RNA encoding hepatocyte nuclear factor 4α|Patients will receive administration of 100μg of CD-801 via hepatic arterial injection every 14 ± 3 days
62018185|NCT01351805|EXPERIMENTAL|Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
62018186|NCT01351805|EXPERIMENTAL|Vitamin D|Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.
62018187|NCT01351805|PLACEBO_COMPARATOR|placebo|Subjects will receive placebo pill.
62018188|NCT01351805|EXPERIMENTAL|Vitamin D and Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
62018189|NCT02348164|EXPERIMENTAL|Treatment 1|Volunteers receive pink grapefruit first followed by tangerines two weeks later
62018190|NCT02348164|EXPERIMENTAL|Treatment 2|Volunteers receive tangerines first followed by pink grapefruit two weeks later
62208723|NCT06575842||Pediatric patients undergoing anesthesia|Pediatric patients who are undergoing a surgical procedure with anesthesia. Patients will have type 1 diabetes and be wearing a continuous glucose monitor as part of routine care.
62208724|NCT05564260|EXPERIMENTAL|The Kaleidescope Group|Kaleidoscope was watched during blood drawing
62208725|NCT05564260|EXPERIMENTAL|The VR Group|watching the application by wearing virtual glasses to the child during the blood drawing
62208726|NCT05564260|NO_INTERVENTION|Control Group|No intervention was made.
62208727|NCT00979576|EXPERIMENTAL|BIBF 1120 BID + Pemetrexed|Phase I part: Find MTD by using low, medium or high BIBF 1120 twice daily and 500mg/m\^2 pemetrexed once every 3 weeks
62208728|NCT00979576|EXPERIMENTAL|BIBF 1120 BID (RD) + Pemetrexed|PHase II part: Study arm
62208729|NCT00979576|EXPERIMENTAL|BIBF 1120 BID(Placebo) + Pemetrexed|Phase II part: Comparator arm
62208730|NCT02622529||Screening through Questionnaires|All of the patients within this single existent Arm will receive the questionnaires.
62018191|NCT02835014||Adolescents with T1DM|Adolescents with type I Diabetes Mellitus diagnosed for at least one year will be screened for mental health symptoms with the PHQ9, SCARED and UCLA PTSD. Self-efficacy regarding self-care and diabetes management will be assessed by using the SEDM. Parenting styles will be assessed by administering the Parenting Styles and Dimensions Questionnaire (PSDQ).
62018192|NCT01754714|EXPERIMENTAL|1000 mg SAMe (S-adenosyl-L-methionine)|
62018193|NCT01754714|EXPERIMENTAL|1500 mg SAMe|
62018194|NCT01754714|EXPERIMENTAL|2000 mg SAMe|
62018195|NCT01754714|NO_INTERVENTION|No treatment|
62018196|NCT05812482|EXPERIMENTAL|Test group|The test arm will be the treated by Drug Balloon
62018197|NCT05812482|OTHER|Control group|The control arm will be treated by Direct vision internal urethrotomy (DVIU)
62018198|NCT00750945|EXPERIMENTAL|A|Treadmill with Music cueing group
62018199|NCT00750945|ACTIVE_COMPARATOR|B|Treadmill group
62018200|NCT00750945|PLACEBO_COMPARATOR|C|Home walking group
62018201|NCT00293540|ACTIVE_COMPARATOR|A|Surgical oophorectomy in history-estimated mid-luteal phase of menstrual cycle plus Tamoxifen
62018202|NCT00293540|ACTIVE_COMPARATOR|B|Surgical oophorectomy in history-estimated mid-follicular phase of menstrual cycle plus Tamoxifen
62018203|NCT06381479|EXPERIMENTAL|probiotics|Probiotic capsules
62018204|NCT06381479|PLACEBO_COMPARATOR|placebo|Placebo capsules
62208731|NCT02081443|EXPERIMENTAL|Ticagrelor 180mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
62208732|NCT02081443|ACTIVE_COMPARATOR|Ticagrelor 90mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
62208733|NCT04536038|NO_INTERVENTION|Opt-in|Patients randomized to opt-in framing will be instructed to visit the Way to Health website to enroll in the study, or to call or email the study coordinator with questions or for assistance in enrolling.
62208734|NCT04536038|EXPERIMENTAL|Opt-out|Patients randomized to opt-out framing will receive an email that frames participation in the study as part of the standard of care, and will be informed that a study coordinator will be calling them in the coming days to start enrollment in the study unless they opt out of participation.
62208735|NCT02999074|ACTIVE_COMPARATOR|Resistance exercise|
62208736|NCT02999074|ACTIVE_COMPARATOR|Aerobic exercise|
62208737|NCT02999074|OTHER|Waitlist control|
62208738|NCT03307005|EXPERIMENTAL|Intervention|
62208739|NCT03307005|PLACEBO_COMPARATOR|Control|
62208740|NCT02078908|ACTIVE_COMPARATOR|40 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour
62406755|NCT01725204|EXPERIMENTAL|Dasatinib + PegIFN|Dasatinib 100mg OD for three months single drug, with subsequent addition of PegIFN 15 μg/ week for 3 months. If well tolerated (less than grade 2 non-hematological or grade 3 hematological AE) the dose should be increased to 25μg weekly for the remaining 9 months on combination treatment. Thereafter dasatinib will be given as monotherapy. Patients will be followed for 24 months totally.
62406756|NCT05562739|EXPERIMENTAL|Active|Arm receiving investigational product (postbiotic)
62406757|NCT05562739|PLACEBO_COMPARATOR|Placebo|Arm receiving placebo
62406758|NCT06422299|EXPERIMENTAL|Online, couples-based intervention|A novel, brief online intervention for young adults community couples who engage in alcohol and cannabis co-use.
62406759|NCT06422299|NO_INTERVENTION|Assessment-only control|Couples in the control condition will not receive an intervention.
62208741|NCT02078908|ACTIVE_COMPARATOR|120 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour
62406760|NCT06208670|EXPERIMENTAL|Progressive Muscle Relaxation Exercises|Progressive Relaxation Exercises (PGE) Practice: The importance and benefits of PGE exercises, situations to be avoided during the exercise, and the process of teaching by practicing and practicing the exercise will be done by the trained researcher for eight weeks, and it will be ensured that they repeat it at home. Progressive relaxation exercise instructions and a practical demonstration of the researcher will be made with the directives in the audio video with music. During the relaxation exercises, individuals will first intentionally tighten the muscle groups in the hands, arms, neck, shoulders, face, chest, abdomen, buttocks, feet, and fingers (muscle groups starting from the hands and ending with the feet) and then relax the muscles according to the commands on the CD.
62406761|NCT06208670|EXPERIMENTAL|Violent tendency Scale|was developed to identify aggression and violence tendencies
62406762|NCT06652880|EXPERIMENTAL|Customized Digital Application group (Intervention)|"Participants are assigned to one of two groups where they will receive one type of parenting support. The intervention group will receive a smartphone app which provides access to comprehensive resources related to parenting and recovery.~The intervention group will be observed to determine how frequently they use the digital app, thoughts about it, and what was found to be helpful. This will occur over a 12-week period.~The intervention group will complete surveys over the study period through the digital app. The times for survey completion are within one week after agreeing to participate in the study, after 6 weeks, and 12 weeks. The surveys include questions about personal history, drug usage and cravings, missed follow-up medical appointments, and parenting outcomes. An interview with the PI at 12 weeks post-delivery."
62208742|NCT02078908|ACTIVE_COMPARATOR|240 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour
62208743|NCT02078908|PLACEBO_COMPARATOR|Placebo|Continuous 2 hour infusion of sodium chloride, 25 ml/hour
62208744|NCT05394753|EXPERIMENTAL|Unified Protocol|8-session group-based intervention
62208745|NCT05394753|NO_INTERVENTION|Wait-list control|Participants in the wait-list control group will receive the same program, two months after their counterparts in the experimental group completed the intervention.
62208746|NCT04668430|OTHER|patients|"Patients for whom orthopedic surgery is indicated and planned among :~* Tibial valgus osteotomy~* Supra-malleolar osteotomy~* Hallux osteotomy for hallux valgus~* Total knee arthroplasty~* Total ankle arthroplasty~* Ankle arthrodesis~* Hallux arthrodesis~* Rear foot torque arthrodesis~* Inverted shoulder prosthesis~* Anterior lumbar interbody arthrodesis"
62208747|NCT06505590|SHAM_COMPARATOR|Educational material aid tool|Educational content on the mobile app Resilience © in the format of articles, videos or podcasts on treatment related symptoms and on validated supportive care interventions.
62208748|NCT06505590|EXPERIMENTAL|Educational material plus self-management program - self-administered version|Mobile app (Resilience ©) with its educational content plus a self-guided fatigue self-management program based on a cognitive behavioral therapy approach.
62208749|NCT06505590|EXPERIMENTAL|Educational material plus self-management program - guided version with mental health professional|Mobile app (Resilience ©) with its educational content and the self-management program of arm 2 plus weekly calls with a certified mental health professional certified in cognitive behavioural therapy for guided coaching across the self-management program.
62208750|NCT06160817|ACTIVE_COMPARATOR|Weekly Sharp Debridement|"* Participants in this arm will undergo sharp debridement on a weekly basis.~* Purpose: Evaluate the effect of weekly sharp debridement, in combination with conventional treatment, on granulation tissue and healing time in diabetic foot ulcers. And assess if this regimen yields better outcomes for ulcers with a specific location.~* Active Comparator: Yes, as it represents an active treatment modality."
62208751|NCT06160817|ACTIVE_COMPARATOR|Biweekly Sharp Debridement|"* Participants in this arm will undergo sharp debridement on a biweekly basis.~* Purpose: Assess the impact of biweekly sharp debridement, in combination with conventional treatment, on granulation tissue and healing time in diabetic foot ulcers. And assess if this regimen yields better outcomes for ulcers with a specific location.~* Active Comparator: Yes, as it represents an active treatment modality."
62406763|NCT06652880|ACTIVE_COMPARATOR|Parenting book as support for control group|"The bibliotherapy control group will receive a book on what to expect as a parent the first year after delivery.~The control group will complete surveys over the study period and are given the option to complete surveys by phone or videoconference with a Team member. The times for survey completion are within one week after agreeing to participate in the study, after 6 weeks, and 12 weeks. The surveys include questions about personal history, drug usage and cravings, missed follow-up medical appointments, and parenting outcomes. An interview with the PI at 12 weeks post-delivery."
62406764|NCT06283056|EXPERIMENTAL|Device Treatment|Eligible subjects will undergo two treatments with the Morpheus8 device using the 3, 5 7 mm depths or sequential (Burst) mode, based on the treating physician's discretion.
62581777|NCT02330367|EXPERIMENTAL|AC0010|Oral AC0010 monotherapy
62208752|NCT03951298||Wolfram Syndrome Patients|Participant has confirmation of a WFS1 mutation OR Both of the following conditions: diabetes mellitus requiring insulin and optic nerve atrophy diagnosed by a physician. Both conditions diabetes mellitus and optic nerve atrophy had to be diagnosed at age younger than 18 years old
62208753|NCT03951298||Proxy Group|Adult Biological parent(s), biological caregiver or non-biological caregiver of adult and minor participants in the any of the groups.
62208754|NCT01316406|EXPERIMENTAL|ATH008 cream 3%|ATH008 cream 3%
62208755|NCT01316406|EXPERIMENTAL|ATH008 cream 8%|ATH008 cream 8%
62208756|NCT01316406|PLACEBO_COMPARATOR|ATH008 cream placebo|ATH008 cream placebo
62208757|NCT03540563|OTHER|blood draw|Blood and saliva specimens will be taken for ctDNA analysis at baseline, weekly during treatment and at 2 weeks after treatment. During follow up both blood and saliva will be obtained in combination with a CT/MRI scan on the same day at 3 months, 6 months, 1 year and 2 years after treatment.
62208758|NCT03765008|ACTIVE_COMPARATOR|High Water intake|5-days of High water intake according to IOM guidelines
62208759|NCT03765008|EXPERIMENTAL|Low Water Intake|5-days of Low water intake of 500 mL/day
62208760|NCT05416944|NO_INTERVENTION|Routine management (control) group|Routine intraoperative blood pressure management with a lower intervention threshold of 65 mmHg. In contrast to the patients assigned to the personalized management group, the individual mean nighttime MAP assessed using preoperative automated blood pressure monitoring is not taken into account and the treating anesthesiologists are blinded to the data of preoperative automated blood pressure monitoring.
62208761|NCT05416944|EXPERIMENTAL|Personalized management (intervention) group|In patients randomized to the personalized management group, intraoperative mean arterial pressure will be maintained at least at the mean nighttime mean arterial pressure (assessed using preoperative automated blood pressure monitoring) with a minimum mean arterial pressure of 65 mmHg, and maximum mean arterial pressure of 110 mmHg. The perioperative trial intervention period starts with the beginning of the induction of general anesthesia and ends two hours after surgery ends.
62208762|NCT00701857|EXPERIMENTAL|Pemetrexed, Cisplatin, Radiation Therapy|Concomitant Pemetrexed and CDDP Plus Radiation Therapy
62208763|NCT05298059|PLACEBO_COMPARATOR|CPP-ACPF PASTE APLICATION|Apply the cpp-acpf paste, at four different times (one each week of whitening treatment), for five minutes in each application and evaluate if it was able to reduce the sensitivity after home whitening with 22% carbamide peroxide.
62208764|NCT05298059|NO_INTERVENTION|Evaluate the effectiviness at home bleaching|To evaluate the effectiveness of at-home bleaching with 22% carbamide peroxide, with the help of the VITA Easyshade 4.0 spectrophotometer
62208765|NCT05298059|PLACEBO_COMPARATOR|LASER APLICATION|Apply the laser at four different times (one every week of whitening treatment), using the spectrum of infrared light with a wavelength of 808 nm with its active medium of Arsento Gallium and Aluminum (AsGaAl), at three points, one in the center of the crown of the tooth, another in the center of the cervical region and the last one in the incisal region, with the light beam directed apically, from all teeth to the second premolar of each upper and lower hemi-arch, with energy of of 1 Joule per point for 10 seconds. and evaluate if it was able to reduce the sensitivity after home whitening with 22% carbamide peroxide.
62208766|NCT05298059|PLACEBO_COMPARATOR|Associate the CPP-ACPF paste with the LASER|Associate the CPP-ACPF paste with the LASER, following the same clinical protocol mentioned above and assess whether the association is more efficient than both treatments alone.
62208767|NCT01879553|EXPERIMENTAL|TIV (18 to ≤ 60 years)|Adult subjects 18 to ≤60 years received one dose of a trivalent, surface antigen inactivated subunit influenza virus vaccine (TIV) formulation 2013/2014 Northern Hemisphere
62208768|NCT01879553|EXPERIMENTAL|TIV (≥ 61 years)|Adult subjects ≥61 years received one dose of a trivalent, surface antigen inactivated subunit influenza virus vaccine (TIV) formulation 2013/2014 Northern Hemisphere
62406765|NCT04558515||Case|Symptomatic patients positive for malaria by PCR
62406766|NCT04558515||Control|Symptomatic patients negative for malaria by PCR
62406767|NCT06346743|EXPERIMENTAL|Fenofibrate adjuvant therapy|Single dose fenofibrate adjuvant to conventional phototherapy
62581778|NCT00536159|ACTIVE_COMPARATOR|Community Care|Medicaid eligible/insured pregnant women and their infants are eligible for risk assessment and up to 18 home visits (9/pregnancy and 9/infancy) from community professional providers as part of a state-sponsored enhanced prenatal and postnatal Medicaid program.
62208769|NCT02627417|EXPERIMENTAL|Dapsone: (Disulone®)|Dapsone: Disulone® given orally at 100 mg per day
62208770|NCT02627417|ACTIVE_COMPARATOR|"Prednisone (Cortancyl®) alone and standard of care"|"Prednisone (Cortancyl®) alone at 1 mg/kg for 3 weeks followed by monitoring and standard of care (control arm)"
62208771|NCT04464785||Treatment|Subjects who receive the CentriMag Circulatory Support System
62406768|NCT06346743|ACTIVE_COMPARATOR|Conventional phototherapy|Only conventional phototherapy
62406769|NCT01077791|EXPERIMENTAL|original cognitive therapy|
62406770|NCT01077791|NO_INTERVENTION|no intervention|
62734472|NCT02290496|PLACEBO_COMPARATOR|Sleep Hygiene (SH)|Attention control placebo comprising sleep hygiene therapy
62734473|NCT06454136|EXPERIMENTAL|Treatment|
62734474|NCT06454136|SHAM_COMPARATOR|Control|
62208772|NCT04564339|EXPERIMENTAL|Ravulizumab: LN Cohort|Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
62208773|NCT04564339|PLACEBO_COMPARATOR|Placebo: LN Cohort|Eligible participants will receive placebo IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
62208774|NCT04564339|EXPERIMENTAL|Ravulizumab: IgAN Cohort|Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
62208775|NCT04564339|PLACEBO_COMPARATOR|Placebo: IgAN Cohort|Eligible participants will receive placebo IV infusion in combination with background therapy during the Initial Evaluation Period (26 weeks) and will switch to ravulizumab for the Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
62208776|NCT05441982|ACTIVE_COMPARATOR|Acesulfame Potassium|Controlled feeding study. Dosage of acesulfame potassium will follow 25% of the acceptable daily intake (equivalent to 3.75 mg/kg). This amount represents 225 mg/day of acesulfame potassium for a 60 kg adult.
62208777|NCT05441982|ACTIVE_COMPARATOR|Saccharin|Controlled feeding study. Dosage of saccharin will follow 25% of the acceptable daily intake (equivalent to 3.75 mg/kg). This amount represents 225 mg/day of saccharin for a 60 kg adult.
62208778|NCT05441982|PLACEBO_COMPARATOR|No NNS|controlled feeding study with no non-nutritive sweeteners
62208779|NCT01447940|PLACEBO_COMPARATOR|Conventional Care|Patients will have conventional care with 2 standard visits (inclusion and 12 months) + HbA1c measure at 6 months. Patients won't use Meos ePortal
62208780|NCT01447940|EXPERIMENTAL|Meos ePortal use|Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
62208781|NCT06540885|EXPERIMENTAL|Palonosetron Group (Group P)|Group P will receive a stat dose of IV palonosetron 1.5mcg/kg diluted in a 5ml preparation of normal saline 0.9% prior to the commencement of general anaesthesia. At the start of wound closure, Group P will receive a 5ml preparation of normal saline 0.9% as a placebo.
62208782|NCT06540885|ACTIVE_COMPARATOR|Granisetron Group (Group G)|Group G will receive a 5ml preparation of normal saline 0.9% as placebo prior to commencement of general anaesthesia. At the start of wound closure, a stat dose of IV granisetron 1mg in 5ml preparation will be administered.
62208783|NCT06520826|EXPERIMENTAL|Vadadustat|Vadadustat, 300 mg tablets, administered orally three times per week
62208784|NCT06520826|ACTIVE_COMPARATOR|Erythropoiesis-stimulating agent (ESA) - Standard of Care (SOC)|Epoetin alfa (EPOGEN), Methoxy polyethylene glycol-epoetin beta (Mircera), or Darbepoetin alfa (Aranesp) administered as per standard of care
62208785|NCT05591885|EXPERIMENTAL|Study product gruop|Nutrilite Memory Builder Ingredients (Cistanche deserticola extract, Ginkgo biloba extract, glucose, microcrystalline cellulose, corn starch, etc.) 60 Tablets / bottle
62208786|NCT05591885|PLACEBO_COMPARATOR|Placebo group|Ingredients (glucose, microcrystalline cellulose, corn starch, caramel pigment, etc.) 60 Tablets / bottle
62208787|NCT04865133||Observational (biospecimen collection, medical record)|Patients undergo blood sample collection at baseline (prior to first COVID-19 vaccination), prior to second vaccination, 1, 6, and 12 months after the last vaccination. Patients receiving a booster vaccine will undergo blood collection prior to and 1-3 months after vaccination. Patients who receive the types of COVID-19 vaccines that do not require the second injection skip blood sample collection at this time point. This study will collect information regarding the type of COVID-19 vaccine received, date of vaccine injection, and any side effects associated with the COVID-19 vaccine that trial participant encountered. This study will also review the medical record for outcomes and information related to the blood testing.
62406771|NCT06087029|EXPERIMENTAL|Upfront TEVAR plus Medical Therapy|Participants randomized to upfront TEVAR will receive a commercially available device customized to their individual anatomical requirements. Stent-graft implantation will be performed either in the operating room with appropriate digital imaging equipment to allow fluoroscopic and trans-esophageal echo (TEE) guidance or the catheterization laboratory, angiographic suite (with digital angiographic equipment).
62406772|NCT06087029|ACTIVE_COMPARATOR|Medical Therapy with surveillance for deterioration|Participants randomized to upfront Medical Therapy with Surveillance for Deterioration will be treated per routine clinical care with suggested antihypertensive therapy and cardiovascular risk factor reduction as per appropriate cardiovascular guidelines.
62406773|NCT06124716|EXPERIMENTAL|Enhanced COACH|Enhanced blood pressure management recommendations that use cognitive and behavioral science to increase the likelihood of self-management goal setting to lower blood pressure. The CDS tool allows participant access to BP visualizations, reminders, and affectively tailored messaging about blood pressure management.
62406774|NCT06124716|ACTIVE_COMPARATOR|Usual Care COACH|Equivalent of usual care delivered through the CDS tool: Blood pressure management with basic information, reduced reminders, and no affective alerts.
62406775|NCT01738282|EXPERIMENTAL|Baclofen|Baclofen 20mg tablet. Titration:increasing dosage regimen to reach the target dosage of 180 mg (9 tablets)in 7 weeks Maintenance period with a constant dosage during 17 weeks Progressive decrease and stop of study treatment in 2 weeks
62406776|NCT01738282|PLACEBO_COMPARATOR|Placebo|Placebo tablet Titration:increasing dosage regimen to reach the target dosage of 9 tablets in 7 weeks Maintenance period with a constant dosage during 17 weeks Progressive decrease and stop of study treatment in 2 weeks
62581779|NCT00536159|EXPERIMENTAL|Nurse-CHW Team|Nurse-CHW team provided both nursing care, with additional focus on mental health and stress, and intensive relationship-based support from a CHW similar in characteristics to women served in the context of state-sponsored Medicaid program.
62581780|NCT05606172|EXPERIMENTAL|PCIP for youth aged 6 to 11|This arm will receive the adapted PCIP intervention lasting from 1-4 weeks, and will complete baseline, post treatment, 1-month, and 3-month follow up assessments.
62581781|NCT05606172|ACTIVE_COMPARATOR|Waitlist Treatment as Usual|Receive standard care treatment and will complete baseline, post treatment, 1-month, and 3-month follow up assessments, and are offered PCIP treatment after conclusion of the study.
62208788|NCT05872191||Upper extremity functional impairment due to chronic stroke|Spanish-native speakers with functional impairment of the upper extremity after stroke in chronic phase.
62208789|NCT00120211|EXPERIMENTAL|Radiotherapy: 6 Fractions|
62208790|NCT00120211|ACTIVE_COMPARATOR|Radiotherapy: 5 fractions|
62208791|NCT00937677||1|63 patients with relapsing-remitting Multiple Sclerosis who are enrolled in the TOUCH program and have been taking Tysabri monotherapy for 2 years.
62208792|NCT00937677||2|22 age- and sex-matched normal controls who completed 1 year follow-up.
62208793|NCT06241573|EXPERIMENTAL|Patients treated in Part I of parent trial 1368-0098 (NCT05819398)|
62208794|NCT06241573|EXPERIMENTAL|Patients treated in Part II of parent trial 1368-0098 (NCT05819398)|
62208795|NCT06241573|EXPERIMENTAL|Patients treated in parent trial 1368-0100|
62406777|NCT01976325|NO_INTERVENTION|Standard Care|This arm will receive no intervention; only standard medical care.
62018205|NCT02510157|ACTIVE_COMPARATOR|dexamethasone|Dexamethasone is administered intravenously before induction of anaesthesia. Deep neuromuscular blockade is induced with rocuronium and is assessed by acceleromyography (post-tetanic count stimulation) on the ulnar nerve of the patient's hand. At the end of surgery, sugammadex 4 mg/kg is administered to reverse neuromuscular blockade.
62208796|NCT01577459|EXPERIMENTAL|TR-701 FA with PSE|TR-701 FA 200 mg oral with PSE
62208797|NCT01577459|PLACEBO_COMPARATOR|TR-701 FA Placebo with PSE|TR-701 FA Placebo 200 mg oral with PSE
62208798|NCT04302974||Sub-study 1: Trajectory study|All HA primary care patients aged 18 years or above with doctor-documented HT and/or DM receiving care in HA General Out-patient Clinics or Family Medicine Clinics (FMC) identified from the HA CMS database between 2006 and 2019, to explore the trajectory patterns for clinical, treatment and complication profiles and investigate the impact of multi-morbidity, continuity-of-care, different service delivery models and management strategies (including investigation frequency and specific drug regimens) on outcomes and health service utilization.
62208799|NCT04302974||Sub-study 2: RAMP-DM|A cohort of patients with i) diagnosis of DM without any known complications on or before September 2010 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2009 and 2019, who attended the first RAMP-DM assessment between August 2009 to September 2010
62208800|NCT04302974||Sub-study 2: usual care only|A cohort of patients with i) diagnosis of DM without any known complications on or before September 2010 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2009 and 2019, who have never attended any RAMP-DM assessment between August, 2009 to December, 2019
62581782|NCT06285851|EXPERIMENTAL|FeSC Cookie|Iron-yeast complex
62208801|NCT04302974||Sub-study 3: RAMP-HT|A cohort of patients with i) diagnosis of HT without DM and any known complications on or before March 2013 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2011 and 2021, who attended the first RAMP-HT assessment between October 2011 to March 2013
62018206|NCT02510157|PLACEBO_COMPARATOR|normal saline|Normal saline is administered intravenously before induction of anaesthesia. Deep neuromuscular blockade is induced with rocuronium and is assessed by acceleromyography (post-tetanic count stimulation) on the ulnar nerve of the patient's hand. At the end of surgery, sugammadex 4 mg/kg is administered to reverse neuromuscular blockade.
62018207|NCT04734379|EXPERIMENTAL|Treatment|Oral fasudil 180 mg/day
62406778|NCT01976325|EXPERIMENTAL|Decision Aid + Standard Care|This group will receive the intervention (the Ottawa Malaria Decision Aid), in addition to standard medical care.
62406779|NCT03381898|EXPERIMENTAL|Telehealth Coordinated Allied Health|rural persons with Parkinson's disease will receive telehealth exercise, speech therapy, medication management for 8 weeks. Exercise, speech therapy, and medication management are usual care for persons with Parkinson's disease. Having the 3 areas coordinated in delivery via telehealth is the new delivery that our aims address
62406780|NCT06558682|EXPERIMENTAL|Disitamab Vedotin Combined with Cisplatin|Locally advanced cervical cancer patient was treated with Disitamab Vedotin combined with Cisplatin for neoadjuvant therapy.
62208802|NCT04302974||Sub-study 3: usual care only|A cohort of patients with i) diagnosis of HT without DM and any known complications on or before March 2013 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2011 and 2021, who have never attended any RAMP-HT assessment between October 2011 to December 2021
62208803|NCT04302974||Sub-study 4: PSCC|A cohort of patients with i) diagnosis of DM without any known complications on or before August 2016, ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2012 and 2021 iii) attended the first RAMP-DM assessment between September, 2012 to August, 2016, who have received the first PSCC call between September, 2012 to August, 2016 after the first RAMP-DM assessment
62208804|NCT04302974||Sub-study 4: without PSCC|A cohort of patients with i) diagnosis of DM without any known complications on or before August 2016, ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2012 and 2021 iii) attended the first RAMP-DM assessment between September, 2012 to August, 2016, who have never received any PSCC services between September 2012 to December 2021
62208805|NCT00261976||Patients in infliximab clinical studies|All patients enrolled in selected Centocor sponsored infliximab clinical studies.
62208806|NCT04020185|EXPERIMENTAL|Ph I Monotherapy|"* Dose escalation design in which administered dose levels of IMSA101 as monotherapy will be escalated stepwise in successive cohorts of 3 to 6 patients per dose group (using a standard 3+3 study design) of IMSA101 until the RP2D or maximum tolerated dose (MTD) level is identified.~* The first patient enrolled in each dose level must complete the first two weeks of Cycle 1 prior to enrolling the second and third patients.~* Dose levels to be evaluated include (although not necessarily limited to) 100 µg (representing 1/60th of the pre-clinical Highest Non-Severely Toxic Dose \[HNSTD\] dose), 200 µg, 400 µg, 800 µg, and 1,200 µg."
62215440|NCT01329692|EXPERIMENTAL|Lifestyle counseling|"This is a seven-week group education, counseling, nutrition, exercise, and journaling program of the Duke Metabolic and Weight Loss Surgery Center designed to help postoperative bariatric surgery patients who are failing to progressively lose weight resume an expected pattern of weight loss and improved overall outcome.~Weeks 1 and 2 consist primarily of a review of current dietary habits. Weeks 3, 4, \& 5 introduces counseling, with specific emphasis on emotional aspects of eating and behavioral modification strategies. Week 6 focuses on the metabolic impact of exercise, and includes an exercise session with a personal trainer. Week 7 incorporates a question and answer session with a sharing of discoveries, as well as an option for additional individual follow-up as needed."
62406781|NCT05251779|EXPERIMENTAL|Cang-Ai Group|The test group inhaled the volatile oil of Cang-Ai at a concentration of 1% by inhalation once a day for 30 minutes
62406782|NCT05251779|ACTIVE_COMPARATOR|Bergamot group|The control group inhaled the bergamot essential oils at a concentration of 1% by inhalation once a day for 30 minutes
62406783|NCT00186875|OTHER|Treatment|Participants receive chemotherapy, intrathecal chemotherapy, steroid therapy, hematopoietic stem cell transplant, and natural killer cell transplant as outlined in the Interventions section, including etoposide, cytarabine, vincristine, dexamethasone, methotrexate, teniposide, PEG-asparaginase, mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine, L-asparaginase, erwinia asparaginase.
62406784|NCT06332924|EXPERIMENTAL|Motivational interviewing group|"The patients in the intervention group will be informed about the study, and after the purpose and method of the study are explained, their consent will be obtained and the Pregnant Information Form will be applied.~* There will be 3 meetings for both groups, one week apart. Interviews will include primipara pregnant women in their 30th, 32nd and 34th weeks of pregnancy.~* Preliminary tests will be conducted before the interviews.~* After the interviews are completed, final tests will be carried out and the study will be terminated.~* Motivational Interviewing Training for the intervention group will be prepared in detail, with the aim of answering the pregnant woman's questions, and with methods that are relevant to her needs and interests by providing body awareness."
62406785|NCT06332924|NO_INTERVENTION|Control group:|Scales will be applied to the control group as pre-test and post-test with a 2-week interval.
62406786|NCT02531958|EXPERIMENTAL|1 Egg|Consumption of 1 egg per day for 4 weeks
62406787|NCT02531958|EXPERIMENTAL|2 Eggs|Consumption of 2 eggs per day for 4 weeks
62406788|NCT02531958|EXPERIMENTAL|3 Eggs|Consumption of 3 eggs per day for 4 weeks
62406789|NCT06269042|EXPERIMENTAL|Intervention group|The EG (experimental group) will perform the diaphragmatic fatigue protocol using a specific inspiratory endurance test, in which volunteers, one-on-one, and in a single session, will breathe against submaximal inspiratory loads equivalent to 60% of their MIP (Maximum Inspiratory Pressure) through a threshold valve device. The participants will follow a free pattern of breathing until they are unable to establish flow during at least 3 maximum inspiratory efforts.
62406790|NCT06269042|NO_INTERVENTION|Control group|they will not receive any intervention. Just sit and wait the same amount of time that the intervention and the activation group needs to finish their protocol (around 10 minutes)
62406791|NCT06269042|ACTIVE_COMPARATOR|Activation group|The activation group will perform the protocol of 2 sets of 30 repetitions at 40% of their MIP, one-on-one, and in a single session, breathing against submaximal inspiratory loads using a threshold valve device. The participants will follow a free pattern of breathing until complete the protocol.
62406792|NCT03544697||Skin expansion and repair with flaps|The tissue expander was inserted into the scalp in 17 patients and supraclavicular area in two patients.
62406793|NCT01387958|EXPERIMENTAL|LCQ908|
62406794|NCT01387958|PLACEBO_COMPARATOR|Placebo|
62406795|NCT01819012|EXPERIMENTAL|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
62406796|NCT01819012|EXPERIMENTAL|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
62406797|NCT01819012|EXPERIMENTAL|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
62406798|NCT05635682||Study Group|Individuals in the process of maintenance therapy with opioid use disorder
62406799|NCT05635682||Control Group|Healty people
62406800|NCT02434029|EXPERIMENTAL|Budesonide|Budesonide 1mg orodispersible tablet twice daily
62406801|NCT02434029|PLACEBO_COMPARATOR|Placebo|Placebo orodispersible tablet twice daily
62208807|NCT04020185|EXPERIMENTAL|Ph I Combination Therapy|"* Ph I combination dosing of IMSA101 shall be evaluated upon satisfaction of the following criteria:~  * A given dose level (combo dose level 1) has been confirmed as safe for monotherapy dosing (i.e. 2/6 patients experience Cycle 1 DLT).~ * The next higher dose level (combo dose level 2) has been confirmed as safe for monotherapy dosing (i.e. 2/6 patients experience Cycle 1 DLT).~ * The dose level (combo dose level 1) is found to demonstrate adequate IMSA101 pharmacodynamic (PD) activity based on exploratory endpoints.~* Eligible patients shall have demonstrated RECIST stable disease through ≥ 4 consecutive cycles of an approved PD-1/PD-L1-targeted ICI with no Grade ≥ 3 CTCAE events considered to be drug-related.~* Safety evaluations and dose escalation of IMSA101 administered in combination with current therapy shall proceed in a manner consistent with monotherapy escalation and shall proceed independently of monotherapy dose escalation."
62208808|NCT04020185|EXPERIMENTAL|Ph II Monotherapy (Arm A)|"* This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as monotherapy~* Tumor type to be evaluated will be identified prior to Phase IIA commencement and will be documented in a protocol amendment."
62208809|NCT04020185|EXPERIMENTAL|Ph II Combination Therapy (Arm B)|"* This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as combination therapy with PD-1/PD-L1 targeted immune checkpoint inhibitors.~* This arm shall include a safety run-in of 5-10 patients.~* Tumor type and corresponding treatment combination will be identified prior to Phase IIA commencement and documented in a protocol amendment."
62208810|NCT04020185|EXPERIMENTAL|Ph II Combination Therapy (Arm C)|"* This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as combination therapy with non-PD-1/PD-L1-targeted immuno-oncology (IO) drugs approved by the FDA.~* This arm shall include a safety run-in of 5-10 patients.~* Tumor type and corresponding treatment combination will be identified prior to Phase IIA commencement and documented in a protocol amendment.."
62208811|NCT03187964|NO_INTERVENTION|PLHIV Centralised Xpert Ultra|Patient sputum specimen collected at Kraaifontein Community Health Centre (KCHC) and sent for centralised Xpert Ultra TB testing at the National Health Laboratory Services (NHLS) facility in Greenpoint, Cape Town, South Africa. Centralised testing uses the established NHLS transportation, testing and report-back to clinic infrastructure according to the national algorithm.
62208812|NCT03187964|ACTIVE_COMPARATOR|PLHIV Point of Care Xpert Ultra|Patient sputum specimen collected at KCHC and Xpert Ultra TB testing done on site at point of care (POC).
62208813|NCT03187964|NO_INTERVENTION|PLHIV Centralised Xpert VL|Patient blood specimen collected at Kraaifontein Community Health Centre (KCHC) and sent for centralised viral load testing at the NHLS facility in Tygerberg Hospital, Cape Town, South Africa. Centralised testing uses the established NHLS transportation, testing and report-back to clinic infrastructure according to the national algorithm.
62208814|NCT03187964|ACTIVE_COMPARATOR|PLHIV Point of Care Xpert VL|Patient blood specimen collected at KCHC and Xpert HIV-1 viral load testing done on site at point of care (POC).
62208815|NCT04195139|EXPERIMENTAL|Nivolumab and Temozolomide|After radiotherapy and 4 week break, participants who are assigned to this arm will receive Nivolumab with concurrent adjuvant temozolomide treatment
62208816|NCT04195139|ACTIVE_COMPARATOR|Temozolomide|After radiotherapy and 4 week break, participants who are assigned to this arm will receive the standard treatment of adjuvant temozolomide treatment
62208817|NCT03457051|ACTIVE_COMPARATOR|Total Knee Arthroplasty (TKA)|In total (complete) knee arthroplasty (TKA), the orthopaedic surgeon removes the damaged areas of the knee and replaces the components with an artificial joint that is made of plastic or metal.
62406802|NCT05814380||Group 1|grade 1-3 cardiac retention of 99mTc-DPD in scintigraphy
62018208|NCT05976529||study group|From the 5th to 25th day of menstrual cycle, 10 mg dydrogesterone was taken orally twice a day for 3 menstrual cycles.
62208818|NCT03457051|EXPERIMENTAL|Unicompartmental Knee Arthroplasty (UKA)|Unicompartment (partial) knee arthroplasty (UKA) has been available for over 40 years and differs from TKA in that only the most affected and symptomatic compartment (most commonly medial, but occasionally lateral and patella femoral) are replaced
62208819|NCT00979550|EXPERIMENTAL|Aldara cream|Imiquimod (Aldara cream) will be applied nightly for four weeks after standard of care laser treatment for port wine stain.
62208820|NCT00979550|PLACEBO_COMPARATOR|non-medicated petroleum cream|Non-medicated petroleum cream will be applied nightly for four weeks after standard of care laser treatment for port wine stain.
62208821|NCT01618253|EXPERIMENTAL|Radiation therapy with concurrent sorafenib|
62208822|NCT01036438|PLACEBO_COMPARATOR|Mepilex product|
62208823|NCT01036438|ACTIVE_COMPARATOR|Mepilex Ag|
62018209|NCT05976529||control group|After postoperative pathological diagnosis, oral dienogest was started, 4 weeks as a course of treatment, and 3 courses of continuous treatment were given.
62215441|NCT01329692|NO_INTERVENTION|RYGB regular post-op care|Regular care and follow-up after RYGB surgery
62406803|NCT05814380||Group 2|first-degree relative of a patient with ATTR
62406804|NCT01953523|EXPERIMENTAL|Deployment of stromal vascular fraction|Administration of autologous adipose derived SVF
62581783|NCT03213314|EXPERIMENTAL|Main cohort|Patients undergoing liver resection
62581784|NCT03213314|EXPERIMENTAL|Nested cohort PVE|Patients undergoing liver resection after portal vein embolisation
62581785|NCT03213314|EXPERIMENTAL|Nested cohort neoadjuvant chemotherapy|Patients undergoing liver resection after neoadjuvant chemotherapy
62581786|NCT03213314|EXPERIMENTAL|Nested cohort TACE|Patients undergoing trans arterial chemoembolisation for presumed hepatocellular carcinoma
62581787|NCT00846001|ACTIVE_COMPARATOR|CABG alone|Standard coronary artery bypass grafting according guidelines
62018210|NCT05622773|EXPERIMENTAL|one-group quasi-experimental study|Materials for Introductory Information Form, Visual Analog Scale (VAS), Visual Similarity Scale for Fatigue (VAS-F), Lower Leg Circumference Measurement Monitoring Form, Lower Extremity Edema Monitoring Form, Anti-Fatigue Mat, Foot Bath will be used in data collection. During the data collection process, the basic measurements of the operating room nurses will be made and then the measurements will be repeated using an anti-fatigue mat. The collection of data will be interrupted for 1 month, and basic measurements will be taken again and the nurses will be provided with a foot bath. After the footbath applications, the measurements will be repeated and recorded.
62018211|NCT03890302|EXPERIMENTAL|Cohort A|0.5 mg/kg study drug, or placebo, administered once
62018212|NCT03890302|EXPERIMENTAL|Cohort B|2 mg/kg study drug, or placebo, administered once
62208824|NCT00384189|ACTIVE_COMPARATOR|Ciclesonide 40 µg|Placebo-matching ciclesonide, inhaled via a metered-dose inhaler (MDI) with 1,1,1,2-hydrofluoroalkane (HFA)-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 40 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
62018213|NCT03890302|EXPERIMENTAL|Cohort C|4 mg/kg study drug, or placebo, administered once
62018214|NCT03890302|EXPERIMENTAL|Cohort D|8 mg/kg study drug, or placebo, administered once
62018215|NCT03890302|EXPERIMENTAL|Cohort E|Starting dose of 2 mg/kg or approximately half the maximum tolerated dose (MTD) in Part 1 (Cohorts A-D), whichever is lower, up to 4 mg/kg; or placebo. Administered 4 times (approximately once every 2 weeks).
62018216|NCT05167838|EXPERIMENTAL|group A|Fresh embryo transfer group
62018217|NCT05167838|EXPERIMENTAL|Group B|Frozen embryo transfer group
62018218|NCT02109055|EXPERIMENTAL|Pilates|Regarding upper limb exercises the limit of flexion and abduction less than 90°, with the exercises involving only the movement of flexion and extension of elbow shoulder will be respected. Along with patient data will be an exercise protocol based on the Pilates method that will be performed by a trained team of physiotherapists. Before and after the exercises the data of heart rate, blood pressure, oxygen saturation and subjective feeling of perceived exertion using the Modified Borg scale will be listed.
62018219|NCT02109055|ACTIVE_COMPARATOR|Convencional Physiotherapy|The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy.
62208825|NCT00384189|ACTIVE_COMPARATOR|Ciclesonide 80 µg|Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 80 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
62208826|NCT00384189|ACTIVE_COMPARATOR|Ciclesonide 160 µg|Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 160 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
62581788|NCT00846001|EXPERIMENTAL|CABG+CRT|Standard coronary artery bypass grafting according guidelines with concomitant three bipolar epicardial leads implantation for cardiac resynchronization therapy
62581789|NCT00708214|EXPERIMENTAL|BIBW 2992|To study BIBW 2992 in association with letrozole in hormonoresistant metastatic breast cancer
62790006|NCT02773485|ACTIVE_COMPARATOR|Systemic Chemotherapy|Irrespective of arm allocation Baseline Positron Emission Tomography(PET) scan and hepatic function assessment will be done. Those randomized to this arm will receive systemic chemotherapy delivered on day 1 and 8 every 3 weekly, with gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2. After first 4 cycles patients will undergo repeat Contrast Enhanced Computed Tomography(CECT)/PET scan. If CECT/PET scan shows stable/ responding disease then patients will continue to receive the same chemotherapy. In case of locally progressive/ systemic disease on chemotherapy patients may be considered for second line palliative chemotherapy or best supportive care. The use of radical chemoradiation is not allowed on disease progression in this arm. However palliative radiation may be used.
62790007|NCT02773485|EXPERIMENTAL|Chemotherapy and radiation|In those randomized to radiation arm with receive high dose radiation with Intensity Modulated Radiation Therapy in addition to systemic and concurrent chemotherapy. The gross tumor will comprise the high dose volume. The adjacent areas of suspected microscopic disease will form the low dose volume. When only external radiation is used the aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
62790008|NCT00567359|EXPERIMENTAL|Erlotinib|
62790009|NCT04079816|EXPERIMENTAL|INVSENSOR00025|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00025 sensor.
62581790|NCT00708214|OTHER|Letrozole|Hormonotherapy for metastatic breast cancer
62790010|NCT02728089|EXPERIMENTAL|MK-7625A|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion every 8 hours for 7 days. The dose may be reduced to 750 mg (ceftolozane 500 mg/tazobactam 250 mg) for participants with a creatinine clearance (CrCl) of 30-50 mL/min.
62790011|NCT04417335|EXPERIMENTAL|Treatment|BCG vaccine (Danish strain 1331, SSI, Denmark)
62790012|NCT04417335|PLACEBO_COMPARATOR|Placebo|0.9% NaCl
62208827|NCT00384189|PLACEBO_COMPARATOR|Placebo|Placebo-matching Ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 2 to 4 week in the Baseline period followed by placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
62208828|NCT02798042||Patient population|Patients undergoing bariatric surgery
62208829|NCT03079453|ACTIVE_COMPARATOR|Group 1|The patients in Group 1 (n:15) were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly at three points (three points on the connection of the uvula, and palatum molle) before tonsillectomy .
62208830|NCT03079453|NO_INTERVENTION|Group 2|Group 2 (n:15) patients had tonsillectomy without dexamethasone injection.
62208831|NCT05656235|EXPERIMENTAL|Enfortumab vedotin with Pembrolizumab|"The study population will include male and female patients over the age of 18 with high grade UTUC (cN0/xM0) and is ineligible for or refuses definitive radical nephroureterectomy (RNU).~Enfortumab vedotin will be administered on Days 1 and 8 at 1.25mg/kg of every 3-week cycle by intravenous (IV) infusion given over approximately 30 minutes. Pembrolizumab will be administered on Day 1 at 200mg of every 3-week cycle by IV infusion over approximately 30 minutes. Enfortumab vedotin and Pembrolizumab may be administered for up to total of 35 cycles (approximately 2 years)."
62208832|NCT06727760|EXPERIMENTAL|massage group|Colic massage is applied to babies with infantile colic
62581791|NCT05624879|EXPERIMENTAL|Accelerated Resolution Therapy Group|Primary caregivers of an immediate family member enrolled in a hospice or palliative care program will receive 4 weekly sessions of accelerated resolution therapy (ART)
62790013|NCT05536687|OTHER|Healthy|
62790014|NCT05322720|ACTIVE_COMPARATOR|EOC202 30 mg+ albumin-bound paclitaxel (100 mg/m2);|One cycle of therapy is 4 weeks (28 days), the subjects in the experimental group will receive albumin-bound paclitaxel 100 mg/m2 iv drip on Day 1 (D1), D8 and D15 of each cycle, and EOC202 30 mg subcutaneously on D2 and D16 of each cycle; the subjects in the control group will receive albumin-bound paclitaxel 100 mg/m2 iv drip on D1, D8 and D15 of each cycle. The treatment will continue until progression of disease, death, intolerable toxicity, start of other antitumor therapy, withdrawal of informed consent, loss of follow-up or termination of study for other reasons, whichever comes first.
62018220|NCT04938037|EXPERIMENTAL|SSNB through the spinoglenoid notch|US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics
62208833|NCT06727760|EXPERIMENTAL|kangaroo care group|Kangaroo care is applied to babies with infantile colic
62208834|NCT06727760|NO_INTERVENTION|control group|No intervention is applied to babies with infantile colic
62208835|NCT01253135|PLACEBO_COMPARATOR|Control|White Petrolatum
62208836|NCT01253135|OTHER|Test article|Vehicle (fibrinogen)
62208837|NCT03440957|OTHER|Osteopathy treatment|
62018221|NCT04938037|ACTIVE_COMPARATOR|SSNB through the suprascapular notch|US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics
62018222|NCT05980312|ACTIVE_COMPARATOR|Immobilized|Patients in the control group will be immobilized for 2 weeks and resume unrestricted motion once the splint is taken off.
62018223|NCT05980312|EXPERIMENTAL|Early Range of Motion|Patients in the experimental group will start early motion immediately after surgery.
62208838|NCT06238570|PLACEBO_COMPARATOR|Manual vitrification (using Vitrolife system)|The vitrification of the oocytes will be carried out by an authorized technician according to the manual protocol validated and used routinely.
62581792|NCT05624879|ACTIVE_COMPARATOR|Information and Support Group|Primary caregivers of an immediate family member enrolled in a hospice or palliative care program will receive four-time and attention matched sessions of a standardized social work intervention consisting of information and provision of emotional support.
62581793|NCT06683040|EXPERIMENTAL|0.030 mg\kg|
62581794|NCT06683040|EXPERIMENTAL|0.100 mg\kg|
62208839|NCT06238570|ACTIVE_COMPARATOR|Semi-automatic vitrification of oocytes using the GAVI® automaton (Merck)|The vitrification of the oocytes will be carried out using the GAVI® automaton
62208840|NCT06069310||Healthy control subjects|Healthy control subjects withouth asthma nor chronic rhinosinusitis or other chronic respiratory diseases
62208841|NCT06069310||Chronic rhinosinusitis with nasal polyps (CRSwNP) patients with comorbid severe asthma|Patients that have chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid severe asthma will be enrolled
62208842|NCT06069310||Chronic rhinosinusitis with nasal polyps (CRSwNP) patients without asthma|Patients that have chronic rhinosinusitis with nasal polyps (CRSwNP) without asthma will be enrolled
62790015|NCT05322720|ACTIVE_COMPARATOR|albumin-bound paclitaxel (100 mg/m2).|One cycle of therapy is 4 weeks (28 days), the subjects in the experimental group will receive albumin-bound paclitaxel 100 mg/m2 iv drip on Day 1 (D1), D8 and D15 of each cycle, and EOC202 30 mg subcutaneously on D2 and D16 of each cycle; the subjects in the control group will receive albumin-bound paclitaxel 100 mg/m2 iv drip on D1, D8 and D15 of each cycle. The treatment will continue until progression of disease, death, intolerable toxicity, start of other antitumor therapy, withdrawal of informed consent, loss of follow-up or termination of study for other reasons, whichever comes first.
62208843|NCT04996004|EXPERIMENTAL|Dose Escalation (Ontorpacept+doxorubicin)|In the dose escalation portion of the study, participants with specific subsets of soft tissue sarcomas who have not received more than one prior line of therapy and have not received an anthracycline in any setting will be enrolled in three escalating dose cohorts to characterize the safety and tolerability of Ontorpacept (TTI-621) when administered in combination with doxorubicin for up to six cycles and followed by Ontorpacept (TTI-621) monotherapy
62208844|NCT04996004|EXPERIMENTAL|Dose Expansion Dose Level A (Cohort A)|Participants with high-grade leiomyosarcoma will receive up to six cycles of Ontorpacept (TTI-621) at a pre-specified dose level (Dose Level A) in combination with fixed-dose doxorubicin followed by Ontorpacept (TTI-621) monotherapy to further characterize safety, tolerability, and clinical activity of the treatment regimen.
62208845|NCT04996004|EXPERIMENTAL|Dose Expansion Dose Level B (Cohort B)|Participants with high-grade leiomyosarcoma will receive up to six cycles of Ontorpacept (TTI-621) at a pre-specified dose level (Dose Level B) in combination with fixed-dose doxorubicin followed by Ontorpacept (TTI-621) monotherapy to further characterize safety, tolerability, and clinical activity of the treatment regimen.
62208846|NCT04996004|EXPERIMENTAL|Dose Expansion Dose Level C (Cohort C)|Participants with high-grade leiomyosarcoma will receive up to six cycles of Ontorpacept (TTI-621) at a pre-specified dose level (Dose Level C) in combination with fixed-dose doxorubicin followed by Ontorpacept (TTI-621) monotherapy to further characterize safety, tolerability, and clinical activity of the treatment regimen.
62208847|NCT04818008|EXPERIMENTAL|Otago Exercise Program|Patients will receive the Otago Exercise Program for 8 weeks plus health awareness videos about topics related to MS.
62208848|NCT04818008|NO_INTERVENTION|Control group|Patients will receive health awareness videos only about topics related to MS.
62208849|NCT05945212|EXPERIMENTAL|Vibration|Stroke patients in subacute rehabilitation phase will be included. In addition of a subacute post-stroke standard rehabilitation program, they will have a vibration program.
62208850|NCT05945212|SHAM_COMPARATOR|no vibration|In addition of a subacute post-stroke standard rehabilitation program, they will have a sham vibration program.
62208851|NCT05372562||patients with recurrent macular edema|after intravitreal injection of OZURDEX, patients with macular edema relapse during follow-up were recruited.
62208852|NCT05372562||patients without recurrent edema|after intravitreal injection of OZURDEX, patients without macular edema relapse during follow-up were recruited.
62208853|NCT04018638|EXPERIMENTAL|Adults with TKR Perform Home Exercise Program|Participants that have a total knee replacement will complete a home-based exercise program
62208854|NCT04018638|NO_INTERVENTION|Healthy Controls Only|Participants that have no history of knee joint dysfunction will serve as age-matched uninjured controls
62208855|NCT02060877||patients suspected of having lung cancer|observational study, there is no study intervention, only patient questionnaires
62208856|NCT03031470|EXPERIMENTAL|Reparixin|"Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.~All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation."
62208857|NCT03031470|OTHER|Control|The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.
62406805|NCT05344417|NO_INTERVENTION|Arm 1: Standard of Care|25 patients undergoing laparoscopic right hemi-colectomies or sigmoid resections using high pneumoperitoneum pressure with conventional insufflation under moderate neuromuscular blockade with rocuronium and neuromuscular blockade reversal with neostigmine. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.
62406806|NCT05344417|EXPERIMENTAL|Arm 2A: Conventional Pneumoperitoneum and Moderate Blockade|25 patients undergoing laparoscopic right hemi-colectomies or sigmoid resections using high pneumoperitoneum pressure with conventional insufflation under moderate neuromuscular blockade with rocuronium and neuromuscular blockade reversal with sugammadex. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.
62018224|NCT05492318|EXPERIMENTAL|Givinostat, Dabigatran etexilate, Midazolam oral and IV.|"On Days 1, 6 and 17, single doses of midazolam 1 mg i.v and dabigatran etexilate 75 mg, administered 1 hour after givinostat administration.~On Days 2, 7 and 18, a single oral dose of midazolam 2.5 mg oral solution will be administered 1 hour after givinostat. From Day 4 to Day 18, givinostat 50 mg as oral suspension will be administered twice a day. On Day 19, givinostat administered once."
62208858|NCT05326412|EXPERIMENTAL|Itepekimab|"This arm includes participants from 2 populations: Part A-former smokers and Part B-current smokers.~Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for 12 weeks"
62406807|NCT05344417|EXPERIMENTAL|Arm 2B: AirSeal® Pneumoperitoneum and Moderate Blockade|25 patients undergoing laparoscopic right hemi-colectomies or sigmoid resections using high pneumoperitoneum pressure with AirSeal® trademark (TM) system under moderate neuromuscular blockade with rocuronium and neuromuscular blockade reversal with sugammadex. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.
62581795|NCT06683040|EXPERIMENTAL|0.170 mg\kg|
62581796|NCT06683040|PLACEBO_COMPARATOR|Placebo|
62208859|NCT03683992||cemented and cementless Triathlon group|cemented group are patients who get randomized to receive cemented knee implant and Patient randomized to receiving cement less knee implant.
62208860|NCT05833100|EXPERIMENTAL|Users of the Blood Glucose/b-Ketone Monitoring System|Participants are individuals who have either been diagnosed with diabetes or not and are naive users of CareSens PRO GK BT.
62208861|NCT06728891||Patients undergoing proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision|
62208862|NCT04296266|EXPERIMENTAL|Alda-341 treatment|Alda-341 treatment at 2 g/day for 14 days up until the day before regular medical care surgery.
62208863|NCT06729281|NO_INTERVENTION|exercise|Regular exercise is also among the factors affecting the formation of posture. A regular and systematic exercise program can change the curvatures of the spine in the sagittal plane.
62208864|NCT06729281|OTHER|exercise and kinesio taping|Regular exercise is also among the factors affecting the formation of posture. A regular and systematic exercise program can change the curvatures of the spine in the sagittal plane. + Kinesiotaping
62208865|NCT03058575|EXPERIMENTAL|Dietary MACs|Dietary fiber supplement (blend of resistant starch and dietary fiber food ingredients providing 15g of microbiota accessible carbohydrate/1 scoop serving) will be provided in a powder that will be mixed with 6-10 oz of water (depending on desired thickness) and consumed as a chocolate shake.
62208866|NCT03058575|OTHER|Control|No Intervention
62208867|NCT05263206|EXPERIMENTAL|Dupilumab|Loading dose administered subcutaneous (SC), followed by SC once every 2 weeks (Q2W) on top of non-sedative antihistamine and moisturizer
62208868|NCT05263206|PLACEBO_COMPARATOR|Placebo|Loading dose administered SC, followed by SC Q2W on top of non-sedative antihistamine and moisturizer
62208869|NCT04694261|EXPERIMENTAL|SM-ART Intervention|Intervention group will receive SM-ART module training along with the flyers on resilience building tips.
62208870|NCT04694261|NO_INTERVENTION|Control Group|Control group will only receive flyer on resilience building tips
62208871|NCT06728813||Working adults|The study included 2,705 individuals aged 19-65 working in various occupations. Data were collected using a demographic structure survey and the Behaviors Scale Towards Sustainable Nutrition (BSSN). A food consumption frequency survey was administered to calculate the EAT-Lancet Index. Occupations were classified into five groups according to the International Standard Classification of Occupations (ISCO)-88: Groups 1-2, 3-4, 5-8, 6-7, and 9-10. Additionally, occupational skill levels were categorized into four levels (1 being the lowest and 4 the highest) based on ISCO-88.
62208872|NCT06205485|ACTIVE_COMPARATOR|FOLFOX OR CAPOX|"FOLFOX= Six cycles of modified FOLFOX consisting of leucovorin, oxaliplatin and bolus fluoruracil (optional), infusional fluorouracil.~CAPOX= Capecitabine twice daily for 14 days and Oxaliplatin on day 1"
62208873|NCT06205485|ACTIVE_COMPARATOR|ChemoRT|Standard dose of infusional 5-Fluorouracil/capecitabine and radiation
62581797|NCT06189144|EXPERIMENTAL|experimental arm|SLS irritation model and Treatment
62018225|NCT05492318|EXPERIMENTAL|Givinostat and Clarithromycin|Days 1 and 8, givinostat 50 mg as oral suspension will be administered as a single dose, 1 hour after clarithromycin administration. From Day 4 to Day 10, clarithromycin 500 mg film-coated tablets will be administered twice a day.
62208874|NCT04331678|NO_INTERVENTION|Usual Care|Participants will be complete survey at enrollment and then again in 3 months.
62208875|NCT04331678|ACTIVE_COMPARATOR|Active|"Participants in the App group will receive usual care and complete survey at enrollment and then again in 3 months.~In addition, they will be asked to download the study app to their mobile device and use it at least once per week during the 3-month study period."
62208876|NCT03623945||Cohort A|Patients who have recently had an abnormal mammogram, followed by a breast biopsy and an initial diagnosis of Stage I, II, III or IV invasive breast cancer, will be invited to participate. Stage I, II and III participants will be further categorized into high-risk and low-risk. For the purposes of this study, participants with at least one of the following will be considered high-risk; any triple negative cancer, any grade III cancer, lymph node involvement, tumor greater than 2cm, or any patient receiving cytotoxic chemotherapy.
62208877|NCT03623945||Cohort B|"Patients who have recently had an abnormal mammogram, followed by a breast biopsy and diagnosed with a benign but high-risk pathology, will be invited to participate. This includes, but is not limited to, atypical ductal hyperplasia, atypical lobular hyperplasia, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), flat epithelia atypia or phylloides.~Accrual to Cohort B is complete."
62208878|NCT03623945||Cohort C|Patients who have recently had an abnormal mammogram, followed by a breast biopsy and diagnosed with a benign tumor, will be invited to participate. This includes, but is not limited to, fibroadenoma, papilloma, fibrocystic changes and Pseudoangiomatous stromal hyperplasia (PASH). Accrual to Cohort C is complete
62208879|NCT03623945||Cohort D|Patients who have had a normal screening mammogram within the last 6 months will be invited to participate. Accrual to Cohort D is complete.
62208880|NCT03623945||Cohort E|"Patients who have recently had an abnormal mammogram, followed by a breast biopsy and an initial diagnosis of Stage I, II, III invasive breast cancer.~Patients who have recently had an abnormal mammogram, followed by a breast biopsy, and diagnosed with a benign but high-risk pathology.~Cohort E has 3 sub-groups. For the purposes of this study, participants with a breast cancer will be categorized as E1-malignant high risk, of E2-malignant low risk.~Patients who have recently had an abnormal mammogram, followed by a breast biopsy, and diagnosed with a benign but high-risk pathology, will be invited to participate.~These patients will be considered E3-benign high-risk."
62208881|NCT06729359||PCOS (Polycystic Ovary Syndrome) group|includes patients diagnosed with PCOS (Polycystic Ovary Syndrome)
62208882|NCT06729359||Contorol group|include women of the same age group with no clinical or laboratory evidence of PCOS (Polycystic Ovary Syndrome)
62208883|NCT05484414|EXPERIMENTAL|Experimental|SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
62790016|NCT01354925|ACTIVE_COMPARATOR|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. .
62208884|NCT05484414|PLACEBO_COMPARATOR|Placebo|Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
62208885|NCT04886726|EXPERIMENTAL|PTCY and uhCG/EGF|PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant
62581798|NCT06189144|PLACEBO_COMPARATOR|placebo comparator|SLS irritation model and No Treatment
62581799|NCT03575221||Enrollees|Individuals with Osteogenesis Imperfecta
62208886|NCT01249950||adolescents|adolescents with morbid obesity
62018226|NCT05492318|OTHER|Givinostat (50 mg oral suspension)|On Day 1 and Day 13, givinostat 50 mg will be administered as a single dose. From Day 5 to Day 12, givinostat 50 mg will be administered twice a day.
62018227|NCT02048761|PLACEBO_COMPARATOR|Placebo Group|After debridement, placebo gel was applied into the periodontal pockets with a syringe and a blunt canula.
62018228|NCT02048761|ACTIVE_COMPARATOR|1% Metformin|After debridement, 1% Metformin gel was applied into the periodontal pockets with a syringe and a blunt canula.
62018229|NCT03529526|EXPERIMENTAL|KN046|
62018230|NCT05848739|EXPERIMENTAL|Dose Escalation Phase|The dose cohorts will be 0.5, 1, 2, 4, 8 \& 12 mg/kg IV once weekly (QW)
62208887|NCT00330252|EXPERIMENTAL|Alemtuzumab & Rituximab|"Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks)~Rituximab- Given intravenously on day 1 of every week for eight weeks (or 16 weeks)"
62208888|NCT06649331|EXPERIMENTAL|A|SHR-A1811 (HER2 ADC)
62208889|NCT06649331|EXPERIMENTAL|B|SHR-A1921 (TROP2 ADC)
62208890|NCT06649331|EXPERIMENTAL|C|SHR-A2009 (HER3 ADC)
62208891|NCT06649331|EXPERIMENTAL|D|SHR-A2102 (Nectin4 ADC)
62406808|NCT05344417|EXPERIMENTAL|Arm 3A: Conventional Pneumoperitoneum and Deep Blockade|25 patients undergoing laparoscopic right hemi-colectomies or sigmoid resections using low pneumoperitoneum pressure with conventional insufflation under deep neuromuscular blockade with rocuronium and neuromuscular blockade reversal with sugammadex. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.
62790017|NCT01354925|ACTIVE_COMPARATOR|Standard treatment during Ramadan|Standard of care according to physicians choice
62018231|NCT05848739|EXPERIMENTAL|ST316 Monotherapy Colon Rectal Cancer (CRC) Expansion phase|ST316 Monotherapy Colon Rectal Cancer (CRC) Expansion phase n=15-30
62208892|NCT04601675|EXPERIMENTAL|Diabetic ME: Ranibizumab and intravitreal Dexamethasone|Participants with diabetic macular edema will receive a combination of Ranibizumab and intravitreal Dexamethasone
62208893|NCT04601675|ACTIVE_COMPARATOR|Diabetic ME: Ranibizumab|Participants with diabetic macular edema (ME) will receive Ranibizumab only.
62581800|NCT02259192|EXPERIMENTAL|Open-label|Cochlear Implant
62581801|NCT03343704|EXPERIMENTAL|Group A - patients with uncontrolled or life-threatening bleeding|
62018232|NCT05848739|EXPERIMENTAL|ST316 & FOLFIRI/Bevacizumab Combination Colon Rectal Cancer (CRC) Expansion phase|ST316 \& FOLFIRI/Bevacizumab Combination Colon Rectal Cancer (CRC) Expansion phase Expansion phase n=15-30
62018233|NCT05848739|EXPERIMENTAL|ST316 & Fruquintinib Combination CRC Expansion phase|ST316 \& Fruquintinib Combination CRC Expansion phase n=15-30
62018234|NCT05848739|EXPERIMENTAL|ST316 & Lonsurf + Bevacizumab Combination CRC Expansion phase|ST316 \& Lonsurf \& bevacizumab n=15-30
62208894|NCT06695130|EXPERIMENTAL|Group 1: RIV (in right or left deltoid) and placebo (in opposite deltoid)|two IM injections on D01
62734475|NCT05808582|EXPERIMENTAL|chidamide combined with fulvestrant|fulvestrant
62018235|NCT00938925|EXPERIMENTAL|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
62018236|NCT00938925|EXPERIMENTAL|nail lacqer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
62208895|NCT06695130|EXPERIMENTAL|Group 2: rC19 (dose 1) (in right or left deltoid) and placebo (in opposite deltoid)|two IM injections on D01
62208896|NCT06695130|EXPERIMENTAL|Group 3: RIV (in right or left deltoid) and rC19 (dose 1) (in opposite deltoid)|two IM injections on D01
62208897|NCT06695130|EXPERIMENTAL|Group 4: RIV + rC19 (dose 1) (in right or left deltoid) and placebo (in opposite deltoid)|two IM injections on D01
62208898|NCT06695130|EXPERIMENTAL|Group 5: RIV + rC19 (dose 2) (in right or left deltoid) and placebo|two IM injections on D01
62208899|NCT06695130|EXPERIMENTAL|Group 6: RIV + rC19 (dose 3) (in right or left deltoid) and placebo|two IM injections on D01
62208900|NCT06695130|EXPERIMENTAL|Group 7: RIV + rC19 (dose 4) (in right or left deltoid) and placebo (in opposite deltoid)|two IM injections on D01
62208901|NCT06088342||study subjects|In this study, participants will participate in the study after reading and approving the informed consent form. Volunteers participating in the study will first fill out the demographic information form. Then, the volunteers will be administered the Tampa Kinesiophobia Scale, Timed Up and Go Test, Trunk Impairment Scale, and Tinetti Fall Effectiveness Scale. This study is a correlation study. Individuals' Tampa Kinesiophobia Scale results will be analyzed and interpreted with other scale results.
62208902|NCT00043472||1|Eligible women at least one intact ovary who have signed written, informed consent that they will undergo screening as per protocol.
62208903|NCT00043472||2|Eligible women with at least one intact ovary who have signed written, informed consent that they will undergo risk reducing surgery
62208904|NCT02227979|EXPERIMENTAL|Group I|The PURPLE Cry Intervention group will get an 11-page booklet and 12-minute DVD to review.
62208905|NCT02227979|ACTIVE_COMPARATOR|Group II|The control intervention group will get 1 brochure and a DVD on infant safety to review.
62208906|NCT06130280|EXPERIMENTAL|MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT)|Participants will undergo simulation including Gd-EOB-DTPAenhanced MR and planning using minimal margins. Ten days later (+/- 3 days) participants will receive 40Gy single fraction treatment on Elekta Unity using Gd-EOB-DTPA-enhanced MR for image guidance and on-line adaptive replanning.
62208907|NCT01457482|EXPERIMENTAL|Art therapy group|Treatment in this arm consists of five Art Therapy sessions and therapeutic conversations.
62208908|NCT01457482|ACTIVE_COMPARATOR|Therapeutic conversation group|Treatment by therapeutic conversations only
62208909|NCT05677360|EXPERIMENTAL|Wave 1: Initial Community Health Centers|Initial group of community health centers to receive intervention
62018237|NCT02229097|EXPERIMENTAL|Normal then Coordinated|normal bolus during 2 weeks then coordinated bolus during 2 weeks
62208910|NCT05677360|EXPERIMENTAL|Wave 2: Second Community Health Centers|Second group of community health centers to receive intervention
62208911|NCT06729151||Healthy Controls|49 healthy control patients complete the questionnaire packet once. No additional follow-up is completed.
62208912|NCT06729151||Bladder pain syndrome treated with conservative management|55 patients with bladder pain syndrome who choose treatment with conservative management complete pre-treatment and 12-week post-treatment questionnaires.
62208913|NCT06729151||Bladder pain syndrome treated with bladder Botox|55 patients with bladder pain syndrome who choose treatment with bladder Botox complete pre-treatment and 12-week post-treatment questionnaires.
62208914|NCT05847673|EXPERIMENTAL|Arm I (EQQUAL A)|Participants receive self-guided online EQQUAL A program on study. Participants also receive motivational messages and smoking cessation information via text messages.
62208915|NCT05847673|ACTIVE_COMPARATOR|Arm II (EQQUAL B)|Participants receive self-guided online EQQUAL B program on study. Participants also receive motivational messages and smoking cessation information via text messages.
62208916|NCT01652495|ACTIVE_COMPARATOR|methylprednisolone acetate group|Single intrabursal injection of methylprednisolone acetate
62208917|NCT01652495|ACTIVE_COMPARATOR|Triamcinolone acetonide group|Single intrabursal injection of Triamcinolone acetonide
62018238|NCT02229097|EXPERIMENTAL|Coordinated then Normal|coordinated bolus during 2 weeks then normal bolus during 2 weeks
62018239|NCT03333746|EXPERIMENTAL|Treatment (lenalidomide, nivolumab)|Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 1 hour on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62208918|NCT00699153|EXPERIMENTAL|Loteprednol Etabonate|Loteprednol Etabonate 0.5%
62208919|NCT00699153|PLACEBO_COMPARATOR|Vehicle|Vehicle of Ophthalmic Loteprednol Etabonate
62208920|NCT03849677||Omnivore|
62208921|NCT03849677||Vegan|
62581802|NCT03343704|EXPERIMENTAL|Group B - patients not bleeding but requiring emergency surgery or invasive procedure|
62790018|NCT04917965||Healthy Term Neonates|Infants born at 37 weeks gestational age or greater born to mothers of any age with uncomplicated pregnancies. Following delivery, cord blood obtained from the placental portion of the umbilical cord will be used for analysis. To assure appropriate dilution, a hematocrit will be measured at the time of blood collection using a blood gas machine for prompt results. Sample blood will immediately be taken by the investigators from the delivery hospital to the children's hospital where the following clotting studies will be performed: PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s. Specimens will be transported utilizing Specimen Transport Guidelines.
62018240|NCT05872139|PLACEBO_COMPARATOR|Placebo|Gelatin capsules
62018241|NCT05872139|EXPERIMENTAL|MitoQ|Capsules containing mitoquinone mesylate (MitoQ, 5 mg/capsule) totaling 80 mg were taken once.
62208922|NCT00218231|EXPERIMENTAL|1|300 mg/day bupropion-sr
62208923|NCT00218231|PLACEBO_COMPARATOR|2|0 mg bupropion-sr
62018242|NCT03766646|EXPERIMENTAL|Speech|Participants were asked to read a standardised script aloud for 3 minutes whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
62018243|NCT03766646|ACTIVE_COMPARATOR|Non-speech|Participants were asked to breathe in and out of their nose for 3 minutes, with a closed mouth, whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
62018244|NCT02578524||Accommodating Lenses|Patients who underwent surgery with an accommodating lens implant.
62208924|NCT05815550||PPI users|
62208925|NCT05157269|ACTIVE_COMPARATOR|Nitazoxanide|Nitazoxanide 300 mg extended release tablets
62208926|NCT05157269|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62208927|NCT04196491|EXPERIMENTAL|Dose Escalation|"* bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 800 x 10\^6 CAR+ T cells after receiving lymphodepleting chemotherapy with a planned starting dose of 450 x 10\^6 CAR+ T cells.~* Lenalidomide maintenance therapy is recommended for all patients and should be initiated upon adequate bone marrow recovery or from 90-day post-bb2121 infusion, whichever is later"
62208928|NCT05684263|EXPERIMENTAL|Weight Science + Healthy Eating Education|In this condition participants will watch two educational videos on the topics of weight science, and healthy eating. The videos were created by a registered psychologist and are each between 20 and 30 minutes in length.
62208929|NCT05684263|OTHER|Weight Science + Healthy Sleep Education|"In this condition participants will watch two educational videos on the topics of weight science, and healthy sleep. The videos were created by a registered psychologist and are each between 20 and 30 minutes in length.~We are interested in the effect of weight science education alone, the healthy sleep video was added as an active control so that each condition was watching the same amount of videos."
62581803|NCT06075901|ACTIVE_COMPARATOR|Blood Flow Restriction with Cuffing|The participant will use the Cuffing for Blood Flow Restriction training
62581804|NCT06075901|EXPERIMENTAL|Blood Flow Restriction with Tissue Flossing|The participant will use Tissue Flossing for Blood Flow Restriction training
62018245|NCT02578524||Multifocal Lenses|Patients who underwent surgery with an multifocal lens implant.
62018246|NCT05482607||SSc-ILD patients|
62018247|NCT02041429|EXPERIMENTAL|Phase I Dose Level 0: Paclitaxel + Ruxolitiniib 10 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 10 mg orally twice daily for 4 cycles~1 cycle = 21 days~Participants with stable disease or better will have the opportunity to continue on single agent 10 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
62018248|NCT02041429|EXPERIMENTAL|Phase I Dose Level 1: Paclitaxel + Ruxolitiniib 15 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 15 mg orally twice daily for 4 cycles~1 cycle = 21 days~Participants with stable disease or better will have the opportunity to continue on single agent 15 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
62018249|NCT02041429|EXPERIMENTAL|Phase I Dose Level 2: Paclitaxel + Ruxolitiniib 20 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 20 mg orally twice daily for 4 cycles~1 cycle = 21 days~Participants with stable disease or better will have the opportunity to continue on single agent 20 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
62208930|NCT05684263|OTHER|Healthy Eating + Healthy Sleep Education|"In this condition participants will watch two educational videos on the topics of healthy eating, and healthy sleep. The videos were created by a registered psychologist and are each between 20 and 30 minutes in length.~We are interested in the effect of healthy eating education alone, the healthy sleep video was added as an active control so that each condition was watching the same amount of videos."
62581805|NCT06685172|ACTIVE_COMPARATOR|f-ESWT Group|Twenty patients with plantar fasciitis received f-ESWT treatment once a week for four weeks.
62581806|NCT06685172|ACTIVE_COMPARATOR|r-ESWT Group|Twenty patients with plantar fasciitis received r-ESWT treatment once a week for four weeks.
62581807|NCT02582242|EXPERIMENTAL|BIAsp 30 TID|
62581808|NCT02582242|ACTIVE_COMPARATOR|BIAsp 30 BID|
62581809|NCT01339923|EXPERIMENTAL|B_2h3h5_11|Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.
62018250|NCT02041429|EXPERIMENTAL|Phase I Dose Level 3: Paclitaxel + Ruxolitiniib 25 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 25 mg orally twice daily for 4 cycles~1 cycle = 21 days~Participants with stable disease or better will have the opportunity to continue on single agent 20 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
62018251|NCT00753324|EXPERIMENTAL|Routine three-drug antiretroviral prophyalxis|Cohort of 160 HIV-infected women, approached at \> 28 weeks gestation and initiated on routine HAART for the purposes of PMTCT.
62018252|NCT00753324|NO_INTERVENTION|Control arm|A cohort of 160 women will be enrolled from the control clinics, from 28 weeks gestation onward. At these sites, the antenatal zidovudine will be offered, with provision of single-dose nevirapine for self-administration in labor. This practice is in accordance with the current standard of care recommended by the Zambian National Guidelines for PMTCT.
62018253|NCT03455283||Clariscan 0.5 mmol/ml|Participants will receive Clariscan 0.5 mmol/ml injection as apart of clinical practice at the medical discretion of the prescribing physician.
62018254|NCT03455283||All Gadolinium-Based Contrast Agents (GBCAs)|Participants will receive GBCA as part of clinical practice at the medical discretion of the prescribing physician.
62018255|NCT04506450|ACTIVE_COMPARATOR|Peripheral nerve block|The participant will receive a combination of lumbar plexus block, sciatic nerve block, lateral femoral cutaneous nerve block and lateral branch of iliohypogastric nerve block
62208931|NCT04873427||early metastatic prostate cancer patients|Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
62581810|NCT01339923|EXPERIMENTAL|B_3h5_11|Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.
62581811|NCT01339923|EXPERIMENTAL|B_68_11|Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.
62581812|NCT01339923|EXPERIMENTAL|B_02_2_5|Subjects, 2-5 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
62581813|NCT01339923|EXPERIMENTAL|B_02_6_10|Subjects, 6-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
62581814|NCT01339923|EXPERIMENTAL|BC_35_12|Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
62581815|NCT01339923|EXPERIMENTAL|C_35_12|Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 and 15 months of age.
62581816|NCT02482948|ACTIVE_COMPARATOR|Collagenase|This is an enzymatic debridement agent to remove non-viable tissue from wounds to be applied daily
62406809|NCT05344417|EXPERIMENTAL|Arm 3B: AirSeal® Pneumoperitoneum and Deep Blockade|25 patients undergoing laparoscopic right hemi-colectomies or sigmoid resections using low pneumoperitoneum pressure with AirSeal® TM system under deep neuromuscular blockade with rocuronium and neuromuscular blockade reversal with sugammadex. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.
62406810|NCT03396601|EXPERIMENTAL|NRX-100 infusion|Infusion of IV NRX-100 (ketamine)
62790019|NCT04917965||Term infants of diabetic mothers|Infants born at 37 weeks gestational age or greater to mothers of any age with gestational diabetes or Type 1 or Type 2 diabetes, managed with either diet or insulin. Following delivery, cord blood obtained from the placental portion of the umbilical cord will be used for analysis. To assure appropriate dilution, a hematocrit will be measured at the time of blood collection using a blood gas machine for prompt results. Sample blood will immediately be taken by the investigators from the delivery hospital to the children's hospital where the following clotting studies will be performed: PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s. Specimens will be transported utilizing Specimen Transport Guidelines.
62018256|NCT04506450|ACTIVE_COMPARATOR|Spinal anesthesia|The participant will receive a combination of spinal anesthesia and lumbar plexus block
62018257|NCT04943926|ACTIVE_COMPARATOR|Energy Restricted Diet|A nutritional complete formula diet for 3 months followed by an energy restricted diet for 12 months.
62018258|NCT04943926|EXPERIMENTAL|Continuous LCHF Diet|A very low-carbohydrate high-fat ketogenic diet (VLCHF) diet for 3 months, followed by a low-carbohydrate high-fat diet (LCHF) for 12 months.
62018259|NCT01820429||First 48 hours|Patients in the first 48 hours of non ST-elevation acute coronary syndromes.
62018260|NCT01820429||3 months after discharge|Patients with 3 months after hospital discharge for non ST-elevation acute coronary syndromes.
62208932|NCT04873427||non-relapsing/non-metastatic patients with indolent malignant disease|Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
62406811|NCT03396601|EXPERIMENTAL|Saline (placebo) infusion|Infusion of IV Saline
62406812|NCT05248919|ACTIVE_COMPARATOR|12 weeks - treatment with sofosbuvir/velpatasvir (usual regime)|134 first-line treatment failure patients randomly allocated to receive 12 weeks treatment with sofosbuvir/velpatasvir. 1:1 random allocation with stratification for the presence of cirrhosis
62581817|NCT02482948|ACTIVE_COMPARATOR|Active leptospermum honey|This is an active medicinal grade honey used to promote autolytic debridement and applied daily
62208933|NCT06092970||RBT-1|Patients undergoing CABG, valve, or combined CABG/valve surgery
62208934|NCT06092970||Placebo|Patients undergoing CABG, valve, or combined CABG/valve surgery
62790020|NCT03753412||ICUAW ECMO group|The physical and psychological effects of ICUAW on patients receiving extracorporeal membrane oxygenation for severe cardiorespiratory failure will be observed. Physical function and HRQoL will be analysed and correlated with RFcsa. Additionally, biological markers will be used to understand molecular and genomic profiles.
62790021|NCT01068899||Children|healthy children
62790022|NCT01068899||Adult|healthy adults
62790023|NCT02674347|EXPERIMENTAL|Cohort 1: 3 g or 6 g of Zidebactam|"Cohort 1 (Zidebactam): 3 g of Zidebactam (1 g every 8 hours \[q8h\]) (n=8) IV infusions administered over 60 minutes.~Cohort 2 (Zidebactam or placebo): 6 g of Zidebactam (2 g q8h) (n=8) IV infusions administered over 60 minutes."
62790024|NCT02674347|PLACEBO_COMPARATOR|Placebo|"Cohort 1: Placebo every 8 hours \[q8h\] (n=2) IV infusions administered over 60 minutes.~Cohort 2: Placebo every q8h (n=2) IV infusions administered over 60 minutes."
62208935|NCT02015364|EXPERIMENTAL|Controlled early mobilization|The intervention group: Must perform controlled mobilization-exercises from the beginning of week 3 to 8
62018261|NCT03089190|ACTIVE_COMPARATOR|DC7-2 alone|Administration of DC7-2, a meat-derived octapeptide.
62208936|NCT02015364|NO_INTERVENTION|Immobilization|The control group: In line with the current treatment regimen the patients must keep the boot on at all times and they are not allowed to move the ankle.
62790025|NCT03671304|EXPERIMENTAL|Just-in-time Adaptive Intervention|Participants will receive a Fitbit Versa and instructions on its use. The study design is not a traditional randomized controlled trial in which participants are randomized to either the intervention or control group. Instead the study utilizes a microrandomized design. This is a within-subjects design in which participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days.
62208937|NCT05877911|EXPERIMENTAL|HIPEC with sodium thiosulfate and hydration|"Sodium sulfate 9 g/m\^2 combined with 0.9% natrium chloride 150 ml were instilled in 20 min as the time when HIPEC with cisplatin was beginning. After that, sodium sulfate 12 g/m\^2 combined with 0.9% natrium chloride 1000 ml was pumped for 6 h .~hydration: On the day of surgery, the day of HIPEC, and 24 hours after HIPEC, daily intravenous rehydration should be performed using natrium chloride, glucose chloride or potassium chloride. The amount of fluid to be replenished should not be less than 3000 milliliters."
62208938|NCT05877911|ACTIVE_COMPARATOR|HIPEC with hydration only|hydration:On the day of surgery, the day of HIPEC, and 24 hours after HIPEC, daily intravenous rehydration should be performed using natrium chloride, glucose chloride or potassium chloride. The amount of fluid to be replenished should not be less than 3000 milliliters.
62208939|NCT06487429|EXPERIMENTAL|Short term radiotherapy with continuous use of Disitamab Vedotin, Sintilimab, and S-1|"Short range radiotherapy, PCTV (Clinical Plan Target Area) DT 25Gy/5F, once daily for a total of 5 days, continuous irradiation, and IMRT (Intensity Modulated Radiotherapy) technology; After a week of rest, radiotherapy and chemotherapy combined with immunotherapy will be performed~* Disitamab Vedotin: 2.5 mg/kg, intravenous infusion, d1，Q3W；~* Sintilimab: 200mg, iv；~* S-1: 40 mg/dose, oral, bid，d1-14；Q3W"
62208940|NCT02316951||single-arm study group|Study participants will be adult patients recovering from orthopedic surgery. The study group will wear a small motion detection device and a regular Webcam will be placed near the wall facing the bed in each patient's hospital room.
62406813|NCT05248919|ACTIVE_COMPARATOR|24 weeks - treatment with sofosbuvir/velpatasvir (intervention)|134 first-line treatment failure patients randomly allocated to receive 24 weeks treatment with sofosbuvir/velpatasvir. 1:1 random allocation with stratification for the presence of cirrhosis
62790026|NCT01149720|EXPERIMENTAL|ARQ 197 Capsule, oral|Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
62208941|NCT02387970|ACTIVE_COMPARATOR|Immediate provisionalization|Individuals will receive temporary dental crowns supported by NobelParallel CC implant at the same day as implant surgery
62208942|NCT02387970|ACTIVE_COMPARATOR|Delayed provisionalization|Individuals will receive temporary dental crowns supported by NobelParallel CC implant 3 months after implant surgery
62208943|NCT06153342|ACTIVE_COMPARATOR|TL-925 Arm|Subjects will be dosed in clinic on days of dosing.
62208944|NCT06153342|PLACEBO_COMPARATOR|Placebo Arm|Subjects will be dosed in clinic on days of dosing.
62406814|NCT05248919|NO_INTERVENTION|Observational|50 patients with decompensated cirrhosis who will receive 24 weeks of sofosbuvir/velpatasvir.
62406815|NCT05558735||case group|The case group is composed of Adult male with a positive biopsy (Gleason score greater than or equal to 7)
62406816|NCT05558735||control group|The control group is made up of adult men performing a biopsy whose Gleason score is less than or equal to 6.
62406817|NCT06132087|EXPERIMENTAL|Treatment (surgical resection)|Patients undergo laparoscopy followed by surgical resection with pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy at the discretion of the surgeon within 2-8 weeks following completion of standard of care neoadjuvant chemotherapy regimen. Patients undergo CT and blood sample collection throughout the study and/or MRI during screening. Patients also undergo tissue collection at time of surgical resection on study.
62406818|NCT01153971|EXPERIMENTAL|1|
62208945|NCT06528847|EXPERIMENTAL|Adjuvant Benmelstobart Group|Enrolled patients will receive adjuvant immunotherapy with the PD-L1 inhibitor Benmelstobart (TQB2450) at a dose of 1200 mg every 3 weeks by intravenous injection, for a maximum of 16 cycles following radical resection.
62208946|NCT00045526|EXPERIMENTAL|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62208947|NCT06729853|EXPERIMENTAL|Mild renal impairment|Subjects with mild renal impairment
62208948|NCT06729853|EXPERIMENTAL|Moderate renal impairment|Subjects with moderate renal impairment
62208949|NCT06729853|EXPERIMENTAL|Severe renal impairment|Subjects with severe renal impairment(Optional)
62208950|NCT06729853|EXPERIMENTAL|Healthy match|Matched healthy subjects with normal renal function
62208951|NCT00452023|EXPERIMENTAL|IFN-alpha2a 90 Microgram (mcg) weekly|Starting dose 90 microgram (mcg) injection under the skin once a week.
62208952|NCT00452023|EXPERIMENTAL|IFN-alpha2a 450 Microgram (mcg) weekly|Starting dose 450 microgram (mcg) injection under the skin once a week.
62018262|NCT03089190|ACTIVE_COMPARATOR|DC7-2 + potato protein isolate|Administration of DC7-2, a meat-derived octapeptide, combined with potato protein isolate that protects DC7-2 from degradation in the GI tract.
62790027|NCT01149720|EXPERIMENTAL|ARQ 197 Tablet, oral|Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
62018263|NCT03089190|ACTIVE_COMPARATOR|Potato protein isolate + placebo|Administration of potato protein isolate combined with inactive whey protein as placebo.
62018264|NCT03089190|PLACEBO_COMPARATOR|Placebo|administration of inactive whey protein
62018265|NCT02125058|OTHER|Transcutaneous sutures|Transcutaneous sutures
62581818|NCT02088671||Anesthesia|"A single study group undergoing general anesthesia procedure to observe post-hoc the effect on the NeuroSENSE monitor readings.~Interventions of interest:~Drug: Propofol induction followed by randomized doses of desflurane; Emergence by stepping down the desflurane ET - See intervention descriptions.~Device: Recording of EEG using NeuroSENSE (blinded to clinicians) - See intervention descriptions.~Other: Data Collection - See intervention descriptions"
62581819|NCT01599936|EXPERIMENTAL|Anascorp|Three vials of Anascorp® will be administered in a total volume of 50 mL, intravenous over not less than 10 minutes or as permitted by IV access
62790028|NCT01149720|EXPERIMENTAL|ARQ 197 Capsule D, oral|Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
62790029|NCT05564312||non-pregnant|Negative b-hCG results 9 days after embryo transfer.
62790030|NCT05564312||pregnant|Positive b-hCG results 9 days after embryo transfer.
62790031|NCT00781833|EXPERIMENTAL|Treatment|Intramuscular Electrical Stimulation
62790032|NCT06267222|EXPERIMENTAL|TRANS-SPINAL STIMULATION IN SCA|The tDCS sessions will be conducted with an intensity of 2mA, utilizing the anodic electrode positioned over the cerebellar region and the cathodic electrode over the thoracic region of the spinal cord (approximately at vertebra T11). These sessions will be integrated into a gait and postural control training protocol, which will progressively increase in difficulty over 4 consecutive weeks on weekdays, excluding weekends. A total of 20 sessions will be administered, each lasting approximately 30 minutes. During each session, the electrodes will be placed, and participants will perform a single leg test on each side of the body. The exercise protocol will then be executed while the tDCS is applied, lasting for 20 minutes. Following the exercise, the single-leg test will be repeated, and the electrodes will be removed.
62018266|NCT02125058|OTHER|Intracutaneous sutures|Intracutaneous sutures
62018267|NCT06316804|EXPERIMENTAL|Video Intervention 1|The video intervention #1 will involve videos of patients describing personal narratives of mental illness, treatment and recovery, and will be delivered over 4 weeks (with two booster sessions in week 6 and 12). Assessments will be completed over 12 months from date of randomization.
62018268|NCT06316804|ACTIVE_COMPARATOR|Video Intervention 2|The video intervention #2 will involve videos of patients describing personal narratives of mental illness, treatment and recovery, and will be delivered over 4 weeks (with two booster sessions in week 6 and 12). Assessments will be completed over 12 months from date of randomization.
62790033|NCT06457711|OTHER|Free diet Group (FDG)|participants were offered nutritional guidance without strict limitations, but were encouraged to adhere to the principles of the Mediterranean diet and follow the dietary recommendations outlined in Harvard's Healthy Eating Plate.
62018269|NCT06316804|PLACEBO_COMPARATOR|Waitlist Video Intervention 3|After the completion of the 6-month waitlist period, the experimental video intervention will be provided. The intervention will involve videos of patients describing personal narratives of mental illness, treatment and recovery, and will be delivered over 4 weeks (with two booster sessions in week 6 and 12). The intervention offered after the waitlist period will follow video intervention 1 (experimental arm).
62018270|NCT06532838|EXPERIMENTAL|Optimized treatment strategies (OTS group)|Patients randomized to OTS group will be treated with optimized treatment strategies.
62018271|NCT06532838|ACTIVE_COMPARATOR|Traditional treatment strategies (TTS group)|Patients randomized to TTS group will be treated with traditional treatment strategies.
62018272|NCT01034904||Patients|Patients who have moderate or severe Hemophilia A, living in Canada and who are using Helixate FS either on-demand or prophylaxis
62018273|NCT01266759|EXPERIMENTAL|NuvaRing|For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
62018274|NCT01266759|ACTIVE_COMPARATOR|Norethisterone Acetate|Norethisterone Acetate tablets at a dose of 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
62018275|NCT00298233|ACTIVE_COMPARATOR|Standard Dose oseltamivir adult cohort|All participants \>= 15 years will receive standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
62018276|NCT00298233|ACTIVE_COMPARATOR|Double Dose oseltamivir Adult cohort|All participants \>= 15 years will receive high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
62018277|NCT00298233|ACTIVE_COMPARATOR|Standard Dose Oseltamivir child cohort|All participants \<15 years will receive standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
62208953|NCT00452023|EXPERIMENTAL|IFN-alpha2a 360 Microgram (mcg) weekly|Starting dose 360 microgram (mcg) injection under the skin once a week.
62208954|NCT00452023|EXPERIMENTAL|IFN-alpha2a 270 Microgram (mcg) weekly|Starting dose 270 microgram (mcg) injection under the skin once a week.
62208955|NCT00452023|EXPERIMENTAL|IFN-alpha2a 180 Microgram (mcg) weekly|Starting dose 180 microgram (mcg) injection under the skin once a week.
62208956|NCT04284605|EXPERIMENTAL|Group1|
62208957|NCT04284605|EXPERIMENTAL|Group2|
62208958|NCT04893252|EXPERIMENTAL|vactosertib in combination with durvalumab|single arm study
62790034|NCT06457711|EXPERIMENTAL|Very low Calorie Ketogenic Diet Group (VLCKDG)|the very low-calorie ketogenic diet (VLCKD) protocol involved limited carbohydrate consumption to less than 30 grams per day. The protocol suggested a protein intake ranging from 1 to 1.5 grams per kilogram of ideal body weight, with fats limited to 15-30 grams per day and total daily calories estimated between 600 and 800 kcal. During the initial three-week phase of the diet, participants replaced two meals per day with meal replacements-specifically, breakfast and one other main meal were substituted with a protein shake. Accompanying the shake for the main meal were low-glycemic-index vegetables in prescribed quantities.
62018278|NCT00298233|ACTIVE_COMPARATOR|Double Dose Oseltamivir child cohort|All Participants \<15 years will receive high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
62018279|NCT05090072|ACTIVE_COMPARATOR|- Advance Directives Group|The group that will receive the principal physician intervention, using Advance Directives document as a communication tool between patients and caregivers, to find its efficacy on the promotion of better-prepared surrogates
62018280|NCT05090072|PLACEBO_COMPARATOR|Control Group|The group that will receive the Placebo Intervention, consisting of a clinical evaluation of patients' clinical status, by the physician
62018281|NCT01032941|PLACEBO_COMPARATOR|Placebo|Patients in this group will be given placebo 2 packets BID for 8 weeks.
62018282|NCT01032941|EXPERIMENTAL|VSL#3|Patients in this group will be given 2 packets of VSL#3 BID for 8 weeks.
62208959|NCT02097953|EXPERIMENTAL|Daptomycin and Rifampin|Drug: Daptomycin Daptomycin 6 mg/kg will be given by IV infusion on the first study day Drug: Rifampin Rifampin 600 mg capsules will be given orally once daily for 14 days starting on study day 2 Drug: Daptomycin Daptomycin 6 mg/kg will be given by IV infusion on study day 15
62018283|NCT06148597||Group M-TAPA|
62018284|NCT06148597||Group Control|
62018285|NCT03299140|OTHER|Family Focused Therapy|Only 1 arm
62018286|NCT01421810|EXPERIMENTAL|dexamethasone, rhCG (Ovidrel)|rhCG (Ovidrel) administered 25 mcg IV; dexamethasone administered 1 mg PO
62208960|NCT04852341||Corneal horizontal diameter ≤9.00mm group|
62208961|NCT04852341||Corneal horizontal diameter 9.00mm~9.50mm group|
62208962|NCT04852341||Corneal horizontal diameter 9.50mm~10.00mm group|
62208963|NCT04852341||Corneal horizontal diameter >10.00mm group|
62208964|NCT06729528||Traumatic pediatric patients|Patients under 18 years old present to the emergency department red area due to trauma.
62208965|NCT05540470|EXPERIMENTAL|Module A|• Module A - PART (Presumptive anti-relapse treatment): This is the core of the strategy for targeting the P. vivax reservoir by identifying individuals with a high probability of being asymptomatic carriers of blood forms and/or hypnozoites (by epidemiological criteria combined with a rapid serological test), and treating these individualswith chloroquine (by 150mgs tablet, according to the following posology: 600mgs on the first day, 450mgs on the second and 300mgs on the third day, or weight-adjusted dosing) and primaquine (in a short regimen of 30 mg per day for seven days, or weight-adjusted dosing) or tafenoquine (300 mg as a single observed dose), after exclusion of contraindications to these treatments. This intervention aims to reduce the likelihood of relapse of a previous infection, and subsequent transmission in forest and urban settings, ultimately helping to reduce the circulation of P. vivax.
62406819|NCT01878968|EXPERIMENTAL|Script and Video|Patients in the Script and CPR/Mechanical ventilation video arm will receive information on CPR and mechanical ventilation via a script and a video.
62018287|NCT01154634|EXPERIMENTAL|First 5 mg, then placebo, then 16 mg, then 40 mg|period 1: AZD2516 5 mg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD2516 16 mg, period 6: washout, period 7: AZD2516 40 mg.
62790035|NCT06457711|ACTIVE_COMPARATOR|Intermittent Fasting Group (IFG)|Our participant followed an intermittent fasting schedule, specifically the 16/8 method, which involves eating only during an eight-hour window each day and fasting for the subsequent sixteen hours. This eating period began at 12:00 noon and ended at 8:00 PM. During this window, the patient consumed three meals, each with a caloric value reduced by 25% from their total daily energy expenditure. The meals were based on the Mediterranean diet, focusing on the balance and quality of macronutrients.
62790036|NCT06209502||Population A|Parkinson's disease patients between H\&Y stages 1.5 and 3
62790037|NCT06209502||Population B|Early Parkinson's disease patients of H\&Y stage 1
62790038|NCT06209502||Population C|Healthy controls
62790039|NCT02410239|EXPERIMENTAL|Mesenchymal Stem Cell|Third party donor Mesenchymal Stem Cells (MSC) will be administered via intrathecal administration at the assigned dose on days 0, 7 and 14. Dose escalation will be guided by a fast track design. One patient is entered per dose level until a DLT is experienced. At that point, two additional patients will be enrolled at the same dose level. Dose levels will be 2.5 x 10e6 MSC/kg per dose, 5 x 10e6 MSC/kg per dose or 7.5 x 10e6 MSC/kg per dose.
62790040|NCT02016079|EXPERIMENTAL|Omega-3|a fruit drink containing omega-3
62018288|NCT01154634|EXPERIMENTAL|First 40 mg, then 16 mg, then placebo, then 5 mg|period 1: AZD2516 40 mg, period 2: washout, period 3: AZD2516 16 mg, period 4: washout, period 5: placebo, period 6: washout, period 7: AZD2516 5 mg.
62018289|NCT01154634|EXPERIMENTAL|First 16 mg, then 5 mg, then 40 mg, then placebo|period 1: AZD2516 16 mg, period 2: washout, period 3: AZD2516 5 mg, period 4: washout, period 5: AZD2516 40 mg, period 6: washout, period 7: placebo.
62018290|NCT01154634|EXPERIMENTAL|First placebo, then 40 mg, then 5 mg, then 16 mg|period 1: placebo, period 2: washout, period 3: AZD2516 40 mg, period 4: washout, period 5: AZD2516 5 mg, period 6: washout, period 7: AZD2516 16 mg
62208966|NCT05540470|OTHER|Module B|• Module B - Malakit: distribution of a self-test and self-treatment kit to individuals in the target population who agree to be trained (and demonstrate understanding of the use of the kit), in order to maintain access to quality test and treatment for malaria attacks that occur in extreme isolation in illegal mining towns in French Guiana
62208967|NCT05540470|OTHER|Pre/post intervention surveys|Two cross-sectional surveys will be conducted in the inclusion sites before and at the end of intervention implementation, during the same period of the year (preferably the last quarter of 2022 and 2024), in order to limit biases associated with seasonality.
62406820|NCT01878968|EXPERIMENTAL|Script only|Patients in the Script only arm will receive information on CPR and mechanical ventilation via a script only.
62406821|NCT02203773|EXPERIMENTAL|ABT-199 + Azacitidine|Treatment Naive Acute Myelogenous Leukemia
62406822|NCT02203773|EXPERIMENTAL|ABT-199 + Decitabine|Treatment Naive Acute Myelogenous Leukemia
62406823|NCT02203773|EXPERIMENTAL|ABT-199+Decitabine+Posaconazole|Treatment Naive Acute Myelogenous Leukemia
62406824|NCT06334627|EXPERIMENTAL|Pre-Primary Intervention|Program consisting of 9 modules focussing on early learning, play, saftey, wellbeing, reading and writing will be delivered approximately every two weeks to groups of 10 parents from the intervention arm.
62581820|NCT06501014|EXPERIMENTAL|Action Observation Therapy-Experimental Group|Patients will be asked to watch the exercises before doing them. For each exercise, patients will first watch the relevant video and do the exercise after the video ends.
62581821|NCT06501014|ACTIVE_COMPARATOR|Conventional Exercises-Control Group|Patients will be asked to perform exercises that are described verbally and/or shown through pictures.
62581822|NCT03604393|EXPERIMENTAL|Practice Facilitation, Cluster 1|Intervention Cluster 1 is the first intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
62790041|NCT02016079|PLACEBO_COMPARATOR|Fruit drink|the same fruit drink given in the experimental arm, but not containing omega-3
62790042|NCT00666406|EXPERIMENTAL|1|Advate rAHF-PFM
62406825|NCT06334627|NO_INTERVENTION|Control|No intervention delivered. Participants will attend any government pre-primary based programmes as standard of care.
62790043|NCT00666406|ACTIVE_COMPARATOR|2|Recombinate rAHF
62790044|NCT02191332||Viramune|
62790045|NCT04104776|EXPERIMENTAL|Phase 2 Cohort M1|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M1: patients with urothelial carcinoma or other advanced/metastatic solid tumors (with known ARID1A mutation)"
62790046|NCT04104776|EXPERIMENTAL|Phase 2 Cohort M2|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M2 patients with ovarian clear cell carcinoma (with known ARID1A mutation)"
62790047|NCT04104776|EXPERIMENTAL|Phase 2 Cohort M3|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M3 patients with endometrial carcinoma (with known ARID1A mutation)"
62208968|NCT05540470|OTHER|QUALITATIVE STUDY|The CUREMA project includes qualitative research that will be conducted before, during and after the intervention by a trained social science researcher. The aim of this research will be to analyse the specific constraints and levers of the intervention under study and the pre-elimination context, in order to draw out lessons that are context-specific but also potentially of universal value. As described above, the study population will be broader and include not only the garimpeiros, but also the study field workers as well as other stakeholders.
62208969|NCT04368364|ACTIVE_COMPARATOR|Group 1 (Control group)|
62581823|NCT03604393|EXPERIMENTAL|Practice Facilitation, Cluster 2|Intervention Cluster 2 is the second intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
62790048|NCT04104776|EXPERIMENTAL|Phase 2 Cohort M4|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M4 patients with peripheral T-cell lymphoma (PTCL) and patients with diffuse large B-cell lymphoma (DLBCL), including patients with documented germinal center B cell like diffuse large B-cell lymphoma (GCB-DLBCL) with at least 1 EZH2 hotspot mutation"
62790049|NCT04104776|EXPERIMENTAL|Phase 2 Cohort M5|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M5 patients with relapsed or refractory malignant pleural or peritoneal mesothelioma with known BAP1 loss"
62790050|NCT04104776|EXPERIMENTAL|Phase 2 Cohort M6|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M6 patients with castration-resistant prostate cancer(mCRPC) with measurable soft tissue disease"
62018291|NCT05106868|EXPERIMENTAL|acupuncture|5 sessions of acupuncture per week for 4 weeks. In each session, acupuncture will be applied bilaterally on acupoints. We will use transcutaneous electric acupoints stimulation (HANS; Han's acupoints nerve stimulator, HANS-200, Nanjing, China) to stimulate the acupoints. Each session will last 30 minutes.
62018292|NCT05106868|SHAM_COMPARATOR|sham acupuncture|5 sessions of sham acupuncture per week for 4 weeks. In each session, acupuncture will be applied bilaterally on non-acupoints. We will use transcutaneous electric acupoints stimulation (HANS; Han's acupoints nerve stimulator, HANS-200, Nanjing, China) to stimulate the non-acupoints. Each session will last 30 minutes.
62018293|NCT05106868|NO_INTERVENTION|waiting-list|
62018294|NCT00085410|EXPERIMENTAL|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.
62018295|NCT06059469|EXPERIMENTAL|Patients with progressive metastatic TNBC and presenting measurable disease on 18F-FDG PET/CT|Patients with progressive metastatic TNBC and presenting measurable disease on 18F-FDG PET/CT
62018296|NCT02056301|ACTIVE_COMPARATOR|Patient Controlled Analgesia|One group will have a patient controlled device connected to an intravenous patient controlled analgesia (IV PCA). This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes.
62018297|NCT02056301|ACTIVE_COMPARATOR|epidural Catheter|The other group will have an epidural catheter inserted under sterile conditions in the thoracic epidural space after anesthesia has been induced. This will be connected to a patient controlled epidural analgesia (PCEA) device for postoperative pain control that works in a similar manner except the medication (a combination of local anesthetics and hydromorphone) will be administered in the thoracic epidural space.
62018298|NCT06657547|ACTIVE_COMPARATOR|Normal conditions|Urine samples collected after various performance tests in normal conditions
62018299|NCT06657547|EXPERIMENTAL|Heated conditions|Urine samples collected after various performance tests in heated conditions
62018300|NCT06657547|OTHER|Salmeterol inhalation and urine samples|Participants are administered daily salmeterol inhalation from an MDI device and are required to collect spot urine samples at home.
62018301|NCT01478945|ACTIVE_COMPARATOR|Dermfix 1000 active 311 nm NB-UVB|"Active hand held NB-UVB unit:~Manual device administering NB-UVB"
62208970|NCT04368364|EXPERIMENTAL|Group 2(Bupivacaine hydrochloride group)|
62208971|NCT04368364|EXPERIMENTAL|Group 3 (ropivacaine hydrochloride group)|
62208972|NCT05734638|EXPERIMENTAL|MIM-DASH|A trained MIM provider (layperson) and a registered dietitian will deliver the MIM DASH group intervention in eight 1-hour (30 minutes MIM and 30 minutes DASH) sessions via telehealth (video and telephone access).
62208973|NCT05734638|EXPERIMENTAL|MIM Only|"The MIM-only intervention group will receive the MIM education only in eight weekly sessions of 30 minutes each. To maintain equipoise among the intervention groups, this group will also have 30 minutes of social time to interact with the trainer and peers."
62208974|NCT05734638|EXPERIMENTAL|DASH Only|"The DASH-only group will receive the DASH education only in eight weekly sessions of 30 minutes each. This group will also have 30 minutes of social time to interact with the trainer and peers, will receive their education from a different interventionist (also a registered dietician) and receive two coaching calls per month for 3 months, in this case focused on healthy eating DASH principles."
62208975|NCT05038163|NO_INTERVENTION|Control Arm|In Part II of the experiment, subjects are not presented with nutrition or warning labels when choosing between beverages.
62208976|NCT05038163|EXPERIMENTAL|Nutrition Labels Arm|In Part II of the experiment, subjects are shown enlarged nutrition labels when choosing between beverages.
62208977|NCT05038163|EXPERIMENTAL|Text Warning Labels Arm|In Part II of the experiment, subjects are shown a warning message about the health risks of sugary beverages when choosing between beverages.
62208978|NCT05038163|EXPERIMENTAL|Graphic Warning Labels Arm|In Part II of the experiment, subjects are shown a graphic warning message about the health risks of sugary beverages when choosing between beverages. The message, for example, could include photos of tooth decay and other negative health outcomes.
62208979|NCT05691946|EXPERIMENTAL|Kinesiology Taping Group|Kinesiology Taping Group
62790051|NCT03562312|EXPERIMENTAL|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
62790052|NCT03562312|PLACEBO_COMPARATOR|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
62018302|NCT01478945|ACTIVE_COMPARATOR|Waldmann active 311 nm NB-UVB|"Active hand held NB-UVB unit:~Manual device administering NB-UVB (Waldmann)"
62018303|NCT01478945|SHAM_COMPARATOR|Dermfix 1000 placebo|Manual placebo hand held NB-UVB unit
62208980|NCT05691946|PLACEBO_COMPARATOR|Placebo Control Group|Placebo Taping Group
62208981|NCT06682793|EXPERIMENTAL|A2B395|Participants receive preconditioning lymphodepletion (PCLD) regimen followed by a single dose of A2B395 intravenously on day 0
62406826|NCT03673124|OTHER|Ribociclib and letrozole|Ribociclib 600mg oral daily for 3 weeks then 1 week off plus Letrozole 2.5 mg oral daily
62581824|NCT03604393|EXPERIMENTAL|Practice Facilitation, Cluster 3|Intervention Cluster 3 is the third intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
62208982|NCT01158287|EXPERIMENTAL|Sorafenib 400mg bd, p.o, continuously|
62018304|NCT05148000|EXPERIMENTAL|QM1114-DP|QM1114-DP
62208983|NCT03400111|EXPERIMENTAL|Low-level laser therapy|Patients upper and lower jaws will be irradiated with low-level laser therapy at specific points on the alveolus around the teeth from the vestibular and lingual sides. This group of patients will be followed up till the end of treatment.
62208984|NCT03400111|EXPERIMENTAL|Panadol-extra|Patients will be given Panadol-extra (565 mg: 500 mg paracetamol and 65 mg caffeine) at specific time points to control pain and discomfort during orthodontic treatment. This group of patients will be followed up till the end of treatment.
62208985|NCT03400111|NO_INTERVENTION|Traditional Treatment|Patients will not undergo any actual irradiation therapy or take any active tablets during orthodontic treatment.
62208986|NCT06728124|EXPERIMENTAL|GZR18|
62208987|NCT06728124|PLACEBO_COMPARATOR|Placebo|
62208988|NCT03405675||SLAS 1|The subjects (N=2800) are recruited from all residents aged 55 years and above in Singapore in the areas covered by the South-East Community Development Council: Geylang, Aljunied, MacPherson, Marine Parade and Bedok (SLAS-I).
62208989|NCT03405675||SLAS 2|An additional 3200 subjects are recruited from residents in the Bukit Merah and Jurong (SLAS-II).
62208990|NCT06717672|ACTIVE_COMPARATOR|Intervention group|intervention group recieve inj lidocaine
62208991|NCT06717672|PLACEBO_COMPARATOR|Control group|control group receive Normal saline
62018305|NCT01462344|EXPERIMENTAL|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
62018306|NCT01462344|EXPERIMENTAL|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
62018307|NCT01462344|ACTIVE_COMPARATOR|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
62018308|NCT01462344|ACTIVE_COMPARATOR|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
62208992|NCT06609109|EXPERIMENTAL|Smoked THC|Each participant in this arm will receive 0, 5, and 30mg of THC over the course of six visits. Each participant will also receive e-cigarette containing 0% and 5.0% nicotine.
62406827|NCT03115320|EXPERIMENTAL|Pregnyl (Human chorionic gonadotropin)|In this group, patients have natural cycle in frozen-thawed embryo transfer and the ovulation is confirmed by administration of hCG (Pregnyl® 5000 IU). The day of transferring embryo is depending on the day of administration of hCG and the age of the embryo. The day zero day is defined by ovulation triggered by hCG.
62406828|NCT03115320|OTHER|Home ovulation test|The patients randomized to the LH surge group perform the ovulation home test daily from the urine. Thus, the ovulation in this group is corfimed by the urine test. The day of transferring embryo is depending on the positive ovulation test and the age of the embryo. The day zero day is defined by positive ovulation test.
62208993|NCT06609109|EXPERIMENTAL|Vaporized THC|Each participant in this arm will receive 0, 5, and 30mg of THC over the course of six visits. Each participant will also receive e-cigarette containing 0% and 5.0% nicotine.
62208994|NCT00400725|EXPERIMENTAL|Initial Phase:- Clobex® Shampoo|In initial open-label phase, participants were applied Clobex® shampoo (Clobetasol Propionate) 0.05 percent (%) weight by weight (W/W) topically to the scalp once daily (twice a week) for 4 weeks (weekly dose was not more than 50 grams \[50 Milliliter\]).
62581825|NCT03604393|EXPERIMENTAL|Practice Facilitation, Cluster 4|Intervention Cluster 4 is the fourth intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
62581826|NCT03604393|EXPERIMENTAL|Practice Facilitation, Cluster 5|Intervention Cluster 5 is the final intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
62208995|NCT00400725|EXPERIMENTAL|Maintenance Phase: Clobex® Shampoo|In maintenance double-blind phase, participants presented with a good efficacy (Global severity score \[GSS\] less than or equal to \[\<=\] 2) in initial phase were randomized to apply Clobetasol Propionate shampoo 0.05 % weight by weight (W/W) twice weekly up to 6 months (wherein weekly dose were not exceeded beyond 50 grams \[50 milliliter\]). In case of relapse (that is \[i.e.\], GSS greater than \[\>\] 2) participants were re-entered to 4-week daily treatment with Clobetasol Propionate shampoo 0.05%. After this 4-week period of daily treatment, if GSS \<= 2, participants were re-entering the maintenance regimen (twice a week).
62208996|NCT00400725|PLACEBO_COMPARATOR|Maintenance Phase: Clobex® Vehicle Shampoo|In maintenance double-blind phase, participants presented with a good efficacy (Global severity score \[GSS\] \<= 2) in initial phase were randomized to apply Clobex® vehicle shampoo twice weekly up to 6 months (wherein weekly dose was not more than 50 grams \[50 milliliter\]). In case of relapse (i.e., GSS \[greater than\] \> 2) participants were re-entered to 4-week daily treatment with Clobetasol Propionate Shampoo 0.05 % (W/W). After this 4-week period of daily treatment, if GSS \<= 2, participants were re-entering the maintenance regimen (twice a week).
62208997|NCT02818244|ACTIVE_COMPARATOR|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
62208998|NCT02818244|ACTIVE_COMPARATOR|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
62208999|NCT02818244|ACTIVE_COMPARATOR|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
62209000|NCT02818244|ACTIVE_COMPARATOR|Apple Watch|Apple Watch Heart Rate Monitoring Device
62209001|NCT02818244|ACTIVE_COMPARATOR|Scosche Rhythm +|Scosche Rhythm + Heart Rate Monitoring Device
62209002|NCT01283152|ACTIVE_COMPARATOR|Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)|
62209003|NCT01283152|OTHER|Lactulose|Per standard of care
62209004|NCT04614168|ACTIVE_COMPARATOR|Group 1 - Standard Care|This group will continue on their standard diabetes care. They will be required to undergo three periods of blinded continuous glucose monitoring each lasting 20-days at: baseline, 4 months and 8 months. Participants in this group will undergo a hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.
62581827|NCT03363776|EXPERIMENTAL|Monotherapy|BMS-986277 administered alone
62581828|NCT03363776|EXPERIMENTAL|Combination Dose Escalation Therapy|BMS-986277 administered in combination with Nivolumab
62581829|NCT03363776|EXPERIMENTAL|Combination Expansion Therapy|BMS-986277 monotherapy with option for subsequent Nivolumab therapy
62581830|NCT05107492|EXPERIMENTAL|Cohort 1|12 participants will be randomly assigned at an allocation ratio of 3:1 to the active treatment 450mg and placebo arms.
62581831|NCT05107492|EXPERIMENTAL|Cohort 2|12 participants will be randomly assigned at an allocation ratio of 3:1 to the active treatment 150mg and placebo arms.
62581832|NCT06261125|EXPERIMENTAL|Arm A|This arm includes the patients who previously had not received PD-1/PD-L1 antibody. Patients assigned to this arm will receive SBRT followed by adebrelimab and lenvatinib. The prescribed dose of SBRT is 33-48 Gy in 6 fractions over 2 weeks. Then all patients will receive lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight \<60 kg) orally once daily in combination with adebrelimab 1200 mg every 3 weeks for up to 35 cycles. The first course of adebrelimab will be given within 1 week after completion of SBRT.
62581833|NCT06261125|EXPERIMENTAL|Arm B|This arm includes the patients who had progressed after receiving PD-1/PD-L1 antibody. Patients assigned to this arm will receive SBRT followed by adebrelimab and lenvatinib. The prescribed dose of SBRT is 33-48 Gy in 6 fractions over 2 weeks. Then all patients will receive lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight \<60 kg) orally once daily in combination with adebrelimab 1200 mg every 3 weeks for up to 35 cycles. The first course of adebrelimab will be given within 1 week after completion of SBRT.
62581834|NCT05047965|EXPERIMENTAL|Diagnostic (standard MRI, Dixon MRI)|Patients undergo MRI with additional Dixon based sequences with fat and water over a total of 49 minutes.
62018309|NCT03046680|EXPERIMENTAL|Health Coaching|Individualized follow-up, supporting the individual for a better autonomy in personal care.
62209005|NCT04614168|EXPERIMENTAL|Group 2- Automated insulin delivery and low carbohydrate diet|This group will be placed on an automated insulin delivery system: Tandem t:slim x2 insulin pump with Control IQ technology and Dexcom G6 continuous glucose monitor. They will also be asked to follow a low-carbohydrate diet of 30-40g of carbohydrate per main meal. At baseline they will have a 20-day period of blinded continuous glucose monitoring. Participants in this group will undergo a stepped hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.
62209006|NCT03666572|ACTIVE_COMPARATOR|B. infantis alone (Bif) in SAM infants|B. infantis alone (Bif) in Severe Acute Malnourished infants
62018310|NCT03046680|ACTIVE_COMPARATOR|Multiprofessional Team|Physician, nurse, nutrionist usual care.
62018311|NCT01024127||Ancillary-correlative (predictors of AML treatment outcomes)|Germline DNA is obtained from previously collected peripheral blood or bone marrow samples for array-based genotyping studies, including genome-wide association studies (single nucleotide polymorphisms) and fine mapping genotyping. Clinical trial simulations are performed to test the clinical applicability of using genetic variation data in the management of infectious complications.
62209007|NCT03666572|ACTIVE_COMPARATOR|B. infantis + prebiotic Lacto-N-neotetraose [LNnT]|B. infantis + prebiotic Lacto-N-neotetraose \[LNnT\] (Bif+prebiotic) in Severe Acute Malnourished infants
62581835|NCT02449382|ACTIVE_COMPARATOR|continuous venovenous hemofiltration|CVVH was mainly determined by the differences of sodium concentration between serum and replacement fluid. The rate of decline serum sodium could be real-time adjusted using different-sodium-concentration replacement fluid according to the updated serum sodium concentration.
62209008|NCT03666572|PLACEBO_COMPARATOR|Placebo (Lactose)|Placebo (Lactose) in Severe Acute Malnourished infants
62209009|NCT03666572|ACTIVE_COMPARATOR|B. infantis alone (Bif) in Not SAM Infants|B. infantis alone (Bif) in not Severe Acute Malnourished infants
62209010|NCT05327816|EXPERIMENTAL|Arm 1a: Respiratory Syncytial Virus (RSV) preFusion (preF) Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in cohort (C) 1 (Group \[G\] 1) and C 2 through intramuscular injection on Day 1.
62581836|NCT02449382|ACTIVE_COMPARATOR|Control group|Treatment of hypernatremia is correction of water deficit.
62209011|NCT05327816|EXPERIMENTAL|Arm 1b: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 1-4) and C 2 through intramuscular injection on Day 1.
62209012|NCT05327816|EXPERIMENTAL|Arm 1c: Placebo|Participants will receive single dose of placebo in C 1 (G 1-4) and C 2 through intramuscular injection on Day 1.
62209013|NCT05327816|EXPERIMENTAL|Arm 2: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.
62406829|NCT04293601|EXPERIMENTAL|Experimental group|"All enrolled neonates will receive interventions that will be performed with different frequency and method according to newborns' risk factors, as well as the following standard interventions received by control group's newborns:~* appropriate use of hydrocolloid, headbands, masks and prongs~* frequently assess skin integrity~* humidity and heat gases"
62406830|NCT04293601|OTHER|Standard care|"Newborns have received the interventions according to local protocol (standard nursing care) in 2018, as detailed in the assigned intervention"
62406831|NCT00375024|OTHER|1: Patient Navigator|Patients will meet with a Patient Navigator regarding their treatment and any related concerns.
62581837|NCT06684262||Group IPLA|Following the extraction of the gallbladder, the surgical team promptly administers a 45 mL local anesthetic solution blend consisting of 20 mL of bupivacaine at a concentration of 0.5%, 10 mL of lidocaine at a concentration of 2%, and 15 mL of 0.9% saline solution to the gallbladder bed and subdiaphragmatic region. This administration is performed via an aspiration catheter under direct visualization provided by the laparoscopic camera
62209014|NCT05327816|EXPERIMENTAL|Arm 3: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.
62209015|NCT05327816|EXPERIMENTAL|Arm 4: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.
62209016|NCT05327816|EXPERIMENTAL|Arm 5: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.
62209017|NCT05327816|EXPERIMENTAL|Arm 6: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.
62209018|NCT05327816|EXPERIMENTAL|Arm 7: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 3) and C 2 through intramuscular injection on Day 1.
62209019|NCT05327816|EXPERIMENTAL|Arm 8: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 3) and C 2 through intramuscular injection on Day 1.
62209020|NCT05327816|EXPERIMENTAL|Arm 9: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 4) and C 2 through intramuscular injection on Day 1.
62209021|NCT05327816|EXPERIMENTAL|Arm 10: RSV preF Based Vaccine|Participants will receive a single dose of selected formulation (based on C 1 and 2 results) in C 3 through intramuscular injection on Day 1.
62209022|NCT05327816|EXPERIMENTAL|Arm 11a: RSV preF Based Vaccine and Placebo|Participants in C 3 will receive a single dose of first vaccination with selected formulation (as per data C1 and 2) plus placebo on Day 1 and re-vaccination with selected formulation whenever revaccination would be needed through intramuscular injection.
62406832|NCT00375024|OTHER|2: Without Navigator|Patient will work with existing clinic staff, which does not include a Patient Navigator.
62406833|NCT02261558|EXPERIMENTAL|Clinical Improvisation Instrumental Music Therapy|Clinical Music Therapy session, 20 minutes. Focus on instrumental improvisation
62406834|NCT02261558|EXPERIMENTAL|Clinical Vocal Improvisation|Clinical Music Therapy session, 20 minutes. Focus on vocal improvisation
62018312|NCT03634579|EXPERIMENTAL|MRI-guided focal laser ablation|Subjects will undergo MRI Guided Focal Laser Interstitial Thermal Ablation of localized low and intermediate risk prostate cancer.
62018313|NCT01898195|ACTIVE_COMPARATOR|Standard Care|Participants in this arm will receive varenicline for smoking cessation.
62018314|NCT01898195|EXPERIMENTAL|Standard Care + Text message|Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts.
62018315|NCT01898195|EXPERIMENTAL|Standard Care + Text Message + ABT|Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts and seven phone developed Adherence Behavioral Therapy sessions
62209023|NCT05327816|EXPERIMENTAL|Arm 11b: RSV preF Based Vaccine and Placebo|Participants in C 3 will receive a single dose of first vaccination with selected formulation (as per data from C 1 and 2) plus placebo on Day 1 and re-vaccination with placebo whenever revaccination would be needed through intramuscular injection.
62209024|NCT05327816|EXPERIMENTAL|Arm 12: RSV preF Based Vaccine and Placebo|Participants in C 3 will receive first vaccination with placebo on Day 1 and re-vaccination with selected formulation (as per data from C 1 and 2) whenever revaccination would be needed through intramuscular injection.
62209025|NCT05327816|EXPERIMENTAL|Arm 13: RSV preF Based Vaccine|Participants in C 3 will receive the mixture of RSV preF-based vaccine plus placebo on Day 1 through intramuscular injection.
62209026|NCT05327816|EXPERIMENTAL|Arm 14: RSV preF Based Vaccine|Participants in C 4 will receive first vaccination with selected formulation (as per data from C 1 and 2) on Day 1 and re-vaccination with selected formulation whenever revaccination would be needed through intramuscular injection.
62209027|NCT05327816|EXPERIMENTAL|Arm 15: RSV preF Based Vaccine and Placebo|Participants in C 4 will receive first vaccination with selected formulation (as per data from C 1 and 2) on Day 1 and re-vaccination with placebo whenever revaccination would be needed through intramuscular injection.
62209028|NCT05327816|EXPERIMENTAL|Arm 16: RSV preF Based Vaccine and Placebo|Participants in C 4 will receive first vaccination with placebo on Day 1 and re-vaccination with selected formulation (as per data from C 1 and 2) whenever revaccination would be needed through intramuscular injection.
62406835|NCT02261558|NO_INTERVENTION|Control Group|Participants enrolled in control group will complete the same study design, without having a clinical music improvisation
62581838|NCT06684262||Group ESP|At the end of the operation and before tracheal extubation, patients will be turned into the lateral decubitus position. Bilateral erector spinae plane block will be applied at the T8 spinous process level. Under asepsis-antisepsis standards, a 12 mHz linear ultrasound probe will be placed approximately 3 cm lateral to the spinous process of the T8 vertebra in a longitudinal parasagittal orientation. After identification of the trapezius, rhomboid major, erector spinae muscles and transverse process, an aspiration test using an 80 mm peripheral nerve block needle, 22.5 ml of local anesthetic mixture (10 mL bupivacaine at 0.5% concentration, 5 mL lidocaine at 2% concentration, 7.5 mL 0.9% NaCl) will be applied bilaterally.
62581839|NCT05172817|EXPERIMENTAL|Advixa|Generic name: Adalimumab Dosage form: Injectable Route of Administration: Subcutaneous Dosage: 40mg/0.4mL Frequency: Once in 2 weeks Duration: Single dose for Phase 2 and 3 months for Phase 3
62018316|NCT05734482|EXPERIMENTAL|Biosimilar Product|CMAB015 150 mg Subcutaneous injection in upper arm
62209029|NCT04657068|EXPERIMENTAL|Part A1|Part A1 will evaluate intermittent and continuous dosing of ART0380 monotherapy. Treatment will be given in 21-day cycles. Up to 50 participants will participate in this dose-escalation arm.
62209030|NCT04657068|EXPERIMENTAL|Part A2|Part A2 will evaluate intermittent dosing of ART0380 in combination with gemcitabine in 21-day cycles. Up to 21 participants will participate in this dose escalation arm.
62209031|NCT04657068|EXPERIMENTAL|Part A3|Part A3 will evaluate intermittent dosing of ART0380 in combination with irinotecan in 21-day cycles. Up to approximately 36 participants will participate in this dose escalation arm.
62406836|NCT06507709|EXPERIMENTAL|Closed sinus augmentation with Calcium Phosphosilicate Putty|Use of CBCT immediately post-operatively after placement of Calcium Phosphosilicate Putty used as standard of care for closed sinus augmentation and at 6 months after surgery.
62406837|NCT01433029||Conventional Rater (CR)|CR Group receives conventional training from PI about how to rate coronary artery bypass (CAB) videos.
62406838|NCT01433029||Video Rater (VR)|VR Group receives conventional training from PI about how to rate CAB videos, along with a video rater training manual.
62581840|NCT05172817|ACTIVE_COMPARATOR|Humira|Generic name: Adalimumab Dosage form: Injectable Route of Administration: Subcutaneous Dosage: 40mg/0.4mL Frequency: Once in 2 weeks Duration: Single dose for Phase 2 and 3 months for Phase 3
62018317|NCT05734482|ACTIVE_COMPARATOR|Reference Product|Cosentyx（Secukinumab ） 150 mg Subcutaneous injection in upper arm
62018318|NCT04317300|EXPERIMENTAL|E-cigarette users|Participants who are regular users of e-cigarettes will be treated with a 12 week course of varenicline for stopping vaping.
62018319|NCT06173817|EXPERIMENTAL|Isocapnic hyperventilation (iHV)|"Loading dose of fomepizole on clinical suspicion; A) History of intake of alcohol of unknown/illegal origin plus symptoms potentially occurring from methanol, or B) history as above and verified methanol poisonings among people drinking the same alcohol, or C) metabolic acidosis of unknown origin (where methanol cannot be excluded as the cause;or D) a combination of these.~● iHV started after a S-methanol concentration \> 50 mg/dL is obtained (typically within 4 hours) and initial acidosis is partly or fully corrected by sodium bicarbonate (BD \<15mM, HCO3- \>10mM)"
62406839|NCT01433029||CAB Recording|CAB recording of performance cardiothoracic surgeon or surgical trainee in 1st, 2nd, or 3rd year of training.
62406840|NCT00671866||1|Agricultural Workers
62406841|NCT00671866||2|Non - Agricultural Workers
62406842|NCT00671866||3|Kibbitz Residents working else where
62406843|NCT05252169|EXPERIMENTAL|Proprioceptive Training|"Proprioceptive training will include : Stair climbing up and down,Standing with feet side by side and up and down,one leg standing,Walking heel to toes,Rising from a standard chair.~Swiss ball activity will be performed passively by the physical therapist in which child will sit on the ball and ball will be rolled from side to side,Extension rotation and flexion rotation will be performed to facilitate trunk rotation that will be performed with stabilized pelvis and hip.~Routine physical therapy will include passive stretching ,strength training and weight bearing exercises. total session will be of 60 minutes."
62209032|NCT04657068|EXPERIMENTAL|Part B1|"In Part B1, up to 7 cohorts making up to a total of approximately 220 participants with solid cancers with alterations in the ATM (ataxia-telangiectasia mutated) gene likely to predict for loss of ATM protein will be treated with either~* ART0380 monotherapy Or~* ART0380 in combination with irinotecan"
62406844|NCT05252169|PLACEBO_COMPARATOR|Routine Physical Therapy|"Group A will be given routine physical therapy which will be of 60 minutes each session. The routine physical therapy will include~* Passive stretching exercises~* Weight bearing exercises~* Functional strength training Duration of the treatment will be 3 days a week for 12 weeks i.e., 36 sessions. Each session will be of 60 minutes."
62581841|NCT03586505|EXPERIMENTAL|Light exposure|"The keratitis eye of the patient is exposed to 6 lights with increasing intensity according to a constant speed.~The patients switch off the light when the discomfort is too elevated"
62581842|NCT02308891|EXPERIMENTAL|vigorous hydration arm|"Patients will be randomly allocated to vigorous hydration arm. Patients in the vigorous hydration arm will receive fluids via infusion by the following protocol.~* Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP~* Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.~* At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour"
62581843|NCT02308891|ACTIVE_COMPARATOR|standard hydration arm|"Patients will be randomly allocated to standard hydration arm. Patients in the standard hydration arm will receive fluids via infusion by the following protocol.~- Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP."
62209033|NCT04657068|EXPERIMENTAL|Part B2|In Part B2, up to 60 participants with high grade serous ovarian, primary peritoneal, or fallopian tube carcinoma will be randomized (open label) 1:1 to either ART0380 in combination with gemcitabine or gemcitabine alone.
62209034|NCT04657068|EXPERIMENTAL|Part B3|in Part B3, up to 40 participants with persistent or recurrent endometrial cancer (EC) will receive ART0380 monotherapy on either a continuous daily dose or on an intermittent schedule for a 21-day cycle..
62581844|NCT05053451|EXPERIMENTAL|dlPFC/TPJ Stimulation + Rest|20 minutes of 2 mA direct current stimulation during rest.
62581845|NCT05392114|EXPERIMENTAL|OLE Participants|Group 1 and Group 2 participants will be administered donidalorsen by SC injection for up to 157 weeks.
62209035|NCT04657068|EXPERIMENTAL|Part B4|In Part B4, up to 40 participants with advanced or metastatic solid tumors will receive ART0380 monotherapy on either a continuous daily dose or on an intermittent schedule for a 21-day cycle.
62406845|NCT01484717|ACTIVE_COMPARATOR|Standard Care|Telephone counseling plus nicotine patch
62406846|NCT01484717|EXPERIMENTAL|Contingency management for abstinence from cigarettes|Telephone counseling and nicotine patch plus contingency management
62581846|NCT00664378|EXPERIMENTAL|I|CYT997
62018320|NCT02567422|EXPERIMENTAL|Treatment (berzosertib, cisplatin, radiation therapy)|Patients receive berzosertib IV over 60 minutes on day -7 and then weekly on day 2 and cisplatin IV over 30-60 minutes weekly on day 1. Patients also undergo radiation therapy once daily, 5 days a week. Treatment continues for up to 7 weeks in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT, PET/CT, or MRI throughout the study.
62018321|NCT03330834|EXPERIMENTAL|Single Arm|CAR-T cells to treat advanced lung cancer. This study has only one arm. All participators will attend the screening and meet the set criteria for the clinical treatment. PD-L1 CAR-T cells are infused on day 0 with 10%, day 3 with 30% and day 7 with 60% , (1-2)×10\^6/kg PD-L1 CAR-T cells total.
62018322|NCT00558675|EXPERIMENTAL|1|Single intravenous infusion of AlloStim
62018323|NCT00558675|EXPERIMENTAL|2|Intravenous AlloStim infusion on day 1 and day 7
62018324|NCT00558675|EXPERIMENTAL|3|Intravenous AlloStim infusion on day 1, day 7 and day 14
62018325|NCT00558675|EXPERIMENTAL|4|Intravenous AlloStim infusion on day 1, day 7, day 14 and day 21
62790053|NCT03845647|EXPERIMENTAL|Tumor diameter<=2cm study group|In order to provides a new theoretical basis for the operation of central lymph node in cN0 differentiated thyroid cancer,researchers are going to complete this study to evaluate the significance of contralateral central lymph node dissection in unilateral cN0 differentiated thyroid carcinoma.At the same time,it may play a certain impact on the revision of surgical guidelines for differentiated thyroid cancer.
62790054|NCT03845647|EXPERIMENTAL|Tumor diameter>2cm study group|In order to provides a new theoretical basis for the operation of central lymph node in cN0(Clinically N0) differentiated thyroid cancer,researchers are going to complete this study to evaluate the significance of contralateral central lymph node dissection in unilateral cN0 differentiated thyroid carcinoma.At the same time,it may play a certain impact on the revision of surgical guidelines for differentiated thyroid cancer.
62209036|NCT04657068|EXPERIMENTAL|Part B5|In Part B5, up to 80 participants with colorectal cancer (CRC) will receive ART0380 in combination with irinotecan on a 21-day cycle.
62209037|NCT06728943|EXPERIMENTAL|The group of patients with failed stone accessibility by semi-rigid ureteroscopy|Direct semi-rigid ureteroscopy will initially be attempted without endodilatation (KARL STORZ, 43 cm, 6°, 7 Fr.). On failure to advance the semi-rigid ureteroscope through the ureter, intra-ureteric instillation of 20 ml of aminophylline (250 mg/10 mL) through ureteric stent and another trial to pass the same scope will be done after 10 minutes of intra-ureteral aminophylline instillation.
62406847|NCT06652906|EXPERIMENTAL|Sodium phosphate powder group|Sodium phosphate powder group: After admission, patients will undergo comprehensive renal function and electrolyte tests. The first medication will be taken at 7pm the day before the examination. One bag of sodium phosphate powder will be diluted with 800ml or more of warm and cool water before taking. The second dose of medication should be taken at 7am on the day of operation or examination (or at least 3 hours before the examination), with the same usage as the first dose, with a 12 hour interval between each dose. The standard dose for each dose is 1 bag, until clear water like stool appears.
62406848|NCT06652906|ACTIVE_COMPARATOR|Polyethylene glycol electrolyte dispersion|Polyethylene glycol electrolyte powder group: After admission, the patient underwent comprehensive renal function and electrolyte examination. The evening before the intestinal examination, 2000ml of polyethylene glycol electrolyte powder III isotonic solution was taken, 250ml every 10-15 minutes, and it was taken within 2 hours. On the day of examination, 2000ml of polyethylene glycol electrolyte powder III isotonic solution was taken again 3-4 hours in advance until clear water like stool appeared.
62406849|NCT05534698|ACTIVE_COMPARATOR|PCI|Revascularization by PCI
62790055|NCT04152915|EXPERIMENTAL|DV3396|Semaglutide administered with the DV3396 pen-injector (semaglutide D, test formulation)
62790056|NCT04152915|EXPERIMENTAL|PDS290|Semaglutide administered with the PDS290 pen-injector (semaglutide reference formulation)
62018326|NCT03320447|EXPERIMENTAL|MAL-PDT|Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT
62018327|NCT03320447|EXPERIMENTAL|AFL-PDT|Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT
62018328|NCT05802745||Extubation failure|Patients who will require to be re-intubated within 72 hours after extubation.
62406850|NCT05534698|ACTIVE_COMPARATOR|CABG|Revascularization based on CABG.
62406851|NCT06361368|EXPERIMENTAL|PS150|Each PS150 (Limosilactobacillus fermentum) capsule contained 5 × 10\^9 colony forming units (CFU) , 1 capsule daily use.
62406852|NCT06361368|PLACEBO_COMPARATOR|Placebo|The placebo capsule contains microcrystalline cellulose, 1 capsule daily use.
62018329|NCT05802745||Extubation success|Patients who will not require reintubation within 72 hours of extubation.
62018330|NCT04695301|EXPERIMENTAL|digital platform rehabilitation|Rehabilitation program through a digital platform for 3 months
62018331|NCT04695301|EXPERIMENTAL|control group|Patients without access to technology will do the exercises using booklets and will compose the control group
62018332|NCT02317575|EXPERIMENTAL|Part A: LY900014 Test A|Test Formulation A. Single dose of LY900014 administered subcutaneously (SC) in one of five periods.
62018333|NCT02317575|EXPERIMENTAL|Part A:Insulin Lispro|Reference formulation. 15 U insulin lispro administered SC in one of five periods.
62406853|NCT06246370||COPD group|patients with COPD aged 40 years and above.
62406854|NCT06246370||control group|aged matced healty patients
62018334|NCT02317575|EXPERIMENTAL|Part A: LY900014 Test B|Test Formulation B. Single dose LY900014 administered subcutaneously (SC) in one of five periods.
62581847|NCT01715727||Parkinson's Disease for follow-up|"1. Patients should fulfill the National Institute of Neurological Disorders and Stroke in USA ( NINDS ) Diagnostic Criteria for Parkinson Disease(37) for probable PD, except for the age of onset.~2. Able to tolerate the disability during the drug-off state, at least for 12 hours.~3. Able to understand and provide signed informed consent.~4. Early to moderate stage defined as Hohen and Yahr stage 1-3,"
62581848|NCT01715727||"Parkinsonss Disease with severity match"|"Parkinsonss Disease with severity match: 30 subjects~1. Patients should fulfill the National Institute of Neurological Disorders and Stroke in USA ( NINDS ) Diagnostic Criteria for Parkinson Disease(37) for probable PD, except for the age of onset.~2. Able to tolerate the disability during the drug-off state, at least for 12 hours.~3. Able to understand and provide signed informed consent.~4. Severity matched with PSP (subjects = 15)/MSA (subjects= 15), the severity was judged by Hohen and Yahr stage"
62790057|NCT04468841|EXPERIMENTAL|Prospective Group|Study participants with untreated, newly diagnosed follicular lymphoma will have blood collected for cfDNA testing before, during, and after their first-line treatment or observation period
62018335|NCT02317575|EXPERIMENTAL|Part A: LY900014 Test C|Test Formulation C. Single dose LY900014administered subcutaneously (SC) in one of five periods.
62018336|NCT02317575|EXPERIMENTAL|Part A: LY900014 Test D|Test Formulation D. Single dose LY900014administered subcutaneously (SC) in one of five periods.
62018337|NCT02317575|EXPERIMENTAL|Part B: LY900014|Test formulation selected from Part A. Single dose of LY900014 administered SC in one of four periods.
62018338|NCT01384344|ACTIVE_COMPARATOR|witness|no mnesic complaint
62018339|NCT01384344|EXPERIMENTAL|Alzheimer disease with apathy|Alzheimer's disease according to criteria of NINCDS-ADRDA with apathy
62018340|NCT01384344|EXPERIMENTAL|Alzheimer's disease without apathy|Alzheimer's disease according to criteria of NINCDS-ADRDA without apathy
62018341|NCT03250962|EXPERIMENTAL|SHR-1210-plus-Decitabine|Decitabine 10 mg/day, days 1-5; SHR-1210 200 mg, day 8, every 3 weeks.
62018342|NCT03250962|EXPERIMENTAL|SHR-1210|SHR-1210 200 mg, day 1, every 3 weeks.
62018343|NCT02455908|EXPERIMENTAL|Proleukin®|"Subcutaneous administration of low doses of IL2 (Proleukin) following the therapeutical scheme indicated for crioglobulinemic nephropathy:~cycle1: IL2 1x106 /m2 s.c for 5 consecutive days cycle2: IL2 1.5 x106 / m2 s.c for 5 consecutive days, starting from 3 weeks after the first cycle.~cycle3: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 6 weeks after the first cycle.~Cycle 4: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 9 weeks after the first cycle."
62018344|NCT06283849|EXPERIMENTAL|Experimental group|Black adults aged 55 and older with T2D
62790058|NCT04468841|EXPERIMENTAL|Retrospective Group|Study participants who have received first-line treatment for follicular lymphoma and are in complete remission will have blood collected for cfDNA testing. In the retrospective cohort, MSKCC patients with CRs lasting ≥10 years after induction therapy will be studied. Initial tumor tissue (if available) will be collected to examine the status of s cfDNA in patients with long-term remissions. Blood samples will be collected once, if the patient has interesting results (e.g. positive cfDNA sample despite CR on imaging, etc.) then additional blood samples may be taken during follow up visits.
62790059|NCT01740414|ACTIVE_COMPARATOR|MN-166 (formerly AV411) First|Participants who began 14-day maintenance on MN-166 (50 mg) first, before switching to Placebo maintenance.
62018345|NCT03854123||Old MS patients|"75 to 77 years old MS patients whose disease began at 65 years old or earlier will be retrieved from the Observatoire français de la sclérose en plaques (OFSEP)."
62209038|NCT02642263|NO_INTERVENTION|Oxytocin|Oxytocin 20 IE in 500 ml G Na intravenous infusion over 6 hours (GlucoSalin 2:1; 2/3 glucose 5%+1/3 NaCl 0.9%), Sintetica-Bioren, Switzerland, after birth of the baby. For blinding purposes a 3ml NaCl 0.9% syringe is administered intravenously after birth of the baby as well.
62209039|NCT02642263|EXPERIMENTAL|Carbetocin|100 mcg of Carbetocin, Ferring, Switzerland, as iv administration after birth of the baby. For blinding purposes an intravenous infusion of 500 ml G Na (GlucoSalin 2:1; 2/3 glucose 5%+1/3 NaCl 0.9%) is administered over 6 hours.
62209040|NCT03727542|EXPERIMENTAL|Short AV-delay pacing|Participants will be their own control. Serum samples will be collected at baseline while the participants were in sinus rhythm and after 3 weeks of short AV-delay pacing serum samples will be recollected to measure matrix metalloproteinase levels .
62209041|NCT04193540||ACE questionnaire|Every patient under mechanical ventilation (intubated or tracheotomized), with or without sedatives, able to communicate and alert (RASS -1 to +1), and not delirious (CAM-ICU negative) will be assessed by Johns Hopkins ACE questionnaire by a person not in charge of the patient.
62209042|NCT06529419|EXPERIMENTAL|AZD8630 dose A|Inhaled AZD8630 administered at a dose A
62209043|NCT06529419|EXPERIMENTAL|AZD8630 dose B|Inhaled AZD8630 administered at a dose B
62018346|NCT01068431|ACTIVE_COMPARATOR|trico bandage|Leg lymphedema stage 2-3
62209044|NCT06529419|EXPERIMENTAL|AZD8630 dose C|Inhaled AZD8630 administered at a dose C
62018347|NCT01068431|EXPERIMENTAL|juxta fit compression device|leg lymphedema stage 2/3
62018348|NCT01673334|EXPERIMENTAL|Fine Needle Aspiration and Core Biospsy|Patients will undergo both FNA and core biopsy during EUS evaluation of a solid pancreatic tumor.
62018349|NCT05748028||Parkinson Disease|Patients affected by Parkinson's disease admitted for rehabilitation in Maugeri Clinical Scientific Institutes
62018350|NCT05748028||Multiple System Atrophy|Patients affected by Multiple System Atrophy admitted for rehabilitation in Maugeri Clinical Scientific Institutes
62018351|NCT03177993|EXPERIMENTAL|IDA 1|"* ivermectin, diethylcarbamazine and albendazole Day 0,~* permethrin Day 0 if excluded from ivermectin~Details of dosing:~* ivermectin: 200 mcg/kg oral~* diethylcarbazine: 6mg/kg oral~* albendazole 400mg oral~* permethrin 5% cream topical: apply to whole body and wash o after 4hrs when less than 2 months; apply to whole body and wash off after 8hrs when 2 months and older."
62018352|NCT03177993|EXPERIMENTAL|IDA 2|"* ivermectin, diethylcarbamazine and albendazole Day 0, ivermectin Day 8~* permethrin Day 0 and Day 8 if excluded from ivermectin~Details of dosing:~* ivermectin: 200 mcg/kg oral~* diethylcarbazine: 6mg/kg oral~* albendazole 400mg oral~* permethrin 5% cream topical: apply to whole body and wash o after 4hrs when less than 2 months; apply to whole body and wash off after 8hrs when 2 months and older."
62209045|NCT06529419|PLACEBO_COMPARATOR|Placebo|Inhaled placebo
62209046|NCT05458570||Breast cancer|Breast cancer patients presenting to single center in Karachi over the period of 10 years. The aim was to look for ethnic predisposition of population, age of breast cancer, stage at arrival and menopausal status specific to our population. No intervention done.
62209047|NCT06436443|ACTIVE_COMPARATOR|Intervention group|In addition to routine physician check-ups, an SMS group was created for the individuals in the intervention group, and basic information messages for diabetes control were sent to this group at regular intervals. In addition, individuals asked questions via this group. At the end of the eight-week follow-up, the data collection forms were filled out again and the study was terminated.
62209048|NCT06436443|NO_INTERVENTION|Control Group|The same data collection forms were filled out at the first interview and eight weeks later by the pregnant women in the control group, and they continued to receive routine follow-ups.
62209049|NCT06692738|EXPERIMENTAL|Arm A|Rilvegostomig in combination with carboplatin and paclitaxel or nab-paclitaxel followed by rilvegostomig
62209050|NCT06692738|ACTIVE_COMPARATOR|Arm B|Pembrolizumab in combination with carboplatin and paclitaxel or nab-paclitaxel followed by pembrolizumab
62209051|NCT05775991||Medical Oncologists and Clinicians|Individuals practicing as medical oncologists or with expertise in medical oncology. Clinicians with expertise in cognitive impairment and dementia
62209052|NCT05775991||Older patients with cancer|Older patients with cancer or older survivors of patients with cancer
62209053|NCT05775991||Caregivers of patients with dementia or cognitive impairment|Caregivers of patients with dementia or cognitive impairment
62581849|NCT01715727||Healthy age matched controls|"Healthy age matched controls: subjects = 112~1. Healthy subjects without a clinically significant abnormal laboratory values, and/or clinically significant or unstable medical or psychiatric illness.~2. Able to understand and provide signed informed consent.~3. Age range and gender matched with Parkinsonss Disease for follow up."
62018353|NCT03177993|ACTIVE_COMPARATOR|DA|"* diethylcarbamazine and albendazole Day 0~* permethrin Day 8 if scabies present in participant or household member~Details of dosing:~* diethylcarbazine: 6mg/kg oral~* albendazole 400mg oral~* permethrin 5% cream topical: apply to whole body and wash off after 4hrs when less than 2 months; apply to whole body and wash o after 8hrs when 2 months and older."
62209054|NCT04592120|EXPERIMENTAL|Coalition Check-Up|The 4-step Coalition Check-Up technical assistance process provides proactive data-driven continuous quality improvement cycles. Step 1 assesses critical dimensions of the coalition's capacity and program implementation. A coalition profile based on assessment data is reviewed in step 2. Here the technical assistance provider works with the coalition to consider several dimensions of coalition capacity and program implementation, celebrating strengths and prioritizing weaknesses. Once priorities are set, the technical assistance provider uses structured action planning in step 3 to help coalition members establish consensus on how to improve prioritized weaknesses. In step 4, technical assistance providers review and support progress on action plan implementation with the coalition. Efforts are evaluated a year after the initial assessment in a continuous quality improvement cycle.
62790060|NCT01740414|PLACEBO_COMPARATOR|Placebo First|Participants who began 14-day maintenance on Placebo first, before switching to MN-166 (50 mg) maintenance.
62790061|NCT02744638|EXPERIMENTAL|probiotic yoghurt & Arilin|probiotic yoghurt, 2 units (125 g), containing living strains of L.crispatus, L.gasseri, L.rhamnosus, L.jensenii, each in a concentration of 1 x 107 CFU/ml product for 4 weeks Two yoghurts are consumed every day for 28 days. 2 tablets Metronidazol 500mg daily for 7 days
62790062|NCT02744638|PLACEBO_COMPARATOR|chemically acidified milk & Arilin|chemically (H3PO4) acidified milk (125g) without bacterial strains. Two products are consumed every day for 28 days. 2 tablets Metronidazol 500mg daily for 7 days
62790063|NCT01427933|EXPERIMENTAL|Ramucirumab and Eribulin|"Ramucirumab 10 milligrams/kilogram (mg/kg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle~Eribulin 1.4 milligrams/square meter (mg/m²) administered by IV bolus on Day 1 and Day 8 of each 3-week cycle"
62790064|NCT01427933|ACTIVE_COMPARATOR|Eribulin Monotherapy|Eribulin 1.4 mg/m² administered by IV bolus on Day 1 and Day 8 of each 3-week cycle
62790065|NCT04141540|OTHER|"Groupe Twin 1"|Twin 1 with psychotic symptoms (PANSS +) Molecular analyses 1
62790066|NCT04141540|OTHER|"Groupe Twin 2"|Twin 2 without psychotic symptoms (PANSS +) Molecular analyses 2
62790067|NCT01651871|EXPERIMENTAL|Treatment Group 1|
62790068|NCT01651871|EXPERIMENTAL|Treatment Group 2|
62790069|NCT01651871|EXPERIMENTAL|Treatment Group 3|
62790070|NCT01651871|ACTIVE_COMPARATOR|Treatment Group 4|
62790071|NCT01651871|PLACEBO_COMPARATOR|Treatment Group 5|
62790072|NCT03420274|EXPERIMENTAL|Intervention|This arm will utilize a point-of-care shared decision-making tool (NEST).
62790073|NCT03420274|PLACEBO_COMPARATOR|Control|This group will utilize usual care with respect to healthcare provider practice for education and counseling.
62790074|NCT04459520|EXPERIMENTAL|Testing Unavailable Group|This arm will complete an online survey where they will be presented a vignette asking them to imagine they have symptoms consistent with COVID-19, a physician telling them they likely have COVID-19, but that COVID-19 testing is not available. All arms will then be asked to fill out the same questions regarding behavior intentions and demographic questions. All participants will have completed five construct questions based off of Theory of Planned Behavior/Reason Action Approch during the pre-test survey.
62790075|NCT04459520|ACTIVE_COMPARATOR|Positive Test Result|This arm will complete an online survey where they will be presented a vignette asking them to imagine they have symptoms consistent with COVID-19, a physician telling them they likely have COVID-19, and a positive COVID-19 test result. All arms will then be asked to fill out the same questions regarding behavior intentions and demographic questions. All participants will have completed five construct questions based off of Theory of Planned Behavior/Reason Action Approch during the pre-test survey.
62209055|NCT04592120|NO_INTERVENTION|Technical assistance as usual|Coalitions in the comparison condition will receive a feedback report but no additional support from technical assistance providers beyond what is already available to them.
62209056|NCT02683772|EXPERIMENTAL|iVAPS with AutoEPAP|This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with AutoEPAP on the first night, and on iVAPS with manual EPAP on the second night.
62406855|NCT01978977||Avastin regimens|Patients who are going to receive chemotherapy plus Avastin (bevacizumab)
62209057|NCT02683772|ACTIVE_COMPARATOR|iVAPS with manual EPAP|This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with manual EPAP on the first night, and on iVAPS with AutoEPAP on the second night.
62209058|NCT03152058|EXPERIMENTAL|Certolizumab Pegol|"All participants are administered certolizumab \[400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter.~1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
62406856|NCT02863874|ACTIVE_COMPARATOR|Vicryl®|The vaginal or and perineal tear is sutured continuously with Vicryl®. The instruments for suturing and the bedcover are clean whereas the gloves are sterile.
62581850|NCT01715727||Parkinson Plus Syndrome Group M|"1. MSA Patients should fulfill the NINDS Consensus statement for the clinical diagnosis of probable MSA~2. Able to tolerate the disability during the drug-off state, at least for 12 hours.~3. Able to understand and provide signed informed consent"
62790076|NCT04459520|PLACEBO_COMPARATOR|Negative Test Result|This arm will complete an online survey where they will be presented a vignette asking them to imagine they have symptoms consistent with COVID-19, a physician telling them they likely have COVID-19, and a negative COVID-19 test result. All arms will then be asked to fill out the same questions regarding behavior intentions and demographic questions. All participants will have completed five construct questions based off of Theory of Planned Behavior/Reason Action Approch during the pre-test survey.
62790077|NCT06311422|EXPERIMENTAL|Lava Ultimate block|Resin nanoceramic block
62209059|NCT05505240|EXPERIMENTAL|Cold temperature|18°C
62209060|NCT05505240|EXPERIMENTAL|Room temperature|22°C
62209061|NCT05505240|EXPERIMENTAL|Thermoneutral temperature|28°C
62209062|NCT05505240|EXPERIMENTAL|Hot temperature|38°C
62209063|NCT02469103|EXPERIMENTAL|C2 & colonoscopy|C2 and colonoscopy
62209064|NCT05366036||Participants with MS|Participants with relapsing-remitting MS who are newly prescribed and will start treatment with Tecfidera in a real-world clinical practice setting will be observed prospectively for up to 24 months.
62209065|NCT02770612|OTHER|Post-cesarean delivery mothers|"1. Identify eligible women on post-operative day 3. A physician member of the study team will approach participants with study information and consent forms.~2. After informed consent is obtained, the participant will be taken through a 10 minute shared decision making session (intervention). The participant will then have the opportunity to ask questions, following which they will indicate the number of prescription opioid tablets to be discharged with (primary outcome)~3. The next contact will be at two weeks after discharge, at which time a member of the study team will contact the participant and administer a brief telephone survey with questions pertaining to perceived pain over time, pain management methods, opioid/pain medication consumption/disposal, and satisfaction with postoperative pain control.~4. A chart review will be performed by physicians in the research group on participants to gather information on demographics, indications for surgery, etc."
62406857|NCT02863874|ACTIVE_COMPARATOR|VicrylPlus®|The vaginal or and perineal tear is sutured continuously with VicrylPlus®. The instruments for suturing and bedcover are clean whereas the gloves are sterile.
62406858|NCT03053102|EXPERIMENTAL|Danicopan|Starting doses of danicopan ranged from 100 to 150 milligrams (mg) three times daily (TID), with subsequent dose escalation up to 200 mg TID based on response (clinical and biochemical) for 28 days (Part 1). Participants with reductions in lactate dehydrogenase (LDH) meeting specified criteria were offered continued dosing beyond Day 28, for up to 8 additional weeks (Part 2).
62406859|NCT00467051|EXPERIMENTAL|Treatment (chemotherapy, biological therapy)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously or IV once daily until blood count returns to normal. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
62406860|NCT05558709|EXPERIMENTAL|Patients|Patients suffering from a neurodegenerative disease (Alzheimer's disease (AD), dementia with Lewy bodies (DCL) or fronto-temporal lobar degeneration (FTD))
62406861|NCT05558709|OTHER|Relatives|Caregivers or relatives of included patients, having regular contact with the patient (≥ 2 times per month).
62406862|NCT06038370|EXPERIMENTAL|Self-induced cognitive trance|
62581851|NCT01715727||Parkinson Plus Syndrome Group P|"1. PSP Patients should fulfill the NINDS-SPSP and Litvan criteria(4) for probable PSP~2. Able to tolerate the disability during the drug-off state, at least for 12 hours.~3. Able to understand and provide signed informed consent."
62581852|NCT03751839|EXPERIMENTAL|Diagnostic|The investigators will examine all participants in the same way by performing biochemical tests, clinical tests, osteodensitometry, HRQCT and HRpQCT measurements.
62581853|NCT02772172|ACTIVE_COMPARATOR|GuideMia surgical template|A radiographic guide is prepared before CT/CBCT scan. The CT/CBCT scan DICOM ﬁles are loaded in GuideMia program and converted into 3D computer images. A surgical template is fabricated through this virtual planning.
62790078|NCT06311422|ACTIVE_COMPARATOR|Celtra Duo block|zirconia-reinforced lithium silicate block
62790079|NCT05645523|EXPERIMENTAL|Indocyanine green (ICG)|Participants will receive Indocyanine green intraoperatively.
62790080|NCT02391363|EXPERIMENTAL|Calmer Life|Cognitive behavior treatment for anxiety
62790081|NCT02391363|ACTIVE_COMPARATOR|Enhanced Community Care|Enhanced information and referral services for mental health and basic needs
62790082|NCT06189924||Mechanically ventilated patients with primary or secondary lung injury|Mechanically ventilated patients with primary or secondary lung injury due to various pathologies. Patients will be treated at intensive care units (ICU).
62209066|NCT00355303|ACTIVE_COMPARATOR|Misoprostol tablet, PGE2 gel|participants are assigned to one of two arms for the duration of the study In one group induction of labour is done by intravaginal misoprostol tablets at 4 hrly interval with maximum of five doses.In other group PGE2 gel is applied in poaterior fornix at six hourly interval.
62209067|NCT06476379|ACTIVE_COMPARATOR|Ejaculate|Patients within this arm will undergo ICSI utilizing ejaculated sperm.
62406863|NCT03317691||ST segment Elevation Myocardial Infarction|ST segment Elevation Myocardial Infarction patients' diagnosis was confirmed by coronary artery angiography. The prior surgery electrocardiogram need to be collected.
62406864|NCT01406327||Subjects prescribed ambrisentan|Subjects with pulmonary arterial hypertension (PAH) prescribed ambrisentan during study period
62581854|NCT02772172|ACTIVE_COMPARATOR|Control surgical template|A radiographic guide is prepared before CT/CBCT scan. The CT/CBCT scan DICOM ﬁles are loaded in control program and converted into 3D computer images. A surgical template is fabricated through this virtual planning.
62581855|NCT01316107|EXPERIMENTAL|ASP group|Concomitant administration of ASP1941 and nateglinide
62581856|NCT02749526|EXPERIMENTAL|Endostar combined with MPFC|"Chemotherapy regimens (er degree + mPFC) :~Endostar:~degrees 30 mg civ24h d0-6;~Liposo:~135 mg/m2 D1; cisplatin: D1-3, 25 mg/m2~Gimeracil and Oteracil Potassium (Tegafur):~(40 mg bid Tegafur), D1-14. A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy."
62209068|NCT06476379|ACTIVE_COMPARATOR|Testicular|Patients within this arm will undergo ICSI utilizing testicular sperm.
62209069|NCT04160026|ACTIVE_COMPARATOR|IPTp-SP|Arm 1. Standard single-day stat course of quality-assured SP (Fansidar ®) of 3 tablets (500 mg of sulphadoxine and 25 mg of pyrimethamine). SP given monthly
62209070|NCT04160026|EXPERIMENTAL|IPTp-DP|Arm 2. Standard 3-day course of 3 to 5 tablets (40/320mg) of DP per day based on bodyweight (Eurartesim®, AlfaSigma, Italy). DP given monthly
62209071|NCT04160026|EXPERIMENTAL|IPTp-DP Plus|Arm 3. Standard 3-day course of 3 to 5 tablets (40/320mg) of DP per day based on bodyweight (Eurartesim®, AlfaSigma, Italy) plus targeted information for health providers.
62209072|NCT02757690|ACTIVE_COMPARATOR|2-dimenasional distal pancreatectomy|device: 2 dimensional laparoscopy of Olympus
62209073|NCT02757690|EXPERIMENTAL|3-dimenasional distal pancreatectomy|device : 3 dimensional laparoscopy of Olympus
62406865|NCT03194594|ACTIVE_COMPARATOR|Group K (n = 31)|will receive a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, at 5 minutes after the induction of anesthesia
62406866|NCT03194594|ACTIVE_COMPARATOR|Group D (n = 31)|will receive dexamethasone 0.5 mg/kg i.v. plus 2 ml normal saline, at 5 minutes after the induction of anesthesia
62406867|NCT03194594|EXPERIMENTAL|Group KD (n = 31)|will receive ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v., at 5 minutes after the induction of anesthesia
62406868|NCT05629559|EXPERIMENTAL|4D-310 Dose Level 1 - AAV Neutralizing Antibody (NAb) Group A|4D-310 Dose Level 1 - AAV NAb Titer Group A patients
62406869|NCT05629559|EXPERIMENTAL|4D-310 Dose Level 1 - AAV NAb Titer Group B|4D-310 Dose Level 1 - AAV NAb titer Group B patients
62209074|NCT05424497||No outcome provided|
62406870|NCT05629559|EXPERIMENTAL|4D-310 Dose Level 2 - AAV NAb Titer Group A and/or B|4D-310 at Dose Level 2 in AAV NAb titer Group A and/or B patients
62406871|NCT05629559|EXPERIMENTAL|4D-310 Dose Expansion|Dose expansion cohort of 4D-310 at the selected dose and selected AAV Nab titer group(s) patients
62406872|NCT06650436||no delirium post-stroke|
62406873|NCT06650436||post-stroke delirium|
62406874|NCT05692570|EXPERIMENTAL|Single-sequence, 3-period|Period 1: single dose of PBI-200; Period 2: daily dosing of ritonavir with a single dose of PBI-200 co-administered once ritonavir steady state reached; Period 3: daily dosing of cobicistat with a single dose of PBI-200 co-administered once cobicistat steady state reached.
62734476|NCT06496308|EXPERIMENTAL|Orelabrutinib + Bendamustine + Rituximab (OBR)|In induction phase, patients will be randomized in two groups, one is OBR and another is BR. Patients in OBR group will receive rituximab 375 mg/m² IV on day 1, bendamustine 90 mg/m² IV on day 1 and 2, and orelabrutinib 150mg/day PO once daily, every 28 day per cycle for 6 cycles.
62018354|NCT02509689|EXPERIMENTAL|Single Arm|"The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions."
62018355|NCT06572436|NO_INTERVENTION|Control Group|Pregnant women in the control group were not given multimedia information before amniocentesis and chorionic villus sampling, but were given brief verbal information about the procedure before amniocentesis and chorionic villus sampling.
62018356|NCT06572436|EXPERIMENTAL|Multimedia information group|Pregnant women in the study group were given multimedia information by watching a short video before amniocentesis and chorionic villus sampling. The multimedia information training consisted of a 5-minute video containing detailed amniocentesis and chorionic villus sampling application information. A 5-minute video was developed by the authors and used for research purposes only. The video was designed to provide pregnant women with a comprehensive overview of the amniocentesis and chorionic villus sampling procedure, its benefits, and potential risks, and included real-life images to depict all aspects of the procedure.
62018357|NCT00721526|EXPERIMENTAL|Disulfiram plus lorazepam|Disulfiram plus lorazepam
62209075|NCT05424497||outcome positive|
62734477|NCT06496308|PLACEBO_COMPARATOR|Bendamustine + Rituximab (BR)|In induction phase, patients will be randomized in two groups, one is OBR and another is BR. Patients in BR group will receive rituximab 375 mg/m² IV on day 1, bendamustine 90 mg/m² IV on day 1 and 2, every 28 day per cycle for 6 cycles.
62209076|NCT05424497||outcome negative|
62209077|NCT05424497||implicit bias group|
62209078|NCT06728826|EXPERIMENTAL|Posterior Pericardiotomy Group|The surgeon will perform posterior pericardiotomy during the patient's cardiac surgery.
62209079|NCT06728826|NO_INTERVENTION|No Posterior Pericardiotomy Group|The surgeon will not perform posterior pericardiotomy during the patient's cardiac surgery.
62406875|NCT05643807|ACTIVE_COMPARATOR|urinary catheter|Urinary cytology will be collected using a Ch.14 bladder catheter after the removal of the cystoscope. Catheter will be placed at the bladder neck level.
62406876|NCT05643807|ACTIVE_COMPARATOR|flexible cystoscope|Urinary cytology will be collected through the flexible cystoscope itself at the end the cystoscopy. Before starting the urinary collection, the cystoscope will either be placed in front of a suspected intravesical lesion (if present) or at the bladder neck (if no lesion present).
62406877|NCT01655810|ACTIVE_COMPARATOR|Vitamin D 4000 IU|PO daily
62406878|NCT01655810|ACTIVE_COMPARATOR|Vitamin D 600 IU|PO daily
62406879|NCT03495765|ACTIVE_COMPARATOR|Well controlled|Eligibile people with diabetic macular oedema and HBA1C \< 7.5
62406880|NCT03495765|ACTIVE_COMPARATOR|Poorly controlled|eligible people with Diabetic macular oedema and HBAIC \>10.0
62406881|NCT03598075|OTHER|Amylin (Pramlintide)|Pramlintide intravenous infusion 120 micrograms over 20 minutes
62406882|NCT03598075|OTHER|CGRP|CGRP intravenous infusion 30 micrograms over 20 minutes
62209080|NCT04701619|OTHER|Immuno-inflammatory profile description in patients with ischemic stroke|Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers
62406883|NCT00312936|NO_INTERVENTION|Wait List|
62406884|NCT00312936|EXPERIMENTAL|MBSR|8 week mindfulness based stress reduction
62406885|NCT02844231|OTHER|Sleepwalker, SW episode|Sleepwalker patients undergo single-photon emission computed tomography during a sleepwalking episode.
62406886|NCT02844231|OTHER|Sleepwalkers, slow wave sleep|Sleepwalker patients undergo single-photon emission computed tomography during slow-wave sleep.
62406887|NCT02844231|OTHER|Control group|Control subjects undergo single-photon emission computed tomography during slow-wave sleep.
62018358|NCT03578900|EXPERIMENTAL|Xeros Group - Lozenge|"Application of Xeros system for 15 days. Lozenge (Malic acid 28.56 mg, Xylitol 421,98 mg, Sodium fluoride 0.55 mg) or Spray (Malic acid 1%, Xylitol 10%, Sodium fluoride 0.05%) 4 times a day. Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires.~Effects of lozenge on hyposalivation and pH variation determined by saliva collection with pre-weighed falcon and a ph electrode at predetermined times during a 20 minute period."
62018359|NCT03578900|ACTIVE_COMPARATOR|Mouthwash group|"Application of citric acid based Mouthwash (0,33% citric acid) for 15 days four times a day. Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires.~Effects of mouthwash on hyposalivation and pH variation determined by saliva collection with pre-weighed falcon and a pH electrode at predetermined times during a 20 minute period."
62018360|NCT03578900|EXPERIMENTAL|Xeros Group - Mouthwash|"Application of Xeros system for 15 days. Mouthwash (Betaine 1.33%, Xylitol 3.30%, Sodium fluoride 0.05%, Allantoin 0.10%) 2 times a day.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
62018361|NCT03578900|EXPERIMENTAL|Xeros Group - Gel|"Application of Xeros system for 15 days. Gel (Betaine 1%, Aloe Vera 0.05%, Xylitol 10%, Sodium Fluoride 0.0033%) before bed.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
62018362|NCT03578900|EXPERIMENTAL|Xeros Group - Toothpaste|"Application of Xeros system for 15 days. Toothpaste (Betaine 4%, Xylitol 10%, Sodium Fluoride 0.33%, Allantoin 0.10%) 3 times a day.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
62209081|NCT02535039|PLACEBO_COMPARATOR|Placebo|Before anesthesia induction, with electroacupuncture can cave, inside the closed cavity, foot three mile point, cupping model for continuous wave type, current pulse frequency of 2 hz, adjust the intensity of the electric acupuncture, with patients complained of needle feeling, can accept no pain and discomfort.Intraoperative sustained electroacupuncture.The same volume of physiological saline will be given.
62209082|NCT02535039|EXPERIMENTAL|Methylprednisolne|in the anaesthesia to 1 mg/kg intravenous methylprednisolone, methylprednisolone continuous use 1 mg/kg \* d until the third day after surgery.Before anesthesia induction, with electroacupuncture can cave, inside the closed cavity, foot three mile point, cupping model for continuous wave type, current pulse frequency of 2 hz, adjust the intensity of the electric acupuncture, with patients complained of needle feeling, can accept no pain and discomfort.Intraoperative sustained electroacupuncture.
62209083|NCT05308706|EXPERIMENTAL|Commercial Apollo System Device|The active experimental group received the commercial Apollo System device.
62209084|NCT05308706|SHAM_COMPARATOR|Sham Apollo System Device|The control experimental group received a sham/placebo device that is identical to the commercial Apollo System device but uses an ultra-low (i.e., effectively zero) frequency pattern of vibrations.
62209085|NCT04411693|ACTIVE_COMPARATOR|Group A: Intravitreal Dexamethasone Implant|Subjects in this arm will be given intravitreal Dexamethasone implant injection at month 0. PRN intravitreal Dexamethasone implant injections will be given for persistent edema, if it has been 10 weeks or more since last implant injection. If it has been less than 10 weeks since last implant injection, subjects will receive PRN intravitreal Aflibercept for persistent edema.
62209086|NCT04411693|ACTIVE_COMPARATOR|Group B: Intravitreal Aflibercept|Subjects in this arm will be given Intravitreal aflibercept at month 0. PRN intravitreal Aflibercept will be given at months 1-6 for persistent edema.
62209087|NCT05784441|EXPERIMENTAL|JNJ-90009530|
62209088|NCT01743989|EXPERIMENTAL|Nilotinib 24-month treatment|Participants were treated with nilotinib 300mg BID for 24 months and, thereafter, entered the 36-month TFR phase
62209089|NCT01743989|EXPERIMENTAL|Nilotinib 36-month treatment|Participants were treated with nilotinib 300mg BID for 36 months and, thereafter, entered the 24-month TFR phase
62209090|NCT01743989|EXPERIMENTAL|Not randomized|Participants were treated with nolotinib 300mg BID for 24 months, but did not achieve a sustained molecular response after 24 months of treatment.
62209091|NCT05181787||AF|Patients with AF
62209092|NCT05181787||AF and stroke|Patients with AF complicated with stroke
62209093|NCT05695846|OTHER|Patients with supra-esophageal gastroesophageal reflux disease|GERD patients with complaints of regurgitation and supra-esophageal symptoms
62209094|NCT03760731|EXPERIMENTAL|Acceptance and Commitment Therapy for Moral Injury (ACT-MI)|Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.
62406888|NCT01961765|EXPERIMENTAL|cabozantinib|Cabozantinib will be administered at a dose of 40mg daily by mouth in the first cohort. Dose escalation will occur in subsequent patient cohorts. We will evaluate 3-6 patients per dose level.
62209095|NCT03760731|ACTIVE_COMPARATOR|Present Centered Therapy|Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right. PCT could provide another treatment option that might be preferable to some Veterans and promote patient choice. Additionally, PCT would require less clinician training and specialization than ACT-MI. Using PCT as an active comparison condition will determine whether it is necessary to train clinicians in ACT-MI or if therapists with exposure to supportive problem-solving therapy approaches can lead a group that impacts functioning among Veterans reporting moral injury-related distress.
62209096|NCT05946187|EXPERIMENTAL|Apolo_Bari Stepped-care intervention group|The Apolo_Bari stepped-care intervention offers two different steps from low- to high-intensity strategies. The intervention will run for 18 months. All participants receive first step intervention. Patients will move through the second step according to the degree of disordered eating behaviors or weight regain which is assessed through a short Monthly Monitoring Questionnaire.
62406889|NCT04960137|EXPERIMENTAL|Button Plates fixation system|Patients receiving surgery fixed with Button Plates fixation system
62406890|NCT04960137|ACTIVE_COMPARATOR|Non-absorbable Suture Anchor|Patients receiving surgery fixed with Non-absorbable suture anchor
62018363|NCT03062891|EXPERIMENTAL|Online CBT for insomnia|"CBT participants will receive six weekly sessions delivered by an animated 'virtual therapist' (The Prof) via the online platform 'Sleepio'. The programme comprises a fully automated media-rich web application, driven dynamically by baseline, adherence, performance and progress data, and provides additional access to elements such as an online library with background information, a community of fellow users, and support, prompts and reminders sent by e-mail.~CBT content was consistent with the literature (4) and covered behavioral (e.g., sleep restriction, stimulus control) and cognitive (e.g., putting the day to rest, thought restructuring, imagery, articulatory suppression, paradoxical intention, mindfulness) strategies, as well as additional relaxation strategies (progressive muscle relaxation and autogenic training) and advice on lifestyle and bedroom factors (sleep hygiene). The intervention was based upon a previously validated manual (4)."
62209097|NCT05946187|ACTIVE_COMPARATOR|Treatment as usual group|Treatment As Usual control group receives the standard intervention for bariatric surgery offered by multidisciplinary teams in Portuguese public hospitals. It consists of endocrinology, nutrition and surgery consultations, usually lasting 30 minutes every 6 months. These consultations usually include a physical exam (weight, height) and personalized diet/lifestyle recommendations. The Treatment as usual intervention is common to the Apolo_Bari Steppped-care intervention group and the treatment as usual control groups.
62209098|NCT01056900||Chondron Implantation|This clinical trial was a follow-up study involving 127 patients from 10 hospitals, for whom autologous chondrocyte transplantation was already performed. All the subjects were investigated as a single group
62209099|NCT03057522|EXPERIMENTAL|Intervention Group|This group will undergo home exercise program designed to increase their running cadence.
62209100|NCT03057522|NO_INTERVENTION|Control Group|This group will not receive any intervention.
62209101|NCT01853475|EXPERIMENTAL|Treatment A|PQP tablets 1440mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.
62209102|NCT01853475|EXPERIMENTAL|Treatment B|PQP tablets 960mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.
62209103|NCT01853475|ACTIVE_COMPARATOR|Treatment C - Reference|PQP Tablets 1440 mg and OZ439 PIB 800mg + full fat cow's milk
62209104|NCT00692731||Active|Tea catechin sport beverage
62209105|NCT00692731||Control|Control beverage
62209106|NCT05396534|EXPERIMENTAL|byLAWT arm|Personalized protocol that uses a contact-force catheter, a multichannel radiofrequency generator, and integrated MDCT-derived Left Atrial Wall Thickness (LAWT) information to adapt the ablation index target to the subjacent LAWT.
62406891|NCT02844829|OTHER|MRI and biomarkers|Prostate MRI. Blood and urine biomarkers. Both prior to biopsy. Tissue samples during prostatectomy.
62406892|NCT00585468|EXPERIMENTAL|Myfortic - Fed State|Mycophenolate sodium taken with a meal.
62406893|NCT00585468|EXPERIMENTAL|Myfortic - Fasting State|Mycophenolate sodium taken separately from food by 2 hours.
62406894|NCT02158949|EXPERIMENTAL|mROAD|1 week of twice daily text messages modeled after SBIRT interventions
62406895|NCT02158949|NO_INTERVENTION|Usual Care|Usual care in ED
62406896|NCT02413710|ACTIVE_COMPARATOR|Usual Protein Group|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
62406897|NCT02413710|EXPERIMENTAL|Soy Protein Group|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the USDA MyPlate program (www.choosemyplate.gov) with the incorporation of two servings of study food providing soy protein per day.
62406898|NCT00118560|EXPERIMENTAL|1|treadmill walking and calf exercise
62406899|NCT01240369||VEGF-C low|
62406900|NCT01240369||VEGF-C high|
62406901|NCT01240369||miR-326 low|
62581857|NCT05620498|EXPERIMENTAL|tislelizumab+lenvatinib+GMOX|"tislelizumab 200mg, Q3W, lenvatinib 8mg/kg, PO, qd, gemcitabine 1g/㎡, D1, D8, Q3W, oxaliplatin 100mg/㎡, D1, Q3W. Imaging evaluation was performed after 3 cycles.~Patients who met surgical criteria will receive R0 resection and adjuvant therapy 4-8 weeks after surgery (tislelizumab 200mg, Q3W, lenvatinib 8mg/kg, PO, qd) for one year or until disease progression or toxicity became intolerable.~Inoperable patients continue to receive ≤4 cycles of treatment, imaging evaluation every two cycles. Patients will receive R0 resection if meet surgical criteria and adjuvant therapy 4-8 weeks after surgery (Tislelizumab 200mg, Q3W, lenvatinib 8mg/kg, PO, qd,) for one year or until disease progression or toxicity became intolerable.~Patients still unable to receive surgery, the experimental group will receive tislelizumab 200mg, Q3W, lenvatinib 8mg/kg, PO, qd for maintained treatment until disease progression or toxicity became intolerable."
61978496|NCT00987077|EXPERIMENTAL|Selective Retinatherapy (SRT)|Treatment was performed with the SRT-Laser system (Medical Laser Center Lübeck, Germany), which consists of a Q-switched frequency doubled Nd:YLF laser (527nm), operating with a pulse repetition rate of 100 Hz. The pulse duration (full width at half maximum) was 1.7 µs. The laser energy was transmitted via fiber to a Lumenis slitlamp allowing the application of a fixed spot size diameter of 200 µm in air. A Mainster central field contact lens with a magnification of 1.05 was used for all irradiations. Per foot switch, 30 pulses are emitted, the pulse energy was chosen by the physician up to a maximum of 370 µJ. According to the treatment protocol, prior to each treatment 5 test shots with increasing energy were applied adjacent to the vessel arcades, in each patient in order to determine the appropriate pulse energy for treatment by recording the OA-value.
62018364|NCT03062891|NO_INTERVENTION|Puzzles|Each week participants will be sent a puzzle to complete online (e.g. logic puzzles, crosswords etc). The puzzles have been designed to be cognitively engaging and take a similar amount of time to one session of Sleepio (20-25 minutes).
62018365|NCT05658692|EXPERIMENTAL|protective ventilation|For ARDS patients with moderate to severe mechanical ventilation(MAQUET), give 6-8ml/kg (ideal body weight PBW), and control the plateau pressure to \<30cmH2O; In patients with respiratory distress, the tidal volume can be increased to 7-8ml/kg (PBW), while the plateau pressure is \<30cmH2O. Adjust breathing rate according to CO2 level, up to 35 breaths/min. PBW, male: 50+0.91 (height cm-152.4); female: 45.5+0.91 (height cm-152.4).
62018366|NCT05658692|EXPERIMENTAL|prone position ventilation (including awake state)|For patients with moderate to severe ARDS who have no contraindications to prone ventilation, protective lung ventilation is given and prone ventilation is performed; the duration is more than 12 hours/time.
62018367|NCT05658692|EXPERIMENTAL|glucocorticoid therapy|Glucocorticoids are used for ARDS patients, with small doses and short courses of treatment in the acute phase (within 14 days). There is no clear recommendation for patients with ARDS from other causes. At present, the main research methods are methylprednisolone program(Solu-Medrol®), dexamethasone program, and hydrocortisone program
62018368|NCT05658692|EXPERIMENTAL|restrictive fluid resuscitation|ARDS patients with circulatory or organ hypoperfusion problems should use as little fluid as possible to maintain treatment and circulation; other ARDS patients should focus on stabilizing circulation during the resuscitation phase, with controlled fluid replacement combined with early vasoactive drugs; ultrasound, Central venous pressure measurement, mixed central venous oxygen saturation, alveolar-arterial oxygen difference, blood lactate, etc. guide fluid resuscitation therapy; stop using vasoactive drugs for more than 12 hours, and use diuretics or diuretics combined with albumin to achieve fluid balance.
62018369|NCT05658692|EXPERIMENTAL|Immunomodulatory therapy|Thymosin Alpha（Thymalfasin for Injection） 1.6mg subcutaneously twice a week.
62018370|NCT05658692|EXPERIMENTAL|Muscle relaxant therapy|For patients with moderate to severe ARDS, if light sedation cannot achieve protective lung ventilation strategy and prone position ventilation, deep sedation combined with intermittent bolus injection of muscle relaxants（Vecuronium Bromide for Injection） is used; if protective lung ventilation strategy and prone position ventilation still cannot be achieved, deep sedation combined with continuous Inject muscle relaxants.
62018371|NCT05658692|EXPERIMENTAL|Integrated Chinese and Western Medicine Treatment|Mechanical ventilation + conventional western medicine + Dachengqi Decoction/Rhubarb-Salvia Injection/Tanreqing/Xuanbai Chengqi Decoction(Drugs determined by syndrome differentiation and treatment)
62018372|NCT05658692|EXPERIMENTAL|statin therapy|There are currently two options: 1) Simvastatin （Simvastatin Tablets）80 mg QD orally for up to 28 days in patients with acute lung injury. 2) Rosuvastatin （Rosuvastatin Calcium Tablets）40 mg for the first time, followed by 20 mg orally daily for 28 days, or 3 days after being transferred out of the ICU, or after the patient died.
62018373|NCT05658692|EXPERIMENTAL|anti-infective treatment|"Refer to the Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. recommendations."
62209107|NCT05396534|ACTIVE_COMPARATOR|CLOSE arm|In the CLOSE arm, the use of MDCT-derived LAWT information will not be available for the operator. We uses a contact-force catheter. Ablation will be performed according to the CLOSE study settings: Power-controlled mode (without ramping) with 25 to 35 W (irrigation flow 30 ml/min). RF will be delivered until an AI of 400 at the posterior wall/roof an 550 at the anterior wall are reached.
62209108|NCT01531673|PLACEBO_COMPARATOR|Group 1-6d Combined: Placebo|All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a, 5b, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.
62209109|NCT01531673|EXPERIMENTAL|Group 1: VX-661 10 mg qd|All participants in group 1 who received VX-661 10 milligram (mg) tablet orally once daily (qd) for up to 28 days.
62406902|NCT01240369||miR-326 high|
62406903|NCT06650501|EXPERIMENTAL|Change to Dabigatran|Patients will have their anticoagulation changed to dabigatran at the monograph approved dose for the indication, bleeding risk, and renal function.
62406904|NCT06650501|ACTIVE_COMPARATOR|Continue current anticoagulant|Patients will continue their currently prescribed apixaban, edoxaban, or rivaroxaban
62406905|NCT05964400|EXPERIMENTAL|duoABLE|Stroke participant-caregiver duos (dyads) will meet with an occupational therapist 12 times (2x/week for 6 weeks, approximately 30 minutes/session) to apply activity monitoring, activity scheduling, collaborative problem solving, self-assessment, and social interdependence to self-selected activities that aim to increase both dyad members' physical activity levels
62406906|NCT03421873||Intervention (Implementation) group|Chest pain patients enrolled during a 10 month period after a change in routine care, i.e. the implementation of a 0h/1h hs-cTnT protocol
62209110|NCT01531673|EXPERIMENTAL|Group 2a: VX-661 30 mg qd|All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet every 12 hours (q12h) for up to 28 days.
62209111|NCT01531673|EXPERIMENTAL|Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h|All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
62209112|NCT01531673|EXPERIMENTAL|Group 3a: VX-661 100 mg qd|All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.
62581858|NCT05620498|ACTIVE_COMPARATOR|tislelizumab+GEMOX|"tislelizumab 200mg, Q3W, gemcitabine 1g/㎡, D1, D8, Q3W, oxaliplatin 100mg/㎡, D1, Q3W. Imaging evaluation was performed after 3 cycles.~Patients who met surgical criteria will receive R0 resection and adjuvant therapy 4-8 weeks after surgery (tislelizumab 200mg, Q3W) for one year or until disease progression or toxicity became intolerable.~Inoperable patients continue to receive ≤4 cycles of treatment, imaging evaluation every two cycles. Patients will receive R0 resection if meet surgical criteria and adjuvant therapy 4-8 weeks after surgery (Tislelizumab 200mg, Q3W) for one year or until disease progression or toxicity became intolerable.~Patients still unable to receive surgery, the experimental group will receive tislelizumab 200mg, Q3W for maintained treatment until disease progression or toxicity became intolerable."
62018374|NCT05658692|EXPERIMENTAL|Extracorporeal Membrane Oxygenation（ECMO）|ECMO (Medtronic) is chosen as rescue therapy for severe ARDS patients with refractory hypoxemia within 7 days of onset. (Oxygenation index \< 50 mmHg for 3 hours, or oxygenation index \< 80 mmHg for 6 hours, or arterial pH \< 7.25, arterial partial pressure of carbon dioxide \[Paco2\] ≥ 60 mmHg \> 6 hours, and respiratory rate increased to every minute 35 breaths, adjusting mechanical ventilation settings to maintain plateau pressure ≤32 cmH2O) despite ventilator optimization (defined as inspired oxygen concentration) ≥ 0.80, tidal volume 6 ml/kg (PBW), and positive end-expiratory pressure \[PEEP\] ≥ 10 cmH2O). V-V mode is preferred.
62209113|NCT01531673|EXPERIMENTAL|Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h|All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
62209114|NCT01531673|EXPERIMENTAL|Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h|All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
62209115|NCT01531673|EXPERIMENTAL|Group 5a: VX-661 150 mg qd|All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.
62581859|NCT01185184|EXPERIMENTAL|1|Subjects will receive in random order, the immediate release tablet containing 10 mg of CP-690,550 and two different controlled-release capsules containing 20 mg of CP-690,550.
62581860|NCT04797741|EXPERIMENTAL|IDEA3 Intervention|
61978497|NCT00987077|NO_INTERVENTION|control group|Patients randomized to control group achieve no treatment and are followed up for three months.
62209116|NCT01531673|EXPERIMENTAL|Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h|All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
62209117|NCT01531673|EXPERIMENTAL|Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h|All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.
62581861|NCT05719142|EXPERIMENTAL|Sweet Food (SW)|Exposure to pictures of sweet food.
62209118|NCT01531673|EXPERIMENTAL|Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h|All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
62209119|NCT01531673|PLACEBO_COMPARATOR|Group 7: Placebo|All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.
62209120|NCT01531673|EXPERIMENTAL|Group 7: VX-661 100 mg qd|All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.
62209121|NCT04385381|EXPERIMENTAL|URECA CTO device|investigate the safety and efficacy of the URECA CTO device in facilitating guidewire re-entry into the true lumen after passing occlusion(s) in the peripheral vasculature.
62209122|NCT03410498|OTHER|MS group|This group will perform walking trials in various conditions, i.e. normal walking, walking whilst performing an attention demanding task and walking while being physically tired.
62209123|NCT03241927|EXPERIMENTAL|Pembrolizumab|200 mg IV infusion every 3 weeks
62209124|NCT03241927|NO_INTERVENTION|Healthy Donors|
62209125|NCT05560243|EXPERIMENTAL|Intervention|Patients will receive a tobacco cessation intervention
62581862|NCT05719142|EXPERIMENTAL|Savoury Food (SA)|Exposure to pictures of savoury food.
61978498|NCT00987077|EXPERIMENTAL|crossover|After 3 months follow up patients of control group with persistence of disease activity were allocated to crossover group and received either SRT. Crossover group was followed up for further 3 months.
62018375|NCT05658692|EXPERIMENTAL|stem cell therapy|Previous clinical studies have found that stem cell therapy is safe, using a single injection of bone marrow stem cells at a dose of 1, 5, 10\*106 cells/kg; START trial, ClinicalTrials.gov NCT02097641, for patients with moderate to severe ARDS, a single intravenous injection of bone marrow stem cells 10\* 106 cells/kg intervention protocol.
62018376|NCT05658692|EXPERIMENTAL|Sedative analgesia/muscle relaxant therapy|For patients with moderate to severe ARDS, if light sedation cannot achieve protective lung ventilation strategy and prone position ventilation, deep sedation（Propofol Injectable Emulsion or Midazolam Injection） combined with intermittent bolus injection of muscle relaxants is used; if protective lung ventilation strategy and prone position ventilation still cannot be achieved, deep sedation combined with continuous Inject muscle relaxants（Vecuronium Bromide for Injection）.
62209126|NCT01835691|EXPERIMENTAL|Vitamin D2 (ergocalciferol)|50,000 units once a week for 12 weeks
62209127|NCT01835691|EXPERIMENTAL|Vitamin D3 (cholecalciferol)|50,000 units once a week for 12 weeks
62406907|NCT03421873||Control group|Chest pain patients managed at the 3 intervention EDs during the corresponding 10 months of the previous year (intervention hospitals acting as their own controls) as well as chest pain patients managed during the corresponding before-and-after period at EDs not implementing the protocol (concurrent controls).
62406908|NCT06617546|EXPERIMENTAL|Part A (SAD): Cohort A1|Single dose (as 1 or 2 SC injection\[s\]) of FTX-101 or placebo in a 3:1 ratio
62406909|NCT06617546|EXPERIMENTAL|Part A (SAD): Cohort A2|"Single dose (as 1 or 2 SC injection\[s\]) of FTX-101 or placebo in a 3:1 ratio~This Cohort may include a nested Absolute Bioavailability Cohort. After the SC dose, there will be a 14-day washout period and a single intravenous infusion of FTX-101 or placebo will be administered."
62406910|NCT06617546|EXPERIMENTAL|Part A (SAD): Cohort A3|"Single dose (as 1 or 2 SC injection\[s\]) of FTX-101 or placebo in a 3:1 ratio~This Cohort may include a nested Absolute Bioavailability Cohort. After the SC dose, there will be a 14-day washout period and a single intravenous infusion of FTX-101 or placebo will be administered."
62581863|NCT05719142|EXPERIMENTAL|Non-Food (NF)|Exposure to pictures of non-food items.
62018377|NCT05658692|EXPERIMENTAL|inotropes therapy|"For unconventional medication, according toSurviving sepsis campaign: international guidelines for the management of sepsis and septic shock 2021."
62018378|NCT05658692|EXPERIMENTAL|Vasoactive drug therapy|"According toSurviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
62018379|NCT00771680||A|
62018380|NCT00399152|EXPERIMENTAL|Perifosine+Sunitinib malate|
62018381|NCT01701375|EXPERIMENTAL|Arm 1|"* PD 0332991 will be given orally days 1,2,3~* Cytarabine (ara-C) will be given by continuous 72 hour intravenous infusion beginning on day 6~* Mitoxantrone will be given over 2 hour infusion day 9, 12 hours after the completion of the ara-C infusion. The mitoxantrone dose may be reduced by 25-50% for patients who have received previous anthracyclines as determined by total previous anthracycline dose"
62018382|NCT06263868||Precocious puberty group|Girl \< 8 years old or boy \< 9 years old when the first signs of development appear.
62581864|NCT01564108|EXPERIMENTAL|Ranibizumab|Series of intravitreal injections of Ranibizumab
62581865|NCT05982236||PCOS patients|
62209128|NCT01774877|EXPERIMENTAL|Xinfeng capsule & placebo|"1. Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months~2. placebo(for leflunomide): 10 mg each time, 1 time a day, Oral,for3 months"
62209129|NCT01774877|ACTIVE_COMPARATOR|leflunomide & placebo|"1. leflunomide :10mg each time, one time a day, by mouth,for 3 months~2. placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for3 months"
62406911|NCT06617546|EXPERIMENTAL|Part A (SAD): Cohort A4|"Single dose (as 1 or 2 SC injection\[s\]) of FTX-101 or placebo in a 3:1 ratio~This Cohort may include a nested Absolute Bioavailability Cohort. After the SC dose, there will be a 14-day washout period and a single intravenous infusion of FTX-101 or placebo will be administered."
62581866|NCT03789149|EXPERIMENTAL|Intraoperative Radiotherapy|Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG)
62581867|NCT02879617|EXPERIMENTAL|durvalumab|1500 mg of durvalumab will be administered intravenously (IV) on day 1 of every 28 day cycle.
62018383|NCT06263868||Advanced puberty group|Girl aged ≥ 8 and \< 10 years or boy ≥ 9 and \< 11 years old when the first signs of development appear.
62018384|NCT06263868||Control group|Boy or girl without any signs of puberty development (Tanner 1)
62406912|NCT06617546|EXPERIMENTAL|Part A (SAD): Cohort A5|Single dose (as 1 or 2 SC injection\[s\]) of FTX-101 or placebo in a 3:1 ratio
62018385|NCT06571123|EXPERIMENTAL|Experimental Group: group using interactive floor|Postoperative mobilization of children in this group will be provided on the interactive floor installed in the relevant ward.
62018386|NCT06571123|NO_INTERVENTION|Control Group|The postoperative mobilization of children in this group will be provided in the corridor, which is the routine of the relevant service, and they will be prevented from seeing the interactive floor before mobilization. Children in this group will be allowed to use the interactive floor in their mobilization after their 3rd mobilization.
62406913|NCT06617546|EXPERIMENTAL|Part A (SAD): Cohort A6|Optional cohort to receive additional single ascending intermediate (lower) or equivalent dose of FTX-101 or placebo in a 3:1 ratio via SC injection
62018387|NCT06489808|EXPERIMENTAL|Cohort 1 transplant-ineligible patients: Linperlisib combined with R-Gemox regimen|Cohort 1 consisted of transplant-ineligible patients who received Linperlisib in combination with R-Gemox. The treatment regimen was as follows: Linperlisib (RP2D dosage) on Days 1-14, rituximab 375 mg/m² on Day 0, gemcitabine 1000 mg/m² on Day 1, and oxaliplatin 130 mg/m² on Day 1, every 21 days for 6 cycles.
62018388|NCT06489808|EXPERIMENTAL|Cohort 2 patients scheduled for transplantation:Linperlisib combined with R-ICE/DHAP/GVM regimens|Cohort 2 consisted of patients scheduled for transplantation who received 3 cycles of Linperlisib (RP2D, D1-14) combined with R-ICE/DHAP/GVM regimen (R-ICE regimen: rituximab, ifosfamide, carboplatin, etoposide; R-DHAP regimen: rituximab, cytarabine, dexamethasone, cisplatin; R-GVM regimen: rituximab, gemcitabine, vinorelbine, mitoxantrone liposome), followed by autologous hematopoietic stem cell transplantation in responding patients.
62018389|NCT02061345||MCI|Prostate cancer patients having mild cognitive impairment (MCI) attributable to ADT with LHRHa
62209130|NCT03784001|ACTIVE_COMPARATOR|Gratitude + No Expectations|Participants will type online lists of up to five items they are grateful for, every two days for two weeks.
62209131|NCT03784001|EXPERIMENTAL|Gratitude + Expectations|Participants will type online lists of up to five items they are grateful for, every two days for two weeks. They will also be told a benefit of gratitude each time they write an online gratitude list.
62209132|NCT03784001|ACTIVE_COMPARATOR|Events Control|Participants will type online lists of up to five events from their day, every two day for two weeks.
62209133|NCT00545753|EXPERIMENTAL|A - NatrOVA 1% - no nit combing|NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
62406914|NCT06617546|EXPERIMENTAL|Part B (MAD): Cohort B1|Once daily dose (as 1 or 2 SC injection\[s\]) of FTX-101 or placebo for 14 days in a 3:1 ratio
62581868|NCT05226871|OTHER|Arm 1|Cetuximab
62581869|NCT05226871|EXPERIMENTAL|Arm 2|Palbociclib plus Cetuximab
62581870|NCT05226871|OTHER|Arm 3|Palbociclib plus Fulvestrant
62581871|NCT05226871|OTHER|Arm 4|Palbociclib plus Letrozole
62581872|NCT05172596|EXPERIMENTAL|PHE885|Patients will receive PHE885
62581873|NCT03503864|EXPERIMENTAL|ATO-combined chemotherapy|Patients receive combined induction chemotherapy with arsenic trioxide.
62581874|NCT06577662|EXPERIMENTAL|individual and family self-management (IFSM) fall prevention program|The IFSM program lasts for ten weeks, two weeks in the hospital, and follow up at eight weeks after patients are discharged to home. It includes 11 sessions, including ten sessions developed in the inpatient department within two weeks and one online booster session developed in the first month (week 4) after discharge in home. There is also one session just for caregivers, which aims to improve caregivers' skills to keep patients' safety. In the process, self-efficacy strategies, self-regulation skills, and social facilitation will be used in every session. The main self-efficacy strategies include skill mastery, vicarious experience, and verbal persuasion. Several self-regulation skills for patients and caregivers are also used in the study, such as self-monitoring and reflective thinking. Additionally, two phone-visit will be provided for follow up after patients discharged from the hospital at week 2 and 4 (week 4 and 6 of the program) except the training.
62734478|NCT06496308|OTHER|Orelabrutinib + Venetoclax (OV)|In maintanance phase, patients will receive different medical regimen according to their TP53 mutation and blastic and pleomorphic variants status. Patients with TP53 mutation or blastic and/or pleomorphic variant will receive orelabrutinib 150mg/day PO once daily and venetoclax for up to 2 years, the dosing of Venetoclax is escalated gradually to reach a target dose of 400 mg.
62790083|NCT06189924||Mechanically ventilated patients without lung injury|Mechanically ventilated patients without lung injury, with various pathologies. Patients will be treated at intensive care units (ICU).
62018390|NCT02061345||Control|Prostate cancer patients on ADT with LHRHa not having mild cognitive impairment
62209134|NCT00545753|EXPERIMENTAL|B - NatrOVA 1% - nit combing required|NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
62209135|NCT00545753|ACTIVE_COMPARATOR|C - NIX|NIX Creme Rinse (permethrin 1%) applied to Over the Counter (OTC) Instructions for Use
62209136|NCT04865198||Patients with Autism Spectrum Disorder (ASD)|Patients diagnosed with ASD in a child psychiatry clinic.
62209137|NCT04865198||Patients with High Functioning Autism (HFA)|Patients diagnosed with ASD in a child psychiatry clinic and with an IQ above 70.
62209138|NCT04865198||Healty control|Healthy volunteers who are in the age range compatible with the patient groups.
62209139|NCT02915484|EXPERIMENTAL|tDCS stimulation A|Intervention: Transcranial Direct Current Stimulation (tDCS) Up to 20 minutes of tDCS applied to the prefrontal cortex.
62209140|NCT02915484|EXPERIMENTAL|tDCS stimulation B|Intervention: Transcranial Direct Current Stimulation (tDCS) Up to 20 minutes of tDCS applied to the prefrontal cortex.
62209141|NCT03280147|EXPERIMENTAL|7-day course of antibiotics|Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 7-day group will not receive any further antibiotics.
62209142|NCT03280147|ACTIVE_COMPARATOR|14-day course of antibiotics|Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 14-day group will receive 7 more days of the same antibiotics, to make it a total of 14 days.
62209143|NCT03746587|EXPERIMENTAL|Arimoclomol I|Arimoclomol, oral capsule
62209144|NCT03746587|EXPERIMENTAL|Arimoclomol II|Arimoclomol, oral capsule
62209145|NCT03746587|EXPERIMENTAL|Arimoclomol III|Arimoclomol, oral capsule
62581875|NCT06577662|NO_INTERVENTION|usual care|the usual care will be provided to post-stroke people and their caregivers. The investigator visits the post-stroke people and caregivers in the control group after admission to develop an oral education about fall prevention. The usual care is routine knowledge education conducted by nursing staff in medical wards, and a fall prevention booklet will be provided for patients and caregivers in the hospital. Plan of fall prevention care documentation will be manually completed in the electronic record. After the patients are discharged to home, a phone visit will be provided for patients within the first month, which just include medication review and professional access. In additional, a fall record sheet will be used to record fall and a phone visit will be developed within the first month.
62581876|NCT02578368|EXPERIMENTAL|Arm A: FLOT chemotherapy + surgery (OP)|"4 cycles (8 weeks) FLOT pre-OP - surgery - 4-8 cycles FLOT (8-16 weeks) post-OP~Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1\*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).~\* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.~For HER-2 positive disease, trastuzumab should be added:~Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1~For PD-L1 positive disease (CPS ≥ 5), nivolumab can be added according to SmPC:~Nivolumab 240 mg i.v. for 30 min, d1, repeated every two weeks (q15d)"
62734479|NCT06496308|OTHER|Orelabrutinib (O)|In maintanance phase, patients will receive different medical regimen according to their TP53 mutation and blastic and pleomorphic variants status. Patients without TP53 mutation or blastic and/or pleomorphic variant will receive orelabrutinib 150mg/day PO once daily for up to 2 years.
62734480|NCT02384044|ACTIVE_COMPARATOR|Crest® Sensi-Stop™ Strips|Professionally Applied
62018391|NCT02329405|EXPERIMENTAL|Rifampicin|Rifampicin 600 mg tablet once a day orally for a week.
62018392|NCT02329405|PLACEBO_COMPARATOR|Placebo|Placebo tablet once a day orally for a week.
62018393|NCT05204524|EXPERIMENTAL|Subjected arm|"temozolomide for injection (once a day, with a fixed dose of 200 mg (body surface area ≤1.7m2) or 300 mg (body surface area \> 1.7 m2), for 5 days, with 21 days as a cycle) combined with epirubicin (60 mg/m2 21-day scheme).~Temozolomide for injection, according to the requirements of GCP, the test drug should be sealed, kept away from light and kept at 2-8℃, with a valid period of 24 months."
62018394|NCT04321460|EXPERIMENTAL|LRG-002|LRG-002 once daily for 14 days
62209146|NCT03746587|PLACEBO_COMPARATOR|Placebo|Placebo oral capsule matching experimental arm
62209147|NCT02756221|EXPERIMENTAL|Probiotics|Probiotics capsules, one capsule daily for 90 days.
62209148|NCT02756221|PLACEBO_COMPARATOR|Placebo|Starch capsules, one capsule daily for 90 days
62209149|NCT03503058|EXPERIMENTAL|Group 1|N=124 will receive PfSPZ Vaccine; three doses of 9x10\^5 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given on day 1, 8 and 29.
62209150|NCT03503058|PLACEBO_COMPARATOR|Group 2|N=62 will receive normal saline; three doses of NS administered by DVI given on day 1, 8 and 29.
62209151|NCT03503058|EXPERIMENTAL|Group 3|"N=124 will receive PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis; three doses of 2x10\^5 PfSPZ of PfSPZ Challenge administered by DVI on day 1, 29 and 57, with weekly CQ.~Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of PfSPZ Challenge."
62209152|NCT03503058|PLACEBO_COMPARATOR|Group 4|"N=62 will receive normal; three doses of NS administered by DVI given on day 1, 29 and 57, with weekly CQ.~Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of PfSPZ Challenge."
62209153|NCT03871582||Participants|Middle to older aged (\>50 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco,Mexico).
62734481|NCT02384044|ACTIVE_COMPARATOR|Colgate® Sensitivity Relief Pen|Professionally Applied
62209154|NCT04893343||Neonatal infection with antibiotics|In-patient neonates with ICD-10 infectious disease diagnosis, treated with antibiotics
62209155|NCT04893343||Neonatal infection without antibiotics|In-patient neonates with ICD-10 infectious disease diagnosis, treated without antibiotics
62018395|NCT04321460|PLACEBO_COMPARATOR|Placebo|Placebo once daily for 14 days
62018396|NCT04795505||Intervention group|A tertiary A-level hospital WeChat-based intervention
62018397|NCT04795505||Control group|Traditional community hospital intervention
62018398|NCT05864339|EXPERIMENTAL|A designed empathy tutorial during the SCC course (Intervention group)|Students who participated in the designed empathy tutorial (viewing videos of four smokers' real-life scenarios, reading four smokers cases text materials, and drawing Health Empathy Map). Students will demonstrate a quit plan by role-playing and will attend focus group interviews during the wrap-up session.
62018399|NCT05864339|ACTIVE_COMPARATOR|Smoking cessation counseling tutorial (Control group)|Students will watch videos of four smokers' real-life scenarios, and read four smokers' case text materials. Students will demonstrate a quit plan by role-playing and will attend focus group interviews during the wrap-up session.
62018400|NCT00009737|EXPERIMENTAL|Capecitabine|Participants received capecitabine 1250 milligram per square meter (mg/m \^ 2) orally, twice a day, for 14 days, followed by a 7-day rest period without treatment, as an intermittent therapy in a 3-week cycle for 8 cycles (24 weeks).
62018401|NCT00009737|ACTIVE_COMPARATOR|5-Fluorouracil + Leucovorin|Participants received leucovorin 20 mg/m \^ 2 followed by 5-fluorouracil at 425 mg/m \^ 2, by rapid intravenous injection, daily, from Days 1 to 5 of the first week in each 4-week cycle for 6 cycles (24 weeks).
62018402|NCT02925975|OTHER|Healthy controls|Healthy volunteers are enrolled as controls to get a normal range of pressure gradient in different sites of hepatic portal system (HPS), such as portal vein, superior mesenteric vein, inferior mesenteric vein and splenic vein. All enrolled healthy subjects should undergo anatomic computed tomographic angiography (CTA) and Doppler ultrasound for only one time, to rebuild a 3D-vHPS by computer.
62209156|NCT06728566|EXPERIMENTAL|Inmersive virtual reality training|Work at heights training with the addition of prior immersive virtual reality training.
62209157|NCT06728566|ACTIVE_COMPARATOR|Conventional training|Training for work at heights using conventional strategy
62209158|NCT05991934|EXPERIMENTAL|Single arm pilot|The micro-randomized trial will determine if CBT and Mindfulness/ACT messages are superior to control messages in reducing the primary outcome momentary smoking urges. Based on participants' training data collected in the initial 14 days of EMA monitoring, intervention messages will be delivered during time-periods and at high-risk locations for smoking. In the intervention phase, participants will be prompted to complete 3 geofence-triggered EMAs per day for a total of 30 days. Each EMA will be followed by an intervention message and the type of message (CBT, Mindfulness/ACT, control) will be randomly selected at each time point (within-subject randomization).
62209159|NCT01758900|ACTIVE_COMPARATOR|Air insufflation regulator|Room air will be used for insufflation as the Active Comparator arm
62406915|NCT06617546|EXPERIMENTAL|Part B (MAD): Cohort B2|Once daily dose (as 1 or 2 SC injection\[s\]) of FTX-101 or placebo for 14 days in a 3:1 ratio
62209160|NCT01758900|EXPERIMENTAL|CO2 insufflation regulator|Device: CO2 insufflation regulator
62406916|NCT06617546|EXPERIMENTAL|Part B (MAD): Cohort B3|Once daily dose (as 1 or 2 SC injection\[s\]) of FTX-101 or placebo for 14 days in a 3:1 ratio
62406917|NCT06617546|EXPERIMENTAL|Part B (MAD): Cohort B4|Optional cohort to receive once daily dose (as 1 or 2 SC injection\[s\]) of FTX-101 or placebo for 14 days in a 3:1 ratio
62406918|NCT04491474|ACTIVE_COMPARATOR|Group 1|bilateral great occipital nerve blockade and bilateral isotonic injection into the supraorbital region.
62406919|NCT04491474|ACTIVE_COMPARATOR|Group 2|bilateral supraorbital nerve blockade and bilateral isotonic injection into the great occipital nerve region
62734482|NCT03080571|EXPERIMENTAL|Stem cell group|autologous BMMNC stem cells with standard care
62734483|NCT03080571|ACTIVE_COMPARATOR|Control|Patients randomised in this group received standard care only
62018403|NCT02925975|EXPERIMENTAL|Treatment group guided by vPVPG|Enrolled cirrhotic patients with virtual portal vein pressure gradient (vPVPG) above 12mmHg are only treated by oral carvedilol. Once there are visible varies under the endoscopy, participants will be treated with routine endoscopic procedures.
62018404|NCT02925975|EXPERIMENTAL|Follow-up group guided by vPVPG|Cirrhotic patients with vPVPG lower than 12mmHg are followed-up with anatomic CTA and Doppler ultrasound every six months. Once vPVPG is higher 12mmHg or visible varies under the endoscopy, participants will be rescheduled to treatment group guided by vPVPG.
62018405|NCT02925975|ACTIVE_COMPARATOR|Follow-up group guided by endoscopy|Cirrhotic patients are followed-up by routine endoscopy. Once there are visible varies, participants will be treated according to Baveno V consensus in portal hypertension, such as oral carvedilol and routine endoscopic procedures.
62018406|NCT05446415|OTHER|Prospective analisys|"Immunohistochemical assays : biopsy sampled from each site was immediately fixated and then embedded in paraffin, cut in thin slide sections and dewaxed. Subsequently, antigen retrieval was performed, with incubations with (1) specific primary antibodies, (2) a second layer of antibodies and (3) a third layer of an avidin-biotin complex. Finally, counterstaining was performed, generating biopsy slides with cells positive for peptide YY (PYY), GLP-1, respectively.~Quantitative real-time polymerase chain reaction (qPCR) : the mRNA expression of the genes of interest glp-1,PYY 3-36 genes as well as the genes used for normalisation 18S were investigated. One biopsy sample from each biopsy site was immediately incubated in RNAlater solution (to preserve mRNA quality) (dna/rna Shield, USA). Subsequently, standard RNA purification, cDNA synthesis and quantitative PCR (qPCR) analysis were performed ."
62406920|NCT04491474|ACTIVE_COMPARATOR|Group 3|bilateral great occipital nerve blockade and bilateral supraorbital nerve blockade
62406921|NCT04491474|SHAM_COMPARATOR|Group 4|saline injection to bilateral great occipital nerve and supraorbital nerve region
62209161|NCT03546400|OTHER|methylphenidate HCl ERCT|methylphenidate HCl ERCT
62209162|NCT06568601|EXPERIMENTAL|Genetic testing arm|The intervention involves: genetic testing; interpretation; and prior to and shortly following an upcoming appointment, communication to patients and providers about the patients' predicted statin efficacy and toxicity, genetic risk for CVD, and individualized recommended statin type/dose.
62209163|NCT06568601|ACTIVE_COMPARATOR|Control|The control condition involves receipt of a report highlighting the risk of cardiovascular disease and benefits of statins (without genetic test results).
62581877|NCT02578368|ACTIVE_COMPARATOR|Arm B: FLOT chemotherapy alone|"4 cycles (8 weeks) FLOT followed by further 4-8 cycles FLOT (8-16 weeks)~Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1\*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).~\* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.~For HER-2 positive disease, trastuzumab should be added:~Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1~For PD-L1 positive disease (CPS ≥ 5), nivolumab can be added according to SmPC:~Nivolumab 240 mg i.v. for 30 min, d1, repeated every two weeks (q15d)"
62018407|NCT01834365|EXPERIMENTAL|Structured education & checklist|Formatted education and checklist every month for 3 months
62018408|NCT01834365|ACTIVE_COMPARATOR|Structured education|Formatted education every month for 3 months
62018409|NCT01834365|ACTIVE_COMPARATOR|Without Structured Education with checklist|No structured education with checklist
62018410|NCT03021187|EXPERIMENTAL|Semaglutide 3 mg|
62018411|NCT03021187|EXPERIMENTAL|Semaglutide 3 mg + 7 mg|
62018412|NCT03021187|EXPERIMENTAL|Semaglutide 3 mg + 7 mg + 14 mg|
62018413|NCT03021187|PLACEBO_COMPARATOR|Placebo|
62018414|NCT04982042|EXPERIMENTAL|Post COVID-19 Outpatient Pulmonary Rehabilitation Program|The outpatient Pulmonary Rehabilitation Program will be carried out at the Pulmonary Rehabilitation Laboratory, consisting of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
62018415|NCT04982042|ACTIVE_COMPARATOR|Post COVID-19 Home Pulmonary Rehabilitation Program|The Home Pulmonary Rehabilitation Program will be carried out at the patients' homes, consisting of the same combination of aerobic and strengthening exercises, lasting 12 weeks, 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance. Patients will be monitored weekly via whatsapp.
62018416|NCT05909189|EXPERIMENTAL|ADRD dyads|This is a single-arm study enrolling 60 ADRD community-based dyads.
62406922|NCT00733642|EXPERIMENTAL|PF-04360365 1 mg/kg|
62581878|NCT06374394|EXPERIMENTAL|Co-Ad Group|Participants receive a single dose of RSVPreF3 OA investigational vaccine and a single dose of COVID-19 mRNA vaccine at Day 1 and are followed up until end of study (6 months post last dose).
62581879|NCT06374394|ACTIVE_COMPARATOR|Control Group|Participants receive a single dose of COVID-19 mRNA vaccine at Day 1, followed by a single dose of RSVPreF3 OA investigational vaccine at Day 31 and are followed up until end of study (6 months post last dose).
62581880|NCT04833270|EXPERIMENTAL|KM non-pharmacological treatment group|Non-pharmacological treatment including Korean medicine will be implemented to the participants twice a week for total 8 weeks. The specific intervention will be determined according to the physician's choice, and information will be recorded in the case report form.
62581881|NCT04833270|ACTIVE_COMPARATOR|Pharmacological treatment group|Pharmacological treatment will be implemented to the participants twice a week for total 8 weeks. The specific intervention will be determined according to the physician's choice, and information will be recorded in the case report form.
62581882|NCT05221151|ACTIVE_COMPARATOR|melatonin|26 patients will receive melatonin 10 mg
62581883|NCT05221151|ACTIVE_COMPARATOR|pregabalin|26 patients will receive pregabalin 150 mg
62581884|NCT05221151|ACTIVE_COMPARATOR|melatonin and pregabalin|26 patients will receive melatonin 5 mg plus pregabalin 75 mg
62581885|NCT03013907|EXPERIMENTAL|UPLIFT|Eligible participants will complete 8 weekly group sessions by phone. The intervention builds cognitive-behavioral and mindfulness skills to help reduce depressive symptoms. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment.
62581886|NCT03013907|ACTIVE_COMPARATOR|Usual Care|Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study for the UC group and outside of the study (for the intervention group) will be assessed at each time point.
62581887|NCT06546020|PLACEBO_COMPARATOR|Placebo, Metabolically Healthy|The placebo supplement will have no polyphenol content and will be carbohydrate-matched to the experimental group. A twice daily dose (10-12 hours apart) will be consumed for 8 weeks.
62581888|NCT06546020|EXPERIMENTAL|Haskap, Metabolically Healthy|The haskap supplement will consist of a haskap berry smoothie. A twice daily dose (10-12) hours apart will be consumed for 8 weeks.
62209164|NCT05889702||KATR Clients|participants in the early stages of recovery and in substance use disorder (SUD) treatment; or those that have completed within the past year SUD treatment for opioid use disorder or stimulant use disorder or have a history of overdose from opioid use.
62209165|NCT00231452|EXPERIMENTAL|Late exposure group|Participants received monthly Sulfadoxine-Pyrimethamine (SP) plus Artesunate (AS) from 2.5-4.5 months of age and monthly placebo from 5.5-9.5 months of age.
62209166|NCT00231452|EXPERIMENTAL|Early exposure group|Participants received monthly placebo from 2.5-4.5 months of age and monthly SP+AS from 5.5-9.5 months of age.
62209167|NCT00231452|PLACEBO_COMPARATOR|Control group|Participants received monthly placebo from 2.5 to 9.5 months of age.
62209168|NCT06686654|EXPERIMENTAL|Group A Stage 1 Sentinel Cohort|1 IM injection of investigational hMPV/RSV vaccine formulation A
62581889|NCT06546020|PLACEBO_COMPARATOR|Placebo, Metabolically Unhealthy|The placebo supplement will have no polyphenol content and will be carbohydrate-matched to the experimental group. A twice daily dose (10-12 hours apart) will be consumed for 8 weeks.
62581890|NCT06546020|EXPERIMENTAL|Haskap, Metabolically Unhealthy|The haskap supplement will consist of a haskap berry smoothie. A twice daily dose (10-12) hours apart will be consumed for 8 weeks.
62581891|NCT04483960|NO_INTERVENTION|(Arm Closed) Antiviral - Standard of care|Standard of care without nafamostat mesilate
62581892|NCT04483960|EXPERIMENTAL|(Arm Closed) Antiviral - nafamostat mesilate|Nafamostat continuous IV infusion for 7 days or until day of hospital discharge at a dose of 0.2mg/kg/hour. No adjustment in dose is needed for renal impairment, including for renal dialysis. The daily dose of nafamostat should be administered in 500 mL (rate of infusion 20.8 mL/hour) of normal saline. Normal saline is recommended (due to the tendency for patients with COVID-19 towards hyponatraemia) but not mandated, and 5% dextrose would be acceptable if felt clinically appropriate.
62581893|NCT04483960|ACTIVE_COMPARATOR|(Arm Closed) Anticoagulation - standard dose thromboprophylaxis|Patients will be administered a standard thromboprophylactic dose of low molecular weight heparin, choice of agent according to availability and local practice at the participating site.
62581894|NCT04483960|EXPERIMENTAL|(Arm Closed) Anticoagulation - intermediate dose thromboprophylaxis|Patients will be administered an intermediate dose of low molecular weight heparin, choice of agent according to availability and local practice at the participating site. The maximum dose of enoxaparin will be 120 mg/d, tinzaparin 125 IU/kg/day (not available within Australia), and Dalteparin 15,000 IU/d.
62581895|NCT04483960|EXPERIMENTAL|(Arm Closed) Anticoagulation - therapeutic anticoagulation|Therapeutic anticoagulation administered with LMWH daily until hospital discharge, admission to ICU or for a maximum of 28 days from randomisation. Choice of LMWH according to availability and local practice at the participating site
62581896|NCT04483960|NO_INTERVENTION|(Arm Never Opened) Antibody - Standard of Care|No hyperimmune globulin
62209169|NCT06686654|EXPERIMENTAL|Group B Stage 1 Sentinel Cohort|1 IM injection of investigational hMPV/RSV vaccine formulation B
62209170|NCT06686654|PLACEBO_COMPARATOR|Group C Stage 1 Sentinel Cohort|1 IM injection of placebo
62209171|NCT06686654|EXPERIMENTAL|Group 1 Stage 1 Main Cohort|1 IM injection of investigational hMPV/RSV vaccine formulation C
62406923|NCT00733642|EXPERIMENTAL|PF-04360365 3 mg/kg|
62406924|NCT00733642|EXPERIMENTAL|PF-04360365 5 mg/kg|
62406925|NCT00733642|EXPERIMENTAL|PF-04360365 10 mg/kg|
62406926|NCT02209272|EXPERIMENTAL|bacteriostatic saline|for ultrasound guided hip joint injection local anesthesia
62406927|NCT02209272|ACTIVE_COMPARATOR|buffered lidocaine|for ultrasound guided hip joint injection local anesthesia
62406928|NCT02173275||derivation cohort|n = 309
62406929|NCT02173275||validation cohort|n = 309
62581897|NCT04483960|EXPERIMENTAL|(Arm Never Opened) Antibody - hyperimmune globulin|2 doses of 30mL (3x10mL vials) of COVID-19 Hyper-Immunoglobulin (Human) given over 2 days within 48 hours of randomisation
62209172|NCT06686654|EXPERIMENTAL|Group 2 Stage 1 Main Cohort|1 IM injection of investigational hMPV/RSV vaccine formulation D
62209173|NCT06686654|EXPERIMENTAL|Group 3 Stage 1 Main Cohort|1 IM injection of investigational hMPV/RSV vaccine formulation E
62209174|NCT06686654|EXPERIMENTAL|Group 4 Stage 1 Main Cohort|1 IM injection of investigational hMPV/RSV vaccine formulation F
62406930|NCT03323034|EXPERIMENTAL|Treatment (pevonedistat, temozolomide, irinotecan)|Patients receive pevonedistat IV over 60 minutes on days 1, 8, 10, and 12, temozolomide PO daily on days 8-12, and irinotecan IV over 90 minutes on days 8-12 of cycle 1. Beginning cycle 2, patients receive pevonedistat IV over 60 minutes on days 1, 3, and 5, temozolomide PO daily on days 1-5, and irinotecan IV over 90 minutes on days 1-5. Treatment repeats every 28 days for cycle 1 and 21 days for subsequent cycles for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
62406931|NCT03126175|ACTIVE_COMPARATOR|Above elbow immobilization|Above elbow immobililization with short radial splint that will be performed with 20cm wide gypsum cut to fit the thumb. The splint will be applied to the radial aspect of the wrist covering the volar and dorsal portion of the radius to the elbow. Additional splint with a 15cm width splint on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
62209175|NCT06686654|EXPERIMENTAL|Group 5 Stage 1 Main Cohort|1 IM injection of investigational hMPV/RSV vaccine formulation G
62209176|NCT06686654|EXPERIMENTAL|Group 6 Stage 1 Main Cohort|1 IM injection of investigational hMPV/RSV vaccine formulation A
62406932|NCT03126175|EXPERIMENTAL|Below elbow immobilization|Below elbow immobilization with exclusively short radial splint that will be performed with 20cm wide gypsum cut to fit the thumb. The splint will be applied to the radial aspect of the wrist covering the volar and dorsal portion of the radius to the elbow.
62581898|NCT04483960|NO_INTERVENTION|Antiviral II - No antiviral agent|Participants will receive no antiviral agents intended to be active against SARS-CoV-2 for 28 days or until hospital discharge, whichever occurs first.
62209177|NCT06686654|EXPERIMENTAL|Group 7 Stage 1 Main Cohort|1 IM injection of investigational hMPV/RSV vaccine formulation B
62209178|NCT06686654|EXPERIMENTAL|Group 8 Stage 1 Main Cohort|1 IM injection of investigational hMPV/RSV vaccine formulation H
62581899|NCT04483960|EXPERIMENTAL|Antiviral II - Nirmatrelvir-ritonavir|The dose of nirmatrelvir-ritonavir is dependent on renal function. Participants will receive 100mg BD oral/enteral Ritonavir and either 150mg BD (if eGFR 30-59 mL/min/1.73m2) or 300mg BD (eGFR \>= 60 mL/min/1.73m2) oral/enteral Nirmatrelvir. Investigators are advised to consider withholding treatment if the participant's eGFR \< 30 mL/min/1.73m2.
62581900|NCT04483960|EXPERIMENTAL|Antiviral II - Remdisivir|The dose of intravenous remdesivir is 200 mg on day 1 followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first. Remdesivir will be administered as an intravenous infusion via a central or peripheral venous catheter over a 30-120 minute period, as per local practice.
62581901|NCT04483960|EXPERIMENTAL|Antiviral II - Nirmatrelvir-ritonavir + remdesivir|Participants will receive both nirmatrelvir-ritonavir and remdesivir using the dose and administration methods described above.
62581902|NCT06125938|EXPERIMENTAL|tent pole technique|The screw tent-pole method is an effective technique to achieve initial reconstruction of alveolar bone deficiencies
62209179|NCT06686654|EXPERIMENTAL|Group 9 Stage 1 Main Cohort|1 IM injection of investigational hMPV/RSV vaccine formulation I
62209180|NCT06686654|EXPERIMENTAL|Group 10 Stage 1 Main Cohort|1 IM injection of investigational hMPV/RSV vaccine formulation J
62406933|NCT04759352|EXPERIMENTAL|Telephone post-test genetic counseling|Post-test genetic counseling delivered by telephone
62406934|NCT04759352|NO_INTERVENTION|In-person post-test genetic counseling|Post-test genetic counseling delivered in-person
62581903|NCT06125938|ACTIVE_COMPARATOR|autogenous bone block technique|Bone block graft has been the gold standard for restoring deficient regions.
62581904|NCT03617770|EXPERIMENTAL|Sleep-Opt-In|Sleep optimization intervention
62581905|NCT03617770|ACTIVE_COMPARATOR|Healthy Living|Health education
62209181|NCT06686654|PLACEBO_COMPARATOR|Group 11 Stage 1 Main Cohort|1 IM injection of placebo
62209182|NCT06686654|EXPERIMENTAL|Group X Stage 2 Expansion Cohort|1 IM injection of selected investigational hMPV/RSV vaccine formulation from Group 1-9 of Stage 1 Main Cohort
62209183|NCT06686654|EXPERIMENTAL|Group 12 Stage 2 Expansion Cohort|1 IM injection of investigational RSV monovalent vaccine
62209184|NCT06686654|EXPERIMENTAL|Group 13 Stage 2 Expansion Cohort|1 IM injection of investigational hMPV monovalent vaccine
62209185|NCT06686654|EXPERIMENTAL|Group 14 Stage 2 Expansion Cohort|1 IM injection of licensed RSV vaccine
62209186|NCT06686654|EXPERIMENTAL|Group 15 Stage 2 Booster Cohort|1 IM injection of selected investigational hMPV/RSV vaccine formulation from Group X of Expansion Cohort
62209187|NCT06686654|PLACEBO_COMPARATOR|Group 16 Stage 2 Booster Cohort|1 IM injection of placebo
62209188|NCT05661422||Participants|
62209189|NCT06316895||surgery group|patients with low-risk papillary thyroid carcinoma who chose thyroid surgery
62209190|NCT06316895||ablation group|patients with low-risk papillary thyroid carcinoma who chose thermal ablation
62209191|NCT02656706|EXPERIMENTAL|Adjuvant treatment|Ipilumumab:1mg/kg q6weeks (1 dose per cycle, 4 planned treatments over 6 months total) Nivolumab:3mg/kg q2weeks (3 doses per cycle, 12 planned treatments over 6 months total)
62209192|NCT04795765||Patients treated with SpineJack system|SpineJack system procedure
62209193|NCT04795765||Patients treated with vertebral augmentation|Vertebral augmentation procedures may include either balloon kyphoplasty (BKP) or vertebroplasty (VP).
62209194|NCT00159263|PLACEBO_COMPARATOR|Placebo|placebo
62209195|NCT00159263|EXPERIMENTAL|Formoterol|Oxis(®) 12 μg
62209196|NCT00159263|EXPERIMENTAL|Budesonide low dose|Pulmicort(®) 200 μg
62209197|NCT00159263|EXPERIMENTAL|Budesonide high dose|Pulmicort(®) 800 μg
62209198|NCT00159263|EXPERIMENTAL|Budesonide/formoterol combination single|single 100/6 μg SYM100
62209199|NCT00159263|EXPERIMENTAL|Budesonide/formoterol combination double|double 200/12 μg SYM200
62406935|NCT03842202|EXPERIMENTAL|Semaglutide|Participants will receive increasing doses of semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks.
62406936|NCT03842202|PLACEBO_COMPARATOR|Placebo (Semaglutide)|Participants will receive placebo (semaglutide). The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks
62581906|NCT02278939|EXPERIMENTAL|Fit and Trim group|This groups will start with the Filipinos Fit and Trim Weight Loss Program mobile phone based (smartphone) intervention with social networking for 3 months, a pedometer/accelerometer, access to a study private Facebook virtual social networking group, and and 4 in-person intervention session with individually tailored goals for physical activity, diet, and weight. At 3months, the Fit and Trim group will transition to a maintenance phase for 3 months, receive one in-person session for maintenance support (at 4.5 months) and complete the study at month 6.
62581907|NCT02278939|ACTIVE_COMPARATOR|Pedometer only group|This group will start with the pedometer/accelerometer only to monitor/ track their physical activity step-counts for the initial 3 months. In addition, subjects will receive an educational materials on Hepatitis B and Tuberculosis. At 3 months the pedometer only group will transition to receive the Filipinos Fit and Trim Weight Loss Program intervention (as previously described) for the next 3 months and complete the study at month 6.
62581908|NCT00334074|EXPERIMENTAL|Clofarabine and Cytarabine|Five consecutive days of clofarabine 40 mg/m\^2 IVI over 1 hour followed 4 hours later by cytarabine 1000 mg/m\^2 IVI over 2 hours
62406937|NCT01857011|EXPERIMENTAL|IV Iron|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
62406938|NCT01857011|ACTIVE_COMPARATOR|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
62406939|NCT00741026|PLACEBO_COMPARATOR|Placebo|Placebo
62406940|NCT00741026|EXPERIMENTAL|Olanzapine|Olanzapine 10mg po daily x 3 days
62406941|NCT04698668||1|Patients with pancreatic fluid collection treated with traditional EUS-drainage
62581909|NCT02382497|EXPERIMENTAL|AN Active tDCS|"Treatment as usual plus experimental treatment"
62406942|NCT04698668||2|Patients with pancreatic fluid collection treated with fusion imaging
62406943|NCT00003726|EXPERIMENTAL|Lepirudin|Dose level 1: 10 mg once daily -\> (total dose, 10 mg/d) Dose level 2: 15 mg once daily -\> (total dose, 15 mg/d) Dose level 3: 10 mg twice daily -\> (total dose, 20 mg/d) Dose level 4: 15 mg twice daily -\> (total dose, 30 mg/d) Dose level 5. 20 mg twice daily -\> (total dose, 40 mg/d) Dose level 6: 25 mg twice daily -\> (total dose, 50 mg/d)
62406944|NCT03183739|EXPERIMENTAL|ASP8062 lower dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
62581910|NCT02382497|SHAM_COMPARATOR|AN Sham tDCS|"Treatment as usual plus placebo treatment"
62406945|NCT03183739|EXPERIMENTAL|ASP8062 middle dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
62406946|NCT03183739|EXPERIMENTAL|ASP8062 higher dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
62406947|NCT03183739|PLACEBO_COMPARATOR|Placebo|Subjects will receive a single dose of Placebo on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
62406948|NCT06525506|ACTIVE_COMPARATOR|Arm 2: IBI311 (3-20 mg)|Arm 2: IBI311 (3-20 mg). Participants will receive 8 intravenous infusions of IBI311 with an interval of 3 weeks. Dose conversion was performed at week 12.
62406949|NCT06525506|ACTIVE_COMPARATOR|Arm 4: IBI311 (20 mg)|Arm 4: IBI311 (20 mg). Participants will receive 8 intravenous infusions of IBI311 with an interval of 3 weeks.
62406950|NCT06525506|ACTIVE_COMPARATOR|Arm 3: IBI311 (10 mg)|Arm 3: IBI311 (10 mg). Participants will receive 8 intravenous infusions of IBI311 with an interval of 3 weeks.
62406951|NCT06525506|ACTIVE_COMPARATOR|Arm 1: IBI311 (3-10 mg)|Arm 1: IBI311 (3-10 mg). Participants will receive 8 intravenous infusions of IBI311 with an interval of 3 weeks. Dose conversion was performed at week 12.
62406952|NCT02003248|EXPERIMENTAL|dyskinesia of PD|The proposed study is to evaluate the safety and initial effectiveness of the ExAblate Transcranial MRI-guided focused ultrasound (MRgFUS) treatment of patients with dyskinesia of Parkinson's Disease (PD)
62406953|NCT05632055||Pregnancy with GDM|Pregnant women who positive test for 100gm OGTT (abnormal 2 or more blood glucose level according NDDG (National Diabetes Data Group) criteria)
62581911|NCT02382497|EXPERIMENTAL|BED Active tDCS|"Treatment as usual plus experimental treatment"
62209200|NCT04777201|EXPERIMENTAL|Main Study: Faricimab PTI|
62209201|NCT04777201|EXPERIMENTAL|Substudy: Faricimab PTI|
62209202|NCT03017820|EXPERIMENTAL|Group A (VSV-IFNbeta-NIS)|Patients receive VSV-IFNbeta-NIS intravenously (IV) while on study. Patients undergo SPECT, CT scan, PET scan throughout the study. Patients may undergo tumor biopsy, bone marrow biopsy and blood sample collection throughout the study.
62406954|NCT05632055||Pregnancy without GDM|Pregnant women who negative test for 100gm OGTT
62406955|NCT00762073|PLACEBO_COMPARATOR|1|
62406956|NCT00762073|EXPERIMENTAL|2|Low Dose Group
62406957|NCT00762073|EXPERIMENTAL|3|Medium Dose Group
62406958|NCT00762073|EXPERIMENTAL|4|High Dose Group
62406959|NCT03716440|EXPERIMENTAL|Nature group|Nature exposure intervention.
62406960|NCT03716440|ACTIVE_COMPARATOR|Non-nature group|Non-nature exposure intervention.
62406961|NCT01495793|EXPERIMENTAL|Rotigotine|In the Titration Period a subject received the first dose of rotigotine then the dose was increased weekly by a dose step over 4 weeks.
62581912|NCT02382497|SHAM_COMPARATOR|BED Sham tDCS|"Treatment as usual plus placebo treatment"
62581913|NCT03838315|EXPERIMENTAL|Neural Mobilization with Soft Tissue Mobilization|"Neural Mobilization with Soft Tissue Mobilization group will be assessed by spurling's test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Neural mobilization Techniques which involve Median, Radial and Ulnar Nerve Mobilization and Post Isometric Relaxation Techniques.~Frequency for Neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 40mints each session)"
62209203|NCT03017820|EXPERIMENTAL|Group B (VSV-IFNbeta-NIS, ruxolitinib, cyclophosphamide)|\*\* Group B no longer enrolling \*\*
62209204|NCT03017820|EXPERIMENTAL|Group C (VSV-IFNbeta-NIS, ruxolitinib, nivolumab)|\*\* Group C no longer enrolling \*\*
62209205|NCT03017820|EXPERIMENTAL|Group D (VSV-IFNbeta-NIS, ruxolitinib, cemiplimab) - Multiple Myeloma (MM) only|Multiple myeloma patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1, ipilimumab IV over 30 minutes on day -3 and cemiplimab IV over 30 minutes on day -3 in the absence of disease progression or unacceptable toxicity. Patients undergo SPECT, CT scan, PET scan throughout the study. Patients may undergo tumor biopsy, bone marrow biopsy and blood sample collection throughout the study.
62209206|NCT03017820|EXPERIMENTAL|Group E (VSV-IFNbeta-NIS, ipilimumab, cemiplimab) - Peripheral T-cell lymphoma (PTCL) only|PTCL patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1, ipilimumab IV over 30 minutes on day -3 and cemiplimab IV over 30 minutes on day -3 in the absence of disease progression or unacceptable toxicity. Patients undergo SPECT, CT scan, PET scan throughout the study. Patients may undergo tumor biopsy, bone marrow biopsy and blood sample collection throughout the study.
62209207|NCT03017820|EXPERIMENTAL|Group F (VSV-IFNbeta-NIS alone) - B-Cell Leukemia (BCL) Expansion Cohort|BCL patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients undergo SPECT, CT scan, PET scan throughout the study. Patients may undergo tumor biopsy, bone marrow biopsy and blood sample collection throughout the study.
62209208|NCT03017820|EXPERIMENTAL|Group G (VSV-IFNbeta-NIS alone) - PTCL Expansion Cohort|PTCL patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients undergo SPECT, CT scan, PET scan throughout the study. Patients may undergo tumor biopsy, bone marrow biopsy and blood sample collection throughout the study.
62209209|NCT06225505|EXPERIMENTAL|Experimental arm|In the experimental arm, patients and their treating physician will be made aware of the molecular relapse (positive ctDNA detection results) in study steps 1 (ctDNA monitoring). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician.
62406962|NCT03245359|ACTIVE_COMPARATOR|Short-term ON-Q|Single port, select-a-flow pump and ON-Q 750mL ball filled with bupivacaine 0.125% saphenous (adductor canal) nerve block and single port, fixed flow pump and 400mL ON-Q ball with bupivacaine 0.125% wide field posterior knee block to provide analgesia from surgery until medication has been depleted (typically 2-4 days)
62581914|NCT03838315|ACTIVE_COMPARATOR|Neural mobilization without Soft Tissue Mobilization|Neural Mobilization without Soft Tissue Mobilization group will be assessed by spurling's test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Neural Mobilization Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 30mints each session)
62018417|NCT06574100|ACTIVE_COMPARATOR|Single Oral Dose Administration of 250mg Buccally or 1000 mg Orally of two CBD formulations|participants receiving the buccal formulation will be required to receive 10 strips by the cheeks, they will be instructed to only swallow at maximum once every 2 mins for the first 5 mins. This is to minimize the amount of CBD that will be carried into the GIT. This buccal administration group will receive 2 strips at a time, one on each cheek side, following 5 mins of dissolving, patients will receive 100mL of water to swish the residue in their mouths and swallow, then receive another pair of strips to repeat the process for a total of 5 times over the course of 30 minutes (i.e., 10 strips total). The group receiving the 1000mg oral CBD extract will mimic the buccal group in that they will receive that dose over the course of 30 minutes in 5 parts, 200mg per part, and will drink 100mL of water to accompany its administration
62018418|NCT06574100|ACTIVE_COMPARATOR|Single Oral Dose Administration of 3000mg CBD Extract in Fed vs Fasting|In the fasting group, participants will be asked to fast overnight (at least 10 hours fast) but are allowed to drink water.In the fed state group, participants will start their meal 30 minutes prior to receiving the dose. The meal will consist of high caloric (800-1000 Cal), high fat (\~50% of total calories), with protein, and carbohydrates (\~150 kcal, and \~250 kcal, respectively) content. No food will be administered 4 hours after the dose, and no water will be given 1 hour prior to dose administration and 1 hour after administration. The dose will be given however with a total of 235 mL of water.
62209210|NCT06225505|SHAM_COMPARATOR|Control arm|In the control arm, patients and their treating physician will not be made aware of the molecular relapse and will continue the standard surveillance with repeated ctDNA test every 3 months (blinded). ). At the time of the clinical/radiological diagnosis of relapse, similar procedures will be performed (18F-FDG PET-CT, 68Ga-FAPI-46-PET-CT, and tumor genetic landscape assessment by ctDNA analysis).
62209211|NCT06729684|NO_INTERVENTION|control (Conventional Treatment)|"* breast cancer surgery with CTx/RTx/HTx~* brochure training"
62209212|NCT06729684|EXPERIMENTAL|intervention (digital health)|"* breast cancer surgery with CTx/RTx/HTx~* brochure training~* add digital health (application + smartwatch)"
62209213|NCT04885855|EXPERIMENTAL|8-week|Patient will be receiving treatment of tablet Sofosbuvir 400mg and tablet Ravidasvir 200mg combination once daily for the duration of 8 weeks.
62209214|NCT04885855|ACTIVE_COMPARATOR|12-week|Patient will be receiving treatment of tablet Sofosbuvir 400mg and tablet Ravidasvir 200mg combination once daily for the duration of 12 weeks.
62209215|NCT04326322|EXPERIMENTAL|Methionine Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
62209216|NCT04700631|ACTIVE_COMPARATOR|healthy subject|healthy subjects : no medical history, in particular cardiovascular, without drug treatment, without proteinuria, normal BMI
62209217|NCT04700631|EXPERIMENTAL|CRF patients|CRF patients : eGFR estimated according to the MRDR formula less than 89 mL/min/1,73m²
62406963|NCT03245359|EXPERIMENTAL|Long-term ON-Q|Single port, select-a-flow pump and two 750mL ON-Q balls filled with bupivacaine 0.125% saphenous (adductor canal) nerve block and single port, fixed flow pump and two 400mL ON-Q ball with bupivacaine 0.125% wide field posterior knee block to provide analgesia from surgery up to 7 days post-operative. The second ball for each location will be provided pre-operatively, along with patient education for connection.
62406964|NCT03818542|EXPERIMENTAL|Arm 1: ABBV-181 IV|A single dose of ABBV-181 administered via intravenous (IV) infusion on Day 1.
62581915|NCT04393480|ACTIVE_COMPARATOR|Robotic therapy|Robotic rehabilitation and conventional rehabilitation
62581916|NCT04393480|SHAM_COMPARATOR|Conventional therapy|Conventional rehabilitation
62209218|NCT02943239|EXPERIMENTAL|Panel A|REGN1033 + REGN2477 (Regimen 1) or placebo
62209219|NCT02943239|EXPERIMENTAL|Panel B|Panel B - REGN1033 + REGN2477 (Regimen 2) or Placebo
62209220|NCT02943239|EXPERIMENTAL|Panel C|Panel C - Patients will receive either REGN1033 + REGN2477 (Regimen 3) or Placebo
62581917|NCT04693026|EXPERIMENTAL|Group A: Remdesivir + Baricitinib treatment group|"Remdesivir (Injectable solution):~A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (\>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (\>40kg) daily following randomization.~+~Baricitinib (oral tablet form):~Baricitinib tablets 4 mg/day for 2 to 4weeks"
62581918|NCT04693026|ACTIVE_COMPARATOR|Group B: Remdesivir + Tocilizumab treatment group|"Remdesivir (Injectable solution) A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (\>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (\>40kg) daily following randomization.~+~Tocilizumab (Injectable solution):~Tocilizumab I/V 8mg/Kg up to 800mg highest 12 hours apart."
62209221|NCT02943239|EXPERIMENTAL|Panel D|Panel D - Patients will receive either REGN1033 + REGN2477 (Regimen 4), REGN1033, REGN2477 (high dose) or Placebo
62209222|NCT02943239|EXPERIMENTAL|Panel E|REGN2477 (Regimen 5) or placebo
62209223|NCT02943239|EXPERIMENTAL|Panel F|REGN2477 + REGN1033 (Regimen 6) or placebo
62209224|NCT02943239|EXPERIMENTAL|Panel G|REGN2477 (Regimen 7) or placebo
62581919|NCT05200182|OTHER|Study A|Validation of the reward system-related fMRI task, as determined by an increased activation on the brain reward structure (striatum) under the task.
62581920|NCT05200182|EXPERIMENTAL|Study B - Neurofeedback|"The neurofeedback protocol will be the same during the 8 sessions constituting the protocol and taking place over a period of 4 weeks (2 neurofeedback sessions per week, the first and the last one in an MRI context). It will last 15 minutes per session, and during each session, the volunteer will have to increase the brain activity of his/her dlPFC using a visual gauge representing the activity level of his/her own dlPFC. No specific instructions will be given to the volunteer so that he/she can develop his/her own internal strategy to increase this activity level."
62209225|NCT06364787|EXPERIMENTAL|γδ T cells+ PD-1 monoclonal antibody+ targeted drugs|Patients will receive 4 cycles of ex-vivo expanded allogeneic γδ T cells treatments, at three-weeks' intervals. Ex-vivo expanded γδ T cells are transfused to patients in a typical 3+3 dose-escalation design (Dose escalation, 1×10\^8/kg, 2×10\^8/kg,4×10\^8/kg).
62581921|NCT05200182|SHAM_COMPARATOR|Study B - Control|In the control group with neurofeedback sham, the participants will receive the same instruction but will be shown a random signal, the goal being that the control strategy the participant tries to implement is not correlated with the visual feedback provided by the gauge.
62581922|NCT04832607|EXPERIMENTAL|Multivirus (CMV, EBV, AdV)-specific T cells|"Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of Cytomegalovirus, Adenovirus and Epstein-Barr Virus~Max dose:~* HLA-matched (8/8) donors: 1.0 x 10e5 T cells/kg recipient BW~* HLA-mismatched donors: 2.5 x 10e4 T cells/kg recipient BW~Min. dose:~- 10 T cells/kg recipient BW"
62581923|NCT04832607|PLACEBO_COMPARATOR|Sodium chloride|Suspension of multivirus-specific T cells in 20 mL of 0.9% NaCl + 0.5% HSA
62581924|NCT01507883||human oocytes/embryos|Sibling oocytes cultured in single or sequential media until day6
62581925|NCT01600456|ACTIVE_COMPARATOR|Choice: Prolonged exposure (PE)|"Participants randomized to choice who choose prolonged exposure (PE)."
62018419|NCT05341089|EXPERIMENTAL|LY3502970 (Formulation 1)|LY3502970 administered orally.
62018420|NCT05341089|EXPERIMENTAL|LY3502970 (Formulation 2)|LY3502970 administered orally.
62018421|NCT04231656|EXPERIMENTAL|Sequence A before sequence B|Patients eligible for intermediate risk surgery requiring the placement of an invasive continuous blood pressure measurement device and stroke volume monitoring for fluid management. Sequence A of positioning (before the procedure), and sequence B after the procedure.
62018422|NCT04231656|EXPERIMENTAL|Sequence B before sequence A|Patients eligible for intermediate risk surgery requiring the placement of an invasive continuous blood pressure measurement device and stroke volume monitoring for fluid management. Sequence B of positioning before the procedure, and sequence A after the procedure.
62209226|NCT06364787|ACTIVE_COMPARATOR|PD-1 monoclonal antibody+ targeted drugs|PD-1 monoclonal antibody+ targeted drugs
62209227|NCT05709340|EXPERIMENTAL|study group|
62209228|NCT05709340|ACTIVE_COMPARATOR|control group|
62209229|NCT01044225|ACTIVE_COMPARATOR|Cilengitide EMD 121974|A dose of 2000 mg by iv administration 2 weekly.
62209230|NCT01044225|ACTIVE_COMPARATOR|Cetuximab|An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
62209231|NCT05052021||Perioperative or Recent Covid19 Infection|"Patients will be classified as having Perioperative Covid19 Infection if they test positive for SARS-CoV-2 within 7 days before and 30 days after surgery.~Patients will be classified as having Recent Covid19 infection if they tested positive for Covid19 within 1-6 weeks before surgery.~These patients will be analysed together as a group, as it is likely that their risk for complications will be similar."
62406965|NCT03818542|EXPERIMENTAL|Arm 2: ABBV-368 IV|A single dose of ABBV-368 administered via intravenous (IV) infusion on Day 1.
62209232|NCT05052021||No or Previous Covid19 Infection|"Patients will be classified as having No Covid19 Infection if they have never tested positive for Covid19.~Patients will be classified as having Previous Covid19 Infection when they tested positive for Covid19 infection 7 weeks or more before surgery.~These patients will be analysed together as a group, as it is likely that their risk for complications will be similar."
62209233|NCT04032613|EXPERIMENTAL|Vascular access quality improvement program participants|All participants enrolled in the study who are involved in the Vascular Access Navigation and Education Quality Improvement Program.
62209234|NCT03976492||Normal group|normal population
62209235|NCT03976492||Brain injury group|patients with traumatic brain injury within 24 hours
62018423|NCT06559397||Proprioceptive deficit positive group|This group consists of young participants who exhibit a proprioceptive error in their cervical proprioception test. Proprioceptive error refers to an inaccurate perception of the head's position in space. In this study, participants with a deviation greater than 5 degrees during the test will be classified into this group.
62406966|NCT03818542|EXPERIMENTAL|Arm 3: ABBV-927 IV|A single dose of ABBV-927 administered via intravenous (IV) infusion on Day 1.
62581926|NCT01600456|ACTIVE_COMPARATOR|Choice: PE plus sertraline|"Participants randomized to choice who choose PE plus sertraline."
62018424|NCT06559397||Proprioceptive deficit negative goup|This group includes young participants who do not show any proprioceptive error in the cervical proprioception test. These participants accurately perceive the position of their head and thus do not have a proprioceptive deficit (less than 5 degrees)
62209236|NCT03976492||Non-brain injury group|Non-brain injury group refers to patients with limb injury or systemic injury except brain injury.
62581927|NCT01600456|ACTIVE_COMPARATOR|No choice: Prolonged exposure (PE)|"Participants randomized to no choice who are then randomized to PE."
62209237|NCT05635942|EXPERIMENTAL|optimized quadruple therapy (Qo-14)|patients allocated to experimental group receive an optimized quadruple therapy (Qo-14) including 3 grams of Amoxicillin plus standard dose of clarithromycin, metronidazole and esomeprazole for 14 days.
62581928|NCT01600456|ACTIVE_COMPARATOR|No Choice: PE plus sertraline|"Participants randomized to no choice who are then randomized to PE plus sertraline."
62018425|NCT02606136|EXPERIMENTAL|Pamrevlumab|Participants will receive pamrevlumab 35 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion every 2 weeks for a minimum of 104 weeks. Participants who complete the main study, will continue to receive pamrevlumab 35 mg/kg by IV infusion every 2 weeks for a minimum of up to 208 weeks in the OLE.
62209238|NCT05635942|ACTIVE_COMPARATOR|standard quadruple therapy (Qs-14)|patients allocated to this group receive standard quadruple therapy (Qs-14) including : amoxicillin 1g twice daily ,clarithromycin 500mg twice daily ,metronidazole 500mg twice daily and esomeprazole 40 mg twice daily for 14 days
62209239|NCT01012362|EXPERIMENTAL|Optimum Tolerated Dose Determination|"Patient receives assigned dose level:~Dose Level 1 = 400 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 2 = 400 milligrams (mg) of pazopanib and ixabepilone 40 mg/m2. Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 4 = 800 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2."
62209240|NCT01012362|EXPERIMENTAL|Optimum Tolerated Dose Confirmation|Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2.
62209241|NCT00633646|ACTIVE_COMPARATOR|1|low protein diet
62209242|NCT00633646|ACTIVE_COMPARATOR|2|low protein diet with keto acids
62209243|NCT00633646|ACTIVE_COMPARATOR|3|high protein diet
62209244|NCT05979415|ACTIVE_COMPARATOR|Staccato Apomorphine|1mg, 2mg, 3mg, 4mg
62406967|NCT03818542|EXPERIMENTAL|Arm 4: ABBV-927 IT|A single dose of ABBV-927 administered via intratumoral (IT) injection on Day 1.
62406968|NCT02753582|ACTIVE_COMPARATOR|Intervention|SOD+Gliadin capsule is given in a dosage of 250 mg twice a day, for 24 weeks.
62406969|NCT02753582|PLACEBO_COMPARATOR|Placebo|Placebo capsule is given in a dosage of 250 mg twice a day, for 24 weeks.
62209245|NCT05979415|PLACEBO_COMPARATOR|Staccato Placebo|Placebo
62209246|NCT00433212|ACTIVE_COMPARATOR|A|Non-invasive respiratory support via nasal intermittent positive pressure ventilation
62406970|NCT01628159|EXPERIMENTAL|Lutonix Drug Coated Balloon|Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
62406971|NCT06396208|EXPERIMENTAL|Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2)|Completing a pack (28 pills) of Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2), starting on day 7-9 of menstrual cycle
62406972|NCT06396208|ACTIVE_COMPARATOR|Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)|Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle
62581929|NCT03570632|NO_INTERVENTION|Usual care|
62581930|NCT03570632|EXPERIMENTAL|Metformin|
62581931|NCT05304416||Cardiovascular Surgical Patients Preoperative Exam|All enrolled participants will undergo a baseline Fiberoptic Endoscopic Evaluation of Swallowing (FEES) or a Simultaneous FEES and Videofluoroscopy instrumental swallowing exam before their surgery to determine baseline / preoperative swallowing function. Those with confirmed dysphagia will not be asked to complete the postoperative swallowing exam, given our desire to examine contributing risk factors for dysphagia development and mechanisms within cardiovascular surgical patients. In addition to the instrumental exam, systematic collection of demographic, medical, surgical, and intubation-related candidate predictor variables will be conducted over the entire perioperative period.
62581932|NCT05304416||Cardiovascular Surgical Patients Postoperative Exam|Participants without preoperative dysphagia will be seen for a postop exam within 72 hours of extubation. Simultaneous imaging using FEES and videofluoroscopy (or a FEES or VFSS exam in isolation) will be performed at the bedside, as well as a battery of clinical tests. Completion of these postoperative tests will indicate study completion for participants without evidence of dysphagia, while participants who demonstrate acute-phase postoperative dysphagia will continue to participate if they desire. During their standard of care one-month follow-up appointment, a third research evaluation will be offered for participants with previously identified postoperative dysphagia. During this exam, the same imaging and clinical tests from the previous research exam will be performed. Finally, participants with persisting dysphagia will be offered the opportunity to continue to be studied for a fourth and final research exam during their standard of care six-month follow-up clinic visit.
62581933|NCT05303298|EXPERIMENTAL|Anti-reflux Oesophageal Stent Group (AOSG)|All patients randomised to this arm will receive an anti-reflux fully covered self-expanding metal oesophageal stent
62018426|NCT01541657|NO_INTERVENTION|Control Group|This group will only take part in the data collection sessions. After the first testing session (Pre-Intervention) the participants will be asked to rest comfortably for 5 minutes. After the rest period, they will be reassessed. Upon completion of the second testing, they will be asked to maintain the same lifestyle over the course of 2 weeks. They will then be asked to return to the lab after the 2 week interval to be tested again. Upon completion of the third testing session, they will be contacted after 1 month to complete the self-reported function questionnaires.
62209247|NCT00433212|ACTIVE_COMPARATOR|B|Non-invasive respiratory support via nasal Continuous Positive Airway Pressure
62209248|NCT02850289||Pegylated Interferon (PEG-IFN) alfa-2a and Ribavirin|Participants with hepatitis C who were to be treated with combination of pegylated interferon (PEG-IFN) alfa-2a and ribavirin, within 7 days of baseline, with ongoing management at investigator's discretion.
62209249|NCT04799743|EXPERIMENTAL|Resveratrol group|Resveratrol group (treatment group) will be instructed to consume with capsules (1.0 g, orally once a day) for six months.
62209250|NCT04799743|PLACEBO_COMPARATOR|Placebo group|Placebo group (control group) will be instructed to orally take placebo (edible paraffin, 1.0) once a day.
62406973|NCT06045377|EXPERIMENTAL|Armolipid|"One tablet of Armolipid (Rottapharm S.p.A., Monza, Italia), containing 200 mg red yeast rice, 10 mg policosanols, 0.2 mg folic acid, 2.0 mg coenzyme Q10 and 0.5 mg astaxanthin was administered once-daily with lunch.~Clinical and laboratory evaluation took place before and 6 (IQR: 5-8) and 16 (IQR: 11-19.7) months after treatment."
62209251|NCT04198064|EXPERIMENTAL|Group A- Bag Squeeze|"Participants will receive a bag squeeze of irrigation fluid (500 ml/\~2 cups of %0.9 saline solution) during the insertion of the cystocopy tube during their cystoscopy."
62209252|NCT04198064|OTHER|Group B- No Bag Squeeze|Participants will receive a standard cystoscopy procedure.
62209253|NCT06233604|PLACEBO_COMPARATOR|Placebo|0.2% ropivacaine for erector spinae plane block
62406974|NCT02231606|NO_INTERVENTION|Group 1: Pure Control|Provision of glasses prescription only
62406975|NCT02231606|EXPERIMENTAL|Group 2: Free Glasses|Free glasses for all, no upgrade glasses offered
62406976|NCT02231606|EXPERIMENTAL|Group 3: Free + Upgrade Glasses 1|Free glasses for all, optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
62209254|NCT06233604|EXPERIMENTAL|Dexamethasone|0.2% ropivacaine + 4mg Dexamethasone for erector spinae plane block
62018427|NCT01541657|EXPERIMENTAL|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
62018428|NCT01541657|EXPERIMENTAL|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
62209255|NCT06233604|EXPERIMENTAL|Dexmedetomidine|0.2% ropivacaine + 50ug Dexmedetomidine for erector spinae plane block
62581934|NCT05303298|ACTIVE_COMPARATOR|Conventional Oesophageal Stent Group (COSG)|All patients randomised to this arm will receive a conventional fully covered self-expanding metal oesophageal stent that does not contain an anti-reflux mechanism
62209256|NCT03942484|EXPERIMENTAL|Treatment Group|Treatment with the investigational device - rPMS
62209257|NCT06728696|EXPERIMENTAL|Group I (Test group):|17 patients with non-restorable tooth in the esthetic zone will receive atraumatic extraction followed by immediate implant placement with dual zone technique using concentrated growth factor graft.
62209258|NCT06728696|ACTIVE_COMPARATOR|Group II (Control group):|17 patients with non-restorable tooth in the esthetic zone will receive atraumatic extraction followed by immediate implant placement with dual zone technique using connective tissue graft.
62209259|NCT04329468|EXPERIMENTAL|DS-MCE examination|Subjects with or without digestive symptoms will be enrolled to take DS-MCE and conventional esophagogastroduodenoscopy (EGD) within 48h successively.
62209260|NCT04228926|EXPERIMENTAL|0.002% ZKY001 eye drops|Experimental group A: 35 subjects .0.002% ZKY001 eye drops . 4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).
62406977|NCT02231606|EXPERIMENTAL|Group 4: Free + Upgrade Glasses 2|Free glasses for all, optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
62406978|NCT05434975|EXPERIMENTAL|Blocked|All participants will have single-shot interscalene brachial plexus block with same technique. There is no comparing.
62406979|NCT06329375|NO_INTERVENTION|SoC group|Standard of care (SOC)
62406980|NCT06329375|EXPERIMENTAL|Nutrition program (Intervention)|"Patients in the intervention group will be provided the following two resources in addition to SOC:~1. Enhanced access to nutritious food (twice daily meal delivery up to 90 days post-discharge).~2. Education at discharge and continuing outreach to enhance knowledge for better diet and food options."
62406981|NCT06440044||Patients with adverse anticoagulant outcomes|Patients with adverse anticoagulant outcomes in the study period. Adverse anticoagulant outcomes include venous thromboembolism recurrence, major bleeding, and clinical relevant non major bleeding.
62581935|NCT03867812|NO_INTERVENTION|Fasting + alcoholic drink|No food (0 calories) but 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
62581936|NCT03867812|EXPERIMENTAL|SOBAR bar + alcoholic drink|One 70g bar (210 calories) plus 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
62406982|NCT06440044||Patients without any adverse anticoagulant outcomes|Patients without any adverse anticoagulant outcomes in the study period.
62406983|NCT00168766|EXPERIMENTAL|1|interferon-beta-1a in combination with methylprednisolone
62406984|NCT00168766|PLACEBO_COMPARATOR|2|interferon-beta-1a in combination with placebo
62581937|NCT03867812|ACTIVE_COMPARATOR|Control food + alcoholic drink|48.5g of General Mills Chexmix (Honey Nut Flavor, 210 calories) plus 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
62581938|NCT03867812|ACTIVE_COMPARATOR|Full meal + alcoholic drink|Stouffer's Bistro Crostini 5 Cheeses, Oikos Strawberry yogurt, Tropicana Orange juice, Dad's oatmeal cookie (635 calories total) followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
62406985|NCT06650059||Patients|Adult sickle cell patients followed in a sickle cell reference center (hôpital Henri Mondor, hôpital Necker-Enfants Malades and hôpital européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris).
62734484|NCT01364480|EXPERIMENTAL|Brain-Machine Interface Users|All participants enrolled in the study will undergo Implantation of NeuroPort Arrays in the motor cortex. There is no control group.
62790084|NCT02618044||Obese patients without preoperative GER|Obese patients selected for laparoscopic Roux-en-Y Gastric Bypass without preoperative GER at 24h-impedance pH monitoring (Group G-)
62790085|NCT02618044||Obese patients with preoperative GER|Obese patients selected for laparoscopic Roux-en-Y Gastric Bypass with preoperative GER at 24h-impedance pH monitoring (Group G+)
62790086|NCT00917761|EXPERIMENTAL|Entecavir and peginterferon (52 weeks)|Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
62790087|NCT00917761|EXPERIMENTAL|Peginterferon (96 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-96
62209261|NCT04228926|EXPERIMENTAL|0.004% ZKY001 eye drops|Experimental group B: 35 subjects .0.004% ZKY001 eye drops . 4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).
62581939|NCT06685263||Development group|The development group comprises 385 individuals. Following the data collection process, the independent risk factors for the development of delirium will be identified through statistical analysis. A delirium prediction model will then be developed based on the identified risk factors.
62209262|NCT04228926|PLACEBO_COMPARATOR|The placebo|Placebo group C: ZKY001 simulated eye drops .4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 simulated eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).
62209263|NCT05131269|EXPERIMENTAL|Prolotherapy|"A solution of 7.5 ml of 15% dextrose with 2 ml of 40% lidocaine and 10.5 water is given to these shoulder segments as follows.~1. Supraspinatus muscle 2-4 ml~2. Infraspinatus muscle 2-4 ml~3. Teres minor muscle 2-3 ml,~4. Subscapularis muscle 2-3 ml.~5. Intraarticular glenohumeral joint 5 ml~6. Bursa sub acromial 1-2 ml,~7. Long head tendon biceps 1-2 ml~8. Acromioclavicular joint 1 ml"
62209264|NCT05131269|PLACEBO_COMPARATOR|Normal Saline 0.9%|"A solution of 20 ml normal saline 0.9% is given to these shoulder segments as follows.~1. Supraspinatus muscle 2-4 ml~2. Infraspinatus muscle 2-4 ml~3. Teres minor muscle 2-3 ml,~4. Subscapularis muscle 2-3 ml.~5. Intraarticular glenohumeral joint 5 ml~6. Bursa sub acromial 1-2 ml,~7. Long head tendon biceps 1-2 ml~8. Acromioclavicular joint 1 ml"
62209265|NCT06728605|EXPERIMENTAL|EECP group|Patients randomly assigned to EECP received 3 half-h sessions of EECP for 3 days before surgery. Three pneumatic cuffs will be placed around the lower limbs and buttocks and will be inflated sequentially upward at the onset of diastole, and released rapidly and simultaneously before the onset of systole. The protocol-specified applied pressure will be 300 mm Hg and will be reached within 5 min of the initiation of treatment. Pulse oximetry will be monitored continuously during the treatment session, and the subject's clinical status will be re-evaluated if the oxygen saturation dropps by 4%.
62209266|NCT06728605|SHAM_COMPARATOR|Control group|Patients randomly assigned to control received 3 half-h sessions of sham for 3 days before surgery. Three pneumatic cuffs will be placed around the lower limbs and buttocks and will be inflated sequentially upward at the onset of diastole, and released rapidly and simultaneously before the onset of systole. The protocol-specified applied pressure will be 70 mm Hg and will be reached within 5 min of the initiation of treatment. Pulse oximetry will be monitored continuously during the treatment session, and the subject's clinical status will be re-evaluated if the oxygen saturation dropps by 4%.
62209267|NCT04538560|EXPERIMENTAL|Polar body biopsy group|The study group will undergo polar body biopsy, and the NGS technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores.
62209268|NCT04538560|NO_INTERVENTION|Control group|The control group will undergo routine culture and the transfer priority is determined according to the morphological score only.
62581940|NCT06685263||Validation group|The validation group comprises 385 individuals. The delirium prediction model, constructed using the data from the development group, will be validated by testing the data from the validation group. This process will enable the evaluation of the model's suitability and calibration for predicting delirium.
62581941|NCT04673474|EXPERIMENTAL|Arm A|Hemay022 Period 1, Fasted control → Period 2, Fed control
62209269|NCT03112629||symptomatic AS|Patients diagnosed with severe aortic stenosis in echocardiography who display one or more of the following symptoms: exertional shortness of breath, chest pain, exertional dizziness or syncope.
62209270|NCT03112629||asymptomatic AS|Patients diagnosed with severe aortic stenosis in echocardiography who do not display symptoms
62209271|NCT00124787|EXPERIMENTAL|Dimenhydrinate|dimenhydrinate PO x 4 doses
62209272|NCT00124787|PLACEBO_COMPARATOR|Placebo|placebo PO x 4 doses
62209273|NCT04706299|ACTIVE_COMPARATOR|No Mask|Will not wear a mask
62209274|NCT04706299|EXPERIMENTAL|Surgical mask|Will wear a surgical nose and face covering
62209275|NCT06697028||Juvenile Idiopathic Arthritis|Patients diagnosed with JIA followed at the Pediatric Rheumatology Clinic, Department of Pediatrics, Istanbul Faculty of Medicine, will be evaluated.
62790088|NCT00917761|ACTIVE_COMPARATOR|Peginterferon (48 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-48
62209276|NCT06697028||Familial Mediterranean Fever|Patients diagnosed with FMF followed at the Pediatric Rheumatology Clinic, Department of Pediatrics, Istanbul Faculty of Medicine, will be evaluated.
62209277|NCT06697028||Healthy control|The outcomes of individuals with rheumatic diseases will be compared with those of healthy controls.
62209278|NCT05668741|EXPERIMENTAL|Single Ascending Dose (SAD)|Participants grouped into different cohorts will receive a single ascending dose of VX-522.
62209279|NCT05668741|EXPERIMENTAL|Multiple Ascending Dose (MAD) Arm 1: VX-522|Participants grouped into different cohorts will receive multiple ascending doses of VX-522 in treatment arm 1 (T1).
62209280|NCT05668741|EXPERIMENTAL|MAD Arm 2: VX522+ IVA|Following run-in period with ivacaftor (IVA), participants grouped into different cohorts will receive multiple ascending doses of VX-522 with IVA in treatment arm (T2).
62209281|NCT06032143|EXPERIMENTAL|Intervention Doulas|Doulas randomized to the intervention group will engage in a one-hour online course about exposure to phthalates and the relationship with reproductive health.
62406986|NCT03901339|EXPERIMENTAL|Sacituzumab Govitecan-hziy|Participants will receive sacituzumab govitecan-hziy 10 mg/kg via intravenous (IV) injection administered on Day 1 and Day 8 of a 21-day cycle.
62581942|NCT04673474|EXPERIMENTAL|Arm B|Hemay022 Period 1, Fed control → Period 2, Fasted control
62581943|NCT04781608|EXPERIMENTAL|Intervention group|Gains access to the digital intervention program
62581944|NCT04781608|NO_INTERVENTION|Wait-list- control group|Does not gain access to the intervention (until end of study)
62581945|NCT04961762|EXPERIMENTAL|Navigator Program|In addition to receiving Standard Care, participants in the intervention arm will be assigned to a Homeless Outreach Counsellor. The Homeless Outreach Counsellor will connect with the participant as soon as possible during the admission and will provide support during the hospital admission and for approximately 90 days after hospital discharge.
62734485|NCT03388216|EXPERIMENTAL|Stage I - Drug: INM004 Dose 1|
62734486|NCT03388216|PLACEBO_COMPARATOR|Stage I - Placebo Dose 1|
62734487|NCT03388216|EXPERIMENTAL|Stage I- Drug: INM004 Dose 2|
62734488|NCT03388216|PLACEBO_COMPARATOR|Stage I- Placebo Dose 2|
62734489|NCT03388216|EXPERIMENTAL|Stage II- Drug: INM004 Repeated Dose|
62734490|NCT03388216|PLACEBO_COMPARATOR|Stage II- Placebo Repeated Dose|
62209282|NCT06032143|SHAM_COMPARATOR|Control Doulas|Doulas randomized to the control group will access a worksheet about an alternative environmental exposure and the relationship with reproductive health.
62406987|NCT03901339|ACTIVE_COMPARATOR|Treatment of Physician's Choice (TPC)|"Participants will receive TPC determined prior to randomization from one of the following single-agent treatment:~Dosing per National Comprehensive Cancer Network (NCCN) guidelines (with dose modifications for if toxic)~* Eribulin: 1.4 mg/m\^2 for North American sites, 1.23 mg/m\^2 for European sites) via IV on Days 1 and 8 of a 21-day cycle~* Capecitabine: 1000-1250 mg/m\^2 orally twice daily for 2 weeks followed by a 1-week rest period given as a 21-day cycle~* Gemcitabine: 800-1200 mg/m\^2 via IV on Days 1, 8, and 15 of each 28-day cycle or per institution~* Vinorelbine: 25 mg/m\^2 via IV on Day 1 weekly cycle per institution"
62406988|NCT05726123|PLACEBO_COMPARATOR|Control group (G1)|Control group (G1): in which the suit shall be switched on, but with the current of all electrodes at 0 mA.
62406989|NCT05726123|EXPERIMENTAL|Suit group (G2)|Suit group (G2): will only receive treatment with the neuromodulation suit at the intensity preset by the manufacturer and according to the assessment criteria. The duration of the treatment will be 1 hour. Exopulse Molly Suit with all 58 electrodes active with an intensity of 2 milliamperes (mA) and pulse width of 30 milliseconds (ms)
62406990|NCT05726123|EXPERIMENTAL|Suit + VR group (G3):|Suit + VR group (G3): the intervention on this group was carried out in the same way as the suit group. However, the session was different as the participant wore VR glasses besides wearing the suit for an hour. The patient sees the same room he is in and a person performing a series of exercises he must follow as indicated by the video by video and voice commands. As exercise are performed in a laying position the patient must stay in this position for the whole session.
62406991|NCT05726123|EXPERIMENTAL|Exercise group (G4):|Exercise group: The procedure carried out is the same as in the suit group, but the session performed was a 1-hour session of strength exercise carried out by a certified professional.
62406992|NCT05874544|ACTIVE_COMPARATOR|Tetracycline Bismuth Quadruple Therapy|Vonoprazan 20mg bid, Bismuth Potassium Citrate 110mg qid, Tetracycline 500mg qid, Metronidazole 400mg qid
62406993|NCT05874544|EXPERIMENTAL|Rifabutin Triple Therapy|Vonoprazan 20mg bid, amoxicillin 1000mg tid, rifabutin 150mg bid
62406994|NCT05874544|EXPERIMENTAL|Dual Therapy|Vonoprazan 20mg bid, amoxicillin 1000mg tid
62018429|NCT01541657|EXPERIMENTAL|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
62209283|NCT06032143|EXPERIMENTAL|Intervention Pregnant Individuals|Pregnant individuals working with intervention doulas will be asked to have a conversation with their doulas about environmental chemicals (phthalates).
62209284|NCT06032143|SHAM_COMPARATOR|Control Pregnant Individuals|Pregnant individuals working with control doulas will be asked to have a conversation with their doulas about environmental chemicals (distinct from phthalates).
62209285|NCT03718351|ACTIVE_COMPARATOR|transanal endoscopic microsurgery|a TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
62209286|NCT03718351|EXPERIMENTAL|endoscopic submucosal dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
62790089|NCT01884896|ACTIVE_COMPARATOR|'TOPROL-XL®' ER Tablets 200 mg|'TOPROL-XL®' ER Tablets 200 mg of Astrazeneca LP, USA
62406995|NCT03839693|PLACEBO_COMPARATOR|Vehicle|Vehicle
62406996|NCT03839693|EXPERIMENTAL|ET-01 345U|botulinum toxin, Type A, Dose 1, 345 U
62406997|NCT03839693|EXPERIMENTAL|ET-01 1100U|botulinum toxin, Type A, Dose 2, 1100 U
62406998|NCT01748162|EXPERIMENTAL|Inhaled steroids|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
62406999|NCT01748162|ACTIVE_COMPARATOR|Oral control|Patient and clinician observation with short term oral prednisolone as needed. Offered at 1mg/kg (body weight) daily dosing for symptomatic treatment on as needed basis for three days, but may be modified per managing physician's discretion.
62407000|NCT02476058|EXPERIMENTAL|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
62407001|NCT02476058|EXPERIMENTAL|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
62209287|NCT05599555||Unvaccinated blood donors|Blood donors who were unvaccinated with any COVID-19 vaccine by study recruitment
62209288|NCT05599555||Blood donors vaccinated with BNT162b2|Blood donors who were vaccinated with one or more doses of the mRNA vaccine Comirnaty (BNT162b2 mRNA, BioNTech/Fosun-Pharma, Mainz, Germany/Shanghai, China) by study recruitment.
62209289|NCT05599555||Blood donors vaccinated with CoronaVac|Blood donors who were vaccinated with one or more doses of the inactivated CoronaVac (Sinovac life Sciences, Beijing, China) vaccine by study recruitment.
62209290|NCT01656200|EXPERIMENTAL|Vaccine|Single dose live attenuated Japanese encephalitis vaccine SA14-14-2
62209291|NCT04670289|EXPERIMENTAL|Treatment|TenoMiR intralesional injection
62209292|NCT04670289|PLACEBO_COMPARATOR|Placebo|0.9% saline intralesional injection
62209293|NCT02315300|EXPERIMENTAL|Study Tretament|Long term ECG measurement is performed with the 12-lead ECG system medilog® DARWIN FD12 from Schillermed to detect different ECG parameter. The continuous glucose monitoring (CGM) system G4 from Dexcom use a tiny sensor inserted under the skin to check glucose levels in tissue fluid. The sensor stays in place for 7 days in parallel to the ECG measurement. A transmitter sends information about glucose levels via radio waves from the sensor to a pagerlike wireless monitor.
62209294|NCT01511705|EXPERIMENTAL|Ondansetron Hydrochloride Tablets 8 mg|Ondansetron Hydrochloride Tablets 8 mg of Dr. Reddy's Laboratories Limited
62209295|NCT01511705|ACTIVE_COMPARATOR|Zofran Tablets 8 mg|Zofran Tablets 8 mg of GlaxoSmithKline
62209296|NCT00299442|EXPERIMENTAL|1|Self-help Triple P Behavioural Family Intervention
62407002|NCT02476058|PLACEBO_COMPARATOR|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
62407003|NCT00995462|NO_INTERVENTION|Control|
62407004|NCT00995462|EXPERIMENTAL|Small-group seminar for 2 years|
62407005|NCT00995462|EXPERIMENTAL|Small-group seminars for 1 year followed by email intervention|
62407006|NCT02080624|EXPERIMENTAL|Rapamycin|Topical rapamycin applied once a day
62209297|NCT00299442|NO_INTERVENTION|2|Wait-list control
62209298|NCT06323980|EXPERIMENTAL|INHANCE Stemless Reverse|INHANCE(TM) Stemless Reverse Total Shoulder
62209299|NCT06323980|ACTIVE_COMPARATOR|INHANCE Stemmed Reverse|INHANCE(TM) Stemmed Reverse Total Shoulder
62407007|NCT05285553|EXPERIMENTAL|MiSight 1 day|MiSight 1 day
62407008|NCT05285553|ACTIVE_COMPARATOR|Proclear 1 day|Proclear 1 day
62209300|NCT04109716|EXPERIMENTAL|Interpersonal Psychotherapy-Adolescent Skills Training|Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST) is an indicated group depression prevention program. In IPT-AST, adolescents learn communication (e.g., using I statements, striking while the iron is cold) and interpersonal problem-solving strategies and apply these strategies to their relationships to decrease conflict, increase social support, and improve overall social functioning. IPT-AST consists of 1 or 2 individual pre-group sessions, 1 mid-group session, 8 weekly group sessions, and up to 6 individual booster sessions. Parents are invited to attend the mid-group session so the adolescents can apply the interpersonal strategies in a conversation with a parent. The purpose of the booster sessions is to monitor symptoms and apply the interpersonal strategies to current stressors. These sessions are designed to help solidify the interpersonal skills and address current problems before they result in a worsening of symptoms.
62209301|NCT04109716|ACTIVE_COMPARATOR|Services as Usual (SAU)|Investigators anticipate that counselors in SAU will see youth in the study for brief, periodic sessions and/or will refer youth for treatment in the community. Counselors will be permitted to see the adolescents as often as they would like throughout the course of the study (up to 15-months post-baseline). Investigators will ask counselors to complete a form each time they see a teen, noting the length of the session, whether the session was scheduled or not, and the topics discussed.
62209302|NCT02296723|EXPERIMENTAL|Valganciclovir Hydrochloride Tablets 450 mg|Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddys Laboratories Limited
62209303|NCT02296723|ACTIVE_COMPARATOR|Valcyte|Valcyte® 450 mg tablets of Genentech USA Inc., Sanfrancisco
62209304|NCT00564577|OTHER|CFA/I and CS17 challenge strain|Colonization factor antigen (CFA/I) and CS17 challenge strainAscending dose finding study in 5-10 subjects per dose; to identify the dose able to give a diarrheal attack rate greater than or equal to 80%.
62407009|NCT03844802|EXPERIMENTAL|Local dry needling and exercise|The intervention protocol will combine a home-based neck and shoulder exercise program and the use of deep dry needling in the locus of active or latent myofascial trigger points of different neck-shoulder muscles. Patients will receive 1 dry needling session a week during 3 consecutive weeks (3 sessions in total). They will also undergo the neck exercise program at home during these three weeks, and for the next three months.
62407010|NCT03844802|ACTIVE_COMPARATOR|Distal dry needling and exercise|The intervention protocol will combine a home-based neck and shoulder exercise program and the use of deep dry needling in distant area from the location of active or latent myofascial trigger points of different neck-shoulder muscles. Therefore, dry needling will be applied in the same muscle but at a remote site from the locus of the myofascial trigger point, and, therefore, without evoking local twitch responses. Patients will receive 1 dry needling session a week during 3 weeks (3 sessions in total). They will also undergo the neck exercise program at home during these three weeks, and for the next three months.
62734491|NCT02429804|EXPERIMENTAL|Diagnostic (18F NaF/18F FDG PET/MRI, contrast-enhanced MRI)|Patients receive 18F NaF and 18F FDG IV over 30 seconds-1 minute and then undergo PET/MRI and contrast-enhanced MRI after 45-60 minutes. Patients undergo imaging at baseline, after course 3 (12 weeks), and after course 6 (24 weeks) of treatment with Ra-223.
62734492|NCT04790669|EXPERIMENTAL|Daily adjustable progressive resistance exercises (DAPRE)|DAPRE technique, hot pack, stretching exercises.
62790090|NCT01884896|EXPERIMENTAL|Metoprolol Succinate ER Tablet 200 mg|Metoprolol Succinate ER Tablet 200 mg of Ipca Laboratories Limited, India
62581946|NCT04961762|NO_INTERVENTION|Standard Care|Standard Care consists of support from Care Transition Facilitators who work with patients during their hospital stay to arrange discharge plans and make follow-up arrangements. Care Transition Facilitators do not routinely work with patients after hospital discharge. As part of the routine discharge process, the health care team provides patients with medical recommendations, appointments for follow-up care as needed, a written discharge summary, and prescriptions as needed. If the patient has an identified primary care provider, a copy of the discharge summary is sent electronically to the primary care provider.
62581947|NCT04058093|EXPERIMENTAL|Functional Training Program|"Functional training program (FTP) will last for 6 months and will include:~1. Functional training sessions (each 45-minutes long, twice a week);~2. Group nutrition counseling (each 90-minutes long, in three different moments throughout the intervention: week 1, 12 and 20)."
62581948|NCT04058093|NO_INTERVENTION|Waiting list control group|Participants will not participate in any specific intervention, but will receive the FTP after the experimental period (6 months).
62581949|NCT05794776|EXPERIMENTAL|BurstDR stimulation|BurstDR spinal cord stimulation during hyperglycemic clamp
62581950|NCT05794776|EXPERIMENTAL|Tonic stimulation|Tonic spinal cord stimulation during hyperglycemic clamp
62581951|NCT05794776|PLACEBO_COMPARATOR|No stimulation|No spinal cord stimulation during hyperglycemic clamp
62581952|NCT02989376|EXPERIMENTAL|carotid duplex ultrasound|Single arm study. After detection of occluded vessels by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment.
62581953|NCT05787496|EXPERIMENTAL|NC525|Escalating dose levels will be explored.
62581954|NCT06482190|EXPERIMENTAL|RSN0402 Part 1|Part 1 is SAD with 5 cohorts (1 to 5) where each participant will receive single dose of RSN0402 powder for inhalation or placebo following a 10hour fast. Cohort 2 will also receive single dose of nintedanib oral soft capsule.
62581955|NCT06482190|EXPERIMENTAL|RSN0402 Part 2|Part 2 is MAD with 4 cohorts (6 to 9) where each participant will receive multiple doses powder for inhalation or placebo following a 10 hr fast.
62581956|NCT06482190|PLACEBO_COMPARATOR|Placebo|Matching doses of placebo
62581957|NCT05957211|EXPERIMENTAL|All participants|All participants will have a refrigerated 0.09% cyclosporine drop instilled in one eye, and a non-refrigerated 0.09% cyclosporine drop instilled in the other eye. The eye that receives the refrigerated drop is randomly determined.
62581958|NCT02962778||treatment-resistant hypertension|patients with Treatment-resistant arterial hypertension receiving standard antihypertensive treatment with at least 3 antihypertensive agents including one diuretic
62581959|NCT06601322|OTHER|No Ventricular Pacing (NVP)|Assessment 1 (No Ventricular Pacing) will be performed with no ventricular pacing to assess baseline right and left ventricular function at rest and during exercise.
62581960|NCT06601322|ACTIVE_COMPARATOR|Non-selective or Selective Left Bundle Branch Area Pacing (nsLBBAP)|Phase 2 (non-selective or selective Left Bundle Branch Area Pacing or ns/sLBBAP) will assess right and left ventricular function at rest and during exercise with non-selective or selective left bundle branch area pacing
62581961|NCT06601322|EXPERIMENTAL|Left Bundle Branch Area Pacing with Anodal Capture (aLBBAP)|Phase 3 (Left Bundle Branch Area Pacing with Anodal Capture or aLBBAP) will assess right and left ventricular function at rest and during exercise with left bundle branch area pacing with anodal capture.
62581962|NCT00931840|EXPERIMENTAL|EZN-2208|"EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.~PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL."
62581963|NCT00931840|EXPERIMENTAL|Cetuximab + EZN-2208|Cetuximab will be administered as an i.v. infusion on weekly basis. EZN-2208 administered as i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
62581964|NCT00931840|ACTIVE_COMPARATOR|Irinotecan + cetuximab|Cetuximab will be administered weekly as an i.v. infusion. Irinotecan will be administered as an i.v. infusion on Weeks 1 and 2 and repeated every 3 weeks.
62581965|NCT06682221|EXPERIMENTAL|Whey protein supplementation.|Protein supplementation will be provided through isolated whey protein, commonly known as whey protein isolate, which was generously donated by the Heroes Science Institute (HSI), as stated in the attached declaration. This whey protein isolate, with a vanilla flavor, is packaged in 25-gram sachets, each providing a total of 20 grams of protein per dose/sachet.
62581966|NCT06682221|EXPERIMENTAL|Resistance training|The resistance training protocol in the study included seven exercises: high pull, leg extension, leg curl, bicep curl, triceps pushdown, lateral raise, and machine bench press, taking about 60 minutes per session. The first week focused on familiarizing participants with the exercises to ensure proper execution before intensive training began. Training occurred three times a week for 12 weeks, with each exercise performed in 3 sets of 8 to 12 repetitions and rest periods of 1 to 2 minutes. The load was progressively increased by 2% to 10% weekly, based on participants' ability to complete repetitions with full range of motion. Assessments were conducted before training and 24 hours after the final session to evaluate the effects on physical and functional parameters.
62581967|NCT06682221|SHAM_COMPARATOR|Whey protein supplementation and Resistance training|The participants would simultaneously apply both protocols, involving both supplementation and resistance training, to assess the combined effects of these interventions on their health and physical conditioning.
62581968|NCT06682221|SHAM_COMPARATOR|Control|The control group will not participate in any of the interventions proposed in the study, meaning it will not receive supplementation or undergo resistance training, serving as a reference to compare the results of the other intervention groups.
62581969|NCT04704804||Prostate cancer|Man with cancer and localized (non-metastatic) prostate cancer
62581970|NCT04704804||Brain cancer|Male or Female with a brain tumor (primitive)
62581971|NCT03158480|EXPERIMENTAL|DC-CIK+interferon Group|dendritic cell-activated cytokine-induced killer cells (DC-CIK) immunotherapy plus interferon intervention
62209305|NCT06667908|EXPERIMENTAL|Part 1: Cohort A and Cohort B|Participants will receive JNJ-90301900 injected intratumorally and/or intranodally (cohort A: 22% gross tumor volume \[GTV\] and cohort B: 33% GTV) along with cCRT (concurrent chemotherapy with radiation therapy) followed by consolidation immunotherapy (cIT) to evaluate feasibility of JNJ-90301900 injection procedure.
62209306|NCT06667908|EXPERIMENTAL|Part 2: Arm A and Arm B|Participants will receive JNJ-90301900 injected intratumorally and/or intranodally (Arm A: 22% GTV and Arm B: 33% GTV) along with cCRT followed by cIT to evaluate the efficacy and safety of JNJ-90301900.
62209307|NCT06667908|ACTIVE_COMPARATOR|Part 2: Arm C: (Control treatment)|Participants will receive treatment with cCRT followed by cIT as control treatment to evaluate the efficacy and safety of JNJ-90301900.
62581972|NCT03158480|PLACEBO_COMPARATOR|Placebo+interferon Group|saline as placebo plus interferon intervention
62581973|NCT00400660|EXPERIMENTAL|Subjects receiving treatment sequence 1: Part 1|Eligible subjects will receive placebo followed by GSK615915A with a starting dose of 250 micrograms.
62209308|NCT02341742||Patients|follow up of patients (children and adolescent) with inflammatory bowel disease in looking for the relationship between the bone mineral density and physical activity.
62581974|NCT00400660|EXPERIMENTAL|Subjects receiving treatment sequence 2: Part 1|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms followed by placebo.
62581975|NCT00400660|EXPERIMENTAL|Subjects receiving treatment sequence 1: Part 2|Eligible subjects will receive placebo followed by GSK615915A with a starting dose of 250 micrograms.
62581976|NCT00400660|EXPERIMENTAL|Subjects receiving treatment sequence 2: Part 2|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms followed by placebo.
62581977|NCT00400660|EXPERIMENTAL|Subjects receiving GSK615915A: Part 3|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms.
62018430|NCT03939273|ACTIVE_COMPARATOR|Active group|A preoperative seven day course of oral ciprofloxacin 500 mg twice a day, oral vancomycin 500 mg thrice per day, oral metronidazole 500 mg thrice per day and a six day course of oral fluconazole 200 mg once per day.
62018431|NCT03939273|PLACEBO_COMPARATOR|Control group|A preoperative seven day course of placebo, consisting of pills and capsules identical in appearance and number to the active group
62018432|NCT06097052||FloTrac|Subject received standard advanced hemodynamic monitoring. Hypotensive episodes were treated using a reactive approach.
62209309|NCT05139251|EXPERIMENTAL|Recovering from Intimate partner violence through Strengths and Empowerment (RISE) +ePALS|
62209310|NCT04635475|NO_INTERVENTION|Control Group|Consented parents of a concussed high school student who will receive CDC Head's UP Concussion Guidelines during a five week program. 75 Participants.
62209311|NCT04635475|EXPERIMENTAL|Intervention Group|Consented parents of a concussed high school student who will receive the CDC Head's Up Concussion Guidelines and intervention RTL Student Protocol during a five week program. 75 Participants.
62581978|NCT00400660|EXPERIMENTAL|Subjects receiving placebo: Part 3|Eligible subjects will receive placebo.
62581979|NCT04734990|EXPERIMENTAL|Treatment (azacitidine, seclidemstat)|Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7. Patients also receive seclidemstat PO QD on day 1 of cycle 1 and PO BID on days 2-28 of cycle 1 and on days 1-28 of all subsequent cycles. There are 6 planned dose levels for seclidemstat: 300 mg, 450 mg, 600 mg, 900 mg, 1200 mg and 1500 mg. Successive cohorts of eligible patients will be treated with azacitidine. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62581980|NCT00373672|ACTIVE_COMPARATOR|1|armodafinil (Nuvigil) 150 mg
62209312|NCT05096221|EXPERIMENTAL|Delandistrogene Moxeparvovec followed by Placebo|Participants will receive single intravenous (IV) infusion of delandistrogene moxeparvovec on Day 1. Then, participants will receive a single IV infusion of matching placebo at Year 2.
62209313|NCT05096221|PLACEBO_COMPARATOR|Placebo followed by Delandistrogene Moxeparvovec|Participants will receive matching placebo IV infusion on Day 1. Then, participants will have the opportunity to receive a single IV infusion of delandistrogene moxeparvovec at Year 2.
62209314|NCT03800953|EXPERIMENTAL|Avelumab (Bavencio)|This is a single arm, and open label study. All the subjects recruited will receive Avelumab.
62209315|NCT06728930||Latent TB screenees|Patients attending TB clinic who are being screened for latent TB. Includes recent migrants from a country with high TB prevalence, occupational health referrals with a positive IGRA, household contacts of TB cases and patients who are about to start biological therapy (eg. anti-TNF)
62209316|NCT06728930||Active TB patients|Patients with active TB who are not already on anti-tuberculous treatment
62209317|NCT06728865|EXPERIMENTAL|Furmonertinib Combined with Bevacizumab Treatment Group|The treatment regimen is Furmonertinib combined with Bevacizumab.
62209318|NCT04903392|EXPERIMENTAL|Backward Walking Group|Conventional therapy + Backward Walking Training
62209319|NCT04903392|OTHER|Forward Walking Group|Conventional therapy + Forward Walking Training
62209320|NCT05945589|EXPERIMENTAL|Singapore A-Health Group|A 12-week professionally led participatory art program at the gallery with each week comprising one 2-hour art session, totaling 24 hours of museum tours and participatory art activities.
62209321|NCT05945589|NO_INTERVENTION|Control Group|No art-based activities offered and advised not to participate in concurrent health and art-based interventions during the 12-week research period.
62209322|NCT03663673|OTHER|Clinical pilot study|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
62209323|NCT02842762|SHAM_COMPARATOR|Non-paced|"* cardiac surgery~* 3D TEE measurements of systolic dyssynchrony~* right ventricular epicardial pacemaker lead (off)"
62581981|NCT00373672|PLACEBO_COMPARATOR|2|identical in appearance to active comparator
62209324|NCT02842762|EXPERIMENTAL|Paced|"The patient is randomized to the order of measurements taken, and serves as his own control.~* cardiac surgery~* 3D TEE measurements of systolic dyssynchrony~* right ventricular epicardial pacemaker lead (on)"
62209325|NCT06728774|EXPERIMENTAL|Motivationally Enhanced Compensatory Cognitive Training for Major Depressive Disorder|Motivationally Enhanced Compensatory Cognitive Training for Major Depressive Disorder (ME-CCT-MDD) is a manualized group-based behavioral intervention (8 weeks, 2 hour per week) designed to improve cognitive functioning in Veterans with Major Depressive Disorder (MDD) and cognitive complaints.
62209326|NCT06728774|ACTIVE_COMPARATOR|Goal-focused Supportive Contact|Goal-focused Supportive Contact (GSC) is a group therapy intervention that provides the same frequency (8 weeks , 2 hours per week) and amount of therapist and other group member contact as ME-CCT-MDD.
62209327|NCT05715385|ACTIVE_COMPARATOR|Laser photocoagulation|"Grid laser was performed under topical anesthesia with frequency doubled Nd YAG laser of wavelength 532 nm.~Laser Parameters for grid photocoagulation Lens used: Mainster grid lens Spot size: 75-100μ The burn intensity for grid laser: barely visible (light grey) Power: 80-100mw depending on the condition of the laser, the opacities in the media and background pigmentation.~Duration: 100msec No. of spots: 80-100 Laser burns were placed at least one burn width apart. Wider if the thickening was less severe. If necessary, the grid laser extended up to 2 disc diameters superiorly, inferiorly and temporally from the centre of the macula. Treating the area within 500 microns of the disc margin or the centre of the macula was avoided."
62209328|NCT05715385|ACTIVE_COMPARATOR|Bromfenac 0.09%|Twice daily eye drop bromfenac 0.09% for 6 weeks
62209329|NCT05715385|PLACEBO_COMPARATOR|Observation|Eye drop carboxymethyl cellulose 0.5% to be instilled thrice a day for 6 weeks
62209330|NCT03205397|EXPERIMENTAL|Accompanying and information procedure|Preparation for anesthesia (explanations, film, booklet), the presence of a relative in the operating room and the awakening of the child.
62209331|NCT03205397|OTHER|Usual care|Consultation of anesthesia and the care of the child without parental presence
62209332|NCT02988362|EXPERIMENTAL|Candesartan 16mg and Amlodipine 10mg|Candesartan 16mg and Amlodipine 10mg
62209333|NCT02988362|EXPERIMENTAL|HL068|HL068(combination of Candesartan 16 mg and Amlodipine 10 mg)
62209334|NCT03592745|EXPERIMENTAL|active tVNS + robotic arm therapy|Transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting \~60 minutes, 3x per week for 3 weeks.
62209335|NCT03592745|SHAM_COMPARATOR|sham tVNS + robotic arm therapy|Sham (placebo) transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting \~60 minutes, 3x per week for 3 weeks.
62209336|NCT03465904|EXPERIMENTAL|Verum|2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
62790091|NCT03979859|EXPERIMENTAL|WCK 4873|200 and 400 mg tablets Dosage form : Oral tablets Doses : To be determined based on the safety, tolerability and PK results of the single dose and food effect study
62209337|NCT03465904|SHAM_COMPARATOR|Sham|2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
62209338|NCT02296502||Autism Spectrum Disorder (DSM IV & 5)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in both DSM-IV and DSM-5
62209339|NCT02296502||Autism Spectrum Disorder (DSM 5 only)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in DSM-5 but not DSM-IV
62209340|NCT02296502||Autism Spectrum Disorder (DSM IV only)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in DSM-IV but not DSM-5
62581982|NCT06389760|EXPERIMENTAL|Nimotuzumab+ mFOLFIRINOX/GX|Patients will receive chemotherapy (either mFOLFIRINOX or GX) plus Nimotuzumab as postoperative adjuvant therapy.
62734493|NCT04790669|EXPERIMENTAL|Close kinetic chain exercises (CKC).|CKC exercises, hot pack, stretching exercises
62790092|NCT03979859|PLACEBO_COMPARATOR|Placebo|Visually matching placebo
62209341|NCT02296502||Non-Autism Spectrum Disorder|All children and adolescents seen for autism diagnostic evaluations at the study sites who do not meet diagnostic criteria for ASD.
62209342|NCT05202210||patients with Noonan syndrome|extra sample of blood and urine will be collected and stored for research utilisation
62209343|NCT02726100|EXPERIMENTAL|Intervention arm|Participants in intervention communities will receive the SMARTHealth Diabetes intervention that connects community health service centers and family health providers for diabetes management. Medical staff and FHPs in the intervention communities will be provided with an initial training session on the installation and use of the platform.
62209344|NCT02726100|NO_INTERVENTION|Control arm|"Control group doesn't use SMARTHealth Diabetes.The usual-care in our study will be conducted in a standard way which is defined in the Guidance of National Essential Public Health Service. All the relevant doctors in control group will be trained and required to record the activities defined in the guidance."
62209345|NCT04646967|ACTIVE_COMPARATOR|No ketorolac|15 mg/kg oral dose of acetaminophen is administered prior to surgery. General anesthesia will be induced with sevoflurane via facemask. After establishing venous access, a laryngeal mask will be inserted, and anesthesia maintained with 1 minimum alveolar anesthetic concentration (MAC) of sevoflurane in oxygen/air 50/50 mixture. The DPNB nerve block is done using a 23 GA needle inserted below the Buck fascia. Once the needle tip is positioned appropriately and after a negative aspiration test, 0.2mL/kg (maximum 10mL) of 0.25% bupivacaine is injected in small aliquots, with intermittent aspiration throughout. In all patients, skin incision is performed at least 5 min after placement of the nerve block. Patients will be advised to take ibuprofen and acetaminophen postoperatively as needed.
62209346|NCT04646967|EXPERIMENTAL|Peri-operative ketorolac|Exactly same as the no ketorolac group except at the beginning of the circumcision, once the patient is asleep, patients in the perioperative ketorolac group will also receive a 0.5 mg/kg intravenous dose of ketorolac.
62209347|NCT05366426|EXPERIMENTAL|Experimental group|Pelvic floor muscle training exercise program will be applied with EMG biofeedback.
62209348|NCT05366426|SHAM_COMPARATOR|Sham Group|Pelvic floor muscle training exercise program will be applied with EMG biofeedback as a sham.
62209349|NCT05366426|OTHER|Control Group|Pelvic floor muscle training program will be applied as home exercise
62581983|NCT04685616|ACTIVE_COMPARATOR|ABVD +/- ISRT|"2 x 28 day cycles of ABVD: Doxorubicin 25mg/m\^2 IV days 1 \& 15 Bleomycin 10000 IU/m\^2 days 1 \& 15 Vinblastine 6mg/m\^2 days 1 \& 15 Dacarbazine 375mg/m\^2 days 1 \& 15~PET-CT after 2 cycles will determine subsequent treatment:~Deauville score 1-3 (PET CMR): 1 further cycle of ABVD then follow up Deauville score 4 (PET positive): 2 further cycles of ABVD followed by involved site radiotherapy (ISRT) Deauville score 5: withdraw from trial treatment; further treatment will be given at the treating clinician's discretion. Enter follow up for the trial."
62734494|NCT02298868|EXPERIMENTAL|Treatment|All patients will be administered a standing dose of Baclofen initially at 5 mg three times a day for the first week and then increased to 10 mg three times a day for the next 3 weeks with a tapering dose the final week, a total of 5 weeks of therapy.
62209350|NCT02459002||NSCLC - Current Palliative Care Referral Practices|Early palliative consultation impact assessment via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
62209351|NCT02459002||Primary Caregiver|Caregiver satisfaction with quality of care and early palliative consultation impact assessed via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
62209352|NCT02459002||NSCLC - After Early Palliative Care Consult System|Palliative consultation impact assessment via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
62209353|NCT03859245|EXPERIMENTAL|Experimental group|Subjects in the experimental group will receive clinically prescribed meal plans designed to facilitate prolonged benign dietary ketosis (BDK) purposed at glucose regulation, improved insulin sensitivity and restored metabolic flexibility. Photobiomodulation therapy, via Joovv red light/infrared LED device, will be administered three times per week, 20 minutes per session.
62209354|NCT03859245|ACTIVE_COMPARATOR|Control group|Subjects in the control group will follow current dietary protocol (Standard American Diet- SAD). Photobiomodulation therapy,via Joovv red light/infrared LED device, will be administered three times per week, 20 minutes per session.
62209355|NCT04021979|EXPERIMENTAL|Enteral Nutritional+PEG|Enteral Nutritional Powder with low volume 1.5L PEG
62209356|NCT04021979|PLACEBO_COMPARATOR|Self-controlled diet+PEG|Self-controlled diet with normal amount of 2L PEG
62209357|NCT03340831||CGM/BGM Group|single-group, whereby participant is their own control. Use of a Blood Glucose Meter (BGM) for 6 months is compared to use of the G5 and G6 CGM System for 6 months, with collection of major diabetes related events (mild/severe hypoglycemia and DKA).
62790093|NCT00038064|ACTIVE_COMPARATOR|rHuEPO|
62790094|NCT00038064|EXPERIMENTAL|Darbepoetin alfa|
62209358|NCT03337659|EXPERIMENTAL|FICare Intervention Group|Study participants received Family Integrated Care (intervention) while their infant(s) was/were admitted to a Level II NICU.
62790095|NCT03893032|EXPERIMENTAL|Modafinil 200mg|single, 200 mg dose of modafinil
62018433|NCT06097052||HPI|Subject were monitored using the hypotension predictive index coupled with standard advanced hemodynamic monitoring. Hypotensive episodes were treated using a proactive approach.
62018434|NCT06532903|EXPERIMENTAL|Study group|Patients with peripheral facial paralysis who will receive muscle reeducation in front of the mirror and selective muscle electrostimulation with exponential currents
62018435|NCT06532903|ACTIVE_COMPARATOR|control group|Patients with peripheral facial paralysis who will receive facial muscle reeducation in front of the mirror without selective muscle electrostimulation with exponential current
62209359|NCT03337659|NO_INTERVENTION|FICare Control Group|Study participants received standard care while their infant(s) was/were admitted to a Level II NICU.
62209360|NCT06728553|PLACEBO_COMPARATOR|Placebo|Subjects will be given one sublingual tablet of matching placebo and instructed to take the tablet after the onset of a migraine of moderate to severe intensity.
62209361|NCT06728553|EXPERIMENTAL|Active|Subjects will be given one 2 mg sublingual tablet of the investigational product (MTX101) and instructed to take the tablet after onset of a migraine of moderate to severe intensity.
62209362|NCT02615002|EXPERIMENTAL|Piromelatine 5 mg|2 weeks of Placebo (run-in), followed by 26 weeks of 5 mg tablets once daily.
62209363|NCT02615002|EXPERIMENTAL|Piromelatine 20 mg|2 weeks of Placebo (run-in), followed by 26 weeks of 20 mg tablets once daily.
62209364|NCT02615002|EXPERIMENTAL|Piromelatine 50 mg|2 weeks of Placebo (run-in), followed by 26 weeks of 50 mg tablets once daily.
62209365|NCT02615002|PLACEBO_COMPARATOR|Placebo|2 weeks of Placebo (run-in), followed by 26 weeks of Placebo tablets once daily.
62581984|NCT04685616|EXPERIMENTAL|A2VD +/- ISRT|"2 x 28 day cycles of A2VD: Doxorubicin 25mg/m\^2 IV days 1 \& 15 Brentuximab vedotin 1.2mg/kg (max 120mg) days 1 \& 15 Vinblastine 6mg/m\^2 days 1 \& 15 Dacarbazine 375mg/m\^2 days 1 \& 15 Filgrastim (or equivalent haematopoietic growth factor) for 5-7 days from day 2 and day 16 (or single dose of peg-filgrastim on days 2 \& 16)~PET-CT after 2 cycles will determine subsequent treatment:~Deauville score 1-3 (PET CMR): 1 further cycle of A2VD then follow up Deauville score 4 (PET positive): 2 further cycles of A2VD followed by involved site radiotherapy (ISRT) Deauville score 5: withdraw from trial treatment; further treatment will be given at the treating clinician's discretion. Enter follow up for the trial."
62581985|NCT06682286|NO_INTERVENTION|Breathing route assessment: Awake and off pressure support|Breathing route will be recorded in awake participants without the use of NIV for approximately 30 min.
62581986|NCT06682286|EXPERIMENTAL|Breathing route assessment: Awake and on pressure support|Awake participants will be placed on their prescribed pressure support settings and will use two different non-invasive ventilation (NIV) masks, each for about 30 minutes.
62581987|NCT06682286|EXPERIMENTAL|Breathing route assessment: Asleep and on pressure support|Participants will be placed on their prescribed pressure support settings and will go to sleep. After 60 minutes, they will be awakened to change their mask. They will use two different non-invasive ventilation (NIV) masks, each for a minimum of 60 minutes
62790096|NCT03893032|EXPERIMENTAL|mixed amphetamine salts|single 10 mg dose of mixed amphetamine salts
62790097|NCT03893032|PLACEBO_COMPARATOR|placebo|placebo
62790098|NCT01991236|EXPERIMENTAL|Video|An educational video discussing the benefits and risk associated with long term usage of systemic corticosteroids.
62790099|NCT01991236|OTHER|Standard script|Standard scripted discussion of risks and benefits of systemic corticosteroids read to participants.
62790100|NCT04340544|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine 600mg daily for 7 days
62790101|NCT04340544|PLACEBO_COMPARATOR|Placebo|Equivalent number of placebo capsules
62790102|NCT05771740||Pulmonary Fibrosis Patient|Participants under the clinical care of the interstitial lung disease team at the Royal Devon University Healthcare NHS Trust, UK
62790103|NCT05771740||Healthy Control|Healthy participants visiting the Royal Devon University Healthcare NHS Trust, UK
62790104|NCT00880295|ACTIVE_COMPARATOR|endoscopic surgery|
62790105|NCT00880295|ACTIVE_COMPARATOR|open surgery|
62790106|NCT04561908|ACTIVE_COMPARATOR|Conventional transseptal puncture|Under the guidance of fluoroscopy and echocardiography, transseptal puncture was performed with Brockenbrough-needle.
62790107|NCT04561908|EXPERIMENTAL|Microguidewire-assisted transseptal puncture|"The Brockenbrough needle, with transseptal dilator and sheath, was introduced into the right atrium and engaged in the fossa ovalis, which was confirmed with angiographical and echocardiographical tenting sign. 1) the hard-end of a 0.014-inch microguidewire drilled through atrial septum through Brockenbrough-needle; 2) then the needle was advanced into left atrium over the fixed microguidewire; 3) finally the soft-end of microguidewire was introduced into left atrium/left superior pulmonary vein through Brockenbrough-needle, which was further advanced over the fixed microguidewire."
62790108|NCT01944540|ACTIVE_COMPARATOR|conventional ESD|Conventional ESD arm indicates the group in which conventional ESD method is applied for the dissection of colorectal neoplasm.
62790109|NCT01944540|EXPERIMENTAL|Optimized ESD with snaring|Optimized ESD with snaring arm indicates the group in which optimized ESD with snaring method is applied for the dissection of colorectal neoplasm.
62790110|NCT02907684|EXPERIMENTAL|Almonds|Almond snacks
62790111|NCT02907684|PLACEBO_COMPARATOR|Control muffins/crackers|Muffin/Cracker snacks
62018436|NCT02137629||Korean patients|All Korean patients intended to be treated with Vidaza® according to the approved package insert
62018437|NCT02677545|EXPERIMENTAL|Ticagrelor & Aspirin|Participants will receive a loading dose of 180 mg ticagrelor 1-3 days before stenting followed by a maintenance dose of 90 mg twice daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.
62018438|NCT02677545|ACTIVE_COMPARATOR|Clopidogrel & Aspirin|Participants will receive a loading dose of 300 mg clopidogrel 1-3 days before stenting followed by a maintenance dose of 75 mg once daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.
62018439|NCT06534606|ACTIVE_COMPARATOR|Conventional physical therapy Group|"Both Group A and Group B will receive this conventional physical therapy protocol for cervicogenic headache.~* Moist heat therapy: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks.~* TENS application: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks.~In addition to this, they will receive Headache SNAGs (Sustained Natural Apophyseal Glides) 5 sets of 10 repetitions. Each repetition will be given with a 10 second hold.~• Frequency: 3 times a week for 2 weeks. 6 sessions in total."
62018440|NCT06534606|EXPERIMENTAL|Conventional physical therapy with sternocleidomastoid release|"Both Group A and Group B will receive this conventional physical therapy protocol for cervicogenic headache.~* Moist heat therapy: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks.~* TENS application: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks.~Headache SNAGs: In addition to the conventional physical therapy protocol, they will receive Headache SNAGs (Sustained Natural Apophyseal Glides) 5 sets of 10 repetitions. Each repetition will be given with a 10 second hold.~* Frequency: 3 times a week for 2 weeks. 6 sessions in total. Sternocleidomastoid Release: Group B will also receive Sternocleidomastoid release in addition with headache SNAGs. Release to the sternocleidomastoid muscle will be given once per session for 5-8 minutes.~* Frequency: 3 times a week for 2 weeks. 6 sessions in total."
62581988|NCT00507819|ACTIVE_COMPARATOR|Sildenafil, then Placebo|Sildenafil will be given at a dose of 20 mg three times-a-day for six weeks followed by a six week washout period followed by placebo for an additional six weeks.
62581989|NCT00507819|ACTIVE_COMPARATOR|Placebo, then Sildenafil|Placebo will be given for six weeks followed by a six week washout period followed by Sildenafil which will be given at a dose of 20 mg three times-a-day for six weeks
62581990|NCT05066204|OTHER|Sequence: self-study, then teaching video|Participants first do self-study, then right afterwards watch a teaching video, then become tested on a simulator and are videorecorded for evaluation
62581991|NCT05066204|OTHER|Sequence: teaching video, then self study|Participants first watch a teaching video, then do self-study, then become tested on a simulator and are videorecorded for evaluation
62581992|NCT04422912|EXPERIMENTAL|DSG3-CAART or CABA-201|"Cohort A: Fractionated infusions of DSG3-CAART at increasing dose levels (6-9 groups) administered as a single cycle.~Cohort B: Consolidation of infusion of DSG3-CAART to fewer fractionations than in Cohort A using the selected dose from Cohort A (1 group) administered as a single cycle.~Cohort C: Infusion of final selected dose and fractionation of DSG3-CAART from Cohorts A and B (1 group) administered as a single cycle.~OR~CABA-201 Cohort: Single infusion of CABA-201."
62581993|NCT01976650||OZURDEX®|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
62581994|NCT05676931|EXPERIMENTAL|A1: Domvanalimab + Zimberelimab|Domvanalimab and Zimberelimab, both administered by IV infusion
62581995|NCT05676931|EXPERIMENTAL|A2: Domvanalimab + Zimberelimab|Domvanalimab and Zimberelimab, both administered by IV infusion
62581996|NCT05676931|EXPERIMENTAL|A3: Quemliclustat + Zimberelimab|Quemliclustat and Zimberelimab, both administered by IV infusion
62018441|NCT06152094|EXPERIMENTAL|BP Activate Letter|Participants in the BP Activate Letter arm will receive a BP Report letter that includes computerized algorithm recommendations for medication changes they should discuss with their clinician.
62581997|NCT05676931|EXPERIMENTAL|B1: Quemliclustat + Zimberelimab + Platinum Doublet Chemotherapy|Quemliclustat, zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion
62581998|NCT05676931|EXPERIMENTAL|B2: Domvanalimab + Zimberelimab + Platinum Doublet Chemotherapy|Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion
62581999|NCT05676931|EXPERIMENTAL|B3: Domvanalimab + Quemliclustat + Zimberelimab + Platinum Doublet Chemotherapy|Domvanalimab, Quemliclustat, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion
62018442|NCT06152094|ACTIVE_COMPARATOR|Control Letter|Participants in the Control Letter arm will receive a Control letter suggesting they talk to their clinician about their blood pressure (without BP history or specific medication recommendations).
62018443|NCT06152094|NO_INTERVENTION|Usual Care|Participants in the Usual Care arm will not receive any letter or any other intervention.
62018444|NCT04117828|ACTIVE_COMPARATOR|Control|50 g of glucose will be given to the individuals
62018445|NCT04117828|EXPERIMENTAL|1st Intervention group|50 g of Aseel dates will be given to the individuals
62582000|NCT05676931|EXPERIMENTAL|B4: Domvanalimab + Zimberelimab + Platinum Doublet Chemotherapy|Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion
62582001|NCT05676931|EXPERIMENTAL|B5: Domvanalimab + Zimberelimab + Platinum Doublet Chemotherapy|Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion
62582002|NCT05676931|EXPERIMENTAL|C1: Quemliclustat + Zimberelimab + Docetaxel|Quemliclustat, Zimberelimab, and Docetaxel, all administered by IV infusion
62582003|NCT05676931|EXPERIMENTAL|C2: Domvanalimab + Zimberelimab + Docetaxel|Domvanalimab, Zimberelimab, and Docetaxel, all administered by IV infusion
62018446|NCT04117828|EXPERIMENTAL|2nd Intervention group|50 g of Ajwa dates will be given to the individuals
62209366|NCT04546217|EXPERIMENTAL|Treadmill training +Transfer package (TT+TP)|"The TT+TP group will receive 24 sessions (3x week for 8 weeks) of robotic treadmill gait training in a robotic device called KineAssist. In combination with the gait training, participants in this group will also receive a group of behavioral strategies called the Transfer Package (TP). Each intervention session will last 1.5h, 1h for the gait training and 30 minutes dedicated for the transfer package.~Participants will be assessed pre-, post-intervention, 3 and 6 months after the end of the intervention. Also, participants will be interviewed to investigate their perceptions about each element of the intervention, benefits, side effects and suggestion for change."
62209367|NCT04546217|ACTIVE_COMPARATOR|Treadmill training (TT)|"The TT group will receive 24 sessions (3x week for 8 weeks) of robotic treadmill gait training in a robotic device called KineAssist.~Participants will be assessed pre-, post-intervention, 3 and 6 months after the end of the intervention. Also, participants will be interviewed to investigate their perceptions about each element of the intervention, benefits, side effects and suggestion for change."
62209368|NCT05206097|EXPERIMENTAL|Physical Activity Program|
62209369|NCT04932577|EXPERIMENTAL|Faecal microbiota transplantation|The patients will receive three applications of FMT consisting of 50 g cryopreserved, homogenized faeces from healthy donors. The faecal material will be dispensed into double-coated, acid-resistant enterocapsules or cryobags. Faeces will be screened according to international guidelines.
62209370|NCT04932577|PLACEBO_COMPARATOR|Placebo|The placebo products is produced from a suspension of glycerol, saline and food colouring and cannot be distinguished from the active FMT products.
62018447|NCT04117828|EXPERIMENTAL|3rd Intervention group|50 g of Karbala dates will be given to the individuals
62018448|NCT06141642|EXPERIMENTAL|Self-adaptive serious game|"Participants in this arm will follow, during three consecutive days, a serious game (REAsmashVR) intervention whose difficulty is automatically and progressively adapted to their motor and cognitive performance.~REAsmashVR involves finding a target as fast as possible. The virtual target (a mole wearing a red miner's helmet) is presented with distractors (moles wearing different helmets). Participants use a controller to hit the target mole with a virtual hammer.~In this arm, the REAsmashVR version uses a regulator to continuously moderate the location and timing of appearance of the target mole, the number and type of distractors and the working area. This regulator enables users to score 75% successful performance (driving motivation to play / learn)."
62582004|NCT05756803|EXPERIMENTAL|Low Intensity Acoustic Shockwave Therapy|The device applies a low-intensity shockwave to the surface of the penis using an ultrasound gel as the coupling agent. The low-intensity shockwave therapy device will be used with the purpose of improving penile blood flow and restoring sexual function in men with impaired erectile function.
62582005|NCT01176149|EXPERIMENTAL|SMBG + intensive education|Patients will receive specific educational interventions to teach them how to perform Self monitoring Blood Glucose (SMBG), how to modify diet and level of physical activity according to blood glucose levels, and the actions to be undertaken in case of abnormal values (hypoglycemia, particularly elevated glucose levels). Patients will be instructed to modify their lifestyle habits (diet, physical activity) in order to reach specific goals (weight reduction, reduction in fat consumption intake, reduction in saturated fat intake, increase in fiber intake, regular physical activity.
62582006|NCT01176149|NO_INTERVENTION|Usual Care|Usual Care
62582007|NCT02037191|PLACEBO_COMPARATOR|ARM A : METHOTREXATE|"Arm A: methotrexate 20 to 25 mg / week for 6 months. Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).~Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):~* methotrexate alone or~* methotrexate associated with prednisone 0.3 mg/Kg/day"
62582008|NCT02037191|PLACEBO_COMPARATOR|ARM B : PLACEBO|"Arm B placebo Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).~Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):~* methotrexate alone or~* methotrexate associated with prednisone 0.3 mg/Kg/day"
62582009|NCT04583878||Participants with Pulmonary Embolism|The target accrual is based on the primary endpoint (exercise intolerance and dyspnea on exertion). To achieve adequate power and precision in the primary analysis, the target enrollment is 80 children. Both males and females of all races and ethnic groups are eligible for this study.
62582010|NCT04583878||Control Group|A positive control group that has not had pulmonary embolism (PE) but is prescribed physical activity restrictions expected to produce a similar deconditioning effect as patients with PE will be enrolled from UT Southwestern only (cohort 1) or children who are no prescribed physical activity restrictions and are otherwise considered healthy (cohort 2). The target accrual of the positive control group is based on feasibility and availability of funds and will be limited to 25 controls.
62582011|NCT03971955||Adult Onset Autoimmune Diabetes/Latent Autoimmune Diabetes|
62582012|NCT03971955||Type 2 Diabetes|
62582013|NCT03971955||Type 1 Diabetes|
62582014|NCT03971955||Healthy Normal Volunteers (HNV)|
62582015|NCT02171234|EXPERIMENTAL|Group 1- 200 mg b.i.d. (twice daily)|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
62407011|NCT03844802|ACTIVE_COMPARATOR|Sham/placebo dry needling and exercise|"The intervention protocol will combine a home-based neck and shoulder exercise program and the use of deep dry needling in the locus of active or latent myofascial trigger points of different neck-shoulder muscles. Patients will receive 1 placebo dry needling session a week during 3 weeks (3 sessions in total). Therefore, participants in this group will receive simulated dry needling (with sham placebo needles, that will not actually penetrate the skin) in those neck muscles with active or latent myofascial trigger points. As formerly stated, the placebo needles evoke mechanical stimulation without piercing the skin; hence, patients experience a pressure sensation similar to that of a real needle.They will also undergo the neck exercise program at home during these three weeks, and for the next three months."
62582016|NCT02171234|EXPERIMENTAL|Group 2 - 400 mg b.i.d.|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
62582017|NCT02171234|EXPERIMENTAL|Group 3- 800 mg o.d. (once daily)|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
62582018|NCT02171234|EXPERIMENTAL|Group 4 - either 800 mg b.i.d or 1200 mg o.d.|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
62582019|NCT01665625|EXPERIMENTAL|regional interventional chemotherapy group|
62582020|NCT01665625|NO_INTERVENTION|systemic chemotherapy|
62582021|NCT02828501|EXPERIMENTAL|Lumbar manipulation group|Spinal Manipulation
62582022|NCT02828501|EXPERIMENTAL|Cervical manipulation group|Spinal Manipulation
62582023|NCT02828501|NO_INTERVENTION|Control group|This group will receive a 2 minute supine rest between measurements
62582024|NCT03180684|EXPERIMENTAL|VGX-3100 + EP|Participants with histologically confirmed vulvar high-grade squamous intraepithelial lesion (HSIL) associated with human papilloma virus (HPV) 16 and/or 18, received four doses of 6 mg VGX-3100 as an intramuscular (IM) injection on Day 0, Week 4, Week 12, and Week 24 followed by electroporation (EP) using the CELLECTRA™ 2000 device. Participants with vulvar HSIL who had a reduction in lesion size or no increase in lesion size at Week 48, received a fifth dose of VGX-3100 at Week 52.
62582025|NCT03180684|EXPERIMENTAL|VGX-3100 + EP + Imiquimod|Participants with histologically confirmed vulvar HSIL associated with HPV-16 and/or 18, received four doses of 6 mg VGX-3100 as an IM injection on Day 0, Week 4, Week 12, and Week 24 followed by EP using the CELLECTRA™ 2000 device. Participants with vulvar HSIL who had a reduction in lesion size or no increase in lesion size at Week 48, received a fifth dose of VGX-3100 at Week 52. In addition, participants applied imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
62209371|NCT04611009|EXPERIMENTAL|motor training|intervention: motor training
62209372|NCT04611009|ACTIVE_COMPARATOR|awareness training|intervention: mindfulness exercises
62209373|NCT06515613|EXPERIMENTAL|CTIM-76|"Phase 1a: Dose Escalation-each dose cohort will assess toxicity 28 days following the first dose of CTIM76; anticipate a total of 9 dose cohorts.~Phase 1b: Dose Expansion - 30 subjects will be evaluated using 2 different doses of CTIM-76"
62209374|NCT06651229|EXPERIMENTAL|JNJ-90189892|Participants will receive JNJ-90189892 in Part 1 (Dose escalation) of the study and the dose levels will be escalated sequentially based on the decisions of the study evaluation team (SET) until the recommended phase 2 dose (RP2D) has been identified. Participants in Part 2 (Dose expansion) will receive JNJ-90189892 at the RP2D determined in Part 1.
62209375|NCT04751942|EXPERIMENTAL|Non-compressive Bioactive Garment|The non-compressive bioactive garment is a commercially available garment that is designed to reflect infrared waves generated by the wearer back into the soft tissue surrounded by the garment. The reflection of the infrared waves is intended to improve pain and swelling at the site. Patients following Total knee replacement are intended to wear morning and night for the first 2 weeks post-operatively, and then as tolerated for 4 weeks afterwards. The patients will then discontinue use of the sleeve after 6 weeks.
62209376|NCT04751942|ACTIVE_COMPARATOR|Thrombo-Embolic Deterrent|a gradient compression stocking that is currently the gold standard for deterring thromboembolic events and assisting with post-operative swelling after total knee replacements. Patients following Total knee replacement are intended to wear the TED hose morning and night for the first 2 weeks post-operatively, and then as tolerated for 4 weeks afterwards. The patients will then discontinue use of the sleeve after 6 weeks.
62209377|NCT02550353|EXPERIMENTAL|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery
62407012|NCT03844802|ACTIVE_COMPARATOR|Neck Exercise|The intervention protocol will consist only a home-based neck and shoulder exercise program. Participants in this group will be also assessed for the presence of active or latent myofascial trigger points in the neck-shoulder muscles. As in the other groups, they will be advised to carry out the exercise protocol for three weeks and the following three months.
62407013|NCT05252273||Open-label observational study|This study will evaluate the reliability and responsiveness of patient-reported symptoms and endoscopic and histologic items for assessing pouchitis disease activity in 43 patients undergoing standard of care (SOC) antibiotic therapy.
62407014|NCT01556659|NO_INTERVENTION|vitamin K antagonist +|Treatment with carbasalaatcalcium 100 mg/day, P2Y12 inhibitors (clopidogrel 1x 75mg, ticagrelor 2x 90 mg or prasugrel 1x 10mg/day) and vitamin K antagonist (acenocoumarol)
62407015|NCT01556659|ACTIVE_COMPARATOR|vitamin K antagonist -|Treatment with carbasalaatcalcium 100 mg/day, P2Y12 inhibitors (clopidogrel 1x 75mg, ticagrelor 2x 90 mg or prasugrel 1x 10mg/day)
62407016|NCT03988049|ACTIVE_COMPARATOR|1,550 laser|This arm is the side of the face treated with the 1550-nanometer Fracionated Photothermolysis laser.
62407017|NCT03988049|ACTIVE_COMPARATOR|755 laser|This arm is the side of the face treated with the 755-nanometer alexandrite picosecond laser.
62407018|NCT02594566|EXPERIMENTAL|Research Subjects|A total of 3 injections of the vaccine (CyMVectin) will be given at Days 0, 28 (+4 days), and 56 (+4 days).
62407019|NCT04470830||Participants With Essential Hypertension|Participants diagnosed with essential hypertension who have been treated with azilsartan medoxomil/chlorthalidone FDC as an early therapy for participants whose blood pressure is not properly controlled by monotherapy or who require administration of multiple drugs in order to reach the target blood pressure, will be observed prospectively over a period of 5 years.
62407020|NCT02503696||IBD|Subjects will be men and women, 18-84 years of age, inclusive, who have been diagnosed with IBD. Each with a screening colonoscopy resulting in normal findings.
62407021|NCT00824993|EXPERIMENTAL|Ibandronate + Calcium + Vitamin D|Ibandronate infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant. Calcium 500 mg by mouth everyday for 12 months. Vitamin D 400 units by mouth 2 times a day for 12 months.
62407022|NCT00824993|EXPERIMENTAL|Calcium + Viatmin D|Calcium 500 mg by mouth everyday for 12 months. Vitamin D 400 units by mouth 2 times a day for 12 months.
62582026|NCT05924425|EXPERIMENTAL|Daridorexant 50 mg|"Patients will receive daridorexant 50 mg during one month (Period A or Period B).~Daridorexant is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed for the treatment of insomnia."
62209378|NCT02550353|EXPERIMENTAL|FS assisted laser in situ keratomileusis|The patients in this group chose to receive the femtosecond laser-assisted laser in situ keratomileusis surgery.
62209379|NCT06727786|NO_INTERVENTION|Control|No intervention/training
62209380|NCT06727786|EXPERIMENTAL|Serious Game|Serious Game training to respond to opioid overdose
62209381|NCT02817802||Magmaris|Magmaris Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold
62209382|NCT03240705|EXPERIMENTAL|Gratitude journaling|Students perform gratitude journaling 3 times per week on a form. This activity consists of writing elements of their day that brought happiness to them. Can be in keyword form or in sentences.
62407023|NCT04020614||Survey|All of the patients that enrolled in this study will be in this group.
62407024|NCT02424357|EXPERIMENTAL|5% povidone iodine ophthalmic solution|patient received 1 drop of 5% povidone-iodine instilled over the adjustable suture noose in addition to routine antibiotic/steroid ointment to operated eye at surgery completion
62407025|NCT02424357|ACTIVE_COMPARATOR|no povidone-iodine ophthalmic solution|patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
62407026|NCT01905631|NO_INTERVENTION|Untreated Control Group|Subjects will apply nothing for the entire three days of the trial. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
62407027|NCT01905631|ACTIVE_COMPARATOR|Treatment Group (Aurstat)|Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
62582027|NCT05924425|PLACEBO_COMPARATOR|Placebo-controlled arm|Patients will receive a placebo matching to daridorexant 50 mg during one month (Period A or Period B).
62582028|NCT04355611||Patients with MS or NMO|Cohort study evaluating the epidemiological characteristics of coronavirus infection (SARS-CoV-2) in patients with MS or NMO
62209383|NCT03240705|NO_INTERVENTION|No intervention|Students proceed with their surgical clerkship as is standard in our institution.
62209384|NCT06728917||Subjects living with HIV switching to long acting therapy|The study will include subjects living with HIV, followed at the San Luigi Center (Infectious Diseases), IRCCS Ospedale San Raffaele in Milan, Integrated Infectious Risk Management Department, Policlinico S. Orsola-Malpighi in Bologna, and the Department of Mental and Physical Health and Medicine prevention, University of Campania L. Vanvitelli of Naples, who agree to the switch from the current antiretroviral regimen which includes drugs active on HIV/HBV to long acting therapy.
62209385|NCT02713646||patients with primary trigeminal neuralgia|
62582029|NCT06682845||EV patients|Adult patients who have received enfortumab vedotin treatment at the Centre Léon Bérard or Hôpital Lyon Sud, and who do not object to the collection of their data.
62582030|NCT05299554|EXPERIMENTAL|Chronocort (hydrocortisone modified-release capsule)|Chronocort (hydrocortisone modified-release capsules) supplied as 5 mg and 10 mg per capsule for oral administration.
62582031|NCT06684587|ACTIVE_COMPARATOR|Group TX (Telehealth Exercise)|Participants in this group will receive a group-based, supervised exercise session twice a week for 10 weeks along with a structured home exercise program. These sessions will be delivered via Boston University HIPAA-compliant Zoom videoconferencing software.
62582032|NCT06684587|EXPERIMENTAL|Group TMX (Telehealth Exercise and Mindfulness)|Participants in this group will receive a group-based, supervised, integrated mindfulness and exercise program twice a week for 10 weeks along with a structured home program. Similar to the exercise intervention, these sessions will be delivered via Boston University HIPAA-compliant Zoom videoconferencing software.
62582033|NCT03445546||oral P2Y12 inhibition|Patients with cardiac arrest and myocardial infarction treated with oral P2Y12 Inhibitor (from the historic cohort of NCT02914795)
62582034|NCT03445546||intravenous P2Y12 inhibition|Patients with cardiac arrest and myocardial infarction treated with intravenous P2Y12 Inhibitor (cangrelor)
62582035|NCT03822663|EXPERIMENTAL|Caffeine supplementation|Group taking oral CAF (Caffeine) supplementation in a different-dose crossover regimen.
62582036|NCT03822663|PLACEBO_COMPARATOR|Placebo treatment|Group taking oral supplementation with placebo.
62582037|NCT05347004|EXPERIMENTAL|BI 425809 fed state (Test, T) then BI 425809 fasting state (Reference, R)|
62582038|NCT05347004|EXPERIMENTAL|BI 425809 fasting state (Reference, R) then BI 425809 fed state (Test, T)|
62582039|NCT02777346|EXPERIMENTAL|Absorbable|Suture material: Polyglactin 910 thread (Vicryl Rapide®, Ethicon Inc).
62582040|NCT02777346|ACTIVE_COMPARATOR|Non Absorbable|Suture material: Polypropylene thread (Prolene®, Ethicon Inc).
62209386|NCT02713646||healthy subjects|
62582041|NCT03670446|EXPERIMENTAL|Pharmacists' intervention|A group of participants assigned to a pharmaceutical intervention
62582042|NCT03670446|NO_INTERVENTION|Routine therapy|A group of participants assigned to a control (routine therapy)
62407028|NCT04828551|OTHER|MGH and UCSD Study subjects|"This study will enroll patients with suspected or confirmed diagnosis of NAFLD. Based on protocol-specified FIB-4 values, about one-third are expected to have low, one-third to have intermediate, and one-third to have high likelihood of advanced fibrosis.~Sex: 50:50 - Note- no stratification will be done based on sex Age: ≥ 18 yrs Demographic group: Patients with a high probability of NAFLD based on the eligibility criteria General health status: Patients with suspected or confirmed diagnosis of NAFLD Geographic location: Boston, MA (greater metropolitan areas) and San Diego, CA (greater metropolitan areas)"
62407029|NCT02021019|EXPERIMENTAL|Renal Denervation|Renal denervation using a catheter-based Radio-frequency approach
62407030|NCT02021019|NO_INTERVENTION|Usual Care|Usual care
62582043|NCT05069831|ACTIVE_COMPARATOR|Abrocitinib 100mg|This arm will receive 100mg of the study drug
62582044|NCT05069831|ACTIVE_COMPARATOR|Abrocitinib 200mg|This arm will receive 200mg of the study drug
62582045|NCT02787824|EXPERIMENTAL|continuous iv administration of iron sucrose|Prior to the study, all our patients were receiving intravenous iron sucrose in an intermittent mode (every 1-4 weeks).Patients on this arm will receive the same previous dose of iron glucose but in a continuous mode (smaller doses of iron sucrose in every session).
62582046|NCT02787824|ACTIVE_COMPARATOR|intermittent iv administration of iron sucrose|Patients on this arm will continue to receive the same previous intermittent mode of iron sucrose.
62582047|NCT01524484||Anesthesia staff Interviewees|Staff entering quality data into the electronic anesthesia record are interviewed regarding working conditions and record layout
62582048|NCT01524484||Anesthesia records|Anesthesia records (all types of procedures) are checked for correct reporting of defined events
62582049|NCT04288921|EXPERIMENTAL|Nasal swab|Nasal swab from subjects with signs and symptoms of influenza and/or RSV-like illness
62407031|NCT06566638|EXPERIMENTAL|SOC plus NucleoCapture|Participants in the treatment arm will receive SOC plus three apheresis treatment sessions with the NucleoCapture device. The device consists of 100ml NucleoCapture selective adsorber.
62209387|NCT06728800|EXPERIMENTAL|FBT 2.0|Dyads assigned to receive FBT 2.0 will receive all eight modules over the six-month trial, completing one module every two weeks. Dyads will have free access to all completed modules for the duration of the six-month trial. Each module is expected to take approximately two to three sessions to complete, each session lasting approximately 45 minutes. At least one interventionist-led session (20-30 minutes) will occur per week, with additional sessions or coach support as needed via text exchange and/or videoconferencing supported on the website. Families will be able to engage with the software for as long as desired during the six-month trial.
62209388|NCT06728800|OTHER|Information-and-referral Control|Caregiver-youth dyads randomized to the information-and-referral control intervention will be given written educational materials. Prior to starting the intervention trial, dyads will meet for 20 minutes with a trained researcher who will provide them with educational materials used in investigators' prior studies which teaches about the impact of eating and activity behaviors on weight. Caregivers will be asked to monitor their health by using daily paper-and-pencil diaries to record eating and activity behaviors. Youth without a medical provider will be given referrals to a primary care provider in their community.
62209389|NCT01599494|EXPERIMENTAL|Single-Dose MK-8962 + recFSH|
62209390|NCT01599494|ACTIVE_COMPARATOR|Reference Group recFSH only|
62209391|NCT00342888||Childhood Leukemia Cases|Cases were diagnosed at 9 hospitals in Northern California
62407032|NCT06566638|NO_INTERVENTION|SOC|Participants in the SOC arm will receive SOC alone, in accordance with ESICM guidelines.
62582050|NCT04288921|EXPERIMENTAL|Nasopharyngeal swab|Nasopharyngeal swab from subjects with signs and symptoms of influenza and/or RSV-like illness
62582051|NCT01415869||Cross Sectional|Patients with implanted non-pulsatile ventricular assist devices of any type and at any time after implantation
62582052|NCT01415869||Prospective|Patients with usual VAD indications will be invited to participate, when, in the opinion of their treating physician a VAD will be highly likely within one month.
62582053|NCT06531941|EXPERIMENTAL|400 µg once-weekly by subcutaneous injection|
62582054|NCT06531941|EXPERIMENTAL|200-1600 µg once-weekly by subcutaneous injection|
62582055|NCT06031415|EXPERIMENTAL|Part A: Rheumatoid Arthritis (RA) Cohorts: GS-0272 or Placebo|"Part A will include participants with RA. Part A will have 3 cohorts. Each cohort in Part A will be randomized in a 3:1 ratio to receive either ascending doses of GS-0272 or placebo for 12 weeks.~Dosing will begin in Cohort 1. Cohorts 2 and 3 will be initiated upon review of blinded safety data from the preceding cohort."
62582056|NCT06031415|EXPERIMENTAL|Part B: Active RA Cohort: GS-0272 or Placebo|Part B will include participants with moderate-to-severe RA. Part B will have only 1 cohort (Cohort 4). Participants in Cohort 4 will be randomized in a 2:1 ratio to receive either GS-0272 or placebo for 12 weeks.
62582057|NCT06177652|ACTIVE_COMPARATOR|Paravertebral Block|Ultrasound (US) -guided paravertebral block (PVB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the PVB group.
62582058|NCT06177652|ACTIVE_COMPARATOR|Serratus Plane Block|Ultrasound (US) -guided serratus plane block (SPB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the SPB group.
62582059|NCT02694783|EXPERIMENTAL|Treatment Arm|ex vivo generated polyomavirus-specific T cells from HLA-matched donor
62582060|NCT05113251|EXPERIMENTAL|Arm A|Trastuzumab deruxtecan
62582061|NCT05113251|EXPERIMENTAL|Arm B|T-DXd, followed by THP
62582062|NCT05113251|ACTIVE_COMPARATOR|Arm C|doxorubicin and cyclophosphamide, followed by THP
62582063|NCT05906511|ACTIVE_COMPARATOR|Dronabinol 5mg|Dronabinol 5 mg
62407033|NCT01584050|ACTIVE_COMPARATOR|L-MTHF|
62407034|NCT01584050|ACTIVE_COMPARATOR|folic acid|
62407035|NCT01584050|PLACEBO_COMPARATOR|placebo (methyl cellulose)|
62407036|NCT04984694|EXPERIMENTAL|Computerized virtual reality training programs group (Hot-Plus group)|Participants who are in Hot-Plus group will divide several small groups which will be 4 persons with mild cognitive impairment. Participants will receive computerized virtual reality training program by Hot-Plus as a group activity for one hour, once a week for 12 weeks.
62582064|NCT05906511|PLACEBO_COMPARATOR|Dronabinol 10mg|Dronabinol 10 mg
62407037|NCT04984694|ACTIVE_COMPARATOR|Social interaction group|The participants in the social interaction group will come as a group for social interaction one hour weekly for 12 weeks.
62582065|NCT05906511|ACTIVE_COMPARATOR|Vaporized THC 2mg|Vaporized THC 2mg
62582066|NCT05906511|ACTIVE_COMPARATOR|Vaporized THC 4mg|Vaporized THC 4 mg
62582067|NCT05906511|PLACEBO_COMPARATOR|Placebo|Masked oral placebo or vaporized saline
62582068|NCT01926613|ACTIVE_COMPARATOR|Supported Employment Only|Supported employment is an evidence based practice designed to help people with serious mental illness obtain competitive work. This vocational model adheres to the principles of zero inclusion, rapid job search, no prevocational training, attention to client preferences and integration with clinical services.
62209392|NCT00342888||Matched Controls|Controls were matched on age, gender and race/ethnicity from birth certificates in Northern California
62209393|NCT01217853||SENSIMED Triggerfish|
62209394|NCT05003609|ACTIVE_COMPARATOR|Intervention Group|ECMO early rehabilitation is led by a senior physiotherapist who has specialised training in ECMO care and coordinates individualised early physical training from randomisation to day 28 in ICU and liaises with the patient through to hospital discharge. The early rehabilitation intervention involves physical activity, functional retraining, strengthening exercises and mobilisation based on a reproducible, physiological approach.
62209395|NCT05003609|NO_INTERVENTION|Control Group|The control group will receive standard care from nursing and physiotherapy staff not involved in the early, co-ordinated rehabilitation.
62209396|NCT01364792|EXPERIMENTAL|Valaciclovir|The patients in the experimental group will be treated with 4 times 2 grams valaciclovir per day for seven days.
62209397|NCT01364792|PLACEBO_COMPARATOR|Placebo|Patient receives placebo four times a day for seven days.
62209398|NCT05887154|OTHER|Microwave ablation|Each patient will undergo Microwave ablation of breast tumor before the standard clinical care (surgery)
62209399|NCT03831386|ACTIVE_COMPARATOR|Vacuum|The pleural fluid will be drained by the syringe system with a one-way valve tubing system provided in the kit. Selection of the vacuum pressure will be at the discretion of the proceduralist, as per standard of care. Participants in this arm will undergo Vacuum-Based IPC.
62209400|NCT03831386|EXPERIMENTAL|Gravity|The pleural fluid will be drained using gravity drainage to a bag positioned at bedside. Participants in this arm will undergo Gravity-Based IPC.
62407038|NCT04984694|NO_INTERVENTION|Control group|The control group will maintain regular activities.
62407039|NCT00561600|ACTIVE_COMPARATOR|A|ASR™-XL Modular Acetabular Cup System stem
62582069|NCT01926613|EXPERIMENTAL|Thinking Skills for Work|The Thinking Skills for Work Program includes 5 components delivered by a Cognitive Specialist who works collaboratively with the consumer's Employment Specialist: a) assessing the consumer's strengths and weaknesses in cognitive functioning, and analysis of the contribution of cognitive impairments and other factors to job losses and difficulties obtaining a job; b) teaching coping strategies for dealing with cognitive challenges associated with job search or maintaining a job; c) computer cognitive training involving cognitive exercises with a commercially available software program, which is designed to improve the broad range of cognitive skills through a combination of practice and strategy coaching by the Cognitive Specialist; d) job search planning; and e) job support consultation.
62582070|NCT03182543|EXPERIMENTAL|AM1|Mango pulp beverage
61978499|NCT00541034|EXPERIMENTAL|cyclophosphamide, pentostatin & rituximab|Patients receive cyclophosphamide IV followed by pentostatin IV on day 1 in course 1. Beginning in course 2 and in all subsequent courses, patients receive cyclophosphamide IV on day 1, pentostatin IV on day 1, and rituximab IV on day 1 or on days 1 and 2. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62209401|NCT04976244|ACTIVE_COMPARATOR|Brolucizumab|Arm B
62209402|NCT04976244|ACTIVE_COMPARATOR|Aflibercept|Arm A
62209403|NCT04119024|EXPERIMENTAL|Treatment (chemotherapy, IL13Ralpha2)|Patients may receive cyclophosphamide IV over 60 minutes on days -5 to -3 and fludarabine phosphate IV over 15-30 minutes on days -5 to -2. Patients then receive IL13Ralpha2 CAR T cells IV on day 0. Patients also undergo biopsy at baseline and on study, CT, or PET and CT scan at screening and on study, magnetic resonance imaging (MRI) throughout the trial, and collection of blood samples throughout the trial. Patients with disease progression may receive a second cycle with an infusion of IL13Ralpha2 CAR T cells.
62407040|NCT00561600|ACTIVE_COMPARATOR|B|Pinnacle™ acetabular shell, with a 28mm or 36mm ULTAMET® metal liner, and a 28mm or 36mm Articul/eze M head.
62407041|NCT01201122|EXPERIMENTAL|Weight based Mesalamine: Once daily|
62582071|NCT03182543|EXPERIMENTAL|AM2|Mango pulp and peel beverage
62582072|NCT03182543|PLACEBO_COMPARATOR|Control|Control beverage
62209404|NCT05384938|OTHER|Benralizumab|Single arm, Phase-IV
62209405|NCT04548102|EXPERIMENTAL|Fetal Movement Counting|Fetal movement counting
62209406|NCT04548102|NO_INTERVENTION|standard antenatal follow up care|Women in the control group received the antenatal hospital standard care.
62209407|NCT04905459||Retinal Imaging and Mydriatic Agents|Subjects will undergo several types of retinal imaging before and after administration of mydriatic agent. Subjects will be administered mydriatic medication to dilate their pupils.
62209408|NCT03396276|EXPERIMENTAL|Suboxone induction into MAT in the ED|Suboxone induction into medication-assisted treatment (MAT) in the emergency department (ED)
62209409|NCT01911390|PLACEBO_COMPARATOR|Control Arm|No bean or rice bran additive in smoothie or muffin.
62407042|NCT01201122|EXPERIMENTAL|Weight based Mesalamine: Twice daily|
62407043|NCT03041818|EXPERIMENTAL|hippotherapy|16 sessions of horseback riding therapy
62407044|NCT03381807|EXPERIMENTAL|TCRA and intrauterine infusion of hAESCs|hAESCs is infused into uterine cavity after TCRA.
62407045|NCT00241059|EXPERIMENTAL|EC-MPS arm|
62209410|NCT01911390|ACTIVE_COMPARATOR|Bean powder|1/4 cup beans (17.5 grams powder)/day in smoothie or muffin.
62209411|NCT01911390|ACTIVE_COMPARATOR|Rice bran|15 grams rice bran/day in smoothie or muffin.
62407046|NCT04401995|EXPERIMENTAL|Nivolumab and Vidutolimod (CMP-001) Combination with [18F]F-AraG PET/CT|"Prime Phase - Nivolumab 240mg IV, every 2 weeks starting with Cycle 2 (Cycles 2,4,6) for 6 weeks in combination with Vidutolimod 5mg subcutaneous 1st dose, and the remaining injections, 10mg intra-tumorally will be administered Weeks 2-7. \[18F\]F-AraG PET/CT, single bolus injection of 5 (±10%) mCi IV into a vein, Screening and at Week 2.~Boost Phase - Nivolumab 480mg IV, every 4 weeks and CMP-001 5mg subcutaneous every 4 weeks up to 48 weeks."
62407047|NCT04401995|EXPERIMENTAL|Nivolumab with [18F]F-AraG PET/CT|"Prime Phase - Nivolumab 240mg IV, every 2 weeks starting with Cycle 2 (Cycles 2, 4, 6) for 6 weeks. \[18F\]F-AraG PET/CT, single bolus injection of 5 (±10%) mCi IV into a vein, Screening and at Week 3.~Boost Phase - Nivolumab 480mg IV, every 4 weeks starting from the time of surgery recovery for up to 48 weeks."
62582073|NCT06412757|EXPERIMENTAL|Silexan 160 mg|Participants in the Silexan arm will take Silexan 160 mg daily in the morning for 12 weeks in addition to their usual prescribed psychoactive medications. Participants will be followed up at 2, 4, 6, 8 and 12 weeks of the intervention period, as well as at 4 weeks post-treatment (off-treatment follow-up period).
62582074|NCT06412757|PLACEBO_COMPARATOR|Placebo|Participants in this arm will take two placebo capsules daily in the morning for 12 weeks in addition to their usual medications. Participants will be followed up at 2, 4, 6, 8 and 12 weeks of the intervention period, as well as at 4 weeks post-treatment (off-treatment follow-up period).
62018449|NCT06141642|SHAM_COMPARATOR|Non-adaptive serious game|"Participants in this arm will follow, during three consecutive days, a serious game (REAsmashVR) intervention whose difficulty is not automatically adapted to their motor and cognitive performance.~In this arm, the REAsmashVR version does not use a regulator to continuously adapt exercise difficulty according to user performance. Instead, the game randomly moderates the location of the target mole, the working area and the type of distractors. The appearance timing remains constant at 7 seconds, while the number of distractors gradually increases over time to simulate an adaptive game environment, ensuring participants are kept unaware of the intervention."
62018450|NCT00661063|EXPERIMENTAL|K|drug - ketamine 1% gel
62018451|NCT00661063|PLACEBO_COMPARATOR|P|vehicle gel
62018452|NCT00661063|EXPERIMENTAL|M|association of ketamine and clonidine gel
62018453|NCT00661063|EXPERIMENTAL|C|clonidine gel
62018454|NCT02667912|EXPERIMENTAL|Distal renal denervation|Endovascular denervation of segmental branches of renal artery
62018455|NCT02667912|ACTIVE_COMPARATOR|Conventional renal denervation|Endovascular denervation of main trunk of renal artery
62018456|NCT03565718|ACTIVE_COMPARATOR|Standard Group|Participants in this group will receive counseling, informational materials, and recipes for following a vegan diet. Participants in this group will receive gift cards to go shopping at their local supermarkets and follow the diet for 3 weeks. At the end of the 3 week period each participant will have a follow-up meeting and provide feedback to the study personnel. The Dietary Intervention: Standard/Grocery includes intervention meetings and dietary counseling.
62018457|NCT03565718|EXPERIMENTAL|Restaurant Group|"Participants in this group will receive counseling, informational materials, and recipes for following a vegan diet. Participants in this group will receive gift cards to go and eat out a few times a week at local vegan soul food restaurants and follow the diet for 3 weeks. At the end of the 3 week period each participant will have a follow-up meeting and provide feedback to the study personnel.~The Dietary Intervention: Restaurant condition includes intervention meetings and dietary counseling."
62018458|NCT06098599|EXPERIMENTAL|Doxorubicin hydrochloride liposome injection(LY01612)|20mg/10mL, 50mg/m2, intravenously for 90min (±3min) with an infusion pump on day 1 and day 29 of the trial.
62018459|NCT06098599|ACTIVE_COMPARATOR|Doxorubicin hydrochloride liposome injection(CAELYX®)|20mg/10mL, 50mg/m2, intravenously for 90min (±3min) with an infusion pump on day 1 and day 29 of the trial
62018460|NCT05368805|EXPERIMENTAL|Part A|On Day 1, a single oral dose of dabigatran etexilate 150 mg will be given under fasted conditions and serial PK samples will be collected as indicated on the schedule of events. On Day 5, subjects will receive a single oral dose of fruquintinib 5 mg at approximately 1 hour prior to administration of a single oral dose of dabigatran etexilate 150 mg under fasted conditions and serial PK samples will be collected
62582075|NCT06533137|EXPERIMENTAL|Active Placebo|"Following the 10-minute warm-up, participants will be presented with a hypoglycemic energy drink (actually a ginger-flavored beverage) to be taken as needed, explicitly stating, You have 10 ml of this particularly energizing, hypoglycemic, caffeine-based drink, which is designed to reduce fatigue and improve performance. You can decide when to take it. The researcher will note the time of consumption."
62582076|NCT06533137|ACTIVE_COMPARATOR|Passive Placebo|"Following the 10-minute warm-up, they will be presented with a hypoglycemic energy drink (actually a ginger-flavored beverage) to be taken as needed, explicitly stating, Before proceeding, consume this particularly energizing, hypoglycemic, caffeine-based drink, which is designed to reduce fatigue and improve performance."
62582077|NCT06533137|SHAM_COMPARATOR|Control|"Following the 10-minute warm-up, they will be presented with a mineral salt-based drink (actually a ginger-flavored beverage), described as such (Before proceeding, consume this mineral salt-based drink), which the participant will consume before continuing with the proposed exercise."
62018461|NCT05368805|EXPERIMENTAL|Part B|On Day 1, a single oral dose of rosuvastatin 10 mg will be given under fasted conditions and serial PK samples will be collected as indicated on the schedule of events. On Day 5, subjects will receive a single oral dose of rosuvastatin 10 mg with fruquintinib 5 mg under fasted conditions and serial PK samples will be collected
62018462|NCT03566719|EXPERIMENTAL|Intervention group|
62018463|NCT03566719|NO_INTERVENTION|Control group|
62018464|NCT04975373|OTHER|study group|study group women in this group will receive intrauterine hyaluronic acid injection after operative hysteroscopy
62018465|NCT04975373|NO_INTERVENTION|control group|women will not receive hyaluronic acid after operative hysteroscopy
62018466|NCT01427244|EXPERIMENTAL|Trastuzumab|Open Label
62018467|NCT00766415|EXPERIMENTAL|AZD1981|
62018468|NCT00766415|PLACEBO_COMPARATOR|Placebo|
62209412|NCT01911390|ACTIVE_COMPARATOR|Bean powder and rice bran|9 grams bean powder/day and 8 grams rice bran /day in smoothie or muffin.
62209413|NCT02412787|EXPERIMENTAL|Idursulfase-IT|Participants will receive 10 milligrams (mg) of idursulfase-IT intrathecally via intrathecal drug delivery device (IDDD) or lumbar puncture (LP) once every 28 days along with standard-of-care therapy with Elaprase for 480 weeks. Participants who are younger than 3 years of age will receive an adjusted dose of 7.5 mg (greater than \[\>\] 8 months to 30 months of age) and 10 mg (\>30 months to 3 years of age) of idursulfase-IT.
62209414|NCT05900180|ACTIVE_COMPARATOR|Every-other-week therapy with home programming|Receipt of standard speech therapy care (every-other-week) for 8.0 sessions
62209415|NCT05900180|EXPERIMENTAL|Weekly therapy with home programming|Receipt of speech therapy care (every week) for 8.0 sessions
62209416|NCT05165927|EXPERIMENTAL|BFR Group|BFR cuffs will be used for specific exercises and added to the current SOC for post hip scope PT.
62209417|NCT05165927|NO_INTERVENTION|SOC Group|Current SOC for post hip scope PT will be assigned.
62407048|NCT06566235|EXPERIMENTAL|Culturally adapted DBT-A-ST group|"The culturally adapted DBT-A-ST consists of 15 weekly group sessions, each lasting 120 minutes, including a 10-minute break. It maintains the core elements of standard DBT-A, including its philosophical foundation and treatment strategies.~Therapists focus on teaching DBT skills through various methods such as modeling, structured behavioral rehearsals, and feedback. Each session begins with a 40-minute group mindfulness exercise and homework review, followed by 60 minutes dedicated to skill-specific didactics and experiential activities, concluding with a 10-minute homework assignment. Two group leaders facilitate the sessions, and participants track their skill usage daily with diary cards, which are reviewed weekly."
62582078|NCT03449654|OTHER|Liraglutide|
62582079|NCT03449654|OTHER|placebo|
62582080|NCT02049892||Metal Ion|
62582081|NCT01702285|EXPERIMENTAL|CUDC-101|200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
62582082|NCT06651112||First episode psychosis|"Individuals aged 18 to 35 from the Estrie region who have been evaluated by the PEP team (First episode psychosis intervention Team of the pschiatric department of the CIUSSS de l'Estrie-CHUS) and wish to start an antipsychotic (AP) for the treatment of a first episode of psychosis."
62209418|NCT01120730|ACTIVE_COMPARATOR|HES|Fluid resuscitation with HES
62209419|NCT01120730|PLACEBO_COMPARATOR|ringers lactat|Standard treatment
62209420|NCT02430051|NO_INTERVENTION|Regular Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Regular dental environment no sensory characteristics of the dental environment are altered, the cleaning is conducted as per usual.
62582083|NCT06171932||HYDROCORTISONE|Group A will comprise of 30 patients will be treated with 200 mg hydrocortisone followed by 3 doses of hydrocortisone 100 mg 6 hours apart for next 24hrs
62209421|NCT02430051|EXPERIMENTAL|Sensory Adapted Dental Environment|In the Sensory Adapted Dental Environment the sensory characteristics of the dental environment are altered (visual, auditory, tactile adaptations).
62209422|NCT05897320|EXPERIMENTAL|Eptinezumab 300 mg|Participants will receive a single intravenous (IV) infusion of eptinezumab 300 mg (weight adjusted).
62209423|NCT05897320|PLACEBO_COMPARATOR|Placebo|Participants will receive a single IV infusion of matching placebo to eptinezumab.
62209424|NCT05897320|EXPERIMENTAL|Eptinezumab 100 mg|Participants will receive a single IV infusion of eptinezumab 100 mg (weight adjusted).
62582084|NCT06171932||METHYLPREDNISOLONE|Group B will be treated with methylprednisolone 125 mg stat
62209425|NCT01694316|ACTIVE_COMPARATOR|Engaging in Computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
62582085|NCT06339463|EXPERIMENTAL|Self-Distancing|"Youth will be randomized to OST exposure therapy with Self-Distancing. In this arm, participants will be instructed to describe exposure tasks from a self-distanced perspective (e.g., Emily is going to touch the spider)."
62582086|NCT06339463|ACTIVE_COMPARATOR|Classic Exposure|"Youth will be randomized to OST using classic exposure. In this arm, participants will be instructed to describe exposure tasks from a self-immersed perspective (e.g.,I'm going to touch the spider)"
62582087|NCT04845919|EXPERIMENTAL|5-ALA mediated sonodynamic therapy|
62582088|NCT06682260|EXPERIMENTAL|Nitroglycerin|Infusion of intravenous nitroglycerin titrated towards a vasodilatory state which we predefined as a 20-30% decrease in mean arterial pressure (MAP) for 1.5 hours followed by a phase of 1.5 hours with no vasodilation.
62582089|NCT03697174|EXPERIMENTAL|Exposure group|Subjects in exposure group will be exposed to 200 ppb ozone for 2 hours in a chamber.
62582090|NCT03697174|SHAM_COMPARATOR|Control group|Subjects in control group will be exposed to 0 ppb ozone (clean air) for 2 hours in a chamber.
62209426|NCT01694316|EXPERIMENTAL|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
62582091|NCT05940376||Control|Group A was assigned to receive preservative-free lubricants and prophylactic antibiotics.
62582092|NCT05940376||Study|Group B was assigned to receive topical insulin \[1 unit per drop\] 4 times per day (QID) in addition to previous treatment.
62209427|NCT02392052|EXPERIMENTAL|Reinvention Protocol Participants|This group will receive 6 instructor-led 2 hour long didactic presentations regarding 8 key principles of self-efficacy and experiential exercises, including goal setting and problem solving with extensive group discussion. At the end of each session, tasks are assigned to participants to be completed outside the group during the week between sessions. Experiences from these activities and practice implementing the intervention principles will be shared and discussed each week, providing additional opportunities for problem solving and positive feedback.
62209428|NCT02392052|OTHER|Waitlist Group|This group will include individuals randomized to receive no treatment for the 18 weeks during which the interventional group will receive the active treatment and have their progress tracked.
62209429|NCT02559895|EXPERIMENTAL|ALD403 Dose Level 1|ALD403 Dose Level 1 (IV)
62582093|NCT06649968|EXPERIMENTAL|Experimental Group|Hand rehabilitation using the device
62582094|NCT06649968|SHAM_COMPARATOR|Sham Group|Hand rehabilitation while wearing the device, without providing vibrations to the patients.
62582095|NCT06649968|ACTIVE_COMPARATOR|Control Group|Hand rehabilitation without using the device
62582096|NCT04042701|EXPERIMENTAL|Part 1 (Dose Escalation)|HER2-positive breast cancer, HER2-low expressing breast cancer, HER2-expressing NSCLC, and HER2-mutant NSCLC participants who received escalating doses of DS8201a (initial dose 3.2 mg/kg Q3W) and pembrolizumab 200 mg.
62582097|NCT04042701|EXPERIMENTAL|HER2-positive breast cancer (Part 2 Dose Expansion)|HER2-positive breast cancer participants with prior ado-trastuzumab emtansine (T-DM1) with disease progression and who received DS8201a at the RDE in combination with pembrolizumab 200 mg.
62582098|NCT04042701|EXPERIMENTAL|HER2-low breast cancer (Part 2 Dose Expansion)|HER2 low breast cancer participants with prior failed standard treatments who received DS8201a at the RDE in combination with pembrolizumab 200 mg.
62582099|NCT04042701|EXPERIMENTAL|HER2-expressing NSCLC (Part 2 Dose Expansion)|HER2-expressing NSCLC participants who had not received any prior treatment with anti-PD-1, anti-PD-L1, or HER2 agents and received DS8201a at the RDE in combination with pembrolizumab 200 mg.
62209430|NCT02559895|EXPERIMENTAL|ALD403 Dose Level 2|ALD403 Dose Level 2 (IV)
62209431|NCT02559895|EXPERIMENTAL|ALD403 Dose Level 3|ALD403 Dose Level 3 (IV)
62209432|NCT02559895|PLACEBO_COMPARATOR|Placebo|Placebo (IV)
62209433|NCT06310408|EXPERIMENTAL|nasal mask|Give noninvasif respiratory support with interface nasal mask
62209434|NCT06310408|ACTIVE_COMPARATOR|nasal prong|Give noninvasif respiratory support with interface nasal prong
62209435|NCT06729463|ACTIVE_COMPARATOR|Group A: Humira Group|About 20 patients suffering from psoriasis disease and they will take Humira vials about 40 mg every two weeks by subcutaneous injection for 3 months
62209436|NCT06729463|ACTIVE_COMPARATOR|Group B: Cosentyx Group|"About 20 patients suffering from severe psoriasis will take Cosentyx vials by intravenous infusion as :~1-Loading dose about(300 mg) then decreasing the dose to be 150 mg every month for 3 months."
62209437|NCT06729463|PLACEBO_COMPARATOR|Group C: control Group|About 10 Healthy participants and will take no medical treatment
62209438|NCT02276417||Sepsis|Blood Collection. Urine collection. Bioimpedance analysis. Quality-of-life questionnaires, physical function tests and cognitive function tests.
62209439|NCT02276417||Healthy Controls|Blood Collection.
62209440|NCT04958200|EXPERIMENTAL|mhealth-pc for alcohol and chronic pain|Smartphone-based intervention
62209441|NCT04958200|ACTIVE_COMPARATOR|Treatment As Usual|In person session that provides enhanced treatment as usual
62209442|NCT05743387|ACTIVE_COMPARATOR|Intervention villages|"In the intervention villages, CC-VHWs will offer~* a T2D care package including lifestyle counselling, firstline antidiabetic (metformin) and lipid-lowering (statin) treatment for uncomplicated T2D and treatment support and regular check-ups for complicated T2D at village-level according to clinical algorithms based on international guidelines for primary healthcare management of T2D and the updated Lesotho Standard Treatment Guidelines.~* Direct guidance for treatment initiation, drug prescription, counselling and monitoring will be provided via the ComBaCaL app.~* In case of complicated disease (i.e. if treatment targets are not reached with metformin alone), unclear diagnosis, relevant comorbidities or presence of clinical alarm signs or symptoms, participants will be referred to the closest health facility for further management."
62209443|NCT05743387|ACTIVE_COMPARATOR|Control villages|In control villages, CC-VHWs will refer participants to the responsible health facility for therapeutic management after enrolment and baseline assessment.
62209444|NCT02045420||Normal Participants|"The investigators will use normal age-matched volunteers to compare against the Idiopathic Parkinson's Disease Patients"
62209445|NCT02045420||Idiopathic Parkinson's Disease Patients|The investigators will observe the MR scans to determine the vascular flow, brain lesions and brain iron levels in this group.
62209446|NCT04548544|EXPERIMENTAL|TARA training|
62209447|NCT04548544|NO_INTERVENTION|Control|
62407049|NCT06566235|PLACEBO_COMPARATOR|Activities-based support group (ASG)|ASG, based on principles of client-centered supportive therapy, is widely used by occupational therapists in mental health settings. ASG therapists aim to foster a sense of belongingness, maintain unconditional positive regard, and provide empathy, psychoeducation, and a treatment structure. Two group leaders held the sessions; teaching DBT skills and using cognitive behavioral strategies are prohibited. Each session starts with a review of their experiences over the last week (30 min), a support-building activity (30 min), and ends with an open group discussion about topics participants choose each week (50 min). For homework, participants will be asked to think about issues discussed and to track daily social support on diary cards.
62582100|NCT04042701|EXPERIMENTAL|HER2-mutant NSCLC (Part 2 Dose Expansion)|HER2-mutant NSCLC participants who had not received any prior treatment with anti-PD-1, anti-PD-L1, or HER2 agents and received DS8201a at the RDE in combination with pembrolizumab 200 mg.
62582101|NCT06664099|EXPERIMENTAL|One Anastomosis Gastric Bypass at 150 cm from Duodenojejunal Junction|Participants in this arm will undergo One Anastomosis Gastric Bypass surgery with the bypass performed at a distance of 150 centimeters from the duodenojejunal junction. This approach aims to achieve weight loss while potentially minimizing nutritional deficiencies by utilizing a shorter bypass length. Postoperative outcomes will be monitored, focusing on weight loss, total weight loss percentage, excess weight loss percentage, and nutritional markers such as albumin, calcium, and iron levels.
62582102|NCT06664099|EXPERIMENTAL|One Anastomosis Gastric Bypass at 170 cm from Duodenojejunal Junction|Participants in this arm will undergo One Anastomosis Gastric Bypass surgery with the bypass performed at a distance of 170 centimeters from the duodenojejunal junction. This approach aims to balance effective weight loss and nutritional outcomes with an intermediate limb length. Postoperative outcomes will include measurements of weight loss, total weight loss percentage, excess weight loss percentage, and nutritional markers, such as albumin, calcium, and iron levels.
62209448|NCT06415149|EXPERIMENTAL|High power short duration ablation with 50 W|Group 1 (n=95): pulmonary vein isolation for treatment of atrial fibrillation was performed with power of 50 watts in Ia subgroup (n=55) AI (ablation index) was 400-450 arbitrary units (au) for the posterior wall and 500-550 au for the anterior wall, in Ib (n=40) AI was 400-450 au for the posterior wall and 450-500 au for the anterior wall.
62209449|NCT06415149|EXPERIMENTAL|High power short duration ablation with 45 W|Group 2 (n=90): Pulmonary vein islolation was performed at a power of 45 watts, in IIa subgroup (n=50) with target AI of 400-450 au for the posterior wall and 500-550 au for the anterior wall in IIb (n=40) AI of 400-450 au for the posterior wall and 450-500 au for the anterior wall.
62209450|NCT02819167|OTHER|neurologic and neuropsychological evaluation|
62209451|NCT02277353||All enrolled patients|This study enrolls patients undergoing elective spine surgery in prone position and all enrolled subjects may receive fluid loading with hemodynamic monitoring by Flotrac/Vigileo and NICOM, but the investigator does not assign specific interventions to the subjects of the study because this is a prospective observational study.
62209452|NCT02675647|EXPERIMENTAL|Intervention group|"Obese patients, randomized to receive an initial IV bolus of Heparin, before beginning of the cardiopulmonary bypass, at the dosage of 340 UI/kg based on ideal body weight of the obese patients.~The objective is to obtain an ACT target ≥ 400 s before the beginning of CPB. If necessary, additional boluses of heparin are administered at the dose of 100 UI/kg based on ideal body weight, to maintain this target during the CPB."
62209453|NCT02675647|ACTIVE_COMPARATOR|Control group|"Obese patients, randomized to receive an initial IV bolus of Heparin, before beginning of the cardiopulmonary bypass, at the usual dosage of 300 UI/kg based on total body weight of the obese patients.~The objective is to obtain an ACT target ≥ 400 s before the beginning of CPB. If necessary, additional boluses of heparin are administered at the dose of 100 UI/kg based on total body weight, to maintain this target during the CPB."
62209454|NCT05038800|EXPERIMENTAL|MK-0482 7.5 mg Q3W|Participants will receive 7.5 mg of MK-0482 via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks \[Q3W\]) for up to 35 cycles (approximately 24 months).
62209455|NCT05038800|EXPERIMENTAL|MK-0482 25 mg Q3W|Participants will receive 25 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).
62407050|NCT02495636|EXPERIMENTAL|Safety Run Up Group|The first 12 patients to be enrolled will initiate therapy with CDX-1401 alone, with the addition of MPDL3280A the day of their 4th CDX-1401 vaccination (week 7). These patients will undergo a tumor biopsy prior to initiation of trial therapy, after their 3rd CDX-1401 vaccination (during week 6) and after their 3rd MPDL3280A infusion (during week 14 or 15, if there are no dose delays). Although we don't expect significant synergistic toxicities of combination therapy based on mechanism of action/ formulation/ administration/ distribution of CDX-1401 and past vaccine/ immune checkpoint trials, these first 12 patients will constitute a safety run in group.
62018469|NCT03383432|OTHER|Trans-abdominal ultrasound intrauterine device group.|Those will be subjected to intrauterine device insertion under trans-abdominal ultrasound guidance. In this method the participant will be asked to have a full bladder. Full bladder helps to displace the bowel out of the pelvis and acts as an acoustic window for high frequency sound waves and to straighten the angle between the uterine body and cervix in anteverted uterus, performing the function of the tenaculum. Then, then ultrasound will be done and the intrauterine device will be introduced vaginally under ultrasound vision.
62209456|NCT05038800|EXPERIMENTAL|MK-0482 75 mg Q3W|Participants will receive 75 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).
62018470|NCT03383432|OTHER|Uterine Sounding Sparing intrauterine device group|The sonographer performs ultrasound using transvaginal probe to evaluate the uterine position and the endometrial length in the sagittal view of the uterus. The intrauterine device was inserted directly into the uterine cavity without using uterine sounding.
62209457|NCT05038800|EXPERIMENTAL|MK-0482 225 mg Q3W|Participants will receive 225 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).
62209458|NCT05038800|EXPERIMENTAL|MK-0482 750 mg Q3W|Participants will receive 750 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).
62209459|NCT02433574|EXPERIMENTAL|Neoadjuvant stereotactic body radiation|Single arm study. Four cohorts of 5 patients will undergo neo-adjuvant SBRT for lung cancer. Eligible patients will have operable, borderline resectable lung cancer , they will be treated with SBRT, prior to undergoing surgical resection.
62209460|NCT04695184|OTHER|ICG-NIRF Imaging|ICG-NIRF imaging is used intraoperatively to visualise precisely the blood supply and bowel perfusion rate in the area of ileal pouch formation and the ileal pouch-anal anastomosis.
62209461|NCT02079480|EXPERIMENTAL|Panel 1: BMS-986090 (0.5 mg) or Placebo|"BMS-986090 0.5 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
62407051|NCT02495636|EXPERIMENTAL|Expanded Trial Group|If there are no unexpected toxicities (no more than 3 of 12 patients with grade 3+ treatment related events as defined in 4.1.1), an additional 28 patients will be enrolled. Unlike the first 12 patients, these additional 28 patients will initiate both CDX-1401 and MPDL3280A on the same day, and will undergo tumor biopsies before starting trial therapy and after their 3rd CDX-1401 vaccination (during week 6).
62582103|NCT06664099|EXPERIMENTAL|One Anastomosis Gastric Bypass at 200 cm from Duodenojejunal Junction|Participants in this arm will undergo One Anastomosis Gastric Bypass surgery with the bypass performed at a distance of 200 centimeters from the duodenojejunal junction. This approach prioritizes maximizing weight loss but may carry a higher risk of nutritional deficiencies due to the longer bypass length. Postoperative outcomes will be evaluated for weight loss, total weight loss percentage, excess weight loss percentage, and nutritional markers, including albumin, calcium, and iron levels.
62582104|NCT05197569|NO_INTERVENTION|Control group|No intervention will be applied to the control group and the measurements will be recorded simultaneously.
62209462|NCT02079480|EXPERIMENTAL|Panel 2: BMS-986090 (3 mg) or Placebo|"BMS-986090 3 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
62209463|NCT02079480|EXPERIMENTAL|Panel 3: BMS-986090 (10 mg) or Placebo|"BMS-986090 10 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
62209464|NCT02079480|EXPERIMENTAL|Panel 4: BMS-986090 (30 mg) or Placebo + KLH (1 mg)|"BMS-986090 30 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once~And Keyhole limpet hemocyanin (KLH) 1 mg solution single intramuscular dose once"
62407052|NCT01988194|NO_INTERVENTION|Usual care|Participants will receive usual care in the hospital.
62407053|NCT01988194|EXPERIMENTAL|Usual care with acupuncture|Participants will receive usual care with acupuncture treatments up to four days per week for the duration of their hospital stay.
62407054|NCT00616889||1|Seroquel added to medication regime and sleep quality measured
62018471|NCT04279574|OTHER|CAD/CAM Onlays|Lithium disilicate chairside CAD/CAM onlays (IPS emaxCAD/Ivoclar) will be adhesively bonded using a selective enamel etch technique with an adhesive (3M) and cement (3M).
62018472|NCT04279574|OTHER|CAD/CAM Crowns|Full contour zirconia crowns (3M Chairside Zirconia/3M) will be cemented using a self-adhesive cement (3M).
62209465|NCT02079480|EXPERIMENTAL|Panel 5: BMS-986090 (100 mg) or Placebo + KLH (1 mg)|"BMS-986090 100 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once~And KLH 1 mg solution single intramuscular dose once"
62209466|NCT02079480|EXPERIMENTAL|Panel 6: BMS-986090 (100 mg) or Placebo|"BMS-986090 100 mg solution single dose intravenously once~OR~Placebo matching with BMS-986090 0 mg solution single dose intravenously once"
62209467|NCT02079480|EXPERIMENTAL|Panel 7: BMS-986090 (300 mg) or Placebo + KLH (1 mg)|"BMS-986090 300 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once~And KLH 1 mg solution single intramuscular dose once"
62209468|NCT02079480|EXPERIMENTAL|Panel 8: BMS-986090 (750 mg) or Placebo|"BMS-986090 750 mg solution single dose intravenously once~OR~Placebo matching with BMS-986090 0 mg solution single dose intravenously once"
62209469|NCT02079480|EXPERIMENTAL|Panel 9: BMS-986090 (150 mg) or Placebo|"BMS-986090 150 mg solution subcutaneously once weekly for 4 weeks~OR~Placebo matching with BMS-986090 0 mg solution subcutaneously once weekly for 4 weeks"
62209470|NCT03901482|EXPERIMENTAL|STS101 Low Dose|STS101 (dihydroergotamine nasal powder), low dose
62209471|NCT03901482|EXPERIMENTAL|STS101 High Dose|STS101 (dihydroergotamine nasal powder), high dose
62209472|NCT03901482|PLACEBO_COMPARATOR|STS101 Placebo|STS101 Placebo
62209473|NCT01935973|ACTIVE_COMPARATOR|Arm I (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.
62209474|NCT01935973|EXPERIMENTAL|Arm II (trametinib and Akt inhibitor GSK2141795)|Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62209475|NCT05689203|EXPERIMENTAL|QLS1128|QLS1128 will be administered orally for 5 days.
62209476|NCT05689203|PLACEBO_COMPARATOR|Placebo|Placebo matching to QLS1128 will be administered orally for 5 days.
62018473|NCT01690650|EXPERIMENTAL|Oxygen + Cerebral NIRS|Induced changes in oxygen supply (100% vs. room air). Continuously monitoring of cerebral oxygen saturation.
62018474|NCT02454426|EXPERIMENTAL|Open-Label Treatment|Patients will be initiated on vortioxetine 5 mg/day for 4 days, then increased to 10 mg/day. After the week 2 visit, patients will then be increased to 20 mg/day for the remainder of the study
62018475|NCT05051241|EXPERIMENTAL|Dose escalation Cohort 1|5 mg BID, 14d-on/14d-off
62018476|NCT05051241|EXPERIMENTAL|Dose escalation Cohort 2|10 mg BID, 14d-on/14d-off
62209477|NCT01173497|EXPERIMENTAL|INIPARIB, irinotecan|
62018477|NCT05051241|EXPERIMENTAL|Dose escalation Cohort 3|20 mg BID, 14d-on/14d-off
62018478|NCT05051241|EXPERIMENTAL|Dose escalation Cohort 4|30 mg BID, 14d-on/14d-off
62018479|NCT05051241|EXPERIMENTAL|Dose escalation Cohort 5|40 mg BID, 14d-on/14d-off
62018480|NCT05051241|EXPERIMENTAL|Dose escalation Cohort 6|50 mg BID, 14d-on/14d-off
62018481|NCT05051241|EXPERIMENTAL|Dose escalation Cohort 7|65 mg BID, 14d-on/14d-off
62209478|NCT03435679|EXPERIMENTAL|one-stage|one-stage surgical treatment of the infected knee arthroplasty
62209479|NCT03435679|ACTIVE_COMPARATOR|two-stage|two-stage surgical treatment of the infected knee arthroplasty with a interim period of 8-10 weeks between stages
62209480|NCT06728163|ACTIVE_COMPARATOR|Written Education|All procedures are conducted according to surgery protocol.Patients will receive education on the previous day before surgery, the surgery team will receive education from the previous day.The group receives written education to patients before surgery.
62209481|NCT06728163|EXPERIMENTAL|VR Educational Materials and Breathing Relaxation Language Intervention|All procedures are carried out in accordance with the surgical protocol of Severance Hospital. Patients will receive training from the research team on the surgical procedure they will undergo on the day before the operation. The group will receive VR training materials and Verbal (non-music)-guided breathtaking instructions via VR on the day before the operation.
62209482|NCT06728163|EXPERIMENTAL|VR Educational Materials and Breathing Relaxation Music Intervention|All procedures are performed in accordance with the surgical protocols of Severance Hospital. Patients will receive training from the research team on the surgical procedure they will undergo on the day before the operation. The group will receive VR training materials and music-guided bridging instructions via VR on the day before the operation.
62734495|NCT01717196|EXPERIMENTAL|DIFFERENT VOLUME ASPIRATION BIOPSY|The needle system was in all cases the 22 gauge EUS-FNA (Expect needle). After the puncture the stylet was removed, and we performed three punctures with a 22 G needle with both volume aspiration 10 and 20 cc and without syringe for each lesion. The sequence of different volume aspiration Biopsy/ FNA (10cc, 20cc, no aspiration) was randomly assigned by sealed envelope system.
62018482|NCT05051241|EXPERIMENTAL|Dose escalation Cohort 8|85 mg BID, 14d-on/14d-off
62018483|NCT05051241|EXPERIMENTAL|Dose escalation Cohort 9|85 mg BID, 7d-on/7d-off
62018484|NCT05051241|EXPERIMENTAL|Dose expansion Cohort 10|85 mg BID, 14d-on/14d-off
62018485|NCT04133935|EXPERIMENTAL|Laparoscopic Obturator Urethropexy|Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment
62209483|NCT06728163|EXPERIMENTAL|Written Educational Materials and Breathing Relaxation Music Intervention|All procedures are performed in accordance with the surgical protocols of Severance Hospital. Patients will receive training from the research team on the surgical procedure to be performed on the day before the operation. The group will receive written training materials and music-guided bridging instructions via VR on the day before the operation.
62209484|NCT01239459|EXPERIMENTAL|Severe impaired renal function|Subjects with severe renal impairment as defined by Cockroft-Gault formula
62209485|NCT01239459|EXPERIMENTAL|Normal renal function|Subjects with normal renal function as defined by Cockroft-Gault formula
62209486|NCT01778543||MAC|Participants with MAC and their family members.
62209487|NCT03520751|EXPERIMENTAL|Dose (8.87e11 vg/kg)|Three patients age 18-35 will receive intramuscular injection of recombinant AAV1 carrying a human NFT3 gene under the control of the tMCK promoter (scAAV1.tMCK.NTF3) distributed bilaterally between both limbs at a dose of 8.87e11 vg/kg.
62209488|NCT03778554|EXPERIMENTAL|Beta blocker treatment|"Treatment with beta blockers plus standard of care. Type and dosage according to treating cardiologist choice~* Bisoprolol up to a total dose of 10 mg daily~* Carvedilol up to a total dose of 50 mg daily~* Metoprolol succinate up to a total dose of 200 mg daily~* Nebivolol up to a total dose of 10 mg daily"
62209489|NCT03778554|NO_INTERVENTION|No beta blocker treatment|Standard care without beta blocker treatment
62209490|NCT03799835|ACTIVE_COMPARATOR|Arm A : control arm|"BCG therapy only~BCG therapy will be administered in two phases:~* induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)~* maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1)."
62209491|NCT03799835|EXPERIMENTAL|Arm B: experimental arm|"BCG therapy + administration of atezolizumab~1. BCG therapy will be administered in two phases:~   * induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)~  * maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1).~2. atezolizumab is administered by IV infusion every 3 weeks (21 \[± 2\] days) for 1 year (18 cycles as a maximum)."
62407055|NCT04895046|EXPERIMENTAL|Investigational Group|"Cycle 1-4 (cycle length 4 weeks): Niraparib 300 mg taken orally on days 1-21 and Dostarlimab 500 mg intravenously on day 1~Cycle 5 and above (cycle length 3 weeks): Niraparib 300 mg taken orally on days 1-21 and 1000 mg intravenously on day 1 of every other cycle"
62407056|NCT04441437|EXPERIMENTAL|Splint Group|1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month.
62407057|NCT04441437|PLACEBO_COMPARATOR|No-Splint Group|1-hour task-oriented training without wearing a customized dynamic hand splint, totally 15 times in a duration of one month.
62582105|NCT05197569|EXPERIMENTAL|Thyme oil group|After filling out the forms, thyme oil aromatherapy will be applied to the patients assigned to the experimental group .The oregano oil to be prepared must have a high carvacrol ratio. Thyme oil with a carvacrol ratio of at least 74% will be specific to each patient and will be given to the patient in the form of an inhaler stick. According to expert opinion; The patient's own room should be visited every 8 hours and the patient-specific inhaler stick should be sniffed into 8 breathing lungs. Each patient will use an inhaler stick for 5 days. Hemodynamic parameters (ph, CO 2, O 2 ) and Covid-19 symptoms will be measured before the intervention with the patient (pretest) and at the end of the 5th day (posttest). Vital signs will be measured and recorded three times a day in the patient's room at 08:00, 16:00 and 24:00.
62582106|NCT01741766|EXPERIMENTAL|Stretching Training|Whole body stretching exercises 3 times per wk for 8 weeks
62018486|NCT04133935|ACTIVE_COMPARATOR|Burch Urethropexy|Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
62018487|NCT01428492|EXPERIMENTAL|Part 1-Dose Escalation|GSK2110183 is administered in combination with bortezomib and dexamethasone until MTD is met.
62209492|NCT02409524|EXPERIMENTAL|Treatment|The treatment schedule of AlloVax includes: (1) Priming segment with ID injections of AlloStim on Days 0, 3, 7 and 10. (2) Vaccination segment with ID injections of AlloStim+CRCL on Days 14, 17, 21 and 24. (3) Activation segment with IV push infusion of AlloStim on Day 28. (4) Booster Segment with monthly (every 28 days) ID injections of CRCL alone beginning on Day 56. These injections will continue until all the vaccine is used or the death of the subject
62209493|NCT03214640|ACTIVE_COMPARATOR|Palpation with spinal block (Group C-P)|insertion will be identified by palpation using conventional landmarks (spinous process and iliac crest) for placement of spinal block for cesarean delivery
62209494|NCT03214640|ACTIVE_COMPARATOR|Palpation with neuraxial block (Group L-P)|the needle insertion site for the neuraxial block will be identified with palpation for labor analgesia, using the spinous process and iliac crest for reference
62407058|NCT03811652|EXPERIMENTAL|NSCLC-Sq/HNSCC|Patients with advanced or metastatic NSCLC-Sq or HNSCC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen (platinum-based for HNSCC). PDL-1 positive patients should have received previous PD-1 or PD-L1 inhibitor where available.
62407059|NCT03811652|EXPERIMENTAL|Small Cell Lung Cancer|Patients with advanced SCLC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen.
62407060|NCT03811652|EXPERIMENTAL|Colorectal Cancer|Patients with metastatic adenocarcinoma of the colon or rectum who have received and have progressed, or have documented intolerance, on prior thymidylate synthase inhibitor (eg, 5-fluorouracil (5-FU), capecitabine, raltitrexed, tegafur-uracil (UFT), irinotecan, and oxaliplatin for metastatic disease. If patients progress within 6 months of their last dose of adjuvant therapy this should be considered as a line of therapy in the metastatic setting. Patients with known RAS wildtype tumors must have received and progressed, or have documented intolerance, on anti-EGFR antibody. Patients with microsatellite instability-high or deficient mismatch repair tumors, must have received and progressed, or have documented intolerance on a PD-1 inhibitor, or PD-1 inhibitor plus cytotoxic T-lymphocyte antigen-4 inhibitor treatment where available.
62407061|NCT03811652|EXPERIMENTAL|Pancreatic Ductal Adenocarcinoma|Patients with unresectable, locally advanced or metastatic PDAC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior line of treatment.
62209495|NCT03214640|EXPERIMENTAL|Rivanna Accuro Ultrasound Device with spinal block (Group C-R)|insertion will be identified with Rivanna Accuro U/S device for placement of spinal block for cesarean delivery
62018488|NCT01428492|EXPERIMENTAL|Part 2- Pharmacokinetic/Pharmacodynamics Cohort|Once the MTD(s) has been determined, up to 9 subjects of the total enrolled in Part 2 will be entered in the Pharmacokinetic/Pharmacodynamic Cohort. Subjects will be enrolled in this cohort to explore whether exposure to GSK2110183 at dose identified in Part 1 is similar when GSK2110183 is administered alone or in combination with bortezomib and dexamethasone. The same relationship will be explored for bortezomib and dexamethasone when the two drugs are give alone or in combination with GSK2110183.
62209496|NCT03214640|EXPERIMENTAL|Rivanna Ultrasound Device with neuraxial block (Group L-R)|insertion will be identified with Rivanna Accuro U/S device for placement of neuraxial block (combined spinal epidural) for labor analgesia
62209497|NCT06055608|EXPERIMENTAL|(Group 1): Belatacept+Sirolimus group|Participants in this group will receive antithymocyte globulin (ATG) + steroid taper + belatacept + (tacrolimus bridge, day 0-14) with conversion to sirolimus (day 30 +/-14 days)
62209498|NCT06055608|ACTIVE_COMPARATOR|(Group 2): Tacrolimus + Mycophenolate Mofetil (MMF) group|Participants in this group will receive anti-thymocyte globulin (ATG) + steroid taper + tacrolimus + MMF
62209499|NCT06619860|EXPERIMENTAL|VX-993|Participants will be randomized to receive multiple doses of different dose levels of VX-993.
62209500|NCT06619860|ACTIVE_COMPARATOR|Pregabalin|Participants will be randomized to receive Pregabalin.
62209501|NCT02846272|EXPERIMENTAL|Observational cohort|Observing MRI changes in subjects.
62209502|NCT04227184|EXPERIMENTAL|Placebo/Trospium|Placebo first for 12 weeks followed by Trospium for 12 weeks.
62209503|NCT04227184|EXPERIMENTAL|Trospium/Placebo|Trospium first for 12 weeks followed by Placebo for 12 weeks
62209504|NCT03208036|EXPERIMENTAL|TDCS|TDCS offered concurrent with working memory focused cognitive training
62209505|NCT03208036|SHAM_COMPARATOR|Sham|Sham stimulation offered concurrent with working memory focused cognitive training
62209506|NCT03947697|PLACEBO_COMPARATOR|Control|Participants will receive stimulation only up to sensory level.
62209507|NCT03947697|EXPERIMENTAL|NMES|Participants will receive stimulation up to maximum tolerable level.
62209508|NCT03947697|PLACEBO_COMPARATOR|Resistance Training|Participants will receive exercise training with stimulation up to sensory level.
62209509|NCT03947697|EXPERIMENTAL|Resistance Training + NMES|Participants will receive exercise training with stimulation up to maximum tolerable intensity.
62209510|NCT04233762||Female Natural Cycle Group|Females with regular natural menstrual cycle.
62209511|NCT04233762||Female Oral Contraceptive Pill Group|Females taking the combined oral contraceptive pill.
62209512|NCT04233762||Male Group|Males with no history of anabolic steroid use.
62209513|NCT06188897|EXPERIMENTAL|Experimental group|The experimental group did the intervention, which consisted of self-stretching of the masticatory muscles. This stretch consisted of introducing three knuckles of the non-dominant hand between the incisors for two minutes while sitting
62209514|NCT06188897|PLACEBO_COMPARATOR|Control group|The control group was asked to introduce only two knuckles in the oral cavity and perform a mandibular occlusion, an intervention that serves as a simulated stretch in said group.
62209515|NCT06608147|EXPERIMENTAL|Experimental|
62209516|NCT04652960|EXPERIMENTAL|Treatment (duvelisib, nivolumab)|Patients receive duvelisib PO QD or BID on days 1-28 or days 1-14 and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo PET-CT or CT scan at baseline. Patients also undergo punch biopsy and collection of blood samples throughout the trial.
62209517|NCT06663592|ACTIVE_COMPARATOR|Control group A (conventional treatment)|Conventional treatment, including hot pack, stretching of the neck muscles, cervical isometrics exercise.
62209518|NCT06663592|EXPERIMENTAL|Experimental group B (Tensioning neural mobilization with addition to conventional treatment)|Median nerve neural tensioning mobilization with addition to conventional treatment
62209519|NCT06663592|EXPERIMENTAL|Experimental group C (Sliding neural mobilization with addition to conventional treatment)|Median nerve sliding neural mobilization with addition to conventional treatment
62407062|NCT03811652|EXPERIMENTAL|Metastatic Castration-Resistant Prostate Cancer|Patients with mCRPC who have received prior treatment with abiraterone or enzalutamide, with or without a prior taxane-based chemotherapy in the mCRPC setting.
62209520|NCT02570919|ACTIVE_COMPARATOR|IGRT 45 Gy in 5 fractions of 9 Gy|Arm A: Hypofractionated IGRT at a prescription dose of 45 Gy in 5 fractions of 9 Gy delivered in five consecutive days
62209521|NCT02570919|EXPERIMENTAL|IGRT 24 Gy single dose|Arm B: single fraction IGRT at a prescription dose of 24 Gy
62209522|NCT04613232|EXPERIMENTAL|Apple Watch|The research intervention is continuously monitoring of heart rate and physical activity (minimum 12h/day) with a smartwatch which is connected to a smartphone.
62209523|NCT02395029|EXPERIMENTAL|Injection of PMD-MSCs into the penis|Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based on ultrasound guided measurements of penile plaque(s) post treatment and on patient reported treatment satisfaction.
62209524|NCT03573076|EXPERIMENTAL|Thulium laser + photodynamic therapy|Non-ablative Thulium laser (NAFL) + Photodynamic therapy combination treatment
62209525|NCT03573076|EXPERIMENTAL|RF microneedles + photodynamic therapy|Radio-frequency microneedles (RF-MN) + Photodynamic therapy combination treatment
62209526|NCT03573076|ACTIVE_COMPARATOR|Non-ablative Thulium laser|Non-ablative Thulium laser (NAFL) single treatment
62209527|NCT03573076|ACTIVE_COMPARATOR|RF microneedles|Radio-frequency microneedles (RF-MN) single treatment
62209528|NCT03573076|NO_INTERVENTION|Control|Control receiving no intervention
62407063|NCT03811652|EXPERIMENTAL|Other advanced/metastatic target expressing solid tumors|Patients with advanced or metastatic solid tumors not defined by other treatment arms who have positive expression of the protein target and have exhausted all approved therapies
62582107|NCT01741766|NO_INTERVENTION|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 8 wk.
62018489|NCT01428492|EXPERIMENTAL|Part 2- Safety/Clinical Activity Cohort|"Enrolment into the safety/clinical activity cohort in Part 2 will begin prior to enrollment in the PK/PD cohort. Subjects with relapsed multiple myeloma who are either bortezomib sensitive or naive after failing one line of prior systemic therapy will be enrolled in the Safety/Clinical Activity cohort. Bortezomib sensitive is defined as having a response (PR or better) to the last bortezomib-containing therapy lasting at least 60 days beyond the end of therapy. A minimum of 15 subjects and a total of 40 subjects will be enrolled. This expansion cohort will further characterize the safety and clinical activity profile of GSK2110183 to inform the future development of this combination regimen."
62018490|NCT00127608|EXPERIMENTAL|Varicella Group|Subjects aged between 0 and 16 years of age, with clinically-diagnosed primary varicella disease.
62407064|NCT04891445|ACTIVE_COMPARATOR|As usual|"Patients will be directly referred to their family doctor with a report on the data obtained in the analysis (presence of HCV and positive viral load), so that they can follow the usual treatment (as usual) in these cases in the Andalusian Health Service.~The usual treatment implies, once the presence of Virus C has been confirmed, referral by the patient's family doctor to the specialized service, in this case the Gastroenterology Service of the referral Hospital, through the usual appointment procedure. Generally the delay in this process is usually approx. 2-3 months for the first appointment."
62407065|NCT04891445|EXPERIMENTAL|Nurse-Navigation Programme|"A Clinical Pathway (CP) of nursing monitoring will be activated, that is, patients will be accompanied throughout the evaluation and treatment process until their complete cure is guaranteed.~CP will include the activation of care in the Gastroenterology Service by the nurse. By requesting a first appointment in the Gastroenterology Service, via email, the nurse will activate the patients' access to this first appointment, which consist in a one-step intervention: liver evaluation analysis on the genotype, determine the most appropriate type of treatment and, dispensing treatment by the Hospital Pharmacy Unit. To guarantee attendance, in all cases the patient will be accompanied, either by a competent available family caregiver, or by the mental health nursing team.~All the intervention will be operationalized through the mentioned CP developed for this purpose, with the participation of those involved."
62407066|NCT02230332|EXPERIMENTAL|Alendronate|Alendronate in 10mg capsules taken once daily
62407067|NCT02230332|PLACEBO_COMPARATOR|Placebo|Placebo capsule taken once daily
62407068|NCT01015118|EXPERIMENTAL|BIBF 1120|patients to receive BIBF 1120 standard dose twice daily PO in combination with combination with carboplatin and paclitaxel
62407069|NCT01015118|PLACEBO_COMPARATOR|Placebo|patients to receive capsules identical to those containing BIBF 1120 in combination with combination with carboplatin and paclitaxel
62407070|NCT03217474|EXPERIMENTAL|FLDEB combined with GCV orally|Femtosecond laser-assisted cornea debridement (FLDEB) combined with ganciclovir (GCV) orally.
62407071|NCT03217474|ACTIVE_COMPARATOR|GCV orally|Ganciclovir (GCV) orally only
62407072|NCT01092676|ACTIVE_COMPARATOR|Regular Ibuprofen Dosing|Regular Ibuprofen Dosing throughout 4 days of study
62407073|NCT01092676|ACTIVE_COMPARATOR|PRN Ibuprofen dosing|As needed Ibuprofen dosing
62407074|NCT04837586|ACTIVE_COMPARATOR|Standard Care|Individuals in this arm will receive standard care for their obesity in the Pediatric Weight Management Clinic
62407075|NCT04837586|ACTIVE_COMPARATOR|Simple Scale|Individuals in this arm will receive standard care for their obesity in the Pediatric Weight Management Clinic and will be encouraged to self-weigh daily utilizing a simple scale.
62407076|NCT04837586|ACTIVE_COMPARATOR|EHR-Connected Scale|Individuals in this arm will receive standard care for their obesity in the Pediatric Weight Management Clinic and will be encouraged to self-weigh daily utilizing a Smart scale that is connected to the Electronic Health Record (EHR).
62407077|NCT03984994|EXPERIMENTAL|Aerobic exercise training followed by resistance training|Participants in this arm will undergo 3 months of aerobic exercise training, followed by 3 months of strength training
62407078|NCT03984994|ACTIVE_COMPARATOR|Resistance training followed by aerobic exercise training|Participants in this arm will undergo 3 months of strength training, followed by 3 months of aerobic exercise training
62407079|NCT01412307|EXPERIMENTAL|lenalidomide plus bendamustine|
62407080|NCT03716830|EXPERIMENTAL|verum acupuncture + real tDCS|
62407081|NCT03716830|EXPERIMENTAL|sham acupuncture + real tDCS|
62407082|NCT03716830|EXPERIMENTAL|verum acupuncture + sham tDCS|
62407083|NCT03716830|SHAM_COMPARATOR|sham acupuncture + sham tDCS|
62407084|NCT02837666|ACTIVE_COMPARATOR|Exercise group and supplementation|Supplementation with Spirulina maxima Supplementation with placebo Group with exercise program and supplementation with Spirulina maxima or placebo (4.5 g/d) in capsules during 6 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 6 more weeks. During the 14 weeks of study duration every participant will have a personal isoenergetic diet.
62735044|NCT04417283||Mother-infant dyads|Mother and/or infant participants will provide a series of biological specimens, including blood, urine, and microbiome samples. Additionally, each participant will wear a silicone wrist band each trimester to capture environmental exposures and will fill out study surveys related to diet, environmental exposures, and social factors.
62582108|NCT05933174|EXPERIMENTAL|Prompt-sheet|Question-prompt group patients will receive a simple prompt sheet with the questions with which they will encouraged to use to guide a conversation with their provider at their next visit for routine diabetes care. These questions are based on recommendations from the Agency for Healthcare Research and Quality's Question Builder App and also on recommendations from the Canadian Deprescribing Network which specifically addresses SU use.
62582109|NCT05933174|ACTIVE_COMPARATOR|Usual education|Control group patients will be sent an information brochure with content from the NIDDK about diabetes medications (https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments).
62582110|NCT05339711|EXPERIMENTAL|Robotic Pet Therapy/Robot Cat Group|"In the robot cat group, the patients were given face-to-face personal information about the robot cat for about 15 minutes in the waiting room by the researcher, and the Robot Cat Information Brochure was given. Therefore, in this study, the patients interacted with the robot cat Silver for 20 minutes during the hemodialysis session once a week for eight weeks (two months) under the supervision of the researcher. After eight weeks of robotic pet therapy in the hemodialysis unit, this group of patients was followed up by the researcher with the same applications, without robotic pet therapy for eight more weeks. Data collection tools were applied to this group of patients before the study. Again, in the last week of the 1st, 2nd, 3rd and 4th months of the study, all other data collection tools were applied, except the Structured Patient Information Form."
62582111|NCT05339711|EXPERIMENTAL|Pet Therapy/Betta Fish Group|"In the Betta fish group, the patients were given a 15-minute hands-on, face-to-face, individual information about Betta fish care in the waiting room by the researcher, and a Betta Fish Information Brochure was given to the patients. Then, the patients were asked to take care of the fish given to them at home for two months.This group of patients was given pet therapy for eight weeks, and then followed by the researcher with the same practices for another eight weeks without pet therapy. In order to observe or measure the positive effects of fish on patients, patients should spend at least 10 minutes with fish during the day (52). Data collection tools were applied to this group of patients before the study. Again, in the last week of the 1st, 2nd, 3rd and 4th months of the study, all other data collection tools were applied, except the Structured Patient Information Form."
62582112|NCT05339711|NO_INTERVENTION|Control Group|"This group of patients was only informed about the study and received routine hemodialysis treatment. The patients were followed for four months. Data collection tools were applied to the patients before the study. Again, in the last week of the 1st, 2nd, 3rd and 4th months of the study, all other data collection tools were applied, except the Structured Patient Information Form."
62582113|NCT06336655|EXPERIMENTAL|With LV Unloading|Patients on VA ECMO who randomize to receive LV unloading
62407085|NCT02837666|ACTIVE_COMPARATOR|No exercise group and supplementation|Supplementation with Spirulina maxima Supplementation with placebo Group without exercise program and supplementation with Spirulina maxima or placebo (4.5 g/d) in capsules during 6 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 6 more weeks. During the 14 weeks of study duration every participant will have a personal isoenergetic diet.
62018491|NCT05454293|EXPERIMENTAL|OTAAT|This group will receive the One Talk at a Time curriculum.
62407086|NCT04066101||high caries risk|100 adults will be allowed in the high caries risk group according to DMFT index (DMFT ≥ 14)
62407087|NCT04066101||low caries risk|100 adults will be allowed in the low caries risk group according to DMFT index (DMFT ≤ 5)
62407088|NCT02736006|EXPERIMENTAL|20 meters air dive|
62407089|NCT04833569|EXPERIMENTAL|Indocyanine green mediated photodynamic therapy (ICG-PDT)|Delivery of ICG solution at a concentration of 1 mg/mL will be used. The photosensitizer will be applied until the bottom of the peri-implant pocket using a 1 ml syringe. An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J will be used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction.
62407090|NCT04833569|PLACEBO_COMPARATOR|Peri-implant mechanical debridement|Non-surgical peri-implant mechanical debridement (PIMD) through ultrasonic device with a carbon tip.
62018492|NCT05454293|ACTIVE_COMPARATOR|Parent-Child Communication|This group will receive a curriculum focused on tips and strategies for navigating difficult topics with one's children such as current events and dating.
62018493|NCT00306228|ACTIVE_COMPARATOR|bare-metal stent without tirofiban|implantation of a bare-metal stent with no tirofiban infusion after fibrinolysis
62407091|NCT04756466|PLACEBO_COMPARATOR|Control group|Control group that will receive a daily placebo capsule consisting of maltodextrin during 3 months
62407092|NCT04756466|EXPERIMENTAL|Probiotic group|Experimental group that will receive one capsule with the probiotic strain per day (3x10 9 CFU / day) during 3 months
62407093|NCT02585375|EXPERIMENTAL|Patients with glaucoma or ocular hypertension 1|35 patients with glaucoma or ocular hypertension
62407094|NCT02585375|ACTIVE_COMPARATOR|Patients with glaucoma or ocular hypertension 2|35 patients with glaucoma or ocular hypertension
62407095|NCT00817427|NO_INTERVENTION|Baseline|CKD subjects and healthy, matched controls will have measures of cardiovascular function (BP, HR) measure of hormonal fluid balance (renin/aldosterone) measure and measures of glucose metabolism (response to glucose load and over 24 hr profile) with 3 days of habitual sleep time
62407096|NCT00817427|EXPERIMENTAL|CKD- Sleep extension|Measures as in baseline but with bed time increased by 2 hours
62407097|NCT00817427|EXPERIMENTAL|Controls short sleep|Measures as in baseline but with sleep disruption
62407098|NCT03497000|EXPERIMENTAL|OCTA group|Patients in this group underwent OCTA-guided half-dose photodynamic therapy.
62018494|NCT00306228|ACTIVE_COMPARATOR|bare-metal stent with tirofiban|implantation of a bare-metal stent with tirofiban infusion after fibrinolysis
62018495|NCT00306228|ACTIVE_COMPARATOR|paclitaxel-eluting stent without tirofiban|implantation of a paclitaxel eluting-stent with no tirofiban after fibrinolysis
62018496|NCT00306228|ACTIVE_COMPARATOR|paclitaxel-eluting stent with tirofiban|implantation of a paclitaxel eluting-stent with tirofiban infusion after fibrinolysis
62018497|NCT02240082|EXPERIMENTAL|Web-based COPing with Shiftwork Program|Participants in this condition will use the web-based COPing with Shiftwork web-based program for three months
62018498|NCT02240082|NO_INTERVENTION|Wait List Control|Participants in the wait list control group will not receive any intervention during the study period, but will have access to any program offered by the police department.
62209529|NCT06727565|EXPERIMENTAL|Substudy-01:Treatment Group A: Domvanalimab (DOM) + Zimberelimab (ZIM) + Platinum-based Chemotherapy|Participants will receive DOM + ZIM + platinum-based chemotherapy (paclitaxel + carboplatin).
62209530|NCT06727565|EXPERIMENTAL|Substudy-01: Treatment Group B: Zimberelimab (ZIM) + Platinum-based Chemotherapy|Participants will receive ZIM + platinum-based chemotherapy (paclitaxel + carboplatin).
62209531|NCT00952055||Patients diagnosed with acute coronary syndrome (ACS)|
62209532|NCT00763776|OTHER|1|Liver transection by clamp crushing technique
62209533|NCT00763776|OTHER|2|Liver transection by the ultrasonic dissector
62209534|NCT06727500|EXPERIMENTAL|pre-PHV HIIT plus plyometric training|Twelve weeks, three times per week of HIIT plus plyometric training in a sample of obese pre-APHV (initial biological maturational stage).
62407099|NCT03497000|ACTIVE_COMPARATOR|ICGA group|Patients in this group underwent normal ICGA-guided half dose photodynamic therapy.
62790112|NCT01222780|EXPERIMENTAL|Marqibo|"Marqibo® (Vincristine sulfate liposomal) will be administered intravenously over 60 minutes (±10 minutes) every 7 days (±3 days) (Days 1, 8, 15, 22) for four doses (1 cycle). Cycles may be repeated every 28 days for a maximum of 6 cycles; additional cycles may be offered with evidence of acceptable toxicity and clinical benefit.~* The trial follows a rolling phase I design with 2 to 6 subjects per dose level and standard definitions of MTD and DLT. At the MTD, a total of 6 additional subjects with relapsed or refractory ALL will be evaluated.~* Detailed pharmacokinetic studies will be performed during the first treatment cycle"
62790113|NCT05696886|ACTIVE_COMPARATOR|Group A received Pethidine alone in the period between January 2021 and December 2021,|received Pethidine alone in the period between January 2021 and December 2021, while
62407100|NCT00061568|EXPERIMENTAL|Participants with Severe Beta-globin Disorders in Allogeneic Peripheral Blood Stem Cell Transplants|Nonmyeloablative transplant regiment, consisting of alemtuzumab (1 mg/kg in divided doses), total-body irradiation (300 cGy), sirolimus, and infusion of unmanipulated filgrastim mobilized peripheral blood stem cells from human leukocyte antigen-matched siblings.
62407101|NCT00061568|EXPERIMENTAL|Human Leukocyte Antigens (HLA) Matched Related Stem Cell Donor|Participants received Filgrastim to mobilize peripheral blood stem cells for apheresis collection. Collected stem cells of donor will then be infused to HLA matched sibling.
62407102|NCT04720976|EXPERIMENTAL|JAB-3312+Pembrolizumab dose escalation|Dose escalation
62407103|NCT04720976|EXPERIMENTAL|JAB-3312+ Binimetinib dose escalation|Dose escalation
62407104|NCT04720976|EXPERIMENTAL|JAB-3312+Pembrolizumab dose expansion|Dose expansion
62407105|NCT04720976|EXPERIMENTAL|JAB-3312+Binimetinib dose expansion|Dose expansion
62407106|NCT04720976|EXPERIMENTAL|JAB-3312+Sotorasib dose escalation|Dose escalation
62407107|NCT04720976|EXPERIMENTAL|JAB-3312+ Osimertinib dose escalation|Dose escalation
62407108|NCT04720976|EXPERIMENTAL|JAB-3312+ Sotorasib dose expansion|Dose expansion
62407109|NCT04720976|EXPERIMENTAL|JAB-3312+ Osimertinib dose expansion|Dose expansion
62407110|NCT00090259|EXPERIMENTAL|Losartan 50 mg|50-mg losartan tablet administered daily with 1 tablet of 100-mg losartan placebo beginning Week 1 and continuing to end of study (up to 4 years)
62790114|NCT05696886|ACTIVE_COMPARATOR|Group B got Tramadol with pethidine in the period between January 2022 and December 2022.|Group B got Tramadol with pethidine in the period between January 2022 and December 2022.
62790115|NCT00412243|EXPERIMENTAL|Clofarabine + Cyclophosphamide|Clofarabine 40 mg/m\^2 daily for 3 Days + Cyclophosphamide starting 200 mg/m\^2 every 12 hours for 3 days
62790116|NCT01068002||Control, normotensive, pregnancy|Control, normotensive, pregnancy
62018499|NCT02842567|EXPERIMENTAL|TREATED GROUP|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks.
62018500|NCT02842567|PLACEBO_COMPARATOR|PLACEBO GROUP|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
62790117|NCT01068002||hypertension, pregnancy, no treatment|hypertension, pregnancy, no treatment
62790118|NCT01068002||hypertension, pregnancy, drug treatment|hypertension, pregnancy, drug treatment
62018501|NCT06024447|OTHER|Stage III and Stage IV Periodontitis|Subgingival Instrumentation will be performed in patients with Stage III and Stage IV periodontitis.
62209535|NCT06727500|EXPERIMENTAL|post-APHV HIIT plus plyometric training|Twelve weeks, three times per week of HIIT plus plyometric training in a sample of obese post-APHV (final biological maturational stage).
62209536|NCT06727500|ACTIVE_COMPARATOR|pre-APHV HIIT|Twelve weeks, three times per week of HIIT in a sample of obese pre-APHV (initial biological maturational stage).
62209537|NCT06727500|ACTIVE_COMPARATOR|post-APHV HIIT|Twelve weeks, three times per week of HIIT in a sample of obese post-APHV (initial biological maturational stage).
62209538|NCT05586477|OTHER|Intervention Order (Placebo - Diphenhydramine)|On separate days, participants will march on a treadmill for 60 minutes at a fixed rate of oxygen consumption (\~1.75 liters of oxygen consumption per minute) in \~28°C and 30% relative humidity
62209539|NCT05586477|OTHER|Intervention Order (Diphenhydramine -Placebo)|On separate days, participants will march on a treadmill for 60 minutes at a fixed rate of oxygen consumption (\~1.75 liters of oxygen consumption per minute) in \~28°C and 30% relative humidity
62209540|NCT05540613|SHAM_COMPARATOR|Health Education|A 26 weeks brain health and general health education program with two 1.5-hour sessions weekly.
62209541|NCT05540613|ACTIVE_COMPARATOR|Conventional Exercise|A 26 weeks Conventional Exercise training with two 1.5-hour sessions weekly.
62209542|NCT05540613|EXPERIMENTAL|Tai Chi|A 26 weeks Tai Chi training with two 1.5-hour sessions weekly.
62209543|NCT06558344|EXPERIMENTAL|BI 1569912 (low dose)|
62209544|NCT06558344|EXPERIMENTAL|BI 1569912 (medium dose)|
62407111|NCT00090259|EXPERIMENTAL|Losartan 150 mg|Titrated losartan administration up to daily 150-mg losartan: Week 1, daily 50-mg losartan tablet coadministered with 100-mg losartan placebo; Week 2, daily 50-mg losartan placebo coadministered with 100-mg losartan; Week 3 to end of study (up to 4 years), daily 50-mg losartan tablet coadministered with 100-mg losartan
62407112|NCT03514446|EXPERIMENTAL|Antibiotic therapy duration for 7 days|
62790119|NCT01487265|EXPERIMENTAL|BKM120 and Erlotinib|"Cycle 1: BKM120 80 mg PO daily; Erlotinib 100mg PO daily~Cycles 2 and beyond: BKM120 100 mg PO daily; Erlotinib 100mg PO daily"
62018502|NCT02266238|EXPERIMENTAL|Group 1|DSA guided percutaneous balloon dilatation to expand the stenosis of arteriovenous fistula
62018503|NCT02266238|EXPERIMENTAL|Group 2|Ultrasound guided percutaneous balloon dilatation to expand the stenosis of arteriovenous fistula
62018504|NCT02266238|EXPERIMENTAL|Group 3|Surgical reconstruction of the stenosis to reconstruction the lumen of arteriovenous fistula
62018505|NCT01224041|EXPERIMENTAL|Tacrolimus group|
62790120|NCT01504412|EXPERIMENTAL|DS-5565 Low Dose|DS-5565 10mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
62407113|NCT03514446|NO_INTERVENTION|Antibiotic therapy duration for 14 days|
62407114|NCT03669627|ACTIVE_COMPARATOR|Group 1: aTIV primer, QIV booster|Two doses (0.25 mL) aTIV (FLUAD )received one month apart in year 1. One dose (0.5 mL) QIV (Fluzone) received as booster in year 2.
62407115|NCT03669627|OTHER|Group 2: QIV primer, QIV booster|"Standard of care control group:~Two doses (0.5 mL) QIV (Fluzone) received one month apart in year 1. One dose (0.5 mL) QIV (Fluzone) received as booster in year 2."
62407116|NCT03669627|EXPERIMENTAL|Group 3: aTIV primer, aTIV booster|"This arm is experimental in that some participants will be receiving the MF59-adjuvanted TIV (FLUAD) in year two of the study, after the age of two years, which is off label.~Two doses (0.25 mL) TIV (FLUAD) received one month apart in year 1. One dose (0.25 mL) TIV (FLUAD) received as booster in year 2."
62407117|NCT01082601||Optimal Medical therapy|Subjects with Class I,IIor III congestive heart failure on optimal medical therapy. Planned catheter ablation for paroxysmal or persistent atrial fibrillation. Paroxysmal AF defined as recurrent AF(2 or more episodes in one month) that terminate within seven days. Persistent AF defined as sustained beyond seven days, or lasting less than seven days but requiring pharmacologic or electrical cardioversion.
62407118|NCT03500237|EXPERIMENTAL|Team-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will provide support within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.
62407119|NCT03500237|ACTIVE_COMPARATOR|Self-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no psychological intervention will be provided. A team member from the Unit will contact the participant only if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms).
62407120|NCT02928991|EXPERIMENTAL|Acquired Aplastic Anemia (AA)|Patients with severe or very severe acquired aplastic anemia (AA). Patients will receive a matched related donor bone marrow transplant following reduced intensity conditioning (RIC) including thymoglobulin (ATG), fludarabine and dose-reduced cyclophosphamide.
62582114|NCT06336655|NO_INTERVENTION|Without LV Unloading|Patients on VA ECMO who randomize to receive no LV unloading
62735045|NCT00082368|EXPERIMENTAL|PET (positron emission imaging) Imaging with Tc-94m Sestamibi|PET sestamibi scans followed by tariquidar and repeat imaging
62018506|NCT04870567|ACTIVE_COMPARATOR|High dose rate brachytherapy|After spinal anesthesia steel or plastic needle placement performed under TRUS guidance. Pre- and post-insertion ultrasound based planning is obligatory in all cases. Two fractions of 13Gy are delivered with 2 separate implantations and 2-3 weeks interval. The CTV was defined as the prostate capsule with 1mm (low-risk) - 3 mm (intermediate risk) expansion plus proximal 1/3 of seminal vesicles. The PTV was equal to CTV. The rectum, bladder and urethra are contoured as organs at risk. The dosimetry plan objectives are the following: prostate D90 - above 104% and V100% - above 92%; urethra D10 \< 110% , rectum D2cc\<75% (below 75Gy EQD2).
62018507|NCT04870567|EXPERIMENTAL|Stereotactic ablative radiotherapy|"Before SBRT three fiducial markers are obligatory inserted into the prostate.Planning MRI on diagnostic table with subsequent fusing with simulation CT is obligatory. CTV to planning target volume (PTV) expansion was 3-5 mm in all direction except posteriorly (in the direction of the rectum) where it is 1-3 mm. Dose must be delivered as 5 fraction of 7.25Gy. V100% for PTV ≥ 95%. Main dose constraints are as follows: D 2cm³ ≤ 36Gy for rectum (below 75Gy EQD2)., V 37.5 Gy \<5 cm³ for bladder, V 20 Gy \<10 cm³ for femoral heads. Androgen deprivation therapy is not permitted.~All treatments must be performed on conventional linear accelerators with cone beam CT guidance before each fraction, intrafractional motion monitoring is optional."
62018508|NCT04297878|EXPERIMENTAL|Group A|Taking two SsK12 lozenges at night on days 1, 7 and 14.
62735046|NCT03528876|OTHER|Single arm intervention study|Biweekly FOLFOX for two cycles alternating with FOLFIRI for two cycles (FOLFOX-FOLFIRI)
62790121|NCT01504412|EXPERIMENTAL|DS-5565 Middle Dose|DS-5565 20mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
62790122|NCT01504412|EXPERIMENTAL|DS-5565 High Dose|DS-5565 30mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
62790123|NCT01504412|PLACEBO_COMPARATOR|Placebo|DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day.
62790124|NCT01504412|ACTIVE_COMPARATOR|Pregabalin|Pregabalin capsules 300mg/day administered in 2 doses
62018509|NCT04297878|ACTIVE_COMPARATOR|Group B|One SsK12 daily at night for 14 days.
62018510|NCT06126562|EXPERIMENTAL|Lanifibranor 800 mg|"In Part A, lanifibranor 800 mg is given as a single dose (followed by 14 days follow-up).~In Part B, lanifibranor 800 mg is given once daily for 7 consecutive days (followed by 7 days follow-up)."
62018511|NCT06126562|EXPERIMENTAL|Lanifibranor 120 mg|"In Part A, lanifibranor 1200 mg is given as a single dose (followed by 14 days follow-up).~In Part B, lanifibranor 1200 mg is given once daily for 7 consecutive days (followed by 7 days follow-up)."
62018512|NCT04020731|EXPERIMENTAL|Right-handed healthy volunteers|Magnetoencephalography (MEG) records
62018513|NCT04287062|PLACEBO_COMPARATOR|Placebo|Placebo sleep medication (2 placebo oral capsules)
62018514|NCT04287062|ACTIVE_COMPARATOR|Suvorexant|Sleep medication (20mg suvorexant; 2 10mg capsules; patients can self-titrate to 1 10mg capsule)
62209545|NCT06558344|EXPERIMENTAL|BI 1569912 (high dose)|
62790125|NCT03742583|ACTIVE_COMPARATOR|Square Knot|
62018515|NCT04408963|EXPERIMENTAL|Group 1: CAP256V2LS (5 mg/kg IV)|CAP256V2LS (5 mg/kg) administered by intravenous (IV) infusion (Day 0)
62209546|NCT06558344|PLACEBO_COMPARATOR|Placebo matching BI 1569912|
62407121|NCT02928991|EXPERIMENTAL|Inherited Bone Marrow Failure Syndrome + Trilineage Aplasia|Patients with inherited bone marrow failure (iBMF) syndromes with trilineage aplasia includes those with diagnoses of Fanconi Anemia, Dyskeratosis Congenita, and related conditions. Patients will receive a matched related donor bone marrow transplant following conditioning with fludarabine, cyclophosphamide, thymoglobulin.
62407122|NCT02928991|EXPERIMENTAL|Inherited Bone Marrow Failure Syndrome no Trilineage Aplasia|Patients with inherited bone marrow failure (iBMF) syndromes without trilineage aplasia includes those with diagnoses of Severe Congenital Neutropenia, Diamond-Blackfan Anemia, and related conditions. Patients will receive a matched related donor bone marrow transplant following conditioning with thymoglobulin, busulfan and fludarabine.
62407123|NCT04216992||Three dimensional-rotational epidurography (3D-RE)|3D-RE is obtained on a commercial digital bi-plane angiography system. Reconstruction time was 30 seconds. Detailed information regarding technical performance and reconstruction procedure has been reported. Postprocessing techniques provided by the software included real-time 3D volume rendering and multiplanar reformatting. Real-time 3D volume rendering creates a 3D model of the examined object. The software allows emphasizing bony structures or soft tissue by changing intensity, brightness, and opacity of different X-ray structures. Additionally, rotation of the 3D object in all directions is possible, as is a virtual stereoscopic view provided by the software in combination with special glasses. The multiplanar reformatting modus generates virtual sections according to the three main axes and free defined axes. The section planes can be freely chosen, and curved sectioning is also possible.
62407124|NCT04666870||axis length|1007 healthy students with moderate to high myopia (SE ≤ -4.00D) and 894 without myopia (-0.50D ≤ spherical power ≤ +2.00D) were enrolled.
62407125|NCT04666870||gender|male were 54.29% (N=1032), and female were 45.71% (N=869)
62407126|NCT06135272|ACTIVE_COMPARATOR|Group A|Resin infiltration
62407127|NCT06135272|EXPERIMENTAL|Group B|Resin modified glass ionomer varnish
62582115|NCT04842825|EXPERIMENTAL|kidney-tonifying and blood-regulating herbs treatment group|the treatment group will receive sequential treatment with the Chinese herbal formula for tonifying the kidney, nourishing the blood, and activating the blood 2 months before the proposed ET to regulate menstruation and improve ovarian reserve function. Treatment with the Chinese herbal formula will continue on the 5th day of menstruation after entering the super-ovulation cycle.
62582116|NCT04842825|ACTIVE_COMPARATOR|Western medicine group|The control group will be treated with conventional Western medicine
62582117|NCT05719883|EXPERIMENTAL|Maurora® Sirolimus Eluting Stent System|Device: Maurora® Sirolimus Eluting Stent System A sirolimus eluting intracranial stent system with platform is made of L605 CoCr alloys.
62582118|NCT05719883|ACTIVE_COMPARATOR|APOLLO™ Intracranial Stent System|Device: Apollo Intracranial Stent System A 316L stainless steel balloon-expandable intracranial stent system.
62790126|NCT03742583|ACTIVE_COMPARATOR|Reversing Half-Hitch Alternating Post Knot|
62018516|NCT04408963|EXPERIMENTAL|Group 2: CAP256V2LS (5 mg/kg SC)|CAP256V2LS (5 mg/kg) administered by subcutaneous (SC) injection (Day 0)
62018517|NCT01278524||Critically ill patients|Patients staying in the ICU on the 25th of January
62018518|NCT04787666|EXPERIMENTAL|the first group: non-invasive mask ventilation|Dinamika of the indicator p/F Ratio
62018519|NCT04787666|EXPERIMENTAL|the second group:high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation)|Dinamika of the indicator p/F Ratio
62018520|NCT04787666|EXPERIMENTAL|the third group:non-invasive ventilation with a helmet|Dinamika of the indicator p/F Ratio
62209547|NCT06578741|OTHER|Single Arm|Treatment with GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
62209548|NCT04285398|OTHER|Study Group 1|Four years follow up of patients with ophthalmic examination.
62018521|NCT01621841||Glaucoma subjects|
62018522|NCT01621841||heathly subjects|
62209549|NCT04285398|OTHER|Study Group 2|Four years follow-up of patients with ophthalmic examination and mobility testing.
62018523|NCT06531447|ACTIVE_COMPARATOR|Control group|Doxorubicin 60mg/m2(Adriblastin) plus Cyclophosphamide 600mg/m2 (endoxan) IV, on 1st days every 3 weeks of 4 cycles. Paclitaxel (Taxol) 80mg/m2, IV every week of 12 cycles or 175mg/m2, IV, on 1st days every 3 weeks of 4 cycles.
62018524|NCT06531447|ACTIVE_COMPARATOR|Experimental group|1250 mg/m2 Gemcitabine 1st and 8th days of 6 cycles and 75mg/m2 Cisplatine 1st day every 3 weeks of 6 cycles
62018525|NCT01793857||Study Group|Approximately 1300 primary caregivers of at least one child aged 6 months to less than 30 months who were interviewed during a clinic visit in Panama.
62209550|NCT01249807||1|Patients, Family, Community member
62209551|NCT02324400|ACTIVE_COMPARATOR|Treatment|
62209552|NCT02324400|SHAM_COMPARATOR|Control|
62209553|NCT03632941|ACTIVE_COMPARATOR|VRP-HER2 Vaccine|VRP-HER2 Vaccine 4 x 10EE8 IU given as a single injection every 2 weeks for 3 injections total (Cycle 1: Day 1 and Day 15 Cycle 2: Day 8)
62407128|NCT06135272|EXPERIMENTAL|Group C|Light cured giomer varnish
62407129|NCT02341573|EXPERIMENTAL|chinese medicine group|Children of chinese medicine group will be treated with experienced chinese herbal formula based on different stages and different symptoms.Patients at the acute stage of asthma will be given Shegan mixture ,at the remission stage, will be treated with Huangqi Bushen mixture-based formulation with modification according to their symptoms,10-30 mL , 2 times a day, for 3 months.
62790127|NCT05819697||FIRE Trial Participants|This study only has one group. All participants will receive the same intervention (smart phone app/texting notifications).
62209554|NCT03632941|ACTIVE_COMPARATOR|Pembrolizumab|5 administrations of Pembrolizumab 200 mg every 3 weeks for 5 total IV infusions (Day 1 of each 3 week cycle x 5 cycles)
62209555|NCT03632941|EXPERIMENTAL|VRP-HER2 Vaccine + Pembrolizumab|VRP-HER2 Vaccine 4 x 10EE8 IU given as a single injection every 2 weeks for 3 injections total (Cycle 1: Day 1 and Day 15 Cycle 2: Day 8)+ 5 administrations of Pembrolizumab 200 mg every 3 weeks for 5 total IV infusions (Day 1 of each 3 week cycle x 5 cycles)
62209556|NCT04958642|EXPERIMENTAL|Adrabetadex|All participants receive their prescribed dose of adrabetadex. Dose is allowed to be adjusted down to a minimum of 400 milligrams (mg) or up to a maximum of 900 mg, at the investigator's discretion.
62209557|NCT01202903|EXPERIMENTAL|Omalizumab|Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 mL vial that was designed to deliver 150 mg of omalizumab for subcutaneous administration upon reconstitution with 1.4 mL sterile water for injection. The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
62209558|NCT01202903|PLACEBO_COMPARATOR|Placebo|The placebo was the same mixture of inactive excipients, in quality and quantity, as those used for the drug product. The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
62209559|NCT06727578|EXPERIMENTAL|Treatment|
62209560|NCT02531945|EXPERIMENTAL|Intervention|"The device used in this research to the topography examination is three-dimensional morphometry device of AXS Medical society : the BIOMOD L.~'Use of Biomod device' for all the patient in addition to the conventional X-ray examination."
62209561|NCT06557850|EXPERIMENTAL|Lu AG22515|Participants will receive intravenous (IV) administration of Lu AG22515 per a prespecified dosing schedule.
62209562|NCT06688422|EXPERIMENTAL|Intervention Arm|The study will have one intervention group of patients using incentive spirometry in addition to standard of care treatment, including chemo/radiation and immunotherapy maintenance. For research purposes, patients will be asked to use incentive spirometry. Patients will use the incentive spirometer 10 times (10 breaths) every hour they are awake. Patients will be asked to start using the incentive spirometer as soon as they are enrolled in the study. Patients will be asked to continue to use incentive spirometry daily, including the duration of chemoradiation and up to three months post-treatment. Patients will be asked to to complete QoL assessments.
62209563|NCT04994353|EXPERIMENTAL|Supplementation|"Three days before the intervention, every subject was informed to maintain their normal diet, physical activities, and enough sleep (6-8 hours/day). All subjects fasted 10-12 hours before the intervention. An intravenous cannula was inserted into the cubital vein to provide access to repeated glucose measurement. Peripheral vein whole blood samples were taken for analysis of glucose concentration using a commercially available FreeStyle Optium glucose monitoring system (Abbot Laboratories, Chicago, Illinois, USA) .For the first week, we measured blood glucose to a meal without any intervention and use those data as a baseline. After that, blood glucose was measured at 0, 30, 60, 90, and 120 minutes after intervention and meal. After intervention, the subjects maintain daily predefined ready-meal (470 kcal). The supplementation formulas are food grade, purchased from PT. Lautan Natural Krimerindo (Mojokerto, Jawa Timur, Indonesia)."
62209564|NCT02725021|EXPERIMENTAL|Intervention group|The intervention group receives a school-based module taking about two hours delivered by medical students in the schools.
62209565|NCT02725021|NO_INTERVENTION|Control group|
62209566|NCT04927884|EXPERIMENTAL|All subjects|Sacituzumab plus chemoimmunotherapy (cyclophosphamide, N-803, and PD-L1 t-haNK)
62209567|NCT02928159|EXPERIMENTAL|Low Pulse Amplitude Seizure Therapy|Course of Right Unilateral Ultrabrief LAP-ST using Mecta spectrum 5000Q Device.
62209568|NCT04013568|ACTIVE_COMPARATOR|Group 1 - Agree to Exercise Program|12-week exercise program
62209569|NCT04013568|NO_INTERVENTION|Group 2 - Declines Exercise Program|Same biometric and biomarker assessment at as Group 1 (at baseline, after 12 weeks and annually) however they will not participate in the exercise sessions
62209570|NCT06433947|EXPERIMENTAL|Dose escalation monotherapy|
62790128|NCT02977858||Dissemination|Educational practice for HCPs,Dissemination only - Practices who will participate in education for constipation management guidelines via dissemination of webinar alone.
62790129|NCT02977858||Dissemination + ISE|Educational practice for HCPs,Spaced Education - Practices who will participate in education for constipation management guidelines via dissemination of webinar along with a web-based format referred to as Interactive Spaced Education.
62209571|NCT06433947|EXPERIMENTAL|Dose escalation in combo with dexamethasone|
62209572|NCT06433947|EXPERIMENTAL|Dose expansion|
62209573|NCT04624087|EXPERIMENTAL|High Dose|Participants will perform the food-specific computerized go/no-go training four times per week for 4 weeks.
62209574|NCT04624087|EXPERIMENTAL|Low Dose|Participants will perform the food-specific computerized go/no-go training one time per week for 4 weeks.
62209575|NCT04624087|ACTIVE_COMPARATOR|Active Control|Participants will perform the generalized, nonfood-specific computerized go/no-go training one time per week for 4 weeks.
62209576|NCT04142359||Cohort A: CIS (either study)|Patients with histologically confirmed presence of BCG-unresponsive CIS, \[with or without Ta/T1 papillary disease\].
62790130|NCT03890744|EXPERIMENTAL|ModraDoc006/r|Weekly ModraDoc006/r treatment as ModraDoc006 (oral docetaxel) 10mg tablets combined with ritonavir 100mg tablets
62790131|NCT02150915|EXPERIMENTAL|new acupoint|Subjets in this arm receive acupuncture therapy in a new acupoint (leopard spot needling technique)
62790132|NCT02150915|ACTIVE_COMPARATOR|classical acupoint|Subjects in this arm receive acupuncture therapy in a classical acupoint in the pericardial conduit (leopard spot needling technique)
62790133|NCT03132701|ACTIVE_COMPARATOR|Magnesium group|Mg is administered with dose of 30 mg/kg for 10 minutes and then 10 mg/kg/hr until 5 minutes before surgery ends
62790134|NCT03132701|PLACEBO_COMPARATOR|Control group|Saline is administered with same volume of Mg of magnesium group until 5 minutes before surgery ends
62790135|NCT06298786||Healthy Subjects|Subjects with TMD Screener score \< 3
62790136|NCT06298786||TMD subjects|Subjects with TMD screener score ≥ 3
62790137|NCT01485328|ACTIVE_COMPARATOR|AMARGOL|per oral solution 40 mL single dose
62407130|NCT02341573|ACTIVE_COMPARATOR|western medicine group|Children of western medicine group will be treated with leukotriene receptor antagonist and a bronchial relaxant.Children at the acute stage of asthma will be treated with etinoline,twice a day for 7 days.At the remission stage, they will be given leukotriene receptor antagonist Singulair, once daily for 3 months.
62407131|NCT06647043|EXPERIMENTAL|SMT04 Pro|2 sachets daily for 3 months
62209577|NCT04142359||Cohort B: High-Grade Ta/T1 Papillary Disease (either study)|Patients with histologically confirmed presence of BCG-unresponsive high-grade Ta/T1 papillary disease
62209578|NCT04142359||Cohort C: CIS (QUILT-3.032)|Patients with histologically confirmed presence of BCG-unresponsive CIS, \[with or without Ta/T1 papillary disease\].
62407132|NCT03237000|EXPERIMENTAL|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~* Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~* Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
62018526|NCT02599168|ACTIVE_COMPARATOR|Dexmedetomidine group|Patients will receive a pre-induction loading dose of dexmedetomidine 1-µ/kg over 10 minutes followed by an intraoperative infusion of 0.5-µ/kg/hour . Over and above the use of study drug dexmedetomidine propofol administration will be controlled with Closed Loop Anaesthesia Delivery system to maintain a consistent anaesthetic depth (BIS 40-60) using bispectral index monitor in all the patients
62018527|NCT02599168|PLACEBO_COMPARATOR|Non-Dexmedetomidine group|Patients will receive a pre-induction loading dose of 0.9% saline solution over 10 minutes followed by an intraoperative infusion.Over and above the use of 0.9% saline solution propofol administration will be controlled with Closed Loop Anaesthesia Delivery system to maintain a consistent anaesthetic depth (BIS 40-60) using bispectral index monitor in all the patients
62407133|NCT02848859|ACTIVE_COMPARATOR|Intervention: Go! to Sleep|We are using a web-based cognitive behavioral therapy program called Go! to Sleep. Go! to Sleep is an interactive online program developed by specialists in Cleveland Clinic's Wellness Institute and Sleep Disorders Center. The program is a 6 week self-help program that uses cognitive behavioral therapy techniques that have been proven to be effective in decreasing symptoms of insomnia.
62407134|NCT02848859|PLACEBO_COMPARATOR|General Sleep Hygiene Education|General Sleep Hygiene Education is the first step in the treatment of any sleep disorder. Both arms will have access to a Harvard sleep education web site that provides general information about sleep as well as sleep hygiene.
62407135|NCT04069208|EXPERIMENTAL|IA14|Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
62407136|NCT06103162|ACTIVE_COMPARATOR|group 1 rigid feeding plate|Heat cure polymerizing acrylic resin was used to fabricate the second appliance.
62407137|NCT06103162|ACTIVE_COMPARATOR|group 2 flexible feeding plate|One mm thick clear thermoplastic sheet was adapted over the cast using a vacuum-forming machine.
62407138|NCT06103162|ACTIVE_COMPARATOR|special feeding appliance|special feeding bottle
62407139|NCT04070157|EXPERIMENTAL|Lofexidine|
62407140|NCT04070157|PLACEBO_COMPARATOR|Placebo|
62407141|NCT02556112|ACTIVE_COMPARATOR|Group Lifestyle Balance|Participants receive the Group Lifestyle Balance intervention as per the standard curriculum
62407142|NCT02556112|ACTIVE_COMPARATOR|Better Body Better Life|Participants receive the Better Body Better Life intervention as per the standard curriculum
62407143|NCT02556112|ACTIVE_COMPARATOR|Fitness Improvement Program|Participants take the Fitness Improvement Program on-line
62407144|NCT00750373|NO_INTERVENTION|Conventional|Conventional Treatment based on current guidelines
62407145|NCT00750373|ACTIVE_COMPARATOR|Surgery|Early surgery within 48 hours of randomization
62407146|NCT02248428|EXPERIMENTAL|BiCTd regimen|"Induction and consolidation therapy: BiCTd regimen for 8 cycles. Patients received Clarithromycin 500 mg orally on days 1-28,thalidomide 100-200mg orally on days d1-28, dexamethasone 40mg orally on days on 1,8,15,22, and cyclophosphamide 300mg/m\^2 intravenously on day 1-3. Cycles were repeated every 28 days.~Maintenance therapy:CP regimen (cyclophosphamide 200 mg orally on days 1-14 and prednisone 30mg twice daily orally on days 1-7,repeated every 28 days) until disease progression.~If efficacy \<PR after 4 cycles of induction or disease progression at anytime，patients will be quitted."
62407147|NCT02248428|ACTIVE_COMPARATOR|CTd regimen|"Induction and consolidation therapy: CTd regimen for 8 cycles. Patients received thalidomide 100-200mg orally on days d1-28, dexamethasone 40 mg orally on days on 1,8,15,22, and cyclophosphamide 300 mg/m\^2 intravenously on day 1-3. Cycles were repeated every 28 days.~Maintenance therapy:CP regimen (cyclophosphamide 200 mg orally on days 1-14 and prednisone 30mg twice daily orally on days 1-7,28 Days per Cycle) until disease progression.~If efficacy \<PR after 4 cycles of induction or disease progression at anytime，patients will be quitted.~If no further reduction in the serum and urine M protein in the next cycle，patients may cross over to BiCTd regimen."
62582119|NCT06622161|OTHER|"automated oxygen,"|"Preterm babies will be kept on the SLE 6000 ventilator for 12 hours, where an automated oxygen device called oxygenie will be used to automatically adjust FiO2 to keep SpO2 within the target range. After 12 hours, the other group will be kept on this arm for 12 hours."
62018528|NCT03811912|EXPERIMENTAL|CTP-543 8 mg BID|Participants received 1 x 8 mg CTP-543 tablet and 1 x CTP-543 matching placebo tablet, twice daily (BID) for 24 weeks.
62018529|NCT03811912|EXPERIMENTAL|CTP-543 16 mg QD|Participants received 16 mg (2 x 8 mg) CTP-543 tablets, once daily (QD) and after 12 hours, received 2 x CTP-543 matching placebo tablets, QD for 24 weeks.
62209579|NCT00106587|ACTIVE_COMPARATOR|Uncoated Angioplasty|PTCA of ISR
62209580|NCT00106587|EXPERIMENTAL|DCB Angioplasty|DCB PTCA of ISR
62209581|NCT04839952|EXPERIMENTAL|Healthy Lifestyles Intervention Arm|Participants will receive the healthy lifestyles intervention.
62209582|NCT04839952|ACTIVE_COMPARATOR|Education-Only Control Arm|Participants will receive the education-only intervention.
62209583|NCT01355900|OTHER|I tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before incision, deflation- after bone cement set.
62407148|NCT02894541|EXPERIMENTAL|CKD-519 tablet 100mg|CKD-519 tablet(formulation Ⅱ) 100mg(100mg X 1Tab) Period 1: CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal
62407149|NCT02894541|EXPERIMENTAL|CKD-519 tablet 200mg|CKD-519 tablet(formulation Ⅱ) 200mg(100mg X 2Tabs) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal
62407150|NCT02894541|EXPERIMENTAL|CKD-519 soft capsule 100mg|CKD-519 soft capsule(formulation Ⅲ) 100mg(100mg X 1Cap) Period 1:CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal
62407151|NCT02894541|EXPERIMENTAL|CKD-519 soft capsule 200mg|CKD-519 soft capsule(formulation Ⅲ) 200mg(100mg X 2Caps) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal
62209584|NCT01355900|OTHER|II tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before cement application, deflation- after bone cement set.
62407152|NCT02996942||Replacement therapy|Hemophilia A receiving replacement therapy (prophylaxis or on demand)
62407153|NCT00702286||1|Two arm, double blinded, comparative, randomized, placebo controlled (active:sham - 2:1) study
62407154|NCT00702286||2|Two arm, double blinded, comparative, randomized, placebo controlled (active:sham - 2:1) study
62407155|NCT05969626|EXPERIMENTAL|5-dose group of test vaccine|
62407156|NCT05969626|ACTIVE_COMPARATOR|5-dose group of control vaccine|
62407157|NCT05969626|EXPERIMENTAL|4-dose A group of test vaccine|
62407158|NCT05969626|EXPERIMENTAL|4-dose B group of test vaccine|
62407159|NCT04680390|EXPERIMENTAL|Active-kINSHIP navigation intervention|kINSHIP is a peer-led navigator intervention to address intersectional stigma and improve PrEP treatment initiation and engagement for justice-involved women. The key components of the kINSHIP intervention are to: 1) increase social support; 2) increase self-efficacy in accessing PrEP services; 3) enhance access to healthcare services; 4) improve adaptive coping skills to manage experiences of intersectional stigma.
62407160|NCT04680390|ACTIVE_COMPARATOR|Control-Standard Care|The control arm will be standard-of-care, which is as-needed case management for justice-involved women.
62407161|NCT06148077|EXPERIMENTAL|Manual Therapy|Manual Therapy-based intervention: the session will be performed with the patient in a supine position. If they cannot reach this position, it can be done with the patient sitting in a chair to receive the treatment. The selected maneuvers will focus on the intraoral, cervical, mandibular, and shoulder regions. Afterward, motor control exercises will be conducted.
62407162|NCT06148077|ACTIVE_COMPARATOR|Motor Control|Motor control (exercise): the session will focus on strengthening and stretching exercises for the intraoral, cervical, mandibular, and shoulder musculature.
62407163|NCT06005077|NO_INTERVENTION|Control group|After the hospitalization procedures were completed, the pregnant women in the control group were informed and their written consents were obtained. No intervention was performed on these pregnant women other than routine hospital practices. Data collection forms were applied.
62407164|NCT06005077|EXPERIMENTAL|Perineal Massage|While the pregnant woman was in the lithotomy position, massage was applied with two fingers and rhythmic U-shaped movements starting from the side walls 3-4 cm inside the vagina and towards the rectum. This implementation was done for 10 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
62407165|NCT06005077|EXPERIMENTAL|Perineal Warm Compress Application|Sterile compresses kept in hot water of 40 C were placed on the perineum. Compresses that cooled down and became dirty were changed every 5-8 minutes. This implementation was done for 30 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
62407166|NCT06005077|EXPERIMENTAL|Perineal Massage and Perineal Warm Compress Application|When the cervical dilatation was 3-4 cm, 30 minutes of warm compress and 10 minutes of perineal massage were performed. These two methods were applied when the cervical dilatation was 5-7 cm and 8-10 cm as well.
62407167|NCT04943536|EXPERIMENTAL|Biolen+Radiation Therapy|Localized single delivery of the Biolen implant (polymer + bicalutamide) with radiation therapy
62407168|NCT01013402|EXPERIMENTAL|volunteers for insulin hypoglycemia test|None of the subjects had diabetes mellitus or any other metabolic diseases. They were not taking any medicine and they did not have anemia or polycythemia. Also none of the patients had any condition causing hypoxia or any compromise in peripheral circulation.
62790138|NCT01485328|PLACEBO_COMPARATOR|Vehicle without active principles|per oral solution 40 mL single dose
62209585|NCT01355900|OTHER|III tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before incision, deflation- after wound closure
62790139|NCT02837185|EXPERIMENTAL|Cervical Dystonia|'Botulinum Toxin injection' will be done and 'physiological measures' will then be collected.
62790140|NCT02837185|OTHER|Healthy controls|No Botulinum toxin is injected, 'physiological measures' will be collected as a healthy comparator.
62790141|NCT05476016|EXPERIMENTAL|Open-label, single arm with identical intervention for all participants|Glycated keratin assessed by near-infrared and glycated haemoglobin (HbA1c) assessed based on finger prick blood drop sample
62790142|NCT03483493|EXPERIMENTAL|Exposure Response Prevention for tics|10-weeks, online delivered, therapist supported exposure response prevention (ERP) therapy for tics
62407169|NCT06145399|EXPERIMENTAL|Participants with Breast Cancer|Participants with histologically confirmed AR+ breast cancer
62407170|NCT00998621||Hepatitis C infection|
62407171|NCT00998621||Hepatitis C + HIV infections|
62407172|NCT03591666|EXPERIMENTAL|Study Group|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62407173|NCT00054639|EXPERIMENTAL|Treatment (oblimersen sodium and monoclonal antibody therapy)|Patients receive oblimersen sodium IV continuously on days 1-7, 15-21, and 29-35 and rituximab IV over 4-6 hours on days 3, 8, 15, 22, 29, and 36. Patients achieving stable disease or objective response may receive one additional course of treatment.
62582120|NCT06622161|OTHER|"manual oxygen"|Preterm babies will be kept on the SLE 6000 ventilator for 12 hours, where manual FiO2 adjustment by the bedside staff nurse will be used to keep SpO2 within the target range. After 12 hours, the other group will be kept on this arm for 12 hours.
62582121|NCT05077137|EXPERIMENTAL|Td Vaccine|The first 15 subjects enrolled will receive the Td (tetanus diphtheria) vaccine at cycle 4 of IO therapy. The Td vaccine is administered as 0.5 mL intramuscular injection in the extremity (thigh or upper arm) in closest proximity to the largest tumor.
62582122|NCT05077137|EXPERIMENTAL|IPOL Vaccine|Subjects 16 through 25 will receive the IPOL (polio booster) vaccine at cycle 4 of IO therapy. The IPOL vaccine is administered as 0.5 mL intramuscular or subcutaneous injection in the extremity (thigh or upper arm) in closest proximity to the largest tumor
62018530|NCT02802553|EXPERIMENTAL|Integrated Imaging Goggles|Cardio-GreenTM (indocyanine green) peritumorally injected to breast tumor with 1 cycle. Viewed by Smart Googles and compare lesions detected by commercial FDA approved near infrared camera device (SPY Elite/Quest/PDE) in addition to those detected by gamma probe and blue dyes.
62209586|NCT01355900|OTHER|IV control group|Do not use volume loading test. Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before cement application, deflation- after bone cement set.
62407174|NCT02288234||Vibativ|This is an observational study for patients who were already prescribed Vibativ.
62407175|NCT02928562|NO_INTERVENTION|Control|TKA patients without exercise intervention
62407176|NCT02928562|EXPERIMENTAL|Exercise|TKA patients with exercise intervention ( cyclic exercise, aerobic exercise and resistant training exercise )
62407177|NCT02592070|EXPERIMENTAL|30 minute treadmill walking|All participants will walk on the treadmill for 30 minutes and perform a battery of cognitive tasks immediately prior, immediately after, and one hour after completion of the 30 minute walking period.
62407178|NCT04054934||Normal Circardian rhythm|Regular night sleep, with at least 7 hours length of sleep.
62582123|NCT04203641|EXPERIMENTAL|L-DOS47 + doxorubicin|Patients will be recruited into escalating dosing cohorts of 3, 6 and 9 µg/kg of L-DOS47, with a minimum of 3 and a maximum of 6 patients per cohort. A fixed dose of intravenous doxorubicin \[20 mg/m2/week\] will be administered in combination with L-DOS47 across all cohorts.
62407179|NCT04054934||Reversed circadian rhythm|Night/day circadian clock is opposite, with at least 7 hours length of sleep
62582124|NCT02114229|EXPERIMENTAL|(A) Alisertib alone|"Stratum A: Patients with recurrent/progressive AT/RT or extra-CNS malignant rhabdoid tumors (MRT).~Interventions: alisertib, 35 cycles of 3 weeks each (up to 105 weeks). Surgical resection, if indicated."
62582125|NCT02114229|EXPERIMENTAL|(B) Alisertib, chemotherapy, radiation therapy|"Stratum B: Children \< 36 months old with newly diagnosed AT/RT. AT/RT those with synchronous extraneural AT/RT (Stratum D1) may also be treated on this arm.~Interventions:~* B1 or D1: Induction chemotherapy using methotrexate, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by focal radiation therapy; followed by induction therapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib. Those \<12 months who are not ready for focal radiation therapy will receive consolidation chemotherapy using alisertib, cyclophosphamide, carboplatin and etoposide while RT is delayed. Surgical resection, if indicated.~* B2, B3, D2 or D3: Induction chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by consolidation with topotecan and cyclophosphamide or optional craniospinal irradiation; followed by maintenance alisertib. Surgical resection, if indicated."
62582126|NCT02114229|EXPERIMENTAL|(C) Alisertib, chemotherapy, radiation therapy|"Stratum C: Children ≥36 months old with newly diagnosed AT/RT.~Participants with synchronous extraneural AT/RT (Stratum D4) will also be treated as those assigned to Stratum C.~Interventions: Craniospinal radiation therapy; followed by consolidation chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib, surgical resection, if indicated."
62582127|NCT02398903||Obese women SG|Obese women operated by sleeve gastrectomy
62582128|NCT02398903||Normal weight women|Normal weight women
62582129|NCT02398903||Obese women GBP|Obese women operated by Rougastric bypass
62582130|NCT03973411|ACTIVE_COMPARATOR|Ondansetron group|Patients will receive intravenous ondansetron before spinal anesthesia
62582131|NCT03973411|PLACEBO_COMPARATOR|Control group|Patients will receive intravenous saline before spinal anesthesia
62407180|NCT03302221|OTHER|Group control|In the control group, local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
62407181|NCT03302221|EXPERIMENTAL|Paravertebral Block Group|In Group Paravertebral Block, patients received standardized general anaesthesia supplemented by paravertebral Block. The USG approach for TPVB was used with the patient in the lateral position at the T4-T6 level according to the incision protocol in our centre.
62407182|NCT03302221|EXPERIMENTAL|Epidural Block Group|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography ;general anesthesia combined with epidural block
62407183|NCT00942110|EXPERIMENTAL|CPAP|
62407184|NCT02424851|ACTIVE_COMPARATOR|Arm A (BBD)|Bortezomib, Bendamustine and Dexamethasone
62407185|NCT02424851|ACTIVE_COMPARATOR|Arm B (BTD)|Thalidomide, Bendamustine and Dexamethasone
62407186|NCT02303275|OTHER|Lifestyle Change|Lifestyle Change
62407187|NCT03821805|EXPERIMENTAL|Foot reflexology massage group|The duration of intervention was 30 min (15 min massage duration for each leg)
62407188|NCT03821805|NO_INTERVENTION|Control group|Rest for 30 min
62407189|NCT05489952|EXPERIMENTAL|iron supplement group|
62407190|NCT05489952|NO_INTERVENTION|control group|
62407191|NCT06014008|NO_INTERVENTION|No Intervention group|Not taking test product
62582132|NCT04822792||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected
62582133|NCT04822792||Benign Diseases Arm|Participants with benign diseases corresponding to the tumor types in the Cancer Arm, from whom blood samples will be collected
62582134|NCT04822792||Healthy Arm|Participants without known presence of malignancies or benign disease, from whom blood samples will be collected
62582135|NCT04845308||Group 1|Patients operated with an early secondary alveolar grafting between the ages of 4 to 7 years with a 3D imaging (CT, CBCT or scan) performed between the ages of 8 to 11 years.
62735047|NCT02483858|EXPERIMENTAL|PQR309|Different dose Evaluation (continous and intermittent) 20-160mg daily
62018531|NCT02447731||Sonic Gas Exchange|"Gas exchange rates in the lungs of subjects breathing through a mouthpiece will be compared with their gas exchange rates after addition of sound pressure vibrations into the supplied gas. 'Induction of sound waves in lungs by sonic oscillator' can be as loud as a human screaming or singing very loudly (about 95 dB). The effects of these pressure oscillations on gas exchange will be assessed using 3 tests as explained in the section under detailed description."
62018532|NCT01807585|EXPERIMENTAL|VenaSeal SCS|Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA.
62018533|NCT01807585|ACTIVE_COMPARATOR|RFA (ClosureFast)|Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV). Heat is applied to the target vein using radiofrequency energy to ablate the target vein. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or RFA.
62018534|NCT01807585|EXPERIMENTAL|Roll-in (VenaSeal SCS)|Prior to initiation of the randomized cohort at each site, a non-randomized cohort of 2 subjects per clinical site (roll-in phase) were enrolled and treated with VenalSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.
62018535|NCT06573827||Microbiome in healthy volunteers|Healthy volunteers willing to provide blood and urine samples for microbiome evaluation
62018536|NCT03059173|EXPERIMENTAL|Myo-Inositol + Levomefolic acid|The experimental group will receive the dietary supplement: 4 g of MYO + 0.736 mg of 5-MTHF, glucosamine salts per day per os (in 2 bags per day) in addition to the standard therapy (Clomiphene Citrate).
62209587|NCT02651532||IBS + Confocal Laser Endomicroscopy|Outpatients with irritable bowel syndrome according to Roma III classification: recurrent abdominal pain or discomfort, at least 3 days per month, in the last 3 months and symptoms begin at least 6 months before diagnosis, associated with 2 or more of: improvement with defecation, start associated with changes in the bowel frequency, start associated with changes in stool consistency. Absence of alarm symptoms: gastrointestinal bleeding, weight loss, anemia, night-time symptoms, fever, family history of colorectal cancer or celiac disease, elevated erythrocyte sedimentation rate, positive fecal occult blood test.
62209588|NCT02651532||Control + Confocal Laser Endomicroscopy|Outpatients without IBS symptoms, undergoing colonoscopy for colorectal cancer screening
62209589|NCT03282669|ACTIVE_COMPARATOR|Intrathecal Morphine|Administration of 100µg intrathecal morphine to be given in the operative area.
62582136|NCT04845308||Group 2|Patients operated with a late secondary alveolar graft between the ages of 8 to 11 years with a 3D imaging (CT, CBCT or scan) performed at least 1 year after the operation.
62209590|NCT03282669|ACTIVE_COMPARATOR|Intravenous Hydromorphone|Administration of intravenous hydromorphone give IV pca in the post operative area.
62209591|NCT06239636|EXPERIMENTAL|UP421 transplantation|Intramuscular transplantation of study product UP421
62209592|NCT00529958|ACTIVE_COMPARATOR|Patellar Tendon (PT)|ACL reconstruction using a patellar tendon autograft
62582137|NCT06685211|EXPERIMENTAL|rtACS treatment|Participants will receive 10 days of rtACS treatment in office.
62209593|NCT00529958|ACTIVE_COMPARATOR|Hamstring (HT)|ACL reconstruction using a quadruple-strand semitendinosus/gracilis (hamstring) tendon single-bundle autograft
62582138|NCT06685211|PLACEBO_COMPARATOR|Sham|Participants will be wearing device but no stimulation will occur for 10 treatments in office.
62582139|NCT02807298|ACTIVE_COMPARATOR|2% Lignocaine (lidocaine)|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine (adrenaline)
62582140|NCT02807298|EXPERIMENTAL|4% Articaine|intraligamentary injections of 0.9 ml of 4%articaine and 1:100,000 epinephrine (adrenaline)
62582141|NCT06619574|EXPERIMENTAL|3D Analysis Group|Compass Use
62582142|NCT06619574|ACTIVE_COMPARATOR|Manual Analysis Cohort|Manual Use only
62582143|NCT05587582||Observational (Family Behaviors)|"PRIMARY OBJECTIVES:~I. Use direct observation of medication administration in the home to understand common episode-level barriers and identify the most impactful behavioral parenting skills for intervention.~II. Use daily diary methods to identify contextual barriers to adherence and identify intervention components to help parents anticipate barriers and plan strategies to promote successful adherence.~OUTLINE:~Participants complete a survey over 15-20 minutes at baseline. Family behaviors before, during and after the administration of medication to the child are video-recorded over 40-45 minutes. Participants receive MEMS electronic pill bottle to use for 2 weeks and complete daily survey over 5 minutes for 14 days."
62582144|NCT05256459||Observation group|Those who did not deal with nodules and were closely followed up.
62582145|NCT05256459||Treatment group|Patients with liver nodules were treated by radiofrequency ablation or/and surgery and so on.
62582146|NCT03346356|EXPERIMENTAL|Teenagers as cross-age teachers|After the initial training, the teenage teachers facilitated the curricula associated with the SHCP, Discovering Healthy Choices and Cooking Up Healthy Choices, approximately twice a month. The curricula can be viewed at http://cns.ucdavis.edu/programs/shcp/curriculum.html. Each activity provided step-by-step instructions that the teenage teachers were asked to follow. Younger youth served as participants for the classroom and garden-based activities.
62018537|NCT03059173|PLACEBO_COMPARATOR|Placebo|The control group will receive the standard therapy ( Clomiphene Citrate) and a placebo containing only 0.736 mg of 5-MTHF, glucosamine salts
62018538|NCT04939259|EXPERIMENTAL|New Music Program|The new hearing aid contains the new music program will be worn by all participants at the same time. The participants must switch between the two programs during use to make the comparison.
62018539|NCT04939259|ACTIVE_COMPARATOR|Standard Listening Program|The new hearing aid also contains the standard listening program worn by all participants at the same time. The participants must switch between the two programs during use to make the comparison.
62018540|NCT00501150|EXPERIMENTAL|Patients who fulfilled the study criteria|"IV to oral switch inclusion criteria used~1. Clinical status~   * Temperature less than 38°C for 24 hours~  * White cell count normalising~  * No unexplained tachycardia (Heart rate less than 100 beats per minute)~  * Sensitivity received (if microbiology positive)~2. Oral absorption~   * Patient tolerates oral fluids~  * No medical problems leading to reduced oral absorption (e.g. vomiting, diarrhoea, and gastrointestinal surgery)~  * No surgical operation scheduled within next 36 hours~IV to oral switch exclusion criteria used~1. Continuing sepsis~   * Temperature less than 36°C or more than 38°C~  * White cell count less than 4 × 109/L or more than 12 × 109/L~  * Unexplained tachycardia (Heart rate greater than 100 beats per minute in last 12 hours)~2. Oral route compromised~   * Vomiting or severe diarrhoea~  * Other ongoing or potential absorption problem"
62018541|NCT01037309|EXPERIMENTAL|PRO044, cohort 1|Subcutaneous injection of 0.5 mg/kg on day 1, 8, 15, 22 and 29.
62018542|NCT01037309|EXPERIMENTAL|PRO044, cohort 2|Subcutaneous injection of maximally 1.5 mg/kg on day 1, 8, 15, 22 and 29.
62209594|NCT00529958|ACTIVE_COMPARATOR|Double-Bundle (DB)|ACL reconstruction using a semitendinosus/gracilis (hamstring) tendon double-bundle autograft
62407192|NCT06014008|EXPERIMENTAL|Test product consumption group|Participants will take one bottle (80 ml) of Yakult® drink daily for a period of 4 weeks. Yakult is a branded probiotic drink with 8x10\^9 CFU Lacticaseibacillus paracasei strain Shirota. Subsequently, a two-week follow-up period will follow.
62582147|NCT03346356|NO_INTERVENTION|Comparison group|Youth of similar ages to the intervention group completed the same assessments, but did not receive the intervention.
62582148|NCT02235077|ACTIVE_COMPARATOR|Spironolactone|Spironolactone 25mg or 100 mg orally, once daily while in the hospital for 96 hours
62582149|NCT02235077|PLACEBO_COMPARATOR|Placebo|Placebo 25mg or 100mg orally, once daily while in the hospital for 96 hours
62582150|NCT02084732|EXPERIMENTAL|Sorafenib|drug
62582151|NCT04858061|EXPERIMENTAL|Treatment-as-usual supplemented with virtual reality cue-exposure therapy|Treatment-as-usual supplemented with virtual reality cue-exposure therapy (TAU + VR-CET).
62582152|NCT04858061|ACTIVE_COMPARATOR|Treatment-as-usual|Only treatment-as-usual (TAU)
62582153|NCT01148160||1|Patients with hematologic malignancies who were given voriconazole to treat invasive (pulmonary) aspergillosis at Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
62582154|NCT06575972|EXPERIMENTAL|JoyRise Recovery Powder|Participants in this arm will receive JoyRise Recovery Powder, a dietary supplement containing Dihydromyricetin (DHM) and other natural ingredients.
62018543|NCT01037309|EXPERIMENTAL|PRO044, cohort 3|Subcutaneous injection of maximally 5 mg/kg on day 1, 8, 15, 22 and 29.
62018544|NCT01037309|EXPERIMENTAL|PRO044, cohort 4|Subcutaneous injection of maximally 8 mg/kg on day 1, 8, 15, 22 and 29.
62209595|NCT03374943|EXPERIMENTAL|KB004 dose escalation|Patients will be entered at each KB004 dose level sequentially until 3-6 patients are evaluable for safety. Three sequential cohorts are planned in this study (3.5mg/kg, 5.25 mg/kg, 7.9 mg/kg) Additional dose levels may be explored based on the emerging data in the study.
62582155|NCT06575972|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive a placebo solution that is visually and tastefully similar to the JoyRise Recovery Powder but contains no active ingredients.
62582156|NCT06487000|EXPERIMENTAL|EC-18 1000mg|\[EC-18 2 capsules / Placebo 2 capsules\]
62582157|NCT06487000|EXPERIMENTAL|EC-18 2000mg|\[EC-18 4 capsules\]
62582158|NCT06487000|PLACEBO_COMPARATOR|Placebo|\[Placebo 4 capsules\]
62582159|NCT02452632|EXPERIMENTAL|ASP1941 group|once daily over a 24 week treatment
62018545|NCT01037309|EXPERIMENTAL|PRO044, cohort 5|Subcutaneous injection of maximally 10 mg/kg on day 1, 8, 15, 22 and 29
62209596|NCT05494593|EXPERIMENTAL|ITR + ELAPRASE|"Participants will receive prophylactic ITR which consist of rituximab, methotrexate and IVIG in a 5-week cycle. Following the completion of 1 cycle and at the Month 6, 12, and 18 study visits, an assessment will be made regarding the need for administering another 5-week cycle of the ITR depending on the trend of the participants anti-idursulfase antibody titers and lymphocyte quantitation and CD19 percent (%) recovery.~Elaprase treatment (IV, weekly) will start 1 day after the initiation of the first cycle of ITR and continue for 104 weeks.~The dose of ELAPRASE will be calculated based on the participant's weight at each visit."
62209597|NCT02762643|EXPERIMENTAL|RT group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
62209598|NCT02762643|EXPERIMENTAL|TR group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
62209599|NCT05860634|NO_INTERVENTION|Catheter office-discontinuation group|The patients randomized to the office-discontinuation group will visit the office for a repeat voiding trial on postoperative day 1. At this visit, the patients will undergo a backfill voiding trial.
62209600|NCT05860634|EXPERIMENTAL|Catheter self-discontinuation group|The patients randomized to the catheter self-discontinuation group will be provided with a diagrammatic handout and will be instructed to remove their indwelling urinary catheter at home on the morning of Postoperative day 1.
62209601|NCT03568773|EXPERIMENTAL|High-intensity interval training|"The HIIT protocol is being performed with the cycling mode. The program consists of repeated intense explosions alternating with recovery intervals.~The adaptation period consists of 4 shots of 20 seconds interspersed by 180 seconds interval (active recovery). From the first to the fourth week the volunteers performed from four to six race shots from 30 to 45s with intervals from 180s to 120s. From the fifth week until the end of the intervention, training takes place with six shots of 60s with a 120s interval between running shots. The work intensity for all sessions is above 95% of VO2max, with 30W of recovery. In addition, participants refer to number 19 on the Borg Scale. Sessions range from 12 to 36 minutes without heating and recovery. In total there are 12 weeks of training."
62209602|NCT03568773|EXPERIMENTAL|Aerobic exercise moderate intensity|The training protocol was started, with the sessions held in the open air. From the first to the fourth week, the volunteers gave sessions of 40 to 60 minutes, intensity in L1, three sessions / week. In the fifth week, the intensity was increased to the midpoint between L1 and half of L2, maintaining 60 minutes per session and frequency three times per week. From the sixth week, the weekly frequency increased to five days, with three supervised sessions and two unsupervised sessions, but with a smartphone application that recorded distance traveled and intensity. From the ninth week on, the weekly frequency was maintained and the intensity increased for L2. In supervised sessions, training intensity is also monitored by heart rate using a Polar heart rate monitor.
62209603|NCT03568773|EXPERIMENTAL|Control Group|The control group attends stretching classes once a week and sessions lasting 60 minutes. At the end of the fifteen weeks (three weeks of adaptation and twelve weeks of training) of the study, these volunteers will be invited to engage in the aerobic training program regardless of their participation in the research.
62209604|NCT02522559|EXPERIMENTAL|Spice Intervention|Spice intervention: Student-approved vegetable recipes will be served in the school cafeteria.
62209605|NCT06728033|EXPERIMENTAL|SiFICB Group|Participants will receive an ultrasound-guided SiFICB above the inguinal ligament with 40 ml of 0.25% ropivacaine.
62209606|NCT06728033|ACTIVE_COMPARATOR|Tramadol Group|Participants will receive intravenous tramadol at a dose of 2 mg/kg
62209607|NCT06616597|EXPERIMENTAL|Arm 1: Abiraterone + Dexamethasone|Abiraterone acetate plus dexamethasone
62018546|NCT01037309|EXPERIMENTAL|PRO044, cohort 6|Subcutaneous injection of maximally 12 mg/kg on day 1, 8, 15, 22 and 29
62209608|NCT06616597|EXPERIMENTAL|Arm 2: Abiraterone + Dexamethasone + metronidazole|Abiraterone acetate plus dexamethasone plus metronidazole
62209609|NCT03261687|EXPERIMENTAL|Water Exercise + advice|Each group undertook four, once weekly exercise sessions (including a warm up, cool down, relaxation, pelvic control and stability exercise). Both programmes focused on similar exercise and muscle groups, but due to the aquatic medium programmes were unable to be exactly matched.
62582160|NCT02452632|PLACEBO_COMPARATOR|Placebo group|once daily over a 24 week treatment
62582161|NCT00892671||medical students|
62018547|NCT01037309|EXPERIMENTAL|PRO044, cohort 7|Intravenous injection of maximally 1.5 mg/kg on day 1, 8, 15, 22 and 29
62209610|NCT03261687|EXPERIMENTAL|Land Exercise + advice|Each group undertook four, once weekly exercise sessions (including a warm up, cool down, relaxation, pelvic control and stability exercise). Both programmes focused on similar exercise and muscle groups, but due to the aquatic medium programmes were unable to be exactly matched.
62209611|NCT02562170|ACTIVE_COMPARATOR|TiLoop Bra|immediate breast reconstruction with an implant and TiLoop Bra
62209612|NCT02562170|ACTIVE_COMPARATOR|Protexa|immediate breast reconstruction with an implant and Protexa
62209613|NCT05930613|EXPERIMENTAL|1|Certolizumab (CIMZIA® ; TNF-α antagonist )
62209614|NCT05930613|PLACEBO_COMPARATOR|2|Placebo (NaCl 0.9 % solution)
62209615|NCT01012414|EXPERIMENTAL|oral paricalcitol 2 mcg daily|oral paricalcitol 2 mcg daily
62018548|NCT01037309|EXPERIMENTAL|PRO044, cohort 8|Intravenous injection of maximally 5 mg/kg on day 1, 8, 15, 22 and 29
62018549|NCT01037309|EXPERIMENTAL|PRO044, cohort 9|Intravenous injection of maximally 8 mg/kg on day 1, 8, 15, 22 and 29
62209616|NCT01012414|PLACEBO_COMPARATOR|Placebo|one oral placebo drug daily
62209617|NCT01887704|EXPERIMENTAL|Rotablator|"Rotablator plus conventional angioplasty and/or stenting was performed in 120 patients in the R group.~Rotablator using 140, -160, 000 rpm, small rota burr (burr-to-artery ratio, 0.6:1), avoid drop of \>5000 rpm for 5s.~Conventional intervention will be performed in the rotablator group. All subjects were given 100 mg/day aspirin and clopidogrel (300 mg loading dose and 75 mg/day maintenance dosage) at least 24 h before the procedure. A cutting balloon, buddy wire balloon, buddy wire, or DES (including sirolimus-eluting stent, paclitaxel-eluting stent, everolimus-eluting stent,zotarolimus-eluting stent) was implemented at the discretion of the operator in both groups."
62407193|NCT02260570|EXPERIMENTAL|Functional MRI Arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
62735048|NCT02720523|EXPERIMENTAL|Placebo / Upadacitinib 7.5 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.~Period 2: Participants will receive Upadacitinib 7.5 mg once daily for 248 weeks."
62209618|NCT01887704|ACTIVE_COMPARATOR|Conventional|"Conventional angioplasty and/or stenting was performed in 120 patients in the C group.~Conventional intervention without rotablator was performed in the C group. All subjects were given 100 mg/day aspirin and clopidogrel (300 mg loading dose and 75 mg/day maintenance dosage) at least 24 h before the procedure. A cutting balloon, buddy wire balloon, buddy wire, or DES (including sirolimus-eluting stent, paclitaxel-eluting stent, everolimus-eluting stent,zotarolimus-eluting stent) was implemented at the discretion of the operator in both groups."
62018550|NCT01751568|EXPERIMENTAL|Cohort 1: ≥ 2 to < 6 years of age on TB treatment|Participants in this cohort received chewable raltegravir tablets, starting dose of 12 mg/kg (up to a maximum of 800 mg) orally twice daily, in addition to two NRTIs to treat HIV as part of standard of care, and a rifampicin-containing regimen to treat TB. After a study visit at Day 5 to 8, a fourth ARV medication was added to the regimen.
62018551|NCT01751568|EXPERIMENTAL|Cohort 2: ≥ 6 to < 12 years of age on TB treatment|Participants in this cohort received chewable raltegravir tablets, starting dose of 12 mg/kg (up to a maximum of 800 mg) orally twice daily, in addition to two NRTIs to treat HIV as part of standard of care, and a rifampicin-containing regimen to treat TB. After a study visit at Day 5 to 8, a fourth ARV medication was added to the regimen.
62018552|NCT01751568|EXPERIMENTAL|Cohort 3: : ≥ 4 weeks to < 2 years of age on TB treatment|Participants in this cohort received chewable raltegravir tablets (as a dispersible tablet), starting dose of 12 mg/kg (up to a maximum of 800 mg) orally twice daily, in addition to two NRTIs to treat HIV as part of standard of care, and a rifampicin-containing regimen to treat TB. After a study visit at Day 5 to 8, a fourth ARV medication was added to the regimen.
62209619|NCT02240953|ACTIVE_COMPARATOR|Warfarin|In the first arm only warfarin is given with a target INR level of 2.5-4 to the patients with prosthetic heart valve thrombosis
62018553|NCT01070004|EXPERIMENTAL|Blue light|Exposure to 460-nm monochromatic light (blue light)
62018554|NCT01070004|EXPERIMENTAL|Physical activity|15 minutes of physical activity at a low intensity
62018555|NCT02346565|OTHER|Exercise ECG|Patients will undergo an exercise test using the standard Bruce protocol. Standard end points of exercise testing will include: fatigue, severe ischaemia (severe chest pain, \>2mm ST depression on ECG), hypertension (systolic BP\>220mmHg), hypotension, pre-syncope or arrhythmia.
62018556|NCT02346565|OTHER|Stress Echocardiography|"A two-dimensional echocardiogram will be performed in the lateral decubitus position. Digitized images of the left ventricle (LV) will be obtained in the parasternal long-axis, short-axis, and apical four-, two-, and three-chamber views.~In the case of exercise stress echo, images will be acquired at rest and immediately (within 90 seconds) after peak exercise.~In the case of dobutamine stress echo, images will be acquired at rest, at the end of stage one of dobutamine administration (10mcg/Kg/min) and at peak stress."
62209620|NCT02240953|ACTIVE_COMPARATOR|Warfarin + ASA 100 mg + PPI|In the second arm 100 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
62407194|NCT02154152|EXPERIMENTAL|Homoeopathic Medicine Causticum|The drug namely Causticum 200C potency shall be administered as 4 globules, prescribed once a week for 3 months with placebo to follow for the remaining period.
62407195|NCT05340049|PLACEBO_COMPARATOR|"Primary Group Control"|41 patients of the total sample are part of the placebo group, being these patients without active primitive reflexes and/or cranial blocks, or in smaller quantities than the other participants of the study
62407196|NCT05340049|ACTIVE_COMPARATOR|"Secondary group Rhythmic Movement Therapy"|40 patients of the total sample are part of the rhythmic movement therapy group, having 1 or all of the primitive reflexes active and/or cranial blocks studied.
62407197|NCT05340049|EXPERIMENTAL|"Tertiary group Craniosacral Therapy"|39 patients of the total sample are part of the rhythmic movement therapy group, having 1 or all of the primitive reflexes active and/or cranial blocks studied.
62735049|NCT02720523|EXPERIMENTAL|Placebo / Upadacitinib 15 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks."
62209621|NCT02240953|ACTIVE_COMPARATOR|Warfarin + ASA 300 mg + PPI|In the third arm 300 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
62209622|NCT02240953|ACTIVE_COMPARATOR|Observational Warfarin|This arm is an observational group of patients who do not have prosthetic heart valve thrombosis. These patients also are followed under only warfarin therapy with INR level of 2.5-4.
62209623|NCT06520124|EXPERIMENTAL|A1: Stellest lens wear in front of dominant eye|Stellest lens wear in front of dominant eye.
62209624|NCT06520124|PLACEBO_COMPARATOR|A2: Single vision lens wear in front of non-dominant eye|Single vision lens wear in front of non-dominant eye.
62209625|NCT06520124|EXPERIMENTAL|B1: Stellest lens wear in front of non-dominant eye|Single vision lens wear in front of non-dominant eye
62209626|NCT06520124|PLACEBO_COMPARATOR|B2: Single-vision lens wear in front of dominant eye.|Single vision lens wear in front of dominant eye.
62209627|NCT06729255|EXPERIMENTAL|EpiZact assisted epidural placement|All patients enrolled in the study will receive an epidural to treat labor pain with the assistance of the EpiZact device.
62209628|NCT05490342||tacrolimus-based immunosuppresion|The TAC-based group will include any patient on tacrolimus monotherapy and patients taking multiple IS medications with blood tacrolimus levels \> 5 ng/mL
62209629|NCT05490342||NON-tacrolimus-based immunosuppresion|The NON-TAC-based group will include any patient on TAC-free therapy and patient taking multiple IS medications with blood tacrolimus levels \< 5 ng/mL
62209630|NCT02696876|ACTIVE_COMPARATOR|Control group|Patients in this group will received conventional microfracture treatment as indicated for isolated cartilage defects and defined by the inclusion criteria.
62734496|NCT03281369|ACTIVE_COMPARATOR|1L-Control: mFOLFOX6 (Gastric Cancer)|Participants in the 1L Gastric Cancer Control arm will receive modified FOLFOX6 (mFOLFOX6) treatment consisting of 5-fluorouracil (5-FU), leucovorin (folinic acid), and oxaliplatin. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria. No longer enrolling participants as of June 2018.
62790143|NCT03483493|ACTIVE_COMPARATOR|Active Control (Psychoeducation)|10-weeks, online delivered, therapist supported psychoeducation for tics
62018557|NCT02769091|EXPERIMENTAL|TEV-45478|80 mg (2x40mg) tablets once daily for up to 24 weeks
62018558|NCT02769091|PLACEBO_COMPARATOR|Placebo|Matching placebo
62209631|NCT02696876|EXPERIMENTAL|Intervention group|Patients in this group will also receive microfracture for the treatment of isolated cartilage defects in combination with arthroscopic synovial brushing to access and release synovial MSCs into the joint space.
62209632|NCT05824598|EXPERIMENTAL|Treatment|The cases (active treatment) will be treated with an approach that includes osteopathic treatment for pain control (by the Osteopath Bruno Bordoni), systematic swallowing screening (Speech Therapist, Leone Stilo), psychological counseling (Psychologist, Eleonora Volpato, Giulia Novembre ). The duration of treatment will be that of hospitalization, on average about 3 weeks. The osteopathic treatment will last 5 sessions, while the counseling will have one session at the admission and one at the discharge and up to two sessions a week (variable according to individual needs); the swallowing screening will have one session at the admission and one at discharge and about two-three sessions a week (variable according to individual needs).
62209633|NCT05824598|NO_INTERVENTION|Controls|Controls will follow good clinical practice (in this case systematic screening from a swallowing point of view will not be applied, nor will osteopathic treatment and systematic psychological counseling be considered).
62209634|NCT02241005|ACTIVE_COMPARATOR|Theraworx™|Participants are randomized to use the Theraworx™ bath wipes.
62209635|NCT02241005|ACTIVE_COMPARATOR|Standard|Participants are randomized to use standard bath wipes.
62209636|NCT00955175|EXPERIMENTAL|Group 1|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 24 fractions (total of 72 Gy).
62790144|NCT04364360|EXPERIMENTAL|Sulforaphane supplementation|Daily (2 capsules) consumption of BroccoMax (Jarrow Formulas Los Angeles, CA) for 3-weeks.
62790145|NCT03106636|ACTIVE_COMPARATOR|KEEP-P|Caregivers are randomly assigned to one of two groups. The KEEP-P group completes a basic version of the curriculum. The intervention content is delivered by a KEEP-P group facilitator in a 2-hour weekly group format. Duration of the program is 12 weeks.
62790146|NCT03106636|EXPERIMENTAL|KEEP-P+|Caregivers are randomly assigned to one of two groups. The KEEP-P+ group completes an augmented version of the intervention with curriculum that includes the addition of information about recent findings in early brain development and a video coaching component based on the Filming Interactions to Nurture Development (FIND) program. The intervention content is delivered by a KEEP-P group facilitator in a 2-hour weekly group format. Duration of the program is 12 weeks.
62790147|NCT01063153|EXPERIMENTAL|Concerta|Open-Label Concerta (Osmotic Release Methylphenidate)
62790148|NCT01063153|NO_INTERVENTION|Control group|Healthy subjects without ADHD will be assessed using EEG.
62018559|NCT03474159|OTHER|patients|patients with Bicuspid aortic valve (defined using the Sievers classification) and confirmed with either Transthoracic Echocardiography, computed tomography, or Magnetic Resonance Imaging Carotid pulse rate measured on carotid arteries by UF
62018560|NCT03082339||Neurology|Patients with inflammatory disease, especially multiple sclerosis, who underwent therapy with cortisone (\>=40mg/d)
62209637|NCT00955175|EXPERIMENTAL|Group 2|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 22 fractions (total of 66 Gy).
62209638|NCT00955175|EXPERIMENTAL|Group 3|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 20 fractions (total of 60 Gy).
62209639|NCT03806881||Treatment group|Patients treated with a Glenius Glenoid Reconstruction System
62209640|NCT02713087|ACTIVE_COMPARATOR|Ephedrine|
62209641|NCT02713087|ACTIVE_COMPARATOR|Phenylephrine|
62209642|NCT00835900|EXPERIMENTAL|varenicline|drug plus counseling.
62209643|NCT00835900|ACTIVE_COMPARATOR|placebo|placebo plus counseling
62209644|NCT01510080|EXPERIMENTAL|Computer-assisted live supervision|"Supervisees assigned to this group will receive 8 sessions of computer-assisted live supervision and 4 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. Computer-assisted live supervision is also known as bug-in-the-eye (BITE) supervision. The supervisor observes the therapy session with the help of a webcam and types messages on his computer. The instructions to the supervisee appear on a second monitor located in the therapy room where the supervisee can view it whenever he wants to."
62407198|NCT01726426|EXPERIMENTAL|Patients of palmer arsenical keratosis|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
62407199|NCT01726426|ACTIVE_COMPARATOR|Arsenic exposed controls|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
62582162|NCT06683638|EXPERIMENTAL|Doxycycline 200mg daily for 14 days|Participants diagnosed with early syphilis (primary, secondary, or early latent) with an RPR of 1:4 or greater will receive doxycycline 200mg daily to treat syphilis. Exclusions include pregnant persons, persons under 18 years of age, and persons on doxy PEP. During the two weeks of treatment, participants will perform oral and rectal swabs for syphilis, returned at the end of the 2 weeks by mail. Participants will submit brief online surveys twice over the two weeks of treatment. Repeat blood tests for syphilis, reactive plasma reagin (RPR), will be done at follow-up visits at 3 and 6 months to monitor serological response. Participants with response at the 3-month visit will not need to come to a 6-month visit.
62582163|NCT06264102|EXPERIMENTAL|Intervention group|Physical exercises program
62582164|NCT06264102|NO_INTERVENTION|Control group|Were advised not to change anything about their current lifestyle, and in particular not to undertake any new structured physical activity.
62209645|NCT01510080|EXPERIMENTAL|Delayed video-based supervision|Supervisees assigned to this group will receive 12 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. During delayed video-based supervision the supervisor and the supervisee spend 50 minutes reviewing selected parts of video recorded therapy sessions and discussing the case.
62209646|NCT02358759|ACTIVE_COMPARATOR|Giant Oocytes after ICSI|abnormally produced oocyte after ART or Controlled ovarian stimulation. Correction of abnormally fertilized oocytes using nucleus removal.
62582165|NCT04484142|EXPERIMENTAL|DS-1062a 6.0 mg/kg|Participants will receive 6.0 mg/kg of DS-1062a
62582166|NCT02855554|EXPERIMENTAL|Additional 5 minute research MR scan of heart.|The purpose of this is to evaluate new, faster MR scans
62582167|NCT03268759||PCE|Emerging adult individuals who were exposed to cocaine in-utero
62582168|NCT03268759||NCE|Emerging adult individuals who were not exposed to cocaine in-utero
62582169|NCT02457715||Prostate Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
62582170|NCT02457715||Renal Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
62582171|NCT02457715||Brain Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
62582172|NCT02457715||Amyotrophic Lateral Sclerosis (ALS)|Subjects will use a Jawbone Up24 for 14 weeks.
62018561|NCT03082339||Pulmonology|Patients after LTX (under medication possible prologing QTc-interval), who underwent therapy with cortisone (\>=40mg/d)
62209647|NCT02358759|ACTIVE_COMPARATOR|3PNs zygotes developed after ICSI|Abnormally developed embryos these produced 3PNs. Correction of abnormally fertilized oocytes using nucleus removal.
62209648|NCT05180539|EXPERIMENTAL|SPLASH Intervention Condition|
62582173|NCT00872027|EXPERIMENTAL|1|Participants will receive 8 weeks of escitalopram treatment.
62582174|NCT00872027|PLACEBO_COMPARATOR|2|Participants will receive 8 weeks of placebo pills.
62582175|NCT02171559|EXPERIMENTAL|Dabigatran etexilate capsules after enoxaparin ampoules|
62582176|NCT02171559|ACTIVE_COMPARATOR|Dabigatran etexilate capsules without enoxaparin|
62582177|NCT03403829|EXPERIMENTAL|maintenance arm|Gemcitabine maintenance treatment
62582178|NCT03403829|SHAM_COMPARATOR|control arm|observe and follow-up
62582179|NCT02784210|EXPERIMENTAL|Methylprednisolone|3 day course of intravenous methylprednisolone 1000 mg/day
62582180|NCT02784210|EXPERIMENTAL|prednisone|3-day course of oral prednisone 1250 mg/day
62209649|NCT05180539|OTHER|Diet and Physical Activity Condition|
62209650|NCT01807000|EXPERIMENTAL|Radiolabeled Prucalopride Succinate|
62209651|NCT05822830|EXPERIMENTAL|Tirzepatide|Participants will receive tirzepatide subcutaneously (SC).
62582181|NCT03573700|EXPERIMENTAL|SJCAR19 Therapy|"Patients in both the Phase I and Phase II portion of the study will receive lymphodepleting chemotherapy (unless determined by PI that lymphodepletion is not necessary), followed by a single infusion of the patient-derived SJCAR19 cellular product. The most commonly used lymphodepleting chemotherapy regimen will consist of the agents: Fludarabine and Cyclophosphamide. They will also receive Mesna. Dosing of SJCAR19 on the Phase I study will follow a dose escalation schema, with dose changes based on dose-limiting toxicities. In the Phase II study, SJCAR19 dosing with follow the maximum tolerated dose, as determined in the Phase I portion.~Cells for infusion are prepared using the CliniMACS System."
62209652|NCT05822830|ACTIVE_COMPARATOR|Semaglutide|Participants will receive semaglutide SC.
62209653|NCT02133222|EXPERIMENTAL|Metastatic (stage IV) melanoma|
62407200|NCT01726426|ACTIVE_COMPARATOR|Heathy volunteers|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
62407201|NCT04122339|EXPERIMENTAL|MAX-10181|tablet
62407202|NCT03058081|EXPERIMENTAL|High Flow Nasal Test|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with High Flow Nasal at 60L/min (with or without additional oxygen)
62407203|NCT03058081|NO_INTERVENTION|Control Test|Patient will perform one Constant Work-Rate Exercise Test at 80% of maximum workload on room air or with oxygen supplementation
62407204|NCT06032026|EXPERIMENTAL|11C-HY-2-15 PET|Participants will undergo 11C-HY-2-15 PET scan, they may also have a brain MRI and Amyloid PET scan as well as neurological assessments
62582182|NCT01844648|EXPERIMENTAL|NH004 tropicamide|tropicamide 1 mg thin film, twice daily for 7 days
62582183|NCT01844648|PLACEBO_COMPARATOR|NH004 placebo|placebo thin film, twice daily for 7 days
62582184|NCT05196399|EXPERIMENTAL|Aprocitentan (reference product)|25 mg film-coated tablet
62209654|NCT03814577|ACTIVE_COMPARATOR|Desflurane|Anesthesia will be maintained with Desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen air mixture.Total Intravenous Anesthesia will not be used in this group. While target desflurane minimum alveolar concentration (MAC) will be 1-1.5 and Bispectral Index values will be between 40-60, the flow rate will be adjusted to 2 L/min. Total Antioxidant Status and Total Oxidant Status will be then measured. Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
62209655|NCT03814577|EXPERIMENTAL|Total Intravenous Anesthesia|Total Intravenous Anesthesia: Anesthesia will be maintained with inhalation with a flow of 2 L/min in 0.5 O2 oxygen air mixture. Desflurane will not be used in this group. Total Intravenous Anesthesia (propofol and remifentanyl infusion) will be performed to the patients while target Bispectral Index values were between 40-60. Also the flow rate will be adjusted to 2 L/min. Total Antioxidant Status and Total Oxidant Status will be then measured. Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
62209656|NCT05521503||Biological specimens|Biological specimens taken from cardiovascular procedures
62209657|NCT01828489|ACTIVE_COMPARATOR|Standard arm MEC and ADxE|Standard protocol arm with mitoxantrone in first course (MEC) and standard ADxE treatment in course two
62209658|NCT01828489|EXPERIMENTAL|Experimental DxEC and standard ADxE|Experimental arm with DaunoXome in course one (DxEC) and standard ADxE treatment in course two
62209659|NCT01828489|EXPERIMENTAL|Standard arm MEC and experimental FLADx|Experimental arm with standard MEC in the first course (MEC) and experimental treatment with FLADx in course two
62209660|NCT01828489|EXPERIMENTAL|Experimental DxEC and experimental FLADx|Experimental treatment with DaunoXome in course one (DxEC) and experimental treatment with FLADx in course two
62209661|NCT05495737||Phase 1: Nurse Participants|n=8-10 nurses
62209662|NCT05495737||Phase 1: Patient Participants|n=8-10 patients
62209663|NCT05495737||Phase 2: Nurse Participants|n=8-10 nurses
62209664|NCT05495737||Phase 2: Patient Participants Meaning-Centered Psychotherapy/MCP-PC Intervention Arm|n=35
62209665|NCT05495737||Phase 2: Patient Participants Treatment As Usual/TAU Intervention Arm|n=35
62209666|NCT06131606|EXPERIMENTAL|experimental group|During the angiography, the researcher asked the patient to squeeze the stress ball once for every count of three. The angiography procedure lasted approximately 25-30 minutes.
62209667|NCT06131606|NO_INTERVENTION|control group|No intervention other than the clinic protocol was applied to this group.
62209668|NCT06236555|OTHER|Kahramanmaraş Sütçü İmam University|Patients who apply to our clinic for routine periodontal treatment will be included in the study.
62209669|NCT06729099||Low-risk group|Brain metastasis risk prediction model score 0-4 points.
62209670|NCT06729099||Medium-risk group|Brain metastasis risk prediction model score 5-10 points.
62209671|NCT06729099||High-risk group|Brain metastasis risk prediction model score \>10 points.
62582185|NCT05196399|EXPERIMENTAL|Aprocitentan (test product)|25 mg film-coated tablet
62209672|NCT03001375|ACTIVE_COMPARATOR|Mobilization group|Laparoscopic splenic flexure mobilization will be done.
62582186|NCT02663063|EXPERIMENTAL|SSP treatment group|Case on SSP treatment
62790149|NCT05954000|EXPERIMENTAL|Intervention|Dose-finding study with 14 groups of 3 participants each. To identify the minimum effective dose (MED) to increase medication adherence by 20% between run-in and follow-up periods, the first group of 3 participants will receive a 5-week dose of the multi-BCT intervention. For the next subjects, the doses to administrate will vary between 1 and 10 weeks in length and will be determined by the modified Time-to-Event Continual Reassessment Method (TiTE-CRM) according to the observed responses in the previous subjects.
62018562|NCT05243108|EXPERIMENTAL|NTs Intervention group|The subject of 1200mg has been given orally once a day for 4 months.
62209673|NCT03001375|ACTIVE_COMPARATOR|Non mobilization group|No mobilization of splenic flexure.
62209674|NCT06681870|EXPERIMENTAL|Part 1: ASP1893 (Monotherapy) Dose Escalation|Participants will receive sequential dose levels of ASP1893 intravenously every 2 weeks or 3 weeks, for a duration of up to 2 years (26 Cycles).
62209675|NCT06681870|EXPERIMENTAL|Part 2: ASP1893 (Monotherapy) Dose Expansion|Participants with select tumor types who have progressed on standard therapies, are no longer eligible for standard therapies or have refused standard approved therapies will receive 1 of 2 dose regimens of ASP1893 from the Dose Escalation phase.
62209676|NCT05852704|ACTIVE_COMPARATOR|Active arm|Treatment with dapagliflozin 10 mg once daily.
62209677|NCT05852704|PLACEBO_COMPARATOR|Placebo arm|Treatment with matching placebo once daily.
62209678|NCT01369771|EXPERIMENTAL|Tafluprost 0.0015%|Open, one arm study. Patients who have been using latanoprost 0.005% eye drops (Xalatan®) as their prior medication (at least 6 months) and who fulfil all the inclusion criteria including the specified ocular symptoms and signs, will switch from latanoprost to the assigned preservative-free tafluprost 0.0015% (Taflotan®)eye drops for twelve (12) months.
62790150|NCT05476172|ACTIVE_COMPARATOR|Dienogest|Patients with endometriosis are prescribed dienogest for treatment.
62018563|NCT05243108|PLACEBO_COMPARATOR|placebo control group|The ingredients, dosage, and usage are the same as experimental.
62209679|NCT04083105|EXPERIMENTAL|30% Nitrous Oxide with Midazolam|30 percent nitrous oxide/70 percent oxygen will be administered for 5 minutes prior to intranasal midazolam.
62209680|NCT04083105|EXPERIMENTAL|70% Nitrous Oxide with Midazolam|70 percent nitrous oxide/30 percent oxygen will be administered for 5 minutes prior to intranasal midazolam.
62209681|NCT06303258|EXPERIMENTAL|Core Stabalization Exercises Group|This Group will receive core stability exercises 3 sessions per week for 4 weeks and basic antenatal education.
62209682|NCT06303258|EXPERIMENTAL|Generalized Exercise Group|This Group will receive generalized supervised antenatal exercises that are covered in three phases and basic antenatal education. There will be 3 sessions per week for 10weeks conducted for generalized antenatal exercises including Aerobics, Endurance and Pelvic Floor Muscle Training.
62582187|NCT02663063|SHAM_COMPARATOR|Non-SSP treatment group|Sham SSP treatment
62582188|NCT04545151|EXPERIMENTAL|Verapamil SR|Eligible participants will be randomised into the Verapamil SR arm and receive instructions on frequency of administration (daily intake). 80 participants on the experimental arm are expected to complete the trial.
62209683|NCT06303258|NO_INTERVENTION|Control Group|Basic Antenatal Education for Lumbopelvic Pain Prevention
62209684|NCT05199987|ACTIVE_COMPARATOR|Standard Occupational Therapy|This group will receive standard occupational therapy sessions
62209685|NCT05199987|EXPERIMENTAL|Occupational Therapy with Breathing Control Exercises|This group will receive the same component of the control group + breathing control exercises
62209686|NCT01332630|EXPERIMENTAL|TPI 287|TPI 287 administered at 160 mg/m2 by vein on Day 1 and repeated every three weeks. Day 1 of each subsequent cycle is equivalent of day 22 of the previous cycle; pre TPI 287: Dexamethasone 6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, Dexamethasone 10 mgby vein may be given 30-60 minutes prior to treatment with TPI 287, Benadryl 12.5-25 mg IV push over 30-60 minutes, and Ranitidine 1mg/kg IV over 30-60 minutes.
62209687|NCT05870839|EXPERIMENTAL|VXCO-100 Group 1|Participants 18-55 years of age will receive VXCO-100 at Dose Level 1 via intramuscular (IM) injection
62209688|NCT05870839|EXPERIMENTAL|VXCO-100 Group 2|Participants 18-55 years of age will receive VXCO-100 at Dose Level 2 via intramuscular (IM) injection
62209689|NCT05870839|EXPERIMENTAL|VXCO-100 Group 3|Participants 18-55 years of age will receive VXCO-100 at Dose Level 3 via intramuscular (IM) injection
62209690|NCT05870839|EXPERIMENTAL|VXCO-100 Group 4|Participants 56+ years of age will receive VXCO-100 at Dose Level 1 via intramuscular (IM) injection
62209691|NCT05870839|EXPERIMENTAL|VXCO-100 Group 5|Participants 56+ years of age will receive VXCO-100 at Dose Level 2 via intramuscular (IM) injection
62018564|NCT02131298|OTHER|Fixed sequence|Fixed sequence study with treatment A of palbociclib alone, followed by treatment B (palbociclib with itraconazole)
62209692|NCT05870839|EXPERIMENTAL|VXCO-100 Group 6|Participants 56+ years of age will receive VXCO-100 at Dose Level 3 via intramuscular (IM) injection
62209693|NCT01062802|PLACEBO_COMPARATOR|Placebo|
62209694|NCT01062802|ACTIVE_COMPARATOR|Statin group|
62209695|NCT04929275|OTHER|Enhanced recovery program|
62209696|NCT04322903|EXPERIMENTAL|Trauma-informed mindfulness-based stress reduction program|The program includes three 2-hr sessions to promote physical and emotional wellbeing through mindfulness techniques and health promotion activities; two home visits to provide individualized sessions with a nurse and a community health navigator; and a follow-up session 4 weeks after intervention to discuss perception of the intervention.
62209697|NCT04767243|SHAM_COMPARATOR|open flap debridement and filled with A-PRF|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
62209698|NCT04767243|ACTIVE_COMPARATOR|open flap debridement and filled with Bioactive glass (Perioglas®)|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of Bioactive glass (Perioglas®) in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
62209699|NCT04767243|ACTIVE_COMPARATOR|with open flap debridement and filled Bioactive glass (Perioglas®) and A-PRF.|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of Bioactive glass (Perioglas®) along with A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
62407205|NCT05493683|EXPERIMENTAL|Combination of Disitamab Vedotin and Tislelizumab|Disitamab Vedotin 2.0mg/kg q2w+Tislelizumab 400mg q6w. The treatment of Disitamab Vedotin + Tislelizumab will continue until the tumor progression confirmed by imaging, or up to 2 years, or intolerable toxic reactions, or other conditions determined by the researchers.
62407206|NCT06342791|EXPERIMENTAL|Group A (study group)|received Laser on acupuncture point BL23, BL26, BL40, SP6
62407207|NCT06342791|PLACEBO_COMPARATOR|Group B (Control group)|received sham laser acupuncture on BL23, BL26, BL40, SP6 but the laser was not turned on
62407208|NCT05774080||Disease Cohort|Observational
62018565|NCT03117335|ACTIVE_COMPARATOR|Vinorelbine plus Cisplatin With placebos|The control group
62018566|NCT03117335|EXPERIMENTAL|Vinorelbine plus Cisplatin With Sulijia|The treatment group
62018567|NCT04533841|ACTIVE_COMPARATOR|Misoprostol + propranolol|Patient who receive misoprostol then after 30minutes receive propranolol
62209700|NCT05709600|ACTIVE_COMPARATOR|Fasting mimicking diet|Human fasting mimicking diet (Prolon®) for five days prior to living kidney donation in donor: Day 1 of Prolon® supplies \~4600 kJ, day 2-5 provide \~3000kJ.
62209701|NCT05709600|ACTIVE_COMPARATOR|Ketogenic diet|Isocaloric, ketogenic diet 7 days prior to living kidney donation in the kidney donor with below 5% of energy from carbohydrate (\<20g/day), approximately 15% from protein (\<100g/day) and 80% from fat (\>125g/day) without changes in caloric supply calculated by the Mifflin-St.Jeor formula achieved by the KetoCal 4:1 formula diet (Nutricia Milupa GmbH, Erlangen, Germany).
62407209|NCT05774080||Engaged Cohort|Observational
62209702|NCT05709600|ACTIVE_COMPARATOR|Dietary restriction of sulfur containing amino acids|Isocaloric, dietary restriction of sulfur containing amino acids in the donor without changes in caloric supply calculated by the Mifflin-St.Jeor formula achieved by the X Met X Cys Maxamaid formula diet (Nutricia Milupa GmbH, Erlangen, Germany).
62209703|NCT05709600|ACTIVE_COMPARATOR|Control-Group|Healthy, low-fat, moderate protein and high carbohydrate diet in the donor as described in the current nutritional recommendations of the American Diabetes Association achieved by the Fortimel® diet (Nutricia Milupa GmbH, Erlangen, Germany)
62209704|NCT03694132|EXPERIMENTAL|functional MRI|a group of patients with ALS and a group of gender and age matched healthy subjects will have functional MRI acquisition conditioned by electrical and mechanical stimuli of ADM proprioceptors
62407210|NCT02996604|EXPERIMENTAL|Low-He point(ST36)|Zusanli (ST36, the Low-He point of stomach) is the most important point for gastrointestinal disorder, including functional dyspepsia. Everyone in the group will be punctured at unilateral Zusanli.
62407211|NCT02996604|EXPERIMENTAL|Mu point(CV12)|Zhongwan (CV12, the Mu point of stomach) is also good at regulating gastric function. Everyone in the group will be punctured at Zhongwan.
62407212|NCT02996604|ACTIVE_COMPARATOR|He-Mu-point combination(ST36 and CV12)|In traditional Chinese acupuncture theory，synergistic effect can be produced by acupoints combination and the He-Mu-point combination is a classical acupoints combination formula for gastrointestinal diseases. Everyone in the group will be punctured at unilateral Zusanli and Zhongwan.
62407213|NCT03583840|NO_INTERVENTION|Control group|Participants who will not be directed to the ScreenMen website
62018568|NCT04533841|PLACEBO_COMPARATOR|Misoprostol + placebo|Pt who will receive misoprostol then after 30minutes receive placebo
62018569|NCT05747677|EXPERIMENTAL|HH-120 Nasal Spray|
62018570|NCT02359721|EXPERIMENTAL|test group|Base line scaling and root planing was done. Clarithromycin tablet 500 mg( Clarino-500) was given for a period of 7 days orally two times per day
62018571|NCT02359721|NO_INTERVENTION|control|scaling and root planing
62018572|NCT06057415|NO_INTERVENTION|Standard care|Will receive standard of care according to the institutional protocol and principles of developmental care which currently belongs to (inter-) national guidelines and is regarded as safe.
62018573|NCT06057415|EXPERIMENTAL|Standard care supplemented with HAPTOS intervention|Will receive standard of care according to the principles of developmental care which currently belongs to (inter-) national guidelines plus HAPTOS intervention which includes: tactile/ kinaesthetic massage of the trunk and extremities twice daily and stimulation of oral function by providing perioral stimulation up to 4 times a day. Interventions will be continued until clinical improvement.
62018574|NCT06296342|NO_INTERVENTION|Control (No framing)|Participants will view one message about the front-of-package labeling policy. The message will display the same introductory sentence as all experimental arms, but it will not include a framed message about the objective of the front-of-package labeling policy.
62018575|NCT06296342|EXPERIMENTAL|Information framing|Participants will view one message that frames the objective of the front-of-package labeling policy as providing nutritional information.
62209705|NCT03694132|EXPERIMENTAL|structural MRI|a group of patients with ALS and a group of gender and age matched healthy subjects will have diffusion MRI acquisition to evaluate their brain structures
62209706|NCT03694132|EXPERIMENTAL|EEG/MEG|a group of patients with ALS and a group of gender and age matched healthy subjects will have functional MRI acquisition conditioned by electrical stimuli of ADM proprioceptors
62209707|NCT06560151|EXPERIMENTAL|Treatment Group A|This treatment group of 60 participants (ages 18-64) in Treatment Group A will receive 3.75 µg of Egg-A/Astrakhan/3212/2020 (H5N8) antigen adjuvanted with a full dose of AS03A.
62018576|NCT06296342|EXPERIMENTAL|Healthier choices framing|Participants will view one message that frames the objective of the front-of-package labeling policy as encouraging consumers to make healthier choices.
62209708|NCT06560151|EXPERIMENTAL|Treatment Group B|This treatment group of 120 participants (60 participants ages 18-64 and 60 participants ages ≥65) in Treatment Group B will receive 7.5 µg of Egg-A/Astrakhan/3212/2020 (H5N8) adjuvanted with a full dose of AS03A.
62209709|NCT06560151|EXPERIMENTAL|Treatment Group C|This treatment group of 120 participants (60 participants ages 18-64 and 60 participants age ≥65) will receive 15 µg of Egg-A/Astrakhan/3212/2020 (H5N8) adjuvanted with a full dose of AS03A.
62407214|NCT03583840|EXPERIMENTAL|Intervention group|Participants who will be directed to the ScreenMen website
62407215|NCT03522506|EXPERIMENTAL|TAK-925 Low Dose + Placebo + TAK-925 High Dose + Modafinil|TAK-925 low dose milligram (mg), intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
62018577|NCT06296342|EXPERIMENTAL|Industry framing|Participants will view one message that frames the objective of the front-of-package labeling policy as encouraging the food industry to make healthier products.
62582189|NCT04545151|PLACEBO_COMPARATOR|Placebo|"Eligible participants will be randomised into the placebo arm and receive instructions on frequency of administration (daily intake).~40 participants on the control arm are expected to complete the trial."
62734497|NCT03281369|EXPERIMENTAL|1L-A: mFOLFOX6 + Atezo + Cobi (Gastric Cancer)|Participants in the 1L-A Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab plus cobimetinib. No longer enrolling participants as of June 2018.
62209710|NCT06560151|EXPERIMENTAL|Treatment Group D|This treatment group of 60 participants (ages 18-64) will receive 3.75 µg of Egg-A/Astrakhan/3212/2020 (H5N8) adjuvanted with a half dose of AS03A.
62209711|NCT06560151|EXPERIMENTAL|Treatment Group E|This treatment group of 120 participants (60 participants ages 18-64 and 60 participants age ≥65) will receive 7.5 µg of Egg-A/Astrakhan/3212/2020 (H5N8) adjuvanted with a half dose of AS03A.
62209712|NCT06560151|EXPERIMENTAL|Treatment Group F|This treatment group of 120 participants (60 participants ages 18-64 and 60 participants age ≥65 will receive 15 µg of Egg-A/Astrakhan/3212/2020 (H5N8) adjuvanted with a half dose of AS03A.
62209713|NCT06560151|EXPERIMENTAL|Treatment Group G|This treatment group of 60 participants (ages 18-64) will receive 3.75 µg of Egg-A/Astrakhan/3212/2020 (H5N8) adjuvanted with MF59.
62209714|NCT06560151|EXPERIMENTAL|Treatment Group H|This treatment group of 120 participants (60 participants ages 18-64 and 60 participants age ≥65) will receive 7.5 µg of Egg-A/Astrakhan/3212/2020 (H5N8) adjuvanted with MF59.
62582190|NCT06683066|EXPERIMENTAL|Group A|Patients must be in D - 28 hips intramuscular injection at a time Shot with acetic acid QuPu gonadorelin import (Diphereline) 3.75 mg, after screening the qualified with the method of delamination, block random, stratified factors for treatment (first time and the first) treatment, patients were randomly allocated to group A: T, Subjects were given triprelyn acetate for injection (manufactured and supplied by Qilu Pharmaceutical Co., LTD.) on the day of administration
62582191|NCT06683066|ACTIVE_COMPARATOR|Group B|All patients were injected 3.75mg triprerelin acetate (Diphereline) once into the buttock muscle of D-28 for introduction. After qualified screening, stratified and block randomized methods were adopted. Stratified factors were therapeutic factors (primary treatment and non-primary treatment), and patients were randomly assigned to group B :R, Subjects were given triprerelin acetate for injection on the day of administration (produced by Ipsen Pharma Biotech, supplied by Qilu Pharmaceutical Co., LTD.)
62582192|NCT05606302||Piperacillin group|Blood samples for hemolytic anemia in patients treated with piperacillin were screened for the production of drug antibodies.
62018578|NCT00659646|EXPERIMENTAL|A|Gentamicin sponge applied into wound plus levofloxacin, 750 mg by mouth (po) or intravenous (IV) every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing
62209715|NCT06560151|EXPERIMENTAL|Treatment Group I|This treatment group of 120 participants (60 participants ages 18-64 and 60 participants age ≥65) will receive 15 µg of Egg-A/Astrakhan/3212/2020 (H5N8) adjuvanted with MF59.
62209716|NCT06560151|EXPERIMENTAL|Treatment Group J|This treatment group of 60 participants (ages 18-64) will receive 3.75 µg of Egg-A/bar-headed goose/Qinghai Lake/1A/2005 (H5N1) adjuvanted with a full dose of AS03A.
62209717|NCT06560151|EXPERIMENTAL|Treatment Group K|This treatment group of 120 participants (60 participants ages 18-64 and 60 participants age ≥65) will receive 7.5 µg of Egg-A/bar-headed goose/Qinghai Lake/1A/2005 (H5N1) adjuvanted with a full dose of AS03A.
62209718|NCT06560151|EXPERIMENTAL|Treatment Group L|This treatment group of 60 participants (ages ≥65) will receive 15 µg of Egg-A/bar-headed goose/Qinghai Lake/1A/2005 adjuvanted with a full dose of AS03A.
62018579|NCT00659646|ACTIVE_COMPARATOR|B|Levofloxacin, 750 mg po or IV every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing
62018580|NCT01358513||Control Patients|Patients with normal aortic valves
62209719|NCT06560151|EXPERIMENTAL|Treatment Group M|This treatment group of 60 participants (ages 18-64) will receive 3.75 µg of Egg-A/bar-headed goose/Qinghai Lake/1A/2005 (H5N1) adjuvanted with MF59.
62209720|NCT06560151|EXPERIMENTAL|Treatment Group N|This treatment group of 120 participants (60 participants ages 18-64 and 60 participants age ≥65) will receive 7.5 µg of Egg-A/bar-headed goose/Qinghai Lake/1A/2005 (H5N1) adjuvanted with MF59.
62209721|NCT06560151|EXPERIMENTAL|Treatment Group O|This treatment group of 60 participants (age ≥65) will receive 15 µg of Egg-A/bar-headed goose/Qinghai Lake/1A/2005 (H5N1) adjuvanted with MF59.
62209722|NCT01073787|ACTIVE_COMPARATOR|Normal saline|
62209723|NCT01073787|EXPERIMENTAL|Normal saline and possible medication|
62209724|NCT02169362|EXPERIMENTAL|Platelet Rich Plasma - Bio-Bandage™|Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)
62209725|NCT02169362|SHAM_COMPARATOR|Saline Spray, Standard of Care|
62209726|NCT05183464||Children with primary hypersomnia|Children with primary hypersomnia, i.e. narcolepsy or idiopathic hypersomnia
62209727|NCT05183464||Children with secondary hypersomnia|Children with a secondary hypersomnia, i.e. caused by sleep deprivation, a psychiatric disorder, sleep fragmentation, circadian delay.
62209728|NCT02015455|EXPERIMENTAL|Intervention Arm|Epidemiologic benchmarks included in lumbar imaging reports
62209729|NCT02015455|NO_INTERVENTION|Usual Care Arm|Clinics with typical lumbar imaging reports (no epidemiologic benchmarks included)
62209730|NCT06229652|EXPERIMENTAL|RASMUS Resilience Training|RASMUS is a systematic, behavior-oriented group training in which the following methods are used: mindfulness exercises, exercises in self-compassion/guided meditations, knowledge transfer by means of a teaching talk/lecture, working out the topics in individual and small group work, group exercises, group discussion and exchange, train coping strategies: somatic, cognitive, and emotional levels, independent reflection on what has been learned, homework, weekly protocols, transfer to everyday life, questionnaires on resilience factors, mindfulness, and self-compassion for self-control, linking the course topics with one another.
62209731|NCT06229652|ACTIVE_COMPARATOR|Body-oriented Yoga|The body-oriented yoga classes following the Ashtanga style will run in parallel to the RAMUS resilience group (one-hour, once a week). The yoga instructor will support each participant in the form of verbal and hands-on assistance.
62582193|NCT05606302||Amoxicillin group|Blood samples for hemolytic anemia in patients treated with amoxicillin were screened for the production of drug antibodies.
62209732|NCT04732065|EXPERIMENTAL|Arm A: ONC206 for participants with diffuse midline gliomas + prior therapy|Patients receive ONC206 orally (PO) up to six times per week. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
62407216|NCT03522506|EXPERIMENTAL|TAK-925 High Dose + TAK-925 Low Dose + Modafinil + Placebo|TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
62407217|NCT03522506|EXPERIMENTAL|Modafinil + TAK-925 High Dose + Placebo + TAK-925 Low Dose|Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
62407218|NCT03522506|EXPERIMENTAL|Placebo + Modafinil + TAK-925 Low Dose + TAK-925 High Dose|Placebo, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
62407219|NCT05643859|EXPERIMENTAL|Supportive care (oral fiber)|Patients receive dietary fiber PO QD for 28 days. Patients may undergo standard of care proctoscopy or anoscopy with biopsy on study and at follow up or may undergo standard of care colonoscopy on study. All patients also undergo collection of blood samples on study and at follow up.
62582194|NCT05606302||Cefazolin group|Blood samples for hemolytic anemia in patients treated with cefazolin were screened for the production of drug antibodies.
62582195|NCT05606302||Cefuroxime group|Blood samples for hemolytic anemia in patients treated with cefuroxime were screened for the production of drug antibodies.
62582196|NCT05606302||Ceftriaxone group|Blood samples for hemolytic anemia in patients treated with ceftriaxone were screened for the production of drug antibodies.
62582197|NCT05606302||Cefoxitin sodium group|Blood samples for hemolytic anemia in patients treated with cefoxitin sodium were screened for the production of drug antibodies.
62582198|NCT05606302||Vancomycin group|Blood samples for hemolytic anemia in patients treated with vancomycin were screened for the production of drug antibodies.
62209733|NCT04732065|EXPERIMENTAL|Arm B: ONC206 + radiation therapy for newly diagnosed participants|Patients undergo standard of care radiation therapy daily 5 days a week and receive ONC206 PO up to six times per week. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
62209734|NCT04732065|EXPERIMENTAL|Arm C: ONC206 + radiation therapy, DMGs with evidence of first progression but previously untreated|Patients undergo standard of care radiation therapy daily 5 days a week and receive ONC206 PO up to six times per week. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
62209735|NCT04732065|EXPERIMENTAL|Arm D: ONC206 Therapy, Primary malignant CNS tumors with progression|Patients receive ONC206 PO once a day (QD) up to six times per week. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
62407220|NCT01232764|EXPERIMENTAL|Multi-disciplinary wound care team|Stepped wedge study design i.e. start date of exposure is randomized.
62582199|NCT02038855|ACTIVE_COMPARATOR|IIDEA|Patients in the Integrated Intervention for Dual Problems and Early Action (IIDEA) arm will receive the 10 session intervention administered in person and via telephone.
62582200|NCT02038855|NO_INTERVENTION|Usual Care|Patients in this arm receive usual care for dual-diagnosis symptoms of mental health and substance use. They receive 5 check-in calls from a care manager to assess safety.
62582201|NCT01944839|EXPERIMENTAL|E10030 + ranibizumab|E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection
62018581|NCT01358513||Aortic sclerosis|To undergo PET imaging and follow up with CT and echo for 2 years
62018582|NCT01358513||Mild Aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
62209736|NCT06728657|EXPERIMENTAL|HFRT|Participants will receive upfront hypofractionated radiotherapy (HFRT) of the primary lesion and positive lymph nodes (24 Gy/6 fractions). Afterwards, systemic therapy consisted of CAPOX and PD-1 antibodies will be administered every three weeks, for at least 3 cycles. Then, reassessment will be performed within 4 weeks afterwards. For resectable participants, surgical resections of primary lesion will be performed. Postoperative treatment will be determined by the investigators. For unresectable or inoperable participants, the subsequent treatment will be determined by investigators or MDT.
62209737|NCT06728657|EXPERIMENTAL|PULSAR|Participants will receive treatment every three weeks, for at least 3 cycles. Each cycle of treatment consists of irradiation (6 Gy/1 fraction) to the primary lesion and positive lymph nodes on day 1, and systemic therapy consisted of CAPOX and PD-1 antibodies will be administered on day 2. Then, reassessment was performed within 4 weeks afterwards. For resectable participants, surgical resections of primary lesion will be performed. Postoperative treatment will be determined by the investigators. For unresectable or inoperable participants, the subsequent treatment will be determined by investigators or MDT.
62209738|NCT06050200|ACTIVE_COMPARATOR|PVE|Portal Vein Embolisation Patients in this group will undergo embolisation of branch of portal vein (interventional radiological procedure)
62209739|NCT06050200|ACTIVE_COMPARATOR|LVD|Liver Venous Deprivation Patients in this group will undergo simultaneous embolization of branch of the portal vein and one or two hepatic veins (interventional radiological procedure)
62582202|NCT01944839|ACTIVE_COMPARATOR|Sham + ranibizumab|E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection
62582203|NCT04615013|EXPERIMENTAL|Treatment (NBTXR3, IMRT, chemotherapy)|Patients receive NBTXR3 IT or IN on day 1. Beginning day 15, patients undergo IMRT 5 days per week for 6 weeks for a total of 28 fractions, in the absence of disease progression or unacceptable toxicity. Concurrent with IMRT, patients receive a chemotherapy regimen consisting of either fluorouracil and oxaliplatin with or without leucovorin, oxaliplatin and capecitabine, docetaxel and fluorouracil with or without leucovorin, docetaxel and paclitaxel, or carboplatin and paclitaxel per physician discretion.
62209740|NCT06050200|EXPERIMENTAL|ALPPS|Associating Liver Partition and Portal vein Ligation for Staged hepatectomy: Patients in this group will undergo surgical ligation of portal vein branch with partial liver transection (surgical procedure)
62209741|NCT06641973|EXPERIMENTAL|Experimental Group (G-Hun)|The experimental group (G-Hun), will carry out robotic balance treatment with the hunova® robotic platform lasting 30 minutes per session, 2 times a week for 5 weeks, in addition to their clinical pathway services.
62209742|NCT06641973|NO_INTERVENTION|Control Group (G-Con)|
62209743|NCT04491552||Patients monitored with TruGraf and TRAC testing|Subjects will have TruGraf and TRAC testing at study enrollment (Baseline) and thereafter every 3 months. In addition subjects will have TRAC testing at any time there is a suspicion of acute rejection.
62209744|NCT02113124||Chronic brain injury|Individuals in this group have suffered a brain injury more than 2 years prior to study. Ages range from 21 to 70.
62209745|NCT02113124||Uninjured control|This group of individuals have no history of brain injury. Ages range between 21 and 70.
62209746|NCT06233227|EXPERIMENTAL|Sequence 1- Dutasteride test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= dutasteride 0.5 mg capsule test product, treatment 2= dutasteride 0.5 mg capsule reference product.
62209747|NCT06233227|EXPERIMENTAL|Sequence 2-Dutasteride reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= dutasteride 0.5 mg capsule test product, treatment 2= dutasteride 0.5 mg capsule reference product.
62209748|NCT01305200|PLACEBO_COMPARATOR|Arm I (placebo)|Patients rinse and gargle with placebo over 1 minute QID beginning the first day (about day -7) of the conditioning regimen. Treatment continues until day 20 post-transplantation.
62209749|NCT01305200|EXPERIMENTAL|Arm II (supersaturated calcium phosphate rinse)|Patients rinse and gargle with supersaturated calcium phosphate rinse over 1 minute QID beginning on the first day (about day -7) of the conditioning regimen. Treatment continues until day 20 post-transplantation.
62209750|NCT06727877|EXPERIMENTAL|NEC|diagnosis of NEC according to the Bell classification
62209751|NCT06727877|OTHER|control|children without diagnosis of NEC
62209752|NCT03026192||no PDA|These are infants who do not have a patent ductus arteriosus (PDA) as determine by echocardiography
62582204|NCT06238687|EXPERIMENTAL|Cohort 1(Phase I)|STRO-002 3.5 mg/kg Open Lable
62582205|NCT06238687|EXPERIMENTAL|Cohort 2(Phase I)|STRO-002 4.3 mg/kg Open Lable
62018583|NCT01358513||Moderate Aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
62582206|NCT06238687|EXPERIMENTAL|Cohort 3(Phase I)|STRO-002 5.2 mg/kg Open Lable
62209753|NCT03026192||hsPDA|These are infants who have a hemodynamically significant PDA (hsPDA) as determined by echocardiography
62209754|NCT02952118|EXPERIMENTAL|one night with the device and one night without the device.|"The study duration with each patient will be 48 hours (two nights); at the first night the sleep study will be with PAT device, with snoring recording and without the Forrest epic device. In the second night the sleep study will be with PAT device, with snoring recording and with the Forrest epic device. The order of the sleep studies (with and without the epic device) will be randomly determined by computerized ahead prepared list. The research duration for patients that did not have a sleep study over the last year, will take place for 3 nights; the sleep study will be performed in order to make sure the patient does not suffer from obstructive respiratory disorder during sleep. The sleep studies will take place in a sleep laboratory (Millennium Sleep Labs LTD, Beer Sheva) or as an ambulatory study, at home."
62209755|NCT06629181|NO_INTERVENTION|Control|Elderly people will continue to receive routine care at the family health center.
62209756|NCT06629181|EXPERIMENTAL|Intervention|The group in which the intervention was made
62209757|NCT00542776||1|IBD patients on immunosuppressive therapy
62209758|NCT00542776||2|IBD patients on non-immunosuppressive therapy (e.g., aminosalicylates, antibiotics) or on no medications
62209759|NCT06623357|EXPERIMENTAL|Group A - Pilot Protocol|Participants in Group A will receive training in PROM techniques via a visual handout with pictures and written instructions and video recording using the caregiver's cell phone/tablet of the trainer and/or caregiver performing PROM on the infant. Participants in Group A will also receive supplemental training including a step-by-step checklist for each of the shoulder stretches that are recommended and will be instructed to refer to the checklist each time they perform PROM at home. Participants will be observed performing PROM at their initial visit where training occurs and at their infants' next follow-up visit. The standardized checklist will be used to assess efficacy of caregivers' demonstrated PROM including assessment of positioning, hand placement, and number of cues needed to facilitate accuracy; specific feedback will be given as needed.
62582207|NCT06238687|EXPERIMENTAL|Cohort A(Phase IIa)|Recurrent and/or progressive ovarian epithelial cancer, confirmed by immunohistochemistry \[IHC\] testing with FolRα positive expression (TPS ≥ 75%).
62582208|NCT06238687|EXPERIMENTAL|Cohort B(Phase IIa)|Recurrent and/or progressive ovarian epithelial cancer, confirmed by IHC testing with FolRα positive expression (25% ≤ TPS \< 75%).
62582209|NCT06238687|EXPERIMENTAL|Cohort C(Phase IIa)|Recurrent and/or progressive endometrial cancer, confirmed by IHC testing with FolRα positive expression (TPS ≥ 25%).
62582210|NCT06238687|EXPERIMENTAL|Cohort D(Phase IIa)|Recurrent and/or progressive non-small-cell lung cancer, confirmed by IHC testing with FolRα positive expression (TPS ≥ 25%).
62582211|NCT06238687|EXPERIMENTAL|Cohort E(Phase IIa)|Recurrent and/or progressive triple-negative breast cancer, confirmed by IHC testing with FolRα positive expression (TPS ≥ 25%).
62582212|NCT04172259|EXPERIMENTAL|ACHP-THP|Doxorubicin liposome（PLD）35 mg/m2 Cyclophosphamide（CTX）600 mg/m2 Trastuzumab：first cycle 8mg/kg，then 6mg/kg Pertuzumab：first cycle 840mg，then 420mg Docetaxel（DOC）75 mg/m2 every 3 weeks paclitaxel (PTX) 175 mg/m2 every 3 weeks or paclitaxel (PTX) 80 mg/m2 every week albumin-bound paclitaxel 260 mg/m2 or albumin-bound paclitaxel 100 mg/m2 every week
62582213|NCT04172259|ACTIVE_COMPARATOR|EC-THP|Epirubicin（EPI）90 mg/m2 Cyclophosphamide（CTX）600 mg/m2 Trastuzumab：first cycle 8mg/kg，then 6mg/kg Pertuzumab：first cycle 840mg，then 420mg Docetaxel（DOC）75 mg/m2 every 3 weeks paclitaxel (PTX) 175 mg/m2 every 3 weeks or paclitaxel (PTX) 80 mg/m2 every week albumin-bound paclitaxel 260 mg/m2 or albumin-bound paclitaxel 100 mg/m2 every week
62582214|NCT05325190|EXPERIMENTAL|Intervention group|Granisetron transdermal patch 3.1mg was given 48 hours before the first day of chemotherapy, Dexamethasone 12mg was taken orally on the first day of chemotherapy and dexamethasone 8mg was taken orally on the second and third days of chemotherapy,3.1mg granisetron transdermal patch was replaced on the 5th day of chemotherapy. Granisetron transdermal patch was removed and discarded on the 12th day of chemotherapy.
62582215|NCT01265576|PLACEBO_COMPARATOR|Sorafenib with placebo|Participants randomized to the Control Arm (sorafenib with placebo) receive sorafenib as the standard of care, and placebo for the same periods as participants randomized to the Treatment Arm (sorafenib plus VT-122). Participants randomized to the Control Arm will undergo the same visits and procedures as would the participants randomized to the Treatment Arm.
62582216|NCT01265576|EXPERIMENTAL|Sorafenib plus VT-122|
62582217|NCT00495209||Qigong|"Pre-surgical Qigong therapy for women with breast cancer~External Qi Therapy = EQT"
62582218|NCT00003830|ACTIVE_COMPARATOR|Arm I: Conventional axillary dissection|Sentinel node resection immediately followed by axillary dissection
62582219|NCT00003830|EXPERIMENTAL|Arm II: Sentinel node resection followed by node examination|Sentinel node resection followed by node examination then axillary dissection if positive sentinel node.
62582220|NCT04488211||Prospective survey respondents|Invitations to participate in the survey will be emailed on three occasions to selected fertility specialists worldwide who are affiliated to a public or private fertility clinic.
62582221|NCT04662281|PLACEBO_COMPARATOR|Placebo|Following a 2-week Single-blind Run-in period, participants will receive a single loading dose of matching-placebo to LX9211 tablet, orally, on Day 1 and maintenance doses, orally, once daily from Day 2 to Week 6.
62582222|NCT04662281|EXPERIMENTAL|LX9211|Following a 2-week Single-blind Run-in period, participants will receive a single loading dose of 200 milligrams (mg) tablet, orally, on Day 1 and maintenance doses of 20 mg, orally, once daily from Day 2 to Week 6.
62790151|NCT05476172|ACTIVE_COMPARATOR|Norethindrone Acetate|Patients with endometriosis are prescribed Norethindrone Acetate for treatment.
62407221|NCT02570217|EXPERIMENTAL|HHHFNC|The patients receive respiratory support by mean of Heated Humidified High Flow Nasal cannula
62209760|NCT06623357|ACTIVE_COMPARATOR|Group B - Standard Protocol|Participants in Group B will receive training in PROM techniques via the same visual handout with pictures and written instructions provided to Group A as well as video recording using the caregiver's cell phone/tablet of the trainer and/or caregiver performing PROM on the infant.
62209761|NCT02544009||1|16 subjects who previously participated in the Biggest Loser study
62582223|NCT02090530||Advanced Cancer Patients|Individuals with advanced or refractory cancer must be identified by study personnel or their treating physician, deemed eligible for this study, and voluntarily agree to be enrolled in this protocol through an informed consent. Biospecimen collection includes a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
62582224|NCT03503370|EXPERIMENTAL|Chlorhexidine|Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
62582225|NCT03503370|PLACEBO_COMPARATOR|Placebo|Participants randomized to the placebo will wash their feet using COMFORT BATH CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
62582226|NCT03925038|ACTIVE_COMPARATOR|Treatment as Usual|Participants will receive psychotherapy (treatment as usual).
62582227|NCT03925038|EXPERIMENTAL|Augmented Care|Participants will receive augmented psychotherapy which includes use of an electronic media dashboard as part of treatment.
62582228|NCT03579901|OTHER|Primary Breast Augmentation|Subjects age 22 and over, indicated to increase breast size
62582229|NCT03579901|OTHER|Primary Breast Reconstruction|Subjects age 18 and over, Surgery to replace breast tissue that has been removed due to cancer, prophylactic mastectomy, breast trauma or that has failed to develop properly due to a severe breast anomaly.
62582230|NCT03579901|OTHER|Revision Augmentation|Revision surgery to correct or improve the results of a previous breast augmentation
62582231|NCT03579901|OTHER|Revision Reconstruction|Revision surgery to correct or improve the results of a previous breast reconstruction.
62582232|NCT06418191|EXPERIMENTAL|Mobile app users|Mobile application users will be notified twice per day to perform acupressure. Instructions for performing acupressure are in the mobile app
62582233|NCT06418191|ACTIVE_COMPARATOR|Not a mobile app user|Non-users of the mobile application will be given an explanation of how to perform acupressure at the start of the study and will not be reminded to perform acupressure therapy.
62582234|NCT02014493|ACTIVE_COMPARATOR|HFNC first|4 hours with High Flow Nasal Cannulae (HFNC) 6 l/pr.min, then 4 hours with Continuous Positive Airway Pressure (CPAP) 6l/pr.min.
62582235|NCT02014493|ACTIVE_COMPARATOR|CPAP first|4 hours Continuous Positive Airway Pressure (CPAP) 6 l/pr.min, then 4 hours High Flow Nasal Cannulae (HFNC) 6 l/pr.min.
62582236|NCT04634513|EXPERIMENTAL|Cohort 1: Shigella Vaccine at 10^8 cfu or Placebo|3:1 randomization to one dose of vaccine or placebo (Cohort n=8)
62582237|NCT04634513|EXPERIMENTAL|Cohort 2: Shigella Vaccine at 10^9 cfu or Placebo|3:1 randomization to one dose of vaccine or placebo (Cohort n=8)
62582238|NCT04634513|EXPERIMENTAL|Cohort 3: Shigella Vaccine at 10^10 cfu or Placebo|3:1 randomization to one dose of vaccine or placebo (Cohort n=8)
62582239|NCT04634513|EXPERIMENTAL|Cohort 4: Shigella Vaccine or Placebo|2:2:1 randomization to receive either two doses of vaccine, 1 dose of vaccine and one dose of placebo, or two doses of placebo at Days 1 and 29 (Cohort n=30)
62582240|NCT05410340|ACTIVE_COMPARATOR|Preterm group 1|To analize the brain activation and oxigenation using the Vojta Therapy
62582241|NCT05410340|ACTIVE_COMPARATOR|Preterm Group 2|To analize the brain activation and oxigenation using massotherapy
62209762|NCT02389452|EXPERIMENTAL|Synvisc-One|Single 6 mL IA injection of Synvisc-One (48 mg of cross-linked hylan polymer) at Day 0 (Initial Treatment). Participants received repeat injection based on physician's discretion of safety and efficacy (no major safety concerns and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 subscore \[measurement of pain while walking on flat surface\] between 40-80 mm, measured on a 0-100 mm scale with 0 represents no pain and 100 represents worst possible pain) at Week 26, 39 or 52 (Repeat treatment).
62407222|NCT02570217|ACTIVE_COMPARATOR|NCPAP|Patients receive respiratory support by Nasal Continuous Positive Airways Pressure(NCPAP)
62582242|NCT05410340|PLACEBO_COMPARATOR|Term group 1|To analize the brain activation and oxigenation using the Vojta Therapy
62407223|NCT00694330|EXPERIMENTAL|GM-K562 Vaccination|
62582243|NCT05410340|PLACEBO_COMPARATOR|Term group 2|To analize the brain activation and oxigenation using massotherapy
62582244|NCT06144216|EXPERIMENTAL|CLOE Outreach Intervention|Participants enrolled in CLOE intervention
62582245|NCT06218940|EXPERIMENTAL|HY1272|HY1272 IV weekly
62582246|NCT03107364||Colorectal surgery|Patient who underwent elective colorectal surgery
62582247|NCT03107364||Hip fracture|Patient who underwent urgent surgical procedure for hip fracture
62582248|NCT01163318||Adalimumab 40 mg/0.8 mL syringe for subcutaneous injection|Participants with rheumatoid arthritis who received adalimumab, per approved label
62209763|NCT00635427|EXPERIMENTAL|VPRIV 60 U/kg(VPRIV Parent Study 45 or 60 U/kg- TKT032,GCB039)|"This arm is the Overall velaglucerase alfa (VPRIV) 60 U/kg and includes patients from the following groups:~VPRIV 45 U/kg or 60 U/kg, IV, EOW for 51 weeks in parent study TKT032 (NCT00430625) and switched to 60 U/kg in HGT-GCB-044 to maintain blindness or 60 U/kg, IV, EOW for 39 weeks in parent study HGT-GCB-039 (NCT00553631)"
62209764|NCT00635427|EXPERIMENTAL|VPRIV 60 U/kg (Parent study-imiglucerase(60 U/kg) HGT-GCB-039)|imiglucerase 60 U/kg, IV, EOW for 39 weeks in parent study HGT-GCB-039 (NCT00553631)and switched 60 U/kg VPRIV in HGT-GCB-044
62209765|NCT00635427|EXPERIMENTAL|VPRIV 15-60 U/kg (Parent study VPRIV (15-60 U/kg) TKT034)|VPRIV 15- 60 U/kg, IV, EOW for 51 weeks in parent study TKT034 (NCT00478647) and continued in HGT-GCB-044 at the same dose as prescribed in TKT034
62209766|NCT06665984||Bipolar Patients|
62209767|NCT06665984||Offspring of Bipolar Parents|
62209768|NCT06665984||Healthy Control Subjects|
62209769|NCT06064539|EXPERIMENTAL|Cohort 1|SAR442168 administered alone and together with gemfibrozil. 1 day washout for each administration of SAR442168.
62209770|NCT06064539|EXPERIMENTAL|Cohort 2|SAR442168 administered alone and together with rifampicin. 1 day washout for each administration of SAR442168.
62209771|NCT05617664|PLACEBO_COMPARATOR|patients with primary nocturnal enuresis will be followed up with behavioral therapy alone.|
62209772|NCT05617664|ACTIVE_COMPARATOR|patients with primary nocturnal enuresis will take desmopressin 120 mcg oral tablets.|
62209773|NCT05617664|ACTIVE_COMPARATOR|patients with PNE will take mirabegron 25 mg oral tablets.|
62209774|NCT02057653||Before GDFM Training|Approximate 300 patients' medical record information will be extracted from the UC Irvine Medical Center electronic medical record prior to the start of the training curriculum.
62209775|NCT02057653||After GDFM Training|Approximate 300 patients' medical record information will be extracted from the UC Irvine Medical Center electronic medical record after the training program took place
62209776|NCT05728866|EXPERIMENTAL|Virtual reality (VR) therapy|
62582249|NCT03270852|EXPERIMENTAL|Enhanced reality|"Patients are provided with occupational therapy and physical therapy (task-oriented OT 30 min, FES 20 min) daily for 50 minutes.~ER therapy is provided 2 times a day for 10 minutes for 2 weeks (10 days of treatment week), except for time of installation, calibration, and 3 minute breaks."
62582250|NCT03270852|ACTIVE_COMPARATOR|No Enhanced reality|Patients are provided with occupational therapy and physical therapy (task-oriented OT 30 min, FES 20 min) daily for 50 minutes.
62582251|NCT06017297|EXPERIMENTAL|Durvalumab and Tremelimumab plus gemcitabine/cisplatin|Durvalumab and tremelimumab plus gemcitabine/cisplatin combination therapy. If the tumor is evaluated to be resectable after Cycle 4 (C4), then the patient may proceed with surgical tumor resection. If the tumor is deemed unresectable after C4, then the patient will proceed with Cycle 5-8 followed by reevaluation for surgical resection.
62582252|NCT04191369|PLACEBO_COMPARATOR|EGD evaluation|Esophogagastroduodenoscopy for the evaluation of esophageal varices, gastric varices and hypertensive gastropathy. Portal pressure gradient will be evaluated via interventional radiology as gold standard.
62209777|NCT06200129|EXPERIMENTAL|sws grade 1|The group that defined as scattered white spots on the normal duodenal mucosa that could not be wiped away by washing, appearing as white spots
62209778|NCT06200129|EXPERIMENTAL|sws grade 2|The group that defined as a diffuse or patchy white appearance on villi that could not be wiped away by washing on the mucosa.
62209779|NCT06200129|EXPERIMENTAL|control|The group with a normal appearance of the duodenal mucosa, where scattered white spots were not detected.
62209780|NCT04385108|EXPERIMENTAL|hospitalized patients|"very well-defined population of COVID-19 patients with the following outcomes:~* Patients with severe disease requiring on admission ICU management for ARDS,~* Non-severe hospitalized patients with secondary clinical worsening requiring ICU management,~* Non-severe hospitalized patients without clinical worsening requiring ICU management."
62209781|NCT04385108|EXPERIMENTAL|healthcare workers|mildly symptomatic patients among healthcare workers attending outpatient dedicated clinics will be recruited
62209782|NCT04316351|EXPERIMENTAL|Toripalimab + Pemetrexed + Anlotinib|
62209783|NCT02228759|EXPERIMENTAL|Adductor canal block|The study is an open label pilot study to determine the feasibility of same day discharge following total knee arthroplasty with the use of a fast track regimen employing motor sparing knee blocks. The study will be performed on 25 American Society of Anesthesiologists class (ASA) 1-2 patients satisfying the inclusion criteria and undergoing unilateral primary total knee arthroplasty. First and second patients of the day undergoing surgery between Monday to Thursday in a week will be accessed for the study.
62209784|NCT04630847|EXPERIMENTAL|Autism Subjects|These subjects will be administered fecal microbiota transplant by colonoscopy
62209785|NCT05121558|EXPERIMENTAL|Yoga|Participants will receive twice weekly yoga over the course of 8 weeks.
62209786|NCT05121558|EXPERIMENTAL|Education control (EC)|Participants will receive twice weekly education over the course of 8 weeks
62209787|NCT05121558|ACTIVE_COMPARATOR|Usual care (UC)|8 weeks of usual care
62209788|NCT06619951|EXPERIMENTAL|Group 1: VC004 and itraconazole|
62209789|NCT06619951|EXPERIMENTAL|Group 2: VC004 and rifampicin|
62209790|NCT01472549|ACTIVE_COMPARATOR|Iodine-alcohol|8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)
62209791|NCT01472549|EXPERIMENTAL|Chlorhexidine-alcohol|2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)
62209792|NCT06727929||Periodontally Healthy|PD ≤3 mm, fullmouth bleeding scores (BOP) % \<10, no CAL and radiologic bone loss
62209793|NCT06727929||Gingivitis|PD ≤3 mm, % BOP \>30, no CAL(due to periodontal disease) and radiologic bone loss
62209794|NCT06727929||Periodontitis|These individuals had a minimum of two non-adjacent teeth with sites with PD ≥6 mm, CAL ≥5 mm, BOP ≥30%, tooth loss due to periodontitis ≤4 teeth, the alveolar bone loss at radiographs extending to middle or apical third of the root, the presence of consistent amounts of plaque biofilm/calculus deposits commensurate with the severity of periodontal tissue breakdown, the proportion of percentage bone loss to age values were between 0.25 and 1
62209795|NCT04417465|EXPERIMENTAL|Monotherapy Dose Escalation|ABBV-CLS-579 will be administered as a monotherapy in subjects with solid tumors
62209796|NCT04417465|EXPERIMENTAL|Combination Dose Escalation with PD-1|ABBV-CLS-579 will be administered in combination with Programmed Cell Death-1 Inhibitor in subjects with solid tumors
62209797|NCT04417465|EXPERIMENTAL|Backfill Cohorts with Monotherapy|ABBV-CLS-579 will be administered as a monotherapy in subjects with solid tumors
62209798|NCT04417465|EXPERIMENTAL|Backfill Cohorts in Combination with PD-1|ABBV-CLS-579 will be administered in combination with Programmed Cell Death-1 Inhibitor in subjects with solid tumors
62209799|NCT04417465|EXPERIMENTAL|Combination Expansion with PD-1|ABBV-CLS-579 will be administered at the determined recommended dose in subjects with locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), microsatellite instability-high (MSI-H) tumors, and advanced clear cell renal cell carcinoma (ccRCC)
62209800|NCT04417465|EXPERIMENTAL|Combination Expansion with VEGFR TKI|ABBV-CLS-579 will be administered at the determined recommended dose in combination with Vascular Endothelial Growth (VEGFR) Factor Receptor Tyrosine Kinase Inhibitor (TKI) in subjects with advanced ccRCC.
62209801|NCT00939159|EXPERIMENTAL|LBH589|LBH589 20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.
62209802|NCT05602727|EXPERIMENTAL|MK-1942 5 mg|Participants will receive a single 5 mg MK-1942 capsule twice daily (BID), taken orally for 12 weeks. A mock titration will be done to maintain the study blind despite no changes in dose.
62209803|NCT05602727|EXPERIMENTAL|MK-1942 15 mg|Participants will receive a single 8 mg MK-1942 capsule twice daily (BID), taken orally for one week. Then the dose is titrated up to 15 mg MK-1942 capsule twice daily (BID), taken orally for up to 11 weeks.
62209804|NCT05602727|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo capsule twice daily (BID), taken orally for 12 weeks. A mock titration will be done to maintain the study blind despite no changes in dose.
62209805|NCT05929066|EXPERIMENTAL|Retatrutide Dose 1|Participants will receive retatrutide subcutaneously (SC).
62407224|NCT06556576|EXPERIMENTAL|IMPROVA intervention group|Participants (students, parents, teachers and other school staff) in the IMPROVA group will have access to a series of resources and training with the ultimate goal of promoting mental health and wellbeing among adolescents. This material will be delivered via the IMPROVA platform throughout one school year. IMPROVA platform will be available in app and web-based formats, and participants will be encouraged to utilize it as frequently as possible.
62407225|NCT06556576|NO_INTERVENTION|CONTROL group|Participants in the control group will not have access to the IMPROVA platform. Their school routine and the support they usually receive will remain unchanged. After the intervention period (school year 2024/25), schools, teachers, school staff, adolescents and their families in the control group will be able to access the IMPROVA platform during the school year 2025/26 (waiting list control group).
62407226|NCT03801200|EXPERIMENTAL|Apatinib combined with Radiotherapy|"Drugs: Apatinib Apatinib (500 mg/d) was given orally for one week before the brain radiotherapy, and then, continued to be administered at the same way during the brain radiotherapy period (3 weeks). It was given for another one week after the end of the brain radiotherapy.~Radiotherapy: Intensity-modulated radiotherapy (IMRT).~According to the patients KPS score, GPA score, the number and size of metastatic lesions can be selected:~1. 37.5Gy/15 fractions of whole brain irradiation for multiple brain metastases were more than 5;~2. The whole brain was irradiated with 37.5Gy/15 and simultaneous integrated boost dose of 52.5Gy/15 to patients with 1-5 metastatic lesions."
62407227|NCT03801200|NO_INTERVENTION|Radiotherapy alone|"Radiotherapy: Intensity-modulated radiotherapy (IMRT).~According to the patients KPS score, GPA score, the number and size of metastatic lesions can be selected:~1. 37.5Gy/15 fractions of whole brain irradiation for multiple brain metastases were more than 5;~2. The whole brain was irradiated with 37.5Gy/15 and simultaneous integrated boost dose of 52.5Gy /15 to patients with 1-5 metastatic lesions."
62407228|NCT01906762|EXPERIMENTAL|Acetaminophen|Specified dosage for Acetaminophen was 15 mg/kg. so based on the patient's weight(averagely 70 kg), about 1gr Acetaminophen (one complete Apotel Ampule) was used.
62582253|NCT04191369|EXPERIMENTAL|EUS evaluation|"Endoscopic ultrasound evaluation for the presence of esophageal varices, peri and para-esophageal collateral veins, gastric varices, portal hypertensive gastropathy, azygos vein diameter, blood flow and BFVI.~Portal pressure gradient will be evaluated via interventional radiology as gold standard."
62582254|NCT05901441|EXPERIMENTAL|H1 group|H1 group will be administered with15 ug/ml hydromorphone and 0.08% ropivacaine
62582255|NCT05901441|EXPERIMENTAL|H2 group|H2 group will be administered with17.5 ug/ml hydromorphone and 0.08% ropivacaine
62209806|NCT05929066|EXPERIMENTAL|Retatrutide Dose 2|Participants will receive retatrutide SC.
62209807|NCT05929066|EXPERIMENTAL|Retatrutide Dose 3|Participants will receive retatrutide SC.
62209808|NCT05929066|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62209809|NCT05929066|EXPERIMENTAL|Retatrutide Extension Period|Participants will receive retatrutide after the placebo-controlled 80 week treatment period for an additional 24 weeks.
62018584|NCT01358513||Severe aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
62209810|NCT04821830||Parkinson's disease patients who take levo-dopa as standard of care|Participants will undergo evaluation of the relationship between the LDR and movement vigor. All participants will undergo standard evaluation with standard clinical rating scales and three outcome measures: Tapping Speed Task - Measurement of Bradykinesia; Grip Strength Task - Measurement of Incentive-Outcome Coupling - Movement Vigor; Joystick Movement Task - Measurement of Incentive-Outcome Coupling - Movement Vigor. Some participants may opt in to an additional training and evaluation: Value Driven Attentional Oculomotor Capture.
62209811|NCT02695342|EXPERIMENTAL|Home balance exercise program|The home-based exercise program will be tailored to address the underlying balance deficits in COPD and individualized according to each participant's ability. Physiotherapists will teach the program in four home visits over the first 6 weeks of the study; in the event of an exacerbation, a fifth visit will be provided to modify the program. Participants will be given an exercise DVD (with portable player), and will be instructed to perform the program 3 times/week for 6 months. Therapists will provide bi-monthly telephone support.
62018585|NCT00000435|PLACEBO_COMPARATOR|A|Subjects randomized to arm A received 25mg/day po of placebo
62018586|NCT00000435|ACTIVE_COMPARATOR|B|Subjects randomized to Arm B received 25mg/day po of peptide dnaJP1
62018587|NCT03173222|ACTIVE_COMPARATOR|EA1|
62018588|NCT03173222|ACTIVE_COMPARATOR|EA2|
62209812|NCT06196827|EXPERIMENTAL|LX101 Dose 1|
62209813|NCT06196827|EXPERIMENTAL|LX101 Dose 2|
62209814|NCT02103205|ACTIVE_COMPARATOR|Low iron, with lactoferrin|Low iron, with lactoferrin
62209815|NCT02103205|ACTIVE_COMPARATOR|Low iron, no lactoferrin|Low iron, no lactoferrin
62582256|NCT05901441|EXPERIMENTAL|H3 group|H3 group will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine
62582257|NCT05901441|ACTIVE_COMPARATOR|SF group|SF group will be administered with 40 ug/ml sufentanil and 0.08% ropivacaine
62582258|NCT00604097|EXPERIMENTAL|1|Attachment-Based Family Therapy
62018589|NCT03173222|NO_INTERVENTION|Control|
62018590|NCT01910844|EXPERIMENTAL|Cisplatin - Metronomic Cyclophosphamide|Cisplatin 25 mg/m² from day 1 to day 3 every 3 weeks Metronomic Cyclophosphamide 150 mg from day 1 to day 14 every 3 weeks
62018591|NCT01902849||Group 1 - TIVA-TCI|"* include 35 patients with colorectal cancer undergoing surgery~* anaesthesia is induced and maintained with total intravenous target-controlled infusion ( TIVA-TCI) of propofol and remifentanil.~* for propofol initial target plasma concentration (Cp) is set to 4 micrograms/ml (modified Marsh model)( Base Primea™, Fresenius, France) and then adjusted in steps 0.2 micrograms/ml to maintain the BIS values between 40-55 during surgery.~* for Remifentanil initial Cp is set at induction at 4 ng/ml and then the Cp is maintained between 3-8 ng/mL(increments of 0.5 ng/ml in case of inadequate anesthesia).~* intervention:blood sampling for IL measurement"
62209816|NCT02103205|PLACEBO_COMPARATOR|Normal iron, no lactoferrin|Normal iron, no lactoferrin
62209817|NCT03953755|NO_INTERVENTION|Control 1|no/mild tricuspid regurgitation - left-side surgery alone
62209818|NCT03953755|NO_INTERVENTION|moderate TR - left-side surgery|moderate tricuspid regurgitation - left-side surgery alone
62209819|NCT03953755|EXPERIMENTAL|moderate TR - left-side surgery+TVS|moderate tricuspid regurgitation - left-side surgery+tricuspid valve surgery
62407229|NCT01906762|EXPERIMENTAL|Morphine|Specified dosage for Morphine was 0.1 mg/kg. so based on the patient's weight(averagely 70 kg), about 7 mg Morphine was used.
62582259|NCT00604097|ACTIVE_COMPARATOR|2|Enhanced Usual Care
62582260|NCT03538964|ACTIVE_COMPARATOR|Toric intraocular lens (IOL)|toric intraocular lens for low astigmatism correction
62582261|NCT03538964|SHAM_COMPARATOR|Non toric intraocular lens (IOL)|non toric intraocular lens
62582262|NCT01725581||Inexperienced students|Final year medical students at the end of the Obstetrics and Gynaecology placement
62582263|NCT01725581||Experienced students|Final year medical students at the end of the Obstetrics and Gynaecology placement
62582264|NCT01725581||Junior Doctors|Pre Royal College of Obstetric and Gynaecology registered junior doctors with experience in Obstetrics and Gynaecology
62582265|NCT02389387||Control|Two hundred twenty (220) dialysis facilities will follow standard of care practices in their management of ESRD patients. They will not receive interventions, but they will have access to standard educational materials and quality improvement through End Stage Renal Disease Network 6.
62734498|NCT03281369|EXPERIMENTAL|1L-A2: Atezo+mFOLFOX6 followed by Atezo+Cobi (Gastric Cancer)|Participants in the 1L-A2 Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab during cycles 1 and 2 followed by atezolizumab plus cobimetinib during cycles 3 and beyond. No longer enrolling participants as of June 2018.
62018592|NCT01902849||Group II- ISOFLURANE|"* include 35 patients with colorectal cancer undergoing surgery~* anesthesia is induced with propofol bolus 1,5-2 mg/kg and remifentanil TCI mode (Minto model) (Base Primea™, Fresenius, France) with an initial Cp 4 ng/ml~* maintenance of anesthesia is achieved with isoflurane 1-1.5 MAC in order to maintain the BIS value between the values of 40-55 and remifentanil TCI with Cp between 3-8 ng/mL (increments of 0.5 ng/ml in case of inadequate anesthesia)~* intervention:blood sampling for IL measurement"
62018593|NCT06043414|ACTIVE_COMPARATOR|Triclosan-coated barbed suture group|The active arm of the study will including patients randomized to abdominal fascial closure with using triclosan-coated barbed (STRATAFIX™ Symmetric PDS™, Johnson \& Johnson) suture after emergency exploratory laparotomy.
62018594|NCT06043414|PLACEBO_COMPARATOR|Non-barbed suture group|The control arm of the study will including patients randomized to abdominal fascial closure with using non-barbed triclosan-coated suture(PDS™ Plus, Johnson \& Johnson) or non-coated polydioxanone (PDS™ II,Johnson \& Johnson) suture after emergency exploratory laparotomy.
62018595|NCT00630877|EXPERIMENTAL|NER/ASA|
62018596|NCT00630877|EXPERIMENTAL|NER/ASA Placebo|
62209820|NCT03953755|NO_INTERVENTION|Control 2|tricuspid regurgitation - left-side surgery +tricuspid valve surgery
62209821|NCT04174703|EXPERIMENTAL|Self-compassionate letter-writing intervention|An online self-compassionate letter-writing task once per day (10-20 minutes each) for 2 weeks
62209822|NCT04174703|NO_INTERVENTION|Control condition|
62209823|NCT04567277|EXPERIMENTAL|Early VPS|
62209824|NCT02652325|ACTIVE_COMPARATOR|povidone-iodine|
62209825|NCT02652325|ACTIVE_COMPARATOR|3M Skin and Nasal Antiseptic 5% Povidone-Iodine USP swabs|
62209826|NCT02652325|PLACEBO_COMPARATOR|Saline|
62209827|NCT03767140|EXPERIMENTAL|Verum acupucnture|Real acupuncture treatment
62209828|NCT03767140|SHAM_COMPARATOR|sham acupuncture|False acupuncture treatment using not acupuncture points
62209829|NCT02004470|NO_INTERVENTION|Passive exsufflation|Will not actively suction carbon dioxide from abdomen. Open laparoscopic trocars and allow C02 to passively empty from abdomen.
62407230|NCT03010475|EXPERIMENTAL|Furosemide/Rosuvastatin/SNAC/Semaglutide|
62407231|NCT05531695|EXPERIMENTAL|Aerobic Exercise|Graduated supervised moderate intensity aerobic exercise
62582266|NCT02389387||Intensive Intervention|Two hundred twenty (220) dialysis facilities will follow standard of care practices and the intensive intervention in their management of ESRD patients. The intensive intervention will consist of 1) A multi-module, secure, web-enabled software application called Transplant Referral EXchange (T-REX) to enhance coordination between dialysis and transplant staff and track ESRD patients through the seven primary steps to transplant , 2) educational webinars/seminars for staff, 3) facility-specific performance feedback reports, 4) assistance with and review of center-specific action plans to increase transplant referral, 5) scheduled bi-annual phone calls with an SETC member to monitor progress, 6) patient education on transplant via creation of an Education Station in facility lobby, and 7) development of a Peer Mentor program.
62582267|NCT05353855||Early unmedicated PD patients converted from iRBD|"1. Chinese aged 50 or above;~2. Being capable of giving informed consent for participation of the study;~3. Having a diagnosis of PD confirmed by neurologists according to the United Kingdom Parkinson's Disease Survey Brain Bank.~4. Onset of PD motor symptoms of \< 3 years;~5. In view of the heterogeneity of PD, the investigator will only include those patients with RBD preceding the onset of motor symptoms of PD.~6. Drug naïve (dopaminergic medications have not been started)"
62582268|NCT05353855||Early medicated PD patients converted from iRBD|Inclusion criteria will be the same as that of early unmedicated PD except that they should be on dopaminergic medications.
62582269|NCT05353855||iRBD patients|"1. Chinese aged 50 or above;~2. Being capable of giving informed consent for participation of the study;~3. Having a diagnosis of RBD according to the International classification of sleep disorder 3rd edition (ICSD 3rd), fulfilling both the clinical and video-polysomnography (vPSG) criteria."
62582270|NCT05353855||Healthy controls|"1. Age-and sex-matched with the groups;~2. Being capable of giving informed consent for participation of the study;~3. Without a personal history or a family history of PD or RBD;~4. A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~5. Absence of self-report dream enactment behaviors and RSWA as measured by v-PSG."
62582271|NCT03640559|PLACEBO_COMPARATOR|Placebo|the group were having the administration of Placebo (saline 2.4 mL/kg IP)
62209830|NCT02004470|EXPERIMENTAL|Active lavage and suction|This step is already employed in many ongoing surgeries where normal saline will be used to lavage the right upper quadrant and then will be suctioned out to remove as much Carbon dioxide from the patient's abdomen and to therefore decrease postoperative pain.
62209831|NCT06728709||obstetrics critically ill|critically ill obstetrics patients admitted yo ICU for any cause during pregnancy or postpartum.
62209832|NCT06728709||gynecological critically ill patients|gynecological cases admitted to ICU for any cause of medical or postoperative care
62582272|NCT03640559|EXPERIMENTAL|Seroguard|the group were having the administration of Seroguard 0.41 g/L solution, 2.4 mL/kg IP
62209833|NCT05240079|EXPERIMENTAL|Patients|
62018597|NCT00630877|EXPERIMENTAL|NER Placebo/ASA Placebo|
62018598|NCT02782819|PLACEBO_COMPARATOR|Crystalloid|Isotonic crystalloid solution resuscitation
62209834|NCT02920580|ACTIVE_COMPARATOR|Extubation|Extubation by removal of endotracheal tube.
62209835|NCT02920580|ACTIVE_COMPARATOR|Usual care|The usual clinical practice is removal of the endotracheal tube (extubation), or insertion of tracheostomy, timed according to physicians' discretion
62209836|NCT02775773|EXPERIMENTAL|arm A (TXA)|2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery(third stage after labor)
62209837|NCT02775773|ACTIVE_COMPARATOR|arm B (OXY)|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
62209838|NCT05580562|EXPERIMENTAL|ONC201 Twice Weekly Group|
62209839|NCT05580562|EXPERIMENTAL|ONC201 Once Weekly Group|
62209840|NCT05580562|PLACEBO_COMPARATOR|Placebo Group|
62209841|NCT06127407|EXPERIMENTAL|Ivosidenib|Taken continuously until BICR-confirmed disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, lost to follow-up, or the Sponsor ends the study (estimated average treatment duration of two years).
62209842|NCT06127407|PLACEBO_COMPARATOR|Placebo|Taken continuously until BICR-confirmed disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, lost to follow-up, or the Sponsor ends the study (estimated average treatment duration of two years). Participants randomized to the placebo arm who experience BICR-confirmed disease progression and meet the crossover eligibility criteria will be given the opportunity to cross over and receive ivosidenib.
62209843|NCT01382277|EXPERIMENTAL|Rosuvastatin 20 mg|Rosuvastatin 20 mg for 76 weeks.
62407232|NCT05531695|ACTIVE_COMPARATOR|Flexibility Exercise|Home based self-supervised flexibility exercises
62407233|NCT02074982|EXPERIMENTAL|AIN457 300 mg|patients received AIN457 (secukinumab) 300 mg (two secukinumab 150 mg injections) s.c. (subcutaneously) once every week at weeks 0, 1,2,3, followed by monthly dosing starting at week 4 to week 48 inclusive
62407234|NCT02074982|ACTIVE_COMPARATOR|Ustekinumab|patients received ustekinumab 45/90 mg (weight depended, according to label) s.c. (subcutaneously) and/or placebo secukinumab injections once every week at weeks 0,1,2, and 3 followed by monthly dosing starting at week 4 to week 48 inclusive
62407235|NCT06651242|EXPERIMENTAL|Decision-making information aids|
62407236|NCT06651242|SHAM_COMPARATOR|Routine care|
62582273|NCT04987229|EXPERIMENTAL|All subjects|All subjects will receive OLZ/SAM at a dose determined by the Investigator and based on the olanzapine dosing received in the antecedent study (ALKS 3831-A311 or ALKS 3831-A312 ENLIGHTEN-Youth)
62790152|NCT06072417|PLACEBO_COMPARATOR|Respiratory sleep study at 2840m|Participants will have a respiratory sleep study by polygraphy near their resident altitude at 2840m
62018599|NCT02782819|ACTIVE_COMPARATOR|Crystalloid plus Colloid|Colloid solution resuscitation
62018600|NCT05471973|OTHER|Quality Improvement Program|The quality improvement program will consist of development and/or refinement of participating health system's patient care pathways tailored to address the gaps and barriers around recognition and treatment of CIED infections. Interventions will be customized and modified as needed based on regular reviews and implementation progress.
62018601|NCT01682837|EXPERIMENTAL|KMgCit, KCit, KCl, Placebo|Participants who received study drug in the order: Potassium Magnesium Citrate (KMgCit) powder, Potassium Citrate (KCit) powder, Potassium Chloride (KCl) powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018602|NCT01682837|EXPERIMENTAL|KMgCit, KCit, Placebo, KCl|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Citrate powder, Placebo, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018603|NCT01682837|EXPERIMENTAL|KMgCit, KCl, KCit, Placebo|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Chloride powder, Potassium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018604|NCT01682837|EXPERIMENTAL|KMgCit, KCl, Placebo, KCit|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Chloride powder, Placebo, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018605|NCT01682837|EXPERIMENTAL|KMgCit, Placebo, KCit, KCl|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Placebo, Potassium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018606|NCT01682837|EXPERIMENTAL|KMgCit, Placebo, KCl, KCit|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Placebo, Potassium Chloride powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018607|NCT01682837|EXPERIMENTAL|KCit, KMgCit, KCl, Placebo|Participants who received study drug in the order: Potassium Citrate powder, Potassium Magnesium Citrate powder, Potassium Chloride powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018608|NCT01682837|EXPERIMENTAL|KCit, KMgCit, Placebo, KCl|Participants who received study drug in the order: Potassium Citrate powder, Potassium Magnesium Citrate powder, Placebo, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018609|NCT01682837|EXPERIMENTAL|KCit, KCl, KMgCit, Placebo|Participants who received study drug in the order: Potassium Citrate powder, Potassium Chloride powder, Potassium Magnesium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018610|NCT01682837|EXPERIMENTAL|KCit, KCl, Placebo, KMgCit|Participants who received study drug in the order: Potassium Citrate powder, Potassium Chloride powder, Placebo, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018611|NCT01682837|EXPERIMENTAL|KCit, Placebo, KMgCit, KCl|Participants who received study drug in the order: Potassium Citrate powder, Placebo, Potassium Magnesium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62209844|NCT06729086|PLACEBO_COMPARATOR|sedation using propofol|this group will include all patients who will receive propofol during the cardiac surgery and afterwards in the intensive care unit during the post operative phase
62790153|NCT06072417|EXPERIMENTAL|Respiratory sleep study near sea level (0-30m)|Participants will have a respiratory sleep study by polygraphy near sea level (0-30m)
62790154|NCT01229306|EXPERIMENTAL|reisolation of all PV and additional anterior line|
62018612|NCT01682837|EXPERIMENTAL|KCit, Placebo, KCl, KMgCit|Participants who received study drug in the order: Potassium Citrate powder, Placebo, Potassium Chloride powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018613|NCT01682837|EXPERIMENTAL|KCl, KMgCit, KCit, Placebo|Participants who received study drug in the order: Potassium Chloride powder, Potassium Magnesium Citrate powder, Potassium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018614|NCT01682837|EXPERIMENTAL|KCl, KMgCit, Placebo, KCit|Participants who received study drug in the order: Potassium Chloride powder, Potassium Magnesium Citrate powder, Placebo, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62209845|NCT06729086|ACTIVE_COMPARATOR|sedation using sevoflurane|this group will include all patients who will receive sevoflurance druing the cardiac surgery and afterwards in the intensive care unit during the postoperative phase
62790155|NCT01229306|PLACEBO_COMPARATOR|reisolation of all pulmonary veins|
62790156|NCT02211248|ACTIVE_COMPARATOR|Conventional Group|Conventional treatment and follow up
62790157|NCT02211248|EXPERIMENTAL|Multidisciplinary Group|Multidisciplinary assistance
62582274|NCT04015635||Study group|"80 with hypertension, defined on office BP readings and confirmed with ambulatory blood pressure monitoring.~Clinical and laboratory assessment. NO intervention."
62582275|NCT04015635||Control|"80 WITHOUT hypertension, defined on office BP readings and confirmed with ambulatory blood pressure monitoring.~Clinical and laboratory assessment. NO intervention."
62582276|NCT04997135||Meibography Subjects|Eligible subjects will undergo testing to evaluate the Meibomian gland appearance
62582277|NCT03655470|EXPERIMENTAL|Safety Planning|This brief intervention, consists of an in-person and follow-up phone call that are based on cognitive behavioral principles designed to help identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of nonsuicidal self-injury or suicidal behavior.
62790158|NCT04966949|EXPERIMENTAL|lateral prostate capsule sparing group|Patients will be preverved the lateral prostate capsule during the resection of bladder and prostate of the operation.
62790159|NCT04966949|ACTIVE_COMPARATOR|nerve sparing group|Patients will be preverved the neurovascular bundles during the resection of bladder and prostate of the operation.
62018615|NCT01682837|EXPERIMENTAL|KCl, KCit, KMgCit, Placebo|Participants who received study drug in the order: Potassium Chloride powder, Potassium Citrate powder, Potassium Magnesium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018616|NCT01682837|EXPERIMENTAL|KCl, KCit, Placebo, KMgCit|Participants who received study drug in the order: Potassium Chloride powder, Potassium Citrate powder, Placebo, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018617|NCT01682837|EXPERIMENTAL|KCl, Placebo, KMgCit, KCit|Participants who received study drug in the order: Potassium Chloride powder, Placebo, Potassium Magnesium Citrate powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018618|NCT01682837|EXPERIMENTAL|KCl, Placebo, KCit, KMgCit|Participants who received study drug in the order: Potassium Chloride powder, Placebo, Potassium Citrate powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018619|NCT01682837|EXPERIMENTAL|Placebo, KMgCit, KCit, KCl|Participants who received study drug in the order: Placebo, Potassium Magnesium Citrate powder, Potassium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018620|NCT01682837|EXPERIMENTAL|Placebo, KMgCit, KCl, KCit|Participants who received study drug in the order: Placebo, Potassium Magnesium Citrate powder, Potassium Chloride powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018621|NCT01682837|EXPERIMENTAL|Placebo, KCit, KMgCit, KCl|Participants who received study drug in the order: Placebo, Potassium Citrate powder, Potassium Magnesium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018622|NCT01682837|EXPERIMENTAL|Placebo, KCit, KCl, KMgCit|Participants who received study drug in the order: Placebo, Potassium Citrate powder, Potassium Chloride powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018623|NCT01682837|EXPERIMENTAL|Placebo, KCl, KMgCit, KCit|Participants who received study drug in the order: Placebo, Potassium Chloride powder, Potassium Magnesium Citrate powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018624|NCT01682837|EXPERIMENTAL|Placebo, KCl, KCit, KMgCit|Participants who received study drug in the order: Placebo, Potassium Chloride powder, Potassium Citrate powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
62018625|NCT04887870|EXPERIMENTAL|Phase 2/3: Open label extension of parent study|The current study is designed to allow continued access to sitravatinib and to evaluate the safety and tolerability of sitravatinib alone or in combination with other anticancer therapies in patients who are deriving clinical benefit in a previous parent clinical trial.
62018626|NCT04889560|EXPERIMENTAL|Experimental group|Experimental group receives Home CoRe (Home CoRe Group)
62018627|NCT04889560|OTHER|Control group|Control group receives CoRe software (CoRe Group)
62018628|NCT06308913|EXPERIMENTAL|INCB081776/Pembrolizumab and RT for HNSCC|Cycle 1 of this clinical trial is 56 days in duration to allow for the systematic addition of each agent to the combination regimen. For cycle 2 and all subsequent cycles, the treatment cycle will be 21 days in length.
62018629|NCT04813341|EXPERIMENTAL|Pilates training|Bridging, roll up, one leg circle (both ways); single straight leg stretches; double leg stretches; side kick up and down; side kick circles
62018630|NCT04813341|ACTIVE_COMPARATOR|Aerobic Training|"WALKING: 10 mint brisk walk excluding warm up and cool down in 5 days/ week STATIONARY CYCLE: for 10 mints, 5 days/ week~SITTING EERCISES:~Chest stretch: ask to hold for 5 seconds and perform 5 repetitions Upper body twist: ask to cross the arms against chest and hold for 5 seconds, perform 5 repetitions Hip marching: Ask the client to sit on chair with arm rest and lift each of her leg 5 times~BALANCE EXERCISES:~Sideways walking: ask to perform 10 steps on each way (side to side), 5 days/week.~Heel to Toe walk: perform at least 5 steps and increase gradually in each repetition, 5days/ week Step up and down: Ask to step up and down on given surface, 5 repetitions on each leg, 5 days/ week."
62790160|NCT03906539|PLACEBO_COMPARATOR|Control Group|The patients in control groups will receive tablet atorvastatin (10 mg/day) and a placebo capsule.
62018631|NCT03891524|EXPERIMENTAL|Group A: JNJ-70033093 25 mg + Placebo BID|Participants will receive JNJ-70033093 25 milligram (mg) (1\*25 mg capsule) and 1 placebo capsule twice daily (BID), orally for 10 to 14 postoperative days.
62018632|NCT03891524|EXPERIMENTAL|Group B: JNJ-70033093 50 mg BID|Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.
62790161|NCT03906539|EXPERIMENTAL|VCO Group|The VCO group will receive capsule VCO (1000mg/day) as an add-on to tablet atorvastatin (10 mg/day).
62018633|NCT03891524|EXPERIMENTAL|Group C: JNJ-70033093 100 mg + Placebo BID|Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) and 1 placebo capsule BID orally for 10 to 14 postoperative days.
62018634|NCT03891524|EXPERIMENTAL|Group D: JNJ-70033093 200 mg BID|Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID orally for 10 to 14 postoperative days.
62018635|NCT03891524|EXPERIMENTAL|Group E: JNJ-70033093 25 mg Once Daily + Placebo|Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) once daily and 1 placebo capsule in the morning and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
62018636|NCT03891524|EXPERIMENTAL|Group F: JNJ-70033093 200 mg Once Daily + Placebo|Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
62582278|NCT03655470|ACTIVE_COMPARATOR|Standard Care|"If a teen has a positive screen for suicide risk, the Probation Officer completes a secondary screener built into the court screening instrument to determine whether there is concern of current and/or imminent risk. If a teen endorses nonsuicidal self-injury more than once in the prior year, then the Probation Officer asks about frequency and severity. If there is ongoing concern of risk for self-injurious behavior, then the Probation Officer arranges for a crisis evaluation in the Emergency Department. If the teen is not judged to be at imminent risk, the Probation Officer makes a referral back to the current treatment provider or to a community mental health clinic. In either case, the parents and youth receive a packet with mental health resources"
62790162|NCT02836405||Autism Spectrum Disorder (ASD)|Individuals diagnosed with an Autism Spectrum Disorder (ASD) will receive transcranial magnetic stimulation (TMS) to measure brain plasticity.
62018637|NCT03891524|EXPERIMENTAL|Group G: JNJ-70033093 50 mg once daily + Placebo|Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
62018638|NCT03891524|ACTIVE_COMPARATOR|Group I: Enoxaparin 40 mg Once Daily|Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
62018639|NCT00271336|PLACEBO_COMPARATOR|A|
62018640|NCT00271336|EXPERIMENTAL|B|
62018641|NCT03750136|EXPERIMENTAL|high-dose furosemide & hypertonic saline|furosemide i.v., 3% NaCl
62018642|NCT03750136|ACTIVE_COMPARATOR|high-dose furosemide|furosemide i.v.
62018643|NCT00575848|ACTIVE_COMPARATOR|1|
62018644|NCT00575848|PLACEBO_COMPARATOR|2|
62018645|NCT02696005||Group I|15 patients who will continue participation in Exercise- Based Cardiac Rehabilitation Programme after completion initial 3-months period.
62018646|NCT02696005||Group II|15 patients who will stop participation in Exercise- Based Cardiac Rehabilitation Programme after the initial 3-months period.
62018647|NCT01817972|PLACEBO_COMPARATOR|Certolizumab pegol-Placebo Azathioprine|Certolizumab pegol (Cimzia) 400mg Subcutaneous injection (per standard induction protocol) - which is at week 0, week 2, week4, week 6, then every 4 weeks until week 26. You will also be receiving Azathioprine placebo tablets at a dosage of 1.5mg per kilogram of body weight once a day for 26 weeks. They will be 50mg tablets. This is not active Azathioprine.
62018648|NCT01817972|ACTIVE_COMPARATOR|Certolizumab pegol plus Azathioprine|Certolizumab pegol (Cimzia) 400mg Subcutaneous injection (per standard induction protocol) - which is at week 0, week 2, week4, week 6, then every 4 weeks until week 26. You will also be receiving Azathioprine tablets at a dosage of 1.5mg per kilogram of body weight once a day for 26 weeks. They will be 50mg tablets.
62018649|NCT02762409||patients exposed|Patients exposed will be estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015, and in 17 centers of the group control some study IPREA3 during October 2015
62018650|NCT02762409||patients non exposed|"The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015 and in 17 centers of the interventional group during October 2014"
62018651|NCT04553952||Gummy smile (GS(+))|
62018652|NCT04553952||Gumms smile(GS(-))|
62407237|NCT00783939|EXPERIMENTAL|1|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
62407238|NCT01536522|ACTIVE_COMPARATOR|Nutritional Approach for Asthma|individuals will be provide a pre measured dose of medium chain triglyceride to consume along with their meals. They will be instructed to add the MCT to their meal 3 times per day
62582279|NCT06683781||Mechanically ventilated patients|
62209846|NCT06298669|EXPERIMENTAL|Biventricular Pacing followed by Right Ventricular Pacing|Subjects will be randomly assigned to the order of pacing interventions. After baseline testing (with their CRT device still in the subjects' baseline pacing modality), subjects assigned to BiV-first will have their CRT device reprogrammed to BiV pacing modality in the clinic. After undergoing three months of treatment in this pacing modality, they will return to clinic for retesting. The CRT device will then be reprogrammed to RV pacing for the next 3 months. Subjects will then again return to clinic for retesting, and their CRT device will be reprogrammed to their baseline pacing modality.
62209847|NCT06298669|EXPERIMENTAL|Right Ventricular Pacing followed by Biventricular Pacing|Subjects will be randomly assigned to the order of pacing interventions. After baseline testing (with their CRT device still in the subjects' baseline pacing modality), subjects assigned to RV-first will have their CRT device reprogrammed to RV pacing modality in the clinic. After undergoing three months of treatment in this pacing modality, they will return to clinic for retesting. The CRT device will then be reprogrammed to BiV pacing for the next 3 months. Subjects will then again return to clinic for retesting, and their CRT device will be reprogrammed to their baseline pacing modality.
62209848|NCT04200937||BSC Penile Prothesis Recipients|Men for whom BSC Penile Prothesis is recommended.
62209849|NCT01367639|EXPERIMENTAL|intervention|Inquiry Based Stress Reduction (IBSR) program
62209850|NCT05118828|EXPERIMENTAL|Guided internet-based treatment (AS-iCBT)|
62209851|NCT05118828|ACTIVE_COMPARATOR|Treatment as usual in Prompt Mental Health Care (TAU-PMHC)|
62018653|NCT03217136|EXPERIMENTAL|Ceftolozane/Tazobactam + Metronidazole|Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum 1 g and 0.5 g/dose), plus metronidazole 10 mg/kg (maximum 1.5 g/day) administered intravenously (IV) every 8 to 12 hours for 5 to 14 days.
62018654|NCT03217136|ACTIVE_COMPARATOR|Meropenem + Placebo for Metronidazole|Meropenem 20 mg/kg (maximum 1 g/dose) plus placebo for Metronidazole administered IV every 8 hours for 5 to 14 days.
62018655|NCT01513304|EXPERIMENTAL|Chiropractic manual therapy|
62018656|NCT02660359|EXPERIMENTAL|600 U Dysport® Group|
62018657|NCT02660359|PLACEBO_COMPARATOR|600 U Dysport® Placebo Group|
62018658|NCT02660359|EXPERIMENTAL|800 U Dysport® Group|
62018659|NCT02660359|PLACEBO_COMPARATOR|800 U Dysport® Placebo Group|
62018660|NCT03701477|EXPERIMENTAL|Trans-diagnostic approach|Trans-diagnostic cognitive-behavioral therapy In this arm, patients will participate in 10 sessions of therapy. During each session, specific topics will be discussed and participants will need to complete their homework for the next session. Each session lasts for 120 minutes. Sessions will be held in groups of 5-10 subjects weekly, except the last session that will be held after a two-week interval.
62018661|NCT03701477|SHAM_COMPARATOR|Control|General relaxation/stress management therapeutic session In this arm, patients will attend a 3-hour meeting in which basic techniques of relaxation and overcoming stress and anxiety will be discussed.
62018662|NCT04095858|EXPERIMENTAL|Efprezimod alfa Treatment|Efprezimod alfa: IV infusion, 480 mg (day -1), 240 mg (day +14) and 240 mg (day +28); Tacrolimus: begin on day -3. IV \[0.03 mg/kg/day\] or by mouth (PO) \[0.045 mg/kg/dose\] dosing is permitted; Methotrexate: given IV at a dose of 15 mg/m\^2/dose once daily on Day 1 after hematopoietic cell transplantation (HCT), and at a dose of 10 mg/m\^2/dose on days 3, 6, and 11 after HCT.
62018663|NCT04095858|PLACEBO_COMPARATOR|Placebo|Placebo (Saline solution): 100 ml IV infusion, Day -1, Day 14, Day 28. Tacrolimus: begin on day -3. IV \[0.03mg/kg/day\] or PO \[0.045 mg/kg/dose\] dosing is permitted; Methotrexate: given IV at a dose of 15 mg/m\^2/dose once daily on Day 1 after HCT, and at a dose of 10 mg/m\^2/dose on days 3, 6, and 11 after HCT.
62018664|NCT04198610|NO_INTERVENTION|healthy|Ten patients with clinically healthy gingiva with probing depth less than 3mm and less than or equal to 10% sites with gingival bleeding on probing present.
62018665|NCT04198610|NO_INTERVENTION|chronic gingivitis|Chronic gingivitis was defined as having probing depth (PD) less than or equal to 4mm, relative attachment loss (RAL) ) less than or equal to 3mm and more than to 25% sites with gingival bleeding present (BOP)
62018666|NCT04198610|ACTIVE_COMPARATOR|chronic periodontitis|"Chronic periodontitis was defined as having probing depth more than or equal to 5mm, RAL more than or equal to 8mm, with more than or equal to 10% sites with BOP positive and evidence of bone loss determined radiographically.~Non surgical periodontal therapy (SRP) was concluded in 3 months. Within the duration of the study, all subjects received supportive therapy"
62209852|NCT06427889|EXPERIMENTAL|Canoderm|Topical on feet twice a day
62209853|NCT06427889|EXPERIMENTAL|Oviderm|Topical on feet twice a day
62209854|NCT06427889|ACTIVE_COMPARATOR|Decubal|Topical on feet twice a day
62018667|NCT06097039||NAFLD subjects group|The group including 50 cases with NAFLD, the diagnosis was based on abdominal U/S and Fibroscan with CAP with or without elevated liver enzymes
62018668|NCT06097039||Healthy subjects group|The group including 50 healthy subjects as a control group with normal liver in transabdominal ultrasonography and normal liver enzymes
62018669|NCT05401292|ACTIVE_COMPARATOR|Iodine or Chlorhexidine Preparation|Standard of care with only skin preparation of iodine or chlorhexidine solution prior to sterile draping before surgery.
62209855|NCT04276753|EXPERIMENTAL|Terminalia Chebula fruit extract|"The test product is an emulsion. It contains Terminalia Chebula fruit extract.~Test product will be applied topically on full face twice a day for 8 weeks."
62209856|NCT04276753|PLACEBO_COMPARATOR|Placebo|"The placebo product is an emulsion with same appearance as the experimental product but without Terminalia Chebula fruit extract.~Placebo emulsion will be applied topically on full face twice a day for 8 weeks."
62209857|NCT05305612|EXPERIMENTAL|Early UFH administration|The iv. bolus of UFH (100Units/kg) will be given after obtained femoral vein access and at least 5 minutes prior to the start of the TSP.
62209858|NCT05305612|ACTIVE_COMPARATOR|Late UFH administration|The iv. bolus of UFH (100Units/kg) will be given immediately after TSP, defined as the introduction of transseptal sheath into the left atrium.
62209859|NCT06728787||Hereditary Spastic Paraplegia (HSP)|Patients undergo a combined rehabilitation treatment consisting of 15 sessions on Lokomat and 15 sessions of physical therapy over three weeks for a total of 30 sessions. The same subjects undergo clinical-functional evaluations before, at the end of treatment and after a 3-month follow-up.
62209860|NCT06665256|EXPERIMENTAL|Rapcabtagene autoleucel|Single infusion of rapcabtagene autoleucel (YTB323)
62209861|NCT06665256|ACTIVE_COMPARATOR|Comparator|Investigator choice of treatment as per protocol
62209862|NCT02862717||Hemodialysis (HD)|HD patients in MOH dialysis centres notified to NRR.
62209863|NCT02862717||Continuous ambulatory peritoneal dialysis (CAPD)|CAPD patients in MOH dialysis centres notified to NRR.
62209864|NCT01638143|ACTIVE_COMPARATOR|Gnosis P-1000 capsules|MK-7 capsules containing 75 µg of MK-7 (source: Gnosis, Italy).
62209865|NCT01638143|ACTIVE_COMPARATOR|Gnosis M1500 capsules|MK-7 capsules containing 75 µg of MK-7 (source Gnosis, Italy).
62209866|NCT01638143|ACTIVE_COMPARATOR|MenaQ7 M-1500 capsules|MK-7 capsules containing 75 µg of MK-7 (source: Nattopharma, Norway)
62209867|NCT00004242|EXPERIMENTAL|Arm I|See detailed description.
62209868|NCT00856037|EXPERIMENTAL|Treatment (doxorubicin hydrochloride, topotecan hydrochloride)|Patients receive doxorubicin hydrochloride IV over 3-5 minutes on day 6 of course 1 and on days 6, 13, and 20 of courses 2-5. Patients also receive topotecan hydrochloride PO on days 1-5. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
62209869|NCT06002932|ACTIVE_COMPARATOR|Conventional arm|As per the conventional treatment process, this strategy treats both the main vessel and the branch vessel with stents. The decision among Crush (Mini-crush), DK-Crush, Cullotte, TAP, and T-stenting is left to the discretion of the treatment provider.
62209870|NCT06002932|EXPERIMENTAL|PROVISION-DEB arm|As a principal, the treatment regime will be composed of the stent treatment in the main blood vessel and a drug-eluting balloon in a branch vessel. The order of the treatments done to the main vessel and the branch vessel shall be at the discretion of the treatment provider. Also, at the discretion of the treatment provider, a bail-out stenting can still be performed, depending on the condition of the branch vessel following a drug-eluting balloon treatment. However, bail-out stenting is recommended if there is a TIMI flow disorder, severe coronary artery exfoliation (National Heart, Lung, and Blood Institute type D, E, or F), or significant residual stenosis.
62209871|NCT04055207|EXPERIMENTAL|VVC|Option to receive VA Video Connect (VVC) delivery of HIV care.
62209872|NCT04055207|NO_INTERVENTION|Usual Care|All HIV care available at MEDVAMC will be delivered as usual.
62209873|NCT05440916|EXPERIMENTAL|Study group|"Patients with metastatic Non-Small Cell Lung Carcinoma eligible for first line systemic treatment with chemotherapy and immune checkpoint inhibitors (PDL1 less than 50%)~Radiotherapy: palliative irradiation of 2 to 5 sites (parenchymal/bone/soft tissue metastasis and/or primary lung tumour) with fractionation: 5 fractions of 4Gy (total dose 20Gy) in one week before systemic therapy."
62209874|NCT05440916|OTHER|Historical cohort|"Patients with metastatic Non-Small Cell Lung Carcinoma treated with first line of systemic therapy with chemotherapy and immune checkpoint inhibitors (PDL1 less than 50%).~Radiotherapy: no radiation therapy during the first line of systemic treatment before progression of disease."
62582280|NCT00378508|EXPERIMENTAL|1|The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2 over a 14 day treatment period.
62209875|NCT01301690||Neck masses|Neck mass received US and US-FNA
62582281|NCT00378508|PLACEBO_COMPARATOR|2|Normal saline infusion
62018670|NCT05401292|ACTIVE_COMPARATOR|Iodine or Chlorhexidine Scrub Brush Pre-Scrub with Isopropyl Alcohol and Chlorhexidine Soap|"In addition to standard of care skin preparation with iodine or chlorhexidine solution prior to sterile draping, patients will also receive an additional pre-scrub with isopropyl alcohol and chlorhexidine soap. The operative extremity will be scrubbed for 2 minutes with chlorhexidine soap with a scrub brush until the entire extremity is covered. Isopropyl alcohol will then be wiped onto the skin with a gauze and allowed to evaporate (dry)."
62018671|NCT05036629|EXPERIMENTAL|MRI protocol|Feasibility and use of methods developed in clinical research protocols or cognitive: the reproducibility of the parameters of acquisition, of the design of the activation paradigms development and results according to people will be an important element for the future integration of these methods in clinical or cognitive research protocols.
62209876|NCT06241547|EXPERIMENTAL|stimulation group|accept general drug prevention, wear the equipment, and receive electrical stimulation.
62018672|NCT05968612|EXPERIMENTAL|Treatment A (Test-Fed)|Following a 10-hour overnight fasting period, subjects will eat a high-fat, high-calorie breakfast, and 30 minutes later subjects will receive a single dose of 2 Lumacaftor 200 mg Film-Coated Tablets.
62582282|NCT05534919|EXPERIMENTAL|Nefecon active treatment|Nefecon 16mg once daily for 9 months.
62018673|NCT05968612|ACTIVE_COMPARATOR|Treatment B (Reference-Fed)|Following a 10-hour overnight fasting period, subjects will eat a high-fat, high-calorie breakfast, and 30 minutes later subjects will receive a single dose of 2 Lumacaftor 200 mg/Ivacaftor 125 mg Combination Film-Coated Tablets (Orkambi®)
62209877|NCT06241547|PLACEBO_COMPARATOR|control group|accept general drug prevention and wear the equipment but receive no electrical stimulation
62209878|NCT06375447||Patients with insomnia|Patients with a complaint about insomnia.
62209879|NCT05880901|NO_INTERVENTION|Control|does not attend afterschool or summer programing
62209880|NCT05880901|EXPERIMENTAL|After school|Attends after school programming for 32 weeks during the school year
62209881|NCT05880901|EXPERIMENTAL|Summer camp|Attends summer day camp programming for 8 weeks during the summer vacation from school
62209882|NCT05880901|EXPERIMENTAL|After school and Summer Camp|Attends after school programming for 32 weeks during the school year and summer day camp programming for 8 weeks during the summer vacation from school
62209883|NCT05308264|EXPERIMENTAL|Experimental|Dose Level 1: 250mg PO qd Dose Level 2: 500mg PO qd Dose Level 3: 750 mg PO qd and 1000 mg PO qd
62209884|NCT05612503|SHAM_COMPARATOR|Traditional physical therapy program|For 15 minutes, each child in both groups perform the following specific respiratory exercises: resistance-based diaphragm strengthening exercises, breathing exercises.
62582283|NCT05344703|ACTIVE_COMPARATOR|Standard Y Balance|Subjects will perform Y-balance lower quarter
62582284|NCT05344703|ACTIVE_COMPARATOR|Y Balance Plus Stroboscopic Glasses|Subjects will perform Y-balance lower quarter with and without stroboscopic lenses
62582285|NCT06576960|EXPERIMENTAL|nano silver varnish|new fluoride varnish
62582286|NCT06576960|EXPERIMENTAL|tri calcium phosphate varnish|fluoride varnish contain calcium phosphate
62582287|NCT06576960|NO_INTERVENTION|health education|
62582288|NCT04406584|PLACEBO_COMPARATOR|Saline|Injection of 1cc saline into olfactory cleft x4
62582289|NCT04406584|EXPERIMENTAL|Platelet Rich Plasma|Injection of 1cc patient's own platelet rich plasma (PRP) into olfactory cleft x4
62582290|NCT02414360|EXPERIMENTAL|Shortened Format|Shortened format of a systematic review
62582291|NCT02414360|ACTIVE_COMPARATOR|Control|Full length systematic review
62582292|NCT03738813|EXPERIMENTAL|Treatment Group|"The specific hand intervention consisted of 30 sessions, lasting 60 min/ day, for 6 days/week. All patients will be educated by physiotherapist to perform the movements for wrist, hand and arm in complete autonomy.~In Treatment Group, the movements will be performed using Gloreha ARIA. Gloreha Aria is a sensor-based therapy device designed for motor recovery of impaired upper limb. Gloreha Aria is equipped with sensors that can detect any movements in space: the software processes and displays them on the screen."
62018674|NCT05968612|EXPERIMENTAL|Treatment C (Test-Fasted)|Following a 10-hour overnight fasting period, subjects will receive a single dose of 2 Lumacaftor 200 mg Film-Coated Tablets.
62018675|NCT01067742||Subjects with Mucolipidosis Type IV|
62018676|NCT01055392|EXPERIMENTAL|Lithium|Patients received low doses of lithium salts (from 150 mg to 450 mg of lithium salts daily) to achieve sub-therapeutic lithium levels (target serum lithium level of 0,25 - 0,5 mEq/L). Lithium doses were administered twice a day. Lithium doses were titrated to achieve the target serum lithium levels within the first two weeks after study recruitment. After achieving the target serum lithium level, lithium salts doses remained stable until the end of the study.
62018677|NCT01055392|PLACEBO_COMPARATOR|Placebo|Identical placebo tablets were administered twice-a-day for two years.
62018678|NCT04191902||1|control
62018679|NCT04191902||2|treated
62582293|NCT03738813|ACTIVE_COMPARATOR|Participants Usual Care (PUC)|The specific hand intervention consisted of 30 sessions, lasting 60 min/ day, for 6 days/week. All patients will be educated by physiotherapist to perform the movements for wrist, hand and arm in complete autonomy.In Control Group, these activates will be performed without any device.
62582294|NCT06523075||Sepsis Group|
62582295|NCT06523075||Non-Sepsis Group|
62582296|NCT06685562||Pre-test patients|Prostate cancer patients, breast cancer patients, and melanoma patients from Spain, Denmark and the Netherlands recruited in the pre-test phase to observe care as usual
62582297|NCT06685562||Post-test patients|Prostate cancer patients, breast cancer patients, and melanoma patients from Spain, Denmark and the Netherlands recruited in the pre-test phase to observe care with the implementation of MetroMapping
62582298|NCT05626673|EXPERIMENTAL|Prayer app|Participants will be given the Pray.com app and directed to use it daily.
62582299|NCT05675150|EXPERIMENTAL|Intervention|This arm of participants will be receiving expressive arts-based intervention as intervention
62582300|NCT05675150|NO_INTERVENTION|Wait-list control|This arm of participants will not receive any art-based intervention during the study and are allocated as a wait-list control group
62582301|NCT01316094|EXPERIMENTAL|ASP group|oral
62582302|NCT01316094|PLACEBO_COMPARATOR|placebo group|oral
62582303|NCT03715478|EXPERIMENTAL|GSK2857916 with Pomalidomide and Dexamethasone|This will be a single arm study of GSK2857916 administered with pomalidomide and dexamethasone. GSK2857916 will be administered intravenously either on Day 1 of each 28 day cycle (Single Dose) or on Days 1 and 8 (Split Dose) and up to 4 dose levels will be evaluated during the phase I portion. Pomalidomide will be administered orally on Days 1-21 at 4 mg. Dexamethasone will be administered orally at 40 mg for patients ≤ 75 years old or 20 mg for patients older than 75 on days 1, 8, 15, 22.
62582304|NCT06297291||Prospective Ultrasound Renal Denervation Treatment|Hypertension patients that meet the eligibility criteria for treatment with Recor Medical Paradise Ultrasound Renal Denervation System will be enrolled and followed post-procedure for 5 years.
62582305|NCT06297291||RADIANCE CAP Transfer|Subjects enrolled in the RADIANCE Continued Access Protocol (CAP) study that are still active and have already completed their post-procedure 12-month follow-up visit are invited to participate in US GPS for long-term annual follow-up visits. These subjects will have already received the ultrasound Renal Denervation treatment under the RADIANCE CAP protocol and will not receive the procedure under the US GPS protocol.
62582306|NCT06308575|EXPERIMENTAL|Rivoceranib|Particpants will take rivoceranib by mouth 1 time each day while on study.
62582307|NCT01425216|EXPERIMENTAL|Sorafenib arm|All patients will be treated with sorafenib.
62582308|NCT04508049|OTHER|Early identification of fibrosis.|A pilot study to test the ability of qMT to quantify fibrosis in the post-stenotic human kidney, in comparison to innovative biomarkers of renal dysfunction and tissue damage. We will pursue the Specific Aim that qMT in stenotic human kidneys is feasible and reproducible.
62582309|NCT02361346|EXPERIMENTAL|Part 1: Cohort 1 - 5 Micrograms/Kilogram/Dose (mcg/kg/Dose)|Part 1: MT-3724 5 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Part 1) until recommended phase 2 dose of MT-3724 is determined
62582310|NCT02361346|EXPERIMENTAL|Part 1: Cohort 2- 10 mcg/kg/Dose|Part 1: MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Part) until recommended phase 2 dose of MT-3724 is determined
62018680|NCT06535997||Patients traited for carbonetherapy outside the PHRC-ETOILE programme|Collection of clinical-biological data from medical records (retrospective). For patients alive, completion of a quality-of-life questionnaire and a medico-economic interview (prospective).
62209885|NCT05612503|EXPERIMENTAL|Virtual reality-based exercises|Following a session of traditional physical therapy, the children in study group toke 30 minutes rest then they joined in a 30-minute VR exercise session using Nintendo Wii systems.
62582311|NCT02361346|EXPERIMENTAL|Part 1: Cohort 3- 20 mcg/kg/Dose|Part 1: MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Part 1) until recommended phase 2 dose of MT-3724 is determined
62790163|NCT02836405||Healthy Control|Typically developing individuals without a history of autism will receive transcranial magnetic stimulation (TMS) to measure brain plasticity.
62790164|NCT02536924|EXPERIMENTAL|Waiting room intervention plus TAU|The treatment group will receive waiting room intervention plus treatment as usual.
62790165|NCT02536924|EXPERIMENTAL|Only TAU.|The control group will receive only treatment as usual.
62018681|NCT06038877||Advanced Nephrology Practice Nurses|Advanced Nephrology Practice Nurses in France will be included.
62018682|NCT04919538||Relapsing Polychondritis Cohort|
62018683|NCT05226130|ACTIVE_COMPARATOR|Active cervical transcutaneous vagus nerve stimulation|Participants will be assigned to active transcutaneous vagus nerve stimulation, received once during each of the study visits and self-administered twice a day for a week.
62209886|NCT05642832|EXPERIMENTAL|Throughflow|Throughflow is a novel system that reduces anatomical dead space by providing a constant flow of fresh gas (i.e., gas that is free of CO2) during inspiration in patients receiving invasive mechanical ventilation. By clearing the CO2 that normally remains in the upper airway after exhalation (anatomical dead space), TF can dramatically reduce anatomical dead space without the need to increase the delivered VT, making it a safe strategy in terms of lung protection. This reduction in dead space reduces the ventilatory demands of the patients, reducing respiratory drive.
62209887|NCT06142266|ACTIVE_COMPARATOR|Intervention group|The intervention group (n=60) will undergo a 12-week pulmonary rehabilitation program. This program will consist of twice-weekly supervised exercise sessions, including aerobic training and resistance exercises targeting the lower limbs.
62209888|NCT06142266|ACTIVE_COMPARATOR|Control group|The control group (n=60) will receive usual medical care according to guidelines, which may include bronchodilator/anti-inflammatory therapy but no formal pulmonary rehabilitation.
62209889|NCT06480695|EXPERIMENTAL|Berkeley Life Nitrate-Rich Pro Capsules + High Intensity Exercise (HIE)|Participants assigned to this group will be instructed to take 6 capsules rich in nitrate (\~157mg of nitrate each) 2x a day (morning a night) starting 2-hours before the first exercise session. Participants will complete a supervised bout of exercise on a treadmill 3x a week for 1-month. Participants will exercise at an RPE of 15-17 based on the participant's VO2peak test.
62209890|NCT06480695|PLACEBO_COMPARATOR|Berkeley Life Placebo Capsules + High Intensity Exercise (HIE)|Participants assigned to this group will be instructed to take 6 capsules rich in nitrate-depleted placebo 2x a day (morning a night) starting 2-hours before the first exercise session. Participants will complete a supervised bout of exercise on a treadmill 3x a week for 1-month. Participants will exercise at an RPE of 15-17 based on the participant's VO2peak test.
62209891|NCT06480695|ACTIVE_COMPARATOR|Berkeley Life Nitrate-Rich Pro Capsules + Moderate Intensity Exercise (MIE)|Participants assigned to this group will be instructed to take 6 capsules rich in nitrate (\~157mg of nitrate each) 2x a day (morning a night) starting 2-hours before the first exercise session. Participants will complete a supervised bout of exercise on a treadmill 3x a week for 1-month. Participants will exercise at an RPE of 10-12 based on the participant's VO2peak test.
62209892|NCT06480695|PLACEBO_COMPARATOR|Berkeley Life Placebo Capsules + Moderate Intensity Exercise (MIE)|Participants assigned to this group will be instructed to take 6 capsules rich in nitrate-depleted 2x a day (morning a night) starting 2-hours before the first exercise session. Participants will complete a supervised bout of exercise on a treadmill 3x a week for 1-month. Participants will exercise at an RPE of 10-12 based on the participant's VO2peak test.
62407239|NCT01536522|PLACEBO_COMPARATOR|Standard American Diet|patients will consume their usual diet with a pre measured dose of canola oil in place of the medium chain triglyceride as a control group. They will be instructed to add the placebo dose to their meal 3 times a day
62407240|NCT01536522|ACTIVE_COMPARATOR|Alternate Day Diet|"patients will consume a regular Standard American Diet for 4 weeks and then provided a regulated dosed quantity of low caloric value shakes. they will consume this on alternating days"
62407241|NCT01536522|ACTIVE_COMPARATOR|Whole Lung Allergen Challenge|patients with or without asthma will be given controlled doses of specified allergens
62407242|NCT03933709|NO_INTERVENTION|Follow-up Group (FG)|dietary surveillance and conventional therapy
62407243|NCT03933709|ACTIVE_COMPARATOR|Control Group (CG)|deworming and WHO diet
62407244|NCT03933709|EXPERIMENTAL|Intervention Group (IG)|deworming and the Nutritional Support System (NSS)
62407245|NCT02921607||Observational|One group - all participants will be completing questionnaires and will be followed up with three months post discharge.
62407246|NCT04074109|EXPERIMENTAL|Teleyoga|group will receive instruction via computer tablet
62407247|NCT04074109|ACTIVE_COMPARATOR|In-person yoga|group will receive instruction in-person
62582312|NCT02361346|EXPERIMENTAL|Part 1: Cohort 4- 50 mcg/kg/Dose|Part 1: MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Part 1) until recommended phase 2 dose of MT-3724 is determined
62018684|NCT05226130|PLACEBO_COMPARATOR|Sham cervical transcutaneous vagus nerve stimulation|Participants will be assigned to sham transcutaneous vagus nerve stimulation, received once during each of the study visits and self-administered twice a day for a week.
62018685|NCT02573324|EXPERIMENTAL|Depatuxizumab Mafodotin, Radiation and Temozolomide (TMZ)|Depatuxizumab mafodotin is given on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. Depatuxizumab mafodotin is given on Day 1 and 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
62407248|NCT06384534|EXPERIMENTAL|Ambient air|Patient will perform tests at University Hospital Zurich
62407249|NCT06384534|ACTIVE_COMPARATOR|SOT via basal canula|Supplemental Oxygen Therapy (SOT) at approximately 3l/min will be provided via nasal canula from a small oxygen concentrator while the patient performs tests at University Hospital Zurich.
62407250|NCT06042465|EXPERIMENTAL|TCM group|As decided and performed by the registered Chinese Medicine Practitioners (CMP) on standardized treatment method
62407251|NCT06042465|EXPERIMENTAL|PT group|As decided and performed by physiotherapist of HKBH on standardized treatment method
62018686|NCT02573324|PLACEBO_COMPARATOR|Placebo, Radiation and TMZ|Placebo is given on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. Placebo is given on Day 1 and 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
62407252|NCT06042465|NO_INTERVENTION|Educational Group|Included patients in this group are provided with educational talk on knee health protection. Patients are advised with daily-life protection on their PFPS. Questionnaire assessments are performed to assess the healthy situation of their PFPS.
62407253|NCT03879759|EXPERIMENTAL|Arm 1|NAC - Relapse Prevention (4 wks)
62407254|NCT03879759|PLACEBO_COMPARATOR|Arm 2|NAC - Relapse Prevention (4 wks)
62407255|NCT06129500|EXPERIMENTAL|CBT for mood driven, problematic, impulsive behaviours|All participants will be offered the 12 week CBT intervention
62582313|NCT02361346|EXPERIMENTAL|Part 1: Cohort 5- 100 mcg/kg/Dose|Part 1: MT-3724 100 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
62790166|NCT00350844|EXPERIMENTAL|Hydroxyurea|
62209893|NCT04650542|EXPERIMENTAL|HBI-3000 alone (Period 1) followed by HBI-3000 with Paroxetine (Period 2)|"HBI-3000: 350 mg, 50 mL intravenous infusion (IV) over 30 minutes on Day 1 of Period 1 and approximately 15 days later on Day 1 of Period 2~Paroxetine: 20 mg dose twice a day on Days 1 and 2 of Period 2, and once a day on Days 3 through 7 inclusive of Period 2"
62209894|NCT01998100|EXPERIMENTAL|Prolonged Exposure + Exercise|
62209895|NCT01998100|ACTIVE_COMPARATOR|Prolonged Exposure Alone|
62209896|NCT06059638|EXPERIMENTAL|Treatment Group|AVIM therapy activated with continued stable antihypertensive drug therapy
62209897|NCT06059638|SHAM_COMPARATOR|Control Group|AVIM therapy deactivated with continued stable antihypertensive drug therapy
62209898|NCT06500793|EXPERIMENTAL|PF614 capsule with naltrexone HCl|"PF614 is an oxycodone prodrug. Part 1 doses = 100, 300 and up to 500 mg. Subjects will receive single daily doses at 5-14 days apart.~Naltrexone, 50 mg Oral (Day -1, Day 1 and Day 2). All subjects will receive naltrexone block"
62209899|NCT06500793|EXPERIMENTAL|PF614 capsule concomitantly with nafamostat and naltrexone HCl|PF614 is an oxycodone prodrug. Part 1 doses = 100, 300 and up to 500 mg. Nafamostat Mesylate is a trypsin inhibitor that blocks PF614 activation. Nafamostat IR solution (0.75 - XX mg); Nafamostat ER beads in capsule formulation (0.25 - YY mg) Naltrexone, 50 mg Oral (Day -1, Day 1 and Day 2). All subjects will receive naltrexone block
62209900|NCT05834205|EXPERIMENTAL|Plyometric Training|"Plyometric training regime:~Ankle hops, jump squats, box jump, overhead medicine ball, plyometric push-up, rotational wall with 16x2 reps for week 1\&2.~Ankle hops, jump squats, box jump, overhead medicine ball, plyometric push-up, rotational wall with 10x3 reps for week 3\&4.~Ankle hops, jump squats, box jump, depth jump and alternate lunge jump, overhead medicine ball, plyometric push-up, rotational wall with 8x3 reps for week 5\&6."
62209901|NCT05834205|ACTIVE_COMPARATOR|Drills|Fast bowling drills (hitting a target, football throw, fast bowler grip) and Ladder Drill
62209902|NCT03025035|EXPERIMENTAL|Pembrolizumab + Olaparib|This is an open-label, single-arm pilot study of pembrolizumab (study drug) in combination with Olaparib in 20 subjects with advanced BRCA mutation or HDR-defect associated breast cancer having progressed through at least a standard first line therapy.
62407256|NCT05298124|EXPERIMENTAL|Transcatheter edge-to-edge repair|The experimental arm includes treatment in an intensive care unit with intravenous medications (e.g. vasopressors and inotropes), ventilatory support or mechanical circulatory support plus transcatheter edge-to-edge repair
62582314|NCT02361346|EXPERIMENTAL|Part 1: Cohort 6- 75 mcg/kg/Dose|Part 1b: MT-3724 75 mcg/kg/dose IV for 6 doses over 12 days of 21-Day cycle for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Part 1 portion of the study)
62582315|NCT02361346|EXPERIMENTAL|Part 2: Cohort 7- MTD Expansion Cohort|Part 2: MT-3724 IV for 6 doses administered within 14 days of 21-Day cycle up to 6 Cycles. If the Subject exhibits stable disease or PR after end of Cycle 6 and investigator determines ratio is favorable, treatment with MT- 3724 may be continued for up to additional 6 cycles.
62582316|NCT02361346|EXPERIMENTAL|Part 3: All MT-3724 Treated Participants|Part 3: MT-3724 IV 50 µg/kg/dose administered on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle. Treatment will continue until death, disease progression, unacceptable toxicity, withdrawal of consent, or another reason for withdrawal, or until study discontinuation
62018687|NCT02573324|EXPERIMENTAL|Open-Label Sub-Study: Depatuxizumab Mafodotin, Radiation and TMZ|Depatuxizumab mafodotin is given to participants with hepatic impairment on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. Depatuxizumab mafodotin is given on Day 1 and 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
62018688|NCT01706510|EXPERIMENTAL|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
62018689|NCT01706510|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 600 mg Loading Dose followed by 75 mg Daily for 7 days ± 2 days
62018690|NCT03846024|EXPERIMENTAL|RibFx belt arm|Each patient in the interventional arm will be fitted with a RibFx orthosis belt, which is to be worn during the majority of their day (excluding showering/bathing). It will be encouraged (though not mandatory) to wear at night. Patients in both the control and interventional arm will be expected to participate in pulmonary hygiene / toilet exercises with guided and independent incentive spirometry as per our normal routine and standard of care. There are no other interventions or procedures that the patients will be subjected to for the research trial- other procedures/interventions will be performed only if the clinical care team feels they are indicated.
62209903|NCT01744795|EXPERIMENTAL|induced changes in hemodynamics|Twenty-five patients are planned enrolled. After induction of anesthesia, insertion of the PAC and the CardioQ probe, the patient are placed in the following successive positions: a) supine, b) head-down tilt, c) head-up tilt, d) supine, e) supine with phenylephrine administration f) pace heart rate 80 bpm, g) pace heart rate 110 bpm. CO are measured simultaneously using the CardioQ and thermodilution technique.
62209904|NCT05052177||Patient with systemic right ventricles with severe tricuspid regurgitation and high surgical risk|"* inclusion criteria:~  * \> 18-years-old~ * Right systemic ventricle~ * Severe tricuspid regurgitation~ * Symptomatic patient (NYHA 2 - 4) despite optimal medical therapy~ * High-risk surgical patient deemed not eligible for surgery by a multi-disciplinary and thus having underwent a percutaneous treatment of tricuspid regurgitation~* exclusion criteria - pregnant ou breastfeeding women"
62582317|NCT02361346|EXPERIMENTAL|Part 4: All MT-3724 Treated Participants|Part 4: In this arm, subjects were planned to receive all doses of MT-3724 as IV infusion as confirmed in Part 3.
62582318|NCT03403335|EXPERIMENTAL|Mindfulness Based Practices for Health Care Professionals|
62582319|NCT03403335|NO_INTERVENTION|Control Group|
62209905|NCT05952076|EXPERIMENTAL|Bi-26 supplementation|Bi-26 administered daily.
62209906|NCT05952076|PLACEBO_COMPARATOR|Placebo|Maltodextrin: Placebo administered daily
62582320|NCT01134445|OTHER|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
62018691|NCT03846024|NO_INTERVENTION|Control|"Patients in the control arm receive normal standard of care for rib fractures at the participating institution.~The current standard of care for rib fractures at the University of Vermont (participating institution) is as follows: includes oral and IV analgesia and other multimodal pain control as appropriate, including muscle relaxants such as methocarbamol (robaxin) unless there is a contraindication, pulmonary hygiene/toilet and respiratory care (including frequent evaluations by physicians, respiratory therapists, and nursing staff, early mobilization, and monitoring for pulmonary complication (via vital signs, pulse oximetry, oxygen requirement, chest imaging if appropriate)."
62018692|NCT01059617|EXPERIMENTAL|Flulaval/Arepanrix Group|subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
62018693|NCT01059617|EXPERIMENTAL|Flulaval/Unadjuvanted Arepanrix Group|subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
62582321|NCT04488198|NO_INTERVENTION|Control group|20 CIBD patients do not receive acupuncture or placebo-acupuncture.
62582322|NCT04488198|ACTIVE_COMPARATOR|Acupuncture group|20 CIBD patients receive 8 sessions of acupuncture therapy with 0,3 x 30mm needles (asia-med special number 16).
62582323|NCT04488198|PLACEBO_COMPARATOR|Placebo group|20 CIBD patients receive 8 sessions of sham acupuncture with placebo-needles 0,3 x 30mm (Streitberger).
62018694|NCT01059617|EXPERIMENTAL|Placebo/Arepanrix Group|subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
62209907|NCT06333353|EXPERIMENTAL|Real RepetitiveTranscranial Magnetic Stimulation (rTMS) 5 sessions|The real rTMS intervention will be delivered to the primary motor cortex (M1) on the left side, over the hand representation, using high frequency (HF) rTMS applied by way of a Magstim Rapid² system. The coil position and orientation will be standardized between treatment visits through using a Brainsight neuronavigation system (Rogue Research, Canada). Each of 5 rTMS sessions will consist of a total of 1500 pulses: 15 sets of pulses delivered at 10Hz for 10s at 80% resting motor threshold (RMT), separated by 50s intervals. The real rTMS intervention will be delivered daily over 5 consecutive days.
62215442|NCT04925505||BPB success|The study included patients aged between 20 and 70 yr who are to undergo elective shoulder surgery under general anesthesia. Patients undergo general anesthesia induction before the interscalene block is performed. Ultrasound-guided interscalene brachial plexus block will be performed in anesthetized patients before surgery. PI monitor will be applied to both blocked and non-blocked limbs using two separate oximeters. And the SUCCESS (or failure) of the block will be confirmed by (1) 30% change of heart rate and blood pressure after incision during operation, and (2) pain score, motor and sensory function test after surgery in the post-anesthesia recovery unit.
62582324|NCT06685497|EXPERIMENTAL|experimental group|Colorectal cancer patients enrolled in the 'Internet Plus' post-treatment management platform use the digital medical quality management system based on the 'COLORECTUM+' model for quality evaluation and continuous improvement. The platform integrates AI, using natural language processing and machine learning to analyze patient-reported symptoms, automatically assess severity, and generate alerts. Alerts are classified as yellow, orange, or red. Yellow indicates mild issues with self-care recommendations; consecutive yellow alerts prompt doctor contact within 24 hours. Orange indicates moderate severity, requiring doctor intervention within 24 hours. Red alerts signify serious symptoms or high-risk medication errors, prompting immediate notification of the doctor and emergency team. The system monitors symptom changes and updates alerts to support treatment optimization.
62582325|NCT03406559|OTHER|orthodontic treatment|fixed orthodontic treatment in adolescent males initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion.
62582326|NCT06682390|NO_INTERVENTION|Habitual dietary and physical activity regimen|Participants will maintain their habitual dietary and physical activity regimen for the first 3 months of the study.
62582327|NCT06682390|EXPERIMENTAL|Hypocaloric anti-inflammatory diet|Participants will follow a hypocaloric anti-inflammatory diet for the last 3 months of the study.
62018695|NCT01059617|EXPERIMENTAL|Placebo/Unadjuvanted Arepanrix Group|subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
62018696|NCT03191344||with IPSS record/IPSS|the surgoen use the IPSS in all thyroidectomy
62215443|NCT04925505||BPB failure|The study included patients aged between 20 and 70 yr who are to undergo elective shoulder surgery under general anesthesia. Patients undergo general anesthesia induction before the interscalene block is performed. Ultrasound-guided interscalene brachial plexus block will be performed in anesthetized patients before surgery. PI monitor will be applied to both blocked and non-blocked limbs using two separate oximeters. And the (success or) FAILURE of the block will be confirmed by (1) 30% change of heart rate and blood pressure after incision during operation, and (2) pain score, motor and sensory function test after surgery in the post-anesthesia recovery unit.
62215444|NCT02698605|EXPERIMENTAL|Usability test study of the MirrorPath|This study was a one-arm study and all subjects used the device and received usability test.
62407257|NCT05298124|ACTIVE_COMPARATOR|Medical therapy|Medical therapy includes treatment in an intensive care unit with intravenous medications (e.g. vasopressors and inotropes), ventilatory support or mechanical circulatory support.
62407258|NCT05270772|EXPERIMENTAL|CAR-T-19 Cells|The patients with CD19+ relapse or refractory B-ALL will receive a single infusion of autologous CAR-T-19 cells, with the escalated dose ranging from 0.5×10\^6/kg to 5.0×10\^6/kg CAR+ cells.
62407259|NCT03140813|EXPERIMENTAL|Placebo - Low-Dose - High-Dose|Placebo AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules
62582328|NCT04419532|EXPERIMENTAL|Dose Escalation (DS-1055a)|Participants will be enrolled into groups with each group receiving an increased dose from the previous group as safety assessments permit in order to determine the optimal dose for safety and tolerability.
62582329|NCT01733290|EXPERIMENTAL|Botulinum toxin A|A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
62582330|NCT01733290|PLACEBO_COMPARATOR|Control arm-Normal saline instillation|Normal saline instillation
62582331|NCT01363245|EXPERIMENTAL|Hospital phone counseling|multisession telephone counseling by hospital/study's smoking cessation staff
62582332|NCT01363245|ACTIVE_COMPARATOR|Fax-to-quit|Faxed referral to the state Quitline, which will then perform phone outreach as per Quitline protocol
62582333|NCT06015074|ACTIVE_COMPARATOR|Propofol group|patients in Propofol group receive sufentanil+ propofol
62018697|NCT03191344||Traditionaldescription Group/TD|the surgoen without the IPSS，use Traditional description
62018698|NCT01204892|ACTIVE_COMPARATOR|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
62018699|NCT01204892|ACTIVE_COMPARATOR|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
62018700|NCT03313596|ACTIVE_COMPARATOR|LT-only|patients received orthotopic LT and subsequent immunosuppression therapy
62018701|NCT03313596|EXPERIMENTAL|LT+ADV-TK|ADV-TK therapy was administered in addition to orthotopic LT and subsequent immunosuppression therapy
62018702|NCT06159894|ACTIVE_COMPARATOR|Treatment with LA CAB + RPV and follow-up at Specialist-Care centers (Specialist-Care arm).|Treatment with LA CAB + RPV and follow-up at Specialist-Care centers (Specialist-Care arm).
62215445|NCT03581383|NO_INTERVENTION|Current Care Model (Control)|The Current Care Model will not have any intervention beyond the standard of care for Hepatitis C provided by an interdisciplinary team at the University of Kentucky.
62215446|NCT03581383|EXPERIMENTAL|PREP-C Model|The PREP-C care model will provide Hepatitis C care with the standard interdisciplinary team expanded by a social worker and a patient navigator team. The social worker/ patient navigator team will use the standardized Psychosocial Readiness Evaluation and Preparation for hepatitis C treatment (PREP-C) tool and will guide PREP-C related interventions to overcome barriers to HCV treatment uptake and completion.
62215447|NCT03581383|EXPERIMENTAL|Modified ECHO Model|The modified Extension for Community Healthcare Outcomes (ECHO) Model will provide patient care through collaboration of the expanded interdisciplinary team (including social worker patient navigator team) with community providers.
62215448|NCT03581383|EXPERIMENTAL|Telemedicine Arm|The telemedicine Model will track outcomes and record patient experiences with HCV management and treatment with telemedicine.
62215449|NCT03858699||Individuals with stroke|Participants in sub-acute and chronic phases post-stroke (\>1 month post-stroke) will be recruited for participation in this study.
62215450|NCT03858699||Adult control participants|Even age distributions will be recruited in the adult control group, stratified under 40 years old and over 40 years old.
62018703|NCT06159894|EXPERIMENTAL|Treatment with LA CAB + RPV and follow-up in Polyvalent Day Hospital units (Day Hospital arm).|Treatment with LA CAB + RPV and follow-up in Polyvalent Day Hospital units (Day Hospital arm).
62018704|NCT04590755|EXPERIMENTAL|Interactive father-child sessions and use of website|Intervention group will receive the Run Daddy Run intervention.
62018705|NCT04590755|NO_INTERVENTION|No intervention (no interactive father-child sessions and use of website)|Intervention group will not receive the Run Daddy Run intervention.
62018706|NCT03888144|ACTIVE_COMPARATOR|Oxycodone group|Patients randomized to 20 pills of 5 mg oxycodone by mouth every 6 hours as needed for pain after ureteroscopy.
62018707|NCT03888144|EXPERIMENTAL|Ketorolac group|Patients randomized to 20 pills of 10 mg ketorolac by mouth every 6 hours as needed for pain after ureteroscopy.
62018708|NCT02455986|EXPERIMENTAL|Intervention|"The intervention group includes 150 participants aged 12-14 across three schools. Each participant has been given a Fitbit Zip pedometer to wear for a six month period and enrolled on the StepSmart challenge. Participants within the intervention group will take part in two competitions during this period.~1. School and team based competition. 27/05/15 - 22/06/15 (8 weeks)~2. Individually focused competition. 22/06/15 - 26/10/15 (18 weeks)~Prizes of low monetary value will be given to participants based on competition performance"
62018709|NCT02455986|NO_INTERVENTION|Control|The control group for the study involves approximately 90 participants aged 12 - 14. across two schools. Participants within the control group will complete the same measures as the intervention group including wearing an actigraph GT3X accelerometer for a seven day period and completing all questionnaires at the same time points as the intervention group.
62018710|NCT06574204||healthy individuals with erythromycin skin test|The researchers injected 30 units of erythromycin into the inner right wrist of the subjects, which is a liquid dosage form.
62018711|NCT06574204||healthy individuals with azithromycin skin test|The researchers injected 30 units of azithromycin into the inner right wrist of the subjects, which is a liquid dosage form.
62018712|NCT06574204||healthy individuals with physiological saline|The researchers injected 10-20 μl of physiological saline into the inner left wrist of the subjects, which is a liquid dosage form.
62018713|NCT05576467|ACTIVE_COMPARATOR|MBCT-Telephone|8 weekly classes delivered via telephone.
62018714|NCT05576467|ACTIVE_COMPARATOR|MBCT-Video|8 weekly classes delivered via video.
62209908|NCT06333353|SHAM_COMPARATOR|Sham RepetitiveTranscranial Magnetic Stimulation (rTMS) 5 sessions|The sham rTMS intervention will be delivered to the primary motor cortex (M1) on the left side, over the hand representation, using high frequency (HF) rTMS applied by way of a Magstim Rapid² system interfaced with a placebo coil, whose position and orientation will standardized between treatment visits using a Brainsight neuronavigation system (Rogue Research, Canada) The sham stimulation target will be individually defined at baseline as the site eliciting the highest averaged motor evoked potential (MEP) peak-to-peak amplitude in the first dorsal interosseous (FDI) muscle. Each of 5 sham rTMS sessions will consist of a total of 1500 sham pulses: 15 sets of sham pulses (0% output) delivered at 10Hz for 10s, separated by 50s intervals. The sham intervention will be delivered daily over 5 consecutive days.
62018715|NCT05576467|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|8 weekly online modules delivered via web portal.
62018716|NCT01803906||Mitochondrial disease|Patients with known or suspected DNA mutations that affect mitochondrial function. Patients with suspected mitochondrial disorders
62018717|NCT05522036|EXPERIMENTAL|Patients treated with Methy ALA & 35 minutes white light illumination|Only patients with a minimum of 9 clinically diagnosed grade I and II AK lesions of the scalp (according to the classification by Olsen et al. suggesting the existence of field cancerization, are included in the study. All patients are informed about the purpose of the study and gave informed consent before inclusion. The illumination begins 10 min after the application of MAL cream to the treatment area. In this study, the duration of the light exposure is reduced to 35 min to achieve a PpIX-weighted daylight of 4 J/cm2. MAL cream is removed after the illumination procedure leading to an incubation time of 45 min.
62018718|NCT01879761||Immunosuppressed|"Immunosuppressed includes patients with any one of the following:~1. a diagnosis of a hematological malignancy~2. a diagnosis of HIV~3. myelosuppressive chemotherapy in the previous 90 days~4. immune-modulating medications in the previous 90 days"
62018719|NCT01879761||Non-Immunosuppressed|Subject does not fit immunosuppressed criteria
62582334|NCT06015074|EXPERIMENTAL|Ciprofol group|patients in Ciprofol group receive sufentanil+ ciprofol
62018720|NCT00725894||1|The Pediatric Locking Nail was designed to provide stable sub-rigid fixation of femoral fractures in children
62018721|NCT03834194|EXPERIMENTAL|Lottery + Monthly Weight|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings ($0, $2, $15 or not eligible for lottery due to lack of weighing). Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, participants will be specifically notified that they would have received $14 had they had gained within the recommended range for the month, drawing on research showing that loss aversion can be motivating.
62209909|NCT06333353|EXPERIMENTAL|Real RepetitiveTranscranial Magnetic Stimulation (rTMS) 10 sessions|The real 10-session rTMS intervention will be the same as that delivered for the real 5-session rTMS intervention, but delivered as 5 daily sessions, a two day break, and 5 more daily sessions.
62215451|NCT02160236|ACTIVE_COMPARATOR|dexketoprofen trometamol|before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
62018722|NCT03834194|EXPERIMENTAL|Lottery + Overall Weight + Exercise|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings if any. Participants will be given the IOM GWG recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
62018723|NCT03834194|EXPERIMENTAL|Lottery + Overall Weight|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings ($0, $2, $15 or not eligible for lottery due to lack of weighing). Participants will be given the Institute of Medicine gestational weight gain recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit.
62018724|NCT03834194|EXPERIMENTAL|Lottery + Monthly Weight + Exercise|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings if any. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, they will be notified that they would have received $14 had they had gained within the recommendation for the month. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
62582335|NCT04437368|EXPERIMENTAL|Part 1 - GT005 Low Dose|Approximately 25 subjects are planned, with subjects randomised to GT005 Low Dose.
62209910|NCT06333353|SHAM_COMPARATOR|Sham RepetitiveTranscranial Magnetic Stimulation (rTMS) 10 sessions|The sham 10 session rTMS intervention will be delivered identically to the sham 5 session intervention, but delivered as 5 daily sessions, a two day break, and 5 more daily sessions.
62582336|NCT04437368|EXPERIMENTAL|Part 1 - GT005 High Dose|Approximately 25 subjects are planned, with subjects randomised to GT005 High Dose.
62209911|NCT05550090||Patients with liver metastasis from breast cancer requiring antitumor therapy|Patients with liver metastasis from breast cancer requiring antitumor therapy
62215452|NCT02160236|ACTIVE_COMPARATOR|tenoxicam|before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc
62582337|NCT04437368|NO_INTERVENTION|Part 1 - Untreated control|Approximately 25 subjects are planned, with subjects randomised to untreated control.
62582338|NCT04437368|EXPERIMENTAL|Part 2 - GT005 Low Dose|Approximately 116 subjects are planned, with subjects randomised to Part 2 - GT005 Low Dose.
62582339|NCT04437368|NO_INTERVENTION|Part 2 - Untreated control|Approximately 54 subjects are planned, with subjects randomised to untreated control.
62215453|NCT02160236|PLACEBO_COMPARATOR|serum physiologic|before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
62215454|NCT00823576|ACTIVE_COMPARATOR|1|"Group witness: one receiving a single bolus of analgesic~Seepage simple person the end of intervention of 200mg of ropivacaïne 0,5 % at the level of zones it"
62215455|NCT00823576|ACTIVE_COMPARATOR|2|Group catheter: receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.
62407260|NCT03140813|EXPERIMENTAL|Placebo - High-Dose - Low-Dose|Placebo AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules
62407261|NCT03140813|EXPERIMENTAL|Low-Dose - Placebo - High-Dose|AZD7325 5mg BID in gelatin capsules Placebo AZD7325 15mg BID in gelatin capsules
62407262|NCT03140813|EXPERIMENTAL|Low-Dose - High-Dose - Placebo|AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules Placebo
62582340|NCT05561322||Spinal fusion patients|Patients who have undergone spinal fusion surgery and have had at least 3 years of follow-up.
62582341|NCT05561322||Lumbar arthroplasty patients|Patients who have undergone lumbar arthroplasty with disc replacement and have had at least 3 years of follow-up.
62582342|NCT06056687|EXPERIMENTAL|Alpha Lipoic Acid Group|ALA 600 mg once daily
62582343|NCT06056687|PLACEBO_COMPARATOR|Placebo Group|the second group on placebo once daily
62582344|NCT05577455|EXPERIMENTAL|administration for 2 menstrual cycles group|This group will receive TCM treatment before 2 menstrual cycles of IVF-ET.
62582345|NCT05577455|ACTIVE_COMPARATOR|administration for 3 menstrual cycles group|This group will receive TCM treatment before 3 menstrual cycles of IVF-ET.
62018725|NCT03834194|EXPERIMENTAL|Loss + Monthly Weight|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, participants will be specifically notified that they would have received $14 had they had gained within the recommended range for the month, drawing on research showing that loss aversion can be motivating.
62018726|NCT03834194|EXPERIMENTAL|Loss + Overall Weight + Exercise|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will be given the IOM GWG recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
62582346|NCT01728818|EXPERIMENTAL|Arm A|
62582347|NCT01728818|ACTIVE_COMPARATOR|Arm B|
62018727|NCT03834194|EXPERIMENTAL|Loss + Overall Weight|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will be given the Institute of Medicine gestational weight gain recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit.
62215456|NCT04648722||Left-side hemithyroidectomy|Patients who received a hemithyroidectomy of the left thyroid lobe since 1994
62215457|NCT04648722||Right-side hemithyroidectomy|Patients who received a hemithyroidectomy of the right thyroid lobe since 1994
62407263|NCT03140813|EXPERIMENTAL|High-Dose - Low-Dose - Placebo|AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules Placebo
62407264|NCT03140813|EXPERIMENTAL|High-Dose - Placebo - Low-Dose|AZD7325 15mg BID in gelatin capsules Placebo AZD7325 5mg BID in gelatin capsules
62407265|NCT06650839|EXPERIMENTAL|Treatment MAS|Subjects will be treated with Valvosoft, Ultrasound guided Non-Invasive Ultrasound Therapy (NIUT) medical device, to reduce the symptoms caused by moderate aortic stenosis
62582348|NCT06488443|EXPERIMENTAL|Intervention-yoga|Participants in intervention arm will receive intervention from an instructor who would be trained in the intervention by the yoga adviser. One week of yoga intervention with the first session offline and the rest of the 6 sessions online
62582349|NCT06488443|ACTIVE_COMPARATOR|WHO 5As model intervention|The control group will be given the WHO 5As model intervention to help patients ready to quit.
62582350|NCT03845218||Healthy Controls|Participants without RP
62582351|NCT03845218||Participants with RP|Participants must have evidence of RP as defined by characteristic ERG responses, visual fields, clinical exam and/or genetic testing
62582352|NCT05030298|EXPERIMENTAL|Treatment (stereotactic biopsy, radiosurgery, surgery)|Patients undergo MRI-guided stereotactic biopsy. Within 14 days of registration, patients undergo either standard of care surgery or radiosurgery in 1 fraction. Within 14 days, patients who underwent radiosurgery then undergo surgery. Within 4-6 weeks, all patients then receive standard of care radiation therapy over 30 fraction and temozolomide daily with or without TTF at the discretion of the treating neuro-oncologist. Additionally, patients undergo MRI and blood sample collection and optional biopsy throughout the study.
62209912|NCT02231073|EXPERIMENTAL|Exercise: Agility Boot Camp-Cognitive|Subjects will participate in an 80-minute, group (6 per group) exercise session led by a certified exercise trainer knowledgeable in the Agility Boot Camp-Cognitive (ABC-C) program for 3x/week for 6 weeks. The exercise protocol is an adaptation of our Agility Boot Camp (ABC) exercise program for PD. The exercises are designed as a circuit to challenge movement-skills known to be impaired in PD. Stations will include: Gait training, PWR Moves ©, Agility course, Lunges, Boxing and Tai Chi. Each activity was chosen for its inherent focus on multi-directional movements, dynamic postural transitions, axial mobility, big movements and whole body motor sequencing. Each station (10-20 minutes) has 3 possible progression levels, based on: (1) divided attention with secondary cognitive tasks, (2) response inhibition, (3) limiting external sensory cues, and (4) increasing speed and resistance.
62209913|NCT02231073|ACTIVE_COMPARATOR|Education: Living with Parkinson's disease|The Education arm is a chronic disease education program to teach patients how to live better with their chronic condition. It was developed by our research team to be specific for people with Parkinson's disease. It will include content and discussion of topics such as sleep, nutrition, and medication management. Classes will consist of a group of subjects (up to 6) meeting with the trainer for 90-minute session, once a week for six weeks. In order to match dose of the education intervention with the exercise intervention, participants will be provided relaxation tapes to be used at home 5 times per week for 30 minutes for an overall education dose of 240 minutes; similar to the exercise dose.
62209914|NCT01497353|ACTIVE_COMPARATOR|Position at introitus level|The newborn will be held by the neonatologist at the level of the introitus, the cord will be clamped at 2 minutes after birth. New weigh will be obtained after that.
62209915|NCT01497353|EXPERIMENTAL|Position at Maternal Abdomen|The newborn will be placed on the abdomen and of the mother immediately after the first weigh measurement. The cord will be clamped at 2 minutes after birth .
62209916|NCT06498011|EXPERIMENTAL|iCOSMO|20 participants will receive the iCOSMO intervention. iCOSMO consists of two training approaches that will include active touch and movement exploratory procedures during goal-oriented tasks as well as robotic training using the Kinarm Exoskeleton device.
62209917|NCT06498011|ACTIVE_COMPARATOR|Home GRASP|20 participants will receive the control intervention. The control group will receive a matched dose of a home-based exercise programme. The home-based exercise programme will be based on the Home Graded Repetitive Arm Supplementary Program.
62407266|NCT05252585|EXPERIMENTAL|Everolimus|Participants with confirmed diagnosis of TSC-AML and who fulfil the local (Taiwan) reimbursement criteria of everolimus for TSC-AML treatment
62582353|NCT05856383||Group of ues of inetetamab combined with pyrotinib and vinorelbine|Group of ues of inetetamab combined with pyrotinib and vinorelbine
62582354|NCT01431300|ACTIVE_COMPARATOR|0.03 mmol/kg|FDA-approved dose for lower extremity arterial imaging
62582355|NCT01431300|EXPERIMENTAL|0.02 mmol/kg|
62582356|NCT01431300|EXPERIMENTAL|0.01 mmol/kg|
62582357|NCT05115188|OTHER|2-hr OGTT with glucose beverage|For the 2 hour oral glucose tolerance test (OGTT), women fast for 8 hours and then consume 75g of glucose beverage, and serum glucose levels are taken at fasting, 1 and 2 hours after drinking the glucose beverage. The 75g OGTT is the gold standard and is performed for GDM diagnosis.
62582358|NCT05115188|EXPERIMENTAL|2-hr OGTT with Dex4® tablets|Participants will be asked to ingest 21 Dex4® tablets and no more than 300ml of water within 5 minutes. Blood draws will be performed at fasting (before ingesting the dextrose monohydrate tablets), as well as 1 hour after (+/- 15 minutes) and 2 hours (+/- 15 minutes) after ingesting the dextrose monohydrate tablets.
62582359|NCT02318355|NO_INTERVENTION|Control|Control group that receives no intravenous fluid after blood donation
62582360|NCT02318355|EXPERIMENTAL|Lactated Ringers|Experimental group that receives two liters lactated ringers after blood donation.
62582361|NCT02318355|EXPERIMENTAL|Normal Saline|Experimental group that receives two liters normal saline after blood donation.
62582362|NCT06270316|EXPERIMENTAL|Dose Escalating Low and High Cohorts|"Dose level 1: 6.0 x 10e13 gc/kg - 3 Participants (plus additional 3 if needed to assess dose-limiting toxicity)~Dose level 2: 3.0 x 10e14 gc/kg - 3 Participants (plus additional 3 if needed to assess dose-limiting toxicity)"
62582363|NCT06270316|EXPERIMENTAL|Expansion Dose Cohorts|"Dose level 1: 6.0 x 10e13 gc/kg - Additional 3 if needed to assess dose-limiting toxicity~Dose level 2: 3.0 x 10e14 gc/kg - Additional 3 if needed to assess dose-limiting toxicity"
62209918|NCT05553522|EXPERIMENTAL|Investigational Treatment|
62209919|NCT04375280|EXPERIMENTAL|Cohort 1|Participants will be involved in a long-term evaluation program combining, body composition measures, physical tests as well as self-administered questionnaires. Participants will be followed for 5 years with evaluations taking place at inclusion, 6 months, at 1, 2 and 5 years
62209920|NCT06549790|EXPERIMENTAL|NMS-03597812|"Dose escalation (Phase Ia):~Administered orally once daily (28 consecutive days) in repeated 4-week cycles. Each cycle is 28 days.~Expansion cohorts (Phase Ib, Cohorts A and B):~The dose expansion may comprise up to a total of 2 single arms of NMS-03597812 as single agent:~* Cohort A: in patients with TP53mt relapsed/refractory acute myeloid leukemia (R/R AML) prior unfit to intensive chemotherapy (IC) who have exhausted standard treatment options~* Cohort B: in prior fit or unfit patients to IC with TP53wt R/R AML who have exhausted standard treatment options~Backfill cohorts:~Optional backfill cohorts may be opened at any time during the conduct of the trial to further evaluate the following items: NMS-03597812 dosing alone, pharmacokinetic (PK), drug-drug interactions, food effects, biomarkers and QTc for NMS-03597812 as single agent."
62582364|NCT06575088|ACTIVE_COMPARATOR|Standard tourniquet pressure with cotton pad|Cotton pad was applied as protective filling material. Standard 250 mmHg pressure was applied as pneumatic tourniquet pressure.
62582365|NCT06575088|ACTIVE_COMPARATOR|Standard tourniquet pressure with elastic stockinette|Elastic stockinette was applied as protective filling material. Standard 250 mmHg pressure was applied as pneumatic tourniquet pressure.
62018728|NCT03834194|EXPERIMENTAL|Loss + Monthly Weight + Exercise|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, they will be notified that they would have received $14 had they had gained within the recommendation for the month. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
62582366|NCT06575088|ACTIVE_COMPARATOR|Limb occlusion pressure with cotton pad|Cotton pad was applied as protective filling material. Limb occlusion pressure was applied as pneumatic tourniquet pressure.
62582367|NCT06575088|ACTIVE_COMPARATOR|Limb occlusion pressure with elastic stockinette|Elastic stockinette was applied as protective filling material. Limb occlusion pressure was applied as pneumatic tourniquet pressure.
62582368|NCT06407765|ACTIVE_COMPARATOR|Dual Task Training|This group will receive Dual task training
62582369|NCT06407765|EXPERIMENTAL|Dual task training with Backward walking|This group will receive both Dual task training with Backward walking
62582370|NCT06594133||Nocardia Pneumonia Group (NPG)|This group consists of lung transplant recipients diagnosed with Nocardia pneumonia. The patients in this group are studied to assess the impact of Nocardia infection on the pulmonary microbiota. Samples including bronchoalveolar lavage fluid (BALF) and blood are collected for microbial community analysis.
62582371|NCT06594133||Non-Nocardia Infection Group (NNIG)|This group consists of lung transplant recipients who are not infected with Nocardia. These patients serve as the control group and are matched with the Nocardia pneumonia group based on clinical characteristics such as age, sex, and underlying conditions.
62582372|NCT02591095|EXPERIMENTAL|ABT-263|oral Navitoclax (ABT-263) daily
62582373|NCT03468413|EXPERIMENTAL|Single ascending dose, CP1050 or Placebo|
62582374|NCT03468413|EXPERIMENTAL|Multiple ascending dose, CP1050 or Placebo|
62582375|NCT05532852|SHAM_COMPARATOR|standard-of-care|
62582376|NCT05532852|EXPERIMENTAL|standard-of-care plus Paxlovid|
62582377|NCT03129945|ACTIVE_COMPARATOR|Nifedipine|Participants will be given this medication orally
62582378|NCT03129945|ACTIVE_COMPARATOR|Indomethacin|Participants will be given this medication orally
62582379|NCT06288373|EXPERIMENTAL|Camrelizumab combined neoadjuvant chemotherapy plus radical surgery|Patients receive 1 cycle of cisplatin and nab paclitaxel combined neoadjuvant chemotherapy and subsequent 2 cycles of camrelizumab combined neoadjuvant chemotherapy. Based on the tumor size as indicated by MRI, patients who achieve complete response or partial response (CR/PR，RECIST v1.1) will undergo open radical hysterectomy and pelvic lymph node dissection. Patients who show stable disease or progression (SD/PD，v1.1) will proceed directly to concurrent chemoradiotherapy (CCRT).
62582380|NCT06288373|ACTIVE_COMPARATOR|Concurrent Chemoradiotherapy (CCRT)|Pelvic EBRT + concurrent platinum-containing chemotherapy + brachytherapy
62582381|NCT05012722||Decompensated Heart Failure with reduced ejection fraction (HFrEF)|Pulse wave velocity to be measured during hospitalisation phase and repeated 4 weeks after when participant is in a stable state i.e stable (HFrEF)
62582382|NCT05012722||Decompensated Heart Failure with Preserved ejection fraction (HFpEF)|Pulse wave velocity to be measured during hospitalisation phase and repeated 4 weeks after when participant is in a stable state i.e stable (HFpEF)
62582383|NCT05012722||Acute Kidney Injury in patients with Chronic Kidney Disease stage 3a,3b or 4|Pulse wave velocity to be measured during hospitalisation phase and repeated 4 weeks after when participant is in a stable state i.e. stable Chronic Kidney Disease stage 3a, 3b and 4
62582384|NCT02501954|EXPERIMENTAL|Regimen I|Cisplatin 50 mg/m2 IV Days 1 and 29 plus Volume-directed radiation therapy followed by Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2 q 21 days for 4 cycles
62018729|NCT03112772|EXPERIMENTAL|Group I|Participants who are receiving socket preservation using allograft (Puros® Allograft, Zimmer dental, Zimmer, USA) covered by membrane (size: 15x20mm) made of type I collagen fibers purified from bovine tendon (BioMend® Membrane, Zimmer dental, Zimmer, USA).
62582385|NCT02501954|ACTIVE_COMPARATOR|Regimen II|Carboplatin AUC 6 plus Paclitaxel 175 mg/m2 q 21 days for 3 cycles followed by Volume-directed radiation therapy followed by Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2 q 21 days for 3 cycles
62018730|NCT03112772|EXPERIMENTAL|Group II|Participants who are receiving socket preservation cancellous particulate bovine bone xenograft (CopiOs® Cancellous Particulate, Zimmer dental, Zimmer, USA) covered by membrane (size: 15x20mm) made of type I collagen fibers purified from bovine tendon (BioMend® Membrane, 15x20mm, Zimmer dental, Zimmer, USA).
62018731|NCT03112772|NO_INTERVENTION|Group III|No grafting materials will be inserted, so it serves as a negative control group.
62018732|NCT06206005||Group1 with Haemoglobin A1c ≤6.5%|This group represents a well-controlled type 2 Diabetics mellitus.
62582386|NCT05792332|EXPERIMENTAL|Telemonitoring|Patients are followed up by a nurse-telemonitoring
62582387|NCT05792332|ACTIVE_COMPARATOR|Standard-of-care|Patients are followed up only by the neurologist
62582388|NCT00161421|EXPERIMENTAL|1|Lupron injection at Day -14 with load of dutasteride (24.5 mg) followed by 13 days of Dutasteride. On day 0, 11, 0.5 mg Dutasteride taken daily for next 11 days. Day 1 Oral Testosterone (T) 200mg without food, Day 2 Oral T 400 mg without food, Day 3 Oral T 400 mg with food. During the 2nd week of the study, we will repeat the testosterone doses, with a 2nd formulation of testosterone (Day8, 9, \& 10.
62582389|NCT04881656|EXPERIMENTAL|HIIYH|Help is in Your Hands is a series of online modules for parents with narrated videos of specific interactive strategies for supporting toddlers' communication development.
62582390|NCT04881656|NO_INTERVENTION|Comparison|No additional materials
62582391|NCT06684600|EXPERIMENTAL|Dalpiciclib + Pyrotinib|
62582392|NCT00544401|EXPERIMENTAL|1|Hypnopuncture Treatment
62582393|NCT00544401|NO_INTERVENTION|2|Conventional IVF/ICSI treatment only
62582394|NCT03937219|EXPERIMENTAL|Experimental Arm|Cabozantinib + nivolumab + ipilimumab (4 doses) followed by cabozantinib + nivolumab
62582395|NCT03937219|ACTIVE_COMPARATOR|Control Arm|Cabozantinib-matched placebo + nivolumab + ipilimumab (4 doses) followed by cabozantinib-matched placebo + nivolumab
62209921|NCT05039216||patients initiating a biotherapy or a target treatment|Blood sampling
62209922|NCT05039216||patients with chronic inflammatory rheumatism, weakening osteopathy or mechanical pathology|Blood sampling
62582396|NCT01397396|EXPERIMENTAL|Inspiratory Muscle Training|Inspiratory Muscle Training
62582397|NCT01397396|PLACEBO_COMPARATOR|Sham IMT|Sham Inspiratory Muscle Training
62582398|NCT01749709|EXPERIMENTAL|Instrumental music listening|Daily music listening
62582399|NCT01749709|EXPERIMENTAL|Vocal music listening|Daily music listening
62582400|NCT01749709|ACTIVE_COMPARATOR|Audiobook listening (control)|Daily audiobook listening
62582401|NCT06327529|EXPERIMENTAL|Bean Variety 1|Enriched with Zinc-67, Iron-57
62582402|NCT06327529|EXPERIMENTAL|Bean Variety 2|Enriched with Zinc-70, Iron-58
62582403|NCT06327529|EXPERIMENTAL|Bean Variety 3|Enriched with Zinc-67, Iron-57
62582404|NCT06327529|EXPERIMENTAL|Bean Variety 4|Enriched with Zinc-70, Iron-58
62582405|NCT04560270|EXPERIMENTAL|Only arm|Blood samples to analyze ctDNA
62209923|NCT05499845||Group P (n=40) (Propofol),|
62209924|NCT05499845||Group PS (n=40) (Propofol-Sevoflurane),|
62209925|NCT05499845||Group S (n=40) (Sevoflurane).|
62582406|NCT05605145||Immunocompromised patients|"1. Patients with immunocompromised conditions, including but not limited to HIV infection, long-term systemic use of corticosteroids, use of immunosuppressive agents, hematologic malignancies, solid tumors, hematopoietic stem cell transplantation, solid organ transplantation, radiotherapy and/or chemotherapy for malignancies,primary immunodeficiency disease.~2. Typical clinical manifestations of PJP such as fever,nonproductive cough, shortness of breath, and progressive hypoxemia.~3. Radiological abnormalities suggestive to PJP in bilateral lungs revealed by chest computed tomography (CT).~4. Respiratory tract samples were collected for qPCR and/or mNGS detection."
62018733|NCT06206005||Group 2 with Haemoglobin A1c >6.5%|This group represents a poorly controlled type 2 Diabetics mellitus.
62209926|NCT06024278|EXPERIMENTAL|African American Hospice Caregivers|Culturally tailored educations videos will be administered to African American participants.
62209927|NCT06024278|EXPERIMENTAL|Puerto Rican Hospice Caregivers|Culturally tailored educations videos will be administered to Puerto Rican participants.
62209928|NCT03325491|EXPERIMENTAL|Acipimox plus exercise training|The active supplement will contain the prescription drug Acipimox (250 mgs) , a nicotinic acid precursor traditionally used to lower blood lipid levels. The supplement will be administered 3 times per day, for 6 weeks.
62209929|NCT03325491|PLACEBO_COMPARATOR|Placebo plus exercise training|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
62209930|NCT03183219|EXPERIMENTAL|Group A|In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor.
62209931|NCT03183219|EXPERIMENTAL|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62209932|NCT03183219|EXPERIMENTAL|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
62209933|NCT01552603|EXPERIMENTAL|Artificial Pancreas Control|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 28 hours. For the entire study, the adaptive component of Artificial Pancreas Control Software will be used to control the subject's blood glucose.
62209934|NCT06509906|EXPERIMENTAL|M9466 + Irinotecan (Run-in Cohort)|
62209935|NCT06509906|EXPERIMENTAL|M9466 + FOLFIRI (folinic acid, fluorouracil, irinotecan) + Bevacizumab (Dose Finding Cohorts)|
62407267|NCT00721513|EXPERIMENTAL|TPFChemotherapy + Concomitant Cetuximab & RT|Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab \& Radiation Therapy
62582407|NCT05629689|EXPERIMENTAL|Part A Cohort 1 - 1 mg dose|1 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
62582408|NCT05629689|EXPERIMENTAL|Part A Cohort 2 - 2 mg dose|2 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
62582409|NCT05629689|EXPERIMENTAL|Part A Cohort 3 - 4 mg dose|4 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
62582410|NCT05629689|EXPERIMENTAL|Part A Cohort 4 - 8 mg dose|8 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
62582411|NCT05629689|EXPERIMENTAL|Part A Cohort 5 (optional) - 12 or 15 mg dose|12 or 15 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
62582412|NCT05629689|EXPERIMENTAL|Part A Cohort 6 - Optimal dose|Selected (optimal) mass dose as determined from results of Cohorts 1 through 5 of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
62582413|NCT05629689|EXPERIMENTAL|Part B|Selected (optimal) dose of GEH200520 Injection from Part A with fixed dose of GEH200521 (18F) Injection administered together in 3 sequential repeat imaging visits
62582414|NCT01528826|EXPERIMENTAL|NVBOX regimen|Vinorelbine plus oxaliplatin
62582415|NCT02162641||SCC of the anus|
62582416|NCT02362672|EXPERIMENTAL|NKTR-181|NKTR-181 twice daily (BID) tablets
62582417|NCT02362672|PLACEBO_COMPARATOR|Placebo|Placebo to match NKTR-181 twice daily (BID) tablets
62582418|NCT06166745|EXPERIMENTAL|Sensi-IP toothpaste|Sodium Fluoride Toothpaste with Sensi-IP
62582419|NCT06166745|ACTIVE_COMPARATOR|Sodium fluoride toothpaste|Sodium Fluoride Toothpaste
62582420|NCT00396032|EXPERIMENTAL|1|
62582421|NCT00396032|PLACEBO_COMPARATOR|2|
62582422|NCT06540456||Patients with neuropathic LBP and painful lumbosacral radiculopathy|patients with neuropathic LBP and painful lumbosacral radiculopathy
62582423|NCT01653015|EXPERIMENTAL|Influenza vaccine LAIV|Live attenuated influenza vaccine (LAIV).
62018734|NCT05350293|ACTIVE_COMPARATOR|Molded abutment|A plastic abutment that is provided by the implant manufacturer will be used. This abutment will be modified using wax, and then it will be dismantled, wedged, and poured using a Ni-Cr mixture. A plastic abutment that the implant manufacturer provides will be used. This abutment will be modified using wax, and then it will be dismantled, wedged, and poured using a Ni-Cr mixture.
62582424|NCT01653015|ACTIVE_COMPARATOR|Influenza vaccine TIV|Trivalent inactivated vaccine (TIV).
62582425|NCT03324555|EXPERIMENTAL|ORIC-101|
62582426|NCT04762979|EXPERIMENTAL|Alpelisib + Aromatase Inhibitor or Fulvestrant|Subjects will be treated with Alpelisib in combination with either an Aromatase Inhibitor or Fulvestrant per Standard of Care
62582427|NCT03646240|EXPERIMENTAL|Dosing arm|
62582428|NCT06665555|EXPERIMENTAL|Group 1|Participants in Group 1 will undergo one standardized bronchoscopy with bronchoalveolar lavage after the fifth dose of ceftibuten-ledaborbactam etzadroxil.
62582429|NCT06665555|EXPERIMENTAL|Group 2|Participants in Group 2 will undergo one standardized bronchoscopy with bronchoalveolar lavage after the fifth of dose of ceftibuten alone.
62018735|NCT05350293|EXPERIMENTAL|3D printed abutment|The customised abutment will be made using a laser printer with a Cr-Co mixture after being designed using a special computer program.
62018736|NCT05747846|ACTIVE_COMPARATOR|wide-awake local anesthesia no tourniquet|Patients will be operated under local anesthesia without a tourniquet (WALANT technique)
62018737|NCT05747846|ACTIVE_COMPARATOR|Tourniquet|Patients will be operated under local anesthesia with the use of a tourniquet
62209936|NCT06378996|EXPERIMENTAL|14 day monitoring|
62582430|NCT02422940|ACTIVE_COMPARATOR|dalfampridine-ER 7.5 mg|"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.~Subjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study."
62018738|NCT02063503|EXPERIMENTAL|Motor control therapy|physiotherapy
62018739|NCT02063503|EXPERIMENTAL|Isometric training therapy|physiotherapy
62018740|NCT02063503|EXPERIMENTAL|Combination therapy|physiotherapy
62018741|NCT01235039|EXPERIMENTAL|Formulation A|VIAject®25 for subcutaneous application
62018742|NCT01235039|EXPERIMENTAL|Formulation B|VIAject®7 for subcutaneous application
62018743|NCT01235039|EXPERIMENTAL|Formulation C|Insulin Lispro for subcutaneous application
62209937|NCT05657652|EXPERIMENTAL|CAV regimen|
62209938|NCT00781989||Rheumatoid Arthritis patients|Patients with seropositive Rheumatoid Arthritis with symptom onset of less than three years
62209939|NCT05301491|EXPERIMENTAL|Dance therapy group|This group included in the dance therapy program throughout the study.
62209940|NCT05301491|EXPERIMENTAL|Control group|This group included in the conventional low back pain exercise program throughout the study.
62209941|NCT05526521|EXPERIMENTAL|Dupilumab|Administered subcutaneously (SC) every 4 weeks (Q4W) or every 2 weeks (Q2W) with or without an initial loading dose based on weight and age
62209942|NCT03767582|EXPERIMENTAL|Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist|
62582431|NCT02422940|ACTIVE_COMPARATOR|dalfampridine-ER 10 mg|"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.~Subjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study."
62018744|NCT01772953|EXPERIMENTAL|treosulfan, fludarabine and low-dose TBI prep regimen|"Treosulfan: 10-14 g/m2/day IV over 120 minutes on days -6, -5 and -4. Treosulfan will be administered prior to fludarabine on days -6 to -4 to facilitate PK testing.~Fludarabine: 30 mg/m2 IV for patients \> 10 kg (or 1 mg/kg IV for patients \< 10 kg) once daily per institutional infusion standards on days -6 through -2 for a total dose of 150 mg/m2 (or 5 mg/kg).~A single fraction of 200 cGy TBI will be administered on day -1. Stem cell infusion on day 0"
62018745|NCT03137862|PLACEBO_COMPARATOR|Arm A comparator|Arm A: patients will maintain a commercially available gluten free diet and receive bread containing 3 gr of cornstarch daily for 12 weeks; these patients will serve as controls.
62018746|NCT03137862|EXPERIMENTAL|Arm B|"Dietary supplement: patients will be have to continue the gluten free diet supplemented with 3 gr of gluten friendly bread daily for 12 weeks."
62018747|NCT03137862|EXPERIMENTAL|Arm C|"Dietary supplement: patients will be have to continue the gluten free diet supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
62582432|NCT02582060|OTHER|Severe Hemophilia A Subjects|The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
62582433|NCT06646406|EXPERIMENTAL|Patient letter and clinician communication|Each patient will be mailed a letter and each patient's clinician will receive a monthly email communicating information about making a strong recommendation for influenza and COVID-19 vaccination
62582434|NCT06646406|NO_INTERVENTION|No intervention|No intervention
62582435|NCT02696538|EXPERIMENTAL|Experimental|All participants included in this group and will complete all three outcomes assessment
62582436|NCT03579017||Patients with ALS|Patients with ALS will be tested by two independent testers with the ECAS-N at 4 months (baseline) and 8 months (follow-up), and the MoCA at 4 months (baseline) by one tester
62582437|NCT03579017||Healthy controls|Persons with no cognitive impairment will be tested with the ECAS-N once, by one tester
62582438|NCT03579017||Controls with dementia|Persons with cognitive impairment due to other disorders will be tested with the ECAS-N once, by one tester
62582439|NCT06204458|EXPERIMENTAL|mild hyperthermia group|For the study, the method of passive whole-body hyperthermia is used. The IRATHERM®1000 system (Von Ardenne Institute for Applied Medical Research/Dresden) is used, in which the entire body is heated to a core body temperature above the physiological 37°C under the application of 10L/min oxygen. The aim is to achieve a core body temperature of 38.5°C within the framework of mild whole-body hyperthermia. After this warm-up phase, a temperature plateau phase of about 60 minutes follows, in which an attempt is made to maintain the core body temperature of 38.5°C. In the temperature plateau phase, a slight increase in the body core temperature is usually observed. The total time required for a session is given as 1.5 to 2 hours, but this depends on the individual constitution and daily condition of the patient and can be subject to fluctuations.
62018748|NCT01877421|EXPERIMENTAL|2 mg KSL-W (Phase 1, 1a)|one 2 mg KSL-W tablet at day 0 at Phase 1
62018749|NCT01877421|EXPERIMENTAL|4 mg KSL-W (Phase 1, 2a; Phase 2a, 1b)|one 4 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. one 4 mg KSL-W tablet on days 1-6; two 4 mg KSL-W tablets on days 7-13 and days 14-20; and three 4 mg tablets at days 21-27 at Phase 2a.
62018750|NCT01877421|EXPERIMENTAL|6 mg KSL-W (Phase 1, 3a; Phase 2a, 2b)|One 6 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 6 mg KSL-W tablet on days 1-6; two 6 mg KSL-W tablets on days 7-13 and days 14-20; and three 6 mg tablets at days 21-27 at Phase 2a.
62018751|NCT01877421|EXPERIMENTAL|10 mg KSL-W (Phase 1, 4a; Phase 2a, 3b)|One 10 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 10 mg KSL-W tablet on days 1-6; two 10 mg KSL-W tablets on days 7-13 and days 14-20; and three 10 mg tablets at days 21-27 at Phase 2a.
62018752|NCT01877421|EXPERIMENTAL|20 mg KSL-W (Phase 1, 5a; Phase 2a, 4b)|One 20 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 20 mg KSL-W tablet on days 1-6; two 20 mg KSL-W tablets on days 7-13 and days 14-20; and three 20 mg tablets at days 21-27 at Phase 2a.
62018753|NCT01877421|EXPERIMENTAL|30 mg KSL-W (Phase 1, 6a; Phase 2a, 5b)|One 30 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 30 mg KSL-W tablet on days 1-6; two 30 mg KSL-W tablets on days 7-13 and days 14-20; and three 30 mg tablets at days 21-27 at Phase 2a.
62018754|NCT01877421|EXPERIMENTAL|50 mg KSL-W (Phase 1, 7a; Phase 2a, 6b)|One 50 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 50 mg KSL-W tablet on days 1-6; two 50 mg KSL-W tablets on days 7-13 and days 14-20; and three 50 mg tablets at days 21-27 at Phase 2a.
62209943|NCT03767582|EXPERIMENTAL|Phase II - Arm A: Nivolumab/CCR2/CCR5 dual antagonist|
62790167|NCT03081650|EXPERIMENTAL|Prospective Open label|"All of the patients that will be Selected to participate in the study will be given an AIRVO humidifier by the study sponsor. Patients will be connected to and instructed in the use of the AIRVO. The total flow will be set at 20-25 L/min, exact flow rate will be dependent on the patient's preference. Optiflow oxygen catheter will be used to ensure against unpleasant sensation due to high flow and to avoid push back in the system.~When acceptable flow rated has been established, it is recorded in the patient's folder. The patients is then instructed to use the AIRVO for a minimum eight (8) hour period, preferably at night. Using the humidifier for a longer period of time is allowed. The total number of hours the humidifier was operational will be recorded at the end of the study"
62790168|NCT00791089|EXPERIMENTAL|Fish Oil, Ablation, Sinus Rhythm|Patients in the treatment arm will receive omega-3 fatty acids (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
62790169|NCT00791089|PLACEBO_COMPARATOR|placebo, Ablation, sinus rhythm|Patients in the control arm will not receive any omega-3 fatty acids. However they will receive placebo.
62790170|NCT01242605|EXPERIMENTAL|single armed|This is not a randomised trial, there is only one study group. All patients will receive cisplatin/gemcitabine chemotherapy in addition to oral daily dosing of selumetinib
62790171|NCT05982886||PIK3CA positive: HR+ Her2-|
62790172|NCT05982886||PIK3CA positive: HR- Her2-|
62790173|NCT05982886||PIK3CA positive: HR- Her2+|
62790174|NCT05982886||PIK3CA positive: HR+ Her2+|
62790175|NCT05982886||PIK3CA negative|
62790176|NCT05511571|EXPERIMENTAL|TENS group|Transcutaneous electrical neural stimulation (TENS)
62790177|NCT05511571|EXPERIMENTAL|PRE group|Progressive relaxation exercises (PRE)
62790178|NCT05511571|EXPERIMENTAL|TENS+PRE group|Transcutaneous electrical neural stimulation (TENS) and Progressive relaxation exercises (PRE)
62790179|NCT05511571|NO_INTERVENTION|Control group|
62407268|NCT00778206||1. PKUDOS Registry|Patients with a confirmed diagnosis of Phenylketonuria (PKU) with hyperphenylalaninemia who have either received Kuvan therapy, or currently receive Kuvan therapy, or intend to begin receiving Kuvan therapy within 90 days of entering the registry.
62582440|NCT06204458|SHAM_COMPARATOR|sham group|"Within the patient information, privacy policy, etc., there is talk of gentle hyperthermia and classic, mild hyperthermia. This serves to introduce the sham intervention as a control group compared to the patient. Lighting conditions, procedures, instructions and explanations are indistinguishable. Within the application, patients of the sham group will receive a hyperthermia application almost without overheating. In order to achieve this, the patients will be positioned on the IRATHERM®1000 in accordance with the Von Ardenne Institute's regulations. Due to the insulating blanket and the natural device and body heat, the patients of the sham group experience a gentle warmth, which is not the same as regular whole-body hyperthermia and an increase in the body core temperature of about 1.5 °C. In the sham setting, the core body temperature increases by about 0.3 to 0.4 °C within a 55-minute session."
62582441|NCT06607588||HIV-1 infected men or women >18 years controlled in the day care center of Chokwé Hospital|
62582442|NCT01245517|EXPERIMENTAL|Dietary Phosphorus Education Program|
62582443|NCT01770587|EXPERIMENTAL|Behavioral Insomnia Treatment|Brief Behavioral Insomnia Treatment
62582444|NCT05832502|PLACEBO_COMPARATOR|Placebo (saline) in HIV-uninfected pregnant woman|Placebo (saline control) administered intramuscularly by injecting 0.5 mL into the deltoid muscle
62582445|NCT05832502|ACTIVE_COMPARATOR|GBS6 in HIV-uninfected pregnant woman|GBS6 administered intramuscularly by injecting 0.5 mL into the deltoid muscle
62582446|NCT05832502|PLACEBO_COMPARATOR|Placebo (saline) in HIV-infected pregnant woman|Placebo (saline control) administered intramuscularly by injecting 0.5 mL into the deltoid muscle
62582447|NCT05832502|ACTIVE_COMPARATOR|GBS6 in HIV-infected pregnant woman|GBS6 administered intramuscularly by injecting 0.5 mL into the deltoid muscle
62582448|NCT02844842||1 day initiation schedule|The initiation Schedule consists in administering 0.2 mL and 0.3 mL with 30 minutes of interval in the same day. Thus, the patient will reach the maintenance dose of 0.5 mL in one day.
62582449|NCT02844842||Rapid initiation schedule|The patient will receive 3 increasing doses (0.1 mL + 0.3mL + 0.5 mL) weekly doses till the maintenance dose (0.5 mL) is reached.
62582450|NCT01665157|EXPERIMENTAL|low-residue diet package (Enimaclin®)|Low-residue diet package with normal amount 2L PEG-ELS
62582451|NCT01665157|PLACEBO_COMPARATOR|Self-controlled diet|Self-controlled diet with normal amount of 2L PEG-ELS
62582452|NCT01665157|EXPERIMENTAL|Low-residue diet (Enimaclin®) package|Low-residue diet package with low volume 1.5L PEG-ELS
62582453|NCT01454154|EXPERIMENTAL|Glyburide|Glyburide delivered by injection as an approximately 2 minute loading dose followed by 72 hours of continuous infusion.
62209944|NCT03767582|EXPERIMENTAL|Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist|
62209945|NCT06632756|EXPERIMENTAL|Positive Recovery Smoking Cessation (Individual and Group)|"The Positive Recovery for Smoking program is a 16-week treatment that focuses on the use of identifying signature character strengths and identifying, creating, and enjoying positive life events to facilitate recovery from smoking addiction. The first 4 individual sessions will focus on a self-evaluation of strengths and a focus on the individuals top 5 signature strengths. The participants will then learn about how their signature strengths currently help them function and when and how they can use these strengths to recover from smoking.~The group sessions will begin at 5 weeks (following 4 individual sessions) - sessions are structured to begin with a check-in where patients identify their most used signature strengths and take inventory of their smoking and cessation efforts from the past week. We will then support participants in their efforts to learn new ways to navigate positive recovery."
62209946|NCT01419327||Group 1|Drug (incl. Placebo)
62407269|NCT00778206||2. PKU MOMS Subregistry|Patients with PKU who are pregnant at enrollment in the registry or who become pregnant while participating in the registry.
62582454|NCT01454154|PLACEBO_COMPARATOR|Placebo|Matching placebo delivered by injection as an approximately 2 minute loading dose followed by 72 hours of continuous infusion.
62582455|NCT05381103|EXPERIMENTAL|PSMA-PET and SOC MRI prior to surgery|
62582456|NCT05381103|ACTIVE_COMPARATOR|SOC MRI prior to surgery|
62582457|NCT04133064|OTHER|Pivot Breath Sensor (user group)|Self-reported daily smokers of 10 or more cigarettes per day
62582458|NCT04400864|EXPERIMENTAL|Mediterranean Diet|Nutritional guidelines based on the principals of the Mediterranean Diet
62582459|NCT04400864|EXPERIMENTAL|Paleolithic Diet|Nutritional guidelines based on the principals of thePaleolithic Diet
62582460|NCT03737643|ACTIVE_COMPARATOR|Arm 1|Platinum-based chemotherapy in combination with bevacizumab and durvalumab placebo (saline IV infusion) followed by maintenance bevacizumab, durvalumab placebo (saline IV infusion) and olaparib placebo (tablets).
62582461|NCT03737643|EXPERIMENTAL|Arm 2|Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib placebo.
62582462|NCT03737643|EXPERIMENTAL|Arm 3|Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib.
62582463|NCT03737643|EXPERIMENTAL|tBRCAm cohort|Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib. Bevacizumab is optional according to local practice.
62018755|NCT01877421|EXPERIMENTAL|75 mg KSL-W (Phase 1, 8a; Phase 2a, 7b)|One 75 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 75 mg KSL-W tablet on days 1-6; two 75 mg KSL-W tablets on days 7-13 and days 14-20; and three 75 mg tablets at days 21-27 at Phase 2a.
62018756|NCT01877421|EXPERIMENTAL|100 mg KSL-W (Phase 1, 9a)|one 100 mg KSL-W tablet at day 0 at Phase 1
62582464|NCT06483620||Diabetic Neuropathy group|"The study design was a cross-cultural validation of Neuro Qol the Arabic version, for patients with DFUs. Three expert panels were involved in this study to test the face and content validity of the NeuroQol Arabic version. All experts had experience of not less than 10 years or at least a master's degree in physical therapy; a major part of their work is with the Arabic population; and they were also fluent in Arabic and English.~Ten patients per item were chosen to estimate the sample size for testing the psychometric properties of the Neuro Qol Arabic version. So 290 patients (145 male patients and 145 female patients), were chosen according to specific eligibility criteria."
62209947|NCT05653427|EXPERIMENTAL|Amivantamab Monotherapy|Participants will receive amivantamab monotherapy intravenously once weekly on Days 1 and 2 in Cycle 1 and on Days 1 and 15 from Cycle 2 onwards based on body weight. Each cycle is of 28 days.
62209948|NCT05977036|EXPERIMENTAL|TKa suppressed at Cycle 1 Day 15|"* Study visits will occur at Baseline, Week 2 (C1D15), C2D1, C4D1, and clinical progression. Blood serum samples will be collected and analyzed using DiviTum® TKa at each of these dictated time points.~* Patients with suppressed TKa levels at C1D15 will continue on CDK4/6i + endocrine therapy until clinical progression. There will be an option to elongate the time between restaging scans from Q3M to Q6M if TKa remains suppressed in this group. Physicians may repeat TKa in 2 weeks if TKa rise is noted and if TKa again becomes suppressed, may delay imaging. These patients will undergo TKa level monitoring at C2D1, C4D1, every 3 months thereafter, and at the time of clinical progression. The feasibility endpoint relates specifically to the Week 24 imaging time point."
62582465|NCT05761535||neurological disease patients|150 patients with Alzheimer's disease (AD) and Parkinson's disease (PD) for MRI and PET examinations and laboratory medicine
62209949|NCT05977036|EXPERIMENTAL|TKa unsuppressed at Cycle 1 Day 15|"* Study visits will occur at Baseline, Week 2 (C1D15), C2D1, C4D1, and clinical progression. Blood serum samples will be collected and analyzed using DiviTum® TKa at each of these dictated time points.~* Patients with lack of TKa suppression at C1D15 (defined as \>145 DuA) will be recommended to switch to an alternative therapy after compliance with the medication is ensured (by pill count) and potential drug-drug interactions are reviewed. These patients will have TKa samples drawn at initiation of second-line therapy and on the first day of subsequent cycles until progression."
62209950|NCT05977036|NO_INTERVENTION|Physicians|"-Physicians will be asked to complete surveys as follows:~* Physician Survey 1 for patients in the TKa C1D15 Suppressed group who have the option to delay the Week 24 scan at Week 24~* Physician Survey 2 for patients in the TKa C1D15 Unsuppressed group at C1D15 (after TKa results have returned but before switching therapy)"
62209951|NCT02844634|EXPERIMENTAL|Immediate doxycycline 100mg PO daily|"Individuals will receive tenofovir/emtricitabine one tablet daily in an open-label fashion.~Subjects are randomized to immediate (12 months duration) doxycycline 100mg PO daily."
62209952|NCT02844634|ACTIVE_COMPARATOR|Deferred doxycycline 100mg PO daily|Individuals will receive daily tenofovir/emtricitabine one tablet daily and will begin doxycycline 100mg PO daily after 6 months for a total duration of 6 months
62209953|NCT01253018|EXPERIMENTAL|Robot Therapy|12 weeks of robotic therapy
62209954|NCT01253018|ACTIVE_COMPARATOR|Transition to Task Training|12 weeks of task specific practice combined with robotic therapy
62209955|NCT05737862|EXPERIMENTAL|Moringa oleifera leaf capsule|Subjects in this arm receive experimental capsules containing powdered Moringa oleifera leaf capsules along with IFA tablets
62209956|NCT05737862|ACTIVE_COMPARATOR|Iron and folic acid capsule|Subjects in this arm only receive iron and folic acid (IFA) tablets
62582466|NCT05761535||healthy subjects|Healthy subjects
62018757|NCT01877421|PLACEBO_COMPARATOR|Placebo|Placebo
62018758|NCT02874547|EXPERIMENTAL|Intervention|Patients will receive five visits with a CHW during a 6 month period (two in-person and three by telephone). At the first visit, patients will meet the CHW who is trained in motivational interviewing techniques to deliver coaching to work on behavioral changes and introduce a 60 minute Digital Video Disc of five patient stories of individuals who have managed to control their hypertension.
62018759|NCT02874547|OTHER|Delayed Intervention|Patients will receive print materials at time of consent and randomization. Four to six months after randomization, DI patients will receive an invitation to schedule an in-person visit at the health center to begin receiving the intervention protocol.
62018760|NCT02158039|EXPERIMENTAL|Pancreatic Cyst Ethanol Injection|EUS-guided lavage of a pancreatic cyst with ethanol solution. The ethanol solution was diluted to 80% using normal saline. Final solution also contained 1% lidocaine except in patients allergic to local anesthetics. The ethanol solution was injected into pancreatic cysts at a volume equal to 90% of the aspirated cyst volume. In subjects undergoing re-treatment of a cyst, ethanol was diluted to 90% using normal saline, and injected in a volume equal to 100% of the aspirated cyst volume.
62018761|NCT03162003||Cohort 1|Patient with visceral disease and/or bone lesions (excluding patients who only have nodal disease), who have commenced or are about to commence ADT and whose disease has not shown any evidence of castration resistance.
62582467|NCT05206877|EXPERIMENTAL|Low dose topical insulin|Group 1; N=6: 100 U/ml; 4 units of insulin per application, 1 drop done in clinic daily for 5 days
62582468|NCT05206877|EXPERIMENTAL|High dose topical insulin|Group 2; N=6: 500 U/ml; 20 units of insulin per application, 1 drop done in clinic daily for 5 days
62790180|NCT02380911|EXPERIMENTAL|Intervention Group|The intervention group will receive a multifaceted educational intervention targeting physicians and pharmacist assistants to improve detection, treatment and control of hypercholesterolemia among uninsured patients with moderate-high cardiovascular risk in Argentina.
62018762|NCT03162003||Cohort 2|Patient with castrate-resistant disease at time of treatment change
62018763|NCT06173791|ACTIVE_COMPARATOR|DFDBA Fibers with DBBM|After standard of care elevation of the Schneiderian membrane, a mix of DFDBA fibers with DBBM (50%-50%) will be introduced in the space created between the Schneiderian membrane and the alveolar crest of the maxilla.
61978500|NCT02505230|EXPERIMENTAL|Meal Order 1|"\[P,P+S,HVP,LVP\]~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor)."
62209957|NCT06423664|EXPERIMENTAL|Personalized coaching sessions|A novel program to train birthing parents in contingent responding with the goal of improving neurodevelopmental outcomes in infants prenatally exposed to cannabinoids. 1 personalized coaching session per month for 12 months.
62209958|NCT04881383||Patients from Primary Care Clinics|Participating Chinese adults aged 18-84 from Primary Care clinics to validate the risk prediction function. Each subject will complete an assessment on the relevant risk factors and have a blood test on OGTT and HbA1c on recruitment and at 12 months.
62209959|NCT06728475|ACTIVE_COMPARATOR|Group (A) virtual reality group|this group will receive virtual reality intervention plus designed physical therapy program
62582469|NCT05206877|EXPERIMENTAL|Longer-term topical insulin|Group 3 randomized; N=20: 10 subjects will receive the highest tolerated dose (e.g. from group 1 or group 2), 1 drop per day at home for 1 month, full testing pre- and post-treatment, and 10 subjects will receive 1/5 of the highest tolerated dose (either the lower dose, or if needed will dilute) 1 drop per day at home for 1 month, full testing pre- and post-treatment.
62582470|NCT05206877|EXPERIMENTAL|Low-Dose Insulin twice Daily|Group 4. N=5. 1 drop of 100U/mL insulin administered twice daily for 5 days.
62582471|NCT05206877|EXPERIMENTAL|High-Dose Insulin twice Daily|Group 5. N=5. 1 drop of 500U/mL insulin administered twice daily for 5 days.
62582472|NCT05206877|EXPERIMENTAL|Low-Dose Insulin three times daily|Group 6. N=5. 1 drop of 100U/mL insulin administered three times daily for 5 days.
62582473|NCT05206877|EXPERIMENTAL|High-Dose Insulin three times daily|Group 7. N=5. 1 drop of 500U/mL insulin administered three times daily for 5 days.
62582474|NCT05119322|EXPERIMENTAL|GlutenDetect home urine test|The GlutenDetect home urine test group will receive home use tests for GIP detection in urine to self-monitor the GFD. Tests will be used at their discretion, but using at least 8 tests during the study period (1/week), so that they may receive immediate qualitative feedback regarding the presence of biomarkers of gluten exposure in their urine and they will have to register the results obtained. Additionally, patients will collect a urine and a stool sample every 4 weeks to evaluate their adherence to the GFD in the laboratory.
62582475|NCT05119322|NO_INTERVENTION|Control group|The control group will not receive any home urine tests but will collect a urine and a stool sample every 4 weeks with the purpose of evaluating their adherence to the GFD in the laboratory.
62582476|NCT04893447|EXPERIMENTAL|SPI+: Safety Planning Intervention plus structured phone-based follow-up|The Safety Planning Intervention (SPI+) includes safety planning (moderate or high risk for suicide) or connection \& support planning (low risk for suicide) at the clinic or ED, plus a structured telephone-based intervention from a suicide prevention hotline
62582477|NCT04893447|EXPERIMENTAL|Caring Contacts: Safety Planning Intervention plus Caring Contacts (SP+CC)|SP+CC will include safety planning (moderate or high risk for suicide) or connection \& support planning (low risk for suicide) at the clinic or ED, plus caring text messages or emails from a suicide prevention hotline.
62582478|NCT06604143|ACTIVE_COMPARATOR|Quality Training Group|
62018764|NCT06173791|OTHER|DFDBA Particles with DBBM|After standard of care elevation of the Schneiderian membrane, a mix of DFDBA particles with DBBM (50%-50%) will be introduced in the space created between the Schneiderian membrane and the alveolar crest of the maxilla.
62018765|NCT03295201|EXPERIMENTAL|Pulmonary rehabilitation+exercise group|Active cycle of breathing techniques (ACBT) and postural exercise program
62018766|NCT03295201|ACTIVE_COMPARATOR|Pulmonary rehabilitation group|Active cycle of breathing techniques (ACBT)
62582479|NCT06604143|ACTIVE_COMPARATOR|Goal Training Group|
62582480|NCT04426214|EXPERIMENTAL|Active tDCS|
62790181|NCT02380911|NO_INTERVENTION|No Intervention Group|This group will continue with the usual care. Irrespective of the assignment of the clinic to the intervention or control group, all physicians from participating PCCs have received previous training on global cardiovascular risk management, given by the Ministry of Health
62790182|NCT00278746|EXPERIMENTAL|1|Zinc and ORS were promoted for treatment of diarrhea in underfive children
62018767|NCT01467323|EXPERIMENTAL|A|
62018768|NCT01467323|ACTIVE_COMPARATOR|B|
62209960|NCT06728475|ACTIVE_COMPARATOR|Group (B) mirror therapy group|this group will receive mirror therapy intervention plus designed physical therapy program
62209961|NCT06728475|ACTIVE_COMPARATOR|Group (C) the compound effect of virtual reality and mirror therapy group|this group will receive virtual reality intervention , mirror therapy intervention plus designed physical threrapy program
62209962|NCT06584916|EXPERIMENTAL|Orforglipron|Participants will receive orforglipron orally
62209963|NCT06584916|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo orally
62209964|NCT00218049|EXPERIMENTAL|1|50 mg of GBR 12909
62209965|NCT00218049|EXPERIMENTAL|2|75 mg of GBR 12909
62209966|NCT00218049|EXPERIMENTAL|3|100 mg of GBR 12909
62209967|NCT06728501|ACTIVE_COMPARATOR|Diabetes education|Patients receive diabetes education
62209968|NCT06728501|NO_INTERVENTION|Control|Patients receive no diabetes education
62209969|NCT06683599|NO_INTERVENTION|Standard of care|Tracheal intubation performed with a video laryngoscope with Miller-blade or Macintosh-blade size No. 0 or No. 1 without apneic oxygenation.
62209970|NCT06683599|EXPERIMENTAL|Apneic oxygenation|1 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with conventional nasal cannula during tracheal intubation performed with a video laryngoscope with Miller-blade or Macintosh-blade size No. 0 or No. 1.
62215458|NCT00653523|EXPERIMENTAL|Ezetimibe + Simvastatin|Ezetimibe 10 mg + Simvastatin 20 mg
62582481|NCT04426214|PLACEBO_COMPARATOR|Sham tDCS|
62582482|NCT06647797|EXPERIMENTAL|"Communication intervention HOPE"|"* Patient-facing education materials~* Provider counseling job aid and training"
62582483|NCT06647797|NO_INTERVENTION|Usual care|Usual care
62582484|NCT06434610|EXPERIMENTAL|B013|
62209971|NCT06073782|EXPERIMENTAL|Education Group|"The training material will be created by researchers by reviewing national and international guidelines for colonoscopy practices. Using the Colonoscopy Patient Preparation Guide, individuals will be given face-to-face, information and preparation training on colonoscopy preparation, its importance, the preparation medication to be used and the procedure process for an average of 15-20 minutes in a private room in the unit. After the training, individuals will be given the Colonoscopy Patient Preparation Guide brochure developed by the researchers."
62209972|NCT06073782|EXPERIMENTAL|Text Message Group|Individuals will be subjected to the routine colonoscopy preparation procedure of the hospital by the investigator. Starting three days before the colonoscopy is performed, individuals will be informed via text messages about the foods and beverages that they can consume in their diet and those that are forbidden to consume until the morning of the colonoscopy, the amount of fluids they should consume daily, the use of medication, the use of soda and enema, appointment time reminders.
62209973|NCT06073782|NO_INTERVENTION|Control Group:|Individuals in the control group will be subjected to the standard procedure applied in the clinic. No additional education and educational brochures will be given to these patients and text message reminders will not be applied.
62209974|NCT04241848|EXPERIMENTAL|Powered Orthotic Exoskeleton Training Group|Participant in 36 session ambulation training using a powered orthotic exoskeleton.
62209975|NCT04241848|ACTIVE_COMPARATOR|Control Group|Participant in 36 session ambulation training without using a powered orthotic exoskeleton.
62209976|NCT06350682|NO_INTERVENTION|HealthMPowerment (HMP) Delayed Access|Delayed access for 12 months to the HMP app, individuals will have access but it will be restricted
62582485|NCT06434610|PLACEBO_COMPARATOR|Placebo|
62790183|NCT00278746|OTHER|2|Promoted routine management of diarrhea in underfive with ORS
62790184|NCT03977766|EXPERIMENTAL|nurse then patient digital prevalidation of chemotherapy|"Outpatient Chemotherapy prevalidation will done~* with the help of a nurse, using the digital application, for cycle 2 and 3.~* by the patient alone, using the digital application, for cycle 4 and 5."
62790185|NCT03948841||Neuroendocrine tumor|Patients with liver metastasis from neuroendocrine tumor
62790186|NCT02564185|ACTIVE_COMPARATOR|Control|"The control group will follow usual practice."
62790187|NCT02564185|EXPERIMENTAL|Education program|"The Education program group benefit in addition of a therapeutic education program including nursing follow-up at 1, 3 and 6 months."
62209977|NCT06350682|EXPERIMENTAL|HealthMPowerment (HMP) Open Access|Full access to the HMP app
62209978|NCT06172192|ACTIVE_COMPARATOR|Group A|"Group A will perform Core Strengthening exercises. In addition to core strengthening protocol, non-resistive Diaphragmatic training group will perform self-diaphragm breathing exercises~Core strengthening protocol will comprise of following three phases:~1. Warm up phase:~2. Core strengthening phase:~3. Cool down phase:~After performance of Core Strengthening protocol, Group A will perform Self-Diaphragmatic breathing exercises."
62209979|NCT06172192|EXPERIMENTAL|Group B|"Group B will perform Core Strengthening exercises. In addition to core strengthening protocol, resistive Diaphragmatic training group will perform resisted-diaphragm breathing exercises.~Core strengthening protocol will comprise of following three phases:~1. Warm up phase~2. Core strengthening phase~3. Cool down phase~After performance of Core Strengthening protocol, group B will perform Resistive Diaphragmatic Exercises."
62215459|NCT04554017|EXPERIMENTAL|Intervention arm - All participant (Single arm)|Participants received education or health talks on dietary and physical activity behaviours linked to hypertension
62215460|NCT06272552|EXPERIMENTAL|PROMs and PREMs|
62215461|NCT06272552|ACTIVE_COMPARATOR|PREMs|
62582486|NCT04174040|NO_INTERVENTION|Control 1|Applied any intervention.
62582487|NCT04174040|ACTIVE_COMPARATOR|Control 2|Gross's Process of Emotion Regulation Model interventions applied.
62582488|NCT04174040|ACTIVE_COMPARATOR|Control 3|Musical rhythm interventions applied.
62582489|NCT04174040|EXPERIMENTAL|Experimental|Musical rhythm integrated Gross's Process of Emotion Regulation Model interventions applied.
62582490|NCT02460250|EXPERIMENTAL|Fibroscan|All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked. Liver recipients will be followed up during one year. Biological and medical data used by all transplant sites for the follow-up of transplant patient will be collected
62582491|NCT02111577|EXPERIMENTAL|DCVAC/PCa with standard of care chemotherapy|Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)
62582492|NCT02111577|PLACEBO_COMPARATOR|Placebo with standard of care chemotherapy|Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator
62734499|NCT03281369|ACTIVE_COMPARATOR|2L-Control: Ramucirumab + Paclitaxel (Gastric Cancer)|Participants in the 2L Gastric Cancer Control arm received ramucirumab plus paclitaxel. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
62018769|NCT04153409|EXPERIMENTAL|Active|Subjects will be given two 30 mg capsules of the investigational medicinal product (LAT8881), and instructed to take both capsules within the first hour of the onset of a migraine of moderate to severe intensity.
62018770|NCT04153409|PLACEBO_COMPARATOR|Placebo|Subjects will be given two capsules of placebo, and instructed to take both capsules within the first hour of the onset of a migraine of moderate to severe intensity.
62018771|NCT01756014||Controls|Age matched healthy subjects
62018772|NCT01756014||Mild DCM|Heart failure patients with dilated cardiomyopathy (DCM) with NYHA-functional class II
62018773|NCT01756014||Severe DCM|Heart failure patients with dilated cardiomyopathy (DCM) with NYHA-functional class III/IV
62018774|NCT04663815|OTHER|AB arm|Animal-assisted activity intervention on 2nd day of hospitalization, control intervention on the 4th day of hospitalization.
62209980|NCT03754114|ACTIVE_COMPARATOR|ICP only|ICP guided management strategy: Care in the ICU of research participants randomized to this arm will be guided by a monitoring and treatment strategy in which doctors try to prevent high intracranial pressure (ICP) caused by a swollen brain. This strategy is one of two alternative strategies that is currently used in standard care of patients with traumatic brain injury.
62582493|NCT04270071|EXPERIMENTAL|Yangxin Shengmai Granules|"Patients were given Yangxin Shengmai granules orally 14g (1 bag) each time, 3 times daily for 4 weeks. And nitroglycerin tablets are used when angina attack.~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
62582494|NCT04270071|PLACEBO_COMPARATOR|Placebo|"Patients were given Yangxin Shengmai granules simulation orally 14g (1 bag) each time, 3 times daily for 4 weeks. And nitroglycerin tablets are used when angina attack.~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
62582495|NCT06580717|EXPERIMENTAL|Enavogliflozin 0.3mg|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo.
62582496|NCT06580717|PLACEBO_COMPARATOR|Enavogliflozin placebo|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo.
62582497|NCT02695160|EXPERIMENTAL|Cohort 1|SB-FIX: Low Dose
62582498|NCT02695160|EXPERIMENTAL|Cohort 2|SB-FIX: Medium Dose
62582499|NCT02695160|EXPERIMENTAL|Cohort 3|SB-FIX: High Dose
62582500|NCT05163275||Patients|
62582501|NCT02056561||TIVA (group T n: 15)|Group T were given propofol infusions of 12 mg/kg/hr for the first 10 minutes, 9 mg/kg/hr for the second 10 minutes and 6 mg/kg/hr after that. Patients were ventilated with 50% air and 50% O2 mix at 6 L/min flow.
62018775|NCT04663815|OTHER|BA arm|Control intervention on 2nd day of hospitalization, animal-assisted activity intervention on the 4th day of hospitalization.
62018776|NCT02923037|EXPERIMENTAL|Supportive Care (Yoga)|Patients undergo an initial yoga evaluation for 60 minutes. Patients then undergo their first guided yoga practice session for 30-60 minutes and subsequent guided yoga sessions for 30-90 minutes 3 times a week for 4 weeks, and twice a week for an additional 4 weeks. Patients are also encouraged to complete home yoga practice for 30 to 90 minutes every day for 8 weeks. They will have tape measurement of arms and ldex measurement of arms. Quality-of-Life Assessment will also be made.
62018777|NCT02431975|EXPERIMENTAL|Early ART|All infants enrolled in the trial, regardless of maternal PMTCT regimen, will be initiated on a triple ARV regimen consisting of nevirapine (NVP), zidovudine (ZDV) and lamivudine (3TC) presumptively based on the initial positive result. This regimen will be continued to 42 weeks post menstrual age (PMA). At this time, infants will be switched to LPV/r, ZDV and 3TC to be continued to 104 weeks or longer unless otherwise preferred by the treating clinician or if any clinical or laboratory contraindications are identified.
62018778|NCT06536218|NO_INTERVENTION|Control Group|It is planned to conduct a one-session (60-minute), unstructured, active participation-based group application (the week when the first session is applied to the intervention group) in which participants share their experiences with each other about stress and stressful experiences.
62582502|NCT02056561||Sevoflurane (group S n: 15)|Group S were ventilated with 2% sevoflurane, 50% air and 50% O2 mix at 6 L/min flow.
62582503|NCT02056561||Desflurane (group D n: 15)|Group D cases were given 6% desflurane 50% air and 50% O2 mix at 6 L/min flow.
62209981|NCT03754114|ACTIVE_COMPARATOR|ICP + PbtO2|ICP + PbtO2 guided management strategy: Care in the ICU of research participants randomized to this arm will be guided by a monitoring and treatment strategy in which doctors try to prevent high intracranial pressure (ICP), and also try to prevent low PbtO2 (brain tissue oxygen levels). This strategy is one of two alternative strategies that is currently used in standard care of patients with traumatic brain injury.
62215462|NCT06272552|ACTIVE_COMPARATOR|Control|
62215463|NCT06272552|OTHER|Healthcare professionals|
62215464|NCT04033666|ACTIVE_COMPARATOR|High Flow nasal cannula|It will be administered as part of the high-flow nasal cannula treatment to reduce the symptoms of acute asthma
62582504|NCT03743805|EXPERIMENTAL|Reversal drugs|Flumazenil and naloxone
62734500|NCT03281369|EXPERIMENTAL|2L-1: Atezo + Cobi (Gastric Cancer)|Participants in the 2L-1 Gastric Cancer arm received atezolizumab in combination with cobimetinib. Enrollment completed as of October 2019.
62209982|NCT05808777||ICH|"Patients were eligible for inclusion if they~1. were aged 20 years or older~2. had been admitted to a neurology, neurosurgery, or rehabilitation ward with a diagnosis of primary ICH~3. had a diagnosis of ICH confirmed by a brain CT~4. have written informed consent given by themselves or by their legal representative"
62209983|NCT05020535|EXPERIMENTAL|Experimental|MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
62209984|NCT05020535|PLACEBO_COMPARATOR|Control|Administration of saline within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
62582505|NCT04445974|ACTIVE_COMPARATOR|Expand Your Horizons: More than my skin|Participants allocated to the intervention condition will be asked to follow the adapted instructions for 'Expand Your Horizon'. Participants will be asked to complete three 15 min writing exercises over approximately six days. Participants who complete the first exercise on Qualtrics will be sent links to and asked to complete the second and third writing exercises.
62582506|NCT04445974|EXPERIMENTAL|Control writing activity|Participants in the control condition will be asked to complete three 15 minute creative writing exercises online via Qualtucs over approximately six days. Participants completing the first writing exercise will be sent links to the second and third writing exercises.
62582507|NCT02771223||Study group|patients scheduled for prolonged cardiac surgery (over 3 hours anticipated ECC time) with no known coagulation disorders
62582508|NCT01322490|EXPERIMENTAL|PROSTVAC-V/F-TRICOM + GM-CSF|"* PROSTVAC-V-TRICOM~* PROSTVAC-F-TRICOM~* GM-CSF"
62582509|NCT01322490|EXPERIMENTAL|PROSTVAC-V/F-TRICOM + GM-CSF placebo|"* PROSTVAC-V-TRICOM~* PROSTVAC-F-TRICOM~* GM-CSF placebo"
62582510|NCT01322490|PLACEBO_COMPARATOR|Placebo Control|PROSTVAC V/F Placebo + GM-CSF Placebo
62582511|NCT00737906|EXPERIMENTAL|I|Surgical turbinate reduction procedure
62582512|NCT03964337|EXPERIMENTAL|Cabozantinib Followed by Prostatectomy (Arm A)|Experimental group will received cabozantinib for 4 weeks, followed by a 2 week drug washout before a prostatectomy.
62582513|NCT03964337|ACTIVE_COMPARATOR|Immediate Prostatectomy (Arm B)|Control group will receive an immediate prostatectomy.
62582514|NCT04927416|EXPERIMENTAL|Differentiated thyroid cancer (DTC)|Patients with DTC but not HTC
62582515|NCT04927416|EXPERIMENTAL|Hurthle cell thyroid cancer (HTC)|Molecularly and histologically unique subtype of DTC - Hurthle cell thyroid cancer (HTC),
62582516|NCT04927416|EXPERIMENTAL|Medullary thyroid cancer (MTC)|Patients with metastatic thyroid cancer of neuroendocrine origin - medullary thyroid cancer (MTC)
62582517|NCT02099669|EXPERIMENTAL|Liberal transfusion strategy|"Intervention: Red Blood Cell transfusions. Transfuse pRBC at a higher threshold- maintain Hb level between 110 and 120 g/L: to achieve this, 2 units of pRBCs are transfused when Hb level is \< 105 g/L and 1 unit of RBCs when Hb level is 105-110 g/L.~Transfusions administered more frequently."
62582518|NCT02099669|ACTIVE_COMPARATOR|Restrictive transfusion strategy|Intervention: Red Blood Cell transfusions. Transfuse pRBC at standard of care thresholds- maintain Hb level between 85 and 100 g/L: to achieve this, 2 units of packed red blood cells (pRBCs) will be transfused when the Hb level is \< 80 g/L and 1 unit of pRBCs when Hb level is 80-85 g/L: standard administration
62209985|NCT04601025|EXPERIMENTAL|Yoghurt|
62209986|NCT04601025|EXPERIMENTAL|Chickpea+Yoghurt|
62209987|NCT04601025|EXPERIMENTAL|Oat+Yoghurt|
62209988|NCT00599703||1|neurosurgical patients
62209989|NCT05978141||Participants with T-Cell Lymphoma|Participants with pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma
62209990|NCT01876459|OTHER|"Alzheimer's Disease arm"|Patient with Alzheimer's disease
62209991|NCT01876459|OTHER|"Lewy Body Disease arm"|Patient with Lewy Body Disease
62582519|NCT04874662|ACTIVE_COMPARATOR|Investigational NAM/B6|"2 VCaps® capsules daily (commercial vegetarian capsules made of Hydroxy Propyl Methyl Cellulose, a polymer of cellulose)~Dosage per capsule: 357mg of nicotinamide, 9.5mg of pyridoxine and 195mg of microcrystalline cellulose~Form:The VCaps® Size 00 will be used. They have a volume of 0.95 ml for 23.3 mm length and a diameter of 8.51 mm head / 8.16 mm body.daily of NAM/B6~Frequency and duration: 2 capsules daily for 9 days"
62582520|NCT04874662|PLACEBO_COMPARATOR|Placebo control group|"2 capsules daily of microcrystalline cellulose excipient (337mg per capsule)~Frequency and duration: 2 capsules daily for 9 days"
62582521|NCT06101628|OTHER|EXPERIMENTAL AND CONTROL GROUP|Participants who meet the inclusion criteria of the study will be informed about the research by the researchers and will be included in the study on a voluntary basis and their written permissions will be obtained. Firstly, the personal information of the participants will be recorded in the data collection form. The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the gel nail is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant and recorded in the data form. At the end of the study, SpO2 and pulse values before and after the gel nail application will be compared.
62582522|NCT04230109|EXPERIMENTAL|Sacituzumab Govitecan (monotherapy cohort)|"- The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~* Sacituzumab govitecan via iv, predetermined dosage per protocol, IV, 2 days per each 21-day cycle, for 4 cycles.~* This can be followed by standard chemotherapy at the discretion of treating physician."
62209992|NCT06127875||Home Ovulation Monitoring Group|timed intercourse by predicting the ovulation period or using ovulation test strips
62209993|NCT06127875||Hospital Ovulation Monitoring Group|timed intercourse by ultrasound ovulation monitoring
62209994|NCT05936359|EXPERIMENTAL|Part 1a Dose Escalation Cohort Disease Group A - with MF|INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles as monotherapy to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\[s\]). Participants with myelofibrosis (MF) will enroll in this group.
62209995|NCT05936359|EXPERIMENTAL|Part 1a Dose Escalation Cohort Disease Group A - with ET|INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles as monotherapy to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\[s\]). Participants with with essential thrombocythemia (ET) will enroll in this group.
62215465|NCT04033666|ACTIVE_COMPARATOR|NIV noninvasive ventilation|It will be administered as part of the Noninvasive ventilation treatment to reduce the symptoms of acute asthma
62209996|NCT05936359|EXPERIMENTAL|Part 1a: Dose Escalation Cohort Disease Group B - with TGB-MF SubOpt R|INCA033989 will be administered at a protocol defined starting regimen in 28- day cycles and will allow for the evaluation of INCA033989 in combination with ruxolitinib to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\[s\]). Participants with myelofibrosis (MF) exhibiting suboptimal response (SubOpt R) will enroll in this group.
62209997|NCT05936359|EXPERIMENTAL|Part 1b: Dose Expansion - with MF|INCA033989 will be administered as monotherapy at the RDE(s) identified during Part 1a. Participants with treatment group A (TGA) myelofibrosis MF will enroll in this group.
62209998|NCT05936359|EXPERIMENTAL|Part 1b: Dose Expansion - with TGB-MF SubOpt R|INCA033989 will be administered as an add-on therapy in combination with ruxolitinibat at the RDE(s) identified during Part 1a. Participants with treatment Group B (TGB) MF SubOpt R will enroll in this group.
62209999|NCT05936359|EXPERIMENTAL|Part 1b: Dose Expansion - with ET|INCA033989 will be administered as monotherapy at the RDE(s) identified during Part 1a. Participants with treatment group A (TGA) essential thrombocythemia (ET) will enroll in this group.
62210000|NCT05936359|EXPERIMENTAL|Part 1c: Dose Expansion|INCA033989 will be administered at the dose level found to exhibit an overall positive benefit/risk as monotherapy or as combination therapy with Ruxolitinib. Participants with myelofibrosis (MF) will enroll in this group. The participants enrolled in the monotherapy arm will be offered the option to crossover to combination therapy with ruxolitinib if a suboptimal response to monotherapy is observed after 12 weeks.
62210001|NCT02180243|EXPERIMENTAL|Mindfulness meditation/Acupuncture|Eligible participants may be randomized to participate in iRest Yoga Nidra/ auricular acupuncture group classes.
62210002|NCT02180243|ACTIVE_COMPARATOR|Gulf War Health Education|Eligible participants may be randomized to participate in Gulf War Health Education group classes.
62210003|NCT05488145|EXPERIMENTAL|Single Arm (internet intervention, best practice)|Patients receive access to the app in addition to standard of care for 3 months. Through the app, patients receive weekly reminders about hormone therapy, report any side effects, access educational videos that provide tips to help mitigate some of these side effects, and allow patients to send messages to members of our breast cancer team about any questions patients may have about the side effects they may be experiencing.
62210004|NCT06650189|NO_INTERVENTION|Standard of care|Preterm neonates will receive standard of care.
62210005|NCT06650189|EXPERIMENTAL|Music intervention|Preterm neonates will be exposed to recorded music intervention. Recorded music will be played through a portable Bluetooth speaker (3.1 watt) placed in the incubator, which will be activated and controlled via a smartphone.
62210006|NCT03479853||Cases : suffering from ocular or oculo-cutaneous rosacea|Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.
62210007|NCT03479853||Witnesses|"Without any present or past palpebral meibomian Gland Dysfunction~Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device."
62210008|NCT04546503|ACTIVE_COMPARATOR|Continuous Regional Analgesia group|Sedation using midazolam and sufentanil: Multi-Daily adjustment of doses every 4 hours using Behavioral Pain Scale score \<4 and Ramsay Score \> 4 + perinerval block catheter from 0 to 24h after admission in intensive care unit using ropivacaine 0.2% with a continuous infusion at 1mL/10 Kg /H
62210009|NCT04546503|EXPERIMENTAL|Control Group|group with general anesthesia and without locoregional anesthesia: Sedation using midazolam and sufentanil: Multi-Daily adjustment of doses every 4 hours using Behavioral Pain Scale score \<4 and Ramsay Score \> 4
62582523|NCT04230109|EXPERIMENTAL|Sacituzumab Govitecan and Pembrolizumab (combination cohort)|"- The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~* Sacituzumab govitecan via iv, predetermined dosage per protocol, IV, 2 days per each 21-day cycle, for 4 cycles.~* Pembrolizumab via iv, predetermined dosage per protocol, IV, 1 day per each 21-day cycle, for 4 cycles.~* This can be followed by standard chemotherapy at the discretion of treating physician."
62582524|NCT04507386|EXPERIMENTAL|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
62582525|NCT04507386|NO_INTERVENTION|Control|The control group will receive regular medical care and advice on healthy lifestyle, including physical activity and healthy eating recommendations
62582526|NCT00474045|EXPERIMENTAL|Insulin detemir|Individually adjusted insulin detemir injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn
62582527|NCT00474045|ACTIVE_COMPARATOR|Neutral Protamine Hagedorn (NPH) insulin|Individually adjusted NPH insulin injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn
62582528|NCT02557802|EXPERIMENTAL|Group A|Nasal spray at day 0, intramuscular injection at day 28
62582529|NCT02557802|EXPERIMENTAL|Group B|Intramuscular injection at day 0, nasal spray at day 28
62582530|NCT05924386|ACTIVE_COMPARATOR|All-on-four fixed mandibular prosthesis using conventionally screw retained multiunit abutments.|Edentulous patients receiving All-on-four fixed mandibular prosthesis using conventionally screw retained multiunit abutments.
62582531|NCT05924386|EXPERIMENTAL|All-on-four fixed mandibular prosthesis using OT bridge attachment system|Edentulous patients receiving All-on-four fixed mandibular prosthesis using OT bridge attachment system
62018779|NCT06536218|EXPERIMENTAL|CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION|Conscious Awareness Based Stress Reduction (BFTSA) intervention consists of seven sessions in total and is planned to be completed in a total of seven weeks, with one session per week and each session being 45 minutes. After the results of the patients who underwent PSG are determined according to the randomization criteria and receive certain points from the sleep scale, it is planned to call the patients by phone and explain the meaning and importance of the study, the applications to be performed in the study and its duration. It is planned to have an online individual interview with patients who agree to participate in this study.
62018780|NCT06057051|EXPERIMENTAL|iStent Infinite|iStent Infinite Trabecular Micro-Bypass System
62018781|NCT05015894|EXPERIMENTAL|NNC0480-0389|All participants will be administered a single s.c. dose of 18 mg NNC0480-0389
62210010|NCT04395872||COVID-19|Among patients who were confirmed as COVID-19 and admitted to the COVID-19 management ward of Daegu Catholic University Hospital, patients who were consulted by the Department of psychiatry was selected as participants. Socio-demographic information, medical severity (oxygen saturation, chest x-ray readings, medication being administered), clinical psychological scale (PHQ-9, GAD-7, PC-PTSD-5, AIS, P4, SF-36, SCL-90-R). were collected from participants. It evaluates whether there is a difference in the psychological scale according to the difference in participants' sociodemographic status and medical severity, and evaluates the effectiveness of psychiatric counseling by comparing clinical psychological measures before and after referral to department of psychiatry.
62210011|NCT05078593|EXPERIMENTAL|HLX26|The initial dose of HLX26 is 60 mg, and 7 dose levels are designed: 60 mg, 150 mg, 300 mg, 500 mg, 800 mg , 1200mg, and 1600mg(Q3W).
62210012|NCT06442007|EXPERIMENTAL|Behavioral Activation - single session intervention (BA-SSI)|"This is comprised of 5 five components:~1. Discussion on the rationale of the behavioral activation~2. Awareness raising about distress, including how behavior shapes feelings and thoughts;~3. a life values assessment~4. the creation of an activity action plan~5. an exercise in which youths write about benefits that might result from engaging in each activity, an obstacle that might keep them from doing the activities and a strategy for overcoming the identified obstacles."
62210013|NCT06442007|ACTIVE_COMPARATOR|4-session Mindset intervention|This is comprised of a growth mindset module (2 sessions), a gratitude module (1 session) and a value affirmations module (1 session). Sessions are delivered weekly (over 4 weeks) and each session lasts for an hour. Reading and writing activities and group discussions are included in each session. Participants are supposed to complete homework exercises are assigned between sessions.
62407270|NCT03480243|EXPERIMENTAL|Padsevonil and Erythromycin|"Treatment Period 1 (Day 1 to Day 11):~* Padsevonil 100 mg twice daily (bid) on Day 1 to Day 4~* Padsevonil 100 mg single dose on Day 5~* 1 week of wash-out (from evening of Day 5 to Day 11)~Treatment Period 2 (Day 12 to 22):~* Padsevonil 100 mg twice daily (bid) on Day 12 to Day 15~* Padsevonil 100 mg single dose on Day 16~* 1 week of wash-out (from evening of Day 16 to Day 22)~Treatment Period 3 (Day 23 to Day 38):~* Erythromycin 500 mg twice daily (bid) on Day 23 to Day 25~* Padsevonil 100 mg bid and erythromycin 500 mg bid on Day 26 to Day 32~* Padsevonil 100 mg single dose on Day 33~* Erythromycin 500 mg twice daily (bid) on Day 33 to Day 36~* Erythromycin 500 mg single dose on Day 37"
62407271|NCT03361839|ACTIVE_COMPARATOR|1|patients with RIF
62018782|NCT00667784||Anxiety Assessment|Minor Donors + Sibling Non-Donors + Parents or Legal Guardians
62210014|NCT06442007|NO_INTERVENTION|Waiting list control group|At end of the study, this group will be offered to choose one intervention from two active interventions mentioned above.
62210015|NCT06049992|ACTIVE_COMPARATOR|Lumenless lead|Left bundle branch stimulation using leads without internal lumen (Lumenless; Medtronic Selectsecure 3830, Minneapolis, USA).
62210016|NCT06049992|ACTIVE_COMPARATOR|Stylet-driven lead|Left bundle branch pacing using leads with internal lumen and retractable helix (Tendril STS 2088TC, Abbott, Inc., USA; Solia S60, Biotronik, SE \& Co., KG, Germany; Ingevity +, Boston Scientific, Marlborough, MA, USA).
62407272|NCT03361839|PLACEBO_COMPARATOR|2|fertile arm as r reference for result
62407273|NCT04510870|EXPERIMENTAL|Experimental group|"1. infusion is ferric carboxymaltose, dosage according to the summary of product characteristics (SmPC)~2. infusion is NaCl"
62407274|NCT04510870|EXPERIMENTAL|NaCl infusion group|"1. infusion is NaCl~2. infusion is ferric carboxymaltose, dosage according to the summary of product characteristics (SmPC)"
62407275|NCT03605758|ACTIVE_COMPARATOR|Ivermectin on Days 1 and 2|Participants will receive 200 µg/kg of ivermectin daily for two consecutive days with breakfast.
62407276|NCT03605758|ACTIVE_COMPARATOR|Ivermectin on Days 1 and 14|Participants will receive 200 µg/kg of ivermectin on day one and day 14 with breakfast.
62407277|NCT06445517|EXPERIMENTAL|Dose Escalation: ISM8207|Participants will receive ISM8207 orally once on day 1 during single dose period (3 days) then once daily in repeated 28-day cycles from Cycle 1 onwards.
62407278|NCT06445517|EXPERIMENTAL|Dose Expansion: ISM8207|Participants will receive ISM8207 orally once daily in repeated 28-day cycles.
62407279|NCT02889627|EXPERIMENTAL|FMT with microbiota suspension|Participants undergo repeated FMT with \~50ml microbiota suspension.
62407280|NCT04472273||high-flow nasal cannula group|Group 1
62407281|NCT04472273||classic nasal cannula group|Group 2
62407282|NCT05053594|EXPERIMENTAL|Group N10|Reversal with neostigmine 10 mcg/kg and atropine 5 mcg/kg
62407283|NCT05053594|EXPERIMENTAL|Group N20|Reversal with neostigmine 20 mcg/kg and atropine 10 mcg/kg
62582532|NCT02234830|EXPERIMENTAL|Exoseal closure device|Closure device for femoral artery access closure
62582533|NCT02234830|ACTIVE_COMPARATOR|Angio-Seal closure device|Closure device for femoral artery access closure
62582534|NCT03124589|NO_INTERVENTION|No Intervention|A questionnaire that asks individuals what components of an online intervention they might find useful.
62582535|NCT03124589|EXPERIMENTAL|Online Gambling Internet Intervention|An online gambling Internet intervention (housed at CAMH and developed based on the self-help materials created by Professor David Hodgins)
62582536|NCT02222545|EXPERIMENTAL|OMS721 low dose|Administration of OMS721 at a low dose
62210017|NCT06079372|EXPERIMENTAL|ALXN1850|Starting at Day 1 of the Randomized Evaluation Period participants will receive ALXN1850 for a total of 24 weeks. Participants will receive bodyweight dependent doses of either 20mg, 35mg or 50mg of ALXN1850 once q2w via SC injection. During Part A of the OLE Period, participants will have frequent visits over the first 24 weeks; Part B of the OLE Period participants will have visits every 9 months for up to approximately 108 weeks.
62582537|NCT02222545|EXPERIMENTAL|OMS721 medium dose|Administration of OMS721 at a medium dose
62407284|NCT05053594|EXPERIMENTAL|Group N30|Reversal with neostigmine 30 mcg/kg and atropine 15 mcg/kg
62018783|NCT01702883|NO_INTERVENTION|Control|Randomization occurs after enrollment survey has been completed. This group will not receive the internet intervention for the twelve months. They will be asked to complete the final survey.
62407285|NCT05053594|PLACEBO_COMPARATOR|Group P|Spontaneous reversal (placebo)
62018784|NCT01702883|EXPERIMENTAL|Intervention Group A|Randomization occurs after enrollment survey has been completed. Upon secondary randomization at week eight, this group will continue to receive weekly internet surveys for the entire twelve months. They will be asked to complete the final survey.
62210018|NCT06079372|EXPERIMENTAL|asfotase alfa|Starting at Day 1 of the Randomized Evaluation Period, participants will receive asfotase alfa for a total of 24 weeks. Participants will receive 6 mg/kg/week of asfotase alfa via SC injection as either 2 mg/kg 3 times per week or 1 mg/kg 6 times per week. Part A of the OLE Period participants will have frequent visits over the first 24 weeks; Part B will have visits every 9 months for up to approximately 108 weeks.
62407286|NCT04136522|ACTIVE_COMPARATOR|conventional|The patients who included this group will undergo conventional pancreaticoduodenectomy (PD) or pylorus preserving pancreaticoduodenectomy (PPPD). We will identify and isolate superior mesenteric vein (SMV) before pancreatic resection. The surgeon will dissect tissue around superior mesenteric artery (SMA) and uncinate process of pancreas along the SMA.
62407287|NCT04136522|EXPERIMENTAL|total mesopancreas excision with arterial first approach|The patients who included this group will undergo PD or PPPD including total pancreatic mesopancreas excision and superior mesenteric artery approach. Before pancreatic transection, the surgeon will isolate superior mesenteric vein (SMV) and superior mesenteric artery (SMA). And the surgeon will dissect nerve plexus and lymph node around SMA. inferior pancreaticoduodenal artery (IPDA) and first jejunal artery will be identified and the surgeon will ligate according to surgical margin. Anastomosis will be performed as usual manners.
62582538|NCT02222545|EXPERIMENTAL|OMS721 high dose|Administration of OMS721 at a high dose
62582539|NCT05195138|EXPERIMENTAL|Mindfulness-Based Diabetes Education|Mindfulness-Based Diabetes Education (MBDE) will be delivered in-person in a group of 10-14 participants during 8 weekly sessions followed by 2 bimonthly individual sessions. Sessions integrate Mindfulness-Based Stress Reduction and Diabetes Self-Management Education. MBDE will introduce breath awareness meditation, body scan, walking meditation, mindful yoga, and applying mindfulness to daily activities, as well as core areas from DSME. MBDE will include incremental goal setting to build participants' self-efficacy for diabetes self-management behaviors, mindful attention to diabetes self-management, and on development of social support in the group. Participants will complete daily home mindfulness exercises and self-monitoring of diabetes self-management behaviors.
62582540|NCT05195138|ACTIVE_COMPARATOR|Standard Diabetes Self-Management Education|Standard DSME will be delivered in-person, in a group setting with 10-14 participants per group. Standard DSME will be delivered by a certified diabetes educator in eight weekly sessions of 2 hours duration. Sessions will cover seven core content areas - healthy eating, physical activity, medication usage, self-monitoring, preventing and treating acute and chronic complications, healthy coping, and problem solving.
62582541|NCT01403688||Random Fine Needle Aspiration (RPFNA)|RPFNA
62582542|NCT03943069|EXPERIMENTAL|Patient with PSP|Patient who will be admitted with primary spontaneous pneumothorax.
62582543|NCT06685744|EXPERIMENTAL|TRsA|Telerehabilitation (TR) single Approach - TRsA
62582544|NCT06685744|EXPERIMENTAL|TRcA|Telerehabilitation (TR) combined Approach - TRcA
62582545|NCT06685744|PLACEBO_COMPARATOR|ET|Educational treatment - ET
62582546|NCT01637922|ACTIVE_COMPARATOR|Methadone group|patients on stable methadone therapy (at least 30 days) up to a maximum of 180mg per day
62582547|NCT01637922|ACTIVE_COMPARATOR|Buprenorphine|patients on stable buprenorphine/naloxone therapy (at least 30 days) up to a maximum dose of 24mg/6mg per day.
62582548|NCT02610374|OTHER|Cohort A|HIV-positive individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
62582549|NCT02610374|OTHER|Cohort B|HIV-negative high-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
62582550|NCT02610374|OTHER|Cohort C|HIV-negative low-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
62582551|NCT00585845|EXPERIMENTAL|CRS-207|
62582552|NCT03159871|EXPERIMENTAL|Stratafix suture|
62582553|NCT03159871|ACTIVE_COMPARATOR|Vicryl suture|
62582554|NCT06474988||Tamoxifen|Patients who are receiving treatment with tamoxifen in adjuvant setting
62582555|NCT06474988||Aromatase Inhibitors|Patients who are receiving treatment with an aromatase inhibitor in adjuvant setting
62582556|NCT06474988||Paclitaxel|Patients who are receiving treatment with Paclitaxel in adjuvant setting
62582557|NCT03789578|EXPERIMENTAL|Semaglutide plus insulin 287|Participants will get a single dose of fixed-ratio combination of insulin 287 and semaglutide (NNC0148-0287sema (treatment C)).
62582558|NCT03789578|EXPERIMENTAL|Semaglutide alone|Participants will get a single dose of semaglutide (treatment B) alone.
62790188|NCT04030793|EXPERIMENTAL|Individualized stimulation group|Based on transcranial direct current stimulation (tDCS) simulation, individualized stimulation on leg motor areas during 30 minutes.
62790189|NCT04030793|ACTIVE_COMPARATOR|Conventional stimulation group|Conventional stimulation on leg motor areas during 30 minutes.
62210019|NCT05043116|ACTIVE_COMPARATOR|Vitamin D|Dietary supplement: 2000 IU Vitamin D3 daily dose (oral suspension) for one year.
62210020|NCT05043116|PLACEBO_COMPARATOR|Placebo|Oral suspension with no active substance, identical to the active suspension for one year.
62407288|NCT04011891|ACTIVE_COMPARATOR|Robotic Partial Nephrectomy|Partial nephrectomy performed using the DaVinci robotic surgical system.
62018785|NCT01702883|EXPERIMENTAL|Intervention Group B|Randomization occurs after enrollment survey has been completed. This group will complete weekly internet surveys for eight weeks. Upon secondary randomization at week eight, this group will begin to receive monthly internet surveys. They will be asked to complete the final survey.
62018786|NCT01702883|EXPERIMENTAL|Intervention Group C|Randomization occurs after enrollment survey has been completed. This group will complete weekly internet surveys for eight weeks. Upon secondary randomization at week eight, the group will not receive any more internet surveys. They will be asked to complete the final survey.
62210021|NCT05688852|EXPERIMENTAL|VTX958 Dose A|
62210022|NCT05688852|EXPERIMENTAL|VTX958 Dose B|
62407289|NCT04011891|ACTIVE_COMPARATOR|Open Partial Nephrectomy|Partial nephrectomy performed using the open approach.
62407290|NCT00620776|EXPERIMENTAL|Combined Treatment|Patients who receive combined cognitive behavioral therapy (CBT) plus medication (venlafaxine XR, flexibly dosed between 75-225 mg/day) treatment for GAD. CBT was once/week sessions for 12 weeks. Medication continued for the full 6 months.
62582559|NCT03789578|EXPERIMENTAL|Insulin 287 alone|Participants will get a single dose of insulin 287 (NNC0148-0287 (treatment A)) alone.
62018787|NCT04592757|EXPERIMENTAL|Subacute stroke patients|Training with new virtual mirror therapy application. During 12 sessions of approximately 30 minutes.
62018788|NCT04592757|EXPERIMENTAL|Chronic stroke patients|Training with new virtual mirror therapy application. During 12 sessions of approximately 30 minutes.
62018789|NCT03971617|EXPERIMENTAL|Hydrogen tablets|The ingredient in the tablet producing H2 is magnesium. Each tablet contains 80 mg magnesium, a safe level well below the recommended daily dietary allowance of 420 mg for men/ 320 mg for women. Dissolving one tablet in 250 mL of water will achieve a saturating H2 concentration of approximately 1.6 ppm. Twice a day subjects will dissolve a tablet into water and drink the effervescent water.
62018790|NCT03971617|PLACEBO_COMPARATOR|Placebo tablets|effervescent placebo tablets will also contain 80 mg magnesium but do not generate hydrogen-enriched water
62018791|NCT00105027|ACTIVE_COMPARATOR|CRVO Observation|
62018792|NCT00105027|ACTIVE_COMPARATOR|CRVO 1 mg dose triamcinolone acetonide|
62018793|NCT00105027|ACTIVE_COMPARATOR|CRVO 4 mg dose triamcinolone acetonide|
62018794|NCT00105027|ACTIVE_COMPARATOR|BRVO standard care|
62018795|NCT00105027|ACTIVE_COMPARATOR|BRVO 1 mg dose triamcinolone acetonide|
62018796|NCT00105027|ACTIVE_COMPARATOR|BRVO 4 mg dose triamcinolone acetonide|
62210023|NCT05688852|PLACEBO_COMPARATOR|VTX958 Placebo|
62210024|NCT04900792|EXPERIMENTAL|Cohort 1 (starting)|"Radiation Phase~* Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks.~* Ferumoxytol: 512 g administered intravenously (IV) the day before radiation and then during weeks 5 to 6 of radiation therapy.~* Radiation: 61.2 Gray (given 1.8 Gray once daily, 5 days per week, for about 7 weeks) or 60 Gray (2.0 Gray once daily for 5 days per week for about 6 weeks)~* Temozolomide: 75 mg/m2, taken orally, once daily, every day, for up to 49 days or until radiation is completed (whichever comes first).~Adjuvant Phase~* Temozolomide: 150 to 200 mg/m2, taken orally, once daily, for five days out of 28 days (where 28 days is one cycle of chemotherapy) for up to six cycles~* Ascorbate: 87.5 g administered intravenously (IV) twice each calendar week of the cycle~* Ferumoxytol: 512 g administered intravenously (IV) the first day of the first cycle of chemotherapy."
62582560|NCT06617195||Young|Men and women between the ages of 21-35 years will be recruited for this study. All participants will complete an outpatient study day (body composition, blood draw, treadmill test, strength test) and an inpatient study day (muscle biopsies, fat biopsies, indirect calorimetry, exercise test).
62582561|NCT06617195||Older|Men and women between the ages of 70-85 years will be recruited for this study. All participants will complete an outpatient study day (body composition, blood draw, treadmill test, strength test) and an inpatient study day (muscle biopsies, fat biopsies, indirect calorimetry, exercise test).
62582562|NCT03481101|OTHER|All patients|Both patients receiving chemotherapy and immunotherapy are observed during the same intervention with PET/CT and liquid biopsy. No primary comparison are made between the groups.
62018797|NCT04202159||Perampanel|Participants with PGTC or SGTC seizures may receive perampanel tablets or oral suspension as only add-on therapy based on physicians decision in accordance with summary of product characteristics (SmPC) and will be observed at baseline, 6 months (intermediate visit), and 12 months (final visit).
62018798|NCT02946866||Cerebral cavernous malformation|Patients with newly diagnosed, cerebral cavernous malformation who will visit one of the study centers during the period from June 2016 to December 2017. Patients would be eligible for enrollment if they were 18 years of age or older and had at least 1 cavernous malformation. All patients who would visit a study center during the enrollment period and meet these criteria will be asked to join the study. The cohort will consists of patients who agree to participate. Target population of this study is 228 patients.
62018799|NCT04547959|EXPERIMENTAL|C-CURVE Titane|According the routine practice of the investigator surgeon, the interbody cage C-CURVE in Titane is used
62018800|NCT01621360|ACTIVE_COMPARATOR|Arthroscopic surgery|Arthroscopic surgery of the hip plus optimized medical management
62018801|NCT01621360|ACTIVE_COMPARATOR|Conservative management|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
62407291|NCT00620776|ACTIVE_COMPARATOR|Venlafaxine XR 75-225 mg alone|These patients receive only medication treatment for GAD. Patients take venlafaxine (flexibly dosed from 75-225 mg/day) as part of NCT00183274 and are assessed over a 6 month period. Medication continued for the full 6 months.
62582563|NCT02453035||PTCA - Desolve Scaffold|Patients with coronary artery stenosis who have been treated with a DESolve bioresorbable coronary scaffold
62582564|NCT00803790|EXPERIMENTAL|Sequence 1- alendronate+vitamin D combination then alendronate|Participants in Part 1 received 70mg alendronate+5600 International Units (IU) vitamin D combination tablet in Period 1 followed by 70mg alendronate tablet in Period 2. A washout of at least 12 days separated each treatment period.
62582565|NCT00803790|EXPERIMENTAL|Sequence 2 alendronate then alendronate+vitamin D combination|Participants in Part 1 received 70mg alendronate tablet in Period 1 followed by 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.
62018802|NCT01825551|ACTIVE_COMPARATOR|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor 10 microgram/ kg/ day for 5 days subcutaneously
62018803|NCT01825551|PLACEBO_COMPARATOR|Placebo|normal saline 0.01 ml/kg/day for 5 days subcutaneously
62018804|NCT03937375||High PEEP|Use of high levels of PEEP with recruitment maneuvers
62018805|NCT03937375||Low PEEP|Use of low levels of PEEP without recruitment maneuvers
62018806|NCT03948074|EXPERIMENTAL|High THC/Low CBD Cannabis Oil|THC+THCa = 573 mg CBD+CBDA = 0 mg Total cannabinoids = 573 mg (0.95mg/drop) Dried marijuana equivalent = 5g
62407292|NCT01374516|EXPERIMENTAL|CYD Dengue Vaccine Group|Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.
62407293|NCT01374516|PLACEBO_COMPARATOR|Placebo Group|Participants were to receive a placebo vaccine at 0, 6, and 12 months.
62407294|NCT05637515|ACTIVE_COMPARATOR|Humira continuously|"Subjects receive Humira continuously both during Run-in period and Randomized interchangeable treatment period.~Run-in Period:~Subjects will receive Humira (initial dose of 80 mg \[2 × 40 mg\]; Day 1 administered subcutaneously (SC), followed by 40 mg SC given every other week starting 1 week after the initial dose (last dose at Week 10).~Randomized interchangeable treatment period:~Subjects continue to receive Humira (40 mg every other week) until Week 26"
62407295|NCT05637515|EXPERIMENTAL|Repeated switches Humira - Hulio|"Subjects will receive Humira in Run-in period \& undergo repeated switches between Humira Hulio during randomized interchangeable treatment period~Randomized interchangeable treatment period:~* Subjects undergo repeated switches between Humira and Hulio between week 12 to week 26.~* Hulio (40 mg every other week) at Week 12 and Week 14~* Humira (40 mg every other week) at Week 16 and Week 18, and~* Hulio (40 mg every other week) at Week 20, Week 22, Week 24 and Week 26."
62407296|NCT03523676||Group A|sepsis patients who did not develop atrial fibrillation during ICU stay
62407297|NCT03523676||Group B|sepsis patients with newly developed atrial fibrillation during ICU stay
62407298|NCT05180682|EXPERIMENTAL|Supervised|This group training was supervised by the health care provider.
62407299|NCT05180682|ACTIVE_COMPARATOR|Non-Supervised|This group was non-supervised.
62407300|NCT06652867||Hypoglycemic diabetic patients|Hypoglycemic diabetic patients with type 1 or type 2 diabetes recruited during the incidence of hypoglycemia with awareness of the time when hypoglycemia occurred.
62407301|NCT06652867||Control group of non-hypoglycemic diabetic patients.|Type 1 or type 2 diabetic subjects who don't have hypoglycemia at the time of recruitment or in the last 72 hours.
62407302|NCT01124500|EXPERIMENTAL|methylphenidate via transdermal patch compared to placebo|The proposed study is a within-subject, cross-over, randomized and double-blinded pilot trial, designed to evaluate the efficacy and feasibility of sustained-release, long-acting methylphenidate via transdermal patch compared to placebo in fatigued patients with Head and Neck malignancies
62018807|NCT03948074|EXPERIMENTAL|Low THC/High CBD Cannabis Oil|THC+THCa = 37mg CBD+CBDA = 784mg Total cannabinoids = 821mg (1.37mg/drop) Dried marijuana equivalent = 6g
62018808|NCT03948074|EXPERIMENTAL|Equal amounts of THC/CBD Cannabis Oil|THC+THCa = 516mg CBD+CBDA = 456mg Total cannabinoids = 972mg (1.62mg/drop) Dried marijuana equivalent = 6g
62407303|NCT04580875|ACTIVE_COMPARATOR|Minimally invasive surgery (laparoscopy, laparoscopic-assisted procedures)|This study will be conducted out at 3 pediatric surgery tertiary centers (Al-Azhar University hospitals in Cairo, Prince Mohammed bin Abdulaziz Hospital in Riyadh and Maternity \& Children's Hospital in Bisha) on patients aged from 1-14 years presenting to the ER by stable penetrating abdominal trauma with significant clinical/radiologic findings, in the period from April 2017 to March 2022. Responders to initial resuscitation will be managed by minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures). All patients enrolled in the study will give a written informed consent even for possible conversion to laparotomy if necessary.
62407304|NCT04580875|ACTIVE_COMPARATOR|Conservative management|patients aged from 1-14 years presenting to the ER by penetrating abdominal trauma with imsignificant findings will be managed conservatively.
62018809|NCT03948074|PLACEBO_COMPARATOR|Placebo Oil|Medium Chain Triglyceride (MCT) oil
62018810|NCT03981406|EXPERIMENTAL|Palliative Care|Palliative care is comprehensive, coordinated interdisciplinary care for patients and families facing a potentially life-threatening illness. This consists of specially trained teams of professionals including physicians, nurses, social workers, and chaplains that provide care and support in inpatient and outpatient settings.
62407305|NCT05425550|EXPERIMENTAL|Arm A|Experimental group is using the medidux™ app
62407306|NCT05425550|NO_INTERVENTION|Arm B|
62407307|NCT04389008||Postoperative death|
62407308|NCT04389008||Postoperative non-death|
62018811|NCT03981406|PLACEBO_COMPARATOR|Standard of Care|Standard of care for idiopathic pulmonary fibrosis
62210025|NCT04900792|EXPERIMENTAL|Cohort 2|"Radiation Phase~* Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks.~* Ferumoxytol: 512 g administered intravenously (IV) the day before radiation, about 1 week after dose 1, during weeks 5 to 6 of radiation therapy, and then a week after that (for a total of 4 ferumoxytol infusions).~* Radiation: 61.2 Gray (given 1.8 Gray once daily, 5 days per week, for about 7 weeks) or 60 Gray (2.0 Gray once daily for 5 days per week for about 6 weeks)~* Temozolomide: 75 mg/m2, taken orally, once daily, every day, for up to 49 days or until radiation is completed (whichever comes first).~Adjuvant Phase~* Temozolomide: 150 to 200 mg/m2, taken orally, once daily, for five days out of 28 days (where 28 days is one cycle of chemotherapy) for up to six cycles~* Ascorbate: 87.5 g administered intravenously (IV) twice each calendar week of the cycle~* Ferumoxytol: 512 g administered intravenously (IV) the first day of the first cycle of"
62407309|NCT03366142|EXPERIMENTAL|Single Arm|treatment with ustekinumab based on weight
62407310|NCT01395342|NO_INTERVENTION|blood pressure and heart rate data|
62407311|NCT02880709|EXPERIMENTAL|Special diet|Special diet with taste, energy-and protein content adjusted according to previous finding
62407312|NCT02880709|NO_INTERVENTION|Usual diet|Patients habitual diet
62407313|NCT02774577|EXPERIMENTAL|healthy young and elderly|young adults (20 to 30 years) compare to elderly (60 to 74 years)
62407314|NCT06354127|EXPERIMENTAL|DWP450|
62582566|NCT00803790|EXPERIMENTAL|Sequence 3 alendronate+vitamin D combination then vitamin D|Participants in Part 2 received 70mg alendronate+5600 IU vitamin D combination tablet in Period 1 followed by a single dose of 5600 IU vitamin D, administered as two 2800 IU tablets in Period 2. A washout of at least 12 days separated each treatment period.
62018812|NCT00826501|ACTIVE_COMPARATOR|1|Endoscopic cyst-gastrostomy with a neurolytic block along with oral/transdermal analgesic therapy
62018813|NCT00826501|ACTIVE_COMPARATOR|2|Surgical cyst-gastrostomy with neurolytic block and pain managed by only oral/transdermal analgesic
62018814|NCT03056846|PLACEBO_COMPARATOR|Placebo|Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
62018815|NCT03056846|EXPERIMENTAL|Probiotic Combination|A commercially available probiotic mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
62018816|NCT03056846|EXPERIMENTAL|Bifidobacterium bifidum|A commercially available probiotic strain (Bifidobacterium bifidum) will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
62210026|NCT01503385|EXPERIMENTAL|Celecoxib|"Combination of and concurrent radiotherapy Cisplatin/etoposide with or without Celecoxib.~Intervention: Drug: Celecoxib"
62210027|NCT01509144|ACTIVE_COMPARATOR|nasal active low dose + IM active|Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
62210028|NCT01509144|ACTIVE_COMPARATOR|nasal active mid dose + IM active|Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
62210029|NCT01509144|ACTIVE_COMPARATOR|nasal active full dose + IM active|Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
62210030|NCT01509144|ACTIVE_COMPARATOR|nasal placebo + IM active|Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
62210031|NCT01509144|PLACEBO_COMPARATOR|nasal placebo + IM placebo|Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
62582567|NCT00803790|EXPERIMENTAL|Sequence 4- vitamin D then alendronate+vitamin D combination|Participants in Part 2 received a single dose of 5600 IU vitamin D, administered as two 2800 IU tablets in Period 1 followed by a 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.
62582568|NCT03229863|EXPERIMENTAL|Sweet Potatos|Infants will consume commercially available baby food sweet potato (SP) (Plum Organics, Just Sweet Potato) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of sweet potato to their infant at least three times per day for seven days in a row.
62018817|NCT03056846|EXPERIMENTAL|Bifidobacterium longum|A commercially available probiotic strain (Bifidobacterium longum) will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
62018818|NCT03822169|EXPERIMENTAL|Choline added as a phospholipid|A shake with phospholipid-bound choline (and bound DHA),
62018819|NCT03822169|ACTIVE_COMPARATOR|Choline added as a salt|control shake with choline added as a salt and added DHA.
62018820|NCT05729074|EXPERIMENTAL|Part A-1(SAD1)|IN-A002 Ointment 0.3% or Placebo Ointment, single dose
62210032|NCT02907398||ADHERE|This group will include 250 patients who have been implanted with the Inspire therapy system, enrolled in the ADHERE Registry, and are willing to complete a follow-up home sleep apnea test (HSAT).
62407315|NCT06354127|ACTIVE_COMPARATOR|Botox®|
62407316|NCT04024527|ACTIVE_COMPARATOR|Dual therapy|Esomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days
62407317|NCT04024527|EXPERIMENTAL|Metronidazole plus dual therapy|Esomeprazole 40mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
62407318|NCT01977131|EXPERIMENTAL|stromal cells modified HGF|
62407319|NCT02796365|EXPERIMENTAL|Exercise|Patients will participate in a 10 week outpatient cardiac rehabilitation program. Exercise will consist of 3 days per week of interval training on a treadmill or bike at an intensity between 50-90% of heart rate reserve. Additionally patients will perform resistance exercises 1-2 days per week and attend 8 nutrition and lifestyle classes.
62407320|NCT02796365|NO_INTERVENTION|Usual care|Control group will not be instructed on exercise, but encouraged to follow standard medical advice.
62407321|NCT03857308|EXPERIMENTAL|Mindfulness Training|
62407322|NCT03857308|ACTIVE_COMPARATOR|Reappraisal Training|
62210033|NCT02907398||CONTROL|This group will include 100 patients who have been denied insurance coverage of the Inspire therapy system implant by their provider, have had no intervention (Inspire), and are willing to complete a HSAT and provide information about their OSA treatment after denial.
62210034|NCT01481987|EXPERIMENTAL|Epiretinal Membrane|The investigators prospectively included 49 eyes of 49 patients with idiopathic ERM for which surgical treatment had been planned.
62210035|NCT01481987|NO_INTERVENTION|Control|Subjects with normal visual acuity and OCT profile
62210036|NCT00662142|EXPERIMENTAL|1|DHA 400 mg/day (200mg twice daily), vs DHA 1200 mg/day (400 mg three times daily), vs placebo; 1:1:1 ratio
62210037|NCT02738853|EXPERIMENTAL|Medtronic Transcatheter Aortic Valve 2.0 Replacement System|Treatment of Aortic Stenosis by replacing native valve with the Medtronic Transcatheter Aortic Valve 2.0 System
62210038|NCT04018274|EXPERIMENTAL|Sequence 1|In Treatment Sequence 1, period 1, participants will be dosed with a single administration of oral contraceptive (OC). Participants will continue directly into Period 2 where they will receive PF-06651600 PO for 9 days followed by administration of a single dose of OC on the morning of Day 10.
62210039|NCT04018274|EXPERIMENTAL|Sequence 2|In Treatment Sequence 2, Period 1, participants will be dosed with PF-06651600 PO QD for 9 days and administered a single dose of OC on the morning of Day 10. After a washout period of at least 10 days, participants will continue into Period 2 and will receive an additional single dose of OC.
62210040|NCT03333876|ACTIVE_COMPARATOR|Nasal Dilator|Nasal dilators have been used to treat snoring and sleep apnea. Many studies focus on external nasal dilators like Breathe Right Strips. These interventions largely were not effective in treating OSA. However, there is some evidence to suggest internal to the nose dilators (like Mute) may work to reduce snoring
62210041|NCT03333876|ACTIVE_COMPARATOR|Mandibular Advancement|Mandibular advancement devices have shown to be effective, but not necessarily acceptable to primary snorers.
62210042|NCT03333876|ACTIVE_COMPARATOR|Positional Therapy|Studies have shown mixed results for positional therapy as a whole. Braver and Block reported that foam wedges used to keep patients in a lateral position were not effective in reducing snoring in 20 individuals.
62210043|NCT05532514||GROUP A|exposure in 5x5 fov at 90 voxel size
62407323|NCT06217562|ACTIVE_COMPARATOR|Septic shock treatment strategy involving a lower threshold for vasopressin initiation|Recommended strategy for treatment of septic shock includes initiation of fixed-dose IV vasopressin (1.8 units/hour) as a second-line vasopressor if the combined norepinephrine-equivalent dose of other vasopressors reaches ≥0.1 micrograms/kilogram/minute (mcg/kg/min). Use of the recommended treatment strategy (via entry of an order for threshold-based vasopressin initiation) or an alternative treatment strategy is at the discretion of patients' treating clinical team.
62210044|NCT05532514||GROUP B|exposure in 5x5 fov at 200 voxel size
62210045|NCT04726085|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 600 mg q6 hours for 24 hours- total dose of 2400mg- after emergent cerclage placement
62210046|NCT04726085|ACTIVE_COMPARATOR|Indomethacin|Indomethacin 50 mg q8 hours for 24 hours- total dose of 150mg- after emergent cerclage placement
62210047|NCT05885243|EXPERIMENTAL|ESWT|Group 1 (n:16) will be given once a week, total 5 sessions of ESWT+ home exercise program
62210048|NCT05885243|EXPERIMENTAL|customized insoles|Group 2 (n:16) will be given customized insoles+ home exercise program. Insoles will be used for 12 weeks.
62210049|NCT05885243|EXPERIMENTAL|combined ESWT and customized insoles|Group 3 (n:16) will be given once a week, total 5 sessions of ESWT+ home exercise program. Also, simultaneous insoles will be provided. Insoles will be used for 12 weeks.
62210050|NCT04094168|EXPERIMENTAL|Del Nido Cardioplegia solution|1 liter of Del Nido cardioplegia after aortic cross-clamp will be given. Additional dose will be applied if aortic cross-clamp exceeds 90 minutes or whenever cardiac activity is observed.
62582569|NCT03229863|EXPERIMENTAL|Pears|Infants will consume commercially available baby food pear (P) (Earth's Best, First Pears) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of pears to their infant at least three times per day for seven days in a row.
62018821|NCT05729074|EXPERIMENTAL|Part A-1(SAD2)|IN-A002 Ointment 0.5% or Placebo Ointment, single dose
62582570|NCT05669326|EXPERIMENTAL|NODDI TRACT|"* Diffusion MRI (tractography) Tractography is performed on the basis of a diffusion MRI sequence which, after computer processing, will result in a map of the apparent diffusion coefficient and a diffusion tensor beam reconstruction (DTI tractography) performed with the Sisyphus software.~* Multi-shell diffusion MRI (NODDI-tract)"
62018822|NCT05729074|EXPERIMENTAL|Part A-1(SAD3)|IN-A002 Ointment 1% or Placebo Ointment, single dose
62210051|NCT04094168|ACTIVE_COMPARATOR|Cold blood Cardioplegia solution|Administering of cardioplegia using current standard of care blood-based cardioplegia protocol. An induction dose of whole blood cardioplegia will be given at a temperature of 4-8 degrees, with subsequent doses of cardioplegia every 20 minutes or whenever cardiac activity is observed.
62210052|NCT04165031|EXPERIMENTAL|LY3499446 Phase 1 Cohort A1 High Dose|Participants received high dose LY3499446 as oral monotherapy twice daily (BID) in 21-day cycles.
62210053|NCT04165031|EXPERIMENTAL|LY3499446 Phase 1 Cohort AO Mid Dose|Participant received mid dose LY3499446 as oral monotherapy once every other day (QOD) in 21-day cycles.
62018823|NCT05729074|EXPERIMENTAL|Part A-1(SAD4)|IN-A002 Ointment 3% or Placebo Ointment, single dose
62018824|NCT05729074|EXPERIMENTAL|Part A-1(SAD5)|IN-A002 Ointment 5% or Placebo Ointment, single dose
62018825|NCT05729074|EXPERIMENTAL|Part A-2(MAD1)|IN-A002 Ointment 1% or Placebo Ointment, Twice daily (BID), multiple topical applications for 14 days
62018826|NCT05729074|EXPERIMENTAL|Part A-2(MAD2)|IN-A002 Ointment 3% or Placebo Ointment, Twice daily (BID), multiple topical applications for 14 days
62018827|NCT05729074|EXPERIMENTAL|Part A-2(MAD3)|IN-A002 Ointment 5% or Placebo Ointment, Twice daily (BID), multiple topical applications for 14 days
62018828|NCT05729074|EXPERIMENTAL|Part B(MAD1)|IN-A002 Ointment 1%, Twice daily (BID), multiple topical applications for 28 days
62018829|NCT05729074|EXPERIMENTAL|Part B(MAD2)|IN-A002 Ointment 3%, Twice daily (BID), multiple topical applications for 28 days
62018830|NCT05729074|ACTIVE_COMPARATOR|Part B|"Part B(MAD1), (MAD2):~Elidel Cream 1% (pimecrolimus), Twice daily (BID), multiple topical applications for 28 days"
62018831|NCT00384085|EXPERIMENTAL|Lantus/Apidra-3|Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.
62018832|NCT00384085|EXPERIMENTAL|Lantus/Apidra-1|Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.
62018833|NCT00384085|EXPERIMENTAL|Novolog Mix 70/30|Premixed insulin (Novolog® Mix 70/30) added to oral agents.
62018834|NCT00734526|EXPERIMENTAL|Dose Level 1|"Temozolomide + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle~Temozolomide 75mg/m\^2 daily during radiation therapy, and 150mg/m\^2 in the first cycle of adjuvant therapy. Dose Level 1 will receive sorafenib in the adjuvant phase (following radiation therapy) at the dose of 400mg BID in combination with standard dose temozolomide 150-200 mg/m\^2 two days out of 28 day cycle. Radiotherapy 2.0 Grey (Gy)/day given daily 5 days per week for total of 60.0 Gy over 6 weeks."
62210054|NCT04165031|EXPERIMENTAL|LY3499446 Phase 1 Cohort A-2 Low Dose|Participants received low dose LY3499446 as oral monotherapy once daily (QD) in 21-Day cycles.
62018835|NCT00734526|EXPERIMENTAL|2|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle + Higher Dose Sorafenib
62018836|NCT00734526|EXPERIMENTAL|3|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Lower Dose Sorafenib
62018837|NCT00734526|EXPERIMENTAL|4|Temozolomide + Higher Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Higher Dose Sorafenib
62018838|NCT02376426|EXPERIMENTAL|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
62018839|NCT02376426|EXPERIMENTAL|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
62018840|NCT02376426|EXPERIMENTAL|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
62210055|NCT04165031|EXPERIMENTAL|LY3499446 + Combination Drugs Phase 1|"LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV).~This trial was terminated prior to initiation of combination therapy cohorts."
62210056|NCT04165031|EXPERIMENTAL|LY3499446 Monotherapy + Combination Drugs Phase 2|"LY3499446 as oral monotherapy and LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV).~The trial was terminated prior to initiation of Phase 2 of this study."
62210057|NCT04165031|ACTIVE_COMPARATOR|Docetaxel Phase 2|"Docetaxel IV infusion.~The trial was terminated prior to initiation of Phase 2 of this study."
62210058|NCT01373151|PLACEBO_COMPARATOR|Arm 1|BMS-945429 Placebo/BMS-945429+Methotrexate+Adalimumab Placebo
62582571|NCT04590586|EXPERIMENTAL|Apremilast + Standard of Care|Participants will be randomized to receive 30 mg apremilast orally twice a day (BID) in addition to standard of care treatment for 14 days or until hospital discharge, death, or discontinuation of investigational product, whichever occurred first.
62210059|NCT01373151|EXPERIMENTAL|Arm 2|BMS-945429 + Methotrexate + Adalimumab Placebo
62210060|NCT01373151|EXPERIMENTAL|Arm 3|BMS-945429 + Methotrexate + Adalimumab Placebo
62582572|NCT04590586|PLACEBO_COMPARATOR|Apremilast Placebo + Standard of Care|Participants will be randomized to receive matching placebo to apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, death, or discontinuation of investigational product, whichever occurred first.
62582573|NCT04590586|EXPERIMENTAL|Lanadelumab + Standard of Care|Participants will be randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4 in addition to standard of care.
62018841|NCT02376426|EXPERIMENTAL|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
62018842|NCT02388321|EXPERIMENTAL|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
62018843|NCT02388321|ACTIVE_COMPARATOR|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
62018844|NCT02161718|EXPERIMENTAL|Samidorphan + olanzapine (ALKS 3831)|Active study drug
62018845|NCT02161718|PLACEBO_COMPARATOR|Placebo + olanzapine|
62018846|NCT05786677|EXPERIMENTAL|Patients with fibromyalgia and depression (1)|Patients in this group will receive physiotherapy protocol and medications.
62018847|NCT05786677|ACTIVE_COMPARATOR|Patients with fibromyalgia and depression (2)|Patients in this group will receive medications only.
62018848|NCT05786677|EXPERIMENTAL|Patients with depression only (1)|Patients in this group will receive physiotherapy protocol and medications.
62018849|NCT05786677|ACTIVE_COMPARATOR|Patients with depression only (2)|Patients in this group will receive medications only.
62018850|NCT04198623|OTHER|Montelukast (Singulair)|Montelukast(Singulair) 10mg to be taken in addition to standard institutional premedication
62018851|NCT02823145|EXPERIMENTAL|ZX008|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
62210061|NCT01373151|EXPERIMENTAL|Arm 4|BMS-945429 + Methotrexate + Adalimumab Placebo
62582574|NCT04590586|PLACEBO_COMPARATOR|Lanadelumab Placebo + Standard of Care|Participants will be randomized to receive placebo to lanadelumab by intravenous infusion on Day 1, and a second dose administered on Day 4 in addition to standard of care.
62210062|NCT01373151|EXPERIMENTAL|Arm 5|BMS-945429 + Methotrexate/Methotrexate Placebo + Adalimumab Placebo
62018852|NCT06303765|EXPERIMENTAL|PReDAS intervention|All participants will receive the PReDAS intervention during the study. As per concurrent multiple baseline designs, each participant will be randomized as to WHEN they receive the PReDAS during the 6 month study period. Baseline lengths will vary from 2 to 5 months.
62018853|NCT02575664|EXPERIMENTAL|Buprenorphine|Buprenorphine 5 microg/h/7days patch
62210063|NCT01373151|EXPERIMENTAL|Arm 6|BMS-945429 + Methotrexate/Methotrexate Placebo+Adalimumab Placebo
62210064|NCT01373151|ACTIVE_COMPARATOR|Arm 7|Adalimumab + Methotrexate
62210065|NCT05723159||Clínica Universidad Navarra site|Research subjects will be enrolled at Clínica Universidad Navarra. Research subjects will be instructed to wear the HCMS and a second watch serving as an audio recorder. These devices will be kept on the wrist or within 3 feet (\~91 cm) of the mouth, a behavior abetted by keeping the charging station for both watches on the bedside table. Participants will be asked to go about their day as usual while wearing these devices.
62582575|NCT04590586|EXPERIMENTAL|Zilucoplan + Standard of Care|Participants will be randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment in addition to standard of care.
62582576|NCT04590586|PLACEBO_COMPARATOR|Zilucoplan Placebo + Standard of Care|Participants will be randomized to receive placebo to zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment in addition to standard of care.
62582577|NCT02177526|OTHER|Imaging - CT and MRI examinations|Abdominal and pelvic CT and pelvic MRI imaging will be performed in 30 patients.
62582578|NCT05154019|EXPERIMENTAL|Intervention|Line Managers from organisations in the intervention arm will complete a self-led online training course consisting of 5 modules, over a period of 5-6 weeks
62582579|NCT05154019|NO_INTERVENTION|Waitlist Control|Line Managers from organisations in the intervention arm will receive no training. They will be given access to the online intervention at the end of a 3-month period.
62018854|NCT02575664|PLACEBO_COMPARATOR|Placebo|Placebo patch
62018855|NCT01334697|EXPERIMENTAL|Cardiotrophin-1|
62018856|NCT01334697|PLACEBO_COMPARATOR|Placebo|
62018857|NCT01111500|ACTIVE_COMPARATOR|external rotation immobilization|Patient will wear an external rotation brace to immobilize the injured arm.
62018858|NCT01111500|ACTIVE_COMPARATOR|internal rotation immobilization|Patient will wear an internal rotation brace to immobilize the injured arm.
62018859|NCT01501318|ACTIVE_COMPARATOR|Personalized feedback plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.Treatment as usual with participants receiving a personalized feedback report about the risks associated with their current substance use behaviors and a brief (5-15 minute) motivational interviewing based education session provided by a trained health coach.
62582580|NCT05600621|EXPERIMENTAL|Condition 1: Components 1, 2,3 and 4|"Participants will be assigned to receive all of the four intervention programs:~1. Financial Literacy Training (FLT) Workshops~2. Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~3. A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)~4. Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
62018860|NCT01501318|EXPERIMENTAL|Personalized feedback report alone|Provision of the personalized feedback report alone.
62018861|NCT05910775|NO_INTERVENTION|Treatment as usual (TAU)|Participants receive TAU
62018862|NCT05910775|EXPERIMENTAL|Intervention + TAU|"Participants receive a presentation prior to the first treatment and receive a follow up session within 24 hours after the first treatment in addition to treatment as usual"
62018863|NCT02238301|OTHER|"Patients test (pregnant women with a eutrophic fetus)"|Test the type of mask, oxygen flow and duration of oxygenation, adjustment of MRI machine Adjustment of MRI machine (choice of antenna calibration, verifying Settings of each sequence, adaptation of the number of cuts for the duration of each sequence, checking the correct execution of the succession of sequences, settings of total examination time)
62210066|NCT05723159||OHSU site|Research subjects will be enrolled at OHSU. Research subjects will be instructed to wear the HCMS and a second watch serving as an audio recorder. These devices will be kept on the wrist or within 3 feet (\~91 cm) of the mouth, a behavior abetted by keeping the charging station for both watches on the bedside table. Participants will be asked to go about their day as usual while wearing these devices.
62210067|NCT05723159||Decentralized - US-based|"Research subjects will be enrolled in a decentralized manner ou of the Hyfe North American Clinical Office.~Research subjects will be instructed to wear the HCMS and a second watch serving as an audio recorder. These devices will be kept on the wrist or within 3 feet (\~91 cm) of the mouth, a behavior abetted by keeping the charging station for both watches on the bedside table. Participants will be asked to go about their day as usual while wearing these devices."
62210068|NCT03369327|EXPERIMENTAL|sofosbuvir/daclatasvir|Once daily fixed-dose combination pill of sofosbuvir and daclatasvir for 12 weeks if the patient is non cirrhotic and for 24 weeks if cirrhotic
62407324|NCT06217562|ACTIVE_COMPARATOR|Septic shock treatment strategy involving a higher threshold for vasopressin initiation|Recommended strategy for treatment of septic shock includes initiation of fixed-dose IV vasopressin (1.8 units/hour) as a second-line vasopressor if the combined norepinephrine-equivalent dose of other vasopressors reaches ≥0.4 mcg/kg/min. Use of the recommended treatment strategy (via entry of an order for threshold-based vasopressin initiation) or an alternative treatment strategy is at the discretion of patients' treating clinical team.
62018864|NCT02238301|ACTIVE_COMPARATOR|Pregnant women with a diagnosis of IUGR fetuses|Measure of the BOLD effect in the feto-placental units of IUGR fetuses
62018865|NCT02238301|ACTIVE_COMPARATOR|Pregnant women with eutrophic fetuses|Measure of BOLD effects of fetal-placental unit eutrophic fetuses
62018866|NCT04612270|EXPERIMENTAL|Participants for blood collection|The blood samples of all participants will be treated equally according to the study protocol. No intervention in-vivo.
62407325|NCT05329441||Study Participants|All depressed participants will undergo the same study procedures
62407326|NCT06369077|ACTIVE_COMPARATOR|full dose lat dor-tim; tim-brim-dor-bim|After baseline IOP measurements, subjects in this arm will use the full dose full dose latanoprost and dorzolamide-timolol in phase 2, and then timolol-brimonidine-dorzolamide-bimatoprost in phase 3.
62582581|NCT05600621|EXPERIMENTAL|Condition 2: Components 1, 2 and 3|"1. Financial Literacy Training (FLT) Workshops~2. Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~3. A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)"
62018867|NCT04289389||HUNT4 70+|All inhabitants in Nord-Trøndelag 70 years of age and older were invited.
62018868|NCT04289389||HUNT4 Trondheim 70+|All inhabitants of one district in Trondheim 70 years of age and older were invited.
62018869|NCT06364046|EXPERIMENTAL|Drug-eluting Beads Bronchial Arterial Chemoembolization Combined with Serplulimab|
62018870|NCT06364046|ACTIVE_COMPARATOR|Irinotecan Single-agent Intravenous Chemotherapy Combined with Serplulimab|
62018871|NCT04457648|PLACEBO_COMPARATOR|Conventional|
62018872|NCT04457648|ACTIVE_COMPARATOR|Manuka Honey|
62018873|NCT03453333|EXPERIMENTAL|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
62018874|NCT03453333|EXPERIMENTAL|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
62018875|NCT00472667|EXPERIMENTAL|1|Procalcitonin guided strategy
62018876|NCT05579496||Infants Hospitalized in the NICU|Infants born between 28 0/7 weeks 32 6/7 weeks gestational age, who are within 6 weeks postnatal age, and their caregiver and/or health professional will be recruited for qualitative interview.
62018877|NCT06572761|EXPERIMENTAL|Combination of antibiotics|"Combination of antibiotics (3rd generation of cephalosporin, clarithromycin, metronidazole)~+ routine care (emergency cerclage, vaginal progesterone)"
62018878|NCT06572761|ACTIVE_COMPARATOR|Routine care|Routine care (emergency cerclage, vaginal progesterone)
62407327|NCT06369077|ACTIVE_COMPARATOR|tim-brim-dor-bim; full dose lat dor-tim|After baseline IOP measurements, subjects in this arm will use timolol-brimonidine-dorzolamide-bimatoprost in phase 2, and then full dose latanoprost and dorzolamide-timolol in phase 3.
62582582|NCT05600621|EXPERIMENTAL|Condition 3: Components 1, 2 and 4|"1. Financial Literacy Training (FLT) Workshops~2. Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
62018879|NCT01337245|EXPERIMENTAL|Antivenom|For comparison with historical mortality rate, all patients prospectively enrolled will receive antivenom (Snake \[Micrurus\] North American immune F(ab')2 Equine) for treatment of coral snake bite.
62018880|NCT05494398|EXPERIMENTAL|N-Acetylcysteine|
62018881|NCT04998240|EXPERIMENTAL|Prime BBIBP-CorV, Boost Ad26.COV2.S (A1)|The randomized study participants will receive Prime BBIBP-CorV vaccine followed by Booster dose of Ad26.COV2.S vaccine (A1).
62018882|NCT04998240|EXPERIMENTAL|Prime BBIBP-CorV, Boost BBIBP-CorV (A2)|The randomized study participants will receive Prime BBIBP-CorV vaccine followed by Booster dose of BBIBP-CorV vaccine (A2).
62018883|NCT04998240|EXPERIMENTAL|Prime Ad26.COV2.S, Boost BBIBP-CorV (B1)|The randomized study participants will receive Prime Ad26.COV2.S vaccine followed by Booster dose of BBIBP-CorV vaccine (B1).
62018884|NCT04998240|EXPERIMENTAL|Prime Placebo, Boost Ad26.COV2.S (B2)|The randomized study participants will receive Prime Placebo vaccine followed by Booster dose of Ad26.COV2.S (B2).
62018885|NCT03273764||Preterm neonates with RDS|Singleton Preterm neonates with gestational age between 26 completed weeks to 34 completed weeks with clinical diagnosis of RDS without any major congenital anomalies.
62018886|NCT06535087||Allergic disease group|Receiving: 1) Subcutaneous immunotherapy and 2) Standard Treatment for Asthma and Rhinitis.
62018887|NCT06535087||Healthy control Group|Healthy children aged 5-16 from the Shanghai region, with no history of allergic diseases, and without any intervention.
62018888|NCT02966080|OTHER|Adjusted-dose heparin|Patients in this arm of the study will receive intravenous unfractionated heparin at a dose adjusted to achieve an activated clotting time of 180-200 seconds.
62018889|NCT02966080|OTHER|Fixed low-dose heparin|Patients in this arm of the study will receive intravenous unfractionated heparin at 500 units/hour without activated clotting time monitoring.
62582583|NCT05600621|EXPERIMENTAL|Condition 4: Components 1 and 2|"1. Financial Literacy Training (FLT) Workshops~2. Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)"
62582584|NCT05600621|EXPERIMENTAL|Condition 5: Components 1,3 and 4|"1.Financial Literacy Training (FLT) Workshops~3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
62018890|NCT06272916||sample size of 630 cases was calculated, divided equally into three groups.|"For sample size calculation using Yousefshahi et al. (14) as a reference, a sample size of 630 cases was calculated, divided equally into three groups. This sample size achieves 80% power when the effect size is moderate (=0.12) and using 2 degrees of freedom Chi-Squared test with a significant level of 0.05. Using computer generated randomization program, patients were randomly divided into three equal groups.~Group 1: patient received 100 ml IV infusion of normal saline (control group). Group 2: patient received Aminophylline 1.5 mg/kg IV infusion diluted in normal saline with a total volume of 100 ml.~Group 3: patient received 50 mg/ kg Magnesium sulfate IV infusion diluted in normal saline with a total volume of 100ml."
62018891|NCT06434532|EXPERIMENTAL|v-Care online game|"the v-Care online game consist of a clinical scenario. Participants are requested to join the online game in small groups, consisting of nursing and radiography students, to discuss the patient's condition presented in the scenario. They will also be required to watch relevant mini-videos that cover the knowledge check points within the game.~As part of the activity, participants will be expected to submit a mini interprofessional project that explains their respective roles and responsibilities in managing the patient's condition.~To enhance engagement and motivation, an online game reward system has been implemented. This system includes the opportunity to earn badges upon completing the knowledge check points or participating in learning activities such as watching tutorials or engaging in interprofessional discussions. These discussions will be recorded and summarized to highlight the key points of their conversation."
62210069|NCT04860297|EXPERIMENTAL|mRNA-1273|"Part A: All participants (healthy participants and SOT participants) who were unvaccinated prior to enrollment will receive 2 intramuscular (IM) injections of 100 microgram (µg) mRNA-1273 on Day 1 and Day 29.~All SOT participants who were unvaccinated prior to enrollment will be offered the opportunity to receive a third primary dose of mRNA-1273 at Day 85 as per the emergency use authorization (EUA) Fact Sheet available at the time of protocol finalization.~SOT participants who were previously vaccinated with 2 doses of Moderna COVID-19 vaccine under the EUA prior to enrollment will receive Dose 3 on Day 1.~Part B: All eligible participants from Part A will be offered to receive a 100 µg booster dose of mRNA-1273 who are at least 4 months from the last dose. SOT recipients who completed primary COVID-19 vaccination series under EUA (outside of the mRNA-1273-P304 study) will receive a 100 µg booster dose on booster dose Day 1."
62210070|NCT04303715|EXPERIMENTAL|No SLNB group|The study arm - BCS without SLNB
62210071|NCT04303715|OTHER|SLNB group|The Control Arm - BCS with SLNB(+/-ALND)
62582585|NCT05600621|EXPERIMENTAL|Condition 6: Components 1 and 3|"1.Financial Literacy Training (FLT) Workshops~3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)"
62582586|NCT05600621|EXPERIMENTAL|Condition 7: Components 1 and 4|"1.Financial Literacy Training (FLT) Workshops~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
62582587|NCT05600621|EXPERIMENTAL|Condition 8: Components 1|1.Financial Literacy Training (FLT) Workshops
62582588|NCT05600621|EXPERIMENTAL|Condition 9: Components 2,3 and 4|"2.Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
62582589|NCT05600621|EXPERIMENTAL|Condition 10: Components 2 and 3|"2.Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)"
62582590|NCT05600621|EXPERIMENTAL|Condition 11: Components 2 and 4|"2.Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
62582591|NCT05600621|EXPERIMENTAL|Condition 12: Components 2|2.Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)
62582592|NCT05600621|EXPERIMENTAL|Condition 13: Components 3 and 4|"3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
62582593|NCT05600621|EXPERIMENTAL|Condition 14: Components 3|3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)
62582594|NCT05600621|EXPERIMENTAL|Condition 15: Components 4|4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV.
62582595|NCT05600621|EXPERIMENTAL|Condition 16: No Components|Participants not assigned to any of the 4 components
62582596|NCT06299878||Group 1|Neoadjuvant
62582597|NCT01075256|ACTIVE_COMPARATOR|5% calcium sodium phosphosilicate toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste.
62210072|NCT06593496|EXPERIMENTAL|Text Message|Participants assigned to the interventional group will receive a text message reminding them to take their blood pressure.
62582598|NCT01075256|ACTIVE_COMPARATOR|7.5% calcium sodium phosphosilicate toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste.
62210073|NCT06593496|NO_INTERVENTION|Control/No Text Message|Those assigned to the usual care group will not receive a reminder text message.
62210074|NCT03112460||all patients|all of patients who went through basic and advanced cardiopulmonary resuscitations would be analyzed
62210075|NCT06471504|EXPERIMENTAL|Children Undergoing Developmental Evaluation|Children undergoing a standard of care developmental evaluation will be enrolled into the study. After the completion of the developmental evaluation, research participation includes a one-time eye-tracking activity in which the child will view a series of different pictures and movies while their eye movements are tracked and recorded.
62582599|NCT01075256|PLACEBO_COMPARATOR|Placebo toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with placebo toothpaste.
62582600|NCT01483339|EXPERIMENTAL|Metacognitive Therapy|
62582601|NCT01483339|EXPERIMENTAL|Exposure and Response Prevention|
62582602|NCT06181266|EXPERIMENTAL|Dose Level 1 - ZH9|Part 1 will evaluate SAD of ZH9 administered as an IVI in patients with recurrent NMIBC. A standard 3+3 escalation design will be employed with the dose levels
62582603|NCT06181266|EXPERIMENTAL|Dose Level 2 - ZH9|Part 1 will evaluate SAD of ZH9 administered as an IVI in patients with recurrent NMIBC. A standard 3+3 escalation design will be employed with the dose levels
62582604|NCT06181266|EXPERIMENTAL|Dose Level 3 - ZH9|Part 1 will evaluate SAD of ZH9 administered as an IVI in patients with recurrent NMIBC. A standard 3+3 escalation design will be employed with the dose levels
62582605|NCT06181266|EXPERIMENTAL|Dose Level 4 - ZH9|Part 1 will evaluate SAD of ZH9 administered as an IVI in patients with recurrent NMIBC. A standard 3+3 escalation design will be employed with the dose levels
62018892|NCT06434532|ACTIVE_COMPARATOR|Case-based online discussion|"Participants are requested to engage in case-based discussions within small groups, comprising nursing and radiography students. As part of this activity, students are required to complete a conventional assignment using a worksheet, which will allow them to elaborate on their individual roles and responsibilities in managing the patient's condition.~In addition, students are encouraged to utilize traditional learning and teaching methods by reading and exploring relevant materials pertaining to the patient's condition."
62018893|NCT03175640|EXPERIMENTAL|Implementation intervention|
62018894|NCT02227160|EXPERIMENTAL|Psychosocial group intervention|Subjects will seek outpatient counseling, support groups, in addition to 10 weekly group meetings
62018895|NCT02227160|ACTIVE_COMPARATOR|Control|Subjects will seek outpatient counseling and support groups only
62018896|NCT05685485||Standard Implantation|Standard Implantation
62018897|NCT05685485||Tied off Tube|Tied off Tube
62018898|NCT03526913|EXPERIMENTAL|PRP + STSG|autologous PRP treatments every week prior to graft placement (STSG)
62018899|NCT03526913|ACTIVE_COMPARATOR|STSG Split Thickness Skin Graft|skin graft (STSG) (intervention)
62018900|NCT02591394|EXPERIMENTAL|STEP Clinic|
62018901|NCT02591394|ACTIVE_COMPARATOR|Usual Care|
62018902|NCT01197040|EXPERIMENTAL|B-Experimental|Experimental
62018903|NCT01197040|ACTIVE_COMPARATOR|A-Active Comparator|Active Comparator
62018904|NCT04909697|SHAM_COMPARATOR|Saline|
62018905|NCT04909697|EXPERIMENTAL|Sivelestat Sodium|
62018906|NCT01804959|PLACEBO_COMPARATOR|Active vs Placebo|In phase I, subjects will be randomized into either the Vivomixx probiotics or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotics (4 sachets/ day or 1800 billion bacteria/day) or placebo (4 placebo sachets/day) for the first 60 days.
62018907|NCT01804959|ACTIVE_COMPARATOR|60 days of Active vs 120 days of Active|In phase II, subjects from both arms in phase I will receive Vivomixx probiotics 4 sachets/ day for another 60 days. Comparison will be made between the arm receiving 60 days of Vivomixx probiotics vs 120 days of Vivomixx probiotics
62018908|NCT05517239|EXPERIMENTAL|Gemcitabine, Oxaliplatin|Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
62018909|NCT03701659|EXPERIMENTAL|TUPKRP+MAB Group|These patient will be treated by TUPKRP and MAB.
62018910|NCT03701659|ACTIVE_COMPARATOR|MAB Group|These patient will be treated by MAB only.
62018911|NCT00397423|ACTIVE_COMPARATOR|1|1,G-CSF,intervention
62018912|NCT00397423|PLACEBO_COMPARATOR|2|2,NS,intervention
62018913|NCT03250000||COPD-stable|Stable COPD patients at pulmonology consultation in Ziekenhuis Oost-Limburg (ZOL) Genk
62210076|NCT05618808|EXPERIMENTAL|REGN9933|REGN9933 will be administered by intravenous (IV) infusion
62210077|NCT05618808|ACTIVE_COMPARATOR|Enoxaparin|Enoxaparin will be administered by subcutaneous (SC) administration
62210078|NCT05618808|ACTIVE_COMPARATOR|Apixaban|Apixaban will be administered orally twice a day
62210079|NCT01420887|EXPERIMENTAL|Continuous Passive Motion|Subjects randomized to CPM therapy.
62210080|NCT01420887|ACTIVE_COMPARATOR|Physical Therapy|Subjects randomized to physical therapy.
62210081|NCT04377685||COVID19 patients|Patient tested positive for SARS-CoV-2 who had a CT scan
62582606|NCT05797935|NO_INTERVENTION|Placebo group|Only the standard drugs for type 2 diabetes were given. Dapagliflozin was not given in this group.
62582607|NCT05797935|ACTIVE_COMPARATOR|Dapagliflozin group|The patients were given standard drugs for type 2 diabetes and Dapagliflozin.
62582608|NCT03774498|ACTIVE_COMPARATOR|Sensodyne repair and protect|NovaMin \& fluoride toothpaste
62582609|NCT03774498|NO_INTERVENTION|Sensodyne Daily Care Toothpaste 0.315%|Sodium fluoride toothpaste
62582610|NCT04563884||Patients with deafness|Patients aged 12 months to 17 years with deafness
62582611|NCT04563884||Controls|Normal-hearing patients aged 12 months to 17 years
62407328|NCT01256086|EXPERIMENTAL|24 µg Formoterol Novolizer|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
62407329|NCT01256086|EXPERIMENTAL|12µg Formoterol Novolizer|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
62407330|NCT01256086|ACTIVE_COMPARATOR|24 µg Formoterol Aerolizer|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
62407331|NCT01256086|ACTIVE_COMPARATOR|12µg Formoterol Aerolizer|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
62407332|NCT05847309|ACTIVE_COMPARATOR|Early extubation|Patients randomized to early extubation, will be extubated \< 6 hours after endovascular treatment under general anesthesia.
62582612|NCT03146208||Coronary artery disease patients with type 2 DM|Coronary artery disease patients with type 2 diabetes (age 20-55 years). The present study will be carried on 25 patients attending to cardiology department with coronary artery disease with type 2 diabetes
62582613|NCT03146208||Coronary artery disease patients without type 2 DM|The present study will be carried on 29 patients attending to cardiology department with coronary artery disease without type 2 diabetes (age 20-55 years).
62582614|NCT03146208||Healthy control group|we will include 54 age-matched patients with normal angiogram
62582615|NCT01089608|PLACEBO_COMPARATOR|Unifluid|Eye drops in Single Dose Unit
62210082|NCT01609244|ACTIVE_COMPARATOR|Bilevel|Bilevel therapy
62210083|NCT01609244|ACTIVE_COMPARATOR|Servoventilation|servoventilation therapy
62210084|NCT01008410|EXPERIMENTAL|Budesonide|Participants who were diagnosed with active mild to moderate UP or UPS, will receive 2 milligrams (mg)/25 milliliter (mL) of budesonide foam, rectally twice daily for a period of 2 weeks followed by 2 mg/25 mL of budesonide foam, rectally once daily for a period of 4 weeks.
62407333|NCT05847309|EXPERIMENTAL|Delayed extubation|Patients randomized to delayed extubation, will be extubated 6-12 hours after endovascular treatment under general anesthesia.
62407334|NCT05158972||Dymista®|Dymista® (Azelastine hydrochloride and Fluticasone propionate) nasal spray as prescribed within routine clinical practice
62407335|NCT00690846|EXPERIMENTAL|1|40 mg weekly subcutaneous injection of adalimumab
62407336|NCT05922540||those with favorable prognosis|
62407337|NCT05922540||those with unfavorable prognosis|
62407338|NCT05159713|OTHER|Treatment as Usual (TAU)|Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.
62407339|NCT05159713|EXPERIMENTAL|dCBI + Treatment as Usual|Participants randomly assigned to the intervention group (dCBI+TAU) will receive standard care and also gain access to the dCBI. The dCBI, RxWell, is a trans-Cognitive Behavioral Therapy (CBT) mobile app product addressing depression and anxiety that was developed based on standard CBT techniques.
62582616|NCT01089608|EXPERIMENTAL|Azithromycin|Eye drops Single dose unit
62582617|NCT01987739|EXPERIMENTAL|Arm 1|Subjects were randomized to receive single, oral doses of study medication in the sequence ABFCED, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
62582618|NCT01987739|EXPERIMENTAL|Arm 2|Subjects were randomized to receive single, oral doses of study medication in the sequence BCADFE, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
62582619|NCT01987739|EXPERIMENTAL|Arm 3|Subjects were randomized to receive single, oral doses of study medication in the sequence CDBEAF, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
62582620|NCT01987739|EXPERIMENTAL|Arm 4|Subjects were randomized to receive single, oral doses of study medication in the sequence DECFBA, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
62735050|NCT02720523|EXPERIMENTAL|Placebo / Upadacitinib 30 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks."
62018914|NCT03250000||COPD-Ex|Patients admitted to the respiratory ward of ZOL Genk with a diagnosis of acute exacerbation, based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
62018915|NCT02991209|EXPERIMENTAL|Tostran 2%|1 years treatment with transdermal Tostran 2%
62018916|NCT02991209|PLACEBO_COMPARATOR|Placebo|1 years treatment with placebo gel
62018917|NCT02065466|EXPERIMENTAL|Combination|nab-paclitaxel and temozolomide combined with full dose of bevacizumab
62018918|NCT01746823||Controls, Keratoconus|Sub group of Keratoconus to be treated with anti-inflammatory agents ie Cyclosporine-A
62018919|NCT05961293|OTHER|Control Cohort (Healthy Cohort)|Healthy participants who participate in 1 study visit. The healthy participant will undergo one functional MRI which using the NeuroGlove.
62210085|NCT01008410|PLACEBO_COMPARATOR|Placebo|Participants who were diagnosed with active mild to moderate UP or UPS will receive 25 mL of placebo matching to budesonide foam twice daily for a period of 2 weeks followed by once daily for a period of 4 weeks.
62210086|NCT02791178||STEMI patients|"The patients presenting with a STEMI and undergoing PPCI will be screened and approached to participate in this study.~All patients to do Optical Coherence Tomography (OCT), Index of Microcirculatory Resistance (IMR) and Cardiac MRI."
62210087|NCT00886795|EXPERIMENTAL|Abatacept|4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 weeks, and 8 weeks.
62210088|NCT03055052|ACTIVE_COMPARATOR|Control Formula|Standard formula for preterm infants.
62210089|NCT03055052|EXPERIMENTAL|Experimental formula|Formula with higher protein and new fat blend for preterm infants.
62210090|NCT05029713||liver transplanted patients without sarcopenic obesity (controls)|All liver transplanted patients followed as outpatients at out clinic, which lack at least one of the two conditions (muscle strenght and muscle mass) used to identify sarcopenic obesity.
62210091|NCT05029713||liver transplanted patients with sarcopenic obesity (cases)|All liver transplanted patients followed as outpatients at out clinic, with both muscle strenght and muscle mass.
62018920|NCT05961293|EXPERIMENTAL|Treatment Arm|The treatment cohort will undergo two functional MRIs once at baseline and the final fMRI will occur six weeks after initial study visit after daily use of the NeuroGlove.
62018921|NCT05413538|EXPERIMENTAL|Experimental Group|The experimental group will be invited to listen to a 15-minute mindfulness instructional recording delivered daily through an instant messaging application and to practice accordingly for 14 consecutive days at their own choice of time and place.
62210092|NCT01787149|PLACEBO_COMPARATOR|Placebo|DMARDs alone
62210093|NCT01787149|EXPERIMENTAL|ENIA11|ENIA11 25 mg
62210094|NCT02885844|EXPERIMENTAL|INVERTED VISION|inverted vision (upside down) using commercial off-the-shelf inverting prism goggles
62210095|NCT02885844|ACTIVE_COMPARATOR|NORMAL VISION|During normal vision trials, subject's field of view will be restricted by goggles without lenses (see below) in order to be equivalent to the inverted vision one.
62210096|NCT03181789|EXPERIMENTAL|Group 1 (Treatment): p24CE1/2 pDNA + p55^gag pDNA + IL-12 pDNA|Participants will receive the p24CE1/2 pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Month 1. They will receive the p24CE1/2 pDNA vaccine plus the p55\^gag pDNA vaccine and the IL-12 pDNA adjuvant at Months 3 and 6.
62210097|NCT03181789|PLACEBO_COMPARATOR|Group 1 (Control): Placebo|Participants will receive placebo at Day 0 and Months 1, 3, and 6.
62210098|NCT03181789|EXPERIMENTAL|Group 2 (Treatment): p55^gag pDNA + IL-12 pDNA|Participants will receive the p55\^gag pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Months 1, 3, and 6.
62210099|NCT03181789|PLACEBO_COMPARATOR|Group 2 (Control): Placebo|Participants will receive placebo at Day 0 and Months 1, 3, and 6.
62210100|NCT02019667|EXPERIMENTAL|Placebo|Participants with SSADH Deficiency when on placebo for six months
62582621|NCT01987739|EXPERIMENTAL|Arm 5|Subjects were randomized to receive single, oral doses of study medication in the sequence EFDACB, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
62582622|NCT01987739|EXPERIMENTAL|Arm 6|Subjects were randomized to receive single, oral doses of study medication in the sequence FAEBDC, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
62407340|NCT06651164|EXPERIMENTAL|Intervention: psychosocial risk screening conducted|Patients in the intervention group are interviewed during admission on possible risk factors using the tablet-based screening questionnaire. The survey takes about 10 minutes. Once the screening has been completed, the results are immediately evaluated electronically and can be viewed by the person carrying out the screening. The patient is informed of the result (conspicuous/not conspicuous). If the psychosomatic screening is positive, the patient is asked if she/he is willing to be visited by a psychosomatic consultant. This contact will last about 15-45 minutes. If the social services screening is positive, the social services will introduce themselves in any case. Depending on the needs for regulation or counseling, this will result in a contact of 10-45 minutes. We use established and validated metrics and questionnaires.
62407341|NCT06651164|NO_INTERVENTION|Control: psychosocial risk screening is not conducted|Patients assigned to the control group will be treated as usual. Besides medical treatment this may also include consultations from a psychosomatic specialist and/or a social worker if the patient asks for it or the staff deems it necessary.
62407342|NCT02351297|EXPERIMENTAL|Casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
62407343|NCT02351297|EXPERIMENTAL|Soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
62407344|NCT02351297|PLACEBO_COMPARATOR|Maltrodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
62582623|NCT01366235|EXPERIMENTAL|Southeast Asians|
62582624|NCT01366235|EXPERIMENTAL|Korean|
62582625|NCT01366235|EXPERIMENTAL|Caucasians|
62018922|NCT05413538|NO_INTERVENTION|Waitlist control group|The waitlist control group will only be required to complete the demographic information, pre, post experiment and follow-up questionnaires before they receive the mindfulness training intervention.
62018923|NCT06535698|EXPERIMENTAL|Hormonal Balance Support Supplement|"Participants in this arm will receive Perelel Health hormonal balance support capsules. The dosage regimen is as follows:~Week 1: 1 capsule daily in the evening Week 2: 2 capsules daily in the evening Weeks 3-12: 4 capsules daily (2 in the morning and 2 in the evening) The supplement contains Myo-inositol (1000 mcg), Metabolic balance blend (200 mcg) including Berberine HCl, Alpha lipoic acid, DIM (33'-Diindolylmethane), and D-chiro-inositol (25 mg). Other ingredients include Vegetable cellulose (capsule), plant cellulose, and L-leucine."
62018924|NCT00499889|EXPERIMENTAL|Imatinib, Busulfan, Fludara + Antithymocyte Globulin|Oral Imatinib Mesylate 400 mg twice a day for 9 Days; Busulfan 130 mg/m\^2 by vein (IV) daily for 2 Days; Fludara 40 mg/m\^2 IV daily for 4 Days; Antithymocyte Globulin (ATG) 2.5 mg/kg IV daily for 3 Days; Tacrolimus levels maintained between 5-15 ng/dl, Day -2 to Day 180; Methotrexate 5 mg/m2 on days 1, 3, 6 and 11; and Donor bone marrow or blood stem cells infused on day 0 with possible donor lymphocyte infusion (DLI) for progressive disease.
62210101|NCT02019667|EXPERIMENTAL|Study Drug|Participants with SSADH Deficiency receiving SGS-742 when on study drug for six months
62210102|NCT03525392|EXPERIMENTAL|177Lu-3BP-227|"Screening: 177Lu-IPN01087 - 25 µg 3BP-227 (IPN01087) per 1 GBq of 177Lu. 1 GBq in a total volume of 10 mL.~Treatment phase: 177Lu-IPN01087 - 2.5 to 7.5 GBq escalation dose of 177Lu-3BP-227 (IPN01087) in a total volume of 20 mL for each cycle of administration (2 cycles plus 4 optional additional)."
62210103|NCT00591851|EXPERIMENTAL|1|single arm study
62210104|NCT04734054|EXPERIMENTAL|Rapid maxillary expansion|The rapid maxillary expansion will be conducted using bonded modified Hyrax palatal expander. The expander will be activated twice daily (0.4 mm) until an overcorrection of 2-3 mm will be gained.
62210105|NCT04734054|ACTIVE_COMPARATOR|Slow maxillary expansion|The slow maxillary expansion using a removable plate with a midline screw will be accomplished. The expander will be activated twice weekly until an overcorrection of 2-3 mm will be gained.
62210106|NCT06727630|EXPERIMENTAL|Monotherapy Escalation / Monotherapy Backfill|"Dose escalation arm with PRJ1-3024 which will begin with 3-6 subjects treated at the lowest planned dose level based on previous phase Ia study results. PRJ1-3024 is administered orally once daily. The starting dose is 300mg/day.~After the small dose escalation, one or two dose backfill group will be tested to further explore the efficacy and safety of China patients with unresectable local advanced or metastatic melanoma."
62210107|NCT02192528||cardiac surgical patients|patients undergoing a cardiac surgical procedure
62210108|NCT04512859|EXPERIMENTAL|Stellate Ganglion Block|"Experimental patients will receive a stellate ganglion block with 0.25% ropivacaine 10mL on the same side of vasospasm at the level of the sixth cervical vertebrae (C6) before surgery.~Patients were then assessed using transcranial Doppler"
62407345|NCT02387723|EXPERIMENTAL|Stem cell therapy|Treatment with direct intra-myocardial Injection of 100 million allogeneic adipose derived stem cells (CSCC_ASC) into the heart
62582626|NCT01366235|EXPERIMENTAL|Africans|
62582627|NCT00411242|EXPERIMENTAL|1|
62582628|NCT00411242|EXPERIMENTAL|2|
62582629|NCT00411242|PLACEBO_COMPARATOR|3|
62018925|NCT01640301|EXPERIMENTAL|Arm I (high-risk for relapse after HCT)|Patients with no evidence of leukemia or MDS post-HCT receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 14 and aldesleukin SC BID on days 14-28.
62018926|NCT01640301|EXPERIMENTAL|Arm II (relapsed after HCT)|Patients with evidence of AML (minimal residual disease or overt relapse) post-HCT receive cyclophosphamide IV and fludarabine phosphate IV daily on days -4 to -2. Patients also receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 21 and aldesleukin SC BID on days 14-28.
62018927|NCT02889549|EXPERIMENTAL|Ticagrelor 22.5 mg|Ticagrelor (22.5 mg, twice daily, oral) treatment for 1 month.
62018928|NCT02889549|EXPERIMENTAL|Ticagrelor 45 mg|Ticagrelor (45 mg, twice daily, oral) treatment for 1 month.
62018929|NCT02889549|EXPERIMENTAL|Ticagrelor 90 mg|Ticagrelor (90 mg, twice daily, oral) treatment for 1 month.
62018930|NCT02889549|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel (75mg, once daily, oral) treatment for 1 month.
62018931|NCT04596163|ACTIVE_COMPARATOR|Intervention|Ultrasound guided Regional block using 0.25% levobupivacaine (local anaesthetic agent) 20ml (50mg) on each side of the sternum over 1-2 minutes after general anaesthesia before surgery.
62018932|NCT04596163|PLACEBO_COMPARATOR|Control|Ultrasound guided Regional block using 20ml of 0.9% normal saline on each side of the sternum after general anaesthesia before surgery.
62018933|NCT06202261|EXPERIMENTAL|TQB2930 for injection|TQB2930 for injection,10 mg/kg, quaque week (QW), 21 day as a treatment cycle; TQB2930 for injection, 20 mg/kg, quaque 2 weeks (Q2W), 28 day as a treatment cycle; TQB2930 for injection,30 mg/kg, quaque 3 weeks (Q3W), 21 day as a treatment cycle.
62018934|NCT06202261|EXPERIMENTAL|TQB2930 for injection 30mg/kg + Paclitaxel for injection (albumin-bound)|TQB2930 for injection 30mg/kg combined with paclitaxel (albumin-bound) for injection, 21 days for one treatment cycle
62018935|NCT06202261|EXPERIMENTAL|TQB2930 for injection+TQB3616 capsule for injection + fulvestrant injection|TQB2930 for injection 20mg/kg combined with TQB3616 capsule 120mg or 150mg or 180mg, and fulvestrant injection. Q2W, 28 days a cycle.
62018936|NCT06202261|EXPERIMENTAL|TQB2930 for injection + chemotherapy|TQB2930 for injection 30mg/kg combined with capecitabine tablets or vinorelbine tartrate injection or eribulin mesylate injection or gemcitabine hydrochloride for injection, 21 days a cycle.
62210109|NCT04512859|PLACEBO_COMPARATOR|No Stellate Ganglion Block|"patients will receive a stellate ganglion block with 0.9% saline 10mL on the same side of vasospasm at the level of the sixth cervical vertebrae (C6) before surgery.~Patients were then assessed using transcranial Doppler"
62210110|NCT05523505|SHAM_COMPARATOR|Sham stimulation|Participants receiving sham stimulation.
62407346|NCT03690375|EXPERIMENTAL|BBL Left|Left arm selected to be treated with BBL, right arm not treated
62018937|NCT02174536|ACTIVE_COMPARATOR|Decidual Stromal cell therapy|Decidual stromal cell therapy (approximately 1x10\^6 cells/kg) for hemorrhagic cystitis in addition to Misoprostol therapy (0,2mg, 3 times/day) on two occasions at weekly intervals.
62018938|NCT02174536|PLACEBO_COMPARATOR|Placebo|Receives placebo (masked i.v. infusion, same amount as an infusion of decidual stromal cells) in addition to Misoprostol therapy (0,2mg, 3 times/day).
62407347|NCT03690375|EXPERIMENTAL|BBL Right|Right arm selected to be treated with BBL, left arm not treated
62407348|NCT02376582|EXPERIMENTAL|DNA and protein|4mg DNA and 600 mcg protein formulated with Alum co-administration (IM) at Month 0, 1 and 6 in Schisto infected individuals
62018939|NCT02721212|EXPERIMENTAL|Armeo Spring|"All patients of experimental group were treated according to an established protocol for ARMEO Spring. In the first session the device was adjusted for patients arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station.~Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment 5 days per week, for 6 weeks."
62210111|NCT05523505|EXPERIMENTAL|Reading and Language Network (RLN)|Participants receiving real stimulation to the left angular gyrus and left temporal pole.
62407349|NCT02376582|ACTIVE_COMPARATOR|Vaccination without S. mansoni infection|DNA Protein
62407350|NCT01016366|EXPERIMENTAL|Lu AA24493|
62407351|NCT01016366|PLACEBO_COMPARATOR|Placebo|
62210112|NCT05523505|EXPERIMENTAL|Cognitive Control Network (CCN)|Participants receiving real stimulation to the bilateral dorsolateral prefrontal cortices.
62210113|NCT05523505|EXPERIMENTAL|RLN and CCN|Participants receiving real stimulation to the left dorsolateral prefrontal cortex and left angular gyrus.
62407352|NCT03659032|EXPERIMENTAL|Pediatric Manual Therapy Group|"10 sessions of Pediatric Manual Therapy, once a week. Soft cervical mobilisation, myofascial induction and cranial techniques will be administered. Educational physiotherapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be also administered."
62582630|NCT06668519||children with neurodevelopmental diseases|
62407353|NCT03659032|ACTIVE_COMPARATOR|Control Group|"Only Educational Physical Therapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be administered."
62582631|NCT06668519||healthy children|
62018940|NCT02721212|ACTIVE_COMPARATOR|Control Group|"The conventional treatment, under control of physiotherapist, consists of passive and active assisted mobilization of the upper limbs traditional training based on the Bobath concept (neuromuscular facilitation, postural control and proprioception exercises, verticalization and gait training).~Each training session consisted of 60 minutes with conventional treatment 5 days per week, for 6 weeks in a control group.~The conventional session in the experimental group lasted 30 minutes with the same techniques and methods."
62018941|NCT01020201||PONV group|patients with postoperative nausea and vomiting
62018942|NCT01020201||Control group|patients without postoperative nausea and vomiting
62018943|NCT03013647|OTHER|Actinic Keratosis|Twenty patients with multiple thin AK on the face will be treated with Daylight Photodynamic Therapy with methyl aminolevulinate Skin biopsies before and after treatment will be performed in an AK lesion and in a field cancerization area.
62018944|NCT03791398|EXPERIMENTAL|ONC201 Level 1 (Starting Dose Level)|625mg ONC201 Cycle 1 Day -7 dose then once week
62018945|NCT03791398|EXPERIMENTAL|ONC201 Level 2|500 mg ONC201 Cycle 1 Day -7 dose then once week
62407354|NCT02351050|EXPERIMENTAL|Sonolysis|continual transcranial Doppler monitoring with maximal intensity during endovascular procedure
62582632|NCT01881490|ACTIVE_COMPARATOR|Group 1|120 Children with Crohn's disease undergoing MRE \& colonoscopy will be enrolled and followed for 18 months. MRE exam will be repeated at 18 months.
62018946|NCT03791398|EXPERIMENTAL|ONC201 Level 3|375 mg ONC201 Cycle 1 Day -7 dose then once week
62018947|NCT03791398|EXPERIMENTAL|Nivolumab|240mg IV flat dose q 2 weeks
62018948|NCT06662604|EXPERIMENTAL|Group A (Stem cells ,PRF group) intervention group|
62018949|NCT06662604|ACTIVE_COMPARATOR|Group B (PRF group)|
62018950|NCT03856346||Phaco-vitrectomy|
62018951|NCT01471535|EXPERIMENTAL|peginterferon alpha 2a|the inactive chronic HBsAg carriers were treated with peginterferon alpha 2a for 72 weeks and followed for 24 weeks.
62018952|NCT03868904||OCS Lung INSPIRE Trial|
62018953|NCT03774641||Taking Lamotrigine|Lamotrigine (Lamictal), dosage will be based on a reference concentration of blood-serum levels
62018954|NCT02042482|EXPERIMENTAL|Coenzyme Q10U, L-carnitine|Patients receive combination of coenzyme Q10U 180 milligram and L-carnitine 2000 milligram
62407355|NCT02351050|PLACEBO_COMPARATOR|placebo|sham transcranial Doppler monitoring during endovascular procedure
62407356|NCT02454699|EXPERIMENTAL|1000mg MBX400|6 subjects receive 1000 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
62407357|NCT02454699|EXPERIMENTAL|100mg MBX400|6 subjects receive 100 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
62407358|NCT02454699|EXPERIMENTAL|350mg MBX400|6 subjects receive 350 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
62407359|NCT02454699|EXPERIMENTAL|750mg MBX400|6 subjects receive 750 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
62582633|NCT01881490|ACTIVE_COMPARATOR|Group 2|120 children with Crohn's disease undergoing colonoscopy will be recruited and will have an MRE/pelvic MRI performed. The two or three contending versions of each index (PICMI and pMEDIC) developed based on Group 1, will be then subjected to head-to-head evaluation of Group 2.
62582634|NCT02233764|EXPERIMENTAL|FeZnPM|The FeZnPM arm will consume iron- and zinc-biofortified pearl millet (ICTP8203-Fe).
62018955|NCT01972061|EXPERIMENTAL|CMG group|Foot stimulation will be applied during a cystometrogram (CMG).
62018956|NCT01972061|ACTIVE_COMPARATOR|3 hours group|Foot stimulation will be applied daily for 3 hours in the evening.
62582635|NCT02233764|ACTIVE_COMPARATOR|CtrlPM|The CtrlPM arm will consume conventional pearl millet three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
62582636|NCT01055275||Cook Iliac Branch Graft|Patients implanted with a Cook Iliac Branch Graft
62210114|NCT03391817|ACTIVE_COMPARATOR|Intervention arm|Fecal transplant from a thin donor
62018957|NCT01972061|ACTIVE_COMPARATOR|1/2 hour group|Foot stimulation will be applied daily for 1/2 hour in the evening.
62582637|NCT01081444|ACTIVE_COMPARATOR|1|Active rTMS
62210115|NCT03391817|PLACEBO_COMPARATOR|Placebo arm|Fecal transplant made from patients own feces
62582638|NCT01081444|PLACEBO_COMPARATOR|2|sham rTMS
62582639|NCT01888445|EXPERIMENTAL|ASP1517 Low dose group|Participants received an oral dose of ASP1517 three times a week.
62018958|NCT01972061|ACTIVE_COMPARATOR|3 hour hand group|Hand stimulation will be applied daily for 3 hours in the evening.
62018959|NCT05758662||Intra-annular|Patients with an intra-annular Sapien TAVI prosthesis
62210116|NCT00548262|EXPERIMENTAL|1|
62210117|NCT05767060|EXPERIMENTAL|BAT7104 Injection 0.1 mg/kg|frequency: Q2W
62582640|NCT01888445|EXPERIMENTAL|ASP1517 Middle dose group|Participants received an oral dose of ASP1517 three times a week.
62582641|NCT01888445|EXPERIMENTAL|ASP1517 High dose group|Participants received an oral dose of ASP1517 three times a week.
62582642|NCT01888445|ACTIVE_COMPARATOR|Darbepoetin group|Participants received Darbepoetin alfa intravenously once a week.
62210118|NCT05767060|EXPERIMENTAL|BAT7104 Injection 0.3 mg/kg|frequency: Q2W
62210119|NCT05767060|EXPERIMENTAL|BAT7104 Injection 1 mg/kg|frequency: Q2W
62210120|NCT05767060|EXPERIMENTAL|BAT7104 Injection 3 mg/kg|frequency: Q2W
62582643|NCT03831932|EXPERIMENTAL|Treatment (telaglenastat HCl, osimertinib)|Patients receive telaglenastat hydrochloride PO BID and osimertinib PO QD (starting cycle 1 day 16 of phase I). Patients undergo blood sample collection and may undergo x-ray imaging, CT scan, MRI, or PET scan throughout the study. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62582644|NCT06682858|EXPERIMENTAL|Group Cognitive Behavioural Therapy|
62582645|NCT01268930|ACTIVE_COMPARATOR|Bipolar coagulation|In this arm, after the complete excision of ovarian endometrioma, ovarian hemostasis is provided by bipolar electrocoagulation.
62582646|NCT01268930|ACTIVE_COMPARATOR|Hemostatic matrix|In this arm, after complete excision of ovarian endometrioma, ovarian hemostasis is provided by hemostatic matrix.
62582647|NCT02887248|EXPERIMENTAL|nab-paclitaxel+gemcitabine|"Induction Phase: nab-paclitaxel (125 mg/m²) and gemcitabine (1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle. Responding or stable patients will be treated with a minimum of 3 cycles and up to 6 cycles before starting the single agent maintenance therapy.~Maintenance Phase: Patients completing 3-6 cycles of induction therapy with an objective response (complete or partial response) or stable disease will continue treatment with single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment."
62582648|NCT01188174|EXPERIMENTAL|Clofarabine|
62018960|NCT05758662||Supra-annular|Patients with a supra-annular CoreValve Evolut TAVI prosthesis
62407360|NCT05375110|EXPERIMENTAL|NoYA™ Radiofrequency Interatrial Shunt System|Eligible patients will be enrolled and undergo radiofrequency ablation of the interatrial procedure with the NoYA™ Radiofrequency Interatrial Shunt System (Noya Medtech).
62018961|NCT06116773|EXPERIMENTAL|Training Group|Training group, in addition to secondary prevention approaches and home exercise program, will be applied 3 sessions/week, 60 minutes of supervised cardiac rehabilitation program for 8 weeks.
62018962|NCT06116773|ACTIVE_COMPARATOR|Control Group|Control group will be informed about secondary prevention approaches and a home exercise program will be recommended.
62018963|NCT02639884|EXPERIMENTAL|Evaluation Group|All subjects will be enrolled into the evaluation group and will receive SedLine EEG and RRa monitoring
62018964|NCT01759745||Blepharospasm|Blepharospasm, patient's group
62018965|NCT01759745||Control|Healthy control subjects
62018966|NCT02480621|NO_INTERVENTION|Control|Standard of care: Open Reduction Internal Fixation with no injection of pain medications around the affected ankle.
62018967|NCT02480621|EXPERIMENTAL|Liposomal Bupivacaine with Bupivacaine|Intra-operatively, patients receive a local injection of liposomal bupivacaine with bupivacaine around the affected ankle.
62018968|NCT01491477|EXPERIMENTAL|INFUSE™ Bone Graft|
62018969|NCT01491477|ACTIVE_COMPARATOR|Autogenous bone|
62018970|NCT00780845||AKI (-)|Patients without acute kidney injury after on-pump CABG
62018971|NCT00780845||AKI (+)|Patients with acute kidney injury after on-pump CABG
62018972|NCT04089644|ACTIVE_COMPARATOR|manual group|Hypotension will be corrected by manual infusion of norepinephrine
62210121|NCT05767060|EXPERIMENTAL|BAT7104 Injection 10 mg/kg|frequency: Q2W
62210122|NCT05767060|EXPERIMENTAL|BAT7104 Injection 20 mg/kg|frequency: Q2W
62210123|NCT05767060|EXPERIMENTAL|BAT7104 Injection 40 mg/kg|frequency: Q2W
62210124|NCT02124811|EXPERIMENTAL|High CRP|Subjects with a High Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
62407361|NCT00564473||A|patients hospitalized in the Department of Internal Medicine of the Shaare Zedek Medical Center, Jerusalem, Israel.
62407362|NCT02314130|EXPERIMENTAL|Dietary therapy Standardized diet|The study was constituted by sixty-six patients, thirty-three in each group. Patients on not industrialized enteral diet (standardized diet group) entered at random in the study and were matched by gender, age, socioeconomic status and medical diagnosis to patients using commercial diet (commercial group). The evaluation consisted of anthropometric measures of weight, height, arm circumference, triceps skin fold and biochemical índices at baseline and at the end of the intervention.
62582649|NCT06659094|EXPERIMENTAL|stepped-care Internet-based cognitive behavioral therapy(SC-ICBT) combined with medication|"Patients' OCD severity is initially assessed with the Yale-Brown Obsessive Compulsive Scale (YBOCS). After enrollment, patients receive health education, observe symptoms, learn ERP theory, and create exposure lists on a WeChat mini-program for pre-treatment. They perform daily 1-hour ERP exercises for a week, with online status collection by coordinators. After a week, patients receive twice-weekly online ERP guidance from therapists for two weeks.~After two and four therapy sessions, YBOCS re-evaluations occur via Tencent Meeting. Based on scores, the next three weeks involve either self-guided ERP or a mix of self-guided and therapist-guided ERP. If patients show over a 25% reduction, therapist guidance is suspended, and they switch to self-guided ICBT for the final three weeks."
62018973|NCT04089644|EXPERIMENTAL|closed-loop group|Hypotension will be corrected by closed-loop control of norepinephrine infusion
62018974|NCT02262845||Group A: PEP Risk|In subjects deemed at high risk for acute pancreatitis post-endoscopic retrograde cholangiopancreatography (ERCP)
62210125|NCT02124811|EXPERIMENTAL|Low CRP|Subjects with a Low Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
62582650|NCT06659094|ACTIVE_COMPARATOR|Cognitive Behavioral Group Therapy (CBGT) combined with medication|"OCD patients will be provided with therapist-guided offline Cognitive Behavioral Group Therapy while they will continue with the medications they already have.~A nationally registered psychotherapist, who has undergone systematic professional training, is in charge of a homogeneous closed group and records the sessions live. The treatment takes place in the group psychotherapy room at the Shanghai Mental Health Center, with a group of 6 people, for 6 weeks, twice a week, each session lasting 2 hours. A senior domestic group cognitive therapist supervises the treatment."
62582651|NCT01264081|EXPERIMENTAL|Lapatinib|Lapatinib will be administered as an oral dose of 500 mg twice daily in the morning and evening one hour before or after meals.
62018975|NCT02262845||Group B: Impaired Pancreatic Duct Drainage|In subjects with a pancreatic duct stricture and/or pancreatic duct stones and/or pancreatic duct sludge or debris, possibly, but not exclusively before or after ESWL or before pancreatic surgery
62210126|NCT03286101|EXPERIMENTAL|0.5% Ivermectin Lotion|
62210127|NCT03286101|PLACEBO_COMPARATOR|Vehicle control|
62018976|NCT02262845||Group C: Pancreatic Duct Leak|In subjects with a pancreatic duct leak
62018977|NCT02262845||Group D: Post Pancreatic Surgery|In subjects at risk of pancreatic duct leak or strictures after resection of a pancreatic lesion close to the main pancreatic duct or at the level of the pancreatico-jejunostomy after pancreatico-duodenectomy
62018978|NCT02262845||Group E: Other|In subjects with other indications
62018979|NCT01925183|EXPERIMENTAL|28 weeks of treatment duration|All patients will receive 4 weeks of PEGIFN/RBV lead-in. Patients with undetectable HCV-RNA at treatment week 8 will be treated with 24 weeks of BOC/PEGIFN/RBV triple-therapy resulting in a total treatment duration of 28 weeks.
62210128|NCT04620304|EXPERIMENTAL|Cohort A|receive 4 weekly fixed doses of UB-421 SC at 250 mg
62210129|NCT04620304|EXPERIMENTAL|Cohort B|receive 4 weekly fixed doses of UB-421 SC at 500 mg
62210130|NCT04620304|EXPERIMENTAL|Cohort C|receive 4 weekly fixed doses of UB-421 SC at 700 mg
62210131|NCT06729320|ACTIVE_COMPARATOR|Conventional hematopoietic recovery therapy|Conventional hematopoietic recovery therapy including but not limited to G-CSF, TPO, TPO receptor agonists, transfusions of red blood cells, platelets, etc.
62210132|NCT06729320|EXPERIMENTAL|Conventional hematopoietic recovery therapy+Umbilical cord blood mononuclear cells|Umbilical cord blood mononuclear cells are obtained from umbilical cord blood by density gradient centrifugation
62210133|NCT04192695|EXPERIMENTAL|Cytosponge|"This part of the study will have an active prospective recruitment of patients. Recruitment will involve two patient populations:~1. Patients with ESCC~2. Patients at high risk for ESCC~Following inclusion in the study, subjects will be asked to complete a behavior questionnaire, have blood collected, and undergo a Cytosponge™ procedure followed by diagnostic gastroscopy using advanced imaging with biopsies. During gastroscopy, additional tissue samples will be collected for research purposes. These samples, along with cytological specimens from the Cytosponge™, will be analyzed to assess the diagnostic accuracy of biomarkers in the diagnosis of LG-IEN, HG-IEN, and ESCC."
62210134|NCT03679715|EXPERIMENTAL|Intervention group|The participants in the Intervention group will be participants of the museum participatory art-based activity.
62582652|NCT06138106|EXPERIMENTAL|Natural Product Supplement|The participant will consume a dose of hydrolyzed collagen (20g) supplemented with vitamin C (100 mg), epicatechin (75 mg), vitamin E (350 iU) and stevia extract (225 mg).
62582653|NCT06138106|PLACEBO_COMPARATOR|Placebo|The participant will consume a dose of hydrolyzed collagen (20g) supplemented with vitamin C (100 mg) and sweetener.
62582654|NCT00652626|EXPERIMENTAL|Azacitidine 25 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 25 mg/m\^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m\^2 daily on Days 1-7 of each 28-day cycle.
62210135|NCT03679715|NO_INTERVENTION|Control Group|The Control arm will be composed of older community dwellers matched on age and sex compared to the Intervention group but who will not be participants at the museum participatory art-based activity.
62210136|NCT05622916|EXPERIMENTAL|Intervention|Daily topical application (twice/day, in the morning and 30-60 minutes before bed at night) for 56 days.
62210137|NCT05622916|ACTIVE_COMPARATOR|Comparison|Weekly application (1x/week) by the physician for 8 weeks
62582655|NCT00652626|EXPERIMENTAL|Azacitidine 50 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 50 mg/m\^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m\^2 daily on Days 1-7 of each 28-day cycle.
62582656|NCT00652626|EXPERIMENTAL|Azacitidine 75 mg/m^2|Participants with normal renal function received subcutaneous doses of azacitidine 75 mg/m\^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m\^2 daily on Days 1-7 of each 28-day cycle.
62582657|NCT00652626|EXPERIMENTAL|Azacitidine 100 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 100 mg/m\^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m\^2 daily on Days 1-7 of each 28-day cycle.
62582658|NCT00652626|EXPERIMENTAL|Severe RI: azacitidine 75 mg/m^2|Participants with severe renal impairment (RI; defined as creatinine clearance \< 30 mL/min/1.73 m\^2) received subcutaneous doses of azacitidine 75 mg/m\^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m\^2 daily on Days 1-7 of each 28-day cycle.
62582659|NCT03779750||End Stage Renal Disease Patients|complete blood picture blood urea s.creatinine urine analysis calcium phosphorus parathyroid hormone. 4- Hepatitis BsAg,HCV-Abs and HIV.
62582660|NCT01058993|EXPERIMENTAL|AMD3100 or plerixafor|SINGLE arm study with increasing doses of Plerixafor
62582661|NCT01192061||Normal tension glaucoma group|
62582662|NCT01192061||Control group|
62582663|NCT01698138|PLACEBO_COMPARATOR|Placebo|30 transurethral injections, each of 1 ml solution containing NaCl.
62018980|NCT01925183|EXPERIMENTAL|48 weeks of treatment duration|All patients will receive 4 weeks of PEGIFN/RBV lead-in. Patients with detectable HCV-RNA at treatment week 8 will receive 44 weeks of BOC/PEGIFN/RBV triple-therapy and a total treatment duration of 48 weeks
62582664|NCT01698138|ACTIVE_COMPARATOR|Onabotulinumtoxin A|"30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, Allergan) in 30 ml of NaCl 0.9 %."
62582665|NCT00581698||Surgical|Patients with primary melanomas Clark III and Breslow thickness \> 1 mm, or Clark IV-V and any Breslow thickness, and clinically negative regional nodes
62582666|NCT06017102|EXPERIMENTAL|wired magnetic assisted capsule endoscopy|
62582667|NCT06017102|OTHER|esophagogastroduodenoscopy|
62582668|NCT02164331|EXPERIMENTAL|JNC guideline training|Providers will receive current JNC guideline training for treating patients with uncontrolled hypertension.
62582669|NCT02164331|NO_INTERVENTION|Control|Provider patient panels will be assessed for number of uncontrolled hypertensives before receiving the JNC guidelines training. These baseline characteristics will serve as their control conditions.
62582670|NCT05638672|EXPERIMENTAL|Treatment group|Huashi Baidu Granule+Monapiravir simulant
62582671|NCT05638672|ACTIVE_COMPARATOR|Control group|Monapiravir+Huashi Baidu Granule Simulator
62582672|NCT03928587|EXPERIMENTAL|Active|A lozenge containing 2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine 2% to be taken once daily
62582673|NCT03928587|PLACEBO_COMPARATOR|Placebo|An identical lozenge except for the absence of probiotics and arginine to be taken once daily.
62582674|NCT01766661|ACTIVE_COMPARATOR|Coloanal anastomosis with ileostomy|Hand-sewn coloanal anastomosis protected by a loop ileostomy
62582675|NCT01766661|EXPERIMENTAL|Two stage Turnbull-Cutait anastomosis|Two staged coloanal anastomosis without protective ileostomy (Turnbull-Cutait procedure).
62582676|NCT05566704||Modulus ALIF System|
62582677|NCT01167738|EXPERIMENTAL|PEXG regimen + metformin|cisplatin and epirubicin at 30 mg/mq on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15, Metformin at 2 g days 1-28
62582678|NCT01167738|ACTIVE_COMPARATOR|PEXG regimen|cisplatin and epirubicin at 30 mg/mQ on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15
62582679|NCT02968693||combination therapy group|antibiotic-loaded calcium sulfate and antibiotic-loaded polymethyl methacrylate (PMMA) and Vancomycin
62582680|NCT02968693||PMMA group|antibiotic-loaded polymethyl methacrylate and Vancomycin
62582681|NCT03871946||Experimental group|"Experimental group subjects with impaired fasting glucose (IFG) (Group 1) underwent an oral glucose tolerance test (OGTT), and patients with levels \> 140 mg/dL at the 2nd hour were excluded because they were diagnosed with impaired glucose tolerance"
62018981|NCT04819997|EXPERIMENTAL|Supportive care (videoconference, questionnaire, survey)|Patients participate in 5 videoconference sessions over 30 minutes each over 6 weeks focused on worry management skills, values-based goal setting, and brief mindfulness-based practices, then complete patient workbook activities after each session over 15-20 minutes per day. Patients also complete a survey over 8 minutes at 6 weeks, an exit interview at 7 weeks, and questionnaires over 25 minutes each at baseline, 6 weeks, and 10 weeks.
62210138|NCT00391859|EXPERIMENTAL|Health service provision|Health service provision within the first few months of diagnosis which includes physical examination, radiographs, education, exercise, weight loss, assistive devices and pharmacologic therapy.
62210139|NCT01856452|ACTIVE_COMPARATOR|radioisotope|sentinel lymph node operation using radioisotope in the breast cancer patients
62018982|NCT04795271|EXPERIMENTAL|Orthopedic treatment|"Participants who are referred for orthopedic treatment as indicated by the treating traumatologist or rehabilitating doctor will be evaluated and treated by one of the three orthopedists participating in this study.~After the orthopedic evaluation, the professional will determine the most suitable insole according to the plantar discharge needs required by the patient. The intervention in the insole can include modifications or corrections at the forefoot, midfoot, or hindfoot. The material used in each insole will also be specified. When the insole requires many modifications and raises the height of the subject's foot, the use of orthopedic footwear will also be added to prevent pressure on the dorsum of the foot that could be caused by normal footwear."
62210140|NCT01856452|EXPERIMENTAL|the mixture including indocyanine green|sentinel lymph node operation using the mixture of indocyanine green, blue dye and radioisotope in the breast cancer patients
62210141|NCT02323451|EXPERIMENTAL|Medical Chitosan|Medical Chitosan, 2ml/vial (12mg/ml), intra-articular injection with a volume less than 2ml every two weeks, a total of 3 times
62582682|NCT03871946||control group|The control group (Group 2) comprised 73 patients whose fasting blood glucose level was \<100 mg/dL and who agreed to participate in the study.
62582683|NCT05114096|EXPERIMENTAL|Single-Dose Celestone|"Having already received the first dose of Celestone as part of eligibility criteria, participants randomized to the experimental Single-Dose arm will receive a similar appearing placebo injection."
62582684|NCT05114096|ACTIVE_COMPARATOR|Double-Dose Celestone|"Having already received the first dose of Celestone as part of eligibility criteria, participants randomized to the Double-Dose arm will receive the standard 2nd dose of Celestone injected intramuscularly (i.e. they will receive the standard double-dose regimen)."
62018983|NCT05085457|NO_INTERVENTION|Control Group|On group I (T-ayre and standard protocol), SBT must begin with the pacient in T-ayre, oxygen support that is proprotional to the fraction of inspired oxygen in invasive mechanical ventilation (IMV), during 30 minutes. If the pacient does not show any sign of SBT failure, the rapid shallow beathing index (RSBI) will be calculated and pacients with RSBI lower than 105 L/min will be extubated, meanwhile pacients with RSBI higher than 105 L/min will return to MV for at least 24 hours until the perfomance of a new SBT.
62210142|NCT02323451|ACTIVE_COMPARATOR|Sodium Hyaluronate Injection|Sodium Hyaluronate Injection, 2ml/vial (10mg/ml), intra-articular injection with a volume less than 2ml every one weeks, a total of 5 times.
62210143|NCT04844619|EXPERIMENTAL|KDR2-2 group|The patients with NVG will receive 4.0 mg/ml or 16.0mg/ml KDR2-2 suspension eyedrop and the anti-neovascular effect of KDR2-2 would be evaluated during the follow-up visits.
62210144|NCT05447091|ACTIVE_COMPARATOR|Active high dose treatment|Active LOH game training- high dose
62210145|NCT05447091|ACTIVE_COMPARATOR|Active low dose treatment|Acrive LOH game training - low dose
62210146|NCT05447091|SHAM_COMPARATOR|Sham treatment|Sham LOH game- high dose
62210147|NCT04864262|EXPERIMENTAL|Photovoice|
62210148|NCT06226324||SLE with neuropsychiatric symptoms|"1. Neuropsychiatric symptoms meeting the 1999 ACR definition~2. Ages 18-55y~3. Female~4. Right-handed~5. Can cooperate with MRI and neuropsychiatric examination"
62210149|NCT06226324||SLE without neuropsychiatric symptoms|"1. Patients who meet the 2019 ACR diagnostic criteria for SLE~2. Patients without neuropsychiatric symptoms~3. Age 18-55y~4. Female~5. Right-handed~6. Able to cooperate with MRI and neuropsychiatric examination"
62210150|NCT06226324||Healthy control group|"1. Age and gender matched the case group~2. Right-handed~3. No cerebrovascular, neurological or mental diseases~4. Can cooperate with MRI and neuropsychiatric examination"
62210151|NCT03264911|ACTIVE_COMPARATOR|amoxicillin|Children will be randomized to receive, after consent to the study, an antibiotic (amoxicillin approximately 50 mg/kg/day) orally, twice a day for 6 days.
62210152|NCT03264911|PLACEBO_COMPARATOR|Placebo arm|Children will be randomized to receive, after consent to the study, a placebo orally, twice a day for 6 days.
62582685|NCT05330364|EXPERIMENTAL|Chidamide plus Cladribine|Chidamide 30mg/d per os (p.o.), twice per week, begins at day 1; Cladribine 5mg/m2/d, intravenous injection (i.v.), days 1-5, once per day; A cycle is during 28 days.
62582686|NCT05783297|ACTIVE_COMPARATOR|Comparison|Clinics randomized to the comparison arm will have participants receive standard of care ART adherence support for 3 months, and will receive the TXTXT intervention for 3 months. The standard of care for ART adherence across clinic sites consists of routine follow-up from assigned case managers for appointment reminders and adherence counseling at scheduled visits .
62210153|NCT04749251|EXPERIMENTAL|Individual blood pressure management arm|During the EVT procedure(in general anesthesia), mean arterial blood pressure (MABP) during is targeted to remain within +/- 10 % of a reference value using vasoactive drugs and/or fluids
62734501|NCT03281369|EXPERIMENTAL|2L-2: Atezo + PEGPH20 (Gastric Cancer)|Participants in the 2L-2 Gastric Cancer arm received atezolizumab in combination with PEGylated recombinant human hyaluronidase (PEGPH20). Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
62210154|NCT04749251|ACTIVE_COMPARATOR|Standard blood pressure management arm|During the EVT procedure(in general anesthesia), mean arterial blood pressure (MABP) during is targeted to remain within a fixed range of 70-90 mmHg
62210155|NCT02283970||BAV and aortic regurgitation|BAV Diagnosis, Aortic Regurgitation with surgical indication (according to current clinical guidelines or best clinical practice), normal ascending aorta
62210156|NCT02283970||BAV and Ascending aorta dilatation|BAV diagnosis, no or trivial Aortic Regurgitation, ascending aorta dilatation with surgical indication (according to current clinical guidelines or best clinical practice)
62210157|NCT02283970||BAV, aortic regurgitation and dilatation|BAV diagnosis, Aortic Regurgitation and ascending aorta dilatation with surgical indication (according to current clinical guidelines or best clinical practice).
62018984|NCT05085457|EXPERIMENTAL|ExPreS Group|On group II (T-ayre and ExPreS protocol), the pacient will be submitted to the SBT with T-ayre, with oxygen support that is proprotional to the fraction of inspired oxygen in IMV, during 30 minutes. If the pacient does not show any sign of SBT failure, ExPreS will be calculated. If punctuation is lower than or equal to 44, it indicates weaning failure and the pacient mjust return to MV for 24 hours at least. Punctuation between 45 and 58 must be evaluated if the pacient presents chronic obstructive pulmonary desease (COPD), obesity or heart desease. In this case, non invasive ventilation (NIV) should be scheduled or the weaning must be continued if there isn't any risck factors. Punctuation higher than or equal 59 indicates that the pacient can be extubated.
62018985|NCT04572633|EXPERIMENTAL|HistoSonics System|
62210158|NCT02283970||BAV with aortic stenosis in pts>60yrs|BAV diagnosis, Aortic stenosis with surgical indication (according to current clinical guidelines or best clinical practice). Normal ascending aorta
62210159|NCT00963053|EXPERIMENTAL|VA111913 100mg twice daily|
62582687|NCT05783297|EXPERIMENTAL|Intervention|Clinics randomized to the intervention arm will have participants complete a 6-month intervention period. Clinics will sign up eligible participants to receive automated SMS messages from the Dimagi CommCare platform during the participant's baseline study visit. Participants will have the option to tailor the message content based on their own preferences and will be able to select to receive messages in English or in Spanish, the time the messages are delivered, and frequency of messages. Clinic staff will enter this information in the Dimagi CommCare platform, and then test receipt of text messages by the participant before they complete this baseline visit.
62210160|NCT00963053|PLACEBO_COMPARATOR|Starch pill|
62210161|NCT06409689|EXPERIMENTAL|Oliceridine fumarate low dose group|The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.1 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose; The maximum cumulative daily dose is 27mg. The duration of PCA analgesia was 48 hours.
62210162|NCT06409689|EXPERIMENTAL|Oliceridine fumarate medium dose group|The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.35mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose; The maximum cumulative daily dose is 27mg. The duration of PCA analgesia was 48 hours.
62210163|NCT06409689|EXPERIMENTAL|Oliceridine fumarate high dose group|The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.5 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose; The maximum cumulative daily dose is 27mg. The duration of PCA analgesia was 48 hours.
62407363|NCT02314130|NO_INTERVENTION|Dietary therapy Commercial diet group|The study was constituted by sixty-six patients, thirty-three in each group. Patients on not industrialized enteral diet (standardized diet group) entered at random in the study and were matched by gender, age, socioeconomic status and medical diagnosis to patients using commercial diet (commercial group). The evaluation consisted of anthropometric measures of weight, height, arm circumference, triceps skin fold and biochemical índices at baseline and at the end of the intervention.
62407364|NCT04139369||Type 1 Diabetes Mellitus (T1DM)|Type 1 Diabetes Mellitus (T1DM) Children and adolescents with Type 1 Diabetes Mellitus
62407365|NCT04139369||Controls (C)|Controls (C) Healthy individuals matched for gender and age without any autoimmune disease of their own or their first degree relatives
62407366|NCT01982539|EXPERIMENTAL|Zipsor® (Liquid filled capsules)|25mg/every 6hrs/up to 4 days treatment
62582688|NCT03834636|ACTIVE_COMPARATOR|Nanoparticulated composite - self-etch|
62210164|NCT06409689|EXPERIMENTAL|Morphine group|The first loading dose of morphine was 4 mg in all patients after operation. The PCA dose of the patients was 1 mg, and the locking interval was 6 min. A supplemental dose of 2 mg is allowed once per hour as needed after 1 h of the load dose; The maximum cumulative daily dose is 60 mg. The duration of PCA analgesia was 48 hours.
62210165|NCT01327495|PLACEBO_COMPARATOR|Arm 1: Placebo|Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
62210166|NCT01327495|ACTIVE_COMPARATOR|Arm 2:1.25g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
62582689|NCT03834636|ACTIVE_COMPARATOR|Nanoparticulated composite - total-etch|
62582690|NCT03834636|ACTIVE_COMPARATOR|Nanohybrid composite - self-etch|
62582691|NCT03834636|ACTIVE_COMPARATOR|Nanohybrid composite - total-etch|
62582692|NCT00557011|EXPERIMENTAL|1|NRP104
62582693|NCT00557011|ACTIVE_COMPARATOR|2|Adderall XR
62018986|NCT02464501|EXPERIMENTAL|OPC Treatment|Paclitaxel administration using the OPC for the prevention of restenosis in infrainguinal de novo and restenotic femoropopliteal lesions. Subjects will be treated with the endovascular intervention selected by the treating physician in reference vessels ranging from 4mm to 7mm in diameter. Following the achievement of optimal interventional results (less than thirty (30) percent residual stenosis without stenting) the OPC will be placed at the interventional treatment area and paclitaxel will be delivered to the treated segment. Data will be collected to assess acute safety, long-term safety and durability to demonstrate the safety and efficacy of paclitaxel delivered with the ACT, Inc. OPC device.
62210167|NCT01327495|ACTIVE_COMPARATOR|Arm 3: 2.5g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
62210168|NCT01327495|ACTIVE_COMPARATOR|Arm 4: 5g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
62210169|NCT01327495|ACTIVE_COMPARATOR|Arm 5: 10g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
62210170|NCT01327495|ACTIVE_COMPARATOR|Arm 6: 15g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
62407367|NCT02684526|ACTIVE_COMPARATOR|Eovist Contrast agent|To determine if Eovist contrast agent induces a transient abnormal sensation at first pass, which prevents patients from holding their breath at end of arterial phase liver MRI scans.
62407368|NCT02684526|ACTIVE_COMPARATOR|Non Eovist Contrast agents|To determine if using non-Eovist contrast agents produce the same abnormal sensation at first pass, which prevents patients from holding their breath at end of arterial phase liver MRI scans. Determine if this event is exclusive to Eovist contrast.
62407369|NCT02526017|EXPERIMENTAL|Phase 1a Monotherapy Dose Escalation|Cabiralizumab administered at 2 mg/kg every 2 weeks (Q2W), 4 mg/kg Q2W and 6 mg/kg Q2W in participants with any solid tumor.
62407370|NCT02526017|EXPERIMENTAL|Phase 1a Combination Therapy Dose Escalation|Nivolumab 3 mg/kg Q2W + cabiralizumab at the following doses: 1 mg/kg, 2 mg/kg, 4 mg/kg, and 6 mg/kg Q2W. Also nivolumab 3 mg/kg + cabiralizumab 4 mg/kg every 3 weeks (Q3W). Participants with any solid tumor.
62407371|NCT02526017|EXPERIMENTAL|Phase 1b Combination Therapy Dose Expansion|The expansion phase would use the recommended dose determined in Phase 1a: cabiralizumab 4 mg/kg + nivolumab 3 mg/kg Q2W. Participants are enrolled for the following advanced cancer types: non-small cell lung cancer (anti-programmed cell death 1 \[PD1\] targeted drug naïve), non-small cell lung cancer (prior treatment with anti-PD-1), pancreatic cancer, ovarian cancer, renal cell cancer, glioblastoma, and melanoma.
62582694|NCT00557011|PLACEBO_COMPARATOR|3|Placebo
62210171|NCT00449267|EXPERIMENTAL|1|
62582695|NCT04214561||SB group|Patients diagnosed with SB.
62582696|NCT04214561||Healthy controls|Patients without diagnosed SB.
62018987|NCT02866682|OTHER|Brand Tacrolimus Only : Prograf|Arm 1 will receive brand tacrolimus for the entire study
62210172|NCT01482923||Treatment As Usual (TAU)|This study is a pilot intervention trial examining the feasibility of a motivational smoking cessation intervention using respiratory biomarker feedback in low income PLWHA. The plan is to recruit a pilot sample of 50 eligible and consented participants, randomized at a 1:1 ratio into either the Treatment As Usual (TAU) condition or the experimental (Aspiration, Inspiration Respiration, or AIR) intervention condition.
62210173|NCT01482923||Aspiration, Inspiration Respiration, or AIR|This study is a pilot intervention trial examining the feasibility of a motivational smoking cessation intervention using respiratory biomarker feedback in low income PLWHA. The plan is to recruit a pilot sample of 50 eligible and consented participants, randomized at a 1:1 ratio into either the Treatment As Usual (TAU) condition or the experimental (Aspiration, Inspiration Respiration, or AIR) intervention condition.
62210174|NCT02525718|PLACEBO_COMPARATOR|Placebo|Subjects will be randomly selected to receive saline (placebo), administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.
62210175|NCT02525718|ACTIVE_COMPARATOR|0.25 % bupivacaine w/ epinephrine & 4mg dexamethasone|"Subjects will be randomly selected to receive selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone. The injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue.~Subjects will be randomly selected to receive the local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery."
62210176|NCT04682743|SHAM_COMPARATOR|saline group|
62210177|NCT04682743|ACTIVE_COMPARATOR|ondansetron group|
62210178|NCT04682743|ACTIVE_COMPARATOR|paracetamol group|
62210179|NCT03384160|ACTIVE_COMPARATOR|Group 1-Pain monitor|Use of the anesthetic Mepivacaine 2% in third molar extraction
62210180|NCT03384160|ACTIVE_COMPARATOR|Group 2 -Pain monitor|Use of the anesthetic Articaine 4% in third molar extraction
62582697|NCT02112357||Targeted genetic sequencing of tumour specimen|
62582698|NCT06685341|EXPERIMENTAL|Drug: YZJ-1139 high dose group|Subjects will be into two groups：Young adult subjects and elderly subjects
62582699|NCT06685341|EXPERIMENTAL|Drug: YZJ-1139 low dose group|Subjects will be into two groups：Young adult subjects and elderly subjects
62582700|NCT06685341|PLACEBO_COMPARATOR|Drug: Placebo|
62582701|NCT06685341|ACTIVE_COMPARATOR|Drug: Zolpidem|
62582702|NCT01202942|EXPERIMENTAL|Quest|Participants smoke Quest cigarettes level 1 for 10 days, followed by level 2 for 10 days, and finally by level 3 for 10 days.
62582703|NCT01202942|NO_INTERVENTION|Preferred brand|Participants smoke their preferred brand of cigarettes for the duration of the study.
62582704|NCT02418390|NO_INTERVENTION|No prophylactic central dissection|Patients underwent total thyroidectomy for papillary thyroid carcinoma, without prophylactic central lymph node dissection
62582705|NCT02418390|ACTIVE_COMPARATOR|Prophylactic central dissection|Patients underwent total thyroidectomy for papillary thyroid carcinoma, with prophylactic central lymph node dissection
62582706|NCT02981576|ACTIVE_COMPARATOR|Recipient of AT-MSC|Patients who will receive Autologous Mesenchymal Stem Cells from AdiposeTissue by Intrathecal injection of stem cells that will be performed 3 times.
62018988|NCT02866682|OTHER|Generic A Only|Arm 2 will receive specific generic tacrolimus for the entire study
62018989|NCT03237689|EXPERIMENTAL|Hydrocortisone|Low dose hydrocortisone (10mg orally)
62018990|NCT03237689|PLACEBO_COMPARATOR|Placebo|Placebo tablets, made of starch 1500 powder
62018991|NCT00688805|EXPERIMENTAL|Arm 1|
62407372|NCT05254691|NO_INTERVENTION|Standard care|All children are put on a time-cycled, pressure limited ventilation mode (AVEA, CareFusion, Yorba Linda, CA, USA). Inspiratory pressures are set to deliver a expiratory tidal volume of 5-7 ml/kg ideal bodyweight. The frequency of the delivered machine-breaths is set in accordance with age and disease condition of the patient. Then the patient set rate of breaths per minute delivered by the ventilator is reduced with 25%, allowing for more spontaneous breaths.
62582707|NCT02981576|ACTIVE_COMPARATOR|Recipient of BM-MSC|Patients who will receive Autologous Mesenchymal Stem Cells from Bone marrow by Intrathecal injection of stem cells that will be performed 3 times.
62582708|NCT02600468||Patients who use ORENCIA|Patients who use ORENCIA for the approved indications and who at the start of treatment
62582709|NCT02130089|OTHER|All patients|Intensive tailored education
62582710|NCT06382194|EXPERIMENTAL|Intervention Arm|Participants in this arm will receive the intervention and undergo research assessments.
62582711|NCT01786421||General population|Healthy volunteers,patients with hyperlipidemia,a known medical history of cardiovascular diseases or type 2 diabetes mellitus.
62582712|NCT06683417|EXPERIMENTAL|VestAid|Use of VestAid tablet application to aid vestibular rehabilitation
62582713|NCT06683417|ACTIVE_COMPARATOR|Standard of Care vestibular rehabilitation|Use of standard of care vestibular rehabilitation
62582714|NCT01198561||repetitive Transcranial Magnetic Stimulation|repetitive Transcranial Magnetic Stimulation is a depressive patient group treated with rTMS
62582715|NCT03742089||Treatment|Bone Anchored Hearing Surgery using a BHX implant manufactured by Oticon Medical
62582716|NCT01738503|EXPERIMENTAL|(8 mg) RBP-6000: 50 mg|Participants are stabilized by day -5 on Subutex 8 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 50 mg are given at 28 day intervals.
62582717|NCT01738503|EXPERIMENTAL|(12 mg) RBP-6000: 100 mg|Participants are stabilized by day -5 on Subutex 12 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 100 mg are given at 28 day intervals
62018992|NCT00688805|PLACEBO_COMPARATOR|Arm 2|
62018993|NCT03219112|EXPERIMENTAL|Intervention|15 cp children + 10 typically developing children (anticipated) Will have 8 weeks VR training Will have 1 VR training session
62018994|NCT03219112|NO_INTERVENTION|Control|15 cp children (anticipated) Will not have 8 weeks of VR training Will not have 1 VR training session
62582718|NCT01738503|EXPERIMENTAL|(24 mg) RBP-6000: 200 mg|"Participants are stabilized by day -5 on Subutex 24 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 200 mg are given at 28 day intervals.~Participants who receive RBP-6000 containing 200 mg buprenorphine and reach Day 112 (and have received all 4 planned SC injections) have the option to participate in the Positron Emission Tomography (PET) Pilot substudy. In the PET Pilot sub-study participants remain on 200 mg SC injections at 28 day intervals for an additional 6-9 intervals until they complete an magnetic resonance imaging (MRI) and a PET scan and pharmacokinetic samples at week 1 and week 4 post injection."
62018995|NCT05269264||patients with unilateral or bilateral, primary or secundary lower limb lymphedema (LLL)|patients with unilateral or bilateral, primary or secundary LLL who visit the center for lymphedema at UH Leuven
62018996|NCT05269264||healthy controls|age, BMI and gender matched to the patients with LLL
62407373|NCT05254691|EXPERIMENTAL|Sprinting|The ventilator mode is switched to PS ventilation. The level of PS is set to meet the level of PS set when the patient is ventilated in the SIMV-PS mode. The patient will be in the PS mode until he or she clinically shows increased work-of-breathing (tachypnoea and the presence of nasal flaring and intercostal and/or interjugular retractions indicate increased work of breathing).
62018997|NCT05269264||subgroup (n=40)|a subgroup of subjects (patients \& healthy controls) will be evaluated again 2 weeks later
62018998|NCT02893215||Heart failure|Screening for silent AF with Zenicor thumb-ECG: Patients older than 65 years, diagnosed with heart failure, without any history of atrial fibrillation, ongoing OAC treatment, implanted device or recent stroke/TIA.
62210181|NCT01241825|ACTIVE_COMPARATOR|1.|The subject group will chew sugarless chewing gum for a specific amount of time while undergoing capsule endoscopy.
62018999|NCT02893215||Diabetes mellitus II|Screening for silent AF with Zenicor thumb-ECG: Patients older than 65 years, diagnosed with diabetes mellitus II, without any history of atrial fibrillation, ongoing OAC treatment, implanted device or recent stroke/TIA.
62407374|NCT02801734|EXPERIMENTAL|Intervention|"Participants in the EQUIP intervention group will individually receive four face-to-face sessions with a palliative care nurse.~For all participants, whether in intervention or control, usual care is provided - the primary oncologist may make a referral for palliative care input if deemed appropriate."
62407375|NCT02801734|NO_INTERVENTION|Control|For all participants, whether in intervention or control, usual care is provided - the primary oncologist may make a referral for palliative care input if deemed appropriate.
62407376|NCT04334122|EXPERIMENTAL|Control group|"All patients in the control group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.~As a traditional treatment, patients received hot packs, conventional transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound and exercise.~Hot packs used as superficial heat were wrapped in a towel and applied to the waist area for 20 minutes.~Conventional TENS used as analgesic current were applied to the waist region for 20 minutes with 4 electrodes with 2 outputs, with a current time of 180 ms at a frequency of 80 Hz.~It was applied with a dose of 1Mhz for 5 minutes with ultrasan (Chattanooga Intelect Mobile Combo model device) used to heat deep tissues.~Waist exercises were asked to be done during the treatment, with 10 repetitions, each exercise twice a day (morning and evening)."
62407377|NCT04334122|EXPERIMENTAL|Experiment group|"In addition to the traditional physiotherapy program, tool-assisted soft tissue mobilization was performed 3 times a week (12 sessions with 1 day interval) in the experimental group.~Instrument Assisted Soft Tissue Mobilization (IASTM) treatment was applied to ilicostalis lumborum, priformism, gluteus medius, erector spinas, quadratus lumborum muscles, superficial and deep fascia. Before applying the application, petroleum jelly was applied to the area and the tool was slipped.~IASTM treatment was applied to the treated muscle fibers for 6 minutes, each technique (SWEEP-FAN-BRUSH-SWEEP techniques) with 8-10 repetitions.~Sweep: Applied in all directions at 30 or 60 degree angle. Fan: It was applied by moving one side fixed arm at 30 degree angle. Brush: It was applied in straight steps at 30 degrees angle. Each stage of IASTM treatment was done by the physiotherapist."
62582719|NCT01738503|EXPERIMENTAL|(8 mg) RBP-6000: 100 mg|Participants are stabilized by day -5 on Subutex 8 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 100 mg are given at 28 day intervals.
62582720|NCT01738503|EXPERIMENTAL|(14 mg) RBP-6000: 200 mg|"Participants are stabilized by day -5 on Subutex 14 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 200 mg are given at 28 day intervals.~Participants who receive RBP-6000 containing 200 mg buprenorphine and reach Day 112 (and have received all 4 planned SC injections) have the option to participate in the Positron Emission Tomography (PET) Pilot substudy. In the PET Pilot sub-study participants remain on 200 mg SC injections at 28 day intervals for an additional 6-9 intervals until they complete an magnetic resonance imaging (MRI) and a PET scan and pharmacokinetic samples at week 1 and week 4 post injection."
62019000|NCT03778216|EXPERIMENTAL|FBT-ARFID|Family Based Treatment of child ARFID
62019001|NCT03778216|NO_INTERVENTION|Usual Care|Continued usual care for ARFID with the exception of any Family Based Treatment
62019002|NCT05913297||Malformation Chiari 1|Magnetic Resonance
62019003|NCT05913297||Malformation Chiari 2|Magnetic Resonance
62210182|NCT01241825|PLACEBO_COMPARATOR|2.|The control group will not chew chewing gum while undergoing capsule endoscopy.
62210183|NCT01579500|ACTIVE_COMPARATOR|botulinum toxin A|
62019004|NCT04671511|EXPERIMENTAL|Targeted Axillary Dissection|Ultrasound of the axilla preoperative. Clipped biopsy proven positive node. I125 radioactive seed before surgery. Sentinel node biopsy using Tc99 +/- blue dye. Targeted Axillary Node Dissection performed at surgery
62019005|NCT01661660|ACTIVE_COMPARATOR|Control subjects|Control subjects were people with memory complaints coming for a consultation and prevention.
62019006|NCT01661660|EXPERIMENTAL|Predementia / MCI patients|Subjects at predementia stage or MCI stage
62019007|NCT01661660|EXPERIMENTAL|Dementia patient|Subjects at demential stage
62019008|NCT05874934|EXPERIMENTAL|Intervention|Intrahepatic plastic biliary stent with retrieval string
62019009|NCT00889122|EXPERIMENTAL|Lifestyle Counseling|
62019010|NCT03917290|EXPERIMENTAL|Intervention|Upon clearance to RTP after concussion, participants randomized to NMT will complete training for 20-30 minutes, two times per week, beginning at RTP and continuing at this frequency for 8 weeks.
62019011|NCT03917290|NO_INTERVENTION|Usual Care|Participants cleared to RTP in the usual care arm will return to sports and not undergo any intervention.
62019012|NCT00977041|EXPERIMENTAL|Neurofeedback|See Intervention description below.
62210184|NCT01579500|PLACEBO_COMPARATOR|normal saline|
62210185|NCT06729658|EXPERIMENTAL|Interventional group - Levodopa|Arm Description: Participants will receive Levodopa followed by BCI-mediated training for 6 days.
62210186|NCT06729658|PLACEBO_COMPARATOR|Control group - Placebo|Arm Description: Participants will receive Placebo followed by BCI-mediated training for 6 days.
62210187|NCT01331486|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62210188|NCT01331486|ACTIVE_COMPARATOR|Low dose|
62210189|NCT01331486|ACTIVE_COMPARATOR|Mid dose|
62582721|NCT01738503|EXPERIMENTAL|(8-24 mg) RBP-6000: 300 mg|Participants are stabilized by day -5 on a Subutex between 8-24 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 300 mg are given at 28 day intervals.
62582722|NCT05961072|EXPERIMENTAL|Patients receiving the vibrotactile sensory feedback device|Patients who have undergone a major lower limb amputation and are receiving the vibrotactile sensory feedback device
62019013|NCT02449759|EXPERIMENTAL|ACT Intervention Group|This group will receive an ACT self-help manual to be completed over the course of 6 weeks. They will also receive two brief telephone calls during the reading of the manual by a member of the research team.
62019014|NCT02449759|NO_INTERVENTION|Control Group|This group will receive no intervention
62019015|NCT02942160|EXPERIMENTAL|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
62019016|NCT01678040||Cardiac Magnetic Resonance|"The CMR examinations will be performed in the cardiac MRI scanner (Siemens Avanto, 1.5 Tesla, Erlangen, Germany) at the Hospital for Sick Children. A brief echocardiogram will be performed using a GE Vivid 7 or Vivid E9 machine (General Electric Medical Systems, Wisconsin, USA) We will image from standard parasternal long axis and apical four-chamber before and after completed hydration."
62019017|NCT04585334|EXPERIMENTAL|Arm A Tricortin|Tricortin 1000 by intramuscular route
62019018|NCT04585334|ACTIVE_COMPARATOR|Arm B Itami|Itami Diclofenac sodium medicated plaster by topical application
62019019|NCT04585334|PLACEBO_COMPARATOR|Arm C Placebo|Placebo
62019020|NCT04552782|EXPERIMENTAL|Alcohol Cognitive Bias Modification (CBM) + PTSD CBM|
62019021|NCT04552782|EXPERIMENTAL|Alcohol CBM + PTSD Sham|
62019022|NCT04552782|EXPERIMENTAL|Alcohol Sham + PTSD CBM|
62019023|NCT04552782|SHAM_COMPARATOR|Alcohol Sham + PTSD Sham|
62582723|NCT06287476|EXPERIMENTAL|Control Group|This arm consist of only healthy participants (age (+/- 3 years) and sex matched to the COPD group), which will undergo three study visits
62582724|NCT06287476|EXPERIMENTAL|COPD group|This arm consist of only COPD patients, which will undergo three study visits
62582725|NCT06017466|EXPERIMENTAL|Chronic Vertigo|Chronic vertigo patients can be divided into three groups. The first pathway is episodic vertigo (caused by e.g. migraine, Ménière's disease, benign paroxysmal positional vertigo (BPPV)) progressively leading to chronic dizziness. The second pathway is initiated by a single attack of vertigo (e.g. neuritis vestibularis) with some initial recovery but later on residual symptoms. The third pathway is the presence of chronic, slowly progressive, continuous, or unchanging symptoms (e.g. bilateral vestibular failure, CNS disorders). All patient with chronic vertigo (see above) will included.
62210190|NCT01331486|ACTIVE_COMPARATOR|High dose|
62210191|NCT06330012|EXPERIMENTAL|Spatial transcriptomic approch|Spatial transcriptomic approch for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
62210192|NCT06242860|ACTIVE_COMPARATOR|Single ELM Treatment|"To undergo the ELM procedure, the subject will sit comfortably in an exam chair.~The Headset and Eye Pads will be adjusted to fit comfortably over gently closed eyelids. The subject will rest their head back. The ELM will be turned on, and will be active for 15 minutes wherein patients will feel a warming sensation to their eyes and a gentle vibration. The ELM is then removed."
62210193|NCT06242860|ACTIVE_COMPARATOR|Daily ELM Treatment|"To undergo the ELM procedure, the subject will sit comfortably in an exam chair.~The Headset and Eye Pads will be adjusted to fit comfortably over gently closed eyelids. The subject will rest their head back. The ELM will be turned on, and will be active for 15 minutes wherein patients will feel a warming sensation to their eyes and a gentle vibration. The ELM is then removed. Subject will take personalized ELM home and use it as directed on a daily basis"
62582726|NCT02257645||Euforvac-Hib vaccine|
62582727|NCT00387855|EXPERIMENTAL|1|receive SOS program
62407378|NCT05309317|EXPERIMENTAL|CAUTI-VSG|Preventing Catheter-Associated Urinary Tract Infections with a Virtual Simulation Game
62582728|NCT00384839|EXPERIMENTAL|1|azacitidine for injectable suspension
62019024|NCT05912946|EXPERIMENTAL|Experimental group drug|Generic name: Human interferon a2b injection; Dosage form: solution; Dosage: 1ml: 3 million IU; Frequency and duration: The first 4 weeks were irrigated once a week, a total of 4 times, and the last 4 months were irrigated once a month, a total of 4 times. The total treatment cycle was 5 months, and a total of 8 bladder perfusion treatments were performed.
62019025|NCT05912946|ACTIVE_COMPARATOR|Sodium Hyaluronate|Generic name: Sterile sodium hyaluronate solution; Dosage form: solution; Dosage: 40mg/50ml; Frequency and duration: The first 4 weeks were irrigated once a week, a total of 4 times, and the last 4 months were irrigated once a month, a total of 4 times. The total treatment cycle was 5 months, and a total of 8 bladder perfusion treatments were performed.
62019026|NCT05912946|PLACEBO_COMPARATOR|Sodium chloride injection|Generic name: Sodium chloride injection; Dosage form: solution; Dosage: 50ml: 0.45g; Frequency and duration: The first 4 weeks were irrigated once a week, a total of 4 times, and the last 4 months were irrigated once a month, a total of 4 times. The total treatment cycle was 5 months, and a total of 8 bladder perfusion treatments were performed.
62019027|NCT04277598|EXPERIMENTAL|Lead In Phase: APO-2: 25U/ml|Topical administration of APO-2, 25 U/ml; Approximalety 0.5 ml per square cm wound;
62019028|NCT04277598|PLACEBO_COMPARATOR|Lead In Phase: Placebo|Topical administration of placebo; Approximalety 0.5 ml per square cm wound;
62019029|NCT04277598|EXPERIMENTAL|Main Phase: APO-2: 12.5 U/ml|Topical administration of APO-2, 12.5 U/ml; Approximalety 0.5 ml per square cm wound;
62019030|NCT04277598|EXPERIMENTAL|Main Phase: APO-2: 25 U/ml|Topical administration of APO-2, 25 U/ml; Approximalety 0.5 ml per square cm wound;
62019031|NCT04277598|EXPERIMENTAL|Main Phase: APO-2: 50 U/ml|Topical administration of APO-2, 50 U/ml; Approximalety 0.5 ml per square cm wound;
62019032|NCT04277598|PLACEBO_COMPARATOR|Main Phase: Placebo|Topical administration of placebo; Approximalety 0.5 ml per square cm wound;
62019033|NCT02439346|EXPERIMENTAL|BAY1143269 5 mg|Subjects received BAY1143269 5 milligram (mg) tablet orally, once daily (QD) from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
62210194|NCT02297321|EXPERIMENTAL|DeScribe patch|Comparison of the number of passes achieved using the Describe patch plus laser compared to laser along
62582729|NCT04251793||Er:YAG laser-assisted debridement|Subjects who were randomly selected to receive debridement and surface detoxification of their implant surface and removal of the inflamed tissue with the aid of the laser treatment two years ago at the Graduate Periodontics Clinic at University of Michigan.
62019034|NCT02439346|EXPERIMENTAL|BAY1143269 10 mg|Subjects received BAY1143269 10 mg (2\*5 mg) tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
62019035|NCT02439346|EXPERIMENTAL|BAY1143269 25 mg|Subjects received BAY1143269 25 mg tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
62407379|NCT05309317|ACTIVE_COMPARATOR|Control group|"Training on CAUTI Prevention"
62407380|NCT01363531|ACTIVE_COMPARATOR|Direct antibiotic treatment|The doctor gives to patient an antibiotic prescription for his respiratory infection, which he should start immediately.
62019036|NCT02439346|EXPERIMENTAL|BAY1143269 50 mg|Subjects received BAY1143269 50 mg (2\*25 mg) tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
62019037|NCT00363766|EXPERIMENTAL|LY573636|
62019038|NCT01702233|EXPERIMENTAL|Traumeel S inj.|Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
62019039|NCT01702233|ACTIVE_COMPARATOR|Fortecortin/Dexamethasone 8 mg inj|Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
62019040|NCT01702233|PLACEBO_COMPARATOR|Saline inj.|Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
62019041|NCT04489095|EXPERIMENTAL|Electrophysiology Study pre and Post TAVR|In all patient's undergoing TAVR after informed consent will undergo an electrophysiology study pre and post device deployment in order to determine the need for permanent pacemaker implantation or further testing/monitoring.
62019042|NCT03952884|ACTIVE_COMPARATOR|Leucine|Participants will be allocated to an exercise or non-exercise group. After resistance exercise (or equivalent time point for non-exercise group), participants will consume 2g leucine powder dissolved in 250 mL of water.
62407381|NCT01363531|NO_INTERVENTION|No antibiotic treatment|The doctor doesn't give to patient an antibiotic prescription for his respiratory infection.
62407382|NCT01363531|EXPERIMENTAL|Delayed antibiotic prescription 1|The doctor gives to patient an antibiotic prescription for his respiratory infection with the advice to use it if needed, in case of worsening of symptoms or not improving.
62407383|NCT01363531|EXPERIMENTAL|Delayed antibiotic prescription 2|The doctor leaves the antibiotic prescription, for the respiratory infection of the patient, at the reception of the primary care center 3 days after the first medical visit. This prescription can be collected by patient if he needed, in case of worsening of symptoms or not improving.
62407384|NCT02262507|EXPERIMENTAL|Device wearing|All subjects who meet the study criteria and volunteer to participate will be included in the study. Subjects will undergo repeat oto-acoustic measures both wearing the device and not wearing the device. The intervention will be the auto-acoustic measurement - taken while wearing the collar and then again when not wearing the collar.
62407385|NCT01370291|ACTIVE_COMPARATOR|active Risperidone and active rTMS|active Risperidone and active rTMS for the first-episode schizophrenia patients
62582730|NCT04251793||Standard mechanical debridement|Subjects who were randomly selected to receive debridement and surface detoxification of their implant surface and removal of the inflamed tissue with dental scalers two years ago at the Graduate Periodontics Clinic at University of Michigan.
62210195|NCT04458805|EXPERIMENTAL|NX-13 250mg|Dose escalation in Part A will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A. The starting dose level in Part B will be determined by the SRC based on safety and tolerability data obtained in Part A. A dose level will only be evaluated in Part B if determined to be safe and tolerable in Part A. It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days. NX-13 dose levels to be evaluated in Part B will be in the range of 500 to 4000 mg.
62210196|NCT04458805|PLACEBO_COMPARATOR|Placebo|Dose escalation in Part A will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A. The starting dose level in Part B will be determined by the SRC based on safety and tolerability data obtained in Part A. A dose level will only be evaluated in Part B if determined to be safe and tolerable in Part A. It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days. NX-13 dose levels to be evaluated in Part B will be in the range of 500 to 4000 mg.
62210197|NCT02755818||control|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of greater than 60
62210198|NCT02755818||chronic renal disease (CKD3b)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 30-45
62210199|NCT02755818||chronic renal disease (CKD4)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 15-30
62210200|NCT02755818||chronic renal disease (CKD5)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of less than 15, or on hemodialysis
62210201|NCT02697370|OTHER|Pharmacokinetic based factor VIII dosage|Patient's routine prophylactic factor VIII concentrate infusion will be given in the morning and the exact time (hours and minutes) and dose recorded. There is no wash out so the date, time and dose of the previous 2 prophylactic doses must be accurately known. Samples will be collected that afternoon, the following morning and the following afternoon. Samples can be taken at any convenient time but the exact time must be recorded. Factor VIII levels will be measured and this pharmacokinetic data will be used to calculate the dose of factor VIII (to be infused on alternate days) required to maintain a predicted factor VIII ≥1.5 IU/dL at all times(this will be rounded up to the nearest full 250 IU vial)
62582731|NCT02643758|EXPERIMENTAL|Bifocal soft contact lenses|Device: Bifocal soft contact lenses Use of bifocal contact lenses with nasally decentered optical zone to control the progression of myopia
62582732|NCT02643758|NO_INTERVENTION|Single vision spectacles|Control: Single vision spectacles
62582733|NCT03287635|EXPERIMENTAL|Acthar gel 80 U/ml|Patients who continue to experience clinically significant symptoms of dry eye disease even after utilizing traditional methods of treatment for dry eye including but not limited to artificial tears, warm compresses, topical anti-inflammatories like cyclosporine and/or lifitegrast. Patients will receive repository corticotropin intramuscular injections 80 u/ml 2-3 times weekly for up to 3 months as judged by the investigator.
62582734|NCT06242392||effective group|The tumor size of each diameter of the tumor before and after treatment was measured on magnetic resonance imaging or CT. According to Recist 1.1 criteria, patients who were evaluated as complete remission, partial remission and stable disease were included in the effective group. Patients assessed as having progressive disease were included in the treatment-refractory group.
62210202|NCT05520333|EXPERIMENTAL|Intervention arm|Families receive text messages for three months.
62582735|NCT06242392||ineffective group|The tumor size of each diameter of the tumor before and after treatment was measured on magnetic resonance imaging or CT. According to Recist 1.1 criteria. Patients assessed as having progressive disease were included in the ineffective group.
62582736|NCT06683573|ACTIVE_COMPARATOR|Standard clinical care/TAU|standard clinician-led patient education
62210203|NCT05520333|NO_INTERVENTION|Waitlist-control arm|Families are randomized into a control group for three months and begin receiving text messages for three months.
62210204|NCT05973786|EXPERIMENTAL|Bipolar Depression EIPT: Switch to one of the following combinations:|Bipolar Depression randomized to EIPT: Switch to 1. one of the following: escitalopram, sertraline, or venlafaxine plus 2. two of the following: lithium, valproate acid or quetiapine
62210205|NCT05973786|ACTIVE_COMPARATOR|Bipolar Depression TAU: Switch to quetiapine plus lithium or valproate acid or lamotrigine|Bipolar Depression randomized to TAU: Switch to quetiapine plus lithium or valproate acid Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC).
62210206|NCT04344080|ACTIVE_COMPARATOR|CytoSorb-Therapy|Therapy of COVID-19 with need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation) using standard of care in Addition with hemoadsorption using CytoSorb-Adsorber
62582737|NCT06683573|EXPERIMENTAL|3D Kidney model enhanced patient education|patient education with 3D model
62407386|NCT01370291|EXPERIMENTAL|active rTMS and sham Risperidone|active rTMS and sham Risperidone for the first-episode schizophrenia
62407387|NCT01370291|SHAM_COMPARATOR|sham rTMS and active Risperidone|sham rTMS and active Risperidone for the first-episode schizophrenia patients
62582738|NCT01782625|EXPERIMENTAL|dive to 122 feet, no exercise|Subjects will undergo a simulated dive to a maximum depth of 122 feet of seawater with no exercise at depth
62582739|NCT01782625|EXPERIMENTAL|dive to 158 feet, no exercise|Subjects will undergo a simulated dive to a maximum depth of 154 feet of seawater with no exercise at depth
62582740|NCT01782625|EXPERIMENTAL|dive to 122 feet, exercise|Subjects will undergo a simulated dive to a maximum depth of 122 feet of seawater with exercise at depth
62582741|NCT01782625|EXPERIMENTAL|dive to 158 feet, exercise|Subjects will undergo a simulated dive to a maximum depth of 154 feet of seawater with exercise at depth.
62582742|NCT01672710|EXPERIMENTAL|regimen of niacin, exercise, sauna,|4-5 week daily sauna, exercise and niacin with other supplements
62582743|NCT01672710|OTHER|waitlist|4 week waitlist with treatment as usual
62582744|NCT06682429|NO_INTERVENTION|Usual Care|Participants in the usual care group will receive no TR, but will continue with the recommendations made by their care team. All participants in this group will be offered TR at the end of the study.
62582745|NCT06682429|EXPERIMENTAL|Telerehabilitation + Usual Care|Patients will receive 36 telerehabilitation sessions targeting arm motor function in addition to their usual care. TR consists of 70 minutes/day of activities targeting arm function, 6 days/week for 6 weeks. Half of these sessions are supervised by a licensed therapist, and the other half are done independently.
62582746|NCT03033498|EXPERIMENTAL|ABBV-951 Dose 1|Participants will receive dose 1 of ABBV-951.
62582747|NCT03033498|EXPERIMENTAL|ABBV-951 Dose 2|Participants will receive dose 2 of ABBV-951.
62582748|NCT03033498|EXPERIMENTAL|ABBV-951 Dose 3|Participants will receive dose 3 of ABBV-951.
62582749|NCT03033498|EXPERIMENTAL|ABBV-951 Dose 4|Participants will receive dose 4 of ABBV-951.
62582750|NCT03033498|EXPERIMENTAL|ABBV-951 Dose 5|Participants will receive dose 5 of ABBV-951.
62582751|NCT03033498|EXPERIMENTAL|ABBV-951 Dose 6|Participants will receive dose 6 of ABBV-951.
62582752|NCT03033498|EXPERIMENTAL|ABBV-951 Dose 7|Participants will receive dose 7 of ABBV-951.
62582753|NCT03033498|EXPERIMENTAL|ABBV-951 Dose 8|Participants will receive dose 8 of ABBV-951.
62582754|NCT06685367|EXPERIMENTAL|With Acura AKI|The group with Acura AKI will receive the Acura AKI software, which identifies high-risk AKI patients and sends alert messages to nephrologists and ICU pharmacists. Upon receiving the alert, they will make treatment suggestions.
62582755|NCT06685367|NO_INTERVENTION|Without Acura AKI|The group without Acura AKI will be managed based on standard medical procedures.
62582756|NCT02173678|EXPERIMENTAL|COMBIVENT® HFA|
62582757|NCT02173678|ACTIVE_COMPARATOR|COMBIVENT® CFC|
62210207|NCT04344080|NO_INTERVENTION|Standard of care|Therapy of COVID-19 with need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation) using standard of care
62582758|NCT02173678|PLACEBO_COMPARATOR|Placebo HFA-MDI (metered dose inhaler)|
62210208|NCT04865341|EXPERIMENTAL|IMB|Individuals randomized to this arm will receive a behavioral intervention based on the Information-Motivation-Behavior (IMB) model designed to increase HIV self-testing, among other protective behaviors.
62407388|NCT04530422|EXPERIMENTAL|• Group I (Sofosbuvir plus Ledipasvir)|Patients assigned to this group (125 patients) were received Sofosbuvir plus Ledipasvir, once daily for 15 to 21 days as minimum and maximum duration of therapy, respectively.
62582759|NCT06496854|EXPERIMENTAL|Lorazepam administration prior to IUD insertion procedure|
62582760|NCT03486158|EXPERIMENTAL|CalproSmart application|In addition to regular outpatient clinic visits and a routine CalproSmart test every 3 months, patients are instructed to obtain fecal samples if they experience symptoms suspect of recurrent IBD and to perform home analysis with CalproSmart™ system test kit
62582761|NCT03486158|NO_INTERVENTION|Standard follow-up|In addition to regular outpatient clinic visits and a routine calprotectin test in the same week as the visit date, patients bring home an Fecal-calprotectin tube and envelope and are instructed to obtain fecal samples and send these to local lab if they experience symptoms suspect of recurrent IBD
62582762|NCT04024540|EXPERIMENTAL|isocaloric dietary restriction|Very low caloric diet 400 kcal/d for a week, 600 kcal/d for another week and 800 kcal/d for 2 weeks.
62582763|NCT04024540|ACTIVE_COMPARATOR|Bariatric surgery|Laparoscopic vertical sleeve gastrectomy
62210209|NCT04865341|OTHER|Information-Only Control|Attention-matched comparison condition (information-only)
62210210|NCT00866970|EXPERIMENTAL|1|ALD518
62210211|NCT00866970|EXPERIMENTAL|2|ALD518
62407389|NCT04530422|ACTIVE_COMPARATOR|Group II (Oseltamivir plus HCQ & Azithromycin)|"Patients in this group (125 patients) were received the local medical committee of Almaza Fever Hospital guided standard treatment protocol for COVID-19:~* Oseltamivir 150 mg q 12 hours for 10 days ;~* HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~* Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days.~* Additional conservative medications were also given. Patients were evaluated as scheduled on day 0, 5 \& 11 clinically"
62407390|NCT01891669|EXPERIMENTAL|Part 1|
62582764|NCT02089711||Japanese healthy subjects|subjects with healthy eyes
62582765|NCT01068730|OTHER|Treatment A|500 mg metformin (Diabex): Single oral dose of 500 mg metformin (Diabex) tablet administered in the fed condition
62582766|NCT01068730|OTHER|Treatment B|500 mg metformin (Glucophage™): Single oral dose of 500 mg metformin (Glucophage™) tablet administered in the fed condition
62210212|NCT00866970|EXPERIMENTAL|3|ALD518
62210213|NCT00866970|PLACEBO_COMPARATOR|4|No ALD518
62582767|NCT01068730|OTHER|Treatment C|1000 mg metformin (Diabex): Single oral dose of 1000 mg metformin (Diabex) tablet administered in the fed condition
62582768|NCT01068730|OTHER|Treatment D|1000 mg metformin (Glucophage™): A Single oral dose of 1000 mg metformin (Glucophage™) tablet administered in the fed condition
62582769|NCT06680687|NO_INTERVENTION|"Usual Care"|"Participants receiving Usual Care group (A), will be recruited during the last two months of treatment (T-2). At the end of treatment (T0), participants will complete a knowledge questionnaire and will be followed for another 24 months. At six months after treatment completion (T6), a final follow-up knowledge assessment will be conducted. Participants will be enrolled into group A until the intended sample size of 50 participants is reached. Investigators estimated to have reached this number within four to six months based on recent survival rates."
62734502|NCT03281369|EXPERIMENTAL|2L-3: Atezo + BL-8040 (Gastric Cancer)|Participants in the 2L-3 Gastric Cancer arm received atezolizumab in combination with BL-8040. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
62735051|NCT02720523|EXPERIMENTAL|Upadacitinib 7.5 mg / Upadacitinib 7.5 mg|"Period 1: Participants will receive upadacitinib 7.5 mg once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 7.5 mg once daily for 248 weeks."
62582770|NCT06680687|EXPERIMENTAL|"Educational Intervention"|"A similar procedure will apply to the Educational Intervention group (B). Participants will complete a knowledge assessment before receiving an educational intervention between T-2 and T0. To evaluate early and late knowledge uptake, participants will complete a post-education knowledge assessment at T0 and a follow-up knowledge assessment at T6. Follow-up adherence will be evaluated at every three months for the first year and at every six months during the second year after treatment completion for both groups. Implementation measures will be captured starting at T3 until T24, together with a satisfaction questionnaire that will be administered at T6."
62582771|NCT06680687|OTHER|"Follow-Up Forms implementation"|"Healthcare provider training on survivorship will start at the same timepoint as recruitment of the Educational Intervention group (A) at T-2.~Follow-Up Forms will be introduced at the outpatient clinic once an estimated 30 healthcare providers have done the training (anticipated at T0). Healthcare providers will fill in a knowledge assessment directly pre- and post-training (T-2) and at six months post-training (T4).~Documentation of late effect symptoms will be monitored for twelve months, starting at T0. Implementation measures will be collected weekly starting from T0 and healthcare providers will be assigned to a satisfaction questionnaire at T6."
62210214|NCT00817700|NO_INTERVENTION|Normal (8 hours) sleep time|Subjects are studied under normal sleep time conditions.
62582772|NCT05162625|ACTIVE_COMPARATOR|Topical Moxifloxacin|Pre-surgical prophylaxis with the use of topical 0.5% moxifloxacin eye drops every 3 hours until the surgery.
62582773|NCT05162625|ACTIVE_COMPARATOR|Intravenous Cephazolin and Ciprofloxacin|Pre-surgical prophylaxis with cefazolin 1 gram every 6 hours and ciprofloxacin 400 milligrams intravenously every 12 hours, until the surgery.
62582774|NCT00882778||activated recombinant human factor VII|Male patients diagnosed with haemophilia A or B with inhibitors, who were prescribed activated recombinant human factor VII (rFVIIa) for at least 30 days. All direction for rFVIIa medication usage was at the sole discretion of the physician in accordance within their usual practice. Data was collected for approximately 6 months of pre-prophylaxis, while the prophylaxis period had no limits.
62582775|NCT06312826|ACTIVE_COMPARATOR|US group|Subjects will be evaluated by two rounds of tests with abdominal US for the surveillance of HCC at intervals of 6 months.
62582776|NCT06312826|EXPERIMENTAL|AMRI group|Subjects will be evaluated by two rounds of tests with AMRI for the surveillance of HCC at intervals of 6 months.
62582777|NCT00949403|EXPERIMENTAL|Obese Females (pre-bariatric surgery)|Twenty obese females (18-45 years of age, BMI \> or equal to 45) who are scheduled to undergo bariatric surgery at Barnes-Jewish Hospital will be screened for enrollment over 2 years. They will be imaged with PET/CT and radiopharmaceuticals C-11 Acetate and C-11 Palmitate will be injected.
62582778|NCT02731937|OTHER|GE Healthcare CT Revolution (CT scanner)|Each subject will be scanned twice: the first time will be the subjects' clinically indicated CT exam and the second scan will be performed on the GE Healthcare CT Revolution (CT scanner) both scans will will be obtained.
62582779|NCT01152346|OTHER|ARM 1|Sequence- Azacitidine followed by Vidaza®
62582780|NCT01152346|OTHER|ARM 2|Sequence-Vidaza® followed by Azacitidine
62582781|NCT02644863|EXPERIMENTAL|DC-CIK|After accepting chemotherapy according to guidelines,patients will receive 3 cycles of autologous DC-CIK treatment.
62210215|NCT00817700|EXPERIMENTAL|Sleep restriction|"Sleep restriction to 4 hours of sleep per night.~Overnight sleep recording, measures of endocrine and metabolic (from blood), cardiovascular (measures of blood pressure and heart rate), performance ( before and after sleep restriction and after sleep recovery."
62407391|NCT03301207|EXPERIMENTAL|Ibrutinib + Oral Contraceptives + Probe Drugs (CYP)|Pre-treatment Phase: Participants will receive a single dose of oral contraceptive (OC) consisting of ethinylestradiol (EE) 30 microgram (mcg) and levonorgestrel (LN) 150 mcg on Study Day 1, and probe drugs (CYP) consisting of bupropion 75 milligram (mg) and midazolam 2 mg on Study Day 3, followed by a washout period from Study Days 4 to 7. Treatment Phase: Participants will receive ibrutinib 560 mg (4\*140 mg capsules) once daily (QD) on Days 8 to 26 along with midazolam 2 mg once orally on Study Day 8 (Cycle 1 Day 1), OC once orally on Study Day 22 (Cycle 1 Day 15; EE and LN), and bupropion 75 mg and midazolam 2 mg once orally on Study Day 24 (Cycle 1 Day 17). From Study Day 27 (Cycle 1 Day 20) and onwards participants will continue oral treatment with ibrutinib 420 mg (3\*140 mg capsules) or 560 mg QD (depending on the subtype of B-cell malignancy) up to the end of Cycle 6 (each cycle will consist of 28 days).
62582782|NCT02644863|SHAM_COMPARATOR|Chemotherapy|After the Chemotherapy by Paclitaxel and Cisplatin, patients will just regularly follow up.
62582783|NCT01496963||group a)|Patients with pulmonary artery pressure (PAP) assessed (by echocardiogram) \<36 mmHg or a tricuspid regurgitant jet velocity (TG) \<3 m / sec and data on PAP and mean left ventricular ejection fraction (LVEF) \> 50%
62019043|NCT03952884|EXPERIMENTAL|Leucine Peptide (Dileucine)|Participants will be allocated to an exercise or non-exercise group. After resistance exercise (or equivalent time point for non-exercise group), participants will consume 2g protein peptide powder dissolved in 250 mL of water.
62019044|NCT01200121|EXPERIMENTAL|Arm A Bevacizumab|48 patients randomized into arm A will receive repeated intra¬peritoneal application of Bevacizumab
62019045|NCT01200121|PLACEBO_COMPARATOR|Arm B Placebo|26 patients randomized into arm B will receive repeated intra¬peritoneal application of Placebo
62019046|NCT02585739|EXPERIMENTAL|patient|patient with Cluster headache
62019047|NCT02585739|OTHER|healthy subject|patient without Cluster headache
62019048|NCT05649384||0/1-hour algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 1 hour later in the emergency department.
62407392|NCT02575807|EXPERIMENTAL|Phase 1: CRS-207|"CRS-207 administered in 3-week cycles.~\* CRS-207 (1 x 10e9 colony forming units \[CFU\]) administered by intravenous (IV) infusion. For Cycle 1 through Cycle 6, CRS-207 will be administered on Day 1 of each cycle. After 6 cycles, CRS-207 will be administered on Day 1 once every 6 weeks (every other cycle)."
62407393|NCT02575807|EXPERIMENTAL|Phase 1: CRS-207/IDO 100 mg|"CRS-207 administered in 3-week cycles, IDO administered twice daily (BID).~* CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).~* IDO (100 milligrams \[mg\]) administered by mouth (PO) BID, starting on Day 2 of the first CRS-207 treatment cycle."
62210216|NCT06531993|ACTIVE_COMPARATOR|Pectin group|Pectin treatment
62407394|NCT02575807|EXPERIMENTAL|Phase 1: CRS-207/IDO 300 mg|"CRS-207 administered in 3-week cycles, IDO administered BID.~* CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).~* IDO (300 mg) administered PO BID, starting on Day 2 of the first CRS-207 treatment cycle."
62019049|NCT05649384||0/3-hour algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 3 hours later in the emergency department.
62407395|NCT02575807|EXPERIMENTAL|Phase 2: CRS-207/Pembro/IDO|"CRS-207 and pembrolizumab (pembro) administered in 3-week cycles, IDO administered BID.~* CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).~* Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles.~* IDO (300 mg) administered PO BID, starting on Day 3 of the first CRS-207 treatment cycle."
62019050|NCT00824109|OTHER|Single Arm Study|Consecutive patients meeting the selection criteria
62019051|NCT04831125||Individuals receiving conduction system pacing|
62019052|NCT01543256|ACTIVE_COMPARATOR|Metal stents|The WallFlex Biliary Fully Covered Stent System is being evaluated for treatment of benign biliary strictures secondary to chronic pancreatitis.
62019053|NCT01543256|ACTIVE_COMPARATOR|Plastic Stents|Plastic stents per Investigator preference are being evaluated for treatment of benign biliary strictures secondary to chronic pancreatitis.
62019054|NCT05153018|OTHER|A representative random sample of the population|1,200 non-febrile individuals aged older than 6 years old
62210217|NCT06531993|PLACEBO_COMPARATOR|Placepo group|Standard of care
62210218|NCT00089921|EXPERIMENTAL|001|SCIO-469 30 mg capsule three times daily for 12 weeks
62210219|NCT00089921|EXPERIMENTAL|002|SCIO-469 60 mg capsule three times daily for 12 weeks
62210220|NCT00089921|EXPERIMENTAL|003|SCIO-469 100 mg tablet once daily for 12 weeks
62210221|NCT00089921|PLACEBO_COMPARATOR|004|Placebo 2 capsules three times daily and one tablet daily
62210222|NCT05267340|EXPERIMENTAL|Experimental: TARA Training|"Behavioral: Training for Awareness, Resilience, and Action (TARA)~This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)"
62210223|NCT05267340|ACTIVE_COMPARATOR|Control: Psycho-Education|"Behavioral: Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components~This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components"
62582784|NCT01496963||group b)|"Patients with:~PAP estimated (by echocardiography)\> 40 mmHg or TG\> 3.2 m / sec and LVEF\> 50% As indicated by the Guidelines, patients b) with increased PAP (TG\> 3.2 m / sec or\> 40 mm Hg) will be further studied using RHC and vasoreactivity testing. Angio CAT, 6MWT and BNP."
62582785|NCT01496963||group c)|patients with PAP estimated (by echocardiography) in the range of values \> 3 m / sec (TG) and \<3.2 m / sec or\> 36 mm Hg and \<40 mmHg and LVEF\> 50%
62407396|NCT02575807|EXPERIMENTAL|Phase 2: CRS-207/Pembro|"CRS-207 and pembro administered in 3-week cycles.~* CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).~* Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles."
62582786|NCT02217410|EXPERIMENTAL|Regimen A|CFZ533 administered with the contemporary standard of care (SoC) consists of concentration-controlled tacrolimus (Tac), combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
62582787|NCT02217410|EXPERIMENTAL|Regimen B|CFZ533 administered with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction
62582788|NCT02217410|ACTIVE_COMPARATOR|Regimen C|Standard of care (SoC) \[concentration-controlled tacrolimus (Tac) combined with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction\]
62407397|NCT06567496|EXPERIMENTAL|Intervention|8 week First Resort virtual reality program
62407398|NCT04812548|EXPERIMENTAL|sabatolimab + azacitidine + venetoclax|"Part 1: Safety run-in consisted of 2 subsequent cohorts of a lower dose (cohort 1) and a higher dose (cohort 2) of sabatolimab in combination with fixed dose of venetoclax and azacitidine.~Part 2 (did not start as recruitment was stopped in Part 1) Expansion was to enroll additional participants to further investigate the regimen including sabatolimab at the higher dose, azacitidine and venetoclax. Participants data from Part 1 and Part 2 treated with the higher dose was to have been combined to determine the complete remission rate."
62210224|NCT05929209|EXPERIMENTAL|Assessment of disease biomarkers|
62582789|NCT04913688||suspected DVT group|If deep vein thrombosis (DVT) is suspected among patients who visit the emergency department, the patients become eligible for study subjects.
62019055|NCT04289753|ACTIVE_COMPARATOR|Brief clinician education|Clinicians attributed to clinics in the brief clinician education arm will receive invitation to view an online educational module and be recruited to complete an online survey at baseline and 18 months.
62210225|NCT02928276|EXPERIMENTAL|All patients|All eligible patients
62407399|NCT01546701|EXPERIMENTAL|Buprenorphine|Renal Colic Patients treated by 2 mg sublingual Buprenorphine.
62407400|NCT01546701|ACTIVE_COMPARATOR|Morphine|Renal Colic Patients treated by 0.1 mg/kg intravenous morphine.
62407401|NCT00594581|ACTIVE_COMPARATOR|1|Juvista (avotermin) 50ng/100μl/linear cm wound margin
62407402|NCT00594581|ACTIVE_COMPARATOR|2|Juvista (avotermin) at 200ng/100μl/linear cm
62582790|NCT00312260|EXPERIMENTAL|1|
62582791|NCT00312260|ACTIVE_COMPARATOR|2|
62582792|NCT00765518|EXPERIMENTAL|Ixmyelocel-T|The treatment arm of the study will receive injections of the study cellular product.
62210226|NCT00942760||Research MRI|High Grade Glioma patients who show progression based on MRI
62210227|NCT05673031||68Ga-HA-DOTATATE|68Ga-HA-DOTATATE Intravenous injection of 100-250 MBq 68Ga-HA-DOTATATE
62210228|NCT05932251||Low insulin sensitivity|Women will be classified as having low insulin sensitivity, if their Matsuda-index is in the lowest quartile of a reference cohort
62210229|NCT05932251||Low insulin secretion|Women will be classified as having low insulin secretion if their Stumvoll-index is in the lowest quartile of a reference cohort
62210230|NCT06040593||HR+/HER2-low Breast Cancer|Participants with HR+/HER2-low breast cancer who were treated with neoadjuvant chemotherapy or endocrine therapy identified from the ConcertAI databases.
62210231|NCT06040593||HR+/HER2-negative Breast Cancer|Participants with HR+/HER2-negative breast cancer who were treated with neoadjuvant chemotherapy or endocrine therapy identified from the ConcertAI databases.
62407403|NCT03508076|SHAM_COMPARATOR|Sham Capsule|Patients swallowed 1 sham Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
62407404|NCT03508076|EXPERIMENTAL|Vibration Capsule of low level|Patients swallowed 1 low level vibration Capsule Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
62582793|NCT00765518|OTHER|Standard of Care|Standard of care therapy only.
62582794|NCT05687136|EXPERIMENTAL|Treatment (peposertib, tuvusertib)|Patients receive peposertib PO in combination with tuvusertib PO QD or BID daily on days 1-14 of each cycle. Cycles repeat every 28 days in the absence of disease progression, pregnancy, non-compliance, unacceptable toxicity, termination of the study or the study drug is no longer available. Patients also undergo tumor biopsy before C1D1, C1D10 and at progression and blood sample collection during prestudy and weeks 1, 2, 3, 4, 5, 6, and at progression. Patients additionally undergo PET, CT, and MRI at baseline and are repeated every 8 weeks for 24 weeks then every 12 weeks unless clinically indicated.
62582795|NCT05684575|OTHER|Phone satisfaction questionnaire|Evaluation of the outcome of Covid-19 patients discharged home on oxygen therapy
62790190|NCT02352753|EXPERIMENTAL|Denosumab|"Participants received denosumab 1 mg/kg (up to a maximum of 60 mg) subcutaneously every 6 months (Q6M) for up to 36 months.~Early efficacy and PK data from Q6M dosing supported adjustment of the dosing regimen from Q6M to every 3 months (Q3M). Participants enrolled and still receiving denosumab were transitioned from Q6M to Q3M dosing schedule. Participants could transition to Q3M dosing schedule up to and including the date they attended for their month 36 visit under the Q6M dosing regimen. Those participants received denosumab during the Q3M dosing regimen for 12 months. Participants who transition to Q3M at month 18 of the Q6M dosing regimen received denosumab Q3M for up to 18 months."
62210232|NCT06009757|EXPERIMENTAL|Percutaneous Coronary Intervention with Guiding Catheter GUIDEX|Patients with coronary artery disease during a percutaneous coronary intervention will be treated with one of the guiding catheter
62210233|NCT06009757|EXPERIMENTAL|Percutaneous Coronary Intervention with Guiding Catheter Medtronics|Patients with coronary artery disease during a percutaneous coronary intervention will be treated with one of the guiding catheter
62210234|NCT02544451|EXPERIMENTAL|Treatment Period 1: LUM/IVA to LUM/IVA|
62210235|NCT02544451|EXPERIMENTAL|Treatment Period 1: Placebo (PBO) to LUM/IVA|
62210236|NCT02544451|NO_INTERVENTION|Treatment Period 1: Observational Cohort|
62210237|NCT02544451|EXPERIMENTAL|Treatment Period 2: LUM/IVA|
62210238|NCT06335875|EXPERIMENTAL|Bipolar Disorder|Participants will follow an intervention consisting of dietary changes and ketone ester supplementation for 90 +/- 10 days. The dietary changes are intended to reduce glycemic spiking and include: not consuming sweets, not consuming soda, replacing 'white' grains with whole grain alternatives, and reserving any fruit consumption for the end of meals. During the same time period, participants will consume the ketone ester supplement, consisting of 19 g Juvenescence Cognitive Switch™ (=12.5 g active C8-KE) diluted in water twice per day.
62210239|NCT00075842|EXPERIMENTAL|Arm I|Patients receive oral Valeriana officinalis (Valerian) once daily for 8 weeks.
62210240|NCT00075842|PLACEBO_COMPARATOR|Arm II|Patients receive an oral placebo once daily for 8 weeks.
62210241|NCT06729866|EXPERIMENTAL|Electrogram guided pulse field ablation|In persistent atrial fibrillation patients, traget electrogram was mapped firstly , pulse field ablation of pulmonary veins, posterior wall of left atrium and target electrogram was ablated, until the atrial fibrillation converted to sinus rythm or stable atrial tachycardia. The mapping and ablation procedure was repeated until AF terminated or no target electrogram was found.
62210242|NCT06378385||Observational|Development and validation of a Childhood Early Oral Aging Syndrome index for the primary dentition as a diagnostic and epidemiological survey tool considering the current changes found in the pediatric population.
62210243|NCT02184364|EXPERIMENTAL|Low dose of Klimadynon®|
62210244|NCT02184364|EXPERIMENTAL|Medium dose of Klimadynon®|
62210245|NCT02184364|EXPERIMENTAL|High dose of Klimadynon®|
62210246|NCT02184364|ACTIVE_COMPARATOR|Oestrofeminal®|
62210247|NCT02184364|PLACEBO_COMPARATOR|Placebo|
62210248|NCT00717223||Parents with children with diabetes|parents who have children 18 or younger with diabetes
62210249|NCT06729749|ACTIVE_COMPARATOR|Group A (control group)|lt will include 28 participants suffering from PD who will take vitamin D (vit D) supplementations for three consecutive menstrual cycles.
62210250|NCT06729749|EXPERIMENTAL|Group B (study group)|lt will include 28 participants suffering from PD who will take vitamin D (vit D) supplementations as in group A in addition to Bioptron for 20 min daily for 7 days before menstrual cycle along with the first three days of menstrual flow for three consecutive menstrual cycles.
62407405|NCT03508076|EXPERIMENTAL|Vibration Capsule of high level|Patients swallowed 1 high level vibration Capsule Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
62582796|NCT05405088|OTHER|Open-label cohort, with short follow-up|This is a collection of data from postoperative questionnaires and simple, non-invasive clinical observations. The oral surgery acts in question are performed in daily practice without any change in patient management. The intraoperative data collected come from routine care. Postoperative data (pain and analgesic intake) are collected by self-questionnaires and no visit on purpose is required.
62582797|NCT03033862||Intervention with Bioresorbable Vascular Scaffold|Implant of Abbott Bioresorbable stent
62790191|NCT02533492|ACTIVE_COMPARATOR|Vicryl|Vicryl suture for wound closure after total knee replacement
62210251|NCT01980927|EXPERIMENTAL|NUCCA atlas correction|NUCCA atlas correction for migraine patients
62210252|NCT01711164||patients|Chronic HCV patients who undergo antiviral therapy
62210253|NCT01711164||Healthy controls|healthy controls who are willing to give blood and liver tissue samples
62210254|NCT00223717|EXPERIMENTAL|1: Active drug or intervention|Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt, aliskiren, local heat stress
62210255|NCT00223717|PLACEBO_COMPARATOR|2: Placebo|placebo pill or patch
62210256|NCT05913193||Oral Nutritional Supplement (ONS) Group|2 servings per day as per standard of care during the study period
62210257|NCT03472053|EXPERIMENTAL|BIO-11006 plus standard of care|Aerosolized BIO-11006 (125mg BID) plus standard of care (Pemetrexed plus Carboplatin) is administered for three months.
62210258|NCT03472053|EXPERIMENTAL|Standard of Care|Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's Formula) is administered every three weeks for three months.
62210259|NCT05316623|SHAM_COMPARATOR|Control group|Simulated TENS and personalized exercise program in telerehabilitation (3 sessions/week over 3 weeks) n = 12
62210260|NCT05316623|EXPERIMENTAL|Intervention group|Real TENS and personalized exercise program in telerehabilitation (3 sessions/week over 3 weeks) n = 12
62210261|NCT03788603|EXPERIMENTAL|Rogaratinib (BAY1163877)|Eligible patients will be selected based on the confirmation of high fibroblast growth factor receptor (FGFR) 1, 2, 3 or 4 mRNA expression levels in archival or fresh tumor biopsy specimens collected before the start of screening
62210262|NCT01854138|NO_INTERVENTION|Control|Retrospectively reviewed patients who underwent Total Knee or Hip Arthroplasty and received traditional gauze dressing to cover their clean surgical wound.
62407406|NCT03945929|EXPERIMENTAL|Distraction1 group|Distraction-1 Group (Cards containing optical illusion pictures)
62407407|NCT03945929|NO_INTERVENTION|Control|Control
62407408|NCT03945929|EXPERIMENTAL|Distraction 2 group|Distraction-2 Group
62582798|NCT03033862||Intervention with Drug Eluting Stent|implant of drug eluting stent
62582799|NCT01903967||"Control Group"|Patients cured with no evidence of disease up to 5 years will be the controls.
62582800|NCT01903967||"Case Group"|Patients, in recurrence or progression before 5 years will be the cases
62582801|NCT02609607|PLACEBO_COMPARATOR|Placebo|Every other day placement of a placebo rectal suppository for 4 weeks
62790192|NCT02533492|EXPERIMENTAL|vicryl plus|Vicryl plus suture for wound closure after total knee replacement
62582802|NCT02609607|EXPERIMENTAL|Bisacodyl|Every other day placement of a bisacodyl 10 mg rectal suppository for 4 weeks
62582803|NCT04180852||Neurosurgical patients|"Non-elective admission to the neurosurgical ICU with one of the following acute intracranial pathologies which also serve as predefined subgroups:~1. Intracranial hemorrhage (subarachnoid, subdural hemorrhage or intracerebral hemorrhage)~2. Acute and severe head trauma with an initial Glasgow Coma Scale ≤10"
62019056|NCT04289753|EXPERIMENTAL|Clinical decision support nudges and brief clinician education|Clinicians attributed to clinics randomized to the clinical decision support nudges and brief clinician decision support arm will receive clinical decision support within the EHR when conditions meet alert triggering criteria. These clinicians will also receive invitation to view an online educational module and be recruited to complete an online survey at baseline and 18 months.
62019057|NCT03224468|ACTIVE_COMPARATOR|Medical Marijuana Arm|This group can begin using medical marijuana immediately.
62210263|NCT01854138|EXPERIMENTAL|Prevena Knee/Hip|Prospectively enrolled patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty and receiving Prevena Incision Management System on the clean surgical wound.
62210264|NCT01169740||Neonatal jaundice|Infants born between July 1st 2010 and July 31st 2010 and admitted to normal newborn nursery
62407409|NCT06650891|EXPERIMENTAL|Quercetin|receive 500mg of oral quercetin 1 hour preoperatively.
62407410|NCT06650891|PLACEBO_COMPARATOR|Placebo|receive placebo 1 hour preoperatively
62407411|NCT01904331||Breast cancer patients|Women who were curatively treated with chemo- and/or radiotherapy for breast cancer
62407412|NCT01904331||Controls|Women matched on age and general practitioner with the breast cancer patients
62407413|NCT04780776|EXPERIMENTAL|UVB treatment arm|The treatment group will first undergo an evaluation of each individual's sensitivity to the SOLIUS System UVB using the device titration system for the first 5 weeks. Once the UVB dose is determined during the 5 weeks, the subjects will be enrolled in a 16-week study where they will be exposed to their individualized dose.
62407414|NCT04780776|SHAM_COMPARATOR|Sham comparator arm|The sham comparator group will undergo the procedures as the treatment group with the exception that the SOLIUS System will only be turned on to emit visible radiation.
62407415|NCT05409300|EXPERIMENTAL|BBIBP-CorV|Intramuscular administration of two doses of vaccine at 28 days (+/- 2 days) interval (0.5 mL/dose)
62407416|NCT02826174|EXPERIMENTAL|closed PKP under topical anesthesia|a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
62407417|NCT02826174|ACTIVE_COMPARATOR|open-sky PKP under retrobulbar anesthesia|an open-sky corneal transplantation under retrobulbar anesthesia
62407418|NCT02826174|OTHER|Anti-Rejection Agents|Anti-Rejection Agents for both groups
62210265|NCT04321668|OTHER|Injection of SYNVISC-ONE|Patients suffering from symptomatic knee osteoarthritis (OA), receiving intra-articular (IA) injection of SYNVISC-ONE® (Hylan G-F 20; 10 mL single-injection viscosupplement)
62407419|NCT02826174|OTHER|Anti-Inflammatory Agents|Anti-Inflammatory Agents for both groups
62407420|NCT01146340|EXPERIMENTAL|SBRT|SBRT 40 Gy in 5 fractions over 29 days delivered using step and shoot IGRT
62407421|NCT05117307|ACTIVE_COMPARATOR|Group ESP|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
62407422|NCT05117307|ACTIVE_COMPARATOR|Group TFP|Ultrasound-guided Transversalis Fascia Plane Block block with 20 ml %0.25 bupivacaine, per side
62407423|NCT04832711||the low-risk group for OSA|A Chinese translation of the BQ was used to classify subjects into high risk and low risk for OSA.
62407424|NCT04832711||the high-risk group for OSA|A Chinese translation of the BQ was used to classify subjects into high risk and low risk for OSA.
62210266|NCT03243682|ACTIVE_COMPARATOR|Bidirectional Shock Wave Lithotripsy|alternating bidirectional (under and over table) approach
62407425|NCT00808769|ACTIVE_COMPARATOR|1|Zegerid®
62407426|NCT00808769|EXPERIMENTAL|2|Prilosec OTC®
62407427|NCT05542173|EXPERIMENTAL|BALI 25 + 25 + 15|Three applications per day or more in case of pain, not exceeding six applications per day. The number of drops varies according to the ulcer diameter: 1 to 3 mm: 1 drop; 3 to 6 mm: 2 drops; greater than 6 mm: 3 drops.
62582804|NCT04180852||Elderly patients|Age ≥ 70 years, predefined subgroups: ≥ 70 years and ≥80 years
62582805|NCT04180852||Obese patients|BMI ≥ 35 kg/m2, furthermore predefined subgroups of patients with BMI ≥ 40 kg/m2 and BMI ≥ 45 kg/m2
62582806|NCT04180852||Cardiac surgery patients|"Admission to the cardiosurgical ICU after one of the following procedures using cardiopulmonary bypass, which also serve as predefined subgroups:~1. Coronary revascularization (coronary artery bypass graft)~2. Heart valve surgery~3. Combined or complex heart surgery"
62582807|NCT04180852||Abdominal surgical patients|Admission to the abdominal surgery ICU after abdominal surgery
62582808|NCT05401019|EXPERIMENTAL|Experimental arm|Treatment with pramipexol, once a day, tablet of 0.088, 0.18, 0.35, 0.53 mg per day during 16 weeks
62582809|NCT05401019|ACTIVE_COMPARATOR|Control arm|Treatment with Risperidone, once a day, tablet of 0.5, 1, 1.5, 2 mg per day during 16 weeks + 8 weeks follow-up.
62019058|NCT03224468|NO_INTERVENTION|Waitlist Control Arm|This group agrees to wait 3 months before using medical marijuana.
62019059|NCT03892486|EXPERIMENTAL|The high PUFA diet group|This will receive detailed nutritional recommendations and will consume at least 4 table spoons of olive oil or 30 grams of nuts daily for 12 weeks.
62210267|NCT03243682|ACTIVE_COMPARATOR|Standard Shock Wave Lithotripsy|standard unidirectional approach
62582810|NCT01661829||Biofeedback|Patients will undergo biofeedback therapy between 1st adjuvant chemotherapy and stoma closure(= after 3rd ajduvant chemotherapy)
62210268|NCT00680446|EXPERIMENTAL|1|
62582811|NCT01661829||Kegel|Patients will be trained to take excersise for their anal sphincter by Kegel.
62582812|NCT04670874||Observational (quality of life questionnaire)|Patients complete quality of life questionnaires over 10-20 minutes about symptoms, emotions, and functioning related to diagnosis of cutaneous lymphoma.
62210269|NCT04996732||All Cancers|subgroups according to cancer sites
62210270|NCT03825731|EXPERIMENTAL|GC022|The patients will receive GC022 CAR-T treatment. GC022 dosage ranges from 3×10\^5 to 1×10\^7 CAR+T/Kg.
62210271|NCT06607978||patients with subclinical hypothyroidism admitted to internal medicine department.|patients with subclinical hypothyroidism admitted to internal medicine department.
62210272|NCT06607978||healthy match individual .|healthy match individual
62210273|NCT04422327|EXPERIMENTAL|Probiotic capsule|The participants consume one probiotic capsule a day for 8 weeks
62210274|NCT06611007|EXPERIMENTAL|Arterial embolization of the hand with Lipiodol|The radial artery will be embolized with Lipiodol emulsified 3:1 with iodinated contrast medium (Optiray 300 mg/ml). The most painful hand according to VAS pain will be treated.
62210275|NCT01630421||affected, unaffected|Individuals with diagnosed ACC
62210276|NCT04245943|EXPERIMENTAL|Exercise|18 weeks supervised strength and aerobic exercise training
62019060|NCT03892486|NO_INTERVENTION|Control group|The Control group will receive general nutritional recommendations based on Human Nutrition Recommendations for Polish Population.
62210277|NCT01631227|EXPERIMENTAL|Eprosartan|Eprosartan + Placebo Eprosartan Mesylate
62210278|NCT01631227|ACTIVE_COMPARATOR|Eprosartan Mesylate|Eprosartan Mesylate + Placebo Eprosartan
62582813|NCT00749307|EXPERIMENTAL|1|
62019061|NCT01831089|EXPERIMENTAL|Treatment|PM01183 + paclitaxel +/- bevacizumab
62019062|NCT04002752|EXPERIMENTAL|Panel A: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 1) or matching placebo as single subcutaneous injection.
62019063|NCT04002752|EXPERIMENTAL|Panel B: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 2) or matching placebo as single subcutaneous injection.
62019064|NCT04002752|EXPERIMENTAL|Panel C: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 3) or matching placebo as single subcutaneous injection.
62210279|NCT04136821|PLACEBO_COMPARATOR|Placebo|Participants will engage in a 6 week, whole-body, resistance training program 3-5 days per week will consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days.
62210280|NCT04136821|EXPERIMENTAL|Oceanix™|Participants will engage in a 6 week, whole-body, resistance training program 3-5 days per week will consuming a the treatment condition (Oceanix™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days.
62210281|NCT04059627|EXPERIMENTAL|Experimental arm|"Participants were introduced to Heart-Track mobile app system and its navigational characteristics with standardised instructions. Each participant then performed a self-directed Cardiac rehabilitation session using the app."
62210282|NCT06409429|EXPERIMENTAL|Experimental group (Nimotuzumab+ GX)|
62210283|NCT06409429|PLACEBO_COMPARATOR|Control group (Placebo+ GX)|
62210284|NCT00453193|EXPERIMENTAL|Alemtuzumab + Pentostatin|Alemtuzumab 30 mg intravenous (IV) three times weekly; Pentostatin 4 mg/m\^2 IV weekly for 4 weeks then every 2 weeks
62582814|NCT00749307|PLACEBO_COMPARATOR|2|
62582815|NCT03724747|EXPERIMENTAL|BAY2315497 dose escalation|The thorium-227 dose will be escalated in a step-wise fashion to the MTD, according to a predefined dose escalation scheme. The total antibody dose of 50 mg will be evaluated first; on the basis of emerging clinical data, doses within the range of 20-100 mg may be investigated.
62582816|NCT03724747|EXPERIMENTAL|BAY2315497 dose escalation in combination with darolutamide|The thorium-227 dose will be escalated in a step-wise fashion to the MTD, according to a predefined dose escalation scheme. In addition, Darolutamide oral dosing at the approved dose of twice daily 600 mg will be initiated 14 days prior to the first BAY2315497 Injection dose on Day 1 of the first cycle. Daily darolutamide dosing will continue throughout the entire BAY2315497 Injection treatment period until withdrawal criteria from study treatment period are met.
62582817|NCT03724747|EXPERIMENTAL|BAY2315497 dose expansion:Dose regimen 1|The thorium-227 and total antibody doses, as well as the treatment regimen, will be selected for expansion on the basis of the safety, PK and overall benefit risk profile of BAY2315497 Injection, observed in the course of the dose escalation.
62735052|NCT02720523|EXPERIMENTAL|Upadacitinib 15 mg / Upadacitinib 15 mg|"Period 1: Participants will receive upadacitinib 15 mg once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks."
62582818|NCT03724747|EXPERIMENTAL|BAY2315497 dose expansion:Dose regimen 2|The thorium-227 and total antibody doses, as well as the treatment regimen, will be selected for expansion on the basis of the safety, PK and overall benefit risk profile of BAY2315497 Injection, observed in the course of the dose escalation.
62019065|NCT01769794|ACTIVE_COMPARATOR|Western therapy & Placebo|Western therapy(oral care, skin care and reducing temperature) Placebo for JET(Jinlianqingre Effervescent Tablets )
62582819|NCT01663090|EXPERIMENTAL|Nanoparticle enhanced MRI|
62210285|NCT06729788|EXPERIMENTAL|ICON resin infiltration group (in vivo)|The fissure of selected teeth will be sealed with ICON resin infiltration Material (DMG Dental UK)
62407428|NCT05542173|PLACEBO_COMPARATOR|PLACEBO|Three applications per day or more in case of pain, not exceeding six applications per day. The number of drops varies according to the ulcer diameter: 1 to 3 mm: 1 drop; 3 to 6 mm: 2 drops; greater than 6 mm: 3 drops.
62407429|NCT05858515|PLACEBO_COMPARATOR|Placebo|These participants will receive placebo for 24 weeks (6 mo)
62407430|NCT05858515|EXPERIMENTAL|Intervention #1|These participants will receive baricitinib 4 mg daily for 24 weeks
62407431|NCT03422276|ACTIVE_COMPARATOR|Rehabilitation Discharge Plan|Commission on Accreditation of Rehabilitation Facilities (CARF) standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury, including patient and family education, written discharge care instructions, and telephone follow up from a clinical provider.
62582820|NCT03458806||Control|Subjects with echocardiographically confirmed valvular disease of less than moderate-to-severe grading with regards to aortic stenosis (AS) and mitral regurgitation (MR). Note that within this cohort will be a sub cohort consisting of subjects with structurally normal hearts, with no greater than mild valvular disease of any valve, no prior valvular intervention, and no evidence of congenital heart disease.
62019066|NCT01769794|EXPERIMENTAL|Western therapy & JET|Jinlianqingre Effervescent Tablets plus western therapy
62210286|NCT06729788|PLACEBO_COMPARATOR|Resin-based fissure sealant group (in vivo)|The fissure of selected teeth will be sealed with resin-based fissure sealant (Heliosael)
62407432|NCT03422276|ACTIVE_COMPARATOR|Rehabilitation Transition Plan|Approximately 12 scheduled contacts from a TBI care manager 6 months following discharge in addition to the CARF standards for discharge.
62407433|NCT05238701|EXPERIMENTAL|LPM3770164|LPM3770164 sustained-release tablets will be administrated with single dose from 0.5mg to 60mg
62210287|NCT06729788|EXPERIMENTAL|ICON resin infiltration Material (in vitro)|The fissure of selected teeth will be sealed with ICON resin infiltration Material (DMG Dental UK)
62210288|NCT06729788|PLACEBO_COMPARATOR|Resin-based fissure sealant (in vitro)|The fissure of selected teeth will be sealed with resin-based fissure sealant (Heliosael)\*\*
62210289|NCT02285153|EXPERIMENTAL|Acetylsalicylic acid lysinate|100mg Acetylsalicylic Acid
62407434|NCT05238701|PLACEBO_COMPARATOR|Placebo|LPM3770164 sustained release tablet simulant will be administrated with single dose
62407435|NCT00319488|ACTIVE_COMPARATOR|1|Active ICS plus placebo LTRA plus albuterol inhalation treatments four times daily
62407436|NCT00319488|ACTIVE_COMPARATOR|2|Active LTRA plus placebo ICS plus albuterol inhalation treatment four times daily
62407437|NCT00319488|PLACEBO_COMPARATOR|3|Placebo ICS plus placebo LTRA plus albuterol inhalation treatments four times daily
62407438|NCT04510558|EXPERIMENTAL|Intervention (mesh)|Insertion of a non-resorbable mesh in the subway position.
62582821|NCT03458806||AS Case|Subjects with echocardiographically confirmed aortic stenosis (AS) of moderate-to-severe or greater grading.
62582822|NCT03458806||MR Case|Subjects with echocardiographically confirmed mitral regurgitation (MR) of moderate-to-severe or greater grading.
62582823|NCT03458806||Control Subgroup|Subjects with structurally normal hearts, with no greater than mild valvular disease of any valve, no prior valvular intervention, and no evidence of congenital heart disease.
62582824|NCT01092091|EXPERIMENTAL|PEG-BCT-100|Pegylated Recombinant Human Arginase I
62210290|NCT02285153|PLACEBO_COMPARATOR|0.9% sodium-chloride solution|0.9% sodium-chloride solution
62210291|NCT06197984||Patients with acute cholangitis|Patients admitted to the hospital due to acute cholangitis and undergoing ERCP will be selected. Bile specimens will be obtained after cannulation through the sphincterotome before the therapeutic intervention.
62407439|NCT04510558|SHAM_COMPARATOR|Control (no mesh)|No insertion of mesh.
62407440|NCT03429465|EXPERIMENTAL|EVO|All children receive 4 weeks of EVO 5 days/week for 20 minutes per day in a stepped wedge design.
62407441|NCT01292369||Breast cancer|Women diagnosed with breast cancer by a positive biopsy test after mammography.
62407442|NCT01292369||Breast control|Women with negative biopsy result done due to a suspicious mammography exam.
62210292|NCT04094688|EXPERIMENTAL|Arm I (bevacizumab, chemotherapy, high-dose vitamin D3)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV on days 1-3 or irinotecan hydrochloride IV on day 1, leucovorin calcium IV over 90 minutes on day 1, and fluorouracil IV on days 1-3. Patients also receive high-dose cholecalciferol PO QD on days 1-14. Cycles repeat every 14 days for 5 years in the absence of disease progression or unacceptable toxicity.
62210293|NCT04094688|ACTIVE_COMPARATOR|Arm II (bevacizumab, chemotherapy, standard-dose vitamin D3)|Patients receive bevacizumab and chemotherapy as in Arm I. Patients also receive standard-dose cholecalciferol PO QD on days 1-14. Cycles repeat every 14 days for 5 years in the absence of disease progression or unacceptable toxicity.
62407443|NCT01292369||Colon cancer|Men and women diagnosed with colon cancer by a positive colonoscopy and biopsy.
62407444|NCT01292369||Colon control|Men and women with negative colonoscopy and biopsy tested due to complaints indicating the possibility of colon cancer.
62407445|NCT00029107|OTHER|Immediate treatment|Patients receive treatment with four weekly infusions of rituximab 375mg/m2 immediately following randomization.
62407446|NCT00029107|OTHER|Delayed treatment|Patients treated with standard therapy (corticosteroids, plasma exchange, etc.). After 6 months, they are eligibile to cross over and receive four weekly infusions of rituximab.
62407447|NCT01237717||normotensive subjects|subjects without hypertension, and without diabetes, ischemic heart disease, major arrhythmia, heart failure, secondary hypertension, high grade renal disease,
62407448|NCT01237717||Hypertensive subjects|"subjects with hypertension,~1. currently not treated at least within 6 months~2. without diabetes, ischemic heart disease, major arrhythmia, heart failure, secondary hypertension, high grade renal disease,"
62407449|NCT01905891|OTHER|Subjects at risk of skin cancer|Subjects at risk of skin cancer (sun-damaged skin) a superficial shave biopsy will be performed.
62407450|NCT01905891|OTHER|Subjects with healthy skin|Subjects without sun-damaged skin a superficial shave biopsy will be performed.
62582825|NCT05364281||Study Group|Patients younger than 18 years, who were scheduled for elective adenoidectomy or adenotonsillectomy operation.
62582826|NCT00875108|EXPERIMENTAL|VIAject™|Single injection
62582827|NCT02424630|EXPERIMENTAL|ISB with SSNB|During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL ropivacaine.
62582828|NCT02424630|PLACEBO_COMPARATOR|ISB alone|During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL normal saline.
62019067|NCT02081794|EXPERIMENTAL|Arm I (Tailored education intervention)|Participants receive a tailored educational intervention on the risk of falls comprising one of four two-minute videos determined by which educational group the participant is placed in: high risk/high perception, high risk/low perception, low risk/high perception, or low risk/low perception. Participants also receive tailored printed educational information concerning hospital falls based on the participants' answers given on the Perceived Risk Survey and are tailored to the participants' perception of falls risk. Participants also complete an investigator-constructed satisfaction survey at 24 and 72 hours post-intervention.
62210294|NCT06513065|ACTIVE_COMPARATOR|ARM A (lower dose)|10mg/m2 MMC given intraperitoneal as one single dose at Time 0 of HIPEC
62210295|NCT06513065|EXPERIMENTAL|ARM B (higher dose)|35mg/m2 MMC given in fractionated doses :50% at Time 0, 25% at T30 and 25% at T60
62210296|NCT01998074|EXPERIMENTAL|Study formula|
62407451|NCT00826878|EXPERIMENTAL|Tivozanib (AV-951)|
62407452|NCT00442572|EXPERIMENTAL|PEGASYS|Participants received 4 treatment cycles of continuous intermittent treatment with PEGASYS® (Peginterferon alfa-2a) . Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
62407453|NCT00442572|NO_INTERVENTION|No Intervention|Participants were on non- specific anti-viral treatment.
62407454|NCT04698707||lower limb lymphedema patients|This retrospective cohort study enrolled 131 lower limb lymphedema patients including 10 patients who have received VLNT as their primary lymphedema surgery showing minimal post-VLNT improvement (Group I) and 121 patients without previous lymphatic surgery (Group II).
62407455|NCT03611452|EXPERIMENTAL|Simple continuous|the sutures will be taken continuously by simple method
62407456|NCT03611452|ACTIVE_COMPARATOR|subcuticular|the sutures will be taken subcuticular
62407457|NCT03611452|ACTIVE_COMPARATOR|interrupted|the sutures will be taken interrupted method
62407458|NCT02060526|ACTIVE_COMPARATOR|45 mg Q2W|rhHNS 45 mg administered intrathecally Q2W (once every 2 weeks ie, every 14 days), for 48 weeks via the surgically implanted IDDD (or LP)
62407459|NCT02060526|ACTIVE_COMPARATOR|45 mg Q4W|rhHNS 45 mg administered intrathecally Q4W (once every 4 weeks ie, every 28 days), for 48 weeks via the surgically implanted IDDD (or LP)
62582829|NCT02577120|EXPERIMENTAL|TEWL - Epiceram|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
62582830|NCT02577120|PLACEBO_COMPARATOR|TEWL - Vaseline Petroleum Jelly|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
62582831|NCT01514058|ACTIVE_COMPARATOR|EUS-FNA First|Patients will undergo EUS-FNA first, followed by ERCP with biliary stenting (using a plastic stent).
62582832|NCT01514058|ACTIVE_COMPARATOR|ERCP with stent placement first|Patients will undergo ERCP with stent placement first, followed by EUS-FNA.
62582833|NCT02324387|EXPERIMENTAL|Molecular Breast Imaging (MBI) + Tc99m sestamibi|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled chemotherapy treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
62407460|NCT02060526|PLACEBO_COMPARATOR|Placebo|The comparator group will receive no treatment with rhHNS.
62582834|NCT00187681|EXPERIMENTAL|OCT1-variant Group|Subjects with OCT1-variant alleles will be dosed with 2 doses of Metformin
62582835|NCT00187681|EXPERIMENTAL|OCT1-reference Group|Subjects with OCT1-reference alleles will be dosed with 2 doses of Metformin
62582836|NCT01683266|EXPERIMENTAL|HOE901-U300|HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]).
62210297|NCT02028078|EXPERIMENTAL|Insulin human (Actrapid)|At 22:00 subject will receive insulin human (Actrapid) intravenously in order to obtain a steady state of a PG level of 5.5 mmol/L overnight until approximately 08:00 in the morning of day 2. At 8:00 am, in the morning at day 2, human insulin infusion will be increased to 1.5 mU/kg/min for each subject until approx. 12 pm for hypoglycaemia induction.
62210298|NCT06005545|ACTIVE_COMPARATOR|Passive Ultrasonic Irrigation group (PUI)|Arm 1: Passive ultrasonic irrigation group (PUI); shaping up to WL with 25.06,
62210299|NCT06005545|EXPERIMENTAL|Endoclean group (EC)|Arm 2: Endoclean (EC) group; shaping up to WL with 20.06; EC application tip kept 3mm short of WL, irrigation protocol with NaOCl (sodium hypochlorite)
62210300|NCT06005545|ACTIVE_COMPARATOR|Conventional Group|Arm 3: Conventional group; shaping up to WL of 25.06, irrigation protocol with NaOCl (sodium hypochlorite)
62210301|NCT01544543||COPD Exacerbation Cohort|Patients hospitalized for a COPD exacerbation
62019068|NCT02081794|ACTIVE_COMPARATOR|Arm II (standard fall care)|Participants receive standard care by nurses comprising a falls risk assessment and verbal education and receive an educational instruction sheet on falls prevention.
62210302|NCT02558127||50 asthma patients|50 asthma patients with bronchial mucus hypersecretion
62210303|NCT02558127||asthma patients|50 asthma patients without bronchial mucus hypersecretion
62407461|NCT05779059|EXPERIMENTAL|Initial ticagrelor|All patients will receive standard 180 mg loading dose of ticagrelor, followed by a standard maintenance dose of 90 mg bid for 30 days, after which de-escalation to 60 mg bid will take place and this dosing will be maintained for 15 days. At day 45 all patients will be loaded with standard 60 mg dose of prasugrel followed by reduced maintenance dose of 5 mg qd for 15 days. At day 60 all patients will be switched back to guideline recommended antiplatelet therapy.
62407462|NCT05779059|EXPERIMENTAL|Initial prasugrel|All patients will receive standard 60 mg loading dose of prasugrel, followed by a standard maintenance dose 10 mg qd for 30 days, after which de-escalation to 5 mg qd will take place and this dosing will be maintained for 15 days. At day 45 patients will be loaded with standard 180 mg dose of ticagrelor followed by reduced maintenance dose of 60 mg bid for 15 days. At day 60 all patients will be switched back to guideline recommended antiplatelet therapy.
62407463|NCT04130477|EXPERIMENTAL|Clear aligners with tunnel attachment|Participants will receive traditional clear aligner therapy with virtual set up and will be supplemented by virtually planned tunnel attachments which will be threaded by a light Nickel-Titanium wire
62407464|NCT04130477|ACTIVE_COMPARATOR|Clear aligners|Participants will receive traditional clear aligner therapy with virtual set up
62407465|NCT05681299|ACTIVE_COMPARATOR|Growth hormone|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects. Injections will be performed from the night of day 0 to the night of day 20.
62019069|NCT01694706|EXPERIMENTAL|Reference|faldaprevir medium, fasted
62019070|NCT01694706|ACTIVE_COMPARATOR|Test 1|faldaprevir medium, fed
62019071|NCT01694706|ACTIVE_COMPARATOR|Test 2|faldaprevir medium + omeprazole medium
62019072|NCT02746692|EXPERIMENTAL|Intervention|
62019073|NCT02746692|ACTIVE_COMPARATOR|Comparison|
62019074|NCT02325882|ACTIVE_COMPARATOR|Conventional fentanyl-based epidural PCA|
62210304|NCT01139476||AHS BEEA participants|A subset of 1990 AHS cohort members who are male private pesticide applicators, living and over 50 years of age at the time contact, cancer free, and who completed AHS Phases IIII.
62210305|NCT01139476||Non-AHS BEEA participants|A group of 225 age-, race-, and countymatched, non-AHS controls, who have not lived or worked on a farm as an adult, or held a job applying pesticides.
62210306|NCT06411808|EXPERIMENTAL|SADE Group: Sensory-Adapted Dental Environment|Participants in this arm will experience dental care in a Sensory-Adapted Dental Environment. Modifications such as dimmed lighting, noise-canceling headphones, and specialized dental tools are used to minimize sensory overload and enhance comfort during dental procedures.
62210307|NCT06411808|NO_INTERVENTION|Control Group: Regular Dental Environment|Participants in this arm will receive dental care in a Regular Dental Environment without sensory adaptations, representing standard dental care settings.
62210308|NCT01929629|PLACEBO_COMPARATOR|Placebo fasting|Single or multiple dosing placebo
62210309|NCT01929629|EXPERIMENTAL|Active fed condition|AZD0914 given as single dose
62210310|NCT02174666|ACTIVE_COMPARATOR|Red clover extract|Group recieving daily red clover extract containing isoflavones (80 mg/d), along with calcium (1040 mg/d), vitamin D (25µg/d) and magnesium (487mg/d).
62210311|NCT02174666|PLACEBO_COMPARATOR|Placebo group|Group recieving daily placebo extract (with no isoflavone content), calcium (1040 mg/d), vitamin D (25µg/d) and magnesium (487mg/d).
62210312|NCT06729606|EXPERIMENTAL|Aviptidil + SOC|
62210313|NCT06729606|PLACEBO_COMPARATOR|Placebo + SOC|
62210314|NCT06729736|EXPERIMENTAL|ERAS implemented arm|ERAS protocol implemented patients (single arm).
62210315|NCT02712073||patients undergoing colonoscopy|
62019075|NCT02325882|EXPERIMENTAL|dexmedetomidine to fentanyl-based intravenous PCA|
62019076|NCT02325882|ACTIVE_COMPARATOR|Conventional fentanyl-based intravenous PCA|
62019077|NCT04087057||Observational (interview, medical records review)|Patients complete questionnaires and participate in an interview to answer questions about information patients received before starting chemotherapy, any medical problems after surgery that could have been related to the start of the chemotherapy, how chemotherapy affected patients' life, and anything else patients may remember between the time when the breast surgery ended and the first dose of chemotherapy started. Patients' medical records are also reviewed.
62210316|NCT01283516|EXPERIMENTAL|LDK378 750 mg: Arm 1A and Arm 1B|NSCLC patients previously treated with an ALK inhibitor
62210317|NCT01283516|EXPERIMENTAL|LDK378 750 mg: Arm 2|NSCLC patients not previously treated with an ALK inhibitor
62210318|NCT01283516|EXPERIMENTAL|LDK378 750 mg: Arm 3|Patients with other tumors that are ALK positive other than NSCLC
62582837|NCT01683266|ACTIVE_COMPARATOR|Lantus|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
62582838|NCT06574464||Survivors|Survivors were defined as patients who were still alive after 28 days of admission to the emergency department.
62019078|NCT05776108|EXPERIMENTAL|CAB IR Formulation (reference)/CAB DT Formulation (Test 1)/CAB DT Formulation (Test 2)|Participants will receive CAB IR Formulation (reference) under fasted conditions in treatment period 1 followed by CAB DT Formulation (test 1) under fasted conditions in treatment period 2 followed by CAB DT Formulation (test 2) under fed conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment .
62019079|NCT05776108|EXPERIMENTAL|CAB DT Formulation (Test 1)/CAB IR Formulation (reference)/CAB DT Formulation (test 2)|Participants will receive CAB DT Formulation (test 1) under fasted conditions in treatment period 1 followed by CAB IR Formulation (reference) under fasted conditions in treatment period 2 followed by CAB DT Formulation (test 2) under fed conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment.
62019080|NCT05776108|EXPERIMENTAL|CAB DT Formulation (test 2)/CAB IR Formulation (reference)/CAB DT Formulation (test 1)|Participants will receive CAB DT Formulation (test 2) under fed conditions in treatment period 1 followed by CAB IR Formulation (reference) under fasted conditions in treatment period 2 followed by CAB DT Formulation (test 1) under fasted conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment.
62407466|NCT05681299|ACTIVE_COMPARATOR|Liraglutide|Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly. Injections will be performed from the night of day 0 to the night of day 20.
62407467|NCT05681299|ACTIVE_COMPARATOR|Growth hormone and liraglutide|"GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects. Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.~Injections will be performed from the night of day 0 to the night of day 20."
62019081|NCT05776108|EXPERIMENTAL|CAB IR Formulation (reference)/CAB DT Formulation (test 2)/CAB DT Formulation (test 1)|Participants will receive CAB IR Formulation (reference) under fasted conditions in treatment period 1 followed by CAB DT Formulation (test 2) under fed conditions in treatment period 2 followed by CAB DT Formulation (test 1) under fasted conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment.
62019082|NCT05776108|EXPERIMENTAL|CAB DT Formulation (test 1)/CAB DT Formulation (test 2)/CAB IR Formulation (reference)|Participants will receive CAB DT Formulation (test 1) under fasted conditions in treatment period 1 followed by CAB DT Formulation (test 2) under fed conditions in treatment period 2 followed by CAB IR Formulation (reference) under fasted conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment.
62019083|NCT05776108|EXPERIMENTAL|CAB DT Formulation (test 2)/CAB DT Formulation (test 1)/CAB IR Formulation (reference)|Participants will receive CAB DT Formulation (test 2) under fed conditions in treatment period 1 followed by CAB DT Formulation (test 1) under fasted conditions in treatment period 2 followed by CAB IR Formulation (reference) under fasted conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment.
62407468|NCT05681299|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as one nightly subcutaneous self-injection at 9-11pm from the night of day 0 to the night of day 20.
62407469|NCT05127707|NO_INTERVENTION|No exposure control group|This group was not exposed to any message frame.
62407470|NCT05127707|EXPERIMENTAL|Words Matter - Visual Campaign|Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings.
62407471|NCT05127707|EXPERIMENTAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)|Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a person with opioid use disorder.
62582839|NCT06574464||Non-survivors|Non-survivors had passed away within 28 days of admission to the emergency department
62210319|NCT05031000|EXPERIMENTAL|Subject POCT glucometer measurement|Blood glucose measurement POCT glucometer
62407472|NCT05127707|EXPERIMENTAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a clinician.
62407473|NCT05127707|EXPERIMENTAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a health system administrator/leader.
62407474|NCT05127707|EXPERIMENTAL|Medication Treatment Works - Visual Campaign|Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives.
62210320|NCT06729294|EXPERIMENTAL|Intervention group|Binaural beat music is therapeutic music that provides auditory stimuli at different frequencies to each ear. However, the maximum sound levels of 60 dB help to relax and reduce stress. There are studies that show that a slower rhythm and a slower decibel music makes the heart beats compatible with the rhythm. Support from an audiologist will be sought to adjust the volume of the binaural beat music to 50 dB. Natural sounds such as birdsong, waterfalls, ocean, river and forest sounds will be added to the soothing components of the melodies, tones and rhythms embedded in the binaural beats and 60-minute music arrangements will be created in the computer program. The resulting binaural beat music will be loaded into the Goldplay GP-1001 brand Mp3 player and listened to using headphones.
62210321|NCT06729294|NO_INTERVENTION|Control group|Routine interventions will be applied to the control group without listening to music.
62582840|NCT01857583|EXPERIMENTAL|SRI 15mg (15 mL/min ≤ CLCR < 20mL/min)|Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.
62582841|NCT01857583|EXPERIMENTAL|MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min)|Mild Renal Impairment group orally administered 30mg DU-176b once daily for 14 days.
62582842|NCT01857583|ACTIVE_COMPARATOR|Fondaparinux (20 mL/min ≤ CLCR < 30mL/min)|Fondaparinux subcutaneously administered at a dose of 1.5mg once daily for 14 days.
62790193|NCT06284083|NO_INTERVENTION|Polysomnographic (PSG) diagnosis and scoring.Oxygen saturation mesurment (SpO2)|The participants were put to sleep with polysomnography (PSG) in the sleep laboratory for 1 night and were divided into 3 groups according to their disease severity. (mild, moderate, severe).The apnea/hypopnea index (AHI) was defined as the sum of the apnea and hypopnea number per hour of sleep. The mean SpO2 percentages of the PSG device were measured from the fingertip with a system-defined pulse oximeter.
62790194|NCT06284083|EXPERIMENTAL|Agmatine, Telomerase and Trace element levels measurment|With the permission of the participants, 7 ml of venous, fasting blood was taken after the night's sleep.In the blood serum of the participants, agmatine, telomerase, and trace element levels were measured with a commercial ELISA kit.
62210322|NCT04281459|EXPERIMENTAL|SCT 4/7|Patients receiving 3-drug antiretroviral therapy containing rilpivirine with short cycle scheme of 4 consecutive days on and 3 days off treatment
62210323|NCT04281459|ACTIVE_COMPARATOR|Control|Patients receiving 3-drug antiretroviral therapy containing rilpivirine with standard scheme of 7 days per week of treatment
62210324|NCT03013153|EXPERIMENTAL|Low ligation with apical lymph node dissection|Left colic artery (LCA) is identified according to the CT 3D-reconstruction, tie the sigmoid artery and superior rectal artery, preserved LCA while low ligation of the inferior mesenteric artery is performed. Lymphadenectomy to the apical lymph nodes (No.253)is performed around the IMA until 2 cm from the aorta. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
62210325|NCT03013153|ACTIVE_COMPARATOR|High ligation|Open the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The IMA is ligated and divided at 2 cm from its origin. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
62407475|NCT05127707|EXPERIMENTAL|Medication Treatment Works - Visual Campaign & Narrative Vignette (Person with OUD)|Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a person with opioid use disorder.
62407476|NCT05127707|EXPERIMENTAL|Medication Treatment Works - Visual Campaign & Narrative Vignette (Clinician)|Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a clinician.
62582843|NCT01857583|EXPERIMENTAL|SRI 15mg (20 mL/min ≤ CLCR < 30mL/min)|Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.
62582844|NCT01311765|ACTIVE_COMPARATOR|8 day-antibiotherapy|Duration of antibiotic therapy limited to 8 days: Antibiotics received for up to 8 days following surgery for postoperative peritonitis in patients hospitalised in intensive care unit
62019084|NCT03891212|EXPERIMENTAL|The prone group|Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours.
62019085|NCT03891212|NO_INTERVENTION|The supine group|Patients assigned to the supine group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
62019086|NCT05257889||neonatal seizures cases|Cases of neonatal seizures
62019087|NCT05257889||seizure-free neonates|cases that are seizure free
62019088|NCT02177344|EXPERIMENTAL|Low dose of ipratropium bromide|
62210326|NCT01901419|EXPERIMENTAL|High-dose NTG|Nitroglycerin infusion 1-5 mcg/kg/min
62210327|NCT01901419|ACTIVE_COMPARATOR|Low-dose NTG|Nitroglycerin infusion 0-0.1 mcg/kg/min
62407477|NCT05127707|EXPERIMENTAL|Medication Treatment Works - Visual Campaign & Narrative Vignette (Health System Administrator)|Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a health system administrator/leader.
62210328|NCT00349362|EXPERIMENTAL|Testosterone|Testosterone injections- 200mg- every 2 weeks
62210329|NCT00349362|PLACEBO_COMPARATOR|Placebo|Normal saline injections- every two weeks
62210330|NCT04892914|EXPERIMENTAL|Embr thermal device|Use of the Embr thermal device
62210331|NCT06488508|EXPERIMENTAL|Intervention|Kindergarten staff will participate in 60 hours of professional development over 18 months focused on promotion of movement, play and exploration in the kindergarten setting.
62210332|NCT06488508|NO_INTERVENTION|Control|Staff receive no professional development and children will receive standard care.
62210333|NCT05911906|EXPERIMENTAL|Treatment Group|Five days of Remdesivir infusion delivered by IV.
62210334|NCT01663922|EXPERIMENTAL|St John's Wort, then Boceprevir|D 1-14 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 22-35 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 31-35 Boceprevir 800mg tds D 52-56 Boceprevir 800mg tds
62210335|NCT01663922|EXPERIMENTAL|Boceprevir, then St John's Wort|D 10-14 Boceprevir 800mg tds D 22-35 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 31-35 Boceprevir 800mg tds D 43-56 St. John's Wort 2 x 300mg (Ucalm(r)) QD
62582845|NCT01311765|NO_INTERVENTION|15 day-antibiotherapy|Antibiotics received for up to15 days following surgery for postoperative peritonitis in patients hospitalised in intensive care unit corresponding to usual practice and recommendations
62582846|NCT05083936|EXPERIMENTAL|[18F]FET PET|
62790195|NCT03700567|EXPERIMENTAL|low temperature contrast|A total of 220 patients are assigned to low temperature contrast group after randomization schedule.
62790196|NCT03700567|NO_INTERVENTION|room temperature contrast|A total of 220 patients are assigned to room temperature contrast group after randomization schedule.
62790197|NCT02648568|ACTIVE_COMPARATOR|Hypnosis plus relaxation|Ericksonian hypnosis, based on sensations when awakening partially during N3 ; Jacobson relaxation, based on flexion and relaxation of muscles (serves here as a control procedure)
62019089|NCT02177344|EXPERIMENTAL|High dose of Ipratopium bromide|
62019090|NCT02177344|ACTIVE_COMPARATOR|Atrovent|
62019091|NCT02177344|PLACEBO_COMPARATOR|Placebo|
62019092|NCT02798198||Diabetes group|37 T2DM adults (diabetes group) without DKD
62019093|NCT02798198||Control group|33 healthy adults (control group)
62019094|NCT01963689|PLACEBO_COMPARATOR|Intervention Group 2|Individuals belonging to Group 2 received a bottle containing aromatic gel enriched with ylang ylang essence only in 2% concentration and used massage with essential oil 3 times a day: leaving home to go to work, leaving the shift and before bedtime. The points indicated were the two handles and the sternum. Gel was applied and massaged in a circular motion for 30 seconds.
62019095|NCT01963689|EXPERIMENTAL|Intervention Group 1|Individuals belonging to Group 1 received a bottle containing aromatic gel enriched with essential oil of ylang ylang in a concentration of 2% and used massage with essential oil 3 times a day: leaving home to go to work, leaving the shift and before bedtime. The points indicated were the two handles and the sternum. Gel was applied and massaged in a circular motion for 30 seconds.
62019096|NCT01963689|EXPERIMENTAL|Intervention Group 3|The subjects in Group 3 were responsible for before the beginning of their working, put a drop of essential oil of ylang ylang in cotton located within the freshener personal and should be used throughout your work shift
62019097|NCT05134805|OTHER|BHA group|Patients will undergo Bipolar hemiarthroplasty operation
62210336|NCT04162938|EXPERIMENTAL|Patient-Centered Electronic App Group|Patients assigned to the intervention group will receive individualized reports regarding patients' HCV disease progress/liver fibrosis staging by a Fibrosis-4 score using the personalized HCV educational app. The individualized report will also include comprehensive knowledge to fill the gap on general HCV information, natural history of the disease, and care and treatment, if there is any, as well as level of interest in receiving HCV care based on patients' response to the short survey questionnaires on the tablet. Patients will also receive the investigators' HCV program pamphlet regarding HCV infection and disease progression, treatment, as well as information regarding clinics available for HCV care in Baltimore. Patients will receive standard of care, routine HCV LTC services from the investigators' ED HCV LTC program staff.
62582847|NCT06436898|EXPERIMENTAL|Exoskeleton plus FES|Participants will train gait with an overground exoskeleton and a combined myoelectrically controlled Functional Electrostimulation System (FES) applied to lower limb muscles during execution of gait.
62582848|NCT06436898|ACTIVE_COMPARATOR|Exoskeleton|Participants will train gait with an overground exoskeleton.
62210337|NCT04162938|NO_INTERVENTION|Reference Group|Patients assigned to the reference group will receive the investigators' current 'static' standard of care HCV program pamphlet regarding HCV infection and disease progression, treatment, as well as information regarding clinics available for HCV care in Baltimore City. Patients will also receive standard of care, routine HCV LTC services from the investigators' ED HCV LTC program staff.
62210338|NCT04171323|EXPERIMENTAL|CTa|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
62210339|NCT04171323|EXPERIMENTAL|CTab|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
62407478|NCT01463631|EXPERIMENTAL|LY3007113|Study has a dose escalation phase (Part A) and dose confirmation phase (Part B). Participants in the dose escalation phase will receive 1 of 6 doses of LY3007113 administered orally every 12 hours for at least one cycle. Participants in the dose confirmation phase will receive the maximum tolerated dose from the dose escalation phase administered orally every 12 hours for at least 1 cycle. Three days prior to the start of the first cycle, participants will receive 1 dose at their assigned level to allow for the collection of single dose pharmacokinetics. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
62407479|NCT04793958|EXPERIMENTAL|MRTX849 + Cetuximab|
62407480|NCT04793958|ACTIVE_COMPARATOR|mFOLFOX6 or FOLFIRI|
62407481|NCT03864406|EXPERIMENTAL|Pharmacokinetic study in healthy volunteers|Healthy participants received a single dose of rivaroxaban 10 mg orally on day 1 (phase 1) followed by cobicistat 150 mg once daily from days 2 - 7 and a single dose of rivaroxaban 10 mg on day 7 (phase 2). Participants received darunavir /cobicistat 800/150 mg once daily from days 8 - 13 followed by a single dose of rivaroxaban 10mg on day 13 (phase 3). Serial blood sampling was done on days 1, 7, and 13.
62582849|NCT04223752|EXPERIMENTAL|Group 1: Ceftolozane/Tazobactam 12 to <18 Years of Age|Participants 12 to \<18 years of age with nosocomial pneumonia receive intravenous (IV) ceftolozane/tazobactam every 8 hours for 8-14 days.
62582850|NCT04223752|EXPERIMENTAL|Group 2: Ceftolozane/Tazobactam 7 to <12 Years of Age|Participants 7 to \<12 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
62582851|NCT04223752|EXPERIMENTAL|Group 3: Ceftolozane/Tazobactam 2 to <7 Years of Age|Participants 2 to \<7 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
62582852|NCT04223752|EXPERIMENTAL|Group 4: Ceftolozane/Tazobactam 3 Months to <2 Years of Age|Participants 3 months to \<2 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
62582853|NCT04223752|EXPERIMENTAL|Group 5: Ceftolozane/Tazobactam Birth to <3 Months of Age|Participants from birth to \<3 months of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
62210340|NCT04171323|EXPERIMENTAL|CTac|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
62019098|NCT05134805|OTHER|PFN group|Patients will undergo cehphalo-medullary fixation (Proximal femoral nail)
62582854|NCT01892410|EXPERIMENTAL|Cetaphil Restoraderm Skin Restoring Body Wash|All subjects receive Cetaphil Daily Advance Ultra Hydrating Lotion
62582855|NCT03937921||Group 1 - Dotarem|Group 1 (n=30) will receive the clinically approved gadoterate meglumine (Dotarem, 0.1mmol/kg) as the contrast agent for their clinical perfusion study
62582856|NCT03937921||Group 2 - Gadavist|Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as the contrast agent.
62019099|NCT00871481|EXPERIMENTAL|Treatment (laboratory-treated T cells and ipilimumab)|Patients receive cyclophosphamide IV on day -2, therapeutic cytotoxic T lymphocytes IV over 30-60 minutes on day 0, low-dose aldesleukin SC BID on days 0-13, and ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
62019100|NCT05748639|EXPERIMENTAL|Quit Genius - Alcohol|QG-A is a smart phone application targeting alcohol use disorder. QG-A includes standardized cognitive-behavioral therapy in the form of videos, in-app text, audio recordings, and quizzes. The application provides users with information on how to reduce or abstain from alcohol use. Once successfully enrolled in QG-A, a medical provider will evaluate each QG-A participant for appropriateness for pharmacotherapy during an initial 60-minute assessment to confirm an alcohol use disorder diagnosis and collect relevant medical and psychiatric history of the patient. The medical provider will subsequently prescribe oral naltrexone via the QG-A telemedicine platform. A study counselor will provide manualized CBT-based support to QG-A participants via the video telemedicine function, as well as asynchronously via the in-app chat function.
62019101|NCT05748639|ACTIVE_COMPARATOR|Medical Management|Medical management comprises standard care for alcohol use disorder. A medical provider, upon evaluation of each participant for appropriateness for pharmacotherapy, will subsequently prescribe naltrexone via a non-QG-A telemedicine platform, according to standard clinical practice. Participants will meet with the medical provider monthly over the 6-month course of treatment. In MM, participants receive dose adjustments and brief medical management as normally provided to patients in office-based settings (session duration is 15-20 minutes). The medical provider will deliver education about the study medication and answer any participant questions. Subsequent 15-20 minute sessions will review drinking patterns, overall functioning, medication adherence, and adverse effects. Participants who discontinue medication because of intolerance can continue to attend monthly medical management sessions to support abstinence.
62582857|NCT05833165||Feasibility of a supportive approach|Evaluating a feasibility of an approach
62582858|NCT06383234|EXPERIMENTAL|LG-TAP|The laparoscopic guided TAP Block was performed at the beginning of surgery, injecting 15 ml of Ropivacaine Hydrochloride 0.5% on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
62210341|NCT04171323|EXPERIMENTAL|CTabc|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
62582859|NCT06383234|PLACEBO_COMPARATOR|SALINE|The laparoscopic guided TAP Block was performed at the beginning of surgery, injecting 15 ml of Saline solution (NaCl 0.9%) on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
62210342|NCT04171323|ACTIVE_COMPARATOR|Computerized Cognitive Stimulation|Participants will complete cognitively-stimulating computer activities. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
62210343|NCT01109927|EXPERIMENTAL|Insulin treatment|Insulin given as soon as possible after diagnosis
62210344|NCT01109927|NO_INTERVENTION|Conventional treatment|Diet, oral hypoglycemic agents and insulin first when clinically needed
62210345|NCT06729034|EXPERIMENTAL|Apixaban|Apixaban 5 mg twice daily
62210346|NCT06729034|PLACEBO_COMPARATOR|Placebo|Placebo
62210347|NCT04909827|EXPERIMENTAL|group A|3D printed microfilled hybrid composite Endocrowns
62210348|NCT04909827|EXPERIMENTAL|group B|prefabricated zirconia crowns
62210349|NCT06416644|EXPERIMENTAL|Supera implant|Supera implant
62210350|NCT05623176||Old routine of non-standardised laparotomy care|Group following the old routine of emergency laparotomy care i.e. no existing standardised care protocols.
62210351|NCT05623176||New routine of standardised laparotomy care|Group which has been part of the hospital's new standardised care routine for emergency laparotomy.
62210352|NCT01974778|EXPERIMENTAL|Active|Meal
62210353|NCT01974778|PLACEBO_COMPARATOR|Control|Water
62210354|NCT00626626|EXPERIMENTAL|"Clofar, Cyclophos, Alemtuzumab"|"Phase 1: 1-3 patients will be treated in order to establish Cyclophosphamide and Clofarabine dose and to confirm reasonable safety and engraftment efficacy.~Drug - Clofarabine,Cyclophosphamide \& Alemtuzumab - Clofar (30mg/m2) D -8 to -4; Cyclo (500mg/m2) D -8 \& -7 \& Alem (20mg over 2hrs)"
62210355|NCT00626626|EXPERIMENTAL|"Clofar, Cyclophos,Alemtuzumab(Ph II)"|"Phase II patients 4-9 will treat at the selected dose level of Clofarabine and Cyclophosphamide.~Drug - Clofarabine, Cyclophosphamide \& Alemtuzumab Clofar (30mg/m2) D -8 to -4; Cyclo (1000mg/m2) D -8 \& -7 \& Alem (20mg)-pts."
62210356|NCT04593043||Warfarin|Reference group
62210357|NCT04593043||Dabigatran|Exposure group
62210358|NCT05174221|EXPERIMENTAL|Mezagitamab|Mezagitamab, subcutaneous injection, once weekly for 8 weeks then once every 2 weeks for 16 weeks in the Main Study. Same dosing regimen will be repeated in LTE Retreatment Period.
62210359|NCT04621175|ACTIVE_COMPARATOR|EAA+W & Carbohydrate: Balance (BAL) first, then Deficit (DEF)|Participants will consume an essential amino acid plus whey (EAA+W) beverage with added Carbohydrate during energy balance (BAL) first, then again during energy deficit (DEF).
62210360|NCT04621175|ACTIVE_COMPARATOR|EAA+W & Carbohydrate: DEF first, then BAL|Participants will consume an essential amino acid plus whey beverage with added Carbohydrate during energy deficit first, then again during energy balance.
62210361|NCT04621175|ACTIVE_COMPARATOR|EAA+W & EAA: BAL first, then DEF|Participants will consume an essential amino acid (EAA) plus whey beverage with added EAA during energy balance first, then again during energy deficit.
62790198|NCT02648568|ACTIVE_COMPARATOR|Relaxation|Jacobson relaxation, based on flexion and relaxation of muscles (serves here as a control procedure)
62790199|NCT01919801|EXPERIMENTAL|Icatibant|Icatibant at a dose of 30 mg will be administered as a single subcutaneous injection
62790200|NCT01919801|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as a single subcutaneous injection
62407482|NCT04111666|EXPERIMENTAL|AL101 IV|"* Up to four single ascending doses (SAD IV cohorts)~* Multiple doses of AL101 administered IV (MD IV cohort)"
62582860|NCT01645319||White, non-hispanic - Medication Treatment Pathway|
62582861|NCT01645319||White, non-Hispanic - Laser Surgery Treatment Pathway|
62582862|NCT01645319||White, non-Hispanic - Incisional/Other Treatment Pathway|
62210362|NCT04621175|ACTIVE_COMPARATOR|EAA+W & EAA: DEF first, then BAL|Participants will consume an essential amino acid (EAA) plus whey beverage with added EAA during energy deficit first, then again during energy balance.
62407483|NCT04111666|PLACEBO_COMPARATOR|Saline Solution|"Saline solution will be administered with the following:~* Single IV infusion for four single ascending doses (SAD IV cohorts) in a ratio of 8 active and 3 placebo subjects~* Multiple IV infusions for the MD IV cohort in a ratio of 8 active and 2 placebo subjects"
62582863|NCT01645319||Hispanic - Medication Treatment Pathway|
62407484|NCT04111666|EXPERIMENTAL|AL101 SC|"* Single fixed dose levels of AL101 administered SC~* Multiple fixed dose of AL101 administered SC"
62582864|NCT01645319||Hispanic - Laser Surgery Treatment Pathway|
62582865|NCT01645319||Hispanic - Incisional/Other Surgery Treatment Pathway|
62582866|NCT01645319||Asian - Medication Treatment Pathway|
62210363|NCT03668639|OTHER|Akynzeo plus dexamethasone|Akynzeo (capsule 300mg/0.5mg) Day 1 plus dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 to be administered weekly for five weeks.
62407485|NCT01572610|EXPERIMENTAL|RTA 402|
62407486|NCT03225339|EXPERIMENTAL|Lifestyle Intervention|The intervention includes the use of Low Energy Diet replacement products in combination with physical activity, followed by gradual introduction of food, and increasing physical activity. Behavioural support for the lifestyle intervention will also be provided.
62407487|NCT03225339|NO_INTERVENTION|Usual Care|This will be based on current clinical practice aiming to reduce diabetes symptoms and complications, and general recommendations on diet and physical activity.
62582867|NCT01645319||Asian - Laser Surgery Treatment Pathway|
62582868|NCT01645319||Asian - Incisional/Other Surgery Treatment Pathway|
62582869|NCT01645319||Black - Medication Treatment Pathway|
62582870|NCT01645319||Black - Laser Surgery Treatment Pathway|
62582871|NCT01645319||Black - Incisional/Other Surgery Treatment Pathway|
62582872|NCT05000554|EXPERIMENTAL|Locally advanced gastric cancer|Patients with locally advanced gastric cancer who can receive PD-1 monoclonal antibody combined with neoadjuvant chemotherapy
62210364|NCT00652470|ACTIVE_COMPARATOR|ETV|
62210365|NCT00652470|ACTIVE_COMPARATOR|CSF Shunt|
62582873|NCT06682104|OTHER|Individual intensive short term psychodynamic therapy|The Individual Intensive Short-Term Psychodynamic Psychotherapy (ISTDP) arm for patients with Persistent Physical Symptoms (PPS) focuses on addressing the underlying emotional and psychological factors contributing to these chronic symptoms. In this treatment arm, participants engage in structured, one-on-one psychotherapy sessions with a trained ISTDP therapist.
62582874|NCT04308889|ACTIVE_COMPARATOR|Without Supplementation|No planned dietary supplementation
62582875|NCT04308889|EXPERIMENTAL|With Supplementation|The subject will take 4 capsules (1gram each) of Lovaza daily at 8pm, starting the evening before blister induction and continuing until the second blister fluid has been removed.
62582876|NCT06683872||Patients with hypertrophic cardiomyopathy undergoing septal reduction therapy.|
62582877|NCT06684691|EXPERIMENTAL|Group 1|The escape room game will be applied to the students in the group 1 after the theoretical training.
62582878|NCT06684691|OTHER|Group 2|The escape room game will not be applied to the students in the group 2 after the theoretical training.
62582879|NCT05478460||Group A|Before operation,patients were performed CT -guided hook wire localization(20G×120mm, PAJUNK medizintechnologie, Geisingen in Germany). patients were placed on a CT table in a suitable position(supine, prone, lateral) to obtain the shortest needle insertion route for their initial CT scan. Local anesthesia of the skin and planned puncture tract was performed using 10ml Lidocaine 1%. Next, the needle was inserted into or near the pulmonary nodule.
62582880|NCT05478460||Group B|without hookwire localization
62582881|NCT04113655||acellular pertussis vaccine|Antibody persistence at 2 years after a single dose vaccination of Pertagen (aP BioNet), Boostagen (TdaP BioNet) and Adacel (comparator vaccine) administered in parent protocol TDA202
62210366|NCT03900416|EXPERIMENTAL|Mindfulness App|Guided mindfulness exercises will be delivered via mobile app for three weeks.
62210367|NCT03900416|NO_INTERVENTION|Control condition|Participants will use app for assessment for three weeks, but no mindfulness exercises will be delivered.
62210368|NCT06727851||Group before introduction of the QIC-initiative (before 2017)|The study shall provide the investigators with information whether the introduction of the quality performance measures adopted by the European Society of Gastrointestinal Endoscopy (ESGE) will actually lead to an improvement in quality. The study will compare the quality development in endoscopy based on following time intervals: 1. before introduction of the QIC-initiative (before 2017) 2. after the introduction of the initiative (2017-2023) (both retrospective data) 3. prospectively, from 2024 onwards. The focus of this study we will be the key performance indicator post-ERCP pancreatitis (PEP). In the ESGE-guideline, a minimum standard of \<10% and a target standard of \<5% was recommended. Different studies described the incidence of post-ERCP pancreatitis between 3,47% and 10,2%.
62407488|NCT02524366|EXPERIMENTAL|Transcorporal AUS|The artificial urinary sphincter is placed through the tunica albuginea of the corpora cavernosa in order to theoretically provide a protective backing on the urethra.
62407489|NCT02524366|ACTIVE_COMPARATOR|Standard AUS|The artificial urinary sphincter is placed in the standard fashion.
62582882|NCT06084845|ACTIVE_COMPARATOR|Arm A (chemoradiation)|Patients receive cisplatin or carboplatin IV over 30-60 minutes QW for 6 doses with concurrent IMRT and IGRT five days a week for 30-33 fractions in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, PET-CT, and/or chest x-ray during screening and follow-up. Patients may also undergo blood sample collection during follow-up.
62582883|NCT06084845|EXPERIMENTAL|Arm B (chemoradiation, xevinapant)|Patients receive cisplatin or carboplatin IV over 30-60 minutes QW for 6 doses with concurrent IMRT and IGRT five days a week for 30-33 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive xevinapant PO on days 1-14 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, PET-CT, and/or chest x-ray during screening and follow-up. Patients may also undergo blood sample collection during follow-up.
62582884|NCT05113342|EXPERIMENTAL|Arm 1: Dose Level 1|Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
62582885|NCT05113342|EXPERIMENTAL|Arm 2: Dose Level 2|Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
62407490|NCT01412411|ACTIVE_COMPARATOR|Nutrition Education plus Multiple Micronutrient Fortification|In this group along with the nutritional education, multiple micronutrient fortification was given in the form of Sprinkles
62582886|NCT05113342|EXPERIMENTAL|Arm 3: Dose Level 3|Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
62582887|NCT05113342|EXPERIMENTAL|Arm 4: Dose Expansion|In Arm 2, the MTD established in Arm 1 will be administered for 3 28-day cycles to further evaluate the product's safety and preliminary efficacy.
62582888|NCT04996602|EXPERIMENTAL|2.0 GBq of 177Lu-EB-PSMA|The patients were intravenously injected with the dose about 2.0 GBq (55 mCi) of 177Lu-EB-PSMA and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
62407491|NCT01412411|ACTIVE_COMPARATOR|OIS plus Nutritional Eductaion|In this group, along with the nutritional education, Oral Iron Supplementation was given.
62407492|NCT01412411|ACTIVE_COMPARATOR|Nutrition Education Group|This is group was followed for the growth of the child and was given Nutritional Education to children's mothers.
62582889|NCT03944746||SAMMC Emergency Medicine Residents|Emergency Medicine Residents from San Antonio Military Medical Center in San Antonio, Texas.
62582890|NCT03944746||University Hospital Emergency Medicine Residents|Emergency Medicine Residents from University Hospital in San Antonio, Texas.
62582891|NCT01780038|EXPERIMENTAL|Receipt of Genetic Results|Receipt of Genetic Results indicates that participants have received the results of genotyping for RS1051730
62582892|NCT01780038|ACTIVE_COMPARATOR|No results given|Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
62582893|NCT00676247||preterm|Very-low-birth-weight preterm infants with brain lesion
62582894|NCT00676247||full-term|Healthy fullterm infants
62582895|NCT02064270|ACTIVE_COMPARATOR|Negative Pressure Wound Therapy|Single-Use Negative Pressure Wound Therapy (NPWT)
62019102|NCT04100226|EXPERIMENTAL|Interstitial lung patients with low vitamin D|Arm 1:(interventional group): interstitial lung diseases patients with low vitamine D will receive Vitamin D supplementation in form of Vitamin D3 (1.25(OH)2 cholecalciferol) in dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for deficient vitamin D level patients and every month for 3 months for insufficient vitamin D level patients beside ca supplementation in form ca carbonate 600 mg oral capsule once daily for 3 months for all patients in addition to current treatment.
62790201|NCT05385003|EXPERIMENTAL|Dietary Supplement: anserine|Subjects are instructed to take one capsule of anserine daily for a total of 3 months
62019103|NCT04100226|NO_INTERVENTION|interstitial lung diseases patients with low vitamin D|Arm 2(control group): interstitial lung diseases patients with vitamin D deficient / insufficient will receive their current treatment only without vitamin D supplementation.
62210369|NCT06727851||Group after introduction of the QIC-initiative (2017-2023)|The study shall provide the investigators with information whether the introduction of the quality performance measures adopted by the European Society of Gastrointestinal Endoscopy (ESGE) will actually lead to an improvement in quality. The study will compare the quality development in endoscopy based on following time intervals: 1. before introduction of the QIC-initiative (before 2017) 2. after the introduction of the initiative (2017-2023) (both retrospective data) 3. prospectively, from 2024 onwards. The focus of this study we will be the key performance indicator post-ERCP pancreatitis (PEP). In the ESGE-guideline, a minimum standard of \<10% and a target standard of \<5% was recommended. Different studies described the incidence of post-ERCP pancreatitis between 3,47% and 10,2%.
62407493|NCT06520839|EXPERIMENTAL|Patients with diabetes and erectile dysfunction|We will include in the study 90 patients with diabetes and erectile dysfunction. We will use the IIEF-5 questionnaire to confirm the diagnosis of erectile dysfunction. Patients between the ages of 40 and 65 who score 21 points or less on the IIEF-5 scale will be included in the study. Each patient will receive drug tadalafil 5 mg every day for three months.
62407494|NCT05938413|EXPERIMENTAL|Intervention or CHAMPS|Wise App that delivers medication adherence reminders and community health worker sessions
62407495|NCT05938413|NO_INTERVENTION|Control|Standard of care
62407496|NCT01422876|EXPERIMENTAL|BI 10773/linagliptin FDC (high dose)|Patients receive BI 10773/linagliptin FDC (high dose) once daily
62582896|NCT02064270|ACTIVE_COMPARATOR|Standard dressings|Standard postsurgical dressings
62582897|NCT02375893||Coronary patients|Feces, blood sample, clinical and biological data. Presence (1) of coronary disease defined as the presence of atheroma during the coronary angiogram
62407497|NCT01422876|EXPERIMENTAL|BI 10773/linagliptin FDC (low dose)|Patients receive BI 10773/linagliptin FDC (low dose) once daily
62019104|NCT02278276|PLACEBO_COMPARATOR|0 mg SG1002|Capsules containing 400 mg of placebo will be provided to subjects. Subjects will take two tablets twice each day.
62019105|NCT02278276|ACTIVE_COMPARATOR|1600 mg SG1002|Capsules containing 400 mg of sodium polysulthionate (SG1002) will be provided to subjects. Subjects will take two tablets twice each day, providing subjects with 1600 mg SG1002 daily.
62019106|NCT02091804|ACTIVE_COMPARATOR|Wait-List group|Individuals randomized to the control group will receive the intervention program immediately after their 3-month research visit.
62019107|NCT02091804|EXPERIMENTAL|Immediate Group|Individuals randomized to the Immediate group will receive the intervention program immediately after completing the baseline assessment.
62019108|NCT04949230||COVID-19 Patients|Subjects who have recovered from COVID-19
62019109|NCT01929356|EXPERIMENTAL|chest physiotherapy|session of 20 minutes chest physiotherapy with physiotherapist, use of airway clearance techniques, PEP (positive expiratory pressure) device
62019110|NCT04365322||Severe COVID-19 infection|
62019111|NCT04365322||Light to moderate COVID-19 infection|
62019112|NCT04365322||Cancer patients with COVID-19 infection|
62019113|NCT01465490|EXPERIMENTAL|Monitoring and Feedback Intervention|
62407498|NCT01422876|ACTIVE_COMPARATOR|BI 10773 (high dose)|Patients receive BI 10773 (high dose) once daily
62407499|NCT01422876|ACTIVE_COMPARATOR|BI 10773 (low dose)|Patients receive BI 10773 (low dose) once daily
62582898|NCT02375893||Healthy subjects (2)|Feces, blood sample, clinical and biological data. Absence (2) of atheroma during the coronary angiogram
62582899|NCT06500819|EXPERIMENTAL|Lymphodepletion|Fludarabine 30 mg/m2 per day IV for 4 days: 5, -4, 3, -2 Cyclophosphamide 500 mg/m2 per day IV for 3 days: -5, -4, -3 Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.
62582900|NCT00611910|EXPERIMENTAL|DES|drug-eluting stents
62019114|NCT01465490|NO_INTERVENTION|Treatment as usual|
62019115|NCT04062305|EXPERIMENTAL|Diagnostic (nTMS, sensory testing)|Patients undergo nTMS over 1 hour. Patients also perform 4 tasks that test grip and pinch strength, and the ability to use and feel with their hands for 1 hour.
62019116|NCT04790045|OTHER|Venetoclax-based treatment|Single-arm study Patients enrolled will be receiving venetoclax-based regimens according to the standard of care
62019117|NCT05850533|EXPERIMENTAL|Tai Chi Easy Intervention|8-week/16-session virtual Tai Chi Easy (vTCE) intervention for adults with OUD, anxiety, and chronic pain
62407500|NCT01422876|ACTIVE_COMPARATOR|Linagliptin|Patients receive linagliptin once daily
62407501|NCT03638479||Parkinson's Disease|Participant's diagnosed with Parkinson's Disease
62582901|NCT00611910|ACTIVE_COMPARATOR|BMS|bare metal stents
62582902|NCT01600365|ACTIVE_COMPARATOR|Ganciclovir|Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
62582903|NCT01600365|PLACEBO_COMPARATOR|Ophthalmic gel (placebo)|ophthalmic gel (placebo)in the study eye
62582904|NCT01832558|EXPERIMENTAL|Eplerenone|Eplerenone 25-50mg daily additionally to standard ACE-inhibition with enalapril 20mg daily
62582905|NCT01832558|PLACEBO_COMPARATOR|Placebo|Placebo additionally to standard ACE-inhibition with enalapril 20mg daily
62019118|NCT05038059|ACTIVE_COMPARATOR|1. Ethylene diammine tetra acetic acid group|samples will be rinsed with ethylene diamine tetra acetic acid group, which is the gold standard for final rinse and compares with the experimental group.
62019119|NCT05038059|NO_INTERVENTION|2. Control group|no final irrigant will be used and evaluate the outcomes
62019120|NCT05038059|EXPERIMENTAL|3. Experimental group|final irrigation of root canal will be done with ethanolic extract of sapindus mukorossi
62019121|NCT02021435|EXPERIMENTAL|Salt Substitute|salt substitute
62019122|NCT02021435|NO_INTERVENTION|Control|Participants continue to buy salt at their own expense
62407502|NCT03638479||Essential Tremor|Participant's diagnosed with Essential Tremor or other Movement Disorders
62407503|NCT03638479||No Parkinson's Disease and No Essential Tremor|Participant's with no diagnosis of PD, ET or other Movement Disorders
62407504|NCT06504290|EXPERIMENTAL|Part Ⅰ- in healthy adult subjects|
62407505|NCT06504290|EXPERIMENTAL|Part Ⅱ-in adult patients with schizophrenia|
62019123|NCT04193202|EXPERIMENTAL|Gefapixant|Participants will receive gefapixant at a dose of 45 mg administered as an oral tablet twice daily for 12 weeks.
62019124|NCT04193202|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching gefapixant, administered as an oral tablet twice daily for 12 weeks.
62407506|NCT05859464|EXPERIMENTAL|Part 1: Dose Escalation; ZL-1218|Drug: ZL-1218 ZL-1218 dose escalation
62407507|NCT05859464|EXPERIMENTAL|Part 1: Dose Escalation; ZL-1218 in combination with Pembrolizumab|"Drug: ZL-1218 ZL-1218 dose escalation~Drug: Pembrolizumab (KEYTRUDA®) Combination treatment with ZL-1218"
62407508|NCT05859464|EXPERIMENTAL|Part 2: Cohort Expansion; Prior CPI Therapy|"Drug: ZL-1218 ZL-1218 recommended dose~Drug: Pembrolizumab (KEYTRUDA®) Combination treatment with ZL-1218"
62407509|NCT05859464|EXPERIMENTAL|Part 2: Cohort Expansion; CPI therapy Naive|"Drug: ZL-1218 ZL-1218 recommended dose~Drug: Pembrolizumab (KEYTRUDA®) Combination treatment with ZL-1218"
62407510|NCT02965027|EXPERIMENTAL|Prazosin|Prazosin capsules beginning at 1 mg orally at bedtime. Titrate over 5 weeks to maximum dose of 5 mg in the morning and 20 mg at bedtime.
62582906|NCT05941143|EXPERIMENTAL|mindfulness-based intervention|The intervention consist of 8 sessions in which participants learned three main different practices: body scan, sitting meditation, and yoga practice. Participants are instructed to regularly engage in home mindfulness practice of these new learned skills (45 minutes a day for 6 days a week). Home exercises include formal mindfulness practice (i.e., meditation and yoga) for about 30-35 minutes a day and informal practice focused on bringing mindful awareness to everyday activities for about 10-15 minutes a day. Mp3 audio of meditations proposed at each session are provided to guide personal practice.
62582907|NCT04749641|EXPERIMENTAL|Open surgical biopsy|A total of 15 subjects with open surgical biopsy indications will receive microsurgical resection, followed by conformal radiotherapy and administration of the researched vaccine.
62582908|NCT04749641|EXPERIMENTAL|Stereotactic biopsy|A total of 15 subjects without open surgical biopsy indications will receive stereotactic biopsy, followed by conformal radiotherapy and administration of the researched vaccine.
62407511|NCT02965027|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62582909|NCT03850730|EXPERIMENTAL|Pazopanib|Pazopanib, initiated after a baseline period at 25mg oral dosing daily, for this one treatment arm, to be compared to the patient's baseline. If endpoint not achieved and safety demonstrated in 2-3mths, an advance of dose to 50mg daily for the ensuing 3mths of study will be considered.
62582910|NCT06346821||TTFields-Total|Patients receive standard RT + TMZ, followed by maintenance TMZ, with Optune® starts during peri-radiotherapy period (2 month before to 3 months after radiotherapy). The duration of TTFields lasts for at least 2 months.
62019125|NCT06315491|EXPERIMENTAL|CBX-12 - 125mg/m2 q21d|125mg/m2 CBX-12 administered by intravenous (IV) infusion every 21 days. Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity.
62019126|NCT06315491|EXPERIMENTAL|CBX-12 - 100mg/m2 q21d|100mg/m2 CBX-12 administered by intravenous (IV) infusion every 21 days. Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity.
62582911|NCT06346821||Active Comparator: Temozolomide alone|Patients receive RT and TMZ alone, followed by maintenance TMZ.
62582912|NCT06346821||TTFields-concomitant|Patients receive TTFields at 200 kHz to the brain using the Optune® System together with RT and TMZ, followed by maintenance TMZ concomitant with the Optune® treatment. The duration of TTFields lasts for at least 2 months. If the subject is assigned to this treatment arm, Optune® therapy will begin no later than the 7th day of RT and TMZ treatment.
62582913|NCT06346821||TTFields-adjuvant|Patients receive RT and TMZ alone, followed by maintenance TMZ concomitant with TTFields at 200 kHz to the brain using the Optune® within 3 months after radiotherapy for at least 2 months.
62582914|NCT05236738|EXPERIMENTAL|Treatment Sequence Group 1|
62407512|NCT02585193|OTHER|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
62407513|NCT01735136|EXPERIMENTAL|InSan Bamboo Salt|
62407514|NCT01735136|PLACEBO_COMPARATOR|Placebo|
62407515|NCT06574386|EXPERIMENTAL|Childhood neurodevelopment|Newborns from mothers with congenital heart disease will be subjected to neurodevelopmental assessment
62407516|NCT03106740|EXPERIMENTAL|Minocycline Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 2-week trial of Minocycline Hydrochloride, 100mg capsule
62407517|NCT03106740|PLACEBO_COMPARATOR|Placebo Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after 2 weeks of treatment with a placebo capsule.
62407518|NCT06246630|EXPERIMENTAL|Organoid-Guided therapy|All patients will be included in a single-arm. Participants will undergo biopsy of tumor tissue for subsequent organoid generation and drug sensitivity tests.
62582915|NCT05236738|EXPERIMENTAL|Treatment Sequence Group 2|
62019127|NCT06192511|NO_INTERVENTION|Standard of Care|Standard education provided about the Michigan BioTrust includes a brief verbal description from hospital staff and a brochure. Materials will be provided in English, Spanish, or Arabic.
62407519|NCT05511155||O-15|15 lt/min oxygen
62407520|NCT05511155||O-8|8 lt/min oxygen
62582916|NCT05236738|EXPERIMENTAL|Treatment Sequence Group 3|
62582917|NCT05670860||Anti-epileptic prophylaxis|The first group consists of patients treated between January 2019 and late 2020 who were given systematic prophylaxis
62582918|NCT05670860||NO Anti-epileptic prophylaxis|Patients from the second group were treated between 2021 and 2022 and did not receive any prophylaxis
62582919|NCT04752592|EXPERIMENTAL|SeroSelectTB|The participants in this arm, after providing informed concent, will be tested using the SeroSelectTB rapid assay.
62790202|NCT05385003|EXPERIMENTAL|Dietary Supplement: Sunflower peptide|Subjects are instructed to take one capsule of Sunflower peptide daily for a total of 3 months
62019128|NCT06192511|EXPERIMENTAL|Intervention|The intervention group will receive standard of care in addition to the opportunity to access a website with engaging information about the Michigan BioTrust and a 4-minute video. Materials will be provided in English, Spanish, or Arabic.
62019129|NCT05905965|EXPERIMENTAL|Empagliflozin 20 mg|Patients receiving empagliflozin 20 mg daily
62407521|NCT05511155||A-15|15 lt/min room air
62407522|NCT05511155||A-8|8 lt/min room air
62407523|NCT03488537|OTHER|patients referred for colonoscopy|All patients referred for colonoscopy where invited to participate in our study.
62407524|NCT05624515|EXPERIMENTAL|dry needling group|Subjects undergoing dry needling of the angularis scapulae muscle
62407525|NCT05624515|EXPERIMENTAL|ischaemic compression group|Subjects undergoing ischaemic compression of the angularis scapulae muscle
62407526|NCT02742415|EXPERIMENTAL|Cancer patients receiving hand massage|Caring Hand massage will be provided to the outpatients undergoing chemotherapy
62407527|NCT00719407|EXPERIMENTAL|A|All enrolled patients will be in this single arm, who will receive experimental drug treatment.
62582920|NCT04752592|NO_INTERVENTION|Standard of Care|The participants in this arm, after providing informed consent, will receive the established standard of care.
62582921|NCT06685354|EXPERIMENTAL|experimental group|The participants will receive hepatic arterial infusion of recombinant human adenovirus type 5 injection in combination with first-line targeted and immunotherapy as recommended by the 2024 primary liver cancer treatment guidelines.
62582922|NCT01214083|EXPERIMENTAL|Arm 1|N-acetylcysteine + high-dose naltrexone (150 mg)
62582923|NCT01214083|EXPERIMENTAL|Arm 2|High-dose naltrexone (150 mg) alone
62582924|NCT01214083|ACTIVE_COMPARATOR|Arm 3|Low-dose naltrexone (50 mg) alone
62582925|NCT02881489|EXPERIMENTAL|Autologous BM-MSCs injection|Intervention: Biological: Cell-based therapy of autologous bone marrow-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects.
62582926|NCT03770039|EXPERIMENTAL|2-period, fixed sequence|fixed sequence with 2 treatment period
62582927|NCT03789617|EXPERIMENTAL|EBViNT Cell|
62582928|NCT03860376||Chemorefractory or relapsed patients|We intend to enroll chemorefractory or relapsed pediatric patients with all types of cancers where tumor tissue would be available for ex vivo drug screening and genomic profiling. The results of the drug sensitivity assay and genetic screening will be used to inform treating physician about patient-specific drug sensitivity or resistance guiding best therapy choices.
62582929|NCT00568061|EXPERIMENTAL|Inhaled Nitric Oxide|Inhaled Nitric oxide administered at 80 parts per million (ppm)
62582930|NCT00568061|PLACEBO_COMPARATOR|Placebo|Inhaled nitrogen gas (Placebo) administered at 80 ppm
62019130|NCT05905965|ACTIVE_COMPARATOR|Empagliflozin 10 mg|Patients receiving empagliflozin 10 mg daily
62019131|NCT02033005||Breastfed infants|\>80% of feeds consisting of breast milk at both scanning points
62019132|NCT02033005||Formula-fed infants|\>80% of feeds consisting of formula milk at both scanning points
62582931|NCT01416974|EXPERIMENTAL|consolidative therapy with autologous T cells genetically|A phase I trial of consolidation therapy with autologous T cells genetically targeted to the B cell specific antigen CD19 for patients with chronic lymphocytic leukemia following upfront chemotherapy with pentostatin, cyclophosphamide and rituximab.
62582932|NCT06204315|EXPERIMENTAL|Stereotactic Radiosurgery|A non-invasive, non-surgical procedure that precisely delivers radiation to cancer on the spine while avoiding surrounding, healthy tissue.
62582933|NCT05320705|ACTIVE_COMPARATOR|dexmedetomidine|dexmedetomidine will be administered as a bolus dose, before the surgical incision, followed by infusion and stopped at the end of operation
62582934|NCT05320705|PLACEBO_COMPARATOR|normal saline placebo|similar bolus and infusion volumes of normal saline will be administered
62582935|NCT04459000|ACTIVE_COMPARATOR|STARs Only|Consenting research participant who receive prenatal care services in the STAR clinic, but are not randomized to receive mABC home visiting services.
62582936|NCT04459000|EXPERIMENTAL|STARS + mABC|Consenting research participant who receive prenatal care services in the STAR clinic, and are randomized to receive mABC home visiting services.
62019133|NCT02033005||Mixed-fed infants|20%-80% of feeds consisting of breast milk.
62019134|NCT03430154||Adults with hemophilia and obesity/overweight|Adults (any gender) aged ≥18 years with hemophilia (any severity, with or without inhibitors) self-identified with obesity or overweight
62019135|NCT03430154||Caregivers identified with obesity/overweight|Caregivers of children (any gender) currently aged \<18 years with hemophilia (any severity, with or without inhibitors) caregiver-identified with obesity or overweight
62582937|NCT04459000|NO_INTERVENTION|Control Group/CHOUM Only|These are research participants who were eligible to receive care in the STAR clinic, but did not opt to receive that care.
62582938|NCT01135433|EXPERIMENTAL|ASP group|ASP1941 and metformin
62582939|NCT01135433|PLACEBO_COMPARATOR|Placebo group|placebo and metformin
62790203|NCT05385003|PLACEBO_COMPARATOR|Dietary Supplement: Placebo control|Subjects are instructed to take one capsule of placebo daily for a total of 3 months
62790204|NCT05501717|EXPERIMENTAL|ALXN2030 Dose A|ALXN2030 will be administered as a single dose.
62790205|NCT05501717|EXPERIMENTAL|ALXN2030 Dose B|ALXN2030 will be administered as a single dose.
62019136|NCT03430154||Spouses or partners self-identified with obesity/overweight|Spouses or partners of adults (any gender) aged ≥18 years with hemophilia (any severity, with or without inhibitors) self-identified with obesity or overweight
62019137|NCT03430154||Healthcare profs. managing hemophilia and obesity/overweight|Healthcare professional (pediatric or adult hematologist, nurse, nurse practitioner, physician assistant, physical therapist, social worker) actively working in a federally designated hemophilia-treatment center for at least 3 years and with experience managing patients with hemophilia and obesity or overweight.
62019138|NCT01176903|EXPERIMENTAL|Glyco SD1|Single administration of Glyco pMDI dose level 1
62019139|NCT01176903|EXPERIMENTAL|Glyco SD2|Single administration of Glyco pMDI dose level 2
62019140|NCT01176903|EXPERIMENTAL|Glyco SD3|Single administration of Glyco pMDI dose level 3
62582940|NCT00790244|EXPERIMENTAL|Arm 2|"\<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and 4.~(\>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
62582941|NCT00790244|EXPERIMENTAL|Arm 3|"\<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 45Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and 4.~(\>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
62582942|NCT00790244|EXPERIMENTAL|Group B|"\<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(\>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
62582943|NCT00790244|EXPERIMENTAL|Arm 1|\<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle (\>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)
62582944|NCT03220282|ACTIVE_COMPARATOR|Donor milk|Pasteurized donor breast milk
62582945|NCT03220282|PLACEBO_COMPARATOR|Preterm infant formula|Preterm formula determined by clinical practice
62582946|NCT05864079||Control|22 healthy age-matched normal-weight male subjects (BMI is from 18.5 to \< 25)
62790206|NCT05501717|EXPERIMENTAL|ALXN2030 Dose C|ALXN2030 will be administered as a single dose.
62790207|NCT05501717|EXPERIMENTAL|ALXN2030 Dose D|ALXN2030 will be administered as a single dose.
62210370|NCT06727851||Prospective Group|The study shall provide the investigators with information whether the introduction of the quality performance measures adopted by the European Society of Gastrointestinal Endoscopy (ESGE) will actually lead to an improvement in quality. The study will compare the quality development in endoscopy based on following time intervals: 1. before introduction of the QIC-initiative (before 2017) 2. after the introduction of the initiative (2017-2023) (both retrospective data) 3. prospectively, from 2024 onwards. The focus of this study we will be the key performance indicator post-ERCP pancreatitis (PEP). In the ESGE-guideline, a minimum standard of \<10% and a target standard of \<5% was recommended. Different studies described the incidence of post-ERCP pancreatitis between 3,47% and 10,2%.
62210371|NCT06729177|EXPERIMENTAL|Single Case Research Design: Teacher 1|The PI will work with teachers to increase SISI implementation fidelity through a noncurrent multiple baseline design across teacher participants. Four teachers who serve deaf children between 5 and 8 years old will be recruited from a school of the deaf. SISI fidelity checklist will be used to observe teachers' business-as-usual instruction during language arts time to establish three stable data points in baseline. Each component of SISI is rated with a score of 1 (fully implemented), .5 (partially implemented), or 0 (did not implement) and reported as percentages (e.g., 20% of SISI components implemented). The PI will provide a 1-day training on SISI implementation. Teacher 1 will begin to implement SISI for three weeks, and then Teacher 2 will start implementing on Week 4. Teachers 3 and 4 will start implementing on Week 7 and 10 respectively.
62407528|NCT04532827|EXPERIMENTAL|Case formulation with web-program|"The intervention will start with two video meetings with a psychologist to build up and present an individual case formulation, based on behavioural analysis, and to build up a shared decision of individual goals for the web program. The intervention continues with a web program consisting of ten manualized web-based modules, each at one-week intervals based on relational frame theory (RFT) and acceptance and commitment therapy (ACT). The pilot programme included six two-weeks modules and it was in use until 5/2021. The programme is in Finnish.~Both participants in the intervention arm and in the treatment as the usual arm will receive usual care, meaning that TAU will be enhanced with the study intervention in the intervention arm. In addition to TAU, all participants will be given self-help and educational leaflet based on scientific knowledge related to their condition."
62407529|NCT04532827|NO_INTERVENTION|Treatment as usual|"Treatment as usual includes all the routine care that individual receives when he or she is presenting his or her symptoms at the primary or the occupational health care unit (corresponds primary care level treatment) or other unit that recommends the study for the participant. In practice, TAU may vary between the study participants based on their individual needs e.g. treatments for co-morbid somatic diseases or psychiatric disorders that this study will not interfere.~Both participants in the intervention arm and in the treatment as usual arm will receive usual care, meaning that TAU will be enhanced with the study intervention in the intervention arm. In addition to TAU all participants will be given self-help and educational leaflet based on scientific knowledge related to their condition."
62582947|NCT05864079||Overweight|22 healthy overweight male subjects (BMI is from 25 to \< 30). Patients with cardiovascular diseases, any malignancy, hepatic or renal failure, diabetic, hyperthyroid patients, patients with a previous history of thromboembolic diseases, or with a history of major surgery within 60 days will be excluded.
62407530|NCT00943826|EXPERIMENTAL|Bevacizumab + RT + Temozolomide|In the Concurrent Phase participants will receive radiotherapy (RT) in daily fractions of 2 Gy to be given 5 days per week for 6 weeks and temozolomide 75 mg/m\^2 daily from the first day to the last day of radiotherapy (it may continue for a maximum of 49 days in case of delay to the end of radiation therapy) and bevacizumab 10 mg/kg IV every 2 weeks for 6 weeks. There will be a 4 week treatment break. Participants will then enter the Maintenance Phase where they receive six 28-day cycle of bevacizumab 10 mg/kg IV q2w and temozolomide 150 to 200 mg/m\^2 daily in the first 5 days of each cycle. The participants will then enter the Monotherapy Phase where they will receive bevacizumab 15 mg/kg IV q3w until disease progression/unacceptable toxicity.
62407531|NCT00943826|PLACEBO_COMPARATOR|Placebo + RT + Temozolomide|In the Concurrent Phase participants will receive radiotherapy in daily fractions of 2 Gy to be given 5 days per week for 6 weeks and temozolomide 75 mg/m\^2 daily from the first day to the last day of radiotherapy (it may continue for a maximum of 49 days in case of delay to the end of radiation therapy) and placebo IV every 2 weeks for 6 weeks. There will be a 4 week treatment break. Participants will then enter the Maintenance Phase where they will receive six 28-day cycle of placebo IV q2w and temozolomide 150 to 200 mg/m\^2 daily in the first 5 days of each cycle. The participants will then enter the Monotherapy Phase where they will receive placebo IV q3w until disease progression/unacceptable toxicity.
62407532|NCT04869475|EXPERIMENTAL|Experimental|arsenic trioxide 7mg/m2 ivgtt d1-14, q3w
62407533|NCT02494804|OTHER|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
62407534|NCT02494804|OTHER|Temozolomide+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat
62407535|NCT00153751|EXPERIMENTAL|Traditional Chinese Medicine|They are Common peony root, other herbs.
62407536|NCT00153751|ACTIVE_COMPARATOR|Holopon|Holopon
62407537|NCT00153751|PLACEBO_COMPARATOR|placebo|Placebo
62407538|NCT06653049|EXPERIMENTAL|Reinforcement Learning (RL) Personalised Exercise Prescription|Participants in this arm received personalised exercise sessions via the i80 BPM app, which utilised a reinforcement learning (RL) model. The RL algorithm adapted exercise parameters (e.g., intensity, type of exercise, duration) based on individual preferences, performance, and feedback to optimise user satisfaction and engagement. Sessions were tailored specifically to each participant over the 12-week trial period.
62582948|NCT05864079||Obesity|22 healthy obese male subjects (BMI is ≥ 30). Patients with cardiovascular diseases, any malignancy, hepatic or renal failure, diabetic, hyperthyroid patients, patients with a previous history of thromboembolic diseases, or with a history of major surgery within 60 days will be excluded.
62582949|NCT04537377|EXPERIMENTAL|VTX-801|
62790208|NCT05501717|EXPERIMENTAL|ALXN2030 Dose E|ALXN2030 will be administered as a single dose.
62790209|NCT05501717|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as a single dose.
62790210|NCT01930838||Controls|Matched on age, sex and body mass index
62582950|NCT02907528|PLACEBO_COMPARATOR|BONE Group|bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
62582951|NCT02907528|ACTIVE_COMPARATOR|BONE+EMD Group|mixture of enamel matrix derivative proteins (EMD) (Emdogain® Straumann, Basel, Switzerland) and bone substitute consisting of βTCP/HA (Bone Ceramic® Straumann, Basel, Switzerland);
62210372|NCT06729177|EXPERIMENTAL|Single Case Research Design: Teacher 2|The PI will work with teachers to increase SISI implementation fidelity through a noncurrent multiple baseline design across teacher participants. Four teachers who serve deaf children between 5 and 8 years old will be recruited from a school of the deaf. SISI fidelity checklist will be used to observe teachers' business-as-usual instruction during language arts time to establish three stable data points in baseline. Each component of SISI is rated with a score of 1 (fully implemented), .5 (partially implemented), or 0 (did not implement) and reported as percentages (e.g., 20% of SISI components implemented). The PI will provide a 1-day training on SISI implementation. Teacher 1 will begin to implement SISI for three weeks, and then Teacher 2 will start implementing on Week 4. Teachers 3 and 4 will start implementing on Week 7 and 10 respectively.
62210373|NCT06729177|EXPERIMENTAL|Single Case Research Design: Teacher 3|The PI will work with teachers to increase SISI implementation fidelity through a noncurrent multiple baseline design across teacher participants. Four teachers who serve deaf children between 5 and 8 years old will be recruited from a school of the deaf. SISI fidelity checklist will be used to observe teachers' business-as-usual instruction during language arts time to establish three stable data points in baseline. Each component of SISI is rated with a score of 1 (fully implemented), .5 (partially implemented), or 0 (did not implement) and reported as percentages (e.g., 20% of SISI components implemented). The PI will provide a 1-day training on SISI implementation. Teacher 1 will begin to implement SISI for three weeks, and then Teacher 2 will start implementing on Week 4. Teachers 3 and 4 will start implementing on Week 7 and 10 respectively.
62407539|NCT06653049|ACTIVE_COMPARATOR|Generic Non-Personalised Exercise Prescription|Participants in this arm received generic, non-personalised exercise sessions using the same i80 BPM app. These sessions did not adapt to user preferences or feedback and consisted of pre-designed exercises that were uniform across all participants. This arm served as a control to compare against the RL-personalised intervention.
62582952|NCT02907528|EXPERIMENTAL|EMD Group|enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland)
62582953|NCT06559215|ACTIVE_COMPARATOR|Exparel + Marcaine Group|"* If \< 40 kg: 4 mg Exparel per kg BW and 30 mL 0.9% normal saline~* If 40-70 kg: 10 mL Exparel, 10 mL 0.25% Marcaine, and 10 mL 0.9% normal saline~* If \> 70 kg: 20 mL Exparel and 10 mL 0.25% Marcaine"
62582954|NCT06559215|NO_INTERVENTION|Marcaine Only Group|"* If ≤ 20 kg: 1 mL/kg 0.25% Marcaine~* If \> 20 - 70 kg: 20 mL 0.25% Marcaine and 10 mL 0.9% normal saline~* If \> 70 kg: 30 mL 0.25% Marcaine and 20 mL 0.9% normal saline"
62582955|NCT05406284||double kissing nano culotte stenting|
62582956|NCT05356949|EXPERIMENTAL|Intervention|The participants receive a psychological intervention including six weekly sessions. The intervention is based on methods of cognitive-behavioral therapy and delivered by a psychiatric nurse working in the participant's school.
62582957|NCT04470544|PLACEBO_COMPARATOR|Placebo + Standard of Care|Standard of Care will be defined by the investigators in collaboration with the sponsor on the basis of the best available evidence at the time of study initiation with placebo.
62582958|NCT04470544|EXPERIMENTAL|Camostat + Standard of Care|Patient will receive SOC tablets and Camostat mesilate 200 mg four times a day after each meal with Standard of Care treatment.
62734503|NCT03281369|EXPERIMENTAL|2L-4: Atezo + Linagliptin (Gastric Cancer)|Participants in the 2L-4 Gastric Cancer arm received atezolizumab in combination with linagliptin. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
62790211|NCT01930838||Gastric bypass operation|Patients with gastric bypass operation between 2006 and 2011 in The Central Denmark Region
62790212|NCT05581069|EXPERIMENTAL|STEPS|All participants receive the STEPS intervention
62790213|NCT06127719||patient on the waiting list for knee arthroplasty|adult patient on the waiting list for knee arthroplasty
62019141|NCT01176903|EXPERIMENTAL|Glyco SD4|Single administration of Glyco pMDI dose level 4
62019142|NCT01176903|EXPERIMENTAL|Glyco SD5|Single administration of Glyco pMDI dose level 5
62019143|NCT01176903|PLACEBO_COMPARATOR|Placebo SP|Single administration of Placebo pMDI
62019144|NCT01176903|EXPERIMENTAL|Glyco MD1|Multiple administration of Glyco pMDI dose level 1
62019145|NCT01176903|EXPERIMENTAL|Glyco MD2|Multiple administration of Glyco pMDI dose level 2
62790214|NCT04255589|EXPERIMENTAL|Experimental Group|Patients assigned to this group are treated with one CKD-495 75mg Tab.,and one Placebo Tab.(Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab)
62790215|NCT04255589|ACTIVE_COMPARATOR|Active comparator Group|Patients assigned to this group are treated with one Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and one Placebo Tab.(Placebo of the CKD-495 75mg)
62019146|NCT01176903|EXPERIMENTAL|Glyco MD3|Multiple administration of Glyco pMDI dose level 3
62019147|NCT01176903|PLACEBO_COMPARATOR|Placebo MP|Multiple administration of placebo pMDI
62582959|NCT04786340|PLACEBO_COMPARATOR|Placebo: 4 mL of matching placebo topical solution.|The placebo solution contains the same ingredients as the active solution with the exception of the active WST-057. It is dispensed with a pump to deliver 4 mL to the calves (mid-calf sock line), ankles and the tops of both feet. Both solutions (active and placebo) are applied once-a-day for 12 weeks.
62210374|NCT06729177|EXPERIMENTAL|Single Case Research Design: Teacher 4|The PI will work with teachers to increase SISI implementation fidelity through a noncurrent multiple baseline design across teacher participants. Four teachers who serve deaf children between 5 and 8 years old will be recruited from a school of the deaf. SISI fidelity checklist will be used to observe teachers' business-as-usual instruction during language arts time to establish three stable data points in baseline. Each component of SISI is rated with a score of 1 (fully implemented), .5 (partially implemented), or 0 (did not implement) and reported as percentages (e.g., 20% of SISI components implemented). The PI will provide a 1-day training on SISI implementation. Teacher 1 will begin to implement SISI for three weeks, and then Teacher 2 will start implementing on Week 4. Teachers 3 and 4 will start implementing on Week 7 and 10 respectively.
62210375|NCT06297759||healthcare professionals who care for patients with dementia|Participants will be selected by healthcare professionals who care for patients with dementia. At the first meeting, participants will be informed about the study, will be screened for inclusion criteria, and a written informed consent form will be obtained before testing.
62210376|NCT04690894|ACTIVE_COMPARATOR|Erector spinae group|the child received ultrasound-guided erector spinae muscle block in a dose of 0.4mg/kg of 0.25%bupivacaine between the 10th transverse process and erector spinae muscle
62210377|NCT04690894|ACTIVE_COMPARATOR|caudal group|child received ultrasound-guided caudal block in a dose of 2.5mg/kg of bupivacaine 0.25%
62210378|NCT04690894|NO_INTERVENTION|control|child didn't received any regional block
62210379|NCT05377437|EXPERIMENTAL|Participants|Participants of the study
62582960|NCT04786340|EXPERIMENTAL|WST-057 active: 4 mL of WST-057 (4%; 146 mg of pirenzepine free base monohydrate) topical solution|The WST-057 is the active topical solution and contains pirenzepine free base monohydrate. It is dispensed with a pump to deliver (with 4 pumps) 4 mL to the calves (mid-calf sock line), ankles and the tops of both feet. Both solutions (active and placebo) are applied once-a-day for 12 weeks.
62210380|NCT01143181|EXPERIMENTAL|Brincidofovir|Subjects received either a weight-based or a fixed-dose of oral brincidofovir (BCV) once weekly or twice weekly for up to 3 months until clinical disease was resolved or stabilized and/or viral DNA polymerase chain reaction testing was negative for 4 consecutive weeks, whichever was longer.
62210381|NCT02654951|EXPERIMENTAL|Visual + Force Feedback|Participants will complete a set of trials while receiving visual feedback only. After finishing, participants will continue to a new set of trials while receiving force feedback only.
62210382|NCT02654951|EXPERIMENTAL|Force + Visual Feedback|Participants will complete a set of trials while receiving force feedback only. After finishing, participants will continue to a new set of trials while receiving visual feedback only.
62210383|NCT05041010|EXPERIMENTAL|Neu2000KWL|
62210384|NCT05041010|PLACEBO_COMPARATOR|Placebo|
62210385|NCT04744493|EXPERIMENTAL|treatment arm of Exablate 4000 as a single arm|Only one arm of treatment by Exablate 4000 was established.
62210386|NCT02392520|EXPERIMENTAL|Antagonist|0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
62582961|NCT05797961|EXPERIMENTAL|HIV self-testing with online supervision|HIV self-testing with online supervision
62582962|NCT05797961|OTHER|Control|venue-based HIV testing
62582963|NCT02249169||IBS-C|Patients with a clinical diagnosis of constipation-predominant irritable bowel syndrome
62582964|NCT02249169||IBS-D|Patients with a clinical diagnosis of diarrhea-predominant irritable bowel syndrome
62582965|NCT02249169||Healthy subjects|Subjects without a clinical diagnosis of IBS-C or IBS-D
62582966|NCT02249169||Healthy Controls|Subject without a clinical diagnosis of IBS-C or IBS-D and who is either a first-degree relative of an IBS participant or is not genetically related but resides with the IBS participant
62582967|NCT01676363|EXPERIMENTAL|Diflunisal|
62582968|NCT02993250|EXPERIMENTAL|Cohort 1 (Chronic Hepatitis C Without Cirrhosis)|Participants will receive 800 milligram (mg) AL-335 +odalasvir (ODV) 25 mg+simeprevir (SMV) 75 mg once daily for 8 weeks in Cohort 1.
62019148|NCT01176903|ACTIVE_COMPARATOR|Tiotropium|Multiple administration of tiotropium
62210387|NCT02392520|PLACEBO_COMPARATOR|Conventional|Women with severe early OHSS will be treated with conventional treatment, such as intravenous albumin administration, paracentesis of ascitic fluid, either on an outpatient or inpatient basis.
62210388|NCT05947032|EXPERIMENTAL|Supervised endurance exercise training + Patient Education|
62407540|NCT04715880|ACTIVE_COMPARATOR|Paravertebral Block (PVB) group|"Under complete aseptic precaution, Patient will be in lateral decubitus position a paravertebral catheter will be placed by the surgeon before closure of thoracotomy wound. The catheter will be introduced percutaneously through 18 gauge needle into the pleural cavity.~The tip of catheter will be loaded by anaesthesiologist with 0.25 % isobaric bupivacaine with 20 ml followed by continuous infusion with bupivacaine 0.25 % at 6-8 ml per hour"
62210389|NCT05947032|ACTIVE_COMPARATOR|Home exercises + Patient Education|
62210390|NCT06021457|EXPERIMENTAL|RBT-1|Single IV infusion prior to cardiac surgery
62210391|NCT06021457|PLACEBO_COMPARATOR|Placebo|Single IV infusion prior to cardiac surgery
62210392|NCT04415983|EXPERIMENTAL|Nitazoxanide group|Clarithromycin, Nitazoxanide and Proton pump inhibitor
62210393|NCT04415983|ACTIVE_COMPARATOR|Traditional group|Clarithromycin, Metronidazole and Proton pump inhibitor
62210394|NCT02365727|EXPERIMENTAL|Exparel plus Adductor Canal Block|Adductor canal block with 20 cc 0.5% Ropivacaine with 1:400,000 epinephrine and 100mcg of clonidine
62210395|NCT02365727|PLACEBO_COMPARATOR|Exparel plus Placebo Block|Adductor canal block with 20 cc saline
62210396|NCT04289831|ACTIVE_COMPARATOR|Direct Surgery (DS) group|patients subjected to direct surgery (DS) within 1 week after randomization
62210397|NCT04289831|ACTIVE_COMPARATOR|Preoperative Biliary Drainage (PBD) group|patients managed by Preoperative Biliary Drainage followed by surgery after 4-6 weeks.
62210398|NCT04949061|EXPERIMENTAL|Intervention Arm: Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|The experimental group will receive an 8-session CA-CBI in an online group format.
62210399|NCT04949061|OTHER|Control Arm: Enhanced Treatment as Usual (ETA-U)|The control group will receive the information about freely available psychological support options. Also, they will receive brief psychoeducation about the mental health problems and psychological distress via online leaflets. After all the measurements are completed, the control group will be able to receive the CA-CBI.
62210400|NCT02250677||Patients with myalgia|Patients with myalgia as a side effect to treatment with Simvastatin (minimum 20 mg daily)
62210401|NCT02250677||Patients without myalgia|Patients treated with Simvastatin (minimum 20 mg daily) without any side effects to the treatment
62407541|NCT04715880|ACTIVE_COMPARATOR|Paravertebral block/Intercostal Block (PVB/ICB) group|Under complete aseptic precaution, patient will be in lateral decubitus position a paravertebral catheter will be placed by surgeon into pleural cavity and will not be loaded with bolus dose. At the end of surgery the (consultant anaesthesiologist) will perform intrathoracic unilateral intercostal nerve block two level above and two level below and at site of incision with 4 ml per level of 0.25 % bupivacaine followed by continuous infusion with 0.25 % bupivacaine at 6-8 ml/hour through catheter placed in paravertebral space.
62407542|NCT03592680|ACTIVE_COMPARATOR|Vitamin C|Vitamin C 1000mg PO from 5 days before surgery until 10 days after surgery
62019149|NCT03946332|EXPERIMENTAL|Physical exercise arm|patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization. Furthermore, SMS will be regularly sent to remind them to practice
62210402|NCT02250677||Control group|Patients with elevated serum cholesterol not treated with cholesterol lowering drugs
62210403|NCT01205152|EXPERIMENTAL|asfotase alfa|An initial single intravenous (IV) infusion of 2 mg/kg asfotase alfa, followed by subcutaneous (SC) injections of 1 mg/kg asfotase alfa 3 times per week
62210404|NCT01744938|NO_INTERVENTION|early surgery|only receiving pancreaticoduodenectomy without preoperative biliary drainage
62210405|NCT01744938|EXPERIMENTAL|preoperative biliary drainage|percutaneous preoperative biliary drainage before pancreaticoduodenectomy guided by CT scan
62407543|NCT03592680|PLACEBO_COMPARATOR|Placebo|Placebo as an alternative for Vitamin C tablets
62407544|NCT01205139|EXPERIMENTAL|001|TMC435 150 mg capsule once daily for 11 days
62407545|NCT01205139|EXPERIMENTAL|002|TMC278 25 mg tablet once daily for 11 days
62407546|NCT01205139|EXPERIMENTAL|003|TMC435 + TMC278 150 mg TMC435 capsule + 25 mg TMC278 tablet once daily for 11 days
62407547|NCT01205139|EXPERIMENTAL|004|TMC435 150 mg capsule once daily for 7 days
62407548|NCT01205139|EXPERIMENTAL|005|TDF 300 mg tablet once daily for 7 days
62210406|NCT04716777|EXPERIMENTAL|Brief Transdiagnostic GCBT|Participants receive Brief Transdiagnostic group cognitive-behavioral treatment. Eight weekly sessions.
62210407|NCT04716777|NO_INTERVENTION|Waitlist|Participants receive an 8-week waitlist condition with some attentional-control via monitoring for clinical deterioration. After a post-waitlist assessment, participants in this condition are offered the Brief Transiagnostic GCBT for eight weeks.
62210408|NCT04510311|EXPERIMENTAL|PET/CT scan with radiotracer [18F]3F-PHPG|Novel radiotracer \[18F\]3F-PHPG prior to whole-body PET/CT scan.
62210409|NCT04510311|ACTIVE_COMPARATOR|Planar scintigraphy/SPECT scans with radiotracer [123I]MIBG|FDA approved radiotracer \[123I\]MIBG prior to whole-body planar scintigraphy and SPECT/CT scan (standard clinical imaging procedures).
62210410|NCT02097173|OTHER|SC MTX followed by IM MTX|1 subcutaneous injection of 30 mg methotrexate administered by a prefilled pen (50mg/mL) followed by 1 intramuscular injection of 30 mg methotrexate (comparator) after a wash-out phase of 1 week
62407549|NCT01205139|EXPERIMENTAL|006|TMC435 + TDF 150 mg TMC435 capsule + 300 mg TDF tablet once daily for 7 days
62582969|NCT02993250|EXPERIMENTAL|Cohort 2 (Chronic Hepatitis C With Compensated Cirrhosis)|Participants will receive AL-335 800 milligram (mg)+ODV 25 mg+SMV 75 mg once daily for 12 weeks in Cohort 2. Dosing in cohort 2 will be started according to decision of Data Review Committee (DRC).
62019150|NCT03946332|ACTIVE_COMPARATOR|controlled arm|patients will be hospitalized in the same conditions than the experimental group and will be able to practice if they want.
62019151|NCT00512759|NO_INTERVENTION|Standard of care|Standard of care of acute decompensated heart failure will be according to the current guidelines of the European Society of Cardiology (ESC).
62210411|NCT02097173|OTHER|IM MTX followed by SC MTX|1 intramuscular injection of 30 mg methotrexate (comparator) followed by 1 subcutaneous injection of 30 mg methotrexate by a prefilled pen (50mg/mL) after a wash-out phase of 1 week
62210412|NCT05717439||PTSD positive|Subjects meet criteria for PTSD, with or without comorbid Generalized Anxiety Disorder or Major Depressive Disorder
62210413|NCT05717439||Primary GAD|Subjects DO NOT meet criteria for PTSD, but meet criteria for Generalized Anxiety Disorder
62407550|NCT06567600|EXPERIMENTAL|Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody|"Low-dose Gemcitabine and Cisplatin Chemotherapy:~Gemcitabine 500 mg/m2 Cisplatin 12.5 mg/m2 on day 1 and day 8 of each 21-day cycle for up to eight cycles~PD-1/PD-L1Antibody:~Pembrolizumab 200mg on day 1 of each 21-day cycle Durvalumab 1500 mg on day 1 of each 21-day cycle After completion of gemcitabine and cisplatin, 200mg of Pembrolizumab or 1500 mg of Durvalumab may administer once every 3 or 4 weeks until clinical or imaging (per RECIST v1.1) disease progression or until unacceptable toxicity, withdrawal of consent, or any other discontinuation criteria were met."
62582970|NCT00638404||1|Elective Cesarean Sections-this portion completed
62582971|NCT00638404||3|Any in-patient gynecologic procedure- this portion completed
62407551|NCT01407627|EXPERIMENTAL|Fructose First|"1. Study Day 1 - measurement of renal hemodynamics and blood pressure~2. Subjects will ingest fructose 200g daily x 14d~3. Study Day 2 - measurement of renal hemodynamics~4. Minimum 1 week washout period~5. Subjects will ingest dextrose 200g daily x 14d~6. Study Day 3 - measurement of renal hemodynamics and blood pressure"
62582972|NCT06143345|EXPERIMENTAL|Intervention Group|Intervention participants will complete 24 supervised high-intensity interval training (HIIT) sessions over 8 weeks, with 3 sessions per week on alternate days. Each HIIT session will consist of a 5-minute warm-up, followed by an interval-based workout phase that includes steady up-tempo cadences, sprints, and climbs, interspersed with recovery periods. The session will conclude with a 5-minute cooldown. The workout sessions will initially last 20 minutes and will progressively increase in time based on participants' tolerance and instructor recommendations. Intensity will start at 75% of the estimated maximal heart rate reserve and will increase by 5% weekly, as tolerated and/or deemed necessary by the instructor, over the 8-week intervention period. Participants will receive instructions to maintain a eucaloric diet throughout the study.
62019152|NCT00512759|EXPERIMENTAL|Intervention|Early goal-directed preload and afterload decrement using a fixed therapy schedule including sublingual or nitrospray and transdermal nitrates together with hydralazine, followed by rapid up-titration of ACE-inhibitors , AT-receptor blockers or neprilysin inhibitors/AT-receptor blockers to achieve maximal vasodilatation with a target systolic blood pressure of 90-110 mmHg. All other elements of treatment will be according to the current guidelines of the European Society of Cardiology (ESC)
62019153|NCT05924646|EXPERIMENTAL|Moderate Dietary Salt Plus Additional Salt|6 grams of salt in slow release capsules combined with 6 grams of salt in the diet.
62019154|NCT05924646|PLACEBO_COMPARATOR|Moderate Dietary Salt Alone|6 grams of microcrystalline cellulose in slow release capsules combined with 6 grams of salt in the diet.
62019155|NCT01784705|EXPERIMENTAL|Transcranial bright light therapy|
62019156|NCT01784705|PLACEBO_COMPARATOR|Transcranial placebo treatment|
62019157|NCT05218252|OTHER|Hand soft tissue defects|Patients with mild to moderate hand soft tissue defects with exposed bone, tendons or cartilage resulting from trauma, tumor ablation or postburn deformities.
62019158|NCT01097226|EXPERIMENTAL|Apple flavanols|
62019159|NCT04135131|EXPERIMENTAL|PILATES MAT EXERCISE EFFECT ON LOW BACK PAIN|Patients were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. The evaluations were made at the beginning and end of the treatment. Outcome parameters were VAS, Oswestry Disability Index, Qubec Disability Scale, Short Form-36, Beck Depression Questionnaire, sit and reach, Modified Schöber and sit up tests. Multifidus and abdominal muscle thickness were measured by ultrasound image
62210414|NCT05717439||Primary MDD|Subjects DO NOT meet criteria for PTSD, but meet criteria for Major Depressive Disorder
62210415|NCT05717439||Comorbid GAD/MDD|Subjects DO NOT meet criteria for PTSD, but meet criteria for Generalized Anxiety Disorder and Major Depressive Disorder
62210416|NCT05717439||Trauma-positive, PTSD/GAD/MDD-negative|Subjects have trauma exposure meeting DSM-5-TR Criterion A, but DO NOT meet criteria for PTSD, GAD, or MDD
62210417|NCT05717439||Trauma-negative|Subjects DO NOT have trauma exposure meeting DSM-5-TR Criterion A and DO NOT meet criteria for PTSD, GAD, or MDD
62210418|NCT05109182|EXPERIMENTAL|Intervention (3D model + CT for surgical planning)|Patients in this arm will receive a 3D model which will be used in addition to the CT scan for surgical planning.
62210419|NCT05109182|NO_INTERVENTION|Control (CT for surgical planning)|Patients in this arm will only have the a CT scan used for surgical planning.
62210420|NCT02016040|ACTIVE_COMPARATOR|HIFU hemi-ablation|Focal Therapy Using High Intensity Focused Ultrasound (Ablatherm)
62210421|NCT04620564||Patients|
62210422|NCT04620564||Relatives|
62407552|NCT01407627|ACTIVE_COMPARATOR|Dextrose First|"1. Study Day 1 - measurement of renal hemodynamics and blood pressure~2. Subjects will ingest dextrose 200g daily x 14d~3. Study Day 2 - measurement of renal hemodynamics~4. Minimum 1 week washout period~5. Subjects will ingest fructose 200g daily x 14d~6. Study Day 3 - measurement of renal hemodynamics and blood pressure"
62210423|NCT02408601|ACTIVE_COMPARATOR|Group 1|"split mouth study. one side of the arch that is the lower left permanent 1st molar will be receiving resin based sealants.~Application of the resin sealants as per the standard instructions of the manufacturer~Helioseal -F ( Resin based sealant)~1. isolate the tooth surface~2. etch the fissure anatomy with 37% phosphoric acid for 20 seconds~3. wash the tooth surface and dry it. No salivary contamination is accepted~4. using a syringe based system, apply the sealant onto the fissures, do not overfill the fissures, run an explorer along the fissures to avoid any air entrapment.~5. light cure the sealant~6. check for high points and the occlusion"
62210424|NCT02408601|EXPERIMENTAL|Group 2|"split mouth study. one side of the arch that is the lower right permanent 1st molar will be receiving ART sealants.~Application of the ART sealants as per the standard instructions of the manufacturer~1. isolate the tooth surface~2. condition the fissure anatomy using a GC conditioner for 10 seconds~3. wash the conditioner by using a cotton pellet for a couple of times, do not use a three way syringe.~4. dry the tooth surface~5. mix the GIC according to the standard powder: liquid ratio~6. place the mix onto the fissures using a plastic spatula~7. apply pressure on the occlusal surface with a gloved index finger( the gloved index finger must be coated with petroleum jelly)~8. apply pressure for 10-15 sec and withdraw the finger in a sideways motion~9. scrap out the excess material~10. check for the high points and the occlusion~11. apply petroleum jelly onto the GIC mix~12. advice patient not to eat or drink for 30 minutes."
62210425|NCT01493427|EXPERIMENTAL|TRAVATAN® BAK-free|Travoprost 0.004%, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks
62210426|NCT00240799|EXPERIMENTAL|001|acetaminophen extended release
62210427|NCT00240799|PLACEBO_COMPARATOR|002|placebo
62210428|NCT02655068|OTHER|Computed Tomography (CT)|"Patients who undergo primary surgery will have their first study imaging surveillance at 3 months (+/- 30 days) post-surgery. CT surveillance will continue at 6,9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
62210429|NCT02655068|OTHER|PET/CT|"Patients who undergo primary radiotherapy will have their first study imaging surveillance at 6 months (+/- 30 days) post radiotherapy. The Positron Emission Tomography - Computed Tomography (PET/CT)surveillance will continue at 9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
62210430|NCT05793008|EXPERIMENTAL|Takotsubo Syndrome|"Patients diagnosed with either primary or secondary Takotsubo Syndrome.~TTS diagnosed based on modified Mayo Clinic Diagnostic Criteria as:~* Transient wall motion abnormality in the left ventricle beyond a single epicardial coronary artery distribution;~* Absence of obstructive coronary artery disease or angiographic evidence of acute plaque rupture, which can explain the wall motion abnormality;~* New electrocardiographic abnormalities or elevation in cardiac troponin values;~* Absence of pheochromocytoma or myocarditis."
62407553|NCT05880758|ACTIVE_COMPARATOR|Stable Adequate Sleep (SAS)|Participants will go to bed and wake up at the same time every night, maintaining adequate sleep duration.
62407554|NCT05880758|EXPERIMENTAL|ISS_Alone|Intermittent short sleep (ISS) 5 nights of 5.5 hours time in bed 2 nights of 9.5 hours time in bed with advanced bedtimes and delayed wake times
62407555|NCT05880758|EXPERIMENTAL|ISS_SJL|Intermittent short sleep with short jetlag (SJL) 5 nights of 5.5 hours time in bed 2 nights of 9.5 hours time in bed with constant bedtimes and delayed wake times
62407556|NCT06264765|OTHER|scalp block|Following induction of anesthesia, a scalp block will be performed before the surgery begins.
62407557|NCT06264765|OTHER|incisional infiltration|Following induction of anesthesia, incisional infiltration will be performed before the surgery begins.
62407558|NCT06381115|EXPERIMENTAL|SleepWell24 Smart Application|This group will consists of participates who will be on study for 8 weeks using the Sleepwell24 application. Once 20 people are enrolled on the 8 week cohort, a 6 month cohort will open up for 20 different participants.
62407559|NCT04242901||Colorectal cancer|Patients recently diagnosed colorectal cancer
62407560|NCT04675489|OTHER|Vivity Toric IOL|Patients with cataract that had phacoemulsification and Vivity Toric IOL implantation.
62407561|NCT03876795|ACTIVE_COMPARATOR|Single intra-articular Bone Marrow Concentrate injection|Single intra-articular Bone Marrow Concentrate injection in the knee
62407562|NCT03876795|EXPERIMENTAL|combined Bone Marrow Concentrate injection|combined Bone Marrow Concentrate injection (intra-articular and intra-osseus)
62407563|NCT06466967||Type 1 diabetes patients treated with AHCL (CamAPS-Ypsopump)|Patients with type 1 diabetes on treatment with AHCL (CamAPS-Ypsopump) and a strict programmed glucose target (80-99 mg/dL).
62582973|NCT06143345|ACTIVE_COMPARATOR|Control Group|Control participants will be instructed to refrain from engaging in intense physical activities during the study period. They will also receive instructions to maintain a eucaloric diet throughout the study.
62407564|NCT01095458|EXPERIMENTAL|Phone based weight management group|Group based weight management program delivered via conference calls
62407565|NCT01095458|EXPERIMENTAL|Clinic based weight management group|Traditional clinical based group weight management program
62407566|NCT01720927||Acute Pharyngitis|Subjects presenting with acute pharyngitis
62407567|NCT06439134||Non-COVID-19 group|The group which consists of volunteers who has not been infected by COVID-19 virus
62407568|NCT06439134||Post COVID-19 group|The group which consists of volunteers who has been infected by COVID-19 virus and has at least 3 months or more post-COVID period
62407569|NCT04027777|EXPERIMENTAL|Aktiia.product-P0|Main study arm including 85 subjects
62407570|NCT04027777|EXPERIMENTAL|Aktiia.product-P0 Diabetics|Second study arm including 40 diabetic patients
62210431|NCT05793008|EXPERIMENTAL|Septic patients|"Patients with diagnosis of sepsis and septic shock with or without concurrent LVSD or/and LVDD.~Diagnosis of sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, which can be represented by an increase in the Sequential \[Sepsis-related\] Organ Failure Assessment (SOFA) score of 2 points or more.~Septic shock, defined as vasopressor requirement to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (\>18 mg/dL) in the absence of hypovolemia.~Sepsis-induced cardiomyopathy, defined as left ventricular systolic dysfunction (LVSD) and/or LV diastolic dysfunction (LVDD) following sepsis in patients without known structural or functional cardiac disease."
62407571|NCT04027777|EXPERIMENTAL|Aktiia.product-P0 Aged|Thirs study arm including 40 patients aged 65+
62407572|NCT05731973|EXPERIMENTAL|Intercostal nerve cryoablation|When a patient is allocated to the intercostal nerve cryoablation group, cryoablation will be performed prior to bar placement. In brief, cryoablation will be performed at the level of the bar and two levels above and below, bilaterally. For this, a second portal access will be placed for video guidance on the contralateral side, and the cryoprobe (cryoICE, Atricure, Masion, OH, USA) will be inserted through the thoracic incisions that are already made for bar placement. The probe will be placed at the inferior aspect of the ribs, posterior to the midaxillary line, directly on the neurovascular bundle. One freezing cycle takes 2 minutes, and a temperature of -60 ⁰C will be applied. The probe will be warmed to room temperature before removing it from the pleura to prevent additional trauma. Furthermore, intercostal nerve cryoablation will be combined with single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks placed just anterior to the side of the cryoablation.
62210432|NCT04343287|ACTIVE_COMPARATOR|BRM421 Ophthalmic Solution|A topical solution of BRIM421 ophthalmic drops
62210433|NCT04343287|PLACEBO_COMPARATOR|Placebo|A vehicle ophthalmic drops
62210434|NCT03538301|EXPERIMENTAL|Dose Level 1|ND-L02-s0201 45mg
62210435|NCT03538301|EXPERIMENTAL|Dose Level 2|ND-L02-s0201 90mg
62210436|NCT03538301|PLACEBO_COMPARATOR|Placebo|Control Arm
62210437|NCT03313375|NO_INTERVENTION|Control|Subjects will have no intervention. They will be resting in a chair for the entire length of the visit (4-5 hours) where blood pressure will be taken every 10 min, while other non-invasive cardiac measures are taken (I.E. Cardiac output, systemic vascular resistance, heart rate variability).
62210438|NCT03313375|ACTIVE_COMPARATOR|Continuous exercise|Subjects will be asked to perform a 45 min exercise bout. After a warmup, the exercise will be 30 minutes at a continuous level. After the exercise period subject will remain in the lab and blood pressure will be measured every 10 minutes for the remainder of the visit (4 hours) while other non-invasive cardiac measures are taken continuously as discussed above.
62407573|NCT05731973|ACTIVE_COMPARATOR|Thoracic epidural (local continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))|Prior to surgery, an anesthesiologist will place the thoracic epidural at T5-T6 or T6-T7 interspace in the awake patient. After correct placement, a local continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml) will be started. At the third postoperative day, thoracic epidural analgesia will be ceased and transitioned to oral pain medication at discretion of the pain management team. In general, opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours as needed) will be provided 12 hours before thoracic epidural analgesia is ceased.
62210439|NCT03313375|EXPERIMENTAL|Aerobic Interval Exercise|Subjects will be asked to complete a 43 minute exercise session. After a warmup period, the subjects will complete a 4x4 protocol in that they will alternate 4, 4 minute higher intensity exercise bouts with 3, 3 minute lower intensity bouts. After the exercise, subjects will remain in the lab and blood pressure will be measured every 10 minutes for 4 hours, while other non-invasive cardiac measures are taken continuously as discussed above.
62210440|NCT06228391|EXPERIMENTAL|Ketamine|Twice a week ketamine IV 0.5 mg/kg
62210441|NCT06228391|ACTIVE_COMPARATOR|Midazolam|Twice a week midazolam IV 0.045 mg/kg
62210442|NCT01619553||affected|individuals with keloids
62210443|NCT01619553||unaffected|unrelated unaffected controls or unaffected family members
62407574|NCT02860026|ACTIVE_COMPARATOR|Control|Marketed cow's milk-based infant formula
62407575|NCT02860026|EXPERIMENTAL|Investigational|Cow's milk-based infant formula with added nutrients
62407576|NCT02313246|EXPERIMENTAL|Group Cognitive Behaviour Therapy|Patients will complete an 11-session group cognitive behaviour therapy for IBS that will be led by two clinicians, one of whom will be a registered clinical psychologist, at the Digestive Diseases Clinic at McMaster University Medical Centre. The group cognitive behaviour therapy will include weekly 2-hour sessions for 11 weeks. Sessions will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
62407577|NCT06648213|OTHER|Individualized Physiotherapy|Therapy group: In addition to routine care, they will be arranged according to the needs of the baby in the form of positioning, hand contacts, passive and active movement of the arms and legs for the development of movement, sensory stimuli around the mouth for oral motor organisation. Neurodevelopmental-based application will be applied three days a week, once a day for 10-15 minutes, from the 34th week until 36th week when vital signs are stable.
62210444|NCT04207177|ACTIVE_COMPARATOR|Mycophenolate mofetil|In the subgroup of living donor recipients included before transplantation this group will be treated with mycophenolate mofetil (750 mg BID) for one week
62210445|NCT04207177|ACTIVE_COMPARATOR|Tacrolimus|In the subgroup of living donor recipients included before transplantation this group will be treated with tacrolimus (BID, dose by weight) for one week
62582974|NCT05672680|PLACEBO_COMPARATOR|Placebo|"Normal Saline:~For patients weighing \<100 kg, a total of 50 ml ((25 ml on each side of the abdominal wall) will be received. If patients weigh\>100 kg, a total of 60 ml (30ml on each side of the abdominal wall) will be received."
62019160|NCT04135131|PLACEBO_COMPARATOR|HOME EXERCISE|The exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises. Patients were asked to perform three sets of exercises (10 repetitions) for three times a week for 8 weeks. Exercise training was provided by a physiotherapist. Patients were also provided an illustrated exercise brochure along with an exercise diary to record the number of days on which exercise was performed. They were followed up by phone calls every 2 weeks
62210446|NCT04824690|EXPERIMENTAL|Virtual Reality Group|The virtual reality group watched a 1.5-minute VR video showing the operating theater and explaining the perioperative process. After the surgery, this group watched cartoons during the first standard nursing procedures after the effect of the anesthesia wore off.
62019161|NCT05417711|EXPERIMENTAL|Transcutaneous Vagus Nerve Stimulation Paired with Tailor-Made Notched Music Therapy|The participants receive 30 minutes / time, 4 times / day, continuous 3 months of auditory tVNS combined with TMNMT. The stimulation intensity used in each course was set to the highest level that the patient could tolerate. The participants listen to the tailor-made notched music at the same time.
62407578|NCT06648213|NO_INTERVENTION|Control|Control group: They will be monitored by performing routine care and positioning.
62210447|NCT04824690|NO_INTERVENTION|Control Group|The control group received conventional care and education regarding the perioperative process of surgery.
62210448|NCT01445600||ALTARGO(retapamulin)|The subjects with bacterial skin and skin structure infections (SSSI)
62210449|NCT02104297|ACTIVE_COMPARATOR|Deksmedetomidine infusion|To prevent agitation deksmedetomidine infused during operation and at the end of surgery agitation scor measured by Riker sedation agitation scale.
62210450|NCT02104297|EXPERIMENTAL|Remifentanil infusion|To prevent agitation remifentanil infused during operation at the end of surgery agitation scor measured by Riker sedation agitation scale.
62407579|NCT02524262|EXPERIMENTAL|Slow-release L-cysteine|Oral intake of slow-release L-cysteine 200 mg before challenge with ethanol.
62407580|NCT02524262|PLACEBO_COMPARATOR|Placebo|Oral intake of identically-looking placebo capsules
62407581|NCT02602470||Rosacea treated patients|Patients using topical rosacea treatment
62407582|NCT04812886|EXPERIMENTAL|Epidemiological study|
62407583|NCT02237066|EXPERIMENTAL|Chocolate PTA Balloon|Chocolate PTA Balloon Angioplasty
62582975|NCT05672680|EXPERIMENTAL|Experimental|0.25% bupivacaine: For patients weighing \<100 kg, a total of 50 ml ((25 ml on each side of the abdominal wall) will be received. If patients weigh\>100 kg, a total of 60 ml (30ml on each side of the abdominal wall) will be received.
61978501|NCT02505230|EXPERIMENTAL|Meal Order 2|"\[P+S,HVP,LVP,P\]~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables."
62734504|NCT03281369|EXPERIMENTAL|1L-1:Atezo+Tiragolumab+Cisplatin+5FU(Esophageal Cancer Cohort)|Participants in the 1L-1 Esophageal Cancer arm will receive atezolizumab in combination with tiragolumab and chemotherapy.
62210451|NCT02104297|PLACEBO_COMPARATOR|Saline infusion|Saline infused during operation and at the end of surgery agitation scor measured by Riker sedation agitation scale.
62210452|NCT04349839||ACRODAT study arm|No intervention
62210453|NCT04349839||Standard Practice Arm|No intervention
62210454|NCT02395146|EXPERIMENTAL|Monitoring|intraoperative EBSLN monitoring will take place
62210455|NCT02395146|NO_INTERVENTION|Non-Monitoring|No intraoperative EBSLN monitoring will take place (standard practice)
62210456|NCT04408703||Ulcerative colitis in clinical remission|Clinical remission with SCCAI \<3 at baseline and stable remission for the last 3 months
62734505|NCT03281369|EXPERIMENTAL|1L-2: Atezo+Cisplatin+5-FU (Esophageal Cancer Cohort)|Participants in the 1L-2 Esophageal Cancer arm will receive atezolizumab in combination with chemotherapy.
62210457|NCT06610175||Healthy participants|
62210458|NCT06610175||Patients with CDDD|
62407584|NCT02237066|ACTIVE_COMPARATOR|Standard PTA Balloon|Standard PTA Balloon Angioplasty
62407585|NCT02393404|EXPERIMENTAL|PT-FMT|Functional movement-power training group
62407586|NCT02393404|EXPERIMENTAL|FMT alone|Functional movement training group
62407587|NCT02393404|NO_INTERVENTION|Control|No intervention control group
62407588|NCT05822388||Parkinson's Disease undergoing DBS|This study will recruit 55 patients with Parkinson's disease (PD) participants who will undergo DBS surgery and and are scheduled for a pre-DBS neuropsychological evaluation at MUSC.
62407589|NCT05822388||Healthy Control participants without Parkinson's Disease|This study will recruit 25 healthy controls (age-matched) to serve as a comparison of baseline cognitive and neuroimaging measures.
62407590|NCT06471023|OTHER|TP1 → TP2 → TP3 → TP4 → CP → RP|Each test period will consist of 2 in-clinic visits to assess the pharmacokinetics of one of the assigned study products. On Day 1 of each test period participants will provide a pre-dose blood sample within 90-minutes before a dose of study product, followed by PK blood sample collections for the next 10 h. Participants will return to the clinic the following day for the 24 h PK blood sample collection. Each test period will be separated by a washout period.
62407591|NCT06471023|OTHER|RP → TP1 → TP2 → TP3 → TP4 → CP|Each test period will consist of 2 in-clinic visits to assess the pharmacokinetics of one of the assigned study products. On Day 1 of each test period participants will provide a pre-dose blood sample within 90-minutes before a dose of study product, followed by PK blood sample collections for the next 10 h. Participants will return to the clinic the following day for the 24 h PK blood sample collection. Each test period will be separated by a washout period.
62210459|NCT02908932|EXPERIMENTAL|Phospholipid-bound omega-3 supplement|2.3g/d omega-3 HUFAs (with the EPA to DHA ratio of approximately 2:1), delivered in 8 capsules/day in Krill oil concentrates (Aker BioMarine Antarctic AS, Norway). Participants will receive supplements for the duration of IBOLC (19 weeks) and up until entry in Ranger. Time between completion of IBOLC and entry in Ranger is variable, ranging from 1 weeks to 10 weeks (4 weeks typical). Total duration on supplement thus ranges from 20 to 30 weeks.
62407592|NCT06471023|OTHER|CP → RP → TP1 → TP2 → TP3 → TP4|Each test period will consist of 2 in-clinic visits to assess the pharmacokinetics of one of the assigned study products. On Day 1 of each test period participants will provide a pre-dose blood sample within 90-minutes before a dose of study product, followed by PK blood sample collections for the next 10 h. Participants will return to the clinic the following day for the 24 h PK blood sample collection. Each test period will be separated by a washout period.
62407593|NCT05340309|EXPERIMENTAL|Treatment (atezolizumab and recombinant human hyaluronidase)|Patients receive atezolizumab and recombinant human hyaluronidase SC over 3-8 minutes on day 1. Cycles repeat every 3 weeks for 1 year (early-stage lung cancer) or up to 2 years (late-stage lung cancer) in the absence of disease progression or unacceptable toxicity.
62407594|NCT05396326|EXPERIMENTAL|SOX-TACiE|Preoperative transcatheter arterial chemoinfusion and embolism (TACiE) alternated with systemic chemotherapy.
62019162|NCT05417711|ACTIVE_COMPARATOR|Tailor-made Notched Music Training|Similarly, 30 minutes / time, 4 times / day, continuous 3 months of TMNMT is received every day. The setting of parameters and the selection of music were the same as those in the experimental group. At the beginning of TMNMT, 10 s of sham stimulation set according to the standard of the experimental group is given.
62019163|NCT01071395|EXPERIMENTAL|Amantadine|Amantadine 100mg tab BID or TID for duration of study
62210460|NCT02908932|PLACEBO_COMPARATOR|Placebo supplement|Matching placebo capsules, substituting macadamia nut oil and appropriate colorant for krill oil. Macadamia nut oil has not been associated with psychological, cognitive, or health benefits. Furthermore, it is not typically consumed in large quantities and is therefore useful in tracking blood serum levels to assess compliance within the placebo arm. Placebo capsules have been produced by Aker Biomarine. As with the experimental arm, participants will take 8 capsules daily for the duration of the study (20-30 weeks).
62407595|NCT05076812||Group 1 (Psoriasis only)|contains 24 psoriatic patients, Psoriasis Area Severity Index will be measured, also waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile and finally: plasma level of interleukin 38
62407596|NCT05076812||Group 2 (Psoriasis and metabolic syndrome)|contains 24 psoriatic patients with metabolic syndrome. Psoriasis Area Severity Index will be measured metabolic syndrome is diagnosed after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38
62407597|NCT05076812||Group 3 (Metabolic syndrome only)|contains 24 patients with metabolic syndrome only. full dermatological examination to exclude psoriasis and other inflammatory skin disorders metabolic syndrome is diagnosed after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38
62407598|NCT05076812||Group 4 (Healthy Controls)|contains 24 healthy control subjects full dermatological examination to exclude psoriasis and other inflammatory skin disorders metabolic syndrome is excluded after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38
62210461|NCT01732822|EXPERIMENTAL|Ticagrelor|Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
62407599|NCT04859959|EXPERIMENTAL|68Ga-Pentixafor PET/CT scan|Intravenous Inject 68Ga-Pentixafor and perform PET/CT scan 1h later.
62407600|NCT04791410||Experimental group|patients who met the inclusion criteria were treated with RVLM decompression at the same time of facial nerve decompression.
62019164|NCT01071395|PLACEBO_COMPARATOR|Placebo|Placebo one tab BID or TID for duration of study
62019165|NCT06001398|EXPERIMENTAL|Parent Acceptance and Commitment Therapy (PACT)|PACT-F is a 2-session intervention based on the Focused Acceptance and Commitment Therapy treatment literature.
62407601|NCT04791410||control group|Patients who met the inclusion criteria were followed up for 3 months before surgery
62407602|NCT01564810|EXPERIMENTAL|Arm A|patients received cetuximab in combination with chemotherapy
62582976|NCT04728048|EXPERIMENTAL|Dural puncture epidural (group DPE)|"The epidural space will be identified in the seated position between the L2 and L5 interspaces with a 17G-10 cm Tuohy epidural needle (CHS ®, Oakville, ON, Canada) using a loss of resistance to saline technique. In both groups, a needle-through-needle technique will be performed using a 25G 5-inch Whitacre spinal needle (BD®, Franklin Lakes, NJ, USA). In group DPE, a single dural puncture with confirmation of free-flow CSF will be performed. If there is no free-flow CSF return through the spinal needle, the epidural catheter will be threaded 4-5cm in the epidural space and the patient will still be assigned to the DPE group, as per intent-to-treat protocol."
62019166|NCT06001398|ACTIVE_COMPARATOR|Control|The content of the control intervention covers a range of nutrition and healthy lifestyle topics including USDA's MyPlate.
62019167|NCT03111225|EXPERIMENTAL|CRPS patients|CRPS patients that will be examined for trigger points in the thoracic muscles. 10 out of the 23 will also be included in the intervention stage and will recieve a month of conventional physiotherapy, and a month of conventional physiotherapy with addition of massage to the thoracic area.
62019168|NCT03111225|NO_INTERVENTION|healthy controls|healthy controls that will be examined for trigger points in the thoracic muscles (and will be compared to the CRPS patients)
62019169|NCT00297453|EXPERIMENTAL|Internet|Individual counseling + nicotine replacement. 6 sessions across a 3 month period.
62019170|NCT00297453|EXPERIMENTAL|Counseling|Individual counseling plus nicotine replacement treatment.
62210462|NCT01732822|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
62407603|NCT01564810|ACTIVE_COMPARATOR|Arm B|Patients received chemotherapy (mFOLFOX6 or FOLFIRI) alone. mFOLFOX6 (day 1, oxaliplatin 85 mg/m², folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then 2400 mg/m² over 46 h continuous infusion) FOLFIRI (day 1, irinotecan 180mg/m2, folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then continuous infusion for 46 hours of 2400 mg/m2).
62407604|NCT06540937|EXPERIMENTAL|Leflunomide tablets (20 mg orally, once a day, before going to bed) were administered every 28 days|Eligible patients will receive leflunomide tablets (20 mg orally, once a day, before bed) every 28 days until the disease progresses or adverse reactions become intolerable.
62210463|NCT01302080||Sertraline-treated|enrolled subjects beginning treatment for one of the study qualifying disorders with sertraline
62210464|NCT01302080||psychotherapy only|enrolled subjects beginning treatment for one of the study qualifying disorders with psychotherapy
62407605|NCT02344212|EXPERIMENTAL|ESENCIAL Para Vivir|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
62407606|NCT04158466|EXPERIMENTAL|Kalifilcon A Daily Disposable Contact Lenses|Participants will wear Bausch + Lomb kalifilcon A daily disposable contact lenses for at least 8 hours per day at least 5 days per week for approximately 3 months. Participants will be provided with Bausch + Lomb Sensitive Eyes Drops for use as needed during the study and lens cases for return of worn study lenses to the Investigator at the end of the study.
62407607|NCT04158466|ACTIVE_COMPARATOR|Biotrue ONEday Daily Disposable Contact Lenses|Participants will wear Bausch + Lomb Biotrue ONEday daily disposable contact lenses for at least 8 hours per day at least 5 days per week for approximately 3 months. Participants will be provided with Bausch + Lomb Sensitive Eyes Drops for use as needed during the study and lens cases for return of worn study lenses to the Investigator at the end of the study.
62407608|NCT04589793|NO_INTERVENTION|Control|Conventional treatment
62407609|NCT04589793|ACTIVE_COMPARATOR|Intervention|Motivational interview
62407610|NCT06244134|ACTIVE_COMPARATOR|Study group (group A) will be injected with ultrasound guidance in temporomandibular joint .|uses of ultrasound as a guiding tool for temporomandibular joint injection
62019171|NCT00297453|ACTIVE_COMPARATOR|Self-Help|Self-help Manual plus nicotine replacment treatment.
62019172|NCT04338815|EXPERIMENTAL|Optimal assistance pattern|An optimization algorithm will change the assistance pattern on the hip exoskeleton during walking sessions and the optimal assistance pattern will be determined when gait variability is minimized.
62407611|NCT06244134|PLACEBO_COMPARATOR|control group(group B) conventional non guided injection in temporomandibular joint|without ultrasound guidance only anatomical landmark will be followed during injection
62407612|NCT05831475|EXPERIMENTAL|Peer Pairings|Two older adults paired
62407613|NCT05831475|EXPERIMENTAL|Intergenerational Pairings|A younger adult and older adult paired
62019173|NCT04338815|EXPERIMENTAL|Effects on endurance|Determine effects on endurance of participants using ground reaction force (Bertec treadmill), walking speed (Bertec treadmill), indirect calorimetry (Cosmed), and motion capture (Vicon).
62019174|NCT03207750|EXPERIMENTAL|HRV PCV-free Liq Group|Healthy female or male subjects, between and including 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in PCV-free liquid formulation, according to a 0, 2-month schedule, co-administered with one dose of each Pediarix, Hiberix and Prevnar-13 at three timepoints (day 1, month 2 and month 4). PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
62019175|NCT03207750|ACTIVE_COMPARATOR|HRV Lyo Group|Healthy female or male subjects, between and including 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in lyophilized formulation, according to a 0, 2-month schedule, co-administered with one dose of each Pediarix, Hiberix and Prevnar-13 at three timepoints (day 1, month 2 and month 4).
62210465|NCT05774132|ACTIVE_COMPARATOR|ultrasound guided Subgluteal sciatic nerve block group|using 0.25% bupivacaine ( 0.3ml/Kg )
62210466|NCT05774132|ACTIVE_COMPARATOR|ultrasound guided Caudal block group|using 0.25% bupivacaine ( 1ml/Kg)
62210467|NCT05452304|EXPERIMENTAL|Part 1a - Cohort 1: AZD7798 dose 1|A total of 6 subjects will receive single ascending doses of AZD7798.
62407614|NCT03185949|SHAM_COMPARATOR|Sedation and subcutaneous lidocaine|Lidocaine injected at the femoral artery site. This patients will undergo behavioral therapy for 6 months and will crossover and will receive bariatric embolization.
62407615|NCT03185949|EXPERIMENTAL|interventional: bariatric embolization|• In patients randomized to intervention bariatric embolization will be performed using Endobar Infusion Catheter System. After procedure patients will undergo behavioral therapy
62210468|NCT05452304|EXPERIMENTAL|Part 1a - Cohort 2: AZD7798 dose 2|A total of 6 subjects will receive single ascending doses of AZD7798.
62210469|NCT05452304|EXPERIMENTAL|Part 1a - Cohort 3: AZD7798 dose 3|A total of 6 subjects will receive single ascending doses of AZD7798.
62210470|NCT05452304|EXPERIMENTAL|Part 1a - Cohort 4: AZD7798 dose 4|A total of 6 subjects will receive single ascending doses of AZD7798.
62210471|NCT05452304|EXPERIMENTAL|Part 1a - Cohort 5: AZD7798 dose 5|A total of 6 subjects will receive single ascending doses of AZD7798.
62210472|NCT05452304|EXPERIMENTAL|Part 1a - Cohort 6: AZD7798 dose 6|A total of 6 subjects will receive single ascending doses of AZD7798.
62210473|NCT05452304|EXPERIMENTAL|Part 1a - Cohort 7: AZD7798 dose 7|A total of 6 subjects will receive single ascending doses of AZD7798.
62582977|NCT04728048|ACTIVE_COMPARATOR|Standard epidural (group EPL)|The epidural space will be identified in the seated position between the L2 and L5 interspaces with a 17G-10 cm Tuohy epidural needle (CHS ®, Oakville, ON, Canada) using a loss of resistance to saline technique. In both groups, a needle-through-needle technique will be performed using a 25G 5-inch Whitacre spinal needle (BD®, Franklin Lakes, NJ, USA).In Group EPL, no dural puncture will be performed and the catheter will be threaded 4-5cm in the epidural space.
62210474|NCT05452304|EXPERIMENTAL|Part 1b - Cohort 8: AZD7798 dose 8|A total of 6 subjects will receive repeat doses of AZD7798.
62407616|NCT06491433|EXPERIMENTAL|Test subjects using H2-BP and big ben® Sphygmomanometer|Blood Pressure Measurement with the H2-BP Electronic Sphygmomanometer (H2-BP) and with aneroid Sphygmomanometer(big ben® Sphygmomanometer).
62407617|NCT02363868||CML subjects receiving Dasatinib|CML receiving dasatinib as first or second line therapy will be conducted to assess healthcare costs
62407618|NCT02363868||CML subjects receiving Nilotinib|CML receiving nilotinib as first or second line therapy will be conducted to assess healthcare costs
62407619|NCT00956813|EXPERIMENTAL|Arm I|Patients receive oral flaxseed in the form of a bar similar to a granola bar once daily.
62407620|NCT00956813|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo bar once daily.
62210475|NCT05452304|EXPERIMENTAL|Part 1a - Spare Cohort 9: AZD7798 dose 9|A total of 6 subjects will receive a single ascending dose of AZD7798.
62210476|NCT05452304|EXPERIMENTAL|Part 2 - Cohort 10: AZD7798 + AZD7798|A total of 4 subjects will receive a single dose on Day 1 followed by a single dose on Day 15.
62210477|NCT05452304|EXPERIMENTAL|Part 2 - Cohort 11: Placebo + AZD7798|A total of 2 subjects will receive placebo on day 1 followed by AZD7798 on day 15.
62210478|NCT05452304|EXPERIMENTAL|Part 2 - Cohort 12: AZD7798 + Placebo|A total of 2 subjects will receive AZD7798 on day 1 followed by placebo on day 15.
62210479|NCT05452304|EXPERIMENTAL|Placebo: Part 1a and Part 1b|A total of 2 subjects per cohort will receive placebo.
62210480|NCT05452304|EXPERIMENTAL|Part 3a - Cohort 12: AZD7798|A total of 6 subjects will receive single ascending doses of AZD7798.
62407621|NCT05246982|EXPERIMENTAL|Arm A|HER2 negative and PD-L1 CPS≥5, as first-line therapy
62407622|NCT05246982|EXPERIMENTAL|Arm B|As third-line or above therapy
62407623|NCT03504839|OTHER|Intervention|S-ICD implantation.
62407624|NCT03585894|OTHER|Sumatriptan|Sumatriptan 4 mg/mL I.V will be administrated over 10 min
62407625|NCT03585894|ACTIVE_COMPARATOR|Ketorolac|Ketorolac 30 mg/mL I.V will be administrated over 10 min
62407626|NCT01898884|EXPERIMENTAL|Single dose of VP 20629 or placebo|Four groups of 8 subjects each will receive a single dose of VP 20629 (150 mg, 450 mg, 900 mg, or 1200 mg) or placebo.
62407627|NCT01898884|EXPERIMENTAL|Multiple doses of VP 20629 or placebo|Three groups of 8 subjects each will receive multiple doses of VP 20629 (300 mg, 600 mg, or 900 mg total daily dose) or placebo. VP 20629 or placebo will be administered every 8 hours for 7 days with a single morning dose on Day 8.
62407628|NCT00407966|EXPERIMENTAL|Treatment (alvocidib, cytarabine, mitoxantrone hydrochloride)|"Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Beginning 35-63 days after completion of course 1, patients achieving complete or partial remission may receive a second course of treatment as above.~Patients age 50 and over with core binding factor acute myeloid leukemia (AML) (e.g., t\[8;21\], inv\[16\], or t\[16;16\]) achieving a complete remission after course 1 of treatment may receive 3-4 courses of consolidation therapy comprising high-dose cytarabine at the discretion of the investigator."
62407629|NCT00622622|EXPERIMENTAL|Phase I study|
62407630|NCT06449352|EXPERIMENTAL|Netarsudil|netarsudil 0.02%
62407631|NCT06449352|ACTIVE_COMPARATOR|Brimonidine|brimonidine 0.1%
62407632|NCT02494882|EXPERIMENTAL|Adding Ruxolitinib to Combination of Dasatinib + Dexamethasone|"Steroid Pre-Phase (Days -6 to 0) Prednisone 10 mg/m2/day uptitrated to 60/mg/m2/day oral over seven days (capped at 120 mg/day).~Remission Induction (Days 1 to 84) Dasatinib 140 mg oral once daily. Days 1-84. Dexamethasone 10 mg/m2/day oral (capped at 20 mg/day). Days 1-24. Dexamethasone oral taper 10 mg/m2/day (capped at 20 mg/day) to off. Taper days 25-32. Off day 33.~Ruxolitinib phase I cohort dose oral. Days 1-84. Delivered BID. Delivered per the phase I dose cohort. Methotrexate (MTX) 12 mg Intrathecal (IT) for 4 doses on days 22, 43, 64, 85; +/- 3 days.~Post-Remission Induction Therapy (Starting Day 85) Allogeneic HSCT, at the discretion of the treating physician, at any point post-remission induction.~Or, post-remission induction (consolidation) therapy to be determined per the treating physician"
62407633|NCT01612962||bony debridement or amputation|In this study, the investigators will perform a retrospective chart analysis of patients that underwent a bony debridement or amputation in the operating room at Georgetown University Hospital during 2009-2010 under Drs. Steinberg and Attinger
62407634|NCT02294565|OTHER|VST-1001 & 99mTc-labeled sulfur colloid|"VST-1001 (with medical devices) and 99mTc-labeled sulfur colloid are used together during a SLNB procedure in a single subject. Both drugs are evaluated for lymphatic mapping and localization of lymph nodes. The current standard of care for lymphatic mapping and lymph node localization during a SLNB procedure is a combined-modality technique that employs both a radiotracer (99mTc-labeled sulfur colloid is the radiotracer used in this study) and a vital blue dye (a patient receives both drugs). In this study, the vital blue dye is replaced with VST-1001 and companion medical devices.~VST-1001 is excited by a medical device (blue-light LED illuminator) to fluoresce; the surgeon is wearing blue-light filtering eyewear to improve visualization of the relevant tissue structures."
62019176|NCT00273611|EXPERIMENTAL|Pharmacist education|Pharmacist education about vitamin D
62019177|NCT00273611|NO_INTERVENTION|Usual care|Usual care
62210481|NCT05452304|EXPERIMENTAL|Part 3b - Cohort 13: AZD7798|A total of 6 subjects will receive single ascending doses of AZD7798.
62210482|NCT05452304|EXPERIMENTAL|Placebo: Part 3a and Part 3b|A total of 2 subjects per cohort will receive placebo.
62210483|NCT06728072|NO_INTERVENTION|Standard of care|"First line chemotherapy as directed. Standard of care chemotherapy treatment options include but are not limited to the following:~* FOLFOX every 2 weeks~* FOLFIRI every 2 weeks~* FOLFOX + bevacizumab or panitumumab every 2 weeks~* FOLFIRI + bevacizumab or panitumumab every 2 weeks~* CAPEOX every 3 weeks~* CAPEOX + bevacizumab or panitumumab every 3 weeks"
62582978|NCT06571422|EXPERIMENTAL|WJ47156|If needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial.
62582979|NCT06571422|EXPERIMENTAL|WJ47156+JS001+Bevacizumab|If needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial.
62210484|NCT06728072|EXPERIMENTAL|Metronidazole Ciprofloxacin and Aspirin Therapy|First line chemo therapy (standard of care) + Microbiome modulation therapy MBMT 500 mg metronidazole 3 times daily, 500 mg ciprofloxacin twice daily, and 81 mg aspirin once daily for 28 days
62210485|NCT06729580|EXPERIMENTAL|Behavioural Activation for Depression.|All participants were enrolled in a 10-week standardized risk-targeted behavioural activation intervention.
62210486|NCT02689843|ACTIVE_COMPARATOR|Cyproterone compound + Spironolactone|Cyproterone compound (Cyproterone acetate 2mg+Ethinyl estradiol 35 mcg) once daily + Spironolactone 50 mg twice daily
62210487|NCT02689843|ACTIVE_COMPARATOR|Metformin|Metformin 1500 mg daily
62210488|NCT02689843|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone 30 mg daily
62210489|NCT05682703||EBV virus infector|QPCR/EBV antibody, diagnosed as EBV infection patient
62210490|NCT05682703||nasopharyngeal carcinoma patients|Patients diagnosed as nasopharyngeal carcinoma by pathological diagnosis (2018 WHO standard)
62210491|NCT05682703||Healthy people|healthy people with no history of nasopharynx related diseases or other known diseases that may affect blood lipid/protein metabolism
62210492|NCT01012817|EXPERIMENTAL|Treatment (veliparib and topotecan hydrochloride)|Patients receive veliparib PO on days 1-3, 8-10, and 15-17 (veliparib is omitted on days 1-3 of course 2) and topotecan hydrochloride IV over 30 minutes on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62407635|NCT05432466|EXPERIMENTAL|ACER-002 (celiprolol) 200 mg BID|"ACER-002 200 mg twice daily (BID) (after titration):~200 mg morning and 200 mg evening: 400 mg total daily dose~Titration:~Day 1 to Month 1 - 100 mg once daily (QD) evening: 100 mg total daily dose Month 2 to Month 3 - 100 mg morning and 100 mg evening: 200 mg total daily dose Month 3 to Month 4 - 100 mg morning and 200 mg evening: 300 mg total daily dose Month 4 to End of Treatment Period (BID) - 200 mg morning and 200 mg evening: 400 mg total daily dose"
62407636|NCT05432466|EXPERIMENTAL|Placebo BID|Placebo twice daily (BID) Placebo given orally to mimic ACER-002 (celiprolol) administration
62582980|NCT04136704||Sleeve Gastrectomy in Pediatric Patients|Laparoscopic Sleeve Gastrectomy will be offered as an adjuvant to a multidisciplinary family-based program that focuses on nutrition, physical activity, and behavioral counseling.
62582981|NCT04136704||Sleeve Gastrectomy in Adult Patients|This comparison group will be composed of adult patients who undergo sleeve gastrectomy
62582982|NCT05903105||Overactive Bladder|Adult patients with overactive bladder
62582983|NCT03124316|NO_INTERVENTION|Email #1: FULLY TURNED OFF|No behavioural change techniques (BCTs) 'turned on' in the email. The email would contain only standardized content.
62019178|NCT06193993|EXPERIMENTAL|Abiraterone Acetate|500 mg dose of Abiraterone Acetate plus prednisolone
62210493|NCT02830126|NO_INTERVENTION|Anesthesiology Control Tower Control|Patients managed by anesthesia teams without feedback alerts from the ACT
62407637|NCT00138801|ACTIVE_COMPARATOR|1|Doxycycline
62582984|NCT03124316|EXPERIMENTAL|Email #2: ANTICIPATED REGRET|Anticipated regret content + standardized content
62582985|NCT03124316|EXPERIMENTAL|Email #3: MATERIAL INCENTIVE|Material incentive content + standardized content
62582986|NCT03124316|EXPERIMENTAL|Email #4: PROBLEM SOLVING|Problem solving content + standardized content
62582987|NCT03124316|EXPERIMENTAL|Email #5: REGRET + INCENTIVE|Anticipated regret content + Material incentive content + standardized content
62582988|NCT03124316|EXPERIMENTAL|Email #6: REGRET + PROBLEM SOLVING|Anticipated regret content + Problem solving content + standardized content
62582989|NCT03124316|EXPERIMENTAL|Email #7: INCENTIVE + PROBLEM SOLVING|Material incentive content + Problem solving content + standardized content
62582990|NCT03124316|EXPERIMENTAL|Email #8: ALL BCTs|Anticipated regret content + Material incentive content + Problem solving content + standardized content
62582991|NCT04428658|EXPERIMENTAL|Supplemental video visits|Participants in this intervention arm will receive home-based video visits with a pediatric endocrinologist every month for the duration of 6 months in addition to usual care.
62019179|NCT05604729|EXPERIMENTAL|BoNT A (botulinum neurotoxin type A)|Botulinum neurotoxin, 25 units (U) into each masseter at three sessions.
62210494|NCT02830126|EXPERIMENTAL|Anesthesiology Control Tower Feedback|Patients managed by anesthesia teams with feedback alerts from the ACT
62210495|NCT05228743|EXPERIMENTAL|HIPEC plus Paclitaxel IP/IV, S-1|After laparoscopic exploration, HIPEC was started immediately, at least 4 HIPEC was completed.Three to six weeks after HIPEC was completed, chemotherapy was started.The curative effect was evaluated every 2-4 cycles. If the operation standard of R0 was met, the second laparoscopic staging was performed: if the peritoneal metastasis reached P 0 or P1a, the operator judged that R0 could be removed. Open radical gastrectomy (D2 / D2 +) was performed. For P1b / c cases, the original treatment was continued until the disease progressed.
62407638|NCT00138801|ACTIVE_COMPARATOR|2|cephtriaxone
62407639|NCT03153319|EXPERIMENTAL|Adalimumab|20 mg subQ every other week (weight 15to \<30 kg) 40 mg subQ every other week (weight ≥30 kg). Non-responders will be escalated to weekly dosing.
62407640|NCT03153319|PLACEBO_COMPARATOR|Placebo|Saline placebo comparator
62407641|NCT03153319|EXPERIMENTAL|Open-label adalimumab|Open-label extension of adalimumab dose
62582992|NCT04428658|ACTIVE_COMPARATOR|Standard of Care|The control group will receive usual care, consisting of quarterly visits with the UCD Pediatric Diabetes Clinic.
62582993|NCT04428658|EXPERIMENTAL|Supplemental remote monitoring|Participants in this intervention arm will receive remote glucose monitoring with monthly asynchronous outreach from a pediatric endocrinologist for a duration of six months in addition to usual care.
62210496|NCT05228743|NO_INTERVENTION|Paclitaxel IP/IV, S-1|Within one week after laparoscopic exploration, chemotherapy was started. The curative effect was evaluated every 2-4 cycles. If the operation standard of R0 was met, the second laparoscopic staging was performed: if the peritoneal metastasis reached P 0 or P1a, the operator judged that R0 could be removed. Open radical gastrectomy (D2 / D2 +) was performed. For P1b / c cases, the original treatment was continued until the disease progressed.
62582994|NCT04531462|EXPERIMENTAL|Empagliflozin 10 mg|
62019180|NCT05604729|PLACEBO_COMPARATOR|Placebo|Saline solution
62210497|NCT04495075|EXPERIMENTAL|Visuomotor Therapy|Patients were seated in the isokinetic dynamometer with their hips flexed to 85º. A target sine wave with a maximum amplitude of 30% MVIC and a minimum amplitude of 5% MVIC and a frequency of 0.128 Hz was visually presented to the patient.31 The patient was instructed to match their torque to the presented target throughout the duration of testing. Each visuomotor therapy trial was 60-seconds, followed by 30-seconds of rest for 10 repetitions, totaling 15 minutes.
62210498|NCT04495075|ACTIVE_COMPARATOR|Passive Motion|Patients were seated in the isokinetic dynamometer with their hips flexed to 85º. The dynamometer then passively moved the patient from 80º to 120º of knee flexion for 60-seconds, followed by 30-seconds of rest for 10 repetitions, totaling 15 minutes. The patient was provided visual feedback of their knee position throughout the trials. The patient was instructed to relax their knee throughout the intervention.
62210499|NCT06018727|EXPERIMENTAL|Hydrocortisone + Yohimbine|Participants will ingest hydrocortisone and yohimbine during Session 2 approximately 10 minutes into the session.
62210500|NCT06018727|PLACEBO_COMPARATOR|Placebo + Placebo|Participants will orally ingest two placebos during Session 2 approximately 10 minutes into the session.
62210501|NCT04357600|EXPERIMENTAL|intravenous injection of UC-MSC|The dosage of the intravenous route is 100 million MSCs for each subject.
62210502|NCT04012476|EXPERIMENTAL|ICG|Patients undergoing total thyroidectomy with visualization of the parathyroid glands under infrared light after intraoperative intravenous injection of 5 mg of indocyanine green
62210503|NCT06623344|OTHER|Hospitalized|Participants who were hospitalized due to heart failure (HF) illness.
62210504|NCT06623344|OTHER|Non-Hospitalized|Participants who had heart failure (HF) but did not require hospitalization secondary to the illness.
62210505|NCT05057780|EXPERIMENTAL|Intervention Curriculum|The intervention course consisted of 3 hour-long sessions on communication delivered over a 4-month period. It differed from the control course in subject matter and pedagogy. Subject matter focused on specific skills used in communication: reflective listening, responding to emotion, and providing information within a broad range of communication scenarios. In terms of pedagogy, the intervention course was interactive with a focus on skills practice, communication drills, and improvisation to engage learners. The sessions consisted of fifteen minutes of lecture and 45 minutes of skills practice.
62210506|NCT05057780|ACTIVE_COMPARATOR|Control (Standard) Curriculum|The control course consisted of three hour-long didactic lectures on delivering bad news, discussing prognosis, and talking to patients about pain. The majority of time in these lectures was spent on didactic material. Little, if any, time was spent practicing skills or on interactive skill building. The three parts of the course were delivered over a 4-month period.
62210507|NCT03455608|ACTIVE_COMPARATOR|RE-ACTIVE|Reactive intervention started promptly if/when dysphagia is identified (RE-ACTIVE)
62210508|NCT03455608|ACTIVE_COMPARATOR|PRO-ACTIVE EAT|Early low intensity proactive intervention started before RT commences
62210509|NCT03455608|ACTIVE_COMPARATOR|PRO-ACTIVE EAT + EXERCISE|Early high intensity proactive intervention started before RT commences
62210510|NCT02095288||Healthy volunteers|Blood draw
62210511|NCT05746208|EXPERIMENTAL|Lenvatinib Plus Pembrolizumab|Participants will receive 20 mg once daily of lenvatinib plus 400 mg of pembrolizumab every 6 weeks for up to 18 doses. Eligible participants may also receive a Hyperpolarized 13C-pyruvate (HP 13C) magnetic resonance imaging (MRI) scan
62210512|NCT03815682|EXPERIMENTAL|RPTR-147:1|Arm A: Escalating doses of RPTR-147:1 as a monotherapy in solid tumors and lymphomas
62210513|NCT03815682|EXPERIMENTAL|RPTR-147:1 and Pembrolizumab|Arm B: Escalating doses of RPTR-147:1 in combination with Pembrolizumab in patients with solid tumors and lymphomas
62210514|NCT03815682|EXPERIMENTAL|RPTR-147:2|Arm C: Escalating doses of RPTR-147:2 in patients with HPV-16 positive tumors
62582995|NCT04531462|PLACEBO_COMPARATOR|Placebo|
62210515|NCT06370052||surgical procedure|"HS patients, divided into three groups depending on the stage of hidradenitis, would participate in the study.~The first and second groups would include stage 2-3 patients (according to the Hurley scale) in whom partial or complete clinical remission occurred after biological therapy and surgical treatment was performed according to the guidelines.~In the third (control) group, we would classify the samples obtained from the above-mentioned patients, from whom we would take a sample of normal skin measuring 1 x 1 cm.~GOAL: To determine the pathohistological changes in skin and subcutaneous tissues of patients with HS Hurley stage I and II and healthy patients (control group) and compare them with each other."
62210516|NCT02471105|EXPERIMENTAL|Lumigan 0.01% + Saflutan 15 µg/ml|Bimatoprost 0.01 % Eye drops solution Topical use Once in the evening 3 months
62210517|NCT02471105|EXPERIMENTAL|Saflutan 15 µg/ml + Lumigan 0.01%|Tafluprost Unit Dose Preservative Free 15microgram/ml Eye drops solution Topical use Once in the evening 3 months
62407642|NCT03500029|EXPERIMENTAL|TMS treatment group|In the Transcranial magnetic stimulation (TMS) treatment group patients with severe depression receive rTMS treatment without drug treatment.
62582996|NCT01736397|EXPERIMENTAL|Ferric Citrate|Ferric citrate will be taken with or within one hour of meals or snacks. The starting dose of ferric citrate is 3 tablets/day and titrated by the subject's serum phosphorus results at each treatment visit.
62582997|NCT01736397|PLACEBO_COMPARATOR|Placebo|Placebo will be taken with or within one hour of meals or snacks. The starting dose of placebo is 3 tablets per day and titrated by the subject's serum phosphorus results at each treatment visit.
62582998|NCT02438826|EXPERIMENTAL|Galcanezumab 300 mg|"Double-Blind Treatment Phase: Participants received galcanezumab 300 mg once a month by subcutaneous (SC) injection for 3 months.~Open-Label Treatment Phase: Participants received 300 mg galcanezumab by subcutaneous injections every 30 days, for up to a total of 12 administrations."
62019181|NCT05604729|PLACEBO_COMPARATOR|Control|Saline solution, no tooth wear
62582999|NCT02438826|PLACEBO_COMPARATOR|Placebo|"Double-Blind Treatment Phase: Participants received placebo once a month by subcutaneous (SC) injection for 3 months.~Open-Label Treatment Phase: Participants received 300 mg galcanezumab by subcutaneous injections every 30 days, for up to a total of 12 administrations."
62210518|NCT03122223|ACTIVE_COMPARATOR|ALVAC-HIV + 100mcg Protein/MF59 + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.5 mL100 mcg Protein/MF59 and 0.75 mL placebo injection in the right deltoid on Months 3 and 6.
62210519|NCT03122223|ACTIVE_COMPARATOR|ALVAC-HIV + 100mcg Protein/AS01(B) + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.75 mL100 mcg Protein/AS01(B) and 0.5 mL placebo injection in the right deltoid on Months 3 and 6.
62210520|NCT03122223|ACTIVE_COMPARATOR|ALVAC-HIV + 20mcg Protein/AS01(B) + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.75 mL 20 mcg Protein/AS01(B) and 0.5 mL placebo injection in the right deltoid on Months 3 and 6.
62210521|NCT03122223|PLACEBO_COMPARATOR|Placebo|10 participants will receive 1 mL of the placebo injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.5 mL of the placebo injection and 0.75 mL of a separate placebo injection in the right deltoid on Months 3 and 6.
62583000|NCT06035146|EXPERIMENTAL|Mechanical energy monitoring|In the study subjects randomized into this arm, the value of mechanical energy will be monitored during mechanical ventilation.
62210522|NCT03977181|EXPERIMENTAL|Health Club|A group-based community health club akin to an ART adherence club
62210523|NCT03977181|EXPERIMENTAL|One-on-one|One-on-one adherence counselling and support
62210524|NCT03977181|NO_INTERVENTION|Medication pick-up|Community-based medication dispensary
62210525|NCT04730817|EXPERIMENTAL|Intervention group|This arm will undertake VR simultaneous motor-cognitive training in 30 minutes session, twice a week for 8 weeks.
62210526|NCT04730817|NO_INTERVENTION|Control group|This arm will not be given any kind of treatment and will act as a passive control group.
62210527|NCT03825549|NO_INTERVENTION|Control|No intervention
62210528|NCT03825549|EXPERIMENTAL|Individual Audit|Clinicians will receive individual audit feedback informing them of their performance.
62210529|NCT03825549|EXPERIMENTAL|Peer Comparison|Clinicians will receive peer comparison feedback informing them of how their performance compares to their peers.
62210530|NCT03825549|EXPERIMENTAL|Individual Audit and Peer Comparison|Clinicians will receive individual audit feedback informing them of their performance and peer comparison feedback informing them of how their performance compares to their peers.
62210531|NCT03505177|EXPERIMENTAL|Chitin-glucan|Supplementation during 3 weeks with 4.5g per day of chitin-glucan fiber
62583001|NCT06035146|ACTIVE_COMPARATOR|Conventional mechanical ventilation|Study subjects randomized into this arm will receive conventional mechanical ventilation, to the best of the physician's knowledge.
62583002|NCT03329703|EXPERIMENTAL|Immediate-Treatment|This group will receive Project UPLIFT immediately after completing surveys.
62583003|NCT03329703|ACTIVE_COMPARATOR|Waitlist Control|This group will receive Project UPLIFT after waiting approximately 3 months to begin the intervention.
62583004|NCT05959005||Early GA lesions|Non-interventional
62583005|NCT05862337|EXPERIMENTAL|Anlotinib hydrochloride capsules + Penpulimab injection|Anlotinib hydrochloride capsules + Penpulimab injection, 21 days as a treatment cycle.
62210532|NCT04847791|EXPERIMENTAL|Group A|Standard Anti-Covid-19 Therapy + Oral Administration of Bovine Lactoferrin 400mg (two capsules of Mosiac 200 product) every 12 h (i.e., fixed dose 800 mg / day) for 30 days and still away from meals
62210533|NCT04847791|PLACEBO_COMPARATOR|Group B|Standard anti-Covid-19 therapy + Placebo administration (capsule identical with the same amount as an inert compound, starch of corn powder), according to the same pattern of use.
62210534|NCT02048475|NO_INTERVENTION|desflurane|inhalation concentration
62210535|NCT06155188|EXPERIMENTAL|PT/FLU+CY|The group consisted of fludarabine (40mg/m2, day-5 to day-3 and day+3, day+4), busulfan (100mg/m2, day-6 to day-3), haplo-PBSC (day0), cyclophosphamide (50mg/kg, day+3, day+4) , and UCB (day+6)
62210536|NCT04427059|EXPERIMENTAL|Arm A - laparoscopic assisted TAP block|Patients will undergo the planned bariatric intervention according to the standard of treatment. A solution of 20 ml of the local anesthetic Ropivacaine (0.25%) is then injected for postoperative pain control according to the allocated procedure (TPA).
62210537|NCT04427059|ACTIVE_COMPARATOR|Arm B - PSI|Patients will undergo the planned bariatric intervention according to the standard of treatment. A solution of 20 ml of the local anesthetic Ropivacaine (0.25%) is then injected for postoperative pain control according to the allocated procedure (PSI).
62210538|NCT03605576|EXPERIMENTAL|Fu's subcutaneous needling|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
62583006|NCT05862337|PLACEBO_COMPARATOR|Anlotinib hydrochloride capsules -matching placebo+ Penpulimab injection -matching placebo|Anlotinib hydrochloride capsules -matching placebo+ penpulimab injection -matching placebo, 21 days as a treatment cycle.
62583007|NCT04418830||Base Interfixated System|
62583008|NCT04418830||Brigade Interfixated System|
62583009|NCT04418830||Coalesce Thoracolumbar Interbody|
62583010|NCT04418830||Cohere XLIF Interbody System|
62583011|NCT04418830||CoRoent Ti PLIF Interbody System|
62583012|NCT04418830||CoRoent Ti TLIF Interbody System|
62019182|NCT02662712|EXPERIMENTAL|Part 1: Single Dose Escalation|The single dose escalation phase of the study will consist of 6 dosing sessions (Sessions I to VI) evaluated in 2 panels (Panels 1 and 2). The dose of JNJ-56136379 will be consecutively escalated over 5 levels, alternating between the 2 panels. Panel 1 will receive 3 single doses (SD1, SD3 and SD3fed) in Sessions I, III and V, respectively. Panel 2 will receive 3 single doses (SD2, SD4 and SD5) in Sessions II, IV and VI, respectively. There will be a washout period of at least 14 days between consecutive JNJ-56136379/placebo dosing in each individual participant.
62019183|NCT02662712|EXPERIMENTAL|Part 1: Multiple dose session|After completion of the fifth single dose session another panel of healthy participant (panel 3) receive multiple doses of JNJ-56136379 at one dose level (MDx) or placebo for 12 or 19 consecutive days (Session VII) in fed or fasted conditions.
62583013|NCT04418830||MLX - Medial Lateral Expandable Interbody System|
62583014|NCT04418830||Modulus TLIF Interbody System|
62210539|NCT03605576|ACTIVE_COMPARATOR|Transcutaneous electrical nerve stimulation|In this arm, the subjects will receive the intervention of TENS on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
62583015|NCT04418830||Modulus XLIF Interbody System|
62583016|NCT04418830||TLX Interbody System|
62583017|NCT04418830||XLX ACR Interbody System|
62210540|NCT05477563|EXPERIMENTAL|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive a single infusion of CTX001 through a central venous catheter.
62407643|NCT03500029|ACTIVE_COMPARATOR|medication group|In the medication group patients with severe depression are treated with anti-depressants.
62407644|NCT03500029|NO_INTERVENTION|healthy control group|The control group don't accept intervention and treatment.
62407645|NCT02997475||Women with Bulimia Nervosa|
62407646|NCT02997475||Women Healthy Controls|
62583018|NCT04418830||CoRoent Ti XLIF Interbody System|
62583019|NCT04418830||Cohere TLIF|
62583020|NCT04418830||Modulus ALIF|
62583021|NCT02578381|EXPERIMENTAL|Boston Scientific PW versus St Jude PW|Performance of Boston Scientific PW vs St Jude PW
62583022|NCT02578381|EXPERIMENTAL|Boston Sci PW vs Boston Sci PW|Boston Sci PW vs Boston Sci PW
62583023|NCT02578381|ACTIVE_COMPARATOR|St Jude PW versus St Jude PW|Performance of St Jude PW vs St Jude PW
62583024|NCT05922761|EXPERIMENTAL|Cohort A: Belumosudil + Standard of Care Medications|"30 participants with bronchiolitis obliterans syndrome (BOS) will complete study procedures as follows:~* Drug diary~* CT scans at Cycles 3 and 7 and at End of Treatment.~* Cycle 1~  * Day 1 - 28 of 28-day cycle: Predetermined dose of Belumosudil 1x daily.~ * Predetermined doses of Fluticasone, Montelukast, and Prednisone 1x daily.~ * Predetermined dose of azithromycin 3 days per treatment week.~* Cycle 2 - 3~  * Day 1 - 28 of 28-day cycle: Predetermined dose of Belumosudil 1x daily.~ * Predetermined doses of Fluticasone Montelukast 1x daily. Predetermined doses of Prednisone 1x daily at treating physician's discretion.~ * Predetermined dose of azithromycin 3 days per treatment week.~* Cycle 4 - 12~  * Day 1 - 28 of 28-day cycle: Predetermined dose of Belumosudil 1x daily.~ * Predetermined doses of Fluticasone and Montelukast 1x daily.~ * Predetermined dose of azithromycin 3 days per treatment week."
62583025|NCT05922761|EXPERIMENTAL|Cohort B: Belumosudil|"15 participants with signs concerning developing BOS will complete study procedure as follows:~* Drug diary~* CT scans at Cycles 3 and 7 and at End of Treatment.~* Cycle 1 - 12 - Day 1 - 28 of 28-day cycle: Predetermined dose of Belumosudil 1x daily."
62583026|NCT06598631|EXPERIMENTAL|Volenrelaxin Dose 1|Participants will receive Volenrelaxin subcutaneously (SC)
62583027|NCT06598631|EXPERIMENTAL|Volenrelaxin Dose 2|Participants will receive Volenrelaxin SC
62583028|NCT06598631|EXPERIMENTAL|Volenrelaxin Dose 3|Participants will receive Volenrelaxin SC
62583029|NCT06598631|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo SC
62583030|NCT06186427|EXPERIMENTAL|68Ga-DOTA-GPFAPI-04 PET/CT|Imaging was performed 60 minutes after injection of 5mci 68Ga-DOTA-GPFAPI-04 tracer
62019184|NCT02662712|EXPERIMENTAL|Part 2: Multiple dose escalation|Multiple dose levels will be given in Panel 4 in Session VIII (European sites), Sessions IX and X (European and/or Asian sites) Session XI (Asian sites) for 28 consecutive days in fed conditions. Optional Sessions A-B-C (Panel 4) used for further dose evaluations at European and/or Asian sites. Per session, participants will receive JNJ 56136379 or placebo. Dose progression to the next multiple dose level may be adapted based on the emerging safety and PK outcome of the previous dosing levels.
62583031|NCT01931943|EXPERIMENTAL|Selatinib Ditosilate Tablets|Selatinib Ditosilate either at 450,750,1000,1250mg, p.o. once daily
62583032|NCT03439592||hyperglycemic patients|diabetic patients admitted for STEMI and with hyperglycemia at hospital admission.
62583033|NCT03439592||normoglycemic patients|diabetic patients admitted for STEMI and with normoglycemia at hospital admission.
62583034|NCT06086145||Adults in Davis and the greater Sacramento area of California|Adults in Davis and the greater Sacramento area of California
62583035|NCT04134429||Everion®|The Everion® will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.
62583036|NCT01237041|EXPERIMENTAL|Niacin First|Subjects receive niacin 500mg hourly for 4 hours on day 1 (at 7:30am, 8:30am, 9:30am, and 10:30am) then cross over to receive placebo hourly for 4 hours on day 2 at (7:30am, 8:30am, 9:30am, and 10:30am).
62583037|NCT01237041|EXPERIMENTAL|Placebo First|Subjects receive placebo hourly for 4 hours on day 1 (at 7:30am, 8:30am, 9:30am, and 10:30am) then cross over to receive niacin hourly for 4 hours on day 2 (at 7:30am, 8:30am, 9:30am, and 10:30am).
62583038|NCT01237041|EXPERIMENTAL|Dose-Establishing Study 1 Niacin 250mg|Subjects received Niacin 250 mg every 2 hours for 3 doses (at 6am, 8am, and 10am).
62583039|NCT01237041|EXPERIMENTAL|Dose-Establishing Study 1 Niacin 500mg|Subjects received Niacin 500 mg every 2 hours for 3 doses (at 6am, 8am, and 10am).
62583040|NCT01237041|EXPERIMENTAL|Dose-Establishing Study 2 Niacin 500mg|Subjects received Niacin 500 mg hourly for 4 doses (administered at 7:30am, 8:30am, 9:30am, and 10:30am).
62583041|NCT00626821|EXPERIMENTAL|1|
62583042|NCT06478251|EXPERIMENTAL|NW-301V monotherapy in patients with Solid Tumors with KRAS G12V mutation|
62583043|NCT06478251|EXPERIMENTAL|NW-301D monotherapy in patients with Solid Tumors with KRAS G12D mutation|
62583044|NCT04257123|EXPERIMENTAL|Controlled-Feeding|For two weeks (separated by a wash-out week), participants will consume all meals in the Nutrition Science facility.
62583045|NCT04257123|EXPERIMENTAL|Free-Feeding|For two weeks (separated by a wash-out week), participants will receive no dietary guidance and will be allowed to consume whatever they desire.
62019185|NCT01661959||Non-Operative|
62210541|NCT06524765||ICU health care workers (exposed group)|The infection rate of multidrug-resistant bacteria in critically ill patients in intensive care unit (ICU) is high, the mortality rate of infected patients is high, which becomes the source of pathogen transmission. The front-line medical staff engaged in ICU are constantly in contact with patients and exposed to the intensive care unit (ICU) environment full of pathogens and even drug-resistant bacteria, and this high-risk contact and exposure makes many pathogenic microorganisms and their drug-resistant genes become part of the intestinal microbiota of ICU medical staff and are carried. Therefore, the exposure factor of the exposure group in this study was ICU environment.
62210542|NCT06524765||Non-medical professionals (non-exposed group)|This group is a non-exposed group, so the exposed factor is the daily living environment.
62583046|NCT03360916|PLACEBO_COMPARATOR|Placebo & Exercise Group|Participants randomized to this group will undergo placebo treatment and an aerobic exercise program.
62583047|NCT03360916|EXPERIMENTAL|Low Statin & Exercise Group|Participants randomized to this group will undergo low statin treatment (Lipitor 20Mg Tablet) and an aerobic exercise program.
62583048|NCT03360916|EXPERIMENTAL|High Statin & Exercise Group|Participants randomized to this group will undergo high statin treatment (Lipitor 80Mg Tablet) and an aerobic exercise program.
62583049|NCT06532799|EXPERIMENTAL|Biological Tumor Infiltrating Lymphocytes (TIL) Therapy with Immunotherapy|"Patients receive pembrolizumab IV on day -14, cyclophosphamide IV QD on days -7 to -6, fludarabine IV over 30 minutes QD on days -5 to -1, and TILs IV infusion on day 0. Patients also receive pembrolizumab IV on day 28 and 70, and undergo surgery on day 80.~MAINTENANCE: Patients receive pembrolizumab IV every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
62583050|NCT02953444|NO_INTERVENTION|Wait List Control|Participants receive daily email surveys for two weeks before being given access to the brief-mindfulness-practice training materials.
62583051|NCT02953444|EXPERIMENTAL|Thirty-Second Mindfulness Practice|Participants watch a ten minute mindfulness training video then are given electronic access to an audio recording of guidance for a thirty-second mindfulness meditation practice. Participants are asked to complete this practice using the audio-recorded guidance at least three times a day for two weeks. Participants are sent daily emails that include reminders to complete the practice and a link to a brief online survey.
62019186|NCT01661959||Operative|
62019187|NCT05390489|EXPERIMENTAL|Cascara pulp arabica gayo coffee cream|The installation of a patch test for the cascara pulp cream of Gayo Arabica coffee with a concentration of 10% was carried out on the upper arm and waited for 30 minutes to see if there were any side effects. If no side effects occur, the patch test is left for 48 hours. After 48 hours, patch test was opened and the skin condition was assessed for irritation/redness and skin moisture. This condition was also re-evaluated at 72 and 96 hours later.
62210543|NCT03798782|EXPERIMENTAL|Ross procedure|The patient will undergo the Ross procedure where the surgeon will replace the aortic valve using a pulmonary autograft (Ross procedure) with pulmonary homograft replacement of the pulmonary root.
62407647|NCT05872282|EXPERIMENTAL|ZIPPER aortic arch stentgraft system|
62407648|NCT05045339|EXPERIMENTAL|Exercise Group|Five different ball exercises were implemented for 35 minutes, 3 sessions per week for 2 months.
62583052|NCT02953444|ACTIVE_COMPARATOR|Three-Minute Mindfulness Practice|Participants watch a ten minute mindfulness training video then are given electronic access to an audio recording of guidance for a three minute mindfulness meditation practice. Participants are asked to complete this practice using the audio-recorded guidance at least three times a day for two weeks. Participants are sent daily emails that include reminders to complete the practice and a link to a brief online survey.
62583053|NCT00970840|EXPERIMENTAL|LNS-20gM or LNS-P&L|
62583054|NCT01053663|EXPERIMENTAL|1|
62583055|NCT04267289|EXPERIMENTAL|iCBT treatment group|Subjects were given license to use Beating the Blues, a commercially available iCBT program. Subjects were given 3 months to use the program.
62583056|NCT04080024|EXPERIMENTAL|Single dose (i.v.) SN132D|
62583057|NCT01803217|EXPERIMENTAL|mode switch to atrial pacing|
62583058|NCT01803217|ACTIVE_COMPARATOR|atrioventricular hysteresis function|
62210544|NCT03798782|ACTIVE_COMPARATOR|Conventional aortic valve replacement|The patient will undergo Conventional aortic valve replacement where the surgeon will replace the aortic valve with another prosthesis which can include a mechanical prosthesis, a stented biological prosthesis, a stentless biological valve or root, or a catheter valve.
62210545|NCT01395888|EXPERIMENTAL|Relovair|Inhaled long-acting bronchodilator and corticosteroid combination
62210546|NCT01395888|ACTIVE_COMPARATOR|Tiotropium|Inhaled long-acting anticholinergic
62210547|NCT00958841|EXPERIMENTAL|pasireotide LAR 60mg|Patients received pasireotide LAR at 60 mg approximately once every 28 days for 6 months during the core treatment period and additional treatment cycles up to a total of 48 months during the extension phase.
62407649|NCT05045339|NO_INTERVENTION|Control Group|No exercises were performed in control group
62583059|NCT06685393|ACTIVE_COMPARATOR|Group (I) (nondiabetic PRPgroup)|"Group (Ⅰ) (non-diabetic patients): n=10 subdivided into Test side: received scaling and rootplanning plus the subgingival application of PRP.~Control side: received scaling and rootplanning only."
62583060|NCT06685393|ACTIVE_COMPARATOR|Group (Ⅱ) (non-diabetic patients):|Group (Ⅱ) (non-diabetic patients): n=10 subdivided into Test side: received MD plus subgingival application of I-PRF. Control side: received MD only.
62210548|NCT02580305|ACTIVE_COMPARATOR|Experimental: SUVN-502 Low dose (50 mg)|SUVN-502 Low dose adjunct to base treatment with Donepezil and Memantine
62210549|NCT02580305|ACTIVE_COMPARATOR|Experimental: SUVN-502 High dose (100 mg)|SUVN-502 High dose adjunct to base treatment with Donepezil and Memantine
62210550|NCT02580305|PLACEBO_COMPARATOR|Placebo|Placebo adjunct to base treatment with Donepezil and Memantine
62210551|NCT01262027|EXPERIMENTAL|Dovitinib|A complete treatment cycle defined as 28 days or 4 weeks (+/- 2 days). Patients receive a single daily oral dose of 500 mg of dovitinib for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule).
62210552|NCT01644448|OTHER|Study arm A|Subjects will receive one dose of 5 ml of Autologous Human Platelet Lysate with simultaneous micro-needling on day 2
62210553|NCT01644448|OTHER|Control Arm B|Topical Applications of the standard therapy as directed by the investigator
62210554|NCT04907565||Obese patients|BMI \>30kg/m2
62210555|NCT04907565||non obese patients|BMI between 18 to 29kg/m2
62210556|NCT06454994|EXPERIMENTAL|Noble Lift threads|
62210557|NCT06454994|ACTIVE_COMPARATOR|Croquis threads|
62210558|NCT00727311||PegIntron + Rebetol|Participants with chronic hepatitis C, who are either treatment-naïve or previously relapsed after receiving interferon monotherapy
62210559|NCT05445453|EXPERIMENTAL|Intervention|"Physicians participating in the research project will be able to prescribe a visit to the Museum to any of their patients for whom they deem this museum prescription necessary. Only patients who meet the inclusion criteria will be offered to participate in the research.~If patients refuse or do not meet the inclusion criteria, they may be prescribed a museum visit but will not be offered the study.~After obtaining informed consent, the patient will be asked to complete 2 sets of self-administered questionnaires: in the 2 days prior to the visit and in the 2 days following the MBAM visit."
62210560|NCT02361281||Sarcoidosis patients|Clinically relevant sarcoidosis patients with different stages and treatments.
62210561|NCT02361281||Healthy controls|Healthy people without any pulmonary conditions
62210562|NCT03304197|EXPERIMENTAL|Dehydrated|90 minutes cycling, without the ingestion of any fluids, followed by a 15 minute cycling time trial test
62210563|NCT03304197|EXPERIMENTAL|Hypotonic|90 minutes cycling, with the ingestion of six 250 ml carbohydrate (6g sucrose, 3g glucose) drinks, followed by a 15 minute cycling time trial test
62210564|NCT03304197|EXPERIMENTAL|Isotonic|90 minutes cycling, with the ingestion of six 250 ml carbohydrate (6g glucose, 3g fructose) drinks, followed by a 15 minute cycling time trial test
62210565|NCT03304197|EXPERIMENTAL|Placebo|90 minutes cycling, with the ingestion of six 250 ml taste-matched water drinks, followed by a 15 minute cycling time trial test
62210566|NCT04242043||AI|
62210567|NCT00359125|ACTIVE_COMPARATOR|1|RU-486, 600 mg/day for 1 week.
62210568|NCT00359125|PLACEBO_COMPARATOR|2|Placebo, 600 mg/day for 1 week
62210569|NCT06180031|NO_INTERVENTION|Group C (control)|will have Peng block using 20mg bupivacaine 0.25%
62210570|NCT06180031|ACTIVE_COMPARATOR|Group M|will have PENG block with 2mg magnesium sulphate 10% as an adjuvant to 20mg of bupivacaine 0.25%
62407650|NCT03382691|EXPERIMENTAL|EXPERIMENTAL|Blood pressure check using mobile device and control device
62407651|NCT02729727|OTHER|Single Arm|To evaluate safety and treatment effect of the CryoBalloon Ablation System for the Ablation of human esophageal epithelium in patients scheduled to undergo esophagectomy
62407652|NCT05276934||Evolution of brain imaging in Non-traumatic Intracranial Hemorrhage|This study will use an established local protocol for DCI and intracranial arterial vasospastic stenosis screening, and follow-up to make sure that all patients have the same protocol and don't lose any chance of improvement and good outcome
62210571|NCT00163280|EXPERIMENTAL|1|ATL-104 50mg
62210572|NCT00163280|EXPERIMENTAL|2|ATL-104 100mg
62407653|NCT00472004|ACTIVE_COMPARATOR|1|17B Estradiol (1mg) / (0.125 mg) Trimegestone (TMG) Continuous combined, 1 Daily, 1 year duration
62583061|NCT06685393|ACTIVE_COMPARATOR|Group (Ⅲ) (diabetic patients)|Group (Ⅲ) (diabetic patients): n=10 subdivided into Test side: received MD plus subgingival application of PRP. Control side: received MD only.
62583062|NCT06685393|ACTIVE_COMPARATOR|Group(Ⅳ) (diabetic patients)|Group(Ⅳ) (diabetic patients): n=10 subdivided into Test side: received MD plus the subgingival application of I-PRF Control side: received MD only.
62583063|NCT02699931|EXPERIMENTAL|Electric3D|3D electric toothbrush (Oral-B) with orthodontic head.
62583064|NCT02699931|ACTIVE_COMPARATOR|Manual|Manual orthodontic toothbrush (Oral-B).
62583065|NCT00095238|ACTIVE_COMPARATOR|1|
62583066|NCT00095238|PLACEBO_COMPARATOR|2|
62583067|NCT05507385|EXPERIMENTAL|Intervention: IMAGINE-P|"Experimental intervention: IMAGINE-POSITIVE targeting positive affect (IMAGINE-P):~The intervention will combine aspects of Memory Specificity Training (MeST), which includes information about the links between memories and emotions, with Positive Prospective Mental Imagery (PPMI)."
62210573|NCT00163280|EXPERIMENTAL|3|ATL-104 150mg
62407654|NCT00472004|ACTIVE_COMPARATOR|2|Tibolone 2.5 mg 1 daily, 1 year duration
62583068|NCT05507385|ACTIVE_COMPARATOR|Control:|Control intervention: Non-directive supportive therapy (NDST) consists of individual sessions, with an empathetic, emotionally supportive practitioner and provides non-directive problem solving and monitoring. Using NDST will control for factors that may contribute to change, which are not active components e.g. speaking to an empathetic therapist. NDST will follow treatment guidelines.
62583069|NCT03597750|EXPERIMENTAL|Static air support devices (Repose®)|"Alternating-pressure devices will be replaced by static air support devices (Repose®) during 14 days:~* Repose® Mattress~* Repose® Cushion~* Repose® Wedge or Foot Protectors~The frequency of repositioning remains unchanged."
62583070|NCT03597750|NO_INTERVENTION|Alternating-pressure devices|"Instead of replacing the alternating-pressure devices by static air support devices (Repose®), the residents remain on their alternating-pressure devices.~The frequency of repositioning remains unchanged."
62583071|NCT05051553|EXPERIMENTAL|Treatment 1A|
62210574|NCT00163280|PLACEBO_COMPARATOR|4|Placebo
62210575|NCT04274205|ACTIVE_COMPARATOR|Influence on brief supportive psychotherapy|Intervention group
62210576|NCT04274205|ACTIVE_COMPARATOR|Influence of brief supportive psychotherapy|Control group
62210577|NCT02909764|NO_INTERVENTION|Control Group|Children will receive regularly salted cereal to consume 4 times per week over a 2-month period.
62407655|NCT01187511|ACTIVE_COMPARATOR|GSK561679|GSK561679 was given orally, once a day in the evening, for 21 days, at a dose of 350mg, administered as four tablets consisting of 3 x 100mg tablets plus 1 x 50mg tablet.
62407656|NCT01187511|PLACEBO_COMPARATOR|Placebo|Placebo was given orally, once a day in the evening, for 21 days, in the form of four tablets that matched those of GSK561679
62583072|NCT05051553|EXPERIMENTAL|Treatment 1B|
62583073|NCT05051553|EXPERIMENTAL|Treatment 2A|
62583074|NCT05051553|EXPERIMENTAL|Treatment 2B|
62583075|NCT05051553|EXPERIMENTAL|Treatment 2C|
62583076|NCT00107965|EXPERIMENTAL|1|
62583077|NCT00107965|EXPERIMENTAL|2|
62210578|NCT02909764|EXPERIMENTAL|Low Sodium Group|Intervention: Children will receive low sodium cereal to consume 4 times per week over a 2-month period.
62210579|NCT01016743|ACTIVE_COMPARATOR|Active repetitive transcranial Stimulation|Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).
62210580|NCT02712905|EXPERIMENTAL|INCB059872|
62210581|NCT02712905|EXPERIMENTAL|INCB059872 in combination with other therapies|"Initial cohort dose of INCB059872 to evaluate different doses of INCB0599872 in combination with other therapies in the following treatment groups:~* Combination with all-trans retinoic acid (ATRA) in subjects with relapsed/refractory AML.~* Combination with azacitidine in subjects with newly diagnosed, treatment-naive AML~* Combination with nivolumab in subjects with advanced SCLC previously progressed on platinum-based treatment.~Upon identification of the recommended dose(s) for each treatment combination, expansion cohorts of approximately 30 subjects in each treatment group may begin enrollment to further determine safety, tolerability, efficacy, PK, and PD of the selected dose(s)."
62210582|NCT03507751||Meropenem|Patients who require meropenem and CRRT during ICU (intensive care unit) stay
62407657|NCT06651216||Breast feeding|Exclusively breastfed infants for 2 months
62407658|NCT06651216||Non breast feeding|Infants exclusively fed with formula milk
62407659|NCT01754805|EXPERIMENTAL|ASP015K and methotrexate|Patients receive a single dose of methotrexate on day 1 and day 8 and ASP015K (twice daily) on days 3 through 8 plus the morning of day 9.
62407660|NCT05068700|ACTIVE_COMPARATOR|Integrated Pulmonary Index disabled|Nurses randomized to the experimental arm will be asked to disable the Integrated Pulmonary Index feature of the Medtronic Capnostream 35p monitor when monitoring sedated patients with capnography.
62407661|NCT05068700|EXPERIMENTAL|Integrated Pulmonary Index enabled|Nurses randomized to the experimental arm will be asked to enable the Integrated Pulmonary Index feature of the Medtronic Capnostream 35p monitor when monitoring sedated patients with capnography.
62407662|NCT00834028||1|patients with hepatocellular carcinoma receive transcatheter arterial chemoembolization
62407663|NCT00589966|EXPERIMENTAL|Coping Skills Training|
62407664|NCT00589966|ACTIVE_COMPARATOR|Prostate Cancer Education|
62407665|NCT03225313|PLACEBO_COMPARATOR|control group|normal saline will be injected in the rectus sheath
62407666|NCT03225313|ACTIVE_COMPARATOR|Rectus block group|bupivicaine will be injected in the rectus sheath
62583078|NCT00107965|EXPERIMENTAL|3|
62583079|NCT00107965|PLACEBO_COMPARATOR|4|
62583080|NCT00107965|EXPERIMENTAL|5|
62583081|NCT00107965|EXPERIMENTAL|6|
62583082|NCT00107965|EXPERIMENTAL|7|
62583083|NCT00107965|PLACEBO_COMPARATOR|8|
62583084|NCT02942368|EXPERIMENTAL|tDCS|Patients will receive transcranial direct current stimulation using an adaptive protocol allowing for doses of 0 to 4 mA during the course of the treatment, with twenty 20-minute sessions over the course of 4 to 6 weeks. Treatments will take place daily, 5 days per week.
62583085|NCT06584383|EXPERIMENTAL|Exablate Arm|Subjects will receive Exablate MRgFUS subthalamotomy
62583086|NCT06584383|ACTIVE_COMPARATOR|Control Arm|Subjects will receive best medical treatment. It is contemplated that, if the patients from the control arm require unilateral Exablate MRgFUS subthalamotomy, the treatment could be performed after Month 12 visit.
62583087|NCT06584383|ACTIVE_COMPARATOR|Reference Arm|Patients fulfilling all inclusion/exclusion criteria except for the SDR requirements (and so anatomically not able to undergo MRgFUS subthalamotomy) will be offered the option to receive best medical treatment and will be formally followed as a reference comparator for up to 3 years.
62583088|NCT00577980|EXPERIMENTAL|Testosterone|Testosterone 200 mg administered parenterally by intramuscular (IM) injection every 2 weeks
62583089|NCT03625375|EXPERIMENTAL|Treatment Group|Individuals will perform exercises 3 times a week.
62583090|NCT03625375|NO_INTERVENTION|Control Group|Individuals will not perform exercises
62583091|NCT06197230|EXPERIMENTAL|Intervention group ; Drawing Intervention|The intervention will be applied every week for 6 weeks. The level of depression, resourcefulness, spiritual resourcefulness, and spiritual health will be tested at the first week before the intervention (T0), the 3rd week (T1), the 6th week right after the interventions (T2), 1 month follow-up after the interventions (T3), and 2 months post-intervention.
62583092|NCT06197230|OTHER|Control|The control group will receive standard care in nursing home
62583093|NCT04672252|EXPERIMENTAL|Cohort 1 - CBD|
62583094|NCT04672252|PLACEBO_COMPARATOR|Cohort 2 - Placebo|
62583095|NCT06666569||Intervention Cohort and Clinical Practice Cohort|"Cohort of routine practice, where the clinician will be blinded to these results.~The randomization process will be by blocks and weighted to the ADL/IFX ratio of use of these treatments in the usual clinical practice of the participating hospitals, to guarantee a homogeneous distribution of the treatments in the groups at the beginning/end of the follow-up."
62019188|NCT01669343|OTHER|Post-menopausal Women Using Adjuvant Letrozole|Part A Routine Care Letrozole; Part B Double Dose Letrozole in overweight/obese participants
62407667|NCT03225313|EXPERIMENTAL|Field block group|bupivicaine will be injected locally in a circular fashion surrounding the site of the hernia
62407668|NCT01477658||Congenital AV Block|Patients diagnosed with Congenital Complete Atrioventricular Heart Block
62407669|NCT01477658||Postoperative AV Block|Patients diagnosed with postoperative AV block
62407670|NCT05417477|EXPERIMENTAL|chronic inflammatory rheumatism or osteoarthritis|"The experimental intervention consists in providing the patient with access to a specific version of the application ''MedicApp'' for the duration of the study.~The intervention will be limited for each patient to the entry of their data on the application at regular intervals during the study.~The interface on the rheumatologist side will contain the demographic characteristics of the patient, his history, the treatments and the pathology requiring the use of physiotherapy Then, at regular intervals, the scores of the questionnaires addressed to the patient will be available on his interface. The interface, on the physiotherapist side, will contain the summary of the patient's clinical history, his treatments and the reason for the physiotherapy sessions. Then, at regular intervals, the physiotherapist will indicate the patient's locomotor assessment, the type of intervention performed and the final summary."
62583096|NCT02082574||patients|HIV infected for more than 5 years, aged over 50, treated with ARV
62583097|NCT02082574||control|non HIV (matched for age and gender)
62583098|NCT06683430|ACTIVE_COMPARATOR|Intervention Group High Potassium, Low Sodium Diet|Participants received a diet enriched with potassium (3500 mg K) and reduced sodium (1500 mg Na) for 14 days.
62583099|NCT06683430|PLACEBO_COMPARATOR|Control Group Standard Diet (Low Potassium)|Participants received a standard diet with low potassium (1700 mg K) and high sodium (2000 mg Na) daily for 14 days.
62583100|NCT05660408|EXPERIMENTAL|Recurrent pHGG, Arm 1|"pHGG Arm 1-A single dose of pp65 RNA-LP (DP1) will be administered prior to standard of care surgical resection/biopsy, followed by at least two adjuvant DP1. During production of pp65/tumor mRNA RNA-LP (DP2) vaccines, treatment with DP1 will continue every 2 weeks. DP1 vaccines may continue until production of DP2 is complete (expected 5-8 weeks following initial surgery/biopsy).~pp65/tumor mRNA RNA-LP (DP2) vaccinations will begin 7-14 days after the last dose of pp65 RNA-LP (DP1). DP2 treatment will occur approximately every 2 weeks for the first 3 doses. Following the first 3 doses of DP2, patients will receive 9 cycles of monthly DP2 for a total of 12 DP2 vaccines (minimum of 15 overall vaccines)."
62583101|NCT05660408|EXPERIMENTAL|Recurrent pHGG, Arm 2|"pHGG Arm 2-Standard of care surgical resection/biopsy will occur first and all three pp65 RNA-LP (DP1) will be administered in the adjuvant setting. During production of DP2, treatment will begin with DP1 every 2 weeks, beginning a minimum of 7-14 days after surgery/biopsy. DP1 vaccines may continue until production of DP2 is complete (expected 5-8 weeks following initial surgery/biopsy).~pp65/tumor mRNA RNA-LP (DP2) vaccinations will begin 7-14 days after the last dose of pp65 RNA-LP (DP1). DP2 treatment will occur approximately every 2 weeks for the first 3 doses. Following the first 3 doses of DP2, patients will receive 9 cycles of monthly DP2 for a total of 12 DP2 vaccines (minimum of 15 overall vaccines)."
62583102|NCT05660408|EXPERIMENTAL|Arm 1-Patients with unilateral pulmonary-only metastatic recurrent OSA|"OSA Arm 1-Patients with unilateral pulmonary-only metastatic recurrent OSA~Participants will undergo surgical resection for sterile collection of tumor material to make pp65/tumor mRNA RNA-LP (DP2). During production of DP2 vaccines, participants will begin treatment with off-the-shelf pp65 RNA-LP (DP1) vaccines every 2 weeks. A minimum of 3 DP1 vaccines will be administered and may continue until production of DP2 is complete (expected 5-8 weeks following initial surgery/biopsy).~DP2 vaccinations will begin 7-14 days after the last dose of DP1. DP2 treatment will occur approximately every 2 weeks for the first 3 doses. Participants will receive 9 cycles of monthly DP2 for a total of 12 DP2 vaccines (minimum of 15 overall vaccines)."
62583103|NCT05660408|EXPERIMENTAL|Arm 2-Patients with bilateral pulmonary-only metastatic recurrent OSA|"OSA Arm 2-Patients with bilateral pulmonary-only metastatic recurrent OSA~Participants will undergo surgical resection for sterile collection of tumor material to make pp65/tumor mRNA RNA-LP (DP2). For subjects in Arm 2, surgery will be again performed on contralateral lung nodules within 7 days following DP1 Vaccine #3.~During production of pp65/tumor mRNA RNA-LP (DP2) vaccines, participants will begin treatment with off-the-shelf pp65 RNA-LP (DP1) vaccines every 2 weeks. A minimum of 3 DP1 vaccines will be administered and may continue until production of DP2 is complete (expected 5-8 weeks following initial surgery/biopsy). DP2 vaccinations will begin 14 days after 2nd surgical pulmonary metastectomy. DP2 treatment will occur approximately every 2 weeks for the first 3 doses. Participants will receive 9 cycles of monthly DP2 for a total of 12 DP2 vaccines (minimum of 15 overall vaccines)."
62019189|NCT05316857|OTHER|Orelabrutinib + Rifampin|"Orelabrutinib is a white, round, uncoated table,Subjects take high dose orelabrutinib in the first day and the tenth day.~Rifampin is a capsule,Subjects take 600mg QD rifampin in the third day to the eleventh."
62407671|NCT02649127|EXPERIMENTAL|Imaginal Therapy Only|The imaginal exercise of exposure therapy will be manualized (Rothbaum, Foa \& Hembree, 2007) and adapted with the permission of Dr. Foa for combat-related stress disorders (Peterson, Cigrang \& Riggs, 2008). While traditional exposure therapy includes both imaginal exposure and in vivo exposure, this study will use only the imaginal exposure components. Participants will meet with a therapist the first week of treatment and every-other week for a total of five appointments over eight weeks. During the second session, the therapist will help the participant make an approximately 20-minute voice tape recording of their traumatic experience which they will listen to 5-days/week. A new recording will be made with the therapist during sessions 3 and 4 also, for a total of three tapes.
62407672|NCT02649127|EXPERIMENTAL|Exercise Only|The aerobic exercise regimen will be standardized according to the American College of Sports Medicine recommendations: frequency of a minimum of 5 sessions per week, at a vigorous intensity \[\>60% of oxygen uptake reserve (VO2R)\], time of 20-25 minutes per exercise session. To determine the exercise heart rate intensity, the Karvonen formula for heart rate reserve will be used. The mode of exercise will be purposeful walking or jogging. The goal of the exercise is not training, but rather to keep the participant's heart rate \>60% of their individually-determined heart rate reserve.
62407673|NCT02649127|EXPERIMENTAL|Imaginal Therapy & Exercise Combined|Participants will meet with a therapist the first week of treatment and every-other week for a total of five appointments over eight weeks. During the second session, the therapist will help the participant make an approximately 20-minute voice tape recording of their traumatic experience which they will listen to 5-days/week. A new recording will be made with the therapist during sessions 3 and 4 also, for a total of three tapes. Participants will exercise listening to their tape at least 5-times/week outside of scheduled unit Physical Training. Participants will wear the heart rate monitor to record their exercise activity.
62407674|NCT02649127|ACTIVE_COMPARATOR|Nurse-led Self-Care|The Self-Care Group will use written materials that outline the benefits of thinking about problems the individual is facing as well as the benefits of exercise, however doing the two activities together will not be advocated as part of the material. A fact sheet prepared by the National Center for PTSD, Returning from the War Zone: A Guide for Military Personnel as well as a list of coping strategies and self-care behaviors adapted from the National Center for PTSD guide, Self-Care and Self-Help Following Disasters, will be used to guide the discussion. The research nurse will meet with the participant five times over 8-weeks at weeks 1, 2, 4, 6, and 8 to encourage use of the self-care fact sheet and assess the participant for safety.
62407675|NCT06425718|ACTIVE_COMPARATOR|Transversalis Fascia Plane Block|Bilateral Transversalis Fascia Plane Block (with %0.25 bupivacaine, 20 ml for each side) and intravenous tramadol via Patient Controlled Analgesia device (5 mg/ml tramadol, bolus dose: 1ml, lock time: 10 minutes)
62407676|NCT06425718|ACTIVE_COMPARATOR|Surgical Site Local Anesthetic Infiltration|Local anesthetic infiltration will be applied to the surgical incision area with 0.25% 20 ml bupivacaine and intravenous tramadol via Patient Controlled Analgesia device (5 mg/ml tramadol, bolus dose: 1ml, lock time: 10 minutes)
62407677|NCT02110875||CONTROLS|Age- and Gender-Matched Controls
62583104|NCT05660408|EXPERIMENTAL|Arm 3-Patients with unresectable OSA in any location|"Arm 3-Patients with unresectable OSA in any location.~Participants will undergo surgical biopsy for sterile collection of tumor material to make pp65/tumor mRNA RNA-LP (DP2). For adult subjects only in Arm 3, optional biopsy will be repeated within 7 days following DP2 Vaccine #3 administration once hematologic recovery to eligibility criteria, unless medically contraindicated.~During production of DP) vaccines, participants will begin treatment with off-the-shelf pp65 RNA-LP (DP1) vaccines every 2 weeks, beginning a minimum of 7 days after initial surgery/biopsy. A minimum of 3 DP1 vaccines will be administered and may continue until production of DP2 is complete (expected 5-8 weeks following initial surgery/biopsy). DP2 vaccinations will begin 7-14 days after the last dose of DP1. DP2 treatment will occur approximately every 2 weeks for the first 3 doses. Participants will receive 9 cycles of monthly DP2 for a total of 12 DP2 vaccines (minimum of 15 overall vaccines)."
62583105|NCT06685653|EXPERIMENTAL|Part A: Resectable NSCLC subjects|
62583106|NCT06685653|EXPERIMENTAL|Part B: NSCLC subjects with disease recurrence or metastasis after first-line standard therapy|
62583107|NCT00657488|EXPERIMENTAL|A|Thalidomide 100mg/day. Dexamethasone is administered at a dose of 40 mg/d, on 4 consecutive days (D1 - D4), with one course every four week in case of stable disease after 12 weeks of treatment or in case of Disease Progression
62583108|NCT00657488|ACTIVE_COMPARATOR|B|Thalidomide 400mg/day. Dexamethasone is administered at a dose of 40 mg/d, on 4 consecutive days (D1 - D4), with one course every four week in case of stable disease after 12 weeks of treatment or in case of Disease Progression
62583109|NCT04501640|EXPERIMENTAL|Mirabegron 25 mg fed/Mirabegron 25 mg fasted|Participants received single dose of 25 mg mirabegron tablet under fed condition orally, on day 1 of period 1 followed by single dose of 25 milligram (mg) mirabegron tablet under fasted condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
62210583|NCT06256237|EXPERIMENTAL|Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy|In this arm, 30 patients with limited-stage small cell lung cancer will receive 4 circles of neoadjuvant toripalimab and JS004 combined with etoposide and platinum chemotherapy. And those resectable after neoadjuvant therapy will be treated with surgery. Postoperative patients receive two cycles of toripalimab and JS004 combined with etoposide and platinum chemotherapy. then patients received maintenance treatment with toripalimab and JS004 until the disease progressed.
62210584|NCT04197739|EXPERIMENTAL|Fixed dose|patients will receive a fixed, single daily dose of amikacin, 500 mg, a day.
62210585|NCT04197739|ACTIVE_COMPARATOR|Adjusted body weight dose|patients will receive a weight adjusted dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according to the Barnes Jewish Hospital nomogram.
62583110|NCT04501640|EXPERIMENTAL|Mirabegron 25 mg fasted/Mirabegron 25 mg fed|Participants received single dose of 25 mg mirabegron tablet under fasted condition orally, on day 1 of period 1 followed by single dose of 25 mg mirabegron tablet under fed condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
62583111|NCT04501640|EXPERIMENTAL|Mirabegron 50 mg fed/Mirabegron 50 mg fasted|Participants received single dose of 50 mg mirabegron tablet under fed condition orally, on day 1 of period 1 followed by single dose of 50 mg mirabegron tablet under fasted condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
62583112|NCT04501640|EXPERIMENTAL|Mirabegron 50 mg fasted/Mirabegron 50 mg fed|Participants received single dose of 50 mg mirabegron under fasted condition orally, on day 1 of period 1 followed by single dose of 50 mg mirabegron tablet under fed condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
62583113|NCT00693498|ACTIVE_COMPARATOR|1|Standard leukoreduced irradiated blood cell transfusion group
62583114|NCT00693498|EXPERIMENTAL|2|Washed leukoreduced irradiated blood cell transfusion group
62210586|NCT01593475|EXPERIMENTAL|Induction chemotherapy followed by CCRT|"In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during RT and CRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy.~Radiotherapy~- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively."
62210587|NCT02077101|OTHER|Quantitative study group|Patients complete questionnaires validated and published in the literature: Brief IPQ R and HIV PROQOL \[28, 29\]. The questionnaire RAVVIH therapeutic vaccine has been designed from the literature review and advice of the Scientific Council in particular Dr. Pierre Verger social scientist vaccination and experts on the perception of patients. It was tested on a sample of 15 PWLHA
62210588|NCT02077101|OTHER|Qualitative study group|"An interview guide was developed from the literature and expert community. Data will be collected through qualitative interviews with a psychologist trained to conduct interviews. Volunteers will be recruited according to the different categories of people representative of the HIV population in France.~These interviews will be conducted at the Foch Hospital. The physician investigator propose participation in the investigation and agree on a day appointment with the psychologist. Consent will be collected at that time after reading the prospectus . All interviews will be recorded orally with the agreement of the participants , and transcribed in full . They will be completely anonymous .~The average length of the interviews will be 45-60 minutes. Textual data from these interviews will be analysis."
62210589|NCT01056952|EXPERIMENTAL|Optiflow then CPAP|Standard low flow oxygen therapy then High flow oxygen nasal therapy (Optiflow)then Continuous positive airway pressure (CPAP)
62210590|NCT01056952|EXPERIMENTAL|CPAP then Optiflow|Standard low flow oxygen therapy then Continuous positive airway pressure (CPAP)then High flow oxygen nasal therapy (Optiflow)
62210591|NCT01555476|EXPERIMENTAL|A-IBU|A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits.
62407678|NCT04160273|EXPERIMENTAL|Diagnosis and follow-up arm|"Patients are informed during the 9th month pregnancy consultation consultation at Angers University Hospital by the midwife or obstetrician in charge of the consultation. They are included in the 48 hours following the delivery after their hospitalization in the maternity ward.~During hospitalization, socio-demographic and medical data are collected and the IDP scale is completed before returning home.~Follow-up at one month and one year is carried out by the investigators by means of a telephone call during which the patient answers the PCL-S questionnaire. Also collected during this call are information on the physical and mental state of the patient, the state of health of her newborn and the progress of the return home.~Patients are considered at high risk of PTSD if they have a PCL-S score ≥ 44 at 1 month. A consultation with a psychiatrist is offered to these patients at risk of PTSD in order to make the diagnosis and offer them appropriate care if necessary."
62407679|NCT04548817||Neurocutaneous Melanocytosis|Participants will have Neurocutaneous Melanocytosis (NCM) Including Cutaneous and CNS Involvement
62583115|NCT03359330||Degradable conduit small gap tublization|patients with fresh peripheral nerve injury in the upper extremities,repaired with degradable conduit small gap tublization
62583116|NCT06242535|EXPERIMENTAL|GLY-LOW supplement|This supplement is available for over-the-counter purchase. Each capsule is a combination of vitamins and natural products: Vitamin B1 (100mg); Vitamin B6 (50mg); Niacin (200mg); Alpha Lipoic Acid (150mg); and Piperine (15mg). Each participant will take this supplement daily in a pill form orally once in the morning. The test product will be two capsules a day with breakfast between 7:00 - 11:00 AM. The chosen doses were based on dose conversion from mice to humans and the prior data on safety for each of the compounds in humans.
62583117|NCT03703583||Exclusively/predominantly Breastfeeding group|
62583118|NCT03703583||Exclusively/predominantly Formula feeding group|
62583119|NCT01020006|ACTIVE_COMPARATOR|Gemcitabine|Subjects receive Gemcitabine 1000 mg/m2 weekly intravenous infusion.
62583120|NCT01020006|EXPERIMENTAL|PCI-27483 + Gemcitabine|"Part A: Subjects received PCI-27483 0.8 mg/kg BID as initial dose and may be escalated to 1.2, and 1.5 mg/kg BID. At the same time, subjects received Gemcitabine 1000 mg/m2 weekly intravenous infusion.~Part B: Subjects received the PCI-27483 at 1.2 mg/kg BID and Gemcitabine 1000 mg/m2 weekly intravenous infusion."
62210592|NCT01555476|ACTIVE_COMPARATOR|B-IBU|A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
62407680|NCT03327935|EXPERIMENTAL|Nutrition|Oral nutritional supplements and dietetic advice
62407681|NCT03327935|EXPERIMENTAL|Nutrition and exercise|Oral nutritional supplements, dietetic advice and exercise training
62407682|NCT03327935|NO_INTERVENTION|Control|Standard Hospital Procedure
62583121|NCT01391208|NO_INTERVENTION|peptide application|
62583122|NCT04713839||Participants|The participants were invited to the study, then each participant was asked to complete the self-report questionnaires.
62210593|NCT04182295|EXPERIMENTAL|real acupuncture-full disclosure|Participants in this group will be given real acupuncture once a day for three consecutive days including the very first visit and fully disclosed sham acupuncture information in the informed consent (i.e., fake acupuncture).
62210594|NCT04182295|EXPERIMENTAL|real acupuncture-partial disclosure|Participants in this group will be given real acupuncture once a day for three consecutive days including the very first visit and partially disclosed sham acupuncture information in the informed consent (i.e., different kind of acupuncture).
62210595|NCT04182295|SHAM_COMPARATOR|sham acupuncture-full disclosure|Participants in this group will be given sham acupuncture once a day for three consecutive days including the very first visit and fully disclosed sham acupuncture information in the informed consent (i.e., fake acupuncture).
62210596|NCT04182295|SHAM_COMPARATOR|sham acupuncture-partial disclosure|Participants in this group will be given sham acupuncture once a day for three consecutive days including the very first visit and partially disclosed sham acupuncture information in the informed consent (i.e., different kind of acupuncture).
62210597|NCT03856385|EXPERIMENTAL|Mindful Walking|Four weekly 60 minute sessions of mindful walking.
62210598|NCT03856385|NO_INTERVENTION|Control|Weekly email messages encouraging physical activity.
62210599|NCT02613234|EXPERIMENTAL|Experimental Group|Active Intervention on brain waves by cathode tDCS
62210600|NCT02613234|SHAM_COMPARATOR|Control Group|Sham Intervention on brain waves by cathode tDCS
62210601|NCT05218070|EXPERIMENTAL|Low Dose Vaccine|35 mcg dose for both vaccinations at day 0 and day 14 (low dose, 15 subjects)
62210602|NCT05218070|EXPERIMENTAL|High Dose Vaccine|70 mcg dose for both vaccinations at day 0 and day 14 (high dose, 15 subjects)
62210603|NCT05218070|PLACEBO_COMPARATOR|Placebo|Placebo for both injections at day 0 and day 14 (Placebo, 15 subjects)
62210604|NCT00694824||A|
62210605|NCT02940184|EXPERIMENTAL|Enteral fructose with DPP-4 inhibition|"Enteral fructose + DPP-4 inhibition (sitagliptin)~After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals."
62210606|NCT02940184|EXPERIMENTAL|Enteral fructose without DPP-4 inhibition|Enteral fructose without DPP-4 inhibition (sitagliptin) After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals.
62210607|NCT04902677||School|
62210608|NCT04984447|EXPERIMENTAL|Feasibility of TNIB catheter|The feasibility of using the TNIB catheter to obtain microscopic images of the intestine. Healthy adult volunteers, and healthy pregnant women in their 2nd trimester of pregnancy will be enrolled, and their upper gastrointestinal tract will be imaged by the TNIB device
62210609|NCT02125045|EXPERIMENTAL|L-GSH|Glutathione 100 mg tablets twice a day
62210610|NCT02125045|PLACEBO_COMPARATOR|Placebo|Matching placebo will be administered for 4 weeks in a double blind fashion.
62210611|NCT03942159||Donors|HLA-matched or haploidentical nursing relative donors
62210612|NCT03942159||Patients|recipients of allogeneic HSCT
62210613|NCT03262662|EXPERIMENTAL|Extended Run-In|"\*\* 4 weeks of varenicline prior to the target quit date (TQD) \*\*~+ 11 weeks of post-TQD varenicline~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.~Brief individual counseling at clinic visits"
62210614|NCT03262662|ACTIVE_COMPARATOR|Standard Run-In|"\*\* 3 weeks of placebo followed by 1 week of varenicline prior to the target quit date (TQD) \*\*~+ 11 weeks of post-TQD varenicline~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.~Brief individual counseling at clinic visits"
62210615|NCT05148962|EXPERIMENTAL|Cohort 1: GRT-R910 10 µg, age ≥60 years (Receipt of AstraZeneca vaccine)|Healthy participants of age ≥60 years received prime dose (on Day 1) of GRT-R910 10 microgram (µg) intramuscularly at least 2 months after receiving a first-generation COVID-19 (AstraZeneca) vaccine primary series. A subset of participants elected to receive a booster vaccination of GRT-R910 10 µg which was administered 113 days after the prime vaccination. Participants not receiving booster dose were followed for 12 months, and participants receiving booster dose were followed for 16 months.
62210616|NCT05148962|EXPERIMENTAL|Cohort 2: GRT-R910 30 µg, age ≥60 years (Receipt of AstraZeneca vaccine)|Healthy participants of age ≥60 years received prime dose (on Day 1) of GRT-R910 30 µg intramuscularly at least 2 months after receiving a first-generation COVID-19 (AstraZeneca) vaccine primary series. A subset of participants elected to receive a booster vaccination of GRT-R910 10 µg, which was administered 113 days after the prime vaccination. Participants not receiving booster dose were followed for 12 months, and participants receiving booster dose were followed for 16 months.
62407683|NCT04909879|EXPERIMENTAL|COVI-MSC|Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4
62407684|NCT04909879|PLACEBO_COMPARATOR|Placebo|Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4
62407685|NCT01010724|EXPERIMENTAL|bIAP|Dosage 200 IU bIAP/kg: 1000 IU prior to anaesthesia administered as a bolus followed by intravenous continuous infusion of 5,6 IU/kg/hr for approximately 36 hours.
62407686|NCT01010724|PLACEBO_COMPARATOR|Placebo|
62583123|NCT06665867|EXPERIMENTAL|Video consultation|These participants are randomized for video consultations. Participants will receive two follow-up consultations via video.
62210617|NCT05148962|EXPERIMENTAL|Cohort 3: GRT-R910 10 µg, ≥60 years, (Receipt of AstraZeneca or Janssen COVID-19 vaccine)|Healthy participants of age ≥60 years received two doses (Day 1 and Day 29) of GRT-R910 10 µg (homologous prime-boost), at least 2 months after receiving an adenoviral COVID-19 (AstraZeneca, Janssen) primary series vaccine. Participants were followed for 13 months.
62407687|NCT00859352|EXPERIMENTAL|1|AZD1981 100mg and Midazolam
62583124|NCT06665867|ACTIVE_COMPARATOR|Face-to-face consultation|These participants are randomized for face-to-face consultations. Participants will receive two follow-up face-to-face consultations in the hospital.
62019190|NCT05316857|OTHER|Orelabrutinib + Itraconazole|"Orelabrutinib is a white, round, uncoated table,Subjects take low dose orelabrutinib in the first day and the eighth day.~Itraconazole is a capsule,Subjects take 600mg QD rifampin in the third day to the tenth."
62019191|NCT04407897|EXPERIMENTAL|Radiotherapy|Patients with oligometastatic lesions, fulfilling the inclusion/exclusion criteria's will be assigned to SABR.
62210618|NCT05148962|EXPERIMENTAL|Cohort 4: GRT-R910 10 µg, ≥60 years, (Receipt of Pfizer/BioNTech, Moderna COVID-19 vaccine)|Healthy participants of age ≥60 years received two doses (Day 1 and Day 29) of GRT-R910 10 µg (homologous prime-boost), at least 2 months after receiving a messenger ribonucleic acid (mRNA)-based COVID-19 (Pfizer/BioNTech, Moderna) primary series vaccine. Participants were followed for 13 months.
62210619|NCT05148962|EXPERIMENTAL|Cohort 6: GRT-R910 10 µg, ≥18 to ≤59 years, (Receipt of Pfizer/BioNTech, Moderna COVID-19 vaccine)|Healthy participants of age ≥18 to ≤59 years received two doses (Day 1 and Day 29) of GRT-R910 10 µg (homologous prime-boost), at least 2 months after receiving mRNA-based COVID-19 (Pfizer/BioNTech, Moderna) primary series vaccine. Participants were followed for 13 months.
62210620|NCT01028313|EXPERIMENTAL|1|Systemic Therapy
62019192|NCT02721589|EXPERIMENTAL|Injection SHR-1210 1mg/kg Cohort|
62210621|NCT00954551||All adult patients with SAH in ICU|All adult patients admitted for an expected ICU stay of more than 24 hrs over a 6-month period (tentative) between xx and xx 2009 with a diagnosis of SAH will be prospectively evaluated.
62210622|NCT06445413|EXPERIMENTAL|Tai Chi class|Participation in ten weekly group in-person Tai Chi classes
62210623|NCT06728098|ACTIVE_COMPARATOR|Healthy Subjects on Probiotic|"Healthy Subjects Receiving Probiotic Akk11: One probiotic Akkermansia muciniphila Akk11 capsule daily (1 billion AFU/capsule).~Store in cool and dry place, without exposure to light."
62407688|NCT00859352|EXPERIMENTAL|2|AZD1981 500mg and Midazolam
62407689|NCT01725217|EXPERIMENTAL|MenACWY-CRM|MenACWY-CRM
62583125|NCT01711372|PLACEBO_COMPARATOR|Controls who played Groundskeeper game|Controls played a go/no go task on Sifteo cubes to asses for attentional capabilities.
62019193|NCT02721589|EXPERIMENTAL|Injection SHR-1210 3mg/kg Cohort|
62019194|NCT02721589|EXPERIMENTAL|Injection SHR-1210 200mg Cohort|
62019195|NCT02721589|EXPERIMENTAL|Injection SHR-1210 10mg/kg Cohort|
62019196|NCT04504877|EXPERIMENTAL|cannabidiol plus general clinical supportive measures|The participants will receive CBD 300mg/daily plus general measures (supporting motivational videos, fitness videos). All the participants will perform invasive and non-invasive procedures with the nursing team, the invasive being five blood collections, in their workplaces, to evaluate laboratory parameters, detailed in this project. The non-invasive ones refer to the measurement of height, weight, body temperature, and sleep pattern, as well as five collections of saliva, in a collecting tube, to assess viral load. They will also be monitored through weekly self-assessment scales, applied remotely, electronically (cell phones or computers), with an estimated duration of ten minutes each, which will have their responses recorded in an electronic database by the study coordination team.
62019197|NCT04504877|OTHER|general clinical supportive measures|The participants will receive general measures (supporting motivational videos, fitness videos) alone. All the participants will perform invasive and non-invasive procedures with the nursing team, the invasive being five blood collections, in their workplaces, to evaluate laboratory parameters, detailed in this project. The non-invasive ones refer to the measurement of height, weight, body temperature, and sleep pattern in a collecting tube to assess viral load. Also, they will be monitored through weekly self-assessment scales, applied remotely, electronically (cell phones or computers), with an estimated duration of ten minutes each, which will have their responses recorded in an electronic database by the study coordination team.
62019198|NCT00765167|PLACEBO_COMPARATOR|A|
62019199|NCT00765167|ACTIVE_COMPARATOR|B|
62407690|NCT05388526||Parkinson|"Patients with a diagnosis of PD or secondary parkinsonism belonging to the Health Area V of the Health Service of the Principality of Asturias, Spain.~Patient origin: Rehabilitation Service Instituto de Rehabilitación Astur S.A. and Asociación de Parkinson Jovellanos, from Gijón, Asturias, Spain."
62407691|NCT02647632|EXPERIMENTAL|16 weeks of treatment|Drug : Grazoprevir/Elbasvir + Sofosbuvir + Ribavirin during 16 weeks
62019200|NCT00765167|ACTIVE_COMPARATOR|C|
62019201|NCT01971905||Oben label|There is no intervention on this descriptive study
62407692|NCT02647632|EXPERIMENTAL|24 weeks of treatment|Drug : Grazoprevir/Elbasvir + Sofosbuvir + Ribavirin during 24 weeks
62407693|NCT03325569|ACTIVE_COMPARATOR|NGT|NGT - normal glucose tolerance. Women with PCOS and normal glucose tolerance
62407694|NCT03325569|ACTIVE_COMPARATOR|IGH|IGH - impaired glucose homeostasis Women with PCOS and impaired glucose homeostasis - that means impaired fasting glucose or impaired glucose tolerance.
62583126|NCT01711372|ACTIVE_COMPARATOR|Probands played groundskeeper game|Patients with ADHD played a go/no go task on Sifteo cubes to asses for attentional capabilities
62019202|NCT04090736|EXPERIMENTAL|Arm A: Pevonedistat plus Azacitidine|Pevonedistat 20 mg/m2 IV on days 1, 3, and 5 plus Azacitidine 75 mg/m2 subcutaneous administered on a 5-on/2-off \[weekend\]/2-on schedule in 28-day cycles (intravenous Azacitidine can be administered for any patients who have non-tolerated local reactions)
62019203|NCT04090736|ACTIVE_COMPARATOR|Arm B: Azacitidine|Azacitidine 75 mg/m2 subcutaneous on a 5-on/2-off \[weekend\]/2-on schedule in 28-day cycle (intravenous azacitidine can be administered for any patients who have non-tolerated local reactions)
62019204|NCT05014100|EXPERIMENTAL|The treatment group|Orelabrutinib 150mg once daily in a 28-day cycle. Lenalidomide 25mg once daily for 21 days and rituximab 375mg/m2 for 7 days
62019205|NCT04332744|ACTIVE_COMPARATOR|Control Arm (Arm A)|Patients will receive enzalutamide capsules orally once daily continuously (160 mg) in addition to standard ADT (unless surgical castration).
62019206|NCT04332744|EXPERIMENTAL|Interventional Arm (Arm B)|Patients will receive enzalutamide capsules 160 mg in combination with talazoparib (PF-06944076) capsules 0.5 mg, both orally daily and continuously in 28-day cycle, in addition to standard ADT (unless surgical castration).
62210624|NCT06728098|EXPERIMENTAL|Obese Patients on Probiotic|"Obese Patients Receiving Probiotic Akk11 : One probiotic Akkermansia muciniphila Akk11 capsule daily (1 billion AFU/capsule).~Store in cool and dry place, without exposure to light."
62583127|NCT04287231|EXPERIMENTAL|Dual-tDCS & PT|Dual tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere for 20 mins before physical therapy (about 1 hours). Current intensity is fixed at 2 mA and current will flow continuously. Physical therapist will give an intervention program for lower limb performence.
62019207|NCT01148810|PLACEBO_COMPARATOR|Placebo|
62019208|NCT01148810|EXPERIMENTAL|BAF312|
62019209|NCT00879294|SHAM_COMPARATOR|1 Wristband|Some patients will be randomized to wear a motion sickness wristband which does not have any drug effect.
62210625|NCT06728098|PLACEBO_COMPARATOR|Obese Patients on Placebo|Obese Patients Receiving Placebo : Take 1 maltodextrin capsule every day. Store in cool and dry place, without exposure to light.
62407695|NCT01717729|EXPERIMENTAL|RFA-125I group|The combination RFA and 125I (RFA-125I) (n = 68; 42 men, 26 women; mean age, 50.7 years; age range, 29-73 years) In this group, patients were accepted not only radiofrequency ablation (RFA) but also iodine-125.
62583128|NCT04287231|ACTIVE_COMPARATOR|Sham-tDCS & PT|Sham tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere, current intensity will be 2mA (sham mode). Physical therapist will give an intervention program for lower limb performence.
62019210|NCT00879294|EXPERIMENTAL|Chewing Gum|Patients will be randomized to use chewing gum after surgery.
62583129|NCT00715416|EXPERIMENTAL|1|primary nitinol stent placement of superficial femoral artery lesions
62019211|NCT00879294|NO_INTERVENTION|Control|Usual post-operative care.
62019212|NCT03483623|EXPERIMENTAL|NATO WELP combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on NATO litter and WELP mattress combination
62019213|NCT03483623|EXPERIMENTAL|NATO FIS combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on NATO litter and Fluid Immersion System (FIS) mattress combination
62019214|NCT03483623|EXPERIMENTAL|RAVEN WELP combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on Raven 90C litter and WELP mattress combination
62019215|NCT03483623|EXPERIMENTAL|RAVEN FIS combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on Raven 90C litter and Fluid Immersion System (FIS) mattress combination
62019216|NCT01592513|NO_INTERVENTION|Control|
62019217|NCT01592513|EXPERIMENTAL|BIS monitor|"Patients in this group will be monitored by BIS (placement of an electrode over the forehead before sedation).~Patients in this group will receive propofol (boluses of 10-20 mg) to reach a BIS target value of 80-90."
62583130|NCT00715416|ACTIVE_COMPARATOR|2|balloon angioplasty of superficial artery lesions with secondary stent placement in case of \>30% residual stenosis after the procedure
62019218|NCT06129058|EXPERIMENTAL|tDCS|active tDCS
62210626|NCT04311840||SAH patients with nimodipine|Patients with SAH receiving nimodipine as prevention of vasospasms and as a nootropic drug.
62210627|NCT04311840||SAH patients without nimodipine|Patients with SAH not receiving nimodipine as prevention of vasospasms and as a nootropic drug or in whom the drug has been temporarily discontinued.
62407696|NCT01717729|ACTIVE_COMPARATOR|RFA-only group|(n = 68; 47 men, 21 women; mean age, 48.9 years; age range, 30-74 years) In tis group,the patient were just peformed radiofrequency ablation alnoe.
62407697|NCT02835664|EXPERIMENTAL|Nicotinamide Riboside|Supplementation of Nicotinamide Riboside (Niagen) of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.
62407698|NCT02835664|PLACEBO_COMPARATOR|Placebo|Supplementation of Placebo of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.
62407699|NCT05518058|EXPERIMENTAL|Control group|
62019219|NCT06129058|SHAM_COMPARATOR|Sham|sham tDCS
62407700|NCT05518058|EXPERIMENTAL|Study group|
62407701|NCT04800510|EXPERIMENTAL|NoCDO, CDOA, CDOB, CDOC|Participants will be evaluated without a CDO, then with CDOA, then with CDOB, then with CDOC.
62019220|NCT04091841|EXPERIMENTAL|protein supplement|Intervention patients will be received protein diet (1.2 g/kg/day) and protein supplement (36 g/day) for 1 month after surgery.
62019221|NCT04091841|PLACEBO_COMPARATOR|Carbo Mass|Control patients will be received protein diet (1.2 g/kg/day) and Carbo Mass for 1 month after surgery.
62407702|NCT04800510|EXPERIMENTAL|NoCDO, CDOA, CDOC, CDOB|Participants will be evaluated without a CDO, then with CDOA, then with CDOC, then with CDOB.
62407703|NCT04800510|EXPERIMENTAL|NoCDO, CDOB, CDOA, CDOC|Participants will be evaluated without a CDO, then with CDOB, then with CDOA, then with CDOC.
62734506|NCT03281369|ACTIVE_COMPARATOR|1L-Control: Cisplatin+5-FU (Esophageal Cancer Cohort)|Participants in the 1L-Control Eophageal Cancer arm will receive chemotherapy.
62019222|NCT04718246|OTHER|Dental Implants in hyperlipidemia patients|Implants will be placed at T0, then Implant site exposure will take place 6 months following the implant placement. Insertion of the healing collars in order to obtain adequate soft tissue form for 1-2 weeks then the impressions (indirect, closed tray echnique) shall be taken to fabricate the final crowns, then the final crowns will be fitted in place.
62019223|NCT02684591|EXPERIMENTAL|Aramchol 600 mg orally daily|"Total 600 mg Aramchol (200 mg/tablet and 400 mg/tablet) per day once a day orally for 12 weeks.~Intervention: Aramchol"
62210628|NCT04435678|OTHER|birch pollen allergy|"106 patients with suspicion of birch pollen allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
62210629|NCT04435678|OTHER|grass pollen allergy|"106 patients with suspicion of grass pollen allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
62210630|NCT04435678|OTHER|house dust mite allergy|"148 patients with suspicion of house dust mite allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)"
62210631|NCT04435678|OTHER|cat allergy|"106 patients with suspicion of cat allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
62407704|NCT04800510|EXPERIMENTAL|NoCDO, CDOB, CDOC, CDOA|Participants will be evaluated without a CDO, then with CDOB, then with CDOC, then with CDOA.
62210632|NCT04435678|OTHER|bee venom allergy|"106 patients with suspicion of bee venom allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and an intradermal test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
62210633|NCT04435678|OTHER|vespid venom allergy|"106 patients with suspicion of vespid venom allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and an intradermal test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
62210634|NCT04435678|OTHER|non-allergic individuals|"148 non-allergic individuals will be included in the study. They should have no symptoms that could be related to inhalant allergy or Hymenoptera venom allergy, negative skin test results and undetectable IgE levels.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
62210635|NCT04914429|EXPERIMENTAL|Group 1: Guselkumab|Participants will receive guselkumab 100 milligrams (mg) by subcutaneous (SC) injection at Weeks 0, 4, and then every 8 weeks (q8w) through Week 44. Participants will receive matching placebo at Week 16.
62210636|NCT04914429|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will receive placebo SC injection for guselkumab at Weeks 0, 4, and 12, and then cross over at Week 16 to receive guselkumab 100 mg SC injection at Weeks 16 and 20 and q8w thereafter through Week 44.
62210637|NCT03582943|EXPERIMENTAL|Remote limb ischemic conditioning (RLIC)|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the dominant arm. RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
62210638|NCT03582943|SHAM_COMPARATOR|Sham conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-7.
62210639|NCT06263127|EXPERIMENTAL|OS group|The participants receive the prefeeding oral stimulation intervention twice a day,10 days.
62210640|NCT06263127|EXPERIMENTAL|OS+ IM group|The participants receive both prefeeding oral stimulation and infant massage once a day, in random order, 10 days.
62210641|NCT05237401|ACTIVE_COMPARATOR|Non-Surgical Periodontal treatment (NSPT)|Half of the study participants (controls) will be randomised to receive continued non-surgical periodontal treatment (NSPT). All treatment will be carried out by the same therapist in each centre, including oral hygiene.
62210642|NCT05237401|EXPERIMENTAL|Surgical Periodontal treatment/ Open Flap Debridement (OFD)|"The other half of the study participants (test) will be randomised to receive surgical periodontal treatment in the form of open flap debridement (OFD). The aim of the surgery will be to achieve thorough debridement of the furcation area and (if possible) improve accessibility for patient-performed hygiene in the furcation area.~Some of the included maxillary molars may have additional FI on the same tooth (for example, grade III FI buccal to mesial and grade I, II or III distal). In this occurrence, the other furcation will be treated according to judgment by the treating clinician. We anticipate that, based on inclusion criteria, the majority of cases will have multiple grade III FI."
62210643|NCT06728215||UNIQ capacitive/resistive electrode|subjects with LBP treated with Fisiowarm 7.0 and the new capacitive/resistive electrode (UNIQ electrode Fisiowarm 7.0, Golden Star Srl, Rome, Italy), for 15' at a frequency of 300 KHz (Treated Group)
62210644|NCT06728215||monopolar electrode group|Subject with LBP treated with a classical methodology using the monopolar electrode Activ CT8 INDIBA® at a frequency of 448 KHz in both resistive and capacitive modes, for 10 min each mode with two different electrodes. (Control group).
62407705|NCT04800510|EXPERIMENTAL|NoCDO, CDOC, CDOA, CDOB|Participants will be evaluated without a CDO, then with CDOC, then with CDOA, then with CDOB.
62210645|NCT01903824|EXPERIMENTAL|CEP-26401 5 μg, 25 μg, 125 μg, placebo|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 in each of the dose options: 5, 25 and 125 μg, and one dose that only contains the placebos.)
62210646|NCT01903824|EXPERIMENTAL|CEP-26401 5 μg, 25 μg, placebo, donepezil|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 at 5 and 25 μg, and donepezil at 10mg and one dose that only contains the placebos.)
62407706|NCT04800510|EXPERIMENTAL|NoCDO, CDOC, CDOB, CDOA|Participants will be evaluated without a CDO, then with CDOC, then with CDOB, then with CDOA.
62407707|NCT05487859|EXPERIMENTAL|Arm 1|"Ipilimumab (1 mg/kg) IV q3wks + Nivolumab (3mg/kg) IV q3wks + Acarbose (upto 100 mg PO TID) followed by Nivolumab 480 mg IV q4 wks + Acarbose (upto 100 mg PO TID)~OR~Pembrolizumab 200 mg IV q3 wks or 400 mg IV q6 wks + Lenvatinib (up to 20 mg PO Daily) + Acarbose (upto 100 mg PO TID) \[ Frontline/Refractory pts\]~OR~Lenvatinib (upto 18 mg PO daily) + Everolimus (upto 5 mg PO Daily) + Acarbose (upto 100 mg PO TID) \[ Refractory pts\]~OR~Cabozantinib (upto 60 mg PO Daily) + Acarbose (upto 100 mg PO TID) \[Refractory pts\]"
62210647|NCT01903824|EXPERIMENTAL|CEP-26401 5 μg, 125 μg, placebo, modafinil|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 at 5 and 125 μg, and modafinil at 200mg) and one dose that only contains the placebos.)
62407708|NCT02127788||Micafungin|Patients affected with haemopathy (or affected with solid tumor for paediatric patients) under antifungal prophylaxis with micafungin.
62407709|NCT05248854|EXPERIMENTAL|Sensorimotor exercise training|SM program included combination of traditional hip and knee exercise, various balance and proprioceptive exercises.
62407710|NCT05248854|EXPERIMENTAL|Core Stabilization exercise training|Core stabilization exercise program contained traditional hip and knee ROM exercise combining the core stabilization as mat activities
62019224|NCT02684591|PLACEBO_COMPARATOR|Placebo|Placebo in the form of a tablet; Two bottles will be given to patient and they will take two pills, once a day orally for 12 weeks.
62019225|NCT03391843|EXPERIMENTAL|FOLFOXIRI+Cetuximab|FOLFOXIRI+Cetuximab regimen:Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h and cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle for 4-6 cycles.
62407711|NCT01504126|EXPERIMENTAL|Treatment (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO BID beginning 48-72 hours before treatment. Patients undergoing surgery resume propranolol hydrochloride post-operatively once oral drugs are tolerated and continue until completion of 6 cycles of chemotherapy. Patients undergoing neoadjuvant chemotherapy continue propranolol hydrochloride PO BID during 3 chemotherapy cycles pre-surgery and 3 cycles post-surgery. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62210648|NCT02862587|EXPERIMENTAL|Precision Cells|"precision cells combined with Chemotherapy treatment:~Chemotherapy:~once a week with a total of six times before 60 days prior to the start of drawing blood. precision cells：once per 3 weeks with a total of three periods."
62210649|NCT02862587|ACTIVE_COMPARATOR|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
62210650|NCT04044898|EXPERIMENTAL|Low dose|
62210651|NCT04044898|EXPERIMENTAL|High dose|
62210652|NCT01297153|ACTIVE_COMPARATOR|Aphakia|"* The patient is randomly assigned for aphakia / pseudophakia. This is done only after vitrectomy. If it is aphakia,IOL will not be implanted.Aphakia will be corrected with aphakic glasses / contact lenses. Bilateral aphakes are given both contact lenses and glasses. So when they do not wear contact lenses they can put on aphakic glasses. Unilateral aphakes are given only contact lenses. Contact lenses should be fitted in the eye in OT immediately after the operation.~* Aphakic glasses :~Prescribed within 2 weeks of surgery for both eyes."
62210653|NCT01297153|ACTIVE_COMPARATOR|Pseudophakia|The patient is randomly assigned for aphakia / pseudophakia. This is done only after vitrectomy. Hydrophobic Acrysof IOL is implanted.All pseudophakic children will be refracted and given the residual correction within a month of surgery.
62210654|NCT03339245|EXPERIMENTAL|Glucose, Then Fructose|Participants first receive Glucose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Fructose Solution (75 Grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.
62583131|NCT04399109|ACTIVE_COMPARATOR|TCC-COVID mHealth solution|TCC-COVID is an app-based model of care which includes a smartphone app and a pulse oximeter that measures oxygen saturation, pulse rate and collects symptoms, connected to a back-end clinical database with inbuilt data analytics.
62210655|NCT03339245|EXPERIMENTAL|Fructose, Then Glucose|Participants first receive Fructose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Glucose Solution (75 grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.
62210656|NCT01234051|EXPERIMENTAL|Docetaxel, oxaliplatin, palliative chemotherapy|
62210657|NCT04573088|EXPERIMENTAL|ABICOL|24 hours prior to surgery the patients undergo acceptance-based intervention, incorporating questions about their subjective perception about the surgery, the domains of their lives that have been affected, and on their own expectations from surgery and its effects on their lives. They will be asked to express their fears and worries about their condition and they will be discussed about the likelihood of experiencing postoperative pain.
62210658|NCT04573088|NO_INTERVENTION|CONTROL|No acceptance-based intervention or other discussion related to the patients' fears and worries will be applied.
62210659|NCT05944952|EXPERIMENTAL|high dose|High dose: Participants randomized to the high dose group will receive on day 1 in the clinic an initial dose of 2 mg of buprenorphine/naloxone, followed by a 6 mg dose an hour later, followed by an 8 mg dose an hour later, followed by an 8 mg dose an hour later. On day 2 they will receive a 12 mg dose in the clinic and a 12 mg dose as take-home medication. On days 3 through 7 they will report to the clinic and receive their 12 mg morning dose and a 12 mg dose as a take-home for evening dosing. Thereafter, dosing adjustments can be made in the first three months of the trial.
62210660|NCT05944952|ACTIVE_COMPARATOR|low dose|Low dose: Participants randomized to the low dose group will receive 0.5 mg of buprenorphine/naloxone on day 1, 0.5 mg bid on day 2, 1.0 mg bid on day 3, 2.0 mg bid on day 4, 4.0 mg bid on day 5, 4.0 mg tid on day 6, and 8 mg bid on day 7. Thereafter, dosing adjustments can be made in the first three months of the trial.
62210661|NCT02204501|EXPERIMENTAL|Vapendavir 528 mg QD|Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
62210662|NCT02204501|EXPERIMENTAL|Vapendavir 264 mg BID|Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
62210663|NCT02736383||Tranexamic Acid|Patients that receive 2 gm TXA during surgery
62210664|NCT02736383||No Tranexamic Acid|Patients that receive no TXA during surgery
62210665|NCT03828747|EXPERIMENTAL|Semorinemab|Semorinemab will be administered intravenously in the double-blind treatment period, and semorinemab will be administered intravenously in the optional open-label extension period.
62407712|NCT00539006|ACTIVE_COMPARATOR|FFNS, FPNS|active compound
62407713|NCT00539006|ACTIVE_COMPARATOR|FPNS, FFNS|active compound
62210666|NCT03828747|PLACEBO_COMPARATOR|Placebo|Placebo will be administered intravenously in the double-blind treatment period and semorinemab will be administered intravenously in the optional open-label extension.
62210667|NCT02942277|EXPERIMENTAL|1a|(n=5), to receive 16 microgram Pfs25M-EPA/AS01 on D0, D28, D168
62407714|NCT00539006|PLACEBO_COMPARATOR|placebo FFNS, placebo FPNS|placebo arm
62583132|NCT04399109|NO_INTERVENTION|Control|Propensity matched and synthetic control groups will be utilised from another local health district not participating in the ReCOVER study. The control group will not be actively recruited at the same time as the intervention. The control group will be matched via data linkage at the completion of the trial. However, it is not a historical control, as the control standard of care treatment will be provided simultaneously as our intervention
62210668|NCT02942277|EXPERIMENTAL|1b|(n=10), to receive 47 microgram Pfs25M-EPA/AS01 on D0, D28, D168
62210669|NCT02942277|EXPERIMENTAL|2a|(n=5), to receive 13 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
62210670|NCT02942277|EXPERIMENTAL|2b|(n=10), to receive 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
62210671|NCT02942277|EXPERIMENTAL|2c|(n=60), to receive 40 micrograms Pfs230D1M-EPA/AS01 on D0, D28, D168; all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); 4th vaccination on D476
62210672|NCT02942277|EXPERIMENTAL|2d|(n=60), to receive 40 micrograms Pfs230D1M-EPA/AS01 (500 (Micro)L TBV + AS01) on D0, D28, then 8 micro liters Pfs230D1M- EPA/AS01 (100 (Micro)L TBV + AS01;fractional dose) on D168; all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); 4th vaccination on D476
62210673|NCT02942277|EXPERIMENTAL|3a|(n=5), to receive 16 microgram Pfs25M-EPA/AS01 and 13 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
62210674|NCT02942277|EXPERIMENTAL|3b|(n=10), to receive 47 microgram Pfs25M-EPA/AS01 and 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168 (Bamako)
62407715|NCT00539006|PLACEBO_COMPARATOR|placebo FPNS, placebo FFNS|placebo arm
62407716|NCT05077033|EXPERIMENTAL|Intratumoral phIL12 gene electrotransfer|
62407717|NCT03472391|ACTIVE_COMPARATOR|Intervention|Supervised exercise therapy by physical therapist: patients allocated to physical therapy will participate in a 4-week (2 sessions a week of 40 minutes) supervised and tailored exercise program mainly consisting of light strength training. The exercise program is an add-on treatment to the primary treatment of re-nutrition and somatic stabilization.
62407718|NCT03472391|NO_INTERVENTION|Control|The control group follows ordinary treatment in consisting of re-nutrition and somatic stabilization
62407719|NCT06063980|OTHER|Conventional sinus lift procedure|Participants assigned to conventional sinus augmentation
62407720|NCT06063980|OTHER|Two-stage-sinus-lift procedure|Participants assigned to two-stage - sinus - lift procedure
62407721|NCT04719208|EXPERIMENTAL|Chlorhexidine gluconate (A)|Mouth rinse with 0.2% Chlorhexidine gluconate,
62407722|NCT04719208|EXPERIMENTAL|Hydrogen peroxide (B)|Mouth rinse with 1.5% hydrogen peroxide
62407723|NCT04719208|EXPERIMENTAL|Betadine (C)|Mouth rinse with betadine mouthwash,
62407724|NCT04719208|EXPERIMENTAL|Mouth wash (D)|Mouth rinse with alcohol-based mouthwash
62407725|NCT04719208|PLACEBO_COMPARATOR|Water (E)|Mouth rinse with water
62210675|NCT02942277|ACTIVE_COMPARATOR|4a|(n=10), to receive ENGERIX-B on D0, D28, and D168
62210676|NCT02942277|ACTIVE_COMPARATOR|4b|(n=10), to receive ENGERIX-B on DO, D28, and Dl68
62210677|NCT02942277|ACTIVE_COMPARATOR|4c|(n=120), to receive ENGERIX-B on D0, D28, and D168 (start study with Arm 2c and 2d); all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); vaccination with Menactra on D476
62407726|NCT06415032|EXPERIMENTAL|Quilting sutures without drain placement|
62407727|NCT06415032|ACTIVE_COMPARATOR|Conventional sutures with drain placement|
62407728|NCT02684370|PLACEBO_COMPARATOR|Placebo (Part A)|Participants randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
62407729|NCT02684370|ACTIVE_COMPARATOR|Ustekinumab (Part A)|Participants randomized to receive double-blind (DB) ustekinumab 45 mg or 90 mg (based on screening weight) by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
62407730|NCT02684370|EXPERIMENTAL|Risankizumab (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
62407731|NCT04340570|EXPERIMENTAL|Intervention|Receives pharmacist home televisit for medication management
62407732|NCT04340570|NO_INTERVENTION|Usual Care|Usual care for outpatient medication management
62407733|NCT00617266|ACTIVE_COMPARATOR|Arm 1 Control Group|Distribution of pamphlets containing information on the hazards of tobacco
62407734|NCT00617266|EXPERIMENTAL|Arm 2|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
62407735|NCT00617266|EXPERIMENTAL|Arm 3|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
62407736|NCT00617266|EXPERIMENTAL|Arm 4|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
62407737|NCT00959088||1|HIV-infected individuals with suspected TB co-infection.
62210678|NCT01325311|EXPERIMENTAL|Arm I (cholecalciferol, genistein)|Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
62210679|NCT01325311|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
62583133|NCT02865499|EXPERIMENTAL|acarbose|all participants will receive acarbose
62583134|NCT05249166|PLACEBO_COMPARATOR|Control group|Subjects assigned to this arm will follow the habitual recommendations to develop skills for a healthy diet. No specific foods or cooking methods will be applied
62210680|NCT05526651|EXPERIMENTAL|True electroacupuncture group|the investigators use stainless steel acupuncture needle, disposable : Huanqiu® 0.25 x 0.40 mm Electroacupuncture device : Hwato-SDZ V®, continuous wave, 2 Hz, for 30 minutes
62210681|NCT05526651|SHAM_COMPARATOR|sham electroacupuncture group|"the investigators use the same device like true electroacupuncture group, but the acupuncture needle not puncture on the skin and only attached.~electroacupuncture device, with no electrical stimulation"
62210682|NCT01998503|ACTIVE_COMPARATOR|BD induction followed by ASCT|The BD regimen included bortezomib 1.3 mg/m2 i.v. and dexamethasone 40 mg p.o. on days 1, 4, 8 and 11 of the 21 day cycle. This process was repeated for 2 cycles. After two cycles of BD therapy, the collection of peripheral blood stem cells (PBSC) should be completed within 4 weeks. Patients receive filgrastim (G-CSF) on days 1 to 5 and undergo autologous hematopoietic stem cell (HSC) collection. Patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day 0), while melphalan (day -2) with a dose of 140 or 200 mg/m2 (choosing a dose according to the degree of risk for patients). Melphalan will be administered by central venous catheter.
62210683|NCT01998503|EXPERIMENTAL|ASCT alone|the patients who assigned to this arm will receive ASCT alone as an initial treatment. At first, patients receive the collection of peripheral blood stem cells (PBSC), Patients receive filgrastim (G-CSF) on days 1 to 5 and undergo autologous hematopoietic stem cell (HSC) collection. After then patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day 0), while melphalan (day -2) with a dose of 140 or 200 mg/m2 (choosing a dose according to the degree of risk for patients). Melphalan will be administered by central venous catheter.
62210684|NCT06728878||Patients who received total gastrectomy with D2 lymphadenectomy plus complete mesogastric excision|No additional intervention is imposed on patients except normal clinical diagnosis and treatment.
62210685|NCT01133782|EXPERIMENTAL|Rapid result|Result of diagnostic PCR panel provided the following day
62210686|NCT01133782|NO_INTERVENTION|Delayed result|Result of dagnostic PCR panel provided within 10+/-2 days at follow-up visit.
62210687|NCT05009953|EXPERIMENTAL|Cohort 1: Irinotecan Liposome Injection + 5-FU/LV|The patients in cohort 1 will receive irinotecan liposome injection combined with 5-Fluorouracil (5-FU) and Leucovorin (LV) intravenously on days 1 of every 14-day cycle until disease progression or unacceptable toxicity, or termination of the study for other reasons.
62407738|NCT04998669|EXPERIMENTAL|Loncastuximab tesirine + Rituximab|"During the 12-week Induction Phase (Cycles 1 to 4), participants will receive loncastuximab tesirine on days 1 of each 3-week cycle for Cycles 1 through 4; and rituximab on days 1, 8, 15 of Cycle 1 and day 1 of Cycle 2.~Maintenance Phase 1 (Cycle 5) is 8 weeks: Participants achieving complete response (CR) or partial response (PR) during the Induction Phase will receive loncastuximab tesirine once every 3-weeks; and rituximab once during week 7 or 8. Participants achieving a response of Stable Disease (SD) or Progressive Disease (PD) will be taken off treatment.~Maintenance Phase 2 (Cycles 6 and 7) is 16 weeks:~* Participants achieving CR during Maintenance Phase 1 receive rituximab once during week 7 or 8 of Cycles 6 and 7.~* Participants achieving PR during Maintenance Phase 1 receive loncastuximab tesirine once every 3-weeks over each 8 week cycle; and rituximab once during week 7 or 8 of Cycles 6 and 7.~* Participants achieving SD or PD will be taken off treatment."
62583135|NCT05249166|EXPERIMENTAL|ALINFA group|This group will receive, in addition to the usual recommendations, meals, and foods designed to increase the healthiness of the diet. Foods and meals have been designed to increase the fiber content, decrease sugars and saturated fats, and limit salt intake.
62734507|NCT03281369|EXPERIMENTAL|1L-3: Atezo+Tiragolumab (Esophageal Cancer Cohort)|Participants in the 1L-3 Esophageal Cancer arm will receive atezolizumab + tiragolumab treatment. Participants from the cisplatin + 5-FU esophageal cancer cohort arm may be permitted to enroll in this arm if they progress after receiving chemotherapy.
62210688|NCT05009953|EXPERIMENTAL|Cohort 2: Irinotecan Liposome Injection + SG001 + 5-Fu/LV|The patients in cohort 1 will receive irinotecan liposome injection combined with SG001, 5-Fluorouracil (5-FU) and Leucovorin (LV) intravenously on days 1 of every 14-day cycle until disease progression or unacceptable toxicity, or until 24 months is reached, or the study is terminated for other reasons.
62210689|NCT01603134|EXPERIMENTAL|Allopurinol 300 mg Tablets USP|Allopurinol 300 mg Tablets USP of M/s Ipca Laboratories Limited, India
62210690|NCT01603134|ACTIVE_COMPARATOR|Zyloprim®|Zyloprim® (Allopurinol) 300 mg Tablets manufactured by Catalytica Pharma Inc., USA for Prometheus Laboratories Inc., USA,
62210691|NCT05840575||Solid tumor patients|Patients diagnosed with solid tumor cancers
62583136|NCT00959374|ACTIVE_COMPARATOR|V-loc and Monocryl|Subjects served as their own control, and they were randomized to receive an intervention of a standard closure using 3-0 Monocryl™ on one side of the body and the test closure device, V-Loc 180/90, on the other side. The standard closure technique was agreed on by study investigators for control side, and included mandatory closure of the deep dermal layer with interrupted 3-0 Monocryl™ sutures, spaced no further than 2 cm apart, followed by closure of the intradermal layer with running 3-0 Monocryl™ sutures. The test closure side, closure of the deep dermal layer was optional. If deep dermal sutures were used, interrupted 3-0 Monocryl™ sutures were required to be placed no closer than 5 cm apart followed by closure of the intradermal layer with test device, V-Loc 180/90.
62210692|NCT05840575||Haematological patients|Patients diagnosed with haematological cancers
62583137|NCT00608764||NHW COPD Participants|Non-Hispanic white participants with COPD
62210693|NCT01081132|EXPERIMENTAL|Extended-release Guanfacine HCl|
62210694|NCT01081132|PLACEBO_COMPARATOR|Placebo|
62210695|NCT00528931|EXPERIMENTAL|AA4500 0.58 mg|
62210696|NCT01018667||CRT group|
62210697|NCT01018667||OPT group|
62210698|NCT04630041|EXPERIMENTAL|Social Needs Assessment|Patients in the Emergency Department will complete a social needs assessment screener that may refer them to 211 services
62583138|NCT00608764||NHW Control Group|Non-Hispanic white participants with normal spirometry (do not have COPD)
62583139|NCT00608764||AA COPD Participants|African-American participants with COPD
62583140|NCT00608764||AA Control Group|African-American participants with normal spirometry (do not have COPD)
62210699|NCT06674915|EXPERIMENTAL|Treatment group A|Subjects with mild hepatic impairment.
62210700|NCT06674915|EXPERIMENTAL|Treatment group B|Subjects with moderate hepatic impairment.
62210701|NCT06674915|EXPERIMENTAL|Treatment group C|Subjects with normal hepatic function.
62210702|NCT00717431|EXPERIMENTAL|Hippocampal Stimulation|Hippocampal Stimulation (Stimulator is turned ON) Surgical Intervention
62210703|NCT00717431|SHAM_COMPARATOR|Hippocampal Implantation|Hippocampal Implantation (Stimulator is turned OFF)Surgical Intervention
62210704|NCT02885558|EXPERIMENTAL|L + T-type|8 weeks treatment with efonidipine (1 week 1x20mg, 7 weeks 2x20mg)
62210705|NCT02885558|ACTIVE_COMPARATOR|L-Type|8 weeks treatment with nifedipine (1 week 1x20mg, 7 weeks 2x20mg)
62210706|NCT03974139|EXPERIMENTAL|Obese patients|Patients with body mass index \>30
62210707|NCT01258595|EXPERIMENTAL|High-Dose Trivalent Inactivated Influenza Vaccine|
62210708|NCT01258595|ACTIVE_COMPARATOR|Trivalent Inactivated Influenza Vaccine|
62210709|NCT06729827|EXPERIMENTAL|Predictive monitoring - HPI|In the HPI-group the patients will be treated with a bolus of norepinephrine 5 mcg each time that HPI is 85 or higher.
62583141|NCT04936074|EXPERIMENTAL|Muscle preserving selective laminectomy (L-group)|Muscle-preserving selective laminectomy with a posterior midline incision and dissection through the nuchal fascia. The spinous processes are split in the midline using a high-speed burr/ultrasound knife and without disturbing the deep extensor muscles on either side. Angulating away from the midline, the spinous processes are divided at their bases. Laminectomy is performed with a width no more than 2-3 mm wider than the dural borders. The facet joints are not exposed. Finally, the split spionous processes are sutured together. No collar or restrictions will be used in either group.
62583142|NCT04936074|ACTIVE_COMPARATOR|Laminectomy with instrumented fusion (LF-group)|Laminectomy with instrumented fusion with a midline incision over the appropriate levels defined as the same levels as the extension of laminectomy plus one level above and below but not extending beyond C3-C7. Soft tissue dissection and retraction is performed to identify osseous landmarks. Special care is taken to spare muscle attachments on C2 and C7. Spinal instrumentation is performed with lateral mass or pedicle screws (C3-C7) combined with rod fixation. Laminectomy is performed with a width not extending more than 2 mm outside the dural borders. Facet joint injury should be avoided. Special care is taken to spare the C7 spinous process and distal half of C7 lamina. The sagittal alignment is corrected before spinal fixation. No collar or restrictions will be used in either group.
62583143|NCT03914963|EXPERIMENTAL|Fibrin sealant treatment hemipelvis|•Drug: Following the manufacturer´s instructions, 5 ml of sealant was sprayed evenly across the entire surgical bed in only one hemipelvis (the treated hemipelvis).
62583144|NCT03914963|PLACEBO_COMPARATOR|Control hemipelvis|Other hemipelvis
62583145|NCT02702388|EXPERIMENTAL|24 mg Lenvatinib|Participants will receive 24 mg once daily (QD) as the starting dose. Dose reductions will occur in succession based on the previous dose level (24, 20, 14, 10, or 8 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
62583146|NCT02702388|EXPERIMENTAL|18 mg Lenvatinib|Participants will receive 18mg QD as the starting dose. Dose reductions will occur in succession based on the previous dose level (18,14, 10, 8, or 4 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
62210710|NCT06729827|NO_INTERVENTION|Control group|In the control group a rescue bolus of norepinephrine 5 mcg will be administered by the anesthesia care provider whenever MAP decreases below 65 mmHg.
62583147|NCT03572738||Patients with HS|The set of all Hidradenitis Suppurativa patients (ICD-10 code: L73.2) who visited Wake Forest Baptist Medical Center's dermatology clinic during the last 5 years will either be recruited in person or be mailed the HS Severity Self-Assessment tool and a survey about their demographics, symptoms, treatments, psychological aspects, and lifestyle.
62583148|NCT04504071|OTHER|Dacomitinib Arm|This is a single arm study.
62210711|NCT03395262|EXPERIMENTAL|Active with caffeine|Novel formula with caffeine
62210712|NCT03395262|ACTIVE_COMPARATOR|Active without caffeine|Novel formula without caffeine
62210713|NCT03395262|PLACEBO_COMPARATOR|Placebo|Dextrose
62210714|NCT02503852|EXPERIMENTAL|Fat + High Dose ADRC|Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 1,000,000 ADRC prepared with the Celution System per square centimeter of scalp.
62210715|NCT02503852|EXPERIMENTAL|Fat + Low Dose ADRC|Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 500,000 ADRC prepared with the Celution System per square centimeter of scalp.
62210716|NCT02503852|ACTIVE_COMPARATOR|Fat Alone|Micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System per square centimeter of scalp.
62583149|NCT05028062|ACTIVE_COMPARATOR|XR-NTX 380 mg, intramuscular injection|Subjects will receive an injection of XR-NTX 380 mg (4 mL) repeated once after 4 weeks.
62583150|NCT05028062|PLACEBO_COMPARATOR|Inactive placebo intramuscular injection|Subjects will receive a placebo injection repeated once after 4 weeks.
62583151|NCT05038644|EXPERIMENTAL|Arm Z: Dose Level -1 for Group A (T-ALL, T-LBL)|0.1 mg intravenous (IV) Cycle (C) 1 Day (D) 1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.
62019226|NCT01376752|ACTIVE_COMPARATOR|maximal cytoreductive surgery without HIPEC|The participant will have a regular cytoreductive surgery without the adjunction of HIPEC.
62019227|NCT01376752|EXPERIMENTAL|maximal cytoreductive surgery with HIPEC|The participant will have a regular cytoreductive surgery, then the adjunction of HIPEC: hyperthermic cisplatin will be used at 75mg/m²
62019228|NCT06228092|ACTIVE_COMPARATOR|neostigmine/glycopyrrolate group|neostigmine/glycopyrrolate 50 mikrogr/kg
62019229|NCT06228092|ACTIVE_COMPARATOR|Sugammadex group|Sugammadex 2 mg/kg
62019230|NCT01984398|EXPERIMENTAL|12.5 mg Androxal (formulations A and B)|12.5 mg Androxal formulation A and 12.5 mg Androxal formulation B, a single dose of each formulation
62019231|NCT01984398|EXPERIMENTAL|25 mg Androxal (formulations A and B)|25 mg Androxal formulation A and 12.5 mg Androxal formulation B, a single dose of each formulation
62019232|NCT04018027|ACTIVE_COMPARATOR|Difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg tablet administered twice daily
62019233|NCT04018027|ACTIVE_COMPARATOR|Difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg tablet administered twice daily
62019234|NCT04018027|ACTIVE_COMPARATOR|Difelikefalin 1.0 mg|Oral difelikefalin 1.0 mg tablet administered twice daily
62019235|NCT04018027|PLACEBO_COMPARATOR|Placebo|Oral placebo tablet administered twice daily
62407739|NCT05214339|EXPERIMENTAL|TRIPLET|"Combination Product: Hepatic Arterial Infusion combined with Bevacizumab and Sintilimab Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Bevacizumab and Sintilimab for injection.~Procedure: 1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times. 2. Intravenous infusion of Bevacizumab 7.5mg/kg every 3 weeks on the 4th day. 3. On the 25nd day of treatment, namely the second session of HAIC, intravenous infusion of Sintilimab 200mg every 3 weeks. 4. The cumulative maximum drug use period is up to 1 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
62210717|NCT02503852|PLACEBO_COMPARATOR|No Fat Control|Micro-liposuction followed by subcutaneous scalp injection of normal saline per square centimeter of scalp.
62210718|NCT00957177|PLACEBO_COMPARATOR|Placebo|Placebo
62583152|NCT05038644|EXPERIMENTAL|Arm A: Dose Level 0 (Starting Dose) for Group A (T-ALL, T-LBL)|0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.
62583153|NCT05038644|EXPERIMENTAL|Arm B: Dose Level 1 for Group A (T-ALL, T-LBL)|0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.
62407740|NCT04150107|EXPERIMENTAL|Placebo then Treatment A then Treatment B|"Treatment administered in the following order:~1. Period 1: Placebo (Fish Oil Capsule)~2. Period 2: Treatment A: 24 mg ORMD-0801;(16 mg + 8 mg capsules) Once Daily (QD) at Bedtime~3. Period 3:Treatment B: 8 mg ORMD-0801; one 8 mg capsule three times a day (TID) 45-90 minutes before meals"
62583154|NCT05038644|EXPERIMENTAL|Arm C: Dose Level 2 Group A (T-ALL, T-LBL)|0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.
62583155|NCT05038644|EXPERIMENTAL|Arm D: Dose Level 3 Group A (T-ALL, T-LBL)|0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
62583156|NCT05038644|EXPERIMENTAL|Arm Z: Dose Level -1 Group B (AML)|0.1 mg IV C1D1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.
62210719|NCT00957177|ACTIVE_COMPARATOR|Pregabalin group|Receiving 300mg pregabalin preoperative
62583157|NCT05038644|EXPERIMENTAL|Arm A: Dose Level 0 (Starting Dose) Group B (AML)|0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.
62210720|NCT06727617|EXPERIMENTAL|Serplulimab plus chemoradiotherapy group|Serplulimab plus chemoradiotherapy group
62407741|NCT04150107|EXPERIMENTAL|Placebo then Treatment B then Treatment A|"Treatment administered in the following order:~1. Period 1: Placebo (Fish Oil Capsule)~2. Period 2:Treatment B: 8 mg ORMD-0801; one 8 mg capsule three times a day (TID) 45-90 minutes before meals~3. Period 3: Treatment A: 24 mg ORMD-0801;(16 mg + 8 mg capsules) Once Daily (QD) at Bedtime~Treatment B: 8 mg ORMD-0801; one 8 mg capsule three times a day (TID) 45-90 minutes before meals"
62407742|NCT03362411|EXPERIMENTAL|BMS-986205 intact tablet orally then crushed tablet orally|Single, 100 mg dose
62583158|NCT05038644|EXPERIMENTAL|Arm B: Dose Level 1 Group B (AML)|0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.
62583159|NCT05038644|EXPERIMENTAL|Arm C: Dose Level 2 Group B (AML)|0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.
62583160|NCT05038644|EXPERIMENTAL|Arm D: Dose Level 3 Group B (AML)|0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
62583161|NCT05545514|EXPERIMENTAL|Verum|"Individualized homeopathy (iHOM):~One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000, individually selected as indicated per homeopathic treatment principles. The HMPs are sucrose pillules, impregnated with the specific homeopathic substance and potency and will be administered once at baseline: 5 pillules sublingually. The dosage of the HMP can be repeated or adapted according to the homeopathic treatment principles three times during the course of the study and, in addition, in the event of an acute UTI."
62210721|NCT06727617|PLACEBO_COMPARATOR|chemoradiotherapy group|chemoradiotherapy group
62210722|NCT02523859|ACTIVE_COMPARATOR|Propofol|Propofol for induction will be given as a bolus administered manually at 2.0-2.5 mg/kg slowly over approximately 1 minute. Immediately after the propofol bolus for induction has been given, propofol maintenance will be started at a dose of 3.0-9.0 mg/kg/hr and adjusted as needed.
62210723|NCT02523859|EXPERIMENTAL|Remimazolam|Remimazolam for induction will be given at 6.0 mg/kg/hr, which can be increased to 12.0 mg/kg/hr for one minute if loss of consciousness is not reached after 3 minutes. Immediately after the remimazolam dose for induction has been given, remimazolam maintenance will be given at 1.0 mg/kg/hr and adjusted by down-titration or up-titration to a maximum of 3.0 mg/kg/hr.
62583162|NCT05545514|PLACEBO_COMPARATOR|Placebo|Non-impregnated sucrose pillules, identical to the HMP (verum) in appearance, taste and size.
62583163|NCT06003998|EXPERIMENTAL|Intraperitoneal irinotecan 75 mg + mFOLFOX-4 and bevacizumab|Intraperitoneal irinotecan, 75 mg flat dose + systemic oxaliplatin, 5-Fluorouracil and bevacizumab (mFOLFOX+beva) (dose via standard of care)
62583164|NCT06502054||Autistic parents|Parents who fulfill the main diagnosis of ASD, which includes atypical autism (ICD-10: F84.1) and Asperger syndrome (ICD-10: F84.5), who are ≥ 18 years old and have a child aged 0 to 6 years are included.
62583165|NCT06502054||Non-autistic parents|Parents are included who do not have a lifetime main diagnosis of a psychiatric illness (ICD-10-GM-2016: F10 - F69), who are ≥ 18 years old and have a child aged 0 to 6 years.
62583166|NCT05793801|ACTIVE_COMPARATOR|Control group|Patients receiving normal management with dressings changed once a week according to the SF2H recommendations.
62583167|NCT05793801|EXPERIMENTAL|Experimental group|Patients whose dressings are changed every other day.
62583168|NCT00625417|EXPERIMENTAL|Optical spectroscopy on tumor margins|Optical spectroscopy is performed on breast tumor margins obtained from patients undergoing surgery
62583169|NCT06682065|EXPERIMENTAL|Telemedicine|WhatsApp algorithmic chatbot see further description
62583170|NCT06682065|ACTIVE_COMPARATOR|Standard Care|Standard of care contraceptive counseling with clinic nurse
62210724|NCT01986270|PLACEBO_COMPARATOR|Placebo|
62210725|NCT01986270|EXPERIMENTAL|Eletriptan 40 mg|
62210726|NCT01986270|EXPERIMENTAL|Eletriptan 80 mg|
62210727|NCT01986270|EXPERIMENTAL|Sumatriptan 25 mg|
62210728|NCT01986270|EXPERIMENTAL|Sumatriptan 50 mg|
62210729|NCT01749111|EXPERIMENTAL|Arm A|Graft versus host disease prophylaxis will be done with cyclophosphamide 50 mg/kg on day +3 and day +4
62210730|NCT01749111|ACTIVE_COMPARATOR|Arm B|In this arm, patients will receive a combination of methotrexate and a calcineurin inhibitor as graft versus host disease prophylaxis
62210731|NCT04547283|ACTIVE_COMPARATOR|Usual Care|Participants randomized to this arm will remain in their clinician's team standard practice and their natural choice of position, which is anticipated to favor a supine (rather than prone) position.
62210732|NCT04547283|EXPERIMENTAL|Awake-Prone Positioning Strategy|Participants randomized to this arm will receive guidance from their Inpatient treatment team to assume the prone position for as much time as is tolerable during hospitalization.
62210733|NCT02819427||epilepsy|children with absence epilepsy presenting either typical or atypical seizures
62210734|NCT04482959|EXPERIMENTAL|Carbetocin group|This group will contain 20 patients having single type 0 or I submucous uterine myomas according to International Federation of Gynecology and Obstetrics classification system with a largest diameter ≤ 4 cm and myometrial free margin of at least 10 mm.After induction of general anesthesia, immediately before the operation, participants will receive either 1 ml of carbetocin (100 mcg/ml) IV over 1 minute.
62583171|NCT04850495|EXPERIMENTAL|Treatment (zanubrutinib, R-CHOP)|Patients receive zanubrutinib PO on days 1-21, rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62210735|NCT04482959|PLACEBO_COMPARATOR|• Control group|This group will contain 20 patients having single type 0 or I submucous uterine myomas according to International Federation of Gynecology and Obstetrics classification system with a largest diameter ≤ 4 cm and myometrial free margin of at least 10 mm.After induction of general anesthesia, immediately before the operation, participants will receive either 1 ml of sodium chloride 0.9% IV over 1 minute.
62210736|NCT03578887|ACTIVE_COMPARATOR|Lifestyle Cohort|Participants Undergoing Behavioral Weight Loss Program
62210737|NCT03578887|ACTIVE_COMPARATOR|Surgical Cohort|Participants Scheduled for Roux-en-Y Gastric Bypass Surgery
62583172|NCT00677703|NO_INTERVENTION|Standard Care|Participants will receive standard care without daily reminders.
62583173|NCT00677703|EXPERIMENTAL|Text Messages|Participants will receive a daily text message reminder for 6 months
62583174|NCT01841762|EXPERIMENTAL|Macitentan|Macitentan tablet, dose of 10 mg, once daily
62583175|NCT02857244|OTHER|Open-Label Treatment Arm|"Each patient will take Duloxetine 30mg for 1 week, followed by 60mg qam for 1 week, 90mg qam for 1 week, and 120mg qam for 1 week, if tolerated. The patient will be taking Duloxetine for a total of 4 weeks. The dose of Duloxetine will be reduced if the patient cannot tolerate. Donepezil will then be added to Duloxetine 120mg qam (or the highest dose the patient can tolerate) by 5mg qd for 1 week, followed by 10mg qd for 1 week.~After a 4-week washout period, each patient will take Modafinil 100mg qam for one week, followed by 200mg qam for 1 week.~Patients will come into the medical center on 5 occasions, 1 for screening/baseline, 1 after completion of duloxetine, 1 after completion of duloxetine+donepezil, 1 after four-week washout, 1 after completion of modafinil."
62583176|NCT03083015|EXPERIMENTAL|Revascularization|Blood clot initiation and grey MTA ( Mineral Tri-oxide Aggregate) cervically compacted.
62583177|NCT03083015|ACTIVE_COMPARATOR|Apexfication|Apexification using grey MTA apically compacted without mechanical preparation.
62583178|NCT03916315|EXPERIMENTAL|Transdiagnostic Treatment|Participants in this group will receive from 11 to 17 sessions of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
62583179|NCT03916315|NO_INTERVENTION|Control group|The participants in this group will not receive the treatment, just waiting list. They will be measured one time and then a second time 3 months after. Calculating when 3 months corresponding to 11-12 sessions will take place in the intervention group.
62583180|NCT04532619|EXPERIMENTAL|Intervention|6 weeks of Fathering Through Change videos and 3 individual coaching calls.
62583181|NCT04532619|NO_INTERVENTION|Control|Links to parenting websites
62583182|NCT04581603|ACTIVE_COMPARATOR|MED + CBT-I|This arm will consist of patients treated with topiramate, naltrexone, or topiramate + naltrexone on a clinical basis for 6 weeks and then randomized to Cognitive Behavioral Therapy for Insomnia (CBT-I). They will be continued on MED for the next 8 weeks of CBT-I treatment.
62583183|NCT04581603|PLACEBO_COMPARATOR|MED + SHE|This arm will consist of patients treated with topiramate, naltrexone, or topiramate + naltrexone for 6 weeks on a clinical basis for 6 weeks and then randomized to Sleep Hygiene Education (SHE). They will be continued on MED for the next 8 weeks of SHE treatment.
62583184|NCT03312920|EXPERIMENTAL|active anodal tDCS|active anodal tDCS with Face Name associate Memory task
62583185|NCT03312920|SHAM_COMPARATOR|Sham tDCS|sham tDCS with Face Name associate Memory task
62583186|NCT03312920|EXPERIMENTAL|active cathodal tDCS|active cathodal tDCS with Face Name associate Memory task
62583187|NCT06078150|EXPERIMENTAL|Experimental group: Active video game intervention for 1-6 weeks|One hour three times a week for weeks 1-6 of the intervention (consisting of a 20-minute warm-up and a 40-minute AVG game).
62210738|NCT03578887|NO_INTERVENTION|Healthy Weight Control Cohort|Healthy Weight Controls With No Intervention
62210739|NCT04838275|EXPERIMENTAL|Exercise Arm|antifibrotic therapy + mHealth monitoring + 12-wk mHealth home exercise prescription
62210740|NCT04838275|NO_INTERVENTION|Non-Exercise Arm|antifibrotic therapy + mHealth monitoring
62210741|NCT01174576|EXPERIMENTAL|caffeinated coffee|200 mL caffeinated coffee with 3 mg caffeine per kg body weight
62210742|NCT01174576|EXPERIMENTAL|decaffeinated coffee|200 mL decaffeinated coffee, same amount as caffeinated coffee
62210743|NCT01174576|EXPERIMENTAL|Water|200 mL, control intervention
62210744|NCT06452225|EXPERIMENTAL|External Oblique Intercostal Plane Block|Patients will receive external oblique intercostal plane block.
62583188|NCT06078150|EXPERIMENTAL|Experimental group: Active video game intervention for 7-12 weeks|One hour three times a week for weeks 7-12 of the intervention (consisting of a 10-minute warm-up and a 50-minute AVG game).
62583189|NCT03867136|EXPERIMENTAL|PZA sensitivity guided ultra-short all Oral Regimen|The PZA sensitivity guided ultra-short regimen consists of two periods of 24-36 weeks. During the first 4-8 weeks(waiting for pyrazinamide drug sensitivity test), the regimen consists of levofloxacin, linezolid, cycloserine, pyrazinamide, and clofazimine. Then based on molecular PZA drug sensitivity results, patients will be in divided into two sub-groups: pyrazinamide-susceptible (PZA-S) patients and pyrazinamide-resistant (PZA-R) patients. The Regimen for PZA-S patients, consisting of levofloxacin, linezolid, cycloserine, and pyrazinamide, are given until the 24th week (prolonged to 28 or 32 weeks if no smear conversion by end of 16th and 20th week). PZA-R sub-group regimen, consisting of levofloxacin, linezolid, cycloserine, and clofazimine given until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week)
62019236|NCT05075317|ACTIVE_COMPARATOR|Standard cardiac rehabilitation|The 16-week program consists of physician-directed risk factor management, an individualized aerobic and resistance exercise prescription, and virtual education on disease management and lifestyle behaviors (including exercise safety, stress management, and heart-healthy nutrition), and an assessment with a registered dietitian and individualized recommendations for a heart-healthy diet. Additionally, selected patients with identified issues such as depression, anxiety, trouble sleeping, anger and social and emotional issues will receive one-on-one counselling with a psychologist or social worker.
62210745|NCT06452225|EXPERIMENTAL|Transversus Abdominis Plane Block|Patients will receive ultrasound guided transversus abdominis plane block.
62210746|NCT06078293|EXPERIMENTAL|Exercise|All participants in this single-arm trial will be in the exercise arm and receive the home-based exercise program.
62583190|NCT03867136|ACTIVE_COMPARATOR|Standardized Shorter Regimen|WHO standardized shorter regimen group consists of 36-44 weeks with two phases of treatment. The first is an intensive phase of 16 weeks (extended up a maximum of 20 or 24 weeks in case of lack of smear conversion at the end of 16 or 20 weeks), and included moxifloxacin, amikacin, prothionamide, pyrazinamide, high-dose isoniazid, ethambutol and clofazimine. This is followed by a continuation phase of 20 weeks with the following agents: moxifloxacin, pyrazinamide, ethambutol and clofazimine.
62210747|NCT06203782||Experimental Group|In the experimental group, 51 patients underwent endoscopic stricturoplasty. A transparent cap was mounted on the front end of the endoscope, and a needle knife was inserted through the working channel of the endoscope. Under direct visualization, a radial incision was made at the site of the stricture, with an effort to preserve normal mucosal tissue as much as possible. The stricture was gradually incised until the endoscope could smoothly pass through.
62583191|NCT04690595|EXPERIMENTAL|BAFFR-CAR T cells|B-cell activating factor receptor-Chimeric antigen receptor T cells
62583192|NCT00623389|EXPERIMENTAL|Implant|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.
62210748|NCT06203782||Control Group|In the control group, 51 patients underwent endoscopic balloon dilation. The endoscope was advanced to the site of the stricture, and a dilation guidewire was inserted. After placing the balloon, it was progressively inflated with pressure, each inflation lasting 1-2 minutes, and this process was repeated 2-3 times until the endoscope and sheath could pass through the narrowed segment and enter the distal colon.
62210749|NCT02472990|OTHER|Duchenne muscular dystrophy children|"No drug and no placebo were used in this study. For 2h30 (time)~* Measurement of leg strength using a dynamometer~* Measurement of Motor Function~* Walk test 6 minutes~* Walk test 10 meters~* Walk analysis: 3D recording of walking~* Muscle MRI"
62210750|NCT02472990|OTHER|Healthy children|"No drug and no placebo were used in this study. For 2h30 (time)~* Measurement of leg strength using a dynamometer~* Measurement of Motor Function~* Walk test 6 minutes~* Walk test 10 meters~* Walk analysis: 3D recording of walking~* Muscle MRI"
62210751|NCT00864201|EXPERIMENTAL|bosentan|
62210752|NCT06419413||Cohort A|up to 100 healthy participants,
62210753|NCT06419413||Cohort B|up to 200 mild asthmatics on as-needed low dose inhaled corticosteroids (ICS)-formoterol, or low dose ICS plus as-needed short-acting β2 agonists (SABA), without the need for other controller medication
62583193|NCT02157285|NO_INTERVENTION|Routine Counseling|Subjects randomized to receive routine counseling before selecting a method of contraception
62583194|NCT02157285|EXPERIMENTAL|Peer Mentor counseling|Subjects randomized to receive peer counseling before selecting a method of contraception
62019237|NCT05075317|EXPERIMENTAL|Standard cardiac rehabilitation + TRE|Participants in this group will receive the same standard assessment and individualized recommendations as the comparator group, but will also be counselled to restrict their eating to between 11 am and 7 pm during the program starting the evening of the consultation. They will also be advised to perform their home-based exercise sessions during the fasting period in the morning.
62019238|NCT02310438|EXPERIMENTAL|Early intervention music therapy|"music therapy:~6 stroke patients with hemiparesis begin music therapy treatment in their home as soon as they have completed statutory NHS community rehabilitation."
62210754|NCT06419413||Cohort C|up to 300 moderate to severe asthmatics on low or medium dose ICS-long acting β2 agonists (LABA), high dose ICS alone or in combination with LABA with pre-bronchodilator FEV1 \<80% predictedu
62210755|NCT06419413||Cohort D|up to 200 asthmatics with protocol defined asthma exacerbation.
62210756|NCT02828787|EXPERIMENTAL|Urticaria|15 patients with urticaria
62407743|NCT03362411|EXPERIMENTAL|BMS-986205 crushed tablet orally, then intact tablet orally|Single, 100 mg dose
62583195|NCT02953210|EXPERIMENTAL|GF general free|pre induction midazolam 50ug.kg-1, clonidine 1ug.kg induction dexter ketamine 0.2mg.kg, lidocaine 1.5mg.kg, propofol 2mg.kg,rocuronium 0.6mg.kg maintenance isoflurane 1 CAM, lidocaine 2mg.kg.h
62583196|NCT02953210|ACTIVE_COMPARATOR|GBal general balanced|pre induction with midazolam 50 ug.kg induction fentanyl 3ug.kg, propofol 2mg.kg, rocuronium 0.6mg.k maintenance isoflurane 1 CAM and fentanyl as needed
62583197|NCT06646822||study group|"Undergraduate students at a large public university in Egypt who were 18 years of age or older took the survey in 2024. All survey and recruitment materials were approved by Minia University, faculty of pharmacy.~Students were received survey through email. Students took the survey online at a time and location of their choice."
62583198|NCT06341855|OTHER|ctDNA positive|If the ctDNA test result is positive, the subjects will be stratified to the treatment group or follow-up group at 1:1.
62019239|NCT02310438|ACTIVE_COMPARATOR|Delayed intervention music therapy|"music therapy:~6 stroke patients with hemiparesis begin music therapy treatment in their home 9 weeks after they have been randomised into the wait list group."
62019240|NCT02799433|ACTIVE_COMPARATOR|Usual Services|This group of child care centers receives standard services from the San Francisco Department of Public Health Child Care Health Program. CCHP offers services to child care centers annually. The standard services include nurse consultation, health education, monitoring of nutrition and physical activity resource need, vision, hearing, oral health, and height and weight screenings.
62019241|NCT02799433|EXPERIMENTAL|Usual services + HAP|This group of child care centers receives all the standard services plus invitation to participate in the voluntary Healthy Apple Program (HAP). The Healthy Apple program involves child care provider self-assessment, followed by an iterative process of goal setting, technical assistance/training, and re-assessment.
62407744|NCT03362411|EXPERIMENTAL|BMS-986205 intact tablet orally then suspension via NG tube|Single, 100 mg dose
62407745|NCT03362411|EXPERIMENTAL|BMS-986205 suspension via NG tube then intact tablet orally|Single, 100 mg dose
62407746|NCT04480502|EXPERIMENTAL|Cohort A|Patients treated with 300 mg of single agent envafolimab every three weeks
62407747|NCT04480502|EXPERIMENTAL|Cohort B|Patients treated with envafolimab in combination with ipilimumab. Envafolimab will be given at 300 mg every three weeks. Ipilimumab will be given at 1 mg/kg every three weeks for a total of four doses.
62407748|NCT04480502|EXPERIMENTAL|Cohort C|Patients treated with 600 mg of single agent envafolimab every three weeks
62407749|NCT04480502|EXPERIMENTAL|Cohort D|Patients treated with envafolimab in combination with ipilimumab. Envafolimab will be given at 600 mg every three weeks. Ipilimumab will be given at 1 mg/kg every three weeks for a total of four doses.
62407750|NCT00926042||Healthy Control|Healthy control group for research on autoimmune diseases
62407751|NCT01305460|EXPERIMENTAL|Azacitidine intensified dose|
62407752|NCT02816658|ACTIVE_COMPARATOR|Laparoscopic Surgery|Laparoscopic Inguinal Hernia Repair through a Transabdominal, Preperitoneal Approach
62019242|NCT01773915||AD patients|Subject fulfilling the McKhann criteria for clinical probable AD
62019243|NCT01773915||Healthy elder persons|Healthy controls with abscence of any cognitive disorder
62407753|NCT02816658|ACTIVE_COMPARATOR|Robotic Surgery|Robotic Inguinal Hernia Repair
62407754|NCT03891602||Clinicians|Primary care clinicians (general internists, family physicians, nurse practitioners, physician assistants) who treat lung cancer screening eligible patients
62407755|NCT03891602||Smokers/Former Smokers|Current smoker or former smoker who has quit within the past 15 years
62407756|NCT06327204|ACTIVE_COMPARATOR|Group I|patient received one session / week
62407757|NCT06327204|ACTIVE_COMPARATOR|group II|patient received two session / week
62407758|NCT06327204|ACTIVE_COMPARATOR|Group III|Patient received three session / week
62407759|NCT03078504|EXPERIMENTAL|Experimental arm|The patients will have the blood flow rate adjusted on CRRT gradually increased to assess the effect on hemodynamics
62407760|NCT00335816|EXPERIMENTAL|Group 1 (Closed to Enrollment)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil intravenously continuously over 24 hours 7 days a week for 6 weeks. Patients undergo standard surgical resection after completion of chemoradiation therapy..
62407761|NCT00335816|EXPERIMENTAL|Group 2 (Closed to Enrollment)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1-2. Treatment repeats every 14 days for 2 courses. After the last week of post-radiation chemotherapy, patients undergo standard surgical resection.
62407762|NCT00335816|EXPERIMENTAL|Group 3 (chemotherapy, FOLFOX, conventional surgery)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy as in group II. Treatment repeats every 14 days for 4 courses. After the last week of post-radiation chemotherapy, patients undergo standard surgical resection.
62407763|NCT00335816|EXPERIMENTAL|Group 4 (chemotherapy, FOLFOX, conventional surgery)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy as in group II. Treatment repeats every 14 days for 6 courses. After the last week of post- radiation chemotherapy, patients undergo standard surgical resection. Patients then receive 3 additional courses of FOLFOX-6 chemotherapy or other chemotherapy off study as directed by the physician.
62407764|NCT02706015|EXPERIMENTAL|Cefaliv® & Placebo|Dihydroergotamine mesylate+ dipyrone sodium + caffeine
62210757|NCT02828787|EXPERIMENTAL|Psoriasis|15 patients with psoriasis
62210758|NCT02828787|OTHER|healthy|15 healthy control subjects
62407765|NCT02706015|ACTIVE_COMPARATOR|Neosaldina® & Placebo|Isometheptene mucate + dipyrone sodium + anhydrous caffeine
62407766|NCT03087227|EXPERIMENTAL|NEUTROSIS Intervention Group|The NEUTROSIS Intervention group captures daily its temperature and the occurrence of other symptoms on the smartphone application. This information is then transmitted instantly to the hospital care team through the NEUTROSIS shared information system. The medical oncologist will be alerted in case of fever and will contact the patient.
62407767|NCT03087227|NO_INTERVENTION|CONTROL Group|The control group will monitor daily its temperature and the occurrence of other symptoms on a paper surveillance diary and will have to contact the health team in case of fever as done in the usual care.
62583199|NCT06341855|OTHER|ctDNA negative|If the ctDNA test result is negative, the subjects will belong to follow-up group
62583200|NCT02789722|EXPERIMENTAL|Yerba Mate Extract 750 mg|Yerba Mate Extract - Capsules: daily dose of 2.250 g, distributed in 3 doses of 750 mg, for 28 days.
62019244|NCT05036642|EXPERIMENTAL|Stroke Survivors|Stroke survivors with upper extremity motor impairments
62019245|NCT01954017|EXPERIMENTAL|STP206|Biological
62019246|NCT01954017|PLACEBO_COMPARATOR|Control|Sterile water
62019247|NCT05492136|NO_INTERVENTION|Arm 1: Control|"In this arm it will be permitted one/several conventional methods according to surgeon preference:~* Conventional crusch-clamp or finger fracture technique~* Ultrasonic dissector (CUSA, SONOK..) or Ultrasonic mediated devices~* Water jet dissector~* Argon beam coagulator"
62583201|NCT02789722|PLACEBO_COMPARATOR|Placebo|Starch - Capsules: 3 times daily for 28 days.
62019248|NCT05492136|EXPERIMENTAL|Arm 2: study arm|In this arm it will be permitted to use the radiofrequency devices which have demonstrated evidence in the literature in terms of reducing local recurrence alone or in combination with any conventional method described previously in Arm. (Coolingbis device by VecMedical as well as Aquamantys (Medtronic) These devices and their operating procedure have been described in detail elsewhere Briefly, it consists of a handheld instrument that might be employed not only for margin coagulation but also as hemostatic instrument. After performing the hepatectomy the bladeless part of the device should be applied onto the surgical margin following the protocol 3-4 s/cm2 of liver transection surface at maximum power output.in order to perform an additional margin coagulation
62019249|NCT06155981|EXPERIMENTAL|Coke Zero Arm|The participant will be given a Coke Zero before each night-call duty for consumption.
62019250|NCT06155981|ACTIVE_COMPARATOR|Coke Arm|The participant will be given a Coke before each night-call duty for consumption.
62210759|NCT06444815|EXPERIMENTAL|Group A: VET3-TGI alone intratumoral|Dose escalation of VET3-TGI alone administered by direct injection into tumor(s) x 4. Booster injections of VET3-TGI are permitted for up to 2 years.
62210760|NCT06444815|EXPERIMENTAL|Group B: VET3-TGI intratumoral in combination with pembrolizumab|VET3-TGI will be given in combination with pembrolizumab at the highest tolerated dose from Group A. Pembrolizumab will be administered via intravenous (IV) infusion for up to 2 years.
62210761|NCT06444815|EXPERIMENTAL|Group C: VET3-TGI alone intravenous|Dose escalation of VET3-TGI alone administered by IV infusion x 6. Booster infusions of VET3-TGI are permitted for up to 2 years.
62210762|NCT06444815|EXPERIMENTAL|Group D: VET3-TGI intravenous in combination with pembrolizumab|VET3-TGI will be given in combination with pembrolizumab at the highest tolerated dose from Group C. Pembrolizumab will be administered via intravenous (IV) infusion for up to 2 years.
62210763|NCT03199118|EXPERIMENTAL|CAF+SCTG+PRF|The patients suffering from class I or II gingival recession in the intervention group will receive a subepithelial connective tissue graft (SCTG) covered by platelet rich fibrin membrane (PRF) followed by a coronally advanced flap (CAF)
62583202|NCT01585740|ACTIVE_COMPARATOR|Normal Saline|250 patients in this arm assigned to receive normal saline as the study fluid
62583203|NCT01585740|ACTIVE_COMPARATOR|Ringer's Lactate|250 patients in this arm assigned to receive Ringer's Lactate as the study fluid
62210764|NCT03199118|ACTIVE_COMPARATOR|CAF+SCTG|Control group patients with class I or II gingival recession will receive treatment that consists of CAF+SCTG only
62210765|NCT06728683|EXPERIMENTAL|ASSIST-MH|Participants in the focus group will all be given the same set of study tasks. They will participate in a 60-minute virtual focus group and then rate the proposed Assist-MH product components. Participants in the pilot test will complete the same study tasks as others in their respective group: one group for providers and one group for students. All providers will (a) attend a brief webinar to review research methods and be trained to use Assist-MH, (b) use Assist-MH over a 2-month period with at least 3 students, (c) obtain parent consent for students to use Assist-MH and evaluate their experience, (d) complete pre \& post provider outcomes measures, and (e) rate their experiences with the prototype. All students will (a) use Assist-MH, (b) complete pre \& post student outcomes measures, and (c) rate their experiences with the prototype.
62210766|NCT06727864|EXPERIMENTAL|Intervention/Treatment|Two months of isoniazid (H), ethambutol (E), rifampicin (R) and Pyrazinamide (Z) followed by HR(E) for another two months
62210767|NCT06727864|ACTIVE_COMPARATOR|6-months HERZ (2HERZ/4HRE)|Two months of isoniazid (H), pyrazinamide (Z), rifampicin (R) and Pyrazinamide (Z) followed by HR(E) for another four months
62210768|NCT04772898|EXPERIMENTAL|Children with Autism Spectrum Disorders|Children with autism spectrum disorder will receive a 6 week (once per week) hippotherapy protocol. During the hippotherapy session, the researchers will monitor the heart rate variability of the horse and the rider. Both horse and rider will wear an electrode strap around the upper thorax. Heart rate recordings will be started simultaneously at the beginning of the HPOT session. To assess movement coupling between the horse and rider, five tri-axial inertial sensors (OPAL, APDM, Inc, Portland, OR) will be used. The sensors will collect actively synchronized tri-axial accelerometer and gyroscope data. One inertial sensor will be placed dorsal at the rider's pelvis, one frontal at the top of the forehead, and one frontal at the top of the sternum. The sensors on the horse will be fixed on the back of the horse on the spine level between T8 and T10 and on the head.
62210769|NCT04772898|ACTIVE_COMPARATOR|Children with typical development|Children with autism spectrum disorder and with typical development will receive a 6 week (once per week) hippotherapy protocol. During the hippotherapy session, the researchers will monitor the heart rate variability of the horse and the rider. Both horse and rider will wear an electrode strap around the upper thorax. Heart rate recordings will be started simultaneously at the beginning of the HPOT session. To assess movement coupling between the horse and rider, five tri-axial inertial sensors (OPAL, APDM, Inc, Portland, OR) will be used. The sensors will collect actively synchronized tri-axial accelerometer and gyroscope data. One inertial sensor will be placed dorsal at the rider's pelvis, one frontal at the top of the forehead, and one frontal at the top of the sternum. The sensors on the horse will be fixed on the back of the horse on the spine level between T8 and T10 and on the head.
62210770|NCT05438940|EXPERIMENTAL|STRONG-GEC|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth and remote monitoring through a smart phone app and wearable sensor to allow participants to log food intake while sharing their data with a dietician.
62210771|NCT03537495|NO_INTERVENTION|Control arm|"Subjects in this arm will only receive high-dose rifampicin (\~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.~High-dose rifampicin will consist of weight-banded fixed-dose combination (FDC), including rifampicin (R), isoniazid (H), pyrazinamide (Z) and ethambutol (E) according to international guidelines, combined with 900 mg rifampicin (≤37 kg: two 450 mg tablets) or 1200 mg rifampicin (\>37 kg: two 600 mg tablets) to reach \~35 mg/kg rifampicin in total."
62210772|NCT03537495|EXPERIMENTAL|Linezolid 600|Subjects in this arm will receive 600 mg linezolid QD along with high-dose rifampicin (\~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
62210773|NCT03537495|EXPERIMENTAL|Linezolid 1200|Subjects in this arm will receive 1200 mg linezolid QD along with rifampicin 1350 mg (\~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
62210774|NCT04812197|OTHER|Skin Biopsies|Patients undergo punch biopsies of inflamed and non-inflamed skin and a blood sample collection.
62407768|NCT02505841|ACTIVE_COMPARATOR|Group 1|Curare: Atracurium injection at 0.5 mg/kg
62407769|NCT02505841|EXPERIMENTAL|Group 2|TAP block and curare: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg then atracurium injection at 0.5 mg/kg
62210775|NCT01076647|EXPERIMENTAL|IDeg 3TW|
62210776|NCT01076647|ACTIVE_COMPARATOR|IGlar OD|
62407770|NCT02505841|EXPERIMENTAL|Group 3|TAP block: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
62407771|NCT06342661||Control|
62407772|NCT06342661||Case|
62407773|NCT05185791||Pre-ERAS® implementation phase|"* Current clinical practice~* Current perioperative management~* All consecutive patients included for CRS+-HIPEC treatment~* Period of inclusion : 3 months (01.10.2021 - 31.12.2021)~* Survey of intended changes in clinical practice will be sent to each leader center~No specific intervention. Only descriptive recordings of pre-intra-post-operative clinical endpoints (ERAS® core items) and demographic parameters.~Clinical and surgical outcomes will be recorded until 30 postoperative days (POD). Functional recovery parameters will be recorded for the first 5 POD"
62583204|NCT06608563|ACTIVE_COMPARATOR|Fissure sealant without adhesive system (NO BOND)|Teeth randomised to the control group will be using issure sealant without adhesive system (NO BOND)
62583205|NCT06608563|EXPERIMENTAL|Fissure sealant with adhesive system (BOND)|Teeth randomised to the test group will be treated using fissure sealant with adhesive system (BOND)
62583206|NCT05359419|EXPERIMENTAL|Ameluz|AMELUZ® (aminolevulinic acid hydrochloride) gel, 10% with its approved light source (BF-RhodoLED® lamp, 635 nm ± 9 nm, Biofrontera, Inc., Wakefield, MA, US)
62583207|NCT05359419|ACTIVE_COMPARATOR|Levulan|LEVULAN® KERASTICK® (aminolevulinic acid HCl) topical solution, 20% with its approved light source (BLU-U® Blue light photodynamic Therapy Illuminator Model 4170, 417 nm ± 5 nm, DUSA Pharmaceuticals, Wilmington MA, US)
62583208|NCT05808868||OSA screening|To
62583209|NCT02207803|EXPERIMENTAL|Intervention|Experimental Transition Assistance Program
62583210|NCT02207803|NO_INTERVENTION|Control|Control
62019251|NCT03669081|EXPERIMENTAL|Toradol and Lyrica|Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
62019252|NCT03669081|PLACEBO_COMPARATOR|Placebo and Standard of Care|Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.
62019253|NCT05356559|ACTIVE_COMPARATOR|Fish protein|
62019254|NCT05356559|PLACEBO_COMPARATOR|Control|
62019255|NCT02890381|EXPERIMENTAL|RSV LID cp ΔM2-2 Vaccine|Participants received a single dose of the RSV LID cp ΔM2-2 vaccine at study entry (Day 0).
62019256|NCT02890381|PLACEBO_COMPARATOR|Placebo|Participants received a single dose of placebo at study entry (Day 0).
62210777|NCT04796012|EXPERIMENTAL|Feasibility Cohort: Patients with relapsed or refractory solid tumors|Six (6) participants with relapsed or refractory solid tumor will be enrolled. Atezolizumab will be administered in combination with vincristine, irinotecan, and temozolomide for up to 2 years or until the participant experiences disease progression or an unacceptable toxicity.
62407774|NCT05185791||Post-ERAS® implementation phase|"* After implementation 2 months of delay before starting the recordings~* Clinical practice and perioperative management with new practice according guidelines and local commitment for the new change~* All consecutive patients included for CRS±HIPEC treatment~* Period of inclusion : 3 months (01.03.2022 - 31.05.2022)~* Max 2 months of delay allowed between the two phases~Intervention will take place during an implementation period of 2 months. This period will let the centers to set the newly implemented clinical practices.~After that, the remaining 3 months of the study will consist in descriptive recordings of pre-intra and post-operative clinical endpoints and demographic parameters (ERAS® core items).~Clinical and surgical outcomes will be recorded until 30 postoperative days (POD). Functional recovery parameters will be recorded for the first 5 POD."
62019257|NCT04365036|EXPERIMENTAL|toripalimab with P-GemOx|Patients will receive toripalimab and induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent toripalimab of 240mg will be administered every 3 weeks for 3 cycles during IMRT. Toripalimab 240mg will be given every 3 weeks for 13 cycles, started on day 1 of induction chemotherapy.
62019258|NCT04365036|ACTIVE_COMPARATOR|P-GemOx|Patients will receive induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given.
62019259|NCT00816634|ACTIVE_COMPARATOR|1|"Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr repeat every 3 weeks"
62019260|NCT00816634|ACTIVE_COMPARATOR|2|"XT Regimen:~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs Repeat every 3 weeks"
62019261|NCT05204459||RRMS, SPMS, PPMS, CIS or RIS|Multiple Sclerosis (relapsing-remitting, primary or secondary progressive forms), clinically isolated syndrome, or radiologically isolated syndrome
62019262|NCT05204459||NMOSD|Neuromyelitis optica spectrum disorders
62019263|NCT05204459||MOGAD|Myelin oligodendrocyte glycoprotein antibody disorders
62019264|NCT05204459||Neurological disorder other than MSRD|Neurological disorders due to neurodegenerative, vascular, or headache conditions that are not related to multiple sclerosis or related disorders.
62210778|NCT04796012|EXPERIMENTAL|Rhabdomyosarcoma (RMS) Cohort: Patients with rhabdomyosarcoma|Seventeen (17) participants with RMS, including the six participants from the Feasibility Cohort, will be enrolled. At least 8 of the RMS participants must have a tumor that expresses the protein PD-L1. Atezolizumab will be administered in combination with vincristine, irinotecan, and temozolomide for up to 2 years or until the participant experiences disease progression or an unacceptable toxicity.
62210779|NCT02527863|ACTIVE_COMPARATOR|60 mg Tolvaptan|Oral administration of 60 mg tolvaptan on each examination day.
62210780|NCT02527863|PLACEBO_COMPARATOR|Placebo|Oral administration of a Unikalk tablet.
62210781|NCT05143398|ACTIVE_COMPARATOR|Diet Arm|low-calorie diet normoproteic with an energy deficit of 15% compared to what emerged from the calorimetric value (basal REE)
62210782|NCT05143398|ACTIVE_COMPARATOR|Protein Arm|low-calorie diet normoproteic + an integration of 8.72 g of protein in the form of a nutritional supplement (18-20% protein)
62019265|NCT05204459||Healthy controls|Healthy controls with no known neurological conditions
62019266|NCT01595516|ACTIVE_COMPARATOR|Nebivolol|
62019267|NCT01595516|ACTIVE_COMPARATOR|Metoprolol|
62019268|NCT01595516|PLACEBO_COMPARATOR|Placebo|
62019269|NCT01595516|OTHER|Bradykinin|
62019270|NCT01595516|OTHER|Saline|
62019271|NCT01595516|OTHER|Vitamin C|
62019272|NCT03727893|ACTIVE_COMPARATOR|Roller-based intervention Group (IG)|A group participating in a high-intensity exercise on a roller-based system.
62019273|NCT03727893|PLACEBO_COMPARATOR|Control Group (CG)|A group participating in an independent workout program at an accessible community-based fitness facility.
62019274|NCT04689386|EXPERIMENTAL|"Group I Stimulation of reflex rolling from the Vojta method"|
62019275|NCT04689386|EXPERIMENTAL|Group II Expiratory flow increase technique|
62019276|NCT04689386|NO_INTERVENTION|Control Group|Routine intervention in the NICU with mechanical ventilation.
62583211|NCT03424772||Patients with unexplained DD/ID|Whole genome sequencing will be performed on pediatric patients with unexplained developmental delay(DD)/intellectual disability(ID), multiple congenital abnormalities and other rare and undiagnosed diseases.
62019277|NCT06535815|ACTIVE_COMPARATOR|Interventional: Cyclic enteral nutrition with ketogenic nighttime fasting|"Interventional group:~12 hours of enteral feeding (as per patients´individual calorimetric requirements measured by indirect calorimetry) followed by a fasting period of 12 hours supported by the supplementation of exogenous ketone salts."
62583212|NCT00886743|OTHER|Oprelvekin as subcutaneous injection (50 mg/kg once daily)|Open label treatment with oprelvekin
62583213|NCT05088460|EXPERIMENTAL|Study Arm 1|Randomized to placebo for 12 weeks and then crossover to REGN4461 for 12 weeks
62210783|NCT05143398|ACTIVE_COMPARATOR|EAA Arm|low-calorie diet normoproteic + amino acid supplement (2 sachet/daily; 1 sachet contains protein 0 gr, carbohydrates 6.69 gr , lipids 0 gr, i-leucine 1,2 gr, i-isoleucine 0,6 gr, i-valine 0,6 gr).
62210784|NCT05143398|ACTIVE_COMPARATOR|EAA + TCA|low-calorie diet normoproteic + an amino acid supplement (2 stick/daily; 1 stick pack contains protein 0 gr, carbohydrates 1,046 gr, lipids 0.074 gr, i-leucine 1.2 gr, i-isoleucine 0.6 gr, i-valine 0.6 gr, citric acid, succinic acid and malic acid)
62210785|NCT04406415|EXPERIMENTAL|10 mg|10 mg nafamostat three times a day (t.i.d., approximately q8h) for up to 5 days
62210786|NCT04406415|EXPERIMENTAL|50 mg|50 mg nafamostat three times a day (t.i.d., approximately q8h) for up to 5 days
62210787|NCT04406415|EXPERIMENTAL|100 mg|100 mg nafamostat three times a day (t.i.d., approximately q8h) for up to 5 days
62210788|NCT04406415|EXPERIMENTAL|200 mg|200 mg nafamostat three times a day (t.i.d., approximately q8h) for up to 5 days
62210789|NCT04406415|PLACEBO_COMPARATOR|Placebo|Placebo administered three times a day (t.i.d., approximately q8h) for up to 5 days
62210790|NCT01854398|EXPERIMENTAL|CPAP group|
62210791|NCT01854398|SHAM_COMPARATOR|sham-CPAP group|
62210792|NCT04781257||Household contacts with co-prevalent/incipient TB|Household contacts diagnosed with active TB at baseline/during the study period
62407775|NCT06302075|EXPERIMENTAL|One Day Rehabilitation|discharged home the day after the operation (24 hours) and carrying out outpatient rehabilitation according to the clinical standard
62583214|NCT05088460|EXPERIMENTAL|Study Arm 2|Randomized to receive REGN4461 for 24 weeks
62019278|NCT06535815|NO_INTERVENTION|Control: Conventional continuous enteral nutrition|Control group Continuous enteral nutrition for 24 hours (as per patients´ individual caloric requirements defined by indirect calorimetry).
62019279|NCT03510481|EXPERIMENTAL|Experimental arm 1: Dosing interval 0, 8, 16, and 54 weeks|Participants received 3 doses of PfSPZ Vaccine (9 x 10\^5) via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
62210793|NCT04781257||Household contacts staying healthy|Household contacts without active TB who remain healthy throughout the study
62210794|NCT06057194|EXPERIMENTAL|Letermovir (prospective cohort)|2 tablets of 240 milligrams (mg) Letermovir orally once daily. during 12 months
62210795|NCT06057194|NO_INTERVENTION|Valganciclovir (retrospective cohort)|Retrospective cohort, of patients treated with Valganciclovir during 12 months
62210796|NCT02111317|EXPERIMENTAL|ASP015K and verapamil|Single dose of ASP015K, then repeat dose of verapamil, then a second single dose of ASP015K while continuing verapamil
62210797|NCT05506774||Cohort A: Participants With cHL.|Participants who diagnosed with cHL between January 1, 2018 and March 31, 2021, and have demographic and clinical data available in hospital information system (HIS)/electronic medical records (EMRs) or laboratory information management will be observed retrospectively from the date of diagnosis with cHL until death, loss to follow-up, or end of the study, whichever occurs first.
62210798|NCT05506774||Cohort B: Participants With NHL.|Participants who diagnosed with NHL between January 1, 2018 and March 31, 2021, and have demographic and clinical data available in HIS/EMRs or laboratory information management will be observed retrospectively from the date of diagnosis with NHL until death, loss to follow-up, or end of the study, whichever occurs first.
62407776|NCT06302075|ACTIVE_COMPARATOR|Fast Rehabilitation|discharged to the rehabilitation department of the Institute 48 hours after surgery which carries out rehabilitation during the hospital stay according to the clinical standard
62735053|NCT02720523|EXPERIMENTAL|Upadacitinib 30 mg / Upadacitinib 30 mg|"Period 1: Participants will receive upadacitinib 30 mg once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks."
62019280|NCT03510481|EXPERIMENTAL|Experimental arm 2: Dosing interval 0, 1, 4, and 42 weeks|Participants received 3 doses of PfSPZ Vaccine (9 x 10\^5) via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
62210799|NCT05977959|EXPERIMENTAL|Mentoring Program|Participants in this group will receive the Mentoring Program strategy in addition to Healthy School Recognized Campus.
62407777|NCT03804372|EXPERIMENTAL|Study group|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
62407778|NCT03215602|EXPERIMENTAL|NEMEX and education + strength training|"Participants will undergo 12 weeks of twice weekly exercise. Each exercise session will last for 70-90 min. and will consist of 1 hour of specific exercises to optimize sensorimotor control and achieve compensatory functional stability performed in a multiple-joint weight-bearing specific manner. The final part of the session will consist of focused knee extensor strength training performed in gym machines (knee extension \& leg-press) in a combination of low-load fatiguing exercises (knee-extension) followed by high-load exercises (leg-press).~Additionally, participants will receive 2 educational sessions, which include disease- and exercise specific counseling."
62583215|NCT06441487|EXPERIMENTAL|Trial Mailed FIT Intervention|Subjects randomized to this arm receive a link to a mobile health decision support tool (mPATH™-Cloud). Within mPATH™-Cloud, subjects are invited to answer brief questions to confirm eligibility, view a video to help them identify their CRC screening preference, and request either colonoscopy or fecal immunochemical test (FIT) screening from their primary care provider. Subjects who do not click on the link or select a screening test receive a FIT mailed to their home address.
62583216|NCT06441487|ACTIVE_COMPARATOR|Trial Usual Care|Subjects randomized to this arm receive usual care. Current usual care at the participating community health centers consists of a visit-based colorectal cancer screening recommendation and referral.
62583217|NCT02425878|EXPERIMENTAL|Experimental|Ulipristal Acetate 10 mg, Oral administration. Dose: 10 mg per day, single dose, duration 12 weeks
62583218|NCT02425878|PLACEBO_COMPARATOR|Control|Placebo, 10 mg, Oral administration. Dose: 10 mg per day, single dose, duration 12 weeks
62583219|NCT06448767|EXPERIMENTAL|Multispecies probiotics group|55 participants
62583220|NCT06448767|PLACEBO_COMPARATOR|Control group|55 participants
62583221|NCT01983033|EXPERIMENTAL|active treatment condition (ATC)|training protocol 'drop it'
62583222|NCT01983033|OTHER|waiting list control|no treatment other than treatment as usual
62583223|NCT03921788||Group 1|Patients with venous pelvic pain. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
62210800|NCT05977959|EXPERIMENTAL|Enhanced Resources|Participants in this group will receive the Enhanced Resources strategy in addition to Healthy School Recognized Campus.
62210801|NCT05977959|EXPERIMENTAL|Enhanced Engagement|Participants in this group will receive the Enhanced Engagement strategy in addition to Healthy School Recognized Campus.
62210802|NCT05977959|NO_INTERVENTION|No Intervention|All schools will participate in the HSRC initiative. The requirements for the initiative are to complete a school-wide walking program, 1 youth, and 1 adult program from a list of available programs that make up the initiative.
62210803|NCT05977959|EXPERIMENTAL|Mentoring + Enhanced Resources|Participants in this group will receive the Mentoring Program and Enhanced Resources strategies in addition to Healthy School Recognized Campus.
62210804|NCT05977959|EXPERIMENTAL|Mentoring + Enhanced Engagement|Participants in this group will receive the Mentoring Program and Enhanced Engagement strategies in addition to Healthy School Recognized Campus.
62210805|NCT05977959|EXPERIMENTAL|Enhanced Resources + Enhanced Engagement|Participants in this group will receive the Enhanced Resources and Enhanced Engagement strategies in addition to Healthy School Recognized Campus.
62583224|NCT03921788||Group 2|Patients without venous pelvic pain. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
62583225|NCT03921788||Group 3|Volunteers without pain syndromes of any location. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
62210806|NCT05977959|EXPERIMENTAL|Mentoring + Enhanced Resources + Enhanced Engagement|Participants in this group will receive the Mentoring Program, Enhanced Resources, and Enhanced Engagement strategies in addition to Healthy School Recognized Campus.
62210807|NCT06728956|OTHER|main|"Participant outcomes will be measured at multiple time points (baseline, week 8 and month 6).~assess for any change to outcome variables over time using repeated measures ANOVA, this provides only an overview of interventional impact and assumes homogenous change within the study group.~Latent Growth Curve Modelling (LGCM) can be useful to identify patterns within subgroups of a population to understand who benefits from an intervention and why. Latent Growth Curve Modelling (LGCM) will be used to determine trajectories over time. Changes from baseline to week 8 and baseline to month 6 will be assessed."
62210808|NCT05570773|EXPERIMENTAL|peer support program|"A researcher and peer tutors met students in an online session for 30 minutes every day between 21:00 and 21:30 before bedtime for 30 days. These sessions focused on academic problem solving and academic encouragement of students. In addition, peer tutors and students shared their contact information and continued their sharing by talking on the phone and messaging in the chat group 24/7.~Selection and education of peer tutors: 5 peers with strong communication skills and high academic achievement were selected among the 4th-year volunteer students. These 5 volunteers were selected among students who were not included in the sample, had an appropriate level of anxiety (anxiety score ≤36), and had good sleep quality (PSQI score ≤5). A theoretical and practical session was held with them. In these sessions, peer-supported education was explained and necessary information was given about its purpose and how it was performed."
62210809|NCT05570773|EXPERIMENTAL|progressive relaxation exercise group|The importance of the exercise and how it should be done were explained by the researcher Mixed teaching methods, including lecturing, demonstration, question-answer, and discussion were, used as education methods. The sessions were carried out online by a researcher who is an expert in the field of PRE for 30 minutes every day between 21:00 and 21:30 before bedtime for 30 days.
62210810|NCT05570773|NO_INTERVENTION|control group|The students who formed the control group through randomization were given information about the research, and then they submitted informed consent. Control group students were given the same questionnaire as a pre-and-post-test applied in the intervention groups, but no intervention was applied.
62210811|NCT04134988|EXPERIMENTAL|Medimoov|Bi-weekly 35-minute sessions of an adaptated physical activity administered by a psychomotor therapist for 8 weeks.
62210812|NCT04134988|ACTIVE_COMPARATOR|Standard rehabilitation|Bi-weekly 35-minute sessions of the standard psychomotor therapy for 8 weeks.
62407779|NCT03215602|ACTIVE_COMPARATOR|NEMEX and education|"Participants will undergo 12 weeks of twice weekly exercise. Each exercise session will last for approximately 60 min. and will consist of 1 hour of specific exercises to optimize sensorimotor control and achieve compensatory functional stability performed in a multiple-joint weight-bearing specific manner.~Additionally, participants will receive 2 educational sessions, which include disease- and exercise specific counseling."
62407780|NCT04445259||Critically Ill Patients with COVID-19|We plan to recruit patients who are admitted to intensive care units with COVID-19 diagnosis.
62407781|NCT03910309||1 or 2 level TLIF candidates|Any subject determined to ALREADY be a candidate for 1 or 2 level transforaminal interbody fusion surgery
62583226|NCT02340715||MRI for treatment planning or follow up|MRI for treatment planning for radiation therapy or those who have completed treatment and are receiving follow up care.
62210813|NCT04330924|EXPERIMENTAL|Virtual Reality|3D avatar in a virtual simulation environment
62210814|NCT04330924|NO_INTERVENTION|Live Simulation|Live-based simulation in a simulation ward
62583227|NCT06372587|EXPERIMENTAL|Alzheimer's disease patients|To test engineered proteins in human neurons derived from skin biopsy from Alzheimer's disease patients
62583228|NCT06372587|SHAM_COMPARATOR|Neurotypical control patients|To test engineered proteins in human neurons derived from skin biopsy from neurotypical control patients
62583229|NCT02078973|ACTIVE_COMPARATOR|15 mg tolvaptan|Oral administration of 15 mg tolvaptan on each examination day.
62210815|NCT01317173||Progressive disease|Serum creatinin level rise more than 2 times
62210816|NCT01317173||Non-progressive disease|Serum creatinin level rise less than 2 times
62583230|NCT02078973|ACTIVE_COMPARATOR|30 mg tolvaptan|Oral administration of 30 mg tolvaptan on each examination day.
62583231|NCT02078973|ACTIVE_COMPARATOR|45 mg tolvaptan|Oral administration of 45 mg tolvaptan on each examination day.
62583232|NCT02078973|PLACEBO_COMPARATOR|Placebo|Oral administration of a Unikalk tablet
62583233|NCT05163457||aged of 75 and more living at home|"aged of 75 and more living at home group: patients aged of 75 and more living at home"
62583234|NCT06681948|EXPERIMENTAL|Ketogenic diet|"The subjects initially enter the screening phase (≤ 2 weeks); following randomization, they undergo the titration period (≤ 2 weeks), gradually titrating to the maximum dose stipulated in the protocol or the maximum tolerable dose for the subject; during the treatment period (26 weeks), but if intolerance emerges during the treatment, the subject can revert to the previous tolerated dose for continued treatment.~The dosage was titrated incrementally until reaching the maximum daily dose of 30g \* 3 meals/day as stipulated in the protocol or the maximum tolerable daily dose for the subject. After entering the treatment period (from week 3 to week 28), this dose was maintained for 26 weeks."
62735054|NCT02272036|ACTIVE_COMPARATOR|SMS receiving|Study participants of the SMS group receive in total 14 short messages (SMS) containing time adjusted information on colonoscopy preparation starting 4 days before colonoscopy appointment on their mobile phones.
62407782|NCT05199714|EXPERIMENTAL|Fiasp-and-pramlintide fully automated system (8μg)|Fiasp and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 8μg of pramlintide.
62407783|NCT05199714|ACTIVE_COMPARATOR|Fiasp-alone with carbohydrate-matched boluses|The Fiasp-alone intervention will have a 14 hour duration. During which, carbohydrate counting will inform insulin bolus doses based on insulin to carbohydrate ratios.
62019281|NCT03510481|PLACEBO_COMPARATOR|Placebo comparator 3a: Dosing interval 0, 8, 16, and 54 weeks|Control for Arm 1. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
62019282|NCT03510481|PLACEBO_COMPARATOR|Placebo comparator 3b: Dosing interval 0, 1, 4, and 42 weeks|Control for Arm 2. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
62019283|NCT01523691|EXPERIMENTAL|repeated sleep restriction and recovery|
62583235|NCT06681948|PLACEBO_COMPARATOR|Control|"The subjects initially enter the screening phase (≤ 2 weeks); following randomization, they undergo the titration period (≤ 2 weeks), gradually titrating to the maximum dose stipulated in the protocol or the maximum tolerable dose for the subject; during the treatment period (26 weeks), but if intolerance emerges during the treatment, the subject can revert to the previous tolerated dose for continued treatment.~The dosage was titrated incrementally until reaching the maximum daily dose of 30g \* 3 meals/day as stipulated in the protocol or the maximum tolerable daily dose for the subject. After entering the treatment period (from week 3 to week 28), this dose was maintained for 26 weeks."
62583236|NCT06670170|EXPERIMENTAL|Sequence 1|Participants will receive a single dose of PF-07976016 in up to 3 study periods. In sequence 1, participants will receive formulation A followed by formulation B. There will be 7 days between each dose as a wash out period.
62583237|NCT06670170|EXPERIMENTAL|Sequence 2|Participants will receive single doses of PF-07976016 in up to 3 study periods. In sequence 2, participants will receive formulation B followed by formulation A. There will be 7 days between each dose as a wash out period.
62583238|NCT03706378|OTHER|Glucose Reference 1|50g glucose dissolve in 250 ml of water
62583239|NCT03706378|OTHER|Glucose Reference 2|50g glucose dissolve in 250 ml of water
62583240|NCT03706378|OTHER|Glucose Reference 3|50g glucose dissolve in 250 ml of water
62583241|NCT03706378|EXPERIMENTAL|Wheat Yellow Noodle|Boiled 170.6g of wheat yellow noodle
62583242|NCT03706378|EXPERIMENTAL|Beta-glucan Yellow Noodle|Boiled 230.4g of beta-glucan yellow noodle.
62583243|NCT03706378|EXPERIMENTAL|Rice Roll|Steamed 197.6g of rice roll
62583244|NCT03706378|EXPERIMENTAL|Rice Roll with resistant starch|Steamed 232.6g of rice roll fortified with resistant starch
62583245|NCT03706378|EXPERIMENTAL|Sucrose jelly|Jelly made with 25g of sucrose and 48g of wheat white bread
62583246|NCT03706378|EXPERIMENTAL|Isomaltulose jelly|Jelly made with 25g of isomaltulose and 48g of wheat white bread
62583247|NCT05908032|EXPERIMENTAL|CM310 group|Subcutaneous injection， CM310 4ml for first dose and 2ml for following dose
62583248|NCT05908032|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection，matching placebo
62583249|NCT04439214|EXPERIMENTAL|Treatment (nivolumab)|Patients receive nivolumab IV over 30-60 minutes on days 1 and 15 of cycles 1-4 and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62019284|NCT01523691|EXPERIMENTAL|control sleep|
62019285|NCT03468439|OTHER|femoral nerve block|
62019286|NCT04599881|EXPERIMENTAL|PTR-01 3 mg/kg|All patients will receive a PTR-01 dose of 3.0 mg/kg once weekly every week for a total of 4 doses, followed by a dose of 3.0 mg/kg every other week for a total of 7 doses.
62019287|NCT01100463|PLACEBO_COMPARATOR|Placebo Lotion|
62019288|NCT01100463|EXPERIMENTAL|0.1% Uracil|
62019289|NCT02233712|EXPERIMENTAL|Group 1|G17DT; 250 µg dose administered at 0, 1, and 3 weeks.
62019290|NCT02233712|EXPERIMENTAL|Group 2|G17DT; 100 µg dose administered at 0, 1, and 3 weeks.
62019291|NCT02233712|EXPERIMENTAL|Group 3|G17DT; 500 µg dose administered at 0, 1, and 3 weeks.
62019292|NCT02233712|EXPERIMENTAL|Group 4|G17DT; 500 µg dose administered at 0, 2, and 6 weeks.
62019293|NCT04828759|EXPERIMENTAL|VR-treatment, then Treatment as usual|Participants will receive 8 weeks of VR-treatment. Participants are allowed to practice as much as they wish during the VR-intervention. However, they are given a recommendation of the amount of practice (5 h / week). Before the VR-intervention, the participants will receive a guidance for using the VR-devices (i.e. orientation period) by the SLT. Participants will be able to contact the SLT freely during the 8 weeks VR-intervention period. After the orientation period, the participants will be practicing at their homes independently. However, they will receive remote guidance by the SLT. The guidance includes weekly remote guidance sessions by SLT (8 x 45 min) to ensure that training is fluent and unproblematic. Additionally, the content of exercises can be modified during these sessions. The SLT is also able to monitor the training of participants with the system. Devices: VR headset and controller, Tablet computer.
62019294|NCT04828759|EXPERIMENTAL|Treatment as usual, then VR-treatment|Wait list control group: During the waitlist period the participants will receive the traditional speech and language therapy rehabilitation offered by (if offered) the general health care system in their own home municipality. The amount of rehabilitation is not controlled during the wait list period. However, the amount of received traditional speech and language rehabilitation in waitlist period will be documented. The waitlist control group will receive the same VR intervention period after the 8 weeks waitlist period.
62210817|NCT00766545|EXPERIMENTAL|cilostazol|cilostazol oral tablet 100 mg, twice daily
62210818|NCT00766545|PLACEBO_COMPARATOR|placebo|placebo of cilostazol, twice daily
62210819|NCT02101619||Moderate aortic stenosis.|
62210820|NCT02101619||Severe aortic stenosis.|
62210821|NCT05648630|EXPERIMENTAL|Exercise Rehabilitation+PB125|Participants will be assigned to the Exercise+Placebo or Exercise+PB125 rehabilitation interventions using block randomization.
62210822|NCT05648630|PLACEBO_COMPARATOR|Exercise Rehabilitation with Placebo|Participants will be assigned to the Exercise+Placebo rehabilitation interventions using block randomization.
62210823|NCT05161221|ACTIVE_COMPARATOR|Pre-operative femoral nerve catheter|participants undergoing ACL reconstruction surgery will receive a femoral prior to their surgery
62210824|NCT05161221|ACTIVE_COMPARATOR|Pre-operative adductor canal block with liposomal bupivacaine|participants undergoing ACL reconstruction surgery will receive a nerve block using liposomal Bupivacaine (Exparel)
62210825|NCT02478268|ACTIVE_COMPARATOR|Patients with idiopathic pulmonary fibrosis|
62210826|NCT02478268|ACTIVE_COMPARATOR|Healthy volunteers|
62210827|NCT01026532||Segmental antigen challenge|Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
62210828|NCT05626790|EXPERIMENTAL|PNF Stretching|All participants will join an exercise program that will last 20-30 minutes, 5 days a week for 4 weeks, especially targeting proximal stabilization. In addition to the exercises, three different types of PNF stretching will be applied to the participants in the PNF stretching group for 4 weeks, 5 days a week.
62210829|NCT05626790|ACTIVE_COMPARATOR|Prolonged Stretching|"All participants will join an exercise program that will last 20-30 minutes, 5 days a week for 4 weeks, especially targeting proximal stabilization. The exercise program is expected to take 20-30 minutes. Each exercise will be done in 3 sets. Each set will include 10 repetitions. In weight-bearing exercises, the participant will be asked to hold the position for 10 seconds.~In addition to the exercises given to both of the groups, static stretching will be applied to the elbow flexors in 2 different positions for 4 weeks, 5 days a week."
62019295|NCT03072901||EndoBarrier Gastrointestinal Liner|244 subjects; The registry will be open to subjects who meet the EndoBarrier's Indications for Use and none of the Contraindications in the device's Instructions For Use document. Subjects who successfully receive the device implant at a participating registry center will be included in the registry.
62019296|NCT00803894|ACTIVE_COMPARATOR|A|MK0752 1000 mg
62210830|NCT06007768||Fabry Disease|Patients with Fabry disease, older than 18 years, and without autoimmune or autoinflammatory diseases.
62019297|NCT00803894|ACTIVE_COMPARATOR|B|MK0752 350 mg
62210831|NCT06007768||Control|Subjects without Fabry disease or autoimmune/autoinflammatory diseases, matched for age (± 5 years) and sex.
62210832|NCT04761900||participants were followed for the incidence of T2DM in a cohort study|performed a cohort analysis for T2DM. For incident T2DM cases, calculate the follow-up time from the date of enrollment into our study to the date of T2DM diagnosis.
62407784|NCT05199714|EXPERIMENTAL|Aspart-and-pramlintide fully automated system (10μg)|Aspart and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 10μg of pramlintide.
62407785|NCT05199714|EXPERIMENTAL|Fiasp-and-pramlintide fully automated system (10μg)|Fiasp and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 10μg of pramlintide.
62407786|NCT05199714|EXPERIMENTAL|Aspart-and-pramlintide fully automated system (8μg)|Aspart and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 8μg of pramlintide.
62407787|NCT06653231|ACTIVE_COMPARATOR|SRP with local delivery of Curcumin gel|Scaling and root planing in combination with local delivery of Curcumin gel
62019298|NCT00803894|PLACEBO_COMPARATOR|C|Placebo
62407788|NCT06653231|ACTIVE_COMPARATOR|SRP alone|Scaling and root plaing alone
62583250|NCT06684782||Patients with parkinson's disease|
62019299|NCT04364282||Parent-Child Dyads Taking Part in Weight-Management Programs|Participants in this study will be children and their parents taking part in existing pediatric weight-management programs at participating sites. All participants will be seen at baseline and 6-months for data collection visits.
62019300|NCT04606953|EXPERIMENTAL|Attention Process Training (APT-II)|Patients in the experimental group receive the APT-II training program (Attention Process Training) individually with a psychologist for 8 weeks (2 sessions/week). The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to each patient's profile in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains towards the most problematic daily activities in order to reduce the impact of the patients' cognitive problems in their daily lives.
62019301|NCT04606953|NO_INTERVENTION|Standard care|Patients in the control group receive standard routine care.
62019302|NCT01858454|EXPERIMENTAL|HALS for myomectomy|Hand-assisted laparoscopic surgery for myomectomy
62210833|NCT04761900||participants were followed for the incidence of hypertension in a cohort study|performed a cohort analysis for hypertension. For incident hypertension cases, calculate the follow-up time from the date of enrollment into our study to the date of hypertension diagnosis.
62583251|NCT03310164||COPD|Smokers with clinically stable chronic obstructive pulmonary disease (COPD)
62210834|NCT04761900||participants were followed for the incidence of carotid atherosclerotic plaque in a cohort study|performed a cohort analysis for carotid atherosclerotic plaque. For incident carotid atherosclerotic plaque cases, calculate the follow-up time from the date of enrollment into our study to the date of carotid atherosclerotic plaque diagnosis.
62210835|NCT02989818||Lesion of the Gastrointestinal tract|Investigator will collect prospective data on the Endoscopic Submucosal dissection that is used as part of the subjects standard of care to remove the Gastrointestinal lesion
62210836|NCT02182947|EXPERIMENTAL|Endoscopy Imaging|Wireless-video capsule endoscopy (WCE) compared to the findings of MRE magnetic resonance enterography in same group of patients.
62583252|NCT03310164||healthy control|Age-matched subjects without chronic obstructive pulmonary disease (COPD)
62210837|NCT06465953|EXPERIMENTAL|Ivosidenib monotherapy|
62583253|NCT01198158|ACTIVE_COMPARATOR|Arm I (everolimus)|Patients receive everolimus PO QD on days 1-28.
62583254|NCT01198158|EXPERIMENTAL|Arm II (everolimus with bevacizumab)|Patients receive everolimus PO QD on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 15.
62210838|NCT06465953|EXPERIMENTAL|Azacitidine monotherapy|
62019303|NCT01858454|ACTIVE_COMPARATOR|Open myomectomy|Open surgery for myomectomy
62583255|NCT03733145|EXPERIMENTAL|Participants on ACE inhibitors|Participants taking ACE inhibitors (angiotensin-converting enzyme inhibitors)will be placed into this group. Intervention: Drug: Angiotensin II.
62019304|NCT05797779|EXPERIMENTAL|Skin biopsy|
62019305|NCT04574362|ACTIVE_COMPARATOR|Rimegepant 75mg|One 75mg oral disintegration tablet
62210839|NCT03395977|PLACEBO_COMPARATOR|Placebos PO and IV|PO : per os IV : intraveinously
62210840|NCT03395977|EXPERIMENTAL|Febuxostat PO and Placebo IV|240 mg a day for 3 days
62210841|NCT03395977|EXPERIMENTAL|Febuxostat PO And Rasburicase IV|Febuxostat : 240 mg a day for 3 days. Uricase : 3 mg once.
62583256|NCT03733145|EXPERIMENTAL|Participants on ARBs|Participants taking ARBs (angiotensin-receptor blockers) will be placed into this group. Intervention: Drug: Angiotensin II.
62583257|NCT03733145|EXPERIMENTAL|Other Classes of Antihypertensive Agents|Participants taking any other class of Antihypertensive Agents will be placed into this group. Intervention: Drug: Angiotensin II.
62210842|NCT03395977|EXPERIMENTAL|Placebo PO And Rasburicase IV|Placebo : for 3 days. Uricase : 3 mg once.
62210843|NCT06329973|EXPERIMENTAL|Fruquintinib in combination with Sintilimab and CAPEOX|
62210844|NCT04766359|EXPERIMENTAL|Albumin-Bound paclitaxel combined with radiotherapy|"Albumin paclitaxel (100mg/m2), D1 intravenous drip, start the first week of radiotherapy, use it continuously for 4-6 weeks.~Radiotherapy: The total dose is 66-70Gy, divided into 33-35 times to complete."
62210845|NCT04766359|EXPERIMENTAL|Cisplatin combined with radiotherapy|"Cisplatin (40mg/m2), D1 intravenous drip, start the first week of radiotherapy, use it continuously for 4-6 weeks.~Radiotherapy: The total dose is 66-70Gy, divided into 33-35 times to complete."
62210846|NCT02060539|EXPERIMENTAL|Biofinity XR|Participants dispensed Biofinity XR lenses over two weeks of lens wear
62210847|NCT04642248|ACTIVE_COMPARATOR|Non-intervention|This group will have the analysis and their data will be used to determine risk factors for developing running injuries.
62210848|NCT04642248|EXPERIMENTAL|Intervention|This group will get a personalized program based off of 3D and movement analysis results to judge the ability to reduce musculoskeletal injuries.
62210849|NCT01980680|EXPERIMENTAL|Agonist trigger|Agonist trigger Buserelin 0,5 mg and Pregnyl (hCG)
62210850|NCT01980680|ACTIVE_COMPARATOR|hCG|hCG trigger Pregnyl (hCG) and Progesterone and Estradiol
62210851|NCT05229276|EXPERIMENTAL|Sternum Guard|The treatment of interest was Sternum GuardTM application during sternotomy.
62210852|NCT05229276|ACTIVE_COMPARATOR|Bone wax|The 'bone wax' arm was the control group of active comparator as the widely-used materials during sternotomy.
62210853|NCT04237168||DLBCL patients|newly diagnosed DLBCL (de novo, all ages) patients treated with RCHOP (first-line treatment regimen)
62210854|NCT00506441|EXPERIMENTAL|1|
62210855|NCT00506441|PLACEBO_COMPARATOR|2|
62210856|NCT02367547|EXPERIMENTAL|Hexylaminolevulinate cream|2% Hexylaminolevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream
62210857|NCT02367547|EXPERIMENTAL|Aminolevulinic Acid Nano Emulsion|78 mg/g Aminolevulinic Acid Nano Emulsion
62210858|NCT02367547|ACTIVE_COMPARATOR|Methylaminolevulinate cream|160 mg/g Methylaminolevulinate cream
62210859|NCT06728189|EXPERIMENTAL|CAR-NKT Cells Lymphodepleting regimen|Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells Lymphodepleting regimen, Cyclophosphamide 250mg/m2 IV on day -5 to -3 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of CAR-NKT on day 0.
62210860|NCT04101318|EXPERIMENTAL|The non-Conformité Européene marked product, a Conformité Européene marked product|Participants first received the non-Conformité Européene marked investigational product for 42±3 days. Then there was a cross-over and the participants received one of the five Conformité Européene marked comparators products, which they used the following 42±3 days.
62210861|NCT04101318|EXPERIMENTAL|A Conformité Européene marked product, then the non-Conformité Européene marked product|Participants first received one of the five Conformité Européene marked comparators products for 42±3 days. Then there was a cross-over and the participants received the non-Conformité Européene marked investigational products, which they used the following 42±3 days.
62210862|NCT00910039|EXPERIMENTAL|Sunitinib malate|"Oral sunitinib malate once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.~Patients undergo neuropsychological battery testing at baseline and periodically during study to assess cognitive function (memory, verbal fluency, visual-motor speed, executive function, and motor dexterity), activities of daily living, and quality of life."
62210863|NCT05617430|EXPERIMENTAL|HAIC + Sintilimab + Bevacizumab|HAIC combine with Sintilimab and bevacizumab biosimilar
62210864|NCT04916587|ACTIVE_COMPARATOR|Multifaceted Implementation Strategy|The core implementation strategy components are: 1) short video-trainings for clinic personnel (care team staff and providers) on the administration of caregiver-reported screening tools; 2) technical implementation support using an approach comprised of external academic consultants, and internal FQHC personnel to increase inner context capacity, 3) use of a validated clinical screening tool - Pediatric Symptoms Checklist (PSC-17), used in pediatric primary care settings to assess behavioral and social/emotional development. For this study, we will use the PSC tools that are tailored to children ages 0 to 5 years old with the Baby Pediatric Symptomatology Checklist (BPSC) for ages 0 to 18 months, and the Preschool Pediatric Symptom Checklist (PPSC) for ages 18 to 60 months. This screening tools is needed as the PEARLS only assesses ACEs exposure and not mental health symptomatology; and 4) use of a technology based tailored ACEs algorithm that incorporates multiple data sources.
62210865|NCT04916587|OTHER|ACEs Screening|"Adverse Childhood Experiences (ACEs) are potentially traumatic events occurring before age 18, such as maltreatment, harsh migration experiences or exposure to violence. ACEs screening are increasingly recommended to prevent and address physical and mental health conditions associated with ACEs. To promote ACEs screening uptake, the state of California issued the ACEs Aware 2020 policy; a fee-for-service health policy that provides a financial incentive to Medicaid-serving clinics to promote yearly ACEs pediatric screenings in primary care settings. This study will focus on screening children ages 0-5, in line with the partnering FQHC's ACEs screening priorities."
62210866|NCT02083120|EXPERIMENTAL|nasal High Flow and Oxygen|overnight nasal High Flow (NHF) therapy+ individually titrated supplemental oxygen (2-6 L/min),total 35 L/min, 4 weeks at home
62210867|NCT02083120|ACTIVE_COMPARATOR|Long term Oxygen Therapy (LOT)|individually titrated supplemental oxygen (2-6 L/min), 4 weeks at home
62210868|NCT00699049|PLACEBO_COMPARATOR|Alpha blocker and placebo|
62210869|NCT00699049|EXPERIMENTAL|Alpha blocker and solifenacin|
62210870|NCT01572168|EXPERIMENTAL|Acupuncture|Eight sessions of weekly acupuncture
62210871|NCT01781078|EXPERIMENTAL|MRI Group|Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant.
62210872|NCT01781078|EXPERIMENTAL|Control Group|Those subjects randomized to the Control Group will not undergo s study-specific MRI scan. All follow-up time requirements are the same for the two groups.
62210873|NCT01432184|ACTIVE_COMPARATOR|Intervention|an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
62210874|NCT01432184|NO_INTERVENTION|Control|the cerebral oxymetry screen will be blinded and changes in NIRS values will be unknown to the anesthesiologist. The management of the case will proceed as per normal local practice. The screen will remain blinded in the ICU and the intensivist will not see the values.
62210875|NCT03479762||Liraglutide|Patients in the CPRD primary care database who have been prescribed liraglutide after the UK launch of Saxenda® (and have no liraglutide prescriptions in the previous 12 months)
62583258|NCT05436327|OTHER|Geriatric Assessment (GA)|Clinical staff undergo training in GA and are provided with facilitation and support for one year as they implement GA among older adult patients (65+) considering chemotherapy and their care partners/caregivers.
62583259|NCT01071811|NO_INTERVENTION|Control group|Participants assigned to the control group received a leaflet from the National Board of Health in Denmark recommending all adults to be physical active for 30 minutes each day of moderate intensity.
62583260|NCT01071811|EXPERIMENTAL|Pedometer group|Received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program, a handout with a summary of the pedometer program, and a calendar for registration of daily steps.
62583261|NCT03048292||Mobilized Neurointervention Team|Patients undergoing endovascular stroke interventions.
62210876|NCT00339859||1|The population controls are collected from DMV records in the Baltimore region of MD. The cases are patients at the University of Maryland Medical System, including the associated Veterans' Association Hospital.
62210877|NCT05330598|EXPERIMENTAL|Connected Catheter Users|Device: Connected Urinary Catheter Patients will use the Connected Catheter to empty the bladder during the course of treatment.
62210878|NCT05090670|EXPERIMENTAL|Germanium-Embedded Knee Brace|Following surgery the patients effected limb would be placed in an Germanium-Embedded Knee Brace
62583262|NCT03048292||Mobilized Patient|
62583263|NCT03048292||Core Comprehensive Stroke Center Treatment|
62583264|NCT03320304||Vagal Nerve Simulation (VNS) Therapy|"The aim of this study is to include patients with difficult to treat depression from a global real world (standard of care) population who are referred for treatment with VNS Therapy."
62583265|NCT01402843|EXPERIMENTAL|pitavastatin + valsartan|
62583266|NCT01402843|PLACEBO_COMPARATOR|pitavastatin + placebo|
62583267|NCT01402843|PLACEBO_COMPARATOR|valsartan + placebo|
62583268|NCT01402843|PLACEBO_COMPARATOR|placebo|
62583269|NCT03498378|EXPERIMENTAL|Avelumab, Palbociclib, and Cetuximab|Identify the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) for the combination of palbociclib, avelumab, and cetuximab
62583270|NCT05902299||Before antibiotic susceptibility testing|
62583271|NCT05902299||After antibiotic susceptibility testing|
62583272|NCT05054413||Observational (questionnaire)|Participants complete 3-4 rounds of questionnaires over 20-30 minutes each over 2 weeks.
62583273|NCT05170386|EXPERIMENTAL|study group|receive cognitive training combined with instructive conventional treatment for sleeping disorder
62019306|NCT04574362|PLACEBO_COMPARATOR|Placebo|Matching placebo
62407789|NCT02789241|EXPERIMENTAL|Endotoxin (LPS)|The safety and tolerability will be assessed at different doses that will consist of 4 groups; each consisting of 4 subjects receiving endotoxin (LPS). Group 1 will test the low dose of LPS (0.6 ng/kg); Group 2 will test the 1.0 ng/kg dose; Group 3 will test the 2.0 ng/kg dose and Group 4 will test the 4.0 ng/kg dose.
62583274|NCT05170386|EXPERIMENTAL|control group|receive instructive conventional treatment for sleeping disorder
62583275|NCT06046781|OTHER|Control group|One group served as the control and was advised not to participate in any postoperative exercise.
62019307|NCT02669186|EXPERIMENTAL|'Bupivacaine + Fentanyl' (Opioid Group)|Group 1 (opioid group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
62019308|NCT02669186|ACTIVE_COMPARATOR|Bupivacaine (Local Anesthetic Group)|Group 2 (local anesthetic group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
62210879|NCT05090670|ACTIVE_COMPARATOR|Replica Knee Brace|Following surgery the patients effected limb would be placed in a replica knee brace
62019309|NCT02992639|PLACEBO_COMPARATOR|Control group|No calorie restriction group
62019310|NCT02992639|EXPERIMENTAL|Weight loss group|Mild calorie restriction group (300kcal/day intake reduction)
62210880|NCT06424795||Infants with recurrent wheeze|Infants with recurrent wheeze in the year following primary RSV infection
62210881|NCT06424795||Infants without recurrent wheeze|Infants without recurrent wheeze in the year following primary RSV infection
62019311|NCT00062244|EXPERIMENTAL|Arm I|"Phase I: Patients receive oblimersen IV continuously on days 1-7. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 1-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.~Phase II: Patients receive treatment as in phase I at the MTD of oblimersen. Patients are followed every 3 months for 2 years."
62019312|NCT02066298|EXPERIMENTAL|Mometasone then Tiotropium then Placebo|Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD, followed by Placebo
62019313|NCT02066298|EXPERIMENTAL|Mometasone then Placebo then Tiotropium|Mometasone 220mcg BID, followed by Placebo, followed by Tiotropium Respimat 5mcg QD
62210882|NCT01129700|EXPERIMENTAL|short-course CRT-5FU|
62210883|NCT05539144|EXPERIMENTAL|"Oropharyngeal mucosa as OARs"|"Oropharyngeal mucosa was delineated as OARs and limiting its dose"
62210884|NCT05539144|EXPERIMENTAL|oropharynx as OARs|Oropharynx was delineated as OARs and limiting its dose
62407790|NCT02789241|PLACEBO_COMPARATOR|Placebo|The trial will consist of 4 groups each group will have 2 subjects receiving Placebo (normal saline)\].
62407791|NCT04899219|EXPERIMENTAL|Group A (subjects with severe renal impairment)|
62210885|NCT05539144|EXPERIMENTAL|"Oropharynx and oropharyngeal mucosaas OARs"|"Oropharynx and oropharyngeal mucosa was delineated as OARs and limiting its dose"
62583276|NCT06046781|EXPERIMENTAL|Second week walking group|Postoperative walking initiated 2 weeks following surgery.
62583277|NCT06046781|EXPERIMENTAL|One month walking group|Postoperative walking initiated one month following surgery.
62583278|NCT06046781|EXPERIMENTAL|Second week waist exercise group|Postoperative waist exercise initiated 2 weeks following surgery.
62583279|NCT06046781|EXPERIMENTAL|One month waist exercise group|Postoperative waist exercise 1 month following surgery.
62735055|NCT02272036|ACTIVE_COMPARATOR|Non-SMS receiving|Study participants of the Non-SMS-Group do not receive any SMS before colonoscopy. Preparation is done according to regular written information given to the patient.
62407792|NCT04899219|EXPERIMENTAL|Group B (control subjects)|
62210886|NCT01129102|EXPERIMENTAL|NPC-01|Norethisterone 1mg, Ethinyl estradiol 0.02mg
62210887|NCT01129102|ACTIVE_COMPARATOR|IKH-01|Norethisterone 1mg, Ethinyl estradiol 0.035mg
62210888|NCT01129102|PLACEBO_COMPARATOR|Placebo|Placebo for NPC-01
62407793|NCT06220916||Greek National School of Dance - GNSD|All the GNSD undergraduate students with written consent for participating into the study
62407794|NCT06220916||Higher Vocational Dance School of Maria Grigoriou - Choros|All the Choros undergraduate students with written consent for participating into the study
62407795|NCT06220916||Higher Vocational Dance School Chorochronos|All the Chorochronos undergraduate students with written consent for participating into the study
62583280|NCT01617382||Registry|Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy
62583281|NCT05156372|EXPERIMENTAL|Exercise Intervention|Participants will engage in 2-3 supervised high intensity aerobic and resistance exercise sessions per week.
62583282|NCT05156372|NO_INTERVENTION|Control|Participants will continue daily routine as usual and given an informational flyer on physical activity and cancer.
62583283|NCT03997565||Patients TKR|
62583284|NCT03997565||Healthy subjects|
62583285|NCT03140410||Linezolid-resistant S. epidermidis|Patients affected by blood stream infections caused by meticillin-resistant S.epidermidis strains, tested resistant to linezolid
62583286|NCT03140410||Linezolid-susceptible S.epidermidis|Patients affected by blood stream infections caused by meticillin-resistant S.epidemridis strains, tested susceptible to linezolid
62583287|NCT03079011|EXPERIMENTAL|A- palbociclib + AI|After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme.
62583288|NCT03079011|EXPERIMENTAL|B- Palbociclib + fulvestrant|After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with fulvestrant, a selective estrogen receptor down-regulator, 500 mg administered intramuscularly on Days 1, 15, and 29 and once monthly thereafter.
62583289|NCT03079011|EXPERIMENTAL|Selection - Palbociclib + AI|All patients included into the study will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme
62583290|NCT05737225||Popliteal sciatic nerve block group|regional anesthesia applied patients who will undergo percutaneous transluminal angioplasty (PTA) procedure
62583291|NCT05737225||Control group|patients who will undergo percutaneous transluminal angioplasty (PTA) procedure
62583292|NCT05048147|EXPERIMENTAL|CM Intervention Group|Cluster. RCT of 16 urban and rural communities. Community mobilizers and health education officers will facilitate use of CF-CS (bioethanol and LPG fuels/stoves) and educate households on HAP exposure throughout the intervention period
62583293|NCT05048147|NO_INTERVENTION|Self-Directed Group|Receive information on CFCS use and education on HAP in 16 urban and rural communities; will not receive the CM intervention
62019314|NCT02066298|EXPERIMENTAL|Placebo then Mometasone then Tiotropium|Placebo, followed by Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD
62019315|NCT02066298|EXPERIMENTAL|Placebo then Tiotropium then Mometasone|Placebo, followed by Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID
62210889|NCT06531577||epistaxis group|patients presenting to emergency department with epistaxis
62210890|NCT03268447|ACTIVE_COMPARATOR|Lactobacillus plantarum P8|Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum P8, administered daily at a fixed dosage of 10 log CFU/sachet/day and continue for 12 weeks.
62019316|NCT02066298|EXPERIMENTAL|Tiotropium then Placebo then Mometasone|Tiotropium Respimat 5mcg QD, followed by Placebo, followed by Mometasone 220mcg BID
62019317|NCT02066298|EXPERIMENTAL|Tiotropium then Mometasone then Placebo|Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID, followed by Placebo
62210891|NCT03268447|PLACEBO_COMPARATOR|Placebo|Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks.
62407796|NCT06220916||Higher Vocational Dance School of Moragemou|All the Moragemou undergraduate students with written consent for participating into the study
62407797|NCT06220916||Higher Vocational Dance School Aktina|All the Aktina undergraduate students with written consent for participating into the study
62407798|NCT06220916||Higher Vocational Dance School of Maro Marmarinou|All the Maro Marmarinou undergraduate students with written consent for participating into the study
62210892|NCT04404777||Patients with local recurrence|
62407799|NCT06220916||Higher Vocational Dance School of Athens Conservatoire|All the Athens Conservatoire undergraduate students with written consent for participating into the study
62407800|NCT06220916||Higher Vocational Dance School of Marias Chatzimihali Charlafti|All the Marias Chatzimihali Charlafti undergraduate students with written consent for participating into the study
62407801|NCT02160223|EXPERIMENTAL|Sugammadex|Group S patients will receive 2 mg kg -1 sugammadex at the end of surgery
62583294|NCT02973724|EXPERIMENTAL|Remifentanil|Extubation was performed when remifentanil was maintained a predetermined concentration throughout the emergence periods.
62583295|NCT06078007|EXPERIMENTAL|MyMoodCoach Intervention|
62583296|NCT06078007|NO_INTERVENTION|Treatment-as-usual monitoring control group|
62583297|NCT01637454|ACTIVE_COMPARATOR|Terlipressin and Type-2 HRS|Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour.
62735056|NCT02342288|EXPERIMENTAL|Head raised 10 degrees|Head raised 10 degrees from neutral position using Gardner Wells tongs
62735057|NCT02342288|ACTIVE_COMPARATOR|Head in neutral position|Head in neutral position
62407802|NCT02160223|ACTIVE_COMPARATOR|Neostigmine|Group N patients will receive 50 µg kg-1 neostigmine and 05 mg atropin at the end of surgery
62407803|NCT00718146|EXPERIMENTAL|Group 1|Age 16 to 60 years
62407804|NCT00718146|EXPERIMENTAL|Group 2|Age over 60 years
62407805|NCT05899933|EXPERIMENTAL|Implantoplasty group|6 weeks after completion of non-surgical peri-implant therapy, participants with peri-implant probing pocket depth ≥ 5mm and presence of bleeding on probing and/or suppuration will receive resective surgical treatment. Implantoplasty will be applied as an implant surface modification method.
62407806|NCT05899933|EXPERIMENTAL|Erythritol Air-abrasive device group|6 weeks after completion of non-surgical peri-implant therapy, participants with peri-implant probing pocket depth ≥ 5mm and presence of bleeding on probing and/or suppuration will receive resective surgical treatment. Implant surface decontamination with an air-abrasive device with erythritol powder will be applied.
62583298|NCT01637454|ACTIVE_COMPARATOR|Noradrenaline and Type-2 HRS|Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
62019318|NCT02932631|ACTIVE_COMPARATOR|CONVENTIONAL PHYSICAL THERAPY group|"physical exercises divided into three phases:~1. stretching, strengthening and/or mobilization;~2. functional training of the affected muscles;~3. functional training of the paretic limb."
62019319|NCT02932631|EXPERIMENTAL|containment therapy induced|healthy side is restricted with splinting and exercises in hemiparetic member: carry out functional tasks individually. Each task will be held for 5 minutes, totaling 60 minutes of service
62210893|NCT04738292|EXPERIMENTAL|Onapristone In Combination with Fulvestrant|"All participants will receive onapristone 50 mg p.o. BID (twice) daily and fulvestrant (500 mg) intramuscular injection on days 1, 15 (cycle 1), then two weeks later (cycle 2, day1), then once every 28 days thereafter. A cycle is defined as 28 days.~There will be no breaks between dosing cycles."
62210894|NCT04389151|OTHER|The experimental group|
62210895|NCT06271876|EXPERIMENTAL|Inspiratory muscle fatigue group|The EG (experimental group) will perform the diaphragmatic fatigue protocol using a specific inspiratory endurance test, in which volunteers, one-on-one, and in a single session, will breathe against submaximal inspiratory loads equivalent to 60% of their MIP (Maximum Inspiratory Pressure) through a threshold valve device. The participants will follow a free pattern of breathing until they are unable to establish flow during at least 3 maximum inspiratory efforts.
62210896|NCT06271876|NO_INTERVENTION|Control group|they will not receive any intervention. Just sit and wait the same amount of time that the intervention and the activation group needs to finish their protocol (around 10 minutes)
62407807|NCT05899933|OTHER|Control group|Participants with healthy implants will be the comparator group for the microbiological analysis.
62407808|NCT06329765|EXPERIMENTAL|Exercise with CUped|Participants will exercise with CUped (a motor-assisted, split crank pedaling device) and undergo 50 m of gait training. CUped comprises a left and right pedal; each is attached to the shaft of a motor. There is no mechanical connection between pedals. Participant's feet are secured to the pedals. They are asked to pedal forward and keep the legs 180° out-of-phase. The position of the left and right cranks is monitored. When the phase relationship is not maintained, motors provide torque to assist the lagging limb and resist the leading limb. Motors are under feedback control. Torque is proportional to the magnitude and sign of the error.
62407809|NCT04029766|EXPERIMENTAL|HSK3486|0.288 mg/kg bolus (1 min)+ 1 mg/kg/h constant infusion (30 min) or 0.540 mg/kg bolus (1 min)+ 2 mg/kg/h constant infusion (30 min)
62407810|NCT06566469|EXPERIMENTAL|Combined dexmedetomidine-esketamine|A mixture of dexmedetomidine 0.5 µg/kg and esketamine 0.2 mg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
62407811|NCT06566469|PLACEBO_COMPARATOR|Normal saline|Placebo (normal saline) at the same volume is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
62407812|NCT01160770|EXPERIMENTAL|Clobazam|
62407813|NCT01841710||Women|
62583299|NCT00878202|NO_INTERVENTION|Control|Optimal medical treatment of Heart failure and therapeutic education
62583300|NCT00878202|EXPERIMENTAL|Telemedicine|Optimal medical treatment of heart failure disease and therapeutic education
62583301|NCT00695279||Participants|Venipuncture
62583302|NCT04499300||Covid positive|Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection.
62019320|NCT02885233|ACTIVE_COMPARATOR|Free From Falls|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
62210897|NCT06271876|ACTIVE_COMPARATOR|Inspiratory muscle activation group|The activation group will perform the protocol of 2 sets of 30 repetitions at 40% of their MIP, one-on-one, and in a single session, breathing against submaximal inspiratory loads using a threshold valve device. The participants will follow a free pattern of breathing until complete the protocol.
62407814|NCT03054675||Pneumonia|"Patients suffering from postoperative pneumonia including all three of the following:~1. Clinical signs of a pulmonary infection (i.e. fever ≥ 38°C combined with productive cough and/or dyspnea)~2. A new rise of inflammatory markers (i.e. WBC count ≥ 10.5 x 109 and elevated CRP)~3. New radiographic infiltrates on chest x-ray without another explanation. Patients with pneumonia undergo spirometry before and on every second day after lung surgery"
62210898|NCT05112653||2|"Group of Philadelphia positive leukemic patients will included in the study who divide into:~* patient newly diagnosed CML treated with first line of tyrosine kinase inhibitors therapy.~* Philadelphia positive acute leukemic patients(ALL, mixed-phenotype acute leukemia) on TKI therapy who achieved complete hematological remission(CHR) and who failed to achieve CHR."
62210899|NCT00266227|EXPERIMENTAL|Arm A: Rituximab Retreatment|1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.
62210900|NCT00266227|PLACEBO_COMPARATOR|Arm B: Placebo Retreatment|1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by retreatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/week methotrexate.
62210901|NCT00060424|EXPERIMENTAL|Treatment (enzyme inhibitor, transplant, GVHD prophylaxis)|NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and TBI on day 0. TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplant on day 0. GVHD PROPHYLAXIS: Patients receive cyclosporine PO every 12 hours on days -3 to 180 with taper on day 56 and mycophenolate mofetil PO every 12 hours on days 0-27.
62210902|NCT04879953||PIPAC CHEM|PIPAC associated with systemic chemotherapy
62210903|NCT04879953||ONLY CHEM|systemic chemotherapy alone
62407815|NCT03054675||No Pneumonia|Patients without pneumonia undergo spirometry before and on every second day after lung surgery
62019321|NCT02885233|PLACEBO_COMPARATOR|Waitlist|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
62019322|NCT00582582|EXPERIMENTAL|A|Docetaxel plus doxercalciferol
62019323|NCT00582582|PLACEBO_COMPARATOR|B|Docetaxel plus placebo
62019324|NCT00659165|EXPERIMENTAL|Insulin Detemir|Insulin Detemir
62583303|NCT04499300||Sub-group: deceased patients|Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection, with death as outcome.
62019325|NCT00659165|EXPERIMENTAL|Insulin Glargine|Insulin Glargine
62210904|NCT00129480|EXPERIMENTAL|Assistance with Pain Treatment|Care management intervention including assessment, decision support, patient activation, education and followup, provider education, feedback to providers
62210905|NCT00129480|NO_INTERVENTION|Treatment as usual|Treatment as usual
62210906|NCT05907525|EXPERIMENTAL|Remimazolam group|To induce anesthesia, remimazolam is continuously infused in a dose of 6mg/kg/hr with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). Maintenance dose of remimazolam is 1mg/kg/hr, up to 2mg/kg/hr, and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.
62407816|NCT03054675||Open (no pneumonia)|"Patients undergoing open anatomical lung resection who did not show postoperative pneumonia.~All patients undergo spirometry before and on every second day after lung surgery."
62583304|NCT04499300||Sub-group: patients who survived|Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection, who survived the infection.
62583305|NCT06682442|EXPERIMENTAL|Arm I (de-escalated Intensity Modulated Radiation Therapy (IMRT)|Participants undergo de-escalated IMRT every day (QD) 5 days a week for up to 7 weeks in the absence of disease progression or unacceptable toxicity. Participants also undergo CT, MRI, PET, PET/CT, CT, and/or bone scans as well as providing blood samples throughout the trial.
62019326|NCT06033989|EXPERIMENTAL|Hyaluronic acids|Hyaluronic acid has a huge potential to speed up the healing process and increase implant stability by enhancing bone/implant interaction and new bone formation.
62407817|NCT03054675||Minimally invasive (no pneumonia)|"Patients undergoing minimally invasive anatomical lung resection who did not show postoperative pneumonia.~All patients undergo spirometry before and on every second day after lung surgery."
62407818|NCT04551612||Patients with cholesteatoma|Patients with cholesteatoma in one ear that will compared with the other healthy one.
62019327|NCT06033989|ACTIVE_COMPARATOR|Sandblasting acid etched|"Sandblasting and acid etching is the most commonly used basic method for modifying the surface of dental implants . the sandblasting procedure roughs up the outer layer of the implant , creating a surface that is easier for the bone to grip as the implant heals."
62407819|NCT01891227|EXPERIMENTAL|Capecitabine and Bendamustine|"Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).~Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).~Eligible patients will receive capecitabine in combination with bendamustine for a maximum of eight cycles and afterwards capecitabine mono will be continued until disease progression or unacceptable toxic effects. Safety assessments will be conducted in 3-weekly intervals; efficacy assessments will be conducted every 9 weeks."
62407820|NCT04621227|OTHER|Period 1|Participants will receive the following treatments in this sequence : (i)Rosuvastatin alone (one dose of 10 mg), (ii) Midazolam alone (one dose of 2mg), (iii) PF 06882961 alone (120 mg twice daily), (iv) PF 06882961 (120 mg twice daily) + Rosuvastatin (one dose of 10mg), (v) PF 06882961 (120 mg) + Midazolam (one dose of 2 mg), (vi) PF 06882961 (200 mg) alone, (vii) PF 06882961 (200 mg) + Rosuvastatin (one dose of 10 mg), (viii) PF 06882961 (200 mg)+ Midazolam (one dose of 2 mg) in the study.
62407821|NCT00380861|ACTIVE_COMPARATOR|PFC Sigma RP-F|PFC® Sigma™ RP-F knee implant is a posterior stabilized cemented component cemented that is implanted with a standard posterior stabilized surgical technique.
62407822|NCT00380861|ACTIVE_COMPARATOR|PFC Sigma RP|P.F.C.® Sigma™ Rotating Platform (RP) Cruciate Retaining Knee System has a special insert that helps the knee move more like it did before the knee replacement.
62407823|NCT05971732|EXPERIMENTAL|Ferric derisomaltose|"Iron to be administered as ferric derisomaltose.~The treatment dose (mL) to be administered will be determined by the patient's body weight and hemoglobin (Hb) value.~Where Hb ≥10 g/dL, dosage according to body weight is as follows:~Body weight \<50 kg: 20 mg/kg; Body weight 50 to \<70 kg: 1000 mg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 1500 mg.~Where Hb \<10 g/dL, dosage according to body weight is as follows:~Body weight \<50 kg: 20 mg/kg; Body weight 50 to \<70 kg: 20 mg/kg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 2000 mg.~Infused over a minimum of 15mins for doses up to and including 1000mg, and a minimum of 30 mins for doses \>1000mg"
62407824|NCT05971732|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive normal saline 0.9% in analogy to treatment arm.
62407825|NCT02793258|PLACEBO_COMPARATOR|Placebo tDCS|"Subjects will receive 10 30-minutes sessions of sham tDCS, twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
62583306|NCT06682442|EXPERIMENTAL|Arm II (standard IMRT)|Patients undergo standard IMRT QD 5 days a week for up to 7 weeks in the absence of disease progression or unacceptable toxicity. Participants also undergo CT, MRI, PET, PET/CT, CT, and/or bone scans as well as providing blood samples throughout the trial.
62583307|NCT01483729|ACTIVE_COMPARATOR|Part 1 A|
62019328|NCT00002934|NO_INTERVENTION|Pathology Review, Observation and Follow-up|Pathology review, observation and follow-up
62583308|NCT01483729|EXPERIMENTAL|Part 1 B|
62583309|NCT01483729|EXPERIMENTAL|Part 1 C|
62583310|NCT01483729|ACTIVE_COMPARATOR|Part 2 D|
62019329|NCT04250324|EXPERIMENTAL|BZ019|The subjects are enrolled into 2 dose-escalation cohorts, include 3x10\^6/kg、6x10\^6/kg, and dose-expansion cohorts, maybe 8x10\^6/kg、10x10\^6/kg.
62210907|NCT05907525|ACTIVE_COMPARATOR|Sevoflurane group|To induce anesthesia, 1% propofol 1.5-2.5mg/kg is used with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). After patient loses consciousness, anesthesia is maintained through the inhalation of sevoflurane between 1-2 minimum alveolar concentrations (MAC). Remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.
62210908|NCT06727838|EXPERIMENTAL|Treatment group|
62210909|NCT01460459|EXPERIMENTAL|high frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) one day weekly in group A.
62210910|NCT01460459|EXPERIMENTAL|middle frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) one day per two weeks in group B.
62210911|NCT01460459|EXPERIMENTAL|low frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) Group C: one day monthly
62210912|NCT03056300|EXPERIMENTAL|Powered vascular stapler|Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler
62210913|NCT02513303|EXPERIMENTAL|Treatment Group|AV fistula surgery Single administration of sirolimus-eluting Collagen implant
62210914|NCT02513303|OTHER|Control Group|AV fistula surgery
62407826|NCT02793258|EXPERIMENTAL|Active tDCS|"receive 10 30-minutes sessions of two milliamps tDCS, twice a day for 5 consecutive day.~Stimulation will be performed using an tDCS stimulator with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system) The twice daily sessions will be separated by at least 2 hours."
62583311|NCT01483729|EXPERIMENTAL|Part 2 E|
62583312|NCT01483729|EXPERIMENTAL|Part 2 F|
62210915|NCT00546013||AAA group, control group|AAA group : with AAA Control group: without AAA
62583313|NCT01377922|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
62583314|NCT01377922|EXPERIMENTAL|Amifampridine Phosphate|Amifampridine, 30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets), for 2 weeks.
62019330|NCT02939222|OTHER|Routine implant placement|No comparison needed
62019331|NCT02717949|EXPERIMENTAL|sofosbuvir/ledipasvir|sofosbuvir and ledipasvir fixed dose combination given orally once a day for genotype 1 and 4.
62019332|NCT02717949|EXPERIMENTAL|sofosbuvir and ribavirin|Sofosbuvir 400 mg given orally once a day with weight-base ribavirin of 1200 mg for those \>75 kg and 1000 mg for those \<75kg given in divided dose twice a day. This intervention is for genotype 2 and 3
62019333|NCT02676206|EXPERIMENTAL|Music intervention|Subjects will have headphones placed on 1 minute prior to procedural sedation. Classical music will be played until the subject is fully awake.
62210916|NCT03544853|EXPERIMENTAL|Prosthetic socket evaluation|Intervention: Prosthetic socket for transtibial amputee. A subject's conventional prosthetic socket is compared to a novel prosthetic socket designed as part of the research. For standing and walking exercises the following will be assessed. 1) local skin contact pressures, 2) metabolic power, 3) gait parameters (symmetry indices for joint angles, positions, torques, and also ground reaction forces), and 4) the socket evaluation questionnaire.
62210917|NCT02735577|EXPERIMENTAL|Disulfiram|Patients in this arm will receive disulfiram 250 mg daily for a total of 40 days.
62210918|NCT05863728|EXPERIMENTAL|Piezosurgery assisted group|A Piezosurgery assisted cavity preparation was performed using a IM4A Piezosurgery tip mounted in the handpiece of a Piezosurgery device (PIEZOSURGERY touch, Mectron, Carasco, Italy) at an operating frequency in the range of 24 to 36 kHz with power ratings 55 W for osteotomy and root-end resection
62210919|NCT05863728|EXPERIMENTAL|Trephine Burs assisted group|Trephine bur assisted cavity preparation was performed using a TPB-4 trephine bur mounted in 20:1 contra angled handpiece of an implant motor (ImplaNX, Micro-NX, Republic of Korea) at an operating speed in the range of 800 to 1200 / Torque 30 N for osteotomy and root-end resection
62210920|NCT02022904|EXPERIMENTAL|Metastatic prostate cancer|Near infrared (NIR) emissive nanotechnology
62583315|NCT06496685|EXPERIMENTAL|Experimental Group|"The experimental group carried out a total of 14 one-hour group sessions, on a weekly basis for 14 consecutive weeks. The groups were formed by 8 participants. Sessions included the participation of one certified therapy dog, one technician specialized in AAT and a psychologist. Participants received their usual treatment (pharmacological and/or individual and family cognitive-behavioral treatment).~Intervention:~All sessions: Establishment of structured routines and schedules to help the child organize and manage daily responsibilities. Positive reinforcement to reward and motivate desirable behaviors.~Sessions 1-7: Impulsivity management techniques. Social skills training. Self-control techniques to identify and manage moments of impulsivity.~Sessions 8-14: Reinforcement of attention and concentration through strategies such as dividing tasks into smaller, more manageable parts. Cognitive-behavioral therapy to work on self-esteem, self-control and problem solving."
62583316|NCT06496685|NO_INTERVENTION|Control Group|Treatment as usual (pharmacological and/or individual and family cognitive-behavioral treatment).
62583317|NCT05262907|EXPERIMENTAL|Ventripoint 3D Echocardiogram|Ventripoint 3D Echo performed on subject to validate technology for use in single ventricle patients.
62210921|NCT04137744|ACTIVE_COMPARATOR|ARM preservation ALND|ARM +ve LN PRESERVED , ALND COMPLETED LATER ON
62210922|NCT04137744|ACTIVE_COMPARATOR|conventional ALND|ARM +VE NODES MARKED AND TAKEN WITH ALND
62210923|NCT06533566|ACTIVE_COMPARATOR|Erector Spinae Block|Patients of this group will receive ultrasound guided erector spinae block with injection of (20 ml) of plain bupivacaine 0.25% (max dose 2mg/kg) injected beneath the erector spinae muscle sheath at the level of the fourth transvers process (T4).
62210924|NCT06533566|ACTIVE_COMPARATOR|Drain block|Patients of this group will receive local wound infiltration (drain block) with injection of (20 ml) of plain bupivacaine 0.25% (max dose 2mg/kg) injected in each surgical drain (pectoral and axillary drains) thereafter, the drains would then clamped for 20 minutes and declamped later on.
62210925|NCT05652647|EXPERIMENTAL|One group of healthy adult male participants|
62210926|NCT06727994|EXPERIMENTAL|training group|Providing Genital Hygiene training
62407827|NCT04492488|EXPERIMENTAL|Solid Tumors|Phase I Dose Escalation: MRG002 will be administrated by an IV infusion of escalating doses (starting dose of 2.2 mg/kg, followed by 2.6 mg/kg) on Day 1 of every 3 weeks (21-day cycle).
62583318|NCT05262907|ACTIVE_COMPARATOR|Transthoracic Echocardiogram or Cardiac MRI|Non-invasive imaging of the heart to evaluate structure and function.
62583319|NCT03154190|ACTIVE_COMPARATOR|Arm A (usual care)|Patients receive usual care.
62583320|NCT03154190|EXPERIMENTAL|Arm B (health care coach support)|Patients undergo health care coach support with a baseline introduction (either telephonic or in-person) of the program followed by a visit (telephonic or in-person) with the health care coach after the first oncology appointment to discuss goals of care. The health care coach will contact patient based on patients' ongoing needs (weekly to monthly) and will conduct symptom assessments based on patients' treatment plans and symptoms.
62583321|NCT04447001|EXPERIMENTAL|Tai Chi Prime (TCP)-session 1|This arm will receive Tai chi prime as an intervention. TCP is a combination of two components: (a) Tai-chi fundamental Adapted Program, and (b) home practice coaching.
62210927|NCT03950843|EXPERIMENTAL|Experimental Group|"* Patients assigned to this group are treated with 1 capsule of CKD-825 and 2 placebo capsules(the placebo of CKD-825)~* The necessity of a dose titration is adjudicated every 2 weeks.~* After unblinding at the end of Administration Period, only patients in experimental group are treated with 1 capsule of CKD-825 for additional 4 weeks of Extension Period."
62583322|NCT04447001|NO_INTERVENTION|Wait list control-session 2|Wait-list group will be receiving Tai-chi prime intervention after 8 weeks wait time. At week 7, pre-test measures from wait-list group will be used as a control and compared with the post intervention measures of the experimental group.
62583323|NCT04852562|EXPERIMENTAL|Modified radical endoscopic sinus surgery(MRESS)|The experimental group intends to adopt a modified radical endoscopic sinus surger to remove the mucosa including ethmoid sinus and maxillary sinus, as well as a completly middle turbinate resection to achieve a radical cure of ethmoid sinus. Antrostomies of frontal and sphenoid sinuses were then performed with meticulous operation and preserve the mucosa intactly.
62583324|NCT04852562|EXPERIMENTAL|Functional endoscopic sinus surgery (FESS)|FESS was performed by Messerklinger technique, operation procedures including full maxillary antrostomy, ethmoidectomy, sphenoidotomy and frontal sinusotomy, but with the middle turbinate preservation.
62583325|NCT03119350|OTHER|Physical Training|"There was concurrent physical training intervention: strength and aerobic exercises in the same session.~Duration: 2 weeks of adaptation and learning to exercise, 8 weeks of physical training.~Frequency: 3 times per week Duration: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate."
62019334|NCT02676206|NO_INTERVENTION|Non intervention|Subjects will have headphones placed on 1 minute prior to procedural sedation. No music will be played. The headphones will be removed when the subject is fully awake.
62019335|NCT04751253|ACTIVE_COMPARATOR|1500 J + exercises|consist of 17 patients, they will receive the application of HILT with intensity 1500 J plus exercises.
62019336|NCT04751253|ACTIVE_COMPARATOR|3000 J + exercises|consist of 17 patients, they will receive the application of HILT with intensity 3000 J plus exercises.
62583326|NCT06666556|ACTIVE_COMPARATOR|Bowel preparation with lactulose before de colonoscopy|Patients will be randomized and assigned the bowel preparation the day that provide them the day of the colonoscopy
62583327|NCT06666556|ACTIVE_COMPARATOR|Bowel preparation with plyethylenglycol before the colonoscopy|Patients will be randomized and assigned the bowel preparation the day that provide them the day of the colonoscopy
62019337|NCT04751253|SHAM_COMPARATOR|exercises + sham LASER|consist of 17 patients, they will apply exercises plus sham LASER.
62019338|NCT01316848|EXPERIMENTAL|Fasted dosing followed by fed dosing|Dosing in the fasted state followed by fed dosing
62019339|NCT01316848|EXPERIMENTAL|Fed dosing followed by fasted dosing|Dosing in the fed state followed by fasted dosing
62210928|NCT03950843|PLACEBO_COMPARATOR|Placebo Group|"* Patients assigned to this group are treated with 3 placebo capsules (the placebo of CKD-825)~* The necessity of a dose titration is adjudicated every 2 weeks"
62583328|NCT04959929|EXPERIMENTAL|Focal vibration therapy|Myovolt delivers vibration with a frequency between 50-80 Hz. Myovolt intensity will be set to \~up to 2X the participant's initial Myovolt perception threshold. If the stimulation does not feel strong, the participant will be asked to manually increase the intensity until it feels strong but comfortable.
62583329|NCT03870308|EXPERIMENTAL|Deep Brain Stimulation subjects|
62583330|NCT05924191|EXPERIMENTAL|Experimental Group|Experimental group (n=30 surgeries) - the participants will receive the FBM, 1 hour before the surgical procedure, plus a placebo tablet, with the same physical and organoleptic characteristics, composed of corn starch, without harmful effects on health and simulating Dexamethasone (Celsius Laboratory, Montevideo, Uruguay).).
62583331|NCT05924191|ACTIVE_COMPARATOR|Control Group|Control group (n=30 surgeries) - patients will receive conventional treatment with Dexamethasone 8 mg (Corodex, Laboratorio Celsius, Montevideo, Uruguay) PO 1 hour before surgery (Almeida et al 2019), plus simulation of FBM application. The Laser device will be disconnected and will be applied to the same points as in the experimental group, in the immediate pre-operative period (Baseline).
62019340|NCT04779645|EXPERIMENTAL|GRA (REMD-477) Group|Once weekly, subcutaneous injection of 70mg REMD-477 (in 1 mL solution) for up to 12 weeks.
62210929|NCT02546479||Patientis|patients diagnosed with scoliosis and other spinal deformities
62210930|NCT03651622|EXPERIMENTAL|Hypocaloric, low carbohydrate|Behavioral intervention to include lifestyle counseling on hypocaloric, low carbohydrate diet (15-20% calories from carbohydrate, 59-63% as total fat (\<10% saturated fat, at least 37% monounsaturated fat, remaining as polyunsaturated fat). Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
62210931|NCT03651622|EXPERIMENTAL|Hypocaloric, moderate low fat|Behavioral intervention to include lifestyle counseling on hypocaloric, moderate low fat diet (30% calories from fat) weight management based on the Look AHEAD study. Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
62210932|NCT03651622|EXPERIMENTAL|Mediterranean, no caloric restriction|Behavioral intervention to include lifestyle counseling on selecting a healthy Mediterranean diet, no caloric restriction. Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
62210933|NCT02217475|EXPERIMENTAL|Cenicriviroc (CVC) 150mg/CVC 150 mg|CVC 150 mg tablet in Years 1 and 2.
62019341|NCT04779645|PLACEBO_COMPARATOR|Placebo Group|Once weekly, subcutaneous injection of 1mL saline solution for up to 12 weeks.
62019342|NCT04777279|EXPERIMENTAL|Individual physical exercise group|a 12-weeks physical exercise program (60 minutes/ three times weekly)
62019343|NCT04777279|EXPERIMENTAL|Individual Branched-Chain Amino Acids supplements group|a 12-weeks Branched-Chain Amino Acids supplements (5 g Branched-Chain Amino Acids every day)
62019344|NCT04777279|EXPERIMENTAL|Combination of physical exercise and Branched-Chain Amino Acids supplements group|a 12-weeks physical exercise program (60 minutes/ three times weekly) and a 12-weeks Branched-Chain Amino Acids supplements (5 g Branched-Chain Amino Acids every day)
62019345|NCT04777279|NO_INTERVENTION|Control group|no intervention
62019346|NCT00548782|ACTIVE_COMPARATOR|A|Subjects will be placed on Paleolithic diet and markers of insulin resistance, lipid profiles and vascular reactivity will be measured. a paleolithic diet excludes dairy, grains, legumes and processed foods.
62019347|NCT00548782|ACTIVE_COMPARATOR|B|Subjects will be placed on ADA ( American Diabetes Association) recommended diet and markers of insulin resistance, lipid profiles and vascular reactivity will be measured. An ADA diet is lower fat and more whole grains.
62019348|NCT04537091|EXPERIMENTAL|ESWT group: rESWT|rESWT treatment was applied to patients
62019349|NCT04537091|EXPERIMENTAL|PRP group: PRP injection|PRP treatment was applied to patients
62019350|NCT05623709||COPD and SRBD prescribed NIV or CPAP|"Group 1a: (n=55) Adults with a SRBD and COPD who are newly prescribed NIV treatment within the study period.~Group 1b: (n=55) Adults with a SRBD and COPD who are newly prescribed CPAP treatment within the study period."
62019351|NCT05623709||COPD controls not prescribed CPAP or NIV|Group 2: COPD controls without a SRBD: (n=55) Adults with COPD who undergo sleep diagnostic testing and who are not recommended to start CPAP or NIV
62583332|NCT05553457|EXPERIMENTAL|MyHand-SCI Device Testing|Subjects will attend 1-20 sessions (of approximately 90 mins) to trial a variety of the MyHand-SCI device controls and/or components. Participants will practice various grasp and release activities with the device
62583333|NCT06082063|ACTIVE_COMPARATOR|Multifactorial intervention group|The multifactorial intervention will be determined by the risk profile and risk markers of each individual and the participants will be allocated to Semaglutide, sotagliflozin or finerenone. The intervention will also comprise more ambitious treatment targets for blood pressure and lipid levels. In addition, all participants will take aspirin 75 mg OD.
62019352|NCT01363323|EXPERIMENTAL|Arm 1|
62019353|NCT01363323|EXPERIMENTAL|Arm 2|
62019354|NCT01363323|EXPERIMENTAL|Arm 3|
62210934|NCT02217475|EXPERIMENTAL|Placebo/CVC 150 mg|Placebo-matching CVC tablet in Year 1 then CVC 150 mg tablet in Year 2.
62583334|NCT06082063|NO_INTERVENTION|Standard intervention group|During the whole study period the standard intervention shall be done according to current Danish and international (ADA/EASD) guidelines. This will address similar risk factors as in the intensive group, but to a less ambitious treatment target for blood pressure and lipid lowering and will not include the use of SGTL2i, finerenone or GLP-1RA, unless these drug classes become recommended in future versions of guidelines.
62583335|NCT02177487|EXPERIMENTAL|Telmisartan + Hydrochlorothiazide|
62210935|NCT02217475|PLACEBO_COMPARATOR|Placebo/Placebo|Placebo-matching cenicriviroc (CVC) tablet in Years 1 and 2.
62210936|NCT00531648||1|Families with toddlers that having feeding disorders and SPD
62210937|NCT00943345|ACTIVE_COMPARATOR|GS dual sugar permeability test|"Golden standard GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
62210938|NCT00943345|OTHER|Multi sugar test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
62583336|NCT00679029|EXPERIMENTAL|Chemotherapy with Bevacizumab|"Doxorubicin 60 mg /M2 followed by cyclophosphamide 600 mg/M2 (AC) will be given every 2 weeks for cycles 1-4.~Paclitaxel 175 mg/M2 followed by gemcitabine 1500 mg/M2 (TG) will be given every 2 weeks for cycles 5-8.~Beginning cycle 5, B1= Avastin 10 mg/kg will be given as a single IV dose following each TG treatment every 2 weeks for cycles 5-7."
62583337|NCT02697526|OTHER|Terumo|Patients in this arm will receive Terumo after catheterization
62583338|NCT02697526|OTHER|Tensoplast|Patients in this arm will receive Tensoplast after catheterization
62583339|NCT02964507|EXPERIMENTAL|GSK525762 + Fulvestrant (Phase I)|
62583340|NCT02964507|EXPERIMENTAL|GSK525762 + Fulvestrant (Phase II)|
62583341|NCT02964507|PLACEBO_COMPARATOR|Placebo + Fulvestrant (Phase II)|
62019355|NCT01363323|PLACEBO_COMPARATOR|Arm 4|
62019356|NCT01363323|ACTIVE_COMPARATOR|Arm 5|
62019357|NCT00452634|EXPERIMENTAL|study arm|
62019358|NCT04221516|EXPERIMENTAL|Camrelizumab|Camrelizumab 200mg every 21 days for up to 18 cycles, from 4 to 12 weeks after the completion of radiotherapy.
62019359|NCT01625793|ACTIVE_COMPARATOR|HCV Interferon-alpha group|Subjects receiving treatment with interferon (IFN)-alpha for chronic hepatitis C virus infection.
62019360|NCT01625793|PLACEBO_COMPARATOR|HCV Control Group|Subjects delaying the start of treatment with interferon (IFN)-alpha for chronic hepatitis C virus infection by 7 weeks.
62583342|NCT05457257|EXPERIMENTAL|Olaparib|Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose of 300 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions
62583343|NCT05457257|ACTIVE_COMPARATOR|Enzalutamide OR abiraterone acetate|"Enzalutamide:~Enzalutamide is available as capsules or tablets containing 40 mg of enzalutamide. Subjects will be administered study treatment orally at a dose of 160 mg once daily.~Abiraterone acetate with prednisone: Abiraterone acetate is available as tablets containing 250 mg of abiraterone acetate. Subjects will be administered study treatment orally at a dose of 1,000 mg once daily. Prednisone is 5mg twice daily. Prednisolone is permitted for use instead of prednisone if necessary."
62583344|NCT06589778|EXPERIMENTAL|SHR-A2102 in Combination with Adebrelimab and SHR-8068|
62019361|NCT01187238|NO_INTERVENTION|Arm1-radical radiotherapy alone group|Arm1-radical radiotherapy alone group, the eligibility patients will received radical intensity-modulated radiotherapy alone
62019362|NCT01187238|EXPERIMENTAL|Arm2-concurrent chemoradiotherapy group|Arm2-concurrent chemoradiotherapy group, the eligibility patients will received radiotherapy the same as radical radiotherapy arm,and also will received the concurrent chemotherapy wiht the regimen consist of cisplatin 40mg/m2, weekly for 7weeks.
62019363|NCT02352493|ACTIVE_COMPARATOR|ALN-CC5|
62019364|NCT02352493|PLACEBO_COMPARATOR|Sterile Normal Saline (0.9% NaCl)|
62019365|NCT02671669|ACTIVE_COMPARATOR|Usual Care (UC)|
62019366|NCT02671669|ACTIVE_COMPARATOR|Movn application (MVN)|
62019367|NCT00511862|EXPERIMENTAL|TheraSphere|Single arm, TheraSphere Yttrium 90 glass microspheres at 120 Gy +/- 10%; stratified by type of disease (colorectal cancer, neuroendocrine cancer, non-colorectal/non-neuroendocrine cancer
62583345|NCT01580579||locally advanced lung cancer|Patients with locally advanced lung cancer who are candidates to chemoradiation
62583346|NCT01017276|EXPERIMENTAL|ASP group|
62583347|NCT06601946|OTHER|BLS Paper Based Cognitive Aid|
62583348|NCT06601946|OTHER|First Aid App|
62583349|NCT06601946|OTHER|Corpatch App|
62583350|NCT06574555|EXPERIMENTAL|Sequence A|Patients will be randomly assigned to sequence A who receive the study drug, norepinephrine. The initial bolus doses of norepinephrine will be 0.15 µg/kg.
62583351|NCT06574555|EXPERIMENTAL|Sequence B|Patients will be randomly assigned to sequence B who receive the study drug, norepinephrine. The initial bolus doses of norepinephrine will be 0.13 µg/kg.
62583352|NCT06032377|EXPERIMENTAL|online cognitive behavioral therapy for insomnia, anxiety and depression|10 self-directed modules of cognitive behavioral therapy for insomnia, anxiety and depression, delivered online, once a week
62583353|NCT06032377|ACTIVE_COMPARATOR|online intervention on nutrition and communication in older age|10 self-directed modules on healthy nutrition habits and communication strategies, delivered online, once a week
62583354|NCT06667219|EXPERIMENTAL|Intervention group, a children's physical fitness training program|"Length:12 weeks, 40 minutes one time, twice a week.~Intervention content:~The intervention will be conducted using a relevant physical fitness training program."
62019368|NCT06464835|EXPERIMENTAL|iTBS combined with NMES|On the basis of conventional treatment and swallowing rehabilitation training,The swallowing cortex of the affected hemisphere was stimulated with iTBS first, followed by NMES stimulation for 30 minutes after 10 minutes
62019369|NCT06464835|EXPERIMENTAL|iTBS combined with sham NMES|On the basis of conventional treatment and swallowing rehabilitation training,The swallowing cortex of the affected hemisphere was stimulated with iTBS first, followed by NMES sham stimulation for 30 minutes after 10 minutes
62407828|NCT04492488|EXPERIMENTAL|Locally Advanced or Metastatic Gastric/GEJ Cancer|MRG002 will be administrated by an IV infusion on Day 1 of every 3 weeks (21-day cycle).
62210939|NCT00943345|OTHER|Protein test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
62407829|NCT04725214|EXPERIMENTAL|Experimental|For MGMT unmethylated glioblastoma, during temozolomide adjuvant, concurrent with anti-angiogenesis targeted therapy(Anlotinib capsule,d1-14)
62583355|NCT06667219|EXPERIMENTAL|control group, Physical exercise using kindergarten standards|Duration: 12 weeks. Content: Physical exercise using kindergarten standards.
62583356|NCT06685484|EXPERIMENTAL|Intervention Group|Receives Modified Mindfulness Training Program (MMTP), adapted to address cultural stressors and reduce antenatal depression.
62583357|NCT06685484|NO_INTERVENTION|Control Group|Receives standard antenatal care without mindfulness intervention.
62583358|NCT06684756|ACTIVE_COMPARATOR|Patients with conventional UAS being used in their RIRS operations|The patient population will be selected from cases determined by randomization and used with UAS without an aspiration (conventional) during RIRS.
62583359|NCT06684756|EXPERIMENTAL|Patients with vacuum assisted UAS being used in their RIRS operations|The patient population will be selected from cases determined by randomization and used with UAS with an aspiration and flexible tip, different from the conventional one during RIRS.
62019370|NCT06464835|EXPERIMENTAL|sham iTBS combined with NMES|On the basis of conventional treatment and swallowing rehabilitation training,The swallowing cortex of the affected hemisphere was stimulated with sham iTBS first, followed by NMES stimulation for 30 minutes after 10 minutes
62019371|NCT03196921|EXPERIMENTAL|Symptomatic Cryptococcal Meningitis|CAMB (Encochleated Amphotericin B)
62019372|NCT03196921|EXPERIMENTAL|Asymptomatic Cryptococcal Antigenemia|CAMB (Encochleated Amphotericin B)
62019373|NCT04522947|EXPERIMENTAL|fMRI|Participants are delivered sips of appetizing tastes (milkshake) and tasteless solution throughout the task while in the MRI scanner.
62019374|NCT01065961|ACTIVE_COMPARATOR|Decadron|Subject will be given Decadron 0.2mg/kg intraoperatively. This dose will be followed by 4 mg. every 6 hours for the first 24 hours.
62019375|NCT01065961|PLACEBO_COMPARATOR|Saline|subject will be given a blinded dose of placebo saline intraoperatively followed by placebo doses every 6 hours for 24 hours.
62407830|NCT01782638|EXPERIMENTAL|deep brain stimulation with high frequency|The primary purpose of this study is to compare the effect of deep brain stimulation with high frequency vs low frequency on gait of patients whatever the electrodes placement (STN ou Forel fields) and whatever the medication condition (with or without treatment).
62407831|NCT01782638|OTHER|low frequency on gait of patients|The primary purpose of this study is to compare the effect of deep brain stimulation with high frequency vs low frequency on gait of patients whatever the electrodes placement (STN ou Forel fields) and whatever the medication condition (with or without treatment).
62407832|NCT05712603||Prospective care path arm|"Participants who enter the care path will make up the prospective care path arm.~In patients entering the care path three diagnostic tests for liver fibrosis will be performed. FIB4-score, Vibration controlled transient elastography and Enhanced Liver Fibrosis test"
62407833|NCT05712603||Prospective arm of 'regular care'|Patients who are referred to the hepatologist in participating centers during the study period without using the care path (e.g. because of altered liver function tests for instance), will be the prospective 'regular care' arm
62583360|NCT01063621|EXPERIMENTAL|KW-6500|
62019376|NCT00439777|EXPERIMENTAL|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)
62210940|NCT00943345|OTHER|PEG test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
62583361|NCT03846154|EXPERIMENTAL|Intervention group|"Children and adolescents in the intervention group received:~1. A group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug abuse, anger management, roles within families, developing plans for the future, communication skills, sex education.~2. Access to schools and school material~3. Family visits~4. Their parents received training regarding agriculture and microcredit projects, and financial assistance~5. FORNET if affected by trauma-related symptoms, and/or acting aggressive~6. If needed medical assistance is provided~7. If needed legal assistance is provided"
62583362|NCT03846154|NO_INTERVENTION|Control group|The control group was invited to participate in three interviews getting small amounts of money (\~2,5 €) as decompensation of their time.
62210941|NCT06220136||single group|rocuronium drug administration TOFscan monitoring administration of sugammadex drug recording of classical TOF and modified TOF values
62210942|NCT01580891|EXPERIMENTAL|Naftifine HCl Cream 1%|Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.)
62210943|NCT01580891|ACTIVE_COMPARATOR|Naftin® (Naftifine HCl) Cream 1%|Naftin® (Naftifine HCl) Cream 1% (Merz Pharmaceuticals)
62210944|NCT01580891|PLACEBO_COMPARATOR|Placebo topical cream|Placebo topical cream (Taro Pharmaceuticals Inc.)
62210945|NCT05162573|EXPERIMENTAL|EBRT + 3 GBq Lu-PSMA|
62210946|NCT05162573|EXPERIMENTAL|EBRT + 6 GBq Lu-PSMA|
62407834|NCT05712603||Retrospective arm of 'regular care'|The investigators will do an data extraction of the electronic health records of patients referred to the hepatologist in the five years prior to the study. They will make up the retrospective comparative arm of regular care
62210947|NCT05162573|EXPERIMENTAL|EBRT + 9 GBq Lu-PSMA|
62210948|NCT05162573|EXPERIMENTAL|EBRT + 2x7.4 GBq Lu-PSMA|
62407835|NCT05564507|EXPERIMENTAL|TEE simulation-based training group|"All participants of the TEE simulation group received:~1) a traditional didactic training using e-learning with a national free-access online course; and 2) two teaching sessions using a TEE simulator for 2 hours per session."
62407836|NCT05564507|NO_INTERVENTION|TEE traditional group|All participants of the TEE traditional group received only a traditional didactic training using e-learning with a national free-access online course (same e-learning program allocated for the TEE simulation group).
62210949|NCT01209234|ACTIVE_COMPARATOR|MRSA Decolonization|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
62210950|NCT01209234|ACTIVE_COMPARATOR|Education Arm|Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home. In addition, educational material on hygiene practices to prevent MRSA infection will be provided.
62407837|NCT03504527|EXPERIMENTAL|triple combinations|Budesonide/Fermotil inhalant 160ug/4.5ug bid; Tiotropium bromide inhalants 18ug qd
62407838|NCT03504527|ACTIVE_COMPARATOR|double combinations|Fermotil inhalants 4.5ug bid; Tiotropium bromide inhalants 18ug qd
62210951|NCT01156298||Cohort 1|Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS. Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not. Cohort 1 patients will have annual EDSS, self-report EDSS, medication review and relapse recalculation. SF-36 and SDMT assessments will be performed at years 1 and 5 during routine office visits. A MRI will be performed each patient's 15 year anniversary date.
62210952|NCT01156298||Cohort 2|Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS. Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not. Patients will be waiving written informed consent and asked to provide concomitant medication, self-reported EDSS, and SF-36 only.
62210953|NCT03457870|EXPERIMENTAL|Intermittent Energy Restriction|Dietary intervention: Intermittent energy restriction
62210954|NCT03457870|EXPERIMENTAL|Chewing|Mastication intervention: chewing
62407839|NCT05647395|EXPERIMENTAL|Slowly and evenly draw the gas in the cuff|
62407840|NCT05647395|NO_INTERVENTION|One-time aspiration of tracheal catheter cuff gas|
62407841|NCT03740035||Prostate Cancer Patients|Prostate cancer patients that who have been actively receiving care through Wake Forest Baptist Comprehensive Cancer Center and/or satellite clinics over the past two-year period will be using an eHealth for Sedentary Behavior.
62407842|NCT02450929||Standard Barrel-Cuff ETT|Standard Barrel-Cuff ETT use in surgical patients
62019377|NCT00439777|ACTIVE_COMPARATOR|Enoxaparin/VKA|Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)
62019378|NCT04954365||Cohort 1|Patients that received rescue treatment according to the standard of care (SOC).
62019379|NCT04954365||Cohort 2|Patients that received rescue treatment with IV amisulpride.
62019380|NCT01859455|EXPERIMENTAL|Patient: LGT209 50 mg|50 mg LGT209 subcutaneous (SC) (1 mL injection x 1 site) in statin patients
62210955|NCT03457870|EXPERIMENTAL|Chewing + Intermittent Energy Restriction|Dietary and mastication intervention: Intermittent energy restriction and chewing
62210956|NCT03457870|NO_INTERVENTION|Control|No intervention: Control
62210957|NCT02510898|EXPERIMENTAL|Intervention Arm|All subjects enrolled in the study will receive the intervention. This is a one-arm study.
62210958|NCT04730193|PLACEBO_COMPARATOR|Control|Participants randomized to placebo group will receive placebo capsule
62210959|NCT04730193|EXPERIMENTAL|Caffeine|Participants randomized to caffeine group will receive 100mg caffeine capsule
62210960|NCT00879073|EXPERIMENTAL|A - Cohort 1 Treatment|Cohort 1: Bendamustine 60 mg/m² x 4 weeks
62210961|NCT00879073|EXPERIMENTAL|B - Cohort 2 Treatment|Cohort 2: Bendamustine 80 mg/m² x 4 weeks
62407843|NCT02450929||Taperguard ETT|Taperguard ETT use in surgical patients
62407844|NCT00759369|EXPERIMENTAL|1|Water prescription
62407845|NCT03299439|EXPERIMENTAL|acupuncture at highly sensitive points|Sterile, single-use filiform acupuncture needles (Hwato Needles, Sino-foreign Joint Venture Suzhou Hwato Medical Instruments Co., China) with a length of 40 mm and a diameter of 0.30 mm will be inserted to a depth of 15-30mm in five highly sensitive points.
62407846|NCT03299439|ACTIVE_COMPARATOR|acupuncture at lowly/non-sensitive points|Sterile, single-use filiform acupuncture needles (Hwato Needles, Sino-foreign Joint Venture Suzhou Hwato Medical Instruments Co., China) with a length of 40 mm and a diameter of 0.30 mm will be inserted to a depth of 15-30mm in five low/non-sensitive points.
62407847|NCT03299439|NO_INTERVENTION|no acupuncture (waiting-list)|Patients in the waiting-list group will not receive any acupuncture intervention during the study.
62019381|NCT01859455|EXPERIMENTAL|Patient: LGT209 300 mg|300 mg LGT209 subcutaneous (SC) (1 mL injection x 2 sites) in statin patients
62019382|NCT01859455|EXPERIMENTAL|Healthy Volunteers: LGT209 300 mg|300 mg LGT209 or placebo subcutaneous (SC) (1 mL injection x 2 sites) in healthy volunteers
62019383|NCT01859455|PLACEBO_COMPARATOR|Patient: Placebo|matching placebo subcutaneous (SC) of LGT209 50 mg or 300 mg in statin patients
62210962|NCT00879073|EXPERIMENTAL|C - Cohort 3 Treatment|Cohort 3: Bendamustine 100 mg/m² x 4 weeks
62210963|NCT02261987|ACTIVE_COMPARATOR|Autogenic drainage (AD)|Patients will perform the autogenic drainage technique following the Chevallier and Agostini recommendations.
62210964|NCT02261987|ACTIVE_COMPARATOR|Resistive inspiratory manoeuvre (RIM)|Patients will perform the repetitive inspiratory manoeuvers by breathing through a fixed resistance (Power Breathe device, model KH1) . Each session will comprise to cycles of 5 inspiratory breaths (60% of maximal inspiratory pressure). Patients will be stay in both lateral decubitus position (15 min per side).
62583363|NCT04967885|EXPERIMENTAL|Immediate Intervention|Participants in the Immediate Intervention condition will create their Implementation Intention (II) messages before the two-week EMA + EMI-II period begins. During the EMA + EMI-II period, participants will complete five daily EMAs, and they will also complete weekly assessments reporting their past week cigarette smoking as a distal outcome and rating intervention acceptability. Following the EMA + EMI-II period, participants will enter a two-week follow-up period. During this time, participants will not receive any messages, but will report past week smoking on a weekly basis.
62407848|NCT06542809|EXPERIMENTAL|Belgian and Luxembourgish patients currently under rhGh treatment|Patient population studied are Belgian and Luxembourgish patients currently under rhGh treatment in its various official indications (as per the Belgian RIZIV/INAMI monitor : growth hormone deficiency, Turner Syndrome, chronic renal insufficiency, Prader-Willi syndrome, Small for gestational age, Noonan Syndrome, SHOX gene deficiency) and included in the BELGROW Registry Number.
62407849|NCT06515639|EXPERIMENTAL|Classic IF diet|The 16:8 intermittent fasting model, 45-60% carbohydrates, 10-15% protein, and 25-30% fat dietary model applied.
62019384|NCT01859455|PLACEBO_COMPARATOR|Healthy volunteers: Placebo|matching placebo subcutaneous (SC) of LGT209 300 mg in healthy volunteers
62019385|NCT03814447|EXPERIMENTAL|anti- MESO CAR-T cells|The subjects in this arm will receive Cyclophosphamide 300mg/m2/d and Fludarabine 30mg/m2/d d-4\~-2. Then anti- MESO CAR-T cells will be injected by a dose of 5×106/kg once at d1(rang from d1-3).
62210965|NCT02261987|ACTIVE_COMPARATOR|Resistive inspiratory manoeuvre+autogenic drainage|First, patients will perform the resistive inspiratory manoeuvre during 10 minutes (5 min per side). Right after, patients will perform the autogenic drainage during 20 minutes.The instructions will be similar to described previously.
62407850|NCT06515639|EXPERIMENTAL|Low carb-High fat IF diet|The 16:8 intermittent fasting model, 10-30% carbohydrates and 50-65% fat dietary model applied.
62019386|NCT06177639||Adult (≥18 years) cohort|Adults that may or may not have eye pathology
62407851|NCT04082416|EXPERIMENTAL|RC18 160mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 52 times.
62407852|NCT04082416|PLACEBO_COMPARATOR|Placebo|Patients received the test group Placebo weekly administered subcutaneously for 52 times.
62407853|NCT06174922|ACTIVE_COMPARATOR|Prednisolone|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper 5 mg every 4 weeks and discontinue by 4 months. After breakfast, oral prednisolone will be administered as a morning dose (8-10 am).
62407854|NCT06174922|ACTIVE_COMPARATOR|Itraconazole|Oral SUBA-itraconazole 65 mg 2 capsules BD for 4 months. Oral itraconazole will be given twice daily (9 am and 9 pm) spaced one hour with meals. We will perform therapeutic drug monitoring for itraconazole at two weeks and two months. We will increase the itraconazole dose to a maximum of 390 mg/day (six 65 mg capsules) in those with trough itraconazole levels \<0.5 µg/mL.
62019387|NCT06177639||Minor cohort|Infant/child undergoing clinically-indicated examination that may or may not have eye pathology. We will not enroll inpatient pre-term infants or neonates. The youngest age at enrollment will be 30 days adjusted age using the NICH NRN Web-based Adjusted Age Calculator.
62019388|NCT03878940|OTHER|Primary care patients|All GPs in the municipality of Silkeborg will be invited to participate. Any patient can be referred to the abdominal ´yes-no´ pathway, independently of their willingness to give one´s consent.
62019389|NCT02401672|ACTIVE_COMPARATOR|Active TMS|Repetitive TMS pulse stimulation
62019390|NCT02401672|SHAM_COMPARATOR|Sham TMS|The sham TMS system will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
62019391|NCT05446740|EXPERIMENTAL|YA GSK4382276A Dose level 1 Group|Eligible young adults (YA) participants receive dose level 1 of GSK4382276A study intervention administered at Day 1.
62019392|NCT05446740|EXPERIMENTAL|YA GSK4382276A Dose level 2 Group|Eligible young adults (YA) participants receive dose level 2 of GSK4382276A study intervention administered at Day 1.
62735058|NCT05878873|SHAM_COMPARATOR|Split-belt Treadmill Training without TENS|During this arm, participants will perform split-belt treadmill training with sensory stimulation equipment outfitted but not active during all adaptation sessions.
62407855|NCT06174922|EXPERIMENTAL|Prednisolone plus itraconazole|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper 5 mg every 4 weeks and discontinue by 4 months. After breakfast, oral prednisolone will be administered as a morning dose (8-10 am); and, Oral SUBA-itraconazole 65 mg 2 capsules BD for 4 months. Oral itraconazole will be given twice daily (9 am and 9 pm) spaced one hour with meals. We will perform therapeutic drug monitoring for itraconazole at two weeks and two months. We will increase the itraconazole dose to a maximum of 390 mg/day (six 65 mg capsules) in those with trough itraconazole levels \<0.5 µg/mL.
62407856|NCT06653920||Pressure Pain Thresholds in 98 Patients with Uncomplicated Back and Leg Pain|A computer search (EZ Biz software) for patients diagnosed with sciatica (i.e., ICD10 codes M54.31, M54.32, M54.41, and M54.42) or uncomplicated low back pain (ICD10 M54.4 or M54.50) identified 492 electronic charts. Of these 394 either failed to meet inclusion criteria (n = 62) or met exclusion criteria (n = 332) and were eliminated from the study, leaving pre-and post-treatment data from 98 new patients eligible for statistical reduction. Charts of patients seen consecutively who had been treated between January 1, 2018 and August 25, 2021 who met inclusion and exclusion criteria were included.
62407857|NCT06002828||Observational (questionnaires, biospecimen collection)|Participants complete questionnaires about health-related quality of life and undergo collection of blood samples at baseline and 6, 12, 18, and 24 months.
62583364|NCT04967885|ACTIVE_COMPARATOR|Waitlist|Participants randomized to the Waitlist control condition will begin with a two-week no intervention condition during which they will report past week smoking on a weekly basis but will not receive any other intervention components. At the end of the two-week waitlist control period, participants will begin the two-week EMA plus EMI-II period. During the EMA plus EMI-II active study period, participants will complete five daily EMAs and weekly assessments to report their past week cigarette smoking and rate intervention acceptability. No follow-up is planned for the wait list control condition.
62583365|NCT02621710||Minimally invasive hysterectomy|Patients undergoing scheduled minimally invasive hysterectomy (vaginal, laparoscopic, robotic) for benign condition
62583366|NCT02621710||Abdominal hysterectomy|Patients undergoing scheduled abdominal hysterectomy for benign condition
62583367|NCT03600194|ACTIVE_COMPARATOR|PowerSleep Stim|In this arm soft audio tones (below 65dB) will be administered by the PowerSleep Stim Device during deep sleep as determined by the functionality of the device.
62583368|NCT03600194|PLACEBO_COMPARATOR|PowerSleep Sham|This PowerSleep Sham device is the same as the PowerSleep Stim device, however, it can be configured in a mode that does not play audio tones
62210966|NCT00948649|ACTIVE_COMPARATOR|Varenicline|Participants will complete a 21-day study phase that will include a 10-day drug run-up and monitoring phase (days 1-10), a 3-day abstinence phase (days 11-13), and a programmed lapse (day 14) followed by a 7-day observation phase in which participants are asked to remain abstinent and will receive modest monetary reinforcement for doing so (days 15-21).
62210967|NCT00948649|PLACEBO_COMPARATOR|Placebo|Participants will complete a 21-day study phase that will include a 10-day drug run-up and monitoring phase (days 1-10), a 3-day abstinence phase (days 11-13), and a programmed lapse (day 14) followed by a 7-day observation phase in which participants are asked to remain abstinent and will receive modest monetary reinforcement for doing so (days 15-21).
62407858|NCT03583801|EXPERIMENTAL|aromatherapy group|"The patient has to choose an essential oil among the 3 proposed :~* sweet orange (Citrus sinensis L. Persoon)~* fine lavender (Lavandula angustifolia P. Miller)~* little seed from the mandarin tree (Citrus reticulata blanco)"
62407859|NCT03583801|PLACEBO_COMPARATOR|without aromatherapy|
62407860|NCT01351324|EXPERIMENTAL|SFA|Oral dose of palmitic acid (SFA) given as a chocolate-flavoured drink every 30 min (0-390 min) with a continuous infusion of heparin (60-390 min).
62210968|NCT01875289|EXPERIMENTAL|Ropivacain|Local anaesthesia
62407861|NCT01351324|EXPERIMENTAL|SFA + LC n-3 PUFA|Oral dose of palmitic acid and DHA-rich fish oil (SFA + LC n-3 PUFA) given as a chocolate-flavoured drink every 30 min (0-390 min) together with a continuous infusion of heparin (60-390 min).
62407862|NCT02320734|ACTIVE_COMPARATOR|deep neuromuscular relaxation|continuous infusion of rocuronium 0.6 mg/kg/hr (group 1). On demand bolus rocuronium can be given if demanded by anesthesiologist or surgeon
62407863|NCT02320734|NO_INTERVENTION|on demand neuromuscular relaxation|continuous infusion of NaCl 0.9% 0.06 ml/kg/hr (group 2) On demand bolus of Rocuronium will be given when demanded by anesthesiologist or surgeon.
62583369|NCT03600194|ACTIVE_COMPARATOR|Northwestern Stim|The NorthWestern Stim device is set up will function similarly to the PowerSleep prototype. Acoustic stimulation provided by headphones with an audible soft volume that do not result in arousals will be used.
62583370|NCT03600194|PLACEBO_COMPARATOR|Northwestern Sham|The Northwestern Sham device will be the same as the Northwestern Stim set up, however no audio tones will be played.
62583371|NCT04691843|ACTIVE_COMPARATOR|Standard iron dose|Iron supplementation of 4mg/kg/day will start when infant is on full enteral feedings of 120-150mL/kg/day and at least two weeks old. Iron dosing will be adjusted for weight at weekly intervals to maintain dosing at 4mg/kg/day.
62583372|NCT04691843|EXPERIMENTAL|Early, high-dose iron|Iron supplementation will start at 3mg/kg/day when infant is on enteral feeds of 60mL/kg/day and at least one week old, then increased to 6mg/kg/day when enteral feeds are at 100mL/kg/day. Iron dosing will be adjusted to maintain ferritin level of 70-400ng/mL. At 36 weeks corrected age, iron supplementation will be adjusted to the dose routinely used for preterm infants.
62583373|NCT02407145||PVDF retropubic midurethral sling|Women with urodynamic stress urinary incontinence having a retropubic polyvinylidene fluoride midurethral sling (DynaMesh®-SIS soft).
62583374|NCT05758402|OTHER|EARP group|For the EARP group, the investigator provided this questionnaire to participants, who filled out it based on their symptoms. Afterwards, the investigator calculated the total score of the questionnaire answered by the participant, and further evaluated the participants using the CASPAR.
62583375|NCT05758402|ACTIVE_COMPARATOR|Routine practice group|In the control group, PsA risk was assessed in moderate to severe PsO patients as per routine practice without using the EARP screening. After the completion of PsA risk assessment via routine practice according to the investigator's judgement, the participants were further evaluated using the CASPAR.
62583376|NCT02254967|EXPERIMENTAL|Fidaxomicin Extended Pulsed Regimen (EPFX)|Participants receive 200 mg fidaxomicin from day 1 to day 5 twice daily, followed by a 1-day gap (day 6) before starting alternate day dosing of 1 tablet of fidaxomicin 200 mg once daily from day 7 to day 25.
62583377|NCT02254967|EXPERIMENTAL|Vancomycin|Participants receive 125 mg vancomycin from day 1 to day 10, 4 times daily.
62210969|NCT01875289|PLACEBO_COMPARATOR|NaCl 0.9%|Saline
62210970|NCT04709952|ACTIVE_COMPARATOR|High real stimulation group|2mA tDCS stimulation daily (42 times) for 6 weeks
62210971|NCT04709952|ACTIVE_COMPARATOR|Low real stimulation group|1mA tDCS stimulation daily (42 times) for 6 weeks
62210972|NCT04709952|SHAM_COMPARATOR|Sham stimulation group|sham stimulation daily (42 times) for 6 weeks
62210973|NCT02025959|EXPERIMENTAL|Educational Intervention|Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders
62407864|NCT01103076|ACTIVE_COMPARATOR|Polyamide 210 H|Chronic HD patients will be treated in random order with either polyamide or HCO membranes (Polyflux 210 H or HCO 1100) for one month (12 HD sessions) before the crossover.
62407865|NCT01103076|EXPERIMENTAL|HCO 1100|Chronic HD patients will be treated in random order with either polyamide or HCO membranes (Polyflux 210 H or HCO 1100) for one month (12 HD sessions) before the crossover.
62210974|NCT05317364|ACTIVE_COMPARATOR|Topical vaginal estrogen group|Estradiol vaginal cream 0.01% 1g will be administered vaginally, initiated at 2 weeks postpartum and continued until 6 months postpartum. Beginning at 2 weeks postpartum, 1g estradiol vaginal cream 0.01% will be administered by participants nightly for 2 weeks then twice weekly to complete 6 months therapy
62583378|NCT03643133|ACTIVE_COMPARATOR|Control arm|"Post-operative chemotherapy alone (EI or M-API regimen depending on patient age) :~M-API regimen (≤25 years) :~Doxorubicin 60 mg/m², Day 1 Ifosfamide 3 g/m² Day 1 and 2 Cisplatin 100 mg/m², Day 2~EI regimen (26-50 years) :~Etoposide 75 mg/m²/d, Day 1-4 Ifosfamide 3 g/m²/d, Day 1-4"
62583379|NCT03643133|EXPERIMENTAL|Experimental arm|Post-operative chemotherapy (EI or M-API regimen) combined with Mifamurtide 2 mg/m² twice weekly post-randomisation for 12 weeks then weekly for 24 weeks
62407866|NCT04451512||CSP|
62407867|NCT04451512||HSP|
62583380|NCT05629637|EXPERIMENTAL|Mindfulness-Based Resilience Training (MBRT)|MBRT is an 2.5-day program combining training in standardized mindfulness practices targeting factors that facilitate resilience, cognitive-behavioral therapy (CBT), and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
62583381|NCT05824507|ACTIVE_COMPARATOR|Endometriosis + empiric antibiotic therapy|Women undergoing laparoscopic removal of endometriotic foci due to pain/infertility and endometrial aspiration biopsy for diagnosis of CE followed by empirical antibiotic therapy of CE, if confirmed
62019393|NCT05446740|EXPERIMENTAL|YA GSK4382276A Dose level 3 Group|Eligible young adults (YA) participants receive dose level 3 GSK4382276A study intervention administered at Day 1.
62019394|NCT05446740|EXPERIMENTAL|YA GSK4382276A Dose level 4 Group|Eligible young adults (YA) participants receive dose level 4 of GSK4382276A study intervention administered at Day 1.
62019395|NCT05446740|EXPERIMENTAL|YA GSK4382276A Dose level 6 Group|Eligible YA participants receive dose level 6 of GSK4382276A study intervention administered at Day 1.
62210975|NCT05317364|PLACEBO_COMPARATOR|Placebo group|Placebo cream, 1g will be administered vaginally, initiated at 2 weeks postpartum and continued until 6 months postpartum. Beginning at 2 weeks postpartum, 1g of placebo cream will be administered by participants nightly for 2 weeks then twice weekly to complete 6 months therapy.
62210976|NCT06017934|NO_INTERVENTION|Control|Usual care
62583382|NCT05824507|ACTIVE_COMPARATOR|Endometriosis + no empiric antibiotic therapy|Women undergoing laparoscopic removal of endometriotic foci due to pain/infertility and endometrial aspiration biopsy for diagnosis of CE without empirical antibiotic therapy of CE, if confirmed
62583383|NCT06589245|EXPERIMENTAL|Ciclesonide|Eligible infants will be approached by study team. Parents whose infants consent to the study drug will enter the dose-escalation part of the study. Inhaled Alvesco will be administered daily for 14 days at escalating doses 80mcg, 160mcg and 320mcg.
62583384|NCT06589245|NO_INTERVENTION|Control|Eligible infants will be approached by study team. Parents who refuse consent to the study drug will have standard of care. These parents can accept for their infant's de-identified clinical data to be used as part of the control group.
62583385|NCT02430649|EXPERIMENTAL|IRE Group|irreversible electroporation for Unresectable Prostatic Neoplasms
62583386|NCT02430649|NO_INTERVENTION|Control|The patients without treatment
62583387|NCT06226545|EXPERIMENTAL|Randomized low-dose LASN01 (anti-IGF-1R-naïve TED)|
62583388|NCT06226545|EXPERIMENTAL|Randomized high-dose LASN01 (anti-IGF-1R-naïve TED)|
62583389|NCT06226545|PLACEBO_COMPARATOR|Randomized placebo (anti-IGF-1R-naïve TED)|
62583390|NCT06226545|EXPERIMENTAL|Open-label high dose LASN01 (post-teprotumumab, US only)|
62735059|NCT05878873|EXPERIMENTAL|Split-belt Treadmill Training with TENS|During this arm, participants will perform split-belt treadmill training with active sensory stimulation occuring simultaneously during all adaptation sessions.
62019396|NCT05446740|EXPERIMENTAL|YA GSK4382276A Dose level 7 Group|Eligible YA participants receive dose level 7 of GSK4382276A study intervention administered at Day 1.
62019397|NCT05446740|EXPERIMENTAL|YA GSK4382276A Dose level 8 Group|Eligible YA participants receive dose level 8 of GSK4382276A study intervention administered at Day 1.
62019398|NCT05446740|EXPERIMENTAL|YA GSK4382276A Dose level 9 Group|Eligible YA participants receive dose level 9 of GSK4382276A study intervention administered at Day 1.
62019399|NCT05446740|EXPERIMENTAL|YA GSK4382276A Dose level 10 Group|Eligible YA participants receive dose level 10 of GSK4382276A study intervention administered at Day 1.
62019400|NCT05446740|EXPERIMENTAL|YA GSK4382276A Dose level 11 Group|Eligible YA participants receive dose level 11 of GSK4382276A study intervention administered at Day 1.
62210977|NCT06017934|EXPERIMENTAL|Volunteer-led physical activity|Trained volunteers will deliver walking, or bedside exercises with hospitalised older adults twice per day.
62407868|NCT01366846|EXPERIMENTAL|Peanut avoidance after continuous peanut consumption|These participants were the peanut consumption group of the ITN032AD (LEAP) study
62407869|NCT01366846|EXPERIMENTAL|Continued peanut avoidance|These participants were the peanut avoidance group of the ITN032AD (LEAP) study
62407870|NCT01280760||Non invasive ventilation|Non-invasive ventilation after invasive mechanical ventilation weaning
62210978|NCT01451892|EXPERIMENTAL|Dance therapy|overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
62210979|NCT01451892|ACTIVE_COMPARATOR|Education|overweight individuals participating in a patient education ambulatory program for obese people
62210980|NCT05180331|EXPERIMENTAL|Mobile Application to Prevent Suicide (MAPS)|"Participants receiving MAPS will receive the Safety Planning Intervention (SPI) which will be uploaded into the smartphone app. They will be prompted four times per day to complete a brief ecological momentary assessment check-in inquiring about their cognitions, affect, and behavior, including suicidal thoughts and behaviors. Based on these responses, they will be provided with coping strategies from their safety plans and from a database of coping strategies created by study staff. They will also have access to emergency phone numbers, the coping strategies database, and can communicate with their study clinician through a text-like interface in the app. They will receive this intervention for one month."
62210981|NCT03428529|EXPERIMENTAL|Capecitabine|Neoadjuvant capecitabine plus RT
62210982|NCT03428529|ACTIVE_COMPARATOR|5-Flourouracil|Neoadjuvant 5-Fluorouracil plus RT
62210983|NCT05523843||Treatment seeking individuals|Individuals seeking treatment in the Laureate Psychiatric Clinic and Hospital (LPCH).
62210984|NCT05523843||Healthcare professionals|Healthcare professionals (HCPS) include nurses, psychologists, therapists, medical doctors, dieticians, etc who work at LPCH and are engaged in direct patient care.
62210985|NCT01517295|EXPERIMENTAL|Group 1|Blood will be drawn at 0, 1, 3, and 5 hours after taking one dose of hydrocodone/APAP. Urine will be taken at hour 0 and 3.
62210986|NCT01517295|EXPERIMENTAL|Group 2|Blood will be drawn at 0, 2, 4, and 6 hours after one dose of hydrocodone/APAP. Urine will be taken at hour 0 and 4.
62210987|NCT01378689|EXPERIMENTAL|Online video|Participants in this arm are shown a brief video (\~5 minutes) after ordering a refill for their glucocorticoid use. The video includes real patients telling their own story about the possible side effects of prolonged use of glucocorticoids.
62210988|NCT01378689|NO_INTERVENTION|No video|
62210989|NCT05635305|EXPERIMENTAL|BE study|"Cohort 1 (BE) is a four-period, four-sequence, four-treatment crossover BE and food effect study of zoliflodacin granules for oral suspension manufactured by Dr. Reddy's (test product, ZoliDr) and those manufactured by Patheon (reference product, ZoliPa) as a 3 g oral dose under fasting and a \[specific\] fed condition. This cohort will comprise of approximately 32 subjects (8 healthy subjects per treatment sequence) in 4 x 4 BE treatment arms in fasted and \[specific\] fed conditions. Healthy subjects will be randomized into 4 parallel treatment sequences to receive sequential Treatments A, B, C, and D in William's Square design pattern where:~* Treatment A is ZoliPa fasted~* Treatment B is ZoliDr fasted~* Treatment C is ZoliPa \[specific\] fed condition~* Treatment D is ZoliDr \[specific\] fed condition~Based on William's Square design, below treatment sequences will be followed:~A-B-C-D B-A-D-C C-D-A-B D-C-B-A"
62407871|NCT06452862||Diabetics|Participants with diagnosed Diabetes will undergo the same MRI protocol as the Healthy Volunteers, including Blood Oxygen Level Dependence (BOLD), Intravoxel Incoherent Motion (IVIM), Arterial Spin Labeling (ASL), T1\&T2-mapping imaging and Magnetic Resonance Elastography (MRE). In addition to the imaging, these participants will have their blood creatinine, cystatin C, and blood pressure measured within 3 days before and after the MRE. A renal biopsy will be performed as part of their clinical assessment to evaluate the extent of kidney damage.
62407872|NCT06452862||Healthy Volunteers|Age-matched healthy individuals with no known kidney disease will be recruited. They will undergo the same MRI protocols as the Diabetics group, including Blood Oxygen Level Dependence (BOLD), Intravoxel Incoherent Motion (IVIM), Arterial Spin Labeling (ASL), T1\&T2-mapping imaging and Magnetic Resonance Elastography (MRE), to establish baseline viscoelasticity parameters for comparison with the Diabetics.
62407873|NCT06651463|EXPERIMENTAL|Video Capture|Brain of patients, presenting a brain pathology eligible for a neurosurgery operation requiring a standard functional and/or histological diagnosis at HCL, will be video recorded with colorimetric cameras in order to evaluate the feasibility of identifying tissue.
62583391|NCT03598257|EXPERIMENTAL|Group I (olaparib, radiation therapy)|Patients receive olaparib PO BID the day before standard RT commences (Day 0) and throughout the RT course until the last day of RT administration. Olaparib is also continued on weekends (routine days without RT) throughout the RT course. Patients undergo standard radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study.
62583392|NCT03598257|ACTIVE_COMPARATOR|Group II (radiation therapy)|Patients undergo standard radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study.
62583393|NCT03371017|EXPERIMENTAL|Atezolizumab|Participants will receive Atezolizumab on day 1 of each 3-week treatment cycle
62583394|NCT03371017|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo on day 1 of each 3-week treatment cycle
62210990|NCT05635305|EXPERIMENTAL|DDI study|This is an open-label, 2-period, 2-treatment, fixed sequence crossover DDI study in healthy subjects. It will investigate PK of zoliflodacin (ZoliPa) in the absence and presence of itraconazole. Approximately 18 subjects will receive ZoliPa on Day 1 under fasting condition. After a washout of 72 hours after dosing of ZoliPa, on Day 4, subjects will receive a 400 mg loading dose of itraconazole followed by 200 mg of itraconazole once daily from Day 5-8. From Day 4 to Day 8, itraconazole will be administered immediately after a full meal. On Day 9, both itraconazole and zoliflodacin (ZoliPa) will be administered under fasting conditions at -1 hours and 0 hours, respectively. Itraconazole will then be administered with food at 24 hours (Day 10) and 48 hours (Day 11) after administration of zoliflodacin (ZoliPa).
62210991|NCT00258557|EXPERIMENTAL|002|TMC-114/RTV two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
62210992|NCT00258557|ACTIVE_COMPARATOR|001|LPV/RTV 400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
62210993|NCT01018238|PLACEBO_COMPARATOR|Placebo arm|
62210994|NCT01018238|EXPERIMENTAL|Cohort 1|
62210995|NCT01018238|EXPERIMENTAL|Cohort 2|
62210996|NCT01018238|EXPERIMENTAL|Cohort 3|
62583395|NCT04267757|EXPERIMENTAL|group 1|RVF with Martius flap
62210997|NCT01018238|EXPERIMENTAL|Cohort 4|
62583396|NCT04267757|EXPERIMENTAL|group 2|RVF without Martius flap
62407874|NCT04656249|EXPERIMENTAL|Lenvatinib|Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing \<60 kg and 12mg/d to those ≥60 kg.
62583397|NCT03222089|EXPERIMENTAL|FOLFOXIGIL|"The FOLFOXIGIL chemoimmunotherapy regimen is composed by FOLFOXIRI chemotherapy and the immunotherapy of GM-CSF and IL-2.~FOLFOXIRI: Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, repeated every 2 weeks.~GM-CSF 150ug s.c. d3-7; Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity."
62407875|NCT01473537|ACTIVE_COMPARATOR|calcium lactate solution 75 mM|
62407876|NCT01473537|ACTIVE_COMPARATOR|calcium lactate solution 150 mM|
62583398|NCT03222089|ACTIVE_COMPARATOR|FOLFOXIRI|"Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, Repeated every 2 weeks.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity."
62210998|NCT04744272|ACTIVE_COMPARATOR|Intervention|Participants randomised to the intervention arm will be provided with access to the digital web-based application (app) myAsthma.
62210999|NCT04744272|NO_INTERVENTION|Control|Participants randomised to the control arm will continue with standard care processes
62211000|NCT03231280|EXPERIMENTAL|SB-061|SB-061
62211001|NCT03231280|PLACEBO_COMPARATOR|Placebo|Placebo
62211002|NCT02495792|NO_INTERVENTION|Control group|Group does not receive the biofeedback sensor
62583399|NCT05161780|ACTIVE_COMPARATOR|Normal Saline|This study will be a prospective double blinded randomized controlled trial. Fifteen patients will be randomly assigned to the normal saline group using a random number generator.
62583400|NCT05161780|EXPERIMENTAL|Lactated Ringer's Irrigation|This study will be a prospective double blinded randomized controlled trial. Fifteen patients will be randomly assigned to the lactated reinger group using a random number generator.
62583401|NCT02064712|ACTIVE_COMPARATOR|Low CPAP Wean|NCPAP weaned to 5cm H2O for minimum of 24h, and if the neonate remains clinically stable as defined, wean in 1cm increments to 3cm H2O for minimum of 24h, at which time move to room air or 1L/min nasal cannula if supplemental O2 is required.
62583402|NCT02064712|ACTIVE_COMPARATOR|High CPAP Wean|NCPAP weaned to 5cm H2O for a minimum of 24h, and if the neonate remains clinically stable, move to room air or 1L/min nasal cannula if supplemental O2 is required.
62583403|NCT01258998|EXPERIMENTAL|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62583404|NCT02429661|EXPERIMENTAL|RC (Girls First Resilience Curriculum)|The Girls First Resilience Curriculum is delivered in peer support groups of 12-15 students per group over 23 weekly 1-hour sessions. The curriculum draws from fields such as positive psychology, emotional competence/intelligence, and restorative practices, and aims to improve students' psychosocial assets and wellbeing.
62583405|NCT02429661|EXPERIMENTAL|HC (Girls First Health Curriculum)|The Girls First Health Curriculum is delivered in peer support groups of 12-15 students per group over 21 weekly 1-hour sessions. The curriculum covers topics such as nutrition, sexual and reproductive health, clean water, hygiene, and common diseases, and aims to improve students' physical health and wellbeing.
62583406|NCT02429661|EXPERIMENTAL|RC+HC (Girls First)|Girls First is a combination of the Girls First Resilience Curriculum (RC) and the Girls First Health Curriculum (HC).
62583407|NCT02429661|NO_INTERVENTION|SC (School-as-usual control)|Participants receive no intervention and attend school as they usually would.
62211003|NCT02495792|EXPERIMENTAL|Biofeedback group|Group does receive the biofeedback sensor
62211004|NCT06727981||ICI plus chemotherapy|
62211005|NCT06727981||Chemotherapy|
62211006|NCT05559320|EXPERIMENTAL|Single Joystick Ride-on-car Navigation Training|Participants will first participate in a 6-week control phase followed by a 6-week intervention phase. During the intervention phase, they will receive the ride-on-toy navigation training program. The training will be provided by the researchers twice a week, 30-45 minutes/session for 6 weeks. Caregivers will be asked to provide 2 additional sessions/week during the intervention phase. In this study design, the participants will serve as their own controls.
62583408|NCT06675110||Suscpected scrub typhus cases|"Participants with symptoms and epidemiologic risks for of scrub typhus and testing positive by:~1. StandardQ rapid diagnostic test OR~2. InBios Scrub Typhus Detect IgM~3. Insulated isothermal PCR"
62735060|NCT02991898|EXPERIMENTAL|Treg Infusion|The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion
62211007|NCT06319716|EXPERIMENTAL|VIDEO|Participants assigned to the VIDEO arm will receive one brief Diabetes Self-Management Education and Support (DSMES) video per week for 24 weeks. The videos will be delivered via text message.
62735061|NCT02968446|PLACEBO_COMPARATOR|Group 1: 4 placebo - 0 Vitamin D with Valchlor|Participants will be given 4 placebo capsules and 0 cholecalciferol (Vitamin D) capsules after being treated with Valchlor.
62211008|NCT06319716|EXPERIMENTAL|VIDEO+CHW|Participants assigned to the VIDEO+CHW arm will receive one brief DSMES video per week, in addition to bi-weekly support calls from a community health worker (CHW), for 24 weeks. The DSMES videos will be delivered via text message.
62211009|NCT06319716|NO_INTERVENTION|CONTROL|Participants assigned to the CONTROL group will continue to receive usual care.
62211010|NCT03915964|EXPERIMENTAL|Baricitinib Low Dose|Baricitinib administered orally.
62211011|NCT03915964|EXPERIMENTAL|Baricitinib High Dose|Baricitinib administered orally.
62211012|NCT03915964|ACTIVE_COMPARATOR|TNF Inhibitor|Adalimumab or etanercept administered subcutaneously (SC) per standard of care.
62211013|NCT04411160||Group A|Patients of group A received inhalation of nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose.
62407877|NCT01473537|PLACEBO_COMPARATOR|placebo|
62407878|NCT04633434|EXPERIMENTAL|The Talk Parenting Skill for Alexa - Parent|49 parents will be assessed at enrollment, then provided an Amazon Echo Dot and exposed to the prototype Bedtime Routine module of the Talk Parenting program for 4 weeks, and then re-assessed at 4 weeks (at treatment completion)
62211014|NCT04411160||Group B|While patients of group B received 4 gram of vitamin c slowly intravenous once daily for 4 days duration.
62211015|NCT01416389|EXPERIMENTAL|LY2523355 + pegfilgrastim or filgrastim|LY2523355: Five milligrams per meter squared per day (mg/m\^2/day) (dosage determined by calculating participant's body surface area) administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Pegfilgrastim or Filgrastim: Dosage is determined by standard of care and is administered intravenously on Day 4 of 21-day Cycle for 2 Cycles. If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.
62211016|NCT01416389|ACTIVE_COMPARATOR|ixabepilone|Forty milligrams per meter squared per day (mg/m\^2/day) (dosage determined by calculating participant's body surface area) administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles. If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.
62211017|NCT03412201|ACTIVE_COMPARATOR|Usual Care|Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards
62211018|NCT03412201|EXPERIMENTAL|High Intensity Care|Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 2 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.
62211019|NCT01708304|OTHER|RDAD|Exercise training for caregiver and care recipient. Behavior modification training for caregiver.
62583409|NCT04792801||Patients with HCC and whose liver transplant plan has been validated|"Prospective inclusion of patients who are candidates for a transplant for CHC at the University Hospital of Lille and Rouen whose transplant project has been validated with a AFP score ≤ 2.~The systematic performance of a PET-CT with FDG and a PET-CT with Choline in all patients. At the end of the entire assessment, the patients will be (or not) registered on the transplant list and, for the patients registered on the list, a follow-up will be carried out at the level of a specialized transplant consultation every 3 months at during which the alphafoetoprotein dosage and abdominal imaging will be updated, until liver transplantation."
62583410|NCT06097013||Prolonged disorders of consciousness|Admission criteria for patients with prolonged disorders of consciousness Inclusion Criteria
62583411|NCT06097013||Acute disorders of consciousness|Admission criteria for patients with acute disorders of consciousness Inclusion Criteria
62583412|NCT06085469|EXPERIMENTAL|Intervention Group|Used Temporal Adaptation Approach
62211020|NCT04817761|EXPERIMENTAL|Calaspargase pegol (S95015)|
62211021|NCT02955147|EXPERIMENTAL|Ustekinumab plus prednisone|"1. Ustekinumab: 90 mg of ustekinumab will be administered subcutaneously at baseline, week 4, week 12, week 20, week 28, week 36 and week 44.~2. Prednisone: All patients will receive a prednisone course tapered according to predefined schedules starting at either 60 mg, 40 mg or 20 mg. The initial dose of prednisone will be chosen by the investigators according to disease severity and comorbid medical conditions. The duration of the prednisone taper will be 6 months in all cases."
62211022|NCT02093949||Studied|Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation
62211023|NCT02093949||Control|The validation set included a cohort of 47 patients with symptomatic drug-refractory AF who underwent ablation using a conventional approach.
62211024|NCT05369195|EXPERIMENTAL|LAAC with neuroprotection|Arm in which is used a transcatheter system to protect the cerebral circulation during the left atrial appendage closure procedures.
62583413|NCT06085469|NO_INTERVENTION|Control Group|Follow up via telephone calls
62583414|NCT03567005|OTHER|DACP Digital then DACP|Nelfilcon A digital contact lenses worn first, followed by nelfilcon A contact lenses. Each product worn bilaterally (in both eyes) for 7 days in a daily disposable modality.
62583415|NCT03567005|OTHER|DACP then DACP Digital|Nelfilcon A contact lenses worn first, followed by nelfilcon A digital contact lenses. Each product worn bilaterally for 7 days in a daily disposable modality.
62583416|NCT01826578|EXPERIMENTAL|single port arm|
62583417|NCT01826578|NO_INTERVENTION|Conventional arm|Using 3-4 port for laparosocpic surgery
62583418|NCT01311076|EXPERIMENTAL|TAK-329 50 mg|
62583419|NCT01311076|EXPERIMENTAL|TAK-329 200 mg|
62211025|NCT05369195|PLACEBO_COMPARATOR|LAAC without neuroprotection|Arm in which the left atrial appendage closure procedures are performed without transcatheter cerebral protection.
62211026|NCT06250790||Assigned to Best Medical Therapy (BMT) alone|Patients who have undergone successful lower extremity revascularization and are assigned to BMT alone within 14 days following revascularization.
62211027|NCT06250790||Assigned to Best Medical Therapy (BMT) + coronary CT angiography + CT-FFRct analysis|Patients who have undergone successful lower extremity revascularization and are assigned to BMT plus coronary CT angiography (which must be completed within 14 days of randomization) and FFRct analysis to determine the functional significance of coronary lesions identified on the CT scan.
62211028|NCT04809506||Patient consulting the Centre for Screening and Prevention of Atherosclerosis|2 additional blood samples (2 x 7ml) at every visit
62211029|NCT04138264|ACTIVE_COMPARATOR|Peroperative counseling|
62583420|NCT01311076|ACTIVE_COMPARATOR|Insulin 0.2 U/kg|
62583421|NCT01311076|PLACEBO_COMPARATOR|Placebo|
62583422|NCT05018923|EXPERIMENTAL|RBMD group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and doxycycline 0.1 g bid for 14 days
62211030|NCT04138264|NO_INTERVENTION|No preoperative counseling|
62211031|NCT00736268|EXPERIMENTAL|CST|Telephone-based Enhanced Coping Skills Training (CST)
62211032|NCT00736268|OTHER|UMC|Usual Medical Care and COPD education and symptom monitoring (UMC)
62211033|NCT02597335|EXPERIMENTAL|IDH1/IDH2|
62583423|NCT05018923|ACTIVE_COMPARATOR|RAMT group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and tetracycline 0.5 g qid for 14 days
62583424|NCT00832611|EXPERIMENTAL|Experimental: Group A Anastomotic Coupler|Device: ROX Anastomotic Coupler System (ACS). The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
62211034|NCT06727916|EXPERIMENTAL|BBT-I Group|Participants in the intervention group will receive BBT-I in 4 consecutive sessions in addition to standard care.
62211035|NCT06727916|OTHER|Control Group|Patients in the control group will receive standard care.
62211036|NCT05628168|EXPERIMENTAL|Group A|The NMG received three sessions/week for 4 weeks with each session lasting for 30 min including slider and tension neurodynamic techniques.
62211037|NCT05628168|ACTIVE_COMPARATOR|Group B|The participants only received a selected therapy program similar to the NMG with no change in duration.
62583425|NCT03383640|NO_INTERVENTION|Control|Control Group: Standardized post operative rehabilitation, where active exercises of the replanted digits is postponed until radiologic healing of the amputated bone.
62583426|NCT03383640|OTHER|Intervention|Intervention Group: Early active exercises of the replanted digits started between day 5 and 7 after surgery, as instructed by hand therapist
62583427|NCT05348291|ACTIVE_COMPARATOR|Ventilation tubes|Ventilation tube surgery
62211038|NCT01383564|ACTIVE_COMPARATOR|CPAP group|CPAP group
62407879|NCT04633434|EXPERIMENTAL|The Talk Parenting Skill for Alexa - Child|Although 49 children were considered enrolled participants that actively participate in the intervention, we obtained no assessment data from the children themselves.
62407880|NCT02452775|EXPERIMENTAL|Arm 1|Subjects in ARM 1 will receive the vaccination with OC-L alone
62407881|NCT02452775|EXPERIMENTAL|Arm 2|subjects in ARM 2 will receive vaccination with OC-L admixed with Montanide,
62407882|NCT02452775|EXPERIMENTAL|Arm 3|subjects in ARM3 will receive vaccination with OC-L admixed with 1 mg poly-ICLC (Hiltonol)
62407883|NCT02452775|EXPERIMENTAL|Arm 4|subjects in ARM 4 will receive vaccination with OC-L admixed with both Montanide and 1 mg poly-ICLC.
62407884|NCT02088866|EXPERIMENTAL|Transdermal Lidocaine|All patients will be in this arm. This arm will be the transdermal lidocaine group.
62407885|NCT02513095|EXPERIMENTAL|Ryanodex|Ryanodex (dantrolene sodium) for injectable suspension administered as an IV bolus, in addition to standard of care (SOC) treatment.
62407886|NCT02513095|NO_INTERVENTION|Standard of Care only (SOC)|Standard of Care (SOC) treatment only, consisting of body cooling and supportive measures implemented immediately.
62407887|NCT00681876|EXPERIMENTAL|1|Irinotecan+Avastin+Erbitux
62407888|NCT02477462||Primary Biliary Cirrhosis|Subjects meeting internationally accepted criteria for the diagnosis of primary biliary cirrhosis
62407889|NCT02477462||Control|Subjects without evidence of primary biliary cirrhosis, liver disease, or inflammatory condition who are of similar age and sex distribution to the Primary Biliary Cirrhosis group
62407890|NCT05562232|EXPERIMENTAL|Intervention group|Creatine monohydrate administered once a day for seven weeks - with 5 g/day for the entire period.
62407891|NCT05562232|NO_INTERVENTION|Control group|The control group will receive standard care. However, to our knowledge there is no common accepted description of a standard care in the literature. In general, these participants will be advised to keep themselves as asymptomatic as possible throughout the entire seven weeks, and besides that live as normal a life as they can.
62407892|NCT05562232|PLACEBO_COMPARATOR|Placebo|Powdered Sugar administered once a day for seven weeks - with 5g/day for the entire period.
62407893|NCT05488067|EXPERIMENTAL|Atorvastatin+ALGS-Xanthoma|"Drug: atorvastatin Dosage form: tablet Route of administration: oral Duration: 6 months （After 6 months of medication, according to the actual situation of the patient, choose to maintain the original dosage, gradually reduce the dosage or stop the medication）~Administration method:~Initial dose: ① \< 1 year old: 1.25mg/d, qd; ② 1-5 years old: 2.5mg/d, qd; ③ 6-9 years old: 5mg/d, qd; ④ ≥ 10 years old: 10mg/d, qd. The maximum dose is 40mg/d and not more than 1mg/kg/d. During the follow-up, the medication was adjusted according to the laboratory results until non-HDL-C≤4.2mmol/L（162 mg/dL）, xanthoma disappear, or the patient had moderate or more serious adverse reactions."
62407894|NCT05805072|EXPERIMENTAL|Selinexor+HAAG±HMA|
62583428|NCT05348291|NO_INTERVENTION|Active monitoring|Active monitoring of patients, with the possibility to cross over to other arm if deemed necessary.
62735062|NCT02968446|EXPERIMENTAL|Group 2: 0 placebo - 4 Vitamin D with mechloroethamine|Participants will be given 0 placebo capsules and 4 cholecalciferol capsules to total 200,000 IU of cholecalciferol (Vitamin D) after being treated with Valchlor.
62211039|NCT01383564|PLACEBO_COMPARATOR|non CPAP group|non CPAP group
62211040|NCT03570489|ACTIVE_COMPARATOR|Exercise|Use of an ergometric bicycle where patients will bicycle 5 Days a week for 20 minutes at a predetermine level
62211041|NCT03570489|SHAM_COMPARATOR|Relaxation|Patients will listen to a relaxation exercise involving muscle relaxation. This takes about 20 minutes and will be performed 5 Days/week
62211042|NCT02320981||EGD with Biopsy|Pediatric patients scheduled for standard of care EGD with biopsy also received measurement of mucosal impedance
62211043|NCT04464278||Case group: weight loss ≥ 5%|
62211044|NCT04464278||Control group: weight loss ≤ 5%|
62211045|NCT02877888|EXPERIMENTAL|drug fluoride varnish /strength 22600ppm|intervention: drug :fluoride varnish 22600ppm topical application every 6 months for a total period of 2 years
62211046|NCT02877888|NO_INTERVENTION|placebo comparator|placebo:use of routine dental advice
62211047|NCT03732742|EXPERIMENTAL|TOF repair with preservation of PV|Surgical intervention by repair of Tetralogy of Fallot with preservation of pulmonary valve, recently interested has shifted to preserving the integrity of the pulmonary valve.
62407895|NCT02188927|EXPERIMENTAL|Implementation of ANL|"Intervention: Procedure : Implementation of routine Advanced Notification Letter included in Standard Invitation procedure~Advanced Notification Letter will be implemented in invitation procedure and send two weeks before Standard Invitation (Standard Invitation will be send six weeks before planned screening colonoscopy)"
62407896|NCT02188927|ACTIVE_COMPARATOR|No included ANL|Intervention: Behavioral : No included Advanced Notification Letter Sending Standard Invitation six weeks before planned screening colonoscopy
62407897|NCT05925478|EXPERIMENTAL|Treatment arm|
62407898|NCT01113073|EXPERIMENTAL|Elective open heart surgery|Patients who had undergone elective open heart surgery
62407899|NCT02586909|EXPERIMENTAL|RVT-101 35 mg tablets|once daily, oral tablets
62211048|NCT03732742|EXPERIMENTAL|TOF repair with trans-annular patch|Surgical intervention by repair of Tetralogy of Fallot with trans-annular patch, right ventricular hypertrophy, right ventricular dilatation and pulmonary vavle regurgitation has been recognized as one of the most important risk factors for both right and left ventricular performance after the repair of Tetralogy of Fallot.
62211049|NCT06728371|EXPERIMENTAL|Methadone group: Intervention|0.2mg/kg methadone
62211050|NCT06728371|ACTIVE_COMPARATOR|Morphine group: control|Equipotent dose of morphine (0.2mg/kg)
62211051|NCT06182891|EXPERIMENTAL|Dulaglutide|Dulaglutide was injected subcutaneously at standard dose and frequency for consecutive 12 months.
62211052|NCT06182891|ACTIVE_COMPARATOR|other hypoglycemic agents not including GLP-1 receptor agonists|Other hypoglycemic agents not including GLP-1 receptor agonists were used at standard dose and frequency for consecutive 12 months.
62211053|NCT02886182||group A|pregnants who were positivity for serum HBsAg for more than 6 months and HBeAg , HBV DNA \>106IU/mL, alanine aminotransferase (ALT) below 35 IU/mL (ULN=40IU/mL) and no received nucleoside analogue antiviral therapy were enrolled into group A
62211054|NCT02886182||group B|the CHB infection pregnants with undetectable HBVDNA were enrolled into group B(control group)
62211055|NCT06729554|EXPERIMENTAL|Intervention Group (IG)|Participants are randomized in an intervention group (IG) and a waiting list control group (WLG). The IG receive the intervention with Education \& Care in RARE (all children) and complete the identical questionnaires (all children and their legal guardians) immedeately after inclusion.
62211056|NCT06729554|ACTIVE_COMPARATOR|Waiting List Control Group (WLG)|Compared to the IG, the WLG receives the intervention with Education \& Care in RARE with a time delay (8-12 weeks later) and has one additional appointment for questionnaire evaluation before start of the intervention.
62211057|NCT03347097|EXPERIMENTAL|TIL cells|10 days after the end of chemotherapy or radiotherapy，the 300ml TIL cells ( TIL saline + 0.25% human serum albumin) was injected intravenously 2 times every 30 days .
62211058|NCT03347097|EXPERIMENTAL|PD1-TIL cells|10 days after the end of chemotherapy or radiotherapy，the 300ml PD1-TIL cells ( PD1-TIL saline + 0.25% human serum albumin) was injected intravenously 2 times every 30 days .
62407900|NCT03735680|EXPERIMENTAL|Patients receiving ONM-100|All patients in this arm will receive ONM-100 for injection and undergo intraoperative imaging.
62019401|NCT05446740|ACTIVE_COMPARATOR|YA Control 1 Group|Eligible YA participants receive single dose of FDQ21A-NH administered at Day 1.
62211059|NCT04647552||hydrocortisone|The patients with septic shock who required a noradrenaline infusion rate above 0.5µg/kg
62211060|NCT04647552||control|The patients with septic shock who needed a noradrenaline infusion rate of up to 0.5µg/kg/min to maintain MAP\>65 mmHg
62211061|NCT00960453|OTHER|Sitagliptin 25mg|Repeated administrations for 4 days
62583429|NCT06685549||pregnant patients after first trimester without any complaint|Patients with a similar age and gestational age, who were not exposed to any trauma, who had no health problems, and who applied to the outpatient clinic for follow-up were randomized with a computer program and formed a control group. The birth week, birth weight, type of birth, and admission to the neonatal intensive care unit of the control group were evaluated.
62211062|NCT00960453|OTHER|Sitagliptin 50mg|Repeated administrations for 4 days
62211063|NCT00960453|OTHER|Sitagliptin 100mg|Repeated administrations for 4 days
62211064|NCT02686827|EXPERIMENTAL|Paricalcitol (Vitamin D3)|paricalcitol, (Zemplar® 5 μg/ml Abbvie), will be administered via the subcutaneous route 4 times at 0.5 ml (registered dose of 5 μg/ml, thus 2.5 μg per sub-cutaneous injection). The minimum time interval between two injections is 4 days, which is a significantly lower frequency than the prescribed maximum of 3 times a week or every other day.
62211065|NCT02686827|ACTIVE_COMPARATOR|Placebo|Placebo, the same constituents as Zemplar (propylene glycol 30% (v/v) alcohol 20% (v/v)) but no paricalcitol, same dosage as verum-arm.
62583430|NCT06685549||isolated head trauma and pregnancy group|The criteria for inclusion in the study were as follows: all of the pregnant women over 18 years of age with isolated head trauma (closed blunt trauma) who were evaluated with neurosurgical consultation or computed tomography/magnetic resonance (CT/MRI) and whose birth records are available at our hospital.
62583431|NCT00900159|EXPERIMENTAL|eszopiclone|Treatment with eszopiclone
62019402|NCT05446740|ACTIVE_COMPARATOR|YA Control 2 Group|Eligible YA participants receive single dose of FDQ22A-NH administered at Day 1.
62019403|NCT05446740|EXPERIMENTAL|OA GSK4382276A Group|Eligible OA participants receive single dose of GSK4382276A study intervention at 1 dose level selected from the first 3 dose levels in YAs, administered at Day 1.
62019404|NCT05446740|ACTIVE_COMPARATOR|OA Control Group|Eligible OA participants receive single dose of FDQ21A-NH administered at Day 1.
62019405|NCT04757012|EXPERIMENTAL|Calinage exposition|exposition to a maternal voice and heartbeat recording during hospital stay for preterm newborns at D2, D4 and D6
62019406|NCT04757012|NO_INTERVENTION|no exposition|No exposition to a maternal voice and heartbeat recording during hospital stay for preterm newborns at D1, D3 and D5
62211066|NCT03245853|OTHER|Treatment|Treatment as per protocol, there is no placebo arm.
62211067|NCT06727773|EXPERIMENTAL|Arm 1|Participants will receive study medication (memantine) and Get Real \& Heel exercise guided by the therapist.
62211068|NCT06727773|PLACEBO_COMPARATOR|Arm 2|Participants will receive a placebo and access to the Get Real \& Heel exercise library (exercise Control).
62211069|NCT06727773|EXPERIMENTAL|Arm 3|Participants will receive a study medication (memantine) only.
62211070|NCT05249491||Group 1|Children with black tooth stain
62211071|NCT05249491||Group 2|Children without black tooth stain
62407901|NCT01151709||physicians|primary care practitioners, both family practice and internal medicine physicians from a random sample of providers nationwide
62583432|NCT00900159|PLACEBO_COMPARATOR|matching placebo|Treatment with matching placebo
62583433|NCT03149133|EXPERIMENTAL|Classical Hypertrophy|The classical hypertrophy group performs strength training with 75-80% of 1-Repetition Maximum.
62019407|NCT02863016||Concentrate SelectBag One|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution: first of all concentrate SelectBag One (with 3 mM of acetic acid and 0 mM of citrate)
62211072|NCT03640572||Bone Marrow DTC|Patients with left-sided colorectal cancer and disseminated tumour cells in the bone marrow
62407902|NCT02599298|ACTIVE_COMPARATOR|SGMT arm|Treatment of OSA requires a multidisciplinary approach, involving a sleep physician and paramedical staff with expertise in the management of sleep disorders. An initial medical assessment is needed to confirm the diagnosis of OSA, determine its severity and decide whether CPAP therapy is appropriate. As part of this evaluation, an objective overnight sleep study will be performed. This will be followed by an assessment, education, and counseling at the multidisciplinary therapy clinic.
62407903|NCT02599298|NO_INTERVENTION|Control arm|The patients will be treated according to the standard treatment for acute coronary syndrome in Singapore, which is largely in accordance with the recommendations of the American College of Cardiology and the American Heart Association. Management includes, but is not limited to, antiplatelet and lipid-lowering therapy, early coronary revascularization, and cardiac rehabilitation, with the recommendation to follow the current practice and the most recent international guidelines.
62211073|NCT03640572||No bone marrow DTC|Patients with left-sided colorectal cancer and no disseminated tumour cells in the bone marrow
62211074|NCT01862107||Healthy Volunteer|Any healthy volunteer getting a lumbar puncture done for either clinical care or research purposes.
62211075|NCT01862107||Patient|Any patient getting a lumbar puncture done for either clinical care or research purposes.
62407904|NCT01357382|NO_INTERVENTION|low fat diet|replace high fat, energy dense foods with foods rich in whole grains, fruits and vegetables. The macronutrient distribution of this diet will be approximately 55% carbohydrate, 15% protein and 30% fat. Individuals will also be instructed to reduce sodium intake to \< 2300 mg / day and in individuals with hypertension, \< 1500 mg / day.
62407905|NCT01357382|EXPERIMENTAL|low carbohydrate diet|restrict carbohydrate consumption to \< 20 grams / day while not restricting caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' to increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
62583434|NCT03149133|EXPERIMENTAL|Occlusive Training|The occlusive hypertrophy group performs strength training with %35-50 of 1-Repetition Maximum.
62019408|NCT02863016||Concentrate SelectBag Citrate|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution, then with SelectBag Citrate (with 0 mM of acetic acid and 1 mM of citric acid)
62019409|NCT02291718|ACTIVE_COMPARATOR|Isovue 300 75mL|Isovue 300 75mL injected 120 kVp 250 mAs
62211076|NCT04606108|EXPERIMENTAL|Experimental|camrelizumab in combination with Liposome doxorubicin and Ifosfamide intervention
62211077|NCT00400127|EXPERIMENTAL|amputee|
62211078|NCT06208254||Patients|Patients having at least one rough surface titanium implant in function for more than 5 years.
62211079|NCT05089656|EXPERIMENTAL|OAV101|OAV101 administered as a single, one-time intrathecal dose of 1.2 x 10\^14 vector genomes (vg).
62211080|NCT05089656|SHAM_COMPARATOR|Sham control|A skin prick in the lumbar region without any medication.
62211081|NCT05107128|EXPERIMENTAL|SAGE-718|Participants will receive SAGE-718, once daily for 84 days.
62211082|NCT05107128|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo, once daily for 84 days.
62211083|NCT02046629|EXPERIMENTAL|teriflunomide dose 1|Teriflunomide 14mg tablet, oral single dose, fast condition Cholestyramine power, 8 gram,oral three times a day for 4 days, fed condition
62211084|NCT01719705|PLACEBO_COMPARATOR|Placebo|receive two identical placebo capsules
62211085|NCT01719705|ACTIVE_COMPARATOR|Pregabalin 150 mg group|one capsule of pregabalin 150 mg
62583435|NCT01502332|EXPERIMENTAL|Intensive Alveolar Recruitment|Recruitment with opening pressures of 45 cmH2O in the airways.
62019410|NCT02291718|ACTIVE_COMPARATOR|Isovue 370 75mL|Isovue 370 75mL injected 100 kVp 240 mAs
62019411|NCT02291718|ACTIVE_COMPARATOR|Isovue 370 60mL|Isovue 370 60mL injected 100 kVp 240 mAs
62019412|NCT03892941|EXPERIMENTAL|Imaged based fitting|Mapping of the electrical input of the cochlear implant will be based on an individualized natural frequency alignment as estimated with imaging methods.
62019413|NCT03892941|NO_INTERVENTION|Clinical routine|Mapping of the electrical input of the cochlear implant will be based on a one-size-fits-all, as is part of clinical routine.
62019414|NCT04177693|EXPERIMENTAL|EGCG daily alone.|EGCG daily alone. 800mg
62019415|NCT04177693|EXPERIMENTAL|EGCG with clomiphene citrate|EGCG 800 mg daily with clomiphene citrate 100mg for 5 days.
62211086|NCT01719705|ACTIVE_COMPARATOR|Pregabalin 300 mg group|two capsules of pregabalin 150 mg
62211087|NCT01071655|EXPERIMENTAL|2|"Patients with zero favorable genotype: BVZ + XELIRI.~Patients with one favorable genotype: TS 3'UTR +6bp/+6bp and ERCC1-118 T/T: BVZ + XELOX or TS 3'UTR +6bp/-6bp and ERCC1-118 C/T ó C/C: BVZ + FUIRI.~Patients with two favorable genotypes : BVZ + FUOX."
62211088|NCT01071655|ACTIVE_COMPARATOR|1|BVZ + XELOX
62211089|NCT04097353|EXPERIMENTAL|Harvesting Hope for Kids (HH4K)|Eight weekly, 60-minute sessions at a university-based farm with booster sessions. Learning is structured around fun activities to provide information about the impact of cancer treatment on children's health, as well as the importance of nutrition and physical activity in survivorship. Each session is manualized and devoted to education, a behavioral strategy applied toward a weekly goal, a cooking demonstration/taste testing, and harvesting produce from the survivor garden. Modules are offered in a group format with families together.
62583436|NCT01502332|ACTIVE_COMPARATOR|Moderate Alveolar Recruitment|Recruitment with opening pressures of 20 cmH2O in the airways.
62407906|NCT05568875|EXPERIMENTAL|e-self-management intervention|12-week e-self-management intervention consisting of exercise videos and videos with information about recommended treatment
62019416|NCT04177693|EXPERIMENTAL|EGCG with letrozole|EGCG 800mg daily with letrozole 5mg for 5 days.
62211090|NCT04097353|SHAM_COMPARATOR|Surviving Strong for Kids (SS4K)|Families assigned to enhanced usual care (SS4K) group will receive education in the form of standardized guidelines for nutrition and physical activity for survivors of childhood cancer. In a one-hour session, they will learn about the impact of cancer treatment on health and the importance of nutrition and physical activity for survivors. Families will receive websites for other educational resources. They will not have access to harvesting, remote coaching, the web portal, or behavioral training to address their child's nutrition or activity.
62583437|NCT06661954|EXPERIMENTAL|Healthy Adult Volunteers|One Arm. Repeated measures. All participants are assessed in each of the four bed-position configurations. Bed-position assessment sequence is randomized for each participant.
62583438|NCT05711485|EXPERIMENTAL|Whole blood transfusion|Whole blood transfusion x1 (20 mL/kg)
62019417|NCT03293342|EXPERIMENTAL|D CBT|Dentist administered cognitive behaviioral treatment
62019418|NCT03293342|ACTIVE_COMPARATOR|Control|Treatment as usual
62019419|NCT05091034|EXPERIMENTAL|CAMP Air|This is an e-health intervention consisting of 7 online modules. This behavioral intervention combines instruction, hands-on learning, interactive practice opportunities and tailored sessions. Teens learn about asthma, including treatment and triggers, the importance of seeing a medical provider and how they can overcome their specific barriers to seeing a medical provider, how they can talk to their parents about their asthma, and how they can care for their asthma, including managing stress and triggers. They also receive personalized feedback throughout the intervention and guidance on navigating the health care system.
62019420|NCT05091034|ACTIVE_COMPARATOR|Attention Control Asthma Education Intervention|The control intervention consists of 7 online sessions delivered via PowerPoint slides with voice-over. Teens receive information on asthma and other related health conditions, such as stress and sleep, and will be given a list of relevant websites to learn more about these topics. They will learn how to monitor their health using checklists and will be referred to a medical provider for asthma and other conditions; if they do have a medical provider, they will be provided with a referral. The asthma education component for this group lacks the interactive and personalized elements of CAMP Air, differentiating it from the experimental arm.
62019421|NCT06574087|ACTIVE_COMPARATOR|HPV- related gynecological disease arm|
62019422|NCT06574087|PLACEBO_COMPARATOR|Placebo arm|
62019423|NCT02972580||Cohort A|DMD/BMD Female Carriers who have/had an affected child (n=150)
62019424|NCT02972580||Cohort B|DMD/BMD Female non-carriers controls who have/had an affected child (n=50)
62019425|NCT02972580||Cohort C|Healthy Age-Matched Controls (n=50)
62019426|NCT02972580||Cohort D|DMD/BMD Female Carriers with no affected children (n=25)
62019427|NCT01982916|EXPERIMENTAL|AGR & Placebo|AGR tablet by qd and Placebo by bid for 4 weeks
62211091|NCT01511783|EXPERIMENTAL|E2609|E2609 at ascending doses
62211092|NCT01511783|PLACEBO_COMPARATOR|Placebo|
62211093|NCT02070679|PLACEBO_COMPARATOR|Placebo|
62211094|NCT02070679|ACTIVE_COMPARATOR|Vit-E|600 IU on 12 hours before angiography and 400 IU on 2 hours before angiography
62407907|NCT05568875|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual
62583439|NCT05711485|NO_INTERVENTION|Control|Standard-of-care
62583440|NCT04800887|ACTIVE_COMPARATOR|Extended depth of focus intraocular lens|Eyes of patients implanted with extended depth of focus lens Tecnis Eyhance
62583441|NCT04800887|ACTIVE_COMPARATOR|Monofocal intraocular lens|Eyes of patients implanted with monofocal lens Tecnis ZCB00
62019428|NCT01982916|PLACEBO_COMPARATOR|Placebo|Placebo by bid for 4 weeks
62019429|NCT01982916|ACTIVE_COMPARATOR|Active comparator|Active Comparator and Placebo by bid for 4 weeks
62019430|NCT05640934|ACTIVE_COMPARATOR|Melatonin group|The patients will be given 5 mg melatonin the night before surgery, 12 hours before the scheduled time of surgery, followed by another 5 mg melatonin two hours before surgery.
62583442|NCT00857896|EXPERIMENTAL|Fesoterodine once daily|
62583443|NCT05193539|EXPERIMENTAL|Augmented reality and virtual reality rehabilitation|This group underwent augmented reality and virtual reality rehabilitation for 60 minutes per session, 5 days per week for 2 weeks.
62583444|NCT05193539|ACTIVE_COMPARATOR|Conventional occupational therapy|This group underwent conventional occutational therapy for 60 minutes per session, 5 days per week for 2 weeks.
62211095|NCT04359043|EXPERIMENTAL|Mediational Intervention for Sensitizing Caregivers|Half of the child participants and the careworkers in the Community-based Organization taking care of them, received the Mediational Intervention for Sensitizing Caregivers.
62211096|NCT04359043|OTHER|Treatment as Usual|The other half of child participants and the careworkers in the Community-based Organization taking care of them, received Treatment as Usual which consists of the usual services delivered to children at the CBO: food, help with homework, registrations for birth certificates.
62583445|NCT03269669|EXPERIMENTAL|Arm I (obinutuzumab, umbralisib)|CLOSED TO ACCRUAL: Patients receive obinutuzumab IV on day 1 and umbralisib PO daily on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy and ECHO or MUGA during screening, and PET/CT scans and collection of blood throughout the trial.
62583446|NCT03269669|EXPERIMENTAL|Arm II (obinutuzumab, lenalidomide)|Patients receive obinutuzumab IV on day 1 and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy and ECHO or MUGA during screening, and PET/CT scans and collection of blood throughout the trial.
62583447|NCT03269669|ACTIVE_COMPARATOR|Arm III (obinutuzumab, combination chemotherapy)|"PRIOR BENDAMUSTINE-BASED CHEMOTHERAPY: Patients receive obinutuzumab IV on day 1, cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, and prednisone PO on days 1-5. Treatment with obinutuzumab repeats every 21 or 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Treatment with combination chemotherapy repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~PRIOR CHOP CHEMOTHERAPY: Patients receive obinutuzumab IV on day 1, and bendamustine IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for up to 6 or 12 cycles (bendamustine and obinutuzumab, respectively) in the absence of disease progression or unacceptable toxicity.~Patients undergo biopsy and ECHO or MUGA during screening, and PET/CT scans and collection of blood throughout the trial."
62583448|NCT03990350||Hispanic children with obesity|
62583449|NCT03990350||Hispanic children without obesity|
62583450|NCT03990350||Caucasian non-Hispanic children with obesity|
62583451|NCT03990350||Caucasian non-Hispanic children without obesity|
62583452|NCT02580617|EXPERIMENTAL|ALLO-ASC|Group 1: 5.0 x 10\^7 cells Group 2: 7.5 x 10\^7 cells Group 3: 10.0 x 10\^7 cells
62583453|NCT03157128|EXPERIMENTAL|LOXO-292|Phase 1 - Multiple doses of LOXO-292 (selpercatinib) Phase 2 - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
62211097|NCT04921787|ACTIVE_COMPARATOR|Low Intensity|MOUD training and support through the use of educational materials.
62211098|NCT04921787|EXPERIMENTAL|High Intensity|MOUD training and support through the use of educational materials in addition to practice facilitation.
62211099|NCT04917640||SBRT|Patients treated with Stereotactic Body Radiation Therapy (SBRT)
62583454|NCT01498211|EXPERIMENTAL|Biopsy|
62583455|NCT02632409|EXPERIMENTAL|Nivolumab|Nivolumab dose as specified
62583456|NCT02632409|PLACEBO_COMPARATOR|Placebo|Placebo dose as specified
62583457|NCT00900887|ACTIVE_COMPARATOR|Ketorolac|ocular topic ketorolac used 3 times a day for a week after the selective photocoagulation
62583458|NCT00900887|ACTIVE_COMPARATOR|Nepafenac|ocular topic nepafenac 3 times a day during one week after selective photocoagulation
62583459|NCT00900887|PLACEBO_COMPARATOR|Polietilenglicol 400, propilenglicol|ocular lubricant drops 3 times a day for a week after selective photocoagulation
62583460|NCT00977314|EXPERIMENTAL|SoundBite Hearing System|The objective of this study was to assess the safety and effectiveness of the SoundBite hearing system by Sonitus Medical and to support its intended use for the treatment of unilateral hearing loss. The SoundBite hearing system is a Bone Conduction Device (BCD) and is occasionally referred to as such in the protocol and within this report.
62583461|NCT03798899|EXPERIMENTAL|Penthrox® (Methoxyflurane)|"Patients will be asked to inhale Penthrox® intermittently or continuously to obtain adequate analgesia.~Penthrox® or placebo will be administered in combination with standard analgesic treatments usually used according to the emergency department protocol (SoC).~Duration of treatment: 1 administration (with a maximum of 2 inhalers) during passage to emergency."
62211100|NCT04917640||IMRT|Patients treated with Intensity Modulated Radiation Therapy (IMRT)
62583462|NCT03798899|PLACEBO_COMPARATOR|Normal Saline|"Patients will be asked to inhale Penthrox® intermittently or continuously to obtain adequate analgesia.~Penthrox® or placebo will be administered in combination with standard analgesic treatments usually used according to the emergency department protocol (SoC).~Duration of treatment: 1 administration (with a maximum of 2 inhalers) during passage to emergency."
62211101|NCT02629653|OTHER|Single arm|The endovascular cooling system will be Zoll IVTM. This system consists of a control module (either CoolGard 3000 or Thermogard XP), a CoolGard start-up kit, and an ICY catheter (either IC-3585 AE or IC-3585)
62583463|NCT03814967|EXPERIMENTAL|DLPFC Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex.
62583464|NCT03814967|ACTIVE_COMPARATOR|Occipital Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the occipital cortex.
62211102|NCT06030206|EXPERIMENTAL|Intervention|Access to an investigator-designed web-based educational resource with information about lung transplant for three months.
62211103|NCT06030206|ACTIVE_COMPARATOR|Attention-control|Access to a publicly available web-based educational resource with information about transplant for three months.
62211104|NCT01600248|OTHER|Treatment arm|This is an open-label pilot study with no control group. Participants pre-treatment scores are compared to their post-treatment scores.
62211105|NCT02497521||ADPKD|Patients with diagnosis of ADPKD, who are either evaluated for tolvaptan treatment indication, planned for tolvaptan treatment, or are already treated with tolvaptan
62211106|NCT05398445|EXPERIMENTAL|Arm A|Rocatinlimab Dose 1 every 4 weeks (Q4W) + loading dose at Week 2
62583465|NCT03814967|SHAM_COMPARATOR|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
62583466|NCT02880280|EXPERIMENTAL|Human Menopausal Gonadotropin|Human menopausal gonadotropin contains follicle-stimulating hormone (FSH) and luteinizing hormone (LH)
62583467|NCT02880280|EXPERIMENTAL|Human Chorionic Gonadotropin|Human chorionic gonadotropin (hCG) is a hormone produced by the embryo after implantation
62583468|NCT06604689||Construction of AI models (retrospective cohort)|
62211107|NCT05398445|EXPERIMENTAL|Arm B|Rocatinlimab Dose 2 Q4W + loading dose at Week 2
62583469|NCT06604689||Validation of AI models (prospective cohort)|
62583470|NCT04102748|ACTIVE_COMPARATOR|Conventional|
62019431|NCT05640934|PLACEBO_COMPARATOR|Control group|The patients will be premedicated with placebo tablets, which will be administered at the same times as the melatonin group.
62583471|NCT04102748|ACTIVE_COMPARATOR|I-incision|
62583472|NCT04102748|ACTIVE_COMPARATOR|M-flap|
62583473|NCT03386643|EXPERIMENTAL|Bifidobacterium animalis subsp. lactis|"Intervention:~Bifidobacterium animalis subsp. lactis HN019"
62583474|NCT03386643|ACTIVE_COMPARATOR|Clobetasol propionate 0.05%|"Intervention:~Clobetasol propionate 0.05%"
62583475|NCT03769103|ACTIVE_COMPARATOR|SRS + Osimertinib|Stereotactic radiotherapy will be delivered in 1-5 fractions to each brain metastases according to the volume and location of the metastases and clinician discretion. Osimertinib will start 1-7 days post radiotherapy.
62583476|NCT03769103|EXPERIMENTAL|Osimertinib alone|Osimertinib 80mg PO daily
62583477|NCT03054090|OTHER|Quality Improvement support|A blended support strategy will include practice facilitation, expert consultation, collaborative learning events, an online support center, and data feedback and benchmarking.
62583478|NCT01757938|EXPERIMENTAL|Shang Ring Guided Circumcision|The Shang Ring (SR) (Wuhu Santa Medical Devices Technology Co Ltd, China) male circumcision performed by study surgeon (study PI). In both study groups, participants were cleaned with povidone iodine solution and draped in a sterile fashion. Local anesthesia was administered to the dorsal penile nerve and penile ring blocks using 3mg/kg of 1% lidocaine. The surgeon measured participants in the SR group to determine ring size. Patients for whom a suitable ring size was not available crossed over to the FG group, but remained in the SR group for intention to treat (ITT) analyses.
62735063|NCT03755219||StdPPM|"Standard pure polypropylene mesh.~Standard is defined in SHR by weight ≥ 50 g/square meter."
62019432|NCT03450031|EXPERIMENTAL|NAC (no drug/no device) and NFP|NAC with mixed grass pollen will be conducted. Nasal mucosal inflammatory mediators will be collected via nasal filter paper (NFP)
62019433|NCT03450031|EXPERIMENTAL|NAC (no drug/no device) and NFP AND NLF|NAC with mixed grass pollen will be conducted. Nasal filter paper (NFP)sampling will be conducted from one nostril per time point. Subjects in Cohort B will also undergo nasal lavage (NLF) pre-NAC and at serial time points thereafter up to 8 hours
62019434|NCT02984501|EXPERIMENTAL|Single Arm|Patients treated with induction chemotherapy with gemcitabine and oxaliplatin; for patients without disease progression as detected through restaging exams, chemotherapy was followed by radiochemotherapy which consisted of conformal radiation therapy and concurrent gemcitabine at the dose of 600 mg/mq weekly.
62019435|NCT02013323|ACTIVE_COMPARATOR|Septilin Group|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing
62019436|NCT02013323|PLACEBO_COMPARATOR|Placebo Group|Subjects in placebo group received Placebo tablets thrice daily for 7 days after Scaling and root planing
62019437|NCT04879472||Age 50 years and below|"1. Type of surgery (modality of treatment) either osteosynthesis, Hemiarthroplasty or Total hip replacement~2. Surgical approach either posterior, lateral or anterolateral~3. Type of anaesthesia either general or spinal~4. Presence or absence of comorbidities~5. Sex"
62019438|NCT04879472||Age more than 50 years|"1. Type of surgery (modality of treatment) either osteosynthesis, Hemiarthroplasty or Total hip replacement~2. Surgical approach either posterior, lateral or anterolateral~3. Type of anaesthesia either general or spinal~4. Presence or absence of comorbidities~5. Sex"
62407908|NCT01826201|EXPERIMENTAL|10% MOL4239 ointment & placebo ointment|10% MOL4239 ointment to one target lesion and placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
62583479|NCT01757938|ACTIVE_COMPARATOR|Forceps Guided Circumcision|Standard forceps guided adult male circumcision was performed. In both study groups, participants were cleaned with povidone iodine solution and draped in a sterile fashion. Local anesthesia was administered to the dorsal penile nerve and penile ring blocks using 3mg/kg of 1% lidocaine.
62583480|NCT06573983|EXPERIMENTAL|Fall Risk Identification and Management Model|Participants will be assessed on four fall risk factors including physical, psychological, pharmacological, and environmental. If a participant screens positive for a fall risk factor, they will then be referred to an existing VHA care pathway. The care pathways include: strengthening via physical therapy or Gerofit for physical fall risk, cognitive behavioral therapy via clinical psychology or occupational therapy for psychological fall risk, deprescription via clinical pharmacy for pharmacological fall risk, and home safety modifications via occupational therapy for environmental fall risk.
62211108|NCT05398445|PLACEBO_COMPARATOR|Arm C|Placebo Q4W+ loading dose at Week 2
62211109|NCT00350103|EXPERIMENTAL|Lacosamide Standard Titration (ST)|Subjects had their dose titrated from 100 mg/day to 400 mg/day at weekly intervals of 100 mg. Subjects in this treatment group reach their target dose of 400 mg/day 3 weeks after Visit 2. All subjects completing the Titration Phase enter a 12-week Maintenance Phase.
62407909|NCT06111976|EXPERIMENTAL|rTMS with simultaneous reactivation of traumatic memory in resistant PTSD|rTMS with simultaneous reactivation of traumatic memory in resistant PTSD during 12 sessions (3 to 4 weeks)
62407910|NCT06111976|PLACEBO_COMPARATOR|sham rTMS and simultaneous reactivation of traumatic memory in resistant PTSD|sham rTMS and simultaneous reactivation of traumatic memory in resistant PTSD during 12 sessions (3 to 4 weeks)
62407911|NCT05837884|OTHER|First-degree relative of a patient with a plasma cell dyscrasia or another blood cancer.|Individuals will ensure they are eligible by filling out an eligibility questionnaire confirming they meet all eligibility criteria. Individuals will provide informed consent to complete the baseline questionnaire and provide a blood sample that will be used to determine whether they have a monoclonal protein
62407912|NCT01721941|EXPERIMENTAL|Phase I dose level -1|TH-302 25mg; Doxorubicin 50mg
62407913|NCT01721941|EXPERIMENTAL|Phase I Dose level 1|TH-302 50mg; doxorubicin 50mg
62407914|NCT01721941|EXPERIMENTAL|Phase I Dose level 2|TH-302 100mg; doxorubicin 50mg
62407915|NCT01721941|EXPERIMENTAL|Phase 1 Dose level 3|TH-302 150mg; Doxorubicin 50mg
62407916|NCT01369836|EXPERIMENTAL|20 mg soft gelatin capsule|
62407917|NCT01369836|EXPERIMENTAL|40 mg (20 mg*2) soft gelatin capsule|
62407918|NCT01369836|ACTIVE_COMPARATOR|Placebo|
62407919|NCT03383302|EXPERIMENTAL|Arm 1 Tolerabilty|This is a single arm study of nivolumab administered on completion of stereotactic body radiotherapy (SBRT) to patients with early stage NSCLC. The first 5 patients to enroll must have Eastern Co-operative Oncology Group (ECOG) performance status \< 2 at the time of first dose of investigational medical product (IMP). An Independent Data Monitoring Committee (IDMC) will meet when the first 5 patients have reached 3 months follow up from their 1st dose of nivolumab or have withdrawn consent to follow-up. The IDMC, if satisfied with the safety data from the initial 5 patients, may recommend escalation to include recruitment of patients with ECOG performance status of 2.
62407920|NCT04028531||Sample Collection|"* Blood tests required for assessment~* Specimens and data will also be collected from outside sites~* Clinical data from patients with Chronic Lymphocytic Leukemia will be gathered into a database at Dana Farber Cancer Institute"
62583481|NCT06573983|NO_INTERVENTION|Standard of care|This group will received current standard of care within the Rocky Mountain Regional GeriPACT clinic.
62583482|NCT02401490|ACTIVE_COMPARATOR|Human albumin|human albumin in the 24-48 hours after the hospitalization and at 48+/- 24 hours after the first dose.
62583483|NCT02401490|PLACEBO_COMPARATOR|placebo|saline serum 0.9%
62407921|NCT06234683|ACTIVE_COMPARATOR|Web-based educational video on pneumococcal vaccination and reminder email to be vaccinated|
62407922|NCT06234683|PLACEBO_COMPARATOR|Reminder email to be vaccinated|
62407923|NCT02415634|EXPERIMENTAL|Intervention|Intervention Participants in the experimental group will receive usual care plus the RECAP with ICU therapist follow up after ICU discharge. This will be provided for a period of 3 weeks after intensive care unit discharge.
62407924|NCT02415634|ACTIVE_COMPARATOR|Control|Control Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
62407925|NCT03340246|ACTIVE_COMPARATOR|Immediate phlebectomy|Mechanochemical ablation of main trunk and immediate phlebectomy of varicosities
62407926|NCT03340246|EXPERIMENTAL|Delayed treatment|Mechanochemical ablation of main trunk. Evaluation of varicosities at 3 months with sclerotherapy if required
62407927|NCT05543226|EXPERIMENTAL|PHGG|
62019439|NCT05453305|ACTIVE_COMPARATOR|Control group: Traditional venipuncture, on the stretcher.|the companion will place the child on the stretcher in the supine position with the limb to be punctured in decline. At all times, during the technique, the companion will be present, being able to participate by establishing links of consolation or distraction, as is usually done in the hospital. Simultaneously, a professional from the service will be in charge of holding the chosen extremity, as well as the opposite one. The responsible nurse will perform the venipuncture while another colleague will help with tasks of holding and/or collecting samples.
62211110|NCT00350103|EXPERIMENTAL|Lacosamide Fast Titration (FT)|Subjects receive 200 mg/day LCM for the first 3 days, 300 mg/day for the next 4 days, and reach their target dose of 400 mg/day after 1 week. They undergo sham titration for the remaining 3 weeks of the Titration Phase. All subjects completing the Titration Phase enter a 12-week Maintenance Phase.
62211111|NCT00350103|PLACEBO_COMPARATOR|Placebo|Subjects underwent sham titration for the entire Titration Phase. All subjects completing the Titration Phase enter a 12-week Maintenance Phase
62211112|NCT00467350|ACTIVE_COMPARATOR|enema|Rectal enema containing mixture of milk and molasses
62211113|NCT00467350|ACTIVE_COMPARATOR|PEG 3350|Medication to be taken orally once each day for three consecutive days
62211114|NCT03760445|EXPERIMENTAL|Part 1 - first line (1L) AML|1L acute myeloid leukemia (AML) subjects receiving HDM201 in various doses/schedules in combination with cytarabine/anthracyclines
62583484|NCT02258438|EXPERIMENTAL|Uninterrupted sitting|Patient will refrain from any structured activity and reduce any daily life activity. The patient will spend 24 hours in the calorimeter room. During the 24 hours the patient will remain sedentary for the 24 hours but will be able to watch TV, computer work or read.
62583485|NCT02258438|EXPERIMENTAL|Sitting + 1 bout of activity|The patient will be asked to perform the 45 minutes of moderate-exercise intervention in the morning once per day for two days in their daily life. This bout of exercise will be supervised by study staff on one of the treadmills On day 3 the patient will report at the Clinical and Translational Research Center (CTRC) of the University Hospital of Colorado and will spend 24hr in the room calorimeter. During the day, you will be asked to sit quietly in a chair, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity walking on a treadmill.
62407928|NCT05543226|PLACEBO_COMPARATOR|without PHGG|
62735064|NCT03755219||LWM|"Lightweight mesh: Either a pure polypropylene mesh, or a polypropylene-based composite mesh.~The study uses SHR's classification of light-weight = \<50 g/square meter."
62735065|NCT03755219||Tacks, metal|Metal staples or tacks. Material specification of staples/tacks was introduced in SHR 2012.
62407929|NCT00212446|EXPERIMENTAL|Electrical Intervention|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
62407930|NCT03209154|EXPERIMENTAL|Study Group|Study Group intervention: Therapeutic drug monitoring.
62583486|NCT02258438|EXPERIMENTAL|Sitting + microbursts of activity|The patient will be asked to refrain from any structured exercise running, swimming, lifting weights, yoga, dancing, etc.) for two days but to walk for the 5 minute intervention each hour between 1000 and 1800. On day 3, The patient will report at the CTRC of the University Hospital of Colorado and will spend 24hr in the room calorimeter. During the day, the patient will be asked to rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5 min moderate-intensity walking on a treadmill, which represents a total of 45 min.
62407931|NCT03209154|ACTIVE_COMPARATOR|Control Group|Control Group intervention: No intervention first 3 months. After 3 months of follow-up, half of the patients in the Control Group will be randomized to perform home blood pressure monitoring as an intervention. No intervention in the other half.
62407932|NCT03741335|EXPERIMENTAL|Strength Training|Participants wear a weighted vest while performing exercises using functional movement patterns used in everyday activities (chair rises, 90° squats, side-to-side squats, toe raises, lunges (forward, lateral, backward, walking), multi-directional step ups). Participants attend supervised, group-based moderate-intensity strength training program remotely 3 times per week for 60 minutes per session.
62407933|NCT03741335|ACTIVE_COMPARATOR|Stretching Control|Participants attend a supervised flexibility program where they will perform a series of whole body stretching exercises with a focus on developing and maintaining a healthy back. Participants attend a supervised, group-based supervised flexibility program remotely 3 times per week for 60 minutes per session.
62407934|NCT03741335|EXPERIMENTAL|Tai Ji Quan Training|An integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements. Participants attend a supervised, group-based tai ji quan program remotely where they perform an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements 3 times per week for 60 minutes per session.
62407935|NCT00463593||2|children enrolled in formal schools and children not enrolled in formal schools
62211115|NCT03760445|EXPERIMENTAL|Part 1 - relapsed/refractory (R/R) AML|R/R AML subjects receiving HDM201 in various doses/schedules in combination with cytarabine
62583487|NCT04737252|EXPERIMENTAL|Sage|Immediately receives 12 sessions of couple intervention aimed to improve self-injury thoughts and behaviours, emotion dysregulation, borderline personality disorder symptoms, and intimate relationship dysfunction.
62583488|NCT05969977|EXPERIMENTAL|PPI-1011|Single Ascending: PPI-1011 at 10, 25, 50, 75 and 100 mg/kg. Multiple Dose: PPI-1011 dose to be based on SAD; duration 14 days; one dose daily.
62583489|NCT05969977|PLACEBO_COMPARATOR|Placebo|Placebo arm.
62583490|NCT06303167|EXPERIMENTAL|Treatment (osimertinib)|Patients receive osimertinib (AZD9291) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or MUGA during screening, and biopsy and collection of blood samples on trial and at end of treatment.
62583491|NCT01134679|EXPERIMENTAL|Phone calls|Disease management with close patient follow-up, using phone calls.
62583492|NCT05361902|EXPERIMENTAL|Intervention Arm|All included patients will be treated according to the treatment protocol: Adaptive radiotherapy according to UPRATE
62583493|NCT01612689|EXPERIMENTAL|Physiologic Data Collection|
62583494|NCT04312867|EXPERIMENTAL|Project STRONG|Project STRONG is an active skill-based intervention designed to prevent adolescent dating violence among middle school boys. Boys and a parent will complete the web-based program together focusing on improving communication and emotion regulation.
62583495|NCT04312867|ACTIVE_COMPARATOR|Health Promotion|Health Promotion is an information-based program designed to mimic content areas provided during middle-school health education. The content is provided via a web-based interface to mirror the content delivery in the active intervention (Project STRONG).
62211116|NCT03760445|EXPERIMENTAL|Part 2 - Expansion Cohort 1|1L de novo AML subjects without documented FLT3 mutation receiving HDM201 at the recommended dose of expansion (RDE) in combination with cytarabine/anthracyclines
62583496|NCT04255680||FRDA Subjects|Male and female subjects with FRDA confirmed by genetic testing (aim for a 50:50 distribution of males to females)
62211117|NCT03760445|EXPERIMENTAL|Part 2 - Expansion Cohort 2|1L de novo AML subjects with documented FLT3 mutation status receiving HDM201 at RDE in combination with cytarabine/anthracyclines and midostaurin
62211118|NCT03760445|EXPERIMENTAL|Part 2 - Expansion Cohort 3|1L secondary AML subjects receiving HDM201 at RDE in combination with liposomal cytarabine/daunorubicin
62211119|NCT03760445|EXPERIMENTAL|Part 2 - Expansion Cohort 4|R/R AML subjects receiving HDM201 at RDE in combination with cytarabine
62211120|NCT03760445|EXPERIMENTAL|Part 3 - DDI Cohort 1|R/R AML subjects receiving HDM201 at adjusted recommended Phase 3 dose (RP3D) determined in Part 2 in combination with cytarabine and posaconazole added in Cycle 1
62211121|NCT03760445|EXPERIMENTAL|Part 3 - DDI Cohort 2|R/R AML subjects receiving HDM201 at RP3D in combination with cytarabine and midazolam
62407936|NCT01207219|EXPERIMENTAL|Yoga therapy|Hatha yoga including breathing control (10 minutes), body posture(40-45minutes), and relaxation (5 minutes).
62583497|NCT04255680||Controlled Subjects|Male and female control subjects (matched by age \[+/- 2 years\] and sex)
62583498|NCT01250873|EXPERIMENTAL|LY2216684/sertraline/LY2216684 + sertraline|"Period 1: LY2216684 18 milligram (mg) oral (po) dose on Days 1-3.~Period 2: Sertraline 50 mg po dose on Day 4 followed by sertraline 100 mg po dose on Days 5-10.~Period 3: LY2216684 18 mg po dose + sertraline 100 mg po dose on Days 11-13."
62583499|NCT02990936||head and neck squamous cell carcinoma|Patients with T1 to T4 head and neck squamous cell carcinoma from oral cavity, oropharynx, larynx and hypopharynx eligible for radiotherapy or concomitant chemoradiotherapy
62211122|NCT04024488|EXPERIMENTAL|TI-CBT Intervention Arm|In the Randomized Trial, youth participants will be randomized in a 1:1 ratio with their caregivers to one of two study arms. One arm is the TI-CBT intervention arm consisting of: six 2-hour TI-CBT group sessions lead by Indigenous Youth Leaders (IYL) during weeks 1 - 6 and one 2-hour booster group session at 6-months. The caregivers (willing to participate with youth permission) for youth who are enrolled into the TI-CBT arm will be enrolled onto the same arm, and receive two 2-hour group sessions led by adult study staff during weeks 1-6 and one 2-hour booster group session at 6-months. The youth and caregiver sessions are held separately.
62211123|NCT04024488|ACTIVE_COMPARATOR|Discussion Control Arm|Arm two is the discussion control arm consisting of: six 2 hour discussion group sessions lead by IYL during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The caregivers (willing to participate with youth permission) for youth randomized to the discussion control arm will have two 2-hour discussion group sessions led by adult study staff during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The youth and caregiver sessions are held separately.
62211124|NCT02053792|EXPERIMENTAL|rIX-FP|"Subjects will administer rIX-FP by intravenous infusion as routine prophylaxis, prevention, and on-demand treatment during a treatment period of approximately 3 years.~The routine prophylaxis treatment interval for previously treated patients may be changed at each scheduled 6-month follow-up assessment. On-demand treatment with rIX-FP will be used for all bleeding episodes requiring treatment. Subjects (other than those in France) may participate in a surgical 'substudy' in which rIX-FP may be administered before, during and after surgery. An additional substudy will examine the safety and PK of subcutaneous administration of rIX-FP.~For previously untreated patients, subjects will administer rIX-FP intravenously as weekly prophylaxis and/or on-demand treatment during the first 12 months, and as weekly routine prophylaxis thereafter.~The dose of rIX-FP administered will be based on the subject's previous rIX-FP use and/or pharmacokinetic data."
62583500|NCT05720130|EXPERIMENTAL|mCRPC|"Phase 1b Dose Escalation:~Participants with PSMA-positive mCRPC who have had exposure to at least one ARPi and taxane-based chemotherapy at any time in the course of their disease.~Phase 2a Dose Expansion:~Group 1: Participants with PSMA-positive mCRPC who have had exposure to at least one ARPi at any time in the course of their disease and received taxane-based chemotherapy for the treatment of mCRPC.~Group 2: Participants with PSMA-positive mCRPC who have had exposure to at least one ARPi at any time in the course of their disease and has not received a taxane for the treatment of mCRPC.~Group 3: Participants with PSMA-positive mCRPC who have had exposure to ¹⁷⁷Lu-PSMA at any time in the course of their disease."
62583501|NCT06681935||Subjects undergoing Oral Cavity Reconstruction|The cohort will be oral cancer patients undergoing standard of care oral cavity reconstruction.
62583502|NCT00811330|EXPERIMENTAL|1: Atorvastatin 80 mg.|Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
62583503|NCT00811330|NO_INTERVENTION|2: No Atrovastatine|
62583504|NCT00876655|EXPERIMENTAL|free acid|TR-701 free acid phosphate powder in capsule formulation (equivalent to 150 mg TR-700)
62407937|NCT01207219|EXPERIMENTAL|Aerobic exercise|Aerobic exercise includes walking on the treadmill for 15-20 minutes and stationary cycling for 25-30 minutes.
62407938|NCT01207219|NO_INTERVENTION|Waitlist group|Patients in waiting list will be treated as usual and acted as control group.
62583505|NCT00876655|EXPERIMENTAL|di-sodium phosphate salt|One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)
62583506|NCT02694354|EXPERIMENTAL|BI 685509|
62583507|NCT02694354|PLACEBO_COMPARATOR|Placebo|matching placebo
62583508|NCT02040857|EXPERIMENTAL|Palbociclib With Adjuvant Endocrine Therapy|"* Palbociclib 125 mg PO qd 21 days on, 7 days off~* Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd"
62583509|NCT03477201|EXPERIMENTAL|Laparoscopic robotic DaVinci assisted inguinal hernia repair|Intervention: 30 patients will undergo a robotic assisted laparoscopic inguinal hernia repair. This will be done using the DaVinci Robotic Platform by Intuitive Surgical. This an accepted safe method of repairing inguinal hernia. This platform uses special robotic ports produced and supplied by Intuitive Surgical required to dock the machine to the patient. Monopolar energy will be provided by a ForceTriad system (Covidien, Boulder, CO), standard an common system used in most ORs. This will be used for dissection. The investigators will obtain small biopsies from port site to assess stray energy transfer injury, a model described by earlier studies.
62583510|NCT03477201|ACTIVE_COMPARATOR|Standard Laparoscopic inguinal hernia repair|Intervention: 30 patients will undergo a laparoscopic inguinal hernia repair, an accepted safe method of repairing inguinal hernia. This platform uses standard laparoscopic ports. In our institution we use plastic ports made by Covidien, Boulder, CO. The operation will require two 5mm VersaPort (Covidien) and a Hassan Port. As in the robotic arm, monopolar energy will be provided by a ForceTriad system (Covidien, Boulder, CO), standard an common system used in most ORs. This will be used for dissection. The investigators will obtain small biopsies from port site to assess stray energy transfer injury, a model described by earlier studies.
62583511|NCT05005585|EXPERIMENTAL|vestibuler socket therapy|immediate implant placement in esthatic zone with final crown placement after 2 months with VST technique
62583512|NCT05005585|EXPERIMENTAL|contour augmentation|Early implant placement in esthatic zone with contour augmentation and final crown after 3 months of implant placement
62019440|NCT05453305|EXPERIMENTAL|Experimental group: DAK method venipuncture, simulating a hug.|the caregiver will sit in a chair placing the child on top in front of him, with one leg on each side and the arms resting on the shoulders of the companion. The patient's head will rest on the adult's shoulder, contralateral to the limb to be punctured. Simultaneously, the responsible adult patient will hold the simulating a hug. A professional will take care of immobilizing the chosen limb. The responsible nurse performed the venipuncture while another colleague helped with the tasks of holding and/or collecting samples.
62019441|NCT06534866|ACTIVE_COMPARATOR|Traditional Physcial therapy group|"1. TENS+cold pack (For 10 mins on plantar ascpect of foot)~2. Stretching exercises (5 repetition 2 sets/day) Standing calf stretch Seated plantar fascia stretch Plantar fascia massage Achilles stretch Frozen can roll Towel stretch (30 minutes session thrice a week for 2 consecutive weeks with total of 6 sessions)"
62019442|NCT06534866|EXPERIMENTAL|Kinesio taping + Traditional physical therapy group|"Group B will receive :~1. TENS+cold pack For 10 mins on plantar ascpect of foot~2. Stretching exercises (5 repetition 2 sets/day) Standing calf stretch Seated plantar fascia stretch Plantar fascia massage Achilles stretch Frozen can roll Towel stretch~3. Kinesio taping:~(30 minutes session thrice a week for 2 consecutive weeks with total of 6 sessions)"
62019443|NCT02680691|EXPERIMENTAL|Robot, then conventional training|Robot assisted gait training 4 weeks after conventional gait training
62019444|NCT02680691|ACTIVE_COMPARATOR|Conventional, then robot training|Conventional gait training 4 weeks after robot assisted gait training
62019445|NCT03269032|EXPERIMENTAL|Phase 1 Healthy Volunteers|Healthy volunteers will eat a typical American diet for 2 weeks and then eat a Mediterranean-style diet for 2 weeks.
62019446|NCT03269032|EXPERIMENTAL|Phase 2 IBS Patients|Participants with IBS will eat a typical American diet for 2 weeks and then eat a Mediterranean-style diet for 2 weeks
62019447|NCT05011903|EXPERIMENTAL|PFI+CDF with diary surveys|Participants in this condition receive a Personalized Feedback Intervention (PFI) and Cross-tailored Dynamic Feedback (CDF) related to alcohol use and related sexual behavior. They also complete weekend diary surveys in which they are asked to self-report on weekend behaviors.
62019448|NCT05011903|EXPERIMENTAL|PFI+GHI with diary surveys|Participants in this condition receive a Personalized Feedback Intervention (PFI) related to alcohol use and related sexual behavior, and generic health information (GHI). They also complete weekend diary surveys in which they are asked to self-report on weekend behaviors.
62019449|NCT05011903|EXPERIMENTAL|PFI-only with no diary surveys|Participants in this condition receive a Personalized Feedback Intervention (PFI) related to alcohol use and related sexual behavior. They do not complete weekend diary surveys.
62583513|NCT05400499||Parkinson's disease with DBS|This is the only group. The patients in this group will have bilateral subthalamic region deep brain stimulator. They will be recruited after they are therapeutically optimized on stimulation as well as medical therapy.
62019450|NCT05011903|NO_INTERVENTION|Control|Participants in this condition get no intervention and do not complete weekend diary surveys.
62019451|NCT00725426|EXPERIMENTAL|1|Bosutinib
62211125|NCT06251518|EXPERIMENTAL|vimida + TAU|"Participants allocated to the intervention group will receive access to vimida in addition to treatment as usual (TAU).~vimida is a digital health application designed for individuals with post-Covid conditions who suffer from fatigue, accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT). Topics addressed by vimida are psychoeducation, activity and recovery, attention, stress management, sleep management, cognitive restructuring, and social resources.~The program operates through interactive dialogues, which are accompanied by illustrations, audio recordings, motivational text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days."
62211126|NCT06251518|NO_INTERVENTION|TAU|Participants allocated to the control group will receive access to treatment as usual (TAU).
62211127|NCT01974401|ACTIVE_COMPARATOR|water jet irrigator|patients used supra-gingival irrigators as an oral health measure
62407939|NCT05726110|EXPERIMENTAL|Selinexor、HAD or CAG regimens|"* Selinexor (60 mg) is used twice weekly for two weeks (four times, 240 mg total of selinexor) in combination with HAD or CAG regimens for reinduction therapy in patients with relapsed and refractory AML.~* (Bone marrow image indicates active hyperplasia) HAD regimen: homoharringtonine (HHT) (2mg/ m\^2/d)×7days, daunorubicin (DNR, 40mg/ m\^2/d)×3 days, cytarabine (Ara-C,100-200mg/ m\^2/d)×7 days (no leukocyte drugs should be used throughout the treatment process)；~* (Bone marrow image indicates hypoproliferation)CAG regimen: Granulocyte Colony-Stimulating Factor (G-CSF, 5ug/kg/d, started 12 hours before chemotherapy×14 days (d1-d14), aclacinomycin (20mg/d)×4 days (d1-4), cytarabine (10 mg/ m\^2, subcutaneous injection, 1 time in 12 hours)×14 days (d1-d14).~* G-CSF was discontinued in the CAG regimen when WBC \> 20×10\^9/L, but chemotherapy was not stopped."
62583514|NCT02348801|ACTIVE_COMPARATOR|Healthy Lifestyle Group|Group diabetes educations sessions that focus on diet, exercise, and social support.
62583515|NCT02348801|EXPERIMENTAL|Weight Loss plus Exercise Group|Behavioral therapy for weight loss and exercise training
62583516|NCT04357665|ACTIVE_COMPARATOR|Lap TAPP Group|Patients treated by laparoscopic transabdominal preperitoneal repair using 2 separate meshes fixed by laparoscopic tackers
62583517|NCT04357665|ACTIVE_COMPARATOR|Open PP Group|Patients treated by open preperitoneal single mesh repair fixated using sutures
62583518|NCT04357665|ACTIVE_COMPARATOR|Bilateral LICHT Group|Patients treated by standard bilateral Lichtenstein repair using 2 separate meshes fixed by sutures
62019452|NCT02769143|EXPERIMENTAL|Whole-Body Vibration Group (WBV)|Will be exposed to five minutes on a vibrating platform (Oscillating Platform Semi-Professional Horizontal - Arktus, Cascavel, Brazil), this type of platform vibrates through an anteroposterior axis, causing the right and left sides alternate horizontally denominated: alternating side vibration platforms, will be performed three times per week on alternate days (5 minutes). a frequency of 20 Hz (1 = 1 Hz oscillation / second) and a magnitude of 3.2 g (1 g = 9,81 m / s gravity) is used. The volunteers will be guided to stand on the platform with semi-flexed knees, barefoot and apart about hip width.
62211128|NCT01974401|NO_INTERVENTION|control group|patients in this group received routine oral health care protocols.
62211129|NCT03117829|EXPERIMENTAL|Improve Brain Blood Flow|12 week diet and exercise program to improve brain blood flow
62211130|NCT02154880||HIV positive under 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
62211131|NCT02154880||HIV negative under 50 yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
62211132|NCT02154880||HIV positive over 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
62211133|NCT02154880||HIV negative over 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
62407940|NCT06536894||Fibromyalgia syndrome and obstructive sleep apnea|Fibromyalgia patients who were diagnosed with OSAS as a result of polysomnographic examination
62407941|NCT06536894||Fibromyalgia syndrome|Fibromyalgia patients who were not diagnosed with OSAS as a result of polysomnographic examination
62407942|NCT06536894||Obstructive sleep apnea syndrome.|Patients diagnosed with OSAS as a result of polysomnographic examination and without fibromyalgia
62583519|NCT01355016|EXPERIMENTAL|MDT-637|Active formulation
62583520|NCT01355016|PLACEBO_COMPARATOR|Placebo|Matched Placebo Comparator
62583521|NCT03928899|NO_INTERVENTION|old guideline group|"Women randomized to the old guideline group will be followed up once-weekly by electronic fetal heart rate monitoring and biophysical profile until 40 weeks 0 days (unless a medical indication arises), when induction of labor was then offered."
62583522|NCT03928899|EXPERIMENTAL|new procedure group|"Women randomized to new procedure group will first undergo fetal weight ultrasound estimation at 38 weeks 0 days to 38 weeks 6 days of gestation, if the fetus is estimated to be LGA/macrosomia by ultrasound, women should have an elective induction of labor immediately (at 38 weeks 0 days to 38 weeks 6 days of gestation). On the contrary, if the fetus is estimated to be normal size, the pregnant women were then given a cervical assessment. If the Bishop score ≥6, women will have at least weekly follow-up visits with their doctors and unless a medical indication is present, continue pregnancy and have selective induction at 40 weeks 0 days of gestation. Whereas, if the Bishop score \<6, women will be followed up until 41 weeks 0 days of gestation with a close assessment of fetal wellbeing through the cardiotocographic trace. And women who will not deliver by this gestational age will be admitted for labor induction. Certainly, medical indication should warrant delivery without delay."
62583523|NCT04386824||Behçet's disease|Male patients who arediagnosed as Behçet's disease according to International Study Group Classification Criteria
62583524|NCT02337439|EXPERIMENTAL|Sensory Information Processing Training|Computerized training designed to improve sensory processing
62583525|NCT02337439|ACTIVE_COMPARATOR|Active Control Training|Commercially available computer exercises that were not designed specifically to improve sensory information processing.
62019453|NCT02769143|EXPERIMENTAL|Pilates Group (PG)|Will be exposed to 60 minutes, held three times a week on alternate days. Pilates equipment used for the exercises are: Combo Chair, Cadillac Trapeze, Ladder Barrel, Reformer Universal, Step Barrel and Wall Unit. Will be selected for this study, 21 strengthening exercises and stretching to the main body segments. All exercises are performed in a series of ten repetitions with one minute interval between exercises. To determine the level of effort and consequently to changing loads, will be used verbal command according to the Borg CR10 scale. The level of effort will be maintained during the session heavy (Borg between 5 and 6).
62583526|NCT04542421|EXPERIMENTAL|Lung ultrasound Implementation arm|Hospitalists undergo training to use lung ultrasound in their patients hospitalized with COVID
62019454|NCT02769143|NO_INTERVENTION|Control Group (CG)|The control group will be instructed to maintain their usual activities both in relation to their daily activities, dietary habits, failure to use drugs that can influence the increase in bone mass and participate in monthly meetings to address on issues osteoporosis and postmenopausal women. After the end of the interventions with WBV and GP groups, GC volunteers will be invited to also perform whole body vibration for six months. Exposure of vibration will be for five minutes on a vibrating platform, three times per week on alternate days. a frequency of 20 Hz (1 = 1 Hz oscillation / second) and a magnitude of 3.2 g (1 g = 9,81 m / s gravity) is used. Likewise which was offered for the WBV group.
62407943|NCT01327066|EXPERIMENTAL|Droxidopa - Therapeutic|Droxidopa 600 mg
62407944|NCT01327066|EXPERIMENTAL|Droxidopa - Supratherapeutic Dose|Droxidopa 2000 mg
62407945|NCT01327066|PLACEBO_COMPARATOR|Placebo|Placebo
62583527|NCT00601172|PLACEBO_COMPARATOR|Control|Placebo + standard antiemetics
62583528|NCT00601172|EXPERIMENTAL|Single Dose IV|Casopitant + standard antiemetics
62583529|NCT03628339|EXPERIMENTAL|Midazolam (Reference Treatment)|Participants received single oral dose of 7.5 milligrams (mg) midazolam tablet on Day 1 of treatment period 1. The washout period between midazolam administrations in Period 1 and Period 2 was 12 days.
62583530|NCT03628339|EXPERIMENTAL|Tepotinib + Midazolam (Test Treatment)|All participants who received 7.5 mg midazolam tablet in treatment period 1 received single oral dose of 500 mg tepotinib film-coated tablet from Day 1 to 11 along with 7.5 mg midazolam tablet on Day 11 in treatment period 2.
62583531|NCT06131684|ACTIVE_COMPARATOR|Intrauterine pressure catheter (IUPC) present|An IUPC is placed through the standard of care.
62583532|NCT06131684|ACTIVE_COMPARATOR|Intrauterine pressure catheter (IUPC) absent|No IUPC is required
62583533|NCT03489018|ACTIVE_COMPARATOR|Full dose PCV13 (2p+1 schedule)|Full dose PCV13 administration in 2p+1 schedule
62583534|NCT03489018|EXPERIMENTAL|40% dose PCV13 (2p+1 schedule)|Fractional (40%) dose PCV13 administration in 2p+1 schedule
62407946|NCT01327066|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin 400 mg dose
62407947|NCT05131152|EXPERIMENTAL|cyclosporine group|"Mild DE patients: topical usage of 0.05% cyclosporine Eye Drops BID + 0.1% Sodium Hyaluronate Eye Drops QID, both use for 16 weeks.~Moderate DE patients: topical usage of 0.05% cyclosporine Eye Drops BID +0.1% Sodium Hyaluronate Eye Drops QID, both use for 16 weeks, and 0.02% Fluoromethalone Eye Drops BID for 4 weeks."
62407948|NCT05131152|EXPERIMENTAL|control group|Mild DE patients: 0.1% Sodium Hyaluronate Eye Drops QID for 16 weeks Moderate DE patients: 0.02% Fluoromethalone Eye Drops BID for 4 weeks +0.1% Sodium Hyaluronate Eye Drops QID for 16 weeks.
62583535|NCT03489018|EXPERIMENTAL|20% dose PCV13 (2p+1 schedule)|Fractional (20%) dose PCV13 administration in 2p+1 schedule
62583536|NCT03489018|ACTIVE_COMPARATOR|Full dose PCV10 (2p+1 schedule)|Full dose PCV10 administration in 2p+1 schedule
62583537|NCT03489018|EXPERIMENTAL|40% dose PCV10 (2p+1 schedule)|Fractional (40%) dose PCV10 administration in 2p+1 schedule
62583538|NCT03489018|EXPERIMENTAL|20% dose PCV10 (2p+1 schedule)|Fractional (20%) dose PCV10 administration in 2p+1 schedule
62583539|NCT03489018|ACTIVE_COMPARATOR|Full dose PCV10 (3p+0 schedule)|The current vaccine (PCV10) and schedule (3p+0) in use in the Kenyan routine immunisation programme as an additional comparison arm.
62583540|NCT02507557||Before GDFM Training|About 200 patients' medical record information will be extracted from the 1st Affiliated Hospital of Chongqing Medical University electronic medical record prior to the start of the training curriculum.
62211134|NCT02780908|EXPERIMENTAL|Hypoxia at rest and exercise|The participants will perform a resting test, hypoxia sensitivity test and a graded exercise test to voluntary exhaustion in normoxic condition ((HYPO; FiO2=0.120 corresponding to terrestrial altitude of approx. 4000 m)
62211135|NCT02780908|PLACEBO_COMPARATOR|Normoxia at rest and exercise|The participants will perform a resting test and a graded exercise test to voluntary exhaustion in normoxic condition ((NORM; fraction of inspired oxygen (FiO2)=0.209, placebo)
62583541|NCT02507557||After GDFM Training|About 200 patients' medical record information will be extracted from the 1st Affiliated Hospital of Chongqing Medical University electronic medical record after the training program took place
62583542|NCT06655142|EXPERIMENTAL|ONCObind (Onco-Seraph) 100 Filter is a single use|The ONCObind Filter is a single use, disposable column packed with ultra-high molecular weight polyethylene beads which have been modified to contain endpoint attached heparin on the surface. The devices are sterilized using a standard ethylene oxide cycle, following ISO 11135-1:2007. Chemical Indicator labels are located near the product label. ONCObind is part of the Seraph platform technology that was also developed as an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens from the bloodstream.
62583543|NCT06655142|OTHER|Matched Controls|Study patients will be assigned to receive procedure with the investigational device (ONCObind) and will be matched with 60 site specific controls, 30 PDAC and 30 CRC.
62211136|NCT06729437|EXPERIMENTAL|Experimental group|Participants will undergo an 8-week intervention of supervised eccentric exercise by a physiotherapist (3 sessions/week). During the first 4 weeks, real tDCS will be administered at a rate of 3 sessions per week (12 in total) as an adjunct to exercise . A direct current of 1.5 mA will be applied for 20 minutes to the primary motor cortex (M1) during each session of eccentric exercises. Additionally, all participants will perform the eccentric exercise program on the remaining weekdays at home unsupervised.
62211137|NCT06729437|PLACEBO_COMPARATOR|Sham group|Participants will undergo an 8-week intervention of supervised eccentric exercise by a physiotherapist (3 sessions/week). During the first 4 weeks, sham tDCS will be administered at a rate of 3 sessions per week (12 in total) as an adjunct to exercise. The current will be interrupted after 30 seconds. Additionally, all participants will perform the eccentric exercise program on the remaining weekdays at home unsupervised.
62211138|NCT06728839|EXPERIMENTAL|1L PEG + 50g Magnesium sulfate (Group A)|Take 50g magnesium sulfate and 1L polyethylene glycol for bowel preparation before colonoscopy
62211139|NCT06728839|ACTIVE_COMPARATOR|3L PEG alone (Group B)|Take 3L polyethylene glycol for bowel preparation before colonoscopy
62211140|NCT06728839|ACTIVE_COMPARATOR|4L PEG alone (Group C)|Take 4L polyethylene glycol for bowel preparation before colonoscopy
62583544|NCT03005327|EXPERIMENTAL|X4P-001|"Initial Treatment Phase: Participants will initiate treatment with mavorixafor at 50 milligrams (mg) once daily (QD) orally or a higher dose, with potential escalation based on area under the curve for absolute neutrophil count and absolute leukocyte count (AUCANC/ALC) values to a maximum total daily dose of 400 mg. Participants are expected to receive treatment for 24 weeks in the initial Treatment Period or until development of a treatment-limiting toxicity (TLT).~Extension Phase: All participants will receive mavorixafor; the dose will not exceed 400 mg. In the Extension Phase, treatment may continue until mavorixafor becomes available via an alternative mechanism (for example, drug is commercially available, an expanded access program, etc.) or until the study is terminated by the sponsor."
62583545|NCT03659175||male elderly with SIBO|"male elderly who was diagnosed as SIBO via 'lactulose breath test' (LBT). At the same time, they meet the following criteria:~1. no use of antibiotics in the past 1 month.~2. no use of prokinetic drugs and probiotics in the past 1 week.~3. without these diseases: active inflammation, cardiac insufficiency, respiratory insufficiency, hepatic insufficiency, renal insufficiency, cirrhosis, thyroid diseases, Crohn disease, ulcerative colitis, hepatobiliary and pancreatic disease."
62019455|NCT00781326|OTHER|Open Label Antidepressant|In Phase 1, all participants will be placed on antidepressant medication. In Phase 2, participants will continue with their antidepressant medication and also receive receive either nimodipine or placebo.
62019456|NCT05404438|EXPERIMENTAL|intervention group|single arm study
62211141|NCT05362864||ZNN Bactiguard CMN|Subjects that have received or will receive the ZNN Bacitugard Cephalomedullaryl Nail to treat trochanteric, sub-trochanteric, and shaft fractures and osteotomies according to the cleared/approved indications.
62211142|NCT05562167|EXPERIMENTAL|Potassium Nitrate (KNO3) treatment arm|10 mmol of KNO3 via a single gel capsule to be consumed orally once per day for 6 weeks.
62211143|NCT05562167|PLACEBO_COMPARATOR|Placebo-controlled arm|10 mmol of placebo via a single gel capsule to be consumed orally once per day for 6 weeks.
62211144|NCT06728137||Healthy Volunteers|
62211145|NCT02390700||Golimumab Intravenous|Participants with rheumatoid arthritis (RA) in Canada, will be observed for 24 months. Only data available from source documentation will be collected.
62211146|NCT00875498|ACTIVE_COMPARATOR|active iTBS|iTBS active intensity = 80%MT during 6 minutes. 20 sessions, 2 per day
62019457|NCT05257993|EXPERIMENTAL|Arm A (mFOLFIRINOX)|JPI-547 and Combination Chemotherapy(mFOLFIRINOX) The study is conducted in a 3+3 dose escalation method.
62019458|NCT05257993|EXPERIMENTAL|Arm B (GemAbraxane)|JPI-547 and Combination Chemotherapy (Gemcitabine-nab-paclitaxel) The study is conducted in a 3+3 dose escalation method.
62583546|NCT03659175||male elderly without SIBO|"male elderly without SIBO after 'lactulose breath test'. At the same time, they meet the following criteria:~1. no use of antibiotics in the past 1 month.~2. no use of prokinetic drugs and probiotics in the past 1 week.~3. without these diseases: active inflammation, cardiac insufficiency, respiratory insufficiency, hepatic insufficiency, renal insufficiency, cirrhosis, thyroid diseases, Crohn disease, ulcerative colitis, hepatobiliary and pancreatic disease."
62019459|NCT03280277|EXPERIMENTAL|Diagnostic (ferumoxytol-enhanced MRI)|Patients receive ferumoxytol IV over 15 minutes and then after 24-36 hours undergo ferumoxytol-enhanced MRI before start of neoadjuvant therapy and within 4 weeks before surgery.
62211147|NCT00875498|PLACEBO_COMPARATOR|sham iTBS|iTBS placebo (placebo coil)with same parameters than active
62211148|NCT00022659|EXPERIMENTAL|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62211149|NCT05133700||Qualitative interviews and focus group|Qualitative semi-structured individual interviews and focus groups to be held with people living in care homes (with and without nursing), health and social care staff supporting these people, commissioners and regulators.
62407949|NCT01222962|EXPERIMENTAL|fed treatment|18 healthy volunteers administered with a single dose of Eurartesim
62407950|NCT01222962|EXPERIMENTAL|Fasted Treatment|18 healthy volunteers treated with a single dose of Eurartesim
62407951|NCT06652620|EXPERIMENTAL|Intervention group|Participants in the intervention group are instructed to consume regular Cola in an upright or sitting position after diagnosing with a complete esophageal bolus impaction.
62407952|NCT06652620|NO_INTERVENTION|Control group|Patients in the control group did not receive any pre-endoscopic treatment.
62407953|NCT00314847|NO_INTERVENTION|Control|IABP, inotropic drugs, antiplatelet agents according to site habits.
62407954|NCT00314847|EXPERIMENTAL|Experimental|ECLS +/- IABP, inotropic drugs, antiplatelet agents according to site habits.
62407955|NCT01068418|EXPERIMENTAL|Vitamin D3|15000IU of vitamin D3 daily: open-label, single-arm
62407956|NCT01894542|EXPERIMENTAL|Cod protein from presscake|
62407957|NCT01894542|EXPERIMENTAL|Cod protein from presscake + stickwater|
62583547|NCT02355964|EXPERIMENTAL|exercise|exercise (Aerobe training) 3 times per week
62583548|NCT02355964|EXPERIMENTAL|Diet|A diet with an overall high protein content and a low glycemic index
62583549|NCT02355964|EXPERIMENTAL|Diet+Exercise|A diet with an overall high protein content and a low glycemic index combined with exercise (Aerobe training) 3 times per week.
62583550|NCT02355964|NO_INTERVENTION|control|Regular lifestyle (no intervention)
62019460|NCT05419206||COVID-19 cases with anticytokine therapy|Considering the use of anti-cytokines in these patients, it was found that 53 received tocilizumab, 27 received anakinra, and 10 received both. CMV DNA was positive in 38 (22.7%) of the patients included in the study. CMV positivity was found to be significantly higher in 90 patients (31.11%) compared to 77 patients (16.88%) who did not receive anti-cytokine treatment (p:0.033)
62019461|NCT05419206||COVID-19 cases without anticytokine therapy|MV positivity was found to be significantly higher in 90 patients (31.11%) compared to 77 patients (16.88%) who did not receive anti-cytokine treatment (p:0.033)
62019462|NCT03073603|ACTIVE_COMPARATOR|Drug Continuation Arm|Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include \~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
62019463|NCT03073603|EXPERIMENTAL|Drug Discontinuation Arm|Participants who will discontinue their Disease Modifying Therapies (DMTs). No other changes to their treatment occur. DMTs include \~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
62019464|NCT03570736|EXPERIMENTAL|Minimal Invasive Surgical Technique|
62211150|NCT05133700||Qualitative medicines monitoring tools|Submission of current medicines monitoring tools by care homes and services supporting care homes including community pharmacies.
62407958|NCT01894542|PLACEBO_COMPARATOR|Control|Control group will receive tablet containing only tablet fillers (the same as in the cod protein tablets).
62407959|NCT02130648||Prenatal diagnosis|Prenatal diagnosis witch A sampling of blood de 14 ml
62407960|NCT03815227|EXPERIMENTAL|Outpatient birth|Maternity out the same date or the next day of the birth
62407961|NCT06566144|EXPERIMENTAL|Osteopathy treatment|The osteopathy treatment group (OTG) will be submitted to a clinical method considered the gold standard for the treatment of non-specific low back pain together with osteopathy treatment
62583551|NCT06683937||Patients|Adult patients at very high risk of severe SARS-CoV-2 disease, hospitalized for SARS-CoV-2 infection from June 2023 to April 2024.
62583552|NCT06682910|EXPERIMENTAL|Microtech System|Microtech System
62407962|NCT06566144|ACTIVE_COMPARATOR|Standard treatment|The Standard treatment group (STG) will only receive the gold standard method for the treatment of low back pain.
62407963|NCT04434534|EXPERIMENTAL|Hipocaloric Diet with Açaí Juçara|Individualized diet plans calculated for each participant, reducing 500-1000 daily calories, including 200g of Açaí Juçara (2 pulps).
62407964|NCT04434534|ACTIVE_COMPARATOR|Hipocaloric Diet|Individualized diet plans calculated for each participant, reducing 500-1000 daily calories.
62407965|NCT00566397|EXPERIMENTAL|1|
62407966|NCT00566397|EXPERIMENTAL|2|
62407967|NCT00566397|PLACEBO_COMPARATOR|3|
62407968|NCT01664260|EXPERIMENTAL|N-acetylcysteine + Escitalopram|The subjects with posttraumatic stress disorder, treated with N-acetylcysteine in addition to escitalopram
62407969|NCT01664260|PLACEBO_COMPARATOR|Placebo + Escitalopram|The subjects with posttraumatic stress disorder, treated with placebo in addition to escitalopram
62407970|NCT01042691|EXPERIMENTAL|Oxaliplatin|Subjects who are planning to undergo surgery for placement of HAI therapy pump will be considered for enrollment. Standard HAI therapy requires a laparotomy and placement of an intrahepatic arterial catheter that is connected to one of several commercially available subcutaneous electronic pumps. The pump is then used to deliver FUDR and Leucovorin directly to the liver, usually beginning four weeks after surgery and lasts on average for a period of six to twelve months after the study. This study will examine the addition of a one hour isolated hepatic perfusion with oxaliplatin to this standard treatment
62583553|NCT04731090|ACTIVE_COMPARATOR|Standard antibiotic prophylaxis|IV fluoroquinolone 1 hour preoperatively and oral antibiotics were used for 24h postoperatively.
62583554|NCT04731090|EXPERIMENTAL|enhanced prophylaxis|Patients had urine culture 10 days before the procedure. In addition to the antibiotic prophylaxis, hydrophilic-coated ureteral access sheaths were systematically used.
62211151|NCT02807935|OTHER|OCT imaging of surgical/pharmacological/laser branch|"to evaluate the effect on the conventional outflow pathway, and specifically on the Schlemm's canal (SC) anatomy in the surgical branch:~1. Before and after trabeculotomy~2. Before and after cataract surgery~3. Before and after vitrectomy surgery~4. Before and after XEN™ Gel Stent implant~pharmacological branch-~1. Before and during the treatment with prostaglandins analogs~2. Before and during the treatment with alpha blockers~3. Before and during the treatment with beta blockers~4. Before and during the treatment with carbonic anhydrase inhibitor~laser branch-~1. Before and after trabeculoplasty~2. Before and after laser iridotomy~3. Before and after yag capsulotomy laser"
62211152|NCT05427500|OTHER|Single SGB|This arm will receive a single 5 mL dose of 0.5% preservative-free bupivacaine.
62583555|NCT00741429||Ex-TI|Ex-Technosphere® Insulin Inhalation Powder (subjects previously received TI Inhalation Powder)
62583556|NCT00741429||Non Ex-TI|Non Ex-Technosphere® Insulin Inhalation Powder (subjects previously received another anti-diabetic medication)
62583557|NCT05432154|EXPERIMENTAL|Treatment arm|Patients apply 7-0940 at least 2 times daily for 3 months.
62583558|NCT04062162|ACTIVE_COMPARATOR|Interventional group|Walking football training
62583559|NCT04062162|NO_INTERVENTION|Control group|Usual care
62583560|NCT01655966|ACTIVE_COMPARATOR|Standard of care|Group A: comprises 40 treatment-naive chronic hepatitis c patients who will receive the standard of care treatment: peginterferon Alfa 2a 160 ug once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight \< 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
62583561|NCT01655966|EXPERIMENTAL|Triple therapy|Group B: comprises 40 treatment-naive chronic HCV patients who will receive oral vitamin D 1mcg once daily plus peginterferon alfa-2a (160ug once weekly) and weight-based ribavirin 1000-1200 mg daily (based on body weight \< 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
62019465|NCT03570736|ACTIVE_COMPARATOR|Open Flap Debridement|
62211153|NCT05427500|OTHER|Repeated SGB|This arm will receive two 5 mL doses of 0.5% preservative-free bupivacaine.
62211154|NCT01662375||MIII|
62019466|NCT03309436|EXPERIMENTAL|Use Clomiphene Citrate protocol|Ovulation induction: regular Clomiphene Citrate protocol. Start use rFSH or HMG from day 2/3 of the menstrual cycle, the initial dosage is determined by patients' age, BMI, antral follicle number, FSH, E2, AMH and past ovarian response, usually 150-225IU/d, until hCG injection. At the same time, take CC 100mg/d until hCG injection. The dosage of Gn will be adjust by serum E2, P, LH and the development of follicular.
62211155|NCT04956991||CDAI≤220|According to the Crohn's disease activity index (CDAI) scores, all the patients included in the study were divided into group A (CDAI≤220)
62211156|NCT04956991||CDAI>220|According to the Crohn's disease activity index (CDAI) scores, all the patients included in the study were divided into group B (CDAI\>220)
62407971|NCT06018363|EXPERIMENTAL|ARM|Patients with refractory or relapsed B7H3 positive GBM
62583562|NCT04896398|EXPERIMENTAL|ESWT Group|A total of 5 sessions of ESWT (1000 shock, 1.6 bar, 5 Hz) will be applied to the patients in this group for 2 weeks. Median nerve and tendon shifting exercises will be taught to the patients and they will be asked to do it regularly.
62583563|NCT04896398|NO_INTERVENTION|Control Group|Patients in the control group will be asked to do median nerve and tendon shifting exercises only for the wrist.
62211157|NCT04396652|EXPERIMENTAL|Adductor canal block (ACB) group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal
62407972|NCT00959075|EXPERIMENTAL|Oral thiamin supplementation|Vitamin B1 (Oral thiamin) 100mg BID for 6 months
62019467|NCT03309436|ACTIVE_COMPARATOR|Procedure|Ovulation induction: regular GnRH antagonist protocol. Start use rFSH or HMG from day 2/3 of the menstrual cycle, the initial dosage is determined by patients' age, BMI, antral follicle number, FSH, E2, AMH and past ovarian response, usually 150-225IU/d, until hCG injection. When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection. The dosage of Gn will be adjust by serum E2, P, LH and the development of follicular.
62407973|NCT00959075|PLACEBO_COMPARATOR|Sugar pill|oral placebo 1 tablet BID for 6 months
62407974|NCT02435875||hypertensive|Patients with confirmed hypertension or systolic blood pressure≥140 mmHg or diastolic blood pressure≥90 mmHg without antihypertensive treatment.After anesthesia induction,baroreflex sensitivity will be measured by nitroglycerin.
62583564|NCT04019613|EXPERIMENTAL|Subjects undergoing clinical invasive hemodynamic stress test|Subjects scheduled for standard-of-care, clinically indicated, invasive hemodynamic stress test will undergo lung ultrasound and assessment of extravascular lung water by pulmonary thermodilution technique.
62583565|NCT03207464|EXPERIMENTAL|Multiple Sclerosis|Subjects meeting the definition for Multiple Sclerosis by the International Panel Criteria, with an Expanded Disability Status Scale (EDSS) less than 6.5.
62583566|NCT03207464|EXPERIMENTAL|Healthy Control|This group will serve as non disease population.
62583567|NCT04490603|NO_INTERVENTION|Conventional group|Drug is injected to epidural space for a total of 50 minutes. The drug injection is provided in the same way as the conventional method of injecting drugs in Seoul National University Hospital Pain Center.
62735066|NCT03755219||Tacks, absorbable|Absorbable synthetic staples or tacks. Material specification of staples/tacks was introduced in SHR 2012.
62583568|NCT04490603|EXPERIMENTAL|VR group|Drug is injected to epidural space for a total of 50 minutes. The drug injection is provided with virtual reality experience. Conditions are the same in both arms except for virtual reality experience.
62583569|NCT04868656|ACTIVE_COMPARATOR|Foundational Support|Foundational Support uses the Replicating Effective Program (REP) implementation strategy and includes 5 elements that were developed and tested in our prior Function QUERI work: STRIDE Toolkit; Online shared resources (SharePoint) access for clinical program training materials; Data dashboard to assist hospitals with tracking their own data; Diffusion Networks to promote peer-to-peer sharing and implementation support; and Microsoft TEAMS Channels.
62583570|NCT04868656|EXPERIMENTAL|Enhanced Support|Enhanced Support begins with the same activities as Foundational Support. Hospitals that are randomized to Enhanced Support and do not meet STRIDE initial program benchmarks within 6 months will continue with Foundational support and also receive higher intensity support for a period of 4-6 months. Hospitals that have sustained their implementation will continue low-touch activities while those that have been randomized to the enhanced support arm and met the initial program benchmark at 6-months but have not sustained (did not meet the sustainment benchmark), will begin engaging in high-touch activities. The higher intensity support will consist of facilitation, a process of interactive problem solving and support that occurs in a context of a supportive interpersonal relationship. Facilitation will be provided by Function QUERI team members.
62583571|NCT01609647|EXPERIMENTAL|Prasugrel|Reloading with prasugrel 20mg \& followed by administration of 5mg/day for 30 days
62583572|NCT01609647|ACTIVE_COMPARATOR|Clopidogrel|Reloading with clopidogrel 300mg and followed by administration of clopidogrel 75 mg/day for 30 days
62583573|NCT06031610||Individuals accepted CAS|"Procedure: CAS and Standard medical treatment.~Other:~1. Neuropsychological testing.~2. Multimodal CT: included NCCT+CTP and reconstructed 4D-CTA.~3. Multimodal MRI included T1, T2-FLAIR, DWI, DTI, SWI, fMRI.~4. Optical coherence tomography angiography."
62583574|NCT06031610||Individuals accepted standard medical treatment alone.|"Procedure: Standard medical treatment alone.~Other:~1. Neuropsychological testing.~2. Multimodal CT: included NCCT+CTP and reconstructed 4D-CTA.~3. Multimodal MRI includedT1, FLAIR, MRA, PWI and/or ASL, DTI, DKI, SWI, fMRI.~4. Optical coherence tomography angiography."
62583575|NCT05218343|NO_INTERVENTION|Control|No change in default dose or frequency selected for the eight targeted drugs
62583576|NCT05218343|EXPERIMENTAL|Intervention|The first option a prescriber sees when prescribing any of eight high-risk drugs for elderly hospitalized patients will be modified; the first frequency option a prescriber sees will be modified as well. Providers retain the ability to prescribe any dose or frequency.
62583577|NCT06667622|EXPERIMENTAL|Sodium glycididazole combined with concurrent chemoradiotherapy group|Patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy are treated with sodium glycididazole during concurrent chemoradiotherapy.
62583578|NCT03694847||Asthma with CRSwNP|Asthmatic patients with a diagnosis of CRSwNP
62583579|NCT03694847||Asthma without CRSwNP|Asthmatic patients without a diagnosis of CRSwNP
62583580|NCT06684860||RUT group|The rapid urease test (RUT) was performed for diagnosis of H. pylori infection.
62583581|NCT06684860||Molecular test group|DPO-PCR testing was performed for diagnosis of H. pylori infection.
62211158|NCT04396652|EXPERIMENTAL|Peri-articular injection group|"Patients in group II will receive intraoperative peri-articular (cocktail) injection and will be performed by a single surgeon.~A periarticular cocktail injection consisting of 90 mL of normal saline, 17.5 mL of 0.5% levobupivacaine, 2 mL of ketorolac (30 mg), and 0.5mg (0.5mL) of adrenaline, The total volume of the cocktail will be 110 mL"
62407975|NCT02435875||nonhypertensive|systolic blood pressure \<140 mmHg and diastolic blood pressure\<90 mmHg.After anesthesia induction,baroreflex sensitivity will be measured by nitroglycerin.
62407976|NCT06537336|EXPERIMENTAL|treatment group|The patients in the treatment group underwent aerobic and volumetric incentive spirometry breathing exercises
62407977|NCT06537336|ACTIVE_COMPARATOR|control group|The control group performed only aerobic exercise.
62583582|NCT00910208|EXPERIMENTAL|Patient-controlled analgesia 1 mg demand dose|0.1 mg/kg morphine loading dose plus PCA with 1.0 mg morphine demand dosing every 6 minutes
62583583|NCT00910208|EXPERIMENTAL|Patient-controlled analgesia 1.5 mg demand dose|0.1 mg/kg morphine loading dose plus PCA with 1.5 mg morphine demand dosing every 6 minutes
62583584|NCT00910208|ACTIVE_COMPARATOR|Non-Patient-controlled analgesia comparison group|0.1 mg/kg morphine loading dose plus additional analgesia as needed
62019468|NCT03548844|EXPERIMENTAL|local excision group|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group)
62019469|NCT03548844|ACTIVE_COMPARATOR|total mesorectal excision group|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (local excision group)
62019470|NCT05734313|EXPERIMENTAL|Unified Protocol for Cognitive Behavioral Therapy (UP-CBT) with Continuous Glucose Monitoring|Participants randomized to this arm will receive the Unified Protocol for Cognitive Behavioral Therapy (UP-CBT), enhanced by review of Continuous Glucose Monitoring (CGM) data. Participants will wear study-supplied CGM for the first 6 months of their participation in the trial.
62407978|NCT03028077|EXPERIMENTAL|GS-3K8|GS-3K8 (6 cap/day, 500 mg/cap) for 12 weeks
62407979|NCT03028077|EXPERIMENTAL|GINst15|GINst15 (6 cap/day, 500 mg/cap) for 12 weeks
62019471|NCT05734313|ACTIVE_COMPARATOR|Continuous Glucose Monitoring (CGM) Only|Participants randomized to receive Continuous Glucose Monitoring (CGM) will continue to receive their usual care and will also wear CGM throughout the first 6 months of their participation in the trial.
62407980|NCT03028077|PLACEBO_COMPARATOR|Placebo|Placebo for 12 weeks
62407981|NCT03226574|EXPERIMENTAL|RTX epidural injection|Epidural injection of 1.5mL/min RTX under the guidance of epidurogram.
62407982|NCT03520582||Volunteers|Cohort of 10 healthy subjects. The tube will be placed and removed by a gastroenterologist experienced in performing endoscopic postpyloric tube placement. Secondly, a second tube will be placed and removed.
62407983|NCT03520582||Mechanically ventilated ICU|Cohort of 20 mechanically ventilated intensive care patients requiring a placement of a postpyloric feeding tube on clinical indications.
62583585|NCT02228733|EXPERIMENTAL|KBP-5074: Cohort 1|Healthy Volunteers will receive one dose of KBP-5074
62583586|NCT02228733|EXPERIMENTAL|KBP-5074: Cohort 2|Healthy Volunteers will receive one dose of KBP-5074
62583587|NCT02228733|EXPERIMENTAL|KBP-5074: Cohort 3|Healthy Volunteers will receive one dose of KBP-5074
62583588|NCT02228733|EXPERIMENTAL|KBP-5074: Cohort 4|Healthy Volunteers will receive one dose of KBP-5074
62211159|NCT04396652|EXPERIMENTAL|Adductor canal block and IPACK block group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal IPACK block in which The ultrasound probe will be positioned in the popliteal crease, and needle will be inserted into the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur and 15 ml of 0.25% Levobupivacaine will be injected
62583589|NCT02228733|EXPERIMENTAL|KBP-5074: Cohort 5|Healthy Volunteers will receive one dose of KBP-5074
62583590|NCT02228733|EXPERIMENTAL|KBP-5074: Fed Group|Healthy Volunteers will receive one dose of KBP-5074
62583591|NCT02119793|EXPERIMENTAL|YVOIRE contour|
62583592|NCT02497443|EXPERIMENTAL|study group|Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.anti-epileptic drugs \[AEDs\]) and receiving autologous mesenchymal stem cells
62583593|NCT02497443|NO_INTERVENTION|control group|Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.AEDs)
62583594|NCT03718520||prenatal exposed to cannabis|50 mother-infant pairs with self-reported maternal chronic cannabis use during pregnancy
62211160|NCT05032872|EXPERIMENTAL|Social Exergame Treatment Group|The treatment group will wear a Fitbit step counter for 8 weeks. In addition, participants will use the full version of the Go\&Grow fitness app for 6 weeks.
62211161|NCT05032872|ACTIVE_COMPARATOR|Control Group|The control group will wear a Fitbit step counter for 8 weeks. In addition, participants will use the Go\&Grow fitness app without the social features for 6 weeks.
62211162|NCT04660136|EXPERIMENTAL|CEUS|
62407984|NCT01611285||Robotic Sacrocolpopexy patients|Patients who underwent Robotic Sacrocolpopexy to treat pelvic organ prolapse between 2009 and 2010
62407985|NCT01611285||UPHOLD patients|Patients who underwent the UPHOLD procedure to treat pelvic organ prolapse from 2009-2010.
62019472|NCT02117570|EXPERIMENTAL|High dose of C. difficile vaccine|
62019473|NCT02117570|EXPERIMENTAL|Low dose of C. difficile vaccine|
62019474|NCT02117570|PLACEBO_COMPARATOR|Placebo|
62407986|NCT03917654|EXPERIMENTAL|Arm 1a/3c|Arm 1a (pilot) + Arm 3c (main) to receive 40ug of Pfs230D1M-EPA/AS01 on days 0, 28, 168; receipt of artemether/lumefantrine (AL) on day -7
62407987|NCT03917654|ACTIVE_COMPARATOR|Arm 1b/3d|Arm 1b (pilot) + Arm 3d (main) to receive HAVRIX (day 0), TYPHIM Vi (day 28), HAVRIX (day 168); receipt of AL on day -7
62407988|NCT03917654|EXPERIMENTAL|Arm 2a/3a|Arm 2a (pilot) + Arm 3a (main) to receive 40ug of Pfs230D1M-EPA/AS01 on days 0, 28, 168; receipt of AL on day -7 and 154
62407989|NCT03917654|ACTIVE_COMPARATOR|Arm 2b/3b|Arm 2b (pilot) + Arm 3b (main) to receive HAVRIX (day 0), TYPHIM Vi (day 28), HAVRIX (day 168); receipt of AL on day -7 and 154
62407990|NCT03917654|EXPERIMENTAL|Arm 3e|Arm 3e (main) to receive 40microg of Pfs230D1M-EPA/AS01 on days 0, 28, 168; receipt of AL on day -7
62407991|NCT03917654|ACTIVE_COMPARATOR|Arm 3f|Arm 3f (main) to receive HAVRIX (day 0), TYPHIM Vi (day 28), HAVRIX (day 168); receipt of AL on day -7
62407992|NCT03917654|NO_INTERVENTION|Arm 4a|Receipt of AL on day 154
62019475|NCT06131918|ACTIVE_COMPARATOR|Resveratrol+ Alpha lipoic acid +Superoxide dismutase|This group will receive Resveratrol 1500 mg BD Tab Alpha lipoic acid 600 mg BD Tab Superoxide dismutase 250 mg BD
62019476|NCT06131918|ACTIVE_COMPARATOR|Resveratrol|This group will receive Tab Resveratrol 1500 mg BD
62019477|NCT06131918|ACTIVE_COMPARATOR|Alpha lipoic Acid|This group will receive Tab Alpha lipoic acid 600mg BD
62407993|NCT03917654|NO_INTERVENTION|Arm 4b|Receipt of AL on day 154
62407994|NCT01652807|EXPERIMENTAL|Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching.
62407995|NCT01652807|NO_INTERVENTION|Waitlist (Delayed Yoga)|Participants assigned randomly to the control condition will provided an identical free two-month membership to Bikram Yoga Dallas after the week following their post-intervention session.
62407996|NCT01612988|EXPERIMENTAL|Chemotherapy BOMP|Bendamustine, Ofatumumab and Methylprednisolone prephase and a maximum of 6 cycles every 4 weeks
62407997|NCT04914234|ACTIVE_COMPARATOR|Group A (n=30)|Atenolol group
62407998|NCT04914234|ACTIVE_COMPARATOR|Group M (n=30)|Metoprolol group
62211163|NCT05754164|EXPERIMENTAL|Attention Control Training|The Dot-Probe Paradigm was utilized within the Attention Bias Modification procedure. The training sessions were comprised of 80 trials, which included facial expression photos depicting happiness, neutrality, and sadness, sourced from four male and four female actors. A fixed cross (+) was presented on the computer screen's center for a duration of 500 milliseconds before each stimulus display, followed by the presentation of two images portraying distinct emotional expressions, which persisted for 500 milliseconds. After the disappearance of the images, an arrow appeared in the location where they had been displayed, and participants were instructed to select the arrow that corresponded with the presented arrow. In the ABM procedure, the arrow was consistently presented following the display of a more positive facial expression, such that in the instance of a sad-neutral face pair, the arrow would always appear in the location of the neutral facial expression image.
62211164|NCT05754164|NO_INTERVENTION|Control|
62407999|NCT06192069|EXPERIMENTAL|Sustainable Prevention Program|"Participants will receive the 4-week Sustainable Prevention Program consisting of lectures, demonstrations, group discussions, and educational materials focused on:~Hydration strategies (proper amounts and types of fluids, reminders for intake) Rest breaks (frequency, duration, scheduling) Lightweight reflective clothing~Device: Core Temperature Sensor~Participants might be equipped with a core temperature sensor to monitor their internal body temperatures. This device will provide continuous, real-time data crucial for understanding the physiological impacts of the prevention strategies and ensuring participant safety.~Device: Heart Rate Monitor~A heart rate monitor will be used to track the cardiovascular responses of the participants to heat and physical activity. This data is essential to assess the strain on participants' bodies and the effectiveness of the prevention strategies in mitigating stress.~Portable shade covers"
62408000|NCT06192069|NO_INTERVENTION|Control|Participants will receive no intervention and follow their usual workplace heat strain prevention measures such as basic hydration and voluntary rest breaks
62583595|NCT03718520||prenatal not-exposed to cannabis|60 mother-infant pairs with no self-reported maternal cannabis use during pregnancy
62583596|NCT00671528|EXPERIMENTAL|QUADRIDERME® cream|QUADRIDERME® cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)
62408001|NCT06571955|EXPERIMENTAL|LARS grafted|Patients implanted with grafted ligament (new generation)
62408002|NCT06571955|ACTIVE_COMPARATOR|Control|Patients implanted with non-grafted ligament (current generation)
62408003|NCT04518449||SMA group|the medial border along the left side of superior mesenteric artery (SMA)
62408004|NCT04518449||SMV group|the medial border along the left side of superior mesenteric vein (SMV)
62408005|NCT03948646|EXPERIMENTAL|Active|Sofpironium bromide, 15% gel, once per day
62408006|NCT03948646|PLACEBO_COMPARATOR|Vehicle|Vehicle gel, once per day
62211165|NCT05070585|EXPERIMENTAL|Isothiocyanate Rich Juice|The juices will contain 37,5g isothiocyanate rich sprouts and be delivered frozen to the subjects. The subjects will be instructed to consume two juices per day.
62211166|NCT05070585|PLACEBO_COMPARATOR|Placebo Juice|The juices will contain 37,5g alfalfa sprouts and be delivered frozen to the subjects. The subjects will be instructed to consume two juices per day.
62211167|NCT02946905||SCD participant|No intervention
62211168|NCT02946905||Non-SCD participant|No intervention
62408007|NCT03197506|EXPERIMENTAL|Group 1 (pembrolizumab, surgery, temozolomide, radiation)|"NEOADJUVANT (CYCLE 1): Patients receive pembrolizumab IV over 30 minutes on day 1.~SURGERY (CYCLE 2): Patients undergo standard of care surgery within days 4-7.~CONCURRENT (CYCLE 3): Starting 21-35 days after surgery, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 8-54. Patients also undergo external beam radiation therapy every 5 days per week on days 8-54.~ADJUVANT (CYCLE 4-8): Within 3-5 weeks after completing radiation therapy, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 1-5 every 28 days. Treatment repeats every 63 days for up to 5 cycles in the absence of disease progression or unexpected toxicity."
62408008|NCT03197506|EXPERIMENTAL|Group 2 (pembrolizumab, temozolomide, radiation therapy )|"CONCURRENT (CYCLE 1): Starting 21-35 days after surgery, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 8-54. Patients also undergo external beam radiation therapy every 5 days per week on days 8-54.~ADJUVANT (CYCLES 2-6): Within 3-5 weeks after completing radiation therapy, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 of cycles 2-5 and 1 and 22 of cycle 6 (up to a total of 17 doses). Patients also receive temozolomide PO daily on days 1-5, 29-33, and 57-61 of cycles 2 and 6, days 22-26 and 50-54 of cycle 3, days 15-19 and 43-47 of cycle 4, days 8-12 and 36-40 of cycle 5. Treatment repeats every 63 days for up to 5 cycles in the absence of disease progression or unexpected toxicity."
62408009|NCT04529941|EXPERIMENTAL|Experimental Group|Will receive stimulation ScNS at 3.5mA output
62408010|NCT04529941|SHAM_COMPARATOR|Control Group|Does not receive therapy
62408011|NCT05993299|EXPERIMENTAL|Letetresgene autoleucel|
62408012|NCT02325414|EXPERIMENTAL|Zol|Intravenous infusion of zoledronic acid (zol) 5 mg at baseline.
62408013|NCT02325414|EXPERIMENTAL|Placebo|Intravenous infusion of placebo at baseline.
62583597|NCT00671528|ACTIVE_COMPARATOR|Betamethasone and Gentamicin|Combination of betamethasone diproprionate cream and gentamicin sulfate cream
62583598|NCT00671528|ACTIVE_COMPARATOR|Betamethasone|Betamethasone diproprionate cream
62583599|NCT03468166||Chronic stroke|The data for motor function and gait pattern analysis was obtained.
62583600|NCT03619239|EXPERIMENTAL|Cohort 1|Patients will receive treatment with GX-I7 at a pre-determined dose (Level I) on Day1 of each cycle.
62583601|NCT03619239|EXPERIMENTAL|Cohort 2|Patients will receive treatment with GX-I7 at a pre-determined dose (Level II) on Day1 of each cycle.
62583602|NCT03619239|EXPERIMENTAL|Cohort 3|Patients will receive treatment with GX-I7 at a pre-determined dose (Level III) on Day1 of each cycle.
62583603|NCT03619239|EXPERIMENTAL|Cohort 4|Patients will receive treatment with GX-I7 at a pre-determined dose (Level IV) on Day1 of each cycle.
62211169|NCT02913053|ACTIVE_COMPARATOR|Aerobic exercise|
62211170|NCT02913053|ACTIVE_COMPARATOR|Stretching and Toning|
62211171|NCT02913053|NO_INTERVENTION|Usual care: Control Group|
62211172|NCT01992601|EXPERIMENTAL|1|This arm is consist of 12 subject. Crestor 20mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.
62583604|NCT03619239|EXPERIMENTAL|Cohort 5(Dose-expansion)|Optimal fixed dose of GX-I7 from Dose-escalation stage on Day1 of each cycle (Maximum tolerable dose or Maximum efficacious dose or Maximum administered dose level or consecutive lower or upper dose level which does not exceed Maximum tolerable dose based on Safety Monitoring Committee(SMC) decision)
62583605|NCT03008863|EXPERIMENTAL|Education Intervention|"The investigators will use an electronic learning (E-learning) curriculum with an educational video and a user-centered checklist for anesthesia residents. This E-learning curriculum will cover how to care for geriatric patients in the preoperative, intraoperative and postoperative settings, and specific interventions that have been shown to improve postoperative outcomes in older patients.~The checklist will be user-centered. It will remind providers of what they learned in the video and online curriculum, and how to apply these lessons in real-time while they are caring for older patients."
62583606|NCT03008863|NO_INTERVENTION|Control|Residents randomized to this group will receive the current, standard education provided for all Duke Anesthesiology residents.
62408014|NCT06611085|EXPERIMENTAL|cold application group|The index finger of the child will be used in the cold application group. In this group, cold application will be performed by placing the index finger of the designated hand on a 10 x 10 cm ice pack for 30 seconds and then removing the ice pack immediately.
62583607|NCT02980419|EXPERIMENTAL|intervention arm|In each participant the investigators will assess verticality perception in whole-body upright position by use of the SVV, the SPV and the SHV after static roll-tilt at ±90deg over 5min. Measurements will be obtained on a motor-driven turntable and two different roll-tilt positions will be applied (±90°). A visual line (SVV), a rod (SHV) or the turntable itself will be adjusted to indicate perceived direction of vertical. A total of three measuring sessions, each lasting about 60 minutes are scheduled.
62583608|NCT02898571|PLACEBO_COMPARATOR|Placebo|360ml water based drink containing 50g mix of glucose and fructose plus flavouring
62583609|NCT02898571|EXPERIMENTAL|Vitamin C|360ml water based drink containig 60mg vitamin C and 50g mix of glucose and fructose plus flavouring
62019478|NCT06131918|ACTIVE_COMPARATOR|Superoxide dismutase|This group will receive Tab Superoxide dismutase 250mg BD
62211173|NCT01992601|EXPERIMENTAL|2|This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Crestor 20mg alone for 6 day during period 2.
62408015|NCT06611085|EXPERIMENTAL|vibration group|The middle finger of the child will be used in the vibration group. In this group, vibration was applied by targeting the tip of the middle finger area using a vibrator device measuring 2x1x3 cm. The insertion of the needle will coincide with the application of the vibration stimulation.
62211174|NCT01992601|EXPERIMENTAL|3|This arm is consist of 12 subject. Micardis 80mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.
62211175|NCT01992601|EXPERIMENTAL|4|This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Micardis 80mg alone for 6 day during period 2.
62408016|NCT06611085|EXPERIMENTAL|vibration and ice group|In the vibration and ice group, cold and vibration stimulation will be applied to the child simultaneously. The ring finger of the designated hand was placed on a 10x10 cm ice pack for 30 seconds and subjected to cold application. Simultaneously, vibration stimulation will be applied to the tip of the middle finger area using a vibrator device with dimensions of 3x1 cm and 2x1 cm. After 30 seconds, the ice bag will be removed and the lancet pen will be adjusted for drilling from the fingertip while vibration stimulation continues.
62408017|NCT06611085|NO_INTERVENTION|Control|After determining the hands for intervention and control, measurement will be made according to the clinical routine for the first control. In clinical routine practice, in the measurement of blood glucose level, a puncture is performed with a lancet pen, then the first blood is wiped off and the second blood is measured with a glucometer.
62583610|NCT02898571|EXPERIMENTAL|Epicatechin|360ml water based drink containig 80mg epicatechin and 50g mix of glucose and fructose plus flavouring
62019479|NCT01045447|EXPERIMENTAL|IDegAsp OD|
62408018|NCT03744494|EXPERIMENTAL|Bilateral simple orchidectomy (BSO)|The patients would have the testis, epididymis and distal cord structures excised
62583611|NCT05790512||Both gastric and oral Helicobacter pylori are negative|
62583612|NCT05790512||Negative for Helicobacter pylori for gastric and positive for Helicobacter pylori for oral cavity|
62583613|NCT05790512||Positive for Helicobacter pylori for gastric and negative for Helicobacter pylori for oral cavity|
62583614|NCT05790512||Both gastric and oral Helicobacter pylori are positive|
62583615|NCT00713791|EXPERIMENTAL|1|There are 5 variations of the ZD4054 (Zibotentan) 10mg tablet - A, B, C, D, and E. A minimum washout period of 1 week will occur between each treatment period.
62583616|NCT03316053||Tissue Sample for genetic testing|Biopsy sample
62019480|NCT01045447|ACTIVE_COMPARATOR|IGlar OD|
62211176|NCT04669015|EXPERIMENTAL|Active plus SOC|Inhaled Novaferon, given 20 ug BID, daily for 10 days, plus Standard of Care
62211177|NCT04669015|PLACEBO_COMPARATOR|Placebo plus SOC|Inhaled vehicle formulation (placebo), given BID, daily for 10 days, plus Standard of Care
62019481|NCT02897804|EXPERIMENTAL|Knowledge alone|Participants will have access to the knowledge module for a period up to 3 weeks.
62019482|NCT02897804|EXPERIMENTAL|Self-efficacy alone|Participants will have access to the knowledge module plus the self-efficacy module for a period up to 3 weeks.
62019483|NCT02897804|EXPERIMENTAL|Perceived benefits alone|Participants will have access to the knowledge module plus the perceived benefits module for a period up to 3 weeks.
62019484|NCT02897804|EXPERIMENTAL|Benefits and self-efficacy|Participants will have access to the knowledge module plus the perceived benefits and self-efficacy modules for a period up to 3 weeks.
62019485|NCT02897804|EXPERIMENTAL|Injunctive norms alone|Participants will have access to the knowledge module plus the injunctive norms module for a period up to 3 weeks.
62019486|NCT02897804|EXPERIMENTAL|Injunctive norms and self-efficacy|Participants will have access to the knowledge module plus the injunctive norms and self-efficacy modules for a period up to 3 weeks.
62211178|NCT00733876|EXPERIMENTAL|A|
62211179|NCT05995132||Intensive care unit|This group will be composed of patients admitted to the intensive care unit who did not receive invasive mechanical ventilation.
62408019|NCT03744494|EXPERIMENTAL|Subcapsular orchidectomy (BSCO)|The tunica albuginea was incised longitudinally and the testicular parenchyma scraped off it. The hilar region was secured with a haemostat and the parenchyma excised off it. A haemostatic suture was applied at the hilum. A running interlocking water-tight capsular suture was inserted
62408020|NCT03744494|EXPERIMENTAL|Epididymal-sparing orchidectomy (BESO)|The epididymal sinus was developed. The epididymal vessels were sequentially clamped and divided, removing the testicle from the epididymis. The caput was looped to meet the head and the adjoining surfaces of the body sutured together (epididymoplasty) Vasectomy done to reduce future risk of epididymitis
62408021|NCT02017782|EXPERIMENTAL|Dust, Ozone, Interaction Dust & Ozone|Dust (250-300µg/m3), Ozone (0,1ppm ozone),Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (\<20µg/m3). with at least 2 weeks between each exposure session
62583617|NCT02107859|EXPERIMENTAL|Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 192 weeks.
62583618|NCT02960035|EXPERIMENTAL|etanercept 50mg/week|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 will be randomised to one of three arms (period 2): this arms will receive ETN 50 mg weekly (unchanged). In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
62583619|NCT02960035|EXPERIMENTAL|etanercept 25mg/week|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 were randomised to one of three arms (period 2): this arms will receive ETN 25 mg weekly (half dose). In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
62211180|NCT05995132||Intensive care unit and invasive mechanical ventilation|This group will be composed of patients admitted to the intensive care unit who did receive invasive mechanical ventilation.
62408022|NCT02017782|ACTIVE_COMPARATOR|Interaction Dust & Ozone and placebo Filtered air|Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (\<20µg/m3) with at least 2 weeks between each exposure session.
62408023|NCT06542679|NO_INTERVENTION|Control Group|The control group will receive routine care following the Ministry of Health's Prenatal Care Management Guide of the Republic of Turkey. To enhance adherence among control group participants, weekly antenatal health information unrelated to healthy eating, physical activity, and weight management will be provided via phone.
62408024|NCT06542679|EXPERIMENTAL|Intervention Group|In addition to the routine care provided according to the Turkish Ministry of Health's Prenatal Care Management Guidelines, the intervention group will receive a mobile application intervention. The intervention (mobile application) will begin at the 12th week of pregnancy. Participants in the intervention group will start using the mobile application at the 12th week of pregnancy and continue to use it throughout their pregnancy. The content of the mobile application includes information on healthy nutrition and exercise during pregnancy, as well as monitoring and notifications. Pregnant women will be guided, encouraged, and monitored for healthy nutrition and exercise through the mobile application.
62408025|NCT03996694|EXPERIMENTAL|Treatment A: Belbuca 300 µg and oral placebo|Subjects treated with Belbuca 300 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
62408026|NCT03996694|EXPERIMENTAL|Treatment B: Belbuca 600 µg and oral placebo|Subjects treated with Belbuca 600 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
62735067|NCT03755219||Tacks, uncategorized|"Staples or tacks were in SHR 2005-2011 not further categorized.~This category also includes staples/tacks registered from 2012 and forth, not being specified as either metal or absorbable."
62735068|NCT03755219||Fibrin glue|Biologic glue/sealant produced from human donor blood
62408027|NCT03996694|EXPERIMENTAL|Treatment C: Belbuca 900 µg and oral placebo|Subjects treated with Belbuca 900 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
62211181|NCT03345576|EXPERIMENTAL|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
62408028|NCT03996694|ACTIVE_COMPARATOR|Treatment D: Oxycodone 30 mg and buccal placebo|Subjects treated with Oxycodone 30 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
62408029|NCT03996694|ACTIVE_COMPARATOR|Treatment E: Oxycodone 60 mg and buccal placebo|Subjects treated with Oxycodone 60 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
62408030|NCT03996694|PLACEBO_COMPARATOR|Treatment F: Oral Placebo and buccal placebo|Subjects treated with oral placebo and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
62408031|NCT01198327|EXPERIMENTAL|Ranibizumab as needed|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart; with optional peripheral laser to areas of non-perfusion.
62408032|NCT03286530|EXPERIMENTAL|Ruxolitinib|Following a standard of care allogeneic stem cell transplantation, participants will be started on Ruxolitinib. Ruxolitinib is administered orally 2 times per day at a fixed dose. Each study treatment cycle lasts 28 days. Up to 24 cycles.
62408033|NCT05592704|EXPERIMENTAL|Intervention group|Individuals participated in the 2-month outpatient aerobic exercise training program, which consisted of 40 training sessions on a cycle ergometer 5 times/week for 40 min. Then during motivational consultation, individuals received recommendations for healthy lifestyle and home-based training. After that, study subjects participated in the 6-month home-based aerobic exercise program using wearable device (heart rate monitor), which was connected to the smartphone via Bluetooth. A special smartphone application enabled participants to keep their training heart rate during home-based exercises (or workouts).
62408034|NCT05592704|NO_INTERVENTION|Control group|Individuals participated in the 2-month outpatient aerobic exercise training program, which consisted of 40 training sessions on a cycle ergometer 5 times/week for 40 min. Then during motivational consultation, individuals received recommendations for healthy lifestyle and home-based training. After that, study subjects participated in the 6-month home-based aerobic exercise program without wearable devices and smartphone application.
62408035|NCT01448226||proven or probable aspergillosis|
62211182|NCT03345576|SHAM_COMPARATOR|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
62408036|NCT01448226||possible aspergillosis|
62408037|NCT04374136|EXPERIMENTAL|AL001|AL001 every 4 weeks
62583620|NCT02960035|PLACEBO_COMPARATOR|PLACEBO|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 were randomised to one of three arms (period 2): this arms will receive placebo weekly. In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
62211183|NCT02718430|EXPERIMENTAL|VXM01|VXM01 10E6 or 10E7 CFU
62583621|NCT04768101|EXPERIMENTAL|Parkinson's Disease participants with MCI|Patient volunteers will also undergo a C-11 PiB PET scan. This procedure utilizes a common radiotracer that is used routinely in clinical PET scans and will be purchased here from PETNET and certified for human use. All PET scans will be performed by a certified PET technologist at the Vanderbilt University Institute of Imaging Science.
62583622|NCT02794792|ACTIVE_COMPARATOR|Metformin and placebo|Participants will receive daily dosage of Metformin and Placebo as single tablets.
62583623|NCT02794792|EXPERIMENTAL|Metformin and Ipragliflozin|Participants will receive daily dosage of Metformin and Ipragliflozin (2 dose strengths) as single tablets.
62583624|NCT02794792|OTHER|Metformin, placebo and Ipragliflozin|Participants will receive daily dosage of Metformin, placebo and Ipragliflozin (1 dose strength) as single tablets.
62583625|NCT06675435|EXPERIMENTAL|Acute hypoxemic respiratory failure|Participants (n = 40) with acute hypoxemic respiratory failure will receive inhaled nitric oxide (20 ppm) for 15 min.
62583626|NCT06675435|NO_INTERVENTION|Participants without acute hypoxemic respiratory failure|Participants (n = 20) without acute hypoxemic respiratory failure will not receive inhaled nitric oxide
62583627|NCT02342197|ACTIVE_COMPARATOR|Minidose long protocol|Half dose of GnRH agonist (Decapeptyl 0.05) was started in the midluteal phase and Gn's was started from the second day of the cycle.
62583628|NCT02342197|ACTIVE_COMPARATOR|Microdose flare protocol|Half the dose of GnRH agonist (Decapeptyl 0.05) was started on the second day of the cycle together with Gn's
62583629|NCT06676475|EXPERIMENTAL|Group I: Patients will receive Magnesium Sulfate injection into trigger points|
62583630|NCT06676475|ACTIVE_COMPARATOR|Group II: Patients will receive Botulinum Toxin into trigger points|
62583631|NCT06676475|PLACEBO_COMPARATOR|Group III: Patients will receive Saline injection into trigger points|
62734508|NCT02350335|ACTIVE_COMPARATOR|NRT|"Active smokers with acute aneurysmal hemorrhage randomly assigned to transdermal nicotine replacement after securing of the aneurysm.~Patient management for all patients is according to the institutional treatment guidelines and independent of group assignment.~The dose is dependent on smoke consumption prior to the ictus. Nicorette 7 mg/day for smokers smoking 1-10 cigarettes /day Nicorette 14mg/day for smokers smoking 11-19 cigarettes/day Nicorette 21 mg/day for smokers smoking 20 or more cigarettes daily"
62211184|NCT06728436|EXPERIMENTAL|CuidaTEXT|6 months of CuidaTEXT intervention + 1-month post-treatment
62408038|NCT04374136|PLACEBO_COMPARATOR|Placebo|Placebo every 4 weeks
62408039|NCT04374136|EXPERIMENTAL|Open label - AL001|AL001 every 4 weeks
62408040|NCT01489306|EXPERIMENTAL|MDT-637|Active formulation
62408041|NCT01489306|PLACEBO_COMPARATOR|Placebo|Matched Placebo Comparator
62408042|NCT05584202|EXPERIMENTAL|Part 1: mRNA-1273.214 Dose A|Participants will receive 2 doses of mRNA-1273.214 Dose A by intramuscular (IM) injection approximately 8 weeks apart (Day 1 and Day 57).
62408043|NCT05584202|EXPERIMENTAL|Part 1: mRNA-1273.214 Dose B|Participants will receive 2 doses of mRNA-1273.214 Dose B by IM injection approximately 8 weeks apart (Day 1 and Day 57).
62408044|NCT05584202|EXPERIMENTAL|Part 2: mRNA-1273.214|Participants will receive 2 doses of mRNA-1273.214 by IM injection approximately 8 weeks apart (Day 1 and Day 57).
62408045|NCT05584202|PLACEBO_COMPARATOR|Part 2: Placebo|Participants will receive 2 doses of placebo by IM injection approximately 8 weeks apart (Day 1 and Day 57).
62408046|NCT05429112|ACTIVE_COMPARATOR|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with a endotracheal tube + stylet.
62408047|NCT05429112|ACTIVE_COMPARATOR|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
62408048|NCT03696537|EXPERIMENTAL|Fludarabine + Total Marrow Irradiation|
62408049|NCT06474260|EXPERIMENTAL|A prospective dual site intervention in India|The study will utilize a pre-post study design to evaluate the intervention for intendedoutcomes at the end of Year 1.
62019487|NCT02897804|EXPERIMENTAL|Injunctive norms and perceived benefits|Participants will have access to the knowledge module plus the injunctive norms and perceived benefits modules for a period up to 3 weeks.
62019488|NCT02897804|EXPERIMENTAL|Injunctive norms, perceived benefits,self-efficacy|Participants will have access to the knowledge module plus the injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
62019489|NCT02897804|EXPERIMENTAL|Descriptive norms alone|Participants will have access to the knowledge module plus the descriptive norms module for a period up to 3 weeks.
62408050|NCT05940558|EXPERIMENTAL|MBF-118 100mg oral multiple dose|"Drug: MBF-118 100mg oral capsules. Single daily dose. One hard gelatin capsules during 28 days.~Subjects who have previously completed 28 days treatment with 100 mg MBF-118 and did not show any serious adverse effects will have the option to participate to a 90-day treatment."
62408051|NCT05940558|EXPERIMENTAL|MBF-118 200mg oral multiple dose|Drug: MBF-118 100mg oral capsules. Single daily dose. Two hard gelatin capsules during 28 days
62583632|NCT01949844|OTHER|Suspected coronary artery disease (CAD)|"This pilot study has a single arm/group of subjects with suspected CAD based on the following inclusion criteria:~1. Prior nuclear myocardial perfusion scan (PET/SPECT) with a visual interpretation of definitely abnormal, or prior myocardial infarction; or,~2. Clinically stable individuals with suspected coronary artery disease on the basis of coronary angiography.~The study protocol involved only a myocardial perfusion MRI procedure for detection of ischemia (perfusion deficits) using an improved protocol with the administration of a vasodilator drug (Regadenoson/Lexiscan®) and gadolinium-based MRI contrast agent (Optimark®; dose: 0.2 mmol/kg). Lexiscan® was used off-label as a vasodilator drug during the MRI scan (0.4 mg/5mL) supplied by the manufacturer, Astellas Pharma U.S."
62583633|NCT00006471|EXPERIMENTAL|Fenretinide|
62583634|NCT05954585|ACTIVE_COMPARATOR|Treatment as usual|Emergency department treatment as usual
62019490|NCT02897804|EXPERIMENTAL|Descriptive norms and self-efficacy|Participants will have access to the knowledge module plus the descriptive norms and self-efficacy modules for a period up to 3 weeks.
62019491|NCT02897804|EXPERIMENTAL|Descriptive norms and perceived benefits|Participants will have access to the knowledge module plus the descriptive norms and perceived benefits modules for a period up to 3 weeks.
62019492|NCT02897804|EXPERIMENTAL|Descriptive norms,perceived benefits,self-efficacy|Participants will have access to the knowledge module plus the descriptive norms module for a period up to 3 weeks.
62019493|NCT02897804|EXPERIMENTAL|Descriptive norms and injunctive norms|Participants will have access to the knowledge module plus the descriptive norms and injunctive norms modules for a period up to 3 weeks.
62019494|NCT02897804|EXPERIMENTAL|Descriptive norms, injunctive norms,self-efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
62211185|NCT06728436|NO_INTERVENTION|7-Month Waitlist Control|Participants allocated to this arm will be offered the opportunity to start CuidaTEXT immediately after their 7 Month follow-up assessment
62211186|NCT06727799||Diagnostic Test|One eye of each subject will have corneal marks placed and will be docked at the study visit.
62735069|NCT03755219||Non-fixation|Mesh is deployed without fixation
62019495|NCT02897804|EXPERIMENTAL|Descriptive and injunctive norms, benefits|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
62019496|NCT02897804|EXPERIMENTAL|Descriptive and injunctive norms, benefits,efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
62019497|NCT02897804|EXPERIMENTAL|Expectancies alone|Participants will have access to the knowledge module plus the expectancies module for a period up to 3 weeks.
62408052|NCT01763125||Malignant tumors|"Patients who have one of the Neoplasms stated above under conditions. Blood samples will be taken."
62408053|NCT01763125||Benign controls|"Patients with a benign tumor or an inflammatory disease - to be matched by age and affected organ with a patient with a malignant disease.~Blood samples will be taken."
62408054|NCT01763125||Healthy controls|"People/patients who have no known disease at time of blood sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.~Blood samples will be taken."
62211187|NCT00391287||erythropoietin treatment in CRF|Patients exposed to EPREX or other marketed erythropoietin products administered by the subcutaneous route of administration for the treatment of anemia of Chronic Renal Failure
62408055|NCT06168084|EXPERIMENTAL|Vonorazon and amoxicillin dual therapy|Vonorazon 20 mg daily for 14 days # amoxicillin 1000 mg by mouth three time daily for 14 days
62408056|NCT06168084|ACTIVE_COMPARATOR|Bismuth-containing quadruple therapy|Tetracycline 500mg three time daily for 14 days#furazolidone 100 mg, esomeprazole 40 mg, and Bismuth 220mg by mouth, twice daily for 14 days.
62019498|NCT02897804|EXPERIMENTAL|Expectancies and self-efficacy|Participants will have access to the knowledge module plus the expectancies and self-efficacy modules for a period up to 3 weeks.
62408057|NCT06652464||Active|Group of ulcerative colitis patients considered active according to the Mayo score. (30 patients)
62583635|NCT05954585|EXPERIMENTAL|Family Navigator|Follow provision provided by a Family Navigator for the length of the treatment or until youth attends community-based mental health care
62019499|NCT02897804|EXPERIMENTAL|Expectancies and perceived benefits|Participants will have access to the knowledge module plus the expectancies and perceived benefits modules for a period up to 3 weeks.
62019500|NCT02897804|EXPERIMENTAL|Expectancies, perceived benefits, self-efficacy|Participants will have access to the knowledge module plus the expectancies, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
62019501|NCT02897804|EXPERIMENTAL|Expectancies and injunctive norms|Participants will have access to the knowledge module plus the expectancies and injunctive norms modules for a period up to 3 weeks.
62019502|NCT02897804|EXPERIMENTAL|Expectancies, injunctive norms, and self-efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
62019503|NCT02897804|EXPERIMENTAL|Expectancies, injunctive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
62019504|NCT02897804|EXPERIMENTAL|Expectancies, injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
62019505|NCT02897804|EXPERIMENTAL|Expectancies and descriptive norms|Participants will have access to the knowledge module plus the expectancies and descriptive norms modules for a period up to 3 weeks.
62019506|NCT02897804|EXPERIMENTAL|Expectancies, descriptive norms, and self-efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and self-efficacy modules for a period up to 3 weeks.
62019507|NCT02897804|EXPERIMENTAL|Expectancies, descriptive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and perceived benefits modules for a period up to 3 weeks.
62019508|NCT02897804|EXPERIMENTAL|Expectancies,descriptive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
62019509|NCT02897804|EXPERIMENTAL|Expectancies, descriptive and injunctive norms|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and injunctive norms modules for a period up to 3 weeks.
62019510|NCT02897804|EXPERIMENTAL|Expectancies, descr& injun norms, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
62019511|NCT02897804|EXPERIMENTAL|Expectancies, desc & injun norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
62211188|NCT01588132|EXPERIMENTAL|Single dose gourp 1|Anfibatide injection at the concentration of 0.33μg/60kg in healthy volunteers
62211189|NCT01588132|EXPERIMENTAL|Single dose group 2|Anfibatide injection at the concentration of 0.66μg/60kg in healthy volunteers
62408058|NCT06652464||Remission|Group of ulcerative colitis patients considered remission according to the Mayo score. (30 patients)
62408059|NCT06652464||Control|Group without ulcerative colitis or inflammatory disease. (30 patients)
62408060|NCT04281849|NO_INTERVENTION|Usual care|Patients in the usual care arm will receive educational material from the Heart Failure Society of America (HFSA) with the current recommendations for exercise for patients with heart failure.
62734509|NCT02350335|NO_INTERVENTION|no NRT|Active smokers with acute aneurysmal hemorrhage that were assigned to not receive transdermal nicotine replacement.
62019512|NCT02897804|EXPERIMENTAL|Expectancies,desc & injun norms,benefits,efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
62019513|NCT06536075|OTHER|Sialoscintigraphy (healthy control for nomogram)|Healthy population for nomogram of sialoscintigraphy
62019514|NCT06536075|OTHER|Sialoscintigraphy (sicca patients)|Patients with sicca symptoms. Data of sialoscintigraphy retrieved from medical records.
62019515|NCT02172209|EXPERIMENTAL|BI 10773 tablet administered with food|50 mg BI 10773 after a standardised high fat breakfast
62019516|NCT02172209|ACTIVE_COMPARATOR|BI 10773 tablet administered to fasted subjects|50 mg BI 10773 p.o. after an overnight fast of at least 10 hours
62019517|NCT05035082|EXPERIMENTAL|oral semaglutide|All participants are given tablets used in addition to metformin.
62019518|NCT05035082|ACTIVE_COMPARATOR|other oral glucose lowering medication|All participants are given tablets used in addition to metformin.
62019519|NCT04589065|EXPERIMENTAL|Selective Cytopheretic Device|
62211190|NCT01588132|EXPERIMENTAL|Single dose groups 3|Anfibatide injection at the concentration of1.0μg/60kg in healthy volunteers
62211191|NCT01588132|EXPERIMENTAL|Single dose group 4|Anfibatide injection at the concentration of 1.5μg/60kg in healthy volunteers
62408061|NCT04281849|EXPERIMENTAL|BAMS-HF Program|
62408062|NCT02149277|ACTIVE_COMPARATOR|Filgrastim|Injection Filgrastim 300 ug intravaginally during an IVF cycle or during an embryo transfer
62408063|NCT02149277|PLACEBO_COMPARATOR|Sodium Chloride|Injection of 1 ml of Sodium Chloride intravaginally during an IVF cycle or during an embryo transfer cycle.
62408064|NCT01412294|EXPERIMENTAL|Capecitabine, Cisplatin|
62211192|NCT01588132|EXPERIMENTAL|Single dose group 5|Anfibatide injection at the concentration of 2.0μg/60kg in healthy volunteers
62211193|NCT01588132|EXPERIMENTAL|Single dose group 6|Anfibatide injection at the concentration of 3.0μg/60kg in healthy volunteers
62211194|NCT01588132|EXPERIMENTAL|Single dose group 7|Anfibatide injection at the concentration of 4.0μg/60kg in healthy volunteers
62211195|NCT01588132|EXPERIMENTAL|Single dose group 8|Anfibatide injection at the concentration of 5.0μg/60kg in healthy volunteers
62211196|NCT01588132|EXPERIMENTAL|Multiple dose group 9|Give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours
62211197|NCT01588132|EXPERIMENTAL|Multiple dose group 10|Give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.
62211198|NCT01588132|EXPERIMENTAL|Multiple dose group 11|Give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours
62211199|NCT05638698|EXPERIMENTAL|TG01/QS-21 (Vaccine arm)|TG01 is mixed with adjuvant QS-21 and given subcutaneously. After six administrations given once every two weeks of TG01 vaccine (+adjuvant QS-21) over 12 weeks during weeks 1,3,5,7,9,11, \[priming/booster phase\]), the treatment will then switch to a maintenance phase of TG01 vaccine (+adjuvant QS-21) once every 8 weeks for up to 51 weeks: The maintenance treatments will occur during weeks 19, 27, 35, 43, and 51. Maintenance treatments will end on week 51 or at the time of disease recurrence; whichever is the earliest.
62211200|NCT05638698|EXPERIMENTAL|TG01/QS-21 + Balstilimab (Vaccine + PD-1 arm)|TG01 is mixed with adjuvant QS-21 and given subcutaneously. Balstilimab is given intra-venously as infusion and begins week 3, then given every 2 weeks for up to 51 weeks. After six administrations given once every two weeks of TG01 vaccine (+adjuvant QS-21) over 12 weeks during weeks 1,3,5,7,9,11, \[priming/booster phase\]), the treatment will then switch to a maintenance phase of TG01 vaccine (+adjuvant QS-21) given once every 8 weeks for up to 51 weeks: The maintenance treatments will occur during weeks 19, 27, 35, 43, and 51. Maintenance treatments will end on week 51 or at the time of disease recurrence; whichever is the earliest.
62408065|NCT00285259|EXPERIMENTAL|VCL-CB01|
62408066|NCT00285259|PLACEBO_COMPARATOR|Placebo|PBS
62408067|NCT04354740||Group A : Diabetic|group is subdivided into 2sub-groups: Group 1: Group: underwent PCI(Primary or Rescue) Group 2: underwent CABG Patients diagnosed as multivessel disease or left main coronary artery lesion will be included in the study
62019520|NCT00460512|EXPERIMENTAL|Paliperidone Extended Release (ER)|
62019521|NCT05233072|OTHER|Fracture|Patients with a fracture of the upper neck of the femur
62019522|NCT05233072|OTHER|Control|Patients with no fracture of the upper neck of the femur
62019523|NCT01504438|OTHER|Salto Talaris Total Ankle Replacement|
62019524|NCT01504438|OTHER|STAR Total Ankle Replacement|
62019525|NCT04363905|PLACEBO_COMPARATOR|Placebo|100 mg lactose capsule
62019526|NCT04363905|EXPERIMENTAL|Ferrous sulfate|20 mg ferrous sulfate and lactose capsule
62019527|NCT02515162|EXPERIMENTAL|Fischer Cone Biopsy Excisor|Conization Methode using a triangular electrode , i.e. Fischer Cone Biopsy Excisor
62019528|NCT02515162|ACTIVE_COMPARATOR|Loop Excision Procedure|Conization Methode using a circular electrode , i.e. Loop excision Procedure
62019529|NCT00319423|ACTIVE_COMPARATOR|Patient education|Patient education according to Klassbo et al 2003
62019530|NCT00319423|EXPERIMENTAL|Patient education and supervised exercise|Patient education according to Klassbo et al 2003. Supervised exercise containing strengthening, functional and flexibility exercises.
62019531|NCT01577134|EXPERIMENTAL|Intervention to enhance physical activity|Participants in this arm have high motivation to be regularly physically active. Face-to-face group intervention includes behavior change techniques to enhance physical activity.
62019532|NCT01577134|ACTIVE_COMPARATOR|Active control intervention|Face-to-face group intervention includes behavior change techniques to enhance volunteering and improve attitudes towards volunteering.
62019533|NCT01577134|OTHER|Passive control intervention|Waiting-list control group, who receives all information (that the active groups got) via mail after completion of 8.5 months follow-up.
62019534|NCT04402333||Robotic interval debulking surgery|Surgery will commence with an initial assessment with a camera inserted though the belly button. This visual assessment will be used to determine whether it is feasible to proceed with surgery robotically or whether full debulking surgery to zero macroscopic residual disease would be best carried out through an open surgical approach. If an open surgical approach is considered the optimum treatment for the patient and they have consented for this, then this will be done. If there is disease that cannot be removed Robotically after starting by this route, but can be removed via an open incision the surgery will be converted to an open procedure if it is safe to do so. If there are any complications, we may also need to convert to open surgery. The aim of the surgery whether by robotic or open is to remove all visible disease safely.
62019535|NCT04402333||Open interval debulking surgery|Standard Care. Following initial laparoscopic assessment patients not deemed suitable for minimally invasive robotic surgery will proceed with standard open interval debulking surgery through an extended midline incision. These patients will also be followed up to assess recovery, complication rate and quality of life.
62211201|NCT06455735|EXPERIMENTAL|68Ga-JH04 PET/ CT|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-JH04. Tracer doses of 68Ga-JH04 will be used to detect tumors by PET/CT.
62211202|NCT06455735|EXPERIMENTAL|68Ga-FAPI/18F-FDG PET/ CT|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
62211203|NCT02753153|EXPERIMENTAL|Mucograft®, Geistlich Biomaterials|A Mucograft membrane will be used in state of a connective tissue graft. The dimension of the Mucograft® will be previously calculated according to the site dimensions and inserted into buccal pouch and sutured to be stabilized on the buccal aspect. The membrane is then positioned to cover the socket and inserted and sutured in the palatal pouch by the means of vertical interrupted sutures
62211204|NCT02753153|ACTIVE_COMPARATOR|Soft tissue graft|
62211205|NCT02869529||Chronic lymphatic leukemia diagnosis|
62211206|NCT01715662|EXPERIMENTAL|Wii.n.Walk|Subjects (n=12) in the experimental arm (Wii.n.Walk) will be trained using the Wii Fit for 40-minute sessions, 3 times a week for a period of 4 weeks. Subjects will stand on the Wii Fit balance board and interact with the games through weight shifting or using the Wii remote controller. The intervention protocol includes: 1) Yoga (static single and double leg exercises), 2) Balance games (lateral and poster/anterior weight shifting exercises in standing), 3) Aerobics (running on spot and step class), and 4) Strength training (dynamic single and double leg exercises). The sessions will start in the clinic with a group of 3 participants and will graduate to individualized in-home training starting from week 2. For the in-clinic training sessions, a trained research assistant will administer the intervention and will provide external cueing and correction of the pose if the participants use unsafe technique.
62211207|NCT01715662|PLACEBO_COMPARATOR|Control|Subjects (n=12) in the control arm will play cognitive computer games using Wii Big Brain for the same frequency and duration as the Wii.n.Walk arm. The sessions will start in the clinic with a group of 3 participants and will graduate to individualized in-home training starting from week 2. For the in-clinic sessions, a research assistant will administer the intervention and will provide supervision. Wii Big Brain is a low-cost commercially available gaming software to improve cognitive function.
62211208|NCT02863770|EXPERIMENTAL|Contrast EUS|Undergoing EUS for pancreatic indication (cyst, pancreatitis, mass)
62211209|NCT01395459|NO_INTERVENTION|control|Care as usual is given.
62211210|NCT01395459|EXPERIMENTAL|IVR only|The participants in this study arm receive calls from an Interactive Voice Response (IVR) call system, to remind them that they are in need of breast, cervical and colon cancer screening, as applicable.
62211211|NCT01395459|EXPERIMENTAL|IVR+PCC|The participants in this study arm receive calls from an Interactive Voice Response (IVR) call system, to remind them that they are in need of breast, cervical and colon cancer screening, as applicable. Furthermore, if remained unscreened, these participants receive person to person follow up telephone calls from a prevention care coordinator (PCC) to address barriers.
62211212|NCT06042322||TKA with nerve block no intervention|Patients who received a single shot adductor canal nerve block prior to total knee arthroplasty surgery January 2017-June 2018
62211213|NCT06042322||TKA with nerve block with intervention|Patients who received a single shot adductor canal nerve block prior to total knee arthroplasty surgery during March 2019-March 2020, and received an educational intervention
62211214|NCT03804970|EXPERIMENTAL|Intervention group|Cash rewards for the fellow up+SMS reminders for participants and their family+Showing retinal photos to participants+ Having the Diabetic Club+Watching brief video and basic explanation for disease
62211215|NCT03804970|EXPERIMENTAL|Adjusted intervention group|Cash rewards for the fellow up+SMS reminders for participants and their family+Showing retinal photos to participants+Having the Diabetic Club+Watching brief video and basic explanation for disease( But the intensity of intervention based on the severity of diabetic disease)
62211216|NCT03804970|ACTIVE_COMPARATOR|Control group|Watching brief video and basic explanation for disease
62211217|NCT02651597|EXPERIMENTAL|Low Viscous|Low Viscous Beta Glucan Oatmeal
62583636|NCT03025139|ACTIVE_COMPARATOR|Arm A (MAPs)|Patients attend a mindfulness meditation class over 2 hours once weekly for 6 weeks. Patients then attend in person booster sessions that include guided meditation, questions, and discussion of how to maintain a mindfulness practice over 1 hour once monthly for 2 months.
62583637|NCT03025139|ACTIVE_COMPARATOR|Arm B (SE)|Patients attend a survivorship education class over 2 hours once weekly for 6 weeks. Patients also receive monthly electronic newsletters with tailored information about topics of interest to younger survivors, including cancer-related events in the community and tips about following through on recommendations for healthy living.
62583638|NCT03025139|ACTIVE_COMPARATOR|Arm C (USUAL CARE/DELAYED TREATMENT CONTROL GROUP)|Patients receive usual care for 9 months. Patients are then offered a choice of participating in Arm A or Arm B.
62583639|NCT00931437|EXPERIMENTAL|vitamin K-rich dairy product|one single intake of a dairy product containing several K-vitamins: phylloquinone, menaquinone-7,8,9-and 10.
62583640|NCT03329183|EXPERIMENTAL|HD-FOLFIRI|Advanced CRC patients with Wild-type UGT1A1\*6 and \*28 receive high-dose FOLFIRI regimen (Irinotecan 260mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course.)
62583641|NCT03329183|NO_INTERVENTION|SD-FOLFIRI|Advanced CRC patients with Wild-type UGT1A1\*6 and \*28 receive standard-dose FOLFIRI regimen (Irinotecan 180mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
62211218|NCT02651597|EXPERIMENTAL|Medium Viscous|Medium Viscous Beta Glucan Oatmeal
62211219|NCT02651597|EXPERIMENTAL|High Viscous|High Viscous Beta Glucan Oatmeal
62211220|NCT04625179|EXPERIMENTAL|Melatonin and hyaluronic acid and sinus membrane elevation|melatonin and hyaluronic acid will be placed after maxillary sinus membrane elevation and simultaneous dental implants placement
62211221|NCT04625179|ACTIVE_COMPARATOR|sinus membrane elevation without any materials|no materials will be placed after maxillary sinus membrane elevation and simultaneous dental implants.
62583642|NCT03329183|NO_INTERVENTION|SD-FOLFOX-6|Advanced CRC patients with Wild-type UGT1A1\*6 and \*28 receive standard-dose FOLFOX-6 regimen (Oxaliplatin 130mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
62583643|NCT02858999|EXPERIMENTAL|treatment|12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD) for a total of 4 cycles PAD-VCD
62583644|NCT06057662|ACTIVE_COMPARATOR|Intervention|personalized comprehensive diabetes support for 6 months following type 1 diabetes diagnosis
62583645|NCT06057662|NO_INTERVENTION|Control|
62408068|NCT04354740||Group B: Non diabetic|group is subdivided into 2sub-groups: Group 1: Group: underwent PCI(Primary or Rescue) Group 2: underwent CABG Patients diagnosed as multivessel disease or left main coronary artery lesion will be included in the study
62408069|NCT05497219|OTHER|Healthy adults|Adults aged 18 or older with no history of swallowing impairment
62408070|NCT05497219|OTHER|Parkinson Disease|Adults with a neurologist-confirmed diagnosis of Parkinson Disease who also report symptoms of swallowing impairment, defined as a score \>/= 200 on the Sydney Swallow Questionnaire.
62408071|NCT05497219|OTHER|Chronic Obstructive Pulmonary Disease|Adults with a respirologist-confirmed diagnosis of Chronic Obstructive Pulmonary Disease who also report symptoms of swallowing impairment, defined as a score \>/= 200 on the Sydney Swallow Questionnaire.
62211222|NCT00039390|EXPERIMENTAL|Treatment (capecitabine, gefitinib)|Patients receive oral gefitinib once daily on days 1-14 and oral capecitabine twice daily on days 8-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gefitinib and capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.
62408072|NCT05497219|OTHER|Acute Stroke|Adult inpatients in the acute stage post stroke who are referred for swallowing assessment.
62408073|NCT06593574|EXPERIMENTAL|Robotic laminectomy group|The laminectomy is performed with the assistance of a robot
62408074|NCT06593574|ACTIVE_COMPARATOR|Manual laminectomy group|The laminectomy is performed by the surgeon without the assistance of a robot
62408075|NCT04174443|EXPERIMENTAL|Pulsed radiofrequency + Continuous radiofrequency|
62408076|NCT04174443|ACTIVE_COMPARATOR|Pulsed radiofrequency|
62408077|NCT01876927|EXPERIMENTAL|Arm A|"DOX 4 cycles - Surgery - Follow-up~DOX:~Docetaxel 35 mg/m2 day 1 and 8 by one hour infusion; Oxaliplatin 80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.~Treatment should be administered for 4 cycles before surgery. Each cycle will be repeated every 3 weeks."
62583646|NCT00325156|EXPERIMENTAL|Group A|
62583647|NCT02511964|EXPERIMENTAL|Interval Training at 1% incline|Six Sessions of High Intensity Interval Running (100% VO2Max) at 1% incline; Group metabolically balanced.
62211223|NCT01255332||C13-urea breath test: positive|lansoprazole 30mg bid, amoxicillin 1000mg bid and clarithromycin 500mg bid for 7 days
62211224|NCT01720277|EXPERIMENTAL|HD Fluzone Vaccine|NH facilities randomized to receive high dose trivalent influenza vaccine (HD Fluzone) for the residents.
62211225|NCT01720277|ACTIVE_COMPARATOR|SD Fluzone Vaccine|NH facilities randomized to standard dose trivalent influenza vaccine (SD Fluzone) for the residents.
62583648|NCT02511964|EXPERIMENTAL|Interval Training at 10% incline|Six Sessions of High Intensity Interval Running (100% VO2Max) at 10% incline; Group metabolically balanced.
62211226|NCT06424431|OTHER|Stapler|Simple closure with a closure device for closure of the pancreatic remnant in distal pancreatectomy.
62211227|NCT06424431|EXPERIMENTAL|Stapler combined with electrocautery|Closure with a closure device combined with electrocoagulation for closure of the pancreatic remnant in distal pancreatectomy.
62211228|NCT06204445|EXPERIMENTAL|Green (slightly roasted) coffee|Slightly roasted ground Arabica coffee rich in phenolic compounds (hydroxycinnamic acids). Participants will consume 3 cups of freshly brewed coffee daily (breakfast, mid-morning, early afternoon). Black coffee, no milk.
62408078|NCT01876927|EXPERIMENTAL|Arm B|"DOX 2 cycles - Surgery - DOX 2 cycles - Follow-up~DOX:~Docetaxel 35 mg/m2 day 1 and 8 by one hour infusion; Oxaliplatin 80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.~Treatment should be administered for 2 cycles before surgery and for further 2 cycles after surgery, unless progression of disease or unacceptable toxicity occurs, or patient refusal. In these cases patients will go off treatment.~Each cycle will be repeated every 3 weeks."
62583649|NCT02511964|NO_INTERVENTION|Control|Only Dependent Variables Measures
62583650|NCT06149364|EXPERIMENTAL|Control|Control - usual practice; participants in this arm will be informed that the project is aimed at an economic evaluation of costs associated with usual patterns of office-based routines among desk-based workers. The measurements for both CG and IG will be taken at four times (baseline, 3 months, 6 months, and 12 months).
62583651|NCT03716557|EXPERIMENTAL|Spinal Cord Stimulation 4000Hz|Patients will trial Spinal Cord Stimulation 4000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
62408079|NCT00840762|EXPERIMENTAL|VircoType HIV-1|Genotypic HIV resistance testing results interpreted by VircoType HIV-1 algorithm
62408080|NCT00840762|ACTIVE_COMPARATOR|Local Expert review|Local Expert HIV genotypic review, as per Badri, S. et al CID 2003
62408081|NCT05635929|EXPERIMENTAL|Acute group (Phase 1)|Patients during radiotherapy
62583652|NCT03716557|EXPERIMENTAL|Spinal Cord Stimulation 10000Hz|Patients will trial Spinal Cord Stimulation 10,000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
62583653|NCT03716557|ACTIVE_COMPARATOR|Spinal Cord Stimulation 40Hz|Patients will trial Spinal Cord Stimulation 10,000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
62583654|NCT01068886|NO_INTERVENTION|no stent|no stent through pancreatic anastomosis
62583655|NCT01068886|EXPERIMENTAL|stent|stent through pancreatic anastomosis
62211229|NCT06204445|ACTIVE_COMPARATOR|Roasted coffee|Traditional roasted ground coffee (Arabica). Participants will consume 3 cups of freshly brewed coffee daily (breakfast, mid-morning, early afternoon). Black coffee, no milk.
62211230|NCT04833127|ACTIVE_COMPARATOR|Masibambane - Gender-Enhanced|"A virtual (online) group-based interactive Gender-Enhanced (GE) Workshop (using the WhatsApp® platform). The intervention has components that are conducted by participants on their own time as well as a real-time live interactive session."
62211231|NCT04833127|OTHER|Individually accessed|In this condition women are given access to a PrEP video and to websites that provide information on PrEP and on contraception options.
62211232|NCT02506049|OTHER|S-LPC:Selective Laser Photocoagulation|S-LPC seals connecting vessels, normalizes flow between twins
62211233|NCT04042025|OTHER|Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec-xioi|Participants received treatment with IV onasemnogene abeparvovec-xioi in an onasemnogene abeparvovec-xioi or received treatment with IT onasemnogene abeparvovec-xioi in an onasemnogene.
62211234|NCT02236143||MRI|Subjects undergoing MRI
62211235|NCT05293665|EXPERIMENTAL|double-blind UB-612 boost of ChAdOx1-S|A single injection of UB-612 on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with ChAdOx1-S.
62211236|NCT05293665|ACTIVE_COMPARATOR|double-blind ChAdOx1-S boost|A single injection of ChAdOx1-S on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with ChAdOx1-S.
62211237|NCT05293665|EXPERIMENTAL|double-blind UB-612 boost of BNT162b2|A single injection of UB-612 on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with BNT162b2
62211238|NCT05293665|ACTIVE_COMPARATOR|double-blind BNT162b2 boost|A single injection of BNT162b2 on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with BNT162b2.
62211239|NCT05293665|EXPERIMENTAL|double-blind UB-612 boost of Sinopharm BIBP|A single injection of UB-612 on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with Sinopharm BIBP.
62211240|NCT05293665|ACTIVE_COMPARATOR|double-blind Sinopharm BIBP|A single injection of Sinopharm BIBP on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with Sinopharm BIBP.
62211241|NCT05293665|EXPERIMENTAL|open-label UB-612 boost of BNT162b2|A single injection of UB-612 on Day 1 in an open-label fashion in subjects who completed the primary immunization series with BNT162b2.
62211242|NCT05293665|ACTIVE_COMPARATOR|open-label BNT162b2 boost|A single injection of BNT162b2 on Day 1 in an open-label fashion in subjects who completed the primary immunization series with BNT162b2.
62211243|NCT06180642||Women after breast cancer with UL dysfunctions|
62211244|NCT06180642||Women after breast cancer without UL dysfunctions|
62211245|NCT06180642||Healthy volunteers|age- and gender-matched control group
62211246|NCT05091177||the patience group|underwent the following examinations: serum acetylcholine receptor antibody, erythrocyte deposition rate, hypersensitive C protein, neostigmine test, chest CT, low frequency repetitive nerve stimulation (orbicularis oculi muscle, levator palpebrae muscle, frontalis muscle), thyroid function and color ultrasound.
62211247|NCT05091177||the normal group|underwent the following examinations: serum acetylcholine receptor antibody, erythrocyte deposition rate, hypersensitive C protein, neostigmine test, chest CT, low frequency repetitive nerve stimulation (orbicularis oculi muscle, levator palpebrae muscle, frontalis muscle), thyroid function and ultrasound.
62408082|NCT05635929|EXPERIMENTAL|Chronic group (Phase 2)|Patients 6 months after oncological treatment is finished
62408083|NCT00981565|ACTIVE_COMPARATOR|Operative|
62583656|NCT05425641|EXPERIMENTAL|Goal Setting and Action Planning and Self-Monitoring and Feedback|Participants in this arm will receive daily text messages that include the Goal Setting, Action Planning, Self-Monitoring, and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
62583657|NCT05425641|EXPERIMENTAL|Goal Setting and Action Planning and Feedback|Participants in this arm will receive daily text messages that include the Goal Setting, Action Planning, and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
62583658|NCT05425641|EXPERIMENTAL|Goal Setting and Self-Monitoring and Feedback|Participants in this arm will receive daily text messages that include the Goal Setting, Self-Monitoring, and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
62408084|NCT00981565|ACTIVE_COMPARATOR|Conservative|
62583659|NCT05425641|EXPERIMENTAL|Goal Setting and Action Planning, and Self-Monitoring|Participants in this arm will receive daily text messages that include the Goal Setting, Action Planning, and Self-Monitoring behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
62583660|NCT05425641|EXPERIMENTAL|Action Planning and Self-Monitoring, and Feedback|Participants in this arm will receive daily text messages that include the Action Planning, Self-Monitoring, and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
62408085|NCT02346071|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|Clinical psychiatric and somatic assessment. Standard psychiatric consultation (SPC) given 2 weeks after randomization.
62583661|NCT05425641|EXPERIMENTAL|Goal Setting and Action Planning|Participants in this arm will receive daily text messages that include the Goal Setting and Action Planning behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
62583662|NCT05425641|EXPERIMENTAL|Goal Setting and Self-Monitoring|Participants in this arm will receive daily text messages that include the Goal Setting and Self-Monitoring behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
62583663|NCT05425641|EXPERIMENTAL|Goal Setting and Feedback|Participants in this arm will receive daily text messages that include the Goal Setting and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
62583664|NCT05425641|EXPERIMENTAL|Action Planning and Self-Monitoring|Participants in this arm will receive daily text messages that include the Action Planning and Self-Monitoring behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
62019536|NCT02065128||Healthy Volunteers|Capsaicin cough challenge test. The ILS participants will be asked to attend two study visits at the pulmonary function laboratory at SMH; one before behavioural therapy and one after. The healthy volunteers will be asked to attend one study visit. At each of these study visits, the ILS participants will complete the Leicester Cough Questionnaire (LCQ) (Appendix B) and the Dyspnea Index (DI) Questionnaire (Appendix C). The LCQ is a valid assessment tool for evaluating the impact of cough on QoL.19 The DI is a short, validated questionnaire used to quantify a patient's symptoms of dyspnea.20 Following completion of the questionnaires, participants will complete a capsaicin cough challenge test, which is discussed in the following section.
62019537|NCT02065128||Irritable Larynx Syndrome Patients|Capsaicin cough challenge test. The ILS participants will be asked to attend two study visits at the pulmonary function laboratory at SMH; one before behavioural therapy and one after. The healthy volunteers will be asked to attend one study visit. At each of these study visits, the ILS participants will complete the Leicester Cough Questionnaire (LCQ) (Appendix B) and the Dyspnea Index (DI) Questionnaire (Appendix C). The LCQ is a valid assessment tool for evaluating the impact of cough on QoL.19 The DI is a short, validated questionnaire used to quantify a patient's symptoms of dyspnea.20 Following completion of the questionnaires, participants will complete a capsaicin cough challenge test, which is discussed in the following section.
62019538|NCT02283528|EXPERIMENTAL|Hybrid|Placement of Hybrid arch bars for open or closed reduction of mandible fractures
62019539|NCT02283528|ACTIVE_COMPARATOR|Erich|Placement of Erich archbars for open or closed reduction of mandible fractures
62019540|NCT05335356|EXPERIMENTAL|Bmab1200|Bmab 1200 45 mg Bmab 1200 90 mg
62019541|NCT05335356|ACTIVE_COMPARATOR|Stelara|Stelara 45 mg Stelara 90 mg
62019542|NCT04242316|EXPERIMENTAL|Mirror Therapy|Patients performed customized bimanual upper limb exercises with a mirror. They can observe the mirror visual feedback of their non-paretic hand during the movements.
62019543|NCT04242316|ACTIVE_COMPARATOR|Bilateral arm training|Patients performed customized bimanual upper limb exercises without a mirror.
62019544|NCT03503942|EXPERIMENTAL|Treatment arm|Participants in the treatment arm will receive structured group-based lifestyle interventions with stepwise addition of metformin for selected high-risk participants.
62019545|NCT03503942|NO_INTERVENTION|Control|Participants in the control arm will receive the current standard of care for pre-diabetes which includes counseling on lifestyle modifications and follow up by primary care physicians.
62019546|NCT02453113|OTHER|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
62019547|NCT01657201|EXPERIMENTAL|Sequence 1|SYP-1018 200mg → Voriconazole 200mg
62019548|NCT01657201|EXPERIMENTAL|Sequence 2|Voriconazole 200mg → SYP-1018 200mg
62019549|NCT02033889|EXPERIMENTAL|Ertuglifozin 5 mg|Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
62408086|NCT02346071|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT)|Clinical psychiatric and somatic assessment. Standard psychiatric consultation (SPC) given 2 weeks after randomization. ACT-based group therapy.
62408087|NCT01754012|EXPERIMENTAL|Dietary Intervention|This group will follow for a year the NU-AGE whole diet approach elderly-specific and will be supplemented with 10micrograms per day of Vitamin D (cholecalciferol) from MCOHealth.
62583665|NCT05425641|EXPERIMENTAL|Action Planning and Feedback|Participants in this arm will receive daily text messages that include the Action Planning and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
62583666|NCT05425641|EXPERIMENTAL|Self-Monitoring and Feedback|Participants in this arm will receive daily text messages that include the Self-Monitoring and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
62019550|NCT02033889|EXPERIMENTAL|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
62019551|NCT02033889|PLACEBO_COMPARATOR|Placebo/Glimepiride|Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
62019552|NCT05282004|EXPERIMENTAL|SOK583A1|SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05 mL)
62019553|NCT03512340|EXPERIMENTAL|Part A|Part A will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of SRF231 as a monotherapy in patients with advanced solid tumors and lymphoma/Chronic lymphocytic leukemia.
62019554|NCT03512340|EXPERIMENTAL|Part B Cohort 1|Depending upon the results from Part A of the study and the decision from the Safety Review Committee, 1 or 2 doses or dosing frequencies of SRF231 in select advanced solid and hematologic malignancies.
62019555|NCT06046534||Cohort|SLE patients who participated in the anifrolumab EAPs (AMANA or ATUc).
62019556|NCT01849367|EXPERIMENTAL|Active tDCS (1)|
62019557|NCT01849367|ACTIVE_COMPARATOR|Active tDCS (2)|
62019558|NCT02490124||Type 1 Diabetic|Type 1 Diabetic
62019559|NCT02490124||Control|normal healthy control
62211248|NCT02811679|EXPERIMENTAL|Blinatumomab|Blinatumomab will be administered as a continuous IV infusion through a central venous catheter for a 42 day cycle. Blinatumomab will start with a 7 day infusion at 9mcg/d. If no dose limiting toxicity (table 6.1) after 7 days, the dose will be escalated to 28 mcg/d for 7 additional days. If no dose limiting toxicity (table 6.1) after 14 days, blinatumomab will be infused at a target dose of at 112mcg/d for 28 days. Subjects will be restaged after a 6 week treatment free period by PET CT. All subjects without disease progression will receive an additional 4 week cycle starting at the target dose of 112 mcg/d.
62211249|NCT03111459|EXPERIMENTAL|Primary Study Arm|Patients meeting primary inclusion/exclusion criteria will be enrolled in this arm and treated with the Medtronic Valiant Thoracoabdominal Stent Graft System.
62211250|NCT03111459|EXPERIMENTAL|Expanded Selection Arm|Patients who fail to meet the inclusion criteria of the Primary Study Arm may be enrolled under the Expanded Selection Arm and be treated with the Medtronic Valiant Thoracoabdominal Stent Graft System.
62211251|NCT02448433|OTHER|Phototherapy|
62211252|NCT03275597|EXPERIMENTAL|SBRT followed by Durvalumab+Tremelimumab|"Therapeutic Interventions Stereotactic Body Radiotherapy (SBRT) to all sites of disease between 30 and 50 Gy in five fractions administered over two weeks.~Investigational Product(s), Dose, and Mode of Administration: to begin 7 days (+/- 3 days) after radiation Durvalumab 1500 mg via infusion Q4W (equivalent to 20 mg/kg Q4W) until disease progression in patients \> 30 kg Tremelimumab 300 mg via infusion (equivalent to 4 mg/kg) in one dose in patients \>30 kg Weight-based dosing should be utilized for patients ≤30 kg; durvalumab 20 mg/kg Q4W and tremelimumab 4 mg/kg"
62583667|NCT05425641|EXPERIMENTAL|Goal Setting|Participants in this arm will receive daily text messages with the Goal Setting behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
62019560|NCT02015234|EXPERIMENTAL|TNX-102 SL|1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 12 months
62019561|NCT00723801|ACTIVE_COMPARATOR|Subjects Randomized to Losartan|Losartan: 100 mg PO QD
62019562|NCT00723801|ACTIVE_COMPARATOR|Subjects Randomized to Atenolol|Atenolol: 50 mg PO QD
62019563|NCT06538532|EXPERIMENTAL|(A1) Zamzam water mouthwash|
62019564|NCT06538532|NO_INTERVENTION|(A2) Control group: will be on tooth brushing only|
62211253|NCT04344002||lung cancer+COVID-19|lung cancer patients diagnosed with COVID-19
62211254|NCT05662787|EXPERIMENTAL|Intravascular lithotripsy|
62583668|NCT05425641|EXPERIMENTAL|Action Planning|Participants in this arm will receive daily text messages with the Action Planning behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
62019565|NCT06060405|EXPERIMENTAL|Durvalumab and Oleclumab|Durvalumab, 1500 mg x 1 dose and oleclumab 3000 mg x 2 doses every 2 weeks prior to surgical resection.
62019566|NCT03910335||LSS patients|"Case/control study: Patients from surgical departments awaiting surgery for LSS will will out the questionnaire.~Cohort study: Patients from a medical department will fill out the questionnaire, and a clinician will determine if LSS is present (reference standard)"
62211255|NCT03330405|EXPERIMENTAL|Dose Level 0 Phase 1b|"Drug: Avelumab~Drug: Talazoparib"
62211256|NCT03330405|EXPERIMENTAL|Dose Level -1 Phase 1b|"Drug: Avelumab~Drug: Talazoparib"
62211257|NCT03330405|EXPERIMENTAL|Dose Level -2 Phase 1b|"Drug: Avelumab~Drug: Talazoparib"
62211258|NCT03330405|EXPERIMENTAL|A1. NSCLC Phase 2|"Drug: Avelumab~Drug: Talazoparib"
62211259|NCT03330405|EXPERIMENTAL|A2. NSCLC PD-L1 Resistant DDR+ Phase 2|"Drug: Avelumab~Drug: Talazoparib"
62211260|NCT03330405|EXPERIMENTAL|B1. TNBC Phase 2|"Drug: Avelumab~Drug: Talazoparib"
62211261|NCT03330405|EXPERIMENTAL|B2. HR+BC DDR Defect +Assay Phase 2|"Drug: Avelumab~Drug: Talazoparib"
62211262|NCT03330405|EXPERIMENTAL|C1. Ovarian CA Recurrent Plat-Sensitive Phase 2|"Drug: Avelumab~Drug: Talazoparib"
62408088|NCT01754012|NO_INTERVENTION|Control Group|This group will follow the habitual diet.
62408089|NCT04993937|ACTIVE_COMPARATOR|Control group|Control group will follow their daily routine activities.
62019567|NCT03910335||Non-LSS patients|Case/control study and cohort study: Patients from a medical department will fill out the questionnaire, and a clinician will determine if LSS is present (reference standard)
62019568|NCT05491733|ACTIVE_COMPARATOR|APX001 Treatment A|Oral tablet with a 25% drug load (low-load) in fasted participants
62019569|NCT05491733|EXPERIMENTAL|APX001A Treatment B|Oral tablet with a high drug load in fasted participants
62408090|NCT04993937|EXPERIMENTAL|Experimental group|Interventional group will receive 6 weeks of plyometric training and receive training for week and three sessions in a week.
62408091|NCT01682681||Topiramate|
62211263|NCT03330405|EXPERIMENTAL|C2.Ovarian CA Recurrent Plat-Sensitive BRCA defect Phase 2|"Drug: Avelumab~Drug: Talazoparib"
62211264|NCT03330405|EXPERIMENTAL|D.Urothelial CA Phase 2|"Drug: Avelumab~Drug: Talazoparib"
62408092|NCT03727113||Control cohort|Patients receiving an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
62211265|NCT03330405|EXPERIMENTAL|E1. CRPC Phase 2|"Drug: Avelumab~Drug: Talazoparib"
62211266|NCT03330405|EXPERIMENTAL|E2. CRPC DDR Defect +Assay Phase 2|"Drug: Avelumab~Drug: Talazoparib"
62211267|NCT03330405|EXPERIMENTAL|F: Advanced Solid Tumors with BRCA or ATM defect Phase 2|"Drug: Avelumab~Drug: Talazoparib"
62408093|NCT03727113||Optimization cohort|Patients receiving an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
62408094|NCT03872908||Cohort 1|Evaluation of patient's satisfaction when wearing surgical gloves (dominant hand) versus chilled gloves (non-dominant hand) at the end of paclitaxel administration.
62408095|NCT03872908||Cohort 2|Evaluation of the efficacy of the compression induced by surgical gloves against peripheral neuropathies in patients treated by oxaliplatine after a 595 mg/m2 cumulated dose.
62408096|NCT03899220|EXPERIMENTAL|Intervention|This intervention includes 5 face-to-face therapy sessions with a trained clinician plus a bidirectional text component that queries mood, substance use, and medication adherence.
62408097|NCT03899220|ACTIVE_COMPARATOR|Enhanced Treatment as Usual (E-TAU)|Enhanced treatment as usual includes a one session behavioral engagement in care intervention as well as substance use treatment counseling.
62408098|NCT02940392|EXPERIMENTAL|Rezum Treatment|Patients will receive the Rezūm transurethral needle ablation procedure to treat benign prostatic hyperplasia.
62408099|NCT04796168|ACTIVE_COMPARATOR|post operative Ankle fractures with splint|All patient who meet the inclusion criteria of having ankle fracture that rigidly fixed and randomized to receive splint post operative
62583669|NCT05425641|EXPERIMENTAL|Self-Monitoring|Participants in this arm will receive daily text messages with the Self-Monitoring behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
62019570|NCT05491733|EXPERIMENTAL|APX001A Treatment C|Oral tablet with a high drug load in participants that are not fasted.
62019571|NCT04564352||2|Adansonia digitata (Baobab)
62019572|NCT00182689|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62211268|NCT05404581|SHAM_COMPARATOR|Control|Subjects who respond favorably to test/trial stimulation of the insula will be implanted with DBS devices. In an outpatient clinical trial, each subject will receive 3 months of active stimulation and 3 months of sham stimulation. The assignment for stimulation will be randomized and blinded to the subject and to the outcome assessors.
62211269|NCT05404581|ACTIVE_COMPARATOR|DBS of the insula|Subjects who respond favorably to test/trial stimulation of the insula will be implanted with DBS devices. In an outpatient clinical trial, each subject will receive 3 months of active stimulation and 3 months of sham stimulation. The assignment for stimulation will be randomized and blinded to the subject and to the outcome assessors.
62211270|NCT02866630||Cardiopulmonary bypass (Sevoflurane)|All patients who scheduled for an elective heart surgery in University Malaya Medical Centre using a heart-lung machine and the administration of sevoflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being six additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
62408100|NCT04796168|NO_INTERVENTION|post operative Ankle fractures without splint|All patient who meet the inclusion criteria of having ankle fracture that rigidly fixed and randomized to receive NO splint post operative
62408101|NCT04583592|EXPERIMENTAL|Camostat Mesilate|Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.
62408102|NCT04583592|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo for 14 days in addition to standard of care treatment.
62408103|NCT03954899|EXPERIMENTAL|MCI+ Melatonin 5mg|MCI+ individuals receiving 5mg of melatonin-OTC for a period of 9 months
62408104|NCT03954899|PLACEBO_COMPARATOR|MCI+ placebo|MCI+ individuals receiving placebo for a period of 9 months
62408105|NCT03954899|EXPERIMENTAL|MCI- Melatonin 5mg|MCI- individuals receiving 5mg of melatonin-OTC for a period of 9 months
62408106|NCT03954899|PLACEBO_COMPARATOR|MCI- placebo|MCI- individuals receiving placebo for a period of 9 months
62019573|NCT04468048||Music|"Subjects will put on headphones containing music from the album Nada Himalaya performed by S. G. Sachchidananda. The music will start playing 10 minutes before the colonoscopy procedure and will stop once subjects have woken up from sedation. Subjects will be instructed to not tell anyone if music is playing from their headphones. Subjects will two questionnaires before the procedure asking about their initial anxiety levels and previous procedure history. Two questionnaires following the procedure will be provide asking about their anxiety levels following the procedure and their overall satisfaction with the procedure."
62583670|NCT05425641|EXPERIMENTAL|Feedback|Participants in this arm will receive daily text messages with the Feedback behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
62583671|NCT05425641|NO_INTERVENTION|Control|"Participants in this arm will not receive any daily BCT text messages. Instead, individuals receive daily text messages with the text Please acknowledge that you have received this text message."
62583672|NCT03592667|EXPERIMENTAL|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
62583673|NCT03592667|PLACEBO_COMPARATOR|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
62583674|NCT03732352|EXPERIMENTAL|Treatment (18F-FDG PET, osimertinib)|Within days -28 to -4, patients receive fludeoxyglucose F-18 IV and after 60 minutes undergo PET scan over 15 minutes. After 18-54 hours, patients undergo a second fludeoxyglucose F-18 PET scan. Patients then receive osimertinib PO QD on days -3 to -1 and after 24-72 hours, undergo a third fludeoxyglucose F-18 PET scan. Patients then receive osimertinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62583675|NCT06451419||Glucocerebrosidase associated Parkinson's disease|Patients aged under 70 when symptoms began or with family history of Parkinson's disease who underwent a genetic testing including a pannel of 64 genes associated with Parkinson's diasease and who tested positive for heterozygous glucocerebrosidase mutation.
62583676|NCT06451419||Non glucocerebrosidase associated Parkinson's diasease|Patients aged under 70 when symptoms began or with family history of Parkinson's disease who underwent a genetic testing including a pannel of 64 genes associated with Parkinson's diasease and who tested negative for all the mutations in the pannel.
62583677|NCT01788189|EXPERIMENTAL|Lenalidomide|"The LeMLAR protocol:~Lenalidomide 25 mg p.o., days 1 - 21; Methotrexate 30 - 60 - 90 - 120 - 150 mg/m² i.v. bolus, days 1, 8, 15; Leucovorin 4 x 45 mg p.o. (every 6 hrs), days 2, 9, 16; Cytarabine (Ara-C) 75 - 150 - 225 - 300 - 375 mg/m² i.v. bolus, days 1, 8, 15; Rituximab 375 mg/m² i.v. infusion, day 1.~28-day cycles, maximum 6 cycles, definition of dose-limiting toxicity in cycles 1 and 2, intra-patient dose escalation after cycles 2 and 4 in case of absence of dose-limiting toxicity in previous cycles"
62019574|NCT04468048||Control|Subjects will put on headphones, but there will be no music playing. Subjects are instructed to not tell anyone if music is playing from their headphones. Subjects will two questionnaires before the procedure asking about their initial anxiety levels and previous procedure history. Two questionnaires following the procedure will be provide asking about their anxiety levels following the procedure and their overall satisfaction with the procedure.
62408107|NCT01329562|ACTIVE_COMPARATOR|Treximet|"Subjects randomized to Group A will be provided with 1 tablet of Treximet to be taken at onset of menstrual migraine headache pain.~All subjects will be provided with 1 tablet of Treximet for treatment of persistent or recurring headache between 2 and 24 hours following treatment with study medication at headache onset."
62583678|NCT03573557|ACTIVE_COMPARATOR|Pink Pad|The Pink Pad will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg to determine how much slipping is happening during the procedure.
62583679|NCT03573557|ACTIVE_COMPARATOR|Bean Bag|The Bean Bag will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg to determine how much slipping is happening during the procedure.
62583680|NCT03573557|ACTIVE_COMPARATOR|Gel Pad|The Gel Pad will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg determine how much slipping is happening during the procedure.
62583681|NCT06576115|EXPERIMENTAL|Gemcitabine/Nab-Paclitaxel plus TheraBionic Device|Metastatic pancreatic cancer patients will be treated with amplitude-modulated radiofrequency electromagnetic fields using TheraBionic device in combination with standard chemotherapy, gemcitabine- nab-paclitaxel. amplitude-modulated radiofrequency electromagnetic fields will be delivered by the TheraBionic device.
62583682|NCT05758610|EXPERIMENTAL|ETH-155008|"Dose level: 20mg/day, 40mg/day, 60mg/day, 80mg/day, 100mg/day. Each dose level will recruit 1-6 subjects, taking ETH-155008 tablets once daily.~Intervention: Drug: ETH-155008"
62583683|NCT02048826|EXPERIMENTAL|FINGER I|Subjects participate in 3 weeks of exercising with the experimental device: FINGER robot with first setting at a minimum of 3 days per week, 1 hour per day with the exercise program
62583684|NCT02048826|EXPERIMENTAL|FINGER II|Subjects participate in 3 weeks of exercising with the experimental device: FINGER robot with a second setting at a minimum of 3 days per week, 1 hour per day with the exercise program
62583685|NCT00952796|EXPERIMENTAL|1|patients with intra-abdominal infection treated with moxifloxacin 400mg once daily
62583686|NCT00952796|ACTIVE_COMPARATOR|2|patients with intra-abdominal infection treated with ampicillin/sulbactam 1.5g 4 times daily
62583687|NCT04105803||De novo HTx|"Procedure: Two perprocedural biopsies under transplantation is performed from the left ventricular septum.~Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).~Procedure: is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.~Diagnostic test: Echocardiography and coronary angiography is part of the scheduled standard HTx follow-up visits."
62583688|NCT04105803||Longterm HTx|"Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).~Procedure: Coronary Angiography is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.~Diagnostic test: Echocardiography is part of the scheduled standard HTx follow-up visits. No additional examinations will be performed. We will use the standard recordings to calculate the desired parameters."
62583689|NCT04105803||PET-scan de novo HTx|"Radiation: Two PET-scans with 11C-acetate tracer will be performed.~Procedure: Two perprocedural biopsies under transplantation is performed from the left ventricular septum.~Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).~Procedure: Coronary Angiography is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.~Diagnostic test: Echocardiography is part of the scheduled standard HTx follow-up visits. No additional examinations will be performed. We will use the standard recordings to calculate the desired parameters."
62583690|NCT05932589||RTT Females|Females with Rett Syndrome
62583691|NCT05932589||Controls|Females with typical development
62583692|NCT02322658|EXPERIMENTAL|Eszopiclone Tablets|Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited
62583693|NCT02322658|ACTIVE_COMPARATOR|Lunesta|Lunesta Tablets 3 mg of Sepracor Inc.
62583694|NCT06665451|EXPERIMENTAL|Test Group|Patients with fresh extraction sockets in the anterior maxilla will be treated by immediate implant coated by erythropoietin gel .
62019575|NCT02859194|EXPERIMENTAL|Veno-veno-arterial ECMO group|
62019576|NCT02439086|EXPERIMENTAL|Long Course Radiotherapy|all patients diagnosed with rectal cancer, amenable for neoadjuvant chemoradiotherapy, who agree to participate in this study will undergo 2 PET-CT scans: at baseline and 9 weeks after commencing therapy.
62019577|NCT03021759|NO_INTERVENTION|Control|No intervention
62019578|NCT03021759|EXPERIMENTAL|Active choice|Physicians will be asked to review a list of their patients eligible for statin therapy who are not yet prescribed a statin and make an active choice whether or not to prescribe a statin.
62211271|NCT02866630||Cardiopulmonary bypass (Desflurane)|All patients who scheduled for an elective heart surgery in University Malaya Medical Centre using a heart-lung machine and the administration of desflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being six additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
62408108|NCT01329562|PLACEBO_COMPARATOR|Placebo|"Subjects randomized to Group B will be provided with 1 tablet of placebo to be taken at onset of menstrual migraine headache pain.~All subjects will be provided with 1 tablet of Treximet for treatment of persistent or recurring headache between 2 and 24 hours following treatment with study medication at headache onset."
62408109|NCT01467518|OTHER|Period 1|Subjects will be on individualize stable dose of methdaone for 8 days.
62583695|NCT06665451|ACTIVE_COMPARATOR|Control group|Patients with fresh extraction sockets in the anterior maxilla will be treated by non coated immediate implant .
62583696|NCT03979053||Patients with AIH|60 adult participants will be recruited who are over the age of 18 and are attending a hepatology appointment at KCH NHS FT and are either being investigated for AIH or have confirmed AIH
62583697|NCT00741676|ACTIVE_COMPARATOR|2|
62583698|NCT00741676|EXPERIMENTAL|1|
62583699|NCT04524819||COPD participants|Saliva and Sputum will be collected from patients when they are unwell with a flare up of the COPS and when they are well
62583700|NCT02821741|EXPERIMENTAL|Cymba Conchae|Mild electrical stimulation is applied to the cymba conchae of the left ear, and thermal stimulation is applied to the arms.
62408110|NCT01467518|OTHER|Period 2|Subjects will be on individualize stable dose of methadone and open label doses of 50mg Dolutegravir (DTG) every 12 hours for 5 days.
62408111|NCT06426316|EXPERIMENTAL|Migraine - no autoimmune/inflammatory disease|Migraine - no autoimmune/inflammatory disease group
62408112|NCT06426316|EXPERIMENTAL|No migraine - no autoimmune/inflammatory disease|No migraine - no autoimmune/inflammatory disease group
62408113|NCT06426316|EXPERIMENTAL|No migraine - autoimmune/inflammatory disease (MS, RA, CD, SLE, T1DM, endometriosis)|No migraine - autoimmune/inflammatory disease (MS, RA, CD, SLE, T1DM, endometriosis) group
62583701|NCT02821741|ACTIVE_COMPARATOR|Ear Lobe|Mild electrical stimulation is applied to the earlobe of the left ear, and thermal stimulation is applied to the arms.
62583702|NCT03507322||Ultrasound texturization|Application of ultrasound texturization (2D/3D ultrasound scanning)
62583703|NCT04255810||Women with breast implants and self-reported symptoms of BII|Women undergoing elective breast implant removal without replacement who self-report systemic symptons associated with BII
62583704|NCT04255810||Women with breast implants and no self-reported BII|Women undergoing elective breast implant exchange or removal without self-reported symptoms of BII
62583705|NCT04255810||Women undergoing elective mastopexy (breast lift)|Women undergoing an elective mastopexy (breast lift) without breast implants or soft tissue support
62583706|NCT05689190||patients|Duplex ultrasound, angiogram, PTA intervention
62019579|NCT03021759|EXPERIMENTAL|Active choice with social comparison feedback|Physicians will be asked to review a list of their patients eligible for statin therapy who are not yet prescribed a statin and make an active choice whether or not to prescribe a statin. Physicians will receive social comparison feedback informing them of how their performance compares to their peers
62583707|NCT04750265|EXPERIMENTAL|Robotic assisted early mobilization|Early mobilization therapy assisted with robotics
62583708|NCT04750265|NO_INTERVENTION|Standard Care|Mobilization according to standard care by staff
62583709|NCT05497479|EXPERIMENTAL|Treatment with Schirmer test with no anesthetic|Both eyes will be treated.
62019580|NCT04632667|ACTIVE_COMPARATOR|Comparison School Group|
62408114|NCT06426316|EXPERIMENTAL|Migraine - autoimmune/inflammatory disease (MS, RA, CD, SLE, T1DM, endometriosis)|Migraine - autoimmune/inflammatory disease (MS, RA, CD, SLE, T1DM, endometriosis) group
62583710|NCT05497479|EXPERIMENTAL|Treatment with Schirmer test with anesthetic|Both eyes will be treated.
62583711|NCT00563641|EXPERIMENTAL|1|Early NCPAP plus very early surfactant
62583712|NCT00563641|ACTIVE_COMPARATOR|2|NCPAP alone
62408115|NCT02632448|EXPERIMENTAL|Part A: LY2880070|Multiple oral doses of LY2880070 during 21-day cycles
62583713|NCT04099511|ACTIVE_COMPARATOR|Usual Care Occupational Therapy-Outpatient|
62583714|NCT04099511|EXPERIMENTAL|Cognitive Orientation to daily Occupational Performance|
62583715|NCT06280144|EXPERIMENTAL|Experimental group|Influenza Vaccine, Live, Nasal, Freeze-dried
62583716|NCT06280144|PLACEBO_COMPARATOR|Placebo group|Sterile water for inhalation
62583717|NCT01217476|ACTIVE_COMPARATOR|Trafermin 0.01% spray|
62583718|NCT01217476|PLACEBO_COMPARATOR|Matching placebo spray|
62583719|NCT06663540|NO_INTERVENTION|Control Group|The control group that will continue with their usual school routine
62583720|NCT06663540|EXPERIMENTAL|Experimental Group|The experimental group will participate in weekly sessions that integrate physical exercise and the use of the abacus. This will include physical activities such as sports, outdoor games or physical education classes, for approximately two hours a week. In addition, they will receive teaching sessions that incorporate the abacus to develop mathematical and problem-solving skills.
62583721|NCT05347667|EXPERIMENTAL|Pre-Ovulation Unilateral Resistance Exercise|One leg will undergo 2 sessions of unilateral resistance exercise during the follicular phase of the menstrual cycle (pre-ovulation).
62583722|NCT05347667|EXPERIMENTAL|Post-Ovulation Unilateral Resistance Exercise|One leg will undergo 2 sessions of unilateral resistance exercise during the luteal phase of the menstrual cycle (post-ovulation).
62583723|NCT02258373|EXPERIMENTAL|CGM Only|"Participants will be instructed to check the blood glucose with the standard study BGM for calibration of the CGM and for specific circumstances that are specified in the protocol. This group will make management decisions based on the CGM glucose value without a BGM confirmation measurement as long as the participant is confident that the CGM glucose value is not erroneous.~In addition, participants will be instructed to make a BGM measurement on the blinded study BGM before going to bed, whenever an insulin bolus is given and when treating or attempting to prevent hypoglycemia and a standard BGM measurement has not been made. The participant may be asked to make post-prandial blinded BGM measurements at selected times."
62583724|NCT02258373|ACTIVE_COMPARATOR|CGM+BGM|Participants will be instructed to perform BGM measurements for sensor calibration according to Dexcom specifications and measure the blood glucose whenever a diabetes management decision is made. A BGM measurement is to be made on the study BGM before going to bed, whenever an insulin bolus is given and when treating or attempting to prevent hypoglycemia. Additional BGM measurements can be made on the study BGM at any time that the participant desires.
62019581|NCT04632667|EXPERIMENTAL|Intervention School Group|
62019582|NCT01040130|EXPERIMENTAL|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
62583725|NCT06685666|ACTIVE_COMPARATOR|traditional warm-up method specific to handball|Traditional handball warm-up consists of dynamic and static warm-ups and passing and shooting drills.
62019583|NCT01040130|EXPERIMENTAL|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
62019584|NCT01040130|PLACEBO_COMPARATOR|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler
62019585|NCT03324061|EXPERIMENTAL|Fulvestrant for Injectable Suspension|Fulvestrant for Injectable Suspension (500 mg/vial)
62408116|NCT02632448|EXPERIMENTAL|Part A: LY2880070 with Gemcitabine|Multiple oral doses of LY2880070, and Gemcitabine administered intravenously during 21-day cycles
62583726|NCT06685666|EXPERIMENTAL|elastic band exercises added to the traditional warm-up method specific to handbal|Elastic band exercises added to the traditional handball warm-up consists of exercises for the upper extremity muscles that are active during the throw.
62583727|NCT03960489|EXPERIMENTAL|Treatment Sequence 1 (ABCD)|Participants will receive single dose of 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 3 followed by 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
62583728|NCT03960489|EXPERIMENTAL|Treatment Sequence 2 (BDAC)|Participants will receive 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 1 followed by single dose of 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 3 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
62019586|NCT03324061|ACTIVE_COMPARATOR|Faslodex (R)|Faslodex (250 mg/mL)
62019587|NCT02242786|EXPERIMENTAL|EBRT|
62019588|NCT04180982|EXPERIMENTAL|Treatment group A|SHR4640 dose1 Oral Tablet plus Febuxostat dose1 Oral Tablet Day1\~Day28 qd.
62408117|NCT02632448|EXPERIMENTAL|Part A: LY2880070 (Metabolism Phenotype)|Multiple oral doses of LY2880070 administered during 21 day cycles, to participants who are poor metabolizers
62019589|NCT04180982|EXPERIMENTAL|Treatment group B|SHR4640 dose1 Oral Tablet plus Febuxostat dose2 Oral Tablet Day1\~Day28 qd.
62583729|NCT03960489|EXPERIMENTAL|Treatment Sequence 3 (CADB)|Participants will receive single dose of 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 2 followed by 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 3 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
62583730|NCT03960489|EXPERIMENTAL|Treatment Sequence 4 (DCBA)|Participants will receive single dose of 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 3 followed by 100 mg of roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
62583731|NCT00617890|EXPERIMENTAL|Group 1: 0.3 mg/kg|Participants received robatumumab 0.3 mg/kg intravenously (IV) as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 0.3 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
62583732|NCT00617890|EXPERIMENTAL|Group 1: 10 mg/kg|Participants who received robatumumab 10 mg/kg IV as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 10 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
62583733|NCT00617890|EXPERIMENTAL|Group 2: 10 mg/kg|Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with relapsed and unresectable osteosarcoma refractory to prior chemotherapy with a platinum- and doxorubicin-containing regimen.
62019590|NCT04180982|EXPERIMENTAL|Treatment group C|SHR4640 dose2 Oral Tablet plus Febuxostat dose3 Oral Tablet Day1\~Day28 qd.
62583734|NCT00617890|EXPERIMENTAL|Group 3: 10 mg/kg|Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, or vincristine.
62583735|NCT05650645|EXPERIMENTAL|Incobotulinium toxin A group|Individuals with symptoms of tetanus will receive three serial injections of incobotulinum toxin A into the auricular muscles.
62019591|NCT02700646|NO_INTERVENTION|standard care|Standard care comparison
62019592|NCT02700646|EXPERIMENTAL|inpatient|Inpatient recommendations to parents regarding infant motor activities
62019593|NCT02700646|EXPERIMENTAL|inpatient/outpatient|Inpatient and outpatient recommendations to parents regarding infant motor activities
62019594|NCT02009618|PLACEBO_COMPARATOR|Irritable bowel syndrome patients|placebo tablet was given to another group in same doses for 10 days
62019595|NCT02009618|EXPERIMENTAL|Rifaximin|"Irritable bowel syndrome patients~Rifaximin is given to patients 200 mg tablets, 3x2/daily, for 10 days"
62211272|NCT04004104|ACTIVE_COMPARATOR|Control - Upright Exercise|Participants will perform upright exercise on a cycle ergometer. The opposite test will be completed within 4 weeks.
62211273|NCT04004104|EXPERIMENTAL|Intervention - Supine Exercise|Participants will perform supine exercise on a cycle ergometer. The opposite test will be completed within 4 weeks.
62019596|NCT03737214|EXPERIMENTAL|Lucerastat|Dose will be based on subject's eGFR.
62211274|NCT01226342|EXPERIMENTAL|TCEMS|Patients who will receive transcutaneous electrical muscle stimulation
62211275|NCT06728852|EXPERIMENTAL|Vorolanib treatment group|
62019597|NCT05915065|OTHER|Phantom Limb Pain Management System during at-home use.|"Participants attend either in person at Shirley Ryan AbilityLab or virtually via Zoom~* Educational documents provided on pain and phantom limb pain.~* Participants are measured for an electrode cuff either in person or virtually~* Complete several questionnaires.~* Provided training on the Phantom Limb Pain Program with use of the electrode cuff and muscular contractions of their limb~* Participate in a 8 week home trial (1.5 hours per week of use, 20-40 minutes, 4-5x each week)~* Once home trial is complete - participants will be asked to participate in a phone or Zoom call at weeks 16,24 and 32 to repeat questionnaires."
62583736|NCT05650645|PLACEBO_COMPARATOR|Placebo|Individuals with symptoms of tetanus will receive placebo saline injections.
62583737|NCT06446115|EXPERIMENTAL|Virtual reality|Participants will be asked to use a headset device during 15 to 30 minutes while receiving a chemotherapy infusion. Participants have the option to choose from different virtual reality setting depending on their preference (i.e., nature videos, meditations, interactive applications, among others).
62019598|NCT06574295||Non-intubated Video-assisted Thoracic Surgery Group|This group will undergo non-intubated video-assisted thoracic surgery (VATS), a minimally invasive procedure that avoids the use of endotracheal intubation and mechanical ventilation. Instead, patients maintain spontaneous breathing throughout the surgery under regional anesthesia or sedation. The technique is designed to reduce anesthesia-related complications, improve recovery times, and enhance overall patient comfort compared to traditional intubated thoracic surgeries.
62019599|NCT06574295||Intubated Thoracic Surgery Group|This group will undergo traditional intubated thoracic surgery, where patients are intubated and placed on mechanical ventilation under general anesthesia. This method is commonly used in thoracic surgeries to control the airway and ensure adequate ventilation during the procedure. However, it may be associated with a higher incidence of anesthesia-related complications, such as airway trauma and slower postoperative recovery, compared to non-intubated techniques.
62019600|NCT01621373|OTHER|propofol|All patients receive propofol. Dose will be defined based on response of previous patient in the same stratum.
62019601|NCT02881281|OTHER|Education|Education program
62019602|NCT02881281|OTHER|Control Group|no intervention
62408118|NCT02632448|EXPERIMENTAL|Part B: LY2880070 and Gemcitabine (Breast)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
62408119|NCT02632448|EXPERIMENTAL|Part B: LY2880070 and Gemcitabine (Colorectal)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
62408120|NCT02632448|EXPERIMENTAL|Part B:LY2880070 and Gemcitabine (Ovarian)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
62408121|NCT02632448|EXPERIMENTAL|Part B: LY2880070 and Gemcitabine (Endometrial)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
62583738|NCT06446115|ACTIVE_COMPARATOR|Standard of care|Participants will be asked to choose any activity of your preference during the chemotherapy session (i.e., watching tv, reading a book, listening to music or a podcast, etc.)
62583739|NCT00527033|EXPERIMENTAL|1|Oral
62019603|NCT05360238|EXPERIMENTAL|Phase 1: Patients with aggressive B-cell NHL including, but not limited to, DLBCL and MCL.|MB-106, single intravenous infusion up to 3.3 x 10e7 chimeric antigen receptor t-cells (CAR-T cells)/kg
62019604|NCT05360238|EXPERIMENTAL|Phase 1: Patients with indolent NHL including, but not limited to, FL.|MB-106, single intravenous infusion up to 3.3 x 10e7 CAR-T cells/kg
62019605|NCT05360238|EXPERIMENTAL|Phase 1: Patients with CLL/small lymphocytic lymphoma (SLL).|MB-106, single intravenous infusion up to 3.3 x 10e7 CAR-T cells/kg
62019606|NCT05360238|EXPERIMENTAL|Phase 2: Patients with relapsed or refractory DLBCL|MB-106, single intravenous infusion. Dose based upon outcome Phase 1.
62019607|NCT05360238|EXPERIMENTAL|Phase 2: Relapsed or refractory FL|MB-106, single intravenous infusion. Dose based upon outcome Phase 1.
62019608|NCT05360238|EXPERIMENTAL|Phase 2: Basket - Relapsed or refractory B-cell NHL subtypes|MB-106, single intravenous infusion. Dose based upon outcome Phase 1.
62019609|NCT05360238|EXPERIMENTAL|Phase 2: Relapsed or refractory CLL/SLL|MB-106, single intravenous infusion. Dose based upon outcome Phase 1.
62019610|NCT03229330|EXPERIMENTAL|Intervention|Low-level Light Therapy: Wavelength of 660 nm (red laser) and Conventional treatment: Topical treatment with compressive therapy, exercises of lower extremities, resting; once a week for 16 weeks.
62019611|NCT03229330|ACTIVE_COMPARATOR|Controls|Conventional treatment: Topical treatment with compressive therapy, exercises of lower extremities, resting; once a week for 16 weeks.
62019612|NCT06235749|EXPERIMENTAL|calcium gluconate|Administration of Calcium Gluconate 10% IV following umbilical cord clamping.
62019613|NCT06235749|PLACEBO_COMPARATOR|normal saline 0.9%|Administration of normal saline 0.9% IV following umbilical cord clamping.
62408122|NCT02632448|EXPERIMENTAL|Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
62408123|NCT02632448|EXPERIMENTAL|Part B: LY2880070 and Gemcitabine (Pancreatic)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
62408124|NCT02632448|EXPERIMENTAL|Part C: LY2880070 and Gemcitabine (High Grade Serous Ovarian Cancer)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
62408125|NCT03479619|EXPERIMENTAL|A/28/1|Lancing device A with personal lancet of size 28 G and minimum puncture depth.
62408126|NCT03479619|EXPERIMENTAL|A/28/5|Lancing device A with personal lancet of size 28 G and maximum puncture depth.
62408127|NCT03479619|EXPERIMENTAL|A/30/1|Lancing device A with personal lancet of size 30 G and minimum puncture depth.
62408128|NCT03479619|EXPERIMENTAL|A/30/5|Lancing device A with personal lancet of size 30 G and maximum puncture depth.
62583740|NCT00527033|EXPERIMENTAL|2|Oral
62583741|NCT00527033|EXPERIMENTAL|3|Oral
62583742|NCT00527033|PLACEBO_COMPARATOR|4|Oral
62583743|NCT05681325|ACTIVE_COMPARATOR|green tea group|Mahmood Green Tea Sri Lanka. It will be given 2 cups / day for 30 days.
62583744|NCT05681325|EXPERIMENTAL|matcha tea group|Jade Leaf Organic Japanese Matcha, USA. It will be given 2 cups / day for 30 days.
62211276|NCT00688883|EXPERIMENTAL|Arm 1|
62211277|NCT00218114|EXPERIMENTAL|1|Divalproex sodium (Depakote). This is a parallel groups design lasting a total of six weeks. Participants will be on a fixed-flexible dosing schedule. The dose of depakote will be raised to 750mgs or 1000mgs, depending on weight, in two weeks to achieve blood levels between 50-130 micrograms per milliliter. If a patient does not achieve this blood level on 750mgs or 1000 mgs, the dose may be raised during the second week.
62211278|NCT00218114|PLACEBO_COMPARATOR|2|This is a parallel groups design lasting a total of six weeks. Participants will be on matching placebo for 250 mgs divalproex sodium (Depakote).
62211279|NCT01015040|ACTIVE_COMPARATOR|solifenacin succinate tablet (fasting)|
62211280|NCT01015040|EXPERIMENTAL|solifenacin succinate suspension (fasting)|
62211281|NCT01015040|EXPERIMENTAL|solifenacin succinate suspension (fed)|
62211282|NCT04805788|EXPERIMENTAL|Treatment (SBPT)|Patients undergo 1 SBPT fraction over 20-30 minutes per day for a total of 5 fractions.
62211283|NCT03745911|EXPERIMENTAL|Paclitaxel plus TAK-228|"* Paclitaxel will be given on days 1, 8, and 15 of each 28 day cycle intravenously (every Monday or first day of business week if holiday), the day before the first TAK-228 dose. It should be given over approximately one hour.~* TAK-228 will be given orally on Days 2-4, 9-11, 16-18 and 23-25 of each 28-day cycle."
62211284|NCT04535310|EXPERIMENTAL|Daily Disposable Contact Lens|All subjects are fit into Precision1® contact lenses. Subjects are requested to wear the lenses for a total of two weeks.
62211285|NCT06728176|EXPERIMENTAL|MT1988 Dose 1|MT1988 Dose Level 1 (oral, once daily)
62211286|NCT06728176|EXPERIMENTAL|MT1988 Dose 2|MT1988 Dose Level 2 (oral, once daily)
62211287|NCT06728176|EXPERIMENTAL|MT1988 Dose 3|MT1988 Dose Level 3 (oral, once daily)
62211288|NCT06728176|EXPERIMENTAL|MT1988 Dose 4|MT1988 Dose Level 4 (oral, once daily)
62211289|NCT06728176|PLACEBO_COMPARATOR|Placebo|Placebo (oral, once daily)
62211290|NCT02576587|OTHER|Case (diagnosed with PAF)|"Cases. Patients with Paroxysmal Atrial Fibrillation who present to Electrophysiology Clinic at UHCMC and the Cleveland Clinic Foundation will be approached for recruitment in the study.~Cases found to have an apnea hypopnea index \>=15 will be asked to continue in the study for 3 months wearing a Continuous Positive Airway Pressure (CPAP) machine."
62408129|NCT03479619|EXPERIMENTAL|A/33/1|Lancing device A with personal lancet of size 33 G and minimum puncture depth.
62408130|NCT03479619|EXPERIMENTAL|A/33/5|Lancing device A with personal lancet of size 33 G and maximum puncture depth.
62408131|NCT03479619|EXPERIMENTAL|B/28/1|Lancing device B with personal lancet of size 28 G and minimum puncture depth.
62408132|NCT03479619|EXPERIMENTAL|B/28/5|Lancing device B with personal lancet of size 28 G and maximum puncture depth.
62583745|NCT06304285|EXPERIMENTAL|Acupuncture group|The subjects received acupuncture treatment at the following points: Tianshu, Zusanli, Hegu, Taichong, Shangjuxu, Jigou, Zhaohai, Lanwei and shousanli.
62408133|NCT03479619|EXPERIMENTAL|B/30/1|Lancing device B with personal lancet of size 30 G and minimum puncture depth.
62583746|NCT06304285|SHAM_COMPARATOR|control group|Treatment with comfort needle and comfort embedding needle
62583747|NCT06682585|EXPERIMENTAL|Dietary Intervention|The participants of the arm will follow diet program specially prepared for them for 12 weeks.
62019614|NCT05527496||Patients with Helicobacter pylori infection|Patients with H. pylori infection identified by testing for H. pylori.
62019615|NCT05527496||Patients not infected with Helicobacter pylori|Patients without H. pylori infection identified by H. pylori testing.
62019616|NCT06425172||Infants with with deformational head shapes|Infants who have been referred for custom orthotic treatment for a deformational head shape such as deformational plagiocephaly or deformational brachycephaly.
62211291|NCT02576587|NO_INTERVENTION|Controls|Controls. Patients without AF will be recruited from General Cardiology and Internal Medicine clinics (geographically similar to controls). Selection bias will be minimized as there are a broad range of reasons for patients to present to these clinics.
62211292|NCT04725877|EXPERIMENTAL|VIR-1111|
62211293|NCT04725877|PLACEBO_COMPARATOR|Placebo|
62211294|NCT05604001|EXPERIMENTAL|Symptomatic submucosal myoma|patients with symptomatic submucosal fibroids (heavy menstrual bleeding) were elected for hysteroscopy with laser ablation of the myoma.
62211295|NCT01081665||Chronic Kidney Disease|All eligible patients treated with IV Paricalcitol (Zemplar)
62211296|NCT01056705|EXPERIMENTAL|Cohort 1: Experiment Infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections;
62211297|NCT01056705|EXPERIMENTAL|Cohort 2: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections;
62211298|NCT01056705|EXPERIMENTAL|Cohort 3: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections;
62211299|NCT01056705|EXPERIMENTAL|Cohort 4: Experiment infants|Biological: Oral Poliomyelitis Vaccine (OPV).3x0.1ml oral;
62211300|NCT01056705|EXPERIMENTAL|Cohort 5: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Salk strains). 3x0.5ml intramuscular injections;
62408134|NCT03479619|EXPERIMENTAL|B/30/5|Lancing device B with personal lancet of size 30 G and maximum puncture depth.
62408135|NCT03479619|EXPERIMENTAL|B/33/1|Lancing device B with personal lancet of size 33 G and minimum puncture depth.
62408136|NCT03479619|EXPERIMENTAL|B/33/5|Lancing device B with personal lancet of size 33 G and maximum puncture depth.
62408137|NCT03479619|EXPERIMENTAL|C/28/1|Lancing device C with personal lancet of size 28 G and minimum puncture depth.
62408138|NCT03479619|EXPERIMENTAL|C/28/5|Lancing device C with personal lancet of size 28 G and maximum puncture depth.
62408139|NCT03479619|EXPERIMENTAL|C/30/1|Lancing device C with personal lancet of size 30 G and minimum puncture depth.
62583748|NCT05376371|EXPERIMENTAL|CJC-TraC Intervention|Incarcerated individuals with HIV, hepatitis C, or substance use disorder readying for release will enroll in the CJC-TraC intervention intended to assist in transitioning their health care.
62583749|NCT02658955|EXPERIMENTAL|Short stitch|Patients in which abdominal wall is closed by short stitch technique
62019617|NCT04544046|ACTIVE_COMPARATOR|Usual Care|Participants assigned to the standard care arm will receive standard oncology care and attend regular clinic visits. Participants on the standard care arm will complete questionnaires from baseline up to 6 months following enrollment.
62019618|NCT04544046|EXPERIMENTAL|Supportive Oncology Care at Home|"The research study procedures include:~* Remote monitoring of symptoms, vitals, and body weight~* Questionnaires asking about demographic information (e.g. gender, ethnicity, income) and experience with cancer (e.g. quality of life, symptoms)~* Data collection from medical record"
62211301|NCT04859569|EXPERIMENTAL|LY01011|Subcutaneous injection of LY01011 120 mg (1.7ml) every 4 weeks for a maximum of 13 consecutive doses up to week 49.
62211302|NCT04859569|ACTIVE_COMPARATOR|Xgeva®+LY01011|After subcutaneous injection of Xgeva® 120 mg (1.7ml) every 4 weeks 3 times, patients of Xgeva® group continue to receive LY01011 120 mg (1.7ml) every 4 weeks for ten doses consecutively.
62583750|NCT02658955|NO_INTERVENTION|Large stitch|Patients who didn't receive properly closure according with the protocol
62583751|NCT02049905|EXPERIMENTAL|Aldoxorubicin|Aldoxorubicin is administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously on Day 1 every 21-day cycles until tumor progression or unacceptable toxicity occurs.
62211303|NCT03627273|EXPERIMENTAL|walker|'6 minutes walking test' with a walker
62211304|NCT03627273|ACTIVE_COMPARATOR|no walker|'6 minutes walking test' without walker
62211305|NCT01651221|EXPERIMENTAL|Olfactory|Habituation of olfactory response
62734510|NCT02350335|NO_INTERVENTION|non-smokers|Non-smokers with acute aneurysmal hemorrhage. Non-smokers do not receive transdermal nicotine replacement. This group is to be compared to the group of active smokers receiving transdermal nicotine replacement and to the group of active smokers not receiving transdermal nicotine replacement.
62211306|NCT01651221|EXPERIMENTAL|gustatory|Habituation of gustatory response.
62583752|NCT02049905|ACTIVE_COMPARATOR|Investigator's Choice of Treatment|"These treatments include:~1. Dacarbazine administered at 1000 mg/m2 by intravenous infusion (IVI), over 90±15 minutes on Day 1 every 21 days until tumor progression or unacceptable toxicity occurs;~2. Pazopanib, 800 mg orally each day until tumor progression or unacceptable toxicity occurs;~3. Gemcitabine, 900 mg/m2 by IVI over 90 minutes on Days 1 and 8, plus docetaxel, 100 mg/m2 by IVI over 1 hour on Day 8 of a 28 day cycle until tumor progression or unacceptable toxicity occurs;~4. Doxorubicin, 75 mg/m2 by IVI over 5 to 30 minutes every 21 days for a maximum cumulative dose of 550 mg/m2 or unacceptable toxicity occurs; or~5. Ifosfamide 2.0 g/m2 administered over 2 to 4 hours on Days 1-4 of a 21 day cycle + mesna per standard site administration regimen until tumor progression or unacceptable toxicity occurs."
62211307|NCT01651221|EXPERIMENTAL|olfactory and gustatory|Habituation of olfactory and gustatory response
62211308|NCT00287690|EXPERIMENTAL|Genistein|Supro drink once daily for 3 days
62583753|NCT01547143|EXPERIMENTAL|IST and/or alloHCT|Patients who are newly diagnosed as HLH by HLH-2004 criteria, excluding those with HLH owing to malignancy or rheumatic disorder.
62019619|NCT04877912||Biopsy Group|We will scan 50 women who are scheduled for a breast biopsy. Subjects will receive an MRI exam that is research-only prior to the biopsy.
62211309|NCT00287690|PLACEBO_COMPARATOR|Placebo|Drink identical to Supro but containing no genistein, once daily for 3 days
62211310|NCT06729164|EXPERIMENTAL|Quasi-Experimental Study - Experimental|"This quasi-experimental study involves teachers divided into an experimental group and a control group. Teachers in the experimental group will receive SISI training to support the sign language development of deaf children, while those in the control group will continue with business-as-usual teaching methods. Pre- and post-assessments will be conducted for all deaf children at the beginning and end of the school year."
62211311|NCT06729164|PLACEBO_COMPARATOR|Quasi-Experimental Study - Control|"This quasi-experimental study involves teachers divided into an experimental group and a control group. Teachers in the experimental group will receive SISI training to support the sign language development of deaf children, while those in the control group will continue with business-as-usual teaching methods. Pre- and post-assessments will be conducted for all deaf children at the beginning and end of the school year."
62211312|NCT05616000|EXPERIMENTAL|Acetyl-L-Carnitine group|Acetyl-L-Carnitine (2gm once a day), folic acid 5mg (once a day) 43 Patients with Primary Infertility will receive Acetyl-L-Carnitine (2gm once a day) orally\& folic acid 5mg orally was given to all the participants of this group (once a day).
62211313|NCT05616000|EXPERIMENTAL|Control group|Coenzyme Q10 (400mg once a day) orally was given to all participants\& folic acid 5mg (once a day) was also given orally to these participants 43 Patients with Primary Infertility will receive Coenzyme Q10 (400mg once a day), folic acid 5mg (once a day).
62211314|NCT02800551|EXPERIMENTAL|SBRT (Arm A)|"dose-intensified image-guided SBRT using simultaneous integrated boost:~* in the case of no epidural involvement: 40 Gy and 20 Gy in 5 fractions to the high-dose and conventional-dose target volume, respectively.~* In the case epidural involvement: 48.5 Gy and 30 Gy in 10 fractions to the high-dose and conventional-dose target volume, respectively."
62211315|NCT02800551|ACTIVE_COMPARATOR|Conventional Radiation Therapy (Arm B)|"External 3-dimensional conformal radiotherapy (3D-CRT):~Homogeneous irradiation of the affected vertebra delivering either~* 20 Gy in 5 fractions or~* 30 Gy in 10 fractions."
62211316|NCT02800551|EXPERIMENTAL|SBRT (prospective observational)|Patients eligible for the prospective observational arm will be treated according to the investigational arm (arm A) of the randomised arm of the trial.
62211317|NCT03089138|EXPERIMENTAL|Regan Tangjiang，Simulation Shufengjiere Capsules|
62583754|NCT03024762|EXPERIMENTAL|Intervention arm|The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
62583755|NCT03024762|NO_INTERVENTION|Control arm|The control arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years; consulting in the hospital for any motive. These children will be recruited for HIV testing at the outpatient department (OPD) and this through their accompany parents/guardians. Care providers will be advised to propose HIV testing systematically to all children and adolescents showing up at the OPD irrespective of the chief complaint.
62583756|NCT06683495|EXPERIMENTAL|Mirror Therapy|For mirror therapy, a 50×40 cm mirror will be used. The patient will be positioned in a semi-sitting position at a 45° angle in bed, with the mirror placed on the side of the body where the access will be made. The arm with the fistula will be positioned behind the mirror. The position will be standardized so that the patient's thumb is 30 cm away from the mirror. The arm without the fistula will be supported with a pillow underneath to facilitate the patient's view in the mirror, positioned next to the patient. After observing their arm in the mirror for 15 minutes, the cannulation procedure will be performed.
62583757|NCT06683495|NO_INTERVENTION|Routine Therapy|The routine procedure was performed. The fistula puncture was performed by the same nurse throughout the study.
62583758|NCT03892174|NO_INTERVENTION|Treatment protocol without adsorption|
62583759|NCT03892174|ACTIVE_COMPARATOR|Treatment protocol with adsorption|
62211318|NCT03089138|ACTIVE_COMPARATOR|Simulation Regan Tangjiang，Shufengjiere Capsules|
62583760|NCT06138873|EXPERIMENTAL|AI-guided ablation|Use of AI guidance to conduct the ablation
62583761|NCT06138873|ACTIVE_COMPARATOR|non-AI guided ablation|Ablation without AI guidance, AI values masked to the operator.
62583762|NCT04305691|EXPERIMENTAL|Treatment (ixazomib)|Patients receive ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response may continue treatment for an additional 12 cycles in the absence of disease progression or unacceptable toxicity.
62583763|NCT04679311|EXPERIMENTAL|High ACE Activity Fresh Frozen Plasma|Subjects will be treated with 2 units of fresh frozen plasma that have been preselected to contain ACE activity ≥50 U/L
62583764|NCT04679311|PLACEBO_COMPARATOR|Normal Saline|Subjects will be treated with normal saline 500 cc.
62583765|NCT01797861|ACTIVE_COMPARATOR|Half-dose photodynamic therapy (PDT)|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne ®) is administered, with an infusion time of 10 minutes. At 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~If there still is subretinal fluid on OCT scan at Evaluation Visit 1 (6-8 weeks after Treatment Visit 1 / the first treatment with half-dose PDT), a second treatment with half-dose PDT will be performed (Treatment Visit 2)."
62735070|NCT03755219||3D Mesh|Mesh categorized by anatomical shaped, rather than material or weight. Therefore, this category will be excluded in the original study. Depending on the volume of casess found, the 3D mesh category may eventually be analyzed separately in another study..
62211319|NCT03089138|PLACEBO_COMPARATOR|Simulation Regan Tangjiang and Shufengjiere Capsules|
62211320|NCT03435692|EXPERIMENTAL|Lumbar Plexus Catheter|"Children undergoing pediatric hip surgery will have a lumbar plexus catheter placed (with bolus and continuous infusion of ropivacaine) intraoperatively for perioperative pain control.~An intraoperative pain protocol will dictate if the patient will receive intravenous fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with as needed (PRN) morphine and oxycodone as well as scheduled acetaminophen."
62211321|NCT03435692|ACTIVE_COMPARATOR|Lumbar Epidural Catheter|"Children undergoing pediatric hip surgery will have an epidural catheter placed (with bolus and continuous infusion of ropivacaine) intraoperatively for perioperative pain control.~An intraoperative pain protocol will dictate if the patient will receive intravenous fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with as needed (PRN) morphine and oxycodone as well as scheduled acetaminophen."
62211322|NCT03435692|ACTIVE_COMPARATOR|Patient Controlled Analgesia|"Children undergoing pediatric hip surgery will have patient controlled analgesia (with morphine) started in the post anesthesia care unit for post operative pain control.~An intraoperative pain protocol will dictate if the patient will receive intravenous fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with as needed (PRN) morphine and oxycodone as well as scheduled acetaminophen."
62211323|NCT05101148|EXPERIMENTAL|selumetinib single arm|This is a sequential study consisting of a screening period lasting up to 28 days, a 28 day (1 cycle) treatment period (T1) in a fed state, a 7 day washout period, a further 1 cycle treatment period (T2) in a fasted state and an extension to T2 until results from the primary analysis are available. During Treatment Period 1 and 2 all participants will receive selumetinib (25 mg/m2 bid). If a third treatment period (T3) is required, participants will enter a 7 day washout period followed by a treatment period in a fed state at an adjusted dose for 3 cycles.
62211324|NCT01228253|NO_INTERVENTION|1|Safe voluntary.
62211325|NCT01228253|NO_INTERVENTION|2|patient with psychotrauma but without PSTD and without any psychiatric trouble at the time of inclusion
62211326|NCT01228253|NO_INTERVENTION|3|patient with psychotrauma and PTSD (post-traumatic stress disorder) and in full remission at the time of inclusion
62211327|NCT01228253|NO_INTERVENTION|4.3|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
62211328|NCT01228253|SHAM_COMPARATOR|4.2|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
62211329|NCT01228253|EXPERIMENTAL|4.1|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
62583766|NCT01797861|ACTIVE_COMPARATOR|Micropulse laser (ML) treatment|"ML treatment with an 810 nm diode laser will be performed of the areas identified on mid-phase ICG angiography. Multiple laser spots will be applied, covering the leakage area on mid-phase ICG angiography. The area(s) that has to be treated is determined based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT scan and hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein angiogram.~If there still is subretinal fluid on OCT scan at Evaluation Visit 1 (6-8 weeks after Treatment Visit 1 / the first ML treatment), a second ML treatment will be performed (Treatment Visit 2)."
62583767|NCT01333904|EXPERIMENTAL|PUR118|
62019620|NCT04877912||MRI Unknown Cancer Status Group|We will scan 150 women with dense breasts and/or women who have intermediate risk of breast cancer for this study. Subjects will receive an MRI exam that is research-only.
62019621|NCT06089304||Ischemic cohort|All patients sustaining an ischemic event (i.e., cardiovascular death, myocardial infarction, stroke, or stent thrombosis) within 1 year of PCI.
62019622|NCT06089304||Bleeding cohort|All patients sustaining a major bleeding event (i.e., Bleeding Academic Research Consortium type 3-5) within 1 year of PCI.
62019623|NCT01462734||human vitreous, human blood serum, PCR|Vitreous and bloodserum samples from macula hole patients without previous ocular or systemic disease
62019624|NCT01136837||fragmented QRS positive|fQRS at 48 hours after Primary PCI
62019625|NCT02745626|EXPERIMENTAL|Clear Aligner Appliance|Clear Aligners, Align Technology Inc., Santa Clara, California
62019626|NCT02745626|EXPERIMENTAL|Self-ligating Appliance|Carriere Self-Ligating Bracket, Carlsbad, CA
62019627|NCT02745626|EXPERIMENTAL|Conventional bracket appliance|Preadjusted edge wise brackets using elastomeric ties.
62019628|NCT01286818|EXPERIMENTAL|FOLFIRI plus Ramucirumab (IMC-1121B)|
62019629|NCT01931839|EXPERIMENTAL|Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h|Participants who received lumacaftor (LUM, VX-809) 600 milligram (mg) plus ivacaftor (IVA, VX-770) 250 mg fixed-dose combination (FDC) tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening, in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
62211330|NCT02081417|OTHER|Peer led|"Number sessions of the intervention of an evidenced based practice called Seeking Safety led by a Peer (6 sessions will be used to define treatment completion)"
62583768|NCT04379531|ACTIVE_COMPARATOR|Standard Chest CT|
62583769|NCT04379531|EXPERIMENTAL|Low-dose Chest CT|
62211331|NCT02081417|OTHER|Clinician led|"Number intervention groups of an evidence based practice called Seeking Safety led by a master's level Clinician (6 sessions will be used to define treatment completion)."
62583770|NCT03427099|ACTIVE_COMPARATOR|Control group|usual care
62583771|NCT03427099|EXPERIMENTAL|Intervention group|Rehabilitation with a biopsychosocial focus
62211332|NCT04801277|ACTIVE_COMPARATOR|Acupuncture on PC6 and LI4|Acupuncture on bilateral acupoints, that are PC6 and LI4. The pericardium meridian PC6 point (Neiguan) is defined as follows. The patient's four fingerbreadths will be placed on the medial aspect of their forearm with the edge of the 4th finger on the wrist crease. This is then subtracted from the width of the interphalangeal joint of her thumb. The point between the tendons of extensor carpi radialis and palmaris longus was the pericardium meridian PC6 point (Neiguan). The large intestine LI4 point (Hegu) located on the dorsum of the hand, between the first and second metacarpal bones, at the midpoint of the second metacarpal bone and close to its radial border.
62211333|NCT04801277|SHAM_COMPARATOR|Acupuncture on Sham acupoints|Acupuncture on bilateral non acupoints. In sham/placebo group, patient will have the acupuncture needles inserted at non-acupoint 2cm radial to PC6 and between 2nd and 3rd metacarpal bone bilaterally, superficial skin piercing (adequate depth to let patient feels needle is inserted)
62211334|NCT00944515|ACTIVE_COMPARATOR|azithromycin|azithrimycin 3 days/week
62408140|NCT03479619|EXPERIMENTAL|C/30/5|Lancing device C with personal lancet of size 30 G and maximum puncture depth.
62583772|NCT05411094|EXPERIMENTAL|Treatment (olaparib, durvalumab, radiation therapy)|Patients receive olaparib PO BID on days 1-28 and durvalumab IV over 55-65 minutes on day 1 of each cycle. Beginning cycle 2, patients also undergo radiation therapy daily on weekdays for 3 weeks. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo radiologic evaluation and collection of blood samples throughout the study. Patients may undergo optional collection of buccal samples and optional biopsy at screening and/or on study.
62211335|NCT00944515|PLACEBO_COMPARATOR|placebo|placebo 3 days/week
62211336|NCT02314481|EXPERIMENTAL|No actionable mutation - MPDL3280A|"MPDL3280A 1200mg IV infusion - 3 weekly until progression or unacceptable toxicity.~Or in combination with chemotherapy:~* For non-squamous: Cisplatin or Carboplatin plus pemetrexed \& MPDL3280A - 3 weekly for 4 cycles followed by MPDL3280A and pemetrexed 3 weekly until progression or unacceptable toxicity or completion of a total of 35 cycles. MPDL3280A will then continue 3 weekly until progression or unacceptable toxicity.~* For squamous: Carboplatin plus paclitaxel \& MPDL3280A - 3 weekly for 4 cycles followed by MPDL3280A 3 weekly until progression or unacceptable toxicity."
62211337|NCT02314481|EXPERIMENTAL|BRAF V600 - vemurafenib|Vemurafenib 960mg twice daily until PD
62211338|NCT02314481|EXPERIMENTAL|ALK/RET gene rearrangement - alectinib|Alectinib 600mg twice daily until PD
62408141|NCT03479619|EXPERIMENTAL|C/33/1|Lancing device C with personal lancet of size 33 G and minimum puncture depth.
62408142|NCT03479619|EXPERIMENTAL|C/33/5|Lancing device C with personal lancet of size 33 G and maximum puncture depth.
62408143|NCT04798430|EXPERIMENTAL|LIB003 (lerodalcibep)|300 mg monthly (Q4W) by subcutaneous injection
62408144|NCT00679042|EXPERIMENTAL|Treatment|All subjects will receive up to 3 transplantations of allogeneic human islets of Langerhans.
62408145|NCT01751659||Phase I|"* Semi-structured face-to-face or telephone interviews of 10 ATN-affiliated clinicians.~* The total duration of Phase 1 is expected to last approximately nine months, including data analysis."
62583773|NCT00661609|EXPERIMENTAL|AZD4877|Single agent AZD4877
62583774|NCT03269721||Never Smoker|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
62211339|NCT02314481|EXPERIMENTAL|HER2 amplification - T-DM1|Trastuzumab emtansine (T-DM1) 3.6mg/kg - 3 weekly until PD IV infusion
62211340|NCT05939856|OTHER|1 Lymph node dissection before bladder resection|Lymph node dissection will be performed before bladder resection during radical cystectomy
62583775|NCT03269721||Smoker/Past smoker-No Airflow Limitation|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
62735071|NCT02149355||controls|teeth molding in subjects without congenital fourth nerve palsy
62735072|NCT02149355||congenital fourth nerve palsy|teeth molding in patients suffering from congenital fourth nerve palsy
62211341|NCT05939856|OTHER|2 Lymph node dissection after bladder resection|Lymph node dissection will be performed after bladder resection during radical cystectomy
62211342|NCT03543800|EXPERIMENTAL|ABP|(test treatment)
62211343|NCT03543800|ACTIVE_COMPARATOR|PRP|(active control)
62408146|NCT01751659||Phase II|"* Development of a new theory-based survey instrument and cognitive interview testing of this survey with approximately five clinicians (of those who participated in Phase 1).~* The total duration of Phase 2 is expected to last approximately three months, including qualitative analysis of the interviews and modification of the survey."
62408147|NCT01751659||Phase III|"* Administration of the newly developed survey to approximately 60 ATN-affiliated clinicians.~* The total duration of Phase 3 will last approximately six to nine months."
62408148|NCT01389856|EXPERIMENTAL|1|Bosentan
62408149|NCT01389856|PLACEBO_COMPARATOR|2|Matching placebo
62408150|NCT05662319|EXPERIMENTAL|All participants|"In standard of care (SOC) period, participants will receive on-demand or prophylactic treatment with clotting factor concentrates (CFCs) or bypassing agents (BPAs) for 6 months (from Day -168 to Day -1). In fitusiran treatment period, participants will receive subcutaneous fitusiran prophylaxis once every other month (Q2M) or once monthly (QM) for 36 months (from Day 1 to Day 1009). In case of bleeding events participants will receive IV CFCs or BPAs. Participants may receive Antithrombin concentrate (ATIIIC) as rescue medicine.~."
62408151|NCT01967511||FMD subjects|patients who fulfill standard diagnostic criteria for FMD
62583776|NCT03269721||Smoker/Past smoker-W/Airflow Limitation|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
62211344|NCT05374213|EXPERIMENTAL|Mindfulness-based intervention|Participants will take part in an adapted and abbreviated version of the traditional eight-week MBCT protocol, conducted virtually via Zoom. Participants will meet for five, weekly, two-hour sessions. The group size will be larger than traditional MBCT groups (i.e. 16-20 participants rather than 12 participants).
62408152|NCT01967511||SCAD subjects|patients who fulfill standard diagnostic criteria for SCAD
62408153|NCT01967511||CvAD subjects|patients who fulfill standard diagnostic criteria for CvAD
62408154|NCT01967511||Healthy control subjects|
62408155|NCT01071278||Patients treated within a disease management program|Participant prescribed Tredaptive® for dyslipidemia and also participated in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
62408156|NCT01071278||Patients treated outside a disease management program|Participant prescribed Tredaptive® for dyslipidemia and did not participate in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
62583777|NCT00711568|EXPERIMENTAL|Arm 1|Left dorsolateral frontal 20 Hz TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
62583778|NCT00711568|EXPERIMENTAL|Arm 2|Right dorsolateral frontal 20 Hz TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
62019630|NCT01931839|EXPERIMENTAL|Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening in this study VX12-809-105 up to Week 96.
62019631|NCT01931839|EXPERIMENTAL|Arm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
62019632|NCT01931839|EXPERIMENTAL|Arm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
62019633|NCT01931839|NO_INTERVENTION|Arm 5 Part A: Observational Cohort|Participants who received either LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening OR LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening OR placebo matched to LUM and IVA in the morning and evening, in the previous study VX12-809-103 or VX12-809-104, and will be observed (will not receive study drug) in this study VX12-809-105 for up to 2 years.
62019634|NCT01931839|EXPERIMENTAL|Arm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in Cohort 4 of the previous study VX09-809-102, and will receive the same treatment in this study VX12-809-105 up to Week 96.
62408157|NCT02364882|PLACEBO_COMPARATOR|1|1 g (placebo) 0 mg sildenafil 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
62408158|NCT02364882|ACTIVE_COMPARATOR|2|1 g 50 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
62211345|NCT05374213|NO_INTERVENTION|Waitlist|Participants will be placed in a group with no treatment interventions for the duration of five weeks. Once these five weeks are complete, these participants will be placed in the next mindfulness clinic session to receive treatment. This does not the typical wait-list time for clinical services, which currently exceeds eight weeks
62211346|NCT05193903|EXPERIMENTAL|Intervention: Simulation|Interactive information tools
62211347|NCT05193903|OTHER|Control: Text|Standard text-based information
62211348|NCT06161727||Men with HPV-positive (HPV+) semen samples|
62211349|NCT06161727||Men with HPV-negative (HPV-) semen samples|
62211350|NCT04560010|EXPERIMENTAL|Tranexamic Acid Injection (TXA)|Subjects scheduled to undergo TSA (anatomic and reverse) will receive TXA before surgical incision and 3 hours later.
62211351|NCT04560010|NO_INTERVENTION|No Tranexamic Acid Injection (TXA) given|Subjects scheduled to undergo TSA (anatomic and reverse) will receive no TXA.
62211352|NCT06253078|EXPERIMENTAL|65-69 years old|The initial dose of ciprofol was 0.4mg/ in this group.
62408159|NCT02364882|ACTIVE_COMPARATOR|3|2 g 100 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
62408160|NCT02364882|ACTIVE_COMPARATOR|4|4 g 200 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
62408161|NCT03252665|EXPERIMENTAL|alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
62408162|NCT03252665|EXPERIMENTAL|nicorandil|nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
62408163|NCT03252665|PLACEBO_COMPARATOR|nitroglycerin|nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
62408164|NCT04889378||Pre-habilitation|participants will join prehabilitation with very low calories diet (800-1000kcal/day) and moderate intensive aerobic exercise (1 hour per section; 3 sections per day) for 2 weeks before bariatric surgery.
62408165|NCT03644927|EXPERIMENTAL|Progressive exercise program|"Based on the Active Physical Treatment Model individuals with chronic pain are typically and primarily sedentary or physically deconditioned and need a progressive approach to work up to standard exercise prescriptions as defined by the American College of Sports Medicine. Thus, progressive exercise training can help to minimize the risk or occurrence of a range of exercise-related adverse medical events, particularly with the complex study population which will be starting at a sedentary level and therefore, may not be able to initially achieve the heart rate goals prescribed in standard exercise training protocols. The exercise prescription will be individually designed and geared toward an intensity manageable by the individual."
62211353|NCT06253078|EXPERIMENTAL|70-74 years old|The initial dose of ciprofol was 0.4mg/ in this group.
62408166|NCT03644927|ACTIVE_COMPARATOR|Waitlist Control|The waitlist control participants will be fully screened for eligibility and asked to wait 12 weeks before beginning the 12-week progressive exercise program. They will be assessed again at the end of the 12-week waiting period. These patients will then be compared to patients in the experimental arm and then compared against their own waitlist control data after completing the 12-week exercise program. The exercise program that the waitlist control patients will participate in is identical to the experimental arm.
62583779|NCT00711568|SHAM_COMPARATOR|Arm 3|Left or right dorsolateral frontal 20 Hz sham TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
62211354|NCT06253078|EXPERIMENTAL|75-79 years old|The initial dose of ciprofol was 0.3mg/ in this group.
62211355|NCT06253078|EXPERIMENTAL|80-84 years old|The initial dose of ciprofol was 0.3mg/ in this group.
62408167|NCT04359758|EXPERIMENTAL|Proactive Streamlined Genetic Education and Testing|Participants randomized to this arm will proactively receive genetic education print materials and the option to proceed directly with genetic testing.
62583780|NCT04761198|EXPERIMENTAL|Squamous cell carcinoma of the head and neck|Advanced and/or recurrent or metastatic squamous cell carcinoma of the head and neck
62583781|NCT04761198|EXPERIMENTAL|Cervical cancer on or after chemotherapy|Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1
62211356|NCT06253078|EXPERIMENTAL|Older than 85 years (include 85 years old)|The initial dose of ciprofol was 0.2mg/ in this group.
62211357|NCT06167200||Patients with DoC consecutively admitted to participating units and met the inclusion criteria|Patients in VS or MCS due to severe acquired brain injury with different etiology (traumatic, anoxic, vascular) consecutively admitted at participating neurorehabilitation units. The total sample will be composed of 42 patients (n=7 pts per participating unit).
62211358|NCT01144052|ACTIVE_COMPARATOR|Natalizumab|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.
62211359|NCT01144052|EXPERIMENTAL|Interferon-beta-1b|250 mcg (8 MIU) subcutaneous injections every other day
62211360|NCT04007380|OTHER|CPAP-therapy arm|This single-arm clinical trial will examine the effects of 4-month period CPAP therapy in individuals living with SCI. The CPAP will be adjusted according to the results of the auto-titrating CPAP testing for each participant.
62211361|NCT00020735|EXPERIMENTAL|oral toremifene|
62211362|NCT00020735|OTHER|observation|
62211363|NCT06203067|EXPERIMENTAL|Type 1 Together|In Type 1 Together, families will work with other families who have experience using CGM (Peer Mentors) to overcome common barriers to CGM use. Families in the Type 1 Together program will also have access to CGM-specific educational materials, a digital journal to facilitate patient-provider communication around issues with CGM, and social determinant of health screening and intervention with a diabetes community health worker.
62408168|NCT04359758|ACTIVE_COMPARATOR|Usual Care|Participants in this arm will be sent a referral letter recommending that they schedule a genetic counseling session and providing them with contact information to do so.
62408169|NCT06650826||Spontaneous arterial and/or venous thrombosis|Patients with spontaneous arterial and/or venous thrombosis
62408170|NCT06650826||Infection-associated arterial and/or venous thrombosis|Patients with infection-associated arterial and/or venous thrombosis
62211364|NCT06203067|ACTIVE_COMPARATOR|Standard of Care|Quarterly clinic visits with endocrinology provider.
62211365|NCT05635201|ACTIVE_COMPARATOR|Propofol group|Receives propofol for anesthesia induction
62211366|NCT05635201|EXPERIMENTAL|Remimazolam group|Receives remimazolam for anesthesia induction
62211367|NCT00990795|EXPERIMENTAL|Cyclosporine|Cyclosporine Group: Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
62211368|NCT00990795|PLACEBO_COMPARATOR|Placebo|Placebo: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
62211369|NCT00801554||ASD|Children and adults with Autism Spectrum Disorders.
62211370|NCT00801554||Non-ASD|Healthy volunteers who have never been diagnosed with an Autism Spectrum Disorder in their lifetime.
62211371|NCT05102318|EXPERIMENTAL|Direct Pulp Capping with Biodentine|Direct Pulp Capping with Biodentine
62211372|NCT05102318|EXPERIMENTAL|Partial Pulpotomy with Biodentine|Partial Pulpotomy with Biodentine
62211373|NCT05102318|EXPERIMENTAL|Pulpotomy with Biodentine|Pulpotomy with Biodentine
62211374|NCT05102318|EXPERIMENTAL|Direct Pulp Capping with MTA|Direct Pulp Capping with MTA
62211375|NCT05102318|EXPERIMENTAL|Partial Pulpotomy with MTA|Partial Pulpotomy with MTA
62211376|NCT05102318|EXPERIMENTAL|Pulpotomy with MTA|Pulpotomy with MTA
62211377|NCT03806101|EXPERIMENTAL|Arm 1|Single dose of rosuvastatin on Day 1 of Period 1 and Single dose of rosuvastatin on Day 1 + PF-04965842 on Days 1 to 3 of Period 2.
62211378|NCT03806101|EXPERIMENTAL|Arm 2|Single dose of rosuvastatin on Day 1 + PF-04965842 on Days 1 to 3 of Period 1 and single dose of rosuvastatin on Day 1 of Period 2.
62211379|NCT05225727|EXPERIMENTAL|Intervention|Students randomized to the intervention group will receive Me \& You Tech in place of their standard health education.
62211380|NCT05225727|NO_INTERVENTION|Control|Students assigned to the standard care condition will receive their usual health education which usually includes knowledge-based content on violence prevention taught from the state textbook
62211381|NCT01640470|EXPERIMENTAL|Assistive technology|The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will include recommendations for assistive technology, possibly entailing financial assistance to repair or to acquire new AT, and training. New equipment will likely include devices such as bathroom grab bars, raised toilet seats, walkers, and bath chairs.
62211382|NCT01640470|ACTIVE_COMPARATOR|Customary care|Participants in this arm will receive customary care.
62211383|NCT06352684||Cancer group|confirmed as a breast cancer (DCIS or invasive cancer) through the subsequent biopsy conducted within following 1 year of the ultrasound exam.
62211384|NCT06352684||Benign group|Either confirmed as a benign through the subsequent biopsy conducted within following 1 year of the ultrasound exam or showing stability on more than 2 years of imaging follow-up after initial diagnosis
62408171|NCT06650826||Vaccine-associated arterial and/or venous thrombosis|Patients with vaccine-associated arterial and/or venous thrombosis
62583782|NCT04761198|EXPERIMENTAL|Gastric or gastroesophageal junction adenocarcinoma|Recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
62583783|NCT04761198|EXPERIMENTAL|Endometrial carcinoma post-platinum <3L treatment|Advanced and/or metastatic endometrial carcinoma
62583784|NCT04761198|EXPERIMENTAL|Tumor burden high (TMB-H) and microsatellite stable (MSS) solid tumors|Advanced or metastatic tumor mutational burden-high (TMB-H)
62583785|NCT04761198|EXPERIMENTAL|Rare disease with high prevalence of TIGIT expression|Select rare tumors
62211385|NCT06352684||Normal group|Interpreted as BI-RADS 1 (Negative) with no cancers on the ultrasound exam
62211386|NCT02054559|ACTIVE_COMPARATOR|Total 6 cycles of R-CHOP|
62211387|NCT02054559|EXPERIMENTAL|Total 3 cycles of R-CHOP + RT|Total 3 cycles of R-CHOP followed by radiotherapy (involved field or involved site radiotherapy, 30-50 Gy/ 15-25 fractions)
62211388|NCT00962377|OTHER|AlloMap Molecular testing|Gene expression profiling in the monitoring of asymptomatic heart transplant patients for acute cellular rejection.
62211389|NCT00962377|ACTIVE_COMPARATOR|Endomyocardial biopsy|Right ventricular endomyocardial biopsy in the monitoring of asymptomatic heart transplant patients for acute cellular rejection
62211390|NCT05670730|EXPERIMENTAL|AOC 1044-CS1 Part A - Single Dose Levels 1-5|AOC 1044 will be administered once.
62211391|NCT05670730|PLACEBO_COMPARATOR|AOC 1044-CS1 Part A - Single Dose: Placebo|Placebo will be administered once.
62211392|NCT05670730|EXPERIMENTAL|AOC 1044-CS1 Part B - Multiple Ascending Dose Levels 1-3|AOC 1044 will be administered three times.
62211393|NCT05670730|PLACEBO_COMPARATOR|AOC 1044-CS1 Part B - Multiple Ascending Dose: Placebo|Placebo will be administered three times.
62211394|NCT03835351|OTHER|Intraoperative urinary catheter|After induction of general anesthesia, a standard catheterization kit available at the institution where the surgery is being performed will be used to place the urinary catheter using standard sterile technique.
62211395|NCT03835351|NO_INTERVENTION|No intraoperative urinary catheter|No intraoperative urinary catheter will be used during the case
62211396|NCT01534143|EXPERIMENTAL|Treatment (chemotherapy, enzyme inhibitor)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.~GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0."
62211397|NCT06003140|EXPERIMENTAL|Hypothermic Neonates (90)|A trained study clinician will attach the Celsi Warmer temperature sensor to the abdomen and secure it with the abdominal belt according to the device's instruction manual (such that the temperature sensor is positioned using a vertical line from the mid-clavicular line and just below the ribs). The time of sensor placement will be recorded.
62211398|NCT03053518|ACTIVE_COMPARATOR|Life Style|
62408172|NCT06650826||Recurrent arterial and/or venous thrombosis despite anticoagulant therapy|Patients with recurrent arterial and/or venous thrombosis despite anticoagulant therapy
62583786|NCT04761198|EXPERIMENTAL|Ovarian cancer|Recurrent high grade serous and endometrioid ovarian cancer, fallopian tube cancer or primary peritoneal cancer following front-line platinum-based therapy
62019635|NCT01931839|EXPERIMENTAL|Arm 7 Part B: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in Cohort 4 of the previous study VX09-809-102, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
62211399|NCT03053518|EXPERIMENTAL|Life Style + Metformin|
62211400|NCT03329755|EXPERIMENTAL|Experimental|
62211401|NCT03329755|OTHER|Standard|
62211402|NCT00656097|EXPERIMENTAL|A|CL184 combined with rabies vaccination
62211403|NCT00656097|ACTIVE_COMPARATOR|B|HRIG combined with rabies vaccination
62211404|NCT00656097|PLACEBO_COMPARATOR|C|Placebo combined with rabies vaccination
62211405|NCT06544512|EXPERIMENTAL|the group that performed relaxation exercises|The group that received progressive relaxation exercise and filled out the pain and state-trait anxiety scales
62408173|NCT04748549|EXPERIMENTAL|Immersive VR group|"Patients in the Immersive VR group will don a VR headset connected to a software platform on a tablet, as well as noise cancelling headphones. Patients can choose their desired experience within the VR software from a selection of immersive environments and/or video content. Examples include sitting in a canoe on a river, on a peaceful meadow or in a forest. Patients also have the option to listen to guided meditation or select from a library of videos to watch on a web-based user interface.~To reduce the influence of the anesthesia provider on the determination of sedative requirements, patients will administer their own sedation according to their needs for relaxation and comfort using a patient controlled system."
62408174|NCT04748549|ACTIVE_COMPARATOR|Music group|Patients randomized to the Music group will be equipped with VR headsets but won't view any content. They will also be equipped with noise cancelling headphones in the same fashion as the immersive VR group. A study team member will play from a library of music or other audible content (audiobook, podcast) that was preselected by the patient. Patients in the Sham VR group will also use patient controlled sedation.
62408175|NCT04748549|SHAM_COMPARATOR|Sham VR + Usual Care Control Group|Subjects in the control group will wear VR headsets and headphones but will not view any content or listen to any audible content. They will undergo Monitored Anesthesia Care (MAC) according to a prespecified protocol targeting light or moderate sedation with a propofol infusion.
62408176|NCT03885349|EXPERIMENTAL|SBIP+ ADAPs-IMP|Experimental condition: Standard batterer intervention program (SBIP) plus individualized motivational plan (IMP) focused in alcohol and/or drugs abuse problems (ADAPs).
62583787|NCT04761198|EXPERIMENTAL|Endometrial carcinoma post standard of care therapy|Advanced and/or metastatic endometrial carcinoma
62583788|NCT02040636|EXPERIMENTAL|Study Group 1|Participants randomized to receive Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) at month 0, Hepatitis B at months 1, 2 and 7.
62583789|NCT02040636|ACTIVE_COMPARATOR|Study Group 2|Participants randomized to receive Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) + Hepatitis B at month 0, Hepatitis B at months 1 and 6.
62583790|NCT01209585||Rheumatoid Arthritis|Subject must have RA with inflamed joint
62583791|NCT01209585||Osteoarthritis|Subjects must have OA of the knee
62211406|NCT06544512|NO_INTERVENTION|the group that did not do relaxation exercises|The group that did not receive progressive relaxation exercise and only filled out the pain and state-trait anxiety scales
62211407|NCT00862719|EXPERIMENTAL|Sitagliptin once per day|600 mg sitagliptin once per day orally starting on Day -1 for a total of 4 doses
62583792|NCT01209585||Pseudo gout|Subjects must have peusdo-gout of knee
62583793|NCT06398496|NO_INTERVENTION|Usual Care|Participants allocated to usual care study arm, will continue with their current treatment plan as at study enrollment. This includes any pharmacological treatment they may be receiving, as well as any psychological treatment (i.e., therapy sessions with psychiatrist, psychologist etc.). Participants in usual care group will have the same number of study visits (4 total) across a 12-week period, as the aerobic exercise group.
62019636|NCT00377195|EXPERIMENTAL|1|
62019637|NCT00765115|EXPERIMENTAL|1|100 mg LY 450139 oral
62019638|NCT00765115|EXPERIMENTAL|2|140 mg LY450139 oral
62019639|NCT00765115|EXPERIMENTAL|3|280 mg LY450139 oral
62019640|NCT00765115|EXPERIMENTAL|4|Placebo
62019641|NCT01081860||Carpal tunnel syndrome|Patients with carpal tunnel syndrome
62019642|NCT01081860||Trigger finger|Patients with trigger fingers
62211408|NCT00862719|EXPERIMENTAL|Sitagliptin twice per day|600 mg sitagliptin twice per day orally starting on Day -1 for a total of 8 doses
62211409|NCT00862719|EXPERIMENTAL|Sitagliptin three times per day|600 mg sitagliptin three times per day orally starting on Day -1 for a total of 12 doses
62408177|NCT03885349|ACTIVE_COMPARATOR|SBIP+IMP|Control condition: Standard batterer intervention program plus individualized motivational plan (SBIP+IMP)
62408178|NCT01456351|EXPERIMENTAL|Bendamustine plus Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
62408179|NCT01456351|ACTIVE_COMPARATOR|Fludarabine plus Rituximab|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
62408180|NCT02738606|EXPERIMENTAL|Group I (surgery, chemotherapy)|Patients undergo hepatectomy and receive chemotherapy at the discretion of treating oncologist. Patients whose lung tumors become able to be removed by surgery with chemotherapy may undergo lung metastasectomy.
62583794|NCT06398496|EXPERIMENTAL|Aerobic Exercise + Usual Care|Participants allocated to aerobic exercise study arm, will engage in aerobic exercise for 12-weeks. This will occur alongside participants usual care, as determined at study enrollment, including any pharmacological treatment they may be receiving, as well as any psychological treatment (i.e., therapy sessions with psychiatrist, psychologist etc.). Participants in aerobic exercise group will have the same number of study visits (4 total) across a 12-week period, as the usual care group.
62583795|NCT00544115|ACTIVE_COMPARATOR|Regimen I|Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.
62408181|NCT02738606|ACTIVE_COMPARATOR|Group II (chemotherapy)|Patients receive chemotherapy at the discretion of the treating oncologist. Patients whose lung tumors become able to be removed by surgery with chemotherapy may undergo lung metastasectomy.
62408182|NCT04279483|EXPERIMENTAL|7-11 Group|Participants visit 7-11 5 times per week during the 4-week (20 store visits total) intervention period
62583796|NCT00544115|ACTIVE_COMPARATOR|Regimen II|Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2.
62583797|NCT00544115|ACTIVE_COMPARATOR|Regimen III|Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3.
62019643|NCT01081860||Dupuytren Contracture|Patients with Dupuytren
62019644|NCT01081860||Trauma to the hand|Patients with an acute trauma to the hand
62019645|NCT02223390|EXPERIMENTAL|Mental health treatment|The experimental condition, ImpACT, was developed in the pilot phase of the study. The intervention will be 4 sessions of individual psychological treatment related to stress, coping, and HIV adherence, followed by three group sessions. Sessions will follow an intervention manual and be delivered by a psychiatric nurse (or equivalent nonspecialist in mental health) who is supervised by a trained clinical psychologist.
62019646|NCT02223390|NO_INTERVENTION|Standard of Care|Participants in standard of care will receive the three-session adherence counseling delivered in the clinic, along with referrals for trauma treatment.
62019647|NCT04931849|EXPERIMENTAL|Experimental: Avatrombopag|Avatrombopag 40 mg daily by mouth (PO)
62019648|NCT04923386||Diabetics who receive mRNA COVID-19 vaccine|Patients that have a history of Diabetes Mellitus Type I or Type II who received Pfizer-N-Biotech or Moderna mRNA COVID-19 vaccines
62019649|NCT00799994||1|Patients that have medical intervention in an attempt to lower intraocular pressure (oral or topical)
62019650|NCT00799994||2|Patients who have received no intervention
62019651|NCT00793910|ACTIVE_COMPARATOR|Gabapentin|oral medication
62019652|NCT00793910|PLACEBO_COMPARATOR|placebo|
62019653|NCT02371369|EXPERIMENTAL|Part 1 - Pexidartinib|Participants received blinded treatment of pexidartinib,1000 mg (5 capsules per day ) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks
62019654|NCT02371369|PLACEBO_COMPARATOR|Part 1 - Placebo|Participants received blinded treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks
62019655|NCT02371369|EXPERIMENTAL|Part 2 - All Pexidartinib|Participants received pexidartinib in Part 1 and in Part 2 at their prescribed dose
62583798|NCT00544115|ACTIVE_COMPARATOR|Regimen IV|Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2.
62019656|NCT02371369|EXPERIMENTAL|Part 2 - Placebo-Pexidartinib|Participants received placebo in Part 1 and pexidartinib in Part 2 at their prescribed dose
62583799|NCT00544115|ACTIVE_COMPARATOR|Regimen V|Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.
62019657|NCT03119103|OTHER|Intervention of Functional Bed Sheet|Interventions will be non-invasive where healthy adults (over the age of 17, 10 male and 10 female) sleeps on the functional bed sheet overnight.
62583800|NCT00544115|ACTIVE_COMPARATOR|Regimen VI|Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2.
62583801|NCT02727777|EXPERIMENTAL|Aggressive Non-Hodgkin Lymphoma (NHL) - TAK228|"Phase II - Aggressive NHL: Diffuse Large B Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Transformed Large Cell Lymphoma, and Follicular Lymphoma (FL) grade 3b Group~Participants take TAK-228 1 time every day of a 28 day cycle.~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.~Participant checks blood sugar every day before TAK-228 dose."
62583802|NCT02727777|EXPERIMENTAL|Indolent Non-Hodgkin Lymphoma (NHL) - TAK228|"Phase II - Indolent NHL: Follicular Lymphoma (FL) grade 1-3a, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL) Group~Participants take TAK-228 1 time every day of a 28 day cycle.~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.~Participant checks blood sugar every day before TAK-228 dose."
62019658|NCT03319043|EXPERIMENTAL|treatment group|patients are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation and additional Chanqin granules 10g three times a day. All granules will be taken orally with 200 ml warm water.
62019659|NCT03319043|PLACEBO_COMPARATOR|controlled group|patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation and Chanqin analogous granules. All granules will be taken orally with 200 ml warm water.
62019660|NCT02753751|NO_INTERVENTION|Usual Care|No alert will be fired.
62019661|NCT02753751|EXPERIMENTAL|Electronic AKI Alert|A pop-up alert will fire when a provider opens the electronic health record of a patient with AKI until such time as AKI is documented in the problem list, or AKI resolves.
62019662|NCT02444702||CLBP and degenerative lumbar spine|Participants with CLBP (\>12 weeks) and degenerative changes of the lumbar spine confirmed by CT imaging who were recommended surgery and chose to undergo surgery will be recruited from the department of Orthopedic Surgery at the Meir Medical Center, Kfar-Saba, Israel. Included participants will be men or women, aged 40-80 years, of any race or ethnic background. Participants' diagnosis may include unstable degenerative spondylolisthesis, radicular pain, or documented stenosis with referred pain.
62019663|NCT03449303|ACTIVE_COMPARATOR|EOI|10% dilution of Curcuma longa, Piper nigrum, Pelargonium asperum, Zingiber officinale, Mentha x piperita, and Rosmarinus officinalis ct. cineole in Simmondsia chinensis
62583803|NCT02727777|EXPERIMENTAL|Hodgkin Lymphoma - TAK228|"Phase II - Hodgkin Lymphoma Group~Participants take TAK-228 1 time every day of a 28 day cycle.~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.~Participant checks blood sugar every day before TAK-228 dose."
62408183|NCT04279483|EXPERIMENTAL|CVS Group|Participants visit CVS 5 times per week during the 4-week (20 store visits total) intervention period
62583804|NCT05199571|EXPERIMENTAL|Ofatumumab|Ofatumumab 20 mg subcutaneous injections at Week 0, 1, 2 and monthly thereafter starting at Week 4
62019664|NCT03449303|PLACEBO_COMPARATOR|Placebo|Simmondsia chinensis
62019665|NCT04876027|EXPERIMENTAL|GLP-1 RAs and calorie restrict diet group|Intervention with GLP-1 RAs and calorie restrict diet until reaching the target weight loss(7%)
62019666|NCT04876027|ACTIVE_COMPARATOR|calorie restrict diet group|Intervention with calorie restrict diet until reaching the target weight loss(7%)
62583805|NCT03524235|EXPERIMENTAL|Subjects|Pre-Transplantation Conditioning (Bendamustine, Fludarabine, and Rituximab + Total Body Irradiation) + Haploidentical Stem Cell Transplantation with CD56-enriched donor lymphocyte infusion
62583806|NCT03524235|NO_INTERVENTION|Controls|Patients undergoing standard-of-care reduced-intensity peripheral blood allogeneic stem cell transplantation (any indication, donor source, conditioning regimen) using PTCy GVHD prophylaxis.
62019667|NCT02813031|EXPERIMENTAL|Functional meat products with healthy lipids from olive oil|Healthy people consuming 300g/week of functional meat products with high diglyceride lipid from olive oil
62019668|NCT02813031|PLACEBO_COMPARATOR|Traditional meat products|Healthy people consuming the same amount of traditional meat products
62019669|NCT01978119|EXPERIMENTAL|Sequence 1|Subjects in this Arm will receive Regimen A followed by Regimen B. Regimen A: Placebo administered BID by Multi-Dose Inhaler followed by FSC (250/50 mcg) administered BID by Capsule-Based Inhaler. Regimen B: FSC (250/50 mcg) administered BID by Multi-Dose Inhaler followed by Placebo administered BID by Capsule-Based Inhaler
62583807|NCT05032066|EXPERIMENTAL|HZN-825 300 mg once daily (QD)|Two 150 mg oral tablets given in the morning with a meal and two matching placebo tablets given in the evening with a meal; total daily dose 300 mg HZN-825.
62019670|NCT01978119|EXPERIMENTAL|Sequence 2|Subjects in this Arm will receive Regimen B followed by Regimen A. Regimen B: FSC (250/50 mcg) administered BID by Multi-Dose Inhaler followed by Placebo administered BID by Capsule-Based Inhaler. Regimen A: Placebo administered BID by Multi-Dose Inhaler followed by FSC (250/50 mcg) administered BID by Capsule-Based Inhaler
62019671|NCT05036148||Patients indicated for MH screening|Patients referred to MH center for MH diagnostic
62019672|NCT04168749||local compounding group|the first 100 preterm babies born as from January 1 2015 with a birth weight between 1250-2000g that received at least 10 days of TPN.
62019673|NCT04168749||Numeta G13 group|the first 100 preterm babies as from January 1 2017 with a birth weight between 1250-2000g that received at least 10 days of TPN
62019674|NCT01003418|EXPERIMENTAL|GSK2340272A Group 1|Healthy male or female children, between and including 8 and 12 weeks of age at the time of first vaccination, received 2 primary doses of GSK2340272A vaccine, according to a 0-28 day schedule. Subjects also received routine infant immunisation (Infanrix™-IPV/Hib) and Prevenar™ vaccine at Day 14, Month 3 and Month 10. All vaccines were administered intramuscularly into the anterolateral region of the thigh.
62408184|NCT04279483|NO_INTERVENTION|Control|Participants are not asked to alter their behavior during the 4-week (0 store visits) intervention period
62408185|NCT03187639|EXPERIMENTAL|FFRct default primary investigation|All patients undergo FFRct as the default test assuming they have no pre-specified contraindications to CT angiography. The result of the FFRct will be conveyed to the supervising physician within 24 hours and will be used to determine the subsequent management plan.
62408186|NCT03187639|ACTIVE_COMPARATOR|Standard care|All patients will be assessed and managed exactly as they are usually treated by the randomising centre and the RACP using the local algorithms interpreted from the NICE Chest Pain of Recent Onset Guidance.
62408187|NCT05636618|EXPERIMENTAL|Dose Escalation|"Dose Escalation to determine MTD/MFD in up to 160 patients receiving up to 4 administrations of \[212Pb\]VMT-α-NET approximately 8 weeks apart.~A dosimetry sub-study utilizing \[203Pb\]VMT-α-NET has been incorporated into the study."
62408188|NCT05636618|EXPERIMENTAL|Dose Expansion with RPh2D|Up to 120 patients with NET
62408189|NCT05661903|OTHER|Patients with Implanted Devices on Minimal/No Stimulation Settings|Patients in this arm will be randomized to turn off their spinal cord stimulator (or to minimal settings).
62408190|NCT05661903|OTHER|Patients with Implanted Devices on Usual Stimulation Settings|Patients in this arm will be randomized to turn on their spinal cord stimulator to their usual stimulation settings.
62408191|NCT02973789|EXPERIMENTAL|NovoTTF-200T|Patients receive TTFields using the NovoTTF-200T device together with immune checkpoint inhibitors or docetaxel
62408192|NCT02973789|ACTIVE_COMPARATOR|Best Standard of Care|Patients receive best standard of care with immune checkpoint inhibitors or docetaxel
62583808|NCT05032066|EXPERIMENTAL|HZN-825-300 mg twice daily (BID)|Two 150 mg oral tablets given in the morning with a meal and two 150 mg oral tablets given in the evening with a meal; total daily dose 600 mg HZN-825.
62211410|NCT06729411|EXPERIMENTAL|The experimental group received minimal offloading dressing (MOD) treatments|The MOD device was a monolayer device that can be applied directly to the participants skin via a non-irritative adhesive backing. The MOD was made of medium-density ethyl-vinyl acetate (40-45° Shore A hardness and 250-400-kg/cm2 density). The MOD is predesigned for three different locations: the first metatarsal head, central metatarsal heads, and fifth metatarsal. The MOD size ranged from size 35 to 48, which is measured according to the French system for each increase of 6.66 mm in length and 1.5 mm in width. All edges of the MOD were bevelled, and apertures were made to accommodate sites of plantar DFUs.
62211411|NCT06729411|ACTIVE_COMPARATOR|The control group received 15-mm felted foam treatments|The felted padding used in the control group was made out of semi-compressed wool felt with an adhesive backing (Herbitas lab, 46134 Foios-Valencia, Spain). The padding thickness was 15 mm on the whole foot, and similar apertures to those used with the other offloading device were made to accommodate the sites of plantar ulceration.
62211412|NCT01425892||incomplete sjogren's|patients who meet criteria as incomplete sjogren's
62211413|NCT01425892||primary sjogren's|patients who meet criteria for classification for primary sjogren's
62211414|NCT01425892||secondary sjogren's|patients who meet classification criteria for secondary sjogren's
62211415|NCT06008587|EXPERIMENTAL|Nasal High Flow therapy in association with the standard therapy|
62211416|NCT06008587|ACTIVE_COMPARATOR|Standard therapy alone|
62211417|NCT03814772||Liver transplant|"1. 18 years to 65~2. 48h preoperative biochemical indicators, blood general indicators, coagulation test complete"
62211418|NCT02764047|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62211419|NCT02764047|ACTIVE_COMPARATOR|Probiotic|Probiotic capsule
62211420|NCT02328859|EXPERIMENTAL|Virtual reality gait rehabilitation|Subjects will be trained using a custom treadmill with a virtual environment
62583809|NCT05032066|PLACEBO_COMPARATOR|Placebo BID|Matching placebo tablets (2) given in the morning with a meal and matching placebo tablets (2) given in the evening with a meal; total dose 4 placebo tablets.
62583810|NCT05976269|EXPERIMENTAL|Bilateral Patellofemoral Pain with Fear of Movement|The first group will consist of 20 subjects presenting with bilateral chronic anterior knee pain and high fear of movement with scores on Tampa Kinesiophobia Scale (fear of movement) greater than 37.
62583811|NCT05976269|EXPERIMENTAL|Bilateral Patellofemoral Pain with Low Fear of Movement|The second group with consist of 20 subjects with bilateral chronic anterior knee pain and low fear of movement between ages of 18 and 40 years old.
62583812|NCT05976269|ACTIVE_COMPARATOR|Healthy controls without knee pain|The third group will consist of healthy controls without knee pain between 18 and 40 years old.
62583813|NCT02218099|EXPERIMENTAL|1: Single dose of ASP8232|Subjects receive a single oral dose of ASP8232
62583814|NCT02218099|EXPERIMENTAL|2: Multiple doses of ASP8232 or placebo|Subjects receive multiple oral doses of ASP8232 or placebo
62211421|NCT02328859|ACTIVE_COMPARATOR|Treadmill training gait rehabilitation|Subjects wil be trained using a standard treadmill without any visual display
62211422|NCT05352659|EXPERIMENTAL|Face-to-face and online LGBTQ training+|The Study Intervention arm receives the organization-level LGBTQ climate assessment and technical assistance, the provider-level face-to-face LGBTQ training along with links to publicly available on-line training.
62211423|NCT05352659|OTHER|On-line resources|The Comparison Intervention arm receives only links to publicly available on-line resources.
62211424|NCT03730129|EXPERIMENTAL|Ig replacement|Subjects will receive Hizentra 0.4 mg/kg subq once weekly.
62211425|NCT03798041|EXPERIMENTAL|Debridement group|The subjects in this group will be debrided within 24 hours after surgery.
62211426|NCT03798041|NO_INTERVENTION|Control group|The subjects in this group will experience wound dressing change regularly 24 hours after surgery.
62211427|NCT03390764|ACTIVE_COMPARATOR|4:1 closure group|Patients randomized to and receiving the intervention small stitch 4:1 technique for closure of the abdominal wall.
62211428|NCT03390764|ACTIVE_COMPARATOR|RTL plus 4:1 closure group|Patients randomized to and receiving the intervention reinforced tension-line suture plus small stitch 4:1 technique for closure of the abdominal wall.
62211429|NCT03576729||Hurler syndrome participants|Participants who have MPS IH, also called Hurler syndrome
62211430|NCT03576729||Hurler-Scheie/Scheie participants|Participants who have either MPS IHS or MPS IS. MPS IHS is also called Hurler-Scheie syndrome. MPS IS is also called Scheie syndrome.
62211431|NCT03576729||Healthy Controls|Age-matched healthy controls
62211432|NCT03570567|OTHER|Piranha Treatment|The food impaction will be treated using the Piranha endoscopic device.
62211433|NCT06727747|SHAM_COMPARATOR|Group A|Patients in group A recieved cervical traction with 2 kg load combined with standard rehabilitation program. This group is condidered as sham because the 2 kg load does not have any effect on anatomical structures of the cervical spine.
62211434|NCT06727747|ACTIVE_COMPARATOR|Group B|Patients in group B recieved cervical traction with 8 kg load combined with standard rehabilitation program. The traction load in this group has an effect on muscular structures of the cervical spine without any actual effect on the remaining anatomical structures (intervertabral disks, joints and ligaments).
62211435|NCT06727747|EXPERIMENTAL|Group C|Patients in group C recieved cervical traction with 12 kg load combined with standard rehabilitation program. The traction load in this group has an actual effect on muscles, intervertabral disks, joints, and ligaments of the cervical spine.
62583815|NCT06318988||conservative|compression therapy, and oral or topical venoactive drugs
62583816|NCT06318988||invasive|sclerotherapy, foamsclerotherapy, open surgery, endovenous thermal ablation
62583817|NCT06048562|EXPERIMENTAL|idm|evaluation idm for cardiomyopathy
62583818|NCT03408509|EXPERIMENTAL|Cognitive training|
62583819|NCT04237753|ACTIVE_COMPARATOR|MyHealthebladder|Daily mobile health education with information on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
62583820|NCT04237753|ACTIVE_COMPARATOR|VA Video Connect|Remote telehealth visits with continence care provider who will provide education on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
62583821|NCT01644292|EXPERIMENTAL|EPIC Wheels Training Intervention|EPIC Wheels skills training program
62408193|NCT04241081|NO_INTERVENTION|Control group-no exercise|A no-exercise control. Must maintain \<4,500 steps per day for 3 consecutive days followed by a high fat tolerance test on day 4.
62408194|NCT04241081|EXPERIMENTAL|Exercise intervention 1|Two consecutive days of \<4,500 steps per day followed by an intervention day on day 3. Intervention day consists of interrupting 8-hour sit with bike sprint protocol every 2 hours. Participants must aim to maintain \<2,500 steps on intervention day. A high fat tolerance test will be performed the following day on day 4.
62019675|NCT01003418|EXPERIMENTAL|GSK2340272A Group 2|Healthy male or female children, between and including 8 and 12 weeks of age at the time of first vaccination, received 2 primary doses of GSK2340272A vaccine, according to a 0-4 month schedule. Subjects also received routine infant immunisation (Infanrix™-IPV/Hib) and Prevenar™ vaccine at Day 14, Month 3 and Month 10. All vaccines were administered intramuscularly into the anterolateral region of the thigh.
62019676|NCT05927129|ACTIVE_COMPARATOR|medication therapy group|Patients randomized to the medication therapy group will receive standardized treatment with antidepressant medications according to clinical guidelines.
62211436|NCT02688218|EXPERIMENTAL|Aerobic First, Resistance Second|Subjects will complete three 15 minute periods of aerobic exercise, with 10 minute recovery between each period. This will be followed by 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises.
62211437|NCT02688218|EXPERIMENTAL|Resistance First, Aerobic Second|Subjects will complete 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises. This will be followed by three 15 minute periods of aerobic exercise, with 10 minute recovery between each period.
62211438|NCT04419194||Observation|Observation
62211439|NCT05851703|EXPERIMENTAL|Manual therapy applications:|In lower cervical lateral flexion problems, pushing technique will be applied with instrument support from the articular pillar part of the superior vertebra on the side where the limitation is present
62211440|NCT05851703|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation (PNF) techniques will be applied to the second group.
62211441|NCT06525740|EXPERIMENTAL|Arm I (methadone)|Patients receive methadone IV during induction of general anesthesia for SOC surgery.
62211442|NCT06525740|EXPERIMENTAL|Arm II (hydromorphone)|Patients receive hydromorphone IT prior to induction of general anesthesia for SOC surgery.
62408195|NCT04241081|EXPERIMENTAL|Exercise intervention 2|Two consecutive days of \<4,500 steps per day followed by an intervention day. Intervention day consists of interrupting 8-hour sit with bike sprint protocol every 6 hours. Participants must aim to maintain \<2,500 steps on intervention day. A high fat tolerance test will be performed the following day on day 4.
62408196|NCT02131753|OTHER|Cladribine s.c. injection, HCL treatment|Cladribine 0.14 mg/kg body weight for 5 consecutive days (d 1 - 5) as subcutaneous bolus injection for patients with hairy cell leukemia needing treatment
62408197|NCT05679193|EXPERIMENTAL|Propranolol|Participants will receive Propranolol capsule for a period of 22-28 days, low dose (1 capsule/20mg propranolol twice daily) treatment the first- and last- three days of the treatment period. Higher dose (2 capsules/40mg propranolol twice daily) for the rest of the treatment period.
62211443|NCT03618043|EXPERIMENTAL|SH-1028|Oral Once-Daily Administration of SH-1028
62211444|NCT05672420|EXPERIMENTAL|umbilical cord derived mesenchymal stem cells (UC-MSCs)|In the Phase Ib study, participants will be those with treatment-induced myelosuppression and acute myeloid leukemia/acute lymphoblastic leukemia, UC-MSCs will be preset with 5 escalation dose levels: dose A , dose B, dose C ,dose D and dose E, frequency of infusion will be preset with 3 escalation levels: frequency 1, frequency 2, frequency 3, total course of treatment: 2 weeks; In the Phase II study, participants will be those with treatment-induced myelosuppression and acute myeloid leukemia/acute lymphoblastic leukemia/primary hematological maligancies who are going to receive hematopoietic stem cell transplantation, UC-MSCs will be preset according to the recommended phase II dose (RP2D) from the Phase Ib study, total course of treatment: 2 weeks.
62211445|NCT05332353||BCG responders|Non-muscle invasive bladder cancer patients who do not have T1/Ta HG recurrence within 6 months of adequate BCG therapy.
62211446|NCT05332353||BCG non-responders|Non-muscle invasive bladder cancer patients who have T1/Ta HG recurrence within 6 months of adequate BCG therapy or CIS within 12 months of BCG therapy
62408198|NCT05679193|PLACEBO_COMPARATOR|Placebo|Participants will receive Propranolol capsule for a period of 22-28 days, low dose (1 capsule twice daily) treatment the first- and last- three days of the treatment period. Higher dose (2 capsules twice daily) for the rest of the treatment period.
62408199|NCT02594254|EXPERIMENTAL|Study Arm 1|Subjects in Study Arm 1 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush.
62408200|NCT02594254|EXPERIMENTAL|Study Arm 2|Subjects in Study Arm 2 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush and custom dental trays.
62583822|NCT04441528|EXPERIMENTAL|Lid wipes containing terpinen-4-ol and sodium hyaluronate|The lid wipes will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.
62408201|NCT02594254|EXPERIMENTAL|Study Arm 3|Subjects in open-label Study Arm 3 will receive 4 ml of 1600 µM study drug administrations for a total of 7 consecutive days. Subjects will receive 4 C16G2 Gel administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the clinic for 6 consecutive days. Study drug will be administered via a manual brush and custom dental trays.
62211447|NCT06728488|EXPERIMENTAL|PENG block|The patients in the PENG block group will provide their consent. Standard monitoring will be applied. The patients will be positioned supine. After antiseptic procedures, 2 ml of 2% lidocaine will be infiltrated into the needle insertion site. The linear ultrasound probe will be placed in the transverse plane over the AIIS. The position of the ultrasound probe will be verified by visualizing the iliopectineal eminence, iliopsoas muscle and tendon, femoral artery, and pectineus muscle. Using a Stimuplex® A 100 mm 20 gauge needle (Braun Melsungen AG, Melsungen, Germany) with the in-plane technique, the needle will be inserted laterally to medially into the space between the psoas tendon and the pubic ramus. Negative aspiration will be performed to ensure no blood is aspirated, and then 20 ml of 0.25% bupivacaine and 8 mg of dexamethasone will be injected to perform the PENG block. After the procedure, the cannula will be removed, and the insertion site will be cleaned and dressed.
62211448|NCT06728488|EXPERIMENTAL|PENG block and pulse radiofrequency ablation|After obtaining consent, the patients in the PENG block and pulse radiofrequency ablation group will be brought into the operating room. Standard monitoring will be applied (ECG, SpO2, NIBP). The patients will be positioned supine. After performing the necessary aseptic and antiseptic procedures, 2 ml of 2% lidocaine will be infiltrated into the needle insertion site. The Boston Scientific unified echogenic 10cmx10mmx20G (0.9mm) radiofrequency cannula will be advanced until it makes contact with the superior ramus near the iliopectineal eminence. Pulse radiofrequency ablation will be performed with two cycles of 90 seconds each, and after each cycle, the needle will be moved 2 mm medially. After pulse radiofrequency ablation, 20 ml of 0.25% bupivacaine and 8 mg of dexamethasone will be applied. After the procedure, the cannula will be removed, and the insertion site will be cleaned and dressed.
62211449|NCT02535429|EXPERIMENTAL|massage|massage
62211450|NCT02535429|NO_INTERVENTION|Control|
62211451|NCT02209870||E-checklist group|The patients after CPR team using E-checklist system
62211452|NCT05714917||Confirmed diagnosis of NOS-induced neurological damage|"Any patient first presented with paraesthesia, weakness, ataxia or gait disturbance with a history of NOS use (age limit 16-30) as of 01/04/2023.~Patients who can read and write in English, so that they can complete the questionnaires."
62211453|NCT00659659|EXPERIMENTAL|1|MEDI-563
62211454|NCT00659659|EXPERIMENTAL|2|MEDI-563
62211455|NCT00659659|PLACEBO_COMPARATOR|4|Placebo
62211456|NCT00659659|PLACEBO_COMPARATOR|5|Placebo
62211457|NCT04712539|EXPERIMENTAL|Arm I (oseltamivir, baloxavir marboxil)|Patients receive oseltamivir PO BID for up to 10 days and baloxavir marboxil PO every 72 hours for a total of 3 doses in the absence of disease progression or unacceptable toxicity.
62583823|NCT04441528|ACTIVE_COMPARATOR|Baby shampoo|Baby shampoo will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.
62583824|NCT02511067|ACTIVE_COMPARATOR|Ranibizumab 0.3 mg|Mandatory monthly treatments with Intravitreal (IVT) ranibizumab (0.3 mg) starting at Baseline (BL) until Month 6. Starting at Month 6, treatments will be administered on as-needed basis, based on retreatment criteria.
62211458|NCT04712539|ACTIVE_COMPARATOR|Arm II (oseltamivir)|Patients receive oseltamivir PO BID for up to 10 days in the absence of disease progression or unacceptable toxicity.
62211459|NCT03620058|EXPERIMENTAL|CART22-65s monotherapy|
62211460|NCT03620058|EXPERIMENTAL|CART22-65s in combination with huCART19|
62211461|NCT01656252|EXPERIMENTAL|Phase I- Cytarabine & Eltrombopag|Cycle 1= Cytarabine twice daily on Days 1, 3 and 5 and Eltrombopag (Open-Label) until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.
62211462|NCT01656252|EXPERIMENTAL|Phase II- Sequence A|Cytarabine twice daily on Days 1, 3 and 5. Eltrombopag(dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo with 2nd cycle. Treatment sequence will be blinded to the patient and all study/sponsor personnel.
62211463|NCT01656252|EXPERIMENTAL|Phase II- Sequence B|Cytarabine twice daily on Days 1, 3 and 5. Placebo with 1st cycle of high-dose consolidation therapy and Eltrombopag(dose and schedule as determined in Phase I) with 2nd cycle. Treatment sequence will be blinded to the patient and all study/sponsor personnel.
62211464|NCT03501602|ACTIVE_COMPARATOR|LMA protector group|The LMA Protector is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts
62211465|NCT03501602|ACTIVE_COMPARATOR|I-gel LMA group|The I-gel is an alternative supraglottic device which provides the seal over the airway versus an inflatable cuff.
62408202|NCT02594254|EXPERIMENTAL|Study Arm 4|Subjects in open-label Study Arm 4 will receive 4 ml 800 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.
62408203|NCT02594254|EXPERIMENTAL|Study Arm 5|Subjects in open-label Study Arm 4 will receive 4 ml of 1600 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.
62211466|NCT04787887|ACTIVE_COMPARATOR|Abcertin|Abcertin 60IU/kg
62211467|NCT04787887|ACTIVE_COMPARATOR|Cerezyme|EU-sourced Cerezyme
62408204|NCT02594254|EXPERIMENTAL|Study Arm 6|If initiated, subjects in Study Arm 6 will receive 4 ml of 1600 µM study drug over a 7 day study drug administration period. Subjects will receive 4 C16G2 Gel or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
62583825|NCT02511067|EXPERIMENTAL|Tocilizumab (8.0 mg/kg)|Mandatory monthly Intravenous (IV) infusions with tocilizumab (8.0 mg/kg) starting at Baseline (BL) until Month 6. Starting at Month 6, treatments will be administered on as-needed basis with IVT ranibizumab (0.3 mg), based on the retreatment criteria.
62211468|NCT06598449|EXPERIMENTAL|Fenfluramine|"The dose of FENFLURAMINE for the duration of the Treatment Period will range from 0.2 mg/kg/day to a maximum of 0.7 mg/kg/day, not to exceed a total daily dose of 26 mg/day; for patients concurrently being prescribed stiripentol, the maximum will be 0.4 mg/kg/day, not to exceed a total daily dose of 17 mg/day.~Under this treatment plan, FENFLURAMINE will be administered twice daily in equally divided doses, with at least 8 hours and no more than 12 hours between doses in a single day."
62211469|NCT02166294|EXPERIMENTAL|NEOX® CORD 1K|Cryopreserved, umbilical cord allograft (NEOX® CORD 1K) with off-loading instructions.
62211470|NCT02166294|ACTIVE_COMPARATOR|Pressure bandage|Standard of Care Pressure bandage with off-loading instructions
62211471|NCT02166294|EXPERIMENTAL|Standard of Care Cross over to NEOX|Subjects in the Standard of Care (pressure bandage) group that have not healed greater than 50% at the Week 12 visit, or have a wound that is worsening, will be offered participation in the cross-over arm of the trial. The cross-over arm of the study will be treated with NEOX CORD 1K and followed for 12 weeks.
62211472|NCT01194375|EXPERIMENTAL|Low Strength IDP-107|
62408205|NCT02594254|EXPERIMENTAL|Study Arm 7|If initiated, subjects in Study Arm 7 will receive 4 ml of 800 µM or 1600 µM study drug on a single day once a week or once a month for a total of 4 days of C16G2 Gel or placebo administration. Subjects will receive 4 study drug administrations on the day of dosing. Study drug will be administered via manual toothbrush and custom dental trays.
62408206|NCT05848518|EXPERIMENTAL|Concurrent rehabilitation program|Endurance plus resistance exercises
62408207|NCT05848518|EXPERIMENTAL|Endurance rehabilitation program|Endurance exercises
62408208|NCT05848518|EXPERIMENTAL|Strength rehabilitation program|Resistance exercises
62408209|NCT05848518|NO_INTERVENTION|Control group|No exercise
62408210|NCT00761735|OTHER|PEG-IFN + RBV: LTFU|Pediatric participants who completed treatment with peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) in P02538 Part 1 of this study (NCT00104052) were enrolled in a 5-year Long Term Follow-Up (LTFU) during P02538 Part 2 (NCT00761735). No study treatment was administered in Part 2.
62408211|NCT03713125|ACTIVE_COMPARATOR|Reading Tutoring Intervention|20 hours of one-on-one reading tutoring administered over 6 weeks
62408212|NCT03713125|NO_INTERVENTION|Business as Usual|Instruction as usual within schools
62408213|NCT05278624|ACTIVE_COMPARATOR|Active plus vehicle arm|Subjects will be dispensed a tube containing roflumilast and vehicle in topical formulation
62408214|NCT05278624|PLACEBO_COMPARATOR|Vehicle arm|Subjects will be dispensed a tube containing vehicle only in a topical formulation
62408215|NCT03958045|EXPERIMENTAL|Patients with Stage IV SCLC|Patients with extensive stage (IV) SCLC (small cell lung cancer)
62583826|NCT02511067|EXPERIMENTAL|Tocilizumab (8.0 mg /kg) plus Ranibizumab 0.3 mg|Mandatory Intravitreal (IVT) ranibizumab 0.3 mg at Baseline (BL) followed with an IV infusion of tocilizumab (8.0 mg/kg) on same day starting at Baseline (BL) until Month 6. Combination treatments (IVT ranibizumab 0.3 mg followed by IV tocilizumab 8.0 mg/kg infusion administered at same visit) will be given every month until Month 6. Starting at Month 6, treatments will continue to be administered on as-needed basis with IVT ranibizumab (0.3 mg), based on retreatment criteria.
62583827|NCT05175885|EXPERIMENTAL|Experimental group|Ex vivo normothermic perfusion (EVNP) of the graft with the Ark Kidney System
62583828|NCT05175885|ACTIVE_COMPARATOR|Historical control group|Nonrandomized historical control group formed by patients transplanted without ex vivo normothermic perfusion (EVNP) in the period Sept 2015-Sept 2020, selected by retrospective matching.
62583829|NCT01794182|PLACEBO_COMPARATOR|Matching Placebo|Participants received a bolus dose of matching placebo over 2 minutes, followed by a continuous matching placebo infusion for 72 hours.
62408216|NCT06650735|ACTIVE_COMPARATOR|BMR resection|Bilateral medial rectus muscle resection
62583830|NCT01794182|EXPERIMENTAL|Glyburide for Injection|Participants received a 0.13 mg bolus dose of glyburide over 2 minutes, followed by a 0.16 mg/hr continuous infusion for 6 hours and than a 0.11 mg/hr for 66 hours for a total dosing period of 72 hours.
62408217|NCT06650735|ACTIVE_COMPARATOR|BLR recession|Bilateral lateral rectus muscle recession
62408218|NCT03337373|EXPERIMENTAL|Cisatracurium|Patients who require paralysis with cisatracurium as part of their clinical care in ICU
62408219|NCT04517630||Severe pneumoniae|Evaluate the progression to AKI during first 30 days of recruitment
62583831|NCT01609543|EXPERIMENTAL|Single Arm|
62211473|NCT01194375|EXPERIMENTAL|High Strength IDP-107|
62211474|NCT01194375|PLACEBO_COMPARATOR|Placebo|
62211475|NCT05524753|EXPERIMENTAL|AquOTic|Dose of 10 weeks of aquatic occupational therapy
62211476|NCT05524753|NO_INTERVENTION|Control|No intervention
62211477|NCT04748653|EXPERIMENTAL|Multi-component reintegration intervention|There is one arm for the feasibility and acceptability study - all intervention participants will receive the intervention: health education, psychosocial counseling, physiotherapy, and economic investment.
62211478|NCT02833870|EXPERIMENTAL|Musical intervention|
62211479|NCT02833870|EXPERIMENTAL|Non-musical (cooking) intervention|
62211480|NCT02833870|ACTIVE_COMPARATOR|Control with no intervention|
62211481|NCT04305717|EXPERIMENTAL|ReDS-guided strategy|For patients in this arm, daily measurements from the device will be revealed to the treating physician. Discharge can be planned when the clinical stability is achieved and the ReDS value is ≤35%. In case of a ReDS value \>35%, treating physicians will follow a predefined algorithm before discharge to improve the results of ReDS test.
62211482|NCT04305717|NO_INTERVENTION|Standard of care strategy|The drugs dosage, especially diuretics, will be selected according to the presence of symptoms and signs of systemic congestion and according to current recommendations. All the daily ReDS measurements will be blinded to the treating physician.
62211483|NCT03598959|EXPERIMENTAL|Treatment|Treated with tofacitinib and chidamide for 4 cycles.
62211484|NCT06729515|ACTIVE_COMPARATOR|PCA group|patient-controlled analgesia
62408220|NCT05186974|EXPERIMENTAL|Sacituzumab Govitecan-hziy (SG) + Pembrolizumab (Cohort A)|Participants assigned to Cohorts A according to tumor proportion score (TPS) status will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle.
62408221|NCT05186974|EXPERIMENTAL|SG + Pembrolizumab (Cohort B)|Participants assigned to Cohorts B according to TPS status will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle.
62211485|NCT06729515|ACTIVE_COMPARATOR|CEA group|continuous epidural analgesia
62211486|NCT06729515|EXPERIMENTAL|RISS group|the rhomboid intercostal block combined with subserratus plane block
62211487|NCT04018677|EXPERIMENTAL|Beta Testing|For the beta testing, input will be provided by cancer patient/survivor, caregivers, and clinicians. TOGETHER app will be downloaded on smart phone. Subjects will be asked to answer questions and/or perform activities on his/her smartphone device. Project information will include responses to surveys and giving additional feedback on app user experience.
62211488|NCT04018677|EXPERIMENTAL|Usability testing|For the usability testing, caregivers will be the primary type of stakeholder providing input. TOGETHER app will be downloaded on smart phone. Subjects will be asked to answer questions and/or perform activities on his/her smartphone device. Project information will include responses to surveys and giving additional feedback on app user experience.
62211489|NCT03419832|EXPERIMENTAL|NEAT Form|Study participants will be randomized to the NEAT form and the materials that accompany it (also detailing the ARIC study).
62211490|NCT03419832|ACTIVE_COMPARATOR|Standard Form|Study participants will be randomized to the traditional standard consent form (detailing the ARIC study).
62211491|NCT06728423|OTHER|Temporary Target|Temporary target during an anaerobic training session
62211492|NCT06728423|OTHER|SmartGuard|SmartGuard during an anaerobic training session
62211493|NCT01969370|EXPERIMENTAL|Experimental|Option to request non-medically actionable incidental information (after receiving education about them)
62211494|NCT01969370|NO_INTERVENTION|Control|No option to request non-medically actionable incidental information
62211495|NCT01698190|ACTIVE_COMPARATOR|Fine needle aspiration (FNA)|Endoscopic ultrasound guided needle tissue acquisition: Tissue acquisition using a standard FNA needle
62211496|NCT01698190|ACTIVE_COMPARATOR|Fine needle biopsy (FNB)|Endoscopic ultrasound guided needle tissue acquisition: Tissue acquisition using a new Core needle (Procore; Fine Needle Biopsy).
62211497|NCT05589805|EXPERIMENTAL|ESWT group|In addition to wrist splint, ESWT treatment (1.5 bar, 5Hz, 1000 beats) will be applied to the patients with the Elmed Vibrolith Ortho brand ESWT device, which we routinely use in the treatment of carpal tunnel syndrome, for 3 weeks, once a week.
62211498|NCT05589805|EXPERIMENTAL|Laser group|In addition to the wrist splint, the patients will be treated with the BTL-4110 Laser Topline model low-intensity laser device, which we routinely use in the treatment of carpal tunnel syndrome in our hospital, 5 days a week for 15 sessions of laser treatment.
62211499|NCT05589805|ACTIVE_COMPARATOR|Control group|Patients will only be given a wrist splint to keep the wrist in neutral position.
62211500|NCT06610084|EXPERIMENTAL|Hypno-breastfeeding|"The research was conducted in a total of 6 sessions. Session 1 (32nd week): After the introduction, hypno-breastfeeding practice was performed face-to-face.~Session 2 (33rd-34th week): Hypno-breastfeeding practice was repeated with online interviews.~Session 3 (35th week): Hypno-breastfeeding practice was repeated face-to-face. Session 4 (36th week): Hypno-breastfeeding practice was repeated online. Session 5 (37th week): Hypno-breastfeeding practice was repeated face-to-face. Session 6 (38th-40th week): Hypno-breastfeeding practice was performed in the ward at the 8th hour postpartum.~Postpartum 2nd to 4th week: The audio recording prepared by the researcher was used for the hypno-breastfeeding application given to the mother. The researcher guided the mother to perform the application once a day and followed up with daily telephone calls.~Translated with DeepL.com (free version)"
62211501|NCT06610084|EXPERIMENTAL|progressive muscle relaxation exercise|"Applications for experimental group 2 (progressive muscle relaxation exercise) The research was conducted in a total of 6 sessions. Session 1 (32nd week): After the introduction, progressive muscle relaxation exercise was performed face-to-face.~Session 2 (Week 33-34): Progressive muscle relaxation exercise was repeated with online interview.~Session 3 Week 35: In Phase 3, the progressive muscle relaxation exercise was repeated face-to-face.~Session 4 Week 36: Progressive muscle relaxation exercise was repeated online. Session 5 Week 37: Progressive muscle relaxation exercise, repeated face-to-face.~Session 6 38.-40th Week: It was performed in the ward at the 8th hour postpartum.~Postpartum 2nd to 4th week: The video prepared by the researcher was used for the progressive relaxation exercise training given to the mother. The researcher guided the mothers to perform the practice once a day and follow-up was ensured through daily telephone calls."
62211502|NCT01736800|EXPERIMENTAL|Temozolomide/Topotecan|Temozolomide pills are to be taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule. Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
62211503|NCT00209716|EXPERIMENTAL|1|
62211504|NCT06727656|EXPERIMENTAL|HNO: High intensity interval training (HIIT) + nitrate supllementation (NO3-).|Performed 12 high-intensity interval-training (HIIT) sessions during a 4-week period (3 sessions/ week) under normobaric hypoxia conditions (FiO2=\~13%, \~3000 m) with NO3- supplement.
62211505|NCT06727656|ACTIVE_COMPARATOR|HPL: High intensity interval training (HIIT) + placebo supllementation.|Performed 12 high-intensity interval-training (HIIT) sessions during a 4-week period (3 sessions/ week) under normobaric hypoxia conditions (FiO2=\~13%, \~3000 m) with placebo supplement.
62211506|NCT06727656|PLACEBO_COMPARATOR|CON: High intensity interval training (HIIT) + placebo supllementation.|Performed 12 high-intensity interval-training (HIIT) sessions during a 4-week period (3 sessions/ week) under normoxic conditions (FiO2=\~20.9%) with placebo supplement.
62211507|NCT01378052||urothelial carcinoma pateints|
62211508|NCT01378052||healthy controls|Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
62211509|NCT04823676|ACTIVE_COMPARATOR|Probiotic composition|A capsule containing a mix of probiotic strains (1.5 x 10\^9 CFU/capsule ) administered once daily for 4 months
62211510|NCT04823676|PLACEBO_COMPARATOR|Placebo|A capsule containing placebo administered once daily for 4 months
62211511|NCT01047813||Type 2 diabetes|This group contains 25 participants with type 2 diabetes
62211512|NCT01047813||control group|This group contains 25 participants withput type 2 diabetes. The control group is matched with age, education and lifestyle to the diabetes group.
62211513|NCT02862522||Women With CED|All subjects had blood work with included measurement of C-reactive protein, complete blood count with differential, basic chemistry panel, and uric acid level. All subjects completed a standardized questionnaire to assess baseline characteristics. All subjects underwent comprehensive coronary endothelial function assessment. Subjects completed a questionnaire of overall health several years after the index coronary angiogram and endothelial function study.
62211514|NCT02862522||Women Without CED|All subjects had blood work with included measurement of C-reactive protein, complete blood count with differential, basic chemistry panel, and uric acid level. All subjects completed a standardized questionnaire to assess baseline characteristics. All subjects underwent comprehensive coronary endothelial function assessment. Subjects completed a questionnaire of overall health several years after the index coronary angiogram and endothelial function study.
62211515|NCT05271370|EXPERIMENTAL|PRO 140 350 mg|PRO 140 350mg weekly SQ injection.
62211516|NCT05271370|EXPERIMENTAL|PRO 140 525 mg|PRO 140 525mg weekly SQ injection.
62211517|NCT05271370|EXPERIMENTAL|PRO 140 700 mg|PRO 140 700mg weekly SQ injection.
62211518|NCT06043427|ACTIVE_COMPARATOR|Paclitaxel and Ramucriumab|
62211519|NCT06043427|EXPERIMENTAL|Zanidatamab + Paclitaxel and Ramucirumab|
62211520|NCT03141905|ACTIVE_COMPARATOR|Sick-Day Protocol|Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVRSDRS weekly remote monitoring
62211521|NCT03141905|PLACEBO_COMPARATOR|Usual Care|Standard clinical care
62408222|NCT05186974|EXPERIMENTAL|SG + Pembrolizumab + Carboplatin Safety Run-in|Participants will receive SG (de-escalating dose levels: 10.0 mg/kg, 7.5 mg/kg, or 5.0 mg/kg) on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin area under the concentration versus time curve (AUC)5 on Day 1 of a 21-day cycle.
62408223|NCT05186974|EXPERIMENTAL|SG + Pembrolizumab + Cisplatin Safety Run-in (Optional)|Participants will receive SG (either 10 mg/kg or 7.5 mg/kg) on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + cisplatin 75 mg/m\^2 on Day 1 of a 21-day cycle.
62583832|NCT06667349|EXPERIMENTAL|Tiacgrelor (Tissara) 90 mg pod BID|Ticagrelor 90 mg bid give for atleast two weeks and ideally upto a month
62211522|NCT03980808|EXPERIMENTAL|ASL-ADE Intervention Arm|One-half of enrolled participants will view the ASL-ADE video intervention.
62211523|NCT03980808|SHAM_COMPARATOR|Control Arm|One-half of enrolled participants will view a non-health related video approximately the same length as the video intervention.
62211524|NCT02952534|EXPERIMENTAL|Rucaparib|Oral rucaparib (monotherapy)
62211525|NCT03775434|EXPERIMENTAL|B244|B244 suspension in 30ml/bottle
62211526|NCT06100081|EXPERIMENTAL|Patients|Patients with cancer of unknown primary most probable originating from the head and neck area
62211527|NCT03913923|EXPERIMENTAL|BCD-217 and BCD-100|Patients will receive 4 blinded infusions of BCD-217 plus Placebo. Starting with the fith infusion patients will receive unblinded BCD-100 monotherapy.
62211528|NCT03913923|ACTIVE_COMPARATOR|BCD-100 monotherapy|Patients will receive 4 blinded infusions of BCD-100 plus Placebo. Starting with the fith infusion patients will receive unblinded BCD-100 monotherapy.
62211529|NCT02588105|EXPERIMENTAL|Safety and Tolerability|All patients will receive AZD0156 as a monotherapy or in combination with either olaparib, cytotoxic chemotherapies, or novel anti-cancer agents to assess safety and tolerability
62211530|NCT01844024|OTHER|misoprostol by midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
62211531|NCT01844024|NO_INTERVENTION|Misoprostol by physician|Women with incomplete abortion is diagnosed and treated with misoprostol by physician
62211532|NCT02534506|EXPERIMENTAL|Urelumab (+ Nivolumab) intravenous (IV) infusion|
62211533|NCT03659864|SHAM_COMPARATOR|Exposure 1|filtered air
62408224|NCT05186974|EXPERIMENTAL|SG + Pembrolizumab + Carboplatin or Cisplatin (Cohort C)|Participants assigned to Cohort C according to disease status will receive SG RP2D as determined during the safety run-in cohorts on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin AUC5 or cisplatin 75 mg/m\^2 as determined during the safety run-in cohorts on Day 1 of a 21-day cycle.
62583833|NCT06667349|ACTIVE_COMPARATOR|standard arm clopidogrel 75 mg qday|
62211534|NCT03659864|EXPERIMENTAL|Exposure 2|nanoparticle 1 (either DEP or s-GO depending on group)
62211535|NCT03659864|EXPERIMENTAL|Exposure 3|nanoparticle 2 (either CB or us-GO depending on group)
62211536|NCT05101018|EXPERIMENTAL|Romosozumab Baseline to Month 11 followed by Denosumab Month 12 to Month 24|"Of the forty (40) individuals with subacute spinal cord injury (SCI) enrolled in this study, twenty (20) participants will be randomly selected to receive romosozumab (210mg SQ) once a month for 12 months.~After 12 months the same twenty (20) individuals will receive denosumab (60mg SQ) at month 12 and 18."
62583834|NCT05334485|EXPERIMENTAL|Pyridostigmine|Patients randomized to this group will be given 60mg of pyridostigmine bromide orally, every 12 hours. Pyridostigmine will be administered from the time of diagnosis of postoperative ileus until the return of bowel function, or for a maximum of 48 hours.
62583835|NCT05334485|PLACEBO_COMPARATOR|Placebo|Patients randomized to this group will be given starch orally, every 12 hours for a maximum of 48 hours.
62019677|NCT05927129|ACTIVE_COMPARATOR|Interpersonal Psychotherapy group|The participants will receive standardized IPT treatment for 12 weeks. IPT therapists have received training from IPT workshops in both China and the United States and obtained the corresponding certifications. IPT therapists focus on the interpersonal domains associated with the onset and maintenance of depression. They guide clients in identifying the connections between their emotional changes and interpersonal difficulties, exploring problems, actively seeking potential interpersonal support and assistance, improving interpersonal skills, helping clients alleviate symptoms, enhance their quality of life, and adapt better to society.
62211537|NCT05101018|ACTIVE_COMPARATOR|Denosumab Baseline to Month 24|Of the forty (40) individuals with subacute spinal cord injury (SCI) enrolled in this study, twenty (20) participants will be randomly selected to receive denosumab (60 mg SQ) at baseline and 6, 12, and 18 months.
62211538|NCT04600830|EXPERIMENTAL|Dry Needling Group|Dry needling will be applied to the myofascial trigger points of the gastrocnemius muscle. With the dry needle (0.3 x 40 mm. Myofib, Toledo, Spain). Thus, insert the needle until you get the first twitch response. Once the first twitch response is obtained, the needle will move about 2-3 mm vertically quickly. Twenty-five insertions without leaving the skin. The approximate frequency of 1 Hz for 25 to 30 seconds.
62211539|NCT04600830|ACTIVE_COMPARATOR|Foam Roller Group|The myofascial self-release technique with the FR Black Roll PRO (Bottighogen, Switzerland). The subject will move his body in the same direction as the muscle fibers, using his hands to propel and get the roller to slide back and forth. The device will only be applied at the muscular level, avoid the area of the Achilles tendon. It will be repeated on the contralateral leg. A total of three 60-second steps is executed on each leg and a 30-second break between both.
62211540|NCT05983380|EXPERIMENTAL|Experimental|Participants will receive hand mobility and grip strengthening exercises in addition to the usual care for breast cancer-related lymphedema of the upper limb.
62211541|NCT05983380|ACTIVE_COMPARATOR|Comparison|Participants will receive only the usual care for breast cancer-related lymphedema.
62211542|NCT03818724||CoolLoop® cryoablation system|Cryoablation for treatment of atrial fibrillation using the CoolLoop® cryoablation system
62211543|NCT04746053|OTHER|patient with a mutation in the HNF1B gene|Patient with a mutation in the HNF1B gene and which are followed in the reference centers
62211544|NCT01702324|EXPERIMENTAL|DD-25|A concentration of 0.025% of topical DD-25 cream.
62211545|NCT02112708|EXPERIMENTAL|Rational-Emotive-Behavioral Therapy|A social worker held eight 30 minutes sessions fortnightly of Rational-Emotive-Behavioral Therapy. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
62211546|NCT02112708|ACTIVE_COMPARATOR|Control Group|The control group (GC) will take the usual medical care for dysthymia, according with up-dated guidelines.
62211547|NCT00942305|PLACEBO_COMPARATOR|Placebo|"* Cohort 1 = 40 mg of matching placebo administered once weekly (QW)~* Cohort 2 = 100 mg of matching placebo administered QW~* Cohort 3 = 200 mg of matching placebo administered QW~* Cohort 4 = 200 mg of matching placebo administered twice weekly (BIW)~* Cohort 4A = 100 mg of matching placebo administered BIW"
62211548|NCT00942305|EXPERIMENTAL|Brincidofovir|"* Cohort 1 = 40 mg brincidofovir (BCV) administered once weekly (QW)~* Cohort 2 = 100 mg BCV administered QW~* Cohort 3 = 200 mg BCV administered QW~* Cohort 4 = 200 mg BCV administered twice weekly (BIW)~* Cohort 4A = 100 mg BCV administered BIW"
62211549|NCT02191410|ACTIVE_COMPARATOR|High Frequency Positive Pressure Ventilation|
62211550|NCT02191410|PLACEBO_COMPARATOR|Continuous Positive Airway Pressure|
62211551|NCT06329700||No post-chemotherapy liver atrophy|Patients treated with systemic chemotherapy, then hepatectomy for colorectal liver metastases. No occurrence of post-chemotherapy liver atrophy as measured by computed-tomography liver volumetry.
62211552|NCT06329700||Yes post-chemotherapy liver atrophy|Patients treated with systemic chemotherapy, then hepatectomy for colorectal liver metastases. Yes, occurrence of post-chemotherapy liver atrophy as measured by computed-tomography liver volumetry.
62408225|NCT05186974|EXPERIMENTAL|SG + Pembrolizumab + Carboplatin or Cisplatin (Cohort D)|Participants assigned to Cohort D according to disease status will receive SG RP2D as determined during the safety run-in cohorts on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin AUC5 or cisplatin 75 mg/m\^2 as determined during the safety run-in cohorts on Day 1 of a 21-day cycle.
62583836|NCT04828213|EXPERIMENTAL|Tooth-borne RME appliance (Hyrax)|"In the Tooth-borne RME expander group, bands were placed to the maxillary right and left upper 1st premolar and 1st molar teeth. The impression of the upper jaw was obtained with the bands in mouth by using alginate impression material. In the laboratory process, a hyrax (Forestadent, Pforzheim, Germany; Forestadent USA, St Louis, Missouri, USA) expansion appliance with an expansion screw in the middle was prepared on the models by the same technician under standard conditions.~RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months."
62211553|NCT04870229|ACTIVE_COMPARATOR|Carnosine|Each participant will be given a daily oral dose 1g of methycellulose powder for 6 months
62211554|NCT04870229|PLACEBO_COMPARATOR|Placebo|Each participant will be given a daily oral dose 1g of placebo for 6 months
62408226|NCT05186974|EXPERIMENTAL|SG + Pembrolizumab + Cisplatin (Cohort E)|Participants assigned to Cohort E will receive SG RP2D, as determined following safety review of Cohorts C and D, on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + cisplatin 75 mg/ m\^2 on Day 1 of a 21-day cycle.
62583837|NCT04828213|EXPERIMENTAL|Hybrid hyrax RME appliance|"Rapid Maxillary Expansion Treatment. In the Hybrid hyrax RME appliance group, mini-screws of 2 mm diameter and 9 mm length (Benefit mini-implants; PSM Medical Solutions; Tuttlingen, Germany) were placed 3 mm posterior and 1 to 5 mm paramedian to the incisive foramina.~RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months."
62583838|NCT05635435||primary glioma patients|We collected the information of clinical characteristics, inflammatory factors and immune factors of patients with primary glioma.
62583839|NCT03937440|EXPERIMENTAL|Deep neuromuscular block group|
62408227|NCT04998396|EXPERIMENTAL|Dose-Finding Phase: BBP-812 Dose Level 1 (Cohort 1)|Participants will receive a single intravenous (IV) infusion of low-dose BBP-812 on Day 0 in the dose-finding phase of the study.
62583840|NCT03937440|EXPERIMENTAL|Moderate neuromuscular block group|
62583841|NCT04431908||Outpatients (Drive Thru)|Patients receiving testing through a drive thru location.
62211555|NCT01470053|EXPERIMENTAL|mometasone furoate + azelastin HCl|opaque suspension, four times each naris per day
62211556|NCT01470053|ACTIVE_COMPARATOR|mometasone furoate|opaque suspension, four times each naris per day
62211557|NCT01470053|ACTIVE_COMPARATOR|azelastine HCl|lucidus colorless liquid, two times each naris per day
62583842|NCT04431908||High Risk Asymptomatics|Asymptomatic patients (residents) in a high risk location.
62408228|NCT04998396|EXPERIMENTAL|Dose-Finding Phase: BBP-812 Dose Level 2 (Cohort 2)|Participants will receive a single IV infusion of high-dose BBP-812 on Day 0 in the dose-finding phase of the study.
62408229|NCT04998396|EXPERIMENTAL|Enrollment Expansion Phase: BBP-812|Participants will receive a single IV infusion of BBP-812 at the selected dose from the dose-finding phase on Day 0 in expansion phase of the study.
62408230|NCT06085586|EXPERIMENTAL|1) Early Full Weight Bearing|Full weight bearing (100%) initiated at 4 weeks postoperatively
62583843|NCT00986921|EXPERIMENTAL|mifepristone|women in the mifepristone are would take mifepristone 200 mg for cervical preparation the day before their procedure, and not have dilators inserted. In this group, the sstandard procedure of osmotic dilator insertion is NOT performed.
62583844|NCT00986921|ACTIVE_COMPARATOR|Osmotic dilator insertion|Women assigned to this arm would have the standard procedure for cervical preparation, which is insertion of osmotic dilators the day before the abortion procedure
62583845|NCT02526979|EXPERIMENTAL|mirabegron|single dose
62583846|NCT04392375|ACTIVE_COMPARATOR|Nifedipine 30MG|Oral administration of 30mg Nifedipine XL q24 hours until delivery
62583847|NCT04392375|PLACEBO_COMPARATOR|Placebo|Matching placebo group q24hrs until delivery
62583848|NCT03109353|EXPERIMENTAL|ALA-ECP|Extracorporeal photopheresis (ECP) with 5-aminolevulinic acid replacing psoralen
62583849|NCT06682416|EXPERIMENTAL|Observation group|Participants will be assigned to receive 37°C local anesthetic solutions.
62211558|NCT04007250||FENIX participants|Individuals being treated with the FENIX™ Continence Restoration System.
62211559|NCT04063475|EXPERIMENTAL|cyanoacrylate beside sutures for FGG fixation|butyl cyanoacrylate
62211560|NCT06729671|PLACEBO_COMPARATOR|placebo|hydroxypropylmethylcellulose (HPMC) capsule with maltidextrin
62211561|NCT06729671|ACTIVE_COMPARATOR|active|Bifidobacterium longum APC1472 hydroxypropylmethylcellulose (HPMC) capsules
62211562|NCT03483259|EXPERIMENTAL|Arm A-Sulfatinib T capsule|The subjects in this arm will receive sulfatinib T capsules from Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd.
62211563|NCT03483259|EXPERIMENTAL|Arm B-Sulfatinib R capsule|The subjects in this arm will receive sulfatinib R capsules from Beijing Yiling Bioengineering Technology Co., Ltd.
62408231|NCT06085586|ACTIVE_COMPARATOR|2) Normal Full Weight Bearing|Full weight bearing (100%) initiated at 6 weeks postoperatively
62408232|NCT06652841|EXPERIMENTAL|Patients with severe aortic valve stenosis scheduled for TAVR|transShield Embolic Protection System
62408233|NCT01556490|NO_INTERVENTION|Control group|Standard-of-care sorafenib, with no added therapy
62408234|NCT01556490|EXPERIMENTAL|Treatment group|Standard-of-care sorafenib plus TheraSphere
62408235|NCT03277859|EXPERIMENTAL|YOGA-NOW|Participant will start the SAA-TBI (yoga) about 2 weeks (+/- 2 weeks) after Study Visit 3.
62408236|NCT03277859|ACTIVE_COMPARATOR|YOGA-WAIT|Participant will start SAA-TBI (yoga) about 10 weeks (+/- 2 weeks) after Study Visit 3.
62583850|NCT06682416|NO_INTERVENTION|Control group|Participants will be assigned to receive 23°C local anesthetic solutions.
62211564|NCT05557500|EXPERIMENTAL|Fibromyalgia patients with use of rtms sessions for treatment|Repitetive transcranial magnetic stimulation on primary motor area with 20 HZ for 20 sessions
62211565|NCT05557500|EXPERIMENTAL|Fibromyalgia pt with use of sphenopalatine ganglion block as treatment|Pain killing intervention for pain control of myofacial pain in fibromyalgia patients
62211566|NCT05651828|ACTIVE_COMPARATOR|A: Continuous Vismodegib|Participants will receive continuous 150 mg by mouth daily vismodegib as per commercially available package insert.
62211567|NCT05651828|EXPERIMENTAL|Arm B: Fixed Intermittent Vismodegib|Participants will receive intermittent 150 mg dose vismodegib by mouth with a 12 weeks on/8 weeks off regimen. Participants will take vismodegib for first 12 weeks, then off 8 weeks, and alternate in fixed cycles.
62211568|NCT05651828|EXPERIMENTAL|Arm C: Personalized Intermittent Vismodegib (Adaptive)|Participants will start with an 8-week run in period with vismodegib 150 mg dose by mouth daily. Participants will take vismodegib for the first 8 weeks, then start personalized dosing based on specific model.
62211569|NCT05651828|EXPERIMENTAL|Arm D: Personalized Intermittent Vismodegib (TGI model)|Participants will start with an 8-week run in period with vismodegib 150 mg dose by mouth daily. Participants will take vismodegib for the first 8 weeks, then start personalized dosing based on TGI model.
62211570|NCT06409000||Observational (3D surface scans, medical records)|Patients undergo 3D surface scans on study. Patient's medical records are also reviewed on study.
62211571|NCT04109105||NHS-PEG coated collagen patch cohort|Patients diagnosed of colon adenocarcinoma that have ileocolic anastomosis after undergoing a laparoscopic right hemicolectomy surgery.
62211572|NCT03947307|EXPERIMENTAL|Experimental Intervention (treatment / medical device)|Patients in the experimental group will receive lymphtaping using Easytape® according to common practice on day 1 after surgery by specifically trained physiotherapists. The tape has an elasticity of 150%. The material is moisture- and air-permeable with a hypoallergenic adhesive coating that is activated by body temperature to increase durability of contact. If possible the taping will be left for 7 days, in case of insufficient adhesion taping will be repeated.
62211573|NCT03947307|ACTIVE_COMPARATOR|Control Intervention (compression treatment )|Patients in the control group will be treated with manual lymphatic drainage followed by compression treatment using compressive stockings if accepted or compressive bandaging in cases with pronounced swelling depending on medical necessity.
62408237|NCT04027634|NO_INTERVENTION|Control group|The control group (CG) received routine care and was required to walk during 6-7 pm.
62211574|NCT03947307|SHAM_COMPARATOR|Control Intervention (sham taping)|Patients in the control group will be treated by sham taping with Leukotape® Classic, a non-elastic tape, that in all other respects resembles Easytape®.
62211575|NCT03311477|EXPERIMENTAL|ABBV-399|ABBV-399 via intravenous administration at escalating dose levels.
62211576|NCT00929110|EXPERIMENTAL|Glycopyrronium bromide 50 μg|Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62211577|NCT00929110|PLACEBO_COMPARATOR|Placebo to glycopyrronium bromide|Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62211578|NCT00929110|ACTIVE_COMPARATOR|Tiotropium 18 μg|Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62211579|NCT05901623||Case|Infants with THoP
62211580|NCT05901623||Control|Healthy infants
62211581|NCT03904225|EXPERIMENTAL|tegio|Tegio 60mg bid d1-28 q6wks was administered until disease progression, unacceptable toxicity,or over 12monthes within 3monthes after curative chemoradiation
62211582|NCT03904225|NO_INTERVENTION|control|patients was oberved
62408238|NCT04027634|EXPERIMENTAL|Baduanjin program|The entire program continued for 3 months (mid-September to mid-December 2014), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
62408239|NCT03146819||iTotal PS KRS|Patients who have had an iTotal (posterior stabilized) knee replacement at least 6 months prior to testing.
62211583|NCT04266600|EXPERIMENTAL|Prospective arm (extended mesenteric resection)|"Surgery can be performed either laparoscopically or open depending on surgeon preference and the circumstances of the surgery. Surgeons will perform a high ligation of the ileocolic pedicle, between the superior mesenteric artery and the bifurcation of the ileal and right colic branches, and to fully mobilize the mesentery off of the retroperitoneum prior to bowel transection and anastomosis. The entire mesentery related to the specimen will be removed.~Outcomes in the prospective arm will be compared to historical controls."
62211584|NCT04266600|NO_INTERVENTION|Retrospective arm|Retrospective patient data will be obtained by querying the Opera operating room database of both study institutions. Electronic records will be analyzed for all patients undergoing a first-time ileocolic resection for Crohn's Disease between January 1, 2009 - December 31, 2018.
62211585|NCT06274229||Aarhus, installation site|Residents of Aarhus (DK), living at or nearby the site of the installed Intervention
62211586|NCT06274229||Aarhus, control site|Residents of Aarhus (DK), living at or nearby the control site
62211587|NCT06274229||Bucharest, intervention site|Residents of Bucharest (RO), living at or nearby the site of the installed Intervention
62211588|NCT06274229||Bucharest, control site|Residents of Bucharest (RO), living at or nearby the control site
62211589|NCT06274229||Castelló, intervention site|Residents of Castelló (ES), living at or nearby the site of the installed Intervention
62211590|NCT06274229||Castelló, control site|Residents of Castelló (ES), living at or nearby the control site
62211591|NCT06274229||Orvieto, intervention site|Residents of Orvieto (IT), living at or nearby the site of the installed Intervention
62211592|NCT06274229||Orvieto, control site|Residents of Orvieto (IT), living at or nearby the control site
62211593|NCT06274229||Potsdam, intervention site|Residents of Potsdam (DE), living at or nearby the site of the installed Intervention
62211594|NCT06274229||Potsdam, control site|Residents of Potsdam (DE), living at or nearby the control site
62211595|NCT01806623|EXPERIMENTAL|Fluconazole|
62211596|NCT03045835|EXPERIMENTAL|BASKA mask|Selection of size : size 3 (30-50kg), size 4 (50-70kg), size 5 (70-100kg)
62583851|NCT06018298||Therapeutic security|assessment of residents in REMS for need for therapeutic security, treatment response relevant to forensic need and forensic recovery.
62583852|NCT06018298||Risk Measures of Need (RISKMON)|assessed symptom severity, risk and protective factors for violence, global function, personality factors.
62211597|NCT03045835|ACTIVE_COMPARATOR|Endotracheal intubation|Selection of size : ID 7.0-7.5mm (women), ID 7.5-8.0mm (men)
62211598|NCT00922753|ACTIVE_COMPARATOR|BiPAP6 assisted preoxygenation|
62583853|NCT06045455||Patients with neurological deficits (stroke or SM)|"All patients with acute neurological deficits (stroke or SM) will undergo neuroimaging diagnostic procedures initial multimodal brain CT (NCCT, CTP, CTA); then the follow-up NCCT within 24-36 hours.~All patients without a confirmed concordant hypoperfusion or cerebral ischemia on their previous CT scans will undergo a magnetic resonance imaging (MRI) examination between the 3rd and 7th day after the admission to the hospital in order to confirm the diagnosis of SM."
62583854|NCT06598592|SHAM_COMPARATOR|Audio Emergency Call|An Emergency Call will be performed
62583855|NCT06598592|ACTIVE_COMPARATOR|Video-Emergency Call|Video-Emergency Call
62583856|NCT04647799||forward head position|nerve conduction velocity and f-wave applied to median , ulnar and radial nerve before and after 10,20 and 30 minutes in forward head position while Children will sit on chair with their feet on the ground without any tension, the upper limbs are rested in a table then, the angle between the line passing horizontally from the spinous process of C7 and the line passing between the tragus and spinous process of C7 will be measured by goniometer and goniometer pro application to evaluate the craniovertebral angle recording, we will fix the craniovertebral angle between 40.7° and 43.2°(severe FHP )
62211599|NCT00922753|ACTIVE_COMPARATOR|BiPAP4 assisted preoxygenation|
62211600|NCT00922753|ACTIVE_COMPARATOR|Standard preoxygenation (VS)|
62211601|NCT03748069||Influenza positive CAPIV|All consecutive patients older than 18 years, admitted to the ICU with respiratory distress with microbiologically confirmed diagnosis of influenza
62211602|NCT03748069||Influenza negative CAPIV|All consecutive patients older than 18 years, admitted to the ICU for respiratory distress due to community-acquired pneumonia (CAP) and with a microbiologically confirmed absence of influenza
62211603|NCT02611336|EXPERIMENTAL|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
62211604|NCT05287711|EXPERIMENTAL|Motivational Enhancement Therapy|Motivational enhancement therapy for alcohol use problems, which includes empathic support, feedback and advice, strategies for enhancing self-efficacy, techniques for eliciting self-motivational statements from the participant, strategies for addressing participant ambivalence about change and participant resistance to change, and methods for eliciting and affirming commitment to a specific change plan (active intervention).
62211605|NCT05287711|EXPERIMENTAL|Alcohol Education Control|Psychoeducational intervention intended to: (1) dispel myths about the effects of alcohol, (2) provide information about the general risks of drinking and process of recovery from alcohol problems, (3) provide information about the specific risks related to family relationships and IPV, (4) offer self-help program information and related strategies to address drinking problems, (5) promote and encourage healthy decision-making, and (6) reinforce the benefits of abstinence or controlled drinking.
62211606|NCT05287711|OTHER|Telephone Monitoring|Brief supportive telephone monitoring sessions that are commonly delivered while Veterans wait to begin their groups (treatment as usual).
62211607|NCT03896620||Stage II-III Sarcomas undergoing preoperative radiation therapy (RT)|This group will have preoperative chemotherapy (if administered), preoperative radiation and surgery.
62211608|NCT03896620||Stage II-III Sarcomas undergoing postoperative RT|This group will have surgery, postoperative radiation, post operative chemotherapy (if administered).
62211609|NCT03896620||Stage IV Sarcomas|This group will only have chemotherapy.
62211610|NCT00848939|EXPERIMENTAL|treprostinil diethanolamine|
62211611|NCT02797275|EXPERIMENTAL|Albuterol & Placebo|Participants will be placed on the albuterol treatment (2 puffs twice a day, equivalent to 360 mcg per day) after the completion of the baseline screening visit. They will use albuterol for 4 weeks prior to their scheduled second visit during which they will undergo testing. Subsequently, and after a minimum washout period of 2 weeks, they will be placed on the placebo treatment for 4 weeks prior to their scheduled third visit, after which they will come back to undergo testing.
62408240|NCT03146819||Off-the-Shelf KRS|Patients who have had an off-the-shelf (posterior stabilized) knee replacement at least 6 months prior to testing.
62408241|NCT00870415|EXPERIMENTAL|Surgerie|
62408242|NCT04125498|ACTIVE_COMPARATOR|OMT|Osteopathic manual treatment
62583857|NCT04647799||neutral position|nerve conduction velocity and f-wave applied to median , ulnar and radial nerve before and after 10,20 and 30 minutes while Children will sit on chair with their feet on the ground with head in anatomical position, the upper are rested in a table and used both hand on touch screen of mobile phone
62583858|NCT05849883|EXPERIMENTAL|Omeprazole 20 mg capsules|Subjects were given a single dose of 20 mg omeprazole of either formulation (test or reference) with 240 ml of water
62583859|NCT05849883|ACTIVE_COMPARATOR|Losec® 20 mg capsules|Subjects were given a single dose of 20 mg omeprazole of either formulation (test or reference) with 240 ml of water
62583860|NCT06371495||Group ABC|GroupA: recieve rosuvastatin 40mg
62211612|NCT02797275|EXPERIMENTAL|Placebo & Albuterol|Participants will be placed on the placebo treatment after the completion of the baseline screening visit. They will use placebo for 4 weeks prior to their scheduled second visit during which they will undergo testing. Subsequently, and after a minimum washout period of 2 weeks, they will be placed on the albuterol treatment (2 puffs twice a day, equivalent to 360 mcg per day) for 4 weeks prior to their scheduled third visit, after which they will come back to undergo testing.
62211613|NCT05221359|EXPERIMENTAL|test arm|All patients will be enrolled in same arm which contains the two interventions (device + drug) and follow mandatory phases of trial: screening, implantation, treatment with ExOlin, explantation.
62583861|NCT06371495||Group B|Group B :recive rosuvastatin20
62583862|NCT01353690|EXPERIMENTAL|AMDC|
62583863|NCT04176419|EXPERIMENTAL|Treatment Group|"Perioperative intervention (preoperative acetaminophen, gabapentin, and celecoxib and intraoperative ketamine and lidocaine).~The Investigational Drug Service will mix and prepare the study medications necessary for each participant. An Investigational Drug Service staff member will deliver the oral medications to the nursing team in the preoperative holding unit and the IV medications to the anesthesia team in the OR unit."
62583864|NCT04176419|PLACEBO_COMPARATOR|Control Group|"Perioperative placebo~Placebo oral drugs will be encapsulated versions provided by the Investigational Drug Service and will appear identical to the interventional oral drugs. Placebo IV infusions will be prepared by Investigational Drug Service as per institutional guidelines and will appear identical to the interventional IV drugs."
62583865|NCT01850147|EXPERIMENTAL|Sunitinib|
62583866|NCT05045781|EXPERIMENTAL|Eptinezumab 100 mg|
62583867|NCT05045781|EXPERIMENTAL|Eptinezumab 300 mg|
62583868|NCT04206813|EXPERIMENTAL|Intervention group|240 eligible women will receive a 2-dose regimen of Gardasil 9 at (0 and 6 months, followed by a rescue 3rd dose at month 12)
62211614|NCT06311344|OTHER|Biological samples|M. perstans microfilariae and Schistosoma spp eggs, obtained from the routine diagnostic procedures carried out on patients, specifically migrants and travellers, visited in the centres participating to this study
62583869|NCT04206813|ACTIVE_COMPARATOR|Control group|120 eligible women will receive the standard 3-dose regimen of Gardasil 9 at (0, 2, 6 months)
62583870|NCT03233529|EXPERIMENTAL|Crisaborole ointment|
62583871|NCT03233529|PLACEBO_COMPARATOR|Placebo ointment (vehicle)|
62583872|NCT05000684|EXPERIMENTAL|JS004 200 mg in combination with toripalimab 240 mg was administered every 3 weeks as planned|
62211615|NCT04222764||Real-time three-dimensional echocardiography|
62211616|NCT06384508|ACTIVE_COMPARATOR|SHINE-VR Baseline 1 week|"Participants will receive SHINE-VR additionally to regular trauma treatment. The baseline phase starts after trauma processing, e.g. after module 6 of TF-CBT or processing of the traumatic event with EMDR.~This group has a one week baseline, 3 weeks intervention, and 2 week follow-up phase."
62211617|NCT06384508|ACTIVE_COMPARATOR|SHINE-VR Baseline 2 weeks|"Participants will receive SHINE-VR additionally to regular trauma treatment. The baseline phase starts after trauma processing, e.g. after module 6 of TF-CBT or processing of the traumatic event with EMDR.~This group has a two week baseline, 3 weeks intervention, and a 1 week follow-up phase."
62211618|NCT02880267|OTHER|CGM Users|Glucose challenge during a clinic sessions to assess performance of CGM compared to reference measurement
62408243|NCT04125498|ACTIVE_COMPARATOR|OMT plus self-massage|Patients will be submitted to OMT and then they will be invited to practice a self-massage at home.
62583873|NCT06519357|OTHER|Lamivudine 300|Participants receive 300 mg of Lamivudine daily for 24 weeks
62583874|NCT04269304||Observational|Intermediate Age-Related Macular Degeneration Patients
62583875|NCT06471569|EXPERIMENTAL|Low Amount/Moderate Intensity (Low/Mod)|Six months of low amount/moderate intensity aerobic exercise
62583876|NCT06471569|EXPERIMENTAL|High Amount/Moderate Intensity (High/Mod)|Six months of high amount/moderate intensity aerobic exercise
62583877|NCT06471569|EXPERIMENTAL|High Amount/Vigorous Intensity (High/Vig)|Six months of high amount/vigorous intensity aerobic exercise
62583878|NCT05837845|EXPERIMENTAL|MDMA-assisted therapy (MDMA-AT)|This arm consists of three, 90-minute, non-drug Preparatory Sessions and a \~12-week Treatment Period comprised of three Experimental Sessions with MDMA (\~ 8 hours), each followed by three 90-minute, non-drug Integration Sessions. Participants will receive 60mg MDMA HCl for first Experimental Session and 60mg or 120mg MDMA HCl for following Experimental Sessions. During each Experimental Session, participants will have the option of receiving a supplemental dose of 40mg or 60mg MDMA HCl 1.5-2 hours after the initial dose. Participants will have the option to crossover to the CPT arm 6 months after all study visits are completed.
62211619|NCT01253070|EXPERIMENTAL|Treatment (daunorubicin, cytarabine, sorafenib tosylate)|"INDUCTION THERAPY: Daunorubicin hydrochloride 60 mg/m\^2/day by IV push or short IV on days 1-3, cytarabine 100 mg/m\^2/day by continuous IV on days 1-7, and sorafenib tosylate orally every 12 hours on days 1-7.~CONSOLIDATION THERAPY - Every 28 days for 2 cycles: Cytarabine 2 g/m\^2/day by IV on days 1-5 and sorafenib tosylate 400 mg orally every 12 hours on days 1-28.~MAINTENANCE - Every 28 days for up to 12 cycles: Sorafenib tosylate 400 mg orally every 12 hours on days 1-28."
62408244|NCT04125498|SHAM_COMPARATOR|Placebo|Similar to OMT without pressure.
62583879|NCT05837845|EXPERIMENTAL|Cognitive processing therapy|This arm consists of one, 60-minute, introductory meeting with the therapist followed by a \~12-week Treatment Period comprised of 12 1-hour CPT sessions with three optional additional sessions, each approximately one week apart. Participants will have the option to crossover to the MDMA-AT arm 6 months after all study visits are completed.
62583880|NCT00078975|EXPERIMENTAL|Triapine in combination with Gemcitabine|
62583881|NCT05387473|EXPERIMENTAL|cognitive behavioral therapy for insomnia (CBT-I) integrated in best-evidence usual care (CBTi-UC)|18 individual sessions provided by physiotherapists, over 14 weeks.
62211620|NCT05266443|PLACEBO_COMPARATOR|Irritable bowel syndrome with normal mood receiving placebo|A total of 35 patients diagnosed with IBS as per Rome IV criteria who scored CESD-R less than 16 will be supplemented with placebo drinks.
62583882|NCT05387473|ACTIVE_COMPARATOR|Best-evidence usual care (UC) plus information sessions|18 individual sessions provided by physiotherapists, over 14 weeks.
62211621|NCT05266443|ACTIVE_COMPARATOR|Irritable bowel syndrome with normal mood receiving probiotics|A total of 35 patients diagnosed with IBS as per Rome IV criteria who scored CESD-R less than 16 will be given lactobacillus-containing cultured milk drinks.
62211622|NCT05266443|PLACEBO_COMPARATOR|Irritable bowel syndrome with subthreshold depression receiving placebo|A total of 35 patients diagnosed with IBS as per Rome IV criteria who scored CESD-R of 16 or above will be supplemented with placebo drinks.
62211623|NCT05266443|EXPERIMENTAL|Irritable bowel syndrome with subthreshold depression receiving probiotics|A total of 35 patients diagnosed with IBS as per Rome IV criteria who scored CESD-R of 16 or above will be given lactobacillus-containing cultured milk drinks.
62211624|NCT02824354|PLACEBO_COMPARATOR|placebo|"The placebo will have the same composition as the active treatment (without the drug substance) and an identical appearance. White, oval, biconvex, 6.0 x 8.75 mm film-coated tablet engraved with S on one side."
62211625|NCT02824354|EXPERIMENTAL|Nalmefene|"Drug : 'Nalmefene (Selincro®) 18 mg tablet is a white, oval, biconvex, 6.0 x 8.75 mm film-coated tablet engraved with S on one side. It contains 18.06 mg nalmefene (in the form of hydrochloride dihydrate).~Nalmefene must be taken as-needed: on each day the patient perceives a risk of drinking alcohol, one tablet should be taken, preferably 1-2 hours prior to the anticipated time of drinking. If the patient has started drinking alcohol without taking nalmefene, the patient should take one tablet as soon as possible.~The maximum dose of nalmefene is one tablet per day. Nalmefene can be taken with or without food."
62211626|NCT04654026||CAA Group|Patients with cardiovascular and cerebrovascular disease with cerebral amyloidosis
62211627|NCT04654026||None CAA Group|Patients with cardio-cerebrovascular disease without cerebral amyloid vascular disease
62211628|NCT02396329|EXPERIMENTAL|chlorhexidine _based antisepsis|"Including cases undergoing elective\&non elective caesarean section.Patients will be were prepared similarly by three applications of 2%chlorhexidine solution time given between each application about 30 seconds followed by drying with a sterile towel and three applications of 70% alcohol after one minute The area scrubbed was from the xiphoid to the knee, reaching the midaxillary line laterally. In both groups, patients received preoperative prophylactic i.v antibiotics (cefotrixone 1 gm) one hour before skin incision.~."
62583883|NCT00600561|ACTIVE_COMPARATOR|1-Day MBSR|One-day condensed MBSR class
62583884|NCT00600561|EXPERIMENTAL|8-week MBSR|8-week Mindfulness-Based Stress Reduction Intervention
62408245|NCT04125498|ACTIVE_COMPARATOR|Placebo plus self-massage|Patients will be submitted to placebo manual treatment and then they will be invited to practice a self-massage at home.
62408246|NCT00616304|ACTIVE_COMPARATOR|A|L-arginine infusion
62408247|NCT00616304|PLACEBO_COMPARATOR|S|Normal saline infusion
62408248|NCT03352544|EXPERIMENTAL|Exercise|Exercise training for 12 weeks (aerobic and resistance training trice a week).
62408249|NCT03352544|NO_INTERVENTION|Usual treatment|Usual treatment during 12 weeks, coinciding with exercise intervention time frame.
62408250|NCT00323362|EXPERIMENTAL|Gemcitabine hydrochloride and imatinib mesylate|
62408251|NCT02328170||EUROIMMUN Allergy|Immunoblot assay
62408252|NCT02328170||ImmunoCap|Fluoroallergosorbent test
62408253|NCT03994991|EXPERIMENTAL|Active TMS|Patients in the active TMS group will receive active TMS 2 times a day for 5 days. In addition, these patients will have MRI before the first TMS session and after the last TMS session.
62408254|NCT03994991|SHAM_COMPARATOR|Sham TMS|Patients in the shamTMS group will receive sham TMS 2 times a day for 5 days. In addition, these patients will have MRI before the first TMS session and after the last TMS session.
62408255|NCT04999137|EXPERIMENTAL|Intravenous vitamin C 1.5g + intravenous vitamin B1|intravenous vitamin C (1.5 grams) every 6 hours for 16 doses in combination with intravenous vitamin B1 (200 mg) every 12 hours
62408256|NCT04999137|EXPERIMENTAL|Intravenous Vitamin C 3g + intravenous vitamin B1|Intravenous vitamin C (3 grams) every 6 hours for 16 doses in combination with intravenous vitamin B1 (200 mg) every 12 hours
62408257|NCT04999137|NO_INTERVENTION|Usual Care|Usual care
62583885|NCT06470022|ACTIVE_COMPARATOR|Medtronic Evolut FX|TAVI procedure performed with Medtronic Evolut FX
62583886|NCT06470022|ACTIVE_COMPARATOR|Edwards Sapien Ultra 3 Resilia|TAVI procedure performed with Edwards Sapien Ultra 3 Resilia
62583887|NCT01356303|EXPERIMENTAL|Cisplatin, Docetaxel|Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of D5W or NS administered as a 1-hour intravenous infusion, followed by cisplatin at dose of 75 mg/m2administered as a 2-hour intravenous infusion every 3 weeks per cycle for 4-6 cycles
62583888|NCT04325022||Primary Total Hip Arthroplasty (THA)|OR3O Dual Mobility System used in primary THA
62583889|NCT04325022||Revision Total Hip Arthroplasty (THA)|OR3O Dual Mobility System used in revision THA
62583890|NCT00200174|ACTIVE_COMPARATOR|A|Raloxifene followed by combination therapy
62583891|NCT00200174|ACTIVE_COMPARATOR|B|Exemestane followed by combination therapy
62583892|NCT06588868||Patients enrolled|Patients affected by Cutaneous T-cell Lymphoma who have received first dose of a systemic therapy, lasted at least 3 months, between 1 January 2016 and 31 December 2021 in a real life setting.
62583893|NCT05063357|OTHER|Radioactive iodine-labeled monoclonal antibody omburtamab|Single arm
62583894|NCT06028802||Visible lesion|Patients where an ischaemic lesion is visible on non-enhanced CT acquired at baseline.
62583895|NCT06028802||Non-visible lesion|Patients where an ischaemic lesion is not visible on non-enhanced CT acquired at baseline.
62583896|NCT00507728|EXPERIMENTAL|Bupropion|Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).
62583897|NCT00507728|EXPERIMENTAL|Varenicline|Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).
62583898|NCT00507728|PLACEBO_COMPARATOR|Placebo|Placebo by mouth for 12 weeks.
62583899|NCT06458335|EXPERIMENTAL|Cognitive-Behavioral Therapy|CBT delivered over the course of 6, \~45 minute sessions delivered via telehealth
62583900|NCT06458335|ACTIVE_COMPARATOR|therapist-delivered Health Education|Health education sessions delivered over the course of 6, \~45 minute sessions delivered via telehealth.
62583901|NCT06458335|ACTIVE_COMPARATOR|self-guided Health Education|Health education sessions that are self-guided over the course of 6 sessions
62583902|NCT06665893|EXPERIMENTAL|Digi-physical treatment in Abu Dhabi|The participants will receive digi-physical treatment using the Evira treatment tool. During the first 2 weeks, participants will receive information about the system and how to utilize the daily weighings and communication system. The families will be informed to perform lifestyle changes that they consider feasible in their specific living situations. The families will get one or two scales, depending on the family situation, and the phone applications installed in the parent's smart phones and, depending on the age of the child, in the child's phone as well. Clinical investigations will be completed and includes physical and abdominal examinations, weight, height, blood pressure and blood sampling. All participants will also be asked to answer questionnaires including quality of life, eating disorders, and treatment satisfaction.
62583903|NCT01188980||NoBE (control)|
62583904|NCT01188980||BE without dysplasia|
62211629|NCT02396329|ACTIVE_COMPARATOR|povidone_iodine based antisepsis|Including cases undergoing elective\&nonelective caesarean section.Patients will be scrubbed preoperative with an applicator that contain 10%povidone-iodine scrub aqueous solution(3 consecutive applications)followed by drying with sterile towel and 3 application of 70% alcohol after one minute The area scrubbed was from the xiphoid to the knee, reaching the midaxillary line laterally. In both groups, patients received preoperative prophylactic i.v antibiotics (cefotrixone 1 gm) one hour before skin incision
62211630|NCT00534144|ACTIVE_COMPARATOR|Iron Sucrose|
62211631|NCT00534144|ACTIVE_COMPARATOR|Ferric Gluconate|
62211632|NCT00834327|EXPERIMENTAL|1|aplindore 0.05 mg MR total daily dose
62211633|NCT00834327|EXPERIMENTAL|2|aplindore 0.1 mg MR total daily dose
62211634|NCT00834327|EXPERIMENTAL|3|aplindore 0.25 mg MR total daily dose (to include short titration)
62211635|NCT00834327|EXPERIMENTAL|4|aplindore 0.5 mg MR total daily dose (to include short titration)
62211636|NCT00834327|PLACEBO_COMPARATOR|5|Placebo
62211637|NCT02739555|ACTIVE_COMPARATOR|1: Percutaneous treatment|Percutaneous treatment of OO is a thermal tumor destruction by radiofrequency or laser photocoagulation performed under CT control with strict aseptic approach and most often under general anesthesia. The introductive needle is inserted toward the nidus. Then the optic fiber or the radiofrequency probe is inserted in the nidus center and thermal destruction of the tumor is obtained.When the distance between the nidus and a nerve or the skin is less than 10 mm, infusion of normal saline or CO2 is introduced as spacing agent. When the nidus is in the subchondral bone, cold normal saline is introduced in the joint to protect the cartilage. In addition, a thermocouple is placed in the epidural or foraminal space to continuously monitor the temperature. A procedure typically required between 1 and 2 h from the time the patient entered the CT unit.
62211638|NCT02739555|EXPERIMENTAL|2: Bisphosphonate treatment|"The treatment consists of 3 infusions of zoledronic acid administered at a monthly interval. Bisphosphonate treatment is considered finished 1 month after the third bisphosphonate infusion (V4 visit). In few cases, the analgesic efficacy provided by 3 bisphosphonate infusions cannot be sufficient: 1 to 3 additional infusions could be proposed to the patient.~Zoledronic acid is supplied as a 4 mg/100 ml solution for infusion. It will be administered as infusion over 30 minutes under the supervision of a nurse. Adults will receive intravenous infusion of 4 mg of zoledronic acid. Children will receive infusion of 0.025 mg/kg of zoledronic acid.~The investigators propose abacus corresponding to zoledronic acid volume to infuse during 30 minutes for children."
62583905|NCT01188980||BE with dysplasia|
62583906|NCT05206253|EXPERIMENTAL|Whole egg powder|Dietary supplementation with whole egg powder after resistance training sessions
62583907|NCT05206253|ACTIVE_COMPARATOR|Whey protein powder|Dietary supplementation with whey protein powder after resistance training sessions
62583908|NCT05206253|PLACEBO_COMPARATOR|Maltodextrin placebo|Dietary supplementation with maltodextrin placebo after resistance training sessions
62583909|NCT01563614|EXPERIMENTAL|Treatment|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
62583910|NCT04161638|EXPERIMENTAL|High Blood Pressure|Ambulatory BP measurement was used to confirm the laboratory BP group classification according to the European Society of Hypertension. Participants were placed in the high blood pressure (HBP) group if they met any of the following criteria: 1) 19-hour average systolic BP/diastolic BP (SBP/DBP) \> 130/80 mmHg, 2) daytime (awake) average SBP/DBP \> 135/85 mmHg, or 3) nighttime (sleep) average SBP/DBP \> 120/70 mmHg.
62583911|NCT04161638|EXPERIMENTAL|Normal Blood Pressure|Participants were placed in the normal BP (NBP) group if they met all of the following criteria: 1) 19-hour average SBP/DBP \< 130/80 mmHg, 2) daytime (awake) average SBP/DBP \< 135/85 mmHg, and 3) night-time (asleep) average SBP/DBP \<120/70 mmHg.
62583912|NCT05811676|EXPERIMENTAL|study group|Intravenous administration of 10 mL (1 g of tranexamic acid) diluted in 40 ml of normal saline, over 10 minutes after umbilical-cord clamping, the routine prophylactic uterotonic administration
62211639|NCT02124603||single group|Patients undergone cataract surgery
62583913|NCT05811676|PLACEBO_COMPARATOR|control group|Intravenous administration of 10 mL placebo (0.9% sodium chloride), diluted in 40 ml of normal saline, over 10 minutes after umbilical-cord clamping, the routine prophylactic uterotonic administration
62583914|NCT00943150|EXPERIMENTAL|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
62583915|NCT00943150|ACTIVE_COMPARATOR|Standard of Care (SOC)|The scalpel and electrocautery will be used for the abdominoplasty procedure.
62583916|NCT03554148||SSI|This group receives an additional swab of the surgical site infection. Follow up is terminated at the occurence of SSI.
62211640|NCT01014208|EXPERIMENTAL|OFATUMUMAB + DHAP CHEMOTHERAPY REGIMEN|This study is a parallel arm study, with ofatumumab + DHAP. The Investigators are required to prospectively choose to treat all of their subjects with either DHAP chemotherapy regimens in combination with ofatumumab. All subjects will receive the same ofatumumab regimen and dose.
62211641|NCT01014208|ACTIVE_COMPARATOR|RITUXIMAB + DHAP CHEMOTHERAPY REGIMEN|This study is a parallel arm study, with rituximab + DHAP. The Investigators are required to prospectively choose to treat all of their subjects with either DHAP chemotherapy regimens in combination with rituximab. All subjects will receive the same rituximab regimen and dose.
62211642|NCT00904046|EXPERIMENTAL|Pioglitazone|For 60 Aim 2 Subjects Only - Pioglitazone (Actos)
62211643|NCT00904046|PLACEBO_COMPARATOR|Placebo|For 60 Subjects in Aim 2 Only - Placebo for Pioglitazone
62211644|NCT00939822|EXPERIMENTAL|Simvastatin|40 mg. Simvastatin/day
62211645|NCT00939822|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62211646|NCT05738824||Healthy Volunteers|18 years old and up
62583917|NCT03554148||No SSI|This group is systematically followed up until 30 days after surgery (one year if a implant is implanted, e.g. mesh) by a third party (www.swissnoso.ch).
62211647|NCT05738824||Patients|greater than 12 years
62583918|NCT06681987|EXPERIMENTAL|simulation|One group of students will practice computer-based simulation for pre-eclampsia and eclampsia case management skills using a high-fidelity simulator (n = 15) (subgroups n=3), while the other group will practice with a low-fidelity model (n = 15; subgroups n=3). In the first stage, the case will be written for the high-fidelity simulator and will be submitted to the opinions of experts in the field. After the necessary arrangements are made, the groups will be randomized and allocated. In the second stage, the experimental group will be presented with a virtual reality simulator, and the control group will be presented with a case example of preeclampsia and eclampsia with a low-level simulator. In order to evaluate and increase the teamwork skills of the students in the experimental and control groups, the students will be divided into subgroups of three.
62583919|NCT06681987|NO_INTERVENTION|control|application will be made in a low reality model
62583920|NCT04687046||Cohort 1 JUVÉDERM VOLUX® with 3D Imaging|Treatment will be determined according to the physician's experience and Directions for Use. Cohort 1 will have follow-up on-site visits, including 3D imaging, at Months 1, 3, 6, and 12.
62583921|NCT04687046||Cohort 2 JUVÉDERM VOLUX®|Treatment will be determined according to the physician's experience and Directions for Use. Cohort 2 will have follow-up on-site visits at Months 1 and 3 and follow-up telephone calls at Months 6 and 12.
62583922|NCT05390242||Smoking Patients with Dental Implantes|Smoking Patients rehabilitated with dental implants at the Dentistry Hospital of the University of Barcelona (Campus of Bellvitge).
62583923|NCT05390242||Non-Smoking Patients with Dental Implantes|Non-Smoking Patients rehabilitated with dental implants at the Dentistry Hospital of the University of Barcelona (Campus of Bellvitge).
62583924|NCT04505072|EXPERIMENTAL|PR-ESSENCE treatment|PR-ESSENCE treatment 10 weeks
62583925|NCT04505072|ACTIVE_COMPARATOR|Control|Treatment as usual 10 weeks
62583926|NCT01940887|EXPERIMENTAL|E10030 + bevacizumab or aflibercept|E10030 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection
62583927|NCT01940887|ACTIVE_COMPARATOR|Sham + bevacizumab or aflibercept|E10030 sham injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection
62211648|NCT06611878|EXPERIMENTAL|Intensive followed by minimal music training|"Music training conducted by a trained instructor (music therapist or music educator):~2 sessions per week for 5 months (intensive); no intervention for 2 months (washout period);~1 session per month for 5 months (minimal)."
62211649|NCT06611878|EXPERIMENTAL|Minimal followed by intensive music training|"Music training conducted by a trained instructor (music therapist or music educator):~1. session per month for 5 months (minimal); no intervention for 2 months (washout period);~2. sessions per week for 5 months (intensive)."
62583928|NCT05337306|EXPERIMENTAL|GogyUp|"Participants in the GogyUp arm will have the GogyUp Reader app preloaded on a cellular-enabled tablet with the same patient education documents as the Control arm. Patients will be able to use on-demand / in-the-moment assistive-reading technologies to understand any word or phrase:~* Speech-to-Text~* Word-by-Word Translation~* Alternative Formatting~* Simplified and Contextualized Definitions~* No-Fail Comprehension Questions~* Personalized Training in Phonemic Awareness"
62583929|NCT05337306|NO_INTERVENTION|Control|Participants in the Standard Care arm will receive the standard after-visit patient education documents the clinics current provide for type 2 diabetes education and self-management.
62583930|NCT06574789|ACTIVE_COMPARATOR|Control: standard dosing|"Enrolled participant will receive standard dosing of IV Ganciclovir dependent on renal function:~* CrCl \>/= 70mL/min: 5 mg/kg IV 12 hourly~* CrCl \>/= 50-69: 2.5 mg/kg/ IV 12 hourly~* CrCl \>/= 25-49: 2.5 mg/kg IV 24 hourly"
62583931|NCT06574789|ACTIVE_COMPARATOR|Intervention: individualised dosing using a web app|Enrolled participant will receive a personalised dosing of IV Ganciclovir calculated using an individualised IV ganciclovir dosing app, that considers the patient's weight, creatinine level, and at a target drug exposure (AUC24 between 40-100 mg.h/L), allowing for tailored dosing based on individual pharmacokinetic parameters.
62583932|NCT00747370|OTHER|1|16 healthy volunteers with no complaints of urinary symptoms and without urogenital prolapse of more than first degree.
62583933|NCT00747370|OTHER|2|Forty two stress urinary incontinence patients without prior urogenital prolapse or incontinence operation and without genital prolapse more than first degree
62583934|NCT00747370|OTHER|3|16 genital prolapse women without prior prolapse operations or any symptoms of incontinence
62583935|NCT06320717||Patients with Borderline Resectable (Cohort A)|Pathological response of Patients with borderline resectable disease (per NCCD Criteria) treated with standard care chemotherapy
62583936|NCT06320717||Patients with Resectable (Cohort B)|Pathological response of Patients with resectable disease (per NCCN criteria) treated with standard care chemotherapy
62583937|NCT01366703||heart failure patients|stable heart failure patients, NYHA 1-2, EF \> 35%, no AF, No OAC, CHADS score \>2
62019678|NCT05927129|EXPERIMENTAL|combination of medication therapy and Interpersonal Psychotherapy group|Patients randomized to this group will receive standardized treatment with antidepressant medications according to clinical guidelines. The participants will also receive standardized IPT treatment for 12 weeks. IPT therapists have received training from IPT workshops in both China and the United States and obtained the corresponding certifications. IPT therapists focus on the interpersonal domains associated with the onset and maintenance of depression. They guide clients in identifying the connections between their emotional changes and interpersonal difficulties, exploring problems, actively seeking potential interpersonal support and assistance, improving interpersonal skills, helping clients alleviate symptoms, enhance their quality of life, and adapt better to society.
62019679|NCT01538875|EXPERIMENTAL|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes (Maximum number of doses: 3).
62019680|NCT01538875|ACTIVE_COMPARATOR|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
62019681|NCT03495960|EXPERIMENTAL|Lenalidomide (experimental arm of part A)|"Patients in part A will receive 2 courses of induction chemo-immunotherapy:~Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11.~The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy.~Lenalidomide is given 25 mg/d per os, days 1 to 21 every 4 weeks for 24 courses"
62211650|NCT02124447|ACTIVE_COMPARATOR|PEG+E|Split dose 4 liter polyethylene glycol with electrolytes
62583938|NCT04197336|SHAM_COMPARATOR|Control Arm|27 participants enrolled in the procedure arm. Participants randomized to the control arm will follow the same screening. Pre-procedure assessment will take the same pre-procedure meds. Procedure day, interventional radiologist will determine radial or groin access. After the participant and procedure area are prepped, participants will be under standard moderate sedation medications; all participants will receive lidocaine \& a skin nick to their groin or their wrist as determined by the operating physician. Participant will have a blind fold placed \& their hearing damped either with ear plugs or noise cancelling headphones. Participants randomized to the control arm will not receive other procedural intervention. Procedural team will follow a prescribed simulated protocol. Participants randomized to the control arm will be given under skin lidocaine and receive a skin nick on the wrist or groin.
62211651|NCT02124447|ACTIVE_COMPARATOR|PEG+Asc|Split dose 2 liter polyethylene glycol with ascorbic acid
62211652|NCT02124447|ACTIVE_COMPARATOR|P+MC|Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid
62211653|NCT02124447|ACTIVE_COMPARATOR|sulfate|Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution
62019682|NCT03495960|ACTIVE_COMPARATOR|Procarbazine (comparator arm of part A)|"Patients in part A will receive 2 courses of induction chemo-immunotherapy:~Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11.~The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy.~Procarbazine is given 100 mg/d per os, days 1 to 5 every 4 weeks for 6 courses"
62019683|NCT03495960|OTHER|Radiotherapy, temozolomide and rituximab (single arm part B)|"Patients ineligible for high-dose-methotrexate will be treated in the single-arm phase II part B of the trial and will receive~* whole-brain radiotherapy (2340 cGy in 5 weekly fractions)~* temozolomide 75 mg/m2/d during radiotherapy~* 4 weekly doses of rituximab 375 mg/m2, starting on day 2 of the whole-brain radiotherapy.~Patients will then receive maintenance therapy with 12 courses of temozolomide administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses."
62019684|NCT03771729|EXPERIMENTAL|LCZ696 treatment|LCZ696 200mg twice daily
62211654|NCT04509037||Liposuction Assisted Breast Reduction|
62211655|NCT04509037||Open Incision Breast Reduction|
62583939|NCT04197336|ACTIVE_COMPARATOR|Bariatric Embolization Procedure|27 subjects will be enrolled in the bariatric embolization(BM) procedure arm. BM procedure will be performed under moderate sedation. Procedure will take 1.5 hr to 3 hr subject will be placed on the X-ray fluoroscopy table. Radial or femoral vascular access will be achieved using a small gauge needle, dilated over a guidewire to accommodate a 5 French vascular sheath. Standard catheters, 3 dimensional imaging will be acquired of the stomach, the arteries supplying the fundus arising off the celiac vessel. Microcatheter into the left gastric and/or gastroepiploic arteries supplying the fundus and small calibrated spheres will be infused until stasis of anterograde arterial flow is achieved, with particular care to avoid infusion of non-target arteries. The left gastric and/or gastroepiploic arteries will be embolized. Repeat 3 dimensional imaging: assess bead distribution and fundal coverage. Subject will be monitored in the recovery room and will be observed overnight.
62583940|NCT06091917|SHAM_COMPARATOR|Control group|Use of unmodified infant formula for 12 weeks
62583941|NCT06091917|EXPERIMENTAL|Betaine supplementation group|Use of infant formula supplemented with betaine (final concentration of 100 µmol/L) for 12 weeks
62583942|NCT01167673|ACTIVE_COMPARATOR|treatment with study drug|patients receiving study drug for 4 weeks. 3 capsules a day of coltect
62583943|NCT01167673|PLACEBO_COMPARATOR|placebo|patients receiving similar capsules but no active ingredients
62583944|NCT04166344|EXPERIMENTAL|Intervention Group|Participants in the IG will be given free access to the HappyAir platform during a 6-month period. This platform combines online/offline content to help patients with chronic respiratory diseases monitor their symptoms and improve self-management. In addition to tailored information on their condition, participants will be encouraged to fill in daily data on their physical activity levels, symptomatology, use of rescue medication and mood. In children under 12 years, parents or caregivers will fill in this information. Patients will be asked to record their peak expiratory flow using an electronic peak flow meter twice daily. Every patient will be assigned a respiratory coach who will monitor patient during the study and whom the patients can contact at any time.
62583945|NCT04166344|NO_INTERVENTION|Control Group|Subjects in the CG will receive standard care consisting of periodic visitations at the Allergology or Paediatric Pulmonology Unit in their respective hospitals every 4 - 8 weeks according to their physician's criteria. In addition, patients and caregivers in both groups will receive one educational session regarding the correct use of their inhalers.
62019685|NCT04897048|EXPERIMENTAL|Oxygen|Supplemental oxygen will be applied via a mask during CPET
62019686|NCT04897048|SHAM_COMPARATOR|Air|Sham ambient air will be applied via mask during CPET
62211656|NCT00063531||GeneSTAR participant meeting entry criteria|Healthy siblings of patients with early onset CAD (\<60 years old) and the adult offspring of the siblings or probands
62211657|NCT00106210|EXPERIMENTAL|1|Behavioral Intervention (experimental)
62211658|NCT00106210|ACTIVE_COMPARATOR|2|Behavioral Intervention 2
62211659|NCT04260048||Normal weight|Group defined based on BMI percentile for age and sex.
62211660|NCT04260048||Overweight|Group defined based on BMI percentile for age and sex.
62211661|NCT04260048||With obesity|Group defined based on BMI percentile for age and sex.
62211662|NCT06729307|EXPERIMENTAL|oral ondansetron and dyclonine hydrochloride mucilage|
62211663|NCT06729307|OTHER|dyclonine hydrochloride mucilage only|Patients are treated with only topical pharyngeal anesthesia (dyclonine hydrochloride mucilage to be gurgled 15 minutes prior to endoscopic process), with no antiemetic drug or placebo.
62211664|NCT06533358|EXPERIMENTAL|MT1002 Injection|MT1002 is infused once only, once for 4h
62211665|NCT01145209|EXPERIMENTAL|FO Arm (fludarabine and ofatumumab)|For patients with non-high risk FISH changes
62211666|NCT01145209|EXPERIMENTAL|FCO Arm (fludarabine, cyclophosphamide, and ofatumumab)|For patients with high risk FISH changes
62211667|NCT00920075||1 Alendronate for 12 months, post study|Participants earlier were treated with alendronate for 12 months either in an open label study (without control) or double blind study with placebo control. These studies were completed. In this post study evaluation, available participants will be scheduled for one clinic visit to assess their current status of the bone density and no treatment is involved.
62583946|NCT03064815|EXPERIMENTAL|Spondylarthropathies with GI symptoms|Subjects in this arm will have spondylarthropathies and gastrointestinal symptoms and will undergo a colonoscopy, videocapsule endoscopy, biomarker testing (PROMETHEUS® IBD sgi Diagnostic™ and fecal calprotectin)
62583947|NCT03064815|EXPERIMENTAL|Spondylarthropathies without GI symptoms|Subjects in this arm will have spondylarthropathies without gastrointestinal symptoms and will undergo a colonoscopy, videocapsule endoscopy, biomarker testing (PROMETHEUS® IBD sgi Diagnostic™ and fecal calprotectin)
62583948|NCT02504853||Affected Genetic|Have a suspected genetic or congenital disorder potentially associated with food allergy or related condition, as determined by the principal investigator (PI) or associate investigators (AIs).
62583949|NCT02504853||Affected Non-Syndromic Food|Individuals with a clinical history of immediate hypersensitivity reaction to foods and sensitized to food allergen(s) as evidenced by SPT or allergen-specific IgE testing.
62583950|NCT02504853||Allergic GI Disease|Individuals with a diagnosis or clinical suspicion of eosinophilic esophagitis (EoE), as determined by the principal investigator (PI) or associate investigators (AIs).
62019687|NCT06300645|EXPERIMENTAL|SPLATT|Children with congenital talipes who have been treated with split tibialis anterior tendon transfer to peroneus brevis
62019688|NCT06300645|EXPERIMENTAL|TATT|Children with congenital talipes who have been treated with total ribialis anterior tendon transfer to lateral cuneiform
62583951|NCT02504853||Unaffected Relative / Healthy Volunteer|Unaffected relatives are relatives of affected; unaffected by food allergy or the genetic condition under study. Healthy volunteers are not related to affected and serve as controls.
62583952|NCT04240626|ACTIVE_COMPARATOR|Standard of Care|The group will receive the standard of care pain control protocol after index Bariatric Surgery which includes the use of a PCA (patient controlled analgesia) with Dilaudid or Morphine Sulphate, transitioning to oral narcotic based pain control medications.
62583953|NCT04240626|EXPERIMENTAL|Multi-Modal|Patients will receive Gabapentin pre-operatively on-call 120 minutes prior to surgery starting. Patients at the conclusion of surgery will have additional doses of Ofirmev (IV Tylenol) and Gabapentin via IV based on patients pre-operative weight. Post surgery the patient will be transitioned to oral pain medications (Tylenol and Gabapentin) with rescue medications available for breakthrough pain control.
62583954|NCT04676451|EXPERIMENTAL|Femto-AK Patients|Femtosecond laser assisted cataract surgery with creation of astigmatic keratotomies for the correction of corneal astigmatism.
62583955|NCT02571842|EXPERIMENTAL|Rituximab|"Drug: Rituximab~•Rituximab 375 mg/m2 on treatment month 1, 2, 3, 4~Other Name: Mabthera"
62019689|NCT01778192|ACTIVE_COMPARATOR|Same day PEG|group 1 (same day PEG, N=50) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
62019690|NCT01778192|ACTIVE_COMPARATOR|split PEG|group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
62019691|NCT01778192|ACTIVE_COMPARATOR|SPMC 2|group 3 (SPMC 2, N=50) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
62019692|NCT01778192|ACTIVE_COMPARATOR|SPMC 3|group 4 (SPMC 3, N=50) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
62019693|NCT00856856|EXPERIMENTAL|Absorb stent|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)
62583956|NCT02571842|ACTIVE_COMPARATOR|ACEI/ARB plus corticosteroids|"Drug: ACEI/ARB~* An ACEI and /or ARBs will be used to achieve proteinuria reduction and a blood pressure goal of \<130/80 mmHg. Patients not attaining the target blood pressure with an ACEI or ARB alone should be treated with the combination of ACEI + ARB~* Corticosteroids will be used as prednisolone 0.5 mg/kg/day with gradually taper off in 6-8 weeks to 5mg/day daily~Other Name: Enalapril, Lorsartan, Prednisolone"
62583957|NCT04644926|EXPERIMENTAL|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is performed at inclusion and repeated 12 h and 24 h later.
62583958|NCT03660774||Patients with hemophilia|Children and young adults with hemophilia A or B, all severities, treated in the hemophilia treatment center (comprehensive care) setting, including participation of caregivers/parents completing questionnaires designed to evaluate neurologic, neurocognitive and neurobehavioral function and development.
62019694|NCT00930358|EXPERIMENTAL|MEOPA|MEOPA : equimolar nitrous oxide/oxygen mixture
62019695|NCT00930358|ACTIVE_COMPARATOR|General anesthesia|Gold standard
62019696|NCT04620317|ACTIVE_COMPARATOR|Synbiotic|The product contained three clinically studied active ingredients namely inulin-oligofructose (prebiotic; derived from chicory root), at least 6 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01 (probiotic) and 4 B CFU of Bifidobacterium lactis BB12 (probiotic) per sachet.
62019697|NCT04620317|PLACEBO_COMPARATOR|Placebo|Placebo contains only maltodextrin without any active ingredients, equally same in physical form, freeze-dried white powder with characteristic odor and water soluble as the synbiotic supplement.
62211668|NCT04234919||Consented adult lung transplant recipients|
62211669|NCT00710021|EXPERIMENTAL|vitamin D3 2000 IU|Participants in this arm take a vitamin D3 dose of 2000 international units (IU) daily by mouth for a duration of 12 weeks.
62583959|NCT03688178|EXPERIMENTAL|Gr1: DC vaccine (DC pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m\^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 1 patients will receive autologous unpulsed DC vaccines administered to a single side of the groin and saline administered to the contralateral side the day prior to the 4th DC vaccine as pre-conditioning.
62211670|NCT00710021|EXPERIMENTAL|vitamin D3 4000 IU|Participants in this arm take a vitamin D3 dose of 4000 international units (IU) daily by mouth for a duration of 12 weeks.
62211671|NCT00710021|PLACEBO_COMPARATOR|vitamin D3 placebo|Participants in this arm take a vitamin D3 placebo daily by mouth for a duration of 12 weeks.
62211672|NCT06727682|EXPERIMENTAL|Remote stress management programme|Ten-hour, three-course stress management programme with a psychologist via video conferencing over 2 months
62211673|NCT06727682|NO_INTERVENTION|Waiting list|No intervention during the study duration. However, after the end of the study, after the last evaluations, participants in this control cluster will be offered the opportunity to follow the stress management programme.
62019698|NCT06533514||mild|According to the APACHE II score, SOFA score and PSI score, the enrolled patients were divided into three groups: mild, moderate and severe.
62211674|NCT01244529|OTHER|galy A Plus/ galy A / seno A|"Pair 1: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8)."
62583960|NCT03688178|EXPERIMENTAL|Gr2: DC Vaccine (Td pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m\^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 2 patients will receive a single dose of Td toxoid administered to a single side of the groin and saline administered to the contralateral side the day prior to the 4th DC vaccine, which is always given bilaterally at the groin site.
62583961|NCT03688178|EXPERIMENTAL|Gr3:DC Vaccine+varlilumab(Td pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m\^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 3 patients will receive the first 3 DC vaccines every 2 weeks, same as Groups 1 and 2, but they will also receive varlilumab intraveneously (IV) 7 days before vaccine #1 and again at the same visit as vaccine #1, as well as 7 days before every DC vaccine except vaccine #2. Prior to the 4th vaccine, patients will receive a single dose of Td toxoid administered to a single side of the groin and saline administered to the contralateral side.
62583962|NCT01280032|EXPERIMENTAL|Kypho-IORT|
62211675|NCT01244529|OTHER|galy A Plus / seno A / galy A|"Pair 1: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 3: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
62211676|NCT01244529|OTHER|galy A / galy A Plus / seno A|"Pair 1: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8)."
62211677|NCT01244529|OTHER|galy A / seno A / galy A Plus|"Pair 1: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 3: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
62211678|NCT01244529|OTHER|seno A / galy A / glay A Plus|"Pair 1: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 2: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
62211679|NCT01244529|OTHER|seno A / galy A Plus / galy A|"Pair 1: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 2: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: galy A -subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
62211680|NCT05694013|EXPERIMENTAL|Cohort A - Arm 1|Participants with metastatic non-small cell lung carcinoma (mNSCLC), extensive-stage small-cell lung carcinoma (ES-SCLC), and advanced or unresectable hepatocellular carcinoma (HCC) and who are prescribed an anticancer regimen including intravenous (IV) atezolizumab will use the Roche Digital Patient Monitoring (DPM) Module along with local standard of care (SOC) support.
62211681|NCT05694013|EXPERIMENTAL|Cohort A - Arm 2|Participants with mNSCLC, ES-SCLC, and HCC who are prescribed an anticancer regimen including IV atezolizumab will receive local SOC support.
62211682|NCT05694013|EXPERIMENTAL|Cohort B|Participants with resected Stage IIB-IIIB NSCLC will use the Roche DPM Module along with subcutaneous (SC) atezolizumab in both the hospital and flexcare (home) setting.
62211683|NCT05955300|EXPERIMENTAL|Training program and nutrition therapy|The intervention group receive the GLA:D® training program for 6 weeks and a nutrition therapy for 9 months.
62211684|NCT05955300|ACTIVE_COMPARATOR|Training program|The control group receive GLA:D® training program for 6 weeks and general information regarding a healthy life style for 9 months.
62211685|NCT04367259|ACTIVE_COMPARATOR|Single puncture arthrocentesis (SPA) group|Patients presenting temporomandibular joint disc displacement without reduction (DDwoR) treated with single puncture arthrocentesis
62408258|NCT06357065|EXPERIMENTAL|MOV-ES group|The design of the intervention requires incorporating content that involves intrapersonal (benefits of active transportation and safety on the way to school), interpersonal (family safety), organizational, community, physical-environmental, and political (safety, infrastructure, quality) factors. It will consist of weekly sessions of 60 to 90 minutes each for 16 weeks. The complete program has a duration of 4 months, during school hours in the subject of Physical Education, and on the premises of each establishment. The contents to be worked on will be organized in a Didactic Unit and will include the presentation of graphic and audiovisual material and practical contents. Each session will be designed based on the results of PHASE 1 of the study, following the recommendations of active transport interventions in schoolchildren , and the material available from the PACO Project.
62408259|NCT06357065|NO_INTERVENTION|Control group|The CG students will participate in the initial and final measurement, but will not receive any intervention, attending their traditional Physical Education classes.
62583963|NCT05929768|ACTIVE_COMPARATOR|Arm I (usual chemo-immunotherapy)|Patients receive paclitaxel IV, carboplatin IV, and pembrolizumab IV on study. Patients then receive doxorubicin IV, cyclophosphamide IV, and pembrolizumab IV on study. Patients then undergo surgery. Patients may receive pembrolizumab after surgery. Patients may optionally undergo collection of blood samples throughout the trial.
62408260|NCT05572944||Never smoker with lung cancer high risk assessment|High risk: above the median of the initial risk model from retrospective study
62583964|NCT05929768|EXPERIMENTAL|Arm II (shorter chemo-immunotherapy)|Patients receive docetaxel IV, carboplatin IV, and pembrolizumab IV on study. Patients then undergo surgery. Patients may receive pembrolizumab after surgery. Patients may optionally undergo collection of blood samples throughout the trial.
62211686|NCT04367259|ACTIVE_COMPARATOR|Double puncture arthrocentesis (DPA) group|Patients presenting temporomandibular joint disc displacement without reduction (DDwoR) treated with double puncture arthrocentesis
62211687|NCT05651152|EXPERIMENTAL|JZP441|Participants who will be randomized to receive an oral dose of JZP441.
62211688|NCT05651152|PLACEBO_COMPARATOR|Placebo|Participants who will be randomized to receive an oral dose of placebo.
62211689|NCT02271776|ACTIVE_COMPARATOR|Galactooligosaccharide|5g 3x per day for 12 weeks
62408261|NCT05572944||Never smoker with lung cancer low risk assessment|Low risk: below the median of the initial risk model from retrospective study
62408262|NCT03250611|EXPERIMENTAL|Occipito-Cervical Instability|Stabilization of the occipito-cervical junction by Occipital Condyle Screw (OCS) as a sole cranial anchor, with posterior bone graft.
62408263|NCT03047512|EXPERIMENTAL|Internet-based program|The internet based program includes the following modules: (1) information and psychoeducational material, (2) symptom monitoring with personalized automatic feedback, (3) forum (peer support moderated by mental health professionals) and (4) chat (individualized support by mental health professionals). It also considers (5) the referral to face-to-face treatment of cases with symptoms that require it. (6) In addition to the web page in the institutions, there will be a monthly health promotion booth during breaks.
62583965|NCT06684665||Healthy group|The healthy subjects were subjects without back pain
62583966|NCT06684665||Acute low back pain group|The acute low back pain group was defined as those with low back pain that lasted less than three months
62583967|NCT06684665||Chronic low back pain group|The chronic low back pain group was the subjects with low back pain, and the duration was greater than or equal to three months
62019699|NCT06533514||moderate|According to the APACHE II score, SOFA score and PSI score, the enrolled patients were divided into three groups: mild, moderate and severe.
62019700|NCT06533514||severe|According to the APACHE II score, SOFA score and PSI score, the enrolled patients were divided into three groups: mild, moderate and severe.
62211690|NCT02271776|PLACEBO_COMPARATOR|maltodextrin|3x per day for 12 weeks (isocaloric to intervention)
62211691|NCT00490724|EXPERIMENTAL|Nesiritide (1+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
62211692|NCT00490724|EXPERIMENTAL|Nesiritide (2+0.005)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
62211693|NCT00490724|EXPERIMENTAL|Nesiritide (2+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
62211694|NCT04687059|EXPERIMENTAL|PQ Grass Standard Dosing Regimen|Cumulative dose 27600 SU
62211695|NCT04687059|EXPERIMENTAL|PQ Grass Alternative Dosing Regimen|Cumulative dose 27600 SU
62211696|NCT04687059|PLACEBO_COMPARATOR|Placebo Option 1|Suspension for injection
62583968|NCT04653246|EXPERIMENTAL|Isa-RVD|"The main study consists of 4 phases a) 28-day screening phase; b) an induction phase inclusive of two 42-day induction treatment cycles: Isatuximab (IV), Bortezomib (SQ). Lenalidomide (PO), Dexamethasone; c) Followed by stem cell mobilization (at the discretion of the Principal Investigator \[PI\]);d) Participants will proceed with either autologous stem cell transplant or two additional induction cycles.~- Induction will be followed by a maintenance phase that continues until disease progression."
62583969|NCT02065375|EXPERIMENTAL|Omaveloxolone Ophthalmic Suspension 1.0%|Patients will receive a single drop of Omaveloxolone Ophthalmic suspension 1.0% instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery
62583970|NCT02065375|EXPERIMENTAL|Omaveloxolone Ophthalmic Suspension 0.5%|Patients will receive a single drop of Omaveloxolone Ophthalmic suspension 0.5% instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery
62211697|NCT04687059|PLACEBO_COMPARATOR|Placebo option 2|Solution for injection
62211698|NCT06728969|EXPERIMENTAL|ADHD group|Subjects will be evaluated for ADHD using clinically established reference standard interviews and psychometric tools with demonstrated validity, including the K-SADS and ADHD-RS-5, in accordance with DSM-5 criteria. IQ will be estimated using two subtests of the WASI.
62211699|NCT06728969|EXPERIMENTAL|Non-ADHD group|Subjects will be evaluated using clinically established reference standard interviews and psychometric tools with demonstrated validity, including the K-SADS and ADHD-RS-5, in accordance with DSM-5 criteria. IQ will be estimated using two subtests of the WASI.
62211700|NCT04532229|EXPERIMENTAL|Experimental|Nimotuzumab+CRT(concurrent IMRT and TMZ)
62583971|NCT02065375|PLACEBO_COMPARATOR|Placebo|Patients will receive a single drop of vehicle for Omaveloxolone Ophthalmic suspension was instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery
62583972|NCT03025815|EXPERIMENTAL|Intervention group|Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.
62211701|NCT05388929|EXPERIMENTAL|primary ventral hernia repair or inguinal hernia repair|"Primary ventral hernias, including umbilical, epigastric, and Spigelian hernias.~Primary or recurrent inguinal hernias."
62211702|NCT05388929|EXPERIMENTAL|open or robotic ventral hernia repair outpatient|Open repair of ventral incisional hernias. Robotic repair of ventral primary or incisional hernias.
62211703|NCT05388929|EXPERIMENTAL|open or robotic hernia repair inpatient|Open repair of ventral incisional hernias. Robotic repair of ventral primary or incisional hernias.
62211704|NCT02627092|EXPERIMENTAL|Copper linen exposure|"Subjects will use copper linens during their hospital stay, consisting of copper hospital gowns, copper bed sheets (top and bottom sheets), and copper pillow covers.~A subset of 50 subjects from this arm will be recruited to provide three types of swabs to calculate the microbial burden on copper linens. Linen swabs, anatomical swabs and environmental swabs will be collected from subjects and subject hospital rooms will be collected to do bacteria counts."
62211705|NCT02627092|NO_INTERVENTION|Non-copper linen exposure|"Subjects will not have exposure to copper linens during their hospital stay. They will use the usual hospital linens provided by hospital, not containing copper.~A subset of 50 subjects from this arm will be recruited to provide three types of swabs to calculate the microbial burden on copper linens. Linen swabs, anatomical swabs and environmental swabs will be collected from subjects and subject hospital rooms will be collected to do bacteria counts."
62211706|NCT00955253|EXPERIMENTAL|Guanfacine (Day 2) then Placebo (Day 4)|All patients received a single dose of guanfacine on Day 2 and a single dose of placebo on Day 4.
62408264|NCT03047512|NO_INTERVENTION|Control Group|The control group will receive two psychoeducational workshops / conferences. In addition, the adolescents in the control group can participate in the monthly health promotion booths offered by the program.
62408265|NCT02127021|EXPERIMENTAL|Norzyme® 40000 IU|Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
62408266|NCT02127021|PLACEBO_COMPARATOR|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal. The formulation and the form of placebo is same with the Norzyme® 40000 IU. Placebo contains microcrystalline cellulose as the main component, titanium oxide, colloidal silica, yellow iron oxide, brown iron oxide, black iron oxide, magnesium stearate, triethyl citrate, talc, and simethicone emulsion in very small amount
62408267|NCT03910439|EXPERIMENTAL|1/Avelumab 800 mg intravenous (IV) every two weeks in combination with radiation therapy|Avelumab 800 mg IV every two weeks in combination with radiation therapy
62583973|NCT03025815|SHAM_COMPARATOR|Control group|sham stimulation program consists of the same researcher placing her hands for 15 minutes.
62583974|NCT05182112|EXPERIMENTAL|Radiation Therapy (RT) and Chemotherapy|Upon enrollment in the study, patients will undergo radiation simulation. Protocol therapy will start upon completion of RT planning (1-2 weeks). Chemoradiation will be initiated 1-2 weeks later depending on RT planning and consist of whole liver irradiation (WLI).
62211707|NCT00955253|EXPERIMENTAL|Placebo (Day 2) then Guanfacine (Day 4)|All patients received a single dose of placebo on Day 2 and a single dose of guanfacine on Day 4.
62211708|NCT05881252||Traditional clinical blood pressure threshold of SBP >= 160 mmHg for acute treatment of hypertension|
62211709|NCT05881252||Updated clinical blood pressure threshold of SBP >= 180 mmHg for acute treatment of hypertension|
62211710|NCT03561662|ACTIVE_COMPARATOR|Low isoflavone|Alpro soya drinks containing 10 mg isoflavones per day
62211711|NCT03561662|ACTIVE_COMPARATOR|Medium isoflavone|Alpro soya drinks containing 35 mg isoflavones per day
62734511|NCT04976881|NO_INTERVENTION|Usual Care|Usual care includes: 1) no specific materials to promote medication reconciliation, reproductive planning, or patient education on diabetes self-management within the context of preconception care, 2) variable physician preconception counseling without any EHR notifications or counseling support; and 3) no specific patient support or prompts to promote healthy behaviors post-visits.
62583975|NCT05239000|EXPERIMENTAL|geriatric co-management|Geriatric co-management involves a consultation with a geriatrician prior to initiating head and neck radiation and chemotherapy. Consultation with geriatricians can occur in-person or remotely via telemedicine. During this visit, the geriatrician will review the results of the eRFA and create a plan to manage geriatric deficits. Geriatric co-management involves optimization of comorbid conditions, management of polypharmacy, and supportive care referrals to address geriatric deficits. Geriatricians also work in conjunction with the treating oncologists to ensure patients have appropriate pain management and bowel regimens. Additional follow up visits after the initial consultation are at the discretion of the geriatrician may vary between patients depending on the clinical need.
62583976|NCT05239000|EXPERIMENTAL|geriatric guided supportive care|Geriatric guided supportive care will be carried out by oncologists. After the patient completes the eRFA, an automated report is generated that identifies the patient's geriatric deficits. The automated report also includes suggested interventions for each deficit (e.g, referral to physical therapy. For instance, automated suggestions for a patient with a history of falls include consultation with physical therapy, neurologic evaluation, a home safety evaluation, or use of supportive devices. Automated recommendations for patient with high level of distress or depression include referral to psychiatry or social work, involvement in a cancer support group, or additional time spent addressing questions and fears. The oncology team will review the automated report from the eRFA and create an intervention plan prior to initiation of head and neck radiation and chemotherapy.
62583977|NCT01964196|EXPERIMENTAL|ASP1517 low dose group|Oral
62583978|NCT01964196|EXPERIMENTAL|ASP1517 middle dose group|Oral
62583979|NCT01964196|EXPERIMENTAL|ASP1517 high dose group|Oral
62211712|NCT03561662|ACTIVE_COMPARATOR|High isoflavone|Alpro soya drinks containing 60 mg isoflavones per day
62583980|NCT01964196|PLACEBO_COMPARATOR|Placebo group|Oral
62583981|NCT03127735|EXPERIMENTAL|BAY1436032|"Dose escalation:~Various doses of study drug will be tested on a small number of patients/dose with the goal of identifying the most appropriate dose(s) for further evaluation in dose expansion. The MTD of the study drug may or may not be identified. It is anticipated that 3-4 patients will be treated at each dose of study drug to be tested and that 15-20 total patients will be treated in this part of the trial.~Dose expansion:~Up to 2 different doses of study drug will be tested on up to 30 patients/dose with the goal of identifying the most appropriate RP2D for further clinical development. The doses to be evaluated in this part of the trial will be selected based on information obtained during dose escalation."
62583982|NCT05076032|EXPERIMENTAL|OXO-001 200 mg|Two tablets of 100 mg have to be taken once daily in the early morning.
62583983|NCT05076032|EXPERIMENTAL|OXO-001 300 mg|Two tablets of 150 mg have to be taken once daily in the early morning.
62583984|NCT05076032|PLACEBO_COMPARATOR|Placebo|Two tablets have to be taken once daily in the early morning.
62583985|NCT06513143||Virtual reality surgery|The investigators have completed the translation of personalized 3D models from CT images into virtual 3D models displayed on VR glasses using Synapse (Fujifilm). Additionally, the investigators can illustrate reference CT scans, chart summaries, laboratory data, and other medical information within the VR environment.
62211713|NCT00759005|EXPERIMENTAL|A, 4|
62211714|NCT06299800||Diabetes mellitus type 2 and cancer|779 patients with cancer and diagnosis of type 2 diabetes mellitus diagnosed between 1990 and 2010
62211715|NCT01252602||Prenatally depressed|Women who tested positive for prenatal depression with a score of \> 12 on the Edinburgh Postnatal Depression Scale
62211716|NCT01252602||Not Prenatally Depressed|Women who tested not depressed on the prenatal depression scale with a score \< 13
62583986|NCT05269173|ACTIVE_COMPARATOR|Active group(low dose group)|Take 5 tablets each time (including 3 tablets of study drug and 2 tablets of placebo), 3 times a day, a total of 2.7g per day. Take it with warm water half an hour before meals.
62583987|NCT05269173|ACTIVE_COMPARATOR|Active group(high dose group)|Take 5 tablets of the study drug each time, 3 times a day, a total of 4.5g per day. Take it with warm water half an hour before meals.
62583988|NCT05269173|PLACEBO_COMPARATOR|Control group|Take 5 tablets of the control drug (placebo) each time, 3 times a day, 4.5g a day. Take it with warm water half an hour before meals.
62583989|NCT06160895|EXPERIMENTAL|TQ-A3334 tablets (once a day)|TQ-A3334 tablets, administered once a day.
62583990|NCT06160895|PLACEBO_COMPARATOR|TQ-A3334 placebo tablets (once a day)|TQ-A3334 placebo tablets, administered once a day.
62583991|NCT06160895|EXPERIMENTAL|TQ-A3334 tablets (every other day)|TQ-A3334 tablets, administered once every other day.
62211717|NCT00831129|ACTIVE_COMPARATOR|Simvastatin + Placebo Rosiglitazone|Subjects will receive 40 mg Simvastatin + 1 tab Placebo Rosiglitazone daily
62211718|NCT00831129|ACTIVE_COMPARATOR|Simvastatin + rosiglitazone|Subjects will receive 40 mg Simvastatin + 4 mg Rosiglitazone once daily
62211719|NCT04719546||NEC Group|All Premature Neonates born in Nancy and Lyon over 10 years and presenting with Necrotizing Enterocolitis
62211720|NCT04719546||Control Group|All Premature Neonates born in Nancy and Lyon over 10 years without Necrotizing Enterocolitis throughout the neonatal period
62408268|NCT03564678|EXPERIMENTAL|Treatment (levocarnitine, vitamin B complex)|Patients receive levocarnitine IV over 2-3 minutes every 6 hours up to 4 times a day (inpatient) or PO TID (outpatient). Patients also receive vitamin B complex PO BID. Treatment continues for up to 30 days after the last dose of either PEG-asparaginase or inotuzumab, or until Tbili of ≤ 1.5 x ULN or at least a 50% reduction in peak Tbili is achieved.
62583992|NCT06160895|PLACEBO_COMPARATOR|TQ-A3334 placebo tablets (every other day)|TQ-A3334 placebo tablets, administered once every other day.
62583993|NCT06160895|EXPERIMENTAL|TQ-A3334 tablets (every three days)|TQ-A3334 tablets, administered once every three days.
62583994|NCT06160895|PLACEBO_COMPARATOR|TQ-A3334 placebo tablets (every three days)|TQ-A3334 placebo tablets, administered once every three days.
62408269|NCT04114591||LARS symptoms|Patient suffering from LARS as identified through LARS questionnaire
62408270|NCT04114591||No LARS symptoms|Absence of LARS symptoms
62408271|NCT01905176|EXPERIMENTAL|Predischarge educational intervention|In person education on heart failure topics before discharge
62583995|NCT01017770|EXPERIMENTAL|Artemether -lumefantrine|Experimental Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso
62583996|NCT01017770|EXPERIMENTAL|Artesunate-amodiaquine|Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso
62583997|NCT03185754|EXPERIMENTAL|early phase lung cancer|sublobar resection and lobectomy
62583998|NCT05920902||Acute ischemia stroke|Best medcine treatment. It including antiplatelet drugs, statins, hypotensive drugs, antidiabetics, neurotrophic drugs, butylphthalide, edaravone.
62211721|NCT05187364|EXPERIMENTAL|COPE Therapy Arm|Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE)
62211722|NCT01756378|EXPERIMENTAL|Muligan mobilization with movement|"Interventions are:~medial glide mobilization with movement lateral glide mobilization with movement rotation mobilization with movement dorsal glide with active knee flexion"
62211723|NCT01756378|ACTIVE_COMPARATOR|traditional physical therapy program|Infra-red, stretching exercises, strengthening exercises,
62211724|NCT00453791|EXPERIMENTAL|Subjects receiving treatment sequence 1: Part 1|Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using Metered Dose Inhaler (MDI).
62211725|NCT00453791|EXPERIMENTAL|Subjects receiving treatment sequence 2: Part 1|Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.
62211726|NCT00453791|EXPERIMENTAL|Subjects receiving treatment sequence 1: Part 2|Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using MDI.
62408272|NCT01905176|EXPERIMENTAL|Telephone educational intervention|Telephone support and education post-discharge
62408273|NCT01905176|EXPERIMENTAL|Combination|Pre-discharge in person education and post-discharge telephone education and support
62408274|NCT01905176|NO_INTERVENTION|Usual care (control group)|Patients receive the routine care provided by the hospital which does not involve protocol driven discharge-planning
62734512|NCT04976881|ACTIVE_COMPARATOR|PREPARED Strategy|Our PREPARED strategy will utilize health information and consumer technologies to 'hardwire' preconception care and promote diabetes self-management among reproductive-aged, adult women with T2DM in primary care. PREPARED will leverage electronic health record technology at clinic visits to: \[1\] promote medication reconciliation and safety, \[2\] prompt provider preconception counseling, and \[3\] deliver low literacy print tools to reinforce counseling and promote diabetes self-care. Post-visit, text messaging will be used to: \[4\] encourage healthy lifestyle behaviors.
62408275|NCT00370929|EXPERIMENTAL|Meditation|
62408276|NCT05785273||Dexmedetomidine|Patient undergoing general anesthesia receving initial administration of dexmedetomidine loading dose of 0.5-1 μg/kg (ADJUSTED weight) over 15 minutes. After intubation maintenance of general anesthesia is administrated with desflurane or sevoflurane (MAC 0.6 - 1, according to Bispectral Index (BIS) or Patient State Index (Psi)), dexmedetomidine (0.2- 0.4 μg/kg/h (Lean Body Weight)) with constant infusion rate unless hypotension or bradycardia not responsive to standard treatments (filling, atropine, ephedrine, ethylephrine) occurred, and remifentanil (0.02 - 0.2 μg/kg/min (LBW)) based on clinical and instrumental assessment (Heart Rate, Blood Pressure, BIS or Psi).
62408277|NCT05785273||No Dexmedetomidine|Patients in this group receive an eventual premedication with benzodiazepines according to anaesthesiologist assessment and patient condition. After intubation general anesthesia is administrated with inhaled (desflurane or sevoflurane; MAC 0.6 - 1) or intravenous (propofol) anesthetics (according to BIS or Psi) and remifentanil (0.02 - 0.2 μg/kg/min (LBW) based on clinical and instrumental assessment (HR, BP, BIS or Psi)).
62019701|NCT06536296|EXPERIMENTAL|Music|"We will create three recordings with increasing complexity for each infant. For each infant developmental stage (32, 34, 36+ weeks PMA), Music Therapists (MTs) in both units will present parents with a curated list of 8-10 musically comparable, familiar lullabies to select from. Songs will be available in different languages reflective of patient diversity, with rhythm, tempo, pitch range/ change, instrumentation, melody, harmony selected drawing on available evidence, including BWH NICU pilot data. Timing: MBI to be administered after regular NICU care and feeding times, which are typically considered stressful times for infants. The goal of the intervention will be to provide a calming and relaxing experience to the infant as they settle back to sleep after handling times. Music delivery will occur via infant-adapted headphones to facilitate blinding."
62211727|NCT00453791|EXPERIMENTAL|Subjects receiving treatment sequence 2: Part 2|Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.
62211728|NCT00453791|EXPERIMENTAL|Subjects receiving GW805858: Part 3|Eligible subjects will receive GW805858 1200 micrograms twice daily administered using MDI.
62211729|NCT00453791|EXPERIMENTAL|Subjects receiving placebo: Part 3|Eligible subjects will receive placebo administered using MDI.
62211730|NCT03629379|ACTIVE_COMPARATOR|ustekinumab arm|First 10 patients who are switched from anti-TNF to ustekinumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
62211731|NCT03629379|ACTIVE_COMPARATOR|vedolizumab arm|First 10 patients who are switched from anti-TNF to vedolizumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
62408278|NCT03751852|EXPERIMENTAL|Exercise coaching group|This intervention is an integration of aerobic exercise, yoga, mindfulness and exercise coaching. Exercise class and coaching will be provided weekly in the first 8 weeks. In the next 8 week, exercise class will be provided weekly while exercise coaching will be provided bi-weekly. The exercise class includes aerobic exercise coached by a well-trained intervention officer, and the yoga and mindfulness coached by a certified yoga instructor. The exercise coaching session followed by some stretching and aerobic exercise session. Both motivational coaching and aerobic exercise will be coached by a well-trained intervention officer.
62408279|NCT03751852|ACTIVE_COMPARATOR|Psychoeducation group|This group is similar with the exercise coaching group while exercise coaching session will be substituted by psychoeducation session.
62408280|NCT00661791|NO_INTERVENTION|A|Control Group receives routine care.
62408281|NCT00661791|EXPERIMENTAL|B.|massage group, receives massage only.
62408282|NCT00661791|EXPERIMENTAL|C.|Massage and Exercise group, receives both massage and exercise.
62408283|NCT06163898|EXPERIMENTAL|Part A|
62408284|NCT06163898|EXPERIMENTAL|Arm B1|
62408285|NCT06163898|EXPERIMENTAL|Arm B2|
62211732|NCT04611308||cases|
62211733|NCT04611308||controls|
62211734|NCT04898959||Group 1|Lower extremity amputees
62211735|NCT02595073|EXPERIMENTAL|DSXS topical product|DSXS Active treatment
62211736|NCT02595073|PLACEBO_COMPARATOR|Placebo topical product|Placebo treatment
62211737|NCT04587752|EXPERIMENTAL|CBT for Weight Bullying|Cognitive-Behavioral Therapy (CBT) for children who have experienced weight-related bullying
62211738|NCT02969239|EXPERIMENTAL|norepinephrine|norepinephrine 5mcg intravenously administered
62211739|NCT02969239|ACTIVE_COMPARATOR|phenylephrine|phenylephrine 100mcg intravenously administered
62211740|NCT06609421||Control Group|Women undergoing in-vitro fertilisation (IVF) with male factor diagnoses.
62211741|NCT06609421||Case Group|Women undergoing IVF with a diagnosis other than male factor.
62408286|NCT06163898|EXPERIMENTAL|Arm C1|
62408287|NCT06163898|EXPERIMENTAL|Arm C2|
62408288|NCT01139138|EXPERIMENTAL|Panitumumab + Irinotecan + Everolimus|
62408289|NCT03087448|EXPERIMENTAL|Ceritinib + Trametinib|"PHASE 1 Standard 3+3 dose escalation starting at dose level 1. Patients with ALK-rearranged, or ROS-1 rearranged NSCLC. 6-18 patients will be enrolled.~Ceritinib dose: 300-450mg orally, once daily over 28 day cycles. Trametinib dose: 1.5mg-2.0mg orally, once daily over 28 day cycles.~PHASE II The study was terminated before Phase II was initiated. The study did not open Phase II for enrollment."
62211742|NCT05484362|EXPERIMENTAL|Glucose as reference food|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
62408290|NCT01100398||NAFLD/NASH prevalence|Any subject between the ages of 18-70 without known fatty liver disease who meet inclusion criteria
62583999|NCT04719052|EXPERIMENTAL|Mediterranean diet group|"1) The MD will be based on high consumption of unsaturated fat from vegetable sources (virgin olive oil and nuts) and minimally processed plant foods (vegetables, fruits, nuts, whole grains and legumes), low consumption of meat (especially red and processed meats) and sweets, and moderate consumption of fish and dairy products (mainly yoghurt and cheese). Accordingly, this diet will provide a high amount of mono and polyunsaturated fatty acids, fibre and phenolic compounds.~Adolescents in the MD group will replace the intake of conventional breads by sourdough bread consumption (2 servings of 50-60 g daily) and incorporate into their diet chickpeas (2 servings of 150 g/week chickpeas, minimum one of them in hummus format), and they will consume at least another serving of legumes which can be chickpeas or another legume), pomegranate juice (4 servings of 200ml/week) and mixed nuts (4 servings of 30 g/week)."
62584000|NCT04719052|ACTIVE_COMPARATOR|Low-fat diet group|2) The low-fat diet (control diet) will be based on low consumption of fats. A low-fat diet is the most used diet for obesity treatment in adolescents. This group will not receive any additional specific food by researchers. This diet will be based on the diet proposed as low-fat diet in the PREDIMED study
62584001|NCT02231138|EXPERIMENTAL|Abelmoschus manihot (AM)|"* age above 12 years old (including 12)：huangkui capsule are given orally at 2.5 g three times per day~* age between 6-12 years old(including 6):huangkui capsule are given orally at 1.5 g three times per day~* age under 6 years old：huangkui capsule are given orally at 1.0 g three times per day"
62584002|NCT05025800|EXPERIMENTAL|Treatment (ALX148, rituximab, lenalidomide)|Patients receive ALX148 IV over 1 hour once on days 1, 8, 15 and 22, or days 1 and 15, or day 1 depending on dose level. Patients also receive rituximab IV over 4-6 hours on days 1, 8, 15 and 22 of cycle 1, then on day 1 of cycles 2-6, and lenalidomide PO QD on days 1-21 of cycles 1-6. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62584003|NCT05840224|EXPERIMENTAL|Phase 1a: GS-4528 Monotherapy Dose Escalation|Participants will receive escalating doses of GS-4528 monotherapy to determine the maximum tolerated dose.
62584004|NCT05840224|EXPERIMENTAL|Phase 1a: GS-4528 Monotherapy Dose Expansion|Participants will receive GS-4528 monotherapy at the dose determined in the escalation phase.
62584005|NCT05840224|EXPERIMENTAL|Phase 1b:Dose Escalation of GS-4528 in Combination With Anti-PD-1 Monoclonal Antibody (zimberelimab)|Participants will receive escalating doses of GS-4528 in combination with anti-PD1 monoclonal antibody (zimberelimab) to determine the maximum tolerated dose of GS-4528 as a combination therapy.
62584006|NCT06493032|EXPERIMENTAL|Body Surface Gastric Mapping|
62408291|NCT03660059|EXPERIMENTAL|ASP015K 100 mg|Participants will receive 100 milligrams (mg) of ASP015K once daily after breakfast for 52 weeks.
62408292|NCT03660059|EXPERIMENTAL|ASP015K 150 mg|Participants will receive 150 mg of ASP015K once daily after breakfast for 52 weeks.
62408293|NCT03660059|PLACEBO_COMPARATOR|Placebo/ASP015K|Participants will receive placebo for 24 weeks, then either 100 mg or 150 mg of ASP015K for 28 weeks as determined randomly at Week 0 in advance.
62408294|NCT06652477||groupe A|patients with atrophic boullos erosive oral lichen planus
62408295|NCT06652477||groupe B|healthy patients
62408296|NCT03724305|EXPERIMENTAL|MBTI|Mindfulness-Based Therapy for Insomnia
62584007|NCT01442311|EXPERIMENTAL|enhanced DOT (PEG/RBV-DOT)|Subjects randomized to the PEG/RBV-DOT arm receive weekly provider-administered pegylated interferon alfa-2a injections plus modified directly observed ribavirin therapy. We describe this as modified because ribavirin ingestion is observed at the methadone window three to six days per week based on the participants' methadone pick-up schedule, and only one of two daily doses is observed.
62584008|NCT01442311|ACTIVE_COMPARATOR|standard DOT (PEG-DOT)|Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
62584009|NCT02109770||Mother child diads or triads|Families with child affected by genetic anomaly, microdeletion, microduplication, or chromosomal anomaly
62584010|NCT02094976|ACTIVE_COMPARATOR|Group C|Group C means active comparator group which use chest rolls intraoperatively for prone position.
62584011|NCT02094976|ACTIVE_COMPARATOR|Group W|Group W means experimental group which use Wilson frame intraoperatively for prone position.
62584012|NCT02094976|EXPERIMENTAL|Group J|Group J means experimental group which use Jackson surgical table intraoperatively for prone position.
62584013|NCT01131143|EXPERIMENTAL|Treatment Group 1|Patients will receive a pre-visit, post-referral and post-contact phone call using providers voice
62584014|NCT01131143|EXPERIMENTAL|Treatment Group 2|Patients will receive a previsit, post-referral and post-contact call using a generic voice
62584015|NCT01131143|NO_INTERVENTION|Treatment Group 3|Patients will be provided usual care with no additional phone calls.
62584016|NCT03759015|OTHER|Health education|This arm's subjects are tasked to create an original 10-minute theater that is required to use the guidelines about physical activity and diet/nutrition.
62734513|NCT03086616|EXPERIMENTAL|Newly Diagnosed DIPG|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI): Nal-IRI given directly into the tumor using a method called CED to newly diagnosed DIPG subjects after completion of radiotherapy. CED will be performed every 4-8 weeks. Drug concentration will start at 20mg/ml and escalate up to 40 mg/ml concentration.
62211743|NCT05484362|EXPERIMENTAL|15mg of Crocus Sativus as beverage|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
62211744|NCT05484362|EXPERIMENTAL|30mg of Crocus Sativus as beverage|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
62211745|NCT05141240||Ribociclib|Participants who initiated CDK4/6i therapy
62211746|NCT05141240||Palbociclib|Participants who initiated CDK4/6i therapy
62408297|NCT00929552|EXPERIMENTAL|Fish oil|Daily dose = 6g fish oil baked into rye bread and wheat rolls. Participants were asked to consume two slices of rye bread and one wheat roll pr day. The fish oil was micro-incapsulated.
62408298|NCT00929552|ACTIVE_COMPARATOR|Vegetable oil (Mix of canola, palm and soy oil)|Daily dose = 6g vegetable oil baked into rye bread and wheat rolls. Participants were asked to consume two slices of rye bread and one wheat roll pr day.
62408299|NCT06466369|NO_INTERVENTION|Controlled group|
62408300|NCT06466369|EXPERIMENTAL|Low-dose intervention group|
62408301|NCT06466369|EXPERIMENTAL|High-dose intervention group|
62408302|NCT03128931|EXPERIMENTAL|Test Group|The subjects will be enrolled in the test group and will receive the Pediatric SedLine forehead EEG sensor.
62408303|NCT02724176|EXPERIMENTAL|carbon nanoparticles|0.1 ml of CN suspension was injected per spot into the tissue surrounding the tumor using a skin test syringe. Two or three randomly selected spots were injected slowly for each tumor, and the total amount injected was no more than 0.5 mL per lobe.
62584017|NCT06299384|EXPERIMENTAL|Lyssn Crisis|"To compare LyssnCrisis to SAU, researchers will use a standard randomized design in which call-takers will have services-as-usual (SAU) and LyssnCrisis phases. All call-takers will start with a 4-week baseline period of SAU where LyssnCrisis is operating in the background, but does not provide AI feedback on suicide risk assessment. Lyssn team members will on-board and train the participating call-takers on the Lyssn software (i.e., reviewing calls, sharing and accessing calls for supervision), using a similar method used in the pilot field trial. After a 4-week baseline phase, call-takers will be randomly assigned to continue SAU or begin feedback with LyssnCrisis (LC) for 12 weeks.~LC arm participants will have access to LyssnCrisis feedback tools for the duration of the 12 week period and will receive onboarding support for LyssnCrisis fidelity feedback tools."
62584018|NCT06299384|NO_INTERVENTION|Services As Usual|"To compare LyssnCrisis to SAU, researchers will use a standard randomized design in which call-takers will have services-as-usual (SAU) and LyssnCrisis phases. All call-takers will start with a 4-week baseline period of SAU where LyssnCrisis is operating in the background, but does not provide AI feedback on suicide risk assessment. Lyssn team members will on-board and train the participating call-takers on the Lyssn software (i.e., reviewing calls, sharing and accessing calls for supervision), using a similar method used in the pilot field trial. After a 4-week baseline phase, call-takers will be randomly assigned to continue SAU or begin feedback with LyssnCrisis (LC) for 12 weeks.~Participants in the SAU arm will continue services-as-usual for an additional 12-week period,where participants receive ProtoCall's regular supervision and feedback. Following this period (16 total weeks of SAU), SAU arm participants will receive LyssnCrisis for 12 weeks."
62584019|NCT06638879|EXPERIMENTAL|Topical Tacrolimus Treatment|
62584020|NCT06205628|EXPERIMENTAL|PART 1 - Active ADX-850 administered to participants with hypertension|"Part 1 includes up to 7 sequential dose cohorts (4 planned and 3 optional) to evaluate doses ranging from 100 to 800 mg (Table 3). In each cohort, 8 participants will be randomized in a 3:1 ratio to ADX-850 or placebo with the option to increase enrollment to 16 participants at the Sponsor's discretion and with SRC agreement.~At the start of each cohort, 2 sentinel participants (1 ADX-850 and 1 placebo) will be treated. The Medical Monitor and Investigator will review the available safety data from the first 48 hours after dosing to ensure safety before continuing enrollment in that cohort."
62211747|NCT05141240||Abemaciclib|Participants who initiated CDK4/6i therapy
62211748|NCT05377775|EXPERIMENTAL|Conventional Implantation of mesh stent|Conventional Implantation of mesh stent in iliac stenosis with high-risk plaques
62211749|NCT06028555||Estetrol/drospirenone (E4/DRSP)|Users: Starters and re-starters
62211750|NCT06028555||Ethinyl estradiol/levonorgestrel (EE/LNG)|Users: Starters and re-starters
62211751|NCT02575716|EXPERIMENTAL|Muscle relaxant|Intubation with McGrath video laryngoscope after fentanyl 1.5 mcg/kg, xylocaine 1.5 mg/kg and propofol 3 mg/kg muscle relaxant use rocuronium 0.6 mg/kg
62408304|NCT01736982|ACTIVE_COMPARATOR|Standard of Care|transdermal nicotine replacement \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\], breath sample monitoring, standard smoking cessation counseling
62408305|NCT01736982|EXPERIMENTAL|Standard of Care plus Contingency Management|Standard smoking cessation intervention plus contingency management
62408306|NCT04520087|EXPERIMENTAL|allograft fixation|Patients with anteroinferior shoulder instability will be clinically treated with a mini-open arthrotomic technique involving the fixation of the corticospongeous bone graft on the glena.
62408307|NCT01977482|EXPERIMENTAL|GSK1278863 4 mg|Subjects will take GSK1278863 4 mg blinded once daily (OD) orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
62211752|NCT02575716|PLACEBO_COMPARATOR|Placebo|Intubation with McGrath video laryngoscope after fentanyl 1.5 mcg/kg, xylocaine 1.5 mg/kg and propofol 3 mg/kg placebo use NSS 0.6 mg/kg
62211753|NCT00924118|EXPERIMENTAL|Sodium Nitrite|Dose escalation of sodium nitrite.
62211754|NCT00924118|NO_INTERVENTION|Open Control|Standard therapy
62211755|NCT05398991|EXPERIMENTAL|Experimental Arm|Subjects in experimental group will be implanted with the Coronary Covered Stents System manufactured by Shanghai MicroPort Medical (Group) Co., Ltd.
62211756|NCT00730106||1|Patients with pre-defined alarm symptoms
62211757|NCT00730106||2|Patients without pre-defined alarm symptoms
62408308|NCT01977482|EXPERIMENTAL|GSK1278863 6 mg|Subjects will take GSK1278863 6 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
62408309|NCT01977482|EXPERIMENTAL|GSK1278863 8 mg|Subjects will take GSK1278863 8 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
62584021|NCT06205628|PLACEBO_COMPARATOR|PART 1 - Placebo administered to participants with hypertension|"Part 1 includes up to 7 sequential dose cohorts (4 planned and 3 optional) to evaluate doses ranging from 100 to 800 mg (Table 3). In each cohort, 8 participants will be randomized in a 3:1 ratio to ADX-850 or placebo with the option to increase enrollment to 16 participants at the Sponsor's discretion and with SRC agreement.~At the start of each cohort, 2 sentinel participants (1 ADX-850 and 1 placebo) will be treated. The Medical Monitor and Investigator will review the available safety data from the first 48 hours after dosing to ensure safety before continuing enrollment in that cohort."
62211758|NCT06012422|OTHER|Individuals aged 65 and over who were screened for sarcopenia|Persons aged 65 and over will be evaluated only once and the assessment will be made through a face-to-face interview.
62211759|NCT05625451|EXPERIMENTAL|20-22 hours of daily total end range time intervention|used the elastic tension digital neoprene orthosis from twenty to twenty-two hours
62211760|NCT05625451|ACTIVE_COMPARATOR|11-13 hours daily total end range time intervention|used the elastic tension digital neoprene orthosis from eleven to thirteen hours
62211761|NCT02864108||Those with trisomy 21|People aged 6 months to 89 years old who have some form of trisomy 21.
62408310|NCT01977482|EXPERIMENTAL|GSK1278863 10 mg|Subjects will take GSK1278863 10 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
62734514|NCT01897727|ACTIVE_COMPARATOR|Spironolactone|Spironolactone 25 mg administered following baseline measurements and uptitrated to 50 mg if BP \> 140/90 mm Hg throughout the 3 month study.
62211762|NCT02864108||Controls|People aged 6 months to 89 years old who do not have trisomy 21. These persons can be related to someone with some form of trisomy 21 but do not have to be related.
62211763|NCT04538001|EXPERIMENTAL|Balloon implantation|Arthroscopic implantation of this sub-acromial balloon
62211764|NCT04538001|ACTIVE_COMPARATOR|Rotator cuff repair|Partial rotator cuff repair
62211765|NCT06251362|NO_INTERVENTION|Normal sleep|The night before the experimental session, where participants will follow their habitual sleep-wake routines.
62211766|NCT06251362|EXPERIMENTAL|Sleep restriction|The night before the experimental session (with sleep restrictions (SR)), where participants will experience acute sleep restriction the night before the test session (i.e., 3 h of early sleep restriction versus normal sleep).
62211767|NCT01293045|EXPERIMENTAL|HC Group|Group of volunteers fed with Hydrolyzed Collagen
62211768|NCT01293045|ACTIVE_COMPARATOR|CT Group|Group of volunteers fed with wheat proteins
62211769|NCT02233543|EXPERIMENTAL|First QVA149 (indacaterol/glycopyrronium), then Placebo|Participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
62211770|NCT02233543|EXPERIMENTAL|First Placebo, then QVA149 (indacaterol/glycopyrronium)|Participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
62211771|NCT01059968||adolescent female endurance athletes|High school female cross country runners in San Diego.
62211772|NCT01231009|ACTIVE_COMPARATOR|Corticosteroids|Patients receive for 7 days intravenous corticosteroids, dexamethasone, and they continue receiving for 7 days corticosteroids per os
62211773|NCT01231009|PLACEBO_COMPARATOR|Vestibular exercises|Patients perform for 15 days certain vestibular exercises under suspicion of an expert physiotherapist
62211774|NCT03625180||Treatment|NAMIC technique
62211775|NCT05322993|ACTIVE_COMPARATOR|With artificial intelligence (AI)|Use of GI Genius artificial intelligence device during colonoscopy.
62211776|NCT05322993|ACTIVE_COMPARATOR|Without artificial intelligence|Use of standard colonoscopy equipment without GI Genius.
62211777|NCT02311231|EXPERIMENTAL|bivalirudin|bivalirudin as intravenous bolus of 0,75 mg per kilogram followed by an infusion of 1,75 mg per kilogram per hour
62211778|NCT02311231|ACTIVE_COMPARATOR|heparin|unfractionated Heparin 5 000 IU/ml as intravenous bolus according to local practice
62211779|NCT03339583|EXPERIMENTAL|zopiclone first group|underwent the medication therapy (zopiclone) for the first two weeks followed by brief behavioral therapy
62211780|NCT03339583|EXPERIMENTAL|BBT-I first group|received two-week brief behavioral therapy followed by medication therapy (zopiclone).
62211781|NCT05310149|EXPERIMENTAL|obturator group(unilalateral maxillary defect)|Prosthetic intervention with maxillary obturator prosthesis is necessary to restore the contours of the resected palate and to recreate the functional separation of the oral cavity and sinus and nasal cavities. Followings are the objectives of maxillary obturator Restoration of esthetics or cosmetic appearance of the patient, Restoration of function, Protection of tissues, Therapeutic or healing effect and psychological therapy.
62211782|NCT05310149|NO_INTERVENTION|Control group|intact side of the same patient
62211783|NCT05559515|ACTIVE_COMPARATOR|National Diabetes Prevention Program|The Diabetes Prevention Program was a successful clinical trial demonstrating that intensive lifestyle support for weight loss reduced diabetes incidence by 58%. The intervention was translated into the National Diabetes Prevention Program (NDPP) and disseminated by the Centers for Disease Control and Prevention as a yearlong group-based program since 2012.
62211784|NCT05559515|EXPERIMENTAL|NDPP-Flex|"NDPP-Flex. The primary difference between NDPP-Flex and the standard NDPP is the approach to goal setting. In NDPP-Flex, coaches use the latest CDC-published curriculum, but adapted such that participants are encouraged to 1) set attainable, individually-tailored goals for risk-reduction, 2) adjust goals over time as needed, and 3) avoid all-or-nothing assessments of goal attainment. At each session, coaches provide a goal setting worksheet (see excerpt) with a simple, fillable format to better accommodate low literacy (e.g., I will limit my soda and sugary drinks to __ per day)."
62211785|NCT01308944|EXPERIMENTAL|Arm 1|"Propranolol 40mg po orally twice daily to begin at least 48 hours prior to surgical debulking. This will ideally be titrated in order to maintain a heart rate between 60 and 80 without hypotension.~After surgery, the patient will resume the propranolol once tolerating clear liquids in the hospital and will remain on them until completion of chemotherapy.~After completion of chemotherapy, the patient will be weaned off the medication over the following two weeks."
62211786|NCT03993600|SHAM_COMPARATOR|Healthy volunteers|sweat test and skin biopsy
62211787|NCT03993600|EXPERIMENTAL|Patients with Cystic fibrosis|sweat test and skin biopsy
62584022|NCT06205628|EXPERIMENTAL|PART 2 - Active ADX-850 administered to participants with hypertension|In Part 2, participants with hypertension will be dosed with ADX-850 in an open-label, parallel arm fashion. Participants whose SBP \>120 mmHg at Day 57 will be administered irbesartan, 150 to 300 mg, once daily. Dosing of the combination treatment group will begin with 2 sentinel participants who will be followed for safety for 48 hours after starting their irbesartan regimen before the decision is made by the Investigator and Medical Monitor to continue with combination treatment for all other participants who meet the criteria for irbesartan administration.
62584023|NCT06205628|EXPERIMENTAL|PART 2 - Active ADX-850 plus ARB therapy administered to participants with hypertension|In Part 2, participants with hypertension will be dosed with ADX-850 in an open-label, parallel arm fashion. Participants whose SBP \>120 mmHg at Day 57 will be administered irbesartan, 150 to 300 mg, once daily. Dosing of the combination treatment group will begin with 2 sentinel participants who will be followed for safety for 48 hours after starting their irbesartan regimen before the decision is made by the Investigator and Medical Monitor to continue with combination treatment for all other participants who meet the criteria for irbesartan administration.
62584024|NCT06628765|ACTIVE_COMPARATOR|8.6 Fr single-use fURS (XFGC-FU-660RC)|8.6 Fr single-use fURS (XFGC-FU-660RC) arm received 8.6 Fr single-use fURS
62019702|NCT06536296|EXPERIMENTAL|Music and parent voice|"The selected lullabies will be pre-recorded by the MT as described above to include a guitar accompaniment track, and a separate vocal track with the MT singing along, in two separate keys to allow variation for parent voice range and comfort. Parents will be invited to sing along with the recorded track of MT singing, and MT will later remove the MT-voice recording track so only the parent voice will be heard with the guitar in the final recording. Timing: MBI to be administered after regular NICU care and feeding times, which are typically considered stressful times for infants. The goal of the intervention will be to provide a calming and relaxing experience to the infant as they settle back to sleep after handling times. Music delivery will occur via infant-adapted headphones to facilitate blinding."
62019703|NCT06536296|ACTIVE_COMPARATOR|Reference/ Standard of care|These are infants recruited in the study who will receive the unit standard of care. They will be listening to the NICU ambient noise via infant-adapted headphones but will not receive any music intervention.
62019704|NCT02108938||Case|Subject's with Crohn's disease at least 18 years of age
62211788|NCT03993600|EXPERIMENTAL|Heterozygotes subjects|sweat test and skin biopsy
62211789|NCT01994759|ACTIVE_COMPARATOR|Training|strengthening and stretching exercises.
62211790|NCT01994759|ACTIVE_COMPARATOR|Glucocorticosteroid injection|Injection of 40 mg methylprednisolone.
62211791|NCT01994759|ACTIVE_COMPARATOR|Training and Glucocorticosteroid injections|A combination treatment of the two above.
62211792|NCT04616872|EXPERIMENTAL|Methotrexate-LDE|Methotrexate carried by a lipid nanoparticle (MTX-LDE)
62211793|NCT04616872|PLACEBO_COMPARATOR|Placebo-LDE|Lipid nanoparticle (LDE)
62211794|NCT01953705|EXPERIMENTAL|omega 3 polyunsaturated fatty acids|1.65 grams of EPA+DHA taken daily over 3 years
62211795|NCT01953705|PLACEBO_COMPARATOR|Soybean oil|1.65 grams of soybean oil taken daily over 3 years
62211796|NCT03049033|EXPERIMENTAL|Neurologic Music Therapy (NMT)|Neurologic Music Therapy is a 5-week intervention using different musical instruments and auditory cues to specifically improve fine motor movements.
62211797|NCT03049033|ACTIVE_COMPARATOR|Occupational Therapy (OT)|Standard of care occupational therapy uses traditional motor training.
62211798|NCT03049033|NO_INTERVENTION|Waitlist Control|Participants assigned to the waitlist-control condition will not immediately receive services. The no-treatment duration for these participants is yoked to the amount of time their respective NMT- and OT-condition participants receive services (5 weeks). After the wait period, these participants will then be randomized to receive either NMT, MST or OT sessions.
62019705|NCT02108938||Control|"Findings from this study will be compared to controls. These controls will come from the well documented CNS changes which have been found in patients with IBS and chronic pancreatitis (HS-IRB# 2013-1561 and HS-IRB 2009-0171)."
62019706|NCT00849342||A|
62019707|NCT00465166||1|Patients who had a documented, accidental dural puncture during placement of their labor epidural.
62019708|NCT06074926|EXPERIMENTAL|Group 1 - Intervention|Participants will attend two laboratory visits and complete a 3-week intervention, which consists of interactive parent-child activities (\~45 min of interactive activities/week) that pair tasting an assigned target vegetable with positive parent-child interactions. Positive interactions will be promoted via positive parenting prompts embedded in the activity instructions (e.g., prompts promoting child-directed play).
62019709|NCT06074926|EXPERIMENTAL|Group 2 - Control|Participants will attend the same two laboratory visits and complete a 3-week intervention, which consists of only individual taste exposures to their target vegetable.
62019710|NCT01072682|EXPERIMENTAL|SCD|Selective Cytopheretic Device
62019711|NCT02426632|EXPERIMENTAL|Session 1: Sequence 1|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
62019712|NCT02426632|EXPERIMENTAL|Session 1: Sequence 2|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
62019713|NCT02426632|EXPERIMENTAL|Session 1: Sequence 3|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
62019714|NCT02426632|EXPERIMENTAL|Session 1: Sequence 4|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
62019715|NCT02426632|EXPERIMENTAL|Session 1: Sequence 5|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
62019716|NCT02426632|EXPERIMENTAL|Session 1: Sequence 6|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
62211799|NCT03049033|ACTIVE_COMPARATOR|Music Supported Therapy (MST)|Music Supported Therapy uses musical instruments to train fine motor movements.
62211800|NCT02365922||Patients with FTLD or family members|Participants with FTLD syndrome diagnoses and/or strong family histories of FTLD.
62019717|NCT02426632|EXPERIMENTAL|Session 2: Sequence 7|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
62019718|NCT02426632|EXPERIMENTAL|Session 2: Sequence 8|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
62019719|NCT02426632|EXPERIMENTAL|Session 2: Sequence 9|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
62019720|NCT02426632|EXPERIMENTAL|Session 2: Sequence 10|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
62211801|NCT03433508|EXPERIMENTAL|Liberal|2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
62211802|NCT03433508|ACTIVE_COMPARATOR|Restrictive|To maintain the target Hemoglobin of 7 to 8 gm/dL.
62584025|NCT06628765|EXPERIMENTAL|6.3 Fr single-use fURS (HugeMed, HU30S)|6.3 Fr single-use fURS (HugeMed, HU30S) arm received 6.3 Fr single-use fURS
62584026|NCT02649244|EXPERIMENTAL|The Family Caregiver Training Program|The experimental group received a 2 hour intervention training on activities of daily throughout the early, middle, and late stages of dementia including communication, eating/feeding, nutrition, bathing, grooming, dressing, toileting, and transferring.
62584027|NCT02649244|NO_INTERVENTION|Standard Care|The control group received a 1 1/2 hour training, however the information was based on what has been deemed standard care by the Alzheimer's Association.
62584028|NCT01546129|EXPERIMENTAL|Dianatal Obstetric Gel|Standard of care according to the established Guidelines of the Department plus use of Dianatal applied with a vaginal applicator in stage I and stage II of labor
62584029|NCT01546129|NO_INTERVENTION|Control|Standard of care according to the established Guidelines of the Department.
62211803|NCT03991208|EXPERIMENTAL|Rest|Pharmacokinetics of Single Dose Malarone at Rest
62211804|NCT03991208|EXPERIMENTAL|Exercise|Pharmacokinetics of Single Dose Malarone under exercise in a heat chamber
62211805|NCT01455389|EXPERIMENTAL|DOTAP + Erlotinib|DOTAP:Chol-TUSC2 0.045 mg/kg by vein over 25-35 minutes on day 1 of each 21 day cycle; and Erlotinib 100 mg by mouth daily for each 21 day cycle.
62211806|NCT03121248|EXPERIMENTAL|WBI - randomized - 5|WBI 5 fractions SIB 5 fractions if needed
62211807|NCT03121248|ACTIVE_COMPARATOR|WBI - randomized - 15|WBI 15 fractions SIB 15 fractions if needed
62211808|NCT03121248|EXPERIMENTAL|WBI - observational - 5|WBI 5 fractions SIB 5 fractions if needed
62584030|NCT03505125||PKU Patients|Adults with PKU will be interviewed about the symptoms and impacts of PKU.
62584031|NCT03505125||Observers|Close friends and family members of adults with PKU will be interviewed about the behaviors they have observed in adults with PKU
62584032|NCT03505125||Clinical Experts|Experienced, practicing clinicians currently treating adults with PKU will be interviewed about the symptoms and impacts of PKU on their patients.
62211809|NCT03121248|ACTIVE_COMPARATOR|WBI - observational - 15|WBI 15 fractions SIB 15 fractions if needed
62211810|NCT03121248|EXPERIMENTAL|WBI + LNI - randomized - 5|WBI 5 fractions SIB 5 fractions if needed LNI 5 fractions
62211811|NCT03121248|ACTIVE_COMPARATOR|WBI + LNI - randomized - 15|WBI 15 fractions SIB 15 fractions if needed LNI 15 fractions
62734515|NCT01897727|SHAM_COMPARATOR|Standard of care BP treatment|Antihypertensive medication added and/or uptitrated to keep BP \< 140/90 mm Hg throughout the study.
62734516|NCT04476901|PLACEBO_COMPARATOR|Genotype A administered with placebo Group|Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the placebo group will receive the placebo intervention.
62584033|NCT05019027|OTHER|On-Off Sequence|This arm will follow an On-Off sequence. This is the only arm in the study. Subjects will begin in the On phase (Period 1), maintaining their beta-blocker dosage as previously prescribed to the subjects by their physician. Subjects will then continue to the Off phase (Period 2) where they will down-titrate their beta-blocker by 50% each week until they are completely off the drug for a total of two weeks. At the end of Period 2, the subjects will have their End of Intervention visit in which they will determine if they would like to continue or discontinue their beta-blockers for the foreseeable future.
62019721|NCT02426632|EXPERIMENTAL|Session 2: Sequence 11|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
62019722|NCT02426632|EXPERIMENTAL|Session 2: Sequence 12|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
62019723|NCT05155436|EXPERIMENTAL|Fixed-Dose Combination pill of Telmisartan and Amlodipine|Fixed-Dose Combination pill of Telmisartan 40 mg and Amlodipine 5 mg, once daily for 3 months
62584034|NCT05040204|EXPERIMENTAL|Experimental Supplement 1|6 subjects will consume 12 grams of dietary supplement 1 daily for 4 weeks
62584035|NCT05040204|EXPERIMENTAL|Experimental Supplement 2|6 subjects will consume 12 grams of dietary supplement 2 daily for 4 weeks
62019724|NCT01446848|EXPERIMENTAL|iron supplement|open-label iron supplement intervention group
62211812|NCT03121248|EXPERIMENTAL|WBI with LNI - observational - 5|WBI 5 fractions SIB 5 fractions if needed LNI 5 fractions
62584036|NCT05040204|EXPERIMENTAL|Experimental Supplement 3|20 subjects will consume 50 grams of dietary supplement 3 daily for 4 weeks
62211813|NCT03121248|ACTIVE_COMPARATOR|WBI with LNI - observational - 15|WBI 15 fractions SIB 15 fractions if needed LNI 15 fractions
62211814|NCT03121248|EXPERIMENTAL|thoracic wall irradiation (TWI) +/- LNI - observational - 5|TWI 5 fractions SIB 5 fractions if needed LNI 5 fractions
62584037|NCT05040204|PLACEBO_COMPARATOR|Placebo Comparator 1|6 subjects will consume 12 grams of placebo dietary supplement daily for 4 weeks
62584038|NCT05040204|PLACEBO_COMPARATOR|Placebo Comparator 2|6 subjects will consume 50 grams of placebo dietary supplement daily for 4 weeks
62584039|NCT02125942|EXPERIMENTAL|meditation|Central Meditation and Imagery Therapy
62584040|NCT02125942|NO_INTERVENTION|wait list|waiting list
62211815|NCT03121248|ACTIVE_COMPARATOR|TWI +/- LNI - observational - 15|TWI 15 fractions SIB 15 fractions if needed LNI 15 fractions
62211816|NCT02441231|EXPERIMENTAL|Probiotic Group|Visbiome probiotic group (900 billion bacteria daily; 2 sachets daily)
62019725|NCT03753126|OTHER|Cardiac CT imaging|
62019726|NCT05264376|EXPERIMENTAL|Diabetes Body Project|
62019727|NCT05264376|ACTIVE_COMPARATOR|Educational Control Group|
62019728|NCT04071873|EXPERIMENTAL|Point-of-care HIV testing (intervention)|Participants will be offered voluntary point-of-care HIV testing during a traditional healer visit.
62019729|NCT04071873|ACTIVE_COMPARATOR|Education on community HIV resources (control)|Participants will be offered education regarding HIV testing and community resources during a traditional healer visit.
62211817|NCT02441231|PLACEBO_COMPARATOR|Placebo Group|Placebo comparator group
62211818|NCT04871880|EXPERIMENTAL|Dietitian led life style modification intervention.|Lifestyle changes supervised by dietitians
62211819|NCT04871880|EXPERIMENTAL|Conventional care (control)|Receive routine care
62211820|NCT02752698|EXPERIMENTAL|Micro Hand S robotic group|Micro Hand S robotic surgery group
62211821|NCT02752698|OTHER|laparoscopic surgery|laparoscopic surgery group
62211822|NCT02752698|OTHER|da Vinci robotic group|da Vinci robotic robotic group
62211823|NCT04706559|EXPERIMENTAL|Group A (Interventional group)|Along with below mentioned conventional treatment, the participants in group A (i.e. Interventional group) will receive conventional treatment of AD for a short duration along with probiotics for 8 weeks. One probiotic sachet twice a day will be prescribed. A sachet of 2 grams containing 1.25 billion cells per gram of 4 strains (Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, and Saccharomyces boulardii) will be used. The child will receive a total of 5 billion cells of probiotics per day.
62584041|NCT04927832|EXPERIMENTAL|Patient with chronic autoimmune pathology|
62584042|NCT04927832|EXPERIMENTAL|Patients with unexplained pain syndrome|
62584043|NCT01847339|EXPERIMENTAL|bupivacaine soaked sponges|Patients will be randomized using a reproducible set of computer-generated random numbers. In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure
62584044|NCT01847339|PLACEBO_COMPARATOR|saline soaked sponges|Patients will be randomized using a reproducible set of computer-generated random numbers. In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in saline solution and then will be placed by the surgeon in the epidural space before final closure.
62584045|NCT01694329||2006-2010 cohort|cohort of children born between 2006 and 2010, and living in Nunavik
62584046|NCT02387957|EXPERIMENTAL|Fovista® plus bevacizumab|Fovista® 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection
62408311|NCT01977482|EXPERIMENTAL|GSK1278863 12 mg|Subjects will take GSK1278863 12 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
62408312|NCT01977482|ACTIVE_COMPARATOR|Control|Subjects will take GSK1278863 matching placebo blinded OD orally for 4 weeks with a glass of water. From Week 4, rhEPO will be administered and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
62584047|NCT02387957|EXPERIMENTAL|Fovista® plus ranibizumab|Fovista® 1.5 mg intravitreal injection + 0.5 mg ranibizumab intravitreal injection
62584048|NCT02387957|EXPERIMENTAL|Fovista® plus aflibercept|Fovista® 1.5 mg intravitreal injection + 2.0 mg aflibercept intravitreal injection
62584049|NCT06665503|NO_INTERVENTION|65 children in cotrol group|Only standard medication.
62211824|NCT04706559|ACTIVE_COMPARATOR|Group B (Conventional group)|All patients (i.e. in both arms) with atopic dermatitis will be prescribed emollients and cleanser as a part of routine skin care. Topical corticosteroid (i.e. Fluticasone 0.05% cream) and topical calcineurin inhibitor (tacrolimus 0.1% ointment) for sensitive areas like periorbital regions, flexures and face, will be given once daily. All patients will be given an oral antihistamine (syrup/ tablet cetirizine 0.3mg/kg) at night. It is referred to as conventional treatment.
62211825|NCT03427853|EXPERIMENTAL|LY06006|LY06006 18mg, 60mg 120mg subcutaneous injection
62211826|NCT03427853|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection
62408313|NCT05498545|EXPERIMENTAL|LUCAR-B68 cells product|Each subject will receive LUCAR-B68 cells
62408314|NCT05615428||observational group|"Inclusion criteria:~* GA ≤29+6, inborn at a participating centre~* Age less than 45 minutes as gastric aspirate must be sampled within 45 minutes from delivery.~Exclusion criteria:~* Treated with surfactant beforerandomisation and obtaining gastric aspirates~* Diagnosis of major malformations (major congenital heart defects, congenital diaphragmatic hernia, gastroschisis/omphalocele, pulmonary abnormalities including pulmonary hypoplasia and trachea-oesophageal fistula~* Antenatal suspicion of significant oligohydramnios and lung hypoplasia~* Any intrauterine intervention except if done for genetic testing"
62584050|NCT06665503|EXPERIMENTAL|65 children in Zinc group|The zinc group received oral zinc supplementation; 2.5 ml every 12 hours for children aged \<1 year and 5 ml every 12 hours for older children.
62584051|NCT06665503|EXPERIMENTAL|65 children in Probiotic group|The probiotics group received oral probiotics; 1 probiotic sachet (KidiLact: Lacticaseibacillus rhamnosus, Lactobacillus reuteri, Lactobacillus acidophilus, Bifidobacterium infantis, Lactobacillus acidophilus, Bifidobacterium bifidum and Streptococcus thermophilus)
62211827|NCT06249659||Extubation in operative room|Patients are extubated in operative room after the end of surgery
62211828|NCT06249659||Extubation in post anesthesia care unit|Patients are extubated in post anesthesia care unit, after transfer from operative room
62408315|NCT00761085|ACTIVE_COMPARATOR|Methadone-Children|Methadone comparison to standard of care for pain management
62408316|NCT00761085|ACTIVE_COMPARATOR|Morphine-Children|Morphine standard of Care pain management
62408317|NCT00761085|ACTIVE_COMPARATOR|Methadone-Adults|Methadone comparison to standard of care for pain management
62584052|NCT02587585|EXPERIMENTAL|Feedback against tailored target|For each two hour epoch, the watch calculate the level of activity for the same epoch the day before, and adds 5% as the new target to be achieved.
62584053|NCT02587585|SHAM_COMPARATOR|No Feedback|For participants assigned to the control group, the smart watch will not provide any activity feedback against a target; it simply shows which two hour epoch a person is in.
62584054|NCT05217641|EXPERIMENTAL|Part A, Group 1: Low dose BG505 MD39.3 mRNA|18 participants Dose: 100mcg of BG505 MD39.3 mRNA formulated administered at months 0, 2, and 6
62584055|NCT05217641|EXPERIMENTAL|Part A, Group 2: Low dose BG505 MD39.3 gp151 mRNA|18 participants Dose: 100mcg of BG505 MD39.3 gp151 mRNA administered at months 0, 2, and 6
62584056|NCT05217641|EXPERIMENTAL|Part A, Group 3: Low dose BG505 MD39.3 gp151 CD4KO mRNA|18 participants Dose: 100mcg of BG505 MD39.3 gp151 CD4KO mRNA administered at months 0, 2, and 6
62584057|NCT05217641|EXPERIMENTAL|Part B, Group 1: BG505 MD39.3 mRNA|18 participants Dose: 250mcg of BG505 MD39.3 mRNA administered at months 0, 2, and 6
62584058|NCT05217641|EXPERIMENTAL|Part B, Group 2: BG505 MD39.3 gp151 mRNA|18 participants Dose: 250mcg of BG505 MD39.3 gp151 mRNA administered at months 0, 2, and 6
62584059|NCT05217641|EXPERIMENTAL|Part B, Group 3: BG505 MD39.3 gp151 CD4KO mRNA|18 participants Dose: 250mcg of BG505 MD39.3 gp151 CD4KO mRNA administered at months 0, 2, and 6
62211829|NCT01843153|OTHER|intermittent|injection of ropivacaine on demand
62211830|NCT01843153|OTHER|continuous|continuous ropivacaine infusion
62211831|NCT02597647|EXPERIMENTAL|Live attenuated influenza vaccine|Healthy adult volunteers given intranasal FluMist (Live Attenuated Influenza vaccine). Subjects will undergo nasal swabs, nasopharyngeal washes, and nasal epithelial brushings at baseline, 1-2 weeks, and 4-6 weeks after LAIV.
62211832|NCT02597647|PLACEBO_COMPARATOR|Saline nasal spray|Healthy adult volunteers given intranasal saline nasal spray. Subjects will undergo nasal swabs, nasopharyngeal washes, and nasal epithelial brushings at baseline, 1-2 weeks, and 4-6 weeks after saline administration.
62211833|NCT02230098|EXPERIMENTAL|Remote Ischemic Conditioning|By use of short-term obstruction of the blood supply to the arm
62211834|NCT02230098|NO_INTERVENTION|Before Remote Ischemic Conditioning|
62211835|NCT03893669|EXPERIMENTAL|Group 1|NBP607 0.5ml
62211836|NCT03893669|ACTIVE_COMPARATOR|Group 2|Agrippal 0.5ml
62211837|NCT04492449||Obese pregnants group|Obese pregnants exposure of coronavirus infection.
62211838|NCT04492449||Normal pregnants group|Normal pregnants exposure of coronavirus infection.
62211839|NCT04492449||children with congenital malformations|Child with congenital malformations
62408318|NCT00761085|ACTIVE_COMPARATOR|Morphine-Adults|Morphine standard of Care pain management
62584060|NCT04161456|EXPERIMENTAL|Apremilast|Apremilast twice daily 30 mg
62584061|NCT00006103|EXPERIMENTAL|irinotecan + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for a total of 5 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year and then every 6 months thereafter."
62584062|NCT02310425|ACTIVE_COMPARATOR|The study group|The study group received S. boulardii supplementation, 50 mg/kg twice daily, compared to no intervention in the control group.
62584063|NCT02310425|PLACEBO_COMPARATOR|The control group|A prospective, Placebo Comparator,randomized case-controlled trial was conducted in infants with a gestational age of 30 to 37 weeks and a birth weight between 1500 to 2500 g.
62584064|NCT05865899|EXPERIMENTAL|surgical|patients who undergo high tibial osteotomy procedure
62584065|NCT05865899|NO_INTERVENTION|conservative|patients who undergo conservative treatment
62211840|NCT04492449||children without congenital malformations|Child without congenital malformations
62211841|NCT02965677|EXPERIMENTAL|LEGFLOW OTW group|in this group subject will be treated by Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) and followed up
62211842|NCT02965677|ACTIVE_COMPARATOR|Admiral Xtreme|in this group subject will be treated by Peripheral Balloon Dilatation Catheter (Admiral Xtreme) and followed up
62211843|NCT02399254||Pulmonary Rehabilitation|Chronic Obstructive Pulmonary Disease (COPD) patients following pulmonary rehabilitation
62408319|NCT03107715|ACTIVE_COMPARATOR|Breastfeeding Champion|The Breastfeeding Champion Intervention (Intervention A) utilizes information about Breastfeeding Champions from the Coffective™ program: participants will be guided to tap and scroll through the content and will receive a follow up handout and encouragement to select a Champion.
62408320|NCT03107715|ACTIVE_COMPARATOR|Positive Messaging|The Positive Messaging Intervention (Intervention B) utilizes positive messaging from several sources and is modelled on the WIC Loving Support™ approach: participants will click on (istock-purchased) photographs which each reveal an informational statement about exclusive breastfeeding benefits and tips, followed by receipt of a summary handout.
62408321|NCT03487146|NO_INTERVENTION|HD(hemodialysis) group|HD group as conventional control arm
62584066|NCT00811811|EXPERIMENTAL|1|Behavioral neurocardiac training
62584067|NCT00811811|ACTIVE_COMPARATOR|2|Autogenic relaxation training
62584068|NCT04254198|PLACEBO_COMPARATOR|Control|Modified Attention Placebo Control
62584069|NCT04254198|EXPERIMENTAL|TERTULIAS structured dialogue peer support groups|Structured Dialogue peer support group
62584070|NCT03086031|EXPERIMENTAL|Program-based vocational rehabilitation|Combined intervention with a neuropsychological, social and community intervention followed by a vocational rehabilitation programme with a total length of 6-9 months.
62734517|NCT04476901|EXPERIMENTAL|Genotype A administered with hMSC Group|Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the treatment group will receive the hMSC intervention.
62734518|NCT04476901|PLACEBO_COMPARATOR|Genotype B administered with placebo Group|Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the placebo group will receive the placebo intervention.
62734519|NCT04476901|EXPERIMENTAL|Genotype B administered with hMSC Group|Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the treatment group will receive the hMSC intervention.
62408322|NCT03487146|ACTIVE_COMPARATOR|HD+HP(hemodialysis+hemoperfusion) group|HD+HP as active interventional group.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.
62408323|NCT06199518|ACTIVE_COMPARATOR|GROUP(A):transperitoneal laparoscopic ureterolithotomy (T-LUL)|extraction of proximal ureteral stones by laparoscopic surgery via transperitoneal approach
62019730|NCT02703935|EXPERIMENTAL|health talk and adventure-based training|Participate will join a four-day adventure-based training programme, which contains education talks, workshop and adventure-based training activities. The programme will be implemented on four different days within six months in a day camp training centre. The integrated programme will be implemented in small group with maximum 12 participants in one group. Health education talks and workshop will be implemented in between adventure-based training activities in day camp centre, which will be conducted by healthcare professionals working in a local university.
62211844|NCT02158988|NO_INTERVENTION|without HIPEC|"Preoperative chemotherapy 3 cycles, each cycle 21 days. Patients with negative or unknown HER-2 status receive Epirubicin 50 mg/m² infusion (maximum 100mg/d). Oxaliplatin 130 mg/m² infusion (maximum 260 mg/d) and capecitabine oral 625 mg/m² two times a day (maximum 2500 mg/d).~Patients with positive HER-2 status receive:~Cisplatin : 80 mg/m² infusion (maximum of 160 mg/d). Capecitabine: oral 1000 mg/m2 (two times a day maximum of 4000 mg/d), on day 1-14.~Trastuzumab: 8 mg/kg infusion (on cycle 1 and 6 mg/kg on cycle 2 and 3). CRS is performed and 4-12 weeks after CRS 3 cycles of postoperative chemotherapy have to be applied. In case of therapy failure patients will be continued to be treated by the responsible investigator according to his medical status."
62211845|NCT02158988|EXPERIMENTAL|With HIPEC|"Patients will be treated with a preoperative chemotherapy as described for the control group. EOX or CCT depending on the HER-2 status.~CRS will be performed 2 to 3 weeks after end of last chemotherapy cycle. HIPEC with mitomycin C and cisplatin either at the time of CRS or a delayed HIPEC within 5-7 days.~HIPEC:~Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied.~Patients may get a HIPEC intervention without surgical cytoreduction if contraindication to the drugs can be excluded.~In case of therapy failure patients will be continued to be treated by the responsible investigator according to his medical status."
62408324|NCT06199518|ACTIVE_COMPARATOR|GROUP (B):retrograde flexible ureteroscopy (R-URS)|laser lithotripsy of proximal ureteral stones via flexible ureteroscopy retrograde
62408325|NCT06199518|ACTIVE_COMPARATOR|GROUP (C):Antegrade mini-percutaneous flexible ureteroscopy (A-URS)|laser lithotripsy of proximal ureteral stones via percutanous antegrade flexible ureteroscopy
62408326|NCT04424732|OTHER|Stereotactic Body Radiotherapy for Breast Bony oligometastases|Newly diagnosed bone only oligometastatic breast cancers with 1-3 bone metastases will be enrolled in this protocol. Patients will receive SBRT to all metastatic sites.
62408327|NCT03209973|EXPERIMENTAL|Tislelizumab|Tislelizumab 200 mg administered intravenously (IV) every-3-weeks (Q3W)
62019731|NCT02703935|PLACEBO_COMPARATOR|Placebo Control|Participants will receive an amount of time and attention that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
62019732|NCT03036566|EXPERIMENTAL|Bridge|Three unit high strength ceramic (lithium disilicate/emaxCAD by Ivoclar) bridges replacing a single tooth.
62019733|NCT00574860|EXPERIMENTAL|EN3285 (NAC ProGelz)|The EN3285 arm is the product under development
62019734|NCT00574860|PLACEBO_COMPARATOR|No active ingredients (placebo)|This will be an oral product that contains no active ingredient
62408328|NCT00683462|PLACEBO_COMPARATOR|1|
62408329|NCT00683462|EXPERIMENTAL|2|
62584071|NCT03086031|ACTIVE_COMPARATOR|Conventional vocational rehabilitation(controls)|Individuals allocated to the control group will receive the conventional VR program provided by the four municipalities over the same period of time. Thus, the participants in the control group will receive VR support by the local municipal authority that may vary in content and intensity. As for the intervention group, each individual in the control group will select a family caregiver that will go through the same questionnaires as the caregivers in the VR intervention group regarding health-related quality of life and functional level. Furthermore, the case manager at the municipalities will oblige to (1) hand out the baseline questionnaires to the participants and their family caregivers, (2) complete a questionnaire about each participants at the beginning, the end of the study, and again at 6-month of follow-up.
62584072|NCT05821634|EXPERIMENTAL|Personalized intervention condition|This experimental condition will test a data-driven, person-specific intervention using CBT skills.
62019735|NCT00574860|OTHER|Standard of Care|This arm will reflect the typical standard of care for the patient
62408330|NCT00683462|EXPERIMENTAL|3|
62408331|NCT02736331|EXPERIMENTAL|Treatment 1 Beverage|Treatment 1
62408332|NCT02736331|PLACEBO_COMPARATOR|Treatment 2 Beverage|Treatment 2
62019736|NCT02256475|EXPERIMENTAL|Adolescents Dose Group 1|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days.
62019737|NCT02256475|EXPERIMENTAL|Adolescents Dose Group 2|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 1 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
62211846|NCT03881176|EXPERIMENTAL|Active|"The study site will deploy either PoNS Treatment Schedule A or PoNS Treatment Schedule B. Both PoNS Treatment Schedules will consist of three stages: an in-clinic training program, a home training program, and an extended home training program.~During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week. Daily evening sessions and training sessions on weekends will always be performed independently, at-home by the subject"
62211847|NCT01253304|EXPERIMENTAL|Normal hepatic function|LY2189265: A single, subcutaneous (SC) 1.5-milligram (mg) injection on Day 1 in participants with normal hepatic function
62211848|NCT01253304|EXPERIMENTAL|Mild hepatic impairment|LY2189265: A single, SC 1.5-mg injection on Day 1 in participants with mild hepatic impairment (Child-Pugh A)
62019738|NCT02256475|EXPERIMENTAL|Adolescents Dose Group 3|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
62019739|NCT02256475|EXPERIMENTAL|Children Dose Group 1|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 1 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
62211849|NCT01253304|EXPERIMENTAL|Moderate hepatic impairment|LY2189265: A single, SC 1.5-mg injection on Day 1 in participants with moderate hepatic impairment (Child-Pugh B)
62211850|NCT01253304|EXPERIMENTAL|Severe hepatic impairment|LY2189265: A single, SC-1.5 mg injection on Day 1 in participants with severe hepatic impairment (Child-Pugh C)
62211851|NCT02297139|EXPERIMENTAL|Dasatinib|This is a continuation roll-over study for patients receiving benefit from prior dasatinib protocols. All subjects will receive dasatinib as per previous protocol
62019740|NCT02256475|EXPERIMENTAL|Children Dose Group 2|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the children dose group 1 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
62019741|NCT02256475|EXPERIMENTAL|Children Dose Group 3|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the children dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
62211852|NCT02497248||- Patients with paroxysmal AF.|Patients with AF episodes that terminates spontaneously or with intervention in less than seven days with clinical indication of pulmonary vein ablation.
62019742|NCT04879238|EXPERIMENTAL|Yoga-Mindfulness Intervention|Completing single session of yoga blended with mindfulness.
62019743|NCT04790253|ACTIVE_COMPARATOR|PCI followed by brain MR surveillance|"Prophylactic cranial irradiation will be delivered at the dose of 25 Gy in 10 fractions to the whole brain.~Patients must have a brain MRI performed within 28 days before randomisation and at 3, 6, 9, 12, 18 and 24 months.~Extracranial imaging is recommended and will be performed per institutional standards at the discretion of the treating physician."
62408333|NCT03725358|EXPERIMENTAL|Control: no training, low subsidies|No provider training and low (status quo) subsidies received: business as usual
62408334|NCT03725358|EXPERIMENTAL|No training, medium-level subsidies|No provider training, but receiving medium-level PBF payments for contraceptive methods provided
62019744|NCT04790253|NO_INTERVENTION|MRI Active Surveillance|Patients must have a brain MRI performed within 28 days before randomisation and at 3, 6, 9, 12, 18 and 24 month. Clinical evaluation will be performed every 3 months.
62019745|NCT05829408|OTHER|Intervention (KOPPeling)|In this arm participants directly receive the KOPPeling intervention.
62019746|NCT05829408|OTHER|Waiting list|In this arm participants are placed on a waiting list (ten to twelve weeks) before receiving the KOPPeling intervention.
62019747|NCT04125693|EXPERIMENTAL|Cancer patients|Patients from completed Bayer clinical trials, who received rogaratinib as monotherapy or combination therapy for the treatment of cancer.
62408335|NCT03725358|EXPERIMENTAL|No training, high-level subsidies|No provider training, but receiving high-level PBF payments for contraceptive methods provided
62019748|NCT05519839|EXPERIMENTAL|Group A (Part 1)|CIC Vaccine Formulation1. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62019749|NCT05519839|EXPERIMENTAL|Group B (Part 1)|CIC Vaccine Formulation 2. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62019750|NCT05519839|EXPERIMENTAL|Group C (Part 1)|CIC Vaccine Formulation 3. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62019751|NCT05519839|EXPERIMENTAL|Group D (Part 1)|CIC Vaccine Formulation 3. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62019752|NCT05519839|EXPERIMENTAL|Group E (Part 1)|CIC Vaccine Formulation 1. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62019753|NCT05519839|EXPERIMENTAL|Group F (Part 1)|CIC Vaccine Formulation 2. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62019754|NCT05519839|EXPERIMENTAL|Group G (Part 1)|CIC Vaccine Formulation 3. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62019755|NCT05519839|EXPERIMENTAL|Group H (Part 1)|CIC Vaccine Formulation 4. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62019756|NCT05519839|EXPERIMENTAL|Group I (Part 1)|CIC Vaccine Formulation 5. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62019757|NCT05519839|EXPERIMENTAL|Group J (Part 1)|CIC Vaccine Formulation 6. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62019758|NCT05519839|EXPERIMENTAL|Group K (Part 1)|CIC Vaccine Formulation 7. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62019759|NCT05519839|EXPERIMENTAL|Group L (Part 1)|qNIV Vaccine Formulation 1. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62408336|NCT03725358|EXPERIMENTAL|Training, low-level subsidies|Providers being trained on modern contraception, but receiving low-level (status quo) PBF payments for contraceptive methods provided
62408337|NCT03725358|EXPERIMENTAL|Training, medium-level subsidies|Providers being trained on modern contraception, but receiving medium-level (status quo) PBF payments for contraceptive methods provided
62408338|NCT03725358|EXPERIMENTAL|Training, high-level subsidies|Providers being trained on modern contraception, but receiving high-level (status quo) PBF payments for contraceptive methods provided
62408339|NCT03725358|EXPERIMENTAL|Training+App, low-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving low-level (status quo) PBF payments for contraceptive methods provided
62019760|NCT05519839|EXPERIMENTAL|Group M (Part 1)|qNIV Vaccine Formulation 2. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62408340|NCT03725358|EXPERIMENTAL|Training+App, medium-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving medium-level (status quo) PBF payments for contraceptive methods provided
62584073|NCT05821634|ACTIVE_COMPARATOR|Therapeutic control condition|This control condition will provide an experimental comparison to test the process of personalization.
62584074|NCT05821634|ACTIVE_COMPARATOR|Tracking control condition|This second control condition will provide an experimental comparison to test the effects of health-related tracking and therapeutic contact.
62584075|NCT03008265||Colonic cancer resection|
62019761|NCT05519839|EXPERIMENTAL|Group N (Part 1)|qNIV Vaccine Formulation 3 . 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62019762|NCT05519839|EXPERIMENTAL|Group O (Part 1)|SARS-CoV-2 rS Vaccine Formulation 1. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62019763|NCT05519839|EXPERIMENTAL|Group P (Part 1)|SARS-CoV-2 rS Vaccine Formulation 2. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62019764|NCT05519839|EXPERIMENTAL|Group Q (Part 1)|SARS-CoV-2 rS Vaccine Formulation 3. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62408341|NCT03725358|EXPERIMENTAL|Training+App, high-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving high-level (status quo) PBF payments for contraceptive methods provided
62408342|NCT04633187|EXPERIMENTAL|EDP-938|
62408343|NCT04633187|PLACEBO_COMPARATOR|Placebo|
62408344|NCT06651892|EXPERIMENTAL|Group A - oral diluted phosphate enema|oral diluted phosphate enema
62408345|NCT06651892|ACTIVE_COMPARATOR|Group B - intravenous sodium glycerophosphate|intravenous sodium glycerophosphate
62019765|NCT05519839|EXPERIMENTAL|Group R (Part 1)|SARS-CoV-2 rS Vaccine Formulation 4. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70
62408346|NCT06011499|EXPERIMENTAL|Arm I (iLIVE)|ARM I: Patients receive online access to an interactive weight loss website and participate in online group based resistance training sessions (iLIVE) on study. Patients also use a Fitbit fitness tracker and Aria smart scale while on study.
62408347|NCT06011499|ACTIVE_COMPARATOR|Arm II (Usual care)|Patients receive usual care with access to online survivorship and exercise recommendations and use a Fitbit fitness tracker and Aria (registered trademark) smart scale while on study.
62408348|NCT05322200|ACTIVE_COMPARATOR|Active drug|Oral Semaglutide + conventional therapy (includes dual antiplatelets, Statin, Angiotensin-converting enzyme inhibitors (ACE inhibitors) and beta-blockers)
62019766|NCT05519839|EXPERIMENTAL|Group S (Part 1)|"Influenza Vaccine Formulation 1.~1 intramuscular (IM) doses of vaccine, on Day 0."
62019767|NCT05519839|EXPERIMENTAL|Group T (Part 2)|CIC Vaccine Formulation 8. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70 (if applicable).
62019768|NCT05519839|EXPERIMENTAL|Group U (Part 2)|CIC Vaccine Formulation 9. 2 intramuscular (IM) doses of vaccine, the first on Day 0 and the second on Day 70 (if applicable).
62019769|NCT05519839|PLACEBO_COMPARATOR|Group S (Part 1)-Placebo|1 intramuscular (IM) doses of placebo, on Day 70.
62019770|NCT05242679|EXPERIMENTAL|Myofascial Release Group|Participants were treated with a conventional physiotherapy program along with myofascial release with a tennis ball.
62408349|NCT05322200|PLACEBO_COMPARATOR|Placebo|placebo (same dose and administration route) + conventional therapy (includes dual antiplatelets, Statin, Angiotensin-converting enzyme inhibitors (ACE inhibitors) and beta-blockers)
62408350|NCT04604353|EXPERIMENTAL|PRS score group|Risk information provided on the basis of Polygenic Risk Score combined with the Pooled Cohort Equation
62408351|NCT04604353|ACTIVE_COMPARATOR|CCS score group|Risk information provided on the basis of Coronary Calcium Score combined with the Pooled Cohort Equation
62408352|NCT05901194|EXPERIMENTAL|Lenvatinib|Lenvatinib will be administred orally and daily at the usual dose ( 8 or 12 mg per day depending on the weight \< or ≥ 60kg) in the 25 patients of the study from TACE failure until LT
62584076|NCT04512534|EXPERIMENTAL|Sinitilimab+Chidamide|Anti-PD-1 antibody Sintilimab 200mg intravenously every 3 weeks; HDAC inhibitor Chidamide 30mg orally twice every week
62584077|NCT02959099||Cases|Patients with acute coronary syndrome (ACS).
62584078|NCT02959099||Controls|Patients without acute coronary syndrome (ACS).
62584079|NCT05525858||Tier 1. Therapeutic use of investigational products (KOSMOS-II drugs)|If there are no drugs available under current regulation or patients are not feasible to any clinical trials, and If tumors have actionable genetic alterations and approved drug in any indications but tumor type is not indicative, the MTB may recommend one of KOSMOS-II drugs, therapeutic use of investigational products.
62584080|NCT05525858||Tier 2: Alternative treatments|If there are no KOSMOS-II drugs (Tier 1) or clinical trials (Tier 3) appropriate for patients, the MTB may recommend alternative treatment options (e.g., conventional therapy, radiotherapy, or supportive care).
62584081|NCT05525858||Tier 3: Clinical trial|If patient is eligible for clinical trials matched for actionable genomic alterations found in NGS testing, the MTB will recommend enrollment to clinical trials.
62734520|NCT04476901|PLACEBO_COMPARATOR|Genotype C administered with placebo Group|Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the placebo group will receive the placebo intervention.
62734521|NCT04476901|EXPERIMENTAL|Genotype C administered with hMSC Group|Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the treatment group will receive the hMSC intervention.
62584082|NCT04434092|EXPERIMENTAL|Arm A (Crovalimab)|Crovalimab will be administered at an initial loading dose of 1000 milligrams (mg) (for participants with body weight between 40 and 100 kg) or 1500 mg (for participants with body weight \>=100kg), as intravenous (IV) injection on Day 1 of Week 1 followed by four weekly subcutaneous (SC) injections of 340 mg starting on Day 2 of Week 1 and then once weekly (QW) at Weeks 2,3 and 4. Thereafter crovalimab will be administered, as SC injection, at a maintenance dose of 680 mg (for participants with body weight between 40 and 100kg) or 1020 mg (for participants with body weight \>=100kg) once every 4 weeks (Q4W) from Week 5 for a total of 24 weeks of study treatment. Participants may continue to receive crovalimab after 24 weeks of treatment up to maximum of 5 years.
62019771|NCT05242679|ACTIVE_COMPARATOR|Conventional Physiotherapy Group|A conventional physiotherapy program was provided including range of motion/flexibility exercises, strength training, postural control, functional mobility exercises, lower limb functional exercises, and gait training.
62408353|NCT02244385||Observation|No intervention
62408354|NCT06567886|EXPERIMENTAL|Light Therapy|"All participants will be asked to attend 8 virtual visits over 5 months.~Participants randomized to the morning light therapy group are asked to wear the glasses for 1 hour per day. The timing of each person's therapy is tailored to their average wake up time during a baseline period. The treatment period is 4 weeks long."
62408355|NCT06567886|EXPERIMENTAL|Sleep Stabilization|All participants will be asked to attend 8 virtual visits over 5 months. Participants randomized to the sleep stabilization arm are asked to follow a fixed sleep schedule tailored to their sleep during a baseline period. The treatment period is 4 weeks.
62408356|NCT06567886|NO_INTERVENTION|Control Group, treatment as usual|Participants will be asked to sleep as per usual.
62211853|NCT02497248||- Patients with persistent AF.|Patients with AF episodes that fails to self-terminate within seven days or require pharmacologic or electrical cardioversion to restore sinus rhythm with clinical indication of pulmonary vein ablation..
62211854|NCT02497248||- Patients with mitral stenosis.|- Patients with mitral stenosis and clinical indication for AF ablation undergoing percutaneous balloon mitral valvuloplasty (PBMV) with clinical indication of pulmonary vein ablation..
62211855|NCT05559788||Participants With Multiple Myeloma|Participants with MM who are first relapsed and will start treatment with selinexor, daratumumab and dexamethasone in a real-world clinical practice setting will be observed prospectively for approximately up to 1 year.
62408357|NCT04957316|NO_INTERVENTION|Control group|Conventional treatment of severe septic shock.
62408358|NCT04957316|EXPERIMENTAL|Blood purification group|Conventional treatment of severe septic shock and blood purification.
62408359|NCT04486573|OTHER|CMRI|"Clinical data will be collected regarding cardiac risk factors, cancer type, and cancer treatment.~CMRI will be performed:~* Within 2 weeks before the first fraction of radiation therapy (RT)~* Within 1 week of the final fraction of RT (before or after)~Any patient with a pre-RT and post-RT MRI scan will be considered evaluable.~Pre- and post-RT CMRI parameters will be compared.~3D reconstructed CMR images will be co-registered with RT treatment plans to assess for spatial associations."
62408360|NCT02355314|EXPERIMENTAL|ICU patients requiring mechanical ventilation|
62408361|NCT02409225|EXPERIMENTAL|Home Monitoring|Remote monitoring od ICD/CRT-D function and patient condition. Device: HM provided by St Jude Medical, Biotronik or Medtronic.
62408362|NCT02409225|ACTIVE_COMPARATOR|HM option not active.|Regular visits in outpatient clinic. Device: no HM
62408363|NCT04572737|EXPERIMENTAL|Experimental|Participants will take part in an 8-week home-based activity plan to break up sitting time by 60 minutes per day.
62408364|NCT05003752|OTHER|Hypofractionated EBRT plus HDR-BT boost|Primarily hypofractionated EBRT consisting of 12 x 3 Gy/fraction, TD 36 Gy will be administered. Followed by HDR-BT boost of the prostate, TD 14 Gy.
62408365|NCT01863160|OTHER|0.1% ZEP-3 cream|250 mg of ZEP-3 Cream 0.1% is applied on the right ventral forearm and 250 mg placebo is applied on the left ventral forearm 4 times daily
62408366|NCT01863160|OTHER|placebo|250 mg of ZEP-3 Cream 1.0% is applied on the right ventral forearm and 250 mg placebo is applied on the left ventral forearm 4 times daily
61978502|NCT02505230|EXPERIMENTAL|Meal Order 3|"\[HVP,LVP,P,P+S\]~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices)."
62019772|NCT02755493|EXPERIMENTAL|Sleep Deprivation|Sleep deprivation
62211856|NCT02964325|EXPERIMENTAL|Mirasol platelets (MIR PLTs)|Leukoreduced, Trima Accel® apheresis platelets stored in 100% plasma, pathogen reduced with the Mirasol® Pathogen Reduction Technology (PRT) System
62211857|NCT02964325|ACTIVE_COMPARATOR|Reference platelets (REF PLTs)|Leukoreduced, apheresis platelets stored in 100% plasma
62211858|NCT02450045|ACTIVE_COMPARATOR|Femoral nerve block|Patients will receive a pre-operative continuous femoral nerve block.
62211859|NCT02450045|NO_INTERVENTION|Control|Patients will receive standard care without a continuous femoral nerve block.
62211860|NCT03943472|EXPERIMENTAL|anti-BCMA CAR-T|Administration of anti-BCMA CAR-T cells to patients with multiple myeloma
62211861|NCT03943472|EXPERIMENTAL|anti-BCMA CAR-T+ Immune inhibitors|Administration of anti-BCMA CAR-T cells + Immune inhibitors to patients with multiple myeloma
62408367|NCT05025904|EXPERIMENTAL|Real-time fMRI neurofeedback (rt-fMRI NFB)|The duration of a session was approximately a half-hour. The course duration was 8 sessions. The preferred frequency was once a week, however, the schedule was flexibly adjusted for patients' convenience.
62019773|NCT05005611|PLACEBO_COMPARATOR|Placebo|
62019774|NCT05005611|EXPERIMENTAL|Probiotics Lactobacillus salivarius AP-32|
62211862|NCT01821352|ACTIVE_COMPARATOR|Erchonia Obesity Laser|The Erchonia® Obesity Laser is made up of 10 independent 17 milliWatts (mW), 532 nanometer (nm) green laser diodes, each diode positioned 120 degrees apart from the next with each titled at a 30 degree angle. The Erchonia® Obesity Laser is a pulsed wave variable frequency device.
62211863|NCT01821352|PLACEBO_COMPARATOR|Placebo Laser|Laser device emitting sham green light that has no therapeutic effect.
62211864|NCT00475124|EXPERIMENTAL|1|Home Monitoring ON
62408368|NCT05025904|ACTIVE_COMPARATOR|Сognitive behavioral therapy (CBT)|The duration of a session was approximately an hour/hour and a half. The course duration was 8 individual and 8 group sessions and included home assignments. The preferred frequency was twice a week, however, the schedule was flexibly adjusted for patients' convenience and for improving benefits of the treatment.
62408369|NCT05025904|ACTIVE_COMPARATOR|EEG neurofeedback (EEG NFB)|"The duration of a session was approximately a half-hour. The course duration was 16 sessions. The preferred frequency was twice a week, however, the schedule was flexibly adjusted for patients' convenience.~Group was preliminarily aborted for lack of time and participants in order to assign more patients to the abovementioned arms."
62408370|NCT03781817|ACTIVE_COMPARATOR|Intravenous ketamine|Participants randomized to IV ketamine will be receive IV ketamine and Intranasal normal saline.
62211865|NCT00475124|ACTIVE_COMPARATOR|2|Home Monitoring OFF
62211866|NCT06378359||Arm 1a|screening for SA carriage and using the three-drug decolonization bundle among patients with SA colonization
62408371|NCT03781817|EXPERIMENTAL|Intranasal ketamine|Participants randomized to Intranasal Ketamine group will receive Intranasal ketamine and IV normal saline.
62408372|NCT00939367|EXPERIMENTAL|Test|Torrent's Zolpidem TartrateTablets 10 mg
62408373|NCT00939367|ACTIVE_COMPARATOR|Reference|Sanofi-Synthelabo Inc's Ambient® Tablets 10 mg
62408374|NCT06016231||LAL in at least one eye|
62408375|NCT06116292|EXPERIMENTAL|Mobile application ESTOI for Asthmatic patients|The intervention group will receive the usual care, in addition to having access to the ESTOI application.
62408376|NCT06116292|NO_INTERVENTION|Standard of care|The intervention group will receive the usual care
62019775|NCT05005611|EXPERIMENTAL|Probiotics Bifidobacterium animalis subsp. lactis CP-9|
62019776|NCT05005611|EXPERIMENTAL|Probiotics Lactobacillus rhamnosus LGG|
62019777|NCT04529577|EXPERIMENTAL|His-bundle pacing first|Patients are allocated to receive His-bundle pacing for a period of 6 months. Then the patients will cross over to traditional right ventricular (RV) apical pacing for 6 months.
62019778|NCT04529577|EXPERIMENTAL|RV apical pacing first|Patients are allocated to receive traditional RV apical pacing for a period of 6 months. Then the patients will cross over to His-bundle pacing for 6 months.
62019779|NCT04183933|ACTIVE_COMPARATOR|Pilates Exercise Group|Pilates exercises will given for 6 weeks, 3 days in a week.
62019780|NCT04183933|ACTIVE_COMPARATOR|Combined Exercise group|Combined exercises will given for 6 weeks, 3 days in a week.
62019781|NCT03556761|EXPERIMENTAL|Oral furosemide|Oral furosemide 20 mg/day for a total of 5 consecutive doses.
62211867|NCT06378359||Arm 1b|non SA carriers in this arm will get two pre-op showers with an antiseptic soap
62408377|NCT02544126|EXPERIMENTAL|eSMART-MH|HIV+ young adults will be randomized to receive Electronic Self-Management Resource Training for Mental Health (eSMART-MH)
62408378|NCT02544126|ACTIVE_COMPARATOR|Attention Control|HIV+ young adults will be randomized to receive screen-based health education
62019782|NCT03556761|PLACEBO_COMPARATOR|Placebo Oral Tablet|Placebo once per day for a total of 5 consecutive doses.
62211868|NCT06378359||Arm 2|"giving pre-surgical patients the three drug decolonization bundle without screening.~Nasal mupirocin, chlorhexidine gluconate (CHG) mouth rinse, and CHG body wash"
62211869|NCT06378359||Arm 3|giving pre-op nasal povidone iodine without screening
62211870|NCT06378359||Arm 4|giving nasal alcohol gel without screening
62211871|NCT05415670||[Training set, N=80] Benign/Malignant Pulmonary Nodule|This is a prospective training-set cohort study. A stratified case-cohort design will be used to select patients with malignant pulmonary nodules and patients with benign pulmonary nodules for analysis. All participants will receive chest CT or low-dose computed tomography (LD-CT) scanning and detection of serum tumor markers, and receive Whole-genome methylation sequencing at baseline. GM-seq will perform methylation analysis to build a prediction model for benign and malignant classification.
62408379|NCT03184467|PLACEBO_COMPARATOR|Control group|Normal saline 0.9%
62408380|NCT03184467|EXPERIMENTAL|Study group 1|GV1001 0.56 mg
62408381|NCT03184467|EXPERIMENTAL|Study group 2|GV1001 1.12 mg
62408382|NCT05259748|EXPERIMENTAL|intervention group|At the beginning, personal information form, behavioural change stage diagnosis form and healthy lifestyle scale II were applied. 6-week psychoeducation, consisting of 6 modules, based on the Transtheoretical model, was applied to the intervention group. Finally, posttests were applied after the psychoeducation.
62584083|NCT04434092|ACTIVE_COMPARATOR|Arm B (Eculizumab)|Participants will receive loading dose of eculizumab 600 mg on Days 1, 8, 15, and 22, followed by maintenance dose of 900 mg on Day 29 and every 2 weeks (Q2W) thereafter until 24 weeks. Participants may switch to receive crovalimab after 24 weeks of eculizumab treatment.
62211872|NCT05415670||[Verification set, N=40] Benign/Malignant Pulmonary Nodule|This is a prospective validation-set cohort study. A stratified case-cohort design was used to select patients with malignant pulmonary nodules and patients with benign pulmonary nodules for analysis. All participants will verify the benign and malignant differentiation model based on GM-seq methylation analysis, and compare the results with histopathological benign and malignant results, so as to develop a clinical benign and malignant differentiation model.
62211873|NCT06417697|EXPERIMENTAL|XEN-101|
62211874|NCT06417697|PLACEBO_COMPARATOR|Placebo|
62211875|NCT00446043|EXPERIMENTAL|Adapalene/Benzoyl Peroxide|Participants were treated with adapalene 0.1 percent (%) \[weight by weight (W/W)\] and benzoyl peroxide 2.5 percent (%) (W/W) gel topically to the face and trunk area once daily in the evening.
62211876|NCT05939232||X-ALD|X-linked adrenoleukodystrophy (X-ALD) patients.
62211877|NCT05939232||Carrier-control (CC)|Carriers of mutation in gene encoding ATP-binding cassette subfamily D member 1 (ABCD1), who have no X-linked adrenoleukodystrophy and are matched with the X-ALD group according to age, sex and education.
62211878|NCT03390582||Hashimoto's thyroiditis|Hashimoto's thyroiditis (HT) is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers.
62211879|NCT03390582||healthy controls|healthy controls are all from normal volunteers
62211880|NCT03390582||treatment_naive GD|GD is primarily a humoral disease where autoantibodies are generated against the thyroid stimulating hormone receptor (TSHR) leading to hyperthyroidism.
62019783|NCT01590602||JHD cases|All ages included, but must have an HD age of onset 25 or below
62019784|NCT02506998|EXPERIMENTAL|DLE plus standard medications|"DLE + Second generation anti histamines + Nasal corticosteroids DLE 2mg/5 milliliters (mL) P.O. every 24h per 5 days, followed by 2 mg/mL P.O. twice weekly for 5 weeks, follow by 2 mg/5mL per week for 5 weeks.~Second generation anti histamines at standard dosis every 24h, and Nasal corticosteroids two spray released per nostril every 24 h per 11 weeks"
62019785|NCT00811083|ACTIVE_COMPARATOR|DMSA- 1 round|Subjects receive 1 round of DMSA (10 mg/kg-dose, 9 doses over 3 days), followed by 3 months of placebo
62211881|NCT03390582||treated GD|GD patients treated by Methimazole Pill
62211882|NCT01979627|EXPERIMENTAL|transulnar approach group|Patients in transulnar group received interventional procedure through ulnar artery
62211883|NCT01979627|OTHER|transradial approach group|patients in transradial group received interventional procedure through radial artery
62211884|NCT04142229|EXPERIMENTAL|Automated Insulin Delivery|Participants will use the Automated Insulin Delivery (AID) iAPS system for 2 weeks in the outpatient setting, and come to the clinical center twice for supervised stress assessments.
62211885|NCT04142229|ACTIVE_COMPARATOR|SAP/PLGS|Participants will use their home pump with a CGM sensor (sensor augmented pump) or in Predictive Low Glucose Suspend (PLGS) mode if their home pump supports this mode, for 2 weeks in the outpatient setting, and come to the clinical center twice for supervised stress assessments.
62019786|NCT00811083|ACTIVE_COMPARATOR|DMSA-7 rounds|Participants receive 7 rounds of DMSA over 4 months; each round consists of 3 days of DMSA (10 mg/kg-dose, 9 doses over 3 days), followed by 11 days off (no treatment), and then repeating.
62019787|NCT00235534|EXPERIMENTAL|Immediate start|Initiate selected birth control method before leaving the clinic at the time of the abortion procedure.
62019788|NCT00235534|ACTIVE_COMPARATOR|Sunday start|Begin birth control the first Sunday after leaving the clinic
62019789|NCT01264302|EXPERIMENTAL|Finasteride tablets 5 mg|Finasteride tablets 5 mg of Dr.Reddy's Laboratories Limited
62019790|NCT01264302|ACTIVE_COMPARATOR|Proscar 5 mg Tablets|Proscar 5 mg Tablets of Merck \& Co. Inc
62211886|NCT03206892|EXPERIMENTAL|LESS surgery|Laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women using laparoendoscopic single-site surgery (single incision through the umbilicus using modified Hasson technique).
62211887|NCT03206892|ACTIVE_COMPARATOR|conventional multi-port laparoscopy|laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women using conventional multi-port laparoscopy (three port system using a closed technique on the umbilicus, left and right lower quadrant areas).
62211888|NCT05774834||All healthy participants|All healthy participants will undergo behavioral assessment and fMRI
62211889|NCT06400940|EXPERIMENTAL|Antiplatelet (antithrombotic) monotherapy|Antiplatelet (antithrombotic) monotherapy, including ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).
62019791|NCT02973451|ACTIVE_COMPARATOR|Laparoscopic|Laparoscopic Guided Transversus Abdominis Plane Block using Bupivacaine
62019792|NCT02973451|ACTIVE_COMPARATOR|local|Trocar Site Infiltration of Bupivacaine
62019793|NCT00836641|ACTIVE_COMPARATOR|pneumococcal immunization (2 mo)|one dose of pneumococcal conjugate vaccine (prevenar) followed after 2 months by one dose of pneumococcal polysaccharide vaccine (pneumovax)
62211890|NCT06400940|ACTIVE_COMPARATOR|Double antiplatelet (antithrombotic) therapy|Double antiplatelet (antithrombotic) therapy (DAT), including a combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).
62211891|NCT01360710|EXPERIMENTAL|Moxonidine|
62211892|NCT01360710|ACTIVE_COMPARATOR|Irbesartan|
62584084|NCT04434092|EXPERIMENTAL|Arm C (Crovalimab) (Exploratory)|Paediatric participants will receive a loading series of Crovalimab comprised of an IV dose on Week 1 Day 1, followed by weekly crovalimab SC doses for 4 weeks on Week 1 (Day 2) then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will be administered Q4W thereafter. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
62584085|NCT06113965|EXPERIMENTAL|Experimental: Post-stroke Stiff-Knee Gait Participants|Individuals with post-stroke Stiff-Knee gait
62211893|NCT02880540|ACTIVE_COMPARATOR|Control Group|Fentanyl 50 micrograms IV every 15 minutes up to 3 doses in postanesthesia recovery room and Morphine 2mg IV every 2 hours for 2days on hospital floor
62019794|NCT00836641|ACTIVE_COMPARATOR|pneumococcal immunization (10 mo)|one dose of pneumococcal conjugate vaccine (prevenar) followed after 10 months by one dose of pneumococcal polysaccharide vaccine (pneumovax)
62019795|NCT06447038||Population|Population of the city of Burgos \> 18 years old.
62211894|NCT02880540|EXPERIMENTAL|Dexmedetomidine Treated|Dexmedetomidine IV bolus 1.5microgram/kilogram and a continuous infusion starting at 0.1 microgram/kilogram/hour during surgery
62211895|NCT03093376|EXPERIMENTAL|Effortful Control Camp|"Children will participate in an interactive, child-friendly camp comprised of short, game-like exercises to teach inhibitory and attentional control, as well as visuospatial and working memory skills."
62211896|NCT04714749|EXPERIMENTAL|Endovenous treatment|Endovenous treatment with cyanoacrylate glue
62584086|NCT05066711||ACP System|
62584087|NCT03444064|NO_INTERVENTION|Control|Participants in this arm receive islet transplant only, and no PolyTregs.
62584088|NCT03444064|EXPERIMENTAL|Treatment|Participants in this arm receive PolyTregs infusion at week 6 post islet transplant.
62584089|NCT02026791|EXPERIMENTAL|The clinical efficacy of the I-gel|The clinical efficacy of the I-gel
62584090|NCT02026791|ACTIVE_COMPARATOR|The clinical efficacy Supreme-LMA|The clinical efficacy Supreme-LMA
62584091|NCT00943553|EXPERIMENTAL|1|
62584092|NCT00943553|EXPERIMENTAL|2|
62408383|NCT05259748|NO_INTERVENTION|control group|At the beginning, personal information form, behavioural change stage diagnosis form and healthy lifestyle scale II were applied. No interventions were applied to the control group. It was contacted with the control group three times, two face to face and one via phone. In the third and final meeting, when the intervention group's sessions are completed, posttests were applied again to the control group.
62584093|NCT04348864|EXPERIMENTAL|Positive-Antigen swab test for SARS-COV-2|Subjects who have tested positive for the presence of SARS-COV-2 viral antigen using a rapid test or LAMP/PCR-based molecular test from nasal pharyngeal self-swab or a swab administered in a clinical setting at the point of care by a trained clinician. Parallel PCR-based testing occurs in an advanced laboratory to obtain Ct values for positive test results.
62584094|NCT04348864|SHAM_COMPARATOR|Negative-Antigen swab test for SARS-COV-2|Subjects who have tested negative for the presence of SARS-COV-2 viral antigen using a rapid test or LAMP/PCR-based molecular nasal pharyngeal self-swab or a swab administered in a clinical setting by a trained clinician. PCR-based testing occurs in an advanced laboratory.
62584095|NCT04808700|OTHER|Focal cartilage lesion|Patients with focal cartilage lesions who underwent a knee surgery using the Episealer implant
62584096|NCT05128955|ACTIVE_COMPARATOR|Active Comparator: Splenic artery embolization with vascular embolic coils|Device: Splenic artery embolization with vascular embolic coils
62584097|NCT05128955|ACTIVE_COMPARATOR|Active Comparator: Splenic artery embolization with vascular embolic plugs|Active Comparator: Splenic artery embolization with vascular embolic plugs
62584098|NCT02177916|EXPERIMENTAL|Traditional teaching|
62584099|NCT02177916|EXPERIMENTAL|DVD|
62584100|NCT02226640||Non-Diabetic Lean Athletes|Athletes with a Body Mass Index (BMI) less than or equal to 25 kg/m2.
62211897|NCT02021552||trauma patients|trauma patients 18 years or older requiring treatment in the ICU \>24 hours. All subjects will undergo blood sampling.
62211898|NCT03667430|EXPERIMENTAL|Normal weight subjects|Healthy normal weight (BMI 20-25) men 18-35 year. Intervention: The participants will take placebo or silica powder with specified doses administrated in vials and with instructions to mix with water as; Placebo (microcrystalline cellulose) day 1-5 Porous silica 1gx3 daily for day 6-9 Porous silica 2gx3 daily for day 10-14 Porous silica 3gx3 daily for day 15-21 Total study time 21 days
62211899|NCT03667430|EXPERIMENTAL|Subjects with obesity|Obese otherwise healthy men (BMI 30-45) 18-35 year Intervention: The participants will take placebo or silica powder with specified doses administrated in vials and with instructions to mix with water as; Placebo (microcrystalline cellulose) day 1-5 Porous silica 1gx3 daily for day 6-9 Porous silica 2gx3 daily for day 10-14 Porous silica 3gx3 daily for day 15-21 The dose of Silica 3gx3 for additional 10 weeks Total study time 84 days
62408384|NCT05153655|EXPERIMENTAL|Ischemic post-conditioning group|The safety and tolerability of ischemic post-conditioning will be investigated using 3+3 dose-escalation trial design.
62408385|NCT01789476|EXPERIMENTAL|CR845|Peripheral kappa opioid receptor agonist
62408386|NCT01789476|PLACEBO_COMPARATOR|Placebo|Matched placebo
62584101|NCT02226640||Non-Diabetic Lean No Diabetes History|Adults with a BMI \< 25 kg/m2 and no family history of diabetes
62584102|NCT02226640||Non-Diabetic Lean Yes Diabetes History|Adults with a BMI \< 25 kg/m2 and family history of diabetes
62584103|NCT02226640||Non-Diabetic Obese|Adults with BMI greater than or equal to 30 kg/m2.
62584104|NCT02226640||Non-Diabetic Obese Female PCOS|Female adults with BMI \> 30 kg/m2 and Polycystic Ovarian Syndrome (PCOS).
62584105|NCT02226640||Diabetic No Medication|Have diabetes and currently receiving no medication or early treatment with one medication. Some participants receiving insulin may also be included in this study
62584106|NCT02226640||Diabetic GAD Ab+|Have diabetes with Latent Autoimmune Diabetes in Adults (LADA).
62584107|NCT02226640||Diabetic With NASH|Have diabetes with Nonalcoholic Steatohepatitis (NASH), which is chronic liver disease with fat in the liver, inflammation, and damage not associated with drinking alcohol.
62408387|NCT06515925|EXPERIMENTAL|Our Whole Lives (OWL)|Our Whole Lives (OWL) is a 9-week online curriculum on the GEMINI platform. OWL is a nine-session, web-accessible, self-paced mindfulness curriculum that has interactive components of self-monitoring and social support (online community).
62584108|NCT06325839|EXPERIMENTAL|HypnoBirthing training and oxytocin massage group|Pregnant women who received HypnoBirthing training and oxytocin massage constituted the experimental group.
62584109|NCT06325839|NO_INTERVENTION|The group without HypnoBirthing training and oxytocin massage|Pregnant women who did not receive HypnoBirthing training and oxytocin massage constituted the control group.
62584110|NCT03909334|ACTIVE_COMPARATOR|Arm A (Osimertinib and Ramucirumab)|Osimertinib and Ramucirumab
62584111|NCT03909334|ACTIVE_COMPARATOR|Arm B (Osimertinib)|Osimertinib
62408388|NCT06515925|ACTIVE_COMPARATOR|Low Dose Mindfulness Training|The GEMINI platform will facilitate the delivery of a low-dose mindfulness version of Our Whole Lives program. Participants will interface with the GEMINI platform's static content.
62584112|NCT03063086|ACTIVE_COMPARATOR|Sequence 1|A-B-C
62584113|NCT03063086|ACTIVE_COMPARATOR|Sequence 2|A-C-B
62584114|NCT03063086|ACTIVE_COMPARATOR|Sequence 3|B-C-A
62584115|NCT03063086|ACTIVE_COMPARATOR|Sequence 4|B-A-C
62584116|NCT03063086|ACTIVE_COMPARATOR|Sequence 5|C-A-B
62584117|NCT03063086|ACTIVE_COMPARATOR|Sequence 6|C-B-A
62584118|NCT06667830|ACTIVE_COMPARATOR|Physical exercise|
62584119|NCT06667830|EXPERIMENTAL|Physical exercise + Neural mobilization|
62019796|NCT04589819|ACTIVE_COMPARATOR|Teriparatide|Study participants will be randomized into either the study medication arm or a placebo arm. The study medication Forteo (teriparatide \[rDNA origin\] injection) (El-Lilly, Indiana, USA), will be administered via an blinded injection pen in the abdominal wall or thigh as described in the product guide. Subjects in the teriparatide arm will receive a 20mg dose of the medication daily via self-injection.
62584120|NCT06664931|EXPERIMENTAL|Group (A) Muscle Energy Technique (MET).|These participants will receive METs, in addition to a standard physical therapy program consisting of deep neck flexor strengthening exercises, isometric exercise, and range of motion exercises (3 sessions per week for 4 weeks).
62211900|NCT03949153|EXPERIMENTAL|Experimental arm|Single Nivolumab 240 mg infusion at D0, followed by cryotherapy using interventional radiology of metastatic lymphadenopathy at D1 and in situ injection with ipilimumab at D2.
62584121|NCT06664931|EXPERIMENTAL|Group (B) Mulligan Mobilization Technique group (MMT).|Participants will receive MMT interventions alongside the standard physical therapy program deep neck flexor strengthening exercises, isometric exercise, and range of motion exercises 3 sessions per week for 4 weeks.
62584122|NCT03220295|EXPERIMENTAL|Dose Escalation of VU319 - Dose 1|Dose Escalation of VU319
62211901|NCT05559762||Day Shift|Nurses regularly working 12hr day shifts
62211902|NCT05559762||Night Shift|Nurses regularly working night shift
62211903|NCT03250923|EXPERIMENTAL|silver citrate complex and acemannan|This is a single arm open pilot trial. All participants will receive study drug.
62211904|NCT03922516|OTHER|Reporting order: Plain Film - ULDCT|"The plain film of half the participants (randomized) will be submitted for reporting by a radiologist as a first imaging method. After finishing this report, the same radiologist will assess the ULDCT of this participant. In this second report, the findings of both examinations will be summarized, and a second report will be filed.~Emergency physicians will first receive the report for the plain film of the chest and will be asked for the diagnosis and its probability. Next, the report for ULDCT will be presented to them. Again, diagnosis and probabilities will be documented."
62019797|NCT04589819|PLACEBO_COMPARATOR|Placebo|The placebo will be administered in a replica, blinded, injection pen in the same fashion. The study participant will self-administer the medication after being given a teaching session on medication administration by the study nurse.
62019798|NCT03866174|EXPERIMENTAL|Psilocybin|Participants will receive a single 25 mg dose of psilocybin along with the Set and Setting (SaS) protocol. Psilocybin is administered orally as a capsule and taken with water.
62211905|NCT03922516|OTHER|Reporting order: ULDCT - Plain Film|"For half the participants (randomized) radiologists will first receive the data from ULDCT of the chest and write a report. Subsequently, they will receive the data from the plain film of the chest and may expand their report (explicitly separated).~Emergency physicians will first receive the report for the ULDCT of the chest and will be asked for probabilities of the nine most frequent diagnoses in chest-imaging plus other. Next, they will be presented with the report for the plain film and will again be asked to give an estimation of the probabilities for the same diagnoses as before."
62211906|NCT02541877|EXPERIMENTAL|Down sizing valve in type-0 BAS|Down Sizing Transcatheter Self-expandable Valve in Type-0 BAS
62211907|NCT02541877|ACTIVE_COMPARATOR|Standard sizing valve in type-0 BAS|Standard Sizing Transcatheter Self-expandable Valve in Type-0 BAS
62211908|NCT02541877|ACTIVE_COMPARATOR|Standard sizing valve in TAS|Standard Sizing Transcatheter Self-expandable Valve in TAS
62211909|NCT05833490|EXPERIMENTAL|Sensory-based priming|Participants will receive rPMS at 10% above motor threshold with the coil placed on the Tibialis Anterior muscle belly. rPMS parameters will be: 40 trains, intermittently (3) seconds on, (19) seconds off, with an intensity \~10% above motor threshold.
62211910|NCT05833490|SHAM_COMPARATOR|Sham Priming|Participants will receive sham rPMS at a very low intensity with the coil placed on the dorsal part of the foot. rPMS parameters will be: 40 trains, intermittently (3) seconds on, (19) seconds off, with an intensity at 5% of maximum stimulator output.
62019799|NCT03866174|ACTIVE_COMPARATOR|Niacin|Participants will receive a single 100 mg dose of niacin along with the Set and Setting (SaS) protocol. Niacin is administered orally as a capsule and taken with water.
62408389|NCT00924313|EXPERIMENTAL|11C-acetate for Prostate Cancer Patients|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
62584123|NCT03220295|PLACEBO_COMPARATOR|Placebo - Dose 1|Dose Escalation of Placebo
62584124|NCT03220295|EXPERIMENTAL|Single Dose of VU319 under Fed State|Single dose of VU319 (50% of the maximum tolerated dose) 30 minutes after a High Fat Standard Breakfast
62584125|NCT03220295|PLACEBO_COMPARATOR|Single Dose of Placebo under Fed State|Single dose of Placebo 30 minutes after a High Fat Standard Breakfast
62408390|NCT00066586|ACTIVE_COMPARATOR|Exemestane|
62408391|NCT00066586|PLACEBO_COMPARATOR|Placebo|
62408392|NCT02495974||Patients with mCRPC prescribed enzalutamide|Oral
62584126|NCT03220295|EXPERIMENTAL|Single Dose of VU319 under Fasted State|Single dose of VU319 (50% of the maximum tolerated dose) after overnight fast
62211911|NCT02781090|EXPERIMENTAL|Positively Smoke Free on the Web (PSFW+)|"Participants were assigned to the multimodal PSFW+ interactive web-based behavioral intervention hosted within an online social network.~PSFW+: PSFW+ is an intensive eight session motivational/educational web-program, based on social cognitive theory, designed to promote cessation among HIV-infected smokers. It included a professionally administered social network/online support community.~Nicotine polacrilex: All participants were offered a 3-month supply of nicotine patches"
62408393|NCT06491719|EXPERIMENTAL|iNK cells infusion patients|Given iNK cell infusion after allo HSCT
62408394|NCT03320031|EXPERIMENTAL|combined group|Drug: linagliptin\&premixed insulin Treated with linagliptin 5mg/d combined with premixed insulin for 12 weeks.
62408395|NCT03320031|ACTIVE_COMPARATOR|linsulin group|Drug: premixed insulin Treated with premixed insulin for 12 weeks.
62408396|NCT01711814|EXPERIMENTAL|ASP015K|Experimental
62408397|NCT06027788|ACTIVE_COMPARATOR|CardioGard Embolic Protection Cannula|In patients assigned to the embolic protection device group, the CardioGard Embolic Protection Cannula is used instead, according to the manufacturer's instructions for use (IFU).
62408398|NCT06027788|PLACEBO_COMPARATOR|Standard Aortic Cannula|In patients assigned to the standard cannula group, standard cannulation techniques are performed using any standard aortic cannula of the surgeon's choice
62408399|NCT01723371|EXPERIMENTAL|Carvedilol|
62584127|NCT03220295|PLACEBO_COMPARATOR|Single Dose of Placebo under Fasted State|Single dose of placebo after overnight fast
62584128|NCT03220295|EXPERIMENTAL|Dose Escalation of VU319 - Dose 2|Dose Escalation of VU319
62211912|NCT02781090|PLACEBO_COMPARATOR|American Heart Association Getting Healthy (AHA)|"Participants were assigned to the AHA Getting Healthy web-based control intervention program (the AHA later changed in name from Getting Healthy to My Life's Check, Life's Simple 7~AHA: The AHA Getting Healthy website is an attention-matched, health-promoting, seven-module website developed by the American Heart Association to encourage healthy behaviors in the general population~Nicotine polacrilex: All participants were offered a 3-month supply of nicotine patches"
62584129|NCT03220295|EXPERIMENTAL|Dose Escalation of VU319 - Dose 3|Dose Escalation of VU319
62584130|NCT03220295|EXPERIMENTAL|Dose Escalation of VU319 - Dose 4|Dose Escalation of VU319
62584131|NCT03220295|EXPERIMENTAL|Dose Escalation of VU319 - Dose 5|Dose Escalation of VU319
62211913|NCT06610747|EXPERIMENTAL|Home-based care group|"Home-based monitoring with home visual acuity tester and home OCT:~For participants in the home-based care group, home service appointments will be scheduled during the 'pro re nada' (PRN) treatment phase. Participants will receive a home self-administered visual acuity tester and a self-administered Home OCT to use at home every 4 weeks after the 5th injection through 48 weeks, and then as needed per the DME treatment regimen protocol provided in the protocol."
62211914|NCT06610747|ACTIVE_COMPARATOR|Standard Hospital/clinic-based care group|"Standard hospital/clinic-based visual acuity and OCT monitoring:~For participants in the standard Hospital/clinic-based group, hospital service appointments will be scheduled during the 'pro re nada' (PRN) treatment phase. Participants will be instructed to return to the clinic for hospital-based visual acuity examinations and standard OCT measurements every 4 weeks after the 5th injection through 48 weeks, and then as needed per the DME treatment regimen protocol provided in the protocol."
62211915|NCT02133209|ACTIVE_COMPARATOR|Stress Management for Headaches|This intervention involves a standardized stress management for headaches (SMH) group intervention that focuses on stress and general stress management skills for managing migraine headaches.
62408400|NCT02611076|EXPERIMENTAL|Stop Smoking for Good Intervention in Spanish|Study II: Stop Smoking for Good Intervention in Spanish (SS-SP) will comprise a series of 10 booklets distributed over 18 months, plus additional monthly contacts via 9 supportive pamphlets developed in Study I. Behavioral: Stop Smoking for Good Intervention in Spanish (SS-SP) Assessments will occur at six-month intervals, through 24 months.
62408401|NCT02611076|ACTIVE_COMPARATOR|Usual Care|Study II: Usual Care (UC) will comprise a single, Spanish-language, smoking cessation booklet developed by the National Cancer Institute (NCI). Behavioral: Usual care (UC) Assessments will occur at six-month intervals, through 24 months.
62584132|NCT03220295|PLACEBO_COMPARATOR|Placebo - Dose 2|Dose Escalation of Placebo
62584133|NCT03220295|PLACEBO_COMPARATOR|Placebo - Dose 3|Dose Escalation of Placebo
62584134|NCT03220295|PLACEBO_COMPARATOR|Placebo - Dose 4|Dose Escalation of Placebo
62584135|NCT03220295|PLACEBO_COMPARATOR|Placebo - Dose 5|Dose Escalation of Placebo
62584136|NCT00430417||3 groups|Group 1: post-partum breastfeeding women
62584137|NCT00430417||Group 2|Group 2: post-partum bottlefeeding women
62584138|NCT00430417||Group 3|Group 3: normal non-pregnant controls who are age and race-matched to Group 1
62584139|NCT02589990|EXPERIMENTAL|Strength training|Strength training, 4 rep of 4RM x 4 sets in leg press.
62584140|NCT06685003|ACTIVE_COMPARATOR|T - Digital Tutorial overview|A digital tutorial consisting of a curriculum dashboard for review of 20 modules, including videos, PDFs, text and quizzes, which are to be unlocked sequentially over seven weeks. Modules remain available during the 6-month study timeframe. Participants receive weekly contact encouraging engagement in all of the materials available to them.
62734522|NCT05753254|NO_INTERVENTION|Baseline session|Baseline measurements will be performed in the same schedule as measurements in the three other arms. In the baseline session, participants are in classroom before starting any firefighting exercise
62211916|NCT02133209|ACTIVE_COMPARATOR|Mindfulness Based Stress Reduction|Intervention involves a standardized mindfulness-based stress reduction (MBSR) group intervention following the guidelines originally conceived and developed by the Center for Mindfulness in Medicine, Health Care and Society at the University of Massachusetts. The intervention also included an extended period of training in addition to the usual 8 weeks.
62584141|NCT06685003|EXPERIMENTAL|TM - Digital Tutorial plus training Materials|Participants receive the digital tutorial (T), plus access to 15 additional in depth modules of digital training materials also released weekly alongside the tutorial modules. Modules remain available during the 6-month study timeframe. Participants receive weekly contact encouraging engagement in all of the materials available to them.
62584142|NCT06685003|EXPERIMENTAL|TMC - Digital Tutorial plus training Materials plus feedback and Coaching|Participants receive the digital tutorial (T) plus the digital Training materials (TM), plus they submit audio recordings of sessions with clients and receive feedback on their application of CRAFT and receive group coaching on how to improve.
62584143|NCT02918474|EXPERIMENTAL|Supportive care (decision making tool)|Patients use decision making tool during consultation with breast cancer surgeon and complete questionnaires before and after consultation.
62211917|NCT05253495|EXPERIMENTAL|Cohort 1a|"Mature B-cell Non-hodgkin Lymphoma \[MB NHL\], GROUP B will receive reduction therapy with dexamethasone, vincristine and cyclophosphamide (DOC), then undergo disease assessment. If tumor reduction ≥ 20%, will get induction 1 and 2 with polatuzumab vedotin, cyclophosphamide, vincristine, methotrexate, rituximab, doxorubicin (Pv-COM3RA25D) 1 and 2, then Consolidation 1 with rituximab, cytarabine, methotrexate (R-CYM) . Patients will undergo disease assessment post Consolidation 1. If no residual disease, they proceed to receive Consolidation 2 with Pv-R-CYM (R-CYM 2).~Cohort Ia patients with \< 20% tumor reduction post DOC will be assigned to Cohort Ib starting at Induction 1. Cohort Ia patients with residual disease post Consolidation 1 will be assigned to Cohort Ib starting at Consolidation 1 polatuzumab vedotin, rituximab, high dose cytarabine, cytarabine, high dose methotrexate, etoposide (Pv-R-CYVE 1)."
62211918|NCT05253495|EXPERIMENTAL|Cohort 1b|MB NHL, GROUP C will receive reduction therapy with DOC. Patients with \< 20% tumor reduction will be off protocol. Patients with ≥ 20% tumor reduction get Induction 1 and 2 with cyclophosphamide, doxorubicin, dexamethasone, high dose methotrexate, polatuzumab vedotin, and triple intrathecal chemotherapy (M8A30D CPR) 1 and 2, then Consolidation 1 with Pv-R-CYVE 1. If no residual disease, they get Consolidation 2 (Pv-R-CYVE 2), followed by Maintenance (M) 1 with M8A30D CP, M 2 with Pv-cytarabine/etoposide, M 3 with cyclophosphamide, doxorubicin, dexamethasone and polatuzumab vedotin (A30D CP), and M 4 with Pv-cytarabine/etoposide. Cohort Ib patients with CNS disease will receive additional intrathecal chemotherapy and high dose methotrexate during Consolidation.
62584144|NCT06302452|NO_INTERVENTION|No Intervention: Standard Care|All trauma patients will receive standard routine care which may include some screening and counseling on gun safety.
62584145|NCT06302452|EXPERIMENTAL|ACTFAST Intervention|During the implementation and maintenance periods, all trauma patients will receive study activities including firearm access screening, counseling on safe storage practices, and referral to safe storage and other community resources as appropriate.
62584146|NCT04061512|ACTIVE_COMPARATOR|DRC Arm|The DRC arm (chemotherapy) is the control arm and consists of rituximab, cyclophosphamide and dexamethasone. It is widely recommended by international consensus as appropriate treatment for first-line therapy for WM.
62584147|NCT04061512|EXPERIMENTAL|RI Arm|The RI arm (chemotherapy free) arm will be using the drug ibrutinib, which in combination with rituximab (RI) will be the experimental arm.
62584148|NCT00520611|ACTIVE_COMPARATOR|Lottery|Participants are entered into daily lotteries to win $10 or $100 every day their weight is at or below daily targets.
62211919|NCT05253495|EXPERIMENTAL|Cohort 2a|Classical Hodgkin lymphoma, INTERMEDIATE RISK will receive 2 cycles of brentuximab vedotin (Bv), doxorubicin, vinblastine, dactinomycin, and rituximab (Bv-AVD-R 1 and 2). Response assessment with FDG-PET scan after 2 cycles of Bv-AVD-R. Rapid early responders (RER) will continue therapy with 2 cycles of Bv, vinblastine, dactinomycin, nivolumab, and rituximab (Bv-NVD-R 1 and 2). RERs will not receive radiation therapy. Patients deemed to be Slow Early Responders (SER) after 2 cycles of Bv-AVD-R will continue therapy with 4 cycles of Bv-NVD-R (Bv-NVD-R 1, 2, 3, and 4). Radiation therapy will be given at completion of therapy only for SER patients NOT achieving complete remission at the end of chemoimmunotherapy.
62019800|NCT03908684||Head and Neck|The research will involve a clinical evaluation consisting of 200 patients in the head and neck cohort. It will assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity), spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
62019801|NCT03908684||Prostate|The research will involve a clinical evaluation consisting of 100 patients in the prostate cohort. It will assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity), spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
62019802|NCT03908684||Rectum|The research will involve a clinical evaluation consisting of 20 patients in the rectal cohort. It will assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity), spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
62019803|NCT06066112|EXPERIMENTAL|Fasting state|The subjects fasted overnight for at least 10 hours, and an indwelling needle was buried before administration. On the morning of administration, one test formulation (T) or one control formulation (R) was administered on an empty stomach, and the start time of administration was recorded. After administration, the oral cavity and medication container should be checked to ensure the correct use of the medication. Do not drink water from 1 hour before medication to 1 hour after medication (except for 20ml of water moistened with the test formulation and 240 mL of water from the control formulation). Control drinking water from 1 hour to 4 hours after medication, and drink freely at other times. Fasting within 4 hours after medication. After medication, keep the upper body upright for 4 hours. The meal time on the day of the two cycles of medication is roughly the same.
62019804|NCT06066112|EXPERIMENTAL|Fed state|Before administration, subjects were placed with an indwelling needle and fasted overnight for at least 10 hours before consuming a high-fat meal. They started eating a high-fat meal 30 minutes before taking the medication on the morning of the day of administration. Control drinking water from 1 hour to 4 hours after taking the medication, and drink freely at other times. Fasting within 4 hours after taking the medication. After medication, keep the upper body upright for 4 hours. The meal time on the day of the two cycles of medication is roughly the same.
62019805|NCT04695691|EXPERIMENTAL|Laser Treatment|
62019806|NCT04289649|EXPERIMENTAL|K-924 LD|K-924 LD tablet once daily
62019807|NCT04289649|EXPERIMENTAL|K-924 HD|K-924 HD tablet once daily
62019808|NCT04289649|ACTIVE_COMPARATOR|Pitavastatin 2 mg|K-924 LD Placebo tablet once daily
62584149|NCT00520611|ACTIVE_COMPARATOR|Deposit|Participants receive $3/day if they are at or below their daily weight goals, plus have opportunity to deposit up to $3/day of their own money, which is then matched 1:1 every day they are at or below their daily weight goals.
62584150|NCT00520611|NO_INTERVENTION|Control|Participants would receive usual care from their providers and have monthly weigh ins.
62584151|NCT01090362||Cohort 1|Cohort complete with 5,088 retrospective patients and 5,499 prospective patients recruited from 19 countries.
62584152|NCT01090362||Cohort 2|Cohort completed with 11,351 patients enrolled from 30 countries
62211920|NCT05253495|EXPERIMENTAL|Cohort 2b|COHORT IIb (Classical Hodgkin lymphoma, HIGH RISK) Cohort IIb patients will receive 2 cycles of brentuximab vedotin (Bv), doxorubicin, vinblastine, dactinomycin, and rituximab (Bv-AVD-R 1 and 2). Response assessment will be performed with FDG-PET scan after 2 cycles of Bv-AVD-R. Rapid early responders (RER) will continue therapy with 4 cycles of Bv, vinblastine, dactinomycin, nivolumab, and rituximab (Bv-NVD-R 1, 2, 3, and 4). RERs will not receive radiation therapy. Patients deemed to be Slow Early Responders (SER) after 2 cycles of Bv-AVD-R will receive 2 cycles of Bv, nivolumab, doxorubicin, vinblastine, dactinomycin, and rituximab (Bv-NAVD-R 1 and 2), followed by 4 cycles of Bv, vinblastine, dactinomycin, nivolumab, and rituximab (Bv-NVD-R 1, 2, 3, and 4). Radiation therapy will be given at completion of therapy only for SER patients NOT achieving complete remission at the end of chemoimmunotherapy.
62211921|NCT01215188|EXPERIMENTAL|V114 Aluminum-adjuvanted|Four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.
62211922|NCT01215188|EXPERIMENTAL|V114 Non-adjuvanted|Four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.
62211923|NCT01215188|ACTIVE_COMPARATOR|Prevnar 13®|Four IM doses at 0.5 mL of Prevnar 13® at 2, 4, 6, and 12 to 15 months of age.
62211924|NCT02901158||Critical care patients|Mechanically ventilated patients in the critical care unit
62211925|NCT02901158||OR-patients|Mechanically ventilated patients in the operating room
62211926|NCT05106413|EXPERIMENTAL|Speech Intelligibility with CROS device|"The focus of this study is on Speech Intelligibility (SI), evaluated by the Oldenburg Sentence test (OLSA), which measures a speech recognition threshold (SRT) in dB SNR (signal to noise ratio).~Therefore each participant will perform the tests with the experimental rechargeable CROS transmitter (CROS) in different interventions, like comparison to monaural fitting and unaided condition.~All participants will perform the same tests. The order of the intervention in the speech test is randomized, but will be performed in the same visit by each participant."
62408402|NCT03596476|EXPERIMENTAL|Patients with persistent GERD|Patients with persistent GERD suggestive symptoms despite PPI therapy. All the patients will undergo an upper gastrointestinal (GI) endoscopy, a wireless pH monitoring and a post prandial esophageal High Resolution Impedance Manometry (HRIM). Optional: 24-h pH-impedance monitoring on PPI
62408403|NCT06650345|NO_INTERVENTION|the control group|non-exercised participants with daily life activities
62408404|NCT06650345|EXPERIMENTAL|exercise group|participants engaged in a 12-week exercise regimen structured thrice weekly.Each session's intensity was customized to match the individual's maximum and resting heart rates. The warm-up involved stretching and a 5 to 10-minute walk. In the core exercise phase, participants aimed to reach their predetermined training heart rate (THR max; between 60 to 70%) for 45-60 minutes through intervals on a treadmill, bike, or stair climber.The exercise protocol was designed to elicit physical exertion equivalent to 30-45% of their maximum oxygen consumption (VO2 max)
62408405|NCT03723668||OPTN data system|In the US, data on the donors and kidney transplant recipients will be obtained using registry data from the Organ Procurement and Transplantation Network (OPTN). The OPTN data system includes data on all donors, waitlisted candidates, and transplant recipients in the US, as submitted by the members of the Organ Procurement and Transplantation Network. The Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services oversees the activities of the OPTN contractor.
62408406|NCT03723668||CRISTAL registry|In France, data on the donors and recipients in the French cohort will be obtained from the national CRISTAL registry, initiated in 1996 and maintained by the Agence de la Biomédecine, which prospectively collects data on all potential donors and organ transplant candidates, along with their outcomes. By law, data collection is provided by all organ procurement organizations and transplant centers in France; research studies based on the national CRISTAL registry are part of the transplant assessment activities and do not require institutional review board approval.
62408407|NCT00807040|ACTIVE_COMPARATOR|Mitral Valve Repair with Annuloplasty|Participants will undergo mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.
62408408|NCT00807040|ACTIVE_COMPARATOR|Mitral Valve Replacement|Participants will undergo mitral valve replacement and complete preservation of the sub-valvular apparatus.
62408409|NCT06170528|OTHER|Mild ADRA and their caregivers|Deployed the AURA_ALZ system at Home
62584153|NCT01090362||Cohort 3|Cohort 3 completed with 11,139 patients enrolled globally from 32 countries
62584154|NCT01090362||Cohort 4|Cohort 4 completed with 11,2780 patients enrolled from 35 countries.
62584155|NCT01090362||Cohort 5|Final cohort completed with 12,186 patients enrolled.
62584156|NCT02710812||Rectum sparing group|"Patients who have all of the following requirements:~1. Major or complete clinical response at restaging after 7-8 weeks from the end of neoadjuvant therapy, confirmed at second restaging (after 11-12 weeks from the end of neoadjuvant therapy);~2. Written informed consent (after 2nd restaging).~Note: They will be subject to wait-and-see approach only patients with cCR."
62019809|NCT04289649|ACTIVE_COMPARATOR|Pitavastatin 4 mg|K-924 HD Placebo tablet once daily
62211927|NCT00857129|NO_INTERVENTION|1|Low risk women with expected normal birth are being Randomized to The Midwife-led Unit, with low amount of intervention, No epidural is offered, no medical augmentation available, unless for the active phase of the second stage. If extended surveillance is necessary or if the birth no longer is considered to be normal and needs to be taken over by a doctor, the woman will be transferred to either the Normal Unit or the Special Unit
62584157|NCT06177535|EXPERIMENTAL|Kava Group|Subjects will receive Kavalactones for 28 days
62584158|NCT06177535|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive placebo for 28 days
62584159|NCT00800592|ACTIVE_COMPARATOR|10 mg sildenafil bolus|10 mg sildenafil bolus
62211928|NCT00857129|EXPERIMENTAL|2|Low-risk women are randomised to this Low-risk maternal unit, The Normal Unit.The unit is organised for low-risk women with expected normal birth. The unit has access to extended surveillance, epidural and operative vaginal deliveries. If extended surveillance is necessary for a woman randomised to this unit, she does not have to be transferred to a higher level of care. Instrumental vaginal deliveries can be carried out at this unit.
62211929|NCT00857129|EXPERIMENTAL|3|Women with expected normal births are being randomised to this Special birth unit designed to take care of women before, under and after birth. The Special Unit cares for women with extended need for surveillance, but does also handle low-risk women.
62211930|NCT05978973|EXPERIMENTAL|elemental diet|subjects will be using the elemental diet packets daily. Subjects who are positive for excessive methane (i.e. methane level\>10 ppm) will be required to complete a single daily fasting methane measurement (SMM) for the duration of the 14 days.
62211931|NCT01887886|EXPERIMENTAL|Onartuzumab + Erlotinib|
62211932|NCT01887886|ACTIVE_COMPARATOR|Placebo + Erlotinib|
62211933|NCT00254631|ACTIVE_COMPARATOR|study group|pre operative medication with 20 mg oxycontine PO
62211934|NCT00254631|PLACEBO_COMPARATOR|placebo group|pre operative medication with placebo tablet PO
62211935|NCT03970655|EXPERIMENTAL|Group 1|a single injection into the LEFT pterygopalatine fossa of 4 milliliters of 0.5% Bupivacaine or Ropivacaine with epinephrine 1:200.000 with the addition of 4 milligrams of dexamethasone (1ml) and a single injection into the RIGHT pterygopalatine fossa fo 4 milliliters of 0.5% Bupivacaine or Ropivacaine without epinephrine with the addition of 4 milligrams of dexamethasone (1mL) after the induction of general anesthesia. (total volume 5 ml per side)
62584160|NCT05708443|ACTIVE_COMPARATOR|lower limbs (LL) group|These patients will participate in a pulmonary rehabilitation program (usual training) on lower limbs
62584161|NCT05708443|EXPERIMENTAL|lower plus upper limbs (L+UL) group|These patients will attend a rehabilitation program combining upper and lower extremity training
62584162|NCT06062238|EXPERIMENTAL|Participants receiving M72/AS01E-4|
62584163|NCT06062238|EXPERIMENTAL|Participants receiving placebo|
62019810|NCT06325098|EXPERIMENTAL|Patients with SSNS|Patients with SSNS and patients undergoing renal transplantation for NS with post-transplant disease recurrence will be enrolled for serum sampling for the study of immunological and/or permeabilizing factors (including anti-nephrin antibodies).
62019811|NCT06325098|EXPERIMENTAL|Patients with SRNS undergoing genetic testing by WES|Patients with SRNS undergoing genetic testing by WES and variant prioritization will undergo serum sampling for the study of immunologic and/or permeabilizing factors (including the anti-nephrin antibodies), and urine sampling for u-RPC cultures.
62408410|NCT02339246|ACTIVE_COMPARATOR|Prograf vs Envarsus XR vs Astagraf XL|Prograft capsules Twice daily for 7 days, followed by Envarsus XR tablets once daily for 7 days followed by Astagraf XL capsules once daily for 7 days.
62584164|NCT06570824|ACTIVE_COMPARATOR|Gamma burst rTMS|Real stimulation with 4 pulses at the frequency of 130Hz repeating at 1 Hz will be delivered on the pre-SMA using the active side of the coil for 30 minutes
62584165|NCT06570824|SHAM_COMPARATOR|Sham gamma burts rTMS|Sham stimulation with 4 pulses at the frequency of 130Hz repeating at 1Hz will be delivered on the pre-SMA with a non-active side of the coil for 30 minutes
62019812|NCT02731001|EXPERIMENTAL|Proton therapy|Patients within the proton arm will receive 66 Gy(RBE) delivered with 6 fractions per week.
62019813|NCT02731001|ACTIVE_COMPARATOR|Photon therapy|Patients within the photon arm will be treated by intensity modulated radiotherapy with 6 fractions per week to a total dose of 66 Gy.
62584166|NCT06570824|ACTIVE_COMPARATOR|Beta burst rTMS|Real stimulation with 4 pulses at the frequency of 20Hz repeating at 1 Hz be delivered on the pre-SMA using the active side of the coil for 30 minutes
62211936|NCT03970655|EXPERIMENTAL|Group 2|a single injection into the LEFT pterygopalatine fossa of 4 milliliters of 0.5% Bupivacaine or Ropivacaine without epinephrine with the addition of 4 milligrams of dexamethasone (1ml) and a single injection into the RIGHT pterygopalatine fossa of 4 milliliters of 0.5% Bupivacaine or Ropivacaine with epinephrine 1:200.00 with the addition of 4 milligrams of dexamethasone (1mL) after the induction of general anesthesia. (total volume 5 ml per side).
62408411|NCT02339246|ACTIVE_COMPARATOR|Prograf vs Astagraf XL vs Envarsus XR|Prograf capsules twice daily for 7 days followed by Astagraf XL capsules once daily for 7 days followed by Envarsus XR tablets once daily.
62019814|NCT00520416||1|There is no control or experimental group. The same patients undergoing endovascular AAA repair with serve as their own control
62019815|NCT01327534|EXPERIMENTAL|prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
62408412|NCT00449761|EXPERIMENTAL|Panobinostat|Participants received panobinostat 20 milligrams (mg) orally once daily (OD), three times a week as part of a 4 week (28 day) treatment cycle. Panobinostat was administered at the same time each morning, and with an 8oz/240 milliliter (ml) of water after a fasting period of at least two hours (water was allowed). Participants could continue this treatment until an unacceptable toxicity that precludes further treatment was experienced, or until disease progression.
62019816|NCT01327534|ACTIVE_COMPARATOR|clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
62019817|NCT01220908|EXPERIMENTAL|permanent Coil(s) implant, QOL measure|Coil implantation as treatment. Treatment is permanent implant.
62019818|NCT02092948|EXPERIMENTAL|All patients|Patients will receive one intravenous dose of 4 mg, 20mg or 40 mg of A11 minibody labeled with 5 mCi (185 MBq) of 124I, followed by \[124I\] PSCA-Minibody PET/CT imaging of the whole body.
62019819|NCT04478097|EXPERIMENTAL|Reference-Reference-Test|
62019820|NCT04478097|EXPERIMENTAL|Reference-Test-Reference|
62019821|NCT04478097|EXPERIMENTAL|Test-Reference-Reference|
62408413|NCT06249035|EXPERIMENTAL|TEE as POCUS modality.|TEE will be performed during cardiac arrest.
62019822|NCT03566641|EXPERIMENTAL|Negative pressure wound therapy|This group of patients will receive negative pressure wound therapy (prevena) as their postoperative wound care method.
62019823|NCT03566641|ACTIVE_COMPARATOR|standard care dressing|This group of patients will receive standard care dressing as their postoperative wound care method.
62019824|NCT00917046|EXPERIMENTAL|1 Interval training|high-intensity Interval Training
62019825|NCT00917046|EXPERIMENTAL|2 Moderate Training|Moderate continuous training
62019826|NCT00917046|ACTIVE_COMPARATOR|3 Recommendation of exercise|Recommendation of regular exercise at moderate intensity at individual choice
62019827|NCT02428036|EXPERIMENTAL|TBI-1401(HF10) - Cohort 1|Oncolytic virotherapy, intratumoral administrations of TBI-1401(HF10)
62211937|NCT00621075||1|Pulmonary Arterial Hypertension
62211938|NCT04668404||COVID-19 positive patient with ARDS|All patients with COVID-19 diagnosed with RT-PCR.
62211939|NCT00561366|PLACEBO_COMPARATOR|1|
62211940|NCT00561366|EXPERIMENTAL|2|
62211941|NCT01423227|EXPERIMENTAL|Home-based pulmonary rehabilitation|Home visit plus 8 weeks of once-weekly telephone calls
62211942|NCT01423227|ACTIVE_COMPARATOR|Hospital-based pulmonary rehabilitation|Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
62408414|NCT04466371||MIU students and staff members|All students and staff members in MIU
62408415|NCT03194295|EXPERIMENTAL|Community Support Intervention|Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Community Support Intervention Group, which requires methadone maintenance treatment (MMT) participants to attend the group with a drug-free family member or friend (community support person; CSP).
62408416|NCT03194295|ACTIVE_COMPARATOR|Standard Care|Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Substance Use Disorder Educational Group as an attention-control for the intervention described in the experimental condition.
62584167|NCT06570824|SHAM_COMPARATOR|Sham beta burst rTMS|Sham stimulation with 4 pulses at the frequency of 20Hz repeating at 1Hz will be delivered on the pre-SMA with a non-active side of the coil for 30 minutes
62584168|NCT04362696|EXPERIMENTAL|active stimulation|
62584169|NCT04362696|SHAM_COMPARATOR|sham stimulation|
62584170|NCT04445714|OTHER|dapagliflozin and saxagliptin|Singe arm once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally
62584171|NCT02469688|EXPERIMENTAL|Part1 ASP4070 intramuscular vaccination group|ASP4070 high dose x 4 times
62584172|NCT02469688|EXPERIMENTAL|Part1 ASP4070 intradermal vaccination group|ASP4070 high dose x 4 times
62584173|NCT02469688|EXPERIMENTAL|Part2 ASP4070 intramuscular vaccination group 1|ASP4070 high dose x 4 times
62584174|NCT02469688|EXPERIMENTAL|Part2 ASP4070 intramuscular vaccination group 2|ASP4070 high dose x 1 time, Placebo x 3 times
62019828|NCT02428036|EXPERIMENTAL|TBI-1401(HF10) - Cohort 2|Oncolytic virotherapy, intratumoral administrations of TBI-1401(HF10)
62211943|NCT05010239|ACTIVE_COMPARATOR|Intervention group|Patients in the intervention group will receive a 30-minute MBST session by a palliative care physician trained in mindfulness practice. The MBST consists of a session that involves interviewing patients with open-ended questions on suffering experiences. During the session, the practitioner will practice mindful breathing simultaneously while listening to patients. The practitioner will acknowledge the distress of patients when it is appropriate, but without losing their attention on mindful breathing. Outcomes will be measured at baseline and at minute 30.
62584175|NCT02469688|PLACEBO_COMPARATOR|Part2 Placebo intramuscular vaccination group|Placebo x 4 times
62584176|NCT02469688|EXPERIMENTAL|Part2 ASP4070 intradermal vaccination group 1|ASP4070 high dose x 4 times
62584177|NCT02469688|EXPERIMENTAL|Part2 ASP4070 intradermal vaccination group 2|ASP4070 low dose x 4 times
62584178|NCT02469688|EXPERIMENTAL|Part2 ASP4070 intradermal vaccination group 3|ASP4070 high dose x 1 time, Placebo x 3 times
62584179|NCT02469688|EXPERIMENTAL|Part2 ASP4070 intradermal vaccination group 4|ASP4070 low dose x 1 time, Placebo x 3 times
62584180|NCT02469688|PLACEBO_COMPARATOR|Part2 Placebo intradermal vaccination group|Placebo x 4 times
62019829|NCT02417246|ACTIVE_COMPARATOR|Study Sequence A|Start with brand name metoprolol ER, switch to Generic B metoprolol, switch back to brand name metoprolol ER, then switch to Generic A metoprolol
62408417|NCT06096246|ACTIVE_COMPARATOR|Experimental: DCCV + PVI|"An implantable loop recorder will be inserted in the pre pectoral area with local anaesthetic at least one week before the randomisation.~Two femoral sheaths will be inserted at the groin area in all patients on the day of the procedure prior randomisation. This will be utilised as the access route for cardiac catheter insertion for ablation and for phrenic nerve pacing during the procedure.~DC cardioversion (DCCV) plus Pulmonary Vein Isolation - At the end of pulmonary vein isolation, DCCV is performed (if the patient is still in AF)."
62408418|NCT06096246|SHAM_COMPARATOR|DC cardioversion (DCCV) + Sham procedure|"An implantable loop recorder will be inserted in the pre-pectoral area with local anaesthetic at least one week before the randomisation.~Two femoral sheaths will be inserted at the groin area in all patients on the day of the procedure prior randomisation. This will be utilised as the access route for cardiac catheter insertion for intermittent phrenic nerve pacing during the procedure.~DC Cardioversion and Sham procedure will be performed after randomisation. Intermittent phrenic nerve pacing will be employed for the sham group through the femoral venous sheath using a quadripolar catheter."
62408419|NCT00938392|EXPERIMENTAL|FluNG Aged Group|Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).
62584181|NCT05567744||CADASIL Registry Participants|Have a loved one or family member with CADASIL, or anyone with or at risk for CADASIL
62584182|NCT06664996|EXPERIMENTAL|treatment|After obtaining informed consent, patients will undergo neoadjuvant therapy combining SBRT with sintilimab. SBRT will be administered on days 1, 3, and 5 at a dose of 8 Gy per fraction, totaling 3 fractions. Concurrently, patients will receive a first dose of sintilimab at 200 mg on day 1, followed by a second dose of 200 mg on day 22 (week 4, ±3 days). A radical hepatectomy is scheduled for day 50 (week 8, ±7 days). Tumor response will initially be evaluated using RECIST v1.1 criteria starting from the first administration, with a second pre-operative tumor imaging assessment at week 8 (±7 days). Post-surgery, patients will begin adjuvant treatment with sintilimab 200 mg every 3 weeks, continuing for 24 weeks. Follow-up assessments will occur every 3 months (±7 days) to collect data on disease status and survival, with a total follow-up duration of 1 year for each patient. This structured approach ensures precise timing and dosing while maintaining academic rigor and a logical sequen
62584183|NCT04384042||Malaysian COVID-19 Cohort (Cases)|A cohort of COVID-19 positive patients will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
62584184|NCT04384042||Healthy Volunteers (Controls)|A cohort of age and sex-matched healthy volunteers will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
62584185|NCT04644705|ACTIVE_COMPARATOR|Part A: verum niclosamide|"The SAD cohorts are planned as follows:~Cohort A1: 200 mg (fasted conditions) Cohort A2: 600 mg (fasted conditions) Cohort A3: 1600 mg (fasted and fed conditions)"
62584186|NCT04644705|PLACEBO_COMPARATOR|Part A: placebo to niclosamide|"The SAD cohorts are planned as follows:~Cohort A1: placebo to niclosamide 200 mg (fasted conditions) Cohort A2: placebo to niclosamide 600 mg (fasted conditions) Cohort A3: placebo to niclosamide 1600 mg (fasted and fed conditions)"
62584187|NCT04644705|ACTIVE_COMPARATOR|Part B: verum as solution (niclosamide)|Two different crossover designs are chosen. Both are randomized, open-label, two-sequence, two periods crossover designs comparing the new niclosamide solution with the marketed chewing tablets. Planned doses are 1600 mg once daily (oral solution), 2000 mg once daily (chewing tablets) and 500 mg three times daily of both dosage forms.
62584188|NCT04644705|ACTIVE_COMPARATOR|Part B: verum as chewing tablet (niclosamide)|Two different crossover designs are chosen. Both are randomized, open-label, two-sequence, two periods crossover designs comparing the new niclosamide solution with the marketed chewing tablets. Planned doses are 1600 mg once daily (oral solution), 2000 mg once daily (chewing tablets) and 500 mg three times daily of both dosage forms.
62584189|NCT04644705|ACTIVE_COMPARATOR|Part C: verum (niclosamide and camostat)|Subjects will receive the combination of niclosamide solution (planned 500 mg three times daily) + camostat (600 mg three times daily) or placebo over a treatment period of 7 days. The dose of the niclosamide solution depends on the safety and pharmacokinetic results of Part A and B but will not exceed 500 mg three times daily.
62584190|NCT04644705|PLACEBO_COMPARATOR|Part C: placebo to niclosamide and camostat|Subjects will receive the combination of niclosamide solution (planned 500 mg three times daily) + camostat (600 mg three times daily) or placebo over a treatment period of 7 days. The dose of the niclosamide solution depends on the safety and pharmacokinetic results of Part A and B but will not exceed 500 mg three times daily.
62584191|NCT01726725||hemifacial spasm, lateral spread, motor evoked potentials|EMG recordings from facial muscles of HFS patients during MVD surgery will be compared during total intravenous anesthesia (propofol), 0.5 MAC desflurane and 1.0 MAC desflurane
62019830|NCT02417246|ACTIVE_COMPARATOR|Study Sequence B|Start with brand name metoprolol ER, switch to Generic A metoprolol, switch back to brand name metoprolol ER, then switch to Generic B metoprolol.
62019831|NCT00058305|EXPERIMENTAL|Treatment (bryostatin 1, vincristine sulfate)|"Patients receive bryostatin 1 IV over 24 hours on days 1 and 15 and vincristine IV on days 2 and 16. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients without disease progression after 6 courses may continue therapy with bryostatin 1 IV over 24 hours on days 1 and 22 and vincristine IV on days 2 and 23. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity."
62019832|NCT03356002|ACTIVE_COMPARATOR|High risk subjects|"Each subject will ingest the C-Scan System capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~Subjects to be enrolled in this study are indicated and scheduled to undergo optical colonoscopy based on the following symptoms or by being classified as higher than average risk based on one or more of the following:~c. Surveillance - Significant findings in previous optical colonoscopy d. Diagnostic - Polyps detected in virtual colonoscopy referred for polypectomy e. Diagnostic - Polyps detected in previous optical colonoscopy (community setting) referred for polypectomy f. Diagnostic - Positive FIT test g. Diagnostic - one or more of the typical symptoms:"
62019833|NCT03356002|EXPERIMENTAL|Average risk|"Each subject will ingest the C-Scan System capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~Average risk based on their age and demographics referred for screening for polyps."
62019834|NCT05177809||RFC1|Participants with genetically confirmed RFC1 repeat expansion disease (ORPHA: 504476; OMIM 102579) will be recruited. Target sample size for the RFC1 cohort is 100 participants.
62019835|NCT05177809||Unrelated healthy controls|Unrelated healthy controls Healthy controls may undergo the same study procedures as the RFC1 cohort. Target sample size for the control cohort is 50.
62019836|NCT02640729|EXPERIMENTAL|Nelotanserin|Nelotanserin 40mg then nelotanserin 80 mg
62019837|NCT02640729|PLACEBO_COMPARATOR|Placebo|Placebo
62019838|NCT02441452|ACTIVE_COMPARATOR|Early rehabilitation|one day before surgery, patients and their families were instructed by physiotherapists than explained the importance to perform physical exercises and breath exercises in postoperative. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation.
62019839|NCT02441452|NO_INTERVENTION|Conventional care|Usual care routine postoperative.
62019840|NCT01166932|ACTIVE_COMPARATOR|amoxicillin/clavulanic acid|patients who received amoxicillin/clavulanic acid
62019841|NCT01166932|ACTIVE_COMPARATOR|ceftriaxone/oxacillin|
62211944|NCT05010239|PLACEBO_COMPARATOR|Control group|Patients in the control group will receive a 30-minute supportive listening session by a palliative care physician who has no experience in mindfulness practice. The session involves interviewing patients with the same open-ended questions on suffering experiences. The practitioner will acknowledge the distress of patients when it is appropriate. Outcomes will be measured at baseline and at minute 30.
62211945|NCT00998790|EXPERIMENTAL|AMS AdVance Sling Group|European Male subjects \>40 years old who were implanted with the AMS AdVance Male Sling to treat Stress Urinary Incontinence.
62211946|NCT02766465|EXPERIMENTAL|Donor Arm|"Donor Arm patients will undergo hematopoietic cell transplant. Patients with a matched unrelated donor will receive a bone marrow transplant (unless PBSC graft is pre-approved per section 2.5.1 using a preparative regimen with Busulfan, Fludarabine and rabbit ATG. Patients with an HLA-identical sibling donor can receive a transplant using one of three regimens:~A. Busulfan, Fludarabine, and rabbit ATG using a bone marrow graft (preferred regimen) B. Alemtuzumab/TBI 300 cGy using a peripheral blood graft C. Alemtuzumab, fludarabine, melphalan using a bone marrow graft"
62211947|NCT02766465|ACTIVE_COMPARATOR|No-Donor Arm|No-donor arm patients will continue with standard of care per their SCD physician.
62211948|NCT00151281|EXPERIMENTAL|Study Treatment Arm|
62211949|NCT04289012|EXPERIMENTAL|Helicobacter Screening|All patients with confirmed MI (both STEMI and NSTEMI) will be tested for Hp infection with bedside UBT.
62211950|NCT00503100||NICU full-term early pain group|
62211951|NCT00503100||NICU premature early pain group|
62211952|NCT00503100||NICU premature control group|
62211953|NCT00503100||Soroka- full-term control group|
62408420|NCT00938392|EXPERIMENTAL|FluNG Fresh Group|Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).
62408421|NCT00681447|OTHER|Group I|Lumbar interlaminar epidural injection with local anesthetic only
62408422|NCT00681447|OTHER|Group II|Lumbar Interlaminar Epidural Injection with local anesthetic wiht 6 mg of non-particulate Celestone
62408423|NCT04443426|EXPERIMENTAL|Single dose oral 3-hydroxybutyrate monoester|Cross-over study in 8 patients receiving single-dose oral 3-hydroxybutyrate monoester, 3-OHB salt and placebo.
62584192|NCT03846830|ACTIVE_COMPARATOR|IVE/VPT 6 week Crossover|Subjects will randomly be placed in one of two groups (IVE or VPT) involving daily exercise for 5 weeks, 6 weeks washout, and then crossover into the other group for a final 5 weeks. The Incremental Velocity Error (IVE) group uses a device worn on the head that delivers a moving target during head motion; while Traditional Vestibular Rehabilitation (VPT) uses the traditional eye and head turning rehabilitation exercises. Gait and balance training offered throughout each of the 5 weeks epochs of training.
62584193|NCT03846830|EXPERIMENTAL|IVE/VPT 3 week Crossover|Subjects will randomly be placed in one of two groups (IVE or VPT) involving daily exercise for 3 weeks, 3 weeks washout, and then crossover into the other group for a final 3 weeks. The Incremental Velocity Error (IVE) group uses a device worn on the head that delivers a moving target during head motion; while Traditional Vestibular Rehabilitation (VPT) uses the traditional eye and head turning rehabilitation exercises. Gait and balance training will not start until the washout period.
62019842|NCT01465334|EXPERIMENTAL|Treatment Naive|"Participants were assigned to 1 of 2 groups based on prior treatment status. Both groups received the same therapy as follows (cycle duration=28 days):~Induction Part A: Ofatumumab + HDMP 2-4 cycles~Ofatumumab: cycle 1 - 300 mg intravenously (IV) Day 1 then 1000 mg IV Days 8, 15, 22; cycles 2-4 - 1000 mg IV Days 1, 8, 15, 22~High-Dose Methylprednisolone (HDMP): 1000 mg/m2 IV Days 1-3~Participants with nodal complete response at cycle 2 re-staging then discontinued Part A therapy.~Induction Part B: Ofatumumab + Alemtuzumab 1-6 cycles~Ofatumumab: 1000 mg IV Day 1~Alemtuzumab: 30 mg subcutaneously Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26~Participants with at least stable disease could continue continue to Part C or, if eligible, proceed to allogeneic stem cell transplant (SCT) off study.~Maintenance Part C: Ofatumumab + Alemtuzumab up to 26 cycles~Ofatumumab: 1000 mg IV Day 1 every other cycle~Alemtuzumab: 30 mg subcutaneously Days 14, 28"
62019843|NCT01465334|EXPERIMENTAL|Relapsed/Refractory|"Participants were assigned to 1 of 2 groups based on prior treatment status. Both groups received the same therapy as follows (cycle duration=28 days):~Induction Part A: Ofatumumab + HDMP 2-4 cycles~Ofatumumab: cycle 1 - 300 mg intravenously (IV) Day 1 then 1000 mg IV Days 8, 15, 22; cycles 2-4 - 1000 mg IV Days 1, 8, 15, 22~High-Dose Methylprednisolone (HDMP): 1000 mg/m2 IV Days 1-3~Participants with nodal complete response at cycle 2 re-staging then discontinued Part A therapy.~Induction Part B: Ofatumumab + Alemtuzumab 1-6 cycles~Ofatumumab: 1000 mg IV Day 1~Alemtuzumab: 30 mg subcutaneously Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26~Participants with at least stable disease could continue continue to Part C or, if eligible, proceed to allogeneic stem cell transplant (SCT) off study.~Maintenance Part C: Ofatumumab + Alemtuzumab up to 26 cycles~Ofatumumab: 1000 mg IV Day 1 every other cycle~Alemtuzumab: 30 mg subcutaneously Days 14, 28"
62019844|NCT04892654|EXPERIMENTAL|Immediate Switch|Two-pill regimen, doravirine (100 mg) + dolutegravir (50 mg) tablets taken orally once daily for 96 weeks.
62019845|NCT04892654|OTHER|Delayed Switch|Participants will continue their current triple cART regimen for 48 weeks. Patients will then be switched to two-pill regimen, doravirine (100 mg) + dolutegravir (50 mg) tablets taken orally once daily for 48 weeks.
62019846|NCT04483453|EXPERIMENTAL|EXPL feeding regimen|Lower protein / lower estimated glycemic index regimen
62019847|NCT04483453|ACTIVE_COMPARATOR|CTRL feeding regimen|Standard protein / standard glycemic index regimen
62408424|NCT04443426|EXPERIMENTAL|Single dose oral 3-hydroxybutyrate Salt|
62211954|NCT02874417|EXPERIMENTAL|Psychoeducation|The program was designed to dispel exaggerated thoughts surrounding the danger of the experience of anxiety symptoms, specifically focusing on fears regarding feelings of cognitive dyscontrol. The psychoeducation portion contains video animation and audio narration throughout, as well as some interactive features . Participants are provided with corrective information about the experience of anxiety-related sensations, with a particular focus on dispelling myths commonly held by individuals with high anxiety sensitivity cognitive concerns . Participants are taught that anxiety-related sensations are not dangerous and that they may have developed a conditioned fear to these symptoms of arousal.
62408425|NCT04443426|PLACEBO_COMPARATOR|Single dose oral placebo|maltodextrin-based, isocaloric to ketone dosis.
62408426|NCT04009681|EXPERIMENTAL|Cohort A-THOR-707 Q2W Monotherapy (Dose Escalation)|Subjects with advanced or metastatic solid tumors will receive THOR-707 in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W) until unacceptable toxicity, disease progression, or withdrawal of consent.
62408427|NCT04009681|EXPERIMENTAL|Cohort B-THOR-707 Q3W Monotherapy (Dose Escalation)|Subjects with advanced or metastatic solid tumors will receive THOR-707 in sequential ascending doses as a monotherapy via IV administration every 3 weeks (Q3W) until unacceptable toxicity, disease progression, or withdrawal of consent.
62584194|NCT03846830|ACTIVE_COMPARATOR|IVE/VPT 3 week crossover|Subjects will randomly be placed in one of two groups (IVE or VPT) involving every other day exercise for 3 weeks, 3 weeks washout, and then crossover into the other group for a final 3 weeks. The Incremental Velocity Error (IVE) group uses a device worn on the head that delivers a moving target during head motion; while Traditional Vestibular Rehabilitation (VPT) uses the traditional eye and head turning rehabilitation exercises. Gait and balance training offered throughout the 3 weeks of exercise.
62584195|NCT06377631|EXPERIMENTAL|Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine|Participants will daily consume the multi-ingredient (L-Histidine, L-Serine, L-Carnosine and N-Acetylcysteine) for 12 weeks.
62584196|NCT06377631|PLACEBO_COMPARATOR|Placebo|Participants will daily consume the placebo (maltodextrin) for 12 weeks.
62211955|NCT02874417|PLACEBO_COMPARATOR|Health and Wellness|The controlled condition consisted Physical Health Education Training (PHET), a computerized presentation which focuses on information on general healthy living. The PHET program contains information on nutrition, alcohol, water consumption, exercise, sexual health, hygiene, stress management, life organization, social support, positive outlook, and sleep.
62211956|NCT03755375|ACTIVE_COMPARATOR|E-stim Group|TENS group was treated with biofeedback, manual therapy, andtranscutaneous electrostimulation (TENS), a peripheral neuromodulation to promote analgesia in pain areas, using two transcutaneous self-adhesive electrodes Axelgaard 5 cm x 5 cm with 2 cm of distance between them. The parameters used were frequency = 100 Hz, pulse width = 50-100 µs, and current intensity according to the patient's sensitivity.
62211957|NCT03755375|ACTIVE_COMPARATOR|Postural Group|Postural group was treated with biofeedback, manual therapy, and postural exercises , which promoted pelvic mobility and functional training associated with respiratory exercises increasing the diaphragmatic excursion.Postural exercises consisted of 10 repetitions of breathing exercises in the lay-down position, 10 repetitions of hip anteversion and retroversion in the sitting position, and 10 repetitions of hip anteversion, retroversion, and lateral movement in the stand-up position.
62408428|NCT04009681|EXPERIMENTAL|Cohort C-THOR-707 Q3W with checkpoint inhibitor (Dose Escalation)|Subjects with advanced or metastatic solid tumors will receive THOR-707 Q3W in sequential ascending doses in combination with a checkpoint inhibitor Q3W or every 6 weeks (Q6W) via IV administration until unacceptable toxicity, disease progression, or withdrawal of consent.
62408429|NCT04009681|EXPERIMENTAL|Cohort D-THOR-707 Q3W with anti-EGFR antibody (Dose Escalation)|Subjects with advanced or metastatic solid tumors will receive THOR-707 Q3W in sequential ascending doses in combination with an anti-EGFR antibody weekly dosing (QW) via IV administration until unacceptable toxicity, disease progression, or withdrawal of consent.
62584197|NCT05755711||Female subjects referred for percutaneous coronary intervention|Female subjects referred for percutaneous coronary intervention (PCI) with coronary IVL and stenting per standard of care.
62584198|NCT00809471|PLACEBO_COMPARATOR|placebo|
62584199|NCT00809471|EXPERIMENTAL|avanafil 100 mg|
62584200|NCT00809471|EXPERIMENTAL|avanafil 200 mg|
62584201|NCT06595303||N2O for labour analgesia|Any woman who received nitrous oxide for childbirth at Hôpital Érasme between October 1, 2024 and April 30, 2025 and who signed the informed consent form for this study.
62584202|NCT06541158|EXPERIMENTAL|Stage I (CAB)|Participants meet with the study research team to develop and refine the TRACT program.
62584203|NCT06541158|EXPERIMENTAL|Stage II Group I (TRACT program)|Patients receive the TRACT program consisting: of 1) Screening of travel barriers; 2) Awareness of transportation obstacles and resources using videos, 3) Assistance with transportation resource application and utilization, and 4) Alignment of community resources to navigate individualized transportation support by the trained travel navigator for 3 months.
62584204|NCT06541158|ACTIVE_COMPARATOR|Stage II Group II (usual care, video, pamphlet)|Patients receive usual care with PAF pamphlet for 3 months.
62211958|NCT03755375|ACTIVE_COMPARATOR|Conventional Group|Conventional group was treated with biofeedback for pelvic floor relaxation and manual therapy to release the tension in the suprapubic, pelvic, and intravaginal areas. The manual therapy consisted of a myofascial trigger point release maneuver using digital pressure and muscle fiber stretching in pain areas. Biofeedback consisted of pelvic floor muscle coordination and relaxation exercises using intravaginal probes. The training program was initiated with 10 fast contractions with 5 seconds of relaxation between them followed by 10 sustained contractions of 5 seconds with 10 seconds of relaxation between them. Finally, one minute of pelvic floor relaxation was performed.
62211959|NCT05203068|EXPERIMENTAL|Recombinant tuberculosis allergen (CFP10-ESAT6)|RTA (CFP10-ESAT6) 0.2 µg/0.1 mL RTA given intradermally on the middle of the forearm
62211960|NCT00673400|OTHER|Stapled transanal rectum resection|patients operated with stapled transanal rectum resection
62211961|NCT01941433|EXPERIMENTAL|Arthritis Health Journal|Participants in this group will use the Arthritis Health Journal in the first 6 months of study.
62211962|NCT01941433|OTHER|Control|Participants in this group will receive a delayed intervention. They will receive usual care for the first 6 months of study, during which time they will contribute control data, and they will use the Arthritis Health Journal in the second 6 months of study, during which time they will contribute intervention data.
62211963|NCT01803412|EXPERIMENTAL|Alternate Intravenous Dosing Arm|Subjects will receive drisapersen as a regimen of 3 mg/kg over 1 hr IV weekly throughout the duration of participation.
62211964|NCT01803412|EXPERIMENTAL|Primary continuous Dosing Arm|Subjects will receive drisapersen 6 mg/kg as SC injection(s) once a week, continuously throughout their duration of participation.
62211965|NCT01803412|EXPERIMENTAL|Alternate Intermittent Dosing Arm|Subjects will receive drisapersen intermittently, as a regimen of 6 mg/kg as SC injection(s) once a week for 8 weeks followed by 4 weeks of no dosing, throughout their duration of participation.
62211966|NCT02746198|EXPERIMENTAL|Verum|2 bottles (á 65ml) of a probiotic dairy drink consumed daily for 6 weeks
62211967|NCT02746198|PLACEBO_COMPARATOR|Placebo|2 bottles (á 65ml) of a dairy drink containing chemically acidified milk without bacterial strains consumed daily for 6 weeks
62211968|NCT03515343||Optical diagnosis with Optivista|Participants for which the optical diagnosis of detected colorectal polyps will be done with the new technique Pentax Optivista.
62211969|NCT03515343||Optical diagnosis with iScan|Participants for which the optical diagnosis of detected colorectal polyps will be done with the oldest technique Pentax iScan.
62211970|NCT00564889|EXPERIMENTAL|CRD|"Lenalidomide 15mg daily (days 1-21)~Cyclophosphamide 300 mg/m\^2 (days 1, 8, 15)~Dexamethasone 40 mg weekly"
62211971|NCT05908253|SHAM_COMPARATOR|sham neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop sham neurofeedback protocol.
62211972|NCT05908253|ACTIVE_COMPARATOR|nonadaptive neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop nonadaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an open-loop attention model of the corresponding human subject.
62408430|NCT04009681|EXPERIMENTAL|Cohort E-THOR-707 Q2W with checkpoint inhibitor (Dose Expansion)|Subjects with advanced or metastatic solid tumors will receiveTHOR-707 Q2W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W; it will consist of one 8-week cycle of THOR-707 monotherapy on Cycle 1 Day 1 followed by THOR-707 Q2W + checkpoint inhibitor Q6W starting at Cycle 1 Day 15. Subsequently treatment will consist of repeated 6-week cycles with combination therapy.
62211973|NCT05908253|ACTIVE_COMPARATOR|adaptive neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop adaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an adaptive algorithm.
62211974|NCT01852968||Patients with type 1 diabetes|"Hippocampal neurochemistry and metabolism will examined in Patients with type 1 diabetes using magnetic resonance spectroscopy.~Patients with type 1 diabetes will also undergo neurocognitive testing to assess hippocampal function"
62211975|NCT01852968||healthy controls|"Hippocampal neurochemistry and metabolism will be examined in healthy controls using magnetic resonance spectroscopy.~Healthy controls will also undergo neurocognitive testing to assess hippocampal function"
62211976|NCT00579800|EXPERIMENTAL|women undergoing routine breast MRI|Conventional images will be taken using the standard sequences consisting of T2-weighted imaging and T1-weighted imaging before and after contrast; these will be used for the diagnostic examination. FIESTA will be performed on 50 patients, while Vibrant-DE and IDEAL will be performed on the other 50 patients.
62211977|NCT00215735|EXPERIMENTAL|APC Treatment|wound debridement and treatment with APC
62211978|NCT05381545|EXPERIMENTAL|group A|This 32-patient research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week, combined with low calorie diet for).This research group will receive an additional laser puncture (with 3-time per-week design). The following points will be directly contacted by laser, for two minutes: GB34\&28, ST25\&36\&40, SP6, and CV4\&9\&12.
62408431|NCT04009681|EXPERIMENTAL|Cohort F-THOR-707 Q3W with checkpoint inhibitor (Dose Expansion)|Subjects with advanced or metastatic solid tumors will receive THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy on Cycle 1 Day 1 followed by THOR-707 Q3W + checkpoint inhibitor at Cycle 1 Day 22. Subsequently treatment will consist of repeated 6-weeks cycles with combination therapy.
62211979|NCT05381545|ACTIVE_COMPARATOR|Group B|This 32-patient research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week, combined with low calorie diet ).
62211980|NCT03499145||Eligible patients for AI test.|Device: ophthalmology diagnostic system. An artificial intelligence to make comprehensive evaluation and treatment decision of ocular diseases.
62211981|NCT06475430|EXPERIMENTAL|Fecal flora transplantation group|
62211982|NCT06475430|ACTIVE_COMPARATOR|Formulated probiotics group|
62408432|NCT04009681|EXPERIMENTAL|Cohort G Monotherapy QW/Q2W (Dose Escalation)|Subjects with advanced or metastatic solid tumors will receive THOR707 monotherapy QW for 6 weeks (induction period), and then every Q2W (maintenance period), which is referred as QW/Q2W thereafter, until unacceptable toxicity, disease progression, or withdrawal of consent.
62211983|NCT02063373|EXPERIMENTAL|biomechanis knee OA and HA injection|Weekly intra- articular Hyaluronic acid injection (20 MG/ 2 ML) into both knees for five weeks
62408433|NCT04009681|EXPERIMENTAL|Cohort H Monotherapy QW/Q2W (Dose Expansion)|Subjects with late-line metastatic melanoma will receive THOR707 monotherapy at RP2D for Cohort G. Cycle 1 will consist of THOR-707 QW for 6 weeks; Cycle 2 and beyond will consist of THOR-707 Q2W.
62408434|NCT03257800|ACTIVE_COMPARATOR|ketamine-propofol group|"Ketamine (50mg/ml) at 0.5 mg.kg-1 was injected intravenously 1min prior 3 mgkg-1 of propofol and 1 min before LMA insertion in Ketamine-propofol group.~sevoflurane 6-7% was used on vaporizer setting with 50% nitrous oxide in oxgen prior intravenous anesthesia. The loss of eyelash reflex was considered as the desired end point for induction."
62408435|NCT03257800|PLACEBO_COMPARATOR|propofol group|"0,9% saline solution ( Placebo ) at the same volume as ketamine (50mg/ml) was injected intravenously 1min prior propofol 3 mg.kg-1 and 1 min before LMA insertion in propofol group.~sevoflurane 6-7% was used on vaporizer setting with 50% nitrous oxide in oxgen prior intravenous anesthesia. The loss of eyelash reflex was considered as the desired end point for induction."
62019848|NCT03969810|EXPERIMENTAL|Rounding Summary|"Surrogates who are assigned to the intervention group will receive a written rounding summary every day or every other day that the patient is in the ICU. The summary will be organized as follows for each of the most important ICU problems: 1) Description of the problem, 2) Ways the ICU team is addressing the problem i.e. consultations, diagnostic tests, and treatments. 3) An assessment of whether the problem is improving or worsening.~For patients assigned to the intervention group, the investigators will forward the previous day's summary to the ICU nurse at the beginning of each day shift. After participating in morning rounds, ICU nurses will be asked to modify the summary based on the plan for the day. Nurses will be asked to use the written summary to guide communication with surrogates that day."
62019849|NCT03969810|NO_INTERVENTION|Usual Care|Usual ICU care
62211984|NCT02295943|OTHER|Positioning measuring device|The supine time during the first postoperative day is measured
62211985|NCT00197587|ACTIVE_COMPARATOR|maternal nevirapine|
62211986|NCT00197587|PLACEBO_COMPARATOR|maternal placebo|
62211987|NCT00677599|ACTIVE_COMPARATOR|Intervention A|Experimental arm enriched with flavonoids
62211988|NCT00677599|PLACEBO_COMPARATOR|Intervention B|
62211989|NCT01593059||Orsiro DES|
62211990|NCT01701687||Decompensated Alcoholic Cirrhosis|Recruited patients will have diagnosed liver cirrhosis (histological, radiological or accepted clinical parameters)admitted with an episode of decompensation. Patients must still be drinking hazardous alcohol quantities (\>14 units for women, \>21 units for men) at study enrollment
62211991|NCT02908295|EXPERIMENTAL|A|Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
62211992|NCT02908295|PLACEBO_COMPARATOR|B|Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
62211993|NCT02016859||Critically ill patients admitted to ICU|those patients who are admitted to ICU with multiorgan failure/injury
62211994|NCT02016859||Neutropinc Fever patients|admitted to ER, haemato-oncology or oncology
62211995|NCT02016859||Patients of Hip's Fracture|admitted to orthopedic departement
62408436|NCT06147856|EXPERIMENTAL|mRNA-3210|Participants will receive single dose of mRNA-3210 by intravenous (IV) infusion every 3 weeks (Q3W), every 2 weeks (Q2W), or every 1 week (Q1W) for up to 12 doses.
62408437|NCT01554696|EXPERIMENTAL|ASP015K lowest dose|ASP015K lowest dose daily in addition to concomitant weekly oral methotrexate
62408438|NCT01554696|EXPERIMENTAL|ASP015K low dose|ASP015K low dose daily in addition to concomitant weekly oral methotrexate
62408439|NCT01554696|EXPERIMENTAL|ASP015K medium dose|ASP015K medium dose daily in addition to concomitant weekly oral methotrexate
62408440|NCT01554696|EXPERIMENTAL|ASP015K high dose|ASP015K high dose daily in addition to concomitant weekly oral methotrexate
62408441|NCT01554696|PLACEBO_COMPARATOR|Placebo|Placebo daily in addition to concomitant weekly oral methotrexate
62408442|NCT03931902|EXPERIMENTAL|Laryngeal Mask Airway (LMA)|Using laryngeal mask airway as the airway device during general anesthesia
62408443|NCT03931902|ACTIVE_COMPARATOR|Endotracheal Tube (ETT)|Using endotracheal tube as the airway device during general anesthesia
62584205|NCT03884699|OTHER|Segmental maxillary lefort I re-positioning|Accuracy of the planned virtually re-positioned segmental Lefort I maxilla using a specifically designed patient implant, comparing the virtual plan to the actual postoperative position.
62408444|NCT06636019|EXPERIMENTAL|Interventional arm|The myopia control contact lens will be administered in this group.
62408445|NCT05400590||Case patients with aniridia|
62408446|NCT05400590||Control patients without aniridia|
62584206|NCT04705363|EXPERIMENTAL|Interaction with a VHA with voice|A virtual health assistant computer-generated doctor who will have a conversation with you.
62584207|NCT04705363|ACTIVE_COMPARATOR|Interaction with a VHA without voice|A virtual health assistant that will consist of photos of the computer-generated doctor with text that will guide you through the interaction. No voice will accompany the photos or text.
62584208|NCT05064878|EXPERIMENTAL|ZX008 0.8 mg/kg/day|Part 1: ZX008 0.8 mg/kg/day will be administered twice a day (BID) in equally divided doses; maximum of 30 mg/day, (subjects taking concomitant stiripentol will receive 0.5 mg/kg/day, \[maximum of 20 mg/day\]) with or without food.
62408447|NCT03771391|EXPERIMENTAL|4 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 4 weeks.
62408448|NCT03771391|EXPERIMENTAL|8 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 8 weeks.
62408449|NCT03771391|EXPERIMENTAL|12 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 12 weeks.
62408450|NCT03790475|NO_INTERVENTION|Current screening practice.|Subjects randomized into this group will receive named invitations for colonoscopy with pre-specified date, contact details of dedicated screening center. Invitations will be sent 6 weeks prior to suggested date of screening test. All subjects not responding to the invitation will receive a reminder letter 3 weeks prior to proposed appointment date. Additionally, a re-invitation for colonoscopy (screening test in 6 weeks) will be sent to participants not responding to the first invitation and the reminding letter.
62584209|NCT05064878|PLACEBO_COMPARATOR|Placebo|Part 1: Matching ZX008 placebo will be administered twice a day (BID) in equally divided doses with or without food.
62584210|NCT05064878|EXPERIMENTAL|ZX008|Part 2: Open-label ZX008 will be administered using a flexible dosing regimen, up to ZX008 0.8 mg/kg/day; maximum dose: 30 mg/day (subjects taking concomitant stiripentol will receive 0.5 mg/kg/day, \[maximum of 20 mg/day\]). ZX008 will be administered twice a day (BID) in equally divided doses with or without food.
62019850|NCT02182544|EXPERIMENTAL|WAL801CL dry syrup + Placebo|
62584211|NCT06529614||Health donor group|
62584212|NCT06529614||Breast cancer group|
62019851|NCT02182544|ACTIVE_COMPARATOR|Ketotifen fumarate dry syrup + Placebo|
62211996|NCT05931432|NO_INTERVENTION|Usual Care|"Participants will be asked to complete an ICF and baseline survey at enrollment. They will be given survey assessments at 0, 18 and 30 months. Survey assessments will include validated measures on well-being, depression, anxiety, stress, resilience, and job satisfaction of physicians.~The control group will have access to usual care well-being resources at Penn Medicine. These include links, classes, groups, social media sites such as Penn Cobalt which require self-awareness to find the resources and access them. In this context, the individual has to pull the resources they need and there may be several barriers to completing each step"
62584213|NCT01510795|NO_INTERVENTION|retrospective control|
62584214|NCT01510795|ACTIVE_COMPARATOR|spironolactone|
62584215|NCT03039621|EXPERIMENTAL|Ergoferon|Tablet for oral use, 1 tablet per intake (outside a meal/feeding). On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day (total 8 tablets). From day 2, one tablet is taken every 8 hours. The drug is administered outside a meal (in the interval between meals or 15 minutes before meal or fluid intake). Keep the tablet in the mouth, without swallowing, until completely dissolved. For young children (aged 6 months to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature. The therapy lasts for 5 days.
62584216|NCT03039621|PLACEBO_COMPARATOR|Placebo|Placebo using Ergoferon scheme.
62584217|NCT06495138|EXPERIMENTAL|Daily Incremental Vestibulo-ocular Reflex Adaptation (D-IVA-GSE)|The dosages of the D-IVA-GSE and I-IVA-GSE are based on the FITT principle of exercise prescription (frequency, intensity, time, and type). The D-IVA-GSE group will perform two, 15- minute GSE sessions (30-minutes total per day), seven days per week.
62019852|NCT02657850||control cohort - study subject self-reporting|Participants who have another cancer (not head and neck cancer) and undergoing treatment will self-report their dysphagia symptoms.
62019853|NCT02657850||study cohort - study subject self-reporting|Participants who have head and neck cancer and undergoing treatment will self-report their dysphagia symptoms.
62584218|NCT06495138|EXPERIMENTAL|Intermittent incremental vestibulo-ocular Reflex Adaptation (I-IVA-GSE)|The I-IVA-GSE group will perform two, 15-minute IVA-GSE sessions (30 minutes total), three days per week, with at least one day between each exercise day.
62584219|NCT01868438|ACTIVE_COMPARATOR|Pyronaridine-artesunate granules (Period 1)|"Period 1: single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate.~Period 2: cross-over to single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate."
62584220|NCT01868438|ACTIVE_COMPARATOR|Pyronaridine-artesunate tablets (Period1)|"Period 1: single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate.~Period 2: cross-over to single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate."
62584221|NCT05087303|ACTIVE_COMPARATOR|Hub and Spoke|
62584222|NCT05087303|ACTIVE_COMPARATOR|Direct to Consumer|
62584223|NCT00005502||Residents of Olmsted County, MN with elevated Troponins|Anyone admitted to St Marys or Rochester Methodist Hospitals who have an elevated troponin during their hospitalization and are residents of Olmsted County, MN
62734523|NCT05753254|EXPERIMENTAL|Firefighting exercises without fire|Firefighting equivalent work, with exercises performed in a clean environment, without fire (no ambient temperature, soot or smoke). This type of exercise usually precedes or complements the training under real fire conditions.
62734524|NCT05753254|EXPERIMENTAL|Firefighting under wood fire|Firefighting under wood fire, with exposure to ambient heat, smoke and soot. This is the most common training scenario used in the training centres. The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models
62584224|NCT03374696|EXPERIMENTAL|Intervention group|The intervention SAFETY was performed in school facilities by professional actors and staff from the municipality's youth guidance center within the county. The actors first enacted a play portraying youths and problems with condom use. Next, a value exercise was held by the youth guidance center staff. The class continued with chlamydia games held by the youth guidance center staff, providing information on symptoms, protection, how to get tested, treatment and consequences. The youth guidance center staff and the actors, playing students, then held a condom school. Lastly, the students came up with new endings to the play. All replays were enacted and the students gave feedback on the new endings. The class ended with condoms being handed out.
62211997|NCT05931432|EXPERIMENTAL|Comprehensive Well-Being Intervention|"Participants will be asked to complete an ICF and baseline survey at enrollment. Participants will complete a full assessment using validated instruments at enrollment, 18 months and 30 months (depression, anxiety, stress, resilience, and job satisfaction). Participants will also complete the brief well-being index (WBI, nine questions) every 3 months over 30 months. The primary endpoint is assessed at 18 months. A secondary endpoint of persistence of effect is measured at 30 months.~The intervention group will receive an 18-month comprehensive suite of services including: 1) monthly automated text messaging reminders about wellbeing resources focused on a range of topics (e.g. mindfulness, stress management, childcare support, racial trauma, diversity and inclusion) and assignment to a one-hour quarterly peer support group with an expectation of regular attendance. Half of these sessions will be self-directed discussion topics and half will be facilitated discussions."
62211998|NCT02055391|ACTIVE_COMPARATOR|Behavioral Weight Loss|State of the art behavioral weight loss treatment
62211999|NCT02055391|EXPERIMENTAL|Enhanced Behavioral Weight Loss|Combines behavioral weight loss skills with skills specifically targeting emotional eating.
62212000|NCT05110170|EXPERIMENTAL|LY01005 3.6 mg|Intramuscular injections of LY01005 3.6 mg every 28 days for a maximum of 3 consecutive doses.
62212001|NCT05110170|ACTIVE_COMPARATOR|ZOLADEX® 3.6 mg|Subcutaneous injections of ZOLADEX® 3.6 mg every 28 days for a maximum of 3 consecutive doses.
62212002|NCT02157701|EXPERIMENTAL|Polyherbal capsule|1 capsule taken with breakfast and 1 capsule with lunch. Capsules should be taken immediately prior to meals and not with carbonated beverages.
62212003|NCT02157701|PLACEBO_COMPARATOR|Placebo capsule|1 capsule taken with breakfast and 1 capsule with lunch. Capsules should be taken immediately prior to meals and not with carbonated beverages.
62408451|NCT03790475|EXPERIMENTAL|Sequential screening strategy.|"Subjects randomized into this group will be initially invited to participate in a screening colonoscopy as per group 1. All subjects who will refuse colonoscopy or do not respond to invitation within 6 weeks since the first letter, will receive another invitation letter with FIT test enclosed.~The screening office will contact persons with a positive test result in order to determine the date of the colonoscopy appointment.~A negative test result will be sent together with a recommendation to have another screening test performed 2 years later and information about the possible delivery of the test in two years."
62408452|NCT03790475|EXPERIMENTAL|Multiple options screening strategy.|"Subjects in this group will receive a letter with an offer to choose between colonoscopy or FIT screening.~The first letter will include an invitation with a scheduled date of colonoscopy (in 6 weeks) and a FIT kit.~Three weeks before a scheduled date of colonoscopy subjects randomized into this group will receive a reminder letter with an information about proposed screening methods. After the scheduled date of the colonoscopy examination, subjects who will not respond to the invitation for colonoscopy and will not send the FIT test back to the laboratory will receive another invitation for colonoscopy (in 6 weeks) and a FIT kit."
62584225|NCT03374696|ACTIVE_COMPARATOR|Control group|The intervention in the control group contained standard education from school staff, based on the sex education guidelines of the Swedish National Agency for Education. Students got education on human sexuality, reproduction, menstruation, love, sex, pregnancy and how STIs and unwanted pregnancy are prevented.
62584226|NCT06521554|EXPERIMENTAL|Phase 1a dose escalation|NVL-330 oral daily dosing
62584227|NCT06521554|EXPERIMENTAL|Phase 1b dose expansion|NVL-330 oral daily dosing
62212004|NCT04110704|ACTIVE_COMPARATOR|Transvaginal cerclage|
62212005|NCT04110704|NO_INTERVENTION|Active monitoring|
62212006|NCT05278039|EXPERIMENTAL|Respiratory-Swallow Phase Training|Participants will be trained to initiate swallowing during expiration.
62212007|NCT05278039|SHAM_COMPARATOR|Swallow Practice|Participants will practice swallowing, but will not learn the key therapeutic element (i.e., initiating swallowing during expiration).
62212008|NCT04502732||Observational|NSSM and GEBT
62212009|NCT00473148|EXPERIMENTAL|1|BNP-guided treatment (Furosemide)
62212010|NCT00473148|NO_INTERVENTION|2|
62212011|NCT00201643|ACTIVE_COMPARATOR|1 Test group|Receive 2nd Course = Study drug (betamethasone or dexamethasone)
62212012|NCT00201643|PLACEBO_COMPARATOR|2 - Control|Placebo group = received placebo course
62212013|NCT02708563|EXPERIMENTAL|Immediate intubation|These infants will have immediate endotracheal suctioning after delivery. They will then have resuscitation per Neonatal Resuscitation Program guidelines.
62584228|NCT02989246|EXPERIMENTAL|Intervention Arm|Ventilator management using the proposed protocol in both acute and weaning phases. Patients will be managed according the the Ventilator protocol using the esophageal catheter for the weaning phase
62584229|NCT01913938||patients with cytopenias|Patients with sepsis and concomitant cytopenias (leukopenia with thrombocytopenia and anemia) who are routinely treated with rhG-CSF will be followed for reconstitution of peripheral blood cell counts. In cooperation with the Department of Hematology, patients are examined for bone marrow cellularity and hemophagocytosis if G-CSF treatment does not result in leukocyte increase.
62584230|NCT01248052|EXPERIMENTAL|LY2979165 (Part A)|single oral doses at dose levels ranging from 20 to 1000 mg
62584231|NCT01248052|PLACEBO_COMPARATOR|Placebo (Part A)|single oral dose
62584232|NCT01248052|EXPERIMENTAL|LY2979165 - low dose (Part B)|single oral low dose of LY297165 (dose to be determined by Part A)
62584233|NCT01248052|EXPERIMENTAL|LY2979165 - high dose (Part B)|single oral high dose of LY2979165 (dose determined from Part A)
62584234|NCT01248052|PLACEBO_COMPARATOR|Placebo - Part B|single oral dose
62584235|NCT01065896||Group 1|
62584236|NCT05662332|EXPERIMENTAL|Insulin Efsitora Alfa|Participants will receive insulin efsitora alfa subcutaneously (SC) once weekly.
62408453|NCT00623688|EXPERIMENTAL|1|Subjects receive active medication (albuterol) delivered by a Proair metered dose inhaler used with an Opti-chamber and placebo (normal saline solution) by nebulizer aerosol.
62408454|NCT00623688|ACTIVE_COMPARATOR|2|Subjects receive active medication (albuterol) delivered by nebulizer and placebo (no medicine) delivered by a demonstrator Placebo metered dose inhaler demonstrator.
62408455|NCT01051076|EXPERIMENTAL|Factor VIII and von Willebrand Factor|
62019854|NCT02657850||study cohort - provider reporting|Participants who have head and neck cancer and undergoing treatment will have their dysphagia symptoms reported by the provider.
62408456|NCT02806700|NO_INTERVENTION|Twitter Diabetes Control|This group will be identified as having diabetes from Twitter. This group will be contacted and asked to complete brief surveys
62408457|NCT02806700|EXPERIMENTAL|Twitter Diabetes Intervention|This group will be identified as having diabetes from Twitter. This group will be contacted and asked to complete brief surveys. This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)
62408458|NCT03207607|EXPERIMENTAL|Control snack|Participants received control snacks prepared by real fruits (pear, orange and mango)
62408459|NCT03207607|EXPERIMENTAL|Maltodextrin snack|Participants received maltodextrin snacks (maltodextrin + control snack)
62408460|NCT03207607|EXPERIMENTAL|Whey protein snack|Participants received whey protein snacks (whey protein + control snack)
62408461|NCT03207607|EXPERIMENTAL|Oat snack|Participants received oat snacks (oat + maltodextrin + control snack)
62408462|NCT03207607|EXPERIMENTAL|Coconut oil snack|Participants received coconut oil snacks (coconut oil + control snack)
62408463|NCT03207607|EXPERIMENTAL|Snack skipping|Participants received snack skipping
62408464|NCT06565897|EXPERIMENTAL|Test regimen|Brush with full ribbon toothpaste, 2x day / 2mins with paste \& toothbrush provided
62408465|NCT06565897|ACTIVE_COMPARATOR|Control regimen|Brush with full ribbon toothpaste, 2x day / 2mins with paste \& toothbrush provided
62408466|NCT00843739|EXPERIMENTAL|EMST|Four week device driven strength training program
62408467|NCT00843739|SHAM_COMPARATOR|sham|Four week sham device driven training program
62408468|NCT00843739|NO_INTERVENTION|Control|Four weeks of no intervention
62408469|NCT02847078|EXPERIMENTAL|Smart phone app|The app contains education materials for secondary prevention of coronary artery disease. So patients can access them very easily. The app pushes heath management recommendation information on the timeline after percutaneous coronary intervention, and also provides health care lecture to help patients to improve their secondary prevention. And online or telephone consultation ways are integrated into the App to provide convenience for patients to communicate with health care professionals.
62408470|NCT02847078|OTHER|Control group|Participants allocated to the control group will receive a booklet with general advice on secondary prevention of coronary artery disease.
62212014|NCT02708563|EXPERIMENTAL|Immediate resuscitation|These infants will have immediate resuscitation per the Neonatal Resuscitation Program guidelines without endotracheal suctioning.
62408471|NCT02765906|NO_INTERVENTION|No intervention|No additional education
62408472|NCT02765906|EXPERIMENTAL|Graphic card|Education with graphic card
62408473|NCT02765906|EXPERIMENTAL|Video|Education with video
62408474|NCT02303977|EXPERIMENTAL|Gemcitabine + Paciltaxel|All patients were treated intravenously with albumin-bound paclitaxel at 100 mg/m2 plus gemcitabine at 1000 mg/m2 on days 1 and 8 of each three-week cycle.
62019855|NCT05166252|EXPERIMENTAL|Experimental group|"1. Installation of the study app.~2. At the beginning of the meal, participants press a button within the App to start a time out from the smartphone at the beginning of a meal (i.e. calls and message are blocked and participants need to press an extra button in order to leave the app). The app instructs all other family members to turn off their phones and to put them away. Then, the participants are instructed to take a picture with their smartphone from the meal table.~3. A time out from the smartphone starts, meaning that all functions of the phone are locked. The time-out is over as soon as the participant presses the stop button.~4. A short questionnaire about the meal is sent via App to the participating family member when the smartphone is used again.~5. During the whole period of the study the App tracks the smartphone behavior (i.e., frequency and duration of smartphone use and the specific applications used). Active comparator: control group"
62019856|NCT05166252|ACTIVE_COMPARATOR|Control group|Control points in time include all parts as in the experimental group except for number 3.
62212015|NCT02436434|ACTIVE_COMPARATOR|pulsed radiofrequency|Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
62212016|NCT02436434|SHAM_COMPARATOR|Sham pulsed radiofrequency|Sham intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in controlled joint
62212017|NCT04021329|OTHER|EMDR Therapy|One arm will be a group subjected to EMDR Therapy
62019857|NCT03868436|OTHER|Methoxyflurane (MEOF)-active treatment|single arm study all subjects will be treated with Methoxyflurane 3 mL
62019858|NCT04598282|PLACEBO_COMPARATOR|Control Arm|All subjects enrolled in the study will receive the standard of care that includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID (four times daily) for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion).
62212018|NCT04021329|OTHER|CBT Therapy|other arm will be a group subjected to CBT Therapy
62212019|NCT02861469||Main carers|Individual semi-structured interviews
62212020|NCT02861469||General practitioners|Individual semi-structured interviews
62212021|NCT04116580||Allergic patients to raw apple and birch|Single-group studies about 28 patients allergic to birch and no longer eating raw rosaceae for at least 6 months. Patients brought back into contact with this family of fruits via the raw golden apple according to an Ultra-Rush protocol.
62408475|NCT05311111|EXPERIMENTAL|distal radial artery approach|Elective percutaneous coronary intervention by forearm radial artery through the distal radial artery in the dorsum of the hand or the anatomical snuff-box
62212022|NCT00626990|ACTIVE_COMPARATOR|Radiotherapy (RT) alone|radiation therapy alone
62212023|NCT00626990|ACTIVE_COMPARATOR|RT & Concurrent CT|Radiotherapy and concurrent temozolomide chemotherapy
62212024|NCT00626990|ACTIVE_COMPARATOR|RT + Adjuvant CT|Radiotherapy plus adjuvant temozolomide chemotherapy
62408476|NCT05311111|ACTIVE_COMPARATOR|conventional radial artery approach|Elective percutaneous coronary intervention through conventional radial artery access
62408477|NCT03205046|EXPERIMENTAL|Part 1 continuous dose for vistusertib|acalabrutinib daily + vistusertib daily
62408478|NCT03205046|EXPERIMENTAL|Part 1 intermittent dose for vistusertib|acalabrutinib daily + vistusertib 5 days on and 2 days off
62408479|NCT02492009|PLACEBO_COMPARATOR|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
62408480|NCT02492009|ACTIVE_COMPARATOR|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
62408481|NCT03289182||MabThera|Participants with NHL will be administered 1400 milligrams (mg) and those with with CLL will be administered 1600 mg MabThera subcutaneously at the discretion of the physician in accordance with local clinical practice and local labeling, and will be observed for 6 years.
62019859|NCT04598282|ACTIVE_COMPARATOR|Treatment Arm|All subjects enrolled in the study will receive the standard of care that includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion). The treatment arm will also receive the placement of PROKERA SLIM for 5-7 days. A second PROKERA SLIM may be applied based on investigator's discretion. For patients with bilateral involvement only the worse eye will be enrolled for the treatment arm.
62019860|NCT04964089|EXPERIMENTAL|KSI-301 (Treatment Group A)|Intravitreal injection of KSI-301 (5 mg) at Day 1 once every 4 weeks via intravitreal injection through Week 44.
62408482|NCT05473546||CRITICALLY ILL PATIENTS|"ADULTS PATIENTS ADMITTED TO ICU DUE TO ACUTE ILLNESS THAT REQUIRE AT LEAST 72H OF STAY.~FOR THE FIRST 7 DAYS OF STAY IN ICU, DATA ABOUT NUTRITIONAL INTERVENTION WILL BE RECORDED SUCH AS: ROUTE OF NUTRITION ADMINISTRATION, AMOUNT OF NUTRITION DELIVERED PER DAY, CALORIC TARGETS, PROTEIN REQUIREMENTS, diarrhea, CONSTIPATION, BIA ANALYSIS."
62408483|NCT00579787||1|Women with early stage cervical cancer undergoing radical trachelectomy
62408484|NCT00579787||2|Women with early stage cervical cancer undergoing radical hysterectomy
62408485|NCT03062878||Breast Cancer/Lymphoma Patient|Breast cancer or lymphoma patients currently undergoing anthracycline-based chemotherapy treatment. Patients are eligible if they have completed at least 1 cycle of chemotherapy. Free of known clinical cardiovascular disease.
62408486|NCT03062878||Breast Cancer/Lymphoma Survivor|Individuals with history of breast cancer or lymphoma (1-5 years removed from last date of chemotherapy) who have a treatment history of anthracycline-based chemotherapy. Free of known clinical cardiovascular disease.
62019861|NCT04964089|ACTIVE_COMPARATOR|Aflibercept (Treatment Group B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 3 monthly doses followed by intravitreal injection of aflibercept (2 mg) once every 8 weeks from Week 16 to Week 44. Sham injections will be administered at each monthly visit where an active treatment is not administered.
62019862|NCT00932893|EXPERIMENTAL|PF-02341066|
62019863|NCT00932893|ACTIVE_COMPARATOR|Pemetrexed or Docetaxel|Investigator selection of either pemetrexed or docetaxel as the active comparator
62019864|NCT00651989||A|healthy individuals
62019865|NCT04409756|OTHER|postassessment of the SRQ-T test|the SRQ -T will be obtained to all patients three days after the first assessment
62019866|NCT00905333|OTHER|Single-arm|3 treatments, 6 sequences, 3 periods, cross-over, single dose arm (Willians' Plan)
62019867|NCT04790149|SHAM_COMPARATOR|Conventional Group|Conventional usual Rehabilitation is administered to a group of patients without any effect on their recovery
62019868|NCT04790149|EXPERIMENTAL|NEUROM|participants received the new protocol of a method called NEUROM consisting of 3 phases of treatment : Motor Imagery training, active rehabilitation and functional rehabilitation
62019869|NCT04790149|EXPERIMENTAL|NEUROM combined with tDCS|same as the second arm of NEUROM combined with transcranial direct stimulation
62019870|NCT06449911|EXPERIMENTAL|HIFU|All participants will be treated using M4.5, level V, with 150 lines on the lower face and submental area; D4.5, level V, 10 Hz, with 4200 dots performed in 7 min on the lower face and the perioral and preauricular areas; M3.0, level V, with 150 lines on the lower face and submental area; D3.0, level V, 10 Hz, with 6000 dots performed in 10 min on the lower face, submental area, and middle face. The microfocused probes were uniformly set to a length of 25 mm with an interval of 1.5 mm. A total of 300 lines and 10,200 dots were performed for each half lower two-thirds of the face and submental area.
62019871|NCT01079221|EXPERIMENTAL|Knee extensor exercise training|High intensity aerobic knee-extensor exercise training
62408487|NCT03062878||Control|Individuals with no history of caner or chemotherapy. Free of known clinical cardiovascular disease
62408488|NCT04905589|PLACEBO_COMPARATOR|ARM A|"Subsequent order of intake :~Iso-voluminous water, breakfast, iso-voluminous water, lunch, iso-voluminous water, dinner"
62408489|NCT04905589|ACTIVE_COMPARATOR|ARM B|"Subsequent order of intake :~MCT in liquid form (75 ml of BetaQuik™), breakfast, iso-voluminous water, lunch, iso-voluminous water, dinner"
62408490|NCT04905589|ACTIVE_COMPARATOR|ARM C|"Subsequent order of intake:~MCT in liquid form (75 ml of BetaQuik™), breakfast, WPI in liquid from (12.5g of WheyBasics in 200ml water), lunch, WPI in liquid from (12.5g of WheyBasics in 200ml water)), dinner"
62584237|NCT05662332|ACTIVE_COMPARATOR|Insulin Glargine|Participants will receive insulin glargine SC once daily.
62584238|NCT06085326|NO_INTERVENTION|Pre-Intervention Phase|PICU patients who are intubated without the Smart checklist
62212025|NCT00626990|ACTIVE_COMPARATOR|RT & Concurrent CT + adjuvant CT|Radiotherapy and concurrent chemotherapy plus adjuvant temozolomide chemotherapy
62019872|NCT02362399|ACTIVE_COMPARATOR|sildenafil citrate|50 mg single oral dose
62019873|NCT02362399|ACTIVE_COMPARATOR|placebo|single tablet of placebo
62019874|NCT05547932|EXPERIMENTAL|Block Group|After endotracheal intubation, patients will be positioned in lateral decubitus position. A linear ultrasound probe will be placed at the edge of scapula at the level of T5-T6. Under sterile conditions, the landmark points (rhomboid major muscle, 5th and 6th ribs, and intercostal muscles) will be observed and a block needle will be directed to the interfacial plane between rhomboid major muscle and intercostal muscle. RIB will be performed by injecting 20 ml of bupivacaine 0.25%. In the same position, the probe will be placed at the midaxillary line at the level of T3, and the landmark points (latissimus dorsi muscle and serratus muscle and intercostal muscles) will be observed. Under sterile conditions, a SAP block will be performed by injecting 20 ml of Bupivacaine 0.25% into the plane between serratus muscle and intercostal muscle.
62019875|NCT05547932|NO_INTERVENTION|Control Group|No block procedures will be performed in this group.
62408491|NCT05736549|EXPERIMENTAL|B-LB in left knee and B-DEX-MPA in right knee|"Participants in this arm will receive B-LB in their left knee and B-DEX-MPA in their right knee.~Nerve block with (B-LB): A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.~Nerve block with (B-DEX-MPA): A medication mixture of 40 ml (40 ml 0.25% plain bupivacaine, 10 mg DEX and 80 mg MPA) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively."
62212026|NCT00502463|EXPERIMENTAL|Single Arm|3 cycles of induction chemotherapy consisting of docetaxel, cisplatin, and 5-FU followed by radiotherapy plus cetuximab
62212027|NCT00707759|EXPERIMENTAL|A: withdrawal steroids|"Arms A: TAC + MMF + withdrawal steroids over a six-days following randomization.~1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~2ºday: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~3°day: Prednisone 2 mg/kg/d in 2 doses~4ºday: Prednisone 1 mg/kg/d in 2 doses~5ºday: Prednisone 0.5 mg/kg/d in 2 doses~6ºday: Prednisone 0.25 mg/kg/d in 2 doses~7ºday: Stop Prednisone"
62212028|NCT00707759|ACTIVE_COMPARATOR|B|"Arms B: TAC + MMF + prednisolone (see schedule)/day~10°days after Tx: 2 mg/kg/d~Day 11 - 20: 1 mg/kg/d~Day 21 - 30: 0.5 mg/kg/d~Day 31 - 60: 0.3 mg/k/d~Week 8 - 12: 0.25 mg/k/d~Week 12 - 16: 0.20 mg/k/d~Week 16 - 20: 0.15 mg/k/d~Month 6 - 12: 0.10 - 0.12 mg/k/d"
62212029|NCT02317432|EXPERIMENTAL|CBT + InVEST exercise|10 sessions of individual CBT plus 36 sessions of InVEST group exercise, provided over a 12-week intervention period.
62408492|NCT05736549|EXPERIMENTAL|B-LB in right knee and B-DEX-MPA in left knee|"Participants in this arm will receive B-LB in their right knee and B-DEX-MPA in their left knee.~Nerve block with (B-LB): A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.~Nerve block with (B-DEX-MPA): A medication mixture of 40 ml (40 ml 0.25% plain bupivacaine, 10 mg DEX and 80 mg MPA) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively."
62408493|NCT05665816||Intervention|Subjects with PAD treated with the PULSAR® -18 T3 Stent will be assessed for eligibility for the registry and consecutively included in the registry. Once informed consent is obtained, the required data will be collected.
62408494|NCT02570399|EXPERIMENTAL|Lymph nodal metastatic lesions|Oligometastatic patients with abdominal-pelvic lymph nodes
62584239|NCT06085326|ACTIVE_COMPARATOR|Post-Intervention Phase|PICU patients who are intubated after implementation of the Smart checklist in the pediatric intensive care unit.
62019876|NCT02138214|EXPERIMENTAL|Arm I (no CND)|Patients undergo total thyroidectomy alone.
62212030|NCT02317432|ACTIVE_COMPARATOR|Enhanced Usual Care|Usual care, as accessed through the community-based organization, plus written material from the NIH on depression, anxiety, and physical health for elders.
62019877|NCT02138214|EXPERIMENTAL|Arm II (CND)|Patients undergo total thyroidectomy with ipsilateral prophylactic CND.
62212031|NCT06470984|EXPERIMENTAL|Acute Care|Nursing leaders will participate voluntarily and will report their leadership role as acute care (hospital settings).
62584240|NCT05702801|EXPERIMENTAL|Exposure to stochastic vibratory stimulation|All participants will be exposed to vibratory stimulations at different levels of 0Hz, 40Hz, and 80Hz.
62584241|NCT01263236|EXPERIMENTAL|LY2940094 - single dose|Single oral dose of 2-800 milligram (mg) LY2940094
62584242|NCT01263236|EXPERIMENTAL|LY2940094 - multiple dose|Daily oral dose of 2-200 mg LY2940094 for 14 days
62212032|NCT06470984|EXPERIMENTAL|Post-Acute Care|Nursing leaders will participate voluntarily and will report their leadership role as post-acute care (ambulatory settings)
62584243|NCT01263236|EXPERIMENTAL|Placebo|Single oral dose or daily oral dose for 14 days
62584244|NCT04647396|EXPERIMENTAL|Intervention group|
62584245|NCT04647396|NO_INTERVENTION|Control group|
62584246|NCT03781362|EXPERIMENTAL|CPI-100 Monotherapy|"Dose Escalation Groups:~CPI-100 will be administered via intravenous infusion once every 2 weeks (Q2W) for up to 5 dose levels and once every 3 weeks (Q3W Arm A) for up to 4 dose levels in a 3 + 3 dose escalation study~Dose Expansion Group: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation group"
62584247|NCT03781362|EXPERIMENTAL|CPI-100 Combination with Capecitabine|CPI-100 will be administered via intravenous infusion once every 3 weeks in combination with oral capecitabine for up to 4 dose levels in a dose escalation study (Q3W Arm B)
62019878|NCT02138214|ACTIVE_COMPARATOR|Arm III (SOC)|Patients who are not eligible for randomization into Arm I or Arm II, Standard of Care (SOC) group. No specific trial intervention, treated as per patient and physician preference
62019879|NCT05904964|EXPERIMENTAL|Disitamab Vedotin|Disitamab Vedotin, 2mg/kg, every 2 weeks
62408495|NCT01699100|EXPERIMENTAL|device|In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure \> 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
62408496|NCT02387944||Cardiopulmonary bypass|Children with congenital heart defect undergoing surgery on cardiopulmonary bypass
62408497|NCT02387944||cardiac catheterism|Children with congenital heart defect undergoing cardiac catheterism
62408498|NCT01991756||AAA|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm will be treated with the Altura Endograft System.
62408499|NCT03949946||High-risk|Female participants confirmed to be BRCA1/2 or TP53 gene carriers
62408500|NCT03949946||Patients|Female participants confirmed to have invasive ductal carcinoma of the breast
62408501|NCT06026514|EXPERIMENTAL|Intranasal Vaccine|B/HPIV3/S-6P vaccine intranasally given in 2 doses, 56 days apart.
62408502|NCT00728273|EXPERIMENTAL|MMF|multi-micronutrient-fortified biscuit plus placebo deworming-treatment
62408503|NCT00728273|EXPERIMENTAL|Alb|placebo biscuit plus deworming treatment with Albendazole
62408504|NCT00728273|EXPERIMENTAL|MMF + Alb|multiple micronutrient-fortified biscuits with deworming treatment with Albendazole
62408505|NCT00728273|PLACEBO_COMPARATOR|placebo|placebo biscuit (non-fortified) and placebo deworming treatment
62408506|NCT02787746|OTHER|donepezil|This is a multi-center single-arm study, which assess the safety and efficacy of donepezil in mild to moderate Alzheimer's disease in China.
62408507|NCT05368376|ACTIVE_COMPARATOR|Group L (n=30)|Labetalol group
62408508|NCT05368376|ACTIVE_COMPARATOR|Group M (n=30)|Metoprolol group
62408509|NCT01503086|EXPERIMENTAL|Arm I (interactive training program)|Patients undergo a home-based, computerized, interactive training program comprising 3-5 sessions of 15-45 minutes every week for 5-9 weeks. The program contains twelve visually engaging and interesting exercises that target skills involving visual-spatial and verbal WM. The program is adaptive in a way that each difficulty task is automatically adjusted on a trial-by-trail basis to match a patient's current WM. Each patient has an interventional coach who has online access to patient's training sessions and outcomes (pass or fail). Coaches are able to modify the training sequence or make suggestions to patients and/or parents about how progress can be maximized. Coaches also have telephone meetings with patients and/or families once a week to ensure compliance, track progress, provide feedback, and answer questions that arise during training.
62408510|NCT01503086|EXPERIMENTAL|Arm II (non-adaptive training program)|Patients undergo a home-based, computerized, interactive, non-adaptive training program comprising 3-5 sessions of 15-45 minutes a week for 5-9 weeks. Each patient also has an interventional coach as in arm I. Patients in both arms complete a brief neuropsychological/behavioral assessment comprising the WIS-IV, the CMS, and the CVLT-C at baseline, after completion of study, and at 6 months after completion of study. Additionally, parents complete a parent-report questionnaire to gather information about patient's behaviors, thoughts, emotions, adaptive skills, and social and functional impairment. Parents and children also complete surveys about the program regarding technical feasibility, adherence, ease-of-use, and satisfaction.
62408511|NCT04401046|EXPERIMENTAL|Post traumatic stress and anxiety evaluation|
62019880|NCT05904964|ACTIVE_COMPARATOR|Endocrine therapy|Doctors choose endocrine therapy independently
62019881|NCT03272100||test side ( horizontal flap)|Horizontal incision was realised in alveolar mucosa, in order to obtain the exposure of the lateral wall of the maxillary sinus, thus accessing the sinus cavity
62019882|NCT03272100||control side ( standard flap)|Trapezoidal flap was realised, using a crestal incision and two deep vertical incisions extended in the fornix to expose the lateral wall of the maxillary sinus
62019883|NCT06204159|EXPERIMENTAL|End Hole Catheter followed by TriNav Catheter|"FDA approved catheter~Randomization End Hole catheter then TriNav catheter"
62408512|NCT05206279|EXPERIMENTAL|ureteral ICG injection|There is only one arm of the study. All patients will undergo normal laparoscopy. After examining the abdominal structures for presence of endometriosis as well as performing photographic documentation, cystoscopy with intraureteral administration of ICG will be performed, after which intervention the ureters will be examined by laparoscopy. ICG is injected cystoscopy-guided into the ureters (cystoscopy-guided) in a dosage of 5 or 10ml (25mg ICG in 5 or 10ml NaCl) per ureter as a bolus injection.
62584248|NCT05193071|EXPERIMENTAL|double antiplatelet group|aspirin 100mg plus clopidogrel 300mg
62212033|NCT02158351||Simple steatosis|We will run a cross-sectional observational study including two groups of human subjects: patients with simple steatosis (SS) or non-alcoholic steatohepatitis (NASH). Grouping in patients SS or NASH will be performed based on the histological diagnosis of the type of NAFLD obtained at operation (sleeve gastrectomy or cholecystectomy). BMI will be considered as a confounding variable to be statistically analyzed. Main hypothesis: GM can lead to liver inflammation in patients with liver fat accumulation.
62019884|NCT06204159|EXPERIMENTAL|TriNav Catheter followed by End Hole Catheter|"FDA approved catheter~Randomization TriNav catheter then End Hold catheter"
62019885|NCT02504645|ACTIVE_COMPARATOR|IPP-201101 200-mcg plus SOC|Patients randomly assigned to IPP-201101 will be administered a dosage of 200 mcg subcutaneously (sc) every 4 weeks for 48 weeks (a total of 13 doses will be administered).
62019886|NCT02504645|PLACEBO_COMPARATOR|PLACEBO plus SOC|Patients randomly assigned to placebo will be administered placebo subcutaneously (sc) every 4 weeks for 48 weeks (a total of 13 doses will be administered).
62408513|NCT06652399||Patients with pediatric myocarditis|Patients diagnosisd or suspected myocarditis based on the Diagnostic Recommendation for Myocarditis in Children (version 2018).
62408514|NCT06035328|EXPERIMENTAL|Four per week|Case wheat allergy that on four times/week dose during one year maintenance phase of wheat OIT
62408515|NCT06035328|NO_INTERVENTION|Once daily|Case wheat allergy that on once daily dose during one year maintenance phase of wheat OIT
62019887|NCT01210768|ACTIVE_COMPARATOR|EC|Cyclophosphamide,600 mg/m2 q3wk and Epirubicin,90 mg/m2 q3wk
62019888|NCT01210768|EXPERIMENTAL|LC|liposomal doxorubicin, 37.5 mg/m2 q3wk, and Cyclophosphamide,600 mg/m2 q3wk
62019889|NCT01474603||1|overweight or obese diabetic
62408516|NCT04130555||CELLIS Rectopexy|Rectal prolapse repair by ventral rectopexy with the CELLIS Rectopexy matrix
62584249|NCT05193071|PLACEBO_COMPARATOR|control group|aspirin placebo plus clopidogrel placebo
62019890|NCT04481256|EXPERIMENTAL|1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy|"Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.~External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy"
62584250|NCT05223647|EXPERIMENTAL|Chemo-immunotherapy plus thoracic radiotherapy|"Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.~Thoracic radiotherapy of 30 Gy/10 fractions between 2nd and 3rd carboplatin/etoposide/durvalumab course."
62584251|NCT05223647|ACTIVE_COMPARATOR|Chemo-immunotherapy|Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
62408517|NCT00684645||Patients treated with SUTENT®|Patients with metastatic or advanced renal cell carcinoma after failure of cytokines therapy.
62408518|NCT06642662||DTGA ASO|D-transposition of the great arteries (DTGA) post arterial switch operation (ASO)
62408519|NCT06642662||S1P|Neonates undergoing stage 1 palliation (S1P) for hypoplastic left heart syndrome (HLHS)
62408520|NCT06642662||BiV|Prior single ventricle palliation now undergoing biventricular (BiV) repair
62408521|NCT04453475|EXPERIMENTAL|Partial digital group: depression|"Burg~Online depression session as a flipped classroom and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
62584252|NCT02478866|EXPERIMENTAL|BPI-9016M|Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg, 600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
62584253|NCT05853861|NO_INTERVENTION|MONITOR|Participants in this arm will be provided with information to track the early development of their infants, along with specific developmentally targeted activities.
62584254|NCT05853861|EXPERIMENTAL|COACH|Participants will be provided with a blended intervention of two evidence tested intervention, JASPER and Babble Bootcamp along with continued monitoring.
62584255|NCT05581303|PLACEBO_COMPARATOR|Placebo|Placebo will be administered by subcutaneous injection
62584256|NCT05581303|EXPERIMENTAL|Olpasiran|Olpasiran will be administered by subcutaneous injection
62584257|NCT01765348|EXPERIMENTAL|Sentence combining|
62584258|NCT01765348|ACTIVE_COMPARATOR|Narrative based method|
62019891|NCT04660981|EXPERIMENTAL|İntervention Group|"The women in the intervention group were individually provided with Training Program on Fear of Childbirth Based on Motivational Interview Method once a week, four sessions in total."
62019892|NCT04660981|NO_INTERVENTION|Control Group|No interventions were made for those in the control group other than routine hospital practices.
62408522|NCT04453475|EXPERIMENTAL|Partial digital group: social work (social medicine)|"NOR~Online lecture with socio-medical content and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
62408523|NCT04453475|EXPERIMENTAL|Partial digital group: depression + social work|"JUL~Online depression session as a flipped classroom and an online lecture with socio-medical content and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
62408524|NCT04453475|ACTIVE_COMPARATOR|Control group: only digital training before rehabilitation|"MOE~Online tobacco cessation a flipped classroom and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
62408525|NCT05726409|EXPERIMENTAL|Mobile application user|Each participant will be sent an email with a link to download a mobile application to access the meal planner function.
62408526|NCT03442894|ACTIVE_COMPARATOR|Standard PT Treatment|"This group will receive manual therapy and exercise interventions provided by their physical therapist. The treatment will occur for 10 sessions over 6 weeks.~Interventions: Manual therapy interventions including mobilization and manipulation of the shoulder girdle spine and ribcage. Exercise interventions will include strengthening and flexibility exercises for rotator cuff and shoulder girdle musculature."
62408527|NCT03442894|EXPERIMENTAL|Standard PT Treatment plus DN|In addition to the standard PT interventions, the Dry Needling (DN) group will receive 6 DN sessions as part of their rehabilitation visits.
62584259|NCT02745613|EXPERIMENTAL|Family history of T2D|The participants will undergo 8 weeks of combined exercise
62584260|NCT02745613|EXPERIMENTAL|No Family history of T2D|The participants will undergo 8 weeks of combined exercise
62584261|NCT05786040|EXPERIMENTAL|Treatment (tafasitamab, rituximab)|Patients receive tafasitamab IV and rituximab IV or SC on study. Patients who have CR or PR after 4 cycles may receive additional tafasitamab and rituximab on study. Patients also undergo PET or CT, biopsy, and collection of blood samples throughout the trial.
62584262|NCT01793961|OTHER|"Cannabis Arm"|patient addicted to cannabis
62584263|NCT01793961|OTHER|"Tobacco Arm"|patient addicted to tobacco
62584264|NCT01793961|OTHER|"Healthy volunteers"|no smokers
62584265|NCT02952092|EXPERIMENTAL|ASP1517 Group|Subjects will take the study drug at two- or three-day intervals.
62584266|NCT02952092|EXPERIMENTAL|Darbepoetin alfa Group|Subjects will take the study drug once a week.
62790216|NCT05505864|EXPERIMENTAL|Intervention Group|"* Participants in the intervention group will be asked to wear an ACTIVPAL4 at week 0, 5, and 11.~* Participants in the intervention group will be asked to fill out questionnaires assessing key variable (demographics, sedentary behaviour, and quality of life) on the SEMA3 app at week 0, 2, 4, 6, and 12.~* Participants in the intervention group will receive a one-on-one behavioural counselling session online through zoom at week 0 to create personalized action plans and coping strategies to reduce and break up sedentary behaviour. The participant will update these action plans and coping strategies at the end of week 2 and 4 on the SEMA3 app.~* Participants in the intervention group will receive tailored text messages the day after receiving their one-on-one counselling session for a 6-week period.~* Participants in the intervention will receive one-on-one qualitative interview on zoom at week 6 to explore participants overall experience engaging in the intervention."
62408528|NCT03442894|SHAM_COMPARATOR|Standard PT Treatment plus Sham DN|In addition to the standard PT treatment, patients in the sham DN group will receive 6 sessions of sham DN intervention.
62019893|NCT01358526|EXPERIMENTAL|OXN|Oxycodone/Naloxone Controlled-release Tablets (OXN)
62408529|NCT04232761||CRPC patients|Patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases who are treated with radium-223 dichloride in routine clinical practice in Taiwan
62408530|NCT05860452|ACTIVE_COMPARATOR|ropivacaine|Participants in this group will receive TAP block with 0,75%, bilaterally.
62408531|NCT05860452|PLACEBO_COMPARATOR|normal saline|Participants in this group will receive TAP block with normal saline, bilaterally.
62408532|NCT00747110|EXPERIMENTAL|A|9mg budesonide OD
62408533|NCT00747110|ACTIVE_COMPARATOR|B|3g mesalazine OD
62408534|NCT04000958|EXPERIMENTAL|PIFR group|
62408535|NCT04000958|ACTIVE_COMPARATOR|control group|
62408536|NCT05186116|EXPERIMENTAL|LDLT, partial graft, whole graft recipients|Patients that undergo LDLT, partial graft or whole graft transplantation for CRLM in the study period
62408537|NCT01568255|EXPERIMENTAL|Vitamin D Treatment|Vitamin D Treatment Group
62584267|NCT05127616|EXPERIMENTAL|Minimal Contact-Cognitive Behavior Therapy|CBT is a goal-focused, learning-based treatment that teaches practical self-management tools and strategies targeting biobehavioral factors that aggravate pelvic pain and urinary symptoms
62790217|NCT05505864|NO_INTERVENTION|Control Group|"* Participants in the control group will be asked to wear an ACTIVPAL4 at week 0, 5, and 11.~* Participants in the control group will be asked to fill out questionnaires assessing key variable (demographics, sedentary behaviour, and quality of life) on the SEMA3 mobile app at week 0, 2, 4, 6, and 12."
62408538|NCT01568255|PLACEBO_COMPARATOR|Placebo Group|Placebo at 50,000IU for 8 weeks
62408539|NCT06652165|EXPERIMENTAL|zanubrutinib combined with BEAM|zanubrutinib combined with camustine, etoposide, cytarabine, and mafaran (BEAM)
62408540|NCT06652165|ACTIVE_COMPARATOR|BEAM|camustine, etoposide, cytarabine, and mafaran (BEAM)
62790218|NCT06209827|EXPERIMENTAL|Intervention for reducing benzodiazepines long-term use.|"It included the multiple components as follows:~(i) an exchange discussion with the patient describing the advantages, disadvantages and alternatives of benzodiazepines use and a tapering protocol with the support of educational material, (ii) the offer of a brief, if necessary, consultation with the family doctor, and (iii) a letter addressed to the patient supported by scientific societies."
62790219|NCT06209827|NO_INTERVENTION|Usual Care|Usual Care
62790220|NCT05564039|EXPERIMENTAL|Tirzepatide|Participants will receive tirzepatide subcutaneously (SC)
62790221|NCT05564039|ACTIVE_COMPARATOR|Dulaglutide|Participants will escalate their dulaglutide dose SC.
62019894|NCT01358526|PLACEBO_COMPARATOR|Placebo|Placebo tablets to match OXN
62019895|NCT03892889|EXPERIMENTAL|Abilify MyCite®|Participants received Abilify MyCite® a combination product of aripiprazole tablet embedded with sensor and wearable patch for 3 months (Months 1 to 3) and continued for an additional 3 months (Months 4 to 6) as per investigators assessment or switch to a standard-of-care treatment of oral atypical antipsychotics or a long acting injectable.
62019896|NCT04911543|EXPERIMENTAL|Part A: [18F]-JNJ-70099731|Participants will receive an intravenous (IV) bolus injection of \[18F\]-JNJ-70099731 on Day 1 of Part A to investigate the total body bio-distribution and measure the radiation dosimetry of \[18F\]-JNJ-70099731.
62408541|NCT00718809|EXPERIMENTAL|Arm I|Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62408542|NCT06537973|EXPERIMENTAL|Experimental group|"In the first 48 hours after birth; A single-session training including postpartum care, breastfeeding and baby care will be given to mothers in the hospital room where they are hospitalized, practices will be taught and mothers will be encouraged to perform the practices.~2nd week; Counseling will be provided to mothers who have previously been trained by contacting them via phone call.~4th week; Phone calls will be planned with mothers, ABBÖ will be implemented, and the counseling and support provided will continue.~6th week; A telephone interview will be planned with the mothers, MBÖ, EÖÖÖ and BAFÖ will be applied, an evaluation will be made and consultancy will be provided on the issues they need.~8th week; A phone call will be planned with the mothers, an evaluation will be made, care plans will be maintained and counseling will be provided.~12th week; Mothers will be contacted via phone and the MBÖ, EÖYÖ and BAFÖ scales will be applied as a posttest."
62019897|NCT04911543|EXPERIMENTAL|Part B: [18F]-JNJ-70099731|Participants will receive an IV bolus injection of \[18F\]-JNJ-70099731 on Day 1 of Part B to measure the uptake, distribution, and clearance of \[18F\]-JNJ-70099731 and to model the tissue specific kinetics of \[18F\]-JNJ-70099731 in the human brain with the appropriate arterial input function.
62019898|NCT04911543|EXPERIMENTAL|Part C: [18F]-JNJ-70099731|Participants will receive an IV bolus injection of \[18F\]-JNJ-70099731 on Day 1 of each period of Part C to determine the test-retest variability in the regional brain kinetics and binding properties of \[18F\]-JNJ-70099731.
62019899|NCT04018872|EXPERIMENTAL|Itraconazole|Itraconazole capsule 300mg twice daily for 6-8 weeks following chemoradation.
62019900|NCT02791048|EXPERIMENTAL|Experimental Group|Music therapy for up to 45 minutes twice a week for three weeks, in addition to usual care from the hospice multidisciplinary team.
62019901|NCT02791048|NO_INTERVENTION|Control Group|Usual care only from the hospice multidisciplinary team. The dose and frequency of usual care will be as deemed appropriate by the hospice practitioner in charge of their treatment.
62212034|NCT02158351||Non-alcoholic steato-hepatitis|We will run a cross-sectional observational study including two groups of human subjects: patients with simple steatosis (SS) or non-alcoholic steatohepatitis (NASH). Grouping in patients SS or NASH will be performed based on the histological diagnosis of the type of NAFLD obtained at operation (sleeve gastrectomy or cholecystectomy). BMI will be considered as a confounding variable to be statistically analyzed. Main hypothesis: GM can lead to liver inflammation in patients with liver fat accumulation.
62212035|NCT02134418|EXPERIMENTAL|Irony CBT training|CBT of irony comprehension
62212036|NCT02134418|NO_INTERVENTION|No Intervention|No Intervention
62212037|NCT05084235|ACTIVE_COMPARATOR|Empaglifloxin|
62212038|NCT05084235|PLACEBO_COMPARATOR|Placebo|
62212039|NCT01800682|EXPERIMENTAL|Tramodol Extended-release (ER), 25 milligram (mg)|Tramodol ER, 25 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
62212040|NCT01800682|EXPERIMENTAL|Tramodol ER, 50 mg|Tramodol ER, 50 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
62212041|NCT01800682|EXPERIMENTAL|Tramodol ER, 100 mg|Tramodol ER, 100 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
62212042|NCT02275793||high PH and normal PVR|Group I, diastolic heart failure with high PH and normal PVR
62212043|NCT02275793||high PH and high PVR|Group II, diastolic heart failure with high PH and High PVR
62212044|NCT02275793||normal PH and normal PVR|Group III, no heart failure, normal PH and normal PVR
62212045|NCT05389917||Consecutive adult patients undergoing pancreaticoduodenectomy|All the consecutive patients who undergo pancreaticoduodenectomy will be recruited into the study after obtaining informed consent
62212046|NCT00935727|OTHER|1|normally functioning transplanted kidneys
62212047|NCT00935727|OTHER|2|transplanted kidney undergoing known rejection or other known abnormality
62212048|NCT00935727|OTHER|3|transplanted kidney with unknown diagnosis
62212049|NCT00721149|EXPERIMENTAL|NaviStar ThermoCool|
62212050|NCT03041974||Transfused critical care patients|Patients included in the Age of BLood Evaluation (ABLE) trial in either arms and included in a French center.
62212051|NCT05560334|EXPERIMENTAL|Pemigatinib|Selective FGFR1-3 inhibitor
62212052|NCT05110352|EXPERIMENTAL|Obstructive Sleep Apnea Syndrome patients with polysomnography planned|Apnea-Hypopnea Index (AHI) \> 15
62212053|NCT05396768||Novices|Junior residents from the departments of surgery, pneumology or emergency medicine. These participants are in their first or second year of residency, and have observed or placed less than 5 CTIs in their career.
62212054|NCT05396768||Experienced|Faculty members from Ghent University Hospital from the departments of surgery, pneumology or emergency medicine. These participants must have finished their residency training, and must be involved in resident education.
62584268|NCT05127616|ACTIVE_COMPARATOR|Education/Support|EDU emphasizes the empowering therapeutic benefits that come from the common across empirically-validated drug or non-drug treatment such as being listened to, support, receipt of science-based information, mobilization of hope, and the establishment of a strong patient-doctor relationship working toward shared goals
62212055|NCT04259151|EXPERIMENTAL|Electric wheelchair with activated assistance module|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance, in a random order established upstream.
62212056|NCT04259151|OTHER|Electric wheelchair with assistance module not activated|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 without activated assistance, in a random order established upstream.
62212057|NCT01132443|EXPERIMENTAL|Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,|Apply topically once daily; clindamycin (CLN); benzoyl peroxide (BPO); methylparaben-free (MPF)
62212058|NCT01132443|ACTIVE_COMPARATOR|Duac/ formulation 1|Apply topically once daily, Topical Gel (CLN 1%-BPO 5%), methylparaben-preserved
62212059|NCT01132443|ACTIVE_COMPARATOR|Duac/ formulation 2|Apply topically once daily, Duac Once Daily Gel (CLN 1%-BPO 5%), MPF
62212060|NCT04487704|OTHER|Camrelizumab in the treatment of liver cancer|Camrelizumab intravenous infusion (no need for prophylactic administration), no less than 30 min
62212061|NCT05873764|EXPERIMENTAL|200 mg RV521/78 µCi [ 14C]-RV521|200 mg RV521/78 µCi \[ 14C\]-RV521
62212062|NCT04693195|EXPERIMENTAL|BLU-5937 oral tablet|Eligible participants will receive BLU-5937 twice a day (BID) orally for 4 weeks.
62212063|NCT04693195|PLACEBO_COMPARATOR|Placebo oral tablet|Eligible participants will receive matching Placebo BID orally for 4 weeks.
62212064|NCT02837224||Preimplementation: Situate Locate System|Subjects/surgeries performed before implementation of the Situate Detection System.
62212065|NCT02837224||Implementation|Subjects/surgeries performed after implementation of the Situate Detection System.
62212066|NCT05331313||patients with a diagnosis of multiple myeloma|This study will involve a single patient group, namely patients with a diagnosis of multiple myeloma diagnosed by a bone marrow aspirate with cytological analysis of the bone marrow smear.Bone marrow samples obtained during the routine follow-up will undergo plasmocyte enrichment using immunopurification using CD138+ beads and nucleic acids will be extracted for sequencing.
62212067|NCT01883232|ACTIVE_COMPARATOR|2% lidocaine with 1:100,000 epinephrine|2% lidocaine with 1:100,000 epinephrine
62212068|NCT01883232|EXPERIMENTAL|Onset Mixing Pen by Onpharma|Sodium Bicarbonate 8.4% mixed with the onset mixing pen
62212069|NCT06609525|EXPERIMENTAL|CTO0303-A|
62212070|NCT06609525|EXPERIMENTAL|CTO0303-B|
62212071|NCT06609525|ACTIVE_COMPARATOR|CTO0303-C|
62584269|NCT06030232||Observation group|Patients who received radioembolization for colorectal cancer liver metastases
62584270|NCT01941745|PLACEBO_COMPARATOR|half normal saline|Single dose of half normal saline at 2 ml/kg given intratracheally times one dose
62212072|NCT05898347||Gorlin syndrome|Children aged six to seventeen years old with Gorlin syndrome and nevoid basal cell carcinomas.
62212073|NCT03914001|OTHER|NMIBC patients|eligible patients will undergo initial mpMRI before initial TURBT, then followed by second mpMRI and second resection TURBT after 4 weeks
62408543|NCT06537973|NO_INTERVENTION|Control Group|The researchers will not provide any training or counseling to the mothers other than the standard care and services offered in the hospital. In order to ensure equality, a prepared training booklet will be given to mothers in the control group.
62408544|NCT02843490|EXPERIMENTAL|Ranibizumab treatment of nAMD patients|nAMD patients will be treated with Ranibizumab (0.5 mg injection) 3 times within three months followed by individual therapy interval based on the clinical progress (PRN) up to 7 times. Analysis of specific biomarker.
62408545|NCT02843490|NO_INTERVENTION|healthy subjects|Analysis of specific biomarker.
62584271|NCT01941745|EXPERIMENTAL|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)in 2 ml/kg given intratracheally times one dose
62019902|NCT00745732|EXPERIMENTAL|Radiation Therapy + ZD6474|"Radiation Therapy - Phase I: 45 Gy at 3 Gy per fractions once a day.~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day.~ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth."
62019903|NCT05507606|EXPERIMENTAL|Osimertinib+Bevacizumab+Carboplatin and Pemetrexed|Bevacizumab, 7.5mg/kg, d1; Pemetrexed, 500mg/m2, d1; Carboplatin AUC5, d1; Osimertinib 80mg/d , d1-21; Q3W/cycle induction therapy for 4 cycle. Then Carboplatin was stopped after 4 cycles, and Osimertinib combined with Bevacizumab and Pemetrexed were given for maintenance treatment every 3 weeks for 2 years. After that, the maintenance treatment of Osimertinib was continued.
62408546|NCT06567756|EXPERIMENTAL|Group A (experimental group): CSPO group|The distal rectum is isolated to the entrance of the internal and external sphincter space, and then an oblique resection line is designed under direct vision according to the tumor site and shape, ensuring that the distal and lateral margins are not less than 1 cm, and preserving the contralateral dentate line and intestinal wall as much as possible, and completing the anastomosis manually or with instruments.
62408547|NCT06567756|ACTIVE_COMPARATOR|Group B (control group): ISR group|Partial, subtotal, or complete resection of the internal sphincter and/or a portion of the longitudinal rectal muscle, expansion of the distal rectal incision margin into the anal canal or to the anal verge, and completion of colorectal-anal anastomosis manually or instrumentally
62408548|NCT06649890|EXPERIMENTAL|Xperience™ Advanced Surgical Irrigation|
62408549|NCT06649890|ACTIVE_COMPARATOR|Dilute Povidone-Iodine|
62408550|NCT04596618|ACTIVE_COMPARATOR|Forearm Cooling|Participants will be actively cooled during rest breaks.
62584272|NCT01941745|EXPERIMENTAL|High dose rhCC10|5 mg/kg of rhCC10 given in 2 ml/kg and administered intratracheally times one dose
62584273|NCT05784584||Infants infected through breast-feeding and perinatally|Infants infected through breast-feeding and perinatally diagnosed with HIV ≤90 days of age and starting ART ≤90 days after diagnosis. For these patients clinical data and blood for viral load, immunology and serology will be collected in the 11 visits.
62584274|NCT06666413|EXPERIMENTAL|avalglucosidase alfa|Avalglucosidase alfa will be administered by IV infusion following reconstitution and dilution at a dose of 20 mg/kg body weight qow
62584275|NCT00381732|PLACEBO_COMPARATOR|1|placebo tablet
62584276|NCT00381732|ACTIVE_COMPARATOR|2|2.5 mg tadalafil tablet
62019904|NCT03396783|EXPERIMENTAL|SPP|during the visit, nurse will make a blood test for biological and immunological analysis, electromyogram and walk test
62019905|NCT03396783|OTHER|Control|during the visit, nurse will make a blood test for biological and immunological analysis
62019906|NCT03609801|EXPERIMENTAL|ACTV|"Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new Batterers Intervention Program (BIP) for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is an innovative BIP in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming."
62212074|NCT05537116|EXPERIMENTAL|Personalized Feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
62019907|NCT03609801|ACTIVE_COMPARATOR|The Duluth Model|The Duluth Model Men's Nonviolence Classes is the most widely used BIP. The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model's Men's Nonviolence Classes (The Duluth Model for short) help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
62019908|NCT03533348||Fasting arm|Patients will need at least 4 hours of fasting prior to contrast-enhanced CT scans.
62019909|NCT03533348||No fasting|Patients are allowed to eat and drink freely prior to contrast-enhanced CT scans.
62019910|NCT03494257|ACTIVE_COMPARATOR|Brinzolamide-Brimonidine fixed combination|1 drop of the brinzolamide-brimonidine fixed combination instilled in the patients cul de sac immediately after surgery
62019911|NCT03494257|NO_INTERVENTION|No topical IOP reducing medication|No IOP reducing drops instilled after surgery
62212075|NCT05537116|EXPERIMENTAL|Personalized feedback and text messages|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.
62212076|NCT05537116|ACTIVE_COMPARATOR|Information only|Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
62408551|NCT04596618|NO_INTERVENTION|No Forearm Cooling|"Participants will participant in passive cooling where they sit in a chair during rest."
62408552|NCT06177626|ACTIVE_COMPARATOR|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre- training capabilities. Participants will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge.
62584277|NCT00381732|ACTIVE_COMPARATOR|3|5 mg tadalafil tablet
62584278|NCT05092022|EXPERIMENTAL|Requested self-sampled HPV test|This group will receive the self-sampled HPV test. Included with the test are the test instructions, a lab requisition form, and a pre-paid mailer so that it can be sent back to the lab for testing. Results of the test will be shared with the participant.
62790222|NCT00942825|EXPERIMENTAL|A CBP501 +Cisplatin + Pemetrexed|CBP501 25 mg/m2 + Cisplatin 75 mg/m2 + Pemetrexed 500mg/m2
62790223|NCT00942825|ACTIVE_COMPARATOR|B Cisplatin + Pemetrexed|Cisplatin + Pemetrexed
62019912|NCT02806986|EXPERIMENTAL|IGSC 20%|13 doses of IGSC 20% in Treatment Stage 1 and 39 doses of IGSC 20% in Treatment Stage 2 for a total of 52 doses if IGSC 20%
62019913|NCT03388580||BAL|patients undergoing elective bronchoalveolar lavage
62019914|NCT02830217||STEMI patients having primary PCI|Patients with STEMI receiving primary PCI in Wuhan Aisa Heart Hospital are included in this study. All patients are the first time to have STEMI, and primary PCIs are performed according to 2013 ACCF/AHA guideline for the management of STEMI. Patients with previous stroke, pneumonia, cirrhosis, autoimmune diseases are excluded from this study.
62790224|NCT04521244|EXPERIMENTAL|Thrust joint lumbar manipulation|Thrust joint lumbar manipulation (Lumbar rotation manipulation) ,Moist Hot pack
62790225|NCT04521244|ACTIVE_COMPARATOR|Lumbar mobilization|Lumbar mobilization (Stretch rotation mobilization), Moist Hot pack
62790226|NCT01210898|EXPERIMENTAL|Group 1|
62790227|NCT01210898|EXPERIMENTAL|Group 2|
62790228|NCT01210898|EXPERIMENTAL|Group 3|
62019915|NCT03017508|EXPERIMENTAL|BHV-0223 (Sublingual Riluzole)|Participants will be given one dose of BHV-0223 (sublingual riluzole) 35mg before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
62790229|NCT01210898|EXPERIMENTAL|Group 4|
62790230|NCT01210898|EXPERIMENTAL|Group 5|
62790231|NCT01210898|EXPERIMENTAL|Group 6|
62790232|NCT01210898|EXPERIMENTAL|Group 7|
62790233|NCT01210898|EXPERIMENTAL|Group 8|
62790234|NCT01210898|EXPERIMENTAL|Group 9|
62790235|NCT01210898|EXPERIMENTAL|Group 10|
62790236|NCT01210898|EXPERIMENTAL|Group 11|
62790237|NCT01210898|EXPERIMENTAL|Group 12|
62790238|NCT01210898|EXPERIMENTAL|Group 13|
62790239|NCT02003170||Neurodevelopmental Disorders|Children who present to various Arkansas Children's Hospital clinics for standard care related to neurodevelopmental disorders.
62212077|NCT02371291|EXPERIMENTAL|Memory Flexibility Training|The MemFlex programme draws on cognitive bias modification and memory specificity training techniques (Raes et al., 2009; Dalgleish et al., 2014), and was developed by clinical psychologists. MemFlex is primarily self-guided and aims to reduce autobiographical memory biases associated with depression. The training material is presented over one face-to-face session and eight self-guided sessions. In the initial session, the researcher introduces cued-recall tasks which are used throughout the workbook, and guides the participant in completion of these tasks. When understanding of the basic principles is satisfactory, the researcher assists the participant to set a schedule for completion of the workbook over the following four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress.
62584279|NCT06030622|EXPERIMENTAL|Gemcitabine and C3 (Combination Digoxin, Simvastatin, and Metformin)|Study participants will be offered metformin (850 mg twice a day), digoxin (0.25 mg once a day), and simvastatin (20 mg once a day) combination (C3) and Gemcitabine.
62790240|NCT03570541|ACTIVE_COMPARATOR|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0,375% single shot.~Every six hours postoperative, all patients are administered 1 g of acetaminophen.~In both arms morphine will be administered IV as part of a patient controlled analgesia (PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment.~On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis.~On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a Quality of recovery-15 questionaire.~Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension."
62215212|NCT06102980|OTHER|Controls|"Patients without requirements of screening following the European Association for the Study of the Liver (EASL) 2016 recommendations. The control group will be compounded by patients who will not present any of the following criteria:~1. Over fifty years old;~2. Body mass index (BMI) over 25 kg/m2;~3. Diabetes mellitus type 2;~4. Metabolic syndrome; and~5. Persistently elevated liver enzymes.~To be a control participant does not mean that the patient is a healthy participant. The control participants are patients who request any type of endoscopy and fulfil the criteria not to screen for liver steatosis. For example, a 48-year-old male with 21 kg/m2 BMI, without diabetes mellitus type 2, any metabolic syndrome-related comorbidities, with normal liver enzymes and who refused an episode of persistently elevated liver enzymes, with persistent reflux disease after two months of proton pump inhibitor therapy,"
62584280|NCT06030622|EXPERIMENTAL|C3 (Combination Digoxin, Simvastatin, and Metformin) only|Study participants will be offered C3 only metformin (850 mg twice a day), digoxin (0.25 mg once a day), and simvastatin (20 mg once a day) combination (C3) if they decline Gemcitabine.
62019916|NCT03017508|PLACEBO_COMPARATOR|Placebo|Participants will be given one dose of an identical looking sublingual placebo before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
62019917|NCT05185024|EXPERIMENTAL|Ferrous Sulfate Capsules|30 mg of elemental iron and 60 mg of vitamin C per capsule.
62019918|NCT05185024|EXPERIMENTAL|>Your< Iron Forte Capsules|30 mg of elemental iron and 60 mg of vitamin C per capsule.
62019919|NCT05185024|EXPERIMENTAL|>Your< Iron Forte Liquid|35 mg of elemental iron, 0.7 mg vitamin B6 and 1.25 mcg vitamin B12 per one dosing (5 ml).
62019920|NCT06418971|NO_INTERVENTION|Control Arm|Participants randomized to the control arm will receive an American Association of Retired Persons (AARP) caregiver handbook and will receive biweekly check-in calls asking about their caregiving situation, service use, and strategies they are using to address needs.
62019921|NCT06418971|EXPERIMENTAL|CarePair Intervention Arm|After completing baseline interviews, caregivers will be introduced to and trained in the use of the CarePair through video tutorials and virtual training sessions via video-conferencing software. They will have access to an email, text, and telephone contact should they experience technical difficulties. They will be instructed to login to CarePair twice per month and complete short questionnaires assessing their use of services and satisfaction with services (if used). If they have not used services, they will be asked to indicate any perceived barriers with use. At the RCT's conclusion, participants will complete a follow-up survey to obtain quantitative and qualitative feedback about their experience. Outcomes will include pilot data on satisfaction with output of service recommendations, interaction and usability of CarePair (primary outcomes), and caregiver self-efficacy, depression and caregiver burden (secondary outcomes).
62408553|NCT06177626|EXPERIMENTAL|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Participants will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
62408554|NCT06507059|EXPERIMENTAL|Immediate Long-Acting Injectable Treatment Group|Immediate switch to long-acting injectable antiretrovirals on enrollment
62019922|NCT05168319|EXPERIMENTAL|pcTBS|pcTBS was administered to the left M1 at 80% resting motor threshold (RMT), consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline.
62019923|NCT05168319|ACTIVE_COMPARATOR|10HZ rTMS|The rTMS protocol included 15 trains of 10-second stimulation given at 10 Hz to the left M1 at 80% resting motor threshold (RMT), with the inter-train interval being set to 50 seconds (1500 pulses)
62019924|NCT05168319|SHAM_COMPARATOR|Sham|The Sham stimulation was delivered using the same protocol, with the coil being orientated at 90° to the scalp so that the magnetic field would be delivered away from the scal
62019925|NCT03283670|EXPERIMENTAL|1. 25% nitrous oxide, 25% nitrogen, 25% oxygen|Participants will be studied for 14 visits over approximately 18 weeks. The participants will receive 1 hour-long gas inhalation mixtures at 3 different times, which are randomly assigned.
62212078|NCT02371291|PLACEBO_COMPARATOR|Psychoeducation|The psychoeducation condition will also complete an initial face-to-face session. This session will cover the symptoms and causes of depression, and the workbook will be introduced. As in the MemFlex condition, the workbook will consist of eight self-guided sessions that the individual will be required to complete over four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress, and clarify any difficulties with the workbook material. The workbook content will cover the presentation of depression and basic information on factors associated with depression, such as worry, procrastination, and sleep difficulties. Each session consists of information on psychological theories of the topic, followed by a series of questions about the material to ensure participant engagement. The workbook was developed by clinical psychologists.
62212079|NCT01971359||Retrospective|
62212080|NCT03211767|ACTIVE_COMPARATOR|Aged garlic extract|2 capsules per day containing aged garlic extract
62212081|NCT03211767|PLACEBO_COMPARATOR|Placebo|2 capsules per day without aged garlic extract
62408555|NCT06507059|ACTIVE_COMPARATOR|Delayed Long-Acting Injectable Treatment Group|Keep on standard all-oral antiretrovirals on enrollment for 24 weeks, then switch to long-acting injectable antiretrovirals
62584281|NCT03728426|EXPERIMENTAL|Letermovir|Open label letermovir will be administered daily for up to 12 weeks. The study allows an optional additional 12 weeks of treatment for secondary prophylaxis if clinically indicated.
62212082|NCT02144792|ACTIVE_COMPARATOR|Control group (healthy persons)|Normal controls take a \[11C\] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using \[11C\] -verapamil, a substrate of P-gp.
62212083|NCT02144792|ACTIVE_COMPARATOR|Patients with drug-resistant epilesy|Patients with drug-resistant epilepsy take a \[11C\] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using \[11C\] -verapamil, a substrate of P-gp.
62212084|NCT02144792|ACTIVE_COMPARATOR|Patients with drug-sensitive epilepsy|Patients with drug-sensitive epilepsy take a \[11C\] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using \[11C\] -verapamil, a substrate of P-gp.
62212085|NCT05958550||Hypothermia group|
62408556|NCT01928810|EXPERIMENTAL|70% VO2max|"Cognitive Behavioural Therapy (CBT)~+ aerobic exercise (30 minutes, 70% VO2max) prior to 5 in-vivo exposure sessions"
62408557|NCT01928810|ACTIVE_COMPARATOR|30% VO2max|"Cognitive Behavioural Therapy (CBT)~+ placebo exercise (30 minutes, 30% VO2max) prior to 5 in-vivo exposure sessions"
62408558|NCT00717808|ACTIVE_COMPARATOR|1|During the study the patient will either receive tranilast (300mg twice a day) or a placebo drug for a period of seven days. The patient will then have a seven day break followed by another period of seven days in which the patient will receive the other medication.
62584282|NCT06555393|PLACEBO_COMPARATOR|Egg white powder (20g)|20 g of egg white powder from the market; negative control; only individuals at risk of diabetes/having type 2 diabetes.
62019926|NCT03283670|EXPERIMENTAL|2. 50% nitrous oxide, 50% oxygen|Participants will be studied for 14 visits over approximately 18 weeks. The participants will receive 1 hour-long gas inhalation mixtures at 3 different times, which are randomly assigned.
62019927|NCT03283670|PLACEBO_COMPARATOR|3. Placebo gas: 50% nitrogen(inert), 50% oxygen|Participants will be studied for 14 visits over approximately 18 weeks. The participants will receive 1 hour-long gas inhalation mixtures at 3 different times, which are randomly assigned.
62019928|NCT04614259|EXPERIMENTAL|intravenous analgesia|
62212086|NCT05958550||Non-hypothermia group|
62408559|NCT00717808|PLACEBO_COMPARATOR|2|The patient will receive the placebo twice a day for 7 days whilst taking their weekly methotrexate dose
62212087|NCT05776641|ACTIVE_COMPARATOR|Active GENUS light and sound|The device is a light and sound device that delivers light stimulation using light-emitting diodes (LED) and sound stimulation through a speaker, with a centrally-mounted tablet that plays videos for entertainment. The device will be positioned on an easel such that the tablet is eye level with the participant while they are sitting 5 feet away. The active device delivers light and sound at 40Hz rate.
62212088|NCT05776641|SHAM_COMPARATOR|Sham GENUS light and sound|The device is the same as the active device but it delivers light and sound at different frequencies.
62212089|NCT05871684|EXPERIMENTAL|The combination treatment group of CAR-T therapy|Patients dicided to receive CAR-T cell therapy will be divided into groups A and B according to their tumor burden. Group A was given a bridging regimen of BTKi (160 mg b.i.d. p.o.) + radiotherapy + chemotherapy, and group B was given a bridging regimen of BTKi (160 mg b.i.d. p.o.) + radiotherapy; BTKi (160 mg b.i.d. p.o.) was given continuously from D1 to D28 after the return of CAR-T after infusion; Based on the results of the first evaluation on day 28 after CAR-T cell infusion, CR patients were divided into groups A1 and B1, and both groups were given BTKi (160 mg b.i.d. p.o.) for 3 months maintenance; PR patients were divided into groups A2 and B2, and both groups were given BTKi (160 mg b.i.d. p.o.) for 3 months maintenance and PD-1 inhibitor (200mg q3w i.v.) for 2 years maintenance;
62212090|NCT02801032|ACTIVE_COMPARATOR|Active Treatment|Tadalafil 20 mg Capsule. MRI of cerebrum pre dose. Transcranial Doppler, near-infrared spectroscopy (NIRS), endothelial response with EndoPAT2000, and endothelial biomarkers (pre and post dose).
62212091|NCT02801032|PLACEBO_COMPARATOR|Control|Placebo Capsule. MRI of cerebrum pre dose. Transcranial Doppler, near-infrared spectroscopy (NIRS), endothelial response with EndoPAT2000, and endothelial biomarkers (pre and post dose).
62408560|NCT01058707|EXPERIMENTAL|MLN0128 QD|MLN0128 2 mg, 4 mg, 6 mg or 7 mg, capsule, orally, once daily (QD) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 52.1 weeks).
62019929|NCT04614259|EXPERIMENTAL|infraorbital nerve block|
62019930|NCT03765437|EXPERIMENTAL|Quadrivalent Influenza Vaccine|Quadrivalent Influenza Vaccine (split-virion, inactivated) Northern hemisphere seasonal formulation 2018-2019
62019931|NCT03971643|EXPERIMENTAL|vilobelimab 800 mg Q2W|"Dose finding with a total of 15 doses of vilobelimab.~Vilobelimab: IV infusions of vilobelimab diluted in sodium chloride.~All patients received vilobelimab 800 mg three times during the first week (Days 1, 4, and 8).~Starting at Day 15:~Group 1 (N=6) continued to receive vilobelimab 800 mg every 2 weeks (Q2W), with option to increase dose from Day 57 to 1600 mg every Q2W."
62019932|NCT03971643|EXPERIMENTAL|vilobelimab 1600 mg Q2W|"Dose finding with a total of 15 doses of vilobelimab.~Vilobelimab: IV infusions of vilobelimab diluted in sodium chloride.~All patients received vilobelimab 800 mg three times during the first week (Days 1, 4, and 8).~Starting at Day 15:~Group 2 (N=6) received vilobelimab 1600 mg every 2 weeks (Q2W), with option to increase dose from Day 57 to 2400 mg every Q2W."
62019933|NCT03971643|EXPERIMENTAL|vilobelimab 2400 mg Q2W|"Dose finding with a total of 15 doses of vilobelimab.~Vilobelimab: IV infusions of vilobelimab diluted in sodium chloride.~All patients received vilobelimab 800 mg three times during the first week (Days 1, 4, and 8).~Starting at Day 15:~Group 3 (N=7) received vilobelimab 2400 mg every Q2W."
62019934|NCT02259621|EXPERIMENTAL|Arm B- Nivolumab|"Nivolumab administration:~Three doses of nivolumab will be administered to enrolled patients on Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days."
62019935|NCT02259621|EXPERIMENTAL|Arm C- Nivolumab, Carboplatin, & Paclitaxel|Nivolumab 360 mg IV, Carboplatin AUC 5 or 6 IV, and Paclitaxel 175 or 200 mg/m2 IV every 21 days for 3 cycles prior to planned surgery on Day 0.
62019936|NCT02259621|EXPERIMENTAL|Arm A- Nivolumab and Ipilimumab|One dose of Nivolumab 3mg/kg IV \& Ipilimumab 1mg/kg will be administered to enrolled patients on Day-42, then 2 doses of Nivolumab 3mg/kg will be administered to enrolled patients on Day-28 and Day-14
62019937|NCT01542528|EXPERIMENTAL|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
62019938|NCT01542528|NO_INTERVENTION|Treatment as Usual (TAU)|Whatever care arrangement the parents have arranged for their child during the same two hour period over the same 15 week period.
62019939|NCT00697749|EXPERIMENTAL|Group A|
62019940|NCT00697749|ACTIVE_COMPARATOR|Group B|
62019941|NCT04170127|EXPERIMENTAL|Right side of the maxilla|the right side of the maxilla
62019942|NCT04170127|NO_INTERVENTION|Left side of the maxilla|left side of the maxilla
62019943|NCT03095417|EXPERIMENTAL|Physical Exercise and Cognitive Training|"Physical Exercise Intervention: The physical exercise portion of the combined intervention consists of 45 minutes of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. The study team will deliver 3 sessions per week for 3 months.~Cognitive Intervention: The cognitive portion of the combined intervention consists of a suite of 24 programs called Brain HQ developed by Posit Science Inc., organized into six categories: attention, speed, memory, people skills, intelligence, and navigation. The DDD-ECT trial will use 45-minute sessions of Brain HQ exercises. The modules are designed to improve time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory."
62019944|NCT03095417|ACTIVE_COMPARATOR|Physical Exercise and Cognitive Control|"Physical Exercise Intervention: The physical exercise portion of the combined intervention consists of 45 minutes of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. The study team will deliver 3 sessions per week for 3 months.~Cognitive Control: This consists of up to 20 minutes of puzzles and games, 2 days per week for 3 months. The participants will use on-line Brain HQ Control Games hosted by Posit Science, Inc. as an attention control."
62212092|NCT03698500|OTHER|Patients with intestinal colitis and control patients|Device: qPCR diagnostic of specific microRNAs in peripheral blood (10 ml)
62212093|NCT04654845|EXPERIMENTAL|Pulpotomy|Only the tissue in the pulp chamber will be removed.
62212094|NCT04654845|ACTIVE_COMPARATOR|Pulpectomy|Both the chamber´s and root´s pulp tissue will be removed up to a 25 gauge.
62212095|NCT03284229|EXPERIMENTAL|Excimer Laser Coronary Atherectomy|ELCA® in patients with single or multivessel CAD either as a stand-alone modality or in conjunction with Percutaneous Transluminal Coronary Balloon Angioplasty (PTCA). The entire procedure will be carried out as per the site routine practice and the device will be used as per the 'Instruction for Use'. Treating physicians/study investigators will be trained by the study Sponsor on the study protocol and procedures prior to clinical investigation procedure. Subject preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted.
62212096|NCT01011153||All Dermatologists|
62212097|NCT05701306|EXPERIMENTAL|APG-115 monotherapy in part1|Multiple dose cohorts, to determine the RP2D of APG-115.
62212098|NCT05701306|EXPERIMENTAL|APG-115 combined with APG-2575 in part2|Multiple dose cohorts of APG-2575, to determine the RP2D of APG-2575 combined with APG-115.
62212099|NCT05559970|ACTIVE_COMPARATOR|Conventional sedation|Conventional sedation receiving analgosedation with fentanyl
62212100|NCT05559970|EXPERIMENTAL|Inhalational sedation|Inhalational sedation receiving isoflurane for sedation for 12 hours
62212101|NCT02008877|EXPERIMENTAL|ganetespib / sirolimus|28-day cycles of ganetespib + sirolimus
62212102|NCT01361594|ACTIVE_COMPARATOR|Intensive insulin treatment|Intensive insulin treatment (BG target: 100-140 mg/dL)
62019945|NCT03095417|ACTIVE_COMPARATOR|Cognitive Training and Stretching Control|"Stretching Control: This consists of up to 10 minutes of gentle stretching. The study team will deliver 3 sessions per week for 3 months.~Cognitive Intervention: The cognitive portion of the combined intervention consists of a suite of 24 programs called Brain HQ developed by Posit Science Inc., organized into six categories: attention, speed, memory, people skills, intelligence, and navigation. The DDD-ECT trial will use 45-minute sessions of Brain HQ exercises. The modules are designed to improve time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory. ly directing one session per week and available as needed for rest of the sessions."
62212103|NCT01361594|ACTIVE_COMPARATOR|Conventional insulin treatment|Conventional insulin treatment (BG target: 141-180 mg/dl)
62212104|NCT02159508|NO_INTERVENTION|Individualised on-demand counselling|Individualized on-demand counselling group was assigned to receive baseline nutritional counselling, that consisted of one dietetic consultation before (chemo)radiotherapy. During (chemo)radiotherapy on-demand counselling group patients received further counselling only on demand.
62212105|NCT02159508|EXPERIMENTAL|Intensive nutritional counselling|Intensive nutritional counselling consisted of protocolled counselling given by a dietitian once at baseline and on the 2nd and 4th week of treatment and at the end of chemoradiotherapy.
62584283|NCT06555393|EXPERIMENTAL|Egg white hydrolysate Thermoase (5 g) (powder)|5 g; dose based on human equivalent dose calculation; only individuals at risk of diabetes/having type 2 diabetes
62212106|NCT03845140|EXPERIMENTAL|Cohort 1a: 4 to 6 years L-PZQ ODT 50 mg/kg|Participants aged 4 to 6 years infected with Schistosoma (S.) mansoni received Levorotatory enantiomer of praziquantel (L-PZQ) orodispersible tablets (ODT) (150 milligrams \[mg\]) orally at a dose of 50 milligram per kilogram (mg/Kg) as a single oral dose after food-intake on Day 1.
62212107|NCT03845140|ACTIVE_COMPARATOR|Cohort 1b: 4 to 6 years Biltricide® 40 mg/kg|Participants aged 4 to 6 years infected with S. mansoni received Racemate Praziquantel tablets (Biltricide®) (600 mg) orally at a dose of 40 mg/kg as a single oral dose after food-intake on Day 1.
62212108|NCT03845140|EXPERIMENTAL|Cohort 2: 2 to 3 years L-PZQ ODT 50 mg/kg|Participants aged 2 to 3 years infected with S. mansoni received L-PZQ ODT (150 mg) tablet orally at a dose of 50 mg/kg as a single oral dose after food-intake on Day 1.
62408561|NCT01058707|EXPERIMENTAL|MLN0128 QW|MLN0128 7 mg, 10 mg, 15 mg, 20 mg, 30 mg or 40 mg capsule, orally, once weekly (QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 139.4 weeks).
62408562|NCT01058707|EXPERIMENTAL|MLN0128 QDx3d QW|MLN0128 6 mg, 9 mg, 12 mg, 16 mg or 20 mg capsule, orally, once daily every 3 days a week (QDx3d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 129.4 weeks).
62212109|NCT03845140|EXPERIMENTAL|Cohort 3: 3 to 24 months L-PZQ ODT 50 mg/kg|Participants aged 3 to 24 months infected with S. mansoni received L-PZQ ODT (150 mg) tablet orally at a dose of 50 mg/kg as a single oral dose after food-intake on Day 1.
62212110|NCT03845140|EXPERIMENTAL|Cohort 4a: 3 months to 6 years L-PZQ ODT 50 mg/kg|Participants aged 3 months to 6 years infected with S. haematobium received L-PZQ ODT (150 mg) tablet orally at a dose of 50 mg/kg as a single oral dose after food-intake on Day 1.
62212111|NCT03845140|EXPERIMENTAL|Cohort 4b: 3 months to 6 years L-PZQ ODT 60 mg/kg|Participants aged 3 months to 6 years infected with S. haematobium received L-PZQ ODT (150 mg) tablet orally at a dose of 60 mg/kg as a single oral dose after food-intake on Day 1.
62212112|NCT00675675|ACTIVE_COMPARATOR|Comprehensive Behavioral Intervention for Tics (CBIT)|Habit Reversal Training (HRT) plus functional assessment/intervention designed to identify and ameliorate environmental triggers for and consequences to tics that might serve to maintain and/or generalize these symptoms
62212113|NCT00675675|OTHER|Minimal Contact Waitlist|Bimonthly phone check-in to assess illness severity and maximize subject retention
62408563|NCT01058707|EXPERIMENTAL|MLN0128 QDx5d QW|MLN0128 7 mg, 10 mg or 13 mg capsule, orally, once daily every 5 days a week (QDx5d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 161.9 weeks).
62212114|NCT01184040|NO_INTERVENTION|(A) Non-contingent control|Participants assigned to the control condition will be told to wear the pedometer daily and select a twice-weekly meeting schedule with research staff for 12 weeks (study weeks 4-15). On days randomly selected as meeting days, participants will be asked to bring in their pedometers. Participants who attend their scheduled meetings will receive a $5 gift card just for attending and bringing the pedometer, so long as it has registered steps walked in at least the past 4 days. They will be congratulated if they walked 10,000 steps or more on the prior 4 days, and encouraged to walk 10,000 steps or more per day on subsequent days.
62212115|NCT01184040|EXPERIMENTAL|VIP CM|Participants assigned to Increasing Variable Interval Prize (VIP) Reinforcement group will be scheduled for the same study visits as those in the Control group, but will also earn chances to win prizes if they have walked more than 10,000 steps in the past 4 days.
62212116|NCT05739682|EXPERIMENTAL|Antimicrobial Corticosteroid mixture|"Each canal will receive 5 minutes of final irrigation with the antimicrobial-corticosteroid solution of a freshly prepared mixture of:~1 ml of Levofloxacin (Tavanic, Sanofi Aventis, Egypt).~1 ml of Fluconazole (Sunny fungal, Sunny pharmaceuticals, Egypt).~1 ml of Dexamethasone sodium phosphate (Dexamethasone, Amriya, Egypt)."
62212117|NCT05739682|ACTIVE_COMPARATOR|Cryotherapy|Each canal will receive final irrigation with 20ml of cold saline (2.5°c) for 5 minutes.
62212118|NCT01363544|EXPERIMENTAL|Neurofeedback|
62212119|NCT01363544|EXPERIMENTAL|Exercise|
62408564|NCT01058707|EXPERIMENTAL|MLN0128 5 mg QD|MLN0128 5 mg, capsule, orally, QD in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 98.3 weeks).
62408565|NCT01058707|EXPERIMENTAL|MLN0128 30 mg QW|MLN0128 30 mg, capsule, orally QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 240 weeks).
62408566|NCT01058707|EXPERIMENTAL|MLN0128 40 mg QW|MLN0128 40 mg, capsule, orally, QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 100.1 weeks).
62584284|NCT06555393|EXPERIMENTAL|Egg white hydrolysate Thermoase (20 g) (powder)|20 g; dose based on energy percentage used in animal experiment; both healthy control group and at risk of diabetes/having type 2 diabetes
62212120|NCT01363544|ACTIVE_COMPARATOR|methylphenidate|optimum dose of methylphenidate (assessed by a double blind placebo-controlled procedure)
62212121|NCT05114473|EXPERIMENTAL|Workshops|This group will attend face-to-face workshops were the educational program will be developed. These workshops will be available in several sites, and specific care providers will be assigned for each of these sites.
62212122|NCT05114473|EXPERIMENTAL|Online-accessed material|This group will be granted online access to a platform were the educational program will be uploaded. They will be given autonomy regarding when to enter the platform and view the content.
62212123|NCT05114473|NO_INTERVENTION|Control group|This group will initially no recieve an intervention and will serve as a control group.
62212124|NCT04825561|ACTIVE_COMPARATOR|Active Comparator|AD-208 and Placebo of AD-2081
62212125|NCT04825561|PLACEBO_COMPARATOR|Placebo Comparator|Placebo of AD-208 and Placebo of AD-2081
62212126|NCT04825561|EXPERIMENTAL|Experimental Comparator|Placebo of AD-208 and AD-2081
62212127|NCT04096833|EXPERIMENTAL|Intervention Group|Participants use as a distracting measure Virtual Reality glasses during the vaccination.
62408567|NCT05168943|ACTIVE_COMPARATOR|Group N (n=30)|Continuous Epidural Anesthesia using Nylon (Polyamide) Epidural Catheter
62408568|NCT05168943|ACTIVE_COMPARATOR|Group P (n=30)|Continuous Epidural Anesthesia using Polyurethane Epidural Catheter
62408569|NCT04470856|EXPERIMENTAL|septic shock patients|"Intubated patients with septic shock receive an end-expiratory occlusion test (EEOT) and, after the test, they receive a 500 ml-fluid challenge.~During these phases the carotid doppler changes will be recorded."
62584285|NCT06555393|ACTIVE_COMPARATOR|Egg white hydrolysate Thermoase + Pepsin (20 g) liberating IRW (powder)|20 g; positive control, only individuals at risk of diabetes/having type 2 diabetes
62584286|NCT05021679|EXPERIMENTAL|AMP Implementation|
62212128|NCT04096833|NO_INTERVENTION|Control Group|Participants use usual non-virtual distracting measures during the vaccination.
62212129|NCT00867204||Short-wire device|The Fusion Short-wire ERCP device was used
62212130|NCT00867204||Long-wire device|The traditional Long-wire ERCP device was used
62215213|NCT03814096|EXPERIMENTAL|Syphilis POC-prenatal screening|Syphilis prenatal screening late in gestation at 24-28 weeks (at the time of the routine prenatal care clinic visit for the routine Glucose Tolerance Test \[GTT\]) using the Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)
62215214|NCT00001159||Thyroid disorders|Patients with thyroid disorders
62584287|NCT01914471|NO_INTERVENTION|Control|These schools did not receive the intervention.
62584288|NCT01914471|EXPERIMENTAL|Students for Nutrition and eXercise|These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
62019946|NCT03095417|SHAM_COMPARATOR|Cognitive Control and Stretching Control|"Stretching Control: This consists of up to 10 minutes of stretching. The study team will deliver 3 sessions per week for 3 months.~Cognitive Control: This consists of up to 20 minutes of puzzles and games, 2 days per week for 3 months. The participants will use on-line Brain HQ Control Games hosted by Posit Science, Inc. as an attention control."
62408570|NCT03714399||ICUAW group|The physical and psychological effects of ICUAW on patients undergoing aortic valvular surgery will be observed. Physical function and HRQoL will be analysed and correlated with RFcsa. Additionally, biological markers will be used to understand molecular and genomic profiles.
62408571|NCT03931707||Sick Neonatal Cohort, Sequencing|Infants and their parents enrolled through Neonatal Intensive Care Unit of member hospitals who are un-randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby's medical history/physical exam, and the results of the genomic sequencing report.
62408572|NCT04672369|EXPERIMENTAL|IBI939 in combination with Sintilimab|
62408573|NCT04672369|ACTIVE_COMPARATOR|sintilimab|
62408574|NCT05970848|EXPERIMENTAL|Group S|Group S patients will receive topical lidocaine anesthesia via the spray nozzle by the spray as-you-go technique during flexible bronchoscopy.
62019947|NCT04286035|ACTIVE_COMPARATOR|Femoral group|
62408575|NCT05970848|NO_INTERVENTION|Group C|Group C patients will receive topical lidocaine anesthesia with the conventional method by the spray as-you-go technique during flexible bronchoscopy.
62408576|NCT03055286|EXPERIMENTAL|CWP232291 in combination with cytarabine (ara-C)|
62408577|NCT03969160|EXPERIMENTAL|Imaginal exposure|The experimental procedure consists of imaginal exposure to mental imagery of phobic and neutral stimuli, prompted through recorded verbal instructions. Participants' repeat the experimental procedure one week later in a follow-up session. Brain imaging data is only collected during day 1
62408578|NCT04327869||Abdominal symptoms group|The investigators selected 10 subjects (male: female = 1: 1) from patients with a recent history of upper-gastrointestinal symptoms who met the indication of taking sucralfate suspension gel
62790241|NCT03570541|PLACEBO_COMPARATOR|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL saline single shot.~Every six hours postoperative, all patients are administered 1 g of acetaminophen.~In both arms morphine will be administered IV as part of a patient controlled analgesia (PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment.~On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis.~On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a Quality of recovery-15 questionaire.~Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension."
62790242|NCT03056339|EXPERIMENTAL|Fludarabine + Cyclophosphamide + CAR-NK Cells|"On Days -5, -4, and -3, participants receive Fludarabine and Cyclophosphamide. Participants also receive Mesna before and after the cyclophosphamide dose.~On Day 0, participants receive genetically modified NK cells as a cell infusion.~If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they receive AP1903 by vein and possibly steroids by mouth or by vein."
62790243|NCT04852939|EXPERIMENTAL|Bowen's Technique|Bowen's Technique
62790244|NCT04852939|ACTIVE_COMPARATOR|Conventional Physical Therapy|Conventional Physical Therapy including stretching and strengthening exercises
62019948|NCT04286035|ACTIVE_COMPARATOR|Adductor group|
62019949|NCT05319314|EXPERIMENTAL|GCC19CART|"Single infusion of GCC19CART at the dose assigned to an individual subject.~All subjects will receive the same investigational therapy with the dose administered dependent upon the dose level they are assigned to in a sequential manner.~Two dose level escalations are planned with one dose de-escalation listed if needed."
62019950|NCT01265953|EXPERIMENTAL|SFN-rich broccoli sprout extract capsules|Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of sulforaphane (SFN) daily, 2 capsules (1 capsule B.I.D.) daily
62408579|NCT04327869||Healthy control group|The investigators selected another 10 subjects (male: female = 1: 1) from healthy volunteers.
62408580|NCT01683786|EXPERIMENTAL|Pegintron + Riba for 36 wks in total|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800\~1400 mg/day for 24 weeks (36 weeks in total HCV treatment)
62408581|NCT01683786|ACTIVE_COMPARATOR|Pegintron + Riba for 48 wks in total|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800\~1400 mg/day for 36 weeks (48 weeks in total HCV treatment)
62019951|NCT01265953|PLACEBO_COMPARATOR|Placebo capsules|Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
62019952|NCT02032901|EXPERIMENTAL|A1:Daclatasvir + Sofosbuvir in treatment-naive subjects|Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks
62408582|NCT03290105||study population|Consecutive critically-ill patients admitted to the ICU and receiving invasive mechanical ventilation for more than 48 hours
62408583|NCT06651918|EXPERIMENTAL|yoga practise|For the experimental study, the researcher will contact the participants to be included in the study and the intervention (yoga group) and control groups will be randomly created. The participants will be informed about the study by the researcher and their voluntary consent will be obtained. The researcher will provide information about the Identifying Characteristics Form for Children Diagnosed with Cancer and Their Families, the Quality of Life Scale for Children (PedsQL) and the Memorial Symptom Assessment Scale to be used in the study. The survey and scales will be applied to each participant individually one day before yoga. Then, the Yoga Group will be applied 3 sessions per week, 3 weeks in a row, each session will be 30 minutes. The researcher will repeat the survey and scale questions that he asked the participants before they started yoga at the end of the 3 weeks.
62408584|NCT06651918|NO_INTERVENTION|survey group|No intervention will be made to the children in this group, only survey and scale questions will be applied.
62019953|NCT02032901|EXPERIMENTAL|A2:Daclatasvir + Sofosbuvir in treatment-experienced subjects|Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks
62408585|NCT05213065|EXPERIMENTAL|Treatment Arm|The participants randomized into this arm will receive the SPG block with 0.5% bupivacaine.
62408586|NCT05213065|PLACEBO_COMPARATOR|Placebo Arm|The participants randomized into this arm will receive the SPG block with saline.
62584289|NCT06592261|EXPERIMENTAL|Reference (healthy control) group|Healthy volunteers with body mass index of 18-25 kg/m2, fasting serum insulin \< 10 mU/L, hemoglobin A1c \< 5.7%, and fasting plasma glucose \< 100 mg/dL
62584290|NCT06592261|EXPERIMENTAL|Euinsulinemic group|Volunteers with body mass index of 30-45 kg/m2, fasting serum insulin \< 10 mU/L, hemoglobin A1c \< 5.7%, and fasting plasma glucose \< 100 mg/dL
62584291|NCT06592261|EXPERIMENTAL|Hyperinsulinemic group|Volunteers with body mass index of 30-45 kg/m2, fasting serum insulin \>= 13 mU/L, hemoglobin A1c \< 5.7%, and fasting plasma glucose \< 100 mg/dL
62584292|NCT05327829|SHAM_COMPARATOR|Sham|No stimulation
62584293|NCT05327829|ACTIVE_COMPARATOR|Stimulation|Stimulation
62019954|NCT04083989||Multimodal treatment for AN|Adolescent patients with AN attending an integrative medicine-based inpatient treatment program
62019955|NCT04083989||Healthy controls|Healthy volunteers assessed once to collect comparative data
62019956|NCT01887431|EXPERIMENTAL|Telecare|Each patient will transmit glucometer and pump data electronically via a web site to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control.
62019957|NCT01887431|ACTIVE_COMPARATOR|Conventional therapy|3-month routine clinic visits
62019958|NCT00701051|ACTIVE_COMPARATOR|Arm 1|Older adults, normal glucose tolerance
62019959|NCT00701051|EXPERIMENTAL|Arm 2|Older adults, impaired glucose tolerance
62215215|NCT01818583|EXPERIMENTAL|Potassium|Potassium chloride infusion at a rate of 15 mmol/h (60 mmol KCl in 1000 ml of 5% glucose with a concentration of 0.05 mmol/mL, flow rate 265 mL/h). If the serum Mg ≤0.8 mmol/L, MgSO4 infusion (0.5 mmol/kg/24 hours in 1000 mL NaCl 0.9% corresponding to an infusion rate of approximately 42 mL/hour) will also be administered.
62215216|NCT01818583|PLACEBO_COMPARATOR|Placebo|5% glucose (flow rate 265 ml/h) as placebo infusion.
62408587|NCT02468167|ACTIVE_COMPARATOR|BRTO|Balloon-occluded retrograde transvenous obliteration
62584294|NCT03045510|EXPERIMENTAL|Ultra small dose decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 5d, every four weeks for one cycle. It will be given six cycles.
62790245|NCT03939975|EXPERIMENTAL|Study arm|"Patients with stable diseases or atypical progression to ICIs monotherapy would be additionally treated with incomplete thermal ablation along with ICIs therapy; and for those who with no lesions eligible for Incomplete ablation, ICIs would be given solely.~Others with complete or partial responses would keep on going with mono-ICIs therapy."
62790246|NCT04523337|EXPERIMENTAL|MISSION-CJ|Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice version (MISSION-CJ) programming targets co-occurring substance use and mental health disorders and other related health outcomes faced by justice-involved homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based services.
62790247|NCT04523337|EXPERIMENTAL|Enhanced Usual Care|Usual care provided by the mental health residential rehabilitation treatment programs, with patients in both groups are enrolled in, in addition to peer support and community outreach case management. Patients receive 2 Peer Support Curriculum sessions per week (24 sessions total). Patients will receive unstructured community outreach and linkage support while enrolled in the mental health residential rehabilitation program. After discharge, patients will continue to receive 1 hour of weekly linkage support per week.
62790248|NCT05873972|ACTIVE_COMPARATOR|ARM A|Chemotherapy regimens are determined based on the clinical experience of specialists
62019960|NCT04344821|PLACEBO_COMPARATOR|Control|No diet or exercise intervention
62408588|NCT02468167|ACTIVE_COMPARATOR|NBCA|Endoscopic cyanoacrylate injection
62584295|NCT02622334|EXPERIMENTAL|Part A|Participants will receive up to 3 multiple ascending dose levels with the starting dose of 0.1% RO5093151 (topical ocular instillation) and sequentially 0.5% and 1% RO5093151 doses or placebo (3:1, active:placebo) twice a day (BID) on Day 1 and once a day (QD) for 6 days.
62584296|NCT02622334|EXPERIMENTAL|Part B|Participants will receive highest feasible dose (HFD) or maximum tolerated dose (MTD) of RO5093151 from Part A or 0.005% latanoprost (topical ocular instillation) once daily for 7 days.
62790249|NCT05873972|EXPERIMENTAL|ARM B|Chemotherapy regimens are determined based on the multimodal deep learning signature
62790250|NCT01060696|EXPERIMENTAL|Hyoscine, Mefenamic acid, Placebo|Blind randomization to three groups. Mefenamic acid group Hyoscine group Placebo group
62790251|NCT02450513||Single-group study|Subjects with active refractory Crohn's disease naïve to TNF antagonists starting adalimumab therapy.
62790252|NCT04910035|ACTIVE_COMPARATOR|Training Group|Throughout 3 weeks SSE training was administered 4 days a week for a length of 45 minutes in each session. All the analyses were conducted at the start and at the end of 3-week long training.
62019961|NCT04344821|EXPERIMENTAL|No Diet plus Exercise|No diet, exercise only intervention
62019962|NCT04344821|EXPERIMENTAL|High Protein Diet plus Exercise|High protein diet and exercise intervention
62019963|NCT04344821|EXPERIMENTAL|High Carbohydrate Diet plus Exercise|High carbohydrate diet and exercise intervention
62019964|NCT03219528|ACTIVE_COMPARATOR|Rifaximin|Rifaximin 550 mg three times daily for 14 days
62019965|NCT03219528|ACTIVE_COMPARATOR|Low FODMAP Group|Low FODMAP diet for 4 weeks
62019966|NCT01677234||Pregnant women|Pregnant women undergoing a cesarean section
62019967|NCT05841745||Robotically-Assisted Percutaneous Coronary Intervention|All patients older than 18 years, who underwent R-PCI (defined as completion of at least one procedural step robotically) with the CorPath GRX System (Corindus Vascular) and completed one-year follow-up including patients with either stable coronary artery disease, unstable angina, or acute myocardial infarction (MI).
62019968|NCT02965560||HC,CHB,AD,ACLF|HC healthy controls; CHB chronic hepatitis B; AD acute decompensated cirrhosis; ACLF acute-on-chronic liver failure.
62019969|NCT05919537|EXPERIMENTAL|Arm A|Participants with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) harboring NRG1 gene fusions
62019970|NCT05919537|EXPERIMENTAL|Arm B|Participants with non-small cell lung cancer (NSCLC) harboring NRG1 gene fusions
62215217|NCT02842450||training with typical definitions established + photos|A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.
62215218|NCT02842450||Training only with definitions|Interns will receive typical definitions of LAP stages
62019971|NCT05919537|EXPERIMENTAL|Arm C|Participants with other solid tumors harboring NRG1 gene fusions
62019972|NCT05919537|EXPERIMENTAL|Arm D|Participants with solid tumors harboring selected HER3 extracellular mutations
62019973|NCT05889936|EXPERIMENTAL|Treatment with the Lev-intervention|Screening of health-related habits using Lev-s + a three step/session intervention including the standard Lev protocol. Typically given over 10-20 weeks.
62408589|NCT06144645|ACTIVE_COMPARATOR|tVNS, Intermittent Stimulation|28 seconds on, 32 seconds off
62019974|NCT01298063|EXPERIMENTAL|Afatinib Group A, B (2), D|healthy subjects, mild and moderate liver impaired subjects to receive one single dose treatment containing the highest dose afatinib
62212131|NCT02677428|EXPERIMENTAL|Remotely Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
62584297|NCT06478017|EXPERIMENTAL|Belatacept + Tacrolimus withdrawal|"1. Maintenance Immunosuppression: NULOJIX (belatacept)~2. Maintenance Immunosuppression: CellCept (mycophenolate mofetil- MMF), or Myfortic (mycophenolate sodium)~3. Calcineurin Inhibitors (CNI) Taper: Prograf® (tacrolimus), or tacrolimus generic~4. Corticosteroid: Prednisone (no less than 5mg per day continued throughout the study period)"
62019975|NCT01298063|EXPERIMENTAL|Afatinib Group B (3), D|healthy subjects, moderate liver impaired subjects to receive one single dose treatment containing the medium dose of afatinib
62212132|NCT02677428|ACTIVE_COMPARATOR|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation \& Pension-related information: (a) the Veterans Benefits Administration (VBA) website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C\&P office where issues pertaining to an individual Veteran's specific application are addressed.
62019976|NCT01298063|EXPERIMENTAL|Afatinib Group B (1), D|healthy subjects, moderate liver impaired subjects to receive one single dose treatment containing the low dose of afatinib
62019977|NCT04509531|EXPERIMENTAL|Experimental: SA, ITP and Resilience|1 hour Wise intervention (based on SA, ITP and resilience) consisting on several tasks to be completed online individually.
62212133|NCT03140280|EXPERIMENTAL|Dietary Intervention|Freeze-dried black raspberry powder administration.
62408590|NCT06144645|ACTIVE_COMPARATOR|tVNS, Continuous Stimulation|continuous stimulation
62408591|NCT03857425|EXPERIMENTAL|Clostridum Butyricum Capsule|Clostridum Butyricum Capsule 3\*420mg, twice daily for 8 weeks
62408592|NCT03857425|EXPERIMENTAL|Bacillus Coagulans Tablets|Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
62408593|NCT03857425|EXPERIMENTAL|Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets|Clostridum Butyricum Capsule 3\*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
62408594|NCT02698319|NO_INTERVENTION|Conventional Triage|Conventional triage using Danish Emergency Process Triage (DEPT).
62408595|NCT02698319|EXPERIMENTAL|Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm is used as triage form in the ED. The Copenhagen Triage Algorithm consists of a few vital parameters and a clinical assessment from the ED nurse.
62408596|NCT06653309||a natural breastfeeding and their corresponding postnatal women group|100 a natural breastfeeding children, aged from 1 month to 1 year, and their corresponding postnatal women .
62408597|NCT06653309||artificial milk feeding group and their corresponding postnatal women group|100 children, aged from 1 month to 1 year, and their corresponding postnatal women . children in this group is depending on artificial milk consumption .
62408598|NCT02596009|EXPERIMENTAL|Breezhaler®|Each patient was required to inhale via Breezhaler® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
62408599|NCT02596009|OTHER|Ellipta®|Each patient were required to inhale via Ellipta® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
62584298|NCT06478017|ACTIVE_COMPARATOR|Standard-of-Care|"1. Maintenance Immunosuppression: Prograf (tacrolimus), or tacrolimus generic;~2. Maintenance Immunosuppression: CellCept (mycophenolate mofetil- MMF), or Myfortic (mycophenolate sodium);~3. Corticosteroid +/- taper: Prednisone"
62584299|NCT06665373|EXPERIMENTAL|Patients Diagnosed with Malignant Glioma|Patients will participate in a 15-week program consisting of two weekly supervised exercise sessions combined with an individualized home exercise program and a modified Atkins diet.
62019978|NCT04509531|OTHER|Standard preventive intervention|1 hour educational intervention (about internet risks such as sexting and grooming) consisting on several tasks to be completed online individually.
62019979|NCT01993524|EXPERIMENTAL|probiotic|At I visit standard treatment(500mg oral metronidazole twice daily for 7 days) and probiotic twice daily for 10 days. At II visit, participants were checked for signs of vaginal infection; if they were still present they were given a targeted antibiotic according to the microbiological analysis. Antibiotic was taken together with probiotic twice daily for 10 days. Participants showing positive response to metronidazole treatment on the II visit were given only the probiotic once daily for 10 days in the peri-menstrual period for the next 3 months. Participants with targeted antibiotic were to come to the visit IIbis, and if treatment was successful they were to proceed for the next 3 months in the same manner as those successfully treated with metronidazole, as described above.
62584300|NCT05093634|EXPERIMENTAL|POMC or PCSK1 variant|1:1 Randomization
62019980|NCT01993524|PLACEBO_COMPARATOR|placebo|At I visit standard treatment (500mg oral metronidazole twice daily for 7 days) and placebo twice daily for 10 days. At the II visit, participants were checked for signs of vaginal infection; if they were present they were given a targeted antibiotic according to the microbiological analysis. Antibiotic was taken together with placebo twice daily for 10 days. Participants showing positive responses to metronidazole on the II visit were given only placebo once daily for 10 days in the peri-menstrual period for the next 3 months. Participants with targeted antibiotic were to come to the visit IIbis, and if treatment was successful they were to proceed for the next 3 months in the same manner as those successfully treated with metronidazole, as described above.
62212134|NCT04330001|EXPERIMENTAL|FAIOL|Implantation of FAIOL in the capsular bag in the posterior chamber of the eye. The IOL is intended to be used over the lifetime of the subject.
62212135|NCT01548534|PLACEBO_COMPARATOR|DHA-free arm|Dietary supplementation with vegetable oil.
62408600|NCT02596009|OTHER|Handihaler®|Each patient were required to inhale via Handihaler® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
62019981|NCT04420299|EXPERIMENTAL|Experimental - therapeutic bemiparin dose|Sub-cutaneous dose of bemiparin at therapeutic dose for 10 days
62408601|NCT03718559|EXPERIMENTAL|Edoxaban alone|
62408602|NCT03718559|ACTIVE_COMPARATOR|Combination of edoxaban plus single antiplatelet|
62408603|NCT06364007|EXPERIMENTAL|Treating with a Designed Protocol|
62408604|NCT06326476|EXPERIMENTAL|siplizumab|All participants will receive a 40 mg subcutaneous dose of siplizumab from week 0 to week 4 then at weeks 6 and 8.
62408605|NCT00333437|EXPERIMENTAL|Treatment|Mycophenolate Mofetil
62408606|NCT01054209|NO_INTERVENTION|A: standard care, no warming|Control arm. Full standard care. No mattress warming. May receive warmed fluids if standard practise for clinician
62408607|NCT01054209|ACTIVE_COMPARATOR|B: electric warming mattress|Warming with warming mattress
62408608|NCT04997031||Latinx Adults 18 - 65 y|
62408609|NCT02049931|EXPERIMENTAL|No brace group|Patients in the no brace treatment group were allowed to ambulate without any braces as long as it would be tolerable.
62019982|NCT04420299|EXPERIMENTAL|Control - prophylactic bemiparin dose|Sub-cutaneous dose of bemiparin at prophilactic dose for 10 days
62019983|NCT02462395|EXPERIMENTAL|Cefaly tDCS|Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.
62019984|NCT04241939|EXPERIMENTAL|Numberless BDS and Modified-MI|Use of numberless BDS (color coded), app, and motivational interviewing. Participants will weigh daily and receive weekly motivational interviewing at clinic visits and via a weekly phone call.
62019985|NCT04241939|ACTIVE_COMPARATOR|Digital Scale|Use standard digital scale (number readout). Participants will weigh daily.
62019986|NCT02897544|EXPERIMENTAL|Health Education Intervention|Study participants will attend Health Education sessions led by health educators over the course of 6 months. The emphasis in the sessions will be to provide engaging educational information on common survivorship issues.
62019987|NCT05872230|NO_INTERVENTION|Control|Patient receives standard postoperative care with no percussion therapy.
62019988|NCT05872230|EXPERIMENTAL|PACU percussion|Patient receives percussion therapy in the PACU immediately after surgery.
62019989|NCT05872230|EXPERIMENTAL|Postoperative appointment percussion|Patient receives percussion therapy in the office on the day of follow up.
62212136|NCT01548534|EXPERIMENTAL|DHA arm|Dietary supplementation with fish oil.
62212137|NCT05286320|EXPERIMENTAL|Target-/Immuno-therapy for advanced HCC w PVTT Lenvatinib/Pembrolizumab plus SBRT combinations|Five-fraction SBRT (week 4-week 5) to PVTT and connected HCC tumor in 2 weeks Lenvatinib 12/8 mg/day for 96 weeks (no lenvatinib from 7 day before SBRT to 7 days after SBRT) Pembrolizumab 200 mg q 3 week x 32 cycles
62212138|NCT06611202|EXPERIMENTAL|six minute walking group|"Intervention:~Physiotherapy Component: A six-minute walking group will be conducted twice a week for 8 weeks, targeting improvements in mobility, endurance, and balance. Occupational Therapy Intervention: Occupational therapists will integrate functional tasks (Games and throwing of balls to court, bean bag target game to enhance exercise relevance to daily activities. Psychological Support: A psychologist will provide mental health support during the sessions, utilising techniques like time focus reminiscence therapy to engage patients"
62212139|NCT00738894|ACTIVE_COMPARATOR|Medical Management|Antiplatelet medical therapy alone
62212140|NCT00738894|EXPERIMENTAL|Device Closure|PFO closure with study septal occluder device plus antiplatelet medical therapy
62212141|NCT06598410|EXPERIMENTAL|Digital Gaming|Children will play digital games during suturing in the Paediatric Emergency Unit
62408610|NCT02049931|ACTIVE_COMPARATOR|Rigid brace group|Patients in the rigid brace immobilization group were strictly maintained on bed rest until fitted a thoraco-lumbo-sacral orthosis. Brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
62408611|NCT02049931|ACTIVE_COMPARATOR|Soft brace group|Because soft back brace was a custom-made, it began to be worn when enrollment for the study. Brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
62408612|NCT02195271|ACTIVE_COMPARATOR|Melatonin|0,25mg/Kg sl before tDCS
62408613|NCT02195271|EXPERIMENTAL|tDCS|Transcranial direct current stimulation once time. Dose 2 mA, 20 seconds.
62408614|NCT04516356|EXPERIMENTAL|Intervention Arm|Korean hand acupressure will be applied to the experimental group 30 minutes before the induction of anesthesia. After determining the pressure / therapy points associated with nausea and vomiting on the patient's hand, a massage will be made for 3-5 minutes with a diagnostic stick. The seeds will then be fixed at these points with a paper patch. Seeds will not be removed for 24 hours. It will be massaged for 3-5 minutes by pressing the seeds every 3-4 hours and making a curling motion at the same time. At the end of the 24th hour, the application will be terminated.
62408615|NCT04516356|NO_INTERVENTION|Control Arm|In the control group, no application will be made during and after the surgical intervention, and routine treatment and care will be applied.
62584301|NCT05093634|EXPERIMENTAL|LEPR variant|1:1 Randomization
62584302|NCT05093634|EXPERIMENTAL|NCOA1 (SRC1) variant|1:1 Randomization
62584303|NCT05093634|EXPERIMENTAL|SH2B1 variant|1:1 Randomization
62019990|NCT05872230|EXPERIMENTAL|Both PACU and Postop appointment percussion.|Patient receives percussion therapy in the PACU and receives percussion therapy in the office on the day of follow up.
62790253|NCT04910035|NO_INTERVENTION|Control Group|This group has no intervention. Evaluations were only made at the start and at the end of 3-week long.
62019991|NCT02396641|EXPERIMENTAL|Single Study Arm|This study arm consists of providers who will identify their baseline in Best Supportive Care, then have the intervention of using a Best Supportive Care checklist.
62019992|NCT02805257|EXPERIMENTAL|Mitomycin-C|0.1 ml of Mitomycin-C 0.4mg/ml injection intraoperatively and twice postoperatively.
62019993|NCT02805257|PLACEBO_COMPARATOR|Balanced Salt Solution (BSS)|0.1ml Balanced Salt Solution injection intraoperatively and twice postoperatively.
62212142|NCT06598410|EXPERIMENTAL|Watching Cartoon|Children will watching cartoon during suturing in the Paediatric Emergency Unit
62212143|NCT06598410|NO_INTERVENTION|Control|Children will not be subjected to any form of distraction
62212144|NCT05574517|EXPERIMENTAL|Experimental group(group 1)|Without reverse insertion of a ureteral catheter in tubeless percutaneous nephrolithotomy.
62212145|NCT05574517|NO_INTERVENTION|Control group(group 2)|Traditional tubeless percutaneous nephrolithotomy need reverse insert a ureteral catheter.
62790254|NCT05118698|EXPERIMENTAL|High-dose group|Participants will be allowed to drink Gynostemma pentaphyllum powder containing 12% saponin, 2 g each time, 3 times a day for 3 months.
62790255|NCT05118698|EXPERIMENTAL|Low-dose group|Participants will be allowed to drink Gynostemma pentaphyllum powder containing 8% saponin, 2 g each time, 3 times a day for 3 months.
62790256|NCT05118698|PLACEBO_COMPARATOR|Placebo group|Participants will be allowed to drink a placebo of spinach powder with almost no saponin content, 2 g each time, 3 times a day for 3 months.
62790257|NCT03566082||Post Approval Study|"The PAS cohort consisted of 137 subjects who were implanted with the R3 delta Ceramic Acetabular System (DoD) in the pivotal study. These patients will continue to be followed to 10 years post-operatively.~The primary endpoint for the PAS study is implant survivorship at 10 years post study procedure."
62790258|NCT00005030|EXPERIMENTAL|SCH 66336|Starting dose of preoperative oral SCH 66336 100 mg twice daily for 7-14 days prior to exploratory laparotomy and/or resection of hepatic metastases with surgery between days 8-15.
62790259|NCT00005030|NO_INTERVENTION|No Treatment|Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization.
62790260|NCT03058900|EXPERIMENTAL|Fecal microbiota transplantation (FMT)|
62212146|NCT00591539||Carotid Ultrasound|Carotid Ultrasound: Irradiated and non-irradiated sides of the neck in long-term survivors of pediatric cancers who received unilateral radiation therapy involving the carotid artery as part of their treatment
62212147|NCT01790841||ICD system with DF4 connection|Iforia/Ilesto ICD with DF4 connection and Linox smart DF4 lead/ Protego
62212148|NCT01790841||ICD system with DF-1 connection|Ilesto/Iforia ICD with DF-1 connection
62212149|NCT04288102|EXPERIMENTAL|Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)|Participants will receive standard of care plus 3 does of UC-MSCs
62790261|NCT03058900|SHAM_COMPARATOR|Placebo (saline)|
62212150|NCT04288102|PLACEBO_COMPARATOR|Placebo|Participants will receive standard of care plus 3 does of placebo
62212151|NCT00822653|EXPERIMENTAL|Calf Muscle Pump Stimulation|Subjects serve as self-control. Six weeks of dialysis data without intervention will be compared to six weeks post intervention
62019994|NCT00647920|EXPERIMENTAL|40 mg|
62019995|NCT00647920|PLACEBO_COMPARATOR|Placebo|
62019996|NCT04511715|ACTIVE_COMPARATOR|Intravitreal Bevacizumab IVB group|
62212152|NCT02630589|EXPERIMENTAL|ABI implantation|All 10 patients included in the study will be neurosurgically implanted with the ABI. This is open label, not blinded. The implant is permanent, but can be switched off.
62584304|NCT05941962||Average Force Production|Average force production of bilateral lower extremities will be collected using the handheld dynamometer, Activbody Activ5.
62584305|NCT02280746|EXPERIMENTAL|A - gluten challenge group|Gluten challenge group - recommended daily intake of at least one normal meal containing gluten such as bread, pita, pasta, biscuits.
62790262|NCT06496880|ACTIVE_COMPARATOR|OxyjunTM|One capsule daily to be taken after breakfast for 56 days
62790263|NCT06496880|PLACEBO_COMPARATOR|Microcrystalline Cellulose|One capsule daily to be taken after breakfast for 56 days
62790264|NCT02152761|EXPERIMENTAL|bimagrumab 700 mg|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab high dose administered via intravenous infusion starting Day 1 until Week 20
62790265|NCT02152761|EXPERIMENTAL|bimagrumab 210 mg|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab medium dose administered via intravenous infusion starting Day 1 until Week 20
62019997|NCT04511715|SHAM_COMPARATOR|undergo regular follow-up for Diabetic Retinopathy|
62212153|NCT02457988|EXPERIMENTAL|Vivify Kit|Patients with cirrhosis will undergo home monitoring for 30 days post-discharge through the use of the Vivify kit which contains a wireless tablet with daily medication/diet/symptom questionnaires and vital sign monitoring.
62212154|NCT02457988|NO_INTERVENTION|Standard of Care|Patients with cirrhosis will undergo standard of care, which includes a post-discharge lab check and follow-up clinic appointment. Otherwise, no day-to-day monitoring of these patients will occur.
62212155|NCT04524026|EXPERIMENTAL|Intervention|recFSH and co-treatment with letrozole 5 mg/day from stimulation day 1 on cycle day 2 or 3 until the day before gonadotrophin releasing hormone(GnRH) agonist administration to trigger final oocyte maturation. GnRH antagonist 0.25 mg/day from stimulation day 5 until day of GnRH agonist administration. No luteal phase support.
62215219|NCT04764643|ACTIVE_COMPARATOR|sodium thiosulfate solution arm|20ml of 5% sodium thiosulfate solution were prepared with 1g sodium thiosulfate crystal dissolved in normal saline in a 20 ml syringe
62212156|NCT04524026|NO_INTERVENTION|Control group|recFSH from stimulation day 1 on cycle day 2 or 3 until the day before GnRH agonist administration to trigger final oocyte maturation. GnRH antagonist 0.25 mg/day from stimulation day 5 until day of GnRH agonist administration. No luteal phase support.
62212157|NCT02941900||Non-melanoma skin cancers (NMSCs)|
62212158|NCT03686332|OTHER|Arm A: Atezolizumab and Radiotherapy|"Patients in this group will concurrently be treated with locoregional radiotherapy and atezolizumab.~Drug: Arm A: Atezolizumab and Radiotherapy~Atezolizumab, 1200 mg, every 3 weeks, by IV infusion and receive 33 fractions of 1.5 or 1.8 Gy irradiation."
62019998|NCT05331183|EXPERIMENTAL|ELX/TEZ/IVA|"Part A: Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening for 96 weeks.~Part B: Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening for an additional 96 weeks."
62212159|NCT03686332|OTHER|Arm B: Atezolizumab|Atezolizumab, 1200 mg, every 3 weeks, by IV infusion.
62212160|NCT00924690|EXPERIMENTAL|1|Behavioral Message Arm
62212161|NCT00924690|ACTIVE_COMPARATOR|2|Generic Message Arm
62212162|NCT00201708|ACTIVE_COMPARATOR|Arm A (Docetaxel before doxorubicin/cyclophosphamide)|"Docetaxel 75 mg/m2 every 2 weeks for 4 cycles followed by A (doxorubicin) 60 mg/m2 \& C (cyclophosphamide) 600 mg/m2 every 2 weeks for 4 cycles."
62212163|NCT00201708|ACTIVE_COMPARATOR|Arm B (Docetaxel after doxorubicin/cyclophosphamide)|"A (doxorubicin) 60 mg/m2 \& C (cyclophosphamide) 600 mg/m2 every 2 weeks for 4 cycles followed by Docetaxel 75 mg/m2 every 2 weeks for 4 cycles."
62212164|NCT03126669|ACTIVE_COMPARATOR|Treratment|100% oxygen at 2 ATA at the hyperbaric chamber
62212165|NCT03126669|PLACEBO_COMPARATOR|Placebo|normal air, in the hyperbaric chamber
62212166|NCT06079619||Group A: expert dermatologists|"Group A is composed of expert dermatologists. Group A doctors will have at their disposal 150 dermoscopic photos, x20 dermatoscopic photos according to the usual practice of pigmented genital tumors.~The dermatologists will characterize the dermatoscopy with a standardized reading grid to assess the different dermatoscopic patterns of genital tumors."
62212167|NCT06079619||Group B: non-dermatologists|"Group B is composed of gynecologists (Group B1) and general practitioners (B2) Group B physicians will only perform dermatoscopy x 400. They will have been given a maximum of 1 hour's training to identify melanosis-type pigmented tumors, which are the most frequent benign tumors in x 400 dermatoscopy.~Only three x400 dermatoscopy patterns will be presented to them to the exclusion of all others, which are sufficient to identify benign lesions."
62212168|NCT06079619||Group C: Artificial intelligence|Artificial intelligence: the skin Artificial intelligence software, a learning base will be provided, different from the evaluation base and the test base.
62212169|NCT01792050|PLACEBO_COMPARATOR|Arm 1A: Docetaxel + Placebo|Arm 1A: Docetaxel 75 mg/m\^2 IV given every 3 weeks (on day 8 of 21 day cycle), plus placebo PO BID (days 1-14 of 21 day cycle).
62212170|NCT01792050|EXPERIMENTAL|Arm 1B: Docetaxel + Indoximod|Arm 1B: Docetaxel 75 mg/m\^2 IV given every 3 weeks (on day 8 of 21 day cycle), plus Indoximod 1200 mg PO BID (days 1-14 of 21 day cycle).
62212171|NCT01792050|PLACEBO_COMPARATOR|Arm 2A: Paclitaxel + Placebo|Arm 2A: Paclitaxel 80 mg/m\^2 IV given weekly x3 followed by a week of rest (28 day cycle), plus placebo PO BID (days 1-21 of 28 day cycle).
62212172|NCT01792050|EXPERIMENTAL|Arm 2B: Paclitaxel + Indoximod|Arm 2B: Paclitaxel 80 mg/m\^2 IV given weekly x3 followed by a week of rest (28 day cycle), plus Indoximod 1200 mg PO BID (days 1-21 of 28 day cycle).
62790266|NCT02152761|PLACEBO_COMPARATOR|placebo|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria received matching placbo administered via intravenous infusion starting Day 1 until Week 20
62790267|NCT02152761|EXPERIMENTAL|Bimagrumab 70 mg|Approximately 35 patients who met all inclusion criteria and none of the exclusion criteria were treated with bimagrumad low dose administered via intravenous infusion starting Day 1 until Week 20
62790268|NCT01279603|EXPERIMENTAL|GO-203-2c|
62790269|NCT02152176|EXPERIMENTAL|Patient Controlled Analgesy group|Titration of morphine by Patient Controlled Analgesy. The opioid titration will be performed by the patient using PCA (Vygon Freedom 5) according to the principle of self with a refractory period of 5 minutes.
62790270|NCT02152176|NO_INTERVENTION|Control group|titration will be perform in the usual manner in accordance with the recommendations : a nurse will assess pain using a visual analog scale in the control group to assess the need for a new bolus of morphine
62212173|NCT02817880|EXPERIMENTAL|rTMS (repetitive transcranial magnetic stimulation)|rTMS (repetitive transcranial magnetic stimulation)
62212174|NCT02817880|EXPERIMENTAL|tDCS (transcranial direct-current stimulation)|tDCS (transcranial direct-current stimulation)
62212175|NCT02817880|EXPERIMENTAL|tsDCS (transcutaneous spinal Direct Current Stimulation)|tsDCS (transcutaneous spinal Direct Current Stimulation)
62212176|NCT02999685|ACTIVE_COMPARATOR|Home-base Pulm Rehab w/ Health Coaching|The intervention group starts with 8 weeks of Home-base Pulmonary Rehab with Health Coaching, followed by 8 weeks of observation.
62212177|NCT02999685|ACTIVE_COMPARATOR|Control/Wait|The Control/Wait group starts with 8 weeks of observation, followed by 8 weeks of intervention (Home-base Pulm Rehab w/ Health Coaching).
62212178|NCT02794415|OTHER|Community-based exercise|
62584306|NCT02280746|NO_INTERVENTION|B - gluten-free diet|Continuation of GFD.
62790271|NCT01302028|ACTIVE_COMPARATOR|Healthy volunteers with normal renal function|Oral
62019999|NCT03286959|ACTIVE_COMPARATOR|PCR WITH CALCIUM HYDROXIDE|PCR WITH CALCIUM HYDROXIDE : A layer of dycal (dentsply) was placed adjacent to pulpal or axial wall after mixing as per manufacturer recommendations followed by etching and restoration with composite using incremental technique.
62215220|NCT04764643|EXPERIMENTAL|N-acetylcysteine solution arm|20ml of 3% N-acetylcysteine solution were prepared with one piece of N-acetylcysteine effervescent tablet （ net weight 0.6g ）dissolved in normal saline in a 20 ml syringe
62584307|NCT03391570|ACTIVE_COMPARATOR|COX-2 inhibitor (Celecoxib)|Celebrex; COX-2 inhibitor
62584308|NCT03391570|PLACEBO_COMPARATOR|Placebo drug (Ramnos)|Ramnos; Lactobacillus casei variety rhamnosus
62790272|NCT01302028|EXPERIMENTAL|T2DM patient with normal renal function|Oral
62790273|NCT01302028|EXPERIMENTAL|T2DM patient with mild renal impairment|Oral
62212179|NCT01964924|EXPERIMENTAL|Treatment (trametinib, Akt inhibitor GSK2141795)|"PART 1: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression continue to Part 2.~PART 2: Patients receive trametinib as in Part 1 and also receive Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62212180|NCT05180500|ACTIVE_COMPARATOR|Q-GRFT Nasal Spray|Q-Griffithsin (Q-GRFT) nasal spray (7.5mg/mL). Two metered doses of 100μL into each nostril, total of 3mg Q-GRFT per administration, administered once daily for 14 consecutive days.
62212181|NCT05180500|PLACEBO_COMPARATOR|Placebo Nasal Spray|Placebo Nasal Spray. Two metered doses of 100μL into each nostril, administered once daily for 14 consecutive days.
62212182|NCT04131166|OTHER|Metabolically healthy lean|Metabolically normal lean - Lean individuals that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.
62212183|NCT04131166|EXPERIMENTAL|Metabolically healthy obese - Mediterranean diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the Mediterranean diet group.
62212184|NCT04131166|EXPERIMENTAL|Metabolically healthy obese - Low-carbohydrate ketogenic diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the low-carbohydrate ketogenic diet group.
62212185|NCT04131166|EXPERIMENTAL|Metabolically normal obese - Low-fat diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the low-fat diet group.
62212186|NCT04131166|EXPERIMENTAL|Metabolically unhealthy obese - Mediterranean diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the Mediterranean diet group.
62212187|NCT04131166|EXPERIMENTAL|Metabolically unhealthy obese - Low-carbohydrate ketogenic diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the low-carbohydrate, ketogenic diet group.
62212188|NCT04131166|EXPERIMENTAL|Metabolically unhealthy obese - Low-fat diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the low-fat diet group.
62212189|NCT05537168||Pediatric cardiac surgery|All patients with pediatric cardiac surgery under cardiopulmonary bypass between 2008 and 2018 will be included
62212190|NCT03189459|ACTIVE_COMPARATOR|HVP Patient-Subject|"Patients will be asked to participate in four study visits, which will involve in-home clinical assessments, a needs assessment, and completion of some questionnaires. Additional information will be obtained from patients' routine medical records: their medical and medication history, family history, neurological examination findings, and office visit records.~Completion of Home Visit Program intervention."
62212191|NCT03189459|ACTIVE_COMPARATOR|HVP Caregiver-Subject|"Caregivers enrolling in the study will be asked to participate in the four home visits, which will involve in-home clinical assessments and completion of some questionnaires. After the first home visit, caregivers will be matched with a peer mentor, an individual who was a prior caregiver to someone with PD who is interested in sharing their knowledge, experience, and time to help improve the lives of current caregivers. Once a week, for a period of 4 months between home visits 2 and 3, caregivers will be asked to meet with their peer mentor, who will be trained to serve as a resource and listening ear, in addition to the medical team.~Completion of Home Visit Program and Caregiver Mentorship Program interventions."
62408616|NCT03125239|EXPERIMENTAL|Merestinib and LY2874455|"Patients who fulfill eligibility criteria will be entered into the trial to receive Merestinib and LY2874455.~After the screening procedures confirm participation in the research study:~* The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have AML, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.~* Merestinib~* LY2874455"
62584309|NCT06244550|EXPERIMENTAL|Placebo + metformin|"Double blinded: matching placebo + metformin~Placebo daily metformin 1500mg daily"
62584310|NCT06244550|EXPERIMENTAL|Ganwei + metformin|"Double blinded: Ganwei + metformin~Ganwei 500mg/15 kg of body weight, daily metformin 1500mg daily"
62584311|NCT06244550|PLACEBO_COMPARATOR|Placebo|"Double blinded: matching placebo~Placebo daily"
62584312|NCT06244550|EXPERIMENTAL|Ganwei|"Double blinded: Ganwei~Ganwei 500mg/15 kg of body weight, daily"
62584313|NCT00001177||healthy volunteers|healthy females
62584314|NCT00001177||patients|females with menstrually-related mood or behavioral difficulties
62584315|NCT03983278|EXPERIMENTAL|School Model|School Model (n=47 schools): Vision screening will be carried out by the vision screeners; refraction will be done at the schools by refractionists, and children who need them will be given free spectacles at the school within two weeks.
62790274|NCT01302028|EXPERIMENTAL|T2DM patient with moderate renal impairment|Oral
62790275|NCT01302028|EXPERIMENTAL|T2DM patient with severe renal impairment|Oral
62212192|NCT03189459|NO_INTERVENTION|De-identified Control Subjects|Control subjects will be drawn from the National Parkinson Foundation Parkinson Outcomes Project (POP). Patient-caregiver dyads will be matched on patient gender, age, and HY stage.
62212193|NCT03189459|ACTIVE_COMPARATOR|HVP Peer Mentors|"Peer mentors enrolled in this study would be asked to complete a five-hour mentor training program. During this training, caregivers will be asked to complete some questionnaires about their background and caregiving experience. After completion of the mentorship training, peer mentors will be paired with a mentee who is a current caregiver enrolled in the home visit study along with their loved one with Parkinson's. Peer mentors will be asked to speak with their mentee once a week for 16 weeks. After a 16 week break, peer mentors will be paired with a second mentee and will repeat the process for another 16-week-long mentoring session.~Completion of Caregiver Mentorship Program intervention."
62212194|NCT05859516||Experimental: Ultrasound|
62212195|NCT04184843|EXPERIMENTAL|iWalk Toolkit|"Intervention period: 5 months~Intervention:~1. A toolkit consisting of 3 components: an educational guide, a smartphone app, and an educational video.~2. Access to a clinical expert by email or phone"
62212196|NCT03818360|EXPERIMENTAL|Smokers attending A&E|Receive an evidence-based smoking cessation intervention comprising brief advice plus active referrals for smokers attending emergency departments in Hong Kong.
62212197|NCT03955562|EXPERIMENTAL|Intervention|Communities that receive a pedestrian footbridge.
62212198|NCT03955562|EXPERIMENTAL|Comparison|Communities that do not receive a pedestrian footbridge.
62408617|NCT00648739|EXPERIMENTAL|Samalizumab|All doses of samalizumab were individualized based on the participant's body surface area in mg/m\^2 based on screening height and weight. Participants were assigned to a dose cohort, ranging from 50 to 600 mg/m\^2, and received a single IV dose of samalizumab. Participants who tolerated the drug and demonstrated at least stable disease received up to 3 additional cycles of samalizumab at the same dose originally received at a minimum of 28-day intervals and beginning no sooner than 6 weeks after the initial dose. If no participants enrolled into a cohort experienced a DLT, escalation to the next dose level occurred with a new cohort. If any 1 of the initial 3 participants in the cohort experienced a DLT, the cohort was expanded to at least 6 participants. Then, if less than one third of participants within the cohort experienced a DLT, escalation to the next dose level occurred with a new cohort. Dose cohorts were enrolled sequentially.
62212199|NCT04484103||251 patients from the MRI-FIRST trial|The mpMRIs were performed at 16 centers with 1.5T or 3T MR units. All mpMRIs included T2-weighted imaging, diffusion-weighted imaging and dynamic contrast-enhanced imaging.
62212200|NCT00365677|EXPERIMENTAL|Zyoptix Tissue Saving Aspheric|The Bausch \& Lomb Zyoptix Tissue Saving Aspheric algorithm is used for treatment with LASIK for the correction of myopia and myopic astigmatism.
62212201|NCT00365677|ACTIVE_COMPARATOR|Zyoptix Tissue Saving|The Bausch \& Lomb Zyoptix Tissue Saving algorithm is used for treatment with LASIK for the correction of myopia and myopic astigmatism.
62408618|NCT05595460|EXPERIMENTAL|RYZ101 + SoC|
62790276|NCT03694431|ACTIVE_COMPARATOR|Standard HBPC|Patients and caregivers in standard HBPC will continue to receive usual care from the palliative care team which includes home visits
62212202|NCT03764527|ACTIVE_COMPARATOR|Artemether-lumefantrine (AL)|One tablet of artemether-lumefantrine (Coartem®) was administered twice daily for 3 days to children with a body weight of 9 to \<15 kg, and 2 tablets were administered twice daily for 3 days to children with a body weight of \>15 to 25 kg. All doses were taken under direct observation.
62408619|NCT04753606|PLACEBO_COMPARATOR|Placebo|once-daily placebo
62408620|NCT04753606|EXPERIMENTAL|obicetrapib 5 mg|once-daily obicetrapib
62584316|NCT03983278|EXPERIMENTAL|Referral Model|Referral Model (47 schools): Vision screening carried out by the vision screeners, and children are referred to nearby Vision Center/ secondary center for refraction and delivery of free spectacles. Teachers will contact families not presenting for follow-up care and for spectacle compliance through SMS, phone call and notations in the school diary.
62408621|NCT04753606|EXPERIMENTAL|obicetrapib 10 mg|once-daily obicetrapib
62790277|NCT03694431|EXPERIMENTAL|Tech-supported HBPC|Patients and caregivers in tech-supported HBPC will receive synchronous video visits with a provider (physician or nurse practitioner) while the nurse is in the patient's home. Home visits by the palliative care team will be determined based on patients/caregivers' needs.
62790278|NCT04921904|EXPERIMENTAL|Abemaciclib plus Ramucirumab|Abemaciclib 150mg dose administered orally twice daily every day plus Ramucirumab dose 8mg/kg iv every 2 weeks until evidence of disease
62408622|NCT04670510|EXPERIMENTAL|Aerobic Exercise|The Aerobic Exercise (AE) condition will involve 150-minutes of moderate-intensity AE per week for 6-months and will involve a graded decline in supervision. Supervised AE will occur in groups, though each participant's AE prescription will be personalized based on baseline exercise capacity, as assessed by a maximal cardiopulmonary fitness test. Supervised AE sessions will involve the treadmill, elliptical, and/or bike, and routines will be varied to promote adherence. Supervised AE sessions will gradually increase to 50-minutes per session; however, participants will be encouraged to engage in home-based AE sessions according to their own preference of length and frequency in order to achieve 150 minutes of AE per week.
62408623|NCT04670510|ACTIVE_COMPARATOR|Social Engagement|The Social Engagement (SE) condition will be designed to control for the social component of the AE intervention (i.e., supervised on-site sessions with professional staff, frequent phone contact from study staff). A variety of enjoyable group-based activities centered around the dimensions of wellness (spiritual wellness, physical wellness, emotional wellness, etc.) will be scheduled throughout the intervention. This condition will involve once weekly meetings (grand total of \~26 sessions). Some participants will meet in-person and others will meet remotely via zoom (this will vary week to week) to increase flexibility to accommodate participant availability to attend as many sessions as possible.
62212203|NCT03764527|ACTIVE_COMPARATOR|Artesunate + Amodiaquine (AA)|Artesunate + amodiaquine (ASAQ) was administered as follows: 4 mg/kg body weight of artesunate plus 10 mg/kg body weight of amodiaquine once daily for 3 days under direct observation.
62408624|NCT06541509|EXPERIMENTAL|Semaglutide Therapy|"Timepoints:~* Baseline (Week 0)~* Week 2 (Visit 1)~* Week 4 (Visit 2)~* Week 12 (Visit 3)~* Week 16 (Visit 4)~Medication Schedule:~Subcutaneous semaglutide (Ozempyc, Novo Nordisk A/S Bagsvaerd, Denmark) First 2 weeks: Semaglutide; 0.25 mg weekly Second 2 weeks: Semaglutide; 0.5 mg weekly Remaining 12 weeks: Semaglutide; 1 mg weekly"
62408625|NCT04071327||Pulmonary arterial hypertension (PAH)|Patients with newly diagnosed or established PAH, within 6 months of first outpatient visit to a PH Care Center
62408626|NCT04071327||Chronic thromboembolic pulmonary hypertension (CTEPH)|Patients with newly diagnosed or established CTEPH, within 6 months of first outpatient visit to a PH Care Center
62212204|NCT01127152|ACTIVE_COMPARATOR|Automatic relays|Automatic relays of noradrenalin using intensive basis.
62408627|NCT04071327||Group 3 PH due to Developmental Lung Disease|Pediatric patients with newly diagnosed or established Group 3 PH due to developmental lung disease, within 6 months of first outpatient visit to a PH Care Center.
62212205|NCT01127152|ACTIVE_COMPARATOR|Manual relays|Relays of noradrenalin using manual method
62408628|NCT00474994|EXPERIMENTAL|Group A|Vascular connective tissue neoplasms, leiomyosarcoma, dermatofibrosarcoma protuberans (DFSP), desmoid tumors. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
62408629|NCT00474994|EXPERIMENTAL|Group B|High grade undifferentiated pleomorphic sarcoma (includes the older designation malignant fibrous histiocytoma \[MFH\]) and other non-GIST connective tissue tumors; may include carcinosarcomas.Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
62408630|NCT00474994|EXPERIMENTAL|Group C|Chordomas. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
62408631|NCT02222168|EXPERIMENTAL|BI 409306 fasted|Single dose 25 mg BI 409306 film-coated tablet, oral administration with 240 ml water in the morning under fasted condition.
62408632|NCT02222168|EXPERIMENTAL|BI 409306 fed|Single dose 25 mg BI 409306 film-coated tablet, oral administration with 240 ml water in the morning under fed condition.
62408633|NCT02222168|EXPERIMENTAL|BI 409306 at bed-time|Single dose 25 mg BI 409306 film-coated tablet, oral administration with 240 ml water at bed-time.
62408634|NCT04928625|EXPERIMENTAL|SHR-A1904|
62408635|NCT06242275||Postoperative delirium (POD) group|Patients who will develop postoperative delirium
62408636|NCT06242275||No Postoperative delirium (POD) group|Patients who will not develop postoperative delirium
62408637|NCT02187406|NO_INTERVENTION|Control|
62408638|NCT02187406|EXPERIMENTAL|Traditional ankle athletic taping|Described by Purcell and Schuckman (2009)
62790279|NCT00660179|EXPERIMENTAL|1|Macitentan (ACT-064992) tablet, 3 mg, once daily
62212206|NCT05882409|EXPERIMENTAL|Education group|In the experimental groups the education whose content (definition and importance of violence and conflict, violence against women, the cycle of violence, who is at risk for violence, characteristics of perpetrators and the victims of violence, types of violence against women, consequences of violence and conflict on individuals, legal aspects of violence, positive coping with violence and conflict, empowering women against violence, conflict resolution) was prepared by the researcher in line with the adult education principles and pertinent literature was given in the school prepared for education beforehand. In accordance with the adult education principles, the students were educated in groups of 12-15 people. During the education, methods such as narration, discussion, question-answer, brainstorming, problem solving and summarizing, data shows, brochures, posters and visual materials were used. The duration of the education lasted 30-40 minutes.
62790280|NCT00660179|EXPERIMENTAL|2|Macitentan (ACT-064992) tablet, 10 mg, once daily
62212207|NCT05882409|NO_INTERVENTION|Standard of care Group|The control group did not receive any treatment.
62790281|NCT00660179|PLACEBO_COMPARATOR|3|Matching placebo, once daily
62215221|NCT00231803|EXPERIMENTAL|Multifactorial intervention|Nurse led clinic involving a nephrologist administering protocol driven interventions aimed at preservation of kidney function, and cardiovascular risk reduction. Blood pressure targets were specified. No specific drugs were specified. Drug classes such as primarily statins for achieving LDL targets, use of an ACE inhibitor or ARB if possible, treatment of acidosis, anemia, hyperphosphatemia, advice on smoking cessation
62790282|NCT02454777|EXPERIMENTAL|ARM I (HIT group)|Participants undergo HIT exercises over 30 minutes, thrice weekly for 8 weeks.
62020000|NCT03286959|ACTIVE_COMPARATOR|PCR WITH RMGIC|PCR WITH RMGIC: A layer of resin modified liner ( GC Fuji II ) was placed adjacent to pulpal or axial wall and light cured for 40 sec. afterwards the cavity was restored with composite as in other groups.
62212208|NCT01445587|EXPERIMENTAL|GSK2110183|The oral dose of GSK2110183 the subjects received will be dependent on when the subject is enrolled to the study. GSK2110183 will be provided in 25mg and 50mg capsules containing the hydrochloride salt form of the API, microcrystalline cellulose, magnesium stearate, and microcrystalline cellulose (optional). They are filled into hard gelatin capsules. The 25mg tablets are opaque, swedish orange, size 2 capsules with no external markings, filled with a white powder. The 50mg tablets are opaque, white, size 1 capsules with no external markings, filled with a white powder.
62212209|NCT01445587|OTHER|Bortezomib|Bortezomib salvage therapy will be administered as a 3 to 5 second intravenous (IV) push at 1.3 mg/m2 on Days 1, 8, and 15 in each 21-day cycle until one of the Treatment Discontinuation Criteria is met.
62212210|NCT04410601|ACTIVE_COMPARATOR|No dysphagia (after total thyroidectomy-TT)|"Patients s/p post-thyroidectomy without complication~\*will NOT be enrolled to standard dysphagia-rehabilitation treatment"
62212211|NCT04410601|EXPERIMENTAL|Dysphagia (with at least one more complication of TT)|"Patients s/p post-thyroidectomy with both dysphagia and other documented TT complication such as vocal cord paralysis/hypocalcemia/surgical site infection etc.~\*will be enrolled to standard dysphagia-rehabilitation treatment for 6-week."
62212212|NCT04410601|EXPERIMENTAL|Dysphagia (the only complication after TT)|"Patients s/p post-thyroidectomy dysphagia only.~\*will be enrolled to standard dysphagia-rehabilitation treatment for 6-week."
62790283|NCT02454777|ACTIVE_COMPARATOR|Arm II (Delayed group)|Participants maintain their current sedentary activity level (\< 60 minutes of total exercise per week) for 8 weeks. Participants document their weekly activity in an exercise log. Following completion of all study visits, participants are given the option to complete the HIT program as in Arm I.
62790284|NCT02181283|ACTIVE_COMPARATOR|W+W|Web-delivered alcohol/prescribed drug misuse brief intervention with Web booster sessions (W+W).
62584317|NCT03983278|EXPERIMENTAL|Referral Model + Cost Recovery|"Referral Model + Cost Recovery (47 schools): Vision screening carried out by the vision screeners; children referred to Vision Center for refraction and delivery of spectacles with an option to purchase upgrade spectacles (which was shown to be appealing to families in the recent PRICE study. These spectacles have scratch-proof coatings and designs selected to appeal to local children. Teachers will contact families not presenting for follow-up care and for spectacle compliance through SMS, phone call and notations in the school diary."
62790285|NCT02181283|ACTIVE_COMPARATOR|W+P|Web-delivered brief intervention with Peer-delivered booster sessions (W+P).
62790286|NCT02181283|NO_INTERVENTION|Enhanced Usual Care|Enhanced usual care.
62020001|NCT03286959|ACTIVE_COMPARATOR|PCR WITH DIRECT COMPOSITE|PCR WITH DIRECT COMPOSITE: After partial caries excavation , etching and bonding was done directly without using any liner and cavity was restored with composite as in other groups
62212213|NCT01170390|OTHER|All participants|A low dose oral contraceptive given cyclically (21 days of active pills/cycle with a 7 day hormonal-free interval) for 2 cycles (56 days).
62212214|NCT01170390|ACTIVE_COMPARATOR|Aviane and Portia|A low dose oral contraceptive given cyclically (30mcg EE component, 21 days of active pills/cycle with a 7 day hormonal-free interval) for two cycles
62212215|NCT01170390|ACTIVE_COMPARATOR|Aviane & Aviane|A very-low dose oral contraceptive given continuously for 56 days (20mcg EE component, 28 days of active pills/cycle with no hormone free interval)
62212216|NCT01153321|EXPERIMENTAL|1|Oral treatment
62212217|NCT01153321|PLACEBO_COMPARATOR|2|Oral treatment
62790287|NCT03852667|NO_INTERVENTION|Control|No intervention between the two test sessions
62790288|NCT03852667|ACTIVE_COMPARATOR|Pain Neuroscience Education|Two sessions (30 min) of Pain Neuroscience Education
62212218|NCT00225017|EXPERIMENTAL|A|"ARM A: Switch current PI to atazanavir 400 mg once daily plus current \> 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) for 24 weeks.~Subjects currently on ritonavir (RTV) (400 mg BID or greater) or RTV-boosted PI (\<400 mg/day) , or tenofovir (TDF) as backbone NRTI therapy, will switch to ATV 300 mg boosted with RTV 100mg once daily."
62020002|NCT02641080|ACTIVE_COMPARATOR|Aspirin|Participants randomized to aspirin alone will be advised to take a 325mg per day as their outpatient DVT/PE prophylaxis.
62020003|NCT02641080|ACTIVE_COMPARATOR|Aspirin with portable Compression Device|Participants randomized to the compression device group are asked to wear the compression devices for 20 hours a day for 2 weeks along with taking an 325mg aspirin per day as their outpatient DVT/PE prophylaxis.
62020004|NCT03230279|ACTIVE_COMPARATOR|Sacroiliac joint fusion|The subject will receive a sacroiliac joint fusion
62020005|NCT03230279|ACTIVE_COMPARATOR|Sacroiliac radio frequency ablation|The subject will receive a sacroiliac joint radiofrequency ablation
62790289|NCT03852667|EXPERIMENTAL|Pain neuroscience education - exercise|2 sessions of PNE and 5 sessions of exercise therapy.
62790290|NCT00978146|EXPERIMENTAL|Desmoid tumor|Patients with desmoid tumors
62790291|NCT01849094|EXPERIMENTAL|Milrinone 6mg|"single oral dose of 6mg ER milrinone tablet (Part A).~1. single intravenous infusion of milrinone (per Alfred Hospital protocol. 50ug/kg loading dose over 15 mins followed by infusion at 0.375 ug/kg/min for 6 hrs) - Part B."
62790292|NCT01849094|ACTIVE_COMPARATOR|Milrinone 10mg ER|single oral dose of 10 mg ER milrinone tablet (Part A) single oral dose of 10 mg ER milrinone tablet (Part B)
62212219|NCT00225017|ACTIVE_COMPARATOR|B|ARM B: Continue current antiretroviral regimen (single or RTV-boosted PI plus \> 2 NRTIs) for 24 weeks
62212220|NCT02665338|SHAM_COMPARATOR|Sham rTMS|The sham TMS system will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
62212221|NCT02665338|ACTIVE_COMPARATOR|Active rTMS|Stimulation frequency for all active subjects: 10 Hertz - Pulse train duration (on time) 5 seconds, Inter-train interval (off time) 10 seconds (15 second cycle time), Power (intensity) level 100% rMT, Total 60 trains, 15 minutes, Total pulses 3000.
62212222|NCT00902928|EXPERIMENTAL|1. YM150, Dose X, twice daily|
62212223|NCT00902928|EXPERIMENTAL|2, YM150, Dose X, once daily|
62212224|NCT00902928|EXPERIMENTAL|3. YM150, Dose Y, twice daily|
62212225|NCT00902928|EXPERIMENTAL|4. YM150, Dose Y, once daily|
62212226|NCT00902928|ACTIVE_COMPARATOR|5. Enoxaparin|
62212227|NCT02880787|OTHER|Adult population 1|TOF-Watch SX® on nondominant arm and TOFScan® on dominant arm
62212228|NCT02880787|OTHER|Adult population 2|TOF-Watch SX® on dominant arm and TOFScan® on nondominant arm
62212229|NCT02880787|OTHER|Pediatric population 1|TOF-Watch SX® on nondominant arm and TOFScan® on dominant arm
62212230|NCT02880787|OTHER|Pediatric population 2|TOF-Watch SX® on dominant arm and TOFScan® on nondominant arm
62408639|NCT02187406|EXPERIMENTAL|modified ankle athletic taping|Described by Montag and Asmussen (1992)
62408640|NCT05991622|EXPERIMENTAL|Preliminary Test of Combined LAI Treatment|"The combined injectable treatment includes a dual-administration of rilpivirine (CAB/RPV) cabenuva for HIV and extended-release buprenorphine (XR-B) sublocade for OUD."
62408641|NCT04667507|EXPERIMENTAL|Dextenza (Group A)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 1-3 days prior to cataract surgery
62408642|NCT04667507|EXPERIMENTAL|Dextenza (Group B)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 6-8 days prior to surgery
62408643|NCT04667507|EXPERIMENTAL|Dextenza (Group C)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 13-15 days prior to surgery
62408644|NCT04667507|EXPERIMENTAL|Dextenza (Group D)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 19-23days prior to surgery
62790293|NCT01849094|ACTIVE_COMPARATOR|Milrinone 14mg|single oral dose of 14 mg ER milrinone tablet (Part A) single dose of 14 mg ER milrinone tablet 4. single oral dose of 18 mg ER milrinone tablet (if the group average plasma milrinone levels is less than 150 ug/L with 15 mg dose) - (Part B)
62408645|NCT04667507|EXPERIMENTAL|Dextenza (Group E)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 26-31 days prior to surgery
62408646|NCT04667507|NO_INTERVENTION|Control|Will not receive Dextenza (dexamethasone ophthalmic insert 0.4mg)
62790294|NCT04482582|EXPERIMENTAL|Image-guided percutaneous ICN (pICN): Group A|Patients who were admitted after a traumatic injury, with rib fractures identified, who are \>= 65 years of age will be randomized to percutaneous image-guided cryoneurolysis (pICN) group within 72 hours of presentation.
62790295|NCT04482582|ACTIVE_COMPARATOR|Standard-of Care : Group B|Patients who were admitted after a traumatic injury, with rib fractures identified, who are \>= 65 years of age will be randomized to standard-of-care group within 72 hours of presentation.
62212231|NCT04143945|EXPERIMENTAL|DV3396 followed by PDS290|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
62212232|NCT04143945|EXPERIMENTAL|PDS290 followed by DV3396|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
62212233|NCT01282502|EXPERIMENTAL|Midostaurin with chemoradiation|
62212234|NCT02880410|EXPERIMENTAL|LITT Treatment w/radiation therapy and temozolomide|This is a single arm study. All eligible study subjects will undergo LITT with the NeuroBlate System in combination with radiation therapy and temozolomide
62212235|NCT04293692|EXPERIMENTAL|UC-MSCs treatment group|Participants will receive conventional treatment plus 4 times of 0.5\*10E6 UC-MSCs /kg body weight intravenously at Day1, Day3, Day5, Day7).
62212236|NCT04293692|PLACEBO_COMPARATOR|Control group|Participants will receive conventional treatment plus 4 times of Placebo intravenously at Day1, Day3, Day5, Day7.
62212237|NCT01886859|EXPERIMENTAL|Treatment (ibrutinib and lenalidomide)|Patients receive a run-up cycle of ibrutinib PO daily on days 1-28. Patients then receive ibrutinib PO and lenalidomide PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients who have achieved CR/CRi, nodular PR, partial remission with persistent lymphocytosis, partial remission, or who have stable disease discontinue lenalidomide and continue ibrutinib.
62212238|NCT05404724|EXPERIMENTAL|Treatment group|itraconazole and SHR0302 tablets
62212239|NCT01422551|EXPERIMENTAL|Cognitive Behavioral Stress Management|10 weekly 2-hour sessions of group-based cognitive behavioral stress management
62212240|NCT01422551|ACTIVE_COMPARATOR|Psycho-educational Control|a single day group-based psycho-educational seminar
62408647|NCT00803582|EXPERIMENTAL|Experimental|Traditional acupuncture
62408648|NCT00803582|SHAM_COMPARATOR|Placebo|Placebo acupuncture
62408649|NCT00803582|NO_INTERVENTION|No-treatment|no treatment
62408650|NCT05079204|ACTIVE_COMPARATOR|Conventional motivation procedure|Conventional motivation procedures defined as a presentation of the modified Bass technique on a dental teaching macro model plus intra oral instruction provided in patient's mouth with a hand mirror.
62408651|NCT05079204|EXPERIMENTAL|Conventional motivation procedure supported by 3D representations|Conventional motivation procedures associated with 3D intra oral procedures. A 3D intra-oral modelization will added to the previously described procedure. Then, a periodontist will show the sites contaminated by dental plaque to the patient.
62408652|NCT05703009|EXPERIMENTAL|Treatment|Subjects will be randomized to take active treatment, sacrosidase, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature) during either Treatment Period 1 or Treatment Period 2. The study treatment period is one week.
62790296|NCT05274269|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks.
62408653|NCT05703009|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to take placebo treatment, sacrosidase placebo, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature) during either Treatment Period 1 or Treatment Period 2. The study treatment period is one week.
62020006|NCT01764334|ACTIVE_COMPARATOR|Fractional flow reserve|"Fractional flow reserve - guided group:~The initial treatment decision and the coronary arteries for fractional flow reserve (FFR) measurement will be established and recorded before randomization. FFR will then be measured by the cardiologist immediately after randomization and the FFR result will used to guide treatment decisions based on a threshold of 0.80. An FFR ≤ 0.80 should result in a treatment decision for revascularization by PCI or CABG combined with optimal medical therapy and an FFR\>0.80 should result in treatment with optimal medical therapy alone. Changes in treatment compared to the treatment plan prior to FFR disclosure will be recorded at the time."
62408654|NCT01497860|EXPERIMENTAL|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
62790297|NCT05274269|EXPERIMENTAL|ELX/TEZ/IVA|Participants 6 to less than (\<) 12 years of age and weighing \<30 kilogram (kg) at Day 1 received ELX 100 milligram (mg)/TEZ 50 mg /IVA 75 mg as fixed dose combination (FDC) tablets in the morning and IVA as mono tablet in the evening and those weighing more than or equal to (≥) 30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks.
62790298|NCT02302872|EXPERIMENTAL|ARTO system|
62790299|NCT06584240|EXPERIMENTAL|Sequence 1|Participants will receive one cycle of JHM03 in the selected overactive upper limb muscles
62790300|NCT06584240|EXPERIMENTAL|Sequence 2|Participants will receive one cycle of JHM03 in the selected overactive upper limb muscles
62790301|NCT06584240|EXPERIMENTAL|Sequence 3|Participants will receive one cycle of JHM03 in the selected overactive upper limb muscles
62790302|NCT06584240|EXPERIMENTAL|Sequence 4|Participants will receive one cycle of JHM03 in the selected overactive upper limb muscles
62790303|NCT06584240|PLACEBO_COMPARATOR|Sequence 5|Participants will receive one cycle of Placebo in the selected overactive upper limb muscles
62408655|NCT00968539|EXPERIMENTAL|GSK2340272A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
62408656|NCT00968539|EXPERIMENTAL|GSK2340269A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
62790304|NCT05266677|EXPERIMENTAL|EXPL|Liquid oral supplement comprising a blend of glycerides at certain proportions
62790305|NCT05266677|OTHER|CTRL|Liquid oral supplement comprising glycerides used in current formulas
62790306|NCT02159976|ACTIVE_COMPARATOR|Sequential therapy|pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)
62790307|NCT02159976|EXPERIMENTAL|Modified bismuth quadruple therapy|pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)
62790308|NCT02501499||Breastfeeding Buddies participants|Mothers that participated in Me Breastfeed workshops. Half will have been in the education-only group and half will have a buddy/peer support person in addition to the workshop.
62790309|NCT02501499||Volunteer Focus Group|Breastfeeding buddies volunteers that deliver education and support programs.
62790310|NCT02024139|EXPERIMENTAL|Chewing Sugarless Gum and Mouthwash|Patients are asked to chew sugarless gum 3 times per day in addition to using a fluoridated mouthwash 3 times per day
62790311|NCT02024139|PLACEBO_COMPARATOR|Using fluoridated mouthwash|Using Mouthwash: Patients are asked to use a fluoridated mouthwash 3 times per day as a placebo
62408657|NCT02912507|EXPERIMENTAL|Investigational Enlighten Device|Tattoo removal treatments with the investigational Cutera enlighten laser
62408658|NCT02912507|ACTIVE_COMPARATOR|Cynosure PicoSure 755 nm laser|Tattoo removal treatments with the Cynosure PicoSure 755 nm laser
62408659|NCT06427382||group E (age > 65 years)|Patients aged 65 years and older
62408660|NCT06427382||group N (age < 65 years)|Patients aged 18 to 65 years
62408661|NCT03602976|NO_INTERVENTION|Observation|
62408662|NCT03602976|EXPERIMENTAL|UDCA at Month 6|
62408663|NCT00435513||Transsexual group|Female-to-male and male-to-female transsexuals
62408664|NCT00435513||Controls|Healthy blood donors
62790312|NCT00654082|ACTIVE_COMPARATOR|Arm 1|
62790313|NCT00654082|PLACEBO_COMPARATOR|Arm 2|
62790314|NCT02699567||Lean AA|Subjects with a BMI\<=25 kg/m2 and carriers of a CD36 gene variation associated with low CD36 expression levels
62790315|NCT02699567||Obese AA|Subjects with a BMI\>29.9 kg/m2 and carriers of a CD36 gene variation associated with low CD36 expression levels
62790316|NCT02699567||Lean GG|Subjects with a BMI\<=25 kg/m2 and carriers of a CD36 gene variation associated with high CD36 expression levels
62790317|NCT02699567||Obese GG|Subjects with a BMI\>29.9 kg/m2 and carriers of a CD36 gene variation associated with high CD36 expression levels
62790318|NCT03676244|EXPERIMENTAL|immediate implant placement in anterior esthetic zone|extraction of badly broken anterior maxillary teeth with immediate implant placement
62790319|NCT03045718|EXPERIMENTAL|Horticultural Therapy|Horticultural Therapy will consists of 1 hour sessions, weekly for 9 months, to engage subjects in gardening-based activities.
62790320|NCT03045718|OTHER|Waitlist Control|The control group will be placed on a waiting list and only be contacted for assessments. They will receive the same Horticultural Therapy intervention after the active treatment group at a later date.
62790321|NCT04402723|EXPERIMENTAL|Donafenib, 0.2g|Donafenib,0.2g,bid,Combination with Cytarabine and Daunorubicin.
62790322|NCT04402723|EXPERIMENTAL|Donafenib,0.3g|Donafenib,0.3g,bid,Combination with Cytarabine and Daunorubicin
62790323|NCT02694900|EXPERIMENTAL|Resuscitation on the flor|2 min asynchronous cardiopulmonary resuscitation. The patient lies on the floor
62212241|NCT01195948|EXPERIMENTAL|B27PD 1 mg|Participants randomly assigned to the B27PD 1 mg arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
62408665|NCT00581334||Robotic Sacrocolpopexy Group|laparoscopic mesh augmented prolapse repair for post-hysterectomy prolapse repair using the Da Vinci robot
62408666|NCT00581334||Open Sacrocolpopexy Group|matched cohort that underwent mesh augmented prolapse repair for post-hysterectomy prolapse performed via open laparotomy
62408667|NCT06650371|ACTIVE_COMPARATOR|Fentanyl infusion|Analgesia will be offered by fentanyl in induction and maintenance according to ideal body weight (IBW).
62408668|NCT06650371|ACTIVE_COMPARATOR|Dexamedomedine and ketamine infusion|Opioid free anesthesia Analgesia will be offered by syringe containing ketamine and dexmedetomidine in induction and maintenance according to IBW.
62408669|NCT06026449|EXPERIMENTAL|Primary sclerosing cholangitis|
62790324|NCT02694900|EXPERIMENTAL|Resuscitation on the stretcher|2 min asynchronous cardiopulmonary resuscitation. The patient lies on a stretcher
62790325|NCT04361578||Patients|All patients enrolled in the study will be in this group.
62790326|NCT05318404|NO_INTERVENTION|Conventinal feeding group|Start oral feeding 5-7 days after esophagectomy and discharge with soft blended diet as major energy source
62790327|NCT05318404|EXPERIMENTAL|Delayed feeding group|Start clear liquid fluid diet 5-7 days after esophagectomy and discharge with jejunostomy feeding as the major energy source. Start oral feeding at postoperative 1st visit
62790328|NCT01455896|EXPERIMENTAL|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
62212242|NCT01195948|EXPERIMENTAL|B27PD 4 mg|Participants randomly assigned to the B27PD 4 mg arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
62790329|NCT01455896|OTHER|ITCA placebo|
62790330|NCT02930902|ACTIVE_COMPARATOR|Arm A (pembrolizumab, paricalcitol)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each course and paricalcitol IV over 15 minutes on days 1, 8, and 15. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Surgical resection is performed within 1 week and up to 4 weeks from last dose of paricalcitol.
62790331|NCT02930902|EXPERIMENTAL|Arm B (pembrolizumab, paricalcitol, chemotherapy)|Patients receive pembrolizumab and paricalcitol as in Arm A. Patients also receive gemcitabine hydrochloride IV over 30 minutes and nab-paclitaxel IV over 30-40 minutes on days 1, 8, and 15 of course 1 in the absence of disease progression or unacceptable toxicity. Surgical resection is performed within 1 week and up to 4 weeks from last dose of paricalcitol.
62790332|NCT03312842|EXPERIMENTAL|CS1001|
62212243|NCT01195948|PLACEBO_COMPARATOR|Placebo|Participants randomly assigned to the placebo arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
62215222|NCT00231803|ACTIVE_COMPARATOR|Usual care|Usual care includes any intervention thought appropriate by the treating family doctor and or specialists involved in the case
62408670|NCT06026449|EXPERIMENTAL|Ulcerative Colitis|
62408671|NCT02317796|PLACEBO_COMPARATOR|Placebo|
62408672|NCT02317796|ACTIVE_COMPARATOR|100 mg q.d.|
62408673|NCT02317796|ACTIVE_COMPARATOR|100 mg b.i.d.|
62408674|NCT02317796|ACTIVE_COMPARATOR|200 mg q.d.|
62408675|NCT02317796|ACTIVE_COMPARATOR|200 mg b.i.d.|
62408676|NCT06491264|EXPERIMENTAL|Personalized tES stimulation #1|tES will be applied with personalized parameters in condition #1 for approximately 20 minutes.
62408677|NCT06491264|EXPERIMENTAL|Personalized tES stimulation #2|tES will be applied with personalized parameters in condition #2 for approximately 20 minutes.
62408678|NCT06491264|EXPERIMENTAL|Personalized tES stimulation #3|tES will be applied with personalized parameters in condition #3 for approximately 20 minutes.
62408679|NCT06491264|EXPERIMENTAL|Standard tES|Standard tES will be applied in condition #4 for approximately 20 minutes.
62790333|NCT01423292|ACTIVE_COMPARATOR|an odd numbered patients|TAP block with local anesthetics
62790334|NCT01423292|PLACEBO_COMPARATOR|an even numbered patients|TAP block without local anesthetics
62790335|NCT03145259|OTHER|Diclofenac patch|Study Session 1: diclofenac epolamine patches (PK) \[51 h study duration\]
62790336|NCT03145259|OTHER|Diclofenac solution|Study Session 2: diclofenac sodium solution (PK) \[47 h study duration\]
62790337|NCT03145259|OTHER|Diclofenac patch and solution|Study Session 3: diclofenac epolamine patch pieces and diclofenac sodium solution (no PK, for skin tape stripping) \[51 h study duration\]
62790338|NCT04756648|EXPERIMENTAL|CT0180 cells|CT0180 Cells infusion after lymphocyte-depleting with fludarabine and cyclophosphamide.
62790339|NCT04090242|ACTIVE_COMPARATOR|App plus Nano|Use of BD Diabetes Care Application for Mobile devices PLUS the use of BD Nano 2nd Gen Pen Needle for delivery of insulin
62790340|NCT04090242|NO_INTERVENTION|Standard Care|Standard of Care/Subject is to continue on their current diabetes management regime
62790341|NCT05492097|EXPERIMENTAL|Exercise Group|For the patients in this group, 3 days a week for 4 weeks; various exercises and walking training will be given in sitting, crawling, kneeling, half-kneeling and standing positions and 20 minutes NMES will be applied.
62790342|NCT05492097|EXPERIMENTAL|Exercise and Robotic Group|In addition to the exercise group treatment, patients will receive gait training for 4 weeks, 3 sessions a week, with the last effector fixed robot Lokohelp.
62020007|NCT01764334|PLACEBO_COMPARATOR|Angiography-guided|FFR is measured by but not disclosed to the clinical team. Treatment decisions are therefore guided by angiography but not by FFR. The patient and the clinical team, including the cardiologists and nurses, will be blinded to FFR. The RadiAnalyzer Xpress (St Jude Medical) will be turned away from the clinical team who will not see the pressure wire data. FFR will not be displayed on any other monitor. Quality control checks, such as assessments of equalized pressure, will be done in the usual way, by the unblinded clinical research team. These steps will be followed for all FFR measurements. Adherence to the blinding protocol, including any non-protocol FFR disclosure at any time, will be prospectively recorded and blinding procedures will be monitored with site visits.
62020008|NCT00338026|EXPERIMENTAL|ECO-4601|
62020009|NCT02687334||Standard general anesthesia induction|Patients scheduled for elective surgery at the First Hospital of China Medical University will be recruited for the study beginning in February 2016.We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia
62408680|NCT06491264|SHAM_COMPARATOR|Sham tES stimulation|A sham (placebo) comparison condition will be applied in condition #5 for approximately 20 minutes.
62408681|NCT05156866|EXPERIMENTAL|Monotherapy Dose Dose Finding - Part 1|TORL-2-307-ADC
62408682|NCT05156866|EXPERIMENTAL|Expansion as Monotherapy - Part 2|TORL-2-307-ADC
62408683|NCT02181127|ACTIVE_COMPARATOR|Glucagon-only Bionic Pancreas (active)|Glucagon-only Bionic Pancreas will deliver glucagon during 7 of the 14 days. The order of the glucagon days will be randomized in blocks of 2, with no more than 2 days in a row of glucagon.
62790343|NCT00104650|ACTIVE_COMPARATOR|IV Bisphosphonates q 4 weeks|This is an open-label randomization to receive IV bisphosphonate (administered per package insert) every 4 weeks during the treatment phase. If subjects are enrolled into the extension phase, they will receive AMG 162 180mg (SC) every 4 weeks.
62790344|NCT00104650|EXPERIMENTAL|180 mg AMG 162 (SC) q 12 weeks|This is an open-label randomization to receive 180 mg AMG 162 (SC) every 12 weeks during the treatment phase. If subjects are enrolled into the extension phase, they will continue to receive 180 mg AMG 162 (SC) every 12 weeks.
62212244|NCT02992600||study group|300 male and female patients undergoing non-cardiac surgery are enrolled at the Affiliated Hospital of Xuzhou Medical University \[Jiangsu China\]. Patients will be divided into POCD and non-POCD groups according to the scores of neuropsychological tests.
62212245|NCT02992600||control group|30 healthy volunteers are enrolled for calculating the Z-scores of study group.
62212246|NCT03245151|EXPERIMENTAL|Phase 1: Phase 1; Recurrent or refractory solid tumors|During Phase 1 (Treatment Phase: 1 cycle; 28 days of treatment), utilizing a rolling 6 design, participants with recurrent or refractory solid tumors will receive escalating doses of lenvatinib in combination with everolimus for determination of the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Participants who complete 1 cycle of treatment will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
62212247|NCT03245151|EXPERIMENTAL|Phase 2: Cohort 1, Ewing sarcoma|During Phase 2 (four 28-day cycles \[up to 16 weeks of treatment\]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory Ewing sarcoma (Cohort 1) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1. Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
62212248|NCT03245151|EXPERIMENTAL|Phase 2: Cohort 2, Rhabdomyosarcoma|During Phase 2 (four 28-day cycles \[up to 16 weeks of treatment\]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory rhabdomyosarcoma (Cohort 2) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks of treatment). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
62790345|NCT00104650|EXPERIMENTAL|180 mg AMG 162 (SC) q 4 weeks|This is an open-label randomization to receive 180 mg AMG 162 (SC) every 4 weeks during the treatment phase. If subject is enrolled into the extension phase, they will continue to receive 180 mg AMG 162 (SC) every 4 weeks.
62212249|NCT03245151|EXPERIMENTAL|Phase 2: Cohort 3, High Grade Glioma (HGG)|During Phase 2 (four 28-day cycles \[up to 16 weeks of treatment\]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory HGG (Cohort 3) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
62790346|NCT05034419|EXPERIMENTAL|Active stimulation|Patients undergoing cardiac surgery will be randomized to active low level tragus stimulation for 30 min (pulse width of 200 μs, amplitude of 20 mA and a pulse frequency of 20 Hz). Stimulation will be provided using the Parasym device.
62790347|NCT05034419|SHAM_COMPARATOR|Sham stimulation|Patients undergoing cardiac surgery will be randomized to sham stimulation for 30 min. The Parasym device will be placed on the patient's tragus, but no current will be delivered.
62790348|NCT05733052|EXPERIMENTAL|Polyester suture arm|A No 3 polyester suture will be inserted into the external urethral ligament, into the uurethral part of pubourethral ligament and into the pubic part of the pubourethral lgament then will be tied, but not tightly. The interventions will be carried on either side of the urethra that will be opened up by an 2.5 cm incision in the periurethral sulci.
62790349|NCT04304872|EXPERIMENTAL|Gamification Intervention|"Participants sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day, they are told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who receives a weekly email with the participant's progress. The study group will hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, the study group will have a follow up call if the participant is stuck in a lower level and restart them back at the middle level."
62790350|NCT04304872|EXPERIMENTAL|Loss-Framed Financial Incentive Intervention|Participants are informed that each week that $14 is placed in a virtual account for them. Each day, the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.
62790351|NCT04304872|EXPERIMENTAL|Gamification and Loss-Framed Financial Incentive Intervention|Participants receive both of the interventions described in the Gamification Intervention arm and the Financial Incentive Intervention arm.
62790352|NCT01564147|OTHER|Immediate Education therapeutic|Access to the course of immediate therapeutic education
62790353|NCT01564147|OTHER|therapeutic education delayed|Group receiving therapeutic education 6 months later (control group)
62790354|NCT05632302|EXPERIMENTAL|TBI-ICP monitoring|Optical signals acquisition from the nICP probe stuck to the patient's forehead
62790355|NCT05411289|EXPERIMENTAL|acupressure|Pressures were applied on three points consecutively, firstly on two points bilaterally Hugo point (LI4) and He-7 (Shenmen), then pressure was applied on sanyinjiao (SP6)
62790356|NCT05411289|SHAM_COMPARATOR|sham acupressure|
62790357|NCT05711823|EXPERIMENTAL|Aprepitant in combination with granisetron and dexamethasone|Patients with unresectable hepatocellular carcinoma will receive aprepitant in combination with granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
62790358|NCT05711823|ACTIVE_COMPARATOR|granisetron and dexamethasone|Patients with unresectable hepatocellular carcinoma will receive granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
62790359|NCT02932748|EXPERIMENTAL|Group Phone Conference Call|Delivery: Group Phone Diet: PCMs
62790360|NCT02932748|EXPERIMENTAL|Individual Phone Call|Delivery: Individual Phone Call Diet: PCMs
62790361|NCT02932748|ACTIVE_COMPARATOR|Enhanced Usual Care|Delivery: Face-to-Face Diet: Conventional Diet
62790362|NCT04168099|EXPERIMENTAL|Cefotaxime|Cefotaxime intravenous
62790363|NCT04168099|ACTIVE_COMPARATOR|Gemifloxacin|Oral Gemifloxacin
62790364|NCT05624073||Air-QTM Blocker|GA (n=35): Air-Q Blocker TM will be used as a conduit for blind endotracheal intubation.
62790365|NCT05624073||LarySealTM Pro Laryngeal Mask|GL (n=35): Laryseal TM Pro will be used as a conduit for blind endotracheal intubation.
62790366|NCT03933761|EXPERIMENTAL|Pamiparib (BGB-290)|Drug: Pamiparib Oral capsules 60mg twice daily continuously Although treatment is continuous, a cycle is defined as 4 weeks or 28 days.
62790367|NCT03156283|EXPERIMENTAL|SleepWell24 Application|A mobile health smartphone application based on evidence-based health behavior change theory and interventions to promote adherence to positive airway pressure therapy
62790368|NCT03156283|OTHER|Usual Care Plus Activity Monitor|Per usual clinical care standards within the Center for Sleep Medicine at Mayo Clinic Arizona, all patients will receive instructions/education on positive airway pressure (PAP) use, multiple mask fittings, encouragement to use PAP every night, and staff is available in the event of problems. Control patients will also receive a wearable activity monitor to use during the study. The wearable sensor will be used to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
62790369|NCT03454607|EXPERIMENTAL|FREE robot|Patients undergoing sinus surgery with the FREE robot
62790370|NCT03749720|OTHER|Cervical cancer patients|Baseline- and follow-up blood samples are collected from the cervical cancer patients at time of diagnosis and during treatment and clinical follow-up. HPV DNA is measured in these samples.
62212250|NCT02712710|EXPERIMENTAL|wear a functional knee brace|20 subjects with symptomatic medial compartment knee OA, with grade 2 to 4 on Kellgren and Lawrence scale, and showing willing to wear a functional knee brace. All of the subjects received 4 weeks' rehabilitation treatment (3 times a week)
62212251|NCT02712710|NO_INTERVENTION|no wear a functional knee brace|Another 20 subjects with comparable body height, weight, and sex. All of the subjects received 4 weeks' rehabilitation treatment (3 times a week)
62212252|NCT04837651||Ocrelizumab Treated Multiple Sclerosis Patients|
62212253|NCT04837651||Natalizumab Treated Multiple Sclerosis Patients|
62212254|NCT00864253|EXPERIMENTAL|ABI-007|Treatment Arm A (ABI-007): Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
62212255|NCT00864253|ACTIVE_COMPARATOR|Dacarbazine|Treatment Arm B (dacarbazine): Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
62212256|NCT02374177||Propofol group|Patient anesthetized using propofol
62212257|NCT02374177||Sevoflurane group|Patients anesthetized using sevoflurane
62212258|NCT03282825|EXPERIMENTAL|Decitabine|"A standard 3+3 trial design will be used for Decitabine dose escalation cohorts.~The number of cohorts is three. The subjects will be administered Decitabine on every seven days in a 28day cycle and Decitabine is sequential administered with Paclitaxel.~Cohort 1: Decitabine 15mg/m2, Cohort 2: Decitabine 20mg/m2, Cohort 3: Decitabine 25mg/m2"
62408684|NCT02181127|PLACEBO_COMPARATOR|Glucagon-only Bionic Pancreas (placebo)|Glucagon-only Bionic Pancreas will deliver placebo during 7 of the 14 days. The order of the placebo days will be randomized in blocks of 2, with no more than 2 days in a row of placebo.
62408685|NCT04827576|EXPERIMENTAL|Safety Run-in Cohort 1, mNSCLC, mUC, mSCLC (Magrolimab + Docetaxel)|Participants with solid tumors (metastatic non-small cell lung cancer (mNSCLC), metastatic urothelial cancer (mUC), metastatic small cell lung cancer (mSCLC)) will receive an escalating dose of magrolimab and docetaxel.
62212259|NCT04954729||Experimental Group|The experimental group underwent neuropsychological testing, 18F-FDG PET/CT, 3T resting state fMRI examinations.
62212260|NCT04954729||MRI Control Group|The MRI control group underwent neuropsychological testing and 3T resting state fMRI examinations
62212261|NCT04954729||PET Control Group|The PET control group underwent 18F-FDG PET/CT examination
62212262|NCT05870605||Database Survey|All prescriptions for Intuniv available in the database in Denmark, Germany, Norway, Spain, Sweden, and the United Kingdom will be analyzed.
62212263|NCT05870605||Physician Survey|The physicians will collect participant records of those who have been prescribed Intuniv® at least once during the study period of 4 years. This will be done in Belgium, Finland, Ireland, and the Netherlands.
62212264|NCT01983189|EXPERIMENTAL|Low frequency rTMS|low frequency, repetitive transcranial magnetic stimulation (rTMS) for 20 minutes daily, 5 times a week for 3 weeks
62212265|NCT00151632|EXPERIMENTAL|MMF+FK|Low doses of tacrolimus in association with mycophenolate mofetil
62212266|NCT00151632|ACTIVE_COMPARATOR|FK|Full recommended doses of tacrolimus
62212267|NCT03097081|EXPERIMENTAL|No orthosis|The intervention consists of a deviation of the standard protocol; patients post-operatively do not receive an orthosis.
62212268|NCT03097081|ACTIVE_COMPARATOR|Orthosis|As in correspondence with local and international guidelines, patients receive an orthosis as standard post-operative care. This is considered the control group.
62212269|NCT00929747|ACTIVE_COMPARATOR|Toric IOL|AcrySof IQ Toric IOL
62212270|NCT00929747|ACTIVE_COMPARATOR|Limbal Relaxing Incision|AcrySof IQ with Limbal Relaxing Incision
62212271|NCT04365023||1|Well-differentiated grade 3 gastrointestinal neuroendocrine tumors patients who receive first line platinum based chemotherapy
62212272|NCT04365023||2|Well-differentiated grade 3 gastrointestinal neuroendocrine tumors patients who receive receiving first line non-platinum chemotherapy
62212273|NCT00847067|ACTIVE_COMPARATOR|Block|
62212274|NCT00847067|SHAM_COMPARATOR|Sham injection|Skin injections with Normal Saline
62020010|NCT02908269|EXPERIMENTAL|Fluzone Quadrivalent Vaccine Group 1: 3 to < 9 Years|Participants aged 3 to \< 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per Advisory Committee on Immunization Practices (ACIP) guidance, a second dose of Fluzone Quadrivalent vaccine was administered at Day 28.
62212275|NCT02570204|EXPERIMENTAL|Self-assessment of abortion outcome|Patients enrolled in the study will self-assess the outcomes of their medical abortion with the aid of a multi-level pregnancy test (MLPT) which they will perform at home.
62212276|NCT03552952||Preterm infants|100 preterm infants
62408686|NCT04827576|EXPERIMENTAL|Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)|Participants with mNSCLC will receive magrolimab at the recommended Phase 2 dose (RP2D) determined in the Safety Run-in Cohort 1 and docetaxel.
62408687|NCT04827576|EXPERIMENTAL|Phase 2 Cohort 1b, mUC (Magrolimab + Docetaxel)|Participants with mUC will receive magrolimab at the RP2D determined in the Safety Run-in Cohort 1 and docetaxel.
62408688|NCT04827576|EXPERIMENTAL|Phase 2 Cohort 1c, mSCLC (Magrolimab + Docetaxel)|Participants with mSCLC will receive magrolimab at the RP2D determined in the Safety Run-in Cohort 1 and docetaxel.
62020011|NCT02908269|EXPERIMENTAL|Fluzone Quadrivalent Vaccine Group 2: 18 to < 65 Years|Participants aged 18 to \< 65 years received one 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
62408689|NCT00029159|ACTIVE_COMPARATOR|1|
62408690|NCT00029159|PLACEBO_COMPARATOR|2|
62408691|NCT03393039|EXPERIMENTAL|Behavioral|Negative Affect Task
62790371|NCT06236685|EXPERIMENTAL|General anesthesia|Patients undergoing general anesthesia with mechanical ventilation will be monitored by electrical impedance tomography in addition to standard monitoring. Moreover, esophageal pressure catheter will be used in cases where indicated by clinician or in case of an indication of nasogastric tube, as esophageal pressure can be measured by a combined catheter.
62790372|NCT06236685|EXPERIMENTAL|Intensive Care Unit|Patients ventilated in the ICU for various reasons will receive standard care, including advanced monitoring of mechanical ventilation.
62790373|NCT04776512|EXPERIMENTAL|Epidural Analgesia|Patients of this group Will receive an epidural analgesia through a lumbar epidural catheter
62790374|NCT04776512|EXPERIMENTAL|ESP Block|Bilateral ESP block performed at the level of the 3 rd Lumbar transverse process.
62790375|NCT03503760|EXPERIMENTAL|true-sham|"Patients first received the true LIMFA Therapy® treatment for 3 weeks followed by 3 weeks of washout and then six sham sessions for 3 weeks more."
62408692|NCT03076307|EXPERIMENTAL|Parkinson's disease|
62408693|NCT03076307|ACTIVE_COMPARATOR|Control group|
62408694|NCT03390010|ACTIVE_COMPARATOR|Extra medication group|"-Procedure : Giving misoprostol plus syntocinon during CS~this group in which prevention of uterine atony is made by intrauterine misoprostol plus the usual syntocinon and using extra uterotonic drugs when needed ; methergine , carboprost"
62408695|NCT03390010|ACTIVE_COMPARATOR|Active management of labour group|"* Procedure: Giving syntocinon during cesarean section~* this group in which prevention of uterine atony is made by the usual active management of labour syntocinon and using extra uterotonic drugs when needed ; methergine , carboprost"
62790376|NCT03503760|EXPERIMENTAL|sham-true|"Patients first received the sham treatment for 3 weeks followed by 3 weeks of washout and then six true LIMFA Therapy® sessions for 3 weeks more."
62408696|NCT02201732|EXPERIMENTAL|Arm A : Operative hysteroscopy|operative hysteroscopy with direct visualization
62408697|NCT02201732|ACTIVE_COMPARATOR|Arm B : Aspirative curettage|curettage is the standard surgical treatment in most centers
62790377|NCT05426278|OTHER|FAW and Bair Hugger Group|Group B, the intervention group (with FAW and Bair Hugger).
62790378|NCT05426278|NO_INTERVENTION|Control group|Group A, the control group (No FAW or Bair Hugger)
62790379|NCT01524146||Photodynamic therapy|Subjects who will receive photodynamic therapy for palliation of unresectable Cholangiocarcinoma.
62020012|NCT02908269|EXPERIMENTAL|Fluzone High-Dose Vaccine Group 3: ≥ 65 Years|Participants aged ≥ 65 years received one 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
62212277|NCT03552952||Term infants|100 term healthy infants
62212278|NCT02484053|EXPERIMENTAL|Rheumatologic disease|Rituximab is administered over 120 minutes, 12.5% of the dose will be given over the first 30 minutes and the remaining 87.5% of the dose will be given over 90 minutes.
62212279|NCT02484053|EXPERIMENTAL|Cancer or blood disorder|Rituximab is administered over 90 minutes, 20% of the dose will be given over the first 30 minutes and the remaining 80% of the dose will be given over 60 minutes.
62790380|NCT02500953|EXPERIMENTAL|Japanese male single fasted ASP dose-1|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
62790381|NCT02500953|EXPERIMENTAL|Japanese male single fasted ASP dose-2|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
62790382|NCT02500953|EXPERIMENTAL|Japanese male single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
62790383|NCT02500953|EXPERIMENTAL|Japanese male single fasted ASP dose-4|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
62790384|NCT02500953|EXPERIMENTAL|Japanese male single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
62790385|NCT02500953|EXPERIMENTAL|Japanese male single fasted ASP dose-6|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
62790386|NCT02500953|EXPERIMENTAL|Japanese male single fasted ASP dose-7|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
62790387|NCT02500953|EXPERIMENTAL|Japanese female single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
62790388|NCT02500953|EXPERIMENTAL|Japanese female single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
62790389|NCT02500953|EXPERIMENTAL|Caucasian male single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
62212280|NCT00357331|EXPERIMENTAL|Potassium Citrate|Potassium Citrate 20 meq twice daily
62790390|NCT02500953|EXPERIMENTAL|Caucasian male single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
62212281|NCT00357331|PLACEBO_COMPARATOR|Placebo|Placebo
62790391|NCT02500953|EXPERIMENTAL|Japanese male single fed ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects after a meal.
62790392|NCT02500953|EXPERIMENTAL|Japanese male single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
62790393|NCT02500953|EXPERIMENTAL|Japanese female single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
62020013|NCT01722331|EXPERIMENTAL|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered subcutaneously (SC) once a week at Weeks 0 and 4 and then every 12 weeks.
62020014|NCT01722331|EXPERIMENTAL|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC once a week at Weeks 0 and 4 and then every 12 weeks.
62020015|NCT01722331|PLACEBO_COMPARATOR|Placebo|Matching placebo administered SC once a week at Weeks 0 and 4.
62020016|NCT01546415|EXPERIMENTAL|Desferasirox|
62020017|NCT04871139|EXPERIMENTAL|Diagnostic (iodine-based contrast, CEM)|Patients receive iodine-based contrast agent IV and the undergo CEM over 10-15 minutes.
62212282|NCT04041453|ACTIVE_COMPARATOR|Albendazole 400mg|Albendazole 400mg in single dose
62212283|NCT04041453|EXPERIMENTAL|Albendazole/Ivermectin|Combination of albendazole 400mg + ivermectin 600mcg/kg in single dose.
62212284|NCT04041453|EXPERIMENTAL|Albendazole 400mg x 3|Albendazole 400mg/day for 3 consecutive days
62212285|NCT04041453|EXPERIMENTAL|Albendazole/Ivermectin x 3|Combination of albendazole 400mg/day + ivermectin 600mcg/kg/day for 3 consecutive days
62212286|NCT01048801|ACTIVE_COMPARATOR|Rapid diagnostic test and treatment|
62212287|NCT01048801|OTHER|Treatment without rapid daignostic test|
62020018|NCT01368458|EXPERIMENTAL|Conversion to mono therapy|Conversion from 2 to 1 antipsychotic
62020019|NCT01368458|NO_INTERVENTION|control|No change in antipsychotics
62020020|NCT01409694|ACTIVE_COMPARATOR|Intervention|All participants start the treatment with memantine on the first day of the study and immediately start vitamin D supplementation.
62212288|NCT03995862||Patients in care, at high risk of HIV infection|Patients in care, at high risk of HIV infection, according to the criteria defined by the French Ministry Of Health for the use of FTC / TDF in PreP (men who have sex with men, transgender, heterosexual women migrants or not, sex workers (sexual intercourse in exchange for money, drugs, housing, food), intravenous drug users) HIV-negative, exposed by their sexual practices to a high risk of HIV infection.
62212289|NCT05174936|EXPERIMENTAL|PLWH intervention sessions|The PLWH in this arm will receive five 2-hour intervention sessions delivered over five weeks (one session per week) in the clinics. Two trained facilitators will deliver the materials through interactive trainings that include multimedia presentations, group discussions, role-play, personal testimonies, and/or games. The same two facilitators will deliver all five sessions within a clinic to increase group cohesion and rapport with PLWH. The goal of this intervention is to assist PLWH in identifying and developing internal and external resilience resources to aid in coping HIV stigma.
62212290|NCT05174936|EXPERIMENTAL|Family member intervention|The intervention sessions for family members will be similar to PLWH sessions in terms of format and content and will be led by trained facilitators. Family member intervention sessions will emphasize supporting PLWH to cope with HIV-related stigma and to improve their clinical outcomes. The goal of this intervention is to provide social support for PLWH's resilience building as well as foster resilience at the family level.
62212291|NCT05174936|EXPERIMENTAL|Health care provider intervention|The HCP intervention curriculum consists of four 1.5-hour sessions (e.g., one per week) that will be delivered in small groups in the clinic setting by trained facilitators (e.g., health educators from Guangxi CDC). The delivery schedule and format will be flexible and individually tailored (e.g., four sessions can be given one per week or consolidated into two longer sessions). The goal of this intervention is to reduce the institutional stigmatizing attitudes and practices toward PLWH and other social identities, such as MSM, sex workers, and drug users, and improving the provider-patient relationships.
62212292|NCT02384265|EXPERIMENTAL|IM/SMS + Incentive Condition|"Participants in the intervention condition will consist of the PWD and their two STMs. The PWD and STM will receive the same protocols that the Usual Care participants receive, including an introductory educational session, written materials on diabetes, a blood glucose log, and a physical activity monitoring log. The PWDs in this condition will also receive training in action planning with their STMs. They will also receive SMS messages supporting diabetes self-care from the study team. The study team will also encourage the STMs to interaction in person and via text messages with the PWD."
62212293|NCT02384265|NO_INTERVENTION|Control|Control group participants will consist of the person with diabetes (PWD) and their two support team members (STM). The PWD will receive regular medical care from their usual providers. They will also receive an introductory educational session and written materials on diabetes, the importance of its control, and diabetes self-care strategies, and a blood glucose and physical activity monitoring log. They will be invited for study visits at 3, 6, and 12 months to measure cholesterol, A1c (for those with diabetes), blood pressure, height, and weight measurement. PWDs and STMs in the control condition will receive generic health promotion information during in-person visits or by mail. They will receive follow-up messages by text to remind them about study related events.
62408698|NCT06568289|EXPERIMENTAL|Lignocaine group|A perineal infiltration of a 5-ml of the drug (100 mg of lignocaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
62790394|NCT02500953|EXPERIMENTAL|Caucasian male single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
62790395|NCT02500953|EXPERIMENTAL|Japanese male single fed placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects after a meal.
62020021|NCT01409694|PLACEBO_COMPARATOR|Placebo|Participants in this arm start the treatment with memantine in the same way as the 'Intervention' group. They also immediately start Vitamin D placebo administered at the same pace.
62020022|NCT02199782|ACTIVE_COMPARATOR|Welsh|Participants will complete the cognitive assessment in Welsh and in English these will be compared to assess whether first language Welsh speakers perform better in Welsh.
62020023|NCT02199782|ACTIVE_COMPARATOR|English|Participants will complete the cognitive assessment in Welsh and in English these will be compared to assess whether first language Welsh speakers perform better in Welsh.
62020024|NCT06196723||TIPS|transjugular intrahepatic portal shunt
62020025|NCT06196723||LVP+A|large volume paracenteses plus albumin
62020026|NCT02621905|ACTIVE_COMPARATOR|Sporanox|100 mg
62020027|NCT02621905|EXPERIMENTAL|Lozanoc|50 mg
62020028|NCT05090501|EXPERIMENTAL|Green|Green exercise participants will exercise in the nature-based condition.
62020029|NCT05090501|EXPERIMENTAL|Indoor|Indoor participants will exercise in the indoor condition.
62020030|NCT03735966|EXPERIMENTAL|Pyrotinib plus trastuzumab and docetaxel and carboplatin|Pyrotinib + trastuzumab + docetaxel+carboplatin
62020031|NCT04557722|ACTIVE_COMPARATOR|Group 1: 0-30° technique.|Procedure: 0-30° Biplanar Fluoroscopic Puncture Technique for Percutaneous Nephrolithotomy.
62020032|NCT04557722|ACTIVE_COMPARATOR|Group 2: new 0-90° technique.|Procedure: new 0-90° Fluoroscopic Puncture Technique for Percutaneous Nephrolithotomy.
62212294|NCT04193826|EXPERIMENTAL|Non-valvular AF adults|Left atrial appendage closure (LAAC) with the Conformal LAAC device will be performed according to the device Instructions for Use, based on ICE and angiographic guidance, femoral venous access and inter-atrial septum crossing.
62408699|NCT06568289|EXPERIMENTAL|Bupivacaine group|A perineal infiltration of a 5-ml of the study drug (20 mg of Bupivacaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
62408700|NCT04968873|EXPERIMENTAL|Patients with Choledocholithiasis|Patients were managed by elective open cholecystectomy and operative exploration of the common bile duct.
62408701|NCT05543629|EXPERIMENTAL|Part A: BMS-986442 + Nivolumab|
62408702|NCT05543629|EXPERIMENTAL|Part B1: BMS-986442 + Nivolumab|Second line (2L) + Post-immuno-oncology (IO)/Platinum-Doublet Non-small cell lung cancer (NSCLC)
62408703|NCT05543629|EXPERIMENTAL|Part B2: BMS-986442 + Nivolumab|Post IO Gastric Cancer/Gastroesophageal Junction and Post-IO squamous cell carcinoma of the head and neck (SCCHN)
62212295|NCT02349425|EXPERIMENTAL|Cohort 1: Gefapixant>Placebo|50, 100, 150, and 200 mg gefapixant twice daily (BID) for 4 days each in Period 1 and placebo BID for 16 days in Period 2. For Cohort 1, there was a 3 to 7 day washout period between treatment periods.
62408704|NCT05543629|EXPERIMENTAL|Part C: BMS-986442 + Nivolumab + Docetaxel|
62408705|NCT05543629|EXPERIMENTAL|Part D: BMS-986442 + Nivolumab + Carboplatin + Pemetrexed|
62408706|NCT05543629|EXPERIMENTAL|Part E: BMS-986442 + Nivolumab + Carboplatin + Paclitaxel|
62408707|NCT03900481|EXPERIMENTAL|Vertical gastric plication|Vertical gastric plication ( without cutting gastric wall) is a novel surgical approach for reducing the stomach capacity. A transoral or endoluminal approach (i.e. a procedure that requires no incision, because access is granted through the mouth) offers some potential additional benefit to the patient, because the procedures continue to become more and more minimally invasive
62408708|NCT03146078||Primary Cohort|"Participants with baseline visual acuity ETDRS letter score of 54 or more \[approximate Snellen equivalent 20/80 or better\] and stable fixation and clinically determined \[on Octopus 900 Pro\] kinetic visual field III4e area 10° or more in the study eye (primary cohort) will be enrolled into the longitudinal natural history study"
62790396|NCT02500953|EXPERIMENTAL|Japanese male multiple ASP dose-3|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
62790397|NCT02500953|EXPERIMENTAL|Japanese male multiple ASP dose-4|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
62790398|NCT02500953|EXPERIMENTAL|Japanese male multiple ASP dose-5|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
62790399|NCT02500953|EXPERIMENTAL|Japanese female multiple ASP dose-3|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
62212296|NCT02349425|EXPERIMENTAL|Cohort 1: Placebo>Gefapixant|Placebo BID for 16 days in Period 1 and gefapixant 50, 100, 150, and 200 mg BID for 4 days each in Period 2. For Cohort 1, there was a 3 to 7 day washout period between treatment periods.
62408709|NCT03146078||Secondary Cohort|"Participants with baseline visual acuity ETDRS letter score of 53 or less \[approximate Snellen equivalent 20/100 or worse\] or unstable fixation or clinically determined \[on Octopus 900 Pro\] kinetic visual field III4e area less than 10°in the study eye (secondary cohort) will be enrolled in the cross-sectional baseline study"
62790400|NCT02500953|EXPERIMENTAL|Japanese female multiple ASP dose-4|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
62790401|NCT02500953|EXPERIMENTAL|Japanese female multiple ASP dose-5|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
62790402|NCT02500953|EXPERIMENTAL|Japanese male multiple Placebo|Placebo will be administered with 240 mL of water, three times a day, just after a meal.
62790403|NCT02500953|EXPERIMENTAL|Japanese female multiple Placebo|Placebo will be administered with 240 mL of water, three times a day, just after a meal.
62790404|NCT02500953|EXPERIMENTAL|Japanese male ASP dose-5 before a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
62790405|NCT02500953|EXPERIMENTAL|Japanese male ASP dose-5 during a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
62790406|NCT02500953|EXPERIMENTAL|Japanese male ASP dose-5 after a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
62790407|NCT05791227|ACTIVE_COMPARATOR|Sonographer Annotation|Currently, sonographer technicians provide preliminary interpretations prior to validation and overreading by cardiologists. This staggered, stepwise evaluation allows for the introduction of AI decision support with minimal impact on patient care. Physicians are already used to adjusting the preliminary report given the variable training of sonographers and on the lookout for changes, variation, or adjustments that need to be made.
62790408|NCT05791227|EXPERIMENTAL|Artificial Intelligence Annotation|A novel AI algorithm developed to assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd). The AI will provide preliminary assessments for cardiologist evaluation.
62790409|NCT00206440|EXPERIMENTAL|Esomeprazole|Patients receiving chemotherapy (anthracycline-based) will be randomized to esomeprazole for Cycle 1 Days 1-5 and Cycle 2 Days 1-5
62790410|NCT00206440|PLACEBO_COMPARATOR|Sugar pill|Subjects will be given placebo Cycle 1 Days 1-5 and Cycle 2 Days 1-5.
62790411|NCT05678634|EXPERIMENTAL|Children with developmental language disorder|
62790412|NCT02749565||asthmatic patients with OSA|
62790413|NCT02749565||asthmatic patients without OSA|
62790414|NCT02989883|OTHER|Peroral endoscopic myotomy (POEM)|Patients who received POEM
62790415|NCT03566706|EXPERIMENTAL|Unhealthy Eating|
62790416|NCT03566706|EXPERIMENTAL|Marijuana Use|
62790417|NCT03566706|EXPERIMENTAL|Sedentary Behavior|
62790418|NCT00126776|ACTIVE_COMPARATOR|1|CAse/self management for COPD
62790419|NCT00126776|OTHER|2|usual care
62790420|NCT05535413|EXPERIMENTAL|UDT1 combined with capecitabine|
62020033|NCT05590091|EXPERIMENTAL|Experimental group|roup A were given precise dietary guidance and enteral and parenteral nutrition support treatment using only nutrition software. It is recommended that the precise recommended time covers the start of enrollment until 100 days after transplantation
62020034|NCT05590091|NO_INTERVENTION|The control group|Group B patients were given the routine nutritional support treatment plan commonly used in clinics. Patients in both groups were monitored and followed up at -5d before transplantation and at +6d, +30d, +60d, +100d, +180d, and +360d after transplantation.
62020035|NCT06534177||Participants with long-term conditions affecting movement|A total number of 50 people with long-term conditions affecting their movement include people with Parkinson's
62212297|NCT02349425|EXPERIMENTAL|Cohort 2: Gefapixant>Placebo|Gefapixant 7.5, 15, 30, and 50 mg BID for 4 days each in Period 1 and placebo BID for 16 days in Period 2. For Cohort 2, there was a 14 to 21 day washout period between treatment periods.
62584318|NCT06005285|EXPERIMENTAL|Early Start Denver Model (ESDM)|Early Start Denver Model (ESDM) is a comprehensive model that integrates principles of applied behavior analysis (ABA), relationship-based, developmental, and play-based orientations into an individualized and yet manualized treatment. Core features include the use of naturalistic ABA strategies, sensitivity to typical developmental sequence, caregiver involvement, a focus on interpersonal exchange and positive affect within everyday activities. Providers in the ESDM condition will receive training in caregiver coaching strategies and will be asked to conduct caregiver coaching in the strategies at least monthly.
62020036|NCT06534177||Healthy control|A total number of 30 healthy people with no condition impacting their movement and walking ability.
62020037|NCT02395354|OTHER|Placing a self-expanding metallic stent|Placing a self-expanding metallic stent
62584319|NCT06005285|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Treatment as usual will vary based on the agency. However, a majority of CBAs use Discrete trial teaching (DTT) based on the Lovaas model.19 DTT involves 10 components described in numerous research publications: capturing child physical and visual attention, adult presentation of the stimuli and instruction (antecedent), child behavior, adult reinforcement, correction procedures, 3-5 second interstimulus interval between trials, behavior-specific praise, and data recording. Most CBAs include caregivers in some way as caregiver involvement is required by most funders. Often, caregivers observe treatment sessions or learn the teaching approach being used with their child. Providers often provide consultation on addressing behavioral concerns.
62584320|NCT06236607|ACTIVE_COMPARATOR|Multiple daily injections|Participants randomized into this arm will use multiple daily injections of insulin.
62790421|NCT00434109|EXPERIMENTAL|Sunitinib Malate and Hepatic Artery Embolizations|Sunitinib Malate and Selective Hepatic Artery Embolizations: Sunitinib malate (Sutent) at a dose of 37.5mg. 1-3 selective hepatic artery embolizations.
62790422|NCT02913378|EXPERIMENTAL|Locking plate|Surgical treatment with open reduction and osteosynthesis with locking plate
62790423|NCT02913378|ACTIVE_COMPARATOR|Conservative|Conservative treatment with sling and rehabilitation
62790424|NCT01843023|EXPERIMENTAL|Extended Release Naltrexone|Participants randomly assigned to XR-NTX who do not have opioid withdrawal signs or symptoms within 4 hours of administration of the 25 mg oral dose naltrexone will be given an intramuscular injection of XR-NTX \[Vivitrol®\] at a dose of 4cc (380mg of naltrexone)\] and will subsequently have the same dose administered to alternating sides of the buttocks every four weeks for up to 6 months. All participants will also receive psychosocial treatment.
62790425|NCT01843023|ACTIVE_COMPARATOR|Treatment as Usual|Participants randomly assigned to TAU will participate in the standard youth opioid program at the treatment center which includes either buprenorphine taper or ongoing buprenorphine treatment during the 6 months of the study for as long as they and their physicians think is appropriate. The general target dose will be 12-20 mg buprenorphine per day. All participants in TAU will receive psychosocial treatment.
62020038|NCT02395354|OTHER|A balloon dilatation|A balloon dilatation
62020039|NCT02473614|EXPERIMENTAL|Music Glove|Music Glove is a glove with sensors attached to the tips of all 5 fingers. The glove is connected to a software musical program like guitar hero. Participants will follow the rhythm or musical notes of the songs and move their fingers accordingly. Participants are reinforced with biofeedback that includes visual and auditory cues when the correct sequences are achieved.
62212298|NCT02349425|EXPERIMENTAL|Cohort 2: Placebo>Gefapixant|Placebo BID for 16 days in Period 1 and gefapixant 7.5, 15, 30, and 50 mg BID for 4 days each in Period 2. For Cohort 2, there was a 14 to 21 day washout period between treatment periods.
62212299|NCT03385343|EXPERIMENTAL|VLE imaging of stage EAC|All subjects will receive VLE imaging for staging EAC. Volumetric laser endomicroscopy (VLE) is an imaging platform that uses infrared light to generate cross-sectional views of the human esophagus with microscopic resolution.
62212300|NCT03452930|EXPERIMENTAL|Stage 1 (tinostamustine)|Patients who have completed TMZ and RT receive tinostamustine IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62212301|NCT03452930|EXPERIMENTAL|Stage 2 (RT, tinostamustine)|Patients who have received no treatment other than surgery undergo RT 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive tinostamustine over 60 minutes IV on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62212302|NCT03670966|EXPERIMENTAL|Treatment (211At-BC8-B10, chemotherapy, TBI, MMF, G-CSF)|"PREPARATIVE REGIMEN: Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 infusion over 6-8 hours on day -8, fludarabine IV over 30 minutes on days -6 to -2, and cyclophosphamide IV over 1 hour on days -6 and -5. Patients also undergo TBI on day -1.~TRANSPLANT: Patients undergo PBSC or bone marrow transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID on days 5-35, and tacrolimus IV over 1-2 hours (changed to PO once tolerated) on days 5-180 with taper beginning on day 84 per physician discretion. Patients also begin G-CSF IV or SC on day 5 to continue until ANC \> 1000/mm\^3 x 3 days.~Patients undergo bone marrow biopsy and aspiration and blood sample collection throughout the study."
62020040|NCT02473614|ACTIVE_COMPARATOR|Conventional Hand Exercise Program|Conventional Hand Exercise Program includes range of motion exercises, strengthening exercises, coordinating exercises of the hand and fingers. This exercise program is designed by an occupational therapist and is a general exercise program that a stroke patient will receive when he/she is being discharged from the hospital.
62020041|NCT01841749|OTHER|Surgery|sentinel node biopsy and mastectomy
62215223|NCT04019990|OTHER|Wheelchair basketball and ambulant basketball players|13 players from the North Cyprus wheelchair Basketball Team and 15 players from the Koop Bank Basketball Men's Team voluntarily will participate in the study. Subjects will include to study if they fulfil criteria. Athletes will involve in 8 weeks Thrower's Ten exercise program. After 8. Weeks and 12. Weeks assessments will be repeated.
62408710|NCT03146078||Virtual Reality (VR) Cohort|"A subset of sites participating in the VR ancillary study will complete a feasibility questionnaire, including assessment of available space for running the testing procedures. Selected sites will work with VR vendor to complete installation, training, and certification requirements. Eligible participants will be presented with the opportunity to participate in the RUSH2A Extension Study at sites participating in the VR Ancillary Study.~Participants at VR Sites must consent to the VR Ancillary Study to participate in the RUSH2A Extension Study."
62408711|NCT04104152|EXPERIMENTAL|ENDS 2.4% nicotine|Subjects will be assigned to one of four flavors variants of 2.4% ENDS products based on their preferred UB flavor.
62408712|NCT04104152|EXPERIMENTAL|ENDS 5.0% nicotine|Subjects will be assigned to one of four flavors variants of 5.0% ENDS products based on their preferred UB flavor.
62408713|NCT04518527|ACTIVE_COMPARATOR|true taping+ exercise|The true taping method was applied to the first group according to the method determined by Kase. According to this method, a 2-inch (5 cm) wide beige-colored Kinesio tape (Kinesio® Tex Gold FP) was measured from the second-third metacarpal base to the lateral epicondyle while the elbow was extended and the wrist was in the neutral position and the tape was applied in the shape of a 'Y'. In a position where the wrist-ankle extensors were most tense (wrist-ankle extension - forearm pronation), the anchor point of the tape was applied to the insertion of the muscle without creating any tension. Then, the tape was applied to the medial and lateral edges of the wrist extensors by applying a 15-25% tension towards the origin of the muscle. Both ends of the Y-shaped tape were terminated without tension on the lateral epicondyle.
62408714|NCT04518527|PLACEBO_COMPARATOR|sham taping+exercise|In the placebo group, the 10 cm I-shaped tape was placed 5 cm inferior to the lateral epicondyle using the same Kinesio tape in the study group. It was applied transversely, starting from the painless side of the midline on the forearm extensor face directing towards the lateral side of the forearm without a tension.
62790426|NCT00972530|NO_INTERVENTION|Activity|Normal activity without restrictions
62790427|NCT00972530|ACTIVE_COMPARATOR|immobilisation|48 hours postinjection rest
62790428|NCT02214290|ACTIVE_COMPARATOR|Caffeine|200 mg caffeine tablet produced by CVS Pharmacy, USA
62790429|NCT02214290|PLACEBO_COMPARATOR|Placebo|Placebo pill produced by NOW FOODS, USA
62790430|NCT02214290|EXPERIMENTAL|L-citrulline|L-citrulline capsule (750 mg) provided by NOW FOODS
62790431|NCT05835180|EXPERIMENTAL|TVB-2640 50 mg - normal hepatic function|Healthy subjects with normal hepatic function receive 50 mg PO daily from Day 1 to Day 4
62790432|NCT05835180|EXPERIMENTAL|TVB-2640 50 mg - mild hepatic function|Subjects with mild hepatic impairment will receive 50 mg PO daily from Day 1 to Day 4
62790433|NCT05835180|EXPERIMENTAL|TVB-2640 50 mg - moderate hepatic function|Subjects with moderate hepatic impairment will receive 50 mg PO daily from Day 1 to Day 4
62790434|NCT05835180|EXPERIMENTAL|TVB-2640 50 mg - severe hepatic function|Subjects with severe hepatic impairment will receive 50 mg PO daily from Day 1 to Day 4
62790435|NCT03690895||Cases|
62790436|NCT01428531||Patients prescribed fondaparinux|
62212303|NCT05335551||Patients monitored with TruGraf/TRAC Liver testing|"Subjects in the biomarker arm will have TruGraf Liver and TRAC Liver testing at study enrollment (1-2 months post-liver transplant) and thereafter every month for 6 months. Subjects will also have Trugraf Liver and TRAC Liver testing at months 9 and 12 following transplantation (7-8 and 10-11 months postbaseline)~The TruGraf and TRAC Liver results will be used in the biomarker arm in conjunction with all other clinical parameters available to guide decisions of the Principal Investigator and Sub-Investigators related to immunosuppression management.~changes."
62408715|NCT05527301|EXPERIMENTAL|HEM1036 (Lactobacillus fermentum)|Daily dose of 1 × 10\^10 colony-forming units divided in 2 equal doses as a powder for BID oral administration
62790437|NCT04847765|EXPERIMENTAL|Combined pressure measurement and MRI|Gastric motility is evaluated simultaneously by means of the investigational medical device and by means of cine-MRI.
62790438|NCT01626092|EXPERIMENTAL|Intent-To-Treat Patients|Patients with high-risk lysosomal and peroxisomal disorders treated with preparative regimen (Campath-1H 0.3 mg/kg intravenous (IV) on days -12 through -8, clofarabine 40 mg/m\^2 IV on days -9 through -5, melphalan 140 mg/m\^2 IV on day -4 and Total Body Irradiation with Marrow Boosting \[ first dose of 200 cGy single dose; 5 doses of 160cGy for marrow boosting - 1000cGy cumulative exposure\] by Volumetric-Modulated Arc Therapy \[VMAT\] on days -3 through -1). Hematopoietic stem cell transplantation will be infused on Day 0. Post-transplant immunosuppression to follow: Mycophenolate mofetil (MMF) begin day -3 and continue to day +30 or 7 days after engraftment, whichever is later; Cyclosporine A (CsA) begin day -3 and then taper at day +100 if related donor, day +180 for unrelated donor.
62790439|NCT03991455|OTHER|Apyx device treatment|The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system. Using the device, SSLF can be performed transvaginally without the need for any incisions or blind dissections and without the requirement of heavy anesthesia.
62790440|NCT04926246|EXPERIMENTAL|Part 1: R1-T2-T4-T1-T3|
62790441|NCT04926246|EXPERIMENTAL|Part 1: T1-T4-T2-T3-R1|
62790442|NCT04926246|EXPERIMENTAL|Part 1: T2-T1-T3-R1-T4|
62790443|NCT04926246|EXPERIMENTAL|Part 1: T3-R1-T1-T4-T2|
62790444|NCT04926246|EXPERIMENTAL|Part 1: T4-T3-R1-T2-T1|
62790445|NCT04926246|EXPERIMENTAL|Part 2: R2-T7-T6-T5|
62790446|NCT04926246|EXPERIMENTAL|Part 2: T5-T6-T7-R2|
62790447|NCT04926246|EXPERIMENTAL|Part 2: T6-T5-R2-T7|
62212304|NCT05335551||Patients not monitored with TruGraf/TRAC Liver testing|Patients in control/ stamdard of care arm will have immusuppresion reduction based on the clinical judgement and management of the Principal Investigator and Sub-Investigators.
62212305|NCT05910151||reference group A|healthy newborns aged 1-7 days
62408716|NCT05527301|PLACEBO_COMPARATOR|Placebo|2g Powder for BID oral administration
62584321|NCT06236607|EXPERIMENTAL|BetaBionics iLet HCL system|Participants randomized into this arm will use the BetaBionics iLet HCL system.
62584322|NCT06236607|EXPERIMENTAL|Insulet OP 5 HCL system|Participants randomized into this arm will use the Insulet OP 5 HCL system.
62584323|NCT06236607|EXPERIMENTAL|Tandem Control IQ HCL system|Participants randomized into this arm will use the Tandem Control IQ HCL system.
62790448|NCT04926246|EXPERIMENTAL|Part 2: T7-R2-T5-T6|
62790449|NCT04926246|EXPERIMENTAL|Part 3: R3-T10-T9-T8|
62790450|NCT04926246|EXPERIMENTAL|Part 3: T8-T9-T10-R3|
62212306|NCT05910151||reference group B|healthy children aged 8 days - 7 years
62212307|NCT05910151||reference group C|healthy children aged 8 - 18 years
62212308|NCT05910151||selective group A|children aged 1 day - 7 days suspected with IEM
62212309|NCT05910151||Selective group B|children aged 8 days - 7 years suspected with IEM
62790451|NCT04926246|EXPERIMENTAL|Part 3: T9-T8-R3-T10|
62790452|NCT04926246|EXPERIMENTAL|Part 3: T10-R3-T8-T9|
62790453|NCT00943332||spica casting|
62790454|NCT00943332||intramedullary nailing|
62790455|NCT00943332||submuscualr plating|
62790456|NCT01661894|ACTIVE_COMPARATOR|Intervention|Subjects will undergo the BrainpalTM intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the BrainpalTM treatment in the first 8 weeks of the trial.
62790457|NCT01661894|NO_INTERVENTION|Wait-List Control|The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards. They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.
62212310|NCT05910151||Selective group C|children aged 8-18 years suspected with IEM
62212311|NCT01737424|PLACEBO_COMPARATOR|Placebo|Placebo
62212312|NCT01737424|EXPERIMENTAL|LC28-0126|LC28-0126(IV)
62408717|NCT01100073||Patients with Parkinson's disease|Early and advanced Parkinson's disease patients
62408718|NCT02064127||Patients with abdominal pain|Adult patients admitted to the Emergency Department with a main complaint of abdominal pain
62408719|NCT02590146|EXPERIMENTAL|Intervention Group|Patients in this group will participate in pain management counseling and choose non-pharmacologic pain control supports to use during their procedure in addition to the standard of care pain management offered in the office
62408720|NCT02590146|NO_INTERVENTION|Control group|Patients in this group will receive standard of care pain management offered in the office.
62408721|NCT00106613|EXPERIMENTAL|FK228 (romidepsin)|13 mg/m2 of romidepsin
62584324|NCT06665191||Middle aged Adults NOT suffering from dental wear|Middle aged Adults NOT suffering from dental wear attending dental educational hospital in Cairo University
62790458|NCT03464019|EXPERIMENTAL|Part 1: Etripamil 70 mg Single Dose|Self-administration of a single dose etripamil 70 mg for a perceived episode of PSVT.
62790459|NCT03464019|PLACEBO_COMPARATOR|Part 1: Placebo Single Dose|Self-administration of a single dose of placebo for a perceived episode of PSVT.
62790460|NCT03464019|OTHER|Part 1: Test dose only (etripamil 70 mg)|Single test dose of etripamil 70 mg in sinus rhythm
62020042|NCT00363714|EXPERIMENTAL|1|Single intravitreal injection
62020043|NCT00363714|EXPERIMENTAL|2|Single intravitreal injection
62584325|NCT06665191||Middle aged adults Suffering from dental wear|Middle aged adults Suffering from dental wear attending dental educational hospital in Cairo University
62020044|NCT00363714|EXPERIMENTAL|3|Single intravitreal injection
62408722|NCT02297438|EXPERIMENTAL|Palbociclib + Letrozole|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously)
62212313|NCT00784940|ACTIVE_COMPARATOR|1|Arimidex 1mg + Nolvadex placebo
62212314|NCT00784940|ACTIVE_COMPARATOR|2|Arimidex placebo + Nolvadex 20mg
62408723|NCT02297438|ACTIVE_COMPARATOR|Placebo + Letrozole|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
62408724|NCT05401773|EXPERIMENTAL|COVID-19 patients with olfactory dysfunction|
62408725|NCT05401773|EXPERIMENTAL|COVID-19 patients without olfactory dysfunction|
62790461|NCT03464019|EXPERIMENTAL|Part 2 & Part 3: Etripamil 70 mg with Optional Second Dose|Self-administration of 70 mg etripamil for a perceived episode of PSVT followed 10 minutes later by an optional second dose of 70 mg etripamil, if symptoms persisted. Participants could be enrolled in the open-label period to treat an additional PSVT episode with etripamil.
62408726|NCT05401773|EXPERIMENTAL|Healthy controls|
62408727|NCT05401773|EXPERIMENTAL|Patients with Parkinson's disease|
62408728|NCT00540735|EXPERIMENTAL|1|PDT
62408729|NCT00540735|NO_INTERVENTION|2|
62408730|NCT00905476||NPPV|Patients with chronic respiratory failure receiving domiciliary NPPV
62408731|NCT02688179||Cardiac surgery patients|
62408732|NCT06338176|EXPERIMENTAL|OPTIMUS-SAB care pathway|Province-wide real time automated notifications of new SAB cases will be established and delivered to a centralized SAB care team electronically through Connect Care. The centralized SAB care team consists of a SAB clinical coordinator, ID specialists and other ad hoc representation depending on patient needs. Following patient chart review, the centralized SAB care team contacts the most responsible physician (MRP) to provide preliminary recommendations to optimize care, both verbally and in written format, facilitated by Connect Care (Alberta Health Services electronic medical record).
62584326|NCT03927261|EXPERIMENTAL|Dose Escalation and Dose Expansion of PRGN-3006|Participants will be treated in dose expansion phase to evaluate the safety and efficacy of the identified dose of PRGN-3006.
62790462|NCT03464019|PLACEBO_COMPARATOR|Part 2 & Part 3: Placebo with Optional Second Dose|Self-administration of placebo for a perceived episode of PSVT followed 10 minutes later by an optional second dose of placebo, if symptoms persisted. Participants could be enrolled in the open-label period to treat an additional PSVT episode with etripamil.
62790463|NCT03464019|OTHER|Part 2 & Part 3: Test dose only (etripamil 70 mg + 70 mg)|Repeat Test Dose of etripamil 70 mg (2X 70mg) 10 minutes apart in sinus rhythm
62790464|NCT06259994||women treated with dexamethasone during pregnancy at risk of Congenital Adrenal Hyperplasia|All women treated with DEX during pregnancy at risk of Congenital Adrenal Hyperplasia over the defined period (retrospective and prospective).
62790465|NCT03703089|EXPERIMENTAL|Gemcitabine and Nab-Paclitaxel|Participants received albumin-bound paclitaxel 125 mg/m\^2 followed by gemcitabine 1000 mg/m\^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle.
62408733|NCT06338176|NO_INTERVENTION|Standard of care|
62408734|NCT02676232|EXPERIMENTAL|Intervention|Participants in this arm will follow DARWeb: an online psychosocial intervention for children with recurrent abdominal pain and their parents. This is composed by 7 units for parents and 7 units for children, that have been developed from the cognitive-behavioral model, including setting goals, relaxation and distraction techniques, changing maladaptive thoughts and assertive communication training. The team under the program only contact with families for sending reminders and to answer potential technical problems or doubts
62408735|NCT02676232|NO_INTERVENTION|Control|Participants allocated in this arm will not receive intervention. However, they will be invited to participate once the families allocated to the experimental group complete the program.
62584327|NCT01335048|EXPERIMENTAL|Atorvastatin-Clopidogrel group|Patients who receive Atorvastatin 80 mg/day and Clopidogrel 150 mg/day
62584328|NCT01335048|ACTIVE_COMPARATOR|Clopidogrel group|Patients who receive clopidogrel 150 mg daily
62584329|NCT05761184||Steatosis grade 2-3|Subjects with Prader-Willi syndrome and with steatosis grade 2-3
62584330|NCT05761184||Steatosis grade 0-1|Subjects with Prader-Willi syndrome and with steatosis grade 0-1
62020045|NCT00363714|EXPERIMENTAL|4|Single intravitreal injection
62020046|NCT00363714|EXPERIMENTAL|5|Single intravitreal injection
62020047|NCT00363714|EXPERIMENTAL|6|Single intravitreal injection
62020048|NCT00875394|EXPERIMENTAL|1|sitagliptin + metformin
62020049|NCT00875394|ACTIVE_COMPARATOR|2|metformin + any other oral antidiabetic drug
62020050|NCT00875394|ACTIVE_COMPARATOR|3|metformin
62212315|NCT00784940|ACTIVE_COMPARATOR|3|Arimidex 1mg + Nolvadex 20mg
62212316|NCT04512703||Healthy Group|Healthy male and female volunteers. Subjects older than 21 years of age. Subjects to wear the µCor device for up to 30 days.
62212317|NCT04512703||Arrhythmia Monitoring Group|Patients with a clinical indication for outpatient cardiac monitoring. Subjects older than 21 years of age. Subjects to wear the µCor device for up to 90 days.
62408736|NCT06566092|EXPERIMENTAL|Rhabdomyosarcoma (RMS)|
62408737|NCT06566092|EXPERIMENTAL|Ewing Sarcoma (EWS)|
62408738|NCT06566092|EXPERIMENTAL|Primary Central Nervous System Tumor|
62408739|NCT06566092|EXPERIMENTAL|Melanoma|
62584331|NCT02985645|EXPERIMENTAL|Treatment|maxillary sinus augmentation with CGF
62212318|NCT04512703||Front Position Devices|All devices placed in the front position
62212319|NCT04512703||Side Position Devices|All devices placed in the side position
62212320|NCT04585867|ACTIVE_COMPARATOR|Liposomal bupivacaine|Exparel (266mg) given by surgeon just prior to sternal closure
62212321|NCT04585867|ACTIVE_COMPARATOR|Bupivacaine|40ml of 0.125% bupivacaine given by surgeon just prior to sternal closure
62212322|NCT04712695|EXPERIMENTAL|Graded Motor Imagery Group|
62212323|NCT04712695|EXPERIMENTAL|Mirror Visual Feedback Group|
62212324|NCT04712695|EXPERIMENTAL|Augmented Biofeedback Group|
62212325|NCT04712695|SHAM_COMPARATOR|Diaphragmatic Breathing Group|
62212326|NCT06273059||Diabetic patients and Healthy controls|Diabetic patients and Healthy controls
62408740|NCT04690946|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|14-18 sessions of psychotherapy according to principles of Cognitive Behavioral Therapy
62408741|NCT04690946|ACTIVE_COMPARATOR|Emotion-Focused Therapy|14-18 sessions of psychotherapy according to principles of Emotion Focused Therapy
62584332|NCT03118362|EXPERIMENTAL|Plasmalyte®|Plasmalyte® is a balanced solution containing a low chloride concentration (i.e. 98 mmol/L), it also contains acetate (27 mmol/L) and gluconate (23 mmol/L) as buffer solutions.
62790466|NCT03239080|ACTIVE_COMPARATOR|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
62790467|NCT03239080|PLACEBO_COMPARATOR|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
62408742|NCT06653192|ACTIVE_COMPARATOR|ERCP with SEMS|"Endoscopic retrograde cholangiopancreatography (ERCP) with deployment of a self-expandable metallic stent (SEMS). Gold standard in malignant distal biliary obstruction (MDBO) in current practice.~ERCP technique: Cannulation with papillotome (advanced cannulation techniques are allowed). Sphincterotomy. Self-expandable metallic stent (SEMS) deployment."
62584333|NCT03118362|EXPERIMENTAL|Ringer Lactate®|Ringer Lactate® is a balanced solution containing a low chloride concentration (i.e. 111mmol/L), it also contains lactate (29 mmol/L) as buffer solutions.
62584334|NCT02959021|ACTIVE_COMPARATOR|Self-directed treatment|Participants randomly assigned to this arm will receive written and pre-recorded behavioral weight loss intervention materials (i.e., DVDs, online videos), and they will be instructed to work through the materials independently at their own pace. They will have continued physician contact as needed for routine medical care.
62790468|NCT00535002|OTHER|Cocaine Females, Yohimbine then Placebo|Cocaine dependent females, received yohimbine day 1 and placebo day 2
62790469|NCT00535002|OTHER|Cocaine Females, Placebo the Yohimbine|Cocaine dependent females, received placebo day 1 and yohimbine day 2
62790470|NCT00535002|OTHER|Cocaine Males, Yohimbine then Placebo|Cocaine dependent males, received yohimbine day 1 and placebo day 2
62790471|NCT00535002|OTHER|Cocaine Males, Placebo thenYohimbine|Cocaine dependent males, received placebo day 1 and yohimbine day 2
62020051|NCT02409485|EXPERIMENTAL|Couples Skill-Training (CST)|CST provides education about acute and long-term side-effects of HNC and teaches: 1) self-management skills to control/prevent side-effects; 2) communication skills to facilitate coordination of care; and, 3) strategies to improve communal coping and confidence in the ability to work as a team.
62020052|NCT02409485|NO_INTERVENTION|Usual Medical Care (UMC)|Patients receive standard symptom management education by their health care team.
62020053|NCT01601301|EXPERIMENTAL|PRECICE System|
62790472|NCT00535002|OTHER|Control Females, Yohimbine then Placebo|Non-dependent females, received yohimbine day 1 and placebo day 2
62790473|NCT00535002|OTHER|Control Females, Placebo then Yohimbine|Non-dependent females, received placebo day 1 and yohimbine day 2
62790474|NCT00535002|OTHER|Control Males, Yohimbine then Placebo|Non-dependent males, received yohimbine day 1 and placebo day 2
62790475|NCT00535002|OTHER|Control Males, Placebo then Yohimbine|Non-dependent males, received placebo day 1 and yohimbine day 2
62790476|NCT06334640||Subjects with glaucoma and macular degeneration|Adults subjects affected by glaucoma and macular degeneration
62790477|NCT06334640||Healthy volunteers|Adult healthy volunteers without eye disease
62790478|NCT00870012|ACTIVE_COMPARATOR|Lepicol probiotic & prebiotic formula+simple lifestyle advice|
62790479|NCT00870012|PLACEBO_COMPARATOR|Simple lifestyle advice alone|
62790480|NCT00414518|EXPERIMENTAL|Treatment interruption|Oral Tenofovir disoproxil fumarate/Emtricitabine and Lopinavir/Ritonavir for 12 weeks followed by treatment interruption if CD4 count is 450 mm\^3 or higher. When CD4 count is less than 350 mm\^3 on two separate, consecutive measurements during treatment interruption, therapy will be resumed.
62212327|NCT03664362|EXPERIMENTAL|The BSHAPE Intervention|Participants in the BSHAPE intervention attend a 9 sessions program post-assessments which is a combination of individualized and group-based sessions.
62408743|NCT06653192|EXPERIMENTAL|EUS-CDS with LAMS-Pigtail|"Echoendoscopy-guided Choledochoduodenostomy (EUS-CDS) with deployment of a lumen-apposing metal stent (LAMS) and axis-orienting double-pigtail plastic stent throug LAMS.~EUS-CDS technique: Diagnostic EUS. Classic or free-hand with preloaded guidewire choledochoduodenostomy with LAMS. Pneumatic dilation whithin LAMS is allowed. In case of bile duct \< 15mm is mandatory the 'push' technique. Deployment of a pigtail coaxial to LAMS."
62584335|NCT02959021|EXPERIMENTAL|Peer coach treatment|Participants randomly assigned to this arm will receive a combination of in-person, group-based behavioral weight loss sessions plus individual, telephone contacts. Groups and phone calls will be facilitated by a peer coach interventionist. Similar to the self-directed condition, participants will receive written and pre-recorded intervention materials (i.e., DVDs, online videos). They will also have continued contact with their physician for routine medical care.
62584336|NCT06683521|EXPERIMENTAL|Cohort 1|"Participants will be sequentially enrolled into 3 cohorts of 24 each.~The first cohort will undergo Low Dose OFC to 300 mg food protein. Following interim analysis of Low Dose OFC outcomes in cohort 1, the Low Dose OFC serving size may be amended or continued at 300 mg food protein for cohort 2 \& 3 based on pre-specified criteria."
62020054|NCT05706558||Circumferential resection margin (CRM)|Participants will have a diagnosis of esophageal carcinoma and residual tumor \>1 mm from the CRM
62020055|NCT05706558||Circumferential resection margin (CRM)-close|Participants will have a diagnosis of esophageal carcinoma and residual tumor \>0-1 mm from the CRM
62408744|NCT00285012|PLACEBO_COMPARATOR|placebo|
62020056|NCT05706558||Circumferential resection margin (CRM)+|Participants will have a diagnosis of esophageal carcinoma and residual tumor at the surgical CRM
62212328|NCT03664362|NO_INTERVENTION|Usual care or no treatment control|Participants in the control arm either are receiving no services or are engaged in usual care provided by community-based/health care organizations
62212329|NCT00112827|EXPERIMENTAL|Arm I|See Detailed Description
62408745|NCT00285012|EXPERIMENTAL|varenicline|
62790481|NCT00414518|EXPERIMENTAL|CD4 T cell guided therapy|Anti Retroviral Therapy initiated when AIDS-defining illness occurs or if CD4 count is confirmed at less than 350 mm\^3 at two separate, consecutive measurements
62215224|NCT05531162|OTHER|Microgravity condition|a group of parabolic flyers exposed to micro and partial gravity
62215225|NCT03229070|NO_INTERVENTION|Control Group|Control Group: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) and assessments at discharge
62408746|NCT01797068|EXPERIMENTAL|Patient Navigator|Patients in the experimental group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH).
62584337|NCT06683521|EXPERIMENTAL|Cohort 2|"Participants will be sequentially enrolled into 3 cohorts of 24 each.~Following interim analysis of Low Dose OFC outcomes in cohort 1, Low-Dose OFC may be continued at 300 mg food protein or be amended for cohort 2 and 3 based on pre-specified criteria."
62215226|NCT03229070|EXPERIMENTAL|Interval effort group|Interval effort group: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Active phase (high load) lasting 60 seconds, followed by an active recovery phase with light / moderate load (60% of the maximum load) lasting 4 minutes. The pedaling speed should be maintained between 30-60rpm. There will be 5 cycles that will total 20 minutes of physical effort, and assessments at discharge.
62584338|NCT06683521|EXPERIMENTAL|Cohort 3|"Participants will be sequentially enrolled into 3 cohorts of 24 each.~Following interim analysis of Low Dose OFC outcomes in cohort 1, Low-Dose OFC may be continued at 300 mg food protein or be amended for cohort 2 and 3 based on pre-specified criteria."
62584339|NCT02562469|EXPERIMENTAL|ACTIVATE|ACTIVATE is a computerized neurocognitive training program (ACTIVATE; see: www.c8sciences.com) that simultaneously targets eight core neurocognitive factors (i.e., sustained attention, working memory (WM), response inhibition, speed of information processing, cognitive flexibility and control, multiple simultaneous attention, category formation, and pattern recognition and inductive thinking). ACTIVATE Is completed at home via computer with parent support. ACTIVATE intervention is conducted 3-5 times per week for between 20-30 minutes over the course or 3-4 months.
62584340|NCT06525805|EXPERIMENTAL|Long Abstract|Abstract length: 771 words
62584341|NCT06525805|ACTIVE_COMPARATOR|Short Abstract|Abstract length: 277 words
62584342|NCT06683326|EXPERIMENTAL|Study group|Trainees viewing live broadcasting of the ESD screen, with live explanations by the expert and simultaneous viewing of the expert hands and fingers motion broadcasted by the ROKOKO smart-glove.
62790482|NCT01768364|ACTIVE_COMPARATOR|Antibiotics|will receive antibiotics
62790483|NCT01768364|ACTIVE_COMPARATOR|No antibiotics|will not receive antibiotics
62790484|NCT05846373|ACTIVE_COMPARATOR|Nicotinic Acid Extended-release tablet 500 mg arm|This arm includes 22 Migraine patients receiving beta blocker
62790485|NCT05846373|ACTIVE_COMPARATOR|Nicotinic Acid Extended-release tablet 1000 mg arm|This arm includes 22 Migraine patients receiving beta blocker
62790486|NCT05846373|PLACEBO_COMPARATOR|Control arm|This arm includes 22 Migraine patients receiving beta blocker
62790487|NCT04099121|OTHER|Patients with Pelvic Organ Prolapse|Patients who meet the inclusion criteria will be recruited. Ultrasound images of the pelvic floor and vaginal cavity will be analyzed to predict pessary size and type. This will be compared against the pessary size and type being used already by the patient.
62790488|NCT03325374||BLB patients|Patients admitted for urgent MRI with possible cauda equina syndrome will be consented for questionnaires and examination.
62584343|NCT06683326|NO_INTERVENTION|Control group|Control group, trainees viewing live broadcasting of the ESD screen, with live explanations by the expert
62212330|NCT00953745|ACTIVE_COMPARATOR|Depressed Participants|"Subjects with treatment-resistant depression (TRD) will be administered the Hamilton Depression Rating Scale (HAM-D 17) for entry and will receive escitalopram combined with an adjunctive placebo capsule for 8 weeks.~Subjects who fail to respond will continue to receive escitalopram and additionally change to receive a placebo tablet resembling the active augmentation agent Aripiprazole (ARP) for 2 weeks.~Subjects who fail to respond to escitalopram after the 2 phase placebo treatment will enter the ARP augmentation phase of the study and will receive escitalopram augmentation with ARP.~Subjects will have 3 neuroimaging scans: F-DOPA PET, raclopride PET, and functional MRI conducted after 10 weeks of treatment and repeated after 6 weeks of ARP treatment."
62408747|NCT01797068|ACTIVE_COMPARATOR|Standard of Care|Patients in the active comparator group will experience the usual intake process in the ED setting.
62584344|NCT01054092|EXPERIMENTAL|before meal group|ASP1941 will be administered before meal
62790489|NCT01821859|EXPERIMENTAL|Abraxane/Bevacizumab|"Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.~Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion."
62790490|NCT03606187|EXPERIMENTAL|Test Arm|Subjects randomized to this arm will receive test treatment
62790491|NCT03606187|ACTIVE_COMPARATOR|Control Arm|Subjects randomized to this arm will receive control treatment
62790492|NCT00834262||A|
62790493|NCT02369393|EXPERIMENTAL|Behavioral Activation|BA treatment for depression is a simple, cost-effective method. There is evidence that the behavioral component may be the active mechanism of change in cognitive-behavioral treatments of clinical depression. One of the main objectives of the treatment is to systematically increase exposure to positive activities, and thereby improve affect and corresponding cognitions. Treatment will be delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components are: 1) psycho-education, 2) identifying important values and significant activities, 3) activity structuring and scheduling, 4) relapse prevention. These will be delivered over 4 modules. There will be a minimal therapist support.
62790494|NCT02369393|NO_INTERVENTION|Waiting list control group|In the waiting list control group (WL), subjects will receive no treatment during 8 weeks. We will not interfere but we will monitor carefully through self-report. Then participants will be randomised to the two treatment groups.
62584345|NCT01054092|EXPERIMENTAL|after meal group|ASP1941 will be administered after meal
62790495|NCT02369393|EXPERIMENTAL|Physical Activity|There is evidence to suggest that the addition of cognitive behavioral therapies, specifically exercise, can improve treatment outcomes for many patients. Exercise is a behavioral intervention that has shown great promise in alleviating symptoms of depression. The treatment will be delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the PA treatment are: 1) psychoeducation: understand the mental health benefits of physical activity, 2) learn about the types and amounts of physical activity recommended, 3) motivation to perform and maintain physical activities, 4) relapse prevention. These will be delivered over 4 modules. There will be a minimal therapist support.
62790496|NCT01413139|OTHER|4F portfolio products from Biotronik|The devices under investigation are the 4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18 and Cruiser-18.
62408748|NCT04385719|EXPERIMENTAL|Study A Sequence 1|"Single dose remdesivir 150mg IV on Day 1~Wash out period Day 2-7~TDF/3TC 300/300mg tablets OD from Day 8-14 single dose remdesivir 150mg IV on Day 14"
62408749|NCT04385719|EXPERIMENTAL|Study A Sequence 2|"TDF/3TC 300/300mg tablets OD from Day 1-7 single dose remdesivir 150mg IV on Day 7~Wash out period Day 8-14~Single dose remdesivir 150mg IV on Day 15"
62408750|NCT04385719|EXPERIMENTAL|Study B|TDF/3TC/ATV/r 300/300/300/100mg tablets OD from Day 1-7 single dose remdesivir 150mg IV infusion on Day 7
62790497|NCT05254483|EXPERIMENTAL|Intervention group (IG)|Receiving exercise program immediately
62790498|NCT05254483|ACTIVE_COMPARATOR|Waitlist Control Group (WCG)|Receiving exercise program after 12 week wait.
62790499|NCT04583332|OTHER|Rhymes, Individual Items in Rhymes, Objects|Existing method Post intervention
62408751|NCT06103656|EXPERIMENTAL|Active Comparator::Chinese Herbal Medication|"Interventions:~- Drug: Chinese Herbal Medication (E-B-FAHF-2), dose level was determined using the subject's weight at the screening visit (\>20-30 kg = 5 capsules daily, \>30-70 kg = 8 capsules daily, and \>70 kg = 10 capsules daily)"
62408752|NCT06103656|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|"Interventions:~* Drug: Placebo. Placebo capsules were identical in appearance but contained corn starch~* Drug: Omalizumab. Omalizumab was dosed as per the product insert~* Drug: Multi OIT. An initial rush dose to a maximum of 250 mg of protein of each allergen (total 270 mg of protein) and up-dosing every 2 weeks until the maintenance dose of 1000mg was reached."
62408753|NCT06054750|EXPERIMENTAL|cACB active|Periarticular joint injection (medication) + single shot adductor canal block (medication) + adductor canal catheter infusion (medication)
62790500|NCT01598467|OTHER|Women with pelvic organ prolapse|Women with pelvic organ prolapse (simplified POP-Q \> stage 1)
62790501|NCT03036969||Non-urgent emergencies|Outpatients in the Emergency Department with the MTS-Triage category blue, green or yellow
62408754|NCT06054750|PLACEBO_COMPARATOR|cACB sham|Periarticular joint injection (medication) + single shot adductor canal block (medication) + adductor canal catheter infusion (normal saline)
62408755|NCT02098707||30 Parkinson disease patients|30 patients (12 M, 18 F, mean age 66,8 ± 8,7) diagnosed with PD in stage 3 of Hoen\&Yahr (mean Unified Parkinson Disease Rating Scale \[UPDRS\] III 18.8±10.5) will undergo a balance training using a stabilometric platform.
62408756|NCT00714909||1|
62020057|NCT05095584|EXPERIMENTAL|validity and reliability of 3 meter backward walking test|"This study was conducted as test-retest design and the psychometric properties of 3-m backward walk test were examined in LLA. The Rivermead Mobility Index, 3-m backward walk test, Berg Balance Scale, Timed Up and Go test were applied to the patients. An experienced physiotherapist performed all these tests. In order to measure test-retest reliability, the second evaluations (retest) were carried out by the same physiotherapist two days following the first evaluation (test). A same evaluator collected data in order to avoid the inter-rater variability error rate between the evaluations. The patient was evaluated at one time of the day for test and retest."
62020058|NCT01114646|OTHER|Cemented Hip Hemiarthroplasty|This arm received a hemiarthroplasty with a cemented femoral prosthesis (VerSys LD/Fx, Zimmer, Warsaw, IN).
62020059|NCT01114646|EXPERIMENTAL|Press-Fit Hip Hemiarthroplasty|This arm received a press-fit hemiarthroplasty (VerSys Beaded FullCoat, Zimmer, Warsaw, IN),
62020060|NCT05814341|EXPERIMENTAL|High iCa target|Post-filter iCa between 0,35-0.45 mmol/L
62020061|NCT05814341|ACTIVE_COMPARATOR|Low iCa target|Post-filter iCa between 0.25-0.35 mmol/L
62020062|NCT04770714|OTHER|Breast MRI|Patients in this arm will be randomized to receive a Breast MRI in order to delineate the extent of a known cancer and / or assess for the presence of occult secondary cancers
62020063|NCT04770714|OTHER|Contrast Enhanced Mammography|Patients in this arm will be randomized to receive a Contrast Enhanced Mammograph in order to delineate the extent of a known cancer and / or assess for the presence of occult secondary cancers
62020064|NCT01754558|EXPERIMENTAL|Ajust sling|The sling a a new device for stress urinary incontinence. The sling is ajustable and is not penetrating the skin, i.e. is only attached to the obturator membrane
62020065|NCT01754558|EXPERIMENTAL|TVT/TVT-O, polypropylne slings|TVT/TVT-O system. These two systems is wellknown and used for treatment of stress urinary incontinence. The sling penetrate the skin in order to secure adjustment.
62020066|NCT05117606|OTHER|Vitalsigns|Data from patients (heart rate, respiration, movement, blood pressure) is measured with traditional, standard hospital equipment in parallell with data from LYNG mat captured non-intrusively in the same session.
62020067|NCT04574544|EXPERIMENTAL|Zinc supplementation|The 25 supplemented children had received an oral dose of 10 mg of zinc sulphate per day for 14 days
62020068|NCT04574544|EXPERIMENTAL|Nutrition education of mothers|Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
62020069|NCT05075252||R1|patients affected by acute appendicitis undergoing totally laparoscopic appendectomy
62020070|NCT06439758|EXPERIMENTAL|Metformin|Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose.
62020071|NCT06439758|PLACEBO_COMPARATOR|Lifestyle|The effect is when a person's physical or mental health appears to improve after changing their diary system.
62212331|NCT00953745|NO_INTERVENTION|Control Participants|Non-depressed, age- and sex-matched subjects without a DSM-IV Axis I diagnosis will serve as controls. They will not receive antidepressant, ARP, or any drug augmentation and will be used as quality control to compare the pre-ARP and post-ARP treatment brain images.
62212332|NCT02440945|EXPERIMENTAL|collection of blood|160 old people for the collection of blood
62212333|NCT02169544||RA patients who are prescribed Abatacept|Abatacept
62212334|NCT02169544||Patients who are prescribed other RA treatments|
62212335|NCT03788759|EXPERIMENTAL|Experimental group|25 subjects will be randomized to 100mg of alpha-lipoic acid.
62212336|NCT03788759|PLACEBO_COMPARATOR|Placebo group|25 subjects will be randomized to placebo.
62212337|NCT03387748|EXPERIMENTAL|Gesture elicitation|Observation: hand gesture elicitation task
62212338|NCT01871805|EXPERIMENTAL|Alectinib: Phase I (Dose Escalation)|Participants will receive escalating doses of alectinib capsules orally until disease progression, death or withdrawal for any other reasons.
62020072|NCT06283758|EXPERIMENTAL|Stage 1: Intervention group|"This arm is combined with 3 groups and a total of 30 participants will be 1:1:1 allocated (each group with 10 participants).~Single treatment group: receive treatment once after enrollment; Consecutive treatment group A: receive 3 consecutive treatments, each with an interval of 3 days; Consecutive treatment group B: receive 3 consecutive treatments, each with an interval of 7 days. In Stage 1, the investigators will select optimal treatment strategy and proceed to Stage 2."
62020073|NCT06283758|ACTIVE_COMPARATOR|Stage 2: Intervention group|Participants will receive optimal treatment strategy selected formerly in Stage 1
62020074|NCT06283758|SHAM_COMPARATOR|Stage 2: Sham-control group|In sham control group, participants will receive the sham control therapy (including peri-renal fat ultrasonic measurement and localization, focused ultrasound treatment parameters setting), however, without initiating the focused ultrasound equipment.
62020075|NCT04455919|EXPERIMENTAL|Yoga|Yoga classes once a week for eight weeks
62020076|NCT04455919|OTHER|Wait-list control|The delayed intervention group was to benefit from the intervention after week 8.
62408757|NCT00401414|EXPERIMENTAL|Warfarin|We will develop a nomogram for warfarin dosing that uses rapid turnaround genetic testing and monthly nomogram modification (if necessary) to achieve effective and safe warfarin induction and maintenance. More than 70% of the time, we will maintain warfarin naïve patients within the target therapeutic range. The percent of time in the therapeutic range will be analyzed beginning 2 weeks after initiation of warfarin. Analyses will be stratified by the indication for anticoagulation.
62408758|NCT04936568|NO_INTERVENTION|control|standard oncology care
62408759|NCT04936568|EXPERIMENTAL|intervention|standardized referral to outpatient palliative care by oncologists
62790502|NCT06402006|EXPERIMENTAL|Combined hip joint PENG block and LFCN block|Combined hip joint pericapsular nerve group block(PENG) and lateral femoral cutaneous nerve block
62790503|NCT06402006|EXPERIMENTAL|ESP block|Erector spinae plane block(ESP)
62790504|NCT04138446|EXPERIMENTAL|200-3000|Day 1: 200m (above sea level) asl Day 2: 3000m asl
62020077|NCT04191759|EXPERIMENTAL|Test-Retest reproducibility group|Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
62020078|NCT01747681||Microfracture|Microfracture of articular chondral defect
62020079|NCT04199247|EXPERIMENTAL|Exercise|Within 1 week of injury, participants will be randomized to either a sub symptom threshold exercise program (intervention group) or usual care (recommendation from their doctor). Those in the intervention group will participate in an exercise program 5x/week, 20-30 minutes/session, for 2 months.
62020080|NCT04199247|NO_INTERVENTION|Usual Care|Participants will continue with their return to play progression based upon the advice given to them at their initial post-injury evaluation.
62020081|NCT05495503|EXPERIMENTAL|Prototype (814A-v1)|Application of the prototype (814A-v1) at D0 and D7.
62020082|NCT05495503|EXPERIMENTAL|Prototype (814B-v1)|Application of the prototype (814B-v1) at D0 and D7.
62790505|NCT04138446|EXPERIMENTAL|3000-200|Day 1: 3000m asl Day 2: 200m asl
62020083|NCT05495503|EXPERIMENTAL|Prototype (814C-v1)|Application of the prototype (814C-v1) at D0 and D7.
62790506|NCT04138446|EXPERIMENTAL|200-5000|Day 1: 200m asl Day 2: 5000m asl
62020084|NCT05495503|EXPERIMENTAL|Prototype (814D-v1)|Application of the prototype (814D-v1) at D0 and D7.
62020085|NCT02448615||Birth Cohort|The cohort will comprise approximately 1500 pregnant women and their unborn babies, enrolled to participate in the control arm of a cluster-randomized controlled intervention trial (NCT02208960).
62212339|NCT01871805|EXPERIMENTAL|Alectinib (Phase II: RP2 dose)|Participants will receive recommended Phase II dose as determined from Phase I until disease progression, death or withdrawal for any other reasons.
62212340|NCT04972305|EXPERIMENTAL|Exercise group|12 weeks exercise programme, 3 days a week Bicycle ergonomics will be applied.
62212341|NCT04972305|EXPERIMENTAL|Ergonomics group|Bicycle ergonomics will be applied.
62790507|NCT04138446|EXPERIMENTAL|5000-200|Day 1: 5000m asl Day 2: 200m asl
62212342|NCT04972305|NO_INTERVENTION|Control group|No Intervention
62212343|NCT05698576|EXPERIMENTAL|TPF-LITT ARM|partial gland ablation of the prostate using laser device and imaging fusion
62212344|NCT03716115|EXPERIMENTAL|Colostrum|Colostrum high protein powder (Neovite) given orally or through NG tube 1.5g daily, in addition to standard care following WHO guidelines for management of SAM.
62212345|NCT03716115|EXPERIMENTAL|GInNAC|N-Acetyl glucosamine (GInNAC). Given orally (1g three times daily) for 14 days, gradually increased from 0.5g to avoid osmotic diarrhoea, in addition to standard care following WHO guidelines for management of SAM.
62790508|NCT04138446|EXPERIMENTAL|3000-5000|Day 1: 3000m asl Day 2: 5000m asl
62790509|NCT04138446|ACTIVE_COMPARATOR|5000-3000|Day 1: 5000m asl Day 2: 3000m asl
62790510|NCT01546662|EXPERIMENTAL|E-RH-06 - Low Dose|1 Capsule twice daily
62790511|NCT01546662|EXPERIMENTAL|E-RH-06 - High Dose|2 capsules twice daily
62790512|NCT01546662|PLACEBO_COMPARATOR|Placebo ;|Placebo Comparator
62790513|NCT00292019||Robotic prostatectomy|Patients who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robotics.
62790514|NCT05791968|ACTIVE_COMPARATOR|DONATION GROUP|Participants will be measured before and after a standard blood bank donation (450 mL of whole blood withdrawal)
62790515|NCT05791968|SHAM_COMPARATOR|CONTROL GROUP|Participants will be measured before and after a sham blood donation (0 mL of whole blood withdrawal)
62212346|NCT03716115|EXPERIMENTAL|Teduglutide|Teduglutide s/c. Administration by subcutaneous injection (0.5mg/kg/day) daily for 14 days, in addition to standard care following WHO guidelines for management of SAM.
62212347|NCT03716115|EXPERIMENTAL|Budenoside|Budesonide 3mg orally daily for 14 days, then rapidly tapered, in addition to standard care following WHO guidelines for management of SAM.
62212348|NCT03716115|NO_INTERVENTION|Standard care|Standard care following WHO guidelines for management of SAM.
62212349|NCT01401777||Control, No PercuNav|Patient having procedure without PercuNav Guidance information
62212350|NCT01401777||PercuNav aided procedure|Biopsy procedure aided with use of PercuNav
62212351|NCT01815762|ACTIVE_COMPARATOR|active arm of the study|The number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. The US B-line score (BLS) will be measured before dialysis. In patients presenting moderate to severe lung congestion (≥15 BLS pre-dialysis) LUS measurements will be repeated once a week until the treatment goal was achieved (\<15 BLS pre-dialysis) and once a month thereafter. monthly monitoring frequency will be adopted also in patients without pulmonary congestion (BLS \<15). Patients without evidence of lung congestion at baseline who developed pulmonary congestion (≥ 15 BLS) during the trial will received the same treatment contemplated for those with lung congestion at baseline during the trial.
62212352|NCT01815762|NO_INTERVENTION|Standard care arm|In the control arm of the study, the dry weight will be assessed only clinically.Patients in the control arm of the study will be followed up and managed strictly with standard criteria according to current recommendations (implying optimization of fluids volume control on the basis of clinical criteria and the use of carvedilol, ACE inhibitors/sartans whenever deemed necessary); the use of lung US / bioimpedance assistance was not allowed in these patients.
62212353|NCT03428087||patients undergoing prostatic biopsy|Patients who are candidates for prostate biopsy as suffering from urinary symptoms accompanied by clinical suspicions such as high total PSA value and / or presence of prostate nodule and / or evidence of obvious lesion to available imaging methods.
62212354|NCT04677634|OTHER|Tolerability Arm|This is a single arm study. All subjects will receive the test material. The test material is ISOThrive. It is an approximately 90% pure maltosyl-isomalto-oligosacchride (MIMO) prebiotic syrup produced by bacterial fermentation/bio-conversion of sucrose and maltose. It is taken 1g daily for 30 days.
62212355|NCT03241108|EXPERIMENTAL|NI-0101|A therapeutic humanized monoclonal antibody, administered by intravenous infusion every 2 weeks.
62212356|NCT03241108|PLACEBO_COMPARATOR|Placebo|The placebo matches NI-0101 without active ingredient, administered by intravenous infusion every 2 weeks.
62212357|NCT03759431|EXPERIMENTAL|Vocal-cord Radiotherapy|
62212358|NCT03759431|ACTIVE_COMPARATOR|Complete Larynx Radiotherapy|
62212359|NCT03805087|EXPERIMENTAL|Coil embolization|Transarterial coil embolization of the superior rectal arteries via a transradial left arterial access.
62212360|NCT04737187|EXPERIMENTAL|Trifluridine/Tipiracil + Bevacizumab|Participants were administered 35 milligrams per square meter per dose (mg/m²/dose) trifluridine/tipiracil (FTD/TPI) orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on (Day 1 to 5 and Day 8 to 12) with 2 days off (Day 6 to 7 an Day 13 to 14), over 2 weeks, followed by a 14-day rest; with bevacizumab (5 milligrams per kilogram \[mg/kg\], intravenous \[IV\] infusion administered every 2 weeks (Day 1 and Day 15). This treatment cycle was repeated every 4 weeks.
62212361|NCT04737187|ACTIVE_COMPARATOR|Trifluridine/Tipiracil|Participants were administered 35 mg/m²/dose of FTD/TPI orally BID, within 1 hour after completion of morning and evening meals, 5 days on (Day 1 to 5 and Day 8 to 12) with 2 days off (Day 6 to 7 and Day 13 to 14), over 2 weeks, followed by a 14-day rest. This treatment cycle was repeated every 4 weeks.
62212362|NCT05003518|EXPERIMENTAL|Condition 1: Low Personalisation+Low Frequency|The intervention will have low levels of personalisation and one message a day will be sent to participants.
62212363|NCT05003518|EXPERIMENTAL|Condition 2: High Personalisation+Low Frequency|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname) and one message a day will be sent to participants.
62212364|NCT05003518|EXPERIMENTAL|Condition 3: Low Personalisation+High Frequency|The intervention will have low levels of personalisation and three messages a day will be sent to participants.
62212365|NCT05003518|EXPERIMENTAL|Condition 4: High Personalisation+High Frequency|The intervention will have high levels of personalisation and three messages a day will be sent to participants.
62212366|NCT05003518|EXPERIMENTAL|Condition 5: High Personalisation+Low Frequency+Gamification|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gamified progress updates, and one message a day will be sent to participants.
62212367|NCT05003518|EXPERIMENTAL|Condition 6: Low Personalisation+High Frequency+Gamification|The intervention will have low levels of personalisation, contains gamified progress updates, and three messages a day will be sent to participants.
62212368|NCT05003518|EXPERIMENTAL|Condition 7: High Personalisation+High Frequency+Gamification|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gamified progress updates, and three message a day will be sent to participants.
62212369|NCT05003518|EXPERIMENTAL|Condition 8: Low Personalisation+Low Frequency+Gender Targeting|The intervention will have low levels of personalisation, contains gender targeted messages, and one message a day will be sent to participants.
62212370|NCT05003518|EXPERIMENTAL|Condition 9: High Personalisation+Low Frequency+Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages, and one message a day will be sent to participants.
62212371|NCT05003518|EXPERIMENTAL|Condition 10: Low Personalisation + High Frequency + Gender Targeting|The intervention will have low levels of personalisation, contains gender targeted messages, and three message a day will be sent to participants.
62408760|NCT01070225|EXPERIMENTAL|Hydrocortisone and Propranolol|Participant administered 10 or 20mg propranolol orally. Participants meeting the parameters are randomised to receive 400mg Hydrocortisone intravenously. Participant then receives Histamine PC10 challenge, Administered 5mg Salbutamol via nebuliser, administered 500mcg Ipratropium Bromide via nebuliser; visit end
62408761|NCT01070225|PLACEBO_COMPARATOR|Placebo and propranolol|identical to other arm but participant receive placebo injection as opposed to hydrocortisone
62212372|NCT05003518|EXPERIMENTAL|Condition 11: High Personalisation + High Frequency + Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages, and three message a day will be sent to participants.
62212373|NCT05003518|EXPERIMENTAL|Condition 12: Low Personalisation + Low Frequency + Gamification + Gender Targeting|The intervention will have low levels of personalisation, contains gender targeted messages and gamified progress updates. Participants will be sent one message a day.
62408762|NCT01113060||CAD patients|Representative sample of coronary artery disease patients receiving aspirin therapy for secondary prevention
62408763|NCT00928629|OTHER|All Subjects|ABI Screening Test Population: Subjects of either sex, any race, with at least two of the specified CVD risk factors, with no overt cardiovascular disease.
62408764|NCT01971099|PLACEBO_COMPARATOR|Placebo|patients will use placebo for 120 days
62408765|NCT01971099|EXPERIMENTAL|Tribulus Terrestris|patients will use Tribulus terrestris (750 mg/day) during 120 days
62408766|NCT06325722|EXPERIMENTAL|low-carbohydrate diet then low-fat diet|A low-carbohydrate followed by low-fat diet, each lasting for 4 weeks in adults with overweight or obesity
62020086|NCT02897947||treated in Norway included in NORspine|patients having had surgery for lumbar spinal stenosis in Norway and are included in the national register NORspine
62020087|NCT02897947||treated in Sweden included in Swespine|patients having had surgery for lumbar spinal stenosis in Sweden and are included in the national register Swespine
62408767|NCT06325722|EXPERIMENTAL|low-fat diet then low-carbohydrate diet|A low-fat followed by low-carbohydrate diet, each lasting for 4 weeks in adults with overweight or obesity
62020088|NCT02897947||treated in Denmark included in Danespine|patients having had surgery for lumbar spinal stenosis in Denmark and are included in the national register DANEspine
62020089|NCT05274945|EXPERIMENTAL|total neoadjuvant therapy|patients will be treated by total neoadjuvant therapy, including concurrent chemoradiotherapy in the form of radiotherapy 45 Gy/ 25 fractions then boost 5.4 Gy/3 fractions with concurrent bolus 5-fluorouracil + Calcium leucoverin for first 4 days and last 3 days of radiotherapy or capecitabine at 825 mg\\m2 twice daily. Then, after 2-3 weeks preoperative chemotherapy will be started in the form of 6 cycles of FOLFOX or CAPOX. Then, after 3-4 weeks surgery will be done.
62020090|NCT05274945|ACTIVE_COMPARATOR|standard neoadjuvant therapy|patients will be treated by standard neoadjuvant therapy , including concurrent chemoradiotherapy in the form of radiotherapy 45 Gy/ 25 fractions then boost 5.4 Gy/3 fractions with concurrent bolus 5-fluorouracil + Calcium leucoverin for first 4 days and last 3 days of radiotherapy or capecitabine at 825 mg\\m2 twice daily . Then, after 6-8 weeks surgery will be performed followed by adjuvant chemotherapy.
62020091|NCT02719405|PLACEBO_COMPARATOR|Amino Acid Formula|
62020092|NCT02719405|ACTIVE_COMPARATOR|EHCF|Extensively Hydrolyzed Casein Formula
62020093|NCT02719405|ACTIVE_COMPARATOR|EHCF + LGG|Extensively Hydrolyzed Casein Formula + Lactobacillus GG
62020094|NCT02517060||Healthy participants|Male or female healthy participants
62020095|NCT00523029|EXPERIMENTAL|1|Participants will receive a chronic disease self-management program
62020096|NCT03965260||Bacteria-infected cirrhotic patients|All kind of etiologies for cirrhosis and all kind of bacterial infections (spontaneous bacterial peritonitis, urinary tract infections, pneumonia, skin and soft tissue infections and spontaneous bacteremia)
62020097|NCT01821781|EXPERIMENTAL|Preparative|
62020098|NCT00982020|EXPERIMENTAL|Olanzapine/standard behavioral weight intervention|
62020099|NCT00982020|EXPERIMENTAL|Olanzapine/intense behavioral weight intervention|
62020100|NCT02546245|EXPERIMENTAL|Heroes of Knowledge Game|
62020101|NCT02546245|ACTIVE_COMPARATOR|Attention/Time Control Games|
62020102|NCT01771003|PLACEBO_COMPARATOR|Without CellAegis' autoRIC™ Device|patients will have a blood pressure cuff attached to their arm that will not inflate/deflate as in the active group
62020103|NCT01771003|ACTIVE_COMPARATOR|With CellAegis' autoRIC™ Device|Patients will have the CellAegis' autoRIC™ Device attached and it will inflate to 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles (while under general anesthetic)
62020104|NCT00893659|EXPERIMENTAL|wheat bread with beta-glucan supplementation|
62020105|NCT00893659|PLACEBO_COMPARATOR|wheat bread without beta-glucan|
62408768|NCT05688800|ACTIVE_COMPARATOR|Control group|Each participant include 22 participants will receive conventional physical therapy treatment including TENS, continuous ultrasound ,infra-red radiation and combined stretching and strengthening exercise
62408769|NCT05688800|EXPERIMENTAL|Experimental group 1 :pressure release technique|Each participant include 22 participants will receive the conventional physical therapy treatment in addition to pressure release technique
62408770|NCT05688800|EXPERIMENTAL|Experimental group 2: thoracic spine manipulation|Each participant include 22 participants will receive the conventional physical therapy treatment in addition to thoracic spine manipulation
62020106|NCT02451345|EXPERIMENTAL|Intervention|Personalized risk model+website+phone coaching
62408771|NCT02351206||The experimental group|Patients with intervertebral disc protrusion, extrusion, or migration at L4/5 randomly selected from a population pool of 665 patients with L-spine X-ray and L-spine MRIs taken within a week of the other test.
62408772|NCT02351206||The control group|Patients with normal or disc bulging readings at L4/5 randomly selected from a population pool of 665 patients with L-spine X-ray and L-spine MRIs taken within a week of the other test.
62408773|NCT05688137|ACTIVE_COMPARATOR|DRAINAGE GROUP (D)|This patients will take the abdominal drainage.
62408774|NCT05688137|NO_INTERVENTION|NON DRAINAGE GROUP (ND)|This patients will not take the abdominal drainage.
62408775|NCT04460092|EXPERIMENTAL|"Group A"|"In the first three days, participants in group A will inject 90-degree insulin injections using 5-mm 32-gauge needles. Then, with an interval of one day, in the second three days, they will use 32-gauge needles with a length of 8 mm to inject insulin."
62408776|NCT04460092|EXPERIMENTAL|"GroupB"|"In the first three days, participants in group B will inject 90-degree insulin injections using 8-mm 32-gauge needles. Then, with an interval of one day, in the second three days, they will use 32-gauge needles with a length of 5mm to inject insulin."
62408777|NCT01605539|PLACEBO_COMPARATOR|Control|Subjects will receive pills that resemble the Cannabidiol capsule but do not have have its properties.
62734525|NCT05753254|EXPERIMENTAL|Firefighting under gas fire|Firefighting under gas fire, with exposure to ambient heat, and expectably less smoke and soot than with wood fire. These conditions are used in some Danish training centres, with logistical advantages (ease of turning or putting out the fire and managing the fire fuel) and unknown effect relating to exposure prevention (smoke and soot). The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models
62790516|NCT02717039||Blood Draw|A one time blood draw of 50mL or 15mL will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture. Participants will be enrolled in equal numbers from three categories determined by their observed clinical course: (1) participants without HIT testing negative for heparin/PF4 antibodies (controls); (2) participants without HIT testing positive for heparin/PF4 antibodies (seroconversion cases); (3) participants with HIT testing positive for both heparin/PF4 antibodies (HIT cases).
62790517|NCT00003515|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62020107|NCT00004867|EXPERIMENTAL|FDG-PET scan +/- neoadjuvant chemotherapy + surgery|"Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later by positron emission tomography (PET) imaging. Confirmatory studies, such as biopsy or other imaging studies, are then conducted to confirm the FDG PET imaging results. Patients with no metastases identified by FDG PET imaging may undergo esophagectomy with or without neoadjuvant chemoradiotherapy within 1 month of evaluation.~Patients are followed within 6 months after surgery."
62020108|NCT06260657||Fetal ethmoids|
62020109|NCT03913364|EXPERIMENTAL|Experimental Obese mothers|One portion (50g) of an ice-cream containing the probiotic B. bifidum 900791 (\>10(exp7)/g) every other day during the last month of gestation and the first month of lactation
62790518|NCT02139865|EXPERIMENTAL|30%|Training at 30% 1RM
62020110|NCT03913364|PLACEBO_COMPARATOR|Placebo Obese mothers|One portion (50g) of an ice-cream without probiotic every other day during the last month of gestation and the first month of lactation
62020111|NCT03913364|EXPERIMENTAL|Experimental normal weight mothers|One portion (50g) of an ice-cream containing B. bifidum 900791 (\>10(exp7)/g) every other day during the last month of gestation and the first month of lactation
62408778|NCT01605539|EXPERIMENTAL|Cannabidiol 400|Subjects in Arm Cannabidiol 400 will receive 400 mg of cannabidiol
62408779|NCT01605539|EXPERIMENTAL|Cannabidiol 800|Subjects in Arm Cannabidiol 800 will receive 800mg of cannabidiol
62408780|NCT04045665|ACTIVE_COMPARATOR|Antiplatelet Therapy|Antiplatelet-only strategy
62408781|NCT04045665|ACTIVE_COMPARATOR|Oral Anticoagulant|OAC-based strategy
62734526|NCT06389344|EXPERIMENTAL|esketamine|Esketamine ( 50mg, dissolved in 50ml normal saline ) 0.3mg / kg will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
62408782|NCT01516060|EXPERIMENTAL|Reduced dose Efavirenz arm|Patient's on main study that was randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
62734527|NCT06389344|PLACEBO_COMPARATOR|normal saline|Same amount of normal saline will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
62020112|NCT03913364|PLACEBO_COMPARATOR|Placebo normal weight mothers|One portion (50g) of an ice-cream without probiotic every other day during the last month of gestation and the first month of lactation
62408783|NCT01516060|ACTIVE_COMPARATOR|Normal Efavirenz dose arm|Patient's on main study randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
62212374|NCT05003518|EXPERIMENTAL|Condition 13: High Personalisation + Low Frequency + Gamification + Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages and gamified progress updates. Participants will be sent one message a day.
62408784|NCT00708656|EXPERIMENTAL|1: once daily|Three 800mg tablets of mesalazine (Asacol®) in the morning
62408785|NCT00708656|ACTIVE_COMPARATOR|2: tds|Mesalazine (Asacol®) 800mg given three times daily
62408786|NCT00673868|EXPERIMENTAL|1|
62790519|NCT02139865|EXPERIMENTAL|80%|Training at 80% 1RM
62020113|NCT02999308|EXPERIMENTAL|single arm|
62408787|NCT00673868|NO_INTERVENTION|2|
62408788|NCT05485506|EXPERIMENTAL|Intervention group|Intervention group will add to their training routine a multimodal exercise program (two days per week, during six weeks). This program will include running technical drills, exercises for lumbopelvic stabilization and resisted sprints by using sled.
62020114|NCT04837638||Adults with HeFH|Adult men and women aged 18 to 65 years with genetically-defined HeFH.
62020115|NCT03794089|EXPERIMENTAL|Brief anxiety intervention|Modular anxiety intervention designed for PC-MHI, up to six 30-minute sessions occurring approximately every 2 weeks, patients select modules of interest to them to complete, emphasis on psycho-education and cognitive-behavioral coping strategies for self-management
62020116|NCT03794089|ACTIVE_COMPARATOR|Usual PC-MHI care|Appointment with PC-MHI provider at local primary care clinic, providers delivers whatever interventions they deem appropriate and collaboratively decides with patients whether and when to meet again as in routine PC-MHI care
62212375|NCT05003518|EXPERIMENTAL|Condition 14: Low Personalisation + High Frequency + Gamification + Gender Targeting|The intervention will have low levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages and gamified progress updates. Participants will be sent three message a day.
62408789|NCT05485506|NO_INTERVENTION|Control group|Control group will maintain their training routine.
62408790|NCT05623826|EXPERIMENTAL|Experimental|Experimental (receiving EMA and Imager EMI)
62408791|NCT05623826|NO_INTERVENTION|Control|Control (receiving EMA only)
62408792|NCT05468034|EXPERIMENTAL|Exercise Intervention|Eligible and consented participants randomized to the exercise arm (EX) will work with an exercise trainer 3x weekly for 16 weeks. Training sessions are 60 min. Schedules are determined by participant and trainer with oversight by the study team, ideally occurring at similar times each day in line with IBC theory. Each training session will be delivered virtually over a HIPAA compliant IU Health Zoom platform. The virtual exercise sessions include 3 parts: cardiovascular exercise, resistance training, and balance or stretching exercise. During sessions, patients will wear provided heart rate monitors with a training goal of moderate intensity, defined as 40-60% of heart rate reserve. Based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session, trainers will follow an algorithm designed by the PI and collaborators to progress or regress intensity level. Participant will attend a class on creating and maintaining behavior changes.
62408793|NCT05468034|NO_INTERVENTION|Usual Care|Participants randomized to usual care (UC) will receive care per their treatment team. UC participants are encouraged to exercise but will not be provided components of the intervention. Participants in the UC arm will be given usual care handouts at baseline from the American College of Sports Medicine.
62408794|NCT03669952||Invasive ductal carcinoma|Patients with Invasive ductal carcinoma
62408795|NCT01504074||Patients suffering on CME secondary to cataract surgery|
62790520|NCT05396144|SHAM_COMPARATOR|5% inhaled nitrous oxide|Patients will received 5% nitrous oxide by face mask in addition to standard intravenous sedatives given at the discretion of the care provider.
62020117|NCT04968067|EXPERIMENTAL|App group|In addition to the usual care, the participant will receive a health talk , a CHD app and a briefing from a trained research nurse (A). The app provides features such as structured e-educational contents and supportive features such as knowledge platform and member area.
62212376|NCT05003518|EXPERIMENTAL|Condition 15: High Personalisation + High Frequency + Gamification + Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages and gamified progress updates. Participants will be sent three messages a day.
62212377|NCT05003518|EXPERIMENTAL|Condition 16: Low Personalisation+Low Frequency+Gamification|The intervention will have low levels of personalisation (utilise the user's nickname and their child's nickname), contains gamified progress updates, and one message a day will be sent to participants.
62212378|NCT00469105|ACTIVE_COMPARATOR|Control|Control Arm receives standard diabetes disease management
62790521|NCT05396144|ACTIVE_COMPARATOR|50% inhaled nitrous oxide|Patients will received 50% nitrous oxide by face mask in addition to standard intravenous sedatives given at the discretion of the care provider.
62790522|NCT03360474|EXPERIMENTAL|Intervention|Patients will be placed on the delirium screening intervention protocol arm. They will be screened for delirium twice per day. If positive, they will follow the treatment algorithm and assessed at 4 hour intervals until they reach 4 negative screens. Once 4 negative screens have been reached, they will be assessed twice daily.
62408796|NCT03310931||End and non-END groups|END was denied as NIHSS score increase of 2 or more than 2 within 7 days after admission
62790523|NCT01183949|EXPERIMENTAL|Treatment|Patients will be enrolled into 3 groups which will run sequentially. Groups A and B will receive AT7519M only, whereas Group C will receive AT7519M in combination with Bortezomib.
62020118|NCT04968067|ACTIVE_COMPARATOR|Nursing telephone advice (NTA) group|In addition to the above usual care, the participant will receive a health talk , three monthly 20-minute telephone follow-ups supplemented by take home leaflet will be provided by a trained research nurse for up to 3 months. Patients can ask about their related health problems, if any. The team has set up a telephone advice guide to support the research nurse in giving phone advice and text messages.
62408797|NCT04271241|NO_INTERVENTION|Control (Ctrl)|Ctrl group di not undergo any training
62408798|NCT04271241|EXPERIMENTAL|PS bilateral limbs (PSBil)|PSBil underwent 12 weeks of passive stretching on both the lower limbs
62408799|NCT04271241|EXPERIMENTAL|PS monolateral limb, stretched limb (PSMonoSL)|PSMonoSL underwent 12 weeks of passive stretching on just one lower limb (SL). Outcomes form this group were obtained from the stretched
62790524|NCT03068754|EXPERIMENTAL|Arm A: Treatment Period Acthar|"Participants receive one 0.2 mL subcutaneous (SC) injection (shot under the skin) of the study drug (Acthar), daily for up to 36 weeks.~Those who do not continue into the extension period will have 3 weeks of tapering off the drug, ending their participation by Week 39."
62790525|NCT03068754|PLACEBO_COMPARATOR|Arm B: Treatment Period Placebo|"Participants receive one 0.2 mL SC injection that looks like Acthar, but has no drug in it (Matching Placebo), daily for up to 36 weeks.~Those who do not continue into the extension period will have 3 weeks of simulated tapering, ending their participation by Week 39."
62790526|NCT03068754|EXPERIMENTAL|Arm C: Extension Period Acthar-Acthar|Participants who receive Acthar during the treatment period and continue into the extension period do not go through the treatment-period tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.
62020119|NCT01431066|PLACEBO_COMPARATOR|Control|Sham device that resembles the Actipatch PRFE device, including the light that illuminates when active, but the transmitting function has been disabled.
62408800|NCT04271241|EXPERIMENTAL|PS monolateral limb, contralateral limb PSMonoCL|PSMonoCL involved the same participants as in PSMonoSL. Outcomes form this group were obtained from the contralateral not stretched limb (CL). Data from this limb helped in identify possible PS-induced crossover effects in the vasomotor response.
62408801|NCT06649682|EXPERIMENTAL|Imaging and therapy|68Ga-NYM096 PET/CT and 177Lu-NYM096
62408802|NCT04755088|EXPERIMENTAL|Cohort 1|Subjects with Normal Renal Function: All patients to receive study drug (Surufatinib 300mg) on Day 1
62212379|NCT00469105|EXPERIMENTAL|Intervention Arm|Receives numeracy/literacy sensitive diabetes management
62212380|NCT00992225|EXPERIMENTAL|LY573636-sodium|
62408803|NCT04755088|EXPERIMENTAL|Cohort 2|Subjects with Moderate Renal Impairment: All patients to receive study drug (Surufatinib 300mg) on Day 1
62408804|NCT02604849||Received therapy desconolizacion against Klebsiella pneumoniae|
62408805|NCT02604849||Patients who do not receive the therapy|
62408806|NCT04148469|EXPERIMENTAL|dry needling and TENS|A dry needling treatment was performed on trapezius trigger point number 2, and just after thar, a TENS curretn was applied. Patients will be reassed on fourth day after treatment.
62408807|NCT04148469|PLACEBO_COMPARATOR|Placebo|A placebo dry needling was performed on trapezius trigger point number 2. Patients will be reassed on fourth day after treatment.
62408808|NCT04148469|EXPERIMENTAL|dry needling|A dry needling treatment was performed on trapezius trigger point number 2. Patients will be reassed on fourth day after treatment.
62020120|NCT01431066|EXPERIMENTAL|Actipatch|Use of the Actipatch PRFE device that is integrated into a viscoelastic heel pad for the treatment of plantar fasciopathy
62408809|NCT06540690|ACTIVE_COMPARATOR|Diabetic (D)|Palatal wound healing in diabetic patients
62408810|NCT06540690|ACTIVE_COMPARATOR|Control Group (CG)|Palatal wound healing in normoglycemic patients
62408811|NCT06562556|EXPERIMENTAL|Participant Group/Arm|rThirty patients, will receive a combined treatment program containing respiratory muscle training by the breather device with a conventional exercise program for MTMD for four consecutive weeks (3 sessions/ week)
62408812|NCT06562556|OTHER|Control group/Arm|Thirty patients, who will receive a conventional exercise program for MTMD for four consecutive weeks (3 sessions/ week).
62408813|NCT03099616|ACTIVE_COMPARATOR|CLADS group|Anesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anaesthesia maintenance will be done with Propofol, with the dosing based on adjusted body weight (ABW), and administration controlled with CLADS tuned to consistent anaesthetic depth (BIS-50) feedback from the patients.
62408814|NCT03099616|ACTIVE_COMPARATOR|Desflurane group|Anesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia.Thereafter anaesthesia maintenance will be done with desflurane using an agent specific vaporiser, whose dial concentration will be adjusted to maintain a BIS of 50-55 in all the patients
62408815|NCT05074459|EXPERIMENTAL|Eptinezumab Mammalian Cell Line|Participants will receive a single intravenous (IV) infusion of eptinezumab mammalian cell line on Day 1.
62408816|NCT05074459|ACTIVE_COMPARATOR|Eptinezumab Yeast Cell Line|Participants will receive a single IV infusion of eptinezumab yeast cell line on Day 1.
62584346|NCT05816798|EXPERIMENTAL|Photobiomodulation Intervention|"PBM therapy sessions will be performed with the Therapy EC device (DMC brand) 100mW power, which is a Low Intensity Laser Therapy. During the interventions, the patient will be allowed to choose the position that is most comfortable for him and accompanied by the physical therapist throughout the procedure. Examiner and patient will be wearing protective eyewear. Applications will occur after local asepsis of the device and skin. Patients will receive the PBM therapy described below:~* Paravertebral region at levels L3 to S2:1 cm lateral to the corresponding level, on each right and left side, which are root levels that innervate the knee joint (totaling 10 paravertebral points) with 3 Joules per point (30 s) in each point~* Knees bilaterally (4 points each knee): anteromedial portal; anterolateral portal; apex of patella; base of patella; with 4 J per point (40 s)"
62584347|NCT05816798|PLACEBO_COMPARATOR|Photobiomodulation Placebo|Control group research participants will receive the standard treatment described as well as placebo PBM treatment to mask the treatment. The number of points, dose and PBM application site will be the same as described in the PBM Intervention Group item, however the PBM equipment will be turned off.
62584348|NCT03050853|EXPERIMENTAL|E-Cigarette|The E-cigarette arm will be asked to use e-cigarettes in place of regular tobacco products. The group will be assessed at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 13 weeks, and 26 weeks.
62020121|NCT01263340||People with COPD|
62020122|NCT03855189|EXPERIMENTAL|Mometasone Furoate (MF)|Participants receive 200 mcg nasal MF in the morning upon awakening and placebo approximately 12 hours later in the evening (200 mcg total daily dose) for 29 days.
62408817|NCT00584831|ACTIVE_COMPARATOR|Group 2 LSBO|contact lenses worn in this order: lotrafilcon B toric, senofilcon A toric, balafilcon A toric, omafilcon A toric
62408818|NCT00584831|ACTIVE_COMPARATOR|Group 3 LOSB|contact lenses worn in this order: lotrafilcon B toric, omafilcon A toric, senofilcon A toric, balafilcon A toric
62584349|NCT03050853|NO_INTERVENTION|Assessments only|The Assessment only group will be asked to refrain from use of e-cigarettes during participation. The group will be assessed at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 13 weeks, and 26 weeks.
62408819|NCT00584831|ACTIVE_COMPARATOR|Group 4 LBSO|contact lenses worn in this order: lotrafilcon B toric, balafilcon A toric, senofilcon A toric, omafilcon A toric
62584350|NCT04940286|EXPERIMENTAL|Treatment (durvalumab, oleclumab, nab-paclitaxel, gemcitabine)|Patients receive durvalumab IV over 1 hour on day 1, oleclumab IV over 1 hour, nab-paclitaxel IV, and gemcitabine IV over 1 hour over 30-40 minutes on days 1 and 15. Treatment repeats every 28 days for 2-6 cycles. Within 4-8 weeks after completion of last cycle of treatment, patients undergo surgical resection. After surgical resection, patient may receive adjuvant therapy with durvalumab and oleclumab, durvalumab, oleclumab, gemcitabine, and nab-paclitaxel, other chemotherapy, or observation only at the discretion of the treating physician.
62020123|NCT03855189|ACTIVE_COMPARATOR|Beclomethasone Dipropionate (BDP)|Participants receive 168 mcg nasal BDP in the morning upon awakening and an additional 168 mcg approximately 12 hours later in the evening (336 mcg total daily dose) for 29 days.
62020124|NCT03855189|PLACEBO_COMPARATOR|Placebo|Participants receive nasal placebo in the morning upon awakening and again approximately 12 hours later in the evening for 29 days.
62212381|NCT03957889||Student|
62212382|NCT03957889||Trainers|
62212383|NCT00167167|EXPERIMENTAL|BMT patients|All patients treated.
62408820|NCT00584831|ACTIVE_COMPARATOR|Group 5 LBOS|contact lenses worn in this order: lotrafilcon B toric, balafilcon A toric, omafilcon A toric, senofilcon A
62584351|NCT05540912|EXPERIMENTAL|Sequence 1|Period 1: D064+D701 Period 2: Test1 Period 3: Test2
62584352|NCT05540912|EXPERIMENTAL|Sequence 2|Period 1: Test2 Period 2: D064+D701 Period 3: Test1
62790527|NCT03068754|EXPERIMENTAL|Arm D: Extension Period Placebo-Acthar|Participants who receive Placebo during the treatment period and continue into the extension period do not go through the treatment-period simulated tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.
62020125|NCT02855294|ACTIVE_COMPARATOR|Oral contraceptive pills users|The participants received treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of ring/pill treatment followed by a 1-week pill-free period. The women were randomized in a 1:1 ratio to receive the COC containing 30 μg of EE and 3mg of drospirenone (Yasmin; Schering AG, Berlin, Germany)
62020126|NCT02855294|NO_INTERVENTION|control|no drugs
62020127|NCT01731171|EXPERIMENTAL|Probiotic Supplement|The probiotic supplement compound will consist of capsules containing approximately 10\^8 colony forming units of the probiotic organisms, LactobacillusGG and Bifidobacteria lactis strain Bb12. The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. The participant will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.
62020128|NCT01731171|PLACEBO_COMPARATOR|Inert Compound|The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.
62020129|NCT00870779|EXPERIMENTAL|5-aminolevulinic acid|
62020130|NCT04440111|ACTIVE_COMPARATOR|Control group|One year basic life support training
62020131|NCT04440111|SHAM_COMPARATOR|Experimental group|Two years basic life support training
62584353|NCT05540912|EXPERIMENTAL|Sequence 3|Period 1: Test1 Period 2: Test2 Period 3: D064+D701
62584354|NCT05540912|EXPERIMENTAL|Sequence 4|Period 1: Test2 Period 2: Test1 Period 3: D064+D701
62584355|NCT05540912|EXPERIMENTAL|Sequence 5|Period 1: Test1 Period 2: D064+D701 Period 3: Test2
62584356|NCT05540912|EXPERIMENTAL|Sequence 6|Period 1: D064+D701 Period 2: Test2 Period 3: Test1
62584357|NCT05027477|ACTIVE_COMPARATOR|Radical Prostatectomy|Patients in this group will undergo Radical prostatectomy. There will be about 67 people in this group.
62584358|NCT05027477|EXPERIMENTAL|TULSA Procedure|Patients in this group will undergo TULSA Procedure. There will be about 134 people in this group.
62584359|NCT03843463|EXPERIMENTAL|Naming Treatment + Escitalopram|10 mg escitalopram daily for three months (escalating from 5 mg per day for the first week and tapering to 5 mg per day for the last two weeks)
62584360|NCT03843463|PLACEBO_COMPARATOR|Naming Treatment + Placebo|10 mg placebo daily for three months
62790528|NCT01542710|EXPERIMENTAL|Glaucoma fixed Combination Medications|
62790529|NCT00291486|EXPERIMENTAL|Cohort 1|"20 millicurie (mCi) 131I-huA33, 1500 mg/m2/day capecitabine~All patients received an initial dose of 5 mg huA33 conjugated to 5-8 mCi 131I on day 0.~This was followed 7 ± 2 days later by inpatient administration of a single infusion of 131I-huA33 with a constant protein dose of 10 mg/m2 huA33.~Capecitabine was administered in 2 divided doses per day on days 1-14 of each 21-day cycle for a total of 4 cycles. Daily doses were rounded to the nearest 150 mg."
62584361|NCT06335797|EXPERIMENTAL|SENNA|Group A participants will be prescribed oral senna (Senokot; Atlantis Consumer Healthcare Inc., Bridgewater, NJ) 8.6mg tablets and be instructed to start with two tablets on the morning of Post Operative Day (POD)#1. Participant will continue taking two tablets on the daily. If no bowel movement on the morning of POD#3 participant may take 2 tablets in the morning and another 2 tablets that evening. The same can be replicated on POD#4. If no bowel movement on the morning of POD#5 participant may take magnesium hydroxide (Phillips' Milk of Magnesia; Bayer AG, Leverkusen, Germany) 30 mL by mouth and need to call the urology clinic for further instruction.
62212384|NCT01534689|EXPERIMENTAL|Erchonia FX-405™ Laser|The Erchonia FX-405™ Laser is a dual-diode laser emitting 15.5-17.5 milliWatts (mW) of 635 nanometer (nm) red laser light and 23.5-25.5 mW 405 nm blue laser light. The the power reaching the surface of the skin is 1 mW
62212385|NCT04258202|EXPERIMENTAL|positive end expiratory pressure group|Alveolar recruitment maneuver is performed after intubation, pneumoperitoneum, closure of abdominal fascia. PEEP increased in a stepwise manner from 5 to 20 cmH2O, until plateau pressure 30 cmH2, then 10 breaths. After recruitment, ventilation sets at tidal volume 7 mL/kg with positive end expiratory pressure (PEEP) 5cmH2O.
62212386|NCT04258202|EXPERIMENTAL|tidal volume group|Alveolar recruitment maneuver is performed after intubation, pneumoperitoneum, closure of abdominal fascia. Tidal volume increased in steps of 4mL/kg of ideal body weight until plateau pressure 30 cmH2O, then 10 breaths. After recruitment, ventilation sets at tidal volume 7 mL/kg with PEEP 5 cmH2O.
62212387|NCT00626197|EXPERIMENTAL|OCR 400 mg + SOC|Participants received Ocrelizumab 400 mg i.v. infusion on Days 1 and 15, followed by 400 mg i.v. at Week 16 and then every 16 weeks plus SOC regimen.
62212388|NCT00626197|EXPERIMENTAL|OCR 1000 mg + SOC|Participants received Ocrelizumab 1000 mg i.v. infusion on Days 1 and 15, followed by 1000 mg i.v. at Week 16 and then every 16 weeks plus SOC regimen.
62212389|NCT00626197|PLACEBO_COMPARATOR|Placebo + SOC|Participants received placebo i.v. infusion on Days 1 and 15, followed by placebo infusion at Week 16 and then every 16 weeks plus SOC regimen.
62020132|NCT02566395|EXPERIMENTAL|Haploidentical Stem Cell Transplantation|Subjects will receive pretransplantation conditioning of total-body irradiation (1,200 cGy delivered in 8 fractions over 4 days \[Days -9 through -6\] and cyclophosphamide (60 mg/kg IV daily x 2 on Days -3 and -2). Donor lymphocyte infusion will occur on day -6; donor CD34+ cells will be infused on Day 0.
62020133|NCT06531720|EXPERIMENTAL|0,2% CHX topical use|Patients were asked to use topical medication containing 0,2% chlorhexidine 3 times a day, applying the size of a pea on the oral mucosa lesion until full wound healing or up to 14 days.
62212390|NCT05474495|EXPERIMENTAL|Pelvic floor muscle training|Experimental Group (Group A) will receive pelvic floor muscle training. Two sessions a week for 6 weeks, each session lasting 45 mins.
62408821|NCT00584831|ACTIVE_COMPARATOR|Group 6 SLOB|contact lenses worn in this order: senofilcon A toric, lotrafilcon B toric, omafilcon A toric, balafilcon A toric
62020134|NCT06531720|EXPERIMENTAL|8,7% CHS topical use|Patients were asked to use topical medication containing 8,7% choline salicylate 3 times a day, applying the size of a pea on the oral mucosa lesion until full wound healing or up to 14 days.
62020135|NCT06531720|EXPERIMENTAL|Control|Patients were not using any topical medications.
62020136|NCT02800044|EXPERIMENTAL|Wearing glucose sensor|The study team will measure glucose readings from the non-invasive sensor and from a glucometer at the following time points: fasting, 1.5 to 2 hours after a meal, and before and after 15-30 minutes of pedaling on a stationary bicycle at 80% maximum heart rate..
62212391|NCT05474495|ACTIVE_COMPARATOR|Transverse abdominas strength training|Active Comparator (Group B) will receive transverse abdominas strength training. Treatment will be given 5 days a week and continued for 6 weeks.
62212392|NCT01671397|EXPERIMENTAL|Diet, exercise, sleep hygiene counseling|Subjects will meet with a dietitian and a physician and receive counseling on diet restriction, exercise goals, and good sleep hygiene. Subjects will identify goals in each domain and keep a calendar of the success with achieving these goals.
62212393|NCT01671397|ACTIVE_COMPARATOR|Diet and exercise counseling|Subjects will meet with a dietitian and a physician and receive counseling on calorie restriction and exercise. They will identify goals in each domain and keep a calendar to determine their success with achieving these goals.
62212394|NCT03066349||Patients with PCOS undergoing conventional ovarian stimulation|
62212395|NCT03066349||Patients with PCOS undergoing IVM|
62212396|NCT03811262|ACTIVE_COMPARATOR|ESP BLOCK|Intervention:30 ml of 0.25% Levobupivacaine where: ESP block as described by Forero at T5 level (single injection between transversour process and erector spinae muscles)
62212397|NCT03811262|ACTIVE_COMPARATOR|PECS block|Intervention:30 ml of 0.25% Levobupivacaine where:PECS II block as described by Blanco.
62212398|NCT03986281|ACTIVE_COMPARATOR|Omron HeartGuide Smartwatch|Readings from the Omron HeartGuide Smartwatch
62212399|NCT03986281|ACTIVE_COMPARATOR|Arterial Line|Readings from the arterial line
62212400|NCT04517149|EXPERIMENTAL|4D-125 Dose Exploration|"Dose 1 and Dose 2~4D-125 will be administered at the assigned dose level as a single dose, IVT injection on Day 1. The contralateral eye may also be dosed with 4D-125 as a single dose, IVT injection provided the subject is eligible and provides consent."
62212401|NCT04517149|EXPERIMENTAL|4D-125 Dose Expansion|4D-125 will be administered at the assigned dose level as a single dose, IVT injection on Day 1 in both adults and pediatric participants. For adult participants only, the contralateral eye may also be dosed with 4D-125 as a single dose, IVT injection provided the subject is eligible and provides consent.
62212402|NCT04517149|OTHER|Observational|Natural History
62212403|NCT04050176|EXPERIMENTAL|Blinded Hypnotic Medication Taper (BT)|Participants assigned to the Blinded Taper group will not know the medication dose they receive during the Structured Medication Taper (SMT) phase.
62212404|NCT04050176|ACTIVE_COMPARATOR|Open-Label Hypnotic Medication Taper (OLT)|Participants assigned to the Open-Label Hypnotic Medication Taper group will know the medication dose they receive during the SMT phase.
62584362|NCT06335797|EXPERIMENTAL|DULCOLAX|Group B participants will be prescribed bisacodyl rectal (Dulcolax Suppository; Sanofi S.A., Paris, France) 1 suppository to be placed rectally on the morning of Post Operative Day (POD)#1. Participant will continue placing a nightly rectal suppository until their first bowel movement. If no bowel movement by the morning of POD#5 participant may take magnesium hydroxide (Phillips' Milk of Magnesia; Bayer AG, Leverkusen, Germany) 30 mL by mouth and need to call the clinic for further instruction.
62212405|NCT04100876||primary ITP patients .|60 primary ITP patients .
62020137|NCT06458634||Underweight group|This group will be underweight group according to BMI- for age percentile growth chart ranged from BMI-for-age \< 5th percentiles.
62584363|NCT06683625||Group 1|Eight female athletes
62584364|NCT06683625||Group 2|19 male athletes
62020138|NCT06458634||Normal weight group|This group will be with normal weight according to BMI- for age percentile growth chart which ranged from BMI-for-age 5th to 85th percentiles
62020139|NCT06458634||Overweight group|This group will be an overweight group according to BMI- for age percentile growth chart which ranged from BMI-for-age 85th to 95th percentiles
62020140|NCT06458634||Obese group|This group will be obese group according to BMI- for age percentile growth chart which ranged from BMI-for-age \> 95th percentiles and \<99th percentile
62212406|NCT04100876||healthy subjects .|30 healthy age and sex matched control subjects .
62212407|NCT02141022|EXPERIMENTAL|PACR Program: Plasticity based, Adaptive Cognitve Remediation|PACR Program Use: To use PACR, the participant navigates to the PACR study web site. The participant then logs into the PACR (using a study provided screen name and study identification number). A game-like experience begins, where the participant is presented with games in a set order. Each game consists of targeted exercises that contain the core science stimuli and tasks. The scheduling mechanism ensures that a participant progresses through the exercises in a defined order, generally moving from more simple (early sensory processing) exercises to more complex (multimodal, cognitive control) exercises over the course of the three-month experience.
62408822|NCT00584831|ACTIVE_COMPARATOR|Group 7 SLBO|contact lenses worn in this order: senofilcon A toric, lotrafilcon B toric, balafilcon A toric, omafilcon A toric
62584365|NCT00438607|OTHER|1|BIIB014 at MTD from Part A
62584366|NCT00438607|OTHER|2|BIIB014 at dose immediately below MTD from Part A
62584367|NCT00438607|PLACEBO_COMPARATOR|3|
62584368|NCT05790837|EXPERIMENTAL|Computer prompt + Education (CP+E)|"The intervention group consists of the implementation of the desktop application Stand up for your Health® following the model proposed by the Guide to Physical Activity at Work plus education through an information leaflet"
62020141|NCT06178666|EXPERIMENTAL|Low dose of BCG being tested in dose ranging study|The lowest dose of BCG (standard Malawi BCG vaccine (BCG Bulgaria 150000-600000 cfu) given as intradermal injection) will be used to determine safety and feasibility. The investigators do not expect to be able to meet study endpoints in this arm which will recruit 10 subjects.
62408823|NCT00584831|ACTIVE_COMPARATOR|Group 8 SOLB|contact lenses worn in this order: senofilcon A toric, omafilcon A toric, lotrafilcon B toric, balafilcon A toric
62584369|NCT05790837|NO_INTERVENTION|Only Education (OE)|The control group will receive only education through an information leaflet also following the guidelines of the Work Physical Activity Guide on indications to control the time sitting at work.
62212408|NCT02141022|ACTIVE_COMPARATOR|Ordinary Computer Games|Active Control Program Use (Ordinary Computer Games): The active control program is composed of 13 ordinary computer games matched to the PACR condition overall. This condition is designed to be a face-valid approach to cognitive remediation. The control condition is also designed to account for nonspecific treatment effects, including placebo response, interactions with research personnel, and experience with computers and computer-related activities, and any halo or expectation effect on study assessments.
62790530|NCT00291486|EXPERIMENTAL|Cohort 2|"30 millicurie (mCi) 131I-huA33, 1500 mg/m2/day capecitabine~All patients received an initial dose of 5 mg huA33 conjugated to 5-8 mCi 131I on day 0.~This was followed 7 ± 2 days later by inpatient administration of a single infusion of 131I-huA33 with a constant protein dose of 10 mg/m2 huA33.~Capecitabine was administered in 2 divided doses per day on days 1-14 of each 21-day cycle for a total of 4 cycles. Daily doses were rounded to the nearest 150 mg."
62212409|NCT01010659|EXPERIMENTAL|Lacrimal Tube|Dacryocystorhinostomy with silicone lacrimal intubation
62790531|NCT00291486|EXPERIMENTAL|Cohort 3|"30 millicurie (mCi) 131I-huA33, 1000 mg/m2/day capecitabine~All patients received an initial dose of 5 mg huA33 conjugated to 5-8 mCi 131I on day 0.~This was followed 7 ± 2 days later by inpatient administration of a single infusion of 131I-huA33 with a constant protein dose of 10 mg/m2 huA33.~Capecitabine was administered in 2 divided doses per day on days 1-14 of each 21-day cycle for a total of 4 cycles. Daily doses were rounded to the nearest 150 mg."
62790532|NCT00291486|EXPERIMENTAL|Cohort 4|"40 millicurie (mCi) 131I-huA33, 1000 mg/m2/day capecitabine~All patients received an initial dose of 5 mg huA33 conjugated to 5-8 mCi 131I on day 0.~This was followed 7 ± 2 days later by inpatient administration of a single infusion of 131I-huA33 with a constant protein dose of 10 mg/m2 huA33.~Capecitabine was administered in 2 divided doses per day on days 1-14 of each 21-day cycle for a total of 4 cycles. Daily doses were rounded to the nearest 150 mg."
62790533|NCT00291486|EXPERIMENTAL|Cohort 5|"40 millicurie (mCi) 131I-huA33, 1250 mg/m2/day capecitabine~All patients received an initial dose of 5 mg huA33 conjugated to 5-8 mCi 131I on day 0.~This was followed 7 ± 2 days later by inpatient administration of a single infusion of 131I-huA33 with a constant protein dose of 10 mg/m2 huA33.~Capecitabine was administered in 2 divided doses per day on days 1-14 of each 21-day cycle for a total of 4 cycles. Daily doses were rounded to the nearest 150 mg."
62790534|NCT01819896||pacemakers and defibrillators|
62790535|NCT02161991|EXPERIMENTAL|aprepitant group|Patients assigned to aprepitant group should receive aprepitant for the control of CINV, aprepitant 125 mg for day1, 80mg for day2 and day3.
62790536|NCT02161991|PLACEBO_COMPARATOR|placebo|Patients assigned to placebo group should receive placebo for the control of CINV compared with aprepitant group.
62790537|NCT04091321||Chronic Headache|Women who endorse chronic headache
62790538|NCT04091321||Chronic Back Pain|Women who endorse chronic back pain
62790539|NCT02196935||ERCP/EUS|All patients who undergo ERCP and EUS for clinical indications will undergo a detailed prospective assessment of clinical course.
62790540|NCT03781141|EXPERIMENTAL|Absorbable suture|Wound closure with absorbable suture.
62790541|NCT03781141|ACTIVE_COMPARATOR|Non-absorbable suture|Wound closure with non-absorbable suture.
62790542|NCT02966561|EXPERIMENTAL|Pedometer-based activity promotion|In the context of pulmonary rehabilitation (standard care), the intervention group (IG) additionally receives a pedometer-based physical activity behaviour change intervention (BCI).
62020142|NCT06178666|EXPERIMENTAL|Mid-range dose BCG being tested in dose ranging study|The mid-range dose of BCG (4x standard Malawi dose (BCG Bulgaria 600000-2400000 cfu intradermal) and equal to the model tested in Oxford, UK) will be used to determine safety and feasibility. The investigators hope to to be able to meet study endpoints (measuring microbiological and immunological features of BCG skin lesion) in this arm which will recruit 10 subjects.
62020143|NCT06178666|EXPERIMENTAL|High dose BCG being tested in dose ranging study|The highest dose of BCG (10x standard Malawi dose (BCG Bulgaria 2400000-9600000 cfu intradermal) and equal to USA dose used in Seattle) will be used to determine safety and feasibility. The investigators expect to be able to meet study endpoints in this arm which will recruit 10 subjects. In the event that study endpoints are met in the mid-range dose, the investigators will introduce a rifampicin dosing schedule to this arm.
62020144|NCT04419896||Retrospective|"Inclusion criteria for Retrospective Subjects:~* Men and women 18 years or older;~* Is or was a patient of a Participating Practice and was previously tested with Germline, Genomic, or other Biomarker Tests; and~* For Germline Genetic Test patients, have a diagnosis of cancer or pathogenic or likely pathogenic (P/LP) result."
62020145|NCT04419896||Prospective|"Inclusion criteria for Prospective Subjects:~* Men and women aged 18 years or older;~* Presents consecutively to a Participating Practice and who has previously been screened and tested (i.e., is a new patient scheduled for a visit at a Participating Practice or is an existing patient who returns to a Participating Practice);~* Receives or has received Germline, Genomic, or other Biomarker Testing, either through a prior healthcare provider or a Participating Practice; and~* Consents to be a part of the Registry."
62020146|NCT04426058|EXPERIMENTAL|CMP|Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml
62020147|NCT04426058|ACTIVE_COMPARATOR|Fascia iliaca|Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml
62020148|NCT03666676|ACTIVE_COMPARATOR|Normal Hearing|Signal processing to improve intelligibility
62020149|NCT03666676|ACTIVE_COMPARATOR|Mild hearing loss|Signal processing to improve intelligibility
62020150|NCT03666676|ACTIVE_COMPARATOR|Moderate hearing loss|Signal processing to improve intelligibility
62584370|NCT06257017|EXPERIMENTAL|Gemcitabine plus cisplatin chemotherapy arm (GC arm)|Patients in this group will receive adjuvant chemotherapy of gemcitabine and cisplatin, prior to radiological progression
62584371|NCT06257017|OTHER|Standard management arm (SM arm)|Patients in this group will receive chemotherapy of gemcitabine and cisplatin only after radiological progression is observed
62790543|NCT02966561|ACTIVE_COMPARATOR|Short patient education and exercise|In the context of pulmonary rehabilitation (standard care), the control group (CG) additionally receives a short patient education in combination with related exercise.
62020151|NCT03524391|EXPERIMENTAL|Yoga Counselling Group|Yoga based psychological counselling delivered individually and in group along with conventional care
62212410|NCT01865175|ACTIVE_COMPARATOR|ionic iron|Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine folloowed by 7 days of heme iron.
62212411|NCT01865175|EXPERIMENTAL|heme iron polypeptide|Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
62212412|NCT06599606||Case|Patients diagnosed with spinal muscular atrophy (SMA) who have received at least four loading doses of nusinersen
62212413|NCT06599606||Control|Healthy, age- and sex-matched control individuals
62212414|NCT04705701|EXPERIMENTAL|Arm A group participants receive same day post-op dialysis|Arm A group participants receive same day post-op dialysis
62408824|NCT00584831|ACTIVE_COMPARATOR|Group 9 SBLO|contact lenses worn in this order: senofilcon A toric, balafilcon A toric, lotrafilcon B toric, omafilcon A toric
62584372|NCT06667011|NO_INTERVENTION|Control|
62790544|NCT01770171|EXPERIMENTAL|Carboplatin-paclitaxel-bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg every 3 weeks until disease progression
62212415|NCT04705701|NO_INTERVENTION|Arm B group participants receive dialysis per standard care|Arm B group participants receive dialysis per standard care
62408825|NCT00584831|ACTIVE_COMPARATOR|Group 10 SBOL|contact lenses worn in this order: senofilcon A toric, balafilcon A toric, omafilcon A toric, lotrafilcon B toric
62584373|NCT06667011|EXPERIMENTAL|Feedback|
62790545|NCT01770171|ACTIVE_COMPARATOR|carboplatin-paclitaxel|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
62020152|NCT03524391|ACTIVE_COMPARATOR|Usual Care Group|Usual care provided to patients
62020153|NCT01806337|EXPERIMENTAL|Alemtuzumab, antibody|alemtuzumab - anti CD 52 antibody administered as consolidation, total dose 133 mg
62584374|NCT06682689|EXPERIMENTAL|High-low tVNS|Participants in this group will be instructed to use the tVNS device every day for the first six weeks according to the manufacturer's guidelines, at an intensity where they can feel a tingling sensation but below the pain threshold. After six weeks (T2) of intervention, they will be asked to switch to a different protocol for the next six weeks, using the device at the lowest possible intensity. Additional instructions will be provided, and they will be informed that this stimulation uses different parameters set by the research team.
62584375|NCT06682689|ACTIVE_COMPARATOR|Low-high tVNS|Participants in this group will receive the inverted intervention, with the first six weeks of stimulation at the lowest possible intensity (0.1 mA) with the same instructions regarding duration of stimulations, followed by six weeks of high-intensity stimulation as instructed by the manufacturer.
62584376|NCT06682689|NO_INTERVENTION|No tVNS|This group of participants will be included in all measurements (T1-T3) and check-ups, except for the tVNS stimulation.
62584377|NCT01828983|EXPERIMENTAL|Telephone support groups|Telephone support groups, each with participants and a trained group leader. Each hour-long telephone group will meet bi-monthly for six months for a total of 12 meetings. Groups are structured with education, skills building, and support. Participants will receive and use a Spouse Workbook with information and activities.
62790546|NCT06300073|EXPERIMENTAL|AutoBrush U-shaped power toothbrush, then Manual Toothbrush|Participants first received the AutoBrush U-shaped power toothbrush with fluoride toothpaste for a single brushing use for 30 seconds; after a 2-day washout period, participants received the ADA reference manual toothbrush for a single brushing use for 2 minutes.
62212416|NCT01691170|ACTIVE_COMPARATOR|Quadriceps Strengthening|
62212417|NCT01691170|ACTIVE_COMPARATOR|Stretching Hamstring|
62212418|NCT00568412|ACTIVE_COMPARATOR|1|Zarzenda applied topically twice daily for three weeks
62212419|NCT00568412|ACTIVE_COMPARATOR|2|Elidel 1% cream, applied topically twice daily for three weeks
62212420|NCT04836403||Rhinosinusitis without treatment group|children aged 2 and 12 years with rhinosinusitis not receiving treatment
62212421|NCT04836403||Rhinosinusitis with treatment group|children aged 2 and 12 years with rhinosinusitis receiving treatment
62212422|NCT04836403||healthy volunteers|children aged 2 and 12 years without rhinosinusitis
62212423|NCT06397300|ACTIVE_COMPARATOR|bilateral Ultrasound guided erector spinae plane (ESP) block|. To perform ESP block in the lateral position bilaterally, a linear transducer is placed in a longitudinal parasagittal orientation and erector spinae muscle, trapezius muscle, rhomboid major muscle and transverse process are visualized and local anesthetic is injected (0.25% bupivacaine 20 ml in each side) in the area between transverse process and erector spinae muscle at T10 level.
62408826|NCT00584831|ACTIVE_COMPARATOR|Group 11 OSLB|contact lenses worn in this order: omafilcon A toric, senofilcon A toric, lotrafilcon B toric, balafilcon A toric
62408827|NCT00584831|ACTIVE_COMPARATOR|Group 12 OSBL|contact lenses worn in this order: omafilcon A toric, senofilcon A toric, balafilcon A toric, lotrafilcon B toric
62408828|NCT00584831|ACTIVE_COMPARATOR|Group 13 OBLS|contact lenses worn in this order: omafilcon A toric, balafilcon A toric, lotrafilcon B toric, senofilcon A toric
62408829|NCT00584831|ACTIVE_COMPARATOR|Group 14 OBSL|contact lenses worn in this order: omafilcon A toric, balafilcon A toric, senofilcon A toric, lotrafilcon B toric
62408830|NCT00584831|ACTIVE_COMPARATOR|Group 15 BLSO|contact lenses worn in this order: balafilcon A toric, lotrafilcon B toric, senofilcon A toric, omafilcon A toric
62020154|NCT03062826||Patients with STEMI treated medically|Drug: dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel) for at least 12 months.
62020155|NCT01213758||Liver tumors|Patients where stereotactic body radiation therapy is planned for primary or metastatic liver tumors.
62020156|NCT01539291|EXPERIMENTAL|High-dose Idelalisib|Participants will receive idelalisib 300 mg twice daily (600 mg per day).
62212424|NCT06397300|ACTIVE_COMPARATOR|quadratus lumborum block|In the lateral decubitus position. Right block will be performed; the patient will then repositioned for the left block. An ultrasound device with a convex probe (5-8 MHz) will be placed in the mid-axillary line just above the iliac crest. Then, scan dorsally to keep the transverse orientation until seeing the aponeurosis of the transverses abdominus muscle and by following this aponeurosis, QL muscle will be visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle. A spinal needle (20G) will be inserted in-plane from the anterior to posterior direction, and the tip of the needle will be advanced anterior to the QL muscle. The target site for injection is the plane between the quadratus lumborum and psoas major muscles. This will be followed by injection of 0.25% bupivacaine 20 ml in each side.
62212425|NCT06397300|ACTIVE_COMPARATOR|lumbar epidural|"under strict aseptic precautions, lumbar epidural was performed for patients in Group III using a 16-gauge Touhy epidural needle by a median approach. The T12 - L1 or L1 - L2 interspaces was chosen for the injection.~The epidural space identified by the loss of resistance technique. The catheter was advanced 4 cm cephalad. When the aspiration test results for blood and cerebrospinal fluid were negative, a test dose of (3 mL) 2% lidocaine with 1: 200,000 adrenaline was given after the placement of the epidural catheter.~Then this will be followed by injection of 0.25% bupivacaine 15 ml as a single injection after induction of general anesthesia."
62212426|NCT05170438|EXPERIMENTAL|Lenvatinib 12 or 16 mg/day orally,D28; Paclitaxel 80 mg/m2 in 250-500 mL of NS, IV D 1, 8, 15;|one arm Lenvatinib 16 or 12 mg/day orally day 1-28; Paclitaxel 80 mg/m2 in 250-500 mL of normal saline, intravenously over 2 hours on day 1, 8, 15;
62212427|NCT04972942|OTHER|Interventional|"Phase 1: 3 dose levels to determine safety (15 patients)~Dose expansion:~Daratumumab (DARA) treatment post-HCT~1. Induction: DARA IV weekly x 8 doses (Weeks 1-8)~2. Consolidation: DARA IV every 2 weeks x 8 doses (Weeks 9-24)~3. Maintenance: DARA IV every 4 weeks (Stop at Day +270)"
62212428|NCT04127851|EXPERIMENTAL|Sodium Hyaluronate 0.15% mono-therapy|HA 0.15% group was treated with HA 0.15% six times daily for 12 weeks
62212429|NCT04127851|ACTIVE_COMPARATOR|Cyclosporin 0.05% + carboxymethylcellulose (CMC) 0.5% (standard therapy)|CsA 0.05% + CMC 0.5% group was treated with CsA 0.05% two times daily and CMC 0.5% two \~ six times daily for 12 weeks.
62212430|NCT04127851|OTHER|HA 0.15% + CsA 0.05% (combination therapy)|HA 0.15% + CsA 0.05% group was treated with HA 0.15% six times daily and CsA 0.05% twice daily for 12 weeks.
62408831|NCT00584831|ACTIVE_COMPARATOR|Group 16 BLOS|contact lenses worn in this order: balafilcon A toric, lotrafilcon B toric, omafilcon A toric, senofilcon A toric
62408832|NCT00584831|ACTIVE_COMPARATOR|Group 17 BSOL|contact lenses worn in this order: balafilcon A toric, senofilcon A toric, omafilcon A toric, lotrafilcon B toric
62408833|NCT00584831|ACTIVE_COMPARATOR|Group 18 BOLS|contact lenses worn in this order: balafilcon A toric, omafilcon A toric, lotrafilcon B toric, senofilcon A toric
62408834|NCT00584831|ACTIVE_COMPARATOR|Group 19 BOSL|contact lenses worn in this order: balafilcon A toric, omafilcon A toric, senofilcon A toric, lotrafilcon B toric
62408835|NCT00584831|ACTIVE_COMPARATOR|Group 1 LSOB|contact lenses worn in this order: lotrafilcon B toric/senofilcon A toric/omafilconA toric/balafilcon A toric
62408836|NCT05319652|EXPERIMENTAL|Pain self-management program|Participants log in to the online program and develop practical strategies to manage CNCP.
62408837|NCT04067505|EXPERIMENTAL|Rivaroxaban|Participants will receive rivaroxaban 15mg twice daily for three weeks, then 20mg oral once daily after operation.
62408838|NCT04067505|ACTIVE_COMPARATOR|Warfarin/Nadroparin|Participants will receive nadroparin 1mg/kg twice daily (subcutaneous), plus warfarin 3mg oral once daily for 5 days after the operation, later warfarin(oral) at individually titrated doses(0.75mg to 18mg) to achieve a target international normalized ratio (INR) of 2.0 to 3.0, once daily until 6 months.
62408839|NCT02743598|EXPERIMENTAL|Liraglutide|
62408840|NCT06641687|PLACEBO_COMPARATOR|Sterile water|Participants will be given sterile water which does not contain sugar and is used as a placebo
62408841|NCT06641687|EXPERIMENTAL|Sucrose solution|Participants will be given sugar water which contains 24% sucrose. As per pharmacy at The Hospital for Sick Children, Sucrose is not classified as a drug as per Health Canada.
62408842|NCT02175927|EXPERIMENTAL|High Dose Amoxicillin|High dose amoxicillin/metronidazole-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg tid, Metronidazole 400mg qid
62408843|NCT02175927|ACTIVE_COMPARATOR|Tetracycline|Classical quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid
62408844|NCT00924820|EXPERIMENTAL|Bevacizumab|Bevacizumab 10 mg/kg by vein over about 1 hour, every 2 weeks.
62408845|NCT03707938|EXPERIMENTAL|Treatment (brigatinib, LCT)|Patients receive brigatinib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo LCT for up to 3 weeks in the absence of disease progression or unacceptable toxicity. Within 7 days after completion of LCT, patients receive brigatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62408846|NCT04836637|PLACEBO_COMPARATOR|Product with placebo (no calcium supplementation).|Maltodextrin with 0 mg calcium in capsules and sachets consumed orally daily for one year.
62408847|NCT04836637|ACTIVE_COMPARATOR|Product with calcium-carbonate|800 mg calcium as calcium-carbonate in capsules and sachets consumed orally daily for one year.
62408848|NCT04836637|EXPERIMENTAL|"Product with calcium-enriched permeate Capolac"|800 mg of calcium from calcium-enriched permeate in capsules and sachets consumed orally daily for one year.
62020157|NCT01539291|EXPERIMENTAL|Standard-dose Idelalisib|Participants will receive idelalisib 150 mg twice daily (300 mg per day)
62020158|NCT01806480|EXPERIMENTAL|Person-centred proactive breastfeeding telephone support|Proactive breastfeeding telephone support initiated by the Breastfeeding Support Team (BST) at the NICU from which the infant is discharged. Daily phone calls from one member in the BST to the mother will be performed from day 1 until day 14 after discharge. In addition to this, the mother has the option to call someone in the BST during the same period (reactive). The telephone support will be conducted with a person-centered approach. Thus, the mother is enabled to talk about whatever feels important to her including the situation with the new infant at home and her breastfeeding. The feeding support team member should during the telephone support session: have an authentic presence, characterized by being there for the mother, having an empathic approach, taking time touching base, providing affirmation, being responsive, sharing the mother's experience and enabling a relationship.
62020159|NCT01806480|NO_INTERVENTION|Person-centred reactive breastfeeding telephone support|The control group (and the intervention group) will be offered the possibility to person-centred reactive telephone support initiated by the mother who can phone the feeding support team from day 1 after discharge until day 14 after discharge, between 08.00-16.00 every day. Each NICU will set up a specific telephone number for their telephone support, and schedule the members in the BST for availability. The same level of person-centeredness will be provided in both reactive and proactive telephone support.
62212431|NCT01994837|EXPERIMENTAL|ABT-199|Continuous dosing of venetoclax (ABT-199) QD (once daily) beginning with dose-escalation on Week 1 Day 1. Participants received a dose of 20 mg of ABT-199 on Week 1 Day 1, 50 mg on Day 2, 100 mg on Day 3, 200 mg on Day 4, 400 mg on Day 5, 800 mg on Day 6 and QD thereafter.
62212432|NCT05487196|EXPERIMENTAL|Clonidine|"Bolus dose at epidural initiation, through the epidural catheter:~10 ml Ropivacaine 0.1 % combined with a single dose of Clonidine 60 mcg"
62212433|NCT05487196|EXPERIMENTAL|Dexmedetomidine|"Bolus dose at epidural initiation, through the epidural catheter:~10 ml Ropivacaine 0.1 % combined with a single dose of Dexmedetomidine 30 mcg"
62212434|NCT05487196|ACTIVE_COMPARATOR|Ropivacaine + Fentanyl|"Bolus dose at epidural initiation, through the epidural catheter:~10 ml Ropivacaine 0.1 % combined with a single dose of Fentanyl 100mcg"
62408849|NCT04836637|EXPERIMENTAL|"Product with calcium-enriched permeate Capolac and Inulin"|800 mg of calcium from calcium-enriched permeate and 12 g inulin in capsules and sachets consumed orally daily for one year.
62408850|NCT05123807|OTHER|Cytoreductive surgery|
62408851|NCT02724215||Patients with Sleep Apnea|Patients with increased apnea-hypopnea-index (\>5/h)
62408852|NCT02724215||Patients without Sleep Apnea|Patients with normal apnea-hypopnea-index (5/h and below)
62408853|NCT06540352|PLACEBO_COMPARATOR|Placebo|
62408854|NCT06540352|EXPERIMENTAL|1 mg|
62020160|NCT00920192|EXPERIMENTAL|Foretinib|Phase I starting dose of 30 mg/day escalated to 45 mg/day, de-escalated to 30 mg/day; MTD for Phase II was 30 mg/day
62020161|NCT01149304|EXPERIMENTAL|Group A|Medication group with patients receiving the study medication according to the study protocol for 8 weeks after HDR brachytherapy.
62020162|NCT01149304|NO_INTERVENTION|Group B|Comparison group with patients receiving the standard therapy of HDR brachytherapy without the study specific medication.
62020163|NCT02014961|ACTIVE_COMPARATOR|Mutation Carriers|Whole-exome sequencing (WES) Dermal biopsy Gastro-intestinal questionnaire
62020164|NCT02014961|PLACEBO_COMPARATOR|Non-Mutation Carriers|Whole-exome sequencing (WES) Gastro-intestinal questionnaire
62020165|NCT02014961|OTHER|Spouse|Whole-exome sequencing (WES) 12-Lead ECG
62212435|NCT01788839||women with breast cancer|"This study is a prospective, observational, longitudinal study assessing the prevalence of sexual dysfunction and distress in premenopausal and postmenopausal women with breast cancer. This study will also evaluate the severity, time course, and predictors of sexual dysfunction. Breast cancer patients and survivors will be administered surveys of comprehensive questionnaires related to sexual function. In the case that participants miss the follow up questionnaires, study staff may contact the patient by phone to request and record the patients responses. The study staff may also mail the missed questionnaires to each patient."
62212436|NCT01788839||women with lymphoma|"This study is a prospective, observational, longitudinal study assessing the prevalence of sexual dysfunction and distress in premenopausal and postmenopausal women with Diffuse Large B-cell Lymphoma or Hodgkin's Lymphoma. This study will also evaluate the severity, time course, and predictors of sexual dysfunction. Lymphoma patients and survivors will be administered surveys of comprehensive questionnaires related to sexual function. In the case that participants miss the follow up questionnaires, study staff may contact the patient by phone to request and record the patients responses. The study staff may also mail the missed questionnaires to each patient."
62408855|NCT06540352|EXPERIMENTAL|2 mg|
62408856|NCT06106217|EXPERIMENTAL|bapne|
62408857|NCT06106217|EXPERIMENTAL|qi gong|
62408858|NCT04238494|EXPERIMENTAL|Frail/prefrail|Fried's criteria \>3 = frail, 1 or 2 = prefrail The 5 Fried criteria mainly target the muscle function: low muscle strength, decreased physical activity and low gait speed. One refers to depressive symptoms with the use of 2 CES-D (Centre for Epidemiologic Studies - Depression Scale) questions and one to nutrition with the weight loss criteria. The second most famous definition of frailty was developed by ROCKWOOD and MITNISIKI (2). It describes frailty as the accumulation of deficits including cognitive, functional and social alterations
62408859|NCT04238494|OTHER|non frail|No Fried's criteria
62408860|NCT04003103|EXPERIMENTAL|Islatravir 60 mg|60 mg islatravir + placebo for islatravir administered once monthly, orally in capsule form for 24 weeks
62408861|NCT04003103|EXPERIMENTAL|Islatravir 120 mg|120 mg islatravir administered once monthly, orally in capsule form for 24 weeks
62408862|NCT04003103|PLACEBO_COMPARATOR|Placebo|Placebo for islatravir administered once monthly, orally in capsule form for 24 weeks
62408863|NCT01934062||Surgical patients|Pediatric patients having surgery at Nationwide Children's Hosp. between 1/1/2013 \& 7/31/2013.
62408864|NCT05950204|ACTIVE_COMPARATOR|Group A|100 mg/kg/d of LCPUFA-ω3 with a ceiling dose of 3 g/d, + 1,000 mg of calcium/day and 4,000 IU (100 µg)/d of VD in those children \> 9 years and 20,000 UI/week = 2,857 UI/d in those \< 8 years for 6 weeks
62408865|NCT05950204|ACTIVE_COMPARATOR|Group B|1,000 mg of calcium/day and 4,000 IU (100 µg)/d of VD in those children \> 9 years and 20,000 UI/week = 2,857 UI/d in those \< 8 years for 6 weeks
62020166|NCT05490459|EXPERIMENTAL|Treatment|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
62212437|NCT01386762|EXPERIMENTAL|Exercise intervention|6 months of intense multimodal training.
62408866|NCT01060007|EXPERIMENTAL|Neoadjuvant radiation followed by FOLFOX|"Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.~FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat ever other week for a total of 4 courses (this equals 6 weeks).~If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days."
62408867|NCT06411431|EXPERIMENTAL|Early Chest Tube Removal|"Subjects within the Early Removal group will have their chest tube removed on POD#1 within 24 hours from the end of the surgery."
62408868|NCT06411431|ACTIVE_COMPARATOR|Standard Chest Tube Removal|"Subjects in the Standard Removal group will have their chest tube kept to suction on POD#1 with removal on POD#2."
62212438|NCT06172387|EXPERIMENTAL|intra-arterial group|20% human serum albumin (0.6g/kg) solution will be injected into the artery after revascularization in acute ischemic stroke. All participants will receive mechanical thrombectomy and a standard clinical therapy.
62212439|NCT06172387|OTHER|sham group|All participants have no intra-arterial albumin.
62212440|NCT04014595||Rotational atherectomy + Cutting Balloon|Rotational atherectomy in combination with cutting balloon in severely calcified coronary lesions
62212441|NCT05374200|EXPERIMENTAL|Intervention group|Participants will receive the standard of care for PBC and access to the online intervention. During the intervention period, participants will also receive weekly brief (\~10-minute) motivational interview style telephone check-ins.
62212442|NCT05374200|NO_INTERVENTION|Wait list control group|During the 12-week wait list period, participants will receive the standard of care for PBC in addition to weekly emails with motivational messages.
62212443|NCT00833768|ACTIVE_COMPARATOR|Sevelamer carbonate|
62212444|NCT00833768|PLACEBO_COMPARATOR|Placebo|
62212445|NCT04183036|NO_INTERVENTION|Small EST combined with EPLBD|
62408869|NCT06103617|EXPERIMENTAL|Penicillamine group|Participants in this group are treated with Penicillamine (250mg each time, 4 times per day) during reradiation.
62408870|NCT05349760|EXPERIMENTAL|AMB-05X|AMB-05X will be administered every 4 weeks for 24 weeks (for 6 treatments in total).
62408871|NCT05349760|PLACEBO_COMPARATOR|Placebo|Placebo will be administered every 4 weeks for 24 weeks (for 6 treatments in total).
62408872|NCT03949634|EXPERIMENTAL|PLD plus CTX sequential docetaxel or PTX|pegylated liposomal doxorubicin 35 mg/m2,i.v.,d1, plus cyclophosphamide（CTX） 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel（PTX） 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.
62408873|NCT03949634|ACTIVE_COMPARATOR|DOX plus CTX sequential docetaxel or PTX|doxorubicin（DOX） 60 mg/m2,i.v.,d1, plus cyclophosphamide 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.
62408874|NCT01408836|EXPERIMENTAL|1|Plasma exchange x 7 over 14 days
62584378|NCT01828983|ACTIVE_COMPARATOR|Education webinars|Education Webinar session topics are the same that are covered in the intervention arm without telephone interaction/support and skills building components. Each session is 30-minutes. Each participant receives a Spouse Workbook with information and activities.
62212446|NCT04183036|EXPERIMENTAL|Large EST combined with ECPP|
62584379|NCT05830136|EXPERIMENTAL|Group A|Sodium bicarbonate Ringer's solution group
62790547|NCT06300073|EXPERIMENTAL|Manual Toothbrush|Participants first received the ADA reference manual toothbrush for a single brushing use for 2 minutes; after a 2-day washout period, participants received the AutoBrush U-shaped power toothbrush with fluoride toothpaste for a single brushing use for 30 seconds.
62020167|NCT02341300|EXPERIMENTAL|Cast-Iron Pot|The treatment arm will receive a 12 inch pre seasoned cast iron pot
62020168|NCT02341300|PLACEBO_COMPARATOR|Aluminum Pot|12 inch nonstick aluminum fry pan
62020169|NCT00958919|EXPERIMENTAL|naloxone|
62020170|NCT00958919|PLACEBO_COMPARATOR|normal saline|
62020171|NCT04824846|EXPERIMENTAL|Ambulance drivers with received Integrated back pain module (IBPM)|Behavioral: Integrated back pain module (IBPM)
62020172|NCT04824846|OTHER|Ambulance drivers with received Health Educational Pamphlet.|Other: Health Educational Pamphlet.
62212447|NCT05448105|EXPERIMENTAL|My Diabetes Care (MDC) Mobile|Patients have access to a patient web portal embedded with the My Diabetes Care (MDC) intervention.
62212448|NCT03819790|EXPERIMENTAL|Insulin Glargine + GLP-1 RA|Insulin Soliqua (a titratable combination of insulin Glargine + GLP-1 RA) will be administered at the subject's end-of run-in phase insulin dose (minimum dose of 15 units in both arms) every morning (before first meal of day) and titrate by one unit per day until fasting glucose level of 4-5.5 mmol/L is obtained, with or without metformin.
62212449|NCT03819790|ACTIVE_COMPARATOR|Basaglar/Lantus + gliclazide MR|Basal insulin Basaglar/Lantus will be administered at the subject's end-of run-in phase insulin dose (minimum dose of 15 units in both arms) every morning (before first meal of day) and titrate by one unit per day until fasting glucose level of 4-5.5 mmol/L is obtained, with gliclazide MR 60 mg OD, with or without metformin.
62212450|NCT02939963|EXPERIMENTAL|ATC then pressure support 7 cm H2O PEP 4 cm H2O|spontaneous breathing through endotracheal tube with no ventilator support except for ATC
62212451|NCT02939963|EXPERIMENTAL|pressure support 7 cm H2O PEP 4 cm H2O then ATC|ventilator is set to pressure support ventilation mode at set pressure 7 cm H2O above PEEP level of 4 cm H2O
62212452|NCT04563208|PLACEBO_COMPARATOR|Arm A: Placebo|Placebo administered
62212453|NCT04563208|ACTIVE_COMPARATOR|Arm B: Ribavirin/Nitazoxanide (RBV/NTZ)|Ribavirin/Nitazoxanide (RBV/NTZ) administered
62212454|NCT03210922|EXPERIMENTAL|Collar group|Standard of anesthetic care and nasointubation with patient wearing the Miami cervical collar.
62212455|NCT03210922|NO_INTERVENTION|Non-collar group|Standard of anesthetic care and nasointubation with patient not wearing the Miami cervical collar.
62408875|NCT01408836|ACTIVE_COMPARATOR|2|Methyl prednisolone 1g x 3
62408876|NCT03542929|ACTIVE_COMPARATOR|healthy elderly|healthy elderly were use the Whole body vibration intervention during 10 minutes
62408877|NCT03542929|EXPERIMENTAL|diabetic elderly|diabetic elderly were use the Whole body vibration intervention during 10 minutes
62584380|NCT05830136|ACTIVE_COMPARATOR|Group B|Lactate Ringer's solution group
62584381|NCT04017351|EXPERIMENTAL|Subjects with virtual assistance|Subjects receiving current standard of care for a surgical procedure within the department of plastic surgery will have access to artificial intelligence virtual assistance (AIVA)
62212456|NCT06397326|EXPERIMENTAL|Return to work coordinator + PRATICAdr 2.0|"The primary objective of the Return to work coordinator (RTW-C) is to coordinate, plan, and promote sustainable RTW for employees on sick leave.The RTW-C is responsible for assessing employee functioning while exploring barriers to RTW and available resources to develop a RTW plan. Also, RTW-C enhance communication and collaboration among stakeholders involved in the RTW process.~In this arm, the RTW-C uses PRATICAdr 2.0, a web application including key features (e.g., Facilitation of collaboration among multiple RTW stakeholders across healthcare, enterprise, and insurance sectors; Integration of each stakeholder's action into the sick leave employee's RTW process; sequential process aligned with the three phases of the RTW, inclusion of tools)."
62020173|NCT02087800||F Phase Lab session|Potential participants will complete an interview over the phone, followed by an in clinic office visit, to assess eligibility. Those who meet eligibility criteria will be invited to attend two four-hour lab sessions. Lab sessions will occur in the F (F phase lab session) and L phases (L phase lab session) of menses. In this arm, the F phase lab session will be first. Followed by the L phase lab session.
62790548|NCT00589771|EXPERIMENTAL|A|"1. Capsule Saccharomyces boulardii 250 mg TDS for six weeks.~2. Ispahgula husk 1 Tsf daily after dinner for six weeks."
62790549|NCT00589771|PLACEBO_COMPARATOR|B|"1. Capsule Placebo TDS for six weeks.~2. Ispaghula husk 1 Tsf daily after dinner for six weeks"
62020174|NCT02087800||L Phase Lab Session|Potential participants will complete an interview over the phone, followed by an in clinic office visit, to assess eligibility. Those who meet eligibility criteria will be invited to attend two four-hour lab sessions. Lab sessions will occur in the F (F phase lab session) and L phases (L phase lab session) of menses. In this arm, the L phase lab session will be first. Followed by the F phase lab session.
62020175|NCT01699997|EXPERIMENTAL|Oxytocin|Each treatment will consist of 10 insufflations (5/nostril alternating between nostrils) of OXT Spray, which contains approximately 40 international units (IU) of OXT
62020176|NCT01699997|PLACEBO_COMPARATOR|Placebo vial|Each treatment will consist of 10 insufflations (5/nostril alternating between nostrils) of placebo Spray, which contains all OXT Spray ingredients except for oxytocin.
62020177|NCT00510666|EXPERIMENTAL|1|Butorphanol basal infusion adjunct to morphine PCA
62790550|NCT02457468||Stenosis patients treated with coflex|Patients with a primary diagnosis of lumbar spinal stenosis treated with coflex after decompression
62790551|NCT04548791|EXPERIMENTAL|Cohort 1|For Phase 1, a Coagulation Factor VIIa variant by intravenous route, 18 μg/kg, followed by ascending doses by subcutaneous route, 10 μg/kg, 20 μg/kg, 30 μg/kg, 40 μg/kg, and 60 μg/kg, for PK and PD assessment. For Phase 2, Coagulation Factor VIIa, 20 μg/kg by subcutaneous route, administered on demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis.
62790552|NCT04548791|EXPERIMENTAL|Cohort 2|For Phase 1, a Coagulation Factor VIIa variant by intravenous route, 18 μg/kg, followed by ascending doses by subcutaneous route, 30 μg/kg, 45 μg/kg, 60 μg/kg, 120 μg/kg, and 180 μg/kg, for PK and PD assessment. For Phase 2, Coagulation Factor VIIa, 60 μg/kg by subcutaneous route, administered on demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis.
62790553|NCT04548791|EXPERIMENTAL|Cohort 3|For Phase 1, a Coagulation Factor VIIa variant by intravenous route, 18 μg/kg, followed by ascending doses by subcutaneous route, 30 μg/kg, 45 μg/kg, 60 μg/kg, 120 μg/kg, and 180 μg/kg, for PK and PD assessment. For Phase 2, Coagulation Factor VIIa, 60 μg/kg by subcutaneous route, administered on demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis.
62790554|NCT01363908|EXPERIMENTAL|SPD602 (26 mg/kg)|Oral SSP-004184AQ taken once daily for 48 weeks
62790555|NCT01363908|EXPERIMENTAL|SPD602 (36 mg/kg)|Oral SSP-004184AQ taken once daily for 48 weeks. Starting dose based on transfusion burden and iron overload status. Doses may range from 8-60mg/kg/day depending on clinical response.
62790556|NCT01363908|EXPERIMENTAL|SPD602 (16 mg/kg)|A single dose given in the initial pharmacokinetic phase.
62020178|NCT00510666|EXPERIMENTAL|2|Saline infusion adjunct to morphine PCA
62020179|NCT00510666|EXPERIMENTAL|3|Premedication of Tramadol
62020180|NCT00510666|EXPERIMENTAL|4|Preemptive saline for morphine PCA
62020181|NCT02842775|EXPERIMENTAL|Dynamic balance exercise group|balance perturbation training
62020182|NCT02842775|NO_INTERVENTION|Control group|No intervention
62020183|NCT03907501|EXPERIMENTAL|Synbiotic|Two grams of organic Triphala powder (Banyan Botanicals, Inc.) with 1 capsule VSL#3® (VSL Pharmaceuticals, Inc.) probiotic taken with a few ounces of room temperature water in the morning and at bedtime for 8 weeks. Subjects will be provided both written and verbal instructions and given a kit containing encapsulated Organic Triphala powder (Banyan Botanicals, Inc.) and VSL#3® (VSL Pharmaceuticals, Inc.) capsules.
62020184|NCT03907501|ACTIVE_COMPARATOR|Probiotic|Subjects will be provided both written and verbal instructions and given a kit containing encapsulated Organic Triphala powder (Banyan Botanicals, Inc.). Subjects will take 2 grams of organic Triphala powder with a few ounces of room temperature water in the morning and at bedtime.
62020185|NCT03907501|PLACEBO_COMPARATOR|Placebo|Subjects will be provided both written and verbal instructions and given a kit containing placebo capsules. Subjects will be instructed to take 2 (inert) capsules with room temperature water in the morning and at bedtime.
62212457|NCT06397326|SHAM_COMPARATOR|Return to work coordinator only|"The primary objective of the Return to work coordinator (RTW-C) is to coordinate, plan, and promote sustainable RTW for employees on sick leave.The RTW-C is responsible for assessing employee functioning while exploring barriers to RTW and available resources to develop a RTW plan. Also, RTW-C enhance communication and collaboration among stakeholders involved in the RTW process.~In this arm, the RTW-C does not use PRATICAdr 2.0."
62212458|NCT01603901|EXPERIMENTAL|Investigated Wounds|
62584382|NCT04017351|NO_INTERVENTION|Subjects without virtual assistance|Subjects receiving current standard of care for a surgical procedure within the department of plastic surgery
62584383|NCT00598351||Patients|Patients must have the diagnosis of NF2 by established clinical criteria or genetic testing.
62584384|NCT05652699|ACTIVE_COMPARATOR|High Flow Nasal Oxygen|60L/minute. FiO2 according to clinical protocol. Temperature highest tolerated by patient, starting with 37 degrees Celcius.
62584385|NCT05652699|ACTIVE_COMPARATOR|Conventional Oxygen therapy|
62212459|NCT05922059|EXPERIMENTAL|Vagus nerve stimulation|Transcutaneous vagus nerve stimulation in addition to standard-care physiotherapy
62212460|NCT05922059|EXPERIMENTAL|Heart rate variability biofeedback|Heart rate variability biofeedback in addition to standard-care physiotherapy
62408878|NCT03612830|EXPERIMENTAL|LECS|Laparoscopic and Endoscopic cooperative surgery,LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .
62584386|NCT05286255|EXPERIMENTAL|Allogeneic Mesenchymal Stromal Cell infusion|Intravenous infusion of 1.25-1.5 x 10\^6 cells/kg with a maximal dose of 100 x 10\^6 cells on days 1 and 3 after study enrollment.
62584387|NCT05969964||Re_TUR|Those patients diagnosed with pT1 after initial ERBT with negative vertical and horizontal safety margins will undergo second look as endorsed by the guidelines.
62020186|NCT03790891|EXPERIMENTAL|CD19-TriCAR-T/SILK|CD19-TriCAR-T/SILK cells will be administered intravenously
62020187|NCT05926297|EXPERIMENTAL|NaOCl + HA Group|A NaOCl-based gel will initially be applied in the peri-implant sulcus for 30 seconds, without the need for flushing. Furthermore, mechanical therapy (NSMD) will be performed by means of an ultrasonic scaler with a plastic tip. Finally, the HA-based gel will be applied in the peri-implant sulcus by means of a blunt-tipped needle.
62020188|NCT05926297|ACTIVE_COMPARATOR|NSMD Group|Control group will be treated only through a non-surgical mechanical therapy with curettes or scaler tips.
62020189|NCT04134897|EXPERIMENTAL|Neoadjuvant chemotherapy|Patients will receive 4 cycles of neoadjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks). In case of partial response or stable disease (based on pelvic MRI) patients proceed to surgery within 2 weeks. In case of disease progression patients receive 50 Gy pelvic chemoradiotherapy with capecitabine 825 mg/m2 bid per os on radiation days and then surgery following 8-10 weeks. After surgery patients receive 4 cycles of adjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks).
62020190|NCT04134897|ACTIVE_COMPARATOR|Neoadjuvant radiotherapy|Patients will receive 5x5 Gy radiotherapy and then surgery following 6-8 weeks. After surgery patients receive 8 cycles of adjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks).
62584388|NCT05969964||No re_TUR|Those patients diagnosed with pT1 after initial ERBT with negative vertical and horizontal safety margins won't undergo second look as endorsed by the guidelines and will receive directly intravesical BCG
62584389|NCT06355258|EXPERIMENTAL|Troxerutin+low molecular weight heparin|
62584390|NCT06355258|PLACEBO_COMPARATOR|Placebo+low molecular weight heparin|
62584391|NCT06355258|EXPERIMENTAL|Troxerutin|
62584392|NCT06355258|PLACEBO_COMPARATOR|Placebo|
62584393|NCT00327769|ACTIVE_COMPARATOR|1|Anastrozole
62584394|NCT00327769|EXPERIMENTAL|2|Anastrozole + Fulvestrant
62020191|NCT01594905|EXPERIMENTAL|Entecavir 1.0mg + Tenofovir 300mg|All subjects will orally take investigational drugs once daily for 48 weeks.
62020192|NCT04674345|EXPERIMENTAL|Sorafenib group|Sorafenib will be administered at 45-60 days post-transplantation and taken for one year.
62790557|NCT03909308|NO_INTERVENTION|Control session|Control session without any exercise. The participants remained in seated rest throughout 45 min.
62020193|NCT04674345|NO_INTERVENTION|Non-maintenance group|Neither sorafenib nor other FLT3 inhibitors will be used, unless the patient experiences relapse.
62020194|NCT00727857|EXPERIMENTAL|Pioglitazone 15 mg /Metformin 850 mg BID|
62020195|NCT00727857|ACTIVE_COMPARATOR|Pioglitazone 15 mg BID|
62212461|NCT05922059|ACTIVE_COMPARATOR|standard-care physiotherapy alone|standard-care physiotherapy
62212462|NCT01276379|EXPERIMENTAL|FOLFIRI (m) or FOLFOX-6 (m) + cetuximab|FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.
62212463|NCT01140295|ACTIVE_COMPARATOR|1, Miralax|Miralax colonoscopy preparation
62212464|NCT01140295|ACTIVE_COMPARATOR|2, senna|Senna colonoscopy preparation
62212465|NCT06206187|ACTIVE_COMPARATOR|Electrophysiologist judgment|
62212466|NCT06206187|EXPERIMENTAL|Artificial Intelligence Detection|
62212467|NCT00601159|EXPERIMENTAL|gemcitabine and cisplatin|cisplatin and gemcitabine in the management of triple negative metastatic breast cancer
62212468|NCT03492749||Group Busulfan|Patients submitted a Bone marrow transplantation with the busulfan chemotherapy in the conditioning. Saliva monitoring
62212469|NCT03492749||Group no busulfan|Patients submitted a Bone marrow transplantation without busulfan chemotherapy in the conditioning.Saliva monitoring
62408879|NCT03612830|EXPERIMENTAL|RECS|Robotic and Endoscopic cooperative surgery,RECS resects the tumor completely by Dan Vinchi robot with the help of the precise positioning and guidance of endoscopy .
62408880|NCT06648226|EXPERIMENTAL|Health swaps|"Labels will be health grades for products and replacement swap suggestions will be for items with a better health grade."
62408881|NCT06648226|EXPERIMENTAL|Environment swaps|"Labels will be climate grades for products and replacement swap suggestions will be for items with a better climate grade."
62408882|NCT06648226|EXPERIMENTAL|Combined health and environment swaps|"Labels will be health grades and climate grades for products and replacement swap suggestions will be for items with a better health grade or better environment grade."
62584395|NCT04905602|EXPERIMENTAL|Cohort 1|A single subcutaneous injection of SHR-1905/placebo dose 1 in healthy subjects
62584396|NCT04905602|EXPERIMENTAL|Cohort 2|A single subcutaneous injection of SHR-1905/placebo dose 2 in healthy subjects
62584397|NCT04905602|EXPERIMENTAL|Cohort 3|A single subcutaneous injection of SHR-1905/placebo dose 3 in healthy subjects
62408883|NCT06648226|ACTIVE_COMPARATOR|Control|No labels or swaps.
62020196|NCT00727857|ACTIVE_COMPARATOR|Metformin 850 mg BID|
62408884|NCT06022666|NO_INTERVENTION|Standard of care|Patients will undergo the usual preoperative assessment from preoperative clinic which includes standard general internal medicine and anesthesia assessment.
62408885|NCT06022666|EXPERIMENTAL|PATH geriatric care|Pre-operative assessment through the PATH clinic
62020197|NCT00483522|EXPERIMENTAL|1|Scheduled telephone counseling over 2 years time.
62020198|NCT00483522|NO_INTERVENTION|2|This control group will receive standard care after hospital rehabilitation discharge as directed by their physician.
62020199|NCT01231698|EXPERIMENTAL|esmolol|
62020200|NCT01231698|OTHER|control|
62020201|NCT04211103|EXPERIMENTAL|Pembrolizumab single agent|"Pembrolizumab single agent as neoadjuvant treatment before surgical conization and/or partial or radical vulvectomy.~Pembrolizumab 200 mg flat dose will be administered every 3 weeks for 5 cycles. Within 3 weeks from the last Pembrolizumab administration patients will be submitted to surgical conization or partial or radical vulvectomy."
62020202|NCT03111498|OTHER|theory-based training programme|theory-based training programme (oral presentation including a step-by-step guidance saying)
62020203|NCT03111498|OTHER|practice-based training|practice-based training programme (one-to-one teaching)
62020204|NCT01895465|EXPERIMENTAL|A slitted diaper|An ordinary pediatric urine collection bag used in the ED that will be used together with the slitted diaper
62020205|NCT03950063||Patients with Cutibacterium acnes bone infections|Patients with Cutibacterium acnes orthopedic material infections
62020206|NCT03934268||infants with seizure with KCNQ2 gene mutation.|Infants who met the inclusion criteria were enrolled in this study. The infants will get their own DNA sequencing results by WES technology. The researchers found that some of them carried mutations in the KCNQ2 gene. so they wanted to compare whether there were differences with or without KCNQ2 gene mutations in the efficacy of anticonvulsants or long-term neurodevelopment in different exposure groups.
62020207|NCT04378933|EXPERIMENTAL|Amber Glasses and Fixed Wake|Participants will wear glasses with amber lenses beginning 7 hours before average baseline mid-sleep time until the time of intended sleep onset or until a duration of 7 hours of use is reached. Participants will also be required to wake up at the same time (±30 mins).
62020208|NCT04378933|ACTIVE_COMPARATOR|Clear glasses and Free Wake|Participants will wear identically appearing glasses with clear lenses beginning 7 hours before average baseline mid-sleep time until the time of intended sleep onset or until a duration of 7 hours of use is reached. Participants will not be given instructions regarding sleep schedule.
62020209|NCT05649657|EXPERIMENTAL|CKD patients with exercise training intervention|The participants with 3-5 CKD will go through three phases: 3-month control, 6-month intervention, and 3-month maintenance. No intervention will be performed in the control and maintenance phases
62020210|NCT05649657|NO_INTERVENTION|CKD stage 1 and 2|no inervention
62020211|NCT05649657|NO_INTERVENTION|CKD stage 1 and 2 respectively, and 20 healthy subjects|no inervention
62212470|NCT04450017||Clinical Features of Severe Patients With COVID-19|Critical ill patients with COVID-19 admitted to the ICU. The demographic, clinical data, laboratory data, and Instrumental data will be analysed.
62212471|NCT00652327|EXPERIMENTAL|Ezetimibe + Statin|
62212472|NCT00652327|ACTIVE_COMPARATOR|Double Statin|
62020212|NCT00840970|ACTIVE_COMPARATOR|Efficacy Unilateral Control|Non-coated splint placed unilaterally in the ethmoid sinus opening randomized to receive the active comparator following FESS (control arm)
62020213|NCT00840970|EXPERIMENTAL|Efficacy Unilateral Treatment|Drug-coated splint placed unilaterally in the ethmoid sinus opening randomized to receive the intervention following FESS (treatment arm)
62020214|NCT00840970|EXPERIMENTAL|Safety/PK Bilateral Treatment|Drug-coated splints placed bilaterally in both ethmoid sinus openings following FESS
62020215|NCT01312909|EXPERIMENTAL|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
62212473|NCT01342341|EXPERIMENTAL|Parafon Forte first, then Placebo|Experimental: Forty moderate to heavy social alcohol users (women=10-25 drinks/week, men=14-30 drinks/week) will receive either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (1st intervention; 14 days), followed by a washout (7 days), and then followed by placebo (2nd intervention; 14 days).
62408886|NCT01824095|PLACEBO_COMPARATOR|placebo|Acute phase (1st treatment through Week 4): Placebo. 2 capsules 3 x day. Chronic phase (Weeks 5-16): Placebo. 1 capsule 3 x day.
62408887|NCT01824095|EXPERIMENTAL|dietary supplement|"Acute phase (1st treatment through Week 4): Ligaplex 1. Ligaplex 1 supplies nutrients to support connective tissue and reduce inflammation. The protocol is commonly used in chiropractic practice and suggested by Standard Process: 2 capsules 3 x day.~Chronic phase (Weeks 5-16): Glucosamine Synergy. This supplement maintains connective tissue and joint health. The protocol is commonly used in chiropractic practice and suggested by Standard Process: 1 capsule 3 x day."
62408888|NCT03313388|EXPERIMENTAL|Tart Cherry Juice|290 mL per day of Tart Cherry juice for 7 days
62408889|NCT03313388|ACTIVE_COMPARATOR|Gatorade|290 mL per day of Gatorade for 7 days
62408890|NCT05797948|EXPERIMENTAL|GZL sequential CD19/CD22 CAR-T|"Phase I (combined immunotherapy period):~2-4 cycle of combination chem-free therapy with Obinutuzumab, Zanubrutinib and Lenalidomide . Each cycle is 21 days.~Phase II (CAR-T therapy):~CAR-T therapy with AZA + FC (Azacitidine, Fludarabine and Cyclophosphamide) conditioning regimen. Targets of CAR-T cells are CD19/CD22."
62408891|NCT02558075|EXPERIMENTAL|MoodLifters Program|A program to provide evidence-based education and skills to reduce psychological distress and enrich people's lives.
62020216|NCT01312909|EXPERIMENTAL|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
62020217|NCT01312909|PLACEBO_COMPARATOR|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
62020218|NCT06475157||Patient group with progression of valvular heart diseases|
62020219|NCT06475157||Patient group without progression of valvular heart diseases|
62020220|NCT05827224||Air Optix Aqua Sphere|Lotrafilcon B spherical soft contact lenses worn in both eyes and removed daily for cleaning and disinfection
62020221|NCT05827224||Air Optix plus HydraGlyde Sphere|Lotrafilcon B spherical soft contact lenses with comfort additive worn in both eyes and removed daily for cleaning and disinfection
62020222|NCT05827224||Air Optix plus HydraGlyde Toric|Lotrafilcon B toric soft contact lenses with comfort additive worn in both eyes and removed daily for cleaning and disinfection
62020223|NCT05827224||Biofinity Sphere|Comfilcon A spherical soft contact lenses worn in both eyes and removed daily for cleaning and disinfection
62212474|NCT01342341|PLACEBO_COMPARATOR|Placebo first, then Parafon Forte|Experimental: Forty moderate to heavy social alcohol users (women=10-25 drinks/week, men=14-30 drinks/week) will receive placebo (1st intervention; 14days) followed by a washout (7 days), and then followed by either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (2nd intervention; 14 days).
62020224|NCT05827224||Biofinity Toric|Comfilcon A toric soft contact lenses worn in both eyes and removed daily for cleaning and disinfection
62020225|NCT05230329||Completemesocolic excision by laparoscopy for right sided cancer|
62020226|NCT05230329||Completemesocolic excision by robot for right sided cancer|
62020227|NCT05230329||Standard right hemi colectomy excision by laparoscopy for right sided cancer|
62020228|NCT03818217|EXPERIMENTAL|Coach Pepper group|Pepper is a humanoid socially assistive robot.
62020229|NCT03818217|OTHER|Tablet group|Tablet training
62212475|NCT02342431|ACTIVE_COMPARATOR|Forced air compressible warming|Warming with a compressible forced air mattress
62020230|NCT02390804|EXPERIMENTAL|single-port laparoscopic hysterectomy|total laparoscopic hysterectomy via transumbilical single port
62020231|NCT02390804|ACTIVE_COMPARATOR|multi-port laparoscopic hysterectomy|total laparoscopic hysterectomy via multi-port (3 port)
62020232|NCT05229679|EXPERIMENTAL|HPV-based screening|Women 23-29 invited to cervical screening will have their samples analyzed for HPV.
62020233|NCT04173221|EXPERIMENTAL|Intervention|
62020234|NCT04173221|OTHER|Control|
62020235|NCT06535295||Obesity Group|Older patients with obesity
62020236|NCT06535295||Hypertension Group|Older patients with hypertension
62020237|NCT06535295||Type 2 Diabetes Group|Older patients with type 2 diabetes
62020238|NCT06535295||Healthy Group|Healthy older adults
62020239|NCT06502314|EXPERIMENTAL|intervention group|In the first interview with the students assigned to the intervention group, students were informed about the purpose of the study and the process, and pre-tests were applied to the students after their consent was obtained. After 1 week, students randomly assigned to the intervention group were given psychoeducation on stress management consisting of 7 modules each lasting 120 minutes (with a break), on a day determined during the week for 7 weeks. Two weeks after the training was completed, post-tests were applied to the intervention group students.
62020240|NCT06502314|NO_INTERVENTION|control group|In the first interview with the students assigned to the control group, students were informed about the purpose of the study and the process, and pre-tests were applied to the students after their consent was obtained. Ten weeks after, post-tests were applied to the control group students. During this process, no intervention was applied to the control group. After the study was completed, the same stress management training was given to the control group.
62212476|NCT02342431|EXPERIMENTAL|Forced air non-compressible|Warming with a non-compressible forced air mattress
62212477|NCT04670718|EXPERIMENTAL|OCT probe|The examination of gastrointestinal tract resected specimen with the use of the OCT probe
62408892|NCT04054011|EXPERIMENTAL|deoxycholic acid|Deoxycholic acid (Kybella) 10 mg/ mL will be injected subcutaneously, targeting the medial thigh deep fat compartment (pre-fascial). Subjects will receive deoxycholic acid 2 mg/ cm2, with injections of 0.2 mL spaced evenly 1 cm apart within the treatment area. Bilateral thighs will be treated. Each treatment will consist of a maximum of 8 mL (40 injection sites) of the study drug, with a maximum of 4 mL (20 injection sites) of the study drug for each thigh. Subjects will undergo 1-4 treatment sessions, each treatment session separated by 6 weeks +/- 1 week (Treatment #2, #3, or #4 will be pursued if patient desires more treatment, and if there is sufficient fat for treatment, per investigator's judgment.)
62408893|NCT02448212|EXPERIMENTAL|PART 1 (Test/Retest)|Dosing with \[11C\]TASP0410699 for PET imaging without dosing of TS-121
62408894|NCT02448212|EXPERIMENTAL|PART 2 (PET Receptor Occupancy Study)|Dosing with \[11C\]TASP0410699 for PET imaging with dosing of TS-121
62408895|NCT04375566||IT specialist|20 IT Specialist will evaluate the usability and patient-friendliness of the tool
62408896|NCT04375566||Doctors|13 doctors will evaluate the information in the tool
62408897|NCT04375566||Patients|10-20 patients will evaluate the utility and the contribution of the tool in decision making proces.
62408898|NCT04973670|EXPERIMENTAL|Sivelestat sodium|Sivelestat sodium 0.2mg/kg.h
62408899|NCT04973670|ACTIVE_COMPARATOR|placebo|The same amount of NS containing only sivelestat sodium excipients
62408900|NCT02612649||Ramosetron group|Female patients with diarrhea-predominant irritable bowel syndrome
62408901|NCT05705349|EXPERIMENTAL|DOR/ISL|Participants take DOR/ISL and placebo to BIC/FTC/TAF once daily (qd) for 144 weeks.
62408902|NCT05705349|ACTIVE_COMPARATOR|BIC/FTC/TAF|Participants take BIC/FTC/TAF and placebo to DOR/ISL qd for 144 weeks.
62408903|NCT03240809|EXPERIMENTAL|Cohort 1|(ages 12 to \<18 years): 140 mg SC dose of brodalumab
62408904|NCT03240809|EXPERIMENTAL|Cohort 2|(ages 6 to \<12 years): 70 mg SC dose of brodalumab
62408905|NCT04368117|ACTIVE_COMPARATOR|Standard Therapy (ST)|Patients randomized to the ST group will receive standard of care, routine burn physical therapy.
62408906|NCT04368117|EXPERIMENTAL|Active Therapy (STAT)|Patients randomized to the STAT group will receive an intensive, quantifiable, activity-based physical therapy prescription emphasizing four of the most active components of therapy: mobilization, strength training, aerobic training and functional training.
62408907|NCT03570307|OTHER|drug treatment|Misoprostol for uterine evacuation
62408908|NCT03570307|OTHER|surgical treatment|dilatation and curettage for uterine evacuation
62408909|NCT02452008|EXPERIMENTAL|Arm 1: Enzalutamide with LY2157299|
62212478|NCT03951506|EXPERIMENTAL|Experimental-Multi-modal exercise program|Each session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk,one-leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking. Finally, participants are instructed to walk at their usual pace for at least 10 minutes.
62020241|NCT01172938|EXPERIMENTAL|Apremilast 20 mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
62212479|NCT03951506|EXPERIMENTAL|Experimental-conventional treatment|Each session (48) consist in isotonic exercises of low intensity and joint mobility of the lower extremities. These exercises are usually prescribed in medical consultations for the treatment of knee osteoarthritis.
62212480|NCT03189940|ACTIVE_COMPARATOR|App user group|
62408910|NCT02452008|EXPERIMENTAL|Arm 2: Enzalutamide alone|
62408911|NCT02361801|ACTIVE_COMPARATOR|Liberal dobutamine group|All patients will receive dobutamine at the cardiopulmonary bypass weaning
62584398|NCT04905602|EXPERIMENTAL|Cohort 4|A single subcutaneous injection of SHR-1905/placebo dose 4 in healthy subjects
62020242|NCT01172938|EXPERIMENTAL|Apremilast 30mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
62212481|NCT03189940|SHAM_COMPARATOR|Control group|Control participants, the physicians could assess the lifestyle and recommend further lifestyle modification only on the basis of the participants' recalls
62408912|NCT02361801|ACTIVE_COMPARATOR|Restrictive dobutamine group|Patients will only receive dobutamine if they present clinical signs of cardiogenic shock
62408913|NCT01019746|EXPERIMENTAL|control propofol administration|
62408914|NCT04756167|ACTIVE_COMPARATOR|Conventional Group|The treatment of 21 individuals in the conventional group will be done by the researcher. Among the conservative treatment methods, hot pack(15 minutes) around the glenohumeral joint, conventional TENS(15 minutes) for painful points, ultrasound(1.5 watt / cm² power, 5 minutes) and exercise(passive and active range of motion) approaches will be applied. Individuals will be asked to come to the center where the research will be conducted for a total of fifteen sessions for three weeks, five times a week.
62408915|NCT04756167|ACTIVE_COMPARATOR|Myofascial Release Group|Treatment of 21 individuals in the Myofascial Release group will be done by the researcher. Among the conservative treatment methods, hot pack(15 minutes) around the glenohumeral joint, conventional TENS(15 minutes) for painful points, ultrasound(1.5 watt / cm² power, 5 minutes),exercise(passive and active range of motion) and myofascial release to subscapularis and serratus anterior muscles approaches will be applied. Individuals will be asked to come to the center where the research will be conducted for a total of fifteen sessions for three weeks, five times a week. Myofascial release will be done in the first five sessions of treatment programs.
62584399|NCT04905602|EXPERIMENTAL|Cohort 5|A single subcutaneous injection of SHR-1905/placebo dose 5 in healthy subjects
62584400|NCT04905602|EXPERIMENTAL|Cohort 6|A single subcutaneous injection of SHR-1905/placebo dose 6 in subjects with mild asthma
62584401|NCT03088124|NO_INTERVENTION|active surveillance|Active surveillance without androgen deprivation
62212482|NCT05103371|EXPERIMENTAL|"Mili prevention program, adolescents and active parents"|"The program Mili will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents will also participate by a phone app that will pass the parents activities to do with their children, in parallel to the program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
62212483|NCT05103371|ACTIVE_COMPARATOR|"Mili prevention program, adolescents only"|"The program Mili will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image, no parental involvement in the program. Adolescents will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
62408916|NCT04859699|NO_INTERVENTION|Control Group|This arm will include schools and the enrolled families assigned as the control group, who will not receive the COVID-19 health education comic books and video intervention.
62408917|NCT04859699|ACTIVE_COMPARATOR|COVID-19 Comic Books and Videos|This arm will include schools that are randomized to receive the health education with comic books and videos focused on the benefits of preventive measures for COVID-19.
62408918|NCT03668613|EXPERIMENTAL|secukinumab low dose|secukinumab low dose
62408919|NCT03668613|EXPERIMENTAL|secukinumab high dose|secukinumab high dose
62408920|NCT02257931||HSCT recipient|Allogeneic or autologous HSCT recipients, of all ages, for any indications. From this group we take those with a gram-negative bacteremia within 6 months after HSCT.
62408921|NCT04461912|EXPERIMENTAL|Cataract|Participants with diverse types and severities of cataract, that should realize phacoemulsification surgery
62408922|NCT04461912|PLACEBO_COMPARATOR|Control|Participants on which the presence of cataract have been excluded
62408923|NCT03752866|EXPERIMENTAL|Portico™ Valve, Delivery System(s) and Loading System(s)|Subjects undergoing implantation of a commercially available Portico transcatheter aortic heart valve using the Portico TAVI system will be included.
62408924|NCT03752866|EXPERIMENTAL|Portico™ Valve, FlexNav Delivery and Loading System(s)|Subjects undergoing implantation of a commercially available Portico transcatheter aortic heart valve using the FlexNav Delivery and Loading Systems will be included.
62408925|NCT05181553|EXPERIMENTAL|Canada's Food Guide principles (CFG diet)|During 28 days, participants will receive de CFG diet. The CFG diet emphasizes low intakes of red and processed meats and high intakes of minimally processed plant foods with water as the drink of choice, as per Canada's Food Guide. The number of portions of protein foods, whole-grains, fruits and vegetables to be served daily reflects the recommended ¼-¼-½ proportions. Regarding protein quality, vegetable proteins are served more often than animal proteins as stated in Canada's Food Guide. Weekly, red meat is served once, two days are meatless, and one day is free of animal products.
62408926|NCT05181553|EXPERIMENTAL|Standard North American diet (NAD diet)|During 28 days, participants will receive de NAD diet. The NAD diet reflects current dietary intakes of the French-Canadian adult population in terms of foods, nutrients, and diet quality, as characterized in recent surveys conducted in an age- and a sex-representative sample of adults from the Province of Quebec. Intakes of minimally processed fruits and vegetables will be low; animal proteins, mostly red and processed meats, will be consumed more often than vegetable proteins; grains will be mostly refined; and ready-to-eat/ready-to-heat foods and sugary beverages will be served daily.
62408927|NCT06411002|EXPERIMENTAL|Active Treatment (DAXXIFY)|All subjects will receive DAXXIFY for injection as IM injections.
62408928|NCT01514591||Non-elective Cesarean Delivery|We will only enroll patients undergoing non-elective CS with an 'epidural top-up' for surgical anesthesia. By definition, our study will only apply to laboring women with working labor epidurals (which were provided for labor analgesia).
62408929|NCT04980066|EXPERIMENTAL|sticky bone and EDTA|treatment of gingival recession using sticky bone after root surface biomodification with EDTA
62408930|NCT04980066|ACTIVE_COMPARATOR|Sticky bone|treatment of gingival recession using sticky bone
62212484|NCT05103371|NO_INTERVENTION|control group|The control group will not receive the intervention program. The control group will complete the same self-report questionnaire as the intervention group at baseline, after the program ends, and three months after the completion of the program
62212485|NCT04999618|ACTIVE_COMPARATOR|Group with Haemoblock (A)|
62408931|NCT02797951|EXPERIMENTAL|Galcanezumab|Participants received 300 milligram (mg) Galcanezumab administered subcutaneously (SC) up to once a month.
62408932|NCT04186234|EXPERIMENTAL|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 35 to 50 Grays in 5 fractions over 5 to 14 days.
62408933|NCT04938102|NO_INTERVENTION|Abnormal DI - Control|Patients' whose distensibility index is measured \<2.8 will receive no intervention.
62408934|NCT04938102|ACTIVE_COMPARATOR|Abnormal DI - Botox|Patients' whose distensibility index is measured \<2.8 will be injected with 100 units of botulinum toxin in the lower esophageal sphincter (25 units in each quadrant).
62408935|NCT04938102|NO_INTERVENTION|Normal DI - Control|Patients' whose distensibility index is measured \>2.8 will receive no intervention.
62212486|NCT04999618|PLACEBO_COMPARATOR|Group without Haemoblock (B)|
62408936|NCT05882656||Hip arthroplasty|All adult patients undergoing primary total hip replacement surgery at the Traumatology, Orthopedics and Joint Pathology Clinic of the I.M. Sechenov First Moscow State Medical University (Sechenov University) who meet the inclusion criteria (described below) will be included.
62408937|NCT02504463|EXPERIMENTAL|Samidorphan IV|Samidorphan solution for IV administration
62408938|NCT02504463|EXPERIMENTAL|Samidorphan sublingual|\[14c\]-Samidorphan for sublingual administration
62408939|NCT02504463|EXPERIMENTAL|Samidorphan oral|\[14c\]-Samidorphan for oral administration
62790558|NCT03909308|EXPERIMENTAL|Beach Tennis session|The participants performed a beach tennis training session throughout 45 min.The session started with a standardized 5-minute warm-up consisting of basic techniques (i.e., serve, volley, forehand, and backhand) followed by three 12-minute beach tennis matches with 2-minute intervals between the games. We used regular beach tennis rules in the game, which was played on a regular beach tennis court (i.e., 16 m long by 8 m wide and net 1.70 m high).
62020243|NCT01172938|PLACEBO_COMPARATOR|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
62020244|NCT01172938|PLACEBO_COMPARATOR|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
62020245|NCT04144400|EXPERIMENTAL|BRAVE Group|The BRAVE program aims to examine the effectiveness of an intervention strategy designed to increase personal and work outcomes through the strengthening of quiet ego characteristics. The BRAVE intervention (delivered over four weeks) will ask study participants to use the app each week, with specific instructions on selecting one section each week and first listening to the longer version and reflect. At least two other times during the week they will be asked to listen to a recording of their choice on the same topic. On the final week (week 5) all participants (experimental and control) will return to the lab to complete post-study assessment tools (SART, post-study on-line questionnaire, provide a urine sample, and weight measurement).
62020246|NCT04144400|ACTIVE_COMPARATOR|Time Management Group|The time management program aims to examine the effectiveness of an intervention strategy designed to increase personal and work outcomes through the strengthening of time management characteristics. The time management intervention (delivered over four weeks) will ask study participants to use the time management version of the app each week, with specific instructions on selecting one section each week and first listening to the longer version and reflect. At least two other times during the week they will be asked to listen to a recording of their choice on the same topic. On the final week (week 5) all participants (experimental and control) will return to the lab to complete post-study assessment tools (SART, post-study on-line questionnaire, provide a urine sample, and weight measurement).
62212487|NCT03090139||All Participants|All participants with diagnosis of UC and CD, who initiated treatment with anti-TNF therapy from 01 March 2010 up to 01 March 2015 will be observed. Retrospective data extraction will be done for eligible participants from March 2017 up to approximately February 2018.
62408940|NCT02944344|EXPERIMENTAL|Four Conversations Intervention|Subjects in this arm will participate in Reimagine's online Four Conversations program during the initial study period of four weeks.
62212488|NCT02153073||Omega-3 fatty acid ethyl esters 2 g|Omega-3 fatty acid ethyl esters 2 g, administered orally once or twice daily after meals
62212489|NCT02137889|EXPERIMENTAL|Arm 1- relapsed/refractory CLL patients|Patients with relapsed/refractory CLL with two or three prior treatment regimens
62212490|NCT02137889|EXPERIMENTAL|Arm 2 - rituximab or ofatumumab refractory CLL patients|Patients with relapsed/refractory CLL with four or more prior treatment regimens
62212491|NCT02019303|OTHER|Abnormal lymph nodes|There is only one arm to this study and includes all eligible and consented patients with abnormal axillary lymph node on ultrasound.
62212492|NCT01637805|EXPERIMENTAL|AAV-DC-CTL|
62408941|NCT02944344|OTHER|Waitlisted Control|Subjects in this arm will continue to receive standard care from their healthcare providers during the initial study period (i.e. no intervention). After four weeks, subjects will then participate in Reimagine's online Four Conversations program.
62408942|NCT05580432|EXPERIMENTAL|Immediate behavioral intervention|Participants will receive the intervention immediately
62408943|NCT05580432|ACTIVE_COMPARATOR|Delayed behavioral intervention|Participant will receive the intervention after a 12 month delay
62790559|NCT03223337|EXPERIMENTAL|Subjects with moderate hepatic impairment: Part 1|Approximately 8 subjects with moderate hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 7, one with a score of 8 and one with a score of 9. The group will also include at least one female and at least one male subject.
62212493|NCT02850510|EXPERIMENTAL|Brief Incredible Years parent training|Parent training
62212494|NCT02850510|NO_INTERVENTION|No parent training|No parent training
62212495|NCT04023773|EXPERIMENTAL|Liver perfusion|"Device: Liver Machine Perfusion (MP) Device~The liver grafts will be preserved at hypothermic and normothermic temperature on the institutional-developed Liver MP Device, and have continuous perfusion with oxygen supply in the ex vivo organ preservation phase."
62212496|NCT04900571|EXPERIMENTAL|Nitrofurantoin|Measuring pain score using numerical pain scale post-operatively at different time intervals.
62212497|NCT04900571|EXPERIMENTAL|Calcium Hydroxide|Measuring pain score using numerical pain scale post-operatively at different time intervals.
62212498|NCT04900571|EXPERIMENTAL|Control|Measuring pain score using numerical pain scale post-operatively at different time intervals.
62212499|NCT06363071|EXPERIMENTAL|Stage 1:Healthy people|To establish PAS baseline and reliability.
62212500|NCT06363071|EXPERIMENTAL|Stage 2:PD people|To establish stage 3 training protocol.
62212501|NCT06363071|NO_INTERVENTION|Stage 3:PD people|Control group.
62212502|NCT06363071|EXPERIMENTAL|Stage 3: PD APA training group|Weight shift training and APA feedback.
62212503|NCT06363071|EXPERIMENTAL|Stage 3:PD PAS group|Using PAS to regulate brain plasticity
62212504|NCT04916093|EXPERIMENTAL|Sitagliptin Group|Included 20 recently diagnosed type 2 diabetic subjects. They all received sitagliptin 100 mg therapy once daily before breakfast.
62212505|NCT04916093|EXPERIMENTAL|Vildagliptin Group|Included 20 recently diagnosed type 2 diabetic subjects. They all received vildagliptin 50 mg therapy twice daily before breakfast and supper.
62212506|NCT04916093|ACTIVE_COMPARATOR|Metformin Group|Included 20 recently diagnosed type 2 diabetic subjects. They all received control 1 gm twice daily
62212507|NCT04212637|EXPERIMENTAL|Healthy Volunteers|MRI exam
62408944|NCT01300741|EXPERIMENTAL|Lotrafilcon B|Lotrafilcon B commercially marketed contact lens randomly assigned to one eye, with galyfilcon A commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW modality).
62408945|NCT01300741|ACTIVE_COMPARATOR|Galyfilcon A|Galyfilcon A commercially marketed contact lens randomly assigned to one eye, with lotrafilcon B commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW modality).
62408946|NCT04513665|EXPERIMENTAL|Stage 1|Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy. 16 participants will be accrued. If 2 or greater responses are seen, Stage 2 will accrue additional participants.
62212508|NCT04212637|EXPERIMENTAL|Parkinson patient|MRI exam
62408947|NCT04513665|EXPERIMENTAL|Stage 2|If 2 or greater responses are seen during Stage 1, Stage 2 will accrue an additional 9 participants. Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy.
62408948|NCT03759509|EXPERIMENTAL|aerobic exercise training|three times a week, a total of twenty-four times in eight weeks
62408949|NCT03759509|NO_INTERVENTION|control|routine activity
62408950|NCT06330467|OTHER|Borderline|Borderline patients
62408951|NCT06330467|OTHER|Functional Dissociative Crises (FDC)|FDC patients
62790560|NCT03223337|ACTIVE_COMPARATOR|Matched Healthy controls: Part 1|Approximately 8 healthy controls, matched in gender, age and BMI to subjects with moderate hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
62408952|NCT06330467|OTHER|Early psychosis|Early psychosis patients : mental state at risk for psychosis and first psychotic episode
62408953|NCT01738204||Females with endometriosis|Females with a surgical diagnosis of endometriosis or who undergoing surgery for suspected endometriosis. At this time, we are only recruiting patients of Boston Children's Hospital and Brigham and Women's Hospital for this group.
62408954|NCT01738204||Females without surgical diagnosis of endometriosis|Females do not need to be patients of Boston Children's Hospital or Brigham and Women's Hospital.
62408955|NCT04360213||Children with Asthma|"1. Patients ages 1 to 17 years old~2. Patients in the Emergency Department or admitted to the hospital for asthma exacerbation."
62408956|NCT04360213||Children with allergy|"1. Patients ages 1 to 17 years old~2. Patients scheduled to do an oral food challenge"
62408957|NCT05232643||Cohort 1|Non-valvular atrial fibrillation (NVAF) participants administered oral anticoagulants (OAs)
62408958|NCT05232643||Cohort 2|Non-valvular atrial fibrillation (NVAF) participants not administered oral anticoagulants
62408959|NCT02975882|EXPERIMENTAL|Treatment (nab-rapamycin, temozolomide, irinotecan)|Patients receive nanoparticle albumin-bound rapamycin IV over 30 minutes on days 1 and 8 beginning on cycle 1. Patients also receive temozolomide PO and irinotecan hydrochloride PO on days 1-5 beginning on cycle 2. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
62408960|NCT06647966||Patients with clinical signs of hyperparathyroidism|
62408961|NCT03495752|EXPERIMENTAL|Pre/Post Repeated Measures|Performance on the forward-step-down test (FSDT) before and at one, five, and ten minutes following the Bruce Fatigue Protocol
62408962|NCT05564533|EXPERIMENTAL|Heart-Smile Training Intensive Introductory Program (HST-IIP) Group|The HST-IIP group will complete the Heart-Smile Training Intensive Introductory Program during weeks 1 through 4 of the study.
62408963|NCT05564533|NO_INTERVENTION|Waitlist Control Group|The waitlist arm will not complete any intervention during their time in the study. They will continue their treatment as usual without any change in their therapy session or medication. After their post study visits are complete, they will have the opportunity to participate in Mindfulness-Based Intervention courses through the Cambridge Health Alliance Center for Mindfulness and Compassion.
62408964|NCT03725436|EXPERIMENTAL|Treatment (paclitaxel, ALRN-6924)|Patients receive paclitaxel IV over 1 hour and MDM2/MDMX inhibitor ALRN-6924 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62408965|NCT02471794|NO_INTERVENTION|Standard Shared Medical Appointment|The SMA group will be a standard shared diabetes medical appointment group consisting of up to 10 patients that utilizes the design and curriculum of the SMAs that are currently being held at the Duke Family Medicine Center.
62584402|NCT03088124|EXPERIMENTAL|active surveillance with Apalutamide|Active surveillance during and after 6 months treatment with Apalutamide
62584403|NCT06656312|EXPERIMENTAL|AI Group|Use ASUS EndoAim as an assistant software to perform colonoscopy
62584404|NCT06656312|NO_INTERVENTION|Normal Group|Standard Colonoscopy
62584405|NCT05875025|EXPERIMENTAL|Test Propellant|Placebo HFA-152a propellant
62584406|NCT05875025|PLACEBO_COMPARATOR|Reference Propellant|Placebo HFA-134a propellant
62020247|NCT01842789|OTHER|Acessa Procedure w/o TAG|Acessa Procedure without the use of Targeting Animation Guidance
62020248|NCT01842789|OTHER|Acessa Procedure with TAG|Acessa Procedure with Targeting Animation Guidance
62212509|NCT05645341||Eligible participants for smartphone-based ocular surface tumors diagnosis|
62020249|NCT02664402||Adults|English speaking, physician diagnosed with a life threatening illness.
62020250|NCT03404024|EXPERIMENTAL|Stage 1-Low dose VM202RY|Patients in this group will receive total 1mg of VM202RY. (4 sites of 0.25mg/0.5 mL VM202RY)
62212510|NCT03022253|EXPERIMENTAL|Liberal Platelet transfusion group|"Platelet transfusion to maintain a platelet count above 1,00,000 per microliter until one of the endpoints is met.~As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
62408966|NCT02471794|EXPERIMENTAL|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum.
62408967|NCT02471794|NO_INTERVENTION|Retrospective|A retrospective chart review will be conducted once all participants (both SMA group and PHP SMA group) complete the intervention. The retrospective chart review will collect healthcare utilization data six months prior, during, and after each subject's participation in the SMA.
62408968|NCT06564961|EXPERIMENTAL|Clomiphene|Participants will receive Tab Clomiphene citrate 50 mg orally once daily or 12 weeks
62408969|NCT06564961|PLACEBO_COMPARATOR|Placebo|Participants will receive Clomiphene citrate placebo tablet matching Clomiphene citrate orally once daily for 12 weeks
62020251|NCT03404024|EXPERIMENTAL|Stage 1-Middle dose VM202RY|Patients in this group will receive total 2mg of VM202RY. (8 sites of 0.25mg/0.5 mL VM202RY)
62020252|NCT03404024|EXPERIMENTAL|Stage 1-High dose VM202RY|Patients in this group will receive total 3mg of VM202RY. (12 sites of 0.25mg/0.5 mL VM202RY)
62212511|NCT03022253|ACTIVE_COMPARATOR|Restrictive platelet transfusion group|"Platelet transfusion for standard criteria.~As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
62212512|NCT05718089|EXPERIMENTAL|Continuous aerobic exercise|The participants will complete a 10-min warm up, followed by 40 min of continuous aerobic exercise at an individualized intensity at 64-76% of the maximal heart rate HRmax on a bicycle ergometer/walking.
62212513|NCT05718089|EXPERIMENTAL|High intensity interval training|The training consists of 10 minutes of warm up followed by 25 minutes of high intensity interval training (5 bouts of 4 min at \>85% HRmax interspaced by 4 minutes of low intensity training) and finally a 4 min cool-down.
62408970|NCT00301873|EXPERIMENTAL|IV Zometa|Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
62408971|NCT05072977|EXPERIMENTAL|TransPRK|
62408972|NCT05072977|ACTIVE_COMPARATOR|Alcohol PRK|
62408973|NCT02299661|EXPERIMENTAL|7.5mg DS-1093a|DS-1093a, single oral dose of 7.5 mg
62020253|NCT03404024|PLACEBO_COMPARATOR|Stage 2-Placebo|Patients in this group will receive 6mL of VM202RY vehicle. (12 sites of 0.5mL 0.9% NaCl, 1.1% sucrose)
62020254|NCT03404024|EXPERIMENTAL|Stage 2-Low dose VM202RY|Patients in this group will receive total 6mL of VM202RY and VM202RY vehicle. (The dose of VM202RY can be one of the three candidate-0.5mg VM202RY/1mg VM202RY/1.5mg VM202RY based on the tolerated dose result from Stage 1.)
62408974|NCT02299661|EXPERIMENTAL|25mg DS-1093a|DS-1093a, single oral dose of 25 mg
62408975|NCT02299661|EXPERIMENTAL|50mg DS-1093a|DS-1093a, single oral dose of 50 mg
62408976|NCT06651801|NO_INTERVENTION|Standard client services|Participants will follow-up with their primary care provider (family physician or nurse practitioner).
62408977|NCT06651801|EXPERIMENTAL|Virtual outpatient care|
62584407|NCT06225570|EXPERIMENTAL|Isotretinoin|Weekly isotretinoin (at 1-1.5 mg/kg per week) dose preceded by a 5-day daily loading dose (0.5-1 mg/kg/day). The weekly dose will be given once a week for 4 months.
62584408|NCT06225570|ACTIVE_COMPARATOR|Tetracycline|Daily oral doxycycline (weight-based dosing with maximum dose 200mg daily) or other tetracycline class antibiotic for a 4-month treatment period.
62790561|NCT03223337|EXPERIMENTAL|Subjects with either mild or severe hepatic impairment: Part 2|Approximately 8 subjects with mild or severe hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 5 and one with a score of 6 for mild hepatic impairment and at least one subject with a Child-Pugh score of 10 or 11 and one with a score of 12 or 13 for severe hepatic impairment. The group will also include at least one female and at least one male subject.
62790562|NCT03223337|ACTIVE_COMPARATOR|Matched healthy controls: Part 2|Approximately 8 healthy controls, matched in gender, age and BMI to subjects with mild or severe hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
62790563|NCT04239742|EXPERIMENTAL|18F-PSMA PET/CT and 18F-Fluciclovin PET/CT|patients undergo an 18F-PSMA PET/CT scan and an 18F-Fluciclovin PET/CT scan, within a time frame of two weeks.
62790564|NCT02434562||Medical castration|Patients treated with androgen deprivation therapy (e.g. for hypersexuality, transgender subjects, ...)
62408978|NCT06442774|ACTIVE_COMPARATOR|Control|Participants of this group will have care as usual from healthcare providers. Participants will have the study variables measured (by questionnaires and monitoring via wearable).
62790565|NCT02434562||Male hypogonadism|Patients treated with testosterone replacement therapy (e.g. for late-onset hypogonadism, secondary hypogonadism)
62790566|NCT02434562||Thyroid disorders|Patients treated for hyperthyroidism or hypothyroidism (incl. during treatment for thyroid cancer)
62212514|NCT05718089|EXPERIMENTAL|Resistance training|The participants will complete moderate intensity whole-body resistance training. This will consist of 4 sets with 4 exercises (leg press, chest press, back row, leg extension in appropriate machines) with a brief warm-up prior to each exercise. Each set will be interspersed by 2-min breaks. Each set (including breaks) will thus equate to 2.5 min. Intensity will be set a 12-repetition max (RM, i.e., can repeated no more than 12 times) or 10 repetitions with 1-2 repetitions in reserve (i.e., 10 repetitions where failure would occur within 1-2 more repetitions).
62408979|NCT06442774|EXPERIMENTAL|Mobile application|Participants of this group will have access to the content of the application and will use it regularly from the start of the study until 4 months postpartum. Participants will have the study variables measured (by questionnaires and monitoring via wearable)
62408980|NCT03868917|NO_INTERVENTION|ultrasound group|The participants have continuous thoracic paravertebral block performed using only the ultrasound approach.
62408981|NCT03868917|EXPERIMENTAL|pressure measurement group|The participants have continuous thoracic paravertebral block performed using the ultrasound-guided approach combined with pressure measurement techniqueduring needle advancement.
62408982|NCT04554225||Pulmonary disease patients|Patients with COPD or other pulmonary disease starting to use ambulatory oxygen therapy
62408983|NCT00993525|EXPERIMENTAL|Intravitreal anti-VEGF|Intravitreal injection of 0.5 mg of ranibizumab
62408984|NCT00258310|EXPERIMENTAL|Capecitabine|Surgery, chemotherapy and/or radiotherapy, prior to administration of Capecitabine 1000mg/day for one year.
62408985|NCT04272411|SHAM_COMPARATOR|Sham SCS stimulation|Sham SCS stimulation via implanted neuromodulation device
62584409|NCT06668662|ACTIVE_COMPARATOR|endoactivator|Endoactivator is an irrigation technique which will help to reduce post-operative pain in patients following endodontic treatment.
62790567|NCT02434562||Obesity and weight loss|Patients treated for obesity with weight loss interventions (mainly bariatric surgery)
62790568|NCT02434562||Miscellaneous|Various disorders associated with alterations in SHBG, androgens and/or estrogens
62790569|NCT05688696|EXPERIMENTAL|Orelabrutinib Lower Dose|
62790570|NCT05688696|EXPERIMENTAL|Orelabrutinib Higher Dose|
62790571|NCT05688696|PLACEBO_COMPARATOR|Placebo|
62212515|NCT06477497||study group|Theoretical training, technical supporting and standardized referral process
62212516|NCT06477497||control group|usual care
62408986|NCT04272411|ACTIVE_COMPARATOR|Tonic SCS stimulation|Tonic SCS stimulation via implanted neuromodulation device
62408987|NCT04272411|ACTIVE_COMPARATOR|Burst SCS Stimulation|Burst SCS stimulation via implanted neuromodulation device
62408988|NCT04273659|EXPERIMENTAL|Pulses and Cereal 1|Pulses and cereal 1 containing study product is served. Dietary intervention.
62408989|NCT04273659|EXPERIMENTAL|Pulses and Cereal 2|Pulses and cereal 2 containing study product is served. Dietary intervention.
62408990|NCT01940731|EXPERIMENTAL|Colistimethate sodium|
62408991|NCT05694026|EXPERIMENTAL|IPL+|Participants in the IPL+ group used DQS 1 drop 6 times/per day for four weeks along with 2 sessions of IPL, 2 weeks apart.
62584410|NCT06668662|ACTIVE_COMPARATOR|Conventional irrigation|Conventional irrigation is an irrigation technique which will help to reduce post-operative pain in patients following endodontic treatment.
62790572|NCT02378545|ACTIVE_COMPARATOR|Hyperoxia|Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose. The oxygen delivery device will be set to deliver oxygen at 15 litres per minute. The oxygen will be continuously delivered throughout the patients stay in the Emergency Department.
62790573|NCT02378545|ACTIVE_COMPARATOR|normoxia|Oxygen will not be administered if a patient's oxygen saturations (as measured using a pulse oximeter) are less than 94%. If a patient's oxygen saturations are less than 94%, oxygen will be 'titrated' using a 'venturi' type oxygen delivery device to achieve target saturations of 94%. Following initial dynamic titration (to identify correct oxygen delivery level) the oxygen delivery device will be re-evaluated hourly during the patient's stay in the emergency department.
62790574|NCT05977764|EXPERIMENTAL|lesion target|CEUS on lesion target
62790575|NCT05138315|EXPERIMENTAL|Study Group|Alleye App and M-chart examinations will be performed pre- and postsurgically.
62212517|NCT05938140|OTHER|Paxlovid group|Patients will take Paxlovid.On the first day, Nematavir tablet 300mg/Ritonavir tablet 100mg orally once, then Nematavir tablet 150mg/ Ritonavir tablet 100mg orally once a day for 4 days. Dialysis patients must took the medication after dialysis.
62212518|NCT05837962|EXPERIMENTAL|Nursing intervention to improve knowledge and self-care behaviors in the face of HDP|Behavioral: Educational, behavioral and motivational intervention developed by nurses aimed at improving the level of knowledge and self-care behaviors of pregnant women in the face of HDP.
62212519|NCT05837962|NO_INTERVENTION|Usual management during prenatal care|Behavioral: Nursing education about maternal care and usual education in maternity preparation course
62212520|NCT03684668|EXPERIMENTAL|Psychoeducational intervention|The psychoeducational intervention, with the use of meta-universes,consists of three sessions in which techniques based on three of the four sources of self-efficacy described are applied.
62212521|NCT03684668|NO_INTERVENTION|Control|The control arm will not receive the psychoeducational intervention. Students in this group will complete the questionnaires before the beginning of the intervention and after its end.
62212522|NCT03895905||Genotype of HR-HPV 16/18|Patients with genotype of HR-HPV 16/18 who underwent cervical biopsy with colposcopy
62212523|NCT03895905||Genotype of HR-HPV Non-16/18|Patients with genotype of HR-HPV non-16/18 who underwent cervical biopsy with colposcopy
62212524|NCT02217501|EXPERIMENTAL|DAPT - clinically indicated duration+12m|Clopidogrel 75 mg daily and Acetylsalicylic acid (ASA) 75-100 mg daily for clinically indicated duration plus an additional 12 months
62212525|NCT02217501|ACTIVE_COMPARATOR|DAPT - clinically indicated duration|Clopidogrel 75 mg daily and Acetylsalicylic acid (ASA) 75-100 mg daily for clinically indicated duration with a minimum of 30 days
62408992|NCT05694026|EXPERIMENTAL|IPL|IPL treatment sessions were administered once at 2- weeks interval to all participants for 4 weeks.
62790576|NCT01198639|ACTIVE_COMPARATOR|manual administration of iv anesthetics|
62212526|NCT03085654|EXPERIMENTAL|High anxiety group (single dose)|Oxytocin nasal spray or placebo nasal of one dose in subjects with high trait anxiety.
62212527|NCT03085654|EXPERIMENTAL|High anxiety group (3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with high trait anxiety.
62212528|NCT03085654|EXPERIMENTAL|High anxiety group (5 doses)|Oxytocin nasal spray or placebo nasal spray for 5 days,24 IU per day in subjects with high trait anxiety.
62212529|NCT03085654|EXPERIMENTAL|Low anxiety group (single dose)|Oxytocin nasal spray or placebo nasal spray of one dose in subjects with low trait anxiety.
62790577|NCT01198639|EXPERIMENTAL|closed-loop administration of iv anesthetics|
62212530|NCT03085654|EXPERIMENTAL|Low anxiety group (3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with low trait anxiety.
62212531|NCT03085654|EXPERIMENTAL|Low anxiety group (5 doses)|Oxytocin nasal spray or placebo nasal spray for 5 days in subjects with low trait anxiety.
62212532|NCT02330705|ACTIVE_COMPARATOR|Group A|IUI at time of HCG
62212533|NCT02330705|ACTIVE_COMPARATOR|Group B|IUI 12 hours after HCG
62212534|NCT02330705|ACTIVE_COMPARATOR|Group C|IUI 34-36 hours after HCG
62212535|NCT04638634|EXPERIMENTAL|CSL760 (low dose)|Administered as an intravenous infusion
62212536|NCT04638634|EXPERIMENTAL|CSL760 (high dose)|Administered as an intravenous infusion
62212537|NCT01973244|EXPERIMENTAL|NNC0195-0092 (somapacitan)|
62212538|NCT01973244|ACTIVE_COMPARATOR|Norditropin®|
62790578|NCT02951078|EXPERIMENTAL|Thulium Laser en Bloc Resection of bladder tumor|Thulium Laser en Bloc Resection of the Non-muscle Invasive Bladder tumor with thulium laser
62790579|NCT02951078|ACTIVE_COMPARATOR|Electrical transurethral resection of bladder tumor|Electrical transurethral resection of the Non-muscle Invasive Bladder tumor
62790580|NCT02657304|EXPERIMENTAL|Coaching group|PPC + Coaching
62790581|NCT02657304|ACTIVE_COMPARATOR|Control group|PPC
62212539|NCT00888927|EXPERIMENTAL|Phase 1 Cohort 1|First course: 0.1 mg/kg once a week over 1 hour for 4 weeks Subsequent courses: 0.1 mg/kg over 1 hour every other week
62212540|NCT00888927|EXPERIMENTAL|Phase 1 Cohort 2|First course: 0.3 mg/kg once a week over 1 hour for 4 weeks Subsequent courses: 0.3 mg/kg over 1 hour every other week
62408993|NCT05694026|EXPERIMENTAL|DQS|DQS group will be administered one drop of 3% DQS (Diquas, Santen Pharmaceutical Co., Ltd., Osaka, Japan) six times per day for 4 weeks.
62790582|NCT00954499|ACTIVE_COMPARATOR|Standard care|
62790583|NCT00954499|EXPERIMENTAL|Tactile stimulation|
62790584|NCT04355819|EXPERIMENTAL|Disclosure before|Patients will be told that a hernia was found on CT before the follow-up survey is administered.
62790585|NCT04355819|EXPERIMENTAL|Disclosure after|Patients will be told that a hernia was found on CT after the follow-up survey was administered.
62790586|NCT03487211|ACTIVE_COMPARATOR|Duloxetine Group|Duloxetine 30mg once daily to be started for 1 week. Dose will then be titrated to 60mg once daily and the patients followed for a total of 12 weeks.
62790587|NCT03487211|EXPERIMENTAL|Escitalopram Group|Escitalopram 10mg once daily to be started for 1 week. Dose will then be titrated to 20mg once daily and the patients followed for a total of 12 weeks.
62790588|NCT05971927|EXPERIMENTAL|Experimental group|Simulation education
62790589|NCT05971927|NO_INTERVENTION|Control groups|The control group did not receive any simulation training.
62584411|NCT01172496|EXPERIMENTAL|1 mg tablet; 1mg solution|
62584412|NCT01172496|EXPERIMENTAL|1mg solution; 1mg tablet|
62408994|NCT06653699|EXPERIMENTAL|GROUP A|GROUP A will receive 1 dose of dexamethasone (10mg) with tranexamic acid (20mg/kg), peri operatively
62408995|NCT06653699|EXPERIMENTAL|GROUP B|GROUP B will receive 2 doses of dexamethasone (10mg) with tranexamic acid (20mg/kg), peri operatively
62212541|NCT00888927|EXPERIMENTAL|Phase 1 Cohort 3|First course: 1.0 mg/kg once a week over 1 hour for 4 weeks Subsequent courses: 1.0 mg/kg over 1 hour every other week
62212542|NCT00888927|EXPERIMENTAL|Phase 2|First course: Maximum tolerated dose once a week over 1 hour for 4 weeks Subsequent courses: Maximum tolerated dose over 1 hour every other week
62408996|NCT05275556|NO_INTERVENTION|Colonoscopy (Standard of Care)|The control arm is colonoscopy with High Definition White Light Endoscopy (HD-WLE) per standard of care.
62408997|NCT05275556|EXPERIMENTAL|CADe Device|The intervention arm is colonoscopy with HD-WLE per standard of care plus the CADe Device.
62584413|NCT00991471|EXPERIMENTAL|Interaction with MDRN STAT|Interaction with MDRNSTAT at triage to obtain orders for investigations and/or treatment
62584414|NCT00991471|EXPERIMENTAL|Control: No MDRNSTAT|Control group
62584415|NCT04019340|NO_INTERVENTION|Control|Usual care for patients in the CG is defined as visiting the outpatient wound clinic as prescribed by the physician. Wound size measurement, wound care (including dressing and inspection), and questionnaires will be provided by the institute's nurses.
62790590|NCT00852787|EXPERIMENTAL|Low|0.1mg/kg
62212543|NCT02507453|OTHER|Influence of Gravity on the Size-mass Illusion|to investigate the interaction between perceived size and perceived mass of objects in 0G and 1.8G compared to 1G using the size-mass illusion (SMI)
62408998|NCT04931875||Total-body PET/CT (uExplorer)|The diagnostic value of dynamic parameters(K1、Ki etc) to evaluate the prognosis of lymphoma compared to the static ones(SUV、MTV、TLG etc).
62408999|NCT01175408|ACTIVE_COMPARATOR|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
62409000|NCT01175408|ACTIVE_COMPARATOR|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will send the data to their endocrinologist and receive feedback based on the uploaded glucose data.
62212544|NCT00719147||1|
62409001|NCT01175408|ACTIVE_COMPARATOR|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
62409002|NCT01175408|ACTIVE_COMPARATOR|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
62409003|NCT06182748|EXPERIMENTAL|Training on eccentric ergocycle (experimental group)|In eccentric cycling, pedals push against the user's feet in the opposite direction, user has to slow down pedals and quadriceps muscles lengthen during contraction.
62409004|NCT06182748|ACTIVE_COMPARATOR|Training on concentric ergocycle (control group)|In concentric cycling, quadriceps contract to push pedals.
62584416|NCT04019340|OTHER|Education|Usual care as described for the CG will also be provided to the IG (visit to the outpatient wound clinic as prescribed by the physician). Wound size measurement, wound care (including dressing and inspection), and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by a pluridisciplinary educational program
62584417|NCT06100263|EXPERIMENTAL|Intervention (Supervised exercise)|The individualized resistance exercise program is based on participants' baseline 1-repetition maximum muscular strength assessment (i.e., the maximum lifted for 1 repetition) and is aligned with current cancer-specific exercise recommendations. The resistance exercise program will follow the FITT principle (frequency, intensity, time, and type). Sessions will be 35-45 minutes in duration.
62790591|NCT00852787|EXPERIMENTAL|Medium|0.4mg/kg
62584418|NCT06100263|ACTIVE_COMPARATOR|Control|Participants randomized to health education control condition will receive the American Cancer Society Physical Activity and the Person with Cancer summary for patients and American College of Sports Medicine Exercise is Medicine Effects of Exercise on Health-Related Outcomes in Those with Cancer infographic
62584419|NCT01718795|ACTIVE_COMPARATOR|Bag-valve mask ventilation|"Bag-valve mask ventilation during CPR, i.e. traditional ventilation during CPR. Airway management with bag-valve mask ventilation and efficient ventilation: yes or no?~Intervention is Bag-valve mask ventilation during CPR"
62790592|NCT00852787|EXPERIMENTAL|High|1.6 mg/kg
62790593|NCT00852787|PLACEBO_COMPARATOR|Placebo|
62790594|NCT05371912|ACTIVE_COMPARATOR|left IPL stimulation|half of the subjects will receive TMS on the left inferior parietal lobule.
62790595|NCT05371912|ACTIVE_COMPARATOR|right IPL stimulation|half of the subjects will receive TMS on the right inferior parietal lobule.
62790596|NCT01221350|EXPERIMENTAL|Lipoic acid|Lipoic acid 600 mg oral dose (two 300 mg capsules) once daily in the morning during 60 days
62212545|NCT03657823||Fetal growth cohort|Longitudinal measurements of fetal growth, fetal circulation and maternal circulation
62212546|NCT03657823||Hypertensive cohort|Retrospective cohort of women with heart disease that underwent oregnancy and childbirth
62212547|NCT05589324||3D-printed writing aids group|Thirty subjects were recruited from outpatient rehabilitation of neurologically injured patients with limited hand function. Their basic information was recorded, including basic abilities and pen-holding posture, etc. Using three different angles of 3D printing writing aids, the writing efficiency and the satisfaction of the aids are evaluated by the writing task and the Satisfaction with Assistive Technology.
62212548|NCT05985785|EXPERIMENTAL|Autologous (from subject to self) bone marrow aspirate concentrate (BMAC) injections|"Autologous bone marrow aspirate concentrate (BMAC) will be removed from the subject knee body with a needle, processed and concentrated by an FDA-approved centrifuge (separator) system. The concentrated cells will be injected into the subject knee. Autologous means that the subject is receiving back their own cells that were collected."
62584420|NCT01718795|ACTIVE_COMPARATOR|Laryngeal Tube|"Laryngeal Tube Ventilation during CPR, i.e. the alternative ventilation technique to be compared to the traditional technique. Airway management with laryngeal tube and efficient ventilation: yes or no?~Intervention is Ventilation through laryngeal tube during CPR"
62212549|NCT05985785|ACTIVE_COMPARATOR|Corticosteroid injection|Corticosteroid injection group (ARM 2) will receive a sham incision.
62212550|NCT05985785|OTHER|Crossover Group|Any patient in the corticosteroid injection group that shows no improvement in pain after 24 weeks (12 month follow-up if crossover), per physician discretion, will be allowed crossover to the BMAC injection group (ARM 3).
62212551|NCT04440852|EXPERIMENTAL|TEACCH intervention|TEACCH intervention for ASD
62212552|NCT04440852|NO_INTERVENTION|conventional rehabilitation group|Other conventional interventions
62584421|NCT03566914|EXPERIMENTAL|Tadalafil|Tadalafil 10 mg once daily per oral for 3 months
62790597|NCT01221350|PLACEBO_COMPARATOR|Placebo|Placebo (two placebo capsules) orally once daily in the morning during 60 days
62212553|NCT04465253|EXPERIMENTAL|Health services research (discussion, interview)|Patients participate in a discussion with an occupational therapist via videoconferencing over 15 minutes QW for 4 weeks about their experience with lymphedema and the occupational services they received. After 4 weeks, some patients may also participate in an interview with an occupational therapist via videoconferencing over 60 minutes. During the first week of the study, patients also receive occupational therapy per standard of care.
62212554|NCT05894395|EXPERIMENTAL|MMR Booster Vaccination Arm|Participants (adults 18+ having previously received 2 lifetime doses of MMR-containing vaccine) will receive a single MMR booster vaccination (3rd lifetime dose) as M-M-R-VaxPro.
62212555|NCT05894395|NO_INTERVENTION|Observational Arm|Participants (adults 18+ having previously received 2 lifetime doses of MMR-containing vaccine) will be assessed at study enrollment and at a 1 year follow-up visit
62212556|NCT03114839|EXPERIMENTAL|Dietary Supplement: Lactobacillus casei strain Shirota (LcS)|
62212557|NCT02009098|ACTIVE_COMPARATOR|præoperativ antibiotic|iv Cefuroxime 1,5g administered 15-60 minutes before incision
62212558|NCT02009098|ACTIVE_COMPARATOR|postoperativ antibiotic|iv Cefuroxime 1,5g administered after umbilical cord clamping
62212559|NCT03889704|EXPERIMENTAL|Neuromuscular electrical stimulation|The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. It will be applied for 20 minutes per session. For each patient, there will be 2 sessions per week, spaced 3 to 4 days apart. Each patient will participate in 16 sessions over the 8 weeks of the study. There will be 6 patients total.
62409005|NCT06653829|EXPERIMENTAL|SSD|The study design for participants with SSD is a single-arm open-label intervention study. We will collect descriptive information on feasibility and acceptability. Changes in defeatist beliefs and attitudes toward behavioral changes will be evaluated by comparing self-reported ratings before the app intervention vs. immediately afterward and at the 1-week follow-up. All visits will be conducted over video conference with a trained research coordinator.
62409006|NCT00562874|EXPERIMENTAL|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months.
62409007|NCT00562874|ACTIVE_COMPARATOR|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy flour as an ingredient for 5 days each week for 12 months.
62409008|NCT00562874|SHAM_COMPARATOR|Wheat Biscuit|75 women and one of their children will receive a biscuit containing pm;u wheat flour as a source of protein as an ingredient for 5 days each week for 12 months.
62212560|NCT02155751|EXPERIMENTAL|Full NELIP group|"These women (n=10) will receive the full NELIP intervention and will be introduced to both the dietary program and the exercise program as described above under detailed description."
62212561|NCT02155751|EXPERIMENTAL|Exercise program only/ELIP|These women (n=10) will only be given the exercise component (ELIP) of NELIP, as outlined below in interventions. Once dietary intake has been assessed, this group will not be given any dietary intervention but will be encouraged to eat a healthy, balanced diet. Access to the nutritionist in the clinic is available and encouraged.
62212562|NCT02155751|EXPERIMENTAL|Nutrition program only/NLIP|These women (n=10) will only be given the nutrition program (NLIP) of NELIP as outlined below in intervention. They will be encouraged to be more active but will not be given an exercise intervention.
62212563|NCT02155751|NO_INTERVENTION|Control|A control group (n=30) of obese pregnant women will also be recruited and will be matched by pre-pregnancy BMI, maternal age and parity, with no intervention, but will attend the clinic for standard obstetric care and follow-up.
62212564|NCT06090006|OTHER|No comparison group|In our study sites, a contemporaneous comparison group is not required since no routine screening is currently taking place, and as a result, assessments at baseline will serve as the counterfactual for internal comparisons
62212565|NCT00673959|EXPERIMENTAL|Lubricant Eye Drop FID 111421|Lubricant Eye Drop FID 111421 1 drop each eye one time
62212566|NCT00673959|ACTIVE_COMPARATOR|Optive Lubricant Eye Drop|Optive Lubricant Eye Drop 1 drop each eye one time
62212567|NCT05958030|NO_INTERVENTION|No Interventional|Participants will perform protocol-specific tasks with no device
62584422|NCT03566914|PLACEBO_COMPARATOR|Placebo|Tablet placebo once daily per oral for 3 months
62212568|NCT05958030|EXPERIMENTAL|Investigational Device Arm|GyroGlove
62790598|NCT03735992|EXPERIMENTAL|Mind-body medicine group program|Patients recieve an 11-week mind-body medicine group program including elements of mindfullness based stress reduction (MBSR), yoga, and education + treatment as usual.
62790599|NCT03735992|NO_INTERVENTION|Wait list|Treatment as usual.
62790600|NCT01807598|EXPERIMENTAL|Brentuximab vedotin|Subjects receive a 30-minute IV infusion of brentuximab vedotin once every 21 days for 8 courses, in the absence of disease progression or unacceptable toxicity.
62790601|NCT01902121|EXPERIMENTAL|TI 30 units (10 unit + 20 unit|Technosphere® Insulin 30 units given as 2 cartridges: one 10 unit cartridge + one 20 unit cartridge
62790602|NCT01902121|EXPERIMENTAL|TI 30 units (30 unit cartridge|Technosphere® Insulin 30 units given as one 30 unit cartridge
62790603|NCT01467921|ACTIVE_COMPARATOR|LV5FU2|leucovorin 200 mg/m2 and 5-fluorouracil 400 mg/m2 intravenously on day 1, followed by a 46-h protracted infusion of 5-fluorouracil 2,400 mg/m2
62790604|NCT01467921|EXPERIMENTAL|FOLFOX|leucovorin 200 mg/m2 and 5-fluorouracil 400 mg/m2 intravenously on day 1, followed by a 46-h protracted infusion of 5-fluorouracil 2,400 mg/m2 oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
62790605|NCT03181399|EXPERIMENTAL|Triheptanoin|This is a single arm study.
62790606|NCT03770117||Prehabilitation|"In this arm of the study, participants will undergo prehabilitation prior to surgery. This is intended to increase the participants overall health prior to surgery to try and increase their general well-being during and after surgery.~Prehabilitation is multimodal therapy comprising:~1. Assessment for malnutrition and nutritional support dependent on the outcome~2. Optimisation of management of pancreatic exocrine insufficiency~3. Assessment of muscle mass and strength~4. Individually tailored, goal directed exercise regimen under the care of physiotherapy"
62212569|NCT05958030|PLACEBO_COMPARATOR|Placebo Arm|Placebo
62212570|NCT04966845||Smokers|Exclusive smokers of conventional cigarettes
62212571|NCT04966845||HNBC|Exclusive smokers of Heat-Not-Burn Cigarettes (HNBC)
62212572|NCT04966845||Nonsmokers|Subjects that abstain from smoking for at least one year
62212573|NCT03507777|ACTIVE_COMPARATOR|Coronary PCI guided by OCT|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with OCT guidance according to the algorithm described in the protocol. OCT imaging is required pre and post stent implantation.~At the end of the procedure, a final OCT imaging run must be performed."
62212574|NCT03507777|ACTIVE_COMPARATOR|Coronary PCI guided by Angiography|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with angiography guidance according to local standard practice.~At the end of the procedure, a blinded OCT shall be performed to document final stent dimensions and results."
62212575|NCT04387305|EXPERIMENTAL|Tranexamic acid 15 mg/kg bolus|Subjects will receive a 15 mg/kg bolus of tranexamic acid over 30 minutes followed by a 2 mg/kg/h infusion over 8 hours. This represents 31 mg/kg total dose of TXA.
62790607|NCT03770117||Standard Procedure|In this arm, participants will not receive any Rehabilitation prior to the surgery. This is the current standard care and will act as the control data for this study.
62212576|NCT04387305|EXPERIMENTAL|Tranexamic acid 30 mg/kg bolus|Subjects will receive a 30 mg/kg bolus of tranexamic acid over 30 minutes followed by a 4 mg/kg/h infusion over 8 hours. This represents 62 mg/kg total dose of TXA.
62212577|NCT04387305|EXPERIMENTAL|Tranexamic acid 45 mg/kg bolus|Subjects will receive a 45 mg/kg bolus of tranexamic acid over 30 minutes followed by a 6 mg/kg/h infusion over 8 hours. This represents 91 mg/kg total dose of TXA. This dosing arm will only open if a dose-effect is determined based on accumulating data.
62212578|NCT04387305|PLACEBO_COMPARATOR|Placebo|Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours
62409009|NCT06650657|EXPERIMENTAL|Arm 1|touchpoint method
62409010|NCT06650657|NO_INTERVENTION|Arm 2|usual learning method
62409011|NCT04754529|EXPERIMENTAL|Supportive care (yoga)|Patients receive online yoga intervention QW for 12 weeks.
62790608|NCT01873040|EXPERIMENTAL|Social media plus information pages|Participants will have access to the vaccine social media website with information pages and social media features including discussion forums, blogs, chat with an expert, and ask an expert.
62790609|NCT01873040|EXPERIMENTAL|Information Pages|Participants will have website access to vaccine information pages.
62790610|NCT01873040|NO_INTERVENTION|Usual Care|Participants will not have access to the vaccine website. They will receive pediatric care as usual.
62790611|NCT00825812|EXPERIMENTAL|Sugammadex in Caucasian Subjects|At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
62790612|NCT00825812|ACTIVE_COMPARATOR|Neostigmine in Caucasian Subjects|At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
62790613|NCT00825812|EXPERIMENTAL|Sugammadex in Chinese Subjects|At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
62790614|NCT00825812|ACTIVE_COMPARATOR|Neostigmine in Chinese Subjects|At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
62409012|NCT02058238||Arm 1: Robotic-guided, Open approach|Adult patients (age\> 21 years) undergoing long (\>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
62212579|NCT03013075|EXPERIMENTAL|SPINAL PLUS GENERAL ANESTHESIA|Patient will receive the intervention SPINAL ANESTHESIA before the start of surgery using Bupivacaine heavy 40 mg and Morphine 250 micro grams comprising a total volume of 8 ml to achieve a spinal block up to T2 level followed by general anesthesia
62409013|NCT02058238||Arm 2: control-arm - non-robotic, open approach|Adult patients (age\> 21 years) undergoing long (\>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
62409014|NCT02058238||Arm 3: robotic-guided, MIS approach|Adult patients (age\> 21 years) undergoing long (\>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
62409015|NCT02058238||Arm 4: control-arm - freehand, MIS approach|Adult patients (age\> 21 years) undergoing long (\>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
62409016|NCT00464308|ACTIVE_COMPARATOR|001|Esomeprazole 40mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
62409017|NCT00464308|ACTIVE_COMPARATOR|002|Esomeprazole 20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
62790615|NCT00145574|EXPERIMENTAL|high dose colesevelam|colesevelam HCl 3.750 g
62790616|NCT00145574|EXPERIMENTAL|Low dose colesevelam|Low dose colesevelam 1.875 g
62790617|NCT00145574|PLACEBO_COMPARATOR|placebo|placebo comparator
62020255|NCT03404024|EXPERIMENTAL|Stage 2-High dose VM202RY|Patients in this group will receive total 6mL of VM202RY and VM202RY vehicle. (The dose of VM202RY can be one of the three candidate-1mg VM202RY/2mg VM202RY/3mg VM202RY based on the tolerated dose result from Stage 1.)
62212580|NCT03013075|ACTIVE_COMPARATOR|ONLY GENERAL ANESTHESIA|Patient will receive only general anesthesia before the start of surgery
62790618|NCT03400475|EXPERIMENTAL|Simvastatin group (Treatment)|Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil®), Poloxamer 407 gel (Polox Gel 20%®) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
62790619|NCT03400475|PLACEBO_COMPARATOR|Control group|Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil®), Poloxamer 407 gel (Polox Gel 20%®) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
62790620|NCT03114332|EXPERIMENTAL|Study Group|Patients for whom a subcutaneous drain was used
62790621|NCT03114332|NO_INTERVENTION|Control group|No drain group
62212581|NCT02703181|EXPERIMENTAL|Cohort 1(600 mg Epelsiban or placebo[every 8 hours])|Each subject will receive 200 mg of epelsiban administered TID (every 8 hours) (total daily dose of 600 mg) or a matching placebo administered every 8 hours.
62790622|NCT03992846|EXPERIMENTAL|Linzagolix 75 mg|
62790623|NCT03992846|EXPERIMENTAL|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
62020256|NCT05840653|EXPERIMENTAL|experimental 1: Intervention group|Experiment 1 group will first be given a pre-test, then a 5-week hope placement program will be applied. The final test will be administered after the program is completed.
62212582|NCT02116790|PLACEBO_COMPARATOR|Control Group|10 participants will be given two pills: both will be placebos
62212583|NCT02116790|ACTIVE_COMPARATOR|Standard Treatment / Positive Control Group|10 participants will be given two pills: both will be Naproxen (each pill = 250mg, total dose = 500mg)
62212584|NCT02116790|ACTIVE_COMPARATOR|Experimental Group #1|10 participants will be given two pills: one will be Naproxen (250 mg) and the other will be of Sinemet (carbidopa/levodopa 12.5mg/50mg)
62212585|NCT02116790|ACTIVE_COMPARATOR|Experimental Group #2|10 participants will be given two pills: one will be Naproxen (250 mg) and the other will be of Sinemet (carbidopa/levodopa 25mg/100mg )
62409018|NCT00464308|ACTIVE_COMPARATOR|003|Rabeprazole 20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
62409019|NCT03814213||No-CGA|Patients were not initially offered CGA due to no booking for CGA
62409020|NCT03814213||CGA alone|Patients had CGA, but no tailored follow-up upon identified problems
62409021|NCT03814213||CGA with tailored care|CGA and a tailored follow-up and care for 90 days following the CGA
62409022|NCT02892435|EXPERIMENTAL|Prevena arm|patients underwent to contaminated/dirty surgery who positioned incisional negative pressure wound therapy and kept for six days
62409023|NCT02892435|ACTIVE_COMPARATOR|Control arm|patients underwent to contaminated/dirty surgery who positioned conventional dressing
62409024|NCT04471766|EXPERIMENTAL|Certified cloth face mask plus preventive information|Certified cloth face mask
62409025|NCT04471766|ACTIVE_COMPARATOR|Information on COVID-19 prevention|Advice on how to prevent COVID-19 according to the government´ policy.
62409026|NCT01764776|EXPERIMENTAL|LDE225|LDE225
62790624|NCT03992846|PLACEBO_COMPARATOR|Placebo|
62790625|NCT02794233|EXPERIMENTAL|PD patients with implanted DBS|Impedance measurements at different time points.
62790626|NCT01581060|EXPERIMENTAL|WX-554|
62790627|NCT03630757|EXPERIMENTAL|Treatment|While holding the patient's head with the therapist's hands,the cervical spinous processes with the fingertips palpitate to the occipital condyle towards the proximal.Then the fingers of both hands applied pressure to the axis in the space between the occipital condyle and the spinous process
62790628|NCT03630757|PLACEBO_COMPARATOR|Group 2|reaching to the feet while sitting together with warming and cooling periods
62790629|NCT06583382||Cemented Cup|Patients who received a cemented acetabular component in their primary THA and underwent a revision surgery of the component
62020257|NCT05840653|EXPERIMENTAL|experimental 2 group; Intervention group|A 5-week hope placement program will be applied to the experimental 2 group without the pre-test application. After the program is completed, the final test will be administered.
62212586|NCT02237729|EXPERIMENTAL|PF-06410293|
62212587|NCT02237729|ACTIVE_COMPARATOR|Adalimumab-US|
62020258|NCT05840653|NO_INTERVENTION|control 1 group; not Intervention group|only the pre-test will be applied, other than that, no intervention will be applied in the 5-week period. Then the final test will be applied.
62409027|NCT05054088||Cohort 1|Subjects who have tested positive for SARS-CoV-2 by EUA RT-PCR testing with symptoms compatible with SARS-CoV-2 infection.
62020259|NCT05840653|NO_INTERVENTION|control 2 group; not Intervention group|No intervention will be applied during the pre-test application and the 5-week period. then the final test will be administered.
62020260|NCT02905526|EXPERIMENTAL|Intervention|App plus the contraceptive instant messages
62020261|NCT02905526|PLACEBO_COMPARATOR|Control|App only
62212588|NCT02237729|ACTIVE_COMPARATOR|Adalimumab-EU|Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose
62212589|NCT01734629||Coronary CT Spirometry Cohort|Patients refereed to coronary CT enrolled in the study.
62212590|NCT04333251|EXPERIMENTAL|convalescent plasma|This arm will receive convalescent plasma
62212591|NCT04333251|PLACEBO_COMPARATOR|best supportive care|Oxygen therapy
62409028|NCT05054088||Cohort 2|Subjects who have tested positive for SARS-CoV-2 by EUA RT-PCR testing with symptoms compatible with SARS-CoV-2 infection.
62020262|NCT03407352|ACTIVE_COMPARATOR|Passive Video Game Play|Participants will play video games in a seated position for 60 minutes.
62020263|NCT03407352|EXPERIMENTAL|Active Video Game Play|Participants will play dance dance revolution (video game that requires lower body movement) for 60 minutes.
62020264|NCT04591834||Observational|No Intervention
62212592|NCT02352168|ACTIVE_COMPARATOR|Budesonide nasal spray|Budesonide nasal spray ,64mcg/putt,1 spray/nostril, 2 times/day,for 12 consecutive weeks.
62212593|NCT02352168|PLACEBO_COMPARATOR|Placebo|Placebo:nasal placebo spray,1spray/nostril, 2 times/day,for 12 consecutive weeks.
62409029|NCT03091478|EXPERIMENTAL|Pembrolizumab 200 mg|Pembrolizumab 200 mg every 3 weeks
62409030|NCT05444114|EXPERIMENTAL|Mindful Breathing|Participants follow instructions regarding a mindful breathing exercise on a 10-min audio clip
62790630|NCT06583382||Uncemented Cup|Patients who received an uncemented acetabular component in their primary THA and underwent a revision surgery of the component
62409031|NCT05444114|ACTIVE_COMPARATOR|Control|Participants follow instructions and listen to a 10-min audio clip of a story
62212594|NCT03755076|EXPERIMENTAL|Perceptual cuing|Two perceptual cues will be provided: (a) feedback about the time-lag between the two arms presented as a horizontal tilt of the common goal, and (b) different movement weighting coefficients to each arm to force greater movement contribution of the paretic arm in a bimanual context. The effect of the two cues on bimanual coordination will be determined.
62409032|NCT04330677|EXPERIMENTAL|1. Oxytocin spray, 2. Estrogen gel|
62409033|NCT04330677|EXPERIMENTAL|1. Oxytocin spray, 2. Placebo gel|
62409034|NCT04330677|EXPERIMENTAL|1. Placebo spray, 2. Estrogen gel|
62409035|NCT04330677|PLACEBO_COMPARATOR|1. Placebo spray, 2. Placebo gel|
62409036|NCT04655365|EXPERIMENTAL|Resistant Prostate Cancer and Negative, Equivocal or Oligometastatic Disease on Conventional Imaging|Enrolled subjects will receive a single dose of 9 mCi (333 MBq) 18F-DCFPyL Injection followed by a single PET/CT scan acquired at 1-2 hours post-dosing. After initial 18F-DCFPyL PET/CT, the patients with positive 18F-DCFPyL PET/CT imaging will be treated with enzalutamide (160 mg po id) for M0CRPC disease within less than two weeks. 18F-DCFPyL PET/CT scan will then be repeated 90 days after the start of enzalutamide treatment.
62409037|NCT02217397|EXPERIMENTAL|OA, CPAPm, combination therapy|
62409038|NCT04690959|EXPERIMENTAL|Neural gliding mobilization|Initial participant positioning for gliding will be : lying in supine, shoulder at approximately 90 of abduction, wrist in neutral, elbow at 90 flexion and head/neck neutral. From this starting position, participants actively and simultaneously will perform extension of the elbow (to 45) and ipsilateral neck flexion (to approximately 45) and then returned to 90 of elbow flexion and 45 of contralateral neck flexion while maintaining the shoulder at 90 abduction. According to Silva et al., (2014) this combination of movements was the one that promoted the greatest excursion of the median nerve (10.2 mm) . For gliding, four series of 10 movements at a rhythm of approximately 6 s per cycle and 1-min rest between series was performed.
62409039|NCT04690959|EXPERIMENTAL|Neural tensioning mobilization|Tensioning will be performed with the subject lying supine. The investigator will perform the upper limb neurodynamic test as reported by Butler (2000): shoulder depression; 110 of shoulder abduction; external shoulder rotation; wrist and fingers extension; forearm supination and then elbow extension. The final test position will be defined as either i) end of joint amplitude or ii) the joint amplitude that provokes pain, paresthesia or numbness. In this case, a decrease of 5 to 10 of range of motion (elbow extension) will be allowed for symptoms to disappear and from this end position the investigator will perform repetitive movements of approximately 10 of elbow flexion/extension while maintaining the test end position for all the other joints. For tensioning, four series of 10 movements at a rhythm of approximately 6 s per cycle and 1-min rest between series will be performed. After each cycle of 10 repetitions, the position will be held for 10 seconds.
62790631|NCT02013297|EXPERIMENTAL|SBRT treatment|According to the site to irradiate and to local constraints, SBRT consist in 1 to 8 fractions of 5 to 18 Gy
62212595|NCT05444023|EXPERIMENTAL|Transverse separated suturing technique|During pubocervical fascia reconstruction, the surgeon will perform suturing at the transverse plane with an intermittent stitching technique.
62212596|NCT05444023|ACTIVE_COMPARATOR|circular continue suturing technique|During pubocervical fascia reconstruction, the surgeon will perform a continuous stitching technique which includes the lateral parts of the anterior compartment defect.
62212597|NCT01307579|EXPERIMENTAL|Arm I (caspofungin acetate)|Patients receive caspofungin acetate IV over one hour QD beginning within 24-72 hours following the last dose of chemotherapy for each course. and continuing until ANC \> 100-500/uL following the nadir or the next chemotherapy course begins.
62790632|NCT05223049||Psoriatic Arthritis patients with neuropathic pain|Patients diagnosed with Psa according to The Classification Criteria for Psoriatic Arthritis (CASPAR) psoriatic arthritis criteria. Who has a DN4 score of ≥4 or PainDETECT score of ≥13.
62790633|NCT05223049||Psoriatic Arthritis patients with nonneuropathic pain|Patients diagnosed with Psa according to The Classification Criteria for Psoriatic Arthritis (CASPAR) psoriatic arthritis criteria. Who has a DN4 score of ≤4 or PainDETECT score of ≤13.
62212598|NCT01307579|ACTIVE_COMPARATOR|Arm II (fluconazole)|Patients receive fluconazole IV over 1-2 hours or PO QD beginning within 24-72 hours following the last dose of chemotherapy for each course.
62212599|NCT04559763||Healthy Adult Volunteers|
62212600|NCT05064527||Patients|"* OCD (ICD-10 F42) as the primary or secondary diagnosis, verified with a semi-structured psychopathological interview using Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS-PL).~* CY-BOCS \> 7: mild (8-15), moderate (16-23), severe (24-31), extreme (32-40)~* A psychiatrist determined that the child is eligible for care within psychiatry for their primary diagnosis.~* Patient is age 8 through 17 years (both inclusive)."
62212601|NCT05064527||Controls|"* Ages 8 through 17 years (both inclusive).~* Sex and age (+/- 3months) matched to an included patient."
62212602|NCT05064527||Caregivers of Patients|Parent or guardian of patient with OCD
62212603|NCT05064527||Caregivers of Controls|Parent or guardian of control participant
62212604|NCT01204710|EXPERIMENTAL|Olaratumab + Mitoxantrone|1 cycle = 3 weeks (21 days)
62212605|NCT01204710|ACTIVE_COMPARATOR|Mitoxantrone: Optional Olaratumab Monotherapy|"1 cycle = 3 weeks (21 days)~Participants who experience progressive disease (PD) have the option to receive olaratumab monotherapy treatment."
62212606|NCT04270591|OTHER|SCC244 300mg|Phase Ib: SCC244 300mg, QD Phase II: SCC244 300mg, QD
62212607|NCT02204332|EXPERIMENTAL|Cabazitaxel|"Cabazitaxel at a dose of 25 mg / m² in a 5% dextrose or 0.9% NaCl intravenously over 1 hour, every 3 weeks (1 cycle).~Besides, patient will be treated with BSC."
62409040|NCT04690959|SHAM_COMPARATOR|Control|Participants in the sham group will receive a treatment consisting of maneuvers that mimic the neural mobilization treatment but not to stress the neural tissues in the upper extremity. The sham mobilization consists of passively positioning the participants in the following consecutive positions: (1) a neutral cervical spine (0° of lateral flexion), (2) 45°of shoulder abduction without scapula depression, and (3) 45° of shoulder external rotation combined with 45° of elbow flexion with forearm pronation. This will be immediately followed by 10 cycles of passive wrist flexion/extension at a rate of approximately 6 seconds per cycle (3 seconds into extension and 3 seconds into flexion) . Upon moving from wrist flexion to extension, an initial sense of resistance will be used as a sign to alternate directions. Following the 10th cycle, a static hold will be maintained while in wrist flexion for 10 seconds.
62409041|NCT05621317|EXPERIMENTAL|PVX108 50 nmol in adolescents|Twelve 4-weekly intradermal (ID) doses of PVX108 at 50 nmol in adolescents (Cohort 1)
62409042|NCT05621317|PLACEBO_COMPARATOR|Placebo in adolescents|Twelve 4-weekly ID doses of placebo matching PVX108 in adolescents (Cohort 1)
62409043|NCT05621317|EXPERIMENTAL|PVX108 5 nmol in children|Twelve 4-weekly ID doses of PVX108 at 5 nmol in children (Cohort 2)
62409044|NCT05621317|EXPERIMENTAL|PVX108 50 nmol in children|Twelve 4-weekly ID doses of PVX108 at 50 nmol in children (Cohort 2)
62020265|NCT03471689|EXPERIMENTAL|Mindfulness|
62409045|NCT05621317|PLACEBO_COMPARATOR|Placebo in children|Twelve 4-weekly ID doses of placebo matching PVX-108 in children (Cohort 2)
62409046|NCT06171165||Hospitalized Patients Across Disease Categories|We included the patients, namely, patients with head-and-neck cancer, stroke, and Parkinson's disease, as well as the elderly patients in acute care settings.
62409047|NCT05866159|EXPERIMENTAL|Experimental Intervention|The experimental group will receive double-sided I-shaped kinesiotape. The tape will be applied from the sacroiliac joint to the thoracic 12th vertebrae, with a 10-15% tension. During the application, the participant will be positioned in maximum torso flexion.
62212608|NCT02204332|OTHER|Best Supportive Care|Best Supportive Care (BSC), with evaluations every 3 weeks (1 cycle).
62212609|NCT04155736|EXPERIMENTAL|Renew with coaching|Users will be assigned a study staff member as a support person who is notified when the user engages with the app or if they have not engaged for 7 days. Support persons are provided with psychoeducation material including information about how to be an effective support person for the user and direct messaging capacity to respond to app notifications about user engagement (e.g., user earned X points, user achieved a new level).
62020266|NCT03471689|ACTIVE_COMPARATOR|Positive reappraisal|
62020267|NCT06158711||single drug group, two drugs group, three drugs group and four drugs group|single drug group, patients with heart failure only took one sort of drugs two drugs group, patients with heart failure took two sorts of drugs three drugs group, patients with heart failure took three sorts of drugs four drugs group, patients with heart failure took four sorts of drugs
62020268|NCT02820987|ACTIVE_COMPARATOR|MEROPENEM|After enrollment, patients of MEROPENEM arm will receive an initial 2g bolus of MEROPENEM and 2g infusion over 3 hours every eight hours, during 48 hours, without modification of rhythm and dose according to renal function.
62212610|NCT04155736|ACTIVE_COMPARATOR|Renew without coaching|"Same as Renew with coaching except that the users will not be assigned a study staff member as a support person."
62212611|NCT04155736|NO_INTERVENTION|Wait list|No intervention is provided
62212612|NCT02569593|OTHER|RYGB-patient|Patients with a planned RYGB at UZ Leuven will be recruited. Iron supplements, more specific Ferrodyn and Vista Ferrum will be administrated in these patients before and 1, 3, 6 and 12 months post-RYGB with at least 7 days between the administration of the different supplements.
62212613|NCT05789368|PLACEBO_COMPARATOR|Placebo sachet|consume 1 sachet per day
62212614|NCT05789368|EXPERIMENTAL|VeCollal sachet|consume 1 sachet per day
62212615|NCT05789368|ACTIVE_COMPARATOR|Collagen sachet|consume 1 sachet per day
62212616|NCT02979405|EXPERIMENTAL|group 1|Phenylephrine 40 mcg/min, infusion during 5 minutes
62212617|NCT02979405|PLACEBO_COMPARATOR|group 2|Saline solution 21 cc, infusion during 5 minutes
62409048|NCT05866159|SHAM_COMPARATOR|Control Intervention|For the sham group, the kinesiotape will be applied horizontally to the center of the painful area in the lumbar region without any tension (at 0%).
62409049|NCT06019611|EXPERIMENTAL|Percutaneous Epidural Stimulation|Epidural spinal stimulation will be delivered via percutaneously implanted electrodes during rehabilitation. All implanted electrodes will be removed at the end of trial participation. The effects of epidural stimulation will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures.
62584423|NCT05950737|EXPERIMENTAL|sentinel node biopsy|All patients have undergone completion neck dissection following SNB in the process of standardization. The SNB was localized by peritumoral infiltration of the nano colloid, followed by dynamic planar imaging for 30 minutes, and then SPECT was performed. The surgery was performed on the same day within 6 hours of localisation, and intraoperatively, either methylene blue or indocyanine green was used as an adjunct. Appropriately labelled sentinel nodes were assessed on the frozen section, which was then sectioned into 2-3mm slices perpendicular to the longest axis of the node and submitted entirely for microscopic evaluation. A minimum of 2 sections were evaluated, one stained with Toluidine blue and the other with rapid Haematoxylin and Eosin (HE) stain. The nodes were subsequently subjected to histopathological processing.
62584424|NCT05669131|EXPERIMENTAL|Motor Imagery Training|Participants will do motor imagery training in 5 minute blocks for a total of 20 minutes.
62212618|NCT05613387|EXPERIMENTAL|ZP8396|"Part 1: 2 dose cohorts are planned with 10 subjects in each; 7 participants in each cohort will receive active treatment.~Part 2: 3 dose cohorts are planned with 16 subjects in each; 12 participants in each cohort will receive active treatment."
62584425|NCT05669131|NO_INTERVENTION|Control|Participants will watch a documentary in 5 minute blocks for a total of 20 minutes.
62212619|NCT05613387|PLACEBO_COMPARATOR|Placebo (ZP8396)|"Part 1: In each of the 2 dose cohorts, 3 subjects will receive placebo.~Part 2: In each of the 3 cohorts, 4 subjects will receive placebo."
62020269|NCT02820987|ACTIVE_COMPARATOR|PIPERACILLIN-TAZOBACTAM|After enrollment, patients of PIPERACILLIN - TAZOBACTAM arm will receive an initial 4g bolus of PIPERACILLIN - TAZOBACTAM and a 16g continuous infusion per day, during 48 hours, without modification of rhythm and dose according to renal function.
62020270|NCT02820987|ACTIVE_COMPARATOR|CEFEPIME|After enrollment, patients of CEFEPIME arm will receive an initial 2g bolus of CEFEPIME and a 6g continuous infusion per day, during 48 hours, without modification of rhythm and dose according to renal function.
62212620|NCT02874053||Healthy|Healthy Volunteers
62212621|NCT02746432|NO_INTERVENTION|Control group|Routine intra operative saline infusion to be administered.pre-operation and timed assessment lab set to be obtained.
62409050|NCT01701180|EXPERIMENTAL|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
62409051|NCT01701180|PLACEBO_COMPARATOR|Placebo|Intranasal application, sodium chloride solution, 3 puffs per nostril
62409052|NCT02660489|EXPERIMENTAL|OC459 (CRTH2 antagonist)|OC459 50mg once daily for 5 weeks
62409053|NCT02660489|PLACEBO_COMPARATOR|Placebo|Placebo tablet once daily for 5 weeks
62584426|NCT04980378||Simplify Disc|Extended follow-up of IDE Subjects treated at two continuous levels with the Simplify Cervical Artificial Disc during IDE G150206
62212622|NCT02746432|EXPERIMENTAL|Intervention group.Hyper insulinemic euglycemic clamp|After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin (Human regular insulin) ) infusion, and when the blood glucose is \<6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
62212623|NCT04385550|EXPERIMENTAL|Anlotinib hydrochloride capsule + AK105 injection|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) plus AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.
62790634|NCT03941717|EXPERIMENTAL|Mindfulness-Based Condition|Parents and children in the mindfulness intervention condition will be provided with a tablet and accompanying headphones, and will listen to pre-recorded audio of a mindfulness activity. There is a parent and child version of the mindfulness intervention. Both scripts were developed by Siegel and Bryson (2011), and include a parent and child version of a mindfulness activity targeting worries and anxiety. Adjustments to the child script were informed by the work of Petter and colleagues (2013). Adjustments to the parent script were informed by the work of Garland and colleagues (2015). This activity will last 5-minutes.
62212624|NCT04385550|ACTIVE_COMPARATOR|Standard Second-line Chemotherapy|Participants receive 80 mg/m² IV paclitaxel on Days 1, 8 and 15 of each 28-day cycle, or 75mg/m² docetaxel every 3 weeks of each 21-day cycle until disease progression or unacceptable toxicity.
62020271|NCT03065387|EXPERIMENTAL|Arm I (neratinib, everolimus)|Participants receive neratinib PO daily and everolimus PO daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62212625|NCT04766723|EXPERIMENTAL|NT 201 (IncobotulinumtoxinA, Xeomin)|"Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular injection of NT 201 (130-165 units) into muscles of the upper limb.~Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units) into muscles of the upper limbs."
62212626|NCT04766723|PLACEBO_COMPARATOR|Placebo|"Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular placebo injection into muscles of the upper limb.~Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units per arm) into muscles of the upper limbs."
62212627|NCT02117453|EXPERIMENTAL|Group I|Rosuvastatin 20 mg/day
62212628|NCT02117453|PLACEBO_COMPARATOR|Group II|Placebo
62212629|NCT03000205|EXPERIMENTAL|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder spin
62212630|NCT03000205|PLACEBO_COMPARATOR|Normal Saline|normal saline and Lidocaine as placebo for sham group
62212631|NCT01791374|EXPERIMENTAL|Rilotumumab Monotherapy|Cohort 1A: Rilotumumab 10 mg/kg IV Q2W Cohort 1B: Rilotumumab 20 mg/kg IV Q2W Cohort 1C (if needed): Rilotumumab 15 mg/kg IV Q2W
62212632|NCT01791374|EXPERIMENTAL|Rilotumumab plus CX|Cohort 2A: Rilotumumab 15 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W Cohort 2B (if needed): Rilotumumab 10 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W
62212633|NCT03456427|OTHER|All Study Participants|All subjects will undergo standard of care imaging on one breast. The other breast will be imaged using Patient-Assisted Compression (PAC), followed by Technologist-controlled (TC) Compression.
62212634|NCT00658255|EXPERIMENTAL|1|
62212635|NCT00658255|ACTIVE_COMPARATOR|2|
62212636|NCT02751268|PLACEBO_COMPARATOR|Control|placebo for the realization of infraorbital and infratrochlear block
62584427|NCT03773172|PLACEBO_COMPARATOR|Placebo Control Group|Subjects will receive placebo treatment to mimic active treatment.
62020272|NCT03065387|EXPERIMENTAL|Arm II (neratinib, palbociclib)|Participants receive Neratinib PO daily for 28 days and Palbociclib PO daily for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62584428|NCT03773172|ACTIVE_COMPARATOR|Active treatment|IV push loading dose of 300 mg MEDI6012 followed by a 150 mg maintenance dose of MEDI6012 at 48 hours.
62584429|NCT05449301|ACTIVE_COMPARATOR|Control Group|The control group will receive Conventional Treadmill training for Gait \& balance impairment.
62584430|NCT05449301|EXPERIMENTAL|Rhythmic Auditory Stimulation Training Group|Participants will be trained conventionally (bipedal) on regular treadmill along with Rhythmic Auditory Stimulation.
62409054|NCT05181176|EXPERIMENTAL|Coffee|The coffee group was instructed to consume 2 cups of coffee a day, the amount that was previously described as beneficial in epidemiological studies and safe for children and adolescence. Each cup of coffee contains 250 ml of coffee, which contains approximately 80 mg of caffeine. The children were allowed to add milk to the coffee and sweeten it with artificial sweetener
62212637|NCT02751268|ACTIVE_COMPARATOR|Ropivacaine|ropivacaine for the realization of infraorbital and infratrochlear block
62212638|NCT03472248|EXPERIMENTAL|Acceptance and Commitment Therapy|Eight weeks of smartphone delivered Acceptance and Commitment Therapy for the adolescent and eight weeks of internet delivered parental support to one or two parents of the adolescent.
62409055|NCT05181176|EXPERIMENTAL|Green Tea|The green tea group will be instructed to drink 3 cups (230CC) of Chinese green tea (Wissotzky Tea Israel Ltd). Each tea bag contains 500 g of fine dried herb parts. Each cup contains 84 mg total catechin and 32 mg caffeine. The participants were instructed to leave the tea bag for 2 minutes before drinking.
62409056|NCT05181176|PLACEBO_COMPARATOR|Herbal tea|The control group consumed 3 cups a day of Wissotzky- kid drink (Wissotzky Tea Israel Ltd), which is a drink that is marketed for children containing an infusion of fruits and plants. Each tea bag contains 2.7 gr plants parts with no evidence of polyphenols or caffeine.
62409057|NCT00944125|ACTIVE_COMPARATOR|Dual Site LV Pacing|Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.
62409058|NCT00944125|ACTIVE_COMPARATOR|BiV Pacing|Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.
62409059|NCT05006313|EXPERIMENTAL|Intraoperative fluorescence angiography|Intraoperative fluorescence angiography will be utilized to view initial debridement area. Using a sterile marking pen, the surgeon will mark the areas of tissue on skin, subcutaneous tissue, muscle, bone, or other that he or she wishes to debride further due to poor perfusion. A reference point on uninjured tissue of the same extremity at least 10 cm from the wound will be identified and measured for perfusion (set to reference of 100% perfusion). The area to be further debrided will be measured for percent perfusion relative to this reference point.
62409060|NCT05846152|EXPERIMENTAL|WoundCare medical device|Unique arm. The patients undergo all interventions planned in the study.
62584431|NCT05449301|EXPERIMENTAL|Unilateral Step Training Group|The participants will be trained with regular treadmill for unilateral step for both paretic and non-paretic lower extremity
62409061|NCT00554788|EXPERIMENTAL|Treatment (chemotherapy, radiotherapy, autologous SCI)|"INDUCTION: Patients receive vincristine IV; cisplatin IV; cyclophosphamide IV; and G-CSF SC beginning on day 3 and continuing until blood counts recover.~CONSOLIDATION (stage 4a or 4b disease only): Patients receive carboplatin IV; thiotepa IV; and etoposide IV.~AUTOLOGOUS STEM CELL INFUSION (stage 4a or 4b disease only): Patients undergo autologous stem cell infusion on day 0 and receive G-CSF SC beginning on day 1 and continuing until blood counts recover.~RADIOTHERAPY: Patients with stage 2 or 3 disease (orbital and/or regional involvement) undergo radiotherapy to sites that were initially involved beginning within 42 days after the start of course 4 of induction chemotherapy. Patients with stage 4a or 4b disease undergo radiotherapy to sites initially involved based on response beginning approximately 42 days after autologous stem cell infusion."
62409062|NCT03007615|EXPERIMENTAL|Experimental group|
62584432|NCT03741751|EXPERIMENTAL|active rTMS with computerized cognitive training|Participants will receive 6 sessions of active rTMS followed by a computerized cognitive training session over 2 weeks.
62584433|NCT03741751|SHAM_COMPARATOR|sham rTMS with computerized cognitive training|Participants will receive 6 sessions of sham rTMS followed by a computerized cognitive training session over 2 weeks.
62212639|NCT01699503|NO_INTERVENTION|No Screening|Subjects who are randomized into the non-screening arm will receive the usual standard of care.
62212640|NCT01699503|EXPERIMENTAL|Screening Group|Subjects who are randomized into the screening arm of the study will be screened by the MIS. Subjects with MIS score of less than 5 points will be referred to the Collaborative Dementia Care Program for a subsequent diagnostic assessment, counseling and management.
62212641|NCT06204952|PLACEBO_COMPARATOR|Placebo|Take placebo drug 1T tid for 12 weeks.
62212642|NCT06204952|ACTIVE_COMPARATOR|Test drug|Take Joins®(Clematidis Radix,Trichosanthes Root,Prunella Spike Extract) 1T tid for 12 weeks.
62212643|NCT01163292||Adalimumab|Participants who continued adalimumab treatment after completion of Study NCT00870467 (M06-859)
62584434|NCT06615557|EXPERIMENTAL|Fasedienol Nasal Spray|
62212644|NCT01163292||Non-Adalimumab|Participants who discontinued adalimumab treatment after completion of Study NCT00870467(M06-859)
62020273|NCT03065387|EXPERIMENTAL|Arm III (neratinib, trametinib)|Participants receive neratinib PO daily and trametinib PO daily as directed. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62020274|NCT04908891|EXPERIMENTAL|persons with Multiple Sclerosis|
62020275|NCT04908891|ACTIVE_COMPARATOR|Healthy controls|
62020276|NCT04908891|ACTIVE_COMPARATOR|Stroke Patients|
62020277|NCT04920760|NO_INTERVENTION|Control|Participants receiving standard treatment alone.
62409063|NCT04381117||No Treatment|Subjects who participated in and completed study EN3835-201 and had composite improvement of at least 2-levels on both the Clinician Reported-Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient Reported-Photonumeric Cellulite Severity Scale (PR-PCSS) in EN3835-201 study will be eligible for this study. The study will consist of a single day evaluation approximately 4 years after the first dose of the study drug was received in the EN3835-201 study.
62020278|NCT04920760|EXPERIMENTAL|Vitamin A|Participants receiving standard treatment with an additional vitamin A supplementation.
62020279|NCT00019682|EXPERIMENTAL|Arm I (aldesleukin)|Patients receive aldesleukin IV over 15 minutes every 8 hours for 12 doses. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease 3 weeks after completing 2 courses may receive a maximum of 12 additional courses. Patients with complete response may receive a maximum of 2 additional courses.
62020280|NCT00019682|EXPERIMENTAL|Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin)|Patients receive gp100 antigen emulsified in Montanide ISA-51 SC on day 1. Patients also receive aldesleukin as in Arm I beginning on day 2. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease 3 weeks after completing 2 courses may receive a maximum of 12 additional courses. Patients with complete response may receive a maximum of 2 additional courses.
62020281|NCT01229345|EXPERIMENTAL|Breakfast & exercise|
62020282|NCT01229345|EXPERIMENTAL|Breakfast & no exercise|
62020283|NCT01229345|EXPERIMENTAL|No breakfast & exercise|
62020284|NCT01229345|NO_INTERVENTION|No breakfast & no exercise|
62020285|NCT04285606|EXPERIMENTAL|Patient-led rehab group|Immobilization in arm sling for a short period time followed by patient-led shoulder exercises for rehab following reverse shoulder arthroplasty
62020286|NCT04285606|NO_INTERVENTION|Supervised rehab group|Prolonged immobilization in arm sling followed by supervised physical therapy by therapists for rehab following reverse shoulder arthroplasty
62020287|NCT05101252|ACTIVE_COMPARATOR|TEST Lens|Eligible subjects who are habitual soft contact lens wearers will be randomized to the TEST Lens sequence for the duration of the study.
62020288|NCT05101252|EXPERIMENTAL|CONTROL Lens|Eligible subjects who are habitual soft contact lens wearers will be randomized to the CONTROL Lens sequence for the duration of the study.
62212645|NCT04850872|EXPERIMENTAL|Experimental|PLAYwithHEART Programme is a manualized mindfulness, acceptance, and compassionate-based group intervention for adolescent competitive athletes. It included 8 weekly group sessions, 45 minutes each, run in small groups (ranging from 8 to 12 participants). Participants of this group complete also self-report measures.
62409064|NCT05117294|EXPERIMENTAL|Bocidelpar (ASP0367): Severe Renal Impairment|Participants with severe renal impairment will receive a single dose of Bocidelpar (ASP0367) under fasting conditions on day 1.
62409065|NCT05117294|EXPERIMENTAL|Bocidelpar (ASP0367): Moderate Renal Impairment|Participants with moderate renal impairment will receive a single dose of Bocidelpar (ASP0367) under fasting conditions on day 1.
62020289|NCT05857046|ACTIVE_COMPARATOR|Melatonin group|Melatonin group will receive prolonged released melatonin tablet 10mg for 7 days, then 10 mg for 83 days.
62020290|NCT05857046|PLACEBO_COMPARATOR|Placebo group|Placebo group will receive placebo tablet for 7 days, then for 83 days.
62020291|NCT05234398||Naïve patients|"This study involve non-responder solid organ transplanted patients after an adapted vaccinal scheme (i.e. 3 doses or more of mRNA vaccines).~Patients included in Group 1 are naïve patients; there have never received anti-SARS Cov2 monoclonal antibodies.~They will have additional blood and saliva samplings during their study visits, which are included in their usual medical follow-up."
62020292|NCT05234398||Switched patients|"This study involve non-responder solid organ transplanted patients after an adapted vaccinal scheme (i.e. 3 doses or more of mRNA vaccines).~Patients included in Group 2 have previously received anti-SARS Cov2 monoclonal antibodies.~They will have additional blood and saliva samplings during their study visits, which are included in their usual medical follow-up."
62212646|NCT04850872|NO_INTERVENTION|Control|Participants of control group do not receive the intervention Programme (PLAYwithHEART), nor any other program, and only complete self-report measures.
62212647|NCT03827083||Spinal anesthesia|Evaluation of cognitive functions of patients under 65 years of age with lower extremity surgery by cerebral pulse oximetry
62212648|NCT03827083||General anesthesia|Evaluation of cognitive functions of patients under 65 years of age with lower extremity surgery by cerebral pulse oximetry
62212649|NCT02075476|ACTIVE_COMPARATOR|Hemiarthroplasty Global Fx(DePuy)|in this technique the prosthesis is implanted in similar approach to shoulder anatomy
62212650|NCT02075476|EXPERIMENTAL|reverse arthroplasty Delta Xtent(DePuy)|In this technique the prosthesis is implanted in the inverse mode of shoulder anatomy
62409066|NCT05117294|EXPERIMENTAL|Bocidelpar (ASP0367): Mild Renal Impairment|Participants with mild renal impairment will receive a single dose of Bocidelpar (ASP0367) under fasting conditions on day 1.
62409067|NCT05117294|EXPERIMENTAL|Bocidelpar (ASP0367): Normal Renal Function|Participants with normal renal function will receive a single dose of Bocidelpar (ASP0367) under fasting conditions on day 1.
62409068|NCT06335394|EXPERIMENTAL|Single-arm study|NVD003
62409069|NCT04162301|EXPERIMENTAL|CS3002 CDK4/6 inhibitor|
62409070|NCT06539078||Young, sedentary participants|"* Aged between 18-30 years~* Male or female~* Not currently engaging in any formal exercise training or competitive sports~* No chronic health conditions likely to affect exercise tolerance or the physiological responses to exercise"
62584435|NCT06615557|EXPERIMENTAL|Placebo Nasal Spray|
62409071|NCT06539078||Young endurance-trained participants|"* Aged between 18-30 years~* Male or female~* Currently engaging in formal training (at least 3 times per week) in competitive endurance sports (i.e. running, cycling, swimming, triathlon, etc.)~* No chronic health conditions likely to affect exercise tolerance or the physiological responses to exercise"
62212651|NCT06533696||immunocompromised|immunocompromised cancer, renal failure and undernourished patients
62020293|NCT03841786|PLACEBO_COMPARATOR|Control diet|Participants will be asked to consume a normal diet supplemented with sodium chloride (sodium chloride tablets, USP, 1 gram; 3 tablets per day) and potassium chloride (Klor-Con, 8 mEq; 0.5 tablets per day) for 1 week.
62212652|NCT06533696||immunocompetent|exclude cancer, renal failure patients
62212653|NCT01134172||Breast cancer survivors|Women being treated for stage I-III breast cancer who were employed prior to this diagnosis will be recruited in their physicians' offices.
62020294|NCT03841786|EXPERIMENTAL|Phosphorus-supplemented study diet|Participants will be instructed to consume a normal diet with supplemental phosphorus (K-Phos Neutral tablets, 250 mg; 4 tablets a day) for 1 week.
62212654|NCT01134172||Comparison group|Peer controls will be nominated by participants in the breast cancer survivor group or recruited by community outreach and matched for age, language, and ethnicity. This cohort is no longer recruiting.
62584436|NCT01540214||POP surgery|All women who present with POP at the outpatient clinic of our centre and who will undergo prolapse repair surgery will be asked informed consent for participation in this study
62584437|NCT04421222|EXPERIMENTAL|Part A/Phase 1a: Cohort 1 (Completed)|200 mg EPI-7386
62212655|NCT04664400|EXPERIMENTAL|N-of-few Study of Pain|
62212656|NCT01401400||(Peg) interferon|Patients who are treated for at least 12 weeks with (peg-)interferon for chronic hepatitis B
62212657|NCT04598503||cases|All the babies admitted to the hospital with congenital anomalies during this period were included
62409072|NCT06539078||Middle-aged, sedentary participants|"* Aged between 50-65 years~* Male or female~* Not currently engaging in any formal exercise training or competitive sports~* No chronic health conditions likely to affect exercise tolerance or the physiological responses to exercise"
62409073|NCT06539078||Middle-aged endurance-trained participants|"* Aged between 50-65 years~* Male or female~* Currently engaging in formal training (at least 3 times per week) in competitive endurance sports (i.e. running, cycling, swimming, triathlon, etc.)~* No chronic health conditions likely to affect exercise tolerance or the physiological responses to exercise"
62409074|NCT03145038|EXPERIMENTAL|Treatment A|Single oral dose of 20 x 0.5 mg vericiguat high-dose pediatric formulation, fed, American breakfast
62584438|NCT04421222|EXPERIMENTAL|Part A/Phase 1a: Cohort 2 (Completed)|400 mg EPI-7386
62584439|NCT04421222|EXPERIMENTAL|Part A/Phase 1a: Cohort 3 (Completed)|600 mg EPI-7386
62584440|NCT04421222|EXPERIMENTAL|Part A/Phase 1a: Cohort 4 (Completed)|800 mg EPI-7386
62212658|NCT04598503||control|newborns without congenital anomalies
62212659|NCT01569477|EXPERIMENTAL|Treatment incentives|Incentives for biochemical verification visits, treatment engagement, and abstinence
62212660|NCT01569477|ACTIVE_COMPARATOR|Attendance incentive|Incentives for only attending the biochemical verification visits
62212661|NCT03095131|EXPERIMENTAL|12-lead ECG|
62212662|NCT01637948|ACTIVE_COMPARATOR|Listerine|essential oil mouthrinse
62212663|NCT01637948|NO_INTERVENTION|Negative control|without intervention
62212664|NCT01637948|EXPERIMENTAL|Chinese medicine mouthrinse|5% Fructus Mume extract and 2% sodium bicarbonate
62212665|NCT00515853|EXPERIMENTAL|Biofeedback|Received feedback
62212666|NCT00515853|NO_INTERVENTION|No biofeedback|Did not received feedback
62212667|NCT02948673|PLACEBO_COMPARATOR|Control|4 placebo tablets/day (2 in the morning and 2 in the evening)
62212668|NCT02948673|ACTIVE_COMPARATOR|Glutathione|4 oral GSH tablets/day (2 in the morning and 2 in the evening)
62409075|NCT03145038|EXPERIMENTAL|Treatment B|Single oral dose of 20 x 0.5 mg vericiguat high-dose pediatric formulation, fasted
62409076|NCT03145038|EXPERIMENTAL|Treatment C|Single oral dose of 25 x 0.1 mg vericiguat high-dose pediatric formulation, fed, American breakfast
62409077|NCT03145038|ACTIVE_COMPARATOR|Treatment D|Single oral dose of 10 mg vericiguat intact IR tablet, adult formulation, fed, American breakfast
62409078|NCT03145038|EXPERIMENTAL|Treatment E|Single oral dose of 10 mg vericiguat crushed IR tablet, adult formulation, fed, American breakfast
62409079|NCT03145038|EXPERIMENTAL|Treatment F|Single oral dose of 10 mg vericiguat intact IR tablet, adult formulation, fed, continental breakfast
62584441|NCT04421222|EXPERIMENTAL|Part A/Phase 1a: Cohort 5 (Completed)|1000 mg EPI-7386
62584442|NCT04421222|EXPERIMENTAL|Part A/Phase 1a: Cohort 6 (Completed)|800 mg EPI-7386
62584443|NCT04421222|EXPERIMENTAL|Part A/Phase 1a: Cohort 7 (Completed)|1200 mg EPI-7386
62584444|NCT04421222|EXPERIMENTAL|Part A/Phase 1b: Cohort 1 (Completed)|600 mg EPI-7386 BID
62584445|NCT04421222|EXPERIMENTAL|Part A/Phase 1b: Cohort 2|600 mg EPI-7386 QD
62584446|NCT04421222|EXPERIMENTAL|Part B/Cohort 1a|600 mg EPI-7386 + 1000 mg Abiraterone Acetate + Prednisone
62584447|NCT04421222|EXPERIMENTAL|Part B/Cohort 1b|800 mg EPI-7386 + 1000 mg Abiraterone Acetate + Prednisone
62584448|NCT04421222|EXPERIMENTAL|Part B/Cohort 1c|1200 mg EPI-7386 + 1000 mg Abiraterone Acetate + Prednisone
62584449|NCT04421222|EXPERIMENTAL|Part B/Cohort 2a|600 mg EPI-7386 monotherapy for 12 weeks then 600 mg EPI-7386 + 240 mg Apalutamide
62584450|NCT04421222|EXPERIMENTAL|Part B/Cohort 2b|800 mg EPI-7386 monotherapy for 12 weeks then 800 mg EPI-7386 + 240 mg Apalutamide
62409080|NCT04402580|EXPERIMENTAL|Rituximab biosimilar|"* Drug Name: Rituximab biosimilar monoclonal anti-CD20 antibody~* Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities (of note CD20 is mostly represented on B cells but also in Th17 cells)~* How: RTX IV: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.~* Where: in Hospital~* When and how much: once; diluted in 1000 ml of normal saline."
62409081|NCT04402580|ACTIVE_COMPARATOR|Mycophenolate Mofetil|"Drug Name: Mycophenolate Mofetil (MMF)~* Why: selective and reversible inhibition of inosine monophosphate dehydrogenase with inhibition that particularly affects lymphocytes since they rely almost exclusively de novo purine synthesis~* Procedures: MMF 1,200 mg/1,73 sqm orally divided in 2 daily doses"
62409082|NCT01998659|ACTIVE_COMPARATOR|Px-102|Px-102 drinking solution, single dose
62409083|NCT01998659|PLACEBO_COMPARATOR|Placebo|Placebo drinking solution, single dose
62409084|NCT03253809|EXPERIMENTAL|Coronary Sinus Branch Pacing|"After cannulation, pacing impulses will be delivered via a Biotronik Vision Guidewire to 3 sites (apical, mid ventricular, and basal) within each coronary sinus branch receiving venous blood from the anterior, lateral and posterior regions of the ventricle.~ECG signals will be saved digitally for analysis"
62584451|NCT04421222|EXPERIMENTAL|Part B/Cohort 2c|1200 mg EPI-7386 monotherapy for 12 weeks then 1200 mg EPI-7386 + 240 mg Apalutamide
62584452|NCT05989828|EXPERIMENTAL|Treatment (A2-ESO-1 TCR-T cells)|Patients undergo leukapheresis on day -28 then receive cyclophosphamide IV over 1 hour on days -7 and -6 followed by fludarabine IV over 30 minutes on days -5 to -1. Patients then receive A2-ESO-1 TCR-T cells IV over 30 minutes on day 0 followed by aldesleukin IV over 15 minutes on days 0 to 2. Patients also undergo blood sample collection and CT scans throughout the study. Additionally, patients may undergo a breast biopsy, a mammogram, breast MRI, and breast US at screening and follow up, and ECHO or MUGA at screening.
62790635|NCT03941717|SHAM_COMPARATOR|Unfocused attention Condition|Parents and children in the unfocused attention condition will be provided with a tablet and accompanying headphones, and will listen to pre-recorded audio of an unfocused attention activity. There is a parent and child version of this activity. The parent version has been validated in other research with healthy adults as a control for a mindfulness intervention (Garland, Hanley, Farb, \& Froeliger, 2015). This script was condensed in time from the original reading. The child version of the activity was developed for the current study, and was adapted from a mind-wandering script used for children aged 7-12 in past research (Spann, 2016). It was also informed by the unfocused attention script used for parents (Garland, Hanley, Farb, \& Froeliger, 2015), and work by Cahn and Polich (2009). This activity will last 5-mintues.
62790636|NCT02497885||healthcare personnel group|healthcare worker who was exposed to confirmed MERS patients, irrespective of adequate personal protective equipment.
62790637|NCT01314131|EXPERIMENTAL|Intervention group|
62790638|NCT04289961|OTHER|Single Arm|Observational study of CTC microemboli in portal vein blood samples.
62212669|NCT05658432|EXPERIMENTAL|Intervention|The experimental group will perform an exercise program including aerobic, range of motion, stretching exercises on zoom sessions of 45 minutes each, under the supervision of the investigator, following a prerecorded exercise video. They will exercise thrice a week for 8 weeks, in groups of five.
62409085|NCT04189536|EXPERIMENTAL|SMS Intervention|All subjects will receive customized text messages twice a day, every day for 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
62409086|NCT00997269|EXPERIMENTAL|CoQ-10 supplementation|
62409087|NCT00997269|PLACEBO_COMPARATOR|CoQ-10 placebo supplementation|
62020295|NCT02222220|PLACEBO_COMPARATOR|metoclopramide|61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode
62020296|NCT02222220|EXPERIMENTAL|metocliopramide|61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode
62409088|NCT06224387|EXPERIMENTAL|Dose Escalation/Dose Expansion|4-6 dose groups are pre-specified in Dose Escalation,and 4 arms in Dose Expansion.
62409089|NCT01111968|EXPERIMENTAL|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
62409090|NCT01111968|EXPERIMENTAL|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
62409091|NCT01111968|EXPERIMENTAL|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
62409092|NCT01111968|EXPERIMENTAL|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
62409093|NCT01111968|EXPERIMENTAL|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
62409094|NCT01111968|EXPERIMENTAL|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
62409095|NCT01111968|EXPERIMENTAL|pandemic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
62409096|NCT01111968|EXPERIMENTAL|pandemic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
62409097|NCT01111968|EXPERIMENTAL|pandemic vaccine 13|15µg of A/H1N1 with no adjuvant
62409098|NCT01111968|PLACEBO_COMPARATOR|placebo group 14|placebo
62409099|NCT06362707|EXPERIMENTAL|Fasudil|In recognition that fasudil has only been evaluated in published studies for treatment durations of up to 3 months, we intend to enroll participants in three successive cohorts of 20, 50 and 130 people, respectively. Participants in the initial cohort will undergo a 2-week titration period (60 mg total daily dose; 20 mg tds) before being escalated to the maintenance dose (120 mg total daily dose; 40 mg tds) for up to 50 additional weeks of treatment. The selected dose of 120mg per day is optimized for potential efficacy over the planned 12-month treatment period, while providing a reasonable margin of safety based on available clinical and nonclinical data.
62409100|NCT06362707|PLACEBO_COMPARATOR|Placebo|Following screening procedures, subjects will be randomized at baseline to receive fasudil or matching placebo across all cohorts. 1:1 randomization will be performed.
62409101|NCT02372786|OTHER|Acne Keloidalis Nuchae|2,5% lidocaine / 2,5% prilocaine cream and 7% lidocaine / 7% tetracaine cream will be applied for 60 minutes. After removal of the creams patients will recieve laser hair removal treatment using a neodymium-doped yttrium aluminium garnet (Nd:Yag) laser.
62409102|NCT02372786|OTHER|Tattoo|2,5% lidocaine / 2,5% prilocaine cream and 7% lidocaine / 7% tetracaine cream will be applied for 60 minutes. After removal of the creams patients will recieve laser tattoo removal treatment using a Q-switched nd Yag laser.
62409103|NCT02164084|EXPERIMENTAL|SB204|SB204 8% topically twice daily for 4 days and once on Day 5
62409104|NCT02164084|PLACEBO_COMPARATOR|Vehicle Gel|Vehicle Gel topically twice daily for 4 days and once on Day 5
62409105|NCT03953391|EXPERIMENTAL|Tea-water|Tea before water
62409106|NCT03953391|EXPERIMENTAL|Water-tea|Water before tea
62409107|NCT00399204|ACTIVE_COMPARATOR|Control|Metformin
62409108|NCT00399204|EXPERIMENTAL|Experimental|Pioglitazone
62409109|NCT06493188|EXPERIMENTAL|Intervention Group - High-fidelity interprofessional simulation|
62409110|NCT06493188|ACTIVE_COMPARATOR|Control Group - Low-fidelity interprofessional simulation|
62409111|NCT05270629||Lower limb lymphedema patients|This was a retrospective cohort propensity score-matched study. Patients with lower limb lymphedema were enrolled.
62409112|NCT06008470||covid-19|"Inclusion Criteria:~* Literacy,~* To be between the ages of 18-45,~* To study at Kırıkkale University Faculty of Health Sciences~* Volunteering to participate in the research,"
62790639|NCT01518842|EXPERIMENTAL|test group intravitreal stem cell|"Open-label study of Ischemic Retinopathy patients with best-corrected visual acuity (BCVA) worse than 20/200.~Intervention: Biological: intravitreal injection of autologous bone marrow stem cells"
62020297|NCT04204421|EXPERIMENTAL|Experience Sampling Method (ESM)|Both patients with functional dyspepsia and healthy controls will be asked to fill out ESM questionnaires during 1 week. Moreover, at the end of this week, usual questionnaires for complaints assessment will be filled out.
62020298|NCT02817451|EXPERIMENTAL|Study Group A|HIV exposed and infected infants
62020299|NCT02817451|EXPERIMENTAL|Study Group B|HIV exposed and uninfected infants
62020300|NCT01681082|EXPERIMENTAL|Tai Chi Training|"Subjects will be recruited from the University of Wisconsin-Madison course, Introduction to Martial Arts: Tai Chi."
62020301|NCT01681082|NO_INTERVENTION|Control|"Subjects will be recruited from the University of Wisconsin-Madison course Introduction to Psychology."
62020302|NCT01063205|PLACEBO_COMPARATOR|Placebo|
62409113|NCT06008470||control|
62409114|NCT03810027||OAB with nocturnal polyuria|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. Nocturnal polyuria was defined when the proportion of nighttime voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of nighttime voided volume over 24-hour voided volume was greater than 20% for \<65 year-old women. Precence of nocturnal polyuria will be classified in this group.
62409115|NCT03810027||OAB without nocturnal polyuria|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. Nocturnal polyuria was defined when the proportion of nighttime voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of nighttime voided volume over 24-hour voided volume was greater than 20% for \<65 year-old women. Absence of nocturnal polyuria will be classified in this group.
62584453|NCT05230004|EXPERIMENTAL|Phase II|Phase II involves a two month home trial to determine the comfort and utility of an adjustable prosthetic system for children. Children will be fit at several different locations by their prosthetist with the adjustable socket. They will complete several questionnaires on their current device, as well as have internal socket pressures and a gait analysis completed. They will return one month later to complete the same outcome measures on their conventional device. They will also be given activity monitors to track their activity through the duration of the project.
62212670|NCT05658432|ACTIVE_COMPARATOR|Active control|Control group will have access to the same exercise video and guided for the first session. They will be asked to do the exercises at home, exact the same duration and frequency of the experimental group but without supervision, for 8 weeks.
62212671|NCT04848701|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
62212672|NCT00185965|EXPERIMENTAL|Lymphoma, B-cell low-grade (BCL)|Recurrent low-grade B-cell lymphoma patients (at least one prior treatment failure)
62212673|NCT00185965|EXPERIMENTAL|Mycosis fungoides (MF)|"Mycosis fungoides patients must have failed or have been intolerant of at least 1 topical or 1 systemic treatment~Recurrent mycosis fungoides patients (at least one prior failure of topical or systemic treatment)"
62212674|NCT02639039|ACTIVE_COMPARATOR|Cortisone Injection|Fifty patients with GTPS will be randomized into a CI or TDN group. Treatment will be carried out at the 1st visit following consent according to SOC. Treatment will be administered according to standard of care for up to 6 weeks.
62212675|NCT02639039|ACTIVE_COMPARATOR|Trigger Point Dry Needling|Fifty patients with GTPS will be randomized into a CI or TDN group. Treatment will be carried out at the 1st visit following consent according to SOC. Treatment will be administered according to standard of care for up to 6 weeks.
62212676|NCT05842239|EXPERIMENTAL|Hyperbaric Oxygen Therapy active arm|The protocol comprises of 60 consecutive hyperbaric oxygen treatment (HBOT) sessions, 5 sessions per week within a three months' period.
62212677|NCT01503593|NO_INTERVENTION|Alveolar ridge dimensions|Control group - Only extraction teeth
62212678|NCT01503593|EXPERIMENTAL|Alverolar ridge dimension|Extraction of teeth and implant a bone substitute
62409116|NCT04143477|EXPERIMENTAL|Peficitinib 50 mg|Participants will receive a single dose of 50 milligrams (mg) under fasted condition Day 1, followed by multiple doses of 50 mg under fed condition once daily in the morning from Day 8 till Day 13.
62409117|NCT04143477|EXPERIMENTAL|Peficitinib 100 mg|Participants will receive a single dose of 100 mg under fasted condition Day 1, followed by multiple doses of 100 mg under fed condition once daily in the morning from Day 8 till Day 13.
62790640|NCT01946737|ACTIVE_COMPARATOR|Invasive coronary angiography (ICA)|Routine diagnostic ICA
62790641|NCT01946737|EXPERIMENTAL|HD-CTCA with ASIR|HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)within 4 weeks of routine diagnostic ICA
62790642|NCT01915043|ACTIVE_COMPARATOR|health education for lymphedema prevention|health education for lymphedema prevention
62790643|NCT01915043|EXPERIMENTAL|application smartphone-based group|Health education plus Smartphone-based application sample will have a reminder to do education everyday where patients will have to select if they have done or they haven´t done compliance
62020303|NCT01063205|ACTIVE_COMPARATOR|N-Acetylcysteine (NAC) 1800 mg|
62020304|NCT01063205|ACTIVE_COMPARATOR|N-Acetylcysteine (NAC) 3600 mg|
62212679|NCT00504998|EXPERIMENTAL|1|Dose Level 1 of escalating doses of Rexin-G i.v.
62212680|NCT00504998|EXPERIMENTAL|2|Dose Level 2 of escalating doses of Rexin-G i.v.
62212681|NCT00504998|EXPERIMENTAL|3|Dose Level 3 of escalating doses of Rexin-G i.v.
62212682|NCT00504998|EXPERIMENTAL|4|Dose Level 4 of escalating doses of Rexin-G i.v.
62212683|NCT00504998|EXPERIMENTAL|5|Dose Level 5 of escalating doses of Rexin-G i.v.
62212684|NCT01932125|EXPERIMENTAL|Cohort|
62212685|NCT06489405|EXPERIMENTAL|Horticultural practices|Horticultural practices, consisting of 6 sessions with a one-week interval,was applied face to face to this intervention group. Each session lasted approximately 60 minutes.
62212686|NCT06489405|NO_INTERVENTION|Control|No intervention has been made.
62212687|NCT03347890|EXPERIMENTAL|Liraglutide 3.0 mg|35 obese patient will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg).
62212688|NCT03347890|PLACEBO_COMPARATOR|Placebo|35 obese patient will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Placebo by pen injector.
62212689|NCT00810433|EXPERIMENTAL|Arm 1|
62409118|NCT04143477|EXPERIMENTAL|Peficitinib 150 mg|Participants will receive a single dose of 150 mg under fasted condition Day 1, followed by multiple doses of 150 mg under fed condition once daily in the morning from Day 8 till Day 13.
62409119|NCT03572049|EXPERIMENTAL|SUBA itraconazole|"Stage 1: Day 1-3 two 65 mg capsules three times daily with food. Days 4-42 two 65 mg capsules twice daily with food.~Stage 2 : Days 43-180 two 65 mg capsules twice daily with food"
62409120|NCT03572049|ACTIVE_COMPARATOR|Conventional itraconazole|"Stage 1: Day 1-3 two 100 mg capsules three times daily with food. Days 4-42 two 100 mg capsules twice daily with food.~Stage 2 : Days 43-180 two 100 mg capsules twice daily with food"
62409121|NCT04612712|EXPERIMENTAL|Donafenib+ KN046|Donafenib 50mg BID/100 mg BID/200 mg BID orally + KN046 5mg/kg Q3W iv
62212690|NCT02605655|EXPERIMENTAL|AMP-1915|Instant noodles contained AMP-1915 2 g/pc with meal, 1 pc/day for 3 months.
62409122|NCT05283655|EXPERIMENTAL|Intervention group|10 weekly sessions of gut-directed hypnotherapy (behavioral intervention).
62790644|NCT01391936|OTHER|Tension Band Wiring|Patients in this arm will receive the tension band wiring technique for fixation of their olecranon fracture.
62790645|NCT01391936|OTHER|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
62790646|NCT00665535|OTHER|2. High Risk|High risk for pressure ulcers according to the Braden Scale for Predicting Pressure Sore Risk (Score 10-12)
62790647|NCT00665535|OTHER|1. Moderate Risk|Moderate risk for pressure ulcers according to the Braden Scale for Predicting Pressure Sore Risk (Score 13 and 14)
62790648|NCT06413797|EXPERIMENTAL|FDA warnings + Image|Participants will receive FDA-proposed LCC warnings with images
62790649|NCT06413797|EXPERIMENTAL|FDA Warnings Text-Only Warnings|Participants will receive FDA-proposed text-only LCC warnings.
62212691|NCT02605655|PLACEBO_COMPARATOR|Placebo|Instant noodles with the same sharp and color as Experimental noodles with meal, 1 pc/day for 3 months.
62212692|NCT03831126||betamethasone treatment|
62212693|NCT02754739|EXPERIMENTAL|Pravastatin|Pravastatin 40mg tablet by mouth, once daily for 24 weeks. Also, nutritional education was provided to participants in all arms by a nutritionist, and participants were instructed to follow the educated guideline.
62409123|NCT06622083|ACTIVE_COMPARATOR|Education group|Participants in this group will receive 40 minutes of both theoretical and practical education.
62584454|NCT05230004|EXPERIMENTAL|Phase I|Phase I involves developing a final design for an adjustable, immediate fit prosthesis. We will recruit 5-10 participants age 3-12 to complete in-lab testing and evaluation of several designs. This testing will lead to the final product design to be tested in Phase II.
62212694|NCT02754739|PLACEBO_COMPARATOR|Placebo|Placebo drug indistiguishable from pravastatin 40mg tablet, by mouth, once daily for 24 weeks. Also, nutritional education was provided to participants in all arms by a nutritionist, and participants were instructed to follow the educated guideline.
62212695|NCT02754739|OTHER|Open-label control|No medication. Only nutritional education was provided to participants by a nutritionist, and participants were instructed to follow the educated guideline.
62212696|NCT04688190||Transcatheter Mitral Valve Implantation (TMVI)|Patients with successful TMVI screening, who underwent Transcatheter Mitral Valve Implantation subsequently. All devices may be included.
62212697|NCT04688190||Interventional mitral valve edge-to-edge repair (E2E)|Patients with TMVI screening failure, who subsequently underwent interventional mitral valve edge-to-edge repair.
62212698|NCT04688190||Mitral valve surgery (Surgery)|Patients with TMVI screening failure, who subsequently underwent mitral valve surgery (i.e., mitral valve repair or replacement).
62212699|NCT04688190||Medical therapy (OMT)|Patients with TMVI screening failure, who subsequently underwent conservative or optimal medical therapy (OMT).
62212700|NCT02207569|EXPERIMENTAL|CoreValve Evolut R TAVR system|"The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:~1. Evolut R Transcatheter Aortic Valve (TAV)~2. EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath~3. EnVeo R Loading System (LS)"
62212701|NCT02776839|OTHER|Mobile Sensing|This phase of the study is designed to develop the app. due to algorithms the app should lern to detect depressive symptoms
62409124|NCT06622083|EXPERIMENTAL|Education and Aerobic exercise group|Participants in the exercise group will undergo an aerobic exercise program Following the exercise, participants will receive 40 minutes of both theoretical and practical education.
62584455|NCT04237103|EXPERIMENTAL|methotrexate|Methotrexate once a week orally for 8 months in conjunction with narrow band UVB phototherapy starting 2 months after Methotrexate therapy for 6 months.
62409125|NCT05434949||Effect of food intake on C4|Blood tests to analyse serum C4 pre, and 2 and 4 hours post a standardised meal, and the same 10 patients to analyse serum C4 at 0, 2 and 4 hours, all fasting.
62409126|NCT05434949||Effect of Lipid-lowering therapy on C4|Spare sample collected from patients before and after starting on lipid-lowering therapy will be used to measure C4 before and after lipid-lowering therapy.
62409127|NCT04495296|EXPERIMENTAL|dose escalation Q2W|Dosed every 2 weeks IV with TST001, multiple dose levels will be tested.
62584456|NCT04237103|PLACEBO_COMPARATOR|placebo|Placebo once a week orally for 8 months in conjunction with narrow band UVB phototherapy starting 2 months afterplacebo therapy, for 6 months.
62584457|NCT02283996|EXPERIMENTAL|Physical Therapy with Steroid Injection|Patients will undergo regular physical therapy as defined by the standard of care at Massachusetts General Hospital for Adhesive Capsulitis (Frozen Shoulder). If they are in the inflammatory phase of the condition, they will receive 40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine.
62020305|NCT00345397|EXPERIMENTAL|Subjects Receiving PEC Tube|Percutaneous Endoscopic Colostomy Tube (PEC) Placement
62212702|NCT00162448|EXPERIMENTAL|A1|
62212703|NCT00162448|PLACEBO_COMPARATOR|A2|
62212704|NCT04180033|OTHER|Colonoscopy surveillance in TC survivors|TC survivors treated with platinum-based chemotherapy will be invited to undergo a colonoscopy surveillance.
62212705|NCT04876872||pediatric patients|whole pediatric patients who admitted to the pediatric emergency unit in Farabi Hospital, Trabzon, Turkey
62020306|NCT04636892|EXPERIMENTAL|Severe aortic stenosis|"Patients with echocardiographic evidence of severe aortic stenosis as defined by:~Aortic Vmax ≥4 m/s or mean ΔP ≥40 mmHg AVA ≤1.0 cm2"
62584458|NCT02283996|EXPERIMENTAL|Watchful Waiting with Steroid Injection|Patients will undergo no therapeutic intervention outside of steroid injection. If they are in the inflammatory phase of the condition, they will receive 40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine.
62212706|NCT02249598|EXPERIMENTAL|Univeristy of Sheffield|lactamica
62212707|NCT02249598|PLACEBO_COMPARATOR|Hallam University|Phosphate Buffered Saline (PBS)
62212708|NCT00372645|EXPERIMENTAL|Diet|200 µg folate per day from folate-rich foods
62212709|NCT00372645|EXPERIMENTAL|Folic acid supplement|200 µg folate per day from supplemental folic acid
62212710|NCT00372645|EXPERIMENTAL|Metfolin supplement|200 µg folate per day from supplemental Metafolin®
62212711|NCT00372645|PLACEBO_COMPARATOR|Placebo|Placebo
62212712|NCT00989625|ACTIVE_COMPARATOR|10mg Sumatriptan/60mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
62212713|NCT00989625|ACTIVE_COMPARATOR|30mg Sumatriptan/180mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
62212714|NCT00989625|ACTIVE_COMPARATOR|85mg Sumatriptan/500mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
62584459|NCT02919423|ACTIVE_COMPARATOR|10 Hz TMS|active TMS will be administered
62584460|NCT02919423|ACTIVE_COMPARATOR|1 Hz TMS|active TMS will be administered
62584461|NCT03000426|SHAM_COMPARATOR|Free gingival graft + PBM Sham|The patients allocated to the control group will receive sham irradiation. For this, black rubber protection will be placed at the tip of the laser device, which do not allow the light to reach the tissue. The applications will be performed by a different operator from the one who will measure the study parameters. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by four more applications performed every other day, with a total of 5 laser applications.
62790650|NCT06413797|ACTIVE_COMPARATOR|Surgeon General Text-Only Warnings|Participants will receive Surgeon General text-only LCC warnings.
62020307|NCT04636892|EXPERIMENTAL|Severe mitral regurgitation|"Patients with echocardiographic evidence of severe mitral regurgitation as defined by:~* Central jet MR \>40% LA or holosystolic eccentric jet MR~* Vena contracta ≥0.7 cm~* Regurgitant volume ≥60 mL~* Regurgitant fraction ≥50%~* ERO ≥0.40 cm2~* Angiographic grade 3 to 4+"
62020308|NCT04636892|EXPERIMENTAL|Heart Failure with Reduced EF <35%|Patients with echocardiographic evidence of left ventricular ejection fraction of \< or = to 35%
62020309|NCT04636892|EXPERIMENTAL|Pulmonary Hypertension|Patients with echocardiographic evidence of a mean pulmonary artery pressure (mPAP; supine and at rest) \>20mmHg
62212715|NCT04317365|ACTIVE_COMPARATOR|patients receiving remembering|
62212716|NCT04317365|NO_INTERVENTION|patients not receiving extra remembering|
62212717|NCT05219994|EXPERIMENTAL|Oral Glucose Tolerance Test|Subjects will consume a 75 g glucose drink within 1-min and monitored for 2 hours.
62212718|NCT02683551||Ligasure|Patients underwent to Sutureless Thyroidectomy with Ligasure SmallJaw
62212719|NCT02683551||Harmonic|Patients underwent to Sutureless Thyroidectomy with Harmonic FOCUS
62212720|NCT00720772|EXPERIMENTAL|A|
62212721|NCT00720772|NO_INTERVENTION|B|
62212722|NCT03932812|EXPERIMENTAL|Options Counselor Health Educator Intervention Group|These individuals will receive the Options Counselor Health Educator Intervention
62409128|NCT04495296|EXPERIMENTAL|dose escalation Q3W|Dosed every 3 weeks IV with TST001, multiple dose levels will be tested.
62020310|NCT04636892|EXPERIMENTAL|Suspected coronary artery disease|Patients with plan to undergo elective left heart diagnostic catheterization for the assessment of coronary artery disease
62212723|NCT03932812|NO_INTERVENTION|Control|These individuals will receive the typical standard of care treatment from clinics
62212724|NCT04606771|EXPERIMENTAL|Arm A|"Savolitinib 300 mg oral QD~Osimertinib 80 mg oral QD"
62212725|NCT04606771|EXPERIMENTAL|Arm B|"Savolitinib 300 mg oral QD~Placebo to Osimertinib 80mg oral QD"
62212726|NCT02080559|EXPERIMENTAL|4CMenB - Test group|Administered at 2, 4 and 12 months of age
62212727|NCT02080559|ACTIVE_COMPARATOR|4CMenB - control group|Given at 5, 7 and 13 months of age
62212728|NCT04107168||Cohort 1|"Disease: Unresectable AJCC (American Joint Committee on Cancer) stage 3 or 4 melanoma.~Anti-PD-1 monotherapy (Nivolumab or Pembrolizumab). Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted."
62212729|NCT04107168||Cohort 2|Disease: Unresectable AJCC stage 3 or 4 melanoma. Nivolumab + Ipilimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
62409129|NCT04495296|EXPERIMENTAL|Cohort A|Participants with gastric or gastroesophageal junction cancers and CLDN18.2 expression
62409130|NCT04495296|EXPERIMENTAL|Cohort B|Participants with ductal adenocarcinoma of pancreas and CLDN18.2 expression and CLDN18.2 expression
62020311|NCT03211936|ACTIVE_COMPARATOR|PEEP 4|"We titrate peep, using tomography impedance, making ultrasound after level by level' of peep. After titrated peep we setup peep 4 and maintained during the procedure.~* PEEP 4 cmH2O~* Use ultrasound"
62020312|NCT03211936|EXPERIMENTAL|PEEP TITRATED|"We titrate peep, using tomography impedance, making ultrasound after level by level' of peep. After tritiated peep we setup the best peep for less collapse (using the tomography of electrical impedance) and maintained during the procedure.~* PEEP titrated~* Use ultrasound~* Impedance tomography~* Best PEEP for less collapse"
62020313|NCT01659918|ACTIVE_COMPARATOR|Montelukast|10 mg Tablet
62020314|NCT01659918|ACTIVE_COMPARATOR|Singulair|10 mg Tablet
62020315|NCT03210506|EXPERIMENTAL|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
62020316|NCT03210506|NO_INTERVENTION|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
62020317|NCT04182022|ACTIVE_COMPARATOR|Contingent|The Contingent group will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner.
62212730|NCT04107168||Cohort 3|Disease: Advanced renal cell carcinoma. Anti-PD-(L)1 + kinase inhibitor. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
62790651|NCT05145868|EXPERIMENTAL|Intervention|Participants in this arm will receive the RELATE intervention.
62020318|NCT04182022|SHAM_COMPARATOR|Noncontingent|The Noncontingent group will receive payments each day they successfully provide samples independent of the alcohol content of those samples.
62020319|NCT05875324|EXPERIMENTAL|VR Group|The patients in the VR group were informed about the disease, the goals of post-surgical rehabilitation, the exercises, and the circumstances to be considered following TKA. On the postoperative first day, activities included sitting on the side of the bed and mobilizing in and out of the room using a walker. Patients were discharged 2.5 days after surgery. Patients were provided an exercise program for at-home practice. In addition to the exercise program, VR glasses were used before the exercises in the VR group. The second examination was performed three days after the completion of treatment.
62212731|NCT04107168||Cohort 4|Disease: Advanced renal cell carcinoma Nivolumab + Ipilimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
62212732|NCT04107168||Cohort 5|Disease: Advanced NSCLC Anti-PD-(L)1 (Nivolumab, Pembrolizumab or Atezolizumab) monotherapy in the first line setting. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
62790652|NCT05145868|ACTIVE_COMPARATOR|Attention Control|Participants in this arm will receive supportive control messages.
62790653|NCT02160652||Patients|Patients with malignant ureteral obstruction, treated with laparoscopic ureteral re-implantation, who have a life expectancy of over 6 months and are willing and able to participate in the study.
62790654|NCT00563459|EXPERIMENTAL|001|carisbamate 400-1200 mg/day for 12 months
62790655|NCT00563459|ACTIVE_COMPARATOR|002|topiramate 200-400mg/day for 12 months
62020320|NCT05875324|ACTIVE_COMPARATOR|Exercise Group|Exercise group were informed about the disease, the goals of post-surgical rehabilitation, the exercises, and the circumstances to be considered following TKA. On the postoperative first day, activities included sitting on the side of the bed and mobilizing in and out of the room using a walker. Patients were discharged 2.5 days after surgery. Patients in the exercise group were provided an exercise program for at-home practice. The second examination was performed three days after the completion of treatment.
62020321|NCT04897516|EXPERIMENTAL|Short regimen of benznidazole 2 weeks|"Experimental: Short regimen of benznidazole Participants will receive an investigational treatment of benznidazole for 2 weeks.~Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 2 weeks."
62020322|NCT04897516|EXPERIMENTAL|Short regimen of benznidazole 4 weeks|"Experimental: Short regimen of benznidazole Participants will receive an investigational treatment of benznidazole for 4 weeks.~Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 4 weeks."
62409131|NCT04495296|EXPERIMENTAL|Cohort E|Participants with advanced or metastatic solid tumors other than G/GEJ adenocarcinoma and CLDN18.2 expression
62020323|NCT04897516|ACTIVE_COMPARATOR|Standard treatment with benznidazole|Active Comparator: Standard treatment with benznidazole Benznidazole, 300 mg divided into three daily doses (100 mg every 08 hours), orally for 8 weeks
62020324|NCT02740348|EXPERIMENTAL|ZocDoc Assistance|Research assistant sets up follow-up appointment for subject using ZocDoc.
62020325|NCT02740348|ACTIVE_COMPARATOR|ZocDoc Information|Research assistance provides subject with written information about ZocDoc.
62409132|NCT04495296|EXPERIMENTAL|Cohort C|Participants with HER2 negative or unknown locally advanced or metastatic G/GEJ adenocarcinoma
62409133|NCT04495296|EXPERIMENTAL|Cohort D|Participants with locally advanced or metastatic G/GEJ adenocarcinoma
62212733|NCT04107168||Cohort 6|Disease: Advanced NSCLC Anti-PD-(L)1 (Nivolumab, Pembrolizumab or Atezolizumab) + chemotherapy +/- antiangiogenic (Bevacizumab) in the first line setting. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
62409134|NCT04495296|EXPERIMENTAL|Cohort F|Participants with locally advanced or metastatic biliary tract cancer
62409135|NCT04495296|EXPERIMENTAL|Cohort G|Participants with HER2 negative or unknown locally advanced or metastatic G/GEJ adenocarcinoma
62409136|NCT04495296|EXPERIMENTAL|Cohort H (TST001 plus nivolumab)|Participants with locally advanced or metastatic G/GEJ adenocarcinoma
62020326|NCT02740348|NO_INTERVENTION|Usual Care|ED staff gives written and verbal discharge instructions to subject.
62212734|NCT04107168||Cohort 7|Disease: Resected AJCC stage 3 or 4 melanoma. Anti-PD-1 monotherapy (Nivolumab or Pembrolizumab). Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
62212735|NCT04107168||Cohort 8|Disease: Resected renal cancer Anti-PD-(L)1 monotherapy (Durvalumab or Pembrolizumab). Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
62409137|NCT02765958||Healthy|subjects without heart disease or arrhythmia, no evidence of obstructive sleep apnea
62409138|NCT02765958||OSA|obstructive sleep apnea
62020327|NCT02448303|EXPERIMENTAL|Arm 1|pembrolizumab
62020328|NCT02448303|EXPERIMENTAL|Arm 2|acalabrutinib plus pembrolizumab
62020329|NCT01525082|EXPERIMENTAL|Bevacizumab + Capecitabine + Temozolomide|Cycles repeat every 28 days until disease progression, unacceptable toxicity, or withdrawal.
62020330|NCT02136173|EXPERIMENTAL|sequential balloons|effect of weight loss by applying sequential balloons
62212736|NCT04107168||Cohort 9|Disease: Resected renal cancer Durvalumab + Tremelimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
62409139|NCT02989922|EXPERIMENTAL|SHR-1210 Q2W|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
62409140|NCT02989922|EXPERIMENTAL|SHR-1210 Q3W|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 3 weeks
62409141|NCT00326625|EXPERIMENTAL|40 mg glatiramer acetate (GA)|Pre-filled syringe of 40 mg glatiramer acetate (GA) for injection, administered subcutaneously once a day.
62409142|NCT00326625|PLACEBO_COMPARATOR|Placebo|Pre-filled syringe of matching placebo, administered subcutaneously once a day.
62409143|NCT05552391|PLACEBO_COMPARATOR|bupivacaine|Group bupivacaine(Control) (B) received 0.5 ml/kg bupivacaine 0.25% diluted with isotonic saline (total volume15 ml).
62409144|NCT05552391|ACTIVE_COMPARATOR|bupivacaine - ketamine|Group bupivacaine - ketamine (K) received 0.5 ml/kg bupivacaine 0.25% with ketamine 2 mg/kg, diluted with isotonic saline (total volume15 ml).
62409145|NCT05552391|ACTIVE_COMPARATOR|bupivacaine - Dexametomedine|Group bupivacaine - Dexametomedine (D) received 0.5 mL/kg bupivacaine 0.25% with dexmedetomidine 1 µg/kg. diluted with isotonic saline (total volume 15ml).
62409146|NCT05855967|EXPERIMENTAL|Ixekizumab|"Participants with moderate to severe plaque psoriasis.~Participants with active psoriatic arthritis.~Ixekizumab will be given by subcutaneous (SC) injection."
62020331|NCT02804919|EXPERIMENTAL|Investigational CPAP device|Fisher \& Paykel Healthcare CPAP Device
62020332|NCT02566837|ACTIVE_COMPARATOR|ELEC|electrical stimulation guidance
62020333|NCT02566837|EXPERIMENTAL|ECHO|ultrasound guidance
62020334|NCT01487330|EXPERIMENTAL|Subjects receiving TAVI valve|
62020335|NCT04060940|EXPERIMENTAL|Emotion Regulation Therapy: 8-session version|All participants will be randomly assigned to an 8-session or 16-session version of ERT with equal probability. Participants assigned to the 8-session version of ERT will receive 8 sessions of individualized therapy, each of which is 1-1.5 hours, on a weekly basis. Sessions 1-5 will be 1 hour long, sessions 6 and 7 will be 1.5 hours long, and session 8 will be one hour long, resulting in a total required time commitment of 9 hours over the course of 8 weeks.
62409147|NCT05688527|EXPERIMENTAL|5 Step Skin Care Regimen|The subject uses 5 facial products in the regimen; a cleansing balm, a toner, a serum, a moisturizer and an eye cream.
62409148|NCT05392920||Obese children and adolescents|Obese children and adolescent patients
62409149|NCT03323944|EXPERIMENTAL|Cohort 1: huCART-meso cells via intravenous infusion (IV).|Subjects will receive a single dose of 1-3x10\^7/m\^2 lentiviral transduced huCART-meso cells on day 0 via intravenous infusion.
62409150|NCT03323944|EXPERIMENTAL|Cohort -1: low dose huCART-meso cells via intravenous infusion|In the event that 2 DLTs occur among subjects enrolled in Cohort 1, then enrollment in Cohort 1 will be stopped and the dose will be de-escalated by 10-fold to 1-3x10\^6 cells/m\^2. Subjects will receive a single dose of 1-3x10\^6 cells/m\^2 lentiviral transduced huCART-meso cells on day 0.
62409151|NCT03323944|EXPERIMENTAL|Cohort 2 - huCART meso cells via intraperitoneal infusion (IP)|Permanently closed
62409152|NCT03323944|EXPERIMENTAL|Cohort 3 - huCART meso cells via intrahepatic infusion (hepatic arterial infusion)|Permanently closed
62409153|NCT03323944|EXPERIMENTAL|Cohort 4 - huCART meso cells via intrahepatic infusion (hepatic arterial infusion)|Subjects will receive a single dose of of 1-3x10\^7 cells/m\^2 lentiviral transduced huCART-meso cells on day 0 following a minimum 1 week washout from standard care chemotherapy. This initial intrahepatic infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart.
62409154|NCT02084329|EXPERIMENTAL|Weighted Compression Vest|Weighted Compression Vest
62212737|NCT05996432|EXPERIMENTAL|Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Participants will undergo magnetic resonance imaging (MRI) scans and positron emission tomography (PET) scans and administered the imaging agent 18F-fluoromisonidazole.
62212738|NCT05996432|EXPERIMENTAL|Brain metastases|Participants will undergo magnetic resonance imaging (MRI) scans and positron emission tomography (PET) scans and administered the imaging agent 18F-fluoromisonidazole.
62212739|NCT05529680|EXPERIMENTAL|Scapular mobilization and strengthening exercise|"Group A (study group):~This group included 20 patients with shoulder dysfunction post-mastectomy who received scapular mobilization and strengthening exercise in addition to their conventional physical therapy program in form of joint mobilization, posterior capsule stretching and range of motion exercise (ROM)."
62212740|NCT05529680|ACTIVE_COMPARATOR|Conventional physical therapy program|This group included 20 patients with shoulder dysfunction who received conventional physical therapy programs in form of joint mobilization, posterior capsule stretching, and range of motion exercise (ROM).
62212741|NCT04304625|EXPERIMENTAL|Tranexamic acid|After the routine prophylactic IV or IM injection of the uterotonic used in the hospital protocol's -either oxytocin or carbetocin - (as recommended by the 2014 guidelines for prevention and management of postpartum hemorrhage from the CNGOF), the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped
62212742|NCT04304625|PLACEBO_COMPARATOR|Placebo|After the routine prophylactic IV or IM injection of the uterotonic used in the hospital protocol's -either oxytocin or carbetocin - (as recommended by the 2014 guidelines for prevention and management of postpartum hemorrhage from the CNGOF), the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped
62212743|NCT02144727|ACTIVE_COMPARATOR|D2 distal subtotal gastrectomy|D2 distal subtotal gastrectomy D2 includes Nos.1.3,4sb,4d,5,6,7,8a,9,11p,and 12a nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
62212744|NCT02144727|EXPERIMENTAL|D1+ distal subtotal gastrectomy|D1+ distal subtotal gastrectomy D1+ includes Nos.1,3,4sb,4d,5,6,7,8a,and 9 nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
62212745|NCT03746782||ACS using clopidogrel + aspirin|Apixaban combined with blood specimens (in vitro) from Acute Coronary Syndrome participants prescribed a regimen of DAPT in the form of clopidogrel + aspirin
62212746|NCT03746782||ACS using ticagrelor + aspirin|Apixaban combined with blood specimens (in vitro) from Acute Coronary Syndrome participants prescribed a regimen of DAPT in the form of ticagrelor + aspirin
62409155|NCT02084329|NO_INTERVENTION|Control|
62409156|NCT01465594|ACTIVE_COMPARATOR|transurethral catheter after EERPE/ RALP|Recording of QoL measured by visual analogue ( pain )scale,EORTC QlQ -C 30 and QLQ - PR 25 questionnaires, incontinence rate, complication rate regarding insufficiency and strictures of vesicourethral anastomoses and urinary tract infection; demand of re-catheterization due to urinary retention and demand of antispasmodics
62584462|NCT03000426|EXPERIMENTAL|Free gingival graft + GaAlAs Laser 60|The irradiation will be performed with a GaAlAs diode laser that continuously emits a wavelength of 660 nm with a power of 30 milliwatts (mW). The patients allocated for the group 60 will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 60 Joules/cm2 and a time of 56 seconds per point (1,68 Joules/cm2 per point). During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will repeated by four more applications performed every other day, with a total of 5 laser applications. The power of the equipment will be calibrated prior to each application.
62735073|NCT02277691|EXPERIMENTAL|TAK-536TCH|"For 4 weeks during the run-in period, one tablet of TAK-536CCB (as TAK-536/AML, 20 mg/5 mg, respectively) orally, once daily, before or after breakfast.~For 48 weeks during 52 weeks of the treatment period, one tablet of TAK-536TCH (as TAK-536/AML/HCTZ, 20 mg/5 mg/12.5 mg, respectively) orally, once daily, before or after breakfast. For the remaining 4 weeks of the treatment period, one tablet each of TAK-536CCB and HCTZ 12.5 mg orally, once daily, before or after breakfast."
62212747|NCT03746782||Healthy Donors|Apixaban combined with blood specimens (in vitro) from healthy participants
62212748|NCT03590366|ACTIVE_COMPARATOR|B244|"B244 suspension in 30ml/bottle~Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day."
62212749|NCT03590366|PLACEBO_COMPARATOR|Vehicle|"Vehicle, 30ml/bottle~Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day."
62212750|NCT03929445|ACTIVE_COMPARATOR|AIR-Q group|the group which selected randomly to try AIR-Q device
62212751|NCT03929445|ACTIVE_COMPARATOR|I-LMA group|the group which selected randomly to try I-LMA device
62409157|NCT01465594|ACTIVE_COMPARATOR|suprapubic catheter after EERPE /RALP|Recording of QoL measured by visual analogue ( pain )scale,EORTC QlQ -C 30 and QLQ - PR 25 questionnaires, incontinence rate, complication rate regarding insufficiency and strictures of vesicourethral anastomoses and urinary tract infection; demand of re-catheterization due to urinary retention and demand of antispasmodics
62409158|NCT03693235|EXPERIMENTAL|70 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 70 degrees.
62212752|NCT00961480|ACTIVE_COMPARATOR|Treatment A|50 mg sitagliptin and 500 mg metformin as individual tablets
62212753|NCT00961480|EXPERIMENTAL|Treatment B|sitagliptin/metformin 50 mg/500 mg tablet
62212754|NCT00961480|ACTIVE_COMPARATOR|Treatment C|50 mg sitagliptin and 1000 mg metformin as individual tablets
62409159|NCT03693235|EXPERIMENTAL|80 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 80 degrees.
62409160|NCT03693235|EXPERIMENTAL|90 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 90 degrees.
62735074|NCT02156206||123 women line|Women who call the 123 emergency line and have also immediate services from the 123 women emergency line
62212755|NCT00961480|EXPERIMENTAL|Treatment D|sitagliptin/metformin 50 mg/1000 mg tablet
62409161|NCT04587635|ACTIVE_COMPARATOR|PHGG fiber|PHGG Fiber
62409162|NCT04587635|PLACEBO_COMPARATOR|Placebo Maltodextrin|Maltodextrin
62409163|NCT06650813|EXPERIMENTAL|Patients atteints de drépanocytose|
62409164|NCT03280628|ACTIVE_COMPARATOR|Absorbable Sutures|Patients will have their laceration closed with sutures that absorb on their own and do not need to be removed.
62409165|NCT03280628|EXPERIMENTAL|Steri-Strips|"Patients will have their laceration closed with a special medical tape called Steri-Strips."
62409166|NCT03280628|EXPERIMENTAL|Dermabond|"Patients will have their laceration closed with a special skin glue called Dermabond"
62212756|NCT00961480|ACTIVE_COMPARATOR|Treatment E|50 mg sitagliptin and 850 mg metformin as individual tablets
62212757|NCT00961480|EXPERIMENTAL|Treatment F|sitagliptin/metformin 50 mg/850 mg tablet
62212758|NCT04761107||GU participants with active or past infection of SARS-Co-V-2|GU patients from medical records with active or past infection of SARS-Co-V-2
62212759|NCT06218160|EXPERIMENTAL|Hydromorphone combined with ropivacaine|The posterior quadrat block was performed by adding 1mg hydromorphone to 0.375% ropivacaine in a total of 30ml.
62212760|NCT06218160|ACTIVE_COMPARATOR|ropivacaine|A mixture of 0.375% ropivacaine for a total of 30ml was performed for posterior quadrate block.
62212761|NCT02072785|EXPERIMENTAL|Vincristine Sulfate Liposome|"Vincristine Sulfate For Injection simulation agent 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection: 1.4mg/m2, (2mg, maximum dose), iv, d1, d8, d15, d22.~Duration between these two agents should be more than 2.5h, and saline should be avoided for flushing before Vincristine Sulfate Liposome For Injection."
62212762|NCT02072785|ACTIVE_COMPARATOR|Vincristine Sulfate|"Vincristine Sulfate For Injection 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection simulation agent: 1.4mg/m2,(2mg, maximum dose), iv, d1, 8, 15, 22.~Duration between these two agents should be more than 2.5h, and saline should not be used for flushing before Vincristine Sulfate Liposome For Injection simulation agent."
62212763|NCT05070442|NO_INTERVENTION|Control Arm (Arm 1)|Participants will experience an unmodified version of NUSMart which replicates the traditional shopping experience of online grocery stores.
62212764|NCT05070442|EXPERIMENTAL|Norms Arm (Arm 2)|Participants will experience a modified version of NUSMart with norm-based messaging and peer comparison features enabled. Nutri-Score labels will be enabled and displayed on all products within the store. A floating side panel will provide a visual indicator of the participants' average weighted Nutri-Score.
62409167|NCT04158739|EXPERIMENTAL|Treatment (flotetuzumab, cytarabine)|Patients receive flotetuzumab IV continuously for 28 days. Treatment repeats every 29 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive cytarabine IT on days -6 to 0 prior to cycle 1. Patients may receive additional doses of cytarabine on day 1 of subsequent cycles per physician discretion.
62409168|NCT01432600|EXPERIMENTAL|A: Dose Escalation of Cyclophosphamide|"Phase I: Pomalidomide, high dose dexamethasone and oral cyclophosphamide:~Pomalidomide 4 mg by mouth (PO) days 1-21 of a 28 days cycle.~Dexamethasone 40\* mg PO days 1- 4, 15-18 of a 28 days cycle for the first 4 cycles and subsequently 40 mg PO Days 1,8,15, 22. \*Participants who were \>75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Dose Escalation of Cyclophosphamide, orallly (PO) days 1, 8, 15 as follows:~Level 1: 300 mg; Level 2: 400 mg; Level 3: 500 mg.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
62409169|NCT01432600|ACTIVE_COMPARATOR|B: Pomalidomide and Dexamethasone|"Randomized Phase II - Pomalidomide high dose dexamethasone:~Pomalidomide 4 mg PO days 1-21 of a 28 days cycle.~Dexamethasone 40\* mg PO Days 1,8,15, 22. \*Participants who were \>75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
62735075|NCT02156206||No treatment|Women who call the 123 emergency line and do not have immediate services from the 123 women emergency line
62790656|NCT00563459|ACTIVE_COMPARATOR|003|levetiracetam 1000-3000mg/day for 12 months
62790657|NCT02354872|EXPERIMENTAL|Mini-Lozenge, BR, 5Rs, BA|1; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, 5Rs, BA
62409170|NCT01432600|ACTIVE_COMPARATOR|C: Pomalidomide/Dexamethasone/Cyclophosphamide|"Randomized Phase II - Pomalidomide high dose dexamethasone and oral cyclophosphamide:~Pomalidomide 4 mg PO days 1-21 of a 28 days cycle.~Dexamethasone 40\* mg PO days 1- 4, 15-18 of a 28 days cycle for the first 4 cycles and subsequently 40 mg PO Days 1,8,15, 22. \*Participants who were \>75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Cyclophosphamide 400 mg PO days 1, 8, 15.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
62409171|NCT01432600|OTHER|D: Crossover|Crossover from Arm B to Arm D. Participants who experienced progressive disease in arm B were allowed to crossover to arm D at the discretion of the treating physician, in which case oral weekly Cyclophosphamide (400 mg orally on days 1, 8, and 15) was added to their tolerated dose of pomalidomide and dexamethasone.
62212765|NCT05070442|EXPERIMENTAL|Norms and Incentive Arm (Arm 3)|Same as Arm 2, except participants are notified that they have been awarded an additional $5 towards their participation reimbursement. However, this additional $5 will be forfeited if their basket average weighted Nutri-Score falls below the average of their peers'. (Financial incentive leveraging on loss aversion).
62212766|NCT06427421|OTHER|Newly diagnosed T1DM group|children aged 6 to under 18 on the day of inclusion, with a recent diagnosis of type 1 diabetes
62212767|NCT06427421|OTHER|Control group|children aged 6 to under 18 on the day of inclusion, with no history of type 1 diabetes
62212768|NCT03343327|EXPERIMENTAL|Chronocort®, then Cortef®|Single dose of 20mg Chronocort® (oral administration), followed by a single dose of 20mg Cortef® Immediate Release Hydrocortisone Tablets (oral administration).
62212769|NCT03343327|ACTIVE_COMPARATOR|Cortef®, then Chronocort®|Single dose of 20mg Cortef® Immediate Release Hydrocortisone Tablets (oral administration), followed by a single dose of 20mg Chronocort® (oral administration).
62212770|NCT06017843|EXPERIMENTAL|Intervention|Camps site selection for active case finding for TB using MATCH-AI
62212771|NCT06017843|NO_INTERVENTION|Control|Camps site selection for active case finding for TB using existing approaches.
62212772|NCT04887779|EXPERIMENTAL|Intervention|Patient viewing ex-planted organ and microscopy with pathologist
62212773|NCT04254822|EXPERIMENTAL|HVPG-guided therapy|HVPG will be determined before randomization. In this arm, patients with an adequate reduction in HVPG (responders) receive carvedilol whereas nonresponders receive TIPS.
62212774|NCT04254822|ACTIVE_COMPARATOR|Standard therapy|In this group, both responders and nonresponders will receive combination therapy of carvedilol and endoscopic variceal ligation as first-line therapy. If first-line therapy fails, TIPS will considered.
62212775|NCT04953559|EXPERIMENTAL|Active cTBS first, then sham cTBS|Participants complete an Enrollment Visit followed by one week of at-home actigraphy. Participants return to the lab for Overnight Visit 1 and undergo a MRI scan followed by active cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep. Participants return home and complete another week of at-home actigraphy. Participants then return to the lab for Overnight Visit 2 where they undergo a MRI scan followed by sham cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep.
62212776|NCT04953559|EXPERIMENTAL|Sham cTBS first, then active cTBS|Participants complete an Enrollment Visit followed by one week of at-home actigraphy. Participants return to the lab for Overnight Visit 1 and undergo a MRI scan followed by sham cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep. Participants return home and complete another week of at-home actigraphy. Participants then return to the lab for Overnight Visit 2 where they undergo a MRI scan followed by active cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep.
62212777|NCT01681901||Diagnostic (ultrasound)|Patients undergo breast ultrasound imaging.
62212778|NCT03446326|EXPERIMENTAL|Stroke volume and cardiac output|"Pacing runs will occur at the following rates:~* 50 beats per minute (bpm)~* 60 bpm~* 70 bpm~* 80 bpm~* 90 bpm~* 100 bpm~* 110 bpm~* 120 bpm~* 130 bpm~The finger blood pressure cuff will be calibrated between pacing runs.~Following the final pacing run while supine, the patient will be given 10 minutes to rest prior to the upright portion of the study. They will then be strapped into the table (so they will not fall) and then they will be tilted up to \>70 degrees (almost standing up). They will stand for \~10 minutes prior to commencing the next pacing trains."
62212779|NCT02101528||PD Patients|"PD patients with a diagnosis of clinically probable idiopathic PD in Hoehn-Yahr stage 2-3, with the ability to walk without any assistance, with mini-mental state examination score ≥26, without any relevant comorbidity or vestibular/visual dysfunctions limiting locomotion or balance."
62212780|NCT02101528||Controls|age and sex matched healthy volunteers
62212781|NCT03900364|OTHER|robot-assisted partial nephrectomy|partial nephrectomy performed with the da Vinci Surgical System
62212782|NCT03900364|OTHER|laparoscopic partial nephrectomy|partial nephrectomy performed with conventional laparoscopic surgery
62212783|NCT01127763|EXPERIMENTAL|RAD001+carboplatin|Carboplatin (starting dose was initially AUC 6, later decreased to AUC 5, then AUC 4) every 3 weeks as IV infusion and RAD001 as 5 mg pill each day until disease progression or unacceptable toxicity.
62212784|NCT02976571|EXPERIMENTAL|Sub cutaneous+Intraperitoneal|Sub cutaneous Bupivacaine+ Intraperitoneal bupivacaine
62212785|NCT02976571|ACTIVE_COMPARATOR|Sub cutaneous+Placebo|Sub cutaneous Bupivacaine+ Intraperitoneal Nacl 0.9%
62212786|NCT02976571|ACTIVE_COMPARATOR|Placebo+Intraperitoneal|Sub cutaneous Nacl 0.9%+ Intraperitoneal bupivacaine
62212787|NCT02976571|PLACEBO_COMPARATOR|Placebo+Placebo|Sub cutaneous Nacl 0.9%+ Intraperitoneal Nacl 0.9%
62790658|NCT02354872|EXPERIMENTAL|Mini-Lozenge, BR, 5Rs, No BA|2; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, 5Rs, No BA
62212788|NCT03170895|EXPERIMENTAL|sorafenib and Omacetaxine Mepesuccinate|"The starting dose of sorafenib will be 400 mg twice daily. Sorafenib should be taken continuously throughout the treatment period unless there is no evidence of response at first assessment on day 28 or progressive disease at any time during the treatment.~OM will be given at 1.5 mg/m2/day (maximum dose 3 mg) for 7 days (concurrently with sorafenib) in 28-day cycle.~Sorafenib and OM will be continued until leukemia progression or allogeneic HSCT. Thereafter, patients will be followed up and information about disease status and survival will be collected."
62409172|NCT01997060|EXPERIMENTAL|Intensive Lifestyle Intervention|Intensive Lifestyle Intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction (\~-700KCal/day). Education within nutrition, exercise and healthy living in general.
62409173|NCT06371040|EXPERIMENTAL|CD19-BCMA Targeted CAR-T|
62212789|NCT05967364|EXPERIMENTAL|Wingman Connect|Wingman-Connect (Wyman et al., 2020 \& 2022) uses a network health theoretical framework to strengthen two suicide-protective functions of social networks: 1) Strengthening positive social bonds, and 2) Building healthy norms that incentivize adaptive coping.
62212790|NCT05967364|ACTIVE_COMPARATOR|Active Control|Active control is stress management training of cognitive and behavioral strategies.
62212791|NCT05297006||Breastfeeding group|The mother can breastfeed exclusively until the infants is at least 4 months old, after which complementary foods are added scientifically according to the baby's condition.
62409174|NCT05527288|EXPERIMENTAL|Non-cognitively impaired subjects or mild to moderate Alzheimer disease subjects|Visually and quantitatively assess PET images obtained after single application of 300 MBq \[18F\]florbetaben and PET scanning of patients with healthy subjects and non-cognitively impaired subjects or mild to moderate Alzheimer disease subjects.
62409175|NCT03673137|EXPERIMENTAL|Synchronous treatment group|Gemcitabine was administered over 30 minutes immediately following percutaneous irreversible electroporation. Gemcitabine was then given once weekly for 2 weeks, followed by a week of rest from treatment. Subsequent cycles consisted of once weekly infusions for 3 consecutive weeks out of every 4 weeks.Treatment continued until disease progression was detected by mRECIST or there was unacceptable toxicity.
62409176|NCT03673137|ACTIVE_COMPARATOR|Traditional treatment group|The initial gemcitabine administration was on day 7 following IRE treatment. Once weekly infusions for 3 consecutive weeks out of every 4 weeks.Treatment continued until disease progression was detected by mRECIST or there was unacceptable toxicity.
62790659|NCT02354872|EXPERIMENTAL|Mini-Lozenge, BR, No 5Rs, BA|3; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, No 5Rs, BA
62212792|NCT05297006||Formula group containing new compound functional ingredients|Only use formula milk powder containing oligosaccharides, sialic acid and other ingredients feed the infants for at least 4 months, and then complementary food is added scientifically according to the infant's condition.
62212793|NCT05297006||Formula group without new compound functional ingredients|Only use formula milk powder without oligosaccharides, sialic acid and other ingredients feed the infants for at least 4 months, and then complementary food is added scientifically according to the infant's condition.
62409177|NCT02673827|NO_INTERVENTION|Group control|Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
62790660|NCT02354872|EXPERIMENTAL|Mini-Lozenge, BR, No 5Rs, No BA|4; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, No 5Rs, No BA
62790661|NCT02354872|EXPERIMENTAL|Mini-Lozenge, No BR, 5Rs, BA|5; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, 5Rs, BA
62212794|NCT01587027|ACTIVE_COMPARATOR|Sequence A|Aminophylline, Methazolamide, Aminophylline and Methazolamide
62790662|NCT02354872|EXPERIMENTAL|Mini-Lozenge, No BR, 5Rs, No BA|6; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, 5Rs, No BA
62790663|NCT02354872|EXPERIMENTAL|Mini-Lozenge, No BR, No 5Rs, BA|7; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, No 5Rs, BA
62212795|NCT01587027|ACTIVE_COMPARATOR|Sequence B|Methazolamide, Aminophylline, Aminophylline and Mathazolamide
62212796|NCT06340282|NO_INTERVENTION|Control|Control group
62212797|NCT06340282|EXPERIMENTAL|immersive virtual reality|Patients use virtual reality
62212798|NCT06340282|EXPERIMENTAL|multicomponent physical exercise intervention|Individualized exercise intervention
62409178|NCT02673827|EXPERIMENTAL|experimental group|"Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation.~They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation."
62409179|NCT04340739||Cohort 1 (8 Patients)|A wireframe mock-up of the GEMINI platform will be usability tested by 8 chronic pain patients from whom feedback will be collected by completing a virtual semi-structured interview. Outcomes: Quantitative Testing Data from Usability Testing Prompt. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide.
62409180|NCT04340739||Cohort 2 (16 Patients)|"A live version of GEMINI will be beta-tested by 16 chronic pain patients through completing a faux medical group visit (MGV). This will include things like exploring the education topics available, interacting with the other participating patients, and interacting with a medical provider posing as the faux group's health care provider, all in order to robustly test the system in a live environment. Outcomes: Quantitative Testing/User Experience Data from Usability Testing Prompt, System Usability Scale, Perceived Feature Usefulness Scale, and the Technology Acceptance Model Based Survey. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide."
62212799|NCT06340282|EXPERIMENTAL|Immersive virtual reality and multicomponent physical exercise intervention|Both
62790664|NCT02354872|EXPERIMENTAL|Mini-Lozenge, No BR, No 5Rs, No BA|8; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, No 5Rs, No BA
62790665|NCT02354872|EXPERIMENTAL|No Mini-Lozenge, BR, 5Rs, BA|9; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, 5Rs, BA
62790666|NCT02354872|EXPERIMENTAL|No Mini-Lozenge, BR, 5Rs, No BA|10; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, 5Rs, No BA
62790667|NCT02354872|EXPERIMENTAL|No Mini-Lozenge, BR, No 5Rs, BA|11; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, No 5Rs, BA
62790668|NCT02354872|EXPERIMENTAL|No Mini-Lozenge, BR, No 5Rs, No BA|12; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, No 5Rs, No BA
62212800|NCT06394232|EXPERIMENTAL|Dose Level 1-Cohort 1|Subjects who are allocated to Dose Level 1-Cohort 1 will receive 100,000 cells of Eyecyte-RPE™
62212801|NCT06394232|EXPERIMENTAL|Dose Level 2-Cohort 2|Subjects who are allocated to Dose Level 2-Cohort 2 will receive 200,000 cells of Eyecyte-RPE™
62212802|NCT06394232|EXPERIMENTAL|Dose Level 3-Cohort 3|Subjects who are allocated to Dose Level 3-Cohort 3 will receive 300,000 cells of Eyecyte-RPE™
62212803|NCT03294694|EXPERIMENTAL|Ribociclib and PDR001 (Cohort A)|"* The treatment regimen is defined as ribociclib + PDR001.~* Treatment will be administered on an outpatient basis.~* The study will use a 3 + 3 dose escalation design to determine the MTD/RP2D.~* Three to six evaluable patients will be enrolled in each cohort in the dose escalation phase.~  * Once the RP2D of the combination of ribociclib + PDR001 is determined, there will be an expansion cohort.~    * Cohort A expansion will assess the combination of ribociclib + PDR001 in 12 patients with metastatic ovarian cancer."
62212804|NCT03294694|EXPERIMENTAL|Ribociclib, PDR001 and Fulvestrant (Cohort B)|"* The treatment regimen is defined as ribociclib + PDR001 + fulvestrant .~* Treatment will be administered on an outpatient basis.~* There will be a safety run-in using the MTD/RP2D of ribociclib + PDR001 from Cohort A with the addition of fulvestrant in an initial 6-12 patients.~  * Once the safety of the combination of ribociclib + PDR001 + fulvestrant is established, there will be an expansion cohort.~    * Cohort B expansion will assess the combination of ribociclib + PDR001 + fulvestrant in 24 patients with hormone receptor-positive metastatic breast cancer (HR+ MBC)."
62212805|NCT01927705|EXPERIMENTAL|Treatment|"FURESTEM-AD Inj. 1. 2.5 x 10\^7 stem cells after registration.~FURESTEM-AD Inj. 2. 5.0 x 10\^7 stem cells after registration."
62212806|NCT01143870|OTHER|Hemoglobin A1C|Diabetes control related to patients using standard hemoglobin A1C
62212807|NCT01143870|EXPERIMENTAL|Face|Face expressing emotion used to depict diabetes control
62212808|NCT01143870|EXPERIMENTAL|Letter grade|Letter grade used to express diabetes control
62212809|NCT01326429||Hypernatremia|Patients admitted to the emergency department with a serum sodium exceeding 145 mmol/L.
62212810|NCT01326429||Hyponatremia|Patients admitted to the emergency room with a serum sodium below 135 mmol/L.
62212811|NCT01800734|OTHER|Clamp-Mixed Meal Arm|Twenty adults patients with type 1 diabetes, regularly attending the Division of Endocrinology and Metabolic Diseases of University of Verona School of Medicine, using continuous subcutaneous fast insulin analogue infusion (CSII) through a permanent pump and on subcutaneous glucose sensing will be enrolled.
62212812|NCT05542082|EXPERIMENTAL|Single Arm|CHILLS Procedure
62212813|NCT02092688||Study group|Study group: women between 24 and 36 6/7 weeks of gestation that present with self-reported signs, symptoms or complaints suggestive of preterm labor
62790669|NCT02354872|EXPERIMENTAL|No Mini-Lozenge, No BR, 5Rs, BA|13; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, 5Rs, BA
62212814|NCT02092688||Control group|Control group: women between 24 and 36 6/7 weeks of gestation without signs or symptoms of PTL
62790670|NCT02354872|EXPERIMENTAL|No Mini-Lozenge, No BR, 5Rs, No BA|14; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, 5Rs, No BA
62790671|NCT02354872|EXPERIMENTAL|No Mini-Lozenge, No BR, No 5Rs, BA|15; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, No 5Rs, BA
62790672|NCT02354872|EXPERIMENTAL|No Mini-Lozenge, No BR, No 5Rs, No BA|16; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, No 5Rs, No BA
62790673|NCT04287387|EXPERIMENTAL|Glucophage group|
62212815|NCT02045875|EXPERIMENTAL|Dulera adherence monitoring|Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence
62212816|NCT02045875|ACTIVE_COMPARATOR|Dulera Standard of Asthma Care|Dulera standard of asthma care
62212817|NCT05745701|ACTIVE_COMPARATOR|Period 1: PF-07081532|Participants will receive PF-07081532 as a single dose on Day 1.
62790674|NCT04287387|EXPERIMENTAL|Acarbose group|
62790675|NCT04287387|EXPERIMENTAL|Sitagliptin group|
62790676|NCT04287387|EXPERIMENTAL|Dapagliflozin group|
62790677|NCT04287387|EXPERIMENTAL|Pioglitazone group|
62790678|NCT04287387|EXPERIMENTAL|Glimepiride group|
62790679|NCT01379950||periodontitis|patients diagnosed with periodontal disease
62212818|NCT05745701|EXPERIMENTAL|Period 2: Cyclosporine + PF-07081532|Participants will receive a single dose of PF-07081532 and a single dose of cyclosporine on Day 1.
62212819|NCT05745701|EXPERIMENTAL|Period 3: Itraconazole + PF-07081532|Participants will receive itraconazole daily for 9 days plus a single dose of PF-07081532 on Day 4.
62212820|NCT02380924|ACTIVE_COMPARATOR|DSP loaded RBC using EryDex System|Autologous RBC loaded with DSP using the EDS process, and treated RBC are infused to the subject.
62212821|NCT02380924|SHAM_COMPARATOR|Sham treated RBC using the EryDex System|Autologous RBC are treated with buffer using the EDS process, and treated RBC are infused to the subject.
62212822|NCT03720951|EXPERIMENTAL|Group I(Pudendal n.)|Fluoroscopic-guided pulsed R.F. to pudendal nerve bilaterally under image guidance
62212823|NCT03720951|EXPERIMENTAL|Group II(Sacral n.)|Fluoroscopic-guided pulsed R.F. to nerve roots S 2, 3, 4 bilaterally under image guidance
62735076|NCT02003976|EXPERIMENTAL|Non-Surgical Treatment plus HTO|The optimized non-surgical treatment program consists of medications, physiotherapy and nutritional seminars. The 12-week program will include an assessment by a primary care physician, physiotherapist and orthopaedic surgeon, one supervised physiotherapy session per week, one body recomposition session per week, and a home program. After the 12-week program is completed, patients randomized to this group will undergo a medial opening wedge high tibial osteotomy (HTO). They will continue with their home program and will be followed up for 2 years after baseline.
62790680|NCT04063969||Endovascular team members|"All vascular surgeons, surgical trainees, nurses active in the hybrid angiography suite at one of the participating centers will be invited to participate in the study.~All participating team members complete an online questionnaire containing an assessment of their perceived radiation safety climate (28 items, 5 dimensions), radiation safety behaviors(2 items, 2 dimensions), radiation safety knowledge (single item) and radiation safety motivation (single item). All data will be stored pseudonymized."
62212824|NCT02767960||STEMI group|The study population consists of 30 patients with ST-elevated acute myocardial infarction (STEMI,n = 30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
62212825|NCT02767960||NSTEMI group|The study population consists of 30 patients with non-ST elevated acute myocardial infarction (NSTEMI,n=30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
62212826|NCT02767960||UAP group|The study population consists of 30 patients with unstable angina pectoris (UAP, n = 30). They will all undergo coronary angiography for the diagnosis of acute coronary syndrome. The diagnosis is made according to the criteria of the American Heart Association (AHA, 2014 and 2015). Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
62212827|NCT02767960||control group|15 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Normal group.
62790681|NCT04063969||Vascular surgical patients|"In each center, five patients undergoing primary elective endovascular repair for an infrarenal abdominal aortic aneurysm (EVAR) will be enrolled in the study.~For each participating patient, a set of demographical (BMI, case difficulty, ASA-grade,etc.), procedure-related (procedure duration, contrast use, etc.) and radiation dose parameters (DAP, cumulative air kerma) will be collected and stored in a pseudonymized way.~Participation in this study has no effect on the interventional procedure, or the chosen approach."
62020336|NCT04060940|EXPERIMENTAL|Emotion Regulation Therapy: 16-session version|All participants will be randomly assigned to an 8-session or 16-session version of ERT with equal probability. Participants assigned to the 16-session version of ERT will receive 16 sessions of individualized therapy, each of which is 1-1.5 hours, on a weekly basis. Sessions 1-9 will be 1 hour long, sessions 10-13 will be 1.5 hours long, and sessions 14-16 will be 1 hour long, resulting in a total required time commitment of 18 hours over the course of 16 weeks.
62790682|NCT02073682|EXPERIMENTAL|Edoxaban group|After 5 days of low molecular weight heparin (LMWH), patients receive edoxaban treatment daily - tablet for oral use
62790683|NCT02073682|ACTIVE_COMPARATOR|Dalteparin group|Participants receive Dalteparin treatment daily -solution for subcutaneous injection
62790684|NCT02137096|EXPERIMENTAL|High Dose Conditioning|Single arm - receives high dose Etoposide phosphate, Ifosfamide, and Carboplatin followed by Autologous Stem Cell Transplantation
62790685|NCT03031366|EXPERIMENTAL|3D roadmap|TIPS was established using 3d roadmap guidance
62790686|NCT03031366|ACTIVE_COMPARATOR|conventional TIPS|conventional TIPS procedure using wedged hepatic venography
62790687|NCT03482037|EXPERIMENTAL|Rec 0/0438|Rec 0/0438 1 mg (first cohort), 2 mg (second cohort) to be administered by intravesical instillation once daily for four weeks
62790688|NCT03482037|PLACEBO_COMPARATOR|Placebo|Placebo, to be administered by intravesical instillation once daily for four weeks
62790689|NCT03936257|PLACEBO_COMPARATOR|Breast milk|group receiving breastfeeding
62790690|NCT03936257|ACTIVE_COMPARATOR|infant formula conventional BIO|infant formula with conventional whey BIO
62790691|NCT03936257|ACTIVE_COMPARATOR|infant formula BIO TrueGreen|infant formula with whey BIO TrueGreen
62790692|NCT01237613|EXPERIMENTAL|Artelon|This is an open, prospective study with an anticipated enrollment of 10 patients with chronic or repeat Achilles tendon rupture undergoing surgical repair augmented with Artelon® Tissue Reinforcement.
62790693|NCT02718209|EXPERIMENTAL|Frozen section|Frozen sections taken from women operated on for possible gynecologic malignancies.
62790694|NCT02092792|EXPERIMENTAL|Dose-Escalation Phase|
62790695|NCT02092792|EXPERIMENTAL|Dose-expansion cohort|
62790696|NCT01969695|EXPERIMENTAL|ABT-199|ABT-199 monotherapy
62790697|NCT02987270|EXPERIMENTAL|Mass screening and treatment|Each member (approximately 30,000 individuals) residing within the mass screening and treatment arm were visited three times a year and tested for malaria by rapid diagnostic test; those testing positive were treated with an appropriate antimalarial- dihydroartemisinin-piperaquine was the first-line therapy. Long-lasting insecticidal net (LLIN) coverage was topped up prior to the intervention to universal coverage (one bednet for every two household participants).
62790698|NCT02987270|NO_INTERVENTION|Control arm|Members of the control arm received standard of care, which includes universal (LLIN) coverage and standard malaria case management (laboratory confirmation prior to antimalarial treatment) at the study health facilities.
62790699|NCT02936024|EXPERIMENTAL|Intervention Group: Two-Stage GSLO Technique|Gubernaculum-sparing laparoscopic orchidopexy will be done in two stages
62790700|NCT02936024|OTHER|Control Group: One-Stage GSLO Technique|Gubernaculum-sparing laparoscopic orchidopexy will be done in a single stage
62020337|NCT02755389|PLACEBO_COMPARATOR|0 L/min|These participants will receive 0 L/min oxygen via conventional nasal cannulae during the apneic period.
62020338|NCT02755389|EXPERIMENTAL|15 L/min|These participants will receive 15 L/min oxygen via conventional nasal cannulae during the apneic period.
62212828|NCT01470001|ACTIVE_COMPARATOR|solifenacin|patients in this arm will receive drug
62212829|NCT01470001|PLACEBO_COMPARATOR|placebo|patients is this arm will receive placebo
62212830|NCT02811406|EXPERIMENTAL|Receives IV albumin infusion|IV albumin 20% 50 mL for every 1L of ascitic fluid drained
62212831|NCT02811406|PLACEBO_COMPARATOR|Do not receive IV albumin infusion|No IV albumin infusion
62212832|NCT06525714|EXPERIMENTAL|Cisplatin, oxaliplatin, tegafur.|Cisplatin, oxaliplatin, tegafur.
62212833|NCT04500249|EXPERIMENTAL|CPB|cervical plexus block was performed with 0,5% bupivacaine using Moore's technique
62212834|NCT04500249|EXPERIMENTAL|CPB with SPI guided analgesia|cervical plexus block was performed with 0,5% bupivacaine using Moore's technique alongside with SPI-guided rescue analgesia using 1% lidokaine and intravenous fentanyl
62212835|NCT04500249|EXPERIMENTAL|CPB plus SPI guided analgesia plus carotid artery block|cervical plexus block was performed with 0,5% bupivacaine using Moore's technique combined ith US-guided carotid artery block alongside with SPI-guided rescue analgesia using 1% lidokaine and intravenous fentanyl
62020339|NCT02755389|EXPERIMENTAL|60 L/min|These participants will receive 60 L/min oxygen via high-flow nasal cannulae during the apneic period.
62020340|NCT02450994|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone 4 mg capsules, twice per day, orally
62020341|NCT02450994|PLACEBO_COMPARATOR|Placebo|Placebo capsules twice per day, orally
62020342|NCT06367374|EXPERIMENTAL|Sonrotoclax Plus Zanubrutinib|"* Participants will receive from the start of Cycle 1 a standard dose of zanubrutinib twice daily orally for three cycles and in combination with sonrotoclax starting from Cycle 4 onwards at increasing doses twice a week until the target dose is reached from Cycle 5 and continuing until the end of Cycle 15 (each cycle is 28 days). Patients with a measurable minimal residual disease (MRD) will receive another 12 cycles of Zanubrutinib in combination with sonrotoclax until their MRD is undetectable.~* Interventions:~  * Drug: Sonrotoclax~ * Drug: Zanubrutinib"
62020343|NCT01797146|ACTIVE_COMPARATOR|CARE|All patients in the intervention wards will receive the Catheter Reminder and Evaluation (CARE) intervention.
62212836|NCT00625547|EXPERIMENTAL|1|
62212837|NCT00625547|EXPERIMENTAL|2|
62212838|NCT04973787||axSpA|Patients with clinical diagnosis of axialSpondyloarthritis according to ASAS criteria, with indication for bDMARD (Portuguese Rheumatology Society Guidelines)
62212839|NCT04973787||RA|Patients with clinical diagnosis of Rheumatoid arthritis according to 2010 ACR/EULAR classification criteria, with indication for bDMARD (Portuguese Rheumatology Society Guidelines)
62212840|NCT04973787||Control|Healthy participants, e.g. with no clinical diagnosis of rheumatic inflammatory disease, crossed by age, gender and diet profile
62212841|NCT02566044|EXPERIMENTAL|CQBW276|"Cohorts 1 and 2 will enroll 8 patients each (6:2 QBW276 and placebo, respectively).~Cohort 1: dose is 3 mg bid (6 mg daily) QBW276 or placebo for 7 days. Cohort 2: dose and frequency will be confirmed after cohort 1 is complete. The duration is 14 days.~Cohort 3: dose and frequency will be confirmed after cohort 2 is complete. The duration is approximately 4 months. Patients will be randomized to one of two treatment sequences: QBW276 in Period 1 and Placebo in Period 2 or Placebo in Period 1 and QBW276 in Period 2. Twenty four patients are required to complete cohort 3."
62212842|NCT02566044|PLACEBO_COMPARATOR|Placebo|"Cohorts 1 and 2 will enroll 8 patients each (6:2 QBW276 and placebo, respectively).~Cohort 1: dose is 3 mg bid (6 mg daily) QBW276 or placebo for 7 days. Cohort 2: dose and frequency will be confirmed after cohort 1 is complete. The duration is 14 days.~Cohort 3: dose and frequency will be confirmed after cohort 2 is complete. The duration is approximately 4 months. Patients will be randomized to one of two treatment sequences: QBW276 in Period 1 and Placebo in Period 2 or Placebo in Period 1 and QBW276 in Period 2. Twenty four patients are required to complete cohort 3."
62212843|NCT04291222|EXPERIMENTAL|IBS implantation|Implantation of IBS in PDA in duct-dependent cyanotic CHD
62212844|NCT04268927|EXPERIMENTAL|GnRH ant/letrozole|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
62212845|NCT04268927|ACTIVE_COMPARATOR|GnRH ant|"Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
62212846|NCT06605053|EXPERIMENTAL|Intervention arm (co-produced intervention package to optimize PMTCT care)|Pregnant girls/young women 15-24 years living with HIV (new, previously diagnosed, and transfers) receiving PMTCT services in routine healthcare randomized to the intervention between 01st January and 30th June 2026 and followed up for at least one year to 30th June 2027. While the specific intervention will developed earlier in the project, it may include a package of evidence-based approaches such as peer mentor mothers, male partner involvement, flexible hours for girls/young women and mobile phone reminders. A focal team of 2-3 persons will be trained and engaged to drive the implementation of the interventions at randomized faciltiies. The focal team will orient and engage other staff and stakeholders to deliver the interventions, identify and address gaps, and monitor implementation fidelity and quality using standard operating procedures.
62212847|NCT06605053|NO_INTERVENTION|Control: standard care|Pregnant AGYW living with HIV (new, previously diagnosed, and transfers) receiving vertical HIV prevention services in routine healthcare centres acting as control facilities, between 01st January and 30th June 2026 and followed up for at least one year to 30th June 2027. No intervention is administered to this arm; participants will receive a standard of care for PMTCT services per Tanzania national guidelines.
62212848|NCT01786759|ACTIVE_COMPARATOR|LCT lipid emulsion|the LCT lipid emulsion is Intralipid
62212849|NCT01786759|EXPERIMENTAL|Olive oil lipid emulsion|the olive oil lipid emulsion is ClinOleic
62212850|NCT04629469|EXPERIMENTAL|Hyperfine|For patients that have standard of care head imaging, we will do a secondary analysis to compare their standard of care MRI, CT and/or US exams with Hyperfine MRI exams.
62212851|NCT03103984|EXPERIMENTAL|Control|The volunteers (overweight and obese) will receive nutritional counseling and a weight loss diet.
62212852|NCT03103984|EXPERIMENTAL|Immunosuppressed patients|The volunteers (liver transplantation) will receive nutritional counseling and a weight loss diet.
62212853|NCT04013087|EXPERIMENTAL|Test Formula|Feihe Stage 1 infant formula
62212854|NCT04013087|ACTIVE_COMPARATOR|Control formula|A commercially available product with comparable composition but does not contain sn-2 palmitate enriched vegetable oil as an ingredient (regular vegetable oil is used)
62212855|NCT04013087|OTHER|Breast feeding|Breast fed of human milk
62212856|NCT04522622|EXPERIMENTAL|Teriparatide|Patients receive teriparatide 20 micrograms once daily for 18 months
62212857|NCT04522622|OTHER|Controls|Controls receive no treatment with teriparatide
62212858|NCT04891237|EXPERIMENTAL|10,000 MG01 + 10,000 T517|10,000 TU/mL of MG01 + 10,000 TU/mL of T517 of subcutaneous immunotherapy
62790701|NCT00894361|ACTIVE_COMPARATOR|rotating-platform design TKA|patients who were randomized to receive the rotating platform mobile-bearing TKA design
62790702|NCT00894361|ACTIVE_COMPARATOR|all-polyethylene tibia design TKA|patients who were randomized to receive the all-polyethylene tibial component design
62790703|NCT03202719|ACTIVE_COMPARATOR|IPV at ages 14 weeks and 18 months|Participants in this arm will receive bivalent oral poliovirus vaccine (bOPV) at 6, 10 and 14 weeks of age and inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age
62790704|NCT03202719|ACTIVE_COMPARATOR|IPV at ages 14 weeks, 18 weeks and 18 months|Participants in this arm will receive bivalent oral poliovirus vaccine (bOPV) at 6, 10 and 14 weeks of age and inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age
62212859|NCT04891237|EXPERIMENTAL|30,000 MG01 + 10,000 T517|30,000 TU/mL of MG01 + 10,000 TU/mL of T517 of subcutaneous immunotherapy
62212860|NCT04891237|PLACEBO_COMPARATOR|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients.
62212861|NCT03003455|ACTIVE_COMPARATOR|Conventional Nasotracheal Intubation (CVT)|Blind passage of an endotracheal tube via the nare followed by videolaryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
62212862|NCT03003455|EXPERIMENTAL|Nasotracheal Intubation Over a Bougie (NIB)|Nasotracheal intubation over a bougie, placed with videolaryngoscopy assistance, via a nasopharyngeal airway with or without the aid of Magill forceps
62212863|NCT05684549||stage I/II lung cancer patients|Patients with stage I/II lung cancer will receive radical surgery.
62212864|NCT06227052|PLACEBO_COMPARATOR|Natures Tears|This is the placebo arm. Participants in this arm will receive Natures Tears spray during their gynecologic procedure. They will receive the spray on their cervix right before the paracervical block. Natures Tears is normal saline, which is sprayed from a canister similar to the Num vapocoolant.
62212865|NCT06227052|EXPERIMENTAL|Num Vapocoolant Spray|This is the intervention arm.
62212866|NCT06462703|EXPERIMENTAL|Intervention Group|Patients allocated to the intervention group receive treatment through the myReha therapy software in addition to their usual standard care (i.e., care-as-usual; CAU)
62212867|NCT06462703|NO_INTERVENTION|Control Group|Patients allocated to the control group only receive usual standard care (CAU).
62212868|NCT03518567|EXPERIMENTAL|High THC dose (6% THC)|Smoked marijuana cigarettes (High THC dose \[6% THC\])
62212869|NCT05594381|EXPERIMENTAL|Neoadjuvant Sintilimab plus SOX therapy|"All enrolled subjects were treated with Sintilimab combined with SOX regimen (Oxaliplatin plus Tegafur) for 3 cycles and then underwent radical surgery.~Peripheral blood from all patients will be collected at the following 5 time points: before neoadjuvant therapy (within 3 days before the first dose); before the start of the third cycle of neoadjuvant therapy (within 3 days); before surgery (within 7 days) and after surgery (within 3-7 days). Plasma was tested for ctDNA. All subjects were further stratified according to the detection results of ctDNA and their changes during the neoadjuvant treatment period.~After operation, sintilimab combined with SOX therapy was continued for 5 cycles according to the original plan (if the preoperative treatment did not reach 3 cycles, it should be supplemented to 8 cycles)"
62212870|NCT00526500|EXPERIMENTAL|P-T|
62212871|NCT00526500|EXPERIMENTAL|P- SAH|
62212872|NCT00526500|EXPERIMENTAL|P- A|
62212873|NCT00526500|EXPERIMENTAL|Control|
62212874|NCT02554227||Spondylodiscitis|vertebral osteomyelitis, erosive osteochondrose
62212875|NCT00423631|EXPERIMENTAL|Standard Care and Web|Standard care plus a web site based on cognitive behavioral principals.
62212876|NCT00423631|ACTIVE_COMPARATOR|Standard Care|Subject recieve standard care from their primary care provider.
62212877|NCT05745389||Alopecia Areata|Pts presenting to enrolling sites across the US are invited to enroll if eligible
62212878|NCT04107298|EXPERIMENTAL|SUNDANCE™ Drug Coated Balloon|SUNDANCE™ Drug Coated Balloon
62212879|NCT01081600||AUY922|Patients with HER2 positive breast cancer which has become trastuzumab resistent.
62212880|NCT02506517|EXPERIMENTAL|Afatinib|Afatinib, orally, at a dose of 40 mg once a day, every day of each 28 day cycle.
62212881|NCT03520101|OTHER|SAPIEN|Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received an Edwards (SAPIEN XT or SAPIEN 3) valve.
62212882|NCT03520101|OTHER|COREVALVE|Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received the CoreValve Evolut R or Evolut PRO valve system.
62212883|NCT05928351|EXPERIMENTAL|PNE Group|Pain Neuroscience Education + Standard Physiotherapy Program
62212884|NCT05928351|ACTIVE_COMPARATOR|Control Group|Standard Physiotherapy Program
62212885|NCT06532396|EXPERIMENTAL|QRL-101|Multiple-ascending doses of QRL-101 will be administered orally to healthy participants.
62212886|NCT06532396|PLACEBO_COMPARATOR|Placebo|Multiple-ascending doses of comparator placebo will be administered orally to healthy participants.
62212887|NCT04835350|NO_INTERVENTION|Hybrid closed loop group|Patients using AID system Pancreas4ALL in mode hybrid closed loop.
62212888|NCT04835350|EXPERIMENTAL|Closed loop meal announcment|Patients using AID system Pancreas4ALL in mode meal announcment. They only announce what amout of carbs going to eat. They calculate no bolus
62212889|NCT04835350|EXPERIMENTAL|Full closed loop|Patients using AID system Pancreas4ALL in mode full closed loop. They eating with no permission and they do not calculate and sending bolus anymore.
62212890|NCT03293004|EXPERIMENTAL|Hydrolyzed collagen|First, we aim to determine the optimal amount of hydrolyzed collagen with a constant dose of vitamin C in humans to increase a marker of collagen synthesis (PINP). In a randomized, double-blinded, crossover design subjects consume a nutritional supplement with varying doses of hydrolyzed collagen (control (0 g), 5 10, 20 and 30 g hydrolyzed collagen) with a constant dose of vitamin C (50 mg). Each intervention will be separated by a 6-day wash out. Subjects will be asked to consume the supplement 1 hour before 6-min of jump rope exercise. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours and 24 hours blood samples will be collected. Blood samples will be used for PINP analysis.
62212891|NCT03293004|EXPERIMENTAL|Vitamin C|Second, we aim to determine the optimal amount of vitamin C with the determined optimal dose of hydrolyzed collagen in humans to increase a marker of collagen synthesis (PINP). In a randomized, double-blinded, crossover design subjects consume a nutritional supplement with varying doses of vitamin C (0 (control), 50, 250 and 500 mg) with an optimized dose of hydrolyzed collagen as determined from the first arm. Each intervention will be separated by a 6-day wash out. Subjects will be asked to consume the supplement 1 hour before 6-min of jump rope exercise. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours and 24 hours blood samples will be collected. Blood samples will be used for PINP analysis.
62215227|NCT03229070|EXPERIMENTAL|Continuous effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Intensity used will be mild / moderate, ie 60% of the maximum load reached in the incremental test. The pedaling speed should be maintained between 30-60rpm. The execution time, from this exercise regime will be 20 minutes, and assessments at discharge.
62409181|NCT04340739||Cohort A (8 Healthcare Providers)|Eight healthcare providers will be divided into pairs, and these pairs will each conduct a faux medical group visit (MGV) with faux patients (staff will pose as patients). They will be asked to complete the faux session as if it were actual patients of theirs, conduct pre- and post-session tasks, and provide usability feedback on the platform. Outcomes: Quantitative Testing/User Experience Data from Usability Testing Prompt, System Usability Scale, Perceived Feature Usefulness Scale, and the Technology Acceptance Model Based Survey. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide.
62409182|NCT04103268||Sepsis|
62020344|NCT01797146|NO_INTERVENTION|Control|All patients in the control wards will receive usual care without the CARE intervention.
62409183|NCT04103268||Control|
62409184|NCT01810575|ACTIVE_COMPARATOR|WC3036-11F/Alprostadil in Vehicle 2.5%|Treatment A
62409185|NCT01810575|EXPERIMENTAL|WC3036-12F/Alprostadil in Vehicle 0.5%|Treatment B
62409186|NCT01810575|PLACEBO_COMPARATOR|WC3036-13P/Vehicle Only 0.5%|Treatment C
62020345|NCT06087445|EXPERIMENTAL|NeuroLife EMG-FES Sleeve System|The NeuroLife EMG-FES System is a completely non-invasive system (surface electrodes only, no implantable components) worn on the forearm of participants and has up to 160 electrodes that can record electromyography (EMG), or muscle activity, and also electrically stimulate (FES) muscles. Using this combined, closed-loop technology participants will complete a 12-week protocol with a study therapist practicing functional activities using their hand/forearm while wearing the NeuroLife EMG-FES Sleeve System.
62020346|NCT02509624|EXPERIMENTAL|Moderate hepatic impairment (Cohort 1)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
62020347|NCT02509624|EXPERIMENTAL|Severe hepatic impairment (Cohort 2)|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
62020348|NCT02509624|EXPERIMENTAL|Mild hepatic impairment (Cohort 3)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
62020349|NCT01252251|EXPERIMENTAL|RAD001 and pasireotide LAR|This study will be an open-label, single-arm, phase II study of RAD001 and pasireotide LAR.
62020350|NCT01902017|EXPERIMENTAL|Operative, Ketotifen|Ketotifen 5mg orally twice per day for 6 weeks.
62020351|NCT01902017|EXPERIMENTAL|Non-operative, Ketotifen|Ketotifen 5mg orally twice per day for 6 weeks.
62020352|NCT01902017|PLACEBO_COMPARATOR|Operative, Placebo|Placebo oral medication twice daily for 6 weeks.
62020353|NCT01902017|PLACEBO_COMPARATOR|Non-operative, Placebo|Placebo oral medication twice daily for 6 weeks.
62020354|NCT01463605|OTHER|radiotherapy|It is just a single group assignment
62020355|NCT00934193|ACTIVE_COMPARATOR|Gabapentin|
62212892|NCT03293004|EXPERIMENTAL|Optimized Collagen and Vitamin C supplement|The findings from the first 2 arms of the study will be used to inform a training-based study aimed to determine whether exercise together with this optimal dose of hydrolyzed collagen and vitamin C is sufficient to improve rate of force development (RFD) and performance. A gummy food will be developed with the optimized dose of hydrolyzed collagen and vitamin C as well as a placebo. In a randomized, double-blinded, parallel design with subjects undertake a 3 week exercise protocol. The supplement will be ingested 1 hour prior to each exercise session (Monday/Wednesday/Friday). Exercise testing to assess rate of force development (RFD) will take place at the end of each week (Fridays) and these outcomes will be the basis for determining the effects of the nutrition intervention on performance.
62212893|NCT03293004|PLACEBO_COMPARATOR|Gummy Placebo|A gummy food will be developed with the optimized dose of hydrolyzed collagen and vitamin C as well as a placebo. In a randomized, double-blinded, parallel design with subjects undertake a 3 week exercise protocol. The supplement or placebo will be ingested 1 hour prior to each exercise session (Monday/Wednesday/Friday). Exercise testing to assess rate of force development (RFD) will take place at the end of each week (Fridays) and these outcomes will be the basis for determining the effects of the nutrition intervention on performance.
62212894|NCT02935985||Adults with sICH less than 8h|"Adult patients presenting in one of the study locations and being diagnosed with intracerebral hemorrhage. The onset of the conditions is establised as sonner than 8h.~Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.~Participants will be assessed (clinically or by telephone) over a period of 180 days."
62215228|NCT03971383|EXPERIMENTAL|Aolanti Weipang Tablets|3 tablets one time, 3 times a day(tid)
62215229|NCT03971383|PLACEBO_COMPARATOR|Placebo|3 tablets one time, 3 times a day(tid)
62215230|NCT00639782|ACTIVE_COMPARATOR|ONX|On-X heart Valve Replacement
62215231|NCT00639782|ACTIVE_COMPARATOR|SJM|SJM heart valve replacement
62215232|NCT00575120|NO_INTERVENTION|A|Endothelial Function of forearm assessed by FMD, PAT, BOLD-MRI before 15 min. ischemia reperfusion of forearm
62215233|NCT00575120|ACTIVE_COMPARATOR|B|Endothelial Function of forearm assessed by FMD, PAT, BOLD-MRI after 15 min. ischemia reperfusion
62215234|NCT06594107||1 cohort at Karolinska University Hospital and 1 at the Center for Rheumatology in Stockholm|This cohortstudy is performed at 2 sites.
62215235|NCT04748432||Multi-drug resistant group (MDR)|Patients with resistant NFGNB isolate as MDR group
62020356|NCT00934193|PLACEBO_COMPARATOR|Placebo|
62215236|NCT04748432||Non-Multi-drug resistant group (Non-MDR)|Patients with sensitive NFGNB isolate as Non-MDR group
62409187|NCT02392312||ATF-Fresenius S|intravenous
62409188|NCT00960648||Xience/Promus|Active prospective registration of patients receiving everolimus eluting stent
62409189|NCT00960648||Cypher|Retrospective historical controls that received sirolimus-eluting stent
62409190|NCT05867511|EXPERIMENTAL|Intervention group|This Group will be using the iPAL App for 8 Weeks
62790705|NCT03202719|ACTIVE_COMPARATOR|IPV at ages 14 weeks and 9 months|Participants in this arm will inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age
62790706|NCT03202719|ACTIVE_COMPARATOR|IPV at ages 6 weeks and 9 months|Participants in this arm will inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age
62212895|NCT01290289|ACTIVE_COMPARATOR|Epidura, combined spinal epidura & IV|"Gp 1: received CSE analgesia, 25µg of fentanyl injected intrathecally \& a bolus of 10 ml of 0.5% lidocaine injected epidurally.~Gp 2: received CSE analgesia, 25µg of fentanyl injected intrathecally \& a bolus of 10 ml of 0.0625% bupivacaine injected epidurally.~Gp 3: received 50µg of E fentanyl analgesia, injected intrathecally \& a bolus of 10 ml of 0.5% lidocaine, followed by lidocaine E top-ups.~Gp 4: received 50µg of E fentanyl injected intrathecally and a bolus dose of 10 ml of 0.125% bupivacaine, followed by E bupivacaine top-ups.~Gp 5: 50mg of IV pethidine was administered as a loading dose, followed by 0.5 mg/kg."
62212896|NCT05845034|EXPERIMENTAL|With additional SPEs ablation|Patients who undergo PVI + SPEs ablation using ThermoCool SmartTouch catheter.
62790707|NCT03202719|ACTIVE_COMPARATOR|IPV at ages 6 and 14 weeks|Participants in this arm will inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age
62790708|NCT01040442|EXPERIMENTAL|vibration stimuli|
62790709|NCT03441087|OTHER|Transvaginal ultrasound|Transvaginal ultrasound was applied 216 women with abnormal uterine bleeding.The transvaginal ultrasound diagnoses were compared with the received endometrial samples.
62790710|NCT03441087|OTHER|Hysteroscopy|Hysteroscopy was also performed under general anesthesia.Hysteroscopy was performed by a single operator (NNY).The operator and two supervising endoscopists were blinded to the ultrasound results.After the hysteroscopy, endometrial sampling was also done. The diagnoses were compared with the received endometrial samples.
62020357|NCT06416215|EXPERIMENTAL|Psychological intervention based on WBT and cognitive restructuring|Six weekly online sessions of two hours of a psychological intervention based on WBT elements and cognitive restructuring combined with a nutritional education.
62212897|NCT05845034|ACTIVE_COMPARATOR|Control Group|Patients who undergo PVI alone using ThermoCool SmartTouch catheter.
62212898|NCT01783964|EXPERIMENTAL|[14C]-Elacytarabine Microdose|intravenous (IV) administration of one dose of elacytarabine
62409191|NCT02416505|NO_INTERVENTION|Verbal Discussion: Control Group|"In this group, participants will receive a 10 minute Verbal Only Knee Osteoarthritis Steroid Injection Informed Consent discussion.~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
62409192|NCT02416505|ACTIVE_COMPARATOR|Verbal+Anatomic Model|"This intervention group will receive a 10 minute Knee Osteoarthritis Steroid Injection Informed Consent discussion with the aid of a Knee Model.~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
62409193|NCT02416505|ACTIVE_COMPARATOR|Verbal+Video Presentation|"This intervention group will receive a 10 minute Knee Osteoarthritis Steroid Injection Informed Consent discussion with the aid of a Video.~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
62735077|NCT02003976|ACTIVE_COMPARATOR|Non-Surgical Treatment|The optimized non-surgical treatment program consists of medications, physiotherapy and nutritional seminars. The 12-week program will include an assessment by a primary care physician, physiotherapist and orthopaedic surgeon, one supervised physiotherapy session per week, one body recomposition session per week, and a home program. After the 12-week program is completed, patients randomized to this group will continue with their home program and will be followed up for 2 years after baseline.
62790711|NCT00302211|EXPERIMENTAL|DB inhaled iloprost 6x/day|inhaled iloprost (5 μg) 6 times per day (6×/day) plus sildenafil with or without bosentan during the double blind period
62790712|NCT00302211|EXPERIMENTAL|DB inhaled iloprost 4x/day|Inhaled iloprost (5 μg) 4×/day plus inhaled placebo 2x/day plus sildenafil with or without bosentan during the double blind period
62020358|NCT06416215|ACTIVE_COMPARATOR|Basic Nutritional Intervention|Six weekly online sessions of two hours of a nutritional education.
62020359|NCT04396951|NO_INTERVENTION|Passive external overheating|"Passive external overheating in the environmental temperature control adjusted to thermal comfort.~Measure during 6 hours with indirect calorimetry"
62020360|NCT04396951|ACTIVE_COMPARATOR|Active external overheating with heating plate|Combination of passive and active external heating with heating plate Measure during 6 hours with indirect calorimetry
62212899|NCT03800043||Children with own caries experience|Children with own caries experience (visible on a photo; teeth clearly visible), sufficient compliance
62409194|NCT04936009|ACTIVE_COMPARATOR|Transcranial Magnetic Stimulation - real|Participants will receive active TMS during their study visit
62409195|NCT04936009|PLACEBO_COMPARATOR|Transcranial Magnetic Stimulation - sham|Participants will receive sham stimulation during their study visit simulating TMS
62409196|NCT02736669|ACTIVE_COMPARATOR|Fixed Energy (or Calorie) Reduction|Participants randomly assigned to this arm will be instructed to reduce their food intake by a moderate amount and stay at this level of moderate reduction until their weight loss goal is achieved.
62790713|NCT00302211|PLACEBO_COMPARATOR|DB inhaled placebo 6x/day|Inhaled placebo 6×/day plus sildenafil with or without bosentan during the double blind period
62790714|NCT00302211|EXPERIMENTAL|OL inhaled iloprost 6x/day|Inhaled iloprost (5 μg) 6 times per day (6×/day) plus sildenafil with or without bosentan during the Open-Label treatment period
62790715|NCT00302211|EXPERIMENTAL|OL inhaled iloprost 4x/day|Inhaled iloprost (5 μg) 4 times per day (4×/day) plus sildenafil with or without bosentan during the Open-Label treatment period
62790716|NCT02376179||Cuffed ETT|Pediatric patients intubated with a cuffed endotracheal tube for adenotonsillectomy.
62790717|NCT05982496|EXPERIMENTAL|Cohort A|"* Candidates to surgery as first treatment regardless of cN~* ER+ Her2 negative BC with ki67\>10%"
62212900|NCT03800043||Children without own caries experience|Children without own caries experience (visible on a photo; teeth clearly visible), sufficient compliance
62790718|NCT05982496|EXPERIMENTAL|Cohort B|• ER positive BC treated with induction ET
62212901|NCT02405143|EXPERIMENTAL|Active tACS using DC-Stimulator MC|15 to 30 patients will be randomized to the arm receiving the active transcranial alternating current stimulation (tACS) treatment using DC-Stimulator MC.
62212902|NCT02405143|SHAM_COMPARATOR|Sham stimulation using DC-Stimulator MC|The same number of patients as in the active arm, 15 to 30, will be randomized to receive sham stimulation using DC-Stimulator MC.
62212903|NCT00858364|PLACEBO_COMPARATOR|Placebo|Participants received placebo once every 3 weeks (Q3W) administered subcutaneously until 3 weeks after the completion of chemotherapy or upon determination of disease progression, whichever occurred first.
62212904|NCT00858364|EXPERIMENTAL|Darbepoetin alfa|Participants received darbepoetin alfa 500 µg once every 3 weeks (Q3W) administered subcutaneously until 3 weeks after the completion of chemotherapy or upon determination of disease progression, whichever occurred first.
62020361|NCT04396951|ACTIVE_COMPARATOR|Active external overheating with air blanket|Combination of passive and active external heating with convective air blanket Measure during 6 hours with indirect calorimetry
62212905|NCT04155047|ACTIVE_COMPARATOR|Glycopyrrolate Inhalation Solution|Glycopyrrolate Inhalation Solution 25mcg administered by Magnair
62212906|NCT04155047|PLACEBO_COMPARATOR|Placebo|Placebo Inhalation Solution administered by Magair
62212907|NCT02966327|EXPERIMENTAL|Compression Stockings-Exercise|At T2 (4-6 weeks post-operatively), 25 study participants will be randomized to the intervention group and will be prescribed compression stockings and individualized exercise. They will also receive standard education on lymphedema risk reduction.
62212908|NCT02966327|OTHER|Control Group|At T2 (4-6 weeks post-operatively), 25 study participants will be randomized to the control group and will receive standard education on lymphedema risk reduction.
62212909|NCT02141620|PLACEBO_COMPARATOR|Placebo|Subjects will be maintained on oral placebo.
62212910|NCT02141620|EXPERIMENTAL|n-Acetylcysteine|Subjects will be maintained on oral n-acetylcysteine.
62212911|NCT06609759||Standard chemotherapy regimen|
62212912|NCT04035278|EXPERIMENTAL|Dengusiil|
62212913|NCT04035278|PLACEBO_COMPARATOR|Placebo|
62212914|NCT04369781||Suspected critical limb ischemia|Patients referred for transcutaneous oxygen pressure measurements due to a clinical suspicion of critical limb ischemia
62212915|NCT03807310|EXPERIMENTAL|Group Long-drink|"83 COPD patients will receive:~* Targeted nutrient supplementation (Long-drink) once daily~* Counselling once monthly"
62212916|NCT03807310|PLACEBO_COMPARATOR|Group Placebo|"83 COPD patients will receive:~* Isocaloric placebo supplement once daily~* Counselling once monthly"
62212917|NCT03807310|NO_INTERVENTION|Healthy control group|30 healthy controls will be included for baseline comparison of the microbiome composition. These healthy controls will only perform a subset of baseline measurements and will not be included in the intervention.
62212918|NCT06126003||Arm 1: Advanced ER-positive and HER2-negative Breast Cancer|Advanced ER+ and HER2- breast cancer participants due to receive standard of care CDK4/6 inhibitors (palbociclib, ribociclib, or abemaciclib) in combination with endocrine therapy.
62212919|NCT06292052||Neoadjuvant immunochemotherapy NSCLC group|NSCLC patients who received neoadjuvant immunochemotherapy and underwent surgery.
62212920|NCT04325360|EXPERIMENTAL|Cathodal Transcranial Direct Current Stimulation (c-tDCS)|Participants in this arm of the study will receive cathode transcranial direct current stimulation.
62212921|NCT04325360|SHAM_COMPARATOR|Sham-tDCS|Participants in this arm of the study will receive sham transcranial direct current stimulation.
62212922|NCT03207451|EXPERIMENTAL|Vorapaxar|Subjects with multiple risk factors and antiplatelet naïve to receive Vorapaxar.
62212923|NCT03207451|EXPERIMENTAL|Vorapaxar and Clopidogrel|Subjects with 600 mg Load /75mg QD Clopidogrel QD for ≥ 7 days to receive Vorapaxar
62212924|NCT03207451|EXPERIMENTAL|Vorapaxar and Aspirin|Subjects with 81mg QD Aspirin to receive Vorapaxar
62212925|NCT03207451|EXPERIMENTAL|Vorapaxar, Aspirin, and Clopidogrel|Subjects with 81 mg QD Aspirin+75mg QD Clopidogrel to receive Vorapaxar.
62212926|NCT05581056||CFTR modulators group|Children between 6 and 11 years old that will be treated by CFTR modulators.
62212927|NCT02321202|ACTIVE_COMPARATOR|Control group|For postoperative parenteral nutrition, only Structolipid applied for 5 consecutive days.
62212928|NCT02321202|EXPERIMENTAL|Trial group|For postoperative parenteral nutrition, Omega-3 Fatty Acid-Based Parenteral Nutrition (20% Structolipid and 10% Omegaven) were applied for 5 consecutive days.
62212929|NCT04253873|EXPERIMENTAL|Apatinib mesylate + temozolomide|Apatinib mesylate tablets (0-14 days, 500 mg, qd), one week apart, then temozolomide (150mg/m2, 5 days);Every 28 days is a cycle, the drug until the disease progress, the toxicity of intolerable.
62735078|NCT00751959|ACTIVE_COMPARATOR|2|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
62735079|NCT00751959|EXPERIMENTAL|1|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
62735080|NCT01360424|EXPERIMENTAL|teriparatide|
62212930|NCT02643043|OTHER|UC Subjects|Subjects with confirmed metastatic urothelial cancer willing to participate in biospecimen collection (tissue and blood) for genetic studies.
62212931|NCT02794922|EXPERIMENTAL|Interventional|Name: Neurovit Forte tab Dosage: Each tablet contains Vitamin B1 242.5mg, Vitamin B6 250mg, Vitamin B12 1mg Frequency: One tab, once per day Duration: 6 weeks
62212932|NCT02794922|PLACEBO_COMPARATOR|Placebo|Capsule containing 250mg corn starch
62790719|NCT05982496|EXPERIMENTAL|Cohort C|• Candidates to neoadjuvant chemotherapy
62790720|NCT05982496|EXPERIMENTAL|Cohort D|• Metastatic LumA or ER-positive Lob BC, at first diagnosis or in progression
62790721|NCT02183766|PLACEBO_COMPARATOR|Maltodextrin|6 mL once a day diluted in juice during 30 days.
62790722|NCT02183766|ACTIVE_COMPARATOR|Galactooligosaccharide prebiotic|6 mL once a day diluted in juice during 30 days.
62790723|NCT05705362|EXPERIMENTAL|Simple crossover arm|This arm will receive the main vessel stenting only (with proximal optimization technique).
62790724|NCT05705362|ACTIVE_COMPARATOR|Side branch opening arm|This arm will receive a side branch opening procedure after the main vessel stenting.
62409197|NCT02736669|EXPERIMENTAL|Variable Energy (or Calorie) Reduction|Participants randomly assigned to this arm will be instructed to alternate between two levels of calorie reduction. One level will be a small amount of calorie reduction, while the other will be a more significant amount of calorie reduction. At the instruction of the research team, participants will periodically alternate back and forth between these two goals until their weight loss goal is achieved.
62212933|NCT00066014|ACTIVE_COMPARATOR|treatment modalities changed for comparison|All subjects experienced all treatment modalities being studied.
62212934|NCT02601118|EXPERIMENTAL|training group|41 training students were pre-tested before education with Micro Expression Training Tool (METT) and Subtle Expression Training Tool (SETT) at baseline and then, took second METT and SETT tests after a 1-hour class about interpreting micro and subtle expressions.
62212935|NCT02601118|NO_INTERVENTION|control group|41 control students were pre-tested before education with METT and SETT at baseline and then, took the second tests without attend the training class.
62212936|NCT03208777||control group|taking blood samples from apparently healthy people
62212937|NCT03208777||benign colorectal|taking blood samples from patients
62212938|NCT03208777||malignant colorectal|taking blood samples from patients
62212939|NCT01318018||Magnetic Seizure Therapy Group|Patients receiving magnetic seizure therapy for depression
62212940|NCT01318018||Electroconvulsive Therapy Group|Patients receiving electroconvulsive therapy for depression
62212941|NCT04695522|EXPERIMENTAL|Group of subjects undergoing cell transplantation|
62212942|NCT04695522|SHAM_COMPARATOR|Group of subjects undergoing sham operation|
62212943|NCT04073446|ACTIVE_COMPARATOR|Dorsal Column (DC) Perception|Use of DC Perception based programming
62212944|NCT04073446|ACTIVE_COMPARATOR|Dorsal Root (DR) Perception|Use of DR Perception based programming
62212945|NCT04073446|ACTIVE_COMPARATOR|Dorsal Root (DR) Sub-perception|Use of DR sub-perception based programming
62212946|NCT04073446|ACTIVE_COMPARATOR|Dorsal Column (DC) Sub-perception|Use of DC sub-perception based programming
62212947|NCT06571565|EXPERIMENTAL|working group|Conservative treatment will be applied to the back-neck region. In this treatment, 20 min hotpack, 10 min ultrasound agent (frequency 0.5-3.5MHz), 20 min Transcutaneous Electrical Nerve Stimulation (TENS) agent (Conventional TENS; Frequency 60-80 Hz, current passage time 50-100 microseconds) will be given. 15 sessions will be applied. Unlike the control group, manual lymph drainage treatment, the effect of which is aimed to be investigated, will be applied to the study group. Manual lymph drainage treatment will be performed by a lymphedema physiotherapist trained in Manual Lymph Drainage / Complex Unloading Physiotherapy.
62212948|NCT06571565|ACTIVE_COMPARATOR|control group|Conservative treatment will be applied to the back-neck region. In this treatment, 20 min hotpack, 10 min ultrasound agent (frequency 0.5-3.5MHz), 20 min Transcutaneous Electrical Nerve Stimulation (TENS) agent (Conventional TENS; Frequency 60-80 Hz, current passage time 50-100 microseconds) will be given. 15 sessions will be applied.
62212949|NCT00728897|EXPERIMENTAL|Subjects receiving treatment sequence ABC|Eligible subjects will receive treatment sequence ABC; A= 4x25 milligrams GSK598809 capsule given in fasted state, B= 100 milligrams GSK598809 capsule in given fasted state and C= 100 milligrams GSK598809 capsule given in fed state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
62212950|NCT00728897|EXPERIMENTAL|Subjects receiving treatment sequence ACB|Eligible subjects will receive treatment sequence ACB; A= 4x25 milligrams GSK598809 capsule given in fasted state, C= 100 milligrams GSK598809 capsule given in fed state and B= 100 milligrams GSK598809 capsule in given fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
62212951|NCT00728897|EXPERIMENTAL|Subjects receiving treatment sequence BAC|Eligible subjects will receive treatment sequence BAC; B= 100 milligrams GSK598809 capsule in given fasted state, A= 4x25 milligrams GSK598809 capsule given in fasted state and C= 100 milligrams GSK598809 capsule given in fed state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
62409198|NCT05809999|EXPERIMENTAL|Experimental: Intervention Group|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
62409199|NCT05809999|NO_INTERVENTION|Control Group|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy both random (approximately 32 to 40) and targeted biopsies (and/or removal of any polyps) will be undertaken.
62790725|NCT04119128|ACTIVE_COMPARATOR|Active tDCS|Patients in this group will receive 5 active sessions of low-intensity transcranial electrical stimulation for 20 minutes.
62212952|NCT00728897|EXPERIMENTAL|Subjects receiving treatment sequence BCA|Eligible subjects will receive treatment sequence BCA; B= 100 milligrams GSK598809 capsule in given fasted state, C= 100 milligrams GSK598809 capsule given in fed state and A= 4x25 milligrams GSK598809 capsule given in fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
62212953|NCT00728897|EXPERIMENTAL|Subjects receiving treatment sequence CAB|Eligible subjects will receive treatment sequence CAB; C= 100 milligrams GSK598809 capsule given in fed state, A= 4x25 milligrams GSK598809 capsule given in fasted state and B= 100 milligrams GSK598809 capsule in given fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
62212954|NCT00728897|EXPERIMENTAL|Subjects receiving treatment sequence CBA|Eligible subjects will receive treatment sequence CBA; C= 100 milligrams GSK598809 capsule given in fed state, B= 100 milligrams GSK598809 capsule in given fasted state and A= 4x25 milligrams GSK598809 capsule given in fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
62212955|NCT03804489|EXPERIMENTAL|Decision aids group|Shared decision making using decision aids,
62212956|NCT03804489|NO_INTERVENTION|Control group|Standard oral explanation with booklet.
62212957|NCT05841329|ACTIVE_COMPARATOR|active group|receive active tDCS before VRET
62212958|NCT05841329|SHAM_COMPARATOR|sham group|receive sham tDCS before VRET
62212959|NCT01134952|EXPERIMENTAL|Mycophenolate to sirolimus switch|Liver transplant recipients with Hepatitis C virus switched from mycophenolate mofetil (MMF) to sirolimus (SRL) for 3 months and then switched back to MMF
62212960|NCT00837694||1|Non-obese/0 kcal
62212961|NCT00837694||2|Non-obese/100 kcal
62212962|NCT00837694||3|Non-obese/300 kcal
62212963|NCT00837694||4|Obese/0 kcal
62212964|NCT00837694||5|Obese/100 kcal
62212965|NCT00837694||6|Obese/300 kcal
62212966|NCT05894902|ACTIVE_COMPARATOR|Open label Phase I safety & dose finding study: low dose group|4 study participants will receive a low oral dose (0.5 mL/Kg) of SM-001
62212967|NCT05894902|ACTIVE_COMPARATOR|Open label Phase I safety & dose finding study: medium dose group|4 study participants will receive a medium oral dose (1.0 mL/Kg) of SM-001
62212968|NCT05894902|ACTIVE_COMPARATOR|Open label Phase I safety & dose finding study: high dose group|4 study participants will receive a high oral dose (2.0 mL/Kg) of SM-001
62212969|NCT01629732|EXPERIMENTAL|Arm 1: Daclasasvir + BMS-986094 (100 mg) + Placebo|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 1 to Arm 1a and 1b (additional 12 weeks treatment)"
62212970|NCT01629732|EXPERIMENTAL|Arm 2: Daclasasvir + BMS-986094 (200 mg)|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 2 to Arm 2a and 2b (additional 12 weeks treatment)"
62212971|NCT01629732|EXPERIMENTAL|Arm 3: Daclasasvir + BMS-986094 (100 mg) + Placebo + Ribavirin|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 3 to Arm 3a and 3b (additional 12 weeks treatment)"
62212972|NCT01629732|EXPERIMENTAL|Arm 4: Daclasasvir + BMS-986094 (200 mg) + Ribavirin|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 4 to Arm 4a and 4b (additional 12 weeks treatment)"
62212973|NCT01629732|EXPERIMENTAL|Arm 5: Daclasasvir + BMS-986094 (200 mg)|Genotype 1 PI-failure subjects
62212974|NCT01629732|EXPERIMENTAL|Arm 6: Daclasasvir + BMS-986094 (200 mg)|Genotype 4 naive subjects
62212975|NCT01629732|EXPERIMENTAL|Arm 7: Daclasasvir + BMS-986094 (200 mg)|Genotype 2/3 NR/relapse Subjects
62212976|NCT01758887||Controls|Healthy control
62212977|NCT01758887||patients|clinical high risk subjects for psychosis
62212978|NCT03212495|ACTIVE_COMPARATOR|dexmedetomidine (D group)|intraarticular administration of dexmedetomidine at the end of surgery
62212979|NCT03212495|ACTIVE_COMPARATOR|neostigmine (N group)|intraarticular administration of neostigmine at the end of surgery.
62212980|NCT00469690|OTHER|1|
62212981|NCT00469690|OTHER|2|
62212982|NCT02415517|EXPERIMENTAL|Experimental group|Intervention: Cognitive Training
62212983|NCT02415517|ACTIVE_COMPARATOR|Active control group|Intervention: Test of general knowledge
62212984|NCT02415517|NO_INTERVENTION|Passive control group|No intervention
62212985|NCT01180205|ACTIVE_COMPARATOR|T/A|Telmisartan + Amlopidpine
62212986|NCT01180205|ACTIVE_COMPARATOR|O/HCT|Olmesartan + Hydrochlorothiazide
62212987|NCT00623701|PLACEBO_COMPARATOR|1|sublingual placebo preparation
62212988|NCT00623701|EXPERIMENTAL|2|Sublingual preparation, 40 micro grams Phl p 5 maintenance dose
62212989|NCT00298259|ACTIVE_COMPARATOR|ORIF|open reduction internal fixation of fractured ribs in flail chest patients
62212990|NCT00298259|NO_INTERVENTION|conservative management|current standard conservative management
62212991|NCT02533817|EXPERIMENTAL|Dietary Sugar - Fructose|Each participant consumed 20% daily caloric requirement as fructose.
62212992|NCT02533817|ACTIVE_COMPARATOR|Dietary Sugar - Glucose|Each participant consumed 20% daily caloric requirement as glucose.
62212993|NCT04819776|EXPERIMENTAL|Iloperidone|
62212994|NCT04819776|PLACEBO_COMPARATOR|Placebo|
62212995|NCT01923090|EXPERIMENTAL|Finasteride|Finasteride treatment 5mg for 3 weeks
62212996|NCT01923090|EXPERIMENTAL|Dutasteride|Dutasteride treatment 0.5mg for 3 weeks
62212997|NCT03170791|EXPERIMENTAL|vagal nerve stimulation intervention|All participants consented to the study will undergo an exercise session using equipment such as pedals and cylinders to facilitate activity. During the exercise session the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. Patients will be videoed during the therapy sessions to allow researchers to retrospectively count the number and type of repetitive movements successfully performed. At the end of the exercises, the stimulator clip will be removed from the patient's ear and cleaned with an alcohol disinfectant wipe ready for next use.
62212998|NCT05789329|EXPERIMENTAL|Trauma Informed Guilt Reduction Therapy (TrIGR)|behavioral intervention aimed to reduce trauma-related guilt and shame
62212999|NCT05789329|ACTIVE_COMPARATOR|Cognitive Processing Therapy (CPT)|behavioral intervention aimed at reducing PTSD symptoms
62213000|NCT03078777|EXPERIMENTAL|Pre-Dialysis|Patients will take 120 mg of fexofenadine three hours prior to dialysis and plasma concentration measured three hours following dosing.
62213001|NCT03078777|EXPERIMENTAL|Post-Dialysis|Patients will take 120 mg of fexofenadine at the end of their dialysis session and plasma concentration measured three hours following dosing.
62213002|NCT06094699|NO_INTERVENTION|Standard of care|
62213003|NCT06094699|EXPERIMENTAL|Sleep intervention|
62215237|NCT04748432||Control group (Control)|Patients without suspicion of VAP and other signs of nosocomial infection as the control group
62020362|NCT05507710|ACTIVE_COMPARATOR|Interventional study arm|Surgery will be performed according to local protocol. Flap viability during adequate hemodynamic conditions is evaluated a standard of care. Then after anastomosis of the flap but before the inset, the second intervention is performed. Intervention: evaluation of the perfusion of the skin and fat with fluorescence imaging using ICG. The flap is marked according to the fluorescence imaging evaluation, and parts without perfusion are resected. The remaining flap is inset to the remaining breast skin.
62020363|NCT05507710|NO_INTERVENTION|Control arm|Surgery will be performed according to local protocol.Flap viability during adequate hemodynamic conditions is evaluated as standard of care. Then after anastomosis of the flap but before the inset, the surgeon will leave the room, the researcher will make a recording of the flap and this will have no consequences for the procedure.
62020364|NCT05902195|EXPERIMENTAL|Personal Resource Building and Inclusive Volunteering Intervention (PVI)|All participants in the intervention group will receive the intervention (PVI) in addition to usual care. PVI is a 6-week virtual programme aimed at building up young stroke survivors' personal resources for work through engaging in inclusive volunteering activities.
62409200|NCT04092491||1 blood sample|"1 blood sample during a consultation carried out as part of a medical follow-up:~* 2 PAXgene RNA tubes of 2 ml each~* 1 dry tube for creatinine and IgA assay~* 1 tube of NFs (5ml)"
62790726|NCT04119128|SHAM_COMPARATOR|Sham tDCS|Patients in this group will receive 5 sessions of sham transcranial electrical stimulation for 20 minutes.
62020365|NCT05902195|ACTIVE_COMPARATOR|Control|All participants in the control group will receive usual stroke care services such as medical or health services offered by the hospitals or community-based organisations.
62020366|NCT01053923||MRI Scan|
62213004|NCT02549495||Patients with Diabetes or Hypertension|All patients in the seven study communities will receive the community health worker intervention provided by CES, as it is incorporated into the standard of care. However, they will receive the intervention at different points in time depending on which community they lived in, as community health worker programs can only be started at every-three-month intervals
62213005|NCT03392259|NO_INTERVENTION|Control group|conventional treatment
62213006|NCT03392259|EXPERIMENTAL|App group|conventional treatment + use of smartphone app.
62213007|NCT01511094|EXPERIMENTAL|Eye Surgery|Goniocurettage was used to treat open angle glaucoma patients
62213008|NCT02601300|EXPERIMENTAL|GED-0301 160 mg once daily (QD)|Patients will receive oral GED-0301 160 mg once daily (QD)for duration of 52 week treatment.
62213009|NCT05550545||Parents/caregivers of RSV-infected infants|
62790727|NCT00606619|NO_INTERVENTION|1|Conventional feeding : They begin ingesting sips of water on third postoperative day and continued with a liquid diet for the next two days. Patients were given a soft diet on sixth postoperative day.
62020367|NCT02529020|EXPERIMENTAL|Mouthguard|All subjects perform all tests wearing mouthguard.
62020368|NCT02529020|EXPERIMENTAL|No mouthguard|All subjects perform all tests without mouthguard
62020369|NCT06266221|EXPERIMENTAL|Systemic Corticosteroids|"Oral prednisone at 1 mg/kg/day for 3 days, tapered to 0.75 mg/kg/day for 3 days, 0.50 mg/kg/day for 3 days, 0.25 mg/kg/day for 3 days.~If the oral route is not possible, IV methylprednisolone will be used at 0.8 mg/kg/day for 3 days, ta-pered to 0.6 mg/kg/day for 3 days, 0.4 mg/kg/day for 3 days, 0.2 mg/kg/day for 3 days (equivalent predni-sone dosage).~In the event of a change of route administration (IV then Oral or Oral then IV), the posology of prednisone or methylprednisolone or placebo will correspond to the dosage equivalent to that prescribed at the time of the switch."
62213010|NCT05988359|ACTIVE_COMPARATOR|Dental turbine|In the first group, G1 (n=30) a conventional high-volume evacuator (Monoart® Euronda, Vicenza, Italy) was used to remove aerosols during caries treatment by a dental turbine.
62213011|NCT05988359|EXPERIMENTAL|Laser|In the second G2 (test, n=30) group, a conventional high-volume evacuator (Monoart® Euronda, Vicenza, Italy) was used to remove aerosols during caries treatment by an Er:YAG laser.
62790728|NCT00606619|EXPERIMENTAL|2|Early oral feeding : The patients begin ingesting sips of water on the first postoperative day. If they are tolerable, they continued with a clear liquid diet the next day and a soft diet on the third post operative day.
62020370|NCT06266221|PLACEBO_COMPARATOR|Placebo|Oral or IV placebo with the same decrease of dose: same number of tablets for prednisone placebo and same volume as methylprednisolone for its placebo
62213012|NCT02468219|ACTIVE_COMPARATOR|aortic valve replacement|patients with aortic stenosis submitted to aortic valve replacement procedure
62213013|NCT02468219|EXPERIMENTAL|transcatheter aortic valve implantation|patients with aortic stenosis who underwent to transcatheter aortic valve implantation
62215238|NCT01174290|EXPERIMENTAL|Haloperidol 1mg IV q6h|
62215239|NCT01174290|PLACEBO_COMPARATOR|D5W 0.2mL IV q6h|
62215240|NCT02321332|ACTIVE_COMPARATOR|B-ETS|Bilateral simultaneous endoscopic thoracic sympathectomy: bilateral simultaneous T2-T3 ganglionectomy.
62215241|NCT02321332|ACTIVE_COMPARATOR|S-ETS|unilateral sequential endoscopic thoracic sympathectomy: unilateral T2-T3 ganglionectomy of the dominant side followed by T2-T3 ganglionectomy of the other side after 2 months interval
62213014|NCT00399373||Quality Improvement Initiative|The initial step in the quality improvement initiative was a letter sent from JHHC Care Management Department to the quality improvement initiative group, inviting them to take advantage of the case management services that are part of their current benefits in the Priority Partners MCO. It is similar to the standard letter sent to PPMCO members who are appropriate for a JHHC disease or case management program. A substance abuse outreach staff initiated telephonic contact with the members in the intervention group. The staff member then refered to substance abuse treatment when possible and appropriate and refered to medical case management.
62213015|NCT00399373||Control group|No additional improvement modalities
62213016|NCT01712945|EXPERIMENTAL|Palifermin (and Alemtuzumab)|Palifermin (Kepivance®), at the maximum identified tolerated dose will be administered by intravenous bolus on days -5, -4. -3 prior to, and on days 8, 9 and 10 after each cycle of alemtuzumab, then again on 3 consecutive days at month 1 and month 3 after each cycle of alemtuzumab. Patients will be observed for adverse reactions for at least 1 to 2 hours following each bolus dose. Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
62213017|NCT01712945|PLACEBO_COMPARATOR|Placebo (and Alemtuzumab)|Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
62213018|NCT06263764|EXPERIMENTAL|Qur'an Arm|"Participants in the intervention group will be asked to listen to a Qur'an recital by Surah Ar-Rahman using an MP3 player twice a day for a minimum of 15 minutes each for 40 days.~The participants will listen to the same Qur'an recital (recited by Freed Ghalib) using the same MP3 player."
62213019|NCT06263764|NO_INTERVENTION|Control Arm|The control group will not receive any specific intervention and will continue with their usual routine
62213020|NCT04220619|NO_INTERVENTION|Conventional ACLS|Patients who have conventional ACLS during in-hospital Cardiac arrest, they will not have RescueTEE
62409201|NCT05263024||left atrial appendage clip|Cardiac valvular patients complicated with atrial fibrillation need cardiac valvular surgery, according to the patient's wishes, cardiac auricular clamp at the same time
62213021|NCT04220619|EXPERIMENTAL|RescueTEE guided ACLS|Patients who have RescueTEE guided ACLS
62213022|NCT02910050|EXPERIMENTAL|bicalutamide+ Aromatase Inhibitor|ER(+)/AR(+)/HER2(+) metastatic breast cancer patients that previously treated by an aromatase inhibitor
62409202|NCT05263024||Left atrial appendage treated with conventional methods|Valvular heart disease with atrial fibrillation requires valvular heart surgery and left atrial ligation
62409203|NCT03251443|EXPERIMENTAL|Apatinib|A molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
62409204|NCT06537479|EXPERIMENTAL|Buteyko breathing technique, Chest wall mobilization|Deep breathing exercises for 5 minutes. After the 5-minute resting interval Buteyko breathing technique and chest wall mobilization of 5 minutes Chest wall mobilization with 8-10 repetitions. Total time duration will be 30 minutes. 2 sessions per week
62409205|NCT06537479|ACTIVE_COMPARATOR|Buteyko breathing technique|Deep breathing for 5 minutes as a baseline Buteyko technique of 2 sets of 8-10 repetitions for 2 days a week. Chest wall mobilization will not be included in Group 2. Repeat the breathing cycle for 5-10 minutes, 2-3 times a day. Total time duration will be 30 minutes.
62409206|NCT00247416|OTHER|1 No Dex|No Dexamethasone
62409207|NCT00247416|EXPERIMENTAL|2 Dex|Dexamethasone
62409208|NCT05069129|EXPERIMENTAL|Subject last vaccination time is within 4-6 months（sequential clinical trial group）|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 4-6 months
62584463|NCT03000426|EXPERIMENTAL|Free gingival graft + GaAlAs Laser 15|The irradiation will be performed with a GaAlAs diode laser that continuously emits a wavelength of 660 nm with a power of 30 milliwatts (mW). The patients allocated for the group 15 will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 15 Joules/cm2 and a time of 14 seconds per point (0,42 Joules/cm2 per point). During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by four more applications performed every other day, with a total of 5 laser applications. The power of the equipment will be calibrated prior to each application.
62790729|NCT01196026|EXPERIMENTAL|Fluarix 6-11 months Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
62215242|NCT03466073|EXPERIMENTAL|Single Dose 6 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg v. placebo (NSS) in addition to standard of care
62215243|NCT03466073|EXPERIMENTAL|Multiple Dose 6 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
62409209|NCT05069129|EXPERIMENTAL|Subject last vaccination time is within 7-9 months（sequential clinical trial group）|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 91-180 days 7-9 months
62409210|NCT05069129|EXPERIMENTAL|Subject last vaccination time more than 9 months（sequential clinical trial group）|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time more than 9 months
62409211|NCT05069129|EXPERIMENTAL|Safety Observation Group|Subject have been vaccinated with three doses of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) on 0，30，60 days
62409212|NCT02901912||Active|Women who perform at least 3h of physical activity per week
62735081|NCT00352469|PLACEBO_COMPARATOR|2|Subjects will be randomized to receive either Seroquel SR or placebo
62409213|NCT02901912||Sedentary|Women who did not perform any kind of exercise
62735082|NCT03026816|EXPERIMENTAL|Epidural Spinal Cord Stimulation|Epidural Spinal Cord Stimulation
62735083|NCT05092828|ACTIVE_COMPARATOR|Study Group|Patients in this group will receive intrathecal morphine in addition to standard post-operative pain medications
62790730|NCT01196026|EXPERIMENTAL|Fluarix 12-35 months Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
62790731|NCT01196026|EXPERIMENTAL|Fluarix 3-9 years Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
62584464|NCT05017311|ACTIVE_COMPARATOR|Allocation by Predictive Biomarker Algorithm; Escitalopram + Brexpiprazole|Patients are randomly assigned to the Allocation by Predictive Biomarker Algorithm group. Based on the outcome result from the personalized predictive biomarker algorithm, patients predicted as non-responders to escitalopram monotherapy will receive open-label escitalopram (10-20 mg/d) and blinded brexpiprazole (0.5-2 mg/d) for the first 8 weeks of the study. For the final 4 weeks of the study, patients will continue to receive both medications but the brexpiprazole will no longer be blinded.
62735084|NCT05092828|ACTIVE_COMPARATOR|Control Group|Patients in this group will receive standard post-operative pain medications but will not receive intrathecal morphine
62790732|NCT01196026|ACTIVE_COMPARATOR|Havrix Junior 6-11 months Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
62790733|NCT01196026|ACTIVE_COMPARATOR|Havrix Junior 12-35 months Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
62020371|NCT04352010|EXPERIMENTAL|"Online-Intervention Res-Up!"|Participants in the Res-Up! group get access to Res-Up! while waiting for psychotherapy or in addition to psychotherapy. Participants will answer questionnaires after inclusion as well as six and twelve weeks later.
62020372|NCT04352010|EXPERIMENTAL|"Online-Intervention REMOTION"|Participants in the REMOTION group get access to REMOTION while waiting for psychotherapy or in addition to psychotherapy. Participants will answer questionnaires after inclusion as well as six and twelve weeks later.
62790734|NCT01196026|ACTIVE_COMPARATOR|Havrix Junior 3-9 years Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
62790735|NCT01440816|EXPERIMENTAL|Cohort A: Tavo-EP|Patients in Cohort A received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation, after which they proceeded to definitive treatment (surgery and/or radiation therapy) which started between 2 and 4 weeks after the first injection.
62790736|NCT01440816|EXPERIMENTAL|Cohort B: Tavo-EP|Patients in Cohort B received up to 4 cycles (3 daily treatments on Days 1, 5, and 8, per cycle) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation, with 12 planned weeks between each cycle, lasting up to 12 months.
62020373|NCT04352010|EXPERIMENTAL|Wait-control group|Participants in the wait-control group will not get access to the online-tools while waiting for psychotherapy or while in psychotherapy. Participants will answer questionnaires after inclusion, six weeks later and twelve weeks later.They get access to one of the online-tools after 12 weeks.
62020374|NCT02005341|ACTIVE_COMPARATOR|Autograft bone|
62213023|NCT02799264|EXPERIMENTAL|Cabotegravir 30 mg: Sequence AB (fasted followed by fed)|There will be two administration periods with 14 days of wash out. In Period 1, eligible subjects will receive a single tablet of cabotegravir 30 mg,(micronized 500 mg core weight) orally under fasted condition with at least 10 hours of prior fast. In Period 2, eligible subjects will receive single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally following a high fat meal. Blood samples will be withdrawn from subjects prior to dosing and upto 8 days after the last dose of cabotegravir.
62735085|NCT04741321||Pre-test group|After translation to Spanish, VQ-6 questionnaire is given to 20 patients to assess understanding by the patient.
62790737|NCT04625439|EXPERIMENTAL|Personality Feedback|The intervention arm will read about the Five-Factor model and receive a feedback report with individualized personality results and self-management recommendations.
62790738|NCT04625439|NO_INTERVENTION|No-feedback Control|The control arm will read about the Five-Factor model but will not receive feedback or their personality results until after the study.
62020375|NCT02005341|EXPERIMENTAL|nanOss with bone marrow aspirate|
62020376|NCT05801601|EXPERIMENTAL|Many Ways of Being|In the experimental arm, Equimundo's Many Ways of Being program will be implemented. Youth will receive eight two-hour sessions or 16 one-hour sessions over four to eight weeks for a total of 14 hours and 40 minutes of programming.
62020377|NCT05801601|ACTIVE_COMPARATOR|A career readiness program|In the comparison arm, a curriculum focused on career readiness will be implemented. Youth will receive eight two-hour sessions or 16 one-hour sessions over four to eight weeks for a total of 14 hours and 40 minutes of programming.
62020378|NCT00262834|EXPERIMENTAL|Arm I|Patients receive oral vorinostat twice daily on days -3 to 0. Approximately 2 hours after the final dose of vorinostat, patients undergo conventional surgery of the tumor on day 0. After completion of study treatment, patients are followed for 30 days.
62020379|NCT04485403|EXPERIMENTAL|Ibuprofen|Depending on body weight, patients will be divided into two groups. Women with a body weight \<70 kg will be taking a daily dose of 800 mg ibuprofen orally. Women ≥ 70 kg will take a dose of 1200 mg ibuprofen orally. Before and after 3 weeks of treatment, all subjects will have a full hormonal, biochemical and clinical profile.
62020380|NCT00588562||Primary Hyperoxaluria patients|Registry will include data on patients with confirmed diagnosis of Primary Hyperoxaluria.
62020381|NCT00588562||Dent Disease Patients|Registry will include data on patients with confirmed diagnosis of Dent Disease.
62020382|NCT00588562||Cystinuria Patients|Registry will include data on patients with confirmed diagnosis of Cystinuria.
62020383|NCT00588562||APRT deficiency Patients|Registry will include data on patients with confirmed diagnosis of APRT deficiency.
62020384|NCT02422277|ACTIVE_COMPARATOR|LI-ESWT group|Intervention include that patients will undergo penile low-intensity extracorporeal shock wave therapy, 6-12 sessions, 1500 shocks per session, two sesssions per week for 3 weeks then 3 weeks break and then 2 sessions per week for 3 weeks.
62409214|NCT05898022|OTHER|N-of-1 Trial|Each individual N-of-1 trial will have 2 blocks. In each block patients will crossover between furosemide (plus potassium chloride) for 1 week and placebo (plus placebo electrolyte solution) for 1 week. The total arm length (length of the N-of-1 Trial/Crossover) is 28 days. Patients may receive furosemide (plus potassium chloride) and placebo (plus placebo electrolyte solution) in one of four different treatment order sequences, however, treatment order will not be analyzed for the primary outcomes of feasibility/responder status.
62213024|NCT02799264|EXPERIMENTAL|Cabotegravir 30 mg: Sequence BA (fed followed by fasted)|There will be two administration periods with 14 days of wash out. In Period 1, eligible subjects will receive single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally following a high fat meal. In Period 2, eligible subjects will receive a single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally under fasted condition with at least 10 hours of prior fast. Blood samples will be withdrawn from subjects prior to dosing and upto 8 days after the last dose of cabotegravir.
62213025|NCT05059743|EXPERIMENTAL|[14C]-Larotinib|Patients will receive single dose of \[14C\]-Larotinib (Suspension, 350mg/100μCi).
62409215|NCT04723329|EXPERIMENTAL|web-based education group|Patients will be given a username and password to access the website. The change stage of the patients will be determined by the researcher with the Exercise Change Phase Short Question Form, and it will be ensured that they reach the educational content prepared according to the transtheoretic model. Motivating interviews will be provided to the patients to receive training on the website by contacting them one-on-one. In the following 1st and 3rd months, patients will be contacted individually again to confirm whether they follow the website, and they will be asked to fill in the scales on the website by providing consultancy on the issues they need. In the 6th month, the final test data will be obtained from the website using the same data collection forms.
62213026|NCT05746364|EXPERIMENTAL|RIDE intervention|Cognitive analytic therapy (CAT)-informed brief therapy for young people struggling with disordered eating
62213027|NCT00362739||1: Lung Disease|Individuals with at least one of the following: (1)symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) patients with diseases of organs with known association with lung disease; (7) individuals suspected of history of lung diseased based on history and/or physical examination
62409216|NCT04723329|NO_INTERVENTION|Control Group|In the first interview, the patients in the control group will be collected data and contact information will be obtained using the Patient Information Form, Exercise Change Phase Short Question Form, Change Processes Scale, Decision Making Balance Scale and Self-Efficacy Scale. Later, patients will be given their username and password so that they can log into the website where the scales are located in order to apply the final test. No intervention will be applied to the patients in the control group. At the end of the 6th month, the same scales will be applied on the website as a final test. At the end of the study, it is aimed to gain exercise behavior to the patients in the control group.
62409217|NCT00988039|ACTIVE_COMPARATOR|bPI + 2NRTIs|
62409218|NCT00988039|EXPERIMENTAL|bPI + raltegravir|
62790739|NCT03908359|ACTIVE_COMPARATOR|traditional cataract surgery|Central anterior continuous capsulorhexis opening (5-6 mm)+ lens irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + Anti-vit)
62790740|NCT03908359|EXPERIMENTAL|minimal invasive lens surgery|Peripheral capsulorhexis opening (1.0-1.5 mm)+lens irrigation/aspiration
62213028|NCT00362739||2: Normal Controls|Individuals without a history of lung disease
62213029|NCT02547545||All|The side effects after chemotherapy were observed for all patients. Potential risk factors would be explored for the side effects such as chemotherapy realted vomit.
62213030|NCT00466375||A|Patients with a hemangioma.
62213031|NCT00466375||B.|Patients with a vascular anomaly.
62213032|NCT02549105|ACTIVE_COMPARATOR|EMLA CREAM|EMLA CREAM 5 mg TOPICAL APPLICATION FOR CS WOUND AND ASSESSMENT FOR POST OPERATIVE PAIN IN FIRST 6 HOURS
62213033|NCT02549105|ACTIVE_COMPARATOR|LIDOCAINE INFILTERATION|LIDOCAINE 1 % 20 ml INFILTERATION FOR WOUND AND ASSESSMENT OF POST OPERATIVE PAIN IN FIRST 6 HOURS
62409219|NCT00988039|EXPERIMENTAL|bPI monotherapy|
62409220|NCT01204606|EXPERIMENTAL|MMA group|
62409221|NCT01204606|PLACEBO_COMPARATOR|Control group|
62409222|NCT06110338|EXPERIMENTAL|IBI355 dose 1|IBI355 0.3mg/kg and placebo will be given to the subjects (3:2)
62409223|NCT06110338|EXPERIMENTAL|IBI355 dose 4|IBI355 7.5mg/kg and placebo will be given to the subjects (6:2)
62409224|NCT06110338|EXPERIMENTAL|IBI355 dose 6|IBI355 25mg/kg and placebo will be given to the subjects (6:2)
62409225|NCT06110338|EXPERIMENTAL|IBI355 dose 7|IBI355 35mg/kg and placebo will be given to the subjects (6:2)
62409226|NCT06110338|EXPERIMENTAL|IBI355 dose 2|IBI355 1mg/kg and placebo will be given to the subjects (6:2)
62409227|NCT06110338|EXPERIMENTAL|IBI355 dose 3|IBI355 3mg/kg and placebo will be given to the subjects (6:2)
62409228|NCT06110338|EXPERIMENTAL|IBI355 dose 5|IBI355 15mg/kg and placebo will be given to the subjects (6:2)
62735086|NCT04741321||Test and re-test group|80 patients will be recruited to answer VQ-6 questionnaire and SF-12 questionnaire. After 3-4 weeks, these patients will be re-asked with the same questionnaires.
62020385|NCT02422277|ACTIVE_COMPARATOR|PDE-5 inhibitors group|"Intervention include that patients will intke oral tablets of PDE-5 inhibitors :~- Oral intake of 50 mg once daily for 6 months."
62213034|NCT06424132|EXPERIMENTAL|Obese group|Body Mass Index (BMI) is \> 30, Hemoglobin A1c (HgA1c) \<5.7%
62213035|NCT06424132|EXPERIMENTAL|Obese group with Type II diabetes|Body Mass Index (BMI) is \> 30, Hemoglobin A1c (HgA1c) is \>6.5%
62213036|NCT06424132|EXPERIMENTAL|Lean group|Body Mass Index (BMI) is between 18.5 and 24.9. Hemoglobin A1c (HgA1c) \<5.7%
62735087|NCT05600985||DED after FS-LASIK|patients with dry eye disease (DED) after refractive surgery (RS）
62020386|NCT02422277|NO_INTERVENTION|Control group|Patients will be only followed up without any therapy for assisting erection.
62020387|NCT01055639|ACTIVE_COMPARATOR|In-person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT). ACT is a psychotherapy intervention comprised of meditation, goal-setting, and behavior change.
62020388|NCT01055639|EXPERIMENTAL|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT). Sessions were delivered via videoconferencing system. ACT is a psychotherapy intervention comprised of meditation, goal-setting, and behavior change.
62020389|NCT00648232|EXPERIMENTAL|A|Participants will receive voluntary brief HIV counseling and testing plus enhanced linkage to care.
62020390|NCT00648232|EXPERIMENTAL|B|Participants will receive voluntary brief HIV counseling and testing plus routine referral to care.
62020391|NCT00648232|EXPERIMENTAL|C|Participants will receive voluntary longer, more detailed HIV counseling and testing plus enhanced linkage to care.
62020392|NCT00648232|EXPERIMENTAL|D|Participants will receive voluntary longer, more detailed HIV counseling and testing plus routine referral to care.
62020393|NCT00648232|ACTIVE_COMPARATOR|E|Participants who are found to be healthy will receive voluntary brief HIV counseling and testing only.
62213037|NCT04844645|EXPERIMENTAL|a mini program trial group|Pharmacists conducted a standardized education session to teach the participants how to operate the mobile phone, use mini program, assess pain. The participants in the trial group were asked to complete initial and final pain assessment questionnaires and Medication compliance on the mobile phones provided to them. Participants were encouraged to use mini program as much as possible to record their pain status.
62213038|NCT04844645|SHAM_COMPARATOR|a control group|The control group received conventional pharmaceutical care. Initial and final pain and Medication compliance data were collected. Before the patient was discharged from the hospital, the clinical pharmacist conducted detailed medication education (including medication methods, prevention and treatment of adverse reactions, and precautions) and asked the patient to attempt to maintain a paper version of the pain diary.
62213039|NCT01318395|ACTIVE_COMPARATOR|Aliskiren|
62213040|NCT01318395|PLACEBO_COMPARATOR|Placebo|
62213041|NCT01157767||breast pts who have undergone surgery|This will be a feasibility study designed to evaluate the compliance of an at-home, directed exercise program and its influence on physical measures during post-operative adjuvant chemotherapy and radiation (if applicable).
62213042|NCT03186053|EXPERIMENTAL|sodium creatine phosphate|5g creatine phosphate was dissolved in 50ml saline solution. After induction of anesthesia, the patients were first given a load dose of 1g, 20min (30ml / h) , And then pumped at a rate of 1 g / h (10 ml / h).
62213043|NCT03186053|PLACEBO_COMPARATOR|Control|The control group was treated with saline in the same manner.
62213044|NCT05865132|EXPERIMENTAL|Palbociclib + Afatinib|The first 6 enrolled patients were treated with Palbociclib 125 mg po qd on day 1 to 21, Afatinib 40 mg po qd on day 1 to 14, every 28 days as a cycle; If there are ≥ 2 cases of dose-limiting toxicity (DLT), the following 6 patients will reduce the dose to Palbociclib 125mg po qd on day 1 to 21, Afatinib 30mg po qd on day 1 to 28, every 28 days as a cycle; If ≥ 2 cases of DLT occur again, the following 6 patients will reduce the dose to Palbociclib 100mg po qd on day 1 to 21, Afatinib 30mg po qd on day 1 to 28, every 28 days as a cycle; If ≥ 2 cases of DLT occur again, we will analyze the characteristics of adverse events and determine the subsequent dose.
62213045|NCT03859154||Viper bite victims|Snakebite victims in whom the snake has been brought and positively identified as Viperidae AND simultaneous aPTT has been sent AND consenting to be part of the study
62409229|NCT01136616||Nasal Fracture|"67 patients admitted for facial fractures and who undergo routine CT scans of the face are to be studied. CT scans are evaluated to assess the position, comminution and displacement of the 5 said buttresses.~The buttresses are graded Grade 1 Simple fracture without displacement Grade 2 Simple fracture with displacement Grade 3 Comminuted fracture without displacement Grade 4 Comminuted fracture with minimal displacement Grade 5 Comminuted fractured with displacement~The septum is graded from Grade 0 Septum is straight Grade 1 Septum is deviated by less than 1 half the distance from the midline to the nasal turbinate Grade 2 Septum is deviated by more than 1 half the distance from the midline to the nasal turbinate Grade 3 Septum is almost touching the nasal turbinate"
62735088|NCT05600985||DED without FS-LASIK|patients with dry eye who did not have refractive surgery
62020394|NCT00648232|ACTIVE_COMPARATOR|F|Participants who are found to be healthy will receive voluntary longer, more detailed HIV counseling and testing only.
62020395|NCT02861690|EXPERIMENTAL|Treatment group|patients received Liposomal Paclitaxel and Nedaplatin every 21 days until the presence of progressive disease or unacceptable toxicity
62020396|NCT04352699||Naive patients|Group of naive patients who have undergone elective or emergency surgery during the study period
62020397|NCT01965067|ACTIVE_COMPARATOR|C group|normal thermal condition with core temperatures between 36.5°C and 37°C
62020398|NCT01965067|EXPERIMENTAL|H group|mild hypothermia with core temperatures between 34.5°C and 35°C
62020399|NCT00847873|EXPERIMENTAL|Combined SU/IPV treatment|A combined treatment containing cognitive behavioral therapy addressing partner violence and cognitive behavioral therapy addressing substance abuse
62020400|NCT00847873|ACTIVE_COMPARATOR|control condition|Cognitive behavioral therapy addressing substance abuse
62020401|NCT05961202|EXPERIMENTAL|HCQ group|Hydroxychloroquine 200mg qd and Prednisolone 20mg qd for 12 months
62020402|NCT05961202|ACTIVE_COMPARATOR|Non-HCQ group|Prednisolone 20mg qd for 12 months
62020403|NCT06432712|NO_INTERVENTION|Control|Participants in this arm will receive routine root canal treatment with a prescription of NSAIDs post operatively.
62020404|NCT06432712|EXPERIMENTAL|Experimental|Participants in this arm will receive routine root canal treatment along with 2.5ml of dexamethasone 4mg/ml peri apical infiltration with a prescription of NSAIDs post operatively.
62020405|NCT03086447|EXPERIMENTAL|Experimental: Participating Subjects|Subjects who are habitual soft toric contact lens wearers, aged 18 to 40 years of age, will be dispensed the investigational contact lens to be worn from 28-36 days, to include a total of 5 visits.
62213046|NCT03859154||Nonvenomous snakebite|"age and gender matched victims of snake bite in whom the culprit snake brought along has been identified as a non venomous one.~AND consenting to be part of the study"
62213047|NCT01167764|ACTIVE_COMPARATOR|tranexamic acid|tranexamic acid 250mg po 3 times/day for 1 months
62213048|NCT01167764|PLACEBO_COMPARATOR|placebo|placebo po 3 times/day for 1 months
62213049|NCT04718779|EXPERIMENTAL|Arm A: Prospective|Participants with Gaucher's Disease 1 (GD1) transitioning from SRTs to ERT (VPRIV) or ERT to SRT and then to ERT (VPRIV) in a real-world setting among adults 18 and older will be studied by observing standard patient care and by reviewing the results of tests and assessments that would be performed as part of their routine treatment.
62213050|NCT04718779|EXPERIMENTAL|Arm B: Retrospective|Participants with GD1 transitioning from SRT to ERT (VPRIV) or ERT to SRT and then to ERT (VPRIV) previously (within the past 5 years at the time of enrollment) will be assessed retrospectively after switch to ERT for up to 12 months.
62213051|NCT06265493||derivation cohort|29785 in the derivation cohort
62213052|NCT06265493||internal validation cohort|7445 in the internal validation cohort
62213053|NCT00774930|EXPERIMENTAL|Lanreotide Autogel (Somatuline Depot) 120 mg|"Subjects received deep s.c. lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).~After completing the DB phase (or if they met criteria for early roll over \[ERO\]) the subjects entered the IOL phase during which they received lanreotide Autogel 120 mg deep s.c. every 4 weeks for 32 weeks. During the LTOLE phase, subjects continued treatment with lanreotide Autogel 120 mg deep s.c. every 4 weeks until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained \[whichever occurred first\])."
62213054|NCT00774930|PLACEBO_COMPARATOR|Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE|"Subjects received deep s.c. placebo every 4 weeks (±3 days) for 16 weeks (DB phase).~After completing the DB phase (or if they met criteria for ERO) the subjects entered the IOL phase during which they received lanreotide Autogel 120 mg deep s.c. every 4 weeks for 32 weeks. During the LTOLE phase, subjects continued treatment with lanreotide Autogel 120 mg deep s.c. every 4 weeks until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained \[whichever occurred first\])."
62213055|NCT00291642|PLACEBO_COMPARATOR|Placebo (PBO)|A single dose of placebo was administered orally on Day 1.
62213056|NCT00291642|EXPERIMENTAL|Levocetirizine (LCTZ) 2.5 mg|A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.
62213057|NCT00291642|EXPERIMENTAL|Levocetirizine (LCTZ) 5 mg|A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.
62213058|NCT00291642|EXPERIMENTAL|Cetirizine (CTZ) 5 mg|A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.
62213059|NCT00291642|EXPERIMENTAL|Cetirizine (CTZ) 10 mg|A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.
62213060|NCT04040790|EXPERIMENTAL|Healthy volunteers|15 healthy volunteers for trials with passive artificial iris
62213061|NCT01725789|EXPERIMENTAL|Ferinject® Group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with 7g/dl≤Hb\<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.
62213062|NCT01725789|PLACEBO_COMPARATOR|Placebo Group|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with 7g/dl≤Hb\<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.
62213063|NCT01057329||Anorexia nervosa|36 severe AN patients treated with aripiprazole
62213064|NCT01057329||Anorexia|36 severe anorexia nervosa patients treated with olanzapine
62213065|NCT01057329||Attention Deficit Hyperactivity Disorder|30 ADHD patients treated with atomoxetine
62213066|NCT01057329||Depressive disorder|30 depressed patients treated with duloxetine
62213067|NCT01123070|EXPERIMENTAL|TL011|TL011 infusions
62213068|NCT01123070|ACTIVE_COMPARATOR|MabThera|MabThera infusions
62213069|NCT01323972|EXPERIMENTAL|GSK 257049-Lot 1 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine from the commercial scale lot 1 (formulation 1 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
62213070|NCT01323972|EXPERIMENTAL|GSK 257049-Lot 2 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine, from the commercial scale lot 2 (formulation 2 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
62213071|NCT01323972|EXPERIMENTAL|GSK 257049-Lot 3 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine, from the commercial scale lot 3 (formulation 3 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
62213072|NCT01323972|EXPERIMENTAL|GSK 257049-Pilot Group|Healthy male or female children aged 5 to 17 received 3 doses of the GSK 257049 vaccine from the pilot scale (pilot formulation of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
62735089|NCT05600985||normal control|subjects with no ocular symptoms and no previous ocular surgeries
62409230|NCT03863925|EXPERIMENTAL|Propofol Target Controlled Infusion Group (Group T)|Patients in group T underwent anesthesia with Propofol (dosage form: 10mg/mL) target controlled infusion by Schnider model, starting at concentration of effect site (Ce) of 1.5 mcg/mL and titrating to achieve Observer's Assessment of Alertness/Sedation (OAA/S) Scale level 3 (responds only after name called loudly or repeatedly). Patients were paralyzed with suxamethonium (dosage form: 20mg/mL; dosage: 1mg/kg) once adequate sedation level achieved. TCI was stopped once the psychiatrist applied electroconvulsive stimulation to patients' bilateral frontal regions. Assisted ventilation with bag-valve-mask device by experienced anesthesiologists was began since patients were sedated until adequate spontaneous respiration was regained after each single electroconvulsive therapy (ECT) session. Every patient receive total six to twelve ECT sessions, and each ECT session was conducted one day apart.
62020406|NCT03086447|ACTIVE_COMPARATOR|Control: Participating Subjects|Subjects who are habitual soft toric contact lens wearers, aged 18 to 40 years of age, will be dispensed marketed contact lens to be worn from 28-36 days, to include a total of 5 visits.
62020407|NCT02448784||Participants with DLB|Participants with DLB who will receive donepezil hydrochloride per approved label.
62213073|NCT06488989|OTHER|patients with heart failure and left bundle branch block|"1. Male or female ≥ 18 years of age at Visit 1.~2. Patients with complete left bundle branch block, QRS duration greater than 130 ms, left ventricular ejection fraction (LVEF) less than 35%, and New York Heart Association (NYHA) functional class 2-3, who have been ineffective on optimal medical therapy for at least 3 months.~3. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study."
62409231|NCT03863925|ACTIVE_COMPARATOR|Propofol Bolus Group (Group B)|Patients in group B underwent anesthesia with bolus of propofol for sedation, and the dosage raged between 0.75 to 1.5 mg/kg to achieve at least OAA/S scale level 3. Dosage of suxamethonium, application of electroconvulsive stimulation, ventilation maneuver, frequency of ECT session, and number of total ECT sessions were same as patients in group T.
62409232|NCT01282879|EXPERIMENTAL|itraconazole, prophylaxis, Oral solution|For GVHD patients who are required systemic glucocorticoids therapy, itraconazole oral solution will be administered at a dose of 200mg every 12 hours.
62409233|NCT05552183|EXPERIMENTAL|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment based on Child-Pugh Class B score of 7-9 will receive 14 days of 200 mg BID pacritinib.
62020408|NCT00023452|ACTIVE_COMPARATOR|Daily Isoniazid|Isoniazid (INH) daily for 9 months (240 to 270 total doses).
62020409|NCT00023452|EXPERIMENTAL|Weekly Isoniazid / Rifapentine|Isoniazid / Rifapentine (RPT/INH) weekly for 3 months (11 to 12 total doses) given by Directly Observed Therapy (DOT)
62020410|NCT03200392|EXPERIMENTAL|L-DGG/LRB|laser root surface conditioning \& laser DGG harvesting
62020411|NCT03200392|EXPERIMENTAL|B-DGG/LRB|laser root surface conditioning \& blade DGG harvesting
62020412|NCT03200392|ACTIVE_COMPARATOR|B-DGG|blade DGG harvesting
62020413|NCT01354821|ACTIVE_COMPARATOR|Endovascular therapy branched|Endovascular therapy branched or fenestrated stent-graft
62213074|NCT01788462||HIV and Lipodystrophy|The study population will consist of HIV patients with lipodystrophy who receive Tesamorelin (Egrifta).
62213075|NCT03693859|EXPERIMENTAL|Behavioral Weight Loss + Gaming|Treatment will consist of 12-weekly, one-hour group sessions of approximately 15 participants per group. Participants will provide logs of serious gaming (intervention).
62213076|NCT03693859|ACTIVE_COMPARATOR|Behavioral Weight Loss + Health Segments|Control participants will be asked to spend 30 minutes watching health segments online, five days per week, for 8 weeks. Participants will provide logs of video segment watching (control).
62409234|NCT05552183|EXPERIMENTAL|Severe Hepatic Impairment|Subjects with severe hepatic impairment based on Child-Pugh Class C score of 10-15 will receive 14 days of 200 mg BID pacritinib.
62409235|NCT05552183|EXPERIMENTAL|Normal Hepatic Function|Healthy subjects who have normal hepatic function with age (± 10 years; ≥ 18 years old and ≤ 85 years old), BMI (±20%), and sex, matching with the moderate and severe hepatic impairment cohorts will receive 14 days of 200 mg BID pacritinib.
62409236|NCT03334227|EXPERIMENTAL|High-Flow nasal cannula (HFNC)|"Treatment with HFNC will be adjusted for SpO2 \>92%, even with FiO2 of 0.21, if needed.~The rationale for this HFNC dosage is that minute ventilation can be already reduced with 30 L/min, but functional residual capacity and oxygenation maximally improve at higher flow. On the contrary, flow \>50 L/min is uncomfortable for many patients.~In the case of clinical intolerance, flow will be reduced to 40, 30 or 20 L/min. Yet it is not tolerated, HFNC will be stopped and patients will receive conventional oxygen if required, but will be evaluated as in the HFNC group by intention to treat."
62020414|NCT01354821|OTHER|Open surgical repair|Open surgical repair or aortic replacement with revascularization of visceral arteries
62020415|NCT01540149||ICD implant|
62020416|NCT04563858||Cardiac patients|
62020417|NCT05303987|EXPERIMENTAL|Propofol sedation|2.5 mg/kg loading dose, then continue at an infusion of 250 mcg/kg/minute.
62020418|NCT05303987|EXPERIMENTAL|Dexmedetomidine sedation|1 mcg/kg loading dose, then continue at an infusion of 1 mcg/kg/hour
62020419|NCT04915469|NO_INTERVENTION|Pre-standardization group|Pre intervention- patient level data are abstracted retrospectively from the charts of patients with VL \>1000 copies/ml on demographic characteristics and clinical outcomes and facility level data from summary forms for up to 24 months prior to the implementation of the standardized EAC package.
62020420|NCT04915469|OTHER|Post-standardization group|This group of participants will receive the standardized enhanced adherence package. After implementation of the standardized EAC package, data will be prospectively collected from participants with high viral load (\>1000 copies).
62020421|NCT05101187|ACTIVE_COMPARATOR|Olorofim|Olorofim versus AmBisome followed by Standard of Care (SOC)
62020422|NCT05101187|ACTIVE_COMPARATOR|AmBisome|Olorofim versus AmBisome followed by Standard of Care (SOC)
62213077|NCT02514239|EXPERIMENTAL|Intravenous Infusion of BI 836909 (0.2 μg/d)|
62213078|NCT02514239|EXPERIMENTAL|Intravenous Infusion of BI 836909 (0.4 μg/d)|
62213079|NCT02514239|EXPERIMENTAL|Intravenous Infusion of BI 836909 (0.8 μg/d)|
62213080|NCT02514239|EXPERIMENTAL|Intravenous Infusion of BI 836909 (1.6 μg/d)|
62213081|NCT02514239|EXPERIMENTAL|Intravenous Infusion of BI 836909 (3.2 μg/d)|
62213082|NCT02514239|EXPERIMENTAL|Intravenous Infusion of BI 836909 (6.5 μg/d)|
62213083|NCT02514239|EXPERIMENTAL|Intravenous Infusion of BI 836909 (13 μg/d)|
62409237|NCT03334227|NO_INTERVENTION|Conventional therapy|"Patients assigned to the conventional treatment will receive the standard care given at hospital which consists of adding oxygen on nasal prongs or Venturi mask only if hypoxemia is suggested by SpO2 \< 92% by pulse oximetry.~Target for oxygenation in both arms is SpO2 between 92% and 95%. SpO2 \>95% without oxygen supply is acceptable. On the contrary, SpO2 \<92% may be acceptable when needed for medical reasons, mainly chronic hypercapnic patients."
62409238|NCT04912804||COVID-19 Patient|Patient discharged from a conventional short-stay hospitalization unit.
62409239|NCT03933046|EXPERIMENTAL|children referred to PSG due to suspected SDB|
62409240|NCT02992808|ACTIVE_COMPARATOR|Recombinant preparations|
62409241|NCT02992808|ACTIVE_COMPARATOR|HP-HMG|Highly purified human menopausal gonadotropin
62409242|NCT01569074|EXPERIMENTAL|Dosing A regimen|Oral treatment
62409243|NCT01569074|EXPERIMENTAL|Dosing B regimen|Oral treatment
62409244|NCT01569074|EXPERIMENTAL|Dosing C regimen|Oral treatment
62213084|NCT02514239|EXPERIMENTAL|Intravenous Infusion of BI 836909 (25 μg/d)|
62409245|NCT01569074|EXPERIMENTAL|Dosign D regimen|Oral treatment
62409246|NCT01569074|PLACEBO_COMPARATOR|Dosing E regimen|Oral treatment
62213085|NCT02514239|EXPERIMENTAL|Intravenous Infusion of BI 836909 (50 μg/d)|
62213086|NCT02514239|EXPERIMENTAL|Intravenous Infusion of BI 836909 (100 μg/d)|
62409247|NCT04913311||Observational (biospecimen collection, standard treatment)|Patients undergo collection of blood, stool and saliva samples at baseline. Patients will also have a 6 minute walk and standard of care pulmonary function test at baseline. Patients receive standard of care treatment consisting of concurrent chemoradiation from baseline up to week 10 and immune checkpoint inhibitors from week 10-62. Patients also undergo the collection of blood, stool, saliva and No BAL sample is collected at week 10. During the course of treatment, patients also complete routine tests and procedures to monitor for side effects per standard of care including CT within 4 weeks, lung function tests including home spirometry TIW from week 10-62, bronchoscopy and/or a nasal wash to check for viral infection. Patients also complete questionnaires about symptoms and quality of life QW for weeks 1-10, BIW during weeks 10-62.
62409248|NCT02873195|EXPERIMENTAL|Arm I (atezolizumab, bevacizumab, capecitabine)|Patients receive atezolizumab IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62584465|NCT05017311|PLACEBO_COMPARATOR|Allocation by Predictive Biomarker Algorithm; Placebo|Patients are randomly assigned to the Allocation by Predictive Biomarker Algorithm group. Based on the outcome result from the personalized predictive biomarker algorithm, patients predicted to respond to escitalopram monotherapy will receive open-label escitalopram (10-20 mg/d) and blinded placebo for the first 8 weeks of the study. For the final 4 weeks of the study, responders will continue to receive open-label escitalopram without the placebo and non-responders will receive a combination of open-label escitalopram and open-label brexpiprazole.
62213087|NCT02514239|EXPERIMENTAL|Intravenous Infusion of BI 836909 (200 μg/d)|
62213088|NCT02514239|EXPERIMENTAL|Intravenous Infusion of BI 836909 (400 μg/d)|
62213089|NCT02514239|EXPERIMENTAL|Intravenous Infusion of BI 836909 (800 μg/d)|
62213090|NCT02405728|EXPERIMENTAL|Peripherally inserted central catheters|Peripherally inserted central catheters (PICCs) - Most commonly used vascular access in hematological patients - Randomization between CICCs and PICCs
62735090|NCT00182078|PLACEBO_COMPARATOR|Placebo|Placebo was administered on a flexible fixed schedule and tapered at 12 weeks.
62213091|NCT02405728|ACTIVE_COMPARATOR|Centrally inserted central catheter|Centrally inserted central catheter (CICCs) - New vascular access, with the aim to reduce the complications - Randomization between CICCs and PICCs
62213092|NCT01908192|EXPERIMENTAL|NaBen®|NaBen® is a white oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.
62213093|NCT01908192|PLACEBO_COMPARATOR|Placebo|The control treatment is placebo.
62213094|NCT05791071|EXPERIMENTAL|Floreo VR Building Social Connections|Participants will receive Floreo VR Building Social Connections lessons approximately 3 times a week for no more than 15 minutes per session.
62213095|NCT05791071|SHAM_COMPARATOR|Sham|Participants will receive non-interventional active VR videos approximately 3 times a week for no more than 15 minutes per session.
62213096|NCT00672945|EXPERIMENTAL|PRX-03140|
62213097|NCT00672945|PLACEBO_COMPARATOR|Placebo|
62213098|NCT05335746||Vitiligo patients on therapy|Patients diagnosed as vitiligo and on systemic and local therapy.
62213099|NCT05335746||Control group|Normal subjects recruited from ophthalmology clinic and visit the clinic for regular check-up.
62213100|NCT05630820|EXPERIMENTAL|Bepirovirsen|
62213101|NCT05630820|PLACEBO_COMPARATOR|Placebo|
62213102|NCT04821024||mild-moderate disability|Those whose neck disability index value is 5-34
62790741|NCT04709445|EXPERIMENTAL|ICG-NIRF Imaging and objective perfusion rate|Intraoperatively, ICG-NIRF imaging is used to visualize the blood supply and the rate of tissue perfusion in the area of the anastomotic site. Postoperatively, an additional ingress and egress analysis at specific regions of interest is performed.
62790742|NCT02750319|PLACEBO_COMPARATOR|Amiodarone + Placebo|Amiodarone loading: 150 mg IV in PACU over one hour, then 1.0 gm/24h x 2 + NAC loading matching placebo; 50 mg/kg IV in PACU over one hour, then 50 mg/kg/24h x 2 NAC matched placebo continuously for 48 hours.
62790743|NCT02750319|EXPERIMENTAL|Amiodarone + N-Acetylcysteine|Amiodarone loading: 150 mg IV in PACU over one hour, then 1.0 gm/24h x 2 + NAC loading: 50 mg/kg IV in PACU over one hour, then 50 mg/kg/24h x 2 and then continuously for 48 hours.
62790744|NCT01000259||Ancillary-Correlative|Previously collected tumor tissue samples are analyzed for TIL via immunohistochemistry and double immunofluorescence assays using standard immunostaining.
62213103|NCT04821024||high disability|Those whose neck disability index value is 35 and above
62584466|NCT05017311|ACTIVE_COMPARATOR|Random Allocation; Escitalopram + Brexpiprazole|Patients are randomly assigned to the Random Allocation group and then randomly assigned to receive open-label escitalopram (10-20 mg/d) and blinded brexpiprazole (0.5-2 mg/d) for the first 8 weeks of the study. For the final 4 weeks of the study, patients will continue to receive both medications but the brexpiprazole will no longer be blinded.
62790745|NCT02115763|EXPERIMENTAL|Caffeine|There is only one arm, it receives both caffeine and placebo.
62790746|NCT01883544|EXPERIMENTAL|ALXN1007|Infusion of ALXN1007
62020423|NCT02886845||Chinese Breast Cancers|Woman with breast cancer that have been diagnosed in clinic
62020424|NCT02886845||healthy controls|Woman without breast cancer
62020425|NCT02121145|EXPERIMENTAL|Vivotif + Typherix primary immunization|Vivotif + Typherix primary immunization
62213104|NCT03644303|EXPERIMENTAL|SBRT + ADT|Enzalutamide OR Abiraterone at licensed doses in combination with stereotactic radiotherapy: 30 Gray in 5 fractions
62790747|NCT01883544|PLACEBO_COMPARATOR|placebo|Infusion placebo
62213105|NCT02935660|EXPERIMENTAL|Treatment|Treatment with investigational Cutera enlighten laser for tattoo removal
62409249|NCT02873195|ACTIVE_COMPARATOR|Arm II (placebo, bevacizumab, capecitabine)|Patients receive placebo IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62584467|NCT05017311|PLACEBO_COMPARATOR|Random Allocation; Placebo|Patients are randomly assigned to the Random Allocation group and then randomly assigned to receive open-label escitalopram (10-20 mg/d) and blinded placebo for the first 8 weeks of the study. For the final 4 weeks of the study, responders will continue to receive open-label escitalopram without the placebo and non-responders will receive a combination of open-label escitalopram and open-label brexpiprazole.
62584468|NCT01088672|OTHER|Acute Ischemic Stroke|Single arm post market surveillance study for CE marked mechanical thrombectomy device, Trevo retriever for treatment of eligible patients experiencing acute ischemic stroke Mechanical thrombectomy intervention for all subjects in Acute Ischemic Stroke
62584469|NCT04241250|EXPERIMENTAL|EAW+SCES|Three months of exoskeleton training followed by 6 months of epidural stimulation.
62584470|NCT04241250|EXPERIMENTAL|EAW+TS|Three months of exoskeleton training followed by 6 months of transspinal stimulation.
62584471|NCT01372488|ACTIVE_COMPARATOR|Study group|Study group will be provided with suture removal instructions and suture removal kit and asked to consider removing their own sutures
62584472|NCT01372488|PLACEBO_COMPARATOR|Control group|Control group will be asked to have their sutures removed as they normally would (see family doctor or clinic)
62584473|NCT00986128|EXPERIMENTAL|001|
62020426|NCT02121145|EXPERIMENTAL|Vivotif booster|Volunteers previously immunized with Vivotif, now receiving a Vivotif secondary immunization
62020427|NCT02121145|EXPERIMENTAL|Typherix booster|Volunteers previously immunized with Typherix, now receiving a Typherix secondary immunization
62020428|NCT02121145|EXPERIMENTAL|Vivotif + Typherix booster|Volunteers previously immunized with Vivotif and Typherix, now receiving Vivotif and Typherix as secondary immunization
62213106|NCT03593551|EXPERIMENTAL|relaxation and control|All participants will attend five relaxation treatments and one control. The order of treatments and control will be randomised allocated to participants.
62213107|NCT06132438|EXPERIMENTAL|Glioblastoma|
62213108|NCT05079568|EXPERIMENTAL|Active VR Group|"Subjects will be provided an Oculus Go VR headset pre-loaded with a menu of virtual reality programs which have been designed specifically to treat both acute and chronic pain. Subjects are required to use the VR headset at home four times daily, prior to breakfast, lunch, dinner, and bedtime. Each session will last approximately 15 minutes."
62213109|NCT05079568|SHAM_COMPARATOR|Sham VR Group|Subjects will be provided an Oculus Go VR headset pre-loaded two-dimensional nature video. Subjects are required to use the VR headset at home four times daily, prior to breakfast, lunch, dinner, and bedtime. Each session will last approximately 15 minutes.
62213110|NCT02521987|ACTIVE_COMPARATOR|8mm Port|Participates will be randomized to have an 8 mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
62213111|NCT02521987|EXPERIMENTAL|12mm Port|Participates will be randomized to have an 12mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
62213112|NCT02643303|EXPERIMENTAL|Phase 1, Cohort 1A|Subjects received durvalumab (1500 mg IV every 4 weeks \[Q4W\] for 12 cycles). Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3.
62213113|NCT02643303|EXPERIMENTAL|Phase 1, Cohort 1B|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (75 mg IV Q4W for the first 4 cycles).~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
62020429|NCT04427280||Arm A|Suspected acute COVID-19 infection
62020430|NCT04427280||Arm B|Asymptomatic patients with no clinical suspicion of COVID-19
62020431|NCT06534736|EXPERIMENTAL|Post Facilitation Stretch Group|"Treatment protocol given to both groups will be carried out for 3 sessions per week for 4 weeks.~It will comprise of hot pack for 10 minutes, Tens for 10 minutes. Participants will be instructed to maintain the contraction for 6 to 10 seconds and then relax the muscles as quickly as possible.The stretch will be held for 15 seconds in an attempt to lengthen the shortened facscial structures.The muscles which will be targeted are Levator Scapular Upper Trapezius Sternocleidomastoid scalene Pectoralis Muscles"
62020432|NCT06534736|EXPERIMENTAL|Stabilization Exercises along with the PFS Group|It will comprise of hot pack for 10 minutes, Tens for 10 minutes. Participants will be instructed to maintain the contraction for 6 to 10 seconds and then relax the muscles as quickly as possible.The stretch will be held for 15 seconds in an attempt to lengthen the shortened facscial structures.The muscles which will be targeted are Levator Scapular Upper Trapezius Sternocleidomastoid scalene Pectoralis Muscles Scapular Stabilization exercises protocol will be carried out in 4 weeks , 3 sessions per week. Scapular wall slide exercise will be carried out with body weight .Scapular retraction with body weight. Wall Ball Circle exercise with body weight for the first two weeks and then with dumbbells for the next two weeks. Scapular Squeeze again with the body weight and dumbbells. Wall press ups will be performed. Post Facilitation stretch of the targeted muscles also will be carried out during the sessions
62584474|NCT00986128|EXPERIMENTAL|002|
62020433|NCT05819749|EXPERIMENTAL|DH-Spanish Intervention|Behavioral treatment by a diabetes wellness coach.
62020434|NCT01411189|OTHER|Menthol|20 mL NPO-11
62020435|NCT02270580|EXPERIMENTAL|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
62213114|NCT02643303|EXPERIMENTAL|Cohort 1C + Phase 2; Head + Neck Squamous Cell Carcinoma|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (10 mg) intratumorally on days 1, 8, and 15 of Cycle 1, days 1 and 15 of Cycle 2 and day 1 of Cycles 3 and 4.~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
62213115|NCT02643303|EXPERIMENTAL|Cohort 1C + Phase 2; Locally Recurrent or Metastatic Breast Cancer|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (10 mg) intratumorally on days 1, 8, and 15 of Cycle 1, days 1 and 15 of Cycle 2 and day 1 of Cycles 3 and 4.~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
62213116|NCT02643303|EXPERIMENTAL|Cohort 1C + Phase 2; Sarcoma|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (10 mg) intratumorally on days 1, 8, and 15 of Cycle 1, days 1 and 15 of Cycle 2 and day 1 of Cycles 3 and 4.~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
62213117|NCT02643303|EXPERIMENTAL|Cohort 1C + Phase 2; Merkel Cell Carcinoma|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (10 mg) intratumorally on days 1, 8, and 15 of Cycle 1, days 1 and 15 of Cycle 2 and day 1 of Cycles 3 and 4.~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
62213118|NCT02643303|EXPERIMENTAL|Cohort 1C + Phase 2; Cutaneous T-cell Lymphoma|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (10 mg) intratumorally on days 1, 8, and 15 of Cycle 1, days 1 and 15 of Cycle 2 and day 1 of Cycles 3 and 4.~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
62213119|NCT02643303|EXPERIMENTAL|Cohort 1C + Phase 2; Melanoma After Failure of Available Therapies|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (10 mg) intratumorally on days 1, 8, and 15 of Cycle 1, days 1 and 15 of Cycle 2 and day 1 of Cycles 3 and 4.~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
62213120|NCT02643303|EXPERIMENTAL|Cohort 1C + Phase 2; Genitourinary Cancers with Accessible Metastases|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (10 mg) intratumorally on days 1, 8, and 15 of Cycle 1, days 1 and 15 of Cycle 2 and day 1 of Cycles 3 and 4.~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
62215244|NCT03466073|EXPERIMENTAL|Multiple Dose 12 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 12 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
62584475|NCT00006483|EXPERIMENTAL|aerosolized sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) by nebulizer over 10-15 minutes twice daily on days 1-7 and 14-21. Treatment repeats every 28 days in the absence of disease progression or unaceptable toxicity.~Patients are followed for disease progression and then every 3 months thereafter."
62020436|NCT02270580|ACTIVE_COMPARATOR|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
62735091|NCT00182078|EXPERIMENTAL|Sertraline|Sertraline was administered on a flexible fixed schedule beginning at 25 mg/day and increasing as high as 150 mg/day. At week 12, the medication was tapered at a rate of 25 mg every 3 days until it was discontinued.
62213121|NCT02643303|EXPERIMENTAL|Cohort 1C + Phase 2; Solid Tumors with Accessible Masses|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (10 mg) intratumorally on days 1, 8, and 15 of Cycle 1, days 1 and 15 of Cycle 2 and day 1 of Cycles 3 and 4.~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
62213122|NCT06131489||EBV-HLH patients with intestinal involvement|Epstein-Barr virus associated hemophagocytic lymphohistiocytosis patients with imaging confirmed intestinal involvement
62213123|NCT03437681|EXPERIMENTAL|Insufficient sleep|Each participant will receive 4 nights of insufficient sleep.
62213124|NCT04540887|EXPERIMENTAL|Treatment|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (whole body mat), B. Pad (targeted pelvic mat), and Control Unit. The participant will lay the B. Body mat on any flat surface (i.e. floor, bed, reclining chair, etc.) and lie down on the mat with the smaller B. Pad placed directly over their pelvic area. Then, the participant will turn the PEMF device on using the attached control unit, which has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a four-week period. As this is a single-group assignment, all participants will be given the PEMF device.
62213125|NCT02323178|EXPERIMENTAL|eltrombopag|
62213126|NCT04164121|EXPERIMENTAL|FLZ-150mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 150mg each time from day 8 to day 17.
62213127|NCT04164121|PLACEBO_COMPARATOR|FLZ-150mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 150mg each time from day 8 to day 17.
62213128|NCT04164121|EXPERIMENTAL|FLZ-600mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 600mg each time from day 8 to day 17.
62213129|NCT04164121|PLACEBO_COMPARATOR|FLZ-600mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 600mg each time from day 8 to day 17.
62213130|NCT04164121|EXPERIMENTAL|FLZ-900mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 900mg each time from day 8 to day 17.
62213131|NCT04164121|PLACEBO_COMPARATOR|FLZ-900mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 900mg each time from day 8 to day 17.
62213132|NCT03026127|EXPERIMENTAL|CRISP|Cognitive Reappraisal Intervention for Suicide Prevention (CRISP) is a psychosocial intervention aimed to reduce suicide risk in middle-aged and older adults who have been hospitalized for suicidal ideation or suicide attempt. CRISP offers a combination of emotion regulation techniques, including changing the subject's perspective or the way he/she thinks to improve emotion reactions. Additional strategies taught include the provision of environmental adaptation tools (notes, checklists, calendars, etc), phone calls, and a tablet application called WellPATH.
62213133|NCT03026127|ACTIVE_COMPARATOR|Supportive Therapy (ST)|Supportive Therapy focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
62213134|NCT02894567|EXPERIMENTAL|spiderSTN|It is an Intraoperative test during a deep brain stimulation surgery. The spiderSTN lead is implanted in a selected track in the brain, and is tested for stimulation and recording.
62213135|NCT03014011|OTHER|Hypoglycaemic clamp first, then euglyceamic clamp|First intervention with a hypoglycaemic clamp (one examination day of approximately 5 hours), there after a wash out period of 21-42 days, then second and final intervention day with an euglycaemic clamp (approximately 5 hours).
62213136|NCT03014011|OTHER|Euglycaemic clamp first, then hypoglycaemic clamp|First intervention with an euglycaemic clamp (one examination day of approximately 5 hours), there after a wash out period of 21-42 days, then second and final intervention day with a hypoglycaemic clamp (approximately 5 hours).
62213137|NCT03654521|ACTIVE_COMPARATOR|Diabetes group|Women with gestational or pre-gestational diabetes mellitus.
62213138|NCT03654521|ACTIVE_COMPARATOR|Control group|Women without gestational or pre-gestational diabetes mellitus.
62213139|NCT02902939|NO_INTERVENTION|Uncomplicated cardiac surgery patients|Patients after scheduled cardiac surgery procedures
62213140|NCT02902939|ACTIVE_COMPARATOR|Complicated cardiac surgery patients|MECC systems Cytokines modulation by CytoSorb and PMMA membranes
62213141|NCT01877239||Full Analysis Set|Full Analysis Set (FAS): The FAS contains any patient that has given written informed consent.
62213142|NCT04201340||Subjects Presenting with Normal Eyes|Subjects with no known ocular diseases will be imaged on the DRI OCT Triton with SS-OCT Angio software, Zeiss Cirrus HD-OCT 5000, and TRC-50DX
62213143|NCT04201340||Subjects with retinal pathology present in the vasculature|Subjects with retinal pathology likely to present in the vasculature will be imaged on the DRI OCT Triton with SS-OCT Angio software, Zeiss Cirrus HD-OCT 5000, and TRC-50DX
62213144|NCT02240459|EXPERIMENTAL|Fesoterodine 4mg daily|fesoterodine 4mg oral
62213145|NCT02240459|EXPERIMENTAL|Fesoterodine 8mg|Fesoterodine 8mg in form of 2, 4mg tablets
62790748|NCT03197922|EXPERIMENTAL|MIE Treatment for Two Weeks|Participants in this arm will receive the Multidisciplinary Intervention for Encopresis (MIE) for two weeks. MIE consists of daily clinic appointments, each of which lasts until a continent bowel movement occurs or 3 hours elapse. These participants will discontinue the use of medication previously prescribed for the treatment of constipation, other than the suppositories used in the MIE treatment. During MIE, medical professionals resolve any constipation and oversee a regimen of over the counter medications that increase the predictability of a bowel movement.
62213146|NCT02240459|ACTIVE_COMPARATOR|oxybutynin|oxybutynin immediate release, encapsulated 2, 5mg capsules daily
62409250|NCT01991600|ACTIVE_COMPARATOR|Ferrous Sulphate|The active comparator was the standard-of-care therapy for iron deficiency anaemia (namely ferrous sulphate). Generic uncoated ferrous sulphate tablets BP 300 mg containing 60mg elemental iron were purchased from a local pharmacy. The route of administration was oral. Each participant ingested one ferrous sulphate tablet (60 mg Fe) on one of the study visits.
62409251|NCT01991600|EXPERIMENTAL|ferric iron oxide-organic acid (Fe-OA)|Fifteen different ferric iron oxide-organic acid preparations were investigated. Most organic acids used were generally recognised as safe (GRAS) and all were used at dietary equivalent levels. The dosage was 58 ± 6 mg elemental iron equivalent (average of all compounds). The route of administration was oral using methyl-cellulose capsules. On one of the study visits, each participant ingested a single dose, equivalent to ca. 60 mg iron, of the Fe-OA preparation allocated to her.
62409252|NCT05727865|EXPERIMENTAL|Online CBT following cardiac surgery|The treatment lasts for five weeks and will be provided as an early intervention following cardiac surgery ≥ eight weeks to nine months before assessment. The intervention is psychologist-guided (clinical psychologist and/or resident psychologist under supervision) and delivered via text-based interactive online treatment modules, where patients complete weekly homework assignments and have regular online contact with psychologists with training in CBT for cardiac disease.
62790749|NCT03197922|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Participants randomized to the Treatment as Usual (TAU) group will continue to receive outpatient medical treatment of encopresis according to best practice guidelines by the pediatric gastroenterologist. Additionally, participants in the TAU group will receive a 2-hour long individual appointment with a doctoral level clinician with extensive experience in behavioral treatments for encopresis.
62213147|NCT02240459|PLACEBO_COMPARATOR|placebo capsule|placebo capsule, 2 per day
62213148|NCT01891201||Not exposed to oxytocin|Mother-child dyads in which Oxt had not been administered during the birth process
62409253|NCT06179186|EXPERIMENTAL|Intense Pulsed Light|The hair from axilla of one side of the body will be removed with 4 sessions of Intense Pulsed Light
62409254|NCT06179186|EXPERIMENTAL|Diode laser|The hair from axilla of one side of the body will be removed with 4 sessions of Diode Laser
62409255|NCT06609252|EXPERIMENTAL|breast milk smell|On the day of the study, the mothers of the babies will be contacted and fresh breast milk will be obtained from the mother of each baby. In the study, a sterile sponge will be used to smell the breast milk to the baby. Breast milk will be taken as 2 ml, dripped onto a sterile sponge and held 10 cm away from the baby's nose and sniffed 2 minutes before the examination.
62409256|NCT06609252|EXPERIMENTAL|mother's voice|Mothers of premature babies in the mother voice group will be given a voice recorder on the day of the study and will be encouraged to express their feelings and thoughts and say what they want to say to their babies and will be asked to talk to their babies as they wish. The mother's voice, which is recorded 2 minutes before the procedure, will be placed approximately 30 cm away from the baby's ear and a loudspeaker will be placed at the foot end so that the baby can listen to the sound. The American Academy of Paediatrics recommends a sound level of 45-50 dB for premature babies. Therefore, the sound level will be measured with a decibel meter and set to 50 dB.
62409257|NCT06609252|NO_INTERVENTION|control|In the guideline prepared jointly by the Turkish Neonatology Association and the Turkish Society of Ophthalmology in 2021, it is recommended that the baby should be held by a nurse in such a way that the baby's head and arms are fixed, and the baby's hands and feet should be gently flexed or loosely swaddled during the retinopathy examination. Within the routine practice of the clinic, the babies in the control group are held.
62735092|NCT04586452|EXPERIMENTAL|AAA Group (Aim 3A)|40 (20 men; 20 women) participants with a diagnosis of AAA (above 40 years) will undergo a PET/CT scan prior to their scheduled surgical repair of their condition. The radiotracer, 64Cu-DOTA-ECL1i, will be injected to detect CCR2+ inflammatory cells. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
62213149|NCT00477659|EXPERIMENTAL|Donepezil hydrochloride|
62213150|NCT06478342||Prospective cohort|Non-paroxysmal AF patients
62213151|NCT03024905|EXPERIMENTAL|Division 1|"The first division receives baseline data collection for 6 months then experiences interventions for the remainder of the trial.~Interventions are behavioural and device:~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
62215245|NCT03466073|EXPERIMENTAL|Multiple Dose 24 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 24 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
62215246|NCT05457465|EXPERIMENTAL|Hemp-Derived Cannabidiol Solution|Patients will administer a custom-formulated, hemp-derived, high-CBD solution twice daily for 4 weeks
62409258|NCT06510114|EXPERIMENTAL|Group A|The daily scheme was as follows: 0.5 g methylprednisolone i.v. daily for 5 consecutive days, followed by oral prednisone for 6 months. Oral prednisone started at 40 mg/day for 4 weeks and then the dose was tapered by 5 mg/day every 2-4 weeks.
62213152|NCT03024905|EXPERIMENTAL|Division 2|"The second division receives baseline data collection for 9 months then experiences interventions for the remainder of the trial.~Interventions are behavioural and device:~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
62213153|NCT03024905|EXPERIMENTAL|Division 3|"The third division receives baseline data collection for 12 months then experiences interventions for the remainder of the trial.~Interventions are behavioural and device:~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
62213154|NCT03024905|EXPERIMENTAL|Division 4|"The fourth division receives baseline data collection for 15 months then experiences interventions for the remainder of the trial.~nterventions are behavioural and device: Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
62790750|NCT03197922|EXPERIMENTAL|MIE Treatment for One Week|Participants in this arm will receive the Multidisciplinary Intervention for Encopresis (MIE) for one week. This study arm was discontinued in October 2019.
62790751|NCT05194930|EXPERIMENTAL|The ABC of Insomnia (Acceptance and the Behavioral Changes to|This is the new treatment arm that is being compared to CBT-I, standard treatment for insomnia.
62790752|NCT05194930|ACTIVE_COMPARATOR|Cognitive-Behavioral Therapy for Insomnia|This is the standard treatment for insomnia that is being compared to the new treatment (ABCI).
62790753|NCT03743116||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure \> 20 mmHg and/or diastolic pressure \> 10 mmHg) during mobilisation
62790754|NCT03743116||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure \> 20 mmHg and/or diastolic pressure \> 10 mmHg) during mobilisation
62790755|NCT03968835||Biological Dressings|Bacitracin will be applied and covered with xeroform and gauze
62790756|NCT03968835||Artificial Dressings|the amputated composite skin and soft tissue unit will be thinned out to become a full thickness skin graft
62790757|NCT02531724|ACTIVE_COMPARATOR|Levosimendan|Levosimendan will be given as a loading dose of 12 ug/kg during 30 minutes, and then a continuous infusion of 0,1 ug/kg/min for 180 minutes.
62790758|NCT02531724|PLACEBO_COMPARATOR|Placebo|Sodium chloride will be given as a loading dose during 30 minutes and then a continuous infusion for 180 minutes at a rate mimicking the levosimendan group above.
62790759|NCT04878965|OTHER|Smartwatch|Individuals receiving the smartwatch
62790760|NCT02771197|EXPERIMENTAL|Lymphodepletion plus Pembrolizumab|Fludarabine \& Melphalan followed by autologous stem cell transplantation. Pembrolizumab will begin on Day +1.
62790761|NCT05323474|EXPERIMENTAL|Standard rehabilitation|Classical rehabilitation carried out by a physiotherapist with an evaluation at 6 months post-surgery to authorize the return to sport.
62790762|NCT05323474|ACTIVE_COMPARATOR|Optimized rehabilitation|Classical rehabilitation carried out by a physiotherapist + expert physiotherapist performing monthly clinical and functional assessments with recommendations for exercises and running program sent to the physiotherapist.
62213155|NCT00386282|OTHER|mifepristone-misoprostol treatment|200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone
62213156|NCT02245633||vitamin D levels deficient|Diabetic hemodialysis patients with vitamin D levels deficient
62213157|NCT02245633||vitamin D levels sufficient|Diabetic hemodialysis patients with vitamin D levels sufficient
62213158|NCT03148444|EXPERIMENTAL|Antibiotics treated|Patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) in our institution will be discharged home with recommendations to take antibiotic treatment for 5 days following the procedure (cefalexin 500 mg qid, or in the presence of beta-lactam sensitivity roxithromycin 150 mg bid)
62213159|NCT03148444|NO_INTERVENTION|without Antibiotics Treatment|Patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) in our institution will be discharged home with no recommendations regarding antibiotic treatment.
62409259|NCT06510114|ACTIVE_COMPARATOR|Group B|The weekly protocol was as follows: 0.5 g methylprednisolone i.v. weekly for 6 weeks and then the dose was tapered by 0.25 g/week over the following 6 weeks.
62409260|NCT03136978||Endometriosis|Patients affected by endometriosis (histologically confirmed) at different stages, who will undergo laparoscopic surgery.
62409261|NCT03136978||Ovarian functional cysts|Patients affected by ovarian functional cysts, who will undergo laparoscopic surgery.
62409262|NCT00295919|EXPERIMENTAL|Single Group|
62790763|NCT03871699|EXPERIMENTAL|Iron Reposition|The selected patients will receive 1g of ferric carboxymaltose applied intravenously after dilution in 100ml of crystalline solution. the infusion time will be around 15 minutes realized at the moinhos the vento infusion center.
62790764|NCT04653194|EXPERIMENTAL|Biktarvy treatment|First-line HIV treatment of Biktarvy OD for 48 weeks
62790765|NCT04653194|ACTIVE_COMPARATOR|Symtuza treatment|First-line HIV treatment of Symtuza OD for 48 weeks
62790766|NCT04677010|NO_INTERVENTION|Run-in period, patients with cerebral palsy or muscular dystrophy|10 weeks of no exercise
62790767|NCT04677010|ACTIVE_COMPARATOR|Exercise period, patients with cerebral palsy or muscular dystrophy|10 weeks of exercise
62584476|NCT06101641|OTHER|EXPERIMENTAL AND CONTROL GROUP|Participants who meet the inclusion criteria of the study will be informed about the research by the researchers and will be included in the study on a voluntary basis and their written permissions will be obtained. Firstly, the personal information of the participants will be recorded in the data collection form. The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the shellac nail polish is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant and recorded in the data form. At the end of the study, SpO2 and pulse values before and after the shellac nail polish application will be compared.
62790768|NCT05433922|EXPERIMENTAL|CSA + Avatrombopag|cyclosporine 3 mg/kg orally in two doses, with cyclosporine trough concentrations maintained at 200-250 ng/ml for 3 months to achieve maximum efficacy and then tapered by 25 mg every 3 months; Avatrombopag: two dosing groups, 40 mg orally once daily and 60 mg orally once daily, for a total of 24 weeks.If the 40 mg dose group trial meets the desired trial objectives, the 60 mg dose group trial will not be conducted.
62213160|NCT03051789|EXPERIMENTAL|Menstrual Cup|One menstrual cup (Mooncup®), an insertable menstrual hygiene product, together with handwash soap termly; puberty and hygiene education and cup training given at intervention.
62213161|NCT03051789|EXPERIMENTAL|Cash Transfer|Cash transfer (CT; girls' pocket money; of Ksh 1500 per term) via local community/mobile banking with financial literacy, puberty and hygiene education and cash pocket money financial literacy training given at intervention.
62213162|NCT03051789|EXPERIMENTAL|Cups and Cash|A combination of cup and cash transfer interventions; puberty and hygiene education, cup training, and cash pocket money financial literacy training given at intervention.
62213163|NCT03051789|NO_INTERVENTION|Control|'Usual practice' (control) with handwash soap termly; puberty and hygiene education given at intervention.
62213164|NCT05807529|EXPERIMENTAL|2ccPA|IP name: 2-carba-cyclic phosphatidic acid (2ccPA)
62213165|NCT05807529|PLACEBO_COMPARATOR|placebo|Placebo
62213166|NCT04069481|EXPERIMENTAL|Dance intervention|Participants will receive a 1-hour group dance class twice a week for 12 weeks. Classes will include a seated warm up, dance exercises in standing, dance activities moving across the floor, throughout the space and conclude with a bow exercise. Music and dance styles will vary and personal preference of participants will also be taken into account.
62213167|NCT04069481|ACTIVE_COMPARATOR|Exercise and mindfulness meditation|Participants will receive a 1-hour group exercise class twice a week for 12 weeks. Classes will include resistance training exercises with resistance bands, stretching and range of motion exercises in seated and standing positions. Classes will also include mindfulness exercises. During active exercises music will be played and personal preference of participant will be taken into account.
62790769|NCT00959595|EXPERIMENTAL|EMLA cream|
62790770|NCT00959595|PLACEBO_COMPARATOR|Placebo cream|A placebo cream identical in appearance and consistency to the experimental cream
62790771|NCT00473200|ACTIVE_COMPARATOR|S-adenosylmethionine|S-adenosylmethionine
62790772|NCT00473200|PLACEBO_COMPARATOR|Placebo|Placebo
62790773|NCT05977673|EXPERIMENTAL|Tislelizumab|Tislelizumab single dose every 3 weeks up to 35 total administration
62790774|NCT02687139|EXPERIMENTAL|18F-DCFPyL PET/CT|
62790775|NCT02457156|EXPERIMENTAL|Blumgart Anastomosis|"Re-construction of the pancreatic remnant following pancreatico-duodenectomy using a Blumgart method of pancreatico-jejunostomy.~Octreotide will be administered."
62213168|NCT04554043|EXPERIMENTAL|SHR7280 dose 1(male)|oral administration for 14 days,Phase I(PART 1)
62213169|NCT04554043|EXPERIMENTAL|SHR7280 dose 2(male)|oral administration for 14 days,Phase I(PART 1)
62213170|NCT04554043|EXPERIMENTAL|SHR7280 dose 3(male)|oral administration for 14 days,Phase I(PART 1)
62213171|NCT04554043|EXPERIMENTAL|SHR7280 dose 4(male)|oral administration for 14 days,Phase I(PART 1)
62213172|NCT04554043|EXPERIMENTAL|SHR7280 dose 5(male)|oral administration for 14 days,Phase I(PART 1)
62213173|NCT04554043|EXPERIMENTAL|SHR7280 dose 1(female)|oral administration for 21 days,Phase I(PART 2)
62213174|NCT04554043|EXPERIMENTAL|SHR7280 dose 2(female)|oral administration for 21 days,Phase I(PART 2)
62213175|NCT04554043|EXPERIMENTAL|SHR7280 dose 3(female)|oral administration for 21 days,Phase I(PART 2)
62213176|NCT04554043|EXPERIMENTAL|SHR7280 dose 4(female)|oral administration for 21 days,Phase I(PART 2)
62213177|NCT04554043|EXPERIMENTAL|SHR7280 dose 6(male)|oral administration for 14 days,Phase I(PART 1)
62790776|NCT02457156|ACTIVE_COMPARATOR|Cattell-Warren Anastomosis|"Re-construction of the pancreatic remnant following pancreato-duodenectomy using a Cattell-Warren method of pancreatico-jejunostomy.~Octreotide will be administered."
62020437|NCT04844424|EXPERIMENTAL|Part 1A: Treatment Sequence ABC|Participants will receive a single oral Dose 1 of milvexian as direct compression (DC) tablets under fasting conditions (Treatment A) in Treatment Period 1, followed by a single oral Dose 1 of milvexian as roller compacted (RC) tablets under fasting conditions (Treatment B) in Treatment Period 2 and then a single oral Dose 1 of milvexian Phase 2 oral capsules under fasting conditions (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62213178|NCT04554043|EXPERIMENTAL|SHR7280 dose 7(male)|oral administration for 14 days,Phase I(PART 1)
62213179|NCT03497416||Anemic|
62213180|NCT03497416||Non-anemic|
62213181|NCT06323551|EXPERIMENTAL|Mother's Smell|In the study group that will be made to smell the mother's scent; The mother of each baby whose heel blood will be taken will be given a specially made cover made of 100% cotton yarn, sterilized the day before, and the mother will be asked to put the cover on her bare skin (on her bare skin) after the shower and to keep the cover on the mother's chest for one night (8 hours). one). It will be placed 15 cm away from the baby and smelled 5 minutes before and 5 minutes after the heel prick attempt (1,4). The baby's pain score will be evaluated by the observing nurse according to the NIPS pain scale 5 minutes before, during and 5 minutes after the procedure.
62213182|NCT06323551|EXPERIMENTAL|Mother's Breast Milk Smell|In the study group that will be made to smell the scent of breast milk, the procedures for the scent of the mother will be carried out in the same way, and 20 drops of each baby's own mother's milk will be dropped onto the diaper (4). The cover, which has the scent of breast milk, will be placed 15 cm away from the baby and allowed to smell it from 5 minutes before to 5 minutes after the heel prick blood collection attempt. The baby's pain score will be evaluated by the observing nurse according to the NIPS pain scale 5 minutes before, during and 5 minutes after the procedure.
62213183|NCT06323551|NO_INTERVENTION|Control|Routine care will be provided to the control group and no intervention will be applied.
62213184|NCT01767571|EXPERIMENTAL|A(reference)/B(test)|initial administration of reference and cross-over to test
62213185|NCT01767571|EXPERIMENTAL|B(test)/A(reference)|initial administration of test and cross-over to reference
62213186|NCT05599841|ACTIVE_COMPARATOR|Povidone Iodine Solution|The group whom PI solution will be used at surgery
62213187|NCT05599841|PLACEBO_COMPARATOR|Saline Solution|The group whom only saline solution will be used at surgery
62213188|NCT01428232|EXPERIMENTAL|BFHI steps 1-9|Hospital retrained in BFHI steps 1-9 Mothers can call hospital to obtain BF support/Mothers given phone # of maternity nurse whom she can call or go see if she has BF problems
62213189|NCT01428232|EXPERIMENTAL|BFHI steps 1-9 +well-child clinic|Hospital retrained in BFHI steps 1-9 Mothers can call hospital to obtain BF support/Mothers given phone # of maternity nurse whom she can call or go see if she has BF problems Provision of BF support during 1) clinic visit to obtain birth certificate or home visit if mother does not come into clinic and 2) well-child clinics Flyers to mother with culturally appropriate messages designed to address some of the most important local barrier to EBF
62213190|NCT01428232|NO_INTERVENTION|usual care|
62020438|NCT04844424|EXPERIMENTAL|Part 1A: Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020439|NCT04844424|EXPERIMENTAL|Part 1A: Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020440|NCT04844424|EXPERIMENTAL|Part 1A: Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62213191|NCT02505386|ACTIVE_COMPARATOR|Ertapenem IV|IV administration of ertapenem
62213192|NCT02505386|EXPERIMENTAL|Ertapenem SC|SC administration of ertapenem
62213193|NCT05022901|EXPERIMENTAL|Melphalan/HDS|Eligible patients will be treated with Melphalan/HDS 3.0 mg/kg Ideal Body Weight (IBW). Melphalan/HDS treatment will be administered every 6 weeks for a total of 6 cycles with an acceptable delay of another 2 weeks before the next planned treatment to allow for recovery of melphalan-related toxicity, if needed.
62213194|NCT01597609|EXPERIMENTAL|Cohort A|- 600 Kcal deficit, Sibutramine placebo
62213195|NCT01597609|EXPERIMENTAL|Cohort B|- 600 Kcal deficit, Sibutramine 10 mg once daily
62213196|NCT01597609|EXPERIMENTAL|Cohort C|- 600 Kcal deficit, Moderate exercise (The energy expenditure will be equivalent to 30 minutes of brisk walking/5 times week i.e. \~1,000 Kcal/week) /sibutramine placebo
62213197|NCT02214056||The study population|"There is only one group in this study. Please see the inclusion/exclusion criteria.~Intervention: Patient recruitment Intervention: Mobile team exam"
62213198|NCT00288184|EXPERIMENTAL|Allopurinol|Hypertensive children received both placebo and allopurinol in a cross over design.
62213199|NCT00288184|PLACEBO_COMPARATOR|Placebo|
62213200|NCT03078543|OTHER|ANTHEM™ PS Total Knee System implant|The ANTHEM™ PS Total Knee System will demonstrate non-inferiority of 10 year implant survivorship in patients undergoing total knee arthroplasty for osteoarthritis compared to reported literature
62213201|NCT03599609|EXPERIMENTAL|Treatment|Treatment: Simvastatin 40mg/day
62213202|NCT03723252|EXPERIMENTAL|Dapagliflozin group|Participants will receive dapagliflozin 10mg po qd.
62213203|NCT03723252|PLACEBO_COMPARATOR|Placebo group|Participants will receive placebo po qd.
62409263|NCT03955016|EXPERIMENTAL|Rehabilitation group|15 weeks pulmonary rehabilitation program consisting of 2 weeks inpatient, 2 weeks outpatient and 11 weeks home-based rehabilitation.
62409264|NCT03955016|NO_INTERVENTION|Control group|Usual care
62409265|NCT04457323|EXPERIMENTAL|Test|S-Metoprolol XR 25 mg Film Coated Tablets (first four weeks) S-Metoprolol XR 50 mg Film Coated Tablets (second four weeks)
62409266|NCT04457323|ACTIVE_COMPARATOR|REFERENCE|Beloc® (Metoprolol) Zok 50 mg Controlled Release Film Tablets (first four weeks) Beloc® (Metoprolol) Zok 100 mg Controlled Release Film Tablets (second four weeks)
62409267|NCT05459012||pregnant women with asthma|
62409268|NCT06650917|EXPERIMENTAL|experiment group|
62409269|NCT06650917|ACTIVE_COMPARATOR|control group|
62409270|NCT00877799|EXPERIMENTAL|CR845|CR845 administered as a single 15-min i.v. infusion at doses of 0.008 or 0.024 mg/kg on the day after surgery (Cohort 1), or at a dose of 0.040 mg/kg immediately after surgery (Cohort 2)
62409271|NCT00877799|PLACEBO_COMPARATOR|Placebo|Matched placebo administered as a single 15-min i.v. infusion on the day after surgery (Cohort 1), or the immediately after surgery (Cohort 2)
62409272|NCT06173882|PLACEBO_COMPARATOR|Ordinary moxibustion volume group|
62409273|NCT06173882|EXPERIMENTAL|First group of heavy moxibustion|
62409274|NCT06173882|EXPERIMENTAL|Second groups of heavy moxibustion|
62409275|NCT05309993|ACTIVE_COMPARATOR|Posterior Tibial Nerve Stimulation (PTNS)|Women randomized to the PTNS will be scheduled for sessions once weekly for 30 minutes, for 12 weeks total. The patient sits reclined with their legs elevated on a foot rest. After alcohol swab, a 34 gauge needle is inserted percutaneously 5 cm cephalad to the medial malleolus of the right or left ankle (patient's choice) at a 60 degree angle. A surface electrode is placed on the medial ipsilateral heel. The needle and electrode are connected to a low voltage (9V) electrical stimulator. Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 μsec is increased until flexion of the big toe or fanning of all toes visualized, or until the woman reports a tingling sensation across the heel or sole of the foot. The current is then set to the highest level of tolerable to the patient (0-10 mA) and then she undergoes therapy for 30 minutes.
62409276|NCT05309993|EXPERIMENTAL|Home transcutaneous electrical nerve stimulation (TENS)|"Women randomized to the TENS group will be asked to purchase a TENS 7000 device (estimated cost $30) and will administer self-treatment at home, daily for 20 minutes, for 12 weeks total.~TENS treatment will be performed as follows (adapted from the most common setting from a s systematic review of TENS for OAB):~- Surface electrodes, 2 x 2 in diameter, will be placed 5 cm cephalad to the medial malleolus of the right or left ankle (patient's choice). The second surface electrode is placed on the medial aspect of the ipsilateral calcaneus. The electrodes are connected to the TENS device with pre-set settings.~Women will complete 20-minute daily TENS treatment for 12 weeks total."
62409277|NCT03676439|ACTIVE_COMPARATOR|Treated Arm: Magnetic Spinal Stimulation plus PKT|Three months of kinesthetic and phoniatric treatment, and Magnetic Spinal Stimulation, 80% of the cervical muscles's motor threshold, 100 pulses at 10Hz, lasting 10 seconds, repeated during 30 minutes, twice a week for 3 months on cervical lateral location, focalized on the Lateral Spinal Cord.
62409278|NCT03676439|PLACEBO_COMPARATOR|Sham comparator|They will receive kinesthetic and phoniatric treatment, and during 3 months,with equal periodicity, they will receive a sensible false magnetic stimulation, of equal localization that other arm, with insufficient intensity, to blind clinical experience.
62409279|NCT05090046||Christchurch Health and Development Study (CHDS)|The Christchurch Health and Development Study (CHDS) is a birth cohort study comprising 1265 people born in Christchurch in 1977. Participants have been followed to age 40, with 75-80% retention at data collection points.
62790777|NCT04043572||Participants with Epilepsy|This group comprises pregnant patients with epilepsy who are actively using anti-epileptic drugs
62790778|NCT04043572||Healthy Controls|Healthy volunteers
62790779|NCT04591158|OTHER|LUS ultrasound and standard of care|Subjects will perform a lung ultrasound in order to determine the ability of patients to take an ultrasound from their homes. The lung ultrasound will be coupled with telehealth clinical support to monitor the severity of COVID-19 patients and provide standard of care. All subjects will receive the lung ultrasound technology and daily calls for teleguidance through the ultrasound and standard of care to monitor symptoms.
62790780|NCT02921490|EXPERIMENTAL|PET/MR recipients|All recruited patients will undergo FDG PET/MR of the lumbar spine as the single arm of the study.
62790781|NCT05811169||Early or metastatic non-small cell lung cancer|The formalin-fixed paraffin-embedded specimen will be retrieved for next generation sequencing.
62790782|NCT03661333|EXPERIMENTAL|Adolescents with bipolar disorder|40 adolescents aged 13 to 19 with bipolar disorder (type I, type II, not otherwise specified/nos) will be enrolled in the dialectical behavioral therapy intervention.
62790783|NCT03258086|EXPERIMENTAL|Blood sample|2ml blood sample of of blood will be taken for assessment of vitamin D
62790784|NCT02832635|EXPERIMENTAL|WBRT|Patients with brain metastases (\>3 lesions) ; Whole-brain radiotherapy without avoidance of hippocampus applied.
62215247|NCT03541031|EXPERIMENTAL|Micronutrient & Fish oil|Fish oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Micronutrient capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day.
62790785|NCT02832635|EXPERIMENTAL|WBRT with avoidance of hippocampus|Patients with brain metastases (\>3 lesions) ; Whole-brain radiotherapy with avoidance of hippocampus applied.
62790786|NCT02832635|EXPERIMENTAL|WBRT with TMZ|Patients with brain metastases (\>3 lesions) ; Whole-brain radiotherapy with concurrent TMZ chemotherapy applied.
62790787|NCT02832635|EXPERIMENTAL|WBRT with avoidance of hippocampus and TMZ|Patients with brain metastases (\>3 lesions) ; Whole-brain radiotherapy with avoidance of hippocampus and concurrent TMZ chemotherapy applied.
62790788|NCT03485235|EXPERIMENTAL|D&C|
62409280|NCT04115800|EXPERIMENTAL|Liposomal Sirolimus|Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
62409281|NCT04115800|PLACEBO_COMPARATOR|Liposomal|Subconjunctival liposomal injections in patients with conventional treatments and moderate and severe dry eye disease
62213204|NCT06611254||Neonates with perinatal asphyxia and indication for hypothermia treatment|Included will be neonates with perinatal asphyxia that get an indication for hypothermia treatment (severe azidosis and signs of encephalopathy and under 6h of age and \>36 gest. weeks). They will be monitored with CEUS/ULM at three different time points (T1: within first 6h of life/before hypothermia treatment, T2 = during hypothermia treatment/6-78h of life, T3 = after hypothermia treatment/within first week of life.
62213205|NCT02297659|ACTIVE_COMPARATOR|Crystalloid resuscitation|Patients to receive normal saline resuscitation at a rate of 30cc/hr.
62213206|NCT02297659|ACTIVE_COMPARATOR|Hypertonic saline resuscitation|Patients to receive 3% hypertonic saline resuscitation at a rate of 30cc/hr.
62213207|NCT02548598||AIMS-Full Characterization|Participants in this group undergo characterization at the UCSF Airway Clinical Research Center 6 weeks following their scheduled sinus surgery.
62213208|NCT02548598||AIMS-OR|Participants in this group complete limited questionnaires and provide biological samples that are collected during their scheduled sinus surgery. No further characterization in done in this group.
62213209|NCT02548598||AIMS-M|Participants returning to UCSF Sinus Center clinic following sinus surgery who have nasal secretions that are removed by a study clinician will provide samples at these clinic visits.
62409282|NCT03707145|ACTIVE_COMPARATOR|Professional led with online support|"The consultation is led by the professional and lifestyle recommendations are based on ViviFrail recommendations and personal experience of the professional.~The 12-week intervention includes access to an online monitoring platform. The online platform provides the lifestyle recommendations and consists of a diary of activities, examples of exercises, general advice and instructions for monitoring and self-assessment."
62409283|NCT03707145|ACTIVE_COMPARATOR|Professional led without online support|"The consultation is led by the professional and lifestyle recommendations are based on ViviFrail recommendations and personal experience of the professional.~There is no access to the online monitoring platform, and lifestyle recommendations were provided on paper to the participant."
62409284|NCT03707145|EXPERIMENTAL|Patient empowered with online support|"The consultation is led by the participant, and started with the questions 'What matters to you', and 'What are your goals'. The professional based the lifestyle recommendations based on these responses.~The 12-week intervention includes access to an online monitoring platform. The online platform provides the lifestyle recommendations and consists of a diary of activities, examples of exercises, general advice and instructions for monitoring and self-assessment."
62409285|NCT03707145|ACTIVE_COMPARATOR|Patient empowered without online support|"The consultation is led by the participant, and started with the questions 'What matters to you', and 'What are your goals'. The professional based the lifestyle recommendations based on these responses.~There is no access to the online monitoring platform, and lifestyle recommendations were provided on paper to the participant."
62409286|NCT05427370|EXPERIMENTAL|Revascularization by PCI|Revascularization will be attempted on/for significant lesions in major coronary vessels/side branches as planned by the local Heart Team, with the general recommendation of stenotic/occluded vessels with diameter \>2.0 mm for PCI. The Heart Team consists of a minimum of one heart failure cardiologist, one interventional cardiologist and one cardiac surgeon.
62409287|NCT05427370|EXPERIMENTAL|Revascularization by CABG|Revascularization will be attempted on/for significant lesions in major coronary vessels/side branches as planned by the local Heart Team, with the general recommendation of stenotic/occluded vessels with diameter \>1.5 mm for CABG. The Heart Team consists of a minimum of one heart failure cardiologist, one interventional cardiologist and one cardiac surgeon
62409288|NCT01076140|ACTIVE_COMPARATOR|Nebivolol|Nebivolol 5 mg daily for 2 weeks, then 5 or 10 mg daily for 2 weeks
62409289|NCT01076140|ACTIVE_COMPARATOR|Lisinopril|20 mg once daily for 2 weeks, then 20 or 40 mg once daily for 2 weeks
62409290|NCT06326723|EXPERIMENTAL|25mg group|Dose:25mg daridorexant or placebo Treatment Assignment :Day 1 SD, Day 4 - Day 8 MD (qdy) Number of subjects:16 (12 daridorexant + 4 placebo)
62409291|NCT06326723|EXPERIMENTAL|50mg group|Dose:50mg daridorexant or placebo Treatment Assignment :Day 1 SD, Day 4 - Day 8 MD (qdy) Number of subjects:16 (12 daridorexant + 4 placebo)
62409292|NCT01308762|EXPERIMENTAL|IMM-101|"Patients received an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28. Doses used were:~'Heat killed whole cell M. obuense (IMM-101) 0.1 mg', 'Heat killed whole cell M. obuense (IMM-101) 0.5 mg', or 'Heat killed whole cell M. obuense (IMM-101) 1.0 mg'"
62409293|NCT01828164|EXPERIMENTAL|Treatment Arm|20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated.
62409294|NCT01828164|SHAM_COMPARATOR|Control Arm|The transducers are not activated on the control side of the device.The subjects wear the device for 20 minutes per day for the duration of the study. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the control arm consist of the side of the mouth with the transducers deactivated.
62213210|NCT02668549||Patients with Opioid dispensings|Patients receiving two or more opioid dispensings within 18 months
62213211|NCT02668549||Patients with Diuretic dispensings (neg control)|Patients receiving two or more Diuretics dispensings within 18 months will serve as negative control
62213212|NCT03482466|EXPERIMENTAL|PTSD patients|12 PTSD patients will be recruited to undergo neurofeedback training .
62213213|NCT04420949|EXPERIMENTAL|Healthy|Healthy adults with visually-induced dizziness with undergo the testing and treatment.
62213214|NCT04420949|EXPERIMENTAL|Vestibular-impaired|Adults with unilateral or bilateral, peripheral vestibular loss who also have visually-induced dizziness with undergo the testing and treatment.
62409295|NCT04964960|EXPERIMENTAL|Pembrolizumab with standard of care chemotherapy treatment|Patients will receive 200mg or 400mg of Pembrolizumab (standard of care dosing at the discretion of treating physician) over thirty minutes on day 1 every three or six weeks with standard of care chemotherapy treatment (carboplatin, pemetrexed, paclitaxel, nab-paclitaxel).
62409296|NCT04883892|EXPERIMENTAL|BMAC injection|Single injection of Bone Marrow Aspirate Concentrate (BMAC) into the ankle joint
62790789|NCT03485235|OTHER|No D&C|
62790790|NCT05170763|EXPERIMENTAL|PA9159 10 μg single dose and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 10 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
62790791|NCT05170763|EXPERIMENTAL|PA9159 20 μg single dose and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 20 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
62213215|NCT03007043||Normal responders|Normal response following IVF
62409297|NCT04883892|ACTIVE_COMPARATOR|HA injections|"two injections of Hyaluronic Acid (HA) into the ankle joint - one injection every 15 days.~After 12 months patients are allowed to cross-over in the BMAC arm."
62409298|NCT06415305|EXPERIMENTAL|Winlevi (clascoterone) 1% cream|
62409299|NCT05456321|ACTIVE_COMPARATOR|Cognitive Training and Active tDCS|5 sessions of computerized executive functioning training - plus active tDCS (also 5 sessions).
62409300|NCT05456321|SHAM_COMPARATOR|Cognitive Training and Sham tDCS|5 sessions of computerized executive functioning training - plus sham tDCS (also 5 sessions).
62409301|NCT06652061||Patients presenting for DEXA scan|The study group consists of patients presenting for Bone Mineral Density (BMD) testing using DEXA scans in the Radiology Department, as well as those with available spine and hip X-ray images. This group includes individuals with suspected osteoporosis referred for a BMD test by an attending orthopedic specialist, along with patients undergoing routine testing. The group encompasses a diverse demographic, including males, premenopausal women, and postmenopausal women across various age groups. This diversity enables the evaluation of the AI model across a broad range of conditions and patient backgrounds, enhancing its generalizability and clinical utility.
62213216|NCT03007043||Suboptimal responders|Suboptimal response following IVF
62213217|NCT01151852|EXPERIMENTAL|Imatinib|Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
62213218|NCT01151852|PLACEBO_COMPARATOR|Placebo|Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
62215248|NCT03541031|PLACEBO_COMPARATOR|Olive oil & Safflower oil|Safflower oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Olive oil capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day.
62215249|NCT02314780|EXPERIMENTAL|Heme arginate (high dose)|24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 3 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
62409302|NCT02141373|EXPERIMENTAL|Glubran 2|Glubran 2 will be used at end of surgery
62409303|NCT02141373|NO_INTERVENTION|Standard Surgery|
62409304|NCT00953017|ACTIVE_COMPARATOR|Miralax plus Amitiza|106 patients randomized to Miralax plus Amitiza will take one 24mcg gelcap of Amitiza at noon the day prior to their colonoscopy. On the day prior to the colonoscopy, the patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
62790792|NCT05170763|EXPERIMENTAL|PA9159 40 μg single dose and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 40 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
62213219|NCT03909529|EXPERIMENTAL|LANOXIN® (Digoxin) USP 250 mcg (substrate drug) {Treatment A}|"14 Subjects first administered with LANOXIN® (digoxin) USP 250 mcg (Substrate drug) on Day 6 of in house, after overnight fasting of at least 10.00 hours.~After washout period of 28 days, these 14 subjects were administered with Spironolactone Oral Suspension 100 mg (perpetrator, Carospir® Oral Suspension 20 mL of 25 mg / 5 mL) from day 1 to day 5 and on day 6 the after overnight fasting of at least 10.00 hours, subject was administered with LANOXIN® (digoxin) USP 250 mcg (substrate drug) + Spironolactone Oral Suspension 100 mg (perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL). From day 7 to day 9 the subjects were administered with Spironolactone Oral Suspension 100 mg (perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL)."
62213220|NCT03909529|EXPERIMENTAL|LANOXIN® (Digoxin) USP 250mcg and Carospir® Oral Suspension 20mL of 25 mg/5mL-Treatment B|"14 Subjects first administered with Spironolactone Oral Suspension 100 mg (perpetrator, Carospir® Oral Suspension 20 mL of 25 mg / 5 mL) from day 1 to day 5 and on day 6 the after overnight fasting of at least 10.00 hours, subject was administered with LANOXIN® (digoxin) USP 250 mcg (substrate drug) + Spironolactone Oral Suspension 100 mg (perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL). From day 7 to day 9 the subjects were administered with Spironolactone Oral Suspension 100 mg (perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL).~After washout period of 28 days these 14 Subjects administered with LANOXIN® (digoxin) USP 250 mcg (Substrate drug) on Day 6 of in house, after overnight fasting of at least 10.00 hours"
62213221|NCT05770518|EXPERIMENTAL|Biofeedback|In office video biofeedback performed at the time of the diagnosis.
62213222|NCT05770518|ACTIVE_COMPARATOR|Laryngeal control therapy|A specific type of behavioral therapy performed by speech and language pathologists
62213223|NCT03017898|EXPERIMENTAL|Laser coagulation|Treatment of anal fistulae meeting the inclusion criteria
62213224|NCT05552300|EXPERIMENTAL|Superselective adrenal arterial embolization|"Selectively injects ethanol into adrenal artery to ablate part of the adrenal gland~Interventions:~Procedure: superselective adrenal arterial embolization Drug: traditional triple antihypertensive treatment"
62213225|NCT05552300|ACTIVE_COMPARATOR|Traditional triple antihypertensive treatment|No intervention, but treated with traditional triple antihypertensive treatment
62213226|NCT00658788|ACTIVE_COMPARATOR|Study Treatment|"clobetasol propionate spray 0.05%~Other Names:~Clobex® Spray 0.05% clobetasol propionate spray, 0.05%, applied topically twice daily~calcitriol ointment~Other Names:~Calcitriol Ointment calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily"
62213227|NCT03093103|ACTIVE_COMPARATOR|empagliflozin 10mg|Empagliflozin (Jardiance) 10mg is an SGLT-2inhibitor. The drug will be taken qd for 4 weeks.
62213228|NCT03093103|PLACEBO_COMPARATOR|Placebo|Placebo will be taken qd for 4 weeks.
62213229|NCT04252443|OTHER|Nurse|The research population consisted of 190 nurses working in a university hospital. Because all of the nurses in the research population could not be reached, a sample was selected using a simple random sampling method. One hundred twenty-seven nurses were interviewed in the research population, with a 95% confidence interval and a 5% sampling error.
62213230|NCT00436852|EXPERIMENTAL|Measurable disease by CT or MRI scan (ABT-751 chemotherapy)|Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.
62213231|NCT00436852|EXPERIMENTAL|Evaluable by I-MIBG scintigraphy (ABT-751)|Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.
62213232|NCT05892510|PLACEBO_COMPARATOR|Placebo|Intra-arterial bolus of placebo (0.9% Sodium Chloride solution) representing standard of care (no intra-arterial thrombolytic treatment).
62213233|NCT05892510|EXPERIMENTAL|Intra-arterial tenecteplase injection at the completion of thrombectomy|intra-arterial tenecteplase (0.062mg/kg, maximum 6.25mg) administered as a bolus at the completion of thrombectomy through a microcatheter at the site of the initial-but-now-retrieved intracranial occlusion or in direct contact with the residual thrombus
62213234|NCT03992131|EXPERIMENTAL|Arm A: Rucaparib and Lucitanib|Participants will receive oral rucaparib twice daily (BID) and oral lucitanib once daily (QD) continuously in 28-day cycles.
62213235|NCT03992131|EXPERIMENTAL|Arm B: Rucaparib BID and Sacituzumab Govitecan|Participants will receive oral rucaparib BID, administered continuously, in combination with intravenous (IV) sacituzumab govitecan administration on Day 1 and Day 8 of a 21-day cycle.
62213236|NCT03992131|EXPERIMENTAL|Arm B: Rucaparib QD and Sacituzumab Govitecan|Participants will receive oral rucaparib QD, administered continuously, in combination with IV sacituzumab govitecan administration on Day 1 and Day 8 of a 21-day cycle.
62213237|NCT04636736||HIV POLISH (PL)|HIV infected people with polish nationality, who most probably acquired infection in Poland
62213238|NCT04636736||HIV MIGRANTS (M)|HIV infected people, originating from outside of Poland, where they were diagnosed with HIV infection
62213239|NCT04959539|ACTIVE_COMPARATOR|endoscopic transcanal tympanoplasty with attico-antrostomy|
62213240|NCT04959539|ACTIVE_COMPARATOR|endoscopic assisted canal wall up mastoidectomy|
62213241|NCT00282672|SHAM_COMPARATOR|LGD Sham Procedure first then LGD Radiofrequency Ablation|"Sham procedure plus anti-secretory medication. Subjects with Low Grade Dysplasia (LGD) receive proton pump inhibitor (PPI) with dose of Esomeprazole 40 mg BID.~At 12 month, subjects crossover to receive radiofrequency ablation."
62213242|NCT00282672|ACTIVE_COMPARATOR|LGD:Radiofrequency ablation|Ablation System plus anti-secretory medication. Subjects with Low Grade Dysplasia (LGD) undergo an upper endoscopy with sizing of the esophageal diameter followed by radiofrequency ablation plus standard anti-secretory therapy (proton pump inhibitor, PPI-dose: Esomeprazole 40 mg BID.)
62020441|NCT04844424|EXPERIMENTAL|Part 1A: Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment C in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62213243|NCT00282672|SHAM_COMPARATOR|HGD Sham Procedure first then HGD Radiofrequency Ablation|"Sham procedure plus anti-secretory medication. Subjects with High Grade Dysplasia (HGD) with proton pump inhibitor (PPI) dose: Esomeprazole 40 mg BID.~At 12 month, subjects crossover to receive radiofrequency ablation."
62213244|NCT00282672|ACTIVE_COMPARATOR|HGD:Radiofrequency ablation|Ablation System plus anti-secretory medication. Subjects with High Grade Dysplasia (HGD) undergo an upper endoscopy with sizing of the esophageal diameter followed by radiofrequency ablation plus standard anti-secretory therapy (proton pump inhibitor, PPI-dose: Esomeprazole 40 mg BID.)
62213245|NCT01689571|PLACEBO_COMPARATOR|Placebo DPI|Placebo by inhalation for 9 days
62790793|NCT05170763|EXPERIMENTAL|PA9159 80 μg single dose and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 80 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data.
62020442|NCT04844424|EXPERIMENTAL|Part 1A: Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1 followed by Treatment B in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62213246|NCT01689571|EXPERIMENTAL|CHF6001 DPI Dose 2|CHF6001 by inhalation for 9 days
62213247|NCT01689571|EXPERIMENTAL|CHF6001 DPI Dose1|CHF6001 by inhalation for 9 days
62213248|NCT05460403||Surgery alone|patients without adjuvant radiotherapy after R0 resection.
62213249|NCT05460403||Adjuvant Radiotherapy|patients treated with adjuvant radiotherapy after R0 resection.
62213250|NCT04559321|ACTIVE_COMPARATOR|Holmium laser|General anesthesia, Valdivia-Galdakao position, cystoscopy will be performed, ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with 100 W Holmium laser.
62213251|NCT04559321|EXPERIMENTAL|Trilogy|General anesthesia, Valdivia-Galdakao position, cystoscopy will be performed, ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with LithoClast Trilogy EMS and 1.5 mm x 440 mm probe
62790794|NCT05170763|EXPERIMENTAL|PA9159 20 μg repeated doses and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either 20 μg PA9159 or placebo once a day for 7 days. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
62790795|NCT05170763|EXPERIMENTAL|PA9159 40 μg repeated doses and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either 40 μg PA9159 or placebo once a day for 7 days. There will be a one week follow-up period to review all available clinical and laboratory safety data.
62790796|NCT06241105|EXPERIMENTAL|Lenvatinib+Toripalimab|"1. Administer 8 mg of Lenvatinib orally, once a day, for continuous usage;~2. Administer 240mg of Toripalimab via intravenous infusion, first time seven days post-lenvatinib intake, and subsequently every three weeks thereafter."
62790797|NCT05645965||Patients who underwent implantable cardioverter-defibrillator (ICD) insertion during study period|Patients who underwent implantable cardioverter-defibrillator (ICD) insertion between January 2015 and December 2020
62790798|NCT05711472|EXPERIMENTAL|Experimental|"Intervention Group Three different ball sizes, 55, 65 and 75 cm in diameter, were provided to the pregnant women, and the appropriate ball size was determined according to the height of the participant. In order for the pregnant woman to continue the balance exercises, they were allowed to sit on the round birth ball with their knees and hips at an angle of approximately 90°, with an upright spine. A birth ball of 55 cm was used for women between 150 and 160 cm in height, 65 cm for women between 160 and 170 cm, and 75 cm for women between 170 and 185 cm in height. Exercises with the round birth ball were guided by the researcher and the pregnant women performed the exercises in line with the guide.~These are the movements performed with the round birth ball in 3 different positions: sitting (pelvic rocking movement, forward-backward and right-to-left rocking, forward supported sitting, and springing motion), kneeling, and squatting (ball hugging and pelvic rocking motion)."
62790799|NCT05711472|NO_INTERVENTION|No Intervention|"Control Group~The followings were administered to the pregnant women in the Control Group after they were admitted to the hospital for delivery:~* Information was given about the research,~* Written consent was obtained,~* Routine practices and care were provided in the delivery room (taking anamnesis, taking vital signs, demonstrating correct breathing techniques, ensuring freedom of movement)~* Cervical changes were recorded on the partograph by vaginal examination,~* EFM (Electronic Fetal Monitoring) was applied based on doctor's orders,~* Fetal Heart Sound (FHS) was listened to every half hour and recorded on the partograph."
62790800|NCT01311609|EXPERIMENTAL|Systane|Systane Lubricant Eye Drops
62790801|NCT01232998||Patient Satisfaction with nursing care|
62790802|NCT01232998||satisfaction of waiting time for first time visit|
62790803|NCT01232998||patient satisfaction|
62790804|NCT04368715|EXPERIMENTAL|2780 nm Er:Cr;YSGG laser treated group|Patients treated with Er:Cr;YSGG laser for labial frenectomy
62790805|NCT04368715|EXPERIMENTAL|940 nm Diode laser treated group|Patients treated with 940 nm Diode laser for labial frenectomy
62409305|NCT00953017|ACTIVE_COMPARATOR|Miralax plus Dulcolax|107 patients randomized to Miralax plus Dulcolax will take two 5mg tablets of Dulcolax at noon the day prior to their colonoscopy. On the day prior to the colonoscopy, the patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
62213252|NCT03980600|EXPERIMENTAL|Donor site treatment with NFC dressing/FibDex®|"Patients requiring skin graft donor site treatment were enrolled in the investigation. Patients were selected based on clinical evaluation by a plastic surgeon.~Of the total 33 patients enrolled in the study, nine patients were treated during the optimization phase with experimental NFC dressing Types 1-3. The remaining 24 patients were treated with the final product Type 4 (FibDex®). The mean age of patients treated with NFC dressing/FibDex® was 50 ± 18 years, in the range of 21-74 years.~Suprathel® was used to treat donor sites in the same patients as a reference material. During the optimization phase, Suprathel was intra-individually compared with NFC dressing types 1-3 in five patients out of nine. From the remaining 24 patients, Suprathel was intra-individually compared with FibDex® in 17 patients."
62213253|NCT05837767|EXPERIMENTAL|Participants with metastatic solid tumors|Participants will have metastatic solid tumors and at least two sites of measurable extra-cranial disease
62213254|NCT02440659||Hemodialysis (HD)|Patients who have chronic kidney disease (CKD) and are currently on hemodialysis.
62409306|NCT00953017|ACTIVE_COMPARATOR|Miralax|106 patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
62213255|NCT02440659||Peritoneal Dialysis (PD)|Patients who have chronic kidney disease (CKD) and are currently on peritoneal dialysis.
62213256|NCT05103787|ACTIVE_COMPARATOR|deep parasternal plane block|Subjects will receive bilateral deep parasternal intercostal plane block after induction of anesthesia.
62213257|NCT05103787|PLACEBO_COMPARATOR|control|subjects will receive skin puncture with needle on the same location as the treatment group without administration of local anesthetics after induction of anesthesia,
62213258|NCT04887064|EXPERIMENTAL|Normal Hepatic Function|
62584477|NCT06280807||Androgen Excess States|Polycystic Ovary Syndrome (PCOS);Women who meet criteria for PCOS based on NIH/ Rotterdam or other clinical criteria
62213259|NCT04887064|EXPERIMENTAL|Moderate Hepatic Impairment|
62213260|NCT04887064|EXPERIMENTAL|Severe Hepatic Impairment|
62213261|NCT00800553|EXPERIMENTAL|donepezil|donepezil, 5 mg p.o. for approx 2 weeks
62213262|NCT00800553|PLACEBO_COMPARATOR|placebo|placebo
62790806|NCT04191317|EXPERIMENTAL|Pain Neuroscience Education and gradual exposure|"Education explaining the neurophysiological processes that lead to chronic pain, in order to change maladaptive belief towards disease, reconceptualising them and desensitizing the Central Nervous system.~On first session of gradual exposure the patients are challenged to create a hierarchically list with the functional activities they experience fear, and exposure begins with the one they have less. Both the therapist and participant will determine a specific group of exercises after the patient understands the benign nature of pain, and will be evaluated the maximal performance of the individual to perform each exercise separately."
62790807|NCT04191317|ACTIVE_COMPARATOR|Pilates and postural education|In the first session, basic Pilates principles will be taught and reinforced at the beginning of the follow up sessions, including: postural alignment (neutral spine position, shoulder blade and neck position) and core recruitment along with a controlled breathing. Each session will have a warm up, mobility, stability and strengthening exercises and a cool down period.
62213263|NCT01148147|PLACEBO_COMPARATOR|Placebo|Intracoronary Placebo administration
62213264|NCT01148147|ACTIVE_COMPARATOR|Adenosine|Intracoronary adenosine administration
62213265|NCT06452498|EXPERIMENTAL|Metformin|Metformin 3000 mg divided by three daily doses (3 times 2 capsules of 500 mg; following a step-up schedule) from randomization till delivery, aside from usual preterm preeclampsia care.
62213266|NCT06452498|PLACEBO_COMPARATOR|Placebo|Placebo, divided by three daily doses (3 times 2 capsules; following a step-up schedule) from randomization till delivery, aside from usual preterm preeclampsia care.
62213267|NCT06609980|EXPERIMENTAL|Intervention Arm|Caregivers of the participants in the intervention arm will collect monthly fecal samples while the child is healthy and right before an antibiotic treatment which has been prescribed by the pediatrician for a non-gastrointestinal condition. One day after the last dose of antibiotics, the caregiver will collect another fecal sample and then the child will orally drink 2 ounces of the autologous fecal matter transplant inoculum prepared by the research team by mixing the child's own most recent sample prior to falling ill and mixed with milk. The caregivers then continue collecting samples once a week for a month followed by once a month for five months.
62213268|NCT06609980|NO_INTERVENTION|Control|Participants do not partake in the autologous fecal matter transplant that will be used to re-seed the child's gut with his or her own personalized microbiome composition which was preserved prior to antibiotics use.
62020443|NCT04844424|EXPERIMENTAL|Part 1B: Treatment Sequence DEF|Participants will receive a single oral Dose 1 of milvexian as DC oral tablets under fed conditions (Treatment D) in Treatment Period 1, followed by a single oral Dose 1 of milvexian as RC oral tablets under fed conditions (Treatment E) in Treatment Period 2 and then a single oral Dose 1 of milvexian as Phase 2 oral capsules under fed conditions (Treatment F) in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62213269|NCT03360734|EXPERIMENTAL|Combination|"First part: Combination of Gatipotuzumab (GAT) and Tomuzotuximab (TOM) Treatment: 5 weeks monotherapy with TOM (Day 1: 60mg, Day 2: 660mg, Week 2: 1200mg, Week 4: 1200mg). Then combination of 1200mg TOM with 1400mg of GAT every two weeks until disease progression, as long as patient does not meet any other discontinuation criterion such as unacceptable toxicity.~Second part: Combination of GAT and TOM or an approved anti-EGFR antibody, i.e. Cetuximab, Panitumumab, or Necitumumab Treatment: One week monotherapy with TOM (Week 1, Day 1: 60mg, Day 2: 660mg). Then 1200mg TOM in combination with 1400mg of GAT every two weeks until disease progression, as long as patient does not meet any other discontinuation criterion such as unacceptable toxicity or commercial anti-EGFR antibody (dosage according to local practices) in combination with 1400mg of GAT every two weeks until disease progression or until unacceptable toxicity"
62409307|NCT00953017|ACTIVE_COMPARATOR|Golytely (polyethylene glycol)|106 patients will take 1 gallon of golytley (Polyethylene glycol) and drink 1/2 of the solution at 4 p.m. The remaining 1/2 of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy
62790808|NCT02292563|EXPERIMENTAL|endoscopist only|Single inspection by endoscopist during colonoscopy
62790809|NCT02292563|EXPERIMENTAL|nurse participation|Dual inspection by both an endoscopist and an experienced nurse during colonoscopy
62790810|NCT04706481||Healthy Control|Healthy subjects who have provided consent for specimen collection
62790811|NCT04706481||Cancer or Other Diseases|Diseased subjects who have provided consent for specimen collection
62790812|NCT06725290||low dose isotretinoin|Acne patients taking 20 mg daily isotretinoin
62790813|NCT06725290||high dose isotretinoin|Acne patients taking 0.5 mg/kg daily dose of isotretinoin
62790814|NCT06725290||Normal control|
62790815|NCT01652339|ACTIVE_COMPARATOR|Exforge tab. 10/160mg|"* amlodipine besylate (10mg as amlodipine)~* valsartan 160mg"
62790816|NCT01652339|EXPERIMENTAL|Lodivixx tab. 5/160mg|"* S-amlodipine nicotinate (5mg as S-amlodipine)~* valsartan 160mg"
62790817|NCT02212041|EXPERIMENTAL|Electronic cigarettes|Free disposable electronic cigarettes will be provided during 6 weeks to smokers with serious mental illness.
62790818|NCT01342588|EXPERIMENTAL|Electrical stimulation|Only arm of the study, the experimental
62790819|NCT00889824|EXPERIMENTAL|prosthesis group|balance prosthesis
62790820|NCT00622375|EXPERIMENTAL|1|
62790821|NCT04007016||Pemberton osteotomy （PO）|PO group received Pemberton osteotomy
62790822|NCT04007016||"inner L shaped iliac osteotomy (ILSO)"|"ILSO group received inner L shaped iliac osteotomy"
62790823|NCT01574066|EXPERIMENTAL|Chest CT-scan|Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
62790824|NCT06352749|SHAM_COMPARATOR|Control|Participants will receive advice to be physically active and to reduce their sedentary behavior
62790825|NCT06352749|EXPERIMENTAL|Online exercise|Participants will receive general recommendations for maintaining physically active and reducing sedentary behaviors. This will be done verbally and through written material. In addition, participants will take part in a 6-month multicomponent physical exercise program consisting of 2 online weekly multicomponent sessions.
62790826|NCT06352749|ACTIVE_COMPARATOR|Face-to-face exercise|Participants will receive general recommendations for maintaining physically active and reducing sedentary behaviors. This will be done verbally and through written material. In addition, participants will take part in a 6-month multicomponent physical exercise program consisting of 2 face-to-face weekly multicomponent sessions.
62790827|NCT02761382|EXPERIMENTAL|Mindfulness-based treatment|"The mindfulness-based psychological treatment consists of 10 weekly group sessions of 3 hours duration. The treatment is based on Mindfulness-based stress reduction (MBSR), Mindfulness-based cognitive therapy (MBCT) and Acceptance and commitment therapy (ACT). The intervention is partly manualized to accommodate demands of methodology, accuracy and repeatability. The group sessions will include:~1. mindfulness-training (including meditation and yoga),~2. therapy based on ACT, and~3. patient-education in themes specifically targeted living with endometriosis-related chronic pelvic pain."
62020444|NCT04844424|EXPERIMENTAL|Part 1B: Treatment Sequence EFD|Participants will receive Treatment E in Treatment Period 1, followed by Treatment F in Treatment Period 2 and then Treatment D in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62790828|NCT02761382|EXPERIMENTAL|Non-specific treatment|"The non-specific general psychological treatment is matched the mindfulness-based psychological treatment and consists of 10 weekly group sessions of 3 hours duration. The treatment is based on Client-centered therapy. The intervention is partly manualized to accommodate demands of methodology, accuracy and repeatability. The group sessions will include:~1. relaxation and physical training,~2. therapy based on the non-specific factors of psychological treatment which emphasize a focus on the relation and alliance between the therapist and the client and the therapist being a warm empathic, non-directive and unconditionally accepting support, and~3. patient-education in themes specifically targeted living with endometriosis-related chronic pelvic pain."
62020445|NCT04844424|EXPERIMENTAL|Part 1B: Treatment Sequence FDE|Participants will receive Treatment F in Treatment Period 1, followed by Treatment D in Treatment Period 2 and then Treatment E in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020446|NCT04844424|EXPERIMENTAL|Part 1B: Treatment Sequence DFE|Participants will receive Treatment D in Treatment Period 1, followed by Treatment F in Treatment Period 2 and then Treatment E in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020447|NCT04844424|EXPERIMENTAL|Part 1B: Treatment Sequence EDF|Participants will receive Treatment E in Treatment Period 1, followed by Treatment D in Treatment Period 2 and then Treatment F in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020448|NCT04844424|EXPERIMENTAL|Part 1B: Treatment Sequence FED|Participants will receive Treatment F in Treatment Period 1, followed by Treatment E in Treatment Period 2 and then Treatment D in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62790829|NCT02761382|NO_INTERVENTION|Waiting list control|Participants in this arm will be on the waiting list to participate in one of the two experimental treatments after a period of six months. Participants will receive medical treatment as usual in this period.
62790830|NCT05130749||Primary Healthcare Nurses|Nurses allocated in primary Healthcare settings
62790831|NCT05130749||Non Nurses Primary Healthcare|Other Healthcare providers allocated in primary health care settings
62790832|NCT02348996|OTHER|Clinical assessment|Patients would have dry weight determined by clinical evaluation (blood pressure levels, peripheral edema, pulmonary auscultation and symptoms).
62020449|NCT04844424|EXPERIMENTAL|Part 2A: Treatment Sequence GH|Participants will receive twice daily (BID) oral Dose 1 of milvexian DC oral tablets (Treatment G) in Treatment Period 1, followed by BID oral Dose 1 of milvexian Phase 2 oral capsule (Treatment H) in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2A. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
62020450|NCT04844424|EXPERIMENTAL|Part 2A: Treatment Sequence HG|Participants will receive Treatment H in Treatment Period 1, followed by Treatment G in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2A. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
62790833|NCT02348996|EXPERIMENTAL|Bioimpedance|Patients would have dry weight determined according to volume status with a body composition monitor (BCM)
62790834|NCT06240949|EXPERIMENTAL|Positional release technique|Positional release technique will be applied on iliopsoas muscle.
62020451|NCT04844424|EXPERIMENTAL|Part 2B: Treatment Sequence IJ|Participants will receive BID oral Dose 2 of milvexian DC oral tablet (Treatment I) in Treatment Period 1, followed by BID oral Dose 2 of milvexian Phase 2 oral capsule (Treatment J) in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2B. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
62020452|NCT04844424|EXPERIMENTAL|Part 2B: Treatment Sequence JI|Participants will receive Treatment J in Treatment Period 1, followed by Treatment I in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2B. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
62020453|NCT04844424|EXPERIMENTAL|Part 3A: Treatment Sequence KLM|Participants will receive single oral Dose 1 of milvexian as oral Tablet 1 under fasting conditions (Treatment K) in Treatment Period 1, followed by single oral Dose 1 of milvexian oral Tablet 2 under fasting conditions (Treatment L) in Treatment Period 2 and then single oral Dose 1 of milvexian as Phase 2 oral capsules under fasting conditions (Treatment M) in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020454|NCT04844424|EXPERIMENTAL|Part 3A: Treatment Sequence LMK|Participants will receive Treatment L in Treatment Period 1, followed by Treatment M in Treatment Period 2 and then Treatment K in Treatment Period 3 on Day 1 of each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62213270|NCT06218862||Sivelestat sodium|Sivelestat sodium was administered through a 24-hour continuous intravenous infusion at a rate of 0.2 mg/kg/h, for a maximum duration of 14 days.
62213271|NCT06218862||Control|Not use Sivelestat sodium
62213272|NCT01451827|EXPERIMENTAL|Tolvaptan MR 50 mg|Tolvaptan MR 50 mg capsule and 2 placebo IR tablets ( 8 AM) and 1 placebo IR tablet (4 PM) daily.
62213273|NCT01451827|EXPERIMENTAL|Tolvaptan MR 80 mg|Tolvaptan MR 80 mg capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
62213274|NCT01451827|EXPERIMENTAL|Tolvaptan IR 60/30 mg|Two tolvaptan IR 30-mg tablets and 1 placebo MR capsule (8 AM) and 1 tolvaptan IR 30-mg tablet (4 PM) daily.
62213275|NCT01451827|PLACEBO_COMPARATOR|Placebo|Placebo MR capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
62213276|NCT02168504||Healthy controls|Healthy male and female subjects older than 18 years of age without the symptoms of Parkinson's disease. The ages of subjects in this group will be matching to the ages of subjects in Parkinson's disease group
62213277|NCT02168504||Parkinson's disease patients|male and female subjects older than 18 years of age at the early stage the disease
62213278|NCT00693667|PLACEBO_COMPARATOR|A|Placebo
62213279|NCT00693667|ACTIVE_COMPARATOR|B|250 mg active ingredient
62213280|NCT00693667|ACTIVE_COMPARATOR|C|500 mg active ingredient
62213281|NCT00693667|ACTIVE_COMPARATOR|D|750 mg active ingredient
62213282|NCT00733187|EXPERIMENTAL|1|
62213283|NCT03908957|EXPERIMENTAL|Ga68-Dolacga Injection|The healthy volunteer was injected with Ga68-Dolacga Injection iv and performed PET imaging for liver reserve evaluation.
62213284|NCT02757040|EXPERIMENTAL|Ibrutinib combined with As2O3|Ibrutinib combined with As2O3
62213285|NCT02757040|ACTIVE_COMPARATOR|Ibrutinib|Ibrutinib only
62213286|NCT03664934|EXPERIMENTAL|Patients, Neck-specific exercises|Patients before and after neck-specific exercises, subgroup to NCT01528579 with additional measures
62213287|NCT03664934|NO_INTERVENTION|Healthy controls|Healthy controls, no treatment
62213288|NCT06012227|EXPERIMENTAL|"kent'erbas pecorino from extensive farming with crossover Arm 1"|"This study was a 4-week, randomized, controlled, crossover clinical trial. Arm 1: Volunteers will be randomize to be allocated to eat 350g/week of kent'erbas pecorino from extensive farming with a crossover with arm 2 after 6 weeks of washout."
62213289|NCT06012227|ACTIVE_COMPARATOR|"industrial pecorino from intensive farming with crossover Arm 2"|"This study was a 4-week, randomized, controlled, crossover clinical trial. Arm 2 : Volunteers will be randomize to be allocated to eat 350g/week of industrial pecorino from intensive farming for 4 weeks in total, with a crossover with arm 1 after 6 weeks of washout."
62213290|NCT03490630||All patients|Patients undergoing elective surgery with anesthesia
62213291|NCT00965367|EXPERIMENTAL|Acustimulation|
62213292|NCT00965367|NO_INTERVENTION|Standard treatment group|
62213293|NCT06609551|NO_INTERVENTION|Arm-A|Patients with negative ctDNA；Observation and follow-up
62213294|NCT06609551|EXPERIMENTAL|Arm-B|Patients with negative ctDNA;6-month adjuvant chemotherapy with 5-FU monotherapy
62213295|NCT06609551|EXPERIMENTAL|Arm-C|Patients with positive ctDNA; 6-month adjuvant chemotherapy with 5-FU monotherapy
62213296|NCT06609551|EXPERIMENTAL|Arm-D|Patients with positive ctDNA; XELOX intensive treatment group
62213297|NCT01464372|EXPERIMENTAL|Investigational Device|Treatment using electrical field stimulation of peripheral nerves
62020455|NCT04844424|EXPERIMENTAL|Part 3A: Treatment Sequence MKL|Participants will receive Treatment M in Treatment Period 1, followed by Treatment K in Treatment Period 2 and then Treatment L in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62213298|NCT01464372|SHAM_COMPARATOR|Sham Device|Control group using sham device to mimic sound and sensation of investigational device
62409308|NCT03563716|PLACEBO_COMPARATOR|Placebo + Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
62409309|NCT03563716|EXPERIMENTAL|Tiragolumab + Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle and tiragolumab at a dose of 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
62409310|NCT05661071||Duchenne Muscular Dystrophy|Children with Duchenne Muscular Dystrophy (DMD) between the ages of 7 and 16 who have been diagnosed with DMD as a result of genetic testing
62790835|NCT06240949|EXPERIMENTAL|Manual pressure technique|Manual pressure technique will be applied on iliopsoas muscle.
62790836|NCT03449719|ACTIVE_COMPARATOR|Abiraterone|The treatment phase consists of systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist (control arm).
62790837|NCT03449719|EXPERIMENTAL|Abiraterone associated withAblative Radiation|"the patients in the experimental arm will receive SBRT to all metastatic lesions, concomitantly with abiraterone acetate.~SBRT will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations.~Considering an Alfa/beta of 3, a BED3 \> 100 Gy is recommended"
62790838|NCT04221646|EXPERIMENTAL|Thighs circumference reduction|The subjects will be enrolled and treated once per week. Both legs will be treated consecutively. The therapy will be applied simultaneously.
62790839|NCT04221646|EXPERIMENTAL|Saddlebags fat thickness reduction|The subjects will be enrolled and treated once per week. Both legs will be treated consecutively. The therapy will be applied consecutively too.
62790840|NCT00543777|EXPERIMENTAL|MRE + 2PD MRI|MRE - Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue. 2PD MRI - Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
62790841|NCT06245252|EXPERIMENTAL|group (A)|treated by 40-minute passive stretching exercises,three times per week for 12 weeks
62409311|NCT05661071||Typically Developed Children|Typically Developed Children with similar physical characteristics between the ages of 7 and 16
62790842|NCT06245252|EXPERIMENTAL|group (B)|treated by 30 minutes electrical stimulation three times per week for 12 weeks
62790843|NCT05260827|EXPERIMENTAL|Heated tobacco product|30 puffs of heated tobacco product IQOS
62790844|NCT05260827|EXPERIMENTAL|Sham|sham heated tobacco product
62790845|NCT00716846|ACTIVE_COMPARATOR|statin-1|simvastatin
62790846|NCT00716846|ACTIVE_COMPARATOR|statin-2|atorvastatin
62790847|NCT00716846|ACTIVE_COMPARATOR|statin-3|pitavastatin
62213299|NCT02920437|EXPERIMENTAL|Intervention group|Four-week weekly intervention to reduce salt intake.
62409312|NCT00798902|ACTIVE_COMPARATOR|Control|Iliac Crest Autograft
62790848|NCT00666224|EXPERIMENTAL|Glatiramer acetate|Glatiramer acetate 20 mg once daily by subcutaneous injection is administered in both the double-blind and open label periods.
62790849|NCT00666224|PLACEBO_COMPARATOR|Placebo (DB) to GA (OL)|Placebo matching glatiramer acetate once daily by subcutaneous injection during the double-blind period (DB). Glatiramer acetate (GA) 20 mg once daily by subcutaneous injection during the open-label period (OL).
62790850|NCT01593553|EXPERIMENTAL|ECG screening|Twice daily screening using intermittent ECG recorder (Zenicor) for two weeks
62790851|NCT01593553|NO_INTERVENTION|Control group|Standard of care
62790852|NCT05236257||Larotrectinib|Pediatric patients with IFS harboring an NTRK gene fusion who have been enrolled in the SCOUT study.
62790853|NCT05236257||Standard care|Pediatric patients with IFS harboring an NTRK gene fusion in the eligible external cohort(s).
62790854|NCT02231619|NO_INTERVENTION|Demonstration of LSUPT at baseline|This group conduct a LSUPT on their own urine sample at baseline with assistance from a fieldworker.
62213300|NCT02920437|OTHER|Control group|Usual government pamphlets.
62213301|NCT01315691|EXPERIMENTAL|Arikace™|Liposomal amikacin for inhalation
62213302|NCT01315691|PLACEBO_COMPARATOR|Placebo|Placebo for liposomal amikacin for inhalation
62215250|NCT02314780|EXPERIMENTAL|Heme arginate (low dose)|24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 1 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
62213303|NCT01622114|EXPERIMENTAL|Menstralean group|"Represents a program which is designed to induce weight loss by taking into account the physiology of each menstrual phase in terms of adjusting diet and physical activity to the body's cyclic changes in energy demands.~The diet will be adjusted to match one menstrual cycle in duration (approx. 1 month) and will be separated into three phases corresponding to three menstrual phases: menstruation (days 1-5), the follicular phase (days 6-14), and the luteal phase (days 15-28). All women in this group will start the program at day 1 in their cycle. The diet will be repeated six times for each woman, which equals six months."
62213304|NCT01622114|ACTIVE_COMPARATOR|Control Group:|"Represents a program where subjects engage in a similar diet and exercise program as the Menstralean Group, specifically based on the educational diet system Eat for Life. Importantly, the subjects in Control group will start the program at a random time in their menstrual cycles.~Eat for Life is a simple tool for controlling the energy content and nutritional composition of your diet. The method is based on a system of counters that ensure strict control of the diet whilst still allowing a great deal of freedom of choice. The subjects in the Control Group will also receive exactly the same attention and undergo the same visits and measurements as the Menstralean Group."
62213305|NCT05867823|EXPERIMENTAL|OcuApp Users|the experimental group will use a movile aplication (OcuApp), to generate a personal self-analisys about meaningful activities.
62213306|NCT05867823|ACTIVE_COMPARATOR|Three-part work users|The intervention on the control group will focus on offering to the participants an informative three-part work on the positive effects of performing activities.
62213307|NCT02571153|PLACEBO_COMPARATOR|Saline group|Normal saline 0.9% (5 mL)
62213308|NCT02571153|EXPERIMENTAL|Ketamine 0.2|ketamine 0.2 mg/kg (5 mL)
62409313|NCT00798902|EXPERIMENTAL|Prefix 150|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
62409314|NCT06001736|EXPERIMENTAL|Contralateral C7 root transfer for the treatment of spastic hemiparesis.|The C7 nerve root transfer will occur to the patients on this arm.
62409315|NCT00296192|PLACEBO_COMPARATOR|Placebo 1|Placebo nasal spray 1 - 4 puffs
62409316|NCT00296192|EXPERIMENTAL|Rotigotine 1|Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)
62213309|NCT02571153|EXPERIMENTAL|Ketamine 0.4|ketamine 0.4 mg/kg (5 mL)
62213310|NCT05087901||Silicone-filled eyes|
62213311|NCT02528526|EXPERIMENTAL|Treatment|Add-on application of Myo-inositol trispyrophosphate, total of 9 times, 3 applications per week, over 3 weeks.
62213312|NCT02823405|EXPERIMENTAL|X4P-001 + Pembrolizumab|X4P-001 alone, then adding pembrolizumab
62213313|NCT06341660|EXPERIMENTAL|cadonilimab|
62409317|NCT00296192|EXPERIMENTAL|Rotigotine 2|Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)
62213314|NCT05903547|ACTIVE_COMPARATOR|Dermabond Prineo Group|At time of cesarean delivery, patients in the Dermabond Prineo group will undergo skin closure with the Dermabond Prineo skin adhesive system.
62409318|NCT00296192|EXPERIMENTAL|Rotigotine 3|Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)
62409319|NCT00296192|EXPERIMENTAL|Rotigotine 4|Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)
62409320|NCT06303024|EXPERIMENTAL|personalized combined physical and cognitive intervention|The exercise intervention will be aerobic and performed on a stationary bicycle and will comply with the basic principle of progressive overload, combined with a computer based cognitive rehabilitation program carried out twice a week for 12 weeks, using the Rehacom software.
62409321|NCT02399410|EXPERIMENTAL|bevacizumab and CRS with oxaliplatin|Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin
62409322|NCT02820324|EXPERIMENTAL|Treatment 1 Oliceridine|
62409323|NCT02820324|EXPERIMENTAL|Treatment 2 Oliceridine|
62213315|NCT05903547|PLACEBO_COMPARATOR|Suture Group|At time of cesarean delivery, patients in the Suture group will undergo skin closure with standard subcuticular suture.
62213316|NCT02888210|EXPERIMENTAL|MD-15|Investigational intraocular lens
62213317|NCT03942185|EXPERIMENTAL|Psoriasis with Blood heat syndrome group|Participants in Psoriasis with Blood heat syndrome group will receive Chinese Herbal Medicine internal treatment according with the Chinese Medicine principle of Clearing heat and Cooling blood, such as Cool blood detoxification Decoction I，Cool blood and activating blood prescription compound, Cool blood detoxification Decoction II, Cool blood activating blood Decoction, Tufu drink, Xiaoyin Decoction and etc., two times per day for 8 weeks.
62213318|NCT03942185|EXPERIMENTAL|Psoriasis with Blood stasis syndrome group|Participants in Psoriasis with Blood stasis syndrome group will receive Chinese Herbal Medicine internal treatment according with the Chinese Medicine principle of Promoting blood circulation and Removing blood stasis, such as Huoxue Sanyu Xiaoyin Decoction, Cool blood detoxification Decoction III and etc., two times per day for 8 weeks.
62213319|NCT03942185|EXPERIMENTAL|Psoriasis with Non-Blood heat or Blood stasis syndrome group|Participants in Psoriasis with Non-Blood heat or Blood stasis syndrome group will receive Chinese Herbal Medicine internal treatment according with the Chinese Medicine principle of syndrome differentiation therapy two times per day for 8 weeks.
62213320|NCT03942185|NO_INTERVENTION|Healthy control group|No Intervention.
62213321|NCT02840344|EXPERIMENTAL|Couples MBSR|"Young breast cancer survivors and their partners take part in an 8-week Couples Mindfulness-Based Stress reduction (C-MBSR) intervention. The course will be taught through recorded videos of a trained MBSR instructor. The young breast cancer survivor and partner will be asked to watch a video module, together, each week for a total of 8 weeks. The C-MBSR course consists of practicing mindful stress reduction techniques and filling out handouts.~Both members of the couple will be asked to complete surveys assessing primary and secondary outcome measures administered at baseline and after final session. Participants will be asked to provide a Salivary Cortisol sample at baseline and after the 8th session. Follow up Surveys will be administered at one and three months after intervention."
62213322|NCT02840344|ACTIVE_COMPARATOR|Individual MBSR|"Young breast cancer survivors take part in an 8-week Individual Mindfulness-Based Stress reduction (I-MBSR) intervention. The course will be taught through recorded videos of a trained MBSR instructor. The young breast cancer survivor will be asked to watch a video module each week for 8 weeks in a row. The I-MBSR course consists of practicing mindful stress reduction techniques and filling out handouts.~Both members of the couple will be asked to complete surveys assessing primary and secondary outcome measures administered at baseline and after final session. Participants will be asked to provide a Salivary Cortisol sample at baseline and after the 8th session. Follow up Surveys will be administered at one and three months after intervention."
62213323|NCT05845281|ACTIVE_COMPARATOR|Group ESP, Erector Spina Plane Block (n= 30)|After the surgical procedure was completed in patients who underwent general anesthesia, the necessary sterility was provided for the ESPB procedure while the patient was in the lateral position. 1mg/kg 0.5% bupivacaine + 1mg/kg 2% lidocaine was drawn into the same syringe and the volume was completed to 20 ml with normal saline. A linear 10-18 MHz USG probe was placed at the thoracic 7 level (Esaote MyLab 30, Geneva, Italy) in the paramedian plane between two transverse processes. The prepared local anesthetic drug was administered under the guidance of USG.
62213324|NCT05845281|EXPERIMENTAL|Group PCA, Patient Controlled Analgesia (n= 30)|For patients in the PCA group, 200 mg of tramadol was placed in 100cc of 0.9% NaCl. Set to PCA device. A 50mg loading dose was administered 10 minutes before the patient was extubated. After extubating, a bolus dose of 20 mg was started, with a 30-minute lock-in time, and an infusion dose of 5mg/hour. The 4-hour maximum limit was set to 200 mg.
62213325|NCT01340677|EXPERIMENTAL|001|Canagliflozin 100 mg Type=1 unit=mg number=100 form=tablet route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.,Canagliflozin 300 mg Type=1 unit=mg number=300 form=tablet route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.,Canagliflozin 50 mg Type=1 unit=mg number=50 form=tablet route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
62213326|NCT05858125|NO_INTERVENTION|Routine counseling|Patients randomized to routine counseling will receive usual counseling in the standard fashion of their provider.
62213327|NCT05858125|EXPERIMENTAL|Routine counseling + Social Media Navigation Aid Kit|Patients randomized to the intervention will receive routine counseling in the usual manner as well as receive access to the Social Media Navigation Aid Kit in the format of their choice (hardcopy via trifold, email, text, or QR code)
62213328|NCT01342289|EXPERIMENTAL|Tacrolimus 60|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 60 days.
62213329|NCT01342289|EXPERIMENTAL|Tacrolimus 90|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 90 days.
62213330|NCT01342289|EXPERIMENTAL|Tacrolimus 120|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 120 days.
62213331|NCT06571760|EXPERIMENTAL|Vertex Pulmonary Embolectomy System|Patients presenting with clinical signs and symptoms of acute pulmonary embolism and who meet the study criteria will be treated with the Vertex Pulmonary Embolectomy System
62213332|NCT00490490|EXPERIMENTAL|Tositumomab + XRT + KI|Tositumomab + external beam radiotherapy (XRT) + potassium iodide (KI)
62213333|NCT01912508||preterm labor|pregnant women with signs of preterm labor: uterine contractions or cervical shortening
62213334|NCT01912508||control|pregnant women with no signs or symptoms of preterm labor
62215251|NCT02314780|PLACEBO_COMPARATOR|Placebo|24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of an equivalent volume of 0.9% sodium chloride solution.
62409324|NCT02820324|EXPERIMENTAL|Treatment 3 Oliceridine|
62409325|NCT02820324|PLACEBO_COMPARATOR|Treatment 4 Placebo|
62409326|NCT02820324|ACTIVE_COMPARATOR|Treatment 5 Morphine|
62409327|NCT04185259|EXPERIMENTAL|Acupuncture group|
62409328|NCT04185259|SHAM_COMPARATOR|Sham acupuncture|
62409329|NCT04185259|NO_INTERVENTION|Waitlist control group|Participants will receive no treatment for their heel pain for a period of 16 weeks after randomization, and subsequently have the option of 4 weeks (12 sessions) of acupuncture with free of charge at the end of follow-up.
62409330|NCT06108973||Normal Patients|Normal patients without any Lung Pathology for General Anesthesia
62409331|NCT06108973||COPD patients|Established Chronic Obstructive Pulmonary Disease for General Anesthesia
62409332|NCT06180993||At birth cohort|Subjects born from September 25, 2023 to March 31 in each of the 3 RSV seasons under study 2023/2024, 2024/2025, 2025/2026
62409333|NCT06180993||Risk Cohort|Subjects with risk factors born between 1 October 2021 and 31 March 2023
62213335|NCT04619251|EXPERIMENTAL|SRD part: PM Subjects, BI1323495 10mg|Participants were administered on Day 1 a single oral dose of 10 milligram (mg) of BI 1323495 film-coated tablet together with about 240 milliliter (mL) of water. A standardized meal was served 30 minutes (min) before drug administration. One authorized employee of the trial site was witness of the administration of the trial medication.
62213336|NCT04619251|EXPERIMENTAL|SRD part: PM Subjects, BI1323495 30mg|"Participants were administered on Day 1 a single oral dose of 30 milligram (mg) of BI 1323495 film-coated tablets together with about 240 milliliter (mL) of water. A standardized meal was served 30 minutes (min) before drug administration.~One authorized employee of the trial site was witness of the administration of the trial medication."
62409334|NCT06180993||Catch-up cohort|Subjects born between 1 April and 24 September 2023
62584478|NCT06280807||Congenital Adrenal Hyperplasia / Hyperandrogenism|Women who exhibit evidence of hyperandrogenism not related to Polycystic Ovarian Syndrome (PCOS); Nonclassic Congenital Adrenal Hyperplasia, Extreme hyperinsulism, Idiopathic etc.
62213337|NCT04619251|EXPERIMENTAL|SRD part: PM Subjects, BI1323495 100mg|Participants were administered on Day 1 a single oral dose of 100 milligram (mg) of BI 1323495 film-coated tablets together with about 240 milliliter (mL) of water. A standardized meal was served 30 minutes (min) before drug administration. One authorized employee of the trial site was witness of the administration of the trial medication.
62584479|NCT06280807||Exhibiting signs of a diagnosis of hypogonadism|for example: Bosma arrhinia microphthalmia syndrome (BAMS)
62020456|NCT04844424|EXPERIMENTAL|Part 3A: Treatment Sequence KML|Participants will receive Treatment K in Treatment Period 1, followed by Treatment M in Treatment Period 2 and then Treatment L in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020457|NCT04844424|EXPERIMENTAL|Part 3A: Treatment Sequence LKM|Participants will receive Treatment L in Treatment Period 1, followed by Treatment K in Treatment Period 2 and then Treatment M in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62213338|NCT04619251|EXPERIMENTAL|SRD part: EM Subjects, BI1323495 30mg|Participants were administered on Day 1 a single oral dose of 30 milligram (mg) of BI 1323495 film-coated tablets together with about 240 milliliter (mL) of water. A standardized meal was served 30 minutes (min) before drug administration. One authorized employee of the trial site was witness of the administration of the trial medication.
62213339|NCT04619251|EXPERIMENTAL|SRD part: EM Subjects, BI1323495 70mg|Participants were administered on Day 1 a single oral dose of 70 milligram (mg) of BI 1323495 film-coated tablets together with about 240 milliliter (mL) of water. A standardized meal was served 30 minutes (min) before drug administration. One authorized employee of the trial site was witness of the administration of the trial medication.
62213340|NCT04619251|EXPERIMENTAL|SRD part: EM Subjects, BI1323495 150mg|Participants were administered on Day 1 a single oral dose of 150 milligram (mg) of BI 1323495 film-coated tablets together with about 240 milliliter (mL) of water. A standardized meal was served 30 minutes (min) before drug administration. One authorized employee of the trial site was witness of the administration of the trial medication.
62213341|NCT04619251|PLACEBO_COMPARATOR|SRD part: Placebo|"This arm comprises all placebo treated participants in trial part SRD, regardless of the dose group in which they were treated. Participants were randomized within each dose group in a 3:1 ratio (test treatment to placebo).~Participants were administered on Day 1 a single oral dose of placebo film-coated tablet(s) together with about 240 milliliter (mL) of water. A standardized meal was served 30 minutes (min) before drug administration. One authorized employee of the trial site was witness of the administration of the trial medication."
62213342|NCT04619251|EXPERIMENTAL|MD part: PM Subjects, BI1323495 30mg BID|Participants were administered from Day 1 to Day 10 two times per day (bid) an oral dose of 30 milligram (mg) of BI 1323495 film-coated tablets together with about 240 milliliter (mL) of water, At Day 11 participants were administered only a single dose in the morning. Participants took a normal caloric meal 30 minutes (min) before drug administration. Subjects fasted for 4 hours (h) after intake of morning dose. Morning and evening dose were taken with a 12 h time interval approximately at the same time each day during the treatment phase. One authorized employee of the trial site was witness of the administration of the trial medication.
62213343|NCT04619251|EXPERIMENTAL|MD part: PM Subjects, BI1323495 60mg QD|Participants were administered from Day 1 to Day 11 one time per day (qd) an oral dose of 60 milligram (mg) of BI 1323495 film-coated tablets together with about 240 milliliter (mL) of water. Participants took a normal caloric meal 30 minutes (min) before drug administration. Subjects fasted for 4 hours (h) after intake of morning dose. One authorized employee of the trial site was witness of the administration of the trial medication.
62213344|NCT04619251|PLACEBO_COMPARATOR|MD part: Placebo|This arm comprises all placebo treated participants in trial part MD, regardless of the dose group in which they were treated. Participants were randomized within each dose group in a 3:1 ratio (test treatment to placebo). Participants were administered from Day 1 to Day 11 one time per day (qd) an oral dose of placebo film-coated tablets or two times per day (bid) an oral dose of placebo together with about 240 milliliter (mL) of water. Participants took a normal caloric meal 30 minutes (min) before drug administration. Subjects fasted for 4 hours (h) after intake of morning dose. One authorized employee of the trial site was witness of the administration of the trial medication.
62584480|NCT06280807||Hypogonadism / Infertility|Isolated hypogonadotropic hypogonadism
62213345|NCT04619251|EXPERIMENTAL|DDI part: PM Subjects, BI1323495 / BI1323495+ Itraconazole|"* Period 1: Participants were administered the reference treatment (R) which consisted of a single oral dose of 10 milligram (mg) film-coated tablet of BI 1323495 together with about 240 milliliter (mL) of water on Day 1 of Period 1. One authorized employee of the trial site was witness of the administration of the trial medication.~* Period 2: Participants were administered the test treatment (T) which consisted of a single oral dose of 10 milligram (mg) film-coated tablet of BI 1323495 with about 240 milliliter (mL) of water on Day 1 of Period 2, together with multiple oral doses of 200 mg itraconazole from Day -3 to Day 7, in total 10 doses, as oral solution formulation. One authorized employee of the trial site was witness of the administration of the trial medication.~Administration of BI 1323495 in treatment R and T were separated by at least 11 days."
62213346|NCT05330689|ACTIVE_COMPARATOR|Sample group 1|Sample of subjects with primary osteoarthritis of the knee
62213347|NCT05330689|ACTIVE_COMPARATOR|Sample group 2|Sample of subjects with primary osteoarthritis of the knee
62584481|NCT06280807||Hypothalamic Amenorrhea (HA) (female) Functional Hypogonadism (male)|Participants who experience secondary or primary amenorrhea, or male hypogonadism, in the setting of negative energy balance such dieting, eating disorders or exercise training
62020458|NCT04844424|EXPERIMENTAL|Part 3A: Treatment Sequence MLK|Participants will receive Treatment M in Treatment Period 1, followed by Treatment L in Treatment Period 2 and then Treatment K in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62213348|NCT05330689|ACTIVE_COMPARATOR|Sample group 3|Sample of subjects with primary osteoarthritis of the knee
62213349|NCT05330689|ACTIVE_COMPARATOR|Sample group 4|Sample of subjects with primary osteoarthritis of the knee
62213350|NCT05330689|PLACEBO_COMPARATOR|Sample group 5|Sample of subjects with primary osteoarthritis of the knee
62213351|NCT06335485|EXPERIMENTAL|CBT intervention group|Participants will be asked to wear an activity tracker throughout the duration of the study. In addition, Participants will attend 4 weekly online virtual CBT sessions that will provide information on stress and pain reduction techniques before surgery, and 2 sessions following surgery.
62213352|NCT06335485|NO_INTERVENTION|No CBT group|Participants will be asked to wear an activity tracker throughout the duration of the study.
62213353|NCT02338180|NO_INTERVENTION|Control group A|Children with no caries lesion on adjacent surfaces of second primary molar and first permanent molar
62213354|NCT02338180|EXPERIMENTAL|Group B Preventive sealant|Children with active caries lesion on distal surfaces of second primary molar and sound mesial surface of first permanent molar. In every children a split mouth design was applied, in one mesial surfaces of first molar randomize selected received a proximal preventive sealants, and the other remain as a control
62213355|NCT02338180|EXPERIMENTAL|Group C Therapeutic sealant|Children with active caries lesion on distal surfaces of second primary molar and active lesion on mesial surface of first permanent molar. In every children a split mouth design was applied, in one mesial surfaces of first molar randomize selected received proximal therapeutic sealant, and the other remain as a control
62213356|NCT02018939|EXPERIMENTAL|Pharmacokinetic profiling in Hemodialysis|Patients with chronic intermittent hemodialysis receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
62213357|NCT02018939|EXPERIMENTAL|Pharmacokinetic profiling in CVVH|Patients receiving continuous venovenous renal replacement therapy in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
62584482|NCT06280807||Miscellaneous|Reproductive disorders not related to the above categories. (e.g., secondary to endocrine dysfunction, thyroid disorders, Cushing syndrome, pharmacotherapy, etc.)
62584483|NCT06280807||Precocious or Delayed Puberty|Participants who display clinical evidence of delayed or precocious puberty based on standard criteria.
62213358|NCT02018939|EXPERIMENTAL|Pharmacokinetic profiling in MARS|Patients receiving liver replacement therapy (MARS) in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
62790855|NCT02231619|ACTIVE_COMPARATOR|Baseline verbal instruction of LSUPT|Verbal instruction on how to do LSUPT at baseline
62213359|NCT03635528|EXPERIMENTAL|Test 1\Test 2\Control 2\Test 3\Control 1\Test 4\Test 5|Subjects between ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
62213360|NCT03635528|EXPERIMENTAL|Test 2\Test 3\Test 1\Test 4\Control 2\Test 5\Control 1|Subjects between ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
62213361|NCT03635528|EXPERIMENTAL|Test 3\Test 4\Test 2\Test 5\Test 1\Control 1\Control 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
62584484|NCT06280807||Premature Ovarian InsufficiencyPerimenopause or post-menopausal states|Women who attain menopause before age 40 years (or as defined by clinical criteria). Perimenopausal women are those typically above age 40 years and experience secondary amenorrhea/ oligomenorrhea.
62790856|NCT05917418|EXPERIMENTAL|Nutritional support therapy group|All participants in this group will receive proper nutritional support.
62213362|NCT03635528|EXPERIMENTAL|Test 4\Test 5\Test 3\Control 1\Test 2\Control 2\Test 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
62213363|NCT03635528|EXPERIMENTAL|Test 5\Control 1\Test 4\Control 2\Test 3\Test 1\Test 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
62213364|NCT03635528|EXPERIMENTAL|Control 1\Control 2\Test 5\Test 1\Test 4\Test 2\Test 3|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
62213365|NCT03635528|EXPERIMENTAL|Control 2\Test 1\Control 1\Test 2\Test 5\Test 3\Test 4|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
62213366|NCT03635528|EXPERIMENTAL|Test 5\Test 4\Control 1\Test 3\Control 2\Test 2\Test 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
62213367|NCT03635528|EXPERIMENTAL|Control 1\Test 5\Control 2\Test 4\Test 1\Test 3\Test 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
62213368|NCT03635528|EXPERIMENTAL|Control 2\Control 1\Test 1\Test 5\Test 2\Test 4\Test 3|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
62584485|NCT06280807||Weight *Overweight/Underweight|BMI below or above reference standard (Adult Reference: Asians/ Asian Americans- 18.5-22.9 kg/m2; Other races- 18.5-24.9 kg/m2\*Participants may simultaneously belong to cohort of weight and any other cohort.
62584486|NCT05245149||Prospective Cohort|Patients with a clinical indication for coronary CT angiography will undergo this scan on a photon counting detector CT (PCD-CT).
62790857|NCT05917418|NO_INTERVENTION|Routine hospital management group|All participants in this group will receive routine hospital management, without additional nutritional interventions.
62790858|NCT00596830|EXPERIMENTAL|A|Patients in Arm A will receive CP-751, 871 in combination with paclitaxel and carboplatin intravenously every 21 days for up to six cycles.'
62790859|NCT00596830|ACTIVE_COMPARATOR|B|Patient in Arm B will receive paclitaxel and carboplatin intravenously every 21 days for up to six cycles.
62790860|NCT01340053|PLACEBO_COMPARATOR|Placebo|Capsule that is identical in size and color to other treatments
62790861|NCT01340053|EXPERIMENTAL|Low Dose|10 mg capsule of tenapanor
62790862|NCT01340053|EXPERIMENTAL|Mid Dose|30 mg capsule of tenapanor
62213369|NCT03635528|EXPERIMENTAL|Test 1\Control 2\Test 2\Control 1\Test 3\Test 5\Test 4|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
62213370|NCT03635528|EXPERIMENTAL|Test 2\Test 1\Test 3\Control 2\Test 4\Control 1\Test 5|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
62213371|NCT03635528|EXPERIMENTAL|Test 3\Test 2\Test 4\Test 1\Test 5\Control 2\Control 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
62213372|NCT03635528|EXPERIMENTAL|Test 4\Test 3\Test 5\Test 2\Control 1\Test 1\Control 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
62213373|NCT00017368|EXPERIMENTAL|All Patients|
62213374|NCT00564551|ACTIVE_COMPARATOR|2|High dairy intake and calcium supplement. High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.
62213375|NCT00564551|PLACEBO_COMPARATOR|1|Usual diet of low dairy and calcium intake. Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet.
62213376|NCT03134105|EXPERIMENTAL|Monthly Feedback|Sites will receive monthly reports of their patients enrolled in the study with data for each of their patients participating in the study along with summary data for their practice and all patients participating in the study.
62213377|NCT03134105|ACTIVE_COMPARATOR|End-of-study Feedback|Sites will only receive the report of their patients at the end of the 6 month follow-up period.
62213378|NCT01279213|ACTIVE_COMPARATOR|paliperidone clozapine BPRS|patients assigned to clozapine plus paliperidone controls at 6 and 12 weeks
62409335|NCT05698693|EXPERIMENTAL|Sleep intervention|The sleep extension intervention is a 4-week intervention consisting of weekly one-on-one contact with the goal of increasing total sleep time by 60 minutes by the end of four weeks conducted by Dr. Wu or a trained counselor. The first session will last 60 minutes and the content will include psychoeducation about the importance of sleep, sleep guidelines and target setting, and basic sleep hygiene. Participants in this condition will receive hardcopy weekly daily diary worksheets, and receive an online version of the sleep daily diary every morning to complete via text messaging. Sessions 2-4 will be between 15-30 minutes where Dr. Wu or a trained counselor will review the sleep diary, problem solve barriers to weekly goals, and sleep promoting behaviors will be reinforced. Material that would be covered during a missed session will be included in the next session the participant attends.
62409336|NCT05698693|ACTIVE_COMPARATOR|Contact control|The content of the contacts for this intervention condition will be based on the National Center for Healthy Housing's Healthy Homes program, a program designed by the UT School of Public Health. Participants in this condition will meet with Dr. Wu or a trained research staff member. They will meet through Zoom once a week for four sessions to go through each educational module. Sessions will conclude with the development of an action plan for participants. Staff will check in with participants regarding whether they were able to complete the tasks on their action plan, and if not, the reasons for this and potential strategies that may facilitate completion.
62409337|NCT04129866|EXPERIMENTAL|M-IBM|M-IBM is based on a slightly modified version of the word sentence association paradigm focused on words and sentences related to common concerns among those with elevated anxiety sensitivity cognitive concerns (i.e., losing control of mental processes).
62409338|NCT04129866|PLACEBO_COMPARATOR|Control IBM|Control-IBM is identical to M-IBM except that the sentence that follows the cue word is not related to an anxious-threat interpretation of the cue word.
62409339|NCT05101057||Treated|Patients who underwent ACDF surgery and who received post surgical therapy with the SpinalogicTM Non-Invasive Bone Graft Stimulation Device.
62409340|NCT05101057||Control|Patients who underwent ACDF surgery and did not receive post surgical Bone Graft Stimulation.
62409341|NCT00845377|EXPERIMENTAL|Counseling|
62409342|NCT03985293|PLACEBO_COMPARATOR|Placebo|
62409343|NCT03985293|EXPERIMENTAL|PF-06882961 2.5 milligrams (mg)|
62409344|NCT03985293|EXPERIMENTAL|PF-06882961 10 mg|
62409345|NCT03985293|EXPERIMENTAL|PF-06882961 40 mg|Participants will be titrated up to 2 weeks to reach desired dose level
62409346|NCT03985293|EXPERIMENTAL|PF-06882961 80 mg|Participants will be titrated up to 4 weeks to reach desired dose level
62213379|NCT01279213|PLACEBO_COMPARATOR|clozapine plus placebo BPRS|patients assigned to placebo plus clozapine should show less improvement
62213380|NCT05621889|EXPERIMENTAL|virtual group speech therapy intervention guided by a patient partner|
62213381|NCT00809601|EXPERIMENTAL|1|
62213382|NCT06113887|EXPERIMENTAL|intervention group 1 in which psychoeducation based on acceptance and commitment therapy was applied|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test, acceptance and stability-based psychoeducation consisting of 8 modules will be implemented once a week as a single module. Each session of the acceptance and stability therapy-based psychoeducation, which will last 8 weeks in total, will be implemented for 45-60 minutes. Immediately after the training sessions are completed, the post-test; Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) will be administered. A follow-up test will be administered one month after the post-test, i.e. in the 12th week.
62215252|NCT02309931|ACTIVE_COMPARATOR|Isoperistaltic anastomosis|Patients with right colon cancer who undergo a right laparoscopic hemicolectomy and a isoperistaltic side-to-side ileocecal anastomosis
62409347|NCT03985293|EXPERIMENTAL|PF-06882961 120 mg|Participants will be titrated up to 6 weeks to reach desired dose level
62409348|NCT06519422|EXPERIMENTAL|Tranexamic acid (TXA)|Tranexamic acid 1 gram (2x 500 mg) orally taken three times a day from the first to the last day of the menstrual period for up to 5 days, for 3 successive periods.
62409349|NCT06519422|PLACEBO_COMPARATOR|Placebo|Matched placebo tablets taken three times a day from the first to the last day of the menstrual period for up to 5 days, for 3 successive periods.
62409350|NCT04706494|EXPERIMENTAL|AlphaWave® LTheanine|
62409351|NCT04706494|PLACEBO_COMPARATOR|Placebo|
62584487|NCT05245149||Retrospective Cohort|For comparison, a matched retrospective cohort will be created of patients who had undergone coronary CT angiography on prior CT scanner generations (with energy-integrating detector CT, EID-CT)
62584488|NCT02216656|PLACEBO_COMPARATOR|Plascebo|
62213383|NCT06113887|NO_INTERVENTION|Control group 1|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test is administered, post-test will be administered in the 8th week and follow-up tests will be administered in the 12th week without any intervention.
62213384|NCT06113887|EXPERIMENTAL|Intervention group 2 in which psychoeducation based on acceptance and commitment therapy was applied|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test, acceptance and stability-based psychoeducation consisting of 8 modules will be implemented once a week as a single module. Each session of the acceptance and stability therapy-based psychoeducation, which will last 8 weeks in total, will be implemented for 45-60 minutes. Immediately after the training sessions are completed, the post-test; Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) will be administered. A follow-up test will be administered one month after the post-test, i.e. in the 12th week.
62213385|NCT06113887|NO_INTERVENTION|Control group 2|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test is administered, post-test will be administered in the 8th week and follow-up tests will be administered in the 12th week without any intervention.
62213386|NCT06113887|EXPERIMENTAL|Intervention group 3 in which psychoeducation based on acceptance and commitment therapy was applied|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test, acceptance and stability-based psychoeducation consisting of 8 modules will be implemented once a week as a single module. Each session of the acceptance and stability therapy-based psychoeducation, which will last 8 weeks in total, will be implemented for 45-60 minutes. Immediately after the training sessions are completed, the post-test; Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) will be administered. A follow-up test will be administered one month after the post-test, i.e. in the 12th week.
62213387|NCT06113887|NO_INTERVENTION|Control group 3|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test is administered, post-test will be administered in the 8th week and follow-up tests will be administered in the 12th week without any intervention.
62213388|NCT06113887|EXPERIMENTAL|Intervention group 4 in which psychoeducation based on acceptance and commitment therapy was applied|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test, acceptance and stability-based psychoeducation consisting of 8 modules will be implemented once a week as a single module. Each session of the acceptance and stability therapy-based psychoeducation, which will last 8 weeks in total, will be implemented for 45-60 minutes. Immediately after the training sessions are completed, the post-test; Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) will be administered. A follow-up test will be administered one month after the post-test, i.e. in the 12th week.
62213389|NCT06113887|NO_INTERVENTION|Control group 4|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test is administered, post-test will be administered in the 8th week and follow-up tests will be administered in the 12th week without any intervention.
62213390|NCT06113887|EXPERIMENTAL|Intervention group 5 in which psychoeducation based on acceptance and commitment therapy was applied|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test, acceptance and stability-based psychoeducation consisting of 8 modules will be implemented once a week as a single module. Each session of the acceptance and stability therapy-based psychoeducation, which will last 8 weeks in total, will be implemented for 45-60 minutes. Immediately after the training sessions are completed, the post-test; Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) will be administered. A follow-up test will be administered one month after the post-test, i.e. in the 12th week.
62213391|NCT06113887|NO_INTERVENTION|Control group 5|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test is administered, post-test will be administered in the 8th week and follow-up tests will be administered in the 12th week without any intervention.
62215253|NCT02309931|ACTIVE_COMPARATOR|Antiperistaltic anastomosis|Patients with right colon cancer who undergo a right laparoscopic hemicolectomy and a antiperistaltic side-to-side ileocecal anastomosis
62215254|NCT00607347|EXPERIMENTAL|A|The subjects will be undergoing a oral glucose tolerance test.
62409352|NCT05257109|EXPERIMENTAL|"Experimental E-Liquid Order A"|All participants will be given all e-liquids (i.e. all 16 flavor\*water concentration combinations (4 flavors and four water concentrations)) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across the 2 visits). For each flavor condition, water order will be randomized.
62409353|NCT05257109|EXPERIMENTAL|"Experimental E-Liquid Order B"|All participants will be given all e-liquids (i.e. all 16 flavor\*water concentration combinations (4 flavors and four water concentrations)) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across the 2 visits). For each flavor condition, water order will be randomized.
62790863|NCT01340053|EXPERIMENTAL|High Dose|100 mg capsule of tenapanor
62409354|NCT05257109|EXPERIMENTAL|"Experimental E-Liquid Order C"|All participants will be given all e-liquids (i.e. all 16 flavor\*water concentration combinations (4 flavors and four water concentrations)) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across the 2 visits). For each flavor condition, water order will be randomized.
62409355|NCT05257109|EXPERIMENTAL|"Experimental E-Liquid Order D"|All participants will be given all e-liquids (i.e. all 16 flavor\*water concentration combinations (4 flavors and four water concentrations)) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across the 2 visits). For each flavor condition, water order will be randomized.
62409356|NCT01141569|EXPERIMENTAL|Treatment (RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62790864|NCT02047214|EXPERIMENTAL|TPI 287 + bevacizumab|All subjects will be administered TPI 287 as an IV infusion (1-hour target duration) once every 3 weeks (Days 1 and 22) and bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29) of a 42-day cycle. The dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6 subjects, while the dose of bevacizumab remains constant (10 mg/kg). The planned dose escalation levels are 140, 160, 170, and 180 mg/m2; subsequent dose levels will be increased in increments of 10 mg/m2. If dose de-escalation below the starting dose level of 140 mg/m2 is required, dose levels of 130 and 120 mg/m2 will be used. Once the MTD is identified, 6 additional subjects will be enrolled at the MTD to better characterize the toxicity profile at this level. Subjects may continue on treatment unless they meet one or more of the discontinuation criteria outlined in the protocol.
62790865|NCT02309801|EXPERIMENTAL|Daidzin and alcohol|"Daidzin 80 mg, single dose, oral administration (4 capsules of Super-Absorbable Soy Isoflavones®).~Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml."
62790866|NCT02309801|ACTIVE_COMPARATOR|Alcohol|Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml.
62790867|NCT02321553|EXPERIMENTAL|Brown Rice|Eat 100g of brown rice cake (3 packets) per day for 5 weeks
62790868|NCT02321553|EXPERIMENTAL|White Rice|Eat 100g of white rice cake (3 packets) per day for 5 weeks
62790869|NCT02135237|ACTIVE_COMPARATOR|Control Group|Standard Care
62790870|NCT02135237|EXPERIMENTAL|Experimental Group|Standard Care plus Prize Contingency Management for Alcohol Abstinence
62790871|NCT00558116|EXPERIMENTAL|1|Treatment with Dynasplint device
62215255|NCT03691675|EXPERIMENTAL|Drug coated balloon|Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy
62215256|NCT03154853|NO_INTERVENTION|normal foot|no intervention
62215257|NCT03154853|EXPERIMENTAL|functional flatfoot|Behavioral: short foot exercise
62215258|NCT02765802|EXPERIMENTAL|Lambda 180 μg|Lambda 180 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
62584489|NCT02216656|EXPERIMENTAL|KHK7580 low dose|
62584490|NCT02216656|EXPERIMENTAL|KHK7580 middle dose|
62584491|NCT02216656|EXPERIMENTAL|KHK7580 high dose|
62215259|NCT02765802|EXPERIMENTAL|Lambda 120 μg|Lambda 120 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
62584492|NCT02216656|ACTIVE_COMPARATOR|KRN1493|
62584493|NCT00436475|OTHER|1|Vitamin D3 2,000 IU daily plus Calcium Carbonate 400 mg twice daily
62584494|NCT00436475|OTHER|2|Vitamin D3 2,000 IU daily plus Calcium-Placebo twice daily
62584495|NCT00436475|OTHER|3|Vitamin D3-Placebo plus Calcium Carbonate 400 mg twice daily
62584496|NCT00436475|OTHER|4|Vitamin D3-Placebo plus Calcium-Placebo
62584497|NCT05768230|EXPERIMENTAL|treatment group A|intravenously injected levosimendan 12.5mg with 5% glucose injection 50ml configuration at 2ml/h for 24h
62584498|NCT05768230|PLACEBO_COMPARATOR|treatment group B|treatment group B: control group with 5% glucose injection 2ml/h for 24h
62584499|NCT00417456|ACTIVE_COMPARATOR|1|Office Visits
62584500|NCT00417456|EXPERIMENTAL|2|Evisit
62213392|NCT06113887|EXPERIMENTAL|Intervention group 6 in which psychoeducation based on acceptance and commitment therapy was applied|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test, acceptance and stability-based psychoeducation consisting of 8 modules will be implemented once a week as a single module. Each session of the acceptance and stability therapy-based psychoeducation, which will last 8 weeks in total, will be implemented for 45-60 minutes. Immediately after the training sessions are completed, the post-test; Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) will be administered. A follow-up test will be administered one month after the post-test, i.e. in the 12th week.
62734528|NCT05285761|EXPERIMENTAL|paper brochure + smartphone application|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. They will also receive the new recommendations relating to complementary feeding through an educational device in the form of a smartphone application. This app will deliver information and very short videos illustrating various aspects of responsive feeding during CF and taking up the themes of the paper brochure. These 106 messages will be delivered regularly from the 3rd month until the 36th month of the child. Parents will also receive generic information (48 messages) contained in the health record and in connection with the general development.
62790872|NCT00558116|NO_INTERVENTION|2|Control group; does not receive conservative or surgical treatment.
62790873|NCT03483415|EXPERIMENTAL|Grup L|"IV patient-controlled analgesia (PCA) morphine~+ Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine"
62790874|NCT03483415|ACTIVE_COMPARATOR|Group P|IV patient-controlled analgesia (PCA) morphine
62790875|NCT01363661|EXPERIMENTAL|Molsidomine|Coruno (molsidomine 16 mg tablet; per os; once daily)
62790876|NCT01363661|PLACEBO_COMPARATOR|Placebo|Placebo (16 mg tablet; once a day)
62790877|NCT06090084||Multiple Sclerosis|Multiple sclerosis patients
62790878|NCT06090084||Healthy Controls|Healthy subjects
62790879|NCT06174129||Type 2 diabetes patients with atrial fibrillation|The 12-lead electrocardiography recordings of type 2 diabetes patients were reviewed by a cardiologist to confirm the presence of atrial fibrillation. The clinical parameters, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications were analyzed and compared between atrial fibrillation and non-atrial fibrillation patients.
62790880|NCT06174129||Type 2 diabetes patients without atrial fibrillation|The 12-lead electrocardiography recordings of type 2 diabetes patients were reviewed by a cardiologist to confirm the presence of atrial fibrillation. The clinical parameters, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications were analyzed and compared between atrial fibrillation and non-atrial fibrillation patients.
62790881|NCT02630511|EXPERIMENTAL|Asthma Group|Asthma group to receive mannitol, methacholine or placebo challenge tests
62790882|NCT02630511|EXPERIMENTAL|Control Group|Control group to receive mannitol, methacholine or placebo challenge tests
62790883|NCT02452424|EXPERIMENTAL|PLX3397 and Pembrolizumab (Part 1)|"Open-label, sequential PLX3397 dose escalation with a fixed dose of pembrolizumab in approximately 24 patients with advanced solid tumors.~(Enrollment complete- 33 enrolled)"
62790884|NCT02452424|EXPERIMENTAL|PLX3397 and Pembrolizumab (Part 2)|"Extension cohort at the RP2D of PLX3397 in combination with pembrolizumab in approximately 376 patients with advanced solid tumors~(Enrollment Complete- 45 enrolled)"
62790885|NCT04703764|EXPERIMENTAL|HSG4112 480 mg|60 mg HSG4112 tablet, 8 tablets, once-daily, 14-day multiple oral administration
62790886|NCT04703764|PLACEBO_COMPARATOR|Placebo 480 mg|60 mg placebo tablet, 8 tablets, once-daily, 14-day multiple oral administration
62790887|NCT04703764|EXPERIMENTAL|HSG4112 720 mg|60 mg HSG4112 tablet, 12 tablets, once-daily, 14-day multiple oral administration
62790888|NCT04703764|PLACEBO_COMPARATOR|Placebo 720 mg|60 mg placebo tablet, 12 tablets, once-daily, 14-day multiple oral administration
62213393|NCT06113887|NO_INTERVENTION|Control group 6|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test is administered, post-test will be administered in the 8th week and follow-up tests will be administered in the 12th week without any intervention.
62213394|NCT01290653|EXPERIMENTAL|Dry Needling of trigger point|Deep dry needling will be applied on the upper trapezius myofascial trigger point
62790889|NCT02116452|NO_INTERVENTION|Breast Milk|Breast FED newborns
62790890|NCT02116452|PLACEBO_COMPARATOR|Standard Formula|Standard Formula FED newborns
62790891|NCT02116452|ACTIVE_COMPARATOR|Supplemented Formula|GOS/PDX Formula FED newborns
62213395|NCT01290653|EXPERIMENTAL|Strain-counterstraing technique|This manual technique will be applied at the upper trapezius.
62215260|NCT01353768||No treatment|zanamivir aqueous solution administered previously as part of the Compassionate Use Program
62790892|NCT05502354|EXPERIMENTAL|patients with TDT removal guided by postoperative CRP trajectory|
62790893|NCT04425382||Darunavir/Cobicistat|Patients received Darunavir/Cobicistat (Rezolsta®) as part of the treatment regimen for COVID-19 pneumonia
62790894|NCT04425382||Lopinavir/Ritonavir|Patient received Lopinavir/Ritonavir (Kaletra®) as part of the treatment regimen for COVID-19 pneumonia
62790895|NCT05040568|EXPERIMENTAL|Cetuximab|given to patients with high-risk colorectal cancer
62790896|NCT01629173|EXPERIMENTAL|Dynamic impression insole|We sequentially padded P-cell, Ethylene Vinyl Acetate, and Multiform on the 9-mm thick plastazote under daily walking compression to make dynamic impression insole.
62790897|NCT01629173|EXPERIMENTAL|Custom molded insole|The custom molded insole was made by sequentially padded Multiform, P-cell, EVA, and cork on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
62790898|NCT01629173|EXPERIMENTAL|9-mm uncompressed Plastazote insole|We used 9-mm flat Plastazote as an insole
62409357|NCT05765942||Implant surgery for harvesting healthy implant tissue (group HP)|the preoperative mucosal thickness will be measured clinically using a periodontal probe. A crestal incision will be performed, and a full-thickness flap will be elevated. Following the osteotomy, one or more implants measuring 4.5 or 5.0 mm in diameter will be placed. The implant platform will be positioned 0.5 mm below the bone level. A narrow-diameter healing abutment designed specifically for this study will be screwed in at 20 N, and flaps will be repositioned and sutured to obtain optimal adaptation of the mucosa to the titanium abutment. Healthy tissue samples will be harvested after 2 months of healing. Before the surgery, a guide pin will be connected to each healing abutment, attached to a circular punch 5 mm wide and with a cutting edge, which screwed apically around the abutment. Hence, a 1.5 mm thick collar of peri-implant soft tissue will be harvested Then, a new 4.5-5.0 mm-wide smooth-surfaced healing abutment will be connected to the implant directly.
62213396|NCT01290653|PLACEBO_COMPARATOR|Placebo manual technique|A technique simulating strain-counterstrain, but without any therapeutic manoeuvre will be applied at the upper trapezius site.
62790899|NCT01629173|EXPERIMENTAL|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) as an insole
62213397|NCT03449251|EXPERIMENTAL|Substudy 1A - Apelin|In sub-study 1A Healthy participants will receive systemic infusions of Apelin to establish a dose range
62213398|NCT03449251|EXPERIMENTAL|Substudy 1B - Apelin/Normal Saline|In sub-study 1B , individuals with Type 2 Diabetes and individuals with increase weight will receive systemic infusions of Apelin or Normal Saline
62213399|NCT03449251|EXPERIMENTAL|Substudy 2A - Relaxin/Normal Saline|In sub-study 2A Healthy participants will receive intra-arterial infusions of Relaxin
62213400|NCT03449251|EXPERIMENTAL|Substudy 2B - Relaxin|In sub-study 2B Healthy participants will receive intra-arterial infusions of Relaxin followed by verapamil (on a background infusion of either LN Monomethyl Arginine or Normal Saline, to test effects on nitric oxide)
62213401|NCT03449251|EXPERIMENTAL|Substudy 3A - Relaxin with Apelin/Saline|In sub-study 3A Healthy participants will receive intra-arterial infusions of Relaxin (background infusion apelin/Normal Saline)
62213402|NCT03449251|EXPERIMENTAL|Substudy 3B - Apelin with Relaxin/Saline|In sub-study 3B Healthy participants will receive intra-arterial infusions of Apelin (background infusion Relaxin/Normal Saline)
62213403|NCT03449251|EXPERIMENTAL|Substudy 4 - Apelin and Relaxin|In sub-study 4 Healthy participants, Individuals with Type 2 Diabetes and Individuals with increase weight will receive systemic infusions of Normal saline, Relaxin, Apelin and relaxin
62213404|NCT03449251|EXPERIMENTAL|Substudy 5 - Relaxin/Saline|In sub-study 5 Healthy participants will be allocated to 1 of 4 Relaxin dosing groups and will receive dorsal hand vein infusion of 3 incremental doses of Normal Saline/ D5W and Relaxin
62213405|NCT02347423|EXPERIMENTAL|1/3 IPV-Al SSI|3 vaccinations of 1/3 IPV-Al SSI given at 6, 10 and 14 weeks of age
62213406|NCT02347423|EXPERIMENTAL|1/5 IPV-Al SSI|3 vaccinations of 1/5 IPV-Al SSI given at 6, 10 and 14 weeks of age
62213407|NCT02347423|EXPERIMENTAL|1/10 IPV-Al SSI|3 vaccinations of 1/10 IPV-Al SSI given at 6, 10 and 14 weeks of age
62213408|NCT02347423|ACTIVE_COMPARATOR|IPV Vaccine SSI|3 vaccinations of IPV Vaccine SSI given at 6, 10 and 14 weeks of age, The comparator IPV Vaccine SSI contains: Type 1: 40DU, Type 2: 8 DU and Type 3: 32 DU.
62213409|NCT05821855|EXPERIMENTAL|XEN45|Participants will be implanted with the XEN45 glaucoma treatment system in the study eye on Day 1 and followed for 60 months.
62213410|NCT05821855|ACTIVE_COMPARATOR|Trabeculectomy|Participants will undergo trabeculectomy in the study eye on Day 1 and followed for 60 months.
62213411|NCT02661919|EXPERIMENTAL|Emfit mattress sensor|
62409358|NCT05765942||Implant surgery for harvesting peri-implantitis tissue (group PP)|In each patient, at least one implant site demonstrating signs of peri-implantitis will be selected for biopsy. The site will be anesthetized and two parallel incisions, about 3mm apart, will be made with a 15C scalpel blade through the soft tissue until bone contact would be achieved. The 2 incisions will be connected with a perpendicular incision that will be placed at a distance of 4 mm from the proximal surface of the implant. The biopsies, including the entire supra-crestal soft tissue portion of the diseased site, will be carefully retrieved
62213412|NCT02217579|PLACEBO_COMPARATOR|Control|Isocaloric food without the test protein and prebiotic fiber.
62213413|NCT02217579|EXPERIMENTAL|Protein|Dietary protein consumed as two daily servings of 5 grams protein/serving.
62213414|NCT02217579|EXPERIMENTAL|Fiber|Prebiotic fiber consumed as two daily servings of 8 grams protein/serving.
62213415|NCT02217579|EXPERIMENTAL|Protein plus prebiotic fiber|Protein and prebiotic fiber consumed as two daily servings of 5 grams protein/serving plus 8 grams fiber/serving.
62790900|NCT04340453|ACTIVE_COMPARATOR|Group 1 (Hip and Knee Exercise Program)|Standard exercise physiotherapy treatment of a Hip and Knee Exercise Program plus stretching.
62790901|NCT04340453|EXPERIMENTAL|Group 2 (BFR-training hip and knee exercise group)|BFR-training hip and knee exercise group plus stretching.
62790902|NCT03100604|EXPERIMENTAL|sevoflurane 2%, 1 MAC|Maintenance of anesthesia was provided with 2% sevoflurane in S Group, and 6-9% desflurane in D Group, with 50% air /oxygen mixture and fresh gas flow at 4 l/min in both groups.
62790903|NCT03100604|EXPERIMENTAL|Desfluran 6-9% 1MAC|Maintenance of anesthesia was provided with 2% sevoflurane in S Group, and 6-9% desflurane in D Group, with 50% air /oxygen mixture and fresh gas flow at 4 l/min in both groups.
62213416|NCT04888962||Prospective cohort group|This cohort will include pregnant patients with a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until 24 hours postpartum.
62213417|NCT04888962||Control group|This cohort will include pregnant patients without a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until 24 hours postpartum.
62213418|NCT05715918|EXPERIMENTAL|Vaccine|"Group 1 - 150 volunteers, Vaccine 0.5 ml, 21 days interval, post-vaccination observation period of 21 days.~An additional objective of the study is to evaluate the safety, immunogenicity and efficacy of the CoviVac vaccine in the period from 21 days to 24 weeks after the second vaccination in comparison with placebo throughout the study."
62213419|NCT05715918|PLACEBO_COMPARATOR|Placebo|"No active ingredient in the placebo~Group 2 - 150 volunteers, Placebo 0.5 ml, 21 days interval, post-vaccination observation period of 21 days.~An additional objective of the study is to evaluate the safety, immunogenicity and efficacy of the CoviVac vaccine in the period from 21 days to 24 weeks after the second vaccination in comparison with placebo throughout the study."
62213420|NCT01487447|EXPERIMENTAL|Intervention|
62213421|NCT01487447|ACTIVE_COMPARATOR|Control|
62213422|NCT01384929||ICU patients|All patients present in the ICU on the selected days
62213423|NCT02270541|NO_INTERVENTION|Control|Standard pre-hospital emergency care by the Paramedic Intervention Team, in accordance with their standing operating procedures.
62213424|NCT02270541|EXPERIMENTAL|Telemedicine|In-ambulance teleconsultation by a stroke expert aiming to support the Paramedic Intervention Team by focusing on patient identification, obtaining homeostasis (optimal control of blood pressure, blood oxygenation, temperature, heart rate and rhythm, glycemia), assessment of the patient's neurological status, stroke diagnosis, hospital notification, and patient selection for specific stroke treatment.
62213425|NCT06532786|EXPERIMENTAL|Fractal Paced|Strength training in single leg extension machine, synchronizing each repetition with a fractal-like visual metronome, i.e., a metronome presenting visual external cues with variability within its temporal structure.
62213426|NCT06532786|EXPERIMENTAL|Isochronous Paced|Strength training in single leg extension machine, synchronizing each repetition with a isochronus visual metronome, i.e., a metronome presenting visual external cues withthe same pace in each repetition (without variability)
62790904|NCT05969704|ACTIVE_COMPARATOR|fusion biopsy|This biopsy procedure that combines the pictures from an MRI and an ultrasound to create a detailed 3-D image of the prostate. This procedure makes it easier to see an abnormal area of prostate in order to guide the biopsy needle into the abnormal area. A sample of tissue can then be taken and checked under a microscope for cancer. A fusion biopsy may help find prostate cancer cells that may be missed with other types of biopsies. It may help find cancer at an early stage and plan cancer treatment.
62213427|NCT06532786|EXPERIMENTAL|Self Paced|Strength training in single leg extension machine at participants self pace.
62213428|NCT03505034|EXPERIMENTAL|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
62213429|NCT06502886|EXPERIMENTAL|The intervention group|Use bonded retainer combined with vacuum formed retainer
62213430|NCT06502886|ACTIVE_COMPARATOR|The comparator group|Use bonded retainer
62213431|NCT02624791|EXPERIMENTAL|Lens sequence 1|"No contact lenses; 1-DAY ACUVUE® MOIST contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses"
62213432|NCT02624791|EXPERIMENTAL|Lens sequence 2|"No contact lenses; 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses;~1-DAY ACUVUE® MOIST contact lenses"
62213433|NCT02624791|EXPERIMENTAL|Lens sequence 3|"1-DAY ACUVUE® MOIST contact lenses; No contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses"
62790905|NCT05969704|ACTIVE_COMPARATOR|cognitive biopsy|the biopsy operator reviews the MR images and creates a mental three-dimensional representation of the prostate and of the lesion within it to take a biopsy from it
62213434|NCT02624791|EXPERIMENTAL|Lens sequence 4|"1-DAY ACUVUE® MOIST contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses; No contact lenses"
62213435|NCT02624791|EXPERIMENTAL|Lens sequence 5|"1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses;~1-DAY ACUVUE® MOIST contact lenses; No contact lenses"
62213436|NCT02624791|EXPERIMENTAL|Lens sequence 6|"1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses; No contact lenses;~1-DAY ACUVUE® MOIST contact lenses"
62213437|NCT04512131||Intermittent hemodialysis|patients who are going to undergo intermittent hemodialysis or patients who are going to switch dialysis mode to intermittent hemodialysis from continuous renal replacement therapy Laboratory test including complete blood count, prothrombin time, activated partial thromboplastin time, protein C, protein S and D-dimer, EXTEM of ROTEM and Multiplate® platelet function analysis will be checked just before dialysis initiation and immediately after dialysis termination
62213438|NCT04512131||continuous renal replacement therapy|patients who are going to undergo continuous renal replacement therapy Laboratory test including complete blood count, prothrombin time, activated partial thromboplastin time, protein C, protein S and D-dimer, EXTEM of ROTEM and Multiplate platelet function analysis will be checked within 24 hours after dialysis initiation and 48 hours after taking first blood sample
62215261|NCT04940403|ACTIVE_COMPARATOR|Unimanual robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will undergo 18 one-hour sessions of robot-assisted upper-limb rehabilitation. During the sessions, study participants will only train their hemiparetic arm (unimanual tasks only).
62790906|NCT04744714||GDM group|questionnaire survey and clinical follow-up
62790907|NCT04744714||non-GDM group|questionnaire survey and clinical follow-up
62790908|NCT02386449|EXPERIMENTAL|Picoprep|sodium picosulfate, magnesium oxide and citric acid
62790909|NCT02386449|ACTIVE_COMPARATOR|Mannitol and Bisacodyl|
62790910|NCT00308971|ACTIVE_COMPARATOR|1|
62790911|NCT00308971|PLACEBO_COMPARATOR|2|
62409359|NCT04637815|EXPERIMENTAL|Intervention|The intervention will consist of four sessions spaced two weeks apart that will last approximately 30 minutes each and consist of two parts: a network interview to capture network data about the time period since their last interview and a discussion of a resulting network visualization conducted in a motivational interviewing style. Participants will receive the intervention as part of existing case management.
62790912|NCT06224179|EXPERIMENTAL|Group A|Group A received ultrasound guided subcostal TAP block with 30 ml of local anesthetics and additives
62409360|NCT04637815|ACTIVE_COMPARATOR|Usual Care|As part of residency, participants receive regular case management meetings.
62790913|NCT06224179|EXPERIMENTAL|Group B|Group B received ultrasound guided both subcostal and posterior TAP block with 30 ml of local anesthetics and additives at each side
62790914|NCT02919072|EXPERIMENTAL|Chloroprocaine|Chloroprocaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
62790915|NCT02919072|ACTIVE_COMPARATOR|Ropivacaine|Ropivacaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
62790916|NCT01419886||Dysphagia|
62790917|NCT01994265|ACTIVE_COMPARATOR|Warfarin|Treatment with Warfarin once daily, taken at fast, to maintain INR between 2 and 3.
62790918|NCT01994265|ACTIVE_COMPARATOR|Dabigatran|Dabigatran 150 mg twice daily
62790919|NCT02265718||(Amyloid Negative)|
62790920|NCT02265718||Amyloid Positive|
62790921|NCT02672462|EXPERIMENTAL|Renal denervation|
62790922|NCT01090193|OTHER|obstructive jaundice|
62790923|NCT05458804|EXPERIMENTAL|Active experimental group|The participants were subjected to a 15-minute training session, once a day for 5 consecutive days. HTC VIVE Pro (HTC Corporation, New Taipei, Taiwan) goggles and accessories were used. It is specialized equipment consisting of a high-resolution screen goggles and headphones, using an Intel WiGig Wireless connection, and the technology allows for free 360 degrees of movement. The interaction in virtual reality is performed using two controllers held by the player. The movement of the controllers and goggles is tracked by two sensors. The game area covered about 5m2, in the form of a rectangle, determined by the location of motion sensors, as recommended by the manufacturer. The participant received visual information when approaching the boundaries of the game field. A Beat Saber music game was used to conduct training sessions
62409361|NCT05948826|EXPERIMENTAL|Monotherapy Dose Dose Finding - Part 1|TORL-3-600
62790924|NCT05458804|NO_INTERVENTION|Passive Control group|Participants in the control group did not participate in the training, and were instructed not to perform specific physical activities aimed at improving the examined abilities
62790925|NCT03870399|EXPERIMENTAL|Tamoxifen|The participants will receive tamoxifen 20mg orally once daily with a glass of water. Each cycle will be defined for 42 days (6 weeks).
62790926|NCT00310596|EXPERIMENTAL|Arm 1|
62790927|NCT00310596|EXPERIMENTAL|Arm 2|
62020459|NCT04844424|EXPERIMENTAL|Part 3B: Treatment Sequence NOP|Participants will receive single oral Dose 1 of milvexian oral Tablet 1 under fed conditions (Treatment N) in Treatment Period 1, followed by single oral Dose 1 of milvexian oral Tablet 2 under fed conditions (Treatment O) in Treatment Period 2 and then single oral Dose 1 of milvexian Phase 2 oral capsule under fed conditions (Treatment P) in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020460|NCT04844424|EXPERIMENTAL|Part 3B: Treatment Sequence OPN|Participants will receive Treatment O in Treatment Period 1, followed by Treatment P in Treatment Period 2 and then Treatment N in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020461|NCT04844424|EXPERIMENTAL|Part 3B: Treatment Sequence PNO|Participants will receive Treatment P in Treatment Period 1, followed by Treatment N in Treatment Period 2 and then Treatment O in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62790928|NCT00310596|EXPERIMENTAL|Arm 3|
62790929|NCT00310596|EXPERIMENTAL|Arm 4|
62790930|NCT00310596|ACTIVE_COMPARATOR|Arm 5|
62790931|NCT00310596|PLACEBO_COMPARATOR|Arm 6|
62790932|NCT05802862|EXPERIMENTAL|22011|
62790933|NCT05802862|ACTIVE_COMPARATOR|Ryzodeg|
62790934|NCT04336072|EXPERIMENTAL|Reminder Focused Positive Psychiatry (RFPP)|RFPP aims to enhance contextual discrimination and emotional regulation, and promote the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices
62790935|NCT04336072|ACTIVE_COMPARATOR|Trauma Focused Cognitive Behavioral Therapy (TFCBT)|TFCBT is inclusive of the trauma narrative (TN) \& processing components facilitated the child talking about memories individually and in groups, the last sessions focused on grief-specific elements.
62790936|NCT02595619|EXPERIMENTAL|RRT plus ECCO2R|
62020462|NCT04844424|EXPERIMENTAL|Part 3B: Treatment Sequence NPO|Participants will receive Treatment N in Treatment Period 1, followed by Treatment P in Treatment Period 2 and then Treatment O in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62213439|NCT05705843|ACTIVE_COMPARATOR|Intravenous Vancomycin Administration|Patients will receive the Houston Methodist Hospital orthopedic surgery standard of care pre-operative antibiotic regimen for primary total knee arthroplasty patients. This includes IV antibiotics (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg \[12,13\] generally 1000-1750mg in 500mL NS).
62790937|NCT06236386|OTHER|VR Experience|A VR headset will be loaned to patients to be immersed in a VR environment while undergoing their colonoscopy.
62790938|NCT02518763|EXPERIMENTAL|Vitamin D3, 100 000 IU weekly, 4 times|
62790939|NCT00761696|EXPERIMENTAL|IPI-926|Oral daily dosing
62213440|NCT05705843|EXPERIMENTAL|Intraosseous Vancomycin Administration|"* IV antibiotics (per physician's standard of care): Typically ancef or cefepime is started in pre-op within 1 hour of incision. IV Vancomycin will not be administered preoperatively in this group.~* IO vancomycin is administered via an intraosseous cannulation device (Arrow EZ-IO; Teleflex, Morrisville, NC) in the OR after sterile prep and draping has occurred prior to skin incision (500mg in 150mL NS).~* Injection will take place into the tibial tubercle (within a pre-specified region) immediately prior to incision."
62213441|NCT00221026|EXPERIMENTAL|drug|ECP + Uvadex given for 12 weeks.
62213442|NCT04488770|EXPERIMENTAL|Part 1 (SAD) Cohort 1:Participants receiving GSK3882347|In this single ascending dose phase, participants will receive GSK3882347 50 milligram (mg), 150 mg and 250 mg orally on Day 1 of period 1, 2 and 3 respectively. Period 4 will be conducted to assess food effect based on the observed human PK.
62409362|NCT05948826|EXPERIMENTAL|Expansion as Monotherapy - Part 2|TORL-3-600
62409363|NCT01584804|ACTIVE_COMPARATOR|Monotherapy|Monotherapy with Su-Huang antitussive capsule
62409364|NCT01584804|PLACEBO_COMPARATOR|Sugar pill|Monotherapy with placebo
62584501|NCT06253637|EXPERIMENTAL|Very high risk T-ALL patients treated with daratumumab and the national treatment program|"After a steroid/cyclophosphamide pre-treatment phase, patients will be treated according to the national treatmetn program - as per the previous GIMEMA LAL1913 - plus daratumumab as follows:~* In the first cycle, C1, daratumumab (subcutaneous) 1800 mg will be administered on days 1, 8, 15 and 22~* In the second cycle, C2, daratumumab 1800 mg will be administered on days 1, 8, 15~* In the subsequent cycles C3-C8 daratumumab 1800 mg will be administered on day 1~in addition to chemotherapy according to the national treatment program~Induction/consolidation cycles are administered at 28 (C1-2) and 21(C2-8) day intervals. Dose reductions are required in patients \> 55y~All patients are eligible for allo-SCT after C3. All patients unable to undergo an allo-SCT are eligible for an auto-SCT after C8, If unable to undergo an auto-SCT, these patients are eligible to maintenance at the end of the consolidation program."
62790940|NCT00771966|PLACEBO_COMPARATOR|Standard treatment|
62790941|NCT00771966|ACTIVE_COMPARATOR|SV maximization|
62790942|NCT05020275||Blood samples|Blood samples for further assays
62790943|NCT05549791||General anesthesia cohort|
62790944|NCT05549791||Bronchoscopy sedation cohort|
62213443|NCT04488770|PLACEBO_COMPARATOR|Part 1 (SAD),Cohort 1:Participants receiving Placebo|In this single ascending dose phase, participants will receive matching Placebo orally on Day 1 of period 1, 2 and 3. Period 4 will be conducted to assess food effect based on the observed human PK.
62213444|NCT04488770|EXPERIMENTAL|Part 1 (SAD),Cohort 2: Participants receiving GSK3882347|In this single ascending dose phase, participants will receive GSK3882347 500 mg, 15 mg and 900 mg orally on Day 1 of period 1, 3 and 2 respectively.
62790945|NCT03833063|PLACEBO_COMPARATOR|placebo|injections with sodium chloride
62213445|NCT04488770|PLACEBO_COMPARATOR|Part 1 (SAD),Cohort 2: Participants receiving Placebo|In this single ascending dose phase, participants will receive matching Placebo orally on Day 1 of period 1, 3 and 2.
62213446|NCT04488770|EXPERIMENTAL|Part 2 (MAD),Cohort 3: Participants receiving GSK3882347 50mg|In this multiple ascending dose phase, participants will receive GSK3882347 50 mg orally on Day 1 to Day 7 of the study. The dose to be administered may be changed based on clinical safety, tolerability and PK findings in Part 1.
62790946|NCT03833063|ACTIVE_COMPARATOR|botulinum toxin A|injections with botulinum toxin A
62790947|NCT01966289|EXPERIMENTAL|Cohort 1:CY/GVAX concurrently with SGI-110|During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2, the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 Granulocyte macrophage-colony stimulating factor (GM-CSF) secreting cells, and SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
62409365|NCT02010346|EXPERIMENTAL|Early headgear treatment|Headgear treatment is initiated at the age of 7-8 years and continued as long as Class I occlusion is achieved
62409366|NCT02010346|NO_INTERVENTION|Later headgear treatment|Headgear treatment is initiated in the beginning of the growth spurt.
62409367|NCT03294382|EXPERIMENTAL|Botulinum toxin|5U Botulinum toxin in 0.1 mL normal saline, administered in one of the intercanthus
62790948|NCT01966289|EXPERIMENTAL|Cohort 2: CY/GVAX after SGI-110|During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2, Cyclophosphamide (CY) is administered on Day 8 at 200 mg/m2, and the colon cancer tumor vaccine (GVAX) is administered on Day 9 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
62790949|NCT01966289|EXPERIMENTAL|Cohort 3: CY/GVAX|During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 and the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
62409368|NCT03294382|PLACEBO_COMPARATOR|Normal Saline|0.1 mL normal saline, administered in the other intercanthus
62409369|NCT05651373||patients not using TNF inhibitors(TNFi)|"The cohort includes the RA patients in pregnancy.~Drug: Hydroxychloroquine(HCQ)，200mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Prednisone(Pred)，5-30mg, po, once per day (qd) prescribed at the beginning and adjusted due to patient response."
62584502|NCT00976976|EXPERIMENTAL|DXP|
62790950|NCT01966289|EXPERIMENTAL|Cohort 4: SGI-110|During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
62790951|NCT01514201|EXPERIMENTAL|Treatment (veliparib, temozolomide, 3D-CRT, IMRT)|"DOSE-ESCALATION: Patients receive veliparib PO BID 5 days a week for 6-7 weeks. Patients also undergo concurrent 3D-CRT or IMRT QD 5 days a week for 6-7 weeks.~MAINTENANCE THERAPY: Beginning 3-4 weeks later, patients receive veliparib PO BID on days 1-5 and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 10 courses in the absence of disease progression or unacceptable toxicity."
62790952|NCT03556709|EXPERIMENTAL|Treadmill Ankle Robot Training|
62790953|NCT06404489|EXPERIMENTAL|Prehabilitation|Prehabilitation arm group will receive preoperative intervention which includes exercise training, nutritional therapy and anxiety reducing techniques, aimed at preventing or attenuating surgery-driven functional decline.
62790954|NCT06404489|NO_INTERVENTION|Control group|Standard care treatment. Application of ERAS pathways (Enhanced Recovery After Surgery)
62584503|NCT02282631|EXPERIMENTAL|Intervention group school|School where the incentive scheme will be run.
62790955|NCT03495102|ACTIVE_COMPARATOR|Dulaglutide 1.5 mg|Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.
62790956|NCT03495102|EXPERIMENTAL|Dulaglutide 3 mg|Dulaglutide 3 mg administered SC once a week.
62790957|NCT03495102|EXPERIMENTAL|Dulaglutide 4.5 mg|Dulaglutide 4.5 mg administered SC once a week.
62790958|NCT04489199||Stroke patient|Patient included in the Dijon Stroke Registry.
62790959|NCT02744885|EXPERIMENTAL|Crave Crush|Crave Crush is a plant-based tablet that alters taste perception by affecting sweet taste receptors on the tongue.
62790960|NCT02744885|PLACEBO_COMPARATOR|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
62213447|NCT04488770|PLACEBO_COMPARATOR|Part 2 (MAD),Cohort 3: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
62409370|NCT05651373||patients using TNF inhibitor (TNFi)|"The cohort includes the RA patients in pregnancy.~Drug: Hydroxychloroquine(HCQ)，200mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Prednisone(Pred)，5-30mg, po, once per day (qd) prescribed at the beginning and adjusted due to patient response.~Drug: TNFi ,such as Certolizumab Pegol (Cimzia)，200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response."
62409371|NCT04940091||Epidural labor analgesia|All participants will receive epidural analgesia during labor.
62409372|NCT05362669|EXPERIMENTAL|Experimental - Intervention|SMS invitation to participate in cervical cancer screening using HPV self-sampling.
62409373|NCT05362669|ACTIVE_COMPARATOR|Active Comparator - Usual Care|Phone call invitation to participate in cervical cancer screening using HPV self-sampling.
62409374|NCT05542212|EXPERIMENTAL|TMS treatment group|"1. Receive ICI test and MATRICS test.~2. Receive active iTBS treatment on the dlPFC for 4 weeks, 1 treatment a day and 5 days a week."
62790961|NCT04991662|EXPERIMENTAL|metaraminol group|During the cesarean section, metaraminol 2ug/kg/min is preventively infused after anesthesia to prevent and treat hypotension.
62409375|NCT05542212|SHAM_COMPARATOR|TMS Sham Control Group|"1. Receive ICI test and MATRICS test.~2. Receive sham TMS treatment on the dlPFC for 4 weeks, 1 treatment a day and 5 days a week."
62409376|NCT05542212|NO_INTERVENTION|Normal Control|1. Receive ICI test and MATRICS test.
62213448|NCT04488770|EXPERIMENTAL|Part 2 (MAD),Cohort 4: Participants receiving GSK3882347 150mg|GSK3882347 150 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 4 will be based on PK/PD results from preceding dosing cohorts.
62213449|NCT04488770|PLACEBO_COMPARATOR|Part 2 (MAD),Cohort 4: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
62409377|NCT04053933||Patients treated with ESA|
62409378|NCT04053933||Patients treated with 5'azacitidin|
62409379|NCT04053933||Patients treated with deferoxamine|
62409380|NCT04053933||Patients treated with deferasirox|
62409381|NCT04053933||Patients treated with transfusion only|
62409382|NCT04053933||Patients treated with lenalidomide|
62409383|NCT04053933||Patients treated with intensive chemotherapy|
62790962|NCT04991662|EXPERIMENTAL|phenylephrine group|During cesarean section, preventive infusion of phenylephrine 0.54ug/kg/min after anesthesia to prevent and treat hypotension.
62790963|NCT04991662|EXPERIMENTAL|norepinephrine group|During cesarean section, preventive infusion of norepinephrine 0.08ug/kg/min after anesthesia to prevent and treat hypotension.
62790964|NCT02781480|EXPERIMENTAL|Low dose AAV-RPE65|Subretinal administration of a single low dose of range AAV-RPE65
62790965|NCT02781480|EXPERIMENTAL|Intermediate dose AAV-RPE65|Subretinal administration of a single intermediate dose of range AAV-RPE65
62790966|NCT02781480|EXPERIMENTAL|High dose AAV-RPE65|Subretinal administration of a single high dose of range AAV-RPE65
62213450|NCT04488770|EXPERIMENTAL|Part 2(MAD),Cohort 5: Participants receiving GSK3882347 500mg|GSK3882347 500 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 5 will be based on PK/PD results from preceding dosing cohorts.
62213451|NCT04488770|PLACEBO_COMPARATOR|Part 2 (MAD),Cohort 5: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
62213452|NCT04488770|EXPERIMENTAL|Part 2(MAD),Cohort 6: Participants receiving GSK3882347 900mg|GSK3882347 900 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 6 will be based on PK/PD results from preceding dosing cohorts.
62213453|NCT04488770|PLACEBO_COMPARATOR|Part 2(MAD),Cohort 6: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
62409384|NCT02073591||Ceradan Regimen|Ceradan Cream and Ceradan Wash
62409385|NCT04698252|NO_INTERVENTION|Systemic therapy|Patients will receive standard of care with systemic therapy alone.
62409386|NCT04698252|EXPERIMENTAL|Local therapy + systemic therapy|In addition to systemic therapy, patients will receive local therapy for all oligometastatic sites. Options of local therapy will be radiotherapy, radiofrequency ablation, and/ or surgery.
62409387|NCT00194116|EXPERIMENTAL|Divalproex Sodium ER|
62409388|NCT00194116|PLACEBO_COMPARATOR|Placebo|
62409389|NCT00278473|EXPERIMENTAL|Meta-Cognitive Therapy|Cognitive behavioral group. Cognitive behavioral therapy focuses on changing patterns of thinking and behavior. Each group consists of 6 to 8 members and sessions are led by a psychologist.
62409390|NCT00278473|ACTIVE_COMPARATOR|Supportive Therapy|Social support problem-solving group. Social support problem-solving focuses on general support, problem solving, and information sharing. Each group consists of 6 to 8 members and sessions are led by a psychologist.
62409391|NCT02048059|EXPERIMENTAL|ANG1005|Participants received ANG1005 intravenously (IV) at a dose of 600 mg/m\^2 on Day 1 of each 21-day cycle. ANG1005 will be administered for up to a maximum of one year, or until disease progression or adverse events (AE) that are not tolerated.
62409392|NCT01410747||tacrolimus group|Oral
62584504|NCT02282631|NO_INTERVENTION|Control group school|School with no intervention; ongoing advice on active school travel.
62409393|NCT01353586|EXPERIMENTAL|nMARQ™ System|The nMARQ™ System (Circular and Crescent Mapping and Ablation Catheters as well as the Multi-Channel Radiofrequency Generator) as part of the Multi-Electrode Irrigated Pulmonary Vein (PV) Isolation System will serve as a treatment method for subjects undergoing radiofrequency catheter ablation for drug refractory, symptomatic Paroxysmal Atrial Fibrillation (PAF). The study later included a Subpopulation Neurological Assessments (SNA) substudy which is a prospective, non-randomized, controlled, acute assessment to compare subjects treated with the nMARQ™ System against control subjects treated with the NAVISTAR® THERMOCOOL® Irrigated Tip Catheter.
62409394|NCT00583427|EXPERIMENTAL|Sulodexide|
62409395|NCT05741788|EXPERIMENTAL|Experimental group|Prospective cohort of patients clinically scheduled to undergo spinal cord stimulation for the treatment of chronic back pain or radiculopathy.
62213454|NCT03167372|EXPERIMENTAL|Bright white light vs dim red light|"A balanced sequence (ABBA) over a 12 week period of bright white light and dim red light; alternating bright white and dim red light every 3 weeks.~Subjects will receive 2 Litebook® Advantage lightboxes - 1 bright white and 1 dim red. Information such as mood, fatigue, sleep and light therapy side effects will be self-reported using a smartphone diary; physical activity and sleep will also be reported using a Fitbit Flex2 TM. Data visualization at 12 weeks."
62213455|NCT03167372|ACTIVE_COMPARATOR|Dim white light vs dim red light|"A balanced sequence (ABBA) over a 12 week period of dim white light and dim red light; alternating dim white and dim red light every 3 weeks.~Subjects will receive 2 Litebook® Advantage lightboxes - 1 dim white and 1 dim red. Information such as mood, fatigue, sleep and light therapy side effects will be self-reported using a smartphone diary; physical activity and sleep will also be reported using a Fitbit Flex2 TM. Data visualization at 12 weeks."
62213456|NCT01693705||Tracheostomy Patients|Critical care patients with respiratory failure who were mechanically ventilated and who underwent tracheostomy
62213457|NCT01693705||Non-Tracheostomy Patients|Critical care patients with respiratory failure who were mechanically ventilated but did not undergo tracheostomy
62213458|NCT02892227|EXPERIMENTAL|JET ECHO|Transmitral flow estimation
62213459|NCT02892227|NO_INTERVENTION|NO JET ECHO|no bedside echocardiography
62213460|NCT00128102|EXPERIMENTAL|Vorinostat|Vorinostat three 100 mg capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
62213461|NCT00128102|PLACEBO_COMPARATOR|Placebo|Placebo capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
62213462|NCT00620295|EXPERIMENTAL|Gemcitabine / Bortezomib|"Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose on day 1 and day 8 of a 21 day cycle.~Bortezomib will be given 1 hour after gemcitabine by IVP over 3 to 5 seconds followed by a standard saline on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles."
62409396|NCT04765501||Patients group|Individuals with headache
62409397|NCT01036594|EXPERIMENTAL|Ketoconazole + Hydrocortisone|"po = oral tid = 3 times per day qam = every morning qom = every evening bid = twice daily~1 cycle = 28 days~* Ketoconazole: 200mg during first week of study (run-in phase), then 400mg po tid~* Hydrocortisone 20mg po qam and 10mg po qpm: If participant has ≥ 30% Prostate-specific antigen (PSA) decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by Prostate Specific Antigen Working Group (PSAWG) criteria) is documented. After that, drug will be discontinued. If participant has \< 30% PSA decline at 12 week evaluation, participant goes off study."
62409398|NCT01036594|EXPERIMENTAL|Ketoconazole + Dexamethasone|"* Ketoconazole: 400mg po tid~* Dexamethasone 0.5mg po bid: If ≥ 30% PSA decline (Prostate-specific antigen) at 12 week evaluation, administration starts when disease progression (by RECIST criteria OR by PSAWG criteria) is documented."
62409399|NCT01788969|EXPERIMENTAL|Gait Training with Lexapro|Gait training 2 weeks, gait training 4 weeks (3 X week) with Lexapro (10mg SSRI), wash out period of 1 week, gait training, for 4 weeks with placebo (10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
62409400|NCT01788969|ACTIVE_COMPARATOR|Gait Training with Placebo|Gait training 2 weeks, gait training for 4 weeks (3X week) with Placebo (10 mg), wash out period of 1 week, gait training for 4 weeks with Lexapro(10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
62409401|NCT01728935|OTHER|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
62409402|NCT04681001|EXPERIMENTAL|Coldamaris pro|One puff per nostril three puffs into mouth
62409403|NCT04681001|PLACEBO_COMPARATOR|Coldamaris sine|One puff per nostril three puffs into mouth
62409404|NCT01448070|EXPERIMENTAL|NN729 manufacturing process|
62409405|NCT01448070|ACTIVE_COMPARATOR|Current manufacturing process|
62409406|NCT03752424|ACTIVE_COMPARATOR|Silver nanoparticles group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received Topical silver nanoparticles in different dosage forms.
62409407|NCT03752424|PLACEBO_COMPARATOR|Topical approved anti-microbial gel|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received placebo cream.
62409408|NCT02942537|EXPERIMENTAL|Intervention|Microwave treatment
62213463|NCT01813877|NO_INTERVENTION|Standard Diagnostics without PET|
62213464|NCT01813877|EXPERIMENTAL|Diagnostics with PET|All 18F-DOPA PET/CT studies will be interpreted qualitatively during a clinical readout session. Based on a previous study scans will be classified as positive if tumor regions defined on CT exhibited tracer uptake above the level of the contra-lateral caudate nucleus. Scans will be classified as negative if tumor 18F-FDOPA uptake is lower than that of the contra lateral caudate nucleus. Uptake at the level of the contra-lateral caudate will be considered equivocal for malignancy.
62409409|NCT02942537|ACTIVE_COMPARATOR|Control|Uterine artery embolization
62409410|NCT03626246||Kidney disease|Patients who participate in our study are 40 years old or older and have a Chronic kidney disease stage 3, 4 or 5.
62213465|NCT04662177|EXPERIMENTAL|Group 1: Co-administration of dexmedetomidine and propofol with electrophysiological studies|The group 1 starts with a bolus of dexmedetomidine 0.4 µg/kg over 10 minutes, followed by continuous infusion of dexmedetomidine 0.4 µg/kg/h until the end of burst suppression.
62213466|NCT04662177|NO_INTERVENTION|Group 2: Standard anaesthesia with propofol and electrophysiological studies|The group 2 receive standard anaesthesia management.
62213467|NCT00492102|EXPERIMENTAL|1|Nine VLBW pre-term infants older than 7 days will be enrolled in the study and receive one oral dose of Montelukast based on weight. Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.
62213468|NCT03776227|EXPERIMENTAL|Sotagliflozin Test|One tablet of sotagliflozin administered orally under fasting conditions
62213469|NCT03776227|ACTIVE_COMPARATOR|Sotagliflozin Reference|Two tablets of sotagliflozin administered orally under fasting conditions
62213470|NCT04287595|EXPERIMENTAL|intervention group|inhalation aromatherapy with orange essential oil
62213471|NCT04287595|NO_INTERVENTION|control group|routine care
62213472|NCT01808326|EXPERIMENTAL|chlorambucil|chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
62213473|NCT04949542|EXPERIMENTAL|Bolster|Participants in the experimental arm will be provided access to the Bolster smartphone application designed to support caregivers of young adults with early psychosis. They will also have access to the research team by phone for technical troubleshooting and support as necessary.
62584505|NCT02830113|EXPERIMENTAL|non-surgical periodontal treatment|One session of non-surgical periodontal treatment consisting of a complete scaling, polishing, root planning, and the irrigation of periodontal pockets with a 10% povidone iodine solution.
62790967|NCT01964625|EXPERIMENTAL|PET-CT|Patients who have a negative routine PET-CT evaluation followed by onset and confirmation in accordance with NIH guidelines, will receive another PET-CT scan prior to initiation of therapy for chronic GvHD.
62790968|NCT06309589|EXPERIMENTAL|experimental group|experimental group received UDCA(Losan Pharma GmbH, registration number H20181059, 13-15 mg/day/kg) combined with Vitamin D3 (1200 IU per day) treatment for 1year
62790969|NCT06309589|NO_INTERVENTION|control group|control group received UDCA(Losan Pharma GmbH, registration number H20181059, 13-15 mg/day/kg) treatment for 1 year
62213474|NCT04949542|OTHER|Control|Participants in the control condition will be provided support resources from mental health advocacy organizations representing currently available resources for caregivers (including a selection from the National Alliance on Mental Illness and Mental Health America). They will also have access to the research team by phone for technical troubleshooting and support as necessary.
62213475|NCT04553289|EXPERIMENTAL|exercising into pain|The participants will train during 12 with progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, including 2 in closed kinetic chain exercises and 2 executed with the elastic band or with dumbbell/weight. One exercise will be performed with pain ranging between 4 and 7 on a NPRS (Numeric Pain Rating Scale) and the rest of the exercises will be performed with no/slight pain, ranging between 0 and 2 on NPRS. At week 9, patients will continue to exercise with pain between 0 and 2 in all exercises. 10/15 minutes of manual therapy (posterior capsular release) will be applied during the physiotherapy session.
62584506|NCT02308072|EXPERIMENTAL|Olaparib + Cisplatin + IMRT|"Olaparib: 50, 100, 150 or 200 mg twice a day for between 3-5 sequential days, depending on cohort allocation, in combination with Cisplatin: 35 mg/m\^2 on day 1, and IMRT: 2 Gy radiotherapy given on days 1-5~Treatment will start on day 1 of every week. Patients will receive up to 7 weeks of combination chemotherapy and radiotherapy treatment."
62584507|NCT06355310|EXPERIMENTAL|Study intervention|Empagliflozin 10 mg will be taken daily
62213476|NCT04553289|ACTIVE_COMPARATOR|exercising with no/slight pain|The participants will train during 12 weeks with progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, including 2 in closed kinetic chain exercises and 2 executed with the elastic band or with dumbbell/weight. All the exercises will be performed with no/slight pain, ranging between 0 and 2 on NPRS. 10/15 minutes of manual therapy (posterior capsular release) will be applied during the physiotherapy session.
62213477|NCT02627053|EXPERIMENTAL|rivaroxaban|
62213478|NCT01056718|OTHER|Nebivolol treatment|10 week open label nebivolol treatment.
62213479|NCT01859988|EXPERIMENTAL|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection every week (qw) from Week 1 to Week 15.
62213480|NCT01859988|EXPERIMENTAL|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
62213481|NCT01859988|EXPERIMENTAL|Dupilumab 300 mg q2w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 15.
62213482|NCT01859988|EXPERIMENTAL|Dupilumab 200 mg q2w|Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.
62213483|NCT01859988|EXPERIMENTAL|Dupilumab 300 mg q4w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab every 4 weeks (q4w) and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
62213484|NCT01859988|EXPERIMENTAL|Dupilumab 100 mg q4w|Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
62213485|NCT05269745|ACTIVE_COMPARATOR|Immobilization group (IG)|One group - immobilization group (IG) - will receive the standard treatment.
62790970|NCT05972005|EXPERIMENTAL|Intervention (Stronger at Home model)|This study implements a 14-week home-based rehabilitation program for older adults after hip fractures. Participants will receive 8 home visits by a Physiotherapist (PT) and/or Physio assistant(PTA), focusing on individualized exercise programs and pain self-management. The intervention aims to improve functional recovery and includes PT-led assessments, exercise adjustments, and discharge assessments. PTAs support exercise delivery and education. The clinical team comprises PTs and PTAs, receiving training on exercise principles, pain education, and goal setting. The program emphasizes progressive strengthening, balance, and functional exercises, adhering to evidence-based principles. The intervention aims to enhance efficiency, reduce wait times, and promote adherence.
62213486|NCT05269745|EXPERIMENTAL|Immobilization/Activity Group (IAG)|The other group - Immobilization/Activity Group (IAG) - will be treated with a new approach.
62213487|NCT05269745|OTHER|Control Phase|Before the intervention with the orthotic treatment starts, a control phase of 8 weeks is planned.
62213488|NCT02396628|EXPERIMENTAL|Experimental intervention|Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines.
62213489|NCT02396628|ACTIVE_COMPARATOR|Standard treatment|Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
62213490|NCT03554629|OTHER|Capnography CO2 Sampling Filterline Performance|Adult volunteer exhaled gas was sampled by 8 different CO2 cannula sampling filterline (CCSF) designs connected to a Capnostream 35 for measurement of CO2 during patient simulated scripted activities in order to assess patient interface design performance to provide a quality gas sample for CO2 partial pressure measurement.
62213491|NCT03481543|EXPERIMENTAL|In-line nebulization through NIV mask|Bronchodilator nebulization is given through NIV circuit.
62213492|NCT03481543|ACTIVE_COMPARATOR|Off-NIV nebulization|Bronchodilator nebulization is given during which NIV mask is taken off for a short time and reapplied when nebulization is finished.
62213493|NCT02070224|OTHER|Knee osteoarthritis|
62213494|NCT05841992|EXPERIMENTAL|Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CTscan|Patients of Prostate cancer PET/CT imaging: In two consecutive days each patient underwent a PET/CT scan after intravenous administration of 68Ga-PSMA617 and Al18F-PSMA-617, respectively.
62213495|NCT01827995|OTHER|Duo test|Self assessment
62584508|NCT06355310|PLACEBO_COMPARATOR|Control arm|Placebo oral tablet will be taken daily
62213496|NCT01827995|OTHER|Routine follow up|Follow up in the clinic
62213497|NCT03887949|ACTIVE_COMPARATOR|VCV|Volume controlled ventilation
62213498|NCT03887949|ACTIVE_COMPARATOR|PCV|Pressure controlled ventilation
62213499|NCT03887949|EXPERIMENTAL|PCV-VG|Pressure controlled ventilation with volume guarantee
62213500|NCT05154877||DMI5R|The subject will undergo two PET/CT scans: one on the DMI5R scanner and one on the OMNI scanner.
62213501|NCT05154877||DIQ5R|The subject will undergo two PET/CT scans: one on the DIQ5R scanner and one on the OMNI scanner.
62213502|NCT05565495|EXPERIMENTAL|Hydromorphone|Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the content of hydromorphone and hydromorphone-3-glucuronide (the main metabolite) was detected by quantitative liquid chromatography tandem mass spectrometry. And then a population pharmacokinetic model of hydromorphone in patients under ECMO was established.
62213503|NCT04110639|ACTIVE_COMPARATOR|Validation Group|A validation group of 10 patients with minimally displaced femoral neck fractures (Garden 1) which will be pinned in situ without manipulation
62584509|NCT03991962|EXPERIMENTAL|mFOLFIRINOX followed by SBRT|Patients will receive mFOLFIRINOX, followed stereotactic body radiotherapy (SBRT).
62584510|NCT06683378|ACTIVE_COMPARATOR|Peripheral nerve tissue (PNT) deployment to the Substantia Nigra|
62213504|NCT04110639|EXPERIMENTAL|Study Group|A study group of 20 patients with displaced femoral neck fracture patients (Garden 2-4) treated with open or closed reduction and internal fixation
62213505|NCT01914601|ACTIVE_COMPARATOR|Macintosh-King Vision|laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope
62213506|NCT01914601|ACTIVE_COMPARATOR|King Vision-Macintosh|laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
62213507|NCT03916874||Pregnant females and her newborn.|A longitudinal study of one cohort of 250 pregnant females less than 22 weeks gestation and her newborn. Swabs and samples (low vaginal, skin, urine, blood and stool) will be requested at one time point during each trimester from the participant. In addition, there are three different questionnaires at trimester 2.
62213508|NCT00239551|EXPERIMENTAL|Prevacid|Effect of Prevacid at 8 weeks; EGD(esophagogastroduodenal endoscopy) at day 1 \& EGD at 8 weeks
62213509|NCT06412601|EXPERIMENTAL|RPM (remote patient monitoring)|
62213510|NCT06412601|ACTIVE_COMPARATOR|Non-RPM|
62213511|NCT01856868|EXPERIMENTAL|Treatment with Epicatechin|Purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
62213512|NCT00606060|EXPERIMENTAL|Arm 1|
62213513|NCT04220840||Study Group|All consecutive patients who underwent damage control surgery (DCS) for perforated diverticulitis of the sigmoid colon with generalized Peritonitis in one of the participating centers
62213514|NCT04220840||Control group|All consecutive patients who underwent other than DCS surgery (resection with primary anastomosis, Hartmann´s procedure, laparoscopic lavage) for perforated diverticulitis of the sigmoid colon with generalized Peritonitis in one of the participating centers which do not apply DCS routinely.
62409411|NCT03788785|EXPERIMENTAL|Experimental arm|The specific tobacco cessation intervention of the treatment group will begin during the diagnostic phase of the HNSCC by three ½ hour session of assessment of current addictive behaviors and motivation to change smoking habits occurring within five days top. The most important point is that this intervention will be provided by trained nurses of the health care team within the ENT department, rather than in an external smoking cessation center.
62409412|NCT03788785|OTHER|Control arm|In the control arm, patients will receive the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation (self-help tools).
62790971|NCT05972005|ACTIVE_COMPARATOR|Control (usual care)|The control group will receive usual home care provided by the healthcare system, which could vary between cases. We'll document their received care during follow-ups as it is inconsistent and poorly recorded. Regular check-in calls by the study coordinator will remind them of assessments, reducing attrition.
62213515|NCT02435121|EXPERIMENTAL|SAR125844|Given intravenously weekly at the dose of 570 mg/m\^2 for at least 18 weeks
62213516|NCT02601976|EXPERIMENTAL|PegInterferon alfa-2a and Ribavirin|PegInterferon alfa-2a subcutaneously once weekly Ribavirin administered orally according to the body weight
62213517|NCT02644291|EXPERIMENTAL|mebendazole|oral mebendazole as dose escalation (three groups), or l oral mebendazole at maximum dose for extended cohort. Given in 3 divided doses with meals as chewable 500 mg tablets based on calculated patient surface area.
62213518|NCT02707549|ACTIVE_COMPARATOR|Normal Saline Group|the patients included in this group will receive normal saline solution (0.9% sodium chloride) during surgery and in the first 24 hours after ICU admission.
62213519|NCT02707549|EXPERIMENTAL|Balanced Crystalloid Solution Group|the patients included in this group will receive balanced crystalloid solution during surgery and in the first 24 hours after ICU admission.
62213520|NCT02883998|ACTIVE_COMPARATOR|Outpatient Physical Therapy Group|Once the patient is cleared for discharged from the hospital, the patient will be given a prescription for outpatient physical therapy to attend 3 times per week for 6 weeks.
62213521|NCT02883998|EXPERIMENTAL|Home Base Physical Therapy Group|Patients will be provided a packet of exercises and equipment to perform the home based physical therapy program. Patients will attend a single session of outpatient physical therapy prior to surgery no more than 4 weeks prior to the procedure to teach the patient how to perform the exercises.
62213522|NCT02512640|ACTIVE_COMPARATOR|Volume-controlled ventilation|Volume-controlled ventilation throughout the surgery
62213523|NCT02512640|ACTIVE_COMPARATOR|Pressure-controlled ventilation|Pressure-controlled ventilation throughout the surgery
62213524|NCT03698903|EXPERIMENTAL|Take a STAND 4 Health: Immediate|Receives the coaching calls + mHealth intervention first, then receives only the mHealth intervention after the 4 week assessment.
62213525|NCT03698903|ACTIVE_COMPARATOR|Take a STAND 4 Health: Delayed|Will receive no intervention for the first 4 weeks but then after assessment will be provided the opportunity to receive the full coaching calls + mHealth intervention.
62213526|NCT03218397|ACTIVE_COMPARATOR|Standard blood culture and AST|Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.
62213527|NCT03218397|ACTIVE_COMPARATOR|Rapid organism identification and AST|Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.
62213528|NCT02904031|EXPERIMENTAL|FOLFOX plus panitumumab|"* Panitumumab 6 mg/kg iv over 60 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes;~* Oxaliplatin 85 mg/sqm iv over 2 hours, day 1;~* L-Leucovorin 200 mg/sqm iv over 2 hours, day 1;~* 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance panitumumab at the same dose used at the last cycle of the induction treatment. Panitumumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
62215262|NCT04940403|EXPERIMENTAL|Bimanual robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will undergo 18 one-hour sessions of robot-assisted upper-limb rehabilitation. During the sessions, study participants will train their hemiparetic arm as well as interacting with the contralateral arm for bimanual tasks (unimanual + bimanual tasks).
62409413|NCT02487459|EXPERIMENTAL|BPX-501 and AP1903|"Three cohorts, 3 patients each, will receive two infusions (at the same dose) of BPX-501.~If needed to treat aGVHD, a single dose of AP1903 will be administered IV."
62409414|NCT04491188|EXPERIMENTAL|Probiotic|1 x10-9 CFU Bacillus subtilis DE111 was consumed daily for 28-days
62213529|NCT02904031|EXPERIMENTAL|5FU/LV plus panitumumab|"* Panitumumab 6 mg/kg iv over 60 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes;~* L-Leucovorin 200 mg/sqm iv over 2 hours, day 1;~* 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance panitumumab at the same dose used at the last cycle of the induction treatment. Panitumumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
62213530|NCT00876681|ACTIVE_COMPARATOR|1. Ultrasound|Ultrasound method of placement is selected randomly, using a computer program. The patient is asked their pain and discomfort using a 0-10 scale where 0=no pain/discomfort and 10=worst pain/discomfort imaginable. The patient is asked this question prior to surgery, but after catheter placement and then again the first day after surgery. Time of placement is also measured and begins when the ultrasound probe first touches the skin. Patients are also asked the numbness of their foot and toes based on a 0-10 scale where 0=no numbness and 10=completely numb.
62213531|NCT00876681|ACTIVE_COMPARATOR|2. Electrical Stimulation|Electrical stimulation (nerve stimulation) method of placement is selected randomly, using a computer program. The patient is asked their pain and discomfort using a 0-10 scale where 0=no pain/discomfort and 10=worst pain/discomfort imaginable. The patient is asked this question prior to surgery, but after catheter placement, and then again the first day after surgery. Time of placement is also measured and begins when the nerve stimulation needle first touches the skin. Patients are also asked the numbness of their foot and toes based on a 0-10 scale where 0=no numbness and 10=completely numb.
62213532|NCT05147844|EXPERIMENTAL|Toripalimab +Radiotherapy|
62409415|NCT04491188|PLACEBO_COMPARATOR|Placebo|Maltodextrin placebo was consumed for 28-days
62020463|NCT04844424|EXPERIMENTAL|Part 3B: Treatment Sequence ONP|Participants will receive Treatment O in Treatment Period 1, followed by Treatment N in Treatment Period 2 and then Treatment P in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62213533|NCT05599932|EXPERIMENTAL|Group 1: Healthy Control|Each healthy participant will receive a single dose of HDM201
62409416|NCT03642158|ACTIVE_COMPARATOR|Active TMS|Subjects receive rTMS over the right DLPFC, in 2 second bursts at 10 Hz, followed by a 19 second break, for a total of 20 minutes. Stimulator intensity is set to 80% of motor threshold on day one, and 100% of motor threshold for the remainder of intervention. This paradigm is continued for 5 consecutive days.
62409417|NCT03642158|SHAM_COMPARATOR|Sham TMS|"Identical to active arm, but stimulator intensity is reduced to 30% of motor threshold, and the stimulator coil is oriented tangentially to the skull to stimulate air space above the head instead of cortical tissue."
62409418|NCT02204709|EXPERIMENTAL|Diploid Trout entrees|Subjects will consume a 200 gram portion of 2N trout (diploid; two sets of chromosomes) twice weekly in a prepared meal.
62584511|NCT06683378|ACTIVE_COMPARATOR|Peripheral nerve tissue (PNT) deployment to the nucleus basalis of Meynert|
62020464|NCT04844424|EXPERIMENTAL|Part 3B: Treatment Sequence PON|Participants will receive Treatment P in Treatment Period 1, followed by Treatment O in Treatment Period 2 and then Treatment N in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62213534|NCT05599932|EXPERIMENTAL|Group 2: Mild; Child-Pugh A|Each participant with mild Child-Pugh will receive a single dose of HDM201
62213535|NCT05599932|EXPERIMENTAL|Group 3: Moderate; Child-Pugh B|Each participant with moderate Child-Pugh will receive a single dose of HDM201
62213536|NCT05599932|EXPERIMENTAL|Group 4: Severe; Child-Pugh C|Each participant with severe Child-Pugh will receive a single dose of HDM201
62213537|NCT02823990|EXPERIMENTAL|Treatment TG4010 + nivolumab|Patients receive TG4010 SC once per week for courses 1-3 and every 2 weeks for courses thereafter and nivolumab IV over 30 minutes every 2 weeks. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62790972|NCT05433025|EXPERIMENTAL|Intervention|Cervigard Neck Collar, which is a device used to treat neck pain caused by forward head posture.
62790973|NCT05433025|NO_INTERVENTION|Waitlist Control|This group will receive no intervention for 6 weeks after enrollment. They will receive the device after 6 weeks.
62213538|NCT02835300|EXPERIMENTAL|CampAir Intervention|Adolescents assigned to receive ASMA 2.0 will receive all seven modules over the two month trial, completing one module per week. Adolescents will be assigned one module per week, but will have free access to all completed modules for the duration of the two-month trial. Each module is expected to take between 30-40 minutes to complete, although adolescents will be able to engage with the software for as long as desired.
62790974|NCT02678507||Patients with chronic pain on opioids|
62020465|NCT04844424|EXPERIMENTAL|Part 4 A: Treatment Sequence QRS|Participants will receive single oral Dose 1 of milvexian as Phase 3 oral tablets under fasting conditions (Treatment Q) in Treatment Period 1, followed by single oral Dose 1 of milvexian as Phase 3 oral tablets under fed conditions (Treatment R) in Treatment Period 2 and then single oral Dose 1 of milvexian as Phase 3 oral tablets under fed conditions (Treatment S) in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020466|NCT04844424|EXPERIMENTAL|Part 4A: Treatment Sequence RSQ|Participants will receive Treatment R in Treatment Period 1, followed by Treatment S in Treatment Period 2 and then Treatment Q in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020467|NCT04844424|EXPERIMENTAL|Part 4A: Treatment Sequence SQR|Participants will receive Treatment S in Treatment Period 1, followed by Treatment Q in Treatment Period 2 and then Treatment R in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62213539|NCT02835300|ACTIVE_COMPARATOR|Information and Referral Control|Adolescents assigned to the information-and-referral control condition will be provided access to existing generic asthma education websites. They will also be referred to their medical providers for asthma. After the completion of the trial, all participants will receive access to CampAir.
62213540|NCT05365360|SHAM_COMPARATOR|Sham LaserCap|Sham device
62213541|NCT05365360|EXPERIMENTAL|Lasercap SD|Low fluence LLLT
62213542|NCT05365360|EXPERIMENTAL|Lasercap HD+|High fluence LLLT
62213543|NCT03711344|EXPERIMENTAL|Culturally adapted Cognitive Behavioral therapy|The experimental group will receive the culturally adapted version of cognitive behavioral therapy.
62213544|NCT03711344|ACTIVE_COMPARATOR|Non-adapted Cognitive Behavioral therapy|The control group will receive the original (non-adapted) version of cognitive behavioral therapy.
62213545|NCT02851225|EXPERIMENTAL|telemedicine transmission|telemedicine transmission of biological results in the treatment of transfusion supportive care
62213546|NCT02851225|NO_INTERVENTION|without telemedicine transmission|no telemedicine transmission of biological results in treatment in the treatment of transfusion supportive care
62213547|NCT05452200|EXPERIMENTAL|Lyon hospital employees with high risk of lung cancer.|Lyon Hospital employees meeting criteria for high risk of lung cancer according French recommendation criteria.
62213548|NCT05980481|EXPERIMENTAL|RC48-ADC+Toripalimab+CAPOX|Participants with HER2 positive(IHC2+FISH+ or IHC3+) will receive of RC48-ADC every 2 weeks (Q2W), Toripalimab 2 weeks (Q2W) and CAPOX every 3 weeks (Q3W) , as one treatment period until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
62215263|NCT04782336|OTHER|Sample Collection - Symptomatic Patients|The patient will be completing or has completed a SOC Influenza A/B and/or COVID-19 and/or RSV test on the day of study
62790975|NCT03944512|EXPERIMENTAL|Pravastatin|20 mg pravastatin daily
62790976|NCT03944512|PLACEBO_COMPARATOR|Placebo|Identical appearing daily placebo
62790977|NCT01052506|PLACEBO_COMPARATOR|Placebo|Single dose of saline solution (8 cohorts IV; 1 cohort SC)
62790978|NCT01052506|EXPERIMENTAL|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV; 1 cohort SC)
62790979|NCT05416879||Women newly diagnosed with heart failure|
62790980|NCT02496299|ACTIVE_COMPARATOR|dexametasone (BD),|BD ,a mixture of 0.2mg/kg dexamethasone in 1ml/kg bupivacaine
62790981|NCT02496299|ACTIVE_COMPARATOR|Bupivacaine,B|B ,1ml/kg bupivacaine:
62790982|NCT05796895|EXPERIMENTAL|Intervention Group|Children will be provided with the videogame through which we will teach them symptom management strategies.
62213549|NCT05980481|EXPERIMENTAL|RC48-ADC+Toripalimab+Trastuzumab|Participants with HER2 positive(IHC2+FISH+ or IHC3+) will receive of RC48-ADC every 2 weeks (Q2W), Toripalimab 2 weeks (Q2W) and Trastuzumab every 3 weeks (Q3W) , as one treatment period until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
62213550|NCT05980481|EXPERIMENTAL|RC48-ADC+Toripalimab+CAPOX(HER2-low)|Participants with HER2-low (IHC1+) will receive of RC48-ADC every 2 weeks (Q2W), Toripalimab 2 weeks (Q2W) and CAPOX every 3 weeks (Q3W) , as one treatment period until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first). Oxaliplatin only in the first 3 treatment cycles, 6 study dosing sessions were completed.
62213551|NCT05980481|ACTIVE_COMPARATOR|Toripalimab+Trastuzumab+CAPOX|Participants with HER2 positive(IHC2+FISH+ or IHC3+) will receive of Toripalimab 2 weeks (Q2W) , Trastuzumab every 3 weeks (Q3W) and CAPOX every 3 weeks (Q3W) , as one treatment period until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
62215264|NCT05169398|EXPERIMENTAL|EUS-guided hepaticogastrostomy|EUS-guided hepaticogastrostomy would be performed with the MG-biliary stent (Niti-S, Taewoong Medical, Gyeonggi-do, Korea).
62409419|NCT02204709|EXPERIMENTAL|Triploid Trout entrees|Subjects will consume a 200 gram portion of 3N trout (triploid; three sets of chromosomes) twice weekly in a prepared meal.
62409420|NCT02204709|EXPERIMENTAL|Tilapia entrees|Subjects will consume a 200 gram portion of tilapia twice weekly in a prepared meal.
62409421|NCT05391607|EXPERIMENTAL|Albumin 20%|3mL/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
62409422|NCT05391607|EXPERIMENTAL|Albumin 5%|12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
62409423|NCT05391607|ACTIVE_COMPARATOR|Ringer-lactate|Ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
62409424|NCT01771627|EXPERIMENTAL|Arm I (varenicline)|Patients undergo general smoking cessation counseling and receive varenicline PO QD on days 1-28. Courses repeat every 28 days for up to 12 weeks.
62790983|NCT05796895|ACTIVE_COMPARATOR|Attention Control Group|An attention control group will be used in this study for comparison with the intervention group. Children of the attention control group will receive weekly WhatsApp messages on general health behaviours.
62790984|NCT06170918|EXPERIMENTAL|remimazolam|Remimazolam is given for anesthesia induction. The initial dosage is 0.4mg/kg, and the interval dosage is 0.02mg/kg.
62790985|NCT05981027|EXPERIMENTAL|Mulligan bent leg raise technique|A single session of 3 repetitions of Mulligan bent leg raise was applied to the participants.
62790986|NCT05981027|EXPERIMENTAL|Static stretching exercise|A single session of 5 repetitive stretching exercises was performed on the participants.
62020468|NCT04844424|EXPERIMENTAL|Part 4A: Treatment Sequence QSR|Participants will receive Treatment Q in Treatment Period 1, followed by Treatment S in Treatment Period 2 and then Treatment R in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62215265|NCT04660591|ACTIVE_COMPARATOR|standard femoral stem|standard length femoral stem arthroplasty applied for patients with proximal femoral metastasis either impending or pathological fracture
62409425|NCT01771627|ACTIVE_COMPARATOR|Arm II (nicotine patch)|Patients undergo general smoking cessation counseling and receive nicotine patch continuously for 12 weeks.
62409426|NCT01764594|EXPERIMENTAL|CDP7657|"CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks"
62409427|NCT01764594|PLACEBO_COMPARATOR|Placebo|Placebo
62409428|NCT06566053||Patients who underwent thoracic surgery|Gender:Both Participant age:18-100 Examples include early-stage non-small cell lung cancer (NSCLC), NSCLC patients who have undergone neoadjuvant therapy, esophageal diseases, mediastinal masses, chest wall disorders, and other related conditions.
62409429|NCT02020421|EXPERIMENTAL|rTMS|Participants will receive real rTMS and sham tDCS
62409430|NCT02020421|EXPERIMENTAL|tDCS|Participants will receive real tDCS and sham rTMS
62790987|NCT02200276|OTHER|Influenza Immunization|Influenza immunization in adults over age 75
62790988|NCT06087484|EXPERIMENTAL|MIED-I group|Provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and sleep problems.
62790989|NCT06087484|NO_INTERVENTION|Waitlist control group|
62790990|NCT03632772|EXPERIMENTAL|Solifenacin 5 mg for 4 weeks|Solifenacin 5 mg once-daily for 4 weeks.
62790991|NCT03632772|EXPERIMENTAL|Mirabegron 50 mg for 4 weeks|Mirabegron 50 mg once-daily for 4 weeks.
62790992|NCT03632772|NO_INTERVENTION|Control: non treatment|Control: non treatment.
62790993|NCT04160663|EXPERIMENTAL|Subjects with atrial fibrillation|Subjects with atrial fibrillation that have been clinically scheduled for an electrical cardioversion procedure will have carotid ultrasound testing done before and after the procedure
62790994|NCT03562494|EXPERIMENTAL|VY-AADC02 (NBIb-1817)|Single administration of up to 3.6 x 10\^12 vector genomes (vg) of VY-AADC02
62790995|NCT03562494|PLACEBO_COMPARATOR|Sham (Placebo) Surgery|Sham surgical procedure
62790996|NCT04249921||Experimental|"1. Use acupuncture to treat the patients who received the surgery of CPA tumor. Acupoints of reference: Yifeng(TE17),Tinggong(SI19),Xiaguan(ST07),Wind Pool(GB20),Outer Pass(SJ5),Union Valley(LI4),Yang Mound Spring(GB34),Leg Three Li(ST36).~2. Use questionnaires to evaluate.The questionnaires including House-Brackmann Grading Scale,WHOQOL-BREF Taiwan Version,Functional Assessment of Cancer Therapy: General(FACT-G),Visual Analogue Scale(VAS)."
62790997|NCT04249921||Control|1.Use questionnaires to evaluate.The questionnaires including House-Brackmann Grading Scale,WHOQOL-BREF Taiwan Version,Functional Assessment of Cancer Therapy: General(FACT-G),Visual Analogue Scale(VAS).
62790998|NCT06003660||Patients|Adult recipients of allo-HCST.
62790999|NCT06003660||Controls|Healthy adult subjects
62791000|NCT06164834|ACTIVE_COMPARATOR|Clopidogrel 75 mg|Oral administration of clopidogrel 75 mg tablet once daily for 7 days
62791001|NCT06164834|EXPERIMENTAL|Clopidogrel 75 mg + Tegoprazan 25 mg|Oral administration of clopidogrel 75 mg tablet and tegoprazan 25 mg tablet once daily for 7 days
62409431|NCT02020421|SHAM_COMPARATOR|Sham|Participants will receive both sham rTMS and sham tDCS
62791002|NCT06164834|EXPERIMENTAL|Clopidogrel 75 mg + Esomeprazole 20 mg|Oral administration of clopidogrel 75 mg tablet and esomeprazole 20 mg tablet once daily for 7 days
62791003|NCT06521372||Oocytes with AI|Oocytes assessed by the Magenta software
62791004|NCT06521372||Oocytes without AI|Oocytes randomly selected
62215266|NCT04660591|ACTIVE_COMPARATOR|long femoral stem|long femoral stem arthroplasty applied for patients with proximal femoral metastasis either impending or pathological fracture
62791005|NCT03487744|ACTIVE_COMPARATOR|Promote without fiber|Lower osmolality enteral tube feed formulation
62791006|NCT03487744|ACTIVE_COMPARATOR|Osmolite 1.5|Higher osmolality enteral tube feed formulation
62791007|NCT00241774||NSHS95 samples|In 1995, our study participants enrolled in the Nova Scotia Health Study (NSHS95). At the time of enrollment, epidemiologic data as well as blood samples were obtained. The participants have since been followed prospectively for a variety of health outcomes. We plan to assay stored blood samples collected in 1995 for markers of inflammation and link these results to existing epidemiologic and outcomes data, specifically the 7- year incidence of CAD events.
62791008|NCT03186729|EXPERIMENTAL|Antithrombotic treatment|For patients with vascular disease and indication for antiplatelet drugs: Antiplatelet drugs; For patients with atrial fibrillation and indication for anticoagulant drugs: Anticoagulant drugs
62791009|NCT03186729|NO_INTERVENTION|No antithrombotic treatment|For patients with indication for antiplatelet drugs: No antithrombotic drugs For patients with atrial fibrillation and indication for anticoagulant drugs: No anticoagulant drugs.
62791010|NCT04577430|EXPERIMENTAL|Loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg|10 min before induction of anesthesia,the loading dose of dexmedetomidine is 0.5 μg/kg, and completed in 10 minutes. The maintenance dose is 0.5 μg/kg per hour during the operation until 0.5 h before the operation finished.
62791011|NCT04577430|EXPERIMENTAL|Loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg|10 min before induction of anesthesia,the loading dose of dexmedetomidine is 1 μg/kg, and completed in 10 minutes. The maintenance dose is 0.5 μg/kg per hour during the operation until 0.5 h before the surgery finished.
62791012|NCT04577430|EXPERIMENTAL|Loading dose with 1 μg/kg, maintenance dose with 1 μg/kg|10 min before induction of anesthesia,the loading dose of dexmedetomidine is 1 μg/kg, and completed in 10 minutes. The maintenance dose is 1 μg/kg per hour during the operation until 0.5 h before the surgery finished.
62409432|NCT04163328|EXPERIMENTAL|HydroEye®|Subjects will take a total of four capsules daily, with meals (two capsules taken orally, twice a day).
62409433|NCT04163328|PLACEBO_COMPARATOR|Placebo|Subjects will take a total of four capsules daily, with meals (two capsules taken orally, twice a day).
62020469|NCT04844424|EXPERIMENTAL|Part 4A: Treatment Sequence RQS|Participants will receive Treatment R in Treatment Period 1, followed by Treatment Q in Treatment Period 2 and then Treatment S in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020470|NCT04844424|EXPERIMENTAL|Part 4A: Treatment Sequence SRQ|Participants will receive Treatment S in Treatment Period 1, followed by Treatment R in Treatment Period 2 and then Treatment Q in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020471|NCT04844424|EXPERIMENTAL|Part 4B: Treatment Sequence TU|Participants will receive single oral Dose 1 of milvexian as Phase 3 oral tablet under fed conditions (Treatment T) in Treatment Period 1, followed by single oral Dose 2 of milvexian as Phase 3 oral tablet under fed conditions (Treatment U) in Treatment Period 2 on Day 1 of each Treatment Period during Part 4B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020472|NCT04844424|EXPERIMENTAL|Part 4B: Treatment Sequence UT|Participants will receive Treatment U in Treatment Period 1, followed by Treatment T in Treatment Period 2 on Day 1 of each Treatment Period during Part 4B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020473|NCT04844424|EXPERIMENTAL|Subpart 4A: Treatment Sequence VW|All participants of Subpart 4A will undertake a mandatory taste assessment on Day 5 of period 3 or Day 15 before the discharge and will receive milvexian tablet dispersed in water without a sweetener orally via syringe (Treatment V) in Treatment Period 1, followed by milvexian tablet dispersed in water with sucralose sweetener orally via syringe (Treatment W) in Treatment Period 2. Participants will cleanse their palates using 2 rinse of mineral water and one unsalted cracker and wait for a time interval of at least 1-2 hours from start of dosing before the next taste round.
62213552|NCT05980481|ACTIVE_COMPARATOR|Toripalimab+CAPOX(HER2-low)|Participants with HER2-low (IHC1+) will receive of Toripalimab 2 weeks (Q2W) and CAPOX every 3 weeks (Q3W) , as one treatment period until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first). Oxaliplatin only in the first 3 treatment cycles, 6 study dosing sessions were completed.
62213553|NCT00741559|EXPERIMENTAL|1|
62213554|NCT04480138|EXPERIMENTAL|Pegylated Interferon-α2b + Standard of care|"Test :- Pegylated Interferon-α2b + Standard of care (SOC)~Pegylated Interferon-α2b-Initial 1 mcg/kg will be administered on day 1. After safety evaluation of first dose, next dose (second dose) 1 mcg/kg on day 8 will be administered along with the recommended standard of care at the time of conduct of trial."
62213555|NCT04480138|ACTIVE_COMPARATOR|Standard of Care|"Control: Standard of care~Standard of care treatment will be provided as per regulatory recommendation and approval."
62213556|NCT02417519|EXPERIMENTAL|Sequence A|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance A was DAR-LIR-CTR
62213557|NCT02417519|EXPERIMENTAL|Sequence B|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance B was DAR-CTR-LIR
62409434|NCT03854799|EXPERIMENTAL|CHEMORADIOTHERAPY PLUS AVELUMAB|"CHEMORADIOTHERAPY PLUS AVELUMAB:~CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70"
62409435|NCT04615338||Homicidal group|The group of patients presented with homicidal open neck injuries
62409436|NCT04615338||Suicidal group|The group of patients presented with suicidal open neck injuries
62584512|NCT03209622|EXPERIMENTAL|A intervention|"intervention = Nicotine replacement therapy (NRT): initiated in cardiology intensive care unit, Some hours after acute coronary syndrome.~Drug: One or two pachs for each ARM, depending of number of cigarettes consummed every day. The dose is decreased every 4 weeks. The patient leave with an appointment to the external consultation for follow-up."
62584513|NCT03209622|ACTIVE_COMPARATOR|B: control|Intervention: Nicotine replacement therapy (NRT) initiated after hospital discharge, some days after acute coronary syndrome. The patient leave with an appointment to the external consultation for follow-up without pach of nicotine.One or two pachs for each ARM, depending of number of cigarettes consummed every day. The dose is decreased every 4 weeks.
62791013|NCT04577430|PLACEBO_COMPARATOR|Normal saline|
62409437|NCT04615338||Accidental group|The group of patients presented with accidental open neck injuries
62791014|NCT03876119|EXPERIMENTAL|Intraarterial alteplase|"All the patients will be given a 15 minutes IA infusion of alteplase (Actylise®) at a drug concentration of 1.0 mg/ml. At 15 minutes of IA treatment onset, the infusion will be stopped and the angiographic score assessed. If the angiographic score is improved compared with the baseline score the procedure is terminated, otherwise a new angiographic series will be repeated in 10 minutes before the end of the procedure in front and profile projections.~Study drug will be prepared according to the following steps:~1. Dilute 3 vials of 10 mgs (alteplase) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml~2. Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225)"
62791015|NCT03876119|PLACEBO_COMPARATOR|Placebo|"The placebo will consist of a lyophilized white powder containing 0.2 mol/L arginine phosphate, 0.01% polysorbate 80, and pH 7.4 after reconstitution.~Study drug will be prepared according to the following steps:~1. Dilute 3 vials of 10 mgs (placebo) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml~2. Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225)"
62791016|NCT06240104|EXPERIMENTAL|CI group|the cardiac index (CI) is continuously monitored during the weaning process
62791017|NCT06240104|NO_INTERVENTION|control group|No intervention measures
62791018|NCT00566852|EXPERIMENTAL|WBRT+Memantine|Whole brain radiation therapy (WBRT) and memantine
62791019|NCT00566852|ACTIVE_COMPARATOR|WBRT+Placebo|Whole brain radiation therapy (WBRT) and placebo
62791020|NCT03538366|EXPERIMENTAL|Donor FMT|Fecal transplant from unrelated, healthy volunteers
62791021|NCT05822180|EXPERIMENTAL|A bras actif|The experimental arm has received the Nanos product orally with a dose of 30mL, 3 times per day and away from meals (2 hours after a meal or on an empty stomach).
62791022|NCT05822180|PLACEBO_COMPARATOR|B bras controle|The placebo arm has received the Nanos product orally with a dose of 30mL, 3 times per day and away from meals (2 hours after a meal or on an empty stomach).
62791023|NCT03139123||Patients with acute kidney injury|Intensive care unit patients with acute kidney injury. Patients under continuous renal replacement therapy and hemodynamic monitoring.
62791024|NCT04679194|EXPERIMENTAL|Mana 312|"Mana 312 is administered intravenously (IV) within 30 minutes in either an inpatient or outpatient setting; either a central or peripheral IV line may be used. Each cycle of administration of Mana 312 will be 28 days.~Subjects not experiencing dose-limiting toxicity (DLT) following their initial dose may continue receiving their assigned Mana 312 dose every 28 days for an additional 2 doses"
62791025|NCT04789889|EXPERIMENTAL|IORT|intraoperative radiotherapy(IORT) in BCS.
62213558|NCT02417519|EXPERIMENTAL|Sequance C|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance C was LIR-DAR-CTR
62215267|NCT05295420|EXPERIMENTAL|platelet-rich plasma|to assess the role of platelet-rich plasma in the treatment of SUI as a non-invasive method
62213559|NCT02417519|EXPERIMENTAL|Sequence D|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance D was LIR-CTR-DAR
62213560|NCT02417519|EXPERIMENTAL|Sequence E|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance E was CTR-DAR-LIR
62213561|NCT02417519|EXPERIMENTAL|Sequence F|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance F was CTR-LIR-DAR
62213562|NCT03020576|ACTIVE_COMPARATOR|Conventional Therapy|Participants randomized to this arm will receive conventional based therapy to their affected upper limb dose matched with the Robotic Therapy group. These interventions are aimed at increasing range of motion, strength and function at the shoulder, elbow, wrist and hand.
62213563|NCT03020576|EXPERIMENTAL|Robotic Therapy|Participants randomized to this arm will receive robotic based therapy using the Amadeo Hand Robot device to improve range of motion, strength, and coordination to the wrist and hand.
62213564|NCT00701831|EXPERIMENTAL|1|Insulin glargine
62213565|NCT04285138|EXPERIMENTAL|Phantom limb exercises|Participants in this group will be treated with routine physical therapy, mirror therapy and Phantom limb exercises. Treatment time: 1 hour
62791026|NCT04789889|ACTIVE_COMPARATOR|PORT|traditional postoperative radiotherapy following BCS.
62213566|NCT04285138|ACTIVE_COMPARATOR|conventional treatment|In this group, participants will be treated by routine physical therapy and mirror therapy protocol. Treatment time: 35 minutes
62213567|NCT04306406|OTHER|Raspberry Smoothies|Single serving smoothies drink made with red raspberries to be consumed daily for two weeks
62734529|NCT05285761|ACTIVE_COMPARATOR|paper brochure|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will also receive generic information (48 messages) contained in the health record and in connection with the general development.
62213568|NCT04184232|EXPERIMENTAL|Dendritic cells|Patients with the recurrent bladder cancer receiving standard treatment and autologous dendritic cells
62213569|NCT04184232|ACTIVE_COMPARATOR|Control|Patients with the recurrent bladder cancer receiving standard treatment
62213570|NCT06084923||Patients who discontinued ibrutinib|CLL patients enrolled in the front-line GIMEMA LLC1114 study twho discontinued ibrutinib due to reasons other than CLL progression, Richter syndrome, malignancy or death, or lost to the follow-up.
62213571|NCT00410982|EXPERIMENTAL|Gemcitabine + Busulfan + Melphalan + HCT|HCT = Hematopoietic Cell Transplantation
62213572|NCT00760474|EXPERIMENTAL|Pregabalin, then placebo|
62213573|NCT00760474|EXPERIMENTAL|Placebo, then pregabalin|
62213574|NCT03033225|EXPERIMENTAL|Treatment (verteporfin, EUS-guided PDT)|Patients receive verteporfin IV and undergo fluorescence imaging and after 60 minutes undergo EUS-guided PDT.
62213575|NCT01635777|EXPERIMENTAL|12 weeks|miltefosine 12 weeks
62213576|NCT01635777|EXPERIMENTAL|8 weeks|miltefosine 8 weeks
62213577|NCT04469127|EXPERIMENTAL|Arm 1|"Single Arm study Lu-177-DOTAGA-IAC (intracutaneous)~Dosage and Dose Escalation Frequency:~Cohort 1: 75 mCi x 3 (maximum cumulative administered activity, 225mCi) + 100 μgr IAC Cohort 2: 150 mCi x 3 (maximum cumulative administered activity, 450mCi) + 100 μgr IAC Cohort 3: 200 mCi x 3 (maximum cumulative administered activity, 600mCi) + 100 μgr IAC~Three cycles each 4 weeks apart."
62213578|NCT04716335|EXPERIMENTAL|Harmine + DMT|
62213579|NCT04716335|EXPERIMENTAL|Harmine + Placebo(DMT)|
62213580|NCT04716335|PLACEBO_COMPARATOR|Placebo(Harmin & Placebo)|
62734530|NCT05620056||drug exposure|chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs
62734531|NCT02236273|EXPERIMENTAL|Conventional Text Message|Conventional text message reminder
62734532|NCT02236273|EXPERIMENTAL|Enhanced reminders|Enhanced text message reminders
62734533|NCT04427605||ketamine group|ketamine intravenous infusion in pediatric patients refractory to conventional analgesic-sedative strategy lasted more than 12 hours (dose range 10-50 mcg/Kg/min)
62020474|NCT04844424|EXPERIMENTAL|Subpart 4A: Treatment Sequence WV|All participants of Subpart 4A will undertake a mandatory taste assessment on Day 5 of period 3 or Day 15 before the discharge and will receive Treatment W in Treatment Period 1, followed by Treatment V in Treatment Period 2. Participants will cleanse their palates using 2 rinse of mineral water and one unsalted cracker and wait for a time interval of at least 1-2 hours from start of dosing before the next taste round.
62020475|NCT04844424|EXPERIMENTAL|Part 5: Treatment Sequence XYZ|Participants will receive a single oral Dose 1 of milvexian as DC whole tablets under fasting conditions (Treatment X) in Treatment Period 1 followed by a single oral Dose 1 of milvexian as DC tablets dispersed in water and then mixed with apple sauce under fasting conditions (Treatment Y) in Treatment Period 2 and then a single oral Dose 1 of milvexian as DC tablets dispersed in water administered through a nasogastric (NG) tube under fasting conditions (Treatment Z) in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020476|NCT04844424|EXPERIMENTAL|Part 5: Treatment Sequence YZX|Participants will receive Treatment Y in Treatment Period 1 followed by Treatment Z in Treatment Period 2 and then Treatment X in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020477|NCT04844424|EXPERIMENTAL|Part 5: Treatment Sequence ZXY|Participants will receive Treatment Z in Treatment Period 1 followed by Treatment X in Treatment Period 2 and then Treatment Y in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62409438|NCT05866614||CT-P13 SC for RA patients|Patient will be treated as per the SmPC. The enrolled patient with RA will be administered Remsima® SC on the enrolment date and Remsima® SC injections will be continued according to the local standard of care. Study assessment will be done at least every 3 months through outpatient visit or telephone follow-up as part of routine care practice. Each outpatient visit is recommended to be done at least every 6 months and telephone follow-up will be done every 3 months after each outpatient visit to assess the patient.
62409439|NCT05866614||CT-P13 SC for As, PsA and Ps patients|Patient will be treated as per the SmPC. The enrolled patient with AS, PsA, and Ps will be administered Remsima® SC on the enrolment date and Remsima® SC injections will be continued according to the local standard of care. Study assessment will be done at least every 3 months through outpatient visit or telephone follow-up as part of routine care practice. Each outpatient visit is recommended to be done at least every 6 months and telephone follow-up will be done every 3 months after each outpatient visit to assess the patient.
62409440|NCT05866614||CT-P13 IV for As, PsA and Ps patients|Patient will be treated as per the SmPC. The enrolled patient with AS, PsA, and Ps will be administered Remsima® IV on the enrolment date and Remsima® IV infusions will be continued according to the local standard of care. Study assessment will be done at least every 3 months through outpatient visit or telephone follow-up as part of routine care practice. Each outpatient visit is recommended to be done at least every 6 months and telephone follow-up will be done every 3 months after each outpatient visit to assess the patient.
62213581|NCT00169377|ACTIVE_COMPARATOR|Group A|Deep brain stimulation on followed by off
62213582|NCT00169377|SHAM_COMPARATOR|Group B|No stimulation, deep brain stimulation off followed by on
62409441|NCT05666648||Sixty patients completed trial in two groups|
62213583|NCT03319849|EXPERIMENTAL|NT-501|Test product
62584514|NCT05772377|EXPERIMENTAL|Anlotinib+TP then CCRT+Anlotinib|Induction regimen:Anlotinib: 10 mg, po, qd, d1-d14, q3w, 2 consecutive cycles Paclitaxel 175mg/m2 intravenous injection for 3 hours, d1；Cisplatin 75mg/m2, iv, divided into 3 days, q3w;Unable to tolerate, nedaplatin 75mg/m2, iv, d1 can be used instead;21 days as a cycle, a total of 2 cycles;Treatment programs:Anlotinib: 10 mg, po, qd, d1-d14, q3w, 2 consecutive cycles;Cisplatin: 30-35 mg/m2, iv, d1, qw, 5 consecutive cycles;Pelvic external radiation therapy: once a day, 1.8-2 Gy/time, 5 days a week, for 5 consecutive weeks, a total of 45-50 Gy;sequential;High dose rate intracavitary radiotherapy: 6 Gy/time, twice a week, 5 consecutive times, a total of 30 Gy/2.5 weeks, bioequivalent dose of 40 Gy sequential Taxane drugs: including but not limited to paclitaxel, nab-paclitaxel, paclitaxel liposome, etc. The dosage regimen is determined by the investigator;Cisplatin 75mg/m2, iv, divided into 3 days, q3w; Unable to tolerate, nedaplatin 75mg/m2, iv, d1 can be used instead;2 cycles
62213584|NCT03319849|SHAM_COMPARATOR|Sham|A sham surgical procedure was performed to mimic the implant procedure; there was no comparator product.
62213585|NCT05880745|EXPERIMENTAL|patient group|Patients with MS
62213586|NCT05880745|EXPERIMENTAL|healthy group|age-gender matched healthy persons
62213587|NCT05922254|ACTIVE_COMPARATOR|Active cycle of breathing technique|Group A is a control group. First, the patients will receive baseline treatment (pursed lip breathing). Additionally, patients will be administered the Active Cycle of Breathing Technique after receiving the Baseline Treatment
62213588|NCT05922254|EXPERIMENTAL|Autogenic drainage|Both the physiotherapist's hand and the subject's hands were put on the subject's abdomen to feel the activity of the abdominal muscles. The patient inhaled slowly through the nose while using their diaphragm and holding their breath for two to three seconds to allow collateral ventilation to bring air behind their secretions. Exhalation was done through the mouth. The palm of the therapist placed on the upper chest felt the vibration of the mucous. Their positions were disclosed by the vibrations' frequency. Secretions in tiny airways can be seen using high frequencies. The method has phases for unsticking, collecting and evacuation. The mucus was expelled by a stronger expiration or a high lung volume huff at the conclusion of the session.
62213589|NCT06088459|EXPERIMENTAL|NWRD06 by electroporation|Patients will be assigned to three dose groups:1mg, 4mg, and 8mg. Each patient will be administered NWRD06 by electroporation in entire study period. The Maximum Tolerated Dose of NWRD06 will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
62213590|NCT00110877|EXPERIMENTAL|002|LPV/rtv One 400mg LPV tablet twice daily with 100mg RTV
62791027|NCT01022138|EXPERIMENTAL|HER2Bi-armed activated T cells/Cyclophosphamide/biomarker|"HER2Bi-armed activated T cells Immediately after pheresis, the lymphocytes are activated with soluble monoclonal anti-CD3 antibody, which cross-links the CD3 receptors on T cells and activates them.~Cyclophosphamide After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide~Laboratory biomarker analysis The association between the \[18F\]-FDG PET/CT assessments (percent changes from baseline in SUVpeak) and immunologic biomarker changes as well as tumor response will be explored."
62791028|NCT00756990|EXPERIMENTAL|Single group|Depot Naltrexone
62791029|NCT02041338|EXPERIMENTAL|Luminal subtype test|Paclitaxel 175mg/m2, every 2 weeks as a cycle for 4-6 cycles
62791030|NCT02041338|ACTIVE_COMPARATOR|Luminal subtype control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles
62791031|NCT02041338|EXPERIMENTAL|Her2 positive subtype test|Paclitaxel 175mg/m2 plus carboplatin AUC 4 with or without trastuzumab every 2 weeks as a cycle for 4-6 cycles
62791032|NCT02041338|ACTIVE_COMPARATOR|Her2 positive subtype control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 with or without trastuzumab every 3 weeks as a cycle for 4-6 cycles
62791033|NCT02041338|EXPERIMENTAL|Triple negative subtype test|Paclitaxel 175mg/m2 plus carboplatin AUC 4 every 2 weeks as a cycle for 4-6 cycles
62213591|NCT00110877|EXPERIMENTAL|001|TMC114/rtv Two 300mg TMC114 tablets twice daily with 100mg RTV
62791034|NCT02041338|ACTIVE_COMPARATOR|Triple negative subypte control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles
62213592|NCT04076787||Favorable IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as favorable IMDC risk group for having 0 individual risk factor
62791035|NCT03276897|EXPERIMENTAL|Nutriage SPF 30 day cream and Nutriage night cream|Application of the study products (day cream at the morning and night cream at the evening), for an uninterrupted period of 3 months.
62791036|NCT01076036|EXPERIMENTAL|CorPath 200 System|Robotic-assisted PCI with the CorPath 200
62409442|NCT01511562|OTHER|Arm I|Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant.
62213593|NCT04076787||Intermediate IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as intermediate IMDC risk group for having 1 or 2 individual risk factors
62213594|NCT04076787||Poor IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as poor IMDC risk group for having 3 or more individual risk factors
62213595|NCT03789838||Before of sepsis rapid response team|Time from arrival at the Emergency Department to antibiotic is administered, before introduction of sepsis response team in the Emergency Department.
62409443|NCT01511562|OTHER|Arm II|Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy.
62409444|NCT05359146|EXPERIMENTAL|Phase 0a, Group 1|"The first test injection will be with 161Tb-DOTA-LM3; the second one will be with 177Lu-DOTATOC. The \~ 3 therapy cycles will be performed with 177Lu-DOTATOC.~Test injection 1: 0.5 - 1 GBq ≤ 100 μg 161Tb-DOTA-LM3 with renal protection Test injection 2 (Cross over): 0.5 - 1 GBq \~ 200 μg 177Lu-DOTATOC with renal protection Not more than 6 weeks later patients will receive \~ 3 treatment cycles with 5.6 - 7.4 GBq 177Lu-DOTATOC in an interval of about 8 weeks (clinically established amount of activity). This is standard of care and not part of the study."
62409445|NCT05359146|EXPERIMENTAL|Phase 0a, Group 2|"The first test injection will be with 177Lu-DOTATOC; the second one will be with 161Tb-DOTA-LM3. The \~ 3 therapy cycles will be performed with 177Lu-DOTATOC.~Test injection 1: Group 2: 0.5 - 1 GBq \~ 200 μg 177Lu-DOTATOC with renal protection Test injection 2 (Cross over): 0.5 - 1 GBq ≤ 100 μg 161Tb-DOTA-LM3 with renal protection Not more than 6 weeks later patients will receive \~ 3 treatment cycles with 5.6 - 7.4 GBq 177Lu-DOTATOC in an interval of about 8 weeks (clinically established amount of activity). This is standard of care and not part of the study."
62409446|NCT05359146|EXPERIMENTAL|Phase 0b, Group 1|"Both test injections will be with 161Tb-DOTA-LM3 (with different peptide amounts). The \~ 2 therapy cycles will be performed with 161Tb-DOTA-LM3.~Test injection 1: \~ 2 GBq ≤ 100 μg 161Tb-DOTA-LM3 with renal protection Test injection 2: \~ 2 GBq \~ 300 μg 161Tb-DOTA-LM3 with renal protection Not more than 6 weeks later patients will receive \~ 2 cycles with \~ 3 GBq 161Tb-DOTA-LM3 in an interval of about 8 weeks if \~2 GBq is well tolerated"
62409447|NCT05359146|EXPERIMENTAL|Phase 0b, Group 2|"Start with the other peptide amount of 161Tb-DOTA-LM3. The \~ 2 therapy cycles will be performed with 161Tb-DOTA-LM3.~Test injection 1: \~ 2 GBq \~ 300 μg 161Tb-DOTA-LM3 with renal protection Test injection 2: \~ 2 GBq ≤ 100 μg 161Tb-DOTA-LM3 with renal protection Not more than 6 weeks later patients will receive \~ 2 cycles with \~ 3 GBq 161Tb-DOTA-LM3 in an interval of about 8 weeks if \~2 GBq is well tolerated"
62409448|NCT05070507|EXPERIMENTAL|Enzyme containing lozenge|
62409449|NCT05070507|PLACEBO_COMPARATOR|Placebo lozenge|
62409450|NCT04212624|EXPERIMENTAL|test arm|The 25G or 23G conjunctival seamless vitrectomy was performed on the anterior eye to remove the anterior-posterior direction and tangential direction of the rupture hole. The area outside the macular foveal lesion was selected, but 100 μl of HuRPE cell injection was injected within about 2 PD. In combination with the Medone syringe and the combined 35G or 37G needle, the silicone oil injection module is used for injection, and the injection is performed in an amount of 100 μl (depending on the cell concentration). The doses of the three dose groups from low to high were 300,000 cells, 500,000 cells, and 1 million cells, respectively, in a single injection.
62409451|NCT03611920||Tetracycline|Teeth were soaked in topical tetracycline 5% for 5 minutes before replantation
62409452|NCT03611920||Dexamethasone|Teeth were soaked in dexamethasone (60μ ml-1) for 20 minutes before replantation
62409453|NCT05354999|EXPERIMENTAL|Creatine|Subjects ingest creatine monohydrate daily.
62213596|NCT03789838||Sepsis rapid response team|Time from arrival at the Emergency Department to antibiotic is administered, with sepsis response team in the Emergency Department.
62213597|NCT04468945|EXPERIMENTAL|mirror box therapy|The objects use for task-specific mirror therapy are duster, glass, the wooden block of different sizes and shapes, beads, coin, paper cards and spongy ball. In all these activities shoulder horizontal flexion-extension, adduction-abduction, elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, finger flexion-extension, abduction, adduction, opposition, are performed automatically.
62409454|NCT05354999|PLACEBO_COMPARATOR|Placebo|Subjects ingest placebo daily.
62584515|NCT02309411|EXPERIMENTAL|Rivaroxaban|Age and body weight-adjusted twice daily dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily
62213598|NCT04468945|EXPERIMENTAL|Repetitive Facilitation Exercise|Treatment involved rapid passive stretching of the muscles of the targeted joints in conjunction with tapping and rubbing the skin to assist in the generation of a contraction.Shoulder horizontal flexion-extension , adduction-abduction ,elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, finger flexion-extension, abduction, adduction, opposition, are performed
62213599|NCT03988244|EXPERIMENTAL|HeartLight X3|Pulmonary vein isolation using HeartLight X3
62213600|NCT01657786|EXPERIMENTAL|Ondansetron administration group|
62213601|NCT05292092||Coronary Artery Disease (CAD)|
62213602|NCT01094938||Repair|
62213603|NCT03939559|EXPERIMENTAL|Balance Exercises Group|Balance exercises group, 4 exercise packages which include static, dynamic and functional balance exercises will be taught in the first part of exercise period for 4 weeks. After the four weeks, the exercises should be progressed in the last 4 weeks in the second training session
62213604|NCT03939559|EXPERIMENTAL|Dual Task Based Balance Exercises Group|Dual task based balance exercises group, 4 exercise packages which include static, dynamic and functional balance exercises with cognitive or motor dual task will be taught in the first part of exercise period for 4 weeks.
62213605|NCT02007915|EXPERIMENTAL|Pamidronate Disodium|
62213606|NCT02822859|ACTIVE_COMPARATOR|Wright|Methacholine challenge performed using the Wright nebulizer
62584516|NCT05917834||Imframammary|Imframammary- NSM using imframammary incision
62213607|NCT02822859|ACTIVE_COMPARATOR|Bennett-Twin|Methacholine challenge performed using the Bennett-Twin nebulizer
62213608|NCT02822859|ACTIVE_COMPARATOR|Aeroneb Solo|Methacholine challenge performed using the Aeroneb Solo nebulizer
62584517|NCT05917834||Radial/Peri-areolar|Radial/Peri-areolar- NSM using Radial/Peri-areolar incision
62213609|NCT05003427|EXPERIMENTAL|68Ga-FAPI-04 PET/CT|The patients were injected with 55.5-148 MBq (1.5-4mCi) of 68Ga-FAPI-04 in one dose intravenously and underwent SPECT/CT scan 30-90 min later.
62213610|NCT03100877|EXPERIMENTAL|Treatment (mel/TMI, ASCT)|"MOBILIZATION AND APHERESIS: Patients receive cyclophosphamide IV over 2 hours. Beginning 24 hours after cyclophosphamide administration, patients receive filgrastim SC or IV. Patients also undergo apheresis over 4 hours on day 10.~CONDITIONING REGIMEN: Patients receive palifermin IV on days -8, to -6, undergo TMI on days -5 to -2, and receive melphalan IV over 30 minutes on day -1. Patients then undergo ASCT IV on day 0, receive palifermin IV on days 1-3, and receive filgrastim SC or IV on day 5.~MAINTENANCE THERAPY: Beginning 30 days after ASCT, patients receive lenalidomide PO daily."
62791037|NCT06153537||Insulin degludec + dose check|Participants will be treated with commercially available insulin degludec used with Dose Check app according to local label and routine clinical practice at the discretion of the treating physician.
62213611|NCT01004055|EXPERIMENTAL|Procellera™ Wound Dressing|
62584518|NCT04859283|ACTIVE_COMPARATOR|DEX-group|intranasal dexmedetomidine 1 µg/kg
62409455|NCT02264886|EXPERIMENTAL|Arm 1: Stereotactic body radiation therapy|"Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.~All patients will undergo MRI simulation in positioning appropriate for the specific treatment site. When medically feasible and applicable, patients will be simulated with IV and small bowel contrast (for non-thorax cases)."
62409456|NCT00923299|OTHER|cetuximab, trastuzumab|
62409457|NCT00389168|EXPERIMENTAL|Irbesartan|Irbesartan per os titrated to 300 mg od, 48 weeks
62409458|NCT00389168|ACTIVE_COMPARATOR|Atenolol|Atenolol per os titrated to 100 mg od, 48 weeks
62409459|NCT04639050|EXPERIMENTAL|Part 1 (Dose Finding) Cohort 1: Dose Level 1 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 1 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
62584519|NCT04859283|PLACEBO_COMPARATOR|PLACEBO-group|intranasal saline 10 µL/kg
62584520|NCT03841058|ACTIVE_COMPARATOR|Abaloparatide (PM Women)|Abaloparatide 80 mcg dose administered subcutaneously with a pen once daily for 6 months
62791038|NCT02745834|EXPERIMENTAL|Chronic Ankle Instability|Soldiers who suffer from chronic ankle instability who had a first major ankle sprain one year or more ago, and did not sustained any major ankle sprain in the last two months, will go through Gait analysis intervention.
62791039|NCT02745834|EXPERIMENTAL|Healthy controls|Healthy soldiers who are not suffering from chronic ankle instability, will go through Gait analysis intervention.
62791040|NCT02089789||CDG|Patients with a suspected CDG based on biochemical tests or a confirmed CDG based on enzymatic or molecular tests will be eligible to enroll in this protocol
62791041|NCT02769910|OTHER|Cowhage|Cowhage is used to induce non-histaminergic itch on the volar forearm at the locations treated with Capsaicin 24 Hours, Capsaicin 1 Hours and Qutenza Demo Patch.
62584521|NCT03841058|PLACEBO_COMPARATOR|Placebo (PM Women)|Placebo administered subcutaneously with a pen once daily for 6 months
62213612|NCT01004055|ACTIVE_COMPARATOR|ACTICOAT™|
62213613|NCT01004055|ACTIVE_COMPARATOR|Mepilex® Ag|
62213614|NCT04479267|EXPERIMENTAL|Treatment (polatuzumab vedotin, R-CHP)|Patients receive prednisone PO, prednisolone IV, or methylprednisolone IV on days 1-5. Patients also receive rituximab IV, polatuzumab vedotin IV over 30-90 minutes, cyclophosphamide IV, and doxorubicin hydrochloride IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62213615|NCT01308138|EXPERIMENTAL|ExerciseTr|
62213616|NCT01308138|EXPERIMENTAL|Remote ischemic preconditioning group|
62213617|NCT01308138|NO_INTERVENTION|Control patient group|
62213618|NCT02741323|EXPERIMENTAL|Arm 1: Maraviroc (MVC)|Participants will receive MVC at the time of admission for transplantation and prior to transplant. Participants will receive MVC throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
62409460|NCT04639050|PLACEBO_COMPARATOR|Part 1 (Dose Finding) Cohort 1: Placebo|Participants will receive matching placebo to dose level 1 Q4W for 28 weeks followed by a 28-week safety follow-up period.
62409461|NCT04639050|EXPERIMENTAL|Part 1 (Dose Finding) Cohort 2: Dose Level 2 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 2, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
62409462|NCT04639050|PLACEBO_COMPARATOR|Part 1 (Dose Finding) Cohort 2: Placebo|Participants will receive matching placebo to dose level 2, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
62409463|NCT04639050|EXPERIMENTAL|Part 1 (Dose Finding) Cohort 3: Dose Level 3 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 3, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
62584522|NCT03841058|EXPERIMENTAL|Abaloparatide (Men)|Open-label treatment with Abaloparatide 80 mcg dose administered subcutaneously with a pen once daily for 6 months
62584523|NCT03753919|EXPERIMENTAL|Durvalumab + Tremelimumab|Durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks up to 4 cycles followed by durvalumab 1500 mg every 4 weeks until disease progression, unacceptable toxicity or patients' decision.
62213619|NCT02741323|PLACEBO_COMPARATOR|Arm 2: Placebo|Participants will receive placebo at the time of admission for transplantation and prior to transplant. Participants will receive placebo throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
62213620|NCT03438877|EXPERIMENTAL|Intervention group|Intervention group is intensive dosage of PD.
62409464|NCT04639050|PLACEBO_COMPARATOR|Part 1 (Dose Finding) Cohort 3: Placebo|Participants will receive matching placebo to dose level 3, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
62791042|NCT02769910|OTHER|Histamine|Histamine is used to induce histaminergic itch on the volar forearm at the locations treated with Capsaicin 24 Hours, Capsaicin 1 Hour and Qutenza Demo Patch.
62791043|NCT00623870|EXPERIMENTAL|1|
62791044|NCT03657290|ACTIVE_COMPARATOR|Treatment A|vadadustat 3 X 150 mg Tablets in fasted subjects
62791045|NCT03657290|ACTIVE_COMPARATOR|Treatment B|Vadadustat 1 X 450 mg Tablets in fasted subjects
62791046|NCT03657290|ACTIVE_COMPARATOR|Treatment C|vadadustat 1 X 450 mg Tablets in fed subjects
62791047|NCT04971356|EXPERIMENTAL|Experimental arm|1-month of Aspirin + Ticagrelor, followed by 5-month of Ticagrelor monotherapy; Afterward, Aspirin monotherapy for 6 months
62791048|NCT04971356|ACTIVE_COMPARATOR|Reference arm|12-month Aspirin plus Ticagrelor
62791049|NCT05765123||Healthy adults|Healthy male and female participants
62213621|NCT03438877|ACTIVE_COMPARATOR|Control group|Control group is regular dosage of PD.
62213622|NCT02703064|EXPERIMENTAL|Furocyst|Furocyst 500mg capsule, BD
62584524|NCT06666673|PLACEBO_COMPARATOR|Placebo|One lactose pill will be administered as a control.
62213623|NCT01102621||case-control, head and neck cancer with radiotherapy|The group of exposed individuals had to be patients with disease-free survival interval of at least two years subsequent to treatment for head and neck cancer by means of radiotherapy alone or in combination, in which the auditory system was included in the field of irradiation.
62213624|NCT01102621||case-control, head an neck cancer without radiotherapy|The group of non-exposed individuals (control group) had to be patients who had not undergone oncological treatment that put their hearing at risk and who were age-matched (2 years). This group was formed by individuals who had had pelvic tumors or skin tumors and who had only undergone local surgery to remove their tumors, and by female volunteers from the hospital. All of these individuals were asked whether they would be willing to participate in a study, without knowing in advance whether they had any previous hearing problems or complaints.
62213625|NCT03141697|EXPERIMENTAL|Carbon Dioxide|Colonoscopy with Insufflation of Carbon Dioxide
62791050|NCT03654508|ACTIVE_COMPARATOR|ADRB2-genotype guided treatment arm|In the genotype-stratified arm, children will be treated based on their ADRB2 genotype. Children homozygous for the risk variant Arg16 and heterozygotes (Arg16Gly) will be treated with doubling dosages of their ICS. Children homozygous for the wild type allele (Gly16Gly) will receive LABA.
62791051|NCT03654508|ACTIVE_COMPARATOR|Control arm|In the control arm, genotyping will be performed for retrospective analysis, but the genotype information will not be used to guide treatment. Children in this study arm will proceed randomisation between doubling ICS dosage (n=75) or LABA treatment (n=75), the two most commonly preferred add-on options among paediatric pulmonologists in the Netherlands. The investigators choose to randomize between both treatments options, since international guidelines do not agree on the preferred treatment option.
62791052|NCT03423316|NO_INTERVENTION|Healthy Controls|
62213626|NCT03141697|PLACEBO_COMPARATOR|Room Air|Colonoscopy with Insufflatioin of Room Air
62213627|NCT06150274|ACTIVE_COMPARATOR|standard Inoue balloon technique|Those randomized to the standard care will undergo the procedure using the contemporary Inoue balloon system (Toray Industries, Japan), which is available in 4 sizes: 24, 26, 28 and 30 mm.
62791053|NCT03423316|NO_INTERVENTION|Age-Matched Controls|Subjects without PAD who have the same average age as the PAD patients
62791054|NCT03423316|EXPERIMENTAL|PAD Patients|Patients with PAD. Approximately 75% of PAD patients will be enrolled in the 12-week exercise therapy program.
62791055|NCT06526819|EXPERIMENTAL|Part 1 - Dose Escalation & Dose Optimization|"Patient to receive SMP-3124LP continuous IV infusion every 2 weeks (q2w) (Schedule 1). At the discretion of the Safety Review Committee (SRC), Schedule 2 - IV infusion every 3 weeks (q3w) - may be initiated for example, after a maximum tolerated dose (MTD) is reached for Schedule 1 (q2w) or when 2 or more patients experience a dose delay of at least 7 days at the same dose level for Schedule 1.~The provisional dose levels are 20, 40, 60, 90, and 120 mg/m2, and intermediate and additional dose levels may be added as needed."
62791056|NCT06526819|EXPERIMENTAL|Part 2 - Dose Expansion|Patient to receive SMP-3124LP continuous IV infusion at the Recommended Phase 2 Dose as determinated in part 1.
62791057|NCT00858208||Patients with neovascular Age-Related Macula Degeneration|
62791058|NCT00891241|EXPERIMENTAL|Cohort 1|Healthy Population
62791059|NCT00891241|EXPERIMENTAL|Cohort 2|Heart Failure Subjects with a documented ejection fraction of 35% or less, and a diagnosis of NYHA Class II-III heart failure, history of ventricular arrhythmia and ICD placement
62791060|NCT01147055|EXPERIMENTAL|1|There should be at least 14-day washout period between treatment A and B.
62791061|NCT06122974|OTHER|Study Device|Subjects randomized to the Drug Eluting Temporary Spur Stent System
62791062|NCT06122974|OTHER|Control|Subjects randomized to the PTA
62791063|NCT00735722|ACTIVE_COMPARATOR|Concomitant HIFU ablation|HIFU AF Ablation
62213628|NCT06150274|ACTIVE_COMPARATOR|wire assisted crossing|The procedure is performed on a similar fashion until atrial septal entry. Once the atrial wall is traversed, and the Mullins sheath is within the left atrium, the mitral valve is crossed with a flexible 0.032- or 0.035 in- 145 cm J-tipped wire. This step could be assisted by a steerable sheath. Once the mitral valve is crossed, the initial wire will be exchanged with a looped stiff wire (Safari or similar) to the left ventricle by use of a 5/6 f pigtail catheter. A commercially available balloon is used to perform the valvulotomy/commissurotomy procedure. Choice of balloon size is made following the formula: Balloon size = patient height (cm)/10 + 10. Fine tuning of the balloon size will be performed peri-operative based on transesophageal echo findings. Use of a separate stiff wire placed in the left atrium/pulmonary vein to ease passage through the atrial septum is left to the discretion of the operator based on the anatomical challenges faced during the procedure.
62409465|NCT04639050|EXPERIMENTAL|Part 1 (Dose Finding) Cohort 4: Dose Level 4 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 4, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
62584525|NCT06666673|ACTIVE_COMPARATOR|Drug Probe|8 mg Tizanidine
62584526|NCT04414969|EXPERIMENTAL|Anti-PD-1 antibody+Peg-Asparaginase+Chidamide|Anti-PD-1 antibody 200mg ivdrip d1; PEG-ASP 2500U/m2 im d1; Chidamide, 30mg, PO, on d1，d5，d8，d12，d15，d19; repeat every 3 weeks.
62584527|NCT01008371||Obese|Healthy obese subjects
62791064|NCT00735722|NO_INTERVENTION|Best medical treatment|Best medical treatment
62791065|NCT05249569|EXPERIMENTAL|Axitinib / Avelumab /Bavituximab|Axitinib 5 mg PO BID Avelumab 10 mg/kg IV every 2 weeks (2 doses in a 4-week cycle) Bavituximab 3 mg/kg IV every 1 week (4 doses in a 4-week cycle) Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
62791066|NCT05909384||Expert group|"1. Clinical expertise in adult sepsis management, AND~2. Demonstrated involvement with sepsis related research, educations, policy/protocols, professional activities"
62791067|NCT04826939|EXPERIMENTAL|Device usage|All participants will complete a survey and undergo an evaluation to test the movement of their pelvic floor with the PFDx device and leva device
62791068|NCT00286429|PLACEBO_COMPARATOR|Insulin|
62791069|NCT00286429|EXPERIMENTAL|Alogliptin 12.5 mg QD|
62409466|NCT04639050|PLACEBO_COMPARATOR|Part 1 (Dose Finding) Cohort 4: Placebo|Participants will receive matching placebo to dose level 4, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
62409467|NCT04639050|EXPERIMENTAL|Part 1 (Dose Finding) Cohort 5: Dose Level 5 of RO7126209|Participants will receive a total of 2 doses of RO7126209 at dose level 5 Q4W, for 28 weeks followed by an 8-week safety follow-up period.
62584528|NCT01008371||Non-obese|Healthy non-obese subjects
62584529|NCT05907538||Patients with functional disorder (FD)|Patients with fibromyalgia diagnosed using the ACR criteria (American College of Rheumatology, Wolfe et al., 2010; 2016) Patients with chronic fatigue syndrome diagnosed using the CDC criteria (Centers for Disease Control and Prevention; Fukuda et al., 1994)
62584530|NCT05907538||Patients with stress related syndromes (SRS)|Patients with overstrain and burnout according to the multidisciplinary guidelines for overstrain and burnout in primary care from the Dutch Society of Occupational Medicine (NVAB, 2011)
62584531|NCT05907538||Healthy controls|Healthy controls will consist of people who experience few physical complaints in daily life. The healthy controls will thus be screened for inclusion using the CSD (Checklist for Symptoms in Daily life; Walentynowicz, et al., 2018). Only volunteers with a score of 75 or lower on this questionnaire will be included
62584532|NCT03550872|NO_INTERVENTION|Control Group|Patients in the group who are continuously guided as the activities of daily living normally avoiding participation in any regular program of physical exercise does not proceed from the study.
62584533|NCT03550872|EXPERIMENTAL|Training Group|the patients randomized to the physical training group will undergo the supervised physical training program
62584534|NCT06398067|EXPERIMENTAL|Vietnamese Self-Help Plus (vSH+)|Participants randomized into this arm will attend information sessions and receive the Vietnamese Self-Help Plus (vSH+) intervention and a copy of the illustrated guide, 'Doing What Matters inn Times of STress' (DWM).
62791070|NCT00286429|EXPERIMENTAL|Alogliptin 25 mg QD|
62791071|NCT05600244|EXPERIMENTAL|PENG block Technique|Patients will receive ultrasound-guided Pericapsular Nerve Group Block using 30 ml bupivacaine 0.25%.
62791072|NCT05600244|EXPERIMENTAL|Lumbar ESPB Technique|Patients will receive lumbar erector spinae plane block using 30 ml bupivacaine 0.25%
62791073|NCT05600244|EXPERIMENTAL|Transmuscular QLB-t block Technique|Patients will receive transmuscular quadratus lumborum block using 30 ml bupivacaine 0.25%
62791074|NCT03165422||Adult patients with melanoma|Adult patients with melanoma at participating centers in Japan
62791075|NCT04246658|EXPERIMENTAL|Treatment group|gait training on platform swing walkway for 30 minute.
62791076|NCT04246658|EXPERIMENTAL|control group|conventional physical therapy program
62791077|NCT06273397|ACTIVE_COMPARATOR|Furosemide alone|Active comparator arm with intravenous furosemide dosing based on glomerular filtration rate (protocol).
62791078|NCT06273397|EXPERIMENTAL|Acetazolamide plus Furosemide|Experimental arm number 1 corresponds to oral acetazolamide 250mg (once daily) in combination with furosemide according to the protocol.
62409468|NCT04639050|PLACEBO_COMPARATOR|Part 1 (Dose Finding) Cohort 5: Placebo|Participants will receive a total of 2 doses of matching placebo to dose level 5 Q4W, for 28 weeks followed by an 8-week safety follow-up period.
62409469|NCT04639050|EXPERIMENTAL|Part 2 (Expansion) Cohort 1: Dose Level 1 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 1, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
62409470|NCT04639050|PLACEBO_COMPARATOR|Part 2 (Expansion) Cohort 1: Placebo|Participants will receive matching placebo to dose level 1, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
62409471|NCT04639050|EXPERIMENTAL|Part 2 (Expansion) Cohort 2: Dose Level 2 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 2, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
62791079|NCT06273397|EXPERIMENTAL|Metolazone plus Furosemide|Experimental arm number 2 corresponds to oral metolazone 2.5mg (once daily) in combination with furosemide according to the protocol.
62020478|NCT04844424|EXPERIMENTAL|Part 5: Treatment Sequence XZY|Participants will receive Treatment X in Treatment Period 1 followed by Treatment Z in Treatment Period 2 and then Treatment Y in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62020479|NCT04844424|EXPERIMENTAL|Part 5: Treatment Sequence YXZ|Participants will receive Treatment Y in Treatment Period 1 followed by Treatment X in Treatment Period 2 and then Treatment Z in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62409472|NCT04639050|PLACEBO_COMPARATOR|Part 2 (Expansion) Cohort 2: Placebo|Participants will receive matching placebo to dose level 2, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
62409473|NCT04639050|EXPERIMENTAL|Part 2 (Expansion) Cohort 3: Dose Level 3 of RO7126209|Participants will receive a total of 2 doses of RO7126209 at dose level 3, Q4W, for 28 weeks followed by an 8-week safety follow-up period.
62409474|NCT04639050|PLACEBO_COMPARATOR|Part 2 (Expansion) Cohort 3: Placebo|Participants will receive a total of 2 doses of matching placebo to dose level 3, Q4W, for 28 weeks followed by an 8-week safety follow-up period.
62409475|NCT04639050|EXPERIMENTAL|Part 3 (Dose/Frequency/Pharmacodynamic (PD) Relationship): Dose Level 1: RO7126209|Participants will receive multiple doses of RO7126209 in an open-label treatment period at dose level 1, Q4W, for 24 weeks followed by a 28-week safety follow-up period.
62409476|NCT04639050|EXPERIMENTAL|Part 3 Dose/Frequency/PD Relationship: Dose Level 2: RO7126209|Participants will receive multiple doses of RO7126209 in an open-label treatment period at dose level 2, Q12W, for 24 weeks followed by a 28-week safety follow-up period.
62409477|NCT04639050|EXPERIMENTAL|Part 4: Open Label Extension (OLE) phase Arm 1: RO7126209|Participants who completed Part 1, 2, or 3 and have reached amyloid negativity (≤ 24 centiloids) in either of the Study Parts or at the OLE baseline visit will receive RO7126209 Q12W for 101 weeks. The dose level will depend on the dose level in Part 1, 2, and 3.
62409478|NCT04639050|EXPERIMENTAL|Part 4 OLE Phase Arm 2: RO7126209|Participants who completed Part 1, 2, or 3 and who are amyloid positive (≥24 centiloids) will receive RO7126209 Q4W for 12 weeks and will have to reach amyloid negativity (≤ 24 centiloids) before they can switch to Q12W dosing in an open-label treatment period of 89 weeks. The dose level will depend on the dose level received in Part 1,2, and 3.
62409479|NCT04639050|EXPERIMENTAL|Part 4 OLE Phase Arm 3: RO7126209|Participants who completed Part 1, 2, or 3 and who are amyloid positive (≥24 centiloids) at week 12 of OLE will receive RO7126209 Q4W for an additional 12 weeks, before to switch to Q12W dosing for the remaining 77 weeks in an open-label treatment period. The dose level will depend on the dose level received in Part 1,2, and 3.
62791080|NCT01486342||Group 1|Mechanically ventilated patients without acute lung injury and lung injury prediction score \< 4
62791081|NCT03262168|OTHER|Study Group One|Six Minute Walk Test distance \<450metres. Exercise programme including inspiratory muscle trainer for 12 weeks. Contact weekly (via phone or email).
62791082|NCT03262168|OTHER|Study Group Two|Six Minute Walk Test distance \>450metres. Exercise programme including walking for 12 weeks. Contact every second week (via phone or email).
62791083|NCT03262168|OTHER|Study Group One - phase 2|Six Minute Walk Test distance \<450metres. Exercise programme including inspiratory muscle trainer for 12 weeks. Contact weekly (via phone or email).
62791084|NCT03262168|OTHER|Study Group Two - phase 2|Six Minute Walk Test distance \>450metres. Exercise programme including walking for 12 weeks. Contact every second week (via phone or email).
62791085|NCT04550494|EXPERIMENTAL|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy and blood sample collection as well as CT scan or MRI throughout the study.
62791086|NCT01582399|EXPERIMENTAL|Arm A: ASKP1240 intravenous (IV) infusion|
62791087|NCT01582399|EXPERIMENTAL|Arm B: ASKP1240 subcutaneous (SC)|
62020480|NCT04844424|EXPERIMENTAL|Part 5: Treatment Sequence ZYX|Participants will receive Treatment Z in Treatment Period 1 followed by Treatment Y in Treatment Period 2 and then Treatment X in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
62213629|NCT03802604|EXPERIMENTAL|Talimogene laherparepvec + Atezolizumab|"1. Talimogene laherparepvec: Cycle 1 - 10\^6 PFU/mL. Cycle 2, 3, 4 \& 5 - 10\^8 PFU/mL.~2. Atezolizumab 840 mg"
62213630|NCT04421846|OTHER|Group 1 : Status epilepticus|
62213631|NCT04421846|OTHER|Group 2 : Dysimmune encephalitis|
62409480|NCT05412823||Hypoxic group|Participants with hypoxia during intubation (after induction and before endotracheal tube placement)
62409481|NCT05412823||Non-hypoxic group|Participants without hypoxia during intubation (after induction and before endotracheal tube placement)
62409482|NCT06429891|EXPERIMENTAL|89Zr-16A|All study participants will be allocated to this arm (single-arm study). Study participants will undergo 89Zr-16A PET/CT scans.
62409483|NCT03590691|ACTIVE_COMPARATOR|Comparison group|Vietnam National Hypertension Program: a training program for health care workers and a health educational program for general public.
62409484|NCT03590691|EXPERIMENTAL|Intervention group|"Vietnam National Hypertension Program including training program for health care workers and an health educational program for general public.~PLUS~Three selected enhancements integrated into routine clinical care:~1. expanded community health worker services;~2. home blood pressure self-monitoring; and~3. a storytelling intervention."
62409485|NCT01157065|EXPERIMENTAL|AL-78898A|Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up
62409486|NCT01157065|ACTIVE_COMPARATOR|Lucentis|Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up
62791088|NCT04867733|EXPERIMENTAL|Micropatch application|All participants will complete this arm. Three sites each on the upper arm, volar (inner) forearm, and palm will be identified. Baseline measurements of trans-epidermal water loss, electrical resistance, and color will be made at each site. Baseline optical coherence tomography (OCT) scans will be made at each site. Color will only be measured at baseline. One site at each location will undergo the following interventions: 1) micropatch application and an occlusive covering, 2) micropatch application, but remain uncovered, 3) occlusive covering, no micropatch application. Micropatch application will only occur on the first day and does not contain any drug substance. Trans-epidermal water loss and electrical resistance are re-measured after micropatch removal, along with an additional OCT scan. Electrical resistance and OCT scans will be repeated at all sites for 2 days. Measurements from the 2nd and 3rd sites allow each subject to serve as their own control in data analysis.
62791089|NCT00745537|EXPERIMENTAL|Adolescent Mother|aged less than 17 years old and recently gave birth
62791090|NCT06011837|EXPERIMENTAL|Altered Auditory Feedback|Participants in this arm will use the Mumble Melody application over the course of 1 month
62791091|NCT03719742|EXPERIMENTAL|Sponsor Test Products|"1. Baby Bee Foaming Cleanser(at least once daily)~2. BB Baby Ultra Gentle Lotion (twice daily)"
62791092|NCT02150278|EXPERIMENTAL|Brief intervention|The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
62020481|NCT01255358|EXPERIMENTAL|ERY-DEX|Patients treated with monthly treatment of ERY-DEX (dexamethasone sodium phosphate encapsulated in autologous erythrocytes)
62213632|NCT04421846|OTHER|Group 3 : Control patients|
62213633|NCT02002793|OTHER|Early stage abdominal drainage|SAP patients who matches one of the following criteria:1．Intravesical pressure≥20cmH2O or 2.CT images:acute peripancreatic liquid collection should have early stage abdominal drainage immediately;
62213634|NCT02002793|OTHER|Late stage abdominal drainage|Despite that it matches one of the cirteria as the study group:1．Intravesical pressure≥20cmH2O or 2．CT images:acute peripancreatic liquid collection, the patients continue acquire prearranged integrative treatment and will not accept early stage abdominal drainage until any of the followings emerge:1.Intra-abdominal apartment syndrome; 2. Pancreatic pseudocyst;3. Pancreatic or peripancreatic necrosis;
62213635|NCT06139497|EXPERIMENTAL|PLHIV|"The following information is gathered during the visit:~* HIV infection history~* Medical evaluation of disabilities and comorbidities: a complete clinical assessment and cognitive evaluation are conducted.~* Evaluation of functional and activity limitations~* Assessment of social aspects of disability~* Evaluation of associated factors~A qualitative interview will be conducted with a subgroup of the study population (20 participants)"
62213636|NCT06139497|ACTIVE_COMPARATOR|Control|"The following information is gathered during the visit:~* Medical evaluation of disabilities and comorbidities: a complete clinical assessment and cognitive evaluation are conducted.~* Evaluation of functional and activity limitations~* Assessment of social aspects of disability~* Evaluation of associated factors"
62213637|NCT02405403|EXPERIMENTAL|amyotrophic lateral sclerosis (ALS)|\[18F\]DPA-714 PET
62213638|NCT02919930|OTHER|Oronasal - Nasal|Patients undergo polysomnography with oronasal mask during the first night and nasal mask during the second night.
62213639|NCT02919930|OTHER|Nasal - Oronasal|Patients undergo polysomnography with nasal mask during the first night and oronasal mask during the second night.
62409487|NCT05250609|EXPERIMENTAL|"Intervention: Endocrown composite."|Composite Endocrown will be used as an extra-coronal restoration in endodontically treated mutilated first permanent molar
62409488|NCT05250609|NO_INTERVENTION|Comparator / Control: Stainless steel crown.|Stainless steel crown will be used as an extra-coronal restoration in endodontically treated mutilated first permanent molar
62409489|NCT03300804|ACTIVE_COMPARATOR|20-herb formulation|Active herb
62409490|NCT03300804|PLACEBO_COMPARATOR|Placebo|Placebo herb formulation
62409491|NCT01932515|NO_INTERVENTION|Screening|
62409492|NCT00326118|ACTIVE_COMPARATOR|Meningitec + Hiberix Group|Subjects received a single dose of Meningitec™ vaccine co-administered with Hiberix™ and Priorix™ vaccines. The Meningitec vaccine was administered intramuscularly in the left deltoid region, the Hiberix vaccine was administered intramuscularly in the left thigh region and the Priorix vaccine was administered subcutaneously in the right upper arm.
62409493|NCT00326118|EXPERIMENTAL|Menitorix Group|Subjects received a single dose of Menitorix™ vaccine co-administered with Priorix™ vaccine. Menitorix vaccine was administered intramuscularly in the left deltoid region and the Priorix vaccine was administered subcutaneously in the right upper arm.
62409494|NCT06489197|EXPERIMENTAL|Experimental arm|Ivonescimab combined with albumin paclitaxel and cisplatin
62020482|NCT02199457|OTHER|SVSS and reference devices|Vital signs will be measured on the same subject with the reference devices and with the SVSS. The subject will have blood pressure, pulse, blood oxygen, body temperature and respiration rate measured using standard equipment. The same subject will then use the investigational device which measures all vital signs at the same time, by placing the index finger on a sensor.
62020483|NCT05900024|EXPERIMENTAL|Cycle Bites|Participants will consume 1 Cycle Bite per day.
62409495|NCT04749173|EXPERIMENTAL|Cohort 1 (96 mg)|- Ventrogluteal area: 48 mg/0.2 mL x 2 sites
62409496|NCT04749173|EXPERIMENTAL|Cohort 2 (432 mg)|"* Deltoid area: 72 mg/0.3 mL x 2 sites~* Ventrogluteal area: 144 mg/0.6 mL x 2 sites"
62020484|NCT04174521||Mother-Child|Mothers who have delivered at VUMC and their children who are seen by Vanderbilt-affiliated physicians.
62020485|NCT05772767|OTHER|Biological sample collection|Collection of tumor tissue and PBMC for the generation of glioblastoma stem cell cultures and brain organoids.
62409497|NCT04749173|EXPERIMENTAL|Cohort A (144 mg)|- Deltoid area: 72 mg/0.3 mL x 2 sites
62409498|NCT04749173|EXPERIMENTAL|Cohort B (144 mg)|- Ventrogluteal area: 72 mg/0.3 mL x 2 sites
62020486|NCT01116934||PLS patients|Eight PLS patients (one female) from 6 families.
62020487|NCT01116934||Healthy controls|Healthy donors had abstained from taking drugs for two weeks prior to the study. Due to wide spread use of oral contraceptives only male probands were chosen.
62020488|NCT04631666|EXPERIMENTAL|Group 1A (uninfected) - 2.5 mg/kg|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 2.5 mg/kg
62020489|NCT04631666|EXPERIMENTAL|Group 1B (uninfected) - 10 mg/kg|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 10 mg/kg
62020490|NCT04631666|EXPERIMENTAL|Group 1C (uninfected) - 40 mg/kg|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 40 mg/kg
62020491|NCT04631666|EXPERIMENTAL|Group 1D (uninfected) - high dose|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose higher than 40 mg/kg
62020492|NCT04631666|EXPERIMENTAL|Group 2C (infected) - 40 mg/kg|SARS-CoV-2-infected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 40 mg/kg
62213640|NCT01636232||ICU sepsis group|The ICU sepsis group consisting of 105 critically-ill cases diagnosed with sepsis upon admission and sampled within the first 24h of their ICU stay.
62213641|NCT01636232||ICU control group|the ICU control group including 51 critically-ill cases in whom sepsis was clinically excluded and from whom samples were taken upon admission.
62213642|NCT01636232||healthy control group|the healthy control group composed of 50 healthy control outpatients. For the healthy control outpatients, possibilities of acute or past chronic diseases were excluded. Moreover, we made sure that the healthy control subjects had not been hospitalized or taken vitamin-based substitutive drugs in the last 12 months, and proved normal in physical checkups and lab examinations.
62409499|NCT02959398|ACTIVE_COMPARATOR|standard mammography|standard mammography
62409500|NCT02959398|EXPERIMENTAL|standard mammography and tomosynthesis|standard mammography and tomosynthesis
62584535|NCT06398067|ACTIVE_COMPARATOR|Enhanced Usual Care|Participants randomized into this arm will receive usual care and a copy of the illustrated guide, 'Doing What Matters inn Times of STress' (DWM).
62791093|NCT06379776|EXPERIMENTAL|3D model group|Residents having access to the 3D model
62020493|NCT04631666|EXPERIMENTAL|Group 2D (infected) - 40 mg/kg|SARS-CoV-2-infected volunteers will be randomized 2:1 to receive an intravenous infusion of DZIF-10c at a dose of 40 mg/kg or placebo
62213643|NCT04104828||Grass/tree AIT with Allergovit|Collection of blood and data from patients that receive allergen-immunotherapy (AIT) with Allergovit, an aluminium-containing AIT preparations.
62213644|NCT04104828||Grass/tree AIT with Polvac|Collection of blood and data from Patients that receive AIT with Polvac, an MCT-containing AIT preparation.
62213645|NCT04104828||Grass/tree AIT with Pollinex Quattro|Collection of blood and data from patients that receive AIT with Pollinex Quattro, an MCT-MPLA containing AIT preparation.
62213646|NCT05830227||Primary snoring group|Primary snoring group
62213647|NCT05830227||Critical OSAHS group|Critical OSAHS group
62213648|NCT05830227||Mild OSAHS group|Mild OSAHS group
62213649|NCT05830227||Moderate to severe OSAHS group|Moderate to severe OSAHS group
62213650|NCT01940068|EXPERIMENTAL|New Thickened Amino acid based formula|
62213651|NCT01940068|ACTIVE_COMPARATOR|Amino acid based formula|
62213652|NCT05600686|EXPERIMENTAL|Treatment (Lonca-R, DA-EPOCH-R)|Patients receive rituximab IV, loncastuximab tesirine IV, etoposide IV, doxorubicin IV, vincristine IV, prednisone PO, and cyclophosphamide IV on study. Patients also undergo collection of blood samples and bone marrow aspiration and biopsy at screening and CT or PET/CT at screening, throughout the study, and during follow up.
62213653|NCT04165876|ACTIVE_COMPARATOR|Primary motor cortex|
62213654|NCT04165876|ACTIVE_COMPARATOR|Dorsolateral prefrontal cortex|
62213655|NCT04165876|ACTIVE_COMPARATOR|Multi-modal stimulation (DLPFC+M1)|
62213656|NCT04165876|SHAM_COMPARATOR|Sham-stimulation|
62213657|NCT05930886||Hispanic Community|15 adult parents/caregivers self-identified as Hispanic
62213658|NCT05930886||Black/African American Community|15 adult parents/caregivers self-identified as Black/African American
62213659|NCT03210545|ACTIVE_COMPARATOR|betamethasone - physiological dose|Replacing participants hydrocortisone with a daily dose of betamethasone in an estimated physiological dose during one treatment period.
62213660|NCT03210545|ACTIVE_COMPARATOR|betamethasone - supra physiological dose|Replacing participants hydrocortisone with a daily dose of betamethasone in an estimated supra physiological dose during one treatment period.
62213661|NCT05116813|EXPERIMENTAL|Dipraglurant TID|
62213662|NCT03928639||Cohort 1|All patients undergoing consultation for structural and valve interventional procedures are invited to participate in this registry protocol.
62409501|NCT03770481|EXPERIMENTAL|Assess the NLCS' feasibility|"Hypothesis: No significant differences will be observed in recruitment and attrition between NLCS intervention and control groups.~Approach: Determine rates of enrollment and drop-outs between groups."
62791094|NCT06379776|ACTIVE_COMPARATOR|Traditional teaching group|Residents having access to traditional educational support
62791095|NCT01817504|ACTIVE_COMPARATOR|Study group|The study group corresponds to systematic transplantectomy under immunosuppressive therapy within two months after return to dialysis,
62791096|NCT01817504|OTHER|Control group|The control group corresponds to progressive reduction of immunosuppression without systematic transplantectomy after return to dialysis
62791097|NCT01568294|EXPERIMENTAL|pomalidomide|Patients will receive pomalidomide orally on Days 1-21 of each 28-day cycle until when/if a discontinuation criterion, e.g., disease progression, development of an unacceptable toxicity, voluntary withdrawal, or pomalidomide is in market for the target indication.
62791098|NCT00994526|PLACEBO_COMPARATOR|Ham|
62791099|NCT00994526|EXPERIMENTAL|Ham + calcium|
62791100|NCT00994526|EXPERIMENTAL|Ham + vitamin E|
62791101|NCT03005548|EXPERIMENTAL|Active tDCS|Experimental: Transcranial direct current stimulation (tDCS). Patients assigned to the active treatment group (n=31) will receive IV morphine followed by IV morphine PCA (IV morphine bolus 1 mg, lockout time 10 mins.), preceded by tDCS (20 minutes of 2 milliamperes (mA) anodal tDCS over the ipsilateral cortex for 5days/week).
62791102|NCT03005548|SHAM_COMPARATOR|Sham tDCS|Sham Control Group: Patients assigned to the control group (n=31) will receive IV morphine followed by IV morphine PCA (IV morphine bolus 1 mg, lockout time 10 mins.), preceded by sham tDCS stimulation (30 sec over the ipsilateral cortex, 5 days/week).
62791103|NCT01247168|EXPERIMENTAL|1|
62791104|NCT04637425|EXPERIMENTAL|Ismigen|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
62213663|NCT04183439||Surgeons Interviewed|We recruited surgeons from two University academic health centers, one specializing in adults and the other in children. The surgeons were selected through a snowball technique and emailed to participate. DK and GS interviewed eleven surgical attendings representing 10 surgical specialties. (Table 2) Each subject had at least 10 years of experience in their respective fields and regularly taught residents.
62791105|NCT04637425|PLACEBO_COMPARATOR|Placebo|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
62213664|NCT03689959|EXPERIMENTAL|Patients|13 child with fixed knee flexion deformity more than 10° on one or both sides with 12 months or more predicted growth remaining subjected to eight plate hemiepiphysiodesis of the distal femur
62584536|NCT02679391||A|69 consecutive operated patients by general surgeons at Capio S:t Görans Hospital 2011. All post weight loss. , 96% female, BMI by the time of operation 26, mean age 41 (SD 9.5). Their mean weight loss in BMI units: 17.8 (SD 5.12).
62584537|NCT02679391||B|70 consecutive operated patients by plastic surgeons at Karolinska University Hospital 2010-2012. All post weight loss. 86% female, BMI by the time of oepration 26, mean age 38.6 (SD 11.4). Their mean weight loss in BMI units: 17.4 (SD 4.8).
62584538|NCT02679391||C|70 consecutive operated patients by general surgeons at Capio S:t Görans Hospital 2013-2014. All post weight loss. 90% female, BMI by the time of operation 26, mean age 46.8 (SD 10.1). Their mean weight loss in BMI units: 16.3 (SD 5.11)
62584539|NCT00434174|EXPERIMENTAL|everolimus + Pemetrexed - daily|Daily treatment
62584540|NCT00434174|EXPERIMENTAL|everolimus + Pemetrexed - weekly|Weekly treatment
62584541|NCT04903353|ACTIVE_COMPARATOR|Treatment with Risperidone|Patients prescribed Risperidone
62584542|NCT04903353|ACTIVE_COMPARATOR|Treatment with Aripiprazole|Patients prescribed Aripiprazole
62584543|NCT04354012|EXPERIMENTAL|Treatment|methylene blue, gentian violet, and ovine forestomach wound dressings to HS lesions
62213665|NCT02793388|ACTIVE_COMPARATOR|Supervised primaquine arm|Following standard schizontocidal treatment according to national guidelines and if haemoglobin levels are above 8g/dL and G6PD testing is normal, the patient receives primaquine (0.5mg/kg/day) for 14 days for radical cure. Supervision of primaquine is done on alternate days at home (attended by a home visitor) or at the health centre.
62213666|NCT02793388|ACTIVE_COMPARATOR|Unsupervised primaquine arm|Following standard schizontocidal treatment according to national guidelines and if haemoglobin levels are above 8g/dL and G6PD testing is normal, the patient receives primaquine (0.5mg/kg/day) for 14 days for radical cure for self administration.
62409502|NCT03770481|EXPERIMENTAL|Assess the NLCS' acceptability|"Hypothesis: More surrogates agree that the NLCS is suitable, appropriate, effective and willing to adhere versus treatment as usual (TAU) communication.~Approach: Assess outcome using the validated instrument, Client Satisfaction Questionnaire (CSQ-8)."
62213667|NCT05303701|PLACEBO_COMPARATOR|GV1001 Placebo|"GV1001 placebo (0.9% saline) subcutaneous injection will be administered once a week for 4 weeks and then administered every 2 weeks for 20 weeks in a double-blind phase.~During the open-label extension phase, patients assigned to the GV1001 Placebo arm in the double-blind phase will receive a placebo in the first week, followed by 1.12 mg of GV1001 weekly for 4 weeks and then every 2 weeks until EOT (End of Treatment)."
62213668|NCT05303701|EXPERIMENTAL|GV1001 1.12 mg|"GV1001 1.12 mg subcutaneous injection will be administered once a week for 4 weeks and then administered every 2 weeks for 20 weeks in a double blind phase.~During the open-label extension phase, patients will alternate between 1.12 mg of GV1001 and placebo weekly for the first 5 weeks to maintain double blindness, and then 1.12mg of GV1001 every 2 weeks until EOT."
62213669|NCT04963452|PLACEBO_COMPARATOR|Group 1|Normal weight BMI 20-24.9 kg/m2
62213670|NCT04963452|ACTIVE_COMPARATOR|Group 2|Morbid Obese BMI : 40-49.9 kg/m2
62213671|NCT05108545|EXPERIMENTAL|Amphotericin B liposomes|Patients with suspected fungal neutropenia and fever will receive amphotericin B liposome 3 mg/kg intravenously. Treatment will be continued until the ANC≥500 /mm\^3 (0.5×10\^9 /L) for more than 72 hrs in terms of patients without evidence of baseline fungal infection and breakthrough fungal infection; or treatment will be continued according to investigator's judgement with a duration ranging from 14 days to 12 weeks in terms of patients with evidence of baseline fungal infection and breakthrough fungal infection.
62213672|NCT04127708|PLACEBO_COMPARATOR|sham acupuncture|Ten acupuncture sessions were applied over five weeks. In this study, acupuncture style is the traditional Chinese model, acupuncture was performed on 11 acupuncture points (TE21, SI19, GB2, TE22, ST7, TE17, GB20 of the affected side, and GB20, TE05, KI3 of both sides) using sterile, single-use, 0.25 mm thick, 40 mm long needles (Dongbang Medical Co., Boryeong, Korea). The acupuncture points were selected by taking previous studies as reference. The depth of the needle differed depending on the anatomical structure of the participant and the nature of the acupuncture points, but it was approximately 5-10 mm. The acupuncture needles were applied until the participant experienced de-qi and removed after 20 minutes.
62213673|NCT04127708|ACTIVE_COMPARATOR|acupuncture|en acupuncture sessions were applied over five weeks. In this study, acupuncture style is the traditional Chinese model, acupuncture was performed on 11 acupuncture points (TE21, SI19, GB2, TE22, ST7, TE17, GB20 of the affected side, and GB20, TE05, KI3 of both sides) using sterile, single-use, 0.25 mm thick, 40 mm long needles (Dongbang Medical Co., Boryeong, Korea). The acupuncture points were selected by taking previous studies as reference. The depth of the needle differed depending on the anatomical structure of the participant and the nature of the acupuncture points, but it was approximately 5-10 mm. The acupuncture needles were applied until the participant experienced de-qi and removed after 20 minutes.
62213674|NCT05302492|EXPERIMENTAL|Sleep apnea group with CPAP|"Intervention group: CPAP for 3 months in elderly diagnosis with sleep apnea and AHI \> 15/h.~Control group: sleep apnea and patient refuse treatment or poor compliance."
62213675|NCT05302492|EXPERIMENTAL|sleep disturbance without sleep apnea nor PLMS|Intervention group: light box on elderly with sleep disturbance with PSQI \> 5 and no OSA and no PLMS control group: elderly with sleep disturbance with PSQI \> 5 and no OSA and no PLMS refuse light box or poor compliance
62213676|NCT00171808|EXPERIMENTAL|Letrozole|
62213677|NCT02296333|ACTIVE_COMPARATOR|ondansetron|ondansetron iv, 8 mg, skin closure time
62213678|NCT02296333|PLACEBO_COMPARATOR|isotonic|isotonic 2ml, once, skin closure time
62409503|NCT03770481|EXPERIMENTAL|Assess the NLCS' preliminary effects|Hypothesis: NLCS improves communication and decreases surrogates' psychological distress (e.g., anxiety and depression) Approach: Compare pre- and post-intervention scores of the Quality of Communication (QOC) questionnaire, Hospital Anxiety and Depression Scale (HADS), and Decisional Conflict Scale (DCS) between intervention and control groups.
62409504|NCT05558007|ACTIVE_COMPARATOR|Daily oral Tadalafil 5mg + Topical Placebo|Patient that underwent Radical Prostatectomy will receive daily oral Tadalafil 5mg and topical placebo
62213679|NCT03534284|ACTIVE_COMPARATOR|CBT-I|Cognitive Behavioral Therapy for Insomnia sessions: a 30-minute treatment session once weekly for six weeks.
62213680|NCT03534284|ACTIVE_COMPARATOR|Medication- Trazodone|Trazodone (50-100 mg):
62213681|NCT03534284|PLACEBO_COMPARATOR|Medication- Placebo|Placebo (for trazodone)
62409505|NCT05558007|EXPERIMENTAL|Daily oral placebo + topical BZ371A|Patient that underwent Radical Prostatectomy will receive daily oral placebo and topical BZ371A
62409506|NCT05558007|ACTIVE_COMPARATOR|Daily oral Tadalafil 5mg + topical BZ371A|Patient that underwent Radical Prostatectomy will receive daily oral Tadalafil 5mg and topical BZ371A
62213682|NCT01549938|ACTIVE_COMPARATOR|Treatment|20,000 IU cholecalciferol capsule
62213683|NCT01549938|PLACEBO_COMPARATOR|Placebo|Microcellulose capsule
62409507|NCT06068088||Cohort A|Participating patients from 5 radiotherapy center of AP-HP
62409508|NCT06068088||Cohort B|Participating patients from the european hospital Georges-Pompidou
62409509|NCT02352116|EXPERIMENTAL|Additional education|Subjects undergoing ambulatory surgery who receive standard of care management with additional face-to-face education in postoperative pain management.
62409510|NCT02352116|ACTIVE_COMPARATOR|No additional education|Subjects undergoing ambulatory surgery who receive standard of care management with no additional education in postoperative pain management.
62409511|NCT04358822|ACTIVE_COMPARATOR|30 second cord clamping|Infants in this group will receive delayed cord clamping for 30 seconds.
62213684|NCT02064348|EXPERIMENTAL|Arm 1: semaglutide + moxifloxacin placebo|Subjects will receive a single dose of moxifloxacin placebo both before the start of semaglutide treatment and at the end of the semaglutide treatment.
62213685|NCT02064348|ACTIVE_COMPARATOR|Arm 2A:|"Semaglutide placebo + moxifloxacin/moxifloxacin placebo:~Subjects will receive moxifloxacin before the start of semaglutide placebo treatment and moxifloxacin placebo at the end of the semaglutide placebo treatment."
62213686|NCT02064348|EXPERIMENTAL|Arm 2B:|"Semaglutide placebo + moxifloxacin placebo/moxifloxacin:~Subjects will receive moxifloxacin placebo before the start of semaglutide placebo treatment and moxifloxacin at the end of the semaglutide placebo treatment."
62213687|NCT02822105|EXPERIMENTAL|H3N2 M2SR monovalent influenza vaccine|This group will receive a low, medium or high dose of the H3N2 M2SR monovalent influenza vaccine administered intranasally. It will be compared with placebo in a 3:1 ratio.
62213688|NCT02822105|EXPERIMENTAL|placebo|This group will receive saline administered intranasally.
62213689|NCT02943291|EXPERIMENTAL|4x4 minutes interval training|4x4 minutes high intensity interval training with 4 minute intervals
62213690|NCT02943291|EXPERIMENTAL|10x1 minute interval training|10x1 minute high intensity interval training with 1 minute intervals
62213691|NCT06147908|EXPERIMENTAL|Sequence A|cross-over
62213692|NCT06147908|EXPERIMENTAL|Sequence B|cross-over
62213693|NCT04472000|EXPERIMENTAL|Vitamin C|Patients who are assigned to the experimental treatment group will be given extended release capsules with 500 mg of ascorbic acid orally two times daily, packed in PET/PP-bottles identical as used for the licenced product.
62213694|NCT04472000|PLACEBO_COMPARATOR|Placebo|The control intervention of this study consists of treatment with no active substance (placebo) but in the same schedule as the experimental treatment (verum).
62213695|NCT00700492|NO_INTERVENTION|control|
62213696|NCT00700492|EXPERIMENTAL|utrogestan|daily use of vaginal progesterone capsules
62791106|NCT03387020|EXPERIMENTAL|Treatment (ribociclib, everolimus)|Patients receive ribociclib PO QD on days 1-21 of course 1 and subsequent courses and days 2-21 of course 2, and everolimus PO QD on days 3-28 of course 1 and days 1-28 of subsequent courses. Patients who are undergoing surgery also receive ribociclib PO QD on days 7-10 before surgery. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 13 courses may continue receiving ribociclib and everolimus every 28 days for up to 13 additional courses in the absence of disease progression or unacceptable toxicity.
62213697|NCT04571840|ACTIVE_COMPARATOR|mpMRI|Multiparametric MRI
62213698|NCT04571840|EXPERIMENTAL|bpMRI|Biparametric MRI
62213699|NCT01202097|EXPERIMENTAL|Salmeterol/Fluticasone|
62213700|NCT01202097|ACTIVE_COMPARATOR|Seretide|
62213701|NCT06607354|NO_INTERVENTION|Concentrate/ Cereal fed lamb|Participants to consume three portions of lamb per week for four consecutive weeks. The lamb diet was a concentrate/cereal pellet.
62213702|NCT06607354|EXPERIMENTAL|Grass fed lamb|Participants to consume three portions of lamb per week for four consecutive weeks. The lamb diet was grass only.
62213703|NCT02404727|ACTIVE_COMPARATOR|cup fixation cemented|30 of the 60 patients will be randomized to cemented cup fixation
62213704|NCT02404727|ACTIVE_COMPARATOR|cup fixation cementless|30 of the 60 patients will be randomized to cementless cup fixation
62584544|NCT04560985|EXPERIMENTAL|Hydrophilic sealant|UltraSeal XT hydro™ sealant ®
62791107|NCT04942613|EXPERIMENTAL|Multicomponent Telehealth Intervention (Group1)|This group will be randomized to receive the 12-week multicomponent intervention first. They will receive individual physical therapy sessions, group physical therapy sessions, and biobehavioral interventions emphasizing program engagement and increased daily physical activity. Most interventions will be provided synchronously through videoconferencing. Each participant will receive an individualized home exercise program.
62213705|NCT05457075||Case|Stage II-III rectal cancer patients who have neoadjuvant therapy
62213706|NCT03341325|EXPERIMENTAL|animal-assisted intervention|the intervention is a real animal is presented in different forms to the participants
62213707|NCT03341325|ACTIVE_COMPARATOR|control intervention|the control intervention is a stuffed toy animal is presented in different forms to the participants
62213708|NCT01666938|EXPERIMENTAL|Diabetes Education Group & Telephone counseling|This step was done for four months.
62213709|NCT01666938|ACTIVE_COMPARATOR|Telephone counseling about physical activity|This step was done for four months.
62213710|NCT03196895|ACTIVE_COMPARATOR|WR|Weight reduction training
62213711|NCT03196895|ACTIVE_COMPARATOR|GE|PPG training
62213712|NCT03196895|EXPERIMENTAL|GEM|PPG training + discrete BG feedback
62213713|NCT03196895|EXPERIMENTAL|GEM+CGM|PPG training + continuous BG feedback
62213714|NCT02270138|EXPERIMENTAL|Movement-to-music|Three movement-to-music video programs will be used by the participants. First and second videos last about 10 minutes including two songs and their movement preparation. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
62213715|NCT02270138|NO_INTERVENTION|No movement-to-music|Another group will not receive movement-to-music video during intervention. However, their physical activity will be objectively measured as well.
62213716|NCT06610227|EXPERIMENTAL|SapRNA™-MICA/B|Patients will receive the monotherapy with SapRNA™-MICA/B Tumor Vaccine, which will be administered by intramuscular injection on Day 1, Day 14, and Day 28 respectively.
62213717|NCT02886273||Group 1|SCA with first MI (n = 43)
62213718|NCT02886273||Group 2|SCA with AMI and previous MI (n = 10)
62020494|NCT05104658|EXPERIMENTAL|Intervention arm|"Usual rehabilitation: training (1 hour 2 times a week for 6 weeks), dietary training (2x3 hours), cardiac education (2x3 hours), referred to municipal rehabilitation: training (1 hour 2 times a week for 6-12 weeks), patient education (3x2 hours by a cardiac nurse and 1x2 hours by a dietician).~In addition:~* Information book on rehabilitation and physical activities in local community~* 1:1 conversation with patient supporters from the Heart Association~* Employer material on post-treatment and potential work adjustments~* Support café for relatives~* Supported transition to local sports associations~* Motivating phone calls from physiotherapists supporting physical activities.~In addition for patients with vulnerabilities:~* patient education in small groups~* pro-active counselling with a cardiac nurse, a psychologist, or a social worker from the Heart Association~* paid transportation to the municipal rehabilitation Center"
62791108|NCT04942613|OTHER|Education (Group2)|This group will be randomized to 12-week waitlist control condition. They will receive a one-hour education session every 2 weeks (6 sessions total) on general health topics (e.g., basic nutrition, stress reduction, sleep hygiene). At the end of 12 weeks, they will transition to the 12-week multicomponent intervention
62213719|NCT02886273||Group 3|SCA without AMI and without former heart disease (n = 3)
62213720|NCT02886273||Group 4|SCA without AMI and with known heart disease (n = 18)
62584545|NCT04560985|ACTIVE_COMPARATOR|Hydrophobic sealant|Helioseal-F Sealant ®
62791109|NCT04942613|OTHER|Research Participants|Participants will be asked to complete up to 2 semi-structured interviews following completion of the 12-week multicomponent intervention. The first interview will occur within 3 weeks of program completion (by week 15 for Group 1 and by week 27 for Group 2). The second interview will occur between 3 to 6 months after the first interview.
62213721|NCT03981861|EXPERIMENTAL|Overall Study|Treatment with Metformin and Spironolactone
62213722|NCT00480402|EXPERIMENTAL|400 mg Progesterone|Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 400 mg Progesterone Group vaginal pessaries arm.
62213723|NCT00480402|EXPERIMENTAL|200 mg Progesterone Group|Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 200 mg Progesterone Group vaginal pessaries arm.
62020495|NCT05104658|NO_INTERVENTION|Control arm|Usual rehabilitation: training (1 hour 2 times a week for 6 weeks), dietary training (2x3 hours), cardiac education (2x3 hours), referred to municipal rehabilitation: training (1 hour 2 times a week for 6-12 weeks), patient education (3x2 hours by a cardiac nurse and 1x2 hours by a dietician).
62213724|NCT00480402|ACTIVE_COMPARATOR|Placebo|Approximately one third of the bichoronic biamniotic twin pregnant women were randomized to the placebo vaginal pessaries arm.
62213725|NCT01728311|EXPERIMENTAL|Arm 1|
62213726|NCT01446120|EXPERIMENTAL|Insulin loaded Orally Dissolved Films (insulin-ODF)|
62213727|NCT01446120|ACTIVE_COMPARATOR|Human Insulin Specific RIA Kit <5uCi|
62213728|NCT03184038|EXPERIMENTAL|Supportive care (SRS/SBRT, neurocognitive testing)|Patients undergo SRS on day 1 or SBRT for 3 fractions over days 1-7 and undergo neurocognitive testing at baseline, 4, and 12 months after undergoing SRS or SBRT.
62213729|NCT05012501||PVT group|（1) Patients with cirrhosis diagnosed in accordance with the 2019 Guidelines for the Diagnosis and Treatment of Cirrhosis;(2) In accordance with the diagnostic criteria of portal vein thrombosis in the 2015 European Society of Hepatology Clinical Practice Guidelines: Hepatic Vascular Diseases. Color ultrasound, CT, MRI, and other imaging studies confirmed the presence of portal vein thrombosis and the specific location of the thrombosis.
62584546|NCT02135185|EXPERIMENTAL|Rehabilitation effort|custom work endurance combining dietary management adapted to the nutritional status and an APA. Included patients benefit from support for 19 weeks from the start of treatment
62584547|NCT02135185|ACTIVE_COMPARATOR|Control|Control with dietary management adapted to the nutritional status
62584548|NCT04536012|NO_INTERVENTION|Control|Via the Way to Health platform, all patients will receive daily text messages that inform them of their previous day's step count for 24 weeks.
62020496|NCT01394861|EXPERIMENTAL|ESD using MASTER Slave Robotic System|
62020497|NCT02243787|EXPERIMENTAL|COVA322|single i.v. infusion
62213730|NCT05012501||without PVT group|(1) Patients with cirrhosis diagnosed in accordance with the 2019 Guidelines for the Diagnosis and Treatment of Cirrhosis;(2)Color ultrasound, CT, MRI, and other imaging studies confirmed the absence of portal vein thrombosis and the specific location of the thrombosis.
62791110|NCT05627024|EXPERIMENTAL|Experimental: 30% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 30%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Manual lung recruitment maneuvers will be performed after tracheal intubation and before tracheal extubation, however when intraoperative oxygen saturation is less than 92% the manual lung recruitment maneuver will be done too. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
62791111|NCT05627024|PLACEBO_COMPARATOR|Placebo Comparator: 60% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 60%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
62213731|NCT05016518|EXPERIMENTAL|Propofol group|Propofol based total intravenous anesthesia
62213732|NCT05016518|ACTIVE_COMPARATOR|Remimazolam group|Remimazolam based total intravenous anesthesia
62213733|NCT05737368|EXPERIMENTAL|Patients will receive the treatment of fractionated radiotherapy and Cadonilimab|fractionated radiotherapy (500cGy \*5F, 600cGy\*5F, 350cGy\*10F, according to the tumor volume); within 14 days after receiving radiotherapy, Cardunizumab (10mg/kg, Q3W, d1)
62213734|NCT04763421|EXPERIMENTAL|Upper Gastrointestinal/Lower Gastrointestinal/Gynecological|Any upper gastrointestinal/lower gastrointestinal/gynecological procedure where the ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.
62409512|NCT04358822|ACTIVE_COMPARATOR|120 second cord clamping|Infants in this group will receive delayed cord clamping for 120 seconds.
62409513|NCT02359409|ACTIVE_COMPARATOR|water immersion only|Colonoscopy will be performed using the water immersion technique.
62791112|NCT01435135|EXPERIMENTAL|Group I|ALVAC-HIV + AIDSVAX B/E or ALVAC-HIV placebo + AIDSVAX B/E placebo at Weeks 0 and 24
62409514|NCT02359409|EXPERIMENTAL|water immersion with goggle balloon|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique
62791113|NCT01435135|EXPERIMENTAL|Group II|AIDSVAX B/E or AIDSVAX B/E placebo at Weeks 0 and 24
62791114|NCT01435135|EXPERIMENTAL|Group III|ALVAC-HIV or ALVAC-HIV placebo at Weeks 0 and 24
62791115|NCT04389723|OTHER|Placebo→ Qualia Mind|Subjects are first administered the placebo then crossover to the investigational product
62791116|NCT04389723|OTHER|Qualia Mind→ Placebo|Subjects are first administered the investigational product then crossover to the placebo
62791117|NCT01712802|EXPERIMENTAL|Denture Adhesives: Cream|Parallel arm that receives application of Cream denture adhesives.
62791118|NCT01712802|EXPERIMENTAL|Denture Adhesives: Powder|Parallel arm that receives application of powder denture adhesive.
62791119|NCT01712802|PLACEBO_COMPARATOR|control|Parallel arm that receive placebo.
62020498|NCT02243787|PLACEBO_COMPARATOR|Placebo|single i.v. infusion
62409515|NCT03179488|EXPERIMENTAL|Spinal TENS stimulation|"Spinal TENS stimulation: A constant voltage and a symmetric biphasic current of 200 microseg pulse-width at a frequency of 100Hz. The intensity will increase until participants report a strong but comfortable sensation, just below motor threshold."
62734534|NCT05833230|EXPERIMENTAL|Individuals who use cannabis|Participants who are non-treatment seeking cannabis users (30 men, 30 women) ranging from once weekly use to multiple times daily. All participants will be recruited from the greater New Haven community and will complete four weeks of smartphone monitoring. During this monitoring period, they will also complete two three-consecutive days of intensive monitoring including more frequent smartphone surveys, saliva samples, heart rate monitoring, and an alcohol use monitor.
62791120|NCT03475485|EXPERIMENTAL|ID-Capsules- Active|"Randomly-assigned ingestions of ID-Capsules containing ingestible sensors (ID-Capsule- Active) while wearing the ID-Cap Reader (Wearable Sensor) under direct observation~• Subjects will ingest ID-Capsules containing the ingestible sensor which emits a signal from within the subject's stomach. This signal is detected by the wearable Reader, and the ingestion event is recorded."
62791121|NCT03475485|PLACEBO_COMPARATOR|ID-Capsules- Inactive|"Randomly-assigned ingestions of ID-Capsules containing no ingestible sensors while wearing the ID-Cap Reader under direct observation~• Subjects will also ingest empty placebo capsules that do not contain ingestible sensors. In the absence of an ingested sensor, no signal is received by the Reader after the capsule is ingested, and the ingestion event is not recorded."
62791122|NCT05701696||Patients with fibromyalgia|Patients diagnosed with FM according to ACR 2016 criteria
62791123|NCT06324292|ACTIVE_COMPARATOR|conventional denture followed by a digital one|the participants will receive a conventional complete denture followed by a digital one having digital smile design
62791124|NCT06324292|ACTIVE_COMPARATOR|Digital denture followed by a conventional one|the participants will receive a digital complete denture having digital smile design followed by a conventional one
62791125|NCT02172378|EXPERIMENTAL|Tiotropium inhalation capsules|
62791126|NCT02172378|PLACEBO_COMPARATOR|Placebo inhalation capsules|
62791127|NCT02402140|EXPERIMENTAL|1 with pharmaceutical intervention|"Patients allocated to group 1 with pharmaceutical intervention received instructions on the proper use of immunosuppressants as dosage, frequency and administration schedules, importance of immunosuppressive drugs and the risk of rejection.~No more interventions were applied."
62791128|NCT02402140|NO_INTERVENTION|2 without pharmaceutical intervention|"Standard following of the Hospital do Rim, without pharmaceutical intervention. This group was just followed by the nurses of the hospital, but without a standardized intervention.~It was not a intervention, it was the control group"
62791129|NCT05981469||Induction of labour|
62213735|NCT01167361||Children with upper or lower respiratory infections|Respiratory Virus infections in children who are symptomatic with either an Upper Respiratory Tract Infections and/or Lower Respiratory Tract Infections is determined by using a novel highly sensitive and rapid assay for RV detection. An aliquot from the leftover sample remaining after clinical diagnostic testing will be used for FilmArrayTM analysis. Specimens collected will include nasopharyngeal washes, nasopharyngeal swabs, tracheal aspirates and bronchoalveolar lavage as ordered by the treating physician. Diagnostic studies on this specimen will be performed as ordered and the results will be available to the treating physicians after reporting.
62213736|NCT05399277|EXPERIMENTAL|Rivaroxaban Group|Subjects will receive rivaroxaban 15mg tablet to be taken orally once daily for 7 days following transradial access.
62213737|NCT05399277|NO_INTERVENTION|Standard of Care Group|Subjects will receive the usual standard of care following transradial access.
62213738|NCT03626987||Bacterial identification|Describe the MALDI-TOF spectrum to identify peaks that may be associated with epidemiological and clinical characteristics of bacterial strains
62213739|NCT02845843|EXPERIMENTAL|Combination of Lopinavir /Ritonavir and IntErferon Beta 1B|Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days
62213740|NCT02845843|PLACEBO_COMPARATOR|Placebo|Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
62409516|NCT03179488|SHAM_COMPARATOR|Sham stimulation|The same procedures as experimental group, but but will be applied a sham electrical stimulation increasing the current intensity until sensory perception of the stimulus, and then decreased to zero where it will fix until the end of the stimulation.
62409517|NCT05728359||Cardiogenic shock and MI|Patients presenting with acute myocardial infarction and cardiogenic shock who are supported medically (ie. inotropes +/- intra aortic balloon pump only). N=50
62409518|NCT05728359||Cardiogenic shock and MI wtih ECMO|Patients presenting with acute myocardial infarction and cardiogenic shock who are supported medically with ECMO (+/- LV unloading device). N=50
62734535|NCT00723151|EXPERIMENTAL|Low Intensity|One hour of intervention per week
62213741|NCT01376232|EXPERIMENTAL|GSK1278863|100 mg of GSK1278863
62213742|NCT01376232|EXPERIMENTAL|GSK1278863 + food|100 mg of GSK1278863 given with a high fat meal
62213743|NCT01376232|EXPERIMENTAL|GSK1278863 + Gemfibrozil|GSK1278863A 100mg + Gemfibrozil 600mg steady state
62409519|NCT05728359||Cardiogenic shock and MI wtih Impella|Patients presenting with acute myocardial infarction and cardiogenic shock who are supported medically with Impella. N=50
62734536|NCT00723151|EXPERIMENTAL|High Intensity|Five hours of intervention per week, one hour per day for five days per week
62734537|NCT00568594|EXPERIMENTAL|1|
62734538|NCT00568594|PLACEBO_COMPARATOR|2|
62791130|NCT04887519||All Participants|Participants with advanced or metastatic ALK positive NSCLC who have been prescribed with brigatinib in real-world will be observed both prospectively and/or retrospectively at the local clinical practice setting and data will be taken from medical records of the routine visit after every 12 weeks from the start of treatment up to 24 weeks of follow up or death or cancer progression or treatment discontinuation, whichever occurs first.
62791131|NCT01732276|EXPERIMENTAL|gefitinib|gefitinib tablet 250mg/day by mouth until disease progression
62213744|NCT02316327|EXPERIMENTAL|gemcitabine, cisplatin and bevacizumab|"Bevacizumab will be given by I.V infusion at the dose of 7.5 mg/kg on days 1 every 21 days~Cisplatin 80 mg/m2 I.V on day 1~Gemcitabine 1250 mg/m2 I.V on day 1 \& 8~Treatment cycles will be repeated every three weeks up to 6 cycles~Bevacizumab monotherapy as maintenance allowed in non-progressive tumors"
62213745|NCT02239900|EXPERIMENTAL|Group 1 Liver: Concurrent (early) Ipilimumab and SBRT|Participants with at least 1 liver metastasis - Treatment Group 1: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses. SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 1 - 4 of Cycle 1.
62213746|NCT02239900|EXPERIMENTAL|Group 2 Liver: Sequential (late) Ipilimumab and SBRT|Participants with at least 1 liver metastasis - Treatment Group 2: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4. Each cycle is 21 days. SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 29 - 33 of each 21 day cycle.
62213747|NCT02239900|EXPERIMENTAL|Group 3 Lung: Concurrent (early) Ipilimumab and SBRT|Participants with at least 1 lung metastasis - Treatment Group 3: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses. SBRT 50 Gy in 4 fractions to 1 - 4 lung lesion(s) on Days 1 - 4 of Cycle 1.
62213748|NCT02239900|EXPERIMENTAL|Group 4 Lung: Sequential (late) Ipilimumab and SBRT|Participants with at least 1 lung metastasis - Treatment Group 4: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4. Each cycle is 21 days. SBRT 50 Gy in 4 fractions to 1 - 4 lung lesion(s) on Days 29 - 33 of each 21 day cycle.
62213749|NCT02239900|EXPERIMENTAL|Group 5 Liver/Lung Metastasis: (late) Ipilimumab and SBRT|Participants with 1 liver or lung metastasis - Treatment Group 5: Ipilimumab 3 mg/kg by vein on Day 1 of Cycle 1. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 2 - 4. Each cycle is 21 days. SBRT 60 Gy in 10 fractions to 1 - 4 lung, liver, or adrenal lesion (s) on Days 1 - 5 and Days 9 - 12 of Cycle 1.
62213750|NCT02239900|EXPERIMENTAL|Thyroid Expansion Cohort|"Participants enrolled in this arm treated to a total dose of 50 Gy in 4 fractions, 60 Gy in 10 fractions, or 20 Gy in 5 fractions with stereotactic radiotherapy to a liver or lung lesion. The choice of radiation dose will be at the discretion of the treating radiation oncologist.~Participants receive Ipilimumab every 21 days for a total of 4 doses."
62213751|NCT01296802|PLACEBO_COMPARATOR|Placebo|
62213752|NCT01296802|EXPERIMENTAL|Dexfenfluramine|Dexfenfluramine HCL
62213753|NCT00611520||1|Patients with COPD treated with budesonide/formoterol
62213754|NCT05081531|OTHER|Adaptive Radiotherapy in Head and Neck cancer patients|"Patients will be treated with a total dose of 66 Gy, 60 Gy and 54 Gy on PTV1, PTV2 and PTV3, respectively, delivered in 30 fractions, 5 fractions per week.~At week 3 from RT start, patients will repeat contrast simulation CT with, and MRI and FDG-PET scan for treatment replanning. Patient will start with the new plan in week 4."
62213755|NCT04701359|EXPERIMENTAL|Group A (TiN-coating)|Patients with knee osteoarthritis receive total knee arthroplasty with Titanium-Nitride (TiN)-coated implant.
62213756|NCT04701359|ACTIVE_COMPARATOR|Group B (CoCr-alloy)|Patients with knee osteoarthritis receive total knee arthroplasty with Cobalt-Chromium (CoCr)-alloy implant.
62213757|NCT03636477|EXPERIMENTAL|Ad-RTS-hIL-12 + veledimex in combination with nivolumab|Intratumoral Ad-RTS-hIL-12 and varying doses of oral veledimex (activator ligand) given in combination with nivolumab via infusion.
62213758|NCT02791425|EXPERIMENTAL|Brain Computer Interface (BCI) device|The patient uses the Brain Computer Interface (BCI) device in the ICU for communication for 2 hours a day for 3 consecutive days. The patient then uses a communication picture board for 2 hours a day for 3 consecutive days on the same days that the BCI device is used for comparison.
62409520|NCT05728359||MI without cardiogenic shock|Patients presenting with acute myocardial infarction and cardiogenic shock as a control comparator
62734539|NCT00296049|ACTIVE_COMPARATOR|vancomycin|
62734540|NCT00296049|EXPERIMENTAL|daptomycin|
62734541|NCT03026231|ACTIVE_COMPARATOR|PRIM-DJ2727|Subjects with PD will be randomly assigned to receive PRIM-DJ2727 in orally administered enteric-coated capsules
62734542|NCT03026231|PLACEBO_COMPARATOR|Placebo|Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
62734543|NCT01959178|EXPERIMENTAL|LD127025 MF|Mid add daily disposable soft contact lens worn on a daily wear basis for 1 week.
62734544|NCT01959178|ACTIVE_COMPARATOR|Air Optix Aqua MF|Medium add daily disposable soft contact lens worn on a daily wear basis for one week.
62734545|NCT03353363|PLACEBO_COMPARATOR|Normal Saline|Subject will receive 20ml of normal saline infiltration
62734546|NCT03353363|EXPERIMENTAL|Plain Bupivacaine|Subject will receive 20ml of 0.5% plain bupivacaine infiltration (100mg)
62734547|NCT03353363|EXPERIMENTAL|Liposomal Bupivacaine|Subject will receive 20ml of liposomal bupivacaine infiltration (266mg) non-expanded
62734548|NCT00918606|EXPERIMENTAL|LIPO-102|
62734549|NCT05371834|EXPERIMENTAL|Microwave Treatment (Swift System)|5-10 Watts of microwave energy applied locally on each wart for a 2-3 second burst with 3-5 repetitions per lesion.
62734550|NCT05371834|ACTIVE_COMPARATOR|Cryotherapy Treatment|For each wart, two cycles of cryotherapy treatment is administered.
62734551|NCT06291493|OTHER|Precision assessment of Potassium (K) test in capillary blood sample|Prospectively collected capillary specimens from two separate fingerstick blood draws.
62734552|NCT01113177||Distraction splint therapy|All JIA patients with asymmetric mandibular growth due to unilateral TMJ arthritis are offered non-surgical functional orthodontic splint therapy with a distraction splint. Mandibular growth is thereafter evaluated in the affected side compared with the mandibular growth in the healthy side of the same individual.
62734553|NCT00936637|EXPERIMENTAL|Extensively hydrolyzed infant formula|
62734554|NCT06068946|PLACEBO_COMPARATOR|VK2735 (Placebo)|Placebo
62213759|NCT02142296|OTHER|Eylea|The intravitreal dose of Eylea will be 2mg (50ul) per injection. The medication will be supplied in single use vials. Given monthly for 3 months and then every 8 weeks until week 52. This is an open-label study.
62409521|NCT05728359||Non ischemic Cardiogenic Shock ie myocarditis|Patients presenting with myocarditis and cardiogenic shock as a control comparator
62409522|NCT01139242|OTHER|Body & Soul nutritional intervention|This is a standardized intervention to increase fruit and vegetable consumption among church members through pastoral and peer counseling and church activities/menus.
62409523|NCT01139242|EXPERIMENTAL|Newsletters/peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening among church members out-of-date according to screening guidelines. For those up-to-date, promotion is of increased physical activity.
62409524|NCT05032573|EXPERIMENTAL|Olive Oil|Incorporating 60 mL of olive oil into usual diet and Dietary Guidelines recommendations
62409525|NCT05032573|ACTIVE_COMPARATOR|Control|Dietary Guidelines recommendations
62409526|NCT02730039||Cancer Care Providers|"Provider will attend a MCPT two-day intensive workshop that will include:~* Didactic Components~* Experiential Exercises~* Simulated patient role plays with actors~* Provider completes MCPT Workshop Assessment MCPT POST-WORKSHOP IMPLEMTATION (OPTIONAL)~* MCP Core Competency Trainer rated Assessment~* MCP Pre \& Post Workshop Knowledge Assessment~* MCPT Session Evaluation Assessment Provider will participate in training follow-up calls \& webinars for approximately 6 -12 months following completion of MCPT workshop.~* Provider will have ongoing access to MCPT Website with a discussion board, training resources and materials for clinical care.~* Provider will complete follow-up assessment at 3, 6, 9, \& 12 months post-training~* Training Update~* Goal Evaluation Form~* MCP Core Competency Self-Assessment MCPT POST-WORKSHOP IMPLEMTATION (OPTIONAL)"
62409527|NCT06653738|EXPERIMENTAL|Empagliflozin and personalized dietary counseling|Empagliflozin 25 mg once daily per os and personalized dietary counseling for 3 years
62213760|NCT01687907|ACTIVE_COMPARATOR|Fear of childbirth, music|Patients referred to the motherhood out-patient clinic because of fear of childbirth. Advised to active music listening. Followed up by weekly and monthly diaries and three questionnaires (when recruiting, just after the delivery and 6 months after the delivery).
62213761|NCT01687907|NO_INTERVENTION|Fear of childbirth, control|Patients referred to the motherhood out-patient clinic because of fear of childbirth. No intervention. Followed up by three questionnaires (when recruiting, just after the delivery and 6 months after the delivery).
62213762|NCT01687907|ACTIVE_COMPARATOR|Nulliparous, music|300 nulliparous women recruited from the ultrasound screening. Advised to active music listening. Three questionnaires like the other arms, weekly and monthly diaries like the other music group. Screening questionnaires about fear of childbirth.
62213763|NCT01687907|NO_INTERVENTION|Nulliparous, control|300 nulliparous women recruited from ultrasound screening. No intervention. 3 Questionnaires as all the other groups. Screening questionnaire about fear of childbirth.
62409528|NCT06653738|PLACEBO_COMPARATOR|Placebo and personalized dietary counseling|Placebo once daily per os and personalized dietary counseling for 3 years
62409529|NCT06653738|EXPERIMENTAL|Empagliflozin and generic dietary counseling|Empagliflozin 25 mg once daily per os and generic dietary counseling for 3 years
62409530|NCT06653738|PLACEBO_COMPARATOR|Placebo and generic dietary counseling|Placebo once daily per os and generic dietary counseling for 3 years
62409531|NCT03199924|ACTIVE_COMPARATOR|Intravenous Magnesium sulfate combined to Diclofenac|Intravenous Magnesium sulfate combined to Diclofenac
62734555|NCT06068946|EXPERIMENTAL|VK2735 (Dose #1)|VK2735 is a peptide GLP-1 and GIP dual agonist
62791132|NCT00633529|EXPERIMENTAL|I|Single arm: triple combination
62213764|NCT03627013|EXPERIMENTAL|Kidney Custodiol-N|
62213765|NCT03627013|ACTIVE_COMPARATOR|Kidney Custodiol|
62213766|NCT03627013|EXPERIMENTAL|Liver Custodiol-N|
62213767|NCT03627013|ACTIVE_COMPARATOR|Liver Custodiol|
62409532|NCT03199924|ACTIVE_COMPARATOR|intravenous lidocaine combined to diclofenac|intravenous lidocaine combined to diclofenac
62409533|NCT03199924|ACTIVE_COMPARATOR|diclofenac alone|diclofenac alone
62409534|NCT05411848|EXPERIMENTAL|Intervention|Patients will receive a minimum of 1 bottle per day of either (or both of) 2kcal HP PlantBased and/or 2kcal HP PlantBased MultiFibre Tube Feeds for a minimum of 7 days and a maximum of 28 days. During the 12-month follow-up, patients will have access to the same trial prescription as per the 28-day intervention period.
62409535|NCT00998231|ACTIVE_COMPARATOR|Major Depressive Episode (MDE)|20 subjects with major depressive episode will be included and followed during a 6 months interval which includes 4 visits (at the inclusion, 2 and 8 weeks later and finally 6 month later)
62409536|NCT00998231|ACTIVE_COMPARATOR|Control|20 subjects without major depressive episode will be included and followed during a 6 months interval which includes 4 visits (at the inclusion, 2 and 8 weeks later and finally 6 month later)
62409537|NCT05112263|ACTIVE_COMPARATOR|Group A|Group A: Intravenous Cyclosporine 2 mg/kg continuous infusion for 5-7 days and then shifted to oral cyclosporine 4 mg/kg/day in two divided doses for 12 weeks
62409538|NCT05112263|EXPERIMENTAL|Group B|Oral Tofacitinib 10 mg TDS for 3 days, and then 10 mg BD to complete 8 weeks followed by 5 mg BD till follow-up (14 weeks)
62409539|NCT01338909|EXPERIMENTAL|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
62409540|NCT01338909|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 150mg/day starting from Day 1 until Day 5
62734556|NCT06068946|EXPERIMENTAL|VK2735 (Dose #2)|VK2735 is a peptide GLP-1 and GIP dual agonist
62791133|NCT05555706|EXPERIMENTAL|B013+ Nab-Paclitaxel|"B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.~Nab-Paclitaxel 100 mg/m\^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle."
62791134|NCT00751803|EXPERIMENTAL|BI 44370 TA Low Dose|
62791135|NCT00751803|EXPERIMENTAL|BI 44370 TA Medium Dose|
62791136|NCT00751803|EXPERIMENTAL|BI 44370 TA High Dose|
62791137|NCT00751803|PLACEBO_COMPARATOR|Placebo|
62791138|NCT00751803|ACTIVE_COMPARATOR|Eletriptan|
62213768|NCT03627013|EXPERIMENTAL|Kidney/Pancreas Custodiol-N|
62213769|NCT03627013|ACTIVE_COMPARATOR|Kidney/Pancreas Custodiol|
62213770|NCT01680640|ACTIVE_COMPARATOR|Synbiotic|Fructo-oligosacharide with a degree of polymerization \< 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis (BB-12) as minimum of 10 billion colony forming unit (CFU)/day (1 capsule a day).
62213771|NCT01680640|PLACEBO_COMPARATOR|Maltodextrin|4 grams of maltodextrin daily.
62409541|NCT04220723||End-Stage Liver Disease|End-stage liver disease patients who are being followed up at the Department of Gastroentereology of Hacettepe University Faculty of Medicine will be included in the study. When the participants come to the gastroenterology department for control, they will be directed to us and the assessment will begin after written and verbal approval is obtained. The Liver Frailty Index will be used to assess the frailty of the participants. Accordingly, hand grip test, 5 repeat sit-up test and side, semi-tandem and tandem balance measurements will be made and a total frailty score will be obtained. Submaximal aerobic capacities and functional capacities will be evaluated by 6 Minute Walk Test. Then, maximal inspiratory muscle pressure and maximal expiratory muscle pressure of the participants will be measured and respiratory muscle strength will be evaluated. Finally, maximal aerobic capacity will be measured by Shuttle Walk Test.
62409542|NCT06330480|OTHER|Intervention group|This group will be invited for the screening
62409543|NCT06330480|NO_INTERVENTION|Control group|This group will not be invited for the screening
62409544|NCT02220621|EXPERIMENTAL|Treatment|After the hysteroscopic adhesiolysis, crosslinked hyaluronic acid gel is applied into the uterine cavity, then a Foleys balloon catheter is inserted into the uterine cavity.
62213772|NCT04476368|EXPERIMENTAL|yoga|Participants in yoga group will be recruited during prenatal yoga classes at two locations: Maribor and Ljubljana. Women will be instructed to attend one class per week. Classes will consist of pregnancy-adapted yoga practices according to the system Yoga in Daily Life. They will be 90 min in duration and will consist of initial relaxation (10 to 15 min), followed by yoga postures (asanas) and stretching exercises (45 to 60 min), and final breathing (pranayama), concentration (dharana), and meditation (dhyana) techniques (20 to 30 min). Two certified yoga instructors will lead yoga classes. Measurements will be performed before and after yoga session.
62409545|NCT02220621|ACTIVE_COMPARATOR|Control|After hysteroscopic adhesiolysis, a Foleys balloon catheter is inserted into the unterine cavity.
62409546|NCT02014194|PLACEBO_COMPARATOR|attentional bias modification, placebo|Measure of attentional bias modification treatment after 10 sessions of attentional bias modification (two arms). There are two arms with 15 OCD patients each one.
62213773|NCT04476368|ACTIVE_COMPARATOR|control|Control group will consist of healthy pregnant women attending regular prenatal visits at the departments of perinatology of the university medical centers Maribor and Ljubljana. Only women not attending any formal prenatal exercise program will be offered entrance in the study. Measurements in this group will be performed before and after a 20-30 minute walk.
62213774|NCT01869387|NO_INTERVENTION|Standard treatment|Standard treatment consists in bronchodilator and parenteral corticosteroids and oxygen therapy.
62213775|NCT01869387|EXPERIMENTAL|Standard treatment plus non-invasive ventilation|This arm consists in bronchodilator and parenteral corticosteroids and oxygen therapy plus non-invasive ventilation.
62409547|NCT02014194|ACTIVE_COMPARATOR|attentional bias modification, active group|Measure of attentional bias modification treatment after 10 sessions of attentional bias modification (two arms).
62409548|NCT00825669|ACTIVE_COMPARATOR|survival rate (TACE)|to compare the effects of TACE and TACE plus laser ablation for treating patients with PVTT
62409549|NCT00825669|ACTIVE_COMPARATOR|survival rate (TACE plus laser ablation)|to compare the effects of TACE and TACE plus laser ablation for treating patients with PVTT
62734557|NCT06068946|EXPERIMENTAL|VK2735 (Dose #3)|VK2735 is a peptide GLP-1 and GIP dual agonist
62213776|NCT06611215|EXPERIMENTAL|Prebiotic 1|
62213777|NCT06611215|PLACEBO_COMPARATOR|Placebo 1|
62213778|NCT06611215|EXPERIMENTAL|Prebiotic 2|
62213779|NCT06611215|PLACEBO_COMPARATOR|Placebo 2|
62409550|NCT03916354||appropriate GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is in the recommended normal range is in this group.
62409551|NCT03916354||excess GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is over the upper limit of the recommended normal range is in this group.
62213780|NCT01055301|EXPERIMENTAL|treatment|"Ind (1cycle):~bort 1mg/m2 IV/SQ D1,4,8,11 D1-4: thalid 200mg/d \& dex 20mg/d PO; cisplatin \& dox 10mg/m2/d, cyclophos 400mg/m2/d, etoposide 40mg/m2/d contIV; enoxaparin 40mg/d SQ prn.~PBSC Coll: at recovery per local standard~Bridging (before/between trans/after Cons):~thal 50mg/d D1-21 \& dex 20mg D1,8,15 PO~Tandem Trans (x2):~bort 1mg/m2 IV/SQ D-4,-1 D-4to-1: mel 50 mg/m2 IV, thal 200mg/d \& dex 40mg/d PO PBSC \>/=200x10\^6 cells~Cons (1cycle):~same as Ind except cis/dox 7.5mg/m2/d, cyclo 300mg/m2/d, no enox~Maint(\</= 3 yrs):~D1,8,15,22:bort 1mg/m2 IV/SQ, dex 20mg/d PO; len 20mg/d PO D1-20"
62213781|NCT02147899|EXPERIMENTAL|SYM-1219 Low Dose|Administered orally
62213782|NCT02147899|EXPERIMENTAL|SYM-1219 High Dose|Administered orally
62213783|NCT02147899|PLACEBO_COMPARATOR|Placebo|Administered orally
62213784|NCT06002893|EXPERIMENTAL|Cholesfytol NG®) supplement|Patients will receive a single oral dose of 2 tablets a day of Cholesfytol NG®) supplement for 2-months.
62213785|NCT01664962||Patients|Women with severe Vulvodynia
62213786|NCT01664962||Healthy controls|Women without vulvodynia
62213787|NCT00370305|EXPERIMENTAL|Rosiglitazone treatment|Rosiglitazone will be given to the subjects. All subjects will be analyzed before and after treatment
62213788|NCT03994354||1,2|"1. J-P drain group~2. Penrose drain group"
62213789|NCT05086276|ACTIVE_COMPARATOR|FX-322|FX-322, 1 dose
62213790|NCT05086276|PLACEBO_COMPARATOR|Placebo|Placebo, 1 dose
62409552|NCT03916354||insufficient GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is below the lower limit of the recommended normal range is in this group.
62409553|NCT04945226|ACTIVE_COMPARATOR|Propecia|Propecia Tablet, QD, PO
62409554|NCT04945226|EXPERIMENTAL|IVL3001 (A mg)|S.C, Single Dose.
62409555|NCT04945226|EXPERIMENTAL|IVL3001 (B mg)|S.C, Single Dose.
62409556|NCT04945226|EXPERIMENTAL|IVL3001 (C mg)|S.C, Single Dose.
62409557|NCT05168657|EXPERIMENTAL|EN-IP-UC first, Then BP|Random-order cross-over participants managed by ENDOCRINOLOGY with IN-PERSON visits, assigned by randomization to undergo 14 days of Usual Care, followed by 14 days of Bionic Pancreas. There was no washout period between arms.
62409558|NCT05168657|EXPERIMENTAL|EN-TH-UC first, Then BP|Random-order cross-over participants managed by ENDOCRINOLOGY with TELEHEALTH visits, assigned by randomization to undergo 14 days of Usual Care, followed by 14 days of Bionic Pancreas. There was no washout period between arms.
62409559|NCT05168657|EXPERIMENTAL|EN-IP-BP first, Then UC|Random-order cross-over participants managed by ENDOCRINOLOGY with IN PERSON visits, assigned by randomization to undergo 14 days of Bionic Pancreas, followed by 14 days of Usual Care. There was no washout period between arms.
62409560|NCT05168657|EXPERIMENTAL|EN-TH-BP first, Then UC|Random-order cross-over participants managed by ENDOCRINOLOGY with TELEHEALTH visits, assigned by randomization to undergo 14 days of Bionic Pancreas, followed by 14 days of Usual Care. There was no washout period between arms.
62409561|NCT05168657|EXPERIMENTAL|PC-IP-UC first, Then BP|Random-order cross-over participants managed by PRIMARY CARE with IN-PERSON visits, assigned by randomization to undergo 14 days of Usual Care, followed by 14 days of Bionic Pancreas. There was no washout period between arms.
62409562|NCT05168657|EXPERIMENTAL|PC-TH-UC first, Then BP|Random-order cross-over participants managed by PRIMARY CARE with TELEHEALTH visits, assigned by randomization to undergo 14 days of Usual Care, followed by 14 days of Bionic Pancreas. There was no washout period between arms.
62734558|NCT06068946|EXPERIMENTAL|VK2735 (Dose #4)|VK2735 is a peptide GLP-1 and GIP dual agonist
62734559|NCT03742479|EXPERIMENTAL|Hyaluronic Acid Microinjection|
62734560|NCT03983720|EXPERIMENTAL|Patient with multiple sclerosis and lowly fatigued|"Patient with multiple sclerosis and lowly fatigued will be included.~They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
62213791|NCT01177800|EXPERIMENTAL|Infliximab|5 milligram per kilogram (mg/kg) infusion (a fluid or a medicine delivered into a vein by way of a needle) of infliximab administered intravenously (into a vein) at Week 0, 2 and 6 followed by maintenance regimen of 5 mg/kg infliximab at Week 14 and 22. Placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial infusion), matched to infliximab will be given at Week 10, 12 and 16. Total duration of treatment will be 26 weeks.
62213792|NCT01177800|EXPERIMENTAL|Placebo|Placebo infusion, matched to infliximab will be given intravenously at Week 0, 2 and 6. At Week 10, 12 and 16, participants will receive 5 mg/kg infliximab intravenously. Placebo infusion will be again given at Week 14 and 22. Total duration of treatment will be 26 weeks.
62213793|NCT06359925|ACTIVE_COMPARATOR|Group S|Suprazygomatic maxillary nerve block using Dexmedetomidine Plus Bupivacaine
62213794|NCT06359925|PLACEBO_COMPARATOR|Group c( control)|Suprazygomatic maxillary nerve block using Bupivacaine only
62213795|NCT03796702|EXPERIMENTAL|Early closure of preventive ileostomy|A preventive ileostomy is closed 30 days after the primary surgery
62213796|NCT03796702|EXPERIMENTAL|Late closure of preventive ileostomy|A preventive ileostomy is closed 90 days after the primary surgery
62213797|NCT05630872|EXPERIMENTAL|Adults with HIV and newly diagnosed DS-TB not currently on ART|"Participants will receive daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide for 8 weeks followed by daily rifapentine-moxifloxacin plus isoniazid for 9 weeks (referred to as 2HPZM/2HPM) for anti-tuberculosis (anti-TB) therapy at study entry.~DTG-based ART at 50 mg twice daily (BID) will be started after 6 weeks of TB therapy and will be continued for 2 weeks after completion of TB therapy.~Two weeks after completion of TB therapy DTG will be reduced to standard dose 50 mg once daily (QD)."
62213798|NCT02097940|ACTIVE_COMPARATOR|treatment|The treatment group performed of proprioceptive exercises with shifts and one-leg jumps.
62213799|NCT02097940|NO_INTERVENTION|control|The control group remained in soccer training
62409563|NCT05168657|EXPERIMENTAL|PC-IP-BP first, Then UC|Random-order cross-over participants managed by PRIMARY CARE with IN PERSON visits, assigned by randomization to undergo 14 days of Bionic Pancreas, followed by 14 days of Usual Care. There was no washout period between arms.
62409564|NCT05168657|EXPERIMENTAL|PC-TH-BP first, Then UC|Random-order cross-over participants managed by PRIMARY CARE with TELEHEALTH visits, assigned by randomization to undergo 14 days of Bionic Pancreas, followed by 14 days of Usual Care. There was no washout period between arms.
62409565|NCT03746249|EXPERIMENTAL|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62409566|NCT03296592||Investigational subjects|"Patients who have been diagnosed with cervical spondylotic myelopathy and who will be undergoing surgical correction for this diagnosis.~Visit 1 Investigational subjects will undergo a clinical assessment. Patients will undergo a DBSI MRI~Visit 2. 6 months after surgery, investigational subjects will undergo a clinical assessment.~Visit 3 12 months after surgery, investigational subjects will undergo a clinical assessment~Visit 4 18 months after surgery, investigational subjects will undergo a clinical assessment.~Visit 5 24 months after surgery, investigational subjects will undergo a clinical assessment and a DBSI MRI."
62791139|NCT05582772|ACTIVE_COMPARATOR|GA+M Intervention|"GA+M intervention arm All participants in the GA+M intervention arm will undergo a standardized GA by a trained nurse and geriatrician. The GA will include 8 domains (comorbidity, medication review, function, falls risk, nutrition, social supports, cognition, and mood) similar to our 5C protocol.~Based on any detected abnormalities or issues, a standardized set of strategies will be implemented (e.g. increased falls risk will lead to detailed assessment of balance and gait, consideration of gait aid, and referral to outpatient physiotherapy). This follows the standard approach to implementing GA similar to recent trials in geriatric oncology including 5C. Telephone follow-ups at 1, 3 and 6 months by the nurse and review with the geriatrician as needed will be done to ensure identified issues have been addressed."
62020499|NCT03860194|EXPERIMENTAL|Supp group|"Each participant received nutritional counseling and recommended each of them to consume 1.5 g protein/kg body weight (BW)/day. Participants were encouraged to consume a balanced diet with six food groups follow Daily dietary guideline of 2013  as recommended by the Ministry of Health and Welfare of Taiwan. However, 1.2 g protein/kg body weight (BW)/day was suggested from this guideline.~Subjects in the Supp group were provided with Protison with High Protein 51(Original Flavor) containing supplements in addition to their regular daily meals to achieve 1.5 g protein/kg (BW)/day on the basis of this guideline."
62213800|NCT03291288|EXPERIMENTAL|Pexidartinib|"Part 1 (Drug-drug Interaction Phase):~On Day 1, all participants will receive a single oral dose each of midazolam (2 mg) and tolbutamide (500 mg). On Day 3, pexidartinib (800 mg/d) in twice daily (400 mg BID) dosing will be initiated and continue throughout the remainder of Part 1 and into Part 2. On the first day of pexidartinib treatment (Day 3), a single dose of midazolam (2 mg) and tolbutamide (500 mg) will be co-administered with the morning pexidartinib dose (400 mg). On Day 13, a single dose of midazolam (2 mg) and tolbutamide (500 mg) will be co-administered with the morning dose of pexidartinib (400 mg).~Part 2 (Efficacy and Safety Phase):~All participants will continue to receive pexidartinib 400 mg BID."
62213801|NCT02275000|EXPERIMENTAL|Intervention|5 Day physiotherapy programme at the National Hospital for Neurology and Neurosurgery, Queen Square, London UK.
62213802|NCT02275000|ACTIVE_COMPARATOR|Treatment as usual|Participants are referred to their local neuro-physiotherapy service and if appropriate placed on a waiting list for inpatient rehabilitation.
62213803|NCT01270074|EXPERIMENTAL|azithromycin liquid preparation|azithromycin will be given at a dose of 10mg/kg given three times per week from three months of age to three years of age
62213804|NCT01270074|ACTIVE_COMPARATOR|inert liquid preparation|inert liquid preparation will be given three times per week from three months of age to three years of age
62213805|NCT05478239|EXPERIMENTAL|Prostate cancer patients|Men with biochemical recurrence of prostate cancer after initial local therapy.
62213806|NCT00060762|EXPERIMENTAL|Interpersonal Therapy|Interpersonal Therapy is a psychotherapy aimed at resolving interpersonal difficulties
62213807|NCT00060762|ACTIVE_COMPARATOR|Behavioral Weight Loss Treatment|Behavioral Weight Loss Treatment is aimed solely at weight loss, however it has been shown to decrease binge eating
62213808|NCT00060762|ACTIVE_COMPARATOR|Guided Self Help|Guided Self-Help is a brief psychotherapy based on cognitive-behavioral treatment
62213809|NCT02751320|EXPERIMENTAL|Experimental Dentifrice1|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
62409567|NCT03296592||Control group|Healthy volunteers aged 45-65 Visit 1: DBSI MRI Visit 2: 24 months after first MRI, patient will undergo the second MRI
62409568|NCT04769830||AGI group|Collect the characteristic data of intestinal sound, such as 24-hour average intestinal rate, duration of gastrointestinal sound, amplitude, maximum frequency, average frequency, etc., and detect citrulline, intestinal fatty acid binding protein and so on.
62213810|NCT02751320|EXPERIMENTAL|Experimental Dentifrice 2|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
62213811|NCT02751320|EXPERIMENTAL|Experimental Dentifrice 3|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
62409569|NCT04769830||non-AGI group|Collect the characteristic data of intestinal sound, such as 24-hour average intestinal rate, duration of gastrointestinal sound, amplitude, maximum frequency, average frequency, etc., and detect citrulline, intestinal fatty acid binding protein and so on.
62409570|NCT05151991|ACTIVE_COMPARATOR|Groups MET|Patients from this group will undergo orthodontic fixed treatment with stainless steel brackets.
62409571|NCT05151991|ACTIVE_COMPARATOR|Group CER|Patients from this group will undergo orthodontic fixed treatment with ceramic brackets.
62409572|NCT05190562|EXPERIMENTAL|Zinc Sulphate|Zinc Sulphate 25 Mg once daily for one month
62213812|NCT02751320|PLACEBO_COMPARATOR|Reference Product 1|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
62213813|NCT02751320|ACTIVE_COMPARATOR|Reference Product 2|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
62213814|NCT02751320|ACTIVE_COMPARATOR|Reference Product 3|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
62213815|NCT02530164|ACTIVE_COMPARATOR|real tDCS|
62409573|NCT02916056|EXPERIMENTAL|Azeliragon 5 mg|Azeliragon (TTP488) 5mg orally once daily for 2 years
62409574|NCT02237885|EXPERIMENTAL|Neurofeedback|
62409575|NCT03166969|EXPERIMENTAL|Patients taken care in neurovascular unit|
62213816|NCT02530164|PLACEBO_COMPARATOR|sham tDCS|
62213817|NCT01776905||Healthy control subjects|Characterize the baseline PA signals produced by the in vivo PAFC prototype device in healthy volunteers or Develop Standard Curves for the ex vivo CTC assays.
62213818|NCT01776905||Advanced-Stage Melanoma|To validate the in vivo PAFC method of melanoma CTC detection, we will use the PAFC-based prototype device to noninvasively determine CTC concentrations in the blood of subjects who have advanced-stage (Stage III or Stage IV)melanoma, and we will also use current ex vivo methods to determine the CTC concentration in samples of blood drawn from the same subjects.
62213819|NCT01776905||Early-Stage Melanoma|To determine whether in vivo PAFC can detect melanoma CTCs at concentrations below the detection limits of the ex vivo methods, we will use the PAFC-based prototype device to noninvasively detect CTCs in the blood of subjects who have early-stage (Stages I or II) melanoma, and we will also use current ex vivo methods to detect CTCs in samples of blood drawn from the same subjects.
62213820|NCT00223639|EXPERIMENTAL|Topiramate|
62213821|NCT00223639|PLACEBO_COMPARATOR|Placebo|
62734561|NCT03983720|EXPERIMENTAL|Patient with multiple sclerosis and highly fatigued|"Patient with multiple sclerosis and highly fatigued will be included. They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
62734562|NCT03983720|ACTIVE_COMPARATOR|Healthy subjects|"Healthy subjects will be included. They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
62213822|NCT02432196|EXPERIMENTAL|Harpoon Medical TSD-5|This is a prospective, nonrandomized, single-centered European study designed single arm study to demonstrate the performance and safety of the Harpoon Medical TSD-5 in Subjects with degenerative mitral regurgitation.
62409576|NCT04952610|EXPERIMENTAL|Etripamil NS 70 mg|Self- administration of a dose of 70 mg of etripamil. Patients will be provided with a maximum of 4 pre-filled devices at a time. If the symptoms of PSVT persist 10 minutes after the first dose of etripamil NS 70 mg, a second dose of etripamil NS 70 mg can be self-administered by the patient. A second dose of etripamil NS 70 mg should be taken not earlier than 10, and not later than 15 minutes after the first dose.
62409577|NCT01346202||chronic pain|260 consecutive patients with verified chronic pain syndromes
62734563|NCT01380678|ACTIVE_COMPARATOR|bevacizumab|intralesional bevacizumab injection
62213823|NCT03619304|EXPERIMENTAL|no coffee|oral squamous cell carcinoma cell line without intervention
62409578|NCT02709408||Carbapenem-resistant Enterobacteriaceae|Patients with complicated intrabdominal infections, pneumonia, complicated urinary tract infection and bloodstream infection due to carbapenem-resistant Enterobacteriaceae
62409579|NCT02709408||Carbapenem-resistant A. baumannii|Patients with bloodstream infections due to carbapenem-resistant Acinetobacter baumannii
62409580|NCT02709408||Susceptible Enterobacteriaceae|Patients with complicated intrabdominal infections, pneumonia, complicated urinary tract infection and bloodstream infection due to carbapenem-susceptible Enterobacteriaceae matched to carbapenem-resistant ones by centre, type of ward, infection type, acquisition and previous duration of hospitalisation.
62213824|NCT03619304|ACTIVE_COMPARATOR|green coffee|oral squamous cell carcinoma cell line with application of green coffee
62213825|NCT03619304|ACTIVE_COMPARATOR|roasted coffee|oral squamous cell carcinoma cell line with application of roasted coffee
62213826|NCT03619304|ACTIVE_COMPARATOR|decaffeinated coffee|oral squamous cell carcinoma cell line with application of decaffeinated coffee
62213827|NCT02622776|OTHER|Vaginal DNA Collection|Patients with a diagnosis of ovarian cancer or endometrial cancer who have not yet had surgery, chemotherapy or radiation may be able eligible to participate. Patients unaffected by cancer may be able to participate.
62213828|NCT03025685|EXPERIMENTAL|TRUST technique + Coronary Stenting|PCI with coronary stenting using TransRadial Ultra Support technique for support improvement
62213829|NCT03025685|ACTIVE_COMPARATOR|Anchoring technique + Coronary Stenting|PCI with coronary stenting using Wire Anchoring Pass technique for support improvement
62734564|NCT01380678|ACTIVE_COMPARATOR|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
62791140|NCT05582772|ACTIVE_COMPARATOR|RSM Intervention|RSM Intervention All participants in the RSM intervention arm will receive once-weekly symptom monitoring via email-based surveys using the 9-item Edmonton Symptom Assessment Scale within a secure customized REDCap interface. If patients prefer, weekly telephone calls will be done instead by a research assistant to elicit If there are moderate or severe symptoms (score of 4+ out of 10), an oncology nurse will obtain more detailed symptom information and provide evidence-based symptom-targeted recommendations using the pan-Canadian Oncology Symptom Triage and Remote Support (COSTaRS) Practice Guide. Symptom monitoring will continue for 6 months or discontinuation of treatment.
62791141|NCT05582772|ACTIVE_COMPARATOR|GA+RSM intervention|GA+RSM Combination Participants will receive both strategies as detailed above, with a GA at baseline.
62020500|NCT03860194|NO_INTERVENTION|Diet group|"Each participant received nutritional counseling and recommended each of them to consume 1.5 g protein/kg body weight (BW)/day. Participants were encouraged to consume a balanced diet with six food groups follow Daily dietary guideline of 2013  as recommended by the Ministry of Health and Welfare of Taiwan. However, 1.2 g protein/kg body weight (BW)/day was suggested from this guideline.~Subjects in the Diet group were instructed to consume ordinary high protein foods to achieve 1.5 g protein/kg body weight (BW)/day on the basis of this guideline, and suggested to equally distribute their meal time."
62213830|NCT05769712||healthy people|"Inclusion criteria：① Age range (above 18 years old); ② Non-professional athletes; ③ No medical history of shoulder and neck pain; ④ Ultrasound examination (-).~Exclusion criteria: ① pregnant women or postpartum 1 year; ② Shoulder pain with active or passive cervical motion; ③ History of upper extremity trauma; (4) Shoulder surgery or treatment history, intra-articular injection history, use history of glucocorticoids, estrogens, quinolones and cholesterol drugs; (5) Shoulder joint fear test (shoulder joint abduction 90°, slowly increasing external rotation, the subject had a positive expression of fear); (6) Evidence of adhesive shoulder joint bursitis, such as the passive range of motion of the 2 motion planes of the shoulder joint is obviously limited; ⑦ Systemic autoimmune diseases, metabolic diseases, endocrine diseases, psoriasis; ⑧ unable to complete the relevant movements and positions; ⑨ Those who are reluctant to continue the experiment and ask to quit."
62213831|NCT05769712||diabetic|"Inclusion criteria：① Age range (above 18 years old); ② Non-professional athletes; (3) Patients who meet the clinical guidelines for diabetes diagnosis and treatment and are diagnosed with diabetes (ADA guidelines 2020: patients with typical diabetes symptoms and random blood glucose ≥11.1 mmol/L or fasting blood glucose ≥7.0 mmol/L or 2h blood glucose ≥11.1 mmol/L after glucose loading without typical diabetes symptoms); ④ Medical history ≥2 years.~Exclusion criteria: as above."
62213832|NCT03032432|EXPERIMENTAL|Dynamic elastic garment and injection|
62213833|NCT03032432|ACTIVE_COMPARATOR|Corticosteroid injection|
62213834|NCT02030002|EXPERIMENTAL|APC Flash-Free Adhesive Coated Appliance System|APC Flash-Free Adhesive Coated Appliance System
62213835|NCT02030002|ACTIVE_COMPARATOR|APC II Adhesive Coated Appliance System|APC II Adhesive Coated Appliance System
62213836|NCT03965351|EXPERIMENTAL|Probenecid|the study medication (probenecid) as well as a placebo.
62409581|NCT02709408||Admitted control patients|Patients without infection due to Enterobacteriaceae matched to carbapenem-resistant Enterobacteriaceae cases according to centre, ward and previous length of hospitalisation.
62409582|NCT06337344|EXPERIMENTAL|Baduanjin Qigong(BDJ)|
62409583|NCT06337344|ACTIVE_COMPARATOR|Aerobic exercise|
62409584|NCT06337344|SHAM_COMPARATOR|Video viewing|
62409585|NCT05552898|PLACEBO_COMPARATOR|Placebo Control 1|Sleep Product Form 1 - control
62409586|NCT05552898|EXPERIMENTAL|Active Product 1.1|Sleep Product Form 1 - active product 1
62409587|NCT05552898|EXPERIMENTAL|Active Product 1.2|Sleep Product Form 1 - active product 2
62409588|NCT05552898|EXPERIMENTAL|Active Product 1.3|Sleep Product Form 1 - active product 3
62409589|NCT05552898|EXPERIMENTAL|Active Product 1.4|Sleep Product Form 1 - active product 4
62584549|NCT04536012|EXPERIMENTAL|Intervention|"Participants have a 4-week ramp-up towards their step goal and are asked to maintain the goal for the rest of the study. They receive daily texts informing them if they met their step goal and biweekly texts to encourage walking for exercise.~Participants are entered into a game. Each week they receive 70 points. If the step goal was met they keep their points. If not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level. If not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and partner to discuss ways they can help the participant meet their goal. Every 8 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
62791142|NCT05582772|NO_INTERVENTION|Control|Control Usual care consists of brief verbal education and a drug pamphlet to all patients when starting an ARAT. There is no GA+M and no RSM at either site. Patients have access to a 24x7 oncology nursing line or a 24/7 pharmacy line.
62791143|NCT05137899|EXPERIMENTAL|Neoadjuvant Atezolizumab/Bevacizumab|• Arm 1: neoadjuvant atezolizumab 1200 mg IV q3weeks x 4 cycles, and bevacizumab 15 mg/kg IV q3weeks x 4 cycles
62791144|NCT05137899|EXPERIMENTAL|Neoadjuvant SBRT|• Arm 2: neoadjuvant stereotactic body radiation therapy (SBRT), target volume 30 40 Gy, in 6-8 Gy per day over five days, delivered every other day
62791145|NCT00650767|EXPERIMENTAL|ARRY-438162 (Schedule 1)|
62020501|NCT02288429||Colistin|"* Patients ≥ 18 years old receiving intravenous colistimethate sodium for the treatment of infection~* Have cystic fibrosis and/or are critically ill (admitted to a critical care unit)"
62213837|NCT03965351|PLACEBO_COMPARATOR|Placebo|placebo compared to probenecid
62213838|NCT02651857|EXPERIMENTAL|Endoscopy exploratory single arm|
62584550|NCT06389305|PLACEBO_COMPARATOR|peripheral blood lymphocytes|
62213839|NCT06097351||Type 2 diabetes group|The group was based on the clinically confirmed diagnosis of type 2 diabetes
62213840|NCT06097351||Diabetic nephropathy group|The group was based on the clinically confirmed diagnosis of type 2 diabetes.Patients were re-screened strictly according to the following admission criteria: persistent albuminuria and/or decreased eGFR, while other causes of chronic kidney disease (CKD) were excluded. When diabetes mellitus is identified as the cause of kidney damage and other primary and secondary glomerular diseases and systemic diseases are excluded, at least one of the following conditions can be diagnosed as DKD: (1) Urinary Albumin/Creatinine Ratio (UACR)≥30 mg/g or Urinary albumin excretion rate (UAER)≥30 mg/24 h, The UACR or UAER was checked again within 3 to 6 months, and 2 out of 3 times reached or exceeded the critical value; Eliminate other interfering factors such as infection; (2) eGFR\&lt; 60 ml·min-1· (1.73 m2) -1 for more than 3 months; (3) Renal biopsy was consistent with DKD pathological changes
62213841|NCT00409266|OTHER|Functional flexion axis of the knee|The functional flexion axis of the knee can be established by computer-assisted intra-operative data, through range of motion techniques, not specific landmarks such as epicondyles.
62409590|NCT05552898|EXPERIMENTAL|Active Product 1.5|Sleep Product Form 1 - active product 5
62584551|NCT06389305|EXPERIMENTAL|CIK cells|
62791146|NCT00650767|EXPERIMENTAL|ARRY-438162 (Schedule 2)|
62791147|NCT00650767|EXPERIMENTAL|ARRY-438162 (Schedule 3)|
62791148|NCT00650767|PLACEBO_COMPARATOR|Placebo|
62791149|NCT03016065|EXPERIMENTAL|Pea Fiber|Snacks fortified with 10 g of pea hull fiber will be administered for two weeks, followed by a two-week washout, and a two-week period with control snacks.
62791150|NCT03016065|PLACEBO_COMPARATOR|Control|Control snacks will provided for 2 weeks, followed by a two-week washout, and snacks with 10 g/d of pea fiber for 2 weeks.
62791151|NCT01650168||NOMAC-E2|New users of NOMAC-E2
62791152|NCT01650168||LNG-COCs|New users of levonorgestrel-containing COCs
62791153|NCT00498589|PLACEBO_COMPARATOR|1|Methotrexate IM or SC 25 mg/week vs placebo IM or SC for 24 weeks
62791154|NCT00498589|PLACEBO_COMPARATOR|2|1 IM or SC of placebo per week during 24 weeks
62213842|NCT01719419|EXPERIMENTAL|Placebo|Fatty food intake on the day the Modified sham feeding technique with placebo compared to the day modified sham feeding with orlistat.
62791155|NCT02797392|EXPERIMENTAL|Lifestyle intervention|All included citizens receive a questionnaire to estimate risk of disease and risk behavior. Information about lifestyle is collated with existing Electronic Patient Record (EPR) data and the citizen's risk of lifestyle-related disease is estimated based on validated algorithms for risk of type-2 diabetes, cardiovascular disease and COPD (Stratification). All citizens receive an electronic health profile and targeted advice. Citizens at increased risk of disease are offered a preventive program at the GP including an initial health examination and subsequent lifestyle counselling. Citizens with risk behavior are offered lifestyle counselling in the municipality and community health services, if necessary. Citizens diagnosed with a lifestyle related disease are already being treated by the GP, and therefore, like citizens with a healthy lifestyle, they are not offered any further services.
62213843|NCT01719419|EXPERIMENTAL|Orlistat|Fatty food intake on the day of the modified sham feeding technique with orlistat compared to the day with placebo.
62584552|NCT03502070|OTHER|Open-Label Placebo|One dose (4 capsules) of placebo
62213844|NCT01076153||Patients with respiratory tract infection|Thai patients with upper or lower respiratory tract infections on Klacid MR.
62213845|NCT04542889|EXPERIMENTAL|Absolute coronary resistances and IMR after angioplasty|Patients with STEMI by acute occlusion of a large caliber coronary artery that had been admitted to hospital less than 12 hours and revascularized by primary angioplasty with good final result.
62791156|NCT04299035|EXPERIMENTAL|Thoracic surgery + ESPblock|Thoracic surgery + ESPblock + standard pain management
62213846|NCT04666623|ACTIVE_COMPARATOR|intranasal esketamine (56mg)|
62213847|NCT04666623|PLACEBO_COMPARATOR|placebo|
62409591|NCT02988310||Individuals with below knee limb loss|Individuals with below knee limb loss will be participants of the group.
62409592|NCT02988310||Individuals with above knee limb loss|Individuals with above knee limb loss will be participants of the group.
62791157|NCT04299035|EXPERIMENTAL|Abdominal surgery + ESPblock|Abdominal surgery + ESPblock + standard pain management
62791158|NCT04299035|EXPERIMENTAL|Spinal surgery + ESPblock|Spinal surgery + ESPblock + standard pain management
62791159|NCT04299035|NO_INTERVENTION|Thoracic surgery|Thoracic surgery + standard pain management
62791160|NCT04299035|NO_INTERVENTION|Abdominal surgery|Abdominal surgery + standard pain management
62791161|NCT04299035|NO_INTERVENTION|Spinal surgery|Spinal surgery + standard pain management
62213848|NCT02816177|EXPERIMENTAL|Telemedicine|Usual care and telemedicine consultations during12 months.
62213849|NCT02816177|ACTIVE_COMPARATOR|Usual care alone|Usual care during12 months.
62213850|NCT00580242|EXPERIMENTAL|1|This is a Phase I dose escalation trial with three cohorts of 3-6 patients each plus 10 additional patients (up to a maximum total of 28 patients) treated at the candidate maximum tolerated dose.Cohorts will receive increasing doses of bortezomib at 0.7, 1, and 1.3 mg/m2 on days 1, 4, 8, and 11 in combination with lenalidomide at 10 mg a day for Days 1-21. Each cycle will be 28 days. Patients will receive up to 9 cycles of treatment, with efficacy assessed after 3, 6, and 9 cycles.
62213851|NCT03924765|EXPERIMENTAL|Individuals post-stroke using a powered hip exoskeleton|This study will be conducted on a sample population of stroke subjects (single arm). Each subject will test with each condition of the exoskeleton (repeated measures).
62213852|NCT05568238|OTHER|Vacuum Assisted Wound Closure and Permanent On-lay Mesh-mediated fascial traction|Incisional hernia incidence for patients treated with Vacuum Assisted Wound Closure and Permanent On-lay Mesh mediated fascial traction
62213853|NCT00609375|EXPERIMENTAL|I|Administration of cefepime in continuous infusion (3 Gr over 24 hours) for at least 7 days and no more than 14 days days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
62213854|NCT00609375|ACTIVE_COMPARATOR|II|Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for at least 7 days and no more than 14 days days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
62213855|NCT01066429|NO_INTERVENTION|Poor prognosis DLBCL|Newly diagnosed patients with DLBCL and an age-adjusted IPI 2-3
62213856|NCT04203095||patient with PD1 antibody treatment|"Investigators will detect cfDNA CIN of lung cancer patients 1day (Day 0) before treatment with PD1 antibody, then Day 22 and Day 64 after treatment with PD1 antibody, as well as at the time of disease progression confirmed.~The correlation of CIN and drug resistance to PD1 antibody was analyzed."
62213857|NCT01378780|ACTIVE_COMPARATOR|Intervention for diet, exercise|This group will receive the educational intervention for healthy diet and increased physical activity
62213858|NCT01378780|OTHER|Control|This group will get a skin cancer awareness educational message. At the end of the study this group will also receive the diet and exercise intervention but outcomes will not be measured after the crossover.
62213859|NCT02247973|EXPERIMENTAL|Mesenchymal stem cells|Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with severe aplastic anemia.
62409593|NCT02988310||Healthy individuals|Healthy individuals will be participants of the group.
62584553|NCT03606928|EXPERIMENTAL|modified FLOT|modified FLOT Docetaxel 40mg/m2 ivgtt day 1 over 1 hour Oxaliplatin 65mg/m2 ivgtt day 1 over 2hours Dose escalation will be performed. Leucovorin 200mg/m2 ivgtt day 1 over 2 hours 5-FU 2200mg/m2 civ over 24 hours
62584554|NCT03522714|ACTIVE_COMPARATOR|Fluid Immersion Simulation System (FIS)|Pressure ulcer patients are assigned to Fluid Immersion Simulation System (Dolphin) after operative debridement and closure.
62584555|NCT03522714|ACTIVE_COMPARATOR|Air Fluidized Bed System (AFB)|Pressure ulcer patients are assigned to Air Fluidized Bed (Clinitron) after operative debridement and closure
62791162|NCT02313584|ACTIVE_COMPARATOR|Short Group|The patients taking dabigatran for 1 month after the radiofrequent catheter ablation for paroxysmal atrial fibrillation.
62791163|NCT02313584|PLACEBO_COMPARATOR|Conventional Group|The patients taking dabigatran for 2 months after the radiofrequent catheter ablation for paroxysmal atrial fibrillation.
62791164|NCT03813459||Subsyndromal delirium positive|Presence of Subsyndromal delirium in Intensive Care patients
62791165|NCT03813459||Delirium positive|Presence of Delirium in Intensive Care patients
62791166|NCT03813459||No delirium|Non subsyndromal delirium or delirium in Intensive Care patients
62213860|NCT04136743|ACTIVE_COMPARATOR|Corticosteroid|Participants will receive a corticosteroid injection (BMS, Kenacort-A 40 mg \[triamcinolone acetonide\]) into the subacromial space under direct ultrasound guidance by means of a 5-mL syringe with a 22-guage needle.
62409594|NCT04992780|EXPERIMENTAL|Hypo-Fractionation|Participants will receive one fraction of radiation therapy a day for 5 days each week for 5 weeks along with weekly chemotherapy with Paclitaxel 45 milligram per meter squared (mg/m2) through intravenous (IV)infusion for 1 hour followed by Carboplatin area under the curve (AUC) 2 IV for 30 minutes for approximately 5 or 6 weeks. Once complete, participant will receive Durvalumab, 1500 mg, IV every 4 weeks for 12 months.
62213861|NCT04136743|EXPERIMENTAL|Micro-Fragmented Adipose Tissue|Participants will receive a single injection of micro-fragmented adipose tissue into the lesion (e.g. tear, subacromial bursa, glenohumeral joint, acromioclavicular joint) under ultrasound guidance using an 18 gauge x 3.5 inch needle.
62791167|NCT00269867|PLACEBO_COMPARATOR|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
62791168|NCT00269867|EXPERIMENTAL|Infliximab 3 mg/kg every 8 weeks|Infliximab 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
62213862|NCT01144481||breast cancer with metastasis|female breast cancer patients with metastases to any site
62409595|NCT04992780|ACTIVE_COMPARATOR|Standard-Fractionation|Participants will receive one fraction of radiation therapy a day for 5 days each week for 6 weeks along with weekly chemotherapy with Paclitaxel 45 milligram per meter squared (mg/m2) through intravenous (IV)infusion for 1 hour followed by Carboplatin AUC 2 IV for 30 minutes for approximately 5 or 6 weeks. Once complete, participant will receive Durvalumab, 1500 mg, IV every 4 weeks for 12 months.
62409596|NCT03239340|EXPERIMENTAL|Osimertinib|An oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer
62213863|NCT01579331|EXPERIMENTAL|Dynamic Contour Tonometry|All recruited volunteers in present study, that underwent diurnal GAT tonometry (3 measures) and 5 DCT measurements.
62213864|NCT02570087|ACTIVE_COMPARATOR|Successful CTO PCI|Successful chronic total coronary occlusion percutaneous intervention (CTO-PCI)
62734565|NCT02673099|OTHER|HDF online|All patients were started on HF (high-flux) hemodialysis. After 6 months they were then treated by HDF online.
62734566|NCT01181804|EXPERIMENTAL|Boceprevir Tablets then Capsules (fed)|Participants will start therapy with a single dose of boceprevir tablets, orally, in fed condition, and then 4 days later will take a single dose of boceprevir capsules, orally, in fed condition.
62791169|NCT00269867|EXPERIMENTAL|Infliximab 3 mg/kg every 4 weeks|Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.
62791170|NCT00269867|EXPERIMENTAL|Infliximab 10 mg/kg every 8 weeks|Infliximab 10 mg/kg will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
62791171|NCT00269867|EXPERIMENTAL|Infliximab 10 mg/kg every 4 weeks|Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.
62213865|NCT02570087|NO_INTERVENTION|Unsuccessful CTO PCI|Unsuccessful chronic total coronary occlusion percutaneous intervention (CTO-PCI)
62791172|NCT00391027|ACTIVE_COMPARATOR|Insulin Glargine (Lantus®)|
62409597|NCT05476809|EXPERIMENTAL|smart-cloth|The upgraded smart-cloth assisted home nursing integrate smart-cloth monitoring system, home nursing, and family caregiver feedback app. The persons living with dementia will be asked to wear a smart cloth 24 hours a day and will be monitored on abnormal activity level, going out alone, abnormal number of getting-up at night, fall risks. In addition, monitoring for medication, abnormal life pattern, quality of hired help will also be included. The warning signals, along with weekly summary and related information will be sent to the family caregiver interactive App after the assessment of the home care nurses to provide guidance for family care.
62409598|NCT05476809|NO_INTERVENTION|usual care|Routine clinical care will be provided to the participants.
62409599|NCT02284880|EXPERIMENTAL|Group 1 BIA 2-093|Subjects randomly received on period 1 and 2, either a single 400 mg tablet of ESL (MF - marketed formulation), or a single 400 mg tablet of ESL (TBM - o-be-marketed);
62213866|NCT02413853|EXPERIMENTAL|Arm I (PRI-724, mFOLFOX6/bevacizumab)|Patients receive CBP/beta-catenin antagonist PRI-724 IV continuously on days 1-7, bevacizumab IV over 30 minutes, leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV over 46 hours on day 8. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62409600|NCT02284880|EXPERIMENTAL|Group 2 BIA 2-093|Subjects randomly received on period 1 and 2, either a single 800 mg tablet of ESL (MF - marketed formulation), or a single 800 mg dose of ESL (TBM - o-be-marketed).
62409601|NCT03508466||Group 1|adult participants from 18-65 years of age previous hypersensitivity reaction grades I-IV to intravenous ferric carboxymaltose (Ferinject)
62409602|NCT03508466||Group 2|adult participants from 18-65 years of age previous intravenous ferric carboxymaltose (Ferinject) and no hypersensitivity reaction
62409603|NCT03508466||Group 3|adult participants from 18-65 years of age previous hypersensitivity reaction grades I-IV to iron sucrose (Venofer)
62409604|NCT03508466||Group 4|adult participants from 18-65 years of age previous intravenous iron sucrose (Venofer) and no hypersensitivity reaction
62409605|NCT06537921|EXPERIMENTAL|Comorbid depression and obesity|Participants with comorbid major depressive disorder (MDD) and obesity (BMI≥30 kg/m2) and c-reactive protein (CRP) levels ≥3mg/L at screening.
62409606|NCT02150889|NO_INTERVENTION|Lean Trained|Metabolic control
62409607|NCT02150889|EXPERIMENTAL|Obese or Overweight|Running Program Yoga Program
62409608|NCT01790139|NO_INTERVENTION|Control|Control group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte and fecal/fluid tagging. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte.
62409609|NCT01790139|EXPERIMENTAL|Intervention-Oral Simethicone|Intervention group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte, fecal/fluid tagging, and oral administration of simethicone. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte. As the interventional procedure in this intervention group, 10 mL of simethicone is administered orally immediately following the administration of iohexol.
62409610|NCT05288621|EXPERIMENTAL|electroacupuncture at'four sacral points'|The participants in the electroacupuncture at'four sacral points'group will receive treatment that consists of 8 acupuncture sessions over an 4-week period after baseline (2 sessions in each week), each for 30 minutes. Hua Tuo brand disposable acupunctureneedles (size 0.40 × 100mm) and electronic needle therapy instrument SDZ-IIB will be used.The device will be set at a frequency of 2.0 Hz, continuous wave and a moderate intensity the patient can tolerate. Electrostimulation will be performed for 30 min during each treatment. BL30 (Baihuanshu )(both sides and BL35 (Huiyang )(both sides), were selected as acupoints protocol.BL30 is located on either side of the sacrococcygeal joint, approximately 1 cm from the joint. BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
62734567|NCT01181804|EXPERIMENTAL|Boceprevir Capsules then tablets (fed)|Participants will start therapy with a single dose of boceprevir capsules, orally, in fed condition, and then 4 days later will take a single dose of boceprevir tablets, orally, in fed condition.
62213867|NCT02413853|EXPERIMENTAL|Arm II (mFOLFOX6/bevacizumab)|Patients receive bevacizumab, leucovorin calcium, oxaliplatin, and fluorouracil as in Arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62213868|NCT05999643|EXPERIMENTAL|Inject 68Ga-FAPI and then perform PET/CT scan.|Inject 68Ga-FAPI and then perform PET/CT scan
62213869|NCT06326593|EXPERIMENTAL|Group (A): Wii aerobic training|This group included 38 children with inhalation injury post thermal burn; they will receive Wii aerobic training and conservative chest care.
62213870|NCT06326593|SHAM_COMPARATOR|Group (B): control group|This group included 38 children with inhalation post thermal burn; they will receive conservative chest care.
62213871|NCT01239043|EXPERIMENTAL|Menomune® vaccine group|Participants received Menomune® vaccine in MTA29 (NCT00874549)
62213872|NCT01239043|EXPERIMENTAL|Menactra® vaccine group|Participants received Menactra® vaccine in trial MTA29 (NCT00874549)
62213873|NCT03870217||Cochlear implant users with Nucleus and AB devices|Speech recognition will be evaluated after poor electrodes are turned off.
62213874|NCT03527238|ACTIVE_COMPARATOR|Standard of Care|Standard of Care Tacrolimus Drug Dosing
62213875|NCT03527238|EXPERIMENTAL|Phenotypic Precision Medicine (PPM)|PPM-based Computation Assisted Drug Dosing
62213876|NCT03699553|EXPERIMENTAL|Intervention|Participants will receive the online LARKSPUR intervention which lasts about 5-6 weeks, receiving the positive emotions skills through the website, and logging on to the website for about 5-10 minutes each day for that period. Assessments will be taken at baseline, post-intervention (8 weeks after the baseline), and 12 weeks after baseline (1 month post intervention).
62213877|NCT03699553|ACTIVE_COMPARATOR|Emotion Reporting Control|Participants will report their emotions for 5-6 weeks by logging on to the website for about 5 minutes each day. Assessments will be taken at baseline, 8 weeks after baseline, and 12 weeks after baseline. After 12 weeks, participants will receive access to the LARKSPUR intervention online.
62213878|NCT06415539|ACTIVE_COMPARATOR|control|Classic physical therapy program will be applied
62213879|NCT06415539|EXPERIMENTAL|exercise|In addition to the classical physical therapy program, a treatment program including vestibular and proprioceptive exercise training will be applied.
62409611|NCT05288621|ACTIVE_COMPARATOR|conventional electroacupuncture|The participants in the conventional electroacupuncture group will select RN3 (Zhongji), CV4 (Guanyuan), and ST28 (Shuidao, both sides), KL3 (Taixi).A needle measuring 0.25×40 mm will be inserted perpendicularly to a depth of 25- 40 mm to RN3, CV4 and ST28 and 0.5 cun to KL3 to induce a local sensation (distention or sourness).Subsequently, the electrodes from the SDZ-IIB electroacupuncture device will be connected to the needles at these points, with the anode connected to ST28 and RN3, the cathode connected to ST28 and CV4. The protocol includes the same duration, frequency of sessions and the parameter setting of electroacupuncture as for the'four sacral points'treatment.
62584556|NCT05942417|EXPERIMENTAL|Neuromodulation Percutaneous echoguided plus exercise|The experimental group will receive a EPNM in the common peroneal nerve of the affected ankle. . Three interventions will be carried out, in a dosage of 1 per week. Moreover, a 3-week of strength exercises will be carried out with two sessions per week. The strength program includes a protocol for the use of Theraband ® according to that described by Kaminsky et al. Moreover, the participants will have to do a balance exercises program.The EPNM will be applied prior to the exercise program session
62584557|NCT05942417|ACTIVE_COMPARATOR|Strength program|"The strength program includes a Theraband® use protocol as described by Kaminsky et al.~The balance exercise program will consist of performing a series of closed kinetic chain exercises in a weight-bearing standing position that will progress from bilateral to unilateral depending on the acceptance of the load."
62213880|NCT05716048|EXPERIMENTAL|KF-mSMT Plus Aerobic Exercise Training|Participants will undergo 12 weeks of supervised aerobic cycling exercise training. During the last 8 weeks of cycling exercise, participants will also undergo treatment with the Kessler Foundation modified Story Memory Technique as an approach for cognitive rehabilitation.
62213881|NCT05716048|ACTIVE_COMPARATOR|KF-mSMT Plus Stretching Exercise Training|Participants will undergo 12 weeks of supervised stretching and toning exercise training. During the last 8 weeks of stretching exercise, participants will also undergo treatment with the Kessler Foundation modified Story Memory Technique as an approach for cognitive rehabilitation.
62584558|NCT02585128|OTHER|Patients following TAVI|
62584559|NCT05838443|ACTIVE_COMPARATOR|Self-directed mindfulness|
62584560|NCT05838443|ACTIVE_COMPARATOR|Provider-directed mindfulness|
62584561|NCT05838443|OTHER|Conventional care|Control Comparator
62584562|NCT02587507|PLACEBO_COMPARATOR|Water|The subjects will ingest the HFHC meal with 500mL of water.
62584563|NCT02587507|EXPERIMENTAL|Orange juice|The subjects will ingest the HFHC meal with 500mL of orange juice.
62213882|NCT05244564|EXPERIMENTAL|3MDR delivered via Augmented Reality Head Mounted Display|All participants will complete 10-14 treatment sessions (three preparatory sessions, 6 to 10 3MDR therapy sessions, and one concluding session), led by a therapist who has completed training and/or is experienced in the conduct of this form of therapy.
62584564|NCT02587507|ACTIVE_COMPARATOR|Water with glucose|The subjects will ingest the HFHC meal with 500mL of water with glucose (isocaloric control of the orange juice).
62020502|NCT06397794||Gestational parents with Lyme disease|"Participants in this study will be enrolled following a screening call to assess their eligibility. All participants must report that they were diagnosed with acute Lyme disease, PTLDS, and/or Chronic Lyme by a health care provider while they were pregnant OR PTLDS/CL prior to becoming pregnant with ongoing symptoms during pregnancy.~After being consented for the study, participants will then complete a set of online questionnaires and participate in a qualitative interview with a member of the research team."
62409612|NCT04792073|EXPERIMENTAL|Avelumab and Radiation Therapy|Will receive avelumab at the FDA approved dose and schedule of 800 mg IV over 60 minutes (+20 minutes / -10 minutes) every 2 weeks (+/- 3 days) until treatment intolerance or disease progression occurs or 2 years of study therapy have been administered; standard of care Avelumab therapy after 2 years is permitted. Comprehensive Ablative Radiation Therapy (CART) will be initiated between the first and second dose of Avelumab. Comprehensive ablative radiation therapy will be given according to guidelines.
62409613|NCT00991146|EXPERIMENTAL|canakinumab|
62020503|NCT01871298|OTHER|Website access|While this pilot intervention is not a randomized trial, study participants who report internet use at least once a month will told of a Pilot Website Evaluation Component that they will be able to access for a 4-week study period. This website will contain a educational information tailored to the health needs of drug users. Web content will be similar to materials and public health messages released by the NYC Department of Health and therefore, harm is not likely to arise from viewing such content.
62213883|NCT05244564|ACTIVE_COMPARATOR|3MDR delivered via 34-inch curved screen high definition gaming computer monitor|All participants will complete 10-14 treatment sessions (three preparatory sessions, 6 to 10 3MDR therapy sessions, and one concluding session), led by a therapist who has completed training and/or is experienced in the conduct of this form of therapy.
62213884|NCT05530694|NO_INTERVENTION|Control|Usual care
62213885|NCT05530694|EXPERIMENTAL|Intervention|Intervention phase
62213886|NCT02549014|EXPERIMENTAL|Panel A: MK-1064 5 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 5 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
62213887|NCT02549014|EXPERIMENTAL|Panel B: MK-1064 10 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 10 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
62213888|NCT02549014|EXPERIMENTAL|Panel A: MK-1064 25 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 25 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
62213889|NCT02549014|EXPERIMENTAL|Panel B: MK-1064 50 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 50 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
62213890|NCT02549014|EXPERIMENTAL|Panel A: MK-1064 100 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 100 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
62213891|NCT02549014|EXPERIMENTAL|Panel B: MK-1064 150 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 150 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
62409614|NCT03890159|EXPERIMENTAL|Computer Assisted Cognitive Rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours, and patients will progress to the difficulty level automatically. Their performance during this process (response time etc.) will be recorded.
62020504|NCT01871298|NO_INTERVENTION|No website access|Participants who report internet use less than once a month will not receive access to the Pilot Website Evaluation Component.
62409615|NCT03890159|EXPERIMENTAL|Conventional Cognitive Rehabilitation|The home (paper pen) exercise group will take the necessary exercises on paper suitable for their respective levels and the daily tasks suitable for their functional needs and interests.
62409616|NCT03890159|NO_INTERVENTION|Waiting list controls|These patients will get no intervention as means of cognitive rehabilitation, but will get their usual treatments.
62213892|NCT02549014|EXPERIMENTAL|Panel A: MK-1064 200 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 200 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
62213893|NCT02549014|EXPERIMENTAL|Panel B: MK-1064 250 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 250 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
62409617|NCT00586677|ACTIVE_COMPARATOR|RF|Relationship focused where the primary goals are to strengthen the relationship between the parent and the child and to give the parent additional skills that can be used to manage the behavior of the child.
62409618|NCT00586677|ACTIVE_COMPARATOR|HS|The physical health and safety are the primary components of this parenting program where the parent is taught about basic healthcare and safety in the home.
62584565|NCT05514405|EXPERIMENTAL|Remimazolam group|Remimazolam is started during induction of anesthesia at the rate of 6 mg/kg/hr and continued at the rate of 1 mg/kg/hr (within 0.3-2 mg/kg/hr). Remimazolam is stopped 20 minutes before end of operation.
62584566|NCT05514405|ACTIVE_COMPARATOR|Propofol group|Propofol is continuously infused within 1-5 μg/mL.
62584567|NCT04387019||I|30 with uncontrolled type 2 DM patients
62213894|NCT02549014|EXPERIMENTAL|Panel A: MK-1064 25 mg (Fed)|In Period 5, participants received a single MK-1064 dose of 25 mg administered in the evening following a standard high-fat breakfast.
62584568|NCT04387019||II|30 controlled type 2 DM patients
62584569|NCT04387019||III|30 healthy subjects as a control group
62213895|NCT02549014|EXPERIMENTAL|Panel B: MK-1064 50 mg (Night)|In Period 5, participants received a single MK-1064 dose of 50 mg administered in the evening after a 4-hour fast.
62584570|NCT05283902||Effectiveness group|There are an estimated 490,000 eligible individuals aged 60 and over statewide for the effectiveness study.
62213896|NCT02549014|PLACEBO_COMPARATOR|Panels A & B: Placebo|Within each of up to 5 treatment periods, 2 participants were randomly assigned to receive single oral doses of matching placebo in a fasted stated. There was to be a minimum 7-day washout between treatment periods for any given participant.
62213897|NCT01985451|EXPERIMENTAL|Pemetrexed and Temozolomide|Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m2) and temozolomide (200mg/m² day 1-5, 28 day cycle).
62213898|NCT03537547|EXPERIMENTAL|GeneSight Psychotropic test|Participants randomized to have their study clinician have access to their pharmacogenetic report (provided through the GeneSight Psychotropic tool) in order to make treatment decisions for the first 12 weeks. At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will continue to be able to use the results to guide treatment options for an additional 12 weeks.
62213899|NCT03537547|ACTIVE_COMPARATOR|Treatment As Usual|Participants randomized to treatment as usual will receive treatment from study clinicians who do not have access to the participant's report for the first 12 weeks. At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will be unblinded to be able to use the results to guide treatment options for an additional 12 weeks.
62409619|NCT05355506||The Development and Effectiveness of Heart Failure Self-Health Management Application|"Heart Failure can cause physical disability and death. According to the Ministry of Health and Welfare, there were 20,644 deaths from heart disease, ranking second among the top 10 causes of death \[1\]. The World Health Organization (WHO) has advocated nursing guidance with the concept of empowerment, where patients can play an active and aggressive role in managing their health \[2\]. This paperless nursing health education guidance information can be designed through the application, which features non-professional expressions and visualization methods. The users can participate in feedback-based interactions and complete the questionnaires after receiving nursing guidance. This study used the Technology Acceptance Model (TAM) to evaluate patients' acceptance of the nursing guidance application and the effectiveness of such nursing guidance."
62409620|NCT03330275|EXPERIMENTAL|Test/Control 1/Control 2|Subjects will be randomized to 1 of 3 lenses (Test/Control 1/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
62409621|NCT03330275|EXPERIMENTAL|Test/Control 2/Control 1|Subjects will be randomized to 1 of 3 lenses (Test/Control 2/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
62409622|NCT03330275|EXPERIMENTAL|Control 1/Test/Control 2|Subjects will be randomized to 1 of 3 lenses (Control 1/Test/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
62213900|NCT06610214|NO_INTERVENTION|Control group|No intervention
62213901|NCT06610214|EXPERIMENTAL|Intervention group|IMPACT-care intervention
62213902|NCT06034418|ACTIVE_COMPARATOR|Pulse Radiofrequency Group|Pulse radiofrequency therapy will be applied to each nerve in 2 cycles of 120 seconds for patients in the pulse radiofrequency group. After the pulse radiofrequency procedure, 1 cc betamethasone and 1 cc 1% lidocaine will be injected for each nerve.
62213903|NCT06034418|ACTIVE_COMPARATOR|Block Group|For the patients in the block group, nerve block will be performed by applying 1 cc betamethasone and 1 cc 1% lidocaine for each nerve.
62213904|NCT05267431||RA patients recieved biological therapy|RA patients recieved different biological therapy
62213905|NCT05267431||RA patients recieved different DMARDS|RA patients recieved different DMARDS
62213906|NCT01244178|EXPERIMENTAL|Tight Glucose Control Hyperinsulinemic Group|
62213907|NCT01244178|EXPERIMENTAL|Non-Tight Glucose Control Hyperinsulinemic Group|
62213908|NCT01244178|ACTIVE_COMPARATOR|Standard Insulin Protocol Group|
62213909|NCT03368729|EXPERIMENTAL|Phase 1: Niraparib 200 mg + Trastuzumab 6 mg/kg|In phase 1 patients in this first arm will receive 200 mg Niraparib in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.
62213910|NCT03368729|EXPERIMENTAL|Phase 1: Niraparib 100 mg + Trastuzumab 6 mg/kg|In phase 1 patients in this second arm will receive Niraparib 100 mg in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.
62213911|NCT03368729|EXPERIMENTAL|Phase 2: Niraparib 200 mg or 100 mg + Trastuzumab 6 mg/kg|The dosage of Niraparib in phase 2 will be determined by the response of patients in Phase 1. A dosage of Niraparib 200 mg will be given along with Trastuzumab 6 mg/kg IV unless a dose limiting toxicity occurs in Phase 1. If so, Niraparib 100 mg will be given with Trastuzumab 6 mg/kg (instead of Niraparib 200 mg).
62213912|NCT03262142|ACTIVE_COMPARATOR|Standard antibiotic treatment|Intravenous Piperacillin/tazobactam + oral Ciprofloxacin for 14 days
62213913|NCT03262142|NO_INTERVENTION|Antibiotic-free treatment|No antibiotic treatment
62020505|NCT05025293|EXPERIMENTAL|ZOLearly|"Within 3 days after hip fracture surgery: A single dose of 100 ml containing 5mg zoledronate (Aclasta) will be administered intravenously.~The ZOLearly group will have no further infusions during the study period."
62020506|NCT05025293|PLACEBO_COMPARATOR|ZOLlate|"Within 3 days after hip fracture surgery: A single dose of 100 ml containing 100ml NaCl 9mg/ml (placebo) will be administered intravenously.~3 months after hip fracture surgery (at the out-patient clinic): A single dose of 100 ml containing 5mg zoledronate (Aclasta) will administered intravenously."
62213914|NCT05259072|OTHER|Patients with transthyretin amyloid cardiomyopathy enrolled in CARDIO-TTRansform|Patients will undergo serial Tc-99m PYP imaging at baseline, week 61 and end of trial
62584571|NCT05283902||Elderly group - Immunogenicity|240 participants from the Effectiveness group, with quotas distributed by sex (50% male and 50% female) and age group, will be invited to participate in biological sample collection for the immunogenicity study.
62213915|NCT06041048|ACTIVE_COMPARATOR|Modafinil|Single oral dose (200 mg) of medication versus placebo given to healthy control subjects
62020507|NCT01713595|EXPERIMENTAL|Hypertonic Saline Aerosol|a single 5ml dose of 7% Saline aerosol
62213916|NCT06041048|PLACEBO_COMPARATOR|Placebo|Oral placebo
62213917|NCT01802905|EXPERIMENTAL|Sequenced patients|Patients enrolled on the study who have successful sequencing of their cancers will be closely monitored for: what chemotherapy agents are next used, what response and toxicity do they have, is there any early sign of response detected on PET-CT, overall did the genomic information change treatment decision-making.
62213918|NCT06606301||Different Grades of squamous cell carcinoma|Diagnostic test: Biopsy specimens Fresh sections from formalin fixed and paraffin embedded block with sections from the tumor will be prepared followed by Hematoxylin and Eosin staining according to the standard protocol.
62584572|NCT05283902||Immunosupressed group|240 biorepository samples from a cohort of immunosuppressed patients with autoimmune diseases who received the fourth dose, in a study conducted by the same team of researchers.
62213919|NCT02393300|PLACEBO_COMPARATOR|Group1|60 Milliliters（ml）Normal saline (0.9% sodium chloride) will be applied by soaking the knee cavity for at least 3 minutes before wound closure and then sucked away.
62584573|NCT02782949|EXPERIMENTAL|Arm I (curcumin)|Patients receive curcumin PO BID for 180 days in the absence of unacceptable toxicity.
62584574|NCT02782949|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID for 180 days in the absence of unacceptable toxicity.
62584575|NCT05367973|EXPERIMENTAL|IVR: Estradiol 80 ug/day + progesterone 4mg/day|12-week IVR 80/4
62584576|NCT05367973|EXPERIMENTAL|IVR Estradiol 160 ug/day + progesterone 8 mg/day|12-week IVR 160/8
62584577|NCT01273129||Patients|Patients 8 years and older whose seizures are uncontrollable with medication may participate in this study as well as patients with tumor related epilepsy in whom invasive monitoring is indicated.
62584578|NCT03374917|EXPERIMENTAL|ABBV-951|ABBV-951 administered by continuous subcutaneous infusion (CSCI) for 4 weeks.
62584579|NCT04723628|EXPERIMENTAL|Experimental group|Then, each patient was given 45-60 minutes of individual instruction. The patient training content was prepared based on the Knowledge, Motivation and Behavioral Skills Model (IMB). A total of 12 weeks of follow-up was performed with a weekly short reminder message and a two-weekly phone call. The research data were collected again at the end of 12 weeks.
62791173|NCT00391027|ACTIVE_COMPARATOR|Inhaled Human Insulin (Exubera®)|
62791174|NCT04108195|EXPERIMENTAL|Part 1: Dose Escalation|Participants will be assigned to either a combination of 1) daratumumab plus teclistamab or 2) daratumumab plus talquetamab or 3) daratumumab plus talquetamab plus pomalidomide or 4) daratumumab plus teclistamab plus pomalidomide.
62791175|NCT04108195|EXPERIMENTAL|Part 2: Dose Expansion|Participants will be treated with the RP2D(s) for selected treatment combinations determined in Part 1.
62791176|NCT01763606|EXPERIMENTAL|Enoxaparin|Patients assigned to enoxaparin.
62791177|NCT01763606|EXPERIMENTAL|Aspirin|Patients assigned to Aspirin.
62020508|NCT05058911|EXPERIMENTAL|Internet-delivered exposure-based cognitive behavior therapy (Exp-CBT)|10-week self-help treatment delivered via a secure online platform, with regular therapist support.
62020509|NCT05058911|ACTIVE_COMPARATOR|Internet-delivered traditional cognitive behavior therapy (T-CBT)|10-week self-help treatment delivered via a secure online platform, with regular therapist support.
62213920|NCT02393300|EXPERIMENTAL|Group2|two-dose intravenous tranexamic acid will be applied as follow: 10mg/kg of Tranexamic Acid in 100 Milliliters（ml) normal saline (0.9% sodium chloride),the first dose 15' before the tourniquet deflation and the second dose at 180' after the first dosage
62213921|NCT02393300|EXPERIMENTAL|Group 3|3g Tranexamic Acid diluted to 60 Milliliters（ml） with normal saline (0.9% sodium chloride) will be applied by soaking the knee cavity for at least 3 minutes before wound closure and then sucked away.
62213922|NCT01034605|EXPERIMENTAL|inulin|oligofructose
62409623|NCT03330275|EXPERIMENTAL|Control 1/Control 2/Test|Subjects will be randomized to 1 of 3 lenses (Control 1/Control 2/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
62791178|NCT04923568|EXPERIMENTAL|EaseVRx sessions|This is a study of patients with chronic pain to identify interest in participating in a large VR trial and, for those willing to join us to test the device in person, to pilot 2 sessions of VR to assess usability and collect preliminary data on pain and mood and to obtain data on patient satisfaction with device use. The entire session will last 45 minutes to 1 hour. All patients recruited will be in the active arm; this is not a randomized pilot study.
62584580|NCT04723628|NO_INTERVENTION|Control group|All data forms were then completed, and the HbA1c value was taken from the medical data. No additional procedure was performed to the control group. The research data were collected again at the end of 12 weeks.
62791179|NCT03814408|EXPERIMENTAL|RP-L102|RP-L102 is a self-inactivating lentiviral vector carrying the therapeutic FANCA gene
62791180|NCT01848327|EXPERIMENTAL|Caprylic Triglyceride|Caprylic Triglyceride (40 gram packet orally once a day for 90 days)
62213923|NCT01572103|EXPERIMENTAL|Administration of coffee|Administration of 4 cups of coffee/day for 1 month
62409624|NCT03330275|EXPERIMENTAL|Control 2/Test/Control 1|Subjects will be randomized to 1 of 3 lenses (Control 2/Test/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
62584581|NCT05126030|EXPERIMENTAL|Primary Cohort|Device: Topaz TTVR system
62791181|NCT01848327|PLACEBO_COMPARATOR|Placebo|Placebo (40 gram packet orally once a day for 90 days)
62791182|NCT02661243|OTHER|Dentate Sjogren's syndrome arm|30 human adults affected by SS with the need of replacement of missing premolars or molars in the upper or lower jaw. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
62213924|NCT01572103|NO_INTERVENTION|Coffee abstinence|Total coffee and caffeine containing beverages abstinence
62584582|NCT03207919|EXPERIMENTAL|Lullaby Project|
62584583|NCT03207919|NO_INTERVENTION|Control Group|
62584584|NCT02626130|EXPERIMENTAL|Arm A (tremelimumab)|Patients receive tremelimumab IV over 60 minutes at weeks 1 and 5. Within 4-6 weeks later, patients undergo surgery or biopsy. After surgery or biopsy, patients receive tremelimumab IV Q4W for 3 doses, and then every Q12W in the absence of disease progression or unacceptable toxicity.
62791183|NCT02661243|OTHER|Dentate healthy controls arm|30 healthy human adults with the need of replacement of missing premolars or molars in the upper or lower jaw. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
62791184|NCT02661243|OTHER|Edentulous Sjogren's syndrome arm|30 human edentulous adults affected by SS with the need of stabilization of the dentures. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
62213925|NCT00182559|ACTIVE_COMPARATOR|Ciclosporin|Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.
62213926|NCT00182559|ACTIVE_COMPARATOR|Tacrolimus|Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.
62213927|NCT02863289||Children with proximal humerus fractures|Children aged from 10 to 18-year-old in NHS Tayside whom sustained proximal humerus fractures during year 2008 to 2015.
62791185|NCT02661243|OTHER|Edentulous healthy controls arm|30 healthy human edentulous adults with the need of stabilization of the dentures. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
62020510|NCT03934021||Acute stroke patient group|"Consecutive patients diagnosed with acute ischaemic stroke during hospitalization in Prince of Wales Hospital will be recruited.~After an informed consent, stool will be collected from enrolled patients in their first bowel opening after hospitalization and stored in a freezer (-80 degree Celsius) within 24 hours for analysis. If a subject develops constipation, stool sampling will be facilitated by stool softener or laxatives. Stools samples will be stored at -80 degrees Celsius within 24 hours once it is collected.~Subjects will be followed up at 3 and 6 months after trial entry. NIHSS and mRS will be performed at each visit. Stool sample collection will be repeated in 6 months visit only."
62213928|NCT04537416||Women with recurrent pregnancy loss|consecutive women at least 18 years old but not greater than 40 years old with a chief complaint of recurrent pregnancy loss
62213929|NCT00943111|EXPERIMENTAL|Investigational|Eliglustat tartrate
62409625|NCT03330275|EXPERIMENTAL|Control 2/Control 1/Test|Subjects will be randomized to 1 of 3 lenses (Control 2/Control 1/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
62409626|NCT00545493|EXPERIMENTAL|Group 1|"Tacrolimus capsules (Prograf; dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter)"
62409627|NCT00545493|EXPERIMENTAL|Group 2|"Intravenous immunoglobulins (IVIG) infusions (Octagam; dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months)."
62791186|NCT04786795|EXPERIMENTAL|Compound Azintamide Enteric-coated Tablets|If dyspeptic symptoms occur after laparoscopic cholecystectomy and are randomized, the experimental group takes Compound Azintamide Enteric-coated Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit.
62020511|NCT03934021||Control group|Age and disease matched subjects will be invited to join the study as the control. Stool will also be collected for the comparison of gut microbiota with acute stroke patients to look for evidence of gut dysbiosis in acute stroke. We shall match the control cohort with the stroke cohort in terms of age, gender, smoking status, medical co-morbidities including hypertension, hyperlipidaemia, diabetes, (atrial fibrillation), use of medications in particular metformin, proton pump inhibitors and aspirin.
62020512|NCT02157311|EXPERIMENTAL|Four consecutive days on treatment and 3 days off|All patients will take a combination of three HIV treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
62791187|NCT04786795|PLACEBO_COMPARATOR|Oryz-aspergillus Enzyme|If dyspeptic symptoms occur after laparoscopic cholecystectomy and are randomized, the control group takes Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit.
62020513|NCT01168050|EXPERIMENTAL|Nilotinib|
62020514|NCT06532539|EXPERIMENTAL|Treatment Arm|Chemotherapy：TP (Paclitaxel and Cisplatin) Immunotherapy：Cadonilimab Radiotherapy：All tumor lesions will be irradiated
62213930|NCT00943111|ACTIVE_COMPARATOR|Imiglucerase|
62213931|NCT01141647|EXPERIMENTAL|24-Month Supported Employment|Evidence-Based Supported Employment Vocational Rehabilitation or Other Vocational Services
62213932|NCT04689282|EXPERIMENTAL|Intranasal M2-BFs|"Intranasally-Administered Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs). M2 were generated in vitro from peripheral blood of a parent during 7 days. Cell-free culture medium, containing M2-BFs, was collected, and aliquots of 2 mL/vial were cryopreserved.~30 children with speech disorders will receive their first doses (n=2-3) of M2-BFs in Clinic and wait 2 hrs to determine any short-time adverse effects of inhaled dose. The subsequent course of intranasal inhalations (once a day up to 30 days) performed as outpatient treatment."
62213933|NCT01655693|EXPERIMENTAL|Doxorubicin Transdrug (DT) at 20 mg/m2|DT will be infused over 6 hours through the intravenous (IV) route at dose of 20 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
62213934|NCT01655693|EXPERIMENTAL|Doxorubicin Transdrug (DT) at 30 mg/m2|DT will be infused over 6 hours through the IV route at dose of 30 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
62409628|NCT02188667|ACTIVE_COMPARATOR|Providers of Novel Care|Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
62409629|NCT02188667|SHAM_COMPARATOR|Providers of Usual Care|Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
62409630|NCT01046201||Obese Children|
62213935|NCT01655693|ACTIVE_COMPARATOR|Best Standard of Care|Patients randomized in the control group will receive treatment according to the investigator's choice, until disease progression or unacceptable toxicity
62213936|NCT04198753||Parent of Peanut Allergic Child|"The researchers will identify patients or study subjects aged 1-18 who have been diagnosed with peanut allergy based on skin prick testing, serologic testing, and/or history of reaction. They will then contact mothers or fathers of these patients/subjects who are 18 and older and enroll those who do not themselves have a history of food allergy, with a goal of 40 subjects per group.~The researchers will perform a very limited physical exam followed by skin tape stripping (30 strips) for lipid profile and protein expression, and transepidermal water loss (TEWL) measurements every 5 strips. They will obtain blood work to define FLG mutation and vitamin D status. Questionnaires on their background, other concurrent atopic and nonatopic diseases, and exposures, will also be collected."
62409631|NCT04187937|EXPERIMENTAL|Experimental|Stereotactic image-guided non-anatomical resection
62409632|NCT02057224|EXPERIMENTAL|Single arm|15 clinical patients undergoing renal denervation
62409633|NCT01495104|EXPERIMENTAL|Single Arm|
62409634|NCT04034875|EXPERIMENTAL|Patients with acquired brain injury|
62409635|NCT06650020|EXPERIMENTAL|the control group|The control group adhered to the traditional offline model of centralized training
62409636|NCT06650020|EXPERIMENTAL|synchronous online learning group|The experimental group implemented an online training modality.
62409637|NCT01884909|ACTIVE_COMPARATOR|'TOPROL-XL®' ER Tablets 200 mg|'TOPROL-XL®' ER Tablets 200 mg of Astrazeneca LP, USA
62409638|NCT01884909|EXPERIMENTAL|Metoprolol Succinate ER Tablet 200 mg|Metoprolol Succinate ER Tablet 200 mg of Ipca Laboratories Limited, India
62409639|NCT04349501|EXPERIMENTAL|RSI-MRI|Participants will undergo RSI-MRI at three time points: before androgen deprivation therapy (ADT); after neoadjuvant ADT but before radiation therapy (RT); and after RT.
62409640|NCT03730025|EXPERIMENTAL|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
62409641|NCT03730025|ACTIVE_COMPARATOR|Auscultation without NeoTapAS|Pediatric resident responsible for HR assessment will mentally calculate the HR based on auscultation (by counting the number of beats in 6 seconds and multiplying by 10) and will verbally communicate the calculated HR.
62409642|NCT02168569|ACTIVE_COMPARATOR|Cohort 1|5 sites, namely Manhiça, Dondo, Montepuez, Tete and Chokwe
62409643|NCT02168569|ACTIVE_COMPARATOR|Cohort 2|3 sites, namely Montepuez, Dondo and Chokwe
62409644|NCT01797809||Group 1|
62734568|NCT01181804|EXPERIMENTAL|Boceprevir Tablets then Capsules (fasted)|Participants will start therapy with a single dose of boceprevir tablets, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir capsules, orally, following an overnight fast.
62791188|NCT05882461|EXPERIMENTAL|Those receiving the 90Second Caregiver health letter|The 90Second Caregiver health letter is a weekly online publication that addresses topics relevant for caregivers. It combines scientifically-valid, evidence-based information with actionable tips to improve caregiver self efficacy and well-being. Participant in this group will receive a 90Second Caregiver health letter every week, via email.
62791189|NCT05882461|NO_INTERVENTION|The usual care control group|Participants that are randomized to be in the usual care control group will continue on as participants in the Caring Forward Trials within Cohort Study (i.e. filling out questionnaires every 6-months). Participants will continue to participate in the Caring Forward Study until completion in March 2022.
62020515|NCT00616967|ACTIVE_COMPARATOR|Arm I|Patients receive carboplatin IV and paclitaxel albumin-stabilized nanoparticle formulation IV on day 1 and an oral placebo on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
62020516|NCT00616967|EXPERIMENTAL|Arm II|Patients receive carboplatin and paclitaxel albumin-stabilized nanoparticle formulation as in arm I and oral vorinostat on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
62020517|NCT06535529|ACTIVE_COMPARATOR|Acetazolamide + Standard Care|"Participants in this arm will receive:~1. Acetazolamide: 500 mg orally, once daily for 3 days~2. Intravenous loop diuretics: Administered at double the oral maintenance dose, given as follows:~   * Initial dose: Single bolus immediately after randomization~  * Subsequent doses: Split into two or more doses (separated by ≥6 hours) on each of the next 2 days The specific loop diuretic used (e.g., furosemide) will be determined by the treating physician based on the patient's prior medication regimen and clinical status."
62020518|NCT06535529|ACTIVE_COMPARATOR|Dapagliflozin + Standard Care|"Participants in this arm will receive:~1. Dapagliflozin: 10 mg orally, once daily for 3 days~2. Intravenous loop diuretics: Administered as described in Arm 1"
62213937|NCT04198753||Parent of Non-atopic Child|"To establish normal controls, the researchers will enroll parents age 18 or older with no history of food allergy or eczema in themselves or their offspring.~The researchers will perform a very limited physical exam followed by skin tape stripping (30 strips) for lipid profile and protein expression, and transepidermal water loss (TEWL) measurements every 5 strips. They will obtain blood work to define FLG mutation and vitamin D status. Questionnaires on their background, other concurrent atopic and nonatopic diseases, and exposures, will also be collected."
62213938|NCT01628562|ACTIVE_COMPARATOR|GroupE/Esmolol infusion|Heart rate control, Beta blocker
62213939|NCT01628562|EXPERIMENTAL|GroupR/Remifentanil infusion|Heart rate control, opioid
62213940|NCT01716897|OTHER|50 mg E2609 capsule formulation in fasted state|50 mg E2609 capsule formulation
62213941|NCT01716897|OTHER|50 mg E2609 tablet formulation in fasted state|50 mg E2609 tablet formulation in fasted state
62020519|NCT02322944|EXPERIMENTAL|Intervention group|The intervention group will take the treatment quality improvement strategies and tools into implementation.
62020520|NCT02322944|NO_INTERVENTION|Control group|The control group will maintain the routine practice pattern.
62409645|NCT03677973|ACTIVE_COMPARATOR|Active: Dose Escalation|Healthy volunteers will receive AB680 as a single intravenous (IV) infusion at 7 dose levels and as multiple IV infusions at 1 dose level. Assignment to receive AB680 or matching placebo will be random.
62409646|NCT03677973|PLACEBO_COMPARATOR|Placebo: Dose Escalation|Healthy volunteers will receive matching placebo as a single IV infusion and as multiple IV infusions. Assignment to receive AB680 or matching placebo will be random.
62409647|NCT04762212|ACTIVE_COMPARATOR|Hip with the greatest limitation in flexion range of motion|Participants that have limited hip flexion of less than 101 degrees will be randomly assigned to one of two groups: one intervention group will receive Mobilization with Movement and home program of stretching with over-pressure one group will receive only a home program of stretching with over-pressure.
62409648|NCT04762212|ACTIVE_COMPARATOR|Hip with the least limitation in flexion range of motion|Participants least limited hip in flexion range of motion will serve as the control group. This limb will not receive an intervention.
62409649|NCT01856348|EXPERIMENTAL|1, 25 dihydroxyvitamin D3 intake|This is a single arm study.
62409650|NCT05086627|EXPERIMENTAL|Short-course radiotherapy sequential Tislelizumab combined with CapeOX (group A)|"Standard SCRT: A total radiation dose of 25 Gy was delivered in 5 fractions (from day 1 to 5)~Sequential treatment period: After resting for 3-7 days following completion of SCRT, patients were treated with 4 cycles of CapeOX (Oxaliplatin 130 mg/m2 intravenously, day 1; Capecitabine 1000 mg/m2, Bid,days 1-14) and an additional intravenous infusion of 200mg Tislelizumab on the first day of each cycle of CapeOX.~Surgery: After 3 weeks of the completion of neoadjuvant therapy, the TME surgery was performed.~Postoperative adjuvant chemotherapy: Whether postoperative chemotherapy was implemented mainly depended on the patient's wishes, and 2 cycles of CapeOX with or without Tislelizumab will be undergone to these willing cases."
62213942|NCT01716897|OTHER|50 mg tablet formulation in fed state|50 mg E2609 tablet formulation in fed state
62213943|NCT00439322||Group 1|
62409651|NCT05086627|ACTIVE_COMPARATOR|Short-course radiotherapy sequential CapeOX (group B)|"Standard SCRT: A total radiation dose of 25 Gy was delivered in 5 fractions (from day 1 to 5)~Sequential treatment period: After resting for 3-7 days following completion of SCRT, patients were treated with 4 cycles of CapeOX (Oxaliplatin 130 mg/m2 intravenously, day 1; Capecitabine 1000 mg/m2, Bid,days 1-14).~Surgery: After 3 weeks of the completion of neoadjuvant therapy, the TME surgery was performed.~Postoperative adjuvant chemotherapy: Whether postoperative chemotherapy was implemented mainly depended on the patient's wishes, and 2 cycles of CapeOX will be undergone to these willing cases."
62409652|NCT06567210|EXPERIMENTAL|CBCTi|8-weeks online therapist-guided CBCTi including weekly online modules. Guidance is provided via scheduled and ad hoc communications (e.g., email, messaging, telehealth) between the participant and a clinician/physician
62409653|NCT06567210|ACTIVE_COMPARATOR|General sleep information|For 8 weeks, participants will receive assess to general sleep health information and perform daily sleep diaries.
62409654|NCT06649175|ACTIVE_COMPARATOR|group(A):exercise group.|"Control Group (A): will receive the traditional physical therapy (PT) program for one hour two times weekly for six successive weeks.~Intervention: traditional physical therapy program."
62584585|NCT02626130|EXPERIMENTAL|Arm B (tremelimumab and cryoablation)|Patients undergo cryoablation and receive tremelimumab IV over 60 minutes at weeks 1 (2-6 days after cryoablation) and 5. Within 4-6 weeks later, patients undergo surgery or biopsy. After surgery or biopsy, patients receive tremelimumab IV Q34W for 3 doses, and then Q12W in the absence of disease progression or unacceptable toxicity.
62791190|NCT04694027|ACTIVE_COMPARATOR|group a|will receive omega 3 plus vitamin E
62409655|NCT06649175|ACTIVE_COMPARATOR|Group(B): modified exercise group.|Group (B): will receive a program of close kinetic chain exercises for 30 min.
62409656|NCT06002425|ACTIVE_COMPARATOR|Control group|In this arm, participants receive treatment plans directly from clinicians without the assistance of ChatGPT.
62409657|NCT06002425|EXPERIMENTAL|GPT-Assisted Group|In this arm, participants receive treatment plans from clinicians with the assistance of ChatGPT.
62409658|NCT06437522|EXPERIMENTAL|Study treatment|Participants receive BL-B01D1 + PD-1 monoclonal antibody as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62409659|NCT03179462|EXPERIMENTAL|Pork intake|Subjects will consume 2 ounces of cooked lean pork following diet normalization for 3 days.
62409660|NCT03179462|EXPERIMENTAL|Mixed nuts intake|Subjects will consume 1 ounce of mixed nuts following diet normalization for 3 days.
62409661|NCT03179462|EXPERIMENTAL|Tofu intake|Subjects will consume 2 ounces of tofu following diet normalization for 3 days.
62409662|NCT06652659||Patients at age 18 or above with a displaced midshaft clavicle fracture.|
62584586|NCT02566382|EXPERIMENTAL|shoulder arthroscopy arthrodesis|The shoulder surgery will be realized under arthroscopy only.
62020521|NCT02322944|EXPERIMENTAL|Process optimization group|The process optimization group's clinical pathways and team building will be re-organized for the purpose of quality improvement, and develop individualized treatment strategies and process.
62213944|NCT04144101|EXPERIMENTAL|Etoricoxib|Etoricoxib 60 mg QD
62213945|NCT04144101|EXPERIMENTAL|Aceclofenac|Aceclofenac 100 mg BID
62409663|NCT06649877|EXPERIMENTAL|Abdomen Injection|Participants will receive a single dose of MK-6194 injected into the abdomen.
62584587|NCT05152966|EXPERIMENTAL|FARAPULSE™ Endocardial Cardiac Ablation|Ablation using FARAPULSE™ Cardiac Ablation System Plus
62791191|NCT04694027|ACTIVE_COMPARATOR|Group b|will receive vitamin E
62791192|NCT04694027|NO_INTERVENTION|Group c|no intervention just reassurance and analgesics on need
62213946|NCT04715165|ACTIVE_COMPARATOR|Group I|Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline.
62213947|NCT04715165|PLACEBO_COMPARATOR|Group II|Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery
62215268|NCT04237025|EXPERIMENTAL|Nordic walking exercise group|Supervised Nordic walking exercise training 3 times per week for the first two weeks and 2 times per week for next four weeks (total 6 weeks). In addition to independent Nordic walking exercise twice weekly during intervention phase and three times weekly during the 3-month followup phase.
62213948|NCT03434990|EXPERIMENTAL|Spinal manipulation/myofascial release|2x/week, for 3 weeks, performed by a chiropractor. Sessions will last 20 minutes, with 1 individual per session. Myofascial release will be done on paravertebral muscle (Erector spinae, quadratus lumborum) and on gluteus maximus and piriform muscles, the pressure will depend of pain tolerance of each subject. After this procedure, the spinal manipulation will be performed on the sacroiliac join and on the lumbar vertebrae with less mobility.
62213949|NCT03434990|ACTIVE_COMPARATOR|Spinal manipulation|2x/week, for 3 weeks, performed by a chiropractor. Sessions will last 20 minutes, with 1 individual per session. The spinal manipulation will be performed on the sacroiliac join and on the lumbar vertebrae with less mobility.
62213950|NCT06609603|EXPERIMENTAL|HTGT compound|"* Dietary supplement: HTGT compound~  * oral administration of HTGT compound once daily, 2 capsules per day.~* Dietary supplement; Placebo~  * oral administration of placebo once daily, 2 canpules per day"
62409664|NCT06649877|EXPERIMENTAL|Thigh Injection|Participants will receive a single dose of MK-6194 injected into the thigh.
62409665|NCT04846907||Healthcare personnel working in pediatric intensive care units during COVID-19 pandemic|Physicians, registered nurses, nurse technicians, physical therapists and other professionals; on duty, routine staff or fellow/residents working in participants PICU
62409666|NCT01977924|EXPERIMENTAL|polyphenols|600 mg polyphenols (grape extract)
62409667|NCT01977924|PLACEBO_COMPARATOR|Placebo|microcrystalline cellulose
62409668|NCT06653868|EXPERIMENTAL|immediate implant placement surgery with filling the gap distance with alloplastic sticky graft|immediate implant placement surgery with filling the gap distance with injectable platelet rich fibrin combined with alloplast.
62409669|NCT06653868|EXPERIMENTAL|immediate implant placement surgery with filling the gap distance with xenogenic sticky bone|immediate implant placement surgery with filling the gap distance with injectable platelet rich fibrin combined with xenograft.
62409670|NCT03372018|EXPERIMENTAL|Promotora-led intervention (PLI)|PLI -DPP protocol was developed from original DPP materials and culturally tailored for the target population based on formative research. The core PL-DPP curriculum includes 14 group sessions of 90 minutes duration. One promotora will lead each session in Spanish using behavioral strategies to discuss lifestyle behaviors, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
62409671|NCT03372018|ACTIVE_COMPARATOR|Usual care (UC)|UC participants will receive standard educational materials in Spanish discussing mental health and diabetes prevention. UC participants will be encouraged to continue all routine medical care during the study.
62409672|NCT02720796|OTHER|PDX drug sensitivity testing|Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
62409673|NCT05901376||Gastric Cancer|
62409674|NCT05901376||Control|
62409675|NCT05863325|EXPERIMENTAL|HB1801|HB1801 will be given in 21-day cycles until documented disease progression, discontinuation due to toxicity, withdrawal of consent, initiation of a new antitumor therapy, loss of follow-up, death, or study completion, whichever occurs first.
62409676|NCT05863325|ACTIVE_COMPARATOR|Taxotere|Taxotere will be given in 21-day cycles until documented disease progression, discontinuation due to toxicity, withdrawal of consent, initiation of a new antitumor therapy, loss of follow-up, death, or study completion, whichever occurs first.
62409677|NCT00457249|EXPERIMENTAL|Adacel Vaccine Group|
62584588|NCT00105768|OTHER|Arm 1|
62584589|NCT03092297||ICU patients with anaemia|At admission to the ICU all patients, or their legal representatives, expected to stay at the ICU for longer than 24 hours will be asked to participate in the study and will be asked informed consent. ICU patients with anaemia in whom a central venous catheter is already in place and in whom a red cell transfusion is planned, will be included in the study.
62791193|NCT05566171|NO_INTERVENTION|Control Group|This group will be just follow-up for 4 weeks without any intervention
62020522|NCT03869229|ACTIVE_COMPARATOR|osteoarthritis of the knee|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
62020523|NCT03869229|ACTIVE_COMPARATOR|osteoarthritis of the hip|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
62409678|NCT00457249|ACTIVE_COMPARATOR|DECAVAC Vaccine Group|
62409679|NCT03623217||Kidney transplant participants receiving tacrolimus|Transplant participants who have received tacrolimus twice daily for a minimum of 6 months to a maximum of 12 months after the surgery, and who are within 1 month of switching to the once daily regimen of modified release tacrolimus.
62409680|NCT05980013|EXPERIMENTAL|Supine Donation Position|
62584590|NCT05660421|EXPERIMENTAL|Treatment (itacitinib)|Patients receive itacitinib PO and corticosteroids PO or IV. Patients may undergo endoscopy and skin biopsy throughout the study. Patients also undergo blood collection throughout the study.
62791194|NCT05566171|EXPERIMENTAL|Interventional Group|This group will consume 125 g plain Activia Probiotic Yogurt without any aroma/fruit during 4 weeks/1 month
62020524|NCT03869229|ACTIVE_COMPARATOR|osteoarthritis of the glenohumeral joint|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
62020525|NCT00245557|NO_INTERVENTION|Healthy Controls|Healthy Controls undergo MRI and neuropsychological testing
62020526|NCT00245557|EXPERIMENTAL|Depressed|Depressed subjects receive experimental drug
62020527|NCT01853150|EXPERIMENTAL|rTMS Motor cortex|rTMS will be applied over the motor cortex
62020528|NCT01853150|ACTIVE_COMPARATOR|rTMS Supplementary motor area|rTMS will be applied over the supplementary motor area
62020529|NCT06114797|ACTIVE_COMPARATOR|Chamomile mouthwash interventional arm in elderly patients having end-stage renal disease.|"* Chamomile was topically applied to the oral mucosa as oral rinse.~* Based on this protocol, patients were had oral rinses 3 times per day.~* Patients were instructed to perform chamomile rinses in the oral mucosa.~* Patients were instructed not to swallow the chamomile oral rinse."
62020530|NCT06114797|PLACEBO_COMPARATOR|Saline mouthwash control group in elderly patients having end-stage renal disease.|"Patients in the control arm followed the same protocol with normal saline rinses. As stated before, that use of 4% hypertonic saline solution mouthwash by elderly provided better oral health by decreasing xerostomia, oral tongue plaque, halitosis, and the number of oral bacteria.~So the patients in the control group were benefited from the saline oral rinse."
62584591|NCT06684067|EXPERIMENTAL|Patient navigation|Participants in the intervention arm will undergo a patient navigation process
62584592|NCT06684067|NO_INTERVENTION|No navigation|Participants in the control arm will receive standard instructions and not undergo the patient navigation process.
62791195|NCT04863872|ACTIVE_COMPARATOR|Proactive Care Management|
62791196|NCT04863872|EXPERIMENTAL|Proactive Care Management + my hypo compass education program|
62791197|NCT06361589||Advanced ALK+ NSCLC Patients|
62791198|NCT02352844|EXPERIMENTAL|Arm 1 (everolimus)|Everolimus is an oral drug which will be administered on an outpatient basis at a dose of 10 mg daily on a 28-day cycle.
62791199|NCT05550935|EXPERIMENTAL|HFNC Group|Healthy subject will perform one Constant Work-Rate Exercise Test at respiratory compensation point as determined by a cardiopulmonary exercise test with High Flow Nasal at 60L/min (without additional oxygen)
62791200|NCT05550935|SHAM_COMPARATOR|Control Group|Healthy subject will perform one Constant Work-Rate Exercise Test at respiratory compensation point as determined by a cardiopulmonary exercise test with High Flow Nasal at 2L/min (without additional oxygen)
62791201|NCT05580939|NO_INTERVENTION|Control Grup|they receive theoretical first aid training
62791202|NCT05580939|EXPERIMENTAL|Intervention Grup|they receive theoretical first aid training and use web based simulation application
62791203|NCT03785379|ACTIVE_COMPARATOR|Caloric restriction and early SSET|Patients will participate to a short lifestyle intervention (LSI), consisting of four weekly group-led lessons lasting 60-90 minutes to educate them on specific dietary and physical activity recommendations for improving health and metabolic control. At the end of the 1-month LSI, participants will start a caloric restriction and early exercise training (SSET) during the first 12-week, followed by no exercise at health centers for 3 months. Between the 6- and the 12-month assessments, participants will continue caloric restriction and will be encouraged to freely exercise.
62791204|NCT03785379|ACTIVE_COMPARATOR|Caloric restriction and late SSET|Patients will participate to a short lifestyle intervention (LSI), consisting of four weekly group-led lessons lasting 60-90 minutes to educate them on specific dietary and physical activity recommendations for improving health and metabolic control. At the end of the 1-month LSI, participants will start a one-year caloric restriction with no exercise at health centers for 3 months, and then a 12-week exercise training (SSET). Between the 6- and the 12-month assessments, participants will continue caloric restriction and will be encouraged to freely exercise.
62791205|NCT02629822|EXPERIMENTAL|DOR/3TC/TDF|Treatment-naïve HIV-1 infected participants with NNRTI transmitted resistance-associated mutations were treated with open-label MK-1439A (DOR/3TC/TDF 100mg/300mg/300mg) as a FDC tablet taken once daily by mouth for 96 weeks in the Base Study. In addition, eligible participants continued to receive the same MK-1439A regimen from Week 96 to Week 192 during the Extension Study.
62020531|NCT00352534|EXPERIMENTAL|Stratum I (very low-risk disease)|Patients undergo nephrectomy only. If they meet criteria, they are then observed periodically for 5 years. Patients with recurrent disease undergo surgery (immediate or delayed) and receive chemotherapy as in stratum III. Patients with no metachronous renal disease receive radiotherapy. Patients with metachronous disease undergo renal-sparing surgery and chemotherapy as in stratum III, but no radiotherapy. Treatment continues for up to 25 weeks. Additionally, patients undergo chest X-ray, CT or MRI, ultrasound, echocardiography, and blood sample collection throughout the study.
62213951|NCT06609603|PLACEBO_COMPARATOR|Placebo|Once daily, 2 capsules per day
62584593|NCT00356356|EXPERIMENTAL|All subjects|257 subjects
62584594|NCT05478135|EXPERIMENTAL|NAVIFY Oncology Hub|We will first conduct a small number of simulation sessions (3-5) to validate study methods and data collection procedures. Study methods may then be refined before conducting simulation sessions with a larger number of participants (approx. 25). In this phase, each participant will participate in a 90-minute simulation session in which they will use NAVIFY Oncology Hub to review synthetic patient cases. Participants will be tasked with reviewing the cases as if they were preparing to see a patient in a real clinical setting.
62584595|NCT01003314|EXPERIMENTAL|Group 1|
62584596|NCT01003314|EXPERIMENTAL|Group 2|
62584597|NCT06539624|EXPERIMENTAL|Dose escalation-Cohort 1|Genetic : EXG110
62584598|NCT06539624|EXPERIMENTAL|Dose escalation-Cohort 2|Genetic : EXG110
62791206|NCT04753749|EXPERIMENTAL|Shortened DAPT followed by P2Y12 inhibitor monotherapy|
62791207|NCT04753749|ACTIVE_COMPARATOR|Dual Antiplatelet Therapy|
62791208|NCT04906304|EXPERIMENTAL|Evrolimus|The treatment regimen in everolimus group was 0.75 mg/bid everolimus with everolimus C0 3-8 ng/mL plus Sandimmun (Neoral) low dose pluse cellcept
62409681|NCT05980013|EXPERIMENTAL|Reclined Donation Position|
62584599|NCT06539624|EXPERIMENTAL|Dose escalation-Cohort 3|Genetic : EXG110
62584600|NCT06539624|EXPERIMENTAL|Dose escalation-Cohort 4|Genetic : EXG110
62584601|NCT00860197|NO_INTERVENTION|Control|No coffee
62584602|NCT00860197|EXPERIMENTAL|Group 1|Fully torrefied coffee
62584603|NCT00860197|EXPERIMENTAL|Group 2|Partially torrefied coffee
62584604|NCT05871944|ACTIVE_COMPARATOR|control group|kalternborn joint mobilization techniques will be administered for total of 8 weeks at the rate of 2 session per week.
62584605|NCT05871944|EXPERIMENTAL|experimental group|Post stretch facilitation technique will be administered for total of 8 weeks at the rate of 2 session per week.
62213952|NCT04160065|EXPERIMENTAL|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion/time point|"Exposure Escalation:~* The first 3 subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at a single time point (28-day follow-up post last injection); 3/3 patients recruited.~* The second 3 subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at 2 time points 7 days apart (28-day follow-up post last injection); 1/3 patients recruited.~* The third 3 subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at 3 time points 7 days apart (28-day follow-up post last injection); recruitment pending.~Cohort Expansion:~* The remaining 11 subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at 3 time points 7 days apart (28-day follow-up post last injection); recruitment pending."
62213953|NCT06065254|EXPERIMENTAL|Free gingival graft|Free gingival graft will be applied and and followed for 3 months
62213954|NCT06065254|EXPERIMENTAL|Connective tissue graft|Connective tissue graft will be applied and and followed for 3 months
62213955|NCT06065254|OTHER|No grafts will be applied.|No grafts of any types will be applied.
62213956|NCT04220762|EXPERIMENTAL|Test Group 1|The randomized patients are administered 3 tablets of the investigational product (400mg) twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
62213957|NCT04220762|EXPERIMENTAL|Test Group 2|The randomized patients are administered 3 tablets of the investigational product (800mg) twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
62213958|NCT04220762|EXPERIMENTAL|Test Group 3|The randomized patients are administered 3 tablets of the investigational product (1200mg) twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
62213959|NCT04220762|PLACEBO_COMPARATOR|Placebo group|The randomized patients are administered 3 tablets of the placebo drug twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
62213960|NCT05362500|ACTIVE_COMPARATOR|Group A 70% Glycolic acid|Group A: contain 27 patients which had been treated every 2 weeks for 12 weeks with 70% glycolic acid to assess chemical peeling and cold water was used for washing to stop peeling
62213961|NCT05362500|ACTIVE_COMPARATOR|Group B intradermal tranexamic acid|Group B: contain 27 patients treated with an intradermal injection of 0.05 mL of tranexamic acid solution in normal saline (4 mg/mL) into the melasma lesion at 1 cm distance using a sterile insulin syringe, weekly for 12 weeks
62213962|NCT02355990|EXPERIMENTAL|MIMS|Minimally Invasive Micro Sclerostomy
62584606|NCT04111250|EXPERIMENTAL|Crestal sinus lift using iRasie implant|"Device: iRaise Sinus Lift implant (Maxillent, Herzliya, Israel). Procedure: crestal sinus lift augmentation.~We tested crestal versus lateral approach to the sinus. Crestal approach is made by a novel device (iRaise, implant system). Lateral approach is made conventionally with gold standard procedure (lateral approach).~The iRaise Sinus Lift implant is made of Titanium-6 Aluminum-4 Vanadium alloy, have a surface treated with grit blasting using an apatitic calcium phosphate media, followed by acid etching, and have an internal hexagon connection. Implants have an internal l-shape channel to allow saline and graft passage.~This implants system is made to perform crestal sinus lift procedure at the same time of the implant placement using the same device. After implant site preparation and initial implant placement, the hydraulic system is connected to the implant to allow the injection of saline and then graft the material. Then, the implant, is inserted for its full length."
62791209|NCT04906304|ACTIVE_COMPARATOR|Control|0.75 mg/bid everolimus with everolimus C0 3-8 ng/mL plus Sandimmun (Neoral)standard dose plus cellcept
62791210|NCT06163222|EXPERIMENTAL|Getting to your appointment|Additional 14-day message reminder that includes link to new transport index web page
62791211|NCT06163222|EXPERIMENTAL|Help with travel costs|Additional 14-day message reminder that includes link to new 'help with travel costs' web page
62791212|NCT06163222|EXPERIMENTAL|What to expect|Additional 14-day message reminder that includes link to 'what to expect' web page
62791213|NCT06163222|ACTIVE_COMPARATOR|Usual communications|Existing communication strategy used for each of the five clinical specialties e.g. reminder messages 3 and 7 days prior to outpatient appointment
62020532|NCT00352534|EXPERIMENTAL|Stratum II (standard-risk, stage I or II)|Patients undergo nephrectomy. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1, every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 doses of doxorubicin. Treatment continues for up to 25 weeks. Additionally, patients undergo chest X-ray, CT or MRI, ultrasound, echocardiography, and blood sample collection throughout the study.
62791214|NCT03210961|EXPERIMENTAL|PF-06826647 tablet|
62791215|NCT03210961|PLACEBO_COMPARATOR|Placebo tablet|
62213963|NCT04547868|EXPERIMENTAL|Coffee|Caffeinated coffee beverage
62213964|NCT04547868|ACTIVE_COMPARATOR|Decaffeinated coffee|Decaffeinated coffee beverage
62213965|NCT04547868|PLACEBO_COMPARATOR|Warm water|Warm water beverage
62213966|NCT06095687|ACTIVE_COMPARATOR|Mindfulness Meditation|"Condition 1, Mindfulness Meditation (MM): The MM recording will be adapted from Day (2017). It will first instruct the listener to anchor attention on the breath while being mindfully aware of any physical sensations that arise throughout the body. The listener is then encouraged to explore sensations with non-judgmental attentiveness, without attempts to change the sensation in any way. This will implicitly provide training in mindful acceptance. Finally, the listener is instructed to simply label any thinking that arises as thinking, before returning to the object of the meditation."
62215269|NCT03535597|NO_INTERVENTION|Arm 1|TR Band inflated with 10 mL of air, followed by gradual weaning over the subsequent 60 minutes.
62791216|NCT03210961|EXPERIMENTAL|PF-06826647 oral suspension|
62791217|NCT03210961|PLACEBO_COMPARATOR|Placebo oral solution/suspension|
62791218|NCT00960492|EXPERIMENTAL|Arm 1|XL184 will be initiated at the start of the 6-7 week concurrent phase of RT (+TMZ; some subjects found to have specific gene activity in their tumor tissue may not receive TMZ), given as a single agent during the rest phase (4 weeks), if applicable, and continued subsequently in the maintenance phase.
62791219|NCT00960492|EXPERIMENTAL|Arm 2|XL184 will be initiated during the maintenance phase with TMZ
62213967|NCT06095687|ACTIVE_COMPARATOR|Clinical Hypnosis|Condition 2, Clinical Hypnosis (HYP): The HYP recording will be adapted from Jensen (2011). It will take the listener through a standardised self-hypnosis practice that includes an induction, followed by tailored suggestions. Specifically, the HYP session aims to take the listener through four basic ideas: 1) an induction to get the individual into a state of readiness to accept new ideas; 2) instructions to go to a favourite place to deepen the induction and provide a context for feeling heat while being relaxed; 3) linking suggestions for reducing automatic behavioural inhibition system and behavioural activation system (BIS-BAS) activation in response to stressors and enhancing awareness of when to activate each system; 4) suggestions that target enhancing self-confidence in pain management, well-being and the rehabilitation process; and 5) alerting.
62213968|NCT01346475|ACTIVE_COMPARATOR|valacyclovir|
62213969|NCT01346475|EXPERIMENTAL|high dose valacyclovir|
62213970|NCT00859729|EXPERIMENTAL|Cohort I|50 µg DNA/dose, 3 patients
62213971|NCT00859729|EXPERIMENTAL|Cohort II|150 µg DNA/dose, 3 patients
62213972|NCT00859729|EXPERIMENTAL|Cohort III|400 µg DNA/dose, 3 patients
62213973|NCT00859729|EXPERIMENTAL|Cohort IV|1000 µg DNA/dose, 3 patients
62213974|NCT00859729|EXPERIMENTAL|Cohort V|Optimal dose to be determined, 6 patients
62584607|NCT04111250|ACTIVE_COMPARATOR|Lateral sinus lift|"Conventional procedure.~Lateral approach to the sinus was made following the conventional procedure.~A window on the lateral wall of the sinus is performed according to a conventional surgical lateral approach to the sinus cavity. Graft materials is filled inside the sinus cavity. Finally, iSure implants \[Maxillent\] are placed, and flap is sutured."
62584608|NCT05909878|EXPERIMENTAL|Virtual Reality Distraction|Use of Virtual Reality (VR) before the MRI.
62020533|NCT00352534|EXPERIMENTAL|Stratum III (standard-risk, stage III)|Patients undergo nephrectomy, if feasible, or biopsy. For patients who undergo biopsy only, definitive surgery is undertaken at week 7 or 13. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1 every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 dose of doxorubicin hydrochloride. Patients undergo radiotherapy over 5-7 days after nephrectomy. Treatment continues for up to 25 weeks. Additionally, patients undergo chest X-ray, CT or MRI, ultrasound, echocardiography, and blood sample collection throughout the study.
62020534|NCT02520934|EXPERIMENTAL|Case_Miglustat|Besides regular ERT, patients in this group also need to take Miglustat for 24 months.
62020535|NCT02520934|NO_INTERVENTION|Control|Patients will be tested for their pupil cycle time.
62020536|NCT03773744|EXPERIMENTAL|Arm 1: Intravenous Dosing|Low dose cyclophosphamide (300mg/ m2) at Day -3, then a fixed dose of Ad-MAGEA3 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-MAGEA3 administered as 2 intravenous (IV) doses at Day 15 and Day 18 and fixed dose pembrolizumab (200mg) beginning at either Week 6 or Day 1, depending on the cohort.
62020537|NCT03773744|EXPERIMENTAL|Arm 2: Intravenous followed by Intratumoral Dosing|A fixed dose of Ad-MAGEA3 administered IM followed by Pembrolizumab on Day 1. MG1-MAGEA3 administered as an intravenous (IV) dose at Day 15, followed by intratumoral (IT) MG1-MAGEA3 on Day 22, Day 29, and Day 36. IT MG1-MAGEA3 booster injections may be continued every 3 weeks beginning at Day 43 (Week 6).
62020538|NCT03549689|EXPERIMENTAL|Switch|Dolutegravir (DTG) 50MG/ lamivuidne (3TC) 300MG FIXED_DOSE COMBINATION (FDC) DAILY at randomization for 96 weeks
62020539|NCT03549689|ACTIVE_COMPARATOR|Continuation|Continue current tenofovir alafenamide (TAF)-containing ART regimen from weeks 0 to 96.
62020540|NCT02062502|EXPERIMENTAL|VARIVAX™ NSP + M-M-R II™|VARIVAX™ New Seed Process 0.5 mL administered in the left arm and M-M-R II™ vaccine 0.5 mL administered in the right arm by subcutaneous injection on Day 1 and Day 91
62020541|NCT02062502|ACTIVE_COMPARATOR|VARIVAX™ 2007 Process + M-M-R II™|VARIVAX™ 2007 Process 0.5 mL administered in the left arm and M-M-R II™ vaccine 0.5 mL administered in the right arm by subcutaneous injection on Day 1 and Day 91
62213975|NCT03309813|EXPERIMENTAL|Transcranial ExAblate|ExAblate Transcranial MR Guided Focused Ultrasound (MRgFUS)
62213976|NCT03309813|SHAM_COMPARATOR|Sham Transcranial ExAblate|ExAblate MRgFUS Sham Procedure
62584609|NCT05909878|ACTIVE_COMPARATOR|Standard Treatment|Standard Treatment used at the radiology department.
62213977|NCT01901432|EXPERIMENTAL|Givinostat|"In Part A patients will treated in dose levels at the following daily doses of Givinostat:~* 50 mg b.i.d.,~* 100 mg b.i.d.;~* 150 mg b.i.d.,~* 200 mg b.i.d.;~* 150 mg t.i.d.;~* 200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.~In Part B patients will be treated at the Maximum Tolerated Dose established in Part A.~The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each."
62213978|NCT03676491|EXPERIMENTAL|Experimental Group|"Music Intervention: Participants listen to music minimum 30 minutes at bedtime for a period of 4 weeks wearing accelerometer.~Participants are monitored for a 4 week follow up period wearing accelerometer"
62213979|NCT03676491|NO_INTERVENTION|Waitlist Control Group|"No intervention: Participants are monitored for a period of 4 weeks wearing accelerometer.~Participants are monitored for a 4 week follow up period wearing accelerometer."
62213980|NCT00762736|EXPERIMENTAL|Pioglitazone 15 mg QD + Azilsartan 5 mg QD|
62213981|NCT00762736|EXPERIMENTAL|Pioglitazone 15 mg QD + Azilsartan 40 mg QD|
62213982|NCT00762736|ACTIVE_COMPARATOR|Pioglitazone 15 mg QD|
62213983|NCT00762736|EXPERIMENTAL|Pioglitazone 45 mg QD + Azilsartan 5 mg QD|
62213984|NCT00762736|EXPERIMENTAL|Pioglitazone 45 mg QD + Azilsartan 40 mg QD|
62213985|NCT00762736|ACTIVE_COMPARATOR|Pioglitazone 45 mg QD|
62215270|NCT03535597|EXPERIMENTAL|Arm 2|QC pad with a Coban bandage to hold the pad in place to achieve hemostasis.
62409682|NCT05549986||Mortality group|Patients encountered in-hospital mortality or 30-day mortality
62409683|NCT05549986||Survival group|Patients did not encounter in-hospital mortality or 30-day mortality
62409684|NCT01504152||patients who received HSCT at MSKCC between 2005-2010|A self-administered patient questionnaire will be used to collect data that will assess the prevalence of international travel after HSCT and travel related morbidity and exposure risks among HSCT recipients.
62409685|NCT04717934|EXPERIMENTAL|GAL1906|Experimental product for correction of wrinkles
62020542|NCT03499158||1|affected arms of patients who had gone to electrodiagnostic study and diagnosed as carpal tunnel syndrome
62020543|NCT03499158||2|healthy arms of patients who had gone to electrodiagnostic study and diagnosed as carpal tunnel syndrome in the other arms
62409686|NCT04717934|NO_INTERVENTION|Control|No treatment control
62409687|NCT01301248|ACTIVE_COMPARATOR|Radiotherapy/Cisplatin(GroupA)|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)
62409688|NCT01301248|EXPERIMENTAL|Radiotherapy/Cisplatin/Cetuximab(GroupB)|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
62409689|NCT01320176|EXPERIMENTAL|Group A|Subjects received dose A of the investigational HIV vaccine
62409690|NCT01320176|EXPERIMENTAL|Group B|Subjects received dose B of the investigational HIV vaccine
62409691|NCT01640964|EXPERIMENTAL|Part A: Terlipressin acetate|Patients received terlipressin acetate 2 mg intravenous (IV) bolus injection.
62409692|NCT01640964|EXPERIMENTAL|Part A: Serelaxin (RLX030)|Randomized patients received an intravenous serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min.; duration of infusion depends on time required for completion of magnetic resonance angiography (MRA) data acquisition
62409693|NCT01640964|EXPERIMENTAL|Part B Serelaxin (RLX030)|The patients enrolled in this part of the study received an intravenous (iv) serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min; duration of infusion depends on time required for completion of Portal pressure gradient (PPG) data acquisition.
62409694|NCT03004430|EXPERIMENTAL|MAM|Mantra Meditation Group
62409695|NCT03004430|ACTIVE_COMPARATOR|PMR|Progressive Muscle Relaxation Group
62409696|NCT03330977|OTHER|Before and after use of compression garments|"At inclusion, patients will only have medication prescription as usual but without compression garments, and thus, for 4 months.~4 months after inclusion, patients will continue medication but will also be prescribed compression garments Then every 6 months, until 26 months, patients will come back to have new compression garments (as usual practice)"
62409697|NCT01014754||NSF|Biopsy-proven diagnosis of NSF
62409698|NCT01014754||Kidney dysfunction plus gadolinium exposure|Those on dialysis or with eGFR ≤ 30 ml/min/1.73 m2 who have had a medical imaging procedure using GBCA in the 2 years prior to skin biopsy.
62020544|NCT02511249||cohort|"1 evaluation day : The evaluation team included a neuropsychologist, a speech therapist and either a pediatric neurologist or a pediatric physical and rehabilitation medicine practitioner.~tests carried out : Global intellectual functioning (WISC-IV), Oral language (N-EEL), Gross and fine motor abilities (clinical examination, Box \& Block test, 9 Hole Peg test)"
62215271|NCT03535597|EXPERIMENTAL|Arm 3|QC pad with a Tegaderm dressing to hold the pad in place to achieve hemostasis.
62409699|NCT01014754||Kidney dysfunction without gadolinium exposure|Those on dialysis or with eGFR ≤ 30 ml/min/1.73 m2 who have never been exposed to GBCA and have had skin biopsy.
62409700|NCT01014754||Normal kidney function with gadolinium exposure|Those with normal kidney function who have undergone a medical imaging procedure using Gd-based contrast agent (GBCA) in the 2 years prior to a skin biopsy.
62409701|NCT01014754||Normal kidneys without gadolinium exposure|Those with normal kidney function who have never been exposed to GBCA and have had a skin biopsy.
62409702|NCT01014754||Controls|Existing skin tissue from neonatal skin (\<6 months) will be used as controls, as they presumably have never been exposed to gadolinium
62409703|NCT00798161|EXPERIMENTAL|BI 1356 + metformin|BI 1356 low dose + metformin 500 mg, twice daily
62409704|NCT00798161|PLACEBO_COMPARATOR|matching placebo|matching placebo
62584610|NCT04094987|EXPERIMENTAL|Quadratus Lumborum block|We will use the ultrasound guided anterior Quadratus Lumborum Block.A peripheral nerve block catheter will be placed between the quadratus lumborum muscle and the psoas muscle with ultrasound
62584611|NCT04579523|EXPERIMENTAL|Arm A (²¹¹At-OKT10-B10, fludarabine, TBI, HCT)|"Patients with HLA-matched related or unrelated donors receive ²¹¹At-OKT10-B10 IV on day -7 (day -10 to -5) and fludarabine IV over 30 minutes on days -4 to -2. Patients then undergo TBI and allogeneic HCT on day 0.~Additionally, patients undergo x-rays on study, and blood sample collection, bone marrow biopsy, and bone marrow aspiration throughout the study."
62020545|NCT02157558|EXPERIMENTAL|All subjects|All subjects will receive a single oral dose of fexofenadine on Day 1 while fasting. Days 2 to 5 will be Washout days. On Day 6, subjects will begin a 5 day telotristat etiprate regimen. On Day 10 subjects will be given the morning telotristat etiprate dose concomitantly with a single dose of fexofenadine while fasting.
62020546|NCT01665235|ACTIVE_COMPARATOR|amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
62409705|NCT00798161|EXPERIMENTAL|BI 1356+ Metformin|BI 1356 low dose + metformin 1000 mg, twice daily
62409706|NCT00798161|ACTIVE_COMPARATOR|Metformin|Metformin 500 mg, twice daily
62409707|NCT00798161|ACTIVE_COMPARATOR|metformin|Metformin 1000 mg, twice daily
62409708|NCT00798161|EXPERIMENTAL|BI 1356|BI 1356 high dose, once daily
62409709|NCT06207656|EXPERIMENTAL|cetuximab in combination with encorafenib plus binimetinib (EBC)|"Patients will receive the following per 28-day cycle:~* Encorafenib: 300 mg (4 × 75 mg oral capsule) daily (QD)~* Binimetinib: 45 mg (3 × 15 mg oral tablet) twice daily (BID)~* Cetuximab: 500 mg/m2 every 2 weeks as per standard institutional practice."
62409710|NCT04760639||Test group|Participants who have a positive Covid-19 Test or negative Covid-19 test who provide a breath sample.
62409711|NCT00660855|OTHER|Arm 1|
62409712|NCT01443676|ACTIVE_COMPARATOR|Radiotherapy|Radiotherapy
62409713|NCT01443676|EXPERIMENTAL|Radiotherapy plus Bevacizumab|Radiotherapy plus Bevacizumab
62409714|NCT03930615|EXPERIMENTAL|Letermovir|Participants who received HSCT transplant and 100 days of LET prophylaxis were randomized to an additional 100 days of LET (480 mg once daily alone or 240 mg once daily for participants on cyclosporin A) treatment.
62409715|NCT03930615|PLACEBO_COMPARATOR|Placebo|Participants who received HSCT transplant and 100 days of LET prophylaxis were randomized to an additional 100 days of placebo treatment.
62409716|NCT06652087|EXPERIMENTAL|intervention group|Patients of the experimental group will receive standart therapy HFpEF and rifaximin (Alfa Normix®, Alfa Wassermann S.P.A., Italy, registration number LS-001993, 08/31/2010) at a dose of 200 mg 3 times a day for 7 days.
62409717|NCT06652087|ACTIVE_COMPARATOR|control group|Patients of the control group will receive standart therapy HFpEF Without Rifaximin
62020547|NCT01665235|EXPERIMENTAL|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
62213986|NCT01125514|EXPERIMENTAL|Furosemide 60 mg|Treatment period 1 (Day 1 to Day 7): All eligible patients received 60 mg furosemide, 150 mg placebo of aliskiren, and 300 mg placebo aliskiren once daily.
62409718|NCT06167759|EXPERIMENTAL|Opioid Use Agreement|Patients in this group will be administered a safe opioid use agreement by the research coordinator. This agreement is in addition to any routine education and counseling provided by the surgical team.
62584612|NCT04579523|EXPERIMENTAL|Arm B (²¹¹At-OKT10-B10, chemotherapy, TBI, HCT)|"Patients with HLA-matched haploidentical donors receive ²¹¹At-OKT10-B10 IV on day -8 (day -14 to -7), fludarabine IV over 30 minutes on days -6 to -2, and cyclophosphamide IV over 1 hour on day -6 and -5. Patients then undergo TBI on day -1 and allogeneic HCT on day 0.~Additionally, patients undergo x-rays on study, and blood sample collection, bone marrow biopsy, and bone marrow aspiration throughout the study."
62020548|NCT03217045||Before Protocol|72 premature infants born between 26 and 32 weeks gestation, over 6 months period, and involved before the introduction of a strict nutrition protocol
62213987|NCT01125514|EXPERIMENTAL|Furosemide 60 mg + Aliskiren 150 mg|Treatment Period 2 (Day 8 to day 17): Patients received 60 mg furosemide, 150 mg aliskiren and 300 mg placebo once daily.
62213988|NCT01125514|EXPERIMENTAL|Furosemide 60 mg + Aliskiren 300 mg|Treatment Period 3 (Day 18 to day 27): Patients received 60 mg furosemide, 300 mg aliskiren and 150 mg placebo of aliskiren once daily.
62213989|NCT05593445|EXPERIMENTAL|Ruxolitinib cream|Ruxolitinib 1.5% cream BID for 12 weeks followed by ruxolitinb 1.5% cream BID (or QD) for 12-weeks in an open-label extension.
62213990|NCT05593445|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle cream BID for 12 weeks followed by ruxolitinb 1.5% cream BID (or QD) for 12-weeks in an open-label extension.
62213991|NCT00393783|EXPERIMENTAL|1|HER2 ECD DNA.
62213992|NCT00105599|OTHER|Arm 1|
62213993|NCT02614456|EXPERIMENTAL|Interferon-gamma and nivolumab|"Interferon-gamma (IFN-γ): starting dose 50 mcg/m2 subcutaneously Nivolumab: 3 mg/kg intravenously~Induction phase: IFN-γ every other day alone for 1 week Combination phase: IFN-γ every other day \& Nivolumab every 2 weeks for 3 months Single agent phase: Nivolumab every 3 weeks up to 1 year"
62213994|NCT01330732||1|Main group: patients examined in scoliosis clinic for kyphosis with recent lateral spine X-rays.
62213995|NCT02103244|EXPERIMENTAL|carboplatin|An adjusted dosing algorithm will be applied to calculate the dose of carboplatin. in 24 patients blood will be obtained in order to determine the pharmacokinetics of carboplatin after adjusted dosing
62213996|NCT01384266||Subjects undergoing Cataract Surgery|Subjects undergoing routine cataract surgery
62213997|NCT02551718|EXPERIMENTAL|Treatment (chemosensitivity testing, chemotherapy)|Leukemia cells purified from blood or bone marrow samples are analyzed for sensitivity to individual drugs and drug combination and by next generation sequencing.
62213998|NCT05854095|EXPERIMENTAL|Pivot Bridge|transcatheter for short-term treat Functional Tricuspid regurgitation
62213999|NCT01327443|OTHER|Weight loss|10% weight loss in 24 weeks time period through nutritional counseling.
62214000|NCT01327443|ACTIVE_COMPARATOR|Exercise without weight loss|24 weeks under direct supervision.
62409719|NCT06167759|NO_INTERVENTION|Standard of Care|Patients in this group will receive standard care which includes safe opioid education from the surgical care team.
62409720|NCT05704946|EXPERIMENTAL|experiment group|The patients will be given a standard brand of lavender oil by the researcher, and they will be informed about how to use it (they should drop 2 drops of lavender oil on the right side of their pillow and 2 drops on the left side of their pillow every evening for a month after discharge).
62409721|NCT05704946|NO_INTERVENTION|control group|Standard care will be applied.
62409722|NCT05921370|EXPERIMENTAL|Silodosin group (the intervention group)|Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.
62409723|NCT05921370|PLACEBO_COMPARATOR|Placebo group (the control group)|Patients will receive Placebo for 7 days before their scheduled retrograde intrarenal surgery.
62409724|NCT03635021|EXPERIMENTAL|Sequence 1|FOLFOX regimen panitumumab FOLFIRI regimen bevacizumab
62409725|NCT03635021|EXPERIMENTAL|Sequence 2|FOLFOX regimen bevacizumab FOLFIRI regimen panitumumab
62409726|NCT06455163|EXPERIMENTAL|Eerder Erbij (intervention group)|"Informal caregivers and people with dementia assigned to the intervention group will receive the 6-week intervention Eerder Erbij."
62020549|NCT03217045||After Protocol|86 premature infants born between 26 and 32 weeks gestation, over 6 months period, and involved after the introduction of a strict nutrition protocol and a washout period of 6 months
62214001|NCT01327443|NO_INTERVENTION|Control|No change in usual exercise levels or food intake.
62214002|NCT05145140|ACTIVE_COMPARATOR|Standardized Western Medicine Treatment Group|All participants undergo a similar treatment protocol for the diabetic foot, based on the Infectious Diseases Society of America (IDSA).
62214003|NCT05145140|EXPERIMENTAL|Standardized Western Medicine Treatment +TNTL tablet+TNTL cream Group|Treatment with TNTL tablets:the oral administration of TNTL tablets, 4 tablets each time, 3 times a day. Treatment with TNTL cream: topical application of sterile TNTL cream on the wound surface, the dressing is continuously changed according to the wound healing.
62214004|NCT05145140|EXPERIMENTAL|Standardized Western Medicine Treatment +TNTL tablet Group|Treatment with TNTL tablets:the oral administration of TNTL tablets, 4 tablets each time, 3 times a day.
62214005|NCT05145140|EXPERIMENTAL|Standardized Western Medicine Treatment +TNTL cream Group|Treatment with TNTL cream: topical application of sterile TNTL cream on the wound surface, the dressing is continuously changed according to the wound healing.
62214006|NCT04278859|EXPERIMENTAL|0.3mg/kg repeat dose every 21 days up to 2 years|
62214007|NCT04278859|EXPERIMENTAL|1 mg/kg repeat dose every 21 days up to 2 years;|
62214008|NCT04278859|EXPERIMENTAL|3 mg/kg repeat dose every 21 days up to 2 years;|
62214009|NCT04278859|EXPERIMENTAL|10 mg/kg repeat dose every 21 days up to 2 years;|
62214010|NCT03383822|EXPERIMENTAL|Intranasal insulin|40 IU of intranasal insulin
62214011|NCT03383822|PLACEBO_COMPARATOR|Intranasal placebo|Placebo comparator to intranasal insulin
62214012|NCT03462173|EXPERIMENTAL|30 mg single dose|Healthy subjects, receiving a single dose of 30 mg yimitasvir(N=6) or placebo(N=2)
62214013|NCT03462173|EXPERIMENTAL|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg yimitasvir (N=6) or placebo(N=2)
62020550|NCT04848285|ACTIVE_COMPARATOR|Standard care group|Standard of care (SC) mobility protocol performed by the Stroke Unit nursing and physiotherapy staff. The SC consists of one or two sessions per days of out-of-bed sitting and standing, adapted to patient´s tolerability, and one session of physiotherapy per day. Mobilization will be schedule to start from 24 hours from symptoms onset according to the local Stroke Unit protocol.
62584613|NCT06144125|ACTIVE_COMPARATOR|fresh frozen plasma|according to the Rotational thromboelastometry (ROTEM) test, CT-EXTEM prolongation, fresh frozen plasma transfusion (FFP) is performed
62584614|NCT06144125|EXPERIMENTAL|prothrombin complex concentrate|according to the Rotational thromboelastometry (ROTEM) test, CT-EXTEM prolongation, prothrombin complex concentrate (PCC) is administered
62214014|NCT03462173|EXPERIMENTAL|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg yimitasvir (N=6) or placebo(N=2)
62214015|NCT03462173|EXPERIMENTAL|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg yimitasvir (N=6) or placebo(N=2)
62214016|NCT03462173|EXPERIMENTAL|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg yimitasvir (N=6) or placebo(N=2)
62214017|NCT03462173|EXPERIMENTAL|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg yimitasvir (N=6) or placebo(N=2)
62214018|NCT03462173|EXPERIMENTAL|1000 mg single dose|Healthy subjects, receiving a single dose of 1000 mg yimitasvir (N=6) or placebo(N=2)
62214019|NCT05573880|EXPERIMENTAL|generalized joint hypermobility|
62214020|NCT05573880|EXPERIMENTAL|without generalized joint hypermobility|
62214021|NCT03114800|EXPERIMENTAL|E-Scale|Weight monitoring
62214022|NCT04398290|EXPERIMENTAL|iNOpulse Treatment Group|Participants in this group will receive iNO delivered continuously together with supplemental oxygen by nasal cannula during hospitalization for up to 28 days.
62584615|NCT06683703|EXPERIMENTAL|Stage 1 Safety run-in|Utidelone + Bevacizumab
62584616|NCT06683703|EXPERIMENTAL|Stage 1 Extension: Monotherapy group|Utidelone
62214023|NCT04398290|ACTIVE_COMPARATOR|Placebo Group|Participants in this group will receive nitrogen gas delivered continuously together with supplemental oxygen by nasal cannula during hospitalization for up to 28 days
62214024|NCT01147276|EXPERIMENTAL|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
62214025|NCT04439162|EXPERIMENTAL|group A|antegrade cardioplegia
62584617|NCT06683703|EXPERIMENTAL|Stage 1 Extension: Combined treatment group|Utidelone+ Bevacizumab
62584618|NCT06683703|EXPERIMENTAL|Stage 2|Utidelone + Bevacizumab
62584619|NCT01232686|NO_INTERVENTION|Control area|In the control areas we will monitor the prevalence and treatment of communicable diseases without giving the participants online access to disease surveillance information
62584620|NCT01232686|EXPERIMENTAL|Intervention area|In these areas we will give study participants online access to epidemiological data for communicable diseases
62584621|NCT01376661||Active Surveillance/ Prostate Cancer|
62020551|NCT04848285|EXPERIMENTAL|Intensive mobilization group|The Intensive mobilization intervention will include the standard care plus at least two additional sessions each day of at least 20 minutes each session focused on task specific sitting, standing and walking activities. The intervention will be schedule to start at 24 hours from symptoms onset and will last 14 days or until the patient is discharged.
62020552|NCT04174092|EXPERIMENTAL|rheumatoid arthritis|Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (RAID, RAPID-3) Patients will be seen at 3, 6 and 12 months
62020553|NCT04174092|EXPERIMENTAL|spondyloarthritis|"Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI).~Patients will be seen at 3, 6 and 12 months"
62409727|NCT06455163|NO_INTERVENTION|Usual/standard care (control group)|"Participants in the comparison condition will continue to receive usual care. Care for people with dementia in the Netherlands varies across municipalities, but the majority lives at home and especially earlier stages of the disease, most people living with dementia and their informal caregivers use no or very little formal care, apart from occasional visitors to GP or by case manager.~The control group will be shared with another collaborating study from 'Maastricht University', which has the same goals, applies the same inclusion criteria, applies the same study procedures, and obtains the same outcomes. This implies that the data of the participants recruited for the control group for this study will be shared with the collaborating study."
62409728|NCT06650670|PLACEBO_COMPARATOR|Control group|Control group that will receive two capsules with the maltodextrin per day during 12 weeks
62409729|NCT06650670|EXPERIMENTAL|EPP group|Experimental group that will receive two capsules with the bioactive compound per day during 12 weeks
62409730|NCT04007393|OTHER|LSMT x 12 weeks|Participants in this arm will start LSMT at baseline and have a weight loss response assessment at T=12 weeks: if body mass index (BMI) is down 5% at T=12 weeks, the participant will continue with LSMT for the remainder of the study (i.e. for another 36 weeks); if BMI is not down 5% at T=12 weeks, the participant will add phentermine to LSMT (phentermine+LSMT) and undergo a second weight loss response assessment after 12 weeks of phentermine+LSMT; i.e. at T=24 weeks. At T=24 weeks, if BMI is down 5% with phentermine+LSMT, the participant will continue with phentermine+LSMT for the the remainder of study (i.e. for another 24 weeks); if BMI is not down by 5% at T=24 weeks, the participant will be randomized to topiramate+phentermine+LSMT or topiramate+placebo+LSMT for the remainder of the study (i.e. for another 24 weeks).
62409731|NCT04007393|OTHER|LSMT x 24 weeks|Participants in this arm will start LSMT at baseline and have a weight loss response assessment at T=24 weeks: if body mass index (BMI) is down 5% at T=24 weeks, the participant will continue with LSMT for the remainder of the study (i.e. for another 24 weeks); if BMI is not down 5% at T=24 weeks, the participant will add phentermine to LSMT (phentermine+LSMT) and undergo a second weight loss response assessment after 12 weeks of phentermine+LSMT; i.e. at T=36 weeks. At T=36 weeks, if BMI is down 5% with phentermine+LSMT, the participant will continue with phentermine+LSMT for the the remainder of study (i.e. for another 12 weeks); if BMI is not down by 5% at T=36 weeks, the participant will be randomized to topiramate+phentermine+LSMT or topiramate+placebo+LSMT for the remainder of the study (i.e. for another 12 weeks).
62409732|NCT03574818|EXPERIMENTAL|Arm 1|"Chemotherapy and Necitumumab Regimen Gemcitabine 1250mg/m2 IV over 30 minutes, days 1 and 8 following necitumumab, Cisplatin 75mg/m2 IV over 60 minutes, day 1, immediately following gemcitabine,each cycle is 3 weeks (21 days).~Necitumumab 800mg absolute dose IV over a minimum of 60 minutes, days 1 and 8 prior to chemotherapy regimen Each cycle is 3 weeks (21 days).~The regimen will be given for a total of 3 cycles.~The regimen will be given for a total of 3 cycles."
62409733|NCT06353217|OTHER|Patient Involvement|Patients who participate in the study will undergo one Baseline Clinic Visit (baseline usual care), and one Intervention clinic visit.
62214026|NCT03230877|EXPERIMENTAL|Group A|"Participants will be randomized to receive either the Improved Seal or Normal Seal Toffee full face mask for a total of 7 ± 4 days from visit 1. At visit 2 they will return the first mask and be switched to the remaining mask for a total of 7 ± 4 days from visit 2."
62214027|NCT03230877|EXPERIMENTAL|Group B|"Participants will be randomized to receive either the Improved Seal or Normal Seal Toffee full face mask for a total of 7 ± 4 days from visit 1. At visit 2 they will return the first mask and be switched to the remaining mask for a total of 7 ± 4 days from visit 2."
62214028|NCT02816775|ACTIVE_COMPARATOR|Group Laryngoscope|Group Laryngoscope; intubation will be made by Macintosh laryngoscope
62214029|NCT02816775|ACTIVE_COMPARATOR|Group Videolaryngoscope|Group Videolaryngoscope; intubation will be made by McGRATH Videolaryngoscope
62214030|NCT06049225|EXPERIMENTAL|Experimental: High-Tech Intervention Group|Those in the high-tech intervention group will receive 6 months of active intervention (up to 60 minutes weekly health coaching calls and content delivery) and technology access.
62214031|NCT06049225|EXPERIMENTAL|Experimental: Low-Tech Intervention Group|Those in low-tech group will receive 6 months of one weekly coaching calls (last up to 60 minutes) and one weekly email
62214032|NCT06049225|ACTIVE_COMPARATOR|Active Comparator: Attention Control Group|The control group will be used to provide an untreated comparison for the intervention groups and will not receive MNT or technology support. Participants in the control arm will only get a baseline and post-intervention testing.
62214033|NCT04174898|EXPERIMENTAL|Treatment Population|100 million human MSCs in 200mls of normal saline, intravenously, once-off, over 1-2hours
62214034|NCT02272296|ACTIVE_COMPARATOR|Jet Injector_main study|Administration of insulin or placebo injection in main study
62214035|NCT02272296|PLACEBO_COMPARATOR|conventional pen, NovoPen IV|Administration of insulin or placebo injection in main study
62214036|NCT02272296|ACTIVE_COMPARATOR|jet injector_sub study|Administration of insulin or placebo injection in sub study
62214037|NCT02998580|ACTIVE_COMPARATOR|Convential Sequential Bilateral rTMS|"LFR followed by HFL.~1 Hz stimulation of the right DLPFC for 600 pulses followed by 10 Hz stimulation of the left DLPFC for 3000 pulses (4 seconds on 26 seconds off for 75 trains). Treatment will occur 5 times per week for 4 to 6 weeks."
62214038|NCT02998580|EXPERIMENTAL|Bilateral Theta Burst Stimulation|"cTBS followed by iTBS.~continuous theta burst stimulation (cTBS) of the right DLPFC for 600 pulses followed by intermittent theta burst stimulation (iTBS) of the left DLPFC for 600 pulses. Treatment will occur 5 times per week for 4 to 6 weeks."
62214039|NCT00777088|EXPERIMENTAL|Pipeline|Placement of Pipeline Embolization Device in the parent artery at the aneurysm location
62214040|NCT02796300|ACTIVE_COMPARATOR|Bioflo Goup|This group will have dialysis using the Bioflo catheter.
62214041|NCT02796300|ACTIVE_COMPARATOR|Palindrome Group|This group will have dialysis using the Palindrome catheter.
62215272|NCT03535597|EXPERIMENTAL|Arm 4|QC pad with a TR Band to hold the pad in place to achieve hemostasis.
62214042|NCT04229875|EXPERIMENTAL|CAG Bipolar|"1. Patients will be treated in a localized CAG Bipolar clinic within each psychiatric centre increasing the number of bipolar patients for each clinician~2. All clinicians will get certified in diagnosing and treating bipolar disorder by joining an educational course and ongoing courses continuously~3. Treatment will include a group-based psychoeducation program~4. Coordinated targets to improve quality of life of patients by increasing concordance between clinicians, patients and relatives on well-defined treatment goals~5. Continued ongoing supervision of patient cases in CAG Bipolar staff by the Copenhagen Affective Disorder Clinic~6. Three-month bidirectional exchange of two clinical staff members between the Copenhagen Affective Disorder Clinic and each CAG Bipolar clinic~7. Recovery mentors"
62214043|NCT04229875|NO_INTERVENTION|Control group|Standard treatment
62214044|NCT05785377|PLACEBO_COMPARATOR|Bupivacaine group (Group-B)|After cession section, patients Will receive ultrasound (US)-guided bilateral TAP block with 20 mL bupivacaine 0.25% plus 1 mL of normal saline (Total volume of 21mL in each side
62409734|NCT06353217|OTHER|Primary Care Physician (PCP) Involvement|PCPs will be given access to the Hypoglycemia Prevention toolkit
62214045|NCT05785377|ACTIVE_COMPARATOR|Bupivacaine-Neostigmine group (Group-BN)|After cession section, patients Will receive ultrasound (US)-guided bilateral TAP block with 20 mL bupivacaine 0.25% plus 1 mL of 500 mcg neostigmine (Total volume of 21mL in each side
62020554|NCT04174092|EXPERIMENTAL|Psoriatic arthritis|"Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI).~Patients will be seen at 3, 6 and 12 months"
62214046|NCT03554668||1|Post total knee replacement patients
62409735|NCT06353217|OTHER|Clinic Staff Involvement|
62409736|NCT01284413|EXPERIMENTAL|S-1, Gemcitabine, Cisplatin|
62409737|NCT06565884|EXPERIMENTAL|Home radiofrequency skin treatment instrument|Radiofrequency skin therapy instrument with medical ultrasound coupler is used for 20 minutes a day, 5 days a week
62214047|NCT02101385|EXPERIMENTAL|Arm A (Genomically Directed Monotherapy)|Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). Clinical and laboratory monitoring and dose-reductions will follow the FDA package insert guidelines.
62214048|NCT02101385|OTHER|Control Arm B (Observation/Standard Therapy)|Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
62215273|NCT01394978|OTHER|Control|No treatment.
62215274|NCT01394978|EXPERIMENTAL|ProGEL Pleural Air Leak Sealant with standard surgical closure|Standard surgical closure (suturing or stapling of visible air leaks incurred during resection of lung parenchyma) plus Progel Pleural Air Leak Sealant.
62409738|NCT06565884|PLACEBO_COMPARATOR|Medical ultrasound coupler|Medical ultrasound coupler is applied to the face for 20 minutes a day, 5 days a week
62409739|NCT06522360|EXPERIMENTAL|Brigatinib Monotherapy|Given by mouth
62409740|NCT06522360|EXPERIMENTAL|Brigatinib + Carboplatin + Pemetrexed|Given by vein
62409741|NCT06522360|EXPERIMENTAL|Brigatinib + Local Consolidation Therapy (LCT)|Given by vein
62584622|NCT06659705|EXPERIMENTAL|Prospective cohort involving repeated medical imaging with a new radiotracer (FAPI)|All patients of this study must have been previously enrolled in the HoMING cohort (NCT 04363983, sponsor APHP).
62584623|NCT03024684|EXPERIMENTAL|Statin|Atorvastatin 10mg oral once daily
62584624|NCT03024684|PLACEBO_COMPARATOR|Placebo|Matched placebo (sugar pill) once daily
62584625|NCT05087810||Subjects|All subjects will undergo accelerated oral hydration to induce diuresis and then acute psychological stress tasks to induce acute stress. Outcomes will measure changes to perceived bladder sensation in response to acute stress provocation.
62214049|NCT06259552|EXPERIMENTAL|Part 1: Dose escalation and expansion study of SPX-303|"Dose Escalation Phase: SPX-303 will be administered intravenously (IV) every 3 weeks (Q3W). Participants enroll with measurable disease who have progressed on or after prior therapy and who are not eligible or decline treatment options.~Dose Expansion phase: SPX-303 will be administered at the dose level chosen during the escalation phase in the dose expansion cohort."
62214050|NCT06259552|EXPERIMENTAL|Part 2: Dose expansion study of SPX-303 in specific indications|SPX-303 will be administered in specific solid tumor patients to evaluate the preliminary antitumor activity and define the RP2D.
62584626|NCT05457218|EXPERIMENTAL|Whey protein|This arm will be given a supplemental dose of whey protein (0.25 g/kg body weight)
62584627|NCT05457218|EXPERIMENTAL|IPC80|This arm will be given a supplemental dose of IPC80, an insect-derived protein source (0.25 g/kg body weight)
62020555|NCT03830671|EXPERIMENTAL|investigational arm|the arm was given investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months.
62020556|NCT03421197|EXPERIMENTAL|PPC-06 400 mg QD|Tepilamide Fumarate 400 mg once per day
62020557|NCT03421197|EXPERIMENTAL|PPC-06 400 mg BID|Tepilamide Fumarate 400 mg twice per day
62020558|NCT03421197|EXPERIMENTAL|PPC-06 600 mg BID|Tepilamide Fumarate 600 mg twice per day
62214051|NCT00875602|NO_INTERVENTION|control|before-after (retrospective) and concurrent controls as comparators with a prospective intervention group
62020559|NCT03421197|PLACEBO_COMPARATOR|Placebo BID|White placebo tablet to mimic Tepilamide Fumarate
62020560|NCT01025713|EXPERIMENTAL|1|GS-9411 2.4 mg
62020561|NCT01025713|EXPERIMENTAL|2|GS-9411 4.8 mg
62020562|NCT01025713|PLACEBO_COMPARATOR|Placebo|Placebo
62214052|NCT00875602|ACTIVE_COMPARATOR|Study unit|Hospitalized patients in the study group will be continously monitored / supervised by the contact-free device
62214053|NCT05189392|NO_INTERVENTION|21 patients with opsite visible|application of visible opsite plaster on the surgical wound after hip arthroplasty
62214054|NCT05189392|EXPERIMENTAL|21 patients with PICO|application of PICO on the surgical wound after hip arthroplasty
62214055|NCT03866798|EXPERIMENTAL|Panzyga|Panzyga
62214056|NCT03927339||pre and post excercise group|
62584628|NCT05457218|EXPERIMENTAL|Whole Buffalo Powder|This arm will be given a supplemental dose of Whole Buffalo Powder, an insect-derived protein source (0.25 g/kg body weight)
62020563|NCT05928533|ACTIVE_COMPARATOR|Scotchbond Etchant gel ,Single Bond Universal adhesive , Filtek Supreme flowable composite of 3M|After cavity preparation, enamel and dentin will be etched for 15 seconds using Scotchbond Universal Etchant gel 3M. The surface will be rinsed for 10 seconds and dried with compressed air, removing all excess moisture without desiccating the dentin structure then apply two coats of Single Bond Universal adhesive 3M with a micro brush with rubbing action for 20 seconds then evaporate the solvent with gentle air stream until no movement is noticed in the adhesive then finally light cured for 10 seconds. A Filtek Supreme 3M flowable composite will be used to restore the prepared cavity after selecting the appropriate shade. The shade selection for the flowable composite will be done before the cavity preparation. The flowable composite will be applied in increments of 2mm thickness then light cured for 40 seconds using LED light curing unit.
62214057|NCT00156637|OTHER|Arm 1|
62214058|NCT00156637|ACTIVE_COMPARATOR|Arm 2|Dosing \& Side Effect Monitoring
62214059|NCT03235102||People with Obesity|People with obesity, or weight loss patients. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
62214060|NCT03235102||Healthcare Providers|PCPs will include family practitioners; general practitioners; internal medicine; nurse practitioners; and dietitians. Specialists will include endocrinologists and bariatric surgeons, and any of the above if they focus on obesity treatment. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
62214061|NCT03235102||Employers|Employers in Canada. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
62214062|NCT03888157||Liraglutide|Patients with type 2 diabetes in Iran are to receive Victoza® for 26 weeks.
62020564|NCT05928533|EXPERIMENTAL|clean and boost enamel cleanser, RE GEN universal adhesive & flowable composite of vista apex.|After cavity preparation, clean and boost enamel cleanser of vista apex will be used to clean enamel and dentin surface by three steps: 1. With the enclosed flow-thru brush tip, apply Clean \& Boost to the surface to be cleansed, ensuring the surface is completely saturated. 2. Using the delivery brush tip, agitate the Clean \& Boost on the surface for 10 seconds. 3. Rinse thoroughly. The RE GEN universal adhesive from vista apex will be applied with micro brush with rubbing action then air agitation. RE GEN Bio active flowable composite form vista apex will be added to the universal adhesive and then cured together for 20 seconds according to the manufacture instructions.
62020565|NCT04488731||NW/MCC|Normal body mass index (BMI) / with moderate coffee consumption
62214063|NCT05153720|EXPERIMENTAL|Ultrasound guided erector spinae plane block|Unilateral erector spinae plane block will be performed under ultrasound guidance
62409742|NCT05049902|EXPERIMENTAL|10-day treatment group|"Use the following drug combination option for 10 days. Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole + Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's situation.~The dosage of each drug is:~Amoxicillin (Amoxicillin, United Laboratories Co., Ltd.) 1000mg bid Clarithromycin (Klacid, Abbott S.r.l) 500mg bid Tetracycline 500mg qid Metronidazole400mg qid Bismuth Potassium Citrate (Livzon Pharmaceutical Group Inc.) 220mg bid Colloidal Bismuth Pectin (North China Pharmaceutical Co., Ltd.) 200mg bid Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid"
62020566|NCT04488731||NW/HCC|Normal body mass index (BMI) / with heavy coffee consumption
62020567|NCT04488731||OW/MCC|Overweight / with moderate coffee consumption
62020568|NCT04488731||OW/HCC|Overweight / with heavy coffee consumption
62020569|NCT04173533|PLACEBO_COMPARATOR|Control Group|Oral azacitidine (CC-486) matched placebo once daily for first 14 days of each 28 day cycle
62020570|NCT04173533|EXPERIMENTAL|Experimental Group|Oral azacitidine (CC-486) 200 mg once daily for first 14 days of each 28 day cycle
62214064|NCT05153720|ACTIVE_COMPARATOR|Ultrasound guided caudal block|Caudal block will be formed under ultrasound guidance
62214065|NCT04963790|EXPERIMENTAL|Tailored COVID-19 vaccine messaging|Based on the created segments of hesitant participants (reflecting age, language, education level, rurality, sex, gender, ethnicity, and attitudes or reasons for vaccine hesitancy) in the intervention group, a series of tailored messages that are meaningful to the recipients in the different segments will be created and sent to address the factors influencing the willingness to be vaccinated and persuade them to get the COVID-19 vaccine.
62214066|NCT04963790|ACTIVE_COMPARATOR|Other health-related messaging|Patients assigned to the control group will receive health messages unrelated to COVID-19.
62020571|NCT01921348|EXPERIMENTAL|Treatment|34 participants will be randomized to wear acupressure pellets in the designated acupressure points and apply pressure as instructed by the study personnel.
62020572|NCT01921348|SHAM_COMPARATOR|Sham|33 participants will be randomized to wear acupressure pellets in non-specific areas of the ear and apply pressure as instructed by the study personnel.
62020573|NCT03956602|ACTIVE_COMPARATOR|Pretzels|Subjects consume pretzels to examine postprandial response
62020574|NCT03956602|EXPERIMENTAL|Brazil nuts|Subjects consume Brazil nuts to examine postprandial response
62020575|NCT03956602|ACTIVE_COMPARATOR|Potato chips|Subjects consume potato chips to examine postprandial response
62020576|NCT03956602|EXPERIMENTAL|Mixed nuts|Subjects consume mixed nuts to examine postprandial response
62214067|NCT00105001|ACTIVE_COMPARATOR|Arm I (MMF and tacrolimus)|Patients receive tacrolimus IV or PO every 12 hours on days -3 to 180 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-96 with taper beginning on day 40 in the absence of GVHD.
62214068|NCT00105001|EXPERIMENTAL|Arm II (MMF and tacrolimus alternate schedule)|Patients receive tacrolimus IV or PO every 12 hours on days -3 to 150 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-180 with taper beginning on day 150 in the absence of GVHD.
62409743|NCT05049902|ACTIVE_COMPARATOR|14-day treatment group|"Use the following drug combination option for 14 days. Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole + Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's situation.~The dosage of each drug is:~Amoxicillin (Amoxicillin, United Laboratories Co., Ltd.) 1000mg bid Clarithromycin (Klacid, Abbott S.r.l) 500mg bid Tetracycline 500mg qid Metronidazole400mg qid Bismuth Potassium Citrate (Livzon Pharmaceutical Group Inc.) 220mg bid Colloidal Bismuth Pectin (North China Pharmaceutical Co., Ltd.) 200mg bid Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid"
62409744|NCT02760849|EXPERIMENTAL|Arm I (ISDO)|Patients undergo ISDO.
62214069|NCT00105001|EXPERIMENTAL|Arm III (MMF, tacrolimus, and sirolimus)|Patients receive tacrolimus and MMF as in arm II. Patients also receive sirolimus PO once daily on days -3 to 80.
62214070|NCT04306016|EXPERIMENTAL|Sensory stimulation|Participants allocated to the intervention group will receive a model-based sensory stimulation intervention, which is aimed at providing visual and auditory stimulation to ICU patients with additional support from family caregivers.
62214071|NCT04306016|NO_INTERVENTION|Usual care|Participants in the control group will receive usual care routine that they are receiving or planning to receive. The registered ICU nurses will provide the same nursing care as previously, including but not limiting to the use of sedation, analgesia, spontaneous breathing trial, indwelling catheter, feeding, and bowel care.
62409745|NCT02760849|ACTIVE_COMPARATOR|Arm II (RRSO)|Patients undergo RRSO.
62409746|NCT00514501|EXPERIMENTAL|Iodofiltic Acid I 123|
62020577|NCT03956602|ACTIVE_COMPARATOR|White bread|Subjects consume white bread to examine postprandial response
62020578|NCT03956602|EXPERIMENTAL|Dried mango|Subjects consume dried mango to examine postprandial response
62020579|NCT03956602|EXPERIMENTAL|Mango fruit|Subjects consume fresh mango to examine postprandial response
62214072|NCT04580927|EXPERIMENTAL|Randomized to breastfeeding self-efficacy enhancing intervention with nurse|Participants receiving breastfeeding self-efficacy enhancing nurse-led intervention plus postpartum standard of care consisting of postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment, routine postpartum hospital breastfeeding support, as-needed community breastfeeding support, and postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment.
62020580|NCT02398097|ACTIVE_COMPARATOR|Agripal|28 trivalent subunit inactivated intramuscular vaccine (Agripal) recipients: one vaccine injection administered on Day 0
62409747|NCT01696266||Insulin-treated patients with diabetes|
62409748|NCT01687777|ACTIVE_COMPARATOR|Mesenchymal stem cells (MSCs)|Mesenchymal stem cells with a collagen type I membrane (OrthoADAPT)
62409749|NCT01687777|PLACEBO_COMPARATOR|OrthADAPT|Membrane of collagen type I (OrthoADAPT)
62409750|NCT06173674|EXPERIMENTAL|Music intervention|The music intervention will consist of three components, including 1) playlist composition, 2) music intervention delivery, and 3) cleaning or disinfection of the equipment.
62409751|NCT05263804|OTHER|Cohort group|Patient over 18 with an ischemic stroke
62409752|NCT05263804|EXPERIMENTAL|Ancillary study group|Patient over 18 with an ischemic stroke
62020581|NCT02398097|ACTIVE_COMPARATOR|IDflu9μg|30 reduced-content intradermal split vaccine (IDflu9μg) recipients: one vaccine injection administered on Day 0
62020582|NCT02398097|ACTIVE_COMPARATOR|IDflu15μg|28 standard-content intradermal split vaccine (IDflu15μg) recipients: one vaccine injection administered on Day 0
62020583|NCT03594994|NO_INTERVENTION|Control|Normal sleep habits \< 7h
62020584|NCT03594994|EXPERIMENTAL|Sleep Extension|Extend time-in-bed by one hour
62020585|NCT01084044|EXPERIMENTAL|ulinastatin|
62020586|NCT01084044|ACTIVE_COMPARATOR|saline solution|
62020587|NCT01084044|PLACEBO_COMPARATOR|Sugar pill|
62214073|NCT04580927|NO_INTERVENTION|Randomized to usual postpartum care|Participants receiving postpartum standard of care consisting of postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment, routine postpartum hospital breastfeeding support, as-needed community breastfeeding support, and postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment.
62214074|NCT04580927|NO_INTERVENTION|Non-randomized observational arm|Participants who are not planning to breastfeed receiving postpartum standard of care consisting of postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment.
62214075|NCT00967031|EXPERIMENTAL|Lapatinib + capecitabine|lapatinib 1250mg/day + capecitabine 2000mg/m2/day
62214076|NCT04913389|ACTIVE_COMPARATOR|Acetazolamide|Acetazolamide (oral capsules)
62214077|NCT04913389|PLACEBO_COMPARATOR|Placebo|Placebo (oral capsules)
62791220|NCT00960492|EXPERIMENTAL|MTD Expansion|XL184 will be initiated at the start of the 6-7 week concurrent phase of RT (+TMZ; some subjects found to have specific gene activity in their tumor tissue may not receive TMZ), given as a single agent in the rest phase (4 weeks), if applicable, and continued subsequently in the maintenance phase. Subjects in this group will receive XL184 and TMZ at the maximally tolerated dose levels determined in Arms 1 and 2.
62584629|NCT06049966|EXPERIMENTAL|Arm A|Carboplatin 5 AUC D1 plus Etoposide 100mg/m2 D1-D3 plus Atezolizumab 1200 mg, Q21, 4 Cycles and then maintenance Atezolizumab 1200 mg Q21
62791221|NCT01002183|NO_INTERVENTION|single arm|Fos-clin/Arte
62214078|NCT02402673|OTHER|Intervention|
62214079|NCT02422017|EXPERIMENTAL|Timolol|Patients will receive one drop of timolol every 6cm ² every other day for twelve weeks in combination with dressings and compression.
62584630|NCT06049966|ACTIVE_COMPARATOR|Arm B|Carboplatin 5 AUC D1 plus Etoposide 100mg/m2 D1-D3, 4 Cycles and then observation
62791222|NCT04807218|ACTIVE_COMPARATOR|Nutritional Ketosis Intervention Referral|The comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management is the Virta treatment, and while on this treatment, subjects will have access to Virta health coaches and licensed medical providers who will perform medical therapy management, health coaching, nutrition and behavior change education, biometric feedback, and the option to participate in a community for peer support.
62214080|NCT02422017|OTHER|Control|Local care treatment only (dressing and compression applied every other day)
62214081|NCT01569672|ACTIVE_COMPARATOR|Intervention Clinic|Patient Navigator matched with subjects. Patient Navigators will be matched with subjects at the intervention clinics and will assist patients with questions, issues or concerns with their cancer treatment/diagnosis or abnormal test results and followup test or treatments
62584631|NCT04121065||Relapsing MS patients|Single Arm: Relapsing Multiple Sclerosis patients ADA SNPs and other biomarkers analyses in blood samples.
62584632|NCT06682767|EXPERIMENTAL|FMD - Intervention|Participants in the FMD group will be asked to refrain from consuming any calorie-containing foods or drinks other than the provided study foods/drinks during the designated intervention days each month.
62584633|NCT06682767|NO_INTERVENTION|Normal Diet - Control|Participants in the normal diet group will be asked to consume their regular diet.
62791223|NCT04807218|ACTIVE_COMPARATOR|CHHS Standard Care - Delayed Referral to Nutritional Ketosis Intervention|All subjects will be enrolled in Colorado Heart Healthy Solutions (CHHS), which consists of community health worker (CHW) contact and sessions on: 1) cardiovascular disease knowledge; 2) Health behavior change through skill building to improve diet (e.g., portion sizes, increasing fruit/vegetable intake, reducing intake of sugar sweetened beverages, decreasing fast food meals, etc.), increase physical activity, and improve well-being, tailored to individual subjects' risk profile and self-identified goals; and 3) Connection to services including primary care, mental health services if needed, and relevant community programs to address barriers (e.g. food insecurity, need for legal help) or to promote behavior change (e.g. free/low cost exercise programs).
62214082|NCT01569672|PLACEBO_COMPARATOR|Control Clinics|Subjects are mailed informational/educational materials.
62214083|NCT03277092|EXPERIMENTAL|VeinViewer® group|Use of near infrared light to perform blood draw (VeinViewer®)
62214084|NCT03277092|ACTIVE_COMPARATOR|Usual care group|Blood drawing performed traditionally
62214085|NCT05155176||Individuals with Alcohol Use Disorder|Participants who meet the criteria for Alcohol Use Disorder will complete six weeks of smartphone monitoring. During this monitoring period, they will also complete two three-consecutive days of intensive monitoring including more frequent smartphone surveys, saliva samples, heart rate monitoring, and an alcohol use monitor.
62215275|NCT01394978|EXPERIMENTAL|ProGEL Pleural Air Leak Sealant without standard surgical closure|Progel Pleural Air Leak Sealant without standard surgical closure (without suturing or stapling of visible air leaks incurred during resection of lung parenchyma).
62584634|NCT06167733|EXPERIMENTAL|Active|
62214086|NCT05155176||Social drinkers|Participants who have a past year history of alcohol use and do not meet the criteria for Alcohol Use Disorder will complete two weeks of smartphone monitoring. During this monitoring period, they will also complete three consecutive days of intensive monitoring including more frequent smartphone surveys, saliva samples, heart rate monitoring, and an alcohol use monitor.
62409753|NCT04527159|OTHER|desensitizing agents (Fluoraphat Pro and VivaSens®)|"22 participants above the age of 18 years who presented to dental clinics in Riyadh Elm University with dentine hypersensitivity were randomly selected to participate in the study.~Each participant has at least two teeth with natural hypersensitivity which was not caused by any iatrogenic causes or bad oral habits, so there are 44 cases divided into two groups according to the material used, each group has 22 teeth, that make it applicable to apply the studied material with every patient on individual tooth with the same variables of the oral mouth. When teeth in the hypersensitivity group were evaluated for the level of DH, all teeth were found to have Grade 4 sensitivity."
62409754|NCT03609970|NO_INTERVENTION|Control|No intervention
62409755|NCT03609970|EXPERIMENTAL|UVR (Solar simulated radiation)|Twice weekly 1.25 SED (sub-erythemal) (4 weeks)
62409756|NCT03609970|EXPERIMENTAL|Vitamin D3 supplementation|4X 1000IU cholecalciferol tablets daily (28 days)
62791224|NCT01805479|PLACEBO_COMPARATOR|stretching-flexibility|This group will use a stretching and flexibility program designed to utilize minimal levels of aerobic capacity. It was chosen in place of a education-based control group due to the high level of personal interaction that is found in the active arm.
62791225|NCT01805479|ACTIVE_COMPARATOR|aerobic exercise group|aerobic activity targeting 60% peak heart rate for 12 weeks is the active group.
62791226|NCT02709811|EXPERIMENTAL|electrochemotherapy|
62791227|NCT00519272||Cervical Cancer Care Questionnaires|New cervical cancer patients through stage IVB presenting to the LBJ Gyn-Onc Clinic.
62791228|NCT02843503|EXPERIMENTAL|Arterialized-venous reference YSI|CGM monitoring performance per arterialized venous reference measurement (YSI)
62791229|NCT02843503|EXPERIMENTAL|Venous reference samples YSI|CGM monitoring performance per venous reference measurement (YSI)
62791230|NCT04385459||Patients without coronary artery disease|No prior coronary intervention and no significant stenosis noted during coronary angiography.
62791231|NCT04385459||Patients with coronary artery disease|"Our definition of coronary artery disease is:~* Prior coronary artery bypass grafting or percutaneous coronary intervention~* Significant stenosis or occlusion noted during coronary angiography"
62214087|NCT05444582|OTHER|52 mg LNG IUD Same Day Start or EC|"Week 1: Text daily for seven days. Report occurrences of the following in the last day: presence or absence of bleeding, spotting, pain, sexual intercourse, use of other methods of contraception, IUD expulsion or removal, and report any additional medical care received.~Weeks 2 \& 3: Weekly text survey assessing on which days of the previous week participants experienced bleeding and spotting, sexual intercourse, use of other methods of contraception, IUD expulsion or removal, or experienced adverse events.~Week 4 Survey: At 28 days, participants will be asked about pregnancy symptoms, concern about pregnancy, and the result of their urine pregnancy test including a prompt to upload a photo of the test."
62214088|NCT00964964|EXPERIMENTAL|SIBA 3W|
62791232|NCT05275595||chronic renal disease with covid|all patients who have chronic kidney disease with COVID-19 infection
62214089|NCT00964964|EXPERIMENTAL|SIBA OD|
62214090|NCT04798859|EXPERIMENTAL|Family-centered in home rehabilitation|"Seven individualized meetings with the family (7 sessions whereof most will be videoconferences, with the possibility of 1-2 of the sessions being home visits), one parent group seminar and 4 meetings (three videoconferences and one phone call) with school and local care providers during a period of 4-5 months.~Based on target outcomes areas noted by children and parents, individual goals will be established (2-5 per family). Strategies to meet goals will be established for each goal, and goal attainment scaling will be used to quantify goal attainment."
62214091|NCT04798859|ACTIVE_COMPARATOR|Control group|Usual health care and rehabilitation services provided in the municipality, including school.
62409757|NCT01868308||Preterm Labor|"Symptomatic women with singleton pregnancy at high risk for preterm birth between 22 - 33 6/7 weeks gestational age. We define high risk for preterm birth as women who present to our triage unit with complaints of preterm labor, including but not limited to preterm contractions, abdominal cramping, back pain, vaginal pressure, and vaginal bleeding."
62409758|NCT01715675|ACTIVE_COMPARATOR|plant stanol|
62409759|NCT01715675|PLACEBO_COMPARATOR|control|
62409760|NCT02614352|EXPERIMENTAL|AG1502|
62409761|NCT02614352|ACTIVE_COMPARATOR|Candesartan + Atorvastatin|
62409762|NCT00251680|EXPERIMENTAL|Lapaquistat Acetate 50 mg QD|(and stable lipid-lowering therapy)
62409763|NCT00251680|ACTIVE_COMPARATOR|Stable Lipid-lowering therapy|
62409764|NCT04045405|EXPERIMENTAL|CDR132L|
62409765|NCT04045405|PLACEBO_COMPARATOR|Saline|
62409766|NCT04301401|EXPERIMENTAL|Patients being evaluated for changes in microbiota|Patients being evaluated for changes in vaginal microbiota following transvaginal surgery.
62409767|NCT06286397|EXPERIMENTAL|Clascoterone Treatment|Participants will apply 1% clasocterone cream to the affected area twice daily got a total of 12 weeks with assessment visits at weeks 0, 4, 8, and 12. At assessment visits participants will have medical photography of the diseased area, be administered a dermatology-specific quality of life questionnaire, and be assessed for any side effects.
62020588|NCT04280198|NO_INTERVENTION|No Intervention: Group 1 - Control|Participants will attend three laboratory visits: baseline 1, baseline 2, and post-test. At baseline 2 and post-test, the primary outcome of child RRV of food vs. parent child interaction is measured. Other measures include child height and weight, child self-regulation, and parenting in the context of a parent-child interaction task. Participants in the control group will not be assigned to complete any intervention activities during the 4-week intervention phase (which takes place between baseline 2 and post-test visits); however, they will receive contacts from a member of the lab each week in the form of electronic reminders (i.e. texts) to remind them of their upcoming post-test laboratory appointment and will receive some intervention materials after the post-test assessment.
62214092|NCT02673073|PLACEBO_COMPARATOR|Control_Education|All patients will receive patient's information/education booklet on the heart failure including life style modification.
62214093|NCT02673073|EXPERIMENTAL|Intervention_Diary|All patients will receive patient's information/education booklet on the heart failure including life style modification. In addition, patients also receive a patient's diary for self-recording of 6 parameters: body weight, blood pressure, heart rate, number of remaining pills, degree of pitting edema, and degree of dyspnea.
62214094|NCT05043922|EXPERIMENTAL|CYH33|40mg daily
62409768|NCT06286397|PLACEBO_COMPARATOR|Placebo Treatment|Participants will apply a vehicle cream matched in texture, appearance, and odor to clacoterone to the affected area twice daily got a total of 12 weeks with assessment visits at weeks 0, 4, 8, and 12. At assessment visits participants will have medical photography of the diseased area, be administered a dermatology-specific quality of life questionnaire, and be assessed for any side effects.
62020589|NCT04280198|EXPERIMENTAL|Experimental: Group 2 - Intervention|Participants will attend the same three laboratory visits as the control group. The intervention group will also participate in a 4-week intervention, which consists of the parent watching brief weekly parenting videos from the online Triple P Parenting Program and completing interactive parent-child activities from activity boxes created by our laboratory (\~60 min of interactive activities/week). Participants will use their activity boxes to practice specific parenting skills from the week's parenting video. Throughout the intervention phase, participants will receive regular text messages to remind them of the week's activities and ask several questions about engagement in study activities over the past 24 hours. The intervention group will also complete an exit interview about the intervention following the post-test assessment to provide insights on fidelity and acceptability.
62214095|NCT05940428|EXPERIMENTAL|ASKG712|Multiple doses of ASKG712 by intravitreal injection
62214096|NCT01857128|EXPERIMENTAL|Drawtex Hydroconductive Dressing|Gauze-like dressing placed onto wound
62214097|NCT01857128|ACTIVE_COMPARATOR|Negative Pressure Wound Therapy|Usual care including vacuum and canister
62214098|NCT01828632|EXPERIMENTAL|Respiratory Physical Therapy|Patients assigned to interventional group (Respiratory Physical Therapy) were undergone a program of inspiratory muscular training (IMT) and incentive spirometer for a period of 30 days before the actual date of surgery. PiMAX, PeMAX and spirometry parameters were measured at the randomization day (baseline values)
62214099|NCT01828632|NO_INTERVENTION|Control|Usual care for the four weeks before surgery. PiMAX, PeMAX and spirometry parameters were measured at the randomization day (baseline values).
62214100|NCT03934138|ACTIVE_COMPARATOR|Educated open label placebo|These subjects will undergo all the same procedures as in the control group. But before the placebo CTP, they will watch a short movie explaining placebo mechanisms. While applying the placebo cream, they will be told that the cream is inert (placebo), efficient to decrease pain caused by cold and the mechanisms seen in the movie will take place.
62214101|NCT03934138|PLACEBO_COMPARATOR|Conventional placebo|These subjects will watch a video on hand washing. While applying the placebo cream, they will be told that this cream is effective to decreased pain caused by cold.
62409769|NCT01554917|EXPERIMENTAL|Iguratimod|
62409770|NCT03681925|EXPERIMENTAL|Intervention|Dietitians randomized to the intervention arm will have access to their participating patients' Nutrition Literacy Assessment Instrument (NLit) scores, and base their intervention on these results.
62409771|NCT03681925|NO_INTERVENTION|Control|Dietitians randomized to the control arm will not have access to their participating patients' Nutrition Literacy Assessment Instrument (NLit) scores, and will provide the standard-of-care intervention for their patients.
62409772|NCT01623245||Hypertrophic Cardiomyopathy|In the population of Hypertrophic Cardiomyopathy patients, patients suffering from a cardiac amyloidosis
62020590|NCT00795600|EXPERIMENTAL|insulin detemir|Insulin detemir injected subcutaneously (s.c.) in the evening in combination with insulin aspart injected s.c. as mealtime insulin for 26 weeks
62409773|NCT06145451|EXPERIMENTAL|Treatment group|The Family Success Network is a multi-tier, multi-component community-based maltreatment prevention program that offers tailored preventive services for caregivers of children aged 0-18. Average lengths of service completion is approximately 3 months.
62409774|NCT06145451|NO_INTERVENTION|Waitlist Control Group|Families in the Control Group will not receive any FSN services except concrete support of upto $500.
62409775|NCT03861689|ACTIVE_COMPARATOR|Tight control arm|Patients in the tight control arm will have additional FiLAC treatment within 24 months if the anatomy of the fistula is favourable. MRI pelvis will be performed at baseline and every 6 months. Biologic dosage will be adjusted according to MRI pelvis findings.
62409776|NCT03861689|NO_INTERVENTION|Control arm|Patients in the control arm will have management according to physician own decision.
62409777|NCT03628846||Traumatically Injured Adolescent|
62409778|NCT03628846||Not Traumatically Injured Adolescent|
62409779|NCT03638648|ACTIVE_COMPARATOR|Low risk Capecitabine|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based low recurrence risk receiving capecitabine.
62409780|NCT03638648|NO_INTERVENTION|Low risk control|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based low recurrence risk NOT receiving any additional chemotherapy.
62409781|NCT03638648|EXPERIMENTAL|High risk Capecitabine|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based high recurrence risk receiving capecitabine.
62409782|NCT03638648|NO_INTERVENTION|High risk control|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based high recurrence risk NOT receiving any additional chemotherapy.
62409783|NCT04437927||Prospective patients|30 consecutive patients with cardiac FDG PET prescribed
62409784|NCT04437927||Control|30 patients referred for cardiac FDG PET in the nuclear medicine department of the Centre Hospitalier Princesse Grace
62409785|NCT00919932|ACTIVE_COMPARATOR|Paper and pen homework|Treatment as usual: therapy homework is completed by paper and pen.
62409786|NCT00919932|EXPERIMENTAL|Text-message homework|Experimental treatment: therapy homework is completed by text messaging.
62409787|NCT05735717|EXPERIMENTAL|Fludarabine (flu), Total Body Irradiation (TBI), Flu/TBI Regimen|Patients will be treated on the most medically appropriate regimen with a preference for Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
62409788|NCT05735717|EXPERIMENTAL|Fludarabine (flu), Busulfan (bu), Flu/Bu Regimen|Patients will be treated on the most medically appropriate regimen with a preference for Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
62409789|NCT05735717|EXPERIMENTAL|Fludarabine (flu), Busulfan (bu), Melphalan (Mel) Regimen for Pediatric Patients Only|Flu/Bu/Mel will the preference for patients with JMML or infants with leukemia.
62409790|NCT01111032||Treadmill test|
62409791|NCT03974607|EXPERIMENTAL|Physical Activity|Physical Activity Programme (PAP) was planned for the promotion of PA and other healthy habits in inactive adolescents as an agent of change intervention, in which a trained staff actively disseminates effective practices to improve the PA's habits of adolescents.
62409792|NCT03974607|NO_INTERVENTION|No Physical Activity|The control group will be selected in a targeted manner according to the availability of the center. You will not be given any information about healthy habits nor will any physical training program be applied to you, so that you do not give indications that may produce a variation of your habitual behavior.
62409793|NCT02259166|EXPERIMENTAL|EHFP+|Group receiving the intervention EHFP+, in addition to MNPs distribution for 2 months and malaria diagnosis and treatment for children enrolled, at baseline and after 12 months
62409794|NCT02259166|NO_INTERVENTION|Control|MNPs distribution for 2 months and malaria diagnosis and treatment for children enrolled, at baseline and after 12 months
62409795|NCT00301925|ACTIVE_COMPARATOR|Epi-CMF|
62409796|NCT00301925|EXPERIMENTAL|Accelerated Epi-CMF|
62791233|NCT05275595||chronic renal disease without covid|all patients who have chronic kidney disease without COVID-19 infection
62409797|NCT00301925|EXPERIMENTAL|Epi-Capecitabine|
62584635|NCT06167733|SHAM_COMPARATOR|Sham|
62791234|NCT01281540|EXPERIMENTAL|001|Cisapride one 10 mg tablet 4 times a day for 8 weeks
62409798|NCT00301925|EXPERIMENTAL|Accelerated Epi-Capecitabine|
62409799|NCT01371981|EXPERIMENTAL|Arm A|See Detailed Description
62584636|NCT06388642|EXPERIMENTAL|Afamelanotide 16 mg implant|
62020591|NCT00795600|ACTIVE_COMPARATOR|insulin NPH|Insulin isophane (Neutral Protamine Hagedorn, NPH) injected subcutaneously (s.c.) in the evening in combination with insulin aspart injected s.c. as mealtime insulin for 26 weeks
62020592|NCT05219201|SHAM_COMPARATOR|Sham cryotherapy full time patient (inpatient)|"Patients benefiting from 15 session of sham partial-body cryotherapy session (-30°C) during their full-time rehabilitation stay"
62020593|NCT05219201|SHAM_COMPARATOR|sham cryotherapy part-time hospitalized patient (outpatient)|"Patients benefiting from 15 session of sham partial-body cryotherapy session (-30°C) during their part-time rehabilitation stay"
62409800|NCT01371981|EXPERIMENTAL|Arm B|See Detailed Description
62409801|NCT01371981|EXPERIMENTAL|Arm C (Cohort 1)|See Detailed Description
62734569|NCT01181804|EXPERIMENTAL|Boceprevir Capsules then Tablets (fasted)|Participants on this study arm will start therapy with a single dose of boceprevir capsules, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir tablets, orally, following an overnight fast.
62791235|NCT01281540|PLACEBO_COMPARATOR|002|Placebo one placebo tablet 4 times a day for 8 weeks
62214102|NCT06371859|EXPERIMENTAL|"XAI feedback on MCA/UA Doppler spectral curves and gate placement suggestions"|"The XAI feedback group will place a gate on MCA/UA images and evaluate the Doppler spectrum with AI feedback.~N=46 clinicians (Clinicians will be divided into two groups (XAI feedback \& No XAI feedback groups) of 46 each, matched for experience levels across hospitals)"
62214103|NCT06371859|NO_INTERVENTION|"No XAI feedback"|"The control group will place a gate on MCA/UA images and evaluate the Doppler spectrum without AI feedback.~N=46 clinicians (Clinicians will be divided into two groups (XAI feedback \& No XAI feedback groups) of 46 each, matched for experience levels across hospitals)"
62214104|NCT03096080|EXPERIMENTAL|Cohort 1|Single 0.25 mg/kg dose of tesevatinib
62214105|NCT03096080|EXPERIMENTAL|Cohort 2|Single 0.50 mg/kg dose of tesevatinib
62214106|NCT03096080|EXPERIMENTAL|Cohort 3|Single 1.00 mg/kg dose of tesevatinib
62214107|NCT06475963||patients|Patients will be recruited from all subjects treated surgically with scaffolds for partial meniscal defects from January 01, 2009 to December 31, 2019
62214108|NCT04688619|EXPERIMENTAL|"Prevention Program young In Favor of Myself, active parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents will also participate by receiving activities to do with their children, given to the adolescents during the scool program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
62409802|NCT01371981|EXPERIMENTAL|Arm C (Cohort 2)|See Detailed Description.
62020594|NCT05219201|ACTIVE_COMPARATOR|cryotherapy full-time hospitalized patient (inpatient)|"Patients benefiting from 15 session of sham partial-body cryotherapy session (-120°C) during their full-time rehabilitation stay"
62020595|NCT05219201|ACTIVE_COMPARATOR|cryotherapy part-time hospitalized patient (outpatient)|"Patients benefiting from 15 session of sham partial-body cryotherapy session (-120°C) during their part-time rehabilitation stay"
62020596|NCT06395285|EXPERIMENTAL|DF-003|Oral (PO) doses of 140 mg DF-003 on Days 1, 2, and 3 followed by a maintenance dose of 45 mg DF-003 once daily (QD) starting on Day 4 through Day 28. DF-003 will be administered PO with approximately 240 mL of water in the morning once daily for 28 consecutive days.
62020597|NCT06059703|EXPERIMENTAL|Idiopathic intracranial hypertension (IHH) patient|IHH patient with bilateral stenosis of the transversal sinus
62409803|NCT01371981|EXPERIMENTAL|Arm C (Cohort 3)|See Detailed Description. Different dose.
62409804|NCT01371981|EXPERIMENTAL|Arm D|See Detailed Description. May reassigned to Arm C.
62409805|NCT06067191|EXPERIMENTAL|Active|spray-dried dispersion (SDD) for Oral Suspension
62409806|NCT06067191|PLACEBO_COMPARATOR|Placebo|spray-dried dispersion (SDD) for Oral Suspension
62409807|NCT04997369|EXPERIMENTAL|Catheterless group|
62020598|NCT06241365||surgery group|Patients were divided into surgery group and conservative group based on whether they underwent surgery.
62020599|NCT06241365||conservative group|Patients were divided into surgery group and conservative group based on whether they underwent surgery.
62020600|NCT05684887|NO_INTERVENTION|Standard of care model (SOC)|This model is based on the standard of care recommended by the Cameroon National COVID-19 response program.
62020601|NCT05684887|EXPERIMENTAL|Intervention model (ITV)|Implementation of the contact tracing using a digitalized process (addition of the Mamal Pro digital contact tracing module to the Mamal Pro app).
62020602|NCT05187377|EXPERIMENTAL|Growth Hormone then Saline|12 weeks in each treatment phase (rhGH then placebo) and a four week wash-out period between phases.
62214109|NCT04688619|ACTIVE_COMPARATOR|"Prevention Program young In Favor of Myself, passive parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents won't participate in the program, they will get only a brochure about Media literacy, self-esteem, self-image and body image. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
62409808|NCT05813730|OTHER|Healthy neonates|A single arm evaluating creatinine renal excretion in healthy neonates' urine
62409809|NCT05377541||PENG block|To perform the PENG block, the patient will be placed in the supine position and with the convex transducer in a transverse plane over the anteroinferior iliac spine, the probe will be aligned with the iliopectineal eminence of the pubic ramus rotating about 45º medially.
62409810|NCT05377541||Fascia iliaca compartment block|To perform the iliac fascia block, the patient is placed in the supine position and with the linear transducer placed at the junction of the middle third with the lateral third of the inguinal ligament, the needle is inserted through the fascia lata and the iliac fascia.
62409811|NCT02628821||Preterm Infants treated with non-invasive ventilation|"Preterm Infants of less than 32 weeks of Gestational age treated with synchronized non-invasive ventilation (SNIPPV) to prevent intubation or extubation failure based in a prospective protocol:~* nCPAP failure: Preterm infants supported with nCPAP that meet intubation criteria if they are in a stable situation.~* Electively For extubation:~Preterm infants in which nCPAP extubation has previously failed or Prolonged mechanical ventilation (more than 15 days) with high respiratory parameters (PMAP \> 10 cmH2O and FiO2\>35%)."
62734570|NCT05720052|EXPERIMENTAL|Single arm|dose exploration
62734571|NCT01018017|ACTIVE_COMPARATOR|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered eight SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following consumption of a standard morning meal at home (200 cc of Ensure Plus®).
62791236|NCT06207526|EXPERIMENTAL|Blended face-to-face and smartphone intervention for delusional thoughts and experiences|"The blended face-to-face and smartphone intervention is implemented as a four-session intervention that is primarily based on an intervention from Bell et al. (2018/2020) which focused on hallucinations and is now being tailored to delusions. The intervention itself builds on the Coping Strategy Enhancement - program by Tarrier and colleagues (CSE; (Tarrier et al., 1990) by systematically build upon already applied coping strategies and therefore improve coping with psychotic symptoms. Participants receive four therapy sessions in person, while the app is used to collect data between sessions to be used in therapy and to record and train coping strategies between sessions.~All participants are allowed to continue parallel implemented standard scheduled treatment."
62791237|NCT05152771|OTHER|Ketogenic Diet|This will be a prospective cohort study. All families with children who have been newly diagnosed with confirmed SSPE (based on Dyken's Criteria) will be approached to start the low glycemic index diet (liberalized kind of KD). A thorough dietary history will be taken from the parents/caregivers, and they will be counseled by a trained dietitian on the diet, all pros and cons, and the format. After the verbal agreement, formal consent will be taken from the parent/ caregiver for initiation of the diet.
62020603|NCT05187377|PLACEBO_COMPARATOR|Placebo (saline) then Growth Hormone|12 weeks in each treatment phase (placebo then rhGH) and a four week wash-out period between phases.
62020604|NCT06431919|EXPERIMENTAL|Experimental: Simvastatin + Carvedilol-arm|"* Simvastatin fixed dose of 20 mg per day~* Carvedilol: Starting dose of 3.125 mg twice daily targeted upwards q 7 days to achieve target heart rate~* Standard Medical Therapy"
62020605|NCT06431919|ACTIVE_COMPARATOR|Active Comparator: Carvedilol arm|"* Carvedilol: Starting dose of 3.125 mg twice daily targeted upwards q 7 days to achieve target heart rate~* Standard Medical Therapy"
62020606|NCT05218655|EXPERIMENTAL|Vatiquinone|Participants will receive vatiquinone oral solution (100 milligrams \[mg\]/milliliter \[mL\]), up to 400 mg, administered orally or via feeding tube 3 times daily (TID).
62020607|NCT05941650|EXPERIMENTAL|Short Chain Fructooligosaccharides Group|This group will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours for 10 days, diluted in 250 ml
62020608|NCT05941650|PLACEBO_COMPARATOR|Group|This group will receive Corn Starch as a Placebo control 12 gr. every 24 hours for 10 days, diluted in 250 ml
62020609|NCT04007952|NO_INTERVENTION|Intervention 1 (Control)|No anterior gastropexy will be performed.
62020610|NCT04007952|EXPERIMENTAL|Intervention 2 (Treatment)|Anterior gastropexy will be performed.
62020611|NCT04823598|ACTIVE_COMPARATOR|Reference group|Coached pushing and Finnish manual perineal protection
62020612|NCT04823598|EXPERIMENTAL|Study group|Uncoached pushing and Hands-poised perineal protection
62020613|NCT01954654|EXPERIMENTAL|Accelerated treatment|
62791238|NCT05611021|EXPERIMENTAL|Walking Condition|In the walking condition, the patients will perform fifteen bouts of two minutes of treadmill walking with an interval of two minutes between bouts, at an intensity equivalent to 13-15 on Borg's subjective perceived exertion scale. The condition will have a total of sixty minutes of duration.
62791239|NCT05611021|ACTIVE_COMPARATOR|Arm-Cranking Condition|In the arm-cranking condition, the patients will perform fifteen bouts of two minutes of arm-cranking with an interval of two minutes between bouts, at an intensity equivalent to 13-15 on Borg's subjective perceived exertion scale. The condition will have a total of sixty minutes of duration.
62791240|NCT05611021|SHAM_COMPARATOR|Control Condition|The control condition will consist of resting in the standing position for thirty minutes. The patients will be instructed to rest in the sitting position for two minutes at periods equivalent to the intervals from the exercise conditions, totalling sixty minutes of duration.
62791241|NCT01740024|EXPERIMENTAL|1 (Dose-Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations Positive control Negative control
62791242|NCT03058055|PLACEBO_COMPARATOR|Placebo|Usual lifestyle activities
62791243|NCT03058055|EXPERIMENTAL|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
62791244|NCT03058055|EXPERIMENTAL|Reading|Daily reading (out loud into a voice recorder) for one hour
62020614|NCT01954654|ACTIVE_COMPARATOR|Standard treatment|
62791245|NCT04043650|EXPERIMENTAL|HeartSteps Intervention|For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not.
62020615|NCT02618473|NO_INTERVENTION|seloken|"In seloken arm, patients performs the cardiac CT procedure regarding the national scan guidelines, ande receive 5-10 intravenous seloken, until heart rate below 60 beats pr minit is achieved."
62020616|NCT02618473|EXPERIMENTAL|non-seloken|"Patients randomized to non-seloken, do not receive any medication."
62020617|NCT06415201||Survey of unmet medical needs|20 people
62020618|NCT06415201||User experience evaluation|40 people
62020619|NCT06415201||Clinical interview data collection|300 people
62020620|NCT00517920|EXPERIMENTAL|ABT-869|
62020621|NCT05900102||Melanoma of the head and neck|
62020622|NCT05900102||Melanoma of the trunk, arms, or legs|
62409812|NCT00026312|ACTIVE_COMPARATOR|Arm I (isotretinoin) (closed to accrual as of 4/16/2009)|Beginning preferably between day 56 and day 85 post-ASCT, but may be delayed up to day 200, patients receive isotretinoin PO BID for 14 days. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients may cross over to Arm II provided they have not experienced disease progression and have not received any further anti-neuroblastoma therapy following completion of isotretinoin therapy.
62409813|NCT00026312|EXPERIMENTAL|Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin)|Beginning preferably between day 56 and day 85 post-ASCT, but may be delayed up to day 200, patients receive immunotherapy comprising sargramostim SC or IV over 2 hours on days 0-13 during courses 1, 3, and 5 and dinutuximab IV over 10-20 hours on days 3-6 of courses 1-5. Patients also receive aldesleukin IV continuously on days 0-3 and 7-10 during courses 2 and 4. Immunotherapy repeats every 28 days for 5 courses in the absence of disease progression or unacceptable toxicity. Patients also receive isotretinoin as in Arm I beginning on day 11 of immunotherapy.
62409814|NCT04221100|PLACEBO_COMPARATOR|Control|Participants will review the 500 chest radiographs without the assistance of xrAI
62020623|NCT01081977|ACTIVE_COMPARATOR|Early Cord Clamping Group|Early Cord Clamping Group (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate).
62020624|NCT01081977|EXPERIMENTAL|Delayed Cord Clapming Group|Delayed Umbilical Cord Clamping Group (Clamping of Umbilical Cord within 2 minutes of shoulder delivery of neonate).
62020625|NCT01620463|EXPERIMENTAL|NNC 90-1170|
62020626|NCT01620463|PLACEBO_COMPARATOR|Placebo|
62409815|NCT04221100|EXPERIMENTAL|Treatment|Participants will review the 500 chest radiographs with the assistance of xrAI
62020627|NCT00099983|ACTIVE_COMPARATOR|Risperidone|1 mg/day tablet for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day to a maximum of 4 mg/day allowed after a minimum of 4 weeks at the target dose 3 mg/day
62020628|NCT00099983|PLACEBO_COMPARATOR|Sugar Pill|Placebo 1 mg/day tablet for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day to a maximum of 4 mg/day allowed after a minimum of 4 weeks at the target dose 3 mg/day
62020629|NCT04957602||Metastatic non-small cell lung cancer patients|Metastatic non-small cell lung cancer patients who have not initiated their treatment yet (osermertinib or chemotherapy (associated or not with immunotherapy)
62020630|NCT02471924|OTHER|Trans thoraciq cardiac ultrasonography|Trans thoraciq cardiac ultrasonography wil be perforfomed for pregnant women having a spinal or spinal-epidural anesthesia for elective caesarean section. All patients are more 18 years old and more 37 weeks pregnancy
62409816|NCT03345485|EXPERIMENTAL|Tinostamustine (EDO-S101) - Phase 1 - 60mg/m2 (30 min) cohort 1|
62409817|NCT03345485|EXPERIMENTAL|Tinostamustine (EDO-S101) - Phase 1 - 80mg/m2 (30 min) cohort 2|
62791246|NCT02124681|PLACEBO_COMPARATOR|Placebo|Placebo PO
62791247|NCT02124681|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine sulfate 400mg PO QD
62020631|NCT04258020|EXPERIMENTAL|Experimental: alternating BiPAP and HFNC|Patients will be placed on alternating BiPAP and HFNC for 24 hours following extubation
62020632|NCT04258020|NO_INTERVENTION|Historical Control: standard of care|A historical control cohort will be composed of patients treated according to their physician's standard of care following removal from mechanical ventilation.
62020633|NCT05361473|ACTIVE_COMPARATOR|The NeoHilda Point of care method|Evaluating baby including lactate dehydregenase Levels measured in umbilical core blood using the fast point of care method called Neo Hilda
62020634|NCT05361473|SHAM_COMPARATOR|No Measurement of LDH|Evaluating baby without Lactate dehydrogenase result
62020635|NCT06408272||TCAV EIT|Patients with early ARDS, \< 72h of Mechanical ventilation, under TCAV since one hour with EIT.
62020636|NCT06141798|ACTIVE_COMPARATOR|Twice-weekly hemodialysis with incremental approach|
62020637|NCT06141798|NO_INTERVENTION|Thrice-weekly hemodialysis|
62020638|NCT00861939|EXPERIMENTAL|1|Bupropion HCl 300mg Extended Release Tablet
62020639|NCT00861939|ACTIVE_COMPARATOR|2|WELLBUTRIN XL 300mg Tablets
62020640|NCT02917109|EXPERIMENTAL|LearningRx cognitive training|The intervention is a 60-hour, clinician-delivered cognitive training program.
62020641|NCT01808313|EXPERIMENTAL|ambrisentan|ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
62409818|NCT03345485|EXPERIMENTAL|Tinostamustine (EDO-S101) - Phase 1 - 100mg/m2 (30 min) cohort 3|
62409819|NCT03345485|EXPERIMENTAL|Tinostamustine (EDO-S101) - Phase 1 - 60mg/m2 (60 min) cohort 4|
62409820|NCT03345485|EXPERIMENTAL|Tinostamustine (EDO-S101) - Phase 1 - 80mg/m2 (60 min) cohort 5|
62409821|NCT03345485|EXPERIMENTAL|Tinostamustine (EDO-S101) - Phase 1 - 100mg/m2 (60 min) cohort 6|
62409822|NCT03345485|EXPERIMENTAL|Tinostamustine (EDO-S101) - Phase 2 Relapsed/refractory Small Cell Lung Cancer (SCLC) cohort|
62409823|NCT03345485|EXPERIMENTAL|Tinostamustine (EDO-S101) - Phase 2 Relapsed/refractory Soft Tissue Sarcoma (STS) cohort|
62409824|NCT03345485|EXPERIMENTAL|Tinostamustine (EDO-S101) - Phase 2 Relapsed/refractory Triple Negative breast Cancer (TNBC) cohort|
62409825|NCT03345485|EXPERIMENTAL|Tinostamustine (EDO-S101) - Phase 2 Relapsed/refractory Ovarian Cancer (OC) cohort|
62409826|NCT03345485|EXPERIMENTAL|Tinostamustine (EDO-S101) - Phase 2 Relapsed/refractory Endometrial Cancer (EC) cohort|
62409827|NCT03345485|EXPERIMENTAL|Tinostamustine (EDO-S101) - Sub study 1 (SS1)|
62409828|NCT03345485|EXPERIMENTAL|Tinostamustine (EDO-S101) - Sub study 2 (SS2)|
62791248|NCT06060054|EXPERIMENTAL|Sleep Opportunity|Overnight sleep wearing the device
62791249|NCT06060054|EXPERIMENTAL|Sleep Deprivation|Overnight awake wearing the device
62791250|NCT05579808||Epidural Analgesia|
62791251|NCT05579808||No analgesia|
62791252|NCT02360228|EXPERIMENTAL|tACS (alpha)|20 participants: 10Hz tACS with a peak-to-peak amplitude of 2mA for 20 minutes twice daily
62020642|NCT04712318|OTHER|ReLex Smile surgery|"The aim of this study is to investigate the effect of Relex Smile surgery to correct the residual refractive errors (myopic and hyperopic) 6 months after Trifocal IOL Implantation.~At myopic residual refraction (min -0.75 D) (100eyes) 6 months after Trifocal IOL Implantation we used Relex-Smile surgery for treatment."
62020643|NCT04712318|OTHER|ReLex Smile surgery-fresh corneal lenticule implantation|At hyperopic residual refraction 30 eyes 6 months after Trifocal IOL Implantation we used fresh corneal myopic lenticule implantation as allogenic implant that will be taken from myopic patients to implant on pseudophakic patients with residual hypermetropic refraction using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity.
62214110|NCT00912262|ACTIVE_COMPARATOR|Low and High Concentration Capsaicin Topical Liquids|
62214111|NCT05421351||Experimental|All patients with overt HE in ACLF of any etiology.
62734572|NCT01018017|PLACEBO_COMPARATOR|Placebo|The placebo treatment group will be administered eight placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following consumption of a standard morning meal at home (200 cc of Ensure Plus®).
62791253|NCT02360228|EXPERIMENTAL|tDCS|20 participants: 2mA stimulation for 20 minutes twice daily
62791254|NCT02360228|SHAM_COMPARATOR|Sham stimulation|20 participants: Will include 10 seconds of ramp in to 1 minutes of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation twice daily.
62791255|NCT03158441||cases|The patients enrolled for the study will be women scheduled for breast MRI due to high risk screening or pretreatment evaluation. The patients will fill in a form regarding: age, hormonal status, risk factors, prior breast surgery or treatment (a form which is routinely filled out in our institution). They will then undergo a breast MRI scan, using the routine protocol in our institution. This will be directly followed by a DTI sequence, which takes about 10 minutes in addition to the regular examination. The DTI sequence is routinely used in other imaging institutions, as part of the breast MRI protocol.
62791256|NCT03158441||control|same patients , dynamic scan
62791257|NCT01073202|ACTIVE_COMPARATOR|ursodeoxycholic acid|
62791258|NCT01073202|PLACEBO_COMPARATOR|identical-appearing placebo|
62791259|NCT02735343|ACTIVE_COMPARATOR|Standard treatment arm|compazine 10 mg Intravenously along with diphenhydramine 25 mg Intravenously
62791260|NCT02735343|EXPERIMENTAL|Research arm|Ketamine 0.3 mg/kg Intravenously along with ondansetron 4 mg Intravenously
62791261|NCT00577824|EXPERIMENTAL|1|
62791262|NCT00577824|EXPERIMENTAL|2|
62791263|NCT00577824|PLACEBO_COMPARATOR|3|
62791264|NCT06530368|NO_INTERVENTION|Group 1: Control group|Participants in the first group were not subjected to any intervention and were asked not to participate in any exercise program for eight weeks.
62791265|NCT06530368|EXPERIMENTAL|Group 2: Calisthenic home exercise group|Participants in the second group were informed about calisthenic home exercise programs face to face and were asked to perform these exercises as home exercises for eight weeks.
62791266|NCT02411435|EXPERIMENTAL|Treatment A(CAB 30mg)+B (RIF 600mg)+C (CAB 30mg and RIF 600mg)|Subjects will receive a single dose of CAB 30 mg on day 1. Subjects will then receive RIF 600 mg once daily on days 8-28 with co-administration of a single dose of CAB 30 mg on day 21.
62791267|NCT06314607||Group 1|"Patients already included in the first ONCONEUROTEK (retrospective) study and followed up in the participating center : at their next hospitalization or consultation at Pitié Salpêtrière, they will be given an information note and a consent form (NIFC) informing them of the ONCONEUROTEK 2 study.~(This population concerns all patients in the relevant departments with a last news date \< 2 years)"
62791268|NCT06314607||Group 2|"Patients included prospectively : Patients who may be included in this study will be informed of its objectives and procedures by the doctor in charge of their follow-up, during a consultation visit or routine hospitalization, by means of an information note.~(This population concerns around 1,000 patients per year, i.e. around 10,000 patients over 10 years)"
62791269|NCT06314607||Group 3|"This group concerns patients already included in the ONCONEUROTEK study (retrospective) but not currently being followed at the Pitié Salpêtrière hospital. Specifically, patients who are known to the investigators to still be alive. In this case, an information note and a non-opposition form (NINO) will be sent to them by mail to :~* inform them of the regulatory update under the Loi Jardé and the RGPD~* and collect their non-opposition to the re-use of their data and samples.~* If no reply is received within one month, the patient will be deemed not to have objected to the re-use of his or her data and samples in the ONCONEUROTEK 2 study.~(This population concerns all patients in the relevant departments with a last news date \> 2 years)"
62791270|NCT01392365||Crohn' disease|The group of patients whose final diagnosis is Crohn's disease
62791271|NCT01392365||Intestinal tuberculosis|The group of patients whose final diagnosis is intestinal tuberculosis
62020644|NCT05109910|ACTIVE_COMPARATOR|Radical prostatectomy with an extended pelvic lymph node dissection|According to the standard of care, patients in this arm will receive a radical prostatectomy with a standard bilateral ePLND. This includes the removal of lymph nodes within the obturator fossa and bilateral to the external iliac artery, internal iliac artery and common iliac artery up to the ureteral-vessel crossing.
62020645|NCT05109910|NO_INTERVENTION|Radical prostatectomy without an extended pelvic lymph node dissection|Patients in this arm will undergo a radical prostatectomy without a bilateral extended pelvic lymph node dissection. In case of intraoperatively found suspicious lymph nodes, a lymphadenectomy is performed. According to the intention to treat principle, patients with intraoperatively removed lymph nodes remain included in the study.
62020646|NCT03495336|EXPERIMENTAL|Washout period|Coffee abstention phase for 2 weeks.
62020647|NCT03495336|EXPERIMENTAL|Light roast coffee (LR)|Participants will follow LR Coffee consumption procedure and consume at least 3 cups of Light (LR) roast Turkish coffee brews per day for 4 weeks after a washout period (WO) of 2 weeks.
62409829|NCT04707833|EXPERIMENTAL|Patient infected or cured from covid19|"* Patients with an acute SARS-CoV-2 infection confirmed by a positive RT-PCR, hospitalized in COVID units or in COVID resuscitations,~* Nurses at the Rouen University Hospital infected with COVID 19, and cured,~* Patients with a high suggestive clinic for COVID-19 infection but with negative COVID-19 RT-PCR"
62409830|NCT02459470|EXPERIMENTAL|SVV and PPV|"SVV(stroke volume variation): recorded using the Flotrac/Vigileo system (Edwards Lifesciences)~PPV(pulse pressure variation): recorded using philips Intelivue MP70 monitors (Philips Medical System)~Intervention: Other: Fluid loading using HES 130/0.4; voluven; Fresenius Kabi; Stans, Switzerland"
62020648|NCT03495336|EXPERIMENTAL|Second washout period|coffee abstention phase for 2 weeks
62020649|NCT03495336|EXPERIMENTAL|Dark roast coffee (DR)|Participants will follow DR Coffee consumption procedure and consume at least 3 cups of Dark (DR) roast Turkish coffee brews per day for 4 weeks after a washout period (WO) of 2 weeks.
62020650|NCT01717235|EXPERIMENTAL|Test Product|Drug: Ropinirole Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fasting conditions
62020651|NCT01717235|EXPERIMENTAL|Reference Product|REQUIP XL Tablets (containing Ropinirole hydrochloride CR 2mg Tablets)under fasting conditions
62020652|NCT05244356|EXPERIMENTAL|Descriptive Norm (70%)|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~2. Message content describing that about 70% of Malaysians have expressed acceptance for the COVID-19 vaccine.~3. Rally slogan: It's safe and effective!"
62409831|NCT03363724||HaGuide version 1.0 software module|Patients diagnosed with Parkinson's Disease who underwent implantation of DBS electrode in the STN for the treatment of Parkinson's Disease, using the Neuro-Omega device for navigation and procedure's MER digital recorded data is available.
62409832|NCT03375346|EXPERIMENTAL|Whole body vibration group|Whole body vibration group performed a single session of whole body vibration exercise via a vibrating platform (Galileo® Advanced Plus, Novotec Medical, Pforzheim, Germany) with a magnitude of 20 Hz and an amplitude of 4 mm.
62791272|NCT04951583|EXPERIMENTAL|Immune checkpoint inhibitor (ICI) therapy in combination with fecal microbial transplantation (FMT).|"Metastatic or advanced NSCLC: Single-agent Pembrolizumab (2 mg/kg or 200 mg every 3 weeks) in combination with investigational FMT capsules as follows: Full FMT at least 7 days prior to first cycle of Pembrolizumab.~Metastatic melanoma and uveal melanoma: Combination therapy of Ipilimumab plus Nivolumab (Ipilimumab 3 mg/kg every 3 weeks and Nivolumab 1 mg/kg every 3 weeks x 4 doses, followed by Nivolumab 3 mg/kg or 240mg every 2 weeks or 6 mg/kg or 480mg every 4 weeks) in combination with investigational FMT capsules as follows: full FMT at least 7 days prior to first treatment with Ipilimumab plus Nivolumab, followed by supportive FMT within 7 days of the second cycle with combination Ipilimumab plus Nivolumab, followed by supportive FMT within 7 days of the third cycle of Ipilimumab plus Nivolumab."
62791273|NCT06267391|EXPERIMENTAL|ReCET Arm|Treatment Arm will receive the ReCET procedure.
62791274|NCT06267391|SHAM_COMPARATOR|Control Arm|Control Arm will receive a sham procedure.
62791275|NCT01233141||one group only|all participants
61978503|NCT02505230|EXPERIMENTAL|Meal Order 4|"\[LVP,P,P+S,HVP\]~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices)."
62214112|NCT05421351||Disease Control Group|"1. Diseased Control patients with Acute-on-Chronic Liver Failure with no Hepatic Encephalopathy~2. Diseased Control patients with Decompensated Cirrhosis with no Hepatic Encephalopathy"
62214113|NCT05421351||Control Group 2|Healthy Control without any liver disease
62214114|NCT06459700|ACTIVE_COMPARATOR|Probiotic|One arm will receive probiotic supplement in opaque white capsules, 1 each day for six months
62409833|NCT03375346|ACTIVE_COMPARATOR|Exercise only group|The control group performed the same session without vibration.
62409834|NCT06651645||Pre-pandemic admissions|Patients admitted between January 1, 2018 - February 29, 2020 with one of the following five primary diagnoses of acute myocardial infarction, stroke, heart failure, pneumonia, and chronic obstructive pulmonary disease in alignment with the Centers for Medicare and Medicaid Service's (CMS's) condition-specific mortality measures reporting
62791276|NCT04848272|PLACEBO_COMPARATOR|Saline control|Saline control
62791277|NCT04848272|EXPERIMENTAL|Lanadelumab 30 mg|Lanadelumab 30 mg
62791278|NCT04848272|EXPERIMENTAL|Lanadelumab 100 mg|Lanadelumab 100 mg
62791279|NCT04848272|EXPERIMENTAL|Lanadelumab 300 mg|Lanadelumab 300 mg
62214115|NCT06459700|PLACEBO_COMPARATOR|Placebo|One arm will receive identical opaque placebo capsules containing maize starch powder (placebo), 1 each day for six months
62214116|NCT02468180|ACTIVE_COMPARATOR|BRTO|Balloon-occluded retrograde transvenous obliteration
62214117|NCT02468180|ACTIVE_COMPARATOR|NBCA|Endoscopic cyanoacrylate injection
61978504|NCT01206231||1|Patients with hypercholesterolemia
61978505|NCT05502900|EXPERIMENTAL|Melatonin|Melatonin tablet 5 mg. 4 tablets taken at night (20 mg) for 5 years.
61978506|NCT05502900|NO_INTERVENTION|Control|No intervention. Follows the current standard of observation after primary tumor treatment.
62020653|NCT05244356|EXPERIMENTAL|Descriptive Norm|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~2. Message content describing that the COVID-19 vaccine has been widely tested including with the elderly and people with existing health conditions, while subsequently highlighting that the vaccine was already received by millions worldwide.~3. Rally slogan: It's safe and effective!"
62409835|NCT06651645||Post-pandemic admissions|Patients admitted between May 1, 2022 and May 31, 2023 without a diagnosis for COVID-19 and with one of the following five primary diagnoses of acute myocardial infarction, stroke, heart failure, pneumonia, and chronic obstructive pulmonary disease in alignment with the Centers for Medicare and Medicaid Service's (CMS's) condition-specific mortality measures reporting.
62409836|NCT06651645||Pandemic admissions|Patients admitted between March 1, 2020 and April 30, 2022 without a diagnosis for COVID-19 and with one of the following five primary diagnoses of acute myocardial infarction, stroke, heart failure, pneumonia, and chronic obstructive pulmonary disease in alignment with the Centers for Medicare and Medicaid Service's (CMS's) condition-specific mortality measures reporting
62409837|NCT02018601|EXPERIMENTAL|BRILMA&dexketoprofen&paracetamol|dexketoprofen: 50 mg/8h paracetamol: 1gr/6h
62214118|NCT05810129|ACTIVE_COMPARATOR|standard physical therapy|Men with clavicle fracture immobilized for 6 weeks + standard physical therapy for 12 weeks
62214119|NCT05810129|EXPERIMENTAL|concentric-eccentric strength training|Men with clavicle fracture who perform concentric-eccentric strength training on the uninjured limb during the 6-week immobilization period + Posterior Standard PhysicalTherapy.
62214120|NCT05810129|EXPERIMENTAL|eccentric strength training|Men with clavicle fracture who perform eccentric strength training on the unaffected limb during the 6-week period of immobilization + Posterior Standard Physical Therapy.
62214121|NCT03384277|EXPERIMENTAL|Steroid+Rituximab|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）+Rituximab 375mg/m2 for one dose.
62214122|NCT03384277|ACTIVE_COMPARATOR|Steroid +Cyclophosphamide|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks （ then tapering gradually, 8 weeks in total）+ Cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)
61978507|NCT03772275|ACTIVE_COMPARATOR|New york Heart Association Class II-IV|New york Heart Association Class II-IV heart failure
61978508|NCT03772275|ACTIVE_COMPARATOR|New york Heart Association Class I|New york Heart Association Class I with no heart failure
61978509|NCT04940650|OTHER|Recreational cyclists performing the 'étape du tour (EDT) de France 2021|
61978510|NCT03963791|EXPERIMENTAL|Eggshell powder gel|prepared from eggshell powder. applied on the tooth surfaces twice daily (after breakfast and before bedtime) after brushing the teeth.
62214123|NCT01896323|EXPERIMENTAL|CC-223|CC-223 administration on study day 1 of Period 1 and study day 5 of Period 2
62214124|NCT01896323|ACTIVE_COMPARATOR|Ketokonazole|Ketoconazole administration on study days 1 through 8 of Period 2
62214125|NCT04076189|EXPERIMENTAL|Endotracheal suctioning|Procedure includes: Endotracheal intubation-Suctioning-Endotracheal intubation again and initiation of positive pressure ventilation
62214126|NCT04076189|ACTIVE_COMPARATOR|No endotracheal suctioning|Procedure includes: Initiation of positive pressure ventilation without endotracheal suctioning
62214127|NCT01802151|PLACEBO_COMPARATOR|Placebo|Placebo (starch, magnesium stearate, citric acid) capsules once daily for 4 weeks.
62214128|NCT01802151|EXPERIMENTAL|B. subtilis R0179 (10 billion CFU)|"B. subtilis R0179 (approximately 10 billion CFU/capsule) once daily for 4 weeks.~\* CFU (Colony Forming Unit)"
62214129|NCT01802151|EXPERIMENTAL|B. subtilis R0179 (1 billion CFU)|B. subtilis R0179 (approximately 1 billion CFU/capsule) once daily for 4 weeks.
62791280|NCT03852719|EXPERIMENTAL|Delayed Treatment/Bulevirtide 10 mg/day|After an observational period of 48 weeks, participants will receive delayed treatment with bulevirtide 10 mg/day subcutaneously (SC) for 96 weeks and will be followed for up to 96 weeks (Up to Week 240).
62020654|NCT05244356|EXPERIMENTAL|Healthcare worker (HCW) recommendation|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~2. Message content highlights recommendation from Malaysian healthcare workers to get the vaccine, since majority of them has already received it, including the Malaysian Health Director General~3. Rally slogan: It's safe and effective!"
62020655|NCT05244356|EXPERIMENTAL|Negative attribute framing|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~2. Message content describing the rate of side effects occurring with COVID-19 vaccination in a negative frame.~3. Rally slogan: It's safe and effective!"
62020656|NCT05244356|EXPERIMENTAL|Positive attribute framing|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~2. Message content describing the rate of side effects occurring with COVID-19 vaccination in a positive frame.~3. Rally slogan: It's safe and effective!"
62020657|NCT05244356|EXPERIMENTAL|Risky choice framing (Safety)|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~2. Message content describing a risky choice frame which compares the death rates occurring with COVID-19 vaccination versus contracting the virus itself.~3. Rally slogan: It's safe and effective!"
62214130|NCT01802151|EXPERIMENTAL|B. subtilis R0179 (0.1 billion CFU)|B. subtilis R0179 (approximately 0.1 billion CFU/capsule) once daily for 4 weeks.
62214131|NCT02243111|EXPERIMENTAL|Doppler ultrasound|Recording Doppler signals from the lungs
62214132|NCT00254046|PLACEBO_COMPARATOR|002|Placebo 2 tablets b.i.d.96 weeks
62214133|NCT00254046|ACTIVE_COMPARATOR|001|TMC125 2 X100 mg tablets b.i.d.96 weeks
62409838|NCT02018601|ACTIVE_COMPARATOR|paravertebral block&dexketoprofen&paracetamol|dexketoprofen: 50 mg/8h paracetamol: 1g/6h
62791281|NCT03852719|EXPERIMENTAL|Bulevirtide 2 mg/day|Participants will receive bulevirtide 2 mg/day SC for 144 weeks and will be followed for up to 96 weeks (Up to Week 240).
62791282|NCT03852719|EXPERIMENTAL|Bulevirtide 10 mg/day|Participants will receive bulevirtide 10 mg/day SC for 144 weeks and will be followed for up to 96 weeks (Up to Week 240).
62791283|NCT03117985|EXPERIMENTAL|Antiretroviral therapy|Stopping antiretroviral therapy
62791284|NCT03499834|EXPERIMENTAL|Study Group|26 patients who has successfully undergone the screening criteria will be enrolled for treatment. Immune Killer Cells (IKC) will be administered through Intravenous Injection (I.V.) Frequency: One injection per week, twenty-four injections on-treatment
62791285|NCT04305171||coronary heart disease patients with periodontitis|"Coronary heart disease patients confirmed through coronary angiography as having at least 50% diameter stenosis in at least one coronary artery and clinically stable with the absence of any potentially confounding inflammatory conditions for at least 6 months.~Periodontitis classified as havingbleeding on probing (BOP), pocket depth (PD) \> 4 mm, clinical attachment level (CAL) ≥ 5 mm and radiographic evidence of bone loss were presented at the same site of at least 4 teeth."
62020658|NCT05244356|EXPERIMENTAL|Risky choice framing (Side effects)|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~2. Message content describing a risky choice frame that compares the incidence rates of blood clots occurring with COVID-19 vaccination versus contracting COVID-19.~3. Rally slogan: It's safe and effective!"
62020659|NCT05244356|EXPERIMENTAL|Control message|"Control message containing only rally slogan: It's safe and effective!"
62020660|NCT05244356|EXPERIMENTAL|Combination message: Descriptive Norm (70%) + Descriptive Norm|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
62214134|NCT05154981|EXPERIMENTAL|Partners in School with Education Communication Skills (ECS) Training|Parents and teachers in the experimental condition will receive Partners in School with communication training.
61978511|NCT03963791|ACTIVE_COMPARATOR|CPP-ACP crème|CPP-ACP crème (GC Tooth Mousse). applied on the tooth surfaces twice daily (after breakfast and before bedtime) after brushing the teeth.
61978512|NCT03084874|EXPERIMENTAL|Intervention group|Patients in the intervention group will receive an individualized coaching program to increase physical activity and reduce sedentary behavior during 12 weeks
61978513|NCT03084874|NO_INTERVENTION|Control group|Patients in the control group will receive the standard care for patients with COPD during 12 weeks.
61978514|NCT02161627|EXPERIMENTAL|Automatic Control|Automatic Control using Saluda Medical External Trial System
61978515|NCT02161627|ACTIVE_COMPARATOR|Manual Control|Manual Control using Saluda Medical External Trial System
62214135|NCT05154981|ACTIVE_COMPARATOR|Partners in School without Education Communication Skills (ECS) Training|Parents and teachers in the control condition will receive Partners in School without communication training.
62214136|NCT01315808||Low risk group|Patients will be stratified based on risk factors significantly contributing to diabetes type 2.
62214137|NCT01315808||Intermediate risk group|
62214138|NCT01315808||High risk group|
62214139|NCT02858843|EXPERIMENTAL|Lumacaftor-ivacaftor|Subjects will be monitored for glycemic changes before and after starting lumacaftor-ivacaftor.
62214140|NCT02734030||Control Group|"Knee pain-free females with no history of lower limb injuries serving as a control group.~."
62214141|NCT02734030||Anterior Knee Pain Group|Females with anterior knee pain syndrome were enrolled in this group.
62214142|NCT04296539||Sedentary|Involving little exercise or physical activity
62214143|NCT04296539||Exercise|Subjects who were performing regularly pilates exercises for at least six months
62214144|NCT01405833|EXPERIMENTAL|BG00010 (Neublastin)|Participants may be randomized to escalating doses of BG00010
62214145|NCT01405833|PLACEBO_COMPARATOR|Placebo|Participants may be randomised to a matching placebo
62409839|NCT00209235|EXPERIMENTAL|AHO:neurocognitive and pyschosocial|Neurocognitive and psychosocial testing
62214146|NCT02646007|EXPERIMENTAL|BM-MSC|Bone marrow derived mesenchymal stromal/stem cells injection during decompressive surgery in patients with Kienböck's disease.
62214147|NCT00337259|EXPERIMENTAL|Gemcitabine|"* histologically confirmed marginal zone lymphoma~* gemcitabine 1,250 mg/m2 on days 1 and 8 of each cycle, repeated every 3 weeks and continued for 6 cycles, until disease progression, withdrawal due to toxicity, or withdrawal of consent."
62020661|NCT05244356|EXPERIMENTAL|Combination message: Descriptive Norm (70%) + HCW recommendation|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
62020662|NCT05244356|EXPERIMENTAL|Combination message: Descriptive Norm (70%) + Negative attribute framing|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
62409840|NCT02618421||Participants Aged 40 Years or Over|Cross-section of general population of males and females in China, Taiwan, and South Korea
62409841|NCT04038307|PLACEBO_COMPARATOR|control|will receive 100 ml of saline
62020663|NCT05244356|EXPERIMENTAL|Combination message: Descriptive Norm (70%) + Positive attribute framing|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
62214148|NCT00006011|EXPERIMENTAL|Arm I (doxorubicin, cisplatin, filgrastim, pegfilgrastim)|Patients receive doxorubicin IV over 30 minutes immediately followed by cisplatin IV over 1 hour on day 1. Patients also receive filgrastim (G-CSF) SC or pegfilgrastim on days 2-11.
62214149|NCT00006011|EXPERIMENTAL|Arm II (doxorubicin, cisplatin, paclitaxel, filgrastim)|Patients receive doxorubicin and cisplatin as in arm I, paclitaxel IV over 3 hours on day 2, and G-CSF SC or pegfilgrastim on days 3-12. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
62214150|NCT05718063|EXPERIMENTAL|Full MAP for Coaches eLearning Training Course|
62020664|NCT05244356|EXPERIMENTAL|Combination message: Descriptive Norm (70%) + Risky choice framing (Safety)|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
62020665|NCT05244356|EXPERIMENTAL|Combination message: Descriptive Norm (70%) + Risky choice framing (Side effects)|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
62020666|NCT04976920||Treatment Group|"Patients will undergo a routine IVF cycle. This will include ovarian stimulation, egg retrieval and fertilization of oocytes through intracytoplasmic sperm injection (ICSI). All fertilized oocytes will be cultured up to blastocyst for five to six days.~Spent media will be collected on day 5-6 for all embryos reaching blastocyst on day 5, and on day 6 for those reaching blastocyst on day 6. The spent culture media will be sent to a lab for metabolomic analysis.~For the embryo transfer, the best morphology blastocyst will be selected for transfer by the New Hope embryologist. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation."
62020667|NCT03963895|EXPERIMENTAL|AB002 (E-WE-thrombin) Dose 1|Participants will receive a single dose of 1.5 mcg/kg E-WE thrombin.
62214151|NCT05718063|ACTIVE_COMPARATOR|Summarized MAP for Coaches eLearning Training Course|
62409842|NCT04038307|EXPERIMENTAL|paracetamol group|will receive 1gm paracetamol (100ml)
62409843|NCT04827446|EXPERIMENTAL|Intervention Arm|Light intervention delivered through SYNC app + blue-light blocking glasses.
62409844|NCT04827446|ACTIVE_COMPARATOR|Control Arm|Placebo light intervention delivered through SYNC app + clear glasses.
62409845|NCT03622775|EXPERIMENTAL|Treatment (daratumumab)|Beginning 60-120 days after transplant, participants receive daratumumab IV over 4-8 hours on days 1, 8, 15 and 22 of courses 1 and 2 and days 1 and 15 of courses 3-6, then on day 1 of subsequent courses. Courses repeat every 28 days for 3 years in the absence of disease progression or unacceptable toxicity.
62409846|NCT00462241|EXPERIMENTAL|chiropractic treatment|Individualised chiropractic treatment, pragmatic approach
62409847|NCT00462241|SHAM_COMPARATOR|self-management|Self-management: Minimal intervention - practice as usual.
62020668|NCT03963895|EXPERIMENTAL|AB002 (E-WE-thrombin) Dose 2|Participants will receive a single dose of 3.0 mcg/kg E-WE thrombin.
62020669|NCT03963895|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo
62214152|NCT05341401|ACTIVE_COMPARATOR|Budesonide MMX|this study aims to detect the safety and side effects of budesonide MMX in the management of mild to moderate cases of ulcerative colitis in comparison to prednisolone. Budesonide MMX will be given after randomization to patients with mild to moderate cases who failed to respond to mesalazine. The dose will be 9mg as a single dose given for 8 weeks.
62214153|NCT05341401|ACTIVE_COMPARATOR|prednisolone|this study aims to detect the safety and side effects of budesonide MMX in the management of mild to moderate cases of ulcerative colitis in comparison to prednisolone. prdinisolone MMX will be given after randomization to patients with mild to moderate cases who failed to respond to mesalazine. The starting dose will be 40 mg and reduced by 5 mg each weak for 8 weeks .
62214154|NCT04399759|EXPERIMENTAL|A-IADL Group|Approach-Instrumental Activities of Daily Living in home
62214155|NCT04399759|ACTIVE_COMPARATOR|Control group|Home health education
62409848|NCT02159651||1: Dermatomyositis group|patients with interstitial pneumonia associated with dermatomyositis
62409849|NCT02159651||2: Polymyositis group|patients with interstitial pneumonia associated with polymyositis
62791286|NCT04305171||coronary heart disease patients without periodontitisHD|"Coronary heart disease patients confirmed through coronary angiography as having at least 50% diameter stenosis in at least one coronary artery and clinically stable with the absence of any potentially confounding inflammatory conditions for at least 6 months.~Non-periodontitis classified as having PD ≤ 3 mm."
62020670|NCT01750567|EXPERIMENTAL|Metformin (Glucophage)|The starting dose of metformin will be 500 mg po daily for one week. The dose can be escalated to 500 mg twice a day after one week, and further escalated to the final dose of 1000 mg twice a day in week 3 if the medication is tolerated without adverse side effects (refer to holding parameters described in section 9.3.3). All doses should be administered with food to decrease gastrointestinal upset.
62791287|NCT04305171||non-coronary heart disease patients with periodontitis|Periodontitis classified as havingbleeding on probing (BOP), pocket depth (PD) \> 4 mm, clinical attachment level (CAL) ≥ 5 mm and radiographic evidence of bone loss were presented at the same site of at least 4 teeth.
62020671|NCT01678326|ACTIVE_COMPARATOR|EUS-Rendezvous or direct intervention|EUS rendezvous or direct intervention involves: (1) using endoscopic-ultrasound technology to access the bile duct with a small needle and manipulate a wire across the biliary orifice and into the duodenum to be then retrieved endoscopically for ERCP (rendezvous ERCP), or (2) using endoscopic-ultrasound technology to directly puncture and perform intended biliary therapy
62791288|NCT04305171||non-coronary heart disease patients without periodontitis|Non-periodontitis classified as having PD ≤ 3 mm.
62791289|NCT01994044|ACTIVE_COMPARATOR|Multimodal rehabilitation|
62791290|NCT01994044|ACTIVE_COMPARATOR|Cervical fusion|
62020672|NCT01678326|ACTIVE_COMPARATOR|Advanced ERCP Biliary Access Techniques|Advanced ERCP techniques involve the following: precut access sphincterotomy and needle-knife fistulotomy. These are accepted techniques for biliary access in cases of difficult cannulation.
62020673|NCT05456295|NO_INTERVENTION|NoCDO|Participants will be tested with no CDO
62020674|NCT05456295|EXPERIMENTAL|CUFF-A|The first study CDO will be designated CUFF-A
62020675|NCT05456295|EXPERIMENTAL|CUFF-B|The first study CDO will be designated CUFF-B
62020676|NCT05456295|EXPERIMENTAL|CUFF-C|The first study CDO will be designated CUFF-C
62020677|NCT05456295|EXPERIMENTAL|CUFF-D|The first study CDO will be designated CUFF-D
62020678|NCT01253343||inpatient high aggression|
62020679|NCT01253343||inpatient low aggression|
62020680|NCT02171286||No Treatment|
62020681|NCT02688634||Treatment|Participants in this group are randomize to receive post-operative antibiotic of Amoxicillin x7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period. They will be evaluated for infection, fistula formation, and dehiscence upon discharge and at 30-day follow-up based on standards of care.
62020682|NCT02688634||Non-Treatment|Participants in this group will be randomize to no post-operative antibiotic. They will be evaluated for infection, fistula formation, and dehiscence upon discharge and at 30-day follow-up based on standards of care.
62020683|NCT02591693|EXPERIMENTAL|Caregiver Training|"Three home visits by a specialist occupational therapist, each lasting 1-2 hours. Assessment and training to confidently achieve up to three goals relating to practical activities of daily living identified by patient and caregiver.~On-going usual care from multi-professional team at hospice."
62020684|NCT02591693|NO_INTERVENTION|Usual Care|On-going usual care from multi-professional team at hospice.
62020685|NCT04827004|EXPERIMENTAL|Anlotinib Hydrochloride Capsules|This is a multi-target receptor tyrosine kinase inhibitor.
62020686|NCT05542368||Patients with IBD|"All patients were subjected to history taking and physical examination with emphasis on history of autoimmune disease, extraintestinal manifestations of IBD, neck examination for goiter, symptoms and signs of thyroid dysfunction.~b) Laboratory investigations: Thyroid function test (include T3-T4- TSH)~* ESR - CRP - thyroid antibodies: (Anti TPO -Anti Thyroglobulin)~  c)-Imaging:~* Neck U/S on thyroid gland to identify patients with ultrasonographic evidence of autoimmune thyroiditis (diffuse hypoechogenicity or heterogenicity echotexture or both) and to detect thyroid nodularity.~d ) Endoscopic findings regarding diagnosis of IBD confirmed by histopathological examination"
62020687|NCT05542368||Healty individuals as a control group|"All patients were subjected to history taking and physical examination with emphasis on history of autoimmune disease, extraintestinal manifestations of IBD, neck examination for goiter, symptoms and signs of thyroid dysfunction.~b) Laboratory investigations: Thyroid function test (include T3-T4- TSH)~* ESR - CRP - thyroid antibodies: (Anti TPO -Anti Thyroglobulin)~  c)-Imaging:~* Neck U/S on thyroid gland to identify patients with ultrasonographic evidence of autoimmune thyroiditis (diffuse hypoechogenicity or heterogenicity echotexture or both) and to detect thyroid nodularity."
62020688|NCT03290716|EXPERIMENTAL|SS+SSSC|Salt substitute plus stepwise salt supply control
62020689|NCT03290716|EXPERIMENTAL|SS only|Salt substitute only
62214156|NCT04938700|EXPERIMENTAL|Probiotics intervention group|children with definitive diagnosis of allergic rhinitis, asthma，atopic dermatitis and chronic urticaria were enrolled, each with 25 cases. 2) collect manure application of 16s rDNA probe hybridization technique to analyze the fecal flora, and compared with clinical symptoms rating scale and serum sIgE, IgG4 correlation analysis (3) application of probiotic intervention and conventional drugs, again in 3 months, 6 months after collecting dung is used to detect the intestinal flora in children with its correlation with clinical symptoms change were observed.
62214157|NCT04938700|ACTIVE_COMPARATOR|Contrast group|children with definitive diagnosis of allergic rhinitis, asthma，atopic dermatitis and chronic urticaria were enrolled, each with 25 cases. 2) collect manure application of 16s rDNA probe hybridization technique to analyze the fecal flora, and compared with clinical symptoms rating scale and serum sIgE, IgG4 correlation analysis (3) application of conventional drugs, again in 3 months, 6 months after collecting dung is used to detect the intestinal flora in children with its correlation with clinical symptoms change were observed.
62409850|NCT06651814|EXPERIMENTAL|Supervised Exercise Group|Patients receive supervised exercise therapy from a qualified physical therapist or healthcare professional, with a set frequency and duration
62409851|NCT06651814|ACTIVE_COMPARATOR|Home Exercise Group|Patients receive written instructions and demonstrations for performing exercises at home, with recommended frequency and duration
62409852|NCT05934305|EXPERIMENTAL|Matter Intervention|This 5-session text-enhanced intervention is designed to mitigate the negative behavioral consequences of internalized stigma and shame among MSM and gender minority individuals with SUDs that perpetuate sub-optimal engagement in HIV self-care and consequently inconsistent viral suppression. The intervention involves five virtually delivered one-on-one therapy sessions focused on behavioral goal setting skill development and related self-efficacy, increasing meta-cognitive awareness(i.e.,non-judgmental awareness of emotions and cognitions), and teaching and reinforcing compassionate self-restructuring (i.e., self-compassion). Participants also receive daily text messages querying emotions during the one-on-one portion of the intervention. For eight weeks after the one-on-one portion, participants receive their compassionate self-statements via text in response to their indicated emotions. Participants will also receive phone-based resource navigation, as needed.
62791291|NCT01735981|EXPERIMENTAL|video game exercise|Video game exercise using Dance Dance Revolution
62791292|NCT01735981|OTHER|control|hand-held video game control
62791293|NCT05411744|OTHER|1 month Rifapentine, Isoniazid and Vitamin B6|"Participants will receive 28 days of self-administered daily doses of RPT, INH, and pyridoxine (vitamin B6).~There are no multiple arms or multiple interventions. All participants will receive all 3 drugs. There are no comparators."
62791294|NCT02209701|EXPERIMENTAL|Porfiromycin|
62020690|NCT03290716|EXPERIMENTAL|SSSC only|Stepwise salt supply control only
62020691|NCT03290716|NO_INTERVENTION|control|No salt substitute and no stepwise salt supply control
62020692|NCT04681521|EXPERIMENTAL|HOT THERAPY:GROUP A|Hot Compress Group
62020693|NCT04681521|EXPERIMENTAL|COLD THERAPY:GROUP B|Cold Compress Group
62020694|NCT04681521|PLACEBO_COMPARATOR|PLACEBO: GROUP C|Inoperative compress Group
62020695|NCT05093452|EXPERIMENTAL|Motivational interviewing|Educational session based on the motivational interviewing
62020696|NCT05093452|OTHER|Information flyer|Information flyer on childhood vaccines
62409853|NCT05934305|ACTIVE_COMPARATOR|Control Condition|The control condition will involve five sessions of prerecorded asynchronous content related to local resources (e.g., information related to substance use treatment and other ancillary services).
62409854|NCT00448929|EXPERIMENTAL|Trabeculectomy with Oculusgen|
62791295|NCT01959139|ACTIVE_COMPARATOR|Phase II: mFOLFIRINOX|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 1.5 hours on day 2, and 5-fluorouracil (5-FU) IV over 46 hours on days 2-4. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62020697|NCT01490060|EXPERIMENTAL|Single Dose Day 1|Arm 1, Single Dose: Fosaprepitant 150 mg intravenous (IV) Day 1 of Cycle 1 or Day 1 of Cycle 2. Participants randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2); or Group 2 (No Fosaprepitant Cycle 1 and Fosaprepitant Cycle 2). Dexamethasone intravenously (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy. Doxorubicin 25 mg/m\^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m\^2) as part of AI Chemotherapy.
62020698|NCT01490060|EXPERIMENTAL|Two Doses Day 1 + Day 4|Arm 2, Two Doses: Fosaprepitant 150 mg IV Day 1 + Day 4 of Cycle 1 or Day 1 + Day 4 of Cycle 2. Participants randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2); or Group 2 (No Fosaprepitant Cycle 1 and Fosaprepitant Cycle 2). Dexamethasone intravenously (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy. Doxorubicin 25 mg/m\^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m\^2) as part of AI Chemotherapy.
62020699|NCT02565641|EXPERIMENTAL|Capecitabine + Gemcitabine|Participants will receive oral capecitabine (830 milligrams per meter-squared \[mg/m\^2\]) twice daily (BID) as intermittent treatment (Days 1 to 21 every 4 weeks \[q4w\]) along with IV infusion of gemcitabine (1000 mg/m\^2) once weekly as intermittent treatment (4-week cycles of 3-week treatment period and 1-week rest period).
62020700|NCT06149260|EXPERIMENTAL|Semaglutide|Participants will receive once-weekly semaglutide subcutaneous injection at escalating doses from 0.25 mg/week to 0.5 mg/week.
62020701|NCT02473952|EXPERIMENTAL|IGIV-C|"IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified.~An initial loading dose of 2 g/kg of body weight will be administered at Baseline (Week 0, Visit 1) followed by maintenance doses of 1 g/kg of body weight administered every third week through Week 21 (Visit 8)."
62020702|NCT02473952|PLACEBO_COMPARATOR|Placebo|Placebo: Sterile 0.9% sodium chloride injection or equivalent. Placebo will be infused at the Baseline/Week 0 Visit (Visit 1) using the same volume as would be required for the IGIV-C loading dose. Subsequent placebo maintenance doses will be matched in volume to the IGIV-C maintenance doses and administered every third week until Week 21 (Visit 8).
62020703|NCT02486003||mTBI athletes|College athletes who undergo an mTBI during the season
62020704|NCT02486003||Control athletes|College athletes who do not undergo an mTBI during the season
62214158|NCT01097707|EXPERIMENTAL|1mg LY500307|
62409855|NCT00448929|NO_INTERVENTION|Trabeculectomy without Oculusgen or antifibrotic agents|
62734573|NCT04347512|EXPERIMENTAL|Hydroxychloroquine|"Hydroxychloroquine is given for 5 days, with a loading dose of 400 mg qd at D1, and 200 mg qd for the next 4 days (D2-D5).~Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc)"
62791296|NCT01959139|EXPERIMENTAL|Phase II: mFOLFIRINOX + PEGPH20|Patients receive pegylated recombinant human hyaluronidase (PEGPH20) IV over 10 minutes on day 1 and oxaliplatin, leucovorin calcium, irinotecan hydrochloride, and 5-fluorouracil (5-FU) as in Arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62791297|NCT01959139|EXPERIMENTAL|Phase I|PEGPH20, 3 ug/kg on Day 1 and Day 3/4, IV over 15 minutes; Oxaliplatin, 85 mg/m\^2, on Day 2, IV over 2 hours; Leucovorin, 400 mg/m\^2, on Day 2, IV over 2 hours; Irinotecan, 180 mg/m\^2, on Day 2, IV over 1.5 hours; 5-fluorouracil (5-FU), 2,400 mg/m\^2, Days 2-4, IV over 46 hours
62020705|NCT02486003||Control non-athletes|Control non-athletes with long term follow-up of approximately 4-6 weeks and 3-5 months
62020706|NCT00782613|ACTIVE_COMPARATOR|1|Two psoriatic plaques of similar surface area and severity will be identified for each subject. ALT-2074 will be applied topically twice daily to 1 of the 2 target plaques, and the placebo control to the other plaque for a period of 28 days in amounts sufficient to cover the entire surface area of the target plaque, extending to 1 cm outside of the plaque border.
62020707|NCT00782613|PLACEBO_COMPARATOR|2|Placebo
62020708|NCT01272934|PLACEBO_COMPARATOR|Placebo|
62214159|NCT01097707|EXPERIMENTAL|3mg LY500307|
62020709|NCT01272934|EXPERIMENTAL|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%
62214160|NCT01097707|EXPERIMENTAL|10mg LY500307|
62214161|NCT01097707|EXPERIMENTAL|25mg LY500307|
62214162|NCT01097707|PLACEBO_COMPARATOR|Placebo|
62215276|NCT02423278|EXPERIMENTAL|D4 Lymphadenectomy|"This is the interventional group in which additional para-aortic lymph nodes are dissected meanwhile.~Under this arm, main therapeutic measures are listed as follows:~* three-cycle SOX chemo regimen (S-1+Oxaliplatin) as neoadjuvant chemotherapy~* radical gastrectomy plus D4 lymphadenectomy~* five-cycle SOX chemo as adjuvant chemotherapy~* five-year follow-up program to evaluate the prognosis."
62409856|NCT06586658|EXPERIMENTAL|Assigned Interventions|
62409857|NCT04298008|EXPERIMENTAL|AZD6738 + Durvalumab Cohort|This is a study enrolling advanced BTC patients who have been previously treated with immunotherapy, to explore the combination of AZD6738+durvalumab
62409858|NCT04800159|ACTIVE_COMPARATOR|THC Cannabis|11.86% THC/ 1.12% CBD
62409859|NCT04800159|ACTIVE_COMPARATOR|CBD Cannabis|0.35% THC/ 11.27% CBD
62409860|NCT04800159|PLACEBO_COMPARATOR|Placebo|≤ 0.01% THC/ ≤ 0.01% CBD
62409861|NCT04431960|ACTIVE_COMPARATOR|low-BC Group|consume: 1) one tablet containing 392 mg blackcurrant (BC) extract per capsule and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
62734574|NCT04347512|ACTIVE_COMPARATOR|Control|The patient is given antibiotics only. Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc).
62020710|NCT06341218|EXPERIMENTAL|Intervention Group|The intervention group was divided into 5 CPR teams consisting of 5 nurses and 2 physician assistants. While forming the intervention group, stratified random sampling was performed by targeting the years of professional experience of assistant physicians and nurses and homogeneity between subgroups was ensured. CRM-Based Pediatric CPR Training was given to the intervention group.
62020711|NCT06341218|NO_INTERVENTION|Control Group|The Control group was divided into 5 CPR teams consisting of 5 nurses and 2 physician assistants. While forming the control group, stratified random sampling was performed by targeting the years of professional experience of assistant physicians and nurses, and homogeneity between subgroups was ensured. The control group was assumed to know pediatric CPR management as per their clinical duties and no educational intervention was made.
62020712|NCT02356016|ACTIVE_COMPARATOR|Whole body Electromyostimulation (WB-EMS)|18 min of WB-EMS/week (one session/week)
62020713|NCT02356016|ACTIVE_COMPARATOR|WB-EMS and Nutritional Supplements|18 min of WB-EMS/week (one session/week) and supplements with high protein (Leucin) contents
62214163|NCT06424405|EXPERIMENTAL|objective titration procedure|Objective titration procedure will be based on the objective diagnosis and treatment indicator AHI（Apnea-hypopnea index）which will be provided by RISMS (Remotely intelligent sleep monitoring system). SC-500TM is a comfortable contactless under-mattress sleep monitor, as a main component of the RISMS will be given to patients to collect the sleep data every night at home setting. The sleep report will be generated automatically every day providing the value of AHI and uploaded to the clinicians in real-time. The clinicians will contact the patients by phone every 3-7 days and instruct them remotely to adjust the MAD to increase the mandibular advancement by 0.25-1mm each time, according to AHI together with the self-reported evolution of symptoms. The patients will adapt this new mandibular advancement for 3-7 days and the clinicians will contact them again for further adjustment until a significant improvement of AHI and resolution of symptoms occurs.
62409862|NCT04431960|ACTIVE_COMPARATOR|high-BC Group|consume: 1) two capsules containing 392 mg BC extract per tablet (total 784 mg/day) and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
62791298|NCT00726232|EXPERIMENTAL|Ruxolitinib 10 mg BID|Participants received 10 mg Ruxolitinib orally twice a day (BID) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
62791299|NCT00726232|EXPERIMENTAL|Ruxolitinib 25 mg BID|Participants received 25 mg Ruxolitinib orally twice a day (BID) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
62791300|NCT00726232|EXPERIMENTAL|Ruxolitinib 50 mg QD|Participants received 50 mg Ruxolitinib orally once a day (QD) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
62791301|NCT03205683|EXPERIMENTAL|Intraneural facilitation therapy|The intraneural facilitation intervention is a novel manual physical therapy approach with anecdotal evidence in neuropathic pain symptoms through biasing blood flow from an artery through the nutrient vessels into the epineurium of an accompanying nerve. The main concept of intraneural facilitation is the use of two manual holds. The first hold is called facilitation hold and includes putting the contralateral joint in a maximal loose-pack position that is comfortable to the patient. The hypothesis with this initial hold is the nerve will have greater excursion the accompanying artery and the nutrient vessels that are clustered at the joint will be stretched. This stretch may enlarge the opening at the junction of the artery and bridging nutrient vessel, therefore consistently creating a vascular bias into the neural epineurial capillaries. Theoretically, this creates increased epifascicular vascular pressure which may be absent due to epineurial ischemia.
62791302|NCT03205683|SHAM_COMPARATOR|Sham therapy|"Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm Each visit will last about 45 minutes, twice a week for 6 weeks (total 12 sessions).~Missing \> 4 sessions will invalidate subject outcomes."
62791303|NCT03190434||amniotic fluid|amniotic fluid identification by AL-SENSE product
62791304|NCT00156416|EXPERIMENTAL|Meditation group|Participants received 8 weeks of mindfulness meditation instruction and support
62791305|NCT00156416|ACTIVE_COMPARATOR|Education group|Participants received 8 weeks of healthy living instruction
62020714|NCT02356016|SHAM_COMPARATOR|Control|Monthly dietary counseling for 6 months
62020715|NCT01888601||NSCLC eligible for primary surgery|NSCLC eligible for primary surgery
62214164|NCT06424405|ACTIVE_COMPARATOR|subjective titration procedure|The subjective titration procedure in this study will be based on self-reported evolution of symptoms and physical limits of the OSAHS patients. Patients will be recalled to the hospital every 1-2 weeks and will be asked about the subjective changes such as snoring, daytime sleepiness，ache of tooth, temporomandibular pain and so on. Then, the clinicians will adjust the MAD to increase degree of mandibular advancement by 0.5-1mm each time. The patients will adapt this new mandibular advancement for 1-2 weeks and have to come back to hospital for further adjustment until an improvement or a resolution of symptoms occurs, or until the patients could not tolerate any further advancement.
62214165|NCT01729442|OTHER|Patients referred for first-line prostate HIFU ablation|10 patients
62214166|NCT01729442|OTHER|Patients referred for first-line HIFU hemi-ablation|10 patients
62020716|NCT00201071||South Bronx, Harlem, Lower East Side|
62409863|NCT04431960|PLACEBO_COMPARATOR|Control Group|consume: 1) one placebo capsule and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
62409864|NCT00967707|ACTIVE_COMPARATOR|Gabapentin + venlafaxine|
62409865|NCT00967707|ACTIVE_COMPARATOR|Gabapentin + donepezil|
62791306|NCT01888224|EXPERIMENTAL|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
62214167|NCT01729442|OTHER|Patients referred for salvage HIFU after radiotherapy|10 patients
62214168|NCT06273592|ACTIVE_COMPARATOR|Plant-based|"The plant-based arm consists of consuming one plant-based meat meal and then using the Rigiscan™ device to measure the frequency, rigidity, and duration of nocturnal erections.~The meal in the plant-based arm and the meal in the animal-based arm will differ only by whether the meal contains plant-based meat or animal meat."
62214169|NCT06273592|ACTIVE_COMPARATOR|Animal-based|"The animal-based arm consists of consuming one animal meat meal and then using the Rigiscan™ device to measure the frequency, rigidity, and duration of nocturnal erections.~The meal in the plant-based arm and the meal in the animal-based arm will differ only by whether the meal contains plant-based meat or animal meat."
62214170|NCT00601770|EXPERIMENTAL|IC41|8 injections of 4 x 0.125mL
62214171|NCT04850677||Total|All subjects in the study belong to the same group/cohort. As this is an observational study there is no intervention planned.
62214172|NCT02324608|EXPERIMENTAL|Treatment (cetuximab)|Patients receive cetuximab IV over 60-120 minutes once weekly for 8 weeks.
62214173|NCT04708353|PLACEBO_COMPARATOR|control group|the patient will receive one placebo capsule (vitamin c) once one hour before the operation.
62214174|NCT04708353|ACTIVE_COMPARATOR|Group Pregabalin 150|the patient will receive one capsule of pregabalin 150 mg once one hour before the operation
62214175|NCT04708353|ACTIVE_COMPARATOR|Group Pregabalin 300|the patient will receive one capsule of pregabalin 300 mg once one hour before the operation
62409866|NCT06509542|EXPERIMENTAL|Measure of FuncUseRatio using wrist-worn accelerometers and videos|"The wristbands are made from hypoallergenic silicone and weigh 27 grams. They contain three accelerometers (AX3, Axivity, Newcastle Helix, United Kingdom), recording data in the three planes of space at a sampling frequency of 50 Hz and within an acceleration range of ±8 g. The wristbands will be worn on each wrist during the activities.~Two high-definition video cameras, recording at least 50 images per second, will be positioned so that the movements of the patient's upper limbs are always visible. The location of the cameras will depend on the activity and the configuration of the room in which it takes place."
62409867|NCT06279468|EXPERIMENTAL|IDR group|A group designated as the IDR group will undergo subsequent intervertebral disc release following Ponte osteotomy on the predetermined vertebral levels.
62409868|NCT06279468|ACTIVE_COMPARATOR|PO group|The PO group will solely undergo Ponte osteotomy.
62409869|NCT01959984|EXPERIMENTAL|100g Standard Noodles|100g Standard Noodles
62020717|NCT06057012|EXPERIMENTAL|BRII-296 600 mg|Participants will receive BRII-296 600 milligram (mg) by intramuscular injection admixed with Depo Medrol (80 milligram per milliliter \[mg/mL\]) on Day 1.
62791307|NCT01888224|ACTIVE_COMPARATOR|AMNESTEEM|AMNESTEEM 40 mg of Mylan Pharmaceuticals Inc
62214176|NCT02819557|EXPERIMENTAL|Ataluren|Participants will be administered ataluren orally at a dose of 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening (for a total of 40 mg/kg/day) for up to 52 weeks. Dose will be provided based upon the weight of each participant, which will be assessed every 12 weeks.
62214177|NCT01412762||patient interviews|We aim to interview 15 patients with confirmed thyroid malignancy both pre- and postoperatively, for a total of 30 interviews. For the expansion of this study, we will accrue 25 patients with biopsy-proven thyroid cancer undergoing thyroidectomy to be educated with the CITSAV application prior to surgery.
62214178|NCT05861700|ACTIVE_COMPARATOR|Group 1: B) Dbic 35 -30 mmol/L C) Dbic 30- 35 mmol/L|"Week 1 - a constant Dbic 35 mmol/L -Treatment A. Week 2 - Dbic 35 mmol/L for the first two hours followed by 30 mmol/L for the remainder of the treatment- Treatment B.~Week 3 - a constant Dbic 35 mmol/L (wash-out period). Week 4 - Dbic 30 mmol/L for the first two hours followed by 35 mmol/L for the remainder of the treatment -Treatment C."
62409870|NCT01959984|EXPERIMENTAL|75g Oral Glucose|75g Oral Glucose
62791308|NCT02338089|NO_INTERVENTION|Control (no oxytocin) pretreatment|Physiological saline solution (PSS). Every 15-minutes, the PSS will be flushed and fresh PSS will be added.
62791309|NCT02338089|ACTIVE_COMPARATOR|Continuous oxytocin (desensitizing) pretreatment|Continuous oxytocin 10-5M. This desensitizing treatment is based on previous experiments in our laboratory demonstrating this phenomenon (reference 25 of Internal Review). The desensitizing pretreatment mimics the clinical setting of labor augmentation. Every 15-minutes, the 10-5M oxytocin will be flushed and fresh 10-5M oxytocin will be added.
62791310|NCT02338089|ACTIVE_COMPARATOR|Pulsatile oxytocin pretreatment|15-minutes of 10-5M oxytocin, followed by PSS for 15-minutes, followed by 10-5M oxytocin, followed by 15-minutes PSS, and so-on, for a total duration of two-hours,
62409871|NCT01028274|PLACEBO_COMPARATOR|Placebo|
62409872|NCT01028274|EXPERIMENTAL|Investigational Product 1|
62020718|NCT01987713|EXPERIMENTAL|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
62020719|NCT06306482||Group A|Patients with chronic obstructive lung disease, asthma, cystic fibrosis and bronchiectasis.
62020720|NCT06306482||Group B|Patients with diffuse parenchymal lung diseases
62020721|NCT06306482||control group|healthy aged matched individuals.
62020722|NCT00708825||1|surgical outcome, observation
62020723|NCT01046643|ACTIVE_COMPARATOR|Estrogen followed by Placebo|Estrogen treatment with Estradiol (E2) followed by Placebo.
62020724|NCT01046643|ACTIVE_COMPARATOR|Progesterone followed by Placebo|Progesterone (P10) treatment followed by Placebo.
62409873|NCT01028274|EXPERIMENTAL|Investigational Product 2|
62409874|NCT01920698|EXPERIMENTAL|MitraClip Device|Subjects randomized to the MitraClip Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.
62409875|NCT01920698|OTHER|Control|Patients randomized to the Control group will receive optimal therapy alone
62409876|NCT06225401|EXPERIMENTAL|Simcapture PRE|In the PRE intervention group (before the traditional teaching) students will practice in pairs, with the same low fidelity simulator, the blood collection technique without a teacher in the classroom. In the SimCapture for Skills interface, the procedure of how to perform the technique (sequence of actions) will be developed in checklist format for the student to check step by step. They will be provided with the same material and classroom time as in traditional teaching (2h).
62409877|NCT06225401|EXPERIMENTAL|Simcapture POST|In the POST intervention group (after the traditional teaching) the students will practice in pairs, with the same low fidelity simulator, the blood collection technique without a teacher in the classroom. In the SimCapture for Skills interface, the procedure of how to perform the technique (sequence of actions) will be developed in checklist format for the student to check step by step. They will be provided with the same material and classroom time as in traditional teaching (2h).
62584637|NCT06667401||The study will recruit the entire CA1 resident class (n=20)|The study will recruit the entire CA1-2 resident class (n=20-30) who have no prior experience with Ultrasound guided regional anesthesia (UGRA) at the Medical College of Wisconsin/Froedtert Hospital. Inclusion criteria include having no prior experience with UGRA. Exclusion criteria include having undergone the regional elective service prior to the inception of the study (CA-2/3 class). No intervention of interest is noted, the cohort will be accessed based on use of the artificial intelligent Ultrasound.
62584638|NCT04229095|ACTIVE_COMPARATOR|Belsomra,(suvorexant)|20 mg single-dose administration given on an inpatient clinical research unit
62584639|NCT04229095|PLACEBO_COMPARATOR|Placebo|Placebo single-dose administration given on an inpatient clinical research unit
62791311|NCT02199925|EXPERIMENTAL|Gammaplex 5% IGIV|Gammaplex 5% IGIV administered intravenously
62791312|NCT05080530|NO_INTERVENTION|1. Normal Vit D (> 30ng/mL)|Follow-up after 3 months with standard treatment
62791313|NCT05080530|EXPERIMENTAL|2. Insufficient Vit D (20-30ng/mL)|single oral dose capsule 200,000 IU of Cholecalciferol
62791314|NCT05080530|NO_INTERVENTION|3. Insufficient Vit D (20-30ng/mL)|Follow-up after 3 months with standard treatment
62020725|NCT01046643|ACTIVE_COMPARATOR|Placebo followed by Estrogen|Placebo followed by Estrogen treatment with Estradiol (E2)
62735093|NCT04586452|EXPERIMENTAL|Non-AAA Group|10 (5 men; 5 women) participants will have a documented absence of AAA by screening ultrasound that was previously obtained as part of standard of care. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
62020726|NCT01046643|ACTIVE_COMPARATOR|Placebo followed by Progesterone|Placebo followed by Progesterone (P10) treatment.
62020727|NCT02332486|ACTIVE_COMPARATOR|Intervene|For Qingxuan Decoction there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China. Qingxuan Decoction is given two times after breakfast and dinner in 56 days.
62791315|NCT05080530|EXPERIMENTAL|4. Deficient Vit D|single oral dose capsule 200,000 IU of Cholecalciferol
62791316|NCT01800630|EXPERIMENTAL|Gemcitabine HCl Oral Formulation (D07001-F4)|Subjects will receive a single 5-mg (nontherapeutic) dose of gemcitabine (Gemzar®) via an IV push and then treated with Gemcitabine HCl Oral Formulation (D07001-F4)according to assigned cohort (2 mg to 80 mg) on Day 1, 3, 5, 8, 10, and 12 of 4 21-day cycles study treatment period.
62791317|NCT04617730|ACTIVE_COMPARATOR|Control arm|
62791318|NCT04617730|EXPERIMENTAL|Interventional arm|
62791319|NCT01447732|EXPERIMENTAL|Part 1|Dose escalation in subjects with advanced solid tumors with Part 1 which includes intervention of CEP-37250/KHK2804
62791320|NCT01447732|EXPERIMENTAL|Part 2|Subjects with colorectal or pancreatic cancer Part 2 which includes intervention of CEP-37250/KHK2804
62020728|NCT02332486|NO_INTERVENTION|Blank|There is no intervention for people in the blank group.
62020729|NCT06127069|EXPERIMENTAL|chitosan group|debridement of residual periodontal pockets with ultrasonic scaler and the chitosan brush
62020730|NCT06127069|ACTIVE_COMPARATOR|control group|debridement of residual periodontal pockets with ultrasonic scaler only
62020731|NCT03640910|EXPERIMENTAL|OT Equators® (Rhein83)|After gingival healing the newest low-profile OT Equators® (Rhein83) will be screwed on to the implants, using the OT Equator® square screwdriver (Rhein83), with a torque range of 22-25 N cm. The cuff heights ranged from 0.5 to 7.0 mm, depending on the height of the transition zone of each implant, easily measured using the color-coded millimeter Cuff Height Measurer Gauge (Rhein83) after healing abutment removal.
62020732|NCT03640910|ACTIVE_COMPARATOR|Locator® (Zest)|The low-profile attachments Locator® (Zest) will be screwed on to the implants, using the Locator® screwdriver (Zest), with a torque range of 20-25 N cm. The cuff heights of 2.5 or 4.0 mm, depending on the height of the transition zone of each implant, measured using the deep probe of the implant line after healing abutment removal.
62214179|NCT05861700|ACTIVE_COMPARATOR|Group 2: C) Dbic 30- 35 mmol/L B) Dbic 35 -30 mmol/L|"Week 1 - a constant Dbic 35 mmol/L -Treatment A. Week 2 - Dbic 30 mmol/L for the first two hours followed by 35 mmol/L for the remainder of the treatment- Treatment C.~Week 3 - a constant Dbic 35 mmol/L (wash-out period). Week 4 - Dbic 35 mmol/L for the first two hours followed by 30 mmol/L for the remainder of the treatment -Treatment B."
62214180|NCT00566592|EXPERIMENTAL|1|Oral ethanol, overnight
62020733|NCT03561779|EXPERIMENTAL|YYD302|YYD302 (2ml)
62735094|NCT04586452|OTHER|Ex Vivo Human AAA Specimens (Aim 2A)|Tissue samples obtained from an existing tissue bank as well as discarded tissue obtained from participants in this study will be examined to assess the sensitivity and specificity of 64Cu-DOTA-ECL1i binding to ex vivo to human AAA specimens.
62020734|NCT03561779|ACTIVE_COMPARATOR|Synovian Inj.|Synovian Inj. (3ml)
62020735|NCT03384758|ACTIVE_COMPARATOR|mild to moderate PAD|
62020736|NCT03384758|ACTIVE_COMPARATOR|Diabetes mellitus|
62020737|NCT03384758|PLACEBO_COMPARATOR|Healthy volunteers|
62020738|NCT06086912|EXPERIMENTAL|sequence 1|
62020739|NCT06086912|EXPERIMENTAL|sequence 2|
62214181|NCT00566592|EXPERIMENTAL|2|IV ethanol, overnight
62214182|NCT00566592|PLACEBO_COMPARATOR|3|Placebo, overnight
62214183|NCT00566592|PLACEBO_COMPARATOR|4|Placebo, daytime
62020740|NCT06086912|EXPERIMENTAL|sequence 3|
62020741|NCT06532006|EXPERIMENTAL|Experimental group|"Experimental group: HLX22 (15 mg/kg) + trastuzumab + chemotherapy (XELOX) ± placebo (for pembrolizumab), Q3W~Subjects in the experimental group may use one of the treatments below:~HLX22 (15 mg/kg) + trastuzumab + chemotherapy (XELOX) or HLX22 (15 mg/kg) + trastuzumab + chemotherapy (XELOX) + placebo (for pembrolizumab)"
62791321|NCT02269930|EXPERIMENTAL|Group 1|Treatment Sequence 1: Single subcutaneous (SC) dose of BIIB017 on Day 1; and SC doses of Rebif on Days 29, 32, 34, 36, 39, and 41 Treatment Sequence 2: SC doses of Rebif on Days 1, 4, 6, 8, 11, and 13; and a single SC dose of BIIB017 on Day 29
62791322|NCT02269930|EXPERIMENTAL|Group 2|Treatment Sequence 1: SC doses of Rebif on Days 1, 4, 6, 8, 11, and 13; and a single SC dose of BIIB017 on Day 29 Treatment Sequence 2: Single subcutaneous (SC) dose of BIIB017 on Day 1; and SC doses of Rebif on Days 29, 32, 34, 36, 39, and 41
62791323|NCT01186055||Smoking Cessation Counseling|Individuals will receive individual and group counseling for 8 weeks (6 visits) while they quit smoking.
62791324|NCT01554449|EXPERIMENTAL|Serious game|In this group, patients will have a session of conventional retraining with a serious game retraining.
62791325|NCT01554449|ACTIVE_COMPARATOR|control patients|In this group, patients will have the conventional retraining with an other conventional retrainning session. The difference between both groups of patients is the serious game session for one group and conventional session for the other group
62791326|NCT01554449|PLACEBO_COMPARATOR|controls|For the neurologic assessments, patients are compared to healthy patient (without stroke)
62791327|NCT00823667|ACTIVE_COMPARATOR|Phase 1 Usual care|
62791328|NCT00823667|ACTIVE_COMPARATOR|Phase 2 Intervention|
62791329|NCT04666896|EXPERIMENTAL|Evidence-based tailored care (group A)|Patients who were randomized to group A received a tailored exercise program, with exercises developed based on recent hEDS/HSD research data.
62020742|NCT06532006|ACTIVE_COMPARATOR|Control group|"Control group: Placebo (for HLX22) + trastuzumab + chemotherapy (XELOX) ± pembrolizumab, Q3W~Subjects in the control group may use one of the treatments below:~Placebo (for HLX22) + trastuzumab + chemotherapy (XELOX) or Placebo (for HLX22) + trastuzumab + chemotherapy (XELOX) + pembrolizumab"
62020743|NCT00600600|EXPERIMENTAL|Tigecycline|tigecycline titrated dose according to patient age and clinical status
62214184|NCT03001076|EXPERIMENTAL|bempedoic acid|bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
62791330|NCT04666896|ACTIVE_COMPARATOR|Evidence-based standard care (group B)|This exercise program was composed in order to reflect evidence-based standard care, in a telerehabilitation format.
62791331|NCT04339673|ACTIVE_COMPARATOR|MNB- masseteric nerve block|masseteric nerve block with local anesthesia lidocaine single app.
62791332|NCT04339673|ACTIVE_COMPARATOR|LA -trigger point injection with local anesthetic|local anesthetic injections on trigger points in masseter
62791333|NCT04339673|PLACEBO_COMPARATOR|DN-dry needling|dren needling to masseter
62791334|NCT03761238|EXPERIMENTAL|Standard medical treatment + MARS|Patients assigned to the control arm will receive standard medical treatment (SMT) and liver dialysis using Molecular Adsorbent Recirculating System (MARS).
62791335|NCT03761238|ACTIVE_COMPARATOR|Standard medical treatment|Patients assigned to the control arm will receive standard medical treatment (SMT) as specified in the study protocol.
62791336|NCT01776606|ACTIVE_COMPARATOR|Dose A|Dose A: Botulinum toxin type A
62020744|NCT00770016|EXPERIMENTAL|1|the aim of the present study is to characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic - intramyocellular lipids in 12 adult patients, recently diagnosed with hypothyroidism
62409878|NCT02195921|EXPERIMENTAL|Single point CV12|"choose single point:Zhongwan(CV12).Zhongwan(CV12):On the upper abdomen, 4 B-cun superior to the centre of the umbilicus, on the anterior median line.Manipulating until achieving a de Qi sensation,then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
62020745|NCT01027910|EXPERIMENTAL|PCI-24781 without mandated GCSF|PCI-24781 in combination with doxorubicin without mandated GCSF
62409879|NCT02195921|EXPERIMENTAL|Single point ST36|"choose another single point Zusanli（ST36）.Zusanli(ST36):On the anterior aspect of the leg, on the line connecting ST35 with ST41, 3 B-cun inferior to ST35，located on the tibialis anterior muscle..Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
62409880|NCT02195921|EXPERIMENTAL|ST36+CV12 acupoints|"Choose both Zusanli(ST36) and Zhongwan（CV12）.Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
62409881|NCT02195921|ACTIVE_COMPARATOR|only antiemetics|The control group will receive standard antiemetics alone. Standard antiemetics for all groups are based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron , Tropisetron)and dexamethasone are supplied from the first day of chemtherapy,and lasting for 3-5days. If nausea and/or vomiting is persistent and failed to respond to the antiemetic treatment , based on the experience of each clinician, the other advanced 5-HT3 antagonist or a neurokinin 1 antagonist(NK-1) will be chosen.
62409882|NCT06119737|EXPERIMENTAL|Moderate Intensity Continuous Training|
62409883|NCT06119737|ACTIVE_COMPARATOR|Resistance Training|
62409884|NCT06119737|ACTIVE_COMPARATOR|High-Intensity Interval Training|
62409885|NCT06119737|ACTIVE_COMPARATOR|1/2- High-Intensity Interval Training|
62409886|NCT04715321||Training cohort|HCC patients enrolled in our study underwent a perfusion CT examination before surgery . We used CT perfusion parameters to predict the vascular pattern of tumors.
62409887|NCT04715321||Validation cohort|HCC patients who would undergo a perfusion CT examination before surgery will be enrolled in our study from January 15, 2021. We use CT perfusion parameters to predict the vascular pattern of tumors.
62791337|NCT01776606|PLACEBO_COMPARATOR|Dose B|Dose B: Placebo
62020746|NCT01027910|EXPERIMENTAL|PCI-24781 with mandated GCSF|PCI-24781 in combination with doxorubicin with mandated GCSF
62409888|NCT02987114|EXPERIMENTAL|PLT101|PTL101 capsules (50 or 100 mg CBD per capsule) up to 25 mg/kg/day or up to 450 mg/day, the lower of the two. Twice daily (morning and evening).
62409889|NCT00926809|ACTIVE_COMPARATOR|Eradication|Helicobacter pylori eradication
62020747|NCT04624698|EXPERIMENTAL|Implantation|Subjects will undergo cataract surgery and then implantation of the iStent Inject trabecular micro-bypass device.
62214185|NCT03001076|PLACEBO_COMPARATOR|placebo|Matching placebo tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
62409890|NCT00926809|PLACEBO_COMPARATOR|No eradication|No eradication for Helicobacter pylori
62409891|NCT04757402|ACTIVE_COMPARATOR|Control arm|All eligible candidates will be receiving standard preoperative counselling as per the hospital standards and protocols. The patient will fill five-points Amsterdam Preoperative Anxiety and Information Scale (APAIS) form for anxiety evaluation and Seven-points Likert Scale form for satisfaction regarding the counselling.
62791338|NCT00475709|EXPERIMENTAL|Trifecta Aortic Heart Valve|All subjects enrolled into the study are implanted with the Trifecta Aortic Heart Valve.
62214186|NCT02914418|EXPERIMENTAL|Active iTBS|iTBS will be delivered using the 50Hz, 600 pulses protocol for 10 sessions over a period of two weeks. The hand representation of the primary motor cortex will targeted using a circular coil held over the vertex of skull. Intensity will be set to 80% of Resting Motor Threshold (RMT), which will be determined visually by the lowest percentage of stimulator output which can cause upper limb motor twitch in at least 5 out of 10 attempts.
62791339|NCT00342849|EXPERIMENTAL|1|Scuccimer Treatment Group
62791340|NCT00342849|PLACEBO_COMPARATOR|2|In order to provide placebo with an odor comparable to that of succimer, the Drug Distribution Center will place a small canister containing 200 mg of active drug into each bottle of placebo drug. A canister containing 200 mg of placebo will be placed inside each bottle of succimer so that all bottles will appear the same.
62791341|NCT05875298|EXPERIMENTAL|physical therapy protocol|the patients will receive physical therapy protocol three times a week for four weeks
62791342|NCT05875298|EXPERIMENTAL|physical therapy protocol and medical drugs|the patients will receive physical therapy protocol three times a week for four weeks and medication twice daily for four weeks
62791343|NCT05875298|ACTIVE_COMPARATOR|medical drugs|the patients will receive medical drugs twice daily for four weeks
62409892|NCT04757402|EXPERIMENTAL|NSQIP Arm|All eligible candidates will be receiving standard preoperative counselling as per the control arm PLUS the risk will be explained using the scores from the NSQIP surgical risk calculator. The anxiety and the satisfaction scores will be recorded as in the control arm.
62584640|NCT03840759|EXPERIMENTAL|usual care|For the intervention group, a geriatric physician was consulted and recommendations were made by the geriatric consultant and inpatient geriatric consultation team after a complete geriatric assessment (CGA). The CGA includes the assessment of depression, dementia, physical performance of Activity of Daily Living (ADL) and nutrition using Geriatric Depression Scale (GDC-15), Mini-Mental State Examination (MMSE), Barthel Index (BI), and Mini Nutritional Assessment-Short Form (MNA®-SF) respectively. Besides the geriatric physician, our multidisciplinary team included a social worker, nutritionist and physical therapist. In the control group, the participants only received routine hospital care and no geriatric physician was consulted.
62020748|NCT00983229|ACTIVE_COMPARATOR|CTrach|"1. Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~2. Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~3. Insertion of CTrach (sizes 3,4 or 5), establishment of ventilation.~4. Direct evaluation of laryngeal view through CTrach~5. Tracheal intubation through CTrach LMA~6. Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~7. At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
62214187|NCT02914418|SHAM_COMPARATOR|Sham iTBS|Sham iTBS will be delivered using the 50Hz, 600 pulses protocol for 10 sessions over a period of two weeks. Intensity will be set at 80% RMT. Circular coil will be held over vertex of skull but angled away to ensure no neural stimulation.
62214188|NCT04261426|EXPERIMENTAL|IVIG therapy+ standard care|
62214189|NCT04261426|PLACEBO_COMPARATOR|Standard care|
62214190|NCT06419400|EXPERIMENTAL|Supportive Text Messagses|The intervention group will receive a series of supportive text messages over the 6 month trial period, varying in content and frequency. They will also be asked to provide self reported data on their symptoms and their adherence at 3 points in time (start, mid-point, and end of trial).
62214191|NCT06419400|NO_INTERVENTION|Control Group|The control group will receive no supportive text messages over the period of the trial. They will be asked to only provide self reported data on their symptoms and their adherence at 3 points in time (start, mid-point, and end of trial).
62214192|NCT01446757|EXPERIMENTAL|The intervention group|The intervention group will receive Comprehensive Geriatric Assessment and follow up as a complement to the same standard health care services as the control group. The Comprehensive Geriatric Assessment and follow up will be provides through an outpatient facility that tailors care from a holistic perspective and, based on each patient's individual needs in line with the policy program that Sweden's pensioners' organizations have presented in 2010 together with the Swedish Association of Geriatric Medicine. The team includes, among other things. a. geriatricians, nurses, physiotherapists, assistance officer, dietician, pharmacist and co-operation with the dental hygienist.
62214193|NCT01446757|PLACEBO_COMPARATOR|Control group|The control group will receive care in the same way as usual meaning access to primary care, hospital in- and outpatient care and care received by the municipality. The only difference between the two groups are that the control group will not have access to the geriatric care team.
62214194|NCT02869516||Patient with new diagnosis of Acute Leukemia|
62214195|NCT01125631|EXPERIMENTAL|PF-04360365 8.5 mg/kg|
62214196|NCT01125631|PLACEBO_COMPARATOR|Placebo|
62214197|NCT03803839|ACTIVE_COMPARATOR|Clodronate|1 mM clodronate (60 mg in 1000 ml saline) was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the clodronate solution. The time for rinsing was about one minute.
62214198|NCT03803839|PLACEBO_COMPARATOR|Saline|1000 ml saline was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the saline solution. The time for rinsing was about one minute.
62214199|NCT06474819|EXPERIMENTAL|deep|The ventricular lead will be penetrated into the basal interventricular septum aiming at left septal pacing and, if not possible, at least deep septal pacing with a paced QRS duration \<=140ms.
62214200|NCT06474819|ACTIVE_COMPARATOR|Apex|The ventricular lead will be placed in the right ventricular apex.
62214201|NCT01077427|ACTIVE_COMPARATOR|Gemcitabine + Capecitabine|
62214202|NCT01077427|EXPERIMENTAL|Gemcitabine + Cisplatin + regional hyperthermia|
62409893|NCT03562923|EXPERIMENTAL|Test Product|Test Product, 100/50 mcg, 2 x daily
62409894|NCT03562923|ACTIVE_COMPARATOR|Reference Product|Reference Product, 100/50 mcg, 2 x daily
62409895|NCT03562923|PLACEBO_COMPARATOR|Placebo|Placebo Product 2 x daily
62584641|NCT06668714|PLACEBO_COMPARATOR|Placebo pre-diabetes|
62584642|NCT06668714|EXPERIMENTAL|Lactate pre-diabetes|
62584643|NCT06668714|ACTIVE_COMPARATOR|Healthy|We will include 8 healthy, normal-weight individuals (BMI 20-25 kg/m2, age 50+ years) as a healthy control group, who will be studied twice following ingestion of a liquid test meal to determine the differences in meal fat partitioning between insulin-sensitive and insulin-resistant individuals and to determine the intraindividual variation in meal fat partitioning. Furthermore, the extra PET scans performed in the healthy individuals will be used for precise quantification of the radiation exposure with the PET method (dosimetry) and validation of the PET method.
62584644|NCT00282399|EXPERIMENTAL|DACO-019 2mg/m^2|DACO-019 2mg/m\^2 twice daily (BID)
62584645|NCT00282399|EXPERIMENTAL|DACO-019 5mg/m^2|DACO-019 5mg/m\^2 BID
62214203|NCT05659498|EXPERIMENTAL|Intervention|The standard cardiac rehabilitation program consists of the following: a (1) consultation with a kinesiologist to assess level of fitness and to prepare an individually customized exercise plan, (2) consultation with a dietitian to guide the participant with healthy nutrition choices, (3) on site supervised and/or virtual exercise sessions with gradual elaboration of a home program, (4) weekly educational capsules and monthly workshops related to cardiac health, and, (5) if deemed necessary by the treating team, consultation with a psychologist, an occupational therapist, a physiotherapist, or a social worker.
62214204|NCT05659498|NO_INTERVENTION|Control|Participants in the control group will receive educational information on maintaining optimal cardiovascular health. Participants will be encouraged to undergo 30 minutes of moderate-intensity aerobic activity at least 5 days per week. Participants will be given educational materials on recommended diet and exercise.
62214205|NCT00847808|EXPERIMENTAL|1|
62214206|NCT01382368|EXPERIMENTAL|Sildenafil|
62214207|NCT02784951||Single group|Patients in haemorrhagic shock needing volume replacement and receiving prehospital transfusion of blood products, either red blood cells (RBC), freeze dried plasma (FDP) or whole blood (WB).
62214208|NCT02996474|EXPERIMENTAL|Pembrolizumab and Decitabine for treatment of Acute Myeloid Leukemia|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Up to eight cycles of pembrolizumab will be given during the initial induction phase. Each cycle is 21 days. Decitabine will be administered at a dose of 20 mg/m\^2 by intravenous infusion over approximately 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7) for treatment relapsed/refractory AML.
62214209|NCT01034163|EXPERIMENTAL|Panobinostat (PAN)|Participants received 45 mg orally 3 times a week (TIW), every other week (QOW),
62214210|NCT01034163|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo to PAN TIW, QOW.
62409896|NCT05743244|EXPERIMENTAL|Abrocitinib|Abrocitinib will be self-administered as 200-milligram (mg) tablet daily for 52 weeks (12 months). The final prepared product is to be labeled to protect the blind.
62409897|NCT05743244|EXPERIMENTAL|Ritlecitinib|Ritlecitnib will be self-administered via oral administration as a 100-mg capsule daily for 52 weeks (12 months). The final prepared product is to be labeled to protect the blind.
62584646|NCT00282399|EXPERIMENTAL|DACO-019 10mg/m^2|DACO-019 10mg/m\^2 BID
62584647|NCT00730730|EXPERIMENTAL|Complete SE Iliac Stent|Complete SE Iliac Stent
62584648|NCT06083961|EXPERIMENTAL|Alirocumab|The treatment group patients will receive an additional PCSK9 inhibitor (alirocumab 300mg once) at emergency departement in addition to statin therapy, which is conventional medication given for acute ischemic stroke.
62214211|NCT04961619||dabrafenib and trametinib|patients on adjuvant treatment with dabrafenib + trametinib
62214212|NCT05418088|EXPERIMENTAL|Cohort A (lymphodepletion; anti-CD19/CD20/CD22 CAR-T cells)|"LYMPHODEPLETIVE REGIMEN: Patients receive cyclophosphamide IV over 60 minutes on day -6 and fludarabine IV over 30 minutes on days -5 to -3 in the absence of disease progression or unacceptable toxicity.~CAR T-CELL THERAPY: Patients receive anti-CD19/CD20/CD22 CAR-T cells IV over 5-30 minutes on day 0."
62214213|NCT05418088|EXPERIMENTAL|Cohort B (lymphodepletion, anti-CD19/CD20/CD22 CAR-T cells)|"LYMPHODEPLETIVE REGIMEN: Patients receive cyclophosphamide IV over 60 minutes on day -6 and fludarabine IV over 30 minutes on days -5 to -3 in the absence of disease progression or unacceptable toxicity.~CAR T-CELL THERAPY: Patients receive anti-CD19/CD20/CD22 CAR-T cells IV over 5-30 minutes on day 0 and 7."
62409898|NCT05743244|PLACEBO_COMPARATOR|Placebo|200 mg tablet or 100 mg capsule matching either abrocitinib or ritlecitinib will be self-administered via oral administration daily for 52 weeks (12 months). The final product is to be labeled to protect the blind.
62409899|NCT04240665|EXPERIMENTAL|DMN Intervention|Subjects will attend 2-hour weekly sessions for 6- weeks. Participants will continue to use the DMN application for 4-weeks after the intervention is complete.
62409900|NCT06124001|EXPERIMENTAL|Experimental: Single Arm|"VG161:~1)1.0 × 10 \^ 8 PFU daily for 2 consecutive days on Days 1-2 of each cycle (D1-D2); 2)1.0 × 10 \^ 8PFU daily for 3 consecutive days on Days 1-3 of each cycle (D1-D3); camrelizumab: 3 mg/kg every 3 weeks (D8)~Part2:~Depends on the recommended dose in Part1"
62409901|NCT06249438|EXPERIMENTAL|C-CAR168|Autologous C-CAR168 administered by intravenous (IV) infusion
62791344|NCT05342766||Group 1|Half of participants (healthy M and F, no children), randomly assigned. Group assignment will balance sex distribution. Nutrigenetic testing will be performed prior to intervention. Participants will work with a registered dietician, who will assess their current nutrient intakes and corresponding nutrient plasma values (T0). Target nutrient intakes will be determined based on nutrigenetic assessment. Participants undergo a nutrition intervention (first 3 months, Intervention 1), in which the difference between actual intakes and nutrigenetically-recommended intakes will be provided using supplements. At the end of Intervention 1 (T1), nutrient plasma values will be measured. After a wash-out period (3 months, no supplementation), nutrient plasma levels will be measured (T2), and a second intervention (3 months, Intervention 2) will consist of supplements administered according to EFSA recommended levels. At the end of Intervention 2, plasma nutrient levels will be measured (T3).
62409902|NCT01439776|NO_INTERVENTION|Peginterferon alfa 2a+Ribavirin|standard of care for HCV : peginterferon alfa 2a and ribavirin
62214214|NCT01685723|EXPERIMENTAL|Counseling group|"Subjects in this group will receive a face-to-face individualized brief advice based on risk communication for 15-30 minutes from the nurse counselors and a booster intervention (10-15 minutes) at 1 week.~Data collection will be conducted at 1 week, 1, 3, 6, 9, 12 months via telephone.Ten subjects from the intervention group who have not quitted will be invited for a process evaluation in the form of face-to-face interviews by research assistants at 12-month follow-up."
62791345|NCT05342766||Group 2|Half of participants (healthy M and F, no children), randomly assigned. Group assignment will balance sex distribution. Nutrigenetic testing will be performed prior to intervention. Participants will work with a registered dietician, who will assess their current nutrient intakes and corresponding nutrient plasma values (T0). Target nutrient intakes will be determined based on nutrigenetic assessment. Participants undergo a nutrition intervention (first 3 months, Intervention 1), in which the difference between actual intakes and EFSA-recommended intakes will be provided using supplements. At the end of Intervention 1 (T1), nutrient plasma values are measured. After a wash-out period (3 months, no supplementation), nutrient plasma levels will be measured (T2), and a second intervention (3 months, Intervention 2) will consist of supplements administered according to targets recommended by nutrigenetic testing. At the end of Intervention 2, plasma nutrient levels will be measured (T3).
62791346|NCT02133885|ACTIVE_COMPARATOR|Minocycline Group|These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
62214215|NCT01685723|SHAM_COMPARATOR|General supporting|"Subjects in this group will receive standard care without risk communication.~Data collection will be conducted at 1 week, 1, 3, 6, 9, 12 months via telephone."
62409903|NCT01439776|EXPERIMENTAL|Vit D+Peginterferon alfa 2a+Ribavirin|VitD+Peginterferon alfa 2a+Ribavirin
62409904|NCT05019872|ACTIVE_COMPARATOR|Penne hard|20 g penne cooked for 7 minutes
62584649|NCT06083961|NO_INTERVENTION|Standard of care|The control group patients will receive standard and conventional acute ischemic stroke treatment, which includes statin therapy.
62584650|NCT06665399||Observation|"In this study, the definition of observation is that participants cannot receive the following treatments currently considered to have a clear efficacy for NL-GLM/PDM."
62584651|NCT03901833|EXPERIMENTAL|Telemedicine Support|Weekly telemedicine breastfeeding support visits for four weeks, delivered via telemedicine
62791347|NCT02133885|PLACEBO_COMPARATOR|Placebo Group|These subjects will start with placebo (this will look like minocycline) for 16 weeks, followed by a washout period for 3 weeks, then will receive a minocycline for 16 weeks, followed by a washout period for 3 weeks, then will finish with placebo for 16 weeks.
62791348|NCT03039335||Adults with an AAT Deficiency|Subjects over the age of 18 that have been recently diagnosed with an Alpha-1 Antitrypsin deficiency will be enrolled into the study to observe the interval between first symptom and initial diagnosis.
62791349|NCT04131075||Study group|Patients with CAD undergoing FFR-guided revascularisation. FFR, coronary flow reserve (CFR) and the index of hyperemic microvascular resistance (HMR) will be measured with the Doppler guidewire (Combowire, Volcano - Philips corporation) under steady state hyperemia.
62791350|NCT04375111|ACTIVE_COMPARATOR|SAP block for management of post-mastectomy pain|the patients in this group shall undergo Serraturs anterior plane block for management of post-mastectomy pain.
62791351|NCT04375111|ACTIVE_COMPARATOR|TTP block combined with SAP block for post-mastectomy pain|the patients in this group shall undergo combined Serraturs anterior plane block, and Transversus thoracic plane block for management of post-mastectomy pain.
62791352|NCT00694018|ACTIVE_COMPARATOR|Education and Standard Care|Received standard care and participated in an educational program for individuals with chronic back pain. Also received an uploading pedometer but no feedback or goals about their walking activity.
62409905|NCT05019872|ACTIVE_COMPARATOR|Penne soft|20 g penne cooked for 20 minutes
62409906|NCT05019872|ACTIVE_COMPARATOR|Carrot hard|50 g diced carrot cooked for 2 minutes
62409907|NCT05019872|ACTIVE_COMPARATOR|Carrot soft|50 g diced carrot cooked for 20 minutes
62409908|NCT05019872|ACTIVE_COMPARATOR|Penne hard + sauce|20 g penne cooked for 7 minutes + 10 g tomato sauce
62409909|NCT05019872|ACTIVE_COMPARATOR|Penne soft + sauce|20 g penne cooked for 20 minutes + 10 g tomato sauce
62584652|NCT03901833|PLACEBO_COMPARATOR|Control|Standard of care
62214216|NCT05417776|EXPERIMENTAL|Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD)|Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) will receive \[68Ga\]CBP8 and undergo PET-MRI.
62214217|NCT05417776|EXPERIMENTAL|First degree relatives of a family member with pulmonary fibrosis|First degree relatives of a family member with pulmonary fibrosis will receive \[68Ga\]CBP8 and undergo PET-MRI.
62214218|NCT00794144|EXPERIMENTAL|1|Olopatadine Hydrochloride Nasal Spray 0.6%
62214219|NCT00794144|PLACEBO_COMPARATOR|2|Olopatadine Hydrochloride Nasal Spray Vehicle
62214220|NCT03301129|EXPERIMENTAL|Traditional cigarette|smoke one Traditional cigarette (with a mean nicotine content of 0.6 mg according to package label) and in a sub-group smoke a sham cigarette (an traditional cigarette without combustion).
62214221|NCT03301129|EXPERIMENTAL|Electronic cigarette|smoke a tobacco-flavored Electronic cigarette (9 puffs approximately equivalent to 0.6 mg of nicotine content) and in a sub-group smoke a sham cigarette (an electronic cigarette without nicotine).
62214222|NCT03301129|EXPERIMENTAL|Heat-not-burn tobacco products (IQOS)|smoke one IQOS cigarette (with a mean nicotine content of 0.6 mg according to package label).
62214223|NCT04392661||Laparoscopic Sleeve Gastrectomy (group I)|111 morbid obese females underwent LSG (group I). After 5 years follow up, the following were looked at: percentage excess weight loss (%EWL), comorbidity improvement or resolution, postoperative complications or mortality, fertility outcomes and breast feeding.
62214224|NCT04392661||Laparoscopic Roux-en-Y Gastric Bypass (group II)|86 morbid obese females underwent LRYGB (group II). After 5 years follow up, the following were looked at: percentage excess weight loss (%EWL), comorbidity improvement or resolution, postoperative complications or mortality, fertility outcomes and breast feeding.
62214225|NCT02022995||Patients with cetuximab treatment|Patients with cetuximab treatment
62214226|NCT02022995||Patients without cetuximab treatment|Patients without cetuximab treatment
62409910|NCT05019872|ACTIVE_COMPARATOR|Carrot hard + sauce|50 g diced carrot cooked for 2 minutes + 10 g tomato sauce
62214227|NCT00903604|EXPERIMENTAL|AP214|Infusions of sequential ascending dosages of AP214
62214228|NCT00903604|PLACEBO_COMPARATOR|Placebo|Infusions of saline solution
62214229|NCT00736892||A|All patients meeting the American European Consensus definition of acute lung injury will be included, regardless of etiology of respiratory failure. Specifically, all patients with rapid onset of acute lung injury not of cardiac origin (no indication of heart failure or a pulmonary capillary wedge pressure of greater than 18 mmHg, with pulmonary infiltrates in all four quadrants and a PaO2/FIO2 of \> 200 to \<300 mmHg or ≤ 200 mmHg.
62214230|NCT03690583|EXPERIMENTAL|Zinc group|Zinc sulfate 10 mg in children younger than 1 year old, 20 mg in children older than 1 year old
62214231|NCT03690583|PLACEBO_COMPARATOR|Placebo group|Glucose
62214232|NCT04602078|EXPERIMENTAL|AUREA single-arm|"Atezolizumab (1200 mg) intravenously administered every 21 days (one cycle) up to disease progression, unacceptable toxicity or absence of clinical benefit.~Gemcitabine 1000 mg/m2 IV on D1 and 1000 mg/m2 IV on D8 of each 21-day cycle plus Cisplatin 70 mg/m2 by IV on split-dose schedule of 35 mg/m2 on day 1 (D1) and 35 mg/m2 on day 8 (D8) for up to 6 cycles."
62214233|NCT03942900||Cohort LAND|Patients enrolled in OPTIMANAL clinical trial
62214234|NCT04510090|EXPERIMENTAL|EP547 Single Dose|Single doses of EP547
62214235|NCT04510090|EXPERIMENTAL|EP547 Multiple Doses|Multiple doses of EP547
62214236|NCT04510090|PLACEBO_COMPARATOR|Placebo Single Dose|Single doses of placebo
62214237|NCT04510090|PLACEBO_COMPARATOR|Placebo Multiple Doses|Multiple doses of placebo
62214238|NCT02685345|EXPERIMENTAL|DS-8500a 25 mg QD|DS-8500a 25 mg tablets, orally, once daily (QD) for up to 28 days
62214239|NCT02685345|EXPERIMENTAL|DS-8500a 75 mg QD|DS-8500a 75 mg tablets, orally, once daily (QD) for up to 28 days
62214240|NCT02685345|PLACEBO_COMPARATOR|placebo|placebo tablets, orally, once daily for up to 28 days
62214241|NCT06608290|EXPERIMENTAL|Blockade|In patients which parasternal block has been applied
62214242|NCT06608290|EXPERIMENTAL|Control|In patients which parasternal block has not been applied
62214243|NCT06472830||Observational|Participants undergo medical chart review and blood sample collection, as well as complete a questionnaire on study. Participants who test positive for MGUS are notified, along with their primary care physician, so that the necessary follow up and referral is provided as clinically indicated.
62214244|NCT05476302||Cognitive digital treatment|Cognitive digital treatment in patients with Parkinson's disease
62214245|NCT02465853|PLACEBO_COMPARATOR|Placebo group|Injection 0.9% Physiological saline solution\<2.5 ml and physical therapy and occupational therapy
62214246|NCT02465853|EXPERIMENTAL|Hyaluronic Acid|injection Hyaluronic Acid 2.5ml and physical therapy and occupational therapy
62214247|NCT04802720|EXPERIMENTAL|ERT-C: Emotion Regulation Therapy for Cancer Caregivers|Emotion Regulation Therapy for Cancer Caregivers (ERT-C) is an 8-session intervention that builds upon the foundations of CBT-C and addresses earlier motivational processing components of the caregivers context while targeting earlier and later components of internal distress and resultant maladaptive behavioral coping.
62409911|NCT05019872|ACTIVE_COMPARATOR|Carrot soft + sauce|50 g diced carrot cooked for 20 minutes + 10 g tomato sauce
62409912|NCT05019872|ACTIVE_COMPARATOR|Penne hard + carrot hard + sauce|20 g penne cooked for 7 minutes + 50 g diced carrot cooked for 2 minutes + 20 g tomato sauce
62409913|NCT05019872|ACTIVE_COMPARATOR|Penne hard + carrot soft + sauce|20 g penne cooked for 7 minutes + 50 g diced carrot cooked for 20 minutes + 20 g tomato sauce
62409914|NCT05019872|ACTIVE_COMPARATOR|Penne soft + carrot hard + sauce|20 g penne cooked for 20 minutes + 50 g diced carrot cooked for 2 minutes + 20 g tomato sauce
62409915|NCT05019872|ACTIVE_COMPARATOR|Penne soft + carrot soft + sauce|20 g penne cooked for 20 minutes + 50 g diced carrot cooked for 20 minutes + 20 g tomato sauce
62409916|NCT06650943|EXPERIMENTAL|Intervention|The intervention consists of 8 nursing consultations with a mental health nurse trained in healthy habits for individuals with psychosis. During the first 2 months, 4 consultations will focus on dietary habits based on the carbohydrate-insulin theory and physical activity, following a guide developed by experts, incorporating recommendations from the American Diabetes Association. Visits 5 and 6 occur at 3 and 4 months; visit 7 at 6 months to evaluate effectiveness, and visit 8 at 12 months. Weight will be monitored throughout. Assessments at baseline, 6, and 12 months will include labs, vital signs, and scales for psychopathology, quality of life, and activity level. Each session covers key topics, from intervention goals to diet tips and physical activity. The approach is flexible, aiming for gradual habit integration, supported by a therapeutic relationship. Phone reminders will enhance adherence.
62584653|NCT02125786|EXPERIMENTAL|Stratum 1: Local Failure|"Participants exhibit an initial pattern of failure that is local (disease confined to primary site). Treatment is surgery and a second course of focal irradiation. The total dose for the second course of irradiation will be 54Gy.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive \^1\^8F-fluorodeoxyglucose and \^1\^1C-methionine to aid in tumor visualization."
62020749|NCT00983229|ACTIVE_COMPARATOR|Intubating Laryngeal Mask Airway (ILMA)|"1. Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~2. Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~3. Insertion of ILMA (sizes 3,4 or 5), establishment of ventilation.~4. Evaluation of laryngeal view through ILMA using fibrescope~5. Tracheal intubation through ILMA using fibrescope.~6. Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~7. At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
62214248|NCT04802720|EXPERIMENTAL|CBT-C: Cognitive Behavioral Therapy for Cancer Caregivers|Cognitive Behavioral Therapy (CBT-C) is an evidence-based psychotherapeutic approach that is grounded in the cognitive model that purports that a person's emotional, behavioral, and physiological reactions to a situation is based on their appraisal of that situation. The focus of therapy is on changing cognitions and beliefs about a situation and altering automatic behavioral responses evoked by that perception. CBT-C aims to improve emotion regulation by challenging and changing unhelpful cognitions and behaviors and improving personal coping strategies.
62214249|NCT04802720|EXPERIMENTAL|Training case group|Will be assigned to receive ERT-C only and will not complete questionnaires.
62214250|NCT06098404||Cancer Patients|Patients diagnosed with cancer undergoing standard of care treatment.
62214251|NCT06000345|EXPERIMENTAL|AOT + MI group|The AOT + MI group was shown a video (4 minutes) in which a subject (matched for age, sex, and limb affected) performed, in third person view, quadriceps concentric contractions for 2 minutes and isometric contractions for 2 minutes. The video contained visual elements indicating the maximality of the effort. After both concentric and isometric movement video the subjects performed a MI session (1 minute in length each), in which they were asked to imagine in first person the action previously observed in the video.
62214252|NCT06000345|SHAM_COMPARATOR|Control group|The control group was shown a video of landscapes (4 minutes in length). Halfway through and at the end of the video they were asked to imagine what they had just seen for 1 minute.
62214253|NCT04627779|EXPERIMENTAL|Male Group|
62214254|NCT04627779|ACTIVE_COMPARATOR|Female Group|
62214255|NCT03954392|EXPERIMENTAL|CBT+SCT|Cognitive behavioral therapy plus social cognitive skills training (SCT)
62214256|NCT03954392|ACTIVE_COMPARATOR|CBT-only|Cognitive behavioral therapy only (without SCT)
62214257|NCT06487117|EXPERIMENTAL|Huafu Shengji Ointment|After debridement, Huafu Shengji Ointment is applied topically with a coverage thickness of 1mm, followed by sterile gauze dressing. The dressing is changed every other day. The treatment period is 4-8 weeks.
62214258|NCT06487117|ACTIVE_COMPARATOR|ethacridine lactate solution|After debridement, the wound is cleaned and disinfected with ethacridine lactate solution, then covered and dressed with sterile gauze. The dressing is changed every other day. The treatment period is 4-8 weeks.
62214259|NCT04449120|ACTIVE_COMPARATOR|Nutritional education group (NEG)|"Participants in the nutritional education group will be given a leaflet with written nutrition educational information to follow a Mediterranean diet. Participants will be encouraged to adhere to this diet for one-month. Three visits will be scheduled for participants assigned to this group:~(1) before randomization (T1); (2) after randomization and before the program´s beginning (T2); and (3) after three months of follow-up period. In all time-points, questionnaires will be registered and at T2 and T3 blood samples will be collected. Volunteers will be contacted by phone after 1 month and 6 months of the end of the intervention to collect information about food and culinary habits."
62214260|NCT04449120|EXPERIMENTAL|Culinary intervention group (CIG)|"Participants assigned to the culinary intervention group received the written nutrition educational information as well as four online cooking classes (one cooking class per week) during the one-month intervention period. Three visits will be scheduled for participants assigned to this group:~(1) before randomization (T1); (2) after randomization and before the program´s beginning (T2); and (3) after three months of follow-up period. In all time-points, questionnaires will be registered and at T2 and T3 blood samples will be collected.~Participants will attend 4 culinary workshops between visit 2 and 3. Volunteers will be contacted by phone after 1 month and 6 months of the end of the intervention to collect information about food and culinary habits."
62214261|NCT02885324|EXPERIMENTAL|Cabozantinib|Cabozantininb will be taken daily at a dose of 40 mg/m2. Drug cycles will last 28 days and be continuous for up to 12 months of therapy on study.
62214262|NCT01044017|EXPERIMENTAL|A|
62214263|NCT01044017|EXPERIMENTAL|B|
62214264|NCT01044017|PLACEBO_COMPARATOR|C|
62791353|NCT00694018|EXPERIMENTAL|Internet Mediated Enhanced Pedometer|In addition to standard care and participating in an educational program, participants received an enhanced pedometer for uploading step information, e-mail messages with weekly step goals and access to a website that provided step goals and feedback, tailored motivational messages and on on-line community for communication asynchronously with staff and other participants.
62791354|NCT05655949|EXPERIMENTAL|Gemcitabine + Cisplatin + Durvalumab + Yttrium-90 Selective Internal Radiation Therapy|"Participants will receive:~* Cycle 1:~Day 1 of 21 Day cycle: Pre-determined dose(s) of Gemcitabine and Cisplatin (Chemotherapy) plus Durvalumab (immunotherapy).~Day 8 of 21 Day cycle: Pre-determined dose(s) of Gemcitabine and Cisplatin (Chemotherapy)~Week 2 or 3 of 21 Day Cycle: One time treatment of Y-90 radiation.~* Cycles 2-8:~Day 1 of 21 Day cycle: Pre-determined dose(s) of Gemcitabine and Cisplatin (Chemotherapy) plus Durvalumab (immunotherapy).~Day 8 of 21 Day cycle: Pre-determined dose(s) of Gemcitabine and Cisplatin (Chemotherapy)~* Cycles 9+:~Day 1 of 21 Day Cycle: Durvalumab (immunotherapy) maintenance"
62020750|NCT00983229|ACTIVE_COMPARATOR|I-gel|"1. Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~2. Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~3. Insertion of I-gel (sizes 3,4 or 5), establishment of ventilation.~4. Evaluation of laryngeal view through I-gel using fibrescope~5. Tracheal intubation through I-gel using fibrescope~6. Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~7. At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
62020751|NCT02348216|EXPERIMENTAL|Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy|Participants with diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL) will receive conditioning chemotherapy (fludarabine 30 mg/m\^2 intravenously \[IV\] over 30 minutes and cyclophosphamide 500 mg/m\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel chimeric antigen receptor (CAR) transduced autologous T cells administered IV at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg of body weight (BW) on Day 0.
62020752|NCT02348216|EXPERIMENTAL|Phase 2 (Pivotal Study): Cohort 1|Participants with refractory DLBCL will receive conditioning chemotherapy (fludarabine 30 mg/m\^2 IV over 30 minutes and cyclophosphamide 500 mg/m\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered IV at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg of BW on Day 0.
62214265|NCT06370520||Derivation Cohort|Four sites will enroll a derivation cohort (n=1512) of head-injured children. Qualified participants will complete or be evaluated with validated questionnaires. Data related to the mTBI event and the participants medical history will be recorded.
62214266|NCT06370520||Validation Cohort|Three sites will enroll a validation cohort (n=1080) of head-injured children. Qualified participants will complete or be evaluated with validated questionnaires. Data related to the mTBI event and the participants medical history will be recorded.
62214267|NCT03182361|EXPERIMENTAL|Study group|Everybody enrolled in the study will receive BioComp Industries cranio-maxillo-facial (CMF) screw implants
62214268|NCT05347251|EXPERIMENTAL|Group A|Cervicothoracic mobility program
62214269|NCT05347251|OTHER|Group B|Conventional Treatment
62214270|NCT04551404|EXPERIMENTAL|Study Intervention(s) A|"TRNS bilateral temporal regions combined with AS for 20 minutes~Sham-tRNS bilateral temporal regions combined with Sham-AS for 20 minutes"
62214271|NCT04551404|EXPERIMENTAL|Study Intervention(s) B = Control Intervention|"TRNS bilateral temporal regions for 20 minutes~Sham-tRNS bilateral temporal regions for 20 minutes"
62214272|NCT06609629|EXPERIMENTAL|interventional arm|This is a feasibility study. One arm of 10 patients is needed
62214273|NCT06610266|EXPERIMENTAL|The Weifuchun tablet group|Patients in the Weifuchun tablet group will receive oral Weifuchun tablet at a dosage of 1400 mg three times daily for 6 months.
62214274|NCT06610266|ACTIVE_COMPARATOR|The folic acid group|Patients in the folic acid group will receive oral folic acid at a dosage of 5 mg three times daily for 6 months.
62214275|NCT02040259||Mechanical thrombectomy, Trevo Retriever|Mechanical thrombectomy, Trevo Retriever
62020753|NCT02348216|EXPERIMENTAL|Phase 2 (Pivotal Study): Cohort 2|Participants with refractory PMBCL or TFL will receive conditioning chemotherapy (fludarabine 30 mg/m\^2 IV over 30 minutes and cyclophosphamide 500 mg/m\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered IV at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg of BW on Day 0.
62214276|NCT03941951|NO_INTERVENTION|Pre-intervention Cohort|Cohort of patients who have received either empirical or targeted treatment with ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam, ceftolozane-tazobactam or isavuconazole from January 2016 to December 2019 will be included.
62214277|NCT03941951|OTHER|Intervention cohort|Cohort of patients with complex infections treated with ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam, ceftolozane-tazobactam or isavuconazole from January 2010 to June 2021.
62214278|NCT03941951|NO_INTERVENTION|Safety cohort|Cohort of patients with bacteremia due to carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, carbapenem-resistant enterobacteria, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus occurred in participating hospitals from 2017 to 2021 will be collected.
62214279|NCT02929329|EXPERIMENTAL|Omecamtiv Mecarbil|Participants received oral omecamtiv mecarbil (OM) twice daily in addition to standard heart failure therapy. The starting dose of OM was 25 mg; At week 4, participants with week 2 OM predose plasma concentrations \< 200 ng/mL had their dose increased to 50 mg BID; participants with week 2 predose plasma concentrations ≥ 200 and \< 300 ng/mL had their dose increased to 37.5 mg BID and participants with week 2 predose plasma concentrations ≥ 300 ng/mL and \< 1000 ng/mL maintained a 25 mg BID dosing regimen.
62214280|NCT02929329|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo tablets twice a day in addition to standard heart failure therapy.
62791355|NCT06206018|EXPERIMENTAL|PROM_R Knee|"Completed a rehabilitation program based on the updated Journal of Orthopaedic and Sports Physical Therapy (JOSPT) guidelines for knee injuries. These guidelines essentially refer to lower limb massage, mobilization, neuromuscular strengthening and rehabilitation, exercise literacy, neuromuscular electrical stimulation and cryotherapy.~The intervention group will complete the four-week rehabilitation program, with five sessions per week, performed and supervised by the physiotherapist."
62214281|NCT02784249|EXPERIMENTAL|Goniotomy|Procedure: Goniotomy and trabecular excision in combination with planned cataract extraction via Phaco and PCIOL implant.
62214282|NCT02784249|ACTIVE_COMPARATOR|Trabecular Micro-Bypass Stent|Procedure: Device implantation in combination with planned cataract extraction via Phaco and PCIOL implant.
62214283|NCT00505245||Observational (questionnaire, QOL assessment, interview)|Participants complete questionnaires and quality of life assessments, and may also complete interviews over 45 minutes periodically.
62214284|NCT05188339|EXPERIMENTAL|4% sodium citrate group|Dose of 4% sodium citrate is also according to catheter lumen (LVR) instilled into each lumen of catheter after HD session, eg. 1.6 cc/lumen for LV R 1.6, 1.8 cc/lumen for LVR 1.8.
62409917|NCT06650943|NO_INTERVENTION|Control|Ccontrol group will continue their usual follow-up within the EIP, attending consultations with their reference psychiatrist and receiving pharmacological or psychotherapeutic treatment as they did before the intervention. The control group will not receive any specific nursing consultations (beyond the administration of long-acting injectable antipsychotics where appropriate) or dietary or lifestyle advice during the follow-up. If patients in the control group require treatment or assistance for metabolic problems, they will be referred to primary care or endocrinology professionals, as was done previous to the intervention implementation.
62214285|NCT05188339|ACTIVE_COMPARATOR|heparin group|Heparin dosage is based on volume ratio in catheter lumen (LVR) after each HD session, eg. 8000u/lumen in 1.6 LVR, 9000u/lumen in LVR 1.8.
62214286|NCT01860378|ACTIVE_COMPARATOR|No Video: Full price & $5 off|Participants will not view the pertussis video
62214287|NCT01860378|EXPERIMENTAL|Video: Full price & $5 off|Participants will watch a brief (\~ 1 minute) video about Tdap vaccination
62214288|NCT06600776|EXPERIMENTAL|Mealtime and Postmeal Dosing of Ultra Rapid Lispro Insulin (URLi)|This arm consists of participants with Type 1 Diabetes Mellitus (T1DM) who are using the Medtronic 780G hybrid closed-loop system with Ultra Rapid Lispro Insulin (URLi). Participants will undergo two intervention phases: in one phase, URLi will be administered at mealtime (premeal dosing), and in the other phase, URLi will be administered immediately after meals (postmeal dosing). The dosage form is subcutaneous insulin infusion, and the insulin dose is based on individual carbohydrate counting. Each intervention phase will last for up to 4 weeks, with glycemic control and patient preferences assessed at the end of each phase.
62214289|NCT00587626|ACTIVE_COMPARATOR|1|InterX treatment plus rehabilitation exercises
62214290|NCT00587626|PLACEBO_COMPARATOR|2|Inactive InterX treatment plus rehabilitation exercises
62584654|NCT02125786|EXPERIMENTAL|Stratum 2: Metastatic Failure|"Participants exhibit an initial pattern of failure that is metastatic (neuraxis metastatic disease without equivocal evidence of local failure). Treatment is surgery and craniospinal irradiation. Craniospinal irradiation (36-39.6Gy) will include focal boost treatment of metastatic sites (54-59.4Gy) depending on location, extent of resection and target volume.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive \^1\^8F-fluorodeoxyglucose and \^1\^1C-methionine to aid in tumor visualization."
62791356|NCT06206018|NO_INTERVENTION|Crontrol Group|The control group will follow a standard six-week rehabilitation program.
62791357|NCT04696679||Very preterm children group|
62791358|NCT04696679||Control group|
62214291|NCT03406650|EXPERIMENTAL|Durvalumab in combination with standard therapy|Combination of standard therapy consisting (4 cycles cisplatin/ gemcitabin followed by surgery) with 4 cycles of neoadjuvant durvalumab and 10 cycles of adjuvant durvalumab
62214292|NCT06610162|OTHER|Premenopausal women|
62214293|NCT06610162|OTHER|Postmenopausal women|
62791359|NCT04257526|ACTIVE_COMPARATOR|Intervention|Colorectal cancer free participants receive evidence-based diet and lifestyle advice in addition to the 'usual care' following a positive FIT test and diagnostic colonoscopy
62214294|NCT02802189|EXPERIMENTAL|exercise and INIT group|The first group (experimental) followed the exersice programme in combination with the integrated neuromuscular inhibition technique (INIT).
62791360|NCT04257526|NO_INTERVENTION|Control|Colorectal cancer free participants receive the 'usual care' following a positive FIT test and diagnostic colonoscopy
62791361|NCT06071650|NO_INTERVENTION|"Group A - Exercise to Rating of Perceived Exertion (RPE) - Control Group"|Participants prescribed moderate intensity aerobic exercise using their rating of perceived exertion (RPE) with a goal of sustaining an intensity level of 12 to 14 for their prescribed duration.
62409918|NCT05303844|EXPERIMENTAL|H101 + Tislelizumab|(Dose escalation and cohort expansion) H101 administered by Intraperitoneal injection in combination with Tislelizumab administered intravenously (IV).
62791362|NCT06071650|EXPERIMENTAL|"Group B - Exercise to a Heart Rate (HR) Zone - Intervention Group"|Participants prescribed moderate intensity aerobic exercise using personalised heartrate zones with a goal of sustaining an intensity level by maintaining their heartrate above 50 percent of their heartrate reserve level for their prescribed duration.
62791363|NCT00722956|EXPERIMENTAL|1|AZD5672 + atorvastatin
62409919|NCT04279002||Respiratory rehabilitation course|Patients who has completed at least one respiratory rehabilitation course at the Espace du Souffle (Tours France) within the 5 years prior to inclusion
62020754|NCT02348216|EXPERIMENTAL|Phase 2 (Safety Management Study): Cohort 3|Participants with relapsed or refractory transplant ineligible DLBCL, PMBCL, or TFL will receive conditioning chemotherapy (fludarabine 30 mg/m\^2 IV over 30 minutes and cyclophosphamide 500 mg/m\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered IV at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg of BW on Day 0. Participants will also receive a prophylactic regimen of levetiracetam (750 mg orally or IV twice daily (BID) starting on Day 0) and tocilizumab (8 mg/kg IV over 1 hour (not to exceed 800 mg)) on Day 2).
62409920|NCT05631756|EXPERIMENTAL|Patient Population|All patients included in the study, meaning patients in the ICU presenting an interstitial syndrom no matter the aetiology
62791364|NCT04289311|EXPERIMENTAL|Intervention arm|Single group study; all participants are in the intervention arm and receive the intervention
62791365|NCT03832751|EXPERIMENTAL|vitiligo patients|Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy
62791366|NCT03832751|ACTIVE_COMPARATOR|Healthy controls|Tissue levels of human beta-defensin 1 in healthy controls
62791367|NCT06051344|EXPERIMENTAL|A, case group|. Total 92 primary knee OA patients will be enrolled by following the inclusion criteria of ages 50 years and above with primary knee OA informed written consent. Then randomization will be done into group A and group B following a randomization table, each consist of 46 patients. Consecutive sampling technique will be followed. Primary knee OA will be diagnosed on the basis of ACR clinical and radiological criteria. Relevant laboratory investigations will be done. Baseline pain status will be measured by Bangla version of Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), visual analog scale (VAS) and numerical rating scale (NRS) and quality of life will be measure by European quality of life scale (EQ-5D-5L). Then one group will receive single infusion of 5mg zoledronic acid and another group will receive the placebo
62791368|NCT06051344|EXPERIMENTAL|B, control group|. Total 92 primary knee OA patients will be enrolled by following the inclusion criteria of ages 50 years and above with primary knee OA informed written consent. Then randomization will be done into group A and group B following a randomization table, each consist of 46 patients. Consecutive sampling technique will be followed. Primary knee OA will be diagnosed on the basis of ACR clinical and radiological criteria. Relevant laboratory investigations will be done. Baseline pain status will be measured by Bangla version of Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), visual analog scale (VAS) and numerical rating scale (NRS) and quality of life will be measure by European quality of life scale (EQ-5D-5L). Then one group will receive single infusion of 5mg zoledronic acid and another group will receive the placebo
62791369|NCT02652156|ACTIVE_COMPARATOR|Single Injection of Bupivacaine|Subjects will undergo post-operative pain relief treatment with a single injection of Bupivacaine, a local anesthetic injected into the transversus abdominis plane.
62791370|NCT02652156|ACTIVE_COMPARATOR|Single Injection of Exparel®|Subjects will undergo post-operative pain relief treatment with a single injection of Exparel®, a liposomal form of bupivacaine, into the transversus abdominis plane
62214295|NCT02802189|ACTIVE_COMPARATOR|exercise group|"The protocol for this group was identical to the previous group with the sole difference that the application of INIT was not included.~At the end of the exercise programme, relaxing breathing exercise and gentle stretching was applied for 15 min"
62214296|NCT05812417|ACTIVE_COMPARATOR|Normal renal function|eGFR \>=90 mL/min/1.73m\^2
62214297|NCT05812417|EXPERIMENTAL|Mild renal impairment|eGFR 60\~89 mL/min/1.73m\^2
62214298|NCT05812417|EXPERIMENTAL|Moderate renal impairment|eGFR 30\~59 mL/min/1.73m\^2
62791371|NCT02652156|ACTIVE_COMPARATOR|Continuous infusion of Ropivacaine|Subjects will be treated with a continuous infusion of the local anesthetic Ropivacaine with the ON-Q® pump
62791372|NCT02738554|OTHER|Treatment cessation arm|Cessation of treatment as according to European Association for the Study of the Liver Guidelines for chronic hepatitis B
62791373|NCT04124640||treatment group|The study population will be women between 45 and 65 years old, both ages included, who present a decrease in sexual desire or arousal
62791374|NCT02814942||Heart Failure receiving CRT|Heart failure patients with QRS \> 120ms receiving CRT
62791375|NCT03012711|EXPERIMENTAL|Training|Neuromuscular exercise training group will complete a 5 week NME training program
62791376|NCT03012711|NO_INTERVENTION|Control|Control group will have 5 weeks with no intervention prior to being re-tested
62214299|NCT05812417|EXPERIMENTAL|Severe renal impairment|eGFR 15\~29 mL/min/1.73m\^2
62214300|NCT04579718||Eclipse|
62214301|NCT04579718||Zeus Cloud TPS V1.0|
62214302|NCT02587988|EXPERIMENTAL|HCP1302+HGP0904Placebo|HCP1302+HGP0904Placebo for 12weeks
62214303|NCT02587988|ACTIVE_COMPARATOR|HCP1302Placebo+HGP0904|HCP1302Placebo+HGP0904 for 12weeks
62214304|NCT01410968|EXPERIMENTAL|Vaccination|vaccination with investigational Poly-ICLC \& peptide-pulsed dendritic cells
62214305|NCT04013048|EXPERIMENTAL|[14C]-Fluzoparib|Patients will receive single dose of \[14C\]- Fluzoparib.
62214306|NCT00770029|EXPERIMENTAL|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
62214307|NCT00770029|PLACEBO_COMPARATOR|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
62214308|NCT01514253|EXPERIMENTAL|glucose 25%|1 ml of glucose once
62214309|NCT01514253|EXPERIMENTAL|infant formula|Materna RTF stage 1
62791377|NCT06353906|EXPERIMENTAL|Induction chemo-immunotherapy combination followed by consolidative surgical resection|"Patients receive three cycles of induction carboplatin+paclitaxel on days 1, 22 and 43, with two concurrent cycles of fixed-dose pembrolizumab on days 1 and 43.~Within 3-9 weeks after the last cycle of induction chemo-immunotherapy, patients undergo complete resection of remaining tumor tissue.~Patients start subsequent adjuvant immunotherapy with fixed-dose pembrolizumab for up to seven 6-week cycles between 3-9 weeks after surgery."
62214310|NCT01514253|PLACEBO_COMPARATOR|Water for Injection|1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
62584655|NCT02125786|EXPERIMENTAL|Stratum 3: Local and Metastatic Failure|"Participants exhibit an initial pattern of failure that is both local and metastatic (neuraxis metastatic disease with equivocal evidence of local failure). Treatment is surgery and craniospinal irradiation.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive \^1\^8F-fluorodeoxyglucose and \^1\^1C-methionine to aid in tumor visualization."
62214311|NCT04278222|EXPERIMENTAL|Anlotinib Plus Toripalimab|the combination of Anlotinib Plus Toripalimab as first-line treatment
62584656|NCT02125786|EXPERIMENTAL|Stratum 4: Local Failure|"Local Failure Participants exhibit an initial pattern of failure that is local (disease confined to primary site). Age is \>36 months at time of enrollment to \<21 years. Tumor shows presence of 1q gain. Treatment is optional craniospinal irradiation.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive \^1\^8F-fluorodeoxyglucose and \^1\^1C-methionine to aid in tumor visualization."
62214312|NCT00603304|PLACEBO_COMPARATOR|Placebo|Participants will take one 320 mg placebo gelcap daily for 24 weeks one gelcap); followed by 640 mg daily for 24 weeks (two gelcaps) followed by 960 mg daily for 24 weeks (three gelcaps).
62214313|NCT00603304|ACTIVE_COMPARATOR|Saw Palmetto|Extract of Serenoa Repens 320 mg once daily for 24 weeks (one gelcap); followed by 640 mg daily for 24 weeks (two gelcaps) followed by 960 mg daily for 24 weeks (three gelcaps).
62584657|NCT02059499|EXPERIMENTAL|Arm A (imiquimod)|Patients apply imiquimod intra-anally QD for 16 weeks.
62214314|NCT05343520|EXPERIMENTAL|Experimental Group|30 pregnant women in the experimental group, pelvic floor muscle exercise was explained in detail and an exercise brochure was given in addition. Pelvic floor muscle exercises were taught by the researcher G.Y. In order for the exercise to be continued or applied correctly, the experimental group was interviewed by phone every 2 weeks. Information was given about continuing pelvic floor muscle exercises beginning from the 30th week of pregnancy until the postpartum 6th week.
62214315|NCT05343520|NO_INTERVENTION|Control Group|The control group were filled only data collection forms
62584658|NCT02059499|EXPERIMENTAL|Arm B (fluorouracil)|Patients apply fluorouracil intra-anally BID on days 1-5. Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
62584659|NCT02059499|NO_INTERVENTION|Arm C (observation)|Patients receive no treatment. Patients who still have HSIL at week 20 and who agree to randomization may cross-over to Arm A or B.
62584660|NCT02521142||AMD: treatment-naive|
62584661|NCT02521142||AMD: active neovascular AMD|
62584662|NCT04194320|PLACEBO_COMPARATOR|"Group I Placebo"|Ultrasound (US) guided supraclavicular brachial plexus block will be done to the patients who are prepared to undergo upper limb surgeries below the level of the shoulder within the distribution of supraclavicular brachial plexus block using: 30 mL volume of local anesthetics (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) + 2 ml 0.9% normal saline.
62584663|NCT04194320|ACTIVE_COMPARATOR|"Group II Nalbuphine "|Ultrasound (US) guided supraclavicular brachial plexus block will be done to the patients who are prepared to undergo upper limb surgeries below the level of the shoulder within the distribution of supraclavicular brachial plexus block using: 30 mL volume of local anesthetics (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) + 10 mg nalbuphine hydrochloride (completed to 2 ml with 0.9% normal saline).
62584664|NCT04194320|ACTIVE_COMPARATOR|"Group III Dexamethasone"|Ultrasound (US) guided supraclavicular brachial plexus block will be done to the patients who are prepared to undergo upper limb surgeries below the level of the shoulder within the distribution of supraclavicular brachial plexus block using: 30 mL volume of local anesthetics (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) + 2 mL dexamethasone 0.4% (8 mg).
62584665|NCT05284799|EXPERIMENTAL|OVX836 480µg + Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra) at commercial dose|"OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the incluenza virus. One single administration intramuscularly of 480µg dose on Day 1~AND~Fluarix® Tetra (GlaxoSmithKline Biologicals): Inactivated and purified split influenza vaccine."
62584666|NCT05284799|ACTIVE_COMPARATOR|Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra) at commercial dose + Placebo|"Fluarix® Tetra (GlaxoSmithKline Biologicals): Inactivated and purified split influenza vaccine.~AND~Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50mL. One single administration intrumuscularly of a 0.8mL dose on Day 1"
62584667|NCT05284799|PLACEBO_COMPARATOR|OVX836 480µg + Placebo|"OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the incluenza virus. One single administration intramuscularly of 480µg dose on Day 1~AND~Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50mL. One single administration intrumuscularly of a 0.8mL dose on Day 1"
62584668|NCT00712543|EXPERIMENTAL|1|Kristalose®, as prescribed, for 7 days.
62584669|NCT00712543|EXPERIMENTAL|2|Liquid lactulose, as prescribed, for 7 days.
62584670|NCT04821609|EXPERIMENTAL|Resistance training group|Twice a week sessions supervised and group, during 12 weeks
62584671|NCT04821609|NO_INTERVENTION|Control Group|The control group will follow the usual physical therapy management, which does not include resistance training
62584672|NCT06526143|ACTIVE_COMPARATOR|Training-As-Usual|M2VA case managers at sites randomized to TAU will receive an initial 8-hour virtual didactic and experiential workshop conducted by an experienced Motivational Interviewing and M2VAPCP trainer, Dr. Martino, who is a longstanding member of the Motivational Interviewing Network of Trainers. The first four hours of the workshop will focus on principles and practices of Motivational Interviewing. The last four hours will be a review the M2VAPCP protocol, with demonstration and practice of its elements. Following the workshop, case managers will have up to seven opportunities to practice M2VAPCP with simulated patients over a 21-month period
62214316|NCT02699723|EXPERIMENTAL|Treatment (arsenic trioxide, itraconazole)|Patients receive arsenic trioxide PO and itraconazole PO daily for 50 days, followed by maintenance therapy consisting of 2 weeks off treatment and then 2 weeks on treatment for up to 6 months in the absence of disease progression or unacceptable toxicity.
62214317|NCT02666859|EXPERIMENTAL|Unilateral Transradial Amputation|This group includes people with a unilateral transradial amputation. Potential subjects must use a body-powered or myoelectric prosthetic device. This group will be exposed to virtual reality therapy and non-virtual reality therapy.
62214318|NCT02666859|EXPERIMENTAL|Unilateral Transhumeral Amputation|This group includes people with a unilateral transhumeral amputation. Potential subjects must use a body-powered or myoelectric prosthetic device. This group will be exposed to virtual reality therapy and non-virtual reality therapy.
62409921|NCT03099161|EXPERIMENTAL|Preladenant 25 mg Twice a Day (BID)|During an initial dose evaluation phase, participants received 25 mg of preladenant orally twice a day (BID) on Days 1 through 21 of each 21-day cycle (for a maximum of 35 cycles) until the RP2D could be established. The RP2D was to be established based on the number of dose limiting toxicities (DLTs) at each dose level administered. Participants continued receiving 25 mg of preladenant BID on Days 1 through 21 of each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
62409922|NCT03099161|EXPERIMENTAL|Preladenant 50 mg BID|During an initial dose evaluation phase, participants received 50 mg of preladenant orally BID on Days 1 through 21 of each 21-day cycle (for a maximum of 35 cycles) until the RP2D could be established. The RP2D was established based on the number of DLTs at each dose level administered. Participants continued receiving 50 mg of preladenant BID on Days 1 through 21 of each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
62409923|NCT03099161|EXPERIMENTAL|Preladenant + Pembrolizumab|During an initial dose evaluation phase, participants received 25 mg of preladenant administered orally BID on Days 1 through 21 in combination with 200 mg pembrolizumab administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (for a maximum of 35 cycles). Participants continued receiving preladenant 25 mg BID in combination with 200 mg pembrolizumab for each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
62214319|NCT03629743||ECOG and EEG Sensor|Study subjects are neurosurgical patients with medically refractory epilepsy who will have implanted with intracranial ECoG electrodes. The electrodes will be used during a period of inpatient monitoring to identify resectable seizure foci.
62214320|NCT02999802|EXPERIMENTAL|Exercise|Determining the effect of 12 weeks of resistance training exercise on the response of muscle amino acid sensing
62214321|NCT04100278|NO_INTERVENTION|Traditional therapy group|All patients in this group will be given routine diabetes management, including lifestyle education, health guidance, monitoring blood sugar guidance and drug adjustment.
62409924|NCT00609115|EXPERIMENTAL|Test-Phase 1|The Test Group receives 18 half-hour AMES (Assisted Movement with Enhanced Sensation) treatments with the AMES device (Test) in which the hand or wrist is moved, and the subject assists the motion while vibration (60 pulses/sec) is applied to the lengthening muscle. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
62214322|NCT04100278|ACTIVE_COMPARATOR|Shared Care group|The patients download the Shared Care mobile application and connect with the smart-glucometer Bg1 to upload blood glucose dairy in real time. With patient's informed consent, his or her data from each visit will be collected and recorded for analysis. After the patient returns home from the clinic, they can communicate through the APP with online diabetes educators. According to protocol, online diabetes educators answer patients' questions, give suggestions on patients' diet and summarize patients' issues to physicians, who provide high level supervision.
62409925|NCT00609115|SHAM_COMPARATOR|Control-Phase 1|Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) programed to provide placebo therapy. Each treatment session consisting of 30 minutes of sham therapy. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
62409926|NCT00609115|ACTIVE_COMPARATOR|Crossover-Phase 2|Original Control Group receives 18 half-hour crossover treatments with the AMES device (Crossover) in which the hand or wrist is moved, and the subject assists the motion while vibration (60 pulses/sec) is applied to the lengthening muscle. Sessions to be scheduled preferably 2 to 3 times per week with each session one-half hour in length.
62409927|NCT00608075|OTHER|1|Manic Patients
62409928|NCT00608075|OTHER|2|Depressed Patients
62791378|NCT05532202|EXPERIMENTAL|NICU Mom and Baby Net|12-session mobile internet intervention with remote video based coaching targeting maternal mood, sensitive and responsive parenting interactional practices with their infants to facilitate infant social engagement with their mothers. Each session included (1) a web-based self-directed learning program through video-based teaching with check-in questions and provision of immediate corrective feedback, (2) an action plan outlining daily activity practice (homework) based on session content, (3) parent-recorded video and secure upload of session skill practice during interaction with her infant, and (4) a video-based coach call to co-view the parent-recorded video of interaction with her infant.
62214323|NCT06168695|EXPERIMENTAL|anterior crossbite treatment with evaluation of speech and quality of life|"removable anterior expansion screw is used to correct anterior crossbite~Child Perceptions Questionnaire was used to gauge how the anterior crossbite affected the children's OHRQoL.~children were subjected to the Protocol of speech evaluation"
62214324|NCT02008851|EXPERIMENTAL|Implantation of Neo-kidney Augment|Patients receiving one dose (implant) of NKA into the left kidney
62214325|NCT00943839|EXPERIMENTAL|SUVEGIL|
62214326|NCT03057990|EXPERIMENTAL|Pyrimethamine Treatment (Intra-patient)|50mg/100mg/150mg once daily on days 1-28 of each 28-day cycle. Administered using intra-patient dose escalation, starting at 50 mg and up to 150 mg.
62214327|NCT01658332|EXPERIMENTAL|specific procedure|Circulating tumor cells will be search with the Veridex method at inclusion and after the third chimiotherapy
62214328|NCT05614193||Imaging group|Participants with suspecting brain stroke or vascular lesion conducted conventional CT or MR imaging and deep enhanced imaging.
62214329|NCT05965804||Healthy Adults|30 healthy adult participants aged 18-45 years performing the McMurray knee examination test
62214330|NCT04497064||Athlete|those who identified as participating in athletic competitions at DI, intramural, club or competitive levels
62214331|NCT04497064||non-athletes|those who did not identify as participating in athletic competitions at DI, intramural, club or competitive levels
62214332|NCT01992952|EXPERIMENTAL|AZD5363 plus fulvestrant|Fulvestrant 500mg and AZD5363 4 days on 3 days off at dose determined in safety run in (maximum 480mg and minimum 320mg bd)
62214333|NCT01992952|ACTIVE_COMPARATOR|Placebo plus fulvestrant|Fulvestrant 500mg D1, D15 (cycle 1) and D1 of a 28 cycle thereafter. AZD5363 placebo 4 days on 3 days off
62214334|NCT04736901||Group 1|Enoxaparin therapeutic dose
62214335|NCT04736901||Group 2|Enoxaparin prophylactic dose
62214336|NCT04736901||Group 3|Rivaroxaban therapeutic dose
62214337|NCT04736901||Group 4|Rivaroxaban prophylactic dose
62214338|NCT04736901||Group 5|Apixaban therapeutic dose
62791379|NCT05532202|ACTIVE_COMPARATOR|NICU Developmental Awareness System|Identical to NICU Mom and Baby Net in terms of number of sessions and session structure to serve as an equivalent attention control. 12-session mobile internet intervention with remote coaching of mother awareness of infant developmental milestones. Each session included (1) web-based self-directed learning program through video-based teaching with check-in questions and provision of immediate corrective feedback, (2) an action plan outlining daily activity practice (homework) based on session content, (3) parent-recorded video and secure upload of session skill practice during interaction with her infant, and (4) a video-based coach call to co-view the parent-recorded video of interaction with her infant.
62791380|NCT06020703|EXPERIMENTAL|Fermented Foods Diet|Subjects will incorporate fermented food into their diet.
62791381|NCT06020703|NO_INTERVENTION|Normal Diet|Subjects will continue their regular diet.
62791382|NCT05334407|EXPERIMENTAL|GroupA（DE+/DI+）|The treatment includes the combination of implant-supported full-arch fixed prostheses (dental intervention, DE) and dietary intervention tailored to the dental status (dietary intervention, DI) without waiting period
62791383|NCT05334407|ACTIVE_COMPARATOR|GroupB（DE+/DI-）|The treatment includes implant-supported full-arch fixed prostheses (dental intervention, DE) without waiting period and dietary intervention tailored to the dental status (dietary intervention, DI) 4-month later
62791384|NCT05334407|ACTIVE_COMPARATOR|GroupC（DE-/DI+）|The treatment includes dietary intervention tailored to the dental status (dietary intervention, DI) without waiting period and implant-supported full-arch fixed prostheses (dental intervention, DE) 4-month later
62791385|NCT05334407|PLACEBO_COMPARATOR|GroupD（DE-/DI-）|The treatment included implant-supported full-arch fixed prostheses (dental intervention, DE) and dietary intervention tailored to the dental status (dietary intervention, DI) with 4-month waiting period. Only general dietary information is provided at baseline.
62791386|NCT02989753|PLACEBO_COMPARATOR|Placebo|The comparative product is a placebo with the same characteristics of appearance and packaging as studied products and in which all ingredients are replaced by maltodextrin.
62791387|NCT02989753|EXPERIMENTAL|VAL070-A|Studied active product n°1, named VAL070-A, is a dietary supplement in shape of capsule. VAL070-A product contains 4 active plant extracts.
62791388|NCT02989753|EXPERIMENTAL|VAL070-B|Studied active product n°2, named VAL070-B, is a dietary supplement in shape of capsule. VAL070-B product contains 5 active plant extracts.
62791389|NCT02264691||Normal (healthy volunteers)|No Research Intervention. Clinically indicated interventions only.
62791390|NCT02264691||Mild Asthmatics|No Research Intervention. Clinically indicated interventions only.
62791391|NCT02264691||Mild to Moderate Asthmatics|No Research Intervention. Clinically indicated interventions only.
62791392|NCT02264691||Severe Asthmatics|No Research Intervention. Clinically indicated interventions only.
62791393|NCT00264537|EXPERIMENTAL|Group 1: Placebo + Methotrexate|Placebo subcutaneous injections (SC) every 4 weeks from Week 0 for up to 5 years (unless early escape at week 28); Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - if early escape, 50 mg SC injections every 4 weeks from Week 28 up to 5 years; Golimumab - Dr's discretion after unblinding (in participants receiving methotrexate plus placebo), 50 mg SC injections every 4 weeks up to 5 years; Golimumab- Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
62214339|NCT04736901||Group 6|Apixaban prophylactic dose
62214340|NCT04294953|ACTIVE_COMPARATOR|Group (I) (D) : (Duloxetine group)|
62214341|NCT04294953|PLACEBO_COMPARATOR|Group (II) (P): (placebo group)|
62214342|NCT03567824|EXPERIMENTAL|Open label phase|MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months, all subjects.
62214343|NCT03567824|OTHER|Random off phase|MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months or Placebo
62214344|NCT00356408|EXPERIMENTAL|CDP870 400 mg|Certolizumab pegol (CDP870) 400 mg (2 injections of 1 mL) every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2
62214345|NCT02851888|EXPERIMENTAL|Iliac Fascia Block (Ropivacaine)|These patients will receive a preoperative iliac fascia block performed as a single shot in the standard fashion prior to hip arthroscopy with general anesthesia.
62214346|NCT02851888|SHAM_COMPARATOR|Control (Normal Saline Sham Injection)|These patients will receive a preoperative sham block of normal saline in the same fashion as a standard singl shot iliac fascia block prior to hip arthroscopy with general anesthesia.
62214347|NCT06316453||Non pre-existing ASCVD|ASCVD risk in adults will be assessed alongside demographics and clinical history. The study will calculate 10-year, 30-year, and lifetime ASCVD risks, incorporating genetic assessment for Apo B. Personalized management recommendations based on ASCVD risk will be provided, and a six-month follow-up will track ASCVD events.
62020755|NCT02348216|EXPERIMENTAL|Phase 2 (Safety Management Study): Cohort 4|Participants with r/r DLBCL,PMBCL,TFL,or high-grade B-cell lymphoma(HGBCL)after 2 systemic lines of therapy will receive optional bridging therapy(dexamethasone 20mg to 40mg,eitherorally or IV daily for 1 to 4 days or 1g/m\^2 of high-dose methylprednisolone(HDMP)for 3 days with rituximab at 375mg/m\^2 weekly for 3 weeks or bendamustine 90 mg/m\^2 on Days 1 and 2 and rituximab 375mg/m\^2 on Day 1),conditioning chemotherapy(fludarabine 30mg/m\^2 IV and cyclophosphamide 500mg/m\^2 IV)on Days -5,-4, and -3;followed by single infusion of axicabtagene ciloleucel CAR transduced autologous T cells IV at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg of BW. Participants will receive a prophylactic regimen of levetiracetam(750 mg orally or IV twice daily(BID)starting on Day 0).Participants will receive tocilizumab(initiated on persistent Grade 1 cytokine release syndrome(CRS)for over 24 hours)and dexamethasone(persistent Grade 1 CRS for over 72 hours and at onset of Grade 1 neurologic toxicity).
62214348|NCT00490230|EXPERIMENTAL|WR 279,396|CL lesions treated with WR 279396
62214349|NCT00490230|NO_INTERVENTION|Natural Healing|CL lesions healed naturally
62214350|NCT00490230|PLACEBO_COMPARATOR|vehicle control|CL lesions were treated with the vehicle alone
62214351|NCT06609824|EXPERIMENTAL|Training Group|This arm consists of all participants who receive the training intervention. The purpose is to assess longitudinal effectiveness of the training within all participants.
62214352|NCT03959410|ACTIVE_COMPARATOR|HPV-positive patients|Patients who are positive for HPV DNA test
62214353|NCT03959410|ACTIVE_COMPARATOR|HPV-positive patients - Echinacea|
62214354|NCT03959410|NO_INTERVENTION|HPV-positive patients - Standard|
62214355|NCT06610773|EXPERIMENTAL|Experimental group|1×10\^6/Kg UC-MSCs (resuspended in 100 mL normal saline containing 5% albumin) are infused intravenously to the high-risk HPV persistant infected patients at a controlled rate of 60-80 drops/min
62214356|NCT06610773|PLACEBO_COMPARATOR|Control group|Normal saline containing 5% albumins are infused intravenously with an equal volume, similar suspension and appearance package as UC-MSCs to the high-risk HPV persistant infected patients at a controlled rate of 60-80 drops/min
62409929|NCT01569594||Carotid Endarterectomy Subjects|Subjects undergoing patch angioplasty of the carotid artery following carotid endarterectomy using the CorMatrix ECM for Carotid Repair
62791394|NCT00264537|EXPERIMENTAL|Group 2: Golimumab 100 mg + Placebo|Golimumab 100 mg SC injections every 4 weeks from Week 0 for up to 5 years; placebo capsules weekly from Week 0 for up to 5 years (unless early escape at Week 28); Methotrexate - if early escape, 10 to 20 mg weekly from Week 28 up to 5 years; Methotrexate - Dr's discretion after unblinding (in participants receiving golimumab plus placebo) 10 to 20 mg weekly for up to 5 years; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
62791395|NCT00264537|EXPERIMENTAL|Group 3: Golimumab 50 mg + Methotrexate|Golimumab 50 mg SC injections every 4 weeks from Week 0 for up to 5 years (unless early escape at week 28); Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - if early escape, 100 mg SC injections every 4 weeks from Week 28 for up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
62791396|NCT00264537|EXPERIMENTAL|Group 4: Golimumab 100 mg + Methotrexate|Golimumab 100 mg SC injections every 4 weeks from Week 0 for up to 5 years; Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
62791397|NCT01389869|EXPERIMENTAL|Tears|Emotional tears of female volunteers while watching sad video clips
62791398|NCT01389869|PLACEBO_COMPARATOR|Saline|Saline collected after being trickled down women's skin below eyes like tears
62791399|NCT01389869|PLACEBO_COMPARATOR|Fasting|Their own overnight fasting plasma of male volunteers
62791400|NCT01389869|EXPERIMENTAL|Prandial|Their own postprandial plasma of male volunteers
62791401|NCT02701153|EXPERIMENTAL|Treatment (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy on Monday-Friday for 5 days. Beginning 2-12 weeks after completion of radiation therapy, patients undergo surgery.
61978516|NCT03128333|EXPERIMENTAL|RunKeeper app + physiotherapy coaching|Group A will use the RunKeeper app for half a year to self-monitor leisure-time PA. Besides, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is all explained in a brief user's manual. In addition, patients will be educated about the health risks of a sedentary lifestyle, inactivity and (when applicable) other unhealthy lifestyle behaviors (e.g. unhealthy diet, overweight or obesity, sun exposure, alcohol intake). Benefits of a behavior change, becoming physically active and pursuing a healthy lifestyle will be explained by a trained physiotherapist who will also coach the patient during the PA program.
62214357|NCT03472716||Samples|Included patients will undergo 2 biological samples : a 5-ml blood sample included in the standard care and a tumoral sample (from the surgical exeresis or from the initial diagnosis biopsy). Patients with a confirmed pancreatic carcinoma will be followed during 18 months in this cohort. In case of relapse, patients will have 2 new biological samples (blood and tumoral).
62214358|NCT05008523|EXPERIMENTAL|Opioids and Police Safety Occupational Risk Reduction Training|Provides occupational risk reduction training for police in 49 slides including 8 filmed videos (police officers, MDs, SSP staff, a person in recovery). The training is delivered online with secure access only for enrolled study participants.
62409930|NCT05844995|EXPERIMENTAL|Acetaminophen /Naproxen Sodium|Participants with age group 12 to less than (\<) 17 years who undergone a non-surgical orthodontic procedure will enroll and receive fixed dose combination of acetaminophen/naproxen sodium tablet orally on baseline (Day 0).
62409931|NCT05469776|EXPERIMENTAL|bicruciate-retaining total knee arthroplasty|The prosthesis is minimally constrained and allows the preservation of both cruciate ligaments. All implants are cemented.
62791402|NCT01309568||Investigational testing|Pending the outcome of culture, the subject may be treated with an approved antiviral medication at the doctors discretion.
62791403|NCT01771523|ACTIVE_COMPARATOR|Group 1|thyroidectomy
62791404|NCT01771523|ACTIVE_COMPARATOR|Group 2|thyroidectomy use of drain
62791405|NCT01103427|ACTIVE_COMPARATOR|Internet-based coaching .|"Arm 1. Those in the active comparator arm will benefit from automated internet-based coaching. The subjects will be recruited from the general population reporting not to be associated with the University Hospital of North Norway and randomized to arm 1 or 2."
62791406|NCT01103427|EXPERIMENTAL|SMS based coaching|"Arm 2. The subjects will receive automated coachingby SMS.The subjects will be recruited from the general population reporting not to be associated with the University Hospital of North Norway and randomized to arm 1 or 2."
62791407|NCT01103427|EXPERIMENTAL|SMS coaching UNN recruited|Arm 3.The subjects will be recruited from those reporting to be associated with the University Hospital of North Norway and randomized to arm 3 or 4.
62791408|NCT01103427|EXPERIMENTAL|Craving/Panic function. UNN recruited|"Arm 4. The subjects will in addition to the automated coachingby SMS get a SMS panic/craving function. The subjects will be recruited from subjects reporting to be associated with the University Hospital of North Norway and randomized to arm 3 or 4."
62791409|NCT03840707|EXPERIMENTAL|Experimental group|"LIFEwithIBD Programme is a manualized acceptance, mindfulness and compassionate-based group intervention for inflammatory bowel disease patients. It included 9 weekly group sessions, 1.30h hours each, run in small groups (ranging from 10 to 15 participants).~Participants in this group also receive inflammatory bowel disease treatment as usually performed at the Coimbra University Hospital."
62791410|NCT03840707|NO_INTERVENTION|Control group|Treatment as Usual (TAU) Standard personalized treatment of inflammatory bowel disease
62791411|NCT02104466|NO_INTERVENTION|Treatment as Usual (TAU)|Participants randomized to this arm will receive usual care with no acupuncture.
62791412|NCT02104466|EXPERIMENTAL|TAU + 12 wks of acupuncture 1x/week|Participants randomized to this arm will receive usual care with adjunctive acupuncture once per week for a period of 12 weeks.
62791413|NCT02104466|EXPERIMENTAL|TAU + 12 wks of acupuncture 2x/week|Participants randomized to this arm will receive usual care with adjunctive acupuncture twice per week for a period of 12 weeks.
62409932|NCT05469776|ACTIVE_COMPARATOR|posterior-stabilized total knee arthroplasty|The prosthesis requires the excision of both cruciate ligaments
62409933|NCT06650631|EXPERIMENTAL|Group: Patients with moderate knee osteoarthritis|Patient without acute flares or inflammation enrolled. The overall duration of the investigation is expected to be 11 days, including screening days. The maximum treatment duration for each patient is 7 days (8h/d)
62409934|NCT04782258|EXPERIMENTAL|Tolvaptan Suspension|Tolvaptan suspension will be administered orally or via feeding/nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 18 months.
62791414|NCT00769912|EXPERIMENTAL|1|50% N2O- 50%O2 mixture administration during the intervention
62020756|NCT02348216|EXPERIMENTAL|Phase 2 (Safety Management Study): Cohort 5|Participants with r/r DLBCL, PMBCL ,TFL, or HGBCL after 2 systemic lines of therapy will receive debulking therapy (R-CHOP:rituximab 375mg/m\^2 D1,doxorubicin 50mg/m\^2 D1,prednisone 100mg D1 to D5,cyclophosphamide 750mg/m\^2 D1,vincristine 1.4 mg/m\^2 D1 or R-ICE:rituximab 375mg/ m\^2 D1,ifosfamide 5g/m\^2 24h-CI D2,carboplatin AUC5 D2 maximum dose 800mg,etoposide 100 mg/m\^2/day D1 to D3 or R-GEMOX:rituximab 375mg/m\^2 D1,gemcitabine 1000mg/m\^2 D2,oxaliplatin 100mg/m\^2 D2 or R-GDP:rituximab 375mg/m\^2 D1 or D8,gemcitabine 1g/m\^2 D1 \& D8,dexamethasone 40mg D1 to D4,cisplatin 75mg/m\^2 D1(or carboplatin AUC5 D1) or radiotherapy:20 to 30 Gy), conditioning chemotherapy (fludarabine 30mg/m\^2 IV and cyclophosphamide 500mg/m\^2 IV)on Days -5,-4, and -3; followed by single infusion of axicabtagene ciloleucel at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg of BW on Day 0. Participants will also receive a prophylactic regimen of levetiracetam (750 mg orally or IV BID starting on D0).D=Day.
62791415|NCT00769912|PLACEBO_COMPARATOR|2|Placebo (air) during the intervention
62020757|NCT02348216|EXPERIMENTAL|Phase 2 (Safety Management Study): Cohort 6|Participants with r/r DLBCL,PMBCL,TFL orHGBCL after 2 systemic lines of therapy may receive bridging therapy(dexamethasone 20mg to 40mg,orally or IV daily for 1 to 4 days or 1g/m\^2 HDMP for 3 days with rituximab at 375mg/m\^2 weekly for 3 weeks or bendamustine 90 mg/m\^2 on Days 1 and 2 and rituximab 375mg/m\^2 on Day 1),conditioning chemotherapy(fludarabine 30mg/m\^2 IV and cyclophosphamide 500mg/m\^2 IV)on Days -5,-4, and -3; followed by single infusion of axicabtagene ciloleucel CAR transduced autologous T cells IV at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg of BW on Day 0.Participants will also receive a prophylactic regimen of levetiracetam 750 mg orally or IV twice daily(BID)starting on Day 0)and corticosteroids(dexamethasone, 10 mg once daily on Days 0, 1, and 2).Participants will receive tocilizumab(initiated on persistent Grade 1 CRS for over 24 hours)and dexamethasone(persistent Grade 1 CRS for over 72 hours and at onset of Grade 1 neurologic toxicity).
62020758|NCT01506245|NO_INTERVENTION|Control|
62020759|NCT01506245|EXPERIMENTAL|Family-based behavioral therapy|Family-based behavioural therapy either in group or in individual setting. Parents can choose between the 2 types of therapy.
62214359|NCT05008523|ACTIVE_COMPARATOR|COVID Occupational Risk Reduction Training|The COVID-19 and Police Safety training (Control only) includes 22 slides, also narrated by a professional voice narrator.
62214360|NCT04819659|NO_INTERVENTION|Group Control|Without pharyngeal pack insertion
62214361|NCT04819659|EXPERIMENTAL|Group Pharyngeal packing (Group PP)|Pharyngeal pack insertion after endotracheal intubation
62214362|NCT00818168||Infliximab|Subjects with ankylosing spondylitis who were treated with infliximab. The dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC)
62214363|NCT04938492|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT)|CBT delivered over the course of 6, \~45 minute sessions delivered via telehealth.
62214364|NCT04938492|ACTIVE_COMPARATOR|Health Education|Health education sessions delivered over the course of 6, \~45 minute sessions delivered via telehealth.
62214365|NCT04680806|EXPERIMENTAL|Er,Cr:YSGG laser 2780 nm|Group A was treated by an Er,Cr:YSGG laser 2780 nm cylindrical tip (tip 600 μm, 45 millijoule /pulse, average power 2.25 W, frequency 50 Hz, pulse duration 60 µs, energy density 43 J/cm2, water 50%, and air 40%). The procedure was performed completely without anesthesia with the laser tip at angulation \~30° and distance of \~1 mm from the gingival tissue. The laser tip was advancing in scanning movement from in the cervical-apical direction in all pigmented areas. The following settings was used to achieve hemostasis in case of the bleeding was present (tip 600 μm, 30 millijoule /pulse, average power 1.5 W, frequency 50 Hz, pulse duration 700 µs, energy density 28.7 J/cm2, water 10%, and air 20%).
62214366|NCT04680806|EXPERIMENTAL|Diode laser 940 nm|Group B was treated with diode 940 nm Laser. The procedure was performed with a pencil-sized handpiece containing a 400 µm lasing fiber (400 μm initiated tip, average power 0.8 watts, Pulsed mode, Duty cycle 20%, Pulse duration 10 μs, energy density 636.9 J/cm2 per second, no water or air). Infiltration anesthesia was injected for B group . The laser tip was placed in angle \~30° with the gingival surface. Short light paint brush strokes were used in the cervical-apical direction in all pigmented areas.
62214367|NCT03695458|PLACEBO_COMPARATOR|Placebo-Control|Photobiomodulation Therapy with the placebo program will be applied in both legs.
62409935|NCT04782258|EXPERIMENTAL|Tolvaptan Tablets|Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets. Treatment duration is 18 months.
62791416|NCT02914665|EXPERIMENTAL|20 mg elamipretide|20 mg elamipretide once daily for 7 consecutive days
62791417|NCT02914665|PLACEBO_COMPARATOR|Placebo|Placebo once daily for 7 consecutive days
61978517|NCT03128333|OTHER|usual care|In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
61978518|NCT04826770||BNT/BNT/BNT|Subjects receiving two doses of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as homologous basic immunization and one dose of BNT162b2 as booster vaccination
62791418|NCT00370916|EXPERIMENTAL|Arm 1|Physician-initiated medication reconciliation
62791419|NCT00370916|EXPERIMENTAL|Arm 2|Pharmacist-initiated medication reconciliation
62791420|NCT00370916|NO_INTERVENTION|Arm 3|No formal medication reconciliation
62791421|NCT00838240|EXPERIMENTAL|Arm I|Patients receive idarubicin IV over 5 minutes on days 1, 3, and 5, cytarabine IV continuously on days 1-10, and clofarabine IV over 1 hour on days 2, 4, 6, 8, and 10.
62584673|NCT06526143|EXPERIMENTAL|Implementation Facilitation + Training-As-Usual|M2VA case managers at sites randomized to IF+TAU will receive the M2VAPCP training workshop described above and IF delivered virtually for 21 months after receiving the M2VAPCP training workshop. IF for this trial will be organized around three major components: 1) an external facilitation team consisting of clinical and implementation experts who will work with internal facilitators at each site; 2) multifaceted activities to support the use of M2VAPCP; and 3) ongoing formative evaluation.
62020760|NCT05319678||Cochlear implant users|Pre-or perilingual patients aged 6 to 17 years old, and postlingual adults who underwent cochlear implantation from 2000 to January 2023 at La Paz University Hospital
62020761|NCT05319678||Normal hearing subjects|Control group is set up with the normal hearing peers of cochlear implant users
62020762|NCT05437627||Study Group:|Study Group: This will be consisted of sixty (60) stuttering patients. They will be divided into 2 subgroups; children group 30 patients with age ranges from (10-18y) and adult group 30 patients with age ranges from (19-30y)
62020763|NCT05437627||Control Group|Control Group: This will be consisted of sixty (60) subjects who have normal fluency. They will be selected from the relative of the patients attending to the outpatient clinic and will be matched for age, sex and socioeconomic state with the patients group.
62020764|NCT02930096||pulsatility index mesured with doppler ultrasound|
62020765|NCT01633489||LAL Deficiency patients|Patients are those with a diagnosis of LAL Deficiency (living and deceased), irrespective of treatment status or treatment choice.
62214368|NCT03695458|ACTIVE_COMPARATOR|irradiation effect Local|Photobiomodulation Therapy with the active irradiation will be applied on the exercised leg and Photobiomodulation Therapy with the placebo program will be applied on the non-exercised leg.
62791422|NCT00838240|EXPERIMENTAL|Arm II|Patients receive idarubicin IV and cytarabine IV as in arm I. Patients also receive clofarabine IV by push injection over 10 minutes on days 2, 4, 6, 8, and 10.
62020766|NCT04116931|EXPERIMENTAL|clopidogrel-600 mg-12h|clopidogrel 600 mg loading dose (LD) 12 hours after the last maintenance dose（MD） of ticagrelor followed by 75 mg MD daily
62020767|NCT04116931|EXPERIMENTAL|clopidogrel-600 mg-24h|clopidogrel 600 mg loading dose (LD) 24 hours after the last maintenance dose（MD） of ticagrelor followed by 75 mg MD daily
62020768|NCT04116931|EXPERIMENTAL|clopidogrel-75 mg-12h|clopidogrel 75 mg maintenance dose(MD) 12 hours after the last MD of ticagrelor
62020769|NCT04116931|EXPERIMENTAL|clopidogrel-75 mg-24h|clopidogrel 75 mg maintenance dose（MD) 24 hours after the last MD of ticagrelor
62214369|NCT03695458|ACTIVE_COMPARATOR|irradiation effect Systemic|Photobiomodulation Therapy with the active program will be applied on non-exercised leg and Photobiomodulation Therapy with the placebo program will be applied on the exercised leg.
62584674|NCT04830111|EXPERIMENTAL|heart rate variability biofeedback training group|The goal of heart rate variability biofeedback is to increase heart rate variability through paced breathing exercises, which have shown to be effective in reducing stress and anxiety in general adult populations.
62791423|NCT03565380|EXPERIMENTAL|Patients with intervention|12-week community-based Tai Chi rehabilitation program starting at 12 weeks after TKA
62020770|NCT02162810|ACTIVE_COMPARATOR|oral steroids|Systemic high-dose steroids (30 mg/kg methylprednisolone) have been shown in a randomized, double-blind, placebo-controlled trial in humans not to negatively impact wound infection or dehiscence rates, instead benefitting patients in the postoperative period in ways such as decreasing pain. An acute course of oral systemic steroids has been routinely used in patients under the age of 12 with asthma exacerbations (liquid prednisolone at 1-2 mg/kg/day in 1-2 divided doses for up to 10 days, although usually given for 5 days, which is at least 19 times less than the dose proven to be safe in the randomized controlled trial mentioned above) and proven to be safe without adverse effects. Effect of prednisolone on the systemic response and wound healing after colonic surgery.
62020771|NCT02162810|PLACEBO_COMPARATOR|placebo-controlled|Simple Syrup will be used as the placebo
62214370|NCT01637181|ACTIVE_COMPARATOR|EVLA 940 nm|
62584675|NCT04830111|NO_INTERVENTION|Care as usual|In this condition, all of this group take care by hospital routine and the questionnaires were completed over a period with similar intervals.
62791424|NCT03565380|EXPERIMENTAL|Patients without intervention|usual post-operative care
62791425|NCT03565380|EXPERIMENTAL|Asymptomatic controls|untreated asymptomatic controls
62409936|NCT03611595|EXPERIMENTAL|Cabozantinib and 13-cis-retinoic acid|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles, combined with 13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
62584676|NCT05747898|ACTIVE_COMPARATOR|Cannula arm|the cannula's 18 gauge tip was pointed upward and approximately parallel to the skin's surface when it was put into the superficial dermis, 1-2 millimeters away from the targeted scar. In order to completely remove fibrous tissue from the superficial dermis, a lancing motion (linear inserting-withdrawing needle action) was utilized first.
62791426|NCT05107570|OTHER|Cold exposure applied to Western European individuals|Participants rested under thermoneutral conditions for 30 min, which was then followed by exposure to \~ 9°C air temperature for a maximum of 1 hour. Same duration as matched Siberian individuals.
62584677|NCT05747898|ACTIVE_COMPARATOR|Needle arm|The needle's 27 gauge tip was pointed upward and approximately parallel to the skin's surface when it was put into the superficial dermis, 1-2 millimeters away from the targeted scar. In order to completely remove fibrous tissue from the superficial dermis, a lancing motion (linear inserting-withdrawing needle action) was utilized first.
62584678|NCT01019395|EXPERIMENTAL|Group 1|Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion.
62584679|NCT01019395|EXPERIMENTAL|Group 2|Group 2: Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion
62584680|NCT01019395|EXPERIMENTAL|Group 3|Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion.
62791427|NCT05107570|OTHER|Cold exposure applied to Siberian individuals|Participants rested under thermoneutral conditions for 30 min, which was then followed by exposure to \~ 9°C air temperature for a maximum of 1 hour. Same duration as matched European individuals.
62214371|NCT01637181|ACTIVE_COMPARATOR|EVLA 1470 nm|
62214372|NCT01556191|EXPERIMENTAL|Gefinitib + Fulvestrant (patient with EGFR mutations)|
62214373|NCT01556191|ACTIVE_COMPARATOR|Erlotinib (wild type patients)|
62791428|NCT04994548||Cirrhotic patients or with portal hypertension|Patients with early esophageal cancer
62791429|NCT05904795|ACTIVE_COMPARATOR|PNF strengthening exercises|Pnf strengthening exercises along with isometrics and range of motion exercises
62214374|NCT01556191|EXPERIMENTAL|Erlotinib + Fulvestrant (wild type patients)|
62214375|NCT01556191|ACTIVE_COMPARATOR|Gefinib (patient with EGFR mutations)|
62409937|NCT02896621|EXPERIMENTAL|Chlorthalidone plus amiloride|"Chlorthalidone plus amiloride group received 25 mg of chlortalidone and amiloride, 5 mg.~A capsule with both drugs was taken once daily in the morning for eight weeks."
61978519|NCT04826770||AZD/BNT/BNT|Subjects receiving one dose of AZD 1222 (Vaxzevria®, Covishield®, ChadOx1 nCoV-19, Oxford University/Astra-Zeneca) followed by one dose of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as heterologous basic immunization and one dose of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as booster vaccination
62020772|NCT01614210|EXPERIMENTAL|All patients|All patients enrolled in the study.
62409938|NCT02896621|ACTIVE_COMPARATOR|Amlodipine|Amlodipine group received 10 mg. A capsule was taken once daily in the morning for eight weeks. Capsules of amlodipine had identical presentation of that the intervention drug.
62409939|NCT04679649|EXPERIMENTAL|Trial A - Intervention Group (manual mobilisation)|Participants will continue to receive routine care and 13 sessions of manual spinal mobilisation will be administered over a 6 months period to compare routine care vs routine care plus manual spine mobilisation physiotherapy.
62584681|NCT04116658|EXPERIMENTAL|Cohort 1|Multiple dose of EO2041 monotherapy followed by continued EO2401 in combination with nivolumab
62584682|NCT04116658|EXPERIMENTAL|Cohort 2|Multiple dose of EO2041 in combination with nivolumab
62584683|NCT04116658|EXPERIMENTAL|Cohort 3|Multiple dose of EO2041 in combination with nivolumab and bevacizumab
62584684|NCT04409808|EXPERIMENTAL|IRIS vitrectomy device|all subjects in this study are in the experimental treatment arm and vitrectomy by use of prototype IRIS vitrectomy device
62020773|NCT00450424|NO_INTERVENTION|Counseling|Participants will be given one of two counseling interventions regarding MSI testing: standard counseling or a CD-ROM intervention.
62214376|NCT00535756|EXPERIMENTAL|1|
62214377|NCT00535756|PLACEBO_COMPARATOR|2|
62214378|NCT00951002||acellualr dermal matrix|patients treated with acellular dermal matrix plug
62214379|NCT06426420|EXPERIMENTAL|Pelvic Pain|"Patients referred to the gynecology outpatient clinic, with complain of pelvic pain. Positives and negatives for endometriosis will be outlined by an expert gynecologist according to the following criteria:~* Pelvic MRI (Magnetic Resonance Imaging) report;~* Gynecologic exam;~* Clinical symptoms and history;~The intervention is the use of the ATR-FTIR Spectrometer in patient's urine samples to develop and validate a tool for detecting endometriosis."
62214380|NCT04391998|ACTIVE_COMPARATOR|Anemia without parasitic infection|women with anemia without parasitic infection will receive iron treatment
62214381|NCT04391998|ACTIVE_COMPARATOR|parasitic infection treated with iron|women with anemia with parasitic infection will receive oral iron treatment
62214382|NCT04391998|ACTIVE_COMPARATOR|parasitic infection treated with iron and antihelmemsic|women with anemia with parasitic infection will receive oral iron treatment and antihelminsic treatment in the form of metronidazole 500mg tab twice daily for 5 days in cases with Entamoeba or Giardia or albendazol 200mg tab
62214383|NCT01215201|OTHER|Scaling and Root Planing Alone|Control group
62214384|NCT01215201|EXPERIMENTAL|Diode Laser plus Scaling and Root Planing|Diode Laser is used in addition to Scaling and root planing procedure.
62584685|NCT06019845|EXPERIMENTAL|Treatment|Magnetic Interventional Ablation Catheter (MAGiC™)
62214385|NCT04101214|EXPERIMENTAL|Dry needling|One session of dry needling technique will be applied by a physiotherapist specialized in the technique. Dry needling technique will be performed in the muscle of the lower limb whose MMAS score is \>1 by locating a sensitive point within a taut band. After that, a thin needle (0,32x40mm) is introduced directly into those muscle that present spasticity, decide by the clinician expert.
62214386|NCT04101214|SHAM_COMPARATOR|Sham Dry needling|A physiotherapist specialized in dry needling technique will use a sham needle in order to simulate the active intervention. Sham acupuncture uses non-penetrating needles.The palpation and evaluation of the spastic muscle will be exactly the same that in the active group.
62020774|NCT02810535|ACTIVE_COMPARATOR|Allergic rhinitis|Clinical observation of 24 subjects with nasal symptoms and positive prick test for house dust mite
62214387|NCT03167359|EXPERIMENTAL|Participants with Stage 0-III breast cancer|Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.
62214388|NCT01526239|EXPERIMENTAL|Intervention group|Intervention consisted of a pamphlet about the benefit of CRC-S, given to patients prior to their PCP visit and a reminder note about CRC screening to be given to their physician during the encounter.
62214389|NCT01526239|NO_INTERVENTION|Control group|Control group will not receive the pamphlet regarding colorectal cancers.
62214390|NCT00253084|OTHER|IPX054 - CD-LD IR|Subjects received IPX054 200 mg b.i.d and CD-LD IR Placebo q.i.d for 2 weeks and then received IPX054 Placebo b.i.d and CD-LD IR q.i.d for 2 weeks.
62214391|NCT00253084|OTHER|CD-LD IR - IPX054|Subjects received IPX054 Placebo b.i.d and CD-LD IR q.i.d for 2 weeks and then IPX054 200 mg b.i.d and CD-LD IR Placebo q.i.d for 2 weeks.
62214392|NCT03162562|EXPERIMENTAL|Oregovomab plus Poly ICLC (Hiltonol)|Oregovomab Solution, 2 mg IV, every three weeks (weeks 0, 3, 6, and 9) and then once at week 16 plus poly ICLC Suspension, 2 mg IM, 30 minutes post-oregovomab infusion and 48 hours post-oregovomab infusion (total 10 doses)
62214393|NCT00913848|EXPERIMENTAL|1|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
61978520|NCT04826770||AZD/AZD/BNT|Subjects receiving two doses of AZD 1222 (Vaxzevria®, Covishield®, ChadOx1 nCoV-19, Oxford University/Astra-Zeneca) as homologous basic immunization and one dose of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as booster vaccination
62020775|NCT02810535|EXPERIMENTAL|Non-allergic rhinitis|Clinical observation of 24 subjects with nasal symptoms and negative prick test for house dust mite
62214394|NCT00913848|ACTIVE_COMPARATOR|2|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
62214395|NCT00677716|EXPERIMENTAL|131I-chTNT-1/B MAb (Cotara)|
62214396|NCT04315350|EXPERIMENTAL|Curcumin|Participant receives both curcumin and prednisolone. Curcumin for 11 days, prednisolone for 10 days. Curcumin: 2 tablets (each contains 100 mg curcumin) twice daily. Prednisolon: 50 mg (capsule) every morning
62214397|NCT04315350|OTHER|Prednisolon|Participant receives prednisolone and curcumin-placebo. Curcumin-placebo for 11 days, prednisolone for 10 days. Curcumin-placebo: 2 tablets twice daily. Prednisolon: 50 mg (capsule) every morning
62214398|NCT04315350|PLACEBO_COMPARATOR|Placebo|Participant receives prednisolone.placebo and curcumin-placebo. Curcumin-placebo for 11 days, prednisolone-placebo for 10 days. Curcumin-placebo: 2 tablets twice daily. Prednisolon-placebo: One capsule every morning.
62214399|NCT05470647|EXPERIMENTAL|Interleukin-4 receptor responders 1|Interleukin-4 receptor was injected subcutaneously, once every two weeks.
62214400|NCT05470647|EXPERIMENTAL|Interleukin-4 receptor responders 2|Interleukin-4 receptor was injected subcutaneously, once a week.
62214401|NCT05470647|PLACEBO_COMPARATOR|Controls|Placebo was injected subcutaneously.
62214402|NCT00531739|NO_INTERVENTION|A|Colorectal Surgery without use of SurgiWrapTM
62214403|NCT00531739|ACTIVE_COMPARATOR|B|Colorectal Surgery with use of SurgiWrapTM film secured in two study areas: the posterior pelvic rim and directly below the abdominal incision
62214404|NCT05255887|EXPERIMENTAL|Informing patients group|24-48 hours before the surgery, the patients will be shown an informative video about the intensive care environment in a separate room through a one-on-one interview. In the study, the day of discharge from the intensive care unit will be counted as the first day, and on the second day, the 'Intensive Care Experience Scale' will be applied to the patients in the experimental group by face-to-face interview method.
62214405|NCT05255887|NO_INTERVENTION|Control Group|patients who were no intervation
62214406|NCT04313608|EXPERIMENTAL|Arm A: Glofit-GemOx|Participants will receive up to 8 cycles of Glofit-GemOx (glofitamab in combination with gemcitabine and oxaliplatin) administered in 21-day cycles, followed by up to 4 cycles of glofitamab monotherapy. A single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab.
62584686|NCT05510128|EXPERIMENTAL|Management with the protocol|"Patients who participate in the study in the experimental arm benefit from an adapted management, which falls under the application of the national cooperation protocol.~This management may lead to the dispensing of an antibiotic by the pharmacist himself."
62584687|NCT05510128|NO_INTERVENTION|Standard care|"Patients participating in the study in the control arm will benefit from a management comparable to the current one. In addition to a reminder of the hygienic and dietary rules by the pharmacist, the patient may be offered a drug indicated for improving urinary comfort.~The pharmacist should also remind the patient that she can consult a doctor, especially in case of non relief or aggravation of symptoms."
62584688|NCT04903496||In- and outpatients: diabetic with risk factors (RF) [Arm A]|In- and outpatients with diagnosis of diabetes, and with diagnosis of risk factors cardiovascular disease (CVD), heart failure (HF), chronic kidney disease (CKD) or at high cardiovascular (CV) risk identified in the Tianjin regional medical database.
62791430|NCT05904795|ACTIVE_COMPARATOR|de-lorme and watkins progressive resistance exercises|progressive resistance exercises along with isometrics and range of motion exercises
62791431|NCT03769038|OTHER|Chronic Total Occlusion and Restenosis|contemporary antegrade or retrograde dissection and re-entry (ADR or RDR) to open CTO
62791432|NCT03710642|ACTIVE_COMPARATOR|Treatment (Prazosin)|"Eligible participants will be randomized using a 2:1 schedule to prazosin or placebo and stratified by site and gender, and will follow a fixed titration scheme for the first 15 days, followed by a flexible does titration from days 15-29, then a maintenance phase stable dose from days 29 to the end of the 12 weeks study period.~Prazosin Fixed titration dose schedule for Days 1 to 14 1 mg QHS for Days 1 to 3~1 mg QAM and 1 mg QHS for days 4 to 7~1. mg QAM and 2 mg QHS for days 8 to 10~2. mg QAM and 2 mg QHS for days 11 to 14~Prazosin Flexible titration dose schedule for Days 15 to 29. 3 mg QAM and 3 mg QHS on day 15, 4 mg QAM and 4 mg QHS on day 22, 4 mg QAH and 6 mg QHS on day 29,~Dose increases will be allowed only during the fixed and flexible dosing periods."
62791433|NCT03710642|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo medication will be administered in a titration schedule mimicking the active comparator treatment.
62791434|NCT01510158|EXPERIMENTAL|lesinurad 200 mg + allopurinol|
62791435|NCT01510158|EXPERIMENTAL|lesinurad 400 mg + allopurinol|
62791436|NCT01510158|PLACEBO_COMPARATOR|Placebo + allopurinol|
62791437|NCT05499533|EXPERIMENTAL|Hybrid Funnel Technique|Hybrid funnel technique for implant site preparation
62791438|NCT05499533|ACTIVE_COMPARATOR|Conventional Technique|Conventional subtractive Drill technique for implant site preparation
62791439|NCT05938998|EXPERIMENTAL|Social Support and Yoga|This is a single arm trial. This arm includes one hour of a guided social support group and one hour of yoga, weekly for 12 total weeks.
62214407|NCT04313608|EXPERIMENTAL|Arm B: Mosun-GemOx|Participants will receive up to 8 cycles of Mosun-GemOx (mosunetuzumab in combination with gemcitabine and oxaliplatin) administered in 21-day cycles.
62214408|NCT02722642|EXPERIMENTAL|Bronchial basal cells|Patients will receive 10\^6 (1 million)/Kg/person cells of clinical grade bronchial basal cells (BBCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
62409940|NCT04679649|NO_INTERVENTION|Trial A - Control Group (routine care)|Participants in control group will continue to receive routine care, and routine care measurements for axial spondyloarthritis will be taken at baseline, 3 months and 6 months plus follow up.
62409941|NCT06653517|EXPERIMENTAL|Dabrafenib and Trametinib Treatment Arm|"Dabrafenib: 150 mg twice daily, not to be taken if less than 6 hours remain to the next dose.~Trametinib: 2 mg once daily, not to be taken if less than 12 hours remain to the next dose.~Cycle Length: 30 days. Initial Follow-Up: After each of the first two cycles. Toxicity Management: Discontinue if intolerable toxicity occurs. Long-Term Follow-Up: Every two cycles. Criteria for Surgery: Confirmed by at least two chief physicians."
62214409|NCT06181487|EXPERIMENTAL|Experimental group|The experimental group will undergo 60 minutes of high-intensity functional training.
62409942|NCT04513873|EXPERIMENTAL|Equipment Intervention Group|"The intervention group had equipment that looks like a blood tube in front of them during the blood collection process to divert their attention from the blood collection process to the equipment. This equipment was with a fixed arm on the right and a moving arm on the left with a total height of 80 cm as well as a red light-emitting diode(LED) to stimulate the blood collection. It had some answers to common questions of parents as well as the key concerns of the children like  Will it hurt me?. The equipment was made a musical device by loading the most popular children's songs into its database."
62409943|NCT04513873|NO_INTERVENTION|No Intervention Group|Standard blood collection procedures were applied to the control group.
62409944|NCT01016184|ACTIVE_COMPARATOR|vitamin D|
62409945|NCT01016184|ACTIVE_COMPARATOR|placebo|
62409946|NCT01873131|EXPERIMENTAL|Topical Timolol|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the timolol arm will receive twice daily topical application of a physician-specified amount of timolol maleate 0.5% ophthalmic solution (hereby referred to as topical timolol) for up to six months.
62214410|NCT06181487|NO_INTERVENTION|Control group|The control group will follow the curriculum standards set by the Sports University.
62214411|NCT05301647||Active Group|
62020776|NCT02810535|OTHER|Healthy Control|Clinical observation of 20 subjects without nasal symptoms and with negative prick test
62020777|NCT04133844||Extracorporeal membrane oxygenation|
62214412|NCT05301647||Control Group|
62214413|NCT00526838|EXPERIMENTAL|1|once-weekly dosing
62214414|NCT00526838|EXPERIMENTAL|2|twice-weekly dosing
62214415|NCT00415038|EXPERIMENTAL|Rostafuroxin 50 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
62214416|NCT00415038|EXPERIMENTAL|Rostafuroxin 150 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
62214417|NCT00415038|EXPERIMENTAL|Rostafuroxin 500 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
62409947|NCT01873131|NO_INTERVENTION|Observation|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the observation arm will be followed at study visits according to protocol.
62409948|NCT01873131|EXPERIMENTAL|Pulsed Dye Laser|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the pulsed dye laser arm will receive a series of six weekly to semi-weekly laser treatments treatments for up to 6 treatments with potential for reduced number of treatments if the hemangioma completely resolves. A 595-nm pulsed-dye laser (PDL, V-beam Perfecta, Candela Corp, Wayland, MA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions.
62214418|NCT00415038|EXPERIMENTAL|Rostafuroxin 1.5 mg capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
62791440|NCT05456971|EXPERIMENTAL|Art filler Volume|To confirm the capacity of the VOLUME filler to restore a midface volume 3 weeks after the first injection or after 6 weeks if a touch up was performed at 3 weeks.
62791441|NCT05456971|EXPERIMENTAL|Art Filler Lips|To confirm the capacity of the LIPS filler to restored volume of the treated lip 3 weeks after the first injection or at 6 weeks if a top up at 3 weeks is performed.
62409949|NCT03537625|EXPERIMENTAL|Green tea|Green tea extract 2 gram per day
62791442|NCT03265340|ACTIVE_COMPARATOR|A|dTMS standard protocol 10 min session
62020778|NCT05699863|EXPERIMENTAL|Metabolically unhealthy obese (Intervention group)|Obese (BMI: 30.0 - 39.9) participants with non-alcoholic fatty liver disease and metabolic syndrome.
62020779|NCT05699863|NO_INTERVENTION|Metabolically healthy obese (Comparison group 1)|Obese individuals considered metabolically healthy based on them not presenting non-alcoholic fatty liver disease or metabolic syndrome.
62020780|NCT05699863|NO_INTERVENTION|Healthy normal weight (Comparison group 2)|Normal weight individuals without non-alcoholic fatty liver disease or metabolic syndrome.
62020781|NCT06050460|EXPERIMENTAL|SA55 injection|Cohort 1: 150mg; Cohort 2: 300mg; Cohort3: 600 mg; Cohort4: 900 mg
62214419|NCT00415038|EXPERIMENTAL|Rostafuroxin 5 mg capsule|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
62584689|NCT04903496||In- and outpatients: diabetic without RF [Arm B]|In- and outpatients with diagnosis of diabetes, but not with diagnosis of risk factors CVD, HF, CKD or at high CV risk identified in the Tianjin regional medical database.
62584690|NCT04903496||In- and outpatients: non-diabetic with RF [Arm C]|In- and outpatients without diabetes but with diagnosis of risk factors CVD, HF, CKD or at high CV risk identified in the Tianjin regional medical database.
62584691|NCT04903496||In- and outpatients: non-diabetic without RF [Arm D]|In- and outpatients without diabetes and without diagnosis of risk factors CVD, HF, CKD or at high CV risk identified in the Tianjin regional medical database.
62584692|NCT02089308|OTHER|Treatment-Sequence 1|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treament periods.~Treatment -Sequence 1 : Period 1 (test drug) + period 2 (reference)~The duration of each treatment period will be 3 days. Each patch will be applied for 24 hours."
62584693|NCT02089308|OTHER|Treatment-Sequence 2|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treament periods.~Treatment-sequence 2 : Period 1 (reference) + period 2 (test drug)~The duration of each treatment period will be 3 days. Each patch will be applied for 24 hours."
62584694|NCT01549561|NO_INTERVENTION|Services As Usual|Foster care services as usual
62020782|NCT06050460|PLACEBO_COMPARATOR|Placebo for SA55 injection|Cohort 1: 0mg; Cohort 2: 0mg; Cohort3: 0mg; Cohort4: 0mg
62020783|NCT04968548||Cases Series|Subjects with confirmed lung cancer diagnosis
62214420|NCT01755208|EXPERIMENTAL|Diagnostic (light-scattering spectroscopy)|Patients undergo light-scattering spectroscopy of the breast in addition to standard of care as it relates to screening for breast cancer or treatment of breast cancer.
62214421|NCT02958631|EXPERIMENTAL|Fimasartan|Fimasartan 60mg, QD
62584695|NCT01549561|EXPERIMENTAL|Parent and Youth Training|16 Weeks of Parent Training in group context with 5 to 10 relative and non-relative foster caregivers; Youth training with skills coaches
62584696|NCT01549561|EXPERIMENTAL|Parent Training|16 weeks of parent training with 5 to 10 relative and non-relative foster caregivers
62791443|NCT03265340|ACTIVE_COMPARATOR|B|dTMS standard protocol 20 min session
62791444|NCT03265340|ACTIVE_COMPARATOR|C|dTMS standard protocol 40 min session
62791445|NCT02032498|EXPERIMENTAL|Indocyanine Green|superficial injections of Indocyanine Green in the breast
62791446|NCT05606276|ACTIVE_COMPARATOR|Cycling exercise|Cycling on a cycle ergometer instead of doing the experimental eccentric exercise.
62020784|NCT04968548||Screening Series|Subjects undergoing LDCT for lung cancer screening
62214422|NCT02958631|ACTIVE_COMPARATOR|Losartan|Losartan 50mg, QD
62409950|NCT03537625|EXPERIMENTAL|Fermented green tea|Fermented green tea extract 2 gram per day
62409951|NCT03537625|PLACEBO_COMPARATOR|Placebo|Placebo
62791447|NCT05606276|EXPERIMENTAL|Eccentric exercise|Perform 2 sets of maximal eccentric contractions as the single session exercise intervention.
62020785|NCT01971398|EXPERIMENTAL|Positive Brochure|"Women receive a positive FASD education brochure with positive images and are asked to read this brochure in the presence of a data collector."
62020786|NCT01971398|EXPERIMENTAL|Negative Brochure|"Women receive a negative FASD education brochure with negative, vivid images and are asked to read this brochure in the presence of a data collector."
62409952|NCT06653881|EXPERIMENTAL|"GROUP 1: Patient receiving 0.016 A-NiTi (Conventional)archwire."|"Pretreament orthodontic records (T0) of all the patients undergoing study will be taken before bonding. Before bonding, teeth will be isolated and oral prophylaxis will be performed. Enamel will be etched with 37% phosphoric acid gel, rinsed with water and air dried till a frosty appearance of the etched surface was evident. Bonding agent will be applied and cured using LED curing light unit. A conventional orthodontic adhesive will be used to bond brackets with 0.022 ̎×0.028 inch slot. In this group ,1 0.016A-NiTi initial archwire will be securely ligated ."
62409953|NCT06653881|EXPERIMENTAL|"GROUP 2:Patient receiving 0.016 Cu-NiTi archwire."|". Pretreament orthodontic records (T0) of all the patients undergoing study will be taken before bonding. Before bonding, teeth will be isolated and oral prophylaxis will be performed. Enamel will be etched with 37% phosphoric acid gel, rinsed with water and air dried till a frosty appearance of the etched surface was evident. Bonding agent will be applied and cured using LED curing light unit. A conventional orthodontic adhesive will be used to bond brackets with 0.022 ̎×0.028 inch slot. In this group 0.016 Cu-NiTi archwire will be securely ligated."
62409954|NCT06650605|EXPERIMENTAL|Part 1 Dose Escalation & Dose Expansion|"Dose Escalation:~123I-ATT001 Dose Level 1 123I-ATT001 Dose Level 2 123I-ATT001 Dose Level 3~Dose Expansion:~123I-ATT001 Recommended Dose from Dose Escalation"
62409955|NCT00985127|EXPERIMENTAL|40 mg|40 mg BCX4208
62409956|NCT00985127|EXPERIMENTAL|80 mg|BCX4208
62409957|NCT00985127|EXPERIMENTAL|120 mg|BCX4208
62409958|NCT00985127|PLACEBO_COMPARATOR|sugar pill|
62409959|NCT00985127|EXPERIMENTAL|160mg|BCX4208
62409960|NCT00985127|EXPERIMENTAL|240mg|BCX4208
62214423|NCT06349746|ACTIVE_COMPARATOR|Therapeutic exercises|a specific therapeutic exercise program consisted of stretching exercises for posterior capsule and progressive resistance exercises for rotator cuff and scapula stabilizer and home exercise
62409961|NCT00985127|EXPERIMENTAL|320mg|BCX4208
62409962|NCT03408327|EXPERIMENTAL|Experimental group|"1. Wearable technology (fitness wristband \& App)~2. 4 times group activities (2 hr / each times)~3. LINE group interaction~4. Reminder and feedback form researcher"
62409963|NCT03408327|ACTIVE_COMPARATOR|Control group|"1. Wearable technology (fitness wristband + App)~2. Health promotion manual"
62214424|NCT06349746|ACTIVE_COMPARATOR|cervical and thoracic mobilization|cervical unilateral antero-posterior mobilization and thoracic central postro-anterior mobilization added to therapeutic exercises
62409964|NCT05879315|OTHER|risk stratification of fall in patients waiting for hip and knee surgery|
62584697|NCT01938430|EXPERIMENTAL|Cohort A, Group 1 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
62214425|NCT00921687|EXPERIMENTAL|Multifactorial intervention|The multifactorial intervention will consist of a CKD lecture, the CKD reference card, academic detailing, and access to the CKD registry.
62214426|NCT00921687|ACTIVE_COMPARATOR|Education only|Providers in the education only arm will receive a CKD lecture and be given a CKD reference card.
62214427|NCT00628004|EXPERIMENTAL|1|
62214428|NCT00628004|ACTIVE_COMPARATOR|2|
62214429|NCT00628004|NO_INTERVENTION|No treatment|No treatment as wound was healed
62409965|NCT05707156||Low dose|Cumulative dose of corticosteroids 0-10 mg a day (prednisone equivalent) Prednisone: 0-10 mg OR, Dexamethasone: 0-1.5 mg OR, Prednisolone: 0-10 mg OR, Methylprednisolone: 0-8 mg
62584698|NCT01938430|EXPERIMENTAL|Cohort A, Group 1 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
62214430|NCT01788553||patients with generalized anxiety disorder|
62409966|NCT05707156||Medium dose|"Cumulative dose of corticosteroids 10-20 mg a day (prednisone equivalent):~Prednisone: 11-20 mg OR, Dexamethasone: 1.6-3.0 mg OR, Prednisolone: 11-20 mg OR, Methylprednisolone: 9-16 mg"
62409967|NCT05707156||High dose|"Cumulative dose of corticosteroid \>20 mg a day (prednisone equivalent):~Prednisone: \> 20 mg OR, Dexamethasone: \> 3.0 mg OR, Prednisolone: \> 20 mg OR, Methylprednisolone: \>16 mg"
62409968|NCT03506724|OTHER|Oral nifedipine|Oral medication 10mg and 20mg
62409969|NCT03506724|OTHER|Intravenous labetalol|intravenous medication 20mg, 40mg, 80 mg
62409970|NCT01079169|EXPERIMENTAL|Cranberry capsule|
62409971|NCT01079169|PLACEBO_COMPARATOR|Placebo capsule|
62409972|NCT00530621|EXPERIMENTAL|Pemetrexed + Enzastaurin|
62409973|NCT00530621|PLACEBO_COMPARATOR|Pemetrexed + Placebo|
62409974|NCT06565702||Test medical equipment (blood pressure monitor)|Name of device: Medical automatic electronic sphygmomanometer (Model: YE990) Registrant name: Jiangsu Yuyue Medical Equipment Co. Registration Certificate No.: Su Meizhi Quasi 20222071271 The minimum number of valid cases for the evaluation of the electronic sphygmomanometer with auscultation as a control, with sequential measurements in the same arm, was 85, of which 3 valid data sets were provided by each subject, for a total of 255 data sets.
62409975|NCT06565702||Control medical devices (reference sphygmomanometer)|Name of device: Sphygmomanometer - stethoscope health care box (Model: A type) Registrant name: Jiangsu Yuyue Medical Equipment Co. Certificate of Registration No.: SuMeChiQi 20152070947 The minimum number of valid cases for the evaluation of the electronic sphygmomanometer with auscultation as a control, with sequential measurements in the same arm, was 85, of which 3 valid data sets were provided by each subject, for a total of 255 data sets.
62409976|NCT01249625|ACTIVE_COMPARATOR|N95 Respirator|The investigators are comparing specific N95 respirator against specific medical masks.
62409977|NCT01249625|ACTIVE_COMPARATOR|Medical/surgical mask|The investigators are comparing medical/surgical masks against the N95 respirator.
62409978|NCT05773053|EXPERIMENTAL|NT 201 Dose 1|Subjects will receive Dose 1.
62409979|NCT05773053|EXPERIMENTAL|NT 201 Dose 2|Subjects will receive Dose 2.
62584699|NCT01938430|EXPERIMENTAL|Cohort A, Group 2 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
62584700|NCT01938430|EXPERIMENTAL|Cohort A, Group 2 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
62584701|NCT01938430|EXPERIMENTAL|Cohort B, Group 3 (12 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3.
62584702|NCT01938430|EXPERIMENTAL|Cohort B, Group 3 (24 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3
62214431|NCT03666377|NO_INTERVENTION|No gum chewing|Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.
62214432|NCT03666377|EXPERIMENTAL|Gum chewing|"Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.~Intervention: 1 piece of sugarless gum to be chewed three times daily for 1 hour each."
62214433|NCT01823939|OTHER|Males / Females (Healthy)|Part A: This initial part of the study will be conducted in adult Bangladeshi healthy volunteers (4 males, 4 females) to assess the pharmacokinetics, safety, and tolerability of single doses of iOWH032. Participants will be admitted to the Clinical Trial Unit (CTU) of icddr,b (located at a 10 minute drive from the icddr,b main campus) the day prior to dosing and remain for 48 hours after dosing, unless treatment and/or follow-up of an adverse event (AE) require longer in-unit observation or treatment.
62214434|NCT01823939|OTHER|Males (Patient)|Part B: Patients will be eligible for the study if they have clinically severe dehydration and meet all other inclusion and exclusion criteria. Upon signing consent, they will be admitted to the Research Ward of the Dhaka Hospital of icddr,b.
62214435|NCT04155723||Phase 1 group|During phase 1, Midlines are inserted only by doctors.
62214436|NCT04155723||Phase 2 group|During Phase 2, Midlines are preferentially inserted by ICU nurses, and if needed, by doctors.
62214437|NCT05660759||NBCA|Patients that recieved portal vein embolization with n-butyl-cyanoacrylate glue.
62214438|NCT05660759||Particles|Patients that recieved portal vein embolization with micro particles.
62214439|NCT01099215|OTHER|PVS-10200|Each subject will receive one treatment of PVS-10200 delivered by ultrasound guided injection perivascular to the region of the target lesion within 24 hours of the completed angioplasty and stent placement.
62214440|NCT03389373|OTHER|Child with full primary dentition|All children who match inclusion criteria are eligible to have a saliva sample obtained which will act as a proxy for bacterial levels. High bacteria levels are correlated with a higher risk of developing cavities.
62214441|NCT03278860|EXPERIMENTAL|Oxytocin then placebo|Participants first received oxytocin (24 IU). After a washout period of 2 weeks, they then received placebo (24 IU).
62214442|NCT03278860|EXPERIMENTAL|Placebo then oxytocin|Participants first received placebo (24 IU). After a washout period of 2 weeks, they then received oxytocin (24 IU).
62409980|NCT05773053|EXPERIMENTAL|NT 201 Dose 3|Subjects will receive Dose 3.
62214443|NCT02187159|EXPERIMENTAL|DS-5565 QD|Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening
62409981|NCT05773053|PLACEBO_COMPARATOR|Placebo|Subjects will receive matching placebo.
62409982|NCT05966155|EXPERIMENTAL|Depression - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and CYP2C19 and clinical decisions support for antidepressant prescribing to the healthcare provider
62409983|NCT05966155|OTHER|Depression - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and CYP2C19 and return of results after the conclusion of the 6-month follow-up period
62214444|NCT02187159|EXPERIMENTAL|DS-5565 BID|Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)
62214445|NCT02187159|ACTIVE_COMPARATOR|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
62214446|NCT02187159|PLACEBO_COMPARATOR|Placebo|Participants take one each of placebo tablet and capsule BID
62214447|NCT03455621|PLACEBO_COMPARATOR|Pea-size amount of non-F dentifrice|Non-fluoride dentifrice (0 ppm F); to be used twice/day. Amount to be used: 0.3 g (pea-size amount)
62214448|NCT03455621|EXPERIMENTAL|0.025 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.025 g
62214449|NCT03455621|EXPERIMENTAL|0.05 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.05 g
62214450|NCT03455621|EXPERIMENTAL|0.1 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.1 g
62214451|NCT03455621|ACTIVE_COMPARATOR|Pea-size amount of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.3 g (pea-size amount)
62214452|NCT00546026|ACTIVE_COMPARATOR|Active group|Receive assessment of placental function
62214453|NCT04393558||COVID-19|Individuals experiencing COVID-19 like symptoms.
62214454|NCT04393558||Healthy Controls|Individuals without any known significant health problems
62214455|NCT03409627|EXPERIMENTAL|Group 1|Single infusion of INXN-4001, Dose 1
62214456|NCT03409627|EXPERIMENTAL|Group 2|Single infusion of INXN-4001, Dose 2
62214457|NCT04723914|EXPERIMENTAL|Treatment group|Dual target CAR-T cell therapy
62214458|NCT00285428|EXPERIMENTAL|Dose level 1|120 mg/m2
62214459|NCT00285428|EXPERIMENTAL|Dose level 2|200 mg/m2
62214460|NCT00285428|EXPERIMENTAL|Dose Level 3|375 mg/m2
62214461|NCT00285428|EXPERIMENTAL|Dose level 1B|80 mg/m2
62214462|NCT03802461|ACTIVE_COMPARATOR|Fecal Microbiota Transplantation (FMT)|Bowel lavage preparation followed by FMT administered by enema, given on 3 occasions. Fecal filtrate for FMT will be prepared from 50 g of healthy donor stool, homogenized, and diluted in 300 mL sterile normal saline.
62214463|NCT03802461|NO_INTERVENTION|Standard of Care|Patients in this arm will not receive intervention and will be on standard of care .
62214464|NCT00427310|EXPERIMENTAL|Arm 1: Postoperative 5 FU + sodium heparin|Continuous portal vein infusion with 5 FU 600 mg/m2 + 5000 units sodium heparin per day given for a total of 7 consecutive days.
62214465|NCT00427310|ACTIVE_COMPARATOR|Arm 2: Postoperative observation|
62584703|NCT01938430|EXPERIMENTAL|Cohort B, Group 4 (12 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)
62214466|NCT03896659|EXPERIMENTAL|Depressed: Hydrocortisone, then Placebo|"Participants in the depressed' arm will receive a Hydrocortisone 160 mg tablet every day for 3 days. After a washout period of 25 days, they then will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days."
62214467|NCT03896659|EXPERIMENTAL|Depressed: Placebo, then Hydrocortisone|"Participants in the depressed' arm will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days. After a washout period of 25 days, they then will receive a Hydrocortisone 160 mg tablet every day for 3 days."
62214468|NCT03896659|EXPERIMENTAL|Healthy Controls: Hydrocortisone, then Placebo|"Participants in the healthy control arm will receive a Hydrocortisone 160 mg tablet every day for 3 days. After a washout period of 25 days, they then will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days."
62214469|NCT03896659|EXPERIMENTAL|Healthy Controls: Placebo, then Hydrocortisone|"Participants in the healthy control arm will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days. After a washout period of 25 days, they then will receive a Hydrocortisone 160 mg tablet every day for 3 days."
62214470|NCT00444275|EXPERIMENTAL|Esomeprazole 20 mg Once Daily (initial phase)|
62214471|NCT00444275|EXPERIMENTAL|Esomeprazole 40 mg Once Daily (initial phase)|
62214472|NCT00444275|EXPERIMENTAL|Esomeprazole 20 mg Once Daily (Maintenance Phase)|
62214473|NCT00444275|EXPERIMENTAL|Esomeprazole 20 mg on Demand (Maintenance Phase)|
62584704|NCT01938430|EXPERIMENTAL|Cohort B, Group 4 (24 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)
62214474|NCT00444275|EXPERIMENTAL|Antacid Treatment (Maintenance Phase)|
62214475|NCT05446233|EXPERIMENTAL|[14C] Antaitavir Hasophate|Eligible healthy male subjects received a single oral 100 mg (radioactivity of 200µCi) dose of \[14C\] Antaitavir Hasophate
62214476|NCT02169167|EXPERIMENTAL|Resin salve treatment|The resin salve may be spread directly onto the diabetic ulcer, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the ulcer area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of ulcer secretion.
62214477|NCT02169167|ACTIVE_COMPARATOR|Octenidine treatment|Octenidine treatment is implemented with the similar manner as resin salve treatment by using sterile gauze that is impregnated with the octenidine dihydrochloride.
62214478|NCT04196127||TTH|Patients with tension-type headache. They may not experience migraine, but can experience neck pain and/or temporomandibular dysfunction.
62214479|NCT04196127||Healthy controls|Participants without frequent headaches. They may experience neck pain and/or temporomandibular dysfunction.
62214480|NCT05336851||Viral infection|Viral infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree
62214481|NCT05336851||Bacterial infection|Bacterial infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
62214482|NCT05336851||Viral-Viral co-infection|Viral-viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
62214483|NCT05336851||Bacterial-Viral co-infection|Bacterial-Viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
62214484|NCT05336851||Fungal-Mycobacterium co-infection|Bacterial-Viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
62214485|NCT05336851||Infection of uncertain origin|Infection of uncertain origin subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
62214486|NCT05336851||Control Subjects|Control group subjects, if they agree, will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms (if applicable); and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if applicable); and c) 48 hours +/- 6 hours from symptom onset (if applicable).
62214487|NCT02389582|EXPERIMENTAL|Dabigatran|Dabigatran 150mg twice a day for five days
62214488|NCT02389582|ACTIVE_COMPARATOR|Enoxaparin|Enoxaparin 1mg/kg/day twice a day for five days
62214489|NCT04664803|EXPERIMENTAL|Cefecin Tab.|Cefecin Tab./Placebo to Omnicef Cap.
62214490|NCT04664803|ACTIVE_COMPARATOR|Omnicef Cap.|Omnicef Cap./Placebo to Cefecin Tab.
62214491|NCT00662818|EXPERIMENTAL|Telcagepant 300 mg→Acetaminophen/Paracetamol 1000 mg|Participants receive up to 12 doses of telcagepant (280 mg tablet/capsule 300 mg), orally, and placebo to acetaminophen/paracetamol (APAP) (2- 500 mg dry filled capsules), orally, for up to 12 migraine attacks in Period 1 (6 weeks). Participants receive APAP and placebo to telcagepant for up to 12 doses, for up to 12 migraine attacks in Period 2 (6 weeks). The participant may take a blinded optional second dose of study medication or their own rescue medication if 2 hours after initial treatment, the participant still has a moderate or severe migraine headache or if the headache has returned.
62214492|NCT00662818|EXPERIMENTAL|Placebo and APAP 1000 mg→Telcagepant 300 mg|Participants receive 1 dose of placebo to APAP and placebo to telcagepant for the first migraine attack and then up to 11 doses of APAP and placebo to telcagepant for up to 11 migraine attacks in Period 1 (6 weeks). Participants receive up to 12 doses of telcagepant and placebo to APAP for up to 12 migraine attacks in Period 2 (6 weeks). The participant may take a blinded optional second dose of study medication or their own rescue medication if 2 hours after initial treatment, the participant still has a moderate or severe migraine headache or if the headache has returned.
62214493|NCT03344276|ACTIVE_COMPARATOR|Control Group|Patients, as outlined by NASCET criteria, will have between 50 symptomatic stenosis or 70% asymptomatic stenosis of the carotid artery. Patients, undergoing carotid artery stenting for carotid stenosis, will undergo cognitive testing at 2 time points before intervention (1 months, and 2 months). The two preoperative time points will serve as the control group.
62214494|NCT03344276|EXPERIMENTAL|Intervention Group|Patients, as outlined by NASCET criteria, will have between 50 symptomatic stenosis or 70% asymptomatic stenosis of the carotid artery. Patients, undergoing carotid artery stenting for carotid stenosis, will undergo cognitive testing at 2 time points after invention (1 month and 2 months). The two postoperative time points will serve as the intervention group.
62214495|NCT01415531|EXPERIMENTAL|1|Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
62214496|NCT01415531|PLACEBO_COMPARATOR|2|Dose-matched placebo
62214497|NCT01291823|EXPERIMENTAL|Concomitant Gefitinib and radiotherapy|Patients received Gefitinib and radiation therapy
62214498|NCT04421443|ACTIVE_COMPARATOR|3 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 3 days.
62214499|NCT04421443|ACTIVE_COMPARATOR|5 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 5 days.
62214500|NCT04421443|ACTIVE_COMPARATOR|8 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 8 days.
62214501|NCT06611189||Group A|Kidney transplantation performed using the ice bag technique.
62214502|NCT06611189||Group B|Kidney transplantation performed using Raytech sponge technique.
62214503|NCT01242800|ACTIVE_COMPARATOR|Arm I|Patients receive standard palliative therapy, if needed, to address symptoms such as tumor ulceration, pain, bulky adenopathy causing arm symptoms, and other similar situations. Therapy may consist of radiotherapy alone, surgery alone, or a combination of both.
62409984|NCT03654495|EXPERIMENTAL|Exergame Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. In addition training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016; designed to train different aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training.
62020787|NCT01971398|ACTIVE_COMPARATOR|A general women's health brochure|Women receive a brochure on general aspects of women's health and pregnancy that is available in the Russian language and are asked to read this brochure in the presence of a data collector.
62214504|NCT01242800|EXPERIMENTAL|Arm II|Patients undergo surgery comprising breast-conserving therapy (BCT) or total mastectomy according to patient and treating physician preference. Surgery is to occur no later than 10 weeks after completion of 32 weeks of systemic therapy. Free surgical margins must be achieved with re-excision or mastectomy for patients undergoing BCT. After completion of BCT, patients undergo radiotherapy once a day, 5 days per week. Patients who had mastectomy undergo radiotherapy at the discretion of treating physician.
62214505|NCT05483738|OTHER|Cases and controls|Clinical assessment, blood samples, dual energy x-ray absorptiometry (DXA) scan, and assessment of bone marrow, and tetracycline labelled bone biopsy
62214506|NCT06610604||thyroidectomy|patients with thyroid nodules who undergo surgical resection
62214507|NCT06610604||thermal ablation|patients with thyroid nodules who undergo thermal ablation
62214508|NCT04473898|SHAM_COMPARATOR|Patient Education Group|Information training about COViD-19 and its symptoms, hygiene education, family education
62214509|NCT04473898|EXPERIMENTAL|Aerobic Training Group|Teaching and regular follow-up of aerobic exercises shown online
62214510|NCT04473898|EXPERIMENTAL|Aerobic + Respiratory Training Group|Teaching and regular follow-up of aerobic and respiratory exercises shown online
62214511|NCT05253287|NO_INTERVENTION|Standard Medical treatment|Standard medical therapy: diuretics, lactulose, rifaximin, diuretics, albumin infusion, nutritional support (as required)
62409985|NCT03654495|ACTIVE_COMPARATOR|Usual Care Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation.
62409986|NCT01237704|ACTIVE_COMPARATOR|Traditional rehabilitation (TR)|
62409987|NCT01237704|ACTIVE_COMPARATOR|Transcutaneous electrical stimulation (ES)|
62409988|NCT01073176|EXPERIMENTAL|TEAMS|TEAMS has been designed to promote executive skills, memory and fine motor control, and includes game-like activities that allow for increases in task complexity.
62409989|NCT05280613|EXPERIMENTAL|Family Check-Up|"Families randomized to the Family Check-Up arm will be connected with a clinician who will provide the Family Check-Up. The Family Check-Up® (FCU) is an ecologically sensitive, evidence-based intervention that was developed to decrease childhood EBP by 1) assessing known ecological (child, family and contextual) risk and protective factors; 2) engaging parents in a tailored plan to enhance positive parenting and family management skills; and 3) connecting families to a tailored suite of child and family services and supports. Services may include an evidence-based suite of parenting sessions (Everyday Parenting Curriculum \[EPC\]) created by FCU developers for direct tailoring to the FCU feedback session."
62409990|NCT05280613|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as Usual participants will be connected to a Family Service Coordinator within the Autism Program, who can direct the family to appropriate services and resources. Services may include consultation on child behaviours, workshops on various topics, parenting programs, Applied Behaviour Analysis, support groups, and group recreational programs. Families in the treatment as usual arm will be offered the Family Check-Up upon completion of the study.
62409991|NCT00962546||CTA/CTP|Patients undergo CTA/CTP imaging prior to cerebral angiography
62409992|NCT04463992|EXPERIMENTAL|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: proactive symptom assessments for patients for up to 12-months.
62409993|NCT04463992|ACTIVE_COMPARATOR|Behavioral:Program participants|The control group arm will receive usual care as provided by their local oncologists.
62409994|NCT06037148|EXPERIMENTAL|DM-101PX low dose|10 subcutaneous doses starting from 0.05 ug of which first 8 doses are ascending. Thereafter the 8th dose is repeated twice. First 9 doses are administered at 1 week interval, and the 10th dose is administered 2 weeks after the 9th dose.
62409995|NCT06037148|PLACEBO_COMPARATOR|Placebo|10 subcutaneous doses.First 9 doses are administered at 1 week interval, and the 10th dose is administered 2 weeks after the 9th dose.
62409996|NCT06037148|EXPERIMENTAL|DM-101PX middle dose|10 subcutaneous doses starting from 0.1 ug of which first 8 doses are ascending. Thereafter the 8th dose is repeated twice. First 9 doses are administered at 1 week interval, and the 10th dose is administered 2 weeks after the 9th dose.
62214512|NCT05253287|EXPERIMENTAL|Growth hormone + Standard medical therapy|GH therapy will be initiated at a low dose of 2U/day and titrated slowly based on IGF-1 levels) subcutaneously for 1 year.
62214513|NCT04906746|EXPERIMENTAL|Dosing Regimen for Ruxolitinib|"Level 0: Ruxolitinib 0 MG po bid for 1 month (Month 1)~Level 1: Ruxolitinib 10 MG po bid for 1 month (Month 2)~Level 2: Ruxolitinib 15 MG po bid for 1 month (Month 3)"
62214514|NCT00567034|ACTIVE_COMPARATOR|1|taking naltrexone
62409997|NCT06037148|EXPERIMENTAL|DM-101PX high dose|10 subcutaneous doses starting from 0.2 ug of which first 8 doses are ascending. Thereafter the 8th dose is repeated twice. First 9 doses are administered at 1 week interval, and the 10th dose is administered 2 weeks after the 9th dose.
62409998|NCT00608127|EXPERIMENTAL|1|Single arm open label
62584705|NCT01938430|EXPERIMENTAL|Cohort B, Group 5 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
62214515|NCT00567034|PLACEBO_COMPARATOR|2|taking placebo
62214516|NCT03259373|EXPERIMENTAL|Intervention|Educational mailing to (1) AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater) who appear to not have received OAC treatment at time of randomization and (2) their providers, where an individual provider may be identified
62214517|NCT03259373|EXPERIMENTAL|Control|Educational mailing to providers of AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater) who appear to not have received OAC treatment in the time following randomization. These patients will have received 'usual care' for the time between randomization and delayed educational mailing.
62214518|NCT04537494|ACTIVE_COMPARATOR|Prevention|Oral supplementation with the probiotic L. reuteri administered to every newborn within the first week of life for 12 weeks
62214519|NCT04537494|OTHER|Treatment-as-needed|Supplementation with the probiotic L. reuteri after randomization, to infants who develop excessive cry/fuss up to 12 weeks of age
62214520|NCT03635372|EXPERIMENTAL|Alginate|10 cc of Alginate peroral
62214521|NCT03635372|EXPERIMENTAL|Sucralfate|10 cc of Sucralfate peroral
62214522|NCT03635372|EXPERIMENTAL|Hydrotalcite|10 cc of Hydrotalcite peroral
62584706|NCT01938430|EXPERIMENTAL|Cohort B, Group 5 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
62020788|NCT04455100|EXPERIMENTAL|SHR1459|Following a 10-hour overnight fast, subjects will be administered one dose of SHR1459 orally with 240 mL of ambient temperature water on Day 1. D2-D3 was the cleaning period. Itraconazole will be administered orally 200 mg/time/day form D4 to D8 after meal. On D7 following a 10-hour overnight fast, subjects will be administered SHR1459 and itraconazole 200 mg with 240 mL of ambient temperature water.
62409999|NCT03777800|EXPERIMENTAL|Body Therapy|Participants in the intervention condition will be assigned to a 6-month body therapy treatment focused on 24 individual body treatments including conversations and direct physical treatment of the body combined with home-based daily practice of meditation.
62410000|NCT03777800|ACTIVE_COMPARATOR|Treatment As usual|Participants in the control condition will be offered treatment as usual, which is psychiatric medication and/or individual psychotherapy as deemed relevant by the psychiatrist.
62020789|NCT04391231|EXPERIMENTAL|Pentoxifylline Arm|Pentoxifylline (in suspension with SyrSpend SF)
62214523|NCT02738203|EXPERIMENTAL|Experimental, IUD Insertion group|"If the subject is assigned to the experimental group (vaginal lidocaine jelly):~She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo."
62214524|NCT02738203|PLACEBO_COMPARATOR|Control, IUD Insertion group|"If the subject is assigned to the control group (sterile, surgical lubricant jelly):~•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo."
62214525|NCT02754349|EXPERIMENTAL|Validation|SphygmoCor version 7, AtCor Medical, Sydney, Australia
62214526|NCT04152304|EXPERIMENTAL|Feasibility of the SINEX for treatment of shoulder instability|Feasibility of the SINEX program for treatment and evaluation of of traumatic anterior shoulder instability eligible for surgery
62214527|NCT05414994||Cohort A|normal eyes with no ocular disease
62214528|NCT05414994||Cohort B|primary open angle glaucoma/Ocular hypertension defined as mild glaucoma which is well controlled with no more than one drop of prostaglandin use daily for the past 6 months
62214529|NCT05414994||Cohort C|non-infectious keratopathy not using any prescription medication (OTC artificial tears are acceptable)
62214530|NCT05414994||Cohort D|Dry AMD (age related macular degeneration)
62214531|NCT05414994||Cohort E|Wet AMD
62214532|NCT05414994||Cohort F|diabetic retinopathy, any stage
62214533|NCT03758859|EXPERIMENTAL|sodium hyaluronate eye drops|the randomly allocated eye will receive sodium hyaluronate drops, followed by a repeat OCT scan; images are then evaluated for clarity by the masked assessor.
62410001|NCT04973917|EXPERIMENTAL|conventional ventilation mode|respiratory support after cardiac surgery. Vt \< 6 ml/kg PBW, driving pressure \< 13 cmH2O
62410002|NCT04973917|EXPERIMENTAL|intelectual mode - Intelivent ASV|closed loop mode of mechanical ventilation Vt \< 6 ml/kg PBW, driving pressure \< 13 cmH2O
62410003|NCT04427618|EXPERIMENTAL|Intervention group|Intravenous 1g TXA (500mg/5ml, given intermittent over approximately 10 minutes) given within approximately 10 minutes before skin incision, and Intravenous oxytocin 5 units post delivery of the baby.
62410004|NCT04427618|PLACEBO_COMPARATOR|Control group|Intravenous 10ml normal saline (placebo) given within approximately 10 minutes before skin incision, and intravenous oxytocin 5 units post delivery of the baby
62584707|NCT01938430|EXPERIMENTAL|Cohort B, Group 6 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
62584708|NCT01938430|EXPERIMENTAL|Cohort B, Group 6 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
62584709|NCT01938430|EXPERIMENTAL|Cohort B, Group 7 (12 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with FCH
62020790|NCT04391231|PLACEBO_COMPARATOR|Placebo Arm|Placebo (SyrSpend SF only)
62214534|NCT02474485|ACTIVE_COMPARATOR|BVS - Absorb|"BVS - Absorb scaffold group will be treated by implantation of drug eluting bioresorbable vascular scaffold (Absorb®). In this arm following interventions will be performed:~* BVS Absorb implantation. For in stent restenosis treatment during index procedure.~* OCT visualization.During index procedure and at 9 month follow-up.~* Control coronary angiography. Control angiography will be performed at 9 month follow-up.~* Clinical observation. Clinical observation will be performed at 9, 12 and 60 month follow-up."
62214535|NCT02474485|ACTIVE_COMPARATOR|DEB - Sequent Please|"In DEB - Sequent Please Group, dilatation of drug eluting balloon Sequent Please ® will be used for treatment of the narrowed part of the artery. In this arm following interventions will be performed:~* DEB Sequent Please inflation. For in stent restenosis treatment during index procedure.~* OCT visualization.During index procedure and at 9 month follow-up.~* Control coronary angiography. Control angiography will be performed at 9 month follow-up.~* Clinical observation. Clinical observation will be performed at 9, 12 and 60 month follow-up."
62214536|NCT00350233|EXPERIMENTAL|ExAblate MRgFUS|
62020791|NCT05193994|EXPERIMENTAL|Dolutegravir/Abacavir/Lamivudine|"Combination of Dolutegravir, Abacavir and Lamivudine in a single product/capsule.~4 capsules to be taken orally once daily (all 4 at the same time, each capsule is Dolutegravir 12.5mg, Abacavir 150mg and Lamivudine 75mg). Maximum duration is 24months"
62020792|NCT05193994|PLACEBO_COMPARATOR|Placebo|4 capsules to be taken orally once daily (all 4 at the same time). Maximum duration is 24months
62020793|NCT04497701|EXPERIMENTAL|PEG-rhG-CSF group|Patients received subcutaneous injection of PEG-rhG-CSF(Jinyouli®)24\~72 hours after the end of chemotherapy, 100µg/kg, once in each chemotherapy cycle.
62020794|NCT04497701|ACTIVE_COMPARATOR|rhG-CSF group|Patients received subcutaneous injection of rhG-CSF 24\~72 hours after the end of chemotherapy, 100µg/kg/d, and stop using it until the ANC value exceeds the lowest value for 2 consecutive days\> 0.5×10\^9/L.
62020795|NCT04602520||Dying patients|"Behavioral: Focused end of life conversations to promote connections among patients, family members and clinicians.~All eligible dying patients and families in the 3 participating acute care wards are invited to participate in wish elicitation and implementation. For clinician interviews, criterion sampling will be used, based on involvement in the care of enrolled dying patients. We will use qualitative and quantitative methods to collect and analyze data. Quantitative data will include characteristics of patients, families and clinicians. Qualitative data will be based on interviews. Pending the pandemic burden, and the status of their grief, family members of deceased patients may be invited for an interview later months after the death of their loved one."
62020796|NCT04157829|EXPERIMENTAL|Scintilling lamp- Classic lamp|
62214537|NCT03950076|EXPERIMENTAL|Edoxaban 60/30mg daily|Edoxaban 60/30 mg daily (lower dose depending on clinical criteria)
62214538|NCT03950076|ACTIVE_COMPARATOR|Non-anticoagulant medical therapy|Non-anticoagulant medical therapy: no antithrombotic therapy or antiplatelet monotherapy (at discretion of local investigator)
62410005|NCT00685763|EXPERIMENTAL|Proton radiation and chemotherapy|"Chemotherapy and Radiation Combination~Proton radiation 59.4 cobalt gray equivalent(CGE) in 33 fx at 1.8 CGE per fx over 7 weeks.~Capecitabine (Xeloda ®) 1,000 mg by mouth approximately every 12 hrs, 5 days/week starting the first day of radiation until the end of radiation, but on radiation days only.~Consolidation Chemotherapy starting 4 weeks after the completion of radiation~Gemcitabine (Gemzar ®) Suggested Regimen - 1,000mg/m2 by IV over 30 minutes once a week for 3 weeks (followed by a week of rest) for 12 total doses."
62410006|NCT06651489|EXPERIMENTAL|Guselkumab|Participants with HHD with be given guselkumab
62791448|NCT03590353|ACTIVE_COMPARATOR|Dual chamber pacemaker|"1. Patients with sinus node disfunction: sinus node disfunction with obvious clinical symptoms, including sinus pause; patients with chronotropismus disfunction; patients have to take some medicine due to some diseases, but the medicine may result to sinus bradycardia.~2. Adult Acquired Atrioventricular Block (AVB): (1). Third degree or advanced atrioventricular block in any block part with symptomatic bradycardia (2). Patients taking other antiarrhythmic drugs in long term, which could result in third degree or advanced AVB (in any block part) and symptomatic bradycardia;~3. Patients with acute myocardial infarction (AMI) and AVB:~(1). Patients with His-Purkinje system persistent second degree AVB and retardant or third degree AVB after STEMI; (2). Patients with temporary severe second degree AVB or third degree AVB (block part under atrioventricular node) and retardant; 4. Patients with carotid sinus hypersensitivity or neurogenic syncope of the heart;"
62214539|NCT02195154|EXPERIMENTAL|18F-DTBZ for Vascular Parkinsonism|This neuroimaging study includes the 18F-FP-(+)-DTBZ PET, MRI structure images, diffusion tensor imaging, susceptibility weighted imaging, resting state and gait-related imagery task functional MRI. Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject group, each subject will have 3 visits in this study. Safety measurement for 18F-FP-(+)-DTBZ will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
62584710|NCT01938430|EXPERIMENTAL|Cohort B, Group 7 (24 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH
62584711|NCT01282372||Participants with moderate to severe rheumatic disease|Participants with moderate to severe rheumatic disease (RA, PsA, or AS), who received adalimumab in accordance with approved label
62584712|NCT03770962|EXPERIMENTAL|Two midwives|"Two midwives will be present during the active phase of the second stage and the birth of the baby. Midwife no 1 is the midwife who has been responsible for the care of the woman and midwife no 2 will observe the birth or give any assistance needed."
62020797|NCT04157829|EXPERIMENTAL|Classic lamp- Scintilling lamp|
62020798|NCT06052969|EXPERIMENTAL|Group/Cohort|Subjects presenting to the emergency department with AIS, eligible for thrombolytic therapy, and with evidence of an occlusive clot by angiographic imaging will be considered for inclusion in the study. Post-thrombolytic therapy and mechanical thrombectomy eligible Subjects will receive the experimental NanoMED device.
62584713|NCT03770962|NO_INTERVENTION|One midwife|This is standard care. One midwife is responsible for the care of the woman and her unborn baby during labor and birth.
62584714|NCT01477996|ACTIVE_COMPARATOR|Group 1|27-gauge needle
62584715|NCT01477996|ACTIVE_COMPARATOR|Group 2|30-gauge needle
62020799|NCT03738865|EXPERIMENTAL|G-Pen followed by Novo Glucagon|1 mg G-Pen at the first treatment visit followed by 1 mg Novo Glucagon at the second treatment visit
62020800|NCT03738865|ACTIVE_COMPARATOR|Novo Glucagon followed by G-Pen|1 mg Novo Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit
62584716|NCT01559350||RGEA group|A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
62584717|NCT01559350||SVG group|A saphenous vein grafting in the right coronary artery system during OPCAB
62584718|NCT01648725|EXPERIMENTAL|Hypnosis|standard care plus hypnosis followed by closed-loop administration of propofol for anesthesia induction
62584719|NCT01648725|ACTIVE_COMPARATOR|Control|standard care without hypnosis followed by closed-loop administration of propofol for anesthesia induction
62020801|NCT05239806|EXPERIMENTAL|SCTV01C|Participants will receive one dose of SCTV01C on Day 0 and one dose of SCTV01E on Day 180.
62020802|NCT05239806|EXPERIMENTAL|SCTV01E|Participants will receive one dose of SCTV01E on Day 0 and one dose of SCTV01E on Day 180.
62020803|NCT05239806|ACTIVE_COMPARATOR|Sinopharm inactivated COVID-19 vaccine|Participants will receive one dose of Sinopharm inactivated COVID-19 vaccine on Day 0 and one dose of SCTV01E on Day 180.
62020804|NCT05239806|ACTIVE_COMPARATOR|Comirnaty|Participants will receive one dose of Comirnaty on Day 0 and one dose of SCTV01E on Day 180.
62020805|NCT01083030|ACTIVE_COMPARATOR|Conventional PTA|Angioplasty of SFA with uncoated balloon catheters
62791449|NCT03590353|EXPERIMENTAL|His bundle pacemaker|His Bundle Pacemaker: All of the Criteria Inclusion of dual chamber pacemaker excluding patients with block part under the his bundle;
62791450|NCT00894868|EXPERIMENTAL|Vildagliptin|
62020806|NCT01083030|EXPERIMENTAL|Drug coated balloon|Angioplasty of SFA with paclitaxel-coated balloon catheters
62584720|NCT06140355|EXPERIMENTAL|Experimental group|adults with SCI-related neuropathic pain with at least 50% from diverse groups randomized to experimental group
62020807|NCT03937167|NO_INTERVENTION|Control|Standard treatment at Hospital Infanta Leonor with Endocrinology and Psyquiatry
62020808|NCT03937167|EXPERIMENTAL|Completers|Randomized to treatment AND complete treatment 14 sessions are needed
62020809|NCT03937167|NO_INTERVENTION|Drop-out|Randomized to treatment BUT do not assist or do not complete treatment Less than 14 sessions
62020810|NCT01415505|OTHER|1|Nebivolol and Valsartan free tablet combination
62791451|NCT00894868|PLACEBO_COMPARATOR|Placebo|
62791452|NCT01922908|ACTIVE_COMPARATOR|MSC infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
62791453|NCT01922908|PLACEBO_COMPARATOR|SHAM infusion|Infusion of normal saline placebo
62791454|NCT01672424||Group P: High Protein Drink|Patients receiving the high protein drink with 30 grams of protein in 11 fluid ounces.
62791455|NCT01672424||Group C: Ice Chips|The control group consisting patient receiving 11 ounces of ice chips
62791456|NCT04096287|EXPERIMENTAL|PNT001|Single escalating doses of intravenous PNT001 administered as a 30 minute infusion at doses of 33mg, 100mg, 300mg, 900mg, 2700mg, and as a 60 minute infusion at 4000 mg
62791457|NCT04096287|PLACEBO_COMPARATOR|Placebo|Single intravenous dose of vehicle administered as a 30 minute infusion up to 2700 mg and as a 60 minute infusion at 4000 mg
62020811|NCT04287920|EXPERIMENTAL|Alcohol-related liver disease and AUD, MELD-NA less than 20|The first 5 patients enrolled = AUD (alcohol use disorder) w/MELD-Na (model for end stage liver disease sodium) score less than 20.
62020812|NCT04287920|EXPERIMENTAL|Alcohol-related liver disease and AUD, MELD-NA more than 20|The second 5 patients enrolled = AUD (alcohol use disorder) w/MELD-Na (model for end stage liver disease sodium) score more than 20.
62020813|NCT02185352|EXPERIMENTAL|Inductional BEEP regimen|"Induction BEEP regimen:~Every 3 weeks a cycle for a total of 3 cycles (around 2 months)~* Bevacizumab 15mg/kg IVF on D1~* Etoposide 70 mg/m2 IVF QD, D2-4~* Cisplatin 70 mg/m2 IVF on D2~WBRT:~3000cGy in 10 fractions"
62791458|NCT01714765|OTHER|Dovitinib and Everolimus|No Arms
62020814|NCT02185352|NO_INTERVENTION|WBRT alone|"standard WBRT:~3000cGy in 10 fractions"
62020815|NCT03934385|EXPERIMENTAL|Mental Rehearsal|Between-session rehearsal/retrieval exercises focused upon consolidating non-fear learning gained from exposures by prompting reflection of expectancy violation and rehearsal of the inhibitory association between the conditioned stimulus (i.e., spider) and unconditioned stimulus (e.g., bite/attack).
62020816|NCT03934385|ACTIVE_COMPARATOR|Control Rehearsal|Between-session rehearsal/retrieval exercises focused upon an unrelated, recent academic experience.
62020817|NCT05854147|EXPERIMENTAL|Treadmill Training With Visual and Auditory Cues|
62020818|NCT05854147|OTHER|Treadmill Training Without Visual and Auditory Cues|
62020819|NCT00922428||Observational group|Patients suffering from rheumatic disorders of different types and origins, especially those with arthralgia, myalgia, lumbago, or other diagnoses.
62584721|NCT06140355|ACTIVE_COMPARATOR|Active comparison group|adults with SCI-related neuropathic pain with at least 50% from diverse groups randomized to active comparator group
62584722|NCT04276116|NO_INTERVENTION|Usual Care|
62791459|NCT06027099|EXPERIMENTAL|MI-Opioid Taper and tizanidine|
62791460|NCT06027099|EXPERIMENTAL|MI-Opioid Taper and placebo|
62791461|NCT06027099|ACTIVE_COMPARATOR|Enhanced Usual Care|
62791462|NCT03842059|EXPERIMENTAL|Computer-aided detection|
62791463|NCT03842059|PLACEBO_COMPARATOR|Standard colonoscopy|
62584723|NCT04276116|EXPERIMENTAL|Usual care + communication of pulmonary age|
62584724|NCT02219113|EXPERIMENTAL|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected intraarticularly into knee joint.
62791464|NCT03019718|EXPERIMENTAL|GSA-Online plus|Patients receive access to the internet-based aftercare program after inpatient treatment.
62791465|NCT00599794||1|Healty volunteers who are euvolemic.
62791466|NCT00599794||2|Critically ill patients who will be having a central venous catheter with a monitor to measure central venous pressure placed as part of their planned care independent of this study.
62791467|NCT04295239|EXPERIMENTAL|MRI|Pre-operative AND post-operative MRI
62020820|NCT02377986|EXPERIMENTAL|Experimental: BIT+In-home Decluttering|Patients who have not received the BIT workshop through our previous study (IRB 6681) will receive BIT+in-home decluttering practice.
62020821|NCT03129334|EXPERIMENTAL|LST Middle School Online|Students will participate in a series of e-learning modules plus classroom sessions related to drug abuse prevention, including prescription drug abuse
62020822|NCT03129334|NO_INTERVENTION|Treatment as Usual (Control)|Students will not participate in the e-learning modules. They will receive any standard classroom instruction on drug abuse/health education.
62410007|NCT01392469|EXPERIMENTAL|Imatinib + Bosentan + Sildenafil|Participants received treatment with bosentan 125 milligrams (mg) twice daily and sildenafil thrice daily for 8 days in treatment period 1. Participants were on the same sildenafil dose level (20, 40, 50 or 60 mg) they had been at study entry which was well tolerated in conjunction with bosentan. Following treatment period 1, the participants received concomitant treatment of oral imatinib 200 mg daily, bosentan 125 mg twice daily and sildenafil thrice daily for 14 days in treatment period 2. Following treatment period 2, the participants received concomitant treatment of oral imatinib 400 mg daily, bosentan 125 mg twice daily and sildenafil thrice daily for 14 days in treatment period 3.
62410008|NCT04909177|EXPERIMENTAL|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for specific phobia, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
62410009|NCT04909177|NO_INTERVENTION|Waitlist|Participants in the waitlist condition will be offered the intervention directly after post-test.
62584725|NCT05034198|NO_INTERVENTION|Stakeholder Input|Behavioral health staff (BHS) will be asked to complete two semi-structured qualitative interviews and a set of surveys. The first interview will be about perceived barriers and facilitators on utilizing a remote training platform. The second interview will cover perceived feasibility and acceptability of the proposed training, consultation, and the implementation of evidence-based practices. The surveys will ask about the perceived acceptability, appropriateness, and feasibility of the remote training platform.
62020823|NCT06532266|ACTIVE_COMPARATOR|Intervention|
62020824|NCT06532266|PLACEBO_COMPARATOR|Control|
62020825|NCT04465994||primary repair|Patients with acute achilles tendon ruptures who received the treatment of primary repair.
62020826|NCT04465994||gastrocnemius turn-down flaps|Patients with acute achilles tendon ruptures who received the treatment of gastrocnemius turn-down flaps.
62020827|NCT02001727|ACTIVE_COMPARATOR|Hp-screened group|Screened for Helicobacter Pylori and eradication therapy (1998-99)
62020828|NCT02001727|OTHER|Control group|primarily unscreened group
62584726|NCT05034198|NO_INTERVENTION|Asynchronous Training Development|Mental health trainers with expertise in the treatment of externalizing and internalizing behavior disorders will video-record the training modules and produce them using lecture capture technology (i.e., showing speaker and Power Point slides on a split screen). Each training module will be approximately 45 minutes long.
62584727|NCT05034198|EXPERIMENTAL|Initial Mini-Tiral|BHS will be given a procedures manual with instructions on how to access the video-recorded training modules on-demand. All participants will take part in this mini-trial. Immediately after BHS watch the videos, they will be asked to complete three brief surveys regarding the appropriateness, feasibility and acceptability of each training module and provide comments about each.
62735095|NCT04586452|OTHER|Radiotracer and CCR2 (Aim 2B)|Tissue samples obtained from an existing tissue bank as well as discarded tissue obtained from participants in this study will be examined to better understand the relationship between the levels of CCR2+ inflammatory cells and the inflammatory and clinical status of AAA, to gain insight into the importance of proinflammatory monocytes/macrophages in the development of AAA disease at the time of elective AAA repair.
62020829|NCT06573346|PLACEBO_COMPARATOR|Control group|
62020830|NCT06573346|EXPERIMENTAL|Experimental group|
62020831|NCT03659552|EXPERIMENTAL|Temporary diaphragmatic pacing|There is no comparator for this study. Single site and all patients are in the treatment allocated group of temporary diaphragmatic pacing with the LIVE Catheter which is inserted via the left jugular vein.
62214540|NCT06606210|NO_INTERVENTION|Standard of Care|Compression, debridement, reduction of bacterial burden, and proper moisture balance.
62214541|NCT06606210|EXPERIMENTAL|Standard of Care plus Interventional Device|Weekly applications of the study device in conjunction with standard of care including compression, debridement, reduction of bacterial burden, and proper moisture balance,
62214542|NCT04647435|EXPERIMENTAL|APSCTC|Oral tablets every 6h for 3 days
62214543|NCT04647435|ACTIVE_COMPARATOR|Toragesic®|Oral tablets every 6h for 3 days
62214544|NCT04647435|ACTIVE_COMPARATOR|Tramal®|Oral tablets every 6h for 3 days
62410010|NCT06653374||Infant, Premature|"The Infant, Premature group includes neonates born before 37 weeks of gestation at the Isidro Ayora Obstetric-Gynecologic Hospital. This cohort is particularly vulnerable to a range of complications, including respiratory distress syndrome, intraventricular hemorrhage, and infections, which are major contributors to neonatal morbidity and mortality."
62791468|NCT03574636|ACTIVE_COMPARATOR|OCT guidance|"Firehawk stent implantation will be performed with Optical Coherence Tomography guidance.~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
62214545|NCT02086604|EXPERIMENTAL|Starting Dose (brentuximab vedotin & lenalidomide)|"Brentuximab vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
62791469|NCT03574636|ACTIVE_COMPARATOR|IVUS guidance|"Firehawk stent implantation will be performed with Intravascular Ultrasound guidance.~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
62791470|NCT03574636|ACTIVE_COMPARATOR|QCA guidance|"Firehawk stent implantation will be performed with Intravascular Ultrasound guidance.~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
62791471|NCT00962325|EXPERIMENTAL|Activity behaviors counseling|
62020832|NCT01153594|EXPERIMENTAL|Recovery Management Checkups (RMC)|Participants in the RMC group are interviewed quarterly. When they were found to be in need of treatment, the participant was transferred from the interviewer to a linkage manager to receive the intervention (described next). They were also able to re-enter treatment on their own and naturally cycle through multiple periods of substance use, treatment, incarceration and recovery.
62020833|NCT01153594|NO_INTERVENTION|Control Group|Participants in the control group are interviewed quarterly. While they do not receive any active intervention from the research team, they are able to re-enter treatment on their own and naturally cycle through multiple periods of substance use, treatment, incarceration and recovery.
62791472|NCT00962325|NO_INTERVENTION|Standard care control|6 weeks of standard preoperative care
62791473|NCT01989247|EXPERIMENTAL|Self-management program|Seven weekly sessions of a group-based self-management programme for people with anxiety and depressive symptoms
62791474|NCT01989247|NO_INTERVENTION|Control group|
62020834|NCT02929810|EXPERIMENTAL|sleep extension|
62020835|NCT02929810|ACTIVE_COMPARATOR|sleep maintenance|
62020836|NCT03000894|EXPERIMENTAL|CBT-I plus standard care|The group CBT-I will receive both CBT-I and standard care. CBT-I covers sleep-wake cycle as well as sleep hygiene education, activity scheduling, stimulus control, sleep restriction, relaxation training, and cognitive therapy. Standard care will include those treatments provided by the psychiatrists according to their clinical needs.
62214546|NCT02086604|EXPERIMENTAL|Dose Level 1 (brentuximab vedotin & lenalidomide)|"Brentuximab Vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
62214547|NCT02086604|EXPERIMENTAL|Dose Level 2 (brentuximab vedotin & lenalidomide)|"Brentuximab Vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
62214548|NCT00573079||Observation|Premature infants in the NICU; 500-1500g birthweight, \>=25 weeks gestation
62214549|NCT03691480|EXPERIMENTAL|simple exsufflation|
62214550|NCT03691480|EXPERIMENTAL|Fuhrman catheter and ambulatory care|
62214551|NCT05396872|EXPERIMENTAL|CLOSED TO ENROLLMENT: Stage 1 & 2: Patients, Caregivers, Providers|Patient participants will be instructed to install a mobile app to record their medical appointment, which research staff will use to analyze patient-provider communication. All participants will undergo semi-structured interviews and/or focus groups. Post appointment follow-up with surveys and assessments regarding knowledge of disease information, quality of life, and other measures will be administered after the provider-patient appointment.
62214552|NCT05396872|EXPERIMENTAL|Stage 3: Patients, Caregivers using developed GA platform|About 14 days prior to scheduled germline testing appointment, patients and caregivers call or meet with a coach to select decision aid GA platform preference delivery (online, print, or both online and print), review the GA online platform, and possibly undergo consultation and training for audio recording of the scheduled appointment. Patients and caregivers attend the scheduled germline testing appointment on day 1. Patients complete surveys and patients and caregivers may complete an interview on study. Providers participate in focus groups and complete surveys on study.
62791475|NCT05993910||Hyperthermie Register|Hyperthermia simultaneous with Radiotherapy alone, Hyperthermia simultaneous with Chemotherapy alone, Hyperthermia simultaneous with Radiochemotherapy alone
62214553|NCT00107887|NO_INTERVENTION|1|Subjects in clinics that have not received the intervention
62214554|NCT00107887|EXPERIMENTAL|2|Subjects at clinics that have received the intervention
62214555|NCT06610656|EXPERIMENTAL|White noise and pacifier applications group|In this group, infants will receive pacifier and white noise therapy. The white noise will be used to enhance the quality of sleep and reduce restlessness in infants. During the intervention, participants will receive pacifiers, and white noise will be continuously administered.
62791476|NCT00787865||Krabbe Disease|Children with infantile Krabbe disease
62791477|NCT00787865||Low Enzyme/No Krabbe Disease|Children without disease who have low enzyme levels
62791478|NCT00787865||Control|Children with no disease and normal enzyme levels
62410088|NCT04028570|EXPERIMENTAL|Radiation|This study involves a 3+3 design. The starting cohort (n=3) will receive a neoadjuvant Background dose to the affected hemithorax (starting at 0 cGy) as well as concomitant Boost dose (of at least 2100 cGy) to a part of the gross tumour volume (GTV). The radiation will be delivered over 3 alternate days over 5-7 calendar days followed by macroscopically complete extensive pleural resection (either extra-pleural pneumonectomy or extended pleurectomy decortication, at the surgeon's discretion) after 7 to 14 days. If no dose limiting toxicities (DLTs) seen, then the Background RT dose will be increased by 600 cGy (up to 1800 cGy) and the cohort (n=3) for the next dose level will be accrued. If only 1 DLT seen, then an additional 3 patients will be treated on this dose level. If 2 or more DLTs seen at any given dose level, then the previous dose level will be defined as the maximum tolerated dose (MTD). Patients will be stratified by type of resection.
62215466|NCT06439459|EXPERIMENTAL|Stromal vascular fraction transplantation|"Subcutaneous fat was harvested from either the abdomen or the posterior inner thigh region and then digested with 600 U of collagenase (Shanghai Qiaoyuan Biological Pharmaceutical Co., Ltd, Shanghai, China) at 37°C and 150rpm for three hours. After enzymatic digestion, the lower aqueous phase liquid was aspirated to acquire the stromal vascular fraction (SVF). The SVF cell-pellet was washed and adjusted to 2×10\^6 cells/mL. The skin was marked with methylene blue and a total of 0.5ml (around 1×10\^6 cells) were transplanted intradermally at the center of each 2cm×2cm squares.~The expander was inflated two times a week using constant pressure inflation method, where the intracapsular pressure was monitored using a pressure meter and the inflation was halted when the pressure reached 100 mmHg. This procedure was repeated until adequate skin area was achieved for subsequent facial restoration surgery."
62215467|NCT04831151|ACTIVE_COMPARATOR|Drospirenone group: 0,03 mg ethinylestradiol + 3 mg drospirenone|generic name:yasmin dosage form:oral dosage: 0,03 mg ethinylestradiol + 3 mg drospirenone frequency: once a day duration: 3 months
62215468|NCT04831151|ACTIVE_COMPARATOR|cyproterone acetate group: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate|generic name:diane 35 dosage form:oral dosage: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate frequency: once a day duration: 3 months
62410089|NCT02072707|ACTIVE_COMPARATOR|Epicardial VT ablation|Patients will underwent combined epicardial and endocardial mapping and ablation
62410090|NCT02072707|ACTIVE_COMPARATOR|Endocardial VT Ablation|Patients will underwent endocardial only VT mapping and ablation
62410091|NCT02243709|ACTIVE_COMPARATOR|Mifepristone|mifepristone 600-mg/day for a week, in a stress-induced condition triggered by a single dose of 32.4-mg of yohimbine
62410092|NCT02243709|PLACEBO_COMPARATOR|Sugar pill|matching placebo/day for a week, in a stress-induced condition triggered by a single dose of 32.4-mg of yohimbine
62410093|NCT05053737|EXPERIMENTAL|Phase 1 Lead-in SBRT with Neoadjuvant Atezolizumab|Initially 3 patients will be enrolled to receive one dose of neoadjuvant atezolizumab with 3 fractions of 8 Gy SBRT (dose level 2, i.e. starting dose). If there are \< = 1 DLT related to the neoadjuvant therapy, another 3 patients will be enrolled at the same SBRT dose with only one cycle of neoadjuvant atezolizumab. And if there are \<= 1 DLT out of the 6 patients, then determine MTD at this dose level.
62410094|NCT05053737|EXPERIMENTAL|SBRT with Neoadjuvant Atezolizumab|After the MTD is determined, additional patients will be enrolled at this dose level to ensure 14 patients evaluable for the efficacy endpoints (MPR) at the planned interim analysis. The 6 patients treated at the MTD in phase I will be included if evaluable for MPR, so that additional 8 patients will be enrolled in this stage.
62410095|NCT05782309|EXPERIMENTAL|Flavanol|500 mg of flavanols twice daily
62410096|NCT05782309|PLACEBO_COMPARATOR|Placebo|nutrient matched control capsule
62410097|NCT01544465|EXPERIMENTAL|Structured physical activity|Rehabilitation evaluation followed by physical therapy for approximately 8 weeks
62410098|NCT01544465|ACTIVE_COMPARATOR|Sleep hygiene education|Sleep hygiene education consists of educational materials on insomnia published by the American Academy of Sleep Medicine.
62410099|NCT05639894|EXPERIMENTAL|Group 1: Sentinel and Main Cohorts (Stage 1)|1 injection of RSV vaccine candidate (Dose A) via intramuscular injection
62410100|NCT05639894|EXPERIMENTAL|Group 2: Sentinel and Main Cohorts (Stage 1)|1 injection of RSV vaccine candidate (Dose A) via intramuscular injection
62410101|NCT05639894|EXPERIMENTAL|Group 3: Sentinel and Main Cohorts (Stage 1)|1 injection of RSV vaccine candidate (Dose B) via intramuscular injection
62410102|NCT05639894|EXPERIMENTAL|Group 4: Sentinel and Main Cohorts (Stage 1)|1 injection of RSV vaccine candidate (Dose B) via intramuscular injection
62215469|NCT05473559|ACTIVE_COMPARATOR|Adductor canal block with Ipack block|
62410103|NCT05639894|EXPERIMENTAL|Group 5: Sentinel and Main Cohorts (Stage 1)|1 injection of RSV vaccine candidate (Dose C) via intramuscular injection
62215470|NCT05473559|ACTIVE_COMPARATOR|Adductor canal block with selective tibial nerve block|
62215471|NCT00888628|EXPERIMENTAL|Islet transplant|"Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.~For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.~Induction therapy for subsequent transplants will be 2 doses of basiliximab.~All patients will receive Etanercept to promote engraftment."
62215472|NCT00151580|EXPERIMENTAL|1|Ribavirin maintenance treatment
62410104|NCT05639894|EXPERIMENTAL|Group 6: Sentinel and Main Cohorts (Stage 1)|1 injection of RSV vaccine candidate (Dose C) via intramuscular injection
62410105|NCT05639894|PLACEBO_COMPARATOR|Group 7: Main, Sentinel and Booster Cohorts (Stage 1)|1 injection of placebo via intramuscular injection
62410106|NCT05639894|EXPERIMENTAL|Group 0: Phase IIa/Dose-ranging (Stage 2)|1 injection of RSV vaccine candidate (Dose A) via intramuscular injection
62410107|NCT05639894|EXPERIMENTAL|Group 1: Phase IIa/Dose-ranging (Stage 2)|1 injection of RSV vaccine candidate (Dose B) via intramuscular injection
62410108|NCT05639894|PLACEBO_COMPARATOR|Group 2: Phase 11a/Dose-ranging (Stage 2)|1 injection of placebo via intramuscular injection
62410109|NCT05149989|EXPERIMENTAL|Proning|Proned on standard and proning pillows
62410110|NCT00795210|EXPERIMENTAL|GH 6mcg/kg/d|Recombinant human growth hormone 6mcg/kg SC once daily
62410111|NCT00795210|EXPERIMENTAL|GH 2mg daily|Recombinant human growth hormone 2mg SC once daily
62410112|NCT00795210|EXPERIMENTAL|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks
62410113|NCT05571618||Group1|
62215473|NCT00151580|PLACEBO_COMPARATOR|2|
62215474|NCT05794308|ACTIVE_COMPARATOR|Non-Relational Chatbot Physical Activity Intervention|Participants are randomly assigned to a non-relational chatbot in a mobile app. The chatbot will provide physical activity education sessions. The chatbot will not engage in relational conversation behaviors.
62215475|NCT05794308|EXPERIMENTAL|Relational Chatbot Physical Activity Intervention|Participants are randomly assigned to a relational chatbot in a mobile app. The chatbot will provide physical activity education sessions. The chatbot will engage in relational conversation behaviors.
62215476|NCT04341402|EXPERIMENTAL|Experimental|miconazole 3% \& diclofenac sodium 1% \& urea 40% in topical gel daily for 6 months.
62215477|NCT05043766|EXPERIMENTAL|PF614|Part A will utilize a randomized, open-label, multiple-ascending dose design with up to 3 separate dose groups of 8 subjects. Within each dose group, subjects will be randomized to receive repeated BID doses, planned to be 12 hours apart over a 5 day period, for a total of 9 doses. Dose escalation to Dose Groups 2 and 3 will follow a review of pharmacokinetic, safety and tolerability data up to Day 10 of the preceding group. The doses or dosing regimen for Dose groups 2 and 3 may be modified based on a review of the data.
62410114|NCT01389804||Pediatric Solid Organ Transplant|Parents of pediatric solid organ transplant recipients
62791837|NCT02227667|EXPERIMENTAL|Patients with Advanced Colorectal Cancer|This will be a Simon two-stage design, single arm, phase II study. All subjects will receive MEDI4736 via IV infusion. Subjects will continue treatment for 12 months, or until progression of disease, initiation of alternative cancer therapy, unacceptable toxicity, or other reasons to discontinue treatment occur. Following the 12-month treatment period, subjects without evidence for progressive disease or other reason to discontinue treatment will be monitored without further treatment. Upon evidence of PD (with or without confirmation according to RECIST 1.1) during the monitoring period, administration of MEDI4736 may resume at the Q2W schedule, for up to another 12 months. The same treatment guidelines followed during the initial 12-month treatment period will be followed during the retreatment period, including the same dose and frequency of treatments and the same schedule of assessments.
62599942|NCT05320718|ACTIVE_COMPARATOR|thoracic paravertebral block|A needle is inserted into the paravertebral space. After confirming the needle tip position, 20 ml of 0.5% ropivacaine is injected in the paravertebral space. A catheter is inserted through the needle and then connected to a Programmed Electronic Postoperative Analgesia Pump with a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery.
62791838|NCT01588665||Pregnant women and pregnant adolescents|
62791839|NCT06113055|ACTIVE_COMPARATOR|L-serine|"L-serine white or almost white crystalline powder or colourless crystal formulation which will be dissolved in water and administered orally.~The dose will be weight based: 400mg/kg/day (total daily dose)."
62791840|NCT06113055|PLACEBO_COMPARATOR|Dextrose|"Dextrose monohydrate powder: monohydrate form of crystalline D-glucose (dextrose) consisting of odourless, multi-granular white crystals.~The dose will be weight based: 400mg/kg/day (total daily dose)."
62791841|NCT05035732|EXPERIMENTAL|18F-ACBC|
62039659|NCT05856162|ACTIVE_COMPARATOR|Diet/Physical Activity Intervention|Participants randomized to this arm will receive the partial ENRICH pilot which will consist of content on diet and physical activity. They will also receive usual home visiting services.
62039660|NCT05856162|NO_INTERVENTION|Control|Participants randomized to this arm will receive no ENRICH intervention content. They will only receive usual home visiting services.
62039661|NCT06246396|EXPERIMENTAL|Minocycline Hydrochloride|Minocycline hydrochloride 100 mg, administered twice daily for 3 months
62039662|NCT06246396|PLACEBO_COMPARATOR|Placebo|Placebo administered twice daily for 3 months
62215478|NCT05043766|ACTIVE_COMPARATOR|Part B Compare Bioavailability and Bioequivalence|"Part B will utilize an open-label, single-dose, randomized, 4-way crossover design. Following confirmation of eligibility, subjects will be randomized to receive each of the single oral doses of study drugs (one at each treatment period).~PF614 100 mg administered under fasted conditions; PF614 100 mg administered under fed conditions; OxyContin 40 mg administered under fasted conditions; OxyContin 40 mg administered under fed conditions"
62215479|NCT04101552|EXPERIMENTAL|grafted versus graft less socket shield technique|
62215480|NCT02280369||automated abdominal binder|automated abdominal binder with waist and thigh accelerometers, and ActivPAL
62215481|NCT04512794|OTHER|Non-randomized|All subjects with de novo ablation procedure for an atrial arrhythmia using the AcQMap System.
62215482|NCT05297669|EXPERIMENTAL|group1|Generic name: Felbinac Trometamol Injection; Dosage form: Injection Dosage:94.25mg Volume:4ml Frequency:Multi-dose Duration:1 day. A total of 132 subjects received the test drug .
62215483|NCT05297669|PLACEBO_COMPARATOR|group2|Placebo:Normal saline Dosage form:Injection Dosage:0mg Volume:0ml Frequency:Multi-dose Duration:1 day A total of 132 subjects received the placebo.
62215484|NCT03693885|EXPERIMENTAL|OCT-group|Oxytocin challenge test: Oxytocin 5 IU/500 ml Ringer® lactate will be infused at a rate of 12 ml/h and doubled every 10 min until it induced three uterine contractions per 10-min interval at which point it will stopped.
62215485|NCT03693885|NO_INTERVENTION|Control|standard procedure before planned caesarean section
62215486|NCT00183157|ACTIVE_COMPARATOR|1|Patients will receive an assessment, a brief motivational interview performed by a trained peer counselor, direct referrals to community-based resources for adolescents, and a 10-day follow-up phone call.
62215487|NCT00183157|ACTIVE_COMPARATOR|2|Patients will receive an assessment and a list of community resources
62215488|NCT00183157|ACTIVE_COMPARATOR|3|Patients will receive only the list of resources.
62215489|NCT03097484|EXPERIMENTAL|Standard therapy plus Aromatherapy|These infants will receive aromatherapy, consisting of Lavender and Chamomile essential oils, in addition to standard care, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
62215490|NCT03097484|NO_INTERVENTION|Standard therapy ALONE|These infants receive standard care ONLY, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
62791842|NCT04759105|EXPERIMENTAL|Autologous BM-MSC injection|"Two interventions:~* Bone marrow harvesting from the posterior superior iliac crest region~* Single injections of a dose of 15 million of autologous BM-MSC each disc affected by IDD (up to 4 discs) via imaging control"
62215491|NCT05955131|OTHER|Control Bread|Subjects will eat control bread, in an amount containing 50g of carbohydrates
62584941|NCT04999436|EXPERIMENTAL|Counseling Training Program|The APOL1 counseling training program is designed for transplant nephrologists who evaluate live kidney donor candidates of African ancestry who are at risk for having APOL1 risk variants and kidney failure post-donation. The training program aims to increase transplant nephrologists' practical knowledge, self-efficacy, and skills in counseling live donor candidates about APOL1 in a culturally competent manner. The program will include training in: current APOL1 data; the value of APOL1 testing and meaning of positive test results for living donor clinical evaluation; risks of having two APOL1 gene variants on the donor's kidney health; how to engage in shared decision making about donation; how to address cultural concerns about genetic testing; and how to protect donor candidates' privacy and confidentiality with APOL1 test results. The APOL1 counseling training program will be delivered by a genetic counselor through webinars and other interactive modalities and last 2-4 hours.
62584942|NCT02294396|EXPERIMENTAL|Mirabegron + Solifenacin|Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.
62584943|NCT02294396|EXPERIMENTAL|Mirabegron + Propiverine|Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.
62584944|NCT02294396|EXPERIMENTAL|Mirabegron + Imidafenacin|Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.
62584945|NCT02294396|EXPERIMENTAL|Mirabegron + Tolterodine|Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.
62584946|NCT03625765|EXPERIMENTAL|SmartGoggles|The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. Investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nanomolar (nM) concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with optical density (OD) 6 level cut-off. The SmartGoggles is a non-invasive imaging system that does not require contact with patients.
62584947|NCT01139424|EXPERIMENTAL|open label treatment arm|endoscopic suturing
62584948|NCT00730795|EXPERIMENTAL|Group A|Subjects receiving the low-dose antigen candidate TB vaccine
62584949|NCT00730795|EXPERIMENTAL|Group B|Subjects receiving the high-dose antigen candidate TB vaccine
62584950|NCT05754762|EXPERIMENTAL|Age range of 18 to 40 years olds|Based on previous literature and preliminary test results, the initial dose of pre-injection remifentanil is set at 1ug / kg. The dose of remifentanil is based on the patient's degree of myoclonus. If there is no myoclonus (negative response), the dose of remifentanil is reduced for the next patient until the patient develops myoclonus. If there is myoclonus (positive response), the dose of remifentanil will be increased in the next patient until the patient is free of myoclonus.
62584951|NCT05754762|EXPERIMENTAL|Age range of 41 to 55 years olds|Based on previous literature and preliminary test results, the initial dose of pre-injection remifentanil is set at 1ug / kg. The dose of remifentanil is based on the patient's degree of myoclonus. If there is no myoclonus (negative response), the dose of remifentanil is reduced for the next patient until the patient develops myoclonus. If there is myoclonus (positive response), the dose of remifentanil will be increased in the next patient until the patient is free of myoclonus.
62599943|NCT05821296|OTHER|Crystal Peel|2.5 ml of Crystal peel applied up to 3 coats and performed 3 times in the study (i.e: at Day 15, Day 36 and Day 57.
62791843|NCT04759105|SHAM_COMPARATOR|Sham Procedure|"Two sham procedures:~* Simulated bone marrow harvesting without insertion into the posterior iliac crest region~* Simulated injection under only local anaesthesia without disc injection, without placebo injection."
62215492|NCT05955131|EXPERIMENTAL|Bread Supplemented with Chilean Beans|Subjects will eat bread supplemented with Chilean native beans at 30% w/w, in an amount containing 50g of carbohydrates
62215493|NCT05955131|OTHER|Glucose control|Subjects will drink glucose, in an amount containing 50g of carbohydrates
62410115|NCT05062161|EXPERIMENTAL|Sleep Hygiene/Extension Intervention|Participants with short sleep duration will receive a 60-minute educational session on sleep hygiene/extension. Over an 8-week period, participants will receive weekly phone or Zoom video calls from the Educational Research Coordinator to review additional materials including handouts and/or complete questionnaires about sleep. Participants will undergo sleep tracking/monitoring during the 8-week period, and repeat BP/heart rate monitoring for 24 hours after the 8-week period.
62039663|NCT06491147||1st year residency|
62039664|NCT06491147||2nd year residency|
62215494|NCT04599504|EXPERIMENTAL|Lisdexamfetamine dimesylate|
62215495|NCT04599504|PLACEBO_COMPARATOR|Placebo|
62215496|NCT06357403||Intensive care unit patients|Patients who are admitted to an participating intensive care unit who do not receive therapeutic anticoagulation.
62215497|NCT01477164|EXPERIMENTAL|Aerobic Exercise Training|Participants will perform 12-weeks of high intensity aerobic training.
62215498|NCT01477164|ACTIVE_COMPARATOR|Combined|The combined group will have 12-weeks of no exercise followed by 12-weeks of combined aerobic and resistance exercise training. Assessments will be made at three time points: baseline, after 12-weeks of no training, and after 12-weeks of combined training.
62215499|NCT01477164|EXPERIMENTAL|Resistance Exercise Training|Participants will perform 12-weeks of resistance exercise training.
62791844|NCT05391633|PLACEBO_COMPARATOR|Placebo|Starting at 33 0/7 weeks corrected gestational age (regardless of birth gestation), infants randomized to the non-intervention arm will be played a blank recording of approximately 60 minutes duration, once every 24 hours for a 2-week (14 day) period.
62791845|NCT05391633|EXPERIMENTAL|Recorded Voice Exposure|Starting at 33 0/7 weeks corrected gestational age (regardless of birth gestation), infants randomized to the intervention arm will be played a recording of their mother's voice with approximately 60 minutes of scripted content, once per 24 hours for a 2-week (14 day) intervention period. (Mothers will be recorded reading a children's book and the recording will be looped to create the 60 minutes of content).
62791846|NCT06226038|EXPERIMENTAL|With magnet|
62410116|NCT05062161|ACTIVE_COMPARATOR|Control Condition|Participants with short sleep duration will receive a 60-minute educational session on sleep physiology. Over an 8-week period, participants will receive weekly phone or Zoom video calls from the Educational Research Coordinator to review additional materials including handouts. Participants will undergo sleep tracking/monitoring during the 8-week period, and repeat BP/heart rate monitoring for 24 hours after the 8-week period.
62791847|NCT06226038|SHAM_COMPARATOR|Without magnet|
62791848|NCT02625844||Monopegylated Epoetin Beta|Health care personnel performing anemia management tasks for patients using monopegylated epoetin beta.
62791849|NCT02625844||Other Erythropoiesis Stimulating Agents (ESAs)|Health care personnel performing anemia management tasks for patients using other ESAs.
62410117|NCT05312801|EXPERIMENTAL|LMY-920 dose escalation|Open label, dose escalation study with up to four dose levels of LMY-920. The maximum tolerated dose (MTD) of LMY-920 will be determined using dose-escalation 3+3 design.
62791850|NCT01332383||Patients prescribed AMERGE|Patients with migraine disorders prescribed AMERGE during study period
62791851|NCT01318408|EXPERIMENTAL|Levetiracetam|Levetiracetam was titrated over 4 weeks, with initial dosing of 250 mg bis in die (BID). Dosing was flexible and was based on the prescribing physician's discretion.
62791852|NCT01302353|EXPERIMENTAL|Arm 1 (0.0024 ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0024ml/kg.
62791853|NCT01302353|EXPERIMENTAL|Arm 2 (0.006ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.006ml/kg.
62791854|NCT01302353|EXPERIMENTAL|Arm 3 (0.012ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.012ml/kg.
62791855|NCT01302353|EXPERIMENTAL|Arm 4 (0.02ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.02ml/kg.
62791856|NCT01302353|EXPERIMENTAL|Arm 5 (0.0301ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0301ml/kg.
62791857|NCT01302353|EXPERIMENTAL|Arm 6 (0.0391ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0391ml/kg.
62410118|NCT04404192|EXPERIMENTAL|PH94B|Intranasal spray 3.2 micrograms four times a day for 28 days
62410119|NCT04404192|EXPERIMENTAL|Placebo|Intranasal spray four times a day for 28 days
62791858|NCT01302353|EXPERIMENTAL|Arm 7 (0.0508ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0508ml/kg.
62791859|NCT01302353|EXPERIMENTAL|Arm 8 (0.066ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.066ml/kg.
62791860|NCT01302353|EXPERIMENTAL|Arm 9 (0.0859ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0859ml/kg.
62791861|NCT01302353|EXPERIMENTAL|Arm 10 (0.1116ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1116ml/kg.
62791862|NCT01302353|EXPERIMENTAL|Arm 11 (0.1451ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1451ml/kg.
62791863|NCT01302353|EXPERIMENTAL|Arm 12 (0.1886ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1886ml/kg.
62791864|NCT01302353|EXPERIMENTAL|Arm 13 (0.2452ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.2452ml/kg.
62215500|NCT03488420||Atrial Fibrillation and/or Atrial Flutter|Subjects taking edoxaban 30mg or 60 mg will be followed for 2 years. Subjects will perform the Montreal Cognitive Assessment (MoCA) Test at baseline and 1-year follow up. They will also answer the Anti-Clot Treatment questionnaire (ACTS-Q) at 1-year.
62599944|NCT03061201|EXPERIMENTAL|Sequential dose escalation|SB-525 (PF-07055480) is administered as a single infusion
62039665|NCT06491147||3rd year residency|
62039666|NCT06491147||4th year residency|
62039667|NCT06491147||5th year residency|
62215501|NCT00531453|EXPERIMENTAL|1|bortezomib, dexamethasone, and thalidomide
62215502|NCT00531453|EXPERIMENTAL|2|bortezomib, dexamethasone, thalidomide, and cyclophosphamide
62215503|NCT06212882||Lower concentration and lower volume contrast agent group|
62215504|NCT06212882||Lower concentration and normal volume contrast agent group|
62215505|NCT06212882||Normal concentration and normal volume contrast agent group|
62410120|NCT02980939|PLACEBO_COMPARATOR|Euhydration - no thirst|
62410121|NCT02980939|EXPERIMENTAL|Dehydration - no Thirst|
62791865|NCT01302353|EXPERIMENTAL|Arm 14 (0.3188ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.3188ml/kg.
62791866|NCT01302353|EXPERIMENTAL|Arm 15 (0.4144ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.4144ml/kg.
62791867|NCT01302353|EXPERIMENTAL|Arm 16 (0.5387ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.5387ml/kg.
62215506|NCT01580254|ACTIVE_COMPARATOR|IOPIZE© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is IOPIZE©
62791868|NCT05908903|EXPERIMENTAL|Experimental Group|Take drinks with active ingredients such as poria and GABA. Drink half an hour before bedtime, 10ml/bag/day, daily.
62791869|NCT05908903|PLACEBO_COMPARATOR|Control product group|Take a control drink that does not contain GABA and poria. Drink half an hour before bedtime, 10ml/bag/day, daily.
62791870|NCT00955539|ACTIVE_COMPARATOR|CRT group 1|
62791871|NCT00955539|ACTIVE_COMPARATOR|CRT group 2|
62791872|NCT00939536|EXPERIMENTAL|Torrent's Zolpidem Tartrate Tablets 10 mg|Normal Healthy Human Subjects receiving Torrent's Zolpidem Tartrate Tablets 10 mg
62791873|NCT00939536|ACTIVE_COMPARATOR|Sanofi-Synthelabo's Ambien® 10 mg Tablets|Normal Healthy Human Subjects receiving Sanofi-Synthelabo's Ambien® 10 mg Tablets
62410122|NCT05732012|EXPERIMENTAL|Group-1|Interventions applied on Group-1 participants.
62791874|NCT01550809|ACTIVE_COMPARATOR|tBolus (traditional bolus)|Traditional mealtime insulin bolus based on the individual insulin-to-CHO ratio
62791875|NCT01550809|EXPERIMENTAL|iBolus (CGM-based insulin administration)|This is a CGM-based algorithm for prandial insulin administration. An individual patient's model characterizing a 5-hour postprandial period (0-5h PP) is obtained from a 6-day CGM period. A model with interval parameters accounting for patient's variability is calculated considering 20% uncertainty in insulin sensitivity and 10% in carbohydrates (CHO) estimation. Based on this model, constraints on plasma glucose are posed and a set-inversion problem lead to a set of solutions (the iBolus) that contains a bolus insulin dose, a specific mealtime basal insulin dose and the time for restoration of basal to baseline values.
62791876|NCT05233592||T1D Patients Using CGM|Type 1 Diabetes patients using CGM who have received COVID-19 vaccine booster shot (first or second)
62791877|NCT04847934|EXPERIMENTAL|Virtual Reality Group|watching the application by wearing virtual glasses to the child during the intramuscular injection
62791878|NCT04847934|EXPERIMENTAL|Manual Pressure Vibration Technique Group|Application of manual pressure vibration technique to the area where the intervention will be made
62791879|NCT04847934|EXPERIMENTAL|Cold Vibration Group|Buzzy, connecting and operating 5 cm above the area to be injected
62791880|NCT04847934|NO_INTERVENTION|Control Group|Standart care
62791881|NCT05681494|ACTIVE_COMPARATOR|Root canal treatment|after access cavity preparation, the working length will be determined. chemo-mechanical preparation will be done, and teeth will be obturated. final restoration will be placed.
62791882|NCT05681494|EXPERIMENTAL|Vital pulp therapy|exposed pulp will be capped with 3 mm calcium silicate material
62039668|NCT02794285|EXPERIMENTAL|Anifrolumab|Anifrolumab
62215507|NCT01580254|ACTIVE_COMPARATOR|GALAXIA© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is GALAXIA©
62410123|NCT05732012|NO_INTERVENTION|Group-2|No interventions applied on Group-2 participants.
62410124|NCT06652282|EXPERIMENTAL|Pilates exercise|This group includes 20 patients who had mastectomy and will recieve Pilates exercise in addition to conventional physical therapy program (stretching exercises and strengthening exercises), and routine medical treatment. Patients will receive 3 sessions per week for 12 weeks, time of session is 45 - 60 min according to patient ability
62215508|NCT01580254|ACTIVE_COMPARATOR|Latanoprost RATIOPHARM© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is Latanoprost RATIOPHARM©
62215509|NCT03869190|ACTIVE_COMPARATOR|Atezolizumab for mUC Cohort (Stage 1)|"Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.~Enrollment is closed."
62410125|NCT06652282|ACTIVE_COMPARATOR|proprioceptive neuromuscular facilitation (PNF)|This group includes 20 patients who had mastectomy and will receive PNF exercise in addition to conventional physical therapy program (stretching exercises and strengthening exercises) and routine medical treatment. Patients will receive 3 sessions per week for 12 weeks, time of session is 45 - 60 min according to patient ability
62410126|NCT06652282|ACTIVE_COMPARATOR|Conventional exercise|This group includes 20 patients who had mastectomy and will receive conventional physical therapy program (stretching exercises and strengthening exercises) and routine medical treatment. Patients will receive 3 sessions per week for 12 weeks, time of session is 45 - 60 min according to patient ability
62410127|NCT02908191|EXPERIMENTAL|ABI-H0731 or Matching Placebo|ABI-H0731 in varying doses of tablets by mouth for 1 day, 7 days, or 28 days
62410128|NCT02908191|EXPERIMENTAL|ABI-H0731 or Placebo and ETV or TDF|ABI-H0731 and entecavir or tenofovir in combination in a yet to be determined dose by mouth for 28 days
62410129|NCT02908191|EXPERIMENTAL|ABI-H0731 or Placebo and a Nucleos(t)ide and Pegasys|ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days
62410130|NCT04688489|ACTIVE_COMPARATOR|Intervention|The intervention consists of a supplement of maltodextrin at training episodes combined with added dietary carbohydrates at all meals
62410131|NCT04688489|NO_INTERVENTION|Control|The control receives no intervention. Standard treatment will be administered.
62410132|NCT05656430|EXPERIMENTAL|Treatment group|Eight weeks of individually tailored ICBT, were participants receives in total 8 modules out of 20 possible depending on their current problems and described situation with weekly support by a therapist.
62599945|NCT06623838||Spanish group|Group/Cohort Description: 22 students in MA in clinical psychology performing the evolutionarily informed case conceptualization.
62791883|NCT05726006||Non-pregnant adult patients with group B streptococcal infection|all non-pregnant adult patients from the selected hospitals whom group B streptococcus will be isolated from their clinical samples from sterile sites.
62791884|NCT05697562|PLACEBO_COMPARATOR|anticoagulation group with DG HAL|
62791885|NCT05697562|ACTIVE_COMPARATOR|anticoagulation group with SRAE|
62791886|NCT05697562|PLACEBO_COMPARATOR|no anticoagulation group with RBL|
62791887|NCT05697562|ACTIVE_COMPARATOR|no anticoagulation group with SRAE|
62039669|NCT02794285|PLACEBO_COMPARATOR|Placebo|Placebo
62039670|NCT03686046||Exploratory use|Brief (2 hour) exploratory use of prototype self-adjusted wearable Master Hearing Aid
62039671|NCT06265428|EXPERIMENTAL|DB-1303/BNT323|Enrolled patients will receive DB-1303/BNT323 by intravenous (I.V.) infusion
62215510|NCT03869190|EXPERIMENTAL|Atezolizumab + Enfortumab Vedotin for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Enfortumab Vedotin (EV) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
62242977|NCT01809535|ACTIVE_COMPARATOR|The Biweekly EVL|Patients in the Biweekly group received repeating EVL every 2 weeks.
62242978|NCT01794533|PLACEBO_COMPARATOR|Lidocaine with Epinephrine+ Normal saline|
62242979|NCT01794533|ACTIVE_COMPARATOR|Lidocaine with Epinephrine + fentanyl|
62791888|NCT06050694|NO_INTERVENTION|Pola-R-CHP|"Protocol induction: Cycle 1-2~Low-risk group: Cycle 3-4 polatuzumab vedotin 1.8 mg/kg, cyclophosphamide 750 mg/m2 and doxorubicin 50 mg/m2 on day 1, prednisone 100 mg daily days 1-5, and rituximab 375 mg/m2 within 72 hours of polatuzumab vedotin~Cycle 5-6 rituximab 375 mg/m2 on day 1 of cycle 5 and cycle 6"
62791889|NCT06050694|EXPERIMENTAL|Pola-R-CHP and glofitamab|High-risk group: Cycle 3-6 polatuzumab vedotin 1.8 mg/kg, cyclophosphamide 750 mg/m2 and doxorubicin 50 mg/m2 on day 1, prednisone 100 mg daily days 1-5, rituximab 375 mg/m2 within 72 hours of polatuzumab vedotin and Glofitamab 2.5 mg Cycle 3 Day 8 and 10 mg on Day 15 Cycles 3-6
62791890|NCT05195658||Acute ischemic stroke with culprit lesion at the carotid bifurcation|Consecutive patients with acute ischemic stroke culprit lesion at the carotid bifurcation, accepted for emergent interventional management by the NeuroVascular Team Committee according to stroke management guidelines
62791891|NCT05708456|EXPERIMENTAL|Intervention Group|Application of data collection forms for the initial evaluation. Teaching the use of the mobile application, monitoring the use of the mobile application in the experimental group by the researcher for 12 weeks, and applying the data collection forms to the patients in the 6th and 12th weeks.
62791892|NCT05708456|NO_INTERVENTION|Control Group|Application of data collection forms for the initial evaluation. Application of data collection forms to the patients in the 6th and 12th weeks. No intervention will be made to the patients in the control group other than the routine service provided in the outpatient clinic.
62791893|NCT01499615||children undergoing general anesthesia|The intervention was the application of 4 ekg electrodes so as to non-invasivly measure cardiac output
62791894|NCT06070935||pediatric uveitis|pediatric uveitis patients \< 18 years old
62791895|NCT06070935||healthy subjects|healthy subjects\< 18 years old
62791896|NCT02511886|EXPERIMENTAL|Arbaclofen Placarbil (AP)|Orally administered Arbaclofen Placarbil (AP) sustained release (SR) tablets
62791897|NCT02511886|PLACEBO_COMPARATOR|Placebo|Subjects remain on placebo for entire study
62791898|NCT03778450||Analgesics, Opioid|Patients are only included if they have been diagnosed in at least three quarters in the study period with one of the following diagnoses: R51, R52\*, M00\*-M99\*, G43\*-G44\*, G50.0 or G50.1, F45.4\*, G62\*, or E10.4\*-E14.4 plus G63.3. At least one diagnoses must be between 1 January 2012 and index treatment and main and secondary hospital diagnoses (i.e. Haupt- und Nebendiagnosen) will be used to include the patients.
62791899|NCT03778450||Non-Opioid Analgesic|Patients are only included if they have been diagnosed in at least three quarters in 2012 with one of the following diagnoses: R51, R52\*, M00\*-M99\*, G43\*-G44\*, G50.0 or G50.1, F45.4\*, G62\*, or E10.4\*-E14.4 plus G63.3.At least one diagnoses must be between 1 January 2012 and index treatment and main and secondary hospital diagnoses (i.e. Haupt- und Nebendiagnosen) will be used to include the patients.
62791900|NCT00701272||1|Patients undergoing liver transplant for end-stage liver disease due to Hepatitis C
62791901|NCT00701272||2|"Control population:~Patients undergoing liver transplantation for end-stage liver disease due to alcoholic cirrhosis"
62791902|NCT01478334|EXPERIMENTAL|Exercise then control|
62791903|NCT01478334|EXPERIMENTAL|Control then exercise|
62791904|NCT01928641||Discrepancy in stroke onset|Patients with discrepancy in stroke symptom onset based on the diagnosis of the first neurologist who evaluated the patient at emergency room and the next day after admission
62791905|NCT05300776|EXPERIMENTAL|M-ROSE combined with mNGS group|The bronchoalveolar lavage fluid (BALF) of patients undergoes M-ROSE analysis and decide whether the samples are qualified, whether they indicate bacterial infection and identify pathogens, and the qualified samples are sent for mNGS analysis. The individualized anti-infection treatment is comprehensively guided according to the results of M-ROSE, mNGS and clinical examinations.
62215511|NCT03869190|EXPERIMENTAL|Atezolizumab + Niraparib for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Niraparib (Nira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
62791906|NCT05300776|NO_INTERVENTION|mNGS group|BALF samples were directly sent for mNGS analysis, and anti-infective treatment was guided according to clinical examinations.
62791907|NCT01921504|EXPERIMENTAL|Acupuncture|Participants in this group are given twice-a-week acupuncture treatment for 4 weeks.
62039672|NCT06265428|EXPERIMENTAL|T-DM1|Enrolled patients will receive T-DM1 by I.V. infusion
62410133|NCT05656430|NO_INTERVENTION|Control group|The control group is a wait-list control condition. Participants are instructed to wait. After the treatment group has finished their treatment and post-treatment measures has been collected, the control group receive the same treatment as the treatment group got.
62599946|NCT06623838||Polish group|Group/Cohort Description: 22 students in MA in clinical psychology performing the evolutionarily informed case conceptualization.
62039673|NCT03520322|EXPERIMENTAL|Mastoid Oscillator|patients with Menieres Disease
62410134|NCT04619134|EXPERIMENTAL|NCSR Program|Non Pain Contingent Spinal Rehabilitation
62791908|NCT01921504|NO_INTERVENTION|No treatment|The participants in this group are supposed to wait without any intervention for first 4 weeks. Then they receive the identical acupuncture treatments as in the treatment group for the following 4 weeks.
62039674|NCT03520322|PLACEBO_COMPARATOR|Control device|patients with Menieres Disease
62039675|NCT04092374|EXPERIMENTAL|Case arm|
62215512|NCT03869190|EXPERIMENTAL|Atezolizumab + Magrolimab for mUC Cohort (Stage 1)|Participants will receive atezolizumab and magrolimab (Hu5F9-G4) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
62791909|NCT04740775|EXPERIMENTAL|LiquiBand Exceed|Surgical wound closure using the LiquiBand Exceed Topical Skin Adhesive
62791910|NCT04740775|EXPERIMENTAL|Liquiband Rapid|Surgical wound closure using the LiquiBand Rapid Topical Skin Adhesive
62791911|NCT03218436|ACTIVE_COMPARATOR|CAP cohort|Cold Atmospheric plasma intervention
62791912|NCT03218436|NO_INTERVENTION|Control cohort|no intervention
62791913|NCT02597725||Urodynamics|There is no intervention in this study.
62791914|NCT02901418||control group|In this group,these children born in about two hours, we injected HBIG 200 iu and 10 micrograms of hepatitis b vaccine in their left and right thigh respectively, then injected 10 micrograms again in 1 and 6 months.
62215513|NCT03869190|EXPERIMENTAL|Atezolizumab + Tiragolumab for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Tiragolumab (Tira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
62584952|NCT05754762|EXPERIMENTAL|Age range of 56 to 70 years olds|Based on previous literature and preliminary test results, the initial dose of pre-injection remifentanil is set at 1ug / kg. The dose of remifentanil is based on the patient's degree of myoclonus. If there is no myoclonus (negative response), the dose of remifentanil is reduced for the next patient until the patient develops myoclonus. If there is myoclonus (positive response), the dose of remifentanil will be increased in the next patient until the patient is free of myoclonus.
62215514|NCT03869190|EXPERIMENTAL|Atezolizumab + Sacituzumab Govitecan for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Sacituzumab Govitecan (SG) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
62584953|NCT04954001|EXPERIMENTAL|Single Arm|
62021068|NCT01607905|EXPERIMENTAL|Arm A (Colorectal Cancer)|Participants with colorectal cancer and liver metastasis received oral selinexor as single agent in 8 schedules, Schedule1: ≤12milligrams per meter square(mg/m\^2) 3 times weekly(TIW) during Weeks 1 and 3, twice weekly(BIW) during Weeks 2 and 4 up to 10 doses/cycle(28 days/cycle); Schedule2: \>12mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle(28 days/cycle); Schedule3: ≥30mg/m\^2 BIW(Days 1 and 3) up to 8 doses/cycle(28 days/cycle); Schedule4: ≥20mg/m\^2 BIW(Days 1 and 2) up to 8 doses/cycle(28 days/cycle); Schedule5: ≥35mg/m\^2 BIW(Days 1 and 4) up to 8 doses(28 days/cycle); Schedule6: ≥20mg/m\^2 BIW(Days 1 and 4) after 500 mg(Week 1) to 1000 mg(Week 2 onwards) acetaminophen(given 1 hour prior to each selinexor dose) up to 8 doses/cycle (28 days/cycle); Schedule7: ≥50mg/m\^2 once weekly(QW) up to 4 doses/cycle(28 days per cycle); Schedule8: ≥45mg/m\^2 BIW(Days 1 and 3) up to 4 doses/cycle(21 days/cycle), until disease progression, death, or unacceptable toxicity.
62021069|NCT01607905|EXPERIMENTAL|Arm B (Gynecological Cancer)|Participants with gynecological cancer received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
62021070|NCT01607905|EXPERIMENTAL|Arm C (Squamous Cell Cancer)|Participants with squamous cell cancer received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
62584954|NCT06249737|EXPERIMENTAL|Control Group|This group will train the DoF target (shoulder flexo-extension) and DoF dorsi-ankle flexion of the contralateral lower extremity.
62215515|NCT03869190|EXPERIMENTAL|Atezolizumab + Tocilizumab for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Tocilizumab (TCZ) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
62215516|NCT03869190|EXPERIMENTAL|Atezolizumab + RO7122290 for mUC Cohort (Stage 1)|Participants will receive atezolizumab and RO7122290 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
62215517|NCT03869190|EXPERIMENTAL|Atezolizumab + Enfortumab Vedotin for mUC Cohort (Stage 2)|Participants will receive atezolizumab and Enfortumab Vedotin (EV) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
62215518|NCT03869190|EXPERIMENTAL|Atezolizumab + Sacituzumab Govitecan for mUC Cohort (Stage 2)|Participants will receive atezolizumab and Sacituzumab Govitecan (SG) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
62215519|NCT03869190|ACTIVE_COMPARATOR|Atezolizumab for Cisplatin-ineligible MIBC Cohort 1 PD-L1+ Arm 1|Participants will receive Atezolizumab for 3 cycles pre-surgery and 14 cycles post-surgery.
62584955|NCT06249737|EXPERIMENTAL|Proximal Interference Group|This group will train the DoF target and shoulder abduction-adduction DoF.
62584956|NCT06249737|EXPERIMENTAL|Distal Interference Group|This group will train the DoF Tf and the wrist flexion-extension DoF.
62584957|NCT04834505||Derivation sample|The patients conclusively diagnosed as FAIP or PC are retrospectively collected.
62584958|NCT04834505||Validation sample|The patients with difficulty in distinguishing between FAIP and PC are prospectively enrolled.
62584959|NCT02166736|EXPERIMENTAL|Instantaneous wave-free ratio (iFR)|
62584960|NCT02166736|ACTIVE_COMPARATOR|Fractional Flow Reserve (FFR)|
62584961|NCT01971775|ACTIVE_COMPARATOR|Ultrasonically Activated Shear|Dissection and lymphovascular sealing with Ultrasonically Activated Shears
62584962|NCT01971775|ACTIVE_COMPARATOR|Conventional Monopolar Electrocautery|Dissection and lymphovascular sealing with Conventional Monopolar Electrocautery
62584963|NCT06667765|EXPERIMENTAL|RPT1G Single ascending dose (SAD) cohort|All participants will receive single oral dose of RPT1G or placebo in fasted state
62584964|NCT06667765|EXPERIMENTAL|RPT1G Multiple ascending dose (MAD) cohort|All participants will receive twice daily oral doses of RPT1G or placebo in a fasted state for 5 days
62584965|NCT03906032|EXPERIMENTAL|Intra-medullary hip Nail|Surgery
62410135|NCT04619134|ACTIVE_COMPARATOR|Conventional Physical therapy|Conventional Physical Therapy
62584966|NCT03906032|ACTIVE_COMPARATOR|Sliding hip screw|Surgery
62584967|NCT00199238|PLACEBO_COMPARATOR|Placebo|Once daily/ 28 days
62584968|NCT00199238|EXPERIMENTAL|rupatadine 5mg|Once daily/ 28 days
62584969|NCT00199238|EXPERIMENTAL|rupatadine 10 mg|Once daily/ 28 days
62584970|NCT00199238|EXPERIMENTAL|rupatadine 20 mg|Once daily/ 28 days
62584971|NCT05477901|EXPERIMENTAL|Intervention|High supplemental transfer: $40 a month
62584972|NCT05477901|NO_INTERVENTION|Control|Low supplemental transfer: $2 a month
62584973|NCT06685081|ACTIVE_COMPARATOR|Group I|
62584974|NCT06685081|ACTIVE_COMPARATOR|Group II|
62584975|NCT06685081|ACTIVE_COMPARATOR|Group III|
62584976|NCT06685081|ACTIVE_COMPARATOR|Group IV|
62410136|NCT03793309|EXPERIMENTAL|Low dose|Subjects in this group receive 400 IU vitamin D daily for 4 weeks.
62410137|NCT03793309|EXPERIMENTAL|High dose|Subjects in this group receive 800 IU vitamin D daily for 4 weeks.
62410138|NCT04273763|EXPERIMENTAL|Group A|Treatment group
62410139|NCT04273763|ACTIVE_COMPARATOR|Group B|Control group
62410140|NCT01950052|NO_INTERVENTION|Control group|No special diet, patients will continue with a normal diet
62410141|NCT01950052|EXPERIMENTAL|Diet group|Pre-operative liver shrinking diet of 800 Kcal diet is administered for 4 weeks
62410142|NCT05477368|EXPERIMENTAL|Exogenous Ketone Supplement|Participants will be instructed to consume a total of 711 mL of the exogenous ketone supplement drink (for a total of 30 g of beta-hydroxybutyrate) per day (3 doses at 237 mL containing 10 g of beta-hydroxybutyrate each) for a period of 90 days.
62410143|NCT05477368|PLACEBO_COMPARATOR|Inert placebo|Participants will be instructed to consume an equivalent volume (711 mL) of taste- and volume-matched placebo per day (3 doses at 237 mL) for 90 days.
62410144|NCT02033928||Arm I: Transplant patients|
62410145|NCT02033928||Arm II: Plasma cell dyscrasia patients|
62410146|NCT03888651||Observational (questionnaires, quality of life assessment)|Patients complete questionnaires and quality of life assessments over 10-15 minutes at pre-surgery, after-surgery, at discharge, within 2-3 weeks after surgery, and within 90 days after surgery.
62410147|NCT02861534|EXPERIMENTAL|Vericiguat|Participants receive a starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of HF standard of care. The vericiguat dose will be uptitrated to 5 mg and to 10 mg.
62410148|NCT02861534|PLACEBO_COMPARATOR|Placebo|Participants receive a starting matching placebo dose of 2.5 mg taken orally once daily with food, on a background of HF standard of care. The matching placebo dose will be uptitrated to 5 mg and to 10 mg.
62410149|NCT00940446|EXPERIMENTAL|Insorb staples|Subcuticular Absorbable staples
62584977|NCT06685081|ACTIVE_COMPARATOR|Group V|
62584978|NCT06333808|EXPERIMENTAL|Treatment Group 1: Bictegravir (BIC)/ Lenacapavir (LEN) (75/50 mg) + PTM B/F/TAF|"Blinded Phase: Participants will switch from bictegravir/emtricitabine/tenofovir (B/F/TAF) FDC tablets to BIC/LEN (75/50 mg) FDC tablets and placebo-to-match (PTM) B/F/TAF. Participants will receive a 2-day oral loading dose of LEN 600 mg on Day 1 and on Day 2, in addition to the daily doses of BIC/LEN FDC tablet starting on Day 1 up to end of blinded treatment (EBT) visit.~Open-label (OL) Phase: Following treatment in the Blinded Phase, participants from Treatment Group 1 will receive BIC/LEN FDC tablets through Week 48 in the Open-label Phase. At the OL Week 48 visit, participants from Treatment Group 1 will be given the option to continue to receive BIC/LEN FDC tablets until the conclusion of the OL Phase."
62584979|NCT06333808|EXPERIMENTAL|Treatment Group 2: B/F/TAF (50/200/25 mg) + PTM BIC/LEN|"Blinded Phase: Participants will continue with their B/F/TAF (50/200/25 mg) FDC tablets and start PTM BIC/LEN tablets on Day 1. Participants will receive PTM LEN tablets for 2 days (2 PTM LEN tablets on Day 1 and on Day 2. The blinded phase will continue until the EBT visit.~Open Label Phase: Participants in Treatment Group 2 who complete the EBT visit will be given the option to enter the OL phase to receive BIC/LEN FDC tablets until the conclusion of the OL Phase."
62584980|NCT06010693|EXPERIMENTAL|Daridorexant|Participants will receive one daridorexant 50 mg tablet,orally, once daily for about 28 consecutive night on each night approximately 30 minutes before participants intends to try to sleep.
62584981|NCT06010693|PLACEBO_COMPARATOR|Placebo|Participants will receive one placebo matched to daridorexant 50 mg tablet,orally, once daily for about 28 consecutive night on each night approximately 30 minutes before participants intends to try to sleep.
62584982|NCT03048318|EXPERIMENTAL|Arterial and Portal Flushing of Graft|Back table flush of portal vein and graft artery
62410150|NCT00940446|ACTIVE_COMPARATOR|Control|Metal staple wound closure
62410151|NCT05375487|EXPERIMENTAL|Carbonated Natural Mineral Water|750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium and magnesium.
62410152|NCT05375487|PLACEBO_COMPARATOR|Low Mineral Water|750 mL/day of low mineral water.
62410153|NCT01856296|EXPERIMENTAL|Arm A|ARM A patients with an identified oncogenic driver mutations/amplifications/translocations), who will potentially benefit from targeted therapies, either on the market or in clinical trials according to existing knowledge of matching oncogenic events with actionable drugs. This will be detected through Next Generation Sequencing (NGS) performed by Foundation Medicine, CLIA certified.
62584983|NCT03048318|ACTIVE_COMPARATOR|Portal Flushing only of Graft|Back table flush of portal vein only
62584984|NCT03913416|EXPERIMENTAL|3D|Surgery with surgeon trained using a 3D printed model of the pulmonary malformation.
62584985|NCT03913416|OTHER|Control group|Conventional surgery without training using a 3D printed model of the pulmonary malformation.
62584986|NCT05498155|EXPERIMENTAL|Cohort A|Cohort A will consist of a lower-risk population of participants with HER2-negative ER-negative or ER-low defined as having a tumour size \>5 mm and ≤20 mm and N0 (T1b-c/N0).
62791915|NCT02901418||experimental group|In this group,about 2 hours after birth, respectively injecting HBIG 200 IU and 10 micrograms of hepatitis b vaccine in the right and left thigh, and in 1 and 6 months again taking 10 micrograms of standard solution, in addition, offering the additional injection of 200 IU HBIG within 24 hours.
62021071|NCT01607905|EXPERIMENTAL|Arm D (Castrate-resistant Prostate Cancer)|Participants with castrate-resistant prostate cancer (CRPC) received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
62215520|NCT03869190|EXPERIMENTAL|Atezolizumab + Tiragolumab for Cisplatin-ineligible MIBC Cohort 1 PD-L1+ Arm 2|Participants will receive Atezolizumab and Tiragolumab (Tira) for 3 cycles pre-surgery and 14 cycles post-surgery.
62584987|NCT05498155|EXPERIMENTAL|Cohort B|Cohort B will consist of a higher-risk population of participants with HER2-negative ER-negative or ER-low defined as having a tumour size of \>20 mm but ≤50 mm and N0 (T2/N0), or having a tumour size of \>1 mm but ≤20 mm and N1 (T1/N1).
62584988|NCT02208362|EXPERIMENTAL|Arm 1 (Tcm-derived CAR T cells, Intratumoral a/f biopsy [ICTb])|Arm 1 (Tcm-derived CAR T cells, Intratumoral a/f biopsy \[ICTb\]
62584989|NCT02208362|EXPERIMENTAL|Arm 2 (Tcm-derived CAR T cells, ICTb/r)|Arm 2 (Tcm-derived CAR T cells, Intratumoral a/f biopsy \[ICTb\] or Intracavitary a/f resection \[ICTr\])
62584990|NCT02208362|EXPERIMENTAL|Arm 3 (Tcm-derived CAR T cells, Intraventricular [ICV])|Arm 3 (Tcm-derived CAR T cells, Intraventricular \[ICV\])
62584991|NCT02208362|EXPERIMENTAL|Arm 4 (Tcm-derived CAR T cells, Dual delivery: both ICTb/r AND ICV)|Arm 4 (Tcm-derived CAR T cells, Dual delivery: both ICTb/r AND ICV)
62584992|NCT02208362|EXPERIMENTAL|Arm 5 (Tn/mem-derived CAR T cells, Dual delivery: both ICTb/r AND ICV)|Arm 5 (Tn/mem-derived CAR T cells, Dual delivery: both ICTb/r AND ICV)
62584993|NCT04216199|EXPERIMENTAL|Point of care Ultrasound|Point of care Ultrasound for placement of endotracheal tube
62584994|NCT04216199|NO_INTERVENTION|Traditional|Traditional method of insertion of endotracheal tube
62584995|NCT03380078|ACTIVE_COMPARATOR|Standard|Programs assigned to the Standard condition will receive standard EBI training only
62584996|NCT03380078|EXPERIMENTAL|TEAMS Leadership Institute (TLI) ONLY|Programs assigned to the TLI ONLY condition will receive standard EBI training for providers and leaders will participate in TLI.
62584997|NCT03380078|EXPERIMENTAL|Motivational Enhancement (TIPS for Training) ONLY|Programs assigned to the TIPS ONLY condition will receive enhanced TIPS EBI training for providers.
62584998|NCT03380078|EXPERIMENTAL|TIPS + TLI|Programs assigned to the TIPS + TLI condition will receive TIPS EBI training for providers and leaders will participate in TLI
62584999|NCT03169881|EXPERIMENTAL|Darbepoetin|Darbepoetin 10 micrograms/kg/once every week (IV or SC)
62585000|NCT03169881|PLACEBO_COMPARATOR|Placebo|Equal volume normal saline for IV administration, or sham dosing
62585001|NCT04541953|ACTIVE_COMPARATOR|Telerehabilitation|
62585002|NCT04541953|ACTIVE_COMPARATOR|In-Person Rehabilitation|
62585003|NCT04236661|EXPERIMENTAL|Chilipad Arm|Subjects will use chilipad nightly for 5 weeks
62585004|NCT02731651|ACTIVE_COMPARATOR|Open Hysterectomy|Open hysterectomy was performed with taking one of the ovaries at the beginning and the other ovary was removed at the end of the surgery.
62585005|NCT02731651|ACTIVE_COMPARATOR|LaparoscopicAssistedVaginalHysterectomy|Surgery in Group 2 (LAVH): Laparoscopic Assisted Vaginal Hysterectomy was performed with taking one of the ovary at the beginning of the procedure and the other ovary was removed at the end of the surgery.
62585006|NCT06063148|EXPERIMENTAL|Enrolled Participant|During routine arterial blood gas sampling, a coordinator will measure SpO2 from a similar extremity. SpO2 data will be recorded using Masimo Radical-7 oximeters. To minimize ambient light interference or optical cross talk from other SpO2 sensors, all the SpO2 sensors will be fully shielded with cloth wraps provided by Masimo. Each enrolled infant will undergo simultaneous blood gas sampling and SpO2 measurement for each routine blood gas collected. Up to a total of 10 SpO2 measurements will be collected, paired with 10 blood gas samples collected as part of routine care, though We anticipate about 3 paired samples (SaO2 and SpO2) per enrolled infant.
62585007|NCT03131973|EXPERIMENTAL|Methotrexate|Methotrexate single oral dose followed by leucovorin single oral dose on specified days followed by BMS-986195 coadministered with methotrexate single oral dose followed by leucovorin single oral dose on specified days
62599947|NCT06623838||Chinese group|Group/Cohort Description: 22 students in MA in clinical psychology performing the evolutionarily informed case conceptualization.
62791916|NCT02210858|EXPERIMENTAL|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62791917|NCT05524584|EXPERIMENTAL|Fulvestrant + Anastrozole + Abemaciclib|"Fulvestrant, intramuscular, Initial: 500 mg on days 1 and 15; Maintenance: 500 mg once monthly.~Anastrozole, oral, 1mg tablet daily~Abemaciclib 150 mg twice daily"
62791918|NCT00863499|ACTIVE_COMPARATOR|A|Short Acting methylphenidate
62791919|NCT00863499|ACTIVE_COMPARATOR|B|Long Acting Methylphenidate
62791920|NCT00863499|NO_INTERVENTION|C|Healthy Controls
62791921|NCT06407284|EXPERIMENTAL|Produce Prescription Group|
62791922|NCT06407284|ACTIVE_COMPARATOR|Control Group|
62791923|NCT02717494|EXPERIMENTAL|Arm 1A (PPV-23)|In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
62791924|NCT02717494|EXPERIMENTAL|Arm 1B (PCV-10)|In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
62791925|NCT02717494|PLACEBO_COMPARATOR|Arm 1C (placebo)|In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
62791926|NCT02717494|EXPERIMENTAL|Arm 2A (PPV-23)|In Step 2, women who received placebo in step 1 that were randomized to Arm 2A were administered a 0.5 mL dose of PPV-23 intramuscularly once.
62585008|NCT03131973|EXPERIMENTAL|Cytochrome P450 and Transporter Substrates|Caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin single oral dose on specified days, BMS-986195 multiple oral dose administration on specified days, and BMS-986195 coadministered with caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin single oral dose on specified days.
62585009|NCT03691311|EXPERIMENTAL|Denosumab|Denosumab 120 MG/1.7 ML Subcutaneous Solution \[XGEVA\]
62791927|NCT02717494|EXPERIMENTAL|Arm 2B (PCV-10)|In Step 2, women who received placebo in step 1 that were randomized to Arm 2B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
62215521|NCT03869190|ACTIVE_COMPARATOR|Atezolizumab for Cisplatin-ineligible MIBC Cohort 2 PD-L1- Arm 1|Participants will receive Atezolizumab for 3 cycles pre-surgery and 14 cycles post-surgery.
62215522|NCT03869190|EXPERIMENTAL|Atezolizumab + Tiragolumab for Cisplatin-ineligible MIBC Cohort 2 PD-L1- Arm 2|Participants will receive Atezolizumab and Tiragolumab (Tira) for 3 cycles pre-surgery and 14 cycles post-surgery.
62791928|NCT02717494|EXPERIMENTAL|Step 3 (PCV-10)|In Step 3, women who received placebo in step 1 and failed entry into step 2 due to ongoing new pregnancy were administered a 0.5 mL dose of PCV-10 intramuscularly once.
62791929|NCT04082715|EXPERIMENTAL|carbidopa/levodopa+celecoxib|carbidopa/levodopa+celecoxib treatments will be effective.
62791930|NCT04082715|PLACEBO_COMPARATOR|placebo1+celecoxib|A placebo comparator for carbidopa/levodopa+celecoxib .
62791931|NCT04082715|PLACEBO_COMPARATOR|placebo1+placebo2|A placebo comparator for carbidopa/levodopa+celecoxib and placebo1+celecoxib.
62791932|NCT04639024|EXPERIMENTAL|ADCT-301 Infusion|Patients will receive ADCT-301 37.5 ug/kg infused day 1,8, and 15 of a q3week cycle. Patients will have up to 2 cycles to assess response and safety to therapy and if they are not progressing may continue for up to 6 cycles.
62791933|NCT06453681|ACTIVE_COMPARATOR|bupivacain|patients receive bilateral Pecs block with bupivacin 0.25%,
62791934|NCT06453681|ACTIVE_COMPARATOR|dexameditomedine bupivacain|patients received bilateral Pecs block with bupivacin 0.25% plus dexmedetomidine 0.5 μg/Kg as adjuvant.
62215523|NCT03869190|ACTIVE_COMPARATOR|Cisplatin-eligible MIBC Cohort 3 Arm 1|Participants will receive 3 cycles of Atezolizumab, Cisplatin, and Gemcitabine pre-surgery and 14 cycles of Atezolizumab only post-surgery.
62215524|NCT03869190|EXPERIMENTAL|Cisplatin-eligible MIBC Cohort 3 Arm 2|Participants will receive Atezolizumab, Tiragolumab (Tira), Cisplatin and Gemcitabine for 3 cycles pre-surgery and 14 cycles of Atezolizumab and Tiragolumab (Tira) post-surgery.
62215525|NCT05664893|EXPERIMENTAL|Principal arm|registration phase : 3 cycles of 600mg per day of ribociclib Treatment phase : 3 cycles of dose de-escalation of ribociclib (600 or 400 or 200mg per day) Maintenance phase : 600mg per day of ribociclib until 24months of total treatment
62215526|NCT04836689|OTHER|30 breaths per minutes|Using NIPPV with rate of 30 for 1 hour. Measuring trans cutaneous CO2
62215527|NCT04836689|OTHER|10 breaths per minute|Using NIPPV with rate of 10 for 1 hour. Measuring trans cutaneous CO2
62215528|NCT04847076|EXPERIMENTAL|m-health version of WWWT intervention|Include: a) Psychoeducational information for understanding and managing infant behavior and on parenting. This information will be delivered through instant messaging service for mobile phones (i.e., Whatsapp) 3 times a week for four-week period. Each module will include a very brief video offering information regarding a specific topic, a proposed personal exercise and the invitation to assess the perceived usefulness of the information received. Some modules include links to external, complementary information from the Chilean Infancy Policy. b) Contact with the program facilitator. It will allow mothers to ask questions that arise from the topics addressed in the psychoeducational videos. The answers seek to promote the understanding and elaboration of the contents, and operate by providing expert support; c) A virtual group meeting.
62243238|NCT05017220|EXPERIMENTAL|Nature-based stimulation program|Participants will receive a single intervention with a duration of 30 minutes based on a multisensorial nature-based stimulation
62243239|NCT05017220|OTHER|Control intervention|Participants will be involved in a placebo task for 30 minutes
62243240|NCT03687814|EXPERIMENTAL|Low FODMAP diet plus PEG 3350|Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax).
62243241|NCT03687814|SHAM_COMPARATOR|Sham diet plus PEG 3350|Subjects will follow a sham diet and will take PEG 3350 (Miralax).
62585010|NCT03691311|NO_INTERVENTION|Control|Control group
62585011|NCT04713722||MDD/childhood adversity group|subjects with current MDD who experienced childhood adversity
62585012|NCT04713722||rMDD/ childhood adversity|subjects with a history of MDD who experienced childhood adversity
62585013|NCT04713722||MDD|subjects in a current episode of MDD, with no history of childhood adversity
62585014|NCT04713722||Healthy Control|healthy control subjects, with no history of childhood adversity
62585015|NCT06682936|EXPERIMENTAL|outpatient drain and talc pleurodesis|Patients enrolled to the trial will have a chest drain inserted and we will aim to drain to dryness and instill medical grade talc as described in the protocol
62791935|NCT05277558||Normal Weight-Normal Glucose Tolerant (NW-NGT)|(1) a group that is the normal weight (BMI\<85th%) and has normal glucose tolerance (NW-NGT)
62791936|NCT05277558||Overweight and/or obese and has normal glucose tolerance (O-NGT)|(2) a group that is overweight and/or obese (BMI \>85th%) and has normal glucose tolerance (O-NGT)
62791937|NCT05277558||Overweight and/or Obese and has dysglycemia (O-DG)|(3) group that is overweight and/or obese (BMI \>85th%) and has dysglycemia (O-DG; fasting plasma glucose ≥100 mg/dl and/or 2-hour glucose ≥140 mg/dl oral glucose tolerance test (OGTT) and laboratory-based HbA1c ≥5.8 and ≤8.0%, if treatment naïve).
62791938|NCT05833997|EXPERIMENTAL|Holmium Laser En-bloc Resection of Bladder Tumors (HoLERBT) arm|Patients randomized to HoLERBT group will have their tumor resected using the Megapulse 70w (Richard Wolf).
62791939|NCT05833997|ACTIVE_COMPARATOR|Control arm|Patients randomized to control arm will undergo a monopolar transurethral resection of bladder tumor.
62791940|NCT01295593|EXPERIMENTAL|valproic acid combined with CdA|valproic acid, oral daily intake, combined with 2-chlorodeoxyadenosine administered intravenously for 4 cycles
62791941|NCT04136730|NO_INTERVENTION|Control|Usual Care
62791942|NCT04136730|ACTIVE_COMPARATOR|Home-based|Home-based resistance exercise training
62585016|NCT01644799|EXPERIMENTAL|lenalidomide and idelalisib|"Lenalidomide:~Lenalidomide will be administered orally on days 1-21 followed by 7 days of rest, every 28 days. A treatment cycle will be considered 28 days in length. In the absence of intolerable toxicity or disease progression, lenalidomide will be given for a total of 12 cycles.~Idelalisib:~Dosing is fixed in all cohorts receiving idelalisib at 150 mg orally (twice daily) for 12 cycles, with the exception of dose modifications for toxicity."
62585017|NCT04881227|EXPERIMENTAL|Chatbot condition|Participants randomly assigned to this arm will access to a Chatbot condition, in which they had the opportunity to interact with the chatbot on COVID-19 vaccine hesitancy.
62791943|NCT01895595|EXPERIMENTAL|Guided Imagery|The guided imagery program curriculum, added to the lifestyle education curriculum, consists of 12 weekly, 45-minute modules, delivered one-on-one immediately following the lifestyle education class each week. Guided imagery was based on 2 major underlying theoretical principles: 1) relaxation/stress reduction imagery; and 2) imagery designed to improve eating and physical activity behaviors.
62791944|NCT01895595|ACTIVE_COMPARATOR|"Digital storytelling (Control)"|The digital storytelling program curriculum, to control for contact time with research staff, consists of 12 weekly 45-minute modules delivered one-on-one immediately following the lifestyle education class each week.
62791945|NCT04334993|EXPERIMENTAL|Blinatumomab pre-transplant to high risk Ph-negative ALL pts.|Patients designated high risk based on protocol will receive 2 cycles of therapy followed by allogeneic transplantation. Patients ≥45 kg (fixed dose): Cycles 1 and 2: 28 mcg daily administered as a continuous infusion on days 1 to 28 of a 6-week treatment cycle.
62791946|NCT02549001|EXPERIMENTAL|P-3058 10%|P-3058 10%
62791947|NCT02549001|PLACEBO_COMPARATOR|vehicle of P-3058 10%|vehicle of P-3058 10%
62791948|NCT02549001|ACTIVE_COMPARATOR|amorolfine 5%|Loceryl®
62215529|NCT04847076|OTHER|TREATMENT AS USUAL|TAU for children under one year of age include routine health checks by health professionals (nurse or doctor), every month from 0 to 4 months of age, and at 6, 8 and 12 months of age. The objective of the routine health care check is to carry out a comprehensive evaluation of the child's development and growth, guide parents and caregivers regarding child development, health and upbringing of the child. Also, promoting exclusive breastfeeding, healthy mother/child bonding (by detecting relevant alterations in this area) and encouraging paternal participation in upbringing and care of the child. Finally, in the health check-ups at 2 and 6 months of age of the child, Edinburgh Postpartum Depression Scale is used for screening depressive symptoms in mothers. At risk cases are referred for mental health assessment and care.
62215530|NCT01344954|EXPERIMENTAL|25mg TB-402|
62585018|NCT04881227|ACTIVE_COMPARATOR|Control condition|Participants randomly assigned to this arm will access to a brief text describing the way vaccines work.
62585019|NCT01340027|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo tablets orally once a day for 12 weeks
62585020|NCT01340027|ACTIVE_COMPARATOR|Mirabegron 25 mg|Participants received mirabegron 25 mg tablets orally once a day for 12 weeks
62585021|NCT01340027|ACTIVE_COMPARATOR|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks
62585022|NCT01340027|ACTIVE_COMPARATOR|Solifenacin 2.5 mg|Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks
62791949|NCT01520376|ACTIVE_COMPARATOR|Counselling|People receiving a psychiatric evaluation after screening (HADS test \> 12 points) and revised at 1 and 6 months
62791950|NCT01520376|NO_INTERVENTION|Usual care|People after screening (HADS test \> 12 points) and send to their primary care physician
62585023|NCT01340027|ACTIVE_COMPARATOR|Solifenacin 5 mg|Participants received solifenacin 5 mg tablets orally once a day for 12 weeks
62585024|NCT01340027|ACTIVE_COMPARATOR|Solifenacin 10 mg|Participants received solifenacin 10 mg tablets orally once a day for 12 weeks
62585025|NCT01340027|EXPERIMENTAL|Solifenacin 2.5 mg and Mirabegron 25 mg|Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
62791951|NCT05682976||AD patient treated by Tralokinumab|AD patient treated by Tralokinumab
62791952|NCT00644488|EXPERIMENTAL|A1|Active
62791953|NCT06476353|EXPERIMENTAL|5ml Syringe Size|Analyzing the Compression Force required to plunge a 5ml Syringe during a pain management procedure.
62021072|NCT01607905|EXPERIMENTAL|Arm E (Glioblastoma Multiforme)|Participants with glioblastoma multiforme (GBM) received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
62215531|NCT01344954|EXPERIMENTAL|50mg TB-402|
62215532|NCT01344954|ACTIVE_COMPARATOR|10mg QD Rivaroxaban|
62215533|NCT04006353|EXPERIMENTAL|Group 1: ABT|Intravenous infusion of 320 mg ABT on Day 1, 2, 3, and 8.
62215534|NCT04006353|EXPERIMENTAL|Group 2: ABT+RIF|600mg Rifampicin once daily from Day 1 to 16. Intravenous infusion of 320 mg ABT on Day 7, 8, 9 and 14.
62215535|NCT02865226|EXPERIMENTAL|experimental group|paravertebral block by the anesthetist before incision (paravertebral block guided by ultrasound)
62585026|NCT01340027|EXPERIMENTAL|Solifenacin 2.5 mg and Mirabegron 50 mg|Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
62585027|NCT01340027|EXPERIMENTAL|Solifenacin 5 mg and Mirabegron 25 mg|Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
62585028|NCT01340027|EXPERIMENTAL|Solifenacin 5 mg and Mirabegron 50 mg|Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
62585029|NCT01340027|EXPERIMENTAL|Solifenacin 10 mg and Mirabegron 25 mg|Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
62585030|NCT01340027|EXPERIMENTAL|Solifenacin 10 mg and Mirabegron 50 mg|Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
62585031|NCT05720715|ACTIVE_COMPARATOR|group A|receive cyclosporine eye drops together with prednisolone eye drops.
62585032|NCT05720715|PLACEBO_COMPARATOR|group B|receive topical prednisolone with placebo eye drops (tear replacement).
62410154|NCT01856296|EXPERIMENTAL|Arm B|patients negative for oncogene events (which remains the majority), for whom genome based relevant information will be obtained through functional genomics (micro arrays and gene expression profiling) performed by Institut Gustave Roussy, and innovative computational methods enabling a rational choice of therapies. For such patients we will apply a new prediction model of efficacy of existing and under clinical trial drugs, based on differences in gene expression profiling between tumor and normal biopsies to be matched with relevant genes that are related to drug activities.
62410155|NCT05146609|EXPERIMENTAL|HR-HOSPITAL|Patients assigned to the strategy HR-HOSPITAL, who are high risk population (HR), will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the referral hospital.
62410156|NCT05146609|EXPERIMENTAL|HR-DDP|Patients assigned to the strategy HR-DDP, who are high risk population, will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the drug dependence center (DDP) the participants used to attend.
62410157|NCT05146609|EXPERIMENTAL|GP-HOSPITAL|Patients assigned to the strategy GP-HOSPITAL, who are general population (GP), will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the referral hospital.
62410158|NCT05146609|EXPERIMENTAL|GP-PCC|Patients assigned to the strategy GP-PCC, who are general population (GP), will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the primary care center (PCC) to be performed by the general practitioner.
62410159|NCT06566391|EXPERIMENTAL|Ipilimumab + Nivolumab followed by Nivolumab|Neoadjuvant therapy: Ipilimumab 1 mg/kg + Nivolumab 3mg/kg every 3 weeks for 4 cycles; Adjuvant therapy: Nivolumab 480 mg every 4 weeks for 6 cycles
62585033|NCT02805660|EXPERIMENTAL|Phase 1: Dose Escalation - 50 mg|The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this Phase.
62585034|NCT02805660|EXPERIMENTAL|Phase 1: Dose Escalation - 70 mg|The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this Phase.
62791954|NCT06476353|EXPERIMENTAL|10ml Syringe|Analyzing the Compression Force required to plunge a 10ml Syringe during a pain management procedure.
62791955|NCT06476353|EXPERIMENTAL|20ml Syringe Size|Analyzing the Compression Force required to plunge a 20ml Syringe during a pain management procedure.
62215536|NCT02865226|ACTIVE_COMPARATOR|control group|paravertebral block by the thoracic surgeon at chest closure (paravertebral block visual)
62791956|NCT06476353|EXPERIMENTAL|30ml Syringe Size|Analyzing the Compression Force required to plunge a 30ml Syringe during a pain management procedure.
62215537|NCT02650687||Elective Non Cardiac Surgical Patients|65 years of age and older
62215538|NCT03656952|EXPERIMENTAL|Seq 1|PF-06700841-\> placebo-\> moxifloxacin
62215539|NCT03656952|EXPERIMENTAL|Seq 2|PF-06700841-\>moxifloxacin-\>placebo
62215540|NCT03656952|EXPERIMENTAL|Seq 3|Placebo-\>PF-06700841-\>moxifloxacin
62410160|NCT01937546|ACTIVE_COMPARATOR|Anterior shoulder|Primary delivery of the anterior shoulder of the fetus
62410161|NCT01937546|EXPERIMENTAL|Posterior shoulder|Primary delivery of the posterior shoulder of the fetus
62410162|NCT01600612|ACTIVE_COMPARATOR|Oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
62410163|NCT01600612|ACTIVE_COMPARATOR|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
62410164|NCT01600612|ACTIVE_COMPARATOR|misopristol|600 ug of misopristol sublingually will be given intravenously to patients with atonic postpartum hemorrhage
62791957|NCT01947764|NO_INTERVENTION|Usual Care|"The Usual Care components for the control clinics will include the following:~* All clinicians (pediatricians, medical officers, clinical officers, and nurses) caring for children undergo the existing 3-day disclosure training~* Chart materials to guide and document disclosure counseling and visits~* The presence of the AMPATH SOP mandating disclosure to children ages 10 and older.~In Usual Care clinics, no specific personnel will be dedicated to disclosure."
62021073|NCT01607905|EXPERIMENTAL|Arm F (Melanoma)|Participants with Melanoma received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
62215541|NCT03656952|EXPERIMENTAL|Seq 4|Placebo-\>moxifloxacin-\>PF-06700841
62215542|NCT03656952|EXPERIMENTAL|Seq 5|Moxifloxacin-\>PF-06700841-\>placebo
62215543|NCT03656952|EXPERIMENTAL|Seq 6|Moxifloxacin-\>placebo-\>PF-06700841
62215544|NCT06235437|EXPERIMENTAL|ASD141|IV, Monotherapy
62215545|NCT05068141|EXPERIMENTAL|SG001 plus Nab-Paclitaxel|Patients will receive SG001 intravenously at a dose of 240 mg on Days 1 and 15 of every 4-week cycle in combination with nab-paclitaxel at a dose of 100 mg/m\^2 on Days 1, 8, and 15 of every 4-week cycle until disease progression, or unacceptable toxicity, or other discontinuation or termination criteria are met.
62215546|NCT06433973|EXPERIMENTAL|Test group 1 - CM+LLLT+VISTA|After obtaining adequate LA exposed root surfaces of treated teeth are to be scaled with curettes to reduce root convexity and undercuts.CM will be placed on the recession defect using minimally invasive technique. Photobiostimulation will be done using of diode laser.
62215547|NCT06433973|EXPERIMENTAL|Test group 2 - CM+VISTA|After obtaining adequate LA exposed root surfaces of treated teeth are to be scaled with curettes to reduce root convexity and undercuts.CM will be placed on the recession defect using minimally invasive technique.
62215548|NCT06433973|OTHER|Control group - SCTG+VISTA|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with CTG using minimally invasive access technique.
62243242|NCT01125943|EXPERIMENTAL|Acetylcholine|Intra-arterial infusion of acetylcholine in two increasing dosages during 5 minutes each during the intra-arterial infusion of bevacizumab
62243243|NCT01125943|EXPERIMENTAL|Nitroprusside|Infusion of two increasing dosages of nitroprusside during 5 minutes each during the continuous infusion of bevacizumab
62410165|NCT04016909|EXPERIMENTAL|aerobic exercise plus calorie restriction|"The experimental intervention: both exercise and calorie restriction, as described below:~Exercise intervention. 6 months, 72 supervised aerobic exercise training sessions on cycle ergometers, including 3 sessions of training per week. A warm-up procedure consisting of 5 min of low-intensity stretching was completed by all women before the aerobic training. Subsequently, a 50 min aerobic training at an intensity between 60% and 70% of the maximum heart rate (HR) was performed. Thereafter, a cool-down consisting of 5 min of low-intensity stretching and breathing exercises was completed. HR was recorded continuously throughout the training sessions using an HR monitor (S625X, Polar Electro, Kempele, Finland).~Calorie restriction intervention. The CR intervention was designed to create a 12.5% energy deficit, with the goal of reducing body weight by 5%-10% over 6 months."
62410166|NCT04016909|NO_INTERVENTION|Control|No intervention and participants were instructed to maintain their regular physical activity and diet regime for 6 months; they were also prohibited from participating in any weight-loss or exercise program.
62585035|NCT02805660|EXPERIMENTAL|Phase 1: Dose Escalation - 90 mg|The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this Phase.
62585036|NCT02805660|EXPERIMENTAL|Phase 2: Combination Regimen - Cohort 1|Participants with non-small cell lung cancer (NSCLC) who were naïve to treatment with immunotherapy, and had a tumor with no/low programmed cell death ligand 1 (PD-L1) expression were included in this cohort.
62819307|NCT04175613|EXPERIMENTAL|Patients treated with Apremilast|Subjects with a weight between 20 kg to \< 50 kg will receive apremilast 20 mg BID and subjects with weight ≥ 50 kg at Visit 1 will receive apremilast 30 mg BID. Subjects that begin the study receiving apremilast 20 mg BID and later record a body weight ≥ 50 kg, will be switched to apremilast 30 mg BID.
62215549|NCT05565638|EXPERIMENTAL|PROLONGED FASTING INTERVENTION|The prolonged nightly fasting (PROFAST) intervention involves gradually working up to a 14-hour fast during the nighttime hours. Participants will be supported by means of calls with a health coach during the first 4 weeks of the study. Participants will also be asked to use a text messaging platform to record their first and last meal of the day, and will receive personalized feedback based on the meal times they record via the text messaging system. The text messaging system will be used throughout the duration of the study.
62215550|NCT05565638|ACTIVE_COMPARATOR|EDUCATION CONTROL|For participants randomized to the control group, an introductory session with a health coach and educational information will be provided. Participants will also receive one email and one text message per week with tips on healthy living during the 4 months of the study
62215551|NCT00467285||Group 1|140 subjects with type 2 diabetes on pioglitazone.
62215552|NCT00467285||Group 2|140 subjects with type 2 diabetes not on pioglitazone.
62215553|NCT02121951|ACTIVE_COMPARATOR|Local Anesthetic infiltration and MAC|"* Local Anesthetic infiltration with 1% lignocaine~* MAC with IV Midazolam Img\\ml and Fentanyl 10 mic\\ml"
62215554|NCT02121951|EXPERIMENTAL|Quadratus Lumborum block and MAC|"* QL block with 0.25% levobupivacaine (Chirocaine, Abbott, Ireland) and 1% lignocaine~* MAC with IV Midazolam Img\\ml and Fentanyl 10 mic\\ml"
62215555|NCT06060015|EXPERIMENTAL|5mg bupivacaine|Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 5mg
62215556|NCT06060015|EXPERIMENTAL|10mg bupivacaine|Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 10mg
62215557|NCT00098501|EXPERIMENTAL|Arm I|Patients receive oral EKB-569 on days 1-28 and oral CCI-779 on days 1-7 and 15-21.
62215558|NCT03681847|ACTIVE_COMPARATOR|normal saline|Patients will receive normal saline 0.9% 15 ml/kg over 15-20 minutes.
62215559|NCT03681847|ACTIVE_COMPARATOR|Hydroxyethyl starch|Patients will receive hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride 5 ml/kg over 15-20 minutes.
62215560|NCT03681847|ACTIVE_COMPARATOR|Hypertonic saline|Patients will receive hypertonic saline 3% (7ml/kg) over 15-20 minutes.
62215561|NCT00998803||Immunocompromised participants|Immunocompromised (\<= 21 years of age) due to cancer, receipt of stem cell transplant, human immunodeficiency virus (HIV) or Sickle cell disease
62215562|NCT05873478|EXPERIMENTAL|Experimental (High Intensity Interval Training)|High Intensity Interval Training for 8 weeks, which include lunges, squatting sprinting and other exercises.
62215563|NCT05873478|NO_INTERVENTION|Control (No Intervention)|Control Group received no intervention they all will be engaged in normal daily routines.
62215564|NCT02031549||SpermComet Assay|All study subjects will have their surplus sperm analyzed for DNA fragmentation with the SpermComet assay.
62215565|NCT01350739|OTHER|intraumbilical incision|an intraumbilical vertical incision is made
62215566|NCT01350739|OTHER|infraumbilical incision|incision is done in circular fashion at the inferior boarder of umbilicus
62215567|NCT02878005|ACTIVE_COMPARATOR|Intubating laryngeal Tube Suction|Intubating laryngeal Tube Suction
62215568|NCT02878005|ACTIVE_COMPARATOR|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
62215569|NCT03930290||Pregnant patients|Pregnant patients in their 2nd trimester.
62215570|NCT04064073|EXPERIMENTAL|1|
62215571|NCT04064073|EXPERIMENTAL|2|
62215572|NCT04064073|EXPERIMENTAL|3|
62215573|NCT05728320||Gastric bypass|Subjects submitted to gastric bypass
62215574|NCT05728320||Sleeve gastrectomy|Subjects submitted to sleeve gastrectomy
62215575|NCT05728320||Normal control subjects|Subjects not submitted to bariatric surgery with IMC \< 25
62215576|NCT05728320||Obese control subjects|Subjects not submitted to bariatric surgery with IMC \> 30
62215577|NCT01033422|EXPERIMENTAL|CF101 1mg|CF101 1mg orally q12 hours
62215578|NCT01033422|PLACEBO_COMPARATOR|Placebo|matching placebo orally q12 hours
62215579|NCT01033422|EXPERIMENTAL|CF101 2mg|CF101 2mg orally q12 hours
62243244|NCT06734624||Diffuse Large B-cell lymphoma (DLBCL)|Patents with DLBCL receiving CART or Bispecific antibody treatment
62410167|NCT06538961||Main study|Single organ deceased donor kidney transplant recipients. Main study group subjects are enrolled at the time of transplant.
62410168|NCT06538961||Sub-study|Single organ deceased donor Kidney Transplant Recipient who are newly diagnosed with BK Viremia. The sub-study group are enrolled once they are diagnosed with BK viremia post-transplant.
62819308|NCT03306914|ACTIVE_COMPARATOR|Albumin group|Albumin resuscitation Albumin 5%
62819309|NCT03306914|EXPERIMENTAL|Hydroxyethylstarch group|Hydroxyethylstarch resuscitation Hydroxyethylstarch 6%
62791958|NCT01947764|EXPERIMENTAL|HADITHI Intervention|"In addition to the Usual Care components, the HADITHI Intervention clinics will include:~* Modified materials to guide disclosure sessions~* Videotaped narratives for parental counseling~* Dedicated disclosure counselors to initiate and conduct the disclosure process~* Post-disclosure support groups for children~The disclosure counselors will avail themselves for conducting disclosure with any families referred to them by the AMPATH clinicians. They will post fliers that describe their services for parents and caregivers so that families can self-refer for disclosure counseling. Similarly, the post-disclosure support groups for children will be available for anyone enrolled in the clinic and families will be able to self-refer or to be referred by the clinicians."
62410169|NCT02769832|EXPERIMENTAL|Nab-Paclitaxel with Gemcitabine|Nab-paclitaxel 100 mg/m2, day 1 and day 8 of a 21-day cycle Gemcitabine 1000 mg/m2, day 1 and day 8 of a 21-day cycle
62791959|NCT04276519|EXPERIMENTAL|Experimental|Physiotherapeutic non-invasive position-induced opening of the intervertebral foramen and pharmacological treatment with steroid antiinflammatory drugs - dexamethasone, nonsteroid antiinflammatory drugs and pain killers - tramadol.
62791960|NCT04276519|ACTIVE_COMPARATOR|Control group|Pharmacological treatment with steroid antiinflammatory drugs - dexamethasone, nonsteroid antiinflammatory drugs and pain killers - tramadol.
62791961|NCT02317848|OTHER|patients with acute heart failure|polygraphy, echocardiography, ECG during hospitalisation for acute heart failure
62791962|NCT01828229|EXPERIMENTAL|female inactivity and hypercaloric diet|inactivity and hypercaloric diet in women for two weeks
62021074|NCT01607905|EXPERIMENTAL|Arm G (Other Solid Tumors)|Participants with other solid tumors received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m\^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: \>12 mg/m\^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m\^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m\^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m\^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m\^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m\^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
62215580|NCT05351359|ACTIVE_COMPARATOR|Active control|The patients from the active control group will receive brief physical activity advice from their general practitioners at baseline, and they will also receive the Fitbit tracker to self-monitor their daily steps.
62215581|NCT05351359|EXPERIMENTAL|Intervention|The patients in the intervention group will be exposed to the same procedures as those from the active control group, but will also receive a mHealth-enabled just-in-time adaptive intervention and regular monthly phone counselling in the first 6 months.
62021075|NCT00229008|EXPERIMENTAL|001|ceftobiprole plus placebo ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
62791963|NCT01828229|EXPERIMENTAL|inactivity|Inactivity for two weeks
62791964|NCT01828229|EXPERIMENTAL|inactivity and hypercaloric diet|inactivity and hypercaloric diet for two weeks
62215582|NCT02684448||Robotic-Assisted Inguinal Hernia Repair|Subjects who have undergone robotic-assisted (da Vinci) inguinal hernia repair from the initiation of robotic-assisted hernia repair at site through December 2015.
62410170|NCT02006901||microdecompression|surgical microdecompression using a bilateral or unilateral approach depending on the surgeon's preference and the individual patient's anatomy and symptoms.
62791965|NCT01828229|EXPERIMENTAL|normal activity and hypercaloric diet|Normal activity and hypercaloric diet for two weeks
62021076|NCT00229008|ACTIVE_COMPARATOR|002|linezolid plus ceftazidime linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
62215583|NCT02684448||Open Inguinal Hernia Repair|Subjects who have undergone open inguinal hernia repair from the day prior to initiation of robotic-assisted hernia repair through 5 years prior to initiation.
62410171|NCT02006901||laminectomy|the spinous process and the laminae of the involved level(s) as well as the medial aspects of the facet joints are resected
62410172|NCT03908229|EXPERIMENTAL|Trainee colonoscopy|"In the investigation arm colonoscopy will be performed by gastroenterology fellows. The fellows will always start the case and proceed generally until they are unable to make further progress despite coaching from the staff attending.~During the procedures with fellows, the staff attending will always actively participate in the entire procedure and assess for the presence of any lesions."
62410173|NCT03908229|ACTIVE_COMPARATOR|Experienced physician colonoscopy|In the control arm all colonoscopy will be performed by full-time board-certified gastroenterologists who have each done more than 5000 colonoscopy examinations.
62410174|NCT04206072|EXPERIMENTAL|D-0316|D-0316 (75 mg or 100 mg orally, once daily), in accordance with the randomization schedule.
62410175|NCT04206072|ACTIVE_COMPARATOR|Icotinib|Icotinib (125 mg orally, three times daily), in accordance with the randomization schedule.
62410176|NCT03456401|OTHER|Sorafenib or Sunitinib|Sorafenib will be administered at 400 mg bid daily Sunitinib will be administered at 50 mg die orally (4 week on/2 weeks off)
62585037|NCT02805660|EXPERIMENTAL|Phase 2: Combination Regimen - Cohort 2|Participants with non-small cell lung cancer (NSCLC) who were naïve to treatment with immunotherapy, and had a tumor with high programmed cell death ligand 1 (PD-L1) expression were included in this cohort.
62791966|NCT01828229|ACTIVE_COMPARATOR|inactivity and iso-caloric diet|inactivity and iso-caloric diet for two weeks
62791967|NCT00387634|ACTIVE_COMPARATOR|Arm 1|Blood draw only, no vaccine
62791968|NCT00387634|ACTIVE_COMPARATOR|Arm 2|Blood draw only, no vaccine
62791969|NCT00387634|ACTIVE_COMPARATOR|Arm 3|Blood draw only, no vaccine
62791970|NCT00387634|ACTIVE_COMPARATOR|Arm 4|Blood draw only, no vaccine
62791971|NCT06422689|EXPERIMENTAL|Albuterol and budesonide inhalation aerosol|Participants will receive a fixed-dose combination of albuterol (90mcg) and budesonide (80mcg) administered as 2 inhalations (180mcg/160mcg) via pressurized metered dose inhaler (pMDI) as needed for asthma symptoms, for up to 12 inhalations (6 doses) in a 24-hour period.
62791972|NCT03450954||Case(AMT patients)|patients who have undergone amniotic membrane transplant in our unit up till 2016.
62791973|NCT03450954||Control(Patients without AMT)|bullous keratopathy patients awaiting endothelial keratoplasty
62791974|NCT00265317|EXPERIMENTAL|A|
62791975|NCT00265317|ACTIVE_COMPARATOR|B|
62791976|NCT01867502|OTHER|MET + Glibenclamide Group|"Usual Metformin stipulated: 500 or 850mg 3 times a day, if tolerated by patients.~The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). When the adjustments will be done, the dose may reaching the maximum dose allowed, which is 20 mg / day."
62021077|NCT01745263|ACTIVE_COMPARATOR|VitD-Omega3-StrengthExercise|Vitamin D3 (2000 IU/d); Omega-3 fatty acids (1 g/d); Strength Home Exercise (3\*30 minutes/week)
62021078|NCT01745263|ACTIVE_COMPARATOR|VitD-Omega3-FlexibilityExercise|Vitamin D3 (2000 IU/d); Omega-3 fatty acids (1 g/d); Flexibility Home Exercise (3\*30 minutes/week)
62021079|NCT01745263|ACTIVE_COMPARATOR|Placebo-Omega3-StrengthExercise|Placebo Vitamin D3; Omega-3 fatty acids (1 g/d); Strength Home Exercise (3\*30 minutes/week)
62021080|NCT01745263|ACTIVE_COMPARATOR|Placebo-Omega3-FlexibilityExercise|Placebo Vitamin D3; Omega-3 fatty acids (1 g/d); Flexibility Home Exercise (3\*30 minutes/week)
62410177|NCT01656850|EXPERIMENTAL|Almond diet first, then NCEP Diet|In a 28-wk randomized, cross-over, controlled feeding trial with a 2 week washout between alternative diets, subjects were assigned to receive NCEP or almond diet for 12 weeks after a 2-weeks run-in period
62215584|NCT06092619|EXPERIMENTAL|Intervention Group|Patients under Vojta Therapy intervention
62410178|NCT01656850|EXPERIMENTAL|NCEP diet first, then Almond diet|In a 28-wk randomized, cross-over, controlled feeding trial with a 2 week washout between alternative diets, subjects were assigned to receive NCEP or almond diet for 12 weeks after a 2-weeks run-in period
62410179|NCT06651320|EXPERIMENTAL|1 Intervention group: traditional patient education (nurse + physician pre-procedural counseling) +|intervention
62410180|NCT06651320|NO_INTERVENTION|2 The Nonintervention group would receive the traditional patient education before the procedure (vi|
62410181|NCT03573843|PLACEBO_COMPARATOR|Control|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the Control group: They will continue to receive the standard prevention measures: delirium detection, treatment health team education and the patient's family, sleep hygiene plan, early mobilization , resolve sensorial deterioration, and delivery of information of temporal-spatial reorientation in a continuous manner, plus the use of a mobile device without installed delirium prevention software (placebo).
62433228|NCT03101293|EXPERIMENTAL|TAK-831 400 mg Fasted + TAK-831 400 mg Fed|TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 2.
62585038|NCT02805660|EXPERIMENTAL|Phase 2: Combination Regimen - Cohort 3|Participants with non-small cell lung cancer (NSCLC) who have been previously treated with an anti-programmed cell death ligand 1 (PD-L1) or anti-programmed cell death 1 (PD-1) agent with clinical benefit response followed by progression of disease were included in this cohort.
62585039|NCT02805660|EXPERIMENTAL|Phase 2: Combination Regimen - Cohort 4|Participants with non-small cell lung cancer (NSCLC) who have been previously treated with an anti-programmed cell death ligand 1 (PD-L1) or anti-programmed cell death 1 (PD-1) agent who had progression of disease ≤ 16 weeks after initiation of treatment were included in this cohort.
62585040|NCT06104072|PLACEBO_COMPARATOR|Control group (GA)|control group (GA) and study group (GB). Patients in (GA) will be treated by a designed physiotherapy program consisted of aerobic exercise on treadmill, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Graduated active exercises, gait training, Reciprocal and weight shifting exercises in addition to sham computerized cognitive training.
62585041|NCT06104072|EXPERIMENTAL|Study group (GB)|Patients in (GB) will be treated by computer-based cognitive training in addition to the same physiotherapy program as GA.
62585042|NCT00690261||lung cancer|patients diagnosed of lung cancer with malignant pleural effusions
62585043|NCT05204927|ACTIVE_COMPARATOR|Standard Of Care Hormone Therapy|Abiraterone with Prednisone or Enzalutamide
62791977|NCT01867502|OTHER|MET + Vildagliptin Group|"Usual Metformin stipulated: 500 or 850mg 3 times a day, if tolerated by patients.~Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks."
62585044|NCT05204927|EXPERIMENTAL|Investigational Drug|177Lu-PSMA-I\&T
62599948|NCT06623838||Italian group|Group/Cohort Description: 22 students in MA in clinical psychology performing the evolutionarily informed case conceptualization.
62021081|NCT01745263|ACTIVE_COMPARATOR|VitD-Placebo-StrengthExercise|Vitamin D3 (2000 IU/d); Placebo Omega-3 fatty acids; Strength Home Exercise (3\*30 minutes/week)
62410182|NCT03573843|EXPERIMENTAL|Experimental|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the experimental group:They will continue to receive standard prevention measures: Detection of delirium, education of health care team and the patient's family, sleep hygiene plan, early mobilization, resolve sensory impairments, and delivery of information of temporal-spatial reorientation in continuously, plus the use of software installed on a mobile device designed to support the prevention of delirium (Prevention software).
62410183|NCT05802147|EXPERIMENTAL|Early Skin to Skin Contact Group|Women who met the criteria for inclusion in the study and accepted the study (n:180) were told how to apply skin-to-skin contact. Skin-to-skin contact was initiated within the first minutes of normal delivery and skin-to-skin contact was applied to the mothers for a minimum of 15 minutes (due to the high number and frequency of births in the TDL service and hospital conditions). Routine newborn care procedures (eye drops, vaccination, footprints, etc.) performed in the delivery room were performed during skin-to-skin contact. After the skin-to-skin contact between the mother and the newborn was terminated at the end of delivery, 2 hours later, mothers were asked to fill in a personal questionnaire and a traumatic birth scale. The maternal attachment scale was completed 1 month after birth by telephone interview.
62585045|NCT03862131|EXPERIMENTAL|MyoStrain® unblinded treatment arm|"* After consenting to the PROACT study, patients will undergo a baseline MRI to determine their risk stratification for the study. This baseline MyoStrain® MRI must demonstrate 2 or more segments measuring \>-10% or 9 or more segments \>-17% for entrance into the study as the Higher Risk Group~* The unblinded treatment arm will enhance patient management by augmenting standard of care with serial MyoStrain® monitoring of the impact of cancer therapy on myocardial function.~* Higher Risk unblinded patients will continue to undergo MyoStrain® MRI testing, regardless of study arm, at 1 month (+1 week), 3 months (+ 1 week), 6 months (+1 week), 12 months (+ 30 days), 24 months (+30 days), and 36 months (+30 days) after the baseline visit.~* In addition to the MyoStrain® testing, patients will also be asked to complete a brief patient satisfaction questionnaire at each PROACT time point."
62585046|NCT03862131|ACTIVE_COMPARATOR|MyoStrain® blinded control arm|"* After consenting to the PROACT study, patients will undergo a baseline MRI to determine their risk stratification for the study. This baseline MyoStrain® MRI must demonstrate 2 or more segments measuring \>-10% or 9 or more segments \>-17% for entrance into the study as the Higher Risk group~* The blinded control arm will provide investigators with LVEF and LVEDV/LVESV measurements, which are clinical, in conjunction with standard of care~* Higher Risk blinded patients will continue to undergo MyoStrain® MRI testing, regardless of study arm, at 1 month (+1 week), 3 months (+ 1 week), 6 months (+1 week), 12 months (+ 30 days), 24 months (+30 days), and 36 months (+30 days) after the baseline visit.~* In addition to the MyoStrain® testing, patients will also be asked to complete a brief patient satisfaction questionnaire at each PROACT time point."
62585047|NCT04720911|EXPERIMENTAL|In-person TASCS|This intervention is designed to assess the TASCS app administered via an in-person clinician in the ED, with follow-up telephone calls by a clinician
62021082|NCT01745263|ACTIVE_COMPARATOR|VitD-Placebo-FlexiblityExercise|Vitamin D3 (2000 IU/d); Placebo Omega-3 fatty acids; Flexibility Home Exercise (3\*30 minutes/week)
62585048|NCT04720911|ACTIVE_COMPARATOR|Telehealth TASCS|This comparison condition is designed to assess the telehealth modality of TASCS in the ED (in contrast to in-person clinician modality), with follow-up telephone calls by a clinician
62585049|NCT04720911|ACTIVE_COMPARATOR|Self-administered TASCS|This comparison condition is designed to assess the self-administered modality of TASCS (in contrast to clinician modality), with follow-up telephone calls by a clinician
62585050|NCT04339985|EXPERIMENTAL|ATx201 OINTMENT 4%|ATx201 OINTMENT 4%
62585051|NCT04339985|EXPERIMENTAL|ATx201 OINTMENT 7%|ATx201 OINTMENT 7%
62585052|NCT04339985|EXPERIMENTAL|ATx201 OINTMENT vehicle|ATx201 OINTMENT vehicle
62585053|NCT02390102|ACTIVE_COMPARATOR|Erythropoietin|Dose: darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose Administered at days 10 (±4) and 1 (±1) before the index procedure.
62819310|NCT01540279||Cohort one with abdominal wall closure with Monocryl|
62021083|NCT01745263|ACTIVE_COMPARATOR|Placebo-Placebo-StrengthExercise|Placebo Vitamin D3; Placebo Omega-3 fatty acids; Strength Home Exercise (3\*30 minutes/week)
62021084|NCT01745263|SHAM_COMPARATOR|Placebo-Placebo-FlexibilityExercise|Placebo Vitamin D3; Placebo Omega-3 fatty acids; Flexibility Home Exercise (3\*30 minutes/week)
62021085|NCT03165045||patients treated with Spiolto® Respimat®|Patients with COPD
62410184|NCT05802147|NO_INTERVENTION|Control Group|Standard midwifery practices and labor follow-up were applied to women who met the inclusion criteria in the hospital (during the delivery room) (n: 187), agreed to participate in the study, and were in the control group. Neonatal routine care procedures (vaccine, footprint, eye drop application, etc.) of the postpartum hospital were performed. Then, after 2 hours postpartum, mothers were asked to fill in a personal questionnaire and a traumatic birth scale. The maternal attachment scale was completed 1 month after birth by telephone interview.
62585054|NCT02390102|PLACEBO_COMPARATOR|Placebo|Dosage: Saline solution 0.9% Administered at days 10 (±4) and 1 (±1) before the index procedure.
62410185|NCT05789316|EXPERIMENTAL|Ototoxicity Screening Protocol|After enrollment, participants will complete a pre-screening survey. Before their survivorship clinic visit, participants will complete the ototoxicity screening protocol and implementation outcome surveys. During their visit, they will receive counseling on ototoxicity and referral to audiology. After their visit, they will complete the SESMQ and WU-QOLv4 surveys and undergo pure tone audiometry. Each participant will complete this protocol once. The investigators will follow each participant by chart review for at least six months to evaluate for audiologic follow-up.
62021086|NCT06299202|EXPERIMENTAL|Patients with localized breast cancer|Patients with localized breast cancer (stage II or III, HER 2, triple-negative) eligible for a neoadjuvant chemotherapy and not presenting contraindication to angiomammography.
62021087|NCT03644979|EXPERIMENTAL|Skydiving|Tandem skydiving
62410186|NCT04207359|EXPERIMENTAL|Creatine Supplement Group|Participants will engage in three center-based exercise sessions each week for 12 weeks; each session lasting roughly 1-hour. Participants will be given a fitbit (electronic watch that measures steps or heart rate) as well to track heart rate and monitor activity throughout the study.
62410187|NCT04207359|NO_INTERVENTION|Exercise Only Control Group|Participants will not participate in the creatine intervention (creatine supplementation). Participants will engage in three center-based exercise sessions each week for 12 weeks; each session lasting roughly 1-hour. Exercise sessions will be held by trained study staff held at the Medical Arts and Research Center Physical Therapy clinic (address listed above).
62410188|NCT02871921|EXPERIMENTAL|Conversational Engagement|Participants engage in 30-minute face-to-face communications with study staff through internet/webcam 4 times per week for 24 weeks (6 months). Under an exploratory aim, a limited number of participants will be further followed by sustaining dose of 2 times per week of 30 minutes session for additional 24 weeks (6 months). Conversational staff will facilitate content-standardized but naturalistic-style social engagement. Staff and participants will engage in conversation about a wide variety of topics that are culturally and personally relevant and interesting to participants. Each day, participants will be able to choose from topic options. Participants will also receive a phone call once per week that lasts approximately 10 minutes; interviewers ask brief questions to monitor participant social activities and health conditions.
62021088|NCT03644979|NO_INTERVENTION|Negative control|No skydiving
62021089|NCT02691455|ACTIVE_COMPARATOR|Second Aqueous Shunt|"Second Aqueous Shunt~Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used."
62021090|NCT02691455|ACTIVE_COMPARATOR|Transscleral Cyclophotocoagulation|Transscleral Diode Laser Cyclophotocoagulation
62021091|NCT05219877|EXPERIMENTAL|Pre-urodynamic Levofloxacin|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
62021092|NCT05219877|ACTIVE_COMPARATOR|Post-urodynamic Levofloxacin|Levofloxacin 500 mg will be given for 3 days, once daily, post-urodynamic examination
62410189|NCT02871921|NO_INTERVENTION|Control Group|Participants will receive a phone call once per week that lasts approximately 10 minutes; interviewers ask brief questions to monitor participant social activities and health conditions
62410190|NCT02086734||mRCC patients assessed with Perfusion CT|Study population consists of patients with metastasized renal cancer eligible for AAT with either Sunitinib (Sutent®), Pazopanib (Votrient ®), Sorafenib (Nexavar®) evaluated with Perfusion-CT
62410191|NCT03217500|EXPERIMENTAL|Corneal epithelial autograft|pterygium resection combined with femtosecond laser assisted corneal epithelial autograft
62410192|NCT03217500|ACTIVE_COMPARATOR|Limbal conjunctival autograft|pterygium resection combined with diamond knife assisted limbal conjunctival autograft
62410193|NCT03217500|ACTIVE_COMPARATOR|Simple removal|Simple removal of pterygium
62410194|NCT01092286|EXPERIMENTAL|neuromuscular warm-up|coaches in this arm use the prescribed warm-up before team practices
62410195|NCT01092286|NO_INTERVENTION|no warm-up|coaches use their usual warm-up before team practices
62585055|NCT03485495|EXPERIMENTAL|Divaza|Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.
62585056|NCT03485495|PLACEBO_COMPARATOR|Placebo|Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.
62021093|NCT01577394|EXPERIMENTAL|Early stage of dementia|oculomotor measurements
62021094|NCT02382120||Patients undergoing cardiovascular surgery|Patients ASA 3-4 undergoing cardiac surgery.
62021095|NCT02318329|EXPERIMENTAL|Part 1A: FPA144 Dose Escalation Solid Tumors|Dose escalation of FPA144 (0.3 mg/kg to 15 mg/kg)
62021096|NCT02318329|EXPERIMENTAL|Part 1B: FPA144 Dose Escalation Gastric Cancer|Dose escalation of FPA144 (3-10 mg/kg) in patients with gastric cancer
62585057|NCT05419180|OTHER|stiripentol|
62021097|NCT02318329|EXPERIMENTAL|Part 2: FPA144 Dose Expansion Gastric or Other Solid Tumors|Evaluation of objective responses in patients with tumors with various levels of FGFR2b overexpression
62021098|NCT02081651|EXPERIMENTAL|Parmigiano Reggiano cheese|Children treated Parmigiano Reggiano cheese for 12 months
62021099|NCT02081651|NO_INTERVENTION|Control subjects|Children with cow's milk allergy not assuming Parmigiano Reggiano cheese
62021100|NCT03223389|EXPERIMENTAL|10 gastric bypass operated patients|3 different oils ingested at separate study days will be tested against each others ability to induce gut hormone secretion.
62021101|NCT03223389|EXPERIMENTAL|10 healthy control subjects|3 different oils ingested at separate study days will be tested against each others ability to induce gut hormone secretion.
62791978|NCT05932225|EXPERIMENTAL|Systane Complete Preservative-Free|1-2 drops in each eye four times a day for 30 days
62021102|NCT01031823|EXPERIMENTAL|Social Skills Training|All participants will take part in this arm of the study.
62215585|NCT06092619|ACTIVE_COMPARATOR|Control Group|Patients under regular physiotherapy intervention
62215586|NCT06292468|ACTIVE_COMPARATOR|Traditional physical therapy|This group received conventional physical therapy protocol along with foot care guidelines.
62215587|NCT06292468|EXPERIMENTAL|Plantar cutaneous sensory stimulation.|This group received plantar cutaneous sensory stimulation along with conventional physical therapy protocol and foot care guidelines.
62410196|NCT05753592|EXPERIMENTAL|Part 1; LOU064 (Remibrutinib)|Mild and Moderate HI participants and matching healthy participants
62410197|NCT05753592|EXPERIMENTAL|Part 2; LOU064 (Remibrutinib)|Severe HI participants and matching healthy participants
62410198|NCT06650033|ACTIVE_COMPARATOR|Adaptive radiotherapy +/- margin reduction|"Phase 1 and 2: Treating Radiation Therapists (RTs) on the treatment machine will review the treatment target and organs at risk contours that are automatically generated on the plan of the day. They will modify these safely, as required, and then also approve the computer generated re-plan of the day, within the bounds of departmental protocols and decision guides (RT led).~Phase 2 only: Margin reduction facilitated by adaptive radiotherapy."
62791979|NCT02444052|EXPERIMENTAL|Zimmer Puros Cancellous Allograft|Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
62791980|NCT02444052|EXPERIMENTAL|Nobel Biocare Creos Cancellous Allograft|Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
62585058|NCT04562441|EXPERIMENTAL|Axitinib and Avelumab|"Axitinib: 5 mg bd po Day 1 to Day 28~Avelumab: 10mg/kg Day 1 and Day 15 every 4 weeks"
62585059|NCT05978544|EXPERIMENTAL|Itolizumab Dose Level 1|Itolizumab of 50 mg administered by intravenous infusion for once, investigator discretion to continue with the same dose every 3 days up to 7 days.
62585060|NCT05978544|EXPERIMENTAL|Itolizumab Dose Level 2|Itolizumab of 100 mg administered by intravenous infusion for once, investigator discretion to continue with the same dose every 3 days up to 7 days.
62585061|NCT05978544|EXPERIMENTAL|Itolizumab Dose Level 3|Itolizumab of 150 mg administered by intravenous infusion for once, investigator discretion to continue with the same dose every 3 days up to 7 days.
62791981|NCT06056557|EXPERIMENTAL|Interventional|All patients will receive the intervention. That is, all patients will undergo ablation with the experimental catheter (device).
62791982|NCT05154253|EXPERIMENTAL|Device resisted gait training (treatment)|We will conduct a randomized controlled trial (treatment vs. control) to compare functional outcomes following bilateral targeted ankle resistance training (2 visits/week for 12 weeks) vs. dose-matched standard functional gait training.
62791983|NCT05154253|EXPERIMENTAL|Standard gait training (control)|We will conduct a randomized controlled trial (treatment vs. control) to compare functional outcomes following bilateral targeted ankle resistance training (2 visits/week for 12 weeks) vs. dose-matched standard functional gait training.
62791984|NCT05154253|EXPERIMENTAL|Comparison to Standard PT (within subjects control)|We will use a within-subject repeated measures design to compare both gait training groups to matched standard physical therapy.
62021103|NCT03582306|EXPERIMENTAL|High chlorophyll diet - intervention 1st|Participants will complete the 4 week intervention, 4 week washout, then 4 week control period (monitor only)
62215588|NCT00085670||Group 1|Bone marrow failure subjects
62215589|NCT02461329|EXPERIMENTAL|Gelatine solution|"Gelofusine will be administrated like fluid challenge - 250ml of solution will be infused within 5 minutes in case of hypotension ( mean arterial pressure - MAP below 65 mmHg or below 70mmHg in patient with chronic hypertension disease).~The blood pressure and heart rate before and after fluid challenge will be recorded."
62215590|NCT02461329|EXPERIMENTAL|Balanced Crystaloid solution|"Ringerfundin will be administrated like fluid challenge - 250ml of solution will be infused within 5 minutes in case of hypotension ( mean arterial pressure - MAP below 65 mmHg or below 70mmHg in patient with chronic hypertension disease).~The blood pressure and heart rate before and after fluid challenge will be recorded."
62585062|NCT06307860||P group|Perform pulsed field ablation surgery after meeting the inclusion criteria
62585063|NCT06307860||R group|Perform radiofrequency ablation surgery after meeting the inclusion criteria
62585064|NCT04687943||PELOID therapy|A total of 15 sessions of peloid therapy for 3 weeks, 5 days a week for 42 patients in the first group
62215591|NCT00003453|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62410199|NCT06650033|ACTIVE_COMPARATOR|Standard radiotherapy|Patients will receive standard image guided radiotherapy
62410200|NCT06649630|EXPERIMENTAL|Cohort 1 (SAD): NNC0442-0344 A|Participants will receive single dose of NNC0442-0344 A intravenously.
62410201|NCT06649630|EXPERIMENTAL|Cohort 2 (SAD): NNC0442-0344 A|Participants will receive single dose of NNC0442-0344 A intravenously.
62585065|NCT04687943||Kinesio tape|42 patients in group 2 will be given 2 sessions of muscle and fascia correction techniques per week, with kinesio tape application and cold application
62585066|NCT04687943||Exercise|42 patients in the third group will be given 3 sets of 10 repetitions home exercise programs for 3 weeks
62791985|NCT05154253|EXPERIMENTAL|Device assisted ambulation|We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid).
62791986|NCT05154253|EXPERIMENTAL|Passive brace assisted ambulation|We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid).
62215592|NCT00727701|EXPERIMENTAL|1|Will receive usual wound prevention care, aftercare summaries, and regular surveillance.
62215593|NCT00727701|NO_INTERVENTION|2|Will receive usual wound prevention and surveillance only.
62215594|NCT00727701|NO_INTERVENTION|3|Will receive usual wound prevention only.
62215595|NCT04873739||20 patients SLE with dry eye|Anterior segment OCT for SLE patients with dry eye
62599949|NCT06623838||American group|Group/Cohort Description: 22 students in MA in clinical psychology performing the evolutionarily informed case conceptualization.
62791987|NCT05154253|EXPERIMENTAL|No ankle aid ambulation|We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid).
62791988|NCT06486896|ACTIVE_COMPARATOR|Pelvic floor training|The patients will receive pelvic floor training exercise+ advice 3 times/weekly for 8 weeks
62791989|NCT06486896|EXPERIMENTAL|Interferential current|Patients will receive interferential current+pelvic floor training+advice
62791990|NCT02347306||cohort of patients with suspected coronary artery disease|a cohort of patients with suspected coronary artery disease going forward for conventional angiography and (2) whether CT-TCFA is associated with future adverse cardiovascular events.
62791991|NCT00830466|EXPERIMENTAL|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
62791992|NCT05584280||Promus stent on shelf|Control
62791993|NCT05584280||Orsiro stent on shelf|Treatment
62791994|NCT06304623|EXPERIMENTAL|SVF cells treatment|40 subjects were treated with autologous SVF intravenous treatment.
62021104|NCT03582306|EXPERIMENTAL|High chlorophyll diet - control 1st|Participants will complete the 4 week control period (monitor only), 4 week washout, then 4 week intervention
62215596|NCT04873739||30 patients SLE without dry eye|Anterior segment OCT for SLE patients without dry eye
62215597|NCT04873739||50 normal subjects as control group of similar age and gender|Anterior segment OCT for normal subjects
62215598|NCT03836716|EXPERIMENTAL|Arimoclomol|248 mg arimoclomol base (equivalent to 400 mg arimoclomol citrate) 3 times daily
62215599|NCT05451823|EXPERIMENTAL|Post auriclar-frontal|"Frontal sensors will be applied with lead 1 at the center of the forehead; lead 2, 2.8 cm lateral to lead 1; and lead 3 at the temporal area between the lateral canthus and the hairline.~Post auriclar sensors will be applied to the same side of the face, with lead 1 approximately 2.5 cm medial to the mastoid area, post-auricularly next to the hairline. Lead 2 will be attached at the mastoid area and lead 3 will be attached on the same side at the temporal area between the lateral canthus and the hairline."
62410202|NCT06649630|EXPERIMENTAL|Cohort 3 (SAD): NNC0442-0344 A|Participants will receive single dose of NNC0442-0344 A intravenously.
62410203|NCT06649630|EXPERIMENTAL|Cohort 4 (SAD): NNC0442-0344 A|Participants will receive single dose of NNC0442-0344 A intravenously.
62791995|NCT01060852|EXPERIMENTAL|Media Detective|10-lesson elementary school, substance use prevention program developed based upon the Message Interpretation Processing model designed to increase children's critical thinking skills about media messages and reduce intent to use tobacco and alcohol products.
62791996|NCT06168682|EXPERIMENTAL|nasal continuous positive airway pressure|nasal continuous positive airway pressure (3-10cmH20) administered with 6 l/O2 with the SuperNO2VA™ Et produced by Vyaire Medical, Inc.
62791997|NCT06168682|ACTIVE_COMPARATOR|nasal oxygen insufflation|nasal oxygen insufflation with 6 l/02 will be administered as control-group/standard intervention for endoscopy
62791998|NCT02369913||Heart failure subjects|Heart failure subjects undergoing cardiac resynchronization will have a blood drawn for this study.
62215600|NCT05586139|EXPERIMENTAL|Microbiome-directed food (MDF) - MAM|Each (MAM) child will receive a daily ration of MDF corresponding to his weight, for maximum 12 weeks
62791999|NCT02369913||Heart arrhythmia patients|Heart arrhythmia patients undergoing ablation will have a blood drawn for this study.
62792000|NCT05518357|EXPERIMENTAL|LILRB4 STAR-T|LILRB4 STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 25-30mg/m2/day and cyclophosphamide treatment at dose 250-300mg/m2 for 3 days and take a rest for 2 days before infusion. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#1E7 cells/kg
62792001|NCT03987516|EXPERIMENTAL|Active intervention|Patients will be included in an active intervention.
62792002|NCT03987516|NO_INTERVENTION|Control group|Patients in the control group will not receive any intervention
62215601|NCT05586139|ACTIVE_COMPARATOR|Ready-to-use supplementary food (RUSF)|Each (MAM) child will receive a daily ration of MDF corresponding to his weight, for maximum 12 weeks
62410204|NCT06649630|EXPERIMENTAL|Cohort 5 (SAD): NNC0442-0344 A|Participants will receive single dose of NNC0442-0344 A intravenously.
62410205|NCT06649630|EXPERIMENTAL|Cohort 1 (MAD): NNC0442-0344 A|Participants will receive a oral daily dose of NNC0442-0344 A for 10 days.
62215602|NCT05586139|EXPERIMENTAL|Microbiome-directed food (MDF) - SAM|Each (SAM) child will receive a daily ration of MDF corresponding to his weight, for maximum 12 weeks of supplementation.
62215603|NCT05586139|ACTIVE_COMPARATOR|Ready-to-use therapeutic food (RUTF)|Each (SAM) child will receive a daily ration of RUTF corresponding to his weight, for maximum 12 weeks of supplementation
62215604|NCT05712772|EXPERIMENTAL|Blue then Red Light|Blue light (480 nm) then Red light (640 nm)
62410206|NCT06649630|EXPERIMENTAL|Cohort 2 (MAD): NNC0442-0344 A|Participants will receive a oral daily dose of NNC0442-0344 A for 10 days.
62410207|NCT06649630|EXPERIMENTAL|Cohort 3 (MAD): NNC0442-0344 A|Participants will receive a oral daily dose of NNC0442-0344 A for 10 days.
62410208|NCT06649630|EXPERIMENTAL|Cohort 4 (MAD): NNC0442-0344 A|Participants will receive a oral daily dose of NNC0442-0344 A for 10 days.
62792003|NCT01255098||Experimental Group|
62792004|NCT01255098||Control Group|
62792005|NCT00279916|ACTIVE_COMPARATOR|Triamcinolone acetonide|"Triamcinolone acetonide nasal spray; Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms) for 6 weeks duration.~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms) for 6 weeks duration."
62819311|NCT01540279||Cohort two with abdominal wall closure with Monocryl plus|
62819312|NCT01262417|EXPERIMENTAL|- Seprafilm group|patients receiving resorbable barrier membrane during the first surgery
62021105|NCT01323439||Axium™ MicroFX™ PGLA Treated Subjects|This observational evaluation will evaluate early experience using the Axium™ MicroFX™ PGLA COILS as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ Bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol
62215605|NCT05712772|EXPERIMENTAL|Red Light then Blue Light|Red light (640 nm) then Blue light (480 nm)
62215606|NCT00133406|EXPERIMENTAL|a|oral glutamine with juice for 10 days
62215607|NCT00133406|EXPERIMENTAL|b|PO vit A q 4 mo for 1 year plus zinc placebo
62215608|NCT00133406|ACTIVE_COMPARATOR|c|Zinc 40 mg twice weekly Plus Vitamin A Placebo for one year
62215609|NCT00133406|PLACEBO_COMPARATOR|d|oral glycine with juice daily for 10 days
62215610|NCT00133406|PLACEBO_COMPARATOR|e|Vitamin A Placebo plus Zinc Placebo for one year
62215611|NCT00133406|EXPERIMENTAL|f|Vitamin A q 4 months and PO Zinc for 1 year
62215612|NCT06380673|OTHER|Stepwise introduction using gradually shorter heating of cow's milk proteins|"Step 1: open introduction of 20' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 3 months.~Step 2: open introduction of 15' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 3 months.~Step 3: open introduction of 10' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 3 months.~Step 4: open introduction of 5' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 3 months."
62410209|NCT06649630|PLACEBO_COMPARATOR|SAD: Placebo|Participants will receive single dose of placebo intravenously.
62215613|NCT06380673|OTHER|Stepwise introduction using the Flemish Milk Ladder|"The first 5 steps of the Flemish Milk Ladder (each containing a, b and c part) will be gradually introduced at home, each step for 21 days (2-3X a week during 3 consecutive weeks after which 3 days rest). We consider the 6th step the equivalent of tolerance induction so step 6 will be allowed once the OFC with uncooked milk is passed."
62215614|NCT06380673|OTHER|Control arm with introduction of 20' cooked cow's milk|Step 1: open introduction of 20' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 12 months.
62215615|NCT06380673|OTHER|Healthy age-matched subjects|For work package 2, 15 healthy age-matched subjects are included to compare immunological mechanisms with.
62215616|NCT05322746|EXPERIMENTAL|Group A|"Focal Muscle vibration will be apply to:~1. Tibialis anterior~2. The distal quadriceps~3. Belly of the gastrocnemius/soleus muscles.~4. Sinusoidal vibration intensity range 120 Hz.~5. Each muscle will vibration for 10 minutes~6. 10 minutes per muscle duration; total 30 minutes"
62215617|NCT05322746|ACTIVE_COMPARATOR|Group B|"Focal Muscle vibration similar to Group A with following:~Conventional Therapy TENS with pulse width 250ms, intensity 14Hz for 30 minutes~Exercise therapy:~Stretching Exercise to:~1. Calf~2. Hamstring~3. Quadriceps"
62215618|NCT05322746|ACTIVE_COMPARATOR|Group C|"TENS with pulse width 250ms, intensity 14Hz for 30 minutes~Exercise therapy:~Stretching Exercise to:~1. Calf~2. Hamstring~3. Quadriceps"
62215619|NCT05517187|PLACEBO_COMPARATOR|Blood Clot BC (Control arm)|Regenerative endodontic treatment with induced Blood Clot in root canal space as a secondary treatment for failed root canal treated incisors
62215620|NCT05517187|EXPERIMENTAL|Platelets Rich Fibrin PRF (Intervention)|Regenerative endodontic treatment with Platelet- rich fibrin in root canal space as a secondary treatment for failed root canal treated incisors
62215621|NCT04301531|EXPERIMENTAL|Arm 1 (intervention arm)|Arm 1 or the intervention arm will involve seven communities: 4-monthly mass screening, and treatment of those who test positive by CHWs will be conducted. Febrile cases will be tested and treated by CHWs any time
62215622|NCT04301531|OTHER|Arm 2 (control arm)|Arm 2 or the Control arm will involve 2 communities: mass screening and treatment only done at baseline and at evaluation. Febrile cases will be tested and treated by CHWs any time.
62215623|NCT02350985|ACTIVE_COMPARATOR|Propranolol|Propranolol up to 160 mg/day
62215624|NCT02350985|ACTIVE_COMPARATOR|Venlafaxine|Venlafaxine up to 150 mg/day
62410210|NCT06649630|PLACEBO_COMPARATOR|MAD: Placebo|Participants will receive a oral daily dose of Placebo for 10 days.
62215625|NCT06193304|EXPERIMENTAL|Eliglustat|Three repeated doses of eliglustat solution, separated by 2-hour intervals, held in the mouth for 30 seconds with swishing but without ingestion
62215626|NCT00821717|EXPERIMENTAL|1:|
62215627|NCT00821717|PLACEBO_COMPARATOR|2|
62215628|NCT06213259|EXPERIMENTAL|KD6005 (Healthy)|Healthy participants will receive a single dose of KD6005 in dose escalation cohorts subcutaneously (SQ).
62215629|NCT06213259|PLACEBO_COMPARATOR|Placebo (Healthy)|Healthy participants will receive a single dose of placebo, SQ.
62215630|NCT06213259|EXPERIMENTAL|KD6005(RA)|Participants with RA will receive a multiple-dose of KD6005 in dose escalation cohorts, SQ.
62215631|NCT06213259|PLACEBO_COMPARATOR|Placebo (RA)|Participants with RA will receive a multiple-dose of placebo, SQ.
62215632|NCT00765453|EXPERIMENTAL|Intracoronary|Patients will be randomised in a 1:1 ratio to receive intracoronary injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
62215633|NCT00765453|PLACEBO_COMPARATOR|Placebo|Placebo infusion
62215634|NCT02969811||Severely Anaemic|Patients with Hb 90 g/L or less
62215635|NCT02969811||Non-Anaemic|Patients with Hb greater than 90 g/L
62215636|NCT04339959||Phase I|First, we will test proof-of-concept that participants will be able to follow the testing protocol and use the tablet computer to communicate with the investigator (10-12 participants). The test protocol will be refined based on what is learned after a minimum of 10 participants. We anticipate no more than 12 participants needed for this phase.
62215637|NCT04339959||Phase II|Next, 10-20 new participants will be enrolled to evaluate the validity of videoconference vs. face-to-face assessment (i.e., direct observation) of physical performance. Communication will occur between the remote assessor and the participant. The direct observer will not communicate directly to the participant, unless there is a safety issue. After completing 10 participants without a major change in the test protocol, we will proceed to the next phase.
62243245|NCT06734624||Follicular lymphoma (FL)|Patents with newly diagnosed FL, or FL receiving CART or Bispecific antibody treatment
62410211|NCT06649214|EXPERIMENTAL|Olanzapine-samidorphan|
62410212|NCT06649214|ACTIVE_COMPARATOR|Olanzapine|
62021106|NCT04098627|EXPERIMENTAL|Intervention|Once weekly 30-minute long group laughter therapy session for 8 weeks while patients are on dialysis
62021107|NCT04098627|NO_INTERVENTION|Usual Care|Usual care
62215638|NCT04339959||Phase III|This phase involves participants repeating the test protocol, but without the face-to-face assessment (i.e., direct observation). This will test the ability of the participant to receive the box of test instructions and materials in the mail, unpack the box, communicate with the remote assessor via videoconferencing, pack up the box, and return it (postage paid) to the study team. This step will involve 5-10 participants from Phases 1 and 2, who have provided approval for future contact (see approved Future Contact form). Once 5 participants have successfully and safely completed the test protocol, we will proceed to Phase 4.
62215639|NCT04339959||Phase IV|This phase is the same as Phase 3, except it includes newly enrolled participants, i.e., representing the first-time participants have enrolled/participated in this study. This will eliminate the practice effect that will occur in phase 3. This step will enroll 5-10 participants.
62792006|NCT00279916|SHAM_COMPARATOR|Placebo|"Placebo nasal spray; Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily for 6 weeks duration.~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily for 6 weeks duration."
62215640|NCT03069703|ACTIVE_COMPARATOR|Prime-boost strategy|a single dose of 13-valent pneumococcal conjugate vaccine (Prevenar, PCV13) at Day 0 (lying within a window of ± 2 days of the first infusion of rituximab), followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPV23) at month 5 (M5)
62410213|NCT00887965|OTHER|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
62410214|NCT06568523|OTHER|Patients will undergo colonoscopy with the real-time use of the MAGENTIQ-COLO technology.|Endoscopists will assess all colorectal polyps detected during colonoscopy with and without the MAGENTIQ-COLO.
62410215|NCT06006416|EXPERIMENTAL|Fenugreek Fibre|Fenugreek Fibre - 2 x 10g powder per day with/in food
62792007|NCT00649428|EXPERIMENTAL|Active|
62585067|NCT02660281|OTHER|Full Intensity TBI-based Conditioning|Total Body Irradiation 1200 cGy of 150 cGy over 4 or 5 days, days -5 or -4 to -1 Fludarabine 30 mg/m2/day x 3 days, days -6, -5, -4 Stem Cell Infusion, day 0 Post- Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Mesna 50 mg/kg/day x 2 days, days +3 and +4
62585068|NCT02660281|OTHER|Full Intensity Chemo-Only Conditioning|Fludarabine 25 mg/m2/day x 5 days, days -6, -5, -4, -3, -2 Busulfan 130 mg/m2/day x 4 days, days -6, -5, -4, -3 Pre-Stem Cell Infusion Cyclophosphamide 14.5 mg/kg/day x 2 days, days -3 and -2 Pre-Stem Cell Infusion Mesna 14.5 mg/kg/day x 2 days, days -3 and -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell Infusion Mesna 50 mg/kg/day x 2 days, days +3 and +4
62792008|NCT00649428|PLACEBO_COMPARATOR|Control|
62792009|NCT01551849||VA-ECMO patients|Patients placed on VA-ECMO support for primary cardiac dysfunction.
62792010|NCT03213288|ACTIVE_COMPARATOR|Delphinidin type anthocyanins|Bilberry extract
62792011|NCT03213288|ACTIVE_COMPARATOR|Cyanidin type anthocyanins|Black rice extract
62792012|NCT03213288|PLACEBO_COMPARATOR|Placebo|No anthocyanins
62792013|NCT02952833|EXPERIMENTAL|Group 1|5.0 mcg ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25 (2 Sentinel subjects will receive intervention prior to remaining 23 subjects), Placebo for 5 subjects
62215641|NCT03069703|EXPERIMENTAL|Innovative vaccine strategy 1|2 doses of PCV13 at Day 0 and 2 doses of PCV13 at Day 7, followed by a single dose of PPV23 at M5
62215642|NCT03069703|EXPERIMENTAL|Innovative vaccine strategy 2|4 doses of PCV13 at Day 0, followed by a single dose of PPV23 at M5
62215643|NCT06139185||Patients with nasal septum deviation|
62215644|NCT06139185||Patients without nasal septum deviation|
62215645|NCT02201615|EXPERIMENTAL|Perineal Massage & Control|"Perineal Massage every 30 min, a 10 min 4 times in the first stage of labour, 1 times in the second stage of labour.~Control routine care procedure at the clinic."
62215646|NCT00080093|EXPERIMENTAL|1|Participants will receive individual feedback and specially-tailored manuals at study entry and at Months 2 and 4
62410216|NCT06506669|EXPERIMENTAL|Intervention|Oral sedation will be administered to patients prior to the procedure.
62410217|NCT06506669|PLACEBO_COMPARATOR|Placebo|An oral placebo pill will be administered to patients prior to the procedure.
62410218|NCT01655784|ACTIVE_COMPARATOR|Eighteen Coils (0.014-0.0155 inch)|Subjects who randomize to this arm will receive larger diameter bare platinum coils for treatment of their cerebral aneurysm. Subjects in this arm could receive a combination of the following protocol approved intracranial coils depending on the phase: Target XL 360 Standard, Target XL 360 Soft, Target XL 360 Helical, GDC-18 360 Standard, GDC-18 3D, GDC-18 2D, GDC-18 Soft, and/or 0.014-0.0155 inch diameter bare platinum intracranial coils.
62585069|NCT02660281|OTHER|Reduced Intensity Conditioning|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Melphalan 140 mg/m2/day x 1 day, day -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell InfusionMesna 50 mg/kg/day x 2 days, days +3 and +4
62792014|NCT02952833|EXPERIMENTAL|Group 2|2.5 mcg ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25, Placebo for 5 subjects
62792015|NCT02952833|EXPERIMENTAL|Group 3|10 mcg of ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25, (2 Sentinel subjects will receive intervention prior to remaining 23 subjects) Placebo for 5 subjects
62792016|NCT01887184|PLACEBO_COMPARATOR|Normal Saline|Normal saline was given intranasally
62792017|NCT01887184|ACTIVE_COMPARATOR|Dexmedetomidine|1.5mcg dexmedetomidine was given intranasally before procedure
62792018|NCT01961622|EXPERIMENTAL|Florence D2A Closed Loop Glucose control|Subjects glucose levels are controlled by Florence D2A or similar closed loop insulin delivery system
62021108|NCT02970344|EXPERIMENTAL|Diabetes Coping Skills training (DCST)|Twelve sessions are delivered over 6 months using a faded contact model involving 6 weekly sessions, 3 biweekly sessions and 3 monthly sessions.
62215647|NCT00080093|EXPERIMENTAL|2|Participants will receive general HIV information feedback and the best-available informational manual at study entry and at Months 2 and 4
62215648|NCT06493227|ACTIVE_COMPARATOR|Intraoperative strategy|Policy of no routine use of fibrinolysis inhibitors after surgery. Patients in this group will receive the center's routine prophylactic dose of fibrinolysis inhibitor, which is 100%, during surgery.
62215649|NCT06493227|EXPERIMENTAL|Intraoperative and postoperative strategy|Policy of routine use of fibrinolysis inhibitors 4 hours after surgery. Patients in this group will receive 70% of the routine prophylactic dose of fibrinolysis inhibitor administered by the center during surgery. Additionally, they will receive 30% of the dose as an IV infusion within 4 hours after the surgery.
62215650|NCT00905385|EXPERIMENTAL|Low Dose: 3,200 CFU|5 subjects inoculated with 3,200 colony forming units (CFU).
62410219|NCT01655784|ACTIVE_COMPARATOR|Standard Coils (0.014 inch)|Subjects who randomize to this arm will receive the standard diameter bare platinum coils for treatment of their cerebral aneurysm. Subjects in this arm could receive a combination of the following protocol approved intracranial coils depending on the phase: Target 360 Standard, Target 360 Soft, Target 360 Ultra, Target 360 NANO, Target 360 Helical Ultra, GDC-10 360 Standard SR, GDC-10 360 Soft SR, GDC-10 UltraSoft, GDC-10 3D, GDC-10 2D, GDC-10 Soft 2D SR, GDC-10 Soft SR, GDC-10 Soft, and/or any additional 0.014 inch or less diameter bare platinum intracranial coils.
62215651|NCT00905385|EXPERIMENTAL|High Dose: 32,000 CFU|5 subjects inoculated with 32,000 colony forming units (CFU).
62215652|NCT03392285||Internal fixation|Patients above 65years old with an undisplaced femoral neck fractures treated with primary internal fixation with screws.
62215653|NCT03392285||Hip arthroplasty|Patients above 65years old with a displaced femoral neck fractures treated with primary hip arthroplasty.
62215654|NCT03422198|EXPERIMENTAL|Short course vaginal cuff brachytherapy|Participants undergo short course vaginal cuff brachytherapy for 2 fractions with 1 week apart.
62215655|NCT03422198|ACTIVE_COMPARATOR|Vaginal cuff brachytherapy|Participants undergo standard of care vaginal cuff brachytherapy for 3-5 fractions over no more than 3 weeks.
62215656|NCT04752410|EXPERIMENTAL|Selective Brachial plexus block|Selective brachial plexus block will be done under ultrasound guidance to patients scheduled for upper extremity surgeries. Local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 25ml) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anesthetize the whole upper limb.
62215657|NCT01027832|NO_INTERVENTION|Control arm|no intervention
62215658|NCT01027832|EXPERIMENTAL|Experimental arm|antibiotics
62215659|NCT03095677|EXPERIMENTAL|Apnea Group (GApn)|Program of training with exercises including apneas
62215660|NCT03095677|OTHER|Control Group (GC)|Program of training with exercises without apnea
62410220|NCT01966185|NO_INTERVENTION|Tutor function off|The tutor function will be off for 12 out of 12 repeat simulations.
62410221|NCT01966185|EXPERIMENTAL|Tutor function on|The group will have the tutor function on for the 5 first out of 12 repeat simulation sessions.
62410222|NCT01431807|EXPERIMENTAL|SYR-472 group|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
62410223|NCT01826617||Prostate Cancer- Indolent type|Patients diagnosed with Indolent type will be classified according to Epstein Criteria on histopathology results and National Comprehensive Cancer Network (NCCN) guideline recommended classification
62599950|NCT04178642|EXPERIMENTAL|(experimental group)|Evaluating the efficacy of an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin-Lipiodol (experimental group)
62792019|NCT01961622|ACTIVE_COMPARATOR|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (FreeStyle Navigator CGM)
62021109|NCT02970344|NO_INTERVENTION|Diabetes Education|one 60 minute diabetes education session.
62215661|NCT03114787|OTHER|Patient receiving respiratory physiotherapy|
62215662|NCT03114787|OTHER|Patient not receiving respiratory physiotherapy|
62215663|NCT01983254|EXPERIMENTAL|Coping skills training|6 sessions of weekly telephone-based coping skills training delivered by trained interventionist
62215664|NCT01983254|ACTIVE_COMPARATOR|education program|6 week access to a web-based, critical illness-specific education program
62215665|NCT01357941||Prior VTE minor transient risk factor|Pregnant women with a single prior VTE episode that was either unprovoked or associated with a minor transient risk factor - Prophylaxis with fixed-dose LMWH
62215666|NCT01357941||Prior VTE major transient risk factor|Pregnant women with a single prior VTE episode that was provoked by a major transient risk factor - Surveillance
62215667|NCT02248181||Idiopathic PD patients|
62021110|NCT00226941|EXPERIMENTAL|Group 1 - Cetuximab + Capecitabine-800 + XRT + Oxaliplatin-100|"* Cetuximab 250 mg/m² / week~* Capecitabine 800 mg/m²~* Radiotherapy (XRT)~* Oxaliplatin 100 mg/m², Days 2 and 23"
62021111|NCT00226941|EXPERIMENTAL|Group 2 - Cetuximab + Capecitabine-700 + XRT + Oxaliplatin-85|"* Cetuximab 250 mg/m² / week~* Capecitabine 700 mg/m²~* Radiotherapy (XRT)~* Oxaliplatin 85 mg/m², Days 2 and 23"
62215668|NCT02940600|EXPERIMENTAL|Normothermic machine perfusion|Patients undergoing liver transplant with grafts preserved using normothermic machine perfusion
62215669|NCT02940600|ACTIVE_COMPARATOR|Static cold storage|Patients undergoing liver transplant with statically cold preserved grafts
62215670|NCT03848143|EXPERIMENTAL|BOTOX|"Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection.~1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C).~Each patient will receive 50 U of onabotulinum toxin A."
62215671|NCT04677829|EXPERIMENTAL|PNT001 1000mg|PNT001 diluted in 5% dextrose for infusion
62215672|NCT04677829|EXPERIMENTAL|PNT001 4000mg|PNT001 diluted in 5% dextrose for infusion
62599951|NCT04178642|ACTIVE_COMPARATOR|(standard group)|The absence of adjuvant treatment (standard group).
62585070|NCT02660281|OTHER|Non-Myeloablative Conditioning|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Pre-Stem Cell Infusion Cyclophosphamide 14.5 mg/kg/day x 2 days, days -3 and -2 Pre-Stem Cell InfusionMesna 14.5 mg/kg/day x 2 days, days -3 and -2 Total Body Irradiation 200 cGy, day -1 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, day +3 and +4 Post-Stem Cell Infusion Mesna 50 mg/kg/day x 2 days, day +3 and +4
62585071|NCT02660281|OTHER|Reduced Intensity Conditioning with Addition of Thiotepa|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Thiotepa 8 mg/kg, day -3 Melphalan 140 mg/m2/day x 1 day, day -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell InfusionMesna 50 mg/kg/day x 2 days, days +3 and +4
62585072|NCT05986578|EXPERIMENTAL|dlPFC then dmPFC then Sham iTBS|
62585073|NCT05986578|EXPERIMENTAL|dmPFC then dlPFC then sham iTBS|
62585074|NCT05986578|EXPERIMENTAL|dmPFC then sham iTBS then dlPFC|
62585075|NCT05986578|EXPERIMENTAL|dlPFC then sham iTBS then dmPFC|
62585076|NCT05986578|EXPERIMENTAL|sham iTBS then dlPFC then dmPFC|
62585077|NCT05986578|EXPERIMENTAL|shami iTBS then dmPFC then dl PFC|
62585078|NCT06642506||Primary resection|Patients with esophageal adenocarcinoma who underwent esophagectomy without prior neoadjuvant therapy.
62021112|NCT00226941|EXPERIMENTAL|Group A - Cetuximab + Capecitabine-800 + XRT|"* Cetuximab 250 mg/m² / week~* Capecitabine 800 mg/m²~* Radiotherapy (XRT)"
62215673|NCT04677829|PLACEBO_COMPARATOR|Placebo|5% dextrose for infusion
62215674|NCT04997447|EXPERIMENTAL|Intervention group|Two weeks of daily step reduction (limited to 2000 steps per day) followed by four weeks of supervised gym-based exercise rehabilitation (twice per week strength training and twice per week cycle endurance training)
62215675|NCT04997447|NO_INTERVENTION|Control group|Continued monitoring of habitual daily step count without structured intervention. Classic control.
62215676|NCT05048654||Group A: Retrospective|Retrospectively, there will be an abstract of AMH and FSH from survivors seen at CHCO and UCH from October 1st, 2016 to September 31st, 2019 and assess time points.
62410224|NCT01826617||Prostate cancer- aggressive type|Patients diagnosed with aggressive type will be classified according to Epstein criteria on final histopathology findings and NCCN guideline recommended classification
62410225|NCT01826617||Acute Prostatitis|Patient diagnosed with Acute prostatitis- according to histopathology description of Biopsy result
62410226|NCT01826617||Chronic Prostatitis|Patient diagnosed with Chronic prostatitis- according to histopathology description of Biopsy result
62410227|NCT01826617||Benign Prostatic Nodular Hyperplasia|Patient diagnosed with Benign Prostatic Nodular Hyperplasia- according to histopathology description of Biopsy result
62410228|NCT06056323|EXPERIMENTAL|HB0045|HB0045 IV every 3 weeks (q3w)
62410229|NCT02983773|EXPERIMENTAL|High THC dose|1 marijuana cigarette (7.2% THC)
62215677|NCT05048654||Group B: Prospective|Prospectively, survivors will be evaluated by a member of the FPRLE team in the outpatient clinic at 12 months post-therapy completion and every 6 months to 36 months as part of clinical care. Per standard of care AMH and FSH will be drawn at each time point.
62243246|NCT06734624||Haemophagocytic lymphohistiocytosis (HLH)|Patients who develop HLH with any underlying trigger factor.
62410230|NCT02983773|EXPERIMENTAL|Low THC dose|1 marijuana cigarette (3.0% THC)
62410231|NCT02983773|PLACEBO_COMPARATOR|Placebo|Placebo marijuana cigarette
62410232|NCT04035993|EXPERIMENTAL|Intervention group|
62410233|NCT05167994|EXPERIMENTAL|Anlotinib arm|Pre-operative IMRT with concurrent and sequential Anlotinib
62410234|NCT00293605||1|C-stem implant
62410235|NCT00293605||2|Charnley Implant
62410236|NCT00293605||3|Exeter Implant
62410237|NCT06582680|EXPERIMENTAL|Placebo, then Propranolol, then Metoprolol|
62585079|NCT06642506||Regression Grade 1|Patients with esophageal adenocarcinoma who received four cycles of neoadjuvant FLOT chemotherapy and subsequently underwent oncological esophagectomy. Final pathology revealed a regression grade of 1 according to the Becker classification.
62585080|NCT06642506||Regressions Grade 3|Patients with esophageal adenocarcinoma who received four cycles of neoadjuvant FLOT chemotherapy and subsequently underwent oncological esophagectomy. Final pathology revealed a regression grade of 3 according to the Becker classification.
62243247|NCT01081457|ACTIVE_COMPARATOR|ON|Stimulator switched ON
62410238|NCT06582680|EXPERIMENTAL|Placebo, then Metoprolol, then Propranolol|
62410239|NCT06582680|EXPERIMENTAL|Propranolol, then Placebo, then Metoprolol|
62410240|NCT06582680|EXPERIMENTAL|Propranolol, then Metoprolol, then Placebo|
62410241|NCT06582680|EXPERIMENTAL|Metoprolol, then Placebo, then Propranolol|
62410242|NCT06582680|EXPERIMENTAL|Metoprolol, then Propranolol, then Placebo|
62410243|NCT05173922|EXPERIMENTAL|Safety in Dementia|Safety in Dementia is an online tool that, in a stepwise fashion, guides a caregiver individual through decisions related to firearm access for a person with dementia. It includes information and a comparison of the options and their risks and benefits. It guides the caregiver through clarification of personal feelings and values and identifying their decision/plan.
62410244|NCT05173922|ACTIVE_COMPARATOR|Web control|The control group will view National Institute on Aging Home Safety Checklist.
62410245|NCT00488007|EXPERIMENTAL|Active Hearing aids|Active
62410246|NCT00488007|PLACEBO_COMPARATOR|Inactive Hearing aids|Hearing aids turned off
62410247|NCT03461653|OTHER|Telemedicine counselling|intervention group Women who will receive telemedicine counselling
62410248|NCT03461653|NO_INTERVENTION|Standard care|Women who will receive standard face-to-face counselling
62410249|NCT06651307|EXPERIMENTAL|Lifting with elbow sleeves|Lifting with elbow sleeves
62585081|NCT00904761|EXPERIMENTAL|exercise|arm: intervention
62585082|NCT04665037|EXPERIMENTAL|Panel A: POS IV|Posaconazole 6 mg/kg body weight administered in a single dose by IV infusion on Day 1.
62585083|NCT04665037|EXPERIMENTAL|Panel B: POS IV|Posaconazole 6 mg/kg body weight administered twice daily by IV infusion on Day 1, and then once daily from Day 2 to a maximum 84 days.
62585084|NCT04665037|EXPERIMENTAL|Panel B: POS PFS|Following a minimum of 7 days IV dosing, participants as clinically able will be transitioned from POS IV to POS PFS nominal 6 mg/kg body weight based on weight bands administered on Day 8, once daily to a maximum 84 days.
62021113|NCT00226941|EXPERIMENTAL|Group B - Cetuximab + Capecitabine-1000 + XRT|"* Cetuximab 250 mg/m² / week~* Capecitabine 1000 mg/m²~* Radiotherapy (XRT)"
62215678|NCT03683303|EXPERIMENTAL|mobile applications (APP)|"A total of 70 participants were randomized to each group for 35 people, the control group receiving the oral patient education and the experimental group receiving patient education using mobile applications. Both groups collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
62410250|NCT06651307|NO_INTERVENTION|Lifting without elbow sleeves|Lifting without elbow sleeves
62410251|NCT06651424|EXPERIMENTAL|Experimental group|Pregnants will take 1 capsule with a combination of probiotics (no comercial) daily from the 32nd week gestation to the 4th week postpartum (approximately 12 weeks).
62410252|NCT06651424|PLACEBO_COMPARATOR|Control group|Pregnants will take 1 capsule with maltodextrin daily from the 32nd week gestation to the 4th week postpartum (approximately 12 weeks).
62585085|NCT02572076|EXPERIMENTAL|Motus Cleansing System (MCS)|The MCS enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter \& fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
62021114|NCT05126238|EXPERIMENTAL|Lithium|In preoperative period patients will take 300mg of lithium carbonate on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery, they will take 300mg of lithium carbonate 2 hours before surgery. After the surgery, patients will take 300mg of lithium carbonate in the afternoon and 300mg of lithium carbonate in the evening.
62243248|NCT01081457|SHAM_COMPARATOR|OFF|Stimulator switched OFF
62585086|NCT02611271||Piperacillin/Tazobactam|Critically ill patients teated with piperacillin/tazobactam undergoing renal replacement therapy and cytosorb absorption during sepsis
62585087|NCT02611271||Imipenem/Cilastatin|Critically ill patients teated with imipenem/cilastatin undergoing renal replacement therapy and cytosorb absorption during sepsis
62585088|NCT01177293|ACTIVE_COMPARATOR|treatment A - reference w/ water|
62585089|NCT01177293|EXPERIMENTAL|Treatment B - ODT (test) w/o water|
62585090|NCT05448963|EXPERIMENTAL|Robotic mastectomy|Patients receive unilateral or bilateral robot-assisted nipple-sparing mastectomy with or without axillary lymph node dissection
62585091|NCT02360150|EXPERIMENTAL|second propeller arm scanner|The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement to the inclusion visit.
62585092|NCT05726838||Inclisiran|Patients prescribed inclisiran on top of standard of care lipid-lowering therapy
62738612|NCT01604525|EXPERIMENTAL|Tailored Web plus Peer Coaching|Participants randomized to this arm received access to weekly tailored health and wellness web content, plus weekly feedback from a peer health coach (videos uploaded to the web and phone calls).
62738613|NCT01244230|EXPERIMENTAL|Age 6 months - 2 years|Patients between 6 months and 2 years old - Type: Experimental
62738614|NCT01244230|EXPERIMENTAL|Age 2 - 11 years|Patients between 2 and 11 years (and under 10.5 kg)
62738615|NCT01244230|EXPERIMENTAL|Age 2 - 11 years (and over 10.5 kg)|Patients between 2 and 11 years (and over 10.5 kg)
62021115|NCT05126238|PLACEBO_COMPARATOR|Placebo|In preoperative period patients will take placebo on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery, they will take placebo 2 hours before surgery. After the surgery, patients will take placebo in the afternoon and in the evening.
62243249|NCT01116518|ACTIVE_COMPARATOR|physiotherapy|
62021116|NCT05487157||Actively employed social workers in Hungary|"Eligibility criteria: Social workers in Hungary, who are actively employed, 18 years of age or older, working in the field of elderly care.~Exclusion criteria: people, who do not have an active employment; currently have no job; working online; non-professional staff working in social care (eg. cleaning, maintenance)"
62021117|NCT05987267|EXPERIMENTAL|multidisciplinary precision care group|Give the intervention of nurse-led multidisciplinary precision care
62021118|NCT05987267|NO_INTERVENTION|control group|standard care according to guidelines
62243250|NCT01116518|ACTIVE_COMPARATOR|acromioplasty|
62243251|NCT01116518|ACTIVE_COMPARATOR|acromioplasty and rotator cuff reconstruction|
62243252|NCT05231629|EXPERIMENTAL|Arm A|3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance in MRD negative patients
62243253|NCT05231629|ACTIVE_COMPARATOR|Arm B|AHCT intensification followed by 13 cycles of Dara-R maintenance in MRD negative patients
62243254|NCT05231629|EXPERIMENTAL|Arm C|AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance in MRD positive patients
62243255|NCT05231629|ACTIVE_COMPARATOR|Arm D|AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance in MRD positive patients
62243256|NCT05231629|OTHER|Arm M|Induction - 6 cycles of Dara-VRd in all participants
62243257|NCT03846739|ACTIVE_COMPARATOR|Oxytocin & Placebo, 6 IU|Intranasal administration, 6 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
62243258|NCT03846739|ACTIVE_COMPARATOR|Oxytocin & Placebo, 12 IU|Intranasal administration,12 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
62243259|NCT03846739|ACTIVE_COMPARATOR|Oxytocin & Placebo, 24 IU|Intranasal administration, 24 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
62243260|NCT05474066||Pre and Post Training|A sample will be recruited from a group of 20 CAF SOF personnel ages 18-65 will be assessed twice: pre and post-special forces military training. All members enrolled in this training will be invited to participate in the study. Testing periods will be about 4 weeks apart, with post training testing within 1 week of conclusion of the exercise. Patients will be recruited from within the Canadian Special Operation Forces community. Recruitment and study will take place starting in September 2022 and continue until complete which is estimated to be approximately 12 months. Participants will be made aware of the study through recruitment letter sent as part of their training package (Appendix A). They will be allowed questions prior to enrollment or at any point during participation.
62215679|NCT03683303|ACTIVE_COMPARATOR|oral education|"A total of 70 participants were randomized to each group for 35 people, the control group receiving the oral patient education and the experimental group receiving patient education using mobile applications. Both groups collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
62215680|NCT01867333|EXPERIMENTAL|Arm 1 - Enzalutamide alone|Enzalutamide alone. Enzalutamide will be given at the standard dose of 160 mg daily.
62215681|NCT01867333|EXPERIMENTAL|Arm 2 - Enzalutamide with Prostate-Specific Antigen (PSA)-TRICOM|Enzalutamide with PSA-TRICOM. Enzalutamide will be given at the standard dose of 160 mg daily with vaccine given week 1 (vaccinia-PSA-TRICOM, 2x10(8) infectious units subcutaneously) and then week 3, 5 and then monthly fowlpox-vaccine (1x10(9) infectious units subcutaneously).
62215682|NCT03256981|EXPERIMENTAL|SBRT and continued TKI therapy|"Patients will continue to receive background TKI treatment as prior to trial entry.~Simultaneous administration (SBRT \& TKI) or break in TKI during SBRT will be by centre preference and determined prior to commencing recruitment.~Repeat SBRT will be permissible upon development of subsequent OPD lesions dependent on SBRT suitability and total progression lesion number at any one point remaining ≤ 5."
62215683|NCT03256981|ACTIVE_COMPARATOR|Continued TKI therapy alone|Continuation on the same background TKI treatment as prior to trial entry
62410253|NCT05507671|ACTIVE_COMPARATOR|BCG vaccine|BCG (Bacillus Calmette-Guérin) vaccine - 0,1ml intradermal
62585093|NCT05796466|EXPERIMENTAL|How-to Parenting Program|The How-to Parenting Program is a highly structured and skill-based program. It is manualized, teaches 30 concrete, specific, easy-to-grasp (e.g., taught using comic strips), and readily applicable skills. It also optimizes learning with exercises (e.g., perspective taking; role-playing) and practice, and addresses parents' readiness and motivation to change. The program is delivered over six consecutive 2-hour weekly sessions (12 hours in total).
62410254|NCT05507671|PLACEBO_COMPARATOR|Placebo|Solvent of BCG vaccine - 0,1ml intradermal
62410255|NCT05042128|EXPERIMENTAL|Cohort A: Standard Care + LSTA1 (1 dose)|Participants will receive nab-paclitaxel 125mg/m2; LSTA1 3.2mg/kg IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
62585094|NCT05796466|ACTIVE_COMPARATOR|Nobody's Perfect Program|Based on andragogy principles, parents following the Nobody's Perfect curriculum will learn how to solve problems with their child and engage in theme-related activities meant to increase awareness of parents' own needs, child behaviors, development, health, and safety. There is no pre-determined order for themes and time devoted to each one varies according to parents' needs. The program is delivered over six consecutive 2-hour weekly sessions (12 hours in total).
62585095|NCT01475851|EXPERIMENTAL|GSK548470 300 mg|GSK548470 300 mg tablet is administered orally once daily
62585096|NCT06666842|EXPERIMENTAL|Noom Weight|Participate in a 16-week fully remote digital weight management program focusing on weight loss and management via behavioral change
62585097|NCT06666842|ACTIVE_COMPARATOR|Educational Control|Receive 16 weekly weight loss-related educational emails based on the United States Department of Agriculture (USDA) Dietary Guidelines
62585098|NCT02312466||School aged children|
62021119|NCT04368936||FS: Febrile Seizures|Involved patient with diagnosed Febrile Seizures which were hospitalized or recieved ambulatory treatment in University Children´s Hospital in Belgrade. Ages 1-14 years
62021120|NCT04368936||CN: Control group|The control group was made of healthy children older than 5 years of age, which have never had any neurological disorders in their anamnesis and who were patients in preschool or school dispensaries in the city of Belgrade
62410256|NCT05042128|PLACEBO_COMPARATOR|Cohort A: Standard Care + Placebo|Participants will receive nab-paclitaxel 125mg/m2; placebo IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
62410257|NCT05042128|EXPERIMENTAL|Cohort B: Standard Care +LSTA1 (2 doses)|Participants will receive nab-paclitaxel 125mg/m2; LSTA1 3.2mg/kg IV; Gemcitabine 1000mg/m2, and then +\~4hrs LSTA1 3.2mg/kg IV on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
62410258|NCT05042128|PLACEBO_COMPARATOR|Cohort B: Standard Care + Placebo|Participants will receive nab-paclitaxel 125mg/m2; placebo IV; Gemcitabine 1000mg/m2, and then +\~4hrs matching placebo IV on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
62410259|NCT05879796||envafolimab combined with endostar and concurrent chemoradiotherapy|Concurrent Chemoradiation； Envafulimab,150mg, subcutaneous, QW. Maintenance therapy until disease progression, or intolerable toxicity, or up to 1 year; Endostar, administered at a dose of 75 mg/day, QW, was administered by intravenous pump on day 1 of each cycle, and the first dose was administered on the first day of radiotherapy, 6 cycles in total.
62585099|NCT02312466||Pregnant women|
62585100|NCT02312466||Women of reproductive age|
62585101|NCT02881320|EXPERIMENTAL|Cohort 1 (12 to < 18 years of age and weight ≥ 35 kg)|"* Part A: Participants will participate in an Intensive PK evaluation at Week 2 or Week 4 and continue to receive the adult strength B/F/TAF FDC through Week 48.~* Part B: Following confirmation of BIC PK data from Cohort 1 Part A, participants will receive the adult strength B/F/TAF through Week 48."
62819313|NCT01262417|OTHER|- No-treatment control group|patients without seprafilm barrier during the first surgery
62585102|NCT02881320|EXPERIMENTAL|Cohort 2 (6 to < 12 years of age and weight ≥ 25 kg)|"* Part A: Participants will participate in an Intensive PK evaluation at Week 2 or Week 4 and continue to receive the adult strength B/F/TAF FDC through Week 48.~* Part B: Following confirmation of BIC PK data from Cohort 2 Part A, participants will receive the adult strength B/F/TAF FDC through Week 48."
62585103|NCT02881320|EXPERIMENTAL|Cohort 3 (≥ 2 years of age and weight ≥ 14 to < 25 kg)|"* Part A: Participants will participate in an Intensive PK evaluation at Week 2 after which they will continue to receive the low dose B/F/TAF FDC tablet through Week 48.~* Part B: Following confirmation of BIC PK data from Cohort 3 Part A, participants will receive the low dose B/F/TAF FDC tablet through Week 48."
62585104|NCT02881320|EXPERIMENTAL|Cohort 4 Group 1 (≥ 2 years of age and weight ≥ 14 to < 25 kg)|"Due to Cohort 3 Part A Intensive PK evaluation at Week 2 with the low dose B/F/TAF FDC tablet, participants will not participate in an Intensive PK evaluation at Week 2.~Participants will receive B/F/TAF FDC tablets for oral suspension (TOS) once daily through Week 48."
62738616|NCT02263196|EXPERIMENTAL|alcohol and povidone iodine|the efficacy of combination of alcohol and povidone iodine on inflammation related to vascular access
62410260|NCT05879796||concurrent chemoradiotherapy|"Concurrent Chemoradiation:~Cisplatin 40 mg/m2, day1, 7 days as a cycle, 6 cycles in total; External beam radiotherapy was performed using IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45-50.4 Gy;1.8-2.0 Gy/f,25- 28 f. In patients with pelvic lymph node metastasis, para-aortic lymph node metastasis, and retroperitoneal lymph node metastasis, local lesions were simultaneously boosted to 60 Gy. In FIGO stage IIIB, simultaneous or late course boost to 60 Gy was given parametrially.~Brachytherapy: High dose rate (HDR) afterloading brachytherapy was used, with a total dose of 30-40 Gy and a cumulative dose of 80-85 Gy at point A/HRCTV D90; if the tumor diameter was ≥ 4cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90. Brachytherapy combined with external beam radiation therapy was completed within 8 weeks."
62410261|NCT06224504|EXPERIMENTAL|the intervention group|routine health education ， psychological nursing， MBSR therapy ， exercise therapy
62585105|NCT02881320|EXPERIMENTAL|Cohort 4 Group 2 (≥ 1 month of age and weight ≥ 10 to < 14 kg)|Participants will participate in an Intensive PK evaluation at Week 2 after which they will continue to receive B/F/TAF FDC TOS twice daily through Week 48.
62585106|NCT02881320|EXPERIMENTAL|Cohort 4 Group 3 (≥ 1 month of age and weight ≥ 6 to < 10 kg)|Participants will participate in an Intensive PK evaluation at Week 2 after which they will continue to receive B/F/TAF FDC TOS twice daily through Week 48.
62585107|NCT02881320|EXPERIMENTAL|Cohort 4 Group 4 (≥ 1 month of age and weight ≥ 3 to < 6 kg)|Participants will participate in an Intensive PK evaluation at Week 2 after which they will continue to receive B/F/TAF FDC TOS twice daily through Week 48.
62410262|NCT06224504|ACTIVE_COMPARATOR|the control group|routine health education ， psychological nursing
62410263|NCT02162381|EXPERIMENTAL|methylphenidate provided|the study group will be given a single pill containing methylphenidate 10mg to be taken 2 hours before their visual field test
62410264|NCT02162381|ACTIVE_COMPARATOR|control|control group will not be given any placebo and will perform a repeat visual field testing without any prior preparation
62410265|NCT06075927|EXPERIMENTAL|VSTs infusion|"Phase I (dose escalation) : An open, single-arm, dose-escalation clinical study to explore the safety, tolerability, and cytodynamic characteristics of CMV and EBV-specific T cells (VSTs), with initial efficacy observations. Subjects enrolled with refractory CMV and/or EBV infection after allogeneic hematopoietic stem cell transplantation were subjected to a 3+3 dose-climb test. Exploring the safety, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of intravenous infusion of multi-virus VSTs.~(2) Phase II (dose expansion) : According to the clinically recommended or safe and effective dose determined by the phase I climb test, the extended study of 1-2 dose groups with 20 cases per dose was performed after joint review by the investigators and project collaborators."
62410266|NCT06390280||grup I|Intraoperative Fraction of Inspired Oxygen %30 applied
62585108|NCT02881320|EXPERIMENTAL|Open-Label Extension|Following Week 48, participants in countries where B/F/TAF is not available may have the option to receive adult strength B/F/TAF FDC, low dose B/F/TAF FDC, or B/F/TAF FDC TOS (based on age and weight) until it becomes available for use according to the participant's age and weight or the product becomes accessible to participants through an access program.
62585109|NCT05965180||Biopsy|Patients will be identified once prostate biopsies have been scheduled. Once enrolled on trial, patients will undergo standard biopsy procedure as per clinical care. During this biopsy, research measurements will be completed using the fine needle photoacoustic probe.
62585110|NCT06193356|NO_INTERVENTION|Pre learning tool|Assessment of endoscopic images prior to a learning tool about scars and recurrence
62585111|NCT06193356|EXPERIMENTAL|post learning tool|Assessment of endoscopic images after a learning tool about scars and recurrence
62738617|NCT02263196|EXPERIMENTAL|combination of alcohol and betadin|the efficacy of combination of alcohol and povidone iodine on infection related to vascular access
62738618|NCT05182658|ACTIVE_COMPARATOR|Empagliflozin group|Patients in the empagliflozin group will receive 10 mg of empagliflozin once daily for 12 months
62738619|NCT05182658|PLACEBO_COMPARATOR|Control group|Patients in the control group will receive placebo once daily for 12 months
62021121|NCT04368936||SFS : group of individuals with simple FS|Simplex febrile seizures (SFS) last shorter than 15 minutes and their type is tonic-clonic. Also, they did not show signs of recidivism during the first 24 hours and were diagnosed at the patients aged from 6th months to 5th year
62021122|NCT04368936||CFS : group of individuals with complex FS|Complex febrile seizures (CFS) were diagnosed at those patients that had focal seizure or epileptic status or seizure having the body temperature lower than 38 degree, which occurred outside of the typical age group and finally which repeated in the first 24 hours again
62021123|NCT04368936||WFS: group of individuals with FS and without epilepsia|group of children with Febrile Seizure and not developed Epilepsia
62410267|NCT06390280||grup II|Intraoperative Fraction of Inspired Oxygen %80 applied
62410268|NCT03315325|EXPERIMENTAL|Adult men|The average age was 25.80±0.37 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
62410269|NCT03315325|EXPERIMENTAL|Middle age men|The average age was 47.00±0.77 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
62410270|NCT03315325|EXPERIMENTAL|Advance age men|The average age was 73.20±0.91 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
62410271|NCT02139969||GreenLight XPS Laser System|Treatment of BPH in men using the GreenLight XPS Laser System and the MoXy fiber
62792020|NCT04355208|EXPERIMENTAL|Intervention|Restoration of anterior teeth using monochromatic layering technique using body shade (filtek universal from 3m
62792021|NCT04355208|ACTIVE_COMPARATOR|comparator|Restoration of anterior teeth using polychromatic layering technique using Enamel and Dentin shades (filtek Z350 xt from 3m
62792022|NCT02067936|ACTIVE_COMPARATOR|Group A propofol + remifentanil|Propofol highest dose, remifentanil lowest dose, TOL 90% according to Bouillon model
62021124|NCT04368936||EFS: group of individuals with Epilepsia and Febrile Seizures|Group of children with Febrile Seizures, who have developed Epilepsy
62792023|NCT02067936|ACTIVE_COMPARATOR|Group B propofol + remifentanil|Propofol intermediate high, remifentanil intermediate low, TOL90% according to the Bouillon Model
62792024|NCT02067936|ACTIVE_COMPARATOR|Group C propofol + remifentanil|propofol intermediate low+ remifentanil intermediate high: TOL 90% according to the Bouillon interaction model
62021125|NCT02908438|EXPERIMENTAL|GnRHa group|Intervention: additional GnRHa for routine LPS GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
62021126|NCT02908438|NO_INTERVENTION|control group|Control group receive only the routine LPS.
62021127|NCT05643066|EXPERIMENTAL|0.1 mg/kg esketamine group|Procedure sedation was induced using intravenous 0.1 mg/kg esketamine and propofol 1 mg/kg. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
62021128|NCT05643066|EXPERIMENTAL|0.2 mg/kg esketamine group|Procedure sedation was induced using intravenous 0.2 mg/kg esketamine and propofol 1 mg/kg. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
62021129|NCT05643066|PLACEBO_COMPARATOR|Placebo group|Procedure sedation was induced using intravenous 0.9% saline and propofol 1 mg/kg. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
62021130|NCT06034600|EXPERIMENTAL|exercise and taping|Individuals in this group are planned to practice exercise together with taping therapy for eight weeks.
62215684|NCT06423547||postoperative delirium(POD) and postoperative neurocognitive disorder(pNCD)|Delirium (CAM scale ) was assessed 7 days after surgery and divided into POD and non-POD groups; one of the above scenarios indicated postoperative delirium;The patients in the POD group were evaluated for cognitive function at 1 month and 12 months after surgery to determine whether pNCD occurred. The patients in the POD group were further divided into pNCD subgroup and non-PNCD subgroup, and EEG data collection and fMRI scanning were performed
62215685|NCT01100827||EGFR mutation status in patients|
62215686|NCT04288375|EXPERIMENTAL|extremity soft tissue sarcoma (STS)|Postoperative radiation therapy to the primary site with a reduction in radiation dose and volume. Specifically, the tumor bed plus a margin of 2cm craniocaudally and 1.5cm radially will be utilized to create the clinical target volume. The total dose will consist of 50 Gy in 25 fractions.
62215687|NCT02573194|EXPERIMENTAL|Animal source of proteins|Breakfast based on animal proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
62021131|NCT06034600|EXPERIMENTAL|exercise|Individuals in this group are planned to receive only exercise practice for eight weeks.
62215688|NCT02573194|EXPERIMENTAL|Plant source of proteins|Breakfast based on plant proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
62021132|NCT03174886|EXPERIMENTAL|AADvac1 40 µg|The intervention consists of Axon Peptide 108 coupled to keyhole limpet haemocyanin (KLH) 40 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
62410272|NCT06334601||Obstructive Sleep Apnea|Patients evaluated for sleep disorders, who present an at home-polygraphy with at least one EEG channel (PSG) reporting moderate-to severe obstructive sleep apnea (apnea-hypopnea index \>14).
62410273|NCT05959824|EXPERIMENTAL|Group 1|Treatment with OR-AT0222
62792025|NCT02067936|ACTIVE_COMPARATOR|group D propofol + remifentanil|propofol lowest dose+ remifentanil highest dose: TOL 90% according to the Bouillon model
62215689|NCT02573194|EXPERIMENTAL|Animal and plant source of proteins|Breakfast based on both animal and plant proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
62215690|NCT02573194|EXPERIMENTAL|Low protein|Breakfast very low in protein: 1700 kJ, 5 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
62215691|NCT02265627|EXPERIMENTAL|BIIL 284 BS, normal hepatic function|
62792026|NCT02084550|ACTIVE_COMPARATOR|Vaminolac|Intravenous Vaminolac during 3 hours, with an infusion rate of 1,6ml/kilogram bodyweight/h.
62792027|NCT02084550|PLACEBO_COMPARATOR|Saline|Intravenous saline during 3 hours, with an infusion rate of 1,6ml/kilogram bodyweight/h.
62215692|NCT02265627|EXPERIMENTAL|BIIL 284 BS, mild hepatic impairment|
62215693|NCT02265627|EXPERIMENTAL|BIIL 284 BS, moderate hepatic impairment|
62410274|NCT05959824|PLACEBO_COMPARATOR|Group 2|Treatment with Placebo
62410275|NCT06289010|EXPERIMENTAL|Depressed Group|20 children with depression and their parents (40 participants total) will undergo a 12-session course of FFT-CD.
62410276|NCT01850901|EXPERIMENTAL|Renal sympathetic denervation|Catheter-based renal nerve ablation
62410277|NCT01850901|NO_INTERVENTION|Usual care|Antihypertensive treatment according to guidelines
62410278|NCT01995604|EXPERIMENTAL|dHACM|UltraPulse laser therapy with application of dHACM
62410279|NCT01995604|PLACEBO_COMPARATOR|Sterile 0.9% Saline Solution|UltraPulse laser therapy with application of Sterile 0.9% Saline Solution
62410280|NCT06504407|EXPERIMENTAL|Bingo Educational Intervention|Single-arm, interventional study where all participants will engage in the Bingo game as an educational intervention.
62410281|NCT03305926|ACTIVE_COMPARATOR|Conventional CVR|
62410282|NCT03305926|EXPERIMENTAL|eCVR|
62410283|NCT05963022|EXPERIMENTAL|Tirzepatide Dose 1|Participants will receive tirzepatide subcutaneously (SC).
62410284|NCT05963022|EXPERIMENTAL|Tirzepatide Dose 2|Participants will receive tirzepatide SC.
62410285|NCT05963022|EXPERIMENTAL|Tirzepatide Dose 3|Participants will receive tirzepatide SC.
62410286|NCT05963022|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62410287|NCT06232135||Females|CBCT scans of the females enrolled in the study are to be analyzed for the assignment of a calcification stage to their lower left third molar according to the modified Demirjian method.
62410288|NCT06232135||Males|CBCT scans of the males enrolled in the study are to be analyzed for the assignment of a calcification stage to their lower left third molar according to the modified Demirjian method.
62410289|NCT06436690|EXPERIMENTAL|Diagnosis Mandate and Feedback|The intervention will consist of three components: (a) a Refresher Training on antimicrobial resistance, (b) a Diagnosis Mandate, and (c) an Individualized Feedback.
62410290|NCT00474370|EXPERIMENTAL|Test Arm|Vicriviroc 30 mg QD
62410291|NCT00474370|PLACEBO_COMPARATOR|Placebo Control Arm|Placebo
62410292|NCT02269800|EXPERIMENTAL|Benzalkonium chloride solution|Tid, for 7 days.
62410293|NCT02269800|ACTIVE_COMPARATOR|Normal saline|Tid, for 7 days.
62410294|NCT04943510|EXPERIMENTAL|Physical exercices arm|three randomizations will be used to determine the order of the tests that will be proposed to the subjects: on the one hand for the exercise modalities (match, anaerobic, aerobic) and, on the other hand, for the exercise modalities included in the anaerobic and aerobic exercise families: Anaerobic agility / anaerobic - linear sprints Aerobic - shuttle / aerobic - linear
62410295|NCT06566573|OTHER|cervical stenosis degree 0|Pain, range of motion and proprioceptive sensations of patients with spinal stenosis grade 0 according to the Kang grading system will be evaluated on MRI.
62410296|NCT06566573|OTHER|cervical stenosis degree 1|Pain, range of motion and proprioceptive sensations of patients with spinal stenosis grade 1 according to the Kang grading system will be evaluated on MRI.
62410297|NCT06566573|OTHER|cervical stenosis degree 2|Pain, range of motion and proprioceptive sensations of patients with spinal stenosis grade 2 according to the Kang grading system will be evaluated on MRI.
62215694|NCT03310034|ACTIVE_COMPARATOR|Intervention|
62215695|NCT03310034|PLACEBO_COMPARATOR|Control|
62215696|NCT00415077|ACTIVE_COMPARATOR|2|LASEK- laser-assisted subepithelial keratectomy
62215697|NCT00415077|ACTIVE_COMPARATOR|3|Mitomycin C PRK
62215698|NCT00415077|ACTIVE_COMPARATOR|1|PRK- Photorefractive keratectomy
62215699|NCT03780218||Experimental Group:Respiratory function|Patients with burn injury will be included in this study. Their respiratory functions will be evaluated. Pulmonary function test, respiratory muscle strength and peripheral muscle strength will be assessed on the discharge week.
62410298|NCT06566573|OTHER|cervical stenosis degree 3|Pain, range of motion and proprioceptive sensations of patients with spinal stenosis grade 3 according to the Kang grading system will be evaluated on MRI.
62410299|NCT02712359|OTHER|Havrix 1 dose_Year 8 Group|Subjects who received one dose of Havrix vaccine and with more than or equal to (≥) 7 years and less than (\<) 10 years between the administration of the vaccine dose and the Persistence Visit at Year 8 and who participated in the Year 8 cross-sectional survey.
62792028|NCT00972725|EXPERIMENTAL|GSK732461+Nivaquine Group|Subjects received a single dose of Nivaquine® tablets orally, 2 days prior to receiving a booster dose of the GSK732461 vaccine.
62215700|NCT03780218||Control Group:Respiratory function|Healthy subjects will be included in this study.Their respiratory functions will be evaluated. Pulmonary function test, respiratory muscle strength and peripheral muscle strength will be assessed.
62215701|NCT02982824|EXPERIMENTAL|Magnesium add-on|20 children with drug resistant epilepsy will receive oral magnesium sulfate 6 ml per day which equivalent to 400 mg elemental magnesium (Yuen \& Sander, 2012) for 6 months and their regular antiepileptic drugs.
62792029|NCT00972725|ACTIVE_COMPARATOR|GSK732461 Group|Subjects received a booster dose of the GSK732461 vaccine intramuscularly, in the deltoid region of the non-dominant arm.
62585112|NCT04896346||Previous Treatment: Biologic StrataGraft Skin Tissue|"This consists of areas that were treated with Stratagraft Skin Tissue under a previous clinical study STRATA2016.~No new interventions will occur."
62792030|NCT04392843|OTHER|Fasting|Subjects will remain fasted prior to insulin-induced hypoglycemia.
62792031|NCT04392843|ACTIVE_COMPARATOR|Feeding|Subjects will eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
62215702|NCT02982824|PLACEBO_COMPARATOR|Antiepileptic drugs only|20 children with drug resistant epilepsy will receive their regular antiepileptic drugs and placebo for 6 months.
62585113|NCT04896346||Previous Treatment: Autograft Comparator|"This consists of areas that were treated with autograft comparator under a previous clinical study STRATA2016.~No new interventions will occur."
62792032|NCT00959738|OTHER|A|diverting loop ileostomy with rod
62792033|NCT00959738|OTHER|B|diverting loop ileostomy without rod
62792034|NCT01190501|EXPERIMENTAL|complier device|
62792035|NCT06502782||Thin phenotype|A thickness of 1 mm or less is classified as thin gingival tissue.
62792036|NCT06502782||Thick phenotype|A thickness of more than 1 mm is classified as thick gingival tissue.
62792037|NCT00203424|EXPERIMENTAL|Erlotinib + Bevacizumab|Participants received Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
62792038|NCT01641601|NO_INTERVENTION|Usual Management|Patients in the usual management arm will have no pre-hospital cervical ripening and will undergo labor induction according to standard labor induction protocols on an inpatient basis.
62021133|NCT03174886|EXPERIMENTAL|AADvac1 160 µg|The intervention consists of Axon Peptide 108 coupled to KLH 160 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
62792039|NCT01641601|EXPERIMENTAL|Outpatient transcervical Foley balloon|Patients in the experimental group will have a 30 cc transcervical Foley balloon placed in the outpatient setting approximately 12-18 hours prior to their labor induction. Once admitted, they will undergo inpatient labor induction as per usual protocols.
62215703|NCT02982824|NO_INTERVENTION|Healthy controls|To asses serum magnesium level for comparison with the intervention group.
62215704|NCT03848013|ACTIVE_COMPARATOR|Treatment|Treatment of cases of melasma using Q switched Nd YAG laser and Fractional CO2 laser separately and in combination
62792040|NCT04043442|ACTIVE_COMPARATOR|Active + Placebo rTMS for Custom Neural Target Group 1|Custom neural anatomical target 1 defined by neuroimaging data
62792041|NCT04043442|ACTIVE_COMPARATOR|Active + Placebo rTMS for Custom Neural Target Group 2|Custom neural anatomical target 2 defined by neuroimaging data
62792042|NCT04043442|ACTIVE_COMPARATOR|Active + Placebo rTMS for Custom Neural Target Group 3|Custom neural anatomical target 3 defined by neuroimaging data
62792043|NCT04043442|ACTIVE_COMPARATOR|Active + Placebo rTMS for Left DLPFC Neural Target|"Neural anatomical target will be the Left Dorsolateral Prefrontal Cortex identified using the 5cm from the motor hot spot rule."
62792044|NCT00932321|EXPERIMENTAL|24 Day NA/EE|Norethindrone acetate 1 mg /ethinyl estradiol 20 mcg for 24 days of each 28 day cycle
62792045|NCT00932321|ACTIVE_COMPARATOR|21 Day NA/EE|Norethindrone acetate 1 mg/ethinyl estradiol 20 mcg for 21 days of each 28 day cycle
62021134|NCT01988818|ACTIVE_COMPARATOR|Standard wound dressing|As comparator will be used a standard Cosmopor E®adhesive, island wound dressing (Paul Hartmann LTD)after hip or knee arthroplasty or spinal surgery
62215705|NCT03848013|NO_INTERVENTION|Follow -up period|follow up of the treated cases for 2 months
62021135|NCT01988818|EXPERIMENTAL|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
62215706|NCT06146127||Combined hepatocellular cholangiocarcinoma|
62215707|NCT06146127||hepatocellular carcinoma|
62215708|NCT06146127||cholangiocarcinoma|
62215709|NCT03182192|EXPERIMENTAL|Hypoglycemia|Patients with hypoglycemia after gastric bypass
62215710|NCT03182192|ACTIVE_COMPARATOR|Control|Patients without hypoglycemia after gastric bypass
62215711|NCT03822793|PLACEBO_COMPARATOR|Placebo|Patient will be included in this group by randomization and they will receive an intravenous perfusion of NaCl (sodium chloride 9%; placebo) intravenous over 9 minutes, starting at the time of surgical incision.
62792046|NCT03285269||Shock Group|Patients presenting with signs and symptoms of shock will undergo the E-RUSH ultrasound protocol and bioreactance before and after a passive leg raise maneuver.
62792047|NCT01960582|EXPERIMENTAL|New Practice Strategy|Structured strategy for assessment and evaluation before and after intervention
62792048|NCT01960582|NO_INTERVENTION|Ordinary practice|Ordinary practice, not structured
62792049|NCT02761343|OTHER|MRI scan|Post ablation MRI scan will be performed for all subjects who are clinically stable.
62792050|NCT04505332|OTHER|orthopedists|orthopedists working actively and performing arthroplasty every day
62215712|NCT03822793|EXPERIMENTAL|Group 1: perfusion of 300 mg Exacyl|Patient will be included in the group 2 by randomization and they will receive an intravenous perfusion of 300 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
62792051|NCT05936398|ACTIVE_COMPARATOR|Voluntary Isocapnic Hyperpnoea (VIH)|Group performing respiratory muscle training with Voluntary Isocapnic Hyperpnoea (VIH) method.
62792052|NCT05936398|ACTIVE_COMPARATOR|Inspiratory Pressure Threshold Loading (IPTL)|Group performing respiratory muscle training with Inspiratory Pressure Threshold Loading (IPTL) method.
62792053|NCT05234047||CKD-5D patients receiving denosumab|
62792054|NCT04734067||observational group|Patients receiving ICIs for the first time
62792055|NCT03753555|ACTIVE_COMPARATOR|Routine-dose statin group|Routine-dose statin group will be gaven the treatment of atorvastatin 20mg Qd for 12 months
62792056|NCT03753555|EXPERIMENTAL|high-dose statin or PCSK9 inhibitor group|"high-dose statin group will be gaven the treatment of atorvastatin 40-80mg Qd till 6 months at the moment the subjects will be followed up to determine plaques status by HRMRI examination, among which the subjects presenting culprit plaque progression with the significant increasing of plaque burden including intraplaque hemorrhage will be again randomized into two groups at a ratio of 1:1 as followed: atorvastatin-probucol group will be administrated atorvastatin 40-80mg Qd plus probucol 0.5g Bid till 12 months, the other group will maintain the original scheme till 12 months.~PCSK9 inhibitor group will receive the subcutaneous injection of Evolocumab (140mg, 2 / month) for one year."
62792057|NCT04637737|EXPERIMENTAL|Training group|
62585114|NCT05879523|EXPERIMENTAL|HRS-1893 for single ascending dose (SAD) cohorts|Subjects will be assigned to one of 6 planned dose cohorts and receive single dose of HRS-1893
62585115|NCT05879523|PLACEBO_COMPARATOR|Placebo comparator for SAD cohorts|Subjects will be assigned to one of 6 planned dose cohorts and receive single dose of placebo comparator
62792058|NCT04637737|OTHER|Control group|
62792059|NCT03305770|EXPERIMENTAL|DD T2|Verofilcon A contact lenses worn in both eyes for 3 months in a daily wear, daily disposable modality. A new pair of study lenses will be inserted each day and discarded at the end of the day.
62792060|NCT03305770|ACTIVE_COMPARATOR|DT 1|Delefilcon A contact lenses worn in both eyes for 3 months in a daily wear, daily disposable modality. A new pair of study lenses will be inserted each day and discarded at the end of the day.
62215713|NCT03822793|EXPERIMENTAL|Group 2: perfusion of 500 mg Exacyl|Patient will be included in the group 2 by randomization and they will receive an intravenous perfusion of 500 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision..
62792061|NCT02885246||Influenza Virus Positive Group|The group included specimen samples with a laboratory confirmed diagnosis of influenza A and/or B, reported in the Instituto Conmemorativo Gorgas de Estudios de la Salud (ICGES) database of Panama, from January 2011 to December 2017.
62021136|NCT01252472||Flomax|Male patients scheduled for cataract surgery with current or past use of Flomax
62215714|NCT03822793|EXPERIMENTAL|Group 3: perfusion of 1000 mg Exacyl|Patient will be included in the group 3 by randomization and they will receive an intravenous perfusion of 1000 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
62215715|NCT03822793|EXPERIMENTAL|Group 4: perfusion of 3000 mg Exacyl|Patient will be included in the group 4 by randomization and they will receive an intravenous perfusion of 3000 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
62585116|NCT05879523|EXPERIMENTAL|HRS-1893 for multiple ascending dose (MAD) cohorts|Subjects will receive multiple doses of 2-4 planned dose cohorts and receive single dose of placebo comparator for MAD cohorts
62585117|NCT02070016|EXPERIMENTAL|TMS Parameter Condition 1 first|Application of Transcranial Magnetic Stimulation
62585118|NCT02070016|EXPERIMENTAL|TMS Parameter Condition 2 First|Application of Transcranial Magnetic Stimulation
62585119|NCT04298905|NO_INTERVENTION|Standard of Care|Individuals randomized to standard of care will receive a standardized adherence education session and provided with a paper-based diary to track appointments and adherence. Instructions will be provided on the importance of daily adherence in the primary health care facility closest to patients' residence, as per standard of care. Directly observed therapy (DOT) is recommended for all patients at patients' nearest clinic. All patients are seen face-to-face monthly for adherence monitoring, monthly symptom reports and laboratory evaluations per standard of care treatment guidelines. All research participants will also receive a clinic visit quality checklist to ensure completeness of standard of care procedures.
62792062|NCT06303102|EXPERIMENTAL|Experimental|Experimental Group A (Manual PT/ Conventional PT Treatment + Segmental and Pursed Lip Breathing Exercise)
62792063|NCT06303102|OTHER|Controlled|Group B (Manual PT/Conventional PT Treatment)
62792064|NCT05230472|ACTIVE_COMPARATOR|simvastatin group|68 patients who had a ventilator associated pneumonia received simvastatin
62792065|NCT05230472|NO_INTERVENTION|control group|68 patients who had a ventilator associated pneumonia not received simvastatin
62215716|NCT01789567|OTHER|Engager™ aortic valve|Implantation of the Medtronic Engager™ bioprosthesis via direct aortic approach
62215717|NCT01770106|EXPERIMENTAL|Denosumab|Patients in this arm will receive subcutaneous injection of denosumab 60mg every 6 months (1 dose for the study period).
62215718|NCT01770106|ACTIVE_COMPARATOR|Standard treatment|Patients (n=20) in this arm will receive oral alendronate (Fosamax®)70mg once.
62792066|NCT03386487|ACTIVE_COMPARATOR|PF-04457845|Subjects will be randomized to Fatty Acid Amide Hydrolase (FAAH) Inhibitor; 4 mg PF-04457845 QD x 8 weeks
62792067|NCT03386487|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to placebo
62792068|NCT03319134|EXPERIMENTAL|active anodal HD-tDCS|Active anodal HD-tDCS stimulation applied during memory task
62792069|NCT03319134|SHAM_COMPARATOR|sham HD-tDCS|Sham HD-tDCS stimulation during memory task for comparison
62792070|NCT03319134|EXPERIMENTAL|active cathodal HD-tDCS|Active cathodal HD-tDCS stimulation applied during memory task
62021137|NCT01252472||Control|Male adult patients scheduled for cataract surgery with no history of Flomax use
62021138|NCT01105533|EXPERIMENTAL|Cohort 1|
62021139|NCT01105533|EXPERIMENTAL|Cohort 2|
62021140|NCT01105533|EXPERIMENTAL|Cohort 3|
62021141|NCT01105533|EXPERIMENTAL|Cohort 4|
62215719|NCT01373073|EXPERIMENTAL|Experimental Human Milk Fortifier|Experimental human milk fortifier to be added to human milk
62792071|NCT03314064|EXPERIMENTAL|HIV positive subjects continuing DTG|HIV positive subjects who complete taking DTG in studies ING112276, ING113086, ING114915, ING111762 and those subjects who end participation in study 200304 in which they received either DTG or LPV/RTV will be included in this study.
62599952|NCT03775122|PLACEBO_COMPARATOR|Group 1 sedation group|"Elderly patients under colonoscopy with sedation, but no real TAES neiguan(pc6)~sedation is using the typical protocol for the following: Slowly peripheral intravenous injection(0.5ml/s) of fentanyl 50μg, then followed with 1.5-2.5mg/kg propofol until loss of eyelash reflex, the Observer's Assessment of Alertness/Sedation Scale (OAAS) score Level3-5."
62792072|NCT02342899|ACTIVE_COMPARATOR|Control Goup|Inpatient initiation of noninvasive ventilation.
62792073|NCT02342899|ACTIVE_COMPARATOR|Intervention Group|Initiated on NIV during an elective outpatient clinic review during which an arterial blood gas measurement will be obtained to confirm the presence of chronic respiratory failure.
62792074|NCT00982826|EXPERIMENTAL|1|ABT-072 tablet single ascending dose
62792075|NCT00982826|EXPERIMENTAL|2|Placebo tablet
62792076|NCT00982826|EXPERIMENTAL|3|ABT-072 tablet administered under non-fasting conditions.
62792077|NCT00982826|EXPERIMENTAL|4|ABT-072 tablet administered under fasting conditions
62792078|NCT00982826|EXPERIMENTAL|5|ABT-072 tablet multiple ascending dose
62792079|NCT02593942|EXPERIMENTAL|group I|remifentanil
62792080|NCT02593942|EXPERIMENTAL|group II|remifentanil, propofol
62792081|NCT03441386|EXPERIMENTAL|Cognitive Study|Cognitive Responses was analyzed after different intensities physical exercise sessions.
62792082|NCT06098534|EXPERIMENTAL|"Hospi'Senior group"|Patients admitted to the Hospi'Senior room benefit from the innovative technologies available in this room. Patients benefit from standard care throughout their hospital stay.
62792083|NCT06098534|EXPERIMENTAL|"Conventional room group"|Patients admitted to a conventional room receive the standard care throughout their hospital stay.
62792084|NCT03004352|EXPERIMENTAL|control subjects-retrograde flow|Retrograde flow was induced in control subjects.
62792085|NCT03004352|NO_INTERVENTION|control subjects-control|
62792086|NCT03004352|EXPERIMENTAL|hypoxemic COPD-retrograde flow|Retrograde flow was induced in hypoxemic COPD patients.
62792087|NCT03004352|NO_INTERVENTION|hypoxemic COPD-control|
62792088|NCT03004352|EXPERIMENTAL|normoxemic COPD-retrograde flow with oxygen|Retrograde flow was induced in COPD patients with normalized arterial oxygen saturation.
62792089|NCT03004352|EXPERIMENTAL|normoxemic COPD-control with oxygen|COPD patients with normalized arterial oxygen saturation.
62792090|NCT01647893|EXPERIMENTAL|CTB-001 or placebo(mannitol) 0.375mg/kg, single-dose|
62792091|NCT01647893|EXPERIMENTAL|CTB-001 or placebo(mannitol) 0.75mg/kg, single-dose|
62792092|NCT01647893|EXPERIMENTAL|CTB-001 or placebo(mannitol) 1.5mg/kg, single-dose|
62792093|NCT01647893|EXPERIMENTAL|CTB-001 or placebo(mannitol) 0.75mg/kg, and dose escalation|
62792094|NCT04354675|EXPERIMENTAL|Artificial intelligence program|Will complete consult with the use of an artificial intelligence program Chatbot.
62792095|NCT04354675|ACTIVE_COMPARATOR|in-person genetic counseling|Will complete a traditional in-person genetic counseling. consult by meeting with a Genetics Counselor
62021142|NCT01105533|EXPERIMENTAL|Cohort 5|
62021143|NCT01105533|EXPERIMENTAL|Cohort 6|
62792096|NCT02202343|EXPERIMENTAL|School-based health and nutrition education|
62792097|NCT00031759|OTHER|Ablative or excisional therapy|"Patients undergo ablative or excisional therapy.~Quality of life is assessed at baseline, 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.~Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy."
62792098|NCT00031759|EXPERIMENTAL|Ablative or excisional therapy + imiquimod|"Patients have topical imiquimod applied to the cervix for 6-10 hours twice weekly for a total of 5 doses. Within 3-4 weeks after the final application, patients undergo ablative or excisional therapy. Quality of life is assessed at baseline, after last dose of study drug, 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.~Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy."
62792099|NCT02926638|EXPERIMENTAL|Arm I (rilotumumab, erlotinib)|Patients receive rilotumumab IV over 60-120 minutes on day 1 and erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AND INTERVENTION 11/25/2014)
62792100|NCT02926638|ACTIVE_COMPARATOR|Arm II (erlotinib)|Patients receive erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AND INTERVENTION 11/25/2014)
62819314|NCT06650514|EXPERIMENTAL|OMO-103|OMO-103 administered at the recommended phase 2 dose (6.5 mg/kg as a weekly intravenous infusion in 28-day cycles)
62819315|NCT06612944|EXPERIMENTAL|Intervention Group|
62585120|NCT04298905|ACTIVE_COMPARATOR|mHealth intervention|Individuals randomized to the intervention arm will receive the same standardized adherence education, followed by an orientation session to the study intervention. This orientation will include education on basic smartphone operations and use. The CHW will set up appointment reminders for clinic visits as well as daily adherence reminders for submission of the video DOT sessions and symptom reports. A smartphone capable of downloading apps, receiving short message service (SMS) and access wifi and cellular connectivity will be provided to intervention patients. All patients are seen face-to-face monthly for adherence monitoring, monthly symptom reports and laboratory evaluations per standard of care treatment guidelines. All research participants will also receive a clinic visit quality checklist to ensure completeness of standard of care procedures.
62021144|NCT01105533|EXPERIMENTAL|Cohort 7|
62792101|NCT03831100|EXPERIMENTAL|BRIGHT|The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.
62215720|NCT01373073|ACTIVE_COMPARATOR|Control Human Milk Fortifier|Control human milk fortifier to be added to human milk
62021145|NCT01105533|EXPERIMENTAL|Cohort 8|
62215721|NCT04289168|EXPERIMENTAL|Music Class|Music Class attendance
62215722|NCT04289168|NO_INTERVENTION|Play Class|Play date class attendance
62215723|NCT00143676|EXPERIMENTAL|Lapaquistat Acetate 50 mg QD + Atorvastatin|
62792102|NCT03831100|PLACEBO_COMPARATOR|Active Control|The control intervention in this study will be matched to replicate the frequency, intensity, and delivery method of BRIGHT. AC consists of 5 weekly sessions of videos about HNC survivorship that are delivered using a telemedicine platform. Each AC session is a compilation of shorter videos featuring HNC survivors, caregivers, and oncologists discussing non-body image aspects of HNC survivorship.
62792103|NCT01552863|EXPERIMENTAL|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62792104|NCT01552863|EXPERIMENTAL|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62792105|NCT01552863|EXPERIMENTAL|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62792106|NCT01552863|EXPERIMENTAL|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62021146|NCT01105533|EXPERIMENTAL|Cohort 9|
62021147|NCT01105533|EXPERIMENTAL|Cohort 10|
62215724|NCT00143676|EXPERIMENTAL|Lapaquistat Acetate 100 mg QD + Atorvastatin|
62215725|NCT00143676|ACTIVE_COMPARATOR|Atorvastatin|
62215726|NCT05490901||Patients with Unexplained Dyspnea|Patients with dyspnea on exertion
62215727|NCT04444973||Invasive RV assessment|RV conductance catheter assessment of RV performance
62215728|NCT04772820|OTHER|Primary Aim|Brief Behavioral Activation coaching will be delivered by telephone and other remote technology by trained coaches. Over 10 sessions, the coaches will help people to find meaningful activities to decrease loneliness, increase physical activity and improve nutrition.
62215729|NCT05299593|EXPERIMENTAL|tafluprost/timolol|Enrolled patients will be treated with one drop of the fixed combination Tafluprost-Thymol without preservative in the evening at 20.00 (+/- 1 hour). Patients will be administrered with one drop in the conjunctival sac of the affected eye (s) once a day.
62215730|NCT00642733|EXPERIMENTAL|1|
62021148|NCT02761564|EXPERIMENTAL|ScVO2 group|Anemia (\<9g/dL) requiring blood transfusion Measure of ScvO2 : ScVO2 is measured using the central venous catheter placed in the superior vena cava. Transfusion is performed if the ScVO2 is inferior or equal to 65%.
62021149|NCT02761564|OTHER|Control group|Anemia (\<9g/dL) requiring blood transfusion : Transfusion is performed following national guidelines for red blood cell transfusion
62021150|NCT00558285|EXPERIMENTAL|indacaterol/glycopyrrolate 600/100 μg|"Two capsules indacaterol/glycopyrrolate 300/50 μg delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
62021151|NCT00558285|EXPERIMENTAL|indacaterol/glycopyrrolate 300/100 μg|"One capsule indacaterol/glycopyrrolate 300/100 μg and one placebo capsule delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
62215731|NCT01241487|EXPERIMENTAL|1|valsartan/amlodipine
62215732|NCT03526276|ACTIVE_COMPARATOR|CPP-ACP paste|Casein phosphopeptide amorphous calcium phosphate is a product that contains calcium, phosphate, protein and casein.
62215733|NCT03526276|ACTIVE_COMPARATOR|Fluoride toothpaste|Fluoride toothpaste
62215734|NCT03526276|ACTIVE_COMPARATOR|Both (Fluoride and CPP-ACP)|Fluoride toothpaste and CPP-ACP paste
62215735|NCT01133795|EXPERIMENTAL|Midodrine, Albumin|Midodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
62215736|NCT01557114|EXPERIMENTAL|radiation therapy with Ipilimumab|
62215737|NCT06222268|PLACEBO_COMPARATOR|Placebo (PBO) only|In a double-blind, placebo and active-controlled, between-subjects design, the investigators will administer drugs using a vaporizer containing THC (2.5mg), CBD (2.5mg,25mg) or PBO (0mg THC/CBD). Drug is administered immediately prior to exposure therapy sessions 3-6. 75 participants will be randomly assigned to each treatment arm. All participants will receive prolonged exposure therapy.
62215738|NCT06222268|EXPERIMENTAL|Cannabidiol (CBD) only|In a double-blind, placebo and active-controlled, between-subjects design, the investigators will administer drugs using a vaporizer containing THC (2.5mg), CBD (2.5mg,25mg) or PBO (0mg THC/CBD). Drug is administered immediately prior to exposure therapy sessions 3-6. 75 participants will be randomly assigned to each treatment arm. All participants will receive prolonged exposure therapy.
62410300|NCT02712359|OTHER|Havrix 2 doses_Year 8 Group|Subjects who received two doses of Havrix vaccine and with more than or equal to (≥) 7 years and less than (\<) 10 years between the administration of the last vaccine dose and the Persistence Visit at Year 8 and who participated in the Year 8 cross-sectional survey.
62410301|NCT02712359|OTHER|Havrix 1 dose_Year 10 Group|Subjects who received one dose of Havrix vaccine and with more than or equal to (≥) 10 years and less than (\<) 13 years between the administration of the vaccine dose and the Persistence Visit at Year 10 and who participated in the Year 10 cross-sectional survey.
62410302|NCT02712359|OTHER|Havrix 2 doses_Year 10 Group|Subjects who received two doses of Havrix vaccine and with more than or equal to (≥) 10 years and less than (\<) 13 years between the administration of the vaccine dose and the Persistence Visit at Year 10 and who participated in the Year 10 cross-sectional survey.
62215739|NCT06222268|EXPERIMENTAL|Delta-9-tetrahydrocannabinol (THC) only|In a double-blind, placebo and active-controlled, between-subjects design, the investigators will administer drugs using a vaporizer containing THC (2.5mg), CBD (2.5mg,25mg) or PBO (0mg THC/CBD). Drug is administered immediately prior to exposure therapy sessions 3-6. 75 participants will be randomly assigned to each treatment arm. All participants will receive prolonged exposure therapy.
62215740|NCT06222268|EXPERIMENTAL|THC:CBD 1:1|In a double-blind, placebo and active-controlled, between-subjects design, the investigators will administer drugs using a vaporizer containing THC (2.5mg), CBD (2.5mg,25mg) or PBO (0mg THC/CBD). Drug is administered immediately prior to exposure therapy sessions 3-6. 75 participants will be randomly assigned to each treatment arm. All participants will receive prolonged exposure therapy.
62215741|NCT06222268|EXPERIMENTAL|THC:CBD 1:10|In a double-blind, placebo and active-controlled, between-subjects design, the investigators will administer drugs using a vaporizer containing THC (2.5mg), CBD (2.5mg,25mg) or PBO (0mg THC/CBD). Drug is administered immediately prior to exposure therapy sessions 3-6. 75 participants will be randomly assigned to each treatment arm. All participants will receive prolonged exposure therapy.
62410303|NCT05859269|EXPERIMENTAL|Experimental Group: Medrol Dose|The perioperative Medrol dose treatment will consist of a course that lasts six days, with 24 milligrams administered on the first day, 20 milligrams on the second day, 60 milligrams on the third day, 12 milligrams on the fourth day, 8 milligrams on the fifth day, and 4 milligrams on the sixth day. Patients will then be followed up at the clinic for six weeks following their procedure to allow for clinical evaluation and to measure outcome variables.
62410304|NCT05859269|ACTIVE_COMPARATOR|Control Group: Standard of Care|Patients in this group will receive a single intraoperative dose of 10 mg intravenous dexamethasone (control group, IV dexamethasone is standard of care).
62792107|NCT01552863|EXPERIMENTAL|Treatment E|Single dose of 5 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62792108|NCT01552863|EXPERIMENTAL|Treatment F|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62792109|NCT06310421||Screening group|The patient enrollment takes place at the Neonatology Unit of the Institute for Maternal and Child Health Burlo Garofolo and at the Pediatrics Unit of the Gorizia-Monfalcone Hospital, which are the only two birth centers in the area of the Giuliano-Isontina University Health Authority
62792110|NCT01978041|EXPERIMENTAL|Meal prepared with non fluoridated water (<0.1 ppm F)|
62792111|NCT01978041|EXPERIMENTAL|Meal prepared with fluoridated water (1 ppm F)|
62215742|NCT06189638|EXPERIMENTAL|Antimicrobial Peptide PL-5 Topical Spray: 1 mg/g (1‰)|Eligible subjects will be randomized (1:1:1) to receive twice a day, 14 days treatment of Antimicrobial Peptide PL-5 Topical Spray (1‰)
62215743|NCT06189638|EXPERIMENTAL|Antimicrobial Peptide PL-5 Topical Spray:2 mg/g (2‰)|Eligible subjects will be randomized (1:1:1) to receive twice a day, 14 days treatment of Antimicrobial Peptide PL-5 Topical Spray (2‰)
62215744|NCT06189638|PLACEBO_COMPARATOR|Topical placebo (vehicle)|Eligible subjects will be randomized (1:1:1) to receive twice a day, 14 days treatment of Antimicrobial Placebo of Antimicrobial Peptide PL-5 Topical Spray (vehicle).
62215745|NCT01666964||3 months post-injury|Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 3 months prior to enrollment, 50% mild, 50% moderate and severe
62215746|NCT01666964||6 months post-injury|Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 6 months prior to enrollment, 50% mild, 50% moderate and severe
62410305|NCT01019109||Titanium rod|Titanium rods used as a part of PSF construct
62410306|NCT01019109||CoCr Rod|Cobalt Chrome rods used as a part of PSF construct
62410307|NCT04259307|EXPERIMENTAL|Intensive nutrition group|Standard nutritional support with additional intravenous nutrition of 500 kcal per day for 3 weeks
62410308|NCT04259307|NO_INTERVENTION|Control group|Standard nutritional support only per day for 3 weeks
62410309|NCT06563661|EXPERIMENTAL|Dance group (DANG)|The participants in DANG will participate in 12 dance training sessions with the 21-style specific dance exercises (\~120 minutes each with rest breaks) in a group once a week for 12 weeks.
62410310|NCT06563661|ACTIVE_COMPARATOR|Wait-list control group (WLCG)|The participants in the WLCG will be provided a fall prevention pamphlet with a set of conventional fall prevention exercises (e.g., including a set of balance, walking, and resistance exercises) at the start and will receive the training from the 21-style specific dance exercises after three scheduled assessment sessions with two waiting periods of 12 weeks and 3 months in between.
62410311|NCT03718221|ACTIVE_COMPARATOR|Usual Care FIT Screening Strategy|"Mailed outreach invitation to complete FIT include: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage). Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion. Centralized processes to promote guideline-based follow-up."
62410312|NCT03718221|EXPERIMENTAL|GeoMail FIT Screening Strategy|The experimental arm differs from the active comparator in one way: patients living in treated ZIP codes will receive the mailed outreach at the same time.
62215747|NCT04474509|EXPERIMENTAL|FACT Module Engagement|During this module, patients will have the opportunity to increase their motivation to change and encourage the engagement in committed actions, consistent with their life values. Patients are invited to reflect on what is important in their lives, which values make their life worth living, and which actions they could take to live a meaningful life, in accordance with personal values. The use of metaphors and experiential exercises will facilitate the process of exploring personal values, identifying life directions and related behaviors. For example, the 80th Birthday Party metaphor requires participants to imagine there is a party in honor of their birthday and the time comes when people are starting to give speeches and try to answer the question about what they want to hear people at the party say. This exercise help patients in wondering what person they want to be with themselves and others.
62215748|NCT04474509|EXPERIMENTAL|FACT Module Openness|"Participants attending this module are guided to recognize and distancing themselves to stressful thoughts, feelings and sensations. They will learn to read suffering as part of human experience, without self-judgment and self-condemnation. Rather, therapist will encourage the patient's assumption of an open and acceptable approach to internal experiences. Throughout the module, therapist will help patients to reflect on their usual, but ineffective efforts to solve personal problems, and encourage the adoption of new responsive strategies based on acceptance and defusion from personal distress.~An example of metaphor used during the Module is The Passenger on a bus. In this metaphor patient have to imagine to be a driver bus and his every thought is a passenger that gets on and off the bus. This exercise help patients to accept, defuse from, and reduce the power of their thoughts."
62215749|NCT04474509|EXPERIMENTAL|FACT Module Awareness|The module comprises meditation exercises and experiences aimed to learn how to act intentionally with awareness about personal thought and sensations without automatically reacting. Participants are supported to recognize their actions and the context where they occur and learn to choose to respond with action consistent with their values and not automatically. Therapist will propose breathing exercises, body scan and others mindfulness experiences. Participants will be encouraged to sitting comfortably, close the eyes, feel themselves in contact with the present moment they are living, paying attention to their breath, noticing the rhythm and any other aspect of the experience of breathing. Then, the therapist guides the participant's attention on the body, noting any part of their body from the head to feet. Then, the sounds around, any noises that could distract their attention on themselves.
62215750|NCT05602389|EXPERIMENTAL|VL-G-A57|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
62215751|NCT05602389|EXPERIMENTAL|VL-G-E12|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
62215752|NCT05602389|PLACEBO_COMPARATOR|Placebo|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
62215753|NCT02811952||study group|Patients that need that need cystoscopy due to suspicion/known bladder malignancy.
62215754|NCT02811952||control group|Patients that need cystoscopy due to others reasons than malignancy.
62215755|NCT04391634|OTHER|Mechanical ventilation|Preterm infants on mechanical ventilation
62215756|NCT06303271|EXPERIMENTAL|Vagus Nerve Stimulation (VNS) and Caw Thorne Cooksey|Group will receive intervention of 30 minutes daily for 4 weeks (16 sessions).
62215757|NCT06303271|ACTIVE_COMPARATOR|Caw Thorne Cooksey|Group will receive intervention of 30 minutes daily for 4 weeks (16 sessions).
62215758|NCT04842929|ACTIVE_COMPARATOR|Active Stimulation|Active Comparator: Active stimulation with pulses emitted according to intervention description
62215759|NCT04842929|SHAM_COMPARATOR|Sham Stimulation|Sham Comparator: The blinding will be done with a sham coil, which consists of a coil that reproduces the sound that the true coil does, but without generating the magnetic field.
62215760|NCT04279132||TOTAL INTRAVENOUS ANESTHESIA|
62215761|NCT04279132||INHALATION ANESTHESIA|
62410313|NCT05153629|NO_INTERVENTION|Standard care|Participants will follow standard care until the ureteral stent is removed
62585121|NCT02591901|EXPERIMENTAL|Uro Vaxom|Uro Vaxom, Once daily for 3 months
62585122|NCT02591901|PLACEBO_COMPARATOR|Placebo|Placebo identical to main drug in shape and form
62215762|NCT04419272|EXPERIMENTAL|Methylphenidate|Subjects who will receive methylphenidate in the double-blinded period; when assigned to the active drug, the dosage of MPH will begin at 10mg twice per day, at 8am and 12pm, for one week. The dosage will then increase to 20mg twice daily, at 8am and 12pm, for the next 7 weeks.
62215763|NCT04419272|PLACEBO_COMPARATOR|Placebo|Subjects who will receive placebo in the double-blinded period; when assigned to receive the placebo during the double-blinded period, subjects will be given a sugar pill for 8 weeks. The sugar pill will be taken twice per day, at 8am and 12pm.
62215764|NCT04419272|OTHER|Open-Label Methylphenidate|All subjects will be offered open-label methylphenidate during Weeks 9-16. the dosage of MPH will begin at 10mg twice per day, at 8am and 12pm, for one week. The dosage will then increase to 20mg twice daily, at 8am and 12pm, for the next 7 weeks.
62215765|NCT00596401||1|HP eradication group
62215766|NCT00596401||2|No eradication group
62215767|NCT00596401||3|No Hp group
62215768|NCT06444204|EXPERIMENTAL|Rilzabrutinib: Mild Hepatic Impairment|Subjects with mild Hepatic Impairment (HI)
62585123|NCT06660381|EXPERIMENTAL|Psilocybin|Open-label psilocybin will be administered with psychological support to each participant at two dosing sessions approximately 2 weeks apart.
62792112|NCT01978041|EXPERIMENTAL|Non fluoridated water (<0.1 ppm F)|
62410314|NCT05153629|EXPERIMENTAL|TENS device|Participants will use the TENS device until the ureteral stent is removed
62410315|NCT04993287|EXPERIMENTAL|Pilot|45 eligible HF patients
62410316|NCT05812131|EXPERIMENTAL|COPEWEb|online COPEWeb training
62410317|NCT05812131|ACTIVE_COMPARATOR|COPE In person|COPE training delivered in person
62021152|NCT00558285|EXPERIMENTAL|indacaterol/glycopyrrolate 150/100 μg|"One capsule indacaterol/glycopyrrolate 150/50 μg and one capsule 50 μg glycopyrrolate delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
62410318|NCT00761761|EXPERIMENTAL|1- Sensoril (Ashwagandha)|Sensoril (Ashwagandha) will be administered using random assignment at a dose of 250 mg/day, increasing to a dose of 500 mg/day by the second week.
62021153|NCT00558285|ACTIVE_COMPARATOR|indacaterol 300 μg|"One capsule indacaterol 300 μg and one placebo capsule delivered via s single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
62021154|NCT00558285|PLACEBO_COMPARATOR|placebo|"Two placebo capsules delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
62021155|NCT05233826|EXPERIMENTAL|COVI-VAC|COVI-VAC Nose Drops
62021156|NCT01273831|OTHER|atracurium|Patients who underwent general anesthesia received atracurium
62021157|NCT01273831|OTHER|cisatracurium|Patients who underwent general anesthesia received cisatracurium
62021158|NCT04793412|EXPERIMENTAL|AHL/SSD|Children with asymmetric hearing loss or single-sided deafness
62021159|NCT05336240|ACTIVE_COMPARATOR|PCOM Standard Arm|"Providers in participating in the PCOM-standard intervention will be trained on optimizing an in-person provider communication technique about HPV vaccination by training primary care providers in a 2-step verbal communication process: 1) to start the HPV vaccine discussion using a presumptive format, and 2) to use motivational interviewing (MI) techniques to address parental vaccine hesitancy."
62021160|NCT05336240|EXPERIMENTAL|PCOM2 Virtual Arm|"Providers participating in the PCOM2-virtual arm will receive training on this communication method through an adapted virtual model of PCOM-standard.~PCOM2-Virtual intervention will result in a shelf ready intervention and associated User Manual that can be easily incorporated into practices broadly to improve the practice's adolescent HPV vaccination rates. PCOM-Virtual arm will then be compared to that of the original PCOM-standard intervention in its efficacy for increasing HPV vaccination among adolescents."
62021161|NCT05893108|EXPERIMENTAL|Losartan|ethosomal gel bearing losartan 5% applied two times a day for three consecutive months on keloids
62021162|NCT05893108|ACTIVE_COMPARATOR|Triamcinolone|Intralesional injection of triamcinolone acetonide 10 mg/ml every two weeks for three consecutive months on keloid
62021163|NCT05684484|ACTIVE_COMPARATOR|conventional treatment group|Group 1 (n=26): Patients will receive conventional treatment only of ulcerative colitis for 3 months.
62215769|NCT06444204|EXPERIMENTAL|Rilzabrutinib: Moderate Hepatic Impairment|Subjects with moderate Hepatic Impairment (HI)
62215770|NCT06444204|EXPERIMENTAL|Rilzabrutinib: Healthy-Matched Control|Subjects with normal hepatic function
62215771|NCT01967147|EXPERIMENTAL|Systane Balance|Propylene Glycol, 0.6% eye drops, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).
62215772|NCT01967147|ACTIVE_COMPARATOR|Saline|Preservative-Free 0.9% Saline solution, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).
62215773|NCT05923515|EXPERIMENTAL|JMKX000197 Dose 1|eight dose levels of JMKX000197 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.
62215774|NCT05923515|EXPERIMENTAL|JMKX000197 Dose 2|eight dose levels of JMKX000197 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.
62792113|NCT01978041|EXPERIMENTAL|Fluoridated water (1 ppm F)|
62215775|NCT05923515|EXPERIMENTAL|JMKX000197 Dose 3|eight dose levels of JMKX000197 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.
62021164|NCT05684484|EXPERIMENTAL|experimental treatment group|Patients will receive previous conventional treatment and Roflumilast (500 mcg ) orally once daily for 3 months
62215776|NCT05923515|EXPERIMENTAL|JMKX000197 Dose 4|eight dose levels of JMKX000197 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.
62410319|NCT00761761|PLACEBO_COMPARATOR|2 - Placebo|Placebo will be administered using random assignment at a dose of 250 mg/day, increasing to a dose of 500 mg/day by the second week.
62410320|NCT02716519|EXPERIMENTAL|Santyl|Collagenase ointment applied topically once per day for up to six weeks
62410321|NCT02716519|ACTIVE_COMPARATOR|Standard Card|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
62410322|NCT03699956|EXPERIMENTAL|Arm 1|"RRx-001 + eLOOP Device 4 mg IV infusion once weekly for 3 weeks~Cisplatin/carboplatin plus etoposide (up to 4 cycles):~1. Cisplatin or Carboplatin:~   1. Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR~  2. Carboplatin initially dosed at an AUC (area under the curve) of 5 on Day 1 every 3 weeks~2. Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks"
62021165|NCT02073045|EXPERIMENTAL|Supportive care (lymphedema education)|In an educational intervention, participants complete a five question lymphedema survey, designed by the Occupational Therapy staff, as an instrument to assess a patient's knowledge of lymphedema signs/symptoms before surgery. An OT, PT, and/or CLT provide written handouts to participants on the pathophysiology, signs, symptoms, and treatment of lymphedema. Participants repeat the survey at 3 months post-surgery. BUE circumferential measurements are also collected before surgery and at 3 months post-surgery.
62021166|NCT00917345||aldosteronism, hypertension|
62021167|NCT00917345||hypertension|
62021168|NCT04632992|EXPERIMENTAL|Arm A: Entrectinib|Participants in this treatment arm must have a positive tumor biomarker result for ROS1 gene fusion.
62215777|NCT05923515|EXPERIMENTAL|JMKX000197 Dose 5|eight dose levels of JMKX000197 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.
62021169|NCT04632992|EXPERIMENTAL|Arm B: Inavolisib|Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.
62021170|NCT04632992|EXPERIMENTAL|Arm C: Alectinib|Participants in this treatment arm must have a positive tumor biomarker result for ALK rearrangement tumors.
62021171|NCT04632992|EXPERIMENTAL|Arm D: Ipatasertib|Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.
62215778|NCT05923515|EXPERIMENTAL|JMKX000197 Dose 6|eight dose levels of JMKX000197 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.
62215779|NCT05923515|EXPERIMENTAL|JMKX000197 Dose 7|eight dose levels of JMKX000197 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.
62215780|NCT05923515|EXPERIMENTAL|JMKX000197 Dose 8|eight dose levels of JMKX000197 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.
62410323|NCT03699956|ACTIVE_COMPARATOR|Arm 2|"Cisplatin/carboplatin plus etoposide (up to 4 cycles):~1. Cisplatin or Carboplatin:~   1. Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR~  2. Carboplatin initially dosed at an AUC of 5 on Day 1 every 3 weeks~2. Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks"
62410324|NCT04014413|EXPERIMENTAL|Crohn's disease|Fecal Microbiota Transplant will be performed.
62410325|NCT04014413|EXPERIMENTAL|Ulcerative colitis|Fecal Microbiota Transplant will be performed.
62410326|NCT04014413|EXPERIMENTAL|Celiac disease|Fecal Microbiota Transplant will be performed.
62410327|NCT04014413|EXPERIMENTAL|Irritable bowel syndrome|Fecal Microbiota Transplant will be performed.
62410328|NCT04014413|EXPERIMENTAL|Functional dyspepsia|Fecal Microbiota Transplant will be performed.
62410329|NCT04014413|EXPERIMENTAL|Constipation|Fecal Microbiota Transplant will be performed.
62410330|NCT04014413|EXPERIMENTAL|Metabolic disease (diabetes mellitus or obesity)|Fecal Microbiota Transplant will be performed.
62410331|NCT04014413|EXPERIMENTAL|Multidrug-resistant infection|Fecal Microbiota Transplant will be performed.
62410332|NCT04014413|EXPERIMENTAL|Hepatic encephalopathy|Fecal Microbiota Transplant will be performed.
62410333|NCT04014413|EXPERIMENTAL|Multiple sclerosis|Fecal Microbiota Transplant will be performed.
62410334|NCT04014413|EXPERIMENTAL|Pseudo-obstruction|Fecal Microbiota Transplant will be performed.
62410335|NCT04014413|EXPERIMENTAL|CRE infection|Fecal Microbiota Transplant will be performed.
62410336|NCT04014413|EXPERIMENTAL|VRE infection|Fecal Microbiota Transplant will be performed.
62585124|NCT03378219||Cohort 1|Sarilumab-Exposed Cohort: Pregnant women exposed to Kevzara (sarilumab) for the treatment of an approved Kevzara (sarilumab) indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
62792114|NCT01978041|EXPERIMENTAL|Pilot study: Meal providing a fluoride dose of 60 ug F/kg|
62792115|NCT01978041|EXPERIMENTAL|Pilot study: Meal providing a fluoride dose of 120 ug F/kg|
62792116|NCT01181817|OTHER|SCS|patients with Failed back Surgery syndrome treated with SCS
62792117|NCT06009055|EXPERIMENTAL|Remimazolam group|
62792118|NCT06009055|ACTIVE_COMPARATOR|Propofol group|
62792119|NCT04532034|EXPERIMENTAL|Peer-Delivered Decision Support Intervention|
62792120|NCT02732548|ACTIVE_COMPARATOR|NPWT Only|Study subjects who are randomized to the control arm will be treated with Negative Pressure Wound Therapy (NPWT) and additional standard care treatments. No cellular or acellular biological tissue scaffold will be allowed for subjects in this study arm for the first 6 weeks of the study. Subjects who are randomized to this arm and who do not experience at least a 50% surface area reduction of the study wound by the 6 week study visit will have the option to cross over into the NPWT + MIRODERM treatment arm.
62792121|NCT02732548|EXPERIMENTAL|NPWT + MIRODERM|Subjects in this arm will receive NPWT and standard care, plus application(s) of the MIRODERM product.
62792122|NCT02384733|EXPERIMENTAL|Hypofractionated loco-regional RT|40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions weekly
62410337|NCT04014413|EXPERIMENTAL|Multiple organ dysfunction|Fecal Microbiota Transplant will be performed.
62410338|NCT04014413|EXPERIMENTAL|Dysbiotic bowel syndrome|Fecal Microbiota Transplant will be performed.
62410339|NCT04014413|EXPERIMENTAL|MRSA enteritis|Fecal Microbiota Transplant will be performed.
62410340|NCT04014413|EXPERIMENTAL|Pseudomembranous enteritis|Fecal Microbiota Transplant will be performed.
62021172|NCT04632992|EXPERIMENTAL|Arm E: Atezolizumab + Investigator's Choice of Chemotherapy|Participants in this treatment arm must have a positive tumor biomarker result for either tumor mutational burden (TMB) high or microsatellite instability (MSI) high/deficient mismatch repair (dMMR).
62021173|NCT04632992|EXPERIMENTAL|Arm F: Trastuzumab Emtansine + Atezolizumab|Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutations or amplification without known TMB high or MSI high/dMMR.
62410341|NCT04014413|EXPERIMENTAL|Alopecia|Fecal Microbiota Transplant will be performed.
62410342|NCT04014413|EXPERIMENTAL|Autism|Fecal Microbiota Transplant will be performed.
62410343|NCT04014413|EXPERIMENTAL|Graft-versus-host disease|Fecal Microbiota Transplant will be performed.
62410344|NCT04014413|EXPERIMENTAL|Idiopathic thrombocytopenic purpura|Fecal Microbiota Transplant will be performed.
62410345|NCT04014413|EXPERIMENTAL|Atopy or allergy|Fecal Microbiota Transplant will be performed.
62410346|NCT04014413|EXPERIMENTAL|Liver disease|Fecal Microbiota Transplant will be performed.
62410347|NCT04014413|EXPERIMENTAL|Alcohol dependence|Fecal Microbiota Transplant will be performed.
62410348|NCT04014413|EXPERIMENTAL|Antibiotic-associated diarrhea|Fecal Microbiota Transplant will be performed.
62410349|NCT03934242||New born group 1|New born who was born at the maternity of the CHU of Reims during a period of inclusion of one month, before nurses formation on the newborn's bedding
62410350|NCT03934242||New born group 2|New born who was born at the maternity of the CHU of Reims during a period of inclusion of one month, after nurses formation on the newborn's bedding
62410351|NCT04937452|EXPERIMENTAL|Rotigotine 4 mg|Rotigotine 4 mg/24 hours transdermal patch administration
62410352|NCT04937452|EXPERIMENTAL|Rotigotine 6 mg|Rotigotine 6 mg/24 hours transdermal patch administration
62410353|NCT04937452|PLACEBO_COMPARATOR|Placebo|Placebo transdermal patch administration
62410354|NCT04607265||Ventricular tachycardia (VT) group|NICM patients admitted for a VT ablation with a pre-operative cardiac- MRI.
62410355|NCT04607265||Control group|NICM patients without ventricular arrhythmia and a previous cardiac-MRI. The matching with the VT group was based on the age of the patients, the mean LVEF, the time between the initial diagnosis and the MRI examination, and the origin of the NICM.
62410356|NCT06063954|EXPERIMENTAL|Low-frequency continuous wave group|Low-frequency continuous wave EA In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2Hz continuous wave will be used for 20 min.
62599953|NCT03775122|EXPERIMENTAL|Group 2 sedation+TAES group|"Elderly patients under colonoscopy both have TAES neiguan(pc6) and sedation.~sedation is begun followed TAES. sedation is same as group2 do. TAES is same as group3 do."
62410357|NCT06063954|EXPERIMENTAL|Intermittent wave group|Intermittent wave EA In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 40Hz intermittent wave will be used for 20 min.
62410358|NCT02792400|PLACEBO_COMPARATOR|A1: GRA-placebo + MEAL + DPP4-placebo|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + linagliptin placebo
62410359|NCT02792400|PLACEBO_COMPARATOR|A2: GRA-active + MEAL + DPP4-placebo|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + linagliptin placebo
62410360|NCT02792400|ACTIVE_COMPARATOR|A3: GRA-placebo + MEAL + DPP4-active|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + 5 mg linagliptin (Trajenta)
62410361|NCT02792400|ACTIVE_COMPARATOR|A4: GRA-active + MEAL + DPP4-active|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + 5 mg linagliptin (Trajenta)
62410362|NCT02792400|PLACEBO_COMPARATOR|B1: GRA-placebo + MEAL + SGLT2-placebo|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + empagliflozin placebo
62410363|NCT02792400|PLACEBO_COMPARATOR|B2: GRA-active + MEAL + SGLT2-placebo|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + empagliflozin placebo
62410364|NCT02792400|ACTIVE_COMPARATOR|B3: GRA-placebo + MEAL + SGLT2-active|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + 25 mg empagliflozin (Jardiance)
62410365|NCT02792400|ACTIVE_COMPARATOR|B4: GRA-active + MEAL + SGLT2-active|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + 25 mg empagliflozin (Jardiance)
62410366|NCT02404675|EXPERIMENTAL|21 icotinib (250mg)|Patients with EGFR 21 exon positive are randomly assigned to higher dose icotinib group to receive icotinib with a dose of 250 mg three times per day, till progressive disease or unaccepted toxicity.
62410367|NCT02404675|ACTIVE_COMPARATOR|21 icotinib (125mg)|Patients with EGFR 21 exon positive are randomly assigned to routine dose icotinib group to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
62410368|NCT02404675|EXPERIMENTAL|19 icotinib (125mg)|Patients with EGFR del 19 exon positive are assigned to routine dose icotinib group to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
62410369|NCT06254131|EXPERIMENTAL|Ondansetron lozenge (Ondalenz ©)|Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
62410370|NCT06254131|EXPERIMENTAL|Ondansetron IV|Patients will receive 4 mg of ondansetron IV approximately 30 minutes before the end of surgery.
62410371|NCT06254131|NO_INTERVENTION|Control group|Patients will not receive ondansetron as a control group.
62410372|NCT04237831|EXPERIMENTAL|Arm A: Normal Renal Function|
62410373|NCT04237831|EXPERIMENTAL|Arm B: Mild Renal Impairment|
62410374|NCT04237831|EXPERIMENTAL|Arm C: Moderate Renal Impairment|
62410375|NCT04237831|EXPERIMENTAL|Arm D: Severe Renal Impairment|
62410376|NCT03733418||Intervention|Patients who received high dose D3 and completed the neuropsychological evaluations at 12 (+/-4) months after randomization.
62410377|NCT03733418||Placebo|Patients who received placebo and completed the neuropsychological evaluations at 12 (+/-4) months after randomization.
62410378|NCT04716816|NO_INTERVENTION|traditional treatment|received conventional analgesics.
62410379|NCT04716816|EXPERIMENTAL|Stripping massage|received SM twice daily in the active trigger points of the rhomboid for two weeks.
62410380|NCT05695456|ACTIVE_COMPARATOR|CLE positive patients real/sham|In this arm, participants who reacted to one or two nutrients during CLE will follow a personalized exclusion diet consistent of the nutrient to which they reacted, after which they will follow a sham diet in a blinded cross-over fashion.
62410381|NCT05695456|SHAM_COMPARATOR|CLE positive patients sham/real|In this arm, participants who reacted to one or two nutrients during CLE will follow a sham diet for 6 weeks, and than a personalized exclusion diet consistent of the nutrient to which they reacted, in a blinded cross-over fashion.
62410382|NCT05695456|SHAM_COMPARATOR|CLE negative patients|In this arm, participants who did not react to one of the nutrients during CLE will follow a control diet consistent of milk exclusion for 6 weeks, after which they will follow a gluten exclusion diet for 6 weeks, or the other way around.
62410383|NCT02801149|NO_INTERVENTION|No further imaging|Patients randomised to this group will receive standard care, i.e. will not undergo additional imaging scans at A\&E/Urgent Care Centre.
62410384|NCT02801149|EXPERIMENTAL|Wrist Magnetic Resonance Imaging (MRI)|Patients randomised to this group will undergo an additional 3-sequence wrist MRI during the initial A\&E/Urgent Care Centre episode.
62410385|NCT00822237|EXPERIMENTAL|VARIVAX 2007 process + M-M-R II|
62410386|NCT00822237|ACTIVE_COMPARATOR|VARIVAX 1999 process + M-M-R II|
62410387|NCT01438827|ACTIVE_COMPARATOR|Avanz Phleum pratense 15,000 SQ+|
62410388|NCT01438827|ACTIVE_COMPARATOR|Avanz Phleum pratense 4,000 SQ+|
62410389|NCT01438827|PLACEBO_COMPARATOR|Injection with no active grass component|
62410390|NCT06651125|EXPERIMENTAL|Cachectic Cancer Patients|
62410391|NCT06250972|ACTIVE_COMPARATOR|chemotherapy|Continuing chemotherapy using the previous regimen
62410392|NCT06250972|EXPERIMENTAL|Radiotherapy|Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy. Other radiation therapies include stereotactic body radiotherapy (SBRT) and proton could be administered.
62410393|NCT00403611|ACTIVE_COMPARATOR|Praziquantel 40mg/kg|Praziquantel (Distocide) 40mg/kg single oral dose
62410394|NCT00403611|EXPERIMENTAL|Praziquantel 60mg/kg|Praziquantel (Distocide) 60mg/kg single oral dose
62410395|NCT03397576|EXPERIMENTAL|ATHENA|Subjects in the experimental arm will participate in monthly group medication adherence counseling sessions within prison led by a nurse and peer educator. After prison release, subjects in the experimental group will participate in four home visits during which intervention staff (nurses and peer educators working in teams) will deliver individualized medication adherence counseling based on the Freirian educational model.
62410396|NCT03397576|NO_INTERVENTION|Control|Subjects in the control group will receive standard care, which includes a referral for HIV care and ART if prescribed ART within prison.
62410397|NCT05514496|EXPERIMENTAL|Part 1: NX-019 Dose Escalation|Patients will be treated with NX-019 in multiple ascending cohorts.
62599954|NCT05973019|EXPERIMENTAL|rTMS with 10 Hz|6 times/per week for 2 weeks, total 12 times rTMS.
62243261|NCT05794763|EXPERIMENTAL|Body Project: In Person Delivery|In the in-person peer-led group intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique and discuss the costs of pursuing the thin-ideal ideal. The intervention is 4 sessions long (1-hr each) and is administered by trained peer facilitators who use an intervention script. Participants will be asked to complete weekly home exercises throughout the course of the intervention.
62792123|NCT02384733|ACTIVE_COMPARATOR|Normofractionated loco-regional RT|50 Gy / 25 fractions, 2.00 Gy per fraction, 5 fractions weekly
62410398|NCT05514496|EXPERIMENTAL|Part 2: NX-019 Dose Expansion|Patients will be treated with the REDs of NX-019 as determined in Part 1.
62410399|NCT05381025|EXPERIMENTAL|Active to Placebo (Cohort 1)|Participants randomly allocated to Cohort 1 for Phase 1 will begin the study taking the active ingredient and will cross-over to taking placebo in Phase 2 of the study after a washout period.
62021174|NCT04632992|EXPERIMENTAL|Arm G: PH FDC SC|Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
62410400|NCT05381025|EXPERIMENTAL|Placebo to Active (Cohort 2)|Participants randomly allocated to Cohort 2 for Phase 1 will begin the study taking the placebo and will cross-over to taking the active ingredient in Phase 2 of the study after a washout period.
62738620|NCT05273814|EXPERIMENTAL|Tislelizumab+Bevacizumab+Pemetrexed|"Bevacizumab，7.5mg/kg，d1; Pemetrexed，500mg/m2，d1; Tislelizumab，200mg，d4; Q3W for 4 cycles;~Maintenance treatment ： Tislelizumab，200mg，d1; Bevacizumab，7.5mg/kg，d1; Q3W for 2 years"
62738621|NCT03216343|EXPERIMENTAL|Study Arm|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle until objective disease progression
62410401|NCT01907516|ACTIVE_COMPARATOR|Cell phone-internet first|Cell phone-internet home glucose reporting system first
62410402|NCT01907516|PLACEBO_COMPARATOR|Voicemail first|Voicemail home blood glucose reporting first
62410403|NCT04137926|EXPERIMENTAL|Alzheimer's disease|
62410404|NCT04137926|EXPERIMENTAL|MCI due to AD|
62410405|NCT04137926|EXPERIMENTAL|Normal Elderly|
62738622|NCT00851292|ACTIVE_COMPARATOR|Side-firing|prostate biopsies obtained with side-firing probe
62738623|NCT00851292|ACTIVE_COMPARATOR|End-firing|
62738624|NCT04222699|EXPERIMENTAL|Intranasal Mupirocin and Topical Chlorhexidine|Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
62021175|NCT04632992|EXPERIMENTAL|Arm H: PH FDC SC + Investigator's Choice of Chemotherapy|Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
62738625|NCT00136695|EXPERIMENTAL|anastrozole|anastrozole
62738626|NCT00136695|PLACEBO_COMPARATOR|placebo|placebo
62738627|NCT04601532|ACTIVE_COMPARATOR|Silver sulfadiazine|Topical management via dressings provide a barrier against microbial infection. The current gold standard for burn wound dressings is silver (nanoparticulate or ionic), and it has shown some efficacy in treating infections, but it does not demonstrate an ability to prevent infections and some treatment guidelines even recommend against its use. Although silver dressing is preferred for military use, a retrospective review spanning 10 years of use in military environments showed that silver was not more effective than other antimicrobial topical treatments, and a meta-analysis with over 2500 surgical patients found silver sulfadiazine was associated with increased infection rates and hospital length-of-stays were two days longer on average.
62738628|NCT04601532|EXPERIMENTAL|Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser|Synedgen has developed Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser. These products are Food and Drug Administration (FDA) 510(k) cleared wound care medical devices, formulated with a novel biocompatible chitosan derivative, poly (acetyl, arginyl) glucosamine. SynePure™ Wound Cleanser is optimized for the cleansing and debridement of wounds and thermal injuries, and Catasyn™ Advanced Technology Hydrogel serves as a protective gel dressing. Together, these products reduce inflammation in wounds, aggregate bacteria and disrupt bacterial biofilms, and accelerate healing.
62738629|NCT02020434|EXPERIMENTAL|Single dose of RPX7009 and RPX2014|Single dose of combination RPX7009 and RPX2014
62738630|NCT05749991|EXPERIMENTAL|DryShield Isolation|Device: Dryshield DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time. Dryshield was used to isolate teeth that required sealant placement in the assigned participants.
62215781|NCT03093623|EXPERIMENTAL|Physical activity|In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points \* time of each exercise (hours) \* Number of times per week + moderate level 5 points \* time per activity (hours) \* number of times per week + low level 3 points \* time per activity (hours) \* number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (\>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
62215782|NCT03093623|NO_INTERVENTION|Non-Physical activity|the non-physical activity group,investigators do not give them any physical interventions
62215783|NCT06610305|EXPERIMENTAL|Estradiol+Progesterone, then Placebo|Two weeks of luteal phase transdermal estradiol (0.1mg/day)+oral progesterone (200 mg/day) during the first intervention cycle, followed by a one cycle washout, followed by two weeks of luteal phase transdermal/oral placebo
62215784|NCT06610305|EXPERIMENTAL|Placebo, then Estradiol+Progesterone|Two weeks of luteal phase transdermal/oral placebo during the first intervention cycle, followed by a one cycle washout, followed by two weeks of luteal phase transdermal estradiol (0.1 mg/day)+oral progesterone (200 mg/day)
62215785|NCT00141219|EXPERIMENTAL|1|
62215786|NCT00141219|PLACEBO_COMPARATOR|2|
62215787|NCT00322543|EXPERIMENTAL|Drug eluting stent|Corio™ Pimecrolimus-eluting stent
62215788|NCT06610968|EXPERIMENTAL|Vitamin D Group|The treatment intervention will consist of three weeks of one 5000 IU cholecalciferol capsule (Pure Encapsulations, LLC) daily, with breakfast.
62215789|NCT06610968|PLACEBO_COMPARATOR|Placebo Group|The control group will also take a daily, with breakfast, placebo capsule (Zeebo) for the three-week intervention.
62215790|NCT03103490|OTHER|18F-FSPG|Patients receive 18F-FSPG for detection of Cardiac Sarcoidosis or Inflammation
62215791|NCT06349642||Observational|Patients undergo tissue biopsy and may optionally undergo blood sample collection and have their medical records reviewed on study. Patients receive standard treatment with checkpoint inhibitors during the study and undergo standard tumor assessments during screening and follow-up.
62585125|NCT03378219||Cohort 2|Disease-matched Comparison Cohort: Pregnant women diagnosed with Kevzara (sarilumab) approved indication. Approximate frequency matched to the exposed group by disease indication, validated by medical records, who have not been exposed to Kevzara (sarilumab) any time in the current pregnancy, and have taken another biologic DMARD medication for their disease within 2 years before the current pregnancy and have an indication for such treatment at enrollment
62215792|NCT04847232|EXPERIMENTAL|Sodium Zirconium Cyclosilicate|
62215793|NCT04847232|PLACEBO_COMPARATOR|Placebo|
62215794|NCT02027636|ACTIVE_COMPARATOR|Engagement and Counseling for Latinos (ECLA-F)|Patients in this arm (ECLA-F) receive the 6-8 session CBT plus care-management intervention, administered in person.
62021176|NCT04632992|EXPERIMENTAL|Arm I: Trastuzumab Emtansine + Tucatinib|Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
62215795|NCT02027636|ACTIVE_COMPARATOR|Engagement and Counseling for Latinos (ECLA-T)|Patients in this arm received the 6-8 session CBT intervention via telephone.
62215796|NCT02027636|NO_INTERVENTION|Usual Care|Patients in this arm receive usual care for depression from their primary care providers, which could include antidepressant prescription or referral to specialty mental health care.
62215797|NCT00976872|ACTIVE_COMPARATOR|omega-3|"omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA"
62215798|NCT00976872|PLACEBO_COMPARATOR|placebo|hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
62215799|NCT04490200|EXPERIMENTAL|Novel chitosan semi facial respirator (VESTA)|VESTA is a semi facial respirator that follows the same technical specifications of a N95 class PFF2 respirator. However, the VESTA respirator has nanoparticles in the filtering element, which is manufactured with a product of 50 gsm melt blown polypropylene-treated with an electrostatic charge. This filtering element deposits nanoparticles of polymeric biodegradable material known as chitosan. Chitosan can act as a surface for adsorption and viral inactivation.
62410406|NCT04269031|EXPERIMENTAL|Cohort 1|On Day 1, randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 1 (6 subjects) or matching placebo (2 subjects).
62410407|NCT04269031|EXPERIMENTAL|Cohort 2|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 2 (6 subjects) or matching placebo (2 subjects).
62215800|NCT04490200|ACTIVE_COMPARATOR|Conventional N95 semi facial respirator|The N95 PFF2 respirators are manufactured from TNT as defined in ABNT NBR 15052: 2004 and in the resolution of ANVISA RDC No. 356. The filtering element is usually formed by a layer of thin polypropylene fibers arranged at random. This configuration influences the particles (which constitute aerosols) to move along an extensive and tortuous path in relation to their size; thus, increasing the probability of them coming into contact with the fibers and being retained. A number of mechanisms influence the interception of particles by the fibers of the filter element. In addition to the mechanical interception mechanisms, the presence of charges on the surface of the filter material can enhance the association of particles with its fibers and optimize the efficiency of the respirator.
62410408|NCT04269031|EXPERIMENTAL|Cohort 3|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 3 (6 subjects) or matching placebo (2 subjects).
62410409|NCT04269031|EXPERIMENTAL|Cohort 4|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 4 (6 subjects) or matching placebo (2 subjects).
62410410|NCT04269031|EXPERIMENTAL|Cohort 5|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 5 (6 subjects) or matching placebo (2 subjects).
62410411|NCT04269031|EXPERIMENTAL|Cohort 6|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 6 (6 subjects) or matching placebo (2 subjects).
62410412|NCT03176927|EXPERIMENTAL|Gastroparesis|"magnetogastrogram~Diabetes with and without gastroparesis ; Idiopathic gastroparesis"
62410413|NCT03176927|EXPERIMENTAL|Gastrectomy|"magnetogastrogram~Total or partial gastrectomy group"
62410414|NCT03176927|EXPERIMENTAL|Functional dyspepsia|"magnetogastrogram~Children with functional dyspepsia"
62410415|NCT03176927|EXPERIMENTAL|Chronic nausea|"magnetogastrogram~Children with chronic nausea"
62585126|NCT03378219||Cohort 3|Non-diseased Comparison Cohort: Healthy pregnant women not diagnosed with a Kevzara (sarilumab) indication and unexposed to Kevzara (sarilumab) during the course of the pregnancy
62215801|NCT03888053|ACTIVE_COMPARATOR|BB-101 Treatment Arm|BB-101 liquid formulation concentration of 2 µg/mL or 20 µg/mL will be applied on the target lower leg or foot ulcer once a day for 4 consecutive weeks.
62215802|NCT03888053|PLACEBO_COMPARATOR|Placebo Arm|Placebo will be applied on the target lower leg or foot ulcer once a day for 4 consecutive weeks.
62021177|NCT04632992|EXPERIMENTAL|Arm J: Trastuzumab Emtansine + Atezolizumab|Participants in this treatment arm must have positive tumor biomarker results for ERBB2 mutation or amplification and TMB high or MSI high/dMMR.
62021178|NCT04632992|EXPERIMENTAL|Arm K: Ipatasertib + Atezolizumab|Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.
62021179|NCT04632992|EXPERIMENTAL|Arm L: Ipatasertib + Atezolizumab|Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.
62021180|NCT04632992|EXPERIMENTAL|Arm M: Ipatasertib + Paclitaxel|Participants in this treatment arm must have a positive tumor biomarker results for PI3KCA activating mutations and either AKT1/2/3 activating mutation or PTEN loss/loss of function.
62215803|NCT01917539|SHAM_COMPARATOR|Sham Treatment|Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment. All subjects will come for their initial visit where evaluation and treatment #1 will take place. They will also attend 3 follow-up visits spaced approximately 3-4 weeks apart during which they will have subsequent treatments and/or evaluations for their dry eyes. The visit duration will range from approximately 60-90 minutes per clinic visit.
62215804|NCT01917539|EXPERIMENTAL|Pulsed Light Therapy|All subjects will come for their initial visit where evaluation and treatment #1 will take place. They will also attend 3 follow-up visits spaced approximately 3-4 weeks apart during which they will have subsequent treatments and/or evaluations for their dry eyes. The visit duration will range from approximately 60-90 minutes per clinic visit.
62215805|NCT03084341|ACTIVE_COMPARATOR|NMEE Group|Neuromuscular Electrical Elongation
62215806|NCT03084341|ACTIVE_COMPARATOR|PNF Group|Proprioceptive Neuromuscular Facilitation stretching
62215807|NCT03084341|NO_INTERVENTION|Control Group|No intervention
62215808|NCT02176993||Application of surface cooling|Surface cooling during 60 minutes.
62215809|NCT04747327|EXPERIMENTAL|specific vaccine policy 1|Those in this arm will learn about a specific financial incentive or mandate policy.
62215810|NCT04747327|EXPERIMENTAL|specific vaccine policy 2|Those in this arm will learn about a specific financial incentive or mandate policy.
62215811|NCT04747327|EXPERIMENTAL|specific vaccine policy 3|Those in this arm will learn about a specific financial incentive or mandate policy.
62215812|NCT04747327|EXPERIMENTAL|Specific vaccine policy 4|Those in this arm will learn about a specific financial incentive or mandate policy.
62215813|NCT04747327|EXPERIMENTAL|specific vaccine policy 5|Those in this arm will learn about a specific financial incentive or mandate policy.
62410416|NCT03176927|EXPERIMENTAL|Control participants|"magnetogastrogram~Group without any gastrointestinal diseases."
62410417|NCT03962114|EXPERIMENTAL|Intervention group|treatment with vitamin B3
62410418|NCT03788239|EXPERIMENTAL|Arm 1|Right knee wound closure by staples and Left Knee wound closure by sutures
62021181|NCT04632992|EXPERIMENTAL|Arm N: Atezolizumab + Tiragolumab|Participants in this treatment arm must have a positive tumor biomarker result for either TMB high or MSI high/dMMR.
62215814|NCT04747327|EXPERIMENTAL|specific vaccine policy 6|Those in this arm will learn about a specific financial incentive or mandate policy.
62215815|NCT04747327|EXPERIMENTAL|specific vaccine policy 7|Those in this arm will learn about a specific financial incentive or mandate policy.
62215816|NCT04747327|EXPERIMENTAL|specific vaccine policy 8|Those in this arm will learn about a specific financial incentive or mandate policy.
62215817|NCT04747327|EXPERIMENTAL|specific vaccine policy 9|Those in this arm will learn about a specific financial incentive or mandate policy.
62215818|NCT04747327|EXPERIMENTAL|specific vaccine policy 10|Those in this arm will learn about a specific financial incentive or mandate policy.
62215819|NCT04747327|EXPERIMENTAL|sleep financial incentive|Those in this arm will invite adults to join an RCT that uses financial incentives to reward those who increase their sleep.
62410419|NCT03788239|EXPERIMENTAL|Arm 2|Right knee wound closure by sutures and Left Knee wound closure by staples
62410420|NCT01827553|EXPERIMENTAL|Induction CT, chemoradiotherapy|Induction chemotherapy with gemcitabine or FOLFIRINOX; Radiotherapy, 28 x 1.8 Gy; Chemotherapy, gemcitabine;
62410421|NCT01827553|ACTIVE_COMPARATOR|Induction CT, chemotherapy|Induction chemotherapy with gemcitabine or FOLFIRINOX; Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy
62585127|NCT06684808|EXPERIMENTAL|Fitness|The Fitness group engaged in active breaks aimed at improving cardiovascular efficiency. These breaks were designed to provide moderate to vigorous physical activity, incorporating both strength and aerobic exercises such as squats, jumping jacks, lunges, and running in place. Children were instructed to imitate the teacher's movements
62215820|NCT04747327|EXPERIMENTAL|sleep social incentive|Those in this arm will invite adults to join an RCT that uses social (gamification) incentives to reward those who increase their sleep.
62215821|NCT04747327|EXPERIMENTAL|exercise financial incentive|Those in this arm will invite adults to join an RCT that uses financial incentives to reward those who increase their exercise.
62792124|NCT00345865|EXPERIMENTAL|NHL with irradiation|Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
62792125|NCT00345865|EXPERIMENTAL|HL without irradiation|Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
62215822|NCT04747327|EXPERIMENTAL|exercise social incentive|Those in this arm will invite adults to join an RCT that uses social incentives to reward those who increase their exercise.
62215823|NCT06331702|EXPERIMENTAL|Group 1 (JEV-I and MMR co-administration group)|Participants will receive 1 dose of JEV-I and 1 dose of MMR concurrently on Day 0, with each vaccine administered on a different side of the body, and a second dose of JEV-I 7-10 days later. Blood sampling will be performed on Day 0 and 30 days after the second dose of JEV-I.
62215824|NCT06331702|ACTIVE_COMPARATOR|Group 2 (JEV-I administered separately)|Participants will receive 2 doses of JEV-I (7-10 days apart). Blood sampling will be performed on Day 0 and 30 days after the second dose of JEV-I.
62215825|NCT06331702|ACTIVE_COMPARATOR|Group 3 (MMR administered separately)|Participants will receive 1 doses of MMR. Blood sampling will be performed on Day 0 and Day 30.
62410422|NCT01035112|EXPERIMENTAL|Magnetic Resonance Imaging (MRI) of Breast Cancer|Contrast-enhanced magnetic resonance imaging (MRI) using the standard department of Radiology MRI screening procedures. The duration of scanning may be variable, but will not exceed 90 minutes.
62410423|NCT05629741|EXPERIMENTAL|CMTX-101 2.5 mg/kg|CMTX-101 will be administered as a single IV infusion over 60 minutes.
62410424|NCT05629741|EXPERIMENTAL|CMTX-101 5 mg/kg|CMTX-101 will be administered as a single IV infusion over 60 minutes.
62410425|NCT05629741|EXPERIMENTAL|CMTX-101 15 mg/kg|CMTX-101 will be administered as a single IV infusion over 60 minutes.
62021182|NCT04632992|EXPERIMENTAL|Arm O: Pralsetinib|Participants in this treatment arm must have a positive tumor biomarker result for RET fusion.
62021183|NCT03197493|EXPERIMENTAL|High Dose|carbidopa-levodopa 25-100 mg 2 tablets TID
62215826|NCT02075073|EXPERIMENTAL|SB3|SB3, single dose of 6 mg/kg via intravenous infusion (study drug)
62215827|NCT02075073|ACTIVE_COMPARATOR|EU sourced Herceptin®|EU sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
62215828|NCT02075073|ACTIVE_COMPARATOR|US sourced Herceptin®|US sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
62215829|NCT06431477|EXPERIMENTAL|Telmisartan tablet|
62215830|NCT06431477|ACTIVE_COMPARATOR|Losartan tablet|
62215831|NCT03646591||Neoadjuvant chemotherapy|"FLOT Chemotherapy regimen~A cycle consist of Day 1: 5-fluorouracil (5-FU) 2600mg/M2 intravenous Via peripherally inserted central catheter (PICC) for 24 hour Day 1: Leucovorin 200mg/M2 intravenous Day 1: Oxaliplatin 85mg/ M2 intravenous Day 1: Docetaxel 50mg/M2 intravenous Repeated every 15th day"
62215832|NCT00657020|EXPERIMENTAL|Nicotine lozenge|Nicotine lozenge containing 4 mg of nicotine to be placed in mouth and suck to dissolution.
62215833|NCT00657020|PLACEBO_COMPARATOR|Placebo lozenge|Placebo lozenge to be placed in mouth and suck to dissolution.
62410426|NCT05629741|EXPERIMENTAL|CMTX-101 30 mg/kg|CMTX-101 will be administered as a single IV infusion over 60 minutes.
62410427|NCT05629741|PLACEBO_COMPARATOR|CMTX-101 0 mg/kg|Placebo will be administered as a single IV infusion over 60 minutes
62792126|NCT00345865|EXPERIMENTAL|NHL - HIV infected with irradiation|Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
62792127|NCT00345865|EXPERIMENTAL|NHL - HIV infected without irradiation|Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
62792128|NCT00345865|EXPERIMENTAL|NHL without radiation and cyclosporine|Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
62215834|NCT05658497||Diroximel Fumarate|Pregnant women with MS who were exposed to DRF at any time from 2 weeks after the first day of their LMP through the end of pregnancy.
62215835|NCT05658497||Disease Modifying Therapy (DMTs) Exposed|Pregnant women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries) at any time from 2 weeks after the first day of their LMP through the end of pregnancy.
62410428|NCT04838132|EXPERIMENTAL|Transversus thoracis muscle plane and rectus sheath block with ropivacaine|Using the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle (TTP block) and rectus sheath block, give 15ml and 10ml 0.3% ropivacaine respectively.
62410429|NCT04838132|EXPERIMENTAL|Transversus thoracis muscle plane and rectus sheath puncture with saline|Using the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle (TTP block) and rectus sheath block, give 15ml and 10ml 0.9% saline respectively.
62021184|NCT03197493|EXPERIMENTAL|Intermediate Dose|carbidopa-levodopa 25-100 mg 1 tablet TID
62410430|NCT01923207|EXPERIMENTAL|DX-2930|DX-2930 administered by subcutaneous route
62410431|NCT01923207|PLACEBO_COMPARATOR|placebo|inactive formulation of DX-2930
62410432|NCT00446134|EXPERIMENTAL|Group 1: Drug|Oral taribavirin tablet 20 mg/kg/day (Actual doses were 20-24 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
62215836|NCT05658497||DMTs Unexposed|Pregnant women who were unexposed to DMT which is defined as either never received a DMT or discontinued treatment with DRF at least 1 day before 2 weeks after the first day of their LMP or discontinued a non-Registry-specified MS DMT more than 5 times its half-life prior to 2 weeks after the first day of their LMP.
62215837|NCT05658497||Dimethyl Fumarate|Pregnant women with MS who were exposed to DMF at any time from 2 weeks after the first day of their LMP through the end of pregnancy.
62215838|NCT05658497||Women Without MS|Pregnant women with external, general population comparators.
62215839|NCT06479616|EXPERIMENTAL|long term follow up|All participants who complete CS-101-03(NCT0606518) studie after CS-101 infusion will be asked to participate in this long-term follow-up study.
62215840|NCT02141451|EXPERIMENTAL|INCB7839 100 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
62215841|NCT02141451|EXPERIMENTAL|INCB7839 200 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
62410433|NCT00446134|EXPERIMENTAL|Group 2: Drug|Oral taribavirin tablet 25 mg/kg/day (Actual doses were 25-29 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
62819316|NCT03659188|EXPERIMENTAL|Cortico-alveolar perforations|Patients will undergo orthodontic treatment plus cortico-alveolar perforations.
62021185|NCT03465540|EXPERIMENTAL|Part 1A: AMG 397 Dose Escalation|This arm includes subjects with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL).
62021186|NCT03465540|EXPERIMENTAL|Part 1B: AMG 397 Dose Escalation|This arm includes subjects with acute myeloid leukemia (AML).
62021187|NCT03465540|EXPERIMENTAL|Part 2A: AMG 397 Monotherapy|This arm includes subjects with AML or myelodysplastic syndrome (MDS).
62215842|NCT02141451|EXPERIMENTAL|INCB7839 300 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
62215843|NCT02141451|EXPERIMENTAL|INCB7839 (Phase II)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
62215844|NCT00618527|EXPERIMENTAL|1|Rebif with Cellcept
62215845|NCT00618527|PLACEBO_COMPARATOR|2|Rebif alone
62215846|NCT05882552|EXPERIMENTAL|Tilted Gaze Target Test+Conventional Examinations|Tilted gaze target test is before conventional examination
62215847|NCT05882552|ACTIVE_COMPARATOR|Conventional Examinations +Tilted Gaze Target Test|Conventional examination is before tilted gaze target test
62215848|NCT00271531||1|150 subjects greater than 48 weeks post-conception and less than 18 years of age who are mechanically ventilated and have presumed bacterial pulmonary infection.
62215849|NCT00470366|EXPERIMENTAL|Paclitaxel, Ifosfamide, and Cisplatin|-Paclitaxel is administered first, 120 mg/m2 on days 1 and 2 every three weeks for four cycles. Cisplatin is administered at 20 mg/m2 over approximately 30 minutes daily for five days every three weeks for four courses. -The ifosfamide is given last with 1200 mg/m2 daily for five days every three weeks for four cycles.
62215850|NCT02871258|OTHER|The MetaNeb® System Treatment|Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment.
62215851|NCT02138955|EXPERIMENTAL|Liposomeal curcumin ascending dose phase 1b|
62410434|NCT00446134|EXPERIMENTAL|Group 3: Drug|Oral taribavirin 30 mg/kg/day (Actual doses were 30-34 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
62410435|NCT00446134|ACTIVE_COMPARATOR|Group 4: Drug|Oral ribavirin 800 mg/day (body weight \<65 kg), 1000 mg/day (body weight 65-84 kg), 1200 mg/day (body weight 85-104 kg) or 1400 mg/day (body weight greater than or equal to 105 kg) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
62410436|NCT01219270||GFR >= 60|MDRD eGFR 60 or more
62410437|NCT01219270||GFR <60|Under MDRD eGFR 60
62819317|NCT03659188|EXPERIMENTAL|Traditional Corticotomy|Patients will undergo orthodontic treatment plus an acceleration procedure employing traditional corticotomy.
62819318|NCT03659188|NO_INTERVENTION|Control|Patients will undergo orthodontic treatment in which canine retraction will be accomplished using the standard sliding mechanism without any acceleration procedures.
62021188|NCT03465540|EXPERIMENTAL|Part 2B: AMG 397 Monotherapy|This arm includes subjects with AML in Japan only.
62021189|NCT03465540|EXPERIMENTAL|Part 2C: AMG 397 Monotherapy|This arm includes subjects with MM.
62021190|NCT03465540|EXPERIMENTAL|Part 3A: AMG 397 + Azacitidine Combotherapy|This arm includes subjects MDS.
62021191|NCT03465540|EXPERIMENTAL|Part 3B: AMG 397+ Azacitidine Combotherapy|This arm includes subjects AML.
62819319|NCT03626454|ACTIVE_COMPARATOR|group B|'Norepinephrine bolus' of 6 µg plus Normal Saline 0.9% Infusion Solution
62021192|NCT03465540|EXPERIMENTAL|Part 3C: AMG 397+ Dexamethasone Combotherapy|This arm includes subjects MM.
62021193|NCT02344186|EXPERIMENTAL|Liraglutide|Liraglutide will be started first with 0.6 mg/d for 1 week, then increased to 1.2 mg/d from week 2 to week 12, followed by 1.8 mg/d from week 12 to week 24.
62021194|NCT02344186|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo for 12 weeks.
62215852|NCT01879059|EXPERIMENTAL|Exercise|5 days of inactivity followed by a 1 day return to physical activity
62585128|NCT06684808|EXPERIMENTAL|Creative|The Creative group participated in active breaks that combined cognitive-creative and physical demands, incorporating activities like improvisations, dramatizations of events or short stories, simulation, and imitation games. These activities aimed to stimulate the creative process and enhance emotional expression within environmental constraints. Constraints, set by the teacher-such as specific rules, partner positioning, or speed of execution-limited movement options, encouraging students to explore new solutions to complete each task.
62819320|NCT03626454|ACTIVE_COMPARATOR|group I|'Norepinephrine infusion' 6 µg/kg/h plus 'Normal Saline Flush, 0.9% Injectable Solution
62215853|NCT02138084|EXPERIMENTAL|Cohort 1: BMS-663068 + Rifabutin|"Regimen A: BMS-663068 tablet by mouth as specified~Regimen B: BMS-663068 tablet with Rifabutin capsule by mouth as specified"
62215854|NCT02138084|EXPERIMENTAL|Cohort 2: BMS-663068 + Rifabutin + Ritonavir|"Regimen A: BMS-663068 tablet by mouth as specified~Regimen C: BMS-663068 tablet, Rifabutin capsule and Ritonavir (RTV) capsule by mouth as specified"
62585129|NCT06684808|EXPERIMENTAL|Combined|The Combined group took active breaks by combining the Fitness protocol in the first break and the Creative protocol in the second.
62585130|NCT06684808|ACTIVE_COMPARATOR|Control|Regular physical activity at school during the weeks.
62585131|NCT06615401||Transgender and Gender Diverse Veterans|Veterans with documentation of either a gender identity disorder diagnoses, self-identified gender identity as transgender and gender diverse or transgender-related health factor.
62585132|NCT02693171||Dinutuximab administered for 5 cycles|High-risk neuroblastoma patient treated with Unituxin as standard of care
62585133|NCT06681857|ACTIVE_COMPARATOR|Test group: Gelatin Sponge|"The surgical intervention will be executed under local anesthesia. After the elevation of the full-thickness mucoperiosteal flap over the lateral wall of the maxillary sinus, a circular lateral window will be created by sinus low-speed bur grinding of the cortical ring to guard against the Shniederian membrane violation, followed by its separation along the sinus floor, lateral walls and the boundaries of the window to elaborate a smooth superior membrane elevation.~The created spaces beneath the elevated Shniederian membrane will be filled up by an absorbable gelatin sponge for the test group patients followed by the coverage of the side window with collagen membrane, secured with bone tacks to guard against the graft fibroblastic invasion."
62215855|NCT06529510|EXPERIMENTAL|REThink game|Participants in this group will have access to the REThink therapeutic game for four weeks
62215856|NCT06529510|NO_INTERVENTION|Care as usual|Participants in the control group do not receive an intervention but they have access to standard resources from the school
62585134|NCT06681857|ACTIVE_COMPARATOR|Control group: Allogenic Demineralized Bone Matrix|"The surgical intervention will be executed under local anesthesia. After the elevation of the full-thickness mucoperiosteal flap over the lateral wall of the maxillary sinus, a circular lateral window will be created by sinus low-speed bur grinding of the cortical ring to guard against the Shniederian membrane violation, followed by its separation along the sinus floor, lateral walls and the boundaries of the window to elaborate a smooth superior membrane elevation.~The created spaces beneath the elevated Shniederian membrane will be filled up by allogenic (DBM) for the control group patients, followed by the coverage of the side window with collagen membrane, secured with bone tacks to guard against the graft fibroblastic invasion."
62410438|NCT01321970|OTHER|Severe coronary artery disease|Patients in this group have coronary artery disease with a stenosis of \>70%.
62410439|NCT01321970|OTHER|Coronary artery disease|Patients in this group have coronary artery disease with stenosis \< 70%.
62585135|NCT06569173|EXPERIMENTAL|LaiKai Anti-Reflux Ureteral Stent (19903)|LaiKai Anti-Reflux Ureteral Stent (19903) arm received anti-reflux stent.
62585136|NCT06569173|ACTIVE_COMPARATOR|LaiKai Ureteral Stent (92001024)|LaiKai Ureteral Stent (92001024) arm received regular ureteral stent.
62819321|NCT04267120|EXPERIMENTAL|Lenvatinib + Pembrolizumab|"* Lenvatinib 20 mg/day will be administered orally on a daily basis and pembrolizumab 200 mg will be infused once every 3 weeks.~* Subjects may be treated with pembrolizumab for a maximum of 35 cycles or approximately 2 years, but treatment with lenvatinib can continue beyond 2 years if the subject does not meet other treatment discontinuation criteria."
62215857|NCT03621631|EXPERIMENTAL|optimized Tai Chi intervention|optimized Tai Chi intervention
62215858|NCT03621631|ACTIVE_COMPARATOR|traditional Tai Chi intervention|traditional Tai Chi intervention
62215859|NCT03488303||Main group|Study has only one group
62215860|NCT04461093|EXPERIMENTAL|Group I|"Group I (n=45)~1. Acupressure wristband~2. IV Dexamethasone 8mg~3. IV Ondansetron 4mg"
62215861|NCT04461093|ACTIVE_COMPARATOR|Group II|"Group II (n=45)~1. IV Palonosetron 0.075mg"
62215862|NCT03113838||Taking YXSF Capsule Group|The overall individuals taking YXSF Capsule and achieving the inclusion criteria.
62410440|NCT06575348|EXPERIMENTAL|People using YouControl-A-Fib app|
62410441|NCT02304302|PLACEBO_COMPARATOR|Placebo|Identically-looking placebo pills to memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
62410442|NCT02304302|EXPERIMENTAL|Memantine|Memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
62410443|NCT06566651||Amyotrophic Lateral Sclerosis (ALS)|People diagnosed or suspected of having the neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS)
62410444|NCT06566651||Neuromuscular|People diagnosed with a neuromuscular disease other than ALS
62410445|NCT06566651||Control|Healthy people
62410446|NCT01861431|ACTIVE_COMPARATOR|HIVSRR|4 sessions of HIV sexual risk reduction
62410447|NCT01861431|EXPERIMENTAL|HIVSRR + Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
62792129|NCT03301350|EXPERIMENTAL|Neoadjuvant Chemotherapy|"Regimen A (cycles 1-4):~Paclitaxel 80 mg/m2; administer intravenously on day 1, 8, 15 of cycles 1, 2, 3, 4 (every 3 weeks) Carboplatin AUC=2 (dose calculation by determining creatine clearance with Cockroft Gault using adjusted body weight); administer intravenously on day 1, 8, 15 of cycles 1, 2, 3, 4 (every 3 weeks)~Regimen B (cycles 5-8):~Doxorubicin 60 mg/m2; administer intravenously on day 1 of cycles 5, 6, 7, 8 (every 2 weeks) Cyclophosphamide 600 mg/m2; administer intravenously on day 1 of cycles 5, 6, 7, 8 (every 2 weeks) Pegfilgrastim (for use on Doxorubicin/Cyclophosphamide cycles only), filgrastim, or biosimilar support on day 2 - 3 of cycles 5, 6, 7, 8 (every 2 weeks)~There is a one week break between the end of cycle 4 and the beginning of cycle 5.~Regimen C:~Surgical intervention for management of breast cancer diagnosis; procedure and timing as determined by surgical team."
62021195|NCT01617291|EXPERIMENTAL|Induced Hypothermia|Induced hypothermia after the return of spontaneous circulation by the application of ice packs to the axilla and groin with cold IV fluids
62215863|NCT04005573|EXPERIMENTAL|VD3 group|dietary supplement : VD3 group treated with 50000 IU VD3/ week for 8 weeks
62215864|NCT04005573|EXPERIMENTAL|omega 3- FA group|dietary supplement : omega 3- FA group 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
62215865|NCT04005573|EXPERIMENTAL|VD3 and omega 3 FA group|dietary supplement : VD3 and omega-3FA 50000 IU VD3/week for 8 weeks and 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
62215866|NCT04005573|OTHER|control group|no intervention was given
62215867|NCT04903730|EXPERIMENTAL|AER-901 Solution for Nebulization|"The inhalation formulation AER-901 for Part A and Part B (Cohort B1 only) is a sterile, yellow solution composed of imatinib mesylate and sterile water for injection. AER-901 will be supplied in 2 solution strengths (5 mg/mL and 40 mg/mL) for nebulisation.~The AER-901 inhalation formulation for Part D is a sterile yellow solution composed of imatinib mesylate, sterile water for injection and propylene glycol. AER-901 will be supplied in 2 solution strengths (5 mg/mL and 40 mg/mL) and the Pharmacy Manual will provide guidance on preparation for nebulization. Following review of the Part D safety and PK data by the SRC, the SRC will recommend which formulation and dose of AER-901 (sterile water vs propylene glycol) will be used in Parts B (Cohorts B2 and B3) and Part C.~The solution will be filled into a suitable container-closure system and delivered via a nebuliser known as the FOX® MOBILE. The water acts as the medium for nebulisation."
62215868|NCT04903730|PLACEBO_COMPARATOR|Placebo|A volume-matching placebo (0.45% sterile saline for injection) is to be delivered via the FOX® MOBILE device.
62215869|NCT04277351|EXPERIMENTAL|tACS in individuals with and without dyslexia|Each participant in both the group of normo-readers and individuals with dyslexia receive all tACS stimulation conditions (fixed frequencies and sham) over different experimental days.
62215870|NCT05438628||Patients scheduled for total knee arthroplasty surgery|
62215871|NCT05026762|EXPERIMENTAL|Treatment|
62215872|NCT06285279|EXPERIMENTAL|Treatment arm|"Administration of FKC288 Four dose groups of 0.1×10\^6 CAR-T/kg, 0.3×10\^6 CAR-T/kg, 1.0×10\^6 CAR-T/kg, and 3.0×10\^6 CAR-T/kg FKC288 are designed in this study.~Each dose group plans to enroll 1-2 or 3-6 participants with relapsed or refractory autoimmune-mediated kidney diseases (such as lupus nephritis, ANCA-associated vasculitis, membranous nephropathy, IgG4-related diseases) according to observed DLT.~FKC288 will be intravenously infused at least 24 hours after lymphodepletion preconditioning. According to the assigned dose group, the designated dose of FKC288 will be infused in a single infusion within 30 minutes on day 0."
62215873|NCT05648604|EXPERIMENTAL|Mentored Community Gardening|This arm will consist of gardening at least once per week, meeting with a master gardener mentor bi-monthly, and attending a gardening informational workshop once monthly.
62215874|NCT01171807|EXPERIMENTAL|Dex 21-P|"In this arm a dose of 20 ml of Dex 2-P solution was administered every 15 or 30 days for a total of 3 or 6 treatment procedures, respectively.~Specifically, steroid-dependant IBD patients had to undergo a total of 6 procedures at one month interval, while active mesalazine refractory UC patients had to undergo a total of 3 procedures at 15 days interval.~Every procedure implies the collection and re-infusion of autologous erythrocytes previously loaded with Dex 21-P."
62215875|NCT01171807|PLACEBO_COMPARATOR|Placebo|"In this arm placebo solution was administered every 15 or 30 days for a total of 3 or 6 treatment procedures, respectively.~Specifically, steroid-dependant IBD patients had to undergo a total of 6 procedures at one month interval, while active mesalazine refractory UC patients had to undergo a total of 3 procedures at 15 days interval.~Every procedure implies the collection and re-infusion of autologous erythrocytes previously NOT loaded with Dex21-P."
62410448|NCT00526929|EXPERIMENTAL|darbepoetin alfa|darbepoetin alfa (NESP)
62410449|NCT02831478|EXPERIMENTAL|BAY987517|2/3 of subjects testing the test article
62410450|NCT02831478|ACTIVE_COMPARATOR|Sunscreen Lotion|1/3 of subjects testing the marketed control
62410451|NCT04766970|ACTIVE_COMPARATOR|Standardized assessment|
62410452|NCT04766970|EXPERIMENTAL|Telehealth assessment|
62410453|NCT06265376|EXPERIMENTAL|Educational Video Intervention|Participants have been randomly selected into this arm to receive intervention via the educational video in addition to regular treatment and recovery options.
62215876|NCT01960777|EXPERIMENTAL|Onstep|Participants in this group will have an inguinal hernia repair ad modum Onstep.
62215877|NCT01960777|ACTIVE_COMPARATOR|Laparoscopic repair|Participants in this group will receive an inguinal hernia repair by use of a laparoscopic approach.
62215878|NCT01131182|EXPERIMENTAL|Sitagliptin|Sitagliptin 100 mg administered orally daily as monotherapy or in combination with metformin over the Ramadan period.
62215879|NCT01131182|ACTIVE_COMPARATOR|Sulfonylurea|Sulfonylurea administered orally daily as monotherapy or in combination with metformin over the Ramadan period.
62215880|NCT03712904|EXPERIMENTAL|A. Stereotactic body radiation therapy, ziv-aflibercept|Patients undergo stereotactic body radiation therapy over 5 fractions every other week day during days 1-10. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
62410454|NCT06265376|NO_INTERVENTION|No Intervention|Participants have been randomly selected into this arm to not receive intervention and continue with regular treatment and recovery options.
62792130|NCT02285387|EXPERIMENTAL|Rhythm control group|"1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~2. Cardioversion after 1 month~3. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~4. If AF recur, RFCA"
62792131|NCT02285387|ACTIVE_COMPARATOR|Rate control group|"1. No AAD, just anticoagulation~2. HR control between 60\~110bpm (with beta blocker, calcium channel blocker, digoxin)~3. Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study."
62585137|NCT05631093|ACTIVE_COMPARATOR|ART + DOR/ISL|Participants with HIV-1 that has been virologically suppressed for ≥3 consecutive months on a stable oral ART are first treated with standard of care (SOC) ART for 48 weeks, followed by 96 weeks of treatment with DOR/ISL Participants will have the option to continue in an optional study extension and receive DOR/ISL for up to an additional 96 weeks or until DOR/ISL is commercially accessible (whichever comes first).
62585138|NCT05631093|EXPERIMENTAL|DOR/ISL|Participants with HIV-1 that has been virologically suppressed for ≥3 consecutive months on a stable oral ART are treated with DOR/ISL for 144 weeks. Participants will have the option to continue in an optional study extension and receive DOR/ISL for up to an additional 96 weeks or until DOR/ISL is commercially accessible (whichever comes first).
62792132|NCT06056583|OTHER|Healthy Lactating Women|Healthy Lactating Women will be studied on 3 study days and serve as their own control.
62792133|NCT05023993|ACTIVE_COMPARATOR|Arm I (home exercise)|Patients complete 18 home exercise sessions over 30 minutes each, 3 days per weeks for 6 weeks.
62021196|NCT01617291|NO_INTERVENTION|Regular Care|Treatment of the return of spontaneous circulation under standing paramedic protocol without the addition of induced therapeutic hypothermia
62021197|NCT05507268||older patients undergoing noncardiac surgery|older patients (aged ≥65 years) scheduled for noncardiac surgery
62410455|NCT06123624|EXPERIMENTAL|Desflurane group|
62410456|NCT06123624|PLACEBO_COMPARATOR|Sevoflurane group|
62433229|NCT03101293|EXPERIMENTAL|TAK-831 400 mg Fed + TAK-831 400 mg Fasted|TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 2.
62585139|NCT05730959|OTHER|malfunctioning IPAA|Patients with malfunctioning IPAA
62021198|NCT05520138||Enzalutamide cohort|Patients with mCRPC initiating enzalutamide
62021199|NCT05520138||Abiraterone cohort|Patients with mCRPC initiating abiraterone
62021200|NCT06027060||NSAIDs users|90 patients taking NSAIDs for over 3 months
62021201|NCT06027060||non-NSAIDs users|90 non-NSAIDs users undergoing physical examination
62215881|NCT03712904|EXPERIMENTAL|B. Stereotactic body radiation therapy, ziv-aflibercept|Patients undergo stereotactic body radiation therapy as in arm A. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 4 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
62215882|NCT04090255|EXPERIMENTAL|Ultrasonographic guided renal access|The use of ultrasound to make a puncture in kidney for pcn for drainage or evaluation of function or for shunt of urine
62215883|NCT04090255|EXPERIMENTAL|Fluoroscopic guided renal access|The use of fluoroscopy to make a puncture in kidney for pcn for drainage or evaluation of function or for shunt of urine
62215884|NCT01620268|NO_INTERVENTION|Control Group|Patients receive standard of care.
62215885|NCT01620268|EXPERIMENTAL|Treatment Group|Dose adjusted leflunomide plus 600 mg orotic acid.
62215886|NCT06438497|EXPERIMENTAL|RIRS with f-UAS, lateral position|In group 1, patients were placed on operating table in lateral position. A flexible negative-pressure suction ureteric access sheath (f-UAS) is placed under the pelvi-ureteral junction (PUJ) in RIRS.
62215887|NCT06438497|EXPERIMENTAL|RIRS with f-UAS, lithotomy position|In group 2, patients were placed on operating table in lithotomy position. A flexible negative-pressure suction ureteral access sheath (f-UAS) is placed under the pelvi-ureteric junction (PUJ) in RIRS.
62215888|NCT06438497|EXPERIMENTAL|RIRS with traditional UAS, lateral position|In group 3, patients were placed on operating table in lateral position. A traditional ureteric access sheath (UAS) is placed under the pelvi-ureteral junction (PUJ) in RIRS.
62433230|NCT02061150||Asymptomatic newborns that had sepsis workup|Evaluation of medical records of asymptomatic newborns that had sepsis workup in the first 48 hours of life.
62433231|NCT05928728|EXPERIMENTAL|Colchicine|
62585140|NCT04666259|EXPERIMENTAL|Cohort A|40 mg asciminib orally twice daily (BID)
62792134|NCT05023993|EXPERIMENTAL|Arm II (home exercise, nicotinamide riboside)|Patients complete home exercise as in Arm I. Patients also receive nicotinamide riboside PO daily for 6 weeks.
62792135|NCT01629277|ACTIVE_COMPARATOR|Control|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
62792136|NCT01629277|EXPERIMENTAL|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
62792137|NCT00206843|EXPERIMENTAL|Results available|
62792138|NCT00206843|NO_INTERVENTION|Results blinded|
62792139|NCT03531086||Ioflupane I123|Participants will receive Ioflupane I123 as an adjunct diagnostic tool in combination with single photon emission computer tomography (SPECT) to evaluate striatal dopamine transporter. Patients will serve as their own control longitudinally.
62792140|NCT02895100|EXPERIMENTAL|PTG-100 (150 mg QD)|Low dose
62792141|NCT02895100|EXPERIMENTAL|PTG-100 (300 mg QD)|Medium dose
62215889|NCT06438497|ACTIVE_COMPARATOR|RIRS with traditional UAS, lithotomy position|In group 4, patients were placed on operating table in lithotomy position. A traditional ureteral access sheath (UAS) is placed under the pelvi-ureteric junction (PUJ) in RIRS.
62792142|NCT02895100|EXPERIMENTAL|PTG-100 (900 mg QD)|High dose
62215890|NCT02704754|EXPERIMENTAL|suvorexant|10mg administered before bedtime, during the first week; if well tolerated then the dose is increased to 20 mg before bedtime.
62215891|NCT02704754|PLACEBO_COMPARATOR|Placebo pill|"A pill without active ingredients~Randomization occurs 1:1 with stratification for gender and PTSD status."
62215892|NCT05108129|ACTIVE_COMPARATOR|Group M-TAPA|In the operating room, all of the patients will receive standard monitoring. An anesthesiologist will perform anesthesia inductions. After tracheal intubation, a linear probe will be placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will be inserted with in-plane technique and 25 ml 0.25% bupivacaine will be injected between the transversus abdominis muscle and the lower aspect of the costal cartilage. The same procedure will be repeated on the contralateral side. The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol.
62215893|NCT05108129|EXPERIMENTAL|Group OSTAP|In the second group, the patients will receive oblique subcostal TAP block in the supine position immediately after the endotracheal intubation. The anesthesiologist of the operating room will place the ultrasound with a linear probe subcostally and from the xiphoid to the right iliac crest obliquely. Rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin. The needle will be directed to the transversus abdominis fascia. Local anesthetic solution of 25 ml 0.25% will be injected to between rectus abdominis and transversus abdominis muscles along the oblique subcostal line. The same procedure will repeated to the contralateral side. The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol.
62215894|NCT00925132|EXPERIMENTAL|Temozolomide, Decitabine, Panobinostat|"Temozolomide - given each cycle.~Decitabine - 6 cohorts with dose escalation.~Panobinostat - 6 cohorts with dose escalation."
62215895|NCT05210751||Women patients with fibromyalgia|women with fibromyalgia beween age 30-75
62215896|NCT05210751||Control group|Healthy female volunteers aged 30-75 years
62215897|NCT01462032|EXPERIMENTAL|Cognitive enhancing games|Children will be introduced to specific games believed to enhance cognitive functioning. Parent will be encouraged to play these games with their children.
62215898|NCT01462032|ACTIVE_COMPARATOR|Parent support and education|Parents will participate in groups designed to provide information about ADHD and support for working with their child.
62792143|NCT02895100|PLACEBO_COMPARATOR|Placebo group|Placebo control
62792144|NCT00452868|EXPERIMENTAL|Donepozil|Donepezil 5 milligrams a day for 6 weeks
62410457|NCT03456986|EXPERIMENTAL|PATH neurotraining (treatment)|Subject looks at computer screen to determine whether bars in fish-shaped window move left or right relative to background bars. The subject reports which way center pattern moves by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes contrast of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern more similar to that in fish, by increasing pattern's complexity level, and by increasing number of directions of movement from one to two directions of motion. Intervention will be trained for one training cycle, between 10-20 minutes, 3 times each week for 12 weeks.
62215899|NCT03306017|EXPERIMENTAL|LAVD implantation|Ten patients before and after LAVD implantation had blood sampling
62215900|NCT06363396||Patients with fatigue and cognitive dysfunction|Patients that are one to five years after allogeneic stem cell transplantation and have signs of fatigue and cognitive dysfunction measured by international standarts.
62215901|NCT06363396||Patients without fatigue and cognitive dysfunction|Patients that are one to five years after allogeneic stem cell transplantation and have no detectable signs of fatigue and cognitive dysfunction measured by international standarts.
62410458|NCT03456986|ACTIVE_COMPARATOR|Orientation Discrimination (control)|Subject looks at computer screen to determine whether bars in center circular window are tilted left or right relative to vertically oriented background bars. The subject reports which way center pattern is tilted by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes orientation of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern colored or black and white, and by increasing pattern's complexity level. This Intervention will be trained for one training cycle, between 10-20 minutes, 3 times each week for 12 weeks.
62410459|NCT06561048|EXPERIMENTAL|Soquelitinib|Participants will administer soquelitinib 200 mg orally twice daily for up to 2 years
62021202|NCT01801059|ACTIVE_COMPARATOR|Arm I education CRC and CRC screening|Educational intervention: Patients receive CRC and CRC screening information from an educational video and received a brochure focused on healthy hints to prevent CRC. Questionnaire administration prior to and after the intervention.
62215902|NCT03007446|EXPERIMENTAL|Apatinib plus Oxaliplatin/S-1|"1. Apatinib :~   A starting dose of apatinib was administered 500 mg daily on days 1 through 21 of each 3-week cycle.~2. Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle.~3. S-1:40mg，bid，d1-14，po，in a 21 day cycle."
62433232|NCT05928728|PLACEBO_COMPARATOR|Placebo|
62433233|NCT01272193|EXPERIMENTAL|IDegAsp OD|
62585141|NCT04666259|EXPERIMENTAL|Cohort B|80 mg asciminib orally once daily (QD)
62792145|NCT01604252||Cohort|
62792146|NCT05356780||Expert operators|
62792147|NCT05356780||Post-graduate students|
62792148|NCT01005498|EXPERIMENTAL|Low carbohydrate diet (F)|The group attended to low carbohydrate diet
62792149|NCT01005498|ACTIVE_COMPARATOR|Traditional diet (K)|The group attended to traditional diet
62792150|NCT03315312|ACTIVE_COMPARATOR|Fissure sealant|
62792151|NCT03315312|EXPERIMENTAL|Fluoride varnish|
62792152|NCT04086095|EXPERIMENTAL|Intervention Group|Surfactant administration will be done via videolaryngoscopy and the application aid Neofact in neonates with respiratory distress syndrome and airway support with CPAP. Alveofact is used as Surfactant in its standard dosage of 100 mg / kg
62792153|NCT02399774|EXPERIMENTAL|Post-partum primi and multiparous women|"Post-partum primipara and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~1. Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~2. Control group: participants will not receive any device for breastfeeding pain control"
62215903|NCT00209196||pediatric solid organ transplants|Adherence to medical regimens refers to what degree a patient chooses to follow the advice given by his/her healthcare provider.More recently, researchers have started to look at adherence with children who have undergone solid organ transplantation. This is because about 50% of these children are to some degree non-adherent with their medical regimen. This comes at a costly price as ongoing non-adherence in pediatric transplant can lead to the child's body rejecting the new organ and even death. This study has been designed to look at the reasons that pediatric patients may choose to be non-adherent.
62792154|NCT02399774|EXPERIMENTAL|Post-partum women that have already begun breast feeding|2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
62215904|NCT00874692|EXPERIMENTAL|BMS and sterilisation|BMS and sterilisation programme will be delivered
62215905|NCT00874692|NO_INTERVENTION|BMS standard water heating|
62410460|NCT06561048|ACTIVE_COMPARATOR|Standard of Care|Participants will receive physician's choice standard of care treatment of either pralatrexate or belinostat for up to 2 years
62410461|NCT05762588||Patients requiring soft tissue fixation of the shoulder, knee, foot/ankle, elbow, or hip|
62410462|NCT06650488|EXPERIMENTAL|Change to clopidogrel|Patients will have their aspirin discontinued and start clopidogrel.
62410463|NCT06650488|ACTIVE_COMPARATOR|Continue aspirin|Patients will continue their existing aspirin
62410464|NCT00815139||ZES group|Groups who were treated with zotarolimus eluting stent
62410465|NCT00595946|PLACEBO_COMPARATOR|Placebo|0 mcg capsules twice daily (BID)
62410466|NCT00595946|EXPERIMENTAL|Lubiprostone|24 mcg capsules twice daily (BID)
62410467|NCT03083457|EXPERIMENTAL|PEEP2 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=2 cmH2O and scheduled recruiting maneuvers at the beginning of each PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
62410468|NCT03083457|EXPERIMENTAL|PEEP7 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=7 cmH2O and scheduled recruiting maneuvers at the beginning of the PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
62410469|NCT03083457|EXPERIMENTAL|PEEP12 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=12 cmH2O and scheduled recruiting maneuvers at the beginning of the PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
62410470|NCT03083457|EXPERIMENTAL|PEEP2 - RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=2 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
62410471|NCT03083457|EXPERIMENTAL|PEEP7 - RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=7 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
62410472|NCT03083457|EXPERIMENTAL|PEEP12 - RM.|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=12 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
62410473|NCT00502749|EXPERIMENTAL|Exercise program|Daily (Monday-Friday) 45-minute group physical exercise program during each hospital admission for three months or individual 20 minute session bedside.
62410474|NCT02273349|EXPERIMENTAL|Treatment|Patients with Alpha-1-Antitrypsin deficiency treated with endoscopic lung volume reduction using Lung Volume Reduction Coils (PneumRx Inc.)
62792155|NCT00394706|EXPERIMENTAL|1|Use of Impedance Threshold Device (ITD)
62792156|NCT00394706|SHAM_COMPARATOR|2|Sham ITD
62215906|NCT06610253|ACTIVE_COMPARATOR|Whey protein|Healthy men engaged in physical activity. Daily supplementation with the indicated protein preparation for a period of 8 weeks. Whey group receiving 30g of a preparation containing 80% whey protein concentrate
62215907|NCT06610253|EXPERIMENTAL|Pea protein|Healthy men engaged in physical activity. Daily supplementation with the indicated protein preparation for a period of 8 weeks. Pea group receiving 30g of a preparation containing 80% pea protein isolate
62410475|NCT06537661|EXPERIMENTAL|Study group|VR and traditional Ex
62410476|NCT06537661|EXPERIMENTAL|Control group|traditional physical therapy ex
62585142|NCT04666259|EXPERIMENTAL|Cohort C|200 mg asciminib orally twice daily (BID)
62792157|NCT00394706|OTHER|3|Analyze early. Upon EMS (emergency medical services) arrival at the scene of a non-traumatic cardiac arrest, the EMS providers assess the cardiac rhythm as soon as possible. Approximately thirty seconds of CPR (cardiopulmonary resuscitation) may be done prior to an assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
62215908|NCT06610253|EXPERIMENTAL|Rice protein|Healthy men engaged in physical activity. Daily supplementation with the indicated protein preparation for a period of 8 weeks. Rice group receiving 30g of a preparation containing 80% rice protein isolate
62215909|NCT06610253|EXPERIMENTAL|MIX protein|Healthy men engaged in physical activity. Daily supplementation with the indicated protein preparation for a period of 8 weeks. MIX group receiving 30g of a preparation containing 80% rice and pea protein isolate.
62215910|NCT06610565|EXPERIMENTAL|intervention arm|intervention arm where will receive nutritional counseling and the study diet for 5 days each month for 6 months
62433234|NCT01272193|ACTIVE_COMPARATOR|IGlar OD|
62585143|NCT02355938|EXPERIMENTAL|Fidaxomicin Arm|Oral Fidaxomicin 200 mg every 12 hours (Placebo for 2 doses) for 10 days
62585144|NCT02355938|ACTIVE_COMPARATOR|Vancomycin Arm|Oral Vancomycin 125 mg every 6 hours for 10 days
62410477|NCT02772341|ACTIVE_COMPARATOR|Salt room with halogenerator|Asthmatic patients sitting in a salt room with salt aerosol produced by a halogenerator.
62410478|NCT02772341|PLACEBO_COMPARATOR|Salt room without halogenerator|Asthmatic patients sitting in a salt room without salt aerosol
62410479|NCT05870566|EXPERIMENTAL|Corneal Crosslinking (CXL)|In the intervention group, the study intervention (CXL) will be administered to stabilize therecipient cornea (which remains in place after penetrating keratoplasty) and to reduce CoNV 8 to 10 weeks prior to corneal transplantation. The study intervention will be repeated once (after 4 weeks prior to transplantation at the latest at the earliest) if insufficient (less than 50%) reduction of CoNV should be observed (to be decided by the respective surgeon). (Protocol V04_0 Page 45) Corneal transplantation will be performed as standard full-thickness penetrating procedure, and the graft (6.5 to 8.25 in diameter) will be secured with 16-24 interrupted single or 2 double running 10-0 nylon sutures (decision by the surgeon). In case of residual CoNV in the intervention group, visible vessels will may be thermally occluded by fine needle diathermy to avoid intraoperative bleeding and reduce complications (to be decided by the respective surgeon at start of surgery). (Protocol V04_0 Page 46)
62410480|NCT05870566|NO_INTERVENTION|control group|In the control group subjects will be directly scheduled for corneal transplantation without previous CXL. A sham CXL procedure will not be performed. Corneal transplantation will be performed as standard full-thickness penetrating procedure, and the graft (6.5 to 8.25 in diameter) will be secured with 16-24 interrupted single or 2 double running 10-0 nylon sutures (decision by the surgeon). In case of residual CoNV in the intervention group, visible vessels will may be thermally occluded by fine needle diathermy to avoid intraoperative bleeding and reduce complications (to be decided by the respective surgeon at start of surgery). In the control group, no fine needle diathermy will be performed, as this procedure combined with corneal transplantation in previously non-crosslinked eyes might lead to fistulas and thereby to potential intraocular infections. (Protocol V04_0 Page 46)
62215911|NCT06610565|EXPERIMENTAL|control arm|control arm where they will receive only nutritional counseling
62792158|NCT00394706|OTHER|4|Analyze late. Upon the EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is done prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
62410481|NCT01880918||ColonRing|The ColonRing device is intended to be used for the creation of intestinal anastomoses in colorectal surgery in both open and laparoscopic surgeries. This indication is within the currently cleared indication of the ColonRing device, which has been cleared by the US FDA and carries the CE Mark for use throughout the alimentary trct for the creation of circular end-to-end, side-to-end or side-to-side anastomosis.
62410482|NCT06647446|EXPERIMENTAL|Exercise supported by the digital physiotherapy and telerehabilitation software TRAK|Home therapeutic exercise intervention scheduled through the software of digital physiotherapy and telerehabilitation TRAK
62410483|NCT06647446|ACTIVE_COMPARATOR|Standard home-based exercise|Home therapeutic exercise program scheduled through a dossier and an exercise diary
62410484|NCT06652321|EXPERIMENTAL|Inverted DSAEK|
62410485|NCT00912327||Stage 1|
62410486|NCT00912327||Stage 2|
62410487|NCT04540172|EXPERIMENTAL|Music Therapy|music therapy was applied in the practice room. Environmental noise was reduced as much as possible; the room was dimly lit. The students were asked to close their eyes after sitting comfortably in a chair and focus on the music by asking them to imagine a different memory and place that would relax them instead of the thoughts that occupied their minds. The music was played through a portable computer for 15 minutes under the supervision of the researchers using an mp3 player program on the computer.
62410488|NCT04540172|EXPERIMENTAL|Progressive Muscle Relaxation Exercise|"In this study, the steps of applying progressive muscle relaxation exercises were created with the guidance of the Relaxation Exercises  materials of the Turkish Psychological Association. Warning messages were hung on the door of the room, environmental noise was reduced as much as possible, and the room was provided with dim lighting. The students were asked to close their eyes and breathe deeply after sitting comfortably in a chair. After taking two deep breaths, they were told to dangle their arms and relax as much as possible. The hands, shoulders, neck, chest, abdomen, hips, legs, feet, toes, and facial muscles were made to relax while they breathed and relaxed while exhaling. They were asked to store the experience into their memories thoroughly so that they could recall this feeling for comfort during the day."
62410489|NCT04540172|NO_INTERVENTION|Control|No additional method was applied in the control group.
62410490|NCT06566001|EXPERIMENTAL|control group 11 patients|socket shield technique 11 patients
62410491|NCT06566001|EXPERIMENTAL|study group 11 patients|allogenic buccal sheet technique 11 patients
62410492|NCT03960268|EXPERIMENTAL|Intervention|Brodalumab 210mg subcutaneously every 2 weeks for 24 weeks
62410493|NCT03963960|EXPERIMENTAL|Hemodialysis with low dialysate flow|
62792159|NCT02312297|EXPERIMENTAL|Test|Minocycline hydrochloride extended release tablets 135 mg
62792160|NCT02312297|ACTIVE_COMPARATOR|Reference|Solodyn Extended Release Tablets 135 mg
62792161|NCT04957394|EXPERIMENTAL|Experimental (Family Partner)|The treatment group will receive six hours follow-up and support weekly. The service will be provided by a dedicated Family Partner.
62215912|NCT06055790|EXPERIMENTAL|18F-Fluciclovine (Axumin) PET/CT|Patients with recently diagnosed brain metastatic lesion(s) will be recruited based on MRI with or without histological confirmation, per standard of care. All patients will undergo an 18F-fluciclovine head PET/CT scan prior to treatment for brain metastatic lesions, post treatment, and 3 years post treatment.
62410494|NCT03963960|ACTIVE_COMPARATOR|Conventional triweekly high-flow hemodialysis|
62410495|NCT02930538||Children undergoing surgery|Children ages 3-18 undergoing a surgical procedure at Nationwide Children's Hosp.
62410496|NCT02246855|EXPERIMENTAL|Vigam® Liquid infused at up to 3mL/min|Gammaplex® (Human Normal Immunoglobulin)
62792162|NCT04957394|NO_INTERVENTION|Control group|"The control group will receive default support from the child welfare services. The service will be business as usual, provided by the local staff at the child welfare services."
62792163|NCT01079416||Capsule endoscopy|Study device
62792164|NCT01079416||Esophagogastroduodenoscopy|Gold standard
62792165|NCT03769558||JIA patients prescribed abatacept|
62792166|NCT05426135||Lung cancer group|Participants with lung cancer/pulmonary nodules
62215913|NCT04224337|EXPERIMENTAL|Experimental|Durvalumab + doxorubicin + ifosfamide
62585145|NCT05557643|ACTIVE_COMPARATOR|Mindfulness-Based Stress Reduction (MBSR)|Participants in the MBSR arm will complete an 8-week Mindfulness-Based Stress Reduction Curriculum involving a weekly 2 hour group meeting (either in person or virtual) as well as a 8 hour group mindfulness retreat in week 6-7 of the curriculum.
62585146|NCT05557643|EXPERIMENTAL|Mindfulness-Based Stress Reduction (MBSR) + Psilocybin-Assisted Psychotherapy (PAP)|Participants in the MBSR + PAP arm will complete an 8-week Mindfulness-Based Stress Reduction Curriculum involving a weekly 2 hour group meeting (either in person or virtual). They will additionally complete a psilocybin-assisted psychotherapy (PAP) intervention that involves three 2-hour group preparatory sessions, a single 8-hour group psilocybin administration session (done in place of the mindfulness retreat), and three 2-hour group integration sessions. All PAP intervention sessions will utilize a 1:1 therapist to participant ratio with an additional lead therapist present.
62585147|NCT02355821|EXPERIMENTAL|Moxonidine|0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID
62021203|NCT01801059|EXPERIMENTAL|Arm II education and patient activation intervention|Educational intervention administered: Patients receive patient activation intervention comprising CRC and CRC screening information and communication skills training intervention by educational video and brochure, and they also receive a brochure focused on healthy hints to prevent CRC. Questionnaire administration prior to and after the intervention.
62021204|NCT04955626|EXPERIMENTAL|10 µg dose|1 dose
62410497|NCT02246855|EXPERIMENTAL|Gammaplex® infused at up to 3mL/min|Gammaplex® (Human Normal Immunoglobulin)
62410498|NCT02246855|EXPERIMENTAL|Gammaplex® infused at up to 6mL/min|Gammaplex® (Human Normal Immunoglobulin)
62410499|NCT06288490|EXPERIMENTAL|amorphous calcium carbonate|Ten (10) subjects previously diagnosed and chronically treated for primary hypoparathyroidism will be enrolled. The daily CCS intake will be gradually replaced by reduced amount of elemental calcium from ACC. Five (5) subjects will consume the ACC before having a meal and the other five (5) subjects will consume the ACC after having a meal. The safety and the efficacy of the treatment will be closely monitored throughout this phase.
62410500|NCT01815372|EXPERIMENTAL|SPEDI|These are the patients that will be randomized to receive a SPEDI block of the sciatic and saphenous nerve with at single needle penetration of the skin
62410501|NCT01815372|ACTIVE_COMPARATOR|Popliteal sciatic and mid-femoral saphenous|These are the patients that will be randomized to the administration of a popliteal sciatic nerve block combined with a mid-femoral saphenous nerve block with two separate injections
62410502|NCT06548529|EXPERIMENTAL|Al18F-HER2-BCH PET/CT in bladder cancer patients|
62410503|NCT00991211|EXPERIMENTAL|Bendamustine + Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
62410504|NCT00991211|ACTIVE_COMPARATOR|CHOP + Rituximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w
62410505|NCT00003452|EXPERIMENTAL|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62410506|NCT03940898|ACTIVE_COMPARATOR|study group-active rTMS|Participants in the study group received 100%MT(motor threshold) repetitive transcranial magnetic stimulation with the intermittent theta burst stimulation paradigm.
62410507|NCT03940898|SHAM_COMPARATOR|control group-shame rTMS|Participants in the control group received rTMS pseudo-stimulation intervention. The stimulation head was inverted by 180 degrees or 90 degrees according to the model of the stimulation device to achieve pseudo-stimulation and the remaining stimulation parameters were consistent with the study group.
62410508|NCT05109169|SHAM_COMPARATOR|Self-guided multidomain lifestyle intervention|In this group, participants will build their own healthy lifestyle program based on standard healthy lifestyle advice that they will receive at individual consultations with the study physician/nurse as part of the study visits, covering four main components (diet, physical activity, cognitive training, and cardiovascular/metabolic risk monitoring). The intervention duration is 2 years.
62585148|NCT02355821|ACTIVE_COMPARATOR|Bisoprolol|5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID
62585149|NCT03328871|EXPERIMENTAL|Fractional CO2 Laser and PRP injection|One of the striae gravidarum areas will be treated by fractional laser once every three months for 2 times combined with PRP injection once a month for 6 times.
62585150|NCT03328871|EXPERIMENTAL|Nanofat grafting and PRP injection|Another area will be treated by nanofat grafting once every three months for 2 times and PRP therapy once a month for 6 times.
62585151|NCT04859400|EXPERIMENTAL|Intervention|"standardized nutritional program including a nutritional supplement~standardized exercise program~app for monitoring."
62585152|NCT04859400|NO_INTERVENTION|Control|"standard of care~limited version of the app (e.g. without the help function)."
62792167|NCT05426135||Stomach cancer group|Participants with Stomach cancer/Stomach lesion
62792168|NCT05426135||Colorectal cancer group|Participants with Colorectal cancer/Colorectal lesion
62792169|NCT00394550|NO_INTERVENTION|control|If laryngomalacia is found, then in the control group, no supraglottoplasty will be performed. Only the tonsils and adenoids will be removed.
62792170|NCT00394550|EXPERIMENTAL|Treatment|"If laryngomalacia is found, then in the Treatment group, a supraglottoplasty with laser will be performed, as well as removal of the tonsils and adenoids.~Intervention: supraglottoplasty with laser"
62021205|NCT04955626|PLACEBO_COMPARATOR|Placebo|1 dose
62021206|NCT04955626|EXPERIMENTAL|30 µg dose|1 dose
62021207|NCT04955626|EXPERIMENTAL|60 µg dose|1 dose
62021208|NCT01476046|EXPERIMENTAL|GSK1995057|Single intravenous dose
62021209|NCT01476046|PLACEBO_COMPARATOR|Placebo|Single intravenous dose
62215914|NCT00899782||Ancillary-Correlative (lung cancer tissue bank)|Grossly viable tumor and grossly normal lung tissue are identified and removed from patient surgical specimens and cryopreserved until shipment to the CALGB Lung Cancer Tissue Bank for future use in research. Blood specimens are also collected prior to surgery and at 4-12 weeks post-surgery (before the start of adjuvant therapy) and shipped immediately to the Tissue Bank.
62215915|NCT02866097|EXPERIMENTAL|Intervention|mHealth inventory management and referrals via text messaging plus supportive supervision of CHWs via an mHealth strategy
62792171|NCT04031859|EXPERIMENTAL|Group A|In this group a VTE risk stratification procedure will be used
62585153|NCT06675526|EXPERIMENTAL|Detour|Participants have access to Detour for 5 weeks encompassing various elements: (1) Completing a stop plan during the initial week preceding the quit attempt. (2) Engaging in ecological momentary assessments, measuring affect, nicotine withdrawal, and smoking behavior during the first two weeks: one week prior to and one week post quit attempt. (3) Accessing the game for a duration of 4 weeks following the quit attempt. (4) Participating in the social shell, in which participants join private social media channels on Instagram and/or TikTok for the entirety of the intervention period.
62585154|NCT06675526|ACTIVE_COMPARATOR|Digital self-help material|"Participants receive a self-help digital brochure, Jouw eigen plan om te stoppen met roken for smoking cessation in the control group. They will read this on personal demand."
62792172|NCT04031859|NO_INTERVENTION|Group B|In this group a standard VTE risk stratification procedure will be used (Caprini VTE risk assessment tool)
62021210|NCT05933915|EXPERIMENTAL|Intervention Group (Laughter yoga group) (n:40)|Laughter yoga will be practiced to midwives in the intervention group.
62021211|NCT05933915|NO_INTERVENTION|Control Group (n:40)|The control group will not be subjected to any application.
62021212|NCT02019719|EXPERIMENTAL|GSK1278863 4 milligrams (mg)|Subjects will receive GSK1278863 4 mg once daily for 4 weeks
62410509|NCT05109169|ACTIVE_COMPARATOR|FINGER 2.0 multidomain lifestyle-based intervention|"Within this group, participants will receive a structured intensive lifestyle intervention through individual consultations and group meeting sessions. Four main lifestyle components will be included (diet, physical activity, cognitive training, and cardiovascular/metabolic risk monitoring) as well as social interaction through the group meetings/sessions.~In this group, participants eligible for metformin treatment will be further randomised to either:~* 2000mg/day~* 1000mg/day~* placebo.~Metformin and placebo will be dispensed every 3 months, both administered orally. The intervention duration is 2 years"
62410510|NCT04723667|EXPERIMENTAL|Intervention|13-week multimodal intervention
62585155|NCT06230861|EXPERIMENTAL|Quercetin tablets 500mg 1 x pe|Quercetin tablets 500mg 1 x per day
62585156|NCT06230861|PLACEBO_COMPARATOR|Placebo|
62585157|NCT03179020|EXPERIMENTAL|Checklist ICUs|Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
62585158|NCT03179020|ACTIVE_COMPARATOR|Usual Care ICUs|Management of the potential donor according usual care.
62585159|NCT03575793|EXPERIMENTAL|Phase I (Dose Escalation): nivolumab, ipilimumab and plinabulin|"On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV) and plinabulin (escalating cohorts, IV).~After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment criteria occur.~Plinabulin escalation is as follows:~Level -1 : 13.5mg/m\^2~Level 1 (start) : 20mg/m\^2~Level 2 : 30mg/m\^2"
62585160|NCT03575793|EXPERIMENTAL|Phase II: nivolumab, ipilimumab, and plinabulin|"On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV) and plinabulin (MTD from Phase I).~After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment criteria occur ."
62585161|NCT02180139|EXPERIMENTAL|Primary motor cortex (M1) stimulation|Treatment by transcranial direct current stimulation will be targeted to the motor cortex for all treatment sessions with Bilateral M1 with cathode to contralateral M1 and anode to ipsilateral M1, 15 minutes (Goal: decrease contralateral M1 excitability)
62585162|NCT02180139|EXPERIMENTAL|Cerebellum stimulation|Treatment with transcranial direct current stimulation will be targeted to the cerebellum at every session with anode to ipsilateral cerebellum with cathode to ipsilateral side of face, 15 minutes (Goal: increase ipsilateral cerebellum activation which exerts inhibitory effect on motor circuits)
62792173|NCT03088917||lost to follow-up patients|This so-called lost population consists of all patients, that in the past have been diagnosed with hepatitis C at the Radboudumc but who are currently lost to or have been withdrawn from follow-up. The time-span of interest will be 2000-2015.
62792174|NCT03686293|EXPERIMENTAL|Paracetamol and breakfast|One tablet of paracetamol (500 mg) and a standardized breakfast will be consumed within 15 minutes one morning upon 10 hours of fasting
62021213|NCT02019719|EXPERIMENTAL|GSK1278863 6 mg|Subjects will receive GSK1278863 6 mg once daily for 4 weeks
62021214|NCT02019719|EXPERIMENTAL|GSK1278863 8 mg|Subjects will receive GSK1278863 8 mg once daily for 4 weeks
62410511|NCT04723667|ACTIVE_COMPARATOR|Active control|5-week health education programme
62021215|NCT02019719|EXPERIMENTAL|GSK1278863 10 mg|Subjects will receive GSK1278863 10 mg once daily for 4 weeks
62021216|NCT02019719|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo once daily for 4 weeks
62021217|NCT02416323|NO_INTERVENTION|Usual Care|Community therapist delivers routine care to participant child with no training in AIM HI.
62021218|NCT02416323|OTHER|AIM HI Training|Therapist enrolls in AIM HI training
62021219|NCT03963557||Healthy participants|BMI 5th percentile to less than the 85th percentile
62021220|NCT03963557||Overweight/Obese participants|BMI 85th percentile or more
62021221|NCT02264223|ACTIVE_COMPARATOR|Capsule (aglycone)|"single bolus 40mg isoflavone formulation of fermented extract in freeze-dried capsule.~Fermented red clover isoflavones in aglycone form"
62021222|NCT02264223|ACTIVE_COMPARATOR|Tablet (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract in freeze-dried tablet.~Fermented red clover isoflavones in aglycone form"
62021223|NCT02264223|ACTIVE_COMPARATOR|Yoghurt (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract mixed with yoghurt~Fermented red clover isoflavones in aglycone form"
62021224|NCT02264223|ACTIVE_COMPARATOR|Liquid extract (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract in liquid~Fermented red clover isoflavones in aglycone form"
62410512|NCT01065545|EXPERIMENTAL|Clofarabine|
62410513|NCT03458039|EXPERIMENTAL|In-person CETA|This is the in-person delivery method of the Common Elements Treatment Approach (CETA).
62410514|NCT03458039|EXPERIMENTAL|Telephone CETA (T-CETA)|This is the technology-based delivery method for the Common Elements Treatment Approach (CETA).
62215916|NCT02866097|PLACEBO_COMPARATOR|Control|ICCM current standard of care with CHWs operating under standard conditions without enhanced inventory management or supportive supervision by mHealth
62215917|NCT04615884|EXPERIMENTAL|Chinese herbs formula: Shu Yu Wan|Participants will receive Shu Yu Wan capsules, to take 3 times daily for 6 weeks.
62215918|NCT04615884|PLACEBO_COMPARATOR|Placebo|Participants will receive capsules to take 3 times daily for 6 weeks.
62215919|NCT03810768||Intensive Care Patients|Postoperative high-risk patients who have been admitted to intensive care after surgery
62215920|NCT03810768||Operative Control patients|Elective operative patients where control blood samples and muscle ultrasound will be measured.
62215921|NCT02368028||Caries Free|Participants who do not have caries (cavities) will have oral samples collected.
62215922|NCT02368028||Caries Active|Participants who do have caries (cavities) will have oral samples collected.
62215923|NCT02864030|OTHER|Single arm with Eribulin mesylate|
62410515|NCT03458039|ACTIVE_COMPARATOR|Treatment As Usual|This is the treatment as usual control condition who will engage with their usual care in the community and will receive CETA, if desired, following completion of the study.
62410516|NCT04244162||Study Group|brain scans, cognitive tests, blood biomarkers
62433235|NCT05896332|EXPERIMENTAL|Active, Open Label iTBS-rTMS|Individuals will receive 10 sessions of iTBS-rTMS per day, 5 days per week for one week (50 sessions total). All will undergo clinical assessments and brain MRI at pre-treatment and at 1-week post-treatment, and clinical assessments at 4-weeks post-treatment. Weekly post-treatment online self-report assessments will be collected up to four weeks. Resting-state parcellations of pre- and post-fMRI will be completed for personalized targeting and network parcellations.
62433236|NCT04681274||patient with hepatocellular carcinoma|Phenotype signature database building Image features extraction and clustering
62433237|NCT00615771|EXPERIMENTAL|Day 2 embryo transfer|Embryos are transferred 2 days after fertilization.
62215924|NCT03705832|EXPERIMENTAL|Active drug|Subjects assigned to the intervention will receive 2 grams daily of Ginger Extract for 56 days.
62215925|NCT03705832|PLACEBO_COMPARATOR|Placebo|Subjects assigned to the placebo group will receive a matching placebo for 56 days.
62433238|NCT00615771|ACTIVE_COMPARATOR|Day 3 embryo transfer|Standard of care for women undergoing IVF with a limited number of embryos is to transfer all embryos on Day 3 after fertilization
62021225|NCT02264223|ACTIVE_COMPARATOR|Tablet unfermented (glycoside)|"single bolus 40mg isoflavone aglycone equivalent tablet formulation of unfermented red clover isoflavones~Unfermented glycosides (as aglycone equivalents)"
62021226|NCT04858737|EXPERIMENTAL|e-predicD-Work intervention|In this arm, worker participants will receive an online personalized intervention to prevent depression based on ICTs, risk predictive algorithms and decision support systems (DSS).
62215926|NCT05120726|EXPERIMENTAL|Treatment Arm|Patient's pyoderma gangrenosum wounds are treated surgically with EpiFix (dehydrated human amnion/chorion membrane). In another surgery about one week later, we will be covering the treated wounds with split-thickness skin grafts. During each surgery, we will be collecting wound samples for genetic analysis. Routine post-surgery clinic visits will be used to monitor wound healing over a 6-month period.
62215927|NCT04662853||Patients with positive results in the fecal occult blood test.|Patients with positive results in the fecal occult blood test in the Program for Early Detection of Colon and Rectal Cancer, undergone by the Consejeria de Salud de la Junta de Andalucia (Spain), were invited to participate in the CCR-microbiome study. This program is screening Andalusian population aged between 50 and 69 years old for colo-rectal cancer presence by fecal occult blood test, and further colonoscopy when positive for this test. Patients included in CCR-microbiome study were recruited between January 2017 and March 2020, at the Reina Sofia University Hospital (Cordoba, Spain) with the consumption of antibiotic within the previous month as exclusion criteria.
62215928|NCT05680844||normal cholesterol level group|Serum total cholesterol level of \< 5.17 mmol/L
62215929|NCT05680844||hypercholesterolemia group|Serum total cholesterol level of \>= 5.17 mmol/L
62215930|NCT03678428|EXPERIMENTAL|FUDR/Oxaliplatin HAI plus irinotecan|"Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days:~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
62433239|NCT01114542|EXPERIMENTAL|IDeg 0.4 U/kg|
62215931|NCT03678428|ACTIVE_COMPARATOR|FOLFOXIRI|"Patients will receive Systemic FOLFOXIRI every 28 days:~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and Day 15; Oxaliplatin 85 mg/m2 IV in 3-6 hours on Day 1 and Day 15; Leucovorin 200mg/m2 and 5-FU 2400mg/m2 CIV in 46 hours on Day 1 and Day 15."
62215932|NCT05573867|EXPERIMENTAL|Intervention group|"Individualized, digital coaching twice a week for 12 weeks with Physical activity on prescription (FaR) to increase physical activity and reduce PSF after stroke."
62215933|NCT05573867|NO_INTERVENTION|Control group|Control group receive routine written and verbal information about PSF and information about recommended level of physical activity.
62215934|NCT04801121||Pregestational diabetic pregnant|Cases: Women with type 1 or type 2 diabetes before start of pregnancy
62215935|NCT04801121||Non-diabetic pregnant|Controls: Women without metabolic disease before start of pregnancy
62433240|NCT01114542|EXPERIMENTAL|IDeg 0.6 U/kg|
62433241|NCT01114542|EXPERIMENTAL|IDeg 0.8 U/kg|
62433242|NCT01114542|ACTIVE_COMPARATOR|IGlar 0.4 U/kg|
62433243|NCT01114542|ACTIVE_COMPARATOR|IGlar 0.6 U/kg|
62433244|NCT01114542|ACTIVE_COMPARATOR|IGlar 0.8 U/kg|
62433245|NCT04246190|EXPERIMENTAL|Group 1|"* Period 1: CKD-501 and D759~* Period 2: CKD-396"
62433246|NCT04246190|EXPERIMENTAL|Group 2|"* Period 1: CKD-396~* Period 2: CKD-501 and D759"
62433247|NCT01377233|EXPERIMENTAL|Zicronapine open-label lead-in 10 mg daily|
62433248|NCT01377233|EXPERIMENTAL|Zicronapine 10 mg daily|
62433249|NCT01377233|EXPERIMENTAL|Zicronapine 20 mg once weekly|
62433250|NCT01377233|EXPERIMENTAL|Zicronapine 30 mg once weekly|
62410517|NCT05119556|NO_INTERVENTION|Standard of Care|Participants will receive standard of care for COPD management per local guidance. In addition, they will receive 4-weekly phone calls for 13 weeks post discharge to inquire about health status and exacerbations.
62792175|NCT04761133|EXPERIMENTAL|Pleural irrigation with antiseptic|Two applications of 100-250 ml solution of 2% povidone-iodine will be irrigated into the pleural space of eligible patients 12 hours apart. The tube will be clamped for 15 minutes after irrigation and the patient will be asked to change position frequently during this period. The first dose will be applied 24-72 hours after tube insertion.
62410518|NCT05119556|ACTIVE_COMPARATOR|Video Telehealth Pulmonary Rehabilitation|In addition to standard of care, participants will be asked to participate in rehabilitation sessions administered at home via live videoconferencing for approximately 60 minutes a session, three times a week. A total of 36 sessions will be planned to be completed by week 13 post-discharge. Exacerbations and health status will be ascertained every 4-weeks for 13 weeks.
62410519|NCT06647940|EXPERIMENTAL|Orelabrutinib in combination with R-CHOP|"Patients with CD5 positive diffuse large B-cell lymphoma will receive orelabrutinib in combination with R-CHOP regimen from the second cycle of R-CHOP (3 weeks per cycle).~After 8 cycles of induction therapy, if the response is assessed as complete remission (CR), maintenance therapy with orelabrutinib will be conducted."
62410520|NCT05560594|OTHER|Intermittent catheter|Coloplast SpeediCath CH12 male intermittent catheter
62792176|NCT04761133|NO_INTERVENTION|No pleural irrigation|Standard care
62792177|NCT02144857|ACTIVE_COMPARATOR|Anti-TNFa regimen|Etanercept 50 mg
62792178|NCT02144857|ACTIVE_COMPARATOR|Anti IL12/23 regimen|ustekinumab 45 mg
62792179|NCT02144857|ACTIVE_COMPARATOR|Cyclosporine regimen|Cyclosporine 2.5-3 mg/kg
62792180|NCT02144857|ACTIVE_COMPARATOR|anti-interleukin 17 A regimen|secukinumab 300 mg
62792181|NCT02144857|ACTIVE_COMPARATOR|inhibitor of phosphodiesterase-4|apremilast 30mg
62792182|NCT04635319||18-40 years old of both sexes|patient from 18 to 40 years old seeking orthodontic treatment
62792183|NCT01502228|EXPERIMENTAL|62Cu-ETS PET assessment|CT scan for attenuation correction; 15O-water administered by intravenous injection and 6-minute dynamic PET imaging; 62Cu-ETS administered by intravenous injection; Dynamic PET acquisition for 6-minutes; Whole-body PET acquisition from 6-20 minutes post-62Cu-ETS injection
62410521|NCT06537505|EXPERIMENTAL|microwave ablation combined with immunotherapy and anti-angiogenic drugs|microwave ablation combined with adebrelimab and apatinib
62410522|NCT06537505|EXPERIMENTAL|microwave ablation combined with immunotherapy|microwave ablation combined with adebrelimab
62410523|NCT06411782|EXPERIMENTAL|Foam Roller Group|Inspiratory muscle training will be done with a resistive exercise device at 80% of MIP max and for 30 breaths. After training, foam roller application will be applied to the right sternocloideomastoid muscle.
62792184|NCT04632589|EXPERIMENTAL|Losartan|6 weeks of daily (50mg/day) oral losartan potassium tablet
62792185|NCT04632589|PLACEBO_COMPARATOR|Placebo|6 weeks of daily oral placebo tablet
62410524|NCT06411782|EXPERIMENTAL|Non Foam Roller Group|Inspiratory muscle training will be done with a resistive exercise device at 80% of MIP max and for 30 breaths. Foam roller application will not be done.
62410525|NCT01711034|EXPERIMENTAL|OPB-111077|"In escalation stage of study, treatment with a once daily dose of OPB-111077 during cycles 1 and 2 on day 1, followed by 2-day treatment free interval, and then resuming daily dosing on day 4 through day 28. For cycle 3 and beyond, OPB-111077 will be administered for 28 continuous days per cycle until MTD is reached.~In expansion portion of study, established dose of 250mg administered once daily for 28 consecutive days for each cycle. Patient in expansion are defined as those who meet eligibility criteria and have a diagnosed malignancy that is presumed to be susceptible to inhibition by OPB-111077"
62410526|NCT03687580|EXPERIMENTAL|B-Cure Laser Pro|Subjects from the B-Cure Laser Pro group will receive standard care and in addition will self-treat at home daily with the B-Cure device.
62433251|NCT01377233|EXPERIMENTAL|Zicronapine 45 mg once weekly|
62792186|NCT04120961|EXPERIMENTAL|prolonged continuous use of bivalirudine|A total of 165 patients are assigned to group with prolonged continuous use of bivalirudin after randomization schedule.
62792187|NCT04120961|OTHER|bivalirudin use during ePCI|A total of 165 patients are assigned to group with bivalirudin use during ePCI after randomization schedule.
62792188|NCT05297591||breast cancer patients|Women and men diagnosed with breast cancer waiting for surgery
62792189|NCT00300313|ACTIVE_COMPARATOR|1|
62792190|NCT00300313|PLACEBO_COMPARATOR|2|
62792191|NCT01216137|EXPERIMENTAL|Exercise: Vestibular Rehabilitation|Balance and eye movement training
62792192|NCT01216137|ACTIVE_COMPARATOR|Exercise Control|Bicycle ergometry and stretching
62792193|NCT01216137|NO_INTERVENTION|Wait-listed Control|Wait-listed Control
62792194|NCT02145117|OTHER|MBSR Training|Mindfulness Based Stress Reduction (MBSR) Training
62792195|NCT02737124|EXPERIMENTAL|1000 Mg Acetaminophen|Acetaminophen will be given 24 hours before surgery
62792196|NCT02737124|ACTIVE_COMPARATOR|Placebo|A sugar pill will be given 24 hours before the scheduled surgery.
62792197|NCT03449069|EXPERIMENTAL|MSC-AFP|This is a single treatment group study. All patients will receive treatment of a stem cell coated fistula plug.
62215936|NCT02905136||Patient with confirmed diagnosis of autoimmune encephalitis by|"Patient with confirmed diagnosis of autoimmune encephalitis by French rare disease reference center on PNS with :~* with detection in CSF of characterized antibodies against neuronal synaptic receptor or protein (anti-NMDAr, anti-LGI1, anti-CASPR2, Anti-AMPAr, anti-mGluR5, anti-GABAbr)~* or uncharacterized antibodies"
62410527|NCT03687580|SHAM_COMPARATOR|Sham laser|Subjects from the Sham laser group will receive standard care and in addition will self-treat at home daily with the sham B-Cure device.
62410528|NCT06543251|EXPERIMENTAL|High-intensity interval training group (HIIT)|the group with high-intensity interval training at a ratio of 1:2 (HIIT) 3 days per week, over a total period of 12 weeks.
62792198|NCT04459871|EXPERIMENTAL|The experimental group|The topical recombinant human thrombin(rhThrombin) was prepared into 1000IU/mL solution with 10ml normal saline and used in combination with absorbable gelatin spongeat at appropriate bleeding evaluation site(s).
62792199|NCT04459871|PLACEBO_COMPARATOR|The control group|The placebo was prepared into a solution with 10mL normal saline and used in combination with absorbable gelatin sponge at appropriate bleeding evaluation site(s).
62792200|NCT03971409|EXPERIMENTAL|CLOSED TO ENROLLMENT: Arm I (binimetinib, avelumab)|Patients will receive a 15-day lead-in of binimetinib, followed by binimetinib PO BID and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62792201|NCT03971409|EXPERIMENTAL|CLOSED TO ENROLLMENT: Arm II (anti-OX40 antibody PF-04518600, avelumab)|Patients will receive a 15-day lead-in of anti-OX40 antibody PF-04518600, followed by anti-OX40 antibody PF-04518600 IV over 60 minutes and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62215937|NCT00423943|EXPERIMENTAL|D|modafinil
62585163|NCT02180139|EXPERIMENTAL|Combined M1 and Cerebellum stimulation|Treatment with transcranial direct current stimulation will be placed with M1 anode contralateral + cerebellum anode. M1 will first be 'primed' with anode on contralateral M1, cathode on face, for 10 min, followed immediately by 15 min of cerebellar stimulation as in #2. (Goal: prime the contralateral M1 with increased excitability to engage a potentially larger effect from the following ipsilateral cerebellar stimulation that will be excited to exert inhibitory effect on the motor circuits including M1)
62585164|NCT02180139|PLACEBO_COMPARATOR|Sham stimulation|transcranial direct current stimulation will be given in placebo form. Sham stimulation: electrode placement will be same as M1. Sham tDCS will be applied by ramping down current intensity to 0 after 30 seconds following standard practice for sham tDCS.
62792202|NCT03971409|EXPERIMENTAL|CLOSED TO ENROLLMENT: Arm III (utomilumab, avelumab)|Patients will receive a 15-day lead-in of utomilumab, followed by utomilumab IV over 60 minutes every 4 weeks and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62792203|NCT03971409|EXPERIMENTAL|Arm A (avelumab, binimetinib, liposomal doxorubicin)|Patients receive a 15 day lead-in of binimetinib orally (PO) twice daily (BID) in the absence of disease progression or unacceptable toxicity. Patients then receive binimetinib PO BID on days 1-28, avelumab intravenously (IV) over 60 minutes on days 1 and 15, and liposomal doxorubicin IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62792204|NCT03971409|EXPERIMENTAL|Arm B (avelumab, sacituzumab govitecan)|Patients will receive a 15-day lead-in of sacituzumab govitecan given on day -15, followed by sacituzumab govitecan day 8 and day 15 of Cycle (C) 1; day 1,8, and 21 of C2; day 1, 15 and 21 of C3; day 8 and 15 of C4, and schedule continues with two weeks on, one week off for 21-day cycles. Patients also receive 10mg/kg avelumab over 60 minutes on day 1 and day 15 of each 28 day cycle. Cycles repeat in the absence of disease progression or unacceptable toxicity.
62215938|NCT00423943|PLACEBO_COMPARATOR|Placebo|placebo
62410529|NCT06543251|EXPERIMENTAL|Moderate continuous training group (MCT)|the group with moderate continuous training, 3 days per week, over a total period of 12 weeks.
62792205|NCT03971409|EXPERIMENTAL|Arm C (avelumab, liposomal doxorubicin)|Patients will receive a 15-day lead-in of liposomal doxorubicin, followed by liposomal doxorubicin on Day 1 and 10mg/kg avelumab over 60 minutes on Day 1 and Day 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62792206|NCT05357027|EXPERIMENTAL|TC-E202 dose|"This study uses the 3+3 dose escalation method. The initial dose is Dose1, the maximum dose that patients can tolerate is determined as the phase II recommended dose (RPIID), and at least 6 patients are receiving RPIID treatment . If patients develop intolerance in Dose 1 (≥3 subjects with DLT), then the subsequent enrolled patients will receive Dose-1 infusion."
62215939|NCT05198895|EXPERIMENTAL|Open-label, single arm with identical assessment of both biomarkers for all participants|All participants will have their glycated nail keratin assessed by infrared and blood HbA1c levels measured via an assay (based on finger prick blood drop sample)
62215940|NCT02818725|ACTIVE_COMPARATOR|Chemotherapy|Intensified- Methotrexate Vinblastin Doxorubicin Cisplatin
62215941|NCT02818725|EXPERIMENTAL|Arm B: chemotherapy + panitumumab|Intensified- Methotrexate Vinblastin Doxorubicin Cisplatin +/- panitumumab
62215942|NCT02682277|ACTIVE_COMPARATOR|Medical device polyglucosamine|2 times daily 2 polyglucosamine tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity
62585165|NCT00957268|EXPERIMENTAL|Alogliptin 12.5 mg (age 10 to < 14 years)|Alogliptin 12.5 mg, tablets, orally, 1 dose only.
62585166|NCT00957268|EXPERIMENTAL|Alogliptin 25 mg (age 10 to < 14 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
62215943|NCT02682277|PLACEBO_COMPARATOR|Placebo|2 times daily 2 placebo tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity
62410530|NCT06543251|OTHER|Sedentary control group (CON)|
62410531|NCT01902992|EXPERIMENTAL|Depiquick® Birch|At the screening visit (Visit 1), patients will be instructed how to complete the eDiary. Eligible patients will return for visit 2 as soon as they experience significant allergic symptoms. Significant allergic symptoms are defined by a symptom score ≥ 2. If the patients' eligibility has been confirmed according to inclusion/exclusion criteria checklist, randomization to one of the 2 treatment arms will be conducted. Patients will receive two consecutive subcutaneous injections of study medication (0,2 and 0,3 ml) with a time lag of ≥ 30 minutes. Patients return to the study site in weekly intervals for visit 3, visit 4, visit 5, visit 6, and visit 7 to receive study medication injections (0,5 ml each). If treatment is completed before the end of the tree pollen season, patients will be followed-up by telephone calls every 4 weeks until the end of the tree pollen season. The study completion visit will take place 4 weeks after the end of the tree pollen season.
62410532|NCT01902992|PLACEBO_COMPARATOR|Placebo|At the screening visit (Visit 1), patients will be instructed how to complete the eDiary. Eligible patients will return for visit 2 as soon as they experience significant allergic symptoms. Significant allergic symptoms are defined by a symptom score ≥ 2. If the patients' eligibility has been confirmed according to inclusion/exclusion criteria checklist, randomization to one of the 2 treatment arms will be conducted. Patients will receive two consecutive subcutaneous injections of study medication (0,2 and 0,3 ml) with a time lag of ≥ 30 minutes. Patients return to the study site in weekly intervals for visit 3, visit 4, visit 5, visit 6, and visit 7 to receive study medication injections (0,5 ml each). If treatment is completed before the end of the tree pollen season, patients will be followed-up by telephone calls every 4 weeks until the end of the tree pollen season. The study completion visit will take place 4 weeks after the end of the tree pollen season.
62410533|NCT03397940||Year Round School|Children attending year round school
62410534|NCT03397940||Traditional School|Children attending a traditional school with a traditional calendar school year
62585167|NCT00957268|EXPERIMENTAL|Alogliptin 12.5 mg (age 14 to < 18 years)|Alogliptin 12.5 mg, tablets, orally, 1 dose only.
62585168|NCT00957268|EXPERIMENTAL|Alogliptin 25 mg (age 14 to < 18 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
62792207|NCT04849169|EXPERIMENTAL|Experimental Arm|Adult subjects who experience a perforation of a coronary vessel during percutaneous coronary intervention (PCI) and require management of hemorrhage until a definitive treatment is determined.
62585169|NCT00957268|EXPERIMENTAL|Alogliptin 25 mg (age 18 to 65 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
62792208|NCT05599971|ACTIVE_COMPARATOR|Group A|15 patients will receive intralesional 0.1 mL of combined digoxin and furosemide, with maximum 5 warts per session.
62792209|NCT05599971|ACTIVE_COMPARATOR|Group B|15 patients will receive intralesional injection of 5- Fluorouracil (50mg/ml) in full concentration into the wart using a 27- gauge insulin syringe till the entire lesion begins to puff up. The maximum dose injected per session will be 2ml of 5-FU.
62792210|NCT05599971|PLACEBO_COMPARATOR|Group c|15 patients will receive intralesional saline.
62792211|NCT02458833|EXPERIMENTAL|Intervention|Behavioral: Home Plate intervention
62792212|NCT02458833|EXPERIMENTAL|Delayed Entry Control|This Arm will receive the Home Plate intervention 3 months after the Intervention Arm completes the intervention.
62792213|NCT02076282||Healthy volunteers 1 MRI scan|"Healthy volunteers, recruited at the UMC Utrecht, older than 18, who do not meet the exclusion criteria of the department of Radiology.~Healthy volunteers will receive 1 MRI scan without contrast agent."
62792214|NCT02076282||Patients with stage III NSCLC, 1 MRI scan|"Patients with histopathologically or cytologically proven stage III NSCLC (excluding T4N0), older than 18, with a recent (≤ 21 days) GFR value available~Patients will receive 1 MRI scan with contrast agent."
62792215|NCT00529425|ACTIVE_COMPARATOR|Ropivacaine|
62792216|NCT00529425|PLACEBO_COMPARATOR|Saline|
62792217|NCT04451499|EXPERIMENTAL|Intervention group -smartphone app|"All the participants will receive the standard care of 3-6 preparation to bariatric surgery meetings with a dietitian.~All the participants will get access to our study's smartphone app site."
62792218|NCT04451499|NO_INTERVENTION|Control group|All the participants will receive the standard care of 3-6 preparation to bariatric surgery meetings with a dietitian.
62585170|NCT06240702|EXPERIMENTAL|Telerehabilitation Group|Patients in the experimental group will be included in the face-to-face Phase I rehabilitation program until discharge and in the Phase II telerehabilitation program and sleep hygiene training for 3 weeks after discharge. Respiratory exercises will be performed as part of the phase I rehabilitation program until the patients are discharged. In addition, active range of motion and mobility exercises in bed, sitting position and standing, increasing distance walking and stair ascent and descent training will be provided. During the sessions, the patient's vital signs and clinical status will be monitored with a finger pulse oximeter and a blood pressure measuring device according to the patient's perceived degree of difficulty (Borg Scale). As part of the Phase II telerehabilitation program, respiratory exercises, calisthenic exercises and gait training will be performed.
62792219|NCT06213155|EXPERIMENTAL|Cryoneurolysis|
62792220|NCT06213155|SHAM_COMPARATOR|Stimulation|
62792221|NCT05414630|EXPERIMENTAL|Envafolimab|Envafolimab: subcutaneous injection, 300mg, Q3W
62792222|NCT04576026|EXPERIMENTAL|Ketone esters|Ketone esters will be given to mentally fatigued individuals, prior to a 45 minute simulated soccer game in which cognitive function will be assessed.
62792223|NCT04576026|ACTIVE_COMPARATOR|Placebo|Iso-caloric carbohydrate drink will be given to mentally fatigued individuals, prior to a 45 minute simulated soccer game in which cognitive function will be assessed.
62792224|NCT00301418|EXPERIMENTAL|Tarceva (Erlotinib)|
62792225|NCT05938803|NO_INTERVENTION|Control arm|Participants randomized to the control arm of the study will receive a modestly enhanced standard of care. Specifically, they will receive HIV transition information in the form of a paper brochure and/or a video link, and a package of supplies (i.e., a pillbox, a folder to store medical documents). Participants will undergo depression and substance use screening and will be referred as needed.
62792226|NCT05938803|EXPERIMENTAL|Intervention arm|Participants randomized to the intervention arm of the study will receive a modestly enhanced standard of care. Specifically, they will receive HIV transition information in the form of a paper brochure and/or a video link, and a package of supplies (i.e., a pillbox, a folder to store medical documents). Participants will undergo depression and substance use screening and will be referred as needed. Participants allocated to this group will also receive the PASEO intervention.
62215944|NCT05792358|EXPERIMENTAL|Wet cupping arm|This arm is the interventiom group and will receive three consecutive sessions of wet cupping therapy once a month.
62215945|NCT05792358|NO_INTERVENTION|Control arm|This arm is the control group and will not receive any intervention other than the routine medications
62215946|NCT02812693|EXPERIMENTAL|Treatment (pembrolizumab, imatinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and imatinib mesylate orally PO QD on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62215947|NCT02234973||11 First Nations Community and Clinical Teams|11 Community \& Clinical Teams in each First Nation community participated in the intervention.
62215948|NCT04074759|EXPERIMENTAL|FPT155 monotherapy|The study consists of dose escalation and cohort expansions
62215949|NCT04074759|EXPERIMENTAL|FPT155 in combination with pembrolizumab|The study consists of dose escalation and cohort expansions
62215950|NCT05541510|PLACEBO_COMPARATOR|Placebo Comparator|Participants will receive placebo (formulation buffer) on treatment days 1, 3 and 5.
62215951|NCT05541510|EXPERIMENTAL|Low dose treatment group|Participants will receive 20 μg of AD17002 in formulation buffer on treatment days 1, 3 and 5.
62215952|NCT05541510|EXPERIMENTAL|High dose treatment group|Participants will receive 40 μg of AD17002 in formulation buffer on treatment days 1, 3 and 5.
62215953|NCT02387229|ACTIVE_COMPARATOR|Rivaroxaban|Rivaroxaban 15 mg, orally, once daily, preferably at the same time of the day throughout the study.
62215954|NCT02387229|ACTIVE_COMPARATOR|standard of care|standard of care
62215955|NCT03572387|EXPERIMENTAL|5-AZA + ATRA ('early' 5-AZA+ATRA)|Combination of 5-Azacitidine (5-AZA) + all trans retinoic acid (ATRA) group after one month of Lupron, group will receive treatment on a 28-day cycle, in the absence of prohibitive toxicities, for 3 cycles.
62215956|NCT03572387|ACTIVE_COMPARATOR|No therapy ('delayed' 5-AZA+ATRA)|After one month of lupron, patients will receive no therapy for 3 cycles (12 weeks). After this observation period, patients will receive combination of 5-Azacitidine (5-AZA) + all trans retinoic acid (ATRA) group on a 28-day cycle, in the absence of prohibitive toxicities, for 3 cycles.
62215957|NCT03989518|EXPERIMENTAL|Simple stimuli|Two perceptually simple stimuli are used during all experimental phases (geometrical figures).
62215958|NCT03989518|EXPERIMENTAL|Complex stimuli|Two complex stimuli are used in all experimental phases. Stimuli consist of photographs of real objects of the same size and shape as the simple stimuli, but include perceptually more complex patterns, details and colors.
62215959|NCT00130260|EXPERIMENTAL|vaccine, schedule 1|3rd and 4th dose of vaccine, on original schedule
62215960|NCT00130260|EXPERIMENTAL|vaccine, schedule 2|3rd and 4th dose of vaccine on modified schedule
62585171|NCT06240702|NO_INTERVENTION|Control Group|Patients in the control group will be included in the face-to-face Phase I rehabilitation program until discharge and no intervention will be made after discharge. Until the patients in the control group are discharged, respiratory exercises will be performed as in the experimental group within the scope of the phase I rehabilitation program. In addition, active range of motion and mobility exercises in bed, sitting position and standing, increasing distance walking and stair ascent and descent training will be provided. During the sessions, the patient's vital signs and clinical status will be monitored with a finger pulse oximeter and a blood pressure measuring device according to the patient's perceived degree of difficulty (Borg Scale).
62021227|NCT04858737|ACTIVE_COMPARATOR|m-Health control|In this arm, worker participants will continue receiving the usual care from their health providers. In addition, they will use an App with the same appearance as the e-predictD-Work App but it will only send weekly short messages about stress and general health that will be extracted from brochures and websites of official agencies.
62021228|NCT06398353|EXPERIMENTAL|acupuncture|
62215961|NCT00130260|PLACEBO_COMPARATOR|placebo, schedule 1|3rd and 4th dose of placebo, on original schedule
62215962|NCT00130260|PLACEBO_COMPARATOR|placebo, schedule 2|3rd and 4th dose of placebo on modified schedule
62215963|NCT05379478||Unvaccinated, COVID naive|Volunteers with no history of COVID-19 or vaccination. This is an observational study with no intervention
62215964|NCT05379478||Unvaccinated, Convalesced|Volunteers with a history of COVID-19 infection but no COVID-19 vaccination. This is an observational study with no intervention
62215965|NCT05379478||Vaccinated|Volunteers with a history of COVID-19 vaccination. This is an observational study with no intervention
62215966|NCT03803124|ACTIVE_COMPARATOR|Tolvaptan|"Drug: Tolvaptan~1 tablet before renography"
62215967|NCT03803124|PLACEBO_COMPARATOR|Placebo|"Placebo~1 tablet before renography"
62215968|NCT02274571|EXPERIMENTAL|Drug|TSEC (Duavee™, combination of CE and BZA)
62215969|NCT02274571|PLACEBO_COMPARATOR|Placebo|Non active comparator
62410535|NCT02288650|EXPERIMENTAL|Liberal group|Early refeeding
62410536|NCT02288650|SHAM_COMPARATOR|Control group|Refeeding in the day case ward (usual practice)
62215970|NCT02155491||Prospective cohort 1|In order to observe temporal trends in management of VTE a first cohort of 5000 consecutive unselected patients treated for acute VTE will be recruited. This cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis. They will be followed prospectively for 36 months.
62215971|NCT02155491||Prospective cohort 2|In order to observe temporal trends in management of VTE a second cohort of 5000 consecutive unselected patients treated for acute VTE will be recruited. Recruitment into the second cohort will commence when recruitment is completed in the first cohort. This cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis. They will be followed prospectively for 36 months.
62410537|NCT03170271|EXPERIMENTAL|Benralizumab (Medi-563)|Benralizumab (Medi563) Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days) In the open label ANDHI IP sub study, all patients will receive benralizumab subcutaneously at Day 168 (Week 24), Day 196 (Week 28), Day 224 (Week 32), Day 280 (Week 40), Day 336 (Week 48), Day 392 (Week 56), Day 448 (Week 64), and Day 504 (Week 72).
62410538|NCT03170271|PLACEBO_COMPARATOR|Placebo|Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
62410539|NCT05409157|EXPERIMENTAL|Treatment Group 1: BMS-986166|
62410540|NCT02491086|EXPERIMENTAL|Intervention|The intervention group will receive a free pack of one-week NRT. The nurse will help the subject to decide which NRT product (patch, gum and lozenge) he/she can use and advise how to use the NRT based on his/her smoking habit and amount of cigarette consumption, followed by the delivery of the sampling, instructions of using the NRT sampling, an education card about NRT and a 12-page smoking cessation booklet (Figure 1). Based on the experience in the previous trials, the choice of NRT (either patch, lozenge or gum) will be made according to subject's preference, and the counsellors will provide medication counselling \[25-27\]. If the subject is willing to continue the counselling at recruitment, the ambassador will further introduce the NRT's side effects, adherence and effectiveness (Table 1). Otherwise, the ambassador will contact the subject for providing these details and enquiring the usage through telephone within 2 days.
62410541|NCT02491086|ACTIVE_COMPARATOR|Control|The control group subjects will only be advised by the ambassador to purchase the NRT on their own, but will not be given the sampling. The same education card and the 12-page smoking cessation booklet will be provided.
62410542|NCT04917406|EXPERIMENTAL|Use of iontophoresis|Lidocaine (local anesthetic) associated with dexamethasone (corticosteroid) will be administered by iontophoresis technique. Dose per session and iontophoresis: 10 minutes with an intensity of 4 mA.
62410543|NCT04917406|ACTIVE_COMPARATOR|Use of ultrasound|The treatment for the control group will be applied with a frequency of 3 times a week as usually performed in the ACP of the University of Seville. The application dose will be 0.65 Watt for 7 minutes in the area of most painful affectation by means of a circular movement and 1MZ head.
62410544|NCT06415669|EXPERIMENTAL|Single arm|Paclitaxel for injection (albumin-bound) in combination with Apatinib mesylate and adebrelimab
62410545|NCT06651372||Malaria negative return travelers|"Any person, man or woman, aged over 18, treated at the University Hospitals of Strasbourg from January 2024 to December 2025, having received a blood sample as part of the treatment, for a diagnosis of malaria upon return from a recent trip whose result was negative. Any person who has already consented or has not objected to their biological resources being preserved in the Microbiology biocollection and reused for scientific research."
62410546|NCT06065631|OTHER|Control|An eyeglasses prescription and letter to parents, with free eyeglasses at endline.
62410547|NCT06065631|EXPERIMENTAL|Intervention|free ready-made or custom eyeglasses
62410548|NCT01950325|EXPERIMENTAL|Group 1|1mg/kg IV
62410549|NCT01950325|EXPERIMENTAL|Group 2 or Group 3|5 mg/kg IV (Group 2) or 5 mg/kg SC (Group 3)\[only portion of the study that is randomized\]
62410550|NCT01950325|EXPERIMENTAL|Group 4|20 mg/kg IV
62410551|NCT01950325|EXPERIMENTAL|Group 5|40 mg/kg IV
62410552|NCT03434873|ACTIVE_COMPARATOR|Sacral magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks, over sacral roots
62410553|NCT03434873|ACTIVE_COMPARATOR|Cortical magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks, over motor cortex
62585172|NCT05459402|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Participants in treatment as usual group will receive 100% active methadone in AM + placebo in PM.
62215972|NCT04242836||Control group|"1. 70 patients with normal vision (NVG) with adequate literacy of written Greek language~2. 30 patients with low vision (LVG) with adequate literacy of written Greek language~These patients are tested on the printed Greek MNREAD"
62215973|NCT04242836||Study group|The same patients as those in the control group (NVG, LVG) are tested on the digital version of the Greek MNREAD (DeDART)
62215974|NCT04375332|EXPERIMENTAL|HARPOON™ Beating Heart Mitral Valve Repair System|Subjects who were treated with the HARPOON™ Beating Heart Mitral Valve Repair System
62215975|NCT06460753||hospitalized to ICU severe patients with coronavirus infection COVID-19|an analysis of the medical records was carried out
62215976|NCT04700332|EXPERIMENTAL|High risk prostate cancer|DCFPyL PET/CT will be compared to CT/bone scan for detection of unsuspected metastases in patients with high risk prostate cancer and planned prostatectomy or or radiation therapy
62410554|NCT01655173|EXPERIMENTAL|Cognitive behaviour therapy|36 weekly sessions (1 calendar year) of Cognitive behaviour therapy in a group setting.
62215977|NCT04700332|EXPERIMENTAL|Biochemically recurrent prostate cancer|DCFPyL PET/CT will be utilized for detection of unsuspected metastases in patients with biochemically recurrent prostate cancer, but with no evidence of disease on CT/bone scan.
62215978|NCT05608187|EXPERIMENTAL|ILP100Lo|During the Treatment Phase, subjects will continue on standard of care according to the protocol and ILP100Lo (ILP100-Topical, 5x10\^7 colony forming units (CFU)/cm\^2) will be topically administered at two occasions on Day 1 (Baseline and Hour 2), Days 2, 3, and thereafter every second to third day until Day 31.
62410555|NCT01655173|ACTIVE_COMPARATOR|Recreational activity intervention|36 sessions (1 calendar year) of a group intervention to enable social interaction and to break social isolation.
62021229|NCT06398353|SHAM_COMPARATOR|sham acupuncture|
62021230|NCT01573676||Bariatric surgery patients|Candidates for bariatric surgery.
62021231|NCT05487924|EXPERIMENTAL|SVV-GDHT|SVV ≤12% and CI of at least 2.5 L•min-1•m-2 were required. 500 mL of crystalloids was infused during induction, followed by a 2 ml•kg-1•h-1continuous infusion. If SVV was higher than 12% for over 5 minutes, a 250 mL bolus of crystalloid was given. Another 250 ml bolus of colloid was administrated if SVV was still higher than 12% or SVV decreased over 10%. If CI value was below 2.5 L•min-1•m-2, inotropes were applied to reach this minimum CI, serving as a safety parameter to prevent patients from low cardiac output. If SVV and CI were within the target range but MAP was below 65 mmHg, norepinephrine was started. After the initial assessment, patients were reassessed every 5 minutes intraoperatively to maintain values according to the study algorithm
62215979|NCT05608187|EXPERIMENTAL|ILP100Hi|During the Treatment Phase, subjects will continue on standard of care according to the protocol and ILP100Hi (ILP100-Topical, 1x10\^9 CFU/cm\^2) will be topically administered at two occasions on Day 1 (Baseline and Hour 2), Days 2, 3, and thereafter every second to third day until Day 31.
62410556|NCT03922984|EXPERIMENTAL|Glioblastoma Patients|Patients with histologically proven glioblastoma will undergo enhanced MRI with arterial spin labeling at weeks 0, 3, 6, 10, 18, 26, and 34 after beginning standard of care treatment.
62410557|NCT06651138||Pulsed Fluoroscopy|Patients in the study group will receive pulsed (8 frames/second) fluoroscopy for the entirety of the procedure
62215980|NCT05608187|PLACEBO_COMPARATOR|Placebo|During the Treatment Phase, subjects will continue on standard of care according to the protocol and Placebo (ILP100 dilution buffer mixed with the activation peptide SppIP) will be topically administered at two occasions on Day 1 (Baseline and Hour 2), Days 2, 3, and thereafter every second to third day until Day 31.
62410558|NCT06651138||Continuous Fluoroscopy|Non-study arm patients will receive continuous fluoroscopy for the entire procedure
62585173|NCT05459402|EXPERIMENTAL|Split-dosing|Participants in split dosing group will receive 50% active methadone + placebo twice daily.
62792227|NCT03897660|ACTIVE_COMPARATOR|TG form of omega-3|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acidsesterified in a reconstitute triglyceride form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
62215981|NCT00569101|EXPERIMENTAL|single|single arm study (tacrolimus trial group)
62215982|NCT03056989|EXPERIMENTAL|SPX-101 Low Dose|Inhalation Solution twice daily for 7 days.
62215983|NCT03056989|EXPERIMENTAL|SPX-101 Mid Dose|Inhalation Solution twice daily for 7 days.
62215984|NCT03056989|EXPERIMENTAL|SPX-101 High Dose|Inhalation Solution twice daily for 7 days.
62215985|NCT05444218|PLACEBO_COMPARATOR|Control|Open flap debridement + Er: YAG irradiation alone + systemic placebo of metronidazole and amoxicillin thrice a day (TID) for 14 days
62410559|NCT05479734|EXPERIMENTAL|mHealth Intervention + EMA|When families are in the mHealth intervention condition, the mHealth app will deliver parenting tips and strategies daily for 14 days. Furthermore, we plan to administer brief surveys via the mHealth app twice once a day at a pre-determined time. These surveys will ask parents to provide information about where they are and with whom, their emotional state, any recent parent-child interactions, and any current stressors or challenges. Parents will receive these daily surveys and the parenting tips for every day for two weeks. Then they will switch to EMA Only + Services As Usual.
62410560|NCT05479734|NO_INTERVENTION|EMA Only+ Services As Usual|In the EMA only condition, families will continue to receive services utilizing the home visiting model for the program they are enrolled in, including modules on healthy parent-child interaction and promoting parenting skills in high-risk families, but they will not receive parenting tips via the mHealth app during this period (2 weeks). Then, they will switch to mHealth Intervention + EMA.
62410561|NCT06520735|EXPERIMENTAL|Transcutaneous electrical nerve stimulation group|The pregnant women with emesis gravidarum will be treated by transcutaneous electrical nerve stimulation on the P6 acupuncture point.
62215986|NCT05444218|EXPERIMENTAL|Test|Open flap debridement + Er: YAG irradiation alone + systemic metronidazole (400mg) and amoxicillin (500mg) thrice a day (TID) for 14 days
62215987|NCT04351568||medical personel|
62215988|NCT04351568||non medical personel|
62215989|NCT04319523||COPD patients|
62215990|NCT04319523||Healthy subjects|
62410562|NCT06520735|EXPERIMENTAL|Capsicum plaster group|The pregnant women with emesis gravidarum will be treated with capsicum plaster on the P6 acupuncture point.
62792228|NCT03897660|ACTIVE_COMPARATOR|EE form of omega-3|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids in ethyl esters form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
62585174|NCT01054274|ACTIVE_COMPARATOR|novel stent|Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.
62410563|NCT06168201||Treated Individuals|Treated individuals with Achondroplasia. This is an observational study.
62410564|NCT06168201||Untreated Individuals|Untreated individuals with Achondroplasia. This is an observational study.
62410565|NCT02776215|EXPERIMENTAL|Pharmacokinetic Dosing|Single-dose pharmacokinetics of tasimelteon
62410566|NCT00381667|EXPERIMENTAL|GW642444M 12.5|
62410567|NCT00381667|EXPERIMENTAL|GW642444M 100mcg|
62585175|NCT01054274|EXPERIMENTAL|conventional covered stent|Patients undergo placement of a conventional covered stent on day 1.
62585176|NCT04921592|EXPERIMENTAL|transcutaneous stimulation|"1. transcutaneous stimulation 60 sessions~2. Transcutaneous stimulation 40sessions~3. Transcutaneous stimulation 20 sessions"
62585177|NCT01553604|EXPERIMENTAL|Postoperative day 6|Dressing is removed on the sixth postoperative day
62585178|NCT01553604|EXPERIMENTAL|Postoperative day 1|Dressing is removed on the first postoperative day
62215991|NCT01895101|PLACEBO_COMPARATOR|pericardial lavage with 200 ml normothermic saline solution|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.~This arm also receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid."
62215992|NCT01895101|NO_INTERVENTION|No pericardial lavage|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.~In this arm the subjects receives as in standard care no pericardial lavage."
62215993|NCT01895101|EXPERIMENTAL|2 gr tranexamic acid diluted in 200 ml normothermic saline|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.~This arm receives also pericardial lavage with 2 gr TA diluted in 200 ml normothermic saline solution (NaCl 0.9%)."
62215994|NCT04848077|EXPERIMENTAL|Very high dose|Very large proportional increase in stepcount relative to baseline stepcount.
62215995|NCT04848077|EXPERIMENTAL|High dose|Large proportional increase in stepcount relative to baseline stepcount.
62215996|NCT04848077|EXPERIMENTAL|Intermediate dose|Medium proportional increase in stepcount relative to baseline stepcount.
62215997|NCT04848077|ACTIVE_COMPARATOR|Active controls|Small proportional increase in stepcount relative to baseline stepcount.
62215998|NCT00581555|EXPERIMENTAL|etanercept|Participants were administered a 50 mg dose of etanercept subcutaneously once a week after an initial course of ciclosporin.
62410568|NCT00381667|EXPERIMENTAL|GW642444M 400mcg|
62410569|NCT00381667|EXPERIMENTAL|GW642444H 100mcg|
62410570|NCT00381667|EXPERIMENTAL|Placebo|
62410571|NCT05087173|EXPERIMENTAL|Interactive Q&A chatbot|A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of COVID-19 vaccination.
62410572|NCT03409328|EXPERIMENTAL|HIV and substance use prevention|Participants in the intervention condition will receive an HIV and substance use prevention program for self-identified bisexual adolescent men. The intervention content will be developed through formative research during the initial phase of the study.
62410573|NCT03409328|NO_INTERVENTION|Waitlist|The control condition will be a waitlist.
62410574|NCT01145573|PLACEBO_COMPARATOR|Placebo|Inactive pill taken daily
62410575|NCT01145573|ACTIVE_COMPARATOR|Calcium|1000mg of calcium taken daily
62410576|NCT05602025|EXPERIMENTAL|Participants receiving depemokimab via a SSD|
62410577|NCT05602025|EXPERIMENTAL|Participants receiving depemokimab via an autoinjector|
62410578|NCT03176628|EXPERIMENTAL|Basis|Nicotinamide riboside (NR) and pterostilbene oral capsules 250mg/50mg (Step 1) twice daily for 2 days. If the study progresses to Steps 2, 3, and 4, then 2x, 3x, and 4x the doses in Step 1 will be administered.
62410579|NCT03176628|PLACEBO_COMPARATOR|Placebo|Capsules identical in appearance and number to the agent used in Steps 1-4.
62410580|NCT05753085|EXPERIMENTAL|Conavi Medical Novasight Hybrid System intervention|Patients who present with non-ST elevation myocardial infarction (NSTEMI) and require an angiogram and or PCI will have intravascular imaging assessment of the culprit vessel using the Conavi Medical Hybrid System (Novasight Hybrid Catheter, Novasight Hybrid PIM, Novasight Hybrid Hummingbird Console)
62410581|NCT00864604|EXPERIMENTAL|A|Nabumetone 750 mg tablets, single dose
62410582|NCT00864604|ACTIVE_COMPARATOR|B|Nabumetone 750 mg tablets, single dose
62410583|NCT06653322|EXPERIMENTAL|Subjects receiving SHR-1703 dose 1|
62410584|NCT06653322|PLACEBO_COMPARATOR|Placebo|
62410585|NCT04120701|EXPERIMENTAL|Chemotherapy|
62410586|NCT04120701|NO_INTERVENTION|Follow-up within the study|
62410587|NCT04120701|NO_INTERVENTION|Follow-up outside the study|
62410588|NCT03881605|EXPERIMENTAL|MRI screening|Contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain at baseline, 4 months, 8 months and 12 months.
62410589|NCT03881605|NO_INTERVENTION|Symptom-directed surveillance|Imaging of the brain will take place only if patients develop symptoms that are suggestive of brain metastases (e.g. headaches, vision changes, gait instability).
62410590|NCT04048616|ACTIVE_COMPARATOR|whey protein isolate + KHCO3|1.5 gm/kg/day of whey protein and 81 mmol/day of KHCO3
62792229|NCT03897660|EXPERIMENTAL|MaxSimil (MAG form of omega-3)|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids in MaxSimil® form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
62792230|NCT03619772|EXPERIMENTAL|Bilateral|Participants will control game using EMG from both upper limbs.
62021232|NCT05487924|EXPERIMENTAL|O2ER-GDHT|the goal of O2ER is assessed every one hour to keep O2ER\<27% which calculated by the following equation:(SaO2 - SvO2)/SaO2, when O2ER is greated than 27%, CVP lower than 10mmHg, 250ml colloid is given, otherwise, inotropes is given as CVP≥10mmHg.
62021233|NCT05487924|ACTIVE_COMPARATOR|conventional care|MAP was kept between 65 and 90 mmHg, CVP between 8 and 12 mmHg and urinary output more than 0.5 ml•kg-1•h-1. 500 ml of crystalloids was infused during induction, followed by a continuous infusion of crystalloids (4 ml•kg-1•h-1). If the MAP decreased below 65 mmHg, or if the CVP decreased below 8 mmHg, a 250 mL bolus of colloid was given after waiting 5 minutes if any one of the criteria was met. If the MAP decreased below 65 mmHg and remained unresponsive to fluids, norepinephrine or inotropes was given to maintain the MAP above 65 mmHg.
62021234|NCT06529367||Visual Acuity Testing group|"Home vision assessment will be conducted using the Letter Distance Chart PDF document, a modified Early Treatment of Diabetic Retinopathy Study (ETDRS) chart for testing at 5 or 10 feet, and released for public use.~Patients will be asked to use the 5-foot distance for standardization, which allows for visual acuity assessment from 20/16 to 20/200.~Patients will be asked to wear their current corrective lens for distance, to take the test at home in a place with good lighting, and to test each eye separately.~Office-based vision testing will be performed by a trained ophthalmic technician in a dimmed room with the Snellen chart illuminated on a screen. Patients will be asked to wear their current corrective lens for distance and an eye occluder will be used to test each eye separately."
62215999|NCT00581555|PLACEBO_COMPARATOR|placebo|Participants were administered placebo subcutaneously once a week after an initial course of ciclosporin.
62792231|NCT03619772|ACTIVE_COMPARATOR|Unilateral|Participants will control game using the more impaired upper limb.
62792232|NCT05659368|EXPERIMENTAL|Interventional group|Tirzepatide will be injected subcutaneously once-per-week, in the abdomen, thigh or upper arm. To improve gastro-intestinal tolerability, the starting dose will be 5 mg (2.5mg for prepubertal children) and will be increased to a maximum of 15 mg (or highest tolerated dose).
62792233|NCT00933998|EXPERIMENTAL|Metanx|Metanx bid for 2 weeks then daily. Compare to non treated patient population
62021235|NCT06047769|EXPERIMENTAL|Interventional Group|Participants will receive cognitive training in board games including Ludo, Chutes \& Ladder and Chess with both single and multiplayer modes. After 1 week of training, participants will receive intervention of 1 hour per day, three days a week for 8 weeks completing a total of 1440 minutes. With this technique, we will target the cognitive process of information processing, speed and executive function of the patient.
62216000|NCT04674696|EXPERIMENTAL|Experimental|Patients will receive 2 CAPOX cycles, followed by short-course radiotherapy and 4 CAPOX cycles.
62585179|NCT04448457|EXPERIMENTAL|SSTS group|Patients received sufentanil nanotab patient controlled analgesia (PCA) system (Zalviso) 15 mcg with 20 min of lockout interval during 48 hours postoperatively
62792234|NCT03077230|EXPERIMENTAL|Pre/Post Test of a Lung Cancer Screening Decision Aid|
62021236|NCT06047769|NO_INTERVENTION|Control group|Participants will receive no intervention and will be observed for 8 weeks.
62021237|NCT05302765|NO_INTERVENTION|No IV Fluids|The control arm consists of lumbar puncture performed in routine fashion without the administration of intravenous fluids prior to procedure.
62021238|NCT05302765|EXPERIMENTAL|Receives IV Fluids|The experimental arm will receive normal saline intravenous fluid administration (20 milliliters/kilogram) prior to lumbar puncture. Bolus to be complete prior to lumbar puncture in the experimental group.
62021239|NCT02326103|ACTIVE_COMPARATOR|Ciprofloxacin|Oral administration of Ciprofloxacin 500mg twice daily
62021240|NCT02326103|PLACEBO_COMPARATOR|Placebo|Oral administration of Placebo pill twice daily
62021241|NCT06478784|EXPERIMENTAL|ACTIVE GROUP: Resistance training|The experimental group (ACTIVE GROUP) will perform a circuit-based muscular strength program at high intensity, three days per week for 10 weeks.
62021242|NCT06478784|ACTIVE_COMPARATOR|CONTROL GROUP: Low intensity aerobic training|Patients assigned to this CONTROL GROUP will perform exercise in static bicycle.They will perform aerobic training at low-moderate intensity (50% of the maximum power developed in cycloergometer) for 45 minutes three days a week, with a duration of 10 weeks.
62021243|NCT02545894|NO_INTERVENTION|BASELINE TESTING|Language and cognitive assessments conducted
62216001|NCT00962403|EXPERIMENTAL|Yoga treatment|
62216002|NCT00962403|NO_INTERVENTION|Waitlist|Waitlist control, no active treatment, treatment as usual, active treatment offered after waitlist control period. This study began as a single arm treatment trial and then transitioned to a randomized controlled trial.
62216003|NCT06432322|EXPERIMENTAL|Esketamine|Nasal spray solution, 56mg (28mg per nostril), intranasal
62216004|NCT06432322|PLACEBO_COMPARATOR|Placebo|Nasal spray solution, 0.9% NaCl, intranasal
62792235|NCT03196544|EXPERIMENTAL|Social Approach Training (5 sessions)|
62216005|NCT01505218|ACTIVE_COMPARATOR|Propofol sedation by nurse anaesthetist|Nurse anaesthetists managed infusion of propofol 10 mg/ml at doses of 0.2 - 0.8 ml/kg during ERCP. The target of moderate sedation was achieved within 5 minutes from start of the sedation.
62410591|NCT04048616|ACTIVE_COMPARATOR|whey protein isolate + microcrystalline cellulose|1.5 gm/kg/day of whey protein and identical placebo microcrystalline cellulose capsules
62216006|NCT01505218|ACTIVE_COMPARATOR|Patient-controlled propofol sedation|"Self-administration of propofol via patient-controlled sedation pump (CME...). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.~Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness."
62410592|NCT04048616|ACTIVE_COMPARATOR|maltodextrin powder + KHCO3|isocaloric placebo maltodextrin powder and 81 mmol/day of KHCO3
62410593|NCT04048616|PLACEBO_COMPARATOR|maltodextrin powder + microcrystalline cellulose|isocaloric placebo maltodextrin powder and identical placebo microcrystalline cellulose capsules
62792236|NCT03196544|EXPERIMENTAL|Social Approach Training (10 sessions)|
62792237|NCT03196544|NO_INTERVENTION|Delayed Treatment (Waitlist)|
62410594|NCT00011999|EXPERIMENTAL|Surgery, chemotherapy and radiation therapy|Early post-operative paclitaxel followed by paclitaxel and cisplatin concurrent with radiation therapy for resected head and neck cancer.
62792238|NCT01426672|EXPERIMENTAL|Monovision Correctoin|Monovision correction
62410595|NCT05888818|EXPERIMENTAL|cold application group|A cold application (with a cold gel pack) will be applied to the upper part of the neck for 5 minutes.
62410596|NCT05888818|NO_INTERVENTION|standard treatment|No application will be made and the presence of nausea, severity, vomiting and vital signs will be measured after 5 minutes.
62410597|NCT03431285|ACTIVE_COMPARATOR|Morphine Group|Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline (NS) infused over 30 minutes in addition to standard IV hydration.
62410598|NCT03431285|ACTIVE_COMPARATOR|Ketamine Group|Patients will receive low dose ketamine 0.3 mg/kg in 100ml normal saline (NS) infused over 30 minutes in addition to standard IV hydration
62410599|NCT01915498|EXPERIMENTAL|enasidenib|enasidenib administered orally. Multiple doses will be administered to determine the RP2D.
62410600|NCT06062758|EXPERIMENTAL|Nursing Students|The study population will consist of fourth-year students (n=72) of Fenerbahçe University Faculty of Health Sciences, Department of Nursing, Turkish Nursing Program. Sampling calculation and sample selection will not be made in the study, aiming to reach the entire population.
62410601|NCT05935618|EXPERIMENTAL|Combined skill- and strength-based swallowing exercise|The intervention is delivered as face-to-face therapy 2 times per week in 8 weeks
62410602|NCT05966129|EXPERIMENTAL|Acute Pain - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
62410603|NCT05966129|OTHER|Acute Pain - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period
62410604|NCT01269671|EXPERIMENTAL|Melatonin, Peppermint Oil, Simethicone|
62410605|NCT01269671|PLACEBO_COMPARATOR|Sugar pill|
62410606|NCT06164886||Sperimental|Patient on the waiting list for scheduled surgical admissions
62792239|NCT01944124|EXPERIMENTAL|Exercise Prescription + Mobile Health|Received a tailored exercise prescription and mobile health technology kit to track blood pressure, blood glucose, physical activity and body weight.
62792240|NCT01944124|ACTIVE_COMPARATOR|Exercise Prescription|Received a tailored exercise prescription only.
62410607|NCT06487182|EXPERIMENTAL|Reiki|The intervention will be applied to the reiki group in the application hospital room. Reiki therapy will be applied by a practitioner with a Reiki application certificate in the application laboratory for 30 minutes while the participants lie down with their eyes closed. 4 sessions of reiki application will be applied to the intervention group for a week. Reiki application will start , the first anxiety scores will be recorded. Anxiety levels after 4 sessions will be recorded.
62410608|NCT06487182|SHAM_COMPARATOR|Placebo reiki|Placebo Reiki will be applied to the participants in the group in the application hospital room. The practice will be carried out in the application room for 30 minutes, with the participants sitting with their eyes closed. Reiki life energy will not be transferred to participants in the placebo reiki group. Since the participants' eyes are closed, they will not know that there is a transfer. Placebo Reiki application will be performed in the room 4 times during a week. Placebo application will start and the anxiety scores will be recorded. After 4 sessions, anxiety scores will be recorded.
62410609|NCT06487182|NO_INTERVENTION|control|Routine hospital procedure will be applied. Anxiety scores will be recorded. After a week anxiety scores will be recorded.
62410610|NCT06188923|ACTIVE_COMPARATOR|Pregnenolone|Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial.
62410611|NCT06188923|PLACEBO_COMPARATOR|Placebo|Same as active comparator, except placebo dispensed
62792241|NCT02527785|EXPERIMENTAL|Oxaliplatin, Irinotecan, S-1(OIS)|"triple combination with oxaliplatin, irinotecan, and S-1.~Treatment will be delivered as a 2-week cycle.~1. Oxaliplatin 65 mg/m2 iv on day 1~2. Irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day on day 1-7"
62792242|NCT01732315|EXPERIMENTAL|Vaccination Email Reminder|This group of parents in the study will receive email notifications about due/overdue vaccines for their adolescents. Vaccination records will be reviewed to identify adolescent patients in both practices who are newly eligible for a vaccine and/or overdue for a vaccine at the start of every other month. Email notifications will then be sent to the parents of these children.
62021244|NCT02545894|EXPERIMENTAL|Treatment|"Intervention given:~visual tracking pressing a button every time a picture is seen on the screen~* playing dominoes and snap~* pressing a button every time a specific picture is seen on the screen~* Pressing a button every time a specific sound is heard~* Matching objects to a picture~* Matching gestures to objects~* Matching two connected objects~* Sorting objects by categories~* Matching sounds to objects~* Complete the category and odd on out with objects~* Choosing target objects by pointing~* Choosing objects to complete the category by pointing"
62021245|NCT02545894|NO_INTERVENTION|Post intervention|Repeated testing
62021246|NCT02498808||Healthy controls|Staff or patients attending hospital or visitors attending with patients. They should not have vasculitis or inflammatory arthritis
62021247|NCT02498808||Early rheumatoid arthritis|Newly diagnosed patients with rheumatoid arthritis attending hospital, prior to use of biologic therapies
62021248|NCT02498808||New or relapsing ANCA vasculitis|Newly diagnosed or flaring patients with anti-neutrophil cytoplasm antibody associated systemic vasculitis attending hospital
62216007|NCT01505218|NO_INTERVENTION|Midazolam sedation by the ERCP-team|Midazolam doses for sedation during ERCP. Initial dose of 2-3 mg and after ERCP start, 1-2 mg as additional doses. Maximum total dose 6-8 mg. ERCP performing doctor is responsible for dose ordination.
62216008|NCT06610734|EXPERIMENTAL|Group A|Adebrelimab combined with chemotherapy synchronous LDRT
62216009|NCT06610734|ACTIVE_COMPARATOR|Group B|Adebrelimab combined with chemotherapy
62216010|NCT00405366|OTHER|Single Arm Study|
62410612|NCT02122939|EXPERIMENTAL|Escitalopram|
62585180|NCT04448457|ACTIVE_COMPARATOR|Oxycodone group|Patients received oxycodone extended-release tablet (OxyContin) 10 mg every 12 hours systematically plus Oxycodone 5 mg every 6 hours if numeric rating scale is above 3 during the 48 hours postoperatively
62216011|NCT00312923|EXPERIMENTAL|Policosanol|20 mg daily of policosanol
62216012|NCT00312923|PLACEBO_COMPARATOR|Placebo|20 mg of microcrystalline cellulose daily
62216013|NCT06610188|EXPERIMENTAL|Prebiotic group|products containing a total of 9.2 g (4.6 g twice a day) inulin/oligofructose (50/50) mixture (prebiotic group) that individuals should consume daily were delivered to individuals in identical opaque bags.
62216014|NCT06610188|PLACEBO_COMPARATOR|Placebo|products containing a total of 9.2 g (4.6 g twice a day) maltodextrin (placebo group) that individuals should consume daily were delivered to individuals in identical opaque bags
62216015|NCT02107183|EXPERIMENTAL|Nasal high-flow oxygen therapy|High-flow, fully humidified oxygen delivered through nasal cannula (Optiflow, Fisher \& Paykel Healthcare) after extubation up to ICU discharge
62216016|NCT02107183|ACTIVE_COMPARATOR|Venturi mask oxygen therapy|Oxygen delivered through standard Venturi mask after extubation up to ICU discharge
62216017|NCT06008327|EXPERIMENTAL|Group A Topical 15% Trichloroacetic acid|15 % Trichloroacetic acid (TCA) and 0.05%Tretinoin for 02 months Trichloroacetic acid, a superficial chemical exfoliative agent has shown efficacy in treating acanthosis nigricans. 9-10 Data from this would help in establishing it as a treatment of choice thereby lead to reduction in cost and benefit the patient both financially and psychologically.
62216018|NCT06008327|EXPERIMENTAL|Group B Topical 0.05% Tretinoin|Topical tretinoin is the first choice of drug in the treatment of acanthosis nigricans. Despite several therapeutic modalities, acanthosis nigricans (AN) remains a difficult dermatosis to treat.
62410613|NCT06565871|EXPERIMENTAL|HRS9531 Injection low dose|
62585181|NCT00966004|EXPERIMENTAL|YM178 group|oral
62585182|NCT00966004|PLACEBO_COMPARATOR|Placebo group|oral
62585183|NCT00966004|ACTIVE_COMPARATOR|tolterodine group|oral
62585184|NCT02471352||1/ Skin disease or at risk|Subjects with a skin disease or at risk of developing a skin disease/ Family member of persons with a skin disease
62021249|NCT02498808||Newly diagnosed giant cell arteritis|Newly diagnosed patients with giant cell arteritis attending hospital
62216019|NCT04434573||french-speaking digestive surgeons|french-speaking digestive surgeons are visceral and digestive surgeons that have a general surgical activity too. They can have or not an expertise on hernia pathology. They are questioned by survey on decisions about different patient asymptomatic hernia clinical situations.
62792243|NCT01732315|NO_INTERVENTION|Usual Care|This group of parents in the study will not receive email notifications about due/overdue vaccines for their adolescents.
62792244|NCT03243357|EXPERIMENTAL|TF Adaptive (First Apical Binding File)|Endodontic treatment(teeth with periapical periodontitis\&radiolucence).Local anesthesia (4%Articaine with1:100,000 epinephrine),isolation with rubber dam\&standard access cavity preparation.Using 2.5 %sodium hypochlorite,canal negotiation,glide path,coronal flaring with Sx(ProTaper),determining working length\&first apical binding file.Intervention: Root canal instrumentation:TF Adaptive system with enlargement of the root canal performed with up to 3 files larger than the diameter of the initial apical file. Irrigation2.5%NaOCl\&EDTA (Ethylenediaminetetraacetic acid)under activation with ultrasound. Irrigation with saline solution and placement of medication based on calcium hydroxide. After 14 days, obturation: gutta-percha\&epoxy resin sealer.
62792245|NCT03243357|OTHER|TF Adaptive (Control)|In the control group,endodontic treatment (teeth with periapical periodontitis\&radiolucence). Local anesthesia(4% Articaine with 1:100,000 epinephrine), isolation with rubber dam\&standard access cavity preparation. Using 2.5 % sodium hypochlorite, canal negotiation, determining working length\&glide path. Root canal instrumentation:TF Adaptive system according to the protocol recommended by the manufacturer.Irrigation 2.5% NaOCl \& EDTA(Ethylenediaminetetraacetic acid)under activation with ultrasound. Irrigation with saline solution and placement of medication based on calcium hydroxide. After 14 days, the canals will be obturated with gutta-percha and epoxy resin sealer.
62216020|NCT02262624|EXPERIMENTAL|Telmisartan/HCTZ fixed combination|
62216021|NCT02262624|ACTIVE_COMPARATOR|Telmisartan and HCTZ monocomponents|
62216022|NCT02070939|EXPERIMENTAL|SAD cohorts 1-7 Experimental Arm|
62216023|NCT02070939|PLACEBO_COMPARATOR|SAD Cohorts 1-7 Placebo Arm|
62410614|NCT06565871|EXPERIMENTAL|HRS9531 Injection high dose|
62410615|NCT06565871|PLACEBO_COMPARATOR|Placebo|
62410616|NCT06108297|EXPERIMENTAL|Lithium|Lithium capsules titrated to 30-45mg/day based on individual patient subjective benefits and tolerability.
62792246|NCT00933868|EXPERIMENTAL|Magnesium infusion in patients breathing 100% oxygen|Patients will be given six infusions over three weeks. Each infusion will last between 4 and 10 minutes. They will then return to clinic in 1,2 and 3 months for the same tests (but no infusions will be given).
62792247|NCT00933868|PLACEBO_COMPARATOR|Placebo infusion|The patients will receive six placebo infusions after which they will return to clinic at one, two and three months. At the conclusion of the trial those patients who received placebo may elect to receive the active treatment in another (open label) trial that will begin shortly after this one concludes.
62585185|NCT02471352||2/ Healthy Volunteers|Healthy Volunteers
62792248|NCT02075151|OTHER|Bronchial Thermoplasty|Bronchial thermoplasty
62792249|NCT04267835||MICS (Minimal invasive coronary surgery)|Patients undergoing MIDCAB surgery.
62792250|NCT04267835||OPCABG (thoracotomy off-pump CABG)|Patients undergoing thoracotomy OPCABG surgery
62792251|NCT05150015|EXPERIMENTAL|Number of consented patients who complete the antibiotics through an elastomeric pump|Flucloxacillin, piperacillin/taozbactam and benzylpenicillin will be use
62216024|NCT02070939|EXPERIMENTAL|MAD cohorts 2-6 Experimental Arm|
62216025|NCT02070939|PLACEBO_COMPARATOR|MAD cohorts 2-6 Placebo Arm|
62216026|NCT02070939|EXPERIMENTAL|Japanese MAD cohort 7 Experimental arm|
62410617|NCT03869905|EXPERIMENTAL|Aquamin®|To be taken for 180 days
62410618|NCT03869905|PLACEBO_COMPARATOR|Placebo first then Aquamin®|Placebo: To be taken for the first 90 days. Aquamin®: To be taken for the last 90 days (after crossover)
62410619|NCT05465122||Carotid Stenting Group (CAS)|Subjects assigned to the intensive medical management with carotid stenting group in the CREST-2 study (NCT02089217)
62216027|NCT02070939|PLACEBO_COMPARATOR|Japanese MAD cohort 7 Placebo Arm|
62216028|NCT05610202|EXPERIMENTAL|TQB3702 tablets|TQB3702 tablets were administered orally, 28 days as a treatment cycle until the progressive diseases or the investigator judges that it is not suitable for subject to continue to take this medicine.
62216029|NCT06403709|EXPERIMENTAL|Irinotecan, TAS-102 plus Bevacizumab arm|Patients received an intravenous infusion of irinotecan (150mg/m2 on day 1) plus bevacizumab (5 mg/kg on day 1) and an oral administration of TAS-102(30 mg/m2 given bid on days 1-5), repeated every 14 days.
62216030|NCT01630694|ACTIVE_COMPARATOR|Difficult intubation patients|patients who were difficult to intubate during previous anesthetics provided by the staff anesthesiologists.
62216031|NCT01630694|PLACEBO_COMPARATOR|Control|The control group will consist of patients with the easy laryngoscopy and intubation, recruited prospectively.
62216032|NCT05390021|EXPERIMENTAL|PET/MRI IN ENDOMETRIAL CANCER|PET/MRI in one study visit of approximately four hours
62410620|NCT05465122||Carotid Endarterectomy Group (CEA)|Subjects assigned to the intensive medical management with carotid endarterectomy group in the CREST-2 study (NCT02089217)
62410621|NCT05465122||Intensive Medical Management Group - no CAS|Subjects assigned to the intensive medical management alone with no carotid stenting (CAS) group in the CREST-2 study (NCT02089217)
62410622|NCT05465122||Intensive Medical Management Group - no CEA|Subjects assigned to the intensive medical management alone with no carotid endarterectomy (CEA) group in the CREST-2 study (NCT02089217)
62410623|NCT00962013|OTHER|Restoration® Modular|All subjects were enrolled into a single arm and received the Restoration® Modular Revision Hip System to replace the femoral portion of a failed previous implant.
62410624|NCT04559776|EXPERIMENTAL|typically developing toddlers|toddlers with a typical development and with less than 3 years old and less than 6 months of independent walking
62216033|NCT04406740||All Participants|Adult patients \>18 years of age, who are scheduled to undergo any elective procedure under general anesthesia in the MHealth East Bank operating rooms in which the administration of a nondepolarizing neuromuscular blocking drug (rocuronium or cisatracurium) is anticipated.
62216034|NCT05347368|OTHER|Control group (conventional therapy)|
62216035|NCT05347368|EXPERIMENTAL|Primal Reflex release Technique|
62410625|NCT04559776|EXPERIMENTAL|unilateral cerebral palsy toddlers|toddlers with a unilateral cerebral plasy and with less than 3 years old and less than 6 months of independent walking
62410626|NCT03833934||Plasma Next Generation Sequencing (NGS)|Subjects will be sent blood collection kits with the necessary materials for local draws and those specimens will be sent directly by the subjects to the central laboratory (Resolution Bioscience) for plasma NGS. Plasma NGS results will be returned to the subject, their treating physician and study team, aiming to return results within 2 weeks by Resolution Bioscience.
62410627|NCT03191409||Control Group|Health adults with no evidence of brain lesions on conventional magnetic resonance imaging(MRI) and no neural developmental disorders.
62216036|NCT06317532|ACTIVE_COMPARATOR|Lifestyle modification advice|It will include 29 females suffering from primary dysmenorrhea. They will be asked to follow lifestyle modification advice during the program duration.
62410628|NCT03191409||Patients Group|ESRD patients pre-hemodialysis will be collected.The following exclusion criteria were applied in this study: (a)history of drug or alcohol abuse, (b) brain lesions such as a tumor or stroke assessed on the basis of medical history, (c) history of or current psychiatric disorders, and (d) head motion more than 1.0 mm or 1.0°during magnetic resonance imaging. All patients completed laboratory tests to evaluate renal function,serum creatinine, and urea levels within the 12 hours before magnetic resonance imaging.
62410629|NCT06652126||Immunocompromised patients|"* Age ≥ 18 ;~* Admitted to intensive care and whose length of stay exceeds 48 hours ;~* Immunocompromised according to one of the following criteria:~  1. Solid cancer under treatment or in remission for less than 5 years (including cancers diagnosed during hospitalization in intensive care) ;~ 2. Hematologic malignancy under treatment or in remission for less than 5 years (including hematologic malignancies diagnosed during hospitalization in intensive care);~ 3. Neutropenia \< 0.7 G/L for ≥ 7 days;~ 4. Solid organ transplants;~ 5. Patients with systemic or transplant pathologies requiring treatment with corticosteroids (prednisone equivalent \> 10 mg/day) or other high-dose immunosuppressants for \> 28 days;~ 6. Human Immunodeficiency Virus (HIV) infection with CD4+ \<200 μL;~ 7. Genetic immune deficiency.~* Undergoing invasive mechanical ventilation and/or vasopressive amines."
62792252|NCT02956317|ACTIVE_COMPARATOR|STP705|Each subject will receive both active (STP705) and control (Placebo) intradermal injection twice a week for a total of 4 weeks at 20 μg/cm2/day (in Cohort A), 30 μg/cm2/day (in Cohort B) and 40 μg/cm2/day (in cohort C). The total length of linear hypertrophic scar will be divided equally for treatment with STP705 and placebo. STP705 and Placebo will be injected intradermal every 1 cm length on the hypertrophic scar.
62410630|NCT06652126||Immunocompetent patients|"* Age ≥ 18 ;~* Admitted to intensive care and whose length of stay exceeds 48 hours ;~* Immunocompetent ;~* Undergoing invasive mechanical ventilation and/or vasopressive amines."
62792253|NCT02956317|PLACEBO_COMPARATOR|Placebo|Each subject will receive both active (STP705) and control (Placebo) intradermal injection twice a week for a total of 4 weeks at 20 μg/cm2/day (in Cohort A), 30 μg/cm2/day (in Cohort B) and 40 μg/cm2/day (in cohort C). The total length of linear hypertrophic scar will be divided equally for treatment with STP705 and placebo. STP705 and Placebo will be injected intradermal every 1 cm length on the hypertrophic scar
62792254|NCT04215640|EXPERIMENTAL|MIFI group|Patients in the MIFI group receive standard radiofrequency ablation procedure for the supraventricular tachycardia using microfidelity (MIFI) catheter.
62792255|NCT04215640|ACTIVE_COMPARATOR|Control|Patients in the control group receive standard radiofrequency ablation procedure for the supraventricular tachycardia using conventional ablation catheter (Blazer II).
62792256|NCT04270968|EXPERIMENTAL|ESWT Group|received ESWT once a week for 4 weeks (0.25 ml/mm2, 1000 shocks) plus topical none steroidal anti-inflammatory drug (NSAID; 3 times /day for 4 weeks).
62792257|NCT04270968|EXPERIMENTAL|control group|received only topical NSAID.
62792258|NCT05375721|EXPERIMENTAL|ST36 acupoint injection group|Patients in this group will received bilateral ST36 injection with scopolamine 1ml/point
62216037|NCT06317532|EXPERIMENTAL|Lifestyle modification advice + Functional exercises|It will include 29 females suffering from primary dysmenorrhea. They will be given the same lifestyle modification advice as group A, in addition to performing a combination of various functional exercises (including two stretching exercises, one yoga position, two core-strengthening exercises, two pelvic area exercises, and Kegel exercises), for 45 minutes per session, three times /week for eight weeks.
62410631|NCT06568380|EXPERIMENTAL|Noro+ Phage+|Oysters positives for both norovirus genome and infectious bacteriophages
62792259|NCT05375721|PLACEBO_COMPARATOR|pharmacoprophylaxis group|Patients in this group will received bilateral ST36 acupoint injection with normal saline 1ml/point
62792260|NCT03940300|EXPERIMENTAL|Adults with or risk for Type 2 Diabetes|All adult individuals with (non-insulin treated) or at risk for type 2 diabetes are in the treatment group and will receive prescriptions of fresh organic vegetables on a weekly basis for 10 weeks.
62792261|NCT01199419||PCI|
62792262|NCT01199419||CABG|
62216038|NCT01955967|OTHER|Lidocaine|
62216039|NCT04343872|ACTIVE_COMPARATOR|Receive lifestyle modification alone (DPP)|Participants in this arm will receive a lifestyle modification intervention program facilitated by Peer Coach (PC) services
62216040|NCT04343872|EXPERIMENTAL|Receive lifestyle modification with metformin therapy|Participants in this arm will receive a lifestyle modification intervention program facilitated by Peer Coach (PC) services plus metformin recommendation
62216041|NCT05684744|EXPERIMENTAL|Roflumilast|oral roflumilast in a dose of 500 mcg per day
62216042|NCT05684744|ACTIVE_COMPARATOR|Methotrexate|oral methotrexate in a dose of 0.2- 0.4 mg/kg/week
62792263|NCT05924594|EXPERIMENTAL|Experimental: 6.25mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
62216043|NCT00703209|ACTIVE_COMPARATOR|1|Patients who are randomized to receive surgical care, will receive the nerve decompression, along with similar incisions on the opposite leg, but no decompression on that leg. This will serve as the patient's control leg, and also blind them to the treatment leg.
62410632|NCT06568380|EXPERIMENTAL|Noro+ Phage-|Oysters positives for norovirus genome and negatives for infectious bacteriophages
62410633|NCT06568380|EXPERIMENTAL|Noro- Phage+|Oysters negatives for norovirus genome and positives for infectious bacteriophages
62410634|NCT06568380|PLACEBO_COMPARATOR|Noro- Phage-|Oysters negatives for both norovirus genome and infectious bacteriophages
62410635|NCT00886873|EXPERIMENTAL|Group 1|Oral administration of mifepristone 5 mg daily for six months.
62410636|NCT00886873|EXPERIMENTAL|Group 2|Oral administration of mifepristone 10 mg daily for six months.
62410637|NCT02157181|EXPERIMENTAL|HCL, 2CdA +/- Rituximab|"Risk stratification~1. HCL variant will be treated with cladribine plus rituximab, independent of previous therapy~2. Relapses of HCL will be treated with cladribine plus rituximab, duration of remission of the previous therapy is \< 3 years.~3. All repeated relapses (\> 1st relapse) after previous therapies with purine analogues and/or interferon will be treated with cladribine plus rituximab.~   Cladribine (LITAK®) 0.14 mg/kg daily Days 8-12 subcutaneous bolus injection Rituximab (Mabthera®) 375 mg/m2 daily Days 1, 8, 15, 22 infusion~4. Relapses of HCL will be treated with cladribine monotherapy, if the duration of remission of the previous therapy is \> 3 years.~Cladribine (LITAK®) 0.14 mg/kg daily Days 1-5 subcutaneous bolus injection"
62410638|NCT06159699||Non-structured population|The respondent will represent the non-structured population of the Russian Federation invited to participate in the study using the SMS-Target tool provided by OOO T2 Mobile Company.
62585186|NCT03909061|EXPERIMENTAL|Immediate Training (no follow up)|Individuals may decide to participate in the research study training program, but not in any follow up questionnaires. This group will have immediate access to the independent maintenance training materials. They will complete data collection measures embedded in the maintenance training program, including demographics, Online Learning Readiness Scale (OLRS), Moorong Self Efficacy Scale (MSES), Patient Reported Outcome Measurement Information System (PROMIS), Assistive Technology Module Questionnaire (ATM-Q), and the Wheelchair Maintenance Training Questionnaire (WMT-Q).
62021250|NCT02696850|EXPERIMENTAL|Budesonide|"The study intervention will be budesonide powder (0.5 mg/capsule). Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.~Each study bottle will contain 60 capsules of Budesonide and will be assigned with a number from 1-80."
62021251|NCT02696850|PLACEBO_COMPARATOR|Saline Alone|Each study bottle will contain 60 capsules of placebo, which is lactose monohydrate and will be supplied in clear plastic capsules identical to the budesonide capsules. Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.
62410639|NCT02461147||Validation cohort|All patients of the study (single group, single arm) will undergo initial cholecystectomy with intraoperative cholangiogram, followed if required by ERCP, according to the standard protocol of treatment previously implemented at the investigators institution.
62819322|NCT04386317|EXPERIMENTAL|terazosin therapy|Daily oral doses of adrenergic blocker 5 mg or 10 mg. The dosage will be gradually increased from the initial recommended starting dose of 1 mg daily at bedtime and titrated stepwise to 2mg, 5mg or 10 mg weekly, according to patient tolerability, as measured by subjective complaints, arterial blood pressure and heart rate. The target dose will be 5 mg or 10 mg daily based on subject's tolerability.
62021252|NCT03103867|EXPERIMENTAL|CGM augmented pump with PLGS (A)|Administration of Subcutaneous administration of Continuous subcutaneous insulin infusion with integrated continuous glucose monitoring and predicted low glucose suspense (PLGS) Randomised cross over treatment during 5 weeks
62216044|NCT00703209|NO_INTERVENTION|2|Subjects who are not randomized to receive the surgical procedure will be followed up with the same clinic visits as the patients who are receiving the surgical procedure.
62021253|NCT03103867|ACTIVE_COMPARATOR|Insulin pump with CGM (B)|Administration of Subcutaneous administration of Continuous subcutaneous insulin infusion with second device measuring continuous glucose Randomised cross over treatment during 5 weeks
62216045|NCT05094557|EXPERIMENTAL|Experimental Group 1|Participants from the Experimental Group 1 will engage in a self-conversation through embodied perspective taking (body swapping), according to which they will be embodied alternately in their own virtual representation and in their counsellor's virtual body. They will also continue receiving Treatment As usual plus a Psychoeducational video with useful information about how to engage with a healthier lifestyle.
62216046|NCT05094557|EXPERIMENTAL|Experimental Group 2|"Participants from the Experimental Group 2 will be embodied in their own body and will participate in a pre-established discourse provided by their virtual counsellor. Participants will also continue receiving Treatment As usual plus a Psychoeducational video with useful information about how to engage with a healthier lifestyle."
62021254|NCT00835406|EXPERIMENTAL|Alendronate Sodium First|70 mg Alendronate Sodium Tablets test product dosed in first period followed by 70 mg Fosamax® Tablets reference product dosed in second period
62021255|NCT00835406|ACTIVE_COMPARATOR|Fosamax® First|70 mg Fosamax® Tablets reference product dosed in first period followed by 70 mg Alendronate Sodium Tablets test product dosed in second period.
62216047|NCT05094557|ACTIVE_COMPARATOR|Control Group|Participants from the Control Group will receive their Treatment As Usual plus a Psychoeducational video. Treatment as usual will consist of regular medical, nutritional and/or psychiatric follow-ups with the obesity specialists of the Vall d´ Hebron University Hospital and standard routine tests. These visits aim to provide practical recommendations about how to achieve a gradual weight loss and engage more with physical exercise.
62216048|NCT03835429|EXPERIMENTAL|MyTAP oral appliance plus mouth shield|MyTAP plus mouth shield
62216049|NCT01831947|EXPERIMENTAL|Ranibizumab fixed dose|Injection of 0.5 mg Ranibizumab every 2 months for one year, following a monthly injection during the first 3 months.
62216050|NCT01831947|EXPERIMENTAL|Ranibizumab on demand|Injection of 0.5 mg Ranibizumab on demand for one year, following a monthly injection during the first 3 months.
62216051|NCT01767701|EXPERIMENTAL|Raltegravir|All eligible patients will complete a 3 months observation period (no medications) followed by 3 months on treatment period. During the treatment period patients will be treated with open label raltegravir 400mg twice daily.
62216052|NCT03990545||Cases with stroke|
62216053|NCT03990545||Controls without stroke|
62216054|NCT02957851|PLACEBO_COMPARATOR|Oxygen/Nitrogen (22%/78%)|Medical Air
62216055|NCT02957851|ACTIVE_COMPARATOR|Nitrous Oxide/Oxygen (50%/50%)|EMONO
62216056|NCT04751266||Patients with MIRPE|first minimally invasive repair of pectus excavatum
62216057|NCT01239485|EXPERIMENTAL|Irinotecan|
62585187|NCT03909061|EXPERIMENTAL|Immediate Training (with follow up)|Individuals may decide to participate in the research study, but do not want to be randomized. After consent is obtained, these individuals will be directed immediately to the baseline questionnaires (see above) before and after the wheelchair maintenance training. Participants may also be asked to complete a user satisfaction survey.
62021256|NCT05760066|EXPERIMENTAL|Resistance Training Preconditioning (PRECON)|"This group will perform:~1. 6 weeks of lower body focused resistance training~2. 2 weeks of locking brace-induced immobilization of a randomized leg~3. 6 weeks of lower body focused resistance training"
62216058|NCT04642313|PLACEBO_COMPARATOR|PLACEBO group|Placebo treatment: starch tablets (250 mg)
62216059|NCT04642313|EXPERIMENTAL|Magnesium group|Magnesium group: Magnesium gluconate (250 mg)
62216060|NCT04642313|EXPERIMENTAL|Potassium group|Potassium group: Potassium chloride (250 mg)
62216061|NCT04642313|EXPERIMENTAL|Magnesium + Potassium group|Magnesium + Potassium group: Magnesium gluconate (250 mg) + Potassium chloride (250 mg)
62216062|NCT02905955|OTHER|Prevena|
62216063|NCT05424562||Venetoclax Participants|Participants treated with Venetoclax in accordance with approved local label.
62216064|NCT05578781|EXPERIMENTAL|Music Therapy|The Music Therapy (MT) group will participate in 1 live session of music therapy with a board certified Music therapist while wearing an EEG cap. Afterwards, they will complete a brief questionnaire about the experience and pain. They will also complete a brief questionnaire 24 hours later about lasting effects and pain
62216065|NCT05578781|EXPERIMENTAL|Music Medicine|The Music Medicine (MM) group will participate in 1 audio session of music while wearing an EEG cap. Afterwards, they will complete a brief questionnaire about the experience and pain. They will also complete a brief questionnaire 24 hours later about lasting effects and pain
62819323|NCT02432443|EXPERIMENTAL|Motor and pre-literacy program|First group to receive the motor and pre-literacy program.
62216066|NCT05578781|EXPERIMENTAL|Control condition|the Control group will participate in 1 session of an audio of text being read to them while wearing an EEG cap. Afterwards, they will complete a brief questionnaire about the experience and pain. They will also complete a brief questionnaire 24 hours later about lasting effects and pain
62216067|NCT05578781|ACTIVE_COMPARATOR|Control group without low back pain|This group will participate in 1 session of an audio of the music therapy session while wearing an EEG cap. Afterwards, they will complete a brief questionnaire about the experience and pain. They will also complete a brief questionnaire 24 hours later about the lasting effects and pain
62216068|NCT03819998||PCOS group|women who have PCOS
62216069|NCT03819998||control group|women who donnot have PCOS
62216070|NCT04246151|EXPERIMENTAL|Vancomycin & probiotic placebo|Vancomycin 125 mg orally every 12 hours plus probiotic placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
62021257|NCT05760066|ACTIVE_COMPARATOR|Control (CTL)|"This group will perform:~1. 6 weeks of activities of daily living (no training)~2. 2 weeks of locking brace-induced immobilization of a randomized leg~3. 6 weeks of lower body focused resistance training"
62021258|NCT04414644|EXPERIMENTAL|Daytime Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 0800 and 1900.
62021259|NCT04414644|EXPERIMENTAL|Delayed Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 1200 and 2300.
62021260|NCT01469689|EXPERIMENTAL|Google Adwords only|In these areas,the investigators will display online adverts using Google Adwords, with links to the investigators' project website, and from there to four other websites for depression.
62792264|NCT05924594|EXPERIMENTAL|Experimental: 12.5mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
62792265|NCT05924594|EXPERIMENTAL|Experimental: 18.75mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
62792266|NCT05924594|EXPERIMENTAL|Experimental: 25.0mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
62792267|NCT05924594|EXPERIMENTAL|Experimental: 31.25mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
62792268|NCT05924594|EXPERIMENTAL|Experimental: 37.5mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
62792269|NCT05924594|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
62792270|NCT04805437|EXPERIMENTAL|3D TLSO|A 3-dimensional Boston brace will be designed to the patient's individual type of scoliosis. In-brace radiographs will be performed after prescription. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. Patients are encouraged to use the brace for 20 hours per day and to also continue with physical activities for the entirety of the study. Compliance will be monitored with a heat sensor built in the brace that measures wearing time.
62792271|NCT04805437|ACTIVE_COMPARATOR|Standard TLSO|A standard Boston brace will be designed to the patient's individual type of scoliosis. In brace radiographs will be performed after prescription. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. Patients are encouraged to use the brace for 20 hours per day and to also continue with physical activities for the entirety of the study. Compliance will be monitored with a heat sensor built in the brace that measures wearing time.
62792272|NCT04327791|EXPERIMENTAL|baloxavir|Baloxavir: 40 mg po once for wt \< 80 kg OR 80 mg po once for wt \>/= 80 kg
62792273|NCT04327791|PLACEBO_COMPARATOR|placebo|placebo po once
62792274|NCT00313417|ACTIVE_COMPARATOR|1|
62792275|NCT00313417|PLACEBO_COMPARATOR|2|
62792276|NCT00837070|EXPERIMENTAL|1|Percutaneous zygapophyseal cyst rupture
62792277|NCT03642509|EXPERIMENTAL|LAAO group|Patients will be treated with transcatheter left atrial appendage occlusion. The LAAO may be performed with the Amulet or Watchman device.
62792278|NCT03642509|EXPERIMENTAL|NOAC group|Patients will be treated with one of the currently available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban.
62792279|NCT00685113|EXPERIMENTAL|1|
62792280|NCT00685113|EXPERIMENTAL|2|
62792281|NCT00685113|PLACEBO_COMPARATOR|3|
62792282|NCT03956212|EXPERIMENTAL|erythema migrans patients treated with doxycycline|adult patients with erythema migrans will be treated with oral doxycycline
62021261|NCT01469689|EXPERIMENTAL|Local organisation websites|In these areas, the investigators will try to place adverts on the websites of local organizations, with links to the investigators' project website, and from there to four other websites for depression.
62792283|NCT00828763|EXPERIMENTAL|1|\[14C\]-GSK1349572 administered as a single oral dose
62216071|NCT04246151|EXPERIMENTAL|Probiotic & vancomycin placebo|Culturelle probiotic 20 billion active units orally every 12 hours plus vancomycin placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
62216072|NCT04246151|PLACEBO_COMPARATOR|Probiotic placebo & vancomycin placebo|Vancomycin placebo orally every 12 hours and Culturelle placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
62792284|NCT03903419|EXPERIMENTAL|68Ga-PSMA PET-CT and 18F-FDOPA PET-CT|Functional imaging: 68Ga-PSMA and 18F-FDOPA PET-CT Immunohistochemistry of initial chirurgical sample with determination of PSMA expression
62792285|NCT03409783|ACTIVE_COMPARATOR|Active or ENSO Group|Active ENSO device use for two weeks, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
62792286|NCT03409783|SHAM_COMPARATOR|Sham Group|Sham device use for two weeks, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
62792287|NCT02790801||1 group|observation of patients with chronic heart failure and atrial fibrillation
62792288|NCT01433172|EXPERIMENTAL|Phase I Vaccinations|Participants enrolled in the Phase I trial will receive GM.CD40L.CCL21 vaccinations on 3 occasions, at 2 week intervals. Note for the phase I portion: the use of steroid medication is to be avoided for 4 weeks prior to the initiation of vaccine therapy and during the vaccine treatment period.
62819324|NCT02432443|ACTIVE_COMPARATOR|Wait-list comparison|Second group to receive the motor and pre-literacy program after the experimental arm has completed the program.
62216073|NCT02916303||Patients|Patients followed up at least during 3 years at PAFIP clinic
62216074|NCT01139580|EXPERIMENTAL|Calcipotriene Foam|Calcipotriene Foam 0.005%,
62216075|NCT01139580|PLACEBO_COMPARATOR|Vehicle Foam|Vehicle Foam
62021262|NCT01469689|EXPERIMENTAL|Google Ads and local websites|In these areas, the investigators will place Google Adwords and also try to place adverts on the websites of local organizations, with links to the investigators' project website, and from there to four other websites for depression.
62216076|NCT00038012|EXPERIMENTAL|rhTPO-Derived Autologous Platelets Transfusion|
62216077|NCT06610331|SHAM_COMPARATOR|Control Group - Free Gingival Graft|
62216078|NCT06610331|EXPERIMENTAL|Test Group - Free Gingival Graft + polyvinylpyrrolidone sodium hyaluronate gel|
62216079|NCT04619979||preoperative anxiety group|
62216080|NCT04619979||Non-preoperative anxiety group|
62216081|NCT02610907|EXPERIMENTAL|Cohort 01a|"This is a sub-study testing three patches consisting of an adhesive patch and a sleeve. The sleeve can contain one of three solutions:~Buffer Own output Simulated output (digestive enzymes)~All subjects will test the three solutions at the same time, hence the three patches with different solutions will be placed on the peristomal skin simultanously."
62216082|NCT05571371||Epileptic seizure|Measuring inflammatory serum biomarkers in epileptic seizure patients and psychogenic non-epileptic seizure
62216083|NCT05338801|EXPERIMENTAL|Menthol-flavored e-cigarette|All participants will complete a lab visit where they will use menthol-flavored e-cigarette ad libitum for up to 60 minutes.
62216084|NCT05338801|EXPERIMENTAL|Tobacco-flavored e-cigarette|All participants will complete a lab visit where they will use tobacco-flavored e-cigarette ad libitum for up to 60 minutes.
62216085|NCT01636323|ACTIVE_COMPARATOR|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
62216086|NCT01636323|ACTIVE_COMPARATOR|Female Smokers (Early Follicular Phase; cycle days 4-8)|
62216087|NCT01986075|EXPERIMENTAL|Computer-assisted CBT plus Mixed-Amphetamine Salts- Extended Release (MAS-ER)|Patients who are randomized to the computer-assisted behavior therapy plus mixed amphetamine salts (extended release) arm will have their dose titrated to 80 mg or the maximum tolerated extended release mixed amphetamine salts daily. Participants will be asked to take the medication once per day in the morning or early afternoon and will be maintained on this schedule through week 14 of the trial. Computer-assisted behavior therapy based on the Community Reinforcement Approach (CRA) to treating cocaine dependence. CRA is skills based treatment program that incorporates coping skills development and contingency management. Participants will attend the clinic 3x per week and receive counseling 2x per week.
62216088|NCT01986075|PLACEBO_COMPARATOR|Computer-assisted CBT plus placebo|Patients who are randomized to the Computer-assisted CBT plus placebo arm will have their medication dose titrated in a fix-flexible dose schedule matching the active medication arm. Participants will be asked to take the medication once per day in the morning or early afternoon and will be maintained on this schedule through week 14 of the trial. Computer-assisted behavior therapy based on the Community Reinforcement Approach (CRA) to treating cocaine dependence. CRA is skills based treatment program that incorporates coping skills development and contingency management. Participants will attend the clinic 3x per week and receive counseling 2x per week.
62216089|NCT01224392|ACTIVE_COMPARATOR|Concomitant chemoradiotherapy|Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends
62216090|NCT01224392|EXPERIMENTAL|Radiotherapy with boost|Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor
62410640|NCT03024359|ACTIVE_COMPARATOR|obese individuals|Individuals with BMI between 30 and 35 kg/m2 will be included in this group and will receive 4 weeks of extra virgin olive oil. Before and after the intervention period data regarding dietary intake and physical activity, brown/beige adipose tissue activity, body composition (DXA), lipid profile and inflammatory markers and brain activity (18F-FDG PET/MRI; in a subsample of 5 obese individuals)will be collected.
62585188|NCT03909061|EXPERIMENTAL|Randomized Training|Individuals may decide to participate in the research study and agree to be randomized. These individuals will be immediately randomized into an immediate or a wait list control group. The immediate will receive the wheelchair maintenance training program after completing the baseline questionnaires. The wait list control group will wait approximately 6 months before receiving the independent maintenance training program.
62585189|NCT02555787||Patients converted from tacrolimus BD to Advagraf|Oral
62216091|NCT01507519|EXPERIMENTAL|BioMime™|BioMime™ DES
62216092|NCT02845206|EXPERIMENTAL|Patient Specific Cutting Blocks|For the bespoke individualised cutting blocks to be manufactured, the patients will undergo a preoperative CT scan under a set protocol. The CT radiation dose will be considerably less than a conventional diagnostic CT scan.
62216093|NCT02845206|ACTIVE_COMPARATOR|Conventional Cutting Blocks|The patients in this arm will be operated on using conventional instruments.
62216094|NCT00076154||Group 1|
62216095|NCT03041051|EXPERIMENTAL|PCV13|
62216096|NCT03041051|EXPERIMENTAL|PPV23|
62021263|NCT01469689|NO_INTERVENTION|Control|Control areas. No Intervention
62585190|NCT03123835|OTHER|Treatment|Patients meeting inclusion criteria for possible surgical therapies for their current condition (IE Achelasia, Enlarged Gastric Pouch and/or Gastrogastric Fistula after primary weight loss surgery, etc) will be educated on the different therapy options including traditional laparoscopic surgery and/or Endoscopic Interventions including POEM (Percutaneous Oral Endoscopic Myomectomy for the treatment of Achelasia) or Endoscoscopic Pouch/GastroJejunostomy repair or closure of the Gastrogastric Fistula as examples.
62792289|NCT01433172|ACTIVE_COMPARATOR|Phase II Arm A Vaccinations|Arm A participants will receive GM.CD40L cells vaccinations on 3 occasions, at 2 week intervals. Note on either Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
62792290|NCT01433172|ACTIVE_COMPARATOR|Phase II Arm B Vaccinations|Arm B participants will receive GM.CD40L.CCL21 vaccinations on 3 occasions, at 2 week intervals. Note on either Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
62792291|NCT02012660||Hyponatremia, seasonality|Summer months = June, July, August Winter months = December, January, February
62792292|NCT06408038|OTHER|Patients with MBC|
62792293|NCT05318703|EXPERIMENTAL|cognitively enhanced tai ji quan|Participants receive a cognitively enhanced tai ji quan exercise intervention for 16 weeks.
62792294|NCT05318703|ACTIVE_COMPARATOR|stretching exercise|Participants receive a stretching exercise intervention for 16 weeks.
62792295|NCT00927212|EXPERIMENTAL|Group 1|2% AS101 ointment
62792296|NCT00927212|EXPERIMENTAL|Group 2|4% AS101 ointment
62792297|NCT03236077|NO_INTERVENTION|Control|
62216097|NCT05447286|PLACEBO_COMPARATOR|Placebo + Oxycodone|Participants will receive placebo with + 15 mg oxycodone then placebo + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions.
62410641|NCT03024359|ACTIVE_COMPARATOR|normal weight individuals|Individuals with BMI between 18.5 and 24.99 kg/m2 will be included in this group and will receive 4 weeks of extra virgin olive oil. Before and after the intervention period data regarding dietary intake and physical activity, brown/beige adipose tissue activity, body composition (DXA), lipid profile and inflammatory markers and and brain activity (18F-FDG PET/MRI; in a subsample of 10 normal weight individuals) will be collected.
62410642|NCT04512105|EXPERIMENTAL|Dose Level -1 (DL-1)|"Patients receive Pitavastatin (PIT) 1 mg PO daily. For CLL patients, they will also receive stabilized Venetoclax (VEN) 400mg PO daily. For AML patients, they will VEN mg PO daily when dosing in combination with azacitidine or decitabine.~The 1 mg/day dose level will be held in reserve to allow dose reduction in those patients who cannot tolerate DL1."
62410643|NCT04512105|EXPERIMENTAL|Dose Level 1 (DL1)|"Patients receive Pitavastatin (PIT) 2 mg PO daily. For CLL patients, they will also receive stabilized Venetoclax (VEN) 400mg PO daily. For AML patients, they will VEN mg PO daily when dosing in combination with azacitidine or decitabine.~This is the starting dose level for the study."
62410644|NCT04512105|EXPERIMENTAL|Dose Level 2 (DL2)|"Patients receive Pitavastatin (PIT) 4 mg PO daily. For CLL patients, they will also receive stabilized Venetoclax (VEN) 400mg PO daily. For AML patients, they will VEN mg PO daily when dosing in combination with azacitidine or decitabine.~If DL1 is well tolerated, the next cohort will progress to this dose level."
62410645|NCT03105076|EXPERIMENTAL|DAs group|Shared decision making using decision aids
62585191|NCT03174873|OTHER|Laparoscopy for unexplained infertile couples|
62585192|NCT04169048|EXPERIMENTAL|Intervention group (BPD)|Participants (N=60) receive the weekly conducted intervention (group training for mothers with BPD) over the period of 12 weeks (12 sessions). Assessments of each participant: T0 (pre-intervention), T1 (post-intervention) and follow-up (6 months after T1).
62585193|NCT04169048|NO_INTERVENTION|waiting control group (BPD)|Members of this group (N=60) receive no intervention but treatment as usual (TAU). After completing all assessment points (T0, T1, T2), they can receive the intervention of the intervention group (group training).
62585194|NCT04169048|NO_INTERVENTION|clinical control group (AD/MDD)|Mothers with anxiety and/or depression (N=60) receive no intervention. Assessment point only T0.
62585195|NCT04169048|NO_INTERVENTION|healthy control group|Mothers with no actual mental disorder (N=60) receive no intervention.# Assessment points T0, T1, T2.
62585196|NCT06663189|EXPERIMENTAL|Experimental|Treatment withdrawal; patients will stop their Disease Modifying Treatment (DMT)
62792298|NCT03236077|EXPERIMENTAL|Intervention|
62792299|NCT06467461|OTHER|Research participants|Adults under the age of 75; who do not meet criteria for Parkinson's disease, dementia with Lewy bodies, Alzheimer's disease, other diagnosed neurodegenerative disorder, or other known cause of RBD; and have a history of or currently use the SSRIs of interest.
62216098|NCT05447286|ACTIVE_COMPARATOR|NYX-783: 50 mg dose + Oxycodone|Participants will receive NYX-783 50 mg dose with + 15 mg oxycodone then NYX-783 50 mg + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions.
62792300|NCT01756196||Steroid Injection|Reactions associated with spinal steroid injection
62792301|NCT05743361||Autoantibodies|Detection of: ANA, AMA, anti-dsDNA, anti-ENA, anti-MPO, anti-PR3, aPL, RF, ACPA, anti- TPO, anti-TG
62021264|NCT01705457|ACTIVE_COMPARATOR|with Multiple Sclerosis, vitamin A|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type
62792302|NCT04527367||VHD patients|Patients with moderate and severe valvular heart diseases
62792303|NCT01633164|EXPERIMENTAL|SCI Reinvention Protocol Participants|This group will receive 6 instructor-led 2 hour long didactic presentations regarding 8 key principles of self-efficacy and experiential exercises, including goal setting and problem solving with extensive group discussion. At the end of each session, tasks are assigned to participants to be completed outside the group during the week between sessions. Experiences from these activities and practice implementing the intervention principles will be shared and discussed each week, providing additional opportunities for problem solving and positive feedback.
62792304|NCT01633164|OTHER|Waitlist Group|This group will include individuals randomized to receive no treatment for the 30 weeks during which the interventional group will receive the active treatment and have their progress tracked.
62792305|NCT02553395|EXPERIMENTAL|Phenacite contact lens|Study Test Contact Lens
62792306|NCT02553395|ACTIVE_COMPARATOR|comfilcon A contact lens|Control Contact Lens
62792307|NCT04089761|EXPERIMENTAL|Active Device|Treatment of acute migraine with an active form of Nerivio device
62792308|NCT00694668|EXPERIMENTAL|1|Cognitive Behavioural Treatment
62021265|NCT01705457|PLACEBO_COMPARATOR|with multiple sclerosis,placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type
62021266|NCT02248545||Non-celiac Wheat Sensitivity Patients|Consecutive adult patients with irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
62021267|NCT02248545||Celiac Disease Patients|Celiac disease adult patients, sex- and age-matched, diagnosed according to standard criteria, during the same study period, chosen at random and enrolled as first control group.
62585197|NCT06663189|ACTIVE_COMPARATOR|Control arm|Patients will continue their DMT as per routine pratice
62216099|NCT05447286|ACTIVE_COMPARATOR|NYX-783: 150 mg dose + Oxycodone|Participants will receive NYX-783 150 mg dose with + 15 mg oxycodone then NYX-783 150 mg + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions.
62216100|NCT05810259|EXPERIMENTAL|Mindfulness|Participants will take part in 7 repeating digital mindfulness modules using the Caravan Wellness App.
62216101|NCT05810259|EXPERIMENTAL|Light to Moderate Physical Activity|Participants will take part in 7 repeating light to moderate physical activity digital wellness modules using the Caravan Wellness App.
62216102|NCT05810259|NO_INTERVENTION|Control|A no intervention group that will not be using the Caravan Wellness App.
62216103|NCT05987202||Preterm infants born between January 1st, 2018 and December 31st, 2022|All infants born alive before 37 weeks between January 1st, 2018 and December 31st, 2022 with PDA
62216104|NCT02458703|EXPERIMENTAL|Patients with pulmonary AVMs and no airflow obstruction|30 patients with pulmonary AVMs and no airflow obstruction will undergo cardiopulmonary exercise testing
62216105|NCT02458703|EXPERIMENTAL|Patients with pulmonary AVMs and airflow obstruction|30 patients with pulmonary AVMs and airflow obstruction will undergo cardiopulmonary exercise testing
62216106|NCT06402396||Non-Neuropathic pain phenotype|"Based on the PainDETECT Questionnaire (PDQ), patients scoring \<13 will be classified as exposed as they are considered a group with non-neuropathic pain (Non-neuropathic pain phenotype)"
62216107|NCT06402396||Neuropathic pain phenotype|"Based on the PainDETECT Questionnaire (PDQ), patients scoring ≥13 will be classified as un-exposed as they are considered a group with neuropathic pain (neuropathic pain phenotype)"
62585198|NCT04879121|EXPERIMENTAL|Treatment (larotrectinib sulfate)|Patients receive larotrectinib sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of unacceptable toxicity. Patients who experience disease progression and are deriving clinical benefit from larotrectinib may continue treatment per physician discretion.
62585199|NCT00003416|EXPERIMENTAL|treatment|"Ind:~dexamethasone 40 mg/d PO D1-4,9-12,17-20 q35 days x 3 cycles~SC Collection:~cyclophosphamide 1.5gm/m2 IV q3 hrs x 2 mesna 3 gm/m2 conIV start with cyclo GCSF 5mcg/kg/d SQ start 1 day after cyclo until WBC \> 50,000/mcg~Trans (x2):~melphalan 100 mg/m2/d IV D-1,-2 PBSC infusion D0~Maint:~interferon 3 million units/m2 SQ 3x/wk"
62585200|NCT06098729|EXPERIMENTAL|Digital Exercise|
62792309|NCT00694668|EXPERIMENTAL|2|Mindfulness Based Cognitive Therapy-training
62021268|NCT02248545||Irritable Bowel Syndrome Patients|"Irritable Bowel Syndrome adult patients, sex- and age-matched, diagnosed according to Rome II criteria, and unrelated to NCWS or other food intolerance, during the same study period, chosen at random and enrolled as second control group."
62021269|NCT06535282|NO_INTERVENTION|baseline|pre-operative period test results
62021270|NCT06535282|OTHER|follow-up|post-operative period test results
62021271|NCT03864900|EXPERIMENTAL|The intervention group|The medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
62216108|NCT05595447|EXPERIMENTAL|Brentuximab plus PD-1 blocked plus ASCT plus maintenance Brentuximab plus PD-1|Brentuximab plus PD-1 blocked x 8 cycles plus ASCT plus maintenance Brentuximab plus PD-1 x 8 cycles
62216109|NCT02745574|EXPERIMENTAL|Combined maneuver|Combined maneuver: the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity. Then, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm dihydrogen monoxide (H2O). The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
62585201|NCT05929677|EXPERIMENTAL|Alcohol, Then Placebo, then Free-access session|participants will complete two intravenous administration sessions in the lab during which they will receive alcohol then placebo (saline), followed by a third lab session in which they will have free-access to self-administer alcohol (up to 120mg% BrAC) and placebo intravenously for 60 min
62021272|NCT03864900|NO_INTERVENTION|The control group|Participants in the control group received regular medication education, 10-minute individual instruction for health knowledge and six follow-up telephone calls for concerning health.
62021273|NCT05625204|EXPERIMENTAL|Center based attention control|Center based attention control
62021274|NCT05625204|EXPERIMENTAL|Center based HIIT|Center based HIIT
62021275|NCT05625204|EXPERIMENTAL|Home based HIIT|Home based HIIT
62216110|NCT02745574|EXPERIMENTAL|Intraperitoneal infusion|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity.
62216111|NCT02745574|NO_INTERVENTION|Control group|CO2 was removed by passive exsufflation through the port site.
62216112|NCT04772859|EXPERIMENTAL|Online Lifestyle Intervention|Online sessions of nutrition education, physical activity, and family participation.
62216113|NCT04772859|OTHER|Control Group|General nutrition recommendations
62792310|NCT03032341||Patient group|20 patient in poor mobility group (MAT-sf \< 51.38 in men and \<45.61 in women), mid-mobility group (51.38\< MAT-sf≤65.5 in men and 45.61≤MAT-sf\<54.02) and high mobility group (MAT-sf\>65.5 in men and MAT-sf\>54.02 in women) for a total of 60 patients.
62792311|NCT03032341||Surrogate group|A family member/caregiver that attends visits with the patient and will be asked to answer the Mobility Assessment Test questionnaire on behalf of the patient at the initial visit and the follow up visit 1-14 days later.
62792312|NCT05220306|EXPERIMENTAL|Device Arm|Participants will use the MouthLab device for monitoring their vital signs
62819325|NCT05172128|EXPERIMENTAL|Blueberry supplementation|All participants will receive 18 grams lyophilized blueberry supplement mixed with water twice daily for 12 weeks.
62792313|NCT05702138|ACTIVE_COMPARATOR|Conventional Gait and Balance Training (CGBT)|The current approach for walking retraining, Conventional Gait and Balance Training (CGBT) focuses on walking training in a variety of conditions, obstacle management training, functional independence training, strength training, and standing dynamic balance training.
62021276|NCT02449824||magnetic resonance imaging|Participants will undergo MRI at baseline, after 1 cycle, 3 cycles and at completion of neoadjuvant chemotherapy.
62585202|NCT05929677|EXPERIMENTAL|Placebo, Then Alcohol, then Free-access session|participants will complete two intravenous administration sessions in the lab during which they will receive placebo (saline) then alcohol, followed by a third lab session in which they will have free-access to self-administer alcohol (up to 120mg% BrAC) and placebo intravenously for 60 min
62021277|NCT00406029|EXPERIMENTAL|Preladenant 1 mg BID|Participants received preladenant 1 mg twice daily (BID) during the 12-week treatment period.
62021278|NCT00406029|EXPERIMENTAL|Preladenant 2 mg BID|Participants received preladenant 2 mg BID during the 12-week treatment period.
62216114|NCT03133559||Cohort 1|Patients infected with HIV off antiretroviral therapy
62792314|NCT05702138|EXPERIMENTAL|High Intensity Step Training (HIST)|High Intensity Step Training (HIST) focuses on the repetition of stepping at higher cardiovascular intensities and yielding a greater number of steps per training session.
62792315|NCT05702138|EXPERIMENTAL|High Intensity Step Training with Virtual Reality (HISTVR)|The third arm combines virtual reality with HIST, designed to increase cortical excitability while concurrently activating the neuromuscular system.
62792316|NCT05844020|EXPERIMENTAL|TVIC Intervention|
62792317|NCT05844020|NO_INTERVENTION|Usual Care|
62792318|NCT00256724|SHAM_COMPARATOR|Sham ITD|sham Impedance Threshold Device
62792319|NCT00256724|ACTIVE_COMPARATOR|active ITD|active impedance threshold device
62021279|NCT00406029|EXPERIMENTAL|Preladenant 5 mg BID|Participants received preladenant 5 mg BID during the 12-week treatment period.
62021280|NCT00406029|EXPERIMENTAL|Preladenant 10 mg BID|Participants received preladenant 10 mg BID during the 12-week treatment period.
62021281|NCT00406029|PLACEBO_COMPARATOR|Placebo BID|Participants received preladenant matching placebo BID during the 12-week treatment period.
62021282|NCT05871164||Patient to be treated for a tumor of the pancreas|Patient to be treated for a tumor of the pancreas by ultrasound-guided radiofrequency with a fine needle, with Indication of pancreatic radiofrequency validated in a Multidisciplinary Consultation Meeting
62216115|NCT03133559||Cohort 2|Patients infected with HIV experiencing virologic control, but with blunted immunologic recovery
62792320|NCT01559051|EXPERIMENTAL|Intravenous Injection and Inhalation infusion of AD-SVF|AD-SVF harvested from Autologous Adipose Tissue will be deliver after processing via IV and Inhalation
62792321|NCT02598206|EXPERIMENTAL|Experimental 1|"All subjects will receive 2 treatments in one of the indicated sequence orders:~A - B B - A"
62792322|NCT00936000|ACTIVE_COMPARATOR|protandim therapy for 7 days|
62792323|NCT00936000|PLACEBO_COMPARATOR|placebo arm|Individuals will receive a placebo equivalent in two equally divided doses for seven days
62216116|NCT03133559||Cohort 3|Matched healthy volunteers
62216117|NCT01165853|OTHER|Glucose|
62216118|NCT01165853|OTHER|Fructose|
62216119|NCT00116753|ACTIVE_COMPARATOR|Degarelix 240@40/240@40 (1,3,6,9)|240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (40 mg/mL) at months 1, 3, 6 and 9.
62216120|NCT00116753|ACTIVE_COMPARATOR|Degarelix 240@40/240@60(1,3,6,9)|240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 3, 6 and 9.
62216121|NCT00116753|ACTIVE_COMPARATOR|Degarelix 240@40/240@60(1,4,7,10)|240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 4, 7 and 10.
62216122|NCT04490382|EXPERIMENTAL|Patients undergoing Neuromodulation|Patients, who have had a lower limb amputation and undergoing neuromodulation as part of standard of care.
62216123|NCT01367925||Cruciate Substituting Tibial Insert|
62216124|NCT01367925||Posterior Stabilized Tibial Insert|
62216125|NCT01302860|EXPERIMENTAL|Canakinumab|Canakinumab s.c. injection (2 mg/kg) was administered every 8 weeks.
62792324|NCT06128577|EXPERIMENTAL|Sarcopenia group|After completing screening, 30 subjects in the sarcopenia group received a 3-month intensive intervention consisting of an intensive nutritional intervention and an individually designed exercise intervention. Nutritional and exercise prescriptions were co-designed through a nutritionist and rehabilitation physician.
62792325|NCT06128577|NO_INTERVENTION|Normal control group|
62216126|NCT00620282|EXPERIMENTAL|Lira 1.8|Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)
62792326|NCT01670903||ARBs|Hypertensive patients treated with ARBs
62792327|NCT01670903||ACE inhibitors|Hypertensive patients treated with ACE inhibitors
62792328|NCT01670903||non ARB/ACE|Hypertensive patients treated with non ARBs or ACE inhibitors meds
62410646|NCT03105076|NO_INTERVENTION|Control group|Standard oral explanation guided with booklets
62792329|NCT01561521|EXPERIMENTAL|AKF-1 0.025%|
62792330|NCT01561521|EXPERIMENTAL|AKF-1 0.035%|
62792331|NCT01561521|PLACEBO_COMPARATOR|AKF-1 0%|
62792332|NCT02175979|PLACEBO_COMPARATOR|standard|standard of care
62792333|NCT02175979|EXPERIMENTAL|enriched enteral nutrition|enriched enteral tube feeding 1.5ml/ minute perioperative
62792334|NCT01004926|EXPERIMENTAL|Echelon|
62585203|NCT05521698|EXPERIMENTAL|Arm 1 (apalutamide,TURBT)|Patients receive apalutamide PO QD on days 1-21. Patients undergo TURBT on day 21. Up to 28 days of apalutamide prior to TURBT is permitted in the absence of unacceptable toxicity. Patients undergo blood and urine sample collection throughout the study. Patients may optionally undergo tumor biopsy at baseline.
62216127|NCT00620282|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)
62216128|NCT00620282|ACTIVE_COMPARATOR|Glimepiride|Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12
62216129|NCT03090243||Study Group|measurements of IOP before and after virtual colonoscopy
62216130|NCT05158816||COVID-19 patients|COVID-19 patients admitted to the ICU
62216131|NCT01247285|EXPERIMENTAL|Investigational Test Product|90 mg Fluoxetine Hydrochloride Capsules (Teva)
62792335|NCT01460758|EXPERIMENTAL|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
62792336|NCT01460758|EXPERIMENTAL|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
62585204|NCT05521698|PLACEBO_COMPARATOR|Arm 2 (placebo, TURBT)|Patients receive placebo PO QD on days 1-21. Patients undergo TURBT on day 21. Up to 28 days of placebo prior to TURBT is permitted in the absence of unacceptable toxicity. Patients undergo blood and urine sample collection throughout the study. Patients may optionally undergo tumor biopsy at baseline.
62585205|NCT06060158|EXPERIMENTAL|CBT-I online group|Twelve eligible participants will meet weekly for 6 weeks while undergoing the CBT-I program. At the end of each weekly session, participants will complete a survey reviewing the acceptability of undergoing insomnia treatment in an internet-based small-group setting.
62792337|NCT01460758|SHAM_COMPARATOR|Placebo Stimulation|Sham Stimulation (Conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz,2000 Stimuli each session, 110% motor threshold
62021283|NCT03798691|ACTIVE_COMPARATOR|Anti-TNF monotherapy|Patients with IBD on Anti-TNF monotherapy will be given the shingrix vaccine. Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.
62216132|NCT01247285|ACTIVE_COMPARATOR|Reference Listed Drug|90 mg PROZAC WEEKLY® Capsules (Eli Lilly)
62216133|NCT00560560|EXPERIMENTAL|1|Single arm study
62216134|NCT02094287|EXPERIMENTAL|verum, instruction, conditioning|This group received dimetindene and instructions about dimetindene and its effectiveness. One classical conditioning process with saline was applied during the skin prick test procedures.
62216135|NCT02094287|EXPERIMENTAL|verum, instruction, no conditioning|This group received dimetindene and instructions about dimetindene and its effectiveness. No conditioning process were applied
62216136|NCT02094287|EXPERIMENTAL|placebo, instruction, conditioning|This group received a placebo (saline) as intravenously administered substance. But instructions about receiving dimetindene and its effectiveness were given. One classical conditioning process was applied during the skin prick test procedures.
62792338|NCT00727051||1|Liver and lung transplant candidates referred for coronary angiography will be invited to participate in the study.
62792339|NCT01602289|EXPERIMENTAL|LY2875358|Part A. LY2875358 will be administered intravenously (IV) at escalating doses (700 mg up to 2000 mg) on Day 1 and Day 15 of a 28-day cycle, until any discontinuation criterion is met.
62792340|NCT01602289|EXPERIMENTAL|LY2875358+Erlotinib|Part B1. Erlotinib will be administered orally at 150 mg dose level each day. LY2875358 will be administered intravenously (IV) at recommended dose level in Part A on Day 1 and Day 15 of a 28-day cycle. (Part B1 was added per protocol amendment in January, 2013.)
62792341|NCT01602289|EXPERIMENTAL|LY2875358+Gefitinib|Part B2. Gefitinib will be administered orally at 250 mg dose level each day. LY2875358 will be administered intravenously (IV) at recommended dose level in Part A on Day 1 and Day 15 of a 28-day cycle. (Part B2 was added per protocol amendment in January, 2013.)
62216137|NCT02094287|EXPERIMENTAL|verum, no instruction, no conditioning|Dimetindene was covertly administered (unawareness of treatment). No instruction and no conditioning were given.
62216138|NCT01850446|EXPERIMENTAL|Ergoferon|The treatment period is 5 days. Oral Dose per administration: 1 tablet. The tablet should be kept in the mouth until completely dissolution, the drug is taken without regard to food intake.
62216139|NCT01850446|ACTIVE_COMPARATOR|Oseltamivir (Tamiflu)|"The treatment period is 5 days.~1 capsule (75 mg) twice a day during the meal or regardless of meal."
62216140|NCT04520490|ACTIVE_COMPARATOR|Exenatide once weekly extended-release|Weekly subcutaneous injections of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (2mg) for 24 weeks in randomized intervention.
62216141|NCT04520490|PLACEBO_COMPARATOR|Matching placebo|Weekly subcutaneous injections of placebo for 24 weeks.
62585206|NCT01703806||Conventional Treatment|Patients in the conventional treatment group will be treated according to the 2006 ACC/AHA guidelines and they will be referred for surgery if they experience any symptoms, and referred for surgery if exertional dyspnea, LV ejection fraction \<0.60, LV end-systolic dimension \>40 mm, Doppler estimated pulmonary artery pressure \> 50 mmHg, or atrial fibrillation develops.
62585207|NCT01703806||Early Surgery|Patients in the early surgery group should undergo mitral valve surgery within 6 months of enrollment.
62585208|NCT01352949||Healthy Volunteers|Healthy volunteers without scoliosis or obesity
62792342|NCT06160947|ACTIVE_COMPARATOR|Usual Medical Care|This group will consist of eligible, consenting, participants attending centers randomized to ongoing usual medical care.
62216142|NCT04373824|EXPERIMENTAL|Group I- Ivermectin|First group with 25 confirmed cases of COVID 19 shall be treated with Ivermectin 200 to 400mcg per kg body weight on day 1 and day 2 along with standard treatment of the hospital protocol
62216143|NCT04373824|NO_INTERVENTION|Group II- standard treatment|The second group with 25 confirmed cases of COVID 19 shall be treated with standard treatment as per hospital protocol for COVID 19.
62216144|NCT05962801|ACTIVE_COMPARATOR|Lumoral users|Use of Lumoral device and Lumorinse mouthwash once per day for 6 months and performance of oral hygiene twice per day for 6 months.
62216145|NCT05962801|NO_INTERVENTION|Lumoral non-users|No use of Lumoral device and Lumorinse mouthwash. Performance of oral hygiene twice per day for 6 months.
62216146|NCT04491565|NO_INTERVENTION|standard education|
62216147|NCT04491565|ACTIVE_COMPARATOR|educational video|
62216148|NCT04539535|EXPERIMENTAL|Down syndrome|We did the General Movements Assessment on standard mattress and experimental mattress in infants with Down syndrome on the same day.
62585209|NCT01352949||Obesity|Healthy volunteers with obesity
62585210|NCT01352949||Scoliosis|Healthy volunteers with scoliosis but no obesity
62585211|NCT00179777|EXPERIMENTAL|Hydrolysed infant formula|Hydrolysed infant formula
62585212|NCT00179777|PLACEBO_COMPARATOR|Nonhydrolysed infant formula|Nonhydrolysed cow's milk based infant formula
62585213|NCT06682897|EXPERIMENTAL|Exercise|Participants will be asked to choose three time slots per week to come to the lab, and each time slot will consist of a 1-hour workout that includes a 10-minute warm-up, a 45-minute Tai Chi practice, and a 5-minute cool-down.
62585214|NCT06682897|NO_INTERVENTION|Control|Participants replicated all the procedures of the exercise trial except for the different starting phase of the training.
62585215|NCT01985191|EXPERIMENTAL|Arm 1|SAR405838 and pimasertib in escalating doses
62792343|NCT06160947|EXPERIMENTAL|Usual Medical Care + Chiropractic Care|This group will consist of eligible, consenting, participants attending centers randomized to ongoing usual medical care plus chiropractic care.
62792344|NCT02578199|EXPERIMENTAL|motivational interviewing and nutrition|Motivational interviewing and nutritional counseling.
62792345|NCT03186027|ACTIVE_COMPARATOR|Active supplement (CoQ10 plus NADH)|"CFS/ME patients will be randomized to evaluate the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH: 20 mg/day) taking 4 tablets/day during 8-weeks in term.~Active supplement based on Coenzyme Q10 plus NADH"
62216149|NCT04539535|EXPERIMENTAL|Typically infants|We did the General Movements Assessment on standard mattress and experimental mattress in typically infants on the same day.
62021284|NCT03798691|ACTIVE_COMPARATOR|Vedolizumab|"Patients with IBD on vedolizumab monotherapy will be given the shingrix vaccine.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
62410647|NCT04755426||Patients with severe aortic stenosis|Adults with severe aortic stenosis who either have faced or are facing a decision about valve replacement (depending on the phase of the research)
62410648|NCT04755426||Health care providers|HCPs who guide decisions about managing AS, including interventional cardiologists, cardiac surgeons and advanced practice providers (APPs), including nurse practitioners and physician assistants.
62410649|NCT05041868|EXPERIMENTAL|Study group|The program comprises the practice of warm-up, muscle strengthening with free weights and with their own body weight against the action of gravity for the main muscular groups, balance control training, aerobic training, and relaxation exercises. The proposal consists of 3 weekly sessions, for 12 consecutive weeks.
62585216|NCT00981214|EXPERIMENTAL|EUR-1008 (APT-1008)|
62585217|NCT00849511|ACTIVE_COMPARATOR|Placebo first|Placebo 8 weeks, 6 weeks washout, extended-release melatonin 2 mg vesper for 8 weeks
62021285|NCT01370746||Cross-Sectional Study Group|Cross-sectional comparison of perceived barriers to adherence to post-transplant immunosuppressant regimens in parents/legal guardians of children 0-11 years versus adolescents 12-21 years
62021286|NCT01370746||Longitudinal Study Group|Subset of Cross-Sectional Study Group to evaluate whether perceived barriers to adherence increase with time during the first year following transplantation
62021287|NCT00215852|ACTIVE_COMPARATOR|1|500 IU
62216150|NCT02825173|EXPERIMENTAL|Seal-G|A surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.
62216151|NCT02710318|EXPERIMENTAL|Immunization Alert on|Children with visits seen when the immunization alert is on
62410650|NCT03606109|ACTIVE_COMPARATOR|High Tibial Osteotomy (HTO)|
62585218|NCT00849511|ACTIVE_COMPARATOR|Melatonin first|Extended-release melatonin 2 mg vesper for 8 weeks, 6 weeks washout, placebo 8 weeks
62585219|NCT06684834|EXPERIMENTAL|5:2 carbohydrate restriction (5:2CR)|Laboratory measurements will be obtained before and after the intervention. Physical activity, dietary intake and interstitial glucose concentrations will be monitored in free-living conditions throughout the intervention.
62021288|NCT00215852|ACTIVE_COMPARATOR|2|1000 IU
62021289|NCT00215852|ACTIVE_COMPARATOR|3|2000 IU
62021290|NCT05476003|SHAM_COMPARATOR|Sham Technique|Patients will receive general anesthesia plus Ultrasound-guided Bilateral superficial cervical plexus block with injection of 10 ml normal saline bilaterally.
62021291|NCT05476003|ACTIVE_COMPARATOR|Ultrasound-guided Bilateral superficial cervical plexus block|Patients will receive general anesthesia plus Ultrasound-guided Bilateral superficial cervical plexus block with injection of total volume 10 ml containing Bupivacaine 0.25% (5 ml Bupivacaine 0.5 % and 5 ml normal saline).
62021292|NCT03191084|EXPERIMENTAL|Regular Users|People who use marijuana regularly will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the five study visits.
62021293|NCT03191084|EXPERIMENTAL|Occasional Users|People who use marijuana occasionally will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the five study visits.
62021294|NCT04492046||Complex Decongestive physiotherapy|All participants included in the study were included in a treatment protocol consisting of Complex Decongestive physiotherapy.
62021295|NCT01672632|EXPERIMENTAL|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
62021296|NCT01383070|NO_INTERVENTION|Lactational Conseling|The existing staff of the hospitals will be provided training in IYCF by BPNI. They will be encouraged to set up their own systems to continue counseling during the ante natal period, at delivery and during the immunization visits. The participants will be asked to come for the same schedule of visits as in the intervention group where their data will be collected.
62216152|NCT02710318|NO_INTERVENTION|Immunization Alert off|Children with visits seen when the alert is off
62216153|NCT02955732|EXPERIMENTAL|Intranasal dex|Dexmedetomidine 2-4 µg/kg alone
62216154|NCT01675245||Velcade|Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks.
62410651|NCT03606109|ACTIVE_COMPARATOR|Tibial Tubercle Ostetomy (TTO)|
62410652|NCT05876039|EXPERIMENTAL|Group remifentanil of 1.0 ng/mL|Initial remifentanil effect-site concentration of 1.0 ng/mL
62410653|NCT05876039|ACTIVE_COMPARATOR|Group remifentanil 2.0 ng/mL|Initial remifentanil effect-site concentration of 2.0 ng/mL
62410654|NCT03888898|ACTIVE_COMPARATOR|N95 Filtering Facepiece Respirator|control fit testing
62410655|NCT03888898|EXPERIMENTAL|Elastomeric Respirator|experimental rapid conversion fit testing and competency evaluations
62585220|NCT06684834|EXPERIMENTAL|Early time-restricted carbohydrate intake (eTRC)|Laboratory measurements will be obtained before and after the intervention. Physical activity, dietary intake and interstitial glucose concentrations will be monitored in free-living conditions throughout the intervention.
62585221|NCT06684834|NO_INTERVENTION|Lifestyle maintenance (control)|Laboratory measurements will be obtained before and after the intervention. Physical activity, dietary intake and interstitial glucose concentrations will be monitored in free-living conditions throughout the intervention.
62585222|NCT06066996|EXPERIMENTAL|Transdermal Nicotine Patch|Participants assigned to this condition will receive a blinded nicotine patch and will wear the patch on their upper arm, per the manufacturer's instructions.
62216155|NCT05039099|EXPERIMENTAL|AP-101|AP-101 is administered by IV.
62216156|NCT05039099|PLACEBO_COMPARATOR|Placebo|Placebo is administered by IV.
62216157|NCT00501839|ACTIVE_COMPARATOR|Group A|Cyclic progestogens for nine months
62216158|NCT00501839|ACTIVE_COMPARATOR|Group B|CC treatment for further three cycles at the same ovulating doses followed by six months of cyclic progestogens
62216159|NCT00501839|ACTIVE_COMPARATOR|Group C|CC administration at the same ovulating doses for nine cycles
62216160|NCT01635205|EXPERIMENTAL|paraspinous block|Paraspinous anesthetic block in the thoracolumbar region, in sensitized segments
62216161|NCT01635205|SHAM_COMPARATOR|control|Subcutaneous puncture with no anesthetic effect
62216162|NCT04997681|EXPERIMENTAL|Exercise Intervention Training and Cognitive Intervention Training|Combined Aerobic Exercise and Resistance Training (AE + RT) + Cognitive Training (NeuropeakTM)
62410656|NCT01079572|EXPERIMENTAL|web-based|The patient will undergo xrays at the closest PACs enabled imaging centre and will login and answer questions online. The surgeon will review the images and patient responses and determine whether the patient needs to be seen more urgently or a per routine.
62410657|NCT01079572|ACTIVE_COMPARATOR|in-person|Patients will attend their follow-up appointments in-person as per usual
62585223|NCT06066996|PLACEBO_COMPARATOR|Transdermal Placebo Patch|Participants assigned to this placebo nicotine patch condition will receive a blinded patch containing 0mg of nicotine, and will wear the patch on their upper arm, per the manufacturer's instructions.
62021297|NCT01383070|EXPERIMENTAL|Lactation Counseling by Cell Phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
62585224|NCT06066996|NO_INTERVENTION|No Patch|Participants assigned to this condition will not receive a patch.
62585225|NCT00761280|EXPERIMENTAL|trabedersen 10 µM|10 µM trabedersen (AP 12009), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
62021298|NCT05809570||Periodontal examination|Cross- sectional clinical periodontal examinations and measurements were performed using a Williams periodontal probe
62021299|NCT04103229|EXPERIMENTAL|10 ml sterile distilled water|The indwelling urinary catheterization was inflated with 10 ml sterile distilled water (SDW) of the balloon.
62021300|NCT04103229|EXPERIMENTAL|15 ml sterile distilled water|The indwelling urinary catheterization was inflated with 15 ml sterile distilled water (SDW) of the balloon.
62216163|NCT04997681|ACTIVE_COMPARATOR|Exercise Intervention Training and Control Cognitive Training|Combined Aerobic Exercise and Resistance Training (AE + RT) + Control Cognitive Training of Website Searching and Video Watching (WS+V)
62216164|NCT04997681|ACTIVE_COMPARATOR|Control Exercise Training and Cognitive Intervention Training|Control Balance and Toning Exercise Training (BAT) + Cognitive Training (NeuropeakTM)
62216165|NCT04997681|PLACEBO_COMPARATOR|Control Exercise Training and Control Cognitive Training|Control Balance and Toning Exercise Training (BAT) + Control Cognitive Training of Website Searching and Video Watching (WS+V)
62216166|NCT04781400|EXPERIMENTAL|Remote service delivery model PLUS mobile phone support|Remote service delivery plus mobile intervention via SMS will include weekly check-ins from study staff, calls from a trained counsellor on request, and access to a two-way messaging feature.
62216167|NCT04781400|ACTIVE_COMPARATOR|Remote service delivery model|Remote service delivery model.
62216168|NCT00412061|EXPERIMENTAL|Octreotide+ Everolimus|Everolimus was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity. Each treatment cycle lasted 28 days. Patients received their first dose of everolimus at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1, Day 1.
62410658|NCT05666765|EXPERIMENTAL|acne vulgaris patients group 1|acne patients will be rondomly assigned to 1 of the 3 interventions (isotretinoin, silymarin, or both)
62410659|NCT05666765|EXPERIMENTAL|acne vulgaris patients group 2|acne patients will be rondomly assigned to 1 of the 3 interventions (isotretinoin, silymarin, or both)
62585226|NCT00761280|ACTIVE_COMPARATOR|Chemotherapy|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle, up to 26 cycles; carmustine: i.v. administration, up to 200 mg/sqm/day, 1 day per cycle, up to 8 cycles; lomustine: capsules, 110 mg/sqm/day, 1 day per cycle, up to 8 cycles. Only 1 of these 3 drugs/interventions is administered per patient in the comparator arm.
62021301|NCT04103229|EXPERIMENTAL|10 ml 0.9% sodium chloride (NaCL)|The indwelling urinary catheterization was inflated with 10 ml 0.9% sodium chloride (NaCL) of the balloon.
62021302|NCT04103229|EXPERIMENTAL|15 ml 0.9% sodium chloride (NaCL)|The IUC was inflated with 15 ml 0.9% sodium chloride (NaCL) of the balloon.
62021303|NCT05307224|EXPERIMENTAL|intervention group|In the experimental group, patients will receive both routine care and mandala painting. Experimental group will paint mandala for 30 minutes/day in the evening for six consecutive days.
62216169|NCT00412061|PLACEBO_COMPARATOR|Octreotide+ Placebo|Matching placebo was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity; Each treatment cycle lasted 28 days. Patients received their first dose of matching placebo at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1 Day 1.
62216170|NCT01423721|EXPERIMENTAL|Bromihexine hydrochloride granules|16 mg granules
62792346|NCT03186027|PLACEBO_COMPARATOR|Phosphoserine plus vitamin C|"CFS/ME patients will be randomized to assess the effect of placebo (phospho-serine plus vitamin C) taking 4 tablets/day for 8-weeks in term.~Placebo: phosphoserine plus vitamin C"
62216171|NCT01423721|EXPERIMENTAL|Bromihexine hydrochloride syrup|16 mg syrup
62216172|NCT01593956|OTHER|Concussed athletes|
62410660|NCT05666765|EXPERIMENTAL|acne vulgaris patients group 3|acne patients will be rondomly assigned to 1 of the 3 interventions (isotretinoin, silymarin, or both)
62585227|NCT01856478|EXPERIMENTAL|afatinib|oral intake, once daily
62585228|NCT01856478|ACTIVE_COMPARATOR|methotrexate|intravenous bolus injection, once weekly
62585229|NCT05147402|ACTIVE_COMPARATOR|Fasted Treatments with 120 mg midomafetamine HCl|Following an overnight fast of at least 10 hours, participants will be administered 100 mg midomafetamine (equivalent to 120 mg midomafetamine HCl) with 240 mL of water. No food should be allowed for at least 4 hours post-dose.
62792347|NCT04149561||Cerebral Palsy|100 patients over 2 years of age with a diagnosis of cerebral palsy will be included in the study. Demographic information form prepared for the study in terms of demographic information such as age, gender, clinical type of cerebral palsy, drugs used, comorbid diseases will be completed. Communication Function Classification System and Functional Communication Classification System will be used to evaluate patients' communication skills. In addition, patients; The Gross Motor Function Classification System for cerebral palsy and based on child-initiated movements with emphasis on sitting, displacement and mobility, and to hold objects during the daily activities of children with cerebral palsy. The Manual Ability Classification System, which classifies how they use their hands, will also be completed.
62792348|NCT04618744|PLACEBO_COMPARATOR|Placebo|Fish oil
62792349|NCT04618744|EXPERIMENTAL|ORMD-0801 (Insulin) capsule 8 mg BD|ORMD-0801 (insulin) capsule Dose: 8 mg BD Dosage Regimen: 1 capsule twice a day (once in the morning approximately 30 to 45 minutes prior to breakfast and no later than 10 AM, and once at night between 8 PM to Midnight and no sooner than 1 hour after dinner) Mode of Administration: Oral
62792350|NCT06519812|EXPERIMENTAL|• Group I (PCNL group)|50 patients will undergo percutaneous nephrolithotomy (PCNL).
62792351|NCT06519812|EXPERIMENTAL|Group II (ECIRS group)|50 patients will undergo endoscopic combined intrarenal surgery (ECIRS).
62792352|NCT06423924||<50 years|
62792353|NCT06423924||50-69 years|
62792354|NCT06423924||≥70 years|
62792355|NCT00983320|EXPERIMENTAL|medication|quetiapine
62792356|NCT00983320|PLACEBO_COMPARATOR|placebo|placebo
62792357|NCT04865419|EXPERIMENTAL|Module 1: AZD0466 monotherapy|Participants will receive intravenous infusion of AZD0466 monotherapy once weekly during Cycle 1 (35 days), Cycle 2 (28 days) and Cycle 3 (28 days) and also beyond Cycle 3 until progressive disease, unacceptable toxicity, or withdrawal of consent.
62021304|NCT05307224|NO_INTERVENTION|control group|The control group will receive the usual care.
62216173|NCT01593956|OTHER|Healthy controls|
62216174|NCT03292432|ACTIVE_COMPARATOR|Standard of Care (SOC)|Standard of Care for adherence support at Site
62216175|NCT03292432|EXPERIMENTAL|TERA Intervention (TERA)|Triggered, escalating, real-time adherence (TERA) intervention for 12 weeks.
62216176|NCT03732599|ACTIVE_COMPARATOR|Standard DALK|Standard (with the use of a blade) deep anterior lamellar keratoplasty (DALK), which is a partial thickness corneal transplant, which has been shown to be a safe and effective procedure.
62792358|NCT04865419|EXPERIMENTAL|Module 2: AZD0466 + Voriconazole|Participants may receive IV infusion of AZD0466 in combination with or without voriconazole during Cycle 1 (21 days), and Cycle 2 (28 days) and Cycle 3 (28 days) and also beyond Cycle 3 until progressive disease, unacceptable toxicity, or withdrawal of consent.
62216177|NCT03732599|ACTIVE_COMPARATOR|IE-DALK (femtosecond)|Femtosecond deep anterior lamellar keratoplasty (DALK). The femotosecond laser technology allows for the creation of precise and reproducible corneal incisions.
62216178|NCT01354184|EXPERIMENTAL|CRD007 10 mg tablet|
62216179|NCT01354184|EXPERIMENTAL|CRD007 25 mg tablet|
62216180|NCT01354184|EXPERIMENTAL|CRD007 40 mg tablet|
62216181|NCT01354184|PLACEBO_COMPARATOR|CRD007 matching placebo tablet|
62216182|NCT03082118|EXPERIMENTAL|Vesair Arm|Subjects treated with the Vesair Bladder Control System at enrollment.
62216183|NCT01303679|ACTIVE_COMPARATOR|paclitaxel-bevacizumab|Paclitaxel, 80mg/m² at d1, d8, d15 bevacizumab, 10 mg/kg at d1, d15
62216184|NCT01303679|EXPERIMENTAL|exemestane-bevacizumab|exemestane, 25 mg daily dose bevacizumab, 15mg/kg every 3 weeks
62410661|NCT05601414|EXPERIMENTAL|BIO-Z vs. Finapres Nova|Participants will have blood pressure in both arms measured three times using standard methods. The investigators will then fit the Bio-Z watch onto the non-dominant hand's wrist and the Finapres Nova® on the middle finger of the arm with the Bio-Z device. Participants will be asked to perform different exercises and blood pressure readings will be recorded during the exercise and recovery. Each exercise will be repeated three times. 15 Participants will have the option to complete study procedures twice more, spaced one week apart, for a total of three weeks of participation. Each visit will take at most 2 hours to complete study exercises for a total of 6 hours of study time if all the three visits are completed.
62585230|NCT05147402|ACTIVE_COMPARATOR|Fed Treatments with 120 mg midomafetamine HCl|A high-fat (approximately 50 percent of total caloric content of the meal) and high-calorie (approximately 800 to 1000 calories) meal will be used as a test meal for food-effect evaluation. Following an overnight fast of at least 10 hours, participants will start the recommended meal 30 minutes prior to administration of the drug product. Participants will eat this entire meal in 30 minutes or less. 100 mg midomafetamine (equivalent to 120 mg midomafetamine HCl) will be administered 30 minutes after start of the meal with 240 mL of water.
62792359|NCT03716219|OTHER|Healthy Subjects|Healthy control group which received the same exercise training intervention as the experimental group
62792360|NCT03716219|EXPERIMENTAL|Subjects with Asthma|Subjects with asthma who received exercise training
62792361|NCT06341556|EXPERIMENTAL|Experimental group|maintenance of zanubrutinib monotherapy
62410662|NCT04355767|EXPERIMENTAL|Convalescent Plasma|Participants receive 1 unit of convalescent plasma.
62410663|NCT04355767|PLACEBO_COMPARATOR|Placebo|Participants receive 1 unit of saline with multivitamin.
62410664|NCT02194959|EXPERIMENTAL|Peer PN|A scheduling phone call will be made to all patients within 14 days of their initial referral to the study. Following the scheduling of their appointment, each patient will be mailed an informational pamphlet with written instructions for the colonoscopy once they have scheduled the procedure. The first reminder PPN phone call will be made two weeks before a patient's scheduled colonoscopy. The second reminder PPN call will be made three days before the scheduled colonoscopy. For all calls, at least three attempts (at different times of the day and different days of the week) will be made to reach patients. All telephone calls will be audio-recorded to facilitate fidelity monitoring. All colonoscopy appointments will be made within the Division of Gastroenterology at each of the hospital sites. The Project Coordinator will be responsible for confirming completion (and no-shows) for all colonoscopy appointments.
62410665|NCT02194959|ACTIVE_COMPARATOR|Pro PN|Participants randomized to standard patient navigation received care that they would normally receive if they were not participating in the study with navigation from the GI staff, and three phone calls that involved scheduling and reminding the participant about their colonoscopy appointment.
62410666|NCT05494151||SMuRFs|Patients with acute myocardial infraction with a history of at least one standard modifiable risk factor (SMuRF; smoking, diabetes mellitus, dyslipidemia, hypertension)
62585231|NCT06682741|EXPERIMENTAL|excercise|supervised exercise training; twice a week for 12 months
62585232|NCT04689854||Cohere Cervical|
62585233|NCT04689854||Modulus Cervical|
62585234|NCT06669884||machine learning algorithm|machine learning algorithm based on ECG features
62585235|NCT06683079||colloid group|recieve colloids as a maintenance intraoperative fluid .
62585236|NCT06683079||crystalloid group|recieve crystalloids as a maintenance intraoperative fluid .
62792362|NCT02333799|EXPERIMENTAL|Bedaquiline + PA-824 + Linezolid|"bedaquiline 400 mg once daily for 2 weeks then 200mg 3 times per week plus PA-824 200mg once daily plus linezolid 1200mg once daily.~A reduction in the dose of linezolid (to either 600 mg qd or 300 mg qd), or temporary cessation of linezolid (due to a linezolid-specific toxicity), or of the full regimen per Investigator discretion was allowed for suspected drug related toxicity. Re-introduction of the regimen could be considered post a cessation not greater than 35 consecutive days.~If participants had toxicity events related to linezolid prohibiting further treatment with that drug, they could remain on the bedaquiline and pretomanid study IMP if they received the initial total of 1200 mg daily dose of linezolid for at least the first 4 consecutive weeks of treatment and they were smear negative, or with trace/scanty results and judged to be clinically improving by the Investigator."
62792363|NCT00714415||A|Patients with Hemophilia B
62792364|NCT05858892||shoulder musculoskeletal group|The International Classification of Diseases, 10th revision (ICD-10) codes were selected before the study started and included the ICD-10 codes M75 (Shoulder lesions), S42 (Fracture of shoulder and upper arm), S43 (Dislocation and sprain of joints and ligaments of shoulder girdle), and S46 (Injury of muscle, fascia and tendon at shoulder and upper arm level)
62792365|NCT04649515|EXPERIMENTAL|TY027 1,500 mg|1,500 mg of TY027 will be administered via IV infusion over a period of 30 minutes.
62792366|NCT04649515|EXPERIMENTAL|TY027 2,000 mg|2,000 mg of TY027 will be administered via IV infusion over a period of 30 minutes.
62792367|NCT04649515|PLACEBO_COMPARATOR|Placebo|Placebo will be administered via IV infusion over a period of 30 minutes.
62410667|NCT05494151||SMuRF-less|Patients with acute myocardial infraction without history of any SMuRF
62585237|NCT03827330||Patients|Patients who had Candida species growth from blood cultures drawn at the National Institutes of Health
62585238|NCT05636215|EXPERIMENTAL|IBI354|Single arm
62792368|NCT05292716|EXPERIMENTAL|MitraClip + Optimal medical therapy|Patients randomized to this arm will receive percutaneous treatment of secondary mitral regurgitation by MitraClip system and Optimal medical therapy (OMT) for heart failure
62792369|NCT05292716|NO_INTERVENTION|Optimal medical therapy|Patients randomized to this arm will receive only Optimal medical therapy (OMT) for heart failure
62792370|NCT05211427|EXPERIMENTAL|Patients|Patients with oropharynx cancer
62792371|NCT05211427|EXPERIMENTAL|Healthy subjects|Patients with non malignant pharynx pathology
62792372|NCT01669772|OTHER|DA-9701 and placebo|Administer DA-9701 for 1week and assess the study outcomes. After 1 week of washout period, administer placebo for 1week and assess the outcomes again.
62792373|NCT01669772|OTHER|Placebo and DA-9701|Administer placebo for 1 week and study the outcome parameters. After 1 week of washout, administer DA-9701 for 1 week and assess the outcome parameters again.
62792374|NCT03084003|EXPERIMENTAL|Almond group|2 oz. of almonds everyday for 8 weeks
62792375|NCT03084003|ACTIVE_COMPARATOR|Control group|Isoenergetic control group 5 graham cracker sheets everyday for 8 weeks
62216185|NCT06415513|EXPERIMENTAL|intervention|For 7 days, they were asked to watch ASMR videos for 20-30 minutes every evening at 22:00 before going to bed. The videos were downloaded to the student's computer or phone in advance, the student was asked to switch his/her phone to airplane mode to block the stimuli during the viewing, to watch these videos with headphones, to reduce the sounds in the room as much as possible, to lie on his/her bed and to wear comfortable clothes.
62021305|NCT06421233|EXPERIMENTAL|Intervention group|"* Personal introduction form, state and trait anxiety scale and visual similarity scale for fatigue were applied.~* Endorphin massage was applied twice by the researcher for 15 minutes every two hours.~* After the endorphin massage applied for the second time, the visual similarity scale and the state and trait anxiety scale were applied again for fatigue."
62216186|NCT06415513|NO_INTERVENTION|control|no intervention
62216187|NCT06515132|EXPERIMENTAL|SCS group|SCS stimulation therapy is initiated 1 week post-surgery, which is administered continuously for a duration of 6 months.
62216188|NCT06515132|SHAM_COMPARATOR|Sham group|Sham stimulation therapy is initiated 1 week post-surgery, and SCS stimulation therapy is initiated 3 months post-surgery, which is stimulated continuously for a duration of 3 months.
62216189|NCT03927573|EXPERIMENTAL|GEM3PSCA|Application of GEM3PSCA, a PSCA targeted bispecific antibody engaging T-cells
62792376|NCT03838081|EXPERIMENTAL|Group 1|Group 1: Patients who were given only basic information verbally
62216190|NCT00678613|PLACEBO_COMPARATOR|1, Primary prophylaxis|"Patients with liver cirrhosis with ascites having ascitic fluid protein \<1 gm/dl will be included in this arm.~They will be randomized between probiotics and placebo."
62792377|NCT03838081|EXPERIMENTAL|Group 2|Group 2: Patients with detailed written information about preoperative, intraoperative, and postoperative periods
62792378|NCT03838081|EXPERIMENTAL|Group 3|Group 3: Patients with previous experience and knowledge about third molar extraction
62792379|NCT00607087|EXPERIMENTAL|sequence 1|sequence 1: insulin glulisine / insulin aspart / insulin lispro.
62792380|NCT00607087|EXPERIMENTAL|Sequence 2|Sequence 2: insulin aspart / insulin lispro / insulin glulisine
62216191|NCT00678613|ACTIVE_COMPARATOR|2, secondary prophylaxis|"Patients with liver cirrhosis with ascites having history of prior SBP will be included in this arm.~They will be randomized between probiotics and norfloxacin."
62792381|NCT00607087|EXPERIMENTAL|Sequence 3|Sequence 3: insulin lispro / insulin glulisine / insulin aspart
62021306|NCT06421233|NO_INTERVENTION|Control gruop|"* A personal introduction form, state and trait anxiety scale, and visual similarity scale for fatigue were applied.~* Two hours after the first evaluation, the visual similarity scale and the state and trait anxiety scale were applied again for fatigue."
62216192|NCT00839904|EXPERIMENTAL|exercise|two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
62792382|NCT05984589|EXPERIMENTAL|RISE-PSMT|Personalized self-management training using RISE (Re-Invent, Integrate, Strengthen, Expand) program.
62021307|NCT04170192||UCBT-IBD-Case|Very early onset IBD patients who underwent Cord Blood Stem Cell Transplantation.
62216193|NCT00839904|NO_INTERVENTION|control|no intervention
62216194|NCT02668601||GDM Exposed|Children exposed to gestational diabetes in utero
62216195|NCT02668601||Non-GDM Exposed|Children not exposed to gestational diabetes in utero
62216196|NCT04428268|ACTIVE_COMPARATOR|Chloroquine|Patients will receive chloroquine phosphate 450 mg every 12 hours orally
62792383|NCT05984589|PLACEBO_COMPARATOR|SSMT|Standardized self-management training.
62792384|NCT05789394|EXPERIMENTAL|Treatment (AMSCs)|Patients receive AMSCs IT and undergo Ommaya reservoir placement during a craniotomy on study. Patients also undergo MRI on study and during follow-up, as well as blood sample, tissue sample, and CSF sample collection on study.
62792385|NCT03470090|EXPERIMENTAL|Neuromuscular Exercises Group|This group of patients received patient with knee osteoarthritis. It will be applied classical physiotherapy and neuromuscular exercises training
62216197|NCT04428268|EXPERIMENTAL|Chloroquine plus losartan|Patients will receive Chloroquine phosphate 450mg orally every 12hrs plus Losartan 25mg orally every 12hrs
62216198|NCT00944073|EXPERIMENTAL|Group 2: 30 mcg H1N1 Vaccine|300 subjects to receive 30 mcg of Inactivated H1N1 Vaccine on Day 0 and Day 21.
62216199|NCT00944073|EXPERIMENTAL|Group 1: 15 mcg H1N1 Vaccine|300 subjects to receive 15 mcg of Inactivated H1N1 Vaccine on Day 0 and Day 21.
62792386|NCT03470090|ACTIVE_COMPARATOR|Conventional Group|This group of patients received patient with knee osteoarthritis. It will be applied classical physiotherapy and conventional exercises.
62216200|NCT01159002||Critically ill ICU patients|ICU patients with brain injuries who will be receiving a feeding tube.
62216201|NCT06274372|OTHER|control group|patients ventilated with volume controlled ventilation
62216202|NCT06274372|EXPERIMENTAL|flow controlled ventilation|patients ventilated with flow controlled ventilation
62216203|NCT02280694|EXPERIMENTAL|capecitabine, cyclophosphamide, methotrexate, celecoxib|"The Investigational Product: Route and Dosage Form Ambulatory/oral, continuous but not uniform, DAILY treatment~1. Tab. CYCLOPHOSPHAMIDE 50mg, 1X1/day ONLY days 1-5 / week; At evening only (at the end of meal)~2. Tab. CAPECITABINE 500mg, fixed dose of 1500mg/day (1000mg at morning + 500mg at evening) ONLY on days 1-5 / week; At morning AND at evening (at the end of meals)~3. Tab. METHOTREXATE 2.5mg, 1x2/day ONLY on days 6-7/week; At morning AND evening (one hour before meal)~4. Tab. CELECOXIB 200 mg, 1x2/day EVERY day (at the end of meal)"
62216204|NCT03510494|EXPERIMENTAL|Intervention|Trebling of weekly curricular physical education (270 minutes per week)
62410668|NCT06318975|PLACEBO_COMPARATOR|Brief Alcohol Intervention|Those assigned to the BAI condition receive the standard BAI, which we have conducted since 2010, during the 4th week of Technical Training, the last week of enforced abstinence. This BAI has become the de-facto standard of care and is part of USAF Training. The BAI is a group-based, one-hour session which includes the following components: Interactive discussion of the positives and negatives of drinking during training and heavy vs. moderate drinking; Discussion of USAF rules on alcohol use and penalties for violations; Discussion of impact of alcohol on military readiness; effects of alcohol and hangover on performance; Review of standard drinks, blood alcohol levels and tolerance; and normative feedback on the Airmen's drinking level compared to others. We will engage in a conversation about whether they have observed concerning patterns of alcohol misuse among other USAF personnel, and how to handle this, along with harm reduction and alcohol refusal strategies.
62216205|NCT03510494|NO_INTERVENTION|Control|Standard curriculum physical education (90 minutes per week)
62216206|NCT02912923|EXPERIMENTAL|Start with Visual + Force|Participants will complete a set of trials while receiving Visual + Force Feedback. After finishing, participants will continue to a new set of trials while receiving Visual + Force + Game Scores Feedback.
62585239|NCT06684145|EXPERIMENTAL|Kinesiotape application|Kinesiotape application will be performed by a certified researcher using 5cm x 5cm kinesiotape material. In addition to the kinesiotape application, patients will be given a 30-day home exercise program. This consists of passive lumbar flexion (single and double leg stretching), hamstring stretching, pelvic tilt, half sit-up, bridge, straight leg raises, and hip and back extensor strengthening exercises.
62410669|NCT06318975|EXPERIMENTAL|BAI + Texting|Those assigned to this arm will receive the same BAI as the other arm with the addition of automated text messages.
62410670|NCT00682097|EXPERIMENTAL|1|
62410671|NCT00682097|EXPERIMENTAL|2|
62410672|NCT00682097|EXPERIMENTAL|3|
62410673|NCT00682097|EXPERIMENTAL|4|
62410674|NCT00682097|EXPERIMENTAL|5|
62410675|NCT00682097|EXPERIMENTAL|6|
62410676|NCT00682097|EXPERIMENTAL|7|
62410677|NCT01773499||Patient with Cellulitis|Patients with uncomplicated cellulitis treated as outpatients
62410678|NCT06262581|EXPERIMENTAL|dMMR/MSI-H stage I-III CRC patients|Patients will accept 4 dose of Tisleizumab(BGB-A317) treatment after enrollment and the assessment of the therapeutic effect by clinicians would be finished after that. Once the patients has been qualified as cCR , they could be exempted for surgery and continued the watch and wait management. If the patient has been assessed as able to R0 surgery , then they would received surgery. Otherwise ,they would be excluded from the trial.
62021308|NCT05582538|EXPERIMENTAL|TNBC patients treated with ceralasertib, durvalumab e nab-paclitaxel|"Patients will be assessed for eligibility during the 28-day screening period prior to enrollment. Enrolled patients will be treated with:~* Ceralasertib at 240 mg administered orally, twice daily on Days -6 to 0 prior to Day 1 Cycle 1 and thereafter on Days 22 to 28 (priming period) of Cycle 1 and every subsequent cycle;~* Durvalumab at 1500 mg administered via IV infusion on Day 1 of every 28-day cycle; Nab-paclitaxel at 100 mg/m2 administered via IV infusion on Days 1,8 and 15 of every 28- day cycle.~A safety run-in phase will be carried out at the start of the present study using a 3+3 de-escalating schema down to -2 ceralasertib dose level. Nab- paclitaxel or durvalumab doses will not be de-escalated. Once the definitive dose for ceralasertib is established, treatment will be continued until progression or unacceptable toxicity, which ever come first."
62216207|NCT02912923|EXPERIMENTAL|Start with Visual + Force + Game Scores|Participants will complete a set of trials while receiving Visual + Force + Game Scores Feedback. After finishing, participants will continue to a new set of trials while receiving Visual + Force Feedback.
62216208|NCT00269893|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo solution bolus followed by matching placebo solution infusion up to 12 hours.
62410679|NCT05457829|EXPERIMENTAL|AI Regimen|Doxorubicin hydrochloride liposome injection combined with Irinotecan
62410680|NCT05457829|ACTIVE_COMPARATOR|VIT Regimen|Temozolomide combined with Irinotecan and Vincristine
62410681|NCT04548336|EXPERIMENTAL|Motor Imagery|
62410682|NCT04548336|EXPERIMENTAL|Action Observation|
62410683|NCT04548336|PLACEBO_COMPARATOR|Placebo group|
62410684|NCT01736527|EXPERIMENTAL|LE Gel|A single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears.
62410685|NCT00423501|EXPERIMENTAL|1|
62410686|NCT00423501|EXPERIMENTAL|2|
62410687|NCT00423501|EXPERIMENTAL|3|
62410688|NCT00423501|EXPERIMENTAL|4|
62410689|NCT00423501|EXPERIMENTAL|5|
62410690|NCT00423501|PLACEBO_COMPARATOR|6|
62585240|NCT06684145|OTHER|Control group|Exercise program will be performed to the control group
62585241|NCT04523103|NO_INTERVENTION|Control group|Standard ICSI procedure. The MII oocytes that failed fertilization in IVF cycles were injected with activating sperm.
62585242|NCT04523103|EXPERIMENTAL|A1 assisted activation|The MII oocytes that failed fertilization in ICSI cycles were activated in calcium ionophore A23187 activation solution for two times.
62585243|NCT04523103|EXPERIMENTAL|A2 assisted activation|Fertilization failure MII oocytes were collected in ICSI cycles. After CaCl2 was injected, the oocytes were transferred into the calcium ionophore A23187 solution for two times.
62410691|NCT06450522|EXPERIMENTAL|Pharmacist co-management|"In addition to usual care, participants with an initial Post-Discharge Medicine Clinic visit randomized to the intervention arm will receive pharmacist co-management of their medications, with the intent of to achieve rapid, maximum-tolerated pharmacotherapy for HF as outlined in the latest guidelines. This intervention will be delivered by a staff pharmacist at the St. Paul's Hospital, using the standard procedures outlined below:~For HFrEF, where possible, a patient will be prescribed the combination of an ARNI, evidence-based beta-blocker, MRA, and SGLT2i at target HFrEF doses, along with personalized therapies as outlined in the 2021 CCS HF guidelines.~For HFmrEF, we will target ACEI/ARB/ARNI, beta-blocker, MRA, and SGLT2i. For HFpEF, we will target SGLT2i + MRA +/- ACEI/ARB/ARNI. The intervention will incorporate key components identified in a systematic review of observational studies of pharmacist-led optimization of HF."
62410692|NCT06450522|OTHER|Usual care|Usual care: Both the intervention group and comparator group will receive usual care by the Post-Discharge Medicine Clinic, which does not include clinical pharmacy services. The standard pathway in the St. Paul's Hospital Post-Discharge Medicine Clinic consists of an initial consultation with the clinic internist within 2 weeks of discharge, followed by two visits approximately 1 week apart with the Post-Discharge Medicine Clinic internist, followed by discharge from the clinic.
62585244|NCT04523103|EXPERIMENTAL|A3 assisted activation|Fertilization failure MII oocytes were collected in ICSI cycles. Mechanical activation was done for the MII oocytes, and then the oocytes were transferred into the calcium ionophore A23187 solution for two times.
62585245|NCT06600087||PrEP less than a year|
62021309|NCT04952649||pacemaker dependent patients after cardiac surgery|Pacemakers are widely used in cardiotomy patients, while it's common that the patients happen to be pacemaker dependent. When the doctor decides to set the heart rate of the pacemaker, we record the hemodynamic parameters and peripheral perfusion index from 70-80-90-100-110 bpm.
62021310|NCT05811377|EXPERIMENTAL|ICE-MRI|Participants will undergo a single Magnetic Resonance Imaging study: a single breath-hold pre-contrast image followed by sterile placement of a temporary urethral catheter for instillation of a 50 milliliter (mL) solution containing Gadobutrol (302mg) plus ferumoxytol (5 mM) and a second, single breath hold post-contrast image.
62216209|NCT00269893|EXPERIMENTAL|Abciximab and Placebo|Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight of abciximab (c7E3 Fab) bolus injection followed by followed by placebo solution infusion up to 12 hours.
62585246|NCT06600087||PrEP for over a year|
62021311|NCT01243333|EXPERIMENTAL|Diagnostic (multi-tracer PET scans)|Patients undergo Positron Emission Tomography (PET) scans with \[F-18\]fluorodeoxyglucose and \[F-18\]fluorothymidine at baseline and within 7 days of completion of 1 or 2 (if the course is less than 3 weeks) therapeutic agent courses.
62216210|NCT00269893|EXPERIMENTAL|Abciximab|Participants will receive 0.25 mg/kg of body weight of abciximab bolus followed by abciximab (c7E3 Fab) infusion up to 12 hours.
62216211|NCT05857644|EXPERIMENTAL|Healthy subjects|One time dose of 4 capsules taken orally.
62021312|NCT01494285|EXPERIMENTAL|ARK-E021 5% foam|
62216212|NCT05857644|EXPERIMENTAL|Mild Hepatic impaired subjects|One time dose of 4 capsules taken orally.
62216213|NCT05857644|EXPERIMENTAL|Moderate hepatic impaired subjects|One time dose of 4 capsules taken orally
62216214|NCT05857644|EXPERIMENTAL|Severe Hepatic Impaired Subjects|One time dose of 4 capsules taken orally.
62216215|NCT02751541|EXPERIMENTAL|BAY987519|All subjects are patched
62216216|NCT00670631|EXPERIMENTAL|Tandem autologous stem cell transplant|"Induction: DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant 1: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide) Transplant 2: 8 weeks to 6 months after the first transplant, participants will have the second transplant Maintenance: Year 1- VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
62216217|NCT05028907|EXPERIMENTAL|group one (cases with inflamatory punctal stenosis treated with steroids and antibiotics)|patients with inflammatory punctal stenosis were treated by steroids and antibiotics and evaluated by anterior segment optical coherence tomography before and after treatment
62216218|NCT05028907|PLACEBO_COMPARATOR|control group|patients with inflammatory punctal stenosis received only preservative free tear substitutes
62216219|NCT04404127|PLACEBO_COMPARATOR|No induction Arm|
62216220|NCT04404127|ACTIVE_COMPARATOR|Induction with basiliximab|
62216221|NCT04732598|ACTIVE_COMPARATOR|Arm A|
62216222|NCT04732598|EXPERIMENTAL|Arm B|
62216223|NCT01237275|EXPERIMENTAL|SSRI treated group|SSRI treated group are depressive patients treated with fluoxetine, paroxetine or sertraline
62216224|NCT01835418|EXPERIMENTAL|Lisinopril|bedtime administration of lisinopril 20mg
62216225|NCT01835418|EXPERIMENTAL|Amlodipine|Bedtime administration of amlodipine 5mg
62585247|NCT02288845|EXPERIMENTAL|ITI-007|ITI-007 formulated capsule will be administered orally once daily for up to 14 days in up to 14 subjects.
62585248|NCT01625819|EXPERIMENTAL|Tai Chi|32 1-hour group sessions of Tai Chi instruction
62585249|NCT01625819|ACTIVE_COMPARATOR|Resistance Band|32 1-hour bi-weekly group sessions of Resistance Band exercises
62585250|NCT01625819|PLACEBO_COMPARATOR|Health Education|32 1-hour bi-weekly group sessions of health education
62585251|NCT01625819|NO_INTERVENTION|Care as Usual|Receive usual cardiology care for 4 months between pre- and post-treatment testing
62585252|NCT03778918||inflammatory bowel disease|inflammatory bowel disease such as Ulcerative colitis and Crohn's disease
62585253|NCT03778918||IBS or Normal Control|irritable bowel syndrome patients normal patients
62021313|NCT01494285|EXPERIMENTAL|ARK-E021 10% foam|
62021314|NCT01494285|PLACEBO_COMPARATOR|Placebo foam|
62021315|NCT05982743|EXPERIMENTAL|Fermented milk drink|
62216226|NCT05321654|EXPERIMENTAL|Posture Education (PE) Group|PE group members received a 20-minute in-person one-on-one standardized educational session by a research team member in the laboratory on the following topics: health risks associated with forward head posture; postural guidelines for using mobile electronic devices, desktop computers, and laptop computers; as well as rest break guidelines. Participants were asked to adhere to the postural guidelines provided in the educational session for the next 4 weeks.
62216227|NCT05321654|EXPERIMENTAL|Self-Myofascial Release + Stretching (SMRS) Group|This group applied self-myofascial release (SMR) to their thoracic spine with a myofascial roller for 30 sec., then 6 repetitions of myofascial rolling for 90 sec. They applied SMR for 30 sec. to their neck flexors and extensors using their fingertips. They applied SMR to the upper trapezius and pectoralis for 30 sec using a soft tissue mobilization tool. For the first 2 weeks, they performed SMR 3x/wk. During wks. 3 and 4, they progressed SMR to 5 days/wk. Group members also performed stretching to these same muscles after SMR 3 days/wk for the first 2 weeks of the study, progressing to 5 days/wk during weeks 3 and 4.
62216228|NCT05321654|EXPERIMENTAL|Self-Myofascial Release + Stretching + Strengthening (SMRSS) Group|This group performed the same protocol as SMRS group, as well as include the following strengthening exercises: the supine chin tuck (SCT), upper thoracic-lower cervical extension (UTLCE) using an exercise band that provided 5.5 pounds of resistance, and a single-arm row with trunk rotation (SARTR) using exercise tubing that provided 20 pounds of resistance. The SCT was progressed in 3 phases: Week 1: chin tuck held 2 sec., 5 reps. Week 2: same as week 1, but included us of a towel roll placed under the head. Wks. 3 and 4: chin tuck with head lift 1 in., 2 sec. hold. UTLCE: neck extension with exercise band, held 2 sec. SARTR: single arm row with trunk rotation was performed in a controlled and fluid manner using a self-selected speed. The UTLCE and SARTR were performed with 1 X 10 reps for wks 1-2 and progressed to 2 X10 reps in wks 3-4. Strengthening exercises were performed 3x/wk. for 4 wks.
62216229|NCT05321654|NO_INTERVENTION|Control Group (CG)|Participants in the CG did not receive an intervention.
62216230|NCT06182943|EXPERIMENTAL|electroacupuncture group|electroacupuncture combined with surrounding acupuncture
62216231|NCT06182943|SHAM_COMPARATOR|sham electroacupuncture group|sham electroacupuncture
62216232|NCT06182943|PLACEBO_COMPARATOR|ice compress combined with brake rest group|ice compress combined with brake rest
62216233|NCT01621568|EXPERIMENTAL|Group 1 (Thymoma and thymic carcinoma)|Group 1 (Thymoma and thymic carcinoma) treated with sunitinib 50 mg/day, 4 weeks on, 2-weeks off (6 week cycle).
62216234|NCT01621568|EXPERIMENTAL|Group 2 (Thymic carcinoma only)|Group 2 (Thymic carcinoma only) treated with sunitinib 50 mg/day, 2 weeks on, 1 week off (3 week cycle).
62216235|NCT03872024|EXPERIMENTAL|Morbidly obese adult patients|Only one group of patients in the study: morbidly obese adult patients who will have an examination with the XXL probe prototype of the FibroScan 630 Research Model
62216236|NCT01712659|EXPERIMENTAL|Original Phase II Standard Ruxolitinib dose cohort|Ruxolitinib 20 mg orally twice daily for 28 days. Subjects may continue to receive treatment until progressive disease (PD) or unacceptable toxicity.
62216237|NCT01712659|EXPERIMENTAL|2- Phase 1 Dose Escalation cohorts|"Dose level 1: Ruxolitinib 30 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.~Dose level 2: Ruxolitinib: Ruxolitinib 40 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.~Dose level 3: Ruxolitinib: Ruxolitinib 50 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity."
62216238|NCT01712659|EXPERIMENTAL|3- Phase 1 Dose Expansion Cohort|Ruxolitinib at the maximum tolerated dose (MTD) or the maximum administered dose (MAD) defined in the phase 1 dose escalation cohorts. Subjects may continue to receive treatment until progressive disease (PD) or unacceptable toxicity.
62216239|NCT03443050|EXPERIMENTAL|Experimental|Balance training on unstable surfaces
62216240|NCT03443050|ACTIVE_COMPARATOR|Control|Balance training on stable surface
62585254|NCT05831644|EXPERIMENTAL|Treatment arm 1|A single dose of C21 at visit 2 followed by a single dose of placebo at visit 3.
62585255|NCT05831644|EXPERIMENTAL|Treatment arm 2|A single dose of placebo at visit 2 followed by a single dose C21 at visit 3.
62585256|NCT04864886||Healthy volunteers|Control group
62585257|NCT04864886||Patients with atopic dermatitis|Physician-diagnosed atopic dermatitis
62585258|NCT04864886||Patients with primary immunodeficiency|Confirmed by genetic diagnosis or suspected by genetic variant of unconfirmed significance and a history consistent with immunodeficiency
62792387|NCT03935243|EXPERIMENTAL|equine assisted therapy|In the active intervention phase, patients participate twice a week in a equine assisted group therapy, while during the control phase they participate twice a week in a group that includes a non-specific and general activity program. After 15 therapy units in a study phase, the subjects will complete the 15 units of the other study phase (within-subject-design). All participants complete both study phases, with the order being randomized.
62792388|NCT03935243|ACTIVE_COMPARATOR|activating control phase|"In the present study, the interventions in the control phase are based on the sub-program Social Skills of the Integrated Psychological Treatment Program (IPT) for schizophrenic patients (Brenner et al., 1994, Roder et al., 1988, 2002)."
62792389|NCT05852912||elders combined with mild mental illness|elders combined with mild mental illness(120 subjects)
62585259|NCT04864886||Patients with psoriasis|Physician-diagnosed psoriasis
62792390|NCT05852912||elders combined without mild mental illness|elders combined without mild mental illness(120 subjects)
62792391|NCT04030572|EXPERIMENTAL|Clonidine Pill|One week period of clonidine, 0.1 mg tabs, one by mouth daily at bedtime
62792392|NCT05242484|PLACEBO_COMPARATOR|Group 1: Placebo|Participants will receive placebo subcutaneously (SC). All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
62021316|NCT05982743|NO_INTERVENTION|No drink|
62216241|NCT03026985||Observational cohort|"Ultrasound measurement of quadriceps muscle size and echogenicity will be obtained at baseline (within 48 hours of ECMO commencement), 10 days and 20 days after baseline measurement.~Measures of muscle strength and highest mobility level will be obtained at day 10 and day 20 after baseline measurement in order to determine the relationship between these volitional measures and the ultrasound parameters."
62216242|NCT05687357|EXPERIMENTAL|Arm A: Tislelizumab + Chemoradiotherapy|"Neoadjuvant: Prior to surgery, participants receive 4 cycles of Tislelizumab 200 mg via intravenous (IV) infusion on C1D1, C2D1, C2D22, C3D1 PLUS radiotherapy (TOMO or VMAT) 45Gy/1.5f PLUS S-1 initial dose depends on the body surface area, PO, bid, C1D1\~D14，C2D1\~C2D5, C2D8\~C2D12, C2D15\~C2D19, C2D22\~C2D26, C2D29\~C2D33, C3D1\~D14 and oxaliplatin 130mg/m\^2, IV, C1D1 and C3D1 OR S-1 initial dose depends on the body surface area, PO, bid, C1D1\~D14，C3D1\~D14 and nab-paclitaxel, IV 100\~120mg/m\^2，IV，C1D1，C1D8，C2D1，C2D8，C2D16，C2D22，C3D1 and C3D8.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of SOX OR S-1 and nab-paclitaxel AND 3 cycles of S-1, AND up to 16 cycles of Tislelizumab 200 mg via IV infusion on Day 1 Q3W."
62216243|NCT05687357|ACTIVE_COMPARATOR|Arm B: Chemoradiotherapy|"Neoadjuvant: Prior to surgery, participants receive radiotherapy (TOMO or VMAT) 45Gy/1.5f PLUS S-1 initial dose depends on the body surface area, PO, bid, C1D1\~D14，C2D1\~C2D5, C2D8\~C2D12, C2D15\~C2D19, C2D22\~C2D26, C2D29\~C2D33, C3D1\~D14 and oxaliplatin 130mg/m\^2, IV, C1D1 and C3D1 OR S-1 initial dose depends on the body surface area, PO, bid, C1D1\~D14，C3D1\~D14 and nab-paclitaxel, IV 100\~120mg/m\^2，IV，C1D1，C1D8，C2D1，C2D8，C2D16，C2D22，C3D1 and C3D8.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of SOX OR S-1 and nab-paclitaxel AND 3 cycles of S-1."
62585260|NCT05076669|ACTIVE_COMPARATOR|Control|The control group will receive the routine care prescribed by the sites and will be provided with ostomy equipment by FSK.
62792393|NCT05242484|EXPERIMENTAL|Group 2: Guselkumab|Participants will receive guselkumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
62216244|NCT05687357|ACTIVE_COMPARATOR|Arm C: Chemotherapy|"Neoadjuvant: S-1 initial dose depends on the body surface area, PO, bid, D1\~D14，Q 3W for 6 cycles, and oxaliplatin 130mg/m\^2, IV, D1 of each cycle for 6 cycles OR nab-paclitaxel, IV 100\~120mg/m\^2，IV，D1 and D8 for each cycle for 6 cycles.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of SOX OR S-1 and nab-paclitaxel AND 3 cycles of S-1."
62216245|NCT04078243||CardioMEMS HF System|Eligible patients will be recruited and will attend for the implantation in line with standard of care procedures. The patient's details will be uploaded to the CardioMEMS HF system, enabling remote monitoring of their heart failure device. The patient will also be given a Fitbit activity monitor and set up with an account that is accessible to patient and physician to allowing activity to be monitored. The research team will be able to continuously monitor data remotely from the CardioMEMS HF system and Fitbit platform.
62216246|NCT01060579|EXPERIMENTAL|AR-12286 0.5% ophthalmic solution|
62216247|NCT01060579|EXPERIMENTAL|AR-12286 0.25% Ophthalmic Solution|
62216248|NCT01060579|EXPERIMENTAL|Latanoprost 0.005% ophthalmic solution|
62216249|NCT01014143|PLACEBO_COMPARATOR|Fluoride toothpaste|Negative control
62216250|NCT01014143|ACTIVE_COMPARATOR|Triclosan/Fluoride toothpaste|positive control toothpaste
62216251|NCT01014143|ACTIVE_COMPARATOR|Chlorhexidine Oral Rinse|Positive Control mouthrinse
62216252|NCT00578461|EXPERIMENTAL|Stem Cell Transplant|patient's will be recieving a stem cell transplant on study Conditioning includes: Ara C, Cyclophosphamide, MESNA, TBI-Total Body Irradiation
62216253|NCT06609733||MA group|Patients receiving routine care for Class II malocclusion, which may include the use of Clear Aligner with Mandibular Advancement (MA) function appliances
62216254|NCT06609733||TB group|Patients receiving routine care for Class II malocclusion, which may include the use of Twin Block (TB) appliances
62216255|NCT04128761|EXPERIMENTAL|Scarcity Narrative|Participants assigned to the scarcity group will be asked to listen and consider a hypothetical narrative about a sudden loss of resources.
62216256|NCT04128761|SHAM_COMPARATOR|Neutral Narrative|Participants assigned to the neutral group will be asked to listen and consider a hypothetical narrative about a neutral change in resources.
62216257|NCT06609135|EXPERIMENTAL|Electrical Impedance Tomography (EIT) and CO2 monitor|Participating infants will have the EIT belt placed at a minimum of twice per week throughout the NICU stay. A respiratory therapist or physician will place the EIT belt at the end of a feed and remove it at the next feed. A transcutaneous CO2 monitor will be placed concurrently.
62216258|NCT05142488|EXPERIMENTAL|8 week interval|Third dose Covid-19 (recombinante) vaccine 6 months after the second dose of a two dose vaccine schedule with a 8 week interval between the first two doses.
62216259|NCT05142488|ACTIVE_COMPARATOR|12 week interval|Third dose Covid-19 (recombinante) vaccine 6 months after the second dose of a two dose vaccine schedule with a 12 week interval between the first two doses.
62216260|NCT06308848|EXPERIMENTAL|Microbiota Directed Food (MDF)|Each participant will receive 12 weeks of MDF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-month period.
62792394|NCT05242484|EXPERIMENTAL|Group 3: Golimumab|Participants will receive golimumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
62585261|NCT05076669|EXPERIMENTAL|interventional group|The interventional group will benefit from delivery and enhanced follow-up by the FSK HHN provided, in particular, by stomal therapy nurse consultants and patient-relation experts during in-person or remote appointments in addition to the routine care delivered and prescribed by the sites.
62585262|NCT05039684||Primary open angle glaucoma / ocular hypertension - Treatment with Xalatan|Patients with primary open angle glaucoma or ocular hypertension treated with Xalatan
62585263|NCT05039684||Primary open angle glaucoma / ocular hypertension - Treatment with Monoprost|Patients with primary open angle glaucoma or ocular hypertension treated with Monoprost
62021317|NCT02995668|NO_INTERVENTION|Control|Non-active comparator
62792395|NCT05242484|EXPERIMENTAL|Group 4: JNJ-78934804 (High-dose)|Participants will receive JNJ-78934804 dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
62216261|NCT06308848|ACTIVE_COMPARATOR|Ready-to-Use Therapeutic Food (RUTF)|Each participant will receive 12 weeks of RUTF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-month period.
62410693|NCT02353572|EXPERIMENTAL|Melphalan, Bortezomib, Autologous transplant|Patients receive melphalan IV continuously on days -5 to -2 and bortezomib IV over 3-5 seconds on days -4 and -1. Patients also receive dexamethasone IV on day -1 prior to the second dose of bortezomib. Beginning two days after completion of melphalan infusion, patients undergo autologous hematopoietic stem cell transplant. Eligible patients may undergo a second transplant 2-4 months after completion of the first transplant.
62410694|NCT05046275||MCR syndroms|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
62585264|NCT05039684||Primary open angle glaucoma / ocular hypertension - Treatment with Saflutan|Patients with primary open angle glaucoma or ocular hypertension treated with Saflutan
62585265|NCT05039684||Ocular hypertension - No treatment|Patients ocular hypertension untreated
62585266|NCT03602235|EXPERIMENTAL|Low dose melphalan + high dose ascorbate acid (HDAA)|"Patients will receive a test dose of 15g of HDAA prior to starting treatment dose. This will be mainly to rule out allergic reactions.~HDAA + Melphalan:~HDAA on day 1 and day 4 in combination with melphalan 12.5 mg/m2, followed by 2 additional doses of HDAA on day 2 and day 5.~A 3 + 3 cohort method will be used for this study. After successfully completing the test dose, subjects will receive 50gms, 75gms and 100gms of ascorbate per infusion in 3 different cohorts. Dose modifications are not made for weight or body surface area."
62585267|NCT01527695|EXPERIMENTAL|AZD3241|AZD3241 tablets 25 mg or 100 mg, titration first 5 days (50 mg bd on Day 1, 100 mg bd on Day 2, 200 mg bd on Day 3, 300 mg bd on Day 4, 400 mg bd on Day 5) Maintenance treatment from Day 6, 600 mg bd until Day 56±3 days
62585268|NCT01527695|EXPERIMENTAL|Placebo|AZD3241 placebo bid for 8 weeks
62585269|NCT02737969||TEE/Angio fusion software|Patients planned to undergo a transcatheter-based structural heart disease procedure that utilizes TEE and fluoroscopic guidance
62585270|NCT06302153|EXPERIMENTAL|progressive loading exercises|"progressive loading exercises Progressive loading exercises \& stretching protocol will be given. The exercises included are as follows~* Standing calf raise double leg~* Standing calf raise single leg 4 sets with 8 repetitions will be given. Session will be given thrice a week for 40 minutes.~* Soleus wall sits double leg~* Toe taps~* Toe walks forward hops double"
62792396|NCT05242484|EXPERIMENTAL|Group 5: JNJ-78934804 (Mid-dose)|Participants will receive JNJ-78934804 dose regimen 2 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
62021318|NCT02995668|ACTIVE_COMPARATOR|Strength-Function|Active comparator
62021319|NCT02995668|EXPERIMENTAL|Balance-Proprioception|Experimental
62216262|NCT00577876|EXPERIMENTAL|1|Day of Surgery:Patient is admitted through the Preoperative Surgical Center (PSC). If a large APA is identified, then subject will continue on study Dissect APA (without any changes from what is routinely done) with a penile injection of Trimix. Once the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion.
62216263|NCT03675373|EXPERIMENTAL|Intervention group|Alcohol brief intervention+mobile chat-based instant messages
62216264|NCT03675373|ACTIVE_COMPARATOR|control group|Alcohol brief intervention
62216265|NCT04129216|EXPERIMENTAL|Tamoxifen arm|for premenopausal patients
62216266|NCT04129216|EXPERIMENTAL|Letrozole arm|for postmenopausal patients
62216267|NCT04129216|EXPERIMENTAL|Exemestane arm|for postmenopausal patients
62216268|NCT03122132||Spanish cohort with HCV treated with DAA|Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ritonavir 8 weeks and dasabuvir 8 weeks
62216269|NCT06355427|EXPERIMENTAL|FAPI PET-CT|Participants will undergo additional FAPI PET-CT prior to scheduled surgery.
62216270|NCT01182194|EXPERIMENTAL|Investigational Test Product|Drospirenone/Ethinyl Estradiol Tablets, 3 mg/0.02 mg
62216271|NCT01182194|ACTIVE_COMPARATOR|Reference Listed Drug|YAZ® Tablets, 3 mg/0.02 mg
62216272|NCT05446467|EXPERIMENTAL|Pembrolizumab+cisplatin + 5-fluorouracil|Pembrolizumab+ cisplatin+ 5-fluorouracil+ surgery+ adjuvant treatment+ pembrolizumab maintenance
62216273|NCT04371198|EXPERIMENTAL|Organoid|
62410695|NCT05046275||Non MCR syndroms|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
62792397|NCT05242484|EXPERIMENTAL|Group 6: JNJ-78934804 (Low-dose)|Participants will receive JNJ-78934804 dose regimen 3 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
62216274|NCT01141556|PLACEBO_COMPARATOR|Placebo|Placebo (NaCl) i.v. intraoperatively, followed by an daily bolus of Placebo (NaCl) i.v. until discharge from ICU (no longer than 13 days)
62792398|NCT06029569|EXPERIMENTAL|Rapamycin coated balloon dilation catheter for arteriovenous fistula|Experimental group rapamycin balloon therapy for autologous arteriovenous fistulas with stenosis or occlusion
62792399|NCT06029569|SHAM_COMPARATOR|Paclitaxel release high-pressure shunt balloon dilation catheter|Strict or occluded autologous arteriovenous fistula treated with paclitaxel balloon therapy in the control group
62792400|NCT05906433|EXPERIMENTAL|Kenalog with 0ml bupivacaine|The intervention in this study is one intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic,0ml of bupivacaine. The patients will be randomized into this group.
62792401|NCT05906433|EXPERIMENTAL|Kenalog with 4ml bupivacaine|The intervention in this study is one intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic,4ml of bupivacaine. The patients will be randomized into this group.
62021320|NCT03574220|EXPERIMENTAL|Pembrolizumab + Stereotactic Body Radiotherapy|"Lung SBRT 50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-15 days.~Adjuvant Therapy:~Pembrolizumab 200mg IV every 21 days for 6 months"
62021321|NCT05359042|EXPERIMENTAL|ePRO Assessment Tool|Participants will receive either a text message or an email inviting them to engage in the health chat. Participant assessments including HRQOL and user experience will be administered via the platform. Participants will also be able to participate in short, interactive patient education modules related to the infusion and side effect management.
62021322|NCT05359042|NO_INTERVENTION|Standard of Care|Participants in the standard of care arm will report symptoms via standard of care messaging through UCSF MyChart or telephone calls throughout the study period, and complete standard of care HRQoL surveys.
62021323|NCT02886572|EXPERIMENTAL|Stereotactic Radiosurgery|All subjects will receive stereotactic radiosurgery(SRS) following the RTOG Stereotactic Radiotherapy Guidelines available at http://dx.doi.org/10.1016/j.prro.2011.06.014
62021324|NCT03236402||Early young adult (20 years - 30 years)|Adults who were in the age group of 20 - 30 years was the first group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 20-30 years.
62216275|NCT01141556|ACTIVE_COMPARATOR|Selenase|Selenase Bolus 4000 microgram i.v. intraoperatively, followed by an daily bolus of Selenase 1000 microgram i.v. until discharge from ICU (no longer than 13 days)
62216276|NCT06606483|EXPERIMENTAL|90 mg MDR-001|Drug: MDR-001 Administered orally
62792402|NCT05906433|EXPERIMENTAL|Kenalog with 0.25% bupivacaine|The intervention in this study is one intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic,0.25% of bupivacaine. The patients will be randomized into this group.
62021325|NCT03236402||Middle age adult (31 -50 years)|Adults who were in the age group of 31-50 years were in second group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 31-50 years.
62021326|NCT03236402||Late adult (51 years - 65 years)|Adults who were in the age group of 51-65 years were in third group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 51-65 years.
62021327|NCT03236402||>65 years|Adults who were in the age group of \>65 years were in fourth group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of \>65 years.
62216277|NCT06606483|EXPERIMENTAL|120 mg MDR-001|Drug: MDR-001 Administered orally
62216278|NCT06606483|EXPERIMENTAL|150 mg MDR-001|Drug: MDR-001 Administered orally
62216279|NCT06606483|EXPERIMENTAL|180 mg MDR-001|Drug: MDR-001 Administered orally
62792403|NCT04563195|OTHER|open label|open label study; all subjects will receive the same drug at the same dose
62216280|NCT06606483|PLACEBO_COMPARATOR|placebo|Drug: MDR-001 Administered orally
62216281|NCT03748992|EXPERIMENTAL|gNO|Subjects will be receiving nitric oxide every week day for 3 weeks.
62216282|NCT03354585|EXPERIMENTAL|mindfulness group|"Study volunteers will participate in a six-session meditation training regimen. In brief, subjects will be taught that perceived sensory events are momentary and fleeting and do not require further evaluation. There will be an emphasis on breath focus and altering one's perspective of discursive sensory events. This intervention has been found to reliably attenuate the subjective experience of pain."
62216283|NCT03354585|SHAM_COMPARATOR|non-mindfulness group|Study volunteers will participate in a six-session meditation training regimen. In brief, subjects will be taught to take deep breaths and relax.
62792404|NCT00122408|ACTIVE_COMPARATOR|1|
62792405|NCT00122408|PLACEBO_COMPARATOR|2|
62792406|NCT03565783|EXPERIMENTAL|Treatment (cemiplimab)|Patients receive cemiplimab IV over 30 minutes every 3 weeks. Cycles repeat every 3 weeks for up to 6 weeks with or without radiation therapy at the discretion of the treating physician in the absence of disease progression or unacceptable toxicity.
62792407|NCT01908478|EXPERIMENTAL|Combination: veliparib, gemcitabine, and IMRT|
62792408|NCT01985750|PLACEBO_COMPARATOR|Drug: d-cycloserine or placebo|"Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
62792409|NCT01985750|ACTIVE_COMPARATOR|D-cycloserine|"Placebo Comparator: Drug: d-cycloserine or placebo~Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
62021328|NCT02578485|EXPERIMENTAL|AVideogame|Session with active video game lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
62021329|NCT02578485|ACTIVE_COMPARATOR|SVideogame|Session with active video sedentary lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
62216284|NCT03354585|ACTIVE_COMPARATOR|book-listening|Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 6 session intervention is meant to provide the control attention to the facilitator, room setting, social support, conditioning, and the time elapsed during the other respective interventions. We do not expect that this group will demonstrate significant cerebral blood flow changes as a function of the intervention.
62216285|NCT01124331|EXPERIMENTAL|High Oxygen saturation|Higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter, for durations as specified in each trial protocol.
62216286|NCT01124331|ACTIVE_COMPARATOR|Lower oxygen saturation|Lower (SpO2 85-89%) functional oxygen saturation target range from birth, or soon thereafter, for durations as specified in each trial protocol.
62216287|NCT04333641||small AAA patients|all patients with small AAA
62216288|NCT01528553|ACTIVE_COMPARATOR|Staples|Old implant type
62216289|NCT01528553|ACTIVE_COMPARATOR|8plate|New implant type
62216290|NCT00461513||Intervention|The PCDM intervention will include evaluation of CHF care by the collaborative care team, with diagnostic and therapeutic treatment recommendations based on current ACC/AHA national clinical practice guidelines, daily telemonitoring and patient self-care support utilizing the VA telemonitoring system, and screening and treatment for comorbid depression. The Collaborative Care (CC) team at each site will consist of a primary care provider, cardiologist, and psychiatrist, who are local opinion leaders, as well as a nurse site coordinator and pharmacist. For a given intervention patient, there will be an initial assessment of care by the CC team following the enrollment visit. Each intervention patient will be re-reviewed by the CC team a minimum of 2 additional times (at 6-weeks and 6 months). In addition, patients will have daily telemonitoring, and their care will be reviewed by the CC team if the telemonitoring data suggests clinical deterioration.
62216291|NCT00461513||Usual Care|Patients randomized to the usual care arm will continue to receive care at the discretion of their regular VA providers (for a given patient, this could include cardiology specialty care in addition to PCP care, participation in site-specific CHF programs such as CHF patient education classes, etc.), in direct continuity with the care they were receiving prior to enrollment. Patients in the usual care group will also be given information sheets that outline self-care for CHF, and will be provided with a scale, if needed, at the enrollment visit. Patients in the usual care group will have the same amount of interaction with the study team as the intervention patients (i.e. complete questionnaires at the same frequency; have the same study visits). PCPs of usual care patients will be notified of the results of all screening studies (patient survey results, lab tests) as we have done in previous studies.
62216292|NCT03500159|EXPERIMENTAL|AQX-1125|AQX-1125 200 mg
62216293|NCT03500159|PLACEBO_COMPARATOR|Placebo|Matching placebo
62216294|NCT04847206|EXPERIMENTAL|MDMA (100 mg MDMA-hydrochloride)|MDMA (100 mg MDMA-hydrochloride; 84.1 mg MDMA free base)
62216295|NCT04847206|EXPERIMENTAL|MDA (93.9 mg MDA-hydrochloride)|MDA (93.9 mg MDA-hydrochloride; 78.0 mg MDA free base)
62216296|NCT04847206|EXPERIMENTAL|lysine-MDMA (171.7mg lysMDMA dihydrochloride|lysine-MDMA (171.7mg lysMDMA dihydrochloride; 84.1 mg MDMA free base)
62216297|NCT04847206|EXPERIMENTAL|lysine-MDA (165.6 mg lysMDA dihydrochloride;|lysine-MDA (165.6 mg lysMDA dihydrochloride; 78.0 mg MDA free base)
62410696|NCT04406272|EXPERIMENTAL|Before and After Surgery|"VB-111 will be administered intravenously at a pre-determined dose at 14-28 days prior to surgery.~Upon recovering from surgery (within 28-35 days after surgery), participants will receive intravenous VB-111 every 6 weeks. Participants evidencing disease progression may initiate bevacizumab at a pre-determined dose as needed for supportive care and will continue with VB-111 infusions every 6 weeks until tumor growth is evidenced a two consecutive time points."
62410697|NCT04406272|EXPERIMENTAL|After Surgery|"Placebo (IV solution with no medicine) will be administered intravenously at a pre-determined dose at 14-28 days prior to surgery.~Upon recovering from surgery (within 28-35 days after surgery), participants will receive intravenous VB-111 every 6 weeks. Participants evidencing disease progression may initiate bevacizumab at a pre-determined dose as needed for supportive care and will continue with VB-111 infusions every 6 weeks until tumor growth is evidenced a two consecutive time points."
62410698|NCT04406272|EXPERIMENTAL|After Surgery Standard of Care|"Placebo (IV solution with no medicine) will be administered intravenously at a pre-determined dose at 14-28 days prior to surgery.~Upon recovery from surgery, participants will receive standard of care treatment every 6 weeks until tumor growth is evidenced a two consecutive time points."
62410699|NCT05940571|EXPERIMENTAL|MBF-362 128.7 mg|Drug: One MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles
62410700|NCT05940571|EXPERIMENTAL|MBF-362 257.4 mg|Drug: Two MBF-362 128.7 mg hard gelatin capsules EP2/EP4 antagonist 28 days single oral daily dosing cycles
62021330|NCT02578485|PLACEBO_COMPARATOR|EMIntensity|Session with walk on a treadmill with moderate intensity lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
62216298|NCT04847206|PLACEBO_COMPARATOR|Placebo|Placebo
62216299|NCT01518400||Eligible Population|Cancer Survivors of all ages (Must be diagnosed with cancer at 21 years or younger)
62216300|NCT01097122|EXPERIMENTAL|Healthy young adult subjects|Forearm vibration will be applied in healthy young adult subjects
62410701|NCT05940571|EXPERIMENTAL|MBF-362 514.8 mg|Drug: Four MBF-362 128.7 mg hard gelatin capsules EP2/EP4 antagonist 28 days single oral daily dosing cycles
62410702|NCT05940571|EXPERIMENTAL|MBF-362 772.2 mg|Drug: Six MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles
62410703|NCT02190968|EXPERIMENTAL|Mindful Mood Balance|An 8 session internet intervention targeting residual depressive symptoms.
62410704|NCT02190968|ACTIVE_COMPARATOR|Usual Depression Care|Usual Depression Care through Kaiser Permanente Colorado
62410705|NCT02185027||complications and compliance with GIHP recommendations|Description at 1 month post-intervention of an potential event
62021331|NCT02578485|PLACEBO_COMPARATOR|EISVideogame|Session with walk on a treadmill with intensity similar reached in session with VGA and lasting 60 minutes performing heart rate and perceived exertion measurements every 10 minutes.
62216301|NCT01850732|OTHER|ultrasound of aorta|
62216302|NCT06609746|EXPERIMENTAL|Thyme|Taking thyme extract capsules with a low FODMAP diet
62216303|NCT06609746|PLACEBO_COMPARATOR|placebo|Taking placebo capsules with a low FODMAP diet
62021332|NCT02578485|SHAM_COMPARATOR|Control|Participants remained for 60 minutes at rest performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
62585271|NCT06302153|EXPERIMENTAL|Conditioning Exercises|"conditioning exercises Conditioning exercises \& stretching protocol will be given. (31)~* Standing calf raise~* Seated calf raise~* Calf press hold~* Loaded plant walk~* Single leg step hops up 4 sets with 8 repetitions will be given. Session will be given thrice a week for 40 minutes."
62585272|NCT05195255|EXPERIMENTAL|Healthy subjects|Prebiotic administration
62585273|NCT05214183|EXPERIMENTAL|Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma|
62021333|NCT00119444|OTHER|periacetabular osteotomy|
62216304|NCT02505438|EXPERIMENTAL|Young Unilateral Exercise|Young Individuals (18-30y) studied before and after 6 weeks unilateral resistance exercise training
62216305|NCT02505438|EXPERIMENTAL|Old Unilateral Exercise|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training
62216306|NCT02505438|EXPERIMENTAL|Old Unilateral Exercise and HMB|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training with HMB (beta-hydroxy-beta-methylbutyrate) supplementation
62216307|NCT02505438|EXPERIMENTAL|Old Unilateral Exercise and Omega 3|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training with Omega 3 supplementation
62216308|NCT00381615|EXPERIMENTAL|rMenB|"Infants received 4 doses of recombinant meningococcal serogroup B (rMenB) vaccine without outer membrane vesicle (OMV-NZ) at 2, 4, 6 and 12 months of age.~Infants also received routine vaccines - 3 doses each of Diphtheria Tetanus Pertussis-Haemophilus influenzae type b-Inactivated Polio Vaccine (DTaP-Hib-IPV) (at 2, 3, and 4 months) and Heptavalent Pneumococcal Conjugate (PC7) (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and Measles Mumps Rubella (MMR) (at 13 months)."
62216309|NCT00381615|EXPERIMENTAL|rMenB+OMV|"Infants received 4 doses of rMenB vaccine with OMV-NZ at 2, 4, 6 and 12 months of age.~Infants also received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months)."
62216310|NCT00381615|EXPERIMENTAL|Routine|"Infants received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months).~Infants also received single dose of rMenB vaccine without OMV-NZ at 12 months of age."
62216311|NCT00381615|EXPERIMENTAL|Routine+OMV|"Infants received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months).~Infants also received single dose of rMenB vaccine with OMV-NZ at 12 months of age."
62216312|NCT05062759|EXPERIMENTAL|Tezepelumab|Participants will be randomized to receive tezepelumab 210 mg administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.
62216313|NCT05062759|PLACEBO_COMPARATOR|Placebo to Tezepelumab|Participants will be randomized to receive placebo SC Q4W, administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.
62216314|NCT04199832||Nasogastric tube|The patient had difficulty swallowing before chemoradiotherapy and placed a nasogastric tube.
62585274|NCT02410785|ACTIVE_COMPARATOR|Medical device polyglucosamine|2 times daily 2 tablets with the two main meals with the highest fat content. Participants follow the German guideline with a hypo-caloric (-500 kcal daily) lifestyle and increased physical activity.
62585275|NCT02410785|PLACEBO_COMPARATOR|Placebo|2 times daily 2 tablets with the two main meals with the highest fat content. Participants follow the German guideline with a hypo-caloric (-500 kcal daily) lifestyle and increased physical activity.
62585276|NCT02043769||Prospective Cohort|"The prospective cohort surveillance will be built upon and support the routine clinical care, visit schedule and monitoring system at each study site. Eligible HIV-infected ART naïve children who are accessing care at study sites will be recruited sequentially for study enrollment. Children enrolled in the surveillance study will attend study visits co-scheduled to coincide with routine clinical visits. Study nurses will:~1. review routinely collected information;~2. conduct questionnaires with caregiver and child;~3. conduct additional assessments of child;~4. contact the caregiver by phone or through home visits for active follow-up for up to 24 months; and~5. conduct active follow-up including appointment reminders by means of phone calls and defaulter tracking."
62021334|NCT06223945|ACTIVE_COMPARATOR|Thrombotic and hemorrhagic complications of COVID-19|
62585277|NCT04971850|EXPERIMENTAL|Sleep-disordered breathing (SDB)|Patients aged 1 to 20 years old with a suspicion of SDB or a high-risk of SDB due to their pathology and hospitalized at Necker Hospital for a sleep study for their clinical care.
62021335|NCT06223945|ACTIVE_COMPARATOR|Prevention of thrombohemorrhagic complications in COVID-19|
62021336|NCT05153837|EXPERIMENTAL|oral water|Experimental group: oral administration of 500 ml of water.
62216315|NCT04199832||gastrostomy feeding|Patients with dysphagia before chemoradiotherapy began to voluntarily choose gastrostomy feeding.
62216316|NCT04199832||Oral intake|Patients with normal swallowing or not receiving tube feeding.
62216317|NCT02224690|EXPERIMENTAL|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
62216318|NCT02224690|PLACEBO_COMPARATOR|Placebo|Participants received placebo (0 mg/mL CBD), volume matched to the 20 mg/kg/day dose, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
62216319|NCT03674944|EXPERIMENTAL|Behavioral Weight Loss (BWL) + Emotion Regulation (ER)|This program includes: 1) Dialectical Behavior Therapy (DBT) skills 2) Behavioral coaching 3) Emotional Focused Parent Training (EFPT) 4) Behavioral Weight Loss (BWL) skills.
62021337|NCT05153837|ACTIVE_COMPARATOR|intravenous|Active comparator: Administration of 500 mL of saline (NaCl 0.9%) administered by the venous route
62410706|NCT05582655|EXPERIMENTAL|ONLINE|"This strategy will primarily include self-directed family access to the online JASPER modules developed for this project. The online modules follow a stepped hierarchy beginning with foundational concepts (e.g., engagement states) and systematically adding new concepts and strategies each week (e.g., balancing imitation and modeling, play routines). Access to the modules will be paired with a weekly brief (20 minute) check-in call provided by a community interventionist. The call is designed to create a space for the caregiver to ask questions about the week's content and to provide basic troubleshooting for implementation.~Slower responders to phase 1 ONLINE intervention will intensify to receive COACH in phase 2."
62021338|NCT01206335|EXPERIMENTAL|OHR/AVR118|Experimental Drug
62021339|NCT05810922|EXPERIMENTAL|50 g arbutus berry|consumption of 50 g arbutus berry/day for 14 days
62216320|NCT03674944|ACTIVE_COMPARATOR|Behavioral Weight Loss (BWL)|This program includes information about diet and physical activity education, in addition to parent management skills, and behavioral modification principles including: modeling, reinforcement, and operant conditioning.
62216321|NCT05398237|EXPERIMENTAL|TLR4 and TOPK/PRPK Signaling in Sun Damaged Human Skin Acutely Exposed to Solar Simulated Light|We have one arm, which consists of participants with a broad range of sun damage on the forearm. Based on the standardized clinical photodamage scale (Hu C, Curiel-Lewandrowski C. Archives of Dermatology, 2011; 147(1):31-36), we will include mild (N=12), moderate (N=12), and severely (N=12) sun damaged skin.
62585278|NCT04455191|EXPERIMENTAL|Thawing Embryos in Advance|Thawing embryos one day in advance (16:00), 18h before embryos transfer (10:00).
62585279|NCT04455191|EXPERIMENTAL|Thawing Embryos on the Day of Transfer|Thawing embryos on the day of transfer (8:00), 2h before embryos transfer (10:00).
62585280|NCT01640379|EXPERIMENTAL|TECH-N|Participants receive the Technology Enhanced Community Health Nursing Visit (CHN) within 5 days during which Sister to Sister and clinical assessment performed and text-messaging support
62585281|NCT01640379|NO_INTERVENTION|Control|Participants receive enhanced standard of care
62585282|NCT03557931|EXPERIMENTAL|ASP4345 50 milligram (mg)|Participants on stable doses of antipsychotic medication received ASP4345 50 mg, capsules, orally, once daily for 12 weeks.
62585283|NCT03557931|EXPERIMENTAL|ASP4345 150 mg|Participants on stable doses of antipsychotic medication received ASP4345 150 mg, capsules, orally, once daily for 12 weeks.
62585284|NCT03557931|PLACEBO_COMPARATOR|Placebo|Participants on stable doses of antipsychotic medication received ASP4345 placebo matching capsules, orally, once daily for 12 weeks.
62585285|NCT04732546||patients with a mullerian variation|
62021340|NCT05810922|EXPERIMENTAL|200 g arbutus berry|consumption of 200 g arbutus berry/day for 14 days
62021341|NCT02038738|EXPERIMENTAL|Scan|We will perform 68Ga-DOTATATE PET scans on subjects.
62021342|NCT00924950|ACTIVE_COMPARATOR|Taclonex Ointment/Hydrogel Patch Applied Topically Once Daily|Taclonex ointment once daily used to treat one psoriatic plaque, along with the Hydrogel Patch used once daily.
62021343|NCT00924950|ACTIVE_COMPARATOR|Taclonex Ointment Topically Once Daily|
62021344|NCT05778214|EXPERIMENTAL|Interventional Robotic System Assisted Surgery|Experimental group underwent cerebral angiography using the vascular interventional surgical control system
62585286|NCT03961061|ACTIVE_COMPARATOR|Brenner FIT (Standard Care)|Adolescents will participate in Brenner Families in Training along with their caregiver. They will receive all components of standard Brenner FIT treatments.
62021345|NCT05778214|NO_INTERVENTION|Traditional Manual Surgery|The control group process the traditional manual operation for cerebral angiography
62021346|NCT04621305|PLACEBO_COMPARATOR|group P (Placebo group)|Patients were assigned to group P (Placebo group) using a computer-generated random number table
62021347|NCT04621305|EXPERIMENTAL|group B (Bolus group)|Patients were assigned to group B (Bolus group) using a computer-generated random number table
62021348|NCT04621305|EXPERIMENTAL|group C (continuous infusion group)|Patients were assigned to group C (continuous infusion group) using a computer-generated random number table
62021349|NCT05681884|EXPERIMENTAL|Group 1|"Subjects will be administered intravitreal faricimab 6 mg every 4 weeks (defined as every 28 days + 7 days and at least 21 days between injections) through week 48. Starting at Week 48, subjects will be treated every 16 weeks (weeks 48, 64 \& 80) with an end of study visit at week 96.~Rescue: At any visit after Week 48, if rescue criteria are met, faricimab 6mg will be given every 4 weeks and the subject will continue dosing through the end of the trial."
62021350|NCT05681884|EXPERIMENTAL|Group 2|"Subjects are seen and observed every 16 weeks. Starting at Week 48, subjects will be administered intravitreal faricimab 6 mg every 4 weeks from week 48 to week 92, (defined as every 28 days ± 7 days and at least 21 days between injections) with an end of study visit at week 96.~Rescue: At any visit before Week 48, if rescue criteria are met, faricimab 6mg will be given every 4 weeks and the subject will continue dosing through the end of the trial."
62216322|NCT03028727|ACTIVE_COMPARATOR|Ultrasonic Scaling, Root planing|Ultrasonic Scaling and Root planing at day 0 and at 1 week.
62216323|NCT03028727|EXPERIMENTAL|980 nm diode Laser irradiation|Irradiation of periodontal pockets with with 980 nm diode Laser after scaling and root planing at day 0 and after 1 week.
62216324|NCT03023761|ACTIVE_COMPARATOR|low level laser|A single visit Endodontic retreatment was done. After biomechanical preparation, Low Level Laser was irradiated to the buccal and lingual mucosa overlying the apices of the target tooth in the experimental group
62216325|NCT03023761|PLACEBO_COMPARATOR|laser sham|In the control group patients received placebo laser to eliminate the probable psychological effects of laser.
62216326|NCT03166410|EXPERIMENTAL|Cell Treatment|
62216327|NCT00530140|EXPERIMENTAL|A|All patients will receive the same vaccination schedule/formulation
62216328|NCT05399914||Preterm infants with a gestational age (GA) between 26 ≥ and < 32 weeks|
62216329|NCT00809484||1: Low risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily
62216330|NCT00809484||2:Moderate risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, +/- Risedronate 35mg orally once a week
62216331|NCT00809484||3:High risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, Risedronate 35mg orally once a week
62216332|NCT06110390|EXPERIMENTAL|High Flow Nasal Oxygen|HFNO device
62021351|NCT00803634|EXPERIMENTAL|Clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was administered intravenously via a single dedicated line to all patients randomized to the clevidipine arm. Clevidipine was infused at an initial rate of 2 mg/h for the first 3 minutes. If blood pressure was not in the target range at 3 minutes, clevidipine was titrated to effect thereafter by doubling the dose every 3 min, per physician discretion and as tolerated by the patient until the desired effect until the SBP target range was attained. Once target range was achieved, the infusion rate could be increased or decreased as needed to maintain blood pressure for minimum of 30 minutes and a maximum duration of 96 hours. The minimum infusion rate was 1 mg/h and maximum infusion rate was 32 mg/h.
62216333|NCT06110390|EXPERIMENTAL|Non-invasive ventilation|Non-invasive ventilation via tight-fitting facemask
62216334|NCT06110390|ACTIVE_COMPARATOR|Standard Oxygen therapy|Facemask oxygen is the default device used
62216335|NCT05201391|EXPERIMENTAL|"Eat Right Now (ERN) mobile application"|Participants in this single-arm trial will receive the ERN app as the intervention.
62216336|NCT04187807|EXPERIMENTAL|Melatonin 5mg|Melatonin 5mg, every 24 hours for 14 days
62216337|NCT04187807|PLACEBO_COMPARATOR|Placebo|Starch based placebo, every 24 hours for 14 days
62216338|NCT03280589|ACTIVE_COMPARATOR|Sitting Quietly|Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still, and allow the chair to support them. Instructions will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. The total duration of this session will be approximately 40 minutes.
62216339|NCT03280589|EXPERIMENTAL|Deep Breathing Self Paced|Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still, and allow the chair to support them. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. The total duration of this session will be approximately 40 minutes.
62216340|NCT03280589|EXPERIMENTAL|Deep Breathing Externally paced|Participants will have an instructional video with auditory queues prompting them to inhale and exhale at 6 bpm (approximately 4 seconds between inhale and exhale). Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still and allow the chair to support them. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. The total duration of this session will be approximately 40 minutes.
62216341|NCT03280589|EXPERIMENTAL|Sheetali/Sheetkali, self-paced:|Participant will follow on-screen instructions for Sheetali/Sheetkari with shaped lips/mouth as indicated (i.e., inhaling through the mouth held specific to each practice and exhaling through nostrils), fully filling and emptying the lungs with each breath. In Sheetali, the tongue is allowed to protrude from the mouth at a comfortable distance and rolled into a tube. Following 10 minutes of Sheetali practice, participants will have a one minute rest followed by Sheetkari. In Sheetkari, the tongue is not rolled into a tube; instead, it is rolled up to touch the upper palate. The teeth are then exposed and the lips are kept apart for inhalation and the mouth is closed, tongue is relaxed, and exhalation occurs through the nose. Study personnel will monitor their posture and breathing rate and pause the recording if additional coaching is necessary. The total duration of this session will be approximately 40 minutes.
62216342|NCT03280589|EXPERIMENTAL|Sheetali/Sheetkari, externally-paced|The participant will follow on screen instruction for Sheetali/Sheetkari with shaped lips/mouth as indicated, fully filling and emptying the lungs with each breath. The tongue is allowed to protrude from the mouth at a comfortable distance and rolled into a tube. Following 10 minutes of Sheetali practice, participants will have a one-minute rest before continuing. In Sheetkari the teeth are exposed and the lips are kept apart for inhalation and the mouth is closed, tongue is relaxed, and exhalation occurs through the nose. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. There will be an auditory queue to prompt the participant to breathe in and out. Study personnel will monitor their posture and breathing rate and pause the recording if additional coaching is necessary.The total duration of this session will be approximately 40 minutes.
62216343|NCT04379362|EXPERIMENTAL|Low or intermediate grade prostate cancer|
62216344|NCT02289573|EXPERIMENTAL|neurally adjusted ventilatory assist|
62216345|NCT02289573|SHAM_COMPARATOR|pressure support ventilation|
62216346|NCT06071559|OTHER|Obesitysurgery with diabetes|One group with obesity and concomitant type 2 diabetes
62216347|NCT06071559|OTHER|Obesitysurgery and non-diabetes|One group with obesity alone
62216348|NCT00577577|EXPERIMENTAL|rhIGF-I/rhIGFBP-3|
62216349|NCT00577577|PLACEBO_COMPARATOR|Placebo|
62216350|NCT05033431|EXPERIMENTAL|Group 1 [Healthy Chinese Participants]|Participants will receive a single intravenous (IV) infusion of brazikumab dose 1 on Day 1.
62021352|NCT00803634|ACTIVE_COMPARATOR|Standard of Care IV antihypertensive|For patients randomized to standard of care (SOC) IV antihypertensive treatment, a continuous infusion of an intravenous antihypertensive agent represented standard of care. The selection of treatment was at the discretion of the investigator. The infusion was to be administered according to the institution's treatment practice.
62021353|NCT03710434|EXPERIMENTAL|Part A - nano-suspension|Subjects will receive single dose of AZD4635 50mg nano-suspension (reference) in the fasted state.
62216351|NCT05033431|EXPERIMENTAL|Group 2 [Healthy Chinese Participants]|Participants will receive a single IV infusion of brazikumab dose 2 on Day 1.
62216352|NCT05033431|EXPERIMENTAL|Group 3 [Healthy Chinese Participants]|Participants will receive a single subcutaneous (SC) injection of brazikumab dose 3 on Day 1.
62216353|NCT05033431|EXPERIMENTAL|Group 4 [Healthy Chinese Participants]|Participants will receive a single SC injection of brazikumab dose 4 on Day 1.
62216354|NCT05033431|EXPERIMENTAL|Group 5 [healthy White participants]|Participants will receive a single IV infusion of brazikumab dose 2 on Day 1.
62410707|NCT05582655|EXPERIMENTAL|ONLINE + COACH|"Families randomized to add coaching will receive access to the ONLINE intervention program as described above. However, every second check in call will be shifted to a 45-minute live coaching session with their community interventionist. The coaching session will begin with a brief check-in and review of the target content for the session. This will be followed by support to set up the environment. The child will then join the interaction and the interventionist will provide real time coaching supports for the caregiver to practice the intervention strategies with their child. The session will end with a short discussion to debrief on the practice session.~Slower responders to phase 1 ONLINE + COACH intervention will intensify in phase 2 where check in calls are modified to include video feedback and review."
62216355|NCT05033431|EXPERIMENTAL|Group 6 [healthy White participants]|Participants will receive a single SC injection of brazikumab dose 4 on Day 1.
62216356|NCT01942590|EXPERIMENTAL|Clenbuterol|Initially, 40 mcg each morning for one week. Then, increase to 40 mcg BID for the next 5 weeks. If tolerated, will increase to 80 mcg in the morning and 40 mcg in the evening for one week. Then, last dose increase will be 80 mcg BID until week 52.
62216357|NCT01942590|PLACEBO_COMPARATOR|Placebo Comparator|Initially, one capsule each morning for one week. Then, increase to one capsule BID for the next 5 weeks. If tolerated, will increase to two capsules in the morning and one capsule in the evening for one week. Then, last dose increase will be two capsules BID until week 52.
62216358|NCT04667832||abnormal ABI|those patients with ankle brachial index ( ABI) less than 0.9
62216359|NCT04667832||normal ABI|Those patients with ankle brachial index more than 0.9
62216360|NCT02533141|EXPERIMENTAL|Intervention group|10 healthy subjects receiving at first simvastatin for 4 weeks, then crossover. Measurements will be done with the Dynamic Vessel Analyzer (DVA) and Laser Doppler Velocimetry (LDV).
62216361|NCT02533141|PLACEBO_COMPARATOR|Placebo group|10 healthy subjects receiving at first placebo for 4 weeks, then crossover. Measurements will be done with the Dynamic Vessel Analyzer (DVA) and Laser Doppler Velocimetry (LDV).
62216362|NCT06395012|EXPERIMENTAL|Part A: LY3985297 (Cohorts 1-8)|Single ascending dose of LY3985297 administered either intravenously (IV) or subcutaneously (SC). Cohort 5,6 and 7 is conducted in Japanese or Chinese participants.
62216363|NCT06395012|EXPERIMENTAL|Part B: LY3985297 (Cohorts 1-4)|Multiple ascending dose of LY3985297 administered either IV or SC.
62216364|NCT06395012|PLACEBO_COMPARATOR|Placebo Comparator: Part A and B: Placebo|Placebo administered either IV or SC.
62216365|NCT01865968|EXPERIMENTAL|Inactivated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with one-dose regimen.
62216366|NCT01865968|ACTIVE_COMPARATOR|Live attenuated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received live attenuated HAV vaccine containing 6.50 lgCCID50/vial with one-dose regimen.
62216367|NCT01865968|EXPERIMENTAL|Two-dose inactivated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with two-dose regimen.
62216368|NCT02010853|EXPERIMENTAL|patient|"each patient TGA will receive an evaluation in resting state IRMf during three successive visits:~* During the acute phase within 24 hours~* In 72 hours~* In 3 months"
62216369|NCT02010853|OTHER|control|"each control will receive an evaluation in resting state IRMf during three successive visits:~* During the acute phase within 24 hours~* In 72 hours~* In 3 months"
62216370|NCT00598364||Thyroidectomy or neck dissection|Patients with thyroid cancer or benign thyroid disease (nodules or goiter) who underwent thyroidectomy and/or neck dissection as standard of care.
62216371|NCT02734134|ACTIVE_COMPARATOR|One-stage exchange|One surgery where the infected implants are removed and the hip or knee joint are 'washed out' before new joint replacement implants are re-implanted during the same surgical procedure.
62216372|NCT02734134|ACTIVE_COMPARATOR|Two-stage exchange|Two surgeries; during the first surgery the infected implants are removed and a spacer is placed in the hip or knee joint in place of the implants. A second surgery to re-implant the hip or knee joint replacement implants is performed if and when the infection has cleared.
62216373|NCT06324799|EXPERIMENTAL|Position group every 2 hours|Newborns in the study group will change position (supine, prone, lateral) every 2 hours.
62216374|NCT06324799|NO_INTERVENTION|Control group|Newborns in the control group will change position (supine, prone, lateral) every 6 hours.
62216375|NCT04465500|OTHER|Treatment|
62242980|NCT02198092||Patient Group FAP|"Clinical diagnosis of familial adenomatous polyposis (FAP).~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients. Blood draws in FAP patients should always be accompanied by blood draws in their family member controls.~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
62410708|NCT06653673|EXPERIMENTAL|ChatGPT supported Online Guided Self-Help Program (GSHP)|The experimental group will participate in the ChatGPT-supported Online Group Guided Self-Help Program.
62410709|NCT06653673|NO_INTERVENTION|Control group|The control group will consist of participants placed on a waitlist.
62410710|NCT05372211||General hospital group|Questionnaires collected from general hospitals in China
62410711|NCT05372211||Maternity and infant hospital group|Questionnaires collected from Maternity and infant hospitals in China
62792410|NCT06727266||Axial Spondyloarthritis Patients|Demographic information such as age, height, weight and body mass index (BMI) will be recorded. During the physical examination, shoulder range of motion is measured and recorded. Shoulder pain will be assessed using the Visual Analogue Scale (VAS) and the Shoulder Pain and Disability Index (SPADI). Disease activity will be assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Functional status will be assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI). Spinal mobility will be assessed using the Bath Ankylosing Spondylitis Metrology Index (BASMI). Shoulder imaging will be performed using a Mindray DC-8 ultrasound device in accordance with European Society of Musculoskeletal Radiology (ESSR) protocols.
62216376|NCT06357325||Experimental group|"The study was designed as a qualitative (semi-structured) study. The population of the study consisted of women affected by the 2023 Kahramanmaraş-Pazarcık fault line centred earthquake. The sample consisted of women aged 18 years and older who lived in Hatay, Kahramanmaraş and Adana provinces during and after the earthquake and who agreed to participate in the study.~Data collection method: Participants were recruited using snowball sampling. The study plan was given to the people living in the earthquake zone who were reached by the researcher. Then the participants were reached by informing each other about the study. Interviews with the participants were conducted by telephone interviews to avoid spatial, temporal and transport constraints. The study themes were formed according to the responses to the pre-structured open-ended questions."
62410712|NCT05372211||Children's hospital|Questionnaires collected from Children's hospitals in China
62216377|NCT01587859||Cohort|Patients submitted to laparoscopic surgery for Type II-IV hiatus hernia
62216378|NCT04720248||Metamizol postoperatively|Patients submitted to scheduled craniotomy receiving metamizol as analgesic medication postoperatively
62216379|NCT04720248||Paracetamol or other analgesics postoperatively|Patients submitted to scheduled craniotomy receiving paracetamol or other drugs as analgesic medication postoperatively
62216380|NCT04864288||1|male patients (age ≥ 21) with erectile dysfunction (ED) and non-responders to intracorporal injection
62410713|NCT03914209||EHL clotting factor|This study shall not implement any intervention that might alter the normal development of the daily life activities of hemophilia patients included in the study. They will continue with the prophylactic regimen prescribed by their hematologist. Patients will also be asked to continue to develop their physical, work, entertainment and leisure activities in the same way as at baseline.
62410714|NCT02943369|EXPERIMENTAL|Cangrelor|Ticagrelor will be followed by Cangrelor
62410715|NCT02943369|ACTIVE_COMPARATOR|Ticagrelor|Ticagrelor only
62410716|NCT06454695|ACTIVE_COMPARATOR|Treatment as Usual|Participants receive Treatment as Usual (TAU) for their depression (i.e., psychotherapy and/or medication).
62410717|NCT06454695|EXPERIMENTAL|Imagery Rescripting|Participants receive Treatment as Usual (TAU) for their depression (i.e., psychotherapy and/or medication) plus 3-5 future-oriented imagery rescripting therapy (45 minutes weekly sessions).
62410718|NCT00940329|ACTIVE_COMPARATOR|Treatment A|
62410719|NCT00940329|ACTIVE_COMPARATOR|Treatment B|
62410720|NCT06561945||orthodontic patients|Patients who need orthodontic treatment.
62410721|NCT06538779||normal median nerve in carpal tunnel syndrome|Patients' general pain will be assessed with Visual Analog Scale (Global Pain), symptom severity and functional status will be assessed with Boston Carpal Tunnel Questionnaire, hand grip strength will be measured with dynamometer. Patient hand diagram will be marked according to patient's sensory symptoms. Median nerve cross-sectional area measurement at pisiform level with ultrasound, distal motor latency and sensory nerve conduction velocity with emg will be performed and recorded. Median nerve stiffness will be assessed with real-time elastography.
62410722|NCT06538779||median nerve variation in carpal tunnel syndrome|Patients' general pain will be assessed with Visual Analog Scale (Global Pain), symptom severity and functional status will be assessed with Boston Carpal Tunnel Questionnaire, hand grip strength will be measured with dynamometer. Patient hand diagram will be marked according to patient's sensory symptoms. Median nerve cross-sectional area measurement at pisiform level with ultrasound, distal motor latency and sensory nerve conduction velocity with emg will be performed and recorded. Median nerve stiffness will be assessed with real-time elastography.
62410723|NCT00644527|EXPERIMENTAL|1|Listening to one of two different specific music programs (Group A), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
62410724|NCT00644527|EXPERIMENTAL|2|Listening to one of two different specific music programs (Group B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
62410725|NCT00644527|SHAM_COMPARATOR|3|Control I (Group C) : Listening 30 min in the morning and 30 min in the evening to unspecific music (Mozart) over 5 weeks.
62792411|NCT06727266||Healthy individuals|Demographic information such as age, height, weight and body mass index (BMI) will be recorded. During the physical examination, shoulder range of motion is measured and recorded. Shoulder pain will be assessed using VAS (Visual Analogue Scale) and SPADI (Shoulder Pain and Disability Index). Imaging of the shoulder joints will be performed using a Mindray DC-8 ultrasound machine according to European Society of Musculoskeletal Radiology (ESSR) protocols.
62216381|NCT04864288||2|age matched thirty men with normal erectile function
62216382|NCT02884310|EXPERIMENTAL|SPI group|"Remifentanil titration before tracheal intubation and skin incision according to the SPI gradient obtained after a nociceptive test using a tetanic stimulus of 100 Hz, 60 milliamperes during 30 seconds performed at a 3 ng/ml level of the remifentanil concentration.~During surgery, the effect site remifentanil concentration was either increased or decreased by 1 ng/ml to maintain SPI below 40 or above 20, respectively."
62021354|NCT03710434|EXPERIMENTAL|Part A - solid oral formulation|Subjects will receive single dose of AZD4635 50mg solid oral formulation, in the fasted state.
62021355|NCT03710434|EXPERIMENTAL|Part B-solid oral formulation with food|Subjects will receive a single dose AZD4635 solid oral formulation after high fat meal.
62021356|NCT03710434|EXPERIMENTAL|Part B - solid oral formulation with PPI|Subjects will receive 30 mg lansoprazole BID and a single dose of AZD4635 solid oral formulation in the fasted state.
62410726|NCT00644527|NO_INTERVENTION|4|Control II (Group D): Waiting list. - Each 50% of the subjects will be assigned randomly to either Group A (arm 1) and B (arm 2) after 5 weeks of waiting time.
62410727|NCT01915485|EXPERIMENTAL|Lu 177|progressive metastatic medullary thyroid cancer
62021357|NCT03710434|EXPERIMENTAL|Part B - dose exploration 1|If dose adjustment is required, subjects will receive a different single dose (XX mg) of AZD4635 solid oral formulation, in the fasted state.
62021358|NCT03710434|EXPERIMENTAL|Part B - dose exploration 2|If dose adjustment is required, subjects will receive a different single dose (YY mg) of AZD4635 solid oral formulation, in the fasted state.
62410728|NCT06653296|PLACEBO_COMPARATOR|Placebo|Placebo
62021359|NCT03710434|EXPERIMENTAL|Part B - variant 1|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state and optional \[14C\] AZD4635 IV microtracer.
62021360|NCT03710434|EXPERIMENTAL|Part B - variant 2|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
62216383|NCT02884310|ACTIVE_COMPARATOR|Control group|"The remifentanil concentration before tracheal intubation and skin incision was fixed at 4 ng/ml.~During surgery, the remifentanil concentration was adapted according to the hemodynamic answer of the patient. It was changed by 1 ng/ml stepwise variations to maintain heart rate and mean blood pressure within 20% of the patient reference hemodynamic values."
62216384|NCT03134794|EXPERIMENTAL|Educational Intervention|"Education intervention using the TLS. The active group will received an educational intervention applying proven concepts in medical education (cognitive reflection/checklist, traffic light system (TLS). Previous research showed that TL food labels prompted individuals to consider their health and to make healthier choices. A color-coded system influences the valuation process in favor of healthier choices by interfering with automatic decisions and triggering the re-evaluation process (Ena, Krajbich et al Judgement and DM 2016).~The TLS is being implemented to facilitate the identification of patients at risk of developing a clinical and radiological progression that could result in escalation of therapy."
62216385|NCT03134794|NO_INTERVENTION|Control|Usual Care. The control group will make therapeutic decisions without being exposed to the educational intervention as part of the current standard practice.
62216386|NCT06416709|PLACEBO_COMPARATOR|placebo control use saline|saline is used as placebo in the placebo comparator group
62216387|NCT06416709|EXPERIMENTAL|mesenchymal stem cells treatment|Mesenchymal stem cell dose is 5×10\*7/10ml and is transplanted by intravenous infusion. The cells are used once every three days and for three times.
62216388|NCT00476970|EXPERIMENTAL|Patient Navigation Intervention|Participants randomized to this arm will receive language-concordant patient navigation in the form of an introductory letter with educational material followed by phone or in-person contact to provide individually tailored interventions.
62410729|NCT06653296|EXPERIMENTAL|ENX-102 low-dose|ENX-102
62410730|NCT06653296|EXPERIMENTAL|ENX-102 mid-dose|ENX-102
62410731|NCT06653296|EXPERIMENTAL|ENX-102 high-dose|ENX-102
62410732|NCT02504060|PLACEBO_COMPARATOR|Starch capsule|During the 12- weeks treatment phase of the study, the daily dose of 3 tablets will be taken 30 minutes after breakfast, lunch and supper.
62410733|NCT02504060|EXPERIMENTAL|N-acetyl-D-glucosamine|During the 12- weeks treatment phase of the study, the daily dose of 100mg\*3 (3 tablets) will be taken 30 minutes after breakfast, lunch and supper.
62410734|NCT05805293|EXPERIMENTAL|High-Velocity Nasal Insufflation|
62410735|NCT05805293|EXPERIMENTAL|Non-Invasive ventilation|
62410736|NCT05100277||Single arm|All patients will have the test
62410737|NCT02418338|EXPERIMENTAL|dmd children|echocardiography
62410738|NCT02418338|OTHER|healthy children|echocardiography
62410739|NCT04962659|EXPERIMENTAL|Mindfulness-Based Music and Songwriting|The Mindfulness-Based Music and Songwriting (MBMS) program involves up to 8 weekly sessions (\~1 hour) delivered via telehealth.
62410740|NCT04962659|NO_INTERVENTION|Business as Usual Control|No treatment control.
62410741|NCT02780817|EXPERIMENTAL|Error enhancement|Arm reaching rehabilitation training with error-augmentation perturbation forces. One session of about 25 minutes of practicing arm reaching movements on 3D robotic device.
62410742|NCT02780817|OTHER|Control group|Arm reaching rehabilitation training without error-augmentation perturbation forces. One session of about 25 minutes of practicing arm reaching movements on 3D robotic device.
62410743|NCT05439135|EXPERIMENTAL|midgut|A soft TET tube is inserted into the colon via the paraffin-lubricated gastroscope channel. If patients cannot tolerate endoscopy or anesthesia, or it is difficult to confirm the bypass intestine under endoscopy, a nasojejunal tube will be inserted under digital fluoroscopy.
62410744|NCT05439135|EXPERIMENTAL|colonic|A soft TET tube is inserted into the colon via the paraffin-lubricated colonoscope channel.
62410745|NCT04649151|EXPERIMENTAL|mRNA-1273|"Part 1A (Blinded Phase): Participants will receive 2 intramuscular (IM) injections of mRNA-1273 (100 microgram \[ug\] each), 28 days apart, on Day 1 and Day 29.~Part 1B (Open-Label Phase): Participants who cross over from placebo in Part 1A to Part 1B will receive 2 IM injections of mRNA-1273 (100 ug each), 28 days apart on Open Label Day 1 and Open Label Day 29.~Part 2 (Open-Label): Participants will receive 2 IM injections of mRNA-1273 (50 ug each), 28 days apart, on Day 1 and Day 29 and may receive a booster dose on Day 149."
62585287|NCT03961061|EXPERIMENTAL|Brenner mFIT (standard care plus mobile health components)|"Adolescents will participate in Brenner Families in Training along with their caregiver.~Brenner mFIT (Families in Training + mobile health) includes all components of the standard Brenner FIT"
62021361|NCT00887172|EXPERIMENTAL|1|Wind-cold syndrome group were patients classified by Chinese Medicine practitioner of Wind-cold syndrome and took treatment of Jing Fang Bai Du san.
62021362|NCT00887172|PLACEBO_COMPARATOR|2|Wind-cold syndrome group were patients classified by Chinese Medicine practitioner of Wind-cold syndrome and took placebo of Jing Fang Bai Du san.
62410746|NCT04649151|PLACEBO_COMPARATOR|Placebo|Part 1A (Blinded Phase): Participants will receive 2 IM injections of mRNA-1273 matching placebo, 28 days apart, on Day 1 and Day 29.
62585288|NCT06395506|NO_INTERVENTION|Age-Matched Control Group|Women who have never been diagnosed with cancer.
62410747|NCT04649151|EXPERIMENTAL|mRNA-1273 BD|"Part 1C-1 (BD Phase): Participants will receive 1 IM injection of mRNA-1273 (50 ug) on BD-Day 1, 5 months after the last dose of Part 1A and 1B.~Part 1C-2 (BD Phase): Participants will receive 1 IM injection of mRNA-1273 (50 ug) on BD-Day 1, at least 3 months post-last dose."
62216389|NCT00476970|NO_INTERVENTION|Usual Care|Participants randomized to this arm will receive no additional navigation beyond the usual care for the duration of the 9-month intervention. Participants will be offered navigation services after the completion of the intervention period.
62216390|NCT05462392|EXPERIMENTAL|the Micro Hand S robot group|68 patients were randomly allocated in the Micro Hand S robot group and partial nephrectomy, radical cystectomy, and radical prostatectomy will be performed using the Micro Hand S robot.
62410748|NCT04649151|EXPERIMENTAL|mRNA-1273.222|Part 3 (Open-Label): Participants will receive up to 2 IM injections of mRNA-1273.222 (50 ug each), 6 months apart, on Day 1 and Day 181.
62410749|NCT02922231||All Study Participants|Participants with congenital hemophilia B (FIX level ≤5%)
62216391|NCT05462392|OTHER|the da Vinci robot group|68 patients were randomly allocated in the da Vinci robot group and partial nephrectomy, radical cystectomy, and radical prostatectomy will be performed using the da Vinci robot.
62410750|NCT03233659||BMT patients|All patients undergoing Allogeneic Stem Cell Transplantation are enrolled in the study.
62410751|NCT05227937||Single Dose Amikacin|Patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients \>120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.
62410752|NCT01233349|EXPERIMENTAL|Litramine|
62410753|NCT01233349|PLACEBO_COMPARATOR|Placebo|
62216392|NCT00914901|OTHER|Healthy|10 healthy men
62410754|NCT06565975||Participants that received maintenance treatment of oral azacitidine|
62410755|NCT05446116|ACTIVE_COMPARATOR|femoral puncture|Under local anaesthesia, the femoral artery was punctured and 6F sheath was inserted. Splenic artery was catheterized using 4- or 5-F catheters (Cobra C2 cat or Simmons II catheter Imager-Boston Scientific Natick, Massachusetts). Embolization was done using Embospheres (Biosphere Medical, Rockland, MA) 700-900 μ in diameter.
62410756|NCT05446116|ACTIVE_COMPARATOR|Radial puncture|The left radial artery was preferred due to shorter distance from the left wrist to the splenic artery in comparison to the right wrist; also the left radial access theoretically decreases the risk of cerebral emboli. Under local anaesthesia and ultrasound guidance, the radial artery was punctured and 5- or 6-F sheath was introduced. After sheath insertion, the radial cocktail (2.5 mg of verapamil, 100 μg of nitroglycerin, and 5,000 units of heparin) was injected through the sheath over one minute after dilution with 20 ml of blood to decrease the discomfort during injection.
62216393|NCT00914901|OTHER|Asthmatics|10 male asthmatic subjects
62216394|NCT00914901|OTHER|Elite athletes with asthma|10 male elite athletes with asthma
62216395|NCT00406055||1|Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
62792412|NCT04728607|EXPERIMENTAL|Participants|Individuals requiring ring removal.
62792413|NCT05595642|EXPERIMENTAL|Astegolimab SC Q2W|Participants will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W)
62216396|NCT02977273|EXPERIMENTAL|Test Meal 1|Thin/100% portion
62792414|NCT05595642|EXPERIMENTAL|Astegolimab SC Q4W|Participants will receive alternating SC astegolimab and placebo Q2W, thus receiving SC astegolimab Q4W.
62021363|NCT00887172|EXPERIMENTAL|3|Wind-heat syndrome group were patients classified by Chinese Medicine practitioner of Wind-heat syndrome and took treatment of Ying Qiao san.
62216397|NCT02977273|EXPERIMENTAL|Test Meal 2|Thin/150% portion
62216398|NCT02977273|EXPERIMENTAL|Test Meal 3|Thick/100% Portion
62216399|NCT02977273|EXPERIMENTAL|Test Meal 4|Thick/150% Portion
62216400|NCT01485146|EXPERIMENTAL|Cohort 1|8 Healthy Subjects in Phase I Unit
62216401|NCT01485146|EXPERIMENTAL|Cohort 2|8 Healthy Subjects in Phase I Unit
62216402|NCT01485146|EXPERIMENTAL|Cohort 3|8 Healthy Subjects in Phase I Unit
62216403|NCT05079451|EXPERIMENTAL|Study Participants|Participants will receive an infusion of both study drugs (3BNC117-LS and 10-1074-LS) and will then discontinue antiretroviral therapy two days later.
62216404|NCT05470192|EXPERIMENTAL|Qigong Exercise Training and Conventional Physiotherapy and Rehabilitation Group|In addition to the conventional physiotherapy and rehabilitation program, qigong exercise training will be given to the qigong exercise training group by a certified physiotherapist who has received qigong training.
62216405|NCT05470192|NO_INTERVENTION|Conventional Physiotherapy and Rehabilitation Group|A training will be given including information about the postoperative recovery process, the purpose of respiratory physiotherapy and rehabilitation, the importance of physiotherapy and rehabilitation in the postoperative period, attention to speed up recovery and prevention of complications, breathing exercises, coughing training, posture exercises, early mobilization and its importance, and answering patient questions. . The program includes progressive ambulation and progressive shoulder and rib cage exercises. These exercises will be performed under the supervision of a physiotherapist from the first postoperative day. The exercises will be advanced every day by increasing the number of repetitions.
62216406|NCT04179942|ACTIVE_COMPARATOR|Patients|full night PSG (polysomnogram) was done, fractional exhaled nitric oxide and Hs-CRP were measured
62792415|NCT05595642|PLACEBO_COMPARATOR|Placebo SC Q2W|Participants will receive SC placebo Q2W
62792416|NCT05522257|OTHER|Advanced soft tissue sarcoma (n=60) and advanced urothelial cell carcinoma (n=60)|The study population comprises sixty adult patients with diagnosis of advanced (locally irresectable or metastasized) soft tissue sarcoma (cohort 1) and sixty adult patients with diagnosis of advanced (muscle invasive or metastasized) urothelial cell carcinoma (cohort 2).
62792417|NCT02602522|EXPERIMENTAL|Experimental|The patients in this arm will be given 1 bag per time of Shandong Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the first menorrhea period. And then in the next menstrual cycle, the patients will in turn be given 1 bag per time of Sichuan Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the second menorrhea period.
62216407|NCT04179942|PLACEBO_COMPARATOR|control|CRP level was measured
62216408|NCT04048850||Patients living with HCV +/- HIV|HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or peginterferon/ribavirin-experienced patients with HCV genotype 1a, without baseline NS5A resistance, 1b, or 4 and substance use treated with elbasvir/grazoprevir 50-100 mg fixed-dose-combination, 1 tablet by mouth daily, for 12 weeks.
62216409|NCT04997980||Amiodarone group|Patients who did receive amiodarone during the attempt of resuscitation
62216410|NCT04997980||NO Amiodarone|Patients who did receive amiodarone during the attempt of resuscitation
62216411|NCT01427595|EXPERIMENTAL|Metformin, progesterone , estrace|12 weeks Metformin oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days (2X) oral estrace, 0.5-1 mg once a day for seven days (2X)
62216412|NCT03031145|ACTIVE_COMPARATOR|Felis Domesticus treated Non-smoker|
62216413|NCT03031145|ACTIVE_COMPARATOR|Felis Domesticus treated E-cigarette smoker|
62216414|NCT03031145|ACTIVE_COMPARATOR|Felis Domesticus treated Cigarette smoker|
62216415|NCT05805228|EXPERIMENTAL|Experimental Group|"The sexual counseling program was applied to the couples in the experimental group in 2 sessions. The Sexual Counseling I session which includes information about sexual life specific to the pregnancy period, was conducted at least one week later the pre-test, with face-to-face interview method in a private room in the pregnancy outpatient clinic. The Sexual Counseling II session, which contains information on sexual life specific to the postpartum period, was conducted online in the third trimester of pregnancy with the video interview method. Counseling sessions consisted of power point presentations (including figures and drawings) and counseling booklet. The counseling booklet prepared by the researcher in accordance with literature consisted of two parts; sexual life during pregnancy and postpartum sexual life. Each session lasted 45 minutes and additional time was allocated for answering the questions."
62021364|NCT00887172|PLACEBO_COMPARATOR|4|Wind-heat syndrome group were patients classified by Chinese Medicine practitioner of Wind-heat syndrome and took placebo of Ying Qiao san.
62410757|NCT06286813|EXPERIMENTAL|Almond oil group|On the first day of neonates' admission to the clinic, their skin condition will be evaluated using the NSCS, and the hydration of skin will be measured using a digital moisture meter with the recommended usage guide. During morning care at 09:00 a.m., almond oil (10 ml) will be applied to their entire body, except for the head. Three hours after the application, at 12:00 a.m., their skin condition will be assessed, and the hydration will be measured and recorded. This application will continue for 5 days.
62410758|NCT06286813|EXPERIMENTAL|Extra Virgin Olive Oil Group|On the first day of neonates' admission to the clinic, their skin condition will be evaluated using the NSCS, and the hydration of skin will be measured using a digital moisture meter with the recommended usage guide. During morning care at 09:00 a.m., extra virgin olive oil(10 ml) will be applied to their entire body, except for the head. Three hours after the application, at 12:00 a.m., their skin condition will be assessed, and the hydration will be measured and recorded. This application will continue for 5 days.
62792418|NCT02602522|ACTIVE_COMPARATOR|controlled|The patients in this arm will be given 1 bag per time of Sichuan Danshen-Jiang-Fu Granule prepared, twice a day for 5 days before menorrhea and the first 2 days in the first menorrhea period. And then in the next menstrual cycle, the patients will in turn be given 1 bag per time of Shandong Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the second menorrhea period.
62021365|NCT01444534|EXPERIMENTAL|use of the diabetes application|
62021366|NCT01444534|ACTIVE_COMPARATOR|Control arm without app (usual care)|
62410759|NCT01924572|NO_INTERVENTION|Immediate cord clamping|provider clamps and cuts the cord within 10 seconds after birth
62021367|NCT04498936|EXPERIMENTAL|Sofosbuvir/Ledipasvir|This group will receive a fixed combination of Sofosbuvir/Ledipasvir (400 mg and 90 mg, orally) once daily for 14 days, plus the standard care treatment regimen (SCT) for COVID-19 patients according to the Egyptian Ministry of Health (MOH) protocol.
62410760|NCT01924572|EXPERIMENTAL|cord clamping at 2 minutes|Provider places infant on maternal abdomen and cuts cord at 2 minutes after birth
62792419|NCT04259125||Acute symptomatic seizures|This is a cohort of 72 participants who will be enrolled into this study from the neonatal intensive care unit (NICU) after being diagnosed with seizures. They will be asked to contribute a blood specimen obtained ideally 48-96 hours (though blood collection allowed 24-120 hours) after seizures are diagnosed, to participate in an optional blood draw at 2-4 months of age, and to complete surveys at 12 \& 24 months of age.
62021368|NCT04498936|EXPERIMENTAL|Nitazoxanide|This group will receive nitazoxanide (500 mg, orally) four times per day for 14 days, plus the standard care treatment regimen (SCT) for COVID-19 patients according to the Egyptian Ministry of Health (MOH) protocol.
62021369|NCT04498936|NO_INTERVENTION|Standard care treatment|This group will receive only the standard care treatment regimen (SCT) for COVID-19 patients according to the Egyptian Ministry of Health (MOH) protocol.
62021370|NCT03807362|EXPERIMENTAL|CC-11050 treatment|200mg CC-11050 will be administered twice daily as a pill taken with food (at breakfast and evening meal) for participants with moderate to severe ENL for 10 days, then up to 28 days (during Step 1) and then up to 1 year (during Step 2).
62021371|NCT00022516|NO_INTERVENTION|No-CM|No further chemotherapy following standard adjuvant chemotherapy.
62216416|NCT05805228|NO_INTERVENTION|Control Group|Only routine antenatal and postnatal care was given to the couples in the control group
62216417|NCT00536536|ACTIVE_COMPARATOR|Hospital|Care of Childhood Obesity Clinic (COCO)
62792420|NCT04259125||Control|This is a cohort of 15 participants who will be enrolled into this study from the neonatal intensive care unit (NICU) after having an EEG for possible seizures, but found to have a normal EEG. They will be asked to contribute a blood specimen obtained ideally 48-96 hours (though blood collection allowed 24-120 hours) after birth.
62792421|NCT05586984||Laparoscopic uterine lateral suspension|Laparoscopic uterine lateral suspension for apical prolapse. Concomitant anterior and posterior colporrhaphy may be performed.
62792422|NCT05586984||Transvaginal sacrospinous fixation|Uterus-preserving transvaginal sacrospinous fixation for apical prolapse. Concomitant anterior and posterior colporrhaphy may be performed.
62792423|NCT05654168||Professional dancers|Professional dancers with and without groin pain
62216418|NCT00536536|ACTIVE_COMPARATOR|Primary Care|Primary care clinics (x2)
62216419|NCT00701532|EXPERIMENTAL|1|active
62216420|NCT00701532|PLACEBO_COMPARATOR|2|Placebo
62243262|NCT05794763|EXPERIMENTAL|Body Project: Virtual Delivery|In the virtual peer-led group intervention held over Zoom, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique and discuss the costs of pursuing the thin-ideal ideal. The intervention is 4 sessions long (1-hr each) and is administered by trained peer facilitators who use an intervention script. Participants will be asked to complete weekly home exercises throughout the course of the intervention.
62410761|NCT01924572|EXPERIMENTAL|cord clamping at 5 minutes|Provider places the infant on maternal abdomen and clamps and cuts cord at 5 minutes
62410762|NCT01924572|EXPERIMENTAL|cord milking|provider milks the cord 5 times from placenta to infant
62410763|NCT06343922|EXPERIMENTAL|oral motor facilitation technique group|Exercise by using OMFT protocol will be given in the order of warming up technique, key point technique and application technique for 30 min a day.
62410764|NCT06343922|OTHER|traditional oral motor exercises group|Traditional exercises of lips, cheeks, tongue and jaws will be provided for 30 min a day and 3 days/week
62410765|NCT01917175||HIV+ patients with an estimated date of seroconversion|It was estimated that 564 individuals, will be enrolled at the Blood Bank Medical Centre, including 364 individuals already followed-up (former PRIMOCI ANRS 1220 cohort started in 1997) and 200 newly enrolled individuals in this study.
62410766|NCT02098434|EXPERIMENTAL|Montreal Imaging Stress Task|Math task to induce stress response
62410767|NCT00310869|EXPERIMENTAL|E|
62410768|NCT00448110|EXPERIMENTAL|A|intravenous diclofenac dosage level 1
62410769|NCT00448110|EXPERIMENTAL|B|intravenous diclofenac dosage level 2
62410770|NCT00448110|ACTIVE_COMPARATOR|C|intravenous ketorolac
62410771|NCT00448110|PLACEBO_COMPARATOR|D|placebo
62410772|NCT06540430|EXPERIMENTAL|App group|The intervention group will use a mobile application where patients input their stoma condition, allowing healthcare professionals to monitor and manage their care.
62410773|NCT06540430|NO_INTERVENTION|Conventional group|The control group consists of patients who received conventional outpatient-based stoma care without using the application service.
62410774|NCT01901393|EXPERIMENTAL|IV ibuprofen|800mg ibuprofen
62410775|NCT01901393|ACTIVE_COMPARATOR|ketorolac|30mg ketorolac
62410776|NCT03281005||Retinitis pigmentosa in Part 1A|Retinitis pigmentosa patients with severe visual impairment
62410777|NCT03281005||Retinitis pigmentosa in Part 1B|Retinitis pigmentosa patients with severe visual impairment
62410778|NCT03281005||Retinitis pigmentosa in Part 2|Retinitis pigmentosa patients with severe visual impairment
62410779|NCT03281005||Healthy volunteers in Part 3|Healthy volunteers
62410780|NCT06282250|OTHER|Psycho-education and Imagery Focused Cognitive Therapy (in addition to Bright Light Therapy)|"Treatment will be personalized in accordance to one of three options:~1. In case of depressive symptoms.~Bright Light Therapy (BLT) will be administered for 30 minutes on five consecutive days (duration: 1-3 weeks).~1 PE session focused on lifestyle and physical activity will take place. 6 sessions of ImCT will take place. This includes in-depth identification of images, constructing a micro-formulation along the lines of regular Cognitive Behavioural Therapy.~2. In case of hyperactivity symptoms.~The same PE and ImCT will be administered. The exception is that in this case, BLT is replaced by wearing blue-light blocking glasses for 1-3 weeks, 1 hour prior to bedtime.~3. In case of at risk mental state, but no clear depressive or hyperactive symptoms.~The same PE and ImCT will be administered. There will be no light intervention."
62792424|NCT05042076|EXPERIMENTAL|BK with VST|Adult patients with BKV infection and nephropathy (BKN) following kidney transplantation.
62410781|NCT01086007||Pain patients|Patients with pain related sexual dysfunction after laparoscopic inguinal hernia repair
62021372|NCT00022516|EXPERIMENTAL|CM-Maintenance|12-month CM-maintenance regimen (C, cyclophosphamide 50 mg/day orally continuously and M, methotrexate 2.5 mg twice/day orally days 1 and 2 of every week for 1 year)
62410782|NCT01086007||Non-pain patients|Patients with no pain related sexual dysfunction after laparoscopic inguinal hernia repair
62410783|NCT02894060|EXPERIMENTAL|blood|blood tests
62021373|NCT00560833|PLACEBO_COMPARATOR|Placebo|Participants receive placebo, encapsulated tablets, orally (PO), once daily (QD) for up to 12 weeks
62021374|NCT00560833|EXPERIMENTAL|Esmirtazapine 2.25 mg|Participants receive esmirtazapine 2.25 mg, encapsulated tablets, PO, QD for up to 12 weeks
62410784|NCT04761523|ACTIVE_COMPARATOR|Reduced fat arm|Daily calorie intake will be composed of 15% fat, 65% carbohydrates, 20% proteins
62410785|NCT04761523|ACTIVE_COMPARATOR|Standard healthy diet arm|Daily calorie intake will be composed of 30% fat, 50% carbohydrates and 20% proteins.
62410786|NCT05773924|OTHER|Trilift system treatment arm|Single arm with Before \& After photos, triLift treatment protocol study design.
62410787|NCT00745459|EXPERIMENTAL|N|20 mL NPO-11
62410788|NCT06467292|EXPERIMENTAL|Speech Motor Learning and Retention Aim 1|Aim 1: Participants will perform learning tasks while receiving altered/unaltered auditory feedback with cTBS applied to the appropriate area of the brain following learning. Retention of learning is assessed 24 hours later.
62792425|NCT06184750|EXPERIMENTAL|Prevention (tamoxifen)|Participants receive tamoxifen 5mg PO QD for 6 months. Participants with aDAR \>= 10% on mammogram at 6 months continue receiving tamoxifen 5mg PO QD for 12 months. Participants with aDAR \< 10% at 6 months are escalated to receive tamoxifen 10mg PO QD for 6 months. Participants with aDAR \>= 10% after 6 months of tamoxifen 10mg continue receiving tamoxifen 10 mg PO QD for 6 months. Participants with aDAR \< 10% after 6 months of tamoxifen 10mg are given the option of continuing tamoxifen 10mg or escalating to receive tamoxifen 20mg PO QD for 6 months. Participants undergo mammography and collection of blood samples at screening and on study. Participants may optionally undergo biopsy at screening and on study.
62792426|NCT06436404|EXPERIMENTAL|Hammock position group|A hammock inside the incubator, developed by researchers to prevent heat loss and support posture, will be used.
62021375|NCT00560833|EXPERIMENTAL|Esmirtazapine 4.5 mg|Participants receive esmirtazapine 4.5 mg, encapsulated tablets, PO, QD for up to 12 weeks
62216421|NCT06331403|EXPERIMENTAL|Mind-Body Sexual Well-Being Group Intervention|"Participants in the mind-body sexual well-being group intervention arm will participate in 6 weekly group sessions, delivered via videoconferencing, following enrollment. Group sessions will include content related to mind-body medicine (e.g., relaxation, mindfulness, self-compassion) applied to sexual well-being as well as educational information related to women's sexual well-being in cancer survivorship.~Before and after completing the group program, participants will also complete brief self-assessment questionnaires to measure topics including satisfaction with sexuality, coping, loneliness, concern about body image, and stigma."
62216422|NCT04701892||Covid-19 infected patients|In this study male and female patients who were previously infected with covid-19 will be included. Patients will only be eligible if they had a positive covid-19 test before inclusion in the study. More specifically, only patients who had a positive COVID-19 test 2 to 8 weeks before study inclusion are eligible.
62216423|NCT01001338|EXPERIMENTAL|RDEA594 200 mg qd|RDEA594 200 mg qd plus allopurinol qd
62216424|NCT01001338|EXPERIMENTAL|RDEA594 200 mg, 400 mg qd|"RDEA594 200 mg then 400 mg qd plus allopurinol qd.~Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after protocol amendment 16 dated 07 October 2015."
62216425|NCT01001338|PLACEBO_COMPARATOR|Matching Placebo|"RDEA594 matching placebo qd plus allopurinol qd, then allopurinol qd alone in open label period.~Patients on allopurinol qd alone were discontinued after protocol amendment 16 dated 07 October 2015."
62216426|NCT01001338|EXPERIMENTAL|RDEA594 600 mg qd|"RDEA594 200 mg then 400 mg then 600 mg plus allopurinol qd~Patients on lesinurad 600 mg had their dose changed to lesinurad 200 mg after protocol amendment 16 dated 07 October 2015."
62216427|NCT01142232|EXPERIMENTAL|Melphalan with lenalidomide|Melphalan will be given on Day -2 and Day -1. Lenalidomide will be given from Day -7 to Day +2.
62410789|NCT06467292|EXPERIMENTAL|Speech Motor Learning and Retention Aim 2|Aim 2: Participants will perform learning tasks combined with shifted auditory feedback. Motor cortical excitability will be measured using single-pulse TMS to elicit motor evoked potentials.
62792427|NCT06436404|EXPERIMENTAL|Kangaroo care group|Kangaroo care will be applied to these preterm infants.
62216428|NCT02029872|ACTIVE_COMPARATOR|Individual plus household|Standard decolonization regimen for individual plus household: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
62216429|NCT02029872|ACTIVE_COMPARATOR|Individual alone|Standard decolonization regimen for the individual alone: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily, plus a 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
62243263|NCT01388296||Morbidly obese patients|BMI 40-50 k/m2
62243264|NCT01388296||Morbidly obese|BMI 50-60 k/m2
62243265|NCT01388296||Morbidly obeses|BMI 60-70 k/m2
62243266|NCT03217188|EXPERIMENTAL|fractionated full dose re-irradiation|
62410790|NCT06467292|EXPERIMENTAL|Speech Motor Learning and Retention Aim 3|Aim 3: Participants will have fMRI with behavioral measures of speech motor learning.
62410791|NCT06652711|EXPERIMENTAL|2-month access and no incentive|Participants have access to the well-being app for two months and receive no incentive for using the app.
62410792|NCT06652711|EXPERIMENTAL|2-month access and lottery incentive|Participants have access to the well-being app for two months, and participate in a lottery for gift cards if they display sufficient engagement.
62410793|NCT06652711|EXPERIMENTAL|2-month access and direct incentive|Participants have access to the well-being app for two months, and receive a direct payment if they display sufficient engagement.
62410794|NCT06652711|EXPERIMENTAL|4-month access and no incentive|Participants have access to the well-being app for four months and receive no incentive for using the app.
62792428|NCT06436404|NO_INTERVENTION|Contol group|The group will not receive any other intervention.
62021376|NCT00560833|EXPERIMENTAL|Esmirtazapine 9 mg|Participants receive esmirtazapine 9 mg, encapsulated tablets, PO, QD for up to 12 weeks
62021377|NCT00560833|EXPERIMENTAL|Esmirtazapine 18 mg|Participants receive esmirtazapine 18 mg, encapsulated tablets, PO, QD for up to 12 weeks
62021378|NCT04081207|EXPERIMENTAL|AAC-LaRc|all participants receive the experimental treatment
62021379|NCT01099319|EXPERIMENTAL|Renalof|
62021380|NCT01099319|PLACEBO_COMPARATOR|Placebo|
62021381|NCT02445079||HIV infected|HIV infected sub-group
62021382|NCT02445079||HIV uninfected|HIV uninfected sub-group, age and gender matched to the HIV-infected group
62216430|NCT04580082|EXPERIMENTAL|Mindfulness lessons|"There are 14 lessons in total, each lasting approximately 20 minutes. Participants will be asked to listen to one lesson per day for 14 consecutive days, but to allow for possible missed days, they will have up to 25 days to complete as many of these 14 lessons as they can. The lessons will be delivered via the internet, and participants can use a variety of devices (e.g. smartphone, desktop computer, laptop computer, tablet) to access them. While the lessons cannot be downloaded, they are available for streaming anytime and anywhere there is an internet connection. Participants are welcome to revisit any lesson they have listened to previously, but are not allowed to skip ahead to other lessons until they have completed all preceding lessons. This is done because the lessons build on one another, which means that skipping lessons makes continued participation difficult. We will be able to track each participant's usage pattern and will analyze differences across users."
62216431|NCT04580082|OTHER|Delayed-start Mindfulness Lessons|"The control group will not receive the intervention until the intervention group has completed lesson listening. During this waiting period, they will receive periodic emails letting them know that their turn to listen to lessons is coming soon.~Once available, the control group will have 25 days to listen to the 14 lessons."
62216432|NCT00509691|EXPERIMENTAL|Single arm study|
62216433|NCT05333692|ACTIVE_COMPARATOR|NEPRO®|
62216434|NCT05333692|EXPERIMENTAL|Fresubin® Protein Energy DRINK|
62216435|NCT04513652|EXPERIMENTAL|AG-920|Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%, Boric Acid, Mannitol, Sodium Acetate Trihydrate, Glacial Acetic Acid, and Edetate Disodium Dihydrate. The product formulation is adjusted to pH 4.5 to 5.0. Each subject randomized to AG-920 will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
62216436|NCT04513652|PLACEBO_COMPARATOR|Placebo|Placebo ophthalmic solution is identical to the active product, with the exception of the active ingredient. Each subject randomized to placebo will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
62216437|NCT05560438|EXPERIMENTAL|Technorehab|Rehabilitation using Tyromotion Amadeo and Armeo Senso
62216438|NCT02286986|OTHER|Cannabidiol|open label administration
62216439|NCT00371683|ACTIVE_COMPARATOR|A1|+ placebo
62216440|NCT00371683|EXPERIMENTAL|A2|+ placebo
62216441|NCT01242735|EXPERIMENTAL|Exercise|12-week moderate-intensity behavioral exercise intervention (AE)
62216442|NCT01242735|ACTIVE_COMPARATOR|Health and Wellness|12-week health and wellness education control (HEC)
62410795|NCT06652711|EXPERIMENTAL|4-month access and lottery incentive|Participants have access to the well-being app for four months, and participate in a lottery for gift cards if they display sufficient engagement.
62410796|NCT06652711|EXPERIMENTAL|4-month access and direct incentive|Participants have access to the well-being app for four months, and receive a direct payment if they display sufficient engagement.
62410797|NCT06652711|NO_INTERVENTION|control|Participants do not have access to the app during the study.
62410798|NCT06243510|ACTIVE_COMPARATOR|Enoxaparin|Participants randomized to receive script for prophylactic dose of enoxaparin. Dosing will be done based on clinical providers (pharmacists) according to usual care. Participants will fill the script themselves.
62410799|NCT06243510|EXPERIMENTAL|Apixaban|Participants randomized to receive script for prophylactic dose of apixaban. Dosing will be done based on clinical providers (pharmacists) according to usual care. Participants will fill the script themselves.
62410800|NCT02189200|ACTIVE_COMPARATOR|Oat bran group|oat bran (40g per day)
62410801|NCT02189200|PLACEBO_COMPARATOR|Placebo group|refined rice flour (40g per day)
62410802|NCT06652009||Radical surgery group|Patients undergo radical nephroureterectomy
62410803|NCT06652009||Radical radiotherapy cohort|Patients undergo radical radiotherapy with stereotactic body radiation therapy (SBRT) or moderately segmented radiotherapy
62410804|NCT02879552||Traditional upper blepharoplasty|Patients with an odd total number of letters in their first name received traditional upper blepharoplasty.
62410805|NCT02879552||Brassiere suture with blepharoplasty|The rest of the patients received orbicularis oculi muscle fixation to periosteum (brassiere sutures)
62216443|NCT02150343|EXPERIMENTAL|HMD-SPIRE Treatment 1|4 x 12 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart
62216444|NCT02150343|EXPERIMENTAL|HDM-SPIRE Treatment 2|4 x 12 nmol HDM-SPIRE 4 weeks apart followed by a second course of 4 x 12 nmol HDM-SPIRE 4 weeks apart
62216445|NCT02150343|EXPERIMENTAL|HDM-SPIRE Treatment 3|4 x 20 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart
62216446|NCT02150343|PLACEBO_COMPARATOR|Placebo|8 x placebo 4 weeks apart
62216447|NCT01831479|EXPERIMENTAL|Rosuvastatin and Olmesartan|A multiple-dose administration of rosuvastatin, a multiple-dose administration of olmesartan, and a multiple-dose administration of rosuvastatin and olmesartan, given orally with a washout period of 8 days between each administrations
62216448|NCT05766085||hypertension|Those patients suffering from arterial hypertension
62410806|NCT03232775|OTHER|Treatment|Treatment: Physical Exam with Visual Pedagogy and Structure
62216449|NCT05766085||no hypertension|Those patients without arterial hypertension
62216450|NCT06543719|EXPERIMENTAL|Younger adults.|Adults aged 18-30 years with no pre-existing health conditions
62216451|NCT06543719|EXPERIMENTAL|Older adults. Adults aged 50-69 with no pre-existing health conditions|Adults aged 50-69 with no pre-existing health conditions
62216452|NCT04670939|EXPERIMENTAL|SPT|
62216453|NCT03502031|ACTIVE_COMPARATOR|RAAS alone|RAAS (Lisinopril, Enalapril, Perindopril, Losartan, and Valsartan taken each day at maximum tolerated dose that will different for each subject)
62410807|NCT03232775|OTHER|Control|Control: Physical Exam without Visual Pedagogy and Structure
62410808|NCT04429633|ACTIVE_COMPARATOR|Conventional Cardiac intervention|Starting candesartan in patients with left ventricular ejection fraction (LVEF) between 45% and 50% by echocardiogram.
62410809|NCT04429633|ACTIVE_COMPARATOR|Early Cardiac intervention|Starting candesartan in patients with decreased myocardial strain below 18% regardless of LVEF by echocardiogram.
62410810|NCT01354015|EXPERIMENTAL|Use of messaging system|Use of DRMS
62410811|NCT01354015|NO_INTERVENTION|Usual Care|Usual Care
62021383|NCT03208387||Children Medulloblastoma Survivors|Participants previously treated for M0 non-disseminated medulloblastoma with cranio-spinal irradiation plus a boost to the posterior fossa
62021384|NCT03208387||Children Astrocytoma Survivors|Participants previously treated for a low grade cerebellar astrocytoma, with surgery only and neither chemotherapy nor cranial irradiation.
62021385|NCT03208387||Age-Matched Healthy Children Controls|
62410812|NCT05041179|ACTIVE_COMPARATOR|7.2 g of actives (3.6 g NAC and 3.6 g glycine) per day split in two doses (arm A)|"* First dose (1.8 g NAC and 1.8 g glycine) consumed in the morning~* Second dose (1.8 g NAC and 1.8 g glycine) taken in the evening"
62216454|NCT03502031|ACTIVE_COMPARATOR|RAAS in Combination with Spironolactone|RAAS (Lisinopril, Enalapril, Perindopril, Losartan, and Valsartan taken each day at maximum tolerated dose that will different for each subject); Spironolactone taken each day at 25mg
62216455|NCT05687526|EXPERIMENTAL|Telitacicept|The dosing of Telitacicept frequency was based on body weight and age.
62216456|NCT06443580|EXPERIMENTAL|group based interoceptive intervention|an 8 week online group intervention where participants will learn skills to improve interoception and connect with their body.
62216457|NCT06443580|NO_INTERVENTION|waitlist|participants will wait until first group have completed intervention before commencing themselves
62216458|NCT00817713|ACTIVE_COMPARATOR|anthelminthic treatment|Albendazol plus fix-dose Praziquantel plus Ivermectin
62410813|NCT05041179|ACTIVE_COMPARATOR|4.8 g of actives (2.4 g NAC and 2.4 g glycine) per day split in two doses (arm B)|"* First dose (1.2 g NAC and 1.2 g glycine, +1.2 g placebo) consumed in the morning~* Second dose (1.2 g NAC and 1.2 g glycine, +1.2 g placebo) taken in the evening"
62216459|NCT00817713|NO_INTERVENTION|HIV care, no anthelminthic treatment|HIV care as per Tanzanian National AIDS Control Program (NACP) guidelines
62410814|NCT05041179|ACTIVE_COMPARATOR|2.4 g of actives (1.2 g NAC and 1.2 g glycine) per day split in two doses (arm C)|"* First dose (0.6 g NAC and 0.6 g glycine, +2.4 g placebo) consumed in the morning~* Second dose (0.6 g NAC and 0.6 g glycine, +2.4 g placebo) taken in the evening"
62585289|NCT06395506|EXPERIMENTAL|Creatine Supplement Group|Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol. Participants will engage in three center-based exercise sessions each week for 12 weeks; each session lasting roughly 1-hour. Participants will be given a fitbit (electronic watch that measures steps or heart rate) as well to track heart rate and monitor activity throughout the study.
62216460|NCT04428827||Surgery|Patients treated with surgery
62216461|NCT04428827||Medications|Patients treated with mineralocorticoid antagonists or potassium sparing diuretics for primary aldosteronism
62216462|NCT06487845|EXPERIMENTAL|Dose step 1|Participants will receive a low dose of BAY3283142 on Day 1 followed by 1 day without dosing and a multiple dose phase for 7 days.
62216463|NCT06487845|EXPERIMENTAL|Dose step 2|Participants will receive a high dose of BAY3283142 on Day 1 followed by 1 day without dosing and a multiple dose phase for 7 days.
62585290|NCT06395506|NO_INTERVENTION|Non-Creatine Supplement Group|Participants will engage in three center-based exercise sessions each week for 12 weeks; each session lasting roughly 1-hour. Participants will be given a Fitbit (electronic watch that measures steps or heart rate) as well to track heart rate and monitor activity throughout the study.
62021386|NCT04266977|EXPERIMENTAL|Treatment Dexamethasone|"The restrictive DEX regimen is applied from referral to the neurosurgical center until discharge. All administered steroids will be stopped immediately after study inclusion.~If one or more of the previously defined failure criteria occurs, patients will be treated with DEX."
62021387|NCT04994366||Intervention Group|The cohort receiving Thank you cards during their stay.
62021388|NCT04994366||Control Group|The cohort not receiving thank you cards during their stay.
62216464|NCT06487845|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo on Day 1 followed by 1 day without dosing and a multiple dose phase for 7 days.
62216465|NCT05641129||Main Cohort|Consecutive adult patients (≥18 years of age) presenting acutely (i.e. unplanned and non-elective presentation to hospital for urgent or emergency reasons) for symptoms of known or unknown colorectal cancer assessed by hospital surgical teams. Patients should be included regardless of operative or non-operative management, and curative or palliative intent.
62216466|NCT01107821|EXPERIMENTAL|Engenex™-pump|Negative Pressure Wound Therapy with the Engenex™-pump and Bio-Dome™ Dressing
62216467|NCT02855697|EXPERIMENTAL|Olaparib +/- cediranib|Patients are administered two courses of maintenance olaparib following chemotherapy. It is possible for patients to take cediranib during the second course of olaparib if recommended as per the protocol.
62216468|NCT02500810|EXPERIMENTAL|monosialoganglioside|patients receive monosialoganglioside.
62021389|NCT04141293|EXPERIMENTAL|Eligible patients|
62216469|NCT02500810|NO_INTERVENTION|control|blank control
62021390|NCT06531759|OTHER|Patients undergoing nasal surgeries requiring bilateral nasal packs.|After performing the required nasal surgery, hydroxylated polyvinyl acetate packs (known as merocele packs) will be applied bilaterally in patients. The merocele on the left side will be injected with 5 ml volume of normal saline, while The merocele pack in the right side will be injected with 5 ml volume of the diluted fentanyl solution (1ml of fentanyl 50mcg diluted in 10 ml of normal saline).
62410815|NCT05041179|PLACEBO_COMPARATOR|Placebo control (7.2 g isomaltulose)(arm D)|"* First dose (3.6 g isomaltulose) consumed in the morning~* Second dose (3.6 g isomaltulose) taken in the evening"
62410816|NCT04611152|EXPERIMENTAL|KSI-301 (Arm A)|Intravitreal injection of KSI-301 (5 mg) once every 4 weeks for 3 monthly doses followed by an individualized dosing regimen (every 8 to 24 weeks) via intravitreal injection from Week 16 to Week 100.
62410817|NCT04611152|ACTIVE_COMPARATOR|Aflibercept (Arm B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 5 monthly doses followed by aflibercept (2 mg) once every 8 weeks via intravitreal injection from Week 24 to 100.
62021391|NCT03074006|EXPERIMENTAL|low dose|
62021392|NCT03074006|EXPERIMENTAL|high dose|
62021393|NCT00984269|NO_INTERVENTION|No Tourniquet|Patients undergoing hand/wrist surgery without the use of a tourniquet.
62021394|NCT00984269|EXPERIMENTAL|Tourniquet|Patients undergoing hand/wrist surgery with the use of a tourniquet.
62021395|NCT00687258|EXPERIMENTAL|1|VitabranE ViE: Vitamin E-bonded polysulfone dialyzer
62021396|NCT00687258|NO_INTERVENTION|2|APS-U (Asahi Polysulfone APS): Polysulfone dialyzer
62021397|NCT05418621|EXPERIMENTAL|Enamel Matrix Derivative application|"At the completion of the subgingival instrumentation, in all sites with PPD\>6 mm, a solution of 24% EDTA, will be first applied with a sterile syringe with a thin blunt tip (25GX1/4). The tip will be inserted in the gingival crevice and run apically on the instrumented root taking particular care in not penetrating the underlying soft tissues. The sites will be then copiously rinsed with both water-spray and by 5 sec passage of ultrasonic instrument's fine tip in the site with no contact to the root surface. After irrigation, a thorough drying of the site will be performed with an air-spray and a section of an orthodontic floss will be placed in all sites and left in the site for 1 minute at least. Thus, once Superfloss is removed in the test group, EMD (Emdogain FL®, Institute Straumann AG, Basel, Switzerland) will be applied with a dedicated syringe until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues."
62021398|NCT05418621|PLACEBO_COMPARATOR|Saline application|"At the completion of the subgingival instrumentation, in all sites with PPD\>5 mm, a solution of 24% EDTA , will be first applied with a sterile syringe with a thin blunt tip (25GX1/4). The tip will be inserted in the gingival crevice and run apically on the instrumented root taking particular care in not penetrating the underlying soft tissues. The sites will be then copiously rinsed with both water-spray and by 5 sec passage of ultrasonic instrument's fine tip in the site with no contact to the root surface. After irrigation, a thorough drying of the site will be performed with an air-spray and a section of an orthodontic floss will be placed in all sites and left in the site for 1 minute at least. Thus, once Superfloss is removed in the control group, a lavage of sterile saline will be applied with a syringe with a thin blunt tip until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues."
62216470|NCT04492800|OTHER|Paxman Scalp Cooling Device|Patients will undergo scalp cooling via the Paxman Scalp Cooling device for the first 3 cycles of treatment. Cooling will consist of precooling (30 minutes); infusion cooling (will vary depending upon the length of time to infuse the chemotherapy) and post infusion cooling (90 minutes).
62216471|NCT03367429|EXPERIMENTAL|Exp 2 & 3 - Arm 1|"If within-subject design is adopted, subjects will receive one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic LGM and one standard BT injection of of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic MGM.~If between-subjects design is adopted, subjects will receive one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic LGM."
62243267|NCT03217188|EXPERIMENTAL|hypofractionated palliative re-irradiation|
62410818|NCT01169194||Affected|Patients with IBD
62410819|NCT01169194||Unaffected|Individuals who do not have IBD
62410820|NCT04450316|ACTIVE_COMPARATOR|Low-dose naltrexone|4.5mg of naltrexone to be taken one hour prior to bedtime nightly for 8 weeks.
62410821|NCT04450316|PLACEBO_COMPARATOR|Placebo|Placebo tablet (sugar-pill) to be taken one hour prior to bedtime nightly for 8 weeks.
62410822|NCT06652516|ACTIVE_COMPARATOR|cTPE|This group performed the first session of plasma exchange by centrifugation and the second session by membrane filtration
62410823|NCT06652516|ACTIVE_COMPARATOR|mTPE|This group performed the first session of plasma exchange by membrane filtration and the second session by centrifugation
62410824|NCT06064110|EXPERIMENTAL|Intervention arm|
62410825|NCT01505543||chronic obstructive pulmonary disease|
62410826|NCT01505543||healthy matched controls|
62410827|NCT04753879|EXPERIMENTAL|Nab-paclitaxel, Gemcitabine , Cisplatin, Irinotecan, Capecitabine|Maintenance of Pembrolizumab and Olaparib
62410828|NCT05103683|EXPERIMENTAL|Monotherapy Dose Finding - Part 1|TORL-1-23
62021399|NCT03397901|EXPERIMENTAL|transverse colostomy|Diverting transverse colostomy were conducted under general or epidural anesthesia in the operating room. The transverse colon was pulled out through one 2\*2cm incision. The omentum was dissected from transverse colon, and a double-cavity stoma of transverse colon was then created.
62021400|NCT02826226||obstructive ventilation disorder|patients with known or suspected obstructive ventilation disorder and clinical indication for bronchodilator testing
62410829|NCT05103683|EXPERIMENTAL|Expansion as Monotherapy - Part 2|TORL-1-23
62021401|NCT01814722||Raltegravir + 2 NRTIs|Raltegravir is an integrase inhibitor. Two Nucleoside Reverse Transcriptase Inhibitor (NRTIs)
62410830|NCT01939834|EXPERIMENTAL|Overnight CLC followed by SAP|Throughout the trial, participants wore a study CGM. Participants spent 5 nights in a supervised outpatient setting using closed-loop control (CLC) system running on DiAs from 23:00 to 07:00. The participants then subsequently had a week at home in which they wore either their personal pump (UVA) or the study pump (Italy) along with a continuous glucose monitor without running in any specialized mathematical equations (sensor-augmented pump therapy or SAP). Four fingersticks completed each day and carbohydrates will be recorded in bolus calculator of their insulin pump prior to each meal.
62410831|NCT01939834|EXPERIMENTAL|SAP followed by Overnight CLC|Throughout the trial, participants wore a study CGM. Participants in this arm spent a week had a week at home in which they wore either their personal pump (UVA) or the study pump (Italy) along with a continuous glucose monitor without running in any specialized mathematical equations (sensor-augmented pump therapy or SAP). They subsequently spent 5 nights in a supervised outpatient setting using closed-loop control (CLC) system running on DiAs from 23:00 to 07:00. Four fingersticks completed each day and carbohydrates will be recorded in bolus calculator of their insulin pump prior to each meal.
62410832|NCT03620201|EXPERIMENTAL|Treatment (M7824)|Participants receive anti-PD-L1/TGFbetaRII fusion protein M7824 IV over 1 hour on days 1 and 15. During days 28-56 participants receive planned neoadjuvant chemotherapy.
62410833|NCT03953157|EXPERIMENTAL|Arm I (dietary intervention)|Patients receive a controlled anti-inflammatory diet over 12 weeks.
62410834|NCT03953157|EXPERIMENTAL|Arm II (exercise intervention)|Patients undergo controlled exercise sessions with a dedicated trainer 3 times a week for up to 1 hour each over 12 weeks.
62792429|NCT06241053|EXPERIMENTAL|Multimodal therapy with McConnell taping|"Multimodal therapy includes core exercises, hip exercises and vastus medialis training.~MacConnell taping will be applied during exercise and then nearly for 18 hours according to patient's comfort."
62410835|NCT03451474|EXPERIMENTAL|Upper extremity nerve transfer surgery|Upper extremity nerve transfer surgery is a surgical procedure where axons from an intact, functioning upper extremity peripheral nerve are moved to a target muscle that demonstrates significant weakness or paralysis as a result of spinal cord injury. After allowing time for recovery from surgery and for nerve growth to occur, the patient undergoes hand/occupational therapy in order to retrain motor skills.
62410836|NCT03998852|EXPERIMENTAL|Molecular imaging|Positron Emission Tomography (PET) molecular imaging of dopaminergic and cholinergic systems using two radiotracers
62410837|NCT03951701|EXPERIMENTAL|observation cohort|Questionnaire to assess the supportive care needs
62410838|NCT00538473|EXPERIMENTAL|FluAS25 (GSK576389A) Group|Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A).
62410839|NCT00538473|ACTIVE_COMPARATOR|Fluarix Group|Subjects received 1 dose of Fluarix™.
62792430|NCT06241053|EXPERIMENTAL|Multimodal therapy without McConnell taping|Multimodal therapy includes core exercises, hip exercises and vastus medialis training.
62792431|NCT05929287|EXPERIMENTAL|Experimental group 1. Tablet-based CT (NeuroAIreh@b)|"Participants in the NeuroAIreh@b group will perform tablet-based CT tasks personalized to their underlying deficits and performance in each iteration.~Biweekly 30-minute sessions until reaching 12 sessions."
62792432|NCT05929287|EXPERIMENTAL|Experimental group 2. Paper-and-pencil CT (Task Generator).|"Participants in the paper and pencil group will perform CT tasks personalized to their cognitive deficits (according to the MoCA) and generated automatically through the Task Generator website (https://neurorehablab.arditi.pt/TaskGenerator/).~Biweekly 30-minute sessions until reaching 12 sessions."
62792433|NCT05929287|NO_INTERVENTION|passive control group (Waiting-list).|Participants in this group will not be enrolled in any intervention during the course of the study. At the end of the study, participants can integrate a CT intervention of their choice (e.g., CT through the NeuroAIreh@b platform or the TG).
62792434|NCT01049529|PLACEBO_COMPARATOR|Placebo group|This group is receiving sunflower oil (the excipient for DHA)
62792435|NCT01049529|ACTIVE_COMPARATOR|DHA group|This group is receiving the docosahexaenoic acid (DHA) supplement
62792436|NCT03025984|ACTIVE_COMPARATOR|Texting|"Patients in the Texting group will receive reminders based on their individual disease treatment. A text message shall be sent one day (12 to 36 hours) before appointments to remind about the appointment and with instructions to bring glucose and food records to the appointment. If medication changes are made at the appointment, the patient will receive a text message reminder the day after her appointment to reinforce the regimen. Postpartum patients who had GDM will receive a text message reminder to complete their glucose tolerance test. A reminder will be sent at 2 weeks postpartum followed by a reminder at 6 weeks and 10 weeks postpartum if the testing is not completed."
62021402|NCT01814722||NNRTI + 2 NRTIs|Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) could include: delavirdine, efavirenz, etravirine, rilpivirine, nevirapine; and two NRTIs.
62021403|NCT01814722||PI + 2 NRTIs|Protease inhibitors (PI) could include: nelfinavir, lopinavir, saquinavir, tipranavir, atazanavir and darunavir; and two NRTIs.
62021404|NCT06429306|EXPERIMENTAL|Dexamethasone intraocular injection|Dexamethasone implant single injection in the treatment eye after cataract surgery.
62021405|NCT06429306|PLACEBO_COMPARATOR|Placebo|Blank placebo single injection in the treatment eye after cataract surgery.
62216472|NCT03367429|EXPERIMENTAL|Exp 2 & 3 - Arm 2|"If within-subject study design is adopted, subjects will receive one standard BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic LGM and one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic MGM.~If between-subjects design is adopted, subjects will receive one standard BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic LGM."
62216473|NCT06460584|EXPERIMENTAL|Pursed Lip Breathing|For the use of PLB exercise, the intervention will be given every day till the patient discharged from hospital. Patient will perform 5 sets. In each set, 10 times will be included
62216474|NCT06460584|ACTIVE_COMPARATOR|Incentive Spirometer|The intervention will be given every day till the patient discharged from hospital. Patient will perform 5 sets, in each set, 10 times will be included and hold for 3 seconds but not more than 5 seconds. Reading will be taken on every 4rth POD and comparison will be done with 1st POD reading and so on.
62216475|NCT05356299|EXPERIMENTAL|MagneticTape group|The Magnetic Tape bandage will be placed by the patient's care team and will be placed in the anterior superior part of each hemithorax, matching the large vessels and lymph nodes, in the posterior part of the thorax in the paravertebral area from C3 to T9 and in the subcostal region, following the direct innervation of the thorax and shoulder girdle, as well as the dorsal levels with lateral horns that control the vascularisation of the thorax and shoulder girdle.
62216476|NCT03918499|EXPERIMENTAL|Treatment (pembrolizumab, cyclophosphamide, and IRX-2)|Participants receive pembrolizumab IV over 30 minutes on day 1. Participants also receive cyclophosphamide IV on day 1 and IRX-2 SC for 10 days starting on day 4 during cycles 1, 5, 9, 13, 17, 21, 25, 29, and 33. Treatment repeats every 3 weeks for up to 35 cycles in the absence of disease or unacceptable toxicity.
62216477|NCT05920460|EXPERIMENTAL|Experimental Group|The Cognitive Behavioral Therapy group received seven weekly face-to-face sleep group Cognitive Behavioral Therapy sessions lasting for 50-60 min. The Cognitive Behavioral Therapy program was developed by the research team after reviewing the literature and consulting with experts. Cognitive Behavioral Therapy was held in a lecture hall located in the PPFK branch office before individual counseling was initiated.
62216478|NCT05920460|NO_INTERVENTION|Control Group|The study participants of the control arm were interviewed separately and were given general health advice.
62216479|NCT06298240|EXPERIMENTAL|Consensuated nurse intervencion group|Application of a consensual nursing guide with 5 reasons for health consultation where an autonomous role can be applied. Users who come to the emergency center during the first fifteen days of each month are assigned to the experimental group until the necessary sample of 156 subjects is reached.
62216480|NCT06298240|NO_INTERVENTION|Usual medical visit group|Users who come to the emergency center in the second fortnight of each month are assigned to the non-intervention (control) group where the usual medical visit is applied until the required sample of 156 subjects is reached.
62216481|NCT06572098|ACTIVE_COMPARATOR|working group|Patients will receive ten sessions of complex decongestive therapy. Patients will be evaluated for oxidative stress and antioxidant levels in three stages: before treatment, immediately after treatment and one month after the end of treatment.
62216482|NCT06572098|NO_INTERVENTION|control group|As an evaluation parameter, a healthy female control group will be formed at least as many as the number of patients with lymphedema included in the study.
62216483|NCT01967589|EXPERIMENTAL|DC (dosing condition)|Escalation design.
62216484|NCT01967589|EXPERIMENTAL|Oral A|Escalation design. Planned end-dose is 5 mg.
62216485|NCT01967589|EXPERIMENTAL|Oral B|Escalation design. Planned end-dose is 10 mg.
62216486|NCT01967589|EXPERIMENTAL|Oral C|Escalation design. Planned end-dose is 20 mg.
62216487|NCT02926898|EXPERIMENTAL|Cohort 2: ZX008 0.5 mg/kg/day|ZX008 0.5 mg/kg/day (maximum 20 mg/day) dose supplied as an oral solution administered twice a day (BID) in equally divided doses with food.
62216488|NCT02926898|PLACEBO_COMPARATOR|Cohort 2: Matching Placebo|Matching placebo administered twice a day (BID) in equally divided doses with food.
62216489|NCT06039631|EXPERIMENTAL|Organ preservation surgery|In the surgical group, patients will undergo curative surgery for laryngeal/hypopharyngeal cancer along with cervical lymph node dissection. Organ preservation surgery is recommended, and the specific surgical approach will be chosen based on individual case characteristics and the treatment protocols followed at our center. Depending on postoperative pathology results, adjuvant radiotherapy or concurrent radiochemotherapy may be administered as deemed necessary. If postoperative pathology indicates extracapsular invasion of lymph nodes or positive surgical margins, concurrent radiochemotherapy based on cisplatin is recommended. Starting three weeks after the completion of radiotherapy, patients will receive adjuvant immunotherapy using a specific protocol of toripalimab at a dose of 240 mg every 3 weeks for a total of 8 cycles.
62216490|NCT06039631|OTHER|Concurrent chemoradiation|In the concurrent radiochemotherapy group, patients will undergo target delineation based on the scope before induction chemotherapy. Radiotherapy will be administered at a total dose of 70 Gy over 35 fractions, and concurrent chemotherapy will involve weekly administration of cisplatin. Starting three weeks after the completion of radiotherapy, patients will receive adjuvant immunotherapy using a specific protocol of toripalimab at a dose of 240 mg every 3 weeks for a total of 8 cycles.
62216491|NCT01038622|ACTIVE_COMPARATOR|L-arginine|5-day L-arginine treatment (200 mg/kg)
62216492|NCT01038622|PLACEBO_COMPARATOR|placebo|5-day placebo treatment
62792437|NCT03025984|NO_INTERVENTION|No texting|Patients in the contact control group will be enrolled in the text4baby program with assistance from a healthcare provider. As the study will conclude upon the patient's postpartum visit, she will be offered the option of discontinuing messages, which otherwise would continue through the infant's first year of life.
62792438|NCT05163652|EXPERIMENTAL|3 months after two doses|group 1：the third does was given 3 months after two doses CoronaVac group 2：the third does was given 3 months after two doses BBIBP-CorV group 3：the third does was given 3 months after one does CoronaVac and one does BBIBP-CorV
62216493|NCT04621513|EXPERIMENTAL|Collaborative Care Model of TCM and WM|Traditional Chinese Medicine(TCM):laser acupuncture and massage education. Western Medicine (WM):intra-nasal corticosteroid with singulair
62216494|NCT04621513|ACTIVE_COMPARATOR|Western medicine|Western Medicine (WM):intra-nasal corticosteroid with singulair
62216495|NCT03222102|EXPERIMENTAL|Phasix mesh|Phasix mesh will be affixed to the exposed fascia after closure of the Abdomen in the course of liver transplantation.
62216496|NCT03222102|NO_INTERVENTION|Standard surgery|Surgery will be performed according to routine, without the use of Phasix mesh.
62021406|NCT01557946|EXPERIMENTAL|Major Depression|Participants with major depressive disorder received citalopram 20-40 mg daily for 6 weeks. MRI scans were acquired at baseline and days 3, 7, and 42.
62216497|NCT03111511|EXPERIMENTAL|Drospirenone/Ethinylestradiol + Midazolam + JNJ-56136379|Participants will receive single dose of drospirenone/ethinylestradiol 3 milligram (mg)/0.02 mg (oral contraceptive \[OC\]) and single dose of midazolam 2 mg under fasted conditions on Day 1. JNJ-56136379 250 mg twice daily will be administered on Days 6, 7 and JNJ-56136379 170 mg once daily on Days 8 to 25 under fed conditions, except on Day 21 on which Single dose of JNJ-56136379 170 mg + single dose of OC and single dose of midazolam 2 mg will be administered on fasted state. A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg and midazolam 2 mg on Day 21 under fasted conditions.
62216498|NCT06574048|EXPERIMENTAL|Hyperbaric Oxygen Therapy with Dexamethasone|Participants will be treated with hyperbaric oxygen (HBO) therapy within three days of acute carbon monoxide poisoning. Treatment is a minimum of three inpatient sessions. Participants will also receive 10 mg dexamethasone per day while receiving HBO therapy (minimum of two doses, maximum of five doses if participants' stay is longer than three days). After three treatment sessions, participants will discharge home, barring no other medical complications requiring further hospitalization. In addition, continued HBO therapy plus steroids will be offered if participants are still dealing with CO poisoning sequelae as determined by study outcome measures.
62021407|NCT01557946|NO_INTERVENTION|Healthy Volunteers|Healthy volunteer participants did not receive citalopram and performed one MRI scan.
62021408|NCT04842695|ACTIVE_COMPARATOR|kegel´s exercise (pelvic floor exercise)|A midwife/nurse works with the women according to the following protocol: 1.-identify anal sphincter, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2.- identify elevator ani muscle and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting, bent forward, elbows on knees; 3.- contract elevator ani muscle with a position of sitting, lying, and standing; 4.- contract anal sphincter with a position of sitting, lying, and standing. The sessions are conducted by the same midwife/nurse to women in both groups/arms to be performed by the women at home. .
62021409|NCT04842695|EXPERIMENTAL|Electroacupuncture group|"Acupuncture point called bilateral R7 receive acupuncture with 0.25\*40 mm needle with a perpendicular puncture 1.5 cun. The electrical stimulator is applied to bilateral R7, with dilatation wave 50 Hz and direct electric current of 1 milliamperes.. Each session lasts 30 minutes per day. Participants are treated 1 time per week for 12 weeks, total 12 sessions for each patient.~Equipment:~* Electroacupuncture device.~* device made in China"
62021410|NCT03328897|EXPERIMENTAL|Omalizumab 300mg|patients received a dose of omalizumab 300 mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
62216499|NCT06574048|PLACEBO_COMPARATOR|Hyperbaric Oxygen Therapy with Placebo (Saline)|Participants will be treated with hyperbaric oxygen (HBO) therapy within three days of acute carbon monoxide poisoning. Treatment is a minimum of three inpatient sessions. Participants will also a saline placebo instead of dexamethasone while receiving HBO therapy. After three treatment sessions, participants will discharge home, barring no other medical complications requiring further hospitalization. In addition, continued HBO therapy plus steroids will be offered if participants are still dealing with CO poisoning sequelae as determined by study outcome measures.
62216500|NCT02138708|EXPERIMENTAL|Shunt closed|patients with heart disease and shunt who, following hemodynamic exploration, will be selected for closure of their shunt
62585291|NCT02669836|EXPERIMENTAL|Posterior fossa decompression surgery|The bone is surgically removed from the suboccipital region of the skull and Cervical 1 lamina so the constricting epidural band can be resected
62792439|NCT05163652|EXPERIMENTAL|4 months after two doses|group 1：the third does was given 4 months after two doses CoronaVac group 2：the third does was given 4 months after two doses BBIBP-CorV group 3：the third does was given 4 months after one does CoronaVac and one does BBIBP-CorV
62792440|NCT05163652|EXPERIMENTAL|5 months after two doses|group 1：the third does was given 5 months after two doses CoronaVac group 2：the third does was given 5 months after two doses BBIBP-CorV group 3：the third does was given 5 months after one does CoronaVac and one does BBIBP-CorV
62792441|NCT05163652|EXPERIMENTAL|6 months after two doses|group 1：the third does was given 6 months after two doses CoronaVac group 2：the third does was given 6 months after two doses BBIBP-CorV group 3：the third does was given 6 months after one does CoronaVac and one does BBIBP-CorV
62410840|NCT00663039|EXPERIMENTAL|Oxytocin, then Placebo|Participants first received 24IU of Oxytocin administered intranasally with 6 total sprays (three in each nostril) on the morning and at midday of one study visit. Then, after at least month the participants returned for a second study day and received placebo.
62021411|NCT03328897|EXPERIMENTAL|Omalizumab 150mg|patients received a dose of omalizumab 150 mg which consisted of one injection of omalizumab 150 mg vial and one injection of placebo 150 mg vial every 4 weeks (Day 1, Week 4 and Week 8)
62792442|NCT03549104|EXPERIMENTAL|Fear Reduction Efficacy Evaluation (FREE)|The FREE intervention group will participate in eight weekly individual one-hour sessions using CBT and exposure treatment for specific fears.
62792443|NCT03549104|ACTIVE_COMPARATOR|Attention Control|The attention control group will participate in eight weekly individual one-hour Diabetes Self-Management Education (DSME) sessions.
62792444|NCT03124576||control group|Without history of atrial fibrillation/without newly developed atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder
62792445|NCT03124576||group B|Patients without history of atrial fibrillation, with new onset atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder
62792446|NCT03124576||group C|Patients with self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring
62792447|NCT03124576||group D|Patients with non-self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring
62021412|NCT03328897|PLACEBO_COMPARATOR|Placebo|patients received placebo which consisted of two injections of placebo 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
62021413|NCT03789539|ACTIVE_COMPARATOR|LD Universal Influenza Vaccine Uniflu|low dose of Uniflu vaccine 0.5 ml (20 mkg of recombinant protein HBc-4M2eh) administrated intramuscularly 2 times at 21 days intervals
62021414|NCT03789539|ACTIVE_COMPARATOR|HD Universal Influenza Vaccine Uniflu|high dose of Uniflu vaccine 0.5 ml (40 mkg of recombinant protein HBc-4M2eh) administrated intramuscularly 2 times at 21 days intervals
62021415|NCT03789539|PLACEBO_COMPARATOR|Placebo|saline 0.5 ml
62021416|NCT06054646|ACTIVE_COMPARATOR|Amnion Collagen|The right side of the split-face was treated by micro-injection of Amnion Collagen
62021417|NCT06054646|ACTIVE_COMPARATOR|PRP|The left side of the split-face was treated by micro-injection of Platelet-rich plasma (PRP)
62021418|NCT02212223|EXPERIMENTAL|Group 1: Somali immigrant group, 10 µg (400 IU) vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 10 µg (400 IU) vitamin D3 to take for 6 months
62021419|NCT02212223|EXPERIMENTAL|Group 2: Somali immigrant group, 20 µg (800 IU) vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 20 µg (800 IU) vitamin D3 to take for 6 months
62021420|NCT02212223|PLACEBO_COMPARATOR|Group 3: Somali immigrant group, 0 µg vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 0 µg (0 IU) vitamin D3 to take for 6 months
62021421|NCT02212223|EXPERIMENTAL|Group 4: Original Finnish group, 10 µg (400 IU) vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 10 µg (400 IU) vitamin D3 to take for 6 months.
62216501|NCT02774421|EXPERIMENTAL|IT trastuzumab after subQ GM-CSF|Patients with localized recurrent PFEPN will be treated with IT trastuzumab following 5-day course of subQ GM-CSF. Surgical resection should be planned (based on institutional surgical scheduling standards) for ideally 2-7 days after IT trastuzumab dosage.
62216502|NCT02774421|EXPERIMENTAL|IT trastuzumab in combination with subQ GM-CSF|Patients with localized recurrent PFEPN will be treated with IT trastuzumab in combination with GM-CSF to establish a maximum tolerated dosage. GM-CSF will be administered at 250 mcg/m2/dose subQ daily for three (3) days prior to the IT trastuzumab dose.
62216503|NCT03271034|EXPERIMENTAL|Lean women with Lipedema|Body composition, adipose tissue biology, insulin sensitivity assessed before and after low-calorie diet therapy to achieve 5-10% weight loss.
62216504|NCT03271034|EXPERIMENTAL|Women with Obesity and Lipedema|Body composition, adipose tissue biology, insulin sensitivity and immune function/inflammation assessed before and after low-calorie diet therapy to achieve 5-10% weight loss.
62216505|NCT05342064|NO_INTERVENTION|Standard of care|No intervention will be administered. Observational data regarding TPT uptake and adherence will be captured on all participants presenting for care
62216506|NCT05342064|EXPERIMENTAL|TB screening and evaluation followed by TPT via a decentralized delivery system|The intervention phase includes i) enrolling participants who have had TB disease excluded and allowing participant selection of a preferred TPT regimen, and ii) randomizing participants to one of two participant adherence support modalities.
62216507|NCT01153867|EXPERIMENTAL|Schema Focused Therapy|Participants will receive Schema Focused Therapy
62216508|NCT06578637|EXPERIMENTAL|Part A - 10 grams|Study participants will take one 35mL dose of HVMN Ketone-IQ by mouth per day (10 total grams of R-1,3-Butanediol) for 2 weeks
62216509|NCT06578637|EXPERIMENTAL|Part A - 20 grams|Study participants will take two 35mL dose of HVMN Ketone-IQ by mouth per day (20 total grams of R-1,3-Butanediol) for 2 weeks
62216510|NCT06578637|EXPERIMENTAL|Part A - 30 grams|Study participants will take three 35mL dose of HVMN Ketone-IQ by mouth per day (30 total grams of R-1,3-Butanediol) for 2 weeks
62216511|NCT06578637|PLACEBO_COMPARATOR|Part B - Placebo|Study participants will take one 35mL dose of placebo ketone drink by mouth twice daily for 12 weeks
62216512|NCT06578637|EXPERIMENTAL|Part B - 10 grams|Study participants will take one 35mL dose of HVMN Ketone-IQ by mouth per day along with one 35mL dose of placebo ketone drink by mouth per day (10 total grams of R-1,3-Butanediol) for 12 weeks
62216513|NCT06578637|EXPERIMENTAL|Part B - 20 grams|Study participants will take one 35mL dose of HVMN Ketone-IQ by mouth twice per day (20 total grams of R-1,3-Butanediol) for 12 weeks
62410841|NCT00663039|EXPERIMENTAL|Placebo, then Oxytocin|Participants first received a placebo (saline nasal spray) administered intranasally with 6 total sprays (three in each nostril) on the morning and at midday of one study visit. Then, after at least month the participants returned for a second study day and received Oxytocin.
62792448|NCT03600740|EXPERIMENTAL|GPi DBS|Patients selected to undergo GPi DBS placement will be eligible for enrollment in the study. In addition to standard-of-care tests, subjects will undergo an MRI consisting of the proposed novel imaging protocol prior to placement of DBS. The patient will subsequently undergo standard-of-care therapy for DBS placement. Once the stimulator has been programmed post-operatively, the stimulation parameters and corresponding clinical changes will be collected and used to model the volume of activated tissue. The patient will additionally undergo a follow-up MRI used to localize the electrode within the brain to further localize the volume of activated tissue.
62021422|NCT02212223|EXPERIMENTAL|Group 5: Original Finnish group, 20 µg (800 IU) vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 20 µg (800 IU) vitamin D3 to take for 6 months.
62410842|NCT05762796|NO_INTERVENTION|Healthy Controls|Never-concussed age-and gender-matched healthy controls will not receive any intervention. Behavioral and neuroimaging measurements will be administered only once, at the initial visit.
62585292|NCT02669836|EXPERIMENTAL|Dural augmentation surgery|The bone is removed from the suboccipital region of the skull and Cervical 1 lamina so the constricting epidural band can be resected. Then, the dura is opened. Microsurgical dissection is performed and the dura is sewn closed.
62021423|NCT02212223|PLACEBO_COMPARATOR|Group 6: Original Finnish group, 0 µg vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 0 µg (0 IU) vitamin D3 to take for 6 months.
62021424|NCT04541381|NO_INTERVENTION|Control Group|Participants assigned to the control group will receive standard chemotherapy without their doctors receiving any genetic information based on the participants' pharmacogenetic results. DNA (Deoxyribonucleic acid) samples for participants in this group will be stored and tested for genotyping six months later after treatment (or earlier if the participant experiences side effects).
62021425|NCT04541381|EXPERIMENTAL|Pharmacogenomics Group|Participants enrolled in the pharmacogenomics group will give a DNA (deoxyribonucleic acid) sample for immediate pharmacogenomic genotyping. Once the genotyping results are in, cancer doctors caring for each participant will have immediate access to clinical decision support based on the participant's genetic results and can make dosing decisions/changes to the participant's chemotherapy prescription.
62021426|NCT05286918|EXPERIMENTAL|The intervention (CRP-guided) group|"Standard usual care (following GOLD initiative, including bronchodilator, and systemic steroid).~The attending doctor will use the CRP level to inform their decision to continue antibiotics around 3 hours from blood taking. These doctors will be provided pre-study training on CRP interpretation.~Every day from randomization, serum CRP testing will be encouraged to take. Once CRP has declined to \<5mg/dL and the patient has remained afebrile for past 48 hours, antibiotic treatment will be reviewed for discontinuation. Otherwise, antibiotic treatment will be continued. A switch on the administration route, or a change of antibiotics due to adverse effect, allergy, or suggestion from culture result, is permitted according to in-patient physician's decisions. CRP will continue to be monitored daily upon discharge from that hospital (up to 28 days)."
62021427|NCT05286918|NO_INTERVENTION|The usual care (control) group|Patients in the control arm will be treated with usual care (GOLD initiative). No CRP would be measured.No CRP would be measured.
62021428|NCT05201157|ACTIVE_COMPARATOR|Acupressure group|Acupressure will be applied to ST36, LI4 and SP6 points.The Introductory Information Form will be filled in by the researcher and the Visual Similarity Scale for Fatigue will be filled by women once on the post-op 0th day and once on the post-op 2nd day, a total of 2 times.
62021429|NCT05201157|ACTIVE_COMPARATOR|Control Group|No application will be made to this group, and the Introductory Information Form will be filled in by the researcher and the Visual Similarity Scale for Fatigue will be filled in 2 times in total, once on the post-op 0th day and once on the post-op 2nd day.
62021430|NCT01992536|EXPERIMENTAL|Ia: MenABCWY+OMV|Investigational
62021431|NCT01992536|PLACEBO_COMPARATOR|Ib: Placebo|Saline
62021432|NCT01992536|EXPERIMENTAL|IIa: MenABCWY+¼OMV|Investigational
62021433|NCT01992536|PLACEBO_COMPARATOR|IIb: Placebo|Saline
62021434|NCT01992536|EXPERIMENTAL|IIIa: MenABCWY+OMV|Investigational
62021435|NCT01992536|EXPERIMENTAL|IIIb: MenABCWY+¼OMV|Investigational
62021436|NCT01992536|EXPERIMENTAL|IVa: MenABCWY+OMV|Investigational
62021437|NCT01992536|EXPERIMENTAL|IVb: MenABCWY+¼OMV|Investigational
62021438|NCT01992536|PLACEBO_COMPARATOR|IVc: Placebo|Saline
62021439|NCT04181710|EXPERIMENTAL|HEMO2life|HEMO2life® will be used for ex vivo graft preservation at the dose of 1g per liter of preservation solution.
62216514|NCT01278173|OTHER|Sabril|
62216515|NCT03492944||Ultrasound Microbubble Contrast Agent|All subjects will receive intravenous Lumason microbubble contrast agent; there is no comparative ultrasound contrast agent. Contrast Enhanced Ultrasound findings/results will be correlated with comparable, clinically performed, CTE/MRE findings/results
62216516|NCT00672334|PLACEBO_COMPARATOR|2|sodium chloride at 0.5 mmol/kg loading pre-induction and then at 0.2 mmol/kg/hr over 24 hours after induction until the next day
62216517|NCT00672334|EXPERIMENTAL|1|The active intervention is loading (05. mmol/kg) pre-surgery and continuous infusion of bicarbonate at 0.2 mmol/kg/hr for 24 hours after induction
62216518|NCT02362659||Antiplatelet agent plus anticoagulant|an antithrombotic regimen comprising one single antiplatelet agent plus an anticoagulant
62216519|NCT02362659||DAPT alone|an antithrombotic regimen consisting of dual antiplatelet therapy (DAPT) alone
62216520|NCT02362659||DAPT plus anticoagulant|an antithrombotic regimen consisting of DAPT plus anticoagulant therapy
62216521|NCT00488332||OCT + FS + Questionnaire|Optical Coherence Tomography (OCT) + Fluorescence Spectroscopy (FS) and Questionnaire
62216522|NCT02443454||Patients after kidney transplantation|Short and Long-term results containing first 10 years after KTx.
62216523|NCT02443454||Healthy subjects|Medical staff: medical doctors, nurses
62216524|NCT02062593|ACTIVE_COMPARATOR|Coronary angioplasty and optimum medical therapy|Percutaneous coronary intervention and optimal medical therapy
62216525|NCT02062593|PLACEBO_COMPARATOR|Sham procedure and optimum medical therapy|Placebo percutaneous coronary intervention and optimal medical therapy with risk factor modification and anti-anginal therapy
62216526|NCT04072068|EXPERIMENTAL|Edoxaban|edoxaban 60 mg daily
62410843|NCT05762796|EXPERIMENTAL|tDCS in Youth with mild traumatic brain injury|"Behavioral as well as neuroimaging measurements will be administered at the final post-anodal transcranial direct current stimulation (tDCS), final post-sham tDCS, and at 30-day follow-up visits.~tDCS will be administered after the initial behavioral and neuroimaging testing. Ten sessions of 1.5 mA real tDCS and 10 sessions of sham tDCS will be administered using Neurocom (Germany) DC stimulator and two 5x7 electrodes, moistened in saline solution, to 10 participants with mTBI following a cross-over design with a 2-week washout period. The location of the brain regions will be determined using either the Transcranial Magnetic Stimulation Neuronavigation or Brainsight Neuronavigation system. The anode will be placed over pre-determined brain regions, whereas the cathode will be placed either over Fp2 (contralateral supraorbital) or other suitable reference areas."
62410844|NCT06652568|OTHER|Comparison Arm|This arm of patients will undergo an ultrasound scan using the ThinkSono system and a comparison standard of care duplex ultrasound scan.
62410845|NCT04905238|ACTIVE_COMPARATOR|Continuous positive airway pressure|Diet and general life style recommendations plus continuous positive airway pressure (CPAP).
62410846|NCT04905238|NO_INTERVENTION|Conservative treatment|Diet and general life style recommendations.
62410847|NCT02902107|EXPERIMENTAL|surgical resection and intraoperative radiation therapy (IORT)|Brachytherapy will be administered using the CivaSheet, a novel permanent LDR palladium-103 (Pd-103) planar brachytherapy device that is applied directly to the surgical resection bed.
62585293|NCT04124341|EXPERIMENTAL|Prefrontal Cortical Stimulation (PCS)|Stereotactically implanted bilateral PCS
62585294|NCT06458582|EXPERIMENTAL|High-flow-nasal-cannula|In this study, very preterm infants receive High-Flow Nasal Cannula therapy immediately after birth. The intervention includes placental transfusion, followed by administering High-Flow Nasal Cannula at a flow rate of 8 l/min along with intermittent tactile stimulation. Criteria for switching to Continuous Positive Airway Pressure or Positive Pressure Ventilation are established for cases of persistent bradycardia or low SpO2.
62585295|NCT01339637||Diabetes risk factors|Very dark skin subjects with with diabetes risk factors
62585296|NCT06610578||Participants with or without intracranial atherosclerosis|
62216527|NCT03871673|ACTIVE_COMPARATOR|Cornstarch|Ingestion of cornstarch, the standard treatment for hepatic Glycogen Storage Diseases.
62585297|NCT03835624||juvenile idiopathic arthritis|about 60 cases of children with juvenile idiopathic arthritis diagnosed according to ILAR classification criteria of juvenile idiopathic arthritis will be recruited from pediatric rheumatology clinic of Benha university hospital serum interleukin 33 and its relative expression in peripheral blood mononuclear cells (PBMNCs) will be measured in their blood samples also IL-33 will be measured in synovial fluid samples
62216528|NCT03871673|EXPERIMENTAL|Sweet manioc starch|Ingestion of sweet manioc starch, the starch in study.
62585298|NCT03835624||control group|"about 60 apparently healthy children with comparable age and sex to the patients.~serum interleukin 33 and its relative expression in PBMNCs will be measured in their bloodsamples."
62585299|NCT05621746||Participants with Haemophilia A|Participants will be treated with commercially available Esperoct for a total study duration of 24 months according to the local label and local routine clinical practice at the discretion of the physician. The decision to switch to Esperoct will be made prior to and separate from the decision to enrol in the study.
62585300|NCT02261948|ACTIVE_COMPARATOR|Levosimendan|Levosimendan must be diluted before the administration (500 ml of glucose). The intravenous infusion may be administered either by the peripheral or central. The dose and duration of therapy should be decided according to the patient's clinical condition and response to the drug. Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min. A low infusion bolus (6 mcg / kg) is recommended for patients who have a concomitant intravenous treatment with vasodilators or inotropic. The patient's response should be evaluated during the infusion bolus or within 30 to 60 minutes and a dose adjustment based on clinical response.
62792449|NCT03468361|PLACEBO_COMPARATOR|Control Group|Patients in control group will be allowed to continue their conventional medications and with a placebo.
62792450|NCT03468361|EXPERIMENTAL|Intervention Group|Patients in intervention group who would be taking their usual medications along with parsley in a convenient dosage form.
62792451|NCT03694717||Patients|The patients will receive a 500 ml fluid expansion over a standardized 10 minutes period
62021440|NCT04181710|OTHER|Control|Organ preserved in preservation solution routinely used according to the local practice
62216529|NCT01638351|ACTIVE_COMPARATOR|Usual care|Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
62216530|NCT01638351|EXPERIMENTAL|Resistance exercise|Progressive resistance training, 3 times a week for 12 weeks
62792452|NCT06421584|NO_INTERVENTION|Control group|The residents randomized to the control arm will receive traditional intra operative guidance by the mentor holding the laparoscopic camera during the procedure.
62216531|NCT04245228|NO_INTERVENTION|Usual Care Group|Routine caregiver transplant education
62216532|NCT04245228|EXPERIMENTAL|Wellness Coaching Intervention|Caregivers will be assigned a wellness coach
62216533|NCT04582136|EXPERIMENTAL|Sirolimus plus SOC|Sirolimus plus standard therapy (SOC) for SLE; Generic name: sirolimus (0.5mg capsule); Dosage: 1.5mg/day; Administration route: Oral
62216534|NCT04582136|PLACEBO_COMPARATOR|Placebo plus SOC|Placebo plus standard therapy (SOC) for SLE; Drug: Placebo comparator plus SOC; Administration route: Oral
62021441|NCT01789944|EXPERIMENTAL|Provide Treatment|Peers provide treatment to 2nd generation following receipt of the intervention.
62216535|NCT01533597|ACTIVE_COMPARATOR|Solifenacin|
62216536|NCT01533597|EXPERIMENTAL|Solifenacin plus Tamsulosin|
62216537|NCT06505109|EXPERIMENTAL|Intervention group|The intervention group will receive standard CR along with the RESST intervention, consisting of 5-6 on-site group sessions, focused on sleep and stress, integrating principles from Acceptance and Commitment Therapy and Cognitive Behavioral Therapy.
62792453|NCT06421584|EXPERIMENTAL|Interventional arm|The residents randomized to the intervention arm will receive telementored guidance. This guidance is provided by telecommunication setup allowing the remotely located mentor to see the live footage of the laparoscopic procedure and to verbally communicate with the resident performing the surgical procedure.
62585301|NCT02261948|PLACEBO_COMPARATOR|Placebo|Placebo must be diluted before the administration (500 ml of glucose). The intravenous infusion may' be administered either by the peripheral or central. The dose and duration of therapy should be decided according to the patient's clinical condition and response to the drug. Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min. A low infusion bolus (6 mcg / kg) is recommended for patients who have a concomitant intravenous treatment with vasodilators or inotropic. The patient's response should be evaluated during the infusion bolus or within 30 to 60 minutes and a dose adjustment based on clinical response.
62792454|NCT01219985|EXPERIMENTAL|Investigation arm|"standard and respiratory-gated PET acquisitions  for patients included in the trial."
62216538|NCT06505109|NO_INTERVENTION|Control group|The control group will receive standard CR only. Standard CR programs last around 3-4 months and include two supervised exercise sessions per week. In addition, educational sessions are provided, covering topics such as medical information, cardiovascular risk factors, adopting a heart-healthy lifestyle, and coping with emotions. Depending on the patient's specific needs, counselling sessions on stress management, smoking cessation, and healthy diet are available, and individual counselling can be provided by a social worker, dietician, or psychologist/psychiatrist.
62216539|NCT02540928|EXPERIMENTAL|AMG 319 Hydrate|Up to 36 patients will be randomised into the Active Treatment arm to receive AMG 319 400 mg once daily administered orally for a minimum of 20 days and a maximum of 29 days prior to resection surgery
62216540|NCT02540928|PLACEBO_COMPARATOR|Placebo|Up to 18 patients will be randomised into the Placebo arm to receive Placebo once daily administered orally for a minimum of 20 days and a maximum of 29 days prior to resection surgery
62216541|NCT05578131|EXPERIMENTAL|high flow nasal oxygen|
62216542|NCT05578131|ACTIVE_COMPARATOR|face mask|
62216543|NCT00217308|EXPERIMENTAL|Lactobacillus|
62216544|NCT00217308|PLACEBO_COMPARATOR|Placebo capsules|
62216545|NCT03174587|EXPERIMENTAL|CS20AT04|Test group : CS20AT04 (allogenic bone marrow derived mesenchymal stem cells.)
62216546|NCT05799651|EXPERIMENTAL|Step 1 (Low Dose)|A total of 12 participants will receive three injections, spaced by two weeks, of Glycovax-002 Low Dose or placebo (ratio 3:1).
62216547|NCT05799651|EXPERIMENTAL|Step 2 (Medium Dose)|A total of 12 participants will receive three injections, spaced by two weeks, of Glycovax-002 Medium Dose or placebo (ratio 3:1).
62216548|NCT05799651|EXPERIMENTAL|Step 3 (High Dose)|A total of 12 participants will receive three injections, spaced by two weeks, of Glycovax-002 High Dose or placebo (ratio 3:1).
62216549|NCT04708730|EXPERIMENTAL|DELP|Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) is a non-pharmacological therapy for acute stroke, which is approved by China Food and Drug Administration
62216550|NCT04708730|NO_INTERVENTION|control group|
62216551|NCT02723331|EXPERIMENTAL|Nab-paclitaxel and Gemcitabine for R-PDAC|Nab-paclitaxel and gemcitabine, for R-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.
62216552|NCT02723331|EXPERIMENTAL|Nab-paclitaxel and Gemcitabine for BR-PDAC|Nab-paclitaxel and gemcitabine, for BR-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.
62216553|NCT03695939|EXPERIMENTAL|Experimental Treatment: realSKIN (skin xenotransplant)|In the experimental arm, patients are treated with the investigational drug, realSKIN®, in a side-by-side comparison to the active comparator, thus, each patient serves as their own control. The designated realSKIN® product size will be placed on the burn wound and secured in place via suturing or stapling. The Investigator will assess the wounds and identify the matched pair of burn sites then the treatments will be randomly assigned to the sites.
62216554|NCT03695939|ACTIVE_COMPARATOR|Active Comparator: Human Allograft Skin|"In the active comparator arm, patients are treated with human cadaver allograft, in a side-by-side comparison to the investigational drug, thus, each patient serves as their own control.~The allograft active comparator will be placed adjacently to the investigational drug, in the same anatomical location, on wound sites following debridement and secured via suture or staples. All other treatment aspects were consistent with the standard of care. The Investigator will assess the wounds and identify the matched pair of burn sites then the treatments will be randomly assigned to the sites."
62216555|NCT04645667||Adult patients of allogeneic hematopoietic HCT|Patients who receive their first allogeneic HCT transplant and who receive tacrolimus for aGVHD prophylaxis per standard of care.
62216556|NCT01476098|PLACEBO_COMPARATOR|Arm 1|incremental doses capsaicin
62216557|NCT01476098|ACTIVE_COMPARATOR|Arm 2|incremenrtal doses casaicin
62216558|NCT02631824|ACTIVE_COMPARATOR|Standard treatment|open reduction and internal fixation TFNA
62216559|NCT02631824|EXPERIMENTAL|Augmentation|open reduction and internal fixation TFNA Augmentation (Cement)
62216560|NCT02483026|EXPERIMENTAL|Intensive supplements care pre-surgery|Multi vitamins pills vitamin D
62216561|NCT02483026|OTHER|Standard supplements care pre-surgery|vitamin D (Vitamin D will be given in a reduced doses compared to the intervention group)
62216562|NCT02680990|ACTIVE_COMPARATOR|Exercise Education|Distribution of exercise education materials
62216563|NCT02680990|EXPERIMENTAL|Band Together|A strength-training and walking program with or without an exercise partner throughout neoadjuvant therapy.
62216564|NCT03559231|EXPERIMENTAL|dFTRD|Endoscopic full-thickness resection of the duodenal adenoma with the 'duodenal Full-Thickness resection device' (dFTRD).
62585302|NCT06458036|EXPERIMENTAL|Experimental: Selpercatinib Monotherapy with 131I Therapy|"Patients will receive selpercatinib monotherapy for 6 months at the FDA-approved dose.~Patients will receive 131I therapy after 6 months of selpercatinib. Selpercatinib will be continued for 5 days after RAI therapy and then patients will enter a wait and see period off treatment.~Patients who experience disease progression at any point while on selpercatinib will proceed to 131I therapy and discontinue selpercatinib."
62585303|NCT02228798||Rivaroxaban|Patients currently taking rivaroxaban that have atrial fibrillation and require surgery or a procedure.
62792455|NCT03263572|EXPERIMENTAL|Treatment (blinatumomab, chemotherapy, ponatinib)|Patients receive blinatumomab IV nonstop on days 1-28 of cycles 1-5, and methotrexate and cytarabine intrathecally (by spinal tap) on days 1, 15, and 29 of cycles 1-4. Patients also receive ponatinib PO daily. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62792456|NCT06726876|PLACEBO_COMPARATOR|Control Group|"Treatment: Normal saline rinse.~Protocol:~Follow the same protocol as the intervention group but using normal saline rinses instead of Manuka honey.~Additional Treatment: Patients will receive scaling and root debridement and locally delivered 0.5 ml non-diluted Thyme honey on sites with PPD ≥ 5 mm.~Supplementary Care: Motivation, oral hygiene instructions (proper tooth brushing technique, flossing, interdental brush, mouthwash usage), scaling, polishing, and root debridement with an ultrasonic scaler and Gracey curettes."
62792457|NCT06726876|EXPERIMENTAL|Intervention Group|"Treatment: Manuka honey oral rinse.~Protocol:~Applied as an oral rinse based on the Biswal et al. administration protocol.~Patients will have oral rinses (20 ml of Manuka honey diluted in 100 ml of purified water) 3 times per day.~Patients will be instructed not to swallow the Manuka honey oral rinse.~Additional Treatment: Patients will receive scaling and root debridement and locally delivered 0.5 ml non-diluted Thyme honey on sites with PPD ≥ 5 mm.~Supplementary Care: Motivation, oral hygiene instructions (proper tooth brushing technique, flossing, interdental brush, mouthwash usage), scaling, polishing, and root debridement with an ultrasonic scaler and Gracey curettes."
62021442|NCT01789944|EXPERIMENTAL|Treatment Only|Peers receive treatment and return for a 6-month follow-up
62216565|NCT03559231|ACTIVE_COMPARATOR|EMR|Endoscopic Mucosal Resection (EMR) of the duodenal adenoma (=standard therapy).
62792458|NCT05331599||Currently Depressed Participants|Individuals who are currently depressed and receive treatment through an antidepressant treatment
62021443|NCT04225845|EXPERIMENTAL|Phone therapy|Weekly phone calls by lay trained personnel to deliver problem solving therapy.
62216566|NCT06236659|EXPERIMENTAL|Intervention for middle-aged men: Consumption of hydrolyzed collagen (HC) with resistance exercise|Middle-aged male participants consumed one of three different HC doses (0 grams, 15 grams, or 30 grams) with 4 sets of 10 repetitions of leg press exercise at 10-repetition maximum load in a random order and a seven-day wash-out period interspersed between each trial.
62410848|NCT05936788|EXPERIMENTAL|Active cycle of breathing technique|Group A will receive ACBTs with 1 session a day for total 2 days in a week.
62410849|NCT05936788|EXPERIMENTAL|diaphragmatic breathing|Group B will receive diaphragmatic breathing for 1 session a day for total 2 days in a week.
62585304|NCT02228798||Dabigatran|Patients currently taking dabigatran that have atrial fibrillation and require surgery or a procedure.
62792459|NCT05331599||Remitted Depressed Participants|Individuals who have achieved remission from depression within 4 months
62792460|NCT05331599||Remitted Depressed Elders|Individuals who no lifetime history of depression
62792461|NCT05938075|EXPERIMENTAL|VXC0-100 at Dose level 1|Participants will receive VXCO-100 at Dose Level 1 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 1 on Month 6.
62792462|NCT05938075|EXPERIMENTAL|VXC0-100 at Dose level 2|Participants will receive VXCO-100 at Dose Level 2 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 2 on Month 6.
62792463|NCT05938075|EXPERIMENTAL|VXC0-100 at Dose level 3|Participants will receive VXCO-100 at Dose Level 3 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 3 on Month 6.
62021444|NCT04225845|EXPERIMENTAL|Phone therapy plus cash transfer|Weekly phone calls by lay trained personnel to deliver problem solving therapy. Combined with a one-time cash transfer of Rs.1000.
62021445|NCT04225845|EXPERIMENTAL|Cash transfer|One-time cash transfer of Rs.1000.
62021446|NCT04225845|NO_INTERVENTION|Control|Control group.
62021447|NCT01626235||NSAID only|Subjects have their pain treated post-ED care with NSAID medication alone
62021448|NCT01626235||Opioid only|Subjects have their pain treated post-ED care with opioid medication alone
62216567|NCT06236659|EXPERIMENTAL|Intervention for middle-aged women: Consumption of hydrolyzed collagen (HC) with resistance exercise|The intervention procedure is exactly same as Arm 1 except for the number of visits and doses of HC. Middle-aged female participants were asked to visit the laboratory on the day of highest oestrogen (i.e. ovulation) and provided with 0 g or 30 g HC. Dates for the trials were determined based on self-report of onset of menses and previous menstrual cycle length.
62216568|NCT02104843|EXPERIMENTAL|Arm 1: DCV/ASV/BMS-791325 FDC + BMS-791325 + Rosuvastatin|"Treatment A: Rosuvastatin tablet orally on specified days~Treatment B: Daclatasvir, Asunaprevir and BMS-791325 Fixed dose combination (FDC) + BMS-791325 tablet orally on specified days~Treatment C: Daclatasvir, Asunaprevir and BMS-791325 FDC + BMS-791325 + Rosuvastatin tablet orally on specified days"
62216569|NCT01445301|EXPERIMENTAL|GSK2585823(CLDM 1%-BPO 3% gel) once daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime.
62410850|NCT00529165|EXPERIMENTAL|A|with injection-meal-interval,cross over after 3 month, than without injection-meal-interval for 3 month
62410851|NCT00529165|EXPERIMENTAL|B|without injection-meal-interval,cross over after 3 month, than with injection-meal-interval for 3 month
62410852|NCT01615822|EXPERIMENTAL|OZ439 100mg single dose|OZ439 100mg single dose oral suspension
62410853|NCT01615822|EXPERIMENTAL|OZ439 100mg plus MQ 250mg single doses|Single dose OZ439 100mg oral suspension in combination with single dose MQ 250mg tablet
62410854|NCT01615822|EXPERIMENTAL|OZ439 400mg single dose|OZ439 400mg single dose oral suspension
62585305|NCT02228798||Apixaban|Patients currently taking apixaban that have atrial fibrillation and require surgery or a procedure.
62585306|NCT06683027|EXPERIMENTAL|Treatment Group 1|This group will receive the first round of access to the program.
62021449|NCT01626235||NSAID + Opioid|Subjects have their pain treated post-ED care with NSAID medication and opioid as PRN rescue analgesia
62585307|NCT06683027|ACTIVE_COMPARATOR|Treatment as Usual|This group will be given access to the program 10 weeks after group 1 so that data from each condition can be compared.
62792464|NCT05938075|EXPERIMENTAL|COVID-19 mRNA vaccine|Participants will receive a COVID-19 mRNA vaccine on Day 1 and then a boost with the same COVID-19 mRNA vaccine at Day 21.
62792465|NCT04162522|ACTIVE_COMPARATOR|escitalopram (10-20 mg)|"Participants are given escitalopram for 8 weeks. At week 8, participants will be assessed and classified as responders or non-responders. Responders will continue on escitalopram until the study endpoint (16 weeks)."
62792466|NCT04162522|ACTIVE_COMPARATOR|brexpiprazole (0.5-2 mg)|"At week 8, participants classified as non-responders will be given 8 weeks of brexpiprazole as add-on treatment to escitalopram."
62792467|NCT03744767|EXPERIMENTAL|Single treatment arm|
62792468|NCT06292780|EXPERIMENTAL|Phase 1: Cohort 1: Low Dose|Dose Escalation: Non-Randomized
62792469|NCT06292780|EXPERIMENTAL|Phase 1: Cohort 2: High Dose|Dose Escalation: Non-Randomized
62021450|NCT02376049|ACTIVE_COMPARATOR|Pimecrolimus cream|Pimecrolimus 1% cream once daily for 14 days
62021451|NCT02376049|ACTIVE_COMPARATOR|Betamethasone dipropionate cream|Betamethasone dipropionate 0.05% cream once daily for 14 days
62021452|NCT02376049|ACTIVE_COMPARATOR|Clobetasol propionate cream|Clobetasol propionate 0.05% cream once daily for 14 days
62021453|NCT02376049|PLACEBO_COMPARATOR|Glaxal Base cream vehicle|Glaxal Base cream vehicle once daily for 14 days
62021454|NCT03265028||Intervention|Invited to take the TRACE e-learning.
62021455|NCT03265028||Control|Not (yet) invited to take the TRACE e-learning.
62021456|NCT01774903|EXPERIMENTAL|TTS-fentanyl|
62021457|NCT01076595||Group 1|
62021458|NCT03977844|ACTIVE_COMPARATOR|Technical Assistance|Technical Assistance. At the community program level of randomization, community agencies and their staff will be invited to access weekly webinars and toolkits to improve their abilities to support clients' depression care, disaster preparedness and recovery, financial security, and housing security.
62021459|NCT03977844|EXPERIMENTAL|Community Engagement and Planning|Community Engagement and Planning. At the community program level of randomization, community agencies and their staff will be invited to access weekly webinars and toolkits to improve their abilities to support clients' depression care, disaster preparedness and recovery, financial security, and housing security. In addition, community agencies will be invited to meet with one another to develop novel and investigator supported coalitions using principles of community partnered participatory research that will adapt toolkits and other local assets to seek to enhance community resilience related to threats of disaster risk, financial insecurity, housing insecurity, mental health, or other coalition-determined domains.
62021460|NCT03977844|ACTIVE_COMPARATOR|Community Resources (CR)|Community Resources (CR). At the Individual level of randomization, individuals in the Community Resources (CR) arm will receive access to toolkits and local resources related to depression care, disaster preparedness and recovery, financial security, and housing security.
62021461|NCT03977844|EXPERIMENTAL|Community Resources (CR) + eBT|Community Resources + eBT. At the Individual level of randomization, individuals in the CR+eBT arm will receive access to toolkits and local resources related to depression care, disaster preparedness and recovery, financial security, and housing security, along with an interactive component to support CBT-informed coping with mood and stressors at the individual level.
62216570|NCT01445301|EXPERIMENTAL|GSK2585823(CLDM 1%-BPO 3% gel) twice daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be twice daily in the morning and evening/bedtime.
62021462|NCT00432380|EXPERIMENTAL|PLACEBO-ROTARIX-ROTARIX GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 2 oral doses of Rotarix™ liquid vaccine at Month 1 and Month 2, and a single oral dose of placebo at Day 0. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
62410855|NCT01615822|EXPERIMENTAL|OZ439 400mg plus MQ 750mg single doses|Single dose OZ439 400mg oral suspension in combination with single dose MQ 750mg tablets
62792470|NCT06292780|EXPERIMENTAL|Phase 2: Low Dose|Dose Expansion: Participants will be randomized in a 1:1 ratio
62792471|NCT06292780|EXPERIMENTAL|Phase 2: High Dose|Dose Expansion: Participants will be randomized in a 1:1 ratio
62792472|NCT06727357|EXPERIMENTAL|AZD2014|Selective and potent inhibitor of mTOR kinase
62792473|NCT06727357|EXPERIMENTAL|Selumetinib|selective and potent inhibitor of MEK1/2 kinases
62792474|NCT06727357|EXPERIMENTAL|Olaparib|Inhibitor of the PARP enzyme involved in DNA repair
62792475|NCT06727357|EXPERIMENTAL|Bicalutamide|nonsteroidal antiandrogen
62792476|NCT05565196|EXPERIMENTAL|Birth companion intervention arm|Women who deliver in facilities in the experimental arm will be exposed to a facility-based intervention designed to improve companionship in labor, childbirth, and postpartum periods.
62792477|NCT05565196|NO_INTERVENTION|Standard of care arm|Women who deliver in facilities in the experimental arm will be exposed to the standard of care for labor, delivery, and the postpartum period.
62819326|NCT06318741|ACTIVE_COMPARATOR|hospital exercise group|According to the Cardiopulmonary exercise test (KPET) test in Group 1 (medium intensity continuous exercise group), 50 minutes (5 minutes warm-up, 40 minutes exercise, 5 minutes exercise, 5 minutes warm-up, 40 minutes exercise, 5 minutes) for 8 weeks, 3 days a week, at an exercise intensity of 50-60% of the VO2 max level recorded individually in the patients. Aerobic exercise therapy will be organized to be applied on a treadmill (in the form of a minute cool-down).
62819327|NCT06318741|PLACEBO_COMPARATOR|home exercise group|For the home exercise group, walking for 50 minutes, 3 days a week, with an intensity of 12-13 Rate of perceived exertion (RPE) according to the Modified Borg scale will be recommended for 8 weeks.
62792478|NCT03885024|ACTIVE_COMPARATOR|Retention Video|"Participants the peer-driven retention arm will receive video-based and in-person training from Retention Specialists on how to encourage study retention. Participants will watch a 7 minute video that standardizes retention messages. A brief face-to-face conversation with the Retention Specialist follows the video viewing to answer questions and reinforce video messages. At the end of the training, participants receive information about their recruit(s) who consented to release their information to their recruiters. Peers remind their enrolled study buddy to attend their scheduled follow up assessments. Participants meet with a study Retention Specialist by phone or in person, at 3 and 9 months after enrollment to answer questions about peer retention strategies and remind participants of their peers' contact information and follow-up schedules."
62792479|NCT03885024|NO_INTERVENTION|Standard Retention Strategy|Control arm: At NROI enrollment, all participants provide detailed information to assist with retention and/or contact for future research, and contact information for up to three people who should know how to reach the participant if contact information changes. Participants randomized to receive the standard retention strategy are contacted at the mid-point of each follow-up interval (i.e., at 3-month post enrollment and 9-months post-enrollment) to update locator information and remind them about their follow-up appointment date. Study associates contact the participant using their contact information and, if not successful, will try to reach one of their contacts in the locator form.
62792480|NCT05897229||PC - end-stage disease criteria and high risk of death from the disease prior to COVID-19|"Patients with severe forms of COVID-19 (RT-PCR+) admitted to a high-complexity hospital.~Of these, patients with end-stage disease criteria and high risk of death from the disease prior to COVID-19 were admitted, at clinical criteria, to palliative care unit.~If there are patients who received both types of treatment, this group will also be analyzed."
62792481|NCT05897229||ICU - end-stage disease criteria and high risk of death from the disease prior to COVID-19|"Patients with severe forms of COVID-19 (RT-PCR+) admitted to a high-complexity hospital.~Of these, patients with end-stage disease criteria and high risk of death from the disease prior to COVID-19 were admitted, at clinical criteria, to the ICU.~If there are patients who received both types of treatment, this group will also be analyzed."
62021463|NCT00432380|EXPERIMENTAL|ROTARIX-PLACEBO-ROTARIX GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 2 oral doses of Rotarix™ liquid vaccine at Day 0 and Month 2, and a single oral dose of placebo at Month 1. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
62216571|NCT01445301|ACTIVE_COMPARATOR|CLDM 1% gel twice daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be twice daily in the morning and evening/bedtime.
62585308|NCT03275974|EXPERIMENTAL|Treatment|Patients receive carbon C 11 Glutamine (11C-glutamine) IV and undergo PET imaging over 120 minutes. Beginning 2 hours to 7 days after 11C-glutamine PET, patients receive fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) IV and also undergo PET imaging over 120 minutes. During each of the 11C-Glutamine and 18F-FSPG PET/CT scans, venous blood draws will be performed.
62021464|NCT00432380|PLACEBO_COMPARATOR|PLACEBO GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 3 oral doses of placebo at Day 0, Month 1 and Month 2. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
62021465|NCT04996784||Normal weight|"The patients (n=30) will be stratified into 2 groups based on their body mass Index (BMI).The normal weight group will contain 15 patients with a 18.5 ≤ BMI ≤ 25 kg/m2.~Each group will be divided in two subgroups (female/ male)"
62021466|NCT04996784||Obese|"The patients (n=30) will be stratified into 2 groups based on their body mass Index (BMI). The obese group will contain 15 patients with a BMI ≥ 30 kg/m2.~Each group will be divided in two subgroups (female/ male)"
62021467|NCT03593083|EXPERIMENTAL|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
62021468|NCT03593083|EXPERIMENTAL|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
62021469|NCT02451748|OTHER|DMARD's Responder and Non-Responder|In the first group of subjects, blood samples will be obtained from (50) RA subjects with Disease modifying anti rheumatic drugs (DMARDs) such as methotrexate, plaquenil and/or prednisone that achieve remission (DAS28\<2.6). The subjects that achieve remission (DAS28\<2.6), blood will only be taken once at the subjects routine visit. Subject's that are non-responder to DMARDS will go onto group 2.
62216572|NCT05084469||Episodic Cluster Headache patients|Patients will perform two PET-MRI scans: (1) during cluster period and (2) during pain-free remission period. Scans during cluster periods will aim to acquire data before, during and after crisis. Sumatriptan 6mg will be injected subcutaneously under PET-MRI camera to relieve patient pain.
62021470|NCT02451748|OTHER|DMARD's plus Cimzia (Certolizumab pegol)|"The second group will consist of (150) RA subjects that did not respond to DMARDs. These patients will further receive (DMARDs) such as methotrexate, plaquenil and/or prednisone as well as Cimzia®. In this Arm, blood samples will be collected onset of the study as well as 3 and 6 months after treatment with Cimzia at subject's visit through our collaboration with the aforementioned rheumatologists."
62021471|NCT02736539|EXPERIMENTAL|Active|galacto-oligosaccharides
62021472|NCT02736539|PLACEBO_COMPARATOR|Placebo|Placebo
62021473|NCT02498665|EXPERIMENTAL|Dosing Escalation Cohort|Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously. Dose-escalation will proceed according to the Criteria for Dose Escalation and Criteria for Determination of Dose-Limiting Toxicity (DLT) as indicated below. Dose Level I: 3.5 mg, Dose Level II: 10.5 mg, Dose Level III: 17.5 mg
62792482|NCT05897229||PC & ICU - end-stage disease criteria and high risk of death from the disease prior to COVID-19|"Patients with severe forms of COVID-19 (RT-PCR+) admitted to a high-complexity hospital.~Of these, patients with end-stage disease criteria and high risk of death from the disease prior to COVID-19 were admitted, at clinical criteria, to the ICU and palliative care unit.~If there are patients who received both types of treatment, this group will also be analyzed."
62792483|NCT03127293||Hyperemesis Gravidarum group|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
62585309|NCT06545669|EXPERIMENTAL|C-Raven + CHW Smoking Cessation Intervention|Participants will receive a virtual counselor intervention for smoking cessation, be offered the opportunity to utilize nicotine replacement therapies, participate in shared decision-making around lung cancer screening, and be supported by a community health worker. Participants will be followed for a total of 6 months. Assessments will be conducted at baseline, 1 month, 3 months, and 6 months.
62585310|NCT06545669|NO_INTERVENTION|No Intervention|Participants will not receive any intervention during the first 6 months of the study. The participants will receive the study intervention at the end of 6 months, to ensure access to treatment for all participants.
62585311|NCT05817539|EXPERIMENTAL|Corrective strategy|In the experimental group, all patients will have a UFnet settled (2 ml/kg/h ) in order to reach the patient baseline body weight.
62585312|NCT05817539|OTHER|Stabilizing strategy|In the control group, all patients will have a UFnet 2 ml settled (0 to 1 ml/kg/h) in order to stabilize the patient body weight.
62585313|NCT06263855|EXPERIMENTAL|Intervention|Clinicians who care for patients randomized to intervention will have access to CURE to assist with discharge summary writing.
62585314|NCT06263855|NO_INTERVENTION|Control|Clinicians who care for patients randomized to control will continue with standard practice for discharge summary writing.
62792484|NCT03127293||control group|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
62792485|NCT04702841|EXPERIMENTAL|CAR-γδT|Infusion,iv,0.2-5 ×10\^6/ kg,once.
62792486|NCT01069965|EXPERIMENTAL|6. BGP-15|400 mg BGP-15 + Placebo
62792487|NCT01069965|EXPERIMENTAL|5. BGP-15|200 mg BGP-15 BID
62792488|NCT01069965|EXPERIMENTAL|4. BGP-15|200 mg BGP-15 + Placebo
62792489|NCT01069965|EXPERIMENTAL|3. BGP-15|Two 50 mg BGP-15 capsules by mouth in the morning; and two 50 mg BGP-15 capsules by mouth in the evening
62021474|NCT02498665|EXPERIMENTAL|MDS Cohort 1|Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.
62021475|NCT02498665|EXPERIMENTAL|MDS Cohort 2|Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks.
62021476|NCT05156723|EXPERIMENTAL|Group 1: Subunit recombinant vaccine for the prevention of coronavirus infection|5 volunteers have been vaccinated with a single dose (Stage I)
62021477|NCT05156723|EXPERIMENTAL|Group 2: Subunit recombinant vaccine for the prevention of coronavirus infection|15 volunteers have been vaccinated with a single dose (Stage I)
62021478|NCT05156723|EXPERIMENTAL|Group 3: Subunit recombinant vaccine for the prevention of coronavirus infection|45 volunteers will be vaccinated with the coronavirus vaccine intramuscularly twice (Stage II)
62021479|NCT05156723|EXPERIMENTAL|Group 4: Subunit recombinant vaccine for the prevention of coronavirus infection|45 volunteers have been vaccinated with a single dose of the coronavirus vaccine intramuscularly and then treated with a single dose of placebo (Stage II)
62021480|NCT05156723|PLACEBO_COMPARATOR|Group 5: Placebo|45 volunteers have been vaccinated with placebo intramuscularly twice (Stage II)
62021481|NCT03574129|EXPERIMENTAL|Adolescent transition package|Adolescent transition package
62021482|NCT03574129|NO_INTERVENTION|Standard of care|Standard of care adolescent services
62021483|NCT02334735|EXPERIMENTAL|DC Vaccine|"Study subjects receive KLH and NY-ESO-1 and Melan-A/MART-1 peptide-pulsed DCs:~DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) and KLH will be administered intracutaneous as a single vaccine product followed by a subcutaneous injection of Poly-ICLC (Hiltonol®)."
62410856|NCT01615822|PLACEBO_COMPARATOR|Placebo|Placebo
62585315|NCT01187680|EXPERIMENTAL|Spraygel|
62585316|NCT01187680|ACTIVE_COMPARATOR|Control|
62585317|NCT05974488|EXPERIMENTAL|Distal Pharyngeal Airway|Participants in this group will use the McMurray enhanced airway to have oxygen delivered throughout a TEE procedure for up to 60 minutes.
62585318|NCT05974488|ACTIVE_COMPARATOR|Nasal cannula group|Participant in this group will receive oxygen through a nasal cannula during the TEE procedure for up to 60 minutes.
62585319|NCT05088603|EXPERIMENTAL|Clear Mask|Subjects randomized to this group will have a neurologist who wears a clear mask during their procedure and during their interaction with the subject.
62585320|NCT05088603|NO_INTERVENTION|Standard Mask|Subjects randomized to this group will have a neurologist who wears a standard mask during their procedure and during their interaction with the subject.
62792490|NCT01069965|EXPERIMENTAL|2. BGP-15|100 mg BGP-15 + placebo
62792491|NCT01069965|EXPERIMENTAL|1. Placebo|Placebo BID
62792492|NCT06579963|EXPERIMENTAL|Cool roof|Households will receive sunlight reflecting 'cool roof' coating on their roofs.
62792493|NCT06579963|NO_INTERVENTION|No cool roof|No cool roof application. Households will keep their original roofing for the duration of the trial.
62792494|NCT05721521|EXPERIMENTAL|High intensity|
62792495|NCT05721521|EXPERIMENTAL|Moderate intensity|
62792496|NCT05721521|EXPERIMENTAL|Low intensity|
62792497|NCT05721521|PLACEBO_COMPARATOR|No exercise (control)|
62792498|NCT06456645||Group 1:|Smokers (study group)
62792499|NCT06456645||Group 2:|Non-Smokers (control group)
62792500|NCT06726512|OTHER|2 MBq 18F-FDG|Subjects are intravenously administered with 2.0 MBq/kg 18F-FDG, standard tracer used to diagnose and stage the malignancy. After standard of care excision of the primary tumor, a high-resolution PET-CT imaging of the fresh surgical specimen will be performed.
62792501|NCT02087449||E1-Hip Bearing|E1-Hip Bearing, Evaluate E1 Wear, Clinical Performance of E1 Liner in THA in Korean Patient Population
62792502|NCT04366440|OTHER|Order set review and modification|The antimicrobial stewardship program will review and change order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
62216573|NCT05811962||Intrathoracic sarcoidosis cohort|Patients with intrathoracic sarcoidosis, confirmed according to European Respiratory Society/ World Association of Sarcoidosis and Other Granulomatous disease (ERS/WASOG) criteria
62410857|NCT03361540|EXPERIMENTAL|Single dose of ASP8302 dose-1|Subjects will receive a single dose of ASP8302.
62410858|NCT03361540|EXPERIMENTAL|Single dose of ASP8302 dose-2|Subjects will receive a single dose of ASP8302.
62585321|NCT01783028|EXPERIMENTAL|Community Health Worker support|home visits from community health workers providing education and support for self-management of asthma, assessment of the home for environmental triggers, resources for asthma control, and assistance in effective communication with medical providers
62216574|NCT05811962||Healthy controls|Healthy blood donors
62216575|NCT06118203||Open label Semaglutide|Patients presenting with acute intermediate - high risk PE consenting to participation in drug arm of study
62792503|NCT04366440|OTHER|Order Set review and Modification plus facilitation|The antimicrobial stewardship program will receive facilitation training to aid in reviewing and changing order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
62216576|NCT06118203||Control|Patients presenting with acute intermediate - high risk PE consenting to participation in control arm of study
62216577|NCT01696669|EXPERIMENTAL|Chemotherapy + Surgery + Radiotherapy|"Standard risk patients: MP6 Treatment:~CHEMOTHERAPY: 2 cycles of vincristine-doxorubicin + dexrazoxane-cyclophosphamide, 1 cycle of ifosfamide-etoposide. SURGERY: Ideally within 21 days after chemotherapy.~CHEMOTHERAPY: 1 cycle of vincristine-doxorubicin + dexrazoxane-cyclophosphamide, 1 cycle of ifosfamide-etoposide.~RADIOTHERAPY: On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response \<90%.~High risk patients:~CHEMOTHERAPY: Window phase with 2 cycles of gemcitabine + docetaxel. MP6 TREATMENT. CHEMOTHERAPY: Maintenance therapy for 1 year with gemcitabine + docetaxel."
62216578|NCT00278837|EXPERIMENTAL|Mindfulness based meditation program|Meditation and Breast Cancer: Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress reduction and cognitive-affective-behavioral learning.
62216579|NCT02700347|EXPERIMENTAL|Low dose pyrazinamide|Day 0: Pyrazinamide 10mg/kg, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 10mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
62410859|NCT03361540|EXPERIMENTAL|Single dose of ASP8302 dose-3|Subjects will receive a single dose of ASP8302.
62585322|NCT01783028|NO_INTERVENTION|the usual care control group|Usual care is defined as services received by participants in the absence of the intervention plus information about community resources that support asthma self-management (such as classes and support groups) and educational pamphlets
62792504|NCT04880655|EXPERIMENTAL|Intervention|Dressed with WSD and petrolatum gauze
62792505|NCT04880655|ACTIVE_COMPARATOR|Control|Dressed with bacitracin and petrolatum gauze
62792506|NCT04827888||underweight|patients who underwent one of the 25 common orthopaedic surgeries and have a body mass index (BMI) of \<18.5kg/m2
62021484|NCT02334735|ACTIVE_COMPARATOR|Montanide Vaccine|"Study subjects receive KLH and NY-ESO-1 and Melan-A/MART-1 peptides and Montanide® ISA-51 VG:~Vaccine consisting of NY-ESO-1 peptide, Melan-A/MART-1 peptide, and KLH with an oil phase containing Montanide ISA-51 VG adjuvant will be administered subcutaneously as a single vaccine product followed by a subcutaneous injection of Poly-ICLC (Hiltonol®)."
62021485|NCT01854554|EXPERIMENTAL|Intensity Modulated Proton Radiotherapy (IMPT)|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
62021486|NCT01854554|EXPERIMENTAL|Intensity Modulated Radiotherapy (IMRT)|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
62021487|NCT05522140|EXPERIMENTAL|Intervention arm|"The intervention arm will undergo following steps:~1. Groups of 5-15 persons, who lives in Prague. Two trained facilitators support the group dynamics forstering empowerment.~2. Each participant will undergo an individual session with the facilitator(s) aimed at building relationships and trust, and getting to know the expectations and characteristics of the participants.~3. 9 group activities with the aim to promote accessibility and engagement with the nature and outdoor activities available in their town. Collaborative mapping of nature-based community activities will direct the group to activities they want to approach and test."
62021488|NCT05522140|ACTIVE_COMPARATOR|Control arm|Participants randomly assigned to the control arm will receive usual care, which is a list of community resources in the city (Prague). Usual care is an appropriate comparison rather than placebo for complex interventions
62021489|NCT04321837|ACTIVE_COMPARATOR|Coral calcium complex and ibandronate|
62021490|NCT04321837|ACTIVE_COMPARATOR|Ibandronate and vitamin D|
62021491|NCT04321837|ACTIVE_COMPARATOR|Coral calcium complex|
62410860|NCT03361540|EXPERIMENTAL|Single dose of ASP8302 dose-4|Subjects will receive a single dose of ASP8302.
62410861|NCT03361540|PLACEBO_COMPARATOR|Single dose of Placebo|Subjects will receive a single dose of Placebo.
62216580|NCT02700347|EXPERIMENTAL|Standard dose pyrazinamide|Day 0: Pyrazinamide 25mg/kg single dose, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 25mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
62216581|NCT02700347|EXPERIMENTAL|High dose pyrazinamide|Day 0: Pyrazinamide 35mg/kg single dose, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 35mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
62216582|NCT00926627|PLACEBO_COMPARATOR|Placebo|placebo b.i.d.
62216583|NCT00926627|EXPERIMENTAL|Bosentan|62.5 mg/125 mg bosentan b.i.d.
62410862|NCT03361540|EXPERIMENTAL|Multiple dose of ASP8302 dose-5|Subjects will receive once daily dosing of ASP8302 for 14 consecutive days at the same dose level.
62792507|NCT04827888||normal-weight|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI between 18.5kg/m2 and 24.9kg/m2
62792508|NCT04827888||overweight|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI between 25kg/m2 and 29.9kg/m2
62216584|NCT01603823||Healthy volunteers|
62410863|NCT03361540|EXPERIMENTAL|Multiple dose of ASP8302 dose-6|Subjects will receive once daily dosing of ASP8302 for 14 consecutive days at the same dose level.
62410864|NCT03361540|PLACEBO_COMPARATOR|Multiple dose of Placebo|Subjects will receive once daily dosing of Placebo for 14 consecutive days.
62792509|NCT04827888||mildly obese|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI between 30kg/m2 and 34.9kg/m2
62216585|NCT01603823||St.p. Pars plana vitrectomy|
62216586|NCT04075877|EXPERIMENTAL|FOCUS|"Participants will complete a baseline survey battery and learn about The Hero's Journey. Starting at hospital discharge for 10 days, they will do the following: 1) identify which stage of The Hero's Journey they are experiencing; 2) take a picture of something good and write a caption describing the picture and provide advice; and 3) take a picture of something difficult or challenging during the day and write a caption for the photo and provide advice.~Daily text messages will remind participants to take the photographs, write the advice captions, upload both to the server, as well as to take a very brief daily survey. At the conclusion of day 10, participants will be asked to review their photos and captions and provide final advice in the form of a letter to other adolescents with SCD or cancer. Finally, they will complete a post-intervention battery."
62410865|NCT02658578|ACTIVE_COMPARATOR|Active PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
62410866|NCT02658578|PLACEBO_COMPARATOR|Sham PNS|In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
62410867|NCT06468007||Methylprednisolone treatment group|Patients receiving 4 mg or 16 mg methylprednisolone tablets for any of the following conditions: Pulmonary, Rheumatology and musculoskeletal; Neurology and ophthalmology; Dermatology; Endocrinology and metabolic; Gastrointestinal; Hematology and immunology; Nephrology.
62792510|NCT04827888||moderately-to-severely obese|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI ≥35kg/m2
62216587|NCT04075877|NO_INTERVENTION|Control|"In a 30-min visit (in person or virtual) with adolescents during hospitalizations, we will have participants complete a baseline survey battery.~Daily text messages will remind participants to take a very brief daily survey. At the conclusion of day 10, participants will complete a post-intervention battery."
62216588|NCT04849351|EXPERIMENTAL|Relapsed/Refractory MZL and FL|Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
62216589|NCT01540331|EXPERIMENTAL|PNT treatment|all subjects enrolled in the study, that underwent PNT treatment
62216590|NCT00421954|EXPERIMENTAL|Ziprasidone|
62216591|NCT03282240|EXPERIMENTAL|QIV-HD|Participants randomized to receive a single injection of 0.7 mL QIV-HD by intramuscular (IM) route at Day 0.
62216592|NCT03282240|ACTIVE_COMPARATOR|TIV-HD1 (Licensed TIV-HD1)|Participants randomized to receive a single injection of 0.5 mL licensed TIV-HD1 by IM route at Day 0.
62216593|NCT03282240|ACTIVE_COMPARATOR|TIV-HD2 (Investigational TIV-HD2)|Participants randomized to receive a single injection of 0.5 mL investigational TIV-HD2 by IM route at Day 0.
62216594|NCT04831918|EXPERIMENTAL|Mueller cemented cups|Patients undergo total hip arthroplasty with the implant of the Mueller cemented cup as acetabular component.
62216595|NCT02313376|EXPERIMENTAL|GAP3KO|
62216596|NCT05957432|ACTIVE_COMPARATOR|Group 1 , Black seed oil group|45 patients will receive they will receive 1800 mg (4 soft gelatin capsules of 450 mg) black seed oil (2 capsules twice daily 30 min after the meal) for 6 weeks plus vonoprazan-based triple therapy ( conventional therapy ) consists of vonoprazan 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1000 mg twice daily for 14 days
62216597|NCT05957432|ACTIVE_COMPARATOR|Group 2 , control group|This group consists of 45 patients, who will receive vonoprazan-based triple therapy(conventional therapy ) consists of vonoprazan 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1000 mg twice daily for 14 days
62410868|NCT06468007||Prednisolone treatment group|Patients receiving 5 mg or 20 mg prednisolone tablets for any of the following conditions: Pulmonary, Rheumatology and musculoskeletal; Neurology and ophthalmology; Dermatology; Endocrinology and metabolic; Gastrointestinal; Hematology and immunology; Nephrology.
62585323|NCT05323240|EXPERIMENTAL|Filtered air exposure|Subjects will be randomly exposed to three consecutive days of filtered air exposure arm in a double-blind cross-over fashion in an exposure chamber, and exposures will be separated by a minimum of 13 days from the PM2.5 arm.
62792511|NCT01584739|EXPERIMENTAL|AZD8683|
62216598|NCT06261801|ACTIVE_COMPARATOR|Medication Group|Participants in the medication group would take 150-mg pregabalin capsules orally twice daily (total daily dose, 300 mg) for 4 weeks. The follow-up period is 3 months.
62216599|NCT06261801|EXPERIMENTAL|EA Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The follow-up period is 3 months.
62410869|NCT01988337|EXPERIMENTAL|Resin infiltration|"One proximal caries lesion (split mouth design) per patient will be treated using the resin infiltrant Icon (DMG, Hamburg, Germany) according to manufactures´ instructions."
62410870|NCT01988337|SHAM_COMPARATOR|Mock treatment|"A second proximal caries lesion of each patient (split mouth design) will receive a placebo treatment to mimic resin infiltration."
62410871|NCT06568757|EXPERIMENTAL|Wet Cupping Group|The group that will receive wet cupping therapy-cupping application to the head and neck area in addition to medical treatment
62585324|NCT05323240|EXPERIMENTAL|PM exposure|Subjects will be randomly exposed to three consecutive days of PM2.5 exposure arm in a double-blind cross-over fashion in an exposure chamber, and exposures will be separated by a minimum of 13 days from the filtered air arm.
62410872|NCT06568757|ACTIVE_COMPARATOR|Control Group|The group that will not receive any treatment other than medical treatment
62585325|NCT06682780|EXPERIMENTAL|LM2417 Dose Escalation(Q2W/Q3W)|
62585326|NCT06682780|EXPERIMENTAL|LM-2417 combination therapy exploratory|
62585327|NCT06682780|EXPERIMENTAL|LM-2417 combination expansion|
62585328|NCT06001333|EXPERIMENTAL|FMT group|fecal microbiota transplantation using frozen or capsulized stool
62585329|NCT06001333|NO_INTERVENTION|non-FMT group|Simple observation without intervention
62792512|NCT01584739|PLACEBO_COMPARATOR|Placebo to AZD8683|
62792513|NCT01454986|ACTIVE_COMPARATOR|Cohort 1|0.06 mg/kg ALXN1007
62792514|NCT01454986|ACTIVE_COMPARATOR|Cohort 2|0.1 mg/kg ALXN1007
62792515|NCT01454986|ACTIVE_COMPARATOR|Cohort 3|0.3 mg/kg ALXN1007
62792516|NCT01454986|ACTIVE_COMPARATOR|Cohort 4|1.0 mg/kg ALXN1007
62585330|NCT03751735|EXPERIMENTAL|Dose 1|Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up
62585331|NCT02776267|EXPERIMENTAL|Angiolite stent - 3-month angiogram/OCT|Patients scheduled for PCI (and whot meet pre-specified inlcusion criteria) are enrolled to receive the Angiolite DES. They will undergo a scheduled repeat coronary angiogram and OCT evaluation at 3-month post index PCI.
62585332|NCT02776267|EXPERIMENTAL|Angiolite stent - 6-month angiogram/OCT|Patients scheduled for PCI (and whot meet pre-specified inlcusion criteria) are enrolled to receive the Angiolite DES. They will undergo a scheduled repeat coronary angiogram and OCT evaluation at 6-month post index PCI.
62585333|NCT06684730||Individuals with transradial amputees or wrist disarticulation using standard myoelectric hands|
62585334|NCT06684730||Individuals with transradial amputees or wrist disarticulation using bionic hand|
62585335|NCT03148860|ACTIVE_COMPARATOR|Methotrexate naive - Ustekinumab and Methotrexate|Methotrexate naive subjects will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
62216600|NCT06261801|EXPERIMENTAL|EA+Medication Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including electroacupuncture(EA) treatment and combined with pregabalin (0.15g each time, twice daily). The follow-up period is 3 months.
62216601|NCT04595851|OTHER|Pharmacist Coordinated care Oncology Model (PCOM)|The Pharmacist Coordinated care Oncology Model includes patient self-reported symptoms and medication adherence, comprehensive medication review(s) and intentional communication between oncology and primary care pharmacists.
62216602|NCT02654301|PLACEBO_COMPARATOR|Control group|sucrose drink (Control, sucrose 50g + deionized water 100g)
62216603|NCT02654301|ACTIVE_COMPARATOR|5 g xylose group|5 g xylose (Test 1, sucrose : xylose = 10:1),
62216604|NCT02654301|ACTIVE_COMPARATOR|3.33 g xylose group|3.33 g xylose (Test 2, sucrose : xylose = 15:1)
62585336|NCT03148860|PLACEBO_COMPARATOR|Methotrexate naive - Ustekinumab and Placebo to Methotrexate|Methotrexate naive subjects will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
62216605|NCT02654301|ACTIVE_COMPARATOR|2.5 g xylose group|2.5 g xylose (Test 3, sucrose : xylose = 20:1)
62216606|NCT01994655|EXPERIMENTAL|Doing exercise|We want to use Kupperman Index to assess the severity of climacteric symptoms,and assess the effect of doing exercise fof the climacteric symptoms
62216607|NCT06384560|EXPERIMENTAL|Neoadjuvant FOLFIRINOX, SABR and pembrolizumab|Treatment starts with four cycles of neoadjuvant FOLFIRINOX chemotherapy every two weeks, combined with pembrolizumab every six weeks, starting at the same day as the second cycle of FOLFIRINOX. Restaging is performed after cycle 4 of FOLFIRINOX with a CT-scan. Patients with a response or stable disease will undergo SABR 5 X 8 Gy followed by an additional four cycles FOLFIRNOX chemotherapy, combined with pembrolizumab. Restaging is repeated after 8 cycles FOLFRINOX in total. Patients undergo a surgical exploration if they have non-metastatic borderline resectable disease on CT-scan of the chest and abdomen, 3-6 weeks after completion of chemotherapy. Patients also proceed to surgical exploration if they discontinue neoadjuvant FOLFIRINOX and/or pembrolizumab because of toxicity or have local progression at restaging within criteria for borderline resectable disease.
62585337|NCT03148860|ACTIVE_COMPARATOR|Methotrexate pre-treated subjects-Ustekinumab and Methotrexate|subjects pretreated with Methotrexate will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
62216608|NCT05398744|EXPERIMENTAL|Virtual group aerobic training program|16-week, virtual group aerobic training program led by exercise physiologist. Duration: 24 weeks. Four weeks recording of baseline activity through activity monitor; 16-week virtual group aerobic training program, 3 times per week for 30 minutes; and four weeks of follow-up.
62585338|NCT03148860|PLACEBO_COMPARATOR|Methotrexate pre-treated subjects-Ustekinumab and PLC|subjects pretreated with Methotrexate will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
62585339|NCT01694290|EXPERIMENTAL|Chemical Ice packs to neck, groin, axillae|Chemical ice packs will be changed out every 9 minutes
62585340|NCT01694290|EXPERIMENTAL|Chemical Ice Packs to cheeks, palms, soles|Chemical Ice packs will be changed out every 9 minutes
62585341|NCT01694290|NO_INTERVENTION|no chemical ice packs|
62585342|NCT06305598|EXPERIMENTAL|Treatment (Bipolar androgen therapy)|Patients receive testosterone IM on day 1 of each cycle. Cycles repeat every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also continue to receive standard of care leuprolide acetate SC per their standard schedule. Patients undergo CT scan, bone scan and may undergo MRI and tumor biopsy throughout the study.
62585343|NCT06325566|EXPERIMENTAL|Rexlemestrocel-L + HA|Participants will receive rexlemestrocel-L 2.0 mL injection of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with hyaluronic acid (HA) solution on Day 0.
62585344|NCT06325566|SHAM_COMPARATOR|Control Group|Participants will receive saline solution as a sham procedure to simulate the active treatment injection on Day 0.
62216609|NCT05972928|EXPERIMENTAL|Sitagliptin|Sitagliptin at a dose of 100 mg every 24 hours for 3 months
62216610|NCT05972928|NO_INTERVENTION|control|patient won't receive medication
62216611|NCT02608723|ACTIVE_COMPARATOR|Standard shock waves device|3 sessions were applied: one per week.
62216612|NCT02608723|ACTIVE_COMPARATOR|Austere shock waves device|3 sessions were applied: one per week.
62216613|NCT02608723|ACTIVE_COMPARATOR|Sophisticated shock waves device|3 sessions were applied: one per week.
62243268|NCT05891353|ACTIVE_COMPARATOR|Cold Water Immersion|Participants will complete a cold water immersion task to the hand for one minute, four times. Change in Pressure Pain Threshold will be measured between each one-minute interval on the web space of the foot between the first and second toes.
62792517|NCT01454986|ACTIVE_COMPARATOR|Cohort 5|3.0 mg/kg ALXN1007
62410873|NCT05745441|EXPERIMENTAL|Early Dinner First|Participants will be served dinner and a stable isotope of oral \[2H31\] palmitate to measure fat oxidation, at an early dinner time (before DLMO). This arm will then cross-over to Late Dinner as the second metabolic visit.
62585345|NCT02798549|OTHER|Viraemic|
62792518|NCT01454986|ACTIVE_COMPARATOR|Cohort 6|6.0 mg/kg ALXN1007
62792519|NCT01454986|ACTIVE_COMPARATOR|Cohort 7|10.0 mg/kg ALXN1007
62792520|NCT04240574|OTHER|Micro Water Jet Technology (Debritom)|"Debritom is a hydrosurgery device that utilizes micro water jet technology that has been designed to debride acute and chronic wounds precisely and in a tissue-preserving manner.~All subject will get the Debritom."
62792521|NCT06458452|ACTIVE_COMPARATOR|Game Interaction with Voice Recognition (Group VG)|Group VG participants will use AI driven Voice Recognition as game controller interface.
62021492|NCT06068894|EXPERIMENTAL|"lactosamine-enriched humanized galacto-oligosaccharides (hGOS)"|The treatment will consist of 10-15 g/day of hGOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage. The intervention will last for 4 weeks since the research team has shown in adult individuals that a 4-wk period allows for the observation of changes to the gut microbiome. The study will end after the second time-point sample collection at 4 weeks.
62021493|NCT06068894|EXPERIMENTAL|galacto-oligosaccharides (GOS)|The treatment will consist of 10-15 g/day of GOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage. The intervention will last for 4 weeks since the research team has shown in adult individuals that a 4-wk period allows for the observation of changes to the gut microbiome. The study will end after the second time-point sample collection at 4 weeks.
62216614|NCT04945889||Geriatric inpatients at risk for sepsis|"Consecutive patients admitted to an Acute Geriatric Unit for any reason presenting at least one National Institute for Health and Care Excellence (NICE) risk factor for sepsis (age ≥75 years, impaired immune function, long-term corticosteroid therapy, immunosuppressive or antineoplastic drug treatment, surgery or other invasive procedures within 6 weeks, any breach of skin integrity, intravenous drug misuse, indwelling lines or catheters).~In those with suspected infection (i.e. antibiotic prescription and a culture test within 24 hours before-72 hours after), clinical parameters (respiratory rate, blood pressure, heart rate, body temperature, peripheral oxygen saturation, mental status) were assessed at least twice daily throughout hospital stay and used by study investigators to determine the qSOFA, NEWS and MEWS."
62216615|NCT02767284|EXPERIMENTAL|UCST-V1|The UCST-V1 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
62216616|NCT02767284|EXPERIMENTAL|UCST-V2|The UCST-V2 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
62216617|NCT02767284|EXPERIMENTAL|UCST-V3|The UCST-V3 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
62216618|NCT02767284|EXPERIMENTAL|Quick-CSF|The Quick-CSF test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
62410874|NCT05745441|EXPERIMENTAL|Late Dinner First|Participants will be served dinner and a stable isotope of oral \[2H31\] palmitate to measure fat oxidation, at a late dinner time (after DLMO). This arm will then cross-over to Early Dinner as the second metabolic visit.
62410875|NCT02423564|ACTIVE_COMPARATOR|Healthy Population with Digesta Lac|Digesta Lac is Lactobacillus bulgaricus LB-51 at 2.0 billion cfu with non-medicinal ingredients: cellulose, potato powder, chick pea extract, vitamin c, L-leucine, vegetable capsule (hypromellose)
62410876|NCT02423564|PLACEBO_COMPARATOR|Healthy Population with Placebo|Placebo contains: cellulose, Organic Whole Grain Brown Rice Milk Concentrate, L-Leucine, potato powder, vegetable capsule (hypromellose)
62410877|NCT04456998|EXPERIMENTAL|GB002 (seralutinib)|GB002 (seralutinib) inhaled orally twice per day (BID) for 24 weeks
62410878|NCT04456998|PLACEBO_COMPARATOR|Placebo|Placebo inhaled orally BID for 24 weeks
62410879|NCT00989365|OTHER|Patient cousenling|Improve medicine use Self control asthma crisis Ambient hygiene
62410880|NCT01903213||Kiklin group|Oral
62410881|NCT05813392|EXPERIMENTAL|dCBT-I group|The dCBT-I group will receive full self-help dCBT-I through a smartphone APP for 6 weeks.
62585346|NCT02798549|OTHER|Remission|
62792522|NCT06458452|ACTIVE_COMPARATOR|Game Interaction with VR Controllers (Group CG)|Group CG participants will use hand held VR controllers as game controller interface.
62792523|NCT06543810|EXPERIMENTAL|Hula Pilot Intervention|Hula pilot 3 month program for PD patients.
62792524|NCT00935311|EXPERIMENTAL|ABT-712|1 dose of 1 ABT-712 extended-release tablet plus 1 placebo tablet, followed by 1 dose of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
62792525|NCT00935311|ACTIVE_COMPARATOR|Hydrocodone/Acetaminophen|2 doses of 1 hydrocodone/acetaminophen immediate-release tablet plus 1 placebo tablet, administered once every 6 hours for 12 hours (for a total of 2 doses).
62792526|NCT00935311|PLACEBO_COMPARATOR|Placebo|2 doses of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
62792527|NCT05487261|EXPERIMENTAL|Sacubitril and valsartan combination|Patient receive: 1 bottle with Sacubitril/Valsartan tablets and 2nd bottle with placebo to enalapril.
62792528|NCT05487261|ACTIVE_COMPARATOR|Enalapril|Patient receive: 1 bottle with placebo to Sacubitril/Valsartan and 2nd bottle with enalapril.
62792529|NCT02273661|PLACEBO_COMPARATOR|Control|An aerosol of isotonic saline x 1/ week will be administered during 6 months
62792530|NCT02273661|EXPERIMENTAL|Ambisome|An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
62792531|NCT05319158|EXPERIMENTAL|Intervention group|The group intervention will receive MIT-PB.
62792532|NCT05319158|NO_INTERVENTION|control group|The control group will receive standard care
62792533|NCT06364267|EXPERIMENTAL|ARM 1|BabyEXE Arm, 25 mg eod, typically every odd day of the monthly calendar for 12 months.
62792534|NCT06364267|EXPERIMENTAL|ARM 2|BabyTAM Arm, 10 mg eod, typically every odd day of the monthly calendar for 12 months
62792535|NCT04829149||Statin therapy group (No interventional)|Observational. Statin therapy group: Once daily administered per the locally approved product information of rosuvastatin, simvastatin, atorvastatin, pitavastatin etc,. (except Rosuzet Tab.)
62216619|NCT02767284|ACTIVE_COMPARATOR|Pelli-Robson|The Pelli-Robson contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
62585347|NCT03649490||Smooth PEEK Interbody Implants in XLIF|Smooth PEEK interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) provide maximum surface area and structural stability with large central apertures to allow bony through-growth. Multiple length options enable optimal apophyseal support, thus reducing the chance of subsidence. Additionally, lordotic profiles are available to induce proper sagittal alignment.
62021494|NCT06068894|PLACEBO_COMPARATOR|Placebo|The placebo comparator treatment will consist of 10-15 g/day placebo powder, that can be added to any non-alcoholic beverage. The intervention will last for 4 weeks to mirror the treatment arms. The study will end after the second time-point sample collection at 4 weeks.
62585348|NCT03649490||3D-Printed Titanium Interbody Implants in XLIF|3D-printed, fully porous titanium interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) have a porous architecture that mimics the porosity and stiffness of bone for reduced stress shielding and improved radiographic imaging. The advanced microporous surface topography creates an ideal environment for bone in-growth.
62792536|NCT04829149||Rosuzet tablet group (No interventional)|Observational. Rosuzet Tab.(ezetimibe/rosuvastatin) group: once daily administered per the locally approved product information of Rosuzet Tab. 10/5mg, 10/10mg, 10/20mg
62792537|NCT06106958|EXPERIMENTAL|Foot Rehabilitation And Minimalist Shoes (FRAMES)|The intervention group will receive a pair of minimalist shoes along with a home exercise program and a protocol that indicates how to slowly adjust to wearing the shoes.
62792538|NCT06106958|ACTIVE_COMPARATOR|Home Exercise Program (Control)|The intervention group will receive a home exercise program.
62792539|NCT05379595|EXPERIMENTAL|Cohorts A, B, and C: Amivantamab Monotherapy|Participants with left-sided colorectal cancer (CRC) in Cohort A (no prior anti-epidermal growth factor receptor \[EGFR\] therapy) and in Cohort B (post anti-EGFR therapy), and right-sided CRC in Cohort C (with or without anti-EGFR therapy), will be administered intravenous (IV) infusion of amivantamab 1050 milligrams (mg) if body weight (BW) is less than (\<) 80 kilograms (kg) or 1400 mg if BW is greater than or equal to (\>=) 80 kg, as monotherapy on Days 1 and 15 of Cycle 2 (28-days cycle).
62792540|NCT05379595|ACTIVE_COMPARATOR|Cohorts Ph1b-D and D: Amivantamab+5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6)|Participants who are anti-EGFR treatment naïve, have not received oxaliplatin-based chemotherapy in the metastatic setting, will be administered IV infusion of amivantamab 1050 or 700 mg (dose level 0 \[DL0\]) if BW is \<80 kg, or 1400 or 1050 mg (dose de-escalation \[DL-1\]) if BW is \>= 80 kg, on Days -1, -2, 8 and 22 of Cycle 1 and along with mFOLFOX6 SOC chemotherapy on Days 1 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 (each cycle of 28 days) in Phase 1b dose confirmation Cohort (Cohort Ph1b-D). Participant in Phase 2 Cohort (Cohort D) will receive recommended Phase 2 combination dose (RP2CD) of amivantamab along with mFOLFOX6 SOC chemotherapy determined in Cohort Ph1b-D.
62792541|NCT05379595|ACTIVE_COMPARATOR|Cohorts Ph1b-E and E: Amivantamab+5-Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI)|Participants who are anti-EGFR treatment naïve, have not received irinotecan-based chemotherapy in the metastatic setting, will be administered IV infusion of amivantamab along with FOLFIRI SOC chemotherapy on Days -1, -2, and 8 of Cycle 1 and Days 1 and 15 of Cycle 2 in Ph1b-E. For Cohort E, RP2CD determined in Ph1b-E will be administered.
62792542|NCT04339829|OTHER|Dacomitinib 45mg PO ,QD|Single arm
62792543|NCT02641470|EXPERIMENTAL|DA9301|Orally administration of DA9301 (Vaccinium uliginosum extract) pills (1000 mg/day) for 4 weeks.
62792544|NCT02641470|PLACEBO_COMPARATOR|Placebo|Orally administration of placebo pills (1000 mg/day) for 4 weeks.
62792545|NCT04185675|ACTIVE_COMPARATOR|Macintosh laryngoscope|
62216620|NCT02767284|ACTIVE_COMPARATOR|Optec 6500|The Optec 6500 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
62216621|NCT03498859|OTHER|Home-based training|10 weeks of home-based training with no supervision of a physiotherapist
62216622|NCT03498859|OTHER|Physiotherapist-supervised training|Physiotherapist-supervised training once per week during 10 weeks in addition to home-based training
62216623|NCT05734352||Intervention|Completion of questionnaire
62792546|NCT04185675|EXPERIMENTAL|nonadjustable videolaryngoscope|
62792547|NCT04185675|EXPERIMENTAL|adjustable videolaryngoscope|
62792548|NCT04327947|EXPERIMENTAL|women, 18-39 y|Health volunteers, 18-39 y, with vaginal dryness
62792549|NCT04327947|EXPERIMENTAL|premenopause women|Health volunteers, 40 years to premenopause, with vaginal dryness
62792550|NCT04327947|ACTIVE_COMPARATOR|climacteric women|Health volunteers, climacteric, with vaginal dryness
62021495|NCT02755935|EXPERIMENTAL|Implanted|Subjects who meet the specified inclusion criteria and are implanted with the CI532 cochlear implant
62021496|NCT00619021|EXPERIMENTAL|Cohort 1|Patient receives gemcitabine 600 mg/m\^2.
62216624|NCT01979367|EXPERIMENTAL|Anodyne|To evaluate the efficacy treatment of lower extremity pathologies from neurological ischemia disorders using the Monochromatic Infrared Photo Energy (MIRE)
62216625|NCT06610942||Adult patients with psoriasis who have failed local treatment|
62216626|NCT06610942||"Healthy controls (skin)"|
62021497|NCT00619021|EXPERIMENTAL|Cohort 2|Patient receives gemcitabine 800 mg/m\^2.
62216627|NCT06610942||"Healthy controls (stools)"|
62216628|NCT00606125|EXPERIMENTAL|Arm 1|
62216629|NCT00684619|EXPERIMENTAL|Arm A|Nelarabine
62585349|NCT03649490||Porous PEEK Interbody Implants in XLIF|Porous PEEK interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) combine the osseointegration capabilities of porous metal implants with the favorable imaging and mechanical properties of traditional PEEK implants. The Porous PEEK architecture, with 60% porosity and 300 mm average pore size, is specifically tailored to elicit the optimal osteogenic cell response and promote bone tissue ingrowth inside the pores, as demonstrated in preclinical studies.
62585350|NCT04439227|EXPERIMENTAL|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62410882|NCT05813392|NO_INTERVENTION|the wait-list group|The wait-list group will not receive dCBT-I, waiting for treatment.At the end of the 3-month follow-up, the decision whether to receive treatment will be made according to the participants' wishes.
62410883|NCT02753608|SHAM_COMPARATOR|No ventilator-associated pneumonia (VAP)|Collection of exhaled breath condensate (EBC) in patients without clinical signs of VAP
62585351|NCT03840395|ACTIVE_COMPARATOR|Active PES|Patients randomized to receive active Pharyngeal Electrical Stimulation (PES) via a Phagenyx Catheter.
62585352|NCT03840395|SHAM_COMPARATOR|Sham PES|Patients randomized to sham will not receive any Pharyngeal Electrical Stimulation (PES) but will still have the Phagenyx Catheter inserted.
62021498|NCT00619021|EXPERIMENTAL|Cohort 3|Patient receives gemcitabine 1000 mg/m\^2.
62021499|NCT00619021|EXPERIMENTAL|Cohort 4|Patient receives gemcitabine 1200 mg/m\^2.
62585353|NCT04117620||Patients|Patients from 7 to 17 years of age with vestibular deficiency.
62585354|NCT04117620||Controls|Subjects from 7 to 17 years of age without vestibular deficiency
62585355|NCT01489215|EXPERIMENTAL|"Clinical group-presence intervention"|"The Presence intervention is based on based on the principles of graduated extinction, which has been defined has been defined as effective and recommended therapy in the treatment of bedtime problems and night wakings by the Standard of Practice Committee of the American Academy of Sleep Medicine."
62021500|NCT02983578|EXPERIMENTAL|Treatment (danvatirsen, durvalumab)|Patients receive danvatirsen IV over 1 hour on days 7, 5 and 3 prior to cycle 1, then on days 1, 8, 15 and 22. Patients also receive durvalumab IV over 1 hour on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62021501|NCT02745379|EXPERIMENTAL|BFPSC+|The group receives a combination (DFDBA)+buccal fat pad derived stem cells BFPSC and PRF for sinus augmentation
62021502|NCT02745379|ACTIVE_COMPARATOR|BFPSC-|The group receives a combination of demineralized freeze-dried bone allografts DFDBA (lacking any cells) and PRF for sinus augmentation
62021503|NCT01698060|EXPERIMENTAL|Intestinal Delivery|ND1.1
62021504|NCT02528201|ACTIVE_COMPARATOR|Celecoxib 200 milligrams mg QD|celecoxib 200 milligrams (mg) once a day (QD)
62021505|NCT02528201|ACTIVE_COMPARATOR|Celexocib 400 mg QD|celecoxib 400 milligrams (mg) once a day (QD)
62021506|NCT02528201|ACTIVE_COMPARATOR|Diclofenac 50 mg TID|diclofenac 50 milligrams (mg) three times a day (TID)
62021507|NCT02720146||Artificital tear|The epitheliotrophic ability in cell and animal model
62410884|NCT02753608|EXPERIMENTAL|Ventilator-associated pneumonia (VAP)|Collection of exhaled breath condensate (EBC) in patients displaying clinical signs of VAP
62585356|NCT01489215|EXPERIMENTAL|"Clinical group-checking intervention"|"The Checking training is based on the principles of graduated extinction, which has been defined has been defined as effective and recommended therapy in the treatment of bedtime problems and night wakings by the Standard of Practice Committee of the American Academy of Sleep Medicine"
62585357|NCT01489215|NO_INTERVENTION|Control Group|
62585358|NCT03116581|OTHER|Vicarious reward|"If a decision influences the well-being of another (through monetary payoff), the decision making processes should differ from a decision that would influences only oneself. The difference will be reflected in the reaction-times and in the accuracy of the response to the task. The drift diffusion models care then used to estimate le decision parameter in each condition and understand which parameter is influenced by the beneficiary of the payoff associated with a decision.~Once the decision parameter characterized with behavioral experiment, the study aims to better understand the neural network sustaining the influence of others on the decision making process, by assessing the neural activity related to the decision making processes. Also, the research compares how the brain responses for payoff for others and payoffs for oneself, specially to confirm that these responses are located in different areas of the Anterior cingulate Cortex."
62585359|NCT03116581|OTHER|Audience effect|In order to clarify the complex changes in the decision-making processes induced by simple observation by others (audience) , the experiment have two levels of difficulty . These levels of difficulty will be determined in such a way as to achieve better 'public' performance than 'private' when the task is easy (high level of consistency) and poor performance when the task is difficult (low level of coherence) As described in the literature in psychology. Drift diffusion models will be used to better understand the variations in performance, to decipher between a modulation of the diffusion velocity and or of the decision threshold. This study will help characterize how observation by others modulates performance. Once the decision parameter characterized with behavioral experiment, the study aims to better understand the neural network sustaining the impact of observation by others on the decision making process.
62585360|NCT02819752|EXPERIMENTAL|HPV-ve stage IVA/IVB SCCHN|Pembrolizumab and Chemoradiotherapy
62585361|NCT02819752|EXPERIMENTAL|HPV+ve stage IVA/IVB SCCHN|Pembrolizumab and Chemoradiotherapy
62792551|NCT03484247|ACTIVE_COMPARATOR|Group Infraclavicular|Infraclavicular Brachial Plexus Block: The inferolateral of the subclavian artery will be targeted with a 85 mm peripheral nerve stimulator needle with ultrasound guidance. When the needle tip was seen near the posterior cord of brachial plexus local anesthetic will be administered with single injection after aspiration.
62021508|NCT02720146||Human peripheral serum|The epitheliotrophic ability in cell and animal model
62410885|NCT03236337|NO_INTERVENTION|Control|No intervention
62021509|NCT02720146||Human platelet lysate|The epitheliotrophic ability in cell and animal model
62021510|NCT03081338||Study cohort|A mix of incident and prevalent patient cases will be included in order to capture patients at different stages of the disease trajectory.
62021511|NCT06536309|EXPERIMENTAL|Sacubitril/valsartan|Patient randomized to the interventional arm will be treated with sacubitril/valsartan
62021512|NCT06536309|ACTIVE_COMPARATOR|Valsartan|Patient randomized to the active comparator arm will be treated with valsartan
62410886|NCT03236337|EXPERIMENTAL|MOVI intervention|- MOVI-da Fit! is a high intensity interval training intervention that consists on: a) 4 h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
62410887|NCT04824573|EXPERIMENTAL|Inspiratory Muscle Training (IMT)|The program of the IMT group (n=16) consists of individual sessions of approximately 20 minutes and the Powerbreathe device (IMT Technologies Ltd., Birmingham) was used for training.
62585362|NCT05906563|ACTIVE_COMPARATOR|melatonin loaded nanoparticle (test group)|13 patients will be treated with melatonin loaded nanoparticle gel as adjunct to scaling and root planning .it will be applied once weekly for four weeks.
62792552|NCT03484247|ACTIVE_COMPARATOR|Group Axillary|Axillary Brachial Plexus Block: The procedure will be performed with a 50 mm peripheral nerve stimulator needle with ultrasound guidance. Local anesthetic will be administered with multiple injection (radial, ulnar, median and musculocutaneous nerves) after aspiration.
62021513|NCT05043077|EXPERIMENTAL|Study Group|Mydriasis with microdrops
62021514|NCT05043077|ACTIVE_COMPARATOR|Control Group|Mydriasis with standard drops
62216630|NCT02774239|EXPERIMENTAL|SC Treatment Period|"Participants will receive 2gm/kg of Human normal immunoglobulin G (IgG) infused over 4 weeks in a dose escalating manner as follows:~* 1st week: 2-3 SCIG infusions of 10ml per site at four sites (total dose 16 to 24g)\*~* 2nd week: 2-3 SCIG infusions of 15ml per site at four sites (total dose 24 to 36g)\*~* 3rd week: 2-4 SCIG infusions of 20ml per site at four sites (total dose 32 to 64g)\*~* 4th week: 2-4 SCIG infusions of 25ml per site at four sites (total dose 40 to 80g)\*~  * Doses indicated are study recommended. Doses may be adjusted depending on tolerance and total dose required by the patient."
62216631|NCT03028753|EXPERIMENTAL|All subjects|All subjects enrolled in the study will have a back-fill voiding trial performed at the time of catheter removal after urogynecologic surgery.
62216632|NCT02878577||EEG fMRI TBI Mild/Moderate-Severe severity|patient population who suffered a brain trauma (traumatic brain injury, TBI). with a Glasgow Coma Scale between 3-15
62216633|NCT02878577||EEG fMRI Control group|healthy subjects with out a traumatic brain injury
62216634|NCT06602635||RVOT origin|Patients with right ventricular outflow tract (RVOT) arrhythmias origin
62216635|NCT06602635||LVOT origin|Patients with left ventricular outflow tract (LVOT) arrhythmias origin
62216636|NCT05033951||Cohort 1|Patients who start NIV in the first two months after the first visit to the HMV
62216637|NCT05033951||Cohort 2|Patients who do not start NIV in the first two months after the first visit to the HMV.
62216638|NCT02461784||Case|Male subjects with IBD diagnosis currently taking methotrexate (MTX) as treatment for their disease.
62216639|NCT02461784||Control|Male subjects with IBD diagnosis not exposed to methotrexate (MTX) as treatment for their disease.
62216640|NCT01901341|EXPERIMENTAL|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice daily (BID) for a 12-week treatment period
62216641|NCT01901341|PLACEBO_COMPARATOR|Placebo|Placebo administered orally BID for a 12-week treatment period
62216642|NCT05225194||COVID-19 ARDS survivors|Survivors of hospitalization due to ARDS caused by SAS-CoV-2.
62216643|NCT05225194||Non-COVID-19 ARDS survivors|Survivors of hospitalization due to ARDS caused by other etiologies than SARS-CoV-2.
62216644|NCT05225194||Family controls|Family controls of participants with ARDS (either due to COVID-19 or other etiologies) without history of COVID-19 or hospitalization in the last 12 months.
62585363|NCT05906563|ACTIVE_COMPARATOR|melatonin and metformin loaded nanoparticle (test group)|13 patients will be treated with melatonin and metformin loaded nanoparticle gel as adjunct to scaling and root planning .It will be applied once weekly for four weeks.
62585364|NCT05906563|PLACEBO_COMPARATOR|placebo gel (control group)|13 patients will be treated with placebo gel as adjunct to scaling and root planning .It will be applied once weekly for four weeks.
62021515|NCT04724811|EXPERIMENTAL|Weight-bearing as tolerated|Patients are instructed to mobilise the hip and weight-bear as tolerated
62792553|NCT00392730||1|Preterm infants in NICU and age-matched controls
62792554|NCT00392730||2|Term infants in NICU and age-matched controls
62216645|NCT02874924|EXPERIMENTAL|Rapamycin|Rapamycin 1mg taken once daily for 8 weeks
62216646|NCT02874924|PLACEBO_COMPARATOR|Placebo|Placebo taken once daily for 8 weeks
62216647|NCT02874924|EXPERIMENTAL|Rapamycin Alone - Cardiovascular Effects|No placebo control; Rapamycin 1mg once daily for 8 weeks
62216648|NCT06304610|EXPERIMENTAL|Sample taking and questionnaire|"The participant is invited in the colposcopy waiting room by the study nurse and is asked to follow the study nurse to a separate room. Here the participant is given all the information about the study and sampling. If the participant agrees to participate and signs the consent form, the study nurse registers the participant and then asks her to complete a very short questionnaire. After that, the participant will be asked to take a self-sample.~Then the participant will proceed to her appointment for colposcopy. The doctor will take an endocervical samples, similar to a pap smear, before the actual colposcopy examination begins. Her samples will then be analyzed with the newly developed ELEVATE test and with comparative lab tests (standard HPV DNA detection and protein detection tests) in order to validate the newly developed ELEVATE cervical cancer screening test.~Participation is free and the participant can stop your participation at any time."
62216649|NCT02336295|OTHER|Food Frequency Questionnaires|Filling out a Food Frequency Questionnaires (FFQ)
62216650|NCT04719624|EXPERIMENTAL|Adaptos-Si [0.5-1 mm]|Bone augmentation, after tooth extraction, with Adaptos-Si \[0.5-1 mm\] (synthetic bone graft material) in combination with a gelatin sponge.
62216651|NCT04719624|EXPERIMENTAL|Adaptos-Si [1-2 mm]|Bone augmentation, after tooth extraction, with Adaptos-Si \[1-2 mm\] (synthetic bone graft material) in combination with a gelatin sponge.
62216652|NCT04719624|ACTIVE_COMPARATOR|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft) in combination with a gelatin sponge.
62585365|NCT05906563|OTHER|no gel (control group)|13 patients will be treated with only scaling and root planning ..
62585366|NCT06667778|EXPERIMENTAL|Study group|
62585367|NCT06667778|ACTIVE_COMPARATOR|Control group|
62792555|NCT00392730||3|Children on home PN (to age 6) and age-matched controls
62021516|NCT04724811|ACTIVE_COMPARATOR|Touch-down weight-bearing|Patients are instructed to mobilise the hip. Touch-down weight-bearing for 6-8 weeks
62021517|NCT05123209|EXPERIMENTAL|IM83 CAR-T cells|
62021518|NCT05123209|EXPERIMENTAL|IM83 CAR-T cells +The second-line treatment|
62021519|NCT00148343|EXPERIMENTAL|ODFS|Odstock Dropped-Foot Stimulator (ODFS)
62021520|NCT00148343|ACTIVE_COMPARATOR|Standard of Care (inc. AFO)|Conventional Standard of Care (which may include a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) \[Traditional Physical Therapy Treatment\]
62585368|NCT06062121|EXPERIMENTAL|motor-cable-driven system|Receive motor-cable-driven system
62585369|NCT05143229|EXPERIMENTAL|Dose level 1: alpelisib 250 mg plus sacituzumab govitecan 8 mg/kg|Alpelisib: 250 mg by mouth daily Sacituzumab govitecan: 8 mg/kg intravenous on days 1 and 8 of each 21 (+/-2) day cycle
62585370|NCT05143229|EXPERIMENTAL|Dose level 2: alpelisib 250 mg plus sacituzumab govitecan 10 mg/kg|Alpelisib: 250 mg by mouth daily Sacituzumab govitecan: 10 mg/kg intravenous on days 1 and 8 of each 21 (+/-2) day cycle
62021521|NCT01682291|ACTIVE_COMPARATOR|Life-style modifications|"Lifestyle modifications will include:~Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)"
62216653|NCT04719624|PLACEBO_COMPARATOR|Empty extraction socket|Post-extraction the socket filled only by clot.
62216654|NCT04719624|EXPERIMENTAL|Adaptos [1-2 mm]|Bone augmentation, after tooth extraction, with Adaptos \[1-2 mm\] (synthetic bone graft material) in combination with a gelatin sponge.
62216655|NCT02628639|EXPERIMENTAL|electroencephalography recording|Cerebral measurements from high-density electroencephalography after the presentation of personalized stimulations
62216656|NCT06106620|PLACEBO_COMPARATOR|Placebo|12 oz of flavor-matched water.
62216657|NCT06106620|EXPERIMENTAL|Safety Shot|12 oz of Safety Shot containing a blend of vitamins, minerals and botanical extracts.
62216658|NCT03653325|EXPERIMENTAL|interventional arm|"In the interventional arm of the study clinicians will be encouraged to titrate oxygen FiO2 according to the following table:~Interventional arm (FiO2 adaptation every 2-3 min) :~ORI \>0.5 and SatO2\>98% and FiO2\>0.5 FiO2 reduction of 0.2 ORI\>0.01 and ORI\<0.5 and SatO2\>98% and FiO2\>0.5 FiO2 reduction of 0.1 ORI \>0.5 and SatO2\>98% and FiO2≤0.5 FiO2 reduction of 0.1 ORI\>0.01 and ORI\<0.5 and SatO2\>98% and FiO2≤0.5 FiO2 reduction of 0.05 ORI=0 et SatO2 94 - 98% no modification of FiO2 SatO2\<94% + SatO2\> 90% increase FiO2 by 0.05 SatO2\<90% and SatO2\>86 increase FiO2 by 0.1 SatO2\<86% and SatO2\> 80% increase FiO2 by 0.2 SatO2\<80% FiO2 at 1~In the absence of a ORI measurement reading FiO2 will be adapted as in the observational arm according to SatO2 only."
62216659|NCT03653325|ACTIVE_COMPARATOR|Observational arm|"Observational arm (adaptation every 2-3 min):~oxygen saturation measurement SatO2\>98% and FiO2\>0.5 reduction of FiO2 by 0.1 SatO2\>98% and FiO2≤0.5 reduction of FiO2 by 0.05 SatO2 94 - 98% no modification of FiO2 SatO2\<94% + SatO2\> 90% increase FiO2 by 0.05 SatO2\<90% and SatO2\>86 increase FiO2 by 0.1 SatO2\<86% and SatO2\> 80% increase FiO2 by 0.2 SatO2\<80% FiO2 at 1"
62216660|NCT02632435|OTHER|Peripherally inserted central catheter|PICC line will be inserted for the delivery and duration of chemotherapy.
62216661|NCT02632435|OTHER|portacath|PORT will be inserted for the delivery and duration of chemotherapy and trastuzumab.
62585371|NCT05143229|EXPERIMENTAL|Dose level 3: alpelisib 300 mg plus sacituzumab govitecan 10 mg/kg|Alpelisib: 300 mg by mouth daily Sacituzumab govitecan: 10 mg/kg intravenous on days 1 and 8 of each 21 (+/-2) day cycle
62585372|NCT06154980|ACTIVE_COMPARATOR|Preoperative Ultrasound TLIP Group|Participant will receive TLIP in preop with 20cc of 0.2% ropivacaine administered bilaterally, 40cc total. Blocks will be performed under ultrasound guidance with an in-plane technique by a single study investigator.
62585373|NCT06154980|ACTIVE_COMPARATOR|Intraoperative TLIP Group|Participants will receive TLIP with 20cc of 0.2% ropivacaine bilaterally, 40cc total. Blocks will be performed intraoperatively under direct surgical visualization.
62585374|NCT06271772|EXPERIMENTAL|RB-PDT Plus Early Steroids|
62585375|NCT06271772|EXPERIMENTAL|Sham RB-PDT Plus Early Steroids|
62585376|NCT00812981|EXPERIMENTAL|1562902A NP GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the new-processed (NP) 1562902A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Days 0 and 21.
62585377|NCT00812981|EXPERIMENTAL|1562902A CP GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the comparative-processed (CP) 1562902A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Days 0 and 21.
62216662|NCT02691117|EXPERIMENTAL|Garlic concentrate|Garlic gel concentrate- once a day topical application
62585378|NCT05819086|ACTIVE_COMPARATOR|"Big tobacco video message and flyer"|"Participants will view a Big tobacco video message and flyer."
62585379|NCT05819086|ACTIVE_COMPARATOR|"It's never too late video message and flyer"|"Participants will view a It's never too late video message and flyer."
62216663|NCT05922293|ACTIVE_COMPARATOR|Blow Bottle technique|"Blowing with a straw into a water bottle is a good exercise to improve breathing capacity. The user, who has poor pulmonary function, always has his blow bottle handy"
62216664|NCT05922293|EXPERIMENTAL|percussion|Percussion technique should be performed for about 30 seconds and simultaneously with no more than three or four lower thoracic expansion exercises
62216665|NCT05714345|EXPERIMENTAL|Lymphodepletion with ALLO-647, fludarabine, and cyclophosphamide|ALLO-501A CAR T cells infused following lymphodepletion
62216666|NCT05714345|EXPERIMENTAL|Lymphodepletion with fludarabine and cyclophosphamide|ALLO-501A CAR T cells infused following lymphodepletion
62216667|NCT02148640|EXPERIMENTAL|CT-P13|Infusions of biosimilar infliximab (Remsima) with same dose and frequency as pre-inclusion treatment with innovator infliximab (Remicade)
62216668|NCT02148640|ACTIVE_COMPARATOR|INX|Continued infusions of innovator infliximab (Remicade) with same dose and frequency as prior to inclusion
62216669|NCT06019741|EXPERIMENTAL|aspirin and rivaroxaban|post coronary bypass patients, received aspirin 80 mg and rivaroxaban 2.5 mg PO twice daily
62216670|NCT06019741|ACTIVE_COMPARATOR|aspirin|post coronary bypass patients, received aspirin 80 mg
62216671|NCT05971459|EXPERIMENTAL|Individuals with PD|One music therapy session of 30 minutes
62216672|NCT05971459|ACTIVE_COMPARATOR|Healthy Individuals|One music therapy session of 30 minutes
62216673|NCT03674372|EXPERIMENTAL|Fetuses with Left CDH (O/E LHR < 25%)|Fetuses with Left CDH (O/E LHR \< 25%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
62216674|NCT03674372|EXPERIMENTAL|Fetuses with L- sided CDH with O/E LHR <30%.|Fetuses with Left CDH (O/E LHR \< 30%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
62585380|NCT05819086|PLACEBO_COMPARATOR|Placebo Message|Participants will view a water advertisement and flyer.
62021522|NCT01682291|ACTIVE_COMPARATOR|Dietary supplements|Life-style modifications along with a novel combination of dietary supplements that includes: Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
62216675|NCT03674372|EXPERIMENTAL|Fetuses with R- sided CDH with O/E LHR < 45%|Fetuses with Right CDH (O/E LHR \< 45%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
62216676|NCT05949294|EXPERIMENTAL|ARO-SOD1|ARO-SOD1 Injection
62410888|NCT04824573|EXPERIMENTAL|Manual Therapy|In the manual therapy group (n=19), in addition to the approaches applied to the individuals in the IMT group, a total of eight sessions of manual therapy (manipulation, joint mobilization, and soft tissue mobilization) approaches, two days a week for four weeks and at least two days between sessions, were applied by an experienced physiotherapist in manual therapy. Manual therapy applications; included techniques targeting the cervical and thoracic regions. Techniques for the thoracic region; while it consists of manual diaphragm release, thoracic mobilization and High Velocity Low Amplitude (HVLA) thrust manipulation; the techniques applied to the cervical region consisted of soft tissue and joint mobilization.
62216677|NCT06155227|EXPERIMENTAL|Experimental Group|
62216678|NCT06155227|ACTIVE_COMPARATOR|Control Group|
62410889|NCT06631235|OTHER|twin block group|patient treated with twin block appliance
62410890|NCT06631235|EXPERIMENTAL|aesthetic functional group|patient treated with aesthetic functional appliance
62585381|NCT05819086|ACTIVE_COMPARATOR|Fear message video and flyer|Participants will view a fear message video and flyer.
62216679|NCT00469573|OTHER|1.|
62216680|NCT01320059|EXPERIMENTAL|Imaging with 18F-PEG6-IPQA|Radioactive injection given by vein before multiple (3) PET scans.
62216681|NCT04531644|EXPERIMENTAL|Study|the patients in this group will be treated with double stimulation
62216682|NCT04531644|ACTIVE_COMPARATOR|Control|the patients in this group will be treated with conventional ovarian stimulation
62216683|NCT05781100|EXPERIMENTAL|Order of Technology Use during Feeding Conditions: TV Use, Mobile Device Use, Control|This arm will be exposed to the feeding conditions in the following order: TV Use, Mobile Device Use, Control
62216684|NCT05781100|EXPERIMENTAL|Order of Technology Use during Feeding Conditions: TV Use, Control, Mobile Device Use|This arm will be exposed to the feeding conditions in the following order: TV Use, Control, Mobile Device Use
62216685|NCT05781100|EXPERIMENTAL|Order of Technology Use during Feeding Conditions: Mobile Device Use, TV Use, Control|This arm will be exposed to the feeding conditions in the following order: Mobile Device Use, TV Use, Control
62216686|NCT05781100|EXPERIMENTAL|Order of Technology Use during Feeding Conditions: Mobile Device Use, Control, TV Use|This arm will be exposed to the feeding conditions in the following order: Mobile Device Use, Control, TV Use
62216687|NCT05781100|EXPERIMENTAL|Order of Technology Use during Feeding Conditions: Control, TV Use, Mobile Device Use|This arm will be exposed to the feeding conditions in the following order: Control, TV Use, Mobile Device Use
62410891|NCT05518409|EXPERIMENTAL|AD group|20 subjects who met the diagnostic criteria and exclusion criteria of AD were included in the discovery cohort.
62410892|NCT05518409|EXPERIMENTAL|DLB group|Of the 30 subjects who met the DLB diagnostic criteria and exclusion criteria, 20 were included in the discovery cohort and 10 in the validation cohort.
62585382|NCT05934604|EXPERIMENTAL|Magnetic resonance imaging (MRI) group|Healthy volunteers will have two functional magnetic resonance imaging scans (localizer session and the real time functional magnetic resonance imaging neurofeedback session).
62585383|NCT03961958|NO_INTERVENTION|No protocolled propofol reduction|In phase 1, target-controlled infusion propofol anesthesia was adjusted to maintain BIS 40 to 60.
62585384|NCT03961958|EXPERIMENTAL|Two protocolled propofol reductions|In phase 2, there were 2 planned reductions in propofol target concentration: (1) immediately after loss of consciousness-reduction calculated using a predefined formula, and (2) before positioning-reduction equal to the average percentage decrease in CO after knee-chest position in phase
62585385|NCT01665950|EXPERIMENTAL|Simvastatin-Simvastatin|Subjects will receive simvastatin in phase 1 (4 weeks) and phase 2 (4 weeks)
62216688|NCT05781100|EXPERIMENTAL|Order of Technology Use during Feeding Conditions: Control, Mobile Device Use, TV Use|This arm will be exposed to the feeding conditions in the following order: Control, Mobile Device Use, TV Use
62216689|NCT03382379|EXPERIMENTAL|Active|Participants in the active arm will receive 2 milliamp anodal transcranial Direct Current Stimulation (tDCS) over the Dorso-Lateral Pre-Frontal Cortex (DLPFC).
62216690|NCT03382379|PLACEBO_COMPARATOR|Sham|Participants in the Sham arm will receive sham transcranial Direct Current Stimulation (tDCS) over the Dorso-Lateral Pre-Frontal Cortex (DLPFC).
62216691|NCT04403464|EXPERIMENTAL|HABIT-ILE with REAtouch®|Hand and Arm Bimanual Intensive Therapy Including Lower Extremities with an interactive device
62792556|NCT04077853|EXPERIMENTAL|study group|women will be given 17-OHPC 250 mg intra-muscular at admission and every 7 days thereafter in addition to other conservative measures of early-onset PE
62021523|NCT00987207|EXPERIMENTAL|cyclosporine|A single bolus of 2.5 mg/kg cyclosporine is administered before aortic cross-declamping
62216692|NCT04403464|ACTIVE_COMPARATOR|HABIT-ILE without REAtouch®|Hand and Arm Bimanual Intensive Therapy Including Lower Extremities
62216693|NCT05741359|EXPERIMENTAL|Treatment group|2.0 - 10.0×105/kgBW,
62410893|NCT05518409|EXPERIMENTAL|Healthy control group|Among the 30 subjects who met the diagnostic and exclusion criteria of the healthy control group, 20 were included in the discovery cohort and 10 in the validation cohort.
62410894|NCT05589701||Stereotactic Radiotherapy (SBRT)|Standard of care stereotactic radiotherapy.
62410895|NCT05589701||Conventional Radiotherapy (CRT)|Standard of care conventional radiotherapy.
62410896|NCT01843660|EXPERIMENTAL|Tramadol Hydrochloride (HCl)-Paracetamol|
62410897|NCT00568516|EXPERIMENTAL|1.Low dose group|
62410898|NCT00568516|EXPERIMENTAL|2.High dose group|
62410899|NCT04998188|EXPERIMENTAL|Collagen Injection|This group of patients will be treated with single intra-articular injection of collagen.
62585386|NCT01665950|EXPERIMENTAL|Placebo->Simvastatin|Placebo non-responders after the 1st 4 weeks will be re-randomized 1:1 to placebo or simvastatin for the next 4 weeks
62792557|NCT04077853|NO_INTERVENTION|control group|No intervention will be given apart from the usual conservative measures of early-onset PE
62216694|NCT01737827|EXPERIMENTAL|INC280|The protocol consisted of two independent parts (Dose-Determining Part and Dose Expansion Part). Patients were treated with INC280 300 mg twice a day in the Dose-Determining Part. The dose for the Expansion Part could be lower, equal or higher than in the Dose-Determining Part and was determined after the Dose Determining Part at the dose decision analysis.
62216695|NCT06306131|PLACEBO_COMPARATOR|Placebo|The placebo is calcium carbonate 750 milligram (mg) known as TUMS. Each participant will take one tablet orally and repeat 48 hours later.
62792558|NCT03575728|OTHER|Mood disorder|Participants who screen positive for a history of mood disorders
62792559|NCT03575728|OTHER|Other|Participants who do not screen positive for a history of mood disorders
62792560|NCT03223116|EXPERIMENTAL|Radiofrequency|Radiofrequency delivery to the gastroesophageal junction
62216696|NCT06306131|ACTIVE_COMPARATOR|Levonorgestrel plus meloxicam|The active comparator is levonorgestrel 1.5 milligram (mg) and meloxicam 15 milligram (mg) taken together orally and repeated 48 hours later.
62410900|NCT04998188|PLACEBO_COMPARATOR|Placebo (saline solution)|This group of patients will be treated with single intra-articular injection of saline solution (placebo). At the 6-month follow-up visit, patients will be informed about the treatment received. Patients of this group can cross-over to the treatment arm after 6 months.
62410901|NCT04420000|EXPERIMENTAL|Interventional group|Patients having a Mindfulness program
62410902|NCT04420000|PLACEBO_COMPARATOR|Control group|Patients having a routinary managment
62410903|NCT01521429||MPS I|Mucopolysaccharidosis I (Hurler, Scheie, Hurler-Scheie)
62410904|NCT01521429||MPS II|Mucopolysaccharidosis II (Hunter)
62410905|NCT01521429||MPS VI|Mucopolysaccharidosis VI (Maroteaux-Lamy)
62410906|NCT03302130|EXPERIMENTAL|Imaging healthy volunteers|Mood induction: positive, negative, neutral mood (using subjects own memories) Arterial spin labeling MRI Physiological monitoring
62410907|NCT03311386||Patients in AIS receiving actilyse|the patients will receive actilyse intaravenously in a dose of 0.9mg/kg once
62410908|NCT05878405|ACTIVE_COMPARATOR|Standard of Care Mouthwash Group|Patients receive standard of care mouthwash as needed on study.
62792561|NCT01354717|ACTIVE_COMPARATOR|Brand Carac|Treatment of actinic keratosis with active ingredient
62792562|NCT01354717|ACTIVE_COMPARATOR|Generic 0.5% 5-fluorouracil cream|Treatment of actinic keratosis with active ingredient
62792563|NCT01354717|PLACEBO_COMPARATOR|Placebo|treatment of actinic keratosis with placebo cream
62792564|NCT01077401|EXPERIMENTAL|Ranibizumab 0.5mg|Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
62792565|NCT01077401|EXPERIMENTAL|Ranibizumab 2.0 mg|Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
62792566|NCT05010980||retrospective|For the retrospective part of the study, the existing echocardiographic database will be used to retrieve data. The database query includes the last 2 years.
62792567|NCT05010980||prospective|For the prospective part of the study, patients will be included who have the clinical indication for cmr and scintigraphy due to suspected cardiac amyloidosis and fulfill the inclusion criteria.
62216697|NCT05304052|EXPERIMENTAL|Mindfulness meditation intervention|Half of the subjects will be randomly assigned to participate in the mindfulness meditation intervention. This class will meet once a week, for two hours, over the course of six weeks.
62216698|NCT05304052|NO_INTERVENTION|Wait list control|Half of the subjects will be randomly assigned to be in the wait-list control group. These subjects will not be asked to do anything during the six weeks while the mindfulness meditation group takes place, other than to not enroll in a meditation class.
62216699|NCT01529203|OTHER|Azzalure and Restylane|All subjects will be injected with Azzalure and Restylane
62410909|NCT05878405|EXPERIMENTAL|Methylene Blue Mouthwash Group|Patients receive Methylene Blue mouthwash as needed on study.
62410910|NCT01482442|ACTIVE_COMPARATOR|sorafenib group|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
62410911|NCT01482442|ACTIVE_COMPARATOR|radioembolization group|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
62410912|NCT04491773||Patients undergoing Tadalafil|Patients after radical prostatectomy, undergoing Tadalafil 20 mg orally, on alternative days, for more than 6 months
62410913|NCT04491773||Control Group|Healthy controls without previous surgery of radical prostatectomy.
62410914|NCT02473107|OTHER|Control Caries Detection Strategy|Detection and treatment based on more advanced lesions, despite activity status - Advanced caries lesions detection (no activity assessment)
62410915|NCT02473107|OTHER|Test Caries Detection Strategy|Detection and treatment based on all detected caries lesions, considering their activity status as a differential in clinical decision-making - All caries lesions detection (+activity assessment)
62410916|NCT06649357|ACTIVE_COMPARATOR|MoLEP|Endoscopic Prostate Enucleation Using Moses 2.0 Technology Pulse modulation technology in Moses 2.0applied to Holmium Laser Endoscopic Prostate (MoLEP).
62792568|NCT05281198|EXPERIMENTAL|Experimental: tart cherry|dietary supplement: tart cherry juice
62792569|NCT05281198|PLACEBO_COMPARATOR|Placebo|dietary supplement: placebo juice
62792570|NCT00519051|ACTIVE_COMPARATOR|control group|patients can receive pharmacotherapy and psychotherapy and specialized treatment
62792571|NCT06149208||Year 1 - Treatment Change|This group will receive the new treatment standard
62792572|NCT06149208||Year 2 - Sustainability|This group will be used to measure sustainability of the new treatment standard
62792573|NCT00116220|ACTIVE_COMPARATOR|Treatment 1|External beam radiation therapy + 6 months total androgen ablation
62585387|NCT01665950|PLACEBO_COMPARATOR|Placebo-Placebo|Placebo nonresponders for the 1st 4 weeks will be re-randomized 1:1 to placebo or simvastatin for the subsequent 4 weeks
62792574|NCT00116220|ACTIVE_COMPARATOR|Treatment 2|External beam radiation therapy
62792575|NCT03639025||Standard Donor Lungs Primary Analysis Population|Recipients transplanted with primary analysis population eligible donor lungs preserved on the OCS™ Lung System.
62792576|NCT03639025||Donor Lungs Initially Unacceptable Primary Analysis Pop.|Recipients transplanted with primary analysis population eligible donor lungs preserved on the OCS™ Lung System.
62792577|NCT03639025||All Other Enrolled Patients|All OCS Lung transplanted patients that do not meet any of the above analysis populations.
62792578|NCT05717400|EXPERIMENTAL|DAA therapy plus Bevacizumb and Atezolizumab|Participants will receive bevacizumab and atezolizumab about every 3 weeks as part of the standard of care HCC treatment that is managed by your cancer doctor. In addition, Participants will continue receiving your standard of care DAAs (either sofosbuvir + velpatasvir or sofosbuvir + velpatasvir + voxilaprevir)
62792579|NCT00726635|ACTIVE_COMPARATOR|1|Women in this arm will not receive a psychological intervention but rather will have a conversation with a nurse for one hour (attention control).
62792580|NCT00726635|EXPERIMENTAL|2|Cognitive intervention: Women in this arm will receive a cognitive psychological intervention(cognitive technique:self-talk)
62585388|NCT06682156||K-based therapy|if bortezomib related intolerance happens during front line therapy of bortezomib-based triple regimen, then carfilzomib-based therapy will be used
62792581|NCT00726635|EXPERIMENTAL|3|Psycho-physiological intervention: Women in this arm will receive a psycho-physiological intervention (relaxation and guided imagery)
62792582|NCT04275973|OTHER|Healthy controls|The Control participants are for methods development and do not constitute a formal study group
62792583|NCT04275973|EXPERIMENTAL|Prosthesis user with transtibial or transfemoral amputation|Experiments will use standard commercially available prostheses for participants with lower-limb amputation. Specific prostheses will be determined at the time of the study, but they will include prostheses that are fully passive such as energy storage-and-return (ESR) feet, ESR feet with mobilized ankles such as passive hydraulic ankles (PHA), and ESR feet with microprocessor-controlled ankles (MPA).
62792584|NCT04275973|EXPERIMENTAL|Orthoses user with drop-foot|"This arm will consists of participants with drop-foot. A subset of the drop-foot population will be persons with Multiple Sclerosis and currently drop-foot.~For participants in this arm, standard commercially-available orthoses or standard-of-care custom orthoses will be used, as well as standard commercially-available electrical stimulation neuro-orthoses."
62792585|NCT04931251|OTHER|Financial Navigation|includes a financial toxicity screening measure (COST), baseline and post-intervention surveys, and approximately 2-6 visits with a financial navigator to identify financial assistance resources
62792586|NCT05958797||Patients detected with Plasmodium vivax (Chloroquine)|Patients with mono-infection of Plasmodium falciparum with ≥ 250 per µl
62792587|NCT02184858|EXPERIMENTAL|lisinopril|dose titration of investigational product (lisinopril) dependant on blood pressure, levels of renin and aldosterone and on adverse events.
62792588|NCT06373146|EXPERIMENTAL|Tirzepatide (TZP) + Mibavademab (MIBA) [Group A]|Participants will receive TZP subcutaneously (SC) and MIBA for 24 weeks. Participants in Group A will be randomized (Randomization 2) to groups C and D at week 24.
62216700|NCT06610318|EXPERIMENTAL|Imagery rescripting|This condition has three stages. In the first stage, participants were asked to select their most distressing memory related to their appearance (not physical or sexual trauma). They were asked to visualize the selected memory, in detail, as if it were happening to them again. Then, interventionists used a downward arrow technique to identify two-to-three maladaptive core schema. In the second stage, participants were asked to identify a real or imagined trusted adult. Then, they were asked to imagine what their younger self might need to cope with or feel calmer in the situation of their selected memory. In the third stage, the participant was instructed to imagine asking the trusted adult for what they need and to imagine the trusted adult providing their selected interventions and describe how they feel afterwards. These procedures were then repeated with participants' most distressing memory related to eating. This session was remote delivered via Zoom.
62216701|NCT06610318|ACTIVE_COMPARATOR|Nutrition education control|The active control condition consisted of a time- and attention-matched general nutrition education session. The curriculum for this intervention included information from the United States Department of Agriculture's Dietary Guidelines (e.g., food labels, describing the benefits of macronutrients). This session was remote delivered using Zoom.
62216702|NCT02878889|EXPERIMENTAL|Arm 1|S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
62216703|NCT01870908||tacrolimus + biological agents|
62216704|NCT02177591||CAD and MI|Patients with a history of coronary artery disease who have had a myocardial infarction in the past.
62216705|NCT02177591||CAD, no MI|Patients who have a history of coronary artery disease and have not had a myocardial infarction in the past.
62410917|NCT06649357|ACTIVE_COMPARATOR|BiTURP|Bipolar Transurethral Resection of the Prostate
62410918|NCT05846503|OTHER|Intervention|Cluster of clinics receiving the five investigational interventions
62585389|NCT05902273||septic shock patients|mechanically ventilated septic shock patients
62216706|NCT02177591||no CAD|Patients with no documented history of coronary artery disease.
62216707|NCT01293487|EXPERIMENTAL|Arm 1|
62410919|NCT05846503|NO_INTERVENTION|Control|Standard of care
62410920|NCT06061328|EXPERIMENTAL|OASIS DA|Half of the sites will be randomized to receive training on the OASIS decision aid.
62585390|NCT03428113||ICU patient unable to void for 6 hours|ICU patients unable to void after 6 hours after a indwelling urinary catheter is removed or since time of admission
62585391|NCT03428113||renal failure with low urine volume|ICU patients with renal failure, acute kidney injury or acute on chronic with minimal urine output without an indwelling urinary catheter
62585392|NCT06113328|EXPERIMENTAL|Base Study: Dose 1|Participants receive subcutaneous (SC) MK-6194 dose regimen 1.
62585393|NCT06113328|EXPERIMENTAL|Base Study: Dose 2|Participants receive SC MK-6194 dose regimen 2.
62585394|NCT06113328|PLACEBO_COMPARATOR|Base Study: Placebo|Participants receive an SC placebo regimen.
62216708|NCT04659941|EXPERIMENTAL|BCG vaccine|0.1 ml of the reconstituted vaccine to be administered intradermally in the lower insertion of the deltoid muscle, preferably on the right side, in only one occasion
62216709|NCT04659941|PLACEBO_COMPARATOR|0.9% sodium chloride (NaCl) saline solution|0.1 ml of 0.9% NaCl saline solution to be administered intradermally in the lower insertion of the deltoid muscle, preferably on the right side, in only one occasion
62216710|NCT04404985|ACTIVE_COMPARATOR|Surgical AVFs|Participants who initiated dialysis with a catheter or have advanced chronic kidney disease ,these patients who an Surgical AVF intervention group that will undergo a routine surgical AVF creation.
62216711|NCT04404985|EXPERIMENTAL|Endo-vascular AVF|Participants who initiated dialysis with a catheter or have advanced chronic kidney disease ,these patients who an endo-vascular AVF intervention group that will undergo a per-cutaneous AVF creation.
62216712|NCT02842320|EXPERIMENTAL|Additional biological samples|Bone marrow sample and blood collected at J0 (screening visit), and at 3, 6, 12, 18 and 24 months and at each additional consultations (relapse ...)
62216713|NCT03935802||primary non-metastatic breast cancer|primary non-metastatic breast cancer
62216714|NCT04300075||CUSABT|Subject receives use of the CUSA Clarity Bone Tip product during cranial skull base bone removal surgery
62216715|NCT02482168|EXPERIMENTAL|APX005M every 3 week|Subjects receive APX005M intravenously every 3 week until disease progression, unacceptable toxicity or death.
62216716|NCT02482168|EXPERIMENTAL|APX005M every 2 week|Subjects receive APX005M intravenously every 2 week until disease progression, unacceptable toxicity or death.
62216717|NCT02482168|EXPERIMENTAL|APX005M every 1 week|Subjects receive APX005M intravenously every 1 week until disease progression, unacceptable toxicity or death.
62216718|NCT02334982|EXPERIMENTAL|Cohort 1: TAK-137 2 mg|TAK-137 2 mg, tablets, orally, once on Day 1.
62216719|NCT02334982|EXPERIMENTAL|Cohort 2: TAK-137 5 mg|TAK-137 5 mg, tablets, orally, once on Day 1.
62216720|NCT02334982|EXPERIMENTAL|Cohort 3: TAK-137 10 mg|TAK-137 10 mg, tablets, orally, once on Day 1.
62216721|NCT02334982|EXPERIMENTAL|Cohort 4: TAK-137 5 mg Food Effect|TAK-137 5 mg, tablets, orally, under fasted conditions, once on Day 1 of Period 1, followed by 14 days of follow-up, followed by TAK-137 5 mg, tablets, orally, under fed conditions, once on Day 1 of Period 2.
62216722|NCT02334982|EXPERIMENTAL|Cohort 5: TAK-137 0.5 mg|TAK-137 0.5 mg, tablets, orally, once on Day 1.
62216723|NCT02334982|EXPERIMENTAL|Cohort 6: TAK-137 20 mg|TAK-137 20 mg, tablets, orally, once on Day 1.
62216724|NCT02334982|PLACEBO_COMPARATOR|Cohorts 1-6: Placebo|TAK-137 placebo-matching tablets, orally, once on Day 1.
62216725|NCT02871531|EXPERIMENTAL|Pneumatic retinopexy|Patients with retinal detachment allocated to pneumatic retinopexy
62216726|NCT02871531|EXPERIMENTAL|Vitrectomy|Patients with retinal detachment allocated to vitrectomy
62216727|NCT06397677||Patients with RA-ILD|"Assessments include:~* Clinical: height, weight, oxygen saturation at rest, and 6-minute walk test.~* Rheumatological: study Rheumatologist will document rheumatoid arthritis symptoms and clinical findings at baseline and follow-up.~* Pulmonary Function Testing: data will be collected from clinically performed spirometry and diffusing capacity for carbon monoxide.~* High-resolution computed tomography (HRCT) imaging: HRCT scans will be collected at baseline and 12 months in line with standard of care for treatment of RA-ILD.~* Lab specimens: peripheral blood will be obtained for DNA, RNA, serum, and plasma at baseline and at 12 months for all sites or every 3-4 months in Colorado. Buccal swabs (cheek) will also be collected once each year.~* Information collected: will include demographics, co-morbidities, disease history, medication history, pulmonary function, radiographic imaging, and transplant/survival status through questionnaires and medical chart review."
62216728|NCT05337085|ACTIVE_COMPARATOR|Dexmedetomidine|Inj. Dexmedetomidine (precidex) 200/mcg/2ml given to participants in infusion form for 10 mins of surgery and maintenance dose given till the end of surgery
62216729|NCT05337085|ACTIVE_COMPARATOR|Midazolam|Inj midazolam 0.5 mg/kg stat dose will be given to participants during surgery
62216730|NCT05839795|OTHER|Caregivers of Rehabilitation Patients|Caregivers of rehabilitation patients, such as those with neurological, pediatric, and orthopedic disorders
62216731|NCT01679405|EXPERIMENTAL|Dose level 1 (Part A)|30 mg BIBW 2992, Gemcitabin (1.000 mg/m² BSA i.v.)/Cisplatin (25 mg/m² BSA i.v.)
62216732|NCT01679405|EXPERIMENTAL|Dose level -1 (Part A)|30 mg BIBW 2992, Gemcitabin (800 mg/m² BSA i.v.)/Cisplatin (20 mg/m² BSA i.v.)
62216733|NCT01266681|ACTIVE_COMPARATOR|Amiodarone|this group will be given Amiodarone to maintain sinus rhythm powst cardioversion.
62216734|NCT01266681|ACTIVE_COMPARATOR|Dronedarone|this group will be given dronedarone to maintain sinus rhythm post DC cardioversion
62216735|NCT06520800|EXPERIMENTAL|Traumatic and overuse exercise-related injuries|There is no registry of any clinically relevant adverse or unintended event associated with this kind of intervention. Nevertheless, adolescents with severe obesity may be at higher risk of both traumatic and overuse exercise-related injuries. A specific insurance for special risk participants, covering exercise-related injuries and dead (Appendix 1), will be activated in case of any adverse or unintended event during or as consequence of the exercise sessions. The impact of that specific event will be additionally analyzed and reported by the health professionals.
62216736|NCT04686201|EXPERIMENTAL|intervention group|
62585395|NCT06113328|EXPERIMENTAL|Extension: Dose 1|"Participants receive SC MK-6194 dose regimen 1. Participants from the arms Base Study: Dose 1 or Base Study: Placebo may be enrolled in this arm after completing participation in their original arm."
62216737|NCT04686201|NO_INTERVENTION|control group|
62216738|NCT00572039|EXPERIMENTAL|PST|Problem Solving Treatment (PST)
62216739|NCT00572039|PLACEBO_COMPARATOR|ST|Supportive Therapy (ST)
62216740|NCT02466750|EXPERIMENTAL|Primary vaccine|Subjects receive 3 doses off WEE vaccine on Day 0, Day 7 ± 2 days, and Day 28-35 days. A booster will be administered on Day 180 ± 14 days and a sample collected for PRNT80 28-35 days later.
62792589|NCT06373146|EXPERIMENTAL|TZP + Mibavademab-placebo (MIBA-PBO) [Group B]|Participants will receive TZP SC and MIBA-PBO SC for 24 weeks. Participants in Group B will be randomized (Randomization 2) to Groups E, F, G, and H at week 24.
62792590|NCT06373146|EXPERIMENTAL|TZP + MIBA then Tirzepatide-placebo (TZP-PBO) + MIBA [Group C]|Participants will receive TZP SC and MIBA SC for 24 weeks followed by TZP-PBO SC and MIBA SC for 24 weeks.
62792591|NCT06373146|EXPERIMENTAL|TZP + MIBA [Group D]|Participants will receive TZP SC + MIBA SC for 48 weeks.
62792592|NCT06373146|EXPERIMENTAL|TZP + MIBA-PBO [Group E]|Participants will receive TZP SC + MIBA-PBO SC for 48 weeks.
62792593|NCT06373146|EXPERIMENTAL|TZP + MIBA-PBO then TZP-PBO + MIBA [Group F]|Participants will receive TZP SC + MIBA-PBO SC for 24 weeks followed by TZP-PBO SC + MIBA SC for 24 weeks.
62792594|NCT06373146|EXPERIMENTAL|TZP + MIBA-PBO then TZP + MIBA [Group G]|Participants will receive TZP SC + MIBA-PBO SC for 24 weeks followed by TZP SC + MIBA SC for 24 weeks.
62792595|NCT06373146|EXPERIMENTAL|TZP + MIBA-PBO then TZP-PBO + MIBA-PBO [Group H]|Participants will receive TZP SC + MIBA-PBO SC for 24 weeks followed by TZP-PBO SC + MIBA-PBO SC for 24 weeks.
62792596|NCT01288989|EXPERIMENTAL|IMC-3C5|Participants receiving IMC-3C5 intravenously
62410921|NCT06061328|ACTIVE_COMPARATOR|Current DA Tool|Half of the sites will be randomized to receive training on the current decision aid tool.
62410922|NCT06456749||COPD patients with comorbidities|Adult patients diagnosed of stable COPD with/without diabetes and/or hypertension.4000 stable COPD patients, and among them approximately 2000 subjects with hypertension and/or type 2 diabetes complications.
62410923|NCT03666819|EXPERIMENTAL|Treatment (carbon dioxide fractional laser)|Participants undergo carbon dioxide fractional laser therapy over 10-15 minutes on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62410924|NCT06551506|EXPERIMENTAL|Group 1A|Mother receives 120 mcg/0.5ml of maternal RSVpreF (ABRYSVO) administered intramuscularly once during 32 0/7 to 36 6/7 weeks GA and infant does NOT receive nirsevimab. N= 50.
62410925|NCT06551506|EXPERIMENTAL|Group 1B|Mother receives 120 mcg/0.5ml of maternal RSVpreF (ABRYSVO) administered intramuscularly once during 32 0/7 to 36 6/7 weeks GA and infant receives one dose of nirsevimab (BEYFORTUS) 50mg/0.5mL if body weight \<5kg or 100mg/mL if body weight is \>= 5kg at birth. N= 50.
62792597|NCT03377153|ACTIVE_COMPARATOR|Hesperidin and Flaxseed|
62792598|NCT03377153|PLACEBO_COMPARATOR|control|
62792599|NCT02166502||Nevirapine|The patients in this study are newborn infants clinically prescribed combination antiretroviral treatment with nevirapine for prevention of mother-to-child HIV transmission.
62792600|NCT02877303|EXPERIMENTAL|Treatment (blinatumomab, inotuzumab, combination chemotherapy)|See detailed description.
62410926|NCT06551506|EXPERIMENTAL|Group 1C|Mother receives 120 mcg/0.5ml of maternal RSVpreF (ABRYSVO) administered intramuscularly once during 32 0/7 to 36 6/7 weeks GA and infant receives one dose of nirsevimab (BEYFORTUS) 50mg/0.5mL if body weight \<5kg or 100mg/mL if body weight is \>= 5kg at 3-month . N= 50.
62410927|NCT06551506|EXPERIMENTAL|Group 2|Mother does NOT receive maternal RSVpreF and infant receives one dose of nirsevimab (BEYFORTUS) 50mg/0.5mL if body weight \<5kg or 100mg/mL if body weight is \>= 5kg at birth . N= 50.
62410928|NCT01847625||Physicians experienced in lead extraction|Physicians experienced in lead extraction
62410929|NCT03273257|ACTIVE_COMPARATOR|Riociguat|Patients will receive riociguat for 3 months followed by pulmonary endarterectomy.
62410930|NCT03273257|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo for 3 months followed by pulmonary endarterectomy.
62410931|NCT00611780|EXPERIMENTAL|1|Reduced tube voltage of 100kV.
62410932|NCT00611780|ACTIVE_COMPARATOR|2|Standard tube voltage of 120kV.
62410933|NCT06475105|EXPERIMENTAL|Group A (Oral Acetazolamide)|Participants who received intravenous furosemide plus acetazolamide 250 mg / 12 hours orally for up to 3 days.
62410934|NCT06475105|PLACEBO_COMPARATOR|Group B (Placebo)|Participants who received intravenous furosemide plus Placebo / 12 hours orally for up to 3 days.
62410935|NCT05494723|EXPERIMENTAL|Low-dose|Low-dose YB-1113
62792601|NCT04843761|EXPERIMENTAL|Aviptadil + Remdesivir + SOC|
62792602|NCT04843761|PLACEBO_COMPARATOR|Aviptadil + Remdesivir Placebo + SOC|
62792603|NCT04843761|EXPERIMENTAL|Aviptadil Placebo + Remdesivir + SOC|
62792604|NCT04843761|EXPERIMENTAL|Aviptadil Placebo + Remdesivir Placebo + SOC|
62792605|NCT04700540|EXPERIMENTAL|Intervention Group|The PWMC and Care partner in this group will receive the SR. The project will provide a smartwatch and smartphone for the dyads in the study. All others (family, friends, etc.) will be able to download a smartphone app from an online store. Instructional material will be created to show the suggested information that can be entered into the app. Care partners and PWMC are administered surveys at baseline, 3 months and 6 months following enrollment.
62792606|NCT04700540|NO_INTERVENTION|Attention Control Group|Care partners are administered surveys at baseline, 3 months and 6 months following enrollment. The attention control group will receive a contact call from one of the researchers 3-months and 6-months after enrollment. Based on our prior experience, PWMC and care partners in an attention control group will often seek information and psychosocial support during these calls. We will provide free information resources (e.g., brochures or websites of the Alzheimer's Association) at that time.
62792607|NCT02489292|EXPERIMENTAL|HepaStem|Target total dose 50x10E6 cells/kg
62792608|NCT02923570|EXPERIMENTAL|Photon intensity modulated radiation therapy (IMRT)|IMRT to standard dose of 60-66Gy
62021524|NCT00987207|OTHER|Control|No cyclosporine A is administered before aortic cross-declamping
62410936|NCT05494723|EXPERIMENTAL|High-dose|High-dose YB-1113
62410937|NCT00916617|EXPERIMENTAL|1|5 mg/week
62792609|NCT02923570|EXPERIMENTAL|Proton beam radiotherapy (PBRT)|PBRT to standard dose of 60-66Gy
62792610|NCT02905630|EXPERIMENTAL|Exercise training|High intensity aerobic exercise training
62792611|NCT02905630|NO_INTERVENTION|No training|No exercise training, only ordinary daily life activities.
62792612|NCT04208438||BVI Cohort|Cohort to have ultrasound and Mespere BVI device applied.
62792613|NCT06069414||Inhalatory induction|Patients who will be induced via mask with inhalators anesthetic gases
62792614|NCT06069414||Intravenous induction|Patients who will be induced with intravenous anesthetics
62216741|NCT02466750|EXPERIMENTAL|Booster series|Subjects who previously received the WEE vaccine under another protocol and have a PRNT80 \< 1:40. Boosters (and follow-up titers 28-35 days later) may continue while the subject has titers of \< 1:40 for a maximum of 4 booster doses in a year. If the titer remains \< 1:40 after 4 booster doses in 1 year, the subject will not be given WEE vaccine for 1 year. If the titer is \< 1:40 after that interval, one booster dose will be given and the titer will be assayed. If the immune response to the last booster dose is \< 1:40, the subject will be considered to have completed the study as a nonresponder.
62216742|NCT01119872|OTHER|Compliance-guided PEEP group|Positive End-Expiratory Pressure(PEEP) level was set daily, according to the method described by Suter in 1978. Static compliance (Cst) was calculated at different levels of PEEP at a constant tidal ventilation of 6-8 ml/kg of predicted body weight. Cst was determined by dividing tidal volume by the difference between the pressure at the end of inflation hold and the PEEP. The maximum value of Cst in individual patients was considered as the best PEEP.
62792615|NCT02950909|EXPERIMENTAL|Emphasized exercise group|Patients in the emphasized exercise group performed exercises emphasizing the deep cervical extensor muscles applying a resistance at the level of the vertebral arch of C4 either therapeutically with the therapist's fingers or as a home exercise with the aid of a towel or belt. These exercises were performed in sitting and standing in front of a table propped up on both forearms. In the latter position, a dynamic exercise was added moving the head from maximal flexion to maximal extension keeping the gaze fixed at an object lying between both elbows hoping to activate more the extensors in the lower cervical spine.
62792616|NCT02950909|EXPERIMENTAL|General exercise group|Patients in the general exercise group performed exercises targeting all cervical extensor muscles including the superficial ones applying resistance at the head pushing against a wall or the therapist's hand or as a home exercise with the aid of a towel. As in the other group, these exercises were performed in sitting and standing in front of a table propped up on both forearms. In the latter position, the same dynamic exercise was added as in the other group with the only difference that the gaze was fixed at an object lying between both hands hoping to activate all cervical extensors
62792617|NCT06216821|ACTIVE_COMPARATOR|Standard DAPT therapy|Standard DAPT therapy for 12 mouths
62792618|NCT06216821|EXPERIMENTAL|OPT-CAD score guided de-escalation DAPT therapy|Patients at moderate to high risk of ischemic events assessed by the OPT-CAD score will receive DAPT therapy for 3 months followed by P2Y12 inhibitor monotherapy for 9 months; Patients at low risk of ischemic events assessed by the OPT-CAD score will receive DAPT for 1 month follow by P2Y12 inhibitor monotherapy for 11 months.
62792619|NCT04131062|NO_INTERVENTION|Control (no intervention)|Consented using the traditional, human-mediated consent process already in use for MyCode consenting.
62792620|NCT04131062|EXPERIMENTAL|Electronic Consent (iPad)|Consented using the Sage eConsent framework, which presents participants with an iPad that describes MyCode and allows participants to choose to learn more information at various steps along the process.
62792621|NCT00706420|EXPERIMENTAL|1|Islet cell transplantation alone
62216743|NCT01119872|OTHER|FiO2-driven-PEEP group|"PEEP was set based on the patient fraction of inspired oxygen (FiO2) according to the Positive End-Expiratory Pressure(PEEP) strategy reported in 2000:Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network."
62021525|NCT03007316|EXPERIMENTAL|Immediate Implants + VIP graft.|Immediate implants placed with simultaneous vascularized interpositional periosteal (VIP) connective tissue graft augmentation.
62792622|NCT02312050|EXPERIMENTAL|GCS-100 1 mg|Dose level 1 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
62216744|NCT04717245|ACTIVE_COMPARATOR|Fractional CO2 LASER|Vaginal fractional CO2 LASER 3 sessions applications
62216745|NCT04717245|ACTIVE_COMPARATOR|Microablative fractional radiofrequency|Vaginal Microablative fractional radiofrequency 3 sessions application
62410938|NCT05242406|EXPERIMENTAL|H-EMST|"In 60% of the maximum expiratory pressure (MEP), 25 breaths a day, 7 days / week, a total of 12 weeks will be trained with a 1-minute rest cycle in 5 breaths.~Patients will be invited to control every 2 weeks. MEP measurements will be repeated and the training value will be adjusted in 60% of the new measurement."
62792623|NCT02312050|EXPERIMENTAL|GCS-100 3 mg|Dose level 2 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
62792624|NCT02312050|EXPERIMENTAL|GCS-100 9 mg|Dose level 3 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
62792625|NCT02312050|PLACEBO_COMPARATOR|Normal Saline Solution 0.9%|Placebo - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
62792626|NCT00291018|EXPERIMENTAL|ProDisc-C|ProDisc-C total disc replacement device intended to treat single level SCDD in the cervical spine from C3-C7
62792627|NCT00291018|ACTIVE_COMPARATOR|Control|ACDF
62216746|NCT04717245|ACTIVE_COMPARATOR|Promestriene Vaginal|Promestriene vaginal use during 3 months
62021526|NCT03007316|NO_INTERVENTION|Immediate Implants only|Immediate Implants only without soft tissue augmentation.
62021527|NCT05170698|EXPERIMENTAL|coalition excision and arthroereisis|Talocalcaneal bar excision is done and then arthroereisis implant is applied in subtalar joint to correct rigid pes planovalgus in adolescent
62216747|NCT04572308|EXPERIMENTAL|CD7 CAR-T|Patients will be treated with CD7 CAR-T cells
62216748|NCT03656510|EXPERIMENTAL|High Dose: JNJ-53718678|Participants will be randomized to receive JNJ-53718678 2.5 milligram per kilogram (mg/kg) (Age Group 1: greater than or equal to \[\>=\] 28 days and less than \[\<\] 3 months of age), 3 mg/kg (Age Group 2: \>=3 months and \<6 months of age) and 4.5 mg/kg (Age Group 3: \>=6 months and less than or equal to \[\<=3\] years of age) orally twice daily for 7 days.
62585396|NCT06113328|EXPERIMENTAL|Extension: Dose 2|"Participants receive SC MK-6194 regimen 2. Participants from the arms Base Study: Dose 2 or Base Study: Placebo may be enrolled in this arm after completing participation in their original arm."
62792628|NCT06362317|EXPERIMENTAL|Toripalimab, Lenvatinib and Gemox Chemotherapy（Gemox or GC）|
62792629|NCT06362317|EXPERIMENTAL|Toripalimab and Lenvatinib|
62792630|NCT06362317|ACTIVE_COMPARATOR|Toripalimab and Gemox Chemotherapy（Gemox or GC）|
62792631|NCT00674414|ACTIVE_COMPARATOR|Arm I|Patients receive trastuzumab (Herceptin®) IV once weekly for 6 weeks. Patients then undergo surgery.
62216749|NCT03656510|EXPERIMENTAL|Low Dose: JNJ-53718678|Participants will be randomized to receive JNJ-53718678 0.85 mg/kg (Age Group 1: \>=28 days and \<3 months of age), 1 mg/kg (Age Group 2: \>=3 months and \<6 months of age) and 1.5 mg/kg (Age Group 3: \>=6 months and 3 years of age) orally twice daily for 7 days.
62216750|NCT03656510|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive matching placebo (i.e. high volume placebo or low volume placebo to match the calculated volume of the JNJ-53718678 for the high dose or low dose) orally twice daily for 7 days.
62216751|NCT05718466|EXPERIMENTAL|Fractionated Radiosurgery and Bevacizumab|FRS and Bev followed by Bev combined either Irinotecan or Temozolamide or Carboplatin or Etoposide until progression
62216752|NCT05718466|ACTIVE_COMPARATOR|Bev with Chemo|Bev combined either Irinotecan or Temozolomide or Carboplatin or Etoposide until progression
62792632|NCT00674414|EXPERIMENTAL|Arm II|Patients receive trastuzumab as in arm I and oral everolimus once daily for 6 weeks. Within 24 hours after completing everolimus, patients undergo surgery.
62792633|NCT00255788|ACTIVE_COMPARATOR|Arm A|Everolimus - 28 days q 4 wk
62792634|NCT00255788|ACTIVE_COMPARATOR|Arm B|Everolimus - days 1, 8, 15 and 22 q 4wks
62792635|NCT04961424||Symptomatic spinal epidural hematoma Group|Patients who performed thoracic decompression surgery and developed neurological deficit after surgery due to the symptomatic spinal epidural hematoma were enrolled into case group.
62792636|NCT04961424||Control group|hose who did not develop the symptomatic spinal epidural hematoma, underwent the same procedures of similar complexity at the same section of thoracic spine in the same period (the same year or the following year) were randomly selected from the pool of patients.
62792637|NCT00959179||Device therapy patients for CHF.|enroll all consecutive patients undergoing implantable cardioverter defibrillator (ICD) and ICD with biventricular pacemaker (CRT-D) implantation for heart failure from in-patient and out-patient referral setting
62216753|NCT01659788|EXPERIMENTAL|Coenzyme Q10 concomitant treatment|"Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment~Dose: 600 mg by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the CoEnzyme Q10 if conceives or when the study is completed.~Other name: Ubiquinone"
62216754|NCT01659788|PLACEBO_COMPARATOR|Placebo|1 capsule by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the placebo when she conceives or when the study is completed.
62410939|NCT05242406|EXPERIMENTAL|L-EMST|"At 30% of the maximum expiratory pressure (MEP), 25 breaths, 7 days / week, a total of 12 weeks will be trained once a day with a 1-minute rest cycle in 5 breaths.~Patients will be invited to control every 2 weeks. MEP measurements will be repeated and the training value will be adjusted in 30% of the new measurement."
62410940|NCT01067339|EXPERIMENTAL|Darapladib|Subjects randomized to this arm will receive a darapladib tablet, 160 mg, by mouth, once per day for 6 months.
62410941|NCT01067339|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive a placebo tablet matching the study drug, once per day for 6 months.
62410942|NCT06385873|EXPERIMENTAL|Experimental|RC48, Adebrelimab, Apatinib and S-1 regimen for 3-4 cycles (every 3 weeks) before surgery.
62410943|NCT03026894|ACTIVE_COMPARATOR|CD group|Panoramic Radiographs and T-Scan III occlusal system
62216755|NCT01999140||Primary prevention|
62410944|NCT03026894|ACTIVE_COMPARATOR|IOD group|Panoramic Radiographs and T-Scan III occlusal system
62410945|NCT06557473|ACTIVE_COMPARATOR|The lidocaine group|Anesthesia will be induced using 1.5 mg/kg lidocaine in the lidocaine group (L), 2mg/kg propofol, and 0.5 mg atracurium.
62410946|NCT06557473|PLACEBO_COMPARATOR|The fentanyl group|Anesthesia will be induced using 2 µg/kg fentanyl in the fentanyl group (F), 2mg/kg propofol, and 0.5 mg atracurium.
62410947|NCT03063957||Microscopic Colitis|Patients with confirmed microscopic colitis
62410948|NCT03063957||Control|Patients that are not diagnosed with microscopic colitis
62410949|NCT01982045|EXPERIMENTAL|AttraX condition|8-10cc of AttraX® Putty per spinal level at the randomized allocation side of the spine (left or right).
62216756|NCT00909337|OTHER|Bosentan|"In this study, all participants have normal pulmonary arterial pressure at rest and elevated pulmonary arterial pressure during exercise. First, they were followed up for a year and were controlled after 1 year without specific therapy for pulmonary hypertension. Then Bosentan was introduced. A second control showing the effects of the therapy was done after 6 months. The changes in the therapy period can be compared with the changes in the follow up period."
62792638|NCT00959179||ICD and CRT-D patients|enroll all consecutive patients undergoing implantable cardioverter defibrillator (ICD) and ICD with biventricular pacemaker (CRT-D) implantation for heart failure from in-patient and out-patient referral setting
62792639|NCT04556279||hyperaldosteronism surgical treatment|Hypertensive patients with primary hypersldosteronism, treated with surgery
62792640|NCT04556279||hyperaldosteronism medical treatment|Hypertensive patients with primary hypersldosteronism, treated with aldosterone blockade.
62792641|NCT04556279||hypertensive control|Hypertensive patients shown not to have primary hyperaldosteronism
62216757|NCT06155994|EXPERIMENTAL|Group A and B|"Group A: six patients with advanced medullary thyroid carcinoma~Group B: six patients with advanced gastroenteropancreatic and bronchopulmonary neuroendocrine tumours"
62216758|NCT03183726||ALLO-ASC-DFU treatment|Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-DFU-101
62410950|NCT01982045|ACTIVE_COMPARATOR|Autograft condition|8-10cc autologous bone graft per spinal level at the control side of the spine. This can be a combination of local bone and iliac crest bone, but at least 50% of the volume has to be iliac crest bone graft.
62410951|NCT04543539||IN.PACT™ AV Access PAS Primary Cohort|The primary cohort consists of enrolled subjects treated with the IN.PACT™ AV DCB according to labeling requirements who meet the inclusion/exclusion criteria for the primary cohort.
62410952|NCT04543539||IN.PACT™ AV Access PAS Extended Cohort|The extended cohort consists of enrolled subjects who do not meet the eligibility criteria for the primary cohort and receive the IN.PACT™ AV DCB device for treatment of stenosis in the AV circuit.
62410953|NCT01427556||Breakfast Eaters|Women who self-report eating breakfast regularly.
62410954|NCT01427556||Non-Breakfast Eaters|Women who self-report skipping breakfast regularly.
62216759|NCT03316820|EXPERIMENTAL|Treatment A|K0706 tablet
62216760|NCT03316820|EXPERIMENTAL|Treatment B|K0706 tablet
62216761|NCT03316820|EXPERIMENTAL|Treatment C|K0706 tablet
62216762|NCT03316820|EXPERIMENTAL|Treatment D|K0706 capsule
62216763|NCT05439590|EXPERIMENTAL|High dose CSO|Participants will be randomly assigned to a smoothie containing 60 g of CSO per day for four weeks.They will be asked to consume smoothies any time of the day.
62216764|NCT05439590|EXPERIMENTAL|Low dose CSO|Participants will be randomly assigned to a smoothie containing 30 g of CSO per day for four weeks.They will be asked to consume smoothies any time of the day.
62216765|NCT05439590|ACTIVE_COMPARATOR|High dose OO|Participants will be randomly assigned to a smoothie containing 60 g of OO per day for four weeks.They will be asked to consume smoothies any time of the day.
62216766|NCT05439590|ACTIVE_COMPARATOR|Low dose OO|Participants will be randomly assigned to a smoothie containing 30 g of OO per day for four weeks.They will be asked to consume smoothies any time of the day.
62216767|NCT01768637|EXPERIMENTAL|Chronic Kidney Disease|Patients with pre-dialysis stages 4-5 Chronic Kidney Disease will receive open-label aspirin 81 mg once daily for 2 weeks, then 2 weeks of aspirin 81 mg plus clopidogrel 75 mg once daily.
62216768|NCT01768637|ACTIVE_COMPARATOR|Normal controls|Patients without Chronic Kidney Disease will receive open-label aspirin 81 mg once daily for 2 weeks, then 2 weeks of aspirin 81 mg plus clopidogrel 75 mg once daily.
62216769|NCT04247763|EXPERIMENTAL|Arm 1 (Saturated Fat Meal, Oleic Sunflower Oil Meal)|
62792642|NCT02005588|ACTIVE_COMPARATOR|amino acid chelated iron arm|this arm will contain 150 pregnant women with proved iron deficiency anemia and pregnant 14-18 weeks. these pregnant women will be given amino acid chelated iron capsules (15 mg iron/capsule) 1-2 capsules daily according to hemoglobin level (hemoglobin 7-9 g/dl will receive 2 capsules, and hemoglobin 9.1-11 g/dl will receive 1 capsule). complete blood picture and serum ferritin will be assessed at 22-23 weeks, 29-30 weeks and 36-37 weeks. possible side effects (colicky abdominal pains, constipation and metallic taste) will be asked about in each follow up visit.
62216770|NCT04247763|ACTIVE_COMPARATOR|Arm 2 (Oleic Sunflower Oil Meal, Saturated Fat Meal)|
62410955|NCT05180994|EXPERIMENTAL|Topical infliximab following PKP surgery|Additionally to standard post-operative regimen, patients who will be undergoing their first PKP surgery and who meet all inclusion and no exclusion criteria will be included in the experimental group. These patients will administer topical infliximab four times per day for 3 months.
62410956|NCT05180994|ACTIVE_COMPARATOR|No topical infliximab following PKP surgery|Patients who will be undergoing their first PKP surgery, but who are not qualified to receive infliximab or who refuse to receive infliximab, will be included in the control group. These patients will only administer the standard post-operative regimen following their PKP surgery and will not administer topical infliximab. They will be followed with the same follow-up schedule, questionnaires, examinations and non-invasive tests (excluding lab work) as patients in the interventional group.
62410957|NCT02723760|EXPERIMENTAL|99mTc-3PRGD2 SPECT/CT scanning|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and efficacy evaluation of rheumatoid arthritis
62410958|NCT06110767|EXPERIMENTAL|Routine diet + Non-immersive virtual reality-based physical activity application|Non-immersive virtual reality will be applied 30 minutes a day, 3 days a week for 4 weeks.
62410959|NCT06110767|EXPERIMENTAL|Diet Program for healthy eating + Non-immersive virtual reality-based physical activity app|In addition to the 4-week diet program,Non-immersive virtual reality will be applied 30 minutes a day, 3 days a week for 4 weeks.
62216771|NCT05805436|NO_INTERVENTION|Control|Do not receive polyethylene glycol before surgery
62216772|NCT05805436|EXPERIMENTAL|Intervention|Receive polyethylene glycol before surgery
62216773|NCT03131154|EXPERIMENTAL|ADX-102 Ophthalmic Solution (0.5%)|
62216774|NCT03131154|PLACEBO_COMPARATOR|Vehicle of ADX-102 Ophthalmic Solution|
62216775|NCT04428918||Cohort 1|Allogeneic HCT recipient or patient pending receipt of HCT
62216776|NCT00519519|ACTIVE_COMPARATOR|2|regular dose versus high dose
62216777|NCT04014491|EXPERIMENTAL|Scapula control exercise|Subjects will perform three exercises with EMG biofeedback and verbal cues. Three exercises are elevation in scapular plane, sidelying external rotation and dynamic hug plus
62216778|NCT04014491|EXPERIMENTAL|Scapula strengthening exercise|The subjects in the scapular strengthening group will be asked to perform the three exercises the same as scapula control exercise group and with the same number of trials but without any EMG biofeedback and oral cues of movement or posture correction.
62216779|NCT04014491|OTHER|Healthy subject group|Healthy subjects will be included to compare the differences in corticospinal system between healthy subjects and subjects with shoulder impingement syndrome, so this group will not receive any treatment.
62216780|NCT00688558|EXPERIMENTAL|1|JTT-705 600 mg and simvastatin 40 mg
62216781|NCT00688558|PLACEBO_COMPARATOR|2|Placebo and simvastatin 40 mg
62216782|NCT04701177||Subjective cognitive decline (SCD)|subjective perception of cognitive decline in the absence of cognitive impairment in formal neuropsychological assessment.
62216783|NCT04701177||Mild cognitive impairment (MCI)|Single or multidomain cognitive deficits with preservation of activities of daily living.
62216784|NCT04701177||Prodromal Parkinson's Disease|Parkinson's disease (PD) has a prodromal phase during which nonmotor clinical features as well as physiological abnormalities may be present.
62216785|NCT00537654|EXPERIMENTAL|Fasted state|Subjects will be required to fast overnight. Subjects will participate in 3 treatment periods and assigned to one of 12 treatment sequences ( ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) in accordance with the randomization schedule. The three treatment periods will be separated by a minimum washout period of 28 days
62216786|NCT00537654|EXPERIMENTAL|Fed state|Subjects will be served high fat breakfast 30 minutes prior to dosing. Subjects will participate in 3 treatment periods and assigned to one of 12 treatment sequences ( ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) in accordance with the randomization schedule. The three treatment periods will be separated by a minimum washout period of 28 days
62216787|NCT01222026|ACTIVE_COMPARATOR|Strontium Ranelate|Receiving Strontium Ranelate + Ca/Vitamin-D
62792643|NCT02005588|ACTIVE_COMPARATOR|iron salt arm|this arm will contain 150 pregnant women with proved iron deficiency anemia and 14-18 weeks gestation. these women will be given oral iron salt ferrous fumarate capsules (350 mg iron/ capsule containing about 70 mg elemental iron/ capsule) 1-2 capsules daily according to hemoglobin level (hemoglobin 7-9 g/dl will receive 2 capsules daily and hemoglobin 9.1-11 g/dl will receive 1 capsule daily. women will be followed up with complete blood picture and serum ferritin at 22-23 weeks, 29-30 weeks and 36-37 weeks. women will be asked about possible side effects (colicky abdominal pains, constipation, and metallic taste) in each visit.
62021528|NCT05170698|EXPERIMENTAL|coalition excision and corrective osteotomies|Talocalcaneal bar excision is done and then according to degree of deformity either medial displacement calcaneal osteotomy or evans or cotton osteotomy is done or combined together to correct rigid pes planovalgus in adolescents
62216788|NCT01222026|PLACEBO_COMPARATOR|Placebo|Receiving Placebo + Ca/Vitamin D
62216789|NCT00613665|EXPERIMENTAL|1|
62410960|NCT06110767|EXPERIMENTAL|Diet program for healthy eating|4-week diet program will be applied.
62410961|NCT06652854||Patient scheduled for a pre-surgery consultation with a physician anesthesiologist|"After obtaining consent, patients will be asked to respond to the following query: What is the most important question you had hoped to ask your anesthesiologist today about your anesthesia care, pain management or the time immediately around surgery?'."
62410962|NCT06652854||Specialty-trained anesthesiologists in independent practice within the pre-admission|"anesthesiologists will be designated as either response generators or response raters. Response generators will craft answers to patient queries, while response raters-anesthesiologists with over five years of clinical experience-will evaluate the quality of these responses."
62410963|NCT04303065|EXPERIMENTAL|Dexamethasone|"Dexamethasone will be a short and descending course: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).~Dexamethasone (Fortecortin®) will be acquired from ERN, SA. Laboratories (Barcelona, Spain). The Son Espases Pharmacy Department will be in charge of developing and conditioning the 4mg, 2mg and 1mg dexamethasone / placebo capsules needed for 12 days of treatment, keeping the researchers blind"
62792644|NCT05750576|EXPERIMENTAL|Chlorhexidine-impregnated dressings|
62216790|NCT00613665|EXPERIMENTAL|2|
62216791|NCT00613665|EXPERIMENTAL|3|
62216792|NCT00613665|EXPERIMENTAL|4|
62410964|NCT04303065|PLACEBO_COMPARATOR|Control|"The preparation and conditioning of the capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).~The Son Espases Pharmacy Department will be responsible for identifying the containers and sending them by courier to the participating hospitals. A record of the dispensing of test samples will be kept and will be sent in acknowledgment of receipt for control"
62410965|NCT02111265|EXPERIMENTAL|Propofol|Target controlled infusion propofol, the effect compartment concentration is 3-4μg/ ml for induction and maintenance of anesthesia.
62410966|NCT02111265|EXPERIMENTAL|Etomidate|Target controlled infusion etomidate, the effect compartment concentration is 0.5-1.0μg/ ml for induction and maintenance of anesthesia.
62410967|NCT04195867|EXPERIMENTAL|Salmeterol|Subjects receive a 3-day treatment and collect urine from 2 days before first administration to 24 hours post-administration.
62410968|NCT06558799|EXPERIMENTAL|NovoTTF-200T + Pembrolizumab|
62410969|NCT06638866|EXPERIMENTAL|Pancreatic imaging AI screening|"The subject has undergone an abdominal or chest non-contrast CT scan, categorized as follows:~1. Physical exam population~2. Outpatient population~3. Inpatient population~4. Emergency department population"
62216793|NCT00613665|PLACEBO_COMPARATOR|5|
62216794|NCT00613665|EXPERIMENTAL|6|
62216795|NCT00613665|EXPERIMENTAL|7|
62216796|NCT06461702|EXPERIMENTAL|YOLT-101|
62216797|NCT02744911|EXPERIMENTAL|Telemedicine group|People with Parkinson's disease and their caregivers obtaining treatment using the SpeechVive device via the internet using the telemedicine application. Also includes speech-language pathologists providing treatment via the telemedicine application.
62216798|NCT02744911|ACTIVE_COMPARATOR|In person group|People with Parkinson's disease and their caregivers obtaining treatment using the SpeechVive device in person. Also includes speech-language pathologists providing treatment in person.
62216799|NCT05020327|EXPERIMENTAL|Low Risk Patients|This is the group of patients who will undergo the graded oral amoxicillin challenge testing. Total dose of the amoxicillin will be 45 mg/kg (maximum of 1000 mg). 10 % of this dose will be given first followed by 90 % of the dose 30 minutes after. Each dose will be given only once.
62216800|NCT05020327|OTHER|No Risk Patients|Patients in the group will be de-labeled in the electronic medical record for No Risk for allergic reaction to amoxicillin based on screening questionnaire.
62216801|NCT05020327|OTHER|High Risk|Patients in this group are deemed high risk for allergic reaction to penicillin based on screening questionnaire and will remain labeled with allergy in the electronic medical record. They will be referred as outpatient to allergy-immunology for further evaluation.
62585397|NCT02685358|EXPERIMENTAL|Clinician-Supported PTSD Coach|Clinician-supported PTSD Coach is primary care-based treatment. In this treatment a primary care mental health clinician guides patients in using the PTSD Coach mobile app to learn about PTSD symptoms, treatment options, and strategies to cope with common PTSD-related concerns. It consisted of 4 brief sessions over 8 weeks.
62585398|NCT02685358|ACTIVE_COMPARATOR|Primary Care Mental Health Integrated Care as Usual|Existing primary care mental health integrated treatment will serve as the comparison condition
62585399|NCT05197530|EXPERIMENTAL|Early RA (<1 year of disease)|In this single center study, early RA subjects (\<1 year of disease) who are MTX inadequate responders or experience a flare (see inclusion criteria for detail) on MTX and are starting an anti-TNF therapy will be invited to participate to receive ICG injections at Baseline (prior to the start of medication), week 16 and week 52. NIR-ICG imaging will be done immediately post injection and 1 week later for a total of three injection/imaging visits and three imaging visits without injections. See schedule of events for more detail. Total length of participation will be up to 53 weeks (+3days).
62216802|NCT02830360|ACTIVE_COMPARATOR|VT catheter ablation|Catheter ablation of ventricular tachycardia
62216803|NCT02830360|ACTIVE_COMPARATOR|Antiarrhythmic Drug Therapy|Patients will be prescribed either oral amiodarone or sotalol daily (dosage and frequency to be determined based on patient's clinical presentation at the time of the qualifying arrhythmia).
62216804|NCT02129270|ACTIVE_COMPARATOR|Lidocaine HCl 2%|Lidocaine HCl 2% (200mg/10ml) 10 ml.
62216805|NCT02129270|EXPERIMENTAL|Lidocaine HCl 1%|Lidocaine HCl 1% (100mg/10ml) 15-20 ml.
62216806|NCT04368559|EXPERIMENTAL|Group 1: Rezafungin for Injection|Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 13 weeks. Subjects will receive oral placebo for standard antimicrobial regimen (SAR) azole prophylaxis and oral placebo for SAR anti-Pneumocystis pneumonia (PCP) prophylaxis in accordance with the respective SAR dosing regimens for each. For subjects who are switched to a SAR IV regimen, oral placebo for SAR azole prophylaxis will be changed to IV placebo. There is no IV option for SAR anti-PCP prophylaxis.
62410970|NCT00902265||desmopressin|"Participants with benign prostate syndrome suffering from nocturia associated with nocturnal polyuria.~Drug given by prescription."
62410971|NCT03879135|EXPERIMENTAL|On-Demand|Participants will receive recombinant von Willebrand factor (rVWF) (with or without ADVATE).
62410972|NCT03879135|EXPERIMENTAL|Prophylaxis|Participants will receive recombinant von Willebrand factor (rVWF).
62410973|NCT01077167|EXPERIMENTAL|1|
62585400|NCT05197530|EXPERIMENTAL|Established RA (> 10 years of disease)|Patients with symptomatic established RA (\>10 years) will be invited to participate in an ICG injections followed by NIR-ICG imaging and NIR-ICG imaging visit 1 week later. Total length of participation will be up to 1 week (+3 days)
62585401|NCT06023446||Pre-Dementia Alzheimer's|By clinical assessment, these participants will either be cognitively normal, or have mild cognitive impairment. They will enter the study having already completed some biomarker testing for Alzheimer's disease (e.g., amyloid PET, cerebrospinal fluid measurement amyloid and tau). In this group, the biomarker testing is positive/abnormal, indicating a pre-dementia stage of Alzheimer's disease. In the language of the 2018 NIA-AA Research Framework, these participants have A+ in their AT(N) biomarker profile, and are at clinical stage 1-3.
62585402|NCT06023446||No Evidence of Alzheimer's|By clinical assessment, these participants will either be cognitively normal, or have mild cognitive impairment. They will enter the study having already completed some biomarker testing for Alzheimer's disease (e.g., amyloid PET, cerebrospinal fluid measurement amyloid and tau). In this group, the biomarker testing is negative/normal. In the language of the 2018 NIA-AA Research Framework, these participants have A- in their AT(N) biomarker profile, and are at clinical stage 1-3.
62410974|NCT06149988|EXPERIMENTAL|Single dose of THC/CBD S.E powder|On visit 1: Subjects will receive a single dose of THC/CBD S.E powder- 500 mg, given orally.
62585403|NCT05251831|EXPERIMENTAL|Activated plasma rich in platelets|Group A: patients were treated by intradermal injections of PRP activated with Calcium chloride 10% solution.
62585404|NCT05251831|PLACEBO_COMPARATOR|Non- activated plasma rich in platelets|Group B: patients were treated by intradermal injections of PRP without activation.
62585405|NCT06682806|EXPERIMENTAL|PRT3789/Pembrolizumab combination|PRT3789 is administered as an intravenous infusion once weekly for 3 weeks; Pembrolizumab is administered at 200 mg as an intravenous infusion over 30 min every 3 weeks
62410975|NCT06149988|ACTIVE_COMPARATOR|a single dose of THC/CBD oil|On visit 2 (30 days later): Subjects will receive a single dose of THC/CBD oil- 8 mg, given orally (equivalent dose to the powder).
62410976|NCT03950817|ACTIVE_COMPARATOR|0.75 mg/kg|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses of 0.75 mg/kg sub-dissociative dose ketamine (SDK) to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
62585406|NCT05202353|EXPERIMENTAL|Group 1: BI 456906|PET/CT imaging for analysis of the liver
62585407|NCT05202353|EXPERIMENTAL|Group 2: Semaglutide|PET/CT imaging for analysis of the liver
62585408|NCT05202353|ACTIVE_COMPARATOR|Group 3: BI 456906|PET/CT imaging for analysis of the pancreas
62792645|NCT05750576|PLACEBO_COMPARATOR|Non impregnated dressings|
62242981|NCT02198092||Patient Group Lynch Syndrome|"Clinical diagnosis of Lynch Syndrome, also known as HNPCC.~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients.~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
62585409|NCT05202353|ACTIVE_COMPARATOR|Group 4: Semaglutide|PET/CT imaging for analysis of the pancreas
62792646|NCT03434158|EXPERIMENTAL|Olaparib|600 mg/day
62792647|NCT01624116|ACTIVE_COMPARATOR|Diet and lifestyle measures alone.|Type 2 diabetic subjects on lifestyle counselling as part of diabetes treatment would continue as such during Ramadan. They would receive acarbose on one day to be followed by CGMS for a 24 hour period
62585410|NCT04290910|EXPERIMENTAL|Weight Loss Program|Single arm, all participants receive the weight loss program
62585411|NCT01167114|EXPERIMENTAL|STA-9090|All subjects receive STA-9090
62792648|NCT01624116|ACTIVE_COMPARATOR|Metformin monotherapy|Type 2 diabetics on biguanide treatment.
62792649|NCT01624116|ACTIVE_COMPARATOR|Metformin + Sulphonylurea.|Type 2 diabetics on dual oral hypoglycaemics-metformin and glimepiride.
62216807|NCT04368559|ACTIVE_COMPARATOR|Group 2: Oral Antifungal|"Subjects randomized to the SAR will receive either fluconazole or posaconazole as the first-line SAR as per site's standard practice. Fluconazole will be administered orally at once daily doses of 400 mg for 13 weeks. Posaconazole will be administered orally as 300 mg twice daily on the first day and 300 mg once daily thereafter for 13 weeks. Azole-based antifungal therapy (fluconazole or posaconazole) can be switched from oral therapy to IV therapy if there is oral intolerance, at the discretion of the Investigator.~Subjects who started on fluconazole SAR may be switched to posaconazole at the discretion of the Investigator if they develop acute clinically significant GVHD; In addition, subjects in the SAR group will receive anti PCP prophylaxis with oral TMP/SMX (80 mg TMP/ 400 mg SMX) once daily. There is no IV option for SAR anti-PCP prophylaxis."
62216808|NCT02437253|EXPERIMENTAL|Adalimumab first, then Placebo|Participants first received Adalimumab 20 mg subQ every other week (weight 15 to \<30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks.
62410977|NCT03950817|ACTIVE_COMPARATOR|SDK: 1 mg/kg|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses 1 mg/kg sub-dissociative dose ketamine (SDK), to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
62216809|NCT02437253|EXPERIMENTAL|Placebo first, then Adalimumab|Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to \<30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.
62216810|NCT00477321|EXPERIMENTAL|CYT107|CYT107 vs Placebo (4:1 ratio)
62216811|NCT02988518|EXPERIMENTAL|COGMED program|Cognitive remediation using COGMED program on bipolar euthymic patients with memory complaints
62216812|NCT05240742||Dutch COVID-19 patients|"The study population consists of Dutch (former) COVID-19 patients who have been included in one of the cohorts and categorized in various subgroups:~* Patients who suffered from (confirmed) COVID-19 and were admitted to the hospital ward.~* Patient who suffered from (confirmed) COVID-19 and were admitted to the ICU.~* Patients who suffered from (confirmed or suspected) COVID-19 at home.~* Patients who suffered from (confirmed) COVID-19 and were in need of inpatient or outpatient rehabilitation after infection at home or in the hospital (ward and/or ICU)."
62216813|NCT05240742||Dutch controls who did not experience COVID-19|One of the cohorts, the POPCOrn cohort, is a community-based cohort which partly consists of controls who did not experience COVID-19
62410978|NCT03950817|ACTIVE_COMPARATOR|SDK: 1.5 mg/kg.|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses of 1.5 mg/kg sub-dissociative dose ketamine (SDK), to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
62410979|NCT01190202|EXPERIMENTAL|Overall Study Group (Survey 1)|Subjects at least 6 months of age at the time of Survey 1, conducted at Year 1 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
62585412|NCT01075035||Normal Healthy Controls|Individuals with no history of Traumatic Brain Injury.
62585413|NCT01075035||Civilian TBI|Civilians who have had a Traumatic Brain Injury
62585414|NCT01075035||Military TBI|Combat military veterans who have had a Traumatic Brain Injury
62792650|NCT01624116|ACTIVE_COMPARATOR|Metformin + Sitagliptin|Type 2 diabetics managed on dual oral hypoglycaemic therapies: metformin and sitagliptin.
62792651|NCT03432169|ACTIVE_COMPARATOR|Yoga|Stretching with mindfulness
62792652|NCT03432169|ACTIVE_COMPARATOR|Stretching|Stretching exercises without mindfulness
62792653|NCT05668286|ACTIVE_COMPARATOR|posterior intra-articular steroid injection under USG guidance|Intra-articular steroid injection will be performed to the glenohumeral joint from the posterior, 2cm inferior and 2cm medial of the acromion posterolateral corner, under the guidance of USG.
62216814|NCT03203031||Neonates with abdominal surgery and quadratus lumborum block|0-6 months children with abdominal surgery. After standard induction of general anesthesia, patients will receive 0.5 ml/kg of ropivacaine (2 mg/ml) in a quadratus lumborum block. Ultrasonography will be used to guide the injection. In the postoperative period, pain scores and analgesics consumption will be recorded until the 48th hour post surgery.
62585415|NCT06684210|EXPERIMENTAL|External oblique intercostal plane block.|Given 0.5% ropivacaine intercostal nerve block, 2.0ug/kg sufentanil + tropisetron 5mg intravenous analgesia.
62585416|NCT06684210|NO_INTERVENTION|Patient controlled in travenousanalgesia.|Given intravenous analgesia with 2.0ug/kg sufentanil + tropisetron 5 mg.
62585417|NCT05887258|EXPERIMENTAL|Opioid free anesthesia (OFA)|"This arm is administered by the anesthesiologist in charge of the operating room.~It is composed by Dexmedetomidine (Dexdor), Lidocaine, Magnesium Sulfate and ketamine (Ketolar)."
62585418|NCT05887258|ACTIVE_COMPARATOR|Opioid based Anesthesia (OA)|"This arm is administered by the anesthesiologist in charge of the operating room.~This arm is composed of Remifentanil hydrochloride and postoperative rescue analgesia will be morphine."
62585419|NCT04094038|EXPERIMENTAL|Intervention|Intradialytic parenteral nutrition three times weekly during 16 weeks
62585420|NCT04094038|PLACEBO_COMPARATOR|Placebo|5% glucose three times weekly during 16 weeks
62792654|NCT05668286|ACTIVE_COMPARATOR|anterior extra-articular steroid injection under USG guidance|Steroid injection will be performed from the anterior, immediately lateral to the coracoid process, to the CHL localization, to the extra-articular area under the guidance of USG.
62792655|NCT02669251|EXPERIMENTAL|Phase 1b|Phase Ib dose escalation
62792656|NCT02669251|EXPERIMENTAL|Phase 2|MTD po bid on days 1-28
62792657|NCT06507930|NO_INTERVENTION|Usual Care Cohort|"25 participants will complete study procedures as follows:~* Introduction to study and survey by brief, verbal consent via phone call.~* At 4-6 weeks: survey completion via email or phone."
62216815|NCT04539080||Pre-operative transversus abdominis plane block|The group with transversus abdominis plane block before laparoscopic surgeries with a standard pain control protocol
62216816|NCT04539080||Traditional pain control group|The group with a standard pain control protocol
62216817|NCT00778960|EXPERIMENTAL|Slow Breathing Group|
62216818|NCT00778960|EXPERIMENTAL|Meditation Group|
62410980|NCT01190202|EXPERIMENTAL|Overall Study Group (Survey 2)|Subjects at least 6 months of age at the time of Survey 2, conducted at Year 2 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
62585421|NCT02981082|ACTIVE_COMPARATOR|Dimethyl Fumarate (DMF)|Twice daily oral doses of Dimethyl Fumarate (DMF) 120mg for the first 7 days followed by the maintenance dose of Dimethyl Fumarate (DMF) 240mg twice a day. Subjects will be dosed for 24 weeks
62216819|NCT00778960|EXPERIMENTAL|Meditation and Slow Breathing Group|
62216820|NCT00778960|PLACEBO_COMPARATOR|Sitting Quietly Group|
62216821|NCT00540046|ACTIVE_COMPARATOR|A/Immediate|The patients in the immediate arm will have the Copper T 380A IUD inserted within 15 minutes after delivery of the placenta immediately following procedure
62216822|NCT00540046|ACTIVE_COMPARATOR|B/Delayed|The delayed group will have the Copper T 380A IUD inserted at the post-operative visit within 2-4 weeks following the procedure.
62585422|NCT02981082|PLACEBO_COMPARATOR|Placebo|Twice daily oral doses of placebo for 12 weeks
62585423|NCT03108768|EXPERIMENTAL|Successor of Phonak Virto V|The successor of Phonak's Virto V will be fitted to the participants individual hearing loss.
62585424|NCT03108768|ACTIVE_COMPARATOR|Phonak Virto V|Phonak Virto V will be fitted to the participants individual hearing loss.
62585425|NCT06366516|EXPERIMENTAL|Women aged 25-65 years with high-risk HPV infection.|Ten thousand women were recruited who aged 25-65 years and they are positive for high-risk HPV.
62792658|NCT06507930|EXPERIMENTAL|Compassion Cohort|"25 participants will complete study procedures as follows:~* Introduction to study and survey by brief, verbal consent via phone call.~* At 4-6 weeks: survey completion via email or phone.~* 4 weekly check-ins via Zoom or phone call with study team."
62792659|NCT02899091|EXPERIMENTAL|CB-AC-02|Subjects with Alzheimer's disease Intervention: CB-AC-02
62792660|NCT02899091|PLACEBO_COMPARATOR|Placebo|Subjects with Alzheimer's disease Intervention: Placebo
62792661|NCT03648957|EXPERIMENTAL|Behavioral intervention|Usual stroke service care plus additional lifestyle counselling focusing on smoking cessation, physical activity, and adherence to preventive medication. Regular follow-up sessions (3-4 weeks intervals). Physical activity is monitors by an activity tracker.
62792662|NCT03648957|ACTIVE_COMPARATOR|Usual care|Usual stroke service care; including computed tomography brain scan, neurological evaluation, and relevant cardiological/vascular evaluation (48-72 hour telemetry, echocardiography, carotic ultrasound imaging). At discharge all patients will receive written and verbal encouragement to a healthy lifestyle.
62792663|NCT05877755|OTHER|Cardiac MRI acquisition|200 patients with a clinical indication for cardiac magnetic resonance imaging
62792664|NCT05893381|EXPERIMENTAL|Stereotactic Radiotherapy followed by Lu-PSMA (arm A)|Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen. 177Lu-PSMA-I\&T in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 Gigabequerel (GBq)
62216823|NCT01151410|EXPERIMENTAL|Aliskiren|Patients will receive one of the following doses based on the their weight: Low weight (≥20 to \<50 kg) patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg Mid weight (≥50 to \<80 kg) patients: Starting dose 75 mg with optional titration to 150 and then 300 mg High weight (≥80 to ≤150 kg) patients: Starting dose 150 mg with optional titration to 300 and then 600 mg
62216824|NCT01151410|ACTIVE_COMPARATOR|Enalapril|Patients will receive one of the following doses based on their weight: Low weight (≥20 to \<50 kg) patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg Mid weight (≥50 to \<80 kg) patients: Starting dose 5 mg with optional titration to 10 and then 20 mg High weight (≥80 to ≤150 kg) patients: Starting dose 10 mg with optional titration to 20 and then 40 mg
62216825|NCT05220787|EXPERIMENTAL|Cold stored platelets in 100% plasma stored for 10-14 days|Cold stored apheresis platelets in 100% plasma stored for 10-14 days, maximum of up to three units (3x10\^11/unit) from the start of surgery until 24 hours after the end of surgery
62216826|NCT05220787|ACTIVE_COMPARATOR|Room temperature stored platelets in 100% plasma stored for up to 7 days|Room temperature stored platelets in 100% plasma stored for up to 7 days, maximum of up to three units (3x10\^11/unit) from the start of surgery until 24 hours after the end of surgery
62216827|NCT02942524|EXPERIMENTAL|Supportive care (TEPID)|Patients complete the TEPID checklist of items during hospital stay.
62216828|NCT00804531|EXPERIMENTAL|Visipaque - Hydrocortancyl|Administration of two treatments for the experimental arm
62216829|NCT00804531|PLACEBO_COMPARATOR|Visipaque|Administration of only one treatment in intra discal of visipaque
62216830|NCT03584542||Patients in general practitioners' offices|No interventional study. Only one questionnaire will be done
62216831|NCT03584542||Patients of specialized centers for drug addict patients|No interventional study Only one questionnaire will be done
62216832|NCT03584542||General practitioners|No interventional study Only one questionnaire will be done
62216833|NCT00215137|EXPERIMENTAL|Open Label Escitalopram 10-20 mg/daily|Fourteen patients who met criteria for the study were enrolled in the open-label phase. Thirteen of these patients completed the open-label phase, while one patient was terminated early due to side effects.
62792665|NCT05893381|ACTIVE_COMPARATOR|Stereotactic Radiotherapy (arm B)|Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen.
62216834|NCT00215137|PLACEBO_COMPARATOR|Randomizationn Placebo 10-20 mg daily|Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I \< 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).
62410981|NCT01190202|EXPERIMENTAL|Overall Study Group (Survey 3)|Subjects at least 6 months of age at the time of Survey 3, conducted at Year 3 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
62585426|NCT06220175|EXPERIMENTAL|Strepsils Intensiv Arm + Xilocaine Spray|"Patient will take one pill of Strepsils Intensiv containing 8.75mg flurbiprofen 10 to 15 minutes before endoscopy.~The patient will have pharyngeal topical xilocaine spray before upper GI endoscopy, 5 puffs in two applications immediately before examination."
62216835|NCT00215137|ACTIVE_COMPARATOR|Randomization Escitalopram 10-20 mg/daily|Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I \< 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).
62216836|NCT03363672||Patients receiving surgery|No intervention will be administered. Patients included will be asked to return a questionnaire regarding chronic postoperative pain via app.
62585427|NCT06220175|ACTIVE_COMPARATOR|Xilocaine Spray Arm|The patient will have pharyngeal topical xilocaine spray before upper GI endoscopy, 5 puffs in two applications immediately before examination.
62216837|NCT06252948||MULTIPLE MYELOMA at diagnosis GROUP|Multiple myeloma (before starting chemotherapy, radiation or stem cell transplant
62216838|NCT06252948||Amyloid at diagnosis GROUP|AL amyloidosis (before starting chemotherapy or stem cell transplant)
62216839|NCT06252948||Poems at diagnosis GROUP|POEMS at diagnosis (before starting chemotherapy, radiation, or stem cell transplant
62216840|NCT06252948||Poems in Remission GROUP|POEMS in remission (no chemotherapy, radiation, or stem cell transplant for 2 years
62216841|NCT06252948||MGUS GROUP|MGUS -not treated newly diagnosed
62216842|NCT06252948||Health controls in same household GROUP|household member to be a healthy control (no chemotherapy or gastrointestinal illness to participate)
62216843|NCT01064661|ACTIVE_COMPARATOR|Blend probiotic of L-NCFM and B-LBi07|Blend probiotic pills of L-NCFM and B-LBi07 BID (2x10\^10 cfu total bacteria per day)
62216844|NCT01064661|ACTIVE_COMPARATOR|Single probiotic of L-NCFM alone|Single probiotic pills of L-NCFM alone BID (2x10\^10 cfu total bacteria per day)
62216845|NCT00795366|ACTIVE_COMPARATOR|AVP, arginine vasopressin|Vasopressin
62216846|NCT00795366|ACTIVE_COMPARATOR|Standard Catecholamine|levophed, dopamine, phenylephrine)
62216847|NCT01204398|EXPERIMENTAL|eligible hypertension patient|Patients will be given placebo for 2 weeks for wash-out, then qualified patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
62216848|NCT03014076|EXPERIMENTAL|GP2 peptide + GM-CSF + trastuzumab|HLA-A2+/A3+ subjects receive GP2 + GM-CSF vaccine and trastzumab
62216849|NCT03014076|ACTIVE_COMPARATOR|Trastuzumab|HLA-A2-/A3- subjects followed as controls receiving trastuzumab.
62216850|NCT03303846|EXPERIMENTAL|Treatment (breast MRI, biopsy)|Participants undergo standard of care high risk breast cancer screening MRIs at baseline and follow-up and blood sample collection at baseline. Participants also undergo collection of breast tissue samples at any breast biopsy or breast surgery.
62216851|NCT01574378|ACTIVE_COMPARATOR|Control arm|Control arm- conventional method of wound closure
62216852|NCT01574378|EXPERIMENTAL|V-Loc group|V-Loc 90 barbed sutures
62216853|NCT02630108|EXPERIMENTAL|Thermal Ablation & TACE|"Transarterial chemoembolization (TACE) is performed immediately following thermal ablation.~EADM, ultra-fluid lipiodol and gelatin sponge articles are used in TACE."
62216854|NCT02630108|ACTIVE_COMPARATOR|TACE alone|Only TACE is performed. EADM, ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
62216855|NCT04135768|EXPERIMENTAL|Treatment|Participants who will undergo both volar locking plate fixation of the distal radius and the study procedure (wrist joint haematoma washout)
62585428|NCT03618173|EXPERIMENTAL|dexamethasone|IV dexamethasone group : dexamethasone administrated at the induction of general anesthesia, at the dose of 0,2mg/kg (= 0,2mL/kg of a syringe with a 1mg/mL concentration) maximum 8mg (=8mL).
62585429|NCT03618173|PLACEBO_COMPARATOR|Placebos|IV placebo group : saline serum is administrated at the induction of general anesthesia, at the dose of 0,2mL/kg, maximum 8mL.
62216856|NCT04135768|PLACEBO_COMPARATOR|Placebo|Participants who will undergo volar locking plate fixation of the distal radius only
62216857|NCT05368792|EXPERIMENTAL|Complex Carbohydrate|"Participants in the intervention group will be instructed to follow standard bowel preparation guidance AND consume two servings of the complex CHO (12.5% maltodextrin) drink (PREcovery®, Enhanced Medical Nutrition, Toronto, Canada) the evening prior to the procedure, and one serving 2-3 hours prior to the colonoscopy. Participants should not consume anything within 2 hours prior to the procedure's start time. One serving consists of one package (50 g maltodextrin) stirred into 400 mL of cold water.~Standard bowel preparation guidance is as follows a split-dose 2L PEG ± bisacodyl (iso-osmolar) solution (Bi-PegLyte®, Pendopharm, Montreal, Canada) taken according to the physician's order. All participants will be instructed to follow a clear fluid diet starting the day before the procedure. Participants will also be verbally instructed to consume 2L of clear liquids the day before their colonoscopy in addition to the PREcovery."
62410982|NCT01190202|EXPERIMENTAL|Overall Study Group (Survey 4)|Subjects at least 6 months of age at the time of Survey 4, conducted at Year 4 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
62410983|NCT06650280|EXPERIMENTAL|sandblasted acid etched group|sandblasted acid etched coated implants will be allocated to this arm
62410984|NCT06650280|ACTIVE_COMPARATOR|nano-hydroxyapatite group|nano-hydroxyapatite coated implants will be allocated to this arm
62792666|NCT05431855|EXPERIMENTAL|Engagement in biosensor wearing|A subset of the participants will receive the same interventions, namely the reciprocity messages, personalized feedback, or no prompt (as control condition), using micro-randomization procedure that randomly assign one of the condition in the morning and one of the condition in the evening.
62792667|NCT02023996|EXPERIMENTAL|PET Imaging With 89Zr-DFO-Trastuzumab|Patients will receive 5 mCi + 0.5 mCi of 89Zr-DFO-trastuzumab given IV over 5-10 min. Injection of cold trastuzumab will be mixed with 89Zr-DFO-trastuzumab so that total mass is equal to 50 mg \[1\]. In the first ten patients we wish to obtain normal organ dosimetry, pharmacokinetics \& determine optimal imaging time, therefore these patients will undergo imaging at 4 time points post injection, whole body counts \& blood draws. Subsequent patients will receive the antibody \& will only undergo imaging at a single time point (based on the first 10 patients) \& will not have whole body counts or serial bloods for pharmacokinetics. The administration of 89Zr-DFO-trastuzumab to patients undergoing a second study will be identical as for their baseline study. Patients undergoing a second injection will only have one scan that will be performed within 1 day before or 2 days after their optimum imaging time point, determined from their baseline imaging study.
62216858|NCT05368792|NO_INTERVENTION|Fasting|"The Fasting arm will follow the current standard of care for colonoscopy preparations in Ontario, Canada. This includes fasting from midnight before the procedure and following a PEG bowel preparation~All participants will follow a standard bowel preparation guidance, a split-dose 2L PEG ± bisacodyl (iso-osmolar) solution (Bi-PegLyte®, Pendopharm, Montreal, Canada) taken according to the physician's order. All participants will be instructed to follow a clear fluid diet starting the day before the procedure. Participants will also be verbally instructed to consume 2L of clear liquids the day before their colonoscopy. Participants in the fasting arm will be instructed to not have any oral intake after 00:00 of the day of their colonoscopy."
62216859|NCT01146782|EXPERIMENTAL|Treatment|Treatment with the Attune Sleep Apnea System
62216860|NCT03983603|EXPERIMENTAL|Plant stanol group|This arm receives soft chews containing 0.5g of plant stanols (delivered as plant stanol esters).
62216861|NCT03983603|PLACEBO_COMPARATOR|Placebo group|This arm receives soft chews that do not contain 0.5g of plant stanols (delivered as plant stanol esters).
62216862|NCT04055532||Mild Cognitive Impairment|
62216863|NCT04055532||Alzheimer's Disease|
62216864|NCT04055532||Dementia with Lewy Bodies|
62216865|NCT04055532||Frontotemporal Lobar Dementia|
62216866|NCT04055532||Parkinson's Disease with Dementia|
62216867|NCT04055532||Transient Epileptic Amnesia|
62216868|NCT04055532||Temporal Lobe Epilepsy|
62216869|NCT04055532||Spinocerebellar Ataxia|
62216870|NCT04055532||HIV-Associated Neurocognitive Disorder|
62216871|NCT04055532||Amyotrophic Lateral Sclerosis|
62216872|NCT04055532||Primary Lateral Sclerosis|
62216873|NCT02914275|EXPERIMENTAL|Seqirus QIV Cohort A|Seqirus Quadrivalent Inactivated Influenza Vaccine - Subjects 6 months through 35 months of age
62410985|NCT06650280|EXPERIMENTAL|hyaluronic acid group|hyaluronic acid coated implants will be allocated to this arm
62216874|NCT02914275|EXPERIMENTAL|Seqirus QIV Cohort B|Seqirus Quadrivalent Inactivated Influenza Vaccine - Subjects 36 months through 59 months of age
62216875|NCT02914275|ACTIVE_COMPARATOR|Comparator QIV Cohort A|Comparator Quadrivalent Inactivated Influenza Vaccine - Subjects 6 months through 35 months of age
62216876|NCT02914275|ACTIVE_COMPARATOR|Comparator QIV Cohort B|Comparator Quadrivalent Inactivated Influenza Vaccine - Subjects 36 months through 59 months of age
62216877|NCT06198322|EXPERIMENTAL|Platelet-rich Fibrin|A 20 ml blood sample will be drawn from the median cubital vein into a PRF tube. Centrifugation will be done at 700 rpm for 3 minutes and the liquid of PRF will be suctioned out using a separate syringe. PRF will be injected distal to the canine on the experimental side three times; at the beginning of canine retraction (T0), 1 month after the start of canine retraction (T1), and 2 months after the start of canine retraction (T2).
62216878|NCT06198322|EXPERIMENTAL|Vitamin D3|Subjects will receive vitamin Dꝫ injection distal to the canine on the experimental side three times; at the beginning of canine retraction (T0), 1 month after the start of canine retraction (T1), and 2 months after the start of canine retraction (T2).
62216879|NCT01021215|EXPERIMENTAL|Arm I: Zileuton|Zileuton 1200 mg twice orally twice a day on days 1-6.
62216880|NCT01021215|EXPERIMENTAL|Arm II: Zileuton and Celecoxib|Combined Zileuton 1200 mg twice daily plus Celecoxib 200 mg twice daily on days 1-6.
62410986|NCT03918980|EXPERIMENTAL|Part 1 Dose A|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
62410987|NCT03918980|EXPERIMENTAL|Part 1 Dose B|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
62410988|NCT03918980|EXPERIMENTAL|Part 1 Dose C|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
62216881|NCT01620476|EXPERIMENTAL|5 mcg/kg|
62216882|NCT01620476|EXPERIMENTAL|10 mcg/kg|
62216883|NCT01620476|EXPERIMENTAL|15 mcg/kg|
62216884|NCT00477360|EXPERIMENTAL|1|C.A.P
62216885|NCT05213494|ACTIVE_COMPARATOR|Low-dose inulin|3-5 years old: 3g of fiber/day from inulin mixed in a beverage 6-9 years old: 5g of fiber/day from inulin mixed in a beverage
62410989|NCT03918980|EXPERIMENTAL|Part 1 Dose D|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
62410990|NCT03918980|EXPERIMENTAL|Part 1 Dose E|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
62410991|NCT03918980|EXPERIMENTAL|Part 1 Dose F|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
62819328|NCT05052268|EXPERIMENTAL|Phase 1 XTX202 Dose Escalation and Pharmacodynamics Expansion|"Part 1A Dose Escalation of XTX202 administered in ascending doses to patients with advanced or metastatic solid tumors to find the recommended phase 2 doses (RP2Ds).~Part 1B Evaluation of XTX202 in patients with selected advanced solid tumors to further characterize the pharmacodynamic profile of XTX202"
62216886|NCT05213494|EXPERIMENTAL|Low-dose soluble corn fiber|3-5 years old: 3g of fiber/day from soluble corn fiber mixed in a beverage 6-9 years old: 5g of fiber/day from soluble corn fiber mixed in a beverage
62216887|NCT05213494|ACTIVE_COMPARATOR|High-dose inulin|3-5 years old: 6g of fiber/day from inulin mixed in a beverage 6-9 years old: 8g of fiber/day from inulin mixed in a beverage
62216888|NCT05213494|EXPERIMENTAL|High-dose soluble corn fiber|3-5 years old: 6g of fiber/day from soluble corn fiber mixed in a beverage 6-9 years old: 8g of fiber/day from soluble corn fiber mixed in a beverage
62410992|NCT03918980|EXPERIMENTAL|Part 1 Dose G|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
62410993|NCT03918980|EXPERIMENTAL|Part 1 Dose H|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
62410994|NCT03918980|EXPERIMENTAL|Part 1 Dose I|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
62410995|NCT03918980|EXPERIMENTAL|Part 1 Dose J|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
62410996|NCT03918980|PLACEBO_COMPARATOR|Part 1 Placebo|(Single Ascending Dose) Healthy volunteers will receive a single dose of placebo.
62410997|NCT03918980|EXPERIMENTAL|Part 2 Dose K|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
62410998|NCT03918980|EXPERIMENTAL|Part 2 Dose L|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
62410999|NCT03918980|EXPERIMENTAL|Part 2 Dose M|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
62411000|NCT03918980|EXPERIMENTAL|Part 2 Dose N|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
62411001|NCT03918980|EXPERIMENTAL|Part 2 Dose O|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
62411002|NCT03918980|EXPERIMENTAL|Part 2 Dose P|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
62411003|NCT03918980|PLACEBO_COMPARATOR|Part 2 Placebo|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take placebo once daily for 12 days
62411004|NCT03918980|EXPERIMENTAL|Part 3 Dose Fasted|Healthy volunteers will receive a single dose of LOU064 given under fasting conditions followed by a single dose of LOU064 given after a high fat meal (cross-over design).
62411005|NCT03918980|EXPERIMENTAL|Part 3 Dose Fed|Healthy volunteers will receive a single dose of LOU064 given after a high fat meal followed by a single dose of LOU064 given under fasting conditions (cross-over design).
62411006|NCT03918980|EXPERIMENTAL|Part 4 Dose R|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 twice daily for 12 days
62411007|NCT03918980|EXPERIMENTAL|Part 4 Dose S|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 twice daily for 12 days
62411008|NCT03918980|PLACEBO_COMPARATOR|Part 4 Placebo|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take placebo twice daily for 12 days
62411009|NCT03918980|EXPERIMENTAL|Part 5 Formulation A|Healthy Volunteers will receive a single dose of LOU064 formulation A followed by a single dose of LOU064 formulation B (cross-over design).
62411010|NCT03918980|EXPERIMENTAL|Part 5 Formulation B|Healthy Volunteers will receive a single dose of LOU064 formulation B followed by a single dose of LOU064 formulation A (cross-over design).
62411011|NCT03918980|EXPERIMENTAL|Part 6 Dose T|Subjects with atopic dermatitis will receive a twice daily dose of LOU064 for 4 weeks
62411012|NCT03918980|PLACEBO_COMPARATOR|Part 6 Placebo|Subjects with atopic dermatitis will receive a twice daily dose of placebo for 4 weeks
62411013|NCT05263869|EXPERIMENTAL|MRG002|MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
62411014|NCT01539707|EXPERIMENTAL|AD-PED 5 mg|Male and female adolescents aged 12 to less than 18 years old who receive pediatric equivalent dose (PED) of 5 mg of solifenacin succinate.
62216889|NCT05213494|NO_INTERVENTION|Baseline|3-9 years old: pre-intervention.
62411015|NCT01539707|EXPERIMENTAL|CH-PED 5 mg|Male and female children aged 5 to less than 12 years old who receive PED of 5 mg of solifenacin succinate.
62411016|NCT02953873|OTHER|Conversion Arm|Tacrolimus Extended Release Capsule (goal 5 - 12ng/mL) + Mycophenolate Mofetil ≥500mg twice a day OR Mycophenolate Sodium ≥360mg twice a day+ prednisone ≥ 5mg Daily
62411017|NCT03029104|ACTIVE_COMPARATOR|Group 1|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
62411018|NCT03029104|ACTIVE_COMPARATOR|Group 2|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 6 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
62411019|NCT03029104|ACTIVE_COMPARATOR|Group 3|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 30 minutes.
62585430|NCT04996160|EXPERIMENTAL|Cohort 1 -(without Ph+ / Ph like mutation)|Dose expansion phase-10 subjects in Cohort 1, 100 mg/m2/daily palbociclib on Days 1 to 5; 11 to 15; and 21 to 30, in combination with chemotherapy. All subjects will receive palbociclib with dexamethasone, bortezomib, and doxorubicin. dexamethasone of each 30 day cycle for up to 3 cycles for responders which include complete remission, complete remission morphologic, and partial response as defined in section 10.2.1. Bortezomib will be given on Days 7, 10, 17 and 20. Doxorubicin will be given on Days 7 and 17.
62792668|NCT05257629|ACTIVE_COMPARATOR|Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)|Patients in the combination therapy arm will be supplied funds and instructions for the purchase of e-cigarettes and cartridges/pods upon hospital discharge and at the week 4 and 12 clinic visits. As with standard NRTs such as the gum, inhaler, and lozenge, the investigators expect smokers will self-regulate administration according to their withdrawal symptoms. Use will be monitored via self-report for telephone follow-ups. At clinic visits, patients will be asked to bring their e-cigarettes, used and unused cartridges/pods, and purchasing receipts. Patients will be advised regarding the signs and symptoms of nicotine toxicity and of an allergic reaction.
62216890|NCT06127823|EXPERIMENTAL|Intensive dietary care group|Women randomised to the intensive dietary intervention group will receive one initial dietary counselling consultation (60 min), and two mandatory follow-up consultations (2 x 30 min) with a dietitian. In addition, participants in this group will be offered 1-2 follow-up consultations (1-2 x 15-30 min) if needed.
62216891|NCT06127823|ACTIVE_COMPARATOR|Standard dietary care group|Women randomised to the standard dietary care group will receive one dietary counselling consultation (60 min) according to the initial dietary counselling described without any follow-up consultations with a dietitian. Participants are encouraged to follow their dietary plan until delivery.
62216892|NCT03356782|EXPERIMENTAL|Sarcoma-specific CAR-T cells|Peripheral blood mononuclear cells (PBMCs) of patients who have CD133, GD2, Muc1, CD117 or other marker positive sarcoma will be obtained through apheresis, and T cells will be activated and modified to sarcoma-specific CAR-T cells.
62216893|NCT04265820|EXPERIMENTAL|Group 1|The unilateral cataract patients in the Group 1 will undergo phacoemulsification and unilateral implantation of IOLs.The subjects will be divided into three subgroups according to the type of the IOLs.
62216894|NCT04265820|ACTIVE_COMPARATOR|Group 2|The bilateral cataract patients in the Group 2 will undergo phacoemulsification and bilateral implantation of IOLs.The subjects will be divided into three subgroups according to the type of the IOLs.
62216895|NCT05480930|ACTIVE_COMPARATOR|paper-based clinical decision support tool|Providers at the TMDS will use the existing paper-based clinical decision support tools to consult/examine patients.
62411020|NCT03978806|ACTIVE_COMPARATOR|peer navigator|The first PN visit will take place within 1-2 weeks of consent. Each of the 5 subsequent PN visits will take place every 1-2 weeks. We expect patients to complete the intervention within 2-3 months of consent. The function of the initial visit is to establish trust and ensure a more personal approach with participants. The community-based PN intervention is grounded in core Latino values (e.g. trust, personalized relationships). The core elements of the PN intervention include patient motivational interviewing as well as patient activation, empowerment (e.g. help with scheduling of healthcare appointments and re-scheduling of missed HD sessions), education (e.g. education of ESKD and need for renal replacement therapy), and social challenges (e.g. access to resources for transportation, benefits, immigration issues). The duration, individuals present during the visit, and content discussed will be documented in the visit form.
62411021|NCT03978806|PLACEBO_COMPARATOR|Control Arm (standard of care)|Standard of care
62411022|NCT04361006|ACTIVE_COMPARATOR|Radiofrequency (RF)|Twenty patients will be allocated to this group, which will be treated using radiofrequency (RF) ablation technique.
62411023|NCT04361006|ACTIVE_COMPARATOR|Cryotherapy (CRYO)|Twenty patients will be allocated to this group, which will be treated using Cryotherapy (CRYO) ablation technique.
62411024|NCT06652815||Persons with suicide attempt or suicide ideation|Individuals with high suicide ideation or suicide attempts visiting ABVIMS -Dr. RML Hospital for treatment will be screened for this study.
62411025|NCT00556166|EXPERIMENTAL|Enterra Therapy|The Enterra Therapy Gastric Stimulator will be used on subjects who have failed all other medical options to treat gastroparesis and all have a gastric stimulator implanted.
62411026|NCT03681561|EXPERIMENTAL|Phase I:Ruxolitinib and Nivolumab|Participants will receive ruxolitinib at their assigned dose taken orally twice daily on a 28-day cycle combined with nivolumab 480 mg IV administered every 4 weeks (i.e. on Day 1 of a 28-day cycle) until disease progression, unacceptable toxicity, or for a maximum of 2 years.
62411027|NCT03681561|EXPERIMENTAL|Phase II: Ruxolitinib and Nivolumab|Participants will receive ruxolitinib at 20mg orally twice daily on a 28-day cycle combined with nivolumab 480 mg IV administered every 4 weeks (i.e. on Day 1 of a 28-day cycle) until disease progression, unacceptable toxicity, or for a maximum of 2 years.
62411028|NCT01460394||Healthy adolescents and young adults|
62411029|NCT06650046|EXPERIMENTAL|Topping-off group|Topping-off group Patients who have undergone the Topping-off surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.
62411030|NCT06650046|ACTIVE_COMPARATOR|Fusion group|Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University.
62411031|NCT05611372|EXPERIMENTAL|Early Intervention|0-52 week: rasagiline 1 mg/day
62411032|NCT05611372|ACTIVE_COMPARATOR|Delayed Intervention|0-26 week: palcebo 1mg/day 27-52 week: rasagiline 1mg/day
62411033|NCT04980417|EXPERIMENTAL|concomitant cholecystectomy|concomitant cholecystectomy with bariatric procedure
62411034|NCT04980417|ACTIVE_COMPARATOR|delayed cholecystectomy|delayed cholecystectomy
62411035|NCT00104962|EXPERIMENTAL|Treatment (lenalidomide)|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62411036|NCT05242107|EXPERIMENTAL|Omega-3 supplement group|This group included 35 full term Intrauterine Growth Restriction( IUGR) neonates, who received omega-3 supplement (Docosa-hexa-enoic acid (DHA) 40 mg/kg/ day) after establishment of full feeding.
62819329|NCT05052268|EXPERIMENTAL|Phase 2 XTX202 Dose Expansion|"Part 2A will enroll patients with metastatic renal cell carcinoma who have progressed following standard-of-care treatment.~Part 2B will enroll patients with melanoma who have progressed following standard-of-care treatment."
62819330|NCT06511791|PLACEBO_COMPARATOR|Placebo Group|Placebo from day 1 to end of stimulation
62216896|NCT05480930|EXPERIMENTAL|digital clinical decision support (dCDS) tool|Providers at the TMDS will use the new digital clinical decision support (dCDS) tool to consult/examine patients.
62585431|NCT04996160|EXPERIMENTAL|Cohort 2-(Ph+ / Ph like ALL subtypes):|Dose escalation phase- 12 subjects in Cohort 2, Palbociclib dose escalation will begin at 75 mg/m2/day, on Days 1 to 5; 11 to 15; and 21 to 30, and escalate or de escalate. All subjects will receive palbociclib with dexamethasone, bortezomib, and doxorubicin. dexamethasone of each 30 day cycle for up to 3 cycles for responders which include complete remission, complete remission morphologic, and partial response as defined in section 10.2.1. Bortezomib will be given on Days 7, 10, 17 and 20. Doxorubicin will be given on Days 7 and 17. Subjects with Ph+ / Ph-like mutation will receive a tyrosine kinase inhibitor (TKI or KI, either dasatinib or ruxolitinib).3 on 3 dose escalation with 2 dose levels.
62585432|NCT03196466||antiepileptics titration|Titration of valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide and cannabidiol
62585433|NCT03196466||antiepileptics titration and available blood samples|Titration of valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide and cannabidiol
62792669|NCT05257629|OTHER|Varenicline Plus Counseling|All patients will begin varenicline in-hospital upon randomization. For the first 3 days, patients will take a 0.5 mg tablet once a day. They will then take a 0.5 mg tablet twice a day for the following 4 days, and one 1 mg tablet twice a day from day 8 onward for the remainder of the 12-week treatment. Use will be monitored via self-report for telephone follow-ups and return of all unused tablets at the end of the treatment period. Should a patient experience severe side effects (such as headache, nausea, vomiting, dizziness, dyspepsia, fatigue, insomnia, abnormal dreams, constipation, or flatulence) on day 8 onward, the varenicline dose should be reduced from 1 mg twice daily to 0.5 mg twice daily prior to study medication discontinuation.
62216897|NCT04642716|OTHER|Salivary free amino acids profile observation|Saliva samples of periodontitis patients and healthy controls were collected. The AA analysis of the saliva was performed by LC-MS/MS by using the Thermo Scientific TSQ Quantum Access MAX (Thermo Scientific, Schaumburg, IL, USA) .
62216898|NCT00484289|EXPERIMENTAL|Arm 1: Participants from Phase I study (IM101-034)|
62216899|NCT00484289|EXPERIMENTAL|Arm 2: Participants from Phase II study (IM101-071)|
62216900|NCT00484289|EXPERIMENTAL|Arm 3: New Participants with Methotrexate (MTX) Intolerance|
62216901|NCT06031038|NO_INTERVENTION|control group|
62216902|NCT06031038|ACTIVE_COMPARATOR|TECCU group|
62216903|NCT00283088|ACTIVE_COMPARATOR|Group 1|Groups 1 and 2: Parallel groups, randomized to hypothermia or no hypothermia. Both groups receive tPA as a part of standard of care.
62216904|NCT00283088|ACTIVE_COMPARATOR|Group 2|Groups 1 and 2: Parallel groups, randomized to hypothermia or no hypothermia. Both groups receive tPA as a part of standard of care.
62411037|NCT05242107|EXPERIMENTAL|Full feeding without receiving any supplementation group|This group included 35 full term Growth Restriction( IUGR) neonates who were followed up to full feeding without receiving any supplementation.
62411038|NCT02903095|EXPERIMENTAL|TD-1439|Capsule formulation
62411039|NCT02903095|PLACEBO_COMPARATOR|Placebo|Capsule formulation
62411040|NCT01341067||Basal insulin, approved oral medications|
62411041|NCT01004575|EXPERIMENTAL|Kaname|patients that are treated by implanting Kaname Cobalt-Chromium coronary stent
62411042|NCT02911610|EXPERIMENTAL|Arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
62411043|NCT02911610|OTHER|volar plate|surgery of wrist fractures with volar plate
62585434|NCT02229175|EXPERIMENTAL|IVB + laser|Intravitreal bevacizumab (IVB) will be administered at baseline, month 1, and month 2, consistent with previous DME trials. Subvisible laser treatment will be administered at baseline. Patients will then undergo monthly surveillance, as they would with standard of care treatment, allowing for retreatment with monthly IVB and laser therapy every 3 months if defined retreatment criteria are met, as described below.
62585435|NCT02229175|ACTIVE_COMPARATOR|IVB only|IVB monthly at baseline, month 1, and month 2. Patients will then undergo monthly surveillance, as they would with standard of care treatment, allowing for retreatment with monthly IVB if defined retreatment criteria are met, as described below. Patients will also undergo sham laser treatment (patient will be placed in front of laser but no laser will be activated) to mask the patient to the treatment.
62792670|NCT05181644|ACTIVE_COMPARATOR|Control Group|To the Control Group is administered the current standard therapy for 16 weeks.
62819331|NCT06511791|ACTIVE_COMPARATOR|FE 999302 Group|FE 999302 from stimulation day 1 to end-of-stimulation
62216905|NCT00283088|NO_INTERVENTION|Group 3|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
62216906|NCT00283088|ACTIVE_COMPARATOR|Group 4|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
62216907|NCT00283088|ACTIVE_COMPARATOR|Group 5|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
62216908|NCT00283088|ACTIVE_COMPARATOR|Group 6|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
62216909|NCT05559476|EXPERIMENTAL|Co-Ad Group|Participants received one dose of FLU-HD vaccine and one dose of RSVPreF3 OA vaccine, both doses administered at Day 1, and were followed until end of study.
62411044|NCT05093647||patient|"The women who followed up for HrP (high-risk pregnancy ) were invited to participate and women with HrP in the second trimester (14th to 28th gestational weeks), between 20 to 40 years old, and followed up at our perinatology department with a diagnosis of IUGR (intrauterine growth retardation~), cholestasis, diabetes, preeclampsia, or hypertension were included."
62411045|NCT05093647||control|The pregnant women admitted for routine second-trimester ultrasonography assessment but with no risk for pregnancy formed the control group.
62411046|NCT03728257|EXPERIMENTAL|LTGO-Home Based Exercise|The lung transplant recipient will receive LTGO- Home Based Exercise, a behavioral exercise intervention that consists of in-home exercise training integrated with behavioral coaching using tele-rehabilitation.
62216910|NCT05559476|ACTIVE_COMPARATOR|Control Group|Participants received one dose of FLU-HD vaccine at Day 1, followed by one dose of RSVPreF3 OA vaccine at Day 31, and were followed until the study end.
62216911|NCT04201054|EXPERIMENTAL|Fluconazole|Subjects receive a single-dose treatment.Urine samples will be collected after administration (4 fractions: 0-12, 12-24, 24-48, 48-72 hours post-administration).
62216912|NCT06239597|EXPERIMENTAL|lifestyle course|Participants for the experimental group will be recruited from students who enrolled in the lifestyle course in the university during the academic years. Participants in the experimental group engage in the research by providing consent for the analysis of their learning process and by completing questionnaires.
62411047|NCT03728257|ACTIVE_COMPARATOR|Enhanced Usual Care|Enhanced Usual Care (EUC) will involve delivery of monthly newsletters (6 newsletters) on the topics of post-lung transplant management, including food safety, environmental health, flu, mental health, etc. and the provision of a self-monitoring device.
62585436|NCT06366464|EXPERIMENTAL|Double-Blind Treatment Period Pitolisant|Pitolisant tablets administered once daily in the morning upon wakening
62585437|NCT06366464|PLACEBO_COMPARATOR|Double-Blind Treatment Period Placebo|Matching placebo administered tablets once daily in the morning upon wakening
62585438|NCT06366464|OTHER|Open-Label Extension Period Pitolisant|Pitolisant tablets administered once daily in the morning upon wakening
62585439|NCT00915876|ACTIVE_COMPARATOR|Paricalcitol|
62585440|NCT00915876|PLACEBO_COMPARATOR|Placebo|
62585441|NCT05069025|EXPERIMENTAL|music group|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
62585442|NCT05069025|OTHER|non-music group|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
62585443|NCT01590121||Pateints with hereditary haemorrhagic telangiectasia|
62585444|NCT02828046|PLACEBO_COMPARATOR|Placebo|Placebo
62585445|NCT02828046|EXPERIMENTAL|M281|M281
62585446|NCT02698332|ACTIVE_COMPARATOR|Algorithm for UTI|Practices in this groups receives a diagnostic algorithm for UTI by post
62585447|NCT02698332|NO_INTERVENTION|Control|Practices in this group does not receive anything in addition to instructions in the observational registration.
62585448|NCT02578121|EXPERIMENTAL|Ixazomib, Pomalidomide, Dexamethasone|Protasome/IMiD combination of Ixazomib 4mg days 1, 8, and 15, Pomalidomide 4mg days 1-21 amd Dexamethasone 20 mg days 1, 8, 15 and 22 of a 28 day cycle
62216913|NCT06239597|ACTIVE_COMPARATOR|other courses|The control group will be recruited from other courses in the same university, during the same academic years. The control group engages in the research by completing questionnaires.
62216914|NCT03930862|ACTIVE_COMPARATOR|ball and socket|It is an attachment retaining implant overdentures to increase retention and stability of the denture
62585449|NCT03171038|EXPERIMENTAL|Telemonitoring group|6 months of telemonitoring (t0-t1), followed by usual care up until common long-term stopping date (t1-t2).
62585450|NCT03171038|NO_INTERVENTION|Usual care group|Usual care from t0 up until the common stopping date (t2).
62585451|NCT03261674|EXPERIMENTAL|CBTI|Patients in this arm will receive Cognitive Behavioral Therapy for Insomnia (CBT-I)
62216915|NCT03930862|EXPERIMENTAL|Locator attachment|attachment retaining implant overdentures
62411048|NCT01626209|EXPERIMENTAL|BKM120 at: 80 and 100mg/day dose levels|
62411049|NCT05123040|EXPERIMENTAL|Ruxolitinib;hCG (Pregnyl®) ;Corticosteroids|"* Ruxolitinib 10 mg by mouth twice daily (with dose adjustments as indicated) through day 56, followed by taper~* hCG (Pregnyl®) 2,000 units/m2 SQ every other day x 3 doses, followed by twice weekly x 14 doses (total 17 doses through day 56)~* Corticosteroids (Prednisone, or IV methylprednisolone equivalent)~  * Dose level 1 (starting dose) = 1 mg/kg~ * Dose level 2 = 0.5 mg/kg~ * Dose level 3 = 0.25 mg/kg~ * Dose level 4 = 0.1 mg/kg~ * Dose level 5 = 0 mg/kg"
62411050|NCT06566833|EXPERIMENTAL|curodont repair fluoride plus|self-assembling peptide (p11-4) with 0.05% sodium fluoride
62411051|NCT06566833|EXPERIMENTAL|CPP-ACPF varnish|casein phoshphopeptide amorphous calcium phosphate fluoride (CPP-ACPF )
62411052|NCT06566833|ACTIVE_COMPARATOR|5 % sodium fluoride varnish|5% sodium fluoride varnish
62411053|NCT06566027|EXPERIMENTAL|Skeletal, dental, soft tissue index changes in Activator group|Activator The researcher made wax impressions of the study's patients for both the activator and treatment monitoring. The researcher instructed the patients to use the activator device for 12-14 hours daily, with a minimum requirement of 12 hours. Precise ablation of the activator created plastic surfaces that guided the process of tooth eruption.
62411054|NCT06566027|EXPERIMENTAL|Skeletal, dental, soft tissue index changes in EF class II standard group|EF class II standard The researcher monitored the study children through therapy. The research used four types of EF class II standard appliances (Orthoplus, France). Patients were required to wear the EF class II standard device for at least 12 hours every day, including the entire night and at least 2 hours during the day.
62411055|NCT04395157||Veterans engaged in VA mental health rehabilitation/recovery|Veterans must be within 6 weeks of discharge from or current receive mental health treatment services in a VA San Diego Healthcare System psychosocial rehabilitation and recovery center (PRRC), mental health residential rehabilitation treatment program (RRTP), general mental health outpatient treatment, or recent acute mental health inpatient hospitalization.
62411056|NCT06304688|NO_INTERVENTION|Control Group|The control group (CG) will not undergo treatment, which will be evaluated in the pre- and post-phase of the study. Participants assigned to this group will receive general advice on the positive effects of regular physical activity, and they will be given the guide of recommendations for the promotion of physical activity.
62216916|NCT01882205|ACTIVE_COMPARATOR|OLYMPUS CHROMO|Group A: HDTV Olympus colonoscopes and Chromo-endoscopy, methylene blue 0.1%
62216917|NCT01882205|EXPERIMENTAL|OLYMPUS NBI|Group B: Virtual chromoendoscopy: HDTV Olympus colonoscopes and Narrow band Imaging (NBI)
62411057|NCT06304688|EXPERIMENTAL|Experimental Group|The experimental group (EG), after an initial evaluation, will be subjected to a physical training program based on the yoga method, for 12 weeks with 2 weekly sessions (Tuesday and Thursday), with a duration of 45 minutes per session. Once the intervention is finished, you will undergo a final evaluation again to see if there is a difference or not with the results obtained at the beginning. In addition to the yoga intervention, the experimental group received a Mediterranean diet protocol.
62411058|NCT05228990|EXPERIMENTAL|Warm acupuncture - observation group|"Sequence A: Participants will receive warm acupuncture for 20 minutes twice a week for eight weeks.~Sequence B: Patients will be observed without any intervention for eight weeks."
62411059|NCT05228990|EXPERIMENTAL|Observation - warm acupuncture group|Sequence A: Patients will be observed without any intervention for eight weeks. Sequence B: Participants will receive warm acupuncture for 20 minutes twice a week for eight weeks.
62411060|NCT03166670||study group|children with acute secretory diarrhea
62411061|NCT03166670||Control group|normal healthy children
62411062|NCT04758715|OTHER|Food provided|Food provided from a commercial meal service provider for a week
62411063|NCT02626910||Second Life: People with disabilities|People with disabilities recruited from the virtual world, Second life.
62411064|NCT02626910||Second Life: People without disabilities|People without disabilities recruited from the virtual world, Second life.
62411065|NCT02626910||Second Life: Clinicians|Clinicians recruited from the virtual world, Second life.
62411066|NCT02626910||Urban group|People with and without disabilities recruited from an Urban setting.
62411067|NCT03299088|EXPERIMENTAL|Arm A (trametinib, pembrolizumab)|Patients receive trametinib PO daily. Beginning on day 1 of course 2, patients also receive pembrolizumab IV over 30 minutes. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62411068|NCT03299088|EXPERIMENTAL|Arm B (pembrolizumab, trametinib)|Patients receive pembrolizumab IV over 30 minutes on day 1. Beginning on day 1 of course 2, patients also receive trametinib PO daily. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62411069|NCT00568464|EXPERIMENTAL|A|
62216918|NCT01882205|ACTIVE_COMPARATOR|FUJINON CHROMO|Group C: CCD Fujinon colonoscopes and Chromo-endoscopy, methylene blue 0.1%
62216919|NCT01882205|EXPERIMENTAL|FUJINON FICE|Group D: Virtual chromoendoscopy: CCD Fujinon colonoscopes and Fujinon Intelligent Color Enhancement n° 4
62216920|NCT01882205|ACTIVE_COMPARATOR|PENTAX CHROMO|Group E: HD-Pentax colonoscopes and Chromo-endoscopy, methylene blue 0.1%
62216921|NCT01882205|EXPERIMENTAL|PENTX i-scan|Group F: Virtual chromoendoscopy: HD Pentax colonoscopes and I-scan 2 settings
62216922|NCT02665767|NO_INTERVENTION|On-site sonography|The subjects(n=15) performed ultrasonography for the identification of the appendix under mentoring by an onsite expert.
62216923|NCT02665767|ACTIVE_COMPARATOR|Smartphone-based Telesonography|The subjects(n=15) performed ultrasonography for the identification of the appendix under mentoring by an offsite expert.
62216924|NCT04744168|EXPERIMENTAL|Acupuncture|In the experimental arm, pregnant women at term will benefit one or two acupuncture sessions with five points : 4GI, 6RP, 34VB,36E,3F. The first session at 41 amenorrhea weeks and the second at 41 amenorrhea weeks and 3 days if they are not delivered between the both.
62216925|NCT04744168|PLACEBO_COMPARATOR|Placebo acupuncture|"In the placebo arm, pregnant women will benefit one or two acupuncture sessions with one point which is located outside the acupuncture meridian.~The first session at 41 amenorrhea weeks and the second at 41 amenorrhea weeks and 3 days if they are not delivered between the both."
62216926|NCT02734797||Pediatric patients|This is an observational study. Validated measures of nutritional status, dietary intake, body composition, functional status and psychosocial factors will be used to measure outcomes in study patients at 4 time-points: (1) pre-HCT (Baseline), (2) 30-days post-HCT, (3) 100-days post-HCT and (4) one year post-HCT.
62216927|NCT00232544|EXPERIMENTAL|TLC-CPAP|A telephone-linked communication (TLC) system for promoting adherence to continuous positive airway pressure (CPAP)
62216928|NCT00232544|PLACEBO_COMPARATOR|TLC-Control|A TLC system for providing general health education
62216929|NCT04173351|EXPERIMENTAL|Intervention|Pregnant women in intervention group completed the PIQ, W-DEQ-A and CAQ between the 28th and the 34th gestational weeks. Date of the next antenatal follow-up of the participants in the intervention group was recorded and they were given an appointment for the antenatal education. Women, whose date of next antenatal follow-up was unknown, were asked to inform the researchers about their appointment. Following the antenatal follow-up, the pregnant women in the intervention group were given an antenatal childbirth education and an educational brochure after the education. Also, provided telephone counseling to the intervention group one week after the education. Participants in the intervention group filled the W-DEQ-A and CAQ during the 38th and the 40th gestational weeks. Finally, were completed the W-DEQ-B during the first and the second postnatal days.
62411070|NCT03296904|EXPERIMENTAL|CLs++|Baseline assessment, intervention, final assessment
62411071|NCT00658086|ACTIVE_COMPARATOR|1|ALN-RSV01
62411072|NCT00658086|PLACEBO_COMPARATOR|2|Normal saline
62411073|NCT02626273|EXPERIMENTAL|intervention group|an intervention group who will undergo the management program combining physical activity and restrictive diet at Tza Nou Medical House for 10 months
62411074|NCT02626273|OTHER|a control group|a control group who will not undergo any intervention
62585452|NCT03261674|EXPERIMENTAL|ABTI|Arousal-Based Therapy for Insomnia (ABT-I)
62792671|NCT05181644|EXPERIMENTAL|EmoLED Group|The treatment with EmoLED will be carried out once a week in correspondence with the dressing change of the lesion, for sixteen consecutive weeks, for a total of 16 treatments.
62216930|NCT04173351|NO_INTERVENTION|Control|Pregnant women in control group completed the PIQ, W-DEQ-A and CAQ between the 28th and the 34th gestational weeks. Participants in the control group filled the W-DEQ-A and CAQ during the 38th and the 40th gestational weeks. Finally, were completed the W-DEQ-B during the first and the second postnatal days.
62216931|NCT05563285|EXPERIMENTAL|Exercise and Mindfulness-Based Intervention|Patients in the intervention group will be provided exercise and mindfulness-based intervention was shown for the 1-8 weeks.
62216932|NCT05563285|ACTIVE_COMPARATOR|Control Group|Control group will not receive exercise and mindfulness-based intervention however, primary care service providers and mental health professionals will provide any required routine care according to their clinical judgment and available resources.
62585453|NCT06384911|EXPERIMENTAL|Group A (low-value incentive, 6 months [24 weeks])|If the participant is assigned to Group A, they would receive $1.75 for each day that they meet their diabetes self-management goal. This equates to up to $49 every 4 weeks ($1.75 x 28 days = $49), or up to $294 over a period of 24 weeks. They would also receive $2.75 for each week that they meet their clinical outcome goal. This equates to up to $11 every 4 weeks ($2.75 x 4 weeks), or up to $66 over a period of 24 weeks. In total, they could earn up to $60 ($49 + $11) every 4 weeks, or up to $360 over a period of 24 weeks.
62585454|NCT06384911|EXPERIMENTAL|Group B (high-value incentive, 6 months [24 weeks])|If the participant is assigned to Group B, they would receive $3.50 for each day that they meet their diabetes self-management goal. This equates to up to $98 every 4 weeks ($3.50 x 28 days = $98), or up to $588 over a period of 24 weeks. They would also receive $5.50 for each week that they meet their clinical outcome goal. This equates to up to $22 every 4 weeks ($5.50 x 4 weeks), or up to $132 over a period of 24 weeks. In total, they could earn up to $120 ($98 + $22) every 4 weeks, or up to $720 over a period of 24 weeks.
62792672|NCT03674632|EXPERIMENTAL|relaxation meditation tape|Participants in this arm will be asked to use the relaxation therapy during the feed at least once a day. Participants will be given a diary to record when it is used. Participants will be encouraged to use the tape as often as they find it helpful.
62792673|NCT03674632|NO_INTERVENTION|Normal care|Participants in this arm will receive normal care from the Beijing Children Hospital
62792674|NCT03208634|EXPERIMENTAL|Robotic intervention|Robotic intervention.
62792675|NCT06017726||Multiple sclerosis patients without insulin resistance|Cognitive status will be evaluated with BICAMS test. Physical disability will be evaluated by the EDSS score, 9-hole pig and 25-foot-walk test. Patients will be assessed for other comorbid conditions like fatigue and depression. Serum light chain neurofilaments as a laboratory marker for axonal degeneration will be used. brain imaging will be done with with Diffusion tensor imaging.
62792676|NCT06017726||Multiple sclerosis patients with treated insulin resistance|before and after treatment of insulin resistance Cognitive status will be evaluated with BICAMS test. Physical disability will be evaluated by the EDSS score, 9-hole pig and 25-foot-walk test. Patients will be assessed for other comorbid conditions like fatigue and depression. Serum light chain neurofilaments as a laboratory marker for axonal degeneration will be used. brain imaging will be done with with Diffusion tensor imaging.
62792677|NCT06017726||Multiple sclerosis patients with untreated insulin resistance|at the end of the 1st and 2nd year of the study, Cognitive status will be evaluated with BICAMS test. Physical disability will be evaluated by the EDSS score, 9-hole pig and 25-foot-walk test. Patients will be assessed for other comorbid conditions like fatigue and depression. Serum light chain neurofilaments as a laboratory marker for axonal degeneration will be used. brain imaging will be done with with Diffusion tensor imaging.
62792678|NCT00592904|EXPERIMENTAL|1|
62792679|NCT03078894||Districts: Contaminated Water|Subjects in this group are from districts that have contaminated water sources.
62792680|NCT03078894||Districts: Uncontaminated Water|Subjects in this group are from districts that do not have contaminated water sources.
62792681|NCT01378442|EXPERIMENTAL|high level training group|receive high frequency fitness training program(Frequency: three times a week, Duration: 40 minutes).
62792682|NCT01378442|EXPERIMENTAL|low level training group|will receive low frequency fitness training program(Frequency: 1-2 times a week, Duration: 40 minutes).
62792683|NCT01378442|NO_INTERVENTION|control|No intervention, but maintain usual physical activities
62792684|NCT03308708|NO_INTERVENTION|Control group|
62216933|NCT06182553|EXPERIMENTAL|Group (1) : ERCC Group|- The researcher will implement the ERCC technique for 10 minutes as follows: the researcher will use both hands bilaterally to gradually squeeze the rib cage (on the anterolateral region of the chest at the level of the last six ribs) in conjunction with chest-wall vibration during the expiratory phase of the ventilatory cycle. From the end of inspiration to the end of expiration, an attempt will be made to compress the rib cage over the region of the lungs that is most affected and the force will be applied every 2 breaths only during the expiration, synchronizing the maneuver rate with the breathing frequency of the subject. At the end of each expiratory phase, rib-cage compression is interrupted to permit free manual hyperinflation-induced inspiration. The ERCC technique will be implemented twice per day.
62585455|NCT06384911|EXPERIMENTAL|Group C (low-value incentive, 12 months [48 weeks])|If the participant is assigned to Group C, they would receive $1.75 for each day that they meet their diabetes self-management goal. This equates to up to $49 every 4 weeks ($1.75 x 28 days = $49), or up to $588 over a period of 48 weeks. They would also receive $2.75 for each week that they meet their clinical outcome goal. This equates to up to $11 every 4 weeks ($2.75 x 4 weeks), or up to $132 over a period of 48 weeks. In total, they could earn up to $60 ($49 + $11) every 4 weeks, or up to $720 over a period of 48 weeks.
62792685|NCT03308708|EXPERIMENTAL|NE group|
62792686|NCT00780416|EXPERIMENTAL|TRV/PEG/RBV|
62792687|NCT00780416|ACTIVE_COMPARATOR|PEG/RBV|
62792688|NCT02705196|EXPERIMENTAL|Arm 1 Intratumoral LOAd703|"Patients will receive gemcitabine intravenously at a dose of 1000mg/m2 + nab-paclitaxel 125 mg/m2 as per hospital standards. One cycle will be one dose of gemcitabine +nab-paclitaxel given on days 1, 8, and 15 of a 28 day cycle. LOAd703 will be given every other week for 6 doses starting on day 15 of the first cycle of chemotherapy. There is an option for an additional 6 doses if patients benefit from treatment.~The following LOAd703 doses will be evaluated:~Dose level 1: 5 X 10\^10 viral particles per treatment Dose level 2: 1 X 10\^11 viral particles per treatment Dose level 3: 5 X 10\^11 viral particles per treatment"
62819332|NCT06511791|ACTIVE_COMPARATOR|FE 999302 and Placebo Group|FE 999302 from stimulation day 1 to stimulation day 5, and placebo stimulation day 6 to end-of-stimulation
62792689|NCT02705196|EXPERIMENTAL|Arm 2: Intratumoral LOAd703 + atezolizumab|"Patients will receive gemcitabine intravenously at a dose of 1000mg/m2 + nab-paclitaxel 125 mg/m2 as per hospital standards. One cycle will be one dose of gemcitabine +nab-paclitaxel given on days 1, 8, and 15 of a 28 day cycle. LOAd703 will be given every other week for 6 doses starting on day 15 of the first cycle of chemotherapy. There is an option for an additional 6 doses if patients benefit from treatment. A fixed dose of atezolizumab 1680 mg will be given every 4 weeks on day 1 of each chemotherapy cycle.~Patients will be assigned to the following LOAd703 doses:~Dose level 1: 1 X 10\^11 viral particles per treatment Dose level 2: 5 X 10\^11 viral particles per treatment"
62792690|NCT04741919|ACTIVE_COMPARATOR|Superior LPI placement|Each participant will be randomized to receive an LPI placement superiorly in one eye.
62021529|NCT03319927|EXPERIMENTAL|Integrated pest management|The intervention consists of an integrated pest management (IPM) educational workshop and consultation. The child care health consultants (CCHCs) conduct the educational workshop for child care center directors and providers on IPM policies and practices including the providers' practices and beliefs. The workshop includes IPM videos, IPM Toolkit, and IPM toolbox. The (CCHCs) meet with center directors to review the results of the Baseline observational Checklists and to identify center-specific intervention goals. The intervention also includes 7 monthly child care health consultation visits where the CCHC and director review the center's progress towards the intervention goals, discuss problems, and share resources.
62021530|NCT03319927|ACTIVE_COMPARATOR|Physical activity|The intervention consists of a physical activity educational workshop and consultation. The child care health consultants (CCHCs) conduct the educational workshop for the child care center directors and providers on physical activities center policies and best practices over 7 months. The workshop includes a Physical Activity Toolkit and toolbox. The (CCHCs) meet with center directors to review the results of the Baseline observational Checklists and to identify center-specific intervention goals. The intervention also includes 7 monthly child care health consultation visits where the CCHC and director review the center's progress towards the intervention goals, discuss problems, and share resources.
62585456|NCT06384911|EXPERIMENTAL|Group D (high-value incentive, 12 months [48 weeks])|If the participant is assigned to Group C, they would receive $1.75 for each day that they meet their diabetes self-management goal. This equates to up to $49 every 4 weeks ($1.75 x 28 days = $49), or up to $588 over a period of 48 weeks. They would also receive $2.75 for each week that they meet their clinical outcome goal. This equates to up to $11 every 4 weeks ($2.75 x 4 weeks), or up to $132 over a period of 48 weeks. In total, they could earn up to $60 ($49 + $11) every 4 weeks, or up to $720 over a period of 48 weeks.
62792691|NCT04741919|ACTIVE_COMPARATOR|Temporal LPI placement|Each participant will be randomized to receive an LPI placement temporally in one eye.
62792692|NCT04985318||Registergroup|Patients with acquired Thrombotic Thrombocytopenic Purpura, who have been treated with caplacizumab (Cablivi®)
62021531|NCT00123240|ACTIVE_COMPARATOR|High Fat/Protein Diet|
62021532|NCT00123240|ACTIVE_COMPARATOR|High Carbohydrate Diet|
62585457|NCT06384911|NO_INTERVENTION|Group E (usual care, 6 months [24 weeks])|Usual care reflects the standard treatment currently provided to adolescents with type 1 diabetes at Seattle Children's Hospital. All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. They will continue to be offered routine diabetes clinic appointments as is the standard of care. Telephone consultations are available 24/7 as often as necessary between clinic visits.
62792693|NCT06704724|EXPERIMENTAL|Part 1 Dose Escalation|PF-07985045 monotherapy Dose Escalation at prescribed dose and frequency in 28-day cycles
62792694|NCT06704724|EXPERIMENTAL|Part 1 Cohort A1|PF-07985045 monotherapy dose expansion in 2-3L PDAC at prescribed dose and frequency in 28-day cycles
62792695|NCT06704724|EXPERIMENTAL|Part 1 Cohort B1|PF-07985045 monotherapy dose expansion in 2-3L CRC at prescribed dose and frequency in 28-day cycles
62021533|NCT05288998||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
62021534|NCT05288998||Healthy Volunteers|Subjects without a family or personal history of kidney disease or concomitant systemic disorder that might affect the kidney
62792696|NCT06704724|EXPERIMENTAL|Part 1 Cohort C1|PF-07985045 monotherapy dose expansion in 2-3L NSCLC at prescribed dose and frequency in 28-day cycles
62021535|NCT03893448|EXPERIMENTAL|V114|Participants receive 4 total 0.5 mL intramuscular (IM) vaccinations at \~2, 4, 6, and 12 to 15 months of age. Participants will receive other vaccinations (i.e., RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, M-M-R II™, VARIVAX™, and HIBERIX™) as part of their vaccination schedule.
62021536|NCT03893448|ACTIVE_COMPARATOR|Prevnar 13™|Participants receive 4 total 0.5 mL IM vaccinations at \~2, 4, 6, and 12 to 15 months of age. Participants will also receive other vaccines (i.e., RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, M-M-R II™, VARIVAX™, and HIBERIX™) as part of their vaccination schedule.
62792697|NCT06704724|EXPERIMENTAL|Part 1 Cohort D1|PF-07985045 monotherapy dose expansion in other tumor types at prescribed dose and frequency in 28-day cycles
62792698|NCT06704724|EXPERIMENTAL|Part 2 Cohort A2|"Combination (PF-07985045 + Gemcitabine + Nab-paclitaxel) dose escalation/expansion in 1L PDAC.~Prescribed dose and frequency in 28-day cycles"
62792699|NCT06704724|EXPERIMENTAL|Part 2 Cohort B2|"Combination (PF-07985045 + Cetuximab) dose escalation/expansion in 2-3L CRC~Prescribed dose and frequency in 28-day cycles"
62792700|NCT06704724|EXPERIMENTAL|Part 2 Cohort B3|"Combination (PF-07985045 + FOLFOX + Bevacizumab) dose escalation/ expansion in 1L CRC~Prescribed dose and frequency in 28-day cycles"
62792701|NCT06704724|EXPERIMENTAL|Part 2 Cohort C2|"Combination (PF-07985045 + Pembro or sasanlimab) dose escalation/expansion in 1L NSCLC (TPS ≥ 50%)~Prescribed dose and frequency in 21-day (pembro) or 28-day (sasanlimab) cycles"
62792702|NCT06704724|EXPERIMENTAL|Part 2 Cohort C3|"Combination (PF-07985045 + Pembro + Platinum Chemo) dose escalation/expansion in 1L NSCLC (any TPS)~Prescribed dose and frequency in 21-day cycles"
62792703|NCT06704724|EXPERIMENTAL|Part 2 Cohort X|"Combination (PF-07985045 + SHP2) dose escalation/expansion~Prescribed dose and frequency in 21-day cycles"
62792704|NCT05133765|EXPERIMENTAL|SMART B1 - Usual care insulin pump|Usual care pump therapy arm with carbohydrate consumption before exercise
62792705|NCT05133765|EXPERIMENTAL|SMART B2 - Advanced hybrid closed loop insulin pump with carbohydrates before exercise|Advanced hybrid closed loop therapy arm with carbohydrate consumption before exercise
62021537|NCT02660944|EXPERIMENTAL|RSLV-132|10 mg/kg RSLV-132
62021538|NCT02660944|PLACEBO_COMPARATOR|Placebo|Saline placebo
62021539|NCT01538745|EXPERIMENTAL|Ketamine|0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.
62021540|NCT01538745|ACTIVE_COMPARATOR|Morphine|0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.
62021541|NCT05581693|EXPERIMENTAL|A (L04RD1 -> L04TD2)|Administration of 1 tablet of L04RD1, and taking 7-day wash-out period, and then administration of 1 tablet of L04TD2
62585458|NCT06384911|NO_INTERVENTION|Group F (usual care, 12 months [48 weeks])|Usual care reflects the standard treatment currently provided to adolescents with type 1 diabetes at Seattle Children's Hospital. All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. They will continue to be offered routine diabetes clinic appointments as is the standard of care. Telephone consultations are available 24/7 as often as necessary between clinic visits.
62792706|NCT05133765|EXPERIMENTAL|SMART B3 - Advanced hybrid closed loop insulin pump with carbohydrates during exercise|Advanced hybrid closed loop therapy arm with carbohydrate consumption during exercise
62792707|NCT04759157|EXPERIMENTAL|Couples-based treatment- Patient|Participants will attend 3, sessions (75, 50, 50 min) over video with a study therapist to discuss education about OSA and CPAP, strategies adjust to CPAP as a couple and techniques to improve sleep health.
62792708|NCT04759157|EXPERIMENTAL|Couples-based treatment- Partner|Participants will attend 3, sessions (75, 50, 50 min) over video with a study therapist to discuss education about OSA and CPAP, strategies adjust to CPAP as a couple and techniques to improve sleep health.
62792709|NCT04759157|ACTIVE_COMPARATOR|Information Control- Patient|Participants will receive treatment as usual and also standardized information about OSA and CPAP.
62792710|NCT04759157|ACTIVE_COMPARATOR|Information Control- Partner|Participants will receive treatment as usual and also standardized information about OSA and CPAP.
62792711|NCT03266406|EXPERIMENTAL|Effect of hyaluronidase on IOP|
62792712|NCT05452733|EXPERIMENTAL|Sleepwalking patient|
62792713|NCT05452733|ACTIVE_COMPARATOR|Non sleepwalking patient|
62021542|NCT05581693|EXPERIMENTAL|B (L04TD2 -> L04RD1)|Administration of 1 tablet of L04TD2, and taking 7-day wash-out period, and then administration of 1 tablet of L04RD1
62021543|NCT05835726||Cases (prospective cohort)|Patients who fulfill the inclusion criteria (newly diagnosed multiple myeloma patients undergoing daratumumab-containing induction regimens).
62021544|NCT05835726||Controls|Patients with newly diagnosed multiple myeloma who received standard VTD (VTD:bortezomib-thalidomide and dexamethasone) induction, subsequent stem cell mobilization, and tandem autologous stem cell transplant before the introduction of daratumumab in our local practice from January 2020 to December 2021.
62021545|NCT06533124|EXPERIMENTAL|USCOM + ultrafiltration group-experimental group|In the USCOM + ultrafiltration group, cardiac output was monitored using a non-invasive ultrasonic cardiac output monitor, which employed transaortic or transpulmonary Doppler flow tracing and estimated the valve area using a patient's height to estimate their cardiac output. The monitored parameters include, SV index (SVI), SV variation (SVV), cardiac output (CO), cardiac index (CI), inotropy (INO), systemic vascular resistance index (SVRI), systemic vascular resistance (SVR), flow time corrected (FTC) and velocity time integral (VTI) .
62021546|NCT06533124|NO_INTERVENTION|ultrafiltration group-control group|Patients who met the criteria for ultrafiltration were treated with conventional ultrafiltration.
62021547|NCT03354000|PLACEBO_COMPARATOR|Take-home online training|Participants received a link to access the online tutorial videos on their own.
62021548|NCT03354000|ACTIVE_COMPARATOR|In-person online training|Participants received an in-person tutorial of how to use the patient portal website with a trained research assistant.
62792714|NCT01607944||Normal Glucose Tolerance|
62792715|NCT01607944||Type 2 Diabetes|
62792716|NCT01310764|SHAM_COMPARATOR|Mitomycin C|Those with trabeculectomy and intraoperative application of mitomycin C.
62792717|NCT01310764|ACTIVE_COMPARATOR|Bevacizumab|Those with trabeculectomy and adjunctive intraoperative subconjunctival injection of bevacizumab.
62792718|NCT02502942|EXPERIMENTAL|Untreated OSA Muscle Exercise Group|Patients who were previously diagnosed of obstructive sleep apnea (OSA) with apnea hypopnea index (AHI) \> 10 events/hr and have previously failed or refused PAP therapy. In this group, patients will learn and practice upper airway muscle exercise for six weeks.
62792719|NCT02502942|EXPERIMENTAL|PAP Therapy Muscle Exercise Group|OSA patients who are currently treated with PAP for their OSA (with AHI of previous sleep study \> 10 events/hr). In this group, patients will learn and practice upper airway muscle exercise for six weeks.
62792720|NCT02502942|EXPERIMENTAL|Oral Appliance Muscle Exercise Group|OSA patients who are currently treated with an oral appliance with residual AHI \> 10 events/hr. In this group, patients will learn and practice upper airway muscle exercise for six weeks.
62792721|NCT02502942|ACTIVE_COMPARATOR|Normal Control Sham Exercise Group|Patients of untreated OSA group, PAP therapy group, and oral appliance group are randomized to upper airway muscle exercise versus sham exercise.
62792722|NCT02094092|PLACEBO_COMPARATOR|ProTectis drops|Arm A.
62216934|NCT06182553|EXPERIMENTAL|Group (2) : PEEP-ZEEP Group|"* The researcher in the presence of the attending physician will apply the PEEP-ZEEP maneuver in the following manner: During the inspiration phase of the ventilatory cycle, it is proposed to increase PEEP to 15 cmH2O, while maintaining a PIP of 40 cmH2O. Following the completion of five ventilatory cycles, PEEP will be abruptly decreased to 0 cmH2O during the expiration phase, referred to as ZEEP. Subsequently, during the subsequent inspiration phase, PEEP will be restored to the previously established levels. The maneuver will be repeated for a duration of 10 minutes, with a gap of two ventilatory cycles between every repetition.The PEEP-ZEEP maneuver will be implemented twice per day. At the end of the PEEP-ZEEP maneuver, the patient will receive tracheal suction as mentioned before.~* The patients will be monitored continuously, and the maneuver will be interrupted if the patients become hemodynamically unstable or develop psychomotor agitation."
62216935|NCT06182553|EXPERIMENTAL|Group (3) : ERCC + PEEP-ZEEP Group|The ERCC technique will be applied as mentioned above, followed by PEEP-ZEEP maneuvers according to the standard steps mentioned before. Also, the patients will be monitored continuously, and the maneuver will be interrupted if the patients become hemodynamically unstable or develop psychomotor agitation.
62216936|NCT06182553|NO_INTERVENTION|Group (4) : control Group|"* The researcher will observe the conventional nursing care provided by CCNs in the study settings which may affect oxygenation, ventilation, and airway clearance for 30 minutes twice daily for five consecutive days. These conventional nursing practices may include enteral feeding, changing patients' positions, routine suctioning, and other traditional physiotherapies such as chest percussion and vibration.~* Part II of tool one will be used to assess physiological parameters, and tool two will be used to assess oxygenation, ventilation parameters, and airway clearance indicators for patients in the control group twice per day from the 1st day to the 5th day of the study pre and post-conventional nursing care."
62411075|NCT00027573|EXPERIMENTAL|Chemotherapy + stem cell transplantation|"Patients receive fludarabine IV over 30 minutes on days -7 to -3 and cyclophosphamide IV over 1-2 hours on days -4 and -3. Allogeneic peripheral blood stem cells are infused on day 0. Patients then receive filgrastim (G-CSF) subcutaneously daily beginning on day 5 and continuing until blood counts recover.~Patients receive graft-versus-host disease (GVHD) prophylaxis comprising oral tacrolimus twice daily on days -1 to 90 and methotrexate IV on days 1, 3, and 6.~After day 120, patients with persistent disease and no signs of active GVHD may receive donor lymphocyte infusion (DLI). DLI may be repeated every 8 weeks for a total of 2 infusions.~Patients are followed every 2 months for 1 year and then every 6 months for 4 years OR every 2 months for 6 months and then every 6 months for 4.5 years if patient receives DLI."
62021549|NCT01913041||Investigation|This is an epidemiology study in which all the data from the subjects enrolled will be collected and analysis to investigate the current patient warming condition and actual perioperative hyperthermia rate in the elective operation with general anesthesia. During the whole procedure none intervention is administered.
62411076|NCT03427827|EXPERIMENTAL|Adjuvant PD-1 antibody arm|Patients randomized to this arm will receive PD-1 antibody (SHR-1210), 200mg, ivdrip (\>30 minutes), d1, q3w × 12 cycles, begining at 4-6 weeks after chemoradiation
62411077|NCT03427827|NO_INTERVENTION|Best supportive care|Patients randomized to this arm will receive best supportive care after chemoradiation
62411078|NCT00980460|EXPERIMENTAL|High-risk group (regimen H)|Patients receive up front VIT chemotherapy comprising vincristine sulfate IV over 1 minute on days 1 and 8 and irinotecan hydrochloride IV over 90 minutes on days 1-5, and temsirolimus IV over 30 minutes on days 1 and 8. Treatment with VIT repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with disease response then receive 6 courses of C5VD with 4 courses of VIT in between each 2-course block. Patients with no disease response receive 6 courses of C5VD in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection or liver transplant after course 4 of C5VD followed by 2 courses of adjuvant C5VD. Patients may also receive dexrazoxane IV over 5-15 minutes on days 1-2 of courses 5 and 6.
62411079|NCT00980460|EXPERIMENTAL|High-risk group (regimen W)|(regimen W replaced by regimen H as of Amendment 3B) Patients receive up front VI chemotherapy comprising vincristine sulfate IV on days 1 and 8 and irinotecan hydrochloride IV over 90 minutes on days 1-5. Treatment with VI repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with disease response then receive 6 courses of C5VD with 1 courses of VI in between each 2-course block. Patients with no disease response receive 6 courses of C5VD in the absence of disease progression or unacceptable toxicity.
62411080|NCT00980460|EXPERIMENTAL|Intermediate-risk group (regimen F)|Patients receive C5VD chemotherapy comprising cisplatin IV over 6 hours on day 1, fluorouracil IV over 2-4 minutes on day 2, vincristine sulfate IV over 1 minute on days 2, 9, and 16, and doxorubicin hydrochloride IV over 15 minutes on days 1-2. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo surgical resection after course 2 OR surgical resection or liver transplantation after course 4 of C5VD. Patients may also receive dexrazoxane IV over 5-15 minutes on days 1-2 of courses 5 and 6. (Closed to accrual as of 3/12/2012)
62411081|NCT00980460|EXPERIMENTAL|Low-risk group (regimen T)|Patients undergo surgery and then receive adjuvant cisplatin IV over 6 hours on day 1, fluorouracil IV over 2-4 minutes on day 2, and vincristine sulfate IV over 1 minute on days 2, 9, and 16. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
62411082|NCT00980460|EXPERIMENTAL|Very low-risk group|Patients undergo surgery and then receive no further treatment.
62411083|NCT01102608|EXPERIMENTAL|1|
62585459|NCT05397535|NO_INTERVENTION|Self-directed exercise group|Participants in the self-directed exercise group will choose the type and duration of exercise by their preference.
62585460|NCT05397535|ACTIVE_COMPARATOR|Brisk walking group|Participants in Brisk Walking Group will participate in brisk walking for 52 weeks (≥5 days/week, about 30 minutes/day).
62585461|NCT05397535|EXPERIMENTAL|Baduanjin group|Participants in Baduanjin Group will practice Baduanjin singly for 52 weeks (≥5 days/week, about 30 minutes/day).
62585462|NCT02379377|EXPERIMENTAL|Diagnostic (18F-FSPG PET)|Patients undergo an 18F-FSPG PET scan within 4 weeks of surgery or OLT. Patients may also receive a second 18F-FSPG PET scan following standard-of-care treatment.
62585463|NCT02379377|EXPERIMENTAL|Diagnostic (11C-Acetate PET or 18F-FDG PET)|Patients may undergo either carbon-11 (11C)-Acetate PET or 18F-FDG PET scans within 4 weeks of surgery or OLT.
62792723|NCT02094092|PLACEBO_COMPARATOR|Placebo drops|Arm B
62216937|NCT06609785|EXPERIMENTAL|exercise training group|All volunteers had a standardized breakfast, and all tests started at 9:00 a.m. The volunteers successively completed both high intensity interval training (HIIT) and continuous aerobic training (CAT) under the supervision of a professional coach, and the interval between each type of exercise was 7 days. Each training session was initiated with a brief 2-minute standardized warm-up, followed by 20 minutes of cycling consisting of periods of 2 minutes at 80-95% maximal heart rate (HRmax) separated by 2 minutes of active recovery for the HIIT group or 20 minutes of cycling at 60-80% of HRmax for the CAT group. A real-time heart rate monitoring system was continuously used during each training session.
62216938|NCT03403218|EXPERIMENTAL|case group|BESTest, mini-BESTest, Berg scale and FES (falls efficacy scale) (in Spanish version is administrated in case group.
62216939|NCT01238900||benign biliary strictures|All patients who have a medical indication for an ERCP to place a stent in their benign biliary strictures
62021550|NCT02628119|EXPERIMENTAL|Intra-procedural access flow|"Management of access dysfunction based on intra-procedure access flow monitoring.~Criteria for target access flow:~Within 90% of baseline access flow if known 180% increase from pre-intervention flow if access flow not known 600ml/min for thrombosed grafts and 500 ml/min for thrombosed arteriovenous fistula in case baseline access flow not known"
62216940|NCT05778877|EXPERIMENTAL|Cohort 1 - Adolescents|IV infusion of MMA-101 in the first patient on Day 1 IV infusion of SEL-302 in the second and third patient on Day 1, followed by two repeat doses of SEL-110 on Day 28 and Day 56 Adolescents ages ≥12 and \<18
62216941|NCT05778877|EXPERIMENTAL|Cohort 2 - Children|IV infusion of SEL-302 in all patients on Day 1, followed by two repeat doses of SEL-110 on Day 28 and Day 56 Children ages ≥3 and \<12
62216942|NCT06295198|EXPERIMENTAL|Mulligan Group|Participants in the Mulligan group stood in front of the physical therapist at the end of the treatment table and placed their affected lower extremity forward and the other slightly backward. The physical therapist placed both hands on top of each other on the patient's talus to stabilize the talus. The athlete was asked to move until he reached the end of his pain-free ankle dorsiflexion range. Meanwhile, the physiotherapist gave posterior pushing with both hands. The Mulligan mobilization technique was performed 10 times by each athlete.
62216943|NCT06295198|EXPERIMENTAL|Maitland Group|Maitland group, III. degree talus mobilization technique was applied. In this mobilization technique, 120 seconds of application, 60 seconds of rest, and then 120 seconds of application were performed. Maitland III, which takes 5 minutes in total. For the 10-degree mobilization technique, the participant was placed on his back with the foot pointing forward, the ankle was placed in 20° plantar flexion, and the talocrural ligament was in a relaxed position. The hand stabilizing the foot was placed proximal to the malleolus to stabilize the leg. The other hand performing the mobilization grasped the anterior talus using the first web space. The talus was then shifted posteriorly downwards with force.
62216944|NCT02374892|EXPERIMENTAL|Intervention|"Adolescents will attend a single one-on-one session with a nurse. Sessions will be youth-oriented, interactive, and engaging. They will make a health passport, go over their cardiac anatomy, watch videos among other things.~The adolescent will be given a study email address and encouraged to contact the nurse by email or text messaging with follow-up."
62411084|NCT01038076|EXPERIMENTAL|MedCHEC Tablet Computer & Adherence Care|Patients assigned to the intervention answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates provider and patient reports. Patients may be referred to an Adherence Care Manager on the basis of the reports. In addition, patients will receive standard information about adherence.
62411085|NCT01038076|NO_INTERVENTION|Adherence Information Only|Patients assigned to the active comparator arm will receive standard information about adherence.
62411086|NCT04185025|EXPERIMENTAL|CeraVe Moisturising Lotion|
62411087|NCT04185025|ACTIVE_COMPARATOR|Half Mu ceramide body milk|
62411088|NCT06161038|ACTIVE_COMPARATOR|Cohort A-A.therapeutic ultrasound group|"1. Participants: Age between 20-100 years old who diagnosed as myofascial pain syndrome patients and willing to receive treatment.~2. Intervention: Group A (A) receives 1 MHz therapeutic ultrasound for 5 min at a frequency of 2-3 times per week at the painful upper trapezius muscle."
62411089|NCT06161038|ACTIVE_COMPARATOR|Cohort A-B.prolotherapy group|"1. Participants: Age between 20-100 years old who diagnosed as myofascial pain syndrome patients and willing to receive treatment.~2. Intervention: Group B receives hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution."
62411090|NCT06161038|NO_INTERVENTION|Cohort B|"1. Participants: Age between 13-65 years old who diagnosed as idiopathic scoliosis The diagnosis of scoliosis was confirmed by antero-posterior plain Xray with Cobbs angle larger than 10 degrees.~2. Intervention: None"
62411091|NCT03676816|EXPERIMENTAL|Vaginal self-sampling and provider performed endocervical sampling|Patients will take part in both provider-performed endocervical sampling (standard care) and vaginal self-sampling.
62411092|NCT06580041|EXPERIMENTAL|Anhedonia phenotype: PSI|
62585464|NCT04448834|EXPERIMENTAL|Treatment|A single cycle of blinatumomab which includes 4 weeks of CIVI of blinatumomab followed by a 2 week treatment free interval
62585465|NCT05824520|EXPERIMENTAL|CT-derived FFR guided-ITS group|CT-derived FFR≤0.8; ITS plus OMT
62411093|NCT06580041|ACTIVE_COMPARATOR|Anhedonia phenotype: CAU|
62411094|NCT06580041|EXPERIMENTAL|Cognitive deficits: PSI|
62411095|NCT06580041|ACTIVE_COMPARATOR|Cognitive deficits: CAU|
62411096|NCT06580041|EXPERIMENTAL|Stress sensitivity: PSI|
62411097|NCT06580041|ACTIVE_COMPARATOR|Stress sensitivity: CAU|
62585466|NCT05824520|ACTIVE_COMPARATOR|Medical therapy group|CT-derived FFR≤0.8; OMT alone
62585467|NCT00594100|EXPERIMENTAL|GFRS Pivotal Subjects|All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).
62585468|NCT03604679|EXPERIMENTAL|SyB C-0501|"SyB C-0501 (Oral Bendamustine) will be administered orally once a day (specified dose). The treatment period of 21 days (Cohort 1; 7 days of administration + 14 days of observation or Cohort 2; 14 days of administration + 7 days of observation or Cohort 3; 21 days of administration) constitutes 1 cycle.~Part 1: dose escalation to determine MTD, RD and dosing schedule Part 2: dose expansion at RD"
62585469|NCT05854667|PLACEBO_COMPARATOR|Treatment as Usual plus Placebo|Participants will receive treatment as usual at the clinic as well as once daily lisdexamfetamine matched Placebo orally for 15 weeks.
62585470|NCT05854667|PLACEBO_COMPARATOR|Treatment as Usual plus Placebo plus Contingency Management|Participants will receive treatment as usual at the clinic, once daily lisdexamfetamine matched placebo medication orally for 15 weeks, as well as engagement-focused contingency management.
62792724|NCT05930496|EXPERIMENTAL|Arm A (exercise intervention)|Patients receive the supervised exercise intervention over 8 weeks on study. Patients also undergo collection of blood samples at baseline and week 8.
62792725|NCT05930496|ACTIVE_COMPARATOR|Arm B (waitlist control)|Patients receive health-related information for 8 weeks on study. Patients are then offered a session of supervised exercise followed by 7 weeks of tele-coaching sessions. Patients also undergo collection of blood samples at baseline and week 8.
62792726|NCT05970991|ACTIVE_COMPARATOR|MBC Controls|Control group clinicians will complete the Brief Online Training (BOLT) for Measurement-Based Care (MBC) and consultation packages (4 online training modules supported by two 1-hour long, live post-training consultation sessions and expert-facilitated asynchronous online discussion board).
62792727|NCT05970991|EXPERIMENTAL|MBC + VIBRANT|Experimental condition clinicians will complete the same online training modules for MBC (BOLT) as the control group, but also complete the Virtual Implicit Bias Reduction and Neutralization Training (VIBRANT) module (45 minutes). They will also receive two 1-hour long, live post-training consultation sessions and expert-facilitated asynchronous online discussion board.
62792728|NCT02560272|EXPERIMENTAL|Minhai-HIB|Participants at age 1 to 5 years of enrollment will receive one dose on Hib vaccine. Participants at age 6 to 11 months of enrollment will receive 2 doses on Hib vaccine at one months apart. Participants at age 2 to 5 months of enrollment will receive 3 doses on Hib vaccine at one months apart.
62792729|NCT02560272|ACTIVE_COMPARATOR|Act-HIB®|Participants at age 1 to 5 years of enrollment will receive one dose on Hib vaccine. Participants at age 6 to 11 months of enrollment will receive 2 doses on Hib vaccine at one months apart. Participants at age 2 to 5 months of enrollment will receive 3 doses on Hib vaccine at one months apart.
62792730|NCT00842855||1|274 GERD patients, partial responders to PPI treatment
62021551|NCT02628119|ACTIVE_COMPARATOR|Standard Angioplasty|Intervention based on current standards of care i.e. 2 dimensional angiographic views.
62216945|NCT02374892|NO_INTERVENTION|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies.
62792731|NCT01481337||Polypectomy or mucosal endoscopic resection under aspirin|
62585471|NCT05854667|ACTIVE_COMPARATOR|Treatment as Usual plus lisdexamfetamine (LDX-01)|Participants will receive treatment as usual at the clinic as well as once daily over-encapsulated lisdexamfetamine (LDX-01) orally for 15 weeks.
62585472|NCT05854667|ACTIVE_COMPARATOR|Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency Management|Participants will receive treatment as usual at the clinic, once daily over-encapsulated lisdexamfetamine (LDX-01) orally for 15 weeks, as well as engagement-focused contingency management.
62585473|NCT04212884||PLWH|PLWH followed up at the five participating HIV centers
62792732|NCT02270112||Paroxysmal Af|No Intervention is planned. All patients receive a 5 Minute ECG and have their pulse recordes by an iPhone.
62792733|NCT04543227||Retrospective Burn Injuries|Pediatric patients treated at a large academic pediatric medical center for burn injuries between August 2015 - August 2019.
62021552|NCT04118634||Group with PE|"The criteria for confirmation of PE are:~PE on spiral computed tomography (CT) proximal deep vein thrombosis on ultrasound (US) thromboembolic events objectively confirmed during the follow up"
62585474|NCT04212884||HIV-uninfected individuals|Age and sex-matched HIV-uninfected individuals
62585475|NCT04991077||patients group|patients with malignant hypertension
62585476|NCT04991077||Control group|patients with severe hypertension (Grade 2 or 3 hypertension)
62585477|NCT00967785|ACTIVE_COMPARATOR|Treatment Arm|neutropenia and infections
62585478|NCT02890485|EXPERIMENTAL|Glute Dry Needling|Receives dry needling to their gluteal muscles in addition to standard physical therapy treatment.
62585479|NCT02890485|EXPERIMENTAL|Quad Dry Needling|Receives dry needling to their quadriceps muscles in addition to standard physical therapy treatment.
62792734|NCT04543227||Retrospective Knee Arthroscopy|Pediatric patients treated at a large academic pediatric medical center for a knee arthroscopy procedure between August 2015 - August 2019.
62792735|NCT04543227||Prospective Burn Injuries|Pediatric patients treated at a large academic pediatric medical center for burn injuries after July 2020.
62792736|NCT04543227||Prospective Knee Arthroscopy|Pediatric patients treated at a large academic pediatric medical center for a knee arthroscopy procedure after July 2020.
62792737|NCT01332253|EXPERIMENTAL|Intravenous Ibuprofen|
62792738|NCT01332253|PLACEBO_COMPARATOR|Normal Saline|
62792739|NCT05785429|EXPERIMENTAL|Colchicine|One tablet of colchicine 0.5 mg per day
62792740|NCT05785429|PLACEBO_COMPARATOR|Placebo|One tablet of microcrystalline cellulose per day
62792741|NCT04325828|EXPERIMENTAL|Apalutamide plus GnRH Agonist|Participants will receive apalutamide 240 milligram (mg) in combination with a gonadotropin-releasing hormone (GnRH) agonist until disease progression, unacceptable toxicity, death, or the end of the study and each treatment cycle will be of 28 days. Participants who are benefitting from this study will enter long term extension phase.
62792742|NCT06397573|EXPERIMENTAL|Ablative Reirradiation|
62792743|NCT00600210|EXPERIMENTAL|I|
62411098|NCT06580041|EXPERIMENTAL|Anxious distress: PSI|
62411099|NCT06580041|ACTIVE_COMPARATOR|Anxious distress: CAU|
62792744|NCT01667653|EXPERIMENTAL|Augmentin/Probiotic|Participants are provided in double blinded fashion probiotic to take with antibiotics
62792745|NCT01667653|EXPERIMENTAL|Augmentin/placebo|Participants are provided in double blinded fashion placebo to take with antibiotics
62792746|NCT02501590||study|"After the parents sign an informed consent form, they will fill out a demographic questionnaire. Than if the Beery VMI test was not yet administered, it would be performed, as well as the Developmental Coordination Disorder Questionnaire (DCD-Q). Surface electromyography electrodes will be placed on the Upper Trapezius, Extensor Carpi Radialis, and Biceps brachii of the child's dominant hand.~The subject will perform 4 copying tasks and 2 tracing tasks on a tablet placed once on a horizontal surface (while sitting) and once on a vertical surface (while standing)."
62411100|NCT06580041|EXPERIMENTAL|Grief: PSI|
62411101|NCT06580041|ACTIVE_COMPARATOR|Grief: CAU|
62792747|NCT02501590||control|"After the parents sign an informed consent form, they will fill out a demographic questionnaire. Than if the Beery VMI test was not yet administered, it would be performed, as well as the Developmental Coordination Disorder Questionnaire (DCD-Q). Surface electromyography electrodes will be placed on the Upper Trapezius, Extensor Carpi Radialis, and Biceps brachii of the child's dominant hand.~The subject will perform 4 copying tasks and 2 tracing tasks on a tablet placed once on a horizontal surface (while sitting) and once on a vertical surface (while standing)."
62792748|NCT04630145|EXPERIMENTAL|Group A: Bedaquiline (BDQ) + Clarithromycin (CAM) + Ethambutol (EB)|Participants will receive BDQ 400 milligrams (mg) (4\*100 mg tablets) once daily (qd) from Week 1-2 (loading phase), BDQ 200 mg (2\*100mg tablets) bi-weekly (biw) from Week 3 to 48 (maintenance phase) and CAM 400 mg or 500 mg twice daily (2\*200 mg tablets) along with EB 500-750 mg or 15 mg/kg once a day or maximum daily dose of 1.0 gram for up to Week 48.
62792749|NCT04630145|ACTIVE_COMPARATOR|Group B: Rifampicin (RFP) or Rifabutin (RBT) + CAM + EB|Participants will receive maximum of 4 capsules of RFP 450 mg daily (or maximum daily dose of 600 mg), CAM 400 mg or 500 mg (2\*200 mg tablets) twice a day along with EB 500-750 mg daily or 15 mg/kg once a day or maximum daily dose of 1.0 gram for up to Week 48, followed by 2 capsules of RBT 300 mg or 150 mg once a day.
62792750|NCT02777489|EXPERIMENTAL|Perindopril Bluepharma 8 mg|Each participant will have an at least 4-week run-in period, followed by a 6 weeks treatment period with Perindopril 8 mg.
62792751|NCT01870505|EXPERIMENTAL|Arm A: BYL719 plus Letrozole|For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on letrozole, and BYL719 will be added. A treatment cycle will consist of 28 days. Treatment doses for each AI will be fixed at the established dose. Patients will continue on treatment until progression of disease or unacceptable toxicity. The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
62792752|NCT01870505|EXPERIMENTAL|Arm B: BYL719 plus Exemestane|For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on Exemestane, and BYL719 will be added. A treatment cycle will consist of 28 days. Treatment doses for each AI will be fixed at the established dose. Patients will continue on treatment until progression of disease or unacceptable toxicity. The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
62792753|NCT01870505|EXPERIMENTAL|Arm C: BYL719 plus Letrozole|For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added.Letrozole 2.5mg orally once daily with BYL719 given on days 1-7 and 15-21 of a 28 day cycle. The starting dose of BYL719 in Arms C will be 250mg daily. Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
62792754|NCT01870505|EXPERIMENTAL|Arm D: BYL719 plus Exemestane|For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added. Exemestane 25mg orally once daily BYL719 Days 1-5, 8-12, 15-19, 22-26 of 28 day cycle. For Arm D, the established dose is 350mg for BYL719, 10 patients will be assigned to the corresponding arm in the expansion phase of the study. Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
62792755|NCT04381663||conservative treatment|In study A this group will be treated conservatively (stenosis). Study B is a single centre longitudinal study where the same patient groups will be followed up during the course of their treatment
62792756|NCT04381663||surgical treatment (stenosis and myelopathy).|In study A this group that will be treated surgically (stenosis and myelopathy). Study B is a single centre longitudinal study where the same patient groups will be followed up during the course of their treatment
62792757|NCT04784832|EXPERIMENTAL|Sequence 1 - Training with same task - Long follow-up|Motor task (Pretest and Posttests on the same task) Transcranial magnetic stimulation Mental training
62411102|NCT06652789|EXPERIMENTAL|Sleep hygiene teaching|"The intervention will be conducted over 6 weeks, and consist of engaging patients (and caregivers) in two 60-minute face to face sessions 3 weeks apart, and twice weekly telephonic follow ups lasting for 20 minutes each during the 6-week period.~The 2 Direct face to face sessions will focus on health education about sleep. Each session will be conducted by a facilitator who has received training on the program, and will be delivered in a language that the participant is most fluent in (English/ Kannada/ Hindi/ Tamil/ Telugu). In case the participant is unable to come to the hospital for the session, the facilitator will visit the home of the patient to conduct the session (After taking consent)"
62411103|NCT05480488|OTHER|• A (midazolam & warfarin), B (daridorexant, midazolam, & warfarin), & C (daridorexant & midazolam)|"* Treatment A - midazolam and warfarin: In the morning of Day 1, subjects will receive a single oral dose of 2 mg midazolam concomitantly with a single oral dose of 25 mg warfarin under fasted conditions.~* Treatment B - daridorexant, midazolam, and warfarin: Subjects will receive an o.d. oral dose of 50 mg daridorexant in the morning from Day 1 to Day 7 under fasted conditions. In addition, in the morning of Day 1, the oral administration of 50 mg daridorexant will be followed 1 h later by a single oral dose of 2 mg midazolam concomitantly with a single oral dose of 25 mg warfarin under fasted conditions.~* Treatment C - daridorexant and midazolam: In the morning of Day 1, subjects will receive a single oral dose of 50 mg daridorexant followed 1 h later by a single oral dose of 2 mg midazolam under fasted conditions."
62216946|NCT06610825|EXPERIMENTAL|Enhertu for HER2 positive metastatic castrate resistant prostate cancer|
62585480|NCT02890485|SHAM_COMPARATOR|Glute Sham Dry Needling|Receives sham dry needling to their gluteal muscles in addition to standard physical therapy treatment.
62585481|NCT02890485|SHAM_COMPARATOR|Quad Sham Dry Needling|Receives sham dry needling to their quadriceps muscles in addition to standard physical therapy treatment.
62021553|NCT04118634||Group without PE|"The criteria for exclusion of PE are:~low or moderate clinical probability and D-dimer ELISA \<0.50 µg/mL or \<10xage in patients older than 50 years and negative follow up low and moderate clinical probability and negative CT and negative follow up high clinical probability and negative CT, US and follow up."
62021554|NCT04765969||Severe COPD patients|GOLD C and D group patients
62585482|NCT02890485|ACTIVE_COMPARATOR|Control|Receives only standard physical therapy treatment.
62585483|NCT04164043|EXPERIMENTAL|Recreational Therapy Wellness Recovery Program Group|All participants will enter a baseline data collection period for two weeks. They will then participate in a 12-week community-based Recreational Therapy (RT) Wellness Recovery Program (WRP) for individuals with Parkinson's disease (WRP).
62216947|NCT00682669|EXPERIMENTAL|MBSR|A mindfulness-based stress reduction (MBSR) program consisting of an 8-week, 9-session intervention based on systematic and intensive training in mindfulness meditation and mindful hatha yoga and their application to every day life.
62216948|NCT00682669|ACTIVE_COMPARATOR|HLC|A Healthy Living Course (HLC) consisting of an 8-week program of lectures and discussion on health-related topics.
62216949|NCT05676853|EXPERIMENTAL|Pegzilarginase|Weekly subcutaneous dosing of pegzilarginase plus individualized disease management for 52 weeks
62216950|NCT02981108|EXPERIMENTAL|Escalation Cohort 1|Oral Once-Daily Administration of HS-10296 55mg
62216951|NCT02981108|EXPERIMENTAL|Escalation Cohort 2|Oral Once-Daily Administration of HS-10296 110mg
62021555|NCT03584594||Presepsin assessment|Residual blood samples after performing all necessary blood examinations and analyses will be used to determine the level of presepsin, as the potential new biomarker of infection.
62021556|NCT03120975|EXPERIMENTAL|Computerized decision support|
62216952|NCT02981108|EXPERIMENTAL|Escalation Cohort 3|Oral Once-Daily Administration of HS-10296 220mg
62216953|NCT02981108|EXPERIMENTAL|Escalation Cohort 4|Oral Once-Daily Administration of HS-10296 260mg
62216954|NCT02981108|EXPERIMENTAL|Expansion Cohort 1|Oral Once-Daily Administration of HS-10296 55mg
62411104|NCT01330407|EXPERIMENTAL|gp2|Cultured Epidermal Autografts
62021557|NCT03120975|ACTIVE_COMPARATOR|Standard antibiotic stewardship|
62021558|NCT03502343|EXPERIMENTAL|Modified Gemcitabine plus nab-Paclitaxel|The intervention group
62216955|NCT02981108|EXPERIMENTAL|Expansion Cohort 2|Oral Once-Daily Administration of HS-10296 110mg
62216956|NCT02981108|EXPERIMENTAL|Expansion Cohort 3|Oral Once-Daily Administration of HS-10296 220mg
62216957|NCT02981108|EXPERIMENTAL|Phase 2 Extension|Oral Once-Daily Administration of HS-10296 110mg (RP2D)
62216958|NCT05948553|EXPERIMENTAL|Intervention A: Fluoxetine HCl|
62216959|NCT05948553|PLACEBO_COMPARATOR|Intervention A Placebo|
62216960|NCT05426928||HIPEC|"Adults undergoing cytoreductive surgery and who are deemed eligible for HIPEC after surgical exploration in the operating theatre.~The patients will receive HIPEC according to routine practice, as defined by the surgical oncologist."
62216961|NCT01822054||Normal weight|
62216962|NCT01822054||Obese|
62216963|NCT06410768|OTHER|Intervention|The intervention entails a multistage shared decision-making (SDM) program for type 2 diabetes mellitus (T2DM) that combines (1) an online PDA with (2) a preparatory consult for patients, and (3) interprofessional training in the PDA and SDM for healthcare professionals.
62216964|NCT06410768|NO_INTERVENTION|Control|Patients and healthcare professionals in the control practices will provide and receive usual care according to the national guidelines for T2DM of the Dutch College of General Practitioners (NHG). Participants in the control practices will not have access to the multistage SDM program.
62216965|NCT01775475|ACTIVE_COMPARATOR|Arm I (CHOP)|Patients receive CHOP chemotherapy comprising cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62216966|NCT01775475|EXPERIMENTAL|Arm II (oral chemotherapy)|Patients receive lomustine PO QD on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62216967|NCT00413998|EXPERIMENTAL|CABG + Mitral valve repair|
62216968|NCT00413998|ACTIVE_COMPARATOR|CABG only|
62216969|NCT05909852|EXPERIMENTAL|Treatment A: ABP 501-HCF|Participants will be administered a single SC dose of ABP 501-HCF on Day 1.
62216970|NCT05909852|EXPERIMENTAL|Treatment B: ABP 501-LCF|Participants will be administered a single SC dose of ABP 501-LCF on Day 1.
62411105|NCT01330407|ACTIVE_COMPARATOR|gp1|cryopreserved skin allografts.
62585484|NCT04767594||First-line Palbociclib + endocrine therapy|Palbociclib + letrozole, or Palbociclib + anastrozole, or Palbociclib + exemestane, or Palbociclib + fulvestrant after prior endocrine therapy
62585485|NCT05946317|EXPERIMENTAL|Lingual nerve function assessed after removal of Impacted mandibular third molar|"20 patients who had have an impacted mandibular third molar indicated for extraction by lingual split technique with using Walter's lingual retractor for retracting lingual flap.~The neurological function of the lingual nerve was assessed after the demise of local anesthesia, then the location of the disorder and taste function and healing time are determined by sensory neurological tests on a graphic map that divides the tongue into sextants."
62585486|NCT06150716|EXPERIMENTAL|Cohort A: ION356 Dose A|Participants will receive ION356 intrathecally at Dose A in the MAD Period, followed by ION356 Dose A in the LTE Period.
62585487|NCT06150716|EXPERIMENTAL|Cohort B: ION356 Dose B|Participants will receive ION356 intrathecally at Dose B in the MAD Period, followed by ION356 Dose B in the LTE Period.
62585488|NCT00575783||1A, 1B|"Type 1 diabetic subjects with a history of severe hypoglycemia and hypoglycemia unawareness who:~1A) meet criteria for islet cell transplantation and are referred by a participating islet cell transplantation center~1B) meet similar criteria but are not currently planning islet cell transplantation"
62021559|NCT01016795|ACTIVE_COMPARATOR|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
62585489|NCT00575783||2|Type 1 diabetics who are not optimally controlled (\>8% HbA1c) and rarely experience hypoglycemia
62792758|NCT04784832|EXPERIMENTAL|Sequence 1 - Training with same task - Short follow-up|Motor task (Pretest and Posttests on the same task) Transcranial magnetic stimulation Mental training
62792759|NCT04784832|EXPERIMENTAL|Sequence 1 - Training with different tasks - Long follow-up|Motor task (different task in immediate post test) Transcranial magnetic stimulation Mental training
62021560|NCT01016795|ACTIVE_COMPARATOR|Cyclophosphamide and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
62021561|NCT02405455|EXPERIMENTAL|Cerclage|Cervical cerclage.
62216971|NCT03391401||Adip1|Patients with morbid obesity (i.e. BMI \>35 kg/sqm) and age \>18 scheduled for bariatric surgery (all standard procedures included)
62216972|NCT04886622|EXPERIMENTAL|DT2216|DT2216 will be administered by intravenous infusion over 30 minutes twice weekly on a continuous basis. Each treatment cycle will be 28 days in duration. The starting dose of DT2216 will be 0.04 mg/kg and will escalate by 100% increments for the first 5 treatment groups. Thereafter, if additional dose escalations are required, escalation will follow a modified Fibonacci scheme. Treatment may continue for up to 1 year.
62792760|NCT04784832|EXPERIMENTAL|Sequence 1 - Training with different tasks - Short follow-up|Motor task (different task in immediate post test) Transcranial magnetic stimulation Mental training
62216973|NCT04137159|EXPERIMENTAL|FES rowing|Exercise training sessions will be performed 3 times per week for 12 weeks. The initial training sessions will include 6 sets of FES-rowing for 5 min at 60% of VO2 peak with a work-to-rest ratio of 2:1. Participants unable to row continuously for 5 min will row for 2-4 min with 30-second breaks incorporated until they achieve sets totaling 30 min. The goal is for each volunteer to achieve an exercise intensity of 70-85% maintained for a continuous 30-40 min performed 3 times each week.
62216974|NCT04137159|NO_INTERVENTION|Wait list|During the 12-week treatment as usual program, subjects will not participate in FES-rowing.
62216975|NCT03461536|ACTIVE_COMPARATOR|Clinical Decision Support|Participants in this arm will receive the study intervention, the clinical decision support.
62411106|NCT01299428|ACTIVE_COMPARATOR|cerebral oxygenation|
62411107|NCT00696059|OTHER|1|Open-label, one arm only. All patients receiving active drug according to recommendations (adalimumab (Humira) 40 mg subcutaneously every other week).
62411108|NCT01757418|EXPERIMENTAL|Intravenous Immune Globulin (IVIG)|IVIG used in the trial is the GAMUNEX brand, at doses up through 800 mg/kg in Phase 1 and at 400mg/kg in Phase 2.
62411109|NCT01757418|PLACEBO_COMPARATOR|Normal saline|An equivalent volume (weight-based) of normal saline
62021562|NCT02405455|EXPERIMENTAL|Cervical pessary|Cervical pessary
62216976|NCT03461536|NO_INTERVENTION|Usual care|Participants in this arm will not receive the the clinical decision support tool.
62411110|NCT06647576||Test|Patients receiving SCS therapy through Neutrosphere virtual clinic platform (remote pain management group).
62411111|NCT06647576||Control Group|Participants in this group will receive traditional in-person care for their SCS therapy. Group regular clinic visits for therapy adjustments, monitoring, and pain management
62411112|NCT06215872|ACTIVE_COMPARATOR|Upper Extremity Exercises Group|Participants will treated exercises with focused on upper extremity especially wrist muscles.
62411113|NCT06215872|EXPERIMENTAL|Myofascial Chains Exercises Group|Participants will treated exercises with focused on whole body especilly myofascial chains.
62585490|NCT00575783||3|Healthy non-diabetics
62792761|NCT04784832|EXPERIMENTAL|Sequence 1 - Training with muscle contractions - Long follow-up|Motor task (isometric muscle contractions in immediate post test) Transcranial magnetic stimulation Mental training
62792762|NCT04784832|EXPERIMENTAL|Sequence 1 - Training with muscle contractions - Short follow-up|Motor task (isometric muscle contractions in immediate post test) Transcranial magnetic stimulation Mental training
62411114|NCT06215872|NO_INTERVENTION|Control Group|Participants will do any exercises. They will join only assessment sessions.
62792763|NCT04784832|ACTIVE_COMPARATOR|Sequence 1 - Control|Motor task (Pretest and Posttests on the same task) Transcranial magnetic stimulation No mental training
62411115|NCT03252756|EXPERIMENTAL|Placebo for 4 weeks, followed by phytocannabinoid cannabidiol (CBD) for 4 weeks|600mg/day Saline taken by mouth (PO) for 4 weeks, immediately followed by 1200mg saline/ day (PO) for an additional 4 weeks (8 total weeks).
62411116|NCT03252756|EXPERIMENTAL|CBD for 8 weeks|600mg CBD/day (PO) for 4 weeks, immediately followed by 1200mg CBD/day (PO) for an additional 4 weeks (8 total weeks).
62411117|NCT06257459|ACTIVE_COMPARATOR|Lipoma Excision (group A)|excison of spermatic cord lipoma detected during subinguinal varicocelectomy in infertile males
62411118|NCT06257459|ACTIVE_COMPARATOR|Lipoma Preservation (group B)|preservation of spermatic cord lipoma detected during subinguinal varicocelectomy in infertile males
62411119|NCT06250660|NO_INTERVENTION|Control group|Participants in the comparison group will not have intervention and will not receive strawberry supplements, they will follow their conventional treatment and their usual diet. They will be evaluated before the start of the intervention, one month and two months after the intervention.
62411120|NCT06250660|EXPERIMENTAL|Strawberry intervention with Fortuna variety|"This group will receive an intake of strawberries of the Fortuna variety. The participants of this group will have to eat 250 g of this strawberry variety per day for 1 month.~All participants in the intervention group will be invited to participate in focus groups once the intervention has ended, in order to learn about their experiences during it.~They will be evaluated before the start of the intervention, one month and two months after the intervention."
62792764|NCT04784832|ACTIVE_COMPARATOR|Sequence 2 - Physical training with perturbation during preparation - Long follow-up|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Physical training
62792765|NCT04784832|ACTIVE_COMPARATOR|Sequence 2 - Physical training with perturbation during preparation - Short follow-up|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Physical training
62792766|NCT04784832|ACTIVE_COMPARATOR|Sequence 2 - Physical training with perturbation after preparation - Long follow-up|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Physical training
62411121|NCT01265875|OTHER|human secretin|intravenous secretin administration in escalating doses three times daily for three days. After each infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion.
62792767|NCT04784832|ACTIVE_COMPARATOR|Sequence 2 - Physical training with perturbation after preparation - Short follow-up|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Physical training
62216977|NCT02608957|EXPERIMENTAL|Latella Knee Implant System|
62819333|NCT06511791|ACTIVE_COMPARATOR|Placebo and FE 999302|Placebo from stimulation day 1 to stimulation 5, FE 999302 from stimulation day 6 to end-of-stimulation.
62411122|NCT02140801|EXPERIMENTAL|Ticagrelor|Ticagrelor 90mg tablet, twice daily
62411123|NCT02140801|EXPERIMENTAL|Clopidogrel|Clopidogrel 75mg tablet, daily
62411124|NCT05727540||Noninfectious uveitis|
62411125|NCT05727540||Infectious uveitis|
62216978|NCT05405439|EXPERIMENTAL|TQB3823 tablets + abiraterone acetate tablets + prednisone acetate tablets|TQB3823 tablets + abiraterone acetate tablets + prednisone acetate tablets，28 days as a treatment cycle.
62411126|NCT04485026|EXPERIMENTAL|Local Consolidative Radiation Therapy Arm|Definitive external beam radiation therapy will be delivered to all sites of progressive disease for all patients. The technique used to deliver radiation therapy will be determined by the treating radiation oncologist.
62411127|NCT04485026|ACTIVE_COMPARATOR|Standard of Care - Control Arm|Second line systemic therapy is at the discretion of the treating medical oncologist.
62411128|NCT00973167|NO_INTERVENTION|Control|Remains sedentary with normal lifestyle
62411129|NCT00973167|EXPERIMENTAL|Treatment|Receive LMHFV treatment for 18 months.
62411130|NCT01218386|EXPERIMENTAL|Study Group|"Start with estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~If day 25 is Monday: 6 days Tuesday: 10 days Wednesday: 9 days Thursday: 8 days Friday: 7 days Saturday: 6 days Sunday: 6 days of Progynova, 2x2 mg per day After this pretreatment: Standard GnRH antagonist treatment protocol with start rFSH (Puregon®) at a dose of 150 IU From day 2 of the cycle onwards; GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation"
62411131|NCT01218386|ACTIVE_COMPARATOR|Control group|Standard GnRH antagonist treatment protocol with start rFSH (Puregon®) at a dose of 150 IU From day 2 of the cycle onwards; GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation
62411132|NCT03715335|NO_INTERVENTION|Baseline|Current STI screening rates.
62411133|NCT03715335|ACTIVE_COMPARATOR|Targeted STI Screening|"Data from the Sexual Health Screen (SHS) will be integrated into the Electronic Health Record (EHR) and will provide Clinical Decision Support (CDS) for GC/CT testing based on SHS-calculated STI risk. Patients will be classified as at high risk for STIs, at risk or low risk if they deny any history of sexual activity. When patients classify as at high risk, clinicians will receive CDS that STI testing is highly recommended; when they care for patients who classify as at risk, they will receive CDS that STI testing is recommended; when caring for patients who classify as at low risk, they will receive CDS that STI testing is not necessary at this time. If the clinician chooses to follow the recommendation for screening based on patient's risk assessment, and the patient consents to testing on the tablet device, urine GC/CT testing will be performed."
62411134|NCT03715335|ACTIVE_COMPARATOR|Universally Offered STI Screening|During the universally offered screening intervention, STI screening will be offered to all eligible adolescents, regardless of risk. All eligible patients will also complete the SHS, will be informed of the CDC GC/CT testing recommendations and then be given the option to decline STI testing using the tablet device. During this phase, the SHS results will not be available to the clinician. STI testing recommendations will be based only on the patient's decision to undergo GC/CT testing. Like the process followed in the targeted screening phase, if the clinician follows the CDS that informs the clinician that the patient agreed to GC/CT screening and consequently orders testing, urine GC/CT testing will be performed.
62433252|NCT04058678|SHAM_COMPARATOR|CONTROL|"A control group composed of women with normal ovarian reserve (30 to 45 yerras old) is needed to compare telomeric and fertility parameters with the group of women with compromised ovarian reserve. Note that the term normal ovarian reserve referred to older women indicates women that still have follicles in their ovaries -and thus, normal AMH values-, even though the number may be lower tan at a younger age or the quality of oocytes may be lower tan in younger women. In other words, women in the control group irrespective of their age, will have a greater number of follicles compared to women belonging to the group with compromised ovarian reserve."
62585491|NCT05657197|EXPERIMENTAL|Intervention (exercise) group|The patients in the intervention group will follow a personalised and intensive exercise program.
62585492|NCT05657197|OTHER|Control group|The patients in the control group will receive usual care.
62216979|NCT02290730|EXPERIMENTAL|Kinesio tape|Kinesio tape on lower trapezius
62585493|NCT01080118|OTHER|control group|Control group, taught with a standard Macintosh laryngoscope
62585494|NCT01080118|EXPERIMENTAL|Study group|Study group taught with the Airtraq video laryngoscope
62216980|NCT02290730|NO_INTERVENTION|Control|No intervention
62216981|NCT04846673|EXPERIMENTAL|Pregabalin and alpha-lipoic acid combination therapy|Alpha-lipoic acid 480 mg/tablet once daily before breakfast and Pregabalin 150 mg/tablet once daily before bedtime will be administrated for 12 weeks.
62216982|NCT04846673|EXPERIMENTAL|Pregabalin monotherapy|Pregabalin 150 mg/tablet once daily before bedtime will be administrated for 12 weeks.
62216983|NCT04846673|ACTIVE_COMPARATOR|Alpha-lipoic acid monotherapy|Alpha-lipoic acid 480 mg/tablet once daily before breakfast will be administrated for 12 weeks.
62585495|NCT05814016|EXPERIMENTAL|High Dose Danavorexton|Participants will receive danavorexton intravenous (IV) infusion as high dose on Day 1 of the treatment period.
62585496|NCT05814016|EXPERIMENTAL|Low Dose Danavorexton|Participants will receive danavorexton IV infusion as low dose on Day 1 of the treatment period.
62585497|NCT05814016|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo-matching danavorexton IV infusion on Day 1 of the treatment period.
62585498|NCT04081220|EXPERIMENTAL|IMG-7289|
62216984|NCT06444412|EXPERIMENTAL|Diagnostic (Ga-68 PSMA-11, PET/CT)|Patients receive Ga-68 PSMA-11 IV and then undergo PET/CT over 1 hour, 50-100 minutes after injection.
62216985|NCT05361187||single arm, observational post market study|Patients with an acute ischemic stroke with treatment including the BOBBY™ BGC
62216986|NCT06007521||Patients with alternating hemiplegia|Patients with alternating hemiplegia, from 0 to 99 years old
62216987|NCT05253300|EXPERIMENTAL|Semi Recumbent|"The patients' vital signs, pain and analgesic drug use were recorded in the Pain Follow-up Form at the time they came to the clinic, at the 6th and 12th hours after the surgery, by recording from the end-of-operation file. In case the patient had pain, the time when the pain started was recorded, the experimental group was given the semi-recumbent position with analgesic drug and the patient was asked to maintain this position for 2 hours. If the patient has pain again, this position is given again. Patient Satisfaction Evaluation Form was filled in at the 12th hour after the surgery for the patients in the experimental group."
62792768|NCT04784832|EXPERIMENTAL|Sequence 2 - Mental training with perturbation during preparation - Long follow-up|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Mental training
62792769|NCT04784832|EXPERIMENTAL|Sequence 2 - Mental training with perturbation during preparation - Short follow-up|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Mental training
62433253|NCT04058678|EXPERIMENTAL|EXPERIMENTAL|A group of women with diminished ovarian reserve that will take an inactive substance has been included to avoik biases and to set the fertility base line for women with compromised ovarian reserve.
62585499|NCT02655991|EXPERIMENTAL|Telephone Case Monitoring|Telephone care management augmenting treatment as usual
62585500|NCT02655991|ACTIVE_COMPARATOR|Treatment as Usual|Case management, psychotherapy, and pharmacotherapy as usual
62585501|NCT04533646|EXPERIMENTAL|Fixed Dosing, Followed by Carbohydrate Counting|Dosing of premeal insulin with fixed doses
62585502|NCT06457191|PLACEBO_COMPARATOR|Intermittent Theta-Burst Stimulation with Placebo|Intermittent theta-burst stimulation delivered to the left primary motor cortex after the participant has ingested a placebo.
62585503|NCT06457191|EXPERIMENTAL|Intermittent Theta-Burst Stimulation with Roflumilast|Intermittent theta-burst stimulation delivered to the left primary motor cortex after the participant has ingested roflumilast 500mcg.
62585504|NCT06457191|PLACEBO_COMPARATOR|Continuous Theta-Burst Stimulation with Placebo|Continuous theta-burst stimulation delivered to the left primary motor cortex after the participant has ingested a placebo.
62021563|NCT04642105|EXPERIMENTAL|Hospital-based study|The investigators will select 15 patients with refractory focal epilepsy who are admitted to the videoEEG room for longterm videoEEG recording as part of a presurgical evaluation. The Sensor-Dot and Plug 'n Patch recordings will be compared with the gold-standard videoEEG recordings.
62792770|NCT04784832|EXPERIMENTAL|Sequence 2 - Mental training with perturbation after preparation - Long follow-up|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Mental training
62216988|NCT05253300|NO_INTERVENTION|Control|"The patients' vital signs, pain and analgesic drug use were recorded in the Pain Follow-up Form at the time they came to the clinic, at the 6th and 12th hours after the surgery, by recording from the end-of-operation file. In case the patient has pain, the time when the patients' pain started was recorded, and only analgesic medication was administered to the control group."
62585505|NCT06457191|EXPERIMENTAL|Continuous Theta-Burst Stimulation with Roflumilast|Continuous theta-burst stimulation delivered to the left primary motor cortex after the participant has ingested roflumilast 500mcg.
62585506|NCT00650325|EXPERIMENTAL|1|Sertraline Hydrochloride Tablets 100 mg
62585507|NCT00650325|ACTIVE_COMPARATOR|2|Zoloft® Tablets 100 mg
62585508|NCT04052386|EXPERIMENTAL|BASICCS|Participants randomized to the BASICCS condition received a personalized feedback intervention conducted through a web-conferencing platform. They also received up to 24 text messages with protective behavioral strategies for drinking during the following month.
62585509|NCT04052386|NO_INTERVENTION|Control|Participants randomized to the control group did not receive any intervention. They were an assessment-only control group.
62585510|NCT04084561|EXPERIMENTAL|HRHA|High Risk, High Ancestry
62585511|NCT04084561|EXPERIMENTAL|LRLA|Low Risk, Low Ancestry
62585512|NCT04084561|EXPERIMENTAL|HRLA|High Risk, Low Ancestry
62792771|NCT04784832|EXPERIMENTAL|Sequence 2 - Mental training with perturbation after preparation - Short follow-up|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Mental training
62585513|NCT04084561|EXPERIMENTAL|LRHA|Low Risk, High Ancestry
62585514|NCT01756794|OTHER|Transplantation of alcoholic hepatitis|Patients of this arm will be selected for early liver transplantation for severe alcoholic hepatitis not responding to medical therapy. Selection process will be based on a specific algorithm and follow-up time will be 2 years
62585515|NCT01756794|OTHER|Transplantation for alcoholic cirrhosis|Patients of this arm will be selected for liver transplantation for alcoholic cirrhosis using an abstinence period of 6 months. Outcome of these patients will be compared to that of patients transplanted for severe alcoholic hepatitis.
62585516|NCT05364021|EXPERIMENTAL|LP352|Subjects will be titrated up to highest tolerated dose of LP352 during a 15-day period, followed by a 60-day maintenance period and a 15-day taper/down titration period.
62021564|NCT04642105|EXPERIMENTAL|Home-based study|The investigators will select 30 patients with refractory focal epilepsy, 15 patients with refractory idiopathic generalized epilepsy and 15 patients with frequent tonic-clonic seizures, i.e. a group at increased risk for sudden unexpected death in epilepsy (SUDEP).
62021565|NCT01991262||Group 1 phone call and SMS reminder.|cloosed no one enrolled
62021566|NCT01991262||Group 2 phone call only.|cloosed no one enrolled
62021567|NCT01991262||Group 3 SMS reminder only .|cloosed no one enrolled
62021568|NCT01991262||Group 4 (Control) no support|cloosed no one enrolled
62433254|NCT03351218|OTHER|Patients|25 patients with cervical and 25 patients with myoclonus dystonia
62433255|NCT03351218|OTHER|Controls|50 healthy volunteers matched to patents ( age, sex)
62433256|NCT02348619|ACTIVE_COMPARATOR|75, 150, 300 mg of JZP-110|Once Daily Dosing
62433257|NCT02348619|ACTIVE_COMPARATOR|Placebo|Once Daily Dosing
62585517|NCT05364021|PLACEBO_COMPARATOR|Placebo|Placebo for LP352
62585518|NCT05170152|ACTIVE_COMPARATOR|. Group A|Underwent ultrasound guided methyl prednisolone acetate injection, between A1 pulley and tendons
62792772|NCT04784832|EXPERIMENTAL|Sequence 3 - Training (same task) - Long follow-up|Paired Associative Stimulation Mental training (same as the motor task) Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
62021569|NCT06573905||type 1 diabetes|This group comprises participants diagnosed with Type 1 diabetes according to self-reported data. The primary goal of comparing this group with medico-administrative records is to validate the algorithm's ability to accurately classify individuals with Type 1 diabetes, ensuring that they are correctly identified as such without being misclassified into other categories.
62216989|NCT03189745|EXPERIMENTAL|MenACWY-TT Booster|10 year booster dose of MenACWY
62216990|NCT01123876|EXPERIMENTAL|Veliparib and FOLFIRI|Veliparib in combination with FOLFIRI regimen.
62585519|NCT05170152|EXPERIMENTAL|Group B|Underwent ultrasonography-guided percutaneous A1 pulley needle release
62792773|NCT04784832|EXPERIMENTAL|Sequence 3 - Training (same task) - Short follow-up|Paired Associative Stimulation Mental training (same as the motor task) Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
62792774|NCT04784832|EXPERIMENTAL|Sequence 3 - Training (different task) - Long follow-up|Paired Associative Stimulation Mental training (different of the motor task) Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
62792775|NCT04784832|EXPERIMENTAL|Sequence 3 - Training (different task) - Short follow-up|Paired Associative Stimulation Mental training (different of the motor task) Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
62792776|NCT04784832|ACTIVE_COMPARATOR|Sequence 3 - Control 1|Mental Training Motor task (same as the motor task) Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
62792777|NCT04784832|ACTIVE_COMPARATOR|Sequence 3 - Control 2|Paired Associative Stimulation Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
62792778|NCT04784832|EXPERIMENTAL|Sequence 4 - Immobilization - Short follow-up|Transcranial magnetic stimulation Arm immobilization Motor task Mental training
62792779|NCT04784832|EXPERIMENTAL|Sequence 4 - Immobilization - Long follow-up|Transcranial magnetic stimulation Arm immobilization Motor task Mental training
62792780|NCT04784832|EXPERIMENTAL|Sequence 4 - Cathodal - Short follow-up|Transcranial magnetic stimulation Cathodal transcranial direct current stimulation Motor task Mental training
62792781|NCT04784832|EXPERIMENTAL|Sequence 4 - Cathodal - Long follow-up|Transcranial magnetic stimulation Cathodal transcranial direct current stimulation Motor task Mental training
62216991|NCT05109754|EXPERIMENTAL|BPAP EFL|"Phase 1: use device for 2 months~Phase 2: use device for 12 months"
62585520|NCT00565877|EXPERIMENTAL|1 - Neck Ultrasound|post-PICC insertion ultrasound inspection of the ipsilateral neck
62585521|NCT00565877|NO_INTERVENTION|2 - Control|No post-PICC insertion ultrasound inspection of the ipsilateral neck
62216992|NCT00735631|EXPERIMENTAL|1|The single-input-single-output (SISO) model-based predictive closed-loop system will be used to guide patient-individualized ICU sedation with propofol
62216993|NCT00882687|EXPERIMENTAL|0.1% Lifitegrast|
62585522|NCT06178523|ACTIVE_COMPARATOR|Sildenafil & Clomiphene Group|"Sildenafil Acetate (Viagra®) 25 mg as a vaginal tablet 6 hourly for 10 days starting from the fifth day of the menstrual cycle + Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle.~Follow-up by resistance index (RI), pulsatility index (PI), and maximum velocity (T-max) of sub-endometrial, uterine, and ovarian vessels measured by using TVS Colour Doppler ultrasound."
62585523|NCT06178523|ACTIVE_COMPARATOR|IUI & Clomiphene Group|"Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle + Intrauterine insemination (IUI) 42 hours after human chorionic gonadotropin (Pregnyl®) 10,000 IU injection IM.~Follow-up by resistance index (RI), pulsatility index (PI), and maximum velocity (T-max) of sub-endometrial, uterine, and ovarian vessels measured by using TVS Colour Doppler ultrasound."
62585524|NCT06178523|PLACEBO_COMPARATOR|Clomiphene only Group|"Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle.~Follow-up by resistance index (RI), pulsatility index (PI), and maximum velocity (T-max) of sub-endometrial, uterine, and ovarian vessels measured by using TVS Colour Doppler ultrasound."
62585525|NCT06006247|EXPERIMENTAL|CVN424 150 mg|Participants will be administered with CVN424 150 mg.
62585526|NCT06006247|PLACEBO_COMPARATOR|Placebo|Participants will be administered with placebo.
62792782|NCT04784832|EXPERIMENTAL|Sequence 4 - Anodal - Short follow-up|Transcranial magnetic stimulation Anodal transcranial direct current stimulation Motor task Mental training
62792783|NCT04784832|EXPERIMENTAL|Sequence 4 - Anodal - Long follow-up|Transcranial magnetic stimulation Anodal transcranial direct current stimulation Motor task Mental training
62792784|NCT04784832|SHAM_COMPARATOR|Sequence 4 - Control|Transcranial magnetic stimulation Motor task Mental training
62792785|NCT00987311|ACTIVE_COMPARATOR|1-Test product A|1-Dairy product containing probiotics A (test product A)
62792786|NCT00987311|ACTIVE_COMPARATOR|2-Test product B|2-Dairy product containing probiotics B (test product B)
62792787|NCT00987311|SHAM_COMPARATOR|3-Control|3-Dairy product without probiotics (control)
62216994|NCT00882687|EXPERIMENTAL|1.0% Lifitegrast|
62216995|NCT00882687|EXPERIMENTAL|5.0% Lifitegrast|
62216996|NCT00882687|PLACEBO_COMPARATOR|Placebo|
62792788|NCT00610311|EXPERIMENTAL|ALVAC plus anti-gp100:154-162 TCR PBL + HD IL-2|"ALVAC plus anti-gp100:154-162 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + high dose (HD) interleukin-2 (IL-2): ALVAC vaccine two hours prior to cell infusion patients will receive 0.5 ml containing a target dose of 10\^7 cell culture infectious dose 50% (CCID50) (with a range of approximately 10\^6.4 to 107.9/mL of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2mL. This will be repeated on day 14.~Aldesleukin (IL2, Proleukin, Recombinant human interleukin 2)- 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)"
62819334|NCT05295849|EXPERIMENTAL|Habit App|Habit Mobile App
62819335|NCT05141383|OTHER|Patients with prostate cancer|Patients with suspected prostate cancer (MRI or digital rectal examination), or prostatic hyperplasia with a PSA level\> 4 ng / ml
62411135|NCT06649617|EXPERIMENTAL|Control Group (Standard Procedure)|Before the application of nursing interventions ( Intramuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State- Trait Anxiety Scale were evaluated. Then , information was given about the nursing intervention to be performed as a standard procedure . The nursing intervention was applied. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State- Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary for the patients ( Intramuscular , Intravenous , Subcutaneous Injection), that application was applied. No unnecessary procedure was applied.
62411136|NCT06649617|EXPERIMENTAL|Music Therapy Group|Before the application of nursing interventions ( intramuscular , intravenous , subcutaneous injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients were made to listen to Büzürk makam, a Turkish musical makam. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( intramuscular , intravenous , subcutaneous injection), that application was performed on the patients . No unnecessary procedure was performed.
62585527|NCT05237102|EXPERIMENTAL|The patients did not respond to CSF tap test|Participants assigned to the experimental group did not respond to the CSF tap test and did not show improvement in general symptoms of hydrocephalus and disturbance of consciousness, but there may be changes in eeg and imaging parameters (it is unknown whether such changes are related to surgical outcome).
62585528|NCT05237102|OTHER|The patients did respond to CSF tap test|The improvement of symptoms in these participants after the CSF tap test predicts a favorable prognosis for CSF shunt.
62585529|NCT05239403||Observational (questionnaire, biospecimen collection)|Participants complete questionnaires over 10-15 minutes up to 4 weeks prior to day of vaccination and undergo collection of blood samples up to 4 weeks before or on the day of vaccination and within 3 weeks post vaccination. Patients may also undergo collection of stool samples up to 4 weeks prior to day of vaccination.
62585530|NCT01567345|ACTIVE_COMPARATOR|Intrathecal pump with continuous flow|After placement of the implantable pump, continuous flow is scheduled by physician and the patient can't modify it.
62585531|NCT01567345|EXPERIMENTAL|Intrathecal pump with programmable flow.|After placement of the implantable pump, programmable flow is scheduled by physician and patient can do himself morphine bolus injections for a better control of acute episodes of pain.
62792789|NCT04475120|EXPERIMENTAL|Liposomal Lacroferrin|Thirty-two patients (14 hospitalised and 18 in home-based isolation) belonging to the first group received oral and intranasal liposomal bLf. BLf capsules for oral use containing 100 mg of bLf encapsulated in liposome while bLf nasal spray had about 8 mg/ml of bLf encapsulated in liposome. BLf, contained in both products, was tested by SDS-PAGE and silver nitrate staining and its purity was about 95%. The bLf iron saturation was about 5% as detected via optical spectroscopy at 468 nm based on an extinction coefficient of 0.54 (100% iron saturation, 1% solution). The scheduled dose treatment of liposomal bLf for oral use was 1gr per day for 30 days (10 capsules per day) in addition to the same formulation intranasally administered 3 times daily (a total of about 16 mg/nostril)
62792790|NCT04475120|ACTIVE_COMPARATOR|SOC therapy|Thirty-two hospitalized patients belonging to the second group were only treated with SOC regimen according to the national guidelines at the time of the enrollment: lopinavir/ritonavir cps 200/50 mg, 2x2/day (alternatively darunavir 800 mg 1 cp/day+ritonavir 100 mg 1 cp/day or darunavir/cobicistat 800/150 mg 1 cp/day), chloroquine 500 mg, 1x2/day or hydroxychloroquine cp 200 mg, 1x2/day. SOC regimen lasted from 5 to 20 days, with timing to be established according to clinical course.
62792791|NCT04475120|NO_INTERVENTION|Home-based isolation|Twenty-eight patients, in home-based isolation, belonging to the third group did not receive any therapy.
62792792|NCT04475120|NO_INTERVENTION|Healthy volunteers|A control group, comprising 32 healthy volunteers, did not receive any treatment or placebo.
62792793|NCT05179148|EXPERIMENTAL|intervention|The arm will receive motivational interviewing
62792794|NCT04891380|OTHER|Cardiac arrest patients|Cardiac arrest patients receiving cardiopulmonary resuscitation with LUCAS 2 Active Decompression 2.
62792795|NCT04891380|OTHER|Hypotension|Patients developed or may develope hypotension of non traumatic origin.
62792796|NCT04891380|OTHER|Intensive care patient transport|Patients who are transported from one intensive department to another.
62792797|NCT04891380|OTHER|LUCAS 2 Active Decompression|The hemodynamic measurements of the cardiac arrest patients in the present study will be compared with the hemodynamic measurements achieved in the previous study NCT02479152.
62792798|NCT06059989|EXPERIMENTAL|Monotherapy|"Group 1: Monotherapy group~Patients randomized to IFX monotherapy start with subcutaneous IFX 240mg at week 0 and 2 and then from week 4, 120mg s.c.EOW."
62585532|NCT04117646||Patients|Patients of 2 and 12 years of age with chronic rhinosinusitis.
62792799|NCT06059989|EXPERIMENTAL|Combination therapy|"Group 2: Combination therapy group~Patients randomized to IFX combination therapy start with subcutaneous IFX 240mg at week 0 and 2 and then from week 4, 120mg s.c. EOW.~Patients randomized to IFX combination therapy also receive Immunosuppressives EOW."
62792800|NCT01621711|NO_INTERVENTION|Usual Care|Usual CD treatment, including therapy groups and individual counseling sessions, and six 45-min medical education groups. Physician appointments, pharmacotherapy, and SUD medications were be available as needed.
62792801|NCT01621711|EXPERIMENTAL|Linkage patient activation intervention|Usual Care with the exception that the six 45-min Linkage patient activation education groups replaced the six 45-min Usual Care medical education groups, plus a linkage phone call (and/or a facilitated email) with the patient, clinician, and Primary Care physician.
62585533|NCT04117646||Controls|Subjects of 2 and 12 years of age without chronic rhinosinusitis.
62585534|NCT02069912|EXPERIMENTAL|Collaborative depression care|All enrolled patients will receive collaborative depression care management.
62585535|NCT06342401||Early onset colorectal cancer (Training cohort)|Colorectal cancer diagnosed before the age of 50
62585536|NCT06342401||Non-disease controls (Training cohort)|Individuals free from colorectal cancer, younger than 50 years of age
62585537|NCT06342401||Early onset colorectal cancer (Validation cohort)|Colorectal cancer diagnosed before the age of 50
62792802|NCT01567111|EXPERIMENTAL|Subjects with PA|All study subjects have biochemically confirmed PA and undergo adrenal CT, AVS and MTO-PET to diagnose lateralization of aldosterone production.
62792803|NCT03982680|EXPERIMENTAL|Toripalimab combined with Gem/5-FU|All patients were given Toripalimab 3 mg/kg (day 1 and 15); Gem+5-FU (Gem 1250mg/m2+CF 200 mg/m2+5-FU400 mg/m2 intravenous drip+5-FU 2.4-3.6 g/m2 continuous intravenous drip for 48 hours), the first and fifteenth days, four weeks for a cycle, a total of four cycles.After 4 cycles, Toripalimab was maintained at 3 mg/kg Q3 w for a total of 1 year if the disease was not progressing or toxic side effects were tolerated.
62792804|NCT01633658|ACTIVE_COMPARATOR|Vitamin D Cholecalciferol|A single dose of 2500 micrograms cholecalciferol
62792805|NCT01633658|EXPERIMENTAL|25(OH)D|A single dose of 625 micrograms 25(OH)D
62792806|NCT04678635|EXPERIMENTAL|Transcranial direct current stimulation|Transcranial direct current stimulation session: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with cathode will be positioned at contralateral to the dominant limb and the anode charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. The stimulation will happen simultaneously to aerobic exercises for 20 minutes. Total number of stimulation associated with aerobic exercise sessions: 10
62792807|NCT04678635|PLACEBO_COMPARATOR|Placebo|This group will not receive a transcranial direct current stimulation session. However, the patients will do aerobic exercises for 20 minutes. Total number of sham-stimulation associated with aerobic exercise sessions: 10
62792808|NCT02154919||complete revascularization group|this group underwent second PCI procedure on the non-culprit vessels and reveived 100-120 IU/kg unfractionated heparin during PPCI, followed by 3 days administration of low molecular weight heparin or Fondaparinux sodium after procedure. Patients in the CP group and CR group after second PCI procedure were given conservative medicine such as Statins which were not contraindicated to the patients.
62792809|NCT02154919||conservative pharmacotherapy group|patients in conservative group undergoing pharmacotherapy after PPCI. The drugs were the same between two groups.
62792810|NCT00226486|EXPERIMENTAL|1|Identification of individual risk factors for falls and specified intervention aimed diminishing these risk factors in the individual.
62585538|NCT06342401||Non-disease controls (Validation cohort)|Individuals free from colorectal cancer, younger than 50 years of age
62585539|NCT05746416||s-TDAPT group|Ticagrelor 180mg + Aspirin 100mg within 6 months after index PCI
62792811|NCT00226486|PLACEBO_COMPARATOR|2|Usual care
62792812|NCT01068574||Single Observational Cohort|
62792813|NCT05432752|EXPERIMENTAL|Concussed Subjects|Subjects with known history of concussion will be evaluated using current clinical evaluation and also using the Concussion Pen.
62585540|NCT05746416||l-TDAPT group|Ticagrelor 120mg + Aspirin 100mg within 6 months after index PCI
62585541|NCT04946994|EXPERIMENTAL|High intensity interval training|
62585542|NCT04946994|ACTIVE_COMPARATOR|Continuous moderate intensity exercise|
62585543|NCT03492762|EXPERIMENTAL|Healthy Volunteer Group|The healthy volunteer group will receive the same interventions as the ILD documented diagnosed volunteer group
62585544|NCT03492762|EXPERIMENTAL|ILD Documented Diagnosed Volunteer Group|The ILD documented diagnosed volunteer group will receive the same interventions as the healthy volunteer group
62792814|NCT05432752|EXPERIMENTAL|Non-Concussed Subjects|Subjects with no known history of concussion will be evaluated using current clinical evaluation for a concussion and also using the Concussion Pen.
62792815|NCT05196022||G1|Patients with bilateral severe to profound hearing loss that would qualify for reimbursement of en cochlear implant but will not opt for a cochlear implant.
62585545|NCT06684795|EXPERIMENTAL|Presumed low-grade glioma|
62585546|NCT06684795|EXPERIMENTAL|Meningioma|
62585547|NCT01623635|EXPERIMENTAL|Case - adnexal|
62216997|NCT03407937|OTHER|Intervention|Receiving the conditioned pain modulation intervention during the first session and receiving the placebo and the hypnosis or meditation interventions during the second session.
62585548|NCT01623635|PLACEBO_COMPARATOR|placebo - adnexal|
62585549|NCT01623635|EXPERIMENTAL|case - uterine|
62585550|NCT01623635|PLACEBO_COMPARATOR|placebo - uterine|
62585551|NCT04726072|EXPERIMENTAL|Kundalini Yoga|The Kundalini yoga intervention is a mixture of basic yoga, breathing exercises and meditation. Participants were also asked to do at-home practice for half an hour daily.
62585552|NCT04726072|ACTIVE_COMPARATOR|Psychoeducation|The psychoeducation group consisted of teaching participants about healthy aging. Participants were asked to do at-home practice for half an hour daily
62585553|NCT00737295|EXPERIMENTAL|US|There will be no experimental or control group, rather each individual will act as his/her own control.
62585554|NCT03374501|EXPERIMENTAL|2 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink consumed with 2 tablets of Sugardown™
62585555|NCT03374501|EXPERIMENTAL|4 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink consumed with 4 tablets of Sugardown™
62585556|NCT03374501|PLACEBO_COMPARATOR|Soft drink|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink
62792816|NCT05196022||G2|Patients with bilateral severe to profound hearing loss that would qualify for reimbursement of en cochlear implant and receive a cochlear implant
62792817|NCT05196022||G3|Patients with a single-sided deafness in an acute setting
62411137|NCT06649617|EXPERIMENTAL|Virtual Reality Group|Before the application of nursing interventions ( Intamuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients watched 3D videos with relaxation effect with virtual glasses. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( Intamuscular , Intravenous , Subcutaneous Injection), that application was performed on the patients . No unnecessary procedure was performed.
62021570|NCT06573905||type 2 diabetes|This group includes participants diagnosed with Type 2 diabetes based on clinical data. The validation process focuses on assessing the algorithm's accuracy in identifying individuals with Type 2 diabetes, ensuring correct classification and minimizing the risk of misclassification as other diabetes phenotypes or non-diabetic.
62021571|NCT06573905||Latent autoimmune diabete in adults|This group consists of participants diagnosed with Latent Autoimmune Diabetes in Adults (LADA) according to self-reported data. The validation process for this group focuses on assessing the algorithm's ability to accurately identify individuals with LADA, which is often challenging due to its characteristics that overlap with both Type 1 and Type 2 diabetes. Accurate classification of LADA is crucial for improving treatment strategies and understanding its epidemiology.
62585557|NCT06532812|EXPERIMENTAL|Biological Tumor Infiltrating Lymphocytes (TIL) Therapy with Immunotherapy|"Patients receive pembrolizumab IV on day -14, cyclophosphamide IV QD on days -7 to -6, fludarabine IV over 30 minutes QD on days -5 to -1, and TILs IV infusion on day 0. Patients also receive pembrolizumab IV on day 28 and 70, and undergo surgery on day 80.~MAINTENANCE: Patients receive pembrolizumab IV every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
62792818|NCT05196022||G4|Patients with a single-sided deafness in a chronic setting
62792819|NCT03336294|OTHER|Old group|Subjects involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
62792820|NCT03336294|OTHER|Young group|Subjects involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
62021572|NCT06573905||Non-diabetic|This group includes participants who, according to self-reported data from individuals, do not have any phenotypes of diabetes. The comparison of this group's data with medico-administrative records is crucial for identifying false positives and ensuring that the algorithms accurately exclude non-diabetic individuals from being misclassified as having diabetes.
62216998|NCT04312334|EXPERIMENTAL|Treatment 1|Treatment 1: Hand cleaning with the Supertowel for 15 seconds. The Supertowel will be soaked in water by submersing it completely in a bucket filled with tap water. The amount of water absorbed by the ST will be recorded by means of weighing the towel before and after soaking. The volunteers will use the soaked Supertowel for 15 seconds to clean their pre-contaminated hands.
62411138|NCT04034524||New users of GLP1 receptor agonists (exposure)|
62411139|NCT04034524||New users of basal insulin (reference)|
62585558|NCT01694069|ACTIVE_COMPARATOR|Intermittent Infusion piperacillin-tazobactam|Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams), divided in four equal doses, administered over 30 minutes, four times a day
62792821|NCT02289807|EXPERIMENTAL|RT group|intensity modulated-radiotherapy (IMRT) alone Patients receive intensity modulated-radiotherapy (IMRT) alone
62792822|NCT02289807|ACTIVE_COMPARATOR|CCRT group|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles
62792823|NCT01401517|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose NF at 60 mg/capsule, BID
62792824|NCT01401517|EXPERIMENTAL|40 mg Sodium Nitrite|40 mg dose, BID
62792825|NCT01401517|EXPERIMENTAL|80 mg Sodium Nitrite|80 mg dose, BID
62792826|NCT05095259|EXPERIMENTAL|Participants with Type 1 Diabetes Mellitus|Participants with Type 1 Diabetes Mellitus
62216999|NCT04312334|EXPERIMENTAL|Treatment 2|Treatment 2: Hand cleaning with a Supertowel that is damp for 60 seconds The Supertowel will be soaked in water by submersing it completely in a bucket filled with tap water. The water on the Supertowel will then be squeezed out so that it is not dripping. The Supertowel will be weighed before soaking and after squeezing. Volunteers will clean their pre-contaminated hands with the damp Supertowel for 60 seconds.
62217000|NCT04312334|EXPERIMENTAL|Treatment 3|"Treatment 3: Hand cleaning for 60 seconds with a Supertowel that has been soaked in contaminated water.~A Supertowel will be soaked in water which has artificially contaminated with non-pathogenic E.coli. The water will be designed to mimic highly contaminated grey water so it will be contaminated at 2,000 cfu/100 ml which is double the acceptable level of contamination for handwashing. Volunteers will clean their pre-contaminated hands with the contaminated Supertowel for 60 seconds."
62585559|NCT01694069|EXPERIMENTAL|Continuous infusion piperacillin-tazobactam|Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams) as a continuous infusion over 24 hours, once daily
62792827|NCT05095259|ACTIVE_COMPARATOR|Healthy Controls|Healthy Controls
62411140|NCT04387227|EXPERIMENTAL|Treatment (carboplatin, pembrolizumab)|Patients receive carboplatin IV over 30 minutes on day -2 of cycle 1 only. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI throughout the trial. Patients also undergo blood sample collection on the trial.
62411141|NCT06649812|EXPERIMENTAL|Treatment (ViPOR)|Patients receive venetoclax PO QD on days 2-14, ibrutinib PO QD on days 1-14, prednisone PO QD on days 1-7, obinutuzumab IV on days 1 and 2, and Revlimid PO QD on days 1-14 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, PET, CT and/or MRI and optional tumor biopsy and bone marrow aspiration and biopsy throughout the study.
62411142|NCT01928095||Carotid Endocardectomy Patients|Subsequent analyses will be performed on the basis of the pathological grading provided by UK Pathology (e.g do readouts of the Dicer pathway correlate with pathological plaque characteristics).
62411143|NCT01638416|ACTIVE_COMPARATOR|Standard of care|Blood Transfusion Standard of care- oldest blood.
62021573|NCT06573905||other phenotypes|This group contains participants diagnosed with diabetes-related phenotypes other than Type 1, Type 2, or LADA, as well as those with rarer forms of the disease (based on clinical data). The validation aims to determine the algorithm's effectiveness in correctly identifying and classifying these less common phenotypes, which is critical for ensuring comprehensive and accurate diabetes classification.
62021574|NCT05570695|EXPERIMENTAL|neurofeedback|Modulation of brain activity using verum and sham neurofeedback.
62021575|NCT06534073|EXPERIMENTAL|Socks|The intervention will be the daily use of socks with the integration of the customized orthotic element.
62021576|NCT06534073|OTHER|Standard device|The intervention will be the daily use of external orthotic elements (to be put on and taken off daily) and of standard manufacture.
62021577|NCT06534073|OTHER|Foot orthoses|The participants will receive completely personalized plantar supports integrating the relief element.
62021578|NCT02632578||HIV-positive|
62792828|NCT06083753|EXPERIMENTAL|PIPE-307 Dose A|
62792829|NCT06083753|EXPERIMENTAL|PIPE-307 Dose B|
62792830|NCT06083753|PLACEBO_COMPARATOR|Placebo|
62792831|NCT05783414|EXPERIMENTAL|vCST + f2f carer support|vCST followed by in-person carer support programme
62792832|NCT05783414|ACTIVE_COMPARATOR|f2f CST + f2f carer support|In-person CST followed by in-person carer support programme
62792833|NCT05783414|EXPERIMENTAL|vCST + online carer support|vCST followed by online carer support programme
62792834|NCT05783414|EXPERIMENTAL|f2f CST + online carer support|In-person CST followed by online carer support programme
62792835|NCT03116685|EXPERIMENTAL|Oxabact OC5 capsules|Oxabact OC5 - Oxalobacter formigenes HC-1
62021579|NCT02632578||HIV-negative|
62411144|NCT01638416|OTHER|Arm B|Blood Transfusion Freshest blood.
62411145|NCT04076982|EXPERIMENTAL|mung bean|daily oral administration of protein supplement
62411146|NCT04076982|PLACEBO_COMPARATOR|biscuit|daily oral administration of control supplement
62585560|NCT06530680|EXPERIMENTAL|Physical therapy incorporating hippotherapy and the equine environment|Four 1 hour Hippotherapy treatments per week for four weeks.
62792836|NCT03116685|PLACEBO_COMPARATOR|Placebo capsules|Placebo
62792837|NCT05432492|EXPERIMENTAL|Cohort 1|Subjects receive AK112 on Day 1 of every 3-week cycle (Q3W) until progression.
62792838|NCT05432492|EXPERIMENTAL|Cohort 2|Subjects receive AK112 on Day 1 of every 3-week cycle (Q3W) until progression.
62792839|NCT06178107|EXPERIMENTAL|Probiotic|Lactobacillus plantarum (LPLDL®) equivalent to 4 x10\^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
62792840|NCT06178107|PLACEBO_COMPARATOR|placebo|Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
62819336|NCT05141383|OTHER|Patients with suspected cancer without confirmation on biopsy, or with hyperplasia of the prostate|Patients with suspected prostate cancer (MRI or digital rectal examination), or prostatic hyperplasia with a PSA level\> 4 ng / ml
62819337|NCT05141383|OTHER|Healthy donors|Male from 50 to 70 years old with a PSA level \<4 ng / mL
62819338|NCT04642027|ACTIVE_COMPARATOR|Conventional|Conventional sEBRT
62819339|NCT04642027|EXPERIMENTAL|Hypofractionation|Hypofractionated sEBRT
62819340|NCT04908579|ACTIVE_COMPARATOR|- GROUP (I): 30 patients|
62819341|NCT04908579|ACTIVE_COMPARATOR|- GROUP (II): 30 patients|
62819342|NCT04908579|ACTIVE_COMPARATOR|- GROUP (III) (Control): 30 patients|
62819343|NCT03959423|EXPERIMENTAL|Subjects 7-75 years of age|Subjects who have been diagnosed with type 1 diabetes
62819344|NCT06410027|EXPERIMENTAL|Pain Neuroscience Education + Virtual Reality + Therapeutic Exercise|1-hour pain neuroscience education session + 30-minutes exposure to exercise with virtual reality + Therapeutic Exercise
62021580|NCT06200857||association francaise de chirurgie AFC working group|"cohort description included all patients aged over 18, undergoing emergency or elective surgery for sigmoid diverticulitis between 2010 and 2019 and with a follow-up of at least 3 months to determine morbi-mortality on the 90th postoperative day.~minor patient, those with a final colorectal cancer and those operated on for right colonic diverticulitis were excluded~with a follow-up of at least 3 months to determine morbi-mortality on the 90th postoperative day.~Non-inclusion criteria for research subjects :~* Minor patient~* Surgical finding of colorectal cancer The patient operated on for diverticulitis of the right colon"
62021581|NCT05903560|EXPERIMENTAL|the radial group|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via radial approach randomly
62021582|NCT05903560|ACTIVE_COMPARATOR|the femoral group|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via femoral approach randomly
62021583|NCT02200822|NO_INTERVENTION|non-intervention arm|continuation of neurohumoral blocker therapy based on maximum tolerated guideline recommended dose (this group is the control arm for as well withdrawal of beta blocker therapy as withdrawal of RAAS blocker therapy)
62021584|NCT02200822|ACTIVE_COMPARATOR|withdrawal of beta blockers|"Intervention arm with systematic withdrawal of beta blocker therapy at a reverse sequence of guideline recommended uptitration.~(this group is the experimental arm for beta blocker withdrawal. This group receives no intervention with regards to the withdrawal of RAAS blockade). Per 2 weeks:~* bisoprolol: 10mg/d → 5 mg/d → 2,5 mg/d → 1,25 mg/d stop~* metoprolol: 200 mg/d → 100 mg/d → 50 mg/d → 25 mg/d → stop~* nebivolol: 10mg/d → 5 mg/d → 2,5 mg/d → 1,25 mg/d stop~* carvedilol: 50 mg bid → 25 mg bid → 12,5 mg bid → 6,25 mg bid → stop"
62411147|NCT04655339|EXPERIMENTAL|Group-1|Bilateral abdominal Lap-TAP block injection near incision site with 0.25% Bupivacaine HCl (30cc) with 30ml being injected bilaterally. Remaining residual is injected into port incision sites.
62411148|NCT04655339|EXPERIMENTAL|Group-2|Bilateral abdominal Lap-TAP liposomal Bupivacaine (Exparel®) injection with 133mg (20ml) Exparel® plus bupivacaine 0.25% (30ml), plus 10ml of normal saline for a total volume of 60ml, injecting 30ml each side.
62411149|NCT04655339|NO_INTERVENTION|Group-3|
62411150|NCT01152931|ACTIVE_COMPARATOR|COHORT A= Amodiaquine + Artesunate|Amodiaquine will be administered orally at 10mg/kg daily for 3days. Artesunate 50mg will be administered orally daily for 3days.For subjects \>6months\< 1 years 4mg/kg daily for 3 days
62411151|NCT01152931|ACTIVE_COMPARATOR|cohort B= Lumefantrine +Artemether|Artemether 20mg/Lumefantrine 120mg fixed combination administered daily for 3 days
62411152|NCT01152931|EXPERIMENTAL|cohort C = Artesunate + vitamin A|Artesunate 50mg daily for 4days. if \>6 months\< 1 year 4mg/kg daily for 4days + Vitamin A 5000IU daily for 4days if \< 1 year and 10,000IU daily for 4days if \> 1 year respectively
62411153|NCT01152931|EXPERIMENTAL|Artesunate, vitamin E oral administration|Artesunate 50mg daily for 4 days.if \>6 months\< 1 year 4mg/kg daily for 4 days + vitamin E 100mg daily administered orally to the experimental group 4 days.
62411154|NCT01152931|EXPERIMENTAL|cohort E will be given Artesunate and Zinc orally|cohort E will be given Artesunate 50mg daily for 4 days. if \> 6 months\< 1 year 4mg/kg daily for 4 days + zinc gluconate 50mg orally daily for 4 days. if \< 1 year 25 mg daily for 4 days
62411155|NCT01152931|EXPERIMENTAL|cohort F= Artesunate and selenium will be given orally|Artesunate 50mg daily for 4 days. if \> 6 months\< 1 year 4mg/kg daily for 4 days + selenium 100ug daily for 4 days. if \< 1 year 50ug daily for 4 days.
62411156|NCT01152931|EXPERIMENTAL|cohort G = Amodiaqiune and Vitamin A will be given orally|Amodiaquine 10mg/kg daily for 3 days + vitamin A 5000iu daily for 4 days if \< 1 year. 10,000 IU daily for 4 days if \> 1 year.
62411157|NCT01152931|EXPERIMENTAL|cohort H = amodiaquine and vitamin E administerd orally|Amodiaquine 10mg/kg daily for 4 days + vitamin E 100 mg daily for 4 days
62411158|NCT01152931|EXPERIMENTAL|cohort I = Amodiaquine and Zinc will be given orally|Amodiaquine 10mg/kg daily for 4 days + zinc 50mg daily 4 days. if \< 1 year 25 mg daily for 4 days.
62411159|NCT01152931|EXPERIMENTAL|Cohort J = amodiaquine and selenium will be given orally|Amodiaquine 10mg/kg daily for 4 days + selenium 100ug daily for 4 days if \> 1 year. 50ug daily for 4 days if \< 1 year.
62411160|NCT01152931|EXPERIMENTAL|K= Artesunate+ vitamin A + vitamin E|Tab Artesunate 50mg orally dly x 4 days + Vitamin A, 5000IU orally, dly x 4 days if ≤ 1yr. 10,000IU orally dly x 4days if \> 1 yr + vitamin E 100 mg orally dly for 4 days
62819345|NCT06410027|ACTIVE_COMPARATOR|Therapeutic Exercise|Therapeutic Exercise
62819346|NCT04784325|EXPERIMENTAL|Women recruited from a general population subject to I/E criteria|All study participants will administer three blood collection modalities (2 TAP II, 1 ADx card, and phlebotomist-performed venipuncture).
62819347|NCT05642728|EXPERIMENTAL|Case management group|
62819348|NCT05642728|NO_INTERVENTION|Control group|
62819349|NCT06271408|EXPERIMENTAL|Vibrating Mesh Nebulizer First|Participants will receive albuterol delivered via vibrating mesh nebulizer as their first treatment, followed by albuterol delivered via metered dose inhaler and then albuterol delivered via jet nebulizer.
62819350|NCT06271408|EXPERIMENTAL|Jet Nebulizer First|Participants will receive albuterol delivered via jet nebulizer as their first treatment, followed by albuterol delivered via vibrating mesh nebulizer and then albuterol delivered via metered dose inhaler.
62819351|NCT06271408|EXPERIMENTAL|Metered Dose Inhaler First|Participants will receive albuterol delivered via metered dose inhaler as their first treatment, followed by albuterol delivered via jet nebulizer and then albuterol delivered via vibrating mesh nebulizer.
62819352|NCT04887116|EXPERIMENTAL|Virtual Reality Exposure Therapy|Virtual Reality Exposure Therapy
62217001|NCT04312334|EXPERIMENTAL|Treatment 4|"Treatment 4: Hand cleaning for 60 seconds with a Supertowel that is visibly dirty and oily.~The Supertowel will be made visibly dirty and oily for example, by immersing it in a mix of 10 grams of sterile soil (previously autoclaved), 1 ml of clean cooking oil and 100 ml of water .The Supertowel will be rubbed against itself to ensure the soil and oil are spread out across the surface of the Supertowel. Volunteers will clean their pre-contaminated hands with the dirty Supertowel for 60 seconds."
62217002|NCT04312334|EXPERIMENTAL|Treatment 5|"Treatment 5: Hand cleaning for 30 seconds with a Supertowel that is visibly dirty and oily and it is soaked in whater which has artificially contaminated with non-pathogenic E.coli.~The Supertowel will be made visibly dirty and oily for example, by immersing it in a mix of 10 grams of sterile soil (previously autoclaved), 1 ml of clean cooking oil and 100 ml of water (which will be contaminated with E.coli).The Supertowel will be rubbed against itself to ensure the soil and oil are spread out across the surface of the Supertowel. Volunteers will clean their pre-contaminated hands with the dirty Supertowel for 30 seconds."
62217003|NCT04312334|EXPERIMENTAL|Treatment 6|Treatment 6: Hand cleaning with the Supertowel which is fully dry for 60 seconds.
62217004|NCT04312334|OTHER|Control 1|Control 1: Hand washing with bar soap and water for 15 seconds. The control group will wash their pre-contaminated hands with normal bar soap and water for 15 seconds. Hands from volunteers washed with soap will be allowed to dry for 3 minutes.
62217005|NCT04312334|OTHER|Control 2|"Control 2: Handwashing with bar soap and water for 60 seconds The control group will wash their pre-contaminated hands with normal bar soap and water for 60 seconds by following the WHO guidelines for handwashing when hands are visibly soiled (a diagram of the steps was given to them, appendix). After handwashing, hands will be allowed to dry for 3 minutes"
62217006|NCT04312334|OTHER|Control 3|"Control 3: Handwashing with bar soap and contaminated water for 60 seconds. Water which is contaminated with non-pathogenic E.coli. at 2,000 cfu/100ml will be stored in a bucket which has a tap at the base. The control group volunteers will wash their hands with the contaminated water and bar soap for 60 seconds. They will follow the WHO guidelines for handwashing when hands are visibly soiled (a diagram of the steps will be given to them). After handwashing, hands will be allowed to dry for 3 minutes."
62411161|NCT01152931|EXPERIMENTAL|L = Artesunate+ Vitamin A + Zinc|Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if \< 1 year. 10,000IU daily for 4 days if \> 1 year. All administered orally.
62411162|NCT01152931|EXPERIMENTAL|M = Artesunate+ Vitamin A + selenium|Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if \< 1 year. 10,000IU orally daily for 4 days if \> 1 year.
62411163|NCT01152931|EXPERIMENTAL|N = Artesunate + Vitamin E + Zinc|Artesunate 50mg daily for 4 days. vitamin E 100mg daily for 4 days. Zinc 50 mg daily for 4 days if \> 1 year. 25 mg daily for 4 days if \< 1 year.
62411164|NCT01152931|EXPERIMENTAL|O = Artesunate+ Vitamin E + Selenium|Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if \> 1 year. 50 ug orally daily for 4 days if \< 1 year.
62411165|NCT04907994||Older patients and/or with chronic diseases|Retrospective cohort study of exposed/unexposed individuals in the national health data system (SNDS). The study population is composed of individuals aged 70 years or older and patients with a chronic disease. Exposure to containment is defined as the period between 17 March 2020 (beginning of week 12, start of containment) and 10 May 2020 (end of week 19, end of containment). The end of monitoring is set at 12 months after the start of the containment, on 17 March 2021. The unexposed group consists of random samples of comparable individuals (aged 70 years or older and/or chronically ill) for the two years prior to the outbreak (2015 and 2016). The second study period (May 10, 2020 to March 17, 2021) may be subdivided depending on the evolution of the health crisis and the governmental measures adopted. Measurement of the outcome measures and comparison between exposed and unexposed will be carried out at the end of each of the two periods.
62411166|NCT03867500|EXPERIMENTAL|Niacin then saline|All participants will receive intravenous Niacin overnight on day one and then intravenous saline overnight on the second study day
62411167|NCT00946556|PLACEBO_COMPARATOR|Placebo|Participants will be assigned 2 months of placebo or active drug, with an intervening one month washout period.
62411168|NCT00946556|EXPERIMENTAL|Valacyclovir|Participants will be assigned 2 months of placebo or active drug, with an intervening one month washout period.
62411169|NCT00848666|EXPERIMENTAL|I|Patients with tinea pedis
62217007|NCT04312334|OTHER|Control 4|Control 4: Hand cleaning for 60 seconds with a clean Supertowel. The Supertowel will be soaked in water by submersing it completely in a bucket filled with tap water. The amount of water absorbed by the ST will be recordedby means of weighing the Supertowel before and after soaking. The control group will clean their pre-contaminated hands of with thesoaked Supertowel for 60 seconds.
62217008|NCT04312334|OTHER|Control 5|Hand washing with bar soap and water for 30 seconds. The control group will wash their pre-contaminated hands with normal bar soap and water for 30 seconds. Hands from volunteers washed with soap will be allowed to dry for 3 minutes.
62217009|NCT01852253|ACTIVE_COMPARATOR|2% chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline and 1 minute of local application of a 2 % chlorhexidine solution. After 1 minute of saline rinsing the gingival flap will be returned slightly apical (in order to reduce pockets) and will be firmly sutured. The surgery is followed by 2 weeks of rinsing with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds.
62411170|NCT04308759|EXPERIMENTAL|Group I (QuitBot Experimental)|Participants participate in the Quitbot program for 42 days to support quitting smoking. Therapy description withheld to protect the integrity of the study.
62411171|NCT04308759|ACTIVE_COMPARATOR|Group II (QuitBot Control)|Participants participate in the Quitbot program for 42 days to support quitting smoking. Therapy description withheld to protect the integrity of the study.
62411172|NCT04724070||NGS and PDO/PDX establishment|
62585561|NCT06530680|NO_INTERVENTION|Waitlist Control|A waitlist control that will receive hippotherapy intervention (four 1 hour Hippotherapy treatments per week for four weeks.) Four weeks later than the 'Physical therapy incorporating hippotherapy and the equine environment' Group.
62411173|NCT02609932|OTHER|SD or SS|In this study, IFN- γ-1b will be subcutaneously administered a total of 30 subjects in one of two cohorts; Single Dose (SD) or Steady State (SS) dosing. Dosing of IFN- γ-1b will be based upon the time subject became eligible and started study. In this non-randomized, open-label study, subjects will be enrolled on the SD cohort first, and once that cohort has been filled, enrollment to the SS cohort will begin. Although not required, subjects in the SD cohort may also volunteer to participate in the SS cohort if they still meet eligibility criteria. Separate consents will be used for the SD and SS cohorts. In the event not all the SD subjects choose to continue onto the SS cohort, we will plan to recruit new participants from our local campus community.
62411174|NCT02066688|EXPERIMENTAL|FA|Patients receive oral folic acid pill 1 mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects (FA Arm).
62217010|NCT01852253|SHAM_COMPARATOR|0.12% chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline and 1 minute of local application of a 0.12 % chlorhexidine solution. After 1 minute of saline rinsing the gingival flap will be returned slightly apical (in order to reduce pockets) and will be firmly sutured. The surgery is followed by 2 weeks of rinsing with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds.
62217011|NCT05741333|EXPERIMENTAL|Solo+ Tympanostomy Tube Device (Solo+ TTD)|The Solo+ TTD is a disposable surgical tool designed to deliver a tympanostomy tube into the tympanic membrane of patients undergoing a tympanostomy tube placement procedure.
62217012|NCT00583193|OTHER|1|Open-label Study
62411175|NCT02066688|EXPERIMENTAL|FA+Ca|Patients receive oral folic acid pill 1 mg+ calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects(FA+Ca arm).
62411176|NCT02066688|EXPERIMENTAL|Ca|Patients receive oral calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects (Ca Arm).
62411177|NCT02066688|PLACEBO_COMPARATOR|blank control group|Patients receive oral placebo once daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
62411178|NCT04839835|NO_INTERVENTION|standard waiting room|standard chemoterapy waiting room
62411179|NCT04839835|EXPERIMENTAL|waiting room enriched with art objects|waiting room enriched with music, paintings and artificial plants
62411180|NCT02663999|EXPERIMENTAL|diazepam nasal spray (AB)|Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses. The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).
62411181|NCT02663999|EXPERIMENTAL|diazepam nasal spray (BA)|Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses. The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).
62411182|NCT00290511|EXPERIMENTAL|R-FIND + Zevalin|Fludarabine 25 mg/m\^2 intravenous (IV) over 5-30 minutes on Days 2-4. Mitoxantrone 10 mg/m\^2 IV over 5-30 minutes on Day 2. Rituximab 375 mg/m\^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m\^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total). Zevalin 0.3 mCi/kg IV after 4 cycles of R-FND. Dexamethasone 20 mg by mouth (PO) or IV daily on Days 2-6.
62217013|NCT05567354|EXPERIMENTAL|PF614 100 mg capsule|Eligible subjects will be admitted to the clinical site on Day-1. Subjects will receive PF614 100mg capsules in a randomized, double-blind, crossover manner.
62217014|NCT05567354|ACTIVE_COMPARATOR|Oxycodone HCl tablets|Eligible subjects will be admitted to the clinical site on Day -1. Subjects will receive crushed oxycodone HCl IR 40mg in a randomized, double-blind, crossover manner.
62217015|NCT05567354|PLACEBO_COMPARATOR|Placebo powder in capsules|Eligible subjects will be admitted to the clinical site on Day-1. Subjects will receive Placebo powder in a randomized, double-blind, crossover manner.
62217016|NCT05029232|ACTIVE_COMPARATOR|ambulant patient with DMD|patient that walk alone or with minor assist
62217017|NCT05029232|ACTIVE_COMPARATOR|non ambulant patient with DMD|patient need wheel chair
62411183|NCT01900925|ACTIVE_COMPARATOR|Low back treatment only (pragmatic)|"1. advise to stay active,~2. discourage bed rest,~3. appropriate medication use,~4. reassurance.~5. Short term use of manipulation/medication,~6. supervised exercise,~7. cognitive behavioral therapy,~8. multidisciplinary treatment,~9. termination of use of modalities."
62585562|NCT01105078|OTHER|Flow rate|Comparison between a flow rate of 2.5/l/min/m2 versus 3.0/l/min/m2
62217018|NCT05159791|EXPERIMENTAL|Anomalous coronary blood flow|Subjects suspected to have AAOCA will be submitted to angiographic coronary CT imaging to confirm the diagnosis. If the diagnosis of AAOCA will be confirmed, subjects will undergo to invasive coronary blood flow evaluation (intervention).
62217019|NCT00625261|EXPERIMENTAL|1|The mothers of the two-years old children in the intervention group took part at the Heidelberg Parent-based Language Intervention HPLI
62217020|NCT00625261|NO_INTERVENTION|2|Waiting group, no intervention until children were three years of age
62217021|NCT06248099|EXPERIMENTAL|Sequence 1-Nebivolol test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Nebivolol tablets 5 mg test product, treatment 2= Nebivolol tablets 5 mg reference product.
62217022|NCT06248099|EXPERIMENTAL|Sequence 2-Nebivolol reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Nebivolol tablets 5 mg test product, treatment 2= Nebivolol tablets 5 mg reference product.
62217023|NCT04328116||Study Group|Neodent GM Zygomatic Dental Implants will be placed. Multiple implants may be placed in a single subject.
62217024|NCT03732560||Patients undergoing treatment with nivolumab and ipilimumab|
62217025|NCT03732560||Patients undergoing treatment with nivolumab|
62411184|NCT01900925|EXPERIMENTAL|LBP treatment and Hip treatment|Group two will receive the same pragmatically applied, guideline-oriented treatment that is recommended from group 1. In addition, group 2 will receive prescriptive hip exercises that include 1) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge, and the manual therapy treatment techniques of; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone.26 (See Appendix A for photos of the techniques and descriptions)
62585563|NCT00800774|EXPERIMENTAL|1|Nine eyes of nine patients (3 male and 6 female) with high anisometropia (\>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
62585564|NCT06257927|EXPERIMENTAL|Intervention|
62585565|NCT05280366|OTHER|Streamline Surgical System|Streamline Surgical System procedure administered
62585566|NCT05280366|ACTIVE_COMPARATOR|iStent Inject W|iStent Inject W implanted
62585567|NCT04831827|EXPERIMENTAL|IVR Reminder|Participants will receive an interactive voice reminder
62411185|NCT03162276|EXPERIMENTAL|Intervention|Inquiry Based Stress Reduction
62217026|NCT02856477|EXPERIMENTAL|adapted treatment|the treatment dose is adapted to the metabolic capacity of the patient. intervention: urine analysis
62217027|NCT02856477|EXPERIMENTAL|non-adaptated treatment|the treatment dose is adapted to the metabolic capacity of the patient. intervention: urine analysis
62217028|NCT01473004|EXPERIMENTAL|Sirspheres, response evaluation|Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
62217029|NCT01405365|EXPERIMENTAL|Metronidazole|
62217030|NCT01405365|PLACEBO_COMPARATOR|Placebo|
62217031|NCT04328454||COVID-19 patients|Hospitalized patients with COVID-19
62217032|NCT02777138||Young males aged 20-35 years old|"Maintaining a normal daily living lifestyle~* Healthy~* Reasonably active- PAL: 1.4-1.9~* Non-obese- Fat mass index based on DEXA of 4-8kg/m2~* Weight stable for more than 3 months (±3% body mass)~* Non-smoker~* No chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, peripheral arterial disease, insulin- or non-insulin dependent diabetes or other metabolic disorders~* No daily consumption of analgesic or anti-inflammatory drug(s) including NSAIDs and corticosteroids, prescription or non-prescription~* No medications that may influence lipid or carbohydrate metabolism or immune system function~* No known negative reaction to lidocaine~* No participation in heavy resistance training"
62411186|NCT03162276|PLACEBO_COMPARATOR|Control|The placebo group participants will receive a modified form of the intervention at the close of the study
62411187|NCT06519500||Patients undergoing surgery for neuroendocrine neoplasia|At least 10 cultures of organoids of Gastro-entero-pancreatic neoplasms (GEP-NEN) derived from patients undergoing surgery for neuroendocrine neoplasia. This study will allow us to define the success rate in the generation of organoids from gastro-entero-pancreatic neoplasms (GEP-NEN).
62411188|NCT02263222|EXPERIMENTAL|MDT-10013|Subjects will receive MDT-10013.
62411189|NCT04288739||Acute Myeloid Leukemia (AML) group|"patients who are diagnosed as Acute Myeloid Leukemia (AML) based on peripheral blood, bone marrow, immunophenotyping and who fulfill the WHO 2016 criteria.~Complete blood count (CBC), bone marrow aspirate, flow cytometric immunophenotyping, cytogenetic analysis and fluorescence in situ hybridization (FISH) for XIST gene will be performed for all AML patients in the study."
62217033|NCT02777138||Old males aged 65-85 years old|"Maintaining a normal daily living lifestyle~* Healthy~* Reasonably active- PAL: 1.4-1.9~* Non-obese- Fat mass index based on DEXA of 4-8kg/m2~* Weight stable for more than 3 months (±3% body mass)~* Non-smoker~* No chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, peripheral arterial disease, insulin- or non-insulin dependent diabetes or other metabolic disorders~* No daily consumption of analgesic or anti-inflammatory drug(s) including NSAIDs and corticosteroids, prescription or non-prescription~* No medications that may influence lipid or carbohydrate metabolism or immune system function~* No known negative reaction to lidocaine~* No participation in heavy resistance training"
62411190|NCT01267227|ACTIVE_COMPARATOR|High Dose|Pterostilbene 125 mg twice daily
62217034|NCT04498559||Patients undergoing total hip replacement|Patients at HSS Main Campus undergoing primary total hip replacement surgery, age range between 18 and 80 years old, and English speaking
62411191|NCT01267227|ACTIVE_COMPARATOR|Low Dose|Pterostilbene 50 mg twice daily
62411192|NCT01267227|ACTIVE_COMPARATOR|Low Dose Combination|Pterostilbene 50 mg/Grape Extract 100 mg twice daily
62411193|NCT01267227|PLACEBO_COMPARATOR|Placebo|Matching placebo twice daily
62411194|NCT06418932|EXPERIMENTAL|Compressive|Compressive therapy of the lower limbs plus parenteral administration of diuretics
62411195|NCT06418932|ACTIVE_COMPARATOR|Control|Parenteral diuretics alone
62585568|NCT04831827|ACTIVE_COMPARATOR|Personalized Phone Call Reminder|Participants will receive a personalized phone call
62585569|NCT04831827|ACTIVE_COMPARATOR|Portal Message Only|Participants will receive a online patient portal message reminder
62585570|NCT03258658|EXPERIMENTAL|Autologous Engineered Urethral Construct|All subjects enrolled will undergo a full-thickness bladder biopsy as an out-patient surgical procedure. Urothelial and Smooth Muscle Cells recovered from the biopsy will be isolated and expanded over the next 4-6 weeks, and then seeded onto a tubular scaffold to create the autologous engineered urethral construct. Subjects will undergo a second surgical procedure to excise the urethral stricture and implant the urethral construct. All subjects will be followed for 3 years for safety and efficacy.
62585571|NCT06665360||posterior spinal decompression|
62585572|NCT02291601|EXPERIMENTAL|Chlorhexidine Gluconate Cloth|2% CHG, single application
62585573|NCT02291601|PLACEBO_COMPARATOR|Vehicle Cloth|Excipients on cloth
62585574|NCT02291601|ACTIVE_COMPARATOR|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
62585575|NCT03005743|EXPERIMENTAL|MR based BT|Magnetic Resonance Image based Brachytherapy
62585576|NCT03005743|OTHER|Conventional BT|Conventional Radiograph based Brachytherapy
62585577|NCT06388616|EXPERIMENTAL|Group 1|Subjects with Mild Impairment will receive a single oral dose of balcinrenone under fasted conditions.
62585578|NCT06388616|EXPERIMENTAL|Group 2|Subjects with Moderate Impairment will receive a single oral dose of balcinrenone under fasted conditions.
62585579|NCT06388616|EXPERIMENTAL|Group 3|Healthy participants will receive a single oral dose of balcinrenone under fasted conditions.
62411196|NCT01261962|EXPERIMENTAL|Chemotherapy and zinc|Patients in adjuvant chemotherapy supplemented with zinc
62411197|NCT01261962|PLACEBO_COMPARATOR|Chemotherapy placebo|Patients in adjuvant chemotherapy with placebo
62411198|NCT01261962|OTHER|Control and zinc|Healthy patients supplemented with zinc
62411199|NCT01261962|OTHER|Control Placebo|Healthy volunteers received placebo
62411200|NCT04824612|SHAM_COMPARATOR|Sham Group|"intralesional administration of corticoid (IAC): intralesional injection of 20 mg/ml triamcinolone hexacetonide (Triancil®, Apsen Farmacêutica S.A.) - two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.~Sham PBM in the preoperative and postoperative periods of keloid removal surgery: Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month."
62411201|NCT04824612|EXPERIMENTAL|Experimental Group|"Transcutaneous PBM will be performed on the keloid in the preoperative period and on the remaining scar in the postoperative period using blue LED (470 nm, 0,4W, 24J per point on 10 linear points, total 240J). Frequency: Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month.~Intralesional administration of corticoid (IAC): intralesional injection of 20 mg/ml triamcinolone hexacetonide: two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies."
62411202|NCT06565767|EXPERIMENTAL|Group 1|age 7 to 11
62411203|NCT06565767|EXPERIMENTAL|Group 2|age 11 to 17
62411204|NCT06047964|EXPERIMENTAL|De-novo DCB group|Patients with de-novo symptomatic intracranial atherosclerotic stenosis and treated with DCB
62411205|NCT06047964|ACTIVE_COMPARATOR|De-novo POBA group|Patients with de-novo symptomatic intracranial atherosclerotic stenosis and treated with POBA
62411206|NCT06047964|EXPERIMENTAL|Restenosis group|Patients with symptomatic intracranial atherosclerotic re-stenosis after interventional therapy and treated with DCB
62411207|NCT04192747|EXPERIMENTAL|Elixir Bioadaptor (ELX1805J)|The Elixir Bioadaptor (ELX1805J) 2.25 - 4.0 mm diameter and 14,15,18, 23, 28, 32 and 38 mm in length
62411208|NCT04192747|ACTIVE_COMPARATOR|Medtronic Resolute Onyx Stent|The Medtronic Resolute Onyx Stent 2.25 - 4.0 mm diameter and 15, 18, 22, 30, 34 and 38 mm in length
62411209|NCT02674568|EXPERIMENTAL|Rovalpituzumab Tesirine|0.3 mg/kg rovalpituzumab tesirine administered intravenously on Day 1 of each 42-day cycle (every 6 weeks; Q6W) for 2 cycles. An additional 2 cycles of rovalpituzumab tesirine (retreatment) was permitted for eligible participants.
62411210|NCT01296269|EXPERIMENTAL|Vasopressin|vasopressin condition
62411211|NCT01296269|EXPERIMENTAL|oxytocin|oxytocin condition (syntocinon)
62411212|NCT01296269|PLACEBO_COMPARATOR|placebo|
62411213|NCT02016027|EXPERIMENTAL|Carica folia Arm|
62411214|NCT06313697|EXPERIMENTAL|Treatment group 1|single dose
62411215|NCT06313697|EXPERIMENTAL|Treatment group 2|single dose
62411216|NCT06313697|EXPERIMENTAL|Treatment group 3|single dose
62411217|NCT06313697|EXPERIMENTAL|Treatment group 4|single dose
62411218|NCT06313697|EXPERIMENTAL|Treatment group 5|single dose
62411219|NCT06313697|EXPERIMENTAL|Treatment group 6|single dose
62411220|NCT06247930|EXPERIMENTAL|Vitamin D3 + Mental Health Education|"Vitamin D3: 2000 IU per day for 6 weeks (two capsules of 800 IU plus one capsule of 400 IU), followed by 800 IU (one capsule of 800 IU) per day for 6 weeks.~Mental Health Education: consists of providing a brochure with information about mental health problems and a set of educational mental health videos regarding depression."
62411221|NCT06247930|PLACEBO_COMPARATOR|Vitamin D3 placebo + Mental Health Education|Vitamin D3 placebo (i.e., soybean oil). Mental Health Education: consists of providing a brochure with information about mental health problems and a set of educational mental health videos regarding depression.
62411222|NCT04170569|EXPERIMENTAL|Experimental Group|Yoga program was applied.
62411223|NCT04170569|NO_INTERVENTION|Control Group|No yoga program.
62411224|NCT03165253|ACTIVE_COMPARATOR|Synbiotic Group|The patients will be treated with the standard triple therapy that consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month, and the synbiotic Bifidobacterium animalis oral product (5000000000 colony forming units/dose) plus inulin (900 mg) given a single dose for 14 days, concurrently.
62411225|NCT03165253|OTHER|Standard Therapy Group|The patients in this group will be treated with standard triple therapy only. The standard triple therapy consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month.
62411226|NCT03833531|ACTIVE_COMPARATOR|PTSD-ImRS|PTSD treatment
62411227|NCT03833531|EXPERIMENTAL|Integrated SFT-ImRS|Integrated PTSD-PD treatment
62411228|NCT04359888||MMBI|Multi-Modality Balance Intervention (MMBI) Group
62411229|NCT04359888||BRT Group|Balanced Reach Training Group
62411230|NCT02618148|EXPERIMENTAL|ESTROGEN HERBALS 21|"Used for women who wish to monthly menstruation~Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
62411231|NCT02618148|EXPERIMENTAL|ESTROGEN HERBALS 28|"Used for women who do not wish to monthly menstruation~Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
62585580|NCT00323401|EXPERIMENTAL|Interventon|Antenatal classes for the parents
62585581|NCT00323401|NO_INTERVENTION|Control|No programme are offered
62585582|NCT05202158|ACTIVE_COMPARATOR|Irrigation + Genta|Patients treated with gentamicin in irrigation fluid during RIRS
62792841|NCT03080948||History of Melanoma (cases)|Participants at high-risk for melanoma (that is, those having many nevi and morphologically atypical nevi) who either have a history of invasive melanoma (cases) or do not have a history of melanoma (controls) and will perform comprehensive total body imaging of their moles in order to identify phenotypic markers of melanoma risk that aid in melanoma risk stratification. In addition, we will investigate histopathologic and molecular features of moles that are associated with melanoma risk and with melanoma subtypes. The evaluations needed for this study protocol will be primarily performed during routine clinical care.
62411232|NCT04501809|ACTIVE_COMPARATOR|Group I (Misoprostol group):|seventy-nine patients will receive a loading dose of moistened misoprostol tablets ( Cytotec pfizer 400 mg) inserted vaginally and it will be followed by maintenance dose (200 mg) after six hours and repeated every 4 hours till the start of effective uterine contraction with maximum five doses in 24 hours duration .
62021585|NCT02200822|ACTIVE_COMPARATOR|withdrawal of RAAS blockers|"intervention arm with systematic withdrawal of spironolactone followed by withdrawal of ACE-I/ARB at a reverse sequence of guideline recommended uptitration (this group receives no intervention regarding the withdrawal of beta blockers. This group is the experimental arm for withdrawal of RAAS blockers)~* first spironolactone/eplerenone: per two weeks: 25 mg/d→12,5 mg/d → stop~* after 2 weeks stop spironolactone/eplerenone start withdrawal of ACE-I/ARB per two weeks:~  * captopril: 50 mg tid→25 mg tid→12,5 mg tid→6,25 mg tid→stop~ * enalapril: 10 mg bid→5 mg bid→2,5 mg bid→1,25 mg bid→stop~ * lisinopril: 20 mg/d→10 mg/d→5 mg/d→2,5 mg/d→stop~ * ramipril: 10 mg/d→5 mg/d→2,5 mg/d→1,25 mg/d→stop~ * candesartan: 32 mg/d→16 mg/d→8 mg/d→4 m/d→stop~ * valsartan: 160 mg bid→80 mg bid→40 mg bid→20 mg bid→stop"
62217035|NCT00978523|EXPERIMENTAL|Treatment with AR-12|This is a single-agent, open-label, Phase 1, dose-escalation study in adult patients with advanced or recurrent solid tumors or lymphoma. Patients will receive orally administered AR-12 once daily for 28 consecutive days. The first dosing cycle will be followed by at least a 7 day off-treatment period; however, no off-treatment period will be scheduled between subsequent treatment cycles
62411233|NCT04501809|ACTIVE_COMPARATOR|Group II (Combined group):|seventy- nine patients will get intracervical Foleys Catheter insertion .a 16F (french units) Foley catheter will be introduced into the cervical canal to induce cervical ripping. The catheter will be fixed through inflation of the balloon with 30 milliliters of sterile solution when the catheter will be beyond the internal cervical os. After six hours of Foleys catheter fixation, we will start infusion of 10 international units (IU) of oxytocin on 500 ml ringer lactate by rate 125 ml\\hr followed by one hour rest to allow diuresis. Increased gradually of oxytocin dose by 5 IU each time until achieving regular uterine contraction, maximum five doses in twenty -four hours duration.
62217036|NCT05471830||Patient survey|Survey-eligible patients with Commercial or Medicare Advantage health insurance who are current/past users of sMRA therapies and diagnosed with chronic kidney disease (CKD), type 2 diabetes (T2D) or heart failure (HF).
62217037|NCT02316860|OTHER|History of reflex syncope|Passive tilt test in athletes with a history of reflex syncope
62217038|NCT02316860|OTHER|No history of reflex syncope|Passive tilt test in athletes without history of reflex syncope
62217039|NCT02832401|ACTIVE_COMPARATOR|Caffeine|200 mg of caffeine powder administered in capsules
62021586|NCT02200822|ACTIVE_COMPARATOR|withdrawal of RAAS - and beta blockers|"intervention arm with systematic withdrawal of spironolactone, secondly ACE-I/ARB and finally beta blockers. (this group is the experimental group for both study interventions (withdrawal of beta blockers and RAAS blockers)~* First: spironolactone/eplerenone cfr reduction schedule supra~* After 2 weeks of stop spironolactone withdrawal of ACE-I or ARB cfr reduction schedule supra~* After 2 weeks of stop ACE-I/ARB withdrawal of beta blocker cfr reduction schedule supra"
62217040|NCT02832401|PLACEBO_COMPARATOR|Placebo|Cellulose powder administered in capsules
62217041|NCT06446544|EXPERIMENTAL|arm monitoring of the VPFE with intraoperative alveolar recruitment maneuvers|arm monitoring of the VPFE with intraoperative alveolar recruitment maneuvers
62217042|NCT06446544|PLACEBO_COMPARATOR|VPFE monitoring arm without intraoperative alveolar recruitment maneuvers.|VPFE monitoring arm without intraoperative alveolar recruitment maneuvers.
62217043|NCT04521569|EXPERIMENTAL|EVLP with Regadenoson|Following the routine retrieval procedure of the lungs, they will be placed on the EVLP circuit (XVIVO Perfusion System) and infused with the study drug, Regadenoson.
62217044|NCT04521569|PLACEBO_COMPARATOR|EVLP with Steen solution|Following the routine retrieval procedure of the lungs, they will be placed on the EVLP circuit (XVIVO Perfusion System) and infused with the same volume of Steen solution.
62217045|NCT03965689|EXPERIMENTAL|Treatment (paclitaxel, carboplatin, pevonedistat)|Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30-60 minutes on day 1, and pevonedistat IV over 1 hour on days 1, 3, and 5. Treatment repeats every 21 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity.
62217046|NCT05090280|EXPERIMENTAL|PF614 solution|"Cohort 1 and 6 will consist of 6 evaluable subjects. Subjects will receive the PF614 solution alone and concomitantly with nafamostat as an IR solution and/or ER prototype capsules. Subjects will receive naltrexone prior to and following each regimen.~Cohorts 2 to 5 and Cohorts 7 to 10 will consist of 5 evaluable subjects in each cohort.~Only 2 sentinel subjects will be dosed (one male and one female) in Period 2, Cohort 1. After review of the PK data and safety data, the safety advisory committee will decide the nafamostat dose level.~After Cohorts 3 and 8 only: The fed vs fasted regimen will be determined for Cohorts 4 and 9."
62217047|NCT05090280|EXPERIMENTAL|PF614 solution concomitantly with nafamostat|"Cohort 1 and 6 will consist of 6 evaluable subjects. Subjects will receive the PF614 solution alone and concomitantly with nafamostat as an IR solution and/or ER prototype capsules. Subjects will receive naltrexone prior to and following each regimen.~Cohorts 2 to 5 and Cohorts 7 to 10 will consist of 5 evaluable subjects in each cohort.~Only 2 sentinel subjects will be dosed (one male and one female) in Period 2, Cohort 1. After review of the PK data and safety data, the safety advisory committee will decide the nafamostat dose level.~After Cohorts 3 and 8 only: The fed vs fasted regimen will be determined for Cohorts 4 and 9."
62411234|NCT05317923|EXPERIMENTAL|airway management and ventilation in patients with unusual placement of tracheal stenosis|Flow-controlled ventilation (FCV) in patients with unusual placement of tracheal stenosis
62792842|NCT03080948||No Melanoma History (controls)|Participants at high-risk for melanoma (that is, those having many nevi and morphologically atypical nevi) who either have a history of invasive melanoma (cases) or do not have a history of melanoma (controls) and will perform comprehensive total body imaging of their moles in order to identify phenotypic markers of melanoma risk that aid in melanoma risk stratification. In addition, we will investigate histopathologic and molecular features of moles that are associated with melanoma risk and with melanoma subtypes. The evaluations needed for this study protocol will be primarily performed during routine clinical care.
62411235|NCT00577031|EXPERIMENTAL|1|
62792843|NCT00731679|PLACEBO_COMPARATOR|Placebo|Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
62411236|NCT01320826||Physician colonoscopists|"All primary care physicians (family physicians and general internists) who perform colonoscopies were approached to voluntarily participate in the APC-Endo study.~All patients having a colonoscopy done by an APC-Endo study physician endoscopist were approached at the time of their endoscopy to consent to the post procedure telephone survey."
62411237|NCT03449277|ACTIVE_COMPARATOR|take oral nifedipine tablets|Women who take the oral tablets of nifedipine till discharge of hospital
62792844|NCT00731679|EXPERIMENTAL|Rifaximin|Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
62792845|NCT04277065|EXPERIMENTAL|Bulldog tourniquet in laparoscopic Hepatectomy|The bulldog tourniquet , a reusable vessel occlusion instrument forblocking the liver inflow-blood in laparoscopic liver resection, was uniformly employed in all patients randomized to Bulldog laparoscopic hepatectom group in the present study.
62792846|NCT04277065|ACTIVE_COMPARATOR|cotton tourniquet in laparoscopic Hepatectomy|The cotton tourniquet ,a reusable vessel occlusion instrument for blocking the liver inflow-blood in laparoscopic liver resection
62411238|NCT03449277|ACTIVE_COMPARATOR|take oral labetalol tablets|Women who take the oral tablets of labetalol till discharge of hospital
62585583|NCT05202158|SHAM_COMPARATOR|Irrigation|Patients treated only irrigation fluid during RIRS
62792847|NCT01400568|EXPERIMENTAL|LPS challenge and fluticasone propionate|In case LPS induced airway inflammation is reproducible, the effect of a single high dose of inhaled fluticasone propionate will be assessed after a 4-week wash-out period.
62792848|NCT05844280|ACTIVE_COMPARATOR|Control Group|receiving physical therapy with BFR+NMES devices used at sub-therapeutic levels
62411239|NCT03672201|ACTIVE_COMPARATOR|The Integrated Care Pathway (ICP) Arm|The ICP consists of 1) a cleanup phase during which a thorough assessment of pharmacotherapy to discontinue unnecessary medications, is performed; 2) Structured non-pharmacological interventions, which would have started as soon as randomization occurred and would continue before any pharmacological intervention for 2 weeks as stand-alone interventions; and 3) a pharmacological intervention phase: in this phase the medications algorithm for AD-AA is initiated.
62585584|NCT01953601|EXPERIMENTAL|Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)|\[Part 1\] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). \[Part 2\] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 12 mg once daily for an additional 260 weeks.
62585585|NCT01953601|EXPERIMENTAL|Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)|\[Part 1\] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). \[Part 2\] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
62792849|NCT05844280|EXPERIMENTAL|Treatment Group|receiving physical therapy with BFR+NMES devices used at settings that are deemed by prior studies to be therapeutic
62792850|NCT03867448||Adults with Endocrine Disorder|Adults referred to NIH with possible endocrine conditions
62792851|NCT02474420|ACTIVE_COMPARATOR|Deferasirox|deferasirox iron chelation therapy and standard of care by the treating physician
62792852|NCT02474420|EXPERIMENTAL|Deferasirox plus amlodipine|deferasirox iron chelation therapy with amlodipine
62792853|NCT03777761|EXPERIMENTAL|Treatment Sequence ABC|tucatinib + placebo + moxifloxacin (administered in sequential treatment periods)
62792854|NCT03777761|EXPERIMENTAL|Treatment Sequence CAB|moxifloxacin + tucatinib + placebo (administered in sequential treatment periods)
62792855|NCT03777761|EXPERIMENTAL|Treatment Sequence BCA|placebo + moxifloxacin + tucatinib (administered in sequential treatment periods)
62792856|NCT03777761|EXPERIMENTAL|Treatment Sequence CBA|moxifloxacin + placebo + tucatinib (administered in sequential treatment periods)
62792857|NCT03777761|EXPERIMENTAL|Treatment Sequence ACB|tucatinib + moxifloxacin + placebo (administered in sequential treatment periods)
62792858|NCT03777761|EXPERIMENTAL|Treatment Sequence BAC|placebo + tucatinib + moxifloxacin (administered in sequential treatment periods)
62792859|NCT00195039|EXPERIMENTAL|All patients|"Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min."
62792860|NCT02123849|EXPERIMENTAL|Arm I (continuous aspirin)|Participants receive aspirin PO QD for 12 weeks.
62792861|NCT02123849|EXPERIMENTAL|Arm II (intermittent aspirin)|Participants receive placebo PO QD during weeks 1, 3, 5, 7, 9, and 11 and aspirin PO QD during weeks 2, 4, 6, 8, 10, and 12.
62792862|NCT00646360|EXPERIMENTAL|DHA arm|Docosahexonic acid (DHA) (400 mg/day). Pregnant women attending the IMSS General Hospital I are recruited between 18-22 wks gestation and assigned randomly to receive either DHA (400 mg) or a placebo daily until delivery.
62792863|NCT00646360|PLACEBO_COMPARATOR|Placebo arm|Pregnant women attending the IMSS General Hospital I are recruited between 18-22 wks gestation and assigned randomly to receive either DHA (400 mg) or a placebo daily until delivery.
62792864|NCT06110208|EXPERIMENTAL|AML subjects|This study is a single-center clinical study. The main purpose is an IIT clinical trial to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T injection in r/r AML subjects . The included population was patients with relapsed and refractory acute myeloid leukemia (r/r AML) .
62411240|NCT03672201|NO_INTERVENTION|Treatment-As-Usual (TAU) Arm|Following eligibility and baseline assessments, half of the participants will be randomized to TAU. TAU will consist of the typical care that the interdisciplinary team provides at each site for AD-AA. No predetermined cleanup phase, non-pharmacological interventions, algorithmic pharmacological interventions will be systematically part of TAU.
62585586|NCT01953601|PLACEBO_COMPARATOR|Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)|\[Part 1\] Placebo once daily for 104 weeks in Part 1 (Base Study). \[Part 2\] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
62792865|NCT02942758|EXPERIMENTAL|low-dose AZA / ATRA / Pioglitazone|low-dose azacitidine (75 mg/d), ATRA, pioglitazone
62792866|NCT02942758|ACTIVE_COMPARATOR|standard-dose AZA|standard-dose azacitidine (75mg/m²/d)
62792867|NCT05971693|EXPERIMENTAL|OMNYPULSE Bi-Directional Catheter with TRUPULSE Generator|Participants with symptomatic paroxysmal atrial fibrillation (PAF) will undergo the ablation procedure with OMNYPULSE bi-directional catheter used in combination with the TRUPULSE generator for pulmonary vein isolation (PVI).
62792868|NCT03349125||Collar On|Individuals who have been referred for videoflouroscopic swallow study (VFSS) as per standard of care, with a stable cervical injury, will have trials of liquids and solids with the Cervical Brace (Collar) on.
62792869|NCT03349125||Collar Off|Individuals who have been referred for videoflouroscopic swallow study (VFSS) as per standard of care, with a stable cervical injury, will have trials of liquids and solids with the Cervical Brace (Collar) off.
62792870|NCT03864302|EXPERIMENTAL|Motor Imagery|"The intervention group is informed about the concept of motor imagery (MI) for performance enhancement and are instructed in using the modified PETTLEP framework for TURB (table 1).(18) The intervention group performs a MI training session (MITS) prior to each VR simulation procedure.~Table 1: PEELP framework:~Physical: Sitting in front of the simulator, aloud to touch and move the scope Environment: Simulated sounds from the OR, including electrical device feedback from devices and vital measures Task: Four standardized TURB cases Timing: Each MI session is temporal to a simulated TURB case, max. 10 minutes Learning: Think aloud the major steps of the procedure using Emotions: Imagine the emotions when the surgery progresses and when an adverse event occurs Perspectives: Internal perspective thinking then I..."
62792871|NCT03864302|NO_INTERVENTION|Control|The control group proceeds directly to standard VR-simulator training.
62792872|NCT06725862|EXPERIMENTAL|Retrolaminar block group|Pediatric patients in this group will receive a retrolaminar block (RLB) using 0.25% bupivacaine (0.1 mL/kg) injected into the retrolaminar space at the L4 vertebral level under ultrasound guidance after general anesthesia induction.
62411241|NCT04942561|NO_INTERVENTION|Standard of Care (No VR) Randomization|In the standard of care treatment condition, participants will receive the standard CHLA treatment protocol for PIVC placement (i.e., a topical numbing spray and Buzzy® Bee, a vibrating device placed near the PIVC site for pain distraction).
62585587|NCT03745690|EXPERIMENTAL|Treatment (near-infrared image guided surgical resection)|Patients receive indocyanine green IV on day 0 and undergo near-infrared image guided surgical resection on day 1.
62411242|NCT04942561|EXPERIMENTAL|VR Randomization|Children in the VR condition will undergo the invasive procedure while distracted by interaction with an immersive virtual environment (VE) presented via a head mounted display (HMD). The intervention group will receive standard CHLA treatment with VR distraction. Patients began gameplay \<5 minutes before their PIVC placement and concluded after successful vascular access.
62411243|NCT05384119|EXPERIMENTAL|Phase 1b: Dose Escalation|Participants will receive up to 3 dose levels of TTI-101 added to palbociclib and AI or fulvestrant to determine the RP2D.
62411244|NCT05384119|EXPERIMENTAL|Phase 2: Dose Expansion|Enrollment in Phase 2 may commence with approval from the safety review committee. Participants will be enrolled and treated at the RP2D of TTI-101 added to palbociclib or ribociclib and AI or fulvestrant.
62411245|NCT01246102|EXPERIMENTAL|1|starting at 20 mg/m2
62411246|NCT04566666|PLACEBO_COMPARATOR|Placebo of SCD-044 product|Placebo of SCD-044 study drug
62411247|NCT04566666|ACTIVE_COMPARATOR|SCD-044 Tablets_Dose 1|SCD-044 tablets at Dose 1
62411248|NCT04566666|ACTIVE_COMPARATOR|SCD-044 Tablets_Dose 2|SCD-044 tablets at Dose 2
62411249|NCT04566666|ACTIVE_COMPARATOR|SCD-044 Tablets_Dose 3|SCD-044 tablets at Dose 3
62411250|NCT03296267|OTHER|gastroduodenoscopy|all participants undergo a gastroduodenoscopy to use the biopsies in an Ussing chamber experiment.
62585588|NCT04693832|EXPERIMENTAL|5inD|All children receive routine antiemetic therapy before chemotherapy. Children in the experimental group will use the interactive mobile application (5inD) for seven days from the first day of chemotherapy. The games in this application will help distract their attention and manage their nausea and vomiting.
62585589|NCT04693832|NO_INTERVENTION|Control group|All children receive routine antiemetic therapy before chemotherapy.
62585590|NCT05833113|PLACEBO_COMPARATOR|Gruop Control|The patients will be received an ultrasound-guided interscalene brachial plexus block and postoperative Placebo-TENS applied.
62585591|NCT05833113|ACTIVE_COMPARATOR|Group TENS|The patients will be received an ultrasound-guided interscalene brachial plexus block and postoperative TENS applied.
62585592|NCT06152185|EXPERIMENTAL|Mindfulness Training|Mindfulness intervention involving 28 audio-guided lessons plus daily brief practice prompts. Lessons train meditation techniques for 3 mindfulness skills: concentration, sensory clarity, and equanimity. Practice prompts delivered 3x daily build on the skills trained in each lesson.
62585593|NCT06152185|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|Participants in the EUC condition will have no study requirements during the 4-week intervention period, but they will receive a list of stress management resources upon randomization (websites, books, health tracking apps, and mental health services) with no additional intervention support.
62585594|NCT05444725|OTHER|Stage of decision making|"Same questionnaire for all three arms except validated question Stage of decision making followed by question about participation in screening or not when invited at age 50.~This is not an intervention but a survey study with three different versions of the questionnaire."
62411251|NCT03128775|EXPERIMENTAL|Nudge|This group will receive changes in the school environment (nudge strategies). Interventions regarding food consumption were based on nudge strategies to led students to eat more fruits and vegetables. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) are available for use in the school sports court.
62585595|NCT05444725|OTHER|Choice framing|"Same questionnaire for all three arms except text and question presenting breast cancer screening as a choice (between screening and alternative of no screening) followed by question about participation in screening or not when invited at age 50.~This is not an intervention but a survey study with three different versions of the questionnaire."
62585596|NCT05444725|OTHER|Opportunity framing|"Same questionnaire for all three arms except text and question presenting breast cancer screening as an opportunity (no presentation of alternative) followed by question about participation in screening or not when invited at age 50.~This is not an intervention but a survey study with three different versions of the questionnaire."
62411252|NCT03128775|EXPERIMENTAL|Primary prevention|This group will receive educational activities in the classroom. Classroom-based educational activities will be based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans.
62411253|NCT03128775|EXPERIMENTAL|Primary prevention + nudge|This group will receive educational activities and in the classroomchanges in the school environment (nudge).
62217048|NCT04271982||Cohort A|Cohort A includes patients (N=20 000) screened for nutritional risk at Haukeland University Hospital (HUS) during point prevalence surveys between 2008 and 2018. The point prevalence surveys included all adult patients in somatic departments, and were performed 2-4 times per year since 2008. We expect the sample in the study to include approx. 9000 patients ≥ 65 years.
62411254|NCT03128775|NO_INTERVENTION|Control|without any activity
62411255|NCT03856632|ACTIVE_COMPARATOR|Risk Factor Modification (RFM)|A structured risk factor modification (RFM) program currently offered to all patients who are overweight or obese undergoing an ablation procedure for atrial fibrillation.The RFM program is already offered through our Center for Atrial Fibrillation and is managed by a nurse practitioner. The RFM program will provide patient teaching and education on weight, fitness,blood pressure control, glucose control, cholesterol, sleep apnea, smoking, and alcohol.
62411256|NCT03856632|EXPERIMENTAL|RFM plus Liraglutide|In addition to RFM, Liraglutide will be administered. Liraglutide is an FDA approved medication used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management of obese adults with weight-related comorbid conditions.
62411257|NCT06234969|EXPERIMENTAL|Continuous theta burst stimulation to the intraparietal sulcus|Continuous theta burst stimulation will be delivered to the individually targeted intraparietal sulcus site at 100% RMT.
62585597|NCT04801147|EXPERIMENTAL|Immunotherapy|Autologous DC loaded with a autologous tumor lysate, in order to stimulate the immune response of the patient.
62585598|NCT06089109|EXPERIMENTAL|Maternal Injury and Death Intervention|Our research team created a VIP Corps online, interactive learning management system (LMS) training. This VIP Corps online training will be offered to students enrolled in a helping profession. Students are randomized to this experimental intervention arm. This training seeks to provide helping professionals with information and resources to identify, intervene, and prevent maternal injuries from interpersonal violence, substance use/disorder (IPV and SU/D). This training will provide students with the knowledge, skills, and efficacy to intervene and build capacity for prevention of maternal injuries and death due to violence.
62585599|NCT06089109|ACTIVE_COMPARATOR|Development of a Maternal Injury Surveillance System|Proposal of a novel Maternal Injury Surveillance System (MISS) as a complement to the existing maternal mortality surveillance available within Kentucky Violent Death Reporting System (KVDRS)
62585600|NCT04974281|OTHER|PD-1+TACE+Len|PD-1 Antibody and Lenvatinib Plus TACE
62585601|NCT06136598|EXPERIMENTAL|Opevesostat|Participants will receive opevesostat by oral tablets twice daily plus dexamethasone and fludrocortisone by oral tablets once daily continuously until unacceptable toxicity or documented progression. Hydrocortisone will also be provided to participants for use as rescue medication.
62585602|NCT03418584|EXPERIMENTAL|HybridAPC|The patient with Barrett's esophagus is treatment by HybridAPC.
62585603|NCT05108350|EXPERIMENTAL|HR20033 FDC 5/500 mg|
62585604|NCT05108350|EXPERIMENTAL|SHR3824 5mg + Metformin 500 mg XR|
62411258|NCT06234969|PLACEBO_COMPARATOR|Sham continuous theta burst stimulation|We will use the coil's electric stimulation functionality that allows for the delivery of a brief electric pulse to the scalp simultaneous to the pulse to mimic actual stimulation.
62585605|NCT05108350|EXPERIMENTAL|HR20033 FDC 5/1000 mg|
62585606|NCT05108350|EXPERIMENTAL|SHR3824 5 mg + Metformin 1000 mg XR|
62585607|NCT06514430|ACTIVE_COMPARATOR|Oral phenazopyridine|Patients randomized to the oral phenzopyridine arm will receive 200 milligrams (mg) phenazopyridine orally prior to the scheduled procedure.
62585608|NCT06514430|ACTIVE_COMPARATOR|Intravesical lidocaine|Patients randomized to the intravesical lidocaine arm will be administered 50 cubic centimeters (cc) of 1% lidocaine with 50cc sodium bicarbonate within the bladder immediately prior to the procedure.
62585609|NCT01337492|EXPERIMENTAL|Sorafenib|
62585610|NCT06683144|EXPERIMENTAL|Exposure feedback group|
62585611|NCT06683144|EXPERIMENTAL|Interactive education group|
62585612|NCT06683144|EXPERIMENTAL|Social media group|
62585613|NCT02000700|EXPERIMENTAL|Canagliflozin (Dose Group 1)|Participants will receive 100 mg (as 1 x 100-mg tablet) of canagliflozin daily for 14 days.
62585614|NCT02000700|EXPERIMENTAL|Canagliflozin (Dose Group 2)|Participants will be enrolled into Dose Group 2 to receive either 50 mg (as 1 x 50-mg tablet) or 300 mg (as 1 x 300-mg tablet) of canagliflozin daily for 14 days.
62585615|NCT05292989|EXPERIMENTAL|Group 1- Personalised tailored approach|If patients are assigned to this group they will be asked to complete a frailty assessment which includes the Fraility Index short form, an assessment of grip strength, time to complete 5 sit-to-stands, balance test, and gait speed along with some questionnaires on comorbid medical condition. The treating Gastroenterologist will then go through the results of the frailty assessment with the patient and based on this information will discuss the benefits and risks associated with having a surveillance colonoscopy. The patient will then decide if they would like to go ahead with a surveillance colonoscopy and the treating Gastroenterologist will provide further advice as required. The frailty assessment is intended to be done at the time of the appointment with the specialist. However, operational requirements may dictate that e.g. a telehealth delivered occasion of service is done at a separate date.
62585616|NCT05292989|PLACEBO_COMPARATOR|Group 2- Standard Care|Patients assigned to this group will discuss the benefits and risks associated with having a surveillance colonoscopy with the treating Gastroenterologist and will decide whether to proceed with the colonoscopy.
62585617|NCT02799667|ACTIVE_COMPARATOR|Standard Dressing|Women will be randomized to receive the standard dressing (sterile gauze, non absorbent sterile gauze, and a waterproof bandage) at the time of fascial closure in a cesarean delivery.
62585618|NCT02799667|EXPERIMENTAL|Negative Pressure Wound Therapy Dressing|Women will be randomized to receive the Negative Pressure Wound Therapy (NPWT) dressing at the time of fascial closure in a cesarean delivery.
62411259|NCT03172715|ACTIVE_COMPARATOR|ORIF (open reduction-internal fixation)|"Osteosynthesis with locking plate(s) will be performed using medial and/or lateral incision, according to morphology of the fracture. Additional osteosynthesis material will be used when necessary. The articular surface will be reduced and bone transplantation or bone substitute used if required.~Postoperatively, touch-down weight bearing will be allowed for 6 weeks, followed by 2 weeks of half-weight-bearing period. A walker or wheelchair will be used when necessary."
62585619|NCT06632184|EXPERIMENTAL|Ondansetron with Bicarbonate Formulation|Participants in this arm will receive an intraperitoneal formulation of ondansetron combined with bicarbonate during laparoscopic cholecystectomy. The bicarbonate is added to enhance the efficacy of ondansetron in controlling postoperative pain. The intervention will be administered intraoperatively, and the primary outcome measured will be postoperative pain intensity, as well as secondary outcomes such as the need for rescue analgesia and the occurrence of nausea and vomiting.
62217049|NCT04271982||Cohort B|"Cohort B includes older service users (≥65 years) with information on nutrition variables from the KPR-registry in the period 2016 to 2018 (n=approx. 270 560). All Norwegian municipalities report data on nutritional risk screening and nutrition plan for individual service users in Kommunalt pasientregister (KPR). These nutritional data will be linked to registry data on health care services use and patient outcome variables from the The Norwegian Patient Registry (NPR)"
62217050|NCT01775124|EXPERIMENTAL|Ranibizumab 0.5 mg monthly|Monthly intravitreal injections of ranibizumab 0.5 mg in the core treatment period and PRN intravitreal injections of the same dose guided by best-corrected visual acuity (BCVA) stabilization in the extension treatment period
62792873|NCT06725862|ACTIVE_COMPARATOR|Caudal Block (CB) Group|Pediatric patients in this group will receive a caudal block (CB) using 0.125% bupivacaine (1 mL/kg, maximum 20 mL) injected into the sacral canal under ultrasound guidance after general anesthesia induction.
62792874|NCT06725329|EXPERIMENTAL|Adapted and culturally-integrated psychosocial education intervention|Participants will receive the culturally adapted psychosocial educational program for chronic pain management. The investigators will adapt the Learn About My Pain (LAMP) program that has previously been established for efficacy in reducing chronic pain intensity, pain interference, and pain catastrophizing in racialized groups in community settings. The LAMP intervention provides biopsychosocial education sessions about chronic pain and its management.
62792875|NCT03167775|EXPERIMENTAL|Elemene + the best supportive treatment|the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment .
62792876|NCT00931606|EXPERIMENTAL|Sotatercept 0.1 mg/kg|Participants will receive sotatercept 0.1 mg/kg subcutaneously every 28 days up to 4 doses.
62217051|NCT01775124|EXPERIMENTAL|Ranibizumab 0.5 mg pro re nata (PRN)|PRN intravitreal injections of ranibizumab 0.5 mg guided by best-corrected visual acuity (BCVA) stabilization in the 23 month treatment period
62217052|NCT04821687|EXPERIMENTAL|Opicapone 50mg|
62217053|NCT04821687|ACTIVE_COMPARATOR|Levodopa 100mg|
62217054|NCT05416541||pregnant patients|
62792877|NCT00931606|EXPERIMENTAL|Sotatercept 0.3 mg/kg|Participants will receive sotatercept 0.3 mg/kg subcutaneously every 28 days up to 4 doses.
62217055|NCT04410523|EXPERIMENTAL|CSJ117 0.5mg|CSJ117 0.5 mg inhaled once daily
62217056|NCT04410523|EXPERIMENTAL|CSJ117 1mg|CSJ117 1 mg inhaled once daily
62792878|NCT00931606|EXPERIMENTAL|Sotatercept 0.5 mg/kg|Participants will receive sotatercept 0.5 mg/kg subcutaneously every 28 days up to 4 doses.
62792879|NCT00931606|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo subcutaneously every 28 days up to 4 doses.
62217057|NCT04410523|EXPERIMENTAL|CSJ117 2mg|CSJ117 2 mg inhaled once daily
62217058|NCT04410523|EXPERIMENTAL|CSJ117 4mg|CSJ117 4 mg inhaled once daily
62792880|NCT01103583|EXPERIMENTAL|Hydroxyurea|
62792881|NCT01103583|PLACEBO_COMPARATOR|Placebo|
62792882|NCT05477784|EXPERIMENTAL|Group I (enhancing connections-palliative care program)|Patients receive the 5-session EC-PC program bi-weekly with a patient educator about ways to help them talk to and support their child.
62217059|NCT04410523|EXPERIMENTAL|CSJ117 8mg|CSJ117 8 mg inhaled once daily
62217060|NCT04410523|PLACEBO_COMPARATOR|Placebo|Placebo inhaled once daily
62217061|NCT03459443|EXPERIMENTAL|Danicopan|Danicopan was to be administered to participants with C3G or IC-MPGN at a starting dose of 100 milligrams (mg) 3 times daily (TID) for the first 2 weeks, then the dosage was to be increased to 200 mg TID for the remainder of the study.
62217062|NCT01523132||Breast cancer patients|Female breast cancer patients without metastasis and locally advanced disease
62217063|NCT05364892|OTHER|ANCA-associated vasculitis - patient library|It is a description of ANCA-associated vasculitis patients cohort. All the patients are included in one arm. They will undergo various type of samples.
62585620|NCT06632184|ACTIVE_COMPARATOR|Ondansetron with Saline Solution Formulation|Participants in this arm will receive an intraperitoneal formulation of ondansetron combined with saline solution during laparoscopic cholecystectomy. This group serves as a comparator to evaluate the effectiveness of the bicarbonate formulation. As with the first arm, the intervention will be administered intraoperatively, and postoperative pain, need for rescue analgesia, and nausea and vomiting will be assessed.
62792883|NCT05477784|ACTIVE_COMPARATOR|Group II (educational material)|Patients receive carefully selected educational booklet that discuss ways to talk about their cancer with their child and a scripted phone call from a trained phone counselor on study.
62792884|NCT06527781|EXPERIMENTAL|PD5K3 group|Eight subjects will be randomized to receive a single dose of PD5K3 in a double-blind fashion at each dose level.
62792885|NCT06527781|PLACEBO_COMPARATOR|PD5K3 Placebo group|Two subjects will be randomized to receive placebo in a double-blind fashion at each dose level.
62217064|NCT04308395|EXPERIMENTAL|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
62217065|NCT04006054|EXPERIMENTAL|Dexmedetomidine treatment group|Dexmedetomidine will be administrated at a dose of 0.25-0.75 µg/(kg\*h) for 5 days
62217066|NCT04006054|ACTIVE_COMPARATOR|Midazolam treatment group|Midazolam will be administrated at a dose of 0.25-0.75 µg/(kg\*h) for 5 days
62217067|NCT03093077|EXPERIMENTAL|Anatomic alignment|The aim of anatomic alignment is to recreate an individual's pre-operative alignment using the DePuy ATTUNE total knee arthroplasty system.
62217068|NCT03093077|ACTIVE_COMPARATOR|Mechanical alignment|The aim of mechanical alignment is to achieve a neutral mechanical alignment regardless of pre-operative status, using the DePuy ATTUNE total knee arthroplasty system.
62217069|NCT05404750||Providers|Individuals providing service or care to PLWH or people who use drugs at high risk for HIV acquisition working at our study sites in one of the following positions: front desk/patient engagement, social worker, nurse, medical assistant, advanced practice provider, or physician.
62217070|NCT05404750||Patients|PWLH with current or lifetime substance use who receive care at one of our study sites.
62217071|NCT05412797|EXPERIMENTAL|Cycling|Used a DeskCycle during the workday/the intervention increased the amount of time spent being physically active.
62217072|NCT05412797|ACTIVE_COMPARATOR|Control|Regular activities
62217073|NCT01863576|ACTIVE_COMPARATOR|Omega-3|This group is receiving omega-3 supplement.
62217074|NCT01863576|PLACEBO_COMPARATOR|Oil Corn|This group is receiving the placebo comparator.
62585621|NCT04697420|EXPERIMENTAL|Group (P)|the patients were received paravertebral block to control pain postoperatively.
62585622|NCT04697420|EXPERIMENTAL|Group (T)|the patients were received transversus abdomins plane (TAP) block to control pain postoperatively.
62792886|NCT06527781|ACTIVE_COMPARATOR|Pegaspargase group|Four subjects will receive a single dose of pegaspargase at the each dose level, and the dose of pegaspargase is the same with PD5K3. This group is open-labelled.
62585623|NCT05338502|EXPERIMENTAL|160 milligram (mg) Selpercatinib|Participants received a single oral dose of 160 mg Selpercatinib (Study Day 1).
62585624|NCT05338502|EXPERIMENTAL|150 mg Ranitidine dosed with 160 mg Selpercatinib|Participants received 150 mg ranitidine twice a day orally for 11 days (Study Days 8 to 18) with a single oral dose of 160 mg Selpercatinib (Study Day 12).
62792887|NCT06308198|EXPERIMENTAL|Double-Blind Period: AGN-151586|Participants will receive AGN-151586 in the glabellar complex on Day 1.
62792888|NCT06308198|PLACEBO_COMPARATOR|Double-Blind Period: Placebo|Participants will receive Placebo in the glabellar complex on Day 1.
62585625|NCT05338502|EXPERIMENTAL|40 mg Omeprazole dosed with 160 mg Selpercatinib|Participants received 40 mg omeprazole once daily for 11 days (Study Days 19 to 29) with a single oral dose of 160 mg Selpercatinib (Study Day 23).
62585626|NCT02683928|EXPERIMENTAL|GBR 830|Two doses of GBR 830, 10 mg/kg (solution for infusion, prepared in normal saline) administered intravenously (IV) four weeks apart.
62792889|NCT06308198|EXPERIMENTAL|Open-Label: AGN-151586|Participants who meet all retreatment criteria will receive AGN-151586 in the glabellar complex on Day 43.
62792890|NCT05761990|EXPERIMENTAL|POST ISOMTERIC RELAXATION TECHNIQUES|"Participants in Group A will instruct to perform the PIR techniques~These steps are taken when using the PIR approach:~* Stretching the hypertonic muscle to the point when movement resistance is initially felt or just past the point of discomfort.~* For 5 to 10 seconds, a submaximal (10-20%) hypertonic muscle contraction is carried out away from the barrier while resistance is supplied in the other side. To help with this, the individual should breathe in.~* The individual is told to relax while breathing after the isometric contraction. After then, until the next barrier is reached, a gentle stretch is employed to pick up the slack.~* Starting with this new barrier, the procedure is carried out two or three more times."
62792891|NCT05761990|EXPERIMENTAL|NOVEL STRETCHING|"The NS will be performed in a supine posture for Group B participants. Participants will be instructed to open their knees while wearing a resistance band around their knees. Participant will be instructed to bridge as high as he can while keeping his shoulders 90 ° abducted and his elbows 90 ° flexed. By lifting the body weight upward, the bridging motion pins the scapula's medial border against the thorax without immediately squeezing or constricting the posterior shoulder bones. This position is thought to provide more flexibility of mobility while causing less discomfort. The subjects were instructed to hold this position while tightening or squeezing their gluteal muscles. They were also instructed to stretch by jerkily turning their shoulders inward as far as possible. Using the second hand, the stretch was pushed forward to the point of mild discomfort while contraction was maintained."
62819353|NCT03662776||retinoblastoma survivors treated with enucleation|MSK will contact all families of 1-year survivors of unilateral retinoblastoma treated with enucleation or intra-arterial chemotherapy at MSK and TCH between 2006 or later for completion of validated questionnaires integrating the BASC-3 and PROMIS surveys. The survey may be administered in-person during clinic or by mail, based upon participant preference.
62217075|NCT01583231|NO_INTERVENTION|No Prewash|Level 1: participants will be swabbed, then application of brushless scrub, swabbed again
62217076|NCT01583231|EXPERIMENTAL|Prewash|Level 2: participants will be swabbed, perform a wash with soap and water for 1 minute, dry, apply brushless scrub, swabbed again
62217077|NCT06253182|EXPERIMENTAL|Self-Guided PEPP Intervention workbook|Following completion of the virtual consent/baseline visit and the virtual education visit, dyads will work through content of self-guided workbook. Every two weeks, participants will receive a check-in email and/or text message from study staff to assess their adherence and respond to questions or concerns.
62217078|NCT06253182|ACTIVE_COMPARATOR|Self-Guided PEPP Education Workbook|Following completion of the virtual consent/baseline visit and the virtual education visit, dyads will work through content of self-guided workbook. Every two weeks, participants will receive a check-in email and/or text message from study staff to assess their adherence and respond to questions or concerns.
62217079|NCT02316002|EXPERIMENTAL|Pembrolizumab|Pembrolizumab 200 mg every 3 weeks
62217080|NCT00768794|ACTIVE_COMPARATOR|Acidolphilus|In the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.
62217081|NCT01283204|ACTIVE_COMPARATOR|SP(S-1 with cisplatin)|"SP \<Every 3 weeks\>~1. Day 1\~14 : TS-1 80mg/m2/day (PO)~2. Day 1 : CDDP 60mg/m2/day IVF 2hours~3. Day 15\~21 : Rest"
62217082|NCT01283204|ACTIVE_COMPARATOR|FL/Tax(Paclitaxel with Leucovorin with 5-FU)|"FL/Tax \<Every q 3 weeks\>~1. Day1 : Paclitaxel 175mg/m2 IVF for 2hours~2. Day1 : Leucovorin 20mg/m2 IVF for 1hour~3. Day1\~3 : 5-FU 1000mg/m2 IVF for 24hours"
62585627|NCT02683928|PLACEBO_COMPARATOR|Placebo|Two doses of placebo (formulation buffer for infusion, prepared in normal saline) administered IV four weeks apart.
62585628|NCT05846490|EXPERIMENTAL|Continuous positive airway pressure (CPAP)|Standard OSA treatment + BP adjustments with anti-hypertensive therapy
62585629|NCT05846490|ACTIVE_COMPARATOR|Usual Care|BP adjustments with anti-hypertensive therapy
62585630|NCT01512446|ACTIVE_COMPARATOR|Alendronate|
62585631|NCT01512446|PLACEBO_COMPARATOR|Placebo|
62585632|NCT02717416|EXPERIMENTAL|Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group|The intervention group
62585633|NCT02717416|ACTIVE_COMPARATOR|Hemoclip (HX-610-135, Olympus, Japan) or electrical coagulation group|Patients in the control group will undergo endoscopic hemostasis with combination therapy, epinephrine injection therapy and hemoclip or electrical coagulation therapy.
62792892|NCT01128244|EXPERIMENTAL|Vitamin B6 Effects in OC Users|"All subjects will be given an infusion of labeled serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.~The results from analysis of vitamin B6 and these amino acids in blood will provide us with specific measurements of the rates of two aspects of metabolism (Primary Outcomes 1 and 2) and specific measurements of vitamin B6 nutritional status (Primary Outcomes 3 and 4)."
62792893|NCT05839808|OTHER|Individuals who have had a stroke|To evaluate the validity and reliability of the Stroke Exercise Preference Inventory
62792894|NCT06041074||Adults|Patients with adenoid vegetations, 14 years old and older
62792895|NCT06041074||Children|Patients with adenoid vegetations, 13 years old and younger
62792896|NCT02124694|EXPERIMENTAL|HTUG and IPT|This arm includes the Historical Trauma and Unresolved Grief intervention (HUTG) combined with group Interpersonal Psychotherapy (IPT).The HTUG/IPT arm is 12 two-hour sessions delivered weekly on average, except for weather delays, over 16 weeks. HTUG/IPT includes sessions on identifying relationship issues which may trigger depressive symptoms, using group support, and connecting the impact of collective tribal trauma and losses with personal lifespan and current losses. HTUG/IPT is aimed at reducing depressive symptoms related to interpersonal conflicts and grief. HTUG is a Tribal Best Practice which may serve to engage AI in IPT, an empirically supported treatment for depression.
62792897|NCT02124694|NO_INTERVENTION|IPT Only|IPT is a standard empirically supported treatment. This IPT Only group is not receiving the experimental HTUG component and is being compared to the combined HTUG with IPT.
62792898|NCT04936815|EXPERIMENTAL|Echocardiographic screening|Echocardiographic screening for the detection of latent structural heart disease
62792899|NCT04936815|NO_INTERVENTION|Control arm|Routine antenatal care
62792900|NCT06726395|EXPERIMENTAL|Benzylpenicillin treatment|
62792901|NCT06726395|ACTIVE_COMPARATOR|cloxacillin|
62792902|NCT05767112|ACTIVE_COMPARATOR|HMB-Ca in water|Investigate whether the pharmacological form of HMB has any impact on its bioavailability and pharmacokinetic profile.
62217083|NCT01283204|ACTIVE_COMPARATOR|FL/Doc(Decetaxel with Leucovorin with 5-FU)|"FL/Doc \<Every q 3 weeks\>~1. Day1 : Docetaxel 75mg/m2 IVF for 1hour~2. Day1 : Leucovorin 20mg/m2 IVF for 1hour~3. Day1\~3 : 5-FU 1000mg/m2 IVF for 24hours"
62792903|NCT05767112|EXPERIMENTAL|HMB-Ca in capsules|Avaliate AUC of HMB-Calcium form supplementation.
62792904|NCT05767112|EXPERIMENTAL|HMB-FA|Avaliate AUC of HMB-free acid form supplementation.
62792905|NCT00596752|EXPERIMENTAL|Alprostadil|Prostavasin® 40 μg will be infused intravenously twice daily over 2 hours in 50 to 150 ml isotonic sodium chloride solution during a Treatment Phase of 4 weeks.
62792906|NCT00596752|PLACEBO_COMPARATOR|Placebo|Placebo will be infused intravenously twice daily over 2 hours in 50 to 150 ml isotonic sodium chloride solution during a Treatment Phase of 4 weeks.
62792907|NCT05500963|EXPERIMENTAL|Effective dose|• The effective dose of TENS will be set at an intensity to elicit slight contractions in each target muscle, as we have done previously. It will be delivered as 5-Hz bursts (7 pulses at 100 Hz/burst) and applied during the light exercises. The applied current (\<20 mA) will differ slightly for each of the four muscle groups and will be determined while the person is standing. The current will be set at the beginning of every treatment session for both groups of participants.
62217084|NCT01283204|ACTIVE_COMPARATOR|FOLFOX(Oxaliplatin with Leucovorin with 5-FU)|FOLFOX \<Every q 2 weeks\> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1\~2 : 5-FU 1200mg/m2 IVF for 24hours
62217085|NCT02345187|ACTIVE_COMPARATOR|Treatment Arm|Entire content of a sachet of the beverage powder fortified with multiple micronutrients and bacopa monnieri extract will be emptied in a graduated drinking tumbler and reconstituted with 180 mL potable lukewarm water. Water will be added to the tumbler gradually with stirring to avoid lump formation. The reconstituted beverage will be administered to the participants orally twice daily for 17 weeks
62217086|NCT02345187|PLACEBO_COMPARATOR|Control arm|Entire content of a sachet of the non-fortified isocaloric beverage powder will be emptied in a graduated drinking tumbler and reconstituted with 180 mL potable lukewarm water. Water will be added to the tumbler gradually with stirring to avoid lump formation. The reconstituted beverage will be administered to the participants orally twice daily for 17 weeks
62217087|NCT05332431||Patients with Migraine|Patients diagnosed with migraine based on prespecified criteria according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3) established by established by the International Headache Society, for migraine with aura and migraine without aura, attending the neurology outpatient clinic, Assiut University.
62217088|NCT05332431||Control|Age and sex matched healthy control group (with the absence of any pathological headache and eye problems), will be recruited from the outpatient clinic for comparison.
62217089|NCT05641181|EXPERIMENTAL|CRB4101 100mg dose group|Participants will receive a single oral dose of 100mg of CRB4101
62585634|NCT06503783|EXPERIMENTAL|BL-M17D1|Participants receive BL-M17D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62217090|NCT05641181|EXPERIMENTAL|CRB4101 200mg dose group|Participants will receive a single oral dose of 200mg of CRB4101
62217091|NCT05641181|EXPERIMENTAL|CRB4101 400mg dose group|Participants will receive a single oral dose of400mg of CRB4101
62217092|NCT05641181|EXPERIMENTAL|CRB4101 800mg dose group|Participants will receive a single oral dose of 800mg of CRB4101
62217093|NCT05641181|EXPERIMENTAL|CRB4101 1200mg dose group|Participants will receive a single oral dose of 1200mg of CRB4101
62792908|NCT05500963|SHAM_COMPARATOR|Sham dose|• The current intensity for the sham dose will be set at sensory threshold, which will be less than that used for the effective dose. After beginning each exercise set, the current for the sham dose will decay to 0 mA within 30 s. In a preliminary study that included a sham dose of TENS, we found that only two of the experienced dancers in the sham group detected the gradual decline in TENS current from its initial value slightly above motor threshold when performing prescribed exercises.
62792909|NCT01973998|EXPERIMENTAL|Roflumilast|500 ug tablet daily for 180 days
62792910|NCT01973998|PLACEBO_COMPARATOR|Placebo|Placebo 1 tablet daily x 180 days
62792911|NCT00183625|ACTIVE_COMPARATOR|Risperidone Plus Supported Employment|
62217094|NCT05641181|EXPERIMENTAL|CRB4101 1600mg dose group|Participants will receive a single oral dose of 1600mg of CRB4101
62217095|NCT05641181|PLACEBO_COMPARATOR|placebo group|Subjects will receive a placebo
62411260|NCT03172715|EXPERIMENTAL|TKR (total knee replacement)|Arthroplasty of the knee will be performed within two weeks after the fracture. Medial parapatellar approach will be used. The minimal possible constraint of the prosthesis (cruciate retaining, posterior cruciate sacrificing or semi-constrained) will be used. A possible insufficient bone stock may be rebuilt with augments. Hinged prosthesis will be used only if stability of the medial collateral ligament is insufficient. A cemented or uncemented tibial stem extender (minimum length 50mm) will be used in all cases. Additional osteosynthesis will be used when necessary. Postoperatively, the patients will be allowed full weight bearing as tolerated.
62585635|NCT05588973|EXPERIMENTAL|Intervention group|"50 patients will be randomized to the MEDISKIN group and 50 to the panthenol group. Everyone will start using their cream from the start of the treatment and will continue for 2 weeks after the end of the radiation therapy (twice a day). If there are cases of patients using panthenol and it is deemed necessary based on symptoms to use MEDISKIN then they will automatically change group. Before starting to use the skin cosmetic products, patients will be asked to test the product for any allergic reactions. The mini-patch test which is standard of practice is carried out by using the substance on the inner elbow or wrist for 24 hours and observing for any reactions."
62585636|NCT05588973|PLACEBO_COMPARATOR|Control group|The group will be using panthenol istead of the MEDISKIN product
62585637|NCT06682364|ACTIVE_COMPARATOR|Case management using certified recovery specialists|The arm incorporates several best practices in substance use treatment such as the use of Certified Peer Recovery Specialists (CRS) as needed social support, assisting women who do not have stable housing in finding housing, overdose response training, and reducing known barriers to women by assisting with transportation and childcare.
62585638|NCT06682364|EXPERIMENTAL|Case management using certified recovery specialists + Trauma Support Group|Includes all the components in the comparative arm and a 12-session trauma support group led by CRS, which uses the evidence-based curriculum, Beyond Trauma, which was specifically designed for women who use drugs.
62585639|NCT00494052|EXPERIMENTAL|1|Heart to Heart intervention
62585640|NCT00494052|NO_INTERVENTION|2|Usual care
62021587|NCT06208618|EXPERIMENTAL|Motivational interviews|"At the beginning of the study, individual face-to-face diabetes education will be provided for each adolescent in the study group on days corresponding to their routine medical appointments in the diabetes education room. The diabetes education will include the following topics:~* What is Diabetes?~* Treatment in Diabetes~* Insulin Therapy~* Nutritional Therapy~* Physical Activity/Exercise~* Acute Complications of Diabetes~  * Hypoglycemia~ * Hyperglycemia~ * Diabetic Ketoacidosis~* Diabetes Management in IIlness~The adolescents in the study group will undergo a total of 6 motivational interviews, conducted once a month. Three of these interviews will be face-to-face (at the beginning of the study, at the 3rd month, and at the 6th month), while the remaining three will be conducted remotely using the WhatsApp video call feature (in the 2nd, 4th, and 5th months)."
62217096|NCT05274152|EXPERIMENTAL|Patients IVR for Lower Limb and Knee Rehabilitation after surgery in children|"Patients will use the IVR during each physiotherapy session after surgery until their discharge from hospital, which is expected to comprise one 10 minute session per day for 3-5 days.~During each session, child participants will rate their anxiety, perceived pain and feedback any feelings about the experience."
62217097|NCT05274152|OTHER|Occupational Therapist perceptions of the effectiveness of the IVR|"She recruited the patients, gave out devices, administered the outcome measures and provided us with feedback about their experience with the VR game.~At the end of the trial, an interview (10 minutes) with the OT was conducted by a research nurse."
62217098|NCT03789448|NO_INTERVENTION|National HIV Treatment Guidelines|HIV-positive individuals are offered ART per Swaziland's national treatment guidelines
62217099|NCT03789448|EXPERIMENTAL|Early Access to ART for All|HIV-positive individuals who are aged 18 years or older are initiated on ART regardless of client's immunological and clinical staging (excluding pregnant or breastfeeding women)
62411261|NCT05819411|EXPERIMENTAL|Intervention|This intervention includes 6 face-to-face therapy sessions with a trained clinician plus an incentivized directly observed therapy (iDOT) intervention facilitated via a mobile application.
62411262|NCT05819411|ACTIVE_COMPARATOR|incentivized Directly Observed Therapy (iDOT)|Participants in the iDOT condition will be provided a mobile application to facilitate video recording of their daily medication adherence in order to receive small, escalating monetary incentives for HIV medication adherence.
62585641|NCT01522001|NO_INTERVENTION|Hospital-based|"* First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~* Dietary counseling with dietician~* Exercise (1 hour, 2 timer pr week for 12 weeks)~* Smoking cessation if smoker with educated smoking cessation instructor~* Patient education and psychosocial support in 2 to 3 individual consultations with nurse specialized in cardiac rehabilitation~* Examination by cardiologist 8-12 weeks after discharge."
62585642|NCT01522001|ACTIVE_COMPARATOR|Shared care Model|"* First visit at cardiac ambulatory approximately 14 days after discharge includes examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~* Dietary counseling with dietician~* Exercise (1 hour, 2 timer pr week for 12 weeks)~* Smoking cessation if smoker with educated smoking cessation instructor~* Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse~* Examination by the patient´s general practitioner 8-12 weeks after discharge."
62792912|NCT00183625|ACTIVE_COMPARATOR|Olanzapine Plus Supported Employment|
62792913|NCT00183625|ACTIVE_COMPARATOR|Risperidone+Supported Employment+Skills|
62792914|NCT00183625|ACTIVE_COMPARATOR|Olanzapine+Supported Employment+Skills|
62217100|NCT06408480||need of respiratory support > 60 min after birth|Group comprises neonates in need of further respiratory support more than 60 minutes after birth.
62792915|NCT01874080|EXPERIMENTAL|Arm A: Saxagliptin/Metformin XR FDC (Mt. Vernon/Humacao)|Saxagliptin 5 mg /Metformin 1000 mg (Mt. Vernon/Humacao) tablet by mouth once daily on Day 1 of Periods 1 and 2
62792916|NCT01874080|EXPERIMENTAL|Arm B: Saxagliptin/Metformin XR FDC (Mt. Vernon)|Saxagliptin 5 mg/Metformin 1000 mg (Mt. Vernon) tablet by mouth once daily on Day 1 of Periods 1 and 2
62217101|NCT06408480||need of respiratory support < 60 min after birth|Group comprises neonates that show any signs of respiratory distress in the first 60 minutes, but do not need respiratory support more than 60 minutes after birth.
62585643|NCT03464370|EXPERIMENTAL|TLE-AE Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
62792917|NCT01874080|EXPERIMENTAL|Arm C: Saxagliptin/Metformin XR FDC (Mt. Vernon/Humacao)|Saxagliptin 5 mg/Metformin 500 mg (Mt. Vernon/Humacao) tablet by mouth once daily on Day1 of Periods 1 and 2
62792918|NCT01874080|EXPERIMENTAL|Arm D: Saxagliptin/Metformin XR FDC (Mt. Vernon)|Saxagliptin 5 mg/Metformin 500 mg (Mt. Vernon) tablet by mouth once daily Day 1 of Periods 1 and 2
62217102|NCT02000193|EXPERIMENTAL|1|"drug: Fulvestrant treatment : Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, 29, then every 28 days.~The treatment will continue until disease progression or intolerable adverse event"
62411263|NCT04478188||Cardiogenic Shock Patients Needing TMCS|Heart failure patients who undergo TMCS insertion for acute decompensated heart failure and cardiogenic shock.
62411264|NCT05558046||Low Ovarian Reserve|Patients diagnosed as low ovarian reserve were recruited to the study who have Antimüllerian Hormone level of 1 ng/ml or lower. Patients with low ovarian reserve were diagnosed after normal standard infertility evaluation according to the guideline of The Practice Committee of the American Society for Reproductive Medicine which consist of the assesment of spermiogram, ovulation, hysterosalpingogram and if indicated ovarian reserve tests and laparoscopy. Male infertility is an exclusion.
62411265|NCT05558046||Unexplained Infertile (Control group)|Patients diagnosed as unexplained infertility (UI) were recruited to the study who have Antimüllerian Hormone level of 1.5 ng/ml or higher as a control group. UI was diagnosed after normal standard infertility evaluation according to the guideline of The Practice Committee of the American Society for Reproductive Medicine which consist of the assesment of spermiogram, ovulation, hysterosalpingogram and if indicated ovarian reserve tests and laparoscopy.
62585644|NCT03464370|ACTIVE_COMPARATOR|Non AE epileptic Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
62792919|NCT06725589||hypertension, T2DM, obesity, gout, and patients without the above diseases|hypertension, T2DM, obesity, gout, and patients without the above diseases
62792920|NCT06171633|EXPERIMENTAL|Intervention Group / year 1|Beginning in year 1, participants access online video modules through an online learning platform for up to 9 months.
62792921|NCT06171633|EXPERIMENTAL|Control Condition Group / year 1|Beginning in year 1, participants access online video modules through an online learning platform for up to 9 months.
62792922|NCT06171633|EXPERIMENTAL|Intervention Group / year 2|Beginning in year 2, participants access online video modules through an online learning platform for up to 9 months.
62792923|NCT06171633|EXPERIMENTAL|Control Condition Group / year 2|Beginning in year 2, participants access online video modules through an online learning platform for up to 9 months.
62792924|NCT05878847|EXPERIMENTAL|Q-actin|Q-actin gummies (2 x 10mg) daily for 12 weeks
62792925|NCT05878847|PLACEBO_COMPARATOR|Placebo|Placebo gummies (2 x 10mg) daily for 12 weeks
62792926|NCT06725940||Study cohort|Patient receiving 68Ga-GZMB PET/CT
62411266|NCT04705896|ACTIVE_COMPARATOR|20-25% Albumin fluid|100 mL 20-25% Albumin fluid at the initiation of continuous renal replacement therapy (CRRT), prolonged intermittent renal replacement therapy (PIRRT), or intermittent hemodialysis (IHD) and another 100 mL 20-25% Albumin fluid and halfway through RRT sessions in ICU.
62411267|NCT04705896|PLACEBO_COMPARATOR|Normal Saline|100 mL at the initiation of CRRT, SLED or IHD and another 100 mL 0.9% Normal Saline halfway through RRT sessions in ICU.
62217103|NCT01590082|EXPERIMENTAL|Doxycycline, Ipilimumab, and Temozolomide|Doxycycline to start on day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts) twice a day until morning of Day 1 of Cycle 1. After the Day 1 of Cycle 1, participants receive first dose of Ipilimumab, and evening of same day, Temozolomide received by mouth once a day for 4 days. Doxycycline administration will continue twice daily for rest of cycle without interruption; Cycle 1 is 4 weeks of treatment. Starting Cycle 2, Doxycycline with temozolomide and ipilimumab administration start on Day 1. Each cycle is 3 weeks. 4 cycles of therapy given over a 3 month period to complete induction phase. After induction therapy, participants continue on Doxycycline.
62217104|NCT01984073|ACTIVE_COMPARATOR|ER Niacin Oral Fat Challenge|ER Niacin (Niaspan) 2000mg one hour prior to Oral Fat Challenge using fresh cream at a dose of 50 g fat per square meter of body surface area. This is followed by frequent plasma and urine collections for next 12 hours to assess markers of fat metabolism and inflammation.
62411268|NCT06650319|EXPERIMENTAL|Single-Arm|This was a single-arm study with a single intravenous administration
62411269|NCT00902486|EXPERIMENTAL|INCB028050 4 mg QD|INCB028050 4mg Once daily (QD)
62792927|NCT00001379|EXPERIMENTAL|1|Interferon starting at 7.5 million Units subQ 3 times a week and increasing on the designated schedule, as tolerated. Patients continue taking interferon for 1 year beyond CR. Patients who progress may crossover to receive EPOCH-R.
62217105|NCT01984073|ACTIVE_COMPARATOR|IR Niacin Oral Fat Challenge|Immediate-Release Niacin (Nialor) 500 mg one hour prior to Oral Fat Challenge and again 1, 3 and 5 hours after the oral fat load for a total dose of 2 grams.Subjects will undergo plasma and urine collections for 12 hours to assess markers of fat metabolism and inflammation.
62217106|NCT01984073|PLACEBO_COMPARATOR|Placebo Oral Fat Challenge|Placebo one hour before and 1,3, and 5 hours after oral fat load using heavy cream at 50 grams of fat per square meter of body surface area. Plasma and urine collections for 12 hours
62411270|NCT00902486|EXPERIMENTAL|INCB028050 7 mg QD|INCB028050 7mg QD
62411271|NCT00902486|EXPERIMENTAL|INCB028050 10 mg QD|INCB028050 10mg QD
62411272|NCT00902486|PLACEBO_COMPARATOR|Placebo|Placebo group may 'cross-over' following 3 months of treatment to receive either active arm #2 (7mg QD) or active arm #3 (10mg QD) of INCB028050 capsules.
62411273|NCT06568718|EXPERIMENTAL|Longidaze + Tamsulosin|
62411274|NCT06568718|ACTIVE_COMPARATOR|Tamsulosin|
62411275|NCT06652698|EXPERIMENTAL|CMF|
62411276|NCT06652698|EXPERIMENTAL|AAF|
62792928|NCT00001379|EXPERIMENTAL|2|EPOCH-R every 3 weeks for up to 6 cycles, based on response.
62792929|NCT02916901|EXPERIMENTAL|CKD-519 200mg|CKD-519 tab(formulation II) 200mg (100mg X 2tabs)
62792930|NCT02916901|PLACEBO_COMPARATOR|Placebo|placebo
62792931|NCT01969955|EXPERIMENTAL|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
62792932|NCT01336140|EXPERIMENTAL|Aminophylline|75 mg of intravenous aminophylline.
62411277|NCT06652698|EXPERIMENTAL|DHM|
62411278|NCT06652698|EXPERIMENTAL|DHM-P|
62411279|NCT00592007|EXPERIMENTAL|A|Single-arm study
62411280|NCT03632798|ACTIVE_COMPARATOR|Physician Choice treatment|"Participants will be treated with control chemotherapy treatment (Bevacizumab plus standard-of-care chemotherapy chosen by the Physician from the provided list).~Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~* Liposomal Doxorubicin;~* Docetaxel;~* Paclitaxel;~* Carboplatin;~* Cisplatin;~* Gemcitabine;~* Topotecan;~* Carboplatin, Gemcitabine;~* Cisplatin, Gemcitabine;~* Carboplatin, Liposomal Doxorubicin;~* Carboplatin, Paclitaxel;~* Carboplatin, Docetaxel.~The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
62411281|NCT03632798|EXPERIMENTAL|ChemoID-guided treatment|"Participants will be treated with Bevacizumab plus ChemoID-guided standard-of-care chemotherapy drugs from the provided list.~ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:~* Liposomal Doxorubicin;~* Docetaxel;~* Paclitaxel;~* Carboplatin;~* Cisplatin;~* Gemcitabine;~* Topotecan;~* Carboplatin, Gemcitabine;~* Cisplatin, Gemcitabine;~* Carboplatin, Liposomal Doxorubicin;~* Carboplatin, Paclitaxel;~* Carboplatin, Docetaxel.~The treating physician will receive the ChemoID assay results from the ChemoID lab."
62792933|NCT01336140|PLACEBO_COMPARATOR|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
62792934|NCT05490030|EXPERIMENTAL|Group 1 (control)|Healthy control participants with normal hepatic function
62792935|NCT05490030|EXPERIMENTAL|Group 2 (score 5-6)|Mild hepatic impairment: Child-Pugh A
62792936|NCT05490030|EXPERIMENTAL|Group 3 (score 7-9)|Moderate hepatic impairment: Child-Pugh B
62792937|NCT05490030|EXPERIMENTAL|Group 4 (score 10-15)|Severe hepatic impairment: Child-Pugh C. This group may be opened if allowed by the results of the interim analysis of the Groups 1 to 3.
62792938|NCT04200690|EXPERIMENTAL|Interdisciplinary management|Interdisciplinary combined clinical care
62792939|NCT04200690|ACTIVE_COMPARATOR|Usual-care management|Usual-care
62792940|NCT02334293|OTHER|Omegaven|
62792941|NCT06451991|NO_INTERVENTION|Traditional|The control group will use the traditional method data collection form and care plan.
62792942|NCT06451991|EXPERIMENTAL|Concept Map|The experimental group will collect data and make a maintenance plan by using a concept map after the training.
62792943|NCT00811681|EXPERIMENTAL|Pioglitazone|pioglitazone
62792944|NCT00811681|PLACEBO_COMPARATOR|Control|placebo
62792945|NCT01151566||Renal Compromise|Those referred for CT scan with identified renal compromise necessitating use of no contrast agent
62792946|NCT01151566||Sensitivity to CT Contrast Agents|Those referred for CT scan with prior demonstration of contrast sensitivity requiring use of no contrast
62792947|NCT00193206|EXPERIMENTAL|Intervention|Patients were treated with 6 doses of neoadjuvant gemcitabine 2000 mg/m2, epirubicin 50 mg/m2, and albumin-bound paclitaxel 175 mg/m2 intravenously administered at 14-day intervals. Following neoadjuvant chemotherapy, patients underwent either mastectomy or breast conservation surgery; pathologic response to treatment was assessed. Postoperatively, patients received 4 doses of gemcitabine 2000 mg/m2 with albumin-bound paclitaxel 220 mg/m2 at 14-day intervals. Pegfilgrastim 6 mg was administered subcutaneously on day 2 following each dose of chemotherapy.
62217107|NCT05199415|EXPERIMENTAL|HaWC Intervention|These are the buildings that are randomized to receive the intervention during the study period.
62792948|NCT00837213|ACTIVE_COMPARATOR|BPO with clindamycin foam|Benzoyl peroxide (BPO) wash with clindamycin foam
62792949|NCT00837213|ACTIVE_COMPARATOR|BPO + clindamycin foam + doxycycline|Benzoyl peroxide (BPO) wash with clindamycin foam and doxycycline capsules
62792950|NCT00123123|PLACEBO_COMPARATOR|Placebo (Vehicle Control)|Delivered Twice a day
62792951|NCT00123123|EXPERIMENTAL|0.12% chlorhexidine gluconate oral rinse|Delivered twice a day
62792952|NCT00123123|EXPERIMENTAL|0.12% chlorhexidine oral rinse|Delivered once a day, placebo once a day
62792953|NCT02037516|ACTIVE_COMPARATOR|Control Group|qualitative monitoring of neuromuscular paralysis, standard treatment at this facility
62792954|NCT02037516|ACTIVE_COMPARATOR|Study Group|quantitative monitoring of neuromuscular paralysis as described in (Brull Murphy Anesth Analg 2010;111:129-40) Acceleromyography
62792955|NCT06277661|EXPERIMENTAL|Intervention|MOMI PODS is an innovative, dyadic model of PP primary care. Informed by the Chronic Care Model (CCM) and extensive stakeholder engagement, the MOMI PODS suite of services addresses four primary domains, with a focus on preventing PRM and eliminating SES, racial, and ethnic disparities in PRM. First, MOMI PODS is a dyadic model of care, with mothers and infants cared for in tandem throughout the PP year, and beyond. Second, MOMI PODS was strategically designed to facilitate a coordinated obstetric to PP primary care transition. Third, MOMI PODS is delivered in a way that promotes tailored, evidence-based care informed by the obstetric history. Fourth, MOMI PODS systematically integrates clinical and supportive care to concurrently address clinical and psychosocial needs, with MOMI PODS engagement extending beyond the typical referral process to facilitate direct access to needed resources and empower patients.
62792956|NCT06277661|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|Usual care will be enhanced in by implementing an enhanced PP care handoff as an adaptation of typical institutional discharge procedures. Specifically, under current processes, birthing parents are asked to provide the name of their infant's pediatrician during the L\&D admission, must provide the name of their infant's pediatrician prior to discharge, and are assisted with identifying a pediatrician throughout this process as needed. Alternatively, under current processes, mothers are reminded to seek PP care but not required to identify the location of care or assisted with doing so. As a component of EUC, we'll provide participants with information about our 7 EUC sites and actively assist with identifying their preferred location of care and scheduling PP care. Our research team will also engage with EUC recipients throughout the study period to encourage engagement and study retention through small care packages and hand-written notes, as well as data collection.
62792957|NCT03397342|NO_INTERVENTION|standard breath hold|"1. Breath-hold CT and 4D-CT without CPAP~2. Breath-hold MRI and 4D-MRI without CPAP a) T1-weighted, T2-weighted, Dixon fat/water, and ultra-short TE images"
62792958|NCT03397342|EXPERIMENTAL|CPAP intervention|"1. Breath-hold CT without CPAP~2. 4D-CT with and without CPAP~3. 4D-MRI with CPAP~   1. T1-weighted, T2-weighted, Dixon fat/water, and ultra-short TE images"
62792959|NCT04294030||Sexually active persons who self-select for HSV-2 testing|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
62792960|NCT04294030||Expectant mothers|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
62792961|NCT04294030||Low prevalence population|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
62217108|NCT05199415|NO_INTERVENTION|Control|These are the buildings that are randomized to continue as normal (no intervention) during the study period.
62217109|NCT01769651||Drug service users|Those patients who receive Methadone replacement therapy as part of their treatment plan. In addition, those drug user patients who have a first consultation session with their Addiction Nurses.
62411282|NCT00268385|EXPERIMENTAL|Treatment (vorinostat, temozolomide)|"PART I: Patients receive vorinostat PO QD or BID on days 1-7 and 15-21 OR QD or BID on days 1-7. Patients also receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Treatment may continue beyond 13 courses at the discretion of the investigator.~PART II: Patients receive vorinostat and temozolomide as in part I\*.~\[Note: Beginning in course 2, some patients may receive a higher dose of temozolomide.\]"
62411283|NCT00960232|EXPERIMENTAL|Vitamin D|vitamin D 40.000 IU per weel
62217110|NCT00993668|PLACEBO_COMPARATOR|Placebo|Placebo
62217111|NCT00993668|EXPERIMENTAL|Cimzia|Certolizumab pegol
62217112|NCT05762913|EXPERIMENTAL|Diaphragm release|The therapist passes his fingers under the costal arch, during inspiration the therapist accompanies the movement of the ribs, while during expiration he takes his fingers deeper, increasing his pressure. The therapist progresses progressively deeper into the costal arch with each breath. The maneuver will be performed in two sets of 10 deep breaths. The diaphragm release technique will be applied in 3 sessions, with 2 days of rest in between.
62217113|NCT02663518|EXPERIMENTAL|PF-07901800 (TTI-621) Escalation Phase - R/R Lymphoma|The Escalation Phase will include multiple doses of PF-07901800 (TTI-621)
62217114|NCT02663518|EXPERIMENTAL|Indolent B-Cell Lymphoma|Monotherapy expansion cohort with PF-07901800 (TTI-621)
62411284|NCT00960232|PLACEBO_COMPARATOR|Placebo|Placebo
62411285|NCT06351501|EXPERIMENTAL|early hormonal treatment|early hormonal treatment with cross sex hormones at 14 years old +/- 6 months
62217115|NCT02663518|EXPERIMENTAL|Aggressive B-Cell Lymphoma|Monotherapy expansion cohort with PF-07901800 (TTI-621)
62217116|NCT02663518|EXPERIMENTAL|T-Cell Lymphoma|Monotherapy expansion cohort with PF-07901800 (TTI-621)
62217117|NCT02663518|EXPERIMENTAL|Hodgkin Lymphoma|Monotherapy expansion cohort with PF-07901800 (TTI-621)
62411286|NCT06351501|ACTIVE_COMPARATOR|usual treatment|cross sex hormones as usual
62411287|NCT06643975|ACTIVE_COMPARATOR|Titanium dental implants group|Two-implants One-piece titanium dental implants with titanium ball attachments retaining mandibular overdentures
62792962|NCT04294030||Lay users|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years; 1/2 high risk sexual behavior; 1/2 low risk sexual behavior
62792963|NCT06645470|ACTIVE_COMPARATOR|Standard Medical Care|Standard Medical Care will continue to receive their regular standard clinical care during the 6-month intervention period of this study and will also receive brief contacts from the research staff at weeks 6, 12, and 18.
62217118|NCT02663518|EXPERIMENTAL|Chronic Lymphocytic Leukemia|Monotherapy expansion cohort with PF-07901800 (TTI-621)
62792964|NCT06645470|EXPERIMENTAL|Standard Medical Care plus Aerobic Training|Standard Medical Care plus Aerobic Training will continue to receive their regular standard clinical care during the 6-month intervention period of this study and will also receive supervised aerobic exercise in addition to brief contacts from the research staff at weeks 6, 12, and 18.
62792965|NCT06645470|EXPERIMENTAL|Standard Medical Care plus Resistance Training|Standard Medical Care plus Resistance Training will continue to receive their regular standard clinical care during the 6-month intervention period of this study and will also receive supervised resistance exercise in addition to brief contacts from the research staff at weeks 6, 12, and 18.
62792966|NCT05148806||Solid organ transplant patients|Patients who have received a solid organ transplant and who have received at least 3 doses of Covid-19 vaccine
62792967|NCT05148806||Rare autoimmune diseases|Patients with a rare autoimmune disease who have received at least 3 doses of Covid-19 vaccine
62792968|NCT05148806||Blood cancer|Patients with acute myeloid and lymphoid blood cancers who have received at least 3 doses of Covid-19 vaccine.
62792969|NCT05575089|ACTIVE_COMPARATOR|Incentive Spirometer - The Control Group|The control group will receive an aerobic exercise in the cycle ergometer that will be conducted on a cycle ergometer divided into three steps: heat 5 minutes; 20 minutes with a confortable speed ( individuallyprescribed) and 5 minutes recovery. They will also perform active respiratory exercises, and incentive spirometer during 10 face-to-face physical therapy sessions. They will be instructed to do exercises with incentive spirometer at home, 3 times a day with 30 to 40 repetitions, during all preoperative period. The patients will receive a diary to note the exercises frequency.
62792970|NCT05575089|EXPERIMENTAL|Inspiratory muscle training - Powerbreath - The intervention group|This intervention group will receive the same control group protocol: aerobic exercise in cycle ergometer, divided into three steps: heat 5 minutes; 20 minutes with a confortable speed ( individually prescribed) and 5 minutes recovery and active respiratory exercises ( deep inspirations associated to raise upper limbs ( 3 times of 10 repetitions each), and, in addition, inspiratory muscle training with Powerbreath during 10 face-to-face physical therapy sessions. They will be instructed to do exercises with Powerbreath at home, 3 times a day with 30 to 40 repetitions, inspiratory load: 60% of MIP ( first evaluation - protocol admission) during all preoperative period. The patients will receive a diary to note the exercises frequency.
62217119|NCT02663518|EXPERIMENTAL|Multiple Myeloma|Monotherapy expansion cohort with PF-07901800 (TTI-621)
62217120|NCT02663518|EXPERIMENTAL|Acute Myeloid Leukemia|Monotherapy expansion cohort with PF-07901800 (TTI-621)
62217121|NCT02663518|EXPERIMENTAL|Myelodysplastic Syndrome|Monotherapy expansion cohort with PF-07901800 (TTI-621)
62217122|NCT02663518|EXPERIMENTAL|Myeloproliferative Neoplasms|Monotherapy expansion cohort with PF-07901800 (TTI-621)
62217123|NCT02663518|EXPERIMENTAL|Small Cell Lung Cancer|Monotherapy expansion cohort with PF-07901800 (TTI-621)
62217124|NCT02663518|EXPERIMENTAL|Rituximab Combination|Combination therapy expansion cohort with PF-07901800 (TTI-621) plus Rituximab for CD20 positive malignancies
62217125|NCT02663518|EXPERIMENTAL|Nivolumab Combination|Combination therapy expansion cohort with PF-07901800 (TTI-621) plus Nivolumab for Hodgkin Lymphoma
62411288|NCT06643975|ACTIVE_COMPARATOR|Zirconia dental implants group|Two-implants One-piece zirconia dental implants with zirconia ball attachments retaining mandibular overdentures
62411289|NCT04807881|EXPERIMENTAL|Keynatinib treatment group|Keynatinib, 20 mg，BID
62411290|NCT04687358||Active RP|Patients who are currently under the care of a physician for treatment of RP, currently on treatment for RP, and have had an episode (recurrence of typical pericarditis pain associated with supportive objective evidence of pericarditis) in the last 3 years prior to enrollment. Once included in the registry, these patients will have both retrospective and prospective follow-up and data collection (hybrid design).
62411291|NCT04687358||Inactive RP|Patients who have had a diagnosis of RP, have not had an episode for 3 years and have not been prescribed any treatment for RP in the last 3 years, prior to enrolling in the registry. Once included in the registry, data collected from these patients will be retrospective only.
62217126|NCT02663518|EXPERIMENTAL|Cutaneous T-Cell Lymphoma (CTCL)|Monotherapy expansion cohort with PF-07901800 (TTI-621)
62217127|NCT02663518|EXPERIMENTAL|Peripheral T-Cell Lymphoma (PTCL)|Monotherapy expansion cohort with PF-07901800 (TTI-621)
62217128|NCT02663518|EXPERIMENTAL|Part 4: Cutaneous T-Cell Lymphoma (CTCL)|Monotherapy expansion Part 4 (Dose Optimization) cohort with PF-07901800 (TTI-621)
62217129|NCT00248482|EXPERIMENTAL|Irinotecan, Cisplatin & Gleevec™|"Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles~Gleevec™ 400 mg po BID (800mg/day)- for patients with objective response or stable disease.~Irinotecan 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles"
62217130|NCT00544310|EXPERIMENTAL|1|Post surgery adhesion prevention treatment
62021588|NCT06208618|NO_INTERVENTION|Routine follow-up|The routine follow-up conducted by the diabetes education unit will continue for the study group, and no interventions will be made as part of the research. The study group will undergo a pre-test at the beginning of the study, a follow-up test at the 3rd month, and a post-test at the 6th month as part of the research.
62217131|NCT03601377|EXPERIMENTAL|Training away from threat|"Experiment 1 and 2: In the intervention group -training away from threat-, in all angry-neutral faces presentation the probe is presented only after neutral face. Probe type (\< or \>) is not factorially counterbalanced but there is equal possibility of presentation for each of the following: angry-face location, probe location, or actor.~Experiment 1: received 8 times (2 times per week for 4 weeks) Experiment 2: received 4 times (2 times for 2 weeks)"
62792971|NCT05820282|ACTIVE_COMPARATOR|Control|Participants in the control condition are presented with a table with two columns containing the same situations and solutions that participants in the experimental group see. Each situation and solution has a radio button (i.e. a tick box) next to it; participants in the control condition are asked to identify situations and solutions and place a tick next to each one they think would be useful to them. Therefore, participants in the control condition are not asked to form implementation intentions.
62792972|NCT05820282|EXPERIMENTAL|Intervention (volitional help sheet)|Participants in the experimental condition are presented with a table with two columns and nine rows. Nine situations (barriers to delivering behaviour change interventions) are presented in the left hand column and nine solutions (or appropriate responses; processes of change) are presented in the right hand column (as separate drop down menus). Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response from the drop down menu for each critical situation. Participants are told they can make as many situation-solution links as they wanted.
62792973|NCT03430934|EXPERIMENTAL|NAVI mapping with Indocyanine green|Participants will undergo their scheduled Mohs surgery with the addition of the NAVI mapping with ICG dye
62217132|NCT03601377|EXPERIMENTAL|Training towards threat|"Only for Experiment 2: The second ABMT condition -training towards threat- is identical to the first one with the exception that in all angry-neutral face presentations the symbol is presented only after threat face. In addition, at the beginning of every session participants will be informed that a random number of participants will have to repeat their speech. They will also be informed that this instruction will be given right after the dot probe task completion. This will be done in order for the participants to maintain their state anxiety but repetition of the speech task will not actually happen at this stage.~Experiment 2: received 4 times (2 times for 2 weeks)"
62217133|NCT03601377|PLACEBO_COMPARATOR|Placebo|"Experiment 1 and 2: In the placebo group, angry-face location, probe location and actor are fully counterbalanced with regards to their presentation.~Experiment 1: received 8 times (2 times per week for 4 weeks) Experiment 2: received 4 times (2 times for 2 weeks)"
62792974|NCT02186665|EXPERIMENTAL|calcitriol ointment|calcitriol 3 mcg/g ointment
62792975|NCT02186665|PLACEBO_COMPARATOR|placebo|placebo comparator
62792976|NCT05668598|OTHER|Groupe 1 : with neurocognitive disorders|with neurocognitive disorders
62792977|NCT05668598|OTHER|Groupe 2 : without neurocognitive disorders|without neurocognitive disorders
62792978|NCT04903535|EXPERIMENTAL|Healthy Volunteers|Study will enroll to test the assay
62792979|NCT05842252|EXPERIMENTAL|greater trochanter transfer and subtrochanteric valgus osteotomy|greater trochanter transfer, subtrochanteric valgus osteotomy fixation by Wagner \& TB and Locked plate
62792980|NCT00756418|EXPERIMENTAL|1|
62792981|NCT00756418|ACTIVE_COMPARATOR|2|
62792982|NCT01389492|OTHER|frozen meat|250 g of frozen meat meal for 4 days
62792983|NCT01389492|OTHER|frozen meat and wine|250 g of frozen meat and red wine for 4 days
62792984|NCT01389492|OTHER|fresh meat|250 g of fresh meat meal
62792985|NCT01389492|OTHER|fresh meat and wine|250 g of fresh meat meal
62217134|NCT00697697|EXPERIMENTAL|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
62792986|NCT04309474|EXPERIMENTAL|Elezanumab|Participants will receive elezanumab dose A
62792987|NCT04309474|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo for elezanumab
62792988|NCT03348839|EXPERIMENTAL|Cluster 1|NeLLY service is implemented after 8 months.
62217135|NCT00697697|EXPERIMENTAL|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
62792989|NCT03348839|EXPERIMENTAL|Cluster 2|NeLLY service is implemented after 12 months.
62217136|NCT03896412|EXPERIMENTAL|Detection of circulating tumor DNA|sampling of 20 ml of blood the day before surgery, the day after , 6 months after diagnosis and every 3 months thereafter until 18 months of follow up
62792990|NCT03348839|EXPERIMENTAL|Cluster 3|NeLLY service is implemented after 16 months.
62792991|NCT03348839|EXPERIMENTAL|Cluster 4|NeLLY service is implemented after 20 months.
62792992|NCT03348839|EXPERIMENTAL|Cluster 5|NeLLY service is implemented after 24 months.
62792993|NCT03348839|EXPERIMENTAL|Cluster 6|NeLLY service is implemented after 28 months.
62792994|NCT03348839|EXPERIMENTAL|Cluster 7|NeLLY service is implemented after 32 months.
62021589|NCT05689632|PLACEBO_COMPARATOR|Placebo|Placebo - Medium-chain triglyceride
62792995|NCT03790059|EXPERIMENTAL|RFA combined with H101 group|The experimental group was RFA combined H101.H101 has oncolysis in HCC after RFA and reduce tumor recurrence.
62792996|NCT03790059|OTHER|Conventional RFA group|The standard control group was the conventional RFA.Using RFA for the treatment of small HCC.The efficacy was compared with that of the experimental group combined with H101.
62021590|NCT05689632|ACTIVE_COMPARATOR|Vitamin D3|Vitamin D3 - 7000 IU daily
62021591|NCT05689632|EXPERIMENTAL|Vitamin D3 + K2-MK7|Vitamin D3 - 7000 IU + Vitamin K2-MK7 180mcg combined, daily
62021592|NCT05996887|PLACEBO_COMPARATOR|non- enhanced recovery after surgery|All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg and ondansetron 8 mg in addition to standard care protocol.
62792997|NCT03319823|EXPERIMENTAL|Thiazide Therapy Group|• Group (1): Thiazide Therapy Group: Men without diabetes, and mild hypertension - a sleeping systolic blood pressure of 125-139 mm Hg, and an awake average blood pressure of \< 160 mm Hg
62411292|NCT00633009|ACTIVE_COMPARATOR|LtSTA 15 ug|Naive volunteers tested with 15 ug injection of LtSTA. Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin tests were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
62411293|NCT00633009|ACTIVE_COMPARATOR|LtSTA 30 ug|Naive volunteers tested with 30 ug injection of LtSTA.Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin testes were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
62021593|NCT05996887|ACTIVE_COMPARATOR|enhanced recovery after surgery|All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg, and ondansetron 8 mg in addition to following the recommendation of ERAS society guidelines.
62792998|NCT03319823|EXPERIMENTAL|Combination Therapy Group|• Group (2): Combination Therapy Group: Men with diabetes, or with more severe hypertension - a sleeping blood pressure of ≥ 140 mm Hg, or an awake average blood pressure of ≥ 160 mm Hg.
62217137|NCT03644953|EXPERIMENTAL|Hydroxyurea and Transfusion (HAT)|Combination hydroxyurea and simple chronic transfusion therapy
62217138|NCT01608763|EXPERIMENTAL|Full personalized feedback|Participant provided with the full CYD personalized feedback summary.
62217139|NCT01608763|EXPERIMENTAL|Only normative feedback|Participant provided with just the normative feedback component of the CYD personalized feedback summary.
62217140|NCT01608763|EXPERIMENTAL|Just other personalized feedback|Participant provided with all the other personalized feedback components of the CYD intervention (i.e., no normative feedback).
62411294|NCT00633009|ACTIVE_COMPARATOR|LtSTA 50 ug|Naive volunteers tested with 50 ug injection of LtSTA.Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin testes were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
62411295|NCT03713515|EXPERIMENTAL|Practice Faciliation|Will be supported by a practice facilitator
62411296|NCT03713515|NO_INTERVENTION|Usual Care|Using a stepped wedge design, all practice sites begin as part of the Usual Care (UC) control condition and will receive standard hypertension management that is part of the current clinic procedure. No practice facilitation will occur at this time.
62411297|NCT04092608|ACTIVE_COMPARATOR|Low CVP group (restrictive group)|"Standard practice: the goal is to keep the CVP \< 7 mmHg during surgery.~Baseline of crystalloid of 2ml/kg/h max in all patients.~EV 1000 monitoring device (Edwards Lifesciences, Irvine, USA) will be used but values will be blinded to the anesthesiologist in charge of the patient.~Mean Arterial pressure (MAP) should be kept over 65mmHg during surgery (standard practice) with continuous norepinephrine infusion~Additionnal fluid administration is given to the patient at the end of the surgery (standard practice)~UPi is blinded in all groups"
62792999|NCT04044339|EXPERIMENTAL|TD-5202 for SAD (Part A)|6 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive TD-5202
62021594|NCT03050476|EXPERIMENTAL|RESCAP®|Bolus of 1000 IU of bovine intestinal alkaline phosphatase on induction of anaesthesia, followed by an infusion with a sum of 10,000 IU/day over the next 24 or 96 hours.
62021595|NCT03050476|PLACEBO_COMPARATOR|Placebo|Bolus of of media on induction of anaesthesia, followed by an infusion of media over the next 24 or 96 hours.
62021596|NCT02066935||kidney transplant patient|Kidney transplanted patients for at least one year
62021597|NCT06531746|EXPERIMENTAL|Study group (I)|Will consist of 22 patients with lower cross syndrome and will receive extracorporeal shock wave in addition to selected physical therapy program. For 12 sessions every other day, each session for 1 hour.
62021598|NCT06531746|EXPERIMENTAL|Control group (II)|Will consist of 22 patients with lower cross syndrome and will receive selected physical therapy program only same as group (I). For 12 sessions every other day, each session for 1 hour.
62217141|NCT01608763|NO_INTERVENTION|No intervention control|Participant provided with a list describing the components of the CYD intervention but not provided any personalized feedback.
62217142|NCT00752557|EXPERIMENTAL|1|rhBMP-2/CPM , 1.0 mg/mL
62217143|NCT00752557|EXPERIMENTAL|2|rhBMP-2/CPM , 2.0 mg/mL
62217144|NCT00752557|ACTIVE_COMPARATOR|3|Oral bisphosphonate therapy (standard of care)
62217145|NCT06359834|EXPERIMENTAL|Remimazolam|Patient group who receives remimazolam for sedation during endoscopy
62217146|NCT06359834|ACTIVE_COMPARATOR|Propofol|Patient group who receives propofol for sedation during endoscopy
62217147|NCT02656329|EXPERIMENTAL|AdreView™|Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ Heart-to-Mediastinal ratio (H/M) \<1.6 underwent Implantable Cardioverter Defibrillator (ICD) device implantation and H/M \>= 1.6 continued to receive Guideline-Directed Optimal Medical Therapy (GDMT) according to clinical standard practice.
62217148|NCT02656329|EXPERIMENTAL|Standard of Care|Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted Heart Failure (HF) guidelines.
62217149|NCT03929744|EXPERIMENTAL|LY3502970 (Part A)|Single dose of LY3502970 administered orally.
62217150|NCT03929744|PLACEBO_COMPARATOR|Placebo (Part A)|Single dose of placebo administered orally.
62217151|NCT03929744|EXPERIMENTAL|LY3502970 (Part B)|Multiple doses of LY3502970 administered orally. Some participants will also receive atorvastatin and simvastatin or midazolam administered orally.
62793000|NCT04044339|PLACEBO_COMPARATOR|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive placebo
62793001|NCT04044339|EXPERIMENTAL|TD-5202 for MAD (Part B)|6 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-5202
62793002|NCT04044339|PLACEBO_COMPARATOR|Placebo for MAD (Part B)|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo.
62217152|NCT03929744|PLACEBO_COMPARATOR|Placebo (Part B)|Multiple doses of placebo administered orally. Some participants will also receive atorvastatin and simvastatin or midazolam administered orally.
62793003|NCT00749723|EXPERIMENTAL|1: P-HIT-REZ 2005|"intravenous chemotherapy with carboplatin/etoposide,followed by~* high dose chemotherapy with thiotepa, carboplatin, etoposide and autologous stem cell transplantation if patient have achieved a complete remission or~* maintenance therapy with oral trofosfamide, etoposide"
62217153|NCT03929744|EXPERIMENTAL|LY3502970 (Part C)|Single dose of LY3502970 administered orally in each of two study periods.
62411298|NCT04092608|EXPERIMENTAL|GDFT group|"The goal is to keep stroke volume variation below 13% during surgery with mini fluid challenge of 100 ml of balanced crystalloid using the monitoring device (Edwards Lifesciences, Irvine, USA). Of course, the values will not be blinded to the anesthesiologist in charge of the patient.~All patients have a baseline crystalloid: 2ml/kg/h and mini fluid challenges per 100 ml as described above.~Mean Arterial pressure (MAP) should be kept over 65mmHg during surgery (standard practice) with continuous norepinephrine infusion~UPi is blinded in all groups"
62585645|NCT03464370|ACTIVE_COMPARATOR|Extra-temporal epilepsy Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors and then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
62217154|NCT03929744|EXPERIMENTAL|LY3502970 (Part D)|Single dose of LY3502970 administered orally.
62217155|NCT03929744|PLACEBO_COMPARATOR|Placebo (Part D)|Single dose of placebo administered orally.
62585646|NCT03464370|ACTIVE_COMPARATOR|Healthy volunteers Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors
62585647|NCT00890708|NO_INTERVENTION|non-TDM of voriconazole|conventional dose
62585648|NCT00890708|EXPERIMENTAL|TDM of voriconazole|
62217156|NCT03929744|EXPERIMENTAL|LY3502970 Formulation 1 (Part E)|Multiple doses of LY3502970 - formulation 1 administered orally.
62217157|NCT03929744|EXPERIMENTAL|LY3502970 Formulation 2 (Part E)|Multiple doses of LY3502970 - formulation 2 administered orally.
62217158|NCT05843825|ACTIVE_COMPARATOR|(BOS-G) Block out spacer group|(BOS-G)(Control group) : Patients who would be delivered mandibular overdenture retained by three locator attachments picked up using block out spacer .
62411299|NCT02959372|EXPERIMENTAL|lung ultrasound group|lung ultrasound results
62793004|NCT00749723|EXPERIMENTAL|2: P-HIT-REZ 2005|"oral chemotherapy with temozolomide, followed by~* high dose chemotherapy with temozolomide, thiotepa and autologous stem cell transplantation if patient have achieved a complete remission~* maintenance therapy with oral temozolomide or in case of progression with oral trofosfamide, etoposide"
62217159|NCT05843825|ACTIVE_COMPARATOR|(WBOS-G) Without block out spacer group|(WBOS-G) (Study group): Patients who would be delivered mandibular overdenture retained by three locator attachments picked up without using block out spacer .
62217160|NCT03150173|EXPERIMENTAL|O-BMT (onsite treatment)|Over 2 weeks at the syringe-exchange program, participants in the O-BMT arm will see a buprenorphine provider twice, receive weekly blister packs of medication, and then their care will be transferred to a community health center for maintenance buprenorphine treatment
62411300|NCT02959372|PLACEBO_COMPARATOR|control group|The attending physician will not have the result of the lung ultrasound
62411301|NCT06341270|EXPERIMENTAL|TEAS group|Patients who meet the enrollment criteria will be randomized 1:1 to either the transcutaneous electrical acupoint stimulation (TEAS#or the sham groups. In the TEAS group, the acupoints are bilateral neiguan (PC6) , Hegu(L14), Yanglingquan(GB34), Zusanli(ST 36) and Renying(ST9) acupoints. Patients will receive 30min TEAS before anesthesia until be discharged from the post anaesthesia care unit (PACU). The same treatment for 30 min will be performed on the 1st, 2nd and 3rd days after surgery.The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.
62411302|NCT06341270|SHAM_COMPARATOR|sham group|Patients in the sham group will receive electrode attachment but without stimulation.
62585649|NCT05284708|OTHER|Clinical Operators|Experimental: 15 healthcare professionals will be recruited for the study. The group includes physiotherapists (PTs), physiotherapist assistants (PTAs), clinical exercise physiologists (EPs), and rehabilitation technicians (RTs), all resident in US and representing the final users of the device. Operators are representative of the final users of the exoskeleton.
62585650|NCT01639404|EXPERIMENTAL|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood Administration and Active Rehabilitation
62585651|NCT03681678||fCO2 Laser Therapy Group|Women treated with the fCO2 laser
62585652|NCT04617834||Quality Surveillance Data|For this quality surveillance study, data will be collected retrospectively through electronic health record (EHR) queries for all eligible patients treated for acute cardiovascular symptoms by one of the study sites.
62585653|NCT06685419||Control Group|Placebo gum will be used to reduce plaque index scores 5 times a day, after and between meals, for a total of 3 weeks.
62021599|NCT01466816|EXPERIMENTAL|Saturated fatty acid test meal|
62217161|NCT03150173|ACTIVE_COMPARATOR|Enhanced Referral|In the control arm, participants will receive enhanced referral to a community health center for maintenance buprenorphine treatment
62217162|NCT01184144|EXPERIMENTAL|pioglitazone|Pioglitazone study drug
62217163|NCT01184144|NO_INTERVENTION|No drug|"Placebo like comparitor"
62217164|NCT01497600|EXPERIMENTAL|insulin detemir|
62217165|NCT01497600|ACTIVE_COMPARATOR|insulin NPH|
62217166|NCT03018431||Physician routine evaluation|systematic evaluation of the probability of tracheobronchitis or pneumonia based upon clinical and biological, associated with standard radiographs, performed by the physician in chrage of the patient.
62217167|NCT03018431||independent evaluation|systematic evaluation of the probability of tracheobronchitis or pneumonia based upon early CT scan, and repeated lung ultrasonography, performed by an independent operator.
62217168|NCT01010334|ACTIVE_COMPARATOR|Arm 1|Standard of Care Treatment
62217169|NCT01010334|EXPERIMENTAL|Arm 2|Treatment Arm of a separate protocol (physician discretion)
62217170|NCT03438500|EXPERIMENTAL|Active Shockwave Therapy|Patients in this group receive shockwave therapy.
62411303|NCT00711165|PLACEBO_COMPARATOR|Placebo|Placebo, 2 puffs, bid
62793005|NCT00749723|EXPERIMENTAL|3: E-HIT-REZ 2005|Phase II: oral chemotherapy with temozolomide after progression oral trofosfamide, etoposide
62793006|NCT00749723|EXPERIMENTAL|Intraventricular Etoposide|Phase II, intraventricular chemotherapy with etoposide
62793007|NCT02548338|OTHER|electric scalpel (ES)|Breast surgery is performed using regular electric scalpel
62021600|NCT01466816|EXPERIMENTAL|Monounsaturated fatty acid meal|
62217171|NCT00531700|EXPERIMENTAL|I|Exposure to both tailored/targeted health messages about influenza and also to reports about contextualized influenza risk
62217172|NCT00531700|EXPERIMENTAL|II|Exposure to tailored/targeted health messages
62411304|NCT00711165|EXPERIMENTAL|Memetasone|Mometasone
62411305|NCT05064098||Pre-Surgical Breast Cancer Patients|Adult female patients newly diagnosed with stage 0-III breast cancer seen as a surgical consultation from 06/01/2019 to present.
62411306|NCT05064098||Breast Cancer Survivors|Breast Cancer Survivors
62411307|NCT05056740||MS|Patients with a definite MS diagnosis according to the 2017 McDonald criteria
62411308|NCT05056740||Red-flag MS|Patients presenting with clinical, radiological or biological red flags for MS diagnosis who will be ultimately diagnosed as having MS
62411309|NCT05056740||Other CNS autoimmune diseases|Patients with a definite diagnostic of CNS autoimmune disease that is not MS
62411310|NCT05056740||Controls|Patients with a definite diagnostic of non-inflammatory CNS disorder
62411311|NCT00183170|EXPERIMENTAL|Alcohol then Placebo|Participants report for their first dosing night where they receive several alcohol drinks. After a wash out period of 1 week they then return and receive several placebo drinks. Participants sleep at the study site, are monitored overnight, and the next morning are awakened and escorted to the performance trials.
62411312|NCT00183170|EXPERIMENTAL|Placebo then Alcohol|Participants report for their first night where they receive several placebo drinks. After a wash out period of 1 week they then return and receive several alcohol drinks. Participants sleep at the study site, are monitored overnight, and the next morning are awakened and escorted to the performance trials.
62411313|NCT00299546|PLACEBO_COMPARATOR|Group 1: Placebo|Placebo Subcutaneous (SC) injections every 4 weeks (wks) thru Wk 20 (unless early escape at Wk 16); Golimumab - if early escape, 50 mg SC injections from Wk 16 up to 5 yrs; Golimumab - 50 mg SC injections beginning Wk 24 up to 5 yrs (unless early escape); Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-24 database lock.
62411314|NCT00299546|EXPERIMENTAL|Group 2: Golimumab 50 mg|Golimumab 50 mg SC injections every 4 wks from Wk 0 up to 5 yrs (unless early escape at Wk 16); Golimumab - if early escape, 100 mg SC injections every 4 wks beginning Wk 16 up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-24 database lock.
62411315|NCT00299546|EXPERIMENTAL|Group 3: Golimumab 100 mg|Golimumab 100 mg SC injections every 4 wks from Wk 0 up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50 mg. Duration of the blinded period will be until the week-24 database lock.
62411316|NCT03635970|PLACEBO_COMPARATOR|conventional treatment|receive the best conventional therapy
62411317|NCT03635970|ACTIVE_COMPARATOR|experimental treatment|The best medical treatment possible plus celular therapy
62021601|NCT01466816|EXPERIMENTAL|Polyunsaturated fatty acid meal|
62217173|NCT00531700|EXPERIMENTAL|III|Exposure to reports about influenza related contextualized risk
62217174|NCT00531700|ACTIVE_COMPARATOR|IV|Comparison group exposed to community level health promotion messages not generated by the study
62217175|NCT02374684|EXPERIMENTAL|Methosulide|Methosulide, oral administration
62217176|NCT02374684|PLACEBO_COMPARATOR|Placebo|Placebo, oral administration
62217177|NCT01785654||reventilation collapse|
62217178|NCT01156792|EXPERIMENTAL|FP 100mcg BID plus GSK2190915 100mg QD (AM)|FP 100mcg BID plus GSK2190915 100mg QD (AM)
62411318|NCT00440193|EXPERIMENTAL|Rivaroxaban (Xarelto, BAY59-7939)|Participants were to receive rivaroxaban 15 mg oral tablet twice daily for 3 weeks, followed by 20 mg once daily
62021602|NCT06189287||Participants|Patient of legal age agreeing to answer an anonymous questionnaire on their knowledge of clinical research given at the anesthesia consultation for scheduled surgery
62217179|NCT01156792|EXPERIMENTAL|FP 100mcg BID plus GSK2190915 300mg QD (AM)|FP 100mcg BID plus GSK2190915 300mg QD (AM)
62411319|NCT00440193|ACTIVE_COMPARATOR|Enoxaparin/VKA|Participants were to receive 1.0 mg/kg enoxaparin twice daily (subcutaneous) for at least 5 days, plus vitamin K antagonist (VKA) (oral) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 to 3.0)
62411320|NCT02705664|EXPERIMENTAL|Loceryl NL|Amorolfine hydrochloride NL 5% to be applied once weekly for 7 weeks on all affected toenails of one foot
62411321|NCT02705664|ACTIVE_COMPARATOR|Urea Ointment + Bifonazole Cream|"On the opposite foot:~1. Urea 40% ointment to be applied once a day under occlusion for 2-3 weeks depending on the achievement of optimal diseased toenail plates removal)~2. Bifonazole 1% cream to be applied for 4 weeks on affected toenails (after the maximum 3-week treatment period with Urea ointment)"
62217180|NCT01156792|ACTIVE_COMPARATOR|FP 100mcg BID plus montelukast 10mg QD (PM)|FP 100mcg BID plus montelukast 10mg QD (PM)
62217181|NCT01156792|ACTIVE_COMPARATOR|FP 100mcg BID plus placebo BID|FP 100mcg BID plus placebo BID
62793008|NCT02548338|OTHER|argon plasma coagulation (APC)|Breast surgery is performed using argon plasma coagulation scalpel
62793009|NCT03755882|EXPERIMENTAL|TEST/CONTROL|Female subjects between the ages of 18 to 29 years who are habitual reusable soft cosmetic contact lens wearers will be randomized into one of two lens sequences.
62021603|NCT05456581|EXPERIMENTAL|Condition 1 - 'Scotoma awareness' Training|Participants will be asked to report the emotion of an emoji face ('happy' vs 'sad') that could appear anywhere on screen. For the entire duration of the training, an explicit, sharp outlined occluder surrounding the participant's true retinal scotoma will be rendered on screen. This occluder will be generated through a gaze-contingent display. The size and the contrast of the target will change adaptively in response to the patient's performance.
62021604|NCT05456581|EXPERIMENTAL|Condition 2 - Control Training|In the control condition, participants will perform the same task as the scotoma awareness training, without the artificial visible scotoma.
62021605|NCT00650468|EXPERIMENTAL|1|early steroid cessation
62021606|NCT00650468|EXPERIMENTAL|2|long-term maintenance steroids
62021607|NCT05355389|EXPERIMENTAL|Cognitive-motor training group|
62411322|NCT01829659||AA Ticagrelor|African Americans who present with acute coronary syndrome (ACS) to the cath lab, and receive ticagrelor during their hospital stay.
62411323|NCT05649787|NO_INTERVENTION|Usual care|Patients allocated to this arm will receive the usual care plus explicit recommendations for home-based aerobic and strength training.
62411324|NCT05649787|ACTIVE_COMPARATOR|Supervised aerobic training|Patients allocated to this arm will receive the usual care plus supervised aerobic training
62411325|NCT05649787|ACTIVE_COMPARATOR|Supervised aerobic plus low to moderate-intensity strenght training|Patients allocated to this arm will receive the usual care plus supervised aerobic and low to moderate-intensity strength training
62411326|NCT05649787|ACTIVE_COMPARATOR|Supervised aerobic plus moderate to high-intensity strenght training|Patients allocated to this arm will receive the usual care plus supervised aerobic and moderate to high-intensity strength training.
62411327|NCT02768935|OTHER|Diabetes|
62411328|NCT02768935|OTHER|normoglycaemic|
62411329|NCT05032183|EXPERIMENTAL|Treatment (tagraxofusp, chemotherapy)|See Detailed Description
62021608|NCT05355389|ACTIVE_COMPARATOR|Cognitive training group|
62021609|NCT05355389|ACTIVE_COMPARATOR|Motor training group|
62021610|NCT04592692|EXPERIMENTAL|Inhibitors|Patients with inhibitors to FVIII
62021611|NCT04592692|OTHER|Non-inhibitors|Patients without inhibitors to FVIII
62021612|NCT00152295|EXPERIMENTAL|1|
62021613|NCT01762761|EXPERIMENTAL|Eltrombopag (ETB115)|Thrombopoietin- receptor (TPO-R) agonist
62021614|NCT01762761|PLACEBO_COMPARATOR|Placebo|Placebo
62021615|NCT04726709|EXPERIMENTAL|Poised for Parkinson's|Alexander-technique-based online course to increase embodied agency in people with Parkinson's disease and their care partners.
62021616|NCT05178628|EXPERIMENTAL|Patients treated with Innohep® and chemotherapy|The patients in this arm will receive Innohep and chemotherapy with Gemcitabine + Nab-Paclitaxel (NabG) as per clinical practice.
62021617|NCT05178628|ACTIVE_COMPARATOR|Patients treated with chemotherapy|The patients in this arm will receive chemotherapy with Gemcitabine + Nab-Paclitaxel (NabG) as per clinical practice.
62411330|NCT05454488|EXPERIMENTAL|Focal therapy Treatment|Cryoablation is a procedure in which special needles are inserted into the tumor site.
62411331|NCT03731325|EXPERIMENTAL|Episodic Future Thinking Group 7-week baseline|The experimental group will receive the Episodic Future Thinking (EFT) intervention after a 7-week baseline. EFT teaches individuals to pre-experience events, or think prospectively, about future events as if they were happening now \[Atance\].
62411332|NCT03731325|EXPERIMENTAL|Episodic Future Thinking Group 10-week baseline|The experimental group will receive the Episodic Future Thinking (EFT) intervention after a 10-week baseline. EFT teaches individuals to pre-experience events, or think prospectively, about future events as if they were happening now \[Atance\].
62411333|NCT06138041|EXPERIMENTAL|lidocaine group|At the same time of induction of general anesthesia, an intravenous lidocaine bolus of 2mg/kg will be administered, followed by a continuous infusion of intravenous lidocaine at 2 mg/kg/h until the participate transfer out of postoperative anesthesia care unit.
62411334|NCT06138041|PLACEBO_COMPARATOR|control group|The control group will receive the same volume of normal saline in bolus and continuous infusion.
62411335|NCT05163548|EXPERIMENTAL|Subjects that receive PerQseal Plus Device|Subjects undergoing large hole endovascular percutaneous procedures with a femoral arteriotomy created with 14 to 22 F sheaths (arteriotomy up to 26 F)
62411336|NCT05219032|EXPERIMENTAL|Interpreter|Professional Spanish interpreter
62411337|NCT05219032|NO_INTERVENTION|Usual Care|Usual care provided to patients
62793010|NCT03755882|EXPERIMENTAL|CONTROL/TEST|Female subjects between the ages of 18 to 29 years who are habitual reusable soft cosmetic contact lens wearers will be randomized into one of two lens sequences.
62793011|NCT03949608|EXPERIMENTAL|BASIC|"mon cœur, mon BASIC video viewing and installation in the own smartphone or tablet of the patient"
62793012|NCT03949608|NO_INTERVENTION|Control|Usual care
62793013|NCT00271102|ACTIVE_COMPARATOR|Anterior colporrhaphy|Anterior vaginal wall colporrhaphy (repair) for cystocele (dropped bladder)
62793014|NCT00271102|ACTIVE_COMPARATOR|Paravaginal defect repair|Abdominal paravaginal defect repair cystocele (dropped bladder)
62793015|NCT04804163|EXPERIMENTAL|Upper urinary tract disease group|Patients with upper urinary diseases (renal cell carcinoma, nonfunctioning kidney and adrenal tumor) will be treated by telesurgery.
62021618|NCT03153332||MDCT group|The MDCT images of seven hepatic tumors were loaded on software to uniform study conditions, allowing both axial and coronal scans visualization.
62021619|NCT03153332||3D visualization system group|The 3D virtual reconstructions of seven hepatic tumors were loaded on the visualization software which enables the rotation of the virtual model.
62021620|NCT03153332||3D printing group|3D-printed models of seven hepatic tumors were created based on MDCT images, participants were allowed to freely handle them.
62217182|NCT01156792|ACTIVE_COMPARATOR|FP/SAL 100/50mcg BID plus placebo BID|FP/SAL 100/50mcg BID plus placebo BID
62217183|NCT04488718|EXPERIMENTAL|EnergieShake® Junior Powder Complete (test)|EnergieShake® Junior Powder Complete will be consumed by children, as a supplement to normal diet, over a period of 7 day period to determine its acceptability (liking, compliance) and tolerance (gastro-intestinal tolerance). The dose will be the same as currently consumed product (all children recruited to the study will be consuming an oral nutritional supplement).
62217184|NCT01949038|PLACEBO_COMPARATOR|Oral placebo|Patients receive one oral dose of placebo least 30 minutes before the procedure.
62217185|NCT01949038|PLACEBO_COMPARATOR|Sublingual placebo|Patients receive one oral dose of placebo at least 30 minutes before the procedure.
62217186|NCT01949038|ACTIVE_COMPARATOR|Sublingual alprazolam|Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.
62411338|NCT03478813|EXPERIMENTAL|Intervention group|Voiding school (VS) is based on urotherapy guidelines for educating children with incontinence highlighting regular voiding habits and life-style advice. Learning by doing, understanding the body function by concrete example videos and pictures, and discussing are the main teaching methods.The intervention is delivered face-to-face in groups of 4-6 children. The VS includes three sessions one months apart. Duration of each VS session is three hours. The intervention is delivered with detailed manual. The intervention is provided by an urotherapist and a public-health nurse.
62411339|NCT03478813|NO_INTERVENTION|Usual care group|The control group receives treatment according to the new 2016 guidelines of incontinence care in child welfare clinics in the city concerning. Treatment is carried out by public health nurse individually in consulting hours or by telephone.
62793016|NCT02154841|EXPERIMENTAL|Questionnaire, taste test, visual food test|The participants will complete a questionnaire that asks them about their taste preferences. They will also will be shown photos of various food stuffs and asked to choose their preferred meal. They will also be asked to put five sponge sticks (a single use item commonly used for mouth care) dipped in one of a five different liquids into their mouths and give their comments what each taste was and on how much they enjoyed it. These five liquids represent the four well-described tastes (sweet, sour, salty, bitter) and a more recently proposed taste, savoury. The intention of this part of the trial is to assess the patient's ability to detect alteration in pure taste and to identify if any of these tastes are preferred.
62793017|NCT00308854|ACTIVE_COMPARATOR|1|PD P 506 A-PDT
62793018|NCT00308854|PLACEBO_COMPARATOR|2|Placebo-PDT
62217187|NCT01949038|ACTIVE_COMPARATOR|Oral alprazolam|Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.
62021621|NCT06292273|ACTIVE_COMPARATOR|Group Bupivacain Plus dexamethasone|receiving plain bupivacaine 0.1%, 35 ml with dexmedetomidine 0.5
62217188|NCT06072040|EXPERIMENTAL|AUR-201|AUR-201
62411340|NCT06568276|NO_INTERVENTION|Conventional treatment|Unstable Weber B fractures receiving standard treatment, plate and screw fixation of the lateral malleolus only
62021622|NCT06292273|PLACEBO_COMPARATOR|Group bupivacain|plain bupivacaine 0.25%, 25 ml bilaterally
62021623|NCT05377320||Clinical Decision Aid Group|In this group, physicians will use standard care plus the clinical decision aid.
62021624|NCT05377320||Control Group|In this group, physicians will use standard care only.
62021625|NCT06635005|EXPERIMENTAL|Prevention (Low-EDIH dietary pattern intervention)|Participants receive the low-EDIH dietary pattern intervention consisting of 6 group nutrition education sessions focusing on foods to prioritize within each food group, food combinations, food preparation, discussion, simple cooking demonstrations, food tastings, smart shopping advising, and a question/answer period over 2 hours each at weeks 0, 1, 2, 3, 5, and 6. Participants also attend 3 in-person or virtual individual nutrition counseling and motivational interviewing sessions over 30 minutes each at weeks 3 and 5, between weeks 7 and 9, and between weeks 9 and 11. Participants also wear an activity tracker and undergo blood sample collection on study.
62021626|NCT03669003|EXPERIMENTAL|Gelfoam|Gelfoam slurry will be injected at the end of the biopsy procedure.
62217189|NCT05784831|EXPERIMENTAL|Regular Intervention Group|Group using the app delivering reappraisal training for 21 consecutive days.
62217190|NCT05784831|EXPERIMENTAL|Burst Intervention Group|Group using the app delivering reappraisal training for 7 consecutive days, then having 7 days break and again using the app 7 consecutive days.
62217191|NCT05784831|ACTIVE_COMPARATOR|Active Control Group|Group using the ecological momentary assessment app for 21 consecutive days.
62217192|NCT00873431|EXPERIMENTAL|IC47 30 mcg|30 mcg with Alum
62217193|NCT00873431|EXPERIMENTAL|IC47 30 mcg w/o|30 mcg without Alum
62217194|NCT00873431|EXPERIMENTAL|IC47 150 mcg|150 mcg with Alum
62217195|NCT00873431|EXPERIMENTAL|IC47 150 mcg w/o|150 mcg without Alum
62411341|NCT06568276|EXPERIMENTAL|Additional deltoid ligament suture|Unstable Weber B fractures receiving standard treatment, plate and screw fixation of the lateral malleolus and additional deep deltoid ligament suture
62411342|NCT04973748|ACTIVE_COMPARATOR|Treatment as usual (TAU)|"Standard pain regimen with scheduled acetaminophen and ibuprofen, oxycodone as needed for moderate-to-severe pain, and intravenous hydromorphone as needed for breakthrough pain.~Surveys about pain levels, opioid consumption, side effects of opioids, understanding of placebo effect and symptoms of depression."
62585654|NCT06685419||Test Group/Propolis-containing gum group|Propolis-containing gum will be used to reduce plaque index scores 5 times a day, after and between meals, for a total of 3 weeks.
62585655|NCT04540159||Case|Advanced stage Colorectal cancer patients with intraabdominal ascites
62585656|NCT04540159||Control|Liver cirrhosis and congestive heart failure patients with intraabdominal ascites
62021627|NCT03669003|ACTIVE_COMPARATOR|Standard procedure|Standard procedure of lung biopsy
62021628|NCT06019104|EXPERIMENTAL|Task-oriented training group|Among the patients in the task-oriented training group, 12 sessions were given routinely, 3 days a week, for 4 weeks. Task-oriented training consisted of 25 different stations in total, including 9 different gaze stabilization training, 7 balance training, and 9 gait training stations. Gaze stabilization exercises included head-fixed right-left eye movements, head-fixed up-down eye movements, eye fixed right-left head movements, eye fixed up-down head movements, head and eye opposing movements (right-left/ up-down), saccadic and pursuit eye movements (right-left/ up-down). Balance and gait training included these exercises: rolling on the mat, vertical rotation, spinning on a rotary disc, standing on balance bord, jumping, playing dart, reaching, walking forward, walking with head movements (right-left/ up-down), tandem walking, '8' shape walking, walking by picking something up from the ground, walking over an obstacle, walking on treadmill, climbing and descending stairs.
62793019|NCT03912779|EXPERIMENTAL|C2Hear RLOs|C2Hear RLOs (https://www.youtube.com/C2HearOnline): nine (custom earmould) or eight (open fit hearing aid) multi-media learning clips covering practical and psychosocial components of owning a hearing aid, alongside user testimonials (n= 7). Participants asked to watch all relevant to their prospective hearing aid coupling (custom earmould or open fit), with no limit on number of views. A paper diary documented usage during the study duration.
62793020|NCT03912779|PLACEBO_COMPARATOR|Printed hearing aid booklet|A 32-page printed A5 colour booklet, designed and written by local Audiology staff, supplied to all prospective hearing aid owners at the study centre as standard care. Same booklet supplied irrespective of hearing aid style (custom/open fit). All content conveyed via text and supporting pictures only. Participants assigned to the placebo comparator were asked to read the booklet once. A paper diary documented usage during the study duration.
62411343|NCT04973748|EXPERIMENTAL|Conditioned open-label placebo (COLP)|"Standard pain regimen with scheduled acetaminophen and ibuprofen, oxycodone as needed for moderate-to-severe pain, and intravenous hydromorphone as needed for breakthrough pain.~Conditioning (i.e. exposure to clove oil scent) with each dose of oxycodone medication on post-operative day (POD) 1-5.~Scheduled placebo oxycodone medication paired with conditioning (i.e. exposure to clove oil scent) 3 times per day on POD 2-5.~Surveys about pain levels, opioid consumption, side effects of opioids, understanding of placebo effect and symptoms of depression."
62021629|NCT06019104|ACTIVE_COMPARATOR|Control group|Among the patients in the control group with peripheral vestibular disorders, 12 sessions were given routinely, 3 days a week, for 4 weeks. They were asked to perform gaze stabilization exercises for 1 min. Gaze stabilization exercises consist of head-fixed right-left eye movements, head-fixed up-down eye movements, eye fixed right-left head movements, and eye fixed up-down head movements.
62217196|NCT05435768||Group A :RANKL inhibitor subsequently HFRT+GM-CSF+PD-1 inhibitor|Group A(6 patients):patients were subcutaneously injected with 120mg desomumab, and on the second day after injection, the metastatic lesions were treated with hypofractioniated radiotherapy (8Gy×3F or 5Gy×3F), and subcutaneously injected with GM-CSF(200 μg/d) for 7 days, followed by IL-2 (2 million IU/d) for 7 days,and a 200mg PD-1 inhibitor administered within one week after completion of radiotherapy. The course was repeated every 28 days for 2-4 cycles.After combination therapy, maintenance therapy with PD-1inhibitor and desomumab was administered until disease progression or unacceptable toxicity.
62411344|NCT06043102|OTHER|TheraClearX treatment|TheraClearX treatment of the facial area weekly for 6 sessions.
62411345|NCT03624049|OTHER|Community Exercise Program|Participation in Health Class including: Arthritis Exercise Foundation Exercise Class, Tai Chi for Arthritis, EnhanceFitness Class, or Healthier Living Class.
62793021|NCT02360891||patients|follow up of patients with amyotrophic lateral sclerosis from the first signs to the end of the disease
62793022|NCT02360891||neurological controls|patients with other neurological disease
62793023|NCT02360891||healthy controls|age matched healthy controls
62411346|NCT06000007|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual arm entails the patients continuing to receive care from their primary care provider and any specialists they choose to get involved in their care.
62411347|NCT06000007|ACTIVE_COMPARATOR|Intervention arm|Intervention arm includes access to the digital therapeutic mobile app in addition to treatment as usual
62793024|NCT03813264|EXPERIMENTAL|preliminary arm|pairs of patients and their therapists
62793025|NCT01874886||Cannabis users|⋄Heavy Marijuana Users : 60-80 years old; Marijuana use initiated in adolescence with marijuana use of no more than 1-2 x/month after 30 years of age; Used marijuana more than 20 times/month for at least 1 year during this period. Cigarette smoking (tobacco) and alcohol will be allowed in both groups, which will be matched on number of smokers and nicotine dependence, measured according to the Fagerstrőm Test for Nicotine Dependence. Light alcohol use will also be allowed in and matched across both groups (\< 14 drinks/week for men; \< 7 drinks/week for women; may not meet DSM-IV criteria for alcohol dependence).
62793026|NCT01874886||Clean or Non-Users|⋄No marijuana use, may smoke cigarettes, fewer than 7 drinks/week (women) or 14 drinks/week (men). 60-80 years old.
62793027|NCT03850028|OTHER|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo a maximum of 3 89Zr-atezolizumab PET scans.
62411348|NCT02530801|OTHER|Avastin and 5 fluorouracil|Subconjunctival injection of bevacizumab combined with 5 fluorouracil
62585657|NCT00068367|EXPERIMENTAL|Arm I (OSI-774)|"Drug: erlotinib hydrochloride~Other Names:~OSI-774 150 mg per day, daily until disease progression"
62585658|NCT05278546|EXPERIMENTAL|Treatment Arm|There are nine escalating dose cohorts.
62585659|NCT03297606|EXPERIMENTAL|Group 1 - Arm CLOSED, no patients recruited|VEGFR1, VEGFR2, VEGFR3
62585660|NCT03297606|EXPERIMENTAL|Group 2 - Arm CLOSED, no patients recruited|BCR-ABL, SRC
62585661|NCT03297606|EXPERIMENTAL|Group 3 - Arm CLOSED|ALK, ROS1, MET
62585662|NCT03297606|EXPERIMENTAL|Group 4 - Arm CLOSED, no patients recruited|KIT, PDGFRA, PDGFRB, ABL1
62585663|NCT03297606|EXPERIMENTAL|Group 5 - Arm CLOSED|EGFR
62585664|NCT03297606|EXPERIMENTAL|Group 6 - Arm CLOSED|high mutation burden, POLE, POLD1
62585665|NCT03297606|EXPERIMENTAL|Group 7 - Arm CLOSED|BRCA1, BRCA2, mutations in HRD
62217197|NCT05435768||Group B:HFRT+GM-CSF+PD-1 inhibitor subsequently RANKL inhibitor|Group B(6 patients):patients were treated with hypofractioniated radiotherapy (8Gy×3F or 5Gy×3F), and subcutaneously injected with GM-CSF(200 μg/d) for 7 days, followed by IL-2 (2 million IU/d) for 7 days.On the second day after radiotherapy, 200mg pd-1 inhibitor was administered. After treatment, 120mg desomumab was subcutaneously injected. The course was repeated every 28 days for 2-4 cycles.After combination therapy, maintenance therapy with PD-1inhibitor and desomumab was administered until disease progression or unacceptable toxicity.
62217198|NCT06298929|ACTIVE_COMPARATOR|Group 1|patients with PAET who will receive unilateral or bilateral MR fenestration
62217199|NCT06298929|ACTIVE_COMPARATOR|Group 2|patients with PAET who will receive unilateral or bilateral MR recession
62021630|NCT02440152|EXPERIMENTAL|Deep brain stimulation|
62411349|NCT01958502|EXPERIMENTAL|mesenchymal stem cell|stem cells drived from iliac bone marrow with centrifuge and ficoll method then implant in collagenic 3-D scaffold with BMP-2 and put in non union site by surgical approach under general or spinal anesthesia as deemed appropriate by the anesthetist.
62793028|NCT05350449|EXPERIMENTAL|Loving kindness meditation|Loving-kindness meditation is a contemplative practice that focuses on developing compassion for oneself and others through mindfulness. Participants will be shown the recorded loving-kindness training video during the first week of the intervention. Participants will be encouraged to use the mp3 device with guided meditation recording to practice mindfulness meditation for 20-25 minutes every day for 30 days. We will also provide participants with a diary to record their daily meditation experiences. There will be weekly check in. At 60 days we will do a follow-up data collection.
62793029|NCT05350449|NO_INTERVENTION|Waitlist control|The arm will eventually get the intervention.
62793030|NCT04522596|EXPERIMENTAL|Umeclidinium/vilanterol|Umeclidinium/vilanterol 55/22 μg inhaled once a day for 14 days.
62411350|NCT06651736|ACTIVE_COMPARATOR|Arm 1 - Low Vision Rehabilitation LVR|Participants (N \~ 60) without vision-related anxiety will be designated to Arm 1 and receive LVR. This group is intended to be a comparison for the higher vision-related anxiety groups. For this reason, these patients may be placed on a waitlist (meaning participants low-vision rehabilitation may be delayed), until the study team can match with someone in one of the other groups.
62585666|NCT03297606|EXPERIMENTAL|Group 8 - Arm CLOSED|CDKN2A, CDK4, CCND1, SMARCA4
62217200|NCT02935725|EXPERIMENTAL|Low dose AUT00206 800 mg + Ketamine|Low dose AUT00206 (800 mg) + ketamine
62217201|NCT02935725|EXPERIMENTAL|High dose AUT00206 2000 mg + Ketamine|High dose AUT00206 (2000 mg) + ketamine
62217202|NCT02935725|PLACEBO_COMPARATOR|Placebo + Ketamine|Placebo + ketamine
62217203|NCT02935725|PLACEBO_COMPARATOR|Placebo + Saline|Placebo + saline
62217204|NCT02483000|EXPERIMENTAL|Treatment (PRIT)|"B9E9-FP INFUSION: Patients receive B9E9-fusion protein IV over a minimum of 2 hours on day -17.~CLEARING AGENT INFUSION: Patients receive clearing agent IV over a minimum of 30 minutes on day -15.~RADIOBIOTIN INFUSION: Patients receive indium In 111-DOTA-biotin IV and yttrium Y 90 DOTA-biotin IV over 2-5 minutes on day -14.~BEAM CHEMOTHERAPY: Patients receive BEAM chemotherapy comprising carmustine IV over 3 hours on day -7; etoposide IV over 2 hours BID and cytarabine IV over 4 hours BID on days -6 to -3; and melphalan IV over 30 minutes on day -2.~STEM CELL INFUSION: Patients undergo autologous PBSCT on day 0 per standard of care."
62217205|NCT01102010|EXPERIMENTAL|Blood transfusion|"Restrictive strategy: Blood transfusion when hemoglobin is less than 6 mmol/l (9.7 g/dl)~Liberal strategy: Blood transfusion when hemoglobin is less than 7 mmol/l (11.3 g/dl)"
62217206|NCT03152903|EXPERIMENTAL|VPM1002 (Recombinant BCG vaccine)|
62217207|NCT03152903|PLACEBO_COMPARATOR|Placebo|
62411351|NCT06651736|EXPERIMENTAL|Arm 2 - ERT (after randomization) and then concurrent with LVR|Participants with vision-related anxiety (must meet this per protocol by self-reports) randomized to this arm will receive immediate ERT. The LVR therapy will start approximately during 4-6 sessions of ERT.
62411352|NCT06651736|EXPERIMENTAL|Arm 3- LVR with delayed ERT|Participants with vision-related anxiety (must meet this per protocol by self-reports) randomized to this arm will receive LVR with delayed ERT.
62411353|NCT06455475|NO_INTERVENTION|Standard of care|Debridement, offloading, and proper moisture balance dressings
62411354|NCT06455475|EXPERIMENTAL|Derm-Maxx as an addition to standard of care|Device exposure is estimated to be a maximum of 12 weeks
62585667|NCT03297606|EXPERIMENTAL|Group 9 Arm CLOSED|CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL
62585668|NCT03297606|EXPERIMENTAL|Group 10 Arm CLOSED|AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STK11, TSC1, TSC2
62585669|NCT03297606|EXPERIMENTAL|Group 11 - Arm CLOSED|ERBB2
62585670|NCT03297606|EXPERIMENTAL|Group 12 - Arm CLOSED|BRAFV600
62585671|NCT03297606|EXPERIMENTAL|Group 13 - Arm CLOSED|PTCH1, SMO
62585672|NCT03297606|EXPERIMENTAL|Group 14|ERBB2
62793031|NCT04522596|PLACEBO_COMPARATOR|Placebo|Placebo inhaled once a day for 14 days.
62793032|NCT00321464|ACTIVE_COMPARATOR|zoledronic acid|
62793033|NCT00321464|EXPERIMENTAL|denosumab|
62793034|NCT04703426|EXPERIMENTAL|Sargramostim (GM-CSF) + Pembrolizumab (anti-PD-1)|"Participants will receive 12 weeks of sargramostim (GM-CSF) and pembrolizumab (anti-PD-1). Participants may be pre-medicated with drugs to reduce the chance of having a sensitivity reaction to the study treatment of pembrolizumab (anti-PD-1) and sargramostim (GM-CSF).~Study cycles are 21 days in length:~* Pembrolizumab (anti-PD-1) will be given by intravenous infusion once on day 1 of every 21 day cycle~* Sargramostim (GM-CSF) will be self-administered by participants via a subcutaneous (below the skin) injection daily for days 1 - 14 of each 21- day cycle.~Participants will be assessed at 12 weeks for disease response/progression and further study treatment."
62793035|NCT04151433|ACTIVE_COMPARATOR|The combined technique|First step consisting of stripping the cyst wall for 80% of the surface, followed by a second step consisting of ablation of the remaining 20% cyst surface.
62793036|NCT04151433|ACTIVE_COMPARATOR|CO2 laser vaporization only|CO2 laser vaporization only of the complete inner cystic wall after drainage of the cyst content, irrigation and inspection of its inner wall. Ablation of the inner cyst wall using the CO2 laser (Lumenis). Power settings of 30-55W for CO2 laser beam and 6-10W for CO2 fibre are used. The laser should be on the ablate function to widen the beam (e.g. Surgitouch modus). The laser should be applied in Surgitouch modus so that it can ablate the cyst surface while preserving the underlying healthy tissue.
62021631|NCT04351152|EXPERIMENTAL|Lenzilumab Arm|Participants will receive IV infusion of lenzilumab upon randomization at a pre-specified dosing interval and continued administration of standard of care
62021632|NCT04351152|PLACEBO_COMPARATOR|Placebo Arm|Participants will receive IV infusion of preservative-free 0.9% sodium chloride solution upon randomization matched to lenzilumab at same pre-specified dosing interval and continued administration of standard of care
62021633|NCT06535789|EXPERIMENTAL|technosphere insulin (TI)|All participants will ingest one standardized meal using technosphere insulin to manage their blood glucose
62217208|NCT03237546|ACTIVE_COMPARATOR|Serratus blocks|The serratus plane is interstitial tissue, below the serratus muscle. The injection of bupivacaine numbs the anterior branch of the thoracodorsal nerve. This technique allows for the medication to diffuse along the area of the serratus plane to provide numbing of that area. Upon completion of the block, the patient will be evaluated for extubation and emerged from general anesthesia if appropriate.
62793037|NCT04841616|EXPERIMENTAL|Contrast-enhanced EUS (CH-EUS) Arm|After initial evaluation, 2.5ml of second-generation contrast media, SonoVue (Bracco, Ceriano Laghetto, Italy), will be injected. After infusion, the point of puncture will be determined when the parenchyma of the pancreas was enhanced. The contrast-enhanced area was identified and then the biopsy was directed toward that area, while avoiding unenhanced (i.e. necrotic) areas and not changing the target lesion. Rest of the procedure is identical with that in conventional EUS arm.
62819354|NCT03662776||retinoblastoma survivors treated with intra-arteria chemo|MSK will contact all families of 1-year survivors of unilateral retinoblastoma treated with enucleation or intra-arterial chemotherapy at MSK and TCH between 2006 or later for completion of validated questionnaires integrating the BASC-3 and PROMIS surveys. The survey may be administered in-person during clinic or by mail, based upon participant preference.
62021634|NCT06535789|NO_INTERVENTION|Rapid-acting insulin analog|All participants will ingest one standardized meal using their prescribed rapid-acting insulin analog (RAA) to manage their blood glucose
62217209|NCT03237546|ACTIVE_COMPARATOR|PCA-alone (no block)|All subjects will receive fentanyl intravenous patient controlled anesthesia pumps as part of standard care. The amount of fentanyl self-administered by the patient or given by a clinician during 24 hours following surgery will be compared amongst the two groups.
62217210|NCT03568487|EXPERIMENTAL|Intensive scapula-focused approach|
62217211|NCT03568487|ACTIVE_COMPARATOR|Control therapy|
62217212|NCT05277220||Thermography|
62585673|NCT01068210|EXPERIMENTAL|Aerobic Training|A customized and supervised endurance exercise training program that will last 4 months (16 weeks). The regimen will be tailored to the individual fitness level. The exercise program will consist of three supervised sessions per week. During each session, the participant will cycle on a stationary bicycle at moderate intensity for approximately 30-60 minutes.
62021635|NCT00337714|PLACEBO_COMPARATOR|A|in this arm conventional CVCs will be inserted
62217213|NCT03299972|PLACEBO_COMPARATOR|Control|
62217214|NCT03299972|EXPERIMENTAL|Whey Protein|
62217215|NCT03299972|EXPERIMENTAL|Resistance Exercise + Control|
62217216|NCT03299972|EXPERIMENTAL|Resistance Exercise + Whey Protein|
62217217|NCT01917721|EXPERIMENTAL|Doxycycline|These patients will receive doxycycline at the acute phase of their disease
62217218|NCT01917721|ACTIVE_COMPARATOR|Placebo|The comparative arm of the study will receive standard care and placebo for Kawasaki disease, but not doxycycline
62217219|NCT01303029|ACTIVE_COMPARATOR|Control|Gemcitabine+erlotinib
62217220|NCT01303029|EXPERIMENTAL|Experimental|Gemcitabine+erlotinib+capecitabine
62217221|NCT02739867||Unprovoked VTE|Patients aged 40 years or older with a first episode of objectively confirmed, symptomatic, unprovoked deep vein thrombosis of the leg (distal or proximal) or pulmonary embolism
62217222|NCT06125704|OTHER|Morning physical activity first|Randomized to complete 30 minute of moderate intensity walking or stepping in the morning (i.e., between 5am-9am, within 30-40 minutes of starting breakfast) on days 4 and 5, and 30 minute of moderate intensity walking or stepping in the late afternoon/evening (between 4pm-8pm, within 30-40 minutes of dinner) on days 9 and 10.
62217223|NCT06125704|OTHER|Afternoon/evening physical activity first|Randomized to complete 30 minute of moderate intensity walking or stepping in the late afternoon/evening (between 4pm-8pm, within 30-40 minutes of dinner) on days 4 and 5, and 30 minute of moderate intensity walking or stepping in the morning (i.e., between 5am-9am, within 30-40 minutes of starting breakfast) on days 9 and 10.
62021636|NCT00337714|ACTIVE_COMPARATOR|B|group B will receive medicated silver nanoparticles CVC
62217224|NCT03751059|ACTIVE_COMPARATOR|NSAID|Bromfenac 0.07% Oph Susp: used from one week post-op to three months post-op
62217225|NCT03751059|ACTIVE_COMPARATOR|Steroid|Dexamethasone: used from one week post-op to three months post-op
62217226|NCT03142126|EXPERIMENTAL|Early Ambulation|To affirm the safety and efficacy of ambulation of 20 minutes after diagnostic left heart catheterization.
62217227|NCT05842772|EXPERIMENTAL|Intervention group|The DESIRE intervention which includes training of health professionals, a conversation with patients and their relatives, and a patient decision aid.
62217228|NCT05842772|ACTIVE_COMPARATOR|Control group|Usual care
62217229|NCT03724994||Study cohort|All patients with periampullary adenocarcinoma or pancreatic cancer receiving palliative or adjuvant chemotherapy (e.g. Gemcitabine, Folfirinox, etc.) in the Department of Oncology, Skåne University hospital, Malmö and Lund
62217230|NCT06058312|EXPERIMENTAL|Experimental Arms|
62411355|NCT04275830|EXPERIMENTAL|Baseline and HRVB+DS group|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to HRVB+DS arm. This group will receive a standardized HeartMath© Inner balance device and HRV biofeedback training session at the start of the two-week intervention period. They will be asked to attend either a group or one-on-one 30-minute HRVB training session and asked to practice their HRV biofeedback skills at home for 10 minutes each day for a two-week period. Participants will also be asked to watch four digital stories of other HCT patients (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
62217231|NCT06611072|EXPERIMENTAL|Group 1|Patients with OC who undergo primary debulking surgery
62217232|NCT06611072|EXPERIMENTAL|Group 2|Patients with OC who undergo interval debulking surgery
62411356|NCT04275830|OTHER|Baseline and HRVB waitlist +DS control group|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to HRVB waitlist +DS control arm. After the baseline data collection, during two weeks, they will be provided four digital stories of other HCT patients sharing their experiences (challenges, feelings, strategies, coping, each 2-3 minutes long). At the end of the two-week period, participants will be scheduled for a final in-person session including T2 survey and HRV assessment. They will be also provided HRVB training session at T2.
62411357|NCT06340750|EXPERIMENTAL|BAFF CAR T|Autologous BAFF CAR T Therapy
62793038|NCT04841616|ACTIVE_COMPARATOR|Conventional EUS Arm|Patients will undergo EUS FNB with the 22-gauge FNB needle (Acquire®, Boston Scientific Natick, MA). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is \< 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed
62217233|NCT06611072|ACTIVE_COMPARATOR|Group 3|Controls as blood and bone marrow donors
18297164|NCT06361849|EXPERIMENTAL|Experimental: Trocar Placement Assist Device (TPAD)|Participants will receive investigational TPAD device during laparoscopic surgery
18297165|NCT06361849|ACTIVE_COMPARATOR|Standard of Care (SOC)|Standard of care included both direct (unassisted) entry and assisted entry using clamps, if needed, to aid in Veress needle insertion. Upon confirmation that the Veress needle was in the correct location (e.g., drop test), insufflation was initiated.
62217234|NCT00030498|EXPERIMENTAL|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
62217235|NCT05281159|NO_INTERVENTION|Standard of Care|This group will receive a standard SMS text message indicating that they have a MyChart message from their provider about CRC screening and should follow a link to be screened.
62217236|NCT05281159|EXPERIMENTAL|"Risk Information"|This group will receive an SMS text message highlighting their risk for CRC.
62217237|NCT05281159|EXPERIMENTAL|"Risk Information + Action"|This group will receive an SMS message highlighting their risk for CRC and the importance of taking quick action.
62411358|NCT05218096|EXPERIMENTAL|ALXN2050: 180 mg|Participants will receive ALXN2050.
62411359|NCT05218096|EXPERIMENTAL|ALXN2050: 120 mg|Participants will receive ALXN2050.
62411360|NCT05218096|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo followed by ALXN2050.
62217238|NCT00377442|EXPERIMENTAL|1|
62217239|NCT00377442|EXPERIMENTAL|2|
62217240|NCT00377442|EXPERIMENTAL|3|
62217241|NCT06406179|NO_INTERVENTION|Group I : routine group|patients will follow a standard clinical follow-up based on kidney allograft function (serum creatinine, estimated glomerular filtration rate (eGFR), proteinuria) and a surveillance allograft biopsy performed at 3 and 12 months after transplantation (M3 and M12) and for clinical indication whenever considered necessary by the clinician (CI), on the basis of 3 CI visits maximum expected per patient between D0 and M18 The standard of care comprises two biopsy cores: one is dedicated to histology. The paraffin-embedded core dedicated to SOC histology will be used for gene expression profiling and digital pathology imaging after SOC procedures .
62217242|NCT06406179|EXPERIMENTAL|Group II: dd-cfDNA-guided|"Patients will follow a dd-cfDNA-guided strategy based on dd-cfDNA levels in the blood associated with relevant clinical data on the basis of its detection and prediction capacities for rejection at M3, M12 and during visits for clinical indication (3 CI visits maximum expected per patient between D0 and M18 as experienced in the EU-TRAIN Impact clinical study to be analyzed in the context of the AI-CARE trial) to decide whether a biopsy is performed within the first 18 months of follow-up.~Patients will be classified in High risk and Low risk depending on the dd-cfDNA integrative report generated by PARCC INSERM UMR 970 after centralization of dd-cfDNA results.~like in Group I, the standard of care comprises two biopsy cores: one is dedicated to histology. The paraffin-embedded core dedicated to SOC histology will be used for gene expression profiling and digital pathology imaging after SOC procedures in group II high-risk patients."
62411361|NCT00329758|ACTIVE_COMPARATOR|1|
62411362|NCT00329758|PLACEBO_COMPARATOR|2|
62411363|NCT05677763|EXPERIMENTAL|BV-12|Subjects will receive OM-85 treatment for 12 consecutive months. (10 days per month)
62411364|NCT05677763|EXPERIMENTAL|BV-3|Subjects will receive OM-85 treatment for 3 consecutive months, followed by matching placebo for 9 consecutive months. (10 days per month)
62411365|NCT05677763|PLACEBO_COMPARATOR|Placebo|Subjects will receive matching placebo for 12 consecutive months. (10 days per month)
62217243|NCT06609369|EXPERIMENTAL|Experimental health intervention|Experimental health intervention and varenicline starting 4 weeks before and continuing for 4 weeks after a target quit date for a total of 8 weeks
62217244|NCT06609369|ACTIVE_COMPARATOR|Control health intervention|Control health intervention and varenicline starting 4 weeks before and continuing for 4 weeks after a target quit date for a total of 8 weeks
62217245|NCT06610955|ACTIVE_COMPARATOR|High intensity interval training exercise group|After a 10 minutes warm up exercise, participants will exercise with a bicycle ergometry device at 80% of their maximum heart rate for 4 minutes, and the active recovery period will be 3 minutes (4x4 minutes). During the recovery period, the participant will exercise with the Ergoline bicycle ergometry system for 4 sets at 60% of their maximum heart rate for 3 minutes. A total of 45 minutes exercise session will be completed with a 10 minutes cool down exercise. Exercise will be done 5 days a week for a total of 8 weeks. In the first 4 weeks, exercise will be done at 80% intensity, and in the following weeks, the exercise intensity will be increased by 5% each week, respectively, to 85%, 90%, 95%, and 100% in the last week.
62411366|NCT06308107|EXPERIMENTAL|Diazoxide|IV Diazoxide as additive to hypothermic hyperkalemic cardioplegia.
62411367|NCT01165424|EXPERIMENTAL|MFNS 50 μg device|"MFNS 50 μg spray device. The dose will be as follows:~* 3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning."
62411368|NCT02175472|ACTIVE_COMPARATOR|Spectramax light therapy device|Light therapy device which emits a specific bandwidth combination and intensity of light.
62411369|NCT02175472|SHAM_COMPARATOR|Control light device|Light therapy device, identical in appearance and operation to the Spectramax device, except that it produces a different bandwidth and intensity, which is not believed to produce a therapeutic response.
62793039|NCT06149871|EXPERIMENTAL|Intervention|The Experimental groups or physical activity groups were assigned to three groups based on their muscle mass: normal, probable sarcopenia, and sarcopenia groups. The volunteers were provided with instructions on individual physical activities to be practiced at home for 30 weeks, 2-5 days per week and 50 minutes per session. These physical activities consisted of flexibility exercise for 10 minutes, aerobic exercise for 20 minutes, and resistance exercise for 20 minutes, as outlined in supplement 1. The volunteers were instructed on exercise techniques and physical activities by either sports scientists or registered nurses, and caregivers such as relatives or staff from the social club for older adults were allowed to be present during practice.
62793040|NCT06149871|NO_INTERVENTION|Control|The control group did not receive any intervention apart from general suggestions and continued with their usual daily activities.
62793041|NCT01393249||ALL, Asparaginase, pancreatitis|Patients that have been scanned and have had blood tests
62021637|NCT03041415|ACTIVE_COMPARATOR|ALED Alone Physical Activity Program|"* The Active Living Every Day (ALED) comprehensive 12-week PA training and support program is appropriate for delivery by trained instructors from diverse backgrounds.~* Participants are taught self-regulatory skills aimed at increasing and sustaining regular physical activities such as walking."
62021638|NCT03041415|EXPERIMENTAL|ALED + Our Voice PA Program|"* The ALED physical activity program is combined with the Our Voice citizen science engagement program, which teaches participants how to assess the barriers and enablers of neighborhood physical activity using a simple mobile app.~* Residents then share their data and build consensus around major barriers and potential solutions, which they share with local decision makers."
62021639|NCT01162265||Contacts|Contacts of active cases of tuberculosis
62021640|NCT01162265||new entrants|new entrants from high incidence (\>40/100000) countries.
62021641|NCT02281006|EXPERIMENTAL|Treated ear|Trans-tympanic injection of a sodium thiosulfate gel
62217246|NCT06610955|ACTIVE_COMPARATOR|Moderate intensity continuous exercise group|Following a 10 minutes warm up exercise, participants will exercise continuously for 30 minutes at 65% of their maximum heart rate with the Ergoline bicycle ergometry system. A 5 minutes cool down exercise will end the 45 minutes exercise session. The exercise duration is 5 days a week for a total of 8 weeks.
62217247|NCT01129544|EXPERIMENTAL|Gene Transfer|open label single arm study
62217248|NCT02231801||Mother-Infant Dyad|Skin-to-skin holding of preterm infants by their mothers
62217249|NCT06114316|NO_INTERVENTION|control|The control group continued to receive routine treatment (pharmacotherapy and psychoeducation) and follow-up in the Alcohol and Substance Addiction Treatment Center, and no intervention was made.
62411370|NCT03035500|EXPERIMENTAL|Supportive Care (long-term follow-up)|Patients undergo long-term follow-up and receive a written survivorship care plan including comprehensive health evaluation and health education beginning 1 year post surgery.
62793042|NCT04311125|ACTIVE_COMPARATOR|total hip arthroplasty via the mini posterior approach|total hip arthroplasty via the mini posterior approach. This approach was first described by Kocher and Langenbeck and later modified by Gibson in 1950. There is a convex incision centered on the posterior rim of the major trochanter. The incision follows the curve of the buttock and at the height of the posterior lip of the major trochanter, it is peripherally oriented along the posterior outer surface of the femur. The major gluteus is divided along the muscle fibers. Guiding sutures are inserted into the tendon mass of the hip rotor muscles just prior to their origin on the major trochanter and dissected to expose and subsequently retract the posterior hip capsule.
62021642|NCT02281006|NO_INTERVENTION|Control ear|No intervention
62021643|NCT03349710|EXPERIMENTAL|Arm A|Cohort 1
62021644|NCT03349710|EXPERIMENTAL|Arm B|Cohort 1
62021645|NCT03349710|EXPERIMENTAL|Arm C|Cohort 2
62021646|NCT03349710|EXPERIMENTAL|Arm D|Cohort 2
62021647|NCT03926182|EXPERIMENTAL|Fasted AST2818 tablets following a period of fasting|
62021648|NCT03926182|EXPERIMENTAL|High-fat meal AST2818 tablets following a high-fat meal|
62411371|NCT04139642||Group AB|A block randomization scheme by clinic type will be used to assign which clinics receive the Balance+Weight device in the first 9 months and which clinics receive the Balance+Weight device in the second 9 months. The block randomization scheme is proposed instead of simple randomization because of the expected variation between clinics in the types of patients they see. At the 9-month point, OSU personnel will go to every site to reprogram each device from Balance+Weight mode to Weight Only mode or vice versa, and to move the immediate feedback kiosks to the new Balance+Weight sites.
62411372|NCT04139642||Group BA|A block randomization scheme by clinic type will be used to assign which clinics receive the Balance+Weight device in the first 9 months and which clinics receive the Balance+Weight device in the second 9 months. The block randomization scheme is proposed instead of simple randomization because of the expected variation between clinics in the types of patients they see. At the 9-month point, OSU personnel will go to every site to reprogram each device from Balance+Weight mode to Weight Only mode or vice versa, and to move the immediate feedback kiosks to the new Balance+Weight sites.
62021649|NCT03498183|EXPERIMENTAL|ARM experimental|All the patients will have MIBI-Tc99m/Iodine-123 . Following the injections they will have a scintigraphy.
62021650|NCT06572566||Cadmium exceeding standard group|The urine cadmium level exceeding 5 μg/g creatinine for two consecutive times.
62217250|NCT06114316|ACTIVE_COMPARATOR|experimental|"In the first step, the stimuli that led the individuals in the experimental group to drink alcohol were assessed, and the conceptual-theoretical-experimental (CTE) framework of the study was created. The personal behaviors that could be related to recurrence (physiological, self-concept, role function, and mutual commitment) and the stimuli that caused recurrence (focal and affecting) were assessed, objectives were determined, and nursing interventions were carried out in line with these objectives. The interventions planned for diagnosing ineffective coping were selected according to the patients' needs among the support coping interventions under the title of the behavioral area in the Nursing Intervention Classification (NIC). A total of 10 individual interviews were made twice a week for about 45 to 60 minutes. The interviews were evaluated by determining the area specific Nursing outcome classification (NOC) (self respect, social support, mood management, role performance)."
62411373|NCT01421524|EXPERIMENTAL|CC-122 MM-2|A new MM cohort (MM-2) will be enrolled in order to evaluate tolerability, safety and preliminary efficacy of the CC-122 formulated capsule given on an intermittent schedule (5/7 days per week) in 2 parallel dose escalation cohorts (MM-2a and MM-2b, respectively) (DEX) in Pomalidomide naïve subjects
62411374|NCT01421524|EXPERIMENTAL|CC-122- DLBCL-2|A new DLBCL cohort (DLBCL-2) in order to evaluate intermittent schedules of CC-122 (5 continuous days out of 7 days per week \[5/7 days\] and/or 21 continuous days out of 28 days per cycle \[21/28 days\]). Doses to be explored include 4 mg and 5 mg on an intermittent schedule using the 3+3 design described in Part A in order to establish an MTD for the intermittent dosing schedules. Following dose escalation, one or more intermittent dosing schedules may be expanded at or below the new intermittent schedule MTD in at least 20 total subjects per dosing schedule.
62021651|NCT06572566||healthy control group|Urine cadmium ≤ 5 μg/g creatinine.
62021652|NCT02627677|EXPERIMENTAL|Cohort A: Ponatinib 30 mg|Ponatinib 30 mg, tablets, orally, once daily (QD) until achievement of major molecular response (MMR) up to 12 months. Once MMR was achieved, participants received reduced dose of ponatinib 15 mg orally once daily up to 42 months.
62411375|NCT01421524|EXPERIMENTAL|CC-122- GBM-2|A new GBM cohort (GBM-2) in order to evaluate doses of CC-122 above the 3 mg QD MTD determined in all comers in Part A. CC-122 dose will increase in 1 mg increments starting with 4 mg daily on a continuous schedule using the 3+3 design described in Part A in order to establish an MTD specific for GBM subjects. Following dose escalation, the cohort will be expanded at or below the new MTD in up to 20 total subjects.
62411376|NCT01421524|EXPERIMENTAL|Primary Central Nervous System Lymphoma (PCNSL)|During dose expansion of selected intermittent schedules, an additional cohort of up to 10 subjects with PCNSL will also be explored at the same dose and schedule as DLBCL to confirm some safety and preliminary efficacy signal
62411377|NCT01040468|ACTIVE_COMPARATOR|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss
62411378|NCT01040468|ACTIVE_COMPARATOR|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss
62411379|NCT01040468|ACTIVE_COMPARATOR|Intensive Lifestyle Modification|Lifestyle intervention for weight loss
62411380|NCT05965323|EXPERIMENTAL|Intervention|The students in this arm will receive comic books and their parents videos on the benefits of preventive measures of COVID-19
62411381|NCT06541561|EXPERIMENTAL|TEAS group|"Patients who meet the enrollment criteria will be randomized 1:1 to either the transcutaneous electrical acupoint stimulation (TEAS) or the sham groups. In the TEAS group, the acupoints are bilateral neiguan (PC6) and Zusanli(ST 36) acupoints.~Patients will receive 30min TEAS before anesthesia until be discharged from the post anaesthesia care unit (PACU). The same treatment for 30 min will be performed on the 1st, 2nd and 3rd days after surgery. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient."
62411382|NCT06541561|SHAM_COMPARATOR|sham group|Patients in the sham group will receive electrode attachment but without stimulation.
62411383|NCT06650644|EXPERIMENTAL|Test food group|Food name: Lactococcus lactis KD10
62411384|NCT06650644|PLACEBO_COMPARATOR|Control food group|Food name: Placebo of Lactococcus lactis KD10
62585674|NCT01068210|EXPERIMENTAL|Resistance Training|A customized and supervised resistance exercise training program that will last 4 months (16 weeks). Resistance training will be performed on stationary weight machines, modification in equipment may be made by Exercise Physiologist. Patients will be progressively trained to perform two to three sets of 75-85% of maximal strength The participant will be trained to perform different resistance exercise, alternating between lower and upper body muscle groups. The exercise program will consist of three supervised sessions per week. Each session will last approximately 30-60 minutes.
62021653|NCT02627677|EXPERIMENTAL|Cohort B: Ponatinib 15 mg|Ponatinib 15 mg, tablets, orally, QD until achievement of MMR up to 12 months. Once MMR was achieved, participants received reduced dose of ponatinib 15 mg orally once daily up to 45 months.
62021654|NCT02627677|ACTIVE_COMPARATOR|Cohort C: Nilotinib 400 mg|Nilotinib 400 mg, tablets, orally, twice daily up to approximately 42 months.
62793043|NCT04311125|ACTIVE_COMPARATOR|THR via the anterior approach without traction table|The anterior approach is a modification of the classic Smith- Peterson anterior hip approach as described by Berend et al in 2009 \[7\]. This approach utilizes the intermuscular plane between the tendon fascia lata and the sartorius muscle, and laterally repairs the fibers of the rectus femur to expose and enclose the anterior pubic joint. A surgical traction table may be used during surgery.
62793044|NCT04311125|ACTIVE_COMPARATOR|THR via the anterior approach with a traction table|The anterior approach is a modification of the classic Smith- Peterson anterior hip approach as described by Berend et al in 2009 \[7\]. This approach utilizes the intermuscular plane between the tendon fascia lata and the sartorius muscle, and laterally repairs the fibers of the rectus femur to expose and enclose the anterior pubic joint. A surgical traction table may be used during surgery.
62217251|NCT02755051|EXPERIMENTAL|CBT-CI-A Therapy|Participants in this group receive Cognitive Behavioral Therapy for children with Chronic Insomnia and Autism Spectrum Disorder (CBT-CI-A)
62217252|NCT06233344|EXPERIMENTAL|Mindfulness-assisted psilocybin therapy|8 weeks of mindfulness training plus one 25mg dose of psilocybin
62793045|NCT01694056|EXPERIMENTAL|Soy protein diet|High mixed protein diet (20 en%) with 25gr of soy protein per day
62021655|NCT05039268|ACTIVE_COMPARATOR|15mg Dose Group|Participants will receive a fixed dose regimen of five doses of 15mg.
62021656|NCT05039268|ACTIVE_COMPARATOR|30mg Dose Group|Participants will receive a fixed dose regimen of five doses of 30mg.
62021657|NCT01316367|ACTIVE_COMPARATOR|Conventional Health Promotion Education (CHPE).|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
62021658|NCT01316367|EXPERIMENTAL|PRECEDE HPE model|
62021659|NCT02811562|ACTIVE_COMPARATOR|fiberoptic bronchoscope|Tracheal intubation in manikin using fiberoptic bronchoscope
62021660|NCT02811562|EXPERIMENTAL|fiberoptic bronchoscope with pentax-airwayscope|Tracheal intubation in manikin using fiberoptic bronchoscope with pentax-airwayscope
62217253|NCT06233344|ACTIVE_COMPARATOR|Psilocybin only|One 25mg dose of psilocybin
62021661|NCT04135053|EXPERIMENTAL|Challenge|Challenge participants will inoculated intranasallly with reconstituted lyophilised Neisseria lactamica (lyoNlac). The initial dose will be 10\^5 colony-forming units (CFU) and will be escalated or de-escalated by 1/2 - 1 log depending upon the proportion of volunteers colonies with viable N. lactamica.
62217254|NCT02552368|EXPERIMENTAL|IpsiHand|IpsiHand is a device which includes a robotic glove that you wear on your hand and a headset that you wear on your head. The headset picks up your thoughts and sends them to the robotic glove, to control opening and closing of your hand.
62217255|NCT02715349|EXPERIMENTAL|Psychoeducation|3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
62217256|NCT02715349|NO_INTERVENTION|Control|Family and patient do not receive psychoeducation, but still receive standard hospital services for schizophrenia.
62411385|NCT04481399|EXPERIMENTAL|FSI-ECD|The Family Strengthening Intervention for Early Childhood Development (FSI-ECD) is an evidence-based home-visiting behavioral intervention for vulnerable families with children aged 6-36 months. The FSI-ECD targets improving parental emotion regulation and parent-child interactions to improve parental mental health and child development outcomes and reduce family violence. The FSI-ECD will be delivered in weekly 90-minute home visiting sessions for 12 consecutive weeks.
62411386|NCT04481399|OTHER|Control|The control is standard maternal and child health home visiting delivered by community health workers. Families will receive three 90-minute home visiting educational sessions focused on nutrition, hygiene, and post-natal care.
62411387|NCT04534296|EXPERIMENTAL|Early Mobilization Group (EM group)|Early mobilization will be performed in this arm. Critically ill children will be assessed for appropriate activity within 24 hours of intubation. When the safe criteria is met, early mobilization goals will be set according to the children's clinical conditions, developmental maturity, strength and endurance. The detailed mobilization activities include bed repositioning，passive or active range of motion and stretching exercises, passive or active respiratory muscle strengthening, sitting in bed, transfer from lying to sitting at edge of bed. Progressive mobilization goals will be individualized for each subject daily.
62411388|NCT04534296|ACTIVE_COMPARATOR|Routine Care Group (RC group)|Routine care strategy without early mobilization will be performed in this arm. It includes the clinical status management, spontaneous breathing trials, choice of sedation and analgesia and routine nursing care including repositioning every 2 hours and bed head elevation.
62793046|NCT01694056|ACTIVE_COMPARATOR|Control diet|High mixed protein diet (20 en%)
62793047|NCT02478099|EXPERIMENTAL|1 Treatment with MPDL3280A|Treatment with MPDL3280A
62793048|NCT03787550||Model building group|The data from the patients in the model building group will be used to build the population PK/PD model. Two to six blood samples will be collected during at least one dose interval at the steady-state, including one sample from the start of ECMO and one at the end of ECMO.
62793049|NCT03787550||Model validation group|The data from the patients in the model building group will be used to build the population PK/PD model. Two to three blood samples will be collected during at least one dose interval at the steady-state, including one sample from the start of ECMO and one at the end of ECMO.
62411389|NCT06567834|EXPERIMENTAL|Tecnis Symfony Optiblue|Tecnis Symfony Optiblue/Tecnis Symfony Optiblue Toric (ZXR00V/ZXW150)
62793050|NCT06284655|EXPERIMENTAL|Educational intervention|Patients randomized to the intervention group will start with peer co-led group-based psychoeducation, combined with digital video- and written information.
62793051|NCT06284655|ACTIVE_COMPARATOR|Control group|The control group will receive treatment as usual after randomization
62411390|NCT06567834|ACTIVE_COMPARATOR|Tecnis Symfony|Tecnis Symfony/Tecnis Symfony Toric (ZXR00/ZXT150)
62793052|NCT06726278|EXPERIMENTAL|Group A|Participants in this group will receive Misoprostol 400 µg, administered orally. This arm is designed to evaluate the efficacy and safety of Misoprostol for the intended clinical outcome.
62793053|NCT06726278|PLACEBO_COMPARATOR|Group B|Participants in this group will receive a placebo that matches the Misoprostol formulation in appearance, but contains no active ingredients. This arm serves as a control to compare the effects of Misoprostol with a non-active substance.
62411391|NCT06303687|EXPERIMENTAL|VR-PAT|Participant wears the Pico Neo 3 Pro Eye headset and actively plays the VR-PAT game while also wearing the fNIRS, during their clinically scheduled burn dressing change.
62411392|NCT06303687|NO_INTERVENTION|Control|Participant wears the fNIRS and can engage in standard distraction techniques, during their clinically scheduled burn dressing change.
62411393|NCT03936946|EXPERIMENTAL|Group 1--October Start Audio Content 1|This group will listen to audio content 1 daily for 28 days beginning in October, and then will receive no further intervention
62793054|NCT00930930|EXPERIMENTAL|Cisplatin and Paclitaxel + RAD001|Cisplatin 25 mg/m2 IV weekly + RAD001 5 mg PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + RAD001 5 mg PO daily for 11 weeks
62793055|NCT00930930|ACTIVE_COMPARATOR|Cisplatin and Paclitaxel + Placebo|Cisplatin 25 mg/m2 IV weekly + placebo PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + placebo PO daily for 11 weeks
62411394|NCT03936946|OTHER|Group 2--November Start Audio Content 1|This group will not be assigned to any interventions during the first month of the trial and will act as a passive control group at that time. They will be assigned to listen to audio content 1 daily for 28 days beginning in November.
62217257|NCT03950050|EXPERIMENTAL|Ambroxol|"Ambroxol therapy will be dosed up to 600 mg/day divided to twice a day starting 150 mg for the first month, 300 mg for the following month and 600 mg for the following month.~The study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations."
62411395|NCT03936946|SHAM_COMPARATOR|Group 3--October Start Audio Content 2|This group will listen to audio content 2 daily for 28 days beginning in October, and then will receive no further intervention.
62411396|NCT01469845|ACTIVE_COMPARATOR|hypertonic saline and usual care|
62411397|NCT01469845|ACTIVE_COMPARATOR|usual care (oxygen therapy)|
62411398|NCT01264328|EXPERIMENTAL|Panitumumab + Paclitaxel|Treatment consisted of intravenous panitumumab 6 mg/kg q2w, administered in one hour the first day and in 30 minutes thereafter (if no infusional reaction was observed) plus intravenous paclitaxel 80 mg/m2 weekly administered one hour after panitumumab in one hour infusion, until progression or unacceptable toxicity. Panitumumab does not require prophylactic premedication from the first infusion. Paclitaxel was administered with: dexamethasone 10 mg, diphenhydramine 30 mg and antiH2 (cimetidine 300 mg or ranitidine 50 mg). Dose modifications of paclitaxel included 4.8 mg/kg (80% of the initial dose) and 3.6 mg/kg (60%) when recovered from a grade 3-4 skin toxicity to grade ≤2. Continuing paclitaxel on the day of the planned infusion required no grade ≥2 mucositis and hematologic recovery with an absolute neutrophil count ≥1,500/ml and a platelet count ≥75,000.
62411399|NCT03415412|EXPERIMENTAL|Group CU (Clearfil Universal)|Clearfil Univesal Bond (Kuraray Dental, New York, United States of America), adhesive system
62411400|NCT03415412|EXPERIMENTAL|Group IU (Ibond Universal)|IBond Universal (Heraeus Kulzer GmbH, Hanau, Germany), adhesive system
62411401|NCT03415412|EXPERIMENTAL|Group GP (G-Premio)|G-Premio Bond (GC Coorporation, Tokyo, Japan), adhesive system
62217258|NCT03063333|EXPERIMENTAL|Coping-oriented hypnosis|
62217259|NCT03063333|PLACEBO_COMPARATOR|Neutral hypnosis|
62411402|NCT05560802|EXPERIMENTAL|Labour care guide|According to WHO guidelines
62411403|NCT05560802|NO_INTERVENTION|Standard care|Standard delivery care in Sweden
62411404|NCT05645562|EXPERIMENTAL|Intervention group|Intervention group will receive a pain neuroscience education program (once time per month, during 4 months). This program will include information about biological, psychological and perceptual aspects of pain in the sport context.
62411405|NCT05645562|ACTIVE_COMPARATOR|Control group|The control group will receive a self-care education program (once time per month, during 4 months). This program will include information about health habits in the sport.
62411406|NCT01140815|ACTIVE_COMPARATOR|Total|The Smith and Nephew Total Knee System
62793056|NCT03744949|EXPERIMENTAL|Remifentanil dose 0.5 ug/kg|Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
62793057|NCT03744949|EXPERIMENTAL|Remifentnil dose 1 ug/kg|Remifentanil will be given (dosage of 1.0 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
62793058|NCT03744949|EXPERIMENTAL|Remifentanil dose 1.5 ug/kg|Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
62217260|NCT03063333|NO_INTERVENTION|current treatment only|
62793059|NCT03744949|EXPERIMENTAL|Remifentanil dose 2 ug/kg|Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
62793060|NCT06166966|EXPERIMENTAL|flipped training|flipped training
62793061|NCT06166966|EXPERIMENTAL|Course success|Course success
62793062|NCT00994006|ACTIVE_COMPARATOR|Magnesium oxide tables|Subjects will be instructed to take Magnox 520 qd
62793063|NCT00994006|ACTIVE_COMPARATOR|Magnesium citrate tablets|Subjects will be instructed to take magnesium diasporal tablets t.i.d.
62793064|NCT00640848|EXPERIMENTAL|1|
62793065|NCT00640848|EXPERIMENTAL|2|
62793066|NCT00640848|EXPERIMENTAL|3|
62217261|NCT06245148||Hypothermia|
62793067|NCT00640848|EXPERIMENTAL|4|
62793068|NCT00640848|EXPERIMENTAL|5|
62793069|NCT05117190|OTHER|Facial Deformity|Face not the normal shape because of injury or illness.
62793070|NCT01758913|EXPERIMENTAL|Ibuprofen|Infant who was assigned to ibuprofen, an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 hours respectively as a course was given.
62793071|NCT01582711|ACTIVE_COMPARATOR|3HP Directly Observed Therapy (DOT)|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) under Directly Observed Therapy (DOT)
62793072|NCT01582711|EXPERIMENTAL|3HP Self Administered Therapy (SAT)|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) as patient Self Administered Therapy (SAT)
62793073|NCT01582711|EXPERIMENTAL|3HP SAT with SMS Reminders|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) as patient Self Administered Therapy (SAT). In addition, patient receives phone Short Message Service (SMS) reminders weekly.
62217262|NCT06245148||Normothermia|
62411407|NCT01140815|EXPERIMENTAL|Deuce|The Journey Deuce Bicompartmental Knee System
62793074|NCT06119113|ACTIVE_COMPARATOR|Group 1 (Vicryl suture™(Polyglactin 910))|The group whose skin incision was closed with Vicryl suture™ (Polyglactin 910) from patients who had cesarean section for the first time
62793075|NCT06119113|ACTIVE_COMPARATOR|Group 2 (Prolene suture™(polypropylene))|The group whose skin incision was closed with Prolene suture™ (polypropylene) from patients who had cesarean section for the first time
62793076|NCT06119113|ACTIVE_COMPARATOR|Group 3 (Monocryl suture™ (Polyglecaprone 25))|The group whose skin incision was closed with Tekmon suture™ (Polyglecaprone 25) from patients who had cesarean section for the first time
62411408|NCT03515681|EXPERIMENTAL|Intervention|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
62411409|NCT03515681|NO_INTERVENTION|Control|Subjects randomized to the control arm will receive the messages regarding their kiosk blood pressure levels currently provided by higi to kiosk users. These messages are provided at the kiosk at the time of the blood pressure measurement (no text messages).
62411410|NCT01526707|EXPERIMENTAL|inhaled steroid|inhaled steroid treatment for 7 days
62411411|NCT05884866|ACTIVE_COMPARATOR|Dapagliflozin|1 tablet Dapagliflozin 10 mg + 1 capsule Balcinrenone 50mg matching Placebo + 1 capsule Balcinrenone 100 mg matching Placebo
62793077|NCT03472326|EXPERIMENTAL|Part 1 Sentinel Cohort 1: GS-9131 60 mg|Treatment experienced participants will receive GS-9131 60 mg in addition to their current failing ARV regimen for a period of 10 days.
62793078|NCT03472326|EXPERIMENTAL|Part 1 Sentinel Cohort 2: GS-9131 180 mg|Treatment experienced participants will receive GS-9131 180 mg in addition to their current failing ARV regimen for a period of 14 days.
62793079|NCT03472326|EXPERIMENTAL|Part 1: Randomized Cohort|Participants will be randomized in 1:1:1:1 so as to receive GS-9131 in 3 active dose levels up to a maximum of 180 mg or Placebo to match GS-9131 in addition to their current failing ARV regimen for a period of 14 days in Part 1.
62793080|NCT03472326|EXPERIMENTAL|Part 2 Sentinel Cohort 1: GS-9131 + BIC + DRV + RTV|Participants who complete dosing in Sentinel Cohort 1 of Part 1 and show a reduction in plasma HIV RNA \> 0.5 log10 from their pre-GS-9131 baseline value at Day 11 and discontinue their current failing regimen will receive an optimized regimen consisting of GS-9131 60 mg + bictegravir (BIC) 30 mg + darunavir (DRV) 800 mg + ritonavir (RTV) 100 mg for a period of 24 weeks. After Week 24, participants will be given the option to participate in an open label extension and receive GS-9131 60 mg + BIC 75 mg + tenofovir alafenamide (TAF) 25 mg, for an additional 24 weeks or until Gilead Sciences elects to discontinue the study drug in that country, whichever occurs first.
62793081|NCT03472326|EXPERIMENTAL|Part 2 Sentinel Cohort 2: GS-9131 + BIC + TAF|Participants who complete dosing in Sentinel Cohort 2 of Part 1 and show a reduction in plasma HIV RNA \> 0.5 log10 from their pre-GS-9131 baseline value at Day 15 and discontinue their current failing regimen will receive an optimized regimen consisting of GS-9131 180 mg + BIC 75 mg + TAF 25 mg, for a period of 24 weeks. After Week 24, participants will be given the option to participate in an open label extension and receive GS-9131 180 mg + BIC 75 mg + TAF 25 mg, for an additional 24 weeks or until Gilead Sciences elects to discontinue the study drug in that country, whichever occurs first.
62793082|NCT06010342|EXPERIMENTAL|Single arm, Open label|Participants will receive TL118 capsule taken orally with (preferred) or without food, 252 mg twice daily, 28 days for a cycle.
62217263|NCT06312527|EXPERIMENTAL|Silicone dressing|Apply silicone dressing after wound completely healed. Changing the dressing sheet every 7 days by Close the silicone cover for 10 weeks.
62217264|NCT06312527|NO_INTERVENTION|No intervention|Do not apply silicone dressing
62217265|NCT01624103|EXPERIMENTAL|Elderly (32 mL LA volume)|Population over age of 65 undergoing upper limb surgery using US-SCB receiving 32 ml of LA (50:50 mixture of 0.5% levobupivacaine and 2% lidocaine).
62793083|NCT05160896|EXPERIMENTAL|MSS or MSI-L/pMMR, RAS and BRAF are both wild type|"the primary lesion is located in the left colorectal:~SALIRI plus cetuximab~One cycle (cycle duration 14 days) consists of:~Raltitrexed 2 mg/m² iv, 15min. day 1 Irinotecan 180 mg/m² iv, 30 - 90 min. day 1 cetuximab 500 mg/ m² , iv, day 1~the primary lesion is located in the right colorectal:~SALIRI plus bevacizumab~One cycle (cycle duration 14 days) consists of:~Raltitrexed 2 mg/m² iv, 15min. day 1 Irinotecan 180 mg/m² iv, 30 - 90 min. day 1 Bevacizumab 5 mg/kg, iv, day 1"
62793084|NCT03910972|EXPERIMENTAL|Part A, Group A (Sm-TSP-2/Alhydrogel 10 mcg)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, delivered by IM injection on study days 0, 56, and 12; 10 mcg dose
62793085|NCT03910972|EXPERIMENTAL|Part A, Group B (Sm-TSP-2/Alhydrogel 10 mcg + AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine plus AP 10-701, delivered by IM injection on study days 0, 56, and 12; 10 mcg dose
62793086|NCT03910972|EXPERIMENTAL|Part A, Group C (Sm-TSP-2/Alhydrogel 30 mcg)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, delivered by IM injection on study days 0, 56, and 12; 30 mcg dose
62793087|NCT03910972|EXPERIMENTAL|Part A, Group D (Sm-TSP-2/Alhydrogel 30 mcg + AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine plus AP 10-701, delivered by IM injection on study days 0, 56, and 12; 30 mcg dose
62793088|NCT03910972|EXPERIMENTAL|Part A, Group E (Sm-TSP-2/Alhydrogel 100 mcg)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, delivered by IM injection on study days 0, 56, and 12; 100 mcg dose
62793089|NCT03910972|EXPERIMENTAL|Part A, Group F (Sm-TSP-2/Alhydrogel 100 mcg + AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine plus AP 10-701, delivered by IM injection on study days 0, 56, and 12; 100 mcg dose
62793090|NCT03910972|ACTIVE_COMPARATOR|Part A, Group G (HBV)|Hepatitis B Vaccine
62793091|NCT03910972|EXPERIMENTAL|Part B, Group H (Sm-TSP-2/Alhydrogel +/- AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, with or without AP 10-701, dose and formulation determined in Part A
62411412|NCT05884866|EXPERIMENTAL|Balcinrenone|1 capsule Balcinrenone 50mg + 1 capsule Balcinrenone 100 mg + 1 tablet Dapagliflozin matching Placebo
62411413|NCT05884866|EXPERIMENTAL|Dapagliflozin + Balcinrenone|1 tablet Dapagliflozin 10mg + 1 capsule Balcinrenone 50mg + 1 capsule Balcinrenone 100 mg
62411414|NCT05884866|PLACEBO_COMPARATOR|Placebo|1 tablet Dapagliflozin matching Placebo + 1 capsule Balcinrenone 50mg matching Placebo + 1 capsule Balcinrenone 100 mg matching Placebo
62411415|NCT01778309|EXPERIMENTAL|n-acetylcysteine/placebo supplementation|n-acetylcysteine supplementation, orally in three daily dosages, at 20 mg/kg/day, daily for eight days after exercise placebo, orally in three daily dosages, content: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder.
62411416|NCT01650142||NF1GeneModif Cohort|Adult patients with neurofibromatosis 1
62411417|NCT03868176||Experimental: reminder SMS before appointment|SMS before appointment detailing the date of consultation and exams to be performed before
62411418|NCT03868176||Active comparator: standard of care|
62411419|NCT02309541|EXPERIMENTAL|Firmware N|New feedback canceller algorithm
62411420|NCT02309541|ACTIVE_COMPARATOR|Firmware R|Current feedback canceller algorithm (reference)
62411421|NCT02525380|EXPERIMENTAL|Doxorubicin loadeing-DC Bead(Device)|"DC Bead comprises hydrogel microspheres that are biocompatible, hydrophilic, non resorbable, precisely calibrated and capable of loading doxorubicin.~DC Bead is produced from polyvinyl alcohol."
62411422|NCT02539329||patient|Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and positive for anti-FGFR3 antibodies. These patients will have Neurological assessment and Blood sample.
62411423|NCT02539329||control|Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and negative for anti-FGFR3 antibodies
62411424|NCT02825979|ACTIVE_COMPARATOR|Cryoballoon-based PVI|"Sinus rhythm control via a pulmonary vein isolation (PVI) (first-line) procedure utilizing the the Arctic Front Cryoballoon Procedure."
62411425|NCT02825979|ACTIVE_COMPARATOR|Anti-Arrhythmic Drug Therapy|"Sinus rhythm control via the use of anti-arrhythmic drug (AAD) therapy (first-line) based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF."
62411426|NCT05109403||LH post-trigger < 15 UI/l|Oocyte donors that present with LH levels \< 15UI/I, post trigger by agonists of GnRH
62793092|NCT03910972|ACTIVE_COMPARATOR|Part B, Group I (HBV)|Hepatitis B Vaccine
62793093|NCT02825524|EXPERIMENTAL|Endobiliary radiofrequency|
62793094|NCT05695885|EXPERIMENTAL|STEPS|14 session counseling targeting adult independence skills
62793095|NCT05695885|OTHER|Control|Services as usual
62793096|NCT04930900|EXPERIMENTAL|ARS-1 with URTI|ARS-1 with URTI
62411427|NCT05109403||LH post-trigger > 15 UI/l|Oocyte donors that present with LH levels \> 15UI/I, post trigger by agonists of GnRH
62411428|NCT03892902|EXPERIMENTAL|Treatment A (50 mg ACT-541468)|1 tablet of ACT-541468 50 mg + 1 tablet of ACT-541468 matching placebo + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period A.
62411429|NCT03892902|EXPERIMENTAL|Treatment B (100 mg ACT-541468)|2 tablets of ACT-541468 50 mg + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period B.
62411430|NCT03892902|EXPERIMENTAL|Treatment C (7.5 mg zopiclone)|2 tablets of ACT-541468 matching placebo + 1 capsule of zopiclone 7.5 mg administered in the evening on Days 1 and 4 of Treatment Period C. In the evenings of Days 2 and 3, subjects will receive placebo (i.e., 2 tablets of ACT-541468 matching placebo + zopiclone matching placebo).
62411431|NCT03892902|EXPERIMENTAL|Treatment D (placebo)|2 tablets of ACT-541468 matching placebo + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period D.
62411432|NCT02181634|EXPERIMENTAL|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel 125 mg/m² IV and Gemcitabine 1000 mg/m² on days 1, 8 and 15 every 28 days until progression or unacceptable toxicity.
62411433|NCT06005740|EXPERIMENTAL|Monotherapy Dose Dose Finding - Part 1|TORL-4-500 iv once every 3 weeks
62411434|NCT06005740|EXPERIMENTAL|Expansion as Monotherapy - Part 2|TORL-4-500 iv once every 3 weeks
62793097|NCT04930900|EXPERIMENTAL|ARS-1 without URTI|ARS-1 without URTI
62793098|NCT06245733|EXPERIMENTAL|Experimental Group|Participants who will receive the training
62793099|NCT06245733|NO_INTERVENTION|Control Group|participants who will not be interfered with
62021662|NCT03591744|EXPERIMENTAL|Treatment (daratumumab, bortezomib, chemotherapy)|Participants receive daratumumab IV on days 1, 8, 15, and 22, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 1 and 2. Participants then receive daratumumab IV on days 1, and 15, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 3 and 4. Courses repeat every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants may receive up to 8 courses at the discretion of treating physician.
62021663|NCT00788554|ACTIVE_COMPARATOR|1|
62021664|NCT00788554|ACTIVE_COMPARATOR|2|
62793100|NCT06401863|EXPERIMENTAL|Exposure to DDInteract tool in anticoagulated patients|This population will consist in outpatient clinics who treat oral anticoagulated patients where DDInteract has been implemented. This intervention is referred to as DDInteract tool exposure in anticoagulated patients. DDInteract may be accessed by clinicians to evaluate risk of harm from drug-drug interactions for patients on anticoagulants.
62793101|NCT06401863|NO_INTERVENTION|Standard of Care|This population will consist in outpatient clinics who treat oral anticoagulated patients where DDInteract has not yet been implemented.
62021665|NCT01964573|EXPERIMENTAL|Rotigotine group|
62411435|NCT04765345||Vision Cohort 1|"\~25 participants with the better eye Screening Visit visual acuity ETDRS letter score of 54 or more \[approximate Snellen equivalent 20/80 or better\] and visual field diameter 10 degrees or more in every meridian of the central field.~The better eye is defined as the eye with better Screening Visit ETDRS VA. If both eyes have the same VA (defined as the same Snellen equivalent), then the determination will be made at investigator discretion as the eye with better fixation or clearer ocular media to permit highest quality retinal imaging.~The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to or including the Screening Visit date."
62793102|NCT05363189||No venons augmentation|Retrospective group of patients who have not received venous augmentation during their operation.
62793103|NCT05363189||Venous augmentation|Retrospective group of patients who have received venous augmentation during their operation.
62793104|NCT05363189||ERAS protocol|Retrospective group operated according to the traditional ERAS (enhanced recovery after surgery) protocol
62793105|NCT05363189||Sahlgrenska recovery protocol|Prospective group operated according to the Sahlgrenska recovery protocol.
62793106|NCT03040674||Cell therapy treated|All patients/participants enrolled will undergo cell therapy
62793107|NCT00828230|EXPERIMENTAL|1|2mg rectal budesonide per day for 8 weeks
62793108|NCT00828230|PLACEBO_COMPARATOR|2|One application of placebo foam once daily for 8 weeks
62793109|NCT04379206||Men who have sex with men|MSM receiving a self-test kit with optional assistance
62793110|NCT04430504|EXPERIMENTAL|Telerehabilitation (TR)|Multidisciplinary, weekly video meetings, self-exercises at home, digital diary recordings, follow-up assessments
62217266|NCT01624103|EXPERIMENTAL|Elderly (20 ml LA volume)|Population over age of 65 undergoing upper limb surgery using US-SCB receiving 20 ml of LA (50:50 mixture of 0.5% levobupivacaine and 2% lidocaine).
62793111|NCT03796117|EXPERIMENTAL|Experimental Group 1: healthy young|Participants receive two interventions (Pulsed Current - PC, or Russian Current - RC) in a specific order, according to randomization. Evoked torque, discomfort level, current intensity, neuromuscular efficiency, clinical efficiency and fatigability level will be evaluated.
62021666|NCT01964573|PLACEBO_COMPARATOR|Placebo group|Placebo matched to rotigotine will be administered in the same way as within the Rotigotine group.
62411436|NCT04765345||Vision Cohort 2|"\~15 participants with the better eye Screening Visit visual acuity ETDRS letter score of 19-53 \[approximate Snellen equivalent 20/100 - 20/400\] or (visual acuity ETDRS letter score of 54 or more \[approximate Snellen equivalent 20/80 or better\] and visual field diameter less than 10 degrees in any meridian of the central field).~The better eye is defined as the eye with better Screening Visit ETDRS VA. If both eyes have the same VA (defined as the same Snellen equivalent), then the determination will be made at investigator discretion as the eye with better fixation or clearer ocular media to permit highest quality retinal imaging.~The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to or including the Screening Visit date."
62411437|NCT04234516|ACTIVE_COMPARATOR|Buprenorphine|Sublingual buprenorphine-naloxone films
62411438|NCT04234516|ACTIVE_COMPARATOR|Morphine|Oral morphine sulphate tablets
62411439|NCT03131466|EXPERIMENTAL|PRF Group|This group will undergo 42°C high-voltage pulsed radiofrequency treatment.
62411440|NCT03131466|ACTIVE_COMPARATOR|Nerve Block Group|This group will undergo nerve block treatment with steroid and local anesthesia.
62411441|NCT04274101||Nifurtimox|Patients treated with Nifurtimox from 1984 to 2017
62411442|NCT04274101||Benznidazole|Patients treated with Benznidazole from 1984 to 2017
62411443|NCT06519799|EXPERIMENTAL|Combination pill|This arm ( n = 50) is selected based on their contraception use, under the combination pill your menstruation and composition of menstrual blood is altered. In this arm all participants will wear all 5 menstrual products, 1 product per menstruation. The order of products will be randomized over this arm.
62411444|NCT06519799|EXPERIMENTAL|No-hormonal contracteption|This arm (n = 50) is selected based on the use of no hormonal contraception, to investigate a natural menstrual cycle. In this arm all participants will wear all 5 menstrual products, 1 product per menstruation. The order of products will be randomized over this arm.
62411445|NCT04639570|EXPERIMENTAL|KneuroKnits group|Participants in the KneuroKnits group
62411446|NCT00322530|ACTIVE_COMPARATOR|SLED|
62411447|NCT00322530|ACTIVE_COMPARATOR|CVVHD|
62411448|NCT00359073|ACTIVE_COMPARATOR|Montelukast|montelukast (10 mg everyday)
62411449|NCT00359073|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62411450|NCT06568874|EXPERIMENTAL|Exp Group|
62411451|NCT06568874|ACTIVE_COMPARATOR|Control Group|
62411452|NCT02985515|NO_INTERVENTION|Budesonide Nasal Irrigation|"30-day run-in course of budesonide nasal irrigation.~1-month supply of budesonide capsules, an 8-oz sinus rinse bottle, and a 1-month supply of commercially prepared isotonic salt packets.~Participants were instructed to dissolve 2 budesonide capsules (0.5mg per capsule) into the sinus rinse bottle along with the saline mixture and then irrigate both nasal cavities once daily."
62411453|NCT02985515|EXPERIMENTAL|Budesonide Nasal Irrigation + Smell Training|Budesonide nasal irrigation + smell training for 12 weeks
62411454|NCT02985515|NO_INTERVENTION|Controls|Baseline olfaction testing and rs-fMRI
62411455|NCT03657576|EXPERIMENTAL|C134 Treatment|All patients who enroll will receive C134 inoculation into their tumor (one time procedure with 1-5 inoculation sites)
62411456|NCT05887102|EXPERIMENTAL|PACHA program group|Pharmacists and women in the PACHA program group will receive the PACHA program component's.
62411457|NCT05887102|NO_INTERVENTION|Usual care group|Pharmacists and women in the Usual care group will provide/receive usual care.
62411458|NCT05898009|EXPERIMENTAL|BRCA2 mutation detection|
62411459|NCT01913769||Radiation therapy|Thoracic cancer patient s/p scheduled RT will be arranged to undergo Thallium-201 Myocardial Perfusion Study. The scheduled RT will be arranged by clinical judgments of radiation-oncologists. All of the patients will receive myocardial SPECT before and after the scheduled RT.
62585675|NCT01068210|EXPERIMENTAL|Combined Aerobic and Resistance Training|A customized and supervised endurance exercise training program that will last 4 months (16 weeks). The regimen will be tailored to the individual fitness level, and will be a combination of Arm A and Arm B, described above. At each session, the participant will complete aerobic training on a stationary bicycle and also resistance training using stationary weight machines. The exercise program will consist of three supervised sessions per week. Each session will last approximately 30-90 minutes.
62793112|NCT03796117|EXPERIMENTAL|Experimental Group 2: healthy young|Participants receive two interventions (Pulsed Current - PC, or Russian Current - RC) in a specific order, according to randomization. Evoked torque, discomfort level, current intensity, neuromuscular efficiency, clinical efficiency and fatigability level will be evaluated.
62217267|NCT04034446|EXPERIMENTAL|A|Single dose of CD19-CD22 CAR-T cells
62217268|NCT05042908|EXPERIMENTAL|LBL-003|Drug: LBL-003 injection ; Initial dose - MTD; Q2W
62217269|NCT04212273|EXPERIMENTAL|Diagnostic Sonazoid-CEUS and EOB-MRI|Patients with high risk of HCC having suspicious lesions on US will receive Sonazoid-CEUS and EOB-MRI examinations.
62217270|NCT05111054|EXPERIMENTAL|Low-Load|Acute resistance exercise performed at 30% 1RM
62217271|NCT05111054|ACTIVE_COMPARATOR|High-Load|Acute resistance exercise performed at 80% 1RM
62217272|NCT00615745|EXPERIMENTAL|Single Arm|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
62411460|NCT03855930||micturition induced PLP|"10 Patients with chronic post amputation micturition induced PLP.All subjects must fulfill all of the inclusion criteria and meet none of the exclusion criteria.~All patients will go through functional MRI study"
62411461|NCT03855930||non micturition induced PLP|10 Patients with chronic post amputation with PLP and without post amputation micturition induced PLP All subjects must fulfill all of the inclusion criteria and meet none of the exclusion criteria.All patients will go through functional MRI study
62411462|NCT03855930||healthy volunteers|10 healthy volunteers. All patients will go through functional MRI study
62793113|NCT03915314||POD group|POD group refers to the patients who were diagnosed to be delirious by the Confusion Assessment Method.
62793114|NCT03915314||Non-POD group|Non-POD refered to the patients who did not become delirious by the Confusion Assessment Method.
62793115|NCT02037334||Pregnancy|
62411463|NCT03880955||ReUnion RSA System|"Subject's joint has gross rotator cuff deficiency, a functional deltoid muscle and is anatomically and structurally suited to receive the implant and subject has one or more of the following:~* Painful, disabling joint disease of the shoulder resulting from degenerative arthritis or rheumatoid arthritis~* Failed previous shoulder joint replacement"
62793116|NCT06099561||Study group|Individuals with current severe, imminent and lethal self-harm with a history of at least two interventions without sufficient reduction of self-harm or suffering.
62793117|NCT01159015|EXPERIMENTAL|KetoNaph|KetoNaph Ophthalmic Solution
62793118|NCT01159015|PLACEBO_COMPARATOR|Vehicle|Vehicle of KetoNaph Ophthalmic Solution
62793119|NCT01942174|OTHER|Immediate group|"For these patients, the methotrexate treatment is initiated in the same time that the antipneumococcal vaccination by Prevenar13. A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination.~Interventions : biological/vaccine and drug"
62793120|NCT01942174|EXPERIMENTAL|period group|"Methotrexate treatment is initiated 1 month later the first antipneumococcal vaccination by Prevenar13.~A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination~Interventions : biological/vaccine and drug"
62793121|NCT05581459|EXPERIMENTAL|63 Hz vibration group|Vibration of 63 Hz frequency was applied.
62793122|NCT05581459|ACTIVE_COMPARATOR|42 Hz vibration group|Vibration of 42 Hz frequency was applied.
62793123|NCT05581459|SHAM_COMPARATOR|Sham vibration group|No actual vibration was applied.
62411464|NCT02152631|EXPERIMENTAL|Abemaciclib|200 milligrams (mg) abemaciclib administered, orally, every 12 hours plus best supportive care (BSC) on Days 1 to 28 (28 day cycles).
62411465|NCT02152631|ACTIVE_COMPARATOR|Erlotinib|150 mg erlotinib administered, orally, every 24 hours plus BSC on Days 1 to 28 (28 day cycles).
62411466|NCT06385821|EXPERIMENTAL|Grippol Quadrivalent|influenza quadrivalent inactivated subunit adjuvant vaccine
62411467|NCT06385821|ACTIVE_COMPARATOR|Grippol Plus|influenza trivalent inactivated polymer-subunit vaccine
62411468|NCT03916055|EXPERIMENTAL|Exposure and response prevention (ERP)|Therapist-guided and parent-guided internet-delivered exposure and response prevention (ERP)
62411469|NCT03916055|ACTIVE_COMPARATOR|Education on tics|Therapist-guided and parent-guided internet-delivered education on tics
62411470|NCT05863351|ACTIVE_COMPARATOR|Arm I (usual care)|Patients receive standard of care systemic therapy on study. Patients undergo CT or MRI throughout the trial.
62793124|NCT05427240|EXPERIMENTAL|ARM A|"Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor.~Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor."
62793125|NCT05427240|EXPERIMENTAL|ARM B|"Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor.~Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention."
62793126|NCT05427240|EXPERIMENTAL|ARM C|"Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention.~Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor."
62021667|NCT05148715|EXPERIMENTAL|Tacrolimus|Tacrolimus 0.02 mg/kg ideal body weight 4-8 hours before organ recovery
62021668|NCT05148715|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride 4-8 hours before organ recovery
62411471|NCT05863351|EXPERIMENTAL|Arm II (SAbR, usual care)|Patients undergo repeated SAbR until progression and then receive standard of care systemic therapy on study. Patients undergo CT or MRI throughout the trial.
62411472|NCT02461407|EXPERIMENTAL|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62793127|NCT05427240|EXPERIMENTAL|ARM D|"Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention.~Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention."
62793128|NCT04730791||Chronic Pain Patients|Adult patients 18-65 years, with chronic pain lasting for 3 or more months, with a pain intensity of at least 3 on a 0-10 numerical pain rating scale on most days.
62793129|NCT04730791||Control Group|Free pain participants
62793130|NCT06540794|NO_INTERVENTION|Group sPEEP (standard positive end-expiratory pressure)|Patients in this group will receive mechanical ventilation with a PEEP value of 5 cmH2O, following the recruitment maneuver.
62793131|NCT06540794|EXPERIMENTAL|Group kPEEP (personalized positive end-expiratory pressure)|A decremental PEEP titration strategy will be chosen after recruitment to determine the PEEP value that provides the lowest driving pressure. The personalized PEEP value (kPEEP) that provides the lowest driving pressure will be measured and maintained throughout the mechanical ventilation period. To find this value, the PEEP level will first be set at 15 cmH2O and maintained for 12 breathing cycles, after which the driving pressure will be recorded. Subsequently, the PEEP level will be decreased by 1 cmH2O and maintained for 12 breathing cycles, with the driving pressure recorded at each level. This strategy will continue until the PEEP level reaches 5 cmH2O. During these measurements, the tidal volume will be set at 8 ml/kg, the respiratory rate at 12 breaths/min, and the inspiratory: expiratory ratio at 1:2. The PEEP value that provides the lowest driving pressure will be recorded as kPEEP and maintained during pneumoperitoneum.
62793132|NCT06182969|EXPERIMENTAL|APG-2575|Dose escalation
62793133|NCT06182969|PLACEBO_COMPARATOR|Placebo|
62793134|NCT02628561|ACTIVE_COMPARATOR|Active tdcs/M1|Anodal tDCS on primary motor cortex and CIMT (constraint induced movement therapy)
62793135|NCT02628561|EXPERIMENTAL|Active tdcs/Premotor|Anodal tDCS on premotor cortex and CIMT (constraint induced movement therapy)
62793136|NCT02628561|SHAM_COMPARATOR|Sham tdcs|Sham tDCS and CIMT (constraint induced movement therapy)
62793137|NCT00950313|ACTIVE_COMPARATOR|Self Assessment|Patients are approached and asked to complete a risk score that will determine their current risk of diabetes and the likelihood of requiring further testing.
62793138|NCT00950313|ACTIVE_COMPARATOR|Electronic risk score|Patients diabetes riks is determined based on their data held on practice systems. Patients are then invited for further testing based on this score.
62793139|NCT05022966||Older people|
62793140|NCT01259180|EXPERIMENTAL|Acupuncture group|twice a week, 6 weeks real acupuncture treatment, 12 sessions
62793141|NCT01259180|SHAM_COMPARATOR|Sham acupuncture group|twice a week, 6 weeks real acupuncture treatment, 12 sessions
62793142|NCT01259180|NO_INTERVENTION|Control group|observation.
62021669|NCT05358145|EXPERIMENTAL|Tinkering|
62021670|NCT05358145|ACTIVE_COMPARATOR|Control Tinkering|
62021671|NCT05358145|ACTIVE_COMPARATOR|Board Games|
62411473|NCT02461407|PLACEBO_COMPARATOR|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62411474|NCT05570214|EXPERIMENTAL|Virtual Reality Group|Subjects will wear a virtual reality headset during their urological bedside vasectomy.
62411475|NCT05570214|NO_INTERVENTION|Standard of Care Group|Subjects will undergo standard of care urological bedside vasectomy
62021672|NCT04000451|EXPERIMENTAL|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ hydrogen/ oxygen inhaled
62021673|NCT04000451|EXPERIMENTAL|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
62411476|NCT06099886|EXPERIMENTAL|Lithium aspartate|Lithium aspartate capsules will be titrated in each patient to the maximum tolerated dosage between 30-45mg/day.
62411477|NCT02771340|EXPERIMENTAL|ICON-1 0.3 mg Singe Dose|Patients will receive a single intravitreal dose of ICON-1 0.3 mg
62411478|NCT02771340|EXPERIMENTAL|ICON-1 0.3 mg Repeat Dosing|Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart
62411479|NCT02771340|EXPERIMENTAL|ICON-1 0.6 mg Repeat Dosing|Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart
62411480|NCT05326997|EXPERIMENTAL|Photobiomodulation (PBM) with placebo cosmetic treatment.|Participants will receive the intervention with PBM using amber light (DMC E-Light ABR), 20 J/cm² and will also receive a product for daily home topical use containing only the cosmetic base without active.
62411481|NCT05326997|ACTIVE_COMPARATOR|Photobiomodulation (PBM) sham with 5% liposomal tranexamic acid cosmetic product|Participants will receive the simulated intervention with PBM using amber light (DMC E-Light ABR) and will also receive a product for topical home use containing 5% liposomal tranexamic acid.
62411482|NCT05087576|EXPERIMENTAL|Expressive Helping writing|During the first writing session, participants will be informed that people benefit from learning about other cancer caregivers' experiences, and that the first three sessions will consist of writing exercises designed to help them think about their cancer caregiving experiences and to prepare them for writing a helpful letter to other Chinese cancer caregivers during the fourth and final writing session.
62021674|NCT01229228|EXPERIMENTAL|Naproxen Test (lower dose)|200-mg
62021675|NCT01229228|EXPERIMENTAL|Naproxen Test (upper dose)|400-mg (2 x 200-mg)
62021676|NCT01229228|ACTIVE_COMPARATOR|Naprosyn 250 mg|
62021677|NCT01229228|ACTIVE_COMPARATOR|Naprosyn 500 mg|
62021678|NCT01229228|PLACEBO_COMPARATOR|Placebo|
62021679|NCT06296940|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Participants randomized to the TAU condition, which involves the standard clinical services available in a short term residential SUD treatment context. Examples of these services are: Individual counseling/case management; Group psychoeducation; Group counseling; Assessment and addiction related medical treatment from a physician; Pharmacotherapy for substance use disorders; 12-step groups. However, participants in this group do not receive treatment that is targeted at decreasing PTSD symptoms.
62021680|NCT06296940|EXPERIMENTAL|TAU + Written Exposure Therapy (WET)|Participants in this condition receive everything included in TAU plus 5 individual sessions of WET delivered by a therapist. Sessions average less than 60 minutes and primarily involve writing about the traumatic experience that is guided by the therapist.
62021681|NCT03437499|ACTIVE_COMPARATOR|Positive Pressure Ventilation|Positive Pressure Ventilation ( peak pressure set at 25 cmH20 and PEEP set at 5 cmH2O, with 40 inflations per minute)
62021682|NCT03437499|EXPERIMENTAL|Sustained Inflation|Prolonged inflation ( 25 cmH20 for 15 seconds) followed by PEEP set at 5 cmH2O
62021683|NCT02842398|EXPERIMENTAL|Balance Master Training|Children receive one weekly Balance Master training session, in addition to their weekly physical therapy sessions. During Balance Master training, children practice balance on a Balance Master device that simulates crossing a city street.
62021684|NCT02842398|ACTIVE_COMPARATOR|Customary Care|Children received their customary scheduled physical therapy sessions, without Balance Master training
62021685|NCT00339677||Volunteers|Volunteers
62021686|NCT06534190|EXPERIMENTAL|CD8 PET imaging|"89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later. All patients will undergo a 89Zr-Df-crefmirlimab PET scan at baseline and after treatment with the PD-1 antibody. All patients participating in this imaging trial will undergo preferably 2 but at least one tumour biopsy. The biopsy procedure(s) will be performed after the 89Zr-Df-crefmirlimab PET scan at baseline and/or after the 89Zr-Df-crefmirlimab PET on-treatment.~After the first PET scan and tumour biopsy the patients will start treatment with PD-1 antibody nivolumab or cetrelimab."
62021687|NCT05668195|EXPERIMENTAL|aerobic exercise group|The patients aged 6-12 with a diagnose of ADHD of this group receive systematic aerobic exercise and intelligent monitoring system in executive skill training for 13 weeks, including those taking methylphenidate or not.
62021688|NCT05668195|ACTIVE_COMPARATOR|executive skill training group|The patients aged 6-12 with a diagnose of ADHD of this group receive executive skill training for 13 weeks, including those taking methylphenidate or not.
62021689|NCT04815603|EXPERIMENTAL|BGE-117|BGE-117 Capsules (4mg or 12mg) to be taken by mouth once a day for 84 days.
62411483|NCT05087576|ACTIVE_COMPARATOR|Caregiving Facts writing|During each week, participants in the control group will be asked to write facts about their experience with cancer caregiving (e.g., type of treatment their loved one is receiving) and will be asked to avoid writing about their emotions. Participants in this group will be told that their writing will not be shared with others outside of the research team.
62411484|NCT06134687|EXPERIMENTAL|Treatment arm|Will have endoscopic submucosal dissection performed with the use of the Pathfinder Endoscope Overtube.
62411485|NCT06134687|ACTIVE_COMPARATOR|Control arm|Will have endoscopic submucosal dissection performed through conventional means (i.e. without the Pathfinder Endoscope Overtube).
62793143|NCT05044871|EXPERIMENTAL|Arm 1: Pamiparib+ Bevacizumab|Arm1 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer; Biomarkers: BRCA 1/2 mutant): Pamiparib 40mg PO. bid. plus Bevacizumab 7.5mg/kg IV. D1 (q3w.).
62793144|NCT05044871|EXPERIMENTAL|Arm 2: Tislelizumab + Bevacizumab + Nab-paclitaxel|Arm2 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer; Biomarkers: BRCA 1/2 wildtype and ≥3 CD8+ TILs count): Tislelizumab 200mg IV. D1 + Bevacizumab 7.5mg/kg IV. D1 + Nab-paclitaxel 125mg / m2 IV. D1, 8 (q3w).
62411486|NCT03151707|EXPERIMENTAL|Nicotinamide riboside 2g/day|Participants will receive NR at a dose of 2g/day
62793145|NCT05044871|EXPERIMENTAL|Arm 3: Bevacizumab + Nab-paclitaxel|Arm3 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer; Biomarkers: BRCA 1/2 wildtype and \<3 CD8+ TILs count): Bevacizumab 7.5mg/kg IV D1, 15 + Nab-paclitaxel 100mg / m2 IV D1, 8, 15 (Q4w).
62411487|NCT03467373|EXPERIMENTAL|Part 1: Dose Escalation r/r NHL|"Dose finding in participants with r/r NHL: the study will explore different doses of glofitamab in the induction period, starting at a dose of 70 mcg administered in combination with standard of care doses of G/R CHOP and R-CHOP every 3 weeks (Q3W). Participants with r/r NHL will receive 6 cycles of induction treatment (G/R-CHOP). Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6. Participants who achieve a complete response (CR), partial response (PR), or stable disease (SD) at the end of induction (EOInd) may optionally receive post-induction treatment (referred to as maintenance) with glofitamab alone.~The use of G versus R in Cycle 1 will be compared in parallel dose escalation cohorts."
62411488|NCT03467373|EXPERIMENTAL|Part 2: DLBCL G/R-CHOP|Participants with untreated DLBCL will receive G-CHOP or R-CHOP in Cycle 1, followed by G/R-CHOP + glofitamab for subsequent cycles. Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6 (up to 8). The starting dose of glofitamab for each arm may be one or more levels below the MTD/OBD determined in Part I.
62021690|NCT04815603|PLACEBO_COMPARATOR|Placebo|Placebo Capsules to be taken by mouth once a day for 84 days.
62021691|NCT06262620|EXPERIMENTAL|EBUS-transbronchial needle aspiration|Participants would undertake EBUS-transbronchial needle aspiration.
62411489|NCT03467373|EXPERIMENTAL|Part 2: DLBCL Pola-R-CHP|Participants with untreated DLBCL will receive Pola-R-CHP + glofitamab on Day 1 of each 21-day cycle for a maximum of 6 cycles. Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6. The starting dose of glofitamab for each arm may be one or more levels below the MTD/OBD determined in Part I.
62411490|NCT00885937|EXPERIMENTAL|Arm 1|
62793146|NCT05044871|EXPERIMENTAL|Arm 4: Tislelizumab + Bevacizumab + Nab-paclitaxel|Arm4 (Pathological classification: Mucinous Ovarian cancer, Ovarian carcinosarcoma; Biomarkers: ≥3 CD8+ TILs count): Tislelizumab 200mg IV D1 + Bevacizumab 7.5mg/kg IV D1 + Nab-paclitaxel 125mg / m2 IV D1, 8 (q3w).
62411491|NCT00885937|ACTIVE_COMPARATOR|Arm 2|
62411492|NCT00885937|PLACEBO_COMPARATOR|Arm 3|
62585676|NCT01068210|ACTIVE_COMPARATOR|Progressive Stretching Group (Attention-Control)|A customized and supervised progressive stretching program that will last 4 months (16 weeks). The progressive stretching program will consist of a series of stretching exercises alternating between lower and upper body muscle groups/joints. This program will consist of three exercise sessions a week. Each session will last approximately 30-60 minutes.
62585677|NCT06453928|EXPERIMENTAL|Hybrid Closed Loop Insulin Pump System|"Participants will meet 1:1 with our CDE for at least 6 sessions over 6 weeks. Sessions will cover self-management basics, carb counting, CGM interpretation, hypoglycemia and hyperglycemia management and troubleshooting device issues. The investigators will follow up with participants in 24 and 72 hours after CGM and insulin pump initiation, respectively, to answer any device related questions that may arise in between sessions.~Participants will follow up at intervals of 1-4 weeks throughout the study. During visits, the investigators will assess for adherence and adverse effects and evaluate device and safety issues associated with pump settings in the HCL arm. The investigators will repeat A1c at 12 weeks and 24 weeks and administer follow up questionnaires at 12 and 24 weeks."
62793147|NCT05044871|EXPERIMENTAL|Arm 5: Bevacizumab + Nab-paclitaxel|Arm5 (Pathological classification: Mucinous Ovarian cancer, Ovarian carcinosarcoma; Biomarkers: \<3 CD8+ TILs count: Bevacizumab 7.5mg/kg IV. D1, 15 + Nab-paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).
62793148|NCT05357755|EXPERIMENTAL|Group 1: JNJ-77242113 Dose 1|Participants will receive JNJ-77242113 Dose 1 as delayed release tablets orally once daily from Week 0 through Week 16.
62793149|NCT05357755|EXPERIMENTAL|Group 2: JNJ-77242113 Dose 2|Participants will receive JNJ-77242113 Dose 2 as delayed release tablets orally once daily from Week 0 through Week 16.
62793150|NCT05357755|PLACEBO_COMPARATOR|Group 3: Placebo|Participants will receive oral dose of matching placebo once daily from Week 0 through Week 16.
62793151|NCT02343406|EXPERIMENTAL|ABT-414/temozolomide|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks in combination with temozolomide (TMZ) to adult participants
62021692|NCT06262620|EXPERIMENTAL|EBUS-transbronchial mediastinal cryobiopsy via a tunnel|Participants would undertake EBUS-transbronchial mediastinal cryobiopsy via a tunnel.
62021693|NCT06262620|EXPERIMENTAL|EBUS-transbronchial forceps biopsy via a tunnel|Participants would undertake EBUS-transbronchial forceps biopsy via a tunnel.
62021694|NCT02779179|EXPERIMENTAL|Immediate Periodontal treatment group|
62021695|NCT02779179|ACTIVE_COMPARATOR|Delayed Periodontal treatment Group|
62411493|NCT01895829|EXPERIMENTAL|Ferumoxytol + Magnetic Resonance Imaging (MRI)|"On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. The study MRI performed in the same way that a standard MRI is performed.~On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed."
62411494|NCT01170767|EXPERIMENTAL|Avastin|intravitreal injection of bevacizumab
62021696|NCT04613128||Pediatric|Cystic Fibrosis pediatric patients (6-11 years old) prescribed ETI CFTR modulator Therapy.
62021697|NCT06481241|EXPERIMENTAL|Chemotherapy and Sequential CAR-T Cells|Ph-ALL patients receiving CAR-T cells as consolidation therapy after achieving complete remission (CR) with pediatric-inspired regimen and venetoclax.
62021698|NCT02596451|EXPERIMENTAL|Diclofenac Sodium gel, 1%|apply gel to the target knee
62021699|NCT02596451|ACTIVE_COMPARATOR|Voltaren® Gel|apply gel to the target knee
62021700|NCT02596451|PLACEBO_COMPARATOR|Placebo|apply gel to the target knee
62021701|NCT05745857|EXPERIMENTAL|Oral bevacizumab-800CW|Dose finding of oral bevacizumab-800CW and extend optimal dose group (n = 5 - 10)
62793152|NCT02343406|EXPERIMENTAL|ABT-414_adult|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks to adult participants
62793153|NCT02343406|ACTIVE_COMPARATOR|Control_lomustine|Adult participants relapsing during temozolomide (TMZ) treatment or within the first 16 weeks after the first day of the last TMZ cycle received lomustine on Day 1 of every 42-day treatment period until one of the treatment withdrawal criteria was met, up to a maximum of 1 year.
62021702|NCT05745857|EXPERIMENTAL|Oral cetuximab-800CW and combined oral cetuximab-800CW and bevacizumab-800CW|"Dose finding of oral cetuximab-800CW in first five patients and combined oral bevacizumab-800CW and cetuximab-800CW if the investigators see good results with cetuximab-800CW. If not, they will add a control group of non-dysplastic BE patients and administer oral bevacizumab-800CW.~(n = 15)"
62411495|NCT01170767|ACTIVE_COMPARATOR|Lucentis|intravitreal injection of ranibizumab
62411496|NCT06652373|EXPERIMENTAL|Education|perinatal grief counselling training for midwives will be given to the experimental group.
62411497|NCT06652373|NO_INTERVENTION|Standard of care|The training will not be given to the control group during the study.
62411498|NCT04896697|EXPERIMENTAL|Part 1A - vilastobart (XTX101) Monotherapy Dose Escalation|Part 1A Dose Escalation of vilastobart (XTX101) administered in ascending doses to patients with advanced or metastatic solid tumors to find the recommended phase 2 dose (RP2D).
62793154|NCT02343406|ACTIVE_COMPARATOR|Control_ temozolomide|Adult participants relapsing 16 weeks or more after the first day of the last temozolomide (TMZ) cycle received TMZ on Day 1 to Day 5 for the first 28-day cycle, with dose escalation in subsequent cycles in case of adequate tolerance and treatment continuing until one of the treatment withdrawal criteria was met.
62411499|NCT04896697|EXPERIMENTAL|Part 1B - Pharmacodynamic (PD) Dose Expansion|Part 1B vilastobart (XTX101) at the RP2D will be administered to further examine vilastobart (XTX101) as monotherapy in patients with select advanced solid tumors.
62411500|NCT04896697|EXPERIMENTAL|Part 1C - vilastobart (XTX101) Dose Escalation in Combination with Atezolizumab|Part 1C will receive a labeled dose of atezolizumab in combination with vilastobart (XTX101).
62793155|NCT02343406|EXPERIMENTAL|ABT-414_ pediatric|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks to pediatric participants. Temozolomide (TMZ) was only allowed for pediatric participants if its use was in accordance with local clinical practice, and was not considered an investigational product for the study (unless this was a local requirement).
62217273|NCT01920854|EXPERIMENTAL|Soluble Ferric Pyrophosphate|Group/Cohort Designation: Ascending doses of SFP. Each subject will receive a defined dose of SFP IV administered under double-blind conditions. Pharmacokinetics of iron will be measured using a validated assay for iron and transferrin bound iron.
62217274|NCT01920854|PLACEBO_COMPARATOR|Control|Group/Cohort Designation: Each subject will receive placebo IV administered under double-blind conditions.
62217275|NCT05381415||Patients with COPD|"Patients with COPD diagnosis (VEMS/FVC after bronchodilatation \<0.7) will be enrolled in a stable state of disease, diagnosed from at least 12 months \[GOLD\].~Each patient will be studied during three visits. In the first visit it will be established the patient eligibility. Furthermore, the patient will be able to familiarize with the experimental procedure. Chronic inhalation therapy will be suspended 24 (long action) and 8 (short action) hours before the second and third visit. If a patient is on tiotropium bromide, it will be required to be suspended 7 days before the visit.~During the second and third visit, which will be scheduled 30 days one from another, the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from VR or FRC, in a random order. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique."
62411501|NCT04896697|EXPERIMENTAL|Phase 2 - vilastobart (XTX101) Dose Expansion in Combination with Atezolizumab|Phase 2 will receive a labeled dose of atezolizumab in combination with vilastobart (XTX101) at the RP2D(s) in patients with MSS CRC.
62411502|NCT01243307|EXPERIMENTAL|CT327 treatment period 1|Subjects in Group 1 will receive CT327 during treatment/testing period 1 and placebo during treatment/testing period 2
62411503|NCT01243307|EXPERIMENTAL|CT327 treatment period 2|Subjects in Group 2 will receive placebo during treatment/testing period 1 and CT327 during treatment/testing period 2
62411504|NCT03913429|ACTIVE_COMPARATOR|Control Group|"Infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla (blockage of terminal branches of the maxillary nerve) after intubation and previous to surgical incision.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 1amp Lidocaine 2% in physiological saline (SF) 100ml."
62411505|NCT03913429|EXPERIMENTAL|Study Group|"Bilateral ultrasound-guided maxillary nerve block by suprazygomatic route after intubation and previous to surgical incision performed by the anesthesiologist.~A total of 5ml of Ropivacaine 0.37% infiltrated on each side."
62793156|NCT05478083|ACTIVE_COMPARATOR|Direct start|36 months of treatment with study medication
62793157|NCT05478083|OTHER|Delayed start|First 18 months standard care, hereafter 18 months treatment with study medication
62793158|NCT04823442|ACTIVE_COMPARATOR|Study A|Metabolic PET study with mirabegron
62793159|NCT04823442|EXPERIMENTAL|Study B|Metabolic PET study with mirabegron and bisoprolol
62411506|NCT02999646|EXPERIMENTAL|MVX-ONCO-1|MVX-ONCO-1 vaccine treatment once weekly starting on week 1 for 4 weeks followed by two additional treatments 2 weeks apart (total 6 treatments over 8 weeks). Each treatment consists of two macrocapsules containing the MVX-1 cell line and lethally irradiated autologous tumor cells.
62411507|NCT03875716|EXPERIMENTAL|Low Risk|"Observation without adjuvant therapy~* Pathologic T0-2, N0-1~* Minimum of 15 lymph nodes retrieved on neck dissection per dissected side of the neck~* Single positive lymph node up to 3cm~* No extranodal extension~* Clear margins"
62411508|NCT03875716|EXPERIMENTAL|Intermediate Risk|"Reduced-dose radiation (46Gy)~* Pathologic T0-2N0-2 and any one of the following features:~* 2 or more positive lymph nodes~* single node \>3cm~* \<15 lymph nodes retrieved on neck dissection for each side of the neck~* Positive lymph nodes in level IB, IV, or V~  -≤1mm extranodal extension~* Positive lymph node(s) contralateral to the primary tumor~* Close margins"
62411509|NCT03875716|EXPERIMENTAL|High Risk|"Postoperative radiation (60Gy) without chemotherapy~* Pathologic T0-4N0-2 and any one of the following features:~  -\>1mm extranodal extension~* Microscopic positive margins"
62411510|NCT02508649|PLACEBO_COMPARATOR|Placebo|
62411511|NCT02508649|EXPERIMENTAL|Selepressin 1|Starting dose 1.7 ng/kg/min
62793160|NCT04207749|EXPERIMENTAL|LID015385|LID015385 contact lenses worn at least 5 days per week and 8 hours per day in a daily wear modality (that is, not worn while sleeping) for approximately 3 months. CLEAR CARE will be used for nightly cleaning and disinfection.
62411512|NCT02508649|EXPERIMENTAL|Selepressin 2|Starting dose 2.5 ng/kg/min
62021703|NCT05745857|EXPERIMENTAL|Combined topical tracer administration bevacizumab-800CW and cetuximab-800CW|"This arm will only be part of the study when oral administration is not feasible or safe.~Compare single topical tracer administration of bevacizumab-800CW with combined topical tracer administration of bevacizumab-800CW and cetuximab-800CW. Extend combined group when lesion detection is increased or add control group with non-dysplastic BE patients if not.~(n = 20)"
62021704|NCT02295111|ACTIVE_COMPARATOR|EA treatment and TCM health consult|Participants randomized to the EA treatment will receive 2 EA +TCM health consult once a week x 4 weeks (8 total)
62021705|NCT02295111|EXPERIMENTAL|TCM health consult|Participants randomized to TCM health consult will receive 2 TCM health consult once a week x 4 weeks ( 8 total)
62021706|NCT02295111|ACTIVE_COMPARATOR|Usual care|Participants randomized to usual care will continue with their usual care
62021707|NCT02057055|EXPERIMENTAL|Soap 300000027003|Subjects will apply this soap to one of their arms daily in the shower for 3 weeks
62021708|NCT02057055|EXPERIMENTAL|Soap 300000029240|Subjects will apply this soap to one of their arms daily in the shower for 3 weeks
62021709|NCT02783586|EXPERIMENTAL|Quadratus Lumborum Block type II|Unilateral ultrasound guidance QLB on the operated side after induction of general anaesthesia - 20 ml of 0,25%bupivacaine with adrenaline injected with ultraplex needle
62021710|NCT02783586|ACTIVE_COMPARATOR|Transversus Abdominalis Plane Block|Unilateral ultrasound guidance TAPB on the operated side after induction of general anaesthesia - 20 ml of 0,25% bupivacaine with adrenaline injected with ultraplex needle
62411513|NCT02508649|EXPERIMENTAL|Selepressin 3|Starting dose 3.5 ng/kg/min
62217276|NCT00119210|PLACEBO_COMPARATOR|Placebo|Sugar pill
62217277|NCT00119210|EXPERIMENTAL|Bupropion SR|
62411514|NCT02508649|EXPERIMENTAL|Selepressin 4|"Starting dose 5.0 ng/kg/min~The highest dosing regimen of selepressin was not investigated in the trial as the desired primary outcome for selepressin 3 arm was not achieved, and the trial was terminated for futility."
62793161|NCT04207749|ACTIVE_COMPARATOR|Biofinity|Comfilcon A contact lenses worn at least 5 days per week and 8 hours per day in a daily wear modality (that is, not worn while sleeping) for approximately 3 months. CLEAR CARE will be used for nightly cleaning and disinfection.
62793162|NCT03433417|EXPERIMENTAL|Treatment Side|One truSculpt treatment
62217278|NCT05586802|NO_INTERVENTION|Group 1 (Fertility) - positive micro-dissection testicular sperm extraction (mTESE) biopsy 1|Men with Klinefelter syndrome seeking fertility or interested in fertility preservation that undergo mTESE biopsy after wash-out of testosterone replacement therapy and have positive sperm retrieval (detectable spermatozoids)
62217279|NCT05586802|EXPERIMENTAL|Group 1 (Fertility) - negative mTESE biopsy 1, then randomized to Arm A|Men with Klinefelter syndrome seeking fertility or interested in fertility preservation that undergo mTESE biopsy after wash-out of testosterone replacement therapy and have negative sperm retrieval (no detectable spermatozoids), subsequently randomized to receive an hormonal stimulation for 26 weeks
62411515|NCT05744219|EXPERIMENTAL|Iv Iron|Ferric Carboxymaltose, single dose, Intra venous 1000 mg in 100 ml 0.9% NaCl
62411516|NCT05744219|PLACEBO_COMPARATOR|Placebo|Placebo, single dose, Intra venous 0.9% NaCl 100 ml
62411517|NCT06149351|OTHER|Sub-group S-P|20 professional athletes whose weekly sport practice is more than 8 hours of contact sport.
62021711|NCT05776485|EXPERIMENTAL|Chronic tendinopathy patients|
62021712|NCT05776485|EXPERIMENTAL|Healthy controls|
62021713|NCT02631798|EXPERIMENTAL|Dye staining|Food grade dye mucosal staining
62021714|NCT06432127|PLACEBO_COMPARATOR|Placebo|Use Normal saline 3 ml as the injection agent
62021715|NCT06432127|EXPERIMENTAL|Bupivacaine|Use 0.5% Bupivacaine 3ml as the injection agent
62021716|NCT05275777|EXPERIMENTAL|ADG106 combined with dose dense Doxorubicin and Cyclophosphamide (Phase Ib)|Intravenous ADG106 + 2 weekly doxorubicin and cyclophosphamide
62021717|NCT05275777|EXPERIMENTAL|ADG106 combined with Paclitaxel (Phase Ib)|Intravenous ADG106 + weekly paclitaxel
62021718|NCT05275777|EXPERIMENTAL|ADG106 combined with dose dense Doxorubicin and Cyclophosphamide follow by Paclitaxel (Phase II)|Intravenous ADG106 combined with two weekly doxorubicin and cyclophosphamide followed intravenous ADG106 combined with weekly paclitaxel
62021719|NCT06535074||Preterm infants with hypoxemia episodes|Very preterm infants with spontaneous HEs and not receiving invasive mechanical ventilation.
62411518|NCT06149351|OTHER|Sub-group S-L|20 amateur athletes, having moderate physical activity whose weekly sport practice is between 4 and 8 hours of contact sport.
62021720|NCT01301963|ACTIVE_COMPARATOR|Arm I|Patients receive G-CSF SC QD on days 1-4.
62021721|NCT01301963|EXPERIMENTAL|Arm II|Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.
62021722|NCT01455441|ACTIVE_COMPARATOR|Training and liraglutide|Treatment with both training and liraglutide for 16 weeks
62021723|NCT01455441|PLACEBO_COMPARATOR|Training and placebo|Treatment wiht both training and placebo for 16 weeks
62411519|NCT06149351|OTHER|Sub-group S-O|20 control subjects who are occasional sport practitioners, having a low intensity physical activity with weekly practicing time is below 4h, excluding contacted sports.
62411520|NCT02633462|ACTIVE_COMPARATOR|Test Group|Polycystic ovarian syndrome(PCOS) women who have periodontitis and treated with scaling and root planing(SRP) along with Myo-inositol supplementation
62411521|NCT02633462|ACTIVE_COMPARATOR|Control Group|Polycystic ovarian syndrome(PCOS) women who have periodontitis treated with Myo-inositol along with oral hygiene instructions.
62411522|NCT01565655|EXPERIMENTAL|ASP015K lowest dose|ASP015K lowest dose once daily
62021724|NCT00554866|EXPERIMENTAL|VLBW between 6 and12 hours after birth|"Blood sample and buccal swab sample. One blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.~Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab."
62021725|NCT01748435||Qutenza|Single treatment with QUTENZA (topical capsaicin 8%) transdermal patch
62021726|NCT05159752|EXPERIMENTAL|Afamelanotide|
62021727|NCT05635214||Patients with RUQ or Flank Pain|These are patients who present to the emergency department with abdominal pain or flank pain.
62217280|NCT05586802|EXPERIMENTAL|Group 1 (Fertility) - negative mTESE biopsy 1, then randomized to Arm B|Men with Klinefelter syndrome seeking fertility or interested in fertility preservation that undergo mTESE biopsy after wash-out of testosterone replacement therapy and have negative sperm retrieval (no detectable spermatozoids), subsequently randomized to receive an hormonal stimulation for 26 weeks
62411523|NCT01565655|EXPERIMENTAL|ASP015K low dose|ASP015K low dose once daily
62411524|NCT01565655|EXPERIMENTAL|ASP015K medium dose|ASP015K medium dose once daily
62793163|NCT03433417|NO_INTERVENTION|Control Side|Untreated contralateral control
62021728|NCT06321718|EXPERIMENTAL|1. Group (A)|will receive PENG + LFCN block
62021729|NCT06321718|EXPERIMENTAL|2. group (B)|will receive S-FICB
62021730|NCT04393883|EXPERIMENTAL|Standard maintenance programme group|pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
62021731|NCT04393883|EXPERIMENTAL|Improvement maintenance programme group,|pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
62021732|NCT03216174|EXPERIMENTAL|NESS-EFTR|This arm will be received non-exposure simple suturing endoscopic full-thickness resection after sentinel lymph node navigation
62021733|NCT02744313||AP Naive|Group followed over 12 weeks to measure fat deposition, insulin resistance, and glucose tolerance.
62021734|NCT01419418||Peripheral Arterial Disease (PAD)|This is a longitudinal observational study. There were no interventions administered.
62021735|NCT02303964|ACTIVE_COMPARATOR|Type A Thawed Plasma|"Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive 2 units of thawed Type A plasma in the pre-hospital setting administered by EMS first responders.~An exception from informed consent under 21CFR 50.24 is required since enrollment will occur (for the majority of subjects) before consent can be obtained."
62217281|NCT05586802|ACTIVE_COMPARATOR|Group 2 (Metabolic Risk) - randomized to Arm C|Men with Klinefelter syndrome not interested in fertility that present with high metabolic risk and consent to a wash-out of testosterone replacement therapy. They are subsequently randomized to receive an hormonal treatment to improve metabolic health. This arm will receive an active comparator by a testosterone gel
62217282|NCT05586802|EXPERIMENTAL|Group 2 (Metabolic Risk) - randomized to Arm D|Men with Klinefelter syndrome not interested in fertility that present with high metabolic risk and consent to a wash-out of testosterone replacement therapy. They are subsequently randomized to receive an hormonal treatment to improve metabolic health. This arm will receive an an experimental treatment
62217283|NCT05586802|EXPERIMENTAL|Group 2 (Metabolic Risk) - randomized to Arm E|Men with Klinefelter syndrome not interested in fertility that present with high metabolic risk and consent to a wash-out of testosterone replacement therapy. They are subsequently randomized to receive an hormonal treatment to improve metabolic health. This arm will receive an an experimental treatment
62217284|NCT03716700||Cohort 1|Cohort1 will include the participants who have been transitioned to CUVITRU at the time of enrollment in the study.
62217285|NCT03716700||Cohort 2|Cohort 2 will include participants 6 months (±2 weeks) after CUVITRU initiation.
62217286|NCT03716700||Cohort 3|Cohort 3 will include participants 12 months (-1 or +2 months) after CUVITRU initiation.
62217287|NCT03914612|ACTIVE_COMPARATOR|Arm I (placebo, paclitaxel, carboplatin)|"COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.~Patients undergo CT scan throughout the study.~On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm 1 will not receive additional placebo infusions."
62217288|NCT03914612|EXPERIMENTAL|Arm II (pembrolizumab, paclitaxel, carboplatin)|"COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.~Patients undergo CT scan throughout the study."
62217289|NCT06607939|EXPERIMENTAL|Experimental: Dose Escalation ORB-021|ORB-012 Dose Escalation Participants will be administered study drug at dose levels corresponding to their Cohort. Cohort 1 will be treated with the lowest dose, and the dose will be escalated for future cohorts once the previous dose has been observed not to be associated with DLTs. Up to 5 dose cohorts have been pre-specified. Doses from the escalation arms will be selected as RP2D candidates.
62411525|NCT01565655|EXPERIMENTAL|ASP015K high dose|ASP015K high dose once daily
62411526|NCT01565655|PLACEBO_COMPARATOR|Placebo|Matching placebo once daily
62411527|NCT05935930|ACTIVE_COMPARATOR|Group P (n=22)|Propofol group
62411528|NCT05935930|ACTIVE_COMPARATOR|Group S (n=22)|Sevoflurane group
62021736|NCT02303964|PLACEBO_COMPARATOR|Normal saline|Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive normal saline in the pre-hospital setting administered by EMS first responders. Normal saline is standard of care
62217290|NCT01578200|EXPERIMENTAL|Lanthanum carbonate|Patients are given Lanthanum Carbonate oral administration after meals three times per day in total daily dose of 750-2250mg.
62217291|NCT01578200|ACTIVE_COMPARATOR|Calcium Carbonate|Patients are given Calcium carbonate oral administration after meals three times per day in total daily dose of 3.0g.
62819355|NCT03243695|EXPERIMENTAL|Angled abutment|According to the allocation, the experimental group will receive an angled abutment on the immediately placed implant. A vaccum stent will be used to fabricate a temporary crown using tooth colored auto-polymerizing resin(structur 2 SC/ QM , VOCO GmbH, Germany)
62021737|NCT03604250|EXPERIMENTAL|Lifestyle plus prebiotics|Research participants will be asked to wear health monitoring devices, including a continuous glucose monitoring device and an Apple watch. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
62021738|NCT02620553|EXPERIMENTAL|Human Insulin|Oral Insulin at 2.5 mg, 7.5 mg, 22.5 mg, or 67.5 mg per day
62217292|NCT01948700|OTHER|Brief Intervention|Motivational Interviewing (MI)
62411529|NCT06035094|EXPERIMENTAL|High Intensity Interval Training (HIIT) exercise group,|Participants will be asked to exercise independently 4 days/week for 10 weeks, following a high intensity interval training (HIIT) protocol.
62411530|NCT06035094|EXPERIMENTAL|Moderate Intensity Training (MIT) exercise group|Participants will be asked to exercise independently 4 days/week for 10 weeks, following a moderate intensity training (MIT) protocol.
62411531|NCT06035094|ACTIVE_COMPARATOR|Control exercise group|Participants will be advised to follow the American Heart Association (AHA) guidelines on exercise.
62411532|NCT02423746|PLACEBO_COMPARATOR|Control Group|"The control group will include 3 hearing aid (HA) and 3 cochlear implant (CI) caregiver-child dyads.~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
62411533|NCT02423746|EXPERIMENTAL|Intervention Group|"The intervention group will include 3 hearing aid (HA) and 3 cochlear implant (CI) caregiver-child dyads.~Intervention parents receive the initial assessment session followed by the 3-session Family Check Up Behavioral Parenting Training Program (BPT) within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
62411534|NCT05188274|EXPERIMENTAL|T92 group|The dose of T92 was calculated based on body weight, orally twice daily. Supportive care duration: 8 weeks
62411535|NCT05188274|PLACEBO_COMPARATOR|Placebo group|The dose of placebo was calculated based on body weight, orally twice daily. Supportive care duration: 8 weeks
62411536|NCT01892813|EXPERIMENTAL|Tailored intervention|Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.
62411537|NCT01892813|ACTIVE_COMPARATOR|Enhanced standard of care|Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.
62021739|NCT02620553|PLACEBO_COMPARATOR|Placebo|Oral Placebo
62217293|NCT01948700|OTHER|Standard Intervention|Education
62217294|NCT01558401|EXPERIMENTAL|Physical activity program Group|The physical activity program consists of 123 sessions over 52 weeks. The initial assessment is followed by 12 weeks of physical activity. After this ten-week period, a second assessment is performed, followed by 3 weeks of rest. This is followed by a further 17 weeks of activities, 4 weeks of activities followed by 4 weeks of rest. Finally, there were 12 more weeks of activities.
62217295|NCT02982395|EXPERIMENTAL|Nanoxel®M|75 mg in 100mL normal saline
62217296|NCT02982395|ACTIVE_COMPARATOR|Mitomycin|40 mg in 100mL normal saline
62217297|NCT05467189||treatment|The use of antineoplastic agents depends on the clinical practice.
62411538|NCT00641810|EXPERIMENTAL|A|After one week at usual levels of caffeine use, patients are asked to reduce their caffeine consumption to no more than 2 cups of coffee (or equivalent) for one week and then to zero for two weeks.
62411539|NCT04275375||hyperbaric bupivacaine|The dosage of hyperbaric bupivacaine decided by the clinical anesthesiologist. This study is an observational study.
62411540|NCT04275375||plain bupivacaine|The dosage of plain bupivacaine decided by the clinical anesthesiologist. This study is an observational study.
62585678|NCT06453928|NO_INTERVENTION|Control|"Participants in the control arm will receive diabetes education at a similar frequency as the intervention group. Diabetes education for the control group will be a combination of in-person visits with the CDE and telephone brief diabetes education sessions.~Participants will follow up at intervals of 1-4 weeks throughout the study. During visits, the investigators will assess for adherence and adverse effects. The investigators will repeat A1c at 12 weeks and 24 weeks and administer follow up questionnaires at 12 and 24 weeks."
62585679|NCT06462352|EXPERIMENTAL|Navicam endoscopic capsule|Navicam endoscopic capsule device for the study of small bowel pathology.
62585680|NCT06462352|ACTIVE_COMPARATOR|Pillcam endoscopic capsule|Pillcam SB3 endoscopic capsule device for the study of small bowel pathology.
62585681|NCT03951064|EXPERIMENTAL|Optimal PEEP|The waveforms of airway pressure (Paw), esophageal pressure (Pes), and transpulmonary pressure (Ptp) will be visualized on the ventilator. Ptp is obtained from Paw - Pes. PEEP will be increased on the ventilator to achieve a Ptp between 0 and +2 cm H2O (Optimal PEEP). Measurements will be obtained daily and adjustments to PEEP will occur daily. PEEP will be reduced below Optimal PEEP in the setting of hemodynamic compromise (requiring increasing vasoactive medications for blood pressure support).
62411541|NCT03150433|EXPERIMENTAL|Behavioral symptom management|Five sessions working one-on-one with a study interventionist, either in person or by telephone. Includes monitoring of the individual's sleep pattern, feedback and goals for improving sleep and pain management, and addressing cognitive and emotional strategies for managing sleep and pain.
62411542|NCT03150433|OTHER|Sickle cell disease management|Five sessions working one-on-one with a study interventionist, either in person or by telephone. Includes monitoring of the individual's sleep pattern, information about sickle cell disease and its management, and information about improving sleep and managing pain.
62411543|NCT06652217|EXPERIMENTAL|Digitally manufactured occlusal splint|digitally manfactured occlusal splint using intra oral scanner and jaw traccking device for data acqusition and 3d printing for manfacturing of the device
62217298|NCT05179382|ACTIVE_COMPARATOR|Control protocol|The control protocol will consist of an initial 10 minutes of rest, followed by 90 minutes of aerobic activity and 60 minutes of the final recovery. Hydration will not be allowed throughout the protocol.
62217299|NCT05179382|EXPERIMENTAL|Hydration protocol|This intervention will consist of an initial 10 minutes of rest, followed by 90 minutes of aerobic activity and 60 minutes of the final recovery. In this protocol, volunteers will be hydrated with mineral water from the 15th minute of exercise until the end of recovery.
62217300|NCT00833833|EXPERIMENTAL|Phase 1: 2 mg pomalidomide|Pomalidomide 2 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
62217301|NCT00833833|EXPERIMENTAL|Phase 1: 3 mg pomalidomide|Pomalidomide 3 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
62217302|NCT00833833|EXPERIMENTAL|Phase 1: 4 mg pomalidomide|Pomalidomide 4 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
62217303|NCT00833833|EXPERIMENTAL|Phase 1: 5 mg pomalidomide|Pomalidomide 5 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
62217304|NCT00833833|EXPERIMENTAL|Phase 2: pomalidomide + dexamethasone|Combination therapy of 4 mg pomalidomide given once per day on Days 1-21 of each 28-day cycle and the starting dose of dexamethasone (determined by age) on days 1, 8, 15, and 22 of each 28-day cycle. The starting dose of dexamethasone was 40 mg for participants who were ≤ 75 years of age and 20 mg for participants who were \> 75 years of age. Dose reduction steps for dexamethasone were provided for drug-related toxicities.
62217305|NCT00833833|EXPERIMENTAL|Phase 2: pomalidomide|4 mg pomalidomide was given once per day on Days 1-21 of each 28-day cycle until PD. Participants in the single agent pomalidomide treatment arm who developed confirmed PD at any time had the option to receive oral dexamethasone on days 1, 8, 15, and 22 of each 28-day cycle at the starting dose of 20 or 40 mg depending on age in addition to their current dose of pomalidomide, or to discontinue treatment.
62217306|NCT06024759||Retrospective Cohort|Individuals in this group were previously seen by physicians at the Inherited Arrhythmia Clinic at University Hospital, London Health Sciences Centre, yet are no longer being actively followed here anymore. These patients will have their data retrospectively obtained annually, ten years into the past, to collect data on key variables providing insight on LVNC progression over time.
62217307|NCT06024759||Prospective Cohort|Patients being actively followed up by physicians at the Inherited Arrhythmia Clinic will be approached either in person or via e-mail for consent and enrollment into this study. These patients will have their medical charts accessed annually to collect data on key variables providing insight on LVNC progression over time.
62411544|NCT06652217|ACTIVE_COMPARATOR|conventionally manufactured occlusal splint|the occlusal device will be manufactured conventionally using impression and and anterior deprogramer with bite registeration material for data aquesition and usual construction method using clear acrylic.
62585682|NCT03951064|ACTIVE_COMPARATOR|Acute Hypoxic Respiratory Distress Syndrome Network (ARDSNet) High PEEP|PEEP in the control group will be determined by High PEEP ARDSnet PEEP/FiO2 table. Titration of PEEP will occur when clinically indicated by partial pressure of oxygen (PaO2) or oxygen saturation (SpO2), and FiO2. The investigators chose the High PEEP table based on the clinical suspicion that obese patients may require higher PEEP levels on average than non-obese patients to balance the additional pressure of their chest wall. In addition, EPVent2, a study of esophageal balloon PEEP titration in patients with ARDS utilized the High PEEP table. Patients with moderate and severe ARDS benefit from higher levels of PEEP.
62738631|NCT05749991|ACTIVE_COMPARATOR|Cotton Roll Isolation|"Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue).~Cotton roll isolation was used to isolate teeth that required sealant placement in the assigned participants.~With this technique, a high-speed evacuation of saliva and water is used."
62217308|NCT02156739|EXPERIMENTAL|Diagnostic (contrast-enhanced MRI)|Patient receives each of these over one minute. For the gadoxetate disodium, dynamic imaging is performed immediately and imaging is performed at 20 minutes. For the gadobutrol, dynamic imaging is performed immediately.
62217309|NCT01604629|EXPERIMENTAL|Reduced doses of anti-TNF|Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
62411545|NCT00320801|ACTIVE_COMPARATOR|BTDS 5|Buprenorphine transdermal patch 5 mcg/h, applied for 7-day wear
62411546|NCT00320801|EXPERIMENTAL|BTDS 20|Buprenorphine transdermal patch 20 mcg/h, applied for 7-day wear
62411547|NCT04477473||Vulnerable subjects|Patients under long-term non-invasive ventilation (respiratory support) at home for chronic respiratory failure
62411548|NCT06315530|EXPERIMENTAL|Experimental: SOC+Telitacicept arm|Telitacicept 160mg once a week for 48 week as an add-on treatment regimen. SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
62411549|NCT06315530|ACTIVE_COMPARATOR|Experimental: SOC arm|SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
62411550|NCT06652334||Spinal anesthesia|20 patients undergoing spinal anesthesia
62411551|NCT06652334||Erector spinae plane block|20 patients undergoing erector spinae plane block
62411552|NCT02151565|EXPERIMENTAL|HTEMS|High-tone external muscle stimulation 5 times within 10 days
62411553|NCT02151565|ACTIVE_COMPARATOR|TENS|Transcutaneous electrical nerve stimulation 5 times within 10 days
62585683|NCT06557122|OTHER|SOC and Advanced Bioengineered Skin Substitute|The SOC therapy in this study is offloading of the DFU (CAM boots or total contact casting \[TCC\] if the subject's foot is too large for a CAM boot), appropriate sharp or surgical debridement, infection management (systemic antibiotics only in conjunction with debridement) and wound care covering with Helicoll® applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous, second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Dynaflex™ or equivalent).
62738632|NCT04726930||Intercostal nerve block with surface ultrasound|"Number of participants: 10 Intercostal blocks will be performed under guidance of surface ultrasound. After we reach the injection site, the puncture stylet will be replace by Intra-needle ultrasound transducer (INUS). Collect signal from Intra-needle ultrasound transducer and then inject local anesthetics.~Code name: ICNB-INUS-check"
62217310|NCT01604629|ACTIVE_COMPARATOR|Stable doses of anti-TNF|Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis
62411554|NCT00142961|EXPERIMENTAL|1|Atomoxetine prescribed daily
62411555|NCT00142961|PLACEBO_COMPARATOR|2|placebo controlled arm
62411556|NCT03273816|NO_INTERVENTION|Patients without sessions of sophrology|The control group is also composed of Parkinsonian patients waiting for deep brain surgery but will not have any special preparation for the procedure. They will be subjected to the same assessments at the same time as the sophrology group.
62411557|NCT03273816|EXPERIMENTAL|Patients with sessions of sophrology|The experimental group is composed of patients with Parkinson's waiting for deep brain surgery. They will benefit from 10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
62411558|NCT02823782|EXPERIMENTAL|Laminar HP|Structural and functional MRI markers
62217311|NCT04397991|EXPERIMENTAL|Furosemide|Patients will receive nebulised furosemide
62217312|NCT04397991|PLACEBO_COMPARATOR|Placebo|Patients will receive nebulised 0.9% saline
62411559|NCT02823782|EXPERIMENTAL|Complex HP|Structural and functional MRI markers
62217313|NCT04559230|EXPERIMENTAL|Sacituzumab govitecan|Dosing will be at 10 mg/kg on days 1 and 8 of a 21-day cycle
62217314|NCT06610292|NO_INTERVENTION|Control group|Patients did not receive Pharmacist-led medication reconciliation services
62217315|NCT06610292|EXPERIMENTAL|Intervention group|Patients received Pharmacist-led medication reconciliation services
62217316|NCT02751411|EXPERIMENTAL|micro-enema with Promelaxin|2,5 g, 5 g or 2X5 g (calculated considering patient age) have to be administered daily (in the evening) for one week, once every other day for the second week and as needed for the following 6 weeks
62217317|NCT02751411|ACTIVE_COMPARATOR|Macrogol 4000|One/Two sachets of the study treatment has to be solubilized in 50mL of water and then administered daily. The administration should take place in the morning (the first sachet or in the event that only one sachet/day should be administered) and in the evening (second sachet).
62411560|NCT02823782|EXPERIMENTAL|ADHD|Structural and functional MRI markers
62411561|NCT02823782|OTHER|Control|Structural and functional MRI markers
62411562|NCT02439801||Compliance|"Pulmonary compliance (or lung compliance) is a measure of the lung's ability to stretch and expand. In clinical practice it is separated into two different measurements, static compliance and dynamic compliance. Static lung compliance is the change in volume for any given applied pressure. Dynamic lung compliance is the compliance of the lung at any given time during actual movement of air.~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on static and dynamic compliance levels will be investigate."
62411563|NCT02439801||Pulmonary Function tests|"Pulmonary function testing has diagnostic and therapeutic roles and helps clinicians answer some general questions about patients with lung disease.~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on pulmonary function test values will be investigate."
62411564|NCT02439801||volatil agent elimination time|"Volatile anaesthetics are eliminated in the terminal phase via the lungs. A low blood:gas partition coefficient is therefore necessary for quick removal of the anaesthetic.~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on volatil agent elimination time will be investigate."
62411565|NCT05007652|EXPERIMENTAL|multiple myeloma cohort (KRN125)|
62411566|NCT05007652|ACTIVE_COMPARATOR|multiple myeloma cohort (KRN8601)|
62411567|NCT05007652|EXPERIMENTAL|malignant lymphoma cohort|
62021740|NCT02663817|EXPERIMENTAL|IMRT|Study participants being treated according to the standard of care with intensity modulated radiotherapy (IMRT). Several CT scans will be performed for each enrolled subject: one before the radiotherapy course for patient treatment planning purposes (as part of the standard of care), one during the radiotherapy treatment course (between fraction 10 and 20), and one at follow up visit or at least 6 weeks post-radiotherapy treatment (whichever comes first).
62021741|NCT03544034|NO_INTERVENTION|Pre-intervention|Routine/ standard care and retrospective chart review for identifying preventable and ameliorable Adverse drug events as baseline
62411568|NCT03073642|ACTIVE_COMPARATOR|Hydrotherapy|"Patients allocated to this group will perform 12 weeks of hydrotherapy treatment, with global exercises. Hydrotherapy sessions will last 45 minutes and will be performed twice a week.~Exercises will involve aerobic exercises (in the pool) with exercises for upper and lower limbs, and trunk."
62411569|NCT03073642|EXPERIMENTAL|Hydrotherapy and Pain Education|"Patients allocated to this group will perform 12 weeks of hydrotherapy treatment, with global exercises. Hydrotherapy sessions will last 45 minutes and will be performed twice a week.~Exercises will involve aerobic exercises (in the pool) with exercises for upper and lower limbs, and trunk.~During the 12 weeks of hydrotherapy treatment, volunteers will also receive 4 sessions of Pain Therapeutic Education, which is also known as Pain Neuroscience Education, which involves patient education on pain neurophysiology, pain chronification and amplification mechanisms, and chronic pain management. These sessions will be performed in specific dates scheduled according to the volunteers' availability, and with intervals that can last from one to two weeks."
62411570|NCT06621511|EXPERIMENTAL|Intervention group|Couples in the intervention group will have exposure to the OurSleepKit app in addition to usual care.
62411571|NCT06621511|NO_INTERVENTION|Control group|Couples in the control group will not have exposure to the OurSleepKit app during the trial. Patients will receive usual care.
62793164|NCT06042634|EXPERIMENTAL|Online psychoeducation|The online psychoeducation was presented virtually via Zoom videoconferencing for synchronous group meeting. It has two core components: didactic teaching and active participation. The didactic teaching provided information support about dementia caregiving which was delivered via Powerpoint presentations. The programme allowed: (1) hands-on skill training opportunities to rehearse caregiving skills through simulation and written assignments; (2) sharing of caregiving experiences and learning vicariously from other participants through group discussion; (3) reflection on own caregiving approach; and (4) addressing negative emotions through practicing relaxation technique. Participants went through six-weekly psychoeducation sessions in a small group of five to eight. Each psychoeducation session consisted of didactic teaching and active participation which lasted for 120 minutes. Participants went through discussion, simulation and was given home assignment weekly.
62021742|NCT03544034|EXPERIMENTAL|Post-intervention|Hometeam toolkit interventions (including improved discharge education, proactive medication safety assessment in daily rounds and handoffs, safety briefings) applied in all hospitalist services.
62021743|NCT02235766||CRT candidates patients|In accordance with the current ESC/ACCF/AHA indications for CRT in sinus rhythm, all patients in NYHA class II, III and IV with QRS complex greater than 120 msec and ejection fraction equal or less than 35% will be considered eligible to participate in this observational study.
62021744|NCT02541253|EXPERIMENTAL|GC3110A|One injection : 0.5ml or 0.25ml, IM on day 0 Two injection : 0.5ml or 0.25ml, IM on day 0
62021745|NCT02541253|ACTIVE_COMPARATOR|GCFLU Pre-filled Syringe inj.|One injection : 0.5ml or 0.25ml, IM on day 0 Two injection : 0.5ml or 0.25ml, IM on day 0
62021746|NCT02445820||HES|Balanced HES 130/0.4 used as and pump prime and for intraoperative fluid therapy.
62021747|NCT02445820||Crystalloid|Balanced Crystalloid used as a pump prime and for intraoperative fluid therapy.
62021748|NCT05330663|EXPERIMENTAL|Intervention group|Low protein diet with Fresubin® renal
62411572|NCT06055894|EXPERIMENTAL|Omega-3|For 2 weeks, patients will receive omega 3 fatty acid supplements 1640 mg (2 capsules) twice daily Qwell™ Omega 3 by The Veggie Doctor™. Each 820 mg omega 3 supplement capsule contains 700 mg Docosohexaenoic acid, 100 mg Docosapentaenoic acid, and 20 mg Eicosapentaenoic acid. No dietary changes will be made but data on dietary intake will be collected.
62411573|NCT06055894|EXPERIMENTAL|Curcumin|For 2 weeks, patients in the curcumin arm will receive Curcumin C3 complex 1000 mg with 5 mg BioPerine twice daily from Sabinsa pharmaceuticals. No dietary changes will be made but data on dietary intake will be collected.
62411574|NCT06055894|EXPERIMENTAL|Probiotic|For 2 weeks, patients in the probiotic arm will receive Ultra-50 probiotics with 50 billion CFU per capsule (one capsule) twice daily from Vita Miracle pharmaceuticals. No dietary changes will be made but data on dietary intake will be collected.
62411575|NCT06055894|EXPERIMENTAL|Whole food, plant-based diet (WFPBD)|For 2 weeks, on the WFPBD arm, patients will receive 14 items weekly, prepared and shipped by U.S. based company, Daily Harvest once a week. The meals will have range from 2 breakfast, 11 lunch/dinners, 1 snack (provided Week 1), and whole grains items (provided Week 2). The meals will contain legumes, fruits, vegetables, whole grains, and plant-based fats that have undergone minimal processing. Detailed recommendations for additional meals outside those given by Daily Harvet meeting the standard of a WFPBD will also be given to supplement their individual daily calorie needs through the guidance of the research dietitian. Patients will receive a varied menu created by Daily Harvest and the study team on a weekly basis.
62411576|NCT04571164|EXPERIMENTAL|LY03003|
62411577|NCT04571164|PLACEBO_COMPARATOR|Placebo|
62411578|NCT05978570||A personally tailored exercise|A personally tailored exercise program will be offered to the participants after the Physical Therapy assessment, before the surgery.
62021749|NCT05330663|OTHER|Standard of care|Low protein diet with normal food
62021750|NCT02338362|ACTIVE_COMPARATOR|Fluticasone|10 participants will be asked to use fluticasone propionate 250 µg metered-dose inhaler 1 puff twice-daily for 6 weeks.
62021751|NCT02338362|PLACEBO_COMPARATOR|Saline placebo|10 participants will be asked to use a saline placebo metered-dose inhaler 1 puff twice-daily for 6 weeks.
62021752|NCT00647231|EXPERIMENTAL|A, 2, II, HKT-500 Topical Patch|A Randomized, Multicenter, Double-Blind, Single Dose Study of the Analgesic Properties of HKT-500 and Placebo in Subjects With Pain Caused by Mild to Moderate Osteoarthritis of the Knee
62021753|NCT00647231|PLACEBO_COMPARATOR|Placebo Patch|Treatment with placebo patch
62021754|NCT01977118|EXPERIMENTAL|Group B [streptokinase]|50000U of injection streptokinase dissolved in 100ml of normal saline instilled in to the pancreatic and/or peripancreatic collections via the percutaneous catheters and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of normal saline. This procedure will be done thrice daily for five days
62411579|NCT06541756|EXPERIMENTAL|Fibrin Clot-augmented group|Patients in the experimental repair group will undergo routine meniscus repair surgery in addition to a fibrin clot placed within the ruptured sides using arthroscopic all-inside or inside-out sutures. The fibrin clot will be prepared from 50cc of bone marrow aspirate obtained from the iliac crest and mixed for 15 minutes. The clot will be shaped into a cylindrical form and compressed between the torn edges of the meniscus using a trocar system, then secured with sutures.
62585684|NCT06557122|OTHER|SOC and Active Comparator|The SOC therapy in this study is offloading of the DFU (CAM boots or total contact casting \[TCC\] if the subject's foot is too large for a CAM boot), appropriate sharp or surgical debridement, infection management (systemic antibiotics only in conjunction with debridement) and wound care covering with Epifix® or Grafix® followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous, second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Dynaflex™ or equivalent).
62793165|NCT06042634|ACTIVE_COMPARATOR|Face-to-face psychoeducation|Face-to-face psychoeducation had the same content and flow of presentation as online psychoeducation. The only difference was the mode of delivery which was presented physically in the community center.
62819356|NCT03243695|ACTIVE_COMPARATOR|Straight abutment|According to the allocation, the control group will receive on the immediately placed implant a Straight zero degree abutment . A vaccum stent will be used to fabricate a temporary crown using tooth colored auto-polymerizing resin(structur 2 SC/ QM , VOCO GmbH, Germany)
62021755|NCT01977118|PLACEBO_COMPARATOR|Group A [placebo]|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
62217318|NCT06352476|EXPERIMENTAL|sleep hygiene training|Experimental group first interview; Routine treatment of patients will continue. The interview will be face to face, and after obtaining consent from the patients, the Epilepsy Patient Information Form and Pittsburg Sleep Quality Index (PSQI) will be applied. Sleep hygiene training will be provided, and patients will be given a sleep hygiene training booklet and training video. After the training, the Pittsburg Sleep Quality Index (PSQI) will be applied. Patients will be given an Epileptic Seizure Diary and a Sleep Hygiene Chart, and they will be asked and evaluated together at the next meeting. Experimental group second interview; and the third meeting will be held once a month, and sleep hygiene training will be provided through face-to-face meetings with the patients. After the training, the Pittsburg Sleep Quality Index (PSQI) will be applied and the Epileptic Seizure Diary and Sleep hygiene chart will be requested from the patients and evaluated together.
62217319|NCT06352476|NO_INTERVENTION|Placebo Comparator|Routine treatment of the Control/Placebo group will continue. His insomnia and seizures will be monitored for three months. The survey will be filled out during monthly meetings.
62021756|NCT05743985|EXPERIMENTAL|50mg CBG Capsule|50mg cannabigerol (CBG) oil capsule taken daily for 8 weeks. Study surveys and bloodwork completed for 12 weeks total, including 8 weeks of CBG treatment and subsequent 4-week washout period
62021757|NCT04781764||glioma patients|glioma patients with routine surgery
62217320|NCT01745731|EXPERIMENTAL|Experimental|Patients with hepatic space occupying lesion requiring an extended hepatic resection to those who were preoperatively performed a Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
62411580|NCT06541756|ACTIVE_COMPARATOR|Conventionally repaired group|Patients in the control repair group will undergo routine meniscus repair surgery using arthroscopic all-inside or inside-out sutures. The ruptured sides will be approximated as usual and the procedure will be considered completed.
62411581|NCT00563706|EXPERIMENTAL|1|
62411582|NCT00563706|ACTIVE_COMPARATOR|2|4mg/day
62411583|NCT00563706|PLACEBO_COMPARATOR|3|matching placebo
62411584|NCT00871806|ACTIVE_COMPARATOR|Eletriptan commercial tablet with water|Eletriptan commercial tablet given with water
62585685|NCT03395080|EXPERIMENTAL|DKN-01 monotherapy in recurrent EEC|300mg DKN-01 monotherapy in recurrent EEC
62585686|NCT03395080|EXPERIMENTAL|DKN-01+paclitaxel in recurrent EEC|300mg DKN-01+paclitaxel in recurrent EEC
62585687|NCT03395080|EXPERIMENTAL|DKN-01 monotherapy in recurrent EOC|300mg DKN-01 monotherapy in recurrent EOC
62411585|NCT00871806|EXPERIMENTAL|Eletriptan oral disintegrating tablet (ODT) #1 without water|Oral disintegrating tablet formulation #1 without water
62411586|NCT00871806|EXPERIMENTAL|Oral disintegrating tablet formulation (ODT) #2 without water|Oral disintegrating tablet formulation #2 without water
62411587|NCT00871806|EXPERIMENTAL|Oral disintegrating tablet formulation (ODT) #1 with water|Oral disintegrating tablet formulation (ODT) #1 with water
62411588|NCT00871806|EXPERIMENTAL|Oral disintegrating tablet formulation (ODT) #2 with water|Oral disintegrating tablet formulation (ODT) #2 with water
62411589|NCT04911075|EXPERIMENTAL|85% TCA Group|"* Participants are subject who will undergo an elective total hysterectomy procedure for indications of gynecological organ abnormalities, whether benign, pre-cancerous, or malignant other than cervical pathology.~* The 85 percent TCA solution will be applied to participants cervical tissue 24 hours before surgery."
62585688|NCT03395080|EXPERIMENTAL|DKN-01+paclitaxel in recurrent EOC|300mg DKN-01+paclitaxel in recurrent EOC
62021758|NCT01259544|ACTIVE_COMPARATOR|Di -petide breath tests and ePFT secretin induced|Di peptide breath tests will be performed on subjects with known chronic pancreatitis
62021759|NCT01259544|ACTIVE_COMPARATOR|c13 di peptide breath tests|Healthy volunteers to compare breath tests results to subjects with chronic pancreatitis
62021760|NCT06342362|EXPERIMENTAL|treatment group (receiving magnesium sulfate)|Participants would be randomly assigned to either the treatment group (receiving magnesium sulfate) or the control group (receiving a placebo or standard treatment).
62585689|NCT03395080|EXPERIMENTAL|DKN-01 monotherapy in carcinosarcoma|600mg DKN-01 monotherapy in carcinosarcoma
62585690|NCT03395080|EXPERIMENTAL|DKN-01 +paclitaxel in carcinosarcoma|600mg DKN-01 +paclitaxel in carcinosarcoma
62021761|NCT06342362|PLACEBO_COMPARATOR|the control group (receiving a placebo or standard treatment)|Participants would be randomly assigned to either the treatment group (receiving
62021762|NCT06288113|EXPERIMENTAL|Treatment (177Lu-PSMA-617)|Patients receive 177Lu-PSMA-617 IV on day 1 of each cycle. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive gallium Ga 68 gozetotide IV and undergo PET/CT at screening and on study, undergo SPECT/CT on study, and undergo collection of blood samples throughout the trial.
62021763|NCT05831293|EXPERIMENTAL|Experimental|In each session, three sections were discussed and reviewed: (1) last week's experiences, (2) training, and (3) practice. Each session usually began with mindfulness and meditation exercises, followed by group discussion, review of homework activities, and introduction to new exercises. Participants were asked to complete 15-30 minutes of daily practice each week.
62021764|NCT05831293|NO_INTERVENTION|Control|No intervention will be applied to the control group.
62021765|NCT00401570|EXPERIMENTAL|Cohort 1|Volociximab (10 mg/kg every other week (qowk)) and Gemcitabine
62021766|NCT00401570|EXPERIMENTAL|Cohort 2|Volociximab (15 mg/kg weekly (qwk)) and Gemcitabine
62021767|NCT02873923||Patients with a metastatic soft tissue sarcoma|All patients included in eligible clinical trials of the meta-analysis
62021768|NCT02692248|EXPERIMENTAL|Ibrutinib -R-GEMOX-Dexa|"Subjects will receive Ibrutinib with R-GEMOX-Dexa followed by Ibrutinib maintenance according to:~Induction phase:~* Rituximab 375 mg/m2 IV day 1~* Gemcitabine 1000 mg/m2 IV on day 1 or 2 (at investigator discretion).~* Oxaliplatine 100 mg/m2 on day 1 or 2 (after Gemcitabine administration);~* Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3.~* Ibrutinib 560 mg daily for 14 days.~Responding patients will receive 2 (if CR) or 4 (if PR) additional cycles every 14 days.Patients with SD and ABC profile will receive 4 additional cycles.~Maintenance phase: Responding patients will receive Ibrutinib 560 mg daily - Continuous cycles until a maximum of 2 years, disease progression or unacceptable toxicity."
62021769|NCT06158633||Active Intervention|All subjects will be in the active treatment group and receive the study intervention. The study intervention is Prevora.
62411590|NCT04013373||BIS home-based monitoring|
62411591|NCT03895827|ACTIVE_COMPARATOR|Passive Referral Control|Participants will be given information on recently expanded and publicly-funded MAT treatment in their community.
62411592|NCT03895827|EXPERIMENTAL|Recovery Initiation and Management after Overdose (RIMO)|Participants assigned to the RIMO arm will meet with Linkage Managers (LM), who will use motivational interviewing (MI) techniques to: 1) identify the need for treatment and barriers to going, 2) discuss with patients the benefits of their decision to go to treatment, including activities they might enjoy as well as things they do not like about their alcohol/substance use, 3) provide personalized feedback to participants about the status of their condition based on responses to the assessment instruments, 4) help participants resolve ambivalence about their use and move them toward a commitment to change by accessing additional care, 5) address existing barriers to treatment (e.g., childcare, transportation), 6) schedule a treatment appointment, and 7) facilitate medication assisted treatment re-entry and engagement.
62411593|NCT06338280|EXPERIMENTAL|Sonara-enabled|
62411594|NCT06338280|NO_INTERVENTION|Treatment as usual|
62585691|NCT02776891|EXPERIMENTAL|Gallium citrate|The patients will be organized into two cohorts. Cohort 1 will receive 10 mCi and will be imaged 4 and 6 hours post injection. Cohort 2 will receive 15 millicurie (mCi) and will be imaged 4 and 6 hours post injection. Cohort 2 will be imaged if the optimal protocol identified image quality from cohort 1 does not allow for the resolution of cancer lesions.
62585692|NCT01103258|ACTIVE_COMPARATOR|high ligation and stripping|surgery consisting of high ligation in combination with long saphenous stripping
62021770|NCT01591746|EXPERIMENTAL|Group A - Botulinum Toxin Type A|100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast
62021771|NCT01591746|PLACEBO_COMPARATOR|Group B - Placebo|5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast
62021772|NCT06534567||Male|Young male triathletes
62021773|NCT06534567||Female|Young female triathletes
62411595|NCT06226064|EXPERIMENTAL|VES001 (Healthy Participants)|Part A: Ascending single doses and Part B: Multiple ascending dose (seven days of treatment), for healthy volunteers.
62411596|NCT06226064|PLACEBO_COMPARATOR|Placebo (Healthy Participants)|Part A: Ascending single doses and Part B: Multiple ascending dose (seven days of treatment), for healthy volunteers.
62411597|NCT01279265|ACTIVE_COMPARATOR|Nutramigen Lipil with Enflora|Formula with probiotics (Lactobaccillus Rhamnosus GG)
62411598|NCT01279265|PLACEBO_COMPARATOR|Nutramigen A+|Hypoallergenic formula without probiotics (Lactobaccillus Rhamnosus GG)
62585693|NCT01103258|ACTIVE_COMPARATOR|duplex guided foam sclerotherapy|duplex guided foam sclerotherapy
62021774|NCT05824832|EXPERIMENTAL|Interscalene block with the addition of buprenorphine, clonidine, dexamethasone|Interscalene brachial plexus blocks (ISB) is performed with a 22g x 50 mm PAJUNK SonoPlexⓇ II Facet S echogenic needle. Once adequate needle visualization is achieved within the correct anatomic position and plane, 30mL of 0.5% bupivacaine with 100 mcg clonidine, 0.3 mg buprenorphine, and 4 mg dexamethasone will be injected.
62585694|NCT06484348|EXPERIMENTAL|NT1|"Patients with Narcolepsy type 1 will be included in this arm.~They will have following interventions :~1. monitoring of eating behaviors (meals' photos) and sugar consumption (FreeStylePro sensor measuring interstitial glucose)~2. monitoring of sleep/wake rhythm (diary and actigraphy)~3. monitoring of nocturnal sleep parameters (Somfit device)~4. monitoring of sleepiness (Karolinska sleepiness scale and EEG markers of sleepiness with the Somfit device) before and after meals"
62585695|NCT06484348|ACTIVE_COMPARATOR|IH|"Patients with Idiopathic Hypersomnia will be included in this arm.~They will have following interventions :~1. monitoring of eating behaviors (meals' photos) and sugar consumption (FreeStylePro sensor measuring interstitial glucose)~2. monitoring of sleep/wake rhythm (diary and actigraphy)~3. monitoring of nocturnal sleep parameters (Somfit device)~4. monitoring of sleepiness (Karolinska sleepiness scale and EEG markers of sleepiness with the Somfit device) before and after meals"
62021775|NCT05824832|ACTIVE_COMPARATOR|Interscalene block with buprenorphine alone|Interscalene brachial plexus blocks (ISB) is performed with a 22g x 50 mm PAJUNK SonoPlexⓇ II Facet S echogenic needle. Once adequate needle visualization is achieved within the correct anatomic position and plane 30mL of 0.5% bupivacaine will be injected.
62411599|NCT06417749|PLACEBO_COMPARATOR|Control arm|General dietary advice
62411600|NCT06417749|ACTIVE_COMPARATOR|Intervention arm|MIND diet education
62217321|NCT01745731|NO_INTERVENTION|Control|Patients with hepatic space occupying lesion that require an extended liver resection that were performed preoperatively portal embolization of the affected segments.
62217322|NCT03795259|ACTIVE_COMPARATOR|Sevoflurane|Anesthesia will be induced with thiopenthal 5-6 mg/kg and fentanyl 2 mcg/kg. Then rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%. Anesthesia will continue with 2% sevoflurane while the patient is ventilated in volume controlled mode (FiO2: 40%, I/E: 1/1.5, PEEP: 5 cmH2O, tidal volume: 8ml/kg). Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given to measure the time for TOF to reach 90%.
62411601|NCT03378310|EXPERIMENTAL|Reference tablet followed by BMS-986205 tablet with free base|BMS-986205 reference tablet (treatment period 1) followed by BMS-986205 tablet with free base (treatment period 2).
62217323|NCT03795259|ACTIVE_COMPARATOR|Desflurane|Anesthesia will be induced with thiopenthal 5-6 mg/kg and fentanyl 2 mcg/kg. Then rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%. Anesthesia will continue with 6% desflurane while the patient is ventilated in volume controlled mode (FiO2: 40%, I/E: 1/1.5, PEEP: 5 cmH2O, tidal volume: 8ml/kg). Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given to measure the time for TOF to reach 90%.
62411602|NCT03378310|EXPERIMENTAL|BMS-986205 tablet with free base followed by reference tablet|BMS-986205 tablet with free base (treatment period 1) followed by BMS-986205 reference tablet (treatment period 2).
62411603|NCT05285527|EXPERIMENTAL|MiSight 1 Day|MiSight 1 Day
62585696|NCT06484348|ACTIVE_COMPARATOR|HC|"Healthy Controls will be included in this arm.~They will have following interventions :~1. monitoring of eating behaviors (meals' photos) and sugar consumption (FreeStylePro sensor measuring interstitial glucose)~2. monitoring of sleep/wake rhythm (diary and actigraphy)~3. monitoring of nocturnal sleep parameters (Somfit device)~4. monitoring of sleepiness (Karolinska sleepiness scale and EEG markers of sleepiness with the Somfit device) before and after meals"
62585697|NCT03706430|EXPERIMENTAL|Pulse Co-Oximeter sensor|All subjects are enrolled into this arm and will receive an investigational pulse CO-Oximeter sensors.
62585698|NCT05717049|EXPERIMENTAL|Treatment|12 week oral treatment (theophylline)
62021776|NCT04638010|EXPERIMENTAL|Cancer control navigation (CNN) plus General referral (usual care)|"Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.~Additionally, Cancer Control Navigators (CNNs) housed at 2-1-1 call centers aid callers. CNNs receive electronic summary profiles of participants assigned to navigation. Navigators call the participant, build a collaborative relationship with them, identify their needs, work with them to identify barriers to services and coordinate solutions, and provide logistic (e.g., making appointments) and emotional support. Navigation services are provided by telephone only."
62021777|NCT04638010|ACTIVE_COMPARATOR|General referral (usual care)|Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
62217324|NCT02516332|EXPERIMENTAL|Supervised Aerobic Exercise|Patients will exercise three times per week, under medical supervision, at a level of 70-85% of their VO2peak as determined at the time of their baseline exercise stress test. Patients' exercise will consist of 10 minutes of gradual warm-up exercises followed by 35 minutes of continuous walking, biking, or jogging, and 5 minutes of cool down exercises for a total a 50 minutes per session. Patients will be instructed to monitor their radial pulses and will be checked at least three times per session to ensure that they are within their prescribed exercise training ranges.
62411604|NCT06653725|EXPERIMENTAL|1,3-butanediol|1,3-butanediol (Ketone-IQ®) 118 mL (33 g) servings trice daily
62411605|NCT06653725|PLACEBO_COMPARATOR|Placebo|Taste-matched placebo (isovolumic, isoviscous water with stevia) 118 mL servings trice daily
62411606|NCT02064374|EXPERIMENTAL|Cohort 1|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive Metformin immediate release (IR) 500 mg q12h following a moderate fat meal for 5 days (Period 1), followed by Metformin IR 500 mg q12h plus DTG 50 mg q24h following a moderate fat meal for 7 days (Days 1-7 of Period 2), followed by Metformin IR 500 mg q12h following a moderate fat meal (Days 1-10 of period 3).
62411607|NCT02064374|EXPERIMENTAL|Cohort 2|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive Metformin IR 500 mg q12h following a moderate fat meal (Day 1-5 of Period 1), followed by Metformin IR 500 mg q12h plus DTG 50 mg q12h following a moderate fat meal for 7 days (Days 1-7 of Period 2), followed by Metformin IR 500 mg q12h following a moderate fat meal (Days 1-10 of period 3).
62585699|NCT06667934|EXPERIMENTAL|Study Group|Zuoqing powder was dissolved in 100ml normal saline, retained enema, once a night
62585700|NCT06667934|ACTIVE_COMPARATOR|Control Group|Methalazine supposers anal once a day
62585701|NCT03282721||redesigned|the commissure constructions of the cleft side were precised located, include the upper and lower inherent vermilion border, the interior commissure, the outline of commissure, the exterior commissure, the upper skin-mucosa junction and the lower skin-mucosa junction.
62585702|NCT03282721||classical|follows the simple-symmetry rule, the commissure of the healthy side is measured, and then the affected side is located accordingly.
62585703|NCT03551769|EXPERIMENTAL|Cohort 1, Period 1|Study drug administered concurrently with a standard meal
62585704|NCT03551769|EXPERIMENTAL|Cohort 1, Period 2|Study drug administered 30 minutes after a standard meal
62585705|NCT03551769|EXPERIMENTAL|Cohort 1, Period 3|Study drug administered 30 minutes after a high-fat meal
62411608|NCT06468449|EXPERIMENTAL|Experimental Group：power output|by identifying the optimal load at which the athlete achieves the highest power output. The training program is then tailored based on these measurements, ensuring that the athlete trains at the load that maximizes their power output. This approach allows for more efficient and effective strength training, potentially leading to improved athletic performance. Throughout the training period, the VBT equipment continuously monitors the athlete's performance, providing real-time feedback and allowing for adjustments to the load as the athlete's strength and power improve. The goal is to enhance neuromuscular adaptations and optimize the athlete's power development, particularly during explosive movements like the vertical jump and long jump.
62411609|NCT06468449|EXPERIMENTAL|Control Group:speed combined force|Speed combined with strength training is designed to enhance the explosive power of long jumpers' lower limbs. This involves using maximum strength barbell squats and knee jumps to develop athletes' maximum strength and improve the speed of their neural contractions. Additionally, plyometric exercises and sprint drills are incorporated to further boost explosive power and coordination. This comprehensive training approach aims to optimize both the force and velocity aspects of power, leading to better overall performance in explosive movements critical for long jump success. Regular assessments and adjustments ensure that training loads are appropriate and effective for each athlete's progress.
62411610|NCT04936334|EXPERIMENTAL|Men diagnosed with clinically significant prostate cancer who are scheduled for prostatectomy|1. Men diagnosed with clinically significant prostate cancer who are scheduled or for prostatectomy will undergo injection of 68Ga-PSMA-11 at the time of their pre-treatment PSMA PET. Followed until 12 mo post surgery
62411611|NCT04400175|EXPERIMENTAL|B-ESP|B-ESP group will be fed with a feeding system with a valved ergonomic teat.
62411612|NCT04400175|SHAM_COMPARATOR|B-STD|B-STD will be fed with a standard feeding system.
62021778|NCT05457335||PGT-A group|For patients undergoing PGT-A, trophectoderm biopsy was performed on good quality blastocysts and about five cells were aspirated gently and separated from the blastocyst by applying multiple pulses of a noncontact 1.48- μm diode laser (Saturn 5 ActiveTM, Cooper Surgical, Inc., CT, USA) through a zona pellucida opening created by the laser. The biopsied cells were washed three times in 1 × phosphate buffered saline (PBS) (Life Technologies, NY, USA), transferred to a PCR tube containing 2.5 μl 1× PBS and cryopreserved at -80◦C until analysis. Genetic laboratories analyzed and interpreted biopsies. The genetic screening was performed using the next-generation sequencing (NGS)-based assay VeriSeq PGS following standard protocols and manufacturer recommendations (Illumina Inc., San Diego, USA）. The PGT-A report can be euploid, aneuploidy, mosaic and non-conclusive. Euploid embryos were transferred while aneuploid and mosaic embryos were not replaced.
62021779|NCT05457335||Expectant management group|In the this group, one attempt at conception was defined as one calendar months trying to conceive spontaneously. Either in natural cycles for ovulatory women and in clomiphene/letrozol induced cycles for anovulatory women with or without ultrasound monitoring.
62021780|NCT00533390|EXPERIMENTAL|EFAVIRENZ 800mg|Efavirenz 800 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin
62021781|NCT00533390|ACTIVE_COMPARATOR|EFAVIRENZ 600mg|Efavirenz 600 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin
62411613|NCT04014972||Patients with Myocardial Infarction|
62411614|NCT06634407|OTHER|PDA patients|
62021782|NCT04833829|ACTIVE_COMPARATOR|Clinic Patients During the Pre-implementation Period|Patients visiting one of the study clinics prior to implementation of the CHIMES intervention. The Baseline time period consists of study Months 1 - 12. Data are retroactively abstracted from medical records of patients who had clinic visits that occurred between January 1, 2019 and December 31, 2019.
62021783|NCT04833829|EXPERIMENTAL|Clinic Patients During the Implementation Period|Patients visiting one of the study clinics during the Implementation period of the CHIMES intervention. Data will be abstracted from medical records of visits that occur during study Months 13 - 27.
62021784|NCT04833829|EXPERIMENTAL|Clinic Patients During the Maintenance Period|Patients visiting one of the study clinics during the Maintenance period of the CHIMES intervention. Data will be abstracted from medical records of visits that occur during study Months 28 - 33.
62585706|NCT03551769|EXPERIMENTAL|Cohort 1, Period 4|Study drug administered after an overnight fast
62585707|NCT03551769|EXPERIMENTAL|Cohort 2, Period 1|Study drug administered 30 minutes after a standard meal (Asian)
62585708|NCT03551769|EXPERIMENTAL|Cohort 2, Period 2|Study drug administered after an overnight fast (Asian)
62585709|NCT04505267|EXPERIMENTAL|Treatment (NBTXR3, RT)|Patients receive NBTXR3 IT or intranodally on day 1. Within 15 days, patients undergo RT 5 times weekly (Monday-Friday) over 3 weeks for a total of 10-15 fractions.
62585710|NCT01808079||Ancillary-correlative (genetic markers of Wilms tumor)|Samples are analyzed for SNP profiling using real-time PCR and MLPA.
62585711|NCT03105479|EXPERIMENTAL|Part A / Cohort A|Subjects from 12 years to 18 years old (exclusive) will receive cadazolid 500 mg per day for 10 days. The dose may be adjusted based on the pharmacokinetic (PK) and safety data reviewed for the first 3 subjects.
62585712|NCT03105479|EXPERIMENTAL|Part A / Cohort B|Subjects from 6 years to 12 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort A reviewed by the Independent Data Monitoring Committee (IDMC).
62411615|NCT01069458|EXPERIMENTAL|The High Protein Diet Group|The high protein diet (25% energy from protein, 55% energy from fat, 20% energy from carbohydrate) will be hypo-caloric and achieved by restricting the amount of sugar containing foods and drinks, reducing the intake of bread, rice, pasta, fruits and fruit-juices and increasing the intake of vegetables (instead of bread, rice, pasta and potatoes) and increasing the amounts of protein (from chicken, fish, and meat) and fat from oil and dressings for lunch and dinner and by choosing nuts and protein-rich yoghurts, egg, cheese, chicken wings, shellfish, fish and fish products as snacks.
62411616|NCT01069458|ACTIVE_COMPARATOR|The Low Fat Diet Group|The low fat diet (30% energy from fat, 20% energy from protein, 50% energy percent from carbohydrate) will be hypo-caloric and achieved by choosing low-fat diary and meat products, restricting amounts of visible fat and fatty snacks and increasing intake of whole meal bread, muesli, brown rice, whole meal pasta in the main meals and by choosing yoghurt with muesli, oat porridge with milk, fruits and hard bread with jam and soft gout-cheese as snacks.
62411617|NCT04993339|NO_INTERVENTION|Standard Surgery|Participants in this group undergoing standard of care reparative surgery will not receive additional intervention
62411618|NCT04993339|EXPERIMENTAL|Standard Surgery with OOC|Participants in this group undergoing standard of care reparative surgery will receive OOC as an additional intervention
62411619|NCT05793060|ACTIVE_COMPARATOR|Group A (n=30)|Dexmedetomidine group
62411620|NCT05793060|ACTIVE_COMPARATOR|Group B (n=30)|Dexamethasone group
62411621|NCT04843891|EXPERIMENTAL|Healthy Volunteers|In 10 healthy volunteers the radiation dosimetry, normal organ distribution, and safety of \[64Cu\]-Macrin injection will be studied.
62411622|NCT04843891|EXPERIMENTAL|Cardiovascular Disease|In 30 subjects with a history of recent myocardial infarct, the radiation dosimetry, normal organ distribution, and safety of \[64Cu\]-Macrin injection will be studied. In addition, the ability of \[64Cu\] Macrin to concentrate at the infarct site will be correlated with cardiac MRI.
62411623|NCT04843891|EXPERIMENTAL|Cancer|In 30 subjects with an epithelial malignancy the radiation dosimetry, normal organ distribution, and safety of \[64Cu\]-Macrin injection will be studied. In addition, the ability of \[64Cu\] Macrin to concentrate at the tumor site will be correlated with imaging and histopathology, where available.
62411624|NCT04843891|EXPERIMENTAL|Sarcoidosis|In 30 subjects with sarcoidosis the radiation dosimetry, normal organ distribution, and safety of \[64Cu\]-Macrin injection will be studied. In addition, the ability of \[64Cu\] Macrin to concentrate at the tumor site will be correlated with imaging and histopathology, where available.
62411625|NCT03099265|EXPERIMENTAL|patients with borderline resectable pancreatic adenocarcinoma|Borderline resectable disease will be defined by NCCN criteria, and determined centrally by review of a diagnostic pancreas protocol CT scan and/or MRI scan with contrast by a dedicated surgical oncologist and radiologist.
62021785|NCT01573702|OTHER|Stereotactic Radiosurgery Followed by Erlotinib|Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib
62585713|NCT03105479|EXPERIMENTAL|Part A / Cohort C|Subjects from 2 years to 6 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort B reviewed by the IDMC.
62021786|NCT03286491||Patients presenting with acute coronary syndrome|Patients presenting to emergency department with acute coronary syndrome
62021787|NCT00966316|EXPERIMENTAL|pathway|aspirin，Chinese herbs；acupuncture；rehabilitation；health education；
62021788|NCT01070875|ACTIVE_COMPARATOR|UFH 5000 U three times per day|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous three times a day.
62021789|NCT01070875|ACTIVE_COMPARATOR|UFH 5000 U two times per day|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
62021790|NCT02579993|EXPERIMENTAL|Stem Cell Transplantation|Cultivated Limbal Stem Cell Transplantation
62021791|NCT04039516|EXPERIMENTAL|Lutathera Treatment Arm|• 4x cycles of 7.4 GBq (200mCi) of Lutathera therapy (177Lu-DOTA0-Tyr3-Octreotate) with concomitant amino acids for participants randomised onto the Lutathera therapy arm, every 8 weeks, plus long term somatostatin analogues (SSTA).
62021792|NCT04039516|NO_INTERVENTION|Best Supportive Care|Somatostatin analogue treatment according to current standard, routine care
62021793|NCT05630716|EXPERIMENTAL|Non-Invasive Cardiac Output Monitor (NICOM)|adult inpatients with sepsis associated with acute hypotension and/or evidence of septic shock
62021794|NCT02835534|EXPERIMENTAL|rhTNK-tPA|rhTNK-tPA; Dose:16mg; Mode of admin: Single bolus Dose:50mg; Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
62021795|NCT02835534|ACTIVE_COMPARATOR|rt-PA|Drug:alteplase;Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
62021796|NCT01319318||Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
62021797|NCT03799562|EXPERIMENTAL|Pregnenolone|Placebo lead in 14 DAYS, followed by Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial
62021798|NCT03799562|PLACEBO_COMPARATOR|Placebo|Same as pregnenolone (active study medication), except placebo dispensed.
62021799|NCT05582863|EXPERIMENTAL|Intervention group.|"The experimental group attended a VR exercise routine twice a week for 12 weeks.~Device:1 computer virtual reality online software and 3 large projectors were used to project videos on the wall in a wrap-around state."
62021800|NCT05582863|NO_INTERVENTION|Control group.|Participants in the control group received no intervention and had normal daily activites.
62021801|NCT05388448|EXPERIMENTAL|Sanfetrinem cilexetil 1.6 gram 12 hourly|Sanfetrinem cilexetil 1.6g will be given orally 12 hourly for 14 consecutive days.
62021802|NCT05388448|EXPERIMENTAL|Rifampicin 35 mg/kg once daily|Rifampicin 35 mg/kg will be given orally once daily for 14 consecutive days.
62021803|NCT05388448|EXPERIMENTAL|Sanfetrinem cilexetil 3.2 gram once daily|Sanfetrinem cilexetil 3.2 g will be given orally daily for 14 consecutive days.
62021804|NCT05388448|EXPERIMENTAL|Sanfetrinem cilexetil 800 mg 12 hourly|Sanfetrinem cilexetil 800 mg will be given orally 12 hourly for 14 consecutive days.
62585714|NCT03105479|EXPERIMENTAL|Part A/ Cohort D|Subjects from 3 months to 2 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort C reviewed by the IDMC.
62793166|NCT03431350|EXPERIMENTAL|Combination 1:Dose Selection: Niraparib + cetrelimab (Part 1)|Dose regimen 1: The participants will receive niraparib 200 milligram (mg) orally once daily in combination with cetrelimab 240 mg intravenously (IV) once every 2 weeks. Dose regimen 2: The participants will receive niraparib 200 mg orally once daily in combination with cetrelimab 480 mg IV once every 4 weeks in 28-day treatment cycles until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. The safety evaluation team (SET) will determine if an additional cohort is necessary, based on the data from dose regimens 1 and 2. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
62793167|NCT03431350|EXPERIMENTAL|Combination 1:Dose Expansion: Niraparib + cetrelimab (Part 2)|Participants will be assigned to either Cohort 1A (Biomarker \[BM\] positive \[+\]) or Cohort 1B (BM negative \[-\]) and will receive established RP2D of cetrelimab and niraparib, in Part 2 until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. A futility analysis will be performed for the Cohort 1B after 10 BM- participants are enrolled in Part 2. This cohort will be closed if the response is less than predetermined response rate as outlined in the protocol. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
62021805|NCT05388448|EXPERIMENTAL|Sanfetrinem cilexetil 800 mg 8 hourly|Sanfetrinem cilexetil 800 mg will be given orally 8 hourly for 14 consecutive days.
62021806|NCT05388448|EXPERIMENTAL|Sanfetrinem cilexetil 1.6 gram plus amoxicillin/clavulanic acid 250 mg/125 mg 12 hourly|Sanfetrinem cilexetil 1.6 g plus amoxicillin/clavulanic acid 250 mg/125 mg will be given orally 12 hourly for 14 consecutive days.
62021807|NCT05388448|EXPERIMENTAL|Sanfetrinem cilexetil 1.6 gram 12 hourly plus rifampicin 35 mg/kg once daily|Sanfetrinem cilexetil 1.6 g will be given orally 12 hourly plus rifampicin 35 mg/kg orally once daily for 14 consecutive days.
62021808|NCT00618657|EXPERIMENTAL|Arm I (HER-2 positive)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes, carboplatin IV over 60 minutes, and trastuzumab IV over 90 minutes , then weekly over 30-60 minutes. Treatment repeats every week for 12 weeks in the absence of disease progression or unacceptable toxicity. In both arms, beginning 21-40 days later, patients undergo surgery.
62021809|NCT00618657|EXPERIMENTAL|Arm II (HER-2 negative)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as in Arm I. Patients also receive bevacizumab IV over 90 or 60 or 30 minutes once every two weeks for 5 doses in the absence of disease progression or unacceptable toxicity. In both arms, beginning 21-40 days later, patients undergo surgery.
62021810|NCT00209313|OTHER|1|Acyclovir 800 mg twice daily for 8 weeks, two week washout, 8 weeks placebo
62021811|NCT00209313|OTHER|2|8 weeks placebo, 2 week washout, 8 weeks 800 mg acyclovir twice daily
62021812|NCT03747029||Patients with hyperparathyroidism|Patients aged between 18-90 years old with primary hyperparathyroidism. No intervention is provided.
62021813|NCT03747029||Patients with hypoparathyroidism|"Patients aged between 18-90 years old with diagnosed hypoparathyroidism. No intervention is provided.~."
62021814|NCT03747029||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their calcium-phosphorus metabolism state with normal results.~No intervention is provided."
62021815|NCT05198232|NO_INTERVENTION|Control Group|This group will complete normal daily activities. The participants will complete pre-test, 10 weeks of normal daily activities, and post-test. No changes to their daily schedule will be made by the researcher, the control group will participate in normal activities as part of their community day program.
62411626|NCT03979586|EXPERIMENTAL|Patient phototype I to IV|The study will be conducted in the Laser Dermatological and Plastic Center of the Conception Hospital in Marseille. It will be a prospective, controlled, hemiface, single-blind, independent-evaluator pilot study of 20 patients, 30 to 70 years old, with phototype I to IV (Fitzpatrick scale). By this study in hemiface, each patient will be his own witness. Neither the patient nor the examining doctor will know the choice of the hemiface of application of hyaluronic acid. This will be a single-blind study with independent evaluator. Patients will be included for 3 months, and followed for a period of 3 months.
62585715|NCT03105479|EXPERIMENTAL|Part A/ Cohort E|Subjects from birth to 3 months old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort D reviewed by the IDMC.
62021816|NCT05198232|EXPERIMENTAL|Zumba High Tempo|The Zumba high tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the high-tempo group will be played at full speed; the songs in the high-tempo group will be repeated to ensure an equal amount of time moving for both groups. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
62411627|NCT00054275|EXPERIMENTAL|Erlotinib Plus Docetaxel|
62585716|NCT03105479|EXPERIMENTAL|Part B / Cadazolid|Subjects from birth to 18 years old (exclusive) will receive cadazolid for 10 days, at the dose defined in the corresponding age cohort in Part A.
62819357|NCT06323291|OTHER|Digital Health Coaching for Pancreatic Cancer Patients|Initial in-person and/or virtual supportive care, social work, and dietitian consultation within 4 weeks of diagnosis and/or 3 weeks of study enrollment.
62819358|NCT06323291|OTHER|Digital Health Coaching for Caregivers|Initial in-person and/or virtual supportive care, social work, and dietitian consultation within 4 weeks of diagnosis and/or 3 weeks of study enrollment.
62021817|NCT05198232|EXPERIMENTAL|Zumba Low Tempo|The Zumba low tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the low-tempo group will be set to three-fourths speed. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
62021818|NCT04017026||6 mm implants|Patients were treated with 6mm short implants (Straumann, SLA, SLActive, 4.1 or 4.8 mm in diameter).
62021819|NCT04587089|EXPERIMENTAL|Non-instrumental Endodontic Treatment (NIET) + Guedes-Pinto Paste Group|In this group, the canals will not be instrumented and the filling will be performed with Guedes-Pinto paste.
62021820|NCT04587089|EXPERIMENTAL|Non-instrumental Endodontic Treatment (NIET) + CTZ Paste Group|In this group, the canals will not be instrumented and the filling will be performed with CTZ paste (Chlorophenicol, Tetracycline and Zinc Oxide and Eugenol).
62411628|NCT01649999|EXPERIMENTAL|ASP015K lowest dose|Oral
62217325|NCT02516332|EXPERIMENTAL|Lexapro|Treatment in the medication will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service. The investigators will use the SSRI escitalopram (Lexapro), which has received FDA approval for the treatment of anxiety, in 5 mg capsules. Medication will be dispensed as capsules of escitalopram in individually coded bottles. Medication adherence will be assessed using pill count at each study visit. Patients will visit face-to-face with a study psychiatrist at week 0 (baseline), week 1, week 2, week 4, week 8, and week 12 with phone encounters at weeks 3 and 6. The psychiatrist will make all medication adjustments based primarily upon Spielberger Anxiety Scores. Depending on symptoms, daily escitalopram doses will be titrated to 10 mg after week 2 and to 15 mg or placebo equivalent at week 3 if patients show no change or only minimal improvement.
62793168|NCT03431350|EXPERIMENTAL|Combination 2: Dose Expansion: Niraparib + AA-P (Part 2)|Participants will be assigned to one of 4 cohorts based on biomarker status - Cohort 2A (BRCA biallelic loss), 2B (other DRD biallelic loss), 2C (BRCA monoallelic loss), or 2D (other DRD monoallelic loss), and will receive niraparib 200 mg once daily in combination with abiraterone acetate 1000 mg (4\*250 mg) plus 10 mg prednisone (5 mg twice daily) throughout treatment phase. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
62021821|NCT02270346|ACTIVE_COMPARATOR|Treatment group|Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device.
62021822|NCT02270346|SHAM_COMPARATOR|Control group|Sham: Control group received sham inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device .
62411629|NCT01649999|EXPERIMENTAL|ASP015K low dose|Oral
62411630|NCT01649999|EXPERIMENTAL|ASP015K medium dose|Oral
62411631|NCT01649999|EXPERIMENTAL|ASP015K high dose|Oral
62217326|NCT02516332|PLACEBO_COMPARATOR|Placebo|Treatment in the medication and placebo pill arms will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service, who have extensive experience in clinical trials. Medication will be taken once daily in the morning but can be switched to once daily in the evening if deemed necessary. Placebo medication administration will follow the same protocol as outlined for Lexapro.
62411632|NCT01649999|PLACEBO_COMPARATOR|Placebo|Oral
62217327|NCT04506164|OTHER|Stepped-wedge|This stepped-wedge trial relies on sequential roll-out of eScreening to participating sites over time, while using other sites as controls until they begin implementation.
62217328|NCT02807662|EXPERIMENTAL|Experimental|Intervention mothers receive adapted Seeking Safety intervention delivered by prenatal care advocate over 8 sessions
62411633|NCT04483570||Secondary Tethered Cord Syndrome|Children with signs of progressive deterioration in urological or neuroorthopedic system, and suspected Secondary Tethered Cord Syndrome (STCS) following primary untethering surgery.
62585717|NCT03105479|ACTIVE_COMPARATOR|Part B / Vancomycin|Subjects from birth to 18 years old (exclusive) will receive vancomycin capsule (for subjects able to swallow) or vancomycin solution (for the others) during 10 days .
62793169|NCT03431350|EXPERIMENTAL|Combination 3: Niraparib + AA-P|Participants will be assigned to one of three cohorts to receive AA-P with or without niraparib. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
62411634|NCT03125564|EXPERIMENTAL|Fecal Microbiota Transplantation|FMT infusion and Fecal and Mucosal Microbiota Assessment
62411635|NCT03125564|SHAM_COMPARATOR|Sham infusion|Infusion with sham and Fecal and Mucosal Microbiota Assessment
62411636|NCT06650332|EXPERIMENTAL|Cohort 1:AK104+trastuzumab+chemo|AK104 (10 mg/kg, iv, Q3W, D1) in combination with trastuzumab (loading dose 8 mg/kg, iv, Q3W, D1; maintenance dose 6 mg/kg, iv, Q3W, D1) and chemotherapy (XELOX)
62021823|NCT00268528||Health service research (electronic pill monitoring system)|Patients receive an electronic pill monitoring system comprising an empty MEMS\^? medication bottle with TrackCap? CR. The mercaptopurine prescription is filled using this system. Beginning on day 1 of the third or later course of maintenance therapy, patients take all doses of mercaptopurine from the MEMS\^? medication bottle with TrackCap? CR for at least 169 days. The MEMS\^? TrackCap? CR is mailed to the Coordinating Center at the end of study. Patients also receive methotrexate PO as indicated by their individual chemotherapy regimen.
62021824|NCT05586828||different controlling nutritional status score|
62021825|NCT00194922|PLACEBO_COMPARATOR|A|
62021826|NCT06388018|ACTIVE_COMPARATOR|Cohort A1|Patients with POLE-mutated early-stage EC undergo observation on study. Patients undergo chest x-ray and CT or MRI or PET/CT scans during screening and as clinically indicated throughout the trial.
62021827|NCT06388018|EXPERIMENTAL|Cohort A2|Patients with higher-risk POLE-mutated EC undergo observation or EBRT and/or vaginal brachytherapy over 3-5 fractions. Patients undergo chest x-ray and CT or MRI or PET/CT scans during screening and as clinically indicated throughout the trial.
62217329|NCT02807662|NO_INTERVENTION|No intervention|Treatment as usual mothers receive usual services of a prenatal care advocate
62217330|NCT00614601|EXPERIMENTAL|1|Vaccine + chemo + chemoradiation therapy
62411637|NCT06650332|EXPERIMENTAL|Cohort 2:HER2-positive,AK104+RC48+chemo|"Phase Ⅰ:~AK104:6mg/kg，iv，Q2W，D1 RC48:3+3 design,1.5mg/kg、2.0mg/kg、2.5mg/kg chemotherapy:XELOX Phase Ⅱ:AK104 (6 mg/kg, iv, Q2W, D1) in combination with RC48 (recommended Phase I dose, iv, Q2W, D1) and chemotherapy (mFOLFOX6); PS:The chemotherapy treatment cycles will be determined by the investigator based on the participant's tolerability,and the maintenance treatment is AK104 in combination with RC48 and fluorouracil (5-FU) ."
62585718|NCT06122012|OTHER|HSK16149 capsule combined with L-carnitine hydrochloride|HSK16149 capsule (20 mg/ capsule) was administered orally, 1 capsule twice a day for 12 weeks. Acetyl-l-carnitine hydrochloride tablets (0.25g/ tablet) were administered orally after meals, 2 tablets 3 times a day for 12 weeks
62793170|NCT00974623||Spinal Fusion|Patients who undergo a planned spinal fusion procedure requiring approved bone grafting materials (e.g., bone grft substitutes, allograft or autograft).
62021828|NCT06388018|ACTIVE_COMPARATOR|Sub-study B|Patients with p53 wildtype/NSMP ER+ EC undergo observation or vaginal brachytherapy over 3-5 fractions. Patients undergo chest x-ray and CT or MRI or PET/CT scans during screening and as clinically indicated throughout the trial.
62021829|NCT06151262|EXPERIMENTAL|Trilaciclib+mFOLFIRINOX|"The treatment regimen was as follows:~Trilaciclib 240mg/m2 IV infusion, D1, D2，Q2W； Oxaliplatin 68mg/m2 IV infusion, D1; Irinotecan 135mg/m2 IV infusion D1; leucovorin 400mg/m2 IV infusion D1; 5-FU 2.4g/m2 IV infusion for 46h, D1; A total of 12 cycles of treatment were performed every 14 days as a cycle."
62021830|NCT04621448|EXPERIMENTAL|Immediate Start|The Immediate Start group will participate in the 12-week Moving Together program after completing the baseline assessment. Moving Together is a gentle, live-streaming, group movement program designed specifically for people with memory loss (PWML) and caregivers (CG) to do together. It is based on the in-person Preventing Loss of Independence through Exercise (PLIÉ) and Paired PLIÉ programs. The program combines physical movements to help maintain daily function with mindful body awareness exercises and social interactions to provide a comprehensive, multi-domain program.
62021831|NCT04621448|EXPERIMENTAL|Delayed Start|A Delayed Start group will be encouraged to continue with their usual daily activities during the first 12 weeks of the study and will begin the Moving Together program after completing the mid-point assessment.
62021832|NCT02706457||cohort 2012 - 2014|all patients admitted for \> 48 hours on the Intensive Care Unit in 2012, 2013 and 2014
62021833|NCT02378142|EXPERIMENTAL|Arm 1|Pazopanib 800mg oral daily
62021834|NCT05812573||multiple endocrine neoplasia|patients with multiple endocrine neoplasia
62021835|NCT04532892|PLACEBO_COMPARATOR|Placebo|Morning and night tablets with no active ingrédients. Morning and night tablets are different.
62021836|NCT04532892|EXPERIMENTAL|Dietary supplément|Morning and night tablets with active ingrédients. Morning and night tablets are different.
62585719|NCT06122012|OTHER|Lipoic acid combined with L-carnitine hydrochloride|HSK16149 capsule (20 mg/ capsule) was administered orally, 1 capsule twice a day for 12 weeks. Lipoic acid tablets (0.3g/ tablet) were administered half an hour before breakfast, 2 tablets once a day for 11 weeks.
62021837|NCT06334770|EXPERIMENTAL|Group( A) ROXOLID IMPLANT|NINE patients were rehabilitated with implant retained maxillary overdenture where four Straumann BLX® ROXOLID implant were inserted opposed by mandibular complete denture.
62021838|NCT06334770|ACTIVE_COMPARATOR|Group (B) CONVENTIONAL TITANIUM IMPLANT|NINE patients were rehabilitated with implant retained maxillary overdenture where four conventional titanium implants were inserted opposed by mandibular complete denture.
62021839|NCT06533618|EXPERIMENTAL|Thalassemic patients|Patient affected by TDD
62021840|NCT06533618|EXPERIMENTAL|Healthy controls|caucasian; age ≥18 years; body mass index \<25.0 kg/m2; no chronic illness or medications that might affect glucose metabolism; fasting glycemia\<100 mg/dl; HbA1c \<5.7% (39 mmol/mol); no positive islet autoantibodies; HOMA-IR \<2.5
62021841|NCT06533618|EXPERIMENTAL|Euglycemic thalassemic patients|Glucose metrics characteristic: (Time above range≥140 mg/dl: ≤ 6%)
62585720|NCT04331977|EXPERIMENTAL|Quadhelix Group|
62021842|NCT06533618|EXPERIMENTAL|Hyperglicemic thalassemic patients|Glucose metrics characteristic: (Time above range≥140 mg/dl: \>6%)
62021843|NCT02106338|EXPERIMENTAL|Cohort A|10 subjects (8 active, 2 placebo) receive a single oral dose of 200 mg CRS3123 or placebo every 12 hours for 10 days
62021844|NCT02106338|EXPERIMENTAL|Cohort B|10 subjects (8 active, 2 placebo) receive a single oral dose of 100 or 400 mg CRS3123 or placebo every 12 hours for 10 days
62021845|NCT02106338|EXPERIMENTAL|Cohort C|10 subjects (8 active, 2 placebo) receive a single oral dose of 600 mg CRS3123 or placebo every 12 hours for 10 days
62217331|NCT00614601|EXPERIMENTAL|2|Vaccine Only
62217332|NCT00848731|EXPERIMENTAL|iNO|gaseous NO is delivered by facemask
62585721|NCT04331977|ACTIVE_COMPARATOR|Hyrax Group|
62585722|NCT04439968|ACTIVE_COMPARATOR|Targeted Csats|Subjects randomized to the targeted Csat arm will have NIRS monitoring of cerebral saturations (Csat) and will have algorithm-driven clinical interventions to maintain Csat within target range in the first week of life.
62585723|NCT04439968|NO_INTERVENTION|Non-targeted Csats|Subjects randomized to the non-targeted Csat arm will have NIRS (near-infrared spectroscopy) monitoring of Csats, but Csat values will be obscured and not available to providers. These subjects will not have any algorithm-driven clinical interventions for Csat.
62793171|NCT03956966|PLACEBO_COMPARATOR|saline|bilateral quadratus lumborum block using 0.9% normal saline
62793172|NCT03956966|ACTIVE_COMPARATOR|Bupivacaine|bilateral quadratus lumborum block using Bupivacaine hydrochloride 0.25%
62793173|NCT03956966|ACTIVE_COMPARATOR|Bupivacaine and dexamethasone|bilateral quadratus lumborum block using Bupivacaine hydrochloride 0.25% and dexamethasone
62793174|NCT02870153|EXPERIMENTAL|SOX(oxalipaltin+S-1)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days
62793175|NCT02870153|ACTIVE_COMPARATOR|XELOX (oxalipaltin+capecitabine)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
62793176|NCT04891133|EXPERIMENTAL|Active arm|4mg Baricitinib up to 14 days + SoC
62793177|NCT04891133|PLACEBO_COMPARATOR|Comparator|Matching placebo up to 14 days + SoC
62793178|NCT03636126|EXPERIMENTAL|VR + TACS|"1. Complete one chapter of the virtual reality game Land's End while simultaneously using the tACS system (chapters range in length from approximately 5-20 minutes) after waking up each day (or prior to beginning a work shift).~2. Use the tACS system without the VR for 20 minutes just before sleep (or at the end of a work shift, whichever time point is most convenient). Table 1. Timeline of Study Treatment"
62217333|NCT00627263|NO_INTERVENTION|1|Participants will receive the usual cardiologic care for ICD patients provided by their medical team.
62021846|NCT01058200|ACTIVE_COMPARATOR|vacuum extractor 'iCUP'|new vacuum extractor: sterile disposable plastic cup
62217334|NCT00627263|EXPERIMENTAL|2|In addition to the usual cardiologic care for ICD patients provided by the participants medical team, those randomized to Intervention will receive the stress reduction treatment (SRT) program (see below).
62217335|NCT02235831|EXPERIMENTAL|DACP MF|DACP MF worn first, followed by DACP and DACP MF (Low Add) as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF will be worn bilaterally (in both eyes).
62585724|NCT05558982|EXPERIMENTAL|BXCL701 plus Pembrolizumab|
62585725|NCT02549287|EXPERIMENTAL|SafeCare|SafeCare, an evidence-based home visiting program
62793179|NCT03636126|NO_INTERVENTION|No Intervention for 2 Weeks|For 2 weeks of the 4 week study, each group (Group A and Group B) will continue work shifts as usual with no intervention.
62793180|NCT01483183|EXPERIMENTAL|Persistent or Paroxysmal AF Part 1: OPC-108459|To safely meet each of the following Cmax targets: 1.0-10.0 µg/mL. There will be 9 cohorts in all: 1.0, 1.6, 2.4, 3.6, 5.4, 7.0, 8.0, 9.0, and 10.0.
62793181|NCT01483183|PLACEBO_COMPARATOR|Persistent or Paroxysmal AF Part 1: Placebo|
62793182|NCT01483183|EXPERIMENTAL|Persistent or Paroxysmal AF Part 2: OPC-108459|Single dose to safely meet target concentration from Part 1, if subject fails to convert to sinus rhythm within 10 minutes, second dose will be administered to achieve 25% increase when compared to first infusion
62793183|NCT01483183|PLACEBO_COMPARATOR|Placebo Part 2|
62793184|NCT05809193|EXPERIMENTAL|Family-Focused Therapy|Bipolar Disorder and Psychotic Disorder
62793185|NCT01797055|EXPERIMENTAL|human apotransferrin|intravenous apotransferrin every 4-8 weeks
62217336|NCT02235831|ACTIVE_COMPARATOR|DACP|DACP worn first, followed by DACP MF and DACP MF (Low Add), as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP worn as monovision (distance correction in one eye and near correction in the other eye).
62217337|NCT02235831|ACTIVE_COMPARATOR|DACP MF (Low Add)|DACP MF (Low Add) worn first, followed by DACP and DACP MF, as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF (Low Add) worn bilaterally (in both eyes).
62217338|NCT06609941|EXPERIMENTAL|Nostril Breathing along with pharmacological therapy Group|"Patients in this group will receive alternative nostril breathing along with pharmacological management.~Total 4 weeks protocol. Two sessions per week will be supervised by physiotherapist and 5 days at home. A home diary will be provided in order to ensure and follow-up that participants are performing breathing exercise at home."
62217339|NCT06609941|ACTIVE_COMPARATOR|Pharmacological therapy Group|"Patients will receive medication as prescribed by pulmonologist through stepwise approach according to symptoms and severity. Total 4 weeks protocol.~Before and after 4 weeks pre and post interventional values will be taken."
62411638|NCT06650332|EXPERIMENTAL|Cohort 3:HER2-expressing,AK104+RC48+chemo|"AK104:6mg/kg，iv，Q2W，D1 RC48:3+3 design,1.5mg/kg、2.0mg/kg、2.5mg/kg chemotherapy:XELOX Phase Ⅱ:AK104 (6 mg/kg, iv, Q2W, D1) in combination with RC48 (recommended Phase I dose, iv, Q2W, D1) and chemotherapy (mFOLFOX6) PS:The chemotherapy treatment cycles will be determined by the investigator based on the participant's tolerability,and the maintenance treatment is AK104 in combination with RC48 and fluorouracil (5-FU) ."
62411639|NCT04190056|EXPERIMENTAL|Arm A (pembrolizumab, vorinostat, tamoxifen)|Patients receive pembrolizumab IV over 30 minutes on day 1, vorinostat PO QD for 4 days weekly, and tamoxifen PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression of unacceptable toxicity.
62411640|NCT04190056|EXPERIMENTAL|Arm B (pembrolizumab, tamoxifen)|Patients receive pembrolizumab IV over 30 minutes on day 1 and tamoxifen PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression of unacceptable toxicity.
62411641|NCT05137639|EXPERIMENTAL|PRF group|Participants received platelet-rich fibrin (PRF) prior to free skin grafting
62411642|NCT05137639|NO_INTERVENTION|non-PRF group|Standard surgical procedure (free skin grafting to reconstruct donor sites without PRF).
62411643|NCT05273554|EXPERIMENTAL|Pembrolizumab|by vein over about 30 minutes on Day 1 of each cycle.
62411644|NCT05273554|EXPERIMENTAL|Lenvatinib|2 lenvatinib capsules at the same time by mouth every day while on study.
62411645|NCT01728376|EXPERIMENTAL|Daptomycin - 12 to 17 year olds|Participants ages 12-17 years old were administered daptomycin 7 mg/kg infused once daily, intravenously (IV), over 30 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
62411646|NCT01728376|ACTIVE_COMPARATOR|Comparator - 12 to 17 year olds|Participants ages 12-17 years old received IV vancomycin or semi-synthetic penicillin or first-generation cephalosporins or clindamycin, given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
62411647|NCT01728376|EXPERIMENTAL|Daptomycin - 7 to 11 year olds|Participants ages 7 to 11 years old were administered daptomycin 9 mg/kg, infused once daily, IV over 30 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
62411648|NCT01728376|EXPERIMENTAL|Daptomycin - 1 to 6 year olds|Participants ages 1 to 6 years old were administered daptomycin 12 mg/kg, infused once daily, IV over 60 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
62411649|NCT01728376|ACTIVE_COMPARATOR|Comparator - 7 to 11 year olds|Participants ages 7-11 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
62411650|NCT01728376|ACTIVE_COMPARATOR|Comparator - 1 to 6 year olds|Participants ages 1-6 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
62217340|NCT04485858|EXPERIMENTAL|CorNeat KPro|Intraocular implantation of the CorNeat KPro
62217341|NCT05032989|EXPERIMENTAL|Extraction of distoangular and vertically positioned 3rd molar using cowhorn forcep|Extraction with new technique
62217342|NCT05032989|ACTIVE_COMPARATOR|Extraction of distoangular and vertically positioned 3rd molar via conventional method|Extraction with the conventional technique
62217343|NCT05268445|ACTIVE_COMPARATOR|Chemical angioplasty|Chemical angioplasty using intra-arterial Nimodipin
62217344|NCT05268445|ACTIVE_COMPARATOR|Chemical and Mechanical angioplasty|Balloon angioplasty for refractory intracranial arterial vasospastic stenosis with a CE Marked device (Neurospeed balloon) or Adjustable remodeling mesh angioplasty for refractory intracranial arterial vasospastic stenosis with a CE Marked device (Comaneci) in association with intra-arterial Nimodipin
62585726|NCT02549287|ACTIVE_COMPARATOR|Supportive Case Management|Child welfare services as usual
62585727|NCT06630364|ACTIVE_COMPARATOR|Group I (Ketamine group)|The patients in this group will have intravenous ketamine (0.5 mg/kg) during induction
62585728|NCT06630364|EXPERIMENTAL|Group II (Fentanyl Group)|The patients in this group will have intravenous fentanyl (1 µg/kg) during induction
62217345|NCT06418945|NO_INTERVENTION|Arm 1:pg（-）|The routine follow-up review after radical resection of esophageal cancer was performed according to the schedule requirements
62021847|NCT01058200|SHAM_COMPARATOR|reference vacuum extractor|reference cup of the obstetrical ward: metallic cup
62217346|NCT06418945|EXPERIMENTAL|Arm 2:pg（+）|Dental cleaning combined with gum tape treatment every three months until disease progression/recurrence/death or intolerable adverse reactions occur.
62217347|NCT06418945|NO_INTERVENTION|Arm 3:pg（+）|The routine follow-up review after radical resection of esophageal cancer was performed according to the schedule requirements
62021848|NCT03719066|ACTIVE_COMPARATOR|DIG 1 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered two weeks after the first dose.
62217348|NCT06245993||Diaphyseal femoral fracture treated children|
62217349|NCT03191682|EXPERIMENTAL|PRL3-ZUMAB|The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression
62217350|NCT05566067||Anesthesiology residents|We plan to distribute a survey to the Stanford anesthesiology residents to investigate the factors that influence residents' decision to pursue a career as a critical care physician.
62411651|NCT03970252|EXPERIMENTAL|Treatment (nivolumab, mFOLFIRINOX)|Patients receive nivolumab IV over 60 minutes on day 1. Patients also receive fluorouracil IV over 10 minutes and over 46 hours, irinotecan hydrochloride IV over 90-120 minutes, leucovorin calcium IV over 120 minutes, and oxaliplatin IV over 120 minutes on days 1 and 15. Treatments repeat every 28 days for 3-6 cycles in the absence of disease progression or unacceptable toxicity. Within 2-4 weeks after treatment, patients with resectable disease undergo surgery. Within 8-12 weeks after surgery, patients with successful resection may receive 6 additional cycles of fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin in the absence of disease progression or unacceptable toxicity.
62411652|NCT03531684|EXPERIMENTAL|MMFS-205-SR|Oral MMFS-205-SR twice daily (2,000, 3,000, or 4,000 mg/day total, depending on lean body mass and response to initial dose at Week 12) for 24 weeks
62411653|NCT03531684|PLACEBO_COMPARATOR|Placebo|Oral inactive placebo twice daily for 24 weeks
62411654|NCT06566846||LSTV group and control group|
62585729|NCT06665542||Suspected infection/sepsis|Patient presenting with a clinical suspicion of acute infection/sepsis as defined by the attending physician, based on clinical presentation.
62585730|NCT06665542||Healthy Individuals|No clinical suspicion of acute infection.
62585731|NCT04428476|OTHER|Open-label arm|Open-label deramiocel (CAP-1002) will be administered to all subjects enrolled in the trial
62585732|NCT06683404||Breast Cancer patients with cutaneous and/or subcutaneous histologically confirmed metastases|Breast Cancer patients with cutaneous and/or subcutaneous histologically confirmed metastases, regardless of the presence of other metastases, which underwent Electrochemotherapy for the local treatment of their cutaneous and/or subcutaneous metastases.
62585733|NCT04020692|EXPERIMENTAL|"intervention  group"|"Patient At D0, the patient receives his discharge drugs prescription and benefits from a pharmaceutical counselling.~At D+3, he benefits from a telephone follow-up (good understanding of the methods of taking drugs, collection of difficulties).~Community pharmacist At D0, he receives the discharge drugs prescription. At D+3, he is contacted to collect information relating to drugs 'dispensation.~The attending physician At D0, he is informed of the patient's discharge and his drugs treatment~At D45, the data collection is based on telephone interviews \[attending physician, pharmacist and patient (and if applicable the caregiver)\].~It makes possible to collect drugs taken by the patient as well as significant events over the period (acute pathologies, re-hospitalizations, etc.)."
62585734|NCT04020692|NO_INTERVENTION|Control group|"At D0, the patient receives his discharge drugs prescription.~At D45, the data collection is based on telephone interviews \[attending physician, pharmacist and patient (and if applicable the caregiver)\].~It makes possible to collect drugs taken by the patient as well as significant events over the period (acute pathologies, re-hospitalizations, etc.)."
62585735|NCT04914884||intraocular inflammation group|
62585736|NCT04914884||Cataract patients group|
62585737|NCT03072589|EXPERIMENTAL|Regadenoson infusion|Dose escalation of Regadenoson infusion
62585738|NCT03804424|EXPERIMENTAL|Cohort 1: Pilot 64Cu-LLP2A Imaging|"* 16 adult individuals (6-8 patients with known MM; 6-10 healthy volunteers)~* All subjects who enter the study in Cohort 1 will be injected with up to 11 mCi of 64Cu-LLP2A and will undergo body imaging at least twice within 0-30 hrs following administration of 64Cu-LLP2A to study tracer biodistribution and calculate human dosimetry~* 6 subjects will also undergo dynamic study for 60 mins immediately after administration of 64Cu-LLP2A."
62738633|NCT04726930||Paravertebral block with surface ultrasound|Number of participants: 10 Paravertebral blocks will be performed under guidance of surface ultrasound. After we reach the injection site, the puncture stylet will be replace by Intra-needle ultrasound transducer (INUS). Collect signal from Intra-needle ultrasound transducer and then inject local anesthetics.
62021849|NCT03719066|EXPERIMENTAL|DIG 2 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered 6 months after the first dose.
62021850|NCT03719066|EXPERIMENTAL|DIG 3 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered 11 months after the first dose.
62217351|NCT02037464|EXPERIMENTAL|Capsaicin Supplement|
62217352|NCT04535024|EXPERIMENTAL|Treatment Arm|"A total of 60 MSS oligometastatic colorectal cancer patients will receive multisite SABR followed by Sintilimab within one week from completion.~The dosing will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal."
62217353|NCT04279392|ACTIVE_COMPARATOR|Active Infusion|At 6 weeks post surgery, 5 mg of zoledronic acid in 100 ml of saline will be infused intravenously over a 15 minute time period.
62217354|NCT04279392|PLACEBO_COMPARATOR|Non-active Infusion|At 6 weeks post surgery, 100 ml of saline will be infused intravenously over a 15 minute time period.
62217355|NCT02428062|NO_INTERVENTION|Standard-of-Care|The intraoperative hemodynamic management of the patients assigned to this arm will be left to the discretion of the anesthesiologist, without any indication as to the intraoperative hemodynamic strategy to be adopted.
62411655|NCT06566846||1 and 2|"1. for cases with LSTV~2. for normal studies"
62793186|NCT03020927|ACTIVE_COMPARATOR|Therapist Delivered|Children in the therapist-delivered condition will receive two, 60-minute long sessions of Reciprocal Imitation Training each week for ten consecutive weeks. These sessions will be delivered by trained graduate, undergraduate, and post-graduate research staff. Parents will be permitted to observe sessions via live video, but will not be directly involved in intervention.
62793187|NCT03020927|EXPERIMENTAL|Parent + Therapist Delivered|Children in the parent + therapist-delivered condition will receive one, 60-minute long session of Reciprocal Imitation Training each week for ten consecutive weeks. These sessions will be delivered by trained graduate, undergraduate, and post-graduate research staff. During the same period of time, parents/guardians of children will receive one, 60-minute long parent education session per week with graduate and post-graduate research staff, aimed at teaching parents to implement Reciprocal Imitation Training at home with the child.
62793188|NCT02683434|EXPERIMENTAL|KT|Kinesio Taping Application
62411656|NCT02519582|EXPERIMENTAL|Niclosamid|Patients receive 2 g niclosamide orally per day until progression or toxicity
62793189|NCT02683434|NO_INTERVENTION|CONTROL|
62793190|NCT03828331||Participants with Transtibial Amputation|The investigators will recruit participants with unilateral transtibial amputations who are at or above a K3 Medicare functional classification level (MFCL), and 18-55 years old. A K3 MFCL means that a person has the ability or potential for ambulation with variable cadence. A person at K3 MFCL is a typical community ambulator who has the ability to traverse most environmental barriers and may have vocational, therapeutic or exercise activity that demands prosthetic use beyond simple locomotion.
62793191|NCT06169982|EXPERIMENTAL|LY3209590|LY3209590 administered subcutaneously (SC)
62217356|NCT02428062|EXPERIMENTAL|Treatment|The anesthesiologist will have as hemodynamic target for patients assigned to this arm the maintenance of mean arterial blood pressure within 10% of the baseline blood pressure value (recorded at the preoperative evaluation). The strategy to reach this hemodynamic target will be left to the clinical judgment of the anaesthesiologist in charge. The possible strategies include a vasoconstrictor agent (either phenylephrine, ephedrine, epinephrine, norepinephrine or dopamine), intravenous fluids, patient's positioning or reduction of depth of anesthesia.
62217357|NCT02428062|NO_INTERVENTION|Control|"Subjects assigned to this arm will undergo the same geriatric, neuropsychologic and audiologic evaluations administered to patients of the Standard-of-Care and Treatment arms at the same time points (baseline, 3 months and 1 year). These subjects will not undergo any surgical procedure and will therefore not be evaluated for post-operative complications or delirium occurrence."
62217358|NCT04338659|EXPERIMENTAL|Dose Escalation of IBI322|Participants will receive escalating dose levels of IBI322 to determine maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of IBI322
62217359|NCT01620021||Healthy|Ten healthy volunteers with no history of gait and balance issues will be recruited to participate in the study.The participants must be between 18 and 65 years of age.
62217360|NCT01005459|ACTIVE_COMPARATOR|tetracaine 2mg|
62217361|NCT01005459|ACTIVE_COMPARATOR|Bupivacaine 2 mg|
62411657|NCT02784002|EXPERIMENTAL|Ridinilazole (SMT19969)|200 mg capsule of Ridinilazole (SMT19969) twice a day for 10 days
62411658|NCT02784002|ACTIVE_COMPARATOR|Fidaxomicin|200 mg tablet of Fidaxomicin twice a day for 10 days
62411659|NCT03176953|EXPERIMENTAL|prolonged exposure + topiramate|psychotherapy plus active medication
62411660|NCT03176953|ACTIVE_COMPARATOR|prolonged exposure + placebo|psychotherapy plus placebo medication
62411661|NCT04176354||Palbociclib + an aromatase inhibitor|Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
62411662|NCT04176354||Palbociclib + Letrozole|Adult metastatic breast cancer patients who initiated Palbociclib +Letrozole as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
62793192|NCT05349786|EXPERIMENTAL|Intervention Group|A physical activity program lasting at least 30 minutes each session was applied to HF patients in the intervention group, three days a week for three months. A pedometer was used to visualize the walking performed in the physical activity program and to record reliably. Weekly phone calls and monthly home visits were made to the patients in order to determine the continuation of the medical treatment and walking program used by the patients, to increase their motivation and to detect or intervene in any situation related to the walking program.
62217362|NCT00615121||arteries from PAD patients|peripheral arteries from patients undergoing amputation for end stage peripheral arterial occlusive disease
62411663|NCT04176354||Letrozole|Adult metastatic breast cancer patients who initiated Letrozole as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
62411664|NCT02286284|EXPERIMENTAL|Apheresis arm|Apheresis for extracorporal removal of sFlt-1
62217363|NCT00615121||arteries from Free Fib transfers|peripheral arteries from patients without evidence of peripheral arterial occlusive disease
62411665|NCT05563142|EXPERIMENTAL|Group Perclose ProStyle closure|50 patients treated with Perclose ProStyle suture-mediated closure device to achieve hemostasis
62411666|NCT05563142|ACTIVE_COMPARATOR|Group manual compression|50 patients treated with manual compression and one figure of eight suture
62411667|NCT05393830|NO_INTERVENTION|Normal Sleep|Normal Sleep - Healthy participants are permitted normal nights of polysomnography or actigraphy recorded sleep before participating in an emotion regulation task during functional Magnetic Resonance Imaging (fMRI) scanning
62411668|NCT05393830|ACTIVE_COMPARATOR|Sleep Restriction|Healthy Participants are sleep restricted to 4 hours of sleep for 3 consecutive days before participating in an emotion regulation task during functional Magnetic Resonance Imaging (fMRI) scanning
62411669|NCT05393830|NO_INTERVENTION|Patients with Insomnia Disorder|Patients with Insomnia Disorder will also be recruited and will be permitted normal nights of polysomnography or actigraphy recorded sleep before participating in an emotion regulation task during functional Magnetic Resonance Imaging (fMRI) scanning
62793193|NCT05349786|NO_INTERVENTION|Non-Intervention Group|The individuals in the control group, were pre-tested, evaluated at the first, second, and third months, and followed up in the process without any intervention. Patients were reminded that they should continue their routine medical treatment and not start any physical activity program.
62793194|NCT03154996|EXPERIMENTAL|Long term CED of Topotecan|An additional 5 patients will be treated with TPT by CED maintained for 32 days. TPT infusions will be carried out for 32 days using Synchromed II infusion pumps with the same infusion parameters and experimental conditions used in the short term studies.
62793195|NCT03055520|EXPERIMENTAL|arithmetic training (Kumon method)|
62793196|NCT03055520|PLACEBO_COMPARATOR|nonspecific recreation|
62793197|NCT03261219|EXPERIMENTAL|Intrapulmonary Percussive ventilation|
62793198|NCT03261219|ACTIVE_COMPARATOR|Chest Physiotherapy vest|
62793199|NCT00924768|EXPERIMENTAL|Endotoxin|Inhalation of 20K EU CCRE
62793200|NCT03692702|EXPERIMENTAL|WE PLAY|Teachers in this condition received the WE PLAY training.
62793201|NCT03692702|NO_INTERVENTION|Control|Preschools in this condition received the same physical activity equipment that preschools in the WE PLAY condition received. Teachers were not provided with any specific instructions or information about physical activity.
62793202|NCT02816801|EXPERIMENTAL|Intervention|Access to Butler-Program 2.0
62793203|NCT02816801|NO_INTERVENTION|Waitlist|
62793204|NCT01032720|EXPERIMENTAL|Ultrasound-guided knee CS injection|Ultrasound will be used to image knee joint and guide needle for intra-articular knee CS injection.
62411670|NCT00000254|SHAM_COMPARATOR|0% isoflurane|
62411671|NCT00000254|ACTIVE_COMPARATOR|0.2% isoflurane|
62411672|NCT00000254|ACTIVE_COMPARATOR|0.4% isoflurane|
62411673|NCT00000254|ACTIVE_COMPARATOR|0.6% isoflurane|
62411674|NCT00792142|EXPERIMENTAL|Treatment (stem cell transplant, maintenance treatment)|Patients receive high-dose melphalan IV over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation on day 0. Patients receive filgrastim IV or SC beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive oral thalidomide once daily until disease progression.
62411675|NCT02676518||polycystic ovary syndrome women|PCOS women diagnosed by Rotterdam criteria visiting the Gynecologic Unit at King Chulalongkorn Memorial Hospital and meet the inclusion criteria and no exclusion criteria of the study
62411676|NCT05418517||oromaxillofacial surgery|Patients who underwent oromaxillofacial surgery
62411677|NCT06397001|EXPERIMENTAL|nL-SAA1-01|Subject will receive subcutaneous injection of nL-SAA1-01
62411678|NCT06652204||caregivers of patients with COPD|
62793205|NCT01032720|SHAM_COMPARATOR|Sham Ultrasound knee CS injection|CS knee injection will be performed in the same method as the US-guided knee injection but the US machine will be turned off.
62793206|NCT03113994|ACTIVE_COMPARATOR|Rosuvastatin|
62793207|NCT03113994|PLACEBO_COMPARATOR|Placebo|
62793208|NCT02233972|EXPERIMENTAL|Midazolam and Ginkgolides Meglumine Injection|Midazolam: tablet, 7.5 mg. Midazolam will be taken on Day 1 and Day 22. Ginkgolides Meglumine Injection: 25mg, intravenous drip, once a day. It will be used on Day 8 -Day 21, 14 days totally.
62793209|NCT02233972|PLACEBO_COMPARATOR|Midazolam and placebo|Midazolam: tablet, 7.5 mg. Midazolam will be taken on Day 1 and Day 22. Placebo: Sodium Chloride Injection, 250 ml, intravenous drip, once a day. It will be used on Day 8 -Day 21, 14 days totally.
62793210|NCT01415141|ACTIVE_COMPARATOR|PR|"Treatment with Peginterferon and Ribavirin for up to 48 weeks~Those who achieve eRVR will receive 24 weeks of treatment"
62793211|NCT01415141|ACTIVE_COMPARATOR|TPR|"Treatment with Telaprevir, Peginterferon and Ribavirin. Patients will receive all 3 drugs for 12 weeks then switch to Peginterferon and Ribavirin for 36 weeks~Those who achieve eRVR will receive 12 weeks of treatment with all 3 drugs and then 12 weeks of treatment with the 2 drugs."
62793212|NCT00120965|EXPERIMENTAL|1|Autopulse device
62793213|NCT00120965|ACTIVE_COMPARATOR|2|Manual CPR
62411679|NCT06630858|ACTIVE_COMPARATOR|Group S-QLB3|S-QLB3 block (0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline) + iv morphine-PCA
62411680|NCT06630858|ACTIVE_COMPARATOR|Group ITM|ITM Morphine (a total of 0.2 mg of morphine sulfate + 7.5 mg isobaric (plain) bupivacaine ) + iv morphine-PCA
62793214|NCT03315039|EXPERIMENTAL|Liposomal annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
62793215|NCT05282771|EXPERIMENTAL|Halobetasol Propionate and Tazarotene Topical lotion 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks
62793216|NCT05282771|ACTIVE_COMPARATOR|Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks
62793217|NCT05282771|PLACEBO_COMPARATOR|Placebo Control|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks
62793218|NCT04206371|OTHER|Defibrillation testing during ICD replacment|
62793219|NCT01255618||study group, control group|
62793220|NCT05449691|ACTIVE_COMPARATOR|Biological Matrix|Participants will undergo immediate breast reconstruction using biological matrix and implant
62243269|NCT05891353|EXPERIMENTAL|Pain Inducing Stretch|Participants will be seated in a chair and asked to complete an upper trapezius stretch. They will feel a gentle stretch in the area between the top of their shoulder and the base of their neck. Participants will be asked to stretch until the point of pain. They will hold this stretch for 1 minute, 4 times. Change in Pressure Pain Threshold will be examined on the web space of their foot between each one minute interval of the stretch. Participants will be notified that they may stop the stretch at any point if needed.
62793221|NCT05449691|EXPERIMENTAL|Synthetic Mesh|Participants will undergo immediate breast reconstruction using synthetic mesh and implant
62793222|NCT03532126||Dermal filler for midface deficit|There will be one group in this study, the actual treatment group.
62793223|NCT02406911|EXPERIMENTAL|Ticagrelor 90 mg|After randomization, an initial loading dose of ticagrelor (180 mg) was given and low dose ticagrelor (ticagrelor 90 mg once a day) was treated for 14 days.
62793224|NCT02406911|ACTIVE_COMPARATOR|Ticagrelor 180 mg|After randomization, an initial loading dose of ticagrelor (180 mg) was given and usual dose ticagrelor (ticagrelor 90 mg twice a day) was treated for 14 days.
62793225|NCT04054141|EXPERIMENTAL|rTMS arm|"Each patient's participation will last a maximum of 12 weeks and involves 2 sessions of neurophysiological testing (TMS) sessions and 15 neurophysiological treatment sessions (rTMS).~Patients will have a neurophysiological testing session (TMS) at the screening visit (week 0). Patients will then return for 15 neurophysiological treatment sessions (rTMS) within 14 days of screening. Patients must complete three neurophysiological treatment sessions (rTMS) during weeks 1, 2, 3, 4 and 5. The second neurophysiological testing session will be done at the final visit (week 5). Follow-up visits will be scheduled at weeks 7 and 10 (+/- 3 days). That is, the follow-up visits will occur two and five weeks after the final rTMS session which occurs on day 15."
62793226|NCT01511068|EXPERIMENTAL|Inhaled Leukine (rhGM-CSF)|Inhaled recombinant human GM-CSF in individuals with hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
62411681|NCT04051658|EXPERIMENTAL|Anodal-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hour). Anodal on the motor area (M1) of the affected hemisphere, Cathodal on the contralateral supraorbital area. The current intensity is fixed at 1.5 mA and the current will flow continuously. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic.
62411682|NCT04051658|EXPERIMENTAL|Cathodal-tDCS & PT|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hour). Anodal on the supraorbital area of the affected hemisphere, Cathodal on the primary motor area (M1) of the unaffected hemisphere. The current intensity is fixed at 1.5 mA and the current will flow continuously. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic.
62793227|NCT05109624|NO_INTERVENTION|group(A) control group|pronation cycles each last for 16 hours every 24 hours
62793228|NCT05109624|ACTIVE_COMPARATOR|group(B)|pronation cycles each last for 24 hours followed by 6 hours supine position
62793229|NCT03643627|PLACEBO_COMPARATOR|Placebo|
62793230|NCT03643627|EXPERIMENTAL|1 mg/kg|
62793231|NCT03643627|EXPERIMENTAL|3 mg/kg|
62793232|NCT03643627|EXPERIMENTAL|10 mg/kg|
62793233|NCT03643627|EXPERIMENTAL|30 mg/kg|
62793234|NCT04398628||Hemophilia|"This cohort includes three Arms and five Modules:~Previously Untreated Patients (PUPs) Arm~ALTUVIIIO® Module INHIBIT Module~Hemophilia Natural History Arm~Hemlibra® Module~Rebinyn® Module~Hemophilia Gene Therapy Outcomes Arm~HEMGENIX® Module"
62793235|NCT04398628||Congenital Platelet Disorders|"This cohort includes one Arm and Module:~Congenital Platelet Disorders (CPD) Natural History Arm Glanzmann Thrombasthenia (GT) Module"
62793236|NCT04398628||Von Willebrand Disease|No arms or modules
62793237|NCT04398628||Rare Disorders|No arms or modules
62793238|NCT04398628||Bleeding NOS|No arms or modules
62793239|NCT04398628||Thrombosis/Thrombophilia|No arms or modules
62793240|NCT04398628||Non-Neoplastic Hematologic Conditions|No arms or modules
62793241|NCT03005132||Normal brain tissue|Normal brain tissue from GBM patients
62793242|NCT03005132||GBM tissues|GBM tissues from GBM patients
62793243|NCT03005132||Metastasis tissues|Metastasis tissues from GBM patients
62793244|NCT04612257|EXPERIMENTAL|Insulin alone closed-loop|Insulin alone closed-loop algorithm in children with type 1 diabetes in a free-living study.
62793245|NCT02923856|EXPERIMENTAL|Clarithromycin resistance group|Patients who are resistant to clarithromycin in susceptibility test were classified into clarithromycin resistance group.
62793246|NCT02923856|EXPERIMENTAL|7 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 7days standardized treatment.
62793247|NCT02923856|EXPERIMENTAL|7 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 7days standardized treatment.
62793248|NCT02923856|EXPERIMENTAL|10 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 10days standardized treatment.
62793249|NCT02923856|EXPERIMENTAL|10 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 10days standardized treatment.
62793250|NCT02923856|EXPERIMENTAL|14 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 14days standardized treatment.
62793251|NCT02923856|EXPERIMENTAL|14 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 14days standardized treatment.
62793252|NCT01937260|EXPERIMENTAL|Brodalumab 140mg SC|open label, all subjects receive brodulamab
62793253|NCT01937260|EXPERIMENTAL|Midazolam (MDZ) 2mg oral, Brodalumab 210mg SC|MDZ 2mg oral (Day 1 and Day 9), Brodalumab 210mg SC (Day 2)
62793254|NCT01224717|EXPERIMENTAL|PTH134|
62793255|NCT01224717|PLACEBO_COMPARATOR|Placebo|
62793256|NCT01224717|ACTIVE_COMPARATOR|Forsteo|
62793257|NCT03827603|EXPERIMENTAL|patients with AIHA and CLL|patients with CLL and in Steroid Refractory AIHA receive ibrutinib 420 mg per day till progression or intolerance
62411683|NCT04051658|EXPERIMENTAL|Dual-tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over C3-C4 or the motor area (M1) for 20 mins before conventional physical therapy (about 1 hour). Anodal on the affected hemisphere, Cathodal on the unaffected hemisphere. The current intensity is fixed at 1.5 mA and the current will flow continuously. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic.
62217364|NCT04775199|NO_INTERVENTION|Control|Control: In all conditions, the examiners will teach science using the Full Option Science System Next Generation Edition (FOSS, 2015, https://www.fossweb.com/) curriculum that involves 1) Prediction, 2) Experiment, 3) a visual Journal/Reflection, and 4) a pre-recorded reading centered around a given theme such as sound. A research speech-language pathologist will provide two 30-minute interactive science lessons per week for six weeks to children with language learning challenges recruited nationwide. Children will participate in groups of three. Families will log on five additional times during each week to view the science book reading. In the control condition, children will receive these science lessons but no language intervention. Therefore, this intervention constitutes a nonintervention.
62217365|NCT04775199|EXPERIMENTAL|Science + Grammar Intervention|"Grammar: In the science + grammar condition, focused stimulation plus explicit instruction will be employed. Focused stimulation an intervention commonly used to target expressive language, will be used to treat complement clauses during the FOSS activities.. The active ingredients are models (30) and recasts (5 per child) of the target structure (e.g., You measured how long the ramp is). Recasts occur when an examiner responds to a child's naturally occurring utterance by expanding or extending the child's utterance to include a target grammatical structure. Focused stimulation will be supplemented with explicit instruction using choral production and visual supports (3x per lesson) and a definition of the meaning of the structure (1 per lesson)."
62217366|NCT04775199|EXPERIMENTAL|Science + Vocabulary Intervention|Vocabulary: This arm will provide Robust Vocabulary Instruction, an explicit approach that emphasizes multiple and rich encounters in authentic contexts to promote depth of semantic knowledge of 12 words that pertain to scientific practices applicable to the FOSS lessons. The words are: compare, diagram, evidence, explanation, hypothesis, materials, model, multiple, pattern, problem, scientist, search. Two words will be targets in each session. The examiners will ensure that for each target word per session there will be at least one definition model and 3 other models directed to the triad of participants and at least 2 elicitations per child. The recorded books also include 6 additional exposures to the words, for a cumulative exposure of 12.
62793258|NCT05503342|ACTIVE_COMPARATOR|Control|"They will be followed up in a 12-week pharmacotherapeutic follow-up program, where they will have to record three measurements of peak expiratory flow weekly and fill out a questionnaire to assess control on paper.~Depending on the evolution of each patient, the pharmacist will provide the relevant guidelines to improve control, as well as referral to a medical care service, if applicable."
62793259|NCT05503342|EXPERIMENTAL|Application|They will be followed up in a 12-week pharmacotherapeutic follow-up program, where they will have to record three measurements of peak expiratory flow weekly and fill in an exacerbation risk score included in the cell phone application, which the pharmacist will have access to through a web platform. Depending on the evolution of each patient, the pharmacist will provide the relevant guidelines to improve control, as well as referral to a medical care service, if applicable.
62793260|NCT01980381|EXPERIMENTAL|Tree Theme Method ® (TTM) intervention|The TTM involves storytelling and story making, in which the patient draws tree maps representing certain periods of his/her life.
62793261|NCT01980381|NO_INTERVENTION|Control group|Treatment as usual, with focus on the present everyday occupations
62793262|NCT05447481|EXPERIMENTAL|Chicory inulin-type fructan - placebo|Dietary supplement: chicory inulin-type fructan Placebo: maltodextrin
62793263|NCT05447481|EXPERIMENTAL|Placebo - chicory inulin-type fructan|Placebo: maltodextrin Dietary Supplement: chicory inulin-type fructan
62793264|NCT00767806|EXPERIMENTAL|Duloxetine|Participants received duloxetine 60 milligram by mouth once daily for 12 weeks of double-blind treatment
62793265|NCT00767806|PLACEBO_COMPARATOR|Placebo|Patients received placebo by mouth once daily for 12 weeks of double-blind treatment
62793266|NCT02318966|ACTIVE_COMPARATOR|Glycosade|Participants will be randomised to receive the medical food Glycosade as a starch load with a maximum dose of 100g. Glycosade to be taken as one dose.
62793267|NCT02318966|PLACEBO_COMPARATOR|Uncooked corn starch|Participants will be randomised to receive uncooked corn starch as a starch load with a maximum dose of 100g. Uncooked corn starch to be taken as one dose.
62793268|NCT04156035|EXPERIMENTAL|Lamotrigine + Ketamine|Pretreatment with lamotrigine will occur 2 hours before the ketamine infusion
62793269|NCT04156035|EXPERIMENTAL|Placebo + Ketamine|Pretreatment with placebo will occur 2 hours before the ketamine infusion
62793270|NCT04156035|PLACEBO_COMPARATOR|Placebo + Placebo|Pretreatment with placebo will occur 2 hours before the placebo infusion
62793271|NCT04647968|OTHER|Primary closure of tracheo-cutaneous fistula|This group will undergo a protocoled primary closure of their tracheotomy.
62793272|NCT04647968|OTHER|Secondary closure of tracheo-cutaneous fistula|This group will undergo a protocoled secondary closure of their tracheotomy.
62793273|NCT04160858|EXPERIMENTAL|Exercise Condition|The intervention is a personalized exercise prescription based on the International Scientific Spinal Cord Injury (SCI) Exercise Guidelines. Participants begin at the Starting Level guideline: 20 min aerobic exercise, 2x/wk, at 70% of heart rate reserve (or a Borg Continuous Ratio 0-10 rating of 6), \& 3 sets of 10 repetitions of strengthening exercises (each major functioning muscle group at 50-80% of 1-rep max), 2x/wk. Participants will gradually increase aerobic exercise to 30 min, 3x/wk (i.e. the Advanced Level guideline). Exercise implementation will be supported by a fitness trainer and an exercise counsellor with SCI-specific training and experience.
62793274|NCT04160858|ACTIVE_COMPARATOR|Wait-list Control|Control participants will not get an exercise prescription. They will be asked to refrain from lifestyle changes for 6 mos. After the 6-month waitlist period, Controls will receive the same resources as Exercisers.
62585739|NCT03804424|EXPERIMENTAL|Cohort 2: Quantitative 64Cu-LLP2A Imaging|"* 20 patients with MM will be recruited~* Subjects who enter on study in Cohort 2 will undergo a 60-min dynamic imaging over the known site of disease (OR pelvis and lower lumbar spine, if no site of disease is known). Following a simple DIXON MRI or low dose CT scan for attenuation correction, subjects will be injected with a dose of up to11 mCi of 64Cu-LLP2A and a list mode dynamic imaging acquisition will begin for a total of 60 mins. Following the dynamic study, or at the optimal time point determined from cohort 1 imaging, after a simple DIXON or low dose CT scan for body (top of the head to below the knees) attenuation correction, emission scans (2-5 min per bed position) will be performed"
62793275|NCT01382238|EXPERIMENTAL|Single arm|Subjects will have a screening visit within 30 days prior to the first dose of study drug, five treatment periods containing a single dose of study drug, followed by 48 hours of serial PK collection. In the 5 treatment periods subjects will receive DTG granule formulation 1) directly to mouth; 2) with purified water; 3) with Contrex brand water; and 4) with milk-based infant formula. They will also receive the current 50 mg tablet formulation administered with tap water. These treatments will be administered in a random order. Subjects will check out of the unit on Day 3 after the 48 hour PK sample in each period. Study periods will be separated by at least 5 days. Subjects will have a follow-up visit 5-7 days after last dose of DTG given.
62793276|NCT06304363|EXPERIMENTAL|Physical activity|Patients are encouraged to participate in physical exercise at the psychiatric unit
62793277|NCT05662982|EXPERIMENTAL|Intervention Group|Participants will be assessed for 12 weeks in their usual ischial containment socket before receiving a subischial socket to be worn and assessed for 24 weeks.
62793278|NCT05662982|NO_INTERVENTION|Reference Group|Participants will be assessed for 40 weeks in their usual ischial containment socket. No intervention will be provided.
62793279|NCT02270554|EXPERIMENTAL|Reinforced staple|Endo GIA Reinforced Reload with Tri-Staple technology
62793280|NCT04477577|EXPERIMENTAL|New Parent Intervention|
62021851|NCT03891810|EXPERIMENTAL|Calm|"The intervention ran for 8-wks with a 4-wk follow-up period. Intervention participants completed 7 days of Calm during Week 1. For the remaining weeks (Week 2- Week 8) intervention participants were asked to meditate during the weekday from a 10-minute meditation of their choice. Throughout the intervention, the Calm College group were sent reminder texts/emails via Google Voice to participate in the meditation sessions if participants are not meditating for more than 30 minutes a week (see Participant Scripts)."
62021852|NCT03891810|NO_INTERVENTION|Control|This group was a wait list control group who received the treatment following the intervention period.
62585740|NCT03927521|EXPERIMENTAL|Focal HIFU guided by PET-MRI/68Ga-PSMA imaging|Patient with local/focal prostate cancer recurrence after radiotherapy and no distant metastasis (negative PET-Choline imaging confirmed by PET-MRI/68Ga-PSMA) will be treated by Focal-HIFU
62585741|NCT06204471|EXPERIMENTAL|Airbag1|Airbag1 worn for two months
62585742|NCT06204471|EXPERIMENTAL|Airbag2|Airbag2 worn for 2 months
62585743|NCT05761886|EXPERIMENTAL|telehealth-based clinical pharmacy intervention|will involve a pharmacist identifying and addressing medication-related problems (e.g., inappropriate dosage or indications, drug interactions, and therapeutic duplication); optimizing medication regimens (discontinuing if appropriate, providing subsidized and generic options, and reducing medication complexity); and providing T2D education and self-management support
62585744|NCT05761886|NO_INTERVENTION|usual care|will involve routine physician office visits every 3 (for those with HbA1c outside goal) - or every 6 months (for those with HbA1c within goal). Medication regimens are usually managed by physicians, nurse practitioners, and physician assistants, and Patients have access to centralized chronic disease management programs.
62585745|NCT05975034|EXPERIMENTAL|Probiotic|Participants assigned to the probiotic group.
62585746|NCT05975034|PLACEBO_COMPARATOR|Placebo|Participants assigned to the placebo group.
62585747|NCT04754412|ACTIVE_COMPARATOR|Arm I (control writing)|Patients write about facts regarding their cancer diagnosis and treatment for 3 weekly 30-minute sessions.
62585748|NCT04754412|EXPERIMENTAL|Arm II (self-regulation writing)|Patients write about stress and coping, emotional disclosure, and benefit finding for 3 weekly 30-minute sessions.
62585749|NCT04754412|EXPERIMENTAL|Arm III (self-cultivation writing)|Patients write about positive thoughts and feelings regarding their breast cancer experience for 3 weekly 30-minute sessions.
62585750|NCT06582784|OTHER|Treatment as Usual|Participants in the treatment as usual group will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 8 weeks with a final follow up at 12 weeks.
62585751|NCT06582784|EXPERIMENTAL|Moodivate|Participants randomized to the Moodivate condition will be instructed to utilize Moodivate regularly, at least once per day, for the treatment of depressed mood among cancer survivors. Participants in the Moodivate group will receive a download code to download the Moodivate mobile application. Moodivate is a mobile app for individuals with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, and rate mood daily. Participants will be asked to complete questionnaire measures weekly for 8 weeks with a final follow up at week 12.
62585752|NCT06066619|EXPERIMENTAL|100% Cranberry Juice|100% Cranberry Juice will be 100% cranberry juice.
62585753|NCT06066619|EXPERIMENTAL|100% Cranberry Juice + 200 mg L-theanine|100% Cranberry Juice + 200 mg L-theanine will be 100% cranberry juice + L-theanine.
62585754|NCT06066619|PLACEBO_COMPARATOR|Placebo juice|Placebo juice that matches the appearance, taste, and calories of the treatment juices.
62585755|NCT06053203||University of Abuja Teaching Hospital|Pregnant women with Hypertensive Disorder of Pregnancy who seek care in the Federal Capital Territory, attending antenatal clinics on the 2nd or subsequent visit and pregnant women presenting to the labor and delivery room.
62585756|NCT06053203||Amino Kano Teaching Hospital|Pregnant women with Hypertensive Disorder of Pregnancy who seek care in Kano State in Nigeria, attending antenatal clinics on the 2nd or subsequent visit and pregnant women presenting to the labor and delivery room.
62793281|NCT04477577|ACTIVE_COMPARATOR|Safety Control|
62585757|NCT06053203||National Hospital, Abuja|Pregnant women with Hypertensive Disorder of Pregnancy who seek care in the Federal Capital Territory, attending antenatal clinics on the 2nd or subsequent visit and pregnant women presenting to the labor and delivery room.
62585758|NCT06053203||Murtala Muhammad Specialist Hospital|Pregnant women with Hypertensive Disorder of Pregnancy who seek care in Kano State in Nigeria, attending antenatal clinics on the 2nd or subsequent visit and pregnant women presenting to the labor and delivery room.
62585759|NCT05821959|EXPERIMENTAL|Cohort 1a and Cohort 1b|"Cohort 1a: Two participants aged 7 to 17 years old (inclusive) to receive intracochlear administration of AAVAnc80-hOTOF (dose level 1) in the study ear using a sterile, one-time use investigational medical device~Cohort 1b: Up to six eligible participants will be enrolled to receive intracochlear administration of AAVAnc80-hOTOF (dose level 1) in the study ear using a sterile, one-time use investigational medical device; the first three participants will be at least two years of age at the time of AAVAnc80-hOTOF administration and the next three participants may be of any age"
62585760|NCT05821959|EXPERIMENTAL|Cohort 2|Cohort 2: Up to six eligible participants will be enrolled to receive intracochlear administration of AAVAnc80-hOTOF (dose level 2) in the study ear using a sterile, one-time use investigational medical device; the first three participants will be at least two years of age at the time of AAVAnc80-hOTOF administration and the next three participants may be of any age
62585761|NCT05032495||Heart patients who experienced a cardiac arrhythmia while in hospital|Heart patients who experienced a cardiac arrhythmia while in hospital
62585762|NCT05032495||Heart patients who did not experience a cardiac arrhythmia while in hospital|Heart patients who did not experience a cardiac arrhythmia while in hospital
62585763|NCT05032495||Heart patients with an upcoming procedure that have not had a cardiac arrhythmia|Heart patients with an upcoming procedure that have not had a cardiac arrhythmia
62585764|NCT05032495||Members of the general public|Members of the general public
62585765|NCT01983943|EXPERIMENTAL|Hydroxytyrosol|Hydroxytyrosol, the major polyphenol in olive oil, 40mg will be taken once per day for 6 months.
62585766|NCT01983943|PLACEBO_COMPARATOR|Placebo|Placebo 40mg will be taken once per day for 6 months.
62793282|NCT03723772|EXPERIMENTAL|Insulin 287 followed by insulin glargine U100|"Run-in period (2 days to 4 weeks): The basal insulin glargine dose for each subject will be established and optimised.~After run-in, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic sampling where subjects are treated with once daily (OD) insulin glargine.~After insulin 287 treatment, participants will receive insulin glargine U100 OD for 2 weeks."
62585767|NCT04833894|EXPERIMENTAL|Efgartigimod|Patients receiving efgartigimod intravenous (IV) treatment
62585768|NCT05110846|PLACEBO_COMPARATOR|Placebo|Placebo
62585769|NCT05110846|EXPERIMENTAL|CT-868 Low Dose|CT-868
62585770|NCT05110846|EXPERIMENTAL|CT-868 Maximum Tolerated Dose|CT-868
62585771|NCT04768972|EXPERIMENTAL|ION363|ION363 will be administered by lumbar intrathecal (IT) bolus injection every 12 weeks, with an additional loading dose at 4 weeks, over a 60-week double-blind treatment period in Part 1; every 12 weeks for 84 weeks in the open-label extension treatment period (Part 2), with an additional loading dose administered 4 weeks after the first dose. Patients may continue to receive open-label ION363 every 12 weeks in Part 3 for up to 3 additional years or until ION363 becomes commercially available in the patient's country or until the Sponsor discontinues the development program, whichever occurs earlier.
62585772|NCT04768972|PLACEBO_COMPARATOR|Placebo|Placebo will be administered by lumbar IT bolus injection every12 weeks, with an additional loading dose at 4 weeks, over a 60-week double-blind treatment period (Part 1).
62585773|NCT02708537||PRGF in candidates for sperm donors|Prospective study of 58 candidates for sperm donors clinic IVI Bilbao.
62585774|NCT05304793|EXPERIMENTAL|Arm I (TAB)|Patients participate in 4 weekly TAB in-person or video conference sessions over 1 hour each that provide them with skills to cope with their dyspnea. Patients also receive treatment handouts, a CD with an audio file with instructions for progressive muscle relaxation, and a pulse oximeter. Patients may receive additional support calls over 10-15 minutes from the TAB provider within 1 week following each session.
62585775|NCT05304793|ACTIVE_COMPARATOR|Arm II (usual care)|Patients receive usual management of dyspnea from the treating physician.
62585776|NCT06462820|ACTIVE_COMPARATOR|Active SAINT Stimulation|Active SAINT stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC)
62585777|NCT06462820|SHAM_COMPARATOR|Sham Stimulation|Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC)
62585778|NCT01950351|EXPERIMENTAL|Treatment (proton beam radiation therapy)|Patients undergo proton beam radiation therapy in 15 fractions over 5-6 weeks.
62585779|NCT06685133||Intervention/Treatment|Subjects who undergo bronchoscopy of the airways using the Galaxy System.
62585780|NCT05432622||Nivolumab Monotherapy|Participants who started adjuvant nivolumab
62585781|NCT05432622||Pembrolizumab Monotherapy|Participants who started adjuvant pembrolizumab
62793283|NCT03723772|EXPERIMENTAL|Insulin glargine U100 followed by insulin 287|"Run-in period (2 days to 4 weeks): The basal insulin glargine dose for each subject will be established and optimised.~After run-in, participants will receive insulin glargine U100 OD for 2 weeks followed by 1-14 days (at least 1 day is mandatory) of continued insulin glargine treatment.~After insulin glargine treatment, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic sampling."
62793284|NCT01150708||Chiari 1 with syringomyelia|Chiari I malformation with syringomyelia.
62793285|NCT01150708||Chiari 1 without syringomyelia|A Chiari I Malformation without syringomyelia is defined as descent of the cerebellar tonsils \> 5 mm below the foramen magnum 79 without associated syringomyelia.
62793286|NCT01150708||Syringomyelia without chiari|A syrinx or syringomyelia is defined as an intramedullary cyst that extends / length \> 1spinal segment.
62217367|NCT06540534|ACTIVE_COMPARATOR|Adjuvant-free selective trunks block|"In the selective trunk approach,Once the C6 and C5 ventral rami are identified at the level of the C7 transverse process, the probe will be slightly directed caudally to visualize the C6 ventral ramus. Caudal to the superior trunk, the middle trunk and the C8 ventral ramus will be visualized. The T1 ventral ramus can be seen on the 1st rib with the probe directed caudally. After administering 8 ml of the local anesthetic mixture to the lateral aspect of the superior trunk, the needle will be slightly withdrawn and directed towards the middle trunk where another 8 ml of the local anesthetic mixture will be administered. The probe will then be directed caudally to obtain an optimal view of the inferior trunk, and 9 ml of local anesthetic will be administered near the inferior trunk.~In the control group, a total of 25 ml of local anesthetic mixture will be applied, consisting of 23 ml of 0.5% bupivacaine and 2 ml of 0.9% saline."
62217368|NCT06540534|ACTIVE_COMPARATOR|Adjuvant with selective trunks block|"In the selective trunk approach, Once the C6 and C5 ventral rami are identified at the level of the C7 transverse process, the probe will be slightly directed caudally to visualize the C6 ventral ramus. The probe will be used to scan until the area where the upper trunks of C5 and C6 are formed is observed. Caudal to the superior trunk, the middle trunk and the C8 ventral ramus will be visualized. After administering 8 ml of the local anesthetic mixture to the lateral aspect of the superior trunk, the needle will be slightly withdrawn and directed towards the middle trunk where another 8 ml of the local anesthetic mixture will be administered. The probe will then be directed caudally to obtain an optimal view of the inferior trunk, and 9 ml of local anesthetic will be administered near the inferior trunk.~In the dexamethasone group, a total of 25 ml of local anesthetic mixture will be applied, consisting of 23 ml of 0.5% bupivacaine and 8 mg (2 ml of deksamethasone)"
62585782|NCT05432622||Dabrafenib + Trametinib Combination Therapy|Participants who started adjuvant dabrafenib + trametinib combination therapy
62585783|NCT05432622||No Treatment of a Systemic Therapy|Participants with no systemic treatment during the study observation period until record of recurrence
62585784|NCT00665860|PLACEBO_COMPARATOR|1|Placebo
62585785|NCT00665860|ACTIVE_COMPARATOR|2|
62585786|NCT00665860|ACTIVE_COMPARATOR|3|
62585787|NCT06665620|EXPERIMENTAL|ViraBrite|Each day, participants will receive nudges according to a micro-randomized pattern that encourage them to access the ViraBrite app and utilize coping and suicide safety planning skills. One decision point will occur per day. At each decision point, participants will have a seventy-five percent chance of receiving a nudge. Given that they are randomized to receive a nudge, participants have a 33.3% chance of receiving a notification at one of three time points: morning, midday or evening.
62585788|NCT04061616|EXPERIMENTAL|Participants|All the participants volunteer to participate to the study that were included.
62585789|NCT03861702|EXPERIMENTAL|FOLFOX + Irinotecan|"Oxaliplatin 60 mg/m2 Intravenously (IV) over 2 hours~Liposomal Irinotecan (free base) 50 mg/m2 IV over 90 minutes after completion of oxaliplatin~Leucovorin 400 mg/m2 IV over 30 minutes after completion of liposomal irinotecan~5-Fluorouracil 2,400 mg/m2 IV over 46 hours via infusion pump at home~All drugs administered on day 1 of each 14 day cycle."
62585790|NCT06515236|EXPERIMENTAL|Strategic Treatment Assessment for Youth (STAY)|"Clinicians assigned to the STAY condition will receive training and ongoing consultation in the STAY protocol and implementation plan. STAY is a culturally-modified version of measurement-based care (MBC) for racial and ethnic minoritized adolescents. Clinicians in this condition will receive training materials and consultation on standard MBC practices using the PHQ-9-A for depression plus cultural competence training, the Introduce component to assess and address treatment expectations at the start of care, and individualized goal and alliance progress measures."
62793287|NCT00797277|EXPERIMENTAL|IM olanzapine|Patients of this arm received 10 mg IM olanzapine after randomization
62793288|NCT00797277|ACTIVE_COMPARATOR|IM haloperidol plus lorazepam|Patients of this arm received 5 mg IM haloperidol plus 2 mg IM lorazepam after randomization
62793289|NCT01885676|EXPERIMENTAL|PRGF-Endoret|
62793290|NCT01885676|PLACEBO_COMPARATOR|Saline Solution|
62793291|NCT05527444|EXPERIMENTAL|Randomized-SEC group|actived AS patients naïve to ADA and SEC
62793292|NCT05527444|EXPERIMENTAL|Randomized-ADA group|actived AS patients naïve to ADA and SEC
62793293|NCT05527444|EXPERIMENTAL|Non-Randomized-SEC group|AS patients who previously had inadequate response to ADA
62793294|NCT05527444|EXPERIMENTAL|Non-Randomized-ADA group|AS patients who previously had inadequate response to SEC
62793295|NCT06726824||NEOMIX-WP3 cohort|NEOMIX-WP3 cohort corresponds to the patients incluses in the ARMED NEO cohort (NICU patients) between February 2018 And June 2019. These children are now between 6 And 7. Their parents will be asked by validated questionnaries to evaluate the Neurodevelopmental status And eventual risk factors since they got back home after NICU stay
62793296|NCT06024603|EXPERIMENTAL|Drug Sensitivity Testing|The results of the DST and genomic screening will be used to inform treating physician about participant-specific drug sensitivity or resistance guiding best therapy choices. The physician will decide which treatment will be most appropriate for each case. All participants will need to be consented separately for any subsequent investigational treatment if no standard treatment options are available.
62793297|NCT01860313|EXPERIMENTAL|Web-based interactive educational group|This group was submited to the web-based interactive education created for train teachers in child mental health, how to identify mental health problems in children and to know how to deal with problematic children in class.
62793298|NCT01860313|EXPERIMENTAL|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
62411684|NCT04051658|SHAM_COMPARATOR|Sham-tDCS & PT|Dual transcranial direct current stimulation (tDCS) in sham mode will be applied over C3-C4 or the motor area (M1) for 20 mins before conventional physical therapy (about 1 hour). Anodal on the affected hemisphere, Cathodal on the unaffected hemisphere. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
62411685|NCT01143610|EXPERIMENTAL|Newly forming bone|Miller class I or II deep recessions treated by the newly forming bone technique.
62411686|NCT01143610|ACTIVE_COMPARATOR|Subepithelial connective tissue graft|Miller class I or II deep recessions treated by subepithelial connective tissue graft.
62021853|NCT04495712|ACTIVE_COMPARATOR|Spironolactone|Patients randomized to active therapy with spironolactone
62411687|NCT03490175||All patients|Patients undergoing general anesthesia for elective surgery
62021854|NCT04495712|PLACEBO_COMPARATOR|placebo|patients randomized to placebo
62021855|NCT02962830|EXPERIMENTAL|Sufentanil|
62021856|NCT02669329|EXPERIMENTAL|Upper arm treatment with vacuum applicator|Subjects with clearly visible fat sufficient for treatment received bilateral CoolSculpting treatments, 1 treatment on each arm.
62021857|NCT02018055|ACTIVE_COMPARATOR|Aspirin+Ticagrelor|A Group treated with Aspirin+Ticagrelor
62021858|NCT02018055|EXPERIMENTAL|Aspirin+Clopidogrel|A Group treated with Aspirin+Clopidogrel
62021859|NCT05298085|EXPERIMENTAL|OXYTOCIN nasal spray|intranasal administration of Oxytocin
62585791|NCT06515236|ACTIVE_COMPARATOR|Measurement-Based Care (MBC) As Usual|Clinicians assigned to the active comparison condition will receive standard MBC training and ongoing consultation that is routinely used and evaluated by the research team with child and adolescent mental health clinicians. MBC As Usual training materials will be customized to focus on collection and use of the PHQ-A with adolescents and their caregivers using a feedback system. MBC As Usual clinicians will be offered the opportunity to be trained in STAY at the conclusion of data collection
62793299|NCT01860313|NO_INTERVENTION|Waiting List group|This group was used as control group and did not receive any intervention.
62793300|NCT01071421||Control Group (B): Other Infections|Other infections admitted to the hospital
62021860|NCT05298085|PLACEBO_COMPARATOR|PLACEBO|intranasal administration of placebo
62021861|NCT04256733|EXPERIMENTAL|Supra-threshold capsaicin|Participants will be exposed to progressively increasing concentrations of aerosolized capsaicin (the ingredient in chili peppers that makes them spicy, and a known cough stimulant) to stimulate an urge-to-cough. Participants will be coached to implement cough suppression strategies following each exposure.
62021862|NCT04256733|PLACEBO_COMPARATOR|Sub-threshold capsaicin|Participants will be exposed repeatedly to a single sub-threshold dose of aerosolized capsaicin through a nebulizer during treatment. This sub-threshold dose will elicit minimal or no urge-to-cough.
62021863|NCT04198779|EXPERIMENTAL|APPLI|Care support with implementation of the application
62411688|NCT05878600|EXPERIMENTAL|cervical spine strengthening group|"The participant will nod and chin tuck the head against the block with bands supporting the movement.~An air-filled pressure cushion is placed under the occiput behind the cervical spine and conforms to the subject's shape. With a head nod, the pressure on the cuff increases and is shown by the dial. 10 repetitions of 5 seconds hold will be performed for 8 weeks and strength is measured by sphygmomanometer"
62411689|NCT05878600|ACTIVE_COMPARATOR|Kendall exercise group|patient is seated and the exercises are performed which include stretching pectoralis muscle, placing both hands on the occipital area and pulling the elbows back up and performing arm abduction and external rotation; and (2) strengthening shoulder retraction, Strengthening the deep cervical flexors and Stretching the cervical extensors
62411690|NCT01853969||Patients who have carpal tunnel release surgery|
62793301|NCT01071421||Community Acquired Pneumonia (Group A)|Patients admitted to hospital with Community Acquired Pneumonia defined by respiratory symptoms, fever and lung infiltrates
62021864|NCT04198779|NO_INTERVENTION|CONTROL|Conventional care support
62021865|NCT04109989|EXPERIMENTAL|HominisTM Surgical System|Gynecological surgical procedure will be performed with the HominisTM Surgical System
62021866|NCT02832895|EXPERIMENTAL|Transcranial Doppler examination|Transcranial Doppler examination
62021867|NCT02952079|ACTIVE_COMPARATOR|BlephEx treatment|Treatment with the BlephEx instrument (lid margin exfoliation)
62793302|NCT02598440|EXPERIMENTAL|Group A: Ibandronate Then Alendronate|Participants wil receive once-monthly oral ibandronate (150 mg tablet) for 3 months followed by and once-weekly oral alendronate (70 mg tablet) in crossover design for 12 weeks.
62793303|NCT02598440|EXPERIMENTAL|Group B: Alendronate Then Ibandronate|Participants will receive once-weekly oral alendronate (70 mg tablet) for 12 weeks followed by once-monthly oral ibandronate (150 mg tablet) for 3 months.
62793304|NCT04538417|OTHER|Residual Limb Pain in affected amputated limb|Patient has residual limb pain in amputated limb and is scheduled to receive standard of care treatment of cooled radiofrequency ablation.
62793305|NCT05904067|EXPERIMENTAL|Recipient of COVID-19 Convalescent Plasma (CCP) Transfusion|Transfusion of COVID-19 convalescent plasma to participants The experimental group (CCP group): 200 ml of CCP at +14 days, +28 days, +2 months, and +3 months following hematopoietic stem cells transplantation.
62793306|NCT05904067|NO_INTERVENTION|Recipient without COVID-19 Convalescent Plasma (CCP) Transfusion|Control group (supportive therapy): patients were routinely given oral ursodeoxycholic acid for +14 days after transplantation.
62793307|NCT02110667||Prostate cancer, post-prostatectomy|
62793308|NCT04055909|EXPERIMENTAL|nangibotide 1|Treatment with study drug at at dose of 0.3mg/kg/hr
62793309|NCT04055909|EXPERIMENTAL|nangibotide 2|Treatment with study drug at at dose of 1.0mg/kg/hr
62793310|NCT04055909|PLACEBO_COMPARATOR|Placebo|Treatment with a matched placebo infusion
62793311|NCT05336747|EXPERIMENTAL|"Voice Lessons Here, My Voice 2 Program"|"Voice Lessons Here, My Voice 2 Program"
62793312|NCT05336747|EXPERIMENTAL|"Voice Lessons Here, My Voice 3 Program"|"Voice Lessons Here, My Voice 3 Program"
62793313|NCT02636530|EXPERIMENTAL|Ground Reaction Forces|Participants will have an individualized exercise program that includes walking, jogging, stair climbing, and box jumping.
62793314|NCT02636530|EXPERIMENTAL|Joint Reaction Forces|Participants will have an individualized exercise program that includes weight lifting and aerobic rowing.
62793315|NCT04331470|EXPERIMENTAL|Levamisole Pill + Budesonide+Formoterol inhaler+Standard care|This group will take Levamisole + Budesonide/Formoterol along side with standard treatment regime.
62793316|NCT04331470|ACTIVE_COMPARATOR|Standard care|This group will take standard treatment regime introduced by Ministry of health.
62021868|NCT02952079|ACTIVE_COMPARATOR|MiBoFlo treatment|Treatment with the MiboFlo equipment (heat therapy to eyelids)
62021869|NCT01199081|EXPERIMENTAL|Group A|"Dronedarone 400 mg twice daily for 8 weeks starting from randomization.~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
62021870|NCT01199081|EXPERIMENTAL|Group B|"Dronedarone 400 mg twice daily for 6 weeks starting 2 weeks after randomization.~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
62411691|NCT05997316|EXPERIMENTAL|Time restricted eating|Participants will engage in a 12-week time restricted fasting intervention. Each week, participants will work with a clinical psychologist to modify the timing of their eating behaviors to adhere to a 16-hour fast, 2-3 days per week.
62411692|NCT02503800||subjects undergoing venom immunotherapy|The study group will include all the subjects receiving routine venom immunotherapy at the Meir Medical Center Allergy Clinic.
62411693|NCT06563440|EXPERIMENTAL|App/digital system|Experimental Hospital/HCs will be provided with point of care test kits and smart phones loaded with airtime credit and the SCD SIMCS app. The health workers that normally provide pediatric care at the facilities will be trained in using the kits and SCD SIMCS app. Outcome measures to compare the effectiveness of SCD screening with and without the SIMCS will include proportions of accurately interpreted assay results, parents that receive counseling, infants seen for SCD care within 1 month of screening, and infants on penicillin. Variables to compute these outcome measures will be entered into cellphone eCRFs (Controls) or automatically transmitted from the SCD SIMCS App (Experimental) and retrieved from the SCD SIMCS database. Chi-squared test and contingent 95% confidence intervals and p-values will be computed to compare the proportions between SIMCS vs. non-SIMCS hospital/HCs.
62411694|NCT06563440|ACTIVE_COMPARATOR|No App/digital system|Control Hospital/HCs will be provided with point of care test kits and smart phones loaded with airtime credit BUT no SCD SIMCS app. The health workers that normally provide pediatric care at the facilities will be trained in using the kits. To enable independent verification of the accuracy of interpretation of assay results, health workers will use the smart phones to take and send a photographic caption of every used point of care test strip to a designated central study phone from which they will be downloaded into a computer database. Control infants will be IDed by study number in the SCD SIMCS database.
62411695|NCT04865887|EXPERIMENTAL|Pembrolizumab with Lenvatinib|
62411696|NCT04854421||healthy adults|Community dwelling and have no life-threatening conditions or diseases that would alter body composition from what is typical for their age, sex, ethnicity, and BMI.
62411697|NCT03016416||chronic stroke patients|Participants for the study group will be recruited from the Clalit Health Services- Ben Yair Rehabilitation Center in Jaffa Israel.
62793317|NCT05081232|EXPERIMENTAL|Umbilical Cord Allograft Recipients|Male patients undergoing Robot Assisted Radical Prostectomy with bilateral nerve sparing technique will remain eligible to receive allograft during the surgery.
62793318|NCT05144139|EXPERIMENTAL|Low dose group with mRNA vaccine|25μg with COVID-19 mRNA vaccine
62793319|NCT05144139|PLACEBO_COMPARATOR|Low dose group with placebo|Low dose group with placebo
62793320|NCT05144139|EXPERIMENTAL|High dose group with mRNA vaccine|45μg with COVID-19 mRNA vaccine
62793321|NCT05144139|PLACEBO_COMPARATOR|High dose group with placebo|High dose group with placebo
62793322|NCT00321451|EXPERIMENTAL|1|
62793323|NCT00321451|SHAM_COMPARATOR|2|
62793324|NCT00321451|ACTIVE_COMPARATOR|3|
62793325|NCT04807335|EXPERIMENTAL|Investigational medicinal product CT001|intranasal dosage of CT001
62793326|NCT04807335|ACTIVE_COMPARATOR|Comparator 1|Ketamine 10mg iv
62793327|NCT04807335|ACTIVE_COMPARATOR|Comparator 2|Sufentanil 10mcg iv
62793328|NCT02378324|ACTIVE_COMPARATOR|Intervention and control|Intervention arm: screening without fee.
62411698|NCT03016416||control group|The control group will be with equivalent age and lifestyle as the studt group. Participants for the control group will be recruited via solicitation adds at the Ben Yair Rehabilitation Center and at near-by clinics.
62411699|NCT06346080|EXPERIMENTAL|Survey participants|Participants who will complete a survey investigating their preference for diagnosis and assessment of gastro-esophageal cancer
62793329|NCT02378324|NO_INTERVENTION|Control group|Control arm: screening with the regular fee, 100SEK.
62793330|NCT05434390|EXPERIMENTAL|Latino MSM PrEP intervention|The Latino MSM PrEP intervention consists of 4 small group sessions with concurrent peer navigation and counseling.
62793331|NCT05434390|ACTIVE_COMPARATOR|Control condition|The control condition consists of usual care at the study site (i.e., referrals to PrEP services).
62411700|NCT06170632|ACTIVE_COMPARATOR|Intervention group|Intervention group (IG): Patients with flare type SEMS placement
62411701|NCT06170632|ACTIVE_COMPARATOR|Control group (CG)|Control group (CG): Patients with plastic stent placement
62411702|NCT01338701|EXPERIMENTAL|Auricular (Ear) Acupuncture|Auricular (Ear) Acupuncture is administered in a step-wise, algorithmic acupuncture approach in which needles are inserted at specific auricular landmarks. The sequence and location of needled points is determined by the participant's severity of headache pain at presentation and response to needling. Between six and nine points are needled in each treatment session depending on the individual's response (i.e., a decrease or persistence of headache pain). In-dwelling ASP needles are inserted at the end of each session. Participants are instructed to remove the needles after 3 days, or sooner if pain or redness developed at a needle site. Ten 45-minute acupuncture treatment sessions are administered over 6 weeks.
62411703|NCT01338701|EXPERIMENTAL|Traditional Chinese Acupuncture (TCA)|A semi-standardized form of Traditional Chinese Acupuncture (TCA) is administered, incorporating the insertion of up to 22 acupuncture needles associated with each individual participant's: (1) primary headache pattern (up to three pairs of points); (2) secondary headache pattern (up to 2 pairs of points); (3) Ah-Shi or tender points (up to 4 points); (4) constitutional points (source points on two meridians); and, (5) up to 2 pairs of additional points from a selected list. Point selection was reassessed every two weeks per TCM diagnostic and treatment principles. While the majority of points were located on the limbs, points also included local points of tenderness to the head, as well as the front and back of the torso. Ten 60-minute TCA sessions are administered over 6 weeks.
62411704|NCT01338701|OTHER|Usual Care|All study participants continue to receive routine usual care for their TBI, headaches and associated symptoms as determined by their clinical team.
62793332|NCT04197180|EXPERIMENTAL|Hybrid Argon Plasma Coagulation|The Hybrid-Argon Plasma Coagulation probe combines waterjet technology with Argon Plasma Coagulation. The probe comprises a central water channel for the submucosa injection function and a peripheral gas channel for the Argon Plasma Coagulation function
62793333|NCT02292446|EXPERIMENTAL|All patients|All patients will receive ruxolitinib at a starting dose of 10 mg twice daily which could be titrated to most appropriate dose. Dose was not to exceed 25 mg bid nor be less than 5 mg once a day
62793334|NCT03902314|ACTIVE_COMPARATOR|Lidocaine|Lidocaine infusion at 2 mg/kg/hr will be started in the operating room and continue in the recovery period for 60 minutes.
62793335|NCT03902314|PLACEBO_COMPARATOR|Saline|Saline infusion at 2 mg/kg/hr will be started in the operating room and continue in the recovery period for 60 minutes.
62411705|NCT03046966|OTHER|Intervention Control: No Training|Does not receive hands-on intubation training in the Simulation Lab.
62411706|NCT03046966|OTHER|Intervention: Receives Training|Receives hands-on intubation training in the Simulation Lab.
62793336|NCT05681702|ACTIVE_COMPARATOR|DAPT de-escalation|Aspirin 81-mg od and clopidogrel 75-mg qd.
62793337|NCT05681702|EXPERIMENTAL|Potent P2Y12 monotherapy|Potent P2Y12 inhibitor with prasugrel 10 mg od or ticagrelor 90 mg BID.
62793338|NCT00513149|ACTIVE_COMPARATOR|c6|Clopidogrel 600 mg loading
62793339|NCT03822767|EXPERIMENTAL|Experimental Group|sIPV-sIPV-bOPV vaccination schedule
62793340|NCT03822767|ACTIVE_COMPARATOR|Control Group|wIPV-wIPV-bOPV vaccination schedule
62793341|NCT00941915|EXPERIMENTAL|Stereotactic Radiotherapy|Five fractions of 7.4 Gy each
62793342|NCT03151733|EXPERIMENTAL|single incision laparoscopic surgery|patients with colorectal cancer and undergo single incision laparoscopic surgery
62793343|NCT03151733|PLACEBO_COMPARATOR|Conventional laparoscopic surgery|patients with colorectal cancer and undergo conventional laparoscopic surgery
62793344|NCT02639442|EXPERIMENTAL|ClearRing™|subjects will undergo general/spinal/local block anesthesia and cystoscopy and/or x-ray evaluation. One to three implants will be transplanted into the patient prostate, followed by cystoscopy for results evaluation
62793345|NCT04042961|EXPERIMENTAL|Reactive balance training|
62793346|NCT04042961|ACTIVE_COMPARATOR|Aerobic and strength training|
62793347|NCT00413036|EXPERIMENTAL|lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
62793348|NCT03350815|ACTIVE_COMPARATOR|Responders|Patients who achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (total score \<1.3) at both Week 12 and Week 16.
62793349|NCT03350815|ACTIVE_COMPARATOR|Inadequate responders|Patients who have active disease, defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) total score of \>1.3 at both Week 12 and Week 16, and who achieved a decrease (improvement) from baseline in total ASDAS score at both Week 12 and Week 16.
62793350|NCT03350815|ACTIVE_COMPARATOR|Non-responders|"Patients who exhibit no change or an increase (worsening) from baseline in total Ankylosing Spondylitis Disease Activity Score (ASDAS) score at either Week 12 or Week 16.~Non-responders were not entered Treatment Period 2. Non-responders were discontinued from the study at Week 16."
62793351|NCT00445185|EXPERIMENTAL|1|Henogen Hepatitis B vaccine for uremic patients
62793352|NCT00445185|ACTIVE_COMPARATOR|2|Fendrix hepatitis B vaccine for uremic patients
62793353|NCT05883644|EXPERIMENTAL|Durvalumab plus Tremelimumab|Participants will receive a single priming dose of Tremelimumab plus Durvalumab at Day 1 (Week 0), followed by Durvalumab monotherapy starting at Week 4 and continuing until clinical progression, confirmed RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or any intervention discontinuation criteria.
62793354|NCT02100475|EXPERIMENTAL|Insulin degludec/liraglutide + Metformin|
62793355|NCT02100475|ACTIVE_COMPARATOR|Insulin degludec/liraglutide + Insulin Aspart + Metformin|
62793356|NCT04241484|EXPERIMENTAL|Piezowave|"* Initiation of Piezowave MyACT treatment to include parameters from the user manual~* Set for frequency of five pulses per second~* Delivery of 500 to 1000 pulses over multiple injured area sites, not to exceed 4000 pulses per session~* Intensity ranging from 0.1 to 18 millijoule per square millimeter. This intensity if energy flux as the rate of transfer of the energy through the surface of the tissue is applied.~* Focal transducer~* Head size will be variable based on depth of tissue treated. The user manual will be consulted for depth of penetration recommendations"
62793357|NCT01288001|EXPERIMENTAL|Ostenil plus|Patient will get Ostenil plus injection and standard treatment of Osteoarthritis
62793358|NCT02161835|EXPERIMENTAL|Training|Participants exercise 3 times a week, 30 minute, on an ergometer bike.
62793359|NCT02161835|NO_INTERVENTION|Control|Participants is tested with the 4 objective myotonia test and measurements of self-assessed myotonia by the Myotonia Behavior Scale is collected.
62793360|NCT01374633|EXPERIMENTAL|1:patient with severe traumatic brain|
62793361|NCT05112562|EXPERIMENTAL|Computerized attentional bias modification training|
62793362|NCT05112562|PLACEBO_COMPARATOR|Placebo attention control training|
62793363|NCT05380440|EXPERIMENTAL|Pre-FAIR|Participants in this arm will receive the FAIR intervention.
62793364|NCT05380440|ACTIVE_COMPARATOR|Control|Participants in this arm will receive services standard case management and services .
62793365|NCT03130920|NO_INTERVENTION|Control|
62793366|NCT03130920|ACTIVE_COMPARATOR|Remote ischemic preconditioning|
62793367|NCT03130920|ACTIVE_COMPARATOR|Local ischemic preconditioning|
62021871|NCT01199081|EXPERIMENTAL|Group C|"Dronedarone 400 mg twice daily for 4 weeks starting 4 weeks after randomization.~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
62793368|NCT04951622|EXPERIMENTAL|Nipocalimab|"Double-blind Placebo-controlled Phase: Participants will receive nipocalimab intravenous (IV) infusions once every 2 weeks (q2w) up to 24 weeks during double-blind placebo-controlled phase.~Open-label Extension (OLE) Phase: Participants who complete the double-blind placebo-controlled phase will enter the OLE phase and continue to receive nipocalimab q2w IV infusion till study end."
62021872|NCT03900936||Neuropsychological tests|This study is not an intervention as such. We are simply comparing the scores of MCI patients who subsequently went on to develop dementia vs those who did not.
62021873|NCT02088996|ACTIVE_COMPARATOR|IT and LWD on high power|IT and LWD on high power
62021874|NCT02088996|PLACEBO_COMPARATOR|LWD on low power|LWD on low power
62021875|NCT00882843||Group 1|Healthy Able bodied Control
62021876|NCT00882843||Group 2|Spinal Cord Injury
62021877|NCT01468246||Young Women|Young women with newly diagnosed breast cancer
62793369|NCT04951622|PLACEBO_COMPARATOR|Placebo|Double-blind Placebo-controlled Phase: Participants will receive matching placebo of nipocalimab IV infusion q2w up to 24 weeks during double-blind placebo-controlled phase.
62793370|NCT04850469||trial group|Mesenchymal Stem Cell-Derived Exosomes
62793371|NCT04850469||control group|conventional treatment
62793372|NCT01285934|EXPERIMENTAL|Hematopoietic Stem Cell Transplantation|Patients who meet eligibility and have completed pre-HSCT testing in section 7.0 (study parameters) may be enrolled in the transplant arm and will undergo an Autologous Hematopoietic Stem Cell Transplantation
62793373|NCT01285934|OTHER|control arm of intensive insulin therapy|The control arm of intensive insulin therapy (IIT) will enroll all patients who meet eligibility but decline HSCT or whose insurance does not approve payment for HSCT before expiration of eligibility (within 5 months of disease onset)
62793374|NCT04996251|EXPERIMENTAL|subcutaneous infiltration pre-incision|Marcaine (bupivacaine) injected in the umbilical port site subcutaneously, while in the other 4 sites injection under direct visualization
62793375|NCT04996251|EXPERIMENTAL|subcutaneous infiltration post-incision|local anesthetic infiltrated subcutaneously at the end of the procedure after trocar removal and after skin closure with suture
62021878|NCT00681317|EXPERIMENTAL|1|
62021879|NCT03839238|EXPERIMENTAL|Meniscus Injured patients|hESC Derived MSC Like Cell
62021880|NCT04593992|EXPERIMENTAL|HTEMS|High-tone external muscle stimulation 5 times within a week for 12 weeks
62021881|NCT04593992|PLACEBO_COMPARATOR|Placebo|Placebo stimulation 5 times within a week for 12 weeks
62021882|NCT06121713|ACTIVE_COMPARATOR|GCE + Low ALA|Green coffee extract and a low dose of alpha-lipoic acid prior to an oral glucose tolerance test
62021883|NCT06121713|ACTIVE_COMPARATOR|GCE + High ALA|Green coffee extract and a moderate dose of alpha-lipoic acid prior to an oral glucose tolerance test
62021884|NCT06121713|PLACEBO_COMPARATOR|Placebo|Inert placebo pill prior to an oral glucose tolerance test
62411707|NCT05916963|EXPERIMENTAL|Furosemide|Injection of 40 mg of Furosemide during 10 minutes after the end of the flexible ureteroscopy for destruction of kidney stones with laser.
62021885|NCT01882634|EXPERIMENTAL|Ultrasound arm|
62021886|NCT01233817|EXPERIMENTAL|Spinal muscular atrophy|Children and adolescents with diagnosis of SMA type II or III. The intervention group (the only arm/group in this pilot study) receives a home-based, supervised, 12-week progressive strength-training program.
62793376|NCT03910088|PLACEBO_COMPARATOR|control group|received conventional treatment in the form of good oral hydration, 500 mg of acetaminophen plus 65 mg of caffeine oral tablets thrice daily, 3 cups of coffee daily, 50 mg of diclofenac potassium oral tablets twice daily and recumbent positioning for 48 hours
62793377|NCT03910088|ACTIVE_COMPARATOR|Pregabalin|received the conventional treatment plus 100 mg of pregabalin oral tablet every 8 hours for 48 hours
62793378|NCT03910088|ACTIVE_COMPARATOR|Hydrocortisone|received the conventional treatment plus 100 mg of hydrocortisone IV every 8 hours for 48 hours.
62021887|NCT03756558|EXPERIMENTAL|Cross-Seal System|The Cross-Seal System will be used in all subjects enrolled in the study
62021888|NCT03294447|EXPERIMENTAL|Fall Prevention Intervention by OT|Fall prevention interventions implemented by an OT in a geriatric primary care setting for a client immediately following the provider visit within the office.
62021889|NCT03871387|EXPERIMENTAL|Deep Block Group|"* Continuous Rocuronium infusion during surgery~* Maintain TOF = 0 \& PTC= 1\~2~* At the end of surgery, IV Sugammadex injection to reverse muscle relaxation. (Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2)"
62021890|NCT03871387|ACTIVE_COMPARATOR|Moderate Block Group|"* Continuous Rocuronium infusion during surgery~* Maintain TOF 1\~2~* At the end of surgery, IV Sugammadex injection to reverse muscle relaxation. (Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2)"
62021891|NCT06182670|EXPERIMENTAL|Subcrestal implant and gingival former abutment (GFA)|The subjects receive a subcrestal implant and a prosthodontic device (GFA) immediately during the surgery. The GFA will not be removed upon prosthetic load. It will be an integral part of the prosthetic finalization.
62021892|NCT06182670|ACTIVE_COMPARATOR|Crestal implant and traditional abutment|The subjects receive a crestal implant and healing abutment. The healing abutment will be replaced by a definitive abutment to the prosthetic load.
62021893|NCT04861649|EXPERIMENTAL|Effect and mechanism of fecal microbiota transplantation on patients with COPD malnutrition|"During COPD stable period, nasal and intestinal tubes were placed and fecal bacteria were transplanted from healthy people (three transplants per course of treatment).~200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)"
62021894|NCT03943368|EXPERIMENTAL|Experimental: Intervention Arm|Subjects whose surgeon will be viewing Digital 3D models in addition to the source MR image and biopsy results in connection with the case.
62819359|NCT02657096|EXPERIMENTAL|Hybenx treatment|Both quadrants included maxillary teeth 11-16 and 21-26. Each selected subject underwent randomly, without anaesthesia, at the same time and after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional SRP + desiccant (Hybenx). In the maxillary quadrant assigned to SRP + hybenx treatment, hybenx was applied, after SRP, on the marginal gingiva with a 30-second incubation period and then thoroughly rinsed away through abundant irrigation with a sterile saline solution.
62021895|NCT03943368|NO_INTERVENTION|Control Arm|Subjects whose surgeon will only be viewing MR images in connection with the case.
62021896|NCT05642572|EXPERIMENTAL|Arm A (capmatinib, osimertinib, ramucirumab)|Patients receive capmatinib PO, osimertinib PO, and ramucirumab IV on study. Patients also undergo CT scan or MRI and collection of blood samples throughout the trial.
62021897|NCT05642572|EXPERIMENTAL|Arm B (capmatinib, osimertinib)|Patients receive capmatinib PO and osimertinib PO on study. Patients also undergo CT scan or MRI and collection of blood samples throughout the trial.
62021898|NCT06534359|EXPERIMENTAL|Transpyloric tube feeding|Nasal or oral placed feeding tube with the distal end located within the second or third portion of the duodenum. Correct placement confirmed by radiograph.
62021899|NCT06534359|EXPERIMENTAL|Gastric tube feeding|Nasal or oral placed feeding tube with distal end located within the stomach. Correct placement confirmed by point of care aspirate pH testing or radiograph based on local clinical standard.
62021900|NCT01990443|EXPERIMENTAL|Reslizumab IV|Reslizumab 220-mg administered Intravenously (IV)
62021901|NCT01990443|EXPERIMENTAL|Reslizumab SC|Reslizumab 220-mg administered Subcutaneously (SC)
62021902|NCT03268811|EXPERIMENTAL|Teduglutide|Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24-week intervals. If a participant deteriorates during a follow-up period, the participant may be evaluated immediately for additional teduglutide treatment (24-week interval) until teduglutide is commercially available for each participant, the participant's participation in this study is discontinued, or the study is discontinued.
62021903|NCT01267071|EXPERIMENTAL|A|GSK962040 (50 mg, SD, oral)
62021904|NCT01267071|EXPERIMENTAL|B|14C GSK962040 (100 μg, SD, iv)
62021905|NCT02408614||Slow-paced walking|Subjects will complete 47 minutes of walking at slow pace.
62021906|NCT02408614||Moderate-paced walking|Subjects will complete 47 minutes of walking at a moderate pace.
62021907|NCT02408614||Interval training|Subjects will complete 40 minutes of walking alternating between a moderate and fast pace.
62021908|NCT03663114||Lenvatinib|Participants receiving lenvatinib capsules 12 milligrams (mg) based on participant's body weight greater than or equal to (\>=) 60 kilograms (kg) or 8 mg based on participant's body weight less than (\<) 60 kg, orally, once daily dose will be centrally registered and observed prospectively for up to 1 year after the administration of dose.
62021909|NCT06082180|EXPERIMENTAL|test group|prophylactic central neck dissection
62021910|NCT06082180|NO_INTERVENTION|control group|no central neck dissection
62021911|NCT02680600|EXPERIMENTAL|Study arm|"* Cefepime dosing~* Blood sampling~* Urine sampling~* Determination of renal markers~* Population pharmacokinetic modeling~* Covariate screening~* Monte Carlo simulations"
62021912|NCT02678546||patients in outpatients departments|patients from outpatients departments in teaching hospital
62411708|NCT05916963|NO_INTERVENTION|Usual care|Usual care, without injection of Furosemide.
62819360|NCT02657096|SHAM_COMPARATOR|Scaling and Root Planing|The contra-lateral quadrants were treated as conventional Scaling and Root Planing (SRP) alone.
62021913|NCT02678546||General|participants from center of continuing education in China Medical University
62021914|NCT02943746|ACTIVE_COMPARATOR|Control Group (Standard Protein Diet)|"Infants will receive a standard feeding regimen which consists of mother's own milk or donor human milk (DHM) with DHM derived fortifier.~Once daily, a 24 hour batch of human milk is prepared for each infant (standard practice). A 2.5 mL sample will be analyzed for calories, protein, fat, and carbohydrates. Based on the amount of protein in the milk, fortification of feeds with donor human milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day of protein. Data will be recorded for milk analysis, nutrition, and infant growth.~The diet will be continued until approximately 35 to 36 weeks postmenstrual age at which point a DXA scan will be performed.~A serum blood urea nitrogen and creatinine as well as serum calcium, phosphorus, and alkaline phosphatase when the DXA is performed.~Anthropometrics: weekly weight, length, and head circumference by trained research nurse."
62411709|NCT00506558|EXPERIMENTAL|A|Ventral Decompression and Instrumented Fusion
62793379|NCT04692519|EXPERIMENTAL|Intervention|The Duet 2.0 intervention is comprised of six training modules, which include behavioral strategies, real-life and animated examples of high-quality early language interactions, and interactive scenarios. Modules were translated into Spanish. Participants will watch one Duet intervention module a week and have up to 3 months to complete all 6 modules. As intervention families review the modules on their own time at home, they will receive remote coaching from an assigned interventionist and weekly module-specific fidelity/comprehension questions. Interventionists will check-in weekly via phone or video (\~30-60 minutes), whichever is more convenient for the family. During the check-in, interventionists will do teach-back about the module, guide the family on how to incorporate the strategies into their daily lives, and provide feedback. Intervention participants will be scheduled for follow-up data collection at 3 months, 6 months, and pending funding, 1-year after baseline.
62793380|NCT04692519|NO_INTERVENTION|Delayed Access|Participants who are in the delayed access control group will not have to complete the modules and will be scheduled for a 3-month, 6-month, and pending funding, a 1-year follow-up calls. They will have delayed access to the modules, which means that they will receive access to the module videos at their 6-month study session and will be offered the opportunity to contact the research team with any questions.
62021915|NCT02943746|EXPERIMENTAL|Intervention Group (High Protein Diet)|"The intervention group will receive the same standard feeding regimen with the addition of extra milk fortification to give a high protein diet.~Human milk will be prepared and analyzed in the same method as the control group. Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.~The diet will be continued until approximately 35 to 36 weeks PMA at which point a DXA scan will be performed.~Infants will have 3 sets of labs. A serum blood urea nitrogen and creatinine as well as serum calcium, phosphorus, and alkaline phosphatase when the DXA is performed.~Anthropometrics: weekly weight, length, and head circumference by trained research nurse."
62411710|NCT00506558|ACTIVE_COMPARATOR|B|Dorsal Decompression with or without fusion
62411711|NCT05550259|NO_INTERVENTION|control period|the control period corresponds to usual care of centers
62411712|NCT05550259|EXPERIMENTAL|protocolized period|the protocolized period corresponds to a protocolized use of HFNO or NIV after extubation
62411713|NCT06652802|EXPERIMENTAL|Nurse-Conducted Brief Intervention (NCBI). supplemented with mobile based application|Experimental group participants receive Nurse-Conducted Brief Intervention (NCBI). supplemented with mobile based application. Due to the availability of Nurse Conducted Brief intervention (NCBI) service in Gastroenterology department by trained nurse it was done in the gastroentrology department.
62411714|NCT06652802|ACTIVE_COMPARATOR|Nurse-Conducted Brief Intervention (NCBI)|Control group participants receive only Nurse-Conducted Brief Intervention (NCBI).
62411715|NCT05327803|EXPERIMENTAL|epetraborole + OBR|epetraborole + Optimized Background Regimen
62411716|NCT05327803|PLACEBO_COMPARATOR|placebo + OBR|Placebo + Optimized Background Regimen
62411717|NCT04703647||Patients with CRPS type 1: prospective group|"Ambulatory patients of the Clinique romande de réadaptation (CRR) which have a CRPS type 1 of a limb.~Five measurement times (first visit (T0) and then after 3 (T1), 6 (T2), 12 (T3) and 24 (T4) months). At every time point, following data will be collected: physical examination, monitoring of the health and professional status with the physician, and self-administrated questionnaires. Blood sampling will be performed at T0, T1,T2 and T3.~Eight different self-administrated questionnaires will be used, in their French or Portuguese version. Each participants will answer seven questionnaires each time, depending if he/she suffers of arm or leg injury.~We will assess, in blood samples, the expression levels of specific molecules (miRNAs and a selection of cytokines) in patients diagnosed with acute CRPS. In a second time, miRNAs and cytokines profiles will be compared between acute and chronic (CRPS still diagnosed 6 months after the first diagnosis) CRPS patients."
62411718|NCT04703647||control group for blood analysis|"For the blood analysis, we will recruit 30 healthy controls who did not report any kind of pain. They will be recruited via posters that will be posted on the billboards of the Hôpital de Sion (employees and visitors) and on the visitor's billboards of the CRR. If this is not enough, we will expand the recruitment perimeter with other locations. The healthy control will be adjusted for age, sex and BMI with the CRPS groups. They will be informed about the study and procedure. The procedure for the blood samples will be the same as for patients.The screening for miRNAs of interest will be performed using a decision tree-based ensemble method (Random Forest). For this step, miRNAs profile of 30 control patients will be compared to the same number of CRPS patients.~The control group will have just one blood analysis."
62411719|NCT05060913|EXPERIMENTAL|5% EMLA Cream|EMLA cream will be applied over buccal mucosa of one side for 1.5 minutes of Maxillary of Mandibular anterior teeth.
62411720|NCT05060913|ACTIVE_COMPARATOR|20% Benzocaine gel|Benzocaine gel will be applied over buccal mucosa on another side for 1.5 minutes of Maxillary of Mandibular anterior teeth.
62411721|NCT01466907|ACTIVE_COMPARATOR|Intervention group|Control of secondary prevention at three months and one year after stroke and referral to physician if medical interventions are needed. Assessment of functional status and self-reports on health outcome. Supportive counselling provided.
62217369|NCT05785169|EXPERIMENTAL|First Cluster|"The intervention will be implemented across three steps with a total of 6 clinics (two clinics per step). The earliest roll-out of the intervention will be at the clinics randomized to Cluster 1.~The intervention consists of a mix of Workshops, Interactive Trainings and Learning Circles (virtual and in-person). In the first workshop, the investigators will present baseline findings to all clinic members to 1) raise awareness for the need for intervention to reduce Structural Racism and Discrimination (SRD) , 2) facilitate collaborative processes, 3) catalyze change for practice transformation, to 4) guide the intervention process. This workshop will be followed by a series of interactive trainings covering topics from the history of structural racism, to intersectional stigma and discrimination, bias, systems of accountability, and the creation of a manual to guide the implementation and sustainability of SRD reduction efforts."
62217370|NCT05785169|EXPERIMENTAL|Second Cluster|"The intervention will be implemented across three steps with a total of 6 clinics (two clinics per step). The earliest roll-out of the intervention will be at the clinics randomized to Cluster 1.~The intervention consists of a mix of Workshops, Interactive Trainings and Learning Circles (virtual and in-person). In the first workshop, the investigators will present baseline findings to all clinic members to 1) raise awareness for the need for intervention to reduce Structural Racism and Discrimination (SRD) , 2) facilitate collaborative processes, 3) catalyze change for practice transformation, to 4) guide the intervention process. This workshop will be followed by a series of interactive trainings covering topics from the history of structural racism, to intersectional stigma and discrimination, bias, systems of accountability, and the creation of a manual to guide the implementation and sustainability of SRD reduction efforts."
62217371|NCT05785169|EXPERIMENTAL|Third Cluster|"The intervention will be implemented across three steps with a total of 6 clinics (two clinics per step). The earliest roll-out of the intervention will be at the clinics randomized to Cluster 1.~The intervention consists of a mix of Workshops, Interactive Trainings and Learning Circles (virtual and in-person). In the first workshop, the investigators will present baseline findings to all clinic members to 1) raise awareness for the need for intervention to reduce Structural Racism and Discrimination (SRD) , 2) facilitate collaborative processes, 3) catalyze change for practice transformation, to 4) guide the intervention process. This workshop will be followed by a series of interactive trainings covering topics from the history of structural racism, to intersectional stigma and discrimination, bias, systems of accountability, and the creation of a manual to guide the implementation and sustainability of SRD reduction efforts."
62793381|NCT02429830|OTHER|Single arm study|Previous LSG patient will be treated with the LINX device and serve as their own control
62217372|NCT04667182||Combined Diabetes Management Data|Participants with type 1 and type 2 diabetes will use a meal tagging application (app) and fitness tracker. They will upload these data to a web portal where they will be matched with data from their insulin pen and continuous glucose monitor (CGM). Combined data will be used as a complement to standard of care for diabetes management.
62217373|NCT04026659|EXPERIMENTAL|Multi-modal exercise programme|The 10-week multi-modal exercise programme will comprise of twice weekly supervised group-based exercise sessions. Each exercise session will last approximately 1 hour and consist of a combination of aerobic, resistance and balance and flexibility exercises.
62217374|NCT03724773|ACTIVE_COMPARATOR|Long-Arm Cast|Reduction and long-arm cast application will be performed by PGY-1 and up residents with adequate training and/or supervision in the required techniques.
62217375|NCT03724773|ACTIVE_COMPARATOR|Sugar-Tong Splint|Reduction and sugar-tong splint application will be performed by PGY-1 and up residents with adequate training and/or supervision in the required techniques.
62217376|NCT03797677|EXPERIMENTAL|Home based airway clearance with Metaneb|"Patients with CF and MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.~The MN4000 is an airway clearance and lung expansion therapy device that has been cleared to market by the FDA as The MetaNeb® System for Homecare environment, for clearance of pulmonary secretions and for treatment or prevention of pulmonary atelectasis. It is a Class II device, cleared to market on March 17, 2016 under premarket notification 510(k) K151689 as The MetaNeb® 4 System with application for homecare environment."
62217377|NCT04675190||Case|Cases will be patients in the department of surgery above 18 years with ultrasound findings of gall stone disease.
62585792|NCT05805722|EXPERIMENTAL|Behavioral Counseling for Tobacco Cessation|Behavioral counseling for tobacco cessation consists of psychoeducation in combination with evidence-based behavior change techniques including stimulus control, self-monitoring, goal-setting, implementation planning, and problem-solving. Specific content topics include the harms of smoking/benefits of quitting, coping with cravings and withdrawal, setting a quit date, managing social influences, and relapse prevention.
62585793|NCT05805722|NO_INTERVENTION|Observational Arm|Both the behavioral intervention and pharmacotherapy will be conducted as a routine clinical activities (treatment as usual)-not as research activities
62585794|NCT05523011|EXPERIMENTAL|Exosome Ointment|The subjects will apply exosome ointment along with Vesiderm liposome cream (TID per day, 20 days). Each day (from Day 1 to 20), the study product will be applied with a gap of 4 hours between three doses to a healthy area (one hand area) on the forearm using 1 fingertip unit (FTU). The Vesiderm liposome cream is meant to keep the application site moisturized.
62585795|NCT06683183||Pregnant women|Pregnant women will wear the set of wearables (chest band, smart watch and arm band) for 15 minutes. In addition, pregnant woman's ECG and fetal heart rate will be measured with hospital's patient monitor.
62793382|NCT05711134|EXPERIMENTAL|Serial In-Person Feedback|Providers are given recurring individualized in-person feedback on their practice patterns.
62793383|NCT05711134|EXPERIMENTAL|In-Person Feedback with Serial Electronic Feedback|Providers are given one-time individualized in-person feedback on their practice patterns, followed by recurrent individualized electronic feedback.
62793384|NCT05711134|NO_INTERVENTION|Control|Providers are not given any feedback on their practice patterns.
62793385|NCT00961363|EXPERIMENTAL|Sitagliptin|Sitagliptin
62793386|NCT00961363|PLACEBO_COMPARATOR|Placebo|Placebo
62585796|NCT01252563||Amlodipine 10mg Tablet|Subjects taking Amlodipine 10mg Tablet.
62217378|NCT04675190||Control|Controls will be patients in the department of surgery above 18 years with ultrasound findings showing evidence of no gallstones
62793387|NCT02644343|EXPERIMENTAL|Remote Programming Group|"Subjects will undergo remote programming of Nucleus cochlear implants via Custom Sound software using an online interactive meeting platform.~The intervention is the programming of the cochlear implant, the experimental aspect is the remote delivery method."
62793388|NCT03802474||Group A|girls with primary dysmenorrhea subject to three-dimensional analysis of the back will conducted with the 4D formetric device and inclinometer to measure range of motion of spine
62793389|NCT03802474||Group B|girls with normal painless menstruation without primary dysmenorrhea subject to three-dimensional analysis of the back will conducted with the 4D formetric device and inclinometer to measure range of motion of spine
62793390|NCT03986528|EXPERIMENTAL|Kanglaite Injection + Chemotherapy|Participants receive Kanglaite Injection PLUS first-line chemotherapy.
62217379|NCT01312636||A|
62217380|NCT00229437|EXPERIMENTAL|TAK-128 5 mg QD|
62793391|NCT03986528|ACTIVE_COMPARATOR|Chemotherapy|first-line chemotherapy.
62793392|NCT04524364|OTHER|Participants with Paroxysmal Atrial Fibrillation (PAF)|Participants with PAF and who are candidates for catheter ablation will be enrolled.
62793393|NCT05906836|EXPERIMENTAL|Rosuvastatin + Selpercatinib|Rosuvastatin administered orally on day 1 followed by rosuvastatin administered with selpercatinib on day 5 orally.
62793394|NCT03805919||Cohort 1|Participants with germline pathogenic or likely pathogenic variants in prostate cancer-related risk genes
62793395|NCT04078347||Successful Paravertebral block|Pinprick test was evaluated at 20 min after Paravertebral block. Pinprick sensation was assessed using a 22-gauge short bevel needle from T2 to T10 at midclavicular line bilaterally . Pinprick response was recorded quantitatively as 1 (sensation) or 0 (no sensation/numb). Successful block was defined as the pinprick score was 0 at 20 min after block. Otherwise, it was defined as a failed block.
62793396|NCT04078347||Failed Paravertebral block|Pinprick test was evaluated at 20 min after Paravertebral block. Pinprick sensation was assessed using a 22-gauge short bevel needle from T2 to T10 at midclavicular line bilaterally . Pinprick response was recorded quantitatively as 1 (sensation) or 0 (no sensation/numb). Successful block was defined as the pinprick score was 0 at 20 min after block. Otherwise, it was defined as a failed block.
62217381|NCT00229437|EXPERIMENTAL|TAK-128 50 mg QD|
62793397|NCT03965741||Men with Prostate Cancer (PCa)|
62793398|NCT03965741||Men without PCa|
62793399|NCT02709330|EXPERIMENTAL|Lunasin regimen|"The Lunasin regimen consists of:~* LunaRich X Capsules (12 capsules per day)~* Reliv NOW - a mixture of 'vitamins, minerals and super-powered antioxidants' (3 scoops per day)~* Pro-Vantage - a mixture of 'soy protein, medium chain triglycerides, creatine, CoQ10 and supercharged amino acids' (2 scoops per day)~It will be suggested that patients open the LunaRich X capsules and mix the contents of these as well as the other 2 ingredients in water to make a shake. If patients do not tolerate advancing to the next dosage, they will be asked to drop back to the highest dosage they could tolerate."
62793400|NCT02709330|ACTIVE_COMPARATOR|Historical controls|For each enrolled participant, matched historical controls will be identified from the PatientsLikeMe database. Participants will be matched according to their ALSFRS-R progression rate before they start on the Lunasin regimen (estimated by assuming their score was normal at 48 on the date of symptom onset).
62217382|NCT00229437|EXPERIMENTAL|TAK-128 100 mg QD|
62217383|NCT00229437|PLACEBO_COMPARATOR|Placebo QD|
62217384|NCT00600678|EXPERIMENTAL|1|
62217385|NCT01147601|ACTIVE_COMPARATOR|Topical 0.5% Timolol|Half of the enrolled subjects (intervention group) will receive topical 0.5% Timolol.
62217386|NCT01147601|PLACEBO_COMPARATOR|Placebo|Aqueous placebo, 2-3 drops to cover the hemangioma, twice daily
62217387|NCT00672191|EXPERIMENTAL|1|
62217388|NCT03451682|EXPERIMENTAL|procyanidine group|
62217389|NCT03451682|NO_INTERVENTION|Control group|
62217390|NCT03178643|ACTIVE_COMPARATOR|Proguanil Oral Tablet|Proguanil is the current standard of care for chemoprevention of malaria in children with SCA in Kenya. This medication will be taken on a daily basis
62217391|NCT03178643|ACTIVE_COMPARATOR|Sulfadoxine/Pyrimethanine-Amodiaquine|Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ) is a combination therapy comprised of sulfadoxine and pyrimethamine (two antifolate antimicrobials) co-administered with amodiaquine. This medication is taken on a monthly basis.
62411722|NCT01466907|OTHER|Control group|Standard care with no outlined follow-up until one year after stroke. Control of secondary prevention after one year after stroke and referral to physician if medical interventions are needed. Follow-up one year after stroke according to the same protocol as the intervention group.
62585797|NCT04412343|EXPERIMENTAL|Virtual group exercise|Individuals in the (virtual) group-based exercise program, will have the opportunity to take part in (virtual) group exercise classes, delivered via videoconferencing, by experienced older adult exercise instructors. Personnel who analyze the data collected from the study are not aware of the treatment applied to any given group. Classes will be offered multiple days a week at 9am PST (12 noon EST), and will last approximately 50 minutes. Classes include a warm-up component, moderate intensity exercises as the core component of the class, and a cool-down. At the end of classes participants will have the opportunity to connect in small groups (videoconferencing breakout groups) to socially connect over a beverage (coffee, water) from their own homes. Participants in the group condition will also be sent, by mail, a program t-shirt to foster a sense of distinctiveness.
62585798|NCT04412343|EXPERIMENTAL|Personal exercise|Each of the older adult instructors described above will also contribute to delivering pre-recorded exercise classes (involving the same exercises, intensity, music, and so forth as those described above for the group condition). However, in this instance, instructors will deliver those classes to each participant by referring to themselves as each participant's personal trainer/coach, with language directed to the individual and not the group. That is, no sense of 'groupness' or 'shared social identities/connectivity' will be primed. Also, participants in this condition will not have the opportunity to interact with other older adults after classes have ended and will not receive the same program t-shirts designed to foster a sense of group distinctiveness.
62585799|NCT04412343|NO_INTERVENTION|Wait-list control|Those randomized to the wait-list control condition will go about their daily lives for the duration of the 12-week trial. They will be asked to complete the same questionnaires (and will be remunerated in the same way as those in the other two conditions via $10 per questionnaire completion). At the end of the 12-week trial, participants in this condition will have access to the personal exercise programming.
62585800|NCT06002451|EXPERIMENTAL|WEB-BASED PRECONCEPTİONAL CARE AND COUNSELİNG|At the beginning of the study, Pre-test Forms were applied and data were obtained.A total of 9 Module Trainings for PC and maintenance were given over the Web Base for 2 weeks. While the trainings were continuing, the modules were monitored from the Admin Panel and reminder messages were sent to the people who did not watch the modules regularly. During the training, PD and care services were provided via the communication. At the end of the 10th week, the post-test forms were applied and the data were obtained. that they can reach 24/7 for a total of 10 weeks, 2 weeks and the following 8 weeks.
62585801|NCT06002451|NO_INTERVENTION|CONTROL|Pre-test Forms were applied and data were obtained.No attempt has been made. This group received routine training and follow-ups at the family health center and premarital counseling unit.At the end of the 10th week, the post-test forms were applied and the data were obtained.
62585802|NCT00090220|EXPERIMENTAL|qHPV Vaccine in Base Study|Participants received blinded qHPV vaccination at Day 1, Month 2, and Month 6 of the Base Study
62585803|NCT00090220|PLACEBO_COMPARATOR|Placebo in Base Study|Participants received blinded placebo at Day 1, Month 2, and Month 6 in the Base Study. They were eligible to receive open-label qHPV vaccine in Extension 1
62585804|NCT06348030|ACTIVE_COMPARATOR|Surgeon-Assisted|Patients randomized to this arm will undergo RTS with the Medtronic Signia Stapler.
62585805|NCT06348030|EXPERIMENTAL|Totally Robotic|Patients randomized to this arm will undergo RTS with the Da Vinci Vessel Sealer Extend Energy Device and SureForm Stapler.
62585806|NCT02529449|PLACEBO_COMPARATOR|Placebo|once daily
62585807|NCT02529449|EXPERIMENTAL|ASP1941 Low dose group|once daily
62585808|NCT02529449|EXPERIMENTAL|ASP1941 Middle dose group|once daily
62585809|NCT02529449|EXPERIMENTAL|ASP1941 High dose group|once daily
62585810|NCT00971607|ACTIVE_COMPARATOR|1|Sevoflurane
62585811|NCT00971607|PLACEBO_COMPARATOR|2|Oxygen
62021916|NCT05124158||Patients with a diagnosis of COVID-19|"A directed psychiatric evaluation will be carried out and 1 evaluation instrument will be applied: Global Tool for the Evaluation of Mental Health in Primary Care (GMHAT / PC).~The Global Mental Health Assessment Tool / Primary Care (GMHAT / PC) is a computerized, semi-structured clinical interview tool developed to assess and identify mental health problems. The main diagnosis derives from the use of a hierarchical model based on ICD-10. The diagnostic program takes into account the severity of symptoms (moderate to severe). It also generates alternative diagnoses and comorbidity states based on the presence of symptoms of other disorders. In addition, it includes a suicide risk assessment."
62021917|NCT03373591|EXPERIMENTAL|Liposomal Bupivacaine TAP block|Patients will be randomized to receive an intraoperative transverse abdominis peritoneal (TAP) block with liposomal bupivacaine (LB). The solution used to perform the TAP block with LB will comprise of 20mL of liposomal bupivacaine solution, 30mL of 0.25% bupivacaine, and 100mL of normal saline.
62021918|NCT03373591|ACTIVE_COMPARATOR|Regular Bupivacaine TAP block|Patients will be randomized to receive an intraoperative transverse abdominis peritoneal (TAP) block with regular bupivacaine (RB).The solution used to perform the TAP block with RB will comprise of 50mL of 0.25% bupivacaine and 100mL of normal saline.
62217392|NCT03178643|ACTIVE_COMPARATOR|Dihydroartemisinin-Piperaquine (DP)|DP is an artemisinin-combination therapy consisting of the artemisinin derivative dihydroartemisinin and the bisquinoline piperaquine. This medication is taken on a monthly basis.
62217393|NCT05869890|OTHER|Flexible Ureteroscopy with Dusting|Flexible ureteroscopy with the dusting lasing technique. MOSES parameters will be set to an energy of 0.3-0.4 Jules and a frequency of 50-80 hertz
62217394|NCT05869890|OTHER|Flexible Ureteroscopy with Fragmentation|Flexible ureteroscopy utilizing the Fragmentation lasing technique. MOSES parameters will be set to 0.8-1 JULES and a frequency of 8-10 hertz
62217395|NCT05869890|OTHER|Flexible Ureteroscopy with Hybrid|Flexible ureteroscopy utilizing the Hybrid lasing technique which will use both sets of parameters.
62217396|NCT00476710||Normal Glucose Metabolism|Overweight and obese individuals that have normal glucose metabolism and their response to Colesevelam HCl
62217397|NCT00476710||Impaired Glucose Tolerance|Overweight and obese individuals that have impaired glucose tolerance and their response to Colesevelam HCl
62411723|NCT05864287|OTHER|BIM intervention participants|"Specifically, at each of the seven intervention sites, a minimum of 30 male and 30 female-identifying student athletes will participate in the BIM program across the 2022-2023 academic year. Thus, our intervention sample will be a minimum of 210 male and 210 female identifying intervention group athletes. The BIM program is a manualized intervention that consists of a 35-min introductory session, followed by four, 75-min sessions. Athletes participating in BIM who give consent (via electronic consent documentation) to share their de-identified data for research purposes will complete additional surveys beyond the standard MH-CDE set of baseline measures at one time-point and treatment-related measures at five time-points:~* Pre-intervention/Baseline~* Post-intervention (1-2 weeks after)~* 4-months post-intervention~* 12-months post-intervention"
62217398|NCT00476710||Frank type 2 diabetes|Overweight and obese individuals that have frank type 2 diabetes and their response to Colesevelam HCl
62217399|NCT04713800|EXPERIMENTAL|ZR-TiB|Monolithic zirconia screw retained implant-supported cantilever reconstruction supported by titanium base abutments, in a full digital workflow (ZR)
62585812|NCT04604444|EXPERIMENTAL|Multimodal Intensive Rehabilitation of Aphasia/AOS (MIRAA)|A minimum of 3 hour speech-language training daily during 10 days.
62585813|NCT00384748|EXPERIMENTAL|Tele-visit Group|TR intervention targets safe functional mobility within a home environment and consists of: 1) exercise targeting underlying stroke-related impairment and 2) adaptive strategies targeting external factors to help compensate for disability. TR uses a combination of tele-video visits, an in-home messaging device, and telephone contact over a 3-month study period. A video camera is used in the home to provide visual and audio to a therapist located at the base hospital. An interactive, in-home messaging device is used to facilitate adherence with treatment recommendations and to screen for depression, falls, and difficulty with self-care. This allows evaluations of problem areas during tele-visits, rapid response to new functional problems.
62585814|NCT00384748|ACTIVE_COMPARATOR|Usual Care Group|Patients randomized to the Usual Care group receive routine VA care, as directed by their physicians. Therapy services are tracked via a weekly diary for the entire 6 month study period. In this weekly diary, patients in both the usual care and intervention group will record receipt of therapy. Usual Care group will be asked whether they exercised, and if so how frequently. They will be administered telephone interviews at baseline, 3-and 6-months. The interview outcome measures are FONEFIM, Late-Life Function and Disability Instrument, Falls Self Efficacy Scale and Stroke Specific Patient Satisfaction with Care. In addition, sociodemographics, stroke severity, length of time since stroke onset, and depression at baseline will be measured.
62411724|NCT04259905|EXPERIMENTAL|Active video game teleconference support group|Participants will attend enhanced support group meetings via zoom teleconferencing software. Support group meetings will include group play of active video games and discussion of survivorship topics. Participants will self-monitor physical activity using Fitbit wearable activity monitors and will receive a water bottle and tote bag.
62411725|NCT04259905|ACTIVE_COMPARATOR|Standard support group + pedometer|Participants will attend standard in-person support groups currently offered by the UTMB Breast Health Center. They will also receive a standard pedometer and a water bottle and tote bag.
62585815|NCT01940900|EXPERIMENTAL|E10030 + ranibizumab|E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection
62585816|NCT01940900|ACTIVE_COMPARATOR|Sham + ranibizumab|E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection
62585817|NCT02423343|EXPERIMENTAL|Galunisertib + Nivolumab (Cohort 1) Phase 1b|50 milligrams (mg) Galunisertib administered orally once daily (QD) on Day 1 through Day 14 of each 4-week cycle in combination with 3 milligrams per kilogram (3 mg/kg) nivolumab given intravenously (IV), every 2 weeks (Q2W), (Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
62585818|NCT02423343|EXPERIMENTAL|Galunisertib + Nivolumab (Cohort 2) Phase 1b|50 mg Galunisertib administered orally twice daily (BID) on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W,(Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
62585819|NCT02423343|EXPERIMENTAL|Galunisertib + Nivolumab (Cohort 3) Phase 1b|80 mg Galunisertib administered orally BID on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
62585820|NCT02423343|EXPERIMENTAL|Galunisertib + Nivolumab (Cohort 4) Phase 1b|150 mg Galunisertib administered orally BID on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W,(Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
62585821|NCT02423343|EXPERIMENTAL|Galunisertib + Nivolumab - Non-small Cell Lung Cancer (NSCLC) Phase 2|150 mg Galunisertib administered orally BID for the first 14 days of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15) of each 4-week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
62411726|NCT00811031|EXPERIMENTAL|Taxotere + Prednisone|
62585822|NCT02423343|EXPERIMENTAL|Galunisertib + Nivolumab - Hepatocellular Carcinoma (HCC) Phase 2|150 mg Galunisertib administered orally BID for the first 14 days of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15) of each 4-week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
62585823|NCT02782065||Pediatric patients with Asthma|165 patients aged 7 to 18 years, and 30 patients aged 2 to 6 years
62585824|NCT01341340|EXPERIMENTAL|Everolimus Eluting BVS|Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS)
62585825|NCT05410405|EXPERIMENTAL|8 millimeter implants|implant insertion with piezo surgical osteotomy and with osseodensification drills
62585826|NCT05410405|EXPERIMENTAL|10 millimeter implants|implant insertion with piezo surgical osteotomy and with osseodensification drills
62585827|NCT03761030|EXPERIMENTAL|L-DOPA Arm|Those assigned to L-DOPA will begin taking 37.5mg carbidopa/150 mg levodopa once daily (with placebo twice daily) for one week, then increase to 75mg carbidopa/300mg levodopa (37.5 mg carbidopa/150mg levodopa twice daily and placebo once daily) for one week, and finally increase to 112.5mg carbidopa/450mg levodopa (37.5 mg carbidopa/150mg levodopa three times daily and no placebo) for the final six weeks. Each subject assigned to the L-DOPA arm will be titrated to 450mg L-DOPA unless they cannot tolerate higher doses, in which case subjects will have their dosage reduced to the maximum tolerable dose
62411727|NCT05440175|EXPERIMENTAL|Group A|The participants will be given Mirror therapy along with the electrical muscle stimulation and exercises.
62411728|NCT05440175|EXPERIMENTAL|Group B|The participants will be given constraint induced movement therapy (CIMT) along with exercises.
62411729|NCT05440175|EXPERIMENTAL|Group C|The participants will be given mirror therapy and exercises.
62411730|NCT06415279|EXPERIMENTAL|Winlevi (clascoterone) 1% cream|
62411731|NCT05329155|EXPERIMENTAL|Administration of Heparin in ER|Administration of Heparin (100U/Kg body weight) with loading dose of DAPT (Aspirin 300mg and Ticagrelor 180mg) at first medical contact for STEMI patients intended to perform PPCI.
62411732|NCT05329155|ACTIVE_COMPARATOR|Administration of Heparin in Cathlab|Administration of Heparin (100U/Kg body weight) in Cathlab after insertion of artery sheath catheter.
62411733|NCT01114386||COPD patients, CHF patients|COPD and CHF patients with smoking history (\> 10 pack/years), male and female, older than 50 years, referred to Hospital for dyspnea and chronic cough.
62217400|NCT04713800|ACTIVE_COMPARATOR|PFM-GA|Porcelain fused-to metal screw retained implant-supported cantilever reconstruction supported by a gold-abutment, in a conventional workflow (PFM)
62411734|NCT05525429|ACTIVE_COMPARATOR|Nutrition Education|Households in this arm will participate in a multidimensional nutrition education intervention, including (1) didactic training on family nutrition (mothers, fathers, adolescent girls), (2) participatory learning activities (mothers, fathers, adolescent girls), (3) model kitchens (mothers, adolescent girls), and (4) Nutrition Club (adolescent girls).
62411735|NCT05525429|NO_INTERVENTION|Control|No intervention will be provided. After the research period is complete, the Control group will receive all inputs described above, but no data will be collected during this time period.
62411736|NCT01266642|EXPERIMENTAL|Arm I (HF-WBI)|Patients undergo HF-WBI comprising external beam RT 5 days a week for approximately 3 weeks.
62411737|NCT01266642|ACTIVE_COMPARATOR|Arm II (CF-WBI)|Patients undergo CF-WBI comprising external beam RT 5 days a week for approximately 5 weeks.
62021919|NCT03373591|NO_INTERVENTION|No TAP block|Patients will be randomized to receive no TAP block as a control group.
62411738|NCT06560255|EXPERIMENTAL|n-3 fatty acid of 2.4 g per day|Oral intake of 4 capsules daily from week 22-26 of gestation until 1 week after delivery
62411739|NCT06560255|PLACEBO_COMPARATOR|Rape seed oil|Oral intake of 4 capsules daily from week 22-26 of gestation until 1 week after delivery
62411740|NCT05196230|EXPERIMENTAL|Experimental Condition (360° Video)|The 360° video (experimental) group will be mailed a study tablet with the 360° video prior to the dental visit.
62411741|NCT05196230|ACTIVE_COMPARATOR|Control Condition (Social Story)|The treatment-as-usual (control) group will be mailed a study tablet with a social story prior to the dental visit.
62411742|NCT05234619|ACTIVE_COMPARATOR|Group one ( lidocaine or control LE ) Early deflation|Patients in group one (lidocaine or control group LE = 20): will receive 2% lidocaine 3mg/kg (maximum 200 mg) then distal tourniquet deflation occurs after 20 minutes.
62021920|NCT02559908|EXPERIMENTAL|Treatment Group_VYC-25L|VYC-25L injection into the chin and/or jaw areas on Day 1, volume determined by the investigator (up to 4.0 mLs) and repeat treatment if applicable
62021921|NCT02559908|OTHER|Control Group_No treatment then VYC-25L|No treatment for 3 months followed by VYC-25L injection into the chin and/or jaw areas, volume determined by the investigator (up to 4.0 mLs) and repeat treatment if applicable.
62021922|NCT01716247|EXPERIMENTAL|pts at risk for breast cancer|Women at increased risk for breast cancer who are being referred for screening MRI will be offered and consented for CESM at the same time. The 2 examinations will be performed on the same day when at all possible and if not we will make every attempt to perform CESM before MRI. Patients with outside MRI performed within 30 days and of adequate quality will also be eligible for CESM.
62217401|NCT06610721||Elderly patients with a suspected urinary tract infection|
62021923|NCT03132116|EXPERIMENTAL|Gentamicin|intra-nodal injection of gentamicin
62217402|NCT03796962|EXPERIMENTAL|25 mg XEN1101|Capsule filled with 25 mg XEN1101
62411743|NCT05234619|ACTIVE_COMPARATOR|Group two ( lidocaine , ketorolac LKE) Early deflation|Patients in group two (lidocaine ketorolac LKE = 20): will receive 2% lidocaine 3mg/kg (maximum 200 mg) plus ketorolac 0.5mg/kg (maximum 30mg) then distal tourniquet deflation occurs after 20 minutes.
62411744|NCT05234619|ACTIVE_COMPARATOR|Group three ( lidocaine Or control LL ) Late deflation|Patients in group three (lidocaine or control group LL = 20): will receive 2% lidocaine 3mg/kg (maximum 200 mg) then distal tourniquet deflation occurs after 40 minutes.
62411745|NCT05234619|ACTIVE_COMPARATOR|Group four ( lidocaine , ketorolac LKL ) Late deflation|Patients in group four (lidocaine ketorolac LKL = 20): will receive 2% lidocaine 3mg/kg (maximum 200 mg) plus ketorolac 0.5mg/kg (maximum 30mg) then distal tourniquet deflation occurs after 40 minutes.
62411746|NCT05929040|EXPERIMENTAL|Immediate group|"Randomized controlled waitlist study~Behavioral: Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy~An online mindful cognitive intervention is used as a proposed treatment intervention for chemsex among men ho have sex with men in the United Kingdom."
62021924|NCT03132116|PLACEBO_COMPARATOR|Placebo|intra-nodal injection of placebo
62021925|NCT03826277|EXPERIMENTAL|Melanostop peel treatment group|"* Adult women aged between 20-50 years old.~* Melasma on the face~* Fitzpatrick phototypes I-IV~* Presenting facial melasma~* In good health condition"
62411747|NCT05929040|OTHER|Delayed group|"Randomized controlled waitlist study~Behavioral: Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy~An online mindful cognitive intervention is used as a proposed treatment intervention for chemsex among men who have sex with men in the United Kingdom."
62021926|NCT03223818|EXPERIMENTAL|Fast-track Arm|Patients recruited will undergo ERAS perioperative program.
62217403|NCT03796962|EXPERIMENTAL|20 mg XEN1101|Capsule filled with 20 mg XEN1101
62217404|NCT03796962|EXPERIMENTAL|10 mg XEN1101|Capsule filled with 10 mg XEN1101
62217405|NCT03796962|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62585828|NCT03761030|PLACEBO_COMPARATOR|Placebo Arm|Subjects assigned to the placebo arm will take placebo oral tablet three times daily throughout the study.
62793401|NCT06310616|EXPERIMENTAL|Loestrin + VH4524184|Eligible participants entering a run-in period of 21 days (Days -28 through -8) will receive Loestrin (EE and NEA) to stabilize on the combined OCs containing EE and NEA to synchronize the menstrual cycles of multiple participants. Participants completing the run-in period will enter Treatment Period 1 and will be administered Loestrin once daily from Days 1 to 10. On Day 11, participants will enter Treatment Period 2 and will be administered Loestrin + VH4524184 once daily from Days 11 to 20.
62793402|NCT01435486|ACTIVE_COMPARATOR|caffeine Citrate|
62793403|NCT01435486|PLACEBO_COMPARATOR|Normal saline|
62793404|NCT06075589||Arm 1|Participants watch two fifteen-minute educational videos and receive a mental health resource information sheet on study.
62793405|NCT06075589||Arm II|Patients receive enhanced treatment as usual and receive a mental health resource information sheet on study.
62217406|NCT03358251|OTHER|SRP+Pocket-X Gel, split-mouth|This arm is a split-mouth arm, i.e., participants will receive conventional treatment for periodontitis (scaling and root planing) for the entire mouth, and, in addition, will receive experimental treatment (Pocket-X Gel) for periodontal pockets present in one/two mouth segments (quadrants), while the contralateral quadrants will serve as control and will not undergo any further intervention.
62411748|NCT00432367|EXPERIMENTAL|1|OptiMAL® antigen screening and treatment with SP plus LLIN
62411749|NCT00432367|EXPERIMENTAL|2|OptiMAL® antigen screening and treatment with AQ+AS plus LLIN
62411750|NCT00432367|ACTIVE_COMPARATOR|3|SP-IPTp plus LLIN
62411751|NCT05417009|ACTIVE_COMPARATOR|Stimulation|Electrodes attached bliaterally to tragus nerve region of outer ear, with appropriate device settings to deliver current.
62411752|NCT05417009|SHAM_COMPARATOR|Electrode attachment only.|Electrodes attached bliaterally to tragus nerve region of outer ear, with device switched off \[blinded to operator\].
62585829|NCT06684197|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine 0.5 mcg/kg (adjusted body weight) ; Administered via infusion pump (Smith Medical Medfusion® 4000 Syringe Infusion Pump) delivered over 10 minutes during induction of general anesthesia, followed by dexmedetomidine 0.5 mcg.kg-1.h-1 (maximum dose: 2.5mcg.kg-1)
62585830|NCT06684197|PLACEBO_COMPARATOR|Placebo - Normal Saline|Normal saline in volume equivalent of dexmedetomidine dose according to patient weight ; Administered via infusion pump (Smith Medical Medfusion® 4000 Syringe Infusion Pump) so that the full dose is delivered is equivalent to a maximum dose of 2.5mcg.kg-1 of dexemedetomidine
62585831|NCT04950075|EXPERIMENTAL|INBRX-109|IV every three weeks
62585832|NCT04950075|PLACEBO_COMPARATOR|Placebo|IV every three weeks
62585833|NCT02255305|EXPERIMENTAL|FMT Group (Intervention Arm)|Patients randomized to the FMT group will have antimicrobials targeting C. difficile discontinued at least 6 hours prior to undergoing an FMT via retention enema. A second FMT via retention enema will be administered at 24 hours if diarrhea persists.
62793406|NCT04141423|ACTIVE_COMPARATOR|Tregopil 30 mg|Dose level cohort with a sentinel dosing design
62793407|NCT04141423|ACTIVE_COMPARATOR|Tregopil 45 mg|Dose level cohort with a sentinel dosing design
62021927|NCT03223818|NO_INTERVENTION|Conventional Group|Patients recruited to conventional group will undergo conventional perioperative program
62217407|NCT03751046|EXPERIMENTAL|Intervention group. Trial-Based Cognitive Therapy|Participants with therapeutic failure. Fourteen sessions of psychotherapy in group format, using Trial-Based Cognitive Therapy. Frequency: Bi-weekly meetings for seven months. Intervention arm comprises 10 psychotherapy groups with five participants in each group.
62411753|NCT01101269|EXPERIMENTAL|Subjects with diabetic nephropathy|Renal blood flow (RBF) will be measured using contrast enhanced ultrasound (CEU) and urine protein will be measured both on and off angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).
62411754|NCT01101269|ACTIVE_COMPARATOR|Healthy volunteers|Renal blood flow (RBF) will be measured using contrast enhanced ultrasound (CEU) and urine protein will be measured both on and off angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).
62411755|NCT05378269|PLACEBO_COMPARATOR|Placebo|Vaginal insert
62411756|NCT05378269|EXPERIMENTAL|DARE-VVA1 1mg|vaginal insert
62411757|NCT05378269|EXPERIMENTAL|DARE-VVA1 5mg|vaginal insert
62411758|NCT05378269|EXPERIMENTAL|DARE-VVA1 10mg|vaginal insert
62411759|NCT05378269|EXPERIMENTAL|DARE-VVA1 20mg|vaginal insert
62411760|NCT02395536|EXPERIMENTAL|In office Outside walls of hospital|Reveal LINQ insertions will be performed in office setting. The in office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not an ambulatory surgery center.
62411761|NCT02395536|OTHER|Traditional Hospital Setting|Reveal LINQ insertions will be performed in a traditional setting. The traditional hospital setting includes an operating room or electrophysiology laboratory.
62793408|NCT04141423|ACTIVE_COMPARATOR|Tregopil 60 mg|Dose level cohort with a sentinel dosing design
62793409|NCT04141423|ACTIVE_COMPARATOR|Derived Dose level|Derived Dose level cohort with a sentinel dosing design (60 mg fixed preprandial dose plus an additional 30 mg postprandial rescue dose, if required)
62793410|NCT03738618|EXPERIMENTAL|FE 999049 (Follitropin Delta)|
62793411|NCT03738618|PLACEBO_COMPARATOR|Placebo|
62793412|NCT05722548|EXPERIMENTAL|Group A|Patients will be administered 100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia with Standard Medical Treatment
62793413|NCT05722548|ACTIVE_COMPARATOR|Group B|Standard Medical Treatment
62793414|NCT01835158|ACTIVE_COMPARATOR|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62217408|NCT03751046|EXPERIMENTAL|Control group. Standard healthcare.|Participants with therapeutic failure, receiving standard healthcare in the HIV/AIDS Program, which includes at least half-yearly psychology and pharmaceutical chemist consultations (approximately half an hour each). The purpose of these consultations is to approach the importance of adherence and psychoeducation on HIV.
62217409|NCT01843894|PLACEBO_COMPARATOR|placebo|In Stage I, each patient will instill 1 drop of placebo into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
62217410|NCT01843894|EXPERIMENTAL|RU-101|In Stage I, each patient will instill 1 drop of RU-101 ophthalmic solution (5%, 10%, or 15%) into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop of RU-101 ophthalmic solution (selected dose from Stage I) into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
62217411|NCT04639388|EXPERIMENTAL|22q11.2DS|Children aged from 4 to 13 years old with 22q11.2 deletion syndrome
62217412|NCT04639388|ACTIVE_COMPARATOR|Control Group (Non22q11.2DS)|Children aged from 4 to 13 years old without developmental disease
62411762|NCT02729350|EXPERIMENTAL|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention delivered at the baseline (Day 1) visit to determine the immediate effects of guided relaxation intervention on stress and pain in inpatients with sickle cell disease. The GR intervention also includes six video clips, ranging from 2 to 20 minutes in length to determine the short-term (Day 5) effects of guided relaxation intervention on stress and pain.
62585834|NCT02255305|ACTIVE_COMPARATOR|Antimicrobial Group (Control Arm)|Patients randomized to the antimicrobial group will be treated with antibiotics targeting C. difficile according to the Society for Healthcare Epidemiology of America (SHEA) Clinical Practice Guidelines for CDI. FMT will be offered to this group after 90 days if they experience relapsing CDI.
62411763|NCT02729350|OTHER|Sickle cell experience discussion|Attention Control Group: This intervention is a 12-minute sickle cell disease experience discussion. In this computer-based discussion, patients will discuss their experience of having sickle cell disease. The audio-taped questions and onscreen directions were programmed to be self-administered. Subjects' responses will be captured via the microphone so that Data Collectors are not involved in this discussion process, and it is equivalent to the guided relaxation activity.
62411764|NCT04182386||rPVE|Right portal vein embolization. All patients subjected to selective right portal vein embolization prior to planned hepatobiliary surgery.
62411765|NCT04182386||rPVE+S4|Right portal vein embolization including segment 4 portal vein branches. All patients subjected to selective right portal vein embolization including segment 4 portal vein branches prior to planned hepatobiliary surgery.
62411766|NCT03858998|EXPERIMENTAL|Case Management Intervention|A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.
62585835|NCT04096638|EXPERIMENTAL|Part 1a: Monotherapy Dose Escalation|SB 11285 weekly on Days 1, 8, 15 and 22 on repeated 28-day cycles in escalating doses
62021928|NCT04544826|EXPERIMENTAL|Cohort 1: JNJ-77474462 (Low Dose) or Placebo|Participants will receive single low dose of JNJ-77474462 or matching placebo as subcutaneous (SC) injection.
62217413|NCT02557529|EXPERIMENTAL|Progressive Resistance Training|12 weeks progressive resistance training (PRT) during and after concomitant chemoradiotherapy. Also optional/voluntary physical activity performed on their own is registered, as well as diet diary.
62411767|NCT03858998|OTHER|Control|Current routine HIV care in Tanzania.
62411768|NCT06126770|EXPERIMENTAL|The social norm intervention|The married adolescent girls (MAGs) and their spouses, and community members from the intervention clusters will receive the social norm intervention.
62411769|NCT06126770|NO_INTERVENTION|Pure Control|Participants, including married adolescent girls (MAGs), their spouses, and community members from the control clusters, will not receive any intervention.
62411770|NCT01030055|EXPERIMENTAL|TKI258 - bioavailability|
62411771|NCT01030055|EXPERIMENTAL|TKI258 - food|
62411772|NCT03030638||Olodaterol|Patients initiating Olodaterol for the first time
62411773|NCT03030638||Indacaterol|Patients initiating Indacaterol for the first time
62585836|NCT04096638|EXPERIMENTAL|Part 1b: PD-L1 Combination Dose Escalation|SB 11285 weekly on Days 1, 8, 15 and 22 on repeated 28-day cycles in escalating doses plus 1680mg every 4 weeks (Q4W) atezolizumab
62585837|NCT04096638|EXPERIMENTAL|Part 2: Combination Expansion Cohorts at RP2D (Cohort A)|"Cohort A: Patients with Melanoma~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
62793415|NCT01835158|ACTIVE_COMPARATOR|Arm II (sunitinib malate)|Patients receive sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62021929|NCT04544826|EXPERIMENTAL|Cohort 2: JNJ-77474462 (Medium Dose) or Placebo|Participants will receive single medium dose of JNJ-77474462 or matching placebo as SC injection.
62217414|NCT02557529|ACTIVE_COMPARATOR|Control|Control arm. Optional/voluntary physical activity performed on their own is registered, as well as diet diary.
62793416|NCT01520961||Hueter Anterior Approach|
62793417|NCT01520961||posterolateral approach|
62021930|NCT04544826|EXPERIMENTAL|Cohort 3: JNJ-77474462 (High Dose) or Placebo|Participants will receive single high dose of JNJ-77474462 or matching placebo as SC injection.
62411774|NCT01430832||Normal Development|The infant's development level will be assessed using a phone interview with parents
62793418|NCT05786508|EXPERIMENTAL|Partners4Pain program|adults with chronic neck or back pain from populations that experience health disparities due to race/ethnicity or socioeconomic status
62793419|NCT05786508|ACTIVE_COMPARATOR|Key to Wellbeing program|adults with chronic neck or back pain from populations that experience health disparities due to race/ethnicity or socioeconomic status
62021931|NCT05209113|EXPERIMENTAL|Study Group|The self-management module, which will be applied only to the study group, includes the clinical pharmacist informing the patient verbally and in writing about MS disease, the importance of drug compliance, and monitoring of disease symptoms. The first interview will end after the Patient Health Engagement-PHE-s, Multiple Sclerosis Self-Management Revised-MSSM-R, Patient Assessment of Chronic Illness Care-PACIC scales and self-management module are applied to the study group by the clinical pharmacist. When the patients come to the outpatient clinic examination 4 and 8 months after the first interview, second and third face-to-face interview will be held with the clinical pharmacist and all scales will be applied again. During the second and third interview, no written and/or verbal information will be given to the patient again.
62021932|NCT05209113|NO_INTERVENTION|Control Group|Patient Health Engagement (PHE-s), Multiple Sclerosis Self-Management Revised (MSSM-R), Patient Assessment of Chronic Illness Care (PACIC) scales will be administered to the control group patients whose medications and demographic information were obtained in the first face-to-face interview. The same scales will be repeated at the 4th month and 8th month, the self-management module will not be applied to the control group, and within this scope, the patients will not be informed by the clinical pharmacist, and the patient's routine outpatient services will continue.
62411775|NCT01430832||Abnormal Development|The infant's level of development will be assessed using a phone interview with parents
62793420|NCT06482541|EXPERIMENTAL|5 billion exosome group|This arm receives 5 billion WJMSC-exosome treatment on one side of the aforementioned treatment area and an equivalent volume of placebo on the contralateral half of the treatment area.
62793421|NCT06482541|EXPERIMENTAL|50 billion exosome group|This arm receives 50 billion WJMSC-exosome treatment on one half of the aforementioned treatment area and an equivalent volume of placebo on the contralateral half of the treatment area.
62793422|NCT01833559|OTHER|Incidence of GDM|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
62793423|NCT01833559|OTHER|Gestational outcomes|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
62793424|NCT01833559|OTHER|Metabolic disorder|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
62793425|NCT02352623||Cutaneous melanoma AJCC stage IB-III|Patients treated for cutaneous melanoma (AJCC stage IB-III) will fill out a questionnaire, undergo clinical examination and DXA scan
62411776|NCT06264141|ACTIVE_COMPARATOR|Nitric Oxide Releasing Solution|"Nasal spray with nitric oxide releasing solution (NORS) delivered five times per day spaced 1 to 4 hours between each dose while awake.~Maximum volume delivered: 0.56 mL NORS @ 0.11ppm\*hrs"
62411777|NCT06264141|PLACEBO_COMPARATOR|Placebo|"Nasal spray with isotonic saline delivered five times per day spaced 1 to 4 hours between each dose while awake.~Maximum volume delivered: 0.56 mL Saline @ 0.9%"
62411778|NCT01096862|EXPERIMENTAL|Group 1|lowest dose
62411779|NCT01096862|EXPERIMENTAL|Group 2|low dose
62793426|NCT05391906|EXPERIMENTAL|Intravoxel Incoherent Motion(IVIM) MRI|Intravoxel incoherent motion (IVIM) is based on diffusion-weighted imaging (DWI)
62793427|NCT00337207|EXPERIMENTAL|Avastin|
62411780|NCT01096862|EXPERIMENTAL|Group 3|high dose
62411781|NCT01096862|EXPERIMENTAL|Group 4|highest dose
62411782|NCT01096862|EXPERIMENTAL|Group 5|medium dose
62793428|NCT03226834|ACTIVE_COMPARATOR|MUSIC CARE|Listening for 20 min of one of the music style U sequences proposed by the medical device MUSIC CARE
62793429|NCT03226834|EXPERIMENTAL|PERSONAL PLAY-LIST|Listening for 20 min of patient's play-list
62793430|NCT04406649|EXPERIMENTAL|STS101|STS101 (dihydroergotamine nasal powder)
62411783|NCT01096862|PLACEBO_COMPARATOR|Placebo|Matching placebo
62411784|NCT02801201|ACTIVE_COMPARATOR|sedation|Midazolam : 0,10 mg/kg
62411785|NCT02801201|ACTIVE_COMPARATOR|spinal anesthesia|Bupivacain 10 mg
62411786|NCT04598815|EXPERIMENTAL|Sirolimus|Sirolimus for 12 weeks
62411787|NCT04598815|EXPERIMENTAL|Methylprendnisolone|Methylprednisolone for 12 weeks
62411788|NCT01708252|EXPERIMENTAL|Ulthera treatment group|All subjects will receive an Ulthera System Treatment
62411789|NCT06700460|ACTIVE_COMPARATOR|Laser-assisted in Situ Keratomileusis|LASIK-Wavefront Optimized
62411790|NCT06700460|ACTIVE_COMPARATOR|Implantable Collamer Lens placement|EVO ICL
62793431|NCT01107665|EXPERIMENTAL|Pazopanib and Paclitaxel|Treatment on study will be administered in 4-week cycles. Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
62793432|NCT00945256|ACTIVE_COMPARATOR|Young Aerobic Exercise|45 minutes of treadmill walking at 40% VO2 peak
62793433|NCT00945256|ACTIVE_COMPARATOR|Elderly Aerobic Exercise|45 minutes of treadmill walking at 40% VO2 peak
62793434|NCT00945256|ACTIVE_COMPARATOR|Young Sodium Nitroprusside|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
62793435|NCT00945256|ACTIVE_COMPARATOR|Elderly Sodium Nitoprusside|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
62411791|NCT02879630||Obese Patients|Obese patients (patients whose weight is \>190% of ideal body weight) will be receive a single dose of I.V. acyclovir sodium 5mg/kg dosed by adjusted body weight as part of their routine care.
62411792|NCT02879630||Non-obese Patients|Normal weigh patients (patients whose weight is 80-120% of ideal body weight) will be receive a single dose of I.V. acyclovir sodium 5mg/kg dosed by total body weight as part of their routine care.
62411793|NCT01350609|EXPERIMENTAL|Nifedipine/Candesartan (fixed dose)|
62411794|NCT01350609|ACTIVE_COMPARATOR|Nifedipine/Candesartan (loose)|
62411795|NCT05193578|ACTIVE_COMPARATOR|Semaglutide|"Active Comparator: Semaglutide injection once-weekly~The participants start with Semaglutide given as 0.25 mg subcutaneously per week for 4 weeks. Then, the dose is uptitrated to 0.5 mg subcutaneously per week for 4 weeks, whereafter the highest dose is reached: 1 mg subcutaneously per week until the end of the study (week 30).~Subjects, who experience side effects that hinder a stepwise increase in study drug, will remain at the highest possible tolerated dose for the rest of the study."
62411796|NCT05193578|PLACEBO_COMPARATOR|Placebo|"Semaglutide-Placebo injections once weekly.~The Semaglutide-Placebo pens are produced by Novo Nordisk A/S and resemble the pens containing active drug.~Semaglutide-Placebo pens contain vehicle, i.e. no active drug. Semaglutide-Placebo is administered similarly to semaglutide. That is using the same uptitration regime and volume as the active comparator, Semaglutide.~Subjects, who experience side effects that hinder a stepwise increase in Semaglutide-Placebo, will remain at the highest possible tolerated dose for the rest of the study."
62411797|NCT06156046||Group 1|Individuals naïve to beekeeping (\<2 previous bee stings, non in the last 24 months). No history of anaphylaxis
62411798|NCT06156046||Group 2|Beekeepers with \> approximately 10 stings/year who have been beekeeping for \>3 years. No history of anaphylaxis.
62411799|NCT06156046||Group 3|Beekeepers with diagnosis of anaphylaxis to bee venom in the last 12 months who are sensitised to bee venom ( as evidenced by positive IgE and positive skin test to bee venom)
62411800|NCT04485624||Attendees at Paediatric Emergency Department 1 (PED1)|"These participants will be recruited from the children and young people (under the age of 16) attending the PED of a large district general hospital.~There was going to be a second group recruited but COVID meant that the site was not able to support non-COVID studies by the time the necessary approvals were in place."
62411801|NCT04317547|NO_INTERVENTION|Control Group|The Azūga™ in-vehicle driving feedback technology will be installed.32 This driving feedback technology consists of a pager-sized device plugged into the vehicle's on-board diagnostic (OBD) port (installed in the teen's car) and a smartphone app (downloaded on the teen's smartphone). All feedback features will be disabled. Control dyads will receive no driving feedback. The parent will not receive STS. Additionally, a wireless mini-camera will be installed on the dashboard in teen's car to identify the participating driver using facial verification technology.
62217415|NCT02067559|EXPERIMENTAL|ICU Diaries|A bound empty journal will be stored at the patient's bedside near the nurse charting area. All family members and ICU staff are invited to write in the ICU diary at any time. Instructions will be provided to the patient's family at the time of randomization and will be available at the bedside for reference. Staff instructions will be posted at charting area for staff. During the patient's stay in ICU, the diary will never leave the unit. Under no circumstances will any part of an ICU diary be duplicated. Research staff will take a photograph of the patient after consent is obtained and the photograph will be mounted on the first page of the diary. Photographs will be taken with a Polaroid camera; therefore there will be no other record of the photograph.
62411802|NCT04317547|EXPERIMENTAL|Intervention Group|Parents will receive STS, which will include 1) Individualized virtual communication training and a booster session delivered by a traffic safety communication specialist; and 2) An online parent-teen safe driving communication guide. In addition, the Azūga™ in-vehicle device and app will be installed as described above and all feedback features will be enabled. Three types of feedback will be provided to teens: 1) Direct audio feedback; 2) Detailed cumulative driving data; and 3) A customized weekly driving summary report. Parents in this group will receive access to the teen's cumulative driving data and a weekly driving summary report. Additionally, a wireless mini-camera will be installed on the dashboard in teen's car to identify the participating driver using facial verification technology.
62411803|NCT02237768|EXPERIMENTAL|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
62411804|NCT02237768|EXPERIMENTAL|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
62411805|NCT05150197|EXPERIMENTAL|Patient (pathology) group|This group will perform both the standard of care Humphrey Visual Field (HVF) and the VisuALL Virtual Reality Visual Field.
62793436|NCT00945256|ACTIVE_COMPARATOR|Elderly Sodium Nitroprusside and Amino Acid Drink|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min and 7.5g amino acid drink taken orally
62793437|NCT05612256||Infants on mechanical ventilation|
62793438|NCT05612256||Infants on non-invasive respiratory support|
62793439|NCT05783336|EXPERIMENTAL|SSCF+|Stepping Stones and Creating Futures Plus (SSCF+). Small group intervention, comprising approximately 15 sessions (each session \~3 hours), addressing gender, livelihoods, mental health.
62411806|NCT05150197|OTHER|Control group|This group will only perform the VisuALL Virtual Reality Visual Field.
62793440|NCT05783336|NO_INTERVENTION|Control|No intervention control (wait-list)
62793441|NCT06025006|EXPERIMENTAL|AILSI|
62793442|NCT06025006|NO_INTERVENTION|the standard of care|
62793443|NCT01085370|NO_INTERVENTION|Control Group|standard medical care only
62793444|NCT01085370|EXPERIMENTAL|Intervention group|2 sessions with early psychological interventions
62793445|NCT06675955|EXPERIMENTAL|Ocrelizumab|Participants will receive ocrelizumab at the same dose and schedule as the parent study until access to the treatment becomes locally available, unacceptable safety concern, death or withdrawal of consent.
62217416|NCT02067559|EXPERIMENTAL|Psychoeducation|The research nurse will provide a psychoeducational brochure to study participants at ICU discharge (if cognitive capacity is established) or 30 days after ICU discharge. If participants are not well enough 30 days post-discharge, they will be assessed every two weeks by research staff until the brochure is given to them. The brochure will describe procedures in the ICU (sedation, ventilation), and the delirium, hallucinations, and trauma that may result; as well as symptoms of PTSD post-ICU. It will provide instructions for follow-up, information, and emergency care. The brochure will instruct participants to contact their follow-up healthcare provider if they have any questions. The document will also be mailed to the participant's follow-up physician.
62217417|NCT02067559|EXPERIMENTAL|ICU Diary plus Psychoeducation|Participants will receive both ICU diary and psychoeducation interventions, with both documents provided at ICU-discharge, or 30 days post-discharge as above.
62793446|NCT03070535|EXPERIMENTAL|HIGH meal|The HIGH meal is a 700 calorie breakfast style meal, with 50% total fat (25% saturated fat), 30% carbohydrates with a glycemic index of \>70, and 20% protein.
62793447|NCT03070535|EXPERIMENTAL|LOW meal|The LOW meal is a 700 calorie breakfast style meal, with 25% of those calories coming from fat (5% saturated fat), 55% carbohydrate (with a glycemic index of \<55), and 20% protein.
62217418|NCT02067559|NO_INTERVENTION|Treatment as Usual|No additional intervention to usual ICU care will be given.
62217419|NCT00433940||Infantile Hemangioma Patients|Infants with infantile hemangioma being treated clinically with oral prednisolone sodium phosphate suspensions.
62217420|NCT06609993|EXPERIMENTAL|thoracic epidural analgesia using 0,2% ropicavaine with fentanyl|preventive analgesia will be assured using 0,2% ropicavaine (Ropivacaini Hydrochloridum 1%, 10mg/mL, 10 mL, Molteni Farmaceutici, Italy) with fentanyl via thoracic epidural catheter perioperatively
62217421|NCT06609993|EXPERIMENTAL|thoracic epidural analgesia using 0,2% bupicavaine with fentanyl|preventive analgesia will be assured using 0,2% bupicavaine (Bupivacainum Hydrochloricum WZF 0.5%, 5 mg/mL, 10 mL, Polfa Warszawa S.A, Warsaw, Poland) with fentanyl via thoracic epidural catheter perioperatively
62217422|NCT06609993|EXPERIMENTAL|intravenous analgesia using metamizole with tramadol|preventive analgesia will be assured using intravenous infusion using metamizole 5 gram / 24 hours ((Pyralgin 0.5g/ml, 2 ml solution; Polpharma, Poland) with tramadol 400 mg/24h (50 mg/ml, 100 mg/2 ml solution; Polpharma, Poland) perioperatively
62217423|NCT00998335|ACTIVE_COMPARATOR|Insulin detemir only|Patients with uncontrolled T2DM are treated with insulin detemir for 6 months. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl. This group will receive Long-acting bedtime insulin detemir (Levemir).
62217424|NCT00998335|EXPERIMENTAL|Insulin detemir plus aspart|After baseline evaluations, insulin detemir will be given at bedtime and titrated to achieve a fasting plasma glucose between 80-100 mg/dl. After 3 months patients will be admitted to assess the metabolic effects of intervention. After this, insulin aspart (insulin detemir plus aspart) will be added before breakfast, lunch and dinner titrated to normalize the postprandial plasma glucose. After another 3 months patients are readmitted and all study procedures repeated. This group will receive Insulin detemir and pre-meal insulin aspart.
62217425|NCT03912376||Healthy Volunteer|Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history.
62217426|NCT01833845|EXPERIMENTAL|Ribavirin+HCQ|Administration of RBV monotherapy for a period of 8 weeks following administration of up to 16 weeks combination therapy with ribavirin(RBV) plus Hydroxychloroquine(HCQ).
62217427|NCT02113345|EXPERIMENTAL|lifestyle counseling|Metamemory Cognitive Intervention
62217428|NCT04768374|EXPERIMENTAL|VR group|Enrolled into 12 week VR intervention with Microsoft Kinect (twice a week, for 45 minutes) and conventional occupational therapy.
62217429|NCT04768374|ACTIVE_COMPARATOR|Control group|Control group only received conventional occupational therapy for 12 weeks
62217430|NCT03107832|ACTIVE_COMPARATOR|general anesthesia|In general anesthesia group (Group G), and induction was managed using 1.5 mg/kg fentanyl and 2 mg/kg propofol; 0.5 mg/kg rocuronium and sevoflurane in a 50% oxygen /air mixture was used. Blood gas analysis monitoring was performed in the 30th minute before and after pneumoperitoneum
62217431|NCT03107832|EXPERIMENTAL|thoracic epidural anesthesia|In epidural anesthesia group(Group E), a catheter was installed and received 20 mg lidocaine hydrochloride, 15 mg bupivacaine, and 25 mg fentanyl citrate adjusted to 10 cc with normal saline to be injected by the epidural catheter. Bi-spectral index -controlled sedation was provided
62217432|NCT03546764|EXPERIMENTAL|Percutaneous Catheter|14-French Percutaneous catheter (pigtail or non-pigtail) placed at bedside using Seldinger technique
62217433|NCT03546764|ACTIVE_COMPARATOR|Chest tube|Placement of 28-36F chest tube placed at bedside by an open cut-down technique (traditional)
62217434|NCT02625051|ACTIVE_COMPARATOR|Ureteroscopy|Kidney stone of participants in this arm will be treated with ureteroscopy (URS). A ureteral stent will be inserted at the end of the procedure.
62217435|NCT02625051|ACTIVE_COMPARATOR|Percutaneous nephrolithotomy|Kidney stone of participants in this arm will be treated with percutaneous nephrolithotomy (PNL). A percutaneous nephrostomy tube will be inserted at the end of the procedure.
62793448|NCT05248659|EXPERIMENTAL|Sibeprenlimab 400 mg s.c. q 4 weeks|
62793449|NCT06124378|EXPERIMENTAL|Tislelizumab combined with Oxaliplatin and Capecitabine cohort|"Patients with locally advanced colon cancer who met the inclusion criteria received two or four cycles of Tislelizumab combined Capecitabine and Oxaliplatin regimen chemotherapy and were evaluated by enhanced CT. Then, these patients will receive curative surgery for colon cancer.~Interventions:~Drug: Oxaliplatin,130mg/m2 for chemotherapy on Day 1 every 3 weeks and repeat for 2 or 4 cycles.~Drug: Capecitabine, Oral Capecitabine 1000 mg/m2 twice daily from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles.~Drug: Tislelizumab, 200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. Procedure: Colectomy"
62217436|NCT00767416|EXPERIMENTAL|Cohort 1 MEDI-559|MEDI-559
62217437|NCT00767416|PLACEBO_COMPARATOR|Cohort 1 Placebo|Placebo
62217438|NCT06261580||Healthy Volunteers|Adult volunteers (18 years of age and older) who self-identify as being in general good health.
62793450|NCT04417361|EXPERIMENTAL|Galcanezumab|The galcanezumab arm will self-administer a subcutaneous injection of galcanezumab. The first dose (at month 1) will be a loading dose of two injections, or 240 mg in total. After that, at month 2 and month 3, each participant will receive an injection of galcanezumab 120 mg. The injections will be with a pre-loaded syringe containing galcanezumab.
62793451|NCT04417361|PLACEBO_COMPARATOR|Placebo|The placebo arm will self-administer a subcutaneous injection of placebo. The first dose (at month 1) will be a loading dose of two injections, or 240 mg in total. After that, at month 2 and month 3, each participant will receive an injection of placebo 120 mg. The injections will be with a pre-loaded syringe containing placebo.
62217439|NCT00744757|EXPERIMENTAL|Decitabine|Decitabine 20 milligram per square meter (mg per m\^2) will be administered intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
62411807|NCT04925531||Antibiotic use for <3 days|a retrospective chart review to examine if either the utility of antibiotics administered for 3 days make a difference in the clinical outcomes after facial fractures
62411808|NCT04925531||Antibiotic use for 5 days|a retrospective chart review to examine if either the utility of antibiotics administered for 5 days make a difference in the clinical outcomes after facial fractures
62585838|NCT04096638|EXPERIMENTAL|Part 2: Combination Expansion Cohorts at RP2D (Cohort B)|"Cohort B: Patients with HNSCC~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
62793452|NCT01365169|EXPERIMENTAL|Arm I (colorectal cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a heart rate monitor, a GPS device, and a smart phone that prompts patients to electronically answer questions about exercise and health-related symptoms and feelings. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
62793453|NCT01365169|EXPERIMENTAL|Arm II (head and neck cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a weight scale, and a smart phone that prompts patients to electronically answer questions about diet and health-related symptoms. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
62793454|NCT01365169|EXPERIMENTAL|Arm III (head and neck cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a smart phone that prompts patients to electronically answer questions about diet, health-related symptoms, and swallowing exercises. Patients also take video recordings of their neck while performing swallowing exercises. The device is used for 5 consecutive days. After a 2 week period, patients resume use of the device for an additional 5 days.
62217440|NCT05568732|EXPERIMENTAL|Test group|Scaling and root planing will be performed and after resolution of gingival inflammation, root coverage procedure will be done with VCMX using minimally invasive access technique.
62217441|NCT05568732|ACTIVE_COMPARATOR|Control group|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with CTG using minimally invasive access technique.
62793455|NCT01365169|EXPERIMENTAL|Arm IV (cancer survivors that are current/former smokers)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a CO monitor and a smart phone that prompts patients to electronically answer questions about smoking. Patients also take video recordings of themselves while exhaling into the CO monitor. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
62793456|NCT01365169|EXPERIMENTAL|PCS (pancreatic surgery patients)|Patients receive post-surgical wellness program consisting of physical activity, nutrition counseling, and daily monitoring (physical activity, weight, and self-reported data) for up to 7 months post-op.
62217442|NCT04452565|ACTIVE_COMPARATOR|Active Comparator: NA-831 alone|Arm 1: NA-831 30 mg orally twice a day for one day, followed by 30 mg once day for four consecutive days (Five days in total). The drug will be supplied in 30 mg capsule
62217443|NCT04452565|ACTIVE_COMPARATOR|Active Comparator: NA-831 plus Atazanavir Sulfate|"Arm 2: NA-831 60 mg orally twice a day for one day, followed by 30 mg once a day for four consecutive days (Five days in total). The drug will be supplied in 30 mg capsule.~AND Atazanavir 400 mg orally twice a day for one day, followed by 200 mg daily for four consecutive days (five days total). The drug will be supplied in 200 mg tablets."
62411809|NCT02564172|EXPERIMENTAL|CMS group|Conus medullaris stimulation with pentapolar surgical lead plus optimal medical management.
62411810|NCT02564172|ACTIVE_COMPARATOR|OMM group|Optimal medical management alone.
62411811|NCT03224234|EXPERIMENTAL|Insulclock with feedback (Group A)|Participants will use the Insulclock and receive daily information on their smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses. At midpoint (week 12), patients will be converted to the alternate arm.
62793457|NCT01365169|EXPERIMENTAL|TAPS (Technological Approach to Performance Status)|Patients use two Physical Activity monitor devices, the wrist-worn device (Fitbit) continuously and the Actigraph during waking hours. Patients use the devices for 7 consecutive days.
62585839|NCT04096638|EXPERIMENTAL|Part 2: Combination Expansion Cohorts at RP2D (Cohort C)|"Cohort C: Patients with tumor types other then Cohort A and B (Naïve or relapsed refractory to anti PD-1/PD-L1)~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
62585840|NCT06674655|EXPERIMENTAL|Motor Imagery Plus Therapeutic Exercise|
62217444|NCT04452565|ACTIVE_COMPARATOR|Active Comparator: NA-83 plus Dexamethasone|"Active Comparator: NA-831 30 mg capsule plus Dexamethasone 4 mg Arm 3: NA-831 60 mg orally twice a day for one day, followed by 30 mg once a day for four consecutive days (Five days in total). The drug will be supplied in 30 mg capsule.~AND Dexamethasone 8 mg orally twice a day for one day, followed by 4 mg daily for four consecutive days (five days total). The drug will be supplied in 4 mg tablets."
62217445|NCT04452565|ACTIVE_COMPARATOR|Active Comparator: Atazanavir and Dexamethasone|"Atazanavir 400 mg orally twice a day for one day, followed by 200 mg daily for four consecutive days (five days total). The drug will be supplied in 200 mg tablets.~AND Dexamethasone 8 mg orally twice a day for one day, followed by 4 mg daily for four consecutive days (five days total). The drug will be supplied in 4 mg tablets."
62217446|NCT06610006|ACTIVE_COMPARATOR|High Intensity Interval Training|Participants will begin with warm-up exercises for 5-7 mins before the session. Then they will begin high intensity interval training on treadmill with moderate intensity (40-60%HRR) in week 1 to achieve the baseline fitness level and from week 2 to 5 they will progress to high intensity with setting the lower target HR 40-60%HRR and upper target HR 80-85%HRR with 1:4 work to rest ratio followed by 5-7 min of cool-down period.A total of 15 sessions for thrice a week on alternative days for 5 consecutive weeks will be given
62217447|NCT06610006|EXPERIMENTAL|High Intensity Interval Training (HIIT) and Isometric Wall Squat|High intensity interval training on treadmill with moderate intensity (40-60%HRR) in week 1 to achieve the baseline fitness level and from week 2 to 5 they will progress to high intensity with setting the lower target HR 40-60%HRR and upper target HR 80-85%HRR with 1:4 work to rest ratio. For isometric wall squat, each training session will be composed of 4 × 2-min bouts of IWS followed by 2-min rest periods At the end of each bout, participants will be given an RPE score. This score will then be compared to a target RPE value and zone for each bout, There will be total 15 sessions thrice a week for 5 weeks.
62217448|NCT00749034|EXPERIMENTAL|1|VPM1002 in three dosages
62217449|NCT00749034|ACTIVE_COMPARATOR|2|BCG
62217450|NCT00166712|ACTIVE_COMPARATOR|Group 1: Alemtuzumab + TAC + MMF|Receive two doses of alemtuzumab (Campath-1H, 30mg) by intravenous (IV) infusion. One dose during kidney transplant surgery and the second dose on day 2 (post-surgery) to achieve peripheral T-cell depletion. IV glucocorticoids will be given prior to Campath administration to limit cytokine release syndrome in association with this monoclonal antibody. MMF on the day of surgery and continue taking it by mouth, twice daily. TAC started on the 1st day after surgery, and then taken by mouth twice daily.
62585841|NCT06674655|ACTIVE_COMPARATOR|Therapeutic Exercise|
62585842|NCT06674655|SHAM_COMPARATOR|Minimal Intervention|
62585843|NCT06180278|OTHER|Participants with NMOSD exposed to inebilizumab|Participants with NMOSD who previously enrolled in N-MOmentum study, who participated for at least 2 years in the open label phase (OLP) of the study, and participants newly initiating inebilizumab treatment will have hematology, chemistry, B-cell count, serum immunoglobulin (Ig) levels, adverse events, concomitant medications list, NMOSD attacks information, antidrug antibody (ADA) status and titers collected.
62585844|NCT06682988|EXPERIMENTAL|Randomized Phase 2 Cohort: Arm A|Participants will receive Mirvetuximab Soravtansine at the standard dose on Day 1 of a 21-day cycle.
62585845|NCT06682988|EXPERIMENTAL|Randomized Phase 2 Cohort: Arm B|Participants will receive Mirvetuximab Soravtansine at a lower dose than the standard dose on Day 1 and Day 15 of a 28-day cycle .
62585846|NCT06682988|EXPERIMENTAL|Hepatic Impairment Cohort : Mirvetuximab Soravtansine|Participants will receive Mirvetuximab Soravtansine on Day 1 of a 21-day cycle. Different doses will be given to groups of patients to identify a safe and effective dose.
62585847|NCT03511040|EXPERIMENTAL|Lumenate Intraluminal Device|Dilation of vasospastic intracranial vessels
62585848|NCT03137940|EXPERIMENTAL|real tDCS|one-shot of real tDCS session (1.5mA; 0.06 mA/cm2 for 20 minutes) with BrainStim Stimulator. The anode electrode is placed in a primary motor cortex (M1) of ipsilesional hemisphere (EEG 10/20 system), while cathode is placed in the supraorbital region (SO) of the contralateral hemisphere.
62793458|NCT03274544|EXPERIMENTAL|PROLUNG|Herbal formula treatment PROLUNG in additional to current therapy
62793459|NCT01591187||Cancer|Participants with a diagnosis of cancer.
62793460|NCT01591187||Sickle Cell Disease|"Participants with a diagnosis of sickle cell disease.~Interventions: Text messaging, Questionnaire, Interviews"
62793461|NCT04655573||Patient Derived Micro-Organospheres (PDMO)|Subjects will undergo image-guided biopsy as a standard of care clinical biopsy from which extra tissue is taken for research purposes. Following the biopsy, a PDMO will be generated and they will receive a chemotherapy regimen as determined by their treating physician. PDMO are successfully generated, and the patient begins treatment with a hemotherapy backbone. A patient will be considered evaluable if pathology results are available from the biopsy.
62217451|NCT00166712|ACTIVE_COMPARATOR|Group 2: Alemtuzumab + Sirolimus + MMF|"Sirolimus will be taken by mouth before transplant surgery and will continue taking once daily after surgery. Group 2 will also receive 2 doses of Alemtuzumab: one during surgery and the second will be given on the second day after surgery. Mycophenolate mofetil will be give on the day of surgery and twice daily, by mouth, as instructed by the doctor.~If subjects do not experience kidney rejection after 6 months after surgery, they will be weaned off of the sirolimus and continue taking the mycophenolate mofetil."
62217452|NCT02078843|OTHER|All patients|Subsequent performance of index test and standard test
62793462|NCT02041845|ACTIVE_COMPARATOR|A|3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week
62793463|NCT02041845|EXPERIMENTAL|B|3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week
62793464|NCT01316679||group A|Patients with known HCC
62411812|NCT03224234|ACTIVE_COMPARATOR|Insulclock without feedback (Group B)|Participants will use the Insulclock, but will not receive feedback on insulin administration. At midpoint (week 12), patients will be converted to the alternate arm.
62793465|NCT01316679||Group B|Patients with liver disease but no HCC
62793466|NCT01316679||Group C|Control; patients with no known liver disease or HCC
62217453|NCT04981171|EXPERIMENTAL|Electro-thumbtack Needle Therapy (ETN) group|Electro-thumbtack needles (0.25×2 mm) will be inserted into acupoints of Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) after sterilization. Then apply the gel electrodes and stimulation devices, turn on the device to produce a proper electric stimulation that the participant can tolerate.
62411813|NCT03192631|EXPERIMENTAL|with financial incentive|Patients randomized to this arm will start with receiving the financial incentive. Cross-over after 9 months to treatment as usual.
62793467|NCT01330329|EXPERIMENTAL|SBT + technology system (SBT+FIT)|Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention.
62793468|NCT01330329|EXPERIMENTAL|Standard behavioral treatment (SBT)|Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program.
62793469|NCT01970306|EXPERIMENTAL|Surgical intervention|Patients will undergo standard resection and gastrointestinal anastomosis and will then have reinforcement of the anastomosis with MatriStem PSM. Patients undergoing esophagectomy, PG or TG will be evaluated with one routine postoperative contrast swallow study at post-operative day #4-10.
62793470|NCT04538664|EXPERIMENTAL|Arm A: Amivantamab + Chemotherapy|Participants will receive pemetrexed 500 milligram per meter square (mg/m\^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusion on Day 1 of each 21 day cycle, for up to 4 cycles. Participants will receive amivantamab 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by IV infusion once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will continue to receive the amivantamab plus chemotherapy in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment.
62793471|NCT04538664|EXPERIMENTAL|Arm B: Chemotherapy Alone|Participants will receive pemetrexed 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will either continue to receive the chemotherapy or cross over to amivantamab in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment.
62793472|NCT05528393||GDM and Non-GDM|
62793473|NCT05528393||Pregnant group and non-pregnant group|
62411814|NCT03192631|NO_INTERVENTION|treatment as usual|Patients randomized to this arm will start with receiving treatment as usual, cross-over after 9 months to incentive arm.
62411815|NCT05879692|EXPERIMENTAL|study group (Group A)|Will consist of 30 cases suffering from mild to moderate Irritable Bowel Syndrome (IBS) with mild to moderate obesity will receive High Intensity Focused Ultrasound (Cavitation), a dietary regimen that combines Low Caloric Diet (LCD) and low (FODMAPs) diet and aerobic exercises with moderate intensity.
62021933|NCT06535724|EXPERIMENTAL|Study group|Patients underwent endoscopic debridement coupled with heel spur resection. This method emphasizes the removal of pathologically altered tissue while preserving the plantar aponeurosis, with the aim of minimizing procedural morbidity and enhancing recovery outcomes. It specifically targets the crucial roles of the plantar fascia in supporting the foot arch and facilitating foot propulsion. All had experienced persistent plantar fasciitis symptoms for at least six months despite conservative treatment.
62021934|NCT06003595||Surgical stabilization of rib fractures (SSRF) and subsequent hardware removal|Patients treated at the Department of Thoracic Surgery at the University Hospital Basel between 01.09.2017 and start date Remove Study with a diagnosis of rib fracture and with surgical stabilization of rib fracture and subsequent hardware removal will be identified.
62217454|NCT04981171|SHAM_COMPARATOR|Sham Electro-thumbtack Needle Therapy (ETN) group|Sham electro-thumbtack needles (0.25×0.2 mm) which are specially produced have blunt tips instead of sharp needle tip. They will be taped on acupoints of Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) after sterilization. Then apply the gel electrodes and stimulation devices, produce a minimal level of electric stimulation for 30 seconds before turning off the device.
62585849|NCT03137940|SHAM_COMPARATOR|Sham tDCS|one-shot of sham tDCS session with BrainStim Stimulator (20 minutes). The montage of the electrodes will be placed as in the experimental session i.e.the anode electrode will be placed in a primary motor cortex (M1) of ipsilesional hemisphere (EEG 10/20 system), while cathode in the supraorbital region (SO) of the contralateral hemisphere.
62217455|NCT05456802||Acute Coronary Syndrome (ACS)|Patients presenting to the clinic with acute coronary syndrome. This includes: ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI) and unstable angina pectoris (UAP) with confirmed diagnosis of coronary artery disease.
62217456|NCT05456802||Chronic Coronary Syndrome (CCS)|Patients presenting to the clinic with chronic coronary syndrome and confirmed diagnosis of coronary artery disease.
62411816|NCT05879692|ACTIVE_COMPARATOR|control group (Group B)|Will consist of 30 cases suffering from mild to moderate Irritable Bowel Syndrome (IBS) with mild to moderate obesity will receive only the same dietary regimen and aerobic exercise that prescribed for group A.
62411817|NCT05355194|EXPERIMENTAL|Group A: Kinesiotaping with pelvic tilts|Kinesiotape will be applied to patients. In addition, patients will be instructed to perform pelvic tilts.
62411818|NCT05355194|ACTIVE_COMPARATOR|Group B: Kinesiotaping without pelvic tilts|Kinesiotape will be applied to patients.
62585850|NCT06666270|EXPERIMENTAL|SYN818 tablet|SYN818 tablet monotherapy
62585851|NCT01482065|EXPERIMENTAL|CPAP|"Patients with moderate to severe apnea will be randomized to CPAP or deferred CPAP. Those in the CPAP group will be sent home with an autoset CPAP device, which they will be instructed to utilize for 4 months. The CPAP device will be set in the auto mode so that it will automatically adjust the pressure at night to eliminate upper airway obstruction during sleep.~Criteria for OSA severity are specifically designed to target patients with nocturnal hypoxemia, which is hypothesized to contribute to NAFLD progression. According to the guidelines of the American Academy of Sleep Medicine, apnea will be defined as cessation of airflow for ≥ 10 sec. and hypopnea will be defined as decreased airflow for ≥ 10 sec. leading to oxyhemoglobin desaturation ≥ 4%. Mild, moderate and severe OSA will be diagnosed by an Apnea-Hypopnea Index (AHI) of 5-14.9, 15-29.9, and ≥ 30 events/hr, respectively."
62793474|NCT06726343|ACTIVE_COMPARATOR|Group 1: 22 0/7 - 24 6/7 Weeks|All subjects will undergo the same interventions as part of the study procedures but will be divided into groups based on gestational age groups. Each study subject will undergo two 30-minute monitoring sessions (60 minutes total). One with FDA approved device and one with the investigational device. During both monitoring sessions, maternal pulse rate (MPR) will be monitored using SpO2 and the investigator shall be present to adjust the transducer placement as needed
62793475|NCT06726343|ACTIVE_COMPARATOR|Group 2: 25 0/7 - 31 6/7 Weeks|All subjects will undergo the same interventions as part of the study procedures but will be divided into groups based on gestational age groups. Each study subject will undergo two 30-minute monitoring sessions (60 minutes total). One with FDA approved device and one with the investigational device. During both monitoring sessions, maternal pulse rate (MPR) will be monitored using SpO2 and the investigator shall be present to adjust the transducer placement as needed.
62793476|NCT06726343|ACTIVE_COMPARATOR|Group 3: Greater than or equal to 32 0/7 Weeks|All subjects will undergo the same interventions as part of the study procedures but will be divided into groups based on gestational age groups. Each study subject will undergo two 30-minute monitoring sessions (60 minutes total). One with FDA approved device and one with the investigational device. During both monitoring sessions, maternal pulse rate (MPR) will be monitored using SpO2 and the investigator shall be present to adjust the transducer placement as needed.
62217457|NCT05456802||Critical limb ischemia (CLI)|Patients presenting to the clinic with critical limb ischemia. This includes: Resting limb pain (Fontaine III), ulcerations (Fontaine IV) and Ankle brachial index (ABI) \< 0,6 and confirmed diagnosis of peripheral artery disease.
62411819|NCT05035706|EXPERIMENTAL|Treatment (biopsy, biospecimen collection)|Patients undergo biopsy prior to radiation therapy and 7-14 days after radiation therapy. Patients also undergo blood sample collection prior to therapy (within 7 days of starting radiation therapy), 1 and 7 days post completion of radiation therapy. Patients' photographs of the biopsy site are taken before and at 4-6 weeks post completion of radiation, and their medical records are reviewed for up to 2 years.
62411820|NCT00758225|EXPERIMENTAL|only one arm|
62411821|NCT01016925|NO_INTERVENTION|Control|
62411822|NCT01016925|EXPERIMENTAL|femoral tunnelized perineural catheter|
62793477|NCT00819871||PLI|patients with postoperative lung injury
62585852|NCT02759172|EXPERIMENTAL|Safety Planning Intervention|Brown and Stanley's Safety Planning Intervention (SPI) is a brief, adjunctive intervention designed to reduce subsequent suicidal behavior in high-risk populations. The core element of SPI is the collaborative development of the Safety Plan, which is a prioritized written list of coping strategies and supports that individuals can use during or preceding suicidal crises. In this study, safety planning will occur during pretrial jail detention, with telephone follow-up in the community to conduct risk assessment, review the Safety Plan, problem-solve obstacles to treatment, and assist with linkage to services.
62585853|NCT02759172|NO_INTERVENTION|Standard Care|Standard Care for pretrial jail detainees is assessment of risk and stabilization to the extent possible during their jail detention. No post-release community follow-up is typically provided. This study will augment standard care with regular assessment and emergency referral post-release, as well as provision of a list of community resources.
62021935|NCT01336374||Greened Vacant Lot|A cluster of vacant lots is greened. People living around this area make up this cohort.
62021936|NCT01336374||Control Site|The control site is a cluster of vacant lots that will not be greened. The people living around these lots make up the control group.
62411823|NCT05661825||Patients diagnosed with acute myocardial infarction in the emergent department|The cases being admitted to the Emergent Department and than transferred to the general ward due to the diagnosis of acute myocardial infarction were included in the study (from Jan 1, 2012 to Jun 30, 2022). The age of these cases must be older than or equal to 20 years old.
62411824|NCT00925184||medical students, graduate year,|medical students at graduate year will be invited to participate in this study.
62585854|NCT02683395|EXPERIMENTAL|Treatment Group A|Open label, sequential PLX51107 dose escalation in approximately 30 solid tumor subjects.
62585855|NCT02683395|EXPERIMENTAL|Treatment Group B|Open label, sequential PLX51107 dose escalation in approximately 30 subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
62585856|NCT00858533|OTHER|workplace health advice|The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances.
62585857|NCT00858533|NO_INTERVENTION|GP sickness absence consultation|Routine general practitioner care for workplace sickness absence.
62585858|NCT05273190|EXPERIMENTAL|Vibrotactile Stimulation|
62793478|NCT00819871||without PLI|patients without postoperative lung injury
62793479|NCT00819871||PLI/PKI|patients with at least one organ injury of lung or kidney after surgery
62793480|NCT00819871||without PLI/PKI|patients without lung or kidney injury after surgery
62793481|NCT03887715|ACTIVE_COMPARATOR|Active|Group will have VNS activated 2 weeks post implant.
62793482|NCT03887715|SHAM_COMPARATOR|Control|Group will be implanted with VNS but device is not activated for the first 12 months. After 12 months, this group can receive stimulation.
62585859|NCT02179658|EXPERIMENTAL|OPT-80 group|Oral
62585860|NCT02179658|ACTIVE_COMPARATOR|Vancomycin group|Oral
62585861|NCT01062113|EXPERIMENTAL|Celecoxib 400mg|
62585862|NCT01062113|EXPERIMENTAL|Celecoxib 200mg|
62585863|NCT01062113|PLACEBO_COMPARATOR|Placebo|
62021937|NCT01863017|SHAM_COMPARATOR|Sham tDCS|Five consecutive sessions of no tDCS. Each session will last approximately 30 minutes. Current will be applied for 20 minutes. Less than 3 minutes of tDCS has been shown to induce no lasting effects. Normal weight control participants will receive one sham session and one active session.
62021938|NCT01863017|EXPERIMENTAL|Active tDCS|Five consecutive sessions of tDCS administered. Each session will take about 30 minutes. Normal weight control participants will receive one sham session and one active session.
62021939|NCT03049124|EXPERIMENTAL|Exercise|Participants will be asked to complete a 12-week exercise intervention and all study assessments.
62021940|NCT06434961|EXPERIMENTAL|Treatment group|
62021941|NCT06434961|ACTIVE_COMPARATOR|Active Control group|
62021942|NCT01565967||Autotransfusion|All patients undergoing surgery which requires routine use of an autotransfusion system
62021943|NCT01491243|ACTIVE_COMPARATOR|Intensive treatment group|Patients will receive high concentration sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h after PCI in case of abnormal NGAL findings
62585864|NCT02156908|EXPERIMENTAL|D-serine|D-serine
62585865|NCT05727761|EXPERIMENTAL|oral leukoplakia patients|36 total high risk oral leukoplakia patients.
62585866|NCT04852068|EXPERIMENTAL|Investigational Vaccine - 5-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, with a titer of not less than 2.5IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
62793483|NCT05129540|EXPERIMENTAL|Custom-made foot orthoses group|Custom-made foot orthoses will be applied to participants in this arm. The orthoses will consist on a 3-mm thick polypropylene layer from heel to just proximal to the metatarsal heads, and a cover layer of polyethylene foam from heel to toe tips. Both materials will be adapted to the foot positive casts that will be obtained from all participants.
62793484|NCT05129540|PLACEBO_COMPARATOR|Placebo group|The placebo orthoses will consist on a 3-mm thick polyethylene foam layer from heel to toe tips and a 0.8-mm thick resin layer from heel to just proximal to the metatarsal heads. None of the materials will be adapted to the foot positive casts.
62021944|NCT01491243|ACTIVE_COMPARATOR|Standard treament group|Patients will receive i.v. 1 ml/kg/h saline infusion for 48 h after PCI in case of abnormal NGAL findings
62585867|NCT04852068|EXPERIMENTAL|Investigational Vaccine - 4-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, with a titer of not less than 2.5IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
62793485|NCT05370131|EXPERIMENTAL|Avatar-Based Education Program in Hydrocephalus (ABEP-H)|The avatar-based education program in hydrocephalus (ABEP-H) aimed to help parents acquire the knowledge and develop the skills necessary for the care of hydrocephalus children with VP shunts and prevent shunt infection and dysfunction. The intervention group participants will be sent usernames and passwords they can change by accessing their profiles. The main researcher will show them how to log into the program and use it on their phones and computers. This interview will take about 40 minutes. Afterward, they are expected to use the program for six months on a regular basis. Their login frequency and duration will be monitored. After six months, they will be asked to fill out the System Usability Scale (SUS). Moreover, each participant will be phoned once every two weeks as a reminder.
62793486|NCT05370131|NO_INTERVENTION|Control Group|The control group will receive the standard care procedures of the hospital.
62793487|NCT05189847||Patients with MFA|Patients with MFA confirmed by ultrasound examination, ABI or using clinical and medical history data.
62793488|NCT05189847||Patients with a history of established isolated coronary artery disease|The criterion for inclusion of patients in the present study is the diagnosed ischemic heart disease.
62793489|NCT05467384|EXPERIMENTAL|Newly Diagnosed Hypertensive patients|These are the patients that have been clearly diagnosed with diabetes for the first time.
62021945|NCT00443547||1-level|Patients needing a single level cervical fusion with Vectra-T
62021946|NCT00443547||2-level|Patients needing cervical fusion at two consecutive levels with Vectra-T
62021947|NCT00443547||3-level|Patients needing cervical fusion at three consecutive levels with Vectra-T
62021948|NCT00443547||4-level|Patients needing cervical fusion at four consecutive levels with Vectra-T
62021949|NCT05009849|EXPERIMENTAL|Exercise I|Yogic and Routine Exercises (referred to as exercise I) Phase I: 1-7 days (Minimum attendance 4 days), Phase II: 8 - 14 days (Minimum attendance 4 days), Phase III: at 6-9 months or 12-15 months 1 year up gradation of exercises at 6-9 month or 12-15 months 1 year (Depending upon compliance to phase II exercises) Objective assessment at baseline, 14 days, 6-9, 12-15, 18-21, 36-39 and 54-57 months Exercise evaluation will be done at 6-9, 12-15, 30-33, 48-51 and 66-69 months
62021950|NCT05009849|ACTIVE_COMPARATOR|Exercise II|Objective assessment at baseline, 14 days, 6-9, 12-15, 18-21, 36-39 and 54-57 months
62021951|NCT06454513||General anesthesia|There all cases in this group where the surgical anesthesia method is general anesthesia
62021952|NCT06454513||Local anesthesia|There all cases in this group where the surgical anesthesia method is local anesthesia
62021953|NCT05881941|EXPERIMENTAL|using a soundproof nebulizer with a music and a funny mask added|Experimental group 1: using a soundproof nebulizer with a music and a funny mask added
62411825|NCT04645732|EXPERIMENTAL|Personalized exercise therapy and self-management program in addition to usual care|"Participants randomized to the personalized exercise therapy and self-management support program will participate in a 12-week program tailored to people with multimorbidity at one of the intervention sites. The program will consist of 24 exercise therapy and self-management sessions distributed across the program (twice weekly, each lasting around 1.5 hour).~Furthermore, this group will receive the treatment described under usual care below."
62021954|NCT05881941|EXPERIMENTAL|using a silent nebulizer with no extra attachments|Experimental group 2: using a silent nebulizer with no extra attachments
62021955|NCT05881941|EXPERIMENTAL|using a routinely employed nebulizer|Control group: using a routinely employed nebulizer
62411826|NCT04645732|ACTIVE_COMPARATOR|Usual care alone|Usual care is the care that the participants would receive had they not participated in the study, i.e. treatments or services that are routinely provided in the settings from which the participants are recruited. Participants will continue their current treatment, if needed, and be allowed to receive other treatments if their general practitioner or specialist finds it relevant for their particular comorbidities.
62411827|NCT04121169|OTHER|Adults subjects with CDI receiving 20g a day|10 g twice a day for 10 - 14 days
62411828|NCT04121169|OTHER|Adults subjects with CDI receiving 40 g a day|20 g twice a day for 10 - 14 days
62585868|NCT04852068|ACTIVE_COMPARATOR|Control vaccine - 5-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, titer not less than 2.5IU, Liaoning Chengda Biological Co., Ltd.
62585869|NCT04852068|ACTIVE_COMPARATOR|Control vaccine - 4-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, titer not less than 2.5IU, Liaoning Chengda Biological Co., Ltd.
62585870|NCT05969769|ACTIVE_COMPARATOR|Experimental Group|Sustained Natural Apophyseal Glides will be performed with Muscle Energy Technique and Short Wave Diathermy as experimental group.
62793490|NCT05467384|NO_INTERVENTION|Healthy Controls|Healthy Control Group
62793491|NCT00297323||001|
62793492|NCT00475566|OTHER|1|This is a prospective, non-randomized, single-arm, multi-center study. A projected 100 patients will receive the stent(s) in this study at approximately 10-15 European sites. The primary objective is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral or proximal popliteal lesions.
62217458|NCT03123601|EXPERIMENTAL|Risk sign displays|At baseline patients will undertake a screening risk assessment and it will be attributed a correspondent risk display. Study duration will be a minimum of 3 months per participant, including daily record of events and monthly interview assessments. Events data will be compared with historical data extracted retrospectively from medical and nursing charts.
62217459|NCT04531501||Patients suspected to have Covid-19|Individuals suspected to have COVID-19 who are admitted to Gloucestershire Hospitals NHS Foundation Trust facilities for treatment for COVID-19. Individuals with full mental capacity.
62411829|NCT03824483|EXPERIMENTAL|BOVEN regimen|"Patients will be given zanubrutinib (160mg by mouth BID) and obinutuzumab (1000mg IVPB on Days 1\*, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8) starting on Cycle 1 (28-day cycles). \* On Cycle 1, obinituzumab will be administered in split dose at 100mg IVPB on Day 1 and 900mg IVPB on Day 2 in patients at increased risk for IRR (ALC \>25,000 cells/ul or baseline lymph nodes \>5 cm diameter). Venetoclax will be added to the regimen starting on Cycle 3, and will be incorporated into the regimen using the 5-week ramp-up schedule to mitigate the risk of tumor lysis syndrome (beginning at 20mg and gradually increasing to 400mg), and venetoclax will be administered a ta fixed dose level of 400mg by mouth daily of 28-day cycles thereafter."
62217460|NCT04531501||Patients tested positive for Covid-19|Individuals tested positive for COVID-19 at Northern Care Alliance NHS Group using an NHS NPS test who are accessible within 24 hours and consent to providing a saliva sample and further NPS sample for Chronomics.
62217461|NCT06127550|EXPERIMENTAL|Active taVNS|Participants will receive custom current at 5 Hz to the left auricular branch of the vagus nerve while learning new letter-sound relationships.
62793493|NCT03783299|EXPERIMENTAL|Village-based MTAT|"Intervention: For all households in intervention villages, after obtaining informed consent, MTAT will be conducted with all household members aged 18 months and older.~The MTAT team will test each individual using both a standard RDT and HS-RDTs. Positive cases will be treated with age-appropriate doses of Artemether-lumefantrine (AL) and Primaquine Phosphate (SLD-PQ)"
62217462|NCT06127550|SHAM_COMPARATOR|Sham taVNS|Participants will undergo current thresholding but device will be turned off without their knowledge during the training.
62217463|NCT06020053|NO_INTERVENTION|One of the symmetrical Impacted Mandibular Third Molars, control group|Serum at room temperature (25°C) was applied to one of the mandibular impacted third molars
62217464|NCT06020053|EXPERIMENTAL|One of the symmetrical Impacted Mandibular Third Molars, intervention group|Serum at temperature (4°C) was applied to one of the mandibular impacted third molars
62217465|NCT04602221|EXPERIMENTAL|Treatment sequence: T1-T2-R|"Treatments:~T1: Lamotrigine T2: BI 409306 T3: BI 425809 R: Placebo"
62217466|NCT04602221|EXPERIMENTAL|Treatment sequence: T1-R-T2|
62217467|NCT04602221|EXPERIMENTAL|Treatment sequence: T1-T3-R|
62217468|NCT04602221|EXPERIMENTAL|Treatment sequence: T1-R-T3|
62217469|NCT04602221|EXPERIMENTAL|Treatment sequence: T2-T1-R|
62585871|NCT05969769|ACTIVE_COMPARATOR|Control Group|Short wave diathermy will be given with Muscle Energy Techniques.
62585872|NCT06532474||Cohort 1|Current Evrysdi prescription
62585873|NCT06532474||Cohort 2|Current Spinraza or Zolgensma prescription
62585874|NCT06532474||Cohort 3|Changing from Spinraza or Zolgensma to Evrysdi
62585875|NCT06532474||Cohort 4|Have never received any SMN-directed therapies
62585876|NCT06261983||Patients diagnosed with oral squamous cell carcinoma at stages I-II|The patients underwent sentinel node biopsy and posterior neck dissection
62585877|NCT06667063||Cohort 1:COVID-19 infected persons|"Inclusion Criteria:~1. volunteers aged 18 years and above at the time of screening;~2. informed consent obtained from volunteers and volunteers/witnesses able to sign the informed consent form;~3. an interval of ≥3 months from the last COVID-19 or influenza vaccination;~4. an interval of ≥ 3 months from the last respiratory viral infection such as COVID-19 or Influenza virus occurs;~5. COVID-19 antigen-positive and within 48 hours of onset of symptoms of infection;"
62217470|NCT04602221|EXPERIMENTAL|Treatment sequence: T2-R-T1|
62217471|NCT04602221|EXPERIMENTAL|Treatment sequence: T2-T3-R|
62217472|NCT04602221|EXPERIMENTAL|Treatment sequence: T2-R-T3|
62217473|NCT04602221|EXPERIMENTAL|Treatment sequence: T3-R-T1|
62217474|NCT04602221|EXPERIMENTAL|Treatment sequence: T3-T1-R|
62217475|NCT04602221|EXPERIMENTAL|Treatment sequence: T3-T2-R|
62217476|NCT04602221|EXPERIMENTAL|Treatment sequence: T3-R-T2|
62217477|NCT04602221|EXPERIMENTAL|Treatment sequence: R-T1-T2|
62217478|NCT04602221|EXPERIMENTAL|Treatment sequence: R-T2-T1|
62217479|NCT04602221|EXPERIMENTAL|Treatment sequence: R-T1-T3|
62217480|NCT04602221|EXPERIMENTAL|Treatment sequence: R-T3-T1|
62217481|NCT04602221|EXPERIMENTAL|Treatment sequence: R-T2-T3|
62217482|NCT04602221|EXPERIMENTAL|Treatment sequence: R-T3-T2|
62217483|NCT06281899|EXPERIMENTAL|Intervention|Patients will receive a plant-based low protein diet (0.6 g proteins/kg ideal body weight per day) associated with Dapagliflozin 10 mg per day
62217484|NCT06281899|ACTIVE_COMPARATOR|Control|Patients will receive Dapagliflozin 10 mg per day
62217485|NCT03919604||ECLS group|Patients with CF undergoing LUTX. Need for intraoperative extracorporeal life support
62217486|NCT03919604||Non-ECLS group|Patients with CF undergoing LUTX. No need for intraoperative extracorporeal life support
62217487|NCT04470453|EXPERIMENTAL|Patients with active rheumatoid arthritis|30 patients with active rheumatoid arthritis will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
62411830|NCT02427425|EXPERIMENTAL|TENS group|It was applied conventional TENS with FIV effect, frequency of 100 Hertz, a pulse width of 60μs and intensity adjusted according to the individual baseline for each patient without causing muscular contraction. The electrodes were arranged in a cross shape in the paravertebral region (levels T12-L1 and L5 - S1). Treatment consisted of 10 sessions (2x / week / 5 weeks), with each session lasting 30 '.
62217488|NCT04470453|EXPERIMENTAL|Patients with rheumatoid arthritis into remission|30 patients with rheumatoid arthritis into remission will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
62217489|NCT04656704|EXPERIMENTAL|Hyaluronidase 200mg monthly|Hyaluronidase 200mg monthly (Weeks 0, 4, 8, 12, 16, 20); for six doses; a 6-month treatment course with follow-up 1 month after
62217490|NCT01368289||Colonic Polyps|Patients who present with colonic polyps \>20mm
62411831|NCT02427425|PLACEBO_COMPARATOR|Placebo group|In Placebo group the same procedures of the TENS group were adopted, but did not occur electrical stimulus.
62411832|NCT02566460|EXPERIMENTAL|lactate clearance group|Refer to lactate clearance rate to perform resuscitation therapy
62411833|NCT02566460|SHAM_COMPARATOR|SCVO2 group|Refer to SCVO2 to perform resuscitation therapy
62411834|NCT01456598|EXPERIMENTAL|Laparoscopic gastrectomy|Laparoscopic subtotal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer.
62411835|NCT01456598|ACTIVE_COMPARATOR|Open gastrectomy|Open subtotal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer.
62411836|NCT02234427|EXPERIMENTAL|Aspirin|
62411837|NCT01750528||Ankylosing spondylitis|patients aged 18 years or more who meet the 1984 modified New York criteria
62411838|NCT01750528||Control|age- (± 3 years) and gender-matched volunteers who do not have inflammatory arthropathy.
62411839|NCT04014296|EXPERIMENTAL|High Protein Diet|Enrollment in State of Slim (SOS) weight loss program with a high protein diet.
62411840|NCT04014296|EXPERIMENTAL|Resistance Training|Enrollment in State of Slim (SOS) weight loss program with resistance training counseling sessions.
62411841|NCT05097066||Elective neurosurgery|Any elective neurosurgical procedure.
62411842|NCT05097066||Non-elective neurosurgery|Any non-elective neurosurgical procedure.
62411843|NCT04222218|ACTIVE_COMPARATOR|Real Stimulation|Cerebellar Repetitive theta burst stimulation will be performed using a 3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals for a total of 600 pulses. Intensity of rTMS was set at the 80% of Amplitude of Motor Threshold (RMT) obtained in the left motor cortex for each subject.
62411844|NCT04222218|SHAM_COMPARATOR|Sham Stimulation|The rTMS coil stimulation will be applied in the same position of the real stimulation. The Stimulation will be performed like in the real arm with the difference that the coil will be masked and thus will be inactive. The patient will hear the same sound of real stimulation, which will be only functionally inactive but will be completely performed (for the whole time of duration of stimulation)
62411845|NCT05770778|ACTIVE_COMPARATOR|Inclined Backward Intervention Group|Hemiplegic Cerebral Palsy Children
62411846|NCT05770778|ACTIVE_COMPARATOR|Kneel Walk Intervention Group|Hemiplegic Cerebral Palsy Children
62411847|NCT02296671|EXPERIMENTAL|PEMOX|"Pemetrexed will be given intravenously (IV) on an outpatient basis on Day 1 of each 14-day cycle over 10 minutes. Oxaliplatin will be given (IV) on an outpatient basis on Day 1 of each 14-day cycle at a dose over 120 minutes. Drugs may be given in either order.~-Oxaliplatin will be administered on Day 2 for Cycle 1 only. \*\*"
62411848|NCT02296671|EXPERIMENTAL|FOLFOX|"The modified FOLFOX-6 regimen is the following drugs given every 14 days:~* Oxaliplatin on Day 1 of each cycle~* Leucovorin over 120 minutes on Day 1 of each cycle~* 5-FU bolus and continuous infusion over 46 hours beginning on Day 1 of each cycle~  * Oxaliplatin will be administered on Day 2 for Cycle 1 only and the 5-FU infusion will be interrupted at 20 hours so that the FLT-PET scan can be performed (only for FLT-PET scan eligible patients)."
62411849|NCT01130805|EXPERIMENTAL|Pazopanib in combination with capecitabine and oxaliplatin|Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks
62411850|NCT00669110|EXPERIMENTAL|A|
62411851|NCT06539585|ACTIVE_COMPARATOR|Standard ICSI without meiotic spindle imaging.|"A control group of patients who underwent a standard IVF cycle without microscopy of the meiotic spindle. In this control group of patients, ICSI fertilization will be performed 5-6 hours after oocyte collection.~ICSI will be performed according to standard protocol \[6\]. The oocytes will be cultivated individually, and their order preserved, so that the other outcomes (data from timelapse, clinical results) can be associated with individual oocytes. Fertilization after ICSI will be defined as the presence of two pronuclei and 2 polar body. Embryos will be cultivated for 122-144 h."
62433258|NCT06547203|EXPERIMENTAL|Cetuimab plus toripalimab and irinotecan|"Single Arm study, with patients receiving:~Cetuximab: 500 mg/m², intravenous infusion, once every 2 weeks. Toripalimab: 3 mg/kg, intravenous infusion, once every 2 weeks. Irinotecan: 150 mg/m², intravenous infusion, once every 2 weeks.~Patients will continue treatment until any of the following conditions occur: the researcher determines there is no longer a clinical benefit, intolerable toxicity occurs, a new anti-tumor treatment is initiated, withdrawal of informed consent, loss to follow-up, death, or other conditions specified in the protocol requiring termination of treatment."
62433259|NCT01077349|EXPERIMENTAL|high volume hemofiltration|
62217491|NCT00585403||Children|Early and late pubertal girls and boys
62217492|NCT01345695||Treatment|Data collected on persons living in the catchment area for a WHP telemedicine center
62217493|NCT01345695||Control|Data collected on persons living in the catchment area where there is not a WHP telemedicine center
62217494|NCT04084184|EXPERIMENTAL|Sequence 1|Period 1 : Fasted state + HGP1812, Period 2 : Fasted state + HGP1602
62793494|NCT03783299|EXPERIMENTAL|Peer navigator-led FTAT|"Intervention: Peer navigators will actively seek non-village based HRPs in forested areas, rice fields and plantations, and any other non-permanent settlements within target health center catchment areas, and conduct FTAT among all consenting individuals.~The Peer Navigators will test each individual using both a standard RDT and HS-RDT. Positive cases will be treated with age-appropriate doses of Artemether-lumefantrine (AL) and Primaquine Phosphate (SLD-PQ)"
62793495|NCT00653588|EXPERIMENTAL|1|rosuvastatin (40 mg)
62793496|NCT00653588|ACTIVE_COMPARATOR|2|atorvastatin (80 mg)
62793497|NCT05717192|ACTIVE_COMPARATOR|InterVapor®-System|The intervention to be tested is bronchoscopic lung volume reduction (BTVA) using thermal ablation (InterVapor®, Uptake Medical, California, USA). This is performed in addition to standard conservative therapy in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines. The intervention can consist of a maximum of two partial interventions
62793498|NCT05717192|NO_INTERVENTION|Standard of care|Standard conservative therapy in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines without the use of a BTVA (patient-specific documentation of therapeutic measures).
62793499|NCT06022796|EXPERIMENTAL|Healthy Ketogenic Ready-To-Eat (HK-RTE) Meals|"Participants in the HK-RTE group (n=25) will be provided with the Healthfull meals for lunch and dinner in the first month. They will be advised to take these meals as part of a healthy ketogenic diet, with a maximum of 50g total net carbohydrates daily.~Participants will receive nutrition education conducted by dietitians over the course of 6 months (total of 5 dietary workshops covering topics such as ketogenic dietary advice and self-monitoring habits). Participants will also receive health coaching via the Nutritionist Buddy (nBuddy) mobile application to facilitate monitoring of diet intake, physical activity and weight throughout the 6 months study period."
62433260|NCT01077349|ACTIVE_COMPARATOR|standard care|
62433261|NCT01335178|EXPERIMENTAL|Intervention|Participants received the behavioral intervention, which was designed to motivate parents to protect their children from tobacco smoke exposure
62793500|NCT06022796|ACTIVE_COMPARATOR|Healthy Ketogenic Diet (HKD)|"Participants in the reference group will be instructed to follow a Healthy Ketogenic Diet (n = 25), with a maximum of 50g total net carbohydrates daily.~Similar to the experimental group, participants will receive nutrition education conducted by dietitians over the course of 6 months (total of 5 dietary workshops such as ketogenic dietary advice and self-monitoring habit). Participants will also receive health coaching via the Nutritionist Buddy (nBuddy) mobile application to facilitate monitoring of diet intake, physical activity and weight throughout the 6 months study period."
62793501|NCT04397744|EXPERIMENTAL|Unidas por Vida y Salud prevention program|Unidas por Vida y Salud (United for Life and Health) prevention program
62793502|NCT04397744|NO_INTERVENTION|No intervention control|The control arm will not receive the Unidas por Vida y Salud (United for Life and Health) prevention program during the study analysis period (though, the control arm will receive the intervention after study has been completed).
62793503|NCT04774263||General population|general population
62793504|NCT04774263||emergency caregivers|emergency caregivers
62793505|NCT02449161|EXPERIMENTAL|MPA|medroxyprogesterone acetate, 10 mg/day, for 90 days, following endometrial ablation
62793506|NCT02449161|PLACEBO_COMPARATOR|placebo|1 placebo/day, for 90 days, following endometrial ablation
62793507|NCT03349788|EXPERIMENTAL|LCA-nP|The group underwent laparoscopic radical rectectomy without preserving left colic artery. In IMA group, the dissecting based on TME is performed without preserving left colic artery. Surgeon should dissect the lymph nodes and ligated the vessel in the root of inferior mesenteric artery.
62793508|NCT03349788|ACTIVE_COMPARATOR|LCA-P|The group underwent laparoscopic radical rectectomy with preserving left colic artery. In LCA group, the dissecting based on TME is performed with preserving left colic artery. The relationship of inferior mesenteric artery, inferior mesenteric vein and LCA should be identified and ligated separately without LCA.
62021956|NCT04827199|EXPERIMENTAL|ARTUS®|The subjects will be implanted with the experimental medical device ARTUS® Artificial Urinary Sphincter (AUS) during the surgical procedure and will be trained to the use of the Remote Control to control themselves the micturition.
62217495|NCT04084184|EXPERIMENTAL|Sequence 2|Period 1 :Fasted state + HGP1602, Period 2 : Fasted state + HGP1812
62217496|NCT02093000||Bevacizumab|Participants who have received the induction phase of 4-6 cycles of bevacizumab plus platinum doublet chemotherapy will be treated with bevacizumab as maintenance treatment, according to approved label and local reimbursement.
62217497|NCT03663491|EXPERIMENTAL|Unsedated Nasal Gastroscopy|Transnasal Endoscopy. No sedation used. Use of local anesthesia.
62217498|NCT03663491|ACTIVE_COMPARATOR|Oral Gastroscopy, unsedated|Transoral Endoscopy. No sedation used. Use of local anesthesia.
62217499|NCT03663491|ACTIVE_COMPARATOR|Oral Gastroscopy, sedated|Transoral Endoscopy. Intravenous sedation used.
62217500|NCT06306547||IMM patients with tumors|Patients with IMM will be grouped according to the type of positive myositis-specifc autoantibody,and then again according to whether and what type of tumor they had comorbid.
62217501|NCT06306547||IMM patients without tumors|Patients with IMM will be grouped according to the type of positive myositis-specifc autoantibody,and then again according to whether and what type of tumor they had comorbid.
62217502|NCT05956639|EXPERIMENTAL|6-month course of Rezvilutamide|6-month course of Rezvilutamide with ADT and chemotherapy
62217503|NCT05956639|ACTIVE_COMPARATOR|Long-term course of Rezvilutamide|Long-term course of Rezvilutamide with ADT and chemotherapy
62217504|NCT06609954|EXPERIMENTAL|Reduced Exertion High intensity Training (REHIT) Group|Participant will perform a 5 min warm-up exercises then do cycling or treadmill running for 20 min at 40%-60% of HRR and then will conclude with 5 min cool down exercises. From week 2 to 6 participants will be instructed to perform training sessions on a cycle ergometer.A 3-minute cool-down period will conclude each session. Patients in this group will be provided with a caloric restriction plan by a nutritionist that will be followed throughout the training duration.
62021957|NCT06567509|EXPERIMENTAL|Pilot experimental group|"Phase 1: 1. Cross Curl 15 rept × 3 times 120 sec rest between the sets 2. Bridges with leg lifts 20 sec hold × 3 times 120 sec rest between the sets Side bridges (left and right) 20 sec hold × 3 times 120 sec rest between the sets 3. Planks on feet 20 sec hold × 3 times 120 sec rest between the sets 4. Quadripedal stance. 20 sec hold × 3 times 120 sec rest between the sets 5. Bicycles 15 rept × 3 times 120 sec rest between the sets~Phase 2: 1. Cross Curl ups 20 rept × 3 times 120 sec rest between the sets 2. Bridges with leg lifts 30 sec hold × 3 times 120 sec rest between the sets Side bridges (left and right) 30 sec hold × 3 times 120 sec rest between the sets 3. Planks on feet 30 sec hold × 3 times 120 sec rest between the sets 4. Quadripedal stance 30 sec hold × 3 times 120 sec rest between the sets 5. Bicycles 20 rept × 3 times 120 sec rest between the sets"
62021958|NCT06567509|OTHER|Pilot Control group|"Conventional foot exercises for control group (3 times weekly for 6 weeks)~A. Warm up:~Active ROM exercise (Knee and hip flexion) 10 repetitions × 2 sets)~B. Training:~* Active dorsiflexion exercises in long sitting (10 sec hold × 15 repetitions ×2 sets)~* Active plantarflexion exercises in long sitting (10 sec hold × 15 repetitions ×2 sets)~* Active inversion exercises in long sitting (10 sec hold × 15 repetitions ×2 sets)~* Active eversion exercises in long sitting (10 sec hold × 15 repetitions ×2 sets)~C. Cool down:~• Calf stretches in long sitting for 10 sec hold × 3 sets."
62021959|NCT06567509|EXPERIMENTAL|Main RCT Experimental group|"Phase 1: 1. Cross Curl 15 rept × 3 times 120 sec rest between the sets 2. Bridges with leg lifts 20 sec hold × 3 times 120 sec rest between the sets Side bridges (left and right) 20 sec hold × 3 times 120 sec rest between the sets 3. Planks on feet 20 sec hold × 3 times 120 sec rest between the sets 4. Quadripedal stance. 20 sec hold × 3 times 120 sec rest between the sets 5. Bicycles 15 rept × 3 times 120 sec rest between the sets~Phase 2: 1. Cross Curl ups 20 rept × 3 times 120 sec rest between the sets 2. Bridges with leg lifts 30 sec hold × 3 times 120 sec rest between the sets Side bridges (left and right) 30 sec hold × 3 times 120 sec rest between the sets 3. Planks on feet 30 sec hold × 3 times 120 sec rest between the sets 4. Quadripedal stance 30 sec hold × 3 times 120 sec rest between the sets 5. Bicycles 20 rept × 3 times 120 sec rest between the sets"
62021960|NCT06567509|OTHER|Main RCT Control Group|"Conventional foot exercises for control group (3 times weekly for 6 weeks)~A. Warm up:~Active ROM exercise (Knee and hip flexion) 10 repetitions × 2 sets)~B. Training:~* Active dorsiflexion exercises in long sitting (10 sec hold × 15 repetitions ×2 sets)~* Active plantarflexion exercises in long sitting (10 sec hold × 15 repetitions ×2 sets)~* Active inversion exercises in long sitting (10 sec hold × 15 repetitions ×2 sets)~* Active eversion exercises in long sitting (10 sec hold × 15 repetitions ×2 sets)~C. Cool down:~• Calf stretches in long sitting for 10 sec hold × 3 sets."
62021961|NCT01115439||falciparum malaria|Febrile children (above six months of age) and non-pregnant adults with confirmed uncomplicated P. falciparum infection
62217505|NCT06609954|EXPERIMENTAL|High Intensity Interval Training (HIIT)|Participant will perform a 5 min warm-up exercises then do cycling or treadmill running for 20 min at 40%-60% of HRR and then will conclude with 5 min cool down exercises. From week 2 to 6 participants will be instructed to perform a warm up of 5 min, then 4 bouts of 4 min of HIIT will be performed at 80%-95% of HRR separated by 3-min active recovery periods of moderate intensity cycling at 60%-70% of the HRR followed by 5 min cool down exercises. Patients in this group will be provided with a caloric restriction plan by a nutritionist that will be followed throughout the training duration.
62217506|NCT05558631||Residents of the municipality of Leiria aged 18 years or more.|
62411852|NCT06539585|ACTIVE_COMPARATOR|Meiotic spindle imaging followed by standard ICSI.|"MS evaluation will take place in pre-prepared glass-bottomed dishes with about 5μl medium with the HEPES buffer covered with paraffin oil, put to heat one hour before use. The oocyte will be rotated using a needle so that PB and MS are both well visible, and photographs will be taken using optical microscope. The MS status and the angle (α) between MS and PB will be obtained 3-4 hours after oocyte pick-up (OPU). At the same time, the polarized-light microscopy image will be acquired (polarized light microscopy at ×100 magnification. ICSI will be performed typically 2-3 h after the polarization microscopy evaluation, i.e., 5-6 h after OPU.~ICSI will be performed according to standard protocol \[6\]. Fertilization after ICSI will be defined as the presence of two pronuclei and 2 polar body. Embryos will be cultivated for 122-144 h."
62793509|NCT05620888|EXPERIMENTAL|Tailored messages (TM)|"Participants assigned to this arm receive a daily tailored message on the benefits of taking at least 7000 steps daily. Tailoring concerns change-related expectations, risk perception, planning, retention capacity, resilience, and coping skills and is based on the responses provided by participants at baseline evaluation.~In addition, they receive a daily request to declare the number of steps taken (walking self-monitoring).In particular, every evening, the mobile application sends a message to the participants requesting to enter the number of steps taken during the day in a dedicated app section."
62793510|NCT05620888|EXPERIMENTAL|Non tailored messages (NTM)|"Participants assigned to this arm receive a daily non-tailored message on the emotional benefits of taking at least 7000 steps daily.~In addition, they receive a daily request to declare the number of steps taken (walking self-monitoring). In particular, every evening, the mobile application sends a message to the participants requesting to enter the number of steps taken during the day in a dedicated app section."
62793511|NCT05620888|NO_INTERVENTION|No messages (NM)|Participants assigned to this arm receive a daily request to declare the number of steps taken (walking self-monitoring). In particular, every evening, the mobile application sends a message to the participants requesting to enter the number of steps taken during the day in a dedicated app section.
62793512|NCT04488926|ACTIVE_COMPARATOR|Group 1|Normast® MPS (mPEA and umPEA 300mg + 600mg) microgranules for sublingual use, 1800mg/die in 2 doses (morning and evening) for 90 days
62793513|NCT04488926|PLACEBO_COMPARATOR|Group 2|Placebo microgranules for sublingual use, 1800mg/die in 2 doses (morning and evening) for 90 days
62433262|NCT05319340|OTHER|anticoagulants arm|The study embraces patients who are advised to take the anticoagulant therapy (as per the European Society of Cardiology Guidelines). The study evaluates the compliance with the anticoagulant therapy, safety and effectiveness, mortality
62433263|NCT03551678|EXPERIMENTAL|Gait retraining|Eight weeks of active-feedback gait retraining. The gait retraining device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
62793514|NCT05097443|EXPERIMENTAL|Orelabrutinib+R+chemotherapy|Orelabrutinib+R-CHOP;Orelabrutinib+R-DA-EPOCH;Orelabrutinib+R-HD MTX；Orelabrutinib+R+other regimens
62793515|NCT02538042|EXPERIMENTAL|MCE+|Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
62217507|NCT05811390|EXPERIMENTAL|erythritol jet (EMS)|An erythritol jet (Perioflow from EMS) will be used to debride the periodontal pockets of oral implants diagnosed with per-implantitis.
62411853|NCT06539585|ACTIVE_COMPARATOR|MS imaging and ICSI fertilization according MS status.|"Oocytes with MS evaluation will be fertilized according to MS status either 5-6 hours after ovum pick-up (OPU) or 7-8 hours after OPU. MS evaluation will take place in pre-prepared glass-bottomed dishes. The MS status and the angle (α) between MS and PB will be obtained 3-4 hours after oocyte pick-up (OPU). At the same time, the polarized-light microscopy image will be acquired (polarized light microscopy at ×100 magnification. For oocytes with PB/MS in close proximity (angle between PB and MS \< 5◦) or MS not visible ICSI will be performed 4-5 h after the polarization microscopy evaluation, i.e., 7-8 h after OPU (these oocytes are supposed to be not fully mature). For oocytes with MS clearly visible and PB/MS not in close proximity (angle between PB and MS \> 5◦) ICSI will be performed typically 2-3 h after the polarization microscopy evaluation, i.e., 5-6 h after OPU.~ICSI will be performed according to standard protocol \[6\]."
62021962|NCT04855734|EXPERIMENTAL|FACE-Rare Intervention|"FACE-Rare is a behavioral intervention that combines the CSNAT Pediatric Approach and the Respecting Choices® Next Steps ACP over 3 sessions.~Sessions 1\&2: CSNAT is an evidence-based process of family caregiver assessment and support in specialized medical (palliative) care. The CSNAT tool is structured around 16 categories of family caregiver support. With the goal to decrease caregiver burden, this process consists of 5 stages wherein a nurse or practitioner works with the caregiver to create a shared support plan for the child.~Session 3: Respecting Choices® Next Steps- This advanced care planning (pACP) conversation engages families in a process for how to make future medical decisions consistent with their goals and values. The interview is structured in 6 stages to achieve 2 main goals: to facilitate conversations with the family about their child's medical condition, history, fears, values, beliefs, and hopes; and to set the stage for the family's future healthcare decisions."
62217508|NCT05811390|ACTIVE_COMPARATOR|Manual instrumentation|An ultrasonic handpiece will be used to debride the periodontal pockets of oral implants diagnosed with per-implantitis.
62411854|NCT05744635||Liver transplant patients, receiving tacrolimus containing immunosuppression|"1. Patients ≥ 18 years of age~2. Patients after liver- or simultaneous liver and kidney transplantation~3. Having received a tacrolimus containing immunosuppressant therapeutic regimen at least for four weeks (induction therapy), and TL is within 5-20 ng/ml before inclusion. Possible medications are the following (dosages and administration according to local (European) SmPC~   * Envarsus prolonged release tablet~  * Adport hard capsule~  * Advagraf prolonged-release hard capsule~  * Modigraf granule for oral suspension~  * Prograf hard capsule~  * Tacforius hard capsule"
62411855|NCT06651983||1.with complications 2.without complications|non-intervention
62411856|NCT02559778|ACTIVE_COMPARATOR|Standard Immunotherapy without DFMO|One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin. At the end of immunotherapy, DFMO will be given to all subjects BID for 730 days.
62793516|NCT02538042|OTHER|MCE- (Control)|Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
62793517|NCT05357222|EXPERIMENTAL|Straw Phonation|Participants will undergo one session of voice habilitation via a straw phonation exercise protocol. This protocol has been extensively studied and validated in the largest randomized clinical trial in voice therapy by our team.
62411857|NCT02559778|ACTIVE_COMPARATOR|Standard Immunotherapy with DFMO|One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin PLUS 1000mg/m2 BID of DFMO. At the end of immunotherapy, all subjects will go on to receive DFMO BID for 730 days.
62411858|NCT04625907|EXPERIMENTAL|Phase 1b Dose finding: VHR induction - IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . For the phase 1b registration, starting dose of 20 mg/m2.~Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
62411859|NCT04625907|ACTIVE_COMPARATOR|CT1A: VHR induction - IVADO|"Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on day 1 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1. Doxorubicin: 30 mg/m2 as an i.v infusion over 1 hour on days 1 and 2 on cycles 1-4"
62411860|NCT04625907|EXPERIMENTAL|CT1A: VHR Induction IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . Phase 2 recommended dose as determined by IRIVA dose finding arm Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
62793518|NCT06434181|EXPERIMENTAL|Beetroot Juice|Participants in this group are given 7 daily doses of a dietary nitrate supplement (Beet-it Sport beetroot juice shots, ) and asked to drink two doses daily during the week of their final academic examinations of that term in college.
62793519|NCT06434181|PLACEBO_COMPARATOR|Placebo Control|Participants in this group are given 7 daily doses of a placebo matched in appearance and taste (Beet-it Sport placebo juice shots) and asked to drink two doses daily during the week of their final academic examinations of that term in college.
62793520|NCT01377662|PLACEBO_COMPARATOR|Placebo|
62793521|NCT01377662|EXPERIMENTAL|OND-PR002 and MPh-IR|
62793522|NCT04090411|EXPERIMENTAL|Cohort 1|Induction - Placebo SC Q4W, (sub-cutaneous every 4 weeks) Chronic- PF-06480605 50 mg SC Q4W
62793523|NCT04090411|EXPERIMENTAL|Cohort 2|Induction - Placebo SC Q4W, Chronic- PF-06480605 150 mg SC Q4W
62021963|NCT04855734|NO_INTERVENTION|Treatment-as-Usual (TAU) Control|To minimize the burden to families, we have chosen a Treatment-as-Usual (TAU) comparison condition, where patients will receive their normal standard of care. Both study arms will receive palliative (specialized medical) care information at enrollment and complete questionnaires before and after the intervention or TAU period. Current practice for minors with life-limiting illnesses is to defer initial discussions of advanced care planning (pACP) until a medical crisis, so this is what the TAU control arm condition will consist of.
62021964|NCT02429063|EXPERIMENTAL|Bright White Light|Participants use the bright white light intervention for 30 minutes upon waking each morning for 60 days.
62021965|NCT02429063|EXPERIMENTAL|Dim Red Light|Participants use the dim red light intervention for 30 minutes upon waking each morning for 60 days.
62411861|NCT04625907|ACTIVE_COMPARATOR|CT1B: HR Induction IVA|"Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on day 1 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
62585878|NCT06667063||Cohort 2:Influenza virus infected persons|"Inclusion Criteria:~1. volunteers aged 18 years and above at the time of screening;~2. informed consent obtained from volunteers and volunteers/witnesses able to sign the informed consent form;~3. an interval of ≥3 months from the last COVID-19 or influenza vaccination;~4. an interval of ≥ 3 months from the last respiratory viral infection such as COVID-19 or Influenza virus occurs;~5. influenza virus antigen-positive and within 48 hours of onset of symptoms of infection;"
62585879|NCT06667063||Cohort 3:Healthy Volunteers|"Inclusion Criteria:~1. volunteers aged 18 years and above at the time of screening;~2. informed consent obtained from volunteers and volunteers/witnesses able to sign the informed consent form;~3. an interval of ≥3 months from the last COVID-19 or influenza vaccination;~4. an interval of ≥ 3 months from the last respiratory viral infection such as COVID-19 or Influenza virus occurs;~5. COVID-19 and influenza virus antigen-negative, no febrile symptoms, and no symptoms of viral or bacterial respiratory infections."
62793524|NCT04090411|EXPERIMENTAL|Cohort 3|Induction - Placebo SC Q4W, Chronic- PF-06480605 450 mg SC Q4W
62793525|NCT04090411|PLACEBO_COMPARATOR|Cohort 4|Induction- PF-06480605 50 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W
62793526|NCT04090411|EXPERIMENTAL|Cohort 5|Induction- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W
62793527|NCT04090411|EXPERIMENTAL|Cohort 6|Induction- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W
62793528|NCT04090411|EXPERIMENTAL|Cohort 7|Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W
62793529|NCT04090411|EXPERIMENTAL|Cohort 8|Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W
62021966|NCT01916018|OTHER|hypothyroid group|Clinical exams radiologic exams Blood sample
62021967|NCT04480645|EXPERIMENTAL|Treatment|Radioactive bandage applied to surface of the body worn for approximately one week.
62021968|NCT04695093||London (intervention)|1606 children aged 6-9 yrs old, recruited in 44 London primary schools (years 2-4) within the Central London ULEZ area
62021969|NCT04695093||Luton (comparison)|1706 children aged 6-9 yrs old, recruited in 41 Luton and Dunstable primary schools (years 2-4)
62433264|NCT06259929|EXPERIMENTAL|Patients with ER-positive, HER2-negative Early breast cancer|Abemaciclib 150 mg oral twice daily (BID) and giredestrant 30 mg oral once daily (OD) on Days 1-28.
62585880|NCT06571734|EXPERIMENTAL|Treatment (XL092)|Patients receive XL092 PO QD on days 1-14 of each cycle. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA at screening and then as clinically indicated, and blood sample collection on study and CT throughout the study.
62599955|NCT03384784|EXPERIMENTAL|Galantamine first|"This is a crossover study such that all participants receive both placebo and galantamine. Participants were randomized to receive galantamine first and placebo second. Timepoints Week 0 through Week 12 represent the first period and Weeks 16 through 28 represent the second period.~This study follows the FDA-recommended dosing regimen for galantamine extended release (GAL ER): 4 weeks at 8 mg (once a day), 4 weeks at 16 mg (once a day), and 4 weeks at 24 mg (once a day).~The University of Pennsylvania Investigational Drug Service (IDS) will oversee the randomization of all study medication, purchase study medication, manufacture matched placebo, encapsulate and package them in blister packs to maintain double-blind procedures."
62793530|NCT04090411|EXPERIMENTAL|Cohort 9|Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 450 mg SC Q4W
62793531|NCT01849406|ACTIVE_COMPARATOR|Nasal spray Budesonide|one week therapy of nasal budesonide (twice per day)
62793532|NCT01849406|PLACEBO_COMPARATOR|Nasal spray Normal Saline|one week therapy of nasal normal saline (twice per day)
62793533|NCT05671068||DYT-SGCE|Patients with myoclonus dystonia (DYT-SGCE)
62793534|NCT05671068||Healthy volunteers|Control group
62793535|NCT00080301|EXPERIMENTAL|A|
62793536|NCT00080301|ACTIVE_COMPARATOR|B|
62021970|NCT00819182|EXPERIMENTAL|Paced respiration|The paced respiration intervention group received a compact disc with paper booklet. The booklet reinforced instructions on the first audio track for how to accomplish a target breath rate of 6-8 breaths per minute, practice twice per day for 15 minutes, and apply the breathing at the onset of each hot flash. Women were instructed to do slow, deep, abdominal breathing in through the nose and out through the mouth as per international recommendations (4). They were also instructed to practice twice per day for 15 minutes as per the small, laboratory-based studies (5, 6). The second and third tracks contained specially composed, digitally recorded music to help entrain the breath rate and structure the length of practice.
62793537|NCT02291419|EXPERIMENTAL|ticagrelor|ticagrelor 90mg bid
62793538|NCT02291419|ACTIVE_COMPARATOR|aspirin|Patients in the aspirin arm will receive aspirin 81 mg daily orally
62819361|NCT05174247|EXPERIMENTAL|The intervention group (FFRct group)|The people in this group receive an FFRct analysis, which will be included in the treatment plan. If the FFRct analysis shows that there are there is no significant narrowing in your case, then in principle no invasive examination (heart catheterization) performed. If the analysis indicates a significant narrowing, then an invasive cardiac catheterization will usually be required are carried out. The final treatment plan will always be reviewed by your doctor tailored to your individual situation
62793539|NCT04975178|EXPERIMENTAL|MTBVAC|"Both MTBVAC and BCG vaccines are administered by intradermal route in the left deltoid region. One 0.05 mL reconstituted dose of MTBVAC will be defined based on the phase IIa results.~MTBVAC is manufactured by Biofabri. MTBVAC is formulated (1.5 - 8.5 x104 CFU/dose, 1.5 - 8.5 x105 CFU/dose or 1.5 - 8.5 x106 CFU/dose (to be selected) and presented as a lyophilised pellet in 20 dose vials (0.05 mL/dose, after reconstitution with sterile water for injection). MTBVAC vaccine will be released and distributed by BIOFABRI, and imported to the sites following approval by the local regulatory authority. MTBVAC vaccine must be stored at +2°C to +8°C. Reconstituted MTBVAC vaccine must be stored at +2ºC to +8ºC and administered as soon as possible, within 4 hours of reconstitution. A single vaccine vial will be used for each participant."
62021971|NCT00819182|SHAM_COMPARATOR|Sham comparator: Fast, shallow breathing|The sham comparator group received a digital videodisc with paper booklet. The booklet reinforced voice-over and video demonstration to practice twice per day and apply the fast shallow breathing at the onset of each flash. A previously published report provides additional details and data indicating this program was a suitable attention control.
62411862|NCT04625907|EXPERIMENTAL|CT1B: HR Induction IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . Phase 2 recommended dose as determined by IRIVA dose finding arm Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
62585881|NCT04063293|EXPERIMENTAL|PRP injection|PRP is prepared using a special device (VS-400, Genesis Comp, Korea). For each application a kit (e+ PRP, Genesis Comp, Korea) will be used. 18 cc of venous blood will be collected from the patient into the syringe with 2 cc of anticoagulant, and will be gently inverted. The sample will be slowly injected into the e+ PRP kit. The kit will be centrifuged under 1,500G for 4 minutes, which will separate the blood components into 3 different layers. The rot at the top of the kit will be pressed until the bottom of the piston will touch the red blood cell layer, and the rot will be turned clockwise to close it. The cap will be opened and the small syringe will be connected to the cap for extracting PRP. The injection will be performed in operation room under general anesthesia with either IV sedation of laryngeal mask airway (LMA) sedation. 10 cc of PRP will be directly injected in external muscles at 8 locations under the guidance of endoanal ultrasound
62585882|NCT06497894|EXPERIMENTAL|Cognitive Behavioral Therapy for insomnia (CBT-I)|Participants in this experimental arm will receive cognitive behavioral therapy specifically designed to treat insomnia (CBT-I). The therapy will be delivered over 8 weekly sessions, each lasting 60 minutes. The sessions will include techniques such as sleep restriction, stimulus control, cognitive restructuring, and relaxation training. The primary goal is to improve sleep quality and reduce the severity of insomnia.
62793540|NCT04975178|ACTIVE_COMPARATOR|BCG|"BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth.~One 0.05 mL reconstituted dose of BCG contains 2.5 x 105 CFU. The control vaccine will be the BCG vaccine available and recommended in South Africa at time of the trial.~BCG vaccine produced by AJ Biologics (formerly Staten Serum Institute) is the only BCG vaccine (Danish strain) currently licensed for routine use in South Africa. The recommended BCG injection volume for newborn infants (0.05 mL, after reconstitution with BCG diluent) contains approximately 2.5 x 105 CFU (range 1-4 x 105 CFU). BCG vaccine vials should be stored in the site pharmacy at 2-8ºC."
62819362|NCT05174247|NO_INTERVENTION|Standard treatment not using result of FFRct analyses|The people in this group receive the regular treatment. This is usually an invasive cardiac catheterization. The additional FFRct analysis is also included in this group, but it is not included in the treatment plan.
62411863|NCT04625907|EXPERIMENTAL|RT1A: Preoperative Radiotherapy|To be given either 41.4 Gy or 50.4 Gy prior to surgery
62819363|NCT05501236|EXPERIMENTAL|Muscle stimulation|Consented participants who meet eligibility will have a drug induced sleep endoscopy (DISE) and second sleep study and the Grass S88 (or comparable) muscle stimulator.
62819364|NCT00783159|EXPERIMENTAL|A|Training I
62021972|NCT00819182|NO_INTERVENTION|Control: Usual Care|The usual care group received an investigator-signed letter explaining they were not selected to receive any study materials during the 16-week follow-up. These participants received paced respiration materials by mail after study completion.
62411864|NCT04625907|ACTIVE_COMPARATOR|RT1A: Post operative radiotherapy|To be given either 41.4 Gy or 50.4 Gy following surgery
62411865|NCT04625907|EXPERIMENTAL|RT1B: Radiotherapy for resectable disease: dose escalated|To receive 50.4 Gy
62411866|NCT04625907|ACTIVE_COMPARATOR|RT1B: Radiotherapy for resectable disease: standard dose|To receive 41.4 Gy
62411867|NCT04625907|EXPERIMENTAL|RT1C: Radiotherapy for unresectable disease: dose escalated|To receive 59.4 Gy
62585883|NCT06497894|ACTIVE_COMPARATOR|Hormone Replacement Therapy (HRT)|Participants in this experimental arm will receive hormone replacement therapy, specifically a combination of estrogen and progesterone over the course of 8 weeks. The therapy aims to alleviate menopausal symptoms, including insomnia, by addressing hormonal imbalances.
62411868|NCT04625907|ACTIVE_COMPARATOR|RT1C: Radiotherapy for unresectable disease: standard dose|To receive 50.4 Gy
62411869|NCT04625907|EXPERIMENTAL|RT2: Radiotherapy to primary tumour and involved lymph nodes|Radiotherapy to the primary tumour and involved regional lymph nodes only
62411870|NCT04625907|EXPERIMENTAL|RT2: Radiotherapy to all metastatic sites|Radiotherapy given to all metastatic sites
62021973|NCT02759900|EXPERIMENTAL|Non-thermal atmospheric plasma treatment|Device treatment
62021974|NCT02759900|EXPERIMENTAL|Indirect non-thermal atmospheric plasma treatment|A compound of non-thermal atmospheric plasma and medium is used to treat the target by direct application or by on-site generation of the compound
62021975|NCT02073513|EXPERIMENTAL|kinesiotape plus thenar pressure (PPTG)|"In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied which controled the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.~The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions."
62021976|NCT02073513|EXPERIMENTAL|Taping Group (TG)|In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
62021977|NCT02073513|NO_INTERVENTION|Control Group (CG)|No application.
62021978|NCT03361813|ACTIVE_COMPARATOR|trans-cutaneous ultrasound guided peritonsillar infiltration|
62585884|NCT06497894|SHAM_COMPARATOR|Sleep Hygiene|Participants in this sham comparator arm will receive sleep hygiene instructions. Instructions will be delivered over 8 weekly sessions. The instructions will provide general information about healthy sleep habits, such as food and drink choices, a regular sleep schedule, evening routine, etc. Although being widely used in daily clinical practice, sleep hygiene shows no significant effect as monotherapy in patients with an established insomnia. The sleep hygiene condition in this study is matched to CBT-I in frequency and intensity of contact.
62217509|NCT05762289|EXPERIMENTAL|Change in range of motion and within the weight bearing group|. Subjects in Group A or treatment group were seated and given thrust manipulation using belt. Cervical spine was placed in neutral position and belt was stabilized on C4-C5 which is the part that causes most stiffness and pain and lost of range. Patient placed belt in left hand for left sided thrust and caudal force was applied , therapist held other end of the belt and applied stretch in the line of eye ball. The cervical spine of patient was guided in left rotation until resistance was felt and than thrust of high velocity low amplitude was given by therapist . This was done for both sides if the cavitation sound was not heard manipulation was tried for a second time after 10 minutes by repositioning the patient but no more than two times in a day. Therapist performing manipulation was skilled in giving belt thrust manipulation.
62217510|NCT05762289|ACTIVE_COMPARATOR|Control|While Group B received manipulation in supine position by maitland's traditional thrust. Where the neck is slightly flexed by therapist hand on the occipit where therapist is standing behind the head. Neck is guided in right side flexion and opposite rotation and at the end of rang high velocity low amplitude thrust is applied. This was done for both sides if the cavitation sound was not heard manipulation was tried for a second time after 10 minutes by repositioning the patient but no more than two times in a day
62793541|NCT02515734|ACTIVE_COMPARATOR|FOLFOXIRI+Bmab|Patients in the FOLFOXIRI + Bmab group receive until 12 cycles of FOLFOXIRI plus bevacizumab, consisting of a 30-minute infusion of bevacizumab at a dose of 5 mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and bevacizumab every 14 days until disease progression.
62585885|NCT06666985|EXPERIMENTAL|ITM + Usual Care|
62585886|NCT06666985|SHAM_COMPARATOR|Sham ITM + Usual Care|
62793542|NCT02515734|EXPERIMENTAL|FOLFOXIRI+Cmab|Patients in the experimental group received until 12 cycles of FOLFOXIRI plus cetuximab, consisting of a 30-minute infusion of cetuximab first time at a dose of 400 mg per kilogram, after the second time at a dose of 250mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and cetuximab every 14 days until disease progression.
62585887|NCT05743595|EXPERIMENTAL|Cohort A: Personalized neoantigen DNA vaccine + retifanlimab|"* Cohort A will receive the personalized neoantigen DNA vaccine via electroporation mediated IM injection alone during the first two priming doses, then concurrently with retifanlimab during the subsequent boosting doses (Doses 3 through 6)~* The personalized neoantigen DNA vaccine will be given once every 28 days for up to 6 doses. Retifanlimab is given at a fixed dose of 500 mg every 28 days.~* Patients may receive up to 6 doses of personalized neoantigen DNA vaccine and up to 12 months total of retifanlimab"
62793543|NCT04891523|OTHER|Placebo-Probiotic|First receive placebo, then active probiotics.
62793544|NCT04891523|OTHER|Probiotic-Placebo|First receive active probiotics, then placebo.
62793545|NCT06576050||Weight Loss Procedure|Each subject will undergo laparoscopic sleeve gastrectomy, as part of their clinical care. This is a single-arm study, in which the investigators collect data prior to the procedure, 3 months after the procedure, and 12 months after the procedure.
62793546|NCT01679223||<40 years|subjects aged less than 40 years
62793547|NCT01679223||40-60 years|subjects aged 40-60years
62793548|NCT01679223||> 60 years|subjects aged greater than 60 years
62793549|NCT06392334|OTHER|Biopsy|Biopsy of lung tissue will be done
62793550|NCT00328367|EXPERIMENTAL|A|clozapine plus aripiprazole
62793551|NCT00328367|PLACEBO_COMPARATOR|B|clozapine plus placebo
62793552|NCT01731366|PLACEBO_COMPARATOR|Refined grain|Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
62793553|NCT01731366|ACTIVE_COMPARATOR|Whole grain|Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
62793554|NCT05395325|EXPERIMENTAL|KT and steroid injection group|the patients will receive steroid injection for only one time before intervention, and receive KT for 5 days a week, for three weeks. And a 30-minute hand functional training would also be provided once daily every day during the intervention.
62793555|NCT05395325|SHAM_COMPARATOR|KT group|the patients will receive KT for 5 days a week, for three weeks. And a 30-minute hand functional training would also be provided once daily every day during the intervention.
62793556|NCT02919046|EXPERIMENTAL|single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days,the first day,the second day,29 days,30 days Duration:Total five times
62793557|NCT03372135||Trendelenburg group|Patients in trendelenburg group take trendelenburg position and have CO2 pneumoperitoneum. Cerebral oxygen monitor will be needed. Take notes per hour for HR, MAP, CVP, SpO2, SrO2 and etCO2.Preoperative and postoperative ABG, S-100beta , CRP and cognitive dysfunction scales will be tested.
62217511|NCT01843127|ACTIVE_COMPARATOR|Placebo, Ranolazine, Exenatide|
62217512|NCT01843127|ACTIVE_COMPARATOR|Ranolazine, Placebo, Exenatide|
62411871|NCT04625907|EXPERIMENTAL|CT2A: VHR Maintenance - VC|Vinorelbine: 25 mg/m2 i.v. or 60 mg/m2 orally on days 1,8 and 15 Cyclophosphamide 25 mg/m2 orally daily for 28 days
62585888|NCT05743595|EXPERIMENTAL|Cohort B: Personalized neoantigen DNA vaccine + retifanlimab|"* Cohort B will receive the personalized neoantigen DNA vaccine via electroporation mediated IM injection plus concurrent retifanlimab beginning with Dose 1 and continuing for a total of 6 doses.~* The personalized neoantigen DNA vaccine will be given once every 28 days for up to 6 doses. Retifanlimab is given at a fixed dose of 500 mg every 28 days.~* Patients may receive up to 6 doses of personalized neoantigen DNA vaccine and up to 12 months total of retifanlimab"
62585889|NCT00355147|EXPERIMENTAL|Arm 1 Secondary Risk Factor Management|Patient Secondary Stroke Risk Factor Program including Stroke Self Management and Stroke Peer Support and Physician Stroke Guideline Adherence
62793558|NCT03372135||Control group|Patients in control group take horizontal position. Cerebral oxygen monitor will be needed. Take notes per hour for HR, MAP, CVP, SpO2, SrO2 and etCO2.Preoperative and postoperative ABG, S-100beta , CRP and cognitive dysfunction scales will be tested
62793559|NCT04014985|OTHER|Girls with RETT syndrome|100 girls over 18 years old with RETT syndrome
62793560|NCT02255994|EXPERIMENTAL|UGYTEX|Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)
62793561|NCT02255994|ACTIVE_COMPARATOR|No MESH|Patients in this arm had subvesical plication without reinforcement.
62217513|NCT00928018|ACTIVE_COMPARATOR|Sirolimus-Containing Regimen|"The Sirolimus containing arm will consist of the following drugs:~Experimental Arm: tacrolimus + sirolimus + low-dose methotrexate~Tacrolimus: Administered orally at a dose of 0.05 mg/kg based on ABW bid starting on day -3.~Sirolimus:Given as a loading oral dose of 12 mg on day -3, then as a daily maintenance dose of 4 mg starting on day -2.~Methotrexate: Administered by intravenous bolus infusion, per institutional standard, at a dose of 5 mg/m2 on days +1, +3 and +6."
62585890|NCT00355147|PLACEBO_COMPARATOR|Attention Control Group|Received Phone Calls from Staff to Control for Attention
62217514|NCT00928018|ACTIVE_COMPARATOR|Sirolimus-Free regimen|"There are two choices for the Sirolimus free arm:~Control Arm 1: tacrolimus + methotrexate~Tacrolimus:Administered orally at a dose of 0.05 mg/kg based on ABW bid starting on day -3.~Methotrexate:Administered by intravenous bolus infusion at a dose of 5 mg/m2 on days +1, +3 and +6. For patients receiving stem cells from unrelated donors, an additional dose will be given on day +11.~Control Arm 2: cyclosporine + MMF~Cyclosporine: administered orally at a dose of 6 mg/kg based on ABW bid starting on day -3.~MMF:administered at a dose of 3gm daily orally (or intravenously if the patient cannot tolerate oral administration) divided in 2 or 3 doses (bid or tid) depending on physician preference starting on day 3."
62217515|NCT02708329|ACTIVE_COMPARATOR|CTO coronary angioplasty +T-provisional stenting|Coronary angioplasty using T-provisional stenting in patients with bifurcational lesion in Chronic total occlusion segment.
62411872|NCT04625907|NO_INTERVENTION|CT2A: Maintenance -Stop treatment|To stop treatment at the point of randomisation
62411873|NCT04625907|EXPERIMENTAL|CT2B: HR Maintenance - VC|Vinorelbine: 25 mg/m2 i.v. on days 1,8 and 15 Cyclophosphamide 25 mg/m2 orally daily for 28 days
62585891|NCT05799612|EXPERIMENTAL|Dose Escalation/Deescalation|Participants will receive up to 3 doses of the vaccine (each vaccine is given 2 weeks apart). The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen
62217516|NCT02708329|EXPERIMENTAL|CTO coronary angioplasty + Mini-crush stenting|Coronary angioplasty using Mini-crush stenting in patients with bifurcational lesion in Chronic total occlusion segment.
62217517|NCT03935321|ACTIVE_COMPARATOR|Patients with acute cervical spinal cord injury: NG-101|
62217518|NCT03935321|PLACEBO_COMPARATOR|Patients with acute cervical spinal cord injury: Placebo|
62411874|NCT04625907|NO_INTERVENTION|CT2B: HR Maintenance - Stop Treatment|To stop treatment at the point of randomisation
62411875|NCT04625907|ACTIVE_COMPARATOR|CT3: Relpased Chemotherapy - VIRT|Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg) on days 1 and 8 Irinotecan: 50 mg/m2 as an i.v. infusion over 1 hour on days 1-5 Temozolomide: 125 mg/m2 (Escalate to 150mg/m2/day in Cycle 2 if no toxicity \> grade 3) as an oral tablets prior to vincristine and irinotecan on days 1-5
62411876|NCT04625907|EXPERIMENTAL|CT3: Relapsed Chemotherapy - VIRR|Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg) on days 1 and 8 Irinotecan: 50 mg/m2 as an i.v. infusion over 1 hour on days 1-5 Regorafenib: Children between 6 and 24 months = 65 mg/m2, children less than 12 and/or less than 40kg dose = 82 mg/m2 Maximum 120 mg, Fixed dose of 120 mg for patients over 12 years of age AND ≥ 40 kg, as an oral tablets on days 8 to 21.
62411877|NCT02396238|EXPERIMENTAL|Adipose Derived Regenerative Cells|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs administered in 2 injections per digit on both hands.
62411878|NCT02396238|PLACEBO_COMPARATOR|Placebo|Sterile Lactated Ringers Solution mixed with small amount of study subject's own freshly drawn blood and administered in 2 injections per digit on both hands.
62411879|NCT05134545|EXPERIMENTAL|Genoss® DCB|Paclitaxel Coated PTA Balloon Catheter
62585892|NCT05171036|EXPERIMENTAL|Institutionalized elderly people undergoing adapted physical activity|2h/week for 3 months (i.e. 24 sessions), after 3 months of no-APA for gait and balance baseline recordings, with the rehabilitation team in place in the establishments, around the 4 specific programmes
62585893|NCT04446455|EXPERIMENTAL|Functional Power + Cognitive Training|Training sessions began with approximately 30 minutes of cognitive training using a desktop computer followed by 40 minutes of functional power training.
62585894|NCT04446455|ACTIVE_COMPARATOR|Functional Power Training|Training sessions began with 40 minutes of functional power training.
62793562|NCT02862873|EXPERIMENTAL|Ondansetron|
62793563|NCT02862873|PLACEBO_COMPARATOR|Saline solution|
62793564|NCT02722954|EXPERIMENTAL|Demcizumab and Pembrolizumab|Demcizumab will be administered prior to pembrolizumab
62793565|NCT01584310|ACTIVE_COMPARATOR|STAMP using|100 boys and girls aged 1 to 6, attending Clalit Health Care Services Pediatric Centers, will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
62793566|NCT01584310|PLACEBO_COMPARATOR|No STAMP using|150 files shall be reviewed in the beginning of the research and after 6 months in order to estimate the change in medical staff's attention to nutritional status, by way of noting relevant diagnoses, reference to nutritional status- related tests and recording of anthropometric measurements.
62217519|NCT03503461||Control group|Control group is a population of subjects admitted to day hospitalization for renal function tests or in conventional hospitalization, but without kidney transplant. Exosome analysis will be perform in urine sample.
62217520|NCT03503461||Kidney transplants group|Kidney transplants group is a kidney transplant subjects population 3 months ago. Exosome analysis will be perform in urine sample collected at 3 months.
62217521|NCT02096315|EXPERIMENTAL|POL7080|POL7080 administered daily
62217522|NCT04580446|EXPERIMENTAL|Hypofractionated radiotherapy with concurrent chemotherapy (weekly cisplatin 40 mg/m2)|"Level 0: 46.5 Gy in 15 fractions, 5 fractions/week~Level -1: 52 Gy in 20 fractions, 5 fractions/week"
62217523|NCT05101967|EXPERIMENTAL|Dynamic Cervical Implant|
62411880|NCT05134545|ACTIVE_COMPARATOR|IN.PACT Admiral® DCB|Paclitaxel Coated PTA Balloon Catheter
62411881|NCT04423315||patients with covid-19 pneumonia|patients with covid-19 pneumonia above 18 years old who were diagnosed by pcr testing and computed tomography of thorax
62411882|NCT02844088|EXPERIMENTAL|vaccinated group|evaluation of immunity's level against meningococcus C among people vaccinated in 2002 in Puy-de-Dôme
62411883|NCT02844088|OTHER|unvaccinate group|Duration of vaccinal immunity, compare vaccinal immunity to possible natural immunity among unvaccinated people
62411884|NCT02191969|NO_INTERVENTION|Control|This group will be receiving adjuvant chemotherapy for colorectal cancer. They will not participate in the Walk With Ease program. They will be followed up using standard of care.
62411885|NCT02191969|EXPERIMENTAL|Intervention|"This group will be receiving adjuvant chemotherapy for colorectal cancer. They will participate in the Walk With Ease (WWE) program during the course of their chemotherapy treatment. They will be requested to initiate the WWE starting on Day 1 of adjuvant chemotherapy. Participants are asked to walk at a safe and comfortable pace, increasing their minutes per day at a rate they can sustain, with the ultimate goal of 30 minutes/day for at least 5 days/week. They are asked to maintain a daily walking log that is provided to them, entering total minutes per day.~Participants will be asked to do the walking program independently (self-directed, not in a formal group with an instructor) throughout chemotherapy."
62411886|NCT05477940|EXPERIMENTAL|Absorbable zinc alloy drug eluting stent system|"1. Balloon pre dilation is required.~2. Inject nitroglycerin, perform angiography after stent implantation, and record the specification and model of the instrument.~3. After stent expansion, it should reach 100% - 110% of the vessel diameter, and the visual residual stenosis should be less than 20%."
62411887|NCT05774782|EXPERIMENTAL|Cerebral flow diverter|The cerebral flow diverter in the endovascular treatment of wide-necked cerebral aneurysms
62793567|NCT03343834|OTHER|EBV+ allograft population|"Retrospective study (n=80) : Patient who underwent HSCT, in Saint-Antoine hospital, between 2010-2015, treated by rituximab for high level EBV-DNAemia (above 3.3 log copies/mL).~Prospective study (n=58) : Patients who underwent HSCT, in Saint-Antoine hospital and la Pitié-Salpêtrière, in 2016-2017, treated by rituximab for high level EBV-DNAemia (above 10 000c/mL), And/or having post-transplant lymphoproliferative diseases(PTLD) Concerned population Allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients with a high Epstein-Barr virus (EBV) viral load"
62793568|NCT05137028|EXPERIMENTAL|Otago Exercise|Otago Exercise Group
62217524|NCT05101967|ACTIVE_COMPARATOR|Anterior Cervical Discectomt and Fusion|
62217525|NCT03469531|EXPERIMENTAL|experimental group|Patients receive nimotuzumab combined with cisplatin and undergo external-beam radiation and brachytherapy as the patients in experimental group.
62585895|NCT06664385|ACTIVE_COMPARATOR|concurrent physical exercise|It consists of an exercise method that combines strength and endurance. It has a duration of 6 weeks divided into three stages, adaptation, development and maintenance. That for the intervention group and for the control group will only be performing aerobic physical exercise according to their physical tolerance.
62819365|NCT00783159|EXPERIMENTAL|B|Training II
62819366|NCT00783159|ACTIVE_COMPARATOR|C|Control
62217526|NCT03469531|ACTIVE_COMPARATOR|control group|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as the patients in control group.
62217527|NCT03611413||ERAS programme|Patients who have been treated under an ERAS programm
62217528|NCT03611413||conventional care|Patients who have been treated under an conventional care
62217529|NCT05429905|EXPERIMENTAL|Cohort 1 (Dose-escalation)|Dose-finding and dose expansion cohort for intravenous autologous anti-CD22/CD19 CAR-T using a relapsed refractory B-ALL cohort.
62217530|NCT05429905|EXPERIMENTAL|Cohort 2 (High MRD)|Patients with B-ALL with high MRD after induction therapy or after consolidation therapy in replacement of stem cell transplant
62217531|NCT05429905|EXPERIMENTAL|Cohort 3 (Extramedullary ALL)|Patients with testicular or central nervous system B-ALL in replacement of radiation
62217532|NCT06445673||TripleTRE NIS patients|all patients previously treated within the TripleTRE trial who are willing to participate in this NIS
62217533|NCT02618642|ACTIVE_COMPARATOR|Piler light + red filter|Group x: irradiation with a red filter (visible red radiation and infrared; 650-800 nm and 800-3900 nm, respectively) time of phototherapy treatment: 10 minutes for one session 10 irradiations to the biceps brachii muscle
62217534|NCT02618642|ACTIVE_COMPARATOR|Piler light + blue filter|Group y: irradiation with a blue filter (blue radiation; 440-480 nm) time of phototherapy treatment: 10 minutes for one session 10 irradiations to the biceps brachii muscle
62411888|NCT02831686|EXPERIMENTAL|Selinexor (KPT-330), Ixazomib, and Dexamethasone|"Patients with relapsed and/or refractory MM will be treated with ixazomib, selinexor, and dexamethasone, all of which will be administered orally.Ixazomib will be given on Days 1, 8, and 15 on a 28 day cycle.~Selinexor will be given twice weekly for three weeks, then there will be 1 week off (Days 1,3, 8,10, 15, 17) This study will follow a 3-by-3 dose escalation design.~Dexamethasone will be given on all days of Selinexor but will also be given on the week off from Selinexor (Days 1, 3, 8, 10,15, 17, 22, 24)."
62217535|NCT02618642|ACTIVE_COMPARATOR|Piler light without a filter|Group v: irradiation without a filter (white radiation in the entire spectrum and near-infrared radiation; 480-3400 nm) one session lasted 10 minutes 10 irradiations to the biceps brachii muscle
62217536|NCT02618642|PLACEBO_COMPARATOR|placebo|Group z: placebo irradiation (without a filter, 3 min, distance: 100 cm). time of phototherapy treatment: 3 minutes for one session distance of 1meter 10 irradiations to the biceps brachii muscle
62585896|NCT01094301|EXPERIMENTAL|The SPR System|The SPR System is an investigational two-staged device which delivers stimulation to the shoulder. Subjects with chronic post-stroke shoulder pain who meet eligibility criteria for the first stage (SPR Trial Stage) will receive a temporary Lead and External Stimulator. Subjects who qualify and who agreed to proceed will advance to the second stage (SPR Implant Stage) which uses an Implantable Pulse Generator (IPG) and Implantable Lead. Subjects will be followed until 36-months after IPG stimulation has been started.
62585897|NCT02778685|EXPERIMENTAL|Cohort 3 (letrozole, palbociclib, fulvestrant, pembrolizumab)|Patients receive either letrozole PO QD on days -28 to -1 and days 1-28, or fulvestrant on days -28, -14, and day 1 of subsequent cycles. Patients also receive palbociclib PO QD for 3 weeks. Cycles with palbociclib, and letrozole or fulvestrant repeat every 28 days in the absence disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles with pembrolizumab repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62585898|NCT02778685|EXPERIMENTAL|Cohorts 1 and 2 (letrozole, palbociclib, pembrolizumab)|Patients receive letrozole PO QD on days 1-28 and palbociclib PO QD for 3 weeks. Cycles with letrozole and palbociclib repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles with pembrolizumab repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62585899|NCT02129413|EXPERIMENTAL|Delta system treatment|
62585900|NCT06033807||Contacts|School contacts of ATB patients
62585901|NCT04176315|ACTIVE_COMPARATOR|Conventional Rehabilitation Group|Participants follow the usual exercise plan designed at Presidio San Camillo for Total Hip Arthroplasty autonomously
62585902|NCT04176315|EXPERIMENTAL|ReHub Group|Participants follow the usual exercise plan designed at Presidio San Camillo for Total Hip Arthroplasty but use the telerehabilitation platform ReHub to do the exercises at home and to have their progress monitored.
62585903|NCT04375072|EXPERIMENTAL|active tDCS paired with active MBM,|
62585904|NCT04375072|ACTIVE_COMPARATOR|sham tDCS paired with active MBM|
62411889|NCT03653637|EXPERIMENTAL|Project Life Force|"A novel, 10-session intervention to enhance currently mandated VA suicide safety planning in a group setting to support its implementation. PLF is a manualized, weekly 90-minute group treatment lasting 10 weeks coinciding with the time frame for enhanced monitoring of Veterans identified as high-risk. Session content is described in Table 1 (see appendix A). Six of the PLF sessions correspond to a step of the safety plan and teach skills to maximize the use of that particular step of the plan. The use of emotion regulation skills in PLF differs from other DBT interventions in that it focuses primarily on emotion regulation, distraction and developing social support in the specific context of implementing a safety plan. Mindfulness is not covered. PLF is augmented with additional skill modules on physical health management, education pertaining to suicide risk, promoting positive emotion and suicide prevention mobile apps. PLF patients also receive usual care."
62585905|NCT04375072|ACTIVE_COMPARATOR|active tDCS paired with sham MBM|
62585906|NCT04375072|SHAM_COMPARATOR|sham tDCS paired with sham MBM|
62585907|NCT06194370|EXPERIMENTAL|BOPPPS Teaching Model Group|BOPPPS: Bridge-in,Objective,Pre-assessment,Participatory learning,Post-assessment,Summary
62585908|NCT06194370|PLACEBO_COMPARATOR|Regular Teaching Group|
62585909|NCT05423535|ACTIVE_COMPARATOR|Control group: Collagen Matrix|collagen matrix: Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland
62217537|NCT06268548|EXPERIMENTAL|Study|Experimental , diaphragmatic activation with medical treatment ,15patients with gastroesophageal reflux disease do manual diaphragmatic activation in additional to traditional medical treatment
62217538|NCT06268548|NO_INTERVENTION|Control|30 patients with gastroesophageal reflux disease taking traditional medical treatment only
62217539|NCT02704793|EXPERIMENTAL|Bilateral 1 Hz Cerebellar rTMS|Patients will be treated with 900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere for 5 consecutive days.
62217540|NCT02704793|SHAM_COMPARATOR|Sham (electrical stimulation)|Sham treatment will be performed with the same protocol using a small device placed on the TMS coil (not visible to the patients) producing electrical stimulation (less than 3 mili amperes), to simulate the sensation of real TMS.
62217541|NCT02960750|EXPERIMENTAL|Intervention group|Had access to the W@WS website program during 19 weeks.
62217542|NCT02960750|ACTIVE_COMPARATOR|Active comparison group|Maintained habitual behavior.
62217543|NCT00700427|EXPERIMENTAL|Atomoxetine|Atomoxetine 40-100 milligrams per day (mg/day) orally, once daily or twice daily for 24 weeks, followed by atomoxetine 80-100 mg/day orally, once daily or twice daily for 25 weeks.
62217544|NCT00700427|PLACEBO_COMPARATOR|Placebo|Atomoxetine 40-100 mg/day orally, once daily or twice daily for 24 weeks, followed by placebo orally, once daily for 25 weeks.
62217545|NCT02333305|EXPERIMENTAL|1|Coenzyme Q10 (CoQ10) - is a Dietary complement that contains Coenzyme Q10 (Ubidecarenone) well characterized nano particles.
62585910|NCT05423535|EXPERIMENTAL|Test group: Hemostatic Gelatin Sponge|Hemostatic gelatin spons: Spongostan Dental® 1x1x1 cm, Ethicon, Johnson \& Johnson, New Brunswick, VS
62585911|NCT04150211|ACTIVE_COMPARATOR|Exten(d)|Subjects have to take Exten(d) capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks.
62585912|NCT04150211|PLACEBO_COMPARATOR|Placebo|Subjects have to take Placebo capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks.
62217546|NCT02333305|PLACEBO_COMPARATOR|2|Placebo of CoQ10 is a translucent nano-emulsion of well characterized nano particles. Lecithin (and) Alcohol (and) Glycerin (and) Aqua
62217547|NCT02575001||Type 1 diabetes|"Children with Type 1 diabetes, age from 8 to 15 years.~The following interventions/exposures will be administered:~Behavioral: Psychological background determinations, Genetic: Genetic susceptibility determination, Procedure/Surgery: Cortisol release test, Procedure/Surgery: Saliva cortisol measurement."
62217548|NCT02575001||Healthy control|"Healthy primary school pupils, age from 8 to 15 years.~The following interventions/exposures will be administered:~Behavioral: Psychological background determinations, Genetic: Genetic susceptibility determination, Procedure/Surgery: Saliva cortisol measurement."
62217549|NCT04830423|ACTIVE_COMPARATOR|medikal ozone group|medical ozone group patients diagnosed with knee ostheoarthritis
62217550|NCT04830423|OTHER|steroid group|steroid group patients diagnosed with knee ostheoarthritis
62411890|NCT03653637|ACTIVE_COMPARATOR|Treatment-As-Usual|The comparison condition will be an assessment-only treatment-as-usual (TAU). Research team will track number of individual mental health appointments, SPC outreach contacts, and usage patterns of safety plans. Veterans in both randomized conditions will be receiving the mandated monitoring, outreach, and involvement of SPC staff and clinical team management that constitutes standard VA care for suicidal individuals.
62411891|NCT04662424|EXPERIMENTAL|MUSIC|music in labor
62411892|NCT04662424|NO_INTERVENTION|control|no music during labor
62217551|NCT04719975|EXPERIMENTAL|Mental Fatigue (Stroop) - Chair task|Participants will be performing the Chair Task (150 submaximal dynamic knee extensions at 50% of their maximal voluntary contraction (MVC)) when mentally fatigued. A 60 minute variant of the Stroop task will be used to induce the mental fatigue. During the whole trial EEG will be measured.
62217552|NCT04719975|PLACEBO_COMPARATOR|Control Task (Documentary) - Chair Task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content. This will be followed by the Chair Task, During the whole trial EEG will be measured.
62411893|NCT05570058|EXPERIMENTAL|Cohort 1|12:4 (RXC007 : Placebo) Dose level 1: 12 weeks (84 days) dosing
62411894|NCT05570058|EXPERIMENTAL|Cohort 2|12:4 (RXC007 : Placebo) Dose level 2: 12 weeks (84 days) dosing
62411895|NCT05570058|EXPERIMENTAL|Expansion Cohort|12:4 (RXC007 : Placebo) Dose level 3: 12 weeks (84 days) dosing
62585913|NCT04594369|EXPERIMENTAL|Brensocatib 10 mg|Participants will receive brensocatib 10 mg, tablets orally, once daily, for 52 weeks.
62585914|NCT04594369|EXPERIMENTAL|Brensocatib 25 mg|Participants will receive brensocatib 25 mg, tablets orally, once daily, for 52 weeks.
62217553|NCT04719975|EXPERIMENTAL|Mental Fatigue (Stroop) - Bike Task|Participants will be performing the Bike Task (a 9 min cycling task performed at 45 rpm with intensity being constant and will be 10% below VT) when mentally fatigued. A 60 minute variant of the Stroop task will be used to induce the mental fatigue. During the whole trial EEG will be measured.
62411896|NCT05419687|EXPERIMENTAL|Arm 1 De-escalating violence training|The de-escalating violence training intervention will be introduced after a pre-interventional period of 3 months. A refreshment training will be introduced at month 11.
62585915|NCT04594369|PLACEBO_COMPARATOR|Placebo|Participants will receive a brensocatib-matching placebo, tablets orally, once daily, for 52 weeks.
62585916|NCT01925131|EXPERIMENTAL|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 1|Combination chemotherapy and inotuzumab ozogamicin - Dose level 1 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and 0.4 mg/m2 inotuzumab ozogamicin IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62793569|NCT05484011|EXPERIMENTAL|Part A|Patients will have regularly scheduled study visits on days 1, 8, and 15 of each cycle. On Day 1 patients will receive odetiglucan and CDX-1140. On Days 8 \& 15 only odetiglucan. Additional study visits may be required during some cycles for safety, efficacy, and translational assessments. Patients will dose to confirmed progression, a safety event or other administrative reason requiring discontinuation; all patients are allowed to dose up to 2 years (patients continuing to derive benefit may stay on treatment longer following consultation between Investigator and Sponsor). Following discontinuation patients will be followed up to 1 year.
62793570|NCT05484011|EXPERIMENTAL|Part B|Patients will have regularly scheduled study visits on day 1 of each cycle. On Day 1 patients will receive odetiglucan and CDA-1140. Additional study visits may be required during some cycles for safety, efficacy, and translational assessments. Patients will dose to confirmed progression, a safety event or other administrative reason requiring discontinuation; all patients are allowed to dose up to 2 years (patients continuing to derive benefit may stay on treatment longer following consultation between Investigator and Sponsor). Following discontinuation patients will be followed up to 1 year.
62793571|NCT02682732|EXPERIMENTAL|FDG-PET/CT|(Fluorodeoxyglucose positron-emission tomography) FDG-PET/CT guided bone marrow sampling will be performed at diagnosis and at the end of induction chemotherapy (like cytarabine and daunorubicin). Then, patients will be followed to assess their response, and imaging-guided bone marrow sampling will be repeated in the likely event of disease relapse.
62217554|NCT04719975|PLACEBO_COMPARATOR|Control task (Documentary) - Bike Task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content. This will be followed by the Bike Task, During the whole trial EEG will be measured.
62217555|NCT06115629|EXPERIMENTAL|Imaging surveillance|Computed tomography scan every 6 months for 3 years postoperatively. Upper gastrointestinal endoscopy at 12 months postoperatively.
62411897|NCT05419687|EXPERIMENTAL|Arm 2 De-escalating violence training|The de-escalating violence training intervention will be introduced before the second observation period at month 11. A refreshment training will be introduced at month 18.
62217556|NCT06115629|NO_INTERVENTION|Clinical surveillance|Clinical review every 6 months for 3 years postoperatively with further investigation according to symptoms.
62217557|NCT04114864|EXPERIMENTAL|Experimental|This arm will be receiving the 7 ME-WE sessions psycho-educational intervention. The experimental group will involve a blended approach with 'face to face' meetings in three European partner countries and online sessions (via a ME-WE mobile app) and a purely 'f2f' approach in a further three European partner countries.
62217558|NCT04114864|PLACEBO_COMPARATOR|Control|The control-group will be a wait-list, receiving relaxation exercises during waiting.
62217559|NCT01375088|PLACEBO_COMPARATOR|placebo mouth wash|10 patients swish \& swallow 15 ml placebo mouth wash for at least 5 min from the first session of radiotherapy until the last session
62411898|NCT05419687|EXPERIMENTAL|Arm 3 De-escalating violence training|The de-escalating violence training intervention will be introduced before the third observation period at month 18.
62585917|NCT01925131|EXPERIMENTAL|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 2|Combination chemotherapy and inotuzumab ozogamicin - Dose level 2 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.6 mg/m2 on day 1 and 0.4 mg/m2 on day 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62793572|NCT03553524|EXPERIMENTAL|Morning first|"Both arms of the study will perform the baseline measurements during visit 1. Arm 1 of the study will perform HIIT at 08:30 during visit 2, and after a 1-week washout period will perform HIIT at 19:30 during visit 3.~HIIT bout will consist of 3 minutes of warm-up followed by 6 1-minute intervals of full exertion cycling on a cycle ergometer, interspersed by a 1-minute recovery periods and ending with a 3-minute cooldown."
62021979|NCT03361813|PLACEBO_COMPARATOR|trans-oral ultrasound guided peritonsillar infiltration|
62021980|NCT00726531|EXPERIMENTAL|OEP|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
62021981|NCT00726531|EXPERIMENTAL|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
62021982|NCT00726531|NO_INTERVENTION|TAU|Treatment as usual
62411899|NCT05419687|EXPERIMENTAL|Arm 4 De-escalating violence training + Code of conduct|The de-escalating violence training intervention will be introduced after a pre-interventional period of 3 months. The code of conduct via a warning board will be introduced at month 11. A refreshment training will be introduced at month 18.
62021983|NCT01799174|ACTIVE_COMPARATOR|UVA-1 Phototherapy|Receive medium dose UVA-1 (70 J/cm2) 3x/week for 10 weeks
62021984|NCT01799174|SHAM_COMPARATOR|Placebo|"Receive sham UVA1 phototherapy (0 J/cm2) 3x/week for 10 weeks"
62021985|NCT02099006|EXPERIMENTAL|Medications|Each study subject will be sequentially exposed to each of the study drugs and the placebo in a random order. The study is designed as a double blinded, crossover study.
62021986|NCT02099006|PLACEBO_COMPARATOR|Placebo|The compounding base alone will be used as a placebo. Each participant will be given each drug and the placebo sequentially in random order.
62021987|NCT06636292|ACTIVE_COMPARATOR|Patients having sedated TNE or any oesophagogastroduodenoscopy (OGD)|Patients who are only recruited to Stage 1 of study to experience VRDD pre-endoscopy.
62411900|NCT05419687|EXPERIMENTAL|Arm 5 De-escalating violence training + Code of conduct|The de-escalating violence training intervention and the code of conduct via a warning board will be simultaneously introduced at month 11. A refreshment training will be introduced at month 18.
62411901|NCT05419687|EXPERIMENTAL|Arm 6 Code of conduct + De-escalating violence training|The code of conduct via a warning board will be introduced at month 11. The de-escalating violence training intervention will be introduced at month 18.
62021988|NCT06636292|ACTIVE_COMPARATOR|Patients having unsedated TNE|Patients who are recruited to both Stages 1 and 2 of study to experience VRDD pre-endoscopy and during endoscopy.
62217560|NCT01375088|ACTIVE_COMPARATOR|propolis|10 patients swish \& swallow 15 ml propolis mouth wash for at least 5 min from the first session of radiotherapy until the last session
62217561|NCT00952120|EXPERIMENTAL|GSUC|Gauze-based wall suction negative pressure wound therapy for 4-5 days
62217562|NCT00952120|ACTIVE_COMPARATOR|Vacuum-assisted closure|Vacuum-assisted closure (VAC) negative pressure wound therapy using commercially available device (KCI, Inc) for 4-5 days
62217563|NCT06032832|EXPERIMENTAL|Soy protein concentrate meat analog|Meat analog made from soy protein concentrate contains 57Fe as ferrous sulfate. All participants will consume this test meal.
62217564|NCT06032832|EXPERIMENTAL|Soy protein concentrate meat analog without phytic acid|Meat analog made from soy protein concentrate that was removed phytic acid (dephytinization) contains 58Fe as ferrous sulfate. All participants will consume this test meal.
62217565|NCT06032832|EXPERIMENTAL|Farinata_chickpea flour|Farinata (thin pancake) made from chickpea flour contains 57Fe as ferrous sulfate. All participants will consume this test meal.
62217566|NCT06032832|EXPERIMENTAL|Farinata_chickpea flour without phytic acid|Farinata (thin pancake) made from chickpea flour that was removed phytic acid (dephytinization) contains 58Fe as ferrous sulfate. All participants will consume this test meal.
62217567|NCT03026699||Intervention - Primary Brain Tumor|eSNAP Intervention Plus Questionnaires: Family caregivers of primary brain tumor patients.
62217568|NCT03026699||Intervention - Secondary Brain Tumor|eSNAP Intervention Plus Questionnaires: Family caregivers of secondary brain tumor patients.
62217569|NCT03026699||Control - Primary Brain Tumor|Questionnaires Only Control: Family caregivers of primary brain tumor patients.
62021989|NCT02577705|EXPERIMENTAL|Self Empowerment Groups|Intervention activities included helping participants to open savings accounts at a local federal credit union with 1:1 matches of up to twenty dollars per month for 12 months. Participants also received financial empowerment and Peer Support curriculum, weekly for about 3 hours per week for 28 weeks.
62217570|NCT03026699||Control - Secondary Brain Tumor|Questionnaires Only Control: Family caregivers of secondary brain tumor patients.
62411902|NCT05419687|EXPERIMENTAL|Arm 7 De-escalating violence training + Code of conduct|The de-escalating violence training intervention is introduced after a pre-interventional period of 3 months. The code of conduct via a warning board and a refreshment training will be simultaneously introduced at month 18.
62411903|NCT05419687|EXPERIMENTAL|Arm 8 De-escalating violence training + Code of conduct|The de-escalating violence training intervention will be introduced before the second observation period at month 11. The code of conduct via a warning board and a refreshment training will be simultaneously introduced at month 18.
62585918|NCT01925131|EXPERIMENTAL|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 3|Combination chemotherapy and inotuzumab ozogamicin - Dose level 3 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.8 mg/m2 on day 1 and 0.4 mg/m2 on day 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62217571|NCT06135428|EXPERIMENTAL|Experimental|"Training content was prepared in three stages according to the resilience model in midwives. The training will be in the form of 45-minute presentations and sharings, and individual studies will be carried out in the form of homework according to people's methods of coping with stress. These homework assignments may occasionally include more or less individual meetings depending on the person's coping situation. However, at least 3 meetings will be held. Training and interviews will be conducted by researchers. For this, at least one of the researchers will receive training including personal awareness and motivational interviews."
62217572|NCT06135428|NO_INTERVENTION|Control|No intervention
62793573|NCT03553524|EXPERIMENTAL|Afternoon first|"Both arms of the study will perform the baseline measurements during visit 1. Arm 2 of the study will perform HIIT at 19:30 during visit 2, and after a 1-week washout period will perform HIIT at 08:30 during visit 3.~HIIT bout will consist of 3 minutes of warm-up followed by 6 1-minute intervals of full exertion cycling on a cycle ergometer, interspersed by a 1-minute recovery periods and ending with a 3-minute cooldown."
62793574|NCT04571502|EXPERIMENTAL|Full Intervention|Dyads (caregiver, PWD) randomly assigned to the experimental arm will have access to the newly developed My PATI app. Providers' will receive information via the app.
62217573|NCT03212300|ACTIVE_COMPARATOR|Aerobic Exercise Training (AET)|20 sessions of AET over a 4 week period just prior to surgery
62217574|NCT03212300|NO_INTERVENTION|treatment as usual|standard treatment
62217575|NCT02139761|ACTIVE_COMPARATOR|l-tetrahydropalmatine (l-THP)|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
62217576|NCT02139761|PLACEBO_COMPARATOR|Placebo|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
62793575|NCT04571502|NO_INTERVENTION|Usual Care|Dyads (caregiver, PWD) randomly assigned to the usual care condition will receive usual care from the memory clinic.
62793576|NCT06334887|EXPERIMENTAL|Use of esTOCma|Experimental group will use esTOCma until they finish it (within a preestablished 10-days period).
62217577|NCT01812434|EXPERIMENTAL|Sildenafil|Patients will be randomized to sildenafil arm taken three times a day for 28 days and then crossed over to the alternate arm.
62217578|NCT01812434|EXPERIMENTAL|Placebo|Subject randomized to either Sildenafil or placebo arm
62411904|NCT05419687|EXPERIMENTAL|Arm 9 De-escalating violence training + Code of conduct|The code of conduct via a warning board and the violence de-escalating training will be simultaneously introduced at month 18.
62411905|NCT05419687|EXPERIMENTAL|Arm 10 Code of conduct|The code of conduct via a warning board will be introduced at month 11.
62411906|NCT05419687|EXPERIMENTAL|Arm 11 Code of conduct|The code of conduct via a warning board will be introduced at month 18.
62411907|NCT03254407|OTHER|Screening medical record|Screening medical record for possible IV-PO switch Possbile IV/PO switch communicated to prescriber by phone or e-note
62793577|NCT06334887|NO_INTERVENTION|Control group|Control group will do nothing for 10 days.
62793578|NCT04977401|SHAM_COMPARATOR|Group Glycerol|Submucosal injection using glycerol during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.
62793579|NCT04977401|ACTIVE_COMPARATOR|Group Gel ORISE|Submucosal injection using ORISETM gel during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.
62793580|NCT01387841|EXPERIMENTAL|Yoga group|Yoga intervention with standard antiemetic care
62793581|NCT01387841|ACTIVE_COMPARATOR|PMRT/Jacobsons Relaxation training|25 minutes of progressive muscle relaxation training will be given to this group with standard antiemetic care
62793582|NCT01387841|NO_INTERVENTION|Standard antiemetic care|Standard antiemetic care only
62217579|NCT05076084||Patients aged 0 to 18 years followed for Vernal keratoconjunctivitis|Treated (or having been treated) with tacrolimus 0.1% ophthalmic solution previously treated with ciclosporin 2% ophthalmic solution with treatment failure.
62411908|NCT01232387||Fetomaternal hemorrhage - Mothers|Mothers in Mother-baby pairs in which the testing for fetomaternal hemorrhage on the mother's blood demonstrates the presence of fetal cells.
62411909|NCT01232387||Fetomaternal hemorrhage - Babies|Babies in Mother-baby pairs in which the testing for fetomaternal hemorrhage on the mother's blood demonstrates the presence of fetal cells.
62411910|NCT05604209|EXPERIMENTAL|C62|C62 administered at Day 0 and M4 on Day 28
62411911|NCT05604209|EXPERIMENTAL|C1C62|C1C62 administered at Day 0 and M3M4 on Day 28
62021990|NCT02577705|EXPERIMENTAL|Financial Empowerment|Intervention activities included helping participants to open savings accounts at a local federal credit union with 1:1 matches of up to twenty dollars per month for 12 months. Participants also received financial empowerment weekly for about 3 hours per week for 28 weeks.
62217580|NCT03301896|EXPERIMENTAL|LHC165 single agent|LHC165 intratumoral injection given alone
62411912|NCT05604209|PLACEBO_COMPARATOR|Placebo|Placebo administered on Day 0 and Day 28
62411913|NCT04365127|EXPERIMENTAL|Progesterone plus SOC|Progesterone 100 mg will be administered subcutaneously twice daily for 5 days in addition to institutional standard of care
62411914|NCT04365127|NO_INTERVENTION|SOC only|Subjects will receive institutional standard of care only
62411915|NCT06701526|EXPERIMENTAL|Eptinezumab|Participants will receive eptinezumab at Baseline (Day 1) and Week 12
62411916|NCT06253520|EXPERIMENTAL|1/ KRAS TCR + vaccine|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + KRAS TCR-Transduced PBL + high-dose aldesleukin + vaccine (Day 0, weeks 4 and 8 and at week 12 (if no progression)
62585919|NCT01925131|EXPERIMENTAL|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 4|Combination chemotherapy and inotuzumab ozogamicin - Dose level 4 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.8 mg/m2 on day 1 and 0.4 mg/m2 on days 8 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62217581|NCT03301896|EXPERIMENTAL|LHC165 in combination with PDR001|LHC165 intratumoral injection given with PDR001 infusion
62217582|NCT04585854|OTHER|Control|Control population who will undergo two cardiovascular magnetic resonance exams: one at rest and one after drinking caffeine.
62217583|NCT05152420|EXPERIMENTAL|Part 1 - Cohort 1|Single dose cohort
62217584|NCT05152420|EXPERIMENTAL|Part 1 - Cohort 2|Single dose cohort
62217585|NCT05152420|EXPERIMENTAL|Part 1 - Cohort 3|Single dose cohort
62793583|NCT04359160|EXPERIMENTAL|Mobile-app follow-up|The mobile app follow-up group will receive an email, to connect into a secure website. They will answer to periodical questions about their condition. They will have a medical appointment at 6 weeks postoperative and 12 weeks postoperative. All of this information is submitted via the mobile application (Orthense, Digikare Inc. Blagnac, France).The surgeon will have an access to the answer of the patient in real time, and if the patient didn't answer.
62819367|NCT05945121|EXPERIMENTAL|Cardio-oncology program|The cardio-oncology program consists of a multimodal approach, which includes individualized exercise prescription following a detailed CV assessment and medical management of CV risk factors occurring over 8 weeks.
62411917|NCT05490160||Tranexamic acid group|During the total knee arthroplasty, the patients received a 2-g retrograde injection of tranexamic acid through the drain after closure, with subsequent clamping of the drain for 6 hours.
62411918|NCT05490160||Non-tranexamic acid group|During the total knee arthroplasty, the patients did not receive tranexamic acid administration.
62411919|NCT02712736|OTHER|Survey respondents|The patients who consent to participate will be sent home from the clinic with a survey to complete and return via mail in a provided addressed, stamped envelope. The survey consists of the Short Form-36 (SF-36), the Chronic Liver Disease Questionnaire (CLDQ), questions from the PROMIS SexFs v2.0, questions regarding perceived risk for liver transplant, cholangiocarcinoma, and colorectal carcinoma, as well as perceived overall life expectancy, and questions regarding complementary and alternative medicine use.
62411920|NCT00238108|EXPERIMENTAL|1|Melatonin (2,5 mg, by mouth, 1 per day, for 3-4 weeks)
62411921|NCT00238108|PLACEBO_COMPARATOR|2|Placebo
62411922|NCT01199510|EXPERIMENTAL|Standard of Care plus FID 112903|SYSTANE® ULTRA Lubricant Eye Drops dosed 4 times daily
62411923|NCT01199510|ACTIVE_COMPARATOR|Standard of Care only|Post Cataract Standard of Care Regimen
62411924|NCT02085798||Group 1|Low or intermediate-1 risk MDS patients according to IPSS
62411925|NCT02085798||Group 2|Intermediate-2 risk MDS patients according to IPSS
62217586|NCT05152420|EXPERIMENTAL|Part 1 - Cohort 4|Single dose cohort
62217587|NCT05152420|EXPERIMENTAL|Part 1 - Cohort 5|Single dose cohort
62217588|NCT05152420|EXPERIMENTAL|Part 1 - Cohort 6|Single dose cohort
62217589|NCT05152420|EXPERIMENTAL|Part 2 - Cohort 1|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
62411926|NCT02085798||Group 3|Any risk CMML patients according to CPSS
62411927|NCT06652672|EXPERIMENTAL|Organ-sparing surgery|Local resection with sentinel lymph node biopsy
62411928|NCT06652672|ACTIVE_COMPARATOR|Standard of care segmental resection|
62217590|NCT05152420|EXPERIMENTAL|Part 2 - Cohort 2|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
62411929|NCT00219362|EXPERIMENTAL|ALVAC-HIV 4 injections|Arm A: injection of ALVAC-HIV(vCP1452) for a total of 4 injections (W0, W4, W8, W20)
62021991|NCT02577705|NO_INTERVENTION|Control Group|The Control group did not receive assistance in opening a matched savings account, and were required by the County Assistance Office to participate in other Temporary Assistance for Needy Families (TANF) mandated work participation activities according to standard procedure.
62021992|NCT06164912|ACTIVE_COMPARATOR|TMS Neurofeedback|Participants in this Arm will receive TMS neurofeedback
62021993|NCT06164912|PLACEBO_COMPARATOR|TMS Pseudofeedback|Participants in this Arm will receive TMS with pseudofeedback
62217591|NCT05152420|EXPERIMENTAL|Part 2 - Cohort 3|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
62217592|NCT05152420|EXPERIMENTAL|Part 2 - Cohort 4|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
62411930|NCT00219362|EXPERIMENTAL|ALVAC-HIV 3 injections|Arm B: injection of ALVAC-HIV(vCP1452) for a total of injections (W4, W8, W20)
62411931|NCT00219362|PLACEBO_COMPARATOR|Placebo - 4 injections|Arm C1: injection of placebo for a total of 4 injections (W0, W4, W8, W20)
62793584|NCT04359160|ACTIVE_COMPARATOR|Conventional follow-up|Patients in the conventional, questionnaire follow-up group will have the same periodical questions but on paper. They will have to stick personally with the schedule without any reminders. They will have a medical appointment at 6 weeks postoperative and 12 weeks postoperative where they have to bring the questionnaire.
62217593|NCT05152420|EXPERIMENTAL|Part 2 - Cohort 5|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
62217594|NCT05152420|EXPERIMENTAL|Part 2 - Cohort 6|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
62793585|NCT02430857|EXPERIMENTAL|OMT-Group|The OMT-group will get an osteopathic treatment once a week for 1 hour for 5 weeks. The blood will be screened again after the treatment.
62021994|NCT00389324|EXPERIMENTAL|Immune Globulin Intravenous (Human)|Immune Globulin Intravenous (Human), 10%, Caprylate/Chromatography Purified
62021995|NCT02983955|OTHER|SCI with Tetraplegia|
62021996|NCT01359553||Knee pain|Group with knee pain problems referred to an arthroscopy.
62217595|NCT05152420|EXPERIMENTAL|Part 2 - Cohort 7|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
62217596|NCT01052129|EXPERIMENTAL|Naproxen Sodium 550 mg Tablets|Naproxen Sodium 550 mg Tablets of Dr.Reddy's Laboratories Limited
62217597|NCT01052129|ACTIVE_COMPARATOR|Anaprox DS 550 mg Tablets|Anaprox DS 550 mg Tablets of Roche Pharmaceuticals Inc
62217598|NCT06434909|EXPERIMENTAL|Fluorescent guided surgery|Patients with risk of EPE and having robotic prostatectomy for prostate cancer.
62411932|NCT00219362|PLACEBO_COMPARATOR|Placebo - 3 injections|Arm C2: injection of placebo for a total of 3 injections (W4, W8, W20)
62411933|NCT03269877||Liver cirrhosis and hypersplenism|Patients proven to have Liver Cirrhosis and Hypersplenism based on clinical examination, Laboratory findings, and abdominal ultrasound examinaton
62411934|NCT06555952|EXPERIMENTAL|GSE Capsule|150mg Grapeseed Extract MegaNatural BP
62411935|NCT06555952|PLACEBO_COMPARATOR|Placebo Capsule|Placebo supplement in place of GSE capsule
62411936|NCT04649892|EXPERIMENTAL|Naltrexone|A 12 week Naltrexone flexible dose administration plus 4 sessions of a psychoeducational intervention and 4 eye-tracking sessions
62411937|NCT04649892|PLACEBO_COMPARATOR|Placebo|A 12 week placebo matching tablets plus 4 sessions of a psychoeducational intervention and 4 eye-tracking sessions
62793586|NCT02430857|NO_INTERVENTION|Controll Group|This group will receive no treatment. A blood screening is made again after 5 weeks.
62793587|NCT03237715||Breast fed cohort|
62217599|NCT03412747|EXPERIMENTAL|Bimekizumab Arm 1|Subjects will receive bimekizumab dose regimen 1 for 56 weeks. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
62217600|NCT03412747|EXPERIMENTAL|Bimekizumab Arm 2|Subjects will receive bimekizumab dose regimen 1 for 16 weeks and will proceed with bimekizumab dose regimen 2 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
62217601|NCT03412747|ACTIVE_COMPARATOR|Adalimumab Arm|Subjects will receive adalimumab for 24 weeks and will then receive bimekizumab dose regimen 1 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
62411938|NCT01977560|OTHER|Standard Care|Participants randomized to this arm will receive dietary and physical activity instructions as recommended by the American Diabetes Association (ADA) guidelines.
62411939|NCT01977560|EXPERIMENTAL|Intensive Lifestyle intervention|Participants randomized to this arm will be participate in weekly dietary and behavioral education session in addition to four 60-min supervised exercise training sessions per week for 8 months. All dietary and- behavioral education and exercise training sessions will be conducted at the worksite.
62793588|NCT03237715||Formula fed cohort|
62793589|NCT05900544|EXPERIMENTAL|Implementation|New lung cancer screening participants with clinically significant incidental findings received new patient-centered report
62021997|NCT01405391|EXPERIMENTAL|A|Patients will receive PM01183 on Days 1 and 8 q3wk (three weeks = one treatment cycle) as an i.v. infusion, starting at 3.0 mg/day, flat dose (FD), over a minimum total volume of 100 ml dilution (on 5% glucose or 0.9% sodium chloride) via a central catheter or over a minimum total volume of 250 ml via a peripheral line, over one hour (at a fixed rate) and through a pump device.
62021998|NCT04044729|ACTIVE_COMPARATOR|Cannabidiol|"Drug: Cannabidiol An oral dose of Cannabidiol (CBD) will be given once a day for five day with pain ratings taken before and after each dose every day.~Other Names:~CBD"
62021999|NCT04044729|PLACEBO_COMPARATOR|Placebo|"Drug: Placebos An oral placebo will be given once a day for five day with pain ratings taken before and after each dose every day.~Other Names:~placebo"
62022000|NCT06425120|EXPERIMENTAL|Xuesaitong Soft Capsule|Each participant in the Xuesaitong Soft Capsule treatment group will take a daily dose of 1.32g.
62022001|NCT06425120|PLACEBO_COMPARATOR|Placebo|Each participant in the placebo group will take matching placebo.
62022002|NCT06386666|EXPERIMENTAL|The fibrous ring was sutured using a disposable fibrous ring suturing device|
62217602|NCT06096454|EXPERIMENTAL|metformin ,life style|known to have hypothyroidism with insulin resistance received metformin (1000mg,once daily per oral ) and applied life style modification
62793590|NCT05933460|EXPERIMENTAL|Active Group|A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg and Crocus sativus (Saffron extract 28mg) was administered 3 times per day in people with diabetes type 1 for 6 months on continuous glucose monitoring systems.
62411940|NCT00557830|ACTIVE_COMPARATOR|Group A: Escalated Dose|Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen). Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
62217603|NCT06096454|NO_INTERVENTION|placebo|known to have hypothyroidism with insulin resistance not received metformin and not applied life style modification
62585920|NCT01925131|EXPERIMENTAL|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 5|Combination chemotherapy and inotuzumab ozogamicin - Dose level 5 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.8 mg/m2 on day 1 and 0.5 mg/m2 on days 8 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62217604|NCT06077253|OTHER|Arm 1|One eye iridotomy, contralateral eye no intervention
62217605|NCT04875559||Breast cancer surgery patients.|Patients scheduled for day-case unilateral breast conserving surgery or mastectomy with or without axillary lymph node dissection or sentinel lymph node biopsy. No intervention.
62411941|NCT00557830|ACTIVE_COMPARATOR|Group B: Standard Dose|Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen). Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
62411942|NCT06703515|ACTIVE_COMPARATOR|Microlaryngeal surgery (MLS)|For traditional MLS under general anesthesia, after general anesthesia and intubation with microlaryngeal tube, the patient would be positioned on head-ring support for better alignment and access to glottis. A laryngoscope will be inserted transorally under direct vision and suspended. Vocal cord cysts are visualized with microscope, and removed with microsurgery instruments with microflap technique and sent for routine section. After the surgery, the patient is kept nil-by-mouth until fully awake, and is discharged on same day or the next day depending on the post- operative recovery. Patient will be discharged with voice rest for 3 days.
62411943|NCT06703515|EXPERIMENTAL|Awake transnasal laser-assisted surgery (TNLS)|For TNLS, patients are admitted to the day center on the same morning or afternoon of the surgery with fasting prior 6 hours. After local anesthesia application, a 445nm blue laser is introduced via a working channel of bronchoscope and laser ablation of vocal cord cyst is performed. During the operation, patient will receive continuous SpO2 monitoring with regular blood pressure monitoring. After the procedure, patients are kept nil-by-mouth for 2 hours until anesthesia wears off, meanwhile with close observation in day ward with continuous SpO2 monitor for 1 hour. Patients will be discharged on the same day of the procedure, with voice rest for 3 days.
62411944|NCT02253199|ACTIVE_COMPARATOR|1-6 months (Group 1)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
62411945|NCT02253199|ACTIVE_COMPARATOR|7-12 months (Group 2)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
62411946|NCT02253199|ACTIVE_COMPARATOR|13-24 months (Group 3)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
62411947|NCT02253199|ACTIVE_COMPARATOR|25-36 months (Group 4)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
62411948|NCT04278872|EXPERIMENTAL|SJX-653|Participants will receive SJX-653
62411949|NCT04278872|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo
62411950|NCT06271226|EXPERIMENTAL|acupressure|Information about the pre-procedure intervention will be given. Before acupressure, the participant's physiological parameters and pain score will be recorded, then the hands will be washed in preparation for the acupuncture application and the patient will be placed in a supine or semi-sitting position. Compression points are HT7, P6, P7, Li4, Lv3 points and the location will be determined by the patient's own finger size. Before pressing, a relaxing-relaxing patting motion will be applied to these points for 10 seconds. Then, 1.5 minutes, 5 seconds of thumb pressure and 1 second of free pressure to each point will be applied to each point twice a day (morning and evening). In total it will take 15 minutes to press all the dots. At the end of the application and 15 minutes and 30 minutes after the application, the participant's physiological parameter data and pain score will be re-evaluated and recorded. These data will be recorded twice a day (morning and evening) for 2 days.
62585921|NCT01925131|EXPERIMENTAL|Treatment (combination chemotherapy and inotuzumab ozogamicin) - MTD|Combination chemotherapy and inotuzumab ozogamicin - Maximum Tolerated Dose Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.8 mg/m2 on day 1 and 0.5 mg/m2 on days 8 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62793591|NCT05933460|PLACEBO_COMPARATOR|Placebo group|A sachet of a combination of 4 strains of probiotics (1billion CFU(Lactobacillus rhamnosus, Bifidobacterium animalis lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg without crocus sativus was administered 3 times per day in people with diabetes type 1 for 6 months on continuous glucose monitoring systems.
62217606|NCT00254618|EXPERIMENTAL|30 mg|30 mg/kg/day mesalamine
62217607|NCT00254618|EXPERIMENTAL|60 mg|60 mg/kg/day mesalamine
62217608|NCT00254618|EXPERIMENTAL|90 mg|90 mg/kg/day mesalamine
62217609|NCT04223817|EXPERIMENTAL|7.0 Tesla MRI of both hands|Single 7.0 Tesla MRI of both hands for all the SSc and control subjects
62217610|NCT00564460|ACTIVE_COMPARATOR|1|Finasteride 5 mg PO once daily for 8 weeks prior to TURP
62217611|NCT00564460|PLACEBO_COMPARATOR|2|Placebo
62585922|NCT05995860|NO_INTERVENTION|Control group triads|
62793592|NCT06409143|EXPERIMENTAL|Excitatory stimulation on the affected hemisphere & UE rehabilitation|10 minutes sham inhibitory HD-tES over the unaffected hemisphere's M1 followed by 10 minutes of excitatory HD-tES over the affected hemisphere's M1, combined with upper extremity rehabilitation of affected side.
62585923|NCT05995860|EXPERIMENTAL|Intervention group triads|
62022003|NCT04757649|EXPERIMENTAL|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
62411951|NCT06271226|ACTIVE_COMPARATOR|plasebo acupressure|In the placebo group, the preparations and forms applied to the experimental group will be applied in the same way, but in accordance with the literature, an area 1.5 cm away from the acupressure point that has no connection with the acupressure point will be selected and the application will be made in the form of light touch.
62585924|NCT04284397|EXPERIMENTAL|Critical Environmental Limits|Subjects will perform exercise at \~200-300W with ambient temperature or humidity increasing every 5 min throughout the trial until core temperature begins to rise.
62022004|NCT02340039|EXPERIMENTAL|Blackcurrant &Apple|600 mg blackcurrant anthocyanins + 600 mg apple polyphenols delivered in a low sugar fruit drink
62022005|NCT02340039|EXPERIMENTAL|Apple|1200 mg apple polyphenols delivered in a low sugar fruit drink
62022006|NCT02340039|PLACEBO_COMPARATOR|Control drink|No polyphenols delivered in a low sugar fruit drink
62022007|NCT06115759|EXPERIMENTAL|T-REX Twente|The intervention group receives the new T-REX Twente precautions, allowing for more independent activities through the use of the tube model (keeping elbows close to the sides).
62022008|NCT06115759|ACTIVE_COMPARATOR|Usual care|The control group is not allowed to lift, push, or pull for the first 6 weeks. There is little to no evidence for the current strict precautions currently implemented in the department.
62022009|NCT05970029|EXPERIMENTAL|Enhanced communication|"In the enhanced communication study arm the nurse will say to the patient: I will now give you our first line analgesic medication, liquid Dipyrone. It is a very efficient treatment and based on my experience you will very soon feel significant pain relief."
62585925|NCT04284397|EXPERIMENTAL|Aspirin Supplementation|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will repeat critical environmental limits trials. As before, subjects will perform exercise at \~200-300W with ambient temperature or humidity increasing every 5 min throughout the trial until core temperature begins to rise.
62217612|NCT02734576|EXPERIMENTAL|Venous Sinus Stenting|Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain. Under general anesthesia, a catheter will be inserted through a vein the upper part of the leg (groin area) and guided through the veins all the way to neck and the head. Then, a balloon will be advanced through the catheter and positioned across the stenosis. The balloon will be carefully inflated for a few seconds. This process is called angioplasty and will partially re-open the narrowing, making placement of the stent easier. The balloon will be removed and then the stent will be advanced through the catheter in neck across the stenosis and carefully deployed. After the procedure, the participants will stay in the intensive care unit for 24 hours for observation
62243270|NCT05891353|ACTIVE_COMPARATOR|Pain Free Stretch|Participants will be seated in a chair and asked to complete an upper trapezius stretch. They will feel a gentle stretch in the area between the top of their shoulder and the base of their neck. Participants will be asked to stretch in a pain free range. They will hold this stretch for 1 minute, 4 times. Change in Pressure Pain Threshold will be examined on the web space of their foot between each one minute interval of the stretch. Participants will be notified that they may stop the stretch at any point if needed.
62411952|NCT06271226|OTHER|control group|During the study, pain and physiological parameters will be monitored and recorded twice a day (morning and evening) for 2 days, without any application (other than the routine treatment given by the physician).
62411953|NCT04857879|EXPERIMENTAL|Good Life with Osteoarthritis (GLA:D) Program|Participants will attend 2 sessions aimed at providing disease-specific education followed by 12 sessions of neuromuscular exercises, each 1 hour in length, delivered twice a week over 6 weeks.
62585926|NCT06665802||ARFID adolescents|Children between 12 and 17 years old diagnosed with ARFID less than 2 years prior
62585927|NCT06665802||Non ARFID adolescents|Children between 12 and 17 years old with no organic or psychological illness diagnosed
62585928|NCT06683612|EXPERIMENTAL|Healthy volunteers, brain PET imaging|
62793593|NCT06409143|EXPERIMENTAL|Inhibitory stimulation on the unaffected hemisphere & UE rehabilitation|10-minute active inhibitory HD-tES over the unaffected hemisphere's M1 followed by 10 minutes of sham excitatory HD-tES over the affected hemisphere's M1, combined with upper extremity rehabilitation of affected side.
62793594|NCT06409143|EXPERIMENTAL|Simultaneous bilateral stimulation & UE rehabilitation|Combined with upper extremity rehabilitation of affected side.
62022010|NCT05970029|OTHER|Normal communication|In the normal communication study arm the communication between the nurse and patients will be as usual in clinical practice - i.e. - no instruction are given to the nurses regarding on how to communicate with patients while administrating the treatment.
62022011|NCT00463450|EXPERIMENTAL|Arm 1|
62022012|NCT00463450|ACTIVE_COMPARATOR|Arm 2|
62411954|NCT04857879|ACTIVE_COMPARATOR|Control intervention group|Participants allocated to the control intervention will receive disease-specific education and training to learn home exercises in a 1-hour group session. They will receive a booster session 4-weeks after the first session.
62411955|NCT02212834||Mammograms|Surveillance mammograms in women with a personal history of breast cancer
62411956|NCT02212834||Breast MRI|Surveillance breast Magnetic Resonance Imaging (MRI) in women with a personal history of breast cancer
62585929|NCT06683612|EXPERIMENTAL|Healthy volunteers, lung PET imaging|
62585930|NCT06683612|EXPERIMENTAL|Volunteers with PrMS|
62585931|NCT06683612|EXPERIMENTAL|Volunteers with IPF|
62793595|NCT06409143|SHAM_COMPARATOR|Sham stimulation& UE rehabilitation|The sham control group will receive sham HD-tCES combined with upper extremity rehabilitation of affected side.
62217613|NCT03924440||PDG Test strip Users|"Participants were asked to predict ovulation by monitoring changes in cervical mucus and/or tracking luteinizing hormone (LH) via home test kits. Participants were asked to self-report their peak fertility day, which was defined as the first LH surge day and/or day of peak cervical mucus (stretchy and eggwhite in consistence).~Participants collected first morning urine as various times during their cycle, including, prior to, during, and after peak fertility signs were observed. Participants were provided PDG rapid response test strips and self-administered their tests and recorded their results. Test results were reported back researchers via a log sheet. Log sheets recorded testing date, day of cycle, date of peak fertility (if known), personal assessment of results (positive result vs negative result) and a place to tape the completed test strip."
62217614|NCT02908919|ACTIVE_COMPARATOR|Fortrans pulv. sol|Polyethylene glycol solution. Used 4 l before colonoscopy. Bowel preparation interval: QD/BID or one day.
62217615|NCT02908919|ACTIVE_COMPARATOR|Picoprep pulv. sol.|Natrium picosulfate/ magnesium citrate solution. Used 2 l before colonoscopy. bowel preparation interval: QD/BID or one day.
62217616|NCT02908919|ACTIVE_COMPARATOR|Moviprep pulv. sol.|Polyethylene glycol + ascorbic acid solution. Used 2 l before colonoscopy. Bowel preparation interval: QD/BID or one day.
62217617|NCT02659800|EXPERIMENTAL|Arm A - Low Dexamethasone (LD)|"Patients receive single dose of NT-I7 IM. Treatment continues in the absence of disease progression or unacceptable toxicity. Dose Escalation~Laboratory Biomarker Analysis Correlative Studies"
62217618|NCT02659800|EXPERIMENTAL|Arm B High Dexamethasone (HD)|"Patients receive single dose of NT-I7 IM. Treatment continues in the absence of disease progression or unacceptable toxicity. Dose Escalation~Laboratory Biomarker Analysis Correlative Studies"
62217619|NCT02659800|EXPERIMENTAL|Arm A1 (LD) Control - Placebo|"Patients receive single dose Placebo IM (blinded). Patients also on Dexamethasone \</=0.75mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot~Laboratory Biomarker Analysis Correlative Studies"
62217620|NCT02659800|EXPERIMENTAL|Arm A2 (LD) MTD|"Patients receive single dose MTD NT-I7 IM determined in Arm A (Blinded) . Patients also on Dexamethasone \<=0.75mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot~Laboratory Biomarker Analysis Correlative Studies"
62217621|NCT02659800|EXPERIMENTAL|Arm B1 HD MTD|"Patients receive single dose MTD NT-I7 IM determined in Arm B (Blinded) . Patients also on Dexamethasone \>= 4mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot~Laboratory Biomarker Analysis Correlative Studies"
62217622|NCT06373315||Sample of Study|Volunteer participants who constitute the study sample include students and staff studying in different departments at the university. Inclusion criteria; It includes using a smartphone for more than 1 hour a day to send at least 5 emails or text messages a day, play games or browse the internet. Exclusion criteria; It includes students who have an existing injury to the hand or upper extremity (6 months ago) and who have been diagnosed with degenerative, inflammatory, musculoskeletal, neuromuscular and congenital disorders of the hand or upper extremity that affect their use in daily life.
62217623|NCT05125484|EXPERIMENTAL|Experimental Intervention group 1|"Patient was in lying position. Therapist placed thumb on the effected side muscke. Then hooked thumb on lateral edge of muscle to apply pressure against the muscle. Took a pause. Thumb flattened in a medial direction and pluck was created in muscle.~Set of 15-20 bowen moves on upper , middle and lower fibres each with 2 mins gap between each set.~Total treatment time: 20 mins"
62217624|NCT05125484|EXPERIMENTAL|Experimental interventional group II|"Patient was in lying position. MFR applied via ulnar border of both palms while patient being in contralateral side flexion.~20 mins"
62411957|NCT03906929|EXPERIMENTAL|Pediatric forearm fracture fixed by buried or exposed intamedullary implant|compare complication of buried or exposed intamedullary implant
62585932|NCT02527252|EXPERIMENTAL|Craniosacral therapy|"All treatments were applied by two experienced therapists with a 10-year certification in manipulative therapy after completion of their physical therapy degree and more than 20 years of clinical experience with patients. All patients received the intervention on the day of their initial examination. The techniques took 50 minutes and were conducted as follows:~* Pelvic Diaphragm Release.~* Respiratory Diaphragm Release.~* Thoracic Inlet Release.~* Hyoid release.~* Sacral technique for stabilize L5/sacrum.~* CV-4 Still Point Induction."
62585933|NCT02527252|ACTIVE_COMPARATOR|Classic Massage|Classics massage protocol was compounded by the following techniques of soft tissues massage: effleurage, petrissage, friction, and kneading. The techniques took thirty minutes.
62585934|NCT06684938|EXPERIMENTAL|sacroiliac injection|anaesthetic and steroid injection into the SIJ through US guidance
62793596|NCT01036321|ACTIVE_COMPARATOR|Purified Isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler. 40 mg daily.
62793597|NCT01036321|PLACEBO_COMPARATOR|Methyl cellulose blend|Placebo.
62793598|NCT03629522|ACTIVE_COMPARATOR|ondansetron group|Ondansetron 8Mg/4mL Injection: administration of a bolus of 8 mg intravenous Ondansetron diluted in 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia
62793599|NCT03629522|PLACEBO_COMPARATOR|control group|administration of 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia
62793600|NCT04648683|EXPERIMENTAL|Individual telehealth mindfulness|Telehealth mindfulness sessions delivered one-on-one with mindfulness therapist
62217625|NCT00710177||PPHN|Infants born at \>= 34 weeks who are diagnosed with clinical and/or echocardiographic evidence of PPHN
62217626|NCT00710177||Control|Randomly selected, normal healthy infants born at \>= 34 weeks gestational age and do not have PPHN
62243271|NCT03651583|OTHER|Pilot Trial|Behavioral Intervention Kiko exercises-combines breathing and movement all study subjects no placebo or control group
62411958|NCT01436942|EXPERIMENTAL|Exercise group|
62411959|NCT01436942|NO_INTERVENTION|Control group|
62411960|NCT04402944|EXPERIMENTAL|Study Drug|Study drug
62411961|NCT04402944|PLACEBO_COMPARATOR|Placebo|Placebo
62411962|NCT06567054|EXPERIMENTAL|Fracture risk prediction in middle-aged and elderly men and women|All participants are examined with the investigational device (POROUS R3C ultrasound device) and a comparator device (DXA).
62411963|NCT06454955|EXPERIMENTAL|Each patient must undergo dynamic PET/CT imaging with [68Ga]B7H3 Affibody-BCH.|
62585935|NCT05325281|EXPERIMENTAL|CPI-613® (Dose level -1.0 250 mg/m^2)|Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m\^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
62217627|NCT02593721|EXPERIMENTAL|Median Nerve Neural Mobilization|15 minute Median Nerve Neural Mobilization sessions 5 times a week (monday to Friday) during 6 continuous weeks The maximum degree of elbow extension applied in the Median Nerve neural mobilization procedure was determined through the use of a Universal Goniometer Device.
62217628|NCT02593721|ACTIVE_COMPARATOR|Ibuprofen|A single daily 400 mg dose of oral Ibuprofen that can be increased depending on patient tolerance to a maximum dose of 1200 mg/day equally divided in 3 oral intakes of the drug every 8 hours during 6 continuous weeks.
62217629|NCT02039232|EXPERIMENTAL|CarboFix Pedicle Screw System|
62217630|NCT00979134|EXPERIMENTAL|Part A|Ascending doses of AZD4547 administered orally to patients to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD)
62411964|NCT02181673|PLACEBO_COMPARATOR|Treatment Group 1: Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20. At Week 24, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Week 24, 28 and thereafter every 8 weeks up to Week 52.
62411965|NCT02181673|EXPERIMENTAL|Treatment Group 2: Golimumab|Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 24, participants will receive a placebo infusion to maintain the blind.
62411966|NCT06542172|EXPERIMENTAL|500 mL/day of low-fat milk (fat <1.5%)|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
62411967|NCT06542172|EXPERIMENTAL|500 mL/day of full-fat milk from corn-fed cows (fat >3.8%)|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
62585936|NCT05325281|EXPERIMENTAL|CPI-613® (Dose level 1.0 500 mg/m^2)|Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m\^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
62411968|NCT06542172|EXPERIMENTAL|500 mL/day of full-fat milk from grass-fed cows (fat >3.8%)|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
62411969|NCT04210882|EXPERIMENTAL|12-week Moderate-Intensity Exercise Program|"Exercise intervention: Participants will complete 57 total sessions of moderate-intensity exercise (walking while tracking heart rate) over 12 weeks. Exercise intensity, frequency, and session duration will increase during the first 4 weeks of the intervention until participants are completing five (5) sessions weekly and walking for 30 min each session at 60-75% of Heart Rate Reserve (HRR) (moderate-intensity exercise), as follows:~Week 1: Three sessions, lasting ≥ 15 minutes, at 50-75% of HRR; Week 2: Four sessions, lasting ≥ 20 minutes, at 50-75% of HRR; Week 3: Five sessions, lasting ≥ 30 minutes, at 50-75% of HRR; Weeks 4-12: Five sessions, lasting ≥ 30 minutes, at 60-75% of HRR"
62411970|NCT02786810|OTHER|Contrast|All subjects will be recruited into this arm. All subjects will receive 0.03 ml/kg IV sulfur hexafluoride type-a lipid microspheres one time, unless a second, adjusted dose is necessary.
62793601|NCT04648683|EXPERIMENTAL|Group Telehealth Mindfulness|Telehealth mindfulness sessions delivered in a small-group format with mindfulness therapist
62793602|NCT00818051|ACTIVE_COMPARATOR|Arm I (control)|Patients undergo sequential boost dose intensity-modulated radiotherapy (IMRT) 5 days a week for 4.6 weeks (23 fractions; 56 Gy).
62793603|NCT00818051|EXPERIMENTAL|Arm II|Patients undergo concurrent boost dose IMRT 5 days a week for 3 weeks (15 fractions; 48 Gy).
62793604|NCT00818051|EXPERIMENTAL|Arm III|Patients undergo concurrent boost dose IMRT 5 days a week for 3 weeks (15 fractions; 53 Gy).
62793605|NCT01441726||Training of staff|
62793606|NCT01441726||No training of staff|
62793607|NCT04131946|EXPERIMENTAL|Community Intervention Group/Arm 1|"Community navigators will work with local businesses (barber shop, hair salon) to identify and screen eligible community members within or near the South Shore community area. The navigator will engage with each potential participant using the attached script. If the participant is interested, the navigator will document the participant's contact information, and assist the participant in obtaining and returning their FIT.~Community navigators will attend community events to post the informational flyer and provide education about CRC to community members. At these events, they will identify and screen eligible community members within or near the South Shore community area. The navigator will engage with each potential participant using the attached script. If the participant is interested, the navigator will document the participant's contact information, and assist the participant in obtaining and returning their FIT."
62819368|NCT05747443|EXPERIMENTAL|Patient Video only|About 3 weeks after the index LDCT, the study Medical Assistant (MA) will deliver a link to the Patient Voices Video, an educational video about lung cancer screening.
62819369|NCT05747443|EXPERIMENTAL|Stepped Reminders only|"Prior to patient's next LDCT scan is due, MA begins Stepped Reminders intervention:~MA pends LDCT orders to PCP to sign. MA sends reminders to patient when order is placed and follows up by phone if patient has not scheduled LDCT."
62819370|NCT05747443|EXPERIMENTAL|Patient Video and Stepped Reminders|See above. Those assigned to the Patient Video and Stepped Reminders will receive both interventions, as described above.
62217631|NCT00979134|EXPERIMENTAL|Part B|Dose expansion phase, at the RD defined in Part A
62217632|NCT00979134|EXPERIMENTAL|Part C|Expansion phase in patients with FGFR1 and FGFR2 amplified tumours commencing at the RD defined from Part A
62217633|NCT05693701|OTHER|Control group (Usual care)|This arm will receive standard notification that is usually provided by Carter describing need to review with donor's primary care physician the presence of high cholesterol
62217634|NCT05693701|EXPERIMENTAL|Intervention Group (Implementation strategy bundle)|Along with standard high cholesterol notification from Carter BloodCare, this arm will receive Implementation strategy bundle (educational material regarding high cholesterol levels)
62819371|NCT05747443|NO_INTERVENTION|Usual Care|Those assigned to the the Usual Care arm will continue to receive usual lung cancer screening care.
62217635|NCT03520543|EXPERIMENTAL|Part A : Imput function|Compartmental model of the volume of distribution of \[11C\]Yohimbine in Brain by PET
62217636|NCT03520543|EXPERIMENTAL|Part B : validity of the measure|Part B1 : Test Retest Variability in the distribution of \[11C\]Yohimbine Part B2 : Percentage of alpha2-adrenergic receptor occupancy
62217637|NCT01762098||Recurrent miscarriages|
62217638|NCT01762098||Repeated embryo implantation failures|
62411971|NCT06039956|OTHER|Sentinel Lymph Node Biopsy Arm|"Patients with non-metastatic, biopsy and clipped locally advanced breast cancer will start systemic chemotherapy as per institutional best practices. Patients with a clinical complete response will be consented for SLNB followed by immediate ALND. Patients with persistent suspicious clinical adenopathy will be consented for ALND alone. All patients regardless of response to NAC will undergo ALND as per current institutional practices.~Patients undergoing SLNB followed by ALND will have the procedure performed by study the co-PI at OAUTH who is trained in the performance of SLNB. Histopathologic assessment of the breast and axillary contents will follow a standardized reporting procedure, including the assessment of residual cancer burden in both the breast and the axilla. Presence or absence of residual disease will be reported separately for the SLNB specimens, clipped node and remaining axillary contents."
62411972|NCT03258515|EXPERIMENTAL|Cohort 1|"Participants will receive orally single dose of study drugs in the sequence of ABC.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
62217639|NCT00735475|EXPERIMENTAL|Afluria®|
62217640|NCT00735475|ACTIVE_COMPARATOR|Fluzone®|
62217641|NCT03711175|OTHER|Group A|The subscapularis is repaired. Receives device
62411973|NCT03258515|EXPERIMENTAL|Cohort 2|"Participants will receive orally single dose of study drugs in the sequence of ACB.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
62411974|NCT03258515|EXPERIMENTAL|Cohort 3|"Participants will receive orally single dose of study drugs in the sequence of BAC.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
62411975|NCT03258515|EXPERIMENTAL|Cohort 4|"Participants will receive orally single dose of study drugs in the sequence of BCA.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
62411976|NCT03258515|EXPERIMENTAL|Cohort 5|"Participants will receive orally single dose of study drugs in the sequence of CAB.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
62819372|NCT03450161|EXPERIMENTAL|High-Dose Bolus of Fentanyl|"5 minutes prior to sternotomy, patients will receive a fentanyl bolus of 20 mcg/kg BW (verum) and a perfusion pump with sodium chloride (NaCl 0.9%; placebo) will be begun according to the Shibutani dosing scheme.~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
62217642|NCT03711175|OTHER|Group B|The subscapularis is not repaired. Receives device
62022013|NCT02060890||Group A|Patients will undergo collection of tumor at the time of tumor resection and after confirmation of tumor progression and will have blood samples drawn pre-surgery and during standard of care follow-up visits. Patients will then be provided with a specialized tumor board recommendations for personalized treatment options for up to 4 medications based on the specimen analysis results within 35 days of surgery. Patients may then elect to initiate recommended therapy within 42 days of surgery.
62217643|NCT04075994|EXPERIMENTAL|Intervention arm|Receive the relational agent coupled with the AliveCor Kardia heart rate and rhythm monitor for 120-day use.
62217644|NCT04075994|ACTIVE_COMPARATOR|Usual care arm|Receive a brochure on atrial fibrillation, the WebMD app and the AliveCor Kardia heart rate and rhythm monitor for 120-day use.
62217645|NCT04725240|EXPERIMENTAL|Setmelanotide|Participants received setmelanotide once daily (QD) via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and dose escalated up to a maximum dose of 3.0 milligrams (mg) QD.
62411977|NCT03258515|EXPERIMENTAL|Cohort 6|"Participants will receive orally single dose of study drugs in the sequence of CBA.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
62411978|NCT04362761|EXPERIMENTAL|ELX/TEZ/IVA|"Part A: Participants received elexacaftor (ELX) 200 milligram (mg) once daily (qd)/tezacaftor (TEZ)100 mg qd/ivacaftor (IVA)150 mg every 12 hours (q12h) in the treatment period for 48 weeks.~Part B: Participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period up to 86 weeks."
62217646|NCT06209333|EXPERIMENTAL|pelvic physiotherapy|
62217647|NCT06209333|ACTIVE_COMPARATOR|standard patient education|
62217648|NCT02083107|EXPERIMENTAL|sublingual misoprostol & rectal placebo|"will receive 400 microgram of misoprostol (Sigma) sublingual 2 tablets and rectal placebo2 tablets."
62217649|NCT02083107|PLACEBO_COMPARATOR|rectal & sublingual placebo|"will receive rectal placebo2 tablets and sublingual placebo2 tablets."
62217650|NCT02083107|EXPERIMENTAL|rectal misoprostol & sublingual placebo|"will receive 400 microgram of misoprostol (Sigma) rectal 2 tablets and sublingual placebo2 tablets."
62217651|NCT05339217|EXPERIMENTAL|Telitacicept and low dose IL2|"160mg Telitacicept was subcutaneously injected to patients with systemic lupus erythematosus at the outer side of upper arm every week for 24 weeks.~Interleukine-2 was first added to the original treatment for systemic lupus erythematosus with 1 million IU qod for 12 weeks, injected subcutaneously at the outer side of upper arm, abdomen and thigh, then the same dose of IL2 was injected once a week for 12 weeks subcutaneously."
62411979|NCT04512976|EXPERIMENTAL|Burn Survivors (20-40% Burn Surface Area) in Ambient Heat (30°C)|Burn survivors with 20-40% BSA (burn surface area) will exercise for 60 minutes in ambient heat (30°C) while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
62411980|NCT04512976|EXPERIMENTAL|Burn Survivors (20-40% Burn Surface Area) in Ambient Heat (39°C)|Burn survivors with 20-40% BSA (burn surface area) will exercise for 60 minutes in ambient heat (39°C) while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
62217652|NCT05339217|ACTIVE_COMPARATOR|Telitacicept|160mg Telitacicept was subcutaneously injected to patients with systemic lupus erythematosus at the outer side of upper arm every week for 24 weeks.
62585937|NCT05325281|EXPERIMENTAL|CPI-613® (Dose level 2.0 1,000 mg/m^2)|Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m\^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
62585938|NCT05325281|EXPERIMENTAL|CPI-613® (Dose level 3.0 1,500 mg/m^2)|Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m\^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
62585939|NCT05325281|EXPERIMENTAL|CPI-613® Maximum Tolerated Dose (MTD)|MTD of CPI-613® from initiation of treatment to 30 days after treatment. MTD will be determined by testing increasing doses of CPI-613®, starting from 500 mg/m\^2 and up to 1,500 mg/m\^2, on dose escalation cohorts of three patients (maximum 24 patients) in combination with Gem-RT therapy. MTD reflects the highest drug dose that does not cause unacceptable adverse effects, with a target dose-limiting toxicity (DLT) rate of 30%. Final dose will be revised as appropriate.
62585940|NCT06569602||Treatment|Treatment with the Edwards EVOQUE Tricuspid Transcatheter Valve Replacement System
62585941|NCT03745729|EXPERIMENTAL|Treatment group|
62217653|NCT05339217|ACTIVE_COMPARATOR|low dose IL2|Interleukine-2 was first added to the original treatment for systemic lupus erythematosus with 1 million IU qod for 12 weeks, injected subcutaneously at the outer side of upper arm, abdomen and thigh, then the same dose of IL2 was injected once a week for 12 weeks subcutaneously.
62585942|NCT03745729|PLACEBO_COMPARATOR|Control group|
62217654|NCT02560311||HER2+ metastatic breast cancer|
62411981|NCT04512976|EXPERIMENTAL|Non-Burned Individuals in Ambient Heat (30°C)|Non-burned individuals will exercise for 60 minutes in ambient heat (30°C) while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
62411982|NCT04512976|EXPERIMENTAL|Non-Burned Individuals in Ambient Heat (39°C)|Non-burned individuals will exercise for 60 minutes in ambient heat (39°C) while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
62585943|NCT03526536|OTHER|Patients with diabetes and ESRD|Patients with diabetes and end stage renal disease (ESRD)
62585944|NCT03526536|OTHER|Patients with diabetes and no ESRD|Patients with diabetes and no end stage renal disease (ESRD)
62585945|NCT06331260||Preoperative AFP < 400 ng/mL or PIVKA-II < 200mAU/mL|
62585946|NCT06331260||Preoperative AFP ≥ 400 ng/mL and PIVKA-II ≥ 200mAU/mL|
62585947|NCT06175325|OTHER|Trans-radial embolisation of haemorrhoids|Haemorrhoids will be treated using arterial embolisation, using a trans-radial approach
62585948|NCT03647579|ACTIVE_COMPARATOR|midazolam plus ketamine|
62585949|NCT03647579|ACTIVE_COMPARATOR|dexmedetomidine plus ketamine|
62585950|NCT06684184|EXPERIMENTAL|Treatment group|
62585951|NCT03614468|EXPERIMENTAL|Formula A|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age.
62585952|NCT03614468|ACTIVE_COMPARATOR|Formula B|A Commercially available Infant Formula, for healthy term infants 0 to 12 months of age (Enfamil TM, Milk-Based Powder with Iron)
62585953|NCT06684990|EXPERIMENTAL|Outpatients with diabetes who provide consent to POC testing|Intervention: POC testing for HbA1c and cystatin C. Observational follow up: data on fasting glucose, HbA1c, serum creatinine, urine albumin to creatinine ratio (UACR), lipids profile, ...etc.
62217655|NCT00611429|EXPERIMENTAL|Group A|Participants will receive treatment consisting of at least three individual counseling sessions and one group workshop over 12 months
62217656|NCT00611429|ACTIVE_COMPARATOR|Group B|Participants will receive treatment consisting of one individual counseling session and one group workshop during the last month of the study
62217657|NCT00905515|ACTIVE_COMPARATOR|Control Group Cyclosporine|Maintain on Cyclosporine (CsA) at target trough level of 50-250 ng/mL.
62217658|NCT00905515|ACTIVE_COMPARATOR|Low Trough Level Prograf Group|Convert to Prograf (TAC) at target trough levels of 3.0-5.9 ng/mL.
62217659|NCT00905515|ACTIVE_COMPARATOR|High Trough Level Prograf Group|Convert to TAC at target trough levels of 6.0-8.9 ng/mL.
62217660|NCT02615080|ACTIVE_COMPARATOR|CRD007|CRD007 (containing pemirolast sodium) tablets given twice daily for 14 weeks
62217661|NCT02615080|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets given given twice daily for 14 weeks
62217662|NCT03257943|EXPERIMENTAL|Ivermectin Lotion, 0.5%|One 10 minute application, under at-home use conditions
62793608|NCT04131946|NO_INTERVENTION|Standard of Care (Control) Arm 2|"These procedures are a detailed summary of the existing lay navigation program at Mile Square Health Center (MSHC). These procedures are unrelated to our research, except to demonstrate how the existing navigation program from which we will obtain deidentified data works.~Lay clinic navigator use clinic schedules and walk-ins to identify and screen eligible participants within the Englewood MSHC. The navigator engages with each potential participant using standard scripted language. For interested patients, the navigator documents interest and FIT dispensing as appropriate, and assists the patient in obtaining and returning their FIT.~Lay clinic navigators attend community events as normally scheduled to provide community-based health education and referral to the MSHC. At these events, they identify and screen eligible community members within the Englewood community area."
62217663|NCT03257943|ACTIVE_COMPARATOR|SKLICE (ivermectin) Lotion, 0.5%|One 10 minute application, under at-home use conditions
62585954|NCT06684990|NO_INTERVENTION|Outpatients with diabetes who decline to POC testing, but consent to observational follow up|This group will serve as the controls. Follow up data on fasting glucose, HbA1c, serum creatinine, urine albumin to creatinine ratio (UACR), lipids profile, ...etc.
62793609|NCT02133781|EXPERIMENTAL|Age 8-17 years (identical twins )|Participants will be randomized to receive either Fluzone® 2009-2010 Formula or FluMist® 2009-2010 Formula
62217664|NCT03257943|PLACEBO_COMPARATOR|Vehicle of the Test product|One 10 minute application, under at-home use conditions
62585955|NCT05263271|EXPERIMENTAL|Experimental cohort|Gentulizumab administered IV once a week and a dosing cycle is 4 weeks
62585956|NCT02751346||Patients with Pain|Patients with pain identified through the survey will be invited to undergo sensory assessment by quantitative sensory testing (QST) around the surgical scar and a control area: Thermal (cold and heat) detection and pain thresholds; mechanical detection and pain threshold; dynamic mechanical allodynia; temporal summation (wind-up).
62585957|NCT02751346||Patients without Pain|Patients without pain age and gender matched to patients with pain identified through the survey will be invited to undergo sensory assessment by quantitative sensory testing (QST) around the surgical scar and a control area: Thermal (cold and heat) detection and pain thresholds; mechanical detection and pain threshold; dynamic mechanical allodynia; temporal summation (wind-up).
62585958|NCT05579392|EXPERIMENTAL|Bright Light Therapy via ReTimer glasses, Then Placebo|Participants will wear their device for 60 minutes every morning for 28-days (4 weeks)
62585959|NCT05579392|EXPERIMENTAL|No Bright Light Therapy via placebo glasses, Then Bright Light Therapy|Participants will wear their placebo device for 60 minutes every morning for 28-days (4 weeks)
62585960|NCT05971498||cases|
62585961|NCT05971498||control|
62585962|NCT00186966|OTHER|FLAG|
62585963|NCT00186966|OTHER|FLAG and LP Dox|
62585964|NCT02573415|EXPERIMENTAL|Uterus Transplantation|Women will undergo deceased donor uterine transplantation after IVF.
62585965|NCT06666244||Postmenopausal Women|This study aimed to evaluate the effect of carbohydrate quality on quality of life and menopausal symptoms in postmenopausal women. Data were collected from 604 postmenopausal women using a demographic questionnaire, the Menopause-Specific Quality of Life Questionnaire (MENQOL), and the Menopause Rating Scale (MRS). Carbohydrate quality was assessed using food frequency consumption data, and results were analyzed with SPSS 24 software.
62793610|NCT02133781|EXPERIMENTAL|Age 18-30 years (non-twins)|Participants will be receive Fluzone® 2009-2010 Formula
62793611|NCT02133781|EXPERIMENTAL|Age >70 years (non-twins)|Participants will receive Fluzone® 2009-2010 Formula
62022014|NCT02290665|EXPERIMENTAL|Thermosensitive gel formulation|Thermosensitive gel rectal formulation or saline (control) enema with crossover to the other.
62217665|NCT06445829|EXPERIMENTAL|Cocktail injection with Magnesium Sulfate|Cocktail injection with Marcaine, Dexamethasone, normal saline and Magnesium Sulfate
62217666|NCT06445829|NO_INTERVENTION|Cocktail injection without Magnesium Sulfate|Cocktail injection with Marcaine, Dexamethasone, and normal saline
62793612|NCT03027401||Group A|Adult/pediatric with suspected or confirmed malignancy, family history of malignancy, undergoing surgery with no malignancy; tissues collected previously under CLIA or for research.
62793613|NCT01011140||Online Survey|Survey of Palliative care physicians from Latin America and Spain
62793614|NCT03859271|EXPERIMENTAL|brief motivational interviewing|Participants will receive BMI and instant messaging delivered by a trained research nurse. At the time of recruitment, both children and parents will receive an education talk on the significance of and misconceptions about regular physical activity for cancer survivors and strategies for overcoming barriers to engaging in physical activity. Parents will then receive a face-to-face BMI to motivate their children to engage in regular physical activity. Parents will also be encouraged to motivate their children to intensify their physical activity levels progressively, with the ultimate goal of achieving the Global Recommendations on Physical Activity on Health suggested by the World Health Organization. Additionally, they will be invited to download a mobile health application from the Centre for Health Protection, Department of Health, HKSAR website that contains information on physical activity.
62411983|NCT04512976|EXPERIMENTAL|Burn Survivors (>40% Burn Surface Area) in Ambient Heat (30°C)|Burn survivors with \>40% BSA (burn surface area) will exercise for 60 minutes in ambient heat (30°C) while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
62411984|NCT04512976|EXPERIMENTAL|Burn Survivors (>40% Burn Surface Area) in Ambient Heat (39°C)|Burn survivors with \>40% BSA (burn surface area) will exercise for 60 minutes in ambient heat (39°C) while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
62411985|NCT04707014|PLACEBO_COMPARATOR|Attention-Distraction techniques|A high-tech distraction technique (Apple®), passive and chosen by the child, either an animated video or his or her favourite music. After standard intravenous sedation, the child is taken to the operating theatre to watch his or her favourite video or music and this is maintained throughout the procedure.
62411986|NCT04707014|EXPERIMENTAL|HIPNOSIS GROUP|A technique of rapid conversational hypnosis, with focus on therapeutic suggestion (guiding the patient into a hypnotic trance), adapted to the child's cognitive development. Induction with hypnotic suggestion focuses and accompanies the child's body sensations and allows their active participation. After standard sedation, therapeutic suggestion is maintained throughout the surgery and in the post-hypnotic period before awakening.
62411987|NCT03480165|EXPERIMENTAL|20 mg Parecoxib + 0.75% Ropivacaine|1 ml of 20 mg Parecoxib is given concurrently with 19 mls of 0.75% ropivacaine
62585966|NCT03836950|EXPERIMENTAL|active rTMS|For active rTMS, a butterfly coil and MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark) will be used. One rTMS session will consist of 40 trains of 5sec each at 110% of resting motor threshold and 15Hz will be provided at the left DLPFC.
62585967|NCT03836950|SHAM_COMPARATOR|sham rTMS|For sham rTMS, the procedure will be carried out at the left DLPFC but a sham coil will be used. The MagVenture coil has an active side and a placebo side allowing a double-blind study to be conducted. The sham system looks, sounds and feels like active rTMS.
62585968|NCT06666946|EXPERIMENTAL|EA group|For the EA group, participants will be assigned to receive 6 sessions of EA applied at bilateral acupoints Zusanli (ST36) and Yanglingquan (GB34), once daily, with the first session of EA applied within 24 hours after randomization.
62793615|NCT03859271|PLACEBO_COMPARATOR|Placebo Control|Children and parents will receive the education talk on physical activity and ask to download the mobile health application that contains information on physical activity at the time of recruitment similar to the intervention group. However, parents will not receive BMI and instant messaging throughout the study period.
62793616|NCT00007358|EXPERIMENTAL|1|Depending on patient and physician decision, a steroid may be administered during pregnancy.
62793617|NCT05330832||Patients with confirmed SARS-Cov-2 infection|Hospitalized patients with modern or critical condition with confirmed COVID-19 infection. Patients received standard therapy for COVID-19 infection and anticoagulant prophylaxis if needed according to current temporary clinical recommendations.
62793618|NCT06727344|EXPERIMENTAL|Brace and BFR exercise|
62793619|NCT06727344|SHAM_COMPARATOR|Brace and BFR sham|
62793620|NCT06275386|EXPERIMENTAL|Drug-coated balloon|Patients will undergo PCI of the native coronary CTO with a DCB.
62793621|NCT04498143|EXPERIMENTAL|"Project SAVE (Stop Adolescent Violence Everywhere) SSI"|SAVE is a \~30-minute, self-administered, web-based program that uses components of cognitive behavior therapy and dialectical behavior therapy designed to decrease self-injurious behaviors in youth. The Project SAVE SSI has 4 general content sections: (1) explaining the science behind how changing your actions (i.e. decreasing self-injurious behaviors) can positively impact your emotions over time; (2) providing scientific evidence and testimonials from other teens that have successfully decreased their self-injurious behaviors and noticed positive change as a result; (3) evidence-based tips for overcoming common obstacles to decreasing self-injurious behaviors in day to day life; and (4) offering an opportunity for youth to share their own thoughts and advice on what they have learned with other teenagers who are facing similar challenges.
62411988|NCT03480165|ACTIVE_COMPARATOR|0.75% Ropivacaine only|19 ml of Ropivacaine at a concentration of 0.75% is given concurrently with 1 ml of 0.9% saline
62585969|NCT06666946|SHAM_COMPARATOR|Sham EA group|For the sham EA group, participants will be assigned to receive 6 sessions of sham EA on two sham points, once daily, with the first session of sham EA applied within 24 hours after randomization.
62585970|NCT00528489|EXPERIMENTAL|1|PENNVAX-B with 0.8 mg IL-15 administered in both deltoids at Months 0, 1, 3, and 6
62585971|NCT00528489|EXPERIMENTAL|2|PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
62585972|NCT00528489|EXPERIMENTAL|3|PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
62585973|NCT00528489|EXPERIMENTAL|4|PENNVAX-B with 2 mg IL-15 injected into both deltoids at Months 0, 1, 3, and 6
62585974|NCT06389877|EXPERIMENTAL|BEAM-302 Drug Product|
62585975|NCT01872065|EXPERIMENTAL|ARC-520|Single dose, intravenous administration of ARC-520.
62585976|NCT01872065|PLACEBO_COMPARATOR|Normal Saline|Single dose, intravenous administration of Normal Saline
62411989|NCT06033963|ACTIVE_COMPARATOR|RIC+CEA+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily for 6 consecutive days after enrollment. Additionally, the patients will be treated with carotid endarterectomy (CEA) and standard medical treatment according to the Chinese guideline for the secondary prevention of ischemic stroke and transient ischemic attack 2022.
62411990|NCT06033963|PLACEBO_COMPARATOR|Sham RIC+CEA+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. RIC will be conducted twice daily for 6 consecutive days after enrollment. Additionally, the patients will be treated with carotid endarterectomy (CEA) and standard medical treatment according to the Chinese guideline for the secondary prevention of ischemic stroke and transient ischemic attack 2022.
62411991|NCT04047459||Patient undergoing prosthetic surgery|Patients undergoing surgery for the insertion of a hip prosthesis or a cruciate ligament reconstruction will be included. On those patients tissue samples collection and cells isolation will be performed
62411992|NCT03192917|EXPERIMENTAL|Active treatment|This group of participant will receive low intensity shock wave treatment accounted on their penile shaft once every week for 5 weeks.
62411993|NCT03192917|PLACEBO_COMPARATOR|Placebo group|this group of participant will meet up for treatment. The treatment given will be the exact same as the active group, but the transducer used for shock wave treat will me capped, meaning that no shock waves are transmitted to their penis.
62793622|NCT04498143|ACTIVE_COMPARATOR|"Supportive Therapy (Share Your Feelings) SSI"|Supportive Therapy SSI (Schleider \& Weisz, 2018): \~30-minute, self-administered, web-based program that uses components of supportive therapy to encourage feelings sharing. The supportive therapy SSI encourages participants in the control group to identify and express their feelings by (1) explaining why sharing feelings is natural, important, and helpful and (2) including testimonials from teens who have shared their feelings with close others.
62793623|NCT01112787|EXPERIMENTAL|Tazarotene Foam|Subjects will be exposed to patches containing Tazarotene Foam 0.1%,
62793624|NCT01112787|PLACEBO_COMPARATOR|Vehicle Foam|Subjects will be exposed to patches containing Vehicle Foam.
62793625|NCT01112787|ACTIVE_COMPARATOR|Sodium Laural Sulfate|Subjects will be exposed to patches containing Sodium Laural Sulfate.
62793626|NCT01112787|PLACEBO_COMPARATOR|Distilled Water|Subjects will be exposed to patches containing Distilled Water.
62793627|NCT03801174|EXPERIMENTAL|Partner-assisted intervention|Patients and partners will receive intervention
62793628|NCT03801174|ACTIVE_COMPARATOR|Patient-only intervention|Patients will receive intervention
62793629|NCT02255344||ST-Elevation Myocardial Infarction|Consecutive patients of any gender between 18 and 90 years old, diagnosed with ST-Elevation Myocardial Infarction according to international diagnostic criteria - ACC / AHA / ESC, attended in representative hospitals of tertiary and secondary care in the IMSS will be studied
62793630|NCT02255344||Non ST Segment Elevation|Consecutive patients of any gender between 18 and 90 years old, diagnosed with Non ST Segment Elevation (NSTEMI/ Unstable angina) according to international diagnostic criteria - ACC / AHA / ESC, attended in representative hospitals of tertiary and secondary care in the IMSS will be studied
62793631|NCT04137731|EXPERIMENTAL|IFC Treatment|The IFC treatment will be used for 30 minutes, twice a day for two days after the total knee arthroplasty
62793632|NCT04137731|PLACEBO_COMPARATOR|Placebo|One set of device is programmed to be used as Placebo, the subject will feel the vibration but will not receive a therapeutic signal.
62217667|NCT02810574|ACTIVE_COMPARATOR|Active noninvasive brain stimulation and cognitive training|In active condition, subject will receive stimulation during all the 30-minute stimulation period combined with cognitive training.
62217668|NCT02810574|SHAM_COMPARATOR|Sham noninvasive brain stimulation|In sham condition, subject will receive stimulation only during the first 30 seconds of the 30-minute stimulation period combined with cognitive training.
62217669|NCT02730949|EXPERIMENTAL|1 g D-chiro-Inositol + 400 mcg Folic Acid|1 g D-chiro-Inositol + 400 mcg folic acid once daily
62217670|NCT02730949|ACTIVE_COMPARATOR|400 mcg folic|400 mcg folic acid only once daily
62217671|NCT02518789|EXPERIMENTAL|Low-dose Dexmedetomidine|-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 0.5 µg/kg，completed within 15 minutes.
62217672|NCT02518789|EXPERIMENTAL|High-dose Dexmedetomidine|-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 1 µg/kg，completed within 15 minutes.
62217673|NCT02518789|PLACEBO_COMPARATOR|normal saline Control group|-Pretreatment before anesthesia induction：Intravenous injection normal saline equal quantity，completed within 15 minutes.
62217674|NCT06349811|EXPERIMENTAL|BL-M05D1|Participants receive BL-M05D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62217675|NCT00767975|NO_INTERVENTION|2|For patients who diagnosed with LTBI, they choose to receive LTBI treatment depends on their willingness; if they choose not, then they are in no intervention arm.
62217676|NCT00767975|EXPERIMENTAL|1|Provided INH 6m or RMP 4 m; whether enter treatment arm is determined by patient's willingness
62217677|NCT03273296|ACTIVE_COMPARATOR|Amoxicillin|
62217678|NCT03273296|ACTIVE_COMPARATOR|Azithromycin|
62217679|NCT03273296|ACTIVE_COMPARATOR|Vancomycin|
62217680|NCT00923260|EXPERIMENTAL|Roux-en-Y Gastric Bypass/Omentectomy|Laparoscopic Roux-en-Y Gastric Bypass with omentectomy
62217681|NCT00923260|ACTIVE_COMPARATOR|Roux-en-Y Gastric Bypass alone|
62217682|NCT02627170||Healthy adults group|Age 20 to 40 years of age and have myopia with a spherical equivalent (SE) between 0.00 and -11.00 diopters (D)
62217683|NCT00249054|ACTIVE_COMPARATOR|ASR hip prosthesis|DuPuy ASR hip prosthesis
62217684|NCT00249054|ACTIVE_COMPARATOR|ReCap hip prosthesis|Biomet ReCap hip prosthesis
62217685|NCT00723541|EXPERIMENTAL|A|Develop a computer-aided diagnostic system that will aid in the screening and detection of breast abnormalities/cancer
62217686|NCT01844687|OTHER|Active marijuana (MJ) with 0 mg CBD|Active MJ cigarettes contain 5.30% THC
62217687|NCT01844687|OTHER|Active MJ with 200 mg CBD|Active MJ cigarettes contain 5.30% THC
62217688|NCT01844687|OTHER|Active MJ with 400 mg CBD|Active MJ cigarettes contain 5.30% THC
62217689|NCT01844687|OTHER|Active MJ with 800 mg CBD|Active MJ cigarettes contain 5.30% THC
62217690|NCT01844687|OTHER|Inactive MJ with 0 mg CBD|Inactive MJ cigarettes contain 0.01% THC
62217691|NCT01844687|OTHER|Inactive MJ with 200 mg CBD|Inactive MJ cigarettes contain 0.01% THC
62217692|NCT01844687|OTHER|Inactive MJ with 400 mg CBD|Inactive MJ cigarettes contain 0.01% THC
62217693|NCT01844687|OTHER|Inactive MJ with 800 mg CBD|Inactive MJ cigarettes contain 0.01% THC
62217694|NCT01911598|EXPERIMENTAL|A: MEHD7945A+ Cisplatin + 5-FU|Participants with previously untreated R/M SCCHN will receive MEHD7945A 1650 milligrams (mg) intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or protocol violation. Cisplatin will be administered as 100 milligrams per square meter (mg/m\^2) IV infusion on Day 1 of Cycles 1 to 6. 5-FU will be administered as 1000 mg/m\^2/day administered as continuous infusion over Days 1-4 of Cycles 1 to 6.
62217695|NCT01911598|EXPERIMENTAL|B: MEHD7945A + Paclitaxel + Carboplatin|Participants with previously untreated R/M SCCHN will receive MEHD7945A 1650 mg IV infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or protocol violation. Carboplatin will be administered at a dose to achieve an area under the curve (AUC) of 6 milligrams/milliliter/minute (mg/mL/min) as an IV infusion on Day 1 of Cycles 1 to 6. Paclitaxel will be administered as 200 mg/m\^2 IV infusion on Day 1 of Cycles 1 to 6.
62217696|NCT05481658|EXPERIMENTAL|Diphencyprone (DPCP)|0.4% and 0.04% ointment
62217697|NCT01827475|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 800 mg
62217698|NCT01827475|ACTIVE_COMPARATOR|Acetaminophen|Acetaminophen 1 gm
62217699|NCT01827475|EXPERIMENTAL|Ibuprofen-acetaminophen combination|Ibuprofen 800 mg plus acetaminophen 1 gm
62217700|NCT04085185|EXPERIMENTAL|Phase Ia Dose-Escalation Stage:IBI110|Participants will be treated with escalating doses of IBI110 to determine the MTD.
62217701|NCT04085185|EXPERIMENTAL|Phase Ia Expansion Stage:IBI110|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI110 in different cancer types.
62217702|NCT04085185|EXPERIMENTAL|Phase Ib Dose-Escalation Stage:IBI110+ Sintilimab|Participants will be treated with escalating doses of IBI110 in combination with a fixed dose of Sintilimab to determine the MTD.
62217703|NCT04085185|EXPERIMENTAL|Phase Ib Expansion Stage:IBI110+ Sintilimab|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI110 in combination with Sintilimab in different cancer types.
62738634|NCT04726930||Intercostal nerve block with intra-needle and surface ultrasound|"Number of participants: 10 Intercostal blocks will be performed under guidance of intra-needle and surface ultrasound. The intra-needle transducer will be placed inside the puncture needle and it will be the primary guidance to reach target injection site. Surface ultrasound will be the secondary image guide for simultaneous comparison. Collect signal from both Intra-needle ultrasound transducer and surface ultrasound, and then inject local anesthetics.~Code name: ICNB-INUS-guide"
62217704|NCT01004848|EXPERIMENTAL|Peer-Led Lifestyle Education on Weight Loss|"Project HEED (Help Educate to Eliminate Diabetes), a community-based, peer-led weight loss program for overweight adults with pre-diabetes.~The intervention group will participate in an 8-session course held over a 10-week period. Project HEED (Help Educate to Eliminate Diabetes), led by trained peer educators, aims to help participants lose weight, thereby preventing their progression to diabetes."
62217705|NCT01004848|PLACEBO_COMPARATOR|Delayed Intervention|The control group will be offered the chance to participate in the 8-session course 1 year after enrollment into the trial.
62217706|NCT05660343|EXPERIMENTAL|Ozonated olive oil|(0.03PPM ozone + 6-6.5 PH olive oil, viscosity at 25°C 55mPas, relative density gr/ml (20°C) 0.98 pycnometer, Ozonated olive oil, 100 ml bottle, Olive Farm, GÜLLERDAĞI TURİZM TARIM İNŞ), Ozonated Olive Oil is used 3 times a day, every day for four weeks. Patients were instructed to spray three times on each side. To ensure commitment, Oil canisters were marked in the middle, which the patient was required to use until the label in the first two weeks, and the remaining amount in the second two weeks.
62217707|NCT05660343|EXPERIMENTAL|Ozonated olive oil with low level laser therapy|(810 nm diode laser, 3.4 j/cm2 energy density, 0.5w power, CHEESE DEN7A/DEN4A 810, 2 min for each side) was applied non-contact at a distance of 1 cm, the most painful points in the muscles diagnosed during the first examination were irradiated with circular movements and patients were called for 3 sessions per week over four weeks.
62217708|NCT03403582|NO_INTERVENTION|Control arm|A high-fat break fast meal with no raspberries.
62217709|NCT03403582|EXPERIMENTAL|Raspberry arm|A high-fat break fast meal with raspberries (250g frozen)
62217710|NCT02197403|EXPERIMENTAL|alcohol drinker & dexmedetomidine|dexmedetomidine, 200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1\~1.0mcg/Kg infusion during surgery
62217711|NCT02197403|ACTIVE_COMPARATOR|alcohol drinker & propofol|Propofol (2% fresofol) 25\~75mcg/kg/min continuous infusion
62217712|NCT02197403|ACTIVE_COMPARATOR|Non-alcohol drinker & dexmedetomidine|dexmedetomidine, 200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1\~1.0mcg/Kg infusion during surgery
62217713|NCT02197403|ACTIVE_COMPARATOR|Non-alcohol drinker & propofol|Propofol (2% fresofol) 25\~75mcg/kg/min continuous infusion
62243272|NCT05429983||Hypoglossal Nerve Stimulation Candidates|Participants will have a diagnosis of obstructive sleep apnea and have failed treatment with continuous positive airway pressure (CPAP). Participants will be those undergoing drug-induced sleep endoscopy (DISE) as part of routine clinical care for work up of hypoglossal nerve stimulation candidacy as a treatment for obstructive sleep apnea.
62243273|NCT04279262||Anonymised records from 6 ambulance services|The total available sample for analysis for this cohort is estimated to be at least 50,000 incidents across 6 ambulance trusts. The investigators will describe the epidemiology of CFR provision to rural health areas using an anonymised dataset.
62243274|NCT04279262||Interviews with patients (and/or relatives)|The investigators will interview about 15-20 patients (and/or relatives) who have been attended by CFRs.
62243275|NCT04279262||Interviews with CFRs|The investigators will interview about 15-20 CFRs/ CFR scheme leaders.
62411994|NCT02384200|EXPERIMENTAL|Antibiotic|"1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily starting 1 week prior to planned kidney stone surgery (PCNL).~In addition, each patient receives a a dose of ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 60 minutes of surgery start time. Patients with penicillin allergy will receive vancomycin IV (1 g) instead of ampicillin and patients with gentamicin/aminoglycoside allergy will receive ceftriaxone IV (2 g) instead of gentamicin."
62243276|NCT04279262||Interviews with Ambulance staff|The investigators will interview about 15-20 ambulance staff who have experience of working with CFRs.
62243277|NCT04279262||Interviews with GPs and commisioners|The investigators will interview about 10-15 GPs and ambulance service commissioners.
62243278|NCT06559163|EXPERIMENTAL|Obexelimab|Obexelimab will be administered as a subcutaneous injection for 24 weeks.
62793633|NCT01631994|EXPERIMENTAL|Oral Dissolving metoclopramide|Patient's in this arm will receive the oral dissolving metoclopramide along with the capsule during capsule endoscopy.
62793634|NCT01631994|NO_INTERVENTION|control group|This is the control group that will only ingest the capsule during video capsule endoscopy.
62793635|NCT04057807|EXPERIMENTAL|Patients receiving endotoxin|The 20 enrolled subjects will have LPS (0.4 ng/kg) administered intravenously
62793636|NCT06295861||ASCVD cohort|The patient had atherosclerosis in 2 or more vessels
62793637|NCT06295861||healthy cohort|The patient had no atherosclerosis in vessels
62793638|NCT02089074|EXPERIMENTAL|drug use counselling|Pharmacist conducting drug reconciliation, medication reviews and drug use counselling during hospitalisation. Follow up telephone calls 1 week, 1 month, 2 months and three months after discharge from hospital
62793639|NCT02089074|NO_INTERVENTION|Control group|The patients in the control group receive no intervention just treatment and follow up according to national standards
62793640|NCT00645021|EXPERIMENTAL|Mild hepatic function|
62793641|NCT00645021|EXPERIMENTAL|Moderate hepatic function|
62793642|NCT00645021|EXPERIMENTAL|Normal hepatic function|
62793643|NCT04674722|EXPERIMENTAL|Injection of 99mTc-NM-02|All breast cancer patients recruited to the study will be administered 3-12 MBq/kg of 99mTc-NM-02 (99mTc labeled anti-HER2 sdAb) in a single dose injection.
62793644|NCT04674722|EXPERIMENTAL|Injection of 188Re-NM-02|Ten breast cancer patients recruited to the study will be administered 66 MBq/kg of 188Re-NM-02 (188Re labeled anti-HER2 sdAb) in a single dose injection.
62793645|NCT00908804|ACTIVE_COMPARATOR|open appendectomy|
62793646|NCT00908804|ACTIVE_COMPARATOR|laparoscopic appendectomy|
62411995|NCT02384200|ACTIVE_COMPARATOR|No preoperative oral antibiotics|Each patient does receive a a dose of ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 60 minutes of surgery start time. Patients with penicillin allergy will receive vancomycin IV (1 g) instead of ampicillin and patients with gentamicin/aminoglycoside allergy will receive ceftriaxone IV (2 g) instead of gentamicin.
62793647|NCT00346788|EXPERIMENTAL|MIS|minimally invasive incision
62793648|NCT00346788|ACTIVE_COMPARATOR|Standard|Standard incision length
62793649|NCT02125084|EXPERIMENTAL|Everolimus and Enzalutamide|"Dose Escalation Phase (18 patients): 3-6 patients will be treated at each dose level until the Maximum Tolerated Dose (MTD) is determined.~* Everolimus: Orally (PO) once daily (dose to be determined;~* Enzalutamide: 160mg (four 40mg capsules) PO continuous daily dosing.~Dose Expansion Phase (23 patients): Everolimus and Enzalutamide to be administered using the MTD determined in the dose escalation phase."
62793650|NCT03009474|EXPERIMENTAL|CJ-30060|Amlodipine 5 mg/ Valsartan 160 mg/ Rosuvastatin 10 mg
62793651|NCT03009474|ACTIVE_COMPARATOR|Exforge tab 5/160mg, Crestor tab 10mg|Amlodipine 5 mg/ Valsartan 160 mg/ Rosuvastatin 10 mg
62793652|NCT01292187|EXPERIMENTAL|Oral calcitonin at dinner-or bedtime|Intervention: Oral calcitonin at dinnertime or oral calcitonin at bedtime. Postmenopausal subjects with osteopenia were treated for one year (also with vitamin D and calcium supplements) to determine if oral calcitonin tablets would prevent the loss of bone mineral density compared with placebo. Randomization to active or placebo was done 2:1. After randomization, further randomization was done to divide each arm into two groups, one in which dosing was at dinnertime and the other in which dosing was at bedtime to determine if food affected efficacy or safety.
62793653|NCT01292187|EXPERIMENTAL|Oral placebo at dinner- or bedtime|Intervention: oral placebo at dinnertime or oral placebo at bedtime
62793654|NCT04869865|EXPERIMENTAL|Intervention|Detoxification cleanse
62793655|NCT06531070|EXPERIMENTAL|Nitrate|A gel providing 600 mg (9.6 mmol) of nitrate.
62793656|NCT06531070|EXPERIMENTAL|Nitrated and citrulline|A gel, providing 600mg of nitrate (9.6 mmol) and 6 g of citrulline-malate
62243279|NCT06559163|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as a subcutaneous injection for 24 weeks.
62793657|NCT06531070|PLACEBO_COMPARATOR|Placebo|Placebo in gel format providing negligible amount of nitrate
62793658|NCT00966615|EXPERIMENTAL|Balance group|peritoneal dialysis with neutral peritoneal dialysis solution with minimal glucose-degradation-product
62793659|NCT00966615|ACTIVE_COMPARATOR|Control group|conventional PD solution
62793660|NCT05483075|EXPERIMENTAL|HCP-Guided Exercise|"Participants will schedule twice-weekly in-person visits to conduct health care provider (HCP)-supervised exercise activity for a minimum of 30 minutes. At least 3 additional times per week, participants will conduct self-directed exercise at home. Activity and other outcomes will be monitored with an Actigraph Centrepoint Insight Watch.~The HCP guided therapy will continue on a weekly basis for at least 2 weeks and up to a maximum of 4 weeks."
62411996|NCT01603927||Colonoscopy with Narrow band imaging (NBI)|All patients attending for routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
62411997|NCT02250157|EXPERIMENTAL|Part 1|"Part 1 of this study is a 3+3 design to define the MTD of Oratecan in up to 60 evaluable subjects. It will be conducted in 2 parts; 1A will test the oral liquid formulation and 1B will test the oral tablet formulation of irinotecan."
62585977|NCT05581940||Pediatric caudal anesthesia block.|caudal epidural block is a neuraxial block to provide effective pain relief and analgesia in pediatrics undergoing infra-umbilical pediatric surgery this study aimed to compare the effectiveness of adding to general anesthesia in terms of Intra and post-op pain management. A prospective, randomized case-controlled.A total of 72 patients aged two months to six years with (ASA PS) I (ASA I) were recruited over a six-month period between December 2019 and May 2020. Patients were allocated into two groups A performed under general anesthesia with caudal block and group B performed under general anesthesia alone. Both groups were compared based on hemodynamic stability, analgesia need, pain score, and parental satisfaction. Postoperative pain was evaluated by the Pain Scale- Categorical and numerical variables of both groups were compared. Results:
62585978|NCT05362396|EXPERIMENTAL|Inspiratory muscle training|Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Treatment as usual
62585979|NCT05362396|NO_INTERVENTION|No training program|Without inspiratory muscle training. Treatment asusual.
62585980|NCT01382472|EXPERIMENTAL|Rosuvastatin|40 mg rosuvastatin pre PCI and daily during hospital stay
62585981|NCT01382472|OTHER|Historical data (KOMPIS)|Patients from the KOMPIS trial (n=44) will be used as historical controls. They received no statins omn the first day. Low dose simvastatin during hospital stay.
62793661|NCT05483075|NO_INTERVENTION|Control|Participants will not participate in the HCP-guided exercise intervention but will wear the Actigraph Centrepoint Insight Watch.
62217714|NCT06226103|EXPERIMENTAL|Interventional Group (Aerobic Exercise and Computerized Cognitive Training)|"Aerobic Exercise (AE) included walk briskly, increasing intensity and duration progressively. The first week they had to walk 30 min per day, 3 days per week, up to 9-10 on the Borg Rating of Perceived Exertion Scale (BRPES; Borg, 1982) perceived as light intensity; during the second week, the duration was increased to 45 min and the intensity 9-10 and frequency (3 days per week) were maintained; the following 10 weeks they maintained the duration (45 min) and frequency (3 days per week) and increased the intensity up to 12-14 on BRPES perceived as moderate-high effort.~Computerized Cognitive Training (CCT) included a multidomain computer-based cognitive training using the brainHQ software in sessions of 45 min, 3 days per week for 12 weeks. Cognitive tasks targeted attention, recognition, colour and shape, identification, calculation, visual perception, visual spatial processing, memory, and executive function)."
62217715|NCT06226103|ACTIVE_COMPARATOR|Control Group|Participants were exposed to balancing, coordination, stretching, and core exercises. Additionally, they attended brain health lectures to provide a comparative non-interactive cognitive engagement. Both the exercises and lectures were scheduled similar to the intervention group over 12 weeks.
62217716|NCT06485453||Botulinum Toxin A responder|Patients who respond to the 200 IU Onabotulinum toxin-A injections were allocated to Groups 1
62217717|NCT06485453||Botulinum Toxin A non-responder|Patients who did not respond to the 200 IU Onabotulinum toxin-A injections were allocated to Groups 2
62411998|NCT02250157|EXPERIMENTAL|Part 2|Part 2 will enroll an additional 10 subjects at the Part 1 MTD to further characterize the safety, tolerability, pharmacokinetics, and activity of Oratecan at that dose.
62411999|NCT05028881||HIV positive|No interventions
62412000|NCT05028881||HIV uninfected|No interventions
62412001|NCT02326337|ACTIVE_COMPARATOR|Topical Wound Oxygen Device|"Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with Advanced Moist Wound Therapy (AMWT) dressings.~Other Names:~* Topical Wound Oxygen Therapy~* TWO2"
62412002|NCT02326337|PLACEBO_COMPARATOR|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
62585982|NCT05405309|EXPERIMENTAL|Phase Ib: Dose Level -1|To assess the MTD of RP-3500 in combination with olaparib. Patients will receive 40mg of RP-3500 daily and 100mg Olaparib BID.
62585983|NCT05405309|EXPERIMENTAL|Phase Ib: Dose Level 1|To assess the MTD of RP-3500 in combination with olaparib. Patients will receive 50mg of RP-3500 daily and 100mg Olaparib BID.
62585984|NCT05405309|EXPERIMENTAL|Phase Ib: Dose Level 2|To assess the MTD of RP-3500 in combination with olaparib. Patients will receive 80mg of RP-3500 daily and 100mg Olaparib BID.
62585985|NCT05405309|EXPERIMENTAL|Phase Ib: Dose Level 3|To assess the MTD of RP-3500 in combination with olaparib. Patients will receive 80mg of RP-3500 daily and 150mg Olaparib BID.
62585986|NCT05405309|EXPERIMENTAL|Phase II: Dose Expansion Enrichment Cohort|Subjects enrolled into the enrichment cohort must have a del(11q) and/or ATM mutation.
62585987|NCT05405309|EXPERIMENTAL|Phase II: Dose Expansion Eligible Subjects Cohort|Cohort will include all other eligible subjects for Dose Expansion.
62585988|NCT03477253|ACTIVE_COMPARATOR|LC within 72 hours of disease onset|Immediate laparoscopic cholecystectomy within 72 hours of the onset of symptoms was performed in these patients
62585989|NCT03477253|ACTIVE_COMPARATOR|LC after 72 hours of disease onset|Late laparoscopic cholecystectomy after 72 hours of the onset of symptoms was performed in these patients
62585990|NCT00186979|OTHER|1|
62793662|NCT04664374||Mood Disorder|Based on screening questions administered on-line as part of the enrollment process, participants will be divided into two groups: (i) those who screen positive for a history of mood disorders and (ii) all other participants. All outcome measures apply only to the mood disorder group.
62412003|NCT04274426|ACTIVE_COMPARATOR|Control arm with Platinum-based chemotherapy|"1. Carboplatin (AUC5, d1) combined with pegylated liposomal doxorubicin (PLD) (30 mg/m², d1) q28d~2. Carboplatin (AUC4, d1) combined with gemcitabine (1000 mg/m2, d1 \& d8) q21d~3. Carboplatin (AUC5, d1) combined with paclitaxel (175 mg/m², d1) q21d"
62793663|NCT04664374||Other|see above
62793664|NCT00651716||Allogeneic Stem Cell Transplant Patients|Patients undergoing allogeneic stem cell transplant (SCT). Potential study candidates will be identified by participating physicians.
62022015|NCT02290665|EXPERIMENTAL|Saline enema|Thermosensitive gel rectal formulation or saline (control) enema with crossover to the other.
62022016|NCT01198600|OTHER|Phase 1: Habitual no Replacement, then Habitual Replacement|Contact lenses per participant's habitual prescription worn for 30 days with no replacement, followed by contact lenses per habitual prescription worn for 30 days with a replacement pair dispensed at Day 28.
62217718|NCT04490967|EXPERIMENTAL|Silymarin and salicylic acid|There will be one group of patients, that will use salicylic acid peeling on the right side of the face and topical Silymarin cream on the left side
62217719|NCT04385589|ACTIVE_COMPARATOR|Dapagliflozin group|50 patients will receive Dapagliflozin plus insulin (if needed) and Diuretics plus conventional heart failure measures.
62585991|NCT03411980|EXPERIMENTAL|Subjects with moderately decreased renal function|Subjects with moderate renal impairment with an estimated glomerular filtration rate (eGFR) of 30 to 59 mL/min/1.73 m\*2 according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
62217720|NCT04385589|PLACEBO_COMPARATOR|Placebo group|50 patients will receive insulin for control of blood sugar plus diuretics and anti-failure measures.
62217721|NCT04435210|EXPERIMENTAL|Nifedipine arm|Participants in this arm will be pregnant women with severe hypertension who will receive nifedipine
62243280|NCT06734143||Group|patients with diabetes mellitus
62793665|NCT02135510|ACTIVE_COMPARATOR|metoclopramide|
62793666|NCT02135510|ACTIVE_COMPARATOR|dexamethason|
62793667|NCT02135510|ACTIVE_COMPARATOR|palonosetron|
62793668|NCT03819361||Suspected OSA|
62793669|NCT04732689||Groups/Cohorts|The investigators propose to conduct a prospective observational cohort which will include all consecutive adult liver transplant recipients in each center during a one-year period but will exclude same patients who undergo a retransplantation during the same period of observation.
62793670|NCT01132313|EXPERIMENTAL|2|4 weeks of high dose TID BI 207127 and QD BI 201335 in combination with RBV, Part 1
62793671|NCT01132313|EXPERIMENTAL|1|4 weeks of low dose three times per day (TID) BI 207127 and once daily (QD) BI 201335 in combination with RBV, Part 1
62793672|NCT01132313|EXPERIMENTAL|3|16 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
62793673|NCT01132313|EXPERIMENTAL|4|28 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
62793674|NCT01132313|EXPERIMENTAL|5|40 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
62793675|NCT01132313|EXPERIMENTAL|6|28 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 2
62793676|NCT01132313|EXPERIMENTAL|7|28 weeks of TID BI 207127 and QD BI 201335 without RBV, Part 2
62793677|NCT01132313|EXPERIMENTAL|8|16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
62793678|NCT01132313|EXPERIMENTAL|9|24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
62793679|NCT01132313|EXPERIMENTAL|10|24 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 3
62793680|NCT01132313|EXPERIMENTAL|11|16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
62022017|NCT01198600|OTHER|Phase 1: Habitual Replacement, then Habitual no Replacement|Contact lenses per participant's habitual prescription worn for 30 days with replacement pair dispensed at Day 28, followed by contact lenses per habitual prescription worn for 30 days with no replacement.
62022018|NCT01198600|OTHER|Phase 2: Lotrafilcon B Replacement|Contact lenses worn for 56 days with replacement pair dispensed at Day 28.
62022019|NCT01198600|OTHER|Phase 3: Lotrafilcon B Replacement Replacement|Contact lenses worn for 43 days with replacement pair dispensed at Day 1 and Day 28.
62243281|NCT02082587||QOL Assessment|
62243282|NCT00738413|ACTIVE_COMPARATOR|Arm 1|Subjects will be treated for 6 days with deferoxamine.
62243283|NCT00738413|ACTIVE_COMPARATOR|Arm 2|Subjects will be treated for 6 days with deferasirox.
62243284|NCT00738413|EXPERIMENTAL|Arm 3|Subjects will be treated for 6 days with a combination of deferoxamine and deferasirox.
62243285|NCT04755205||Cohort 1|Subjects with confirmed olfactory neuroblastoma.
62243286|NCT05360082||Healthy controls|
62243287|NCT05360082||Premanifest HD mutation carriers|"* HTT CAG repeat length ≥ 40~* UHDRS Diagnostic confidence level \< 4"
62243288|NCT05360082||Manifest HD mutation carriers|"* HTT CAG repeat length ≥ 40~* UHDRS Diagnostic confidence level = 4~* Shoulson-Fahn stage 1-2"
62243289|NCT06692153|EXPERIMENTAL|Single Arm|All participants will use the AID system.
62243290|NCT06692153|EXPERIMENTAL|Randomized Controlled Trial (RCT)|Subjects will be randomized 2:1 in the AID group to SC group.
62793681|NCT01132313|EXPERIMENTAL|12|24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
62022020|NCT01389219|NO_INTERVENTION|Control|Control arm
62022021|NCT01389219|OTHER|Intervention clusters|Focus is to increase the number of visits by LHWs to the newborn baby and to ensure that this visit occurs within 48-72 hours of birth. The purpose of this visit was the provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation, cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.
62022022|NCT06045624|EXPERIMENTAL|Part A|"Drug- OR-101~Dosage level: SAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 150mg, 450mg, 900mg, 1500mg OR-101 in dose escalating manner in cohorts 1-6.~Dosage form: Solution~Route of administration- Oral"
62022023|NCT06045624|EXPERIMENTAL|Part B|"Drug- OR101~Dosage level: Food effect participants (8 subjects in 9 cohorts) will only receive OR-101with a high fat meal prior to administration and subjects in corresponding dose under fasted condition will serve as their reference group.~Dosage form: Solution~Route of administration- Oral"
62412004|NCT04274426|EXPERIMENTAL|Carboplatin + Mirvetuximab soravtansine (IMGN853)|Carboplatin (AUC5, d1) + Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV d1 x 6 cycles q21d, followed by subsequent monotherapy of Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV q3w until disease progression.
62022024|NCT06045624|EXPERIMENTAL|Part C|"Drug- OR-101~Dosage level: MAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 135mg, 270mg, 540mg and 900mg OR-101 in dose escalating manner in cohorts 1-6. Total dosage of cohort 7 and 8 will be decided based on Safety review committe's input where cohort 8 will receive this daily for 7 days.~Dosage form: Solution~Route of administration- Oral"
62217722|NCT04435210|EXPERIMENTAL|Hydralazine|Participants in this arm will be pregnant women with severe hypertension who will receive hydralazine
62412005|NCT03105232||Group A|Morphin, Hydromorfon, Oxycodon
62412006|NCT03105232||Group B|Buprenorfin
62412007|NCT03105232||Group C|Fentanyl
62793682|NCT04642391||RAI|Subjects will be diagnosed with relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol \<9mcg/dL.
62793683|NCT04642391||Non-RAI|Subjects will have not have relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol \>= 9mcg/dL.
62793684|NCT04175028|OTHER|ADHD|Patients with ADHD.
62793685|NCT04175028|OTHER|Healthy Control|Volunteers without Neuropsychiatric Disorders.
62793686|NCT05799131||QBX (5F/6F) Peripheral Balloon Expandable Stent System|
62793687|NCT04206488|EXPERIMENTAL|JNJ-70033093 + Digoxin|Participants will receive JNJ-70033093 as oral capsules (Treatment A) in Period 1, followed by digoxin tablets as loading dose and maintenance doses (Treatment B) in Period 2, and then digoxin tablets along with JNJ-70033093 (Treatment C) in Period 3. There will be a washout period of minimum 5 days (and maximum 7 days) between the last dosing day of Period 1 and the first dosing day of Period 2. There is no washout between Periods 2 and 3 (that is, the last day of Treatment B is to be followed by the first day of Treatment C).
62793688|NCT01375023|EXPERIMENTAL|Anti-Thymocyte Globulin+radiotherapy|triple negative breast cancer patients treated with radiation and Anti-Thymocyte Globulin iv
62793689|NCT01442714|EXPERIMENTAL|Azacitidine plus Lenalidomide|Patients will receive a single dose of azacitidine 75 mg/m² SC or IV on days 1 to 7, followed by lenalidomide 50 mg PO daily on days 8 to 28 of a 42-day cycle.
62793690|NCT00930553|EXPERIMENTAL|Previously treated with alemtuzumab|Alemtuzumab 12 mg per day administered through IV, once a day for 3 consecutive days (participants might receive additional cycles of alemtuzumab upon documented evidence of resumed disease activity, but not within same 12-month period)
62022025|NCT06045624|PLACEBO_COMPARATOR|Placebo|Placebo comparators taken by participants randomised to the placebo arm across Part A and C of the study.
62022026|NCT03575130|EXPERIMENTAL|Glanatec|
62022027|NCT03575130|PLACEBO_COMPARATOR|Placebo|
62022028|NCT03067441|EXPERIMENTAL|Open-Label bempedoic acid|bempedoic acid 180 mg tablet
62412008|NCT03105232||Group D|Opioid rotation
62412009|NCT02829229|NO_INTERVENTION|Usual care (UC)|Usual postpartum WIC care
62412010|NCT02829229|EXPERIMENTAL|Community-based obesity treatment (PP)|The PP arm includes expanded obesogenic behavior change goals, tailored skills training materials, interactive self-monitoring text messages, video testimonials, and interpersonal counseling support through health coach calls and Facebook.
62412011|NCT05517746|EXPERIMENTAL|Group 1|Participants received BAY2395840 dose A as tablets under diet 1 conditions (Period 1). After the safety assessment for Period 1 and a washout period of at least 14 days participants were re-dosed with the same BAY2395840 dose A1 as oral solution under diet 1 conditions (Period 2)
62412012|NCT05517746|EXPERIMENTAL|Group 2|Participants received BAY2395840 dose C as tablets under diet 1 conditions.
62412013|NCT05517746|EXPERIMENTAL|Group 3|Participants received BAY2395840 dose E as tablets under diet 1 conditions.
62793691|NCT00930553|EXPERIMENTAL|Previously treated with interferon beta-1a (Rebif®)|Alemtuzumab 12 mg per day administered through IV, once a day for 5 consecutive days during the first cycle and 12 mg per day administered through IV, once a day for 3 consecutive days during the second cycle, 12 months later. Participants might qualify for as-needed retreatment (12 mg per day administered through IV, once a day for 3 consecutive days) after their second fixed annual cycle.
62793692|NCT06064071|EXPERIMENTAL|Experimental: Nordlys SWT IPL|Subjects will receive up to four study Nordlys SWT IPL treatments and MGX
62585992|NCT03411980|EXPERIMENTAL|Subjects with severely decreased renal function|Subjects with severe renal impairment not on dialysis with an eGFR \<30 mL/min/1.73 m\*2 (CKD-EPI formula).
62585993|NCT03411980|EXPERIMENTAL|Control subjects with normal renal function|Subjects with an eGFR ≥90 mL/min/1.73 m\*2 (CKD-EPI formula) who are matched based on sex, age, race and weight.
62412014|NCT05517746|EXPERIMENTAL|Group 4|Participants received BAY2395840 dose H as tablets under diet 1 conditions
62412015|NCT05517746|EXPERIMENTAL|Group 5|Participants received BAY2395840 dose B as tablets on Day 1 after diet 2, on Days 2 to 7 under diet 1 conditions
62793693|NCT06064071|SHAM_COMPARATOR|Control Group: Sham Treatment|Subjects will receive up to four sham study Nordlys SWT IPL treatments (device turned off) and MGX
62022029|NCT02842060|EXPERIMENTAL|myDEx Intervention|The proposed intervention will consist of a 6-session web-based program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, YMSM will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help YMSM consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
62412016|NCT05517746|EXPERIMENTAL|Group 6|Participants received BAY2395840 dose C as tablets on Day 1 after diet 2, on Days 2 to 7 under diet 1 conditions
62412017|NCT05517746|EXPERIMENTAL|Group 7|Participants received BAY2395840 dose I as tablets under diet 1 conditions
62412018|NCT05517746|EXPERIMENTAL|Group 8|Participants received BAY2395840 dose G as tablets on Day 1, followed by 3 BAY395840 doses of dose F as tablets on Days 2 to 4 and subsequently 7 further BAY395840 doses of dose G as tablets on Days 5 to 11 under diet 1 conditions
62412019|NCT05517746|PLACEBO_COMPARATOR|Placebo matching Group 1|Participants received a dose of placebo as tablets under diet 1 conditions (Period 1). After the safety assessment for Period 1 and a washout period of at least 14 days participants were re-dosed with a single dose of placebo as oral solution under under diet 1 conditions (Period 2)
62412020|NCT05517746|PLACEBO_COMPARATOR|Placebo matching Group 2 to 4 and Group 7|Participants received a dose of Placebo as tablets under diet 1 conditions
62412021|NCT05517746|PLACEBO_COMPARATOR|Placebo matching Group 5 and 6|Participants received Placebo as tablets on Day 1 after diet 2, on Days 2 to 7 under diet 1 conditions
62412022|NCT05517746|PLACEBO_COMPARATOR|Placebo matching Group 8|Participants received a dose of Placebo as tablets on Day 1, followed by 3 doses of Placebo as tablets on Days 2 to 4 and subsequently 7 further doses of Placebo as tablets on Days 5 to 11 under diet 1 conditions.
62412023|NCT01056185||Influenza|Influenza A and subtypes such as H3N2 and 2009 H1N1 or influenza B
62585994|NCT01710371|EXPERIMENTAL|Arginine Stimulation Testing|Establish the methodology for glucose enhanced arginine stimulation testing (AST).
62585995|NCT01710371|EXPERIMENTAL|PET Imaging|Determine if pancreatic PET-determined binding measures of 18F-AV-133 differ in up to 60 subjects determined to be at one of four stages of the natural history of Type 2 Diabetes: Healthy Overweight/obese Volunteers (HOV), Subjects with Pre-diabetes (PD) and Type 2 Diabetes mellitus (T2DM).
62585996|NCT04590170||Patients with Covid19 infection|Patients with Covid19 infection
62793694|NCT02033746|EXPERIMENTAL|Transdermal Electroacupuncture - Arm A|week 1-2 real treatment, week 3-6 sham treatment with Han's Acupoint Nerve Stimulator while receiving concurrent buprenorphine-naloxone as prescribed
62793695|NCT02033746|EXPERIMENTAL|Transdermal Electroacupuncture - Arm B|week 1-2 real treatment, week 3-6 sham treatment with Han's Acupoint Nerve Stimulator treatment while receiving concurrent buprenorphine-naloxone as prescribed
62793696|NCT01247961|EXPERIMENTAL|10 mg intravenous dexamethasone|Subjects randomized to intervention arm will receive single dose of 10 mg intravenous dexamethasone.
62793697|NCT01247961|PLACEBO_COMPARATOR|Placebo|Equal volume of normal saline administered as a single intravenous dose at enrollment.
62793698|NCT01563263|ACTIVE_COMPARATOR|IC43 100 mcg|IC43 100 mcg intramuscular injection, IC43 is a recombinant Pseudomonas aeruginosa fusion protein
62793699|NCT01563263|PLACEBO_COMPARATOR|Placebo|phosphate buffered saline solution containing 0,9 % NaCL
62819373|NCT03450161|EXPERIMENTAL|Low-Dose Bolus of Fentanyl|"5 minutes prior to sternotomy, patients will receive a fentanyl bolus of 3 mcg/kg BW (verum) and a perfusion pump with sodium chloride (NaCl 0.9%; placebo) will be begun according to the Shibutani dosing scheme.~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
62819374|NCT03450161|EXPERIMENTAL|Continuous Dose of Fentanyl|"5 minutes prior to sternotomy, patients will receive a NaCl 0.9% bolus (placebo) and a perfusion pump with fentanyl (verum) will be begun according to the Shibutani dosing scheme.~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
62412024|NCT01056185||Novel Respiratory Virus-1|MERS-CoV (Middle East Respiratory Syndrome Coronavirus
62412025|NCT01056185||Novel Respiratory Virus-2|SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus)
62412026|NCT02290782|EXPERIMENTAL|Intraoperative radiotherapy (IORT)|"IORT (20Gy) as intervention will be given during breast conserving surgery. If risk factors (Tumor \> 3.5 cm, lobular cancer, resection margin \< 2 mm\*, L1, pN+ mulitfocal/multicentric, EIC, negative hormone receptors) are present, external beam radiotherapy will be added.~\* In case of positive margins (\<2 mm resection margin) a re-resection should be done"
62412027|NCT04190251|OTHER|Intervention group A|Intervention group A will benefit of the medication adherence support program during 12 months. Adherence will be monitored using an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd.) during 24 months. At each pharmacy visits, the pharmacist will conduct an 15 minutes, semi-structured interview based on Fisher's sociocognitiv model with the patients. A summary and the adherence graph will be send to all the involved health professionals
62585997|NCT04590170||Control group|Asymptomatic group
62585998|NCT02448537|EXPERIMENTAL|PM01183 and Doxorubicin|"Anthracycline-naïve patients will receive combination of PM01183 and Doxorubicin per cycle.~* PM01183 predetermined dose daily via IV per cycle~* Doxorubicin predetermined dose daily via IV per cycle"
62585999|NCT02448537|EXPERIMENTAL|PM01183 and Gemcitabine|"Prior anthracycline exposure and without prior gemcitabine exposure~* PM01183 predetermined dose given twice via IV per cycle~* Gemcitabine predetermined dose given twice via IV per cycle"
62412028|NCT04190251|OTHER|Intervention group B|Intervention group A will benefit of the medication adherence support program during 6 months. Adherence will be monitored using an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd.) during 24 months. At each pharmacy visits, the pharmacist will conduct an 15 minutes, semi-structured interview based on Fisher's sociocognitiv model with the patients. A summary and the adherence graph will be send to all the involved health professionals
62793700|NCT01761448|EXPERIMENTAL|Device Guided Exercise|Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities of patients.
62793701|NCT03602365|EXPERIMENTAL|OXYGEN CONSUMPTION SINGLE ARM|Single arm Study Volunteer will h lie in supine posture for 20 min and oxygen consumption(VO2) will be measured in duplicate. Gentle Jogger (GJ) will be started in supine posture for 20 min and VO2 measured again in duplicate. The subject will be asked to sit in a chair for 20 min and VO2 will be measured in duplicate. Gentle Jogger (GJ) will be started in seated posture for 20 min and VO2 measured again in duplicate.
62793702|NCT05257291|NO_INTERVENTION|Control group|Group of essential hypertensive patients who have received no additional therapies in addition to their established treatment plan (each patient was on specific antihypertensive therapy that has not been changed).
62793703|NCT05257291|ACTIVE_COMPARATOR|Melatonin treated group|Group of essential hypertensive patients who have received additional therapies consisting in 1 mg/day of melatonin for 1 year, in addition to their established treatment plan.
62793704|NCT06154707|EXPERIMENTAL|Denosumab Group|Denosumab injection 60mg (1.0ml/ branch, Jiangsu Taikang Biological Medicine Co., LTD., s20233111), once every 6 months, 60mg, subcutaneous injection, at the same time to supplement calcium and vitamin D.
62793705|NCT06154707|PLACEBO_COMPARATOR|Placebo Group|Placebo drug, the main component of normal saline injection (1.0ml/ dose). In addition to the different production batch number, its appearance, character, specification, administration mode and frequency are exactly the same as the experimental group of drugs (different production batch number is convenient for later unblinding reference). Take calcium and vitamin D supplements. The study lasted for 12 months.
62793706|NCT03053570|EXPERIMENTAL|Cryoballoon|
62793707|NCT03053570|EXPERIMENTAL|Radiofrequency Energy(Contact Force)|
62793708|NCT04486014|EXPERIMENTAL|Erector spinae plane block (ESP)|Patients would receive erector spinae plane block
62793709|NCT04486014|EXPERIMENTAL|Serratus anterior plane block (SAP)|Patients would receive serratus anterior plane block
62793710|NCT03798327|EXPERIMENTAL|Home Palliative Care|Randomized to Intervention Arm
62793711|NCT03798327|NO_INTERVENTION|Control Arm|Usual Care - Patients will be cared for by the physician who treats their dementia and other illnesses.
62793712|NCT01505374|EXPERIMENTAL|Study Technique Left Leg, Control Technique Right Leg|
62793713|NCT01505374|EXPERIMENTAL|Study Technique Right Leg, Control Technique Left Leg|
62793714|NCT00904488|ACTIVE_COMPARATOR|Addition of PO Thiazide Diuretic|Addition of oral metolazone 5 mg daily to current intravenous bolus furosemide. All subjects will continue their current dose of intravenous bolus furosemide.
62793715|NCT00904488|ACTIVE_COMPARATOR|IV furosemide dose escalation|Current IV furosemide dose will be escalated to 2-2.5 x current dose, given as either IV bolus or continuous infusion over 24 hours.
62793716|NCT00091091||All patients|Self report/Medical record review/ clinical eval
62793717|NCT01076530|EXPERIMENTAL|Arm I|Patients receive oral vorinostat and oral temozolomide once daily on days 1-5. Courses repeat every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
62412029|NCT04914559|ACTIVE_COMPARATOR|Oral Nutrition Supplement Control|The control study intervention is an oral drink that contain protein, carbohydrate and fat and are intended for use as supplemental nutrition.
62586000|NCT02448537|EXPERIMENTAL|Single Agent PM01183|"Patients who have received at least both prior anthracycline and prior gemcitabine~-PM01183 predetermined dose once via IV per cycle"
62586001|NCT04871204|NO_INTERVENTION|Control|Standard treatment
62586002|NCT04871204|EXPERIMENTAL|Octreotide|3 monthly intramuscular injections of 10 mg Octreotide
62586003|NCT01235026|EXPERIMENTAL|Synbiotic|"Dietary Supplement: Synbiotic: combination of the prebiotic Oligofructose with the probiotic Bifidobacterium animalis subsp. lactis Bb12"
62586004|NCT01235026|PLACEBO_COMPARATOR|Placebo|Dietary supplement: placebo: maltodextrin
62586005|NCT03724903|EXPERIMENTAL|Ductal lavage|Ductal lavage and breast massage for two weeks.
62586006|NCT03724903|ACTIVE_COMPARATOR|Corticosteroids therapy|Oral corticosteroids therapy for 6 months.
62793718|NCT02362750||Participating Program Administrators|Eligible survivorship program administrators at selected Commission on Cancer-accredited institutions will complete an organizational interview and organizational survey.
62793719|NCT02362750||Participating Cancer Survivors|"Survivors receiving follow-up care surveys at selected Commission on Cancer-accredited institutions will complete four surveys:~Survivor Survey (1): Pre-Visit Baseline Survivor Survey (2): 1 Week Post-Visit Survivor Survey (3): 3 Months Post-Visit Survivor Survey (4): 6 Months Post-Visit"
62793720|NCT02362750||Participating Clinicians|Survivorship clinicians from clinical survivorship programs at selected Commission on Cancer-accredited institutions will complete a clinician survey.
62586007|NCT05843383|EXPERIMENTAL|Ciprofol group|Ciprofol-based total intravenous anesthesia is given for maintenance of general anesthesia
62586008|NCT05843383|EXPERIMENTAL|Propofol group|Propofol-based total intravenous anesthesia is given for maintenance of general anesthesia
62586009|NCT01399463|EXPERIMENTAL|DEB + BMS|Paclitaxel drug-eluting balloon (DEB) dilatation and bare metal stenting
62793721|NCT05637788||HCC Patients Submitted Surgery|"For the retrospective data collection, the planned number of subjects that will be enrolled will be almost 150/year. Considering the study-period (2010-2020), it is estimated a total of 1500 patients.~For the prospective observational data collection, the estimation of patients'enrolment is based on the number of patients treated per year in the participating centers (globally 150/year). Since the observational nature, patients will be evaluated for their enrolment consecutively. The prospective data collection will be prosecuted for 2 years, leading to a prospective cohort of 300 patients. The whole study is planned to be ended in December 2023. Inclusion and exclusion criteria will be the same among the retrospective and the prospective parts of the study."
62793722|NCT01594619|EXPERIMENTAL|A|Single dose naloxegol 25mg
62793723|NCT01594619|ACTIVE_COMPARATOR|B|Diltiazem 240mg once daily day 4-6
62793724|NCT01594619|ACTIVE_COMPARATOR|C|Diltiazem 240mg once daily day 7 and 8. Single dose naloxegol 25mg day 7
62022030|NCT02842060|ACTIVE_COMPARATOR|Non-tailored HIV Prevention|The investigators will create a 6-session web-based attention-control comparison to match myDEx in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites.
62217723|NCT04558879|EXPERIMENTAL|Cardiovascular training|Cardiovascular training (CT) will be performed on a recumbent stepper. CT will start at low intensity, and through a linear progression will reach vigorous intensity; then, this intensity will be maintained until the end of the intervention. Each session will include five minutes of warm-up and cool-down performed at the beginning and the end of the training, respectively. Furthermore, five minutes of stretching will be performed after the cool down. CT's sessions will approximately last 45 minutes and will be interspersed with at least 48 hours of recovery.
62022031|NCT04725331|EXPERIMENTAL|Phase I, Part A - Dose escalation and safety of BT-001 alone|Dose escalation with repeated administrations of BT-001 directly into tumor as a single agent, in patients with metastatic or advanced solid tumors.
62022032|NCT04725331|EXPERIMENTAL|Phase I, Part B - Safety of BT-001 in combination with pembrolizumab|Repeated administrations of BT-001 directly into tumor in combination with infusions of pembrolizumab in patients with metastatic or advanced soft tissue sarcoma (STS), Merkel cell carcinoma (MCC), melanoma, triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC)..
62022033|NCT04725331|EXPERIMENTAL|Phase IIa - Expansion cohorts of BT-001 in combination with pembrolizumab|Repeated administrations of BT-001 directly into tumor in combination with infusions of pembrolizumab in several cohorts of patients with defined metastatic or advanced solid tumor conditions: soft tissue sarcoma, Merkel cell carcinoma, melanoma, triple negative breast cancer, non-small cell lung cancer.
62022034|NCT01786356|OTHER|HOYA iMics Y-60H|eyes with implanted intraocular lens HOYA iMics Y-60H
62022035|NCT01786356|OTHER|B&L MI60|eyes with implanted intraocular lens B\&L MI60
62022036|NCT04157244|EXPERIMENTAL|Experimental: Tailored Music|4-week tailored music listening intervention delivered to persons with dementia and their caregivers via a tablet.
62022037|NCT04157244|NO_INTERVENTION|4-week Wait-list control|4-week wait-list control (Note: participants will be crossed over to 4-week tailored music listening intervention delivered to persons with dementia and their caregivers via a tablet)
62022038|NCT04408469|EXPERIMENTAL|Online EQuIP|The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
62243291|NCT04554238|EXPERIMENTAL|Armeo spring group|Regarding masking, it is impossible for the treating occupational therapist to be unaware of the treatment to be carried out by the treated patient, just as it is impossible for the patient not to identify the treatment to which they access, therefore, this study is single-blind, considering only who performs the evaluations of the study will not know which group corresponds to the evaluated patient.
62793725|NCT01436786|EXPERIMENTAL|Guided Imagery Intervention|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
62793726|NCT01436786|NO_INTERVENTION|Control group|continues usual plan of care
62793727|NCT05597696||1) Experimental Group: Transfemoral Amputee|Balance assessment in sitting
62793728|NCT05597696||2) Control Group: Healthy Subjects|Balance assessment in sitting
62793729|NCT03517761|EXPERIMENTAL|Bone Marrow Concentrate treatment|Bone marrow concentrate subjects will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow nucleated cell layer. Injectate will then be used to treat the ligaments in the CCJ and upper cervical injections to C0-C3 ligaments and facets.
62793730|NCT03517761|SHAM_COMPARATOR|Sham Control|Control subjects will also undergo a bone marrow aspiration of 30-60 cc to maintain blinding. Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia as well as receive sham upper cervical injections to C0-C3 ligaments and facets.
62793731|NCT06139744|EXPERIMENTAL|DAO supplement group|One tablet of the supplementary study product was taken orally before morning, lunch and dinner every day, and each tablet contained 4.2mg of dehydrated pea seedling powder.
62217724|NCT04558879|EXPERIMENTAL|Resistance training|Resistance training (RT) intensity will be estimated using the percentage of one-maximal repetition (1-RM) defined as the maximal weight liftable for ten maximal repetitions with proper form. The program will include five exercises (leg press, lat machine, leg extension, leg curl, bench press) and will start at high-volume low-intensity. RT will follow a periodization to reach high-intensity low-volume at the end of the intervention (week 12). The training sessions will start with five-minute of warm-up performed on a recumbent stepper and will end with five-minute of stretching (cool-down). RT's sessions will approximately last 45 minutes and will be interspersed with at least 48 hours of recovery.
62022039|NCT04408469|PLACEBO_COMPARATOR|Self-Monitoring|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
62217725|NCT04369859||pregnant women with COVID-19|Pregnant women who have tested positive for COVID-19
62217726|NCT03500601|EXPERIMENTAL|Active treatment|Nut components
62793732|NCT06139744|PLACEBO_COMPARATOR|Placebo group|Placebo was orally supplemented with one tablet each day before morning, lunch and dinner, and placebo did not contain dehydrated pea seedling powder 4.2mg.
62217727|NCT03500601|PLACEBO_COMPARATOR|Placebo|Placebo
62412030|NCT04914559|ACTIVE_COMPARATOR|Oral Nutrition Supplement Test|The test study intervention is an oral drink that contain protein, carbohydrate and fat and are intended for use as supplemental nutrition for people living with diabetes.
62412031|NCT04813653|EXPERIMENTAL|cyclosporine in combination with carfilzomib and dexamethasone|cyclosporine in combination with carfilzomib and dexamethasone in patients with relapsed multiple myeloma refractory to carfilzomib with high expression of the PPIA gene in myeloma cells
62412032|NCT01503502|EXPERIMENTAL|flumatinib 400mg qd|
62793733|NCT05082246|OTHER|Pre- and Post- Intervention|Data will be gathered in participants with pre-intervention and post-intervention comparison.
62793734|NCT03293030|EXPERIMENTAL|Dupilumab treatment|15 subjects will receive dupilumab for a treatment period of 52 weeks (i.e. last injection on week 50). All subjects will undergo skin biopsies for molecular profiling.
62793735|NCT03685227|NO_INTERVENTION|Control|Participant will lie quietly for 90 minutes. They will be allowed to sleep.
62793736|NCT03685227|EXPERIMENTAL|Yoga Nidra|Participant will practice yoga nidra (using a recording) during the first 30 minutes of the 90 minute measurement period. Then they will be allowed to sleep.
62793737|NCT05140460|EXPERIMENTAL|Intervention|
62793738|NCT05140460|ACTIVE_COMPARATOR|Control|
62022040|NCT03359096|EXPERIMENTAL|Therapeutic HGNS|Therapeutic Hypoglossal Nerve Stimulation (HGNS). Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study.
62022041|NCT03359096|SHAM_COMPARATOR|Subtherapeutic 'Sham' HGNS|"Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds."
62022042|NCT02574923|EXPERIMENTAL|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
62022043|NCT06494111|EXPERIMENTAL|Group 1|Beginning at 6 months after radiation therapy, participants will take 40 mg pravastatin by mouth 1 time a day for about 12 months.
62217728|NCT06043752|EXPERIMENTAL|Remsima|
62217729|NCT01193426||Cirrhosis patient|All consecutive patients with cirrhosis admitted to the five participating center Patients were hospitalized or treated in an ambulatory setting for treatment of ascites or complications of cirrhosis. Ascitic fluid was obtained by paracentesis according to the usual clinical management for these patients.
62217730|NCT05427604|OTHER|Sequential intervention|"1. single ingestion of olive oil for assessement of monounsaturated fatty acids peak time in blood (3g)~2. single ingestion of olive oil for collection of blood sample at peak time (3g)~3. single ingestion of DHA-rich oil for assessement of polyunsaturated fatty acids peak time in blood (3g)~4. single ingestion of DHA-rich oil for collection of blood sample at peak time (3g)"
62412033|NCT01503502|EXPERIMENTAL|flumatinib 600 mg qd|
62412034|NCT01503502|ACTIVE_COMPARATOR|imatinib|
62793739|NCT01792037|ACTIVE_COMPARATOR|Etomidate|After taking of the blood samples, patients in Group I will be intubated with 0.3 mg/kg etomidate iv. Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired.
62793740|NCT01792037|ACTIVE_COMPARATOR|etomidate, steroid|After taking of the blood samples, patients in Group II will be intubated with 0.3 mg/kg etomidate iv following a 2mg/kg methylprednisolone iv Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired.
62412035|NCT06515665|ACTIVE_COMPARATOR|therapeutic foot orthosis|foot orthosis will be applied to this group of participants. For 6 weeks they will be asked to use these foot orthoses. Before and after evaluations will be repeated.
62412036|NCT06515665|ACTIVE_COMPARATOR|exercises|this group of participants will be exercised with foot orthoses accompanied by artificial intelligence. For 6 weeks, they will be asked to use these foot orthoses and do their exercises. Before and after evaluations will be repeated.
62412037|NCT06515665|ACTIVE_COMPARATOR|control|this group of participants will be assessed at the beginning and end of the 6 weeks without any intervention.
62217731|NCT05918718|EXPERIMENTAL|methotrexate|The first group will receive a single dose (50 mg/m2) of methotrexate The beta-hcg level is measured on the first day, and the hcg serum level is routinely measured on the fourth, seventh and fourteenth day.
62217732|NCT05918718|EXPERIMENTAL|Letrozole BD|The first group will receive letrozole is given in the form of 2.5 mg tablets twice a day for 10 days. And on the fourth, seventh and fourteenth day, the HCG level is measured.
62217733|NCT05918718|EXPERIMENTAL|Letroozole TDS|letrozole is given in the form of 2.5 mg tablets 3 times a day for 5 days, and hCG levels are measured on days 4, 7, and 14.
62793741|NCT01792037|ACTIVE_COMPARATOR|midazolam|"After taking of the blood samples, patients in Group III will be intubated with 0.01 mg/kg midazolam iv. Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.~Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired."
62793742|NCT05215834|ACTIVE_COMPARATOR|PR group|Propofol and Remifentanil group
62217734|NCT05721404|EXPERIMENTAL|ICO (icodextrin)|When the extracellular water /total body water (ECW/TBW) ≥ 0.40, the patients in the ICO arm will be prescribed icodextrin (Extraneal) for long night dwell to improve fluid overload till their re-measurement of ECW/TBW \< 0.40.
62217735|NCT05721404|OTHER|CON (control)|When the extracellular water /total body water (ECW/TBW) ≥ 0.40, the patients in the CON arm will be prescribed hypertonic Dextrose solution for long night dwell to improve fluid overload till their ECW/TBW \< 0.40
62793743|NCT05215834|EXPERIMENTAL|RR group|Remimazolam and Remifentanil group
62793744|NCT01327677|ACTIVE_COMPARATOR|Pro re nata (PRN) fentanyl|A nurse can give the patient up to 3 doses of fentanyl intravenously (through a vein) each hour whenever a patient indicates that he or she is in pain.
62793745|NCT01327677|ACTIVE_COMPARATOR|Intravenous Patient-controlled Analgesia (IVPCA) fentanyl|Fentanyl will be given with a Patient Controlled Analgesia (PCA) pump.
62793746|NCT01006759|EXPERIMENTAL|leprosy disability|intervention of a series of cases with leprosy that made treatment in a Clinical Hospital
62793747|NCT01362894|OTHER|nelfilcon A / etafilcon A|Nelfilcon A lenses worn first, with etafilcon A lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
62793748|NCT01362894|OTHER|etafilcon A / nelfilcon A|Etafilcon A lenses worn first, with nelfilcon A lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
62217736|NCT01015547|EXPERIMENTAL|Infliximab plus Methotrexate|infliximab 3-5 mg/kg every 6 weeks, plus methotrexate 15 mg/m2 weekly given orally (dose escalation if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.
62217737|NCT01015547|EXPERIMENTAL|Combination of DMARDs|methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75), plus standard doses of sulfasalazine and hydroxychloroquine. no oral prednisolone. intra-articular steroids allowed.
62217738|NCT01015547|ACTIVE_COMPARATOR|Methotrexate alone|Conventional drug therapy: methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.
62217739|NCT02926599|EXPERIMENTAL|Personal Optimization Training|"Personal Optimization Training such as positive reinforcement, personalized psycho-physiological relaxation and mental rehearsal (total 5 hours a few weeks before the simulation).~Having 2 min to focus on techniques they were trained, after briefing of the scenario and before the start of the scenario."
62217740|NCT02926599|NO_INTERVENTION|Control|"No particular training.~Screening of normal labs results during 2 min, after briefing of the scenario and before the start of the scenario."
62217741|NCT05670873|EXPERIMENTAL|rTMS treatment|20 days of repetitive transcranial magnetic stimulation: stimulation site is the left dorsolateral prefrontal cortex, stimulation intensity at 90% RMT, stimulation frequency is 10Hz. A total of 1000 pulses, 10s 10Hz train stimulation, repeated 10 times, each interval 60s, a total of 11 minutes and 40 seconds, 1 treatment per day, a total of 20 days.
62217742|NCT05670873|EXPERIMENTAL|iTBS treatment|20 days of intermittent theta-burst stimulation: stimulation site is the left dorsolateral prefrontal cortex, stimulation intensity at 90% RMT, stimulation frequency is 50Hz. A total of 600 pulses, 3 pulses each time, with an interval of 200 ms, for a total of 2 seconds (10 groups), and then repeat the above process after an interval of 10 seconds, a total of 190 seconds, 1 treatment per day, a total of 20 days.
62217743|NCT01737554||Participants|"Participants include children with cancer and hematologic disorders who, as part of their standard clinical care, have a central venous access device (CVAD) used for infusion, withdrawal of blood, or hemodynamic monitoring.~Intervention: Catheter resistance monitoring"
62217744|NCT02632422|EXPERIMENTAL|Non-ambulatory - dAIH|Non-ambulatory subjects will be randomly assigned to receive 10 sessions of daily acute intermittent hypoxia (dAIH) 10 treatment visits at a frequency of 5 days each week for 2 weeks.
62217745|NCT02632422|SHAM_COMPARATOR|Non-ambulatory - dSHAM|Non-ambulatory subjects will be randomly assigned to receive 10 sessions of daily room air (dSHAM) 10 treatment visits at a frequency of 5 days each week for 2 weeks.
62217746|NCT02632422|EXPERIMENTAL|Ambulatory - dAIH+Walk|Ambulatory subjects will be randomly assigned to receive 10 sessions of daily acute intermittent hypoxia (dAIH) coupled with 60 minutes of walking practice at a frequency of 5 days each week for 2 weeks.
62217747|NCT02632422|SHAM_COMPARATOR|Ambulatory - dSHAM+Walk|Ambulatory subjects will be randomly assigned to receive 10 sessions of daily room air (dSHAM) coupled with 60 minutes of walking practice at a frequency of 5 days each week for 2 weeks.
62793749|NCT06141447|EXPERIMENTAL|Oxytocin|Participants receive 40 units IV oxytocin in 1000 mL of normal saline at the time of tenaculum placement for D\&E.
62793750|NCT06141447|PLACEBO_COMPARATOR|Placebo|Participants receive 1000 mL of normal saline alone at the time of tenaculum placement for D\&E.
62793751|NCT02708810|OTHER|80 Gy Radiation & Unframed Virtual Cone|80 Gy Virtual Cone Radiosurgery unframed (face mask)
62793752|NCT05639140||Color discrimination deficit|
62793753|NCT05639140||Without Color discrimination deficit|
62217748|NCT02632422|OTHER|Ambulatory-Walk|Ambulatory subjects will be randomly assigned to 10 sessions of walking practice only for 5 consecutive sessions/week x 2 weeks.
62793754|NCT06407674||ulcerative colitis|
62793755|NCT06407674||crohn's disease|
62793756|NCT06308666|EXPERIMENTAL|Refit|Refit and dispense participant with delefilcon A contact lenses and evaluate lens performance
62793757|NCT01057186||hereditary hypophosphatemia|Norwegian patients with hereditary hypophosphatemia.
62793758|NCT01057186||Hereditary hyperphosphatemia|Norwegian patients with hereditary hyperphosphatemia (hyperphosphatemic familial tumoral calcinosis and hyperphosphatemia hyperostosis syndrome).
62793759|NCT04323072|EXPERIMENTAL|Group A|Resection of antrum proximally 2 cm to the pylorus
62022044|NCT06494111|EXPERIMENTAL|Group 2|Beginning at 6 months after radiation therapy, participants will take pentoxifylline and vitamin E by mouth 3 times a day for about 12 months.
62217749|NCT02295553|EXPERIMENTAL|Ketamine 0 mg/kg|Ketamine dose will be 0 mg/kg. Propofol dose for the first patient will be 4 mg/kg. Doses for the subsequent patients will increase or decrease by 1.6 mg/kg using the Dixon Up and Down method.
62793760|NCT04323072|ACTIVE_COMPARATOR|Group B|Resection of antrum proximally 6 cm to the pylorus
62793761|NCT04814121|EXPERIMENTAL|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 180 days
62217750|NCT02295553|EXPERIMENTAL|Ketamine 0.25 mg/kg|Ketamine dose will be 0.25 mg/kg. Propofol dose for the first patient will be 3 mg/kg. Doses for the subsequent patients will increase or decrease by 1.2 mg/kg using the Dixon Up and Down method.
62217751|NCT02295553|EXPERIMENTAL|Ketamine 0.5 mg/kg|Ketamine dose will be 0.5 mg/kg. Propofol dose for the first patient will be 2.5 mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
62217752|NCT02295553|EXPERIMENTAL|Ketamine 1.0 mg/kg|Ketamine dose will be 1.0 mg/kg. Propofol dose for the first patient will be 2 mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.
62217753|NCT04596189|EXPERIMENTAL|Dupilumab|Sterile Dupilumab 150 mg/mL will be provided in pre-filled syringes (2.25 total volume) to deliver 300 mg in 2 mL.
62217754|NCT04596189|PLACEBO_COMPARATOR|Placebo|Sterile placebo for Dupilumab will be provided in identically matching pre-filled syringes to deliver 2 mL.
62217755|NCT01281969|EXPERIMENTAL|Group A|Drug: Gamunex Intravenous Immunoglobulin 2.0 gm/kg total, IV (in the vein), over 2 days
62217756|NCT01281969|PLACEBO_COMPARATOR|Group B|Drug: Placebo Normal saline, IV (in the vein), over 2 day
62217757|NCT03456739||suppurative otitis media with effusion|
62217758|NCT03456739||non suppurative otitis media with effusion|
62217759|NCT03820674|EXPERIMENTAL|Energy Conservation plus Problem Solving Therapy Intervention|Receiving experimental intervention
62217760|NCT03820674|ACTIVE_COMPARATOR|Health Education Intervention|Receiving control intervention
62217761|NCT03421626||Primary Enrollment|Initial enrollment of patients with history of CML
62217762|NCT01747993|EXPERIMENTAL|tamsulosin|Tamsulosin (0.4 mg/j) (1 tablet / day for 6 days)
62217763|NCT01747993|PLACEBO_COMPARATOR|placebo|1 tablet / day for 6 days
62217764|NCT04648644||Study population|All patients undergoing emergency abdominal surgery for infection or occlusion and treated with bowel resection with or without anastomosis; intestinal bypass or adhesiolysis
62217765|NCT05736211|EXPERIMENTAL|Phase 2 intervention|In this arm the study will implement an organization-level Youth Engagement prevention strategy by systematically incorporating Youth Engagement into prevention efforts in a community setting.
62217766|NCT05736211|NO_INTERVENTION|Phase 2 control|This arm will receive no intervention. Control group organizations will continue their normal prevention strategy without the inclusion of a Youth Engagement component
62217767|NCT02158052|EXPERIMENTAL|Bone Marrow and Kidney RECIPIENTS|combined bone marrow and kidney transplantation
62217768|NCT02158052|OTHER|Bone Marrow and Kidney DONORS|Donors who donate bone marrow and kidney
62217769|NCT02512367|EXPERIMENTAL|Intervention|
62586010|NCT01399463|ACTIVE_COMPARATOR|Stenting with commonly used Drug Eluting Stents (DES)|
62793762|NCT04814121|PLACEBO_COMPARATOR|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 180 days
62793763|NCT03863431|ACTIVE_COMPARATOR|High-fat diet|"Participants will consume a diet rich in fat (approximately 65% of total energy) and low in carbohydrate for 14 days.~Measurements will be made at 0, 7 and 14 days."
62793764|NCT03863431|ACTIVE_COMPARATOR|High-carbohydrate diet|"Participants will consume a diet rich in carbohydrate (approximately 70% of total energy) and low in fat for 14 days.~Measurements will be made at 0, 7 and 14 days."
62217770|NCT02512367|PLACEBO_COMPARATOR|Surveillance|
62217771|NCT04315259|EXPERIMENTAL|Laser activated irrigation|conventional root canal treatment was done , 2.5% sodium hypochlorite was used and was activated by 980 nm with a repeated pulse mode using a pulse duration of 5 s and a pulse interval of 0.2 ms. The laser irradiation will be delivered for 1 minute into the canal up to 1 mm short of the working length, with circling movements from the apical part moving towards the coronal part (Lite Medics 1.00Watt serial number 148 Ver.SwvM. 150VS108VT.100)
62412038|NCT03597620|EXPERIMENTAL|Nonsystemic Therapy + Herbal Anti-Inflammatory Treatment (HAT1)|Patients who received HAT1 and were not on systemic treatment at time of enrollment. Metaderm cream will be applied topically twice a day to all active lesions. The metaderm scalp spray will be applied daily to the affected areas on the scalp.
62412039|NCT03597620|EXPERIMENTAL|Systemic Therapy + Herbal Anti-Inflammatory Treatment (HAT1)|Patients who received HAT1 and were on systemic treatment at time of enrollment. Metaderm cream will be applied topically twice a day to all active lesions. The metaderm scalp spray will be applied daily to the affected areas on the scalp.
62412040|NCT04141085||Healthy volunteers without infertility|Healthy volunteers without a history of infertility who have regular menstrual cycles and whom have not had any intrauterine procedures performed in the last 90 days prior to participation in the study
62022045|NCT06494111|NO_INTERVENTION|Group 3|Participants will not be given any of the study drugs, as this is the control group.
62022046|NCT01391377|ACTIVE_COMPARATOR|Niacin / Laropiprant|
62022047|NCT01391377|PLACEBO_COMPARATOR|Sugar Pill (Placebo)|
62022048|NCT05902715|EXPERIMENTAL|oral implant placement with socket shield technique|cohort of 20 patients in need of tooth replacement with oral implant
62586011|NCT03636971|EXPERIMENTAL|hyaluronic acid with mannitol|
62586012|NCT03636971|EXPERIMENTAL|hyaluronic acid with sorbitol|
62586013|NCT03636971|ACTIVE_COMPARATOR|saline|
62586014|NCT02727790|EXPERIMENTAL|PES Treatment|Eligible patients will receive daily 5 min PES treatment for two weeks. Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) continuous glucose monitor (CGM) System
62586015|NCT02727790|NO_INTERVENTION|Control|Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) CGM System
62217772|NCT04315259|EXPERIMENTAL|Soft tissue laser application|"Endodontically treated teeth by virtue of a dental applicator positioned at a right angle to the mucosa at the level of the apices.~Application of the laser probe was applied to both the buccal and lingual mucosae overlying the apices of the target tooth. Total exposure time for each tooth was 60 seconds (a dose = 70 j/cm2 for analgesia) The laser unit used in this study used was a diode laser (Lite Medics 1.00Watt serial number 148 Ver.SwvM. 150VS108VT.100) of wavelength 980nm and Max power 15WCW Class IV Laser Product"
62217773|NCT04315259|NO_INTERVENTION|conventional root canal|conventional root canal treatment with irrigation of sodium hypochlorite 2.5% with no laser intervention
62217774|NCT05717101||Observational (medical records)|Patients who have undergo contrast-enhanced harmonic endoscopic ultrasound imaging have their medical records reviewed.
62217775|NCT00871299|EXPERIMENTAL|1|Mindfulness Based Cognitive Therapy (MBCT) + medication management
62217776|NCT00871299|ACTIVE_COMPARATOR|2|The Health Enhancement Program (HEP) + medication management
62217777|NCT01786980||liver cancer, Radical hepatic resection|
62217778|NCT06610448|EXPERIMENTAL|Cuff-based ambulatory blood pressure monitor sequence|Participants will be randomized 1:1 to wear (A) the Spacelabs ambulatory blood pressure monitor on the first day and ABPMPro ambulatory blood pressure monitor on the second day or (B) ABPMPro ambulatory blood pressure monitor on the first day then Spacelabs ambulatory blood pressure monitor on the second day.
62217779|NCT06610448|EXPERIMENTAL|Left versus right upper limb|Participants will be randomized to wear the Aktiia cuffless blood pressure device on either the left upper limb versus the right upper limb on the first day. On the second day, the Aktiia blood pressure device will be switched to the other arm which did not get randomized on the first day. Another wristband (LiveMetric versus Bpro) will be worn on the contralateral arm.
62217780|NCT06610448|EXPERIMENTAL|Wristband sequence (first day versus second day)|Participants will be randomized 1:1 to wear (A) the LiveMetric wristband on the first day and Bpro wristband on the second day or (B) Bpro wristband on the first day then LiveMetric wristband on the second day. The arm side (i.e., right or left) will be determined by the Aktiia cuffless blood pressure device randomization on the first day. For the second day, the Aktiia cuffless blood pressure device will be worn on the arm opposite the first day with the other device (LiveMetric versus Bpro) worn on the contralateral arm.
62793765|NCT03667469|EXPERIMENTAL|Stapleless one anastomosis gastric bypass|Laparoscopic stapleless-separated one anastomosis (mini-) gastric bypass procedures
62793766|NCT03667469|ACTIVE_COMPARATOR|Staple use mini-gastric bypass|Laparoscopic stapler-separated one anastomosis (mini-) gastric bypass procedures
62793767|NCT03667469|ACTIVE_COMPARATOR|Hypocaloric diet therapy|Hypocaloric diet therapy with energy restriction (-500 kcal/d)
62793768|NCT06078059|EXPERIMENTAL|Intervention group|Knee aspiration and the application of UCB-MSCs
62793769|NCT06078059|ACTIVE_COMPARATOR|Control group|Only knee aspiration, without the application of UCB-MSCs
62793770|NCT02728401||INSI|Infection-negative systemic inflammation (INSI). The INSI group consists of children who have undergone congenital cardiac defect corrective surgery requiring cardiopulmonary bypass, known to induce an INSI response for \~24 hours thereafter; all children in this cohort are culture negative. This group is demarcated further by inclusion \& exclusion criteria (see Eligibility section below).
62793771|NCT02728401||CSSS|Clinical severe sepsis syndrome (CSSS). Children assigned to the CSSS group had confirmed or highly suspected infection (microbial culture orders, antimicrobial prescription), exhibited 2 or more systemic inflammatory response syndrome criteria (including temperature and leukocyte criteria), and demonstrated at least cardiovascular ± pulmonary organ dysfunction. This group is demarcated further by inclusion \& exclusion criteria (see Eligibility section below).
62793772|NCT02728401||Viral|The Viral Infection group consists of children who displayed signs and symptoms of severe viral infection, and who tested positive for respiratory viral infection(s) by a molecular virus panel test. These children were clinically evaluated to not have bacterial sepsis. This group is demarcated further by inclusion \& exclusion criteria (see Eligibility section below).
62793773|NCT02755220|EXPERIMENTAL|Cingularbio® Heart valve|the patients will replaced by artificial heart valve
62793774|NCT03605446|EXPERIMENTAL|Animal 12%|Animal based protein biscuit containing 12% of total energy as protein
62793775|NCT03605446|EXPERIMENTAL|Animal 20%|Animal based protein biscuit containing 20% of total energy as protein
62793776|NCT03605446|EXPERIMENTAL|Plant 12%|Plant based protein biscuit containing 12% of total energy as protein
62793777|NCT03605446|EXPERIMENTAL|Plant 20%|Plant based protein biscuit containing 20% of total energy as protein
62793778|NCT03605446|PLACEBO_COMPARATOR|Wheat biscuit|
62793779|NCT01797263|EXPERIMENTAL|Yoga|A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
62793780|NCT01797263|ACTIVE_COMPARATOR|Structured Exercise|A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
62793781|NCT04988529|EXPERIMENTAL|Smartphone-based supported serious game intervention|Group that receives the smartphone-based serious game intervention and receives technical support
62793782|NCT04988529|NO_INTERVENTION|Waiting list control|Group that does not receive any treatment
62022049|NCT06151249|EXPERIMENTAL|Chemotherapy+Meritup|Chemotherapy+Meritup 20ml TID
62022050|NCT06151249|PLACEBO_COMPARATOR|Chemotherapy+Placebo|Chemotherapy+Placebo 20ml TID
62217781|NCT00797251||Right posterior section group|Patients with tumors in the right posterior section of the liver (segments 6-7)
62793783|NCT03748641|EXPERIMENTAL|Cohort 1: Participants with mCRPC and HRR Gene Alteration|Participants with L1 metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alteration will receive combination of niraparib 200 milligrams (mg) or matching placebo and abiraterone acetate (AA) 1000 mg plus prednisone 10 mg. In the open label extension (OLE) phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
62793784|NCT03748641|EXPERIMENTAL|Cohort 2: Participants with mCRPC and No HRR Gene Alteration|Participants with L1 mCRPC and no HRR Gene alteration will receive combination of niraparib 200 mg or matching placebo and AA 1000 mg plus prednisone 10 mg. In the OLE phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
62217782|NCT05212805|EXPERIMENTAL|Aerobic Exercise Promotion|This group will be submitted to an aerobic exercise program combined with upper-limb motor training.
62217783|NCT05212805|ACTIVE_COMPARATOR|Control|This group will be submitted to a standard motor rehabilitation. No aerobic nor sport activity will be delivered to the Control group.
62217784|NCT03488628|ACTIVE_COMPARATOR|Noninvasive ventilation|Noninvasive ventilation delivered through a face mask, in alternance with standard nasal oxygen therapy
62217785|NCT03488628|EXPERIMENTAL|High-Flow Nasal Oxygen therapy|High-Flow Nasal Oxygen therapy delivered continuously over the first 24 hours by the AIRVO2® device (Fisher \& Paykel Healthcare,New Zealand) through nasal canula.
62217786|NCT00692276|EXPERIMENTAL|1|Interspinous Process Spacer Device
62793785|NCT03748641|EXPERIMENTAL|Cohort 3 (Open-label): Participants with mCRPC|Participants with mCRPC will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets plus prednisone 10 mg.
62793786|NCT01035619|EXPERIMENTAL|Moxidectin|
62793787|NCT02402582|EXPERIMENTAL|Family-Centered Empowerment Model|Have the same in-patient, pre-intervention, and post-intervention follow-up care as Control Group. However, rather than routine care and follow-up during the intervention period, they recieved than 4 stage intervention using the Family Centered Empowerment Model.
62793788|NCT02402582|ACTIVE_COMPARATOR|Control|Same in-patient, pre-intervention, and post-intervention follow-up care as Experimental Group. However, rather than 4 stage intervention they receive routine care and follow-up.
62793789|NCT05988879||ART combined with interferon group|The treatment protocol is ART combined with pegylated interferon α-2b injection. The pegylated interferon α-2b injection is administered subcutaneously at a dose of 180ug once a week. Follow-up times are at baseline, and during treatment at weeks 4, 8, 12, 24, 36, 48, 60, and 72.
62793790|NCT05988879||ART group|Continuously using ART treatment, without the use of interferon. Follow-up times are at baseline, and during treatment at weeks 12, 24, 36, 48, 60, and 72.
62793791|NCT03994666|EXPERIMENTAL|simple dose|
62793792|NCT03994666|EXPERIMENTAL|double dose|
62793793|NCT03994666|PLACEBO_COMPARATOR|placebo|
62793794|NCT01814124|ACTIVE_COMPARATOR|Advice and home exercise|All participants will be given a handout consisting of education about avoidance of certain activities as well as 3 stretches and 3 strengthening exercises to be performed as a home exercise program 2-3x/week
62793795|NCT01814124|EXPERIMENTAL|Manual Therapy Plus Exercise|"Participants in this group will be given the same handout consisting of education about avoidance of certain activities as well as 3 stretches and 3 strengthening exercises to be performed as a home exercise program 2-3x/week.~Participants in this group will also receive 12 individualized physical therapy treatment sessions (2x/week for 6 weeks) consisting of both manual therapy and exercise directed at the hip and surrounding areas based upon findings from the initial examination. Participants will also be given additional exercises to be performed at home as directed by the treating physical therapist"
62793796|NCT02458053|EXPERIMENTAL|TEAM Enhanced|The enhanced intervention will include group sessions where the participant attends with partner ( including a couples skill training session), weekly tailored feedback, and weekly lessons.
62793797|NCT02458053|ACTIVE_COMPARATOR|TEAM Traditional|The intervention will include group sessions where the male attends alone, weekly tailored feedback, and weekly lessons.
62819375|NCT05880979|EXPERIMENTAL|Intervention (Engaging Together for Healthy Relationships)|Providers and families in the intervention arm will receive the ETHR program which includes a clinician training, provider scripts, resource guides, a comprehensive website, and warm referral processes.
62022051|NCT04376541||early extubation|the patients extubated in O.R or within 2 hours in the ICU
62217787|NCT00692276|ACTIVE_COMPARATOR|2|Interspinous Process Spacer Device
62217788|NCT03685851||UT-DSAEK|With graft 6 months thick less than 100 µm
62217789|NCT03685851||DSAEK|With graft thicker than 100 µm
62217790|NCT00544375||Neonatal Tissues|Optical measurement neonatal tissues
62217791|NCT05851053||Breast cancer survivors|Survivors of BC, diagnosed ≥11 years ago, who received chemotherapy and/or radiotherapy
62217792|NCT05851053||Reference population|Age and GP matched reference population without a history of cancer
62217793|NCT02934256|EXPERIMENTAL|Icotinib，treatment effect evaluation|Patients use Icotinib hydrochloride tablets during the course of treatment. The drug dosage is 125mg/m3/d. Every course of treatment lasts three months. Patients are designed to receive total four courses of treatment if there is no disease progression.
62217794|NCT03450837||Anabolic androgenic steroids users|"This group had been involved in strength training for at least 2 years, self-administering anabolic androgenic steroids in periodic cycles lasting from 8 to 12 weeks for at least 2 years with 2-4 cycles per year. All participants were on a cycle over the course of the study.~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
62217795|NCT03450837||Anabolic androgenic steroids nonusers|"This group had been involved in strength training for at least 2 years and they have never took anabolic androgenic steroids.~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
62793798|NCT03763019|ACTIVE_COMPARATOR|Respiratory rehabilitation|"Conventional rehabilitation program aiming to normalize movement patterns and minimize spasticity. Including static and dynamic control of position, balance skills, weight shift, and activities of daily living. 45 minutes, once daily.~Respiratory exercises 30 minutes, once daily, (incentive spirometric trainer, forced expiration, percussion, postural drainage etc.)"
62793799|NCT03763019|PLACEBO_COMPARATOR|Conventional rehabilitation|Conventional rehabilitation program aiming to normalize movement patterns and minimize spasticity. Including static and dynamic control of position, balance skills, weight shift, and activities of daily living. 45 minutes, once daily.
62793800|NCT02842164|OTHER|Foley Catheter Balloon with Tension group|a 16 French transcervical Foley catheter balloon will be advanced to or past the internal os and the balloon will be filled. Then catheter will be placed on gentle traction by taping the distal tip to the medial thigh for maximum 24 hours. To maintain gentle traction, periodic repositioning of the distal tip on the thigh will be necessary.
62022052|NCT04376541||late extubation|the patients extubated after 2 hours from O.R
62412041|NCT04141085||Infertile Patients|Infertile patients with a history of infertility but without concern for endometrial dysfunction as the cause of their infertility.
62217796|NCT03450837||Sedentary control|"This group were sedentary men without cardiovascular disease.~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
62217797|NCT05243238|ACTIVE_COMPARATOR|Hesperidin group|
62022053|NCT02249572|EXPERIMENTAL|gamma knife radiosurgery|Single fraction gamma knife radiosurgery given at 12 Gy to tumor periphery for vestibular schwannoma
62022054|NCT02249572|NO_INTERVENTION|Expectation|No active treatment given for vestibular schwannoma
62217798|NCT05243238|ACTIVE_COMPARATOR|Diosmin|
62217799|NCT05243238|ACTIVE_COMPARATOR|Hesperidin and diosmin|
62217800|NCT05243238|NO_INTERVENTION|control group|
62217801|NCT04716998|EXPERIMENTAL|MesenCure treatment|"Clinical interventions:~Health questionnaire, respiratory rate, heart rate, blood pressure, RA O2 saturation, x-ray.~Blood tests: leukocyte and lymphocyte count, CRP, D-Dimer, renal and liver function, optional: cytokine levels."
62217802|NCT02502903|PLACEBO_COMPARATOR|Part A|Single ascending dose (SAD) in NHVs, 7 cohorts, BIVV009 by IV infusion (0.3,1, 3, 10, 30, 60, or 100 mg/kg) or placebo.
62217803|NCT02502903|PLACEBO_COMPARATOR|Part B|Multiple ascending dose (MAD) in NHVs, 2 cohorts, 4 weekly IV doses of BIVV009 (30 or 60mg/kg) or placebo.
62217804|NCT02502903|EXPERIMENTAL|Part C|Multiple dose (MD) in a single cohort of patients with various complement-mediated disorders. All patients in Part C will receive a single IV test dose of BIVV009 of 10 mg/kg followed by 4 weekly doses of 60 mg/kg.
62412042|NCT06023758|EXPERIMENTAL|KN026 combined with KN046|KN026 combined with KN046
62412043|NCT06023758|EXPERIMENTAL|KN026，KN046 and XELOX|KN026，KN046 and XELOX
62412044|NCT04928599||Health Services Research (survey, interview, chart review)|Parents complete surveys over 15-30 minutes at the beginning of their child's induction chemotherapy, at the beginning of maintenance chemotherapy, and at the end of last chemotherapy. Parents may also participate in one-time individual interview over 30-45 minutes. Additionally, children's medical records are reviewed during the study
62412045|NCT04975113|EXPERIMENTAL|Exercise group|Patients were given a progressive neuromuscular exercise program that included stabilization of the knee and hip joint . Green color elastic band was used in resistant exercises. When subjects used the green color Thera-Band®, they started with an easy length and increased relative to the Omni Scale .
62412046|NCT04975113|EXPERIMENTAL|Exercise and Taping group|"Patients in this group received the same exercises given in the exercise group for 12 weeks. In addition to these exercises, mechanical correction tape (5cm, Kinesio Tex Gold®) was applied for the knee and foot."
62412047|NCT04182412|ACTIVE_COMPARATOR|Suture|laparoscopic narrowing of linea alba with continuous suture
62412048|NCT04182412|ACTIVE_COMPARATOR|suture and mesh|narrowing of linea alba with continuous suture and mesh
62022055|NCT03607383|EXPERIMENTAL|Red rice yeast group|Red rice yeast based product will be provided under the brand name Molval Fort, one pill a day, for 8 weeks, for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions
62022056|NCT03607383|ACTIVE_COMPARATOR|Statin group|Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
62022057|NCT03927885|EXPERIMENTAL|Arm I (open labeled placebo)|Patients receive open labeled placebo PO BID for 4 weeks in the absence of disease progression.
62022058|NCT03927885|ACTIVE_COMPARATOR|Arm II (waiting list, open labeled placebo)|Patients are assigned to a waiting list during week 1. Beginning in week 2, patients receive open labeled placebo PO BID for 3 weeks in the absence of disease progression.
62217805|NCT02502903|EXPERIMENTAL|Part E|Multiple dose (MD) in a single cohort of patients with cold agglutinin disease previously treated with BIVV009. All patients in Part E will receive a single IV test dose at week 0, week 1, and every 2 weeks thereafter until EOT. Patients who weigh less than 75 kg will receive fixed doses of 6.5 grams of BIVV009; patients who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009. Dose will be increased from 6.5g to 7.5g dose level if patients current weight is \>= 75 kg and there is evidence of hematologic breakthrough OR patients current weight is \>= 75 kg and there has been at least a 10 percent increase from the patients last recorded weight. Dose will be decreased from 7.5g to 6.5g for patients whose last weight was \>= 75 kg and current weight decreased to \< 75 kg. Dose decrease will require Sponsor approval.
62217806|NCT00903006|ACTIVE_COMPARATOR|Group 1: Fulvestrant|Group 1 will receive Fulvestrant only.
62217807|NCT00903006|ACTIVE_COMPARATOR|Group 2: Fulvestrant + Dasatinib|Group 2 will receive Fulvestrant and Dasatinib.
62217808|NCT00903006|ACTIVE_COMPARATOR|Group 3: Fulvestrant + MK-0646|Group 3 will receive Fulvestrant and MK-0646.
62217809|NCT00903006|ACTIVE_COMPARATOR|Group 4: Fulvestrant, MK-0646 + Dasatinib|Group 4 will receive Fulvestrant, MK-0646, and Dasatinib.
62217810|NCT01350284|EXPERIMENTAL|Dietary supplementation|3g of cinnamon or placebo control were added to a test-meal.
62412049|NCT05415618|ACTIVE_COMPARATOR|Kontrol group|
62412050|NCT05415618|EXPERIMENTAL|MLD group|
62412051|NCT05415618|EXPERIMENTAL|Nerve gliding group|
62793801|NCT02842164|OTHER|Foley Catheter Balloon without tension group|The Foley catheter balloon will be just supported by simple taping to the thigh.
62793802|NCT04498442|NO_INTERVENTION|Yoga Practitioners|Yoga practitioners arm is the observational arm of the study, wherein participants who follow Isha school of yoga and have completed either of the three courses : Inner Engineering Online (IEO), Inner Engineering Completion (Shambhavi Mahamudra kriya) or Shakthi Chalana Kriya can be included in this group. The participant are advised to continue with their routine yoga practice with no change in the duration of practice or frequency of their practices. Participants of this group have expertise in yoga practice and have been practicing yoga for more than 6 weeks before study enrollment.
62022059|NCT03827629|EXPERIMENTAL|Cohort 1: Treatment Sequence A-B-C|Participants received Treatment A on Day 1 of Period 1, Treatment B on Day 1 of Period 2, and Treatment C on Day 1 of Period 3.
62217811|NCT02856854|EXPERIMENTAL|EMB-001 (oral)|EMB-001 will be orally administered for 7 consecutive days, twice daily for 6 days followed on the last day by one EMB-001 oral dose (QD) in the morning. Three hours later Cocaine IV or Saline IV will be administered followed 2 hours by the other (saline or cocaine).
62217812|NCT02856854|PLACEBO_COMPARATOR|Placebo (oral)|PLB-to-match EMB-001 will be orally administered for 7 consecutive days, BID for 6 days, followed on the last day by one PLB oral dose in the morning. Three hours later Cocaine IV or Saline IV will be administered followed 2 hours by the other (saline or cocaine).
62217813|NCT02001298|EXPERIMENTAL|nitroprusside|After induction of anesthesia, controlled hypotension was induced with continuous infusion of nitroprusside. Cardiac index, stroke volume index, and total peripheral resistance index were continuously measured using noninvasive cardiac output monitor (Cheetah NICOM, Cheetah Medical Inc, UK).
62217814|NCT02001298|EXPERIMENTAL|remifentanil|After induction of anesthesia, controlled hypotension was induced with continuous infusion of remifentanil. Cardiac index, stroke volume index, and total peripheral resistance index were continuously measured using noninvasive cardiac output monitor (Cheetah NICOM, Cheetah Medical Inc, UK).
62217815|NCT03104946||Bronchopulmonary Dysplasia|
62793803|NCT04498442|ACTIVE_COMPARATOR|Control Yoga|"Control Yoga is the active comparator arm of the study. Participants who are randomly allocated to this group, practice Simha Kriya, a deep breathing exercise taught by the Isha School of yoga."
62217816|NCT03104946||Retinopathy|
62217817|NCT03104946||Severe Retinopathy|
62217818|NCT03104946||Neonatal Necrotizing Enterocolitis|
62217819|NCT03104946||Brain injury|
62412052|NCT05672225|ACTIVE_COMPARATOR|Control group|Continuous channel: normal saline 100ml, 2ml/h (fixed rate) Selector \& Bolus channel: fentanyl 20mcg/kg (Total 50ml with normal saline), bolus 1ml/10min lock-out
62412053|NCT05672225|EXPERIMENTAL|Dexmedetomidine group|Continuous channel: dexmedetomidine 10mcg/kg (Total 100ml with normal saline), 2ml/h (fixed rate) Selector \& Bolus channel: fentanyl 20mcg/kg (Total 50ml with normal saline), bolus 1ml/10min lock-out
62793804|NCT04498442|PLACEBO_COMPARATOR|Control Idle|Control Idle is the active comparator arm of the study. Participants who are randomly allocated to this group, are advised to either read a book for 15 minutes each day or sit idle for 15 minutes. This is the true control group for the study
62793805|NCT04651868|EXPERIMENTAL|CCK + GLP-2|A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg\^-1 × min\^-1) and a 210 mins intravenous infusion with GLP-2 (10 pmol × kg\^-1 × min\^-1)
62217820|NCT03104946||sepsis|
62217821|NCT03104946||Patent Ductus Arteriosus|
62217822|NCT03104946||Respiratory Distress Syndrome|
62217823|NCT03661203||Qualitative cohort|The cohort consists of MSM with late HIV diagnosis. The person from this cohort will participate to round table called also focus group or individual interview.
62217824|NCT03661203||Quantitative cohort|MSM community will be invited to participate to an online self questionnaire established from the information gathered from the previous cohort.
62217825|NCT05786495|EXPERIMENTAL|Short treatment|Antibiotic treatment will be stopped at the time of allocation to the intervention group
62217826|NCT05786495|ACTIVE_COMPARATOR|Prolonged treatment|Antibiotic treatment will be continued until the resolution of neutropenia (ANC \> 0.5x109/L)
62217827|NCT02534987|EXPERIMENTAL|iCPR2 intervention|EMR integrated clinical prediction rule system guiding antibiotic prescription choices for strep and pneumonia
62217828|NCT02534987|NO_INTERVENTION|iCPR2 control|Standard education/academic detailing on appropriate treatment of strep and pneumonia
62217829|NCT01417143|EXPERIMENTAL|TKI258 (Dovitinib)|TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
62793806|NCT04651868|EXPERIMENTAL|CCK + placebo|A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg\^-1 × min\^-1) and a 210 mins intravenous infusion with isotonic NaCl
62793807|NCT04651868|EXPERIMENTAL|Placebo + GLP-2|A 180 mins intravenous infusion with isotonic NaCl and a 210 mins intravenous infusion with GLP-2 (10 pmol × kg\^-1 × min\^-1)
62217830|NCT01324596|ACTIVE_COMPARATOR|Arm A: R-CHOP|Participants receive 6 cycles of conventional R-CHOP chemotherapy on a standard 21 day schedule: Rituximab 375mg/m2 intravenous Cyclophosphamide 750mg/m2 Intravenous Doxorubicin 50mg/m2 Intravenous Vincristine intravenous Prednisolone 100mg od orally
62217831|NCT01324596|EXPERIMENTAL|Arm B: RB-CHOP|"Participants in this arm will receive 1 cycle of conventional R-CHOP chemotherapy, followed by 5 cycles of R-CHOP:~Cyclophosphamide 750mg/m2 Intravenous Doxorubicin 50mg/m2 Intravenous Vincristine intravenous bortezomib - Intravenous Prednisolone 100mg od orally~."
62217832|NCT05611632|EXPERIMENTAL|Interventional|Blood collection and multi-cancer early detection testing with return of positive test results.
62217833|NCT05611632|NO_INTERVENTION|Control|Blood collection only.
62217834|NCT01466101|ACTIVE_COMPARATOR|Pregabalin administration|Administration of pregabalin
62412054|NCT04074122||Symptomatic LQTS patients|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
62412055|NCT04074122||Asymptomatic LQTS patients|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
62586016|NCT03037346|EXPERIMENTAL|Supportive Care (questionnaires, educational video)|Participants (patients and family caregiver/MPOA) complete questionnaires about knowledge, attitudes, and beliefs of MPOAD. Participants without a MPOAD watch a 4-minute educational video about the importance of the role of MPOA.
62793808|NCT04651868|EXPERIMENTAL|Placebo + placebo|A 180 mins intravenous infusion with isotonic NaCl and a 210 mins intravenous infusion with isotonic NaCl
62793809|NCT05125406|EXPERIMENTAL|Exposure therapy using Virtual Reality (ETVR)|
62793810|NCT05125406|NO_INTERVENTION|No exposure therapy with Virtual Reality.|
62793811|NCT04402879|EXPERIMENTAL|Prone Positioning (PP)|The intervention for this study is PP. Patients at participating sites allocated to the intervention arm of the study will be prompted by ward nurses and respiratory therapists to assume and maintain a prone position for varying durations, four times per day.
62793812|NCT04402879|NO_INTERVENTION|Control - usual management|The control group will consist of standard medical care with no instructions or prompts to change positioning to staff or patients.
62793813|NCT05441267|ACTIVE_COMPARATOR|Oral semaglutide|14mg daily (option to reduce to 7mg daily)
62793814|NCT05441267|PLACEBO_COMPARATOR|Placebo|
62793815|NCT00582374||A|Pregnant Women
62217835|NCT01466101|PLACEBO_COMPARATOR|Placebo|Administration of placebo
62217836|NCT02555852||Users of PPIs|Exposure to proton pump inhibitors (PPIs) will be defined as a prescription for a PPI (esomeprazole, omeprazole, pantoprazole, lansoprazole, rabeprazole, and combinations) on the same day as the cohort entry defining prescription for an NSAID.
62217837|NCT02555852||Users of H2RAs|Exposure to histamine-2 receptor antagonists (H2RAs) will be defined as a prescription for a H2RA (cimetidine, ranitidine, famotidine, nizatidine, niperotidine, roxatidine, ranitidine bismuth citrate, lafutidine, cimetidine combinations, and famotidine combinations) on the same day as the cohort entry defining prescription for an NSAID.
62217838|NCT02555852||Unexposed group (Reference)|Patients that are considered to be unexposed will be defined as patients not prescribed a PPI or H2RA on the same day as the cohort entry defining prescription for an NSAID.
62217839|NCT05867563|EXPERIMENTAL|TQB2103 for Injection|"Dose escalation:~intravenous infusion of TQB2103 for injection once every three weeks, 21 days as one treatment cycle.~(0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 3.0 mg/kg, 4.0 mg/kg, 5.0mg/kg)~Dose expansion:~Chose one or two appropriate dose groups in the dose escalation experiment to expand."
62217840|NCT03753672||preload responsive|defined as an increase in Velocity time integral of the sub-aortic flow greater or equal to 10%
62217841|NCT03753672||preload unresponsive|defined as an increase in Velocity time integral of the sub-aortic flow lower than 10%
62217842|NCT02854787|ACTIVE_COMPARATOR|Phenylephrine|A bolus of 100 mcg
62217843|NCT02854787|ACTIVE_COMPARATOR|Norepinephrine|A bolus of 0,2 mcg/kg
62217844|NCT02432508|ACTIVE_COMPARATOR|laser acupuncture|One hundreds of hemodialysis patients include and give intervention with laser acupuncture (50mW) for 4 weeks. After 4 weeks of wash out period, these patients cross over to shame laser acupuncture treatment (5mW).
62217845|NCT02432508|SHAM_COMPARATOR|sham laser acupuncture|One hundreds of hemodialysis patients include and give intervention with sham laser acupuncture (5mW) for 4 weeks. After 4 weeks of wash out period, these patients cross over to laser acupuncture treatment (50mW).
62217846|NCT04742127||Patients with septic arthritis of the native hip|
62412056|NCT04074122||Healthy controls|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
62412057|NCT00147472|OTHER|PET|All patients receive PET scan and conventional CT imaging.
62412058|NCT02769182|EXPERIMENTAL|Monitoring and training using the system|
62412059|NCT02769182|ACTIVE_COMPARATOR|Standard of care|
62586017|NCT00623740|EXPERIMENTAL|1: hydrocortisone|1: active arm treated with low doses of HC during the first 10 days of life
62793816|NCT05314907|ACTIVE_COMPARATOR|Training group|The Health professional shows the woman how to use the self-sampling device (Evalyn Brush) and then she collects a self-sample at the health centre as a training.
62793817|NCT05314907|PLACEBO_COMPARATOR|No prior training group|The Health professional shows the woman how to use the self-sampling device (Evalyn Brush).
62217847|NCT02237443|OTHER|Post-induction|Anesthesia is induced with propofol and mask ventilation is commenced after patient is unresponsive to a jaw thrust prior to administration of rocuronium, vecuronium bromide, or succinylcholine
62217848|NCT04729413|EXPERIMENTAL|Couples Counseling Intervention|Couples in the intervention group will receive two group health education sessions (one during pregnancy and one postpartum) covering information on pregnancy and postpartum health, as well as three couple counseling visits (one during pregnancy and two postpartum). The couples counseling sessions will provide (1) information on key relationship topics (communication, trust and respect, love and support); (2) relationship skills exercises (role playing); and (3) the opportunity to discuss health and relationship priorities/goals of the couple.
62217849|NCT04729413|SHAM_COMPARATOR|Control|Couples assigned to the control group will receive two group health education sessions (one during pregnancy and one postpartum) covering information on pregnancy and postpartum health. Couples will also have the opportunity after the trial is complete to opt-in to receive a condensed one-session couples counseling visit (data not to be used for study purposes but offered for ethical reasons).
62217850|NCT01729351||IPDI EF HFA-BDP|Patients initiating inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
62217851|NCT01729351||IPDI FP|Patients initiating inhaled corticosteroid therapy as FP via pMDI at the index date
62217852|NCT01729351||IPDI NEF HFA-BDP|Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
62217853|NCT01729351||IPDA EF HFA-BDP|Patients increasing inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
62217854|NCT01729351||IPDA FP|Patients increasing inhaled corticosteroid therapy as FP MDI at the index date
62217855|NCT01729351||IPDA NEF HFA-BDP|Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
62217856|NCT03711331|EXPERIMENTAL|FilmArray® Pneumonia panel plus strategy|patients benefiting from the new strategy based on the system Unyvero ®
62217857|NCT03711331|SHAM_COMPARATOR|Standard care|patients benefiting from usual standard care
62217858|NCT05366101|ACTIVE_COMPARATOR|Lifestyle|Lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
62217859|NCT05366101|ACTIVE_COMPARATOR|Sacubitril/Valsartan|Angiotensin receptor neprilysin inhibitor Sacubitril / Valsartan: The treatment period begins on day 1 with initial dosing of sacubitril/valsartan, followed by uptitration every 2 to 4 weeks to the target dose of 97/103 mg twice daily. 3 doses of sacubitril/valsartan available throughout the study are 24/26 mg, 49/51 mg, and 97/103 mg, each taken by mouth twice daily. If the patient discontinues the study medication, the patient is advised to return to the clinic for an end-of-study visit. Patients undergo treatment for 4 months.
62217860|NCT05366101|NO_INTERVENTION|Usual Care|The participants in control group do not undertake lifestyle or sacubitril / valsartan intervention.
62217861|NCT01335451|EXPERIMENTAL|Active|Each cohort will have 6 subjects that will receive AZD5213
62217862|NCT01335451|PLACEBO_COMPARATOR|Placebo|Each cohort will have 2 subjects that will receive placebo
62217863|NCT02062853|EXPERIMENTAL|Video Group|Subjects view educational video on the use of cream medication for the treatment of actinic keratoses.
62217864|NCT02062853|ACTIVE_COMPARATOR|Verbal Group|Subjects are given verbal instructions on the use of cream medication for the treatment of actinic keratoses.
62586018|NCT00623740|PLACEBO_COMPARATOR|2: Placebo|2:placebo arm treated with placebo at the same conditions than active arm
62217865|NCT00509431|EXPERIMENTAL|Erlotinib + Sirolimus|This is an open-label,phase I single-arm dose-escalation and phase II study of continuous, once daily doses of erlotinib administered orally in combination with sirolimus in adult patients with malignant glioma at first, second or third recurrence
62217866|NCT02553967|EXPERIMENTAL|Immediate breast reconstruction|"* Total mastectomy + immediate reconstructive surgery~* 6 months after surgery : Functional MRI and questionnaires"
62217867|NCT02553967|EXPERIMENTAL|Secondary breast reconstruction|"* Within 2 months before surgery : Functional MRI~* Reconstructive surgery~* 6 months after surgery : Functional MRI and questionnaires"
62217868|NCT02233452|ACTIVE_COMPARATOR|Methadone|Group treated with methadone solution.
62217869|NCT02233452|ACTIVE_COMPARATOR|Ketamine|Group treated with ketamine solution
62022060|NCT03827629|EXPERIMENTAL|Cohort 2: Treatment Sequence B-C-A|Participants received Treatment B on Day 1 of Period 1, Treatment C on Day 1 of Period 2, and Treatment A on Day 1 of Period 3.
62022061|NCT03827629|EXPERIMENTAL|Cohort 3: Treatment Sequence C-A-B|Participants received Treatment C on Day 1 of Period 1, Treatment A on Day 1 of Period 2, and Treatment B on Day 1 of Period 3.
62022062|NCT03827629|EXPERIMENTAL|Cohort 4: Treatment Sequence A-C-B|Participants received Treatment A on Day 1 of Period 1, Treatment C on Day 1 of Period 2, and Treatment B on Day 1 of Period 3.
62217870|NCT02233452|ACTIVE_COMPARATOR|Methadone plus ketamine|Group treated with methadone plus ketamine solution
62217871|NCT00895154|ACTIVE_COMPARATOR|General Tutoring Group|Participants will receive general tutoring in the subject of his/her choice.
62217872|NCT00895154|EXPERIMENTAL|Tutoring + Memory Training Group|Participants will receive tutoring and memory training.
62217873|NCT04247087|EXPERIMENTAL|Intervention group|phytomenadione 10 mg (1 vial in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
62217874|NCT04247087|PLACEBO_COMPARATOR|Control group|1 vial of placebo solution (solution for injection in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
62217875|NCT02883127||The study group|Receives lifestyle intervention with motivational interviewing focusing on following the recommended diabetes diet and gestational weight gain recommendations in addition to routine care
62217876|NCT02883127||The control group|Was given the same routine care with the same treatment goals, but without motivational interviewing.
62217877|NCT06086366||COVID-DNP|Participants that have recovered from mild or moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
62412060|NCT05784311|EXPERIMENTAL|Perioperative plus prolonged antibiotic prophylaxis|Prolonged prophylaxis: a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4 hours of surgery (perioperative prophylaxis) followed by five days of 1500mg IV cefuroxime and 500mg IV metronidazole thrice daily
62793818|NCT05355662||OLDs|Older liver donors (OLDs) and recipients were defined as individuals whose donor age was equal to or greater than 60 years. Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and preoperative and postoperative characteristics of the corresponding recipients and donors were collected and recorded for subsequent analysis.
62793819|NCT05355662||ILDs|Ideal or young liver donors (ILDs) and recipients were defined as donors aged 18-40 years. Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and preoperative and postoperative characteristics of the corresponding recipients and donors were collected and recorded for subsequent analysis.
62793820|NCT05355662||ALDs|Average liver donors (ALDs) and recipients were defined as donor age 40-59 years. Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and preoperative and postoperative characteristics of the corresponding recipients and donors were collected and recorded for subsequent analysis.
62022063|NCT03827629|EXPERIMENTAL|Cohort 5: Treatment Sequence C-B-A|Participants received Treatment C on Day 1 of Period 1, Treatment B on Day 1 of Period 2, and Treatment A on Day 1 of Period 3.
62217878|NCT06086366||Healthy Control|Participants in good physical health, age- and sex-matched to Group 1 and 2 participants.
62217879|NCT02047903||Afatinib|
62217880|NCT04488393||Pregnancies with multiple gestations|
62217881|NCT02162797|EXPERIMENTAL|Placebo supplementation|Intervention Group B: Patients who will orally receive a placebo for 3 months.
62217882|NCT02162797|EXPERIMENTAL|zinc supplementation|Intervention group A. Patients who will orally receive zinc for 3 months.
62217883|NCT02223676|EXPERIMENTAL|Intervention|Clinical pharmacists conduct medication history
62217884|NCT02223676|NO_INTERVENTION|Control|standard procedures for admission is followed
62412061|NCT05784311|NO_INTERVENTION|Only perioperative prophylaxis|Perioperative prophylaxis: a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4 hours of surgery.
62412062|NCT06562582|ACTIVE_COMPARATOR|Bisoprolol|Bisoprolol within 24 hours of PCI
62022064|NCT03827629|EXPERIMENTAL|Cohort 6: Treatment Sequence B-A-C|Participants received Treatment B on Day 1 of Period 1, Treatment A on Day 1 of Period 2, and Treatment C on Day 1 of Period 3.
62022065|NCT00720954|OTHER|A|CT guided pleural needle biopsy
62022066|NCT00720954|OTHER|B|Thoracoscopy
62022067|NCT00786357|EXPERIMENTAL|Intervention|
62022068|NCT06461858|EXPERIMENTAL|This group (Group A) will receive cuevas medek technique (exercise)|The first group, known as the experimental group, group A, receives Cuevas Medek exercises once a week, for 45 minutes per session,for 6 weeks.
62217885|NCT03594201||group1|A+B grade sperm count after treatment=0
62217886|NCT03594201||group2|0\<A+B grade sperm count after treatment≤10\^6
62217887|NCT03594201||group3|10\^6\<A+B grade sperm count after treatment\<2\*10\^6
62022069|NCT06461858|ACTIVE_COMPARATOR|This group (Group B) will receive conventional therapy.|this second group, group B, referred to as the conventional therapy group (Routine physical therapy), follows a regimen of conventional therapy once a week for 6 weeks for 20 mints.
62217888|NCT03594201||group4|A+B grade sperm count after treatment≥2\*10\^6
62217889|NCT04083677||Control GROUP|healthy adult fasting 8 hours before the operation sonographic examination of gastric antrum before anesthesia
62217890|NCT04083677||trauma GROUP|trauma patients fasting 8 hours before the operation sonographic examination of gastric antrum before anesthesia
62217891|NCT03702231|EXPERIMENTAL|Chronic Lymphocytic Leukemia Patients That Are Treatment Naive|Chronic Lymphocytic Leukemia Patients That Are Treatment Naive will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
62217892|NCT03702231|EXPERIMENTAL|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
62217893|NCT03702231|EXPERIMENTAL|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
62217894|NCT05379036|EXPERIMENTAL|Group A|a group of patients who, after the examination, were prescribed therapy with trimebutine 600 mg per day for 2 months
62217895|NCT05379036|EXPERIMENTAL|Group B|a group of patients who, after the examination, were prescribed therapy with rebamipide 300 mg per day for 2 months
62217896|NCT05379036|EXPERIMENTAL|Group C|a group of patients who, after the examination, were prescribed therapy with trimebutine 600 mg per day + rebamipide 300 mg per day for 2 months
62217897|NCT05379036|NO_INTERVENTION|Control|healthy volunteers
62217898|NCT04208282|EXPERIMENTAL|Trial Arm A|Quickset infusion system for the Phase 1. At day 28 or after using 4 sets , the patients will return to a visit, return all the extracted catheters sets and will switch to the 7 day set infusion set, entering Phase 2.
62793821|NCT04602117|EXPERIMENTAL|Vic-trastuzumab duocarmazine (SYD985) + paclitaxel|Single-arm, phase I trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel. The study contains 2 cohorts. Cohort A is the de-escalation cohort. Patients with certain HER-positive advanced solid tumors or HER2-low breast cancer will be enrolled in this cohort. Cohort B is the expansion cohort, in which only patients with HER2-positive or HER2-low breast cancer can be enrolled. Treatment will be administered on an outpatient basis.
62793822|NCT05200676||Main group|"All included in the study will offered to participate in:~* ePatch-monitoring~* Blood pressure measurement~* Cardial vagal tone~* Questionnaire-assessment"
62793823|NCT05200676||Subgroup|"Part of the study-population will be offered to participate in en examination with a SmartPill. The Smartpill measures pressure, pH, temperature and movement in the gut. These measurements gives an indication of the function of the autonomic nervous system (ANS) of the participant. Although measured in the gut, this is relevant as ANS-dysfunction may cause arrhythmias.~Only a subgroup of the study population will be offered to participate due to the cost of this examination."
62793824|NCT02292719|EXPERIMENTAL|Arm A (genotype [GT]3, noncirrhotic)|Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) and sofosbuvir (SOF) 400 mg QD for 12 weeks.
62793825|NCT02292719|EXPERIMENTAL|Arm B (GT3, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided twice daily \[BID\]) for 12 weeks.
62793826|NCT02292719|EXPERIMENTAL|Arm C (GT2, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight- based 1,000 mg or 1,200 mg daily divided BID) for 8 weeks.
62793827|NCT02292719|EXPERIMENTAL|Arm D (GT2, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 6 weeks.
62793828|NCT02292719|EXPERIMENTAL|Arm E (GT3, cirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 12 weeks.
62793829|NCT02292719|EXPERIMENTAL|Arm F (GT3, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD and SOF (400 mg QD) for 12 weeks.
62793830|NCT05922371||Sepsis|Adult patients admitted to critical care with a presumed diagnosis of sepsis.
62217899|NCT04208282|ACTIVE_COMPARATOR|Trial Arm B|7 day set infusion set for the Phase 1. At day 28 or after using 4 sets , the patients will return to a visit, return all the extracted catheters sets and will switch to the Quickset infusion systems , entering Phase 2.
62217900|NCT01847677|ACTIVE_COMPARATOR|Paclitaxel & Carboplatin|"1. Preoperative treatment Cycle 1 to 4 (4 cycles every 3 weeks of chemotherapy pre-surgery)~   * Carboplatin AUC 6 i.v. first day~  * Paclitaxel 175 mg/m2 i.v. first day~2. Surgery~3. Post-Operative treatment~Cycle 5 to 7 (3 cycles every 3 weeks of chemotherapy post-surgery):~* Carboplatin AUC 6 i.v. first day~* Paclitaxel 175 mg/m2 i.v. first day~* Bevacizumab 15 mg/Kg i.v. first day1~When the chemotherapy treatment is completed, the patient will continue with maintenance bevacizumab until 15 months length treatment."
62217901|NCT01847677|EXPERIMENTAL|Paclitaxel & Carboplatin & Bevacizumab|"4 cycles every 3 weeks (at least 3 Bevacizumab neoadjuvant cycles): Carboplatin AUC 6 i.v. first day Paclitaxel 175 mg/m2 i.v. first day Bevacizumab 15 mg/Kg i.v. first day.~b) Surgery Ovarian cancer surgery should be performed according to FIGO guidelines.~c) Postoperative treatment~Both arms:~Cycle 5 to 7 (3 cycles every 3 weeks of chemotherapy post-surgery):~Carboplatin AUC 6 i.v. first day Paclitaxel 175 mg/m2 i.v. first day Bevacizumab 15 mg/Kg i.v. first day.~When the chemotherapy treatment is completed, the patient will continue with maintenance bevacizumab until 15 months length treatment."
62217902|NCT05101031||Denver Health Medical Center|SV machine will be attached if hypotensive and in the emergency department
62217903|NCT03375567|EXPERIMENTAL|Guided Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
62217904|NCT03375567|ACTIVE_COMPARATOR|Standard Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
62217905|NCT02630602|ACTIVE_COMPARATOR|Functional goat cheese|The functional cheese is rich in conjugated linoleic acid (CLA) and omega-3. It was used for obese and overweight people, who need a special diet advice to control of lipid profile. 9,3% of polyunsaturated fatty acids 60 g per day during 12 weeks
62793831|NCT05922371||Cardiac surgery|Adult cardiac surgery patients that are free from infection undergoing their first cardiac surgery.
62412063|NCT06562582|NO_INTERVENTION|No Bisoprolol|no beta blocker until day 7±12 hours
62412064|NCT06562582|ACTIVE_COMPARATOR|Ramipril|Ramipril within 24 hours of PCI
62412065|NCT06562582|NO_INTERVENTION|No Ramipril|no ramipril until day 7±12 hours after PCI
62412066|NCT06562582|ACTIVE_COMPARATOR|Dapagliflozin|Dapagliflozin within 24 hours versus
62412067|NCT06562582|NO_INTERVENTION|No Dapagliflozin|no dapagliflozin treatment until day 7±12 hours after PCI
62412068|NCT03205163|EXPERIMENTAL|Low Dose Cohort: Advate 25 IU/kg Then BIVV001 25 IU/kg|Participants received a single intravenous (IV) dose of Advate 25 international units per kilogram (IU/kg) on Day 1 of Advate treatment period (3 days) followed by a single IV dose of BIVV001 25 IU/kg in BIVV001 treatment period (BTP) (28 days). Advate treatment period (ATP) consisted of a washout of at least 72 hours which was started from the time of Advate dosing.
62217906|NCT02630602|PLACEBO_COMPARATOR|Control cheese|Control cheese, not enriched with conjugated linoleic acid (CLA) and omega-3 4.1% of polyunsaturated fatty acids. 60 g per day during 12 weeks
62217907|NCT06240923|EXPERIMENTAL|Group 1: Single coil spring|A single open coil spring was inserted between the maxillary second premolar and the maxillary first molar with a distalizing force 300 gm.
62217908|NCT06240923|EXPERIMENTAL|Group 2: Double coil spring|Two open coil springs were inserted. The first coil spring was inserted between the maxillary second premolar and the maxillary first molar with a distalization force 300gm, and the second coil spring was inserted between the maxillary first and maxillary second molar with a distalization force 200 gm.
62412069|NCT03205163|EXPERIMENTAL|High Dose Cohort: Advate 65 IU/kg Then BIVV001 65 IU/kg|Participants received a single IV dose of Advate 65 IU/kg on Day 1 of ATP (4 days) followed by a single IV dose of BIVV001 65 IU/kg in BTP (28 days). ATP consisted of a washout of at least 96 hours which was started from the time of Advate dosing.
62022070|NCT04906018||volunteer group - BMI less than 30|Each subject with a BMI less than 30 will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
62022071|NCT04906018||volunteer group - BMI of 30 and above|Each subject with a BMI of 30 and above will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
62022072|NCT01286779|EXPERIMENTAL|BAX 326|
62217909|NCT02968316||Pregnant women|all consecutive pregnant women presenting for prenatal care
62217910|NCT03527550|EXPERIMENTAL|Cognitive Training plus Treatment as Usual|Participants in this arm will receive daily computerized cognitive training sessions during partial hospitalization, in addition to treatment as usual. Cognitive training sessions will alternate between response inhibition training and working memory training.
62586019|NCT03866083|EXPERIMENTAL|Extracorporeal Cytokine hemadsorption therapy|Hemoperfusion will be carried out for one session within 12 hours for all randomized patient using the adsorption columns for Jianfan Biotechnology Co., Zhuhai, China). The hemoperfusion apparatus will be connected in front of the hemodialyzer in series.
62586020|NCT03866083|ACTIVE_COMPARATOR|Stadard Medical treatment|Stadard Medical treatment
62586021|NCT01310088|EXPERIMENTAL|Lifestyle counseling|Treatment protocol The Children's Obesity Clinic Department of Paediatrics Holbaek Hospital, University of Copenhagen Denmark
62022073|NCT01601587|NO_INTERVENTION|Treatment as usual|Patients will receive treatment as usual
62022074|NCT01601587|OTHER|Introduction Seminar|Psychoeducational group
62022075|NCT00844454|EXPERIMENTAL|QFEA|multi-pronged ethanol ablation
62022076|NCT00844454|ACTIVE_COMPARATOR|RFA|radiofrequency ablation
62217911|NCT03527550|NO_INTERVENTION|Treatment as Usual (TAU)|Participants in the Treatment As Usual group will receive usual treatment in the partial hospitalization program.
62586022|NCT01310088|NO_INTERVENTION|Control|Healthy age and gender matched control subjects. Recruited from school visits.
62793832|NCT04205682|EXPERIMENTAL|Cannabidiol (CBD)|Drug: Cannabidiol (day 1: 1200 mg (800 mg BD); day 2-4: 800 mg (400 mg BD); day 5: placebo BD).
62793833|NCT04205682|PLACEBO_COMPARATOR|Placebo|Drug: Placebo (days 1-5: placebo matched BD)
62793834|NCT04768621|EXPERIMENTAL|Winter residents of Southern and Antartic French Lands,|people exposed to stressors over long periods including winter
62793835|NCT04768621|ACTIVE_COMPARATOR|Country people going to Southern and Antartic French Lands|people going to Southern and Antarctic French Lands who benefit from milder conditions and only make short stays
62793836|NCT02969356|EXPERIMENTAL|Dysport|Each subject will undergo two intramuscular injection (treatment) cycles, receiving AbobotulinumtoxinA (Dysport®) 1500 U on Day 1 of each cycle; the two dosing occasions will be separated by at least 12 weeks (maximum 20 weeks). Subjects will also receive daily GSC therapy. The main focus of GSC will be on the primary treatment target (TT) limb (as determined at the Baseline Visit) and then the other limb. All muscle groups requiring active training and/or stretching should be trained. Subjects will be be given a diary to record each day whether they have performed the GSC therapy.
62793837|NCT01969006|EXPERIMENTAL|Injection of Marcaine ½ %|Injection of 40 ml of Marcaine ½ % 2 cm medial, 2 cm downwards from the Anterior Iliac Spine
62793838|NCT01969006|PLACEBO_COMPARATOR|Needle prick|Needle prick 2 cm medial and 2 cm downwards from the Anterior Iliac spine
62793839|NCT03160898|EXPERIMENTAL|Reldesemtiv 150 mg twice daily|Patients in this arm took 1 reldesemtiv 150 mg oral tablet and 2 matching placebo tablets every 12 hours for 12 weeks.
62217912|NCT02632526|EXPERIMENTAL|AZD5718 amorphous form, treatment 1 (Part A)|Starting dose 25 mg/day, single ascending dose
62217913|NCT02632526|EXPERIMENTAL|AZD5718 amorphous form, treatment 2 (Part A)|Single dose of AZD5718 amorphous suspension
62217914|NCT02632526|EXPERIMENTAL|AZD5718 amorphous form, treatment 3 (Part A)|Single dose of AZD5718 amorphous suspension
62217915|NCT02632526|EXPERIMENTAL|AZD5718 amorphous form, treatment 4 (Part A)|Single dose of AZD5718 amorphous suspension
62586023|NCT04523038||Low albumin|Patients presenting with low albumin levels preoperatively (\<3,5 mg/l)
62586024|NCT04523038||Normal albumin|Patients presenting with normal or high albumin levels preoperatively (\>3,5 mg/l)
62793840|NCT03160898|EXPERIMENTAL|Reldesemtiv 300 mg twice daily|Patients in this arm took 2 reldesemtiv 150 mg oral tablets and 1 matching placebo tablet every 12 hours for 12 weeks.
62217916|NCT02632526|EXPERIMENTAL|AZD5718 amorphous form, treatment 5 (Part A)|Single dose of AZD5718 amorphous suspension
62586025|NCT03453099||Study Cohort|Any ASA I or II patients scheduled for elective day case general anaesthesia at Chelsea \& Westminster Hospital, involving a standard propofol-fentanyl induction regimen, aged between 18-65 years . See specific exclusion criteria below.
62793841|NCT03160898|EXPERIMENTAL|Reldesemtiv 450 mg twice daily|Patients in this arm took 3 reldesemtiv 150 mg oral tablets every 12 hours for 12 weeks.
62793842|NCT03160898|PLACEBO_COMPARATOR|Placebo|Patients in this arm took 3 placebo oral tablets every 12 hours for 12 weeks.
62217917|NCT02632526|EXPERIMENTAL|AZD5718 amorphous form, treatment 6 (Part A)|Single dose of AZD5718 amorphous suspension
62217918|NCT02632526|EXPERIMENTAL|AZD5718, crystalline form, treatment 7 (Part A)|Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose
62217919|NCT02632526|EXPERIMENTAL|AZD5718 crystalline form, treatment 8 (Part A)|Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose
62217920|NCT02632526|EXPERIMENTAL|AZD5718 amorphous form, treatment 1 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
62217921|NCT02632526|EXPERIMENTAL|AZD5718 amorphous form, treatment 2 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
62217922|NCT02632526|EXPERIMENTAL|AZD5718 amorphous form, treatment 3 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
62586026|NCT02470065|EXPERIMENTAL|Neo adjuvant afatinib|once daily afatinib at a dose of 40 mg for 8 weeks followed by surgery with curative intent (anatomical resection and systematic lymph node dissection).
62793843|NCT04879966||UC cohort|the patiente of Moderate to Severe Ulcerative Colitis who recieved infliximab(IFX) or corticosteroids(CS) as induction therapy would be enrolled in this cohort
62793844|NCT04327570||ICU-hospitalised COVID-19 patients|COVID-19 positive patients hospitalised in intensive care ('severe disease').
62022077|NCT00813930|EXPERIMENTAL|INTERxVENT Program|Participants in INTERxVENT will complete a 'Baseline Assessment' and 'Follow-up' questionnaire, and will have a health professional visit his/her home for an initial assessment (BP,height,weight,waist measurement) and blood collection (blood glucose and cholesterol levels). As part of the program, each participant will also complete a self-reported 'Health History Questionnaire' (HHQ); a follow-up HHQ will be completed about 12 weeks into the program to monitor progress. Each participant randomized to INTERxVENT receives educational articles which address diabetes management issues. A structured, individualized program, consisting of educational materials and 12 live mentoring/coaching telephone calls will take place over 6 months. The mentors consist of allied health professionals. The sequence by which educational content is administered will be both self-directed and guided by the mentors using an algorithmic approach according to the participant's readiness-to-change scores.
62022078|NCT00813930|NO_INTERVENTION|Usual medical care|Each participant randomized to this group will not receive any formal intervention but will receive the same care over the 6-month period as he/she usually receives from his/her health care team. Participants in this group will undergo the same baseline and outcome assessment as those in the intervention group, including blood pressure (BP) measurement, physical assessment (height, weight, waist measurement) and blood collection (blood glucose and cholesterol levels), as well as completion of the 'Baseline Assessment' and 'Follow-up' questionnaires.
62022079|NCT00871559|EXPERIMENTAL|Q2W|REGN421 (SAR153192) taken once every two weeks (Q2W)
62022080|NCT04414982|EXPERIMENTAL|Intervention Values Affirmation|Compare the effects of the values-affirmation exercise with a control exercise in AI/AN patients with hypertension.
62022081|NCT04414982|ACTIVE_COMPARATOR|Control Values Affirmation|Compare the effects of the values-affirmation exercise in AI/AN patients with its effects in white patients.
62022082|NCT03636152|ACTIVE_COMPARATOR|Hydroxychloroquine (HCQ) Group|These patients will receive HCQ for 18 months
62022083|NCT03636152|PLACEBO_COMPARATOR|Placebo Group|These patients will receive a matching placebo for 18 months
62217923|NCT02632526|EXPERIMENTAL|AZD5718 amorphous form, treatment 4 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
62217924|NCT02632526|EXPERIMENTAL|AZD5718 amorphous/crystalline form, repeat 1 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
62217925|NCT02632526|EXPERIMENTAL|AZD5718 amorphous/crystalline form, repeat 2 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
62586027|NCT02470065|ACTIVE_COMPARATOR|Immediate surgery|immediate surgery with curative intent (anatomical resection and systematic lymph node dissection).
62586028|NCT05397912||Women undergoing euploid, single frozen embryo transfer|Women age 18yo-45yo undergoing euploid, single, frozen embryo transfer with sonographically normal appearing uterus without uterine factor infertility
62586029|NCT02836574|EXPERIMENTAL|Immediate Treatment|Renal Autologous Cell Therapy (REACT) immediate treatment - Patients who are randomized to receive their first treatment of 2 injections of REACT as soon as REACT product is made available.
62793845|NCT04327570||ward-hospitalised COVID-19 patients|COVID-19 positive patients requiring hospitalisation,not on intensive care department ('non-severe').
62586030|NCT02836574|ACTIVE_COMPARATOR|Delayed Treatment|Renal Autologous Cell Therapy (REACT) delayed treatment - Patients who are randomized to receive standard of care treatment for the first 12 months after REACT product is made available before receiving 2 injections of REACT.
62793846|NCT06262113|EXPERIMENTAL|Intervention Arm|
62793847|NCT06262113|EXPERIMENTAL|Enhanced Usual Care Arm|
62793848|NCT02057172|EXPERIMENTAL|HM11260C (0.3 mg)|Weekly administration of 0.3 mg of HMC11260C by subcutaneous injection for 12 weeks
62793849|NCT02057172|EXPERIMENTAL|HM11260C (1 mg)|Weekly administration of 1 mg of HM11260C by subcutaneous injection for 12 weeks
62793850|NCT02057172|EXPERIMENTAL|HM11260C (2 mg)|Weekly administration of 2 mg of HM11260C by subcutaneous injection for 12 weeks
62217926|NCT02632526|EXPERIMENTAL|AZD5718 amorphous/crystalline, repeat 3 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
62217927|NCT02632526|EXPERIMENTAL|AZD5718 amorphous form, repeat 1 (Part B)|Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)
62217928|NCT02632526|EXPERIMENTAL|AZD5718 amorphous form, repeat 2 (Part B)|Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)
62022084|NCT03190382|EXPERIMENTAL|Received Decision Tool|Peripheral artery disease patients that received the decision support tool.
62217929|NCT03426605|EXPERIMENTAL|LAM-003|Open label LAM-003 at three sequentially increasing starting dose levels of 200, 300 and 450 mg.
62217930|NCT00710359|ACTIVE_COMPARATOR|1|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma) given as a single intramuscular injection. The syringe is covered so it is impossible to see whether or not it contains any substance.
62217931|NCT00710359|SHAM_COMPARATOR|2|"The controls receive an intramuscular injection, however, it is only an introduction of the needle into the muscle, but no injections are given. The syringe is covered so it is impossible to see whether or not it contains any substance."
62412070|NCT03373825|EXPERIMENTAL|Arm 1|50 participants will receive a kit containing 10 Rapid Response fentanyl test strips. We will ask participants to use the take-home rapid drug test to test their urine for presence or absence of fentanyl.
62586031|NCT06666062|ACTIVE_COMPARATOR|Study group|
62586032|NCT06666062|PLACEBO_COMPARATOR|Control group|
62586033|NCT05945264|EXPERIMENTAL|Music Intervention (MI) Group|Music therapist will meet individually with each participant and provide music therapy content that reflects their culture and mood states.
62586034|NCT05945264|ACTIVE_COMPARATOR|Sham Control (SC) Group|Music/Verbal therapist will meet individually with each participant but will provide verbal discourse only (i.e., no music therapy and verbal intervention only).
62586035|NCT06584448|EXPERIMENTAL|Light/Non Drinking (LD)|Participants will complete an initial telephone screen. Participants found to be potentially eligible will be scheduled for an in-person Intake Session (consisting of an interview, questionnaires, lab work, and a urine drug screen). Participants found to be eligible will be scheduled for an infusion study. Participants will undergo brain imaging with intravenous administration of deuterated sodium acetate. Deuterium is a naturally occurring, non-radioactive substance that allows us to measure rates of metabolism. Neurocognitive tests will be performed to assess the impact of alcohol drinking.
62586036|NCT06584448|EXPERIMENTAL|Heavy/Non-Dependent Risky Drinking (HD)|Participants will complete an initial telephone screen. Participants found to be potentially eligible will be scheduled for an in-person Intake Session (consisting of an interview, questionnaires, lab work, and a urine drug screen). Participants found to be eligible will be scheduled for an infusion study. Participants will undergo brain imaging with intravenous administration of deuterated sodium acetate. Deuterium is a naturally occurring, non-radioactive substance that allows us to measure rates of metabolism. Neurocognitive tests will be performed to assess the impact of alcohol drinking.
62793851|NCT02057172|EXPERIMENTAL|HM11260C (3 mg)|Weekly administration of 3 mg of HM11260C by subcutaneous injection for 12 weeks
62793852|NCT02057172|EXPERIMENTAL|HM11260C (4 mg)|Weekly administration of 4 mg of HM11260C by subcutaneous injection for 12 weeks
62793853|NCT02057172|PLACEBO_COMPARATOR|Placebo|Weekly administration of placebo by subcutaneous injection for 12 weeks
62793854|NCT02057172|ACTIVE_COMPARATOR|Liraglutide|Liraglutide will be administered daily, at doses of 0.6 mg to 1.8 mg.
62793855|NCT01959841|EXPERIMENTAL|ASP2151(200 mg)|once daily
62793856|NCT01959841|EXPERIMENTAL|ASP2151(400mg)|once daily
62022085|NCT05773417||Low Flow|0.5 L/minute
62022086|NCT05773417||High Flow|4 L/minute
62022087|NCT00383435|EXPERIMENTAL|MF/F MDI 400/10 mcg BID|
62217932|NCT01040039||HCV+HIV+|
62412071|NCT03373825|EXPERIMENTAL|Arm 2|50 participants will receive a kit containing 10 Rapid Response fentanyl test strips. We will ask the participants to use the take-home rapid drug test to test the residue of their drug (ie. instruct them to test bags, cookers, spoons, etc.) for the presence or absence of fentanyl.
62412072|NCT00891527|EXPERIMENTAL|Avastin and/or Gleevec|Patients were all treated with Gleevec (imatinib mesylate) and those without congenital heart disease and those who progressed were also treated with Avastin (bevacizumab).
62412073|NCT05794555|ACTIVE_COMPARATOR|Enhanced Usual Care group|Participants will be in stage 1 for approximately 12 weeks and then be re-randomized for stage 2.
62412074|NCT05794555|EXPERIMENTAL|Treatment (Lactulose) group plus Enhanced Usual Care|Participants will be in stage 1 for approximately 12 weeks and then be re-randomized for stage 2.
62793857|NCT01959841|EXPERIMENTAL|valaciclovir|1000 mg three times daily
62793858|NCT03737539||Colorectal cancer|Patients diagnosed with resectable colorectal cancer
62793859|NCT00502554|NO_INTERVENTION|1|Observation with standard care (macrolides, exercise, oxygen therapy etc.) alone.
62022088|NCT00383435|EXPERIMENTAL|MF/F MDI 200/10 mcg BID|
62022089|NCT00383435|EXPERIMENTAL|MF MDI 400 mcg BID|
62022090|NCT00383435|ACTIVE_COMPARATOR|Formoterol MDI 10 mcg BID|
62217933|NCT01040039||HCV+HIV-|
62412075|NCT05794555|ACTIVE_COMPARATOR|Enhanced Usual Care group followed by investigator recommended exercise|This is considered stage 2 for 12 weeks (for re-randomized participants).
62217934|NCT03246776|EXPERIMENTAL|Halometasone Triclosan Cream|All subjects receive external Use of Halometasone Triclosan Cream
62217935|NCT05322252|EXPERIMENTAL|Simulatenous mifepristone and misoprostol|Participants will receive a dose of 200mg oral mifepristone at time of induction with misoprostol
62217936|NCT05322252|ACTIVE_COMPARATOR|Misoprostol alone|Participants will have labor induced with misoprostol alone
62217937|NCT01191268|EXPERIMENTAL|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
62217938|NCT01191268|EXPERIMENTAL|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
62217939|NCT01191268|ACTIVE_COMPARATOR|Insulin Glargine|"Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
62217940|NCT00698945|ACTIVE_COMPARATOR|2|Alphagan
62217941|NCT00698945|ACTIVE_COMPARATOR|1|Istalol and Optive
62217942|NCT04266418|PLACEBO_COMPARATOR|Placebo|consume 1 sachet per day for 2 months
62217943|NCT04266418|EXPERIMENTAL|Banana flower stamens extract|consume 1 sachet per day for 2 months
62022091|NCT00383435|PLACEBO_COMPARATOR|Placebo MDI BID|
62217944|NCT01942785|EXPERIMENTAL|Brexpiprazole|Brexpiprazole adjunct to open-label commercially available Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) antidepressant treatment (ADT)
62217945|NCT00201786|EXPERIMENTAL|Pentostatin|Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS.
62217946|NCT01959477|EXPERIMENTAL|Treatment (busulfan, etoposide, cyclophosphamide, transplant)|Patients receive busulfan IV over 3 hours on days -9 to -6, etoposide IV continuously over 24-36 hours on days -5 and -4, and cyclophosphamide IV over 4 hours on days -3 and -2. Patients then undergo autologous stem cell transplant on day 0.
62217947|NCT00495105|EXPERIMENTAL|Two Servings of Dairy Snacks|Intervention group received two servings of dairy food per day as a snack at school for 6 months as well as nutrition education.
62217948|NCT00495105|NO_INTERVENTION|No Dairy Snacks|Control Group did not receive any snacks or education.
62217949|NCT02567747||Study cohort|The Total population will include all subjects included in the study. Only aggregated information will be collected for these subjects.
62217950|NCT05408702||Autoimmune Myasthenia Gravis|
62217951|NCT05408702||Congenital Myasthenic Syndrome|
62217952|NCT05408702||Lambert Eaton Syndrome|
62412076|NCT05794555|EXPERIMENTAL|Treatment (Lactulose) plus Enhanced Usual Care then TeleTai-Chi exercise classes|This is considered stage 2 for 12 weeks (for re-randomized participants)
62217953|NCT00760968|EXPERIMENTAL|TAK-783 100 mg QD + Methotrexate|
62217954|NCT00760968|ACTIVE_COMPARATOR|Methotrexate|
62217955|NCT03971903|EXPERIMENTAL|Attention bias modification treatment|12-session of ABMT
62022092|NCT05831098|EXPERIMENTAL|Experimental Diagnostic: Reveal TP (Syphilis) Antibody Test|Participants are tested with investigational devices and conventional syphilis serology tests.
62217956|NCT03971903|PLACEBO_COMPARATOR|Placebo controls|12-session of placebo(i.e.,sham) training
62217957|NCT05538559|EXPERIMENTAL|Test|
62412077|NCT05794555|EXPERIMENTAL|Enhanced Usual Care group followed by Tele-Tai Chi exercise classes|This is considered stage 2 for 12 weeks (for re-randomized participants)
62217958|NCT05538559|ACTIVE_COMPARATOR|Control|
62022093|NCT05746039|EXPERIMENTAL|Study Drug (semaglutide)|Semaglutide Pen Injector 1.0 mg weekly Once weekly subcutaneous injection Other Name: Wegovy
62217959|NCT01449500|PLACEBO_COMPARATOR|Placebo|Placebo
62217960|NCT01449500|ACTIVE_COMPARATOR|L. reuteri|"L. reuteri will be delivered at a dose of 1x108 CFU of each strain of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day.~Intervention: Dietary Supplement: L. reuteri DSM 17938 and ATCC PTA 6475"
62217961|NCT06520254|EXPERIMENTAL|Massage group|Participants in the massage group will receive 6 massage sessions (twice a week for 3 weeks).
62217962|NCT06520254|NO_INTERVENTION|Control group|Participants in the control group will receive 2 massage sessions, first one at the baseline, second one after 3 weeks.
62412078|NCT05794555|EXPERIMENTAL|Treatment (Lactulose) plus Enhanced Usual Care then recommended exercise|This is considered stage 2 for 12 weeks (for re-randomized participants)
62412079|NCT05279807|ACTIVE_COMPARATOR|Zofenopril 30 mg|Single dose Phase (4 weeks): patients will be treated with Zofenopril 30 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Zofenopril 30mg/Amlodipine 5mg will continue with the same therapy.
62793860|NCT00502554|ACTIVE_COMPARATOR|2|2-day cycles of photopheresis every 3 weeks for 3 months
62217963|NCT03090828|NO_INTERVENTION|control|treatment as usual will be provided to patients
62217964|NCT03090828|ACTIVE_COMPARATOR|app-based therapeutic education|patients will have access to the app providing information of the disease as well as educational guidelines
62217965|NCT03090828|EXPERIMENTAL|enhanced app-based therapeutic education|patients will also have access to a chat room and discussion forum
62217966|NCT02792751|ACTIVE_COMPARATOR|Group R (Ramsey)=25 patients|Propofol infusion was administered to provide Ramsey Sedation Scale 3-4 in Group R
62217967|NCT02792751|EXPERIMENTAL|Group B (BIS)=25 patients|Propofol infusion was given to maintain the Bispectral index monitorisation (BIS) levels between 60 and 85 in Group B.
62217968|NCT04574167|EXPERIMENTAL|tDCS with Cognitive Training|Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes)
62586037|NCT06584448|EXPERIMENTAL|Treatment Seeking (TS)|Participants will complete an initial telephone screen. Participants to be potentially eligible will be scheduled for an in-person Intake Session (consisting of an interview, questionnaires, lab work, and a urine drug screen). If found to be eligible participants will be scheduled for an inpatient admission. Participants will take part in an inpatient, medically supervised detoxification. In early sobriety (normally within one week of the last drink) and after approximately one month, participants will undergo brain imaging with intravenous administration of deuterated sodium acetate. Deuterium is a naturally occurring, non-radioactive substance that allows us to measure rates of metabolism. Neurocognitive tests will be performed to assess the impact of alcohol drinking.
62586038|NCT06584448|EXPERIMENTAL|Long-Term Recovery (LTS)|Participants will complete an initial telephone screen. Participants found to be potentially eligible will be scheduled for an in-person Intake Session (consisting of an interview, questionnaires, lab work, and a urine drug screen). Participants found to be eligible will be scheduled for an infusion study. Participants will undergo brain imaging with intravenous administration of deuterated sodium acetate. Deuterium is a naturally occurring, non-radioactive substance that allows us to measure rates of metabolism. Neurocognitive tests will be performed to assess the impact of alcohol drinking.
62586039|NCT05756777|EXPERIMENTAL|gilteritinib + ivosidenib (Cohort 1)|Each patient will take the combination of gilteritinib/ ivosidenib (Cohort 1) , daily, in continuous 28-day cycles at the dose level that they are assigned.
62586040|NCT05756777|EXPERIMENTAL|gilteritinib + enasidenib (Cohort 2)|Each patient will take the combination of gilteritinib/enasidenib (Cohort 2) daily, in continuous 28-day cycles at the dose level that they are assigned.
62586041|NCT06078774|EXPERIMENTAL|Virtual Health Coach - Parent/Child Dyad|Focuses on providing personalized care conveyed in an integrated and visually demonstrated way for parent-child pairs. Healthy lifestyle changes and behaviors covered in sessions are designed to initiate and maintain behavior change in nutrition and physical activity with BMI improvement.
62586042|NCT04353544|ACTIVE_COMPARATOR|Immediate cord clamping|Immediate cord clamping was defined as clampingwithin 15 seconds of birth
62586043|NCT04353544|EXPERIMENTAL|delayed cord clamping|when the cord stopped pulsing, or five minutes
62586044|NCT06684444|EXPERIMENTAL|Intervention (firefighter Sleep Health Coaching Intervention [ffSHC])|In this arm, fire service employees receive a structured sleep health intervention based on Cognitive Behavioral Therapy for Insomnia (CBTi). The intervention includes sleep health promotion, telephone-administered sleep coaching, and implementation strategies to promote better sleep practices. Each cluster will transition from the control arm to this intervention at a fixed time, and outcome data will be collected at multiple time points during and after the intervention phase to assess its effectiveness.
62586045|NCT06684444|ACTIVE_COMPARATOR|Control (Minimally Enhanced Usual Care)|In this arm, fire service workers receive usual care with minimal enhancements but without the full sleep health intervention. During this phase, clusters will serve as the control group, and data on sleep health and related outcomes will be collected for comparison against the intervention phase. Each cluster will remain in this arm until a predetermined time point, at which they transition to the intervention arm after a one-month preparation phase.
62793861|NCT00742417|EXPERIMENTAL|Albutein 5%|Patients allocated to this arm underwent plasma exchange with Albutein 5%.
62793862|NCT00742417|SHAM_COMPARATOR|Control|
62793863|NCT05185999|EXPERIMENTAL|Intervention|Intraperitoneal infusion with 500 mL of sodium-free 30% Icodextrin/ 10% Dextrose solution
62586046|NCT06665490||Mycosis Fungoides patients|Patients with mycosis fungoides will be enrolled at Northwestern Memorial Hospital Dermatology
62793864|NCT00799903|EXPERIMENTAL|Darapladib|Single daily oral tablet
62793865|NCT00799903|PLACEBO_COMPARATOR|Placebo|Single daily oral tablet
62793866|NCT05164627|ACTIVE_COMPARATOR|Group A|patients will receive Dexmedetomidine infusion (0.2 mcg/kg/hr) from the start of the surgery till the end of it.
62793867|NCT05164627|ACTIVE_COMPARATOR|Group B|patients will receive Magnesium infusion (10 mg/kg/hr) from the start of the surgery till the end of it.
62793868|NCT05164627|PLACEBO_COMPARATOR|Group C|Patients will receive Normal Saline 0.9% infusion
62793869|NCT03201419|EXPERIMENTAL|FE 201836 500 μg (Randomized Treatment Period)|FE 201836 500 μg oral solution and placebo orally disintegrating tablet (ODT), administered once daily
62793870|NCT03201419|EXPERIMENTAL|FE 201836 350 μg (Randomized Treatment Period)|FE 201836 350 μg oral solution and placebo ODT, administered once daily
62793871|NCT03201419|EXPERIMENTAL|FE 201836 250 μg (Randomized Treatment Period)|FE 201836 250 μg oral solution and placebo ODT, administered once daily
62793872|NCT03201419|EXPERIMENTAL|FE 201836 150 μg (Randomized Treatment Period)|FE 201836 150 μg oral solution and placebo ODT, administered once daily
62793873|NCT03201419|EXPERIMENTAL|FE 201836 100 μg (Randomized Treatment Period)|FE 201836 100 μg oral solution and placebo ODT, administered once daily
62793874|NCT03201419|EXPERIMENTAL|FE 201836 50 μg (Randomized Treatment Period)|FE 201836 50 μg oral solution and placebo ODT, administered once daily
62793875|NCT03201419|EXPERIMENTAL|Placebo (Randomized Treatment Period)|Placebo oral solution and placebo ODT, administered once daily
62793876|NCT03201419|EXPERIMENTAL|Desmopressin 25 μg (Randomized Treatment Period)|Desmopressin 25 μg ODT and placebo oral solution, administered once daily (female subjects)
62793877|NCT03201419|EXPERIMENTAL|Desmopressin 50 μg (Randomized Treatment Period)|Desmopressin 50 μg ODT and placebo oral solution, administered once daily (male subjects)
62793878|NCT04763941||Memory consultation patient|The study will be conducted on the basis of the patient consulting in Memory Consultation, specifically with the information already collected in normal care and the MEMORA cohort.
62022094|NCT04421144|EXPERIMENTAL|study group|using CAD/CAM surgical cutting guides for maxilla and mandible and customized titanium plates to guide all osteotomies and fixation of both arches.
62022095|NCT04169841|EXPERIMENTAL|GUIDE2REPAIR patients|olaparib + immunotherapy (durvalumab + tremelimumab) during 4 months followed by durvalumab alone as maintenance in patients with solid cancer and in response or stable after prior molecular target therapy by olaparib based on molecular sequencing.
62022096|NCT05860036|EXPERIMENTAL|VRd-based regimen Combined With BCMA CART|"VRd：Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22 in a 28-day cycle.~Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10\^6 anti-BCMA CAR+T cells/kg.~Participants will receive VRD induction, BCMA CAR-T infusion, VR consolidation, R maintenance."
62022097|NCT01681693|EXPERIMENTAL|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
62022098|NCT01663493|OTHER|Fine needle aspiration needle|standard Beacon FNA needle
62022099|NCT01663493|OTHER|fine needle biopsy needle|SharkCore fine needle biopsy needle
62022100|NCT02063789|EXPERIMENTAL|Human immunoglobulin intravenous|Human immunoglobulin intravenous; GC5107A (IV-Globulin SN Inj. 10%); Day 1: GC5107A, 1g/kg, intravenous Day 2: GC5107A, 1g/kg, intravenous; Starting infusion rate: 0.01mg/kg/min (1mg/kg/min) for first 15 minutes, and then 2-fold increase every 30 minutes by maximum 0.08ml/kg/min (8mg/kg/min). Dosing modification is allowed due to tolerance.
62217969|NCT04574167|SHAM_COMPARATOR|Sham tDCS with Cognitive Training|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
62217970|NCT05936294|OTHER|CRT Optimization|Each patient will have atrial pacing 10% higher than the sinus rate or atrial pacing at a rate of 60 bpm if significant sinus bradycardia is present. Each patient will have six ECGs and echocardiographic sequences performed in the same session. In addition six electrical activation evaluations by the Medtronic ECG belt will be done as well. The first study will always be with no ventricular pacing. One study will be echocardiography-optimized BIV pacing and four studies for echocardiography-optimized (?) adaptive RV-only pacing with different AV intervals. A random-sequence will be performed to determine the order for the rest of the studies.
62217971|NCT03982901|EXPERIMENTAL|women with chest pain|women with chest pain and coronary artery stenosis less than 50%
62217972|NCT03982901|SHAM_COMPARATOR|healthy women|women without chest pain and coronary artery stenosis less than 50%
62217973|NCT05534438|EXPERIMENTAL|Participants with oligometastatic breast cancer|Participants with oligometastatic breast cancer with isolated progression after sustained (\>=6 month) response to systemic therapy. Participants will receive image guided, SBRT to the progressive lesion identified on imaging. Participants will be maintained on their existing line of systemic therapy. Systemic therapy will be held during days of radiation and resume following completion of radiation.
62217974|NCT06149910||Platform|Patients in this cohort are participating in the All4Cure platform and there has been an established intention to treat according to the clinical pathway. Additionally, the patient's primary physician will also be a participant in the All4Cure platform.
62586047|NCT00034424||1|individuals from families with familial TGCT
62793879|NCT03960112|EXPERIMENTAL|mpMRI|mpMRI in the detection of prostate cancer in a per patient analysis using cystoprostatectomy specimen
62793880|NCT00640965|EXPERIMENTAL|A|DP-VPA
62793881|NCT00640965|PLACEBO_COMPARATOR|B|
62793882|NCT02925624|EXPERIMENTAL|CLOSE guided PVI and insertable cardiac monitor|
62793883|NCT03097536|EXPERIMENTAL|Luna Bar Intervention|Participants will be asked to monitor their blood sugar during migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. This information will be recorded at times when a Luna bar is not consumed, and at times when a Luna Bar is consumed. Participants will serve as their own controls.
62793884|NCT03097536|NO_INTERVENTION|Morning Migraine|Participants will be asked to monitor their blood sugar on headache free days as well as during migraine. This arm is only for participants who identify as having morning migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. Participants will serve as their own controls.
62793885|NCT05325970||Cohorts Interventions Patients receiving head and neck RT|
62819376|NCT05880979|ACTIVE_COMPARATOR|Control (Receipt of regular well-child care)|Providers and families in the control arm will receive regular well-child care. All providers in the control arm will have access to ETHR after the pilot trial is over
62819377|NCT05064150||NET patient observational cohort|Patients diagnosed with lung or gastrointestinal neuroendocrine tumors
62819378|NCT03297047|ACTIVE_COMPARATOR|upper arm combi cast|standardized treatment
62819379|NCT03297047|EXPERIMENTAL|forearm combi cast|Treatment with a forearm combi cast should be a sufficient immobilization
62217975|NCT06149910||Documentation|Patients in this cohort are not participating in the All4Cure platform but there has been an established intention to treat according to the clinical pathway.
62217976|NCT06149910||Off-pathway|Patients in this cohort are not participating in the All4Cure platform and there has not been in intention to treat according to the clinical pathway that has been established by a landmark time period.
62217977|NCT06027593|OTHER|Prescribing Clinicians|During the pre-intervention period which will last up to approximately 24 months, investigators will retrospectively collect data on appropriate antibiotic prescribing for the conditions. In the post-intervention period of approximately 24 months, investigators will implement a provider-focused intervention, consisting of feedback reports to providers using the validated metrics of antibiotic prescribing. These measures are based on national guidelines for appropriate antibiotic prescribing. Following implementation of the intervention, the investigative team will collect the same measures.
62412080|NCT05279807|ACTIVE_COMPARATOR|Amlodipine 5/10 mg|Single dose Phase (4 weeks): patients will be treated with Amlodipine 5 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Zofenopril 30mg/Amlodipine 5mg will continue with the same therapy.
62412081|NCT02546180|EXPERIMENTAL|YouTube Video Viewers|Subjects in this arm were randomized to viewing YouTube videos.
62793886|NCT05217394|EXPERIMENTAL|OTHIG|"Occupational Therapy Handwriting Intervention Guideline - this is the experimental guideline to be tested in this study.~Section C: Intervention for Handwriting Readiness Skills~* Handwriting development~* Pre-writing skills~* Gross motor skills activities~* Fine motor skills activities~* Motor visual skills activities Section D: Intervention for Handwriting Skills~* Handwriting tools~* Pencil grasp~* Posture and position~* Hand dominance~* Writing capitals, lowercase, and numbers~* Handwriting speed Section E: Handwriting Intervention Module~* Session 1: Development of Handwriting Skills Activities~* Session 2: Pre-writing Skills Activities~* Session 3: Gross and Fine Motor Skills Activities~* Session 4: Writing Capital Letters~* Session 5: Writing Lowercase Letters~* Session 6: Writing Numbers"
62793887|NCT05217394|NO_INTERVENTION|NOTi|"Natural Occupational Therapy Intervention - this means, the participants in this group are not exposed to the OTHIG. They receive natural OT intervention without exposure to the OTHIG.~The natural OT intervention includes:~Gross motor skills, fine motor skills, pre-writing skills, basic handwriting tasks such as copying, tracing, imitating and colouring.~It will follow the occupational therapist intervention set up by the respected therapist in charge. The OT in charge had qualifications from the local university in Malaysia.~The natural OT intervention includes:~Gross motor skills, fine motor skills, pre-writing skills, basic handwriting tasks such as copying, tracing, imitating and colouring.~It will follow the occupational therapist intervention set up by the respected therapist in charge. The OT in charge had qualifications from the local university in Malaysia."
62793888|NCT03088488||Periodontally healthy subjects|
62793889|NCT03088488||Chronic periodontitis patients|
62793890|NCT04270799||Lung Nodules|"A cohort of 1000 patients with incidental lung nodules will be identified using clinical records at participating NHS sites.~Link-anonymised CT scan images and data will be stored using a central database for radiomics and artificial intelligence research, to predict the risk of malignancy."
62793891|NCT02525588|ACTIVE_COMPARATOR|Conventional polyethylene inlay nitrogen/vacuum-packed (N2Vac)|Conventional UHMWPE inlay in a Triathlon Condyle Stabilizing (CS) fixed bearing total knee prosthesis
62793892|NCT02525588|ACTIVE_COMPARATOR|Highly cross-linked polyethylene (X3)|X3 highly cross-linked polyethylene inlay in a Triathlon CS fixed bearing total knee prosthesis
62793893|NCT01409876|EXPERIMENTAL|Brachytherapy|
62793894|NCT05642520|EXPERIMENTAL|oval section abutment of a 2.9mm|"The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed.~Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland)."
62793895|NCT05642520|PLACEBO_COMPARATOR|circular section abutment in 3.3mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Both implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
62793896|NCT05979519|EXPERIMENTAL|Grocery Prescription Program|Those randomized to the Grocery Prescription intervention will receive the Fresh Funds for Mom's through Instacart immediately
62793897|NCT05979519|ACTIVE_COMPARATOR|Standard Medical Care|the delayed control group will receive their usual care through their healthcare provider and then participate in Fresh Funds or MTM after the initial 12-weeks of intervention.
62022101|NCT02055352|EXPERIMENTAL|Budesonide/indacaterol|Participants will receive a fixed combination of fluticasone and salmeterol during 4 weeks followed by a free combination of budesonide and indacaterol for the remainig of study.
62022102|NCT02055352|ACTIVE_COMPARATOR|Fluticasone / salmeterol|Fixed combination of fluticasone and salmeterol
62022103|NCT05205135||Caregivers|Caregivers of persons with dementia supported by the Carer Matters programme
62022104|NCT05205135||Nurses|Ward nurses who collaborate with the Carer Matters team
62793898|NCT05979519|EXPERIMENTAL|MTM (medically tailored frozen meals)|Those randomized to the MTM intervention will receive medically tailored frozen meals from Door Dash
62793899|NCT03871244|EXPERIMENTAL|Restrictive arm (intervention)|Less red blood cell transfusions. The protocol will require that no red blood cell transfusion be given unless the hemoglobin level is below or equal at 70 g per L.
62217978|NCT06027593|NO_INTERVENTION|Patients diagnosed with conditions of interest during study period|Interactions between investigators and patients will be limited to review of existing EHR data. Investigators will have no direct contact with patients. The data from the University of Pennsylvania Health System (UPHS) and Children's Hospital of Philadelphia (CHOP) will be extracted from data warehouses that store data from the electronic health record. These data will be used in feedback report generation as well as in outcome assessment. An estimated total of 10,000 inpatients with CAP (adult and pediatric) will be recruited. Similarly, about 500,000 patients (adult pharyngitis and pediatric acute otitis media combined) will be recruited in the outpatient setting.
62217979|NCT03871023|ACTIVE_COMPARATOR|Simple dressing|Standard, waterproof dressing applied to wound
62217980|NCT03871023|ACTIVE_COMPARATOR|PICO Dressing|Negative Wound pressure applied second cohort
62217981|NCT03871023|ACTIVE_COMPARATOR|PREVENA Dressing|Negative wound presure applied to third cohort
62217982|NCT03973281|ACTIVE_COMPARATOR|Materna Prep Device|Materna Prep Device
62217983|NCT03973281|OTHER|Standard of Care (SOC)|Standard of Care (SOC)
62793900|NCT03871244|ACTIVE_COMPARATOR|Standard care arm (comparator)|Clinical teams will follow their usual transfusion practices.
62793901|NCT02002741|ACTIVE_COMPARATOR|Ibuprofen + Paracetamol|"Ibuprofen 10mg/kg once --\> 5mg/kg twice, q 24h for total of 3 doses~+ Intravenous Paracetamol : Loading dose 20mg/kg --\> 10 mg/kg q6h for total of 12 doses"
62793902|NCT02002741|PLACEBO_COMPARATOR|Ibuprofen + Placebo|"Ibuprofen 10mg/kg once --\> 5mg/kg twice, q 24h for total of 3 doses~+ Placebo (NaCl 0.9%) , Intravenous , at equal volume to the paracetamol in the paracetamol arm, total of 12 doses given q 6h."
62793903|NCT05375227|EXPERIMENTAL|Electric Toothbrush|Electric toothbrush + manufacturer's instructions + professional recommendations + sodium monofluorophosphate (1450 ppm F) toothpaste (elmex® SENSITIVE PROFESSIONAL)
62793904|NCT05375227|ACTIVE_COMPARATOR|Manual toothbrush|Manual toothbrush + manufacturer's instructions + professional recommendations + sodium monofluorophosphate (1450 ppm F) toothpaste (elmex® SENSITIVE PROFESSIONAL)
62793905|NCT01897948|EXPERIMENTAL|Milk-based beverage with DHA at mid-level|
62217984|NCT04992182|EXPERIMENTAL|Inactivated vaccine booster|One standard IM CoronaVac dose (0.5 mL)
62217985|NCT04992182|EXPERIMENTAL|mRNA vaccine booster|One standard IM BNT162b2 dose (0.3 mL)
62217986|NCT04992182|EXPERIMENTAL|Viral vector vaccine booster|One standard IM ChAdOx1 dose (0.5 mL)
62217987|NCT04992182|PLACEBO_COMPARATOR|Placebo|Saline solution IM (0.3 mL)
62217988|NCT05543187|EXPERIMENTAL|TAK-625, Primary cohort|TAK-625 orally, twice daily (BID) for 4 weeks as Dose Escalation Period. The dose in Dose Escalation Period will be increased weekly, 150 mcg/kilograms (kg), 300 mcg/kg, 450 mcg/kg, and 600 mcg/kg. After Dose Escalation Period, TAK-625 600 mcg/kg (or maximum tolerated dose \[MTD\]), orally, BID up to study completion.
62217989|NCT05543187|EXPERIMENTAL|TAK-625, Supplemental cohort|TAK-625 orally, twice daily (BID) for 4 weeks as Dose Escalation Period. The dose in Dose Escalation Period will be increased weekly, 150 mcg/kilograms (kg), 300 mcg/kg, 450 mcg/kg, and 600 mcg/kg. After Dose Escalation Period, TAK-625 600 mcg/kg (or maximum tolerated dose \[MTD\]), orally, BID up to study completion.
62217990|NCT04277182|PLACEBO_COMPARATOR|Control group|It will be accepted as the control group and 4 experimental burn wounds will be created on the back of the rats in the group and no treatment will be given.
62217991|NCT04277182|ACTIVE_COMPARATOR|1% Silver Sulfadiazine|4 experimental burn wounds will be created on the back of the rats in the group and dressing with 1% Silver Sulfadiazine will be done on the back of the rats every day for 21 days.
62217992|NCT04277182|ACTIVE_COMPARATOR|%0.2 Nitrafurozon|4 experimental burn wounds will be created on the back of the rats in the group and dressing with %0.2 Nitrafurozon will be done on the back of the rats every day for 21 days.
62217993|NCT04277182|EXPERIMENTAL|10% Propolis|4 experimental burn wounds will be created on the back of the rats in the group and dressing with 10% Propolis will be done on the back of the rats every day for 21 days.
62217994|NCT04277182|EXPERIMENTAL|15% Propolis|4 experimental burn wounds will be created on the back of the rats in the group and dressing with 15% Propolis will be done on the back of the rats every day for 21 days.
62217995|NCT04277182|ACTIVE_COMPARATOR|Propolis vehicle|4 experimental burn wounds will be created on the back of the rats in the group and dressing with Propolis vehicle will be done on the back of the rats every day for 21 days.
62217996|NCT02567773|EXPERIMENTAL|Part A: GSK2881078|The first cohort subjects will receive GSK2881078 1.5 mg (for males) or 0.75 mg (for females) twice daily for 3 days followed by once daily for 25 days. The subsequent cohort subjects will receive GSK2881078 doses selected after reviewing the unblinded data from at least 2 weeks of dosing of at least 6 subjects in the first cohort. Each cohort subjects will receive GSK2881078 dose twice daily for the first 3 days followed by 25 days of once daily.
62217997|NCT02567773|PLACEBO_COMPARATOR|Part A: Placebo|Subjects will receive placebo twice daily for 3 days followed by once daily for 25 days.
62793906|NCT01897948|EXPERIMENTAL|Milk-based beverage with DHA at high level|
62793907|NCT01897948|ACTIVE_COMPARATOR|Milk-based beverage without DHA|
62793908|NCT03430960|OTHER|Group A - Standard of Care|
62022105|NCT05205135||Programme facilitators|Facilitators of programmes organised through Carer Matters
62412082|NCT02546180|ACTIVE_COMPARATOR|Standard Education|Subjects in this arm were randomized to standard preoperative education.
62793909|NCT03430960|EXPERIMENTAL|Group B - mCare group|
62793910|NCT02757144|EXPERIMENTAL|Cohort 1: DWP14012 Amg|DWP14012 Amg, tablets, orally, single dose administration
62793911|NCT02757144|EXPERIMENTAL|Cohort 2: DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single dose administration
62793912|NCT02757144|EXPERIMENTAL|Cohort 3: DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single dose administration
62793913|NCT02757144|EXPERIMENTAL|Cohort 4: DWP14012 Dmg|DWP14012 Dmg, tablets, orally, single dose administration
62793914|NCT02757144|EXPERIMENTAL|Cohort 5: DWP14012 Emg|DWP14012 Emg, tablets, orally, single dose administration
62217998|NCT02567773|EXPERIMENTAL|Part B: GSK2881078-Itraconazole|Subjects will receive GSK2881078 (dose level will be determined based on the results from Part A) on Day 1 of Period-1 and Day 6 of Period-2. Subjects will also receive itraconazole 200 mg twice daily on Day1 of Period-2 and 200 mg once daily on Days 2-34 of Period-2.
62217999|NCT03274167|EXPERIMENTAL|Gabapentin|300 mg per day once daily before bedtime
62218000|NCT03274167|PLACEBO_COMPARATOR|Control|Capsule identical to the experimental arm, one tablet once daily before bedtime
62218001|NCT04065945||Couples undergoing ART treatment|Couples in reproductive age undergoing ART treatment in Women's Hospital School of Medicine Zhejiang University, The International Peace Maternity \& Child Health Hospital, and Changhai Hospital of Shanghai.
62218002|NCT04065945||Couples getting pregnant naturally|Couples who get pregnant naturally and want to deliver the babies in Women's Hospital School of Medicine Zhejiang University, The International Peace Maternity \& Child Health Hospital, and Changhai Hospital of Shanghai.
62218003|NCT05470049|EXPERIMENTAL|Treatment group A: SHR8554 Injection and SHR0410 Injection|
62218004|NCT05470049|EXPERIMENTAL|Treatment group B: SHR8554 Injection and SHR0410 Injection|
62218005|NCT05470049|PLACEBO_COMPARATOR|Treatment group C: SHR8554 Injection and Placebo for SHR0410 Injection|
62412083|NCT00003861||Ancillary-Correlative (molecular genetic features)|Previously collected blood and tissue samples are analyzed via RT-PCR and flow cytometry.
62412084|NCT06558526|EXPERIMENTAL|Pectin intervention group|This group will orally take 10 g of apple pectin (DE 57%) + 5 g of maltodextrin once a day during 6 months.
62412085|NCT06558526|PLACEBO_COMPARATOR|Placebo group|This group will orally take 5 g of maltodextrin once a day during 6 months.
62412086|NCT02902757|EXPERIMENTAL|Treatment (FDG PET/CT)|Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.
62412087|NCT04484805|EXPERIMENTAL|ICE Unit|"The subject wears the experimental socket with an ICE Unit, which includes a TEC and will be actively cooling the leg whenever the device is powered on. An ambient temperature sensor and step counter is attached to the socket. The subject is only informed that each condition is a different level of cooling to reduce bias. This condition should last approximately one month."
62412088|NCT04484805|SHAM_COMPARATOR|Sham Unit|"The subject wears the experimental socket with a Sham Unit, which excludes a TEC and will not be actively cooling the leg when the device is powered on. An ambient temperature sensor and step counter is attached to the socket. The subject is only informed that each condition is a different level of cooling to reduce bias. This condition should last approximately one month."
62412089|NCT06650774||Group 1|Pirfenidone Group
62412090|NCT06650774||Group 2|Nintedanibe Group
62412091|NCT01125358|EXPERIMENTAL|10 milligrams (mg) LY2140023|
62218006|NCT00844532|EXPERIMENTAL|Absolute Pro™ Peripheral Self-Expanding Stent System|Arm includes both Absolute Pro™ and Absolute Pro™ Long Lesion (LL) Peripheral Self-Expanding Stent Systems
62218007|NCT03299998||BLOCK+|Patients who underwent maxillary and mandibulary block before surgery
62218008|NCT03299998||BLOCK -|Patients who did not undergo maxillary and mandibulary block before surgery.
62218009|NCT03046693|EXPERIMENTAL|Group A|Subjects in group A get citicoline 1000 mg per day for 60 days
62218010|NCT03046693|PLACEBO_COMPARATOR|Group B|Subjects in group B get placebo for 60 days.
62218011|NCT00956059|EXPERIMENTAL|prednisone, MMF and FK506|
62218012|NCT00956059|ACTIVE_COMPARATOR|prednisone|
62218013|NCT01072760|EXPERIMENTAL|K wire|
62218014|NCT02407392|ACTIVE_COMPARATOR|Non targeted quadrantic biopsies|Patients undergo current gold standard Barrett's surveillance with quadrantic Seattle protocol biopsies
62218015|NCT02407392|EXPERIMENTAL|Acetic Acid targeted biopsies|Patients undergo dye spray gastroscopy with Acetic Acid and targeted biopsies for areas of dysplasia.
62218016|NCT06101043|EXPERIMENTAL|PECS II block group|
62218017|NCT06101043|NO_INTERVENTION|No PECS II block group|
62218018|NCT05023681|EXPERIMENTAL|r-SAK treatment group|intravenous injection of single bolus 5 mg r-SAK in 3min
62218019|NCT05023681|PLACEBO_COMPARATOR|saline control group|intravenous injection of 10ml saline in 3min,r-SAK and saline are the same in appearance
62218020|NCT04107987|ACTIVE_COMPARATOR|Reglicemi|Reglicemi is a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate
62412092|NCT01125358|EXPERIMENTAL|80 mg LY2140023|
62412093|NCT01125358|EXPERIMENTAL|160 mg LY2140023|
62793915|NCT02757144|EXPERIMENTAL|Cohort 6: DWP14012 Fmg|DWP14012 Emg, tablets, orally, single dose administration
62218021|NCT04107987|PLACEBO_COMPARATOR|Placebo|Placebo
62218022|NCT00852033|NO_INTERVENTION|1|Assessment Group (no intervention)
62412094|NCT01125358|PLACEBO_COMPARATOR|Placebo|
62412095|NCT06565611|ACTIVE_COMPARATOR|Tirzepatide and Bremelanotide Combination Therapy|
62412096|NCT06565611|PLACEBO_COMPARATOR|Tirzepatide Monotherapy|N=1
62412097|NCT06565611|PLACEBO_COMPARATOR|Bremelanotide Monotherapy|
62412098|NCT06565611|NO_INTERVENTION|Placebo|
62793916|NCT02757144|PLACEBO_COMPARATOR|Cohort 1-6: Placebo|DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, single dose administration
62793917|NCT02757144|ACTIVE_COMPARATOR|Cohort 1-6: Esomeprazole|Nexium® tablets, orally, single dose administration
62022106|NCT05205135||Care Support Nurses|Nurses trained to deliver support and assistance as part of Carer Matters Programme
62022107|NCT05205135||Community partners and hospital leaders|Key policy makers and community leaders who partner with the Carer Matters programme to ensure its success
62022108|NCT05205135||Other clinicians (e.g. Social workers, Physiotherapists, doctors)|Other clinicians who refer caregivers to the Carer Matters programme
62022109|NCT03491735||Group A|Patients referred to glaucoma sub-specialty clinics in Kasr Al-Aini Hospital, Cairo University, Egypt in the year 2018
62022110|NCT03491735||Group B|Patients referred to glaucoma sub-specialty clinics in Sadguru Netra Chikitsalaya Postgraduate Institute of Ophthalmology, Mumbai, India in the year 2018
62022111|NCT01053858|ACTIVE_COMPARATOR|bevacizumab|intravitreal bevacizumab or triamcinolone determined by single physician
62022112|NCT01053858|ACTIVE_COMPARATOR|triamcinolone|
62793918|NCT02757144|EXPERIMENTAL|Cohort 7: DWP14012 Amg|DWP14012 Amg, tablets, orally, repeated dose administration(for 7days)
62022113|NCT02553330|EXPERIMENTAL|Ruxolitinib Phosphate Cream|"Part A: Open-label treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks;~Part B: Double-blind treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks."
62022114|NCT02553330|PLACEBO_COMPARATOR|Placebo Cream|Part B: Double-blind treatment is 24 weeks (and/or treatment with Ruxolitinib Phosphate Cream if eligible) and follow-up is an additional 12 weeks.
62022115|NCT04461522||Exposed group|
62022116|NCT04461522||Control group|
62412099|NCT02788955|ACTIVE_COMPARATOR|Normal Protein Diet|In the normal protein diet, participants will be instructed to follow a diet that will provide them with the amount of calories enough to meet their energy needs without changing their body weight and will contain 1 g of protein per kilogram of body weight. Participants will be instructed to consume protein primarily from animal food sources. A high quality whey protein supplement will be provided as needed.
62793919|NCT02757144|EXPERIMENTAL|Cohort 8: DWP14012 Bmg|DWP14012 Bmg, tablets, orally, repeated dose administration(for 7days)
62793920|NCT02757144|EXPERIMENTAL|Cohort 9: DWP14012 Cmg|DWP14012 Cmg, tablets, orally, repeated dose administration(for 7days)
62793921|NCT02757144|PLACEBO_COMPARATOR|Cohort 7-10: Placebo|DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 7days)
62793922|NCT02757144|ACTIVE_COMPARATOR|Cohort 7-10: Esomeprazole|Nexium®, orally, repeated dose administration(for 7days)
62793923|NCT02757144|EXPERIMENTAL|Cohort 9: DWP14012 Dmg|DWP14012 Dmg, tablets, orally, repeated dose administration(for 7days)
62793924|NCT01277874|ACTIVE_COMPARATOR|Nasal CPAP|Standard Nasal CPAP
62793925|NCT01277874|ACTIVE_COMPARATOR|Oscillatory NCPAP|NCPAP will be given to infant via prongs in the infant's nose. A Bird Industries pneumatic oscillating diaphragm to drive a Bird Industries phasatron which is attached by T-connector to the NCPAP patient circuit.
62793926|NCT01008943|EXPERIMENTAL|1|
62793927|NCT01493973|EXPERIMENTAL|Epoetin alfa|Patients will be treated with Epoetin alfa 1200 IU/Kg s.c. every 12 weeks
62022117|NCT03219944|EXPERIMENTAL|Platelet Rich Fibrin for soft tissue augmentation|blood will be drawn from the patient vein for PRF. The blood sample will be centrifuged for 10-12 min. PRF membrane is obtained
62022118|NCT03219944|ACTIVE_COMPARATOR|sub epithelial connective tissue graft|The connective tissue graft will be harvested from the palate. Then the SCTG will be placed over the recipient site extending palataly and sutured.
62793928|NCT01493973|PLACEBO_COMPARATOR|Placebo|Placebo 1200 IU/Kg s.c. every 12 weeks
62793929|NCT04161937|EXPERIMENTAL|Behavioural Intervention|Half of the randomly selected participants will get behavioural intervention based on Diabetes Prevention Program module.The behavioural intervention classed will be administered by trained nurse weekly for 16 weeks.After completion of behavioural intervention both the experimental and control arm will get cafeteria intervention.
62022119|NCT01621750|EXPERIMENTAL|Clopidogrel|Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited
62022120|NCT01621750|ACTIVE_COMPARATOR|Plavix|Clopidogrel Tablet 300 mg
62022121|NCT01185574|EXPERIMENTAL|Vitamin D supplementation|The study medication (a capsule of 50,000 IU of vitamin D2) will be administered once a week for six months.
62022122|NCT04491500||study group|This is a self-control study. Subjects who plan togo to 4000m altitude to work for two weeks will be enrolled. And before and after they arrive high altitude, they will have visual acuity, OCTA, and intraocular pressure; blood pressure, blood oxygen measurement.
62022123|NCT00298428|OTHER|SPACE group|
62022124|NCT02197923||Biopsy: adenomyosis|Myometrial biopsy Pipelle
62022125|NCT02197923||Biopsy: Healthy|Myometrial Biopsy Pipelle
62022126|NCT04558346|PLACEBO_COMPARATOR|Placebo|"Placebo (40ug/kg) will be self-administered twice daily for 14 days.~ONLY THE PART B (ACUTE) SUBJECTS WILL BE RANDOMIZED AND MAY RECEIVE PLACEBO."
62218023|NCT00852033|ACTIVE_COMPARATOR|2|Brief Motivational Intervention (BMI)
62218024|NCT00852033|ACTIVE_COMPARATOR|3|Parent Based Intervention (PBI)
62793930|NCT04161937|EXPERIMENTAL|Control|Half of the participants will act as a control and will not receive any form of behavioural intervention.
62793931|NCT02488005|EXPERIMENTAL|Small Bowel Ultrasound|Subjects will receive a small bowel ultrasound to measure bowel wall thickness at Week 0 and Week 14
62793932|NCT01822418|EXPERIMENTAL|Treatment|Open-label treatment with agomelatine 25 mg/day (or 50 mg/day after week 3).
62793933|NCT01822197|EXPERIMENTAL|Phototherapy|Bright light phototherapy will be administered for 30 minutes daily over one week in the morning (Days 0-7)
62022127|NCT04558346|EXPERIMENTAL|Ghrelin (OXE-103)|"OXE-103 (40ug/kg) will be self-administered twice daily for 14 days.~PART A (POST-ACUTE) SUBJECTS WILL BE OFFERED EXPERIMENTAL TREATMENT WITHOUT RANDOMIZATION.~PART B (ACUTE) SUBJECTS WILL BE DOUBLE-BLIND RANDOMIZED TO EXPERIMENTAL OR PLACEBO TREATMENT."
62218025|NCT00852033|ACTIVE_COMPARATOR|4|BMI and TBI
62022128|NCT05622981|EXPERIMENTAL|Behavioral intervention|Behavioral intervention for healthy lifestyle goals, four analysis groups divided by age (2-4, 5-8, 9-11, 12-17)
62022129|NCT01332305|EXPERIMENTAL|GEn (XP13512/GSK1838262) 600 mg|GEn (XP13512/GSK1838262) 600 mg
62022130|NCT01332305|EXPERIMENTAL|GEn (XP13512/GSK1838262) 1200 mg|GEn (XP13512/GSK1838262) 1200 mg
62022131|NCT01332305|EXPERIMENTAL|GEn (XP13512/GSK1838262) 1800 mg|GEn (XP13512/GSK1838262) 1800 mg
62218026|NCT00766363|EXPERIMENTAL|EVP-6124 (0.1 mg/day)|
62022132|NCT01332305|EXPERIMENTAL|GEn (XP13512/GSK1838262) 2400 mg|GEn (XP13512/GSK1838262) 2400 mg
62022133|NCT01332305|PLACEBO_COMPARATOR|Placebo|Placebo
62022134|NCT01086072||Myocardial Infarction - STEMI|
62793934|NCT04744922|EXPERIMENTAL|Auraptene and Naringenin Arm|One capsule a day for 9 months
62022135|NCT01086072||Myocardial Infarction - NSTEMI|
62022136|NCT04634357|EXPERIMENTAL|ET140203 T Cells|ET140203 Autologous T Cells
62218027|NCT00766363|EXPERIMENTAL|EVP-6124 (0.3 mg/day)|
62218028|NCT00766363|EXPERIMENTAL|EVP-6124 (1.0 mg/day)|
62218029|NCT00766363|PLACEBO_COMPARATOR|Placebo|
62218030|NCT01905137|ACTIVE_COMPARATOR|Botulinum Toxin Type A|Patients in the treatment group will receive 200 Units of Botulinum toxin diluted in 20 mL of saline injected globally into their pelvic floor muscles followed by 8 treatments of pelvic floor physical therapy.
62218031|NCT01905137|PLACEBO_COMPARATOR|Saline|Patients in the placebo group will receive 20 mL of saline injected globally into their pelvic floor muscles followed by 8 treatments of pelvic floor physical therapy.
62218032|NCT05317845||Patients with Type 2 Diabetes (T2D)|Selected for inclusion in the study by their primary or secondary care physicians
62218033|NCT05939934|NO_INTERVENTION|control group|Patients will be ask not to use any OSAS treatment during the 2 weeks of the study (after the CPAP withdrawal)
62793935|NCT04744922|PLACEBO_COMPARATOR|Control Arm|One capsule a day for 9 months
62412100|NCT02788955|EXPERIMENTAL|High Protein Diet|In the high protein diet, participants will be instructed to follow a diet that will provide them with the amount of calories enough to meet their energy needs without changing their body weight and will contain 2 g of protein per kilogram of body weight. Participants will be instructed to consume protein primarily from animal food sources. A high quality whey protein supplement will be provided as needed.
62022137|NCT00462384|EXPERIMENTAL|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 micrograms per kilogram (mcg/kg) body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
62022138|NCT00253864||Arthroscopic rotator cuff repair|Participants who underwent an arthroscopic rotator cuff repair between 2007-2009.
62022139|NCT05676411|ACTIVE_COMPARATOR|Electrocautery-incision alone group|The skin inicsion will be made using electrocautery during shoulder replacement in patients assigned this group with no other preoperative treatment.
62022140|NCT05676411|EXPERIMENTAL|Electrocautery-incision and BPO group|Patients assigned in this group will undergo an application of topical benzoyl peroxide to the shoulder skin prior to shoulder replacement surgery in addition to their skin incision being made using electrocautery.
62022141|NCT03039413|EXPERIMENTAL|Diagnostic (Copper Cu 64 TP3805 PET/CT)|Patients receive copper Cu 64 TP3805 IV and undergo PET/CT after 60 minutes. Patients then undergo standard of care cystectomy and/or biopsy 1 to 4 weeks later.
62022142|NCT06389812|EXPERIMENTAL|Dual-task group|. The motor-cognitive dual-task group will be additionally asked to do horizontal eye movements by watching a TV screen and following a duck moving from side to side (bilateral condition) while performing strengthening exercises. only one session 30 mins.
62022143|NCT06389812|ACTIVE_COMPARATOR|eye movement exercise group|asked to do horizontal eye movements by watching a TV screen and following a duck moving from side to side (bilateral condition) while performing strengthening exercises. The duck moves successively between left and right banks of a river at a rate of 500 ms (Brunyé et al., 2009) which was previously found to improve cognitive function. only one session 30 mins.
62022144|NCT06389812|NO_INTERVENTION|control|listening a podcast. only one session 30 mins.
62218034|NCT05939934|EXPERIMENTAL|mandibular advancement device|Patients will be asked to use mandibular advancement device during the 2 weeks CPAP withdrawal
62218035|NCT06377046|EXPERIMENTAL|Accelerated pacing (lower rate pacemaker 80bpm)|Patients in the experimental arm will have their pacemaker programmed to a lower rate of 80bpm.
62412101|NCT06651021|EXPERIMENTAL|balcinrenone/dapagliflozin|To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants
62412102|NCT02271100|PLACEBO_COMPARATOR|palpation guidance|placement of spinal or combined spinal epidural needle using palpation to guide entry position
62793936|NCT02742545|EXPERIMENTAL|MayoExpertAdvisor|Clinicians in care teams assigned to the intervention arm will have access to MayoExpertAdvisor (MEA) in the electronic medical record (EMR). MEA will provide patient-specific knowledge and treatment suggestions for patients with hyperlipidemia, atrial fibrillation, and/or heart failure via a clickable tab in the Mayo Clinic EMR.
62218036|NCT06377046|ACTIVE_COMPARATOR|Current standard of care (lower rate pacemaker 60bpm)|Patients in the control arm will have their pacemaker programmed to a lower rate of 60bpm, which is the current standard of care.
62412103|NCT02271100|ACTIVE_COMPARATOR|ultrasound guidance|placement of spinal or combined spinal epidural using ultrasound to guide entry position
62793937|NCT02742545|NO_INTERVENTION|Usual Care|Clinicians in care teams assigned to the standard of care arm will continue to provide up-to-date, patient-specific guideline-based treatment recommendations as is the standard of care at Mayo Clinic.
62793938|NCT02551822|ACTIVE_COMPARATOR|Cycling|"Sacral neuromodulator devices (implanted pulse generator) will be programmed to on-off cycles (on 16 seconds, off 8 seconds). This means the devices are not continuously on. Rather they are on a cycling program."
62793939|NCT02551822|ACTIVE_COMPARATOR|Continuous|"Sacral neuromodulator devices (implanted pulse generator) will be programmed to be on continuously. This means the devices are continuously on. They are on a continuous program."
62793940|NCT02303249|EXPERIMENTAL|Intervention|Review of discharges and cross-sectoral video conferencing immediately after discharge
62793941|NCT02303249|NO_INTERVENTION|Control|Standard health care services
62793942|NCT00350688|OTHER|Helical tomotherapy IMRT|Helical tomotherapy IMRT
62218037|NCT04541498||Population of Poland|Exposure to short term long term effects of air pollution and climate change
62218038|NCT04541498||Patients with Acute Coronary and Cerebral Syndromes|Exposure to short term long term effects of air pollution and climate change
62218039|NCT04018573|ACTIVE_COMPARATOR|Parent Support Film|Parents will watch Lead with Love, a 35-minute documentary style film designed to provide support, information, and behavioral guidance to parents with a lesbian, gay, or bisexual child. One month later, parents will look over material that reviews the major points of the film. All of this material is presented online via our webapp.
62218040|NCT04018573|EXPERIMENTAL|Parent Support Film + PATHS Sexual Communication Toolkit|Parents in this arm will have the option of watching Lead with Love, and then will engage with our parent toolkit, designed to increase the frequency and quality of parent-child communication about HIV and condoms. One month later, parents will engage with booster content, customized to address their self-reported barriers to communicating with their sons. All of this material is presented online via our webapp.
62218041|NCT01498159|EXPERIMENTAL|Pharmacist + Health Promoter|Participants in this group will receive support from both a pharmacist and health promoter. Number of sessions will be determined by the study team member and patient.
62218042|NCT01498159|ACTIVE_COMPARATOR|Pharmacist|Participants will receive support from pharmacist.
62218043|NCT03242720|ACTIVE_COMPARATOR|Active Positive Airway Pressure|Active positive airway pressure for treatment of Obstructive Sleep Apnea
62218044|NCT03242720|SHAM_COMPARATOR|Sham Positive Airway Pressure|Sham positive airway pressure for treatment of Obstructive Sleep Apnea
62218045|NCT04573829|EXPERIMENTAL|Non-drug approaches at home|Non-drug approaches at home three visits per week during six months and psycho-education for the caregivers one time per week for six months.
62218046|NCT02884908|EXPERIMENTAL|Pregabalin + BBCET - NI/I/II type|This group will be comprised of subjects with the NI/I/II type who receive study medication (Pregabalin) and Brief Behavioral Compliance Enhancement Treatment (BBCET).
62218047|NCT02884908|EXPERIMENTAL|Pregabalin + BBCET - NI/NI type|This group will be comprised of subjects with the NI/NI type who receive study medication (Pregabalin) and Brief Behavioral Compliance Enhancement Treatment (BBCET).
62412104|NCT03464110|NO_INTERVENTION|Standard of Care|Investigator will compare patients randomized into the intervention group to those who receive standard of care.
62412105|NCT03464110|EXPERIMENTAL|Communication Intervention|The intervention will contain elements of Motivational Interviewing coaching but also will teach providers how to address patient emotion and increase the efficiency of their visits. Clinicians randomized to the intervention will receive a tailored communication coaching intervention that includes didactic elements, audio recording encounters and providing feedback, and role-playing.
62793943|NCT05331586|NO_INTERVENTION|control intervention|The control group will receive the standard prenatal care in Hospital Center of São Joao (CHUSJ). The standard prenatal care will be regular appointments with obstetrician and midwife nurses, ultrasounds and nutritional appointments. The pregnant women in control group will also receive a pamphlet with the benefits of physical exercise during pregnancy and recommendations for adequate gestational weight gain. Pregnant women in control group will not be discouraged from exercising on their own.
62218048|NCT02884908|PLACEBO_COMPARATOR|Placebo + BBCET - NI/I/II type|This group will be comprised of subjects with the NI/I/II type who receive placebo and Brief Behavioral Compliance Enhancement Treatment (BBCET).
62218049|NCT02884908|PLACEBO_COMPARATOR|Placebo + BBCET - NI/NI type|This group will be comprised of subjects with the NI/NI type who receive placebo and Brief Behavioral Compliance Enhancement Treatment (BBCET).
62412106|NCT01326611|ACTIVE_COMPARATOR|Clarithromycine Group: Active Comparator|Drug: Clarithromycin intravenous clarithromycin (10 mg/kg twice a day for 10 days)
62412107|NCT01326611|PLACEBO_COMPARATOR|Placebo Group: Placebo Comparator|Drug: D5W Dose given daily, IV same volume that Clarithromycin would be to equal 10 mg/kg for first 10 days.
62793944|NCT05331586|EXPERIMENTAL|Exercise intervention|The exercise group intervention will perform home-based remotely monitored exercise
62412108|NCT04341727|ACTIVE_COMPARATOR|Hydroxychloroquine alone|Arm 1: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.
62412109|NCT04341727|ACTIVE_COMPARATOR|Hydroxychloroquine plus azithromycin|"Arm 2: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.~AND Azithromycin 500mg orally once, followed by 250mg daily for four consecutive days (five days total). The drug will be supplied in 250mg tablets."
62412110|NCT04341727|ACTIVE_COMPARATOR|Chloroquine alone|Arm 3: Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg, then 500mg orally twice daily for 4 days (Five days in total). The drug will be supplied in 500mg tablets.
62819380|NCT06690359|EXPERIMENTAL|IgA nephropathy subjects with urinary protein and renal insufficiency|The study plans to recruit 6 patients with IgA nephropathy accompanied by urinary protein and renal dysfunction, including 3 patients receiving a dose of 0.5 × 10 \^ 8 CAR-T cells and 3 patients receiving a dose of 1 × 10 \^ 8 CAR-T cells
62218050|NCT04532554|EXPERIMENTAL|Growth hormone|Recombinant GH will be used for those patients
62218051|NCT04532554|PLACEBO_COMPARATOR|Placebo|Saline will be used
62412111|NCT04341727|ACTIVE_COMPARATOR|Chloroquine plus azithromycin|"Arm 4: Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg, then 500mg orally twice daily for 4 days (Five days in total). The drug will be supplied in 500mg tablets.~AND Azithromycin 500mg orally once, followed by 250mg daily for 4 consecutive days (5 days total).The drug will be supplied in 250mg tablets."
62793945|NCT04463342|EXPERIMENTAL|Non Coated Glass Ionomer|A faster, easier procedure is great, but you want assurance that reducing chair time doesn't mean compromising on performance. KetacTM Universal AplicapTM Glass Ionomer Restorative saves time by eliminating the need for a coating-yet still delivers the compressive strength and surface hardness that are higher than several competitive glass ionomers which require one.This advancement is the latest in 3M's 30-year history of developing proven and trusted glass ionomers.
62022145|NCT03783169||Symptomatic patients|All pregnant women (under the care of the Maternal-Fetal Medicine physicians or Faculty Medical Center physicians with MFM involvement) experiencing a hypertensive emergency (sustained systolic blood pressure \> 160 mmHg or sustained diastolic blood pressure \> 110 mmHg {or both} on at least two consecutive occasions 15 minutes apart). All participants must be over the age of 18 and capable of consenting to the study (conscious, with capacity for medical decision making for themselves).
62022146|NCT03783169||Asymptomatic patients|All asymptomatic pregnant women who are undergoing routine obstetric ultrasound evaluations at any gestational age who elect to undergo cardiovascular sonographic assessment for research purposes at no cost. All participants must be over the age of 18 and capable of consenting to the study (conscious, with capacity for medical decision making for themselves).
62022147|NCT01226745|EXPERIMENTAL|ONO-4641 0.15 milligram (mg) - 0.15 mg|
62022148|NCT01226745|EXPERIMENTAL|ONO-4641 0.10 mg - 0.10 mg|
62022149|NCT01226745|EXPERIMENTAL|ONO-4641 0.05 mg - 0.05 mg|
62218052|NCT05681689|EXPERIMENTAL|Indication for H. pylori testing|Patients who have been treated for H. pylori and need to undergo eradication confirmation testing. Patients will be enrolled for this study if all acceptance criteria are met. Patients will undergo 13C Urea Breath Test in addition to non-invasive diagnostic comparators (H. pylori Stool Testing and Comparator Breath Test) OR invasive diagnostic comparator (Endoscopy for Rapid Urease Testing and Histology).
62218053|NCT01312051||Protocol 1|Healthy, overweight 11 to 17 year old black and white adolescents
62218054|NCT01312051||Protocol 2|Healthy, normal-weight 11 to 17 year old black and white adolescents
62218055|NCT01312051||Protocol 3|Healthy, normal-weight 8 to 12 year old black and white adolescents
62218056|NCT01312051||Protocol 4|Healthy, overweight 11 to 17 year old black and white adolescents
62218057|NCT05261919|EXPERIMENTAL|acupuncture with manipulation group|"30 participant were recruited in this study. All the participants received acupuncture at the acupoints (HT7、HT3、SI5、SI8、BL57、BL40、KI3、KI10) and were measured by an Agilent B1500A semiconductor analyzer.~The investigator perform acupuncture with supplementation manipulation first, followed by a measurement of the electrical characteristics using Agilent B1500A. The investigator remove the acupuncture and then perform acupuncture with draining manipulation, followed by measurements. After one meridian measurements were completed, the investigator removed the needle and proceeded to the next meridian to repeat the same procedure."
62218058|NCT01422421|ACTIVE_COMPARATOR|intensive control|systolic blood pressure less than 120mmHg and LDL cholesterol within 70- 85mg/dl
62218059|NCT01422421|ACTIVE_COMPARATOR|standard control|systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
62218060|NCT04340791|NO_INTERVENTION|Default proportion & no labelling|"No intervention:~Default proportion condition (33% lower energy density items - 67% higher energy density items). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.~No labelling."
62218061|NCT04340791|EXPERIMENTAL|Default proportion & labelling|"When energy density of a food item ≤ median of energy density distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions will introduce the badges to the participants as In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
62218062|NCT04340791|EXPERIMENTAL|Increased proportion & no labelling|The proportion of lower energy density items vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (33% lower - 67% higher). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.
62242982|NCT02198092||Patient Group MAP / MYH|"Clinical diagnosis of MYH-associated polyposis and presence of more than 20 colon polyps.~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. The follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients.~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
62819381|NCT06690359|EXPERIMENTAL|Primary membranous nephropathy|Recruiting 6 patients with medium to high-risk PMN, including 3 patients receiving 0.5 × 10 \^ 8 CAR-T cell dose and 3 patients receiving 1 × 10 \^ 8 CAR-T cell dose, for corresponding doses of IM19 CAR-T cell infusion therapy
62819382|NCT06038409||Chronic Pain|The use of ketamine in chronic pain
62022150|NCT01226745|EXPERIMENTAL|Placebo - ONO4641 0.15 mg|
62022151|NCT01226745|EXPERIMENTAL|Placebo - ONO4641 0.10 mg|
62022152|NCT01226745|EXPERIMENTAL|Placebo - ONO4641 0.05 mg|
62022153|NCT04239989|EXPERIMENTAL|Treatment (itacitinib)|Patents receive itacitinib PO QD for up to 1 year in the absence of disease progression or unacceptable toxicity.
62022154|NCT05569395|EXPERIMENTAL|Study group|Median nerve neuro mobilization group
62022155|NCT05569395|SHAM_COMPARATOR|Control Group|Sham median nerve neuro mobilization group
62218063|NCT04340791|EXPERIMENTAL|Increased proportion & labelling|"The proportion of lower energy density items vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (33% lower - 67% higher). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.~When energy density of a food item ≤ median of energy density distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions will introduce the badges to the participants as In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
62218064|NCT00070824|EXPERIMENTAL|B|Patients with osteoarthritis pain at rest
62218065|NCT00070824|EXPERIMENTAL|A|Normal Subjects without pain
62586048|NCT02586610|EXPERIMENTAL|Neoadjuvant Treatment|"All subjects will receive concurrent chemoradiation and pembrolizumab neoadjuvant treatment for 6 weeks:~* Pembrolizumab 200 mg IV Days 1, 22 and 43~* Capecitabine 825 mg/m2 PO in twice daily doses (total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days~* Radiation therapy 50.4 GY. Daily fractions of 1.8 Gy over a 6 week interval, excludes weekends"
62022156|NCT05205772|EXPERIMENTAL|medial prefrontal cortex - control site - dorsolateral prefrontal cortex|Participants first undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the control site. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex.
62412112|NCT01666067|ACTIVE_COMPARATOR|placebo|placebo
62412113|NCT01666067|ACTIVE_COMPARATOR|vytorin|vytorin
62412114|NCT01666067|ACTIVE_COMPARATOR|simvastatin|simvastatin
62412115|NCT00870714|EXPERIMENTAL|A|Eligible patients with high-risk prostate cancer who are scheduled to undergo radical prostatectomy will receive four cycles of therapy with ketoconazole and docetaxel prior to surgery resection
62412116|NCT05967767|EXPERIMENTAL|3 Session Repeated Sprint Training in Normobaric Hypoxia|Hypoxia group was exposed to normobaric hypoxia equal to 3420 m (FiO2: 13.5-13.6 %).
62412117|NCT05967767|SHAM_COMPARATOR|3 Session Repeated Sprint Training in Normobaric Normoxia|Placebo group was exposed to normobaric normoxia equal to 162 m (FiO2: 20.9 %) through wearing the altitude generator mask.
62412118|NCT05967767|NO_INTERVENTION|Control group|The control group was subjected to only pre and post-test.
62412119|NCT02850783|EXPERIMENTAL|SLN identification with 89-zirconium-nanocoll|Submucosal injection of 2.5 mBq, 0.4 ml 89-Zirconium-Nanocoll and subsequently SLN identification
62412120|NCT04458428|NO_INTERVENTION|Control|No other non-standard of care activities will be performed
62412121|NCT04458428|EXPERIMENTAL|Intervention|Will be signed up for the automated short message service (SMS)
62412122|NCT01816334|ACTIVE_COMPARATOR|methylprednisolone|administration of 60 mg of methylprednisolone at 8:00 am and 100 ml of 0.9 % sodium chloride (placebo) at 6:00 pm
62412123|NCT01816334|ACTIVE_COMPARATOR|Ketoprofen|administration of 100 mg of ketoprofen at 8:00 am and at 6:00 pm
62586049|NCT03360851|EXPERIMENTAL|Low-dose CT|A low-dose chest CT-scan will be performed either directly from the ER or from the medical ward as soon as possible but within 24 hours of admission. The CT will be performed with a radiation dose \<0.5 mSv for a 70kg patient, as a replacement or in addition to the chest radiograph. Pregnancy will be an exclusion criterion for CT because of unwanted radiation exposure. CT interpretation will be performed by a radiologist. Test results will be communicated to the treating physician. Recommendations based on the CT may be to discontinue antibiotics in case of a noninfectious diagnosis that explains the presented signs and symptoms and to start treatment for the alternative diagnosis if needed, or to re-evaluate the CAP diagnosis if no signs of lobar or bronchopneumonia are detected on the CT.
62738635|NCT04726930||Paravertebral nerve block with intra-needle and surface ultrasound|"Number of participants: 10 Paravertebral blocks will be performed under guidance of intra-needle and surface ultrasound. The intra-needle transducer will be placed inside the puncture needle and it will be the primary guidance to reach target injection site. Surface ultrasound will be the secondary image guide for simultaneous comparison. Collect signal from both Intra-needle ultrasound transducer and surface ultrasound, and then inject local anesthetics.~Code name: PVB-INUS-guide"
62412124|NCT01816334|PLACEBO_COMPARATOR|sodium chloride|administration of 100 ml of 0.9% sodium chloride (placebo) at 8:00 am and at 6:00 pm
62738636|NCT06635434|EXPERIMENTAL|Augmented reality-enabled pain assessment deployed on a mobile|Age-stratified (age 7-11 and age 12-17 years old) augmented reality app to evaluate for pain and opioid-related adverse events with equivalent English and Spanish text, audio, and narration
62738637|NCT05965869|EXPERIMENTAL|Diabetes program and education|Receive diabetes program and education
62412125|NCT02766959||PAV/PAV Tasters|Individuals homozygous for the taster allele of the TAS2R38 gene, PAV/PAV.
62412126|NCT02766959||AVI/PAV.|Individuals heterozygous for the taster allele of the TAS2R38 gene, AVI/PAV.
62412127|NCT02766959||AVI/AVI|Individuals homozygous for the non-taster allele of the TAS2R38 gene, AVI/AVI.
62412128|NCT00879762|EXPERIMENTAL|Group A: High Dose|Single high dose of IMVAMUNE® (5x10\^8 TCID50, consisting of two 0.5 mL injections) vaccine on Day 0 and a single saline placebo dose (single 0.5 mL injection) on Day 28 to match the two dose regimen of Group B.
62412129|NCT00879762|ACTIVE_COMPARATOR|Group B: Standard Dose|Standard two dose regimen of IMVAMUNE® (1x10\^8 TCID50) vaccine on Day 0 (consisting of 0.5 mL injection of vaccine and 0.5 mL injection of saline placebo) and Day 28 (single 0.5 mL injection of vaccine).
62218066|NCT02488538|ACTIVE_COMPARATOR|Combined oral contraceptives and Fuoxetine|Group 1 will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® ScheringAG, Egypt) daily for 21 days starting from the 3rd day of menstruation in addition to oral fluoxetine 20 mg daily. .
62218067|NCT02488538|ACTIVE_COMPARATOR|Combined oral contraceptives|Group 2 will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine
62218068|NCT02488538|PLACEBO_COMPARATOR|Placebo|Group 3 will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine.
62218069|NCT04797650|PLACEBO_COMPARATOR|Placebo|Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.
62218070|NCT04797650|EXPERIMENTAL|CTP-543 8 mg BID|Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
62218071|NCT04797650|EXPERIMENTAL|CTP-543 12 mg BID|Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
62218072|NCT02582112|ACTIVE_COMPARATOR|Warming group|Active Comparator: Warming group
62412130|NCT06653335|EXPERIMENTAL|Experimental Group|All students to be included in the study will be pre-tested through Google Form's. After the pre-test, the students in the experimental group will be sent images created by the researchers via text message for 4 weeks (22 days) and consisting of the information given in the Basic Principles and Practices in Midwifery Course. Each visual will contain one piece of information. The researchers will send 6 visuals to the students in the experimental group via text message every day for 4 weeks, except Saturdays and Sundays. The post-test will be applied immediately after the end of the implementation process. The messages will be short and contain a single piece of information.
62412131|NCT06653335|NO_INTERVENTION|Control Group|No treatment will be carried out.
62412132|NCT00823680|PLACEBO_COMPARATOR|Placebo|
62412133|NCT00823680|EXPERIMENTAL|RO5027838 200mg|
62412134|NCT00823680|EXPERIMENTAL|RO5027838 50mg|
62412135|NCT00823680|EXPERIMENTAL|RO5093151 10mg|
62412136|NCT00823680|EXPERIMENTAL|RO5093151 400mg|
62412137|NCT03715816|NO_INTERVENTION|No breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory.
62218073|NCT02582112|PLACEBO_COMPARATOR|Control group|Control group
62218074|NCT05245552|EXPERIMENTAL|Safety group|PhaseⅠ,30 subjects will receive two doses of quadrivalent influenza vaccine(0.5ml) on the immunization schedule of day 0,28.
62218075|NCT05245552|EXPERIMENTAL|Experimental Group of quadrivalent influenza vaccine(0.25ml)|1100 subjects phase III will receive two doses of quadrivalent influenza vaccine(0.25ml) on the immunization schedule of day 0,28.
62218076|NCT05245552|EXPERIMENTAL|Experimental Group of quadrivalent influenza vaccine(0.5ml)|1100 subjects phase III will receive two doses of quadrivalent influenza vaccine(0.5ml) on the immunization schedule of day 0,28.
62218077|NCT05245552|ACTIVE_COMPARATOR|Control Group of trivalent influenza vaccine(BV)|550 subjects phase III will receive two doses of trivalent influenza vaccine(BV) on the immunization schedule of day 0,28.
62218078|NCT05245552|ACTIVE_COMPARATOR|Control Group of trivalent influenza vaccine(BY)|550 subjects phase III will receive two doses of trivalent influenza vaccine(BY) on the immunization schedule of day 0,28.
62412138|NCT03715816|EXPERIMENTAL|Passive breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory, and after 30 and 60 min of work, they will be provided a 2.5-min break during which they can have a rest.
62412139|NCT03715816|EXPERIMENTAL|Active breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory, and after 30 and 60 min of work, they will be provided a 2.5-min break during which they will be performing some mobilisation exercises for the back, shoulder, and neck.
62412140|NCT04587856|OTHER|Biological evaluation|evaluation of molecular changes in CD34+ blast cells at the time of relapse after allo-HSCT.
62819383|NCT06038409||Depressive Disorders|The use of ketamine in depressive disorders
62218079|NCT04869293|EXPERIMENTAL|3D virtual reality|Use of Hypnosis 3D virtual reality headset
62218080|NCT04869293|NO_INTERVENTION|Control|Standard of care : no hypnosis 3D virtual reality headset but a noise cancelling headphone
62218081|NCT01993927||Voglibose 0.2 mg or OD Tablets 0.2 mg|Voglibose 0.2 mg or OD Tablets 0.2 mg will be administered orally three times daily immediately before each meal.
62218082|NCT04545684|EXPERIMENTAL|Mental practice|
62218083|NCT04545684|PLACEBO_COMPARATOR|Placebo group|
62218084|NCT00439803|ACTIVE_COMPARATOR|T1|
62218085|NCT00439803|PLACEBO_COMPARATOR|C1|
62218086|NCT00439803|ACTIVE_COMPARATOR|T2|
62218087|NCT00439803|PLACEBO_COMPARATOR|C2|
62218088|NCT00439803|ACTIVE_COMPARATOR|T3|
62586050|NCT03360851|EXPERIMENTAL|PoC-PCR|The FilmArray real-time multiplex PCR (Biofire; bioMérieux) is a Point-of-Care PCR with a panel of respiratory viruses (adenovirus, coronavirus, human metapneumovirus, human rhinovirus/enterovirus, influenza A and B, parainfluenza virus, and respiratory syncytial virus), and three atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Bordetella pertussis), which will be performed on nasopharyngeal swab samples. Test results will be made available to the treating physician immediately. The treatment recommendation could be adaptation of antibiotic treatment for a documented atypical pathogen, a recommendation to not start or discontinue antibiotics when a virus is the only detected pathogen, or a recommendation to discontinue coverage of atypical pathogens.
62586051|NCT03360851|NO_INTERVENTION|Standard care|All hospitals will continue the antibiotic stewardship activities employed during the baseline period as part of standard care. A representative of the Antibiotics-team (Team consisting of clinical microbiologists, infectious diseases specialist and clinical pharmacists supervising in-hospital antibiotic use) will monitor the empirical antibiotic treatment of patients hospitalized with CAP to non-ICU wards and provide feedback if indicated.
62586052|NCT06366269|EXPERIMENTAL|Acupuncture|"Participants will receive instruction (verbal and written) on recommended changes to diet and urinary habits to treat bladder pain.~They will complete six (6) weekly one hour acupuncture sessions followed by pelvic floor physical therapy."
62586053|NCT06366269|ACTIVE_COMPARATOR|Behavioral Management|Participants will receive instruction (verbal and written) on recommended changes to diet and urinary habits to treat bladder pain for six (6) weeks before starting pelvic floor physical therapy.
62218089|NCT00439803|PLACEBO_COMPARATOR|C3|
62218090|NCT00439803|ACTIVE_COMPARATOR|T4|
62586054|NCT02181582|EXPERIMENTAL|Emapunil Administration|Single Arm Study
62218091|NCT00439803|PLACEBO_COMPARATOR|C4|
62218092|NCT00989534|EXPERIMENTAL|Sleep loss and circadian alignment|Sleep restriction without circadian misalignment
62218093|NCT00989534|EXPERIMENTAL|Sleep loss and circadian misalignment|
62218094|NCT04472559|EXPERIMENTAL|Self-acupressure|
62218095|NCT04472559|NO_INTERVENTION|Control|
62586055|NCT06051838||TD cohort|Tumor deposits (TD) positive group, which was determinded by the pathologists at department of pathology. Any tumor mass, either circumscribed or with irregular contours, devoid of lymph node architecture was identified as a tumor deposit.
62586056|NCT06051838||Non-TD cohort|Tumor deposits (TD) negative group, which was determinded by the pathologists at department of pathology. No visiblet umor mass, either circumscribed or with irregular contours, devoid of lymph node architecture in the sections of specimens from these patients.
62218096|NCT04846309|EXPERIMENTAL|Treatment: all patients|
62218097|NCT03506685|NO_INTERVENTION|control group Standard ACL protocol|This group will receive the standard ACL protocol rehab
62218098|NCT03506685|EXPERIMENTAL|Dry needling and STM group|This group will also receive the standard ACL protocol in addition to STM and DN
62218099|NCT05922384|EXPERIMENTAL|7shRNA modified CD34+stem cells|Patients undergo high-dose chemotherapy or chemoradiotherapy according to institutional guidelines and then received hematopoietic stem cell transplant on day 0
62218100|NCT02589561|ACTIVE_COMPARATOR|face to face fitting|face to face fitting of hearing aids
62218101|NCT02589561|EXPERIMENTAL|remote fitting|remote fitting of hearing aids
62218102|NCT06610435|EXPERIMENTAL|Manual Therapy|The term manual therapy includes a wide variety of detailed applications ranging from joint-oriented applications (joint mobilizations and/or manipulations) or soft tissue techniques (muscle stretching or trigger point therapy) to therapeutic exercises. Manual therapy in our study was used to restore normal temporomandibular joint range of motion, reduce local ischemia, stimulate proprioception, break fibrous adhesions, stimulate synovial fluid production and reduce pain.
62218103|NCT06610435|EXPERIMENTAL|Home Exercise|Exercise therapy, one of the physical therapy applications, has an important place in the rehabilitation of musculoskeletal disorders. With this method, it is aimed to decrease inflammation, increase coordination of muscle activity, promote tissue repair and regeneration, relieve pain and restore normal function. In addition to the special exercises known as Rocabado exercises which are used in the treatment of temporomandibular joint, various studies have been performed in which mobilization, coordination, posture and relaxation exercises were used for the treatment of disorders related to the masticatory system and it has been emphasized that studies on this subject should be continued.
62218104|NCT04222075||Acute Pancreatitis|Patients after acute pancreatitis
62218105|NCT02523599|EXPERIMENTAL|XaraColl|3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose
62218106|NCT02523599|PLACEBO_COMPARATOR|Placebo|3 placebo implants
62218107|NCT03743454||Men|
62218108|NCT03743454||Women|
62586057|NCT05815511|EXPERIMENTAL|Probiotic group|Probiotic mixture in oral capsule format with selected strains in concentrations equal to or greater than 1x10\^10 cfu/dose.
62218109|NCT06143969||EkoSonicTM Endovascular System (EKOSTM, Boston Scientific)|Patients hospitalized with acute intermediate-high risk PE treated with ultrasound-assisted, catheter-directed thrombolysis using EKOSTM.
62218110|NCT00752947|EXPERIMENTAL|A|
62218111|NCT00752947|ACTIVE_COMPARATOR|B|
62218112|NCT04973501|EXPERIMENTAL|Manual physiotherapeutic correction (MFK) Method|The MFK was chosen for our clinical experience- it was developed in Czech Republic.The MFK Method consists of five established steps: anamnesis, assessment, diagnoses, treatment and checkup. In the course of all those steps, the computer MFK System software is used. This software allows us to display and visualize the patient´s functional muscle imbalance at the day of the assesment based on the assessment of muscle strength by manual muscle tests. Hereafter the physiotherapist performs muscle test and records results in the software. Then, the software visually describes the patient´s imbalance at the day of the assessment. Based on these diagnostic maps and the software suggestions the therapist chooses the body areas where the therapeutic techniques may be applied.
62412141|NCT00004123|EXPERIMENTAL|RT + DOX + IORT|Preoperative external beam radiotherapy (RT) combined with doxorubicin (DOX) and followed by intraoperative radiotherapy (IORT); dose-escalation study of external beam radiotherapy.
62586058|NCT05815511|PLACEBO_COMPARATOR|Placebo group|Maltodextrin in oral capsule format
62819384|NCT06038409||Anxiety Disorders|The use of ketamine in anxiety disorders
62218113|NCT04973501|EXPERIMENTAL|Dynamic Neuromuscular Stabilization (DNS) Method|Dynamic Neuromuscular Stabilization (DNS) is a neurophysiological rehabilitative approach encompassing a set of functional tests assessing the quality of postural stabilization patterns and a treatment approach based on developmental kinesiology models. DNS diagnosis is based on comparison of the individual's postural stabilization pattern to the developmental stabilization pattern of healthy infants. The assessor uses DNS evaluation sheet to screen client's posture in 11 developmental positions if the patient can perform them all. If not, only the tests that the patient can perform sufficiently and safely serve for functional assessment. The strategy of DNS manual treatment is to utilize only those functional exercises in developmental positions that are the most suitable for the specific client. The goal is to improve spinal and joint stability by focusing on the global stabilization system consequently improving quality of movement and mobility.
62218114|NCT01160289|EXPERIMENTAL|1 milligram (mg) LY2452473 + 5 mg tadalafil|
62793946|NCT04463342|ACTIVE_COMPARATOR|Conventional Glass Ionomer with Coat|"A bulk-fill, packable and fast-setting conventional glass ionomer. Because it's less technique sensitive than a composite it's ideal for difficult-to-isolate posterior restoration. High compressive strength and marginal integrity make it a glass ionomer of choice for posterior restorations.Ketac Conditioner Dentin Pretreatment is required; Ketac Glaze Light-Cured Varnish applied on the top of the restoration to avoid moisture contamination."
62218115|NCT01160289|EXPERIMENTAL|5 mg LY2452473 + 5 mg tadalafil|
62218116|NCT01160289|EXPERIMENTAL|5 mg LY2452473 + placebo|
62218117|NCT01160289|ACTIVE_COMPARATOR|10 mg tadalafil + placebo|
62218118|NCT01160289|ACTIVE_COMPARATOR|5 mg tadalafil + placebo|
62218119|NCT06598605|EXPERIMENTAL|Parental Reflective Functioning intervention Group|Participants will attend four online psycho-educational workshop sessions via Zoom, where they will learn strategies for emotion regulation and mentalization to improve their relationship with their children on the autism spectrum.
62218120|NCT06598605|NO_INTERVENTION|Waitless control group|Group will undergo same measurements points with no intervention.
62218121|NCT00732589|EXPERIMENTAL|A|Suprascapular nerve block
62412142|NCT05116566||Patients|Three distinct sub-cohorts will be targeted for recruitment to represent perspectives across the advancing illness course: patients ≤3 months from a poor- prognosis diagnosis (cohort 1), patients ≤ 3 months from disease relapse or progression (cohort 2), and patients actively enrolled on a phase I/II trials (cohort 3).For cohorts 1-3, patient-parent dyads will be enrolled when eligible; however, an independent patient is eligible for enrollment if the parent consents for the patient's enrollment but declines his/her own enrollment.
62412143|NCT05116566||Parents|Four distinct sub-cohorts of parents will be targeted for recruitment, including cohorts 1-3 and a fourth bereavement cohort. For cohorts 1-3, patient-parent dyads will be enrolled when eligible; however, an independent parent is eligible for enrollment if the patient declines enrollment, but the parent wishes to participate.
62412144|NCT05116566||Oncologist|Pediatric oncologists who treat or refer patients for treatment at St. Jude Children's Research Hospital (SJCRH) will be eligible to participate.
62586059|NCT06627309||Group 1|"All patients in this cohort receive daratumumab, bortezomib and dexamethasone as treatment.~All patients receive additional sFLC examination in C1D7, C1D14."
62793947|NCT03056742|EXPERIMENTAL|Stem cells|Patients will receive intramuscular and local injection of stempeucel(R) in addition to standard protocol of care
62793948|NCT02665572|NO_INTERVENTION|renal transplant without bladder recycling|the patients allocated to this arm and met inclusion criteria will undergo renal transplant without prior recycling of the bladder
62793949|NCT02665572|ACTIVE_COMPARATOR|renal transplantation with bladder recycling|the patients allocated in this arm will undergo bladder recycling prior to renal transplantation
62218122|NCT00732589|EXPERIMENTAL|B|therapeutic ultrasound
62218123|NCT00700258||1|Patients treated with Temsirolimus for metastatic renal cell carcinoma (mRCC) under usual care settings.
62218124|NCT00700258||2|Patients treated with Temsirolimus for mantle cell lymphoma (MCL) under usual care setting
62218125|NCT00700258||3|Patients treated with Sunitinib for metastatic renal cell carcinoma (mRCC) under usual care setting
62218126|NCT00700258||4|Patients treated with Sunitinib for gastro-intestinal stroma tumor (GIST) under usual care setting
62218127|NCT00700258||5|Patients treated with Axitinib after treatment with Sunitinib or Cytokine for metastatic renal cell carcinoma (mRCC)
62218128|NCT02724969|EXPERIMENTAL|MILK intervention group|Semi-automated text messages sent to participants' cellular phones 3-5 times per week beginning Week 25 of pregnancy, through 8 weeks postpartum, specific to breastfeeding support and prevention of perceived insufficient milk supply.
62218129|NCT02724969|ACTIVE_COMPARATOR|Text4Baby control intervention group|Text4Baby automated texts sent to participants' cellular phones 3-5 times per week from Week 25 of pregnancy through the postpartum period from the national Text4Baby system. Messages provide general prenatal and postpartum support, including breastfeeding.
62218130|NCT05110768|EXPERIMENTAL|FPC 20 mg Fe IV by infusion over 12 hours every other day|Patients in the FPC arm will receive FPC 20 mg Fe IV by infusion over 12 hours every other day (qOD), for a total duration of up to 12 weeks plus a one-week follow-up after the last study drug treatment.For patients whose duration of therapy is \>10 hours, patients will receive a 12-hour infusion of FPC.
62433265|NCT01440478|EXPERIMENTAL|LY2140023 + ammonium chloride|1 g of ammonium chloride administered orally every 3 hours for 33 hours (totaling 12 doses) in combination with a single 80 mg dose of LY2140023 administered orally 17 hours after first dose of ammonium chloride (acidified urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
62586060|NCT03319342|EXPERIMENTAL|Group I (acts of kindness to others)|Participants perform small acts of kindness or generosity for others 3 times per week for 4 weeks and complete weekly online questionnaires.
62793950|NCT00858624|ACTIVE_COMPARATOR|Chronic Cough Patients|
62793951|NCT00858624|ACTIVE_COMPARATOR|Healthy Volunteers|
62819385|NCT06038409||Chronic Condtions|The use of ketamine in chronic conditions
62819386|NCT00611936|PLACEBO_COMPARATOR|2|Second arm is placebo
62819387|NCT00611936|EXPERIMENTAL|1|One arm is atomoxetine 40 mg per day
62819388|NCT01768715||Good response|Patients with severe alcoholic hepatitis and good response to therapy.
62218131|NCT05110768|PLACEBO_COMPARATOR|Placebo|Patients in the placebo arms will receive IV placebo on the same schedule for 12 weeks. All patients are eligible to receive Rescue conventional IV iron if criteria are met and the patient's principal physician agrees.
62218132|NCT06226675|NO_INTERVENTION|Group Control|
62218133|NCT06226675|ACTIVE_COMPARATOR|Group PENG|
62586061|NCT03319342|EXPERIMENTAL|Group II (acts of kindness to self)|Participants perform small acts of kindness for themselves 3 times per week for 4 weeks and complete weekly online questionnaires.
62218134|NCT06226675|ACTIVE_COMPARATOR|Group PENG+LFCN|
62412145|NCT04197882|EXPERIMENTAL|treatment|"This study consisted of 3 stage of neoadjuvant treatment, surgical, and adjuvant treatment. Neoadjuvant treatment period: OrienX010 intratumoral injection in combination with Toripalimab infusion. Toripalimab : 3 mg/kg, IV infusion: Once every 2 weeks for 6 doses ; OrienX010: Maximum injection volume 8 × 108 pfu, intratumoral injection: Once every 2 weeks for 6 doses ; Surgical treatment period: 2 weeks after the last dose of neoadjuvant treatment (± 7 days), the investigator designed the surgical protocol of the melanoma radical surgery according to the patient's individual disease, and performed postoperative care according to the patient's condition.~Adjuvant treatment period: 3 weeks after operation (± 7 days), the patient was given Toripalimab infusion. Toripalimab 3 mg/kg intravenously given every 3 weeks (every 3 weeks per cycle) for up to 1 year (the one-year duration will be counted from 1st dose in neoadjuvant treatment)."
62218135|NCT03256851|ACTIVE_COMPARATOR|In-Person Delivered Exercise|"Participants in the in-person training group will:~1. participate in a home exercise program including aerobic training 2x/week and strength training 3x/week.~2. complete one of their prescribed training sessions (lasting 1 hour total) each week with a physical therapist or trained member of the research team. Training sessions will focus on progression of aerobic and strength training exercises."
62218136|NCT03256851|EXPERIMENTAL|Telephone-Delivered Exercise|"Participants in the telephone-delivered training group will:~1. participate in a home exercise program including aerobic training 2x/week and strength training 3x/week.~2. receive a 60-minute, 1x/week telephone call from a trained research team member. Participants will report their progress from the prior week, discuss/troubleshoot any issues or problems, and receive progressions of both aerobic and strength training exercises for the upcoming week."
62218137|NCT06243692|ACTIVE_COMPARATOR|lacosamide arm|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive Lacosamide 50 mg twice daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
62218138|NCT06243692|ACTIVE_COMPARATOR|Topiramate arm|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive topiramate 100 mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
62218139|NCT02393027|EXPERIMENTAL|patients|10 idopathic parkinson disease
62218140|NCT02393027|ACTIVE_COMPARATOR|controls subjects|10 healthy controls (no parkinson disease)
62586062|NCT03319342|EXPERIMENTAL|Group III (self-kindness meditation)|Participants direct kind, loving thoughts to themselves, via guided meditation, 3 times per week for 4 weeks and complete weekly online questionnaires.
62586063|NCT03319342|ACTIVE_COMPARATOR|Group IV (track daily activities)|Participants keep track of their daily activities, focusing on factual information rather than thoughts and feelings, on 3 separate days each week. At the end of the week, participants report on their activities and complete several online questionnaires.
62218141|NCT06471777|EXPERIMENTAL|Protocol-based fluid removal|"The intervention will consist of 3 components:~The first component of this prescription will be to define the 24h-fluid balance target. The second component is to specify a prescription for fluid removal. The third component is to prompt a daily re-evaluation of fluid intake and fluid balance by the attending care team."
62218142|NCT06471777|NO_INTERVENTION|Usual care|Fluid removal during KRT will be determined by the attending clinical team.
62218143|NCT02424734|EXPERIMENTAL|Ceftaroline Fosamil|Ceftaroline Fosamil
62218144|NCT03229590||Surgical dislocation|Reduction of slipped epiphysis via surgical dislocation technique
62412146|NCT05538663|EXPERIMENTAL|Arm A|Gemcitabine + Docetaxel
62412147|NCT05538663|EXPERIMENTAL|Arm B|BCG
62586064|NCT03359109||Stainless Steel Devices|10 patients with stainless steel devices implanted
62586065|NCT03359109||Titanium or Titanium-alloy Based Devices|30 patients with titanium or titanium-alloy implanted devices
62586066|NCT03359109||De Novo Titanium Implant|10 patients undergoing de novo titanium implant placement who have had no previous orthopedic procedures
62586067|NCT04289376|OTHER|Gaze tracking|No intervention. Monitor gaze as subjects watch a video
62218145|NCT01780181||TCM plus chemotherapy|TCM:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang, four packages,twice a day, three months; Chemotherapy : Intravenous drug use, treated with single-agent chemotherapy :DOC、NVB、GEM.Each cycle was 21-days. Cycles were repeated until disease progression, unacceptable toxicity, or chemotherapy taboo;
62218146|NCT01780181||Placebo plus chemotherapy|TCM Placebo: oral granules,YangYinFang orYiQiFang or YiQiYangYinFang, 10% of the original dose,four packages,twice a day ,three months; Chemotherapy : Intravenous drug use, treated with single-agent chemotherapy :DOC、NVB、GEM.Each cycle was 21-days. Cycles were repeated until disease progression, unacceptable toxicity, or chemotherapy taboo;
62218147|NCT03753737||Chemsex|Men who have Sex with Men (MSM) attending an addiction care center for past or present mild, moderate or severe substance-related disorder(s) according to DSM-V criteria, occurring in a sexual context and concerning cathinones, GHB/GBL, methamphetamine, cocaine and/or ketamine.
62218148|NCT03753737||Control|Men who have Sex with Men (MSM) consulting for a PrEP (HIV Pre-Exposure Prophylaxis) prescription who have never used cathinones, GHB/GBL, methamphetamine, cocaine or ketamine before or during sex.
62218149|NCT01459900|ACTIVE_COMPARATOR|Renal artery ablation|By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to active treatment, renal artery ablation will be carried out straight away.
62218150|NCT01459900|SHAM_COMPARATOR|Sham|By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to sham procedure, no renal artery ablation are performed.
62218151|NCT01077271||Premature infants 33 - 35 wGA prophylaxed with palivizumab|Premature infants 33 - 35 weeks gestational age (wGA) prophylaxed with Synagis (palivizumab)
62412148|NCT05475535|ACTIVE_COMPARATOR|Active Control|
62412149|NCT05475535|EXPERIMENTAL|Cognitive Behavioural Therapy (CBT)|
62412150|NCT05475535|EXPERIMENTAL|Self-Compassion (SC)|
62412151|NCT05475535|EXPERIMENTAL|Cognitive Behavioural Therapy and Self-Compassion (CBT+SC)|
62412152|NCT01411475||Bifurcation restenosis|Patients with either a main vessel or a side branch restenosis following succesful percutaneous coronary intervention
62412153|NCT02416089|EXPERIMENTAL|Tampostat|Tampostat™ is a self-regulating, low cost, pressure based emergency obstetric device designed specifically for use in low-resource settings. It has 6 parts: probe, condom, O ring, nerve centre, tube and bulb pump. It offers significant benefits over the current model by simplifying the insertion process, reducing the need for constant monitoring, eliminating leakage and the need for sterile saline, and using a pressure-based mechanism to apply consistent pressure to all women regardless of uterus size.Women who develop PPH even after applying AMTSL at the hospital or women who visit the hospital with PPH within 24 hours after delivery will be managed by Tampostat for the intervention arm or by the condom catheter tamponade in the control arm(172 patients in each arm)
62586068|NCT02453334|EXPERIMENTAL|Injectafer|2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.
62586069|NCT02453334|PLACEBO_COMPARATOR|Normal Saline|Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.
62412154|NCT02416089|ACTIVE_COMPARATOR|Condom catheter tamponade|Condom catheter tamponade have been used by medical professionals for several years in the management of atonic (primary) PPH. In this approach, Sterile rubber catheter fitted with a condom as a tamponade balloon device and using normal saline to inflate the condom.
62586070|NCT03206541||Cases|The cases are defined as individuals that present with new onset of a neurological syndrome of unknown etiology, including but not limited to encephalitis, myelitis, meningitis, polyneuropathy/Guillain-Barre syndrome and cranial nerve involvement.
62218152|NCT01253109||SENSIMED Triggerfish|
62412155|NCT05444361|ACTIVE_COMPARATOR|Cryoneurolysis|Cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be treated on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 1 cycle of 5.5-minute \[all but 4 participants: 064-067\] or 3 minutes \[only 4 participants 064-067; change based on new laboratory data, then changed back based on inadequate freeze\] argon activation (2000 psi and 100% power) followed by a 30-second helium defrost. For active probes, the gas will be deployed to the tip where a drop in temperature to approximately -70°C will result in cryoneurolysis.
62586071|NCT03206541||Controls|"There are two age-matched control groups:~1. Household controls that have lived with the case for at least three months before the onset of neurological symptoms.~2. Controls with a febrile syndrome of unknown etiology that do not present neurological involvement and is recruited in the same center as the case."
62218153|NCT02338973|EXPERIMENTAL|Interferon Gamma-1b|Topical interferon (IFN) gamma-1b, 112 µg dose, administered in study eye daily for two weeks
62412156|NCT05444361|SHAM_COMPARATOR|Sham Procedure|Sham cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be applied on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[all but 4 participants: 064-067\] or 3 minutes \[only 4 participants 064-067; change based on new laboratory data, then changed back based on inadequate freeze\] of argon and 30 seconds of helium (Varian). However, for sham probes, the gas is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
62586072|NCT00518245|EXPERIMENTAL|1|
62586073|NCT00518245|NO_INTERVENTION|2|
62586074|NCT04967495|EXPERIMENTAL|TACE-Len-I|TACE combined with lenvatinib and iodion-125 seeds brachytherapy
62586075|NCT04967495|ACTIVE_COMPARATOR|TACE-Len|TACE combined with lenvatinib
62738638|NCT02752633|EXPERIMENTAL|Study subjects|Following a 7 day washout period all patients receive allopurinol (400 mg/day) as a single daily dose for 2 weeks. Following another 7 day washout period all participants receive febuxostat, 80 mg/day as a single daily dose, for 2 weeks.
62738639|NCT01260688|EXPERIMENTAL|Arm I|Patients receive oral cediranib maleate once daily and oral dasatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62738640|NCT01260688|EXPERIMENTAL|Arm II|Patients receive cediranib maleate as in arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62218154|NCT00607685|EXPERIMENTAL|1|The participants will receive a subconjunctival injection of a mixture of 5FU with hyaluronic acid.
62218155|NCT00607685|ACTIVE_COMPARATOR|2|Participants will receive a subconjunctival injection of 5 Fluorouracil only.
62412157|NCT03242707|EXPERIMENTAL|Autologous adipose tissue knee injection|Fat will be removed from the abdomen and processed using the Lipogems device. Approximately 5ml of the microfragmented fat product will be injected into the knee joint.
62412158|NCT03242707|ACTIVE_COMPARATOR|Hyaluronic Acid knee injection|Hyaluronic Acid - Synvisc-One®: A high molecular weight sodium hyaluronate (HA). HA is an FDA approved, standard of care treatment.
62412159|NCT00061958|EXPERIMENTAL|Treatment (arsenic trioxide)|Patients receive a loading dose of arsenic trioxide IV over 2 hours on days 1-5 on week 1. Beginning on week 2, patients receive a maintenance dose of arsenic trioxide IV twice weekly thereafter. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving a CR continue to receive therapy for at least 6 months beyond CR.
62022157|NCT05205772|EXPERIMENTAL|medial prefrontal cortex - dorsolateral prefrontal cortex - control site|Participants first undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the control site.
62412160|NCT01679691|NO_INTERVENTION|Control group|Control group in whom no epidural anesthesia will be applied
62412161|NCT01679691|ACTIVE_COMPARATOR|Epidural Anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
62218156|NCT02828878|EXPERIMENTAL|ApoGraft|ApoGraft is a mobilized peripheral blood cell (MPBC) product derived from peripheral blood. There will be 4 cohorts, each differ in the amount of apoptotic mediator Fas Ligand (APO010) to which the graft is exposed during incubation prior to ApoGraft transplant, ranging from 10 ng/ml APO010 in Cohort 1, 25 ng/ml APO010 in Cohort 2, 50 ng/ml APO010 in Cohort 3, and 100 ng/ml APO010 in Cohort 4
62218157|NCT06055348|EXPERIMENTAL|Arm A (SC0191 + Gemcitabine).|SC0191 PO will be taken on days 1-3, 8-10, and 15-17 of each 28 day cycle. Gemcitabine 1000 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
62218158|NCT06055348|EXPERIMENTAL|Arm B (SC0191 + Paclitaxel).|SC0191 PO will be taken on days 1-3, 8-10, and 15-17 of each 28 day cycle. Paclitaxel 80 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
62412162|NCT06500026|EXPERIMENTAL|BL-B01D1|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62412163|NCT06500026|EXPERIMENTAL|Topotecan|Participants receive Topotecan as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62412164|NCT05256940|EXPERIMENTAL|Motivational Interviewing to Address Suicidal Ideation- Revised (MI-SI-R)|Motivational Interviewing to Address Suicidal Ideation (MI-SI-R) was developed to help Veterans resolve ambivalence about living by increasing the motivation to live, and is delivered in three sessions in person, virtually, or by telephone.
62412165|NCT05256940|ACTIVE_COMPARATOR|Enhanced usual care (EUC)|Enhanced usual care (EUC) includes safety plans administered or reviewed by research therapists, care coordination, and access to a 24-hour crisis hotline.
62218159|NCT04491266|EXPERIMENTAL|FBA|N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA) has been developed.
62218160|NCT04491266|PLACEBO_COMPARATOR|placebo|maltodextrins
62218161|NCT04554524|EXPERIMENTAL|Chemotherapy+Pembrolizumab|Chemotherapy combined with pembrolizumab.
62218162|NCT01138059||Acute ischemic stroke patients with unclear onset|
62412166|NCT01912391|EXPERIMENTAL|Selegiline|Transdermal Selegiline 12 mg patch Apply (1) patch daily
62412167|NCT01912391|PLACEBO_COMPARATOR|Placebo (for Selegiline)|Transdermal Placebo patch Apply (1) patch daily
62412168|NCT00558831|ACTIVE_COMPARATOR|Benzoyl Peroxide|Benzoyl Peroxide (BP) 2.5%
62218163|NCT00124293||Factor VII|
62218164|NCT04982835|EXPERIMENTAL|M6-C Artificial Cervical Disc|The M6-C is an investigational device composed of two outer and inner endplates made of titanium with a polycarbonate urethane nucleus (plastic center) and a polyethylene fiber annulus (strong thread-like binding). Around the polyethylene annulus is a polyurethane sheath (plastic cover). The outer endplates have keels to anchor the disc to bone. The outer endplates and keels are both coated with a titanium plasma spray. The M6-C is provided in two heights (6mm and 7mm) and four footprints (Medium, Medium Long, Large, Large Long).
62412169|NCT00558831|ACTIVE_COMPARATOR|Benzoyl Peroxide plus moisturizing lotion|Benzyol Peroxide 2.5% plus moisturizing lotion
62412170|NCT01139086||Cardiovascular disease|Diagnosis of cardiomyopathy or ischemic heart disease without heart failure
62412171|NCT01139086||Chronic heart failure|Diagnosis of cardiomyopathy or ischemic heart disease LVEF \<40%
62412172|NCT01139086||Control|Age and body built matched with chronic heart failure group
62738641|NCT00952328|EXPERIMENTAL|Limited Formula|Participants will supplement feedings with early limited formula following nursing
62738642|NCT00952328|NO_INTERVENTION|Control|Participants are instructed to continue exclusively breastfeeding; no use of formula
62738643|NCT05047302|EXPERIMENTAL|Treatment|The goal of the BlueLeaf System is to percutaneously form one or more functional, autogenous deep venous valves and restore venous competence.
62738644|NCT05126511|ACTIVE_COMPARATOR|Post-Covid patients, anxious, functional device|Applitation of 100µA CES for one hour per day to anxious patients
62738645|NCT05126511|PLACEBO_COMPARATOR|Post-Covid patients, anxious, Sham|Use of Sham CES for one hour per day by anxious patients
62738646|NCT05126511|ACTIVE_COMPARATOR|Post-Covid patients, non anxious, functional device|Application of 100µA CES for one hour per day to non anxious patients
62738647|NCT05126511|PLACEBO_COMPARATOR|Post-Covid patients, non anxious, Sham|Use of Sham CES for one hour per day by non anxious patients
62738648|NCT04662190|ACTIVE_COMPARATOR|Control grup|Conventional surgery.
62412173|NCT04060979|EXPERIMENTAL|Group 1- NO treatment- dose 1|Will comprise of approximately 30 patients and will receive inhalations of dose 1 of NO combined with O2/air for 40 minutes, every 4.5 hours during the day four times a day for up to 5 days in addition to standard supportive treatment.
62412174|NCT04060979|EXPERIMENTAL|Group 2- NO treatment- dose 2|Will comprise of approximately 30 patients and will receive inhalations of dose 2 of NO combined with O2/air for 40 minutes, every 4.5 hours during the day four times a day for up to 5 days in addition to standard supportive treatment.
62412175|NCT04060979|OTHER|Group 3- Control treatment|Will comprise of approximately 30 patients and will receive O2/air using the same treatment schedule and equipment as groups 1 and 2, in addition to standard supportive treatment.
62586076|NCT03341143|EXPERIMENTAL|Fecal Microbiota Transplant (FMT) with Pembrolizumab|"The FMT along with an intestinal biopsy will be performed as outpatient by a gastroenterologist. The FMT is infused into the colon by performing a colonoscopy. FMT will be performed on Cycle 1 Day 1 and will take 15 to 30 minutes.~Pembrolizumab, 200mg, through an IV over 30 minutes on Cycle 1 Day 1 (same day as the FMT), and then again on Day 1 of each 21-day cycle for an additional 3 cycles (Cycles 2 - 4)."
62586077|NCT06665711|ACTIVE_COMPARATOR|Intervention: 3% Hypertonic Saline|In this arm of the study, participants will receive nebulized 3% hypertonic saline as the primary treatment for bronchiolitis. The administration of hypertonic saline is aimed at reducing airway edema and improving mucociliary clearance in infants experiencing respiratory distress due to bronchiolitis.
62586078|NCT06665711|ACTIVE_COMPARATOR|Intervention: Salbutamol (Ventolin)|In this arm of the study, participants will receive nebulized Salbutamol, a bronchodilator commonly used in the management of bronchospasm associated with respiratory conditions, including bronchiolitis. The objective is to evaluate the effectiveness of Salbutamol in comparison to 3% hypertonic saline in improving the clinical outcomes of infants with bronchiolitis.
62586079|NCT02149446|EXPERIMENTAL|Surgisis reinforcement of staple line|The stapler used to divide the pancreas is reinforced with Surgisis (COOK Medical).
62793952|NCT05314335|EXPERIMENTAL|Reflexology socks+Walking|In the first interview; patient diagnosis form and Constipation Quality of Life scale will be applied. In order to evaluate the routine bowel habits of the patients, no application will be made in the first week and the patients will be asked to complete the Defecation Diary, Visual Comparison Scale and the Bristol Stool Consistency Scale for 1 week when defecation occurs. Afterwards, the reflexology socks designed by the researcher for the patients; will be told to wear and walk 30 minutes after breakfast and dinner for 30 minutes 3 days a week (Monday, Wednesday and Friday). Patients will be asked to continue the application for 4 weeks. The patients will be administered the Defecation Diary, the Visual Comparison Scale, and the Bristol Stool Consistency Scale when defecation occurs daily during the application. In addition, on the 30th day of the application, the Constipation Quality of Life Scale will be administered to the patients again.
62793953|NCT05314335|OTHER|Just walking|In the first interview, patient diagnosis form and Constipation Quality of Life scale will be applied. In order to evaluate the routine bowel habits of the patients, no application will be made in the first week and the patients will be asked to complete the Defecation Diary, Visual Comparison Scale and the Bristol Stool Consistency Scale for 1 week when defecation occurs. Subsequently, patients will be instructed to walk for 30 minutes, 3 days a week (Monday, Wednesday, and Friday), 30 minutes after breakfast and dinner. Patients will be asked to continue the application for 4 weeks. The patients will be administered the Defecation Diary, the Visual Comparison Scale and the Bristol Stool Consistency Scale when defecation occurs daily during the application. In addition, on the 130th day of the application, the Constipation Quality of Life Scale will be administered to the patients again.
62793954|NCT04083430|OTHER|Vaccine|Yellow Fever Vaccine
62793955|NCT04966260|EXPERIMENTAL|Standardized Virtual Reality|Participants in the standard virtual reality (VR) group will choose from the general library of VR experiences. Participants will be asked to select an experience they desire but have never experienced in person. The session will be facilitated by the therapeutic recreation staff on the unit.
62819389|NCT01768715||Non transplant candidates|Patients with severe alcoholic hepatitis and poor response to therapy, that are not candidates to transplantation, according to the specified criteria.
62819390|NCT01768715||Transplant candidates|Patients with severe alcoholic hepatitis and poor response to therapy, that are candidates to transplantation, according to the specified criteria.
62819391|NCT04413500|EXPERIMENTAL|adaptive intervention|The patients will receive various adaptive digital interventions through mobile app.
62819392|NCT03164616|EXPERIMENTAL|Treatment Arm 1|durvalumab + tremelimumab combination therapy + SoC chemotherapy
62819393|NCT03164616|EXPERIMENTAL|Treatment Arm 2|durvalumab monotherapy + SoC chemotherapy
62412176|NCT01419405|EXPERIMENTAL|Pregabalin/placebo|
62586080|NCT02149446|NO_INTERVENTION|No reinforcement of staple line|The stapler used to divide the pancreas is not reinforced with any material
62412177|NCT01419405|ACTIVE_COMPARATOR|placebo/remifentanil|
62412178|NCT01419405|PLACEBO_COMPARATOR|placebo/placebo|
62412179|NCT01419405|EXPERIMENTAL|Pregabalin/Remifentanil|
62412180|NCT05268003|EXPERIMENTAL|Ponatinib|Participants will receive ponatinib (45mg daily) as a single agent for 3 days. These will be called Days -3, -2 and -1
62218165|NCT04982835|ACTIVE_COMPARATOR|Anterior Cervical Discectomy & Fusion (ACDF)|"ACDF will be performed using one of four FDA-approved anterior cervical plate systems and corticocancellous allograft bone. The four plating systems used in this study are:~* Orthofix CETRA Anterior Cervical Plate System~* Medtronic Sofamor/Danek Venture Anterior Cervical Plate System~* DePuy Synthes: SKYLINE Anterior Cervical Plate System~* Stryker Aviator Anterior Cervical Plating System"
62218166|NCT04447196||CCHS|20 patients presenting with central hypoventilation syndrome during spontaneous breathing and with Non Invasive Ventilation
62218167|NCT05197725|EXPERIMENTAL|Mask intervention|Communities randomized to the intervention arm will be given masks and behavior change communication to motivate proper mask use. Every adult in communities randomized to the intervention arm will be encouraged to wear a mask when outside their housing compound and around other people. In arms randomized to school promotion, secondary school children will also be encouraged to wear masks both inside and outside of school.
62412181|NCT05268003|EXPERIMENTAL|Venetoclax|Patients will continue venetoclax 400mg daily on days 1-14 of each 28-day cycle.
62218168|NCT05197725|NO_INTERVENTION|Control|Control individuals will receive no masks or behavior change communication.
62218169|NCT04955340|EXPERIMENTAL|[14C]-resminostat|single dose of 400 mg \[14C\]-resminostat
62218170|NCT05112952|EXPERIMENTAL|Part A: Group 1: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral dose of lazertinib.
62218171|NCT05112952|ACTIVE_COMPARATOR|Part A: Group 2: Normal Hepatic Function|Participants with normal hepatic function who qualify for the control group will receive a single oral dose of lazertinib.
62218172|NCT05112952|EXPERIMENTAL|Part B: Group 3 (Optional): Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single oral dose of lazertinib.
62412182|NCT05268003|EXPERIMENTAL|Mini-hyper-CVD|Chemotherapy will be administered in the inpatient setting, starting on day 1 of each of the cycles 2-8.
62412183|NCT06550440||the control group|Very low birth weight infants without extrauterine growth restriction at discharge.
62412184|NCT06550440||the case group|Very low birth weight infants with extrauterine growth restriction at discharge.
62412185|NCT06653270|ACTIVE_COMPARATOR|Mannequin-based simulator|Legacy PROMPT Flex® mannequin
62218173|NCT05112952|EXPERIMENTAL|Part B: Group 4 (Optional): Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single oral dose of lazertinib.
62218174|NCT06448273|EXPERIMENTAL|TQB3702 tablets|TQB3702 tables is administered as a single dose or multiple dose.
62218175|NCT06448273|PLACEBO_COMPARATOR|TQB3702 placebo|TQB3702 placebo is administered as a single dose or multiple dose.
62243292|NCT04554238|ACTIVE_COMPARATOR|Occupational Therapy group|It consists of 5 weeks of intervention, with 3 treatment sessions per week, 40 minutes each time. The patient performs active exercises of the paretic upper limb: bimanual play activities, weight bearing, reaches in various planes of motion that favor shoulder flexion, elbow extension, forearm supination, and dissociated finger movements. In addition to passive mobilizations of the shoulder, elbow and wrist and tactile and proprioceptive sensory stimulation and the use of paretic limbs as support or carrying out prehensions.
62738649|NCT04662190|EXPERIMENTAL|Intervention group|Surgery planned, simulated and guided by 3D printing.
62738650|NCT03474913||Standard MRI first|Patients will have a standard of care MRI, then consent to study participation and have an upright MRI.
62738651|NCT03474913||MRIs in random order|Patients will consent to participate in the study, then do two MRIs in random order.
62738652|NCT01951586|PLACEBO_COMPARATOR|Placebo|Participants received placebo matching to denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received 4 mg zoledronic acid administered as an IV infusion Q4W or Q3W.
62738653|NCT01951586|EXPERIMENTAL|Denosumab|Participants received 120 mg denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received placebo to zoledronic acid administered as an IV infusion Q4W or Q3W.
62738654|NCT05297786|EXPERIMENTAL|Lanadelumab|Subjects will receive lanadelumab (300 mg) subcutaneously at the beginning of the study and 14 days later
62738655|NCT05297786|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo subcutaneously at the beginning of the study and 14 days later
62738656|NCT05748262||Primary infections during March-May 2022|Hospitalized COVID-19 patients infected with BA·2 during 1 March to 23 May 2022 from Huashan Hospital, Renji Hospital, and Shanghai Jing' an Central Hospital.
62738657|NCT05748262||Primary infections during December 2022-January 2023|Primary infections with BA.5-sublineages during 1 December 2022 to 14 January 2023, matched 1:1 by age and sex with reinfections during the same period.
62738658|NCT03832322||Water exchange colonoscopy|During the insertion phase of the first-pass colonoscopy, water exchange (WE) method was used. WE entailed the infusion of water to open the lumen and sequentially suction of water. When the cecum was reached and after most of the water was suctioned to collapse the cecal lumen, CO2 was opened during the withdrawal phase of the first-pass colonoscopy. After the first complete withdrawal of the colonoscope, a second colonoscopic examination aided by CO2 insufflation during insertion and withdrawal was performed by the same endoscopist. The colonoscope was reinserted into the cecum as quickly as possible, and the entire colon was re-examined. Polyp resection was carried out during insertion and withdrawal of the first- and second-pass examinations.
62218176|NCT06373523|EXPERIMENTAL|Dapagliflozin Plus levothyroxine Group|Dapagliflozin 10mg daily will be given to the treatment arm in addition to Levothyroxine replacement therapy. Eligible subjects will be followed up until week 28, and will undergo clinical, anthropometric and laboratory assessments (including liver function test and lipid profile) at baseline, week 14 and week 28. They will undergo LSM and CAP By Transient Elastography at baseline, week 14 and week 28, and MRI-PDFF at baseline and week 28. The primary outcome will be a difference in change of liver fat content (measured by MRI-PDFF) at week 28 from baseline between the two groups. The secondary outcomes will be proportion of participants achieving remission of steatosis (MRIPDFF \<5%) at week 28, reduction of liver fibrosis (LSM) and decrease in hepatic steatosis by 1 stage at week 14 and 28 and other secondary outcomes as mentioned above.
62793956|NCT04966260|EXPERIMENTAL|Personalized Virtual Reality|There are two types of personalized VR: 1) Family/friends provide personalized content (e.g., life stories, photos, videos) that will be used during the VR session. Family/friends of participants in the personalized VR group will have the opportunity to upload custom photos, videos, life stories or capture their own 360° footage of family events using a GoPro camera that will be loaned to them for the study. This content will be uploaded to a cloud-based portal. 2) If the family/friends of those in the personalized VR arm are unavailable/unable/unwilling to provide personalized content the participant will select a video from the VR library of an experience that is personally memorable to them, such as their childhood hometown, a favourite vacation destination. The session will be facilitated by the therapeutic recreation staff on the unit.
62022158|NCT05205772|EXPERIMENTAL|dorsolateral prefrontal cortex - medial prefrontal cortex - control site|Participants first undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the control site.
62243293|NCT05726045|ACTIVE_COMPARATOR|HIIT morning|High-intensity interval training (HIIT) in the morning
62793957|NCT04966260|ACTIVE_COMPARATOR|Two-Dimensional Video|Participants in the active comparator group will choose a two-dimensional video such as a mountain view, ocean view or safari. Participants will view the two-dimensional video on an iPad and the session will be facilitated by the therapeutic recreation staff on the unit.
62793958|NCT02159235||AIHD-patients (ICD-10 I21)|Patients suffering from acute ischemic heart disease according to ICD-10 I21
62793959|NCT02159235||CIHD-patients (ICD-10 I25)|patients suffering from chronic ischemic heart disease according to ICD-10 I25
62793960|NCT03418636|EXPERIMENTAL|Staying Safe (Ssafe)|"Ssafe is delivered in a small group format (consisting of approximately 10-12 participants) by a trained facilitator over 4 2.5-hour sessions (10 hours total). To help promote the maintenance of risk reduction over the trial's 12-month follow-up period, Ssafe participants will be provided with a novel interactive, smartphone-delivered booster application based on core Ssafe principles and risk reduction strategies."
62793961|NCT03418636|ACTIVE_COMPARATOR|Healthy Living|Healthy Living is a time- and attention-matched control intervention of equivalent session structure and duration as Ssafe (4 2.5-hour sessions; 10 hours total), also delivered in a small group format (10-12 participants). Healthy Living participants will be provided with a publicly available, sleep hygiene-focused smartphone app to promote healthy sleep habits over the trial's follow-up period.
62793962|NCT04730856|ACTIVE_COMPARATOR|Tinzaparin 4500 UI/day|Procedure: Tinzaparin 4500 UI/day SC until hospital discharge.
62022159|NCT05205772|EXPERIMENTAL|dorsolateral prefrontal cortex - control site - medial prefrontal cortex|Participants first undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the control site. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the medial prefrontal cortex.
62243294|NCT05726045|EXPERIMENTAL|HIIT evening|High-intensity interval training (HIIT) in the evening
62243295|NCT05726045|ACTIVE_COMPARATOR|HIIT morning + CRT|High-intensity interval training (HIIT) in the morning + cognitive remediation treatment (CRT)
62243296|NCT05726045|EXPERIMENTAL|HIIT evening + CRT|High-intensity interval training (HIIT) in the evening+ cognitive remediation treatment (CRT)
62412186|NCT06653270|ACTIVE_COMPARATOR|Virtual-reality simulator|A in-house developed immersive virtual simulation of a normal vaginal delivery developed using a Unity Engine and installed in Oculus® Quest 2 head-mounted device
62793963|NCT04730856|ACTIVE_COMPARATOR|Tinzaparin 100 UI/Kg/day|Procedure: Tinzaparin 100 UI/Kg/day SC until hospital discharge.
62793964|NCT04730856|ACTIVE_COMPARATOR|Tinzaparin 175 UI/Kg/day|Procedure: Tinzaparin 175 UI/Kg/day SC until hospital discharge.
62412187|NCT06023511|EXPERIMENTAL|Intervention group|Volunteers will receive electrical muscle stimulation.
62412188|NCT01534390|EXPERIMENTAL|Use of in-line microfilters|
62412189|NCT01534390|NO_INTERVENTION|Standard therapy without the use of in-line microfilters|
62412190|NCT05832242||Simple Diverticulitis|Computed tomograpy scan showing isolated inflammation
62793965|NCT03216408|EXPERIMENTAL|Neuronox|Botulinum toxin type A for Injection
62793966|NCT03216408|ACTIVE_COMPARATOR|Botox|Botulinum toxin type A for Injection
62793967|NCT02652351|EXPERIMENTAL|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
62793968|NCT05682001||DC group|Anterior lens capsule tissues from DC patients
62793969|NCT05682001||ARC group|Anterior lens capsule tissues from ARC patients
62793970|NCT05682001||NC group|anterior lens capsules collected from three age-matched transparent crystals of cadaveric eyes
62218177|NCT06373523|PLACEBO_COMPARATOR|Levothyroxine daily and Placebo pill identical to Dapaglifozin for 28 weeks|The placebo pill will be manufactured to identical in appearance to the Dapaglifozin will be given to the Placebo arm in addition to Levothyroxine replacement therapy. Eligible subjects will be followed up until week 28, and will undergo clinical, anthropometric and laboratory assessments (including liver function test and lipid profile) at baseline, week 14 and week 28. They will undergo LSM and CAP By Transient Elastography at baseline, week 14 and week 28, and MRI-PDFF at baseline and week 28. The primary outcome will be a difference in change of liver fat content (measured by MRI-PDFF) at week 28 from baseline between the two groups. The secondary outcomes will be proportion of participants achieving remission of steatosis (MRI PDFF \<5%) at week 28, reduction of liver fibrosis (LSM) and decrease in hepatic steatosis by 1 stage at week 14 and 28 and other secondary outcomes as mentioned above.
62218178|NCT03589508|EXPERIMENTAL|In-Person Sessions: ABCP_P|In-person therapy sessions: 6 Weekly Prevention Session conducted in person (half of participants will attend alone, half of participants will attend with a significant other)
62218179|NCT03589508|EXPERIMENTAL|Video conference sessions: ABCP_T|Video conference therapy sessions: 6 Weekly Prevention Session conducted using videoconference (half of participants will attend alone, half of participants will attend with a significant other)
62218180|NCT00417339||hemodialysis, 4h, twice weekly|hemodialysis, four hours, twice weekly
62412191|NCT05832242||Complicated Diverticulitis|Computed tomograpy scan evidence of diverticulitis with either an associated abscess, fistula, obstruction, bleeding, phlegmon or perforation.
62412192|NCT06651671|EXPERIMENTAL|Treatment; MFR|The treatment group received 30 seconds of direct and indirect myofascial release performed by the same practicing osteopathic physician.
62412193|NCT06651671|SHAM_COMPARATOR|Control|The sham control group received one minute of light sham touch performed by a medical student.
62412194|NCT06564272|EXPERIMENTAL|KC1036|oral administration QD
62412195|NCT06152653|ACTIVE_COMPARATOR|NAC via jet nebulizer|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 10% NAC coadministered with albuterol and delivered via standard jet nebulizer. Participants will each complete 5 treatment visits over the course of 30 days. Each treatment visit will consist of two treatments separated by 4 hours.
62412196|NCT06152653|EXPERIMENTAL|NAC via AeroEclipse-VersaPAP|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 10% NAC coadministered with albuterol and delivered via the AeroEclipse-VersaPAP system. Participants will each complete 5 treatment visits over the course of 30 days. Each treatment visit will consist of two treatments separated by 4 hours.
62793971|NCT01744548|EXPERIMENTAL|tCBT treatment|Participants randomised to the tCBT treatment arm will receive 12 individual, 1-hour tCBT sessions based upon Barlow et al.'s (2011) Unifed Protocol for emotional disorders (UP).
62793972|NCT01744548|NO_INTERVENTION|7-week delayed tCBT treatment|Participants randomised to the delayed-treatment arm will receive a brief telephone call and complete the Hospital Anxiety and Depression Scale (HADS) in order to monitor risk and symptom deterioration during the 7-week delayed treatment phase. They will also receive TAU (e.g. Community Mental Health Team appointments, case reviews, etc) during this time. At the end of 7 weeks, participants in the delayed-treatment arm will crossover into the treatment arm and receive the tCBT intervention. This arm will serve as a control condition in order to enable between-group comparisons.
62793973|NCT03825302||Males with asthma|Induced sputum, methacholine challenge, and mannitol challenge will be performed.
62022160|NCT05205772|EXPERIMENTAL|control site - medial prefrontal cortex - dorsolateral prefrontal cortex|Participants first undergo transcranial magnetic stimulation to the control site. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex.
62218181|NCT00417339||hemodialysis, 8h, twice weekly|hemodialysis, eight hours, twice weekly
62218182|NCT00417339||hemodialysis, 8h, every other day|hemodialysis, eight hours, every other day
62218183|NCT00417339||hemodialysis, 8h, six days per week|hemodialysis, eight hours, six days per week
62218184|NCT05984004|PLACEBO_COMPARATOR|Control|Healthy volunteers in Control group receives a nasal spray containing 0.9% NaCl isotonic saline solution.
62218185|NCT05984004|EXPERIMENTAL|SPEROVID|Healthy volunteers in SPEROVID group receives a nasal spray containing inactivated Bacillus subtilis DSM32444 (postbiotic)
62218186|NCT02225210|EXPERIMENTAL|Group dexmedetomidine ,dexmedetomidine|Continuous pump infusion dexmedetomidine with loading dose of 0.4μg.kg-1 for 10 minutes ,then followed by maintenance dose of 0.2\~0.7µg.kg-1 to maintain Sedation-Agitation Scale between 3 and 4.
62218187|NCT02225210|ACTIVE_COMPARATOR|Group midazolam,midazolam,fentanyl|Quickly inject midazolam and fentanyl with loading dose of 0.1mg.kg-1 and 1 μg.kg-1 separately until attaining Sedation-Agitation Scale between 3 and 4,then followed by maintenance dose of 0.05\~0.1mg.kg-1.h-1 and fentanyl 0.5\~1μg.kg-1.h-1 separately.
62218188|NCT00875927|ACTIVE_COMPARATOR|1 - control|candy not including scraping microcapsules
62218189|NCT00875927|ACTIVE_COMPARATOR|2 - Scraping|candy including scraping TCP microcapsules
62793974|NCT03825302||Females with asthma|Induced sputum, methacholine challenge, and mannitol challenge will be performed.
62793975|NCT04589442|ACTIVE_COMPARATOR|Standard of Care Dermal Graft|Standard of care cryopreserved cadaveric split thickness skin grafts
62218190|NCT00875927|ACTIVE_COMPARATOR|3 - Scraping plus Propolis|candy including scraping Propolis microcapsules
62412197|NCT05645263|EXPERIMENTAL|Cola 1（3d）|The patients in intervention group 1 dieted Coca-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coca-cola period is 3 days.The patients will go through an endoscopy once the Coca-cola dieting therapy is over.
62793976|NCT04589442|EXPERIMENTAL|Standard of Care Dermal Graft - Microsurfaced|Microsurfaced cryopreserved cadaveric split thickness skin grafts
62793977|NCT04736381||Kidney transplanted patients treated with Nulojix|Patients treated with Simulect as induction, and with Nulojix®, mycophenolic acid and steroids as maintenance therapy during the first year of kidney transplant.
62412198|NCT05645263|EXPERIMENTAL|Cola 2（5d）|The patients in intervention group 2 dieted Coca-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coca-cola period is 5 days. The patients will go through an endoscopy once the Coca-cola dieting therapy is over.
62412199|NCT05645263|EXPERIMENTAL|Cola 3（7d）|The patients in intervention group 3 dieted Coca-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coca-cola period is 7 days. The patients will go through an endoscopy once the Coco-cola dieting therapy is over.
62412200|NCT05645263|NO_INTERVENTION|Fragmentation 1|The patients who chose emergently endoscopic fragmentation was enrolled in control group 1. All patients endorsed the informed consent paper, no diet for at least 4 hours, no drink for 2 hours and bring the medical records before endoscopy and go on a mechanical fragmentation through gastroendoscopy
62793978|NCT01793766|EXPERIMENTAL|Brain modulation|10 sessions of brain modulation with Eldith/Neuroconn transcranial Direct Current Stimulation device
62793979|NCT01793766|PLACEBO_COMPARATOR|Placebo (sham modulation)|10 placebo sessions where no brain modulation takes place
62793980|NCT03028610|EXPERIMENTAL|Acessa™ System|radiofrequency generator
62793981|NCT05272475|EXPERIMENTAL|Chamomile Tea|Subjects will consume a single serving of chamomile tea on the visit day. The tea serving will be prepared using 3 grams of chamomile tea steeped in hot water according to the study protocol.
62793982|NCT05272475|EXPERIMENTAL|Chamomile Extract Capsule|Subjects will consume a single chamomile capsule on the visit day. Each capsule consists of 500 milligrams of a chamomile extract that has been standardized to 1.2% apigenin content.
62793983|NCT04492501|NO_INTERVENTION|Supportive Arm|As per Institutional COVID-19 Management Guidelines all patients of moderate, severe and critical COVID-19 received standard protocol of aspirin, anticoagulation, ulcer prophylaxis, awake Proning (if PaO2 \< 80mmHg) and corticosteroids. All patients of Cytokine release storm (CRS) received either Methylprednisolone 1 mg/kg or Dexamethasone 6-12mg/day irrespective of disease severity.
62793984|NCT04492501|EXPERIMENTAL|TPE arm|addition to standard care TPE will be performed once daily using COBE Spectra Apheresis machine version 7 (Manufacturer TERUMO BCT, Lakewood, CO, USA INC) having continuous flow centrifugation. Venous access will be achieved using an ultrasound guided double lumen catheter (Arrow - 12 FR) via femoral vein. Patient's total blood volume will be calculated as per Nadler's formula. Anticoagulant acid dextrose ratio will be 1:10 and flow rate 30-40 ml/minutes (Adjusted as per hemodynamic status). Patients' blood pressure, pulse, oxygen saturation will be monitored throughout procedure. Duration of procedure varied from 2-4 hours and 1-1.5 times total plasma volume will be removed during each procedure. Replacement fluid will be fresh frozen plasma (FFP) and normal saline in 2:1 respectively. All procedures will be performed in intensive care or high dependency unit by Apheresis Department of PEMH. TPE will be continued till recovery.
62819394|NCT03164616|ACTIVE_COMPARATOR|Treatment Arm 3|SoC chemotherapy alone
62819395|NCT04993885|EXPERIMENTAL|Treatment group|Fifty-two subjects will be enrolled with the indicated treatment dose of avatrombopag
62218191|NCT00875927|ACTIVE_COMPARATOR|4 - Scraping plus Zinc|candy including scraping Zinc microcapsules
62022161|NCT05205772|EXPERIMENTAL|control site - dorsolateral prefrontal cortex - medial prefrontal cortex|Participants first undergo transcranial magnetic stimulation to the control site. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the medial prefrontal cortex.
62218192|NCT00875927|ACTIVE_COMPARATOR|5 - Scraping plus Propolis and Zinc|candy including scraping Propolis and Zinc microcapsules
62218193|NCT06417528||Surgery Patients|Data collection will record parameters of patients undergoing surgery at four different times: preoperative assessment (60 to 1 day before the scheduled procedure); evaluation of the perioperative period; and postoperative period (from the third month following surgery).
62218194|NCT01806103|EXPERIMENTAL|Antimicrobial Stewardship Bundle|"An intervention bundle to reduce outpatient antibiotic use in children will include education, creation of and access to guidelines, and audit of and feedback on individual prescribing within the context of achievable benchmarks."
62218195|NCT01806103|NO_INTERVENTION|Control|Control sites will be within strata to maintain balance of treatment arm within strata
62218196|NCT04143958|EXPERIMENTAL|agalsidase beta|Commercially available agalsidase beta treatment at approved dose and regimen;administered once every 2 weeks as an IV infusion
62218197|NCT04143958|ACTIVE_COMPARATOR|agalsidase alfa|Commercially available agalsidase alfa treatment at approved dose and regimen; administered once every 2 weeks as an IV infusion
62218198|NCT00353522|EXPERIMENTAL|Dalcetrapib|Dalcetrapib 900mg po daily for 24 weeks
62412201|NCT05645263|NO_INTERVENTION|Fragmentation 2|The patients who chose emergently endoscopic fragmentation was enrolled in control group 2. All patients endorsed the informed consent paper, no diet for at least 4 hours, no drink for 2 hours and bring the medical records before endoscopy and go on a mechanical fragmentation through gastroendoscopy
62412202|NCT05645263|NO_INTERVENTION|Fragmentation 3|The patients who chose emergently endoscopic fragmentation was enrolled in controlled Group 3. All patients endorsed the informed consent paper, no diet for at least 4 hours, no drink for 2 hours and bring the medical records before endoscopy and go on a mechanical fragmentation through gastroendoscopy
62586081|NCT04566003|EXPERIMENTAL|[18F]PI-2620 PET, then [18F]GTP1 PET|Participants will undergo one \[18F\]PI-2620 PET imaging session, then one \[18F\]GTP1 PET imaging session. Prior to each session, participants will be administered a bolus intravenous injection of approximately 5 millicurie (mCi) of \[18F\]PI-2620 or 7mCi of \[18F\]GTP1.
62586082|NCT04566003|EXPERIMENTAL|[18F]GTP1 PET, then [18F]MK-6240|Participants will undergo one \[18F\]GTP1 PET imaging session, then one \[18F\]MK-6240 PET imaging session. Prior to each session, participants will be administered a bolus intravenous injection of approximately 5 millicurie (mCi) of \[18 F\]MK-6240 or 7mCi of \[18F\]GTP1.
62793985|NCT04492501|EXPERIMENTAL|TPE in combination with other investigational treatments|During TPE, Replacement fluid will be fresh frozen plasma (FFP) and normal saline in 2:1 respectively plus 200-400 ml of convalescent plasma. A predefined number of patients will also receive mesenchymal stem cell therapy and/or Remdesivir
62218199|NCT00353522|PLACEBO_COMPARATOR|Placebo|Placebo po daily for 24 weeks
62218200|NCT02545933|EXPERIMENTAL|DAPT plus vorapaxar|Aspirin plus prasugrel or ticagrelor plus vorapaxar 2.5mg od
62793986|NCT04492501|EXPERIMENTAL|Either alone or combination of MSC, Remdesivir and Tocilizumab|A predefined number of patients will receive either alone Tocilizumab, Remdesivir and Mesenchymal stem cell therapy or their combination
62793987|NCT00648362|EXPERIMENTAL|1|Glimepiride Tablets 1 mg
62793988|NCT00648362|ACTIVE_COMPARATOR|2|Amaryl® Tablets 1 mg
62793989|NCT00965575|EXPERIMENTAL|Melatonin|Subjects will take sustained release melatonin 30 minutes prior to bedtime for four weeks
62218201|NCT02545933|EXPERIMENTAL|Prasugrel/ticagrelor plus vorapaxar|Prasugrel or ticagrelor plus vorapaxar 2.5mg od
62218202|NCT02545933|ACTIVE_COMPARATOR|DAPT|Aspirin in addition to prasugrel or ticagrelor
62218203|NCT06198205|EXPERIMENTAL|Group A|Students will participate in fundamental motor skills(FMS) program that will include 12 basic motor skills.
62218204|NCT06198205|EXPERIMENTAL|Group B|Group B students will do their regular afterschool programs unstructured child's free play
62218205|NCT02766192|EXPERIMENTAL|TIMBER-Ketamine arm|This arm received TIMBER psychotherapy and ketamine infusion.
62218206|NCT02766192|PLACEBO_COMPARATOR|TIMBER-placebo arm|This arm received TIMBER psychotherapy and placebo (normal saline) infusion.
62218207|NCT03450226|EXPERIMENTAL|treatment|patients will receive a stellate ganglion block with 10 ml of 0.25 % bupivacaine
62218208|NCT03450226|NO_INTERVENTION|control|patients will be controlled
62218209|NCT01893021||Postpartum Malawian women|
62218210|NCT03446820|OTHER|Sleep participants|Crossover from standard sheets to hygro cotton sheets
62218211|NCT04334187|EXPERIMENTAL|Smoke Cessation Group|Mindfulness-based smoking cessation sessions will follow the mindfulness based addiction treatment (MBAT) intervention for smoking cessation. Sessions are in group format for two hours, weekly. Two groups of sessions with about 10 participants per group will be organized.
62218212|NCT04642300|ACTIVE_COMPARATOR|Holmich Protocol|Treatment will be administered three times a week (on even or odd days). The duration of each session was about 90 min for module 1 (first two weeks) and 120 min for module 2 (from the third week). From the third week, the athletes were asked to perform exercises from module 1 every other day, between the treatment sessions
62412203|NCT04342390|EXPERIMENTAL|Exercise Group|Study participants in this group will be asked to complete 4 weeks of high-intensity interval training (HIIT).
62412204|NCT04342390|NO_INTERVENTION|Control Group|Study participants in this group will not undergo HIIT exercise training during this study.
62412205|NCT00276458|ACTIVE_COMPARATOR|1|Atorvastatin 40mg tablet + Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day).
62586083|NCT05031416|EXPERIMENTAL|Consumers who smoke at outpatient community mental health clinic|Consumers with serious mental illness who attend outpatient community mental health clinic will participate in a smoking cessation with the LTQ application and nicotine replacement therapy
62586084|NCT04362072|EXPERIMENTAL|Lorlatinib|Participants will take 100 mg (four, 25 mg tablets) once daily.
62793990|NCT00965575|PLACEBO_COMPARATOR|Placebos|Subjects will take a placebo 30 minutes before bedtime for four weeks
62793991|NCT02798978|EXPERIMENTAL|Part 1: GSK1795091 or Placebo|In Part 1, subjects in sequential cohorts will receive single ascending doses of intravenous (IV) injection of GSK1795091 or matching placebo, with a starting dose of 7 nanogram (ng), on Day 1 until the highest dose is evaluated.
62793992|NCT02798978|EXPERIMENTAL|Part 2 Cohort 1: GSK1795091|In Part 2 Cohort 1, subjects will receive IV injection of GSK1795091 on Day 1, at dose determined in part 1, and second dose on Day 8 (one week apart)
62412206|NCT00276458|EXPERIMENTAL|2|Atorvastatin 40mg Pbo tablet + Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day).
62412207|NCT04061655|ACTIVE_COMPARATOR|iron therapy group|Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
62412208|NCT04061655|PLACEBO_COMPARATOR|placebo|Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
62412209|NCT05672394|EXPERIMENTAL|Serratus anterior plane block:|
62793993|NCT02798978|EXPERIMENTAL|Part 2 Cohort 2: GSK1795091|In Part 2 Cohort 2, subjects will receive IV injection of GSK1795091 on Day 1, at dose determined in part 1, and a second dose on Day 15 (two weeks apart)
62022162|NCT01385059|EXPERIMENTAL|Arm I (neoadjuvant enzyme inhibitor and prostatectomy)|Patients receive axitinib PO BID on days 1-28. Patients then undergo prostatectomy and pelvic lymph node dissection. Treatment continues in the absence of disease progression or unacceptable toxicity.
62022163|NCT01385059|ACTIVE_COMPARATOR|Arm II (surgery)|Patients undergo prostatectomy and pelvic lymph node dissection at 5-6 weeks after biopsy confirmation of prostate cancer.
62022164|NCT01519206|EXPERIMENTAL|Ultherapy treatment|Ulthera System Treatment
62793994|NCT02094651|EXPERIMENTAL|divalproex sodium|divalproex sodium will be administered in sprinkle capsule formulation, target dose of 30mg/kg, drug will be administered for 12 weeks
62022165|NCT04720417|EXPERIMENTAL|Treatment (defactinib, VS-6766)|Patients receive defactinib PO BID and VS-6766 PO BIW (Monday and Thursday or Tuesday and Friday) for 3 weeks in every cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62022166|NCT03758898|EXPERIMENTAL|Treatment|Chest physiotherapy and mobilisation were applied on the patients for 4 days. The treatment of the patients was started on the first postoperative day and continued until the postoperative 4th day.
62412210|NCT05672394|ACTIVE_COMPARATOR|Thoracic Epidural|
62412211|NCT00910065|EXPERIMENTAL|Arm 1|
62412212|NCT00910065|EXPERIMENTAL|Arm 2|
62412213|NCT00910065|ACTIVE_COMPARATOR|Arm 3|
62412214|NCT06565065|EXPERIMENTAL|Order 1 - Day 0: OMT, Week 3: Sham, Week 6: Exercise|"Osteopathic Manipulative Treatment (OMT)~followed by a 3-week washout period and then:~Sham protocol~followed by a 3-week washout period and then:~Exercise protocol."
62412215|NCT06565065|EXPERIMENTAL|Order 2 - Day 0: Sham, Week 3: OMT, Week 6: Exercise|"Sham protocol~followed by a 3-week washout period and then:~Osteopathic Manipulative Treatment (OMT)~followed by a 3-week washout period and then:~Exercise protocol."
62793995|NCT02094651|PLACEBO_COMPARATOR|Placebo|Blue and white capsules with equivalent amount of lactose spheres/beads inside Placebo will be formulated to look identical to the active medication
62793996|NCT01199224|EXPERIMENTAL|Arm A|
62793997|NCT01199224|EXPERIMENTAL|Arm B|
62022167|NCT03758898|PLACEBO_COMPARATOR|Group 2|only mobilisation was applied to the patients in the second group
62022168|NCT02215317||OSA group|Patients found to have OSA based on an overnight sleep study
62022169|NCT02215317||Non-OSA group|Patients found not to have OSA based on an overnight sleep study
62022170|NCT06006182|EXPERIMENTAL|Group A-Grape Powder then Placebo|Group A block will be the Grape Powder for the first 8 weeks, and then after the washout period, they will begin the Placebo. The experimental Grape Powder is a food-it is simply freeze-dried grape powder
62022171|NCT06006182|PLACEBO_COMPARATOR|Group B-Placebo-then Grape Powder|Group B block will be the Placebo for the first 8 weeks, and then after the washout period, they will begin the Grape Powder
62022172|NCT05117645||Cases|patients come to surgical emergency unit and complaining of intestinal obstruction and CT Abdomen and pelvis will be done to detect the cause then will be compared with operative findings .
62022173|NCT01316822|EXPERIMENTAL|ARRY-382|
62022174|NCT01870700|EXPERIMENTAL|lactobacillus reuteri|Intervention: supplementation with the probiotic Lactobacillus reuteri (DSM 17938),Reuflor, was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks.
62412216|NCT06565065|EXPERIMENTAL|Order 3 - Day 0: Exercise, Week 3: OMT, Week 6: Sham|"Exercise protocol~followed by a 3-week washout period and then:~Osteopathic Manipulative Treatment (OMT)~followed by a 3-week washout period and then:~Sham protocol."
62412217|NCT01600755|EXPERIMENTAL|Iltamiocel|AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intrasphincteric injection of 250 x 10\^6 cells.
62412218|NCT06277466|EXPERIMENTAL|Comparison of T2DM susceptibility gene expression between newly diagnosed T2DM patients and controls|To determine the effect of gene mutations on the susceptibility of T2DM by comparing the expression levels of T2DM susceptibility genes in newly diagnosed T2DM patients and controls.
62793998|NCT01199224|EXPERIMENTAL|Arm C|
62793999|NCT01199224|EXPERIMENTAL|Arm D|
62794000|NCT04394065||uEXPLORER total-body PET/CT|Newly diagnosed NPC patients will undergo a one-hour total-body dynamic PET/CT examination and subsequently followed by a conventional PET/CT scan within 30 minutes
62022175|NCT01870700|PLACEBO_COMPARATOR|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
62412219|NCT02875340|EXPERIMENTAL|VAL401 treatment|Patients received VAL401 oral formulation once daily according to their level of tolerance (2 mg - 10 mg).
62412220|NCT01145872|EXPERIMENTAL|Mindfulness Based Cognitive Therapy|
62412221|NCT01145872|ACTIVE_COMPARATOR|Health Enhancement Program|
62412222|NCT03370627|EXPERIMENTAL|Patient|
62412223|NCT04102514|OTHER|Real-time Group Video|
62794001|NCT05030168|NO_INTERVENTION|Placebo|Twice weekly hemodialysis program plus regular protein diet (1.0 g/kg/day) every day
62794002|NCT05030168|EXPERIMENTAL|Ketosteril|Incremental hemodialysis program, starting from once weekly hemodialysis/hemodialysis filtration(HDF) plus low protein diet (0.6 g/kg/day) and ketoanologues 0.12g/kg/day supplementation on non-dialysis days and regular protein diet (1.0-1.2 g/kg/day) on dialysis day
62794003|NCT01511016|EXPERIMENTAL|human recombinant leptin (metreleptin)|Each subject received 0.02 mg leptin / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg leptin / kg for two more months.
62412224|NCT04102514|OTHER|Enhanced Usual Care|
62022176|NCT02546544|OTHER|Linsitinib|Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg
62218213|NCT04642300|ACTIVE_COMPARATOR|Myofascial Release Technique|Treatment wiil be given twice a week as individual treatment by the physiotherapist. The duration of treatment is about 30 min.
62794004|NCT01511016|PLACEBO_COMPARATOR|Placebo injection|Each subject received placebo at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by a dose of 0.04 mg / kg for two more months.
62412225|NCT06695910|EXPERIMENTAL|Phase 1: Exploratory MAG-EPA treatment group|This is a single arm phase of the study. Every subject will receive the experimental treatment (MAG-EPA) at 1,5g/day for a period of eight weeks.
62412226|NCT06695910|EXPERIMENTAL|Phase 2: MAG-EPA treatment group|This phase of the study is a parallel design. Subjects will be assigned to experimental treatment (MAG-EPA) by randomization. Every subject in this arm will receive the same treatment at 1,5g/day for a period of eight weeks.
62412227|NCT06695910|PLACEBO_COMPARATOR|Phase 2: Placebo group|This phase of the study is a parallel design. Subjects will be assigned to Placebo treatment (sunflower oil) by randomization. Every subject will receive the same treatment at 2,0g/day for a period of eight weeks.
62412228|NCT05455593|ACTIVE_COMPARATOR|Water aerobics|Aerobic exercises performed in a swimming pool.
62412229|NCT05455593|ACTIVE_COMPARATOR|Metacognitive Training (MCT)|Treatment program for psychosis based on Cognitive-behavioral therapy (CBT), cognitive remediation (CRT) and psychoeducation.
62412230|NCT05455593|EXPERIMENTAL|Combined intervention (water aerobics + MCT)|Combination of water aerobics and MCT sessions.
62412231|NCT04092257|EXPERIMENTAL|VIA and thermocoagulation|Participants will undergo same day VIA and thermocoagulation
62412232|NCT06563128|PLACEBO_COMPARATOR|Clearfil Majesty Posterior|It is a type of composite used in the back group of teeth. It was used for the control group.
62794005|NCT00241345|EXPERIMENTAL|Group A|IV ganciclovir (5mg/kg every 12 hours for 7 days followed by 5mg/kg every 24 hours for 7 days. If CMV viral load \<5000 copies/ml after 14 days then 5mg/kg every 24 hours for a total of 21 total days of therapy. If CMV viral load \>5000/ml but less than index viral load after 14 days then 5mg/kg every 24 hours for a total of 28 total days of therapy. If CMV viral load \>= index viral load after 14 days then 5mg/kg every 12 hours for 7 days. If repeat CMV viral load is \<= the previous CMV viral load then 5mg/kg every 12 hours for an additional 7 days.
62794006|NCT00241345|EXPERIMENTAL|Group B|PO valganciclovir (900 mg every 12 hours for 7 days followed by 900 mg every 24 hours for 7 days. If CMV viral load \<5000 copies/ml after 14 days then 900 mg every day until 21 total days of therapy. If CMV viral load \>5000 copies/ml after 14 days but less than the index viral load then 900 mg every day until 28 total days of therapy. If CMV viral load \>= the index viral load 900 mg every 12 hours for 7 days, if CMV viral load \<= to previous viral load then 900 mg every 12 hours for another 7 days.
62794007|NCT05935371||Case group - women with obstetric anal sphincter injuries|"* Adult women who have had a vaginal delivery~* ≥ 18 years~* Capacity to consent~* English-speaking~* Primiparous/multi-parous"
62794008|NCT05935371||Control group - women without perineal tears|"* Adult women who have had a vaginal delivery~* ≥ 18 years~* Capacity to consent~* English-speaking~* Primiparous/multi-parous"
62794009|NCT01940835||Type 1 Diabetes|Subjects will have an upper endoscopy with small bowel biopsies and brushings. Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC). Stool samples will be collected at baseline for future microbiome and virome studies.
62794010|NCT01940835||Healthy Control Group|Subjects will have an upper endoscopy with small bowel biopsies and brushings. Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC). Stool samples will be collected at baseline for future microbiome and virome studies.
62794011|NCT06023706|EXPERIMENTAL|Capsaicin 179 mg cutaneous patch|"Capsaicin 179 mg cutaneous patch.~1 patch applied once for 1 hour at inclusion visit."
62794012|NCT06023706|PLACEBO_COMPARATOR|Capsaicin low concentration patch|"Capsaicin 0.04 cutaneous patch.~1 patch applied once for 1 hour at inclusion visit"
62794013|NCT01599013|OTHER|Vinflunine plus Gemcitabine|
62794014|NCT01599013|OTHER|Vinflunine plus Carboplatin|
62794015|NCT03826238||ARBD and depression|10 patients with ARBD and at least moderate depressive symptoms (MoCA \< 26, Hamilton Depression Rating Scale ≥ 17). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
62794016|NCT03826238||ARBD and no depression|10 patients with ARBD and no clinically relevant depressive symptoms (MoCA \< 26, Hamilton Depression Rating Scale \< 17). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
62794017|NCT03826238||Healthy|10 healthy controls (no ARDB, no depression, no cognitive deficit). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
62022177|NCT06632041||Neonates with necrotizing enterocolities|
62022178|NCT03889717|EXPERIMENTAL|400 iu|neonates who will receive vitamin d dose at 400 iu per day
62022179|NCT03889717|ACTIVE_COMPARATOR|1000 iu|neonates who will receive vitamin d dose 1000 iu per day
62022180|NCT02357836|OTHER|Itraconazole|600 mg twice daily for 10-14 days
62022181|NCT04825457|ACTIVE_COMPARATOR|Anchoring-tip EMR|AEMR, the snare tip was projected from the sheath by 1-2 mm length. Consequently, a small mucosal incision was made at proximal side of lesion. Then the snare was deployed progressively and adjusted around the lesion trying to obtain free margins.
62022182|NCT04825457|ACTIVE_COMPARATOR|Conventional EMR|After injection of normal saline solution mix, snaring was tried for CEMR.
62218214|NCT04650139||successful CTO|
62218215|NCT04650139||non- successful CTO|
62412233|NCT06563128|EXPERIMENTAL|Omnichroma Universal Group|It is a single-color universal resin composite used in both anterior and posterior group teeth.
62412234|NCT06563128|EXPERIMENTAL|Zen Universal Group|It is a single-color universal resin composite used in both anterior and posterior group teeth.
62412235|NCT06563128|EXPERIMENTAL|Vittra Aps Unique Universal Group|It is a single-color universal resin composite used in both anterior and posterior group teeth.
62794018|NCT03410563||Healthy participants|
62022183|NCT02687152|EXPERIMENTAL|Arginase inhibition|N-hydroxyl-nor-L-arginine, i.a. 0.1 mg/min for 120 min
62022184|NCT04805970||Patients with and without diabetes who were previously diagnosed with COVID-19|
62794019|NCT00895115|SHAM_COMPARATOR|Arm I|Patients receive no supplementation.
62412236|NCT06563128|EXPERIMENTAL|Charisma Diamond Universal Group|It is a single-color universal resin composite used in both anterior and posterior group teeth.
62218216|NCT05534815|NO_INTERVENTION|Usual Care Control group|Participants in the Usual Care Control group will receive methadone or buprenorphine treatment, counseling, and employment services.
62022185|NCT00788840|ACTIVE_COMPARATOR|1. Insulatard|
62022186|NCT00788840|ACTIVE_COMPARATOR|2. Detemir|
62412237|NCT04677894||Group Direct Laringoscopy|Group DL: Group of patients intubated using a Macintoch blade laryngoscope.
62022187|NCT03999606|ACTIVE_COMPARATOR|Mindfulness Training|Participants in the control group will be assigned to a online based mindfulness training.
62022188|NCT03999606|EXPERIMENTAL|Music Training|Participants in the experimental group will be assigned to a online based choir program.
62022189|NCT03789422|ACTIVE_COMPARATOR|Association drugs|levocetirizine 10mg/day + tranexamic acid (AT) 2g/day for a month
62022190|NCT03789422|ACTIVE_COMPARATOR|one drug|Levocetirizine 20 mg/day for a month
62022191|NCT04824547|ACTIVE_COMPARATOR|Stabilization exercise group|"Spinal stabilization exercise will be applied all patients accompanied by physiotherapist.~Sessions will be included selected exercises according to motor learning phases."
62022192|NCT04824547|ACTIVE_COMPARATOR|yoga group|Yoga program will be applied all patients in this group accompanied by physiotherapist. Sessions will be included selected breathing exercises, warm up, asana and relaxation.
62022193|NCT02376907||EUS-BD or ERCP with duodenal SEMS|Patients who underwent endoscopic placement of a duodenal self-expandable metal stent (SEMS) for nonresectable malignant GOO and endoscopic biliary drainage for nonresectable distal MBO.
62022194|NCT02752997|EXPERIMENTAL|Intervention|"Discharge medication services included:~* Discharge medication reconciliation~* Identification of medication discrepancies and resolution~* Medication counseling using health coaching techniques with short term goal setting and follow up phone call"
62022195|NCT02752997|NO_INTERVENTION|Comparator|Current standard of care provided by nursing staff.
62412238|NCT04677894||Group Videolaringoscopy|Group VL: Group of patients intubated using a McGrath video laryngoscope.
62412239|NCT00308230|PLACEBO_COMPARATOR|Normal Heart|Control Group with Normal Heart
62412240|NCT00308230|ACTIVE_COMPARATOR|Congenital Heart Disease|Tetralogy of Fallot, DTGA, CCTGA
62412241|NCT00308230|ACTIVE_COMPARATOR|Heart Failure|Left ventricular heart failure, no congestive heart disease
62412242|NCT00897507||Ancillary-Correlative (genotype assessment)|Tumor tissue samples undergo genotype assessment on the Pyrosequencing platform. Contingency tables and X\^2 test performs a univariate analysis of the risk of relapse and genotype, and multivariable analyses using logistic regression. Cox proportional hazards evaluate the risk of relapse given genotype and other confounders. Genotype patterning, classification and regression trees, and multifactor dimensionality reduction evaluates for patterns of single nucleotide polymorphisms associated with toxicity and relapse risk.
62794020|NCT00895115|EXPERIMENTAL|Arm II|Patients receive oral high γ-tocopherol vitamin E supplementation once daily for 1 week.
62794021|NCT00895115|EXPERIMENTAL|Arm III|Patients receive oral high γ-tocopherol vitamin E supplementation once daily for 2 weeks.
62794022|NCT01897363||Infants with Prader-Willi Syndrome|Infants between ages 2 to 12 months of age with Prader-Willi Syndrome.
62794023|NCT05326646|EXPERIMENTAL|IBS patients|Patients suffering from IBS according to Rome IV criteria
62794024|NCT05211206||Aggressive hydration|Patients with greater than or equal to 2 L of intravenous crystalloid fluids administered within the immediate pre-, peri- and post-procedural period
62022196|NCT05505708|ACTIVE_COMPARATOR|Group (V)|Group (V): will receive hydroxyethyl starch (voluven) Pfizer Inc 500ml over 30 minutes
62022197|NCT05505708|ACTIVE_COMPARATOR|Group (R)|Group (R): will receive ringer acetate 500ml over 30 minutes
62022198|NCT03571295|EXPERIMENTAL|videolaryngoscopy|
62022199|NCT03571295|EXPERIMENTAL|direct laryngoscopy|
62022200|NCT06275646|EXPERIMENTAL|A dartos flap and PRP layer|dartos flap and PRP layer was applied in hypospadias surgery as additional layer
62022201|NCT06275646|EXPERIMENTAL|preputial dartos flap layer|preputial dartos flap layer applied as additional layer
62022202|NCT02332031|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006) & Levothyroxine|Sorafenib be administrated without and with levothyroxine orally
62022203|NCT00693992|EXPERIMENTAL|Arm I (sunitinib malate)|Patients receive sunitinib malate 37.5 mg PO once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62218217|NCT05534815|EXPERIMENTAL|Initiation Only group|Participants assigned to the Initiation Only group will be able to earn abstinence-contingent stipends for working with the employment specialist for up to 20 hours per week and performance stipends for engaging in job-seeking behaviors. When employed, those participants will be able to earn abstinence-contingent wage supplements for up to 40 hours worked (verified by pay stubs) in a community job. Participants can earn from both Therapeutic Workplace Work Hours and from wage supplements for working in a community job, however, participants will only be able to earn stipends and wage supplements for a maximum total of 40 hours.
62412243|NCT01513759|EXPERIMENTAL|EkoSonic® Endovascular System|Participants will receive a total of 24 milligrams (mg) of recombinant t-PA infusion, at an infusion rate of 1 milligrams/hour (mg/hr) per device (2 mg/hour for bilateral PE) delivered through the EkoSonic® Endovascular System. This regimen allows for a recombinant t-PA infusion time of 24 hours for one catheter and 12 hours for two catheters, respectively.
62794025|NCT05211206||Conservative hydration|Patients with less than 1 L of intravenous crystalloid fluids administered within the immediate pre-, peri- and post-procedural period
62412244|NCT01965015|EXPERIMENTAL|V-Wave shunt implant|Implantation of the V-Wave inter-atrial shunt
62022204|NCT00693992|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo 37.5 mg PO once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62412245|NCT05850260||Macintosh laryngoscope|During the pre-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations in the operation room according to the standard of care using the standard Macintosh direct laryngoscope as a first intubation option
62412246|NCT05850260||McGrath Mac videolaryngoscope|During the post-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations using their personal McGrath Mac videolaryngoscope as a first intubation option
62412247|NCT03976817||SA-AVR group|Patients who underwent the supra-annular aortic valve replacement (SA-AVR) technique in our institution between December 2010 and December 2017 were retrospectively reviewed.
62412248|NCT00888472|EXPERIMENTAL|1|
62412249|NCT04785027|OTHER|PSORI-CM01 group|"Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2×10 \^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.~PSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs."
62022205|NCT03564496|ACTIVE_COMPARATOR|Healthy Controls|Healthy Controls will be given approximately 15 minutes of active tDCS during MRI during the initial visit.
62586085|NCT03755414|EXPERIMENTAL|Pilot Study: Itacitinib|"* Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy~* Stem cell transplantation on Day 0~* Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently~* To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure."
62794026|NCT03920943|OTHER|Core and TAT measurements|As part of the standard of care, flight paramedics will insert an esophageal or rectal temperature probe in patients meeting including criteria to enable continuous temperature monitoring. Paramedics will measure core temperature on at least two occasions, the first measurements made at least 5 minutes after insertion of the temperature probe, and also prior to departure from the sending facility.
62022206|NCT03564496|EXPERIMENTAL|MS Patients|MS patients will be given approximately 15 minutes of active tDCS during MRI during the initial visit. After the first MRI visit, MS patients will receive remotely-supervised home tDCS treatment for a month to test the cumulative effects of tDCS. Participants will complete 20 x 2.0mA x 20 minute tDCS sessions paired with cognitive training over 4-week period (20 mins per day and weekend off) with electrodes placed to target the bilateral DLPFC. Around 3 months after the 20-session treatment, MS patients only will be asked to come to the clinic for neuropsychological assessments.
62022207|NCT03564496|ACTIVE_COMPARATOR|Healthy Control subgroup|The Healthy Control subgroup will be given approximately 15 minutes of active tDCS during MRI during the initial visit. Participants in the healthy control subgroup will be given the option to have an additional 15 minutes of brain imaging, which will include 10 minutes of simultaneous tDCS at up to 4.0mA, added to the end of their baseline scan. After the first MRI visit, HC subgroup patients will receive remotely-supervised home tDCS treatment for a month to test the cumulative effects of tDCS. Participants will complete 20 x 2.0mA x 20 minute tDCS sessions paired with cognitive training over 4-week period (20 mins per day and weekend off) with electrodes placed to target the bilateral DLPFC.
62022208|NCT04344067|NO_INTERVENTION|Control Group|
62022209|NCT04344067|EXPERIMENTAL|Far Infrared Therapy Group|In this study, the top radiator of the far infrared emitter was set at a height of 25 cm above the umbilicus with a treatment time of 40 minutes during the initial 1 hour of both the first daily and the last night-time indwelling dialysate of each daily regular peritoneal dialysis regimen.
62022210|NCT02067247|EXPERIMENTAL|SOS forearm test|BeamMed Speed-of-Sound bone strength test at forearm
62022211|NCT00112073|EXPERIMENTAL|0.15 mg/kg active bapineuzumab|
62022212|NCT00112073|PLACEBO_COMPARATOR|0.15 mg/kg placebo|
62412250|NCT04785027|EXPERIMENTAL|Gu Ben Hua Yu group|"Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2×10 \^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.~Gu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs."
62412251|NCT06105697|EXPERIMENTAL|Blood flow restriction (Experimental I)|Running with Blood Flow Restriction on the treadmill for 4 sets of 5 minutes,1' interset rest using a periodization methodology in soccer (Match Day 4 and Match Day 3).
62412252|NCT06105697|EXPERIMENTAL|Non-Blood flow restriction (Experimental II)|Running without Blood Flow Restriction on the treadmill for 4 sets of 5 minutes,1' interset rest using a periodization methodology in soccer (Match Day 4 and Match Day 3).
62794027|NCT05509426|EXPERIMENTAL|Intervention Group|This group will receive an online cognitive rehabilitation programme, offered in addition to usual clinical care, to groups of 4-6 participants weekly for 10 sessions.
62794028|NCT05509426|NO_INTERVENTION|Usual Clinical Care|This group will receive only their usual clinical care, which may include information on cognitive problems as per clinical practice but not specific cognitive rehabilitation.
62586086|NCT03755414|EXPERIMENTAL|Expansion Phase: Itacitinib|"* Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy~* Stem cell transplantation on Day 0~* Itacitinib 200 mg/day from Day -3 to Day 180. After Day 180, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 180, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 180, for patients on study drug hold, discontinue permanently~* To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure."
62586087|NCT06431841|EXPERIMENTAL|DIMS Lenses|Atropine 0,025% + DIMS Lenses
62586088|NCT06431841|ACTIVE_COMPARATOR|Monofocal Lenses|Atropine 0,025% + monofocal (single vision) Lenses
62586089|NCT02718989|EXPERIMENTAL|10 Kilohertz (KHz)|"Transcutaneous application of 10 Kilohertz (KHz) current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
62586090|NCT02718989|EXPERIMENTAL|Transcutaneous Electrical Stimulation|"Transcutaneous application of TENS current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are frequency 100 Hz and pulse width 100 microseconds"
62586091|NCT02718989|SHAM_COMPARATOR|Sham stimulation|Electrodes are placed over the back for a 40 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
62586092|NCT06084949|EXPERIMENTAL|Nordic walking group or inspiratory muscle training|In experimental group, investigator will coordinate with the patients with mild-to-moderate knee osteoarthritis to take the Nordic walking, while the patients with end-stage knee osteoarthritis to take inspiratory muscle training. All participants are required to maintain their daily activities and routine management.
62022213|NCT00112073|EXPERIMENTAL|0.5 mg/kg active bapineuzumab|
62022214|NCT00112073|PLACEBO_COMPARATOR|0.5 mg/kg placebo|
62022215|NCT00112073|EXPERIMENTAL|1.0 mg/kg active bapineuzumab|
62794029|NCT03654937|ACTIVE_COMPARATOR|2h|The participants were asked to report for their vaccination immediately after an intensive bout of training (not later than two hours after). The influenza vaccine was administered via intra-muscular injection into the deltoid muscle of the non-dominant arm in a standardized manner.
62022216|NCT00112073|PLACEBO_COMPARATOR|1.0 mg/kg placebo|
62022217|NCT00112073|EXPERIMENTAL|2.0 mg/kg active bapineuzumab|
62022218|NCT00112073|PLACEBO_COMPARATOR|2.0 mg/kg placebo|
62022219|NCT01281930|EXPERIMENTAL|Wick placement into abscess cavity|
62022220|NCT01281930|ACTIVE_COMPARATOR|Full packing of abscess cavity|
62022221|NCT01194674|EXPERIMENTAL|Microplasmin|
62022222|NCT00591292|EXPERIMENTAL|Single Arm|
62412253|NCT06412380|EXPERIMENTAL|Pain level|"After implant placement, all participants were requested to record their pain level using the 10-cm visual analog scale (VAS) ranging from 0 no pain to 10 worst pain ever. The scale had no other markings along the line. Patients were asked to record their pain level after surgery, 24 hours after surgery, at day 2, day 4 and at week 1, week 2, and week 3."
62586093|NCT06084949|NO_INTERVENTION|Control group|In control group, participants are required to maintain their daily activities and routine management.
62794030|NCT03654937|ACTIVE_COMPARATOR|26h|The athletes of the second group were vaccinated after an entire day (between 24 and 26 hours) after their last training session.The vaccine was administered via intra-muscular injection into the deltoid muscle of the non-dominant arm in a standardized manner.
62794031|NCT00924248||Group 1|
62794032|NCT01789437|ACTIVE_COMPARATOR|Dexamethasone Intravitreal Implant|
62819396|NCT02187848|EXPERIMENTAL|SAR408701 Main Dose Escalation Cohort|Dose escalation administered intravenously, once every two weeks
62412254|NCT06412380|EXPERIMENTAL|Implant torque|Implants were classified into 4 groups based on the IT value; Low: 58 implants (10-29 Ncm); Regular: 95 implants (30-50 Ncm); High: 46 implants (51-100 Ncm); and Very High: 31 implants (101-180 Ncm).
62218218|NCT05534815|EXPERIMENTAL|Initiation and Maintenance group|"The Initiation and Maintenance group procedures will receive the same intervention as the Initiation Only participants for 24 weeks (during the Initiation period). Then, Initiation and Maintenance participants will receive a low-magnitude incentive intervention for 24 weeks (the Maintenance period, weeks 25-48) to maintain drug abstinence and employment. The low-magnitude incentive intervention will be identical to the final weeks of the high magnitude incentive intervention, with two important exceptions.~1. During the low-magnitude intervention, participants will receive money per hour for maintaining drug abstinence and work (stipends for working with the employment specialist and wage supplements for providing pay stubs).~2. During weeks 25-48, if a participant in the Initiation and Maintenance group provides a drug-positive urine sample or misses a required mandatory sample, the participant will not receive any incentive."
62218219|NCT05564728||Intervention|All participants will receive a conversational agent app, Well Feet, to support them in learning foot care self-management.
62794033|NCT03592368|ACTIVE_COMPARATOR|Active IBT, Out of MRI|Interpretation bias training where participants learn more positive judgements of ambiguous facial expressions relative to their own baseline bias. This arm is completed in the clinic.
62794034|NCT03592368|SHAM_COMPARATOR|Sham IBT, Out of MRI|Interpretation bias training where participants' baseline judgements of ambiguous facial expressions is reinforced. This arm is completed in the clinic.
62218220|NCT06188429||Experimental Group|Children with ASD
62794035|NCT03592368|ACTIVE_COMPARATOR|Active IBT, In MRI|Interpretation bias training where participants learn more positive judgements of ambiguous facial expressions relative to their own baseline judgments. This arm is completed in a magnetic resonance imaging machine.
62794036|NCT03592368|SHAM_COMPARATOR|Sham IBT, In MRI|Interpretation bias training where participants' baseline judgements of ambiguous facial expressions is reinforced. This arm is completed in a magnetic resonance imaging machine.
62794037|NCT00713544|ACTIVE_COMPARATOR|1|
62412255|NCT06540807|EXPERIMENTAL|Colovac|The Colovac device will be implanted for approximately 10 days.
62412256|NCT01819467|ACTIVE_COMPARATOR|Treatment Group|Patients in this group will receive Seprafilm onto the uterine incision and the anterior midline of the uterus.
62794038|NCT00713544|EXPERIMENTAL|2|20mg
62412257|NCT01819467|NO_INTERVENTION|Control Group|This arm will be known as the control/no intervention group. This group will not receive Seprafilm or any other adhesion barrier method
62412258|NCT02587117|EXPERIMENTAL|lycopene group|Lycopene- 4 mg capsule by mouth single dose per day for 2 months
62794039|NCT00713544|EXPERIMENTAL|3|50mg
62022223|NCT04346758|OTHER|Modified Shamrock approach|Patients undergoing orthopedic procedures of the lower extremeties are going to be studied. A modified Shamrock approach of the lumbar plexus is going to be used for postoperative analgesia, using an ultrasound-guided technique combined to a nerve stimulatior. The technique is going to be assessed as for accuracy, and safety.
62218221|NCT06188429||Control Group|Normal Children
62412259|NCT02587117|ACTIVE_COMPARATOR|Prednisolone group|Prednisolone- 40 mg capsule by mouth single dose per day for 2 months
62794040|NCT00713544|EXPERIMENTAL|4|100mg
62794041|NCT00713544|EXPERIMENTAL|5|150mg
62794042|NCT00713544|PLACEBO_COMPARATOR|6|
62794043|NCT05546476|EXPERIMENTAL|Double-Blind ponsegromab Treatment low dose followed by Open Label ponsegromab Treatment|ponsegromab low dose subcutaneous injection every 4 weeks
62794044|NCT05546476|PLACEBO_COMPARATOR|Double-Blind Placebo Treatment followed by Open-Label ponsegromab Treatment|Match placebo subcutaneous injection every 4 weeks
62794045|NCT05546476|EXPERIMENTAL|Double-Blind ponsegromab Treatment medium dose followed by Open Label ponsegromab Treatment|ponsegromab medium dose subcutaneous injection every 4 weeks
62794046|NCT05546476|EXPERIMENTAL|Double-Blind ponsegromab Treatment high dose followed by Open Label ponsegromab Treatment|ponsegromab high dose subcutaneous injection every 4 weeks
62794047|NCT02398604|EXPERIMENTAL|Group A - Allo-hMSCs|Group A: Fifteen (20) patients will be treated with Allogenic human mesenchymal stem cells (Allo-hMSCs): A concentration of 5 million cells/ml delivered in a dose of 2.5 x 10\^5 cells per kg of recipient (5 million/20kg) Allo-hMSCs. The entire dose of the cells will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.
62412260|NCT04024254|EXPERIMENTAL|Folic Acid|Folic Acid supplement 1 mg by mouth daily
62412261|NCT04024254|NO_INTERVENTION|No Supplementation|
62412262|NCT06651398|EXPERIMENTAL|Lenient diet|This group can have a less stringent diet compared to the current standard of care and eat a light meal until 18h before drinking the first dose of the bowel preparation on the day before the colonoscopy
62412263|NCT06651398|NO_INTERVENTION|Control group|This group follows the strict diet similar to what is currently used in standard of care.
62412264|NCT05063149|ACTIVE_COMPARATOR|Broncho-Vaxom treatment|"Infants in this arm will be given 3,5mg bacterial lysate (OM-85) 10 days per month from 6 weeks after birth until 12 months of age.~At age 12 months they will be (if informed consent for Protea-2 is provided) randomised over Broncho-Vaxom treatment and placebo again."
62794048|NCT02398604|PLACEBO_COMPARATOR|Group B|Group B: Fifteen (10) patients will be treated with a placebo comparator. The placebo will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.
62794049|NCT02737475|EXPERIMENTAL|Part 1: Dose Escalation|"* BMS-986178 at specified doses at specified intervals~* Enrollment is closed for this arm"
62794050|NCT02737475|EXPERIMENTAL|Part 2: Dose Escalation and Expansion|"* BMS-986178 in combination with Nivolumab at specified doses at specified intervals~* Enrollment is closed for this arm"
62794051|NCT02737475|EXPERIMENTAL|Part 3: Dose Escalation and Expansion|"* BMS-986178 in combination with Ipilimumab at specified doses at specified intervals~* Enrollment is closed for this arm"
62794052|NCT02737475|EXPERIMENTAL|Part 4: Dose Schedule and Exploration|"* BMS-986178/Nivolumab at specified doses at specified intervals~* Enrollment is closed for this arm"
62794053|NCT02737475|EXPERIMENTAL|Part 5: Dose Schedule and Exploration|"* BMS-986178/Ipilimumab at specified doses at specified intervals~* Enrollment is closed for this arm"
62218222|NCT05991284|ACTIVE_COMPARATOR|Intervention arm|Sacubitril-Valsartan (target dose 97/103 mg twice daily) on top of standard of care (including SGLT-2 inhibitor and MRA)
62218223|NCT05991284|PLACEBO_COMPARATOR|Control arm|Standard of care (including SGLT-2 inhibitor and MRA)
62218224|NCT01085968|EXPERIMENTAL|PD Subjects|PD subjects who undergo to PC-based neurorehabilitation intervention. This intervention will train research subjects to improve movement initiation in response to visual stimuli.
62794054|NCT02737475|EXPERIMENTAL|Part 6: Dose Safety and Expansion|"* BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals~* Enrollment is closed for this arm"
62412265|NCT05063149|PLACEBO_COMPARATOR|Placebo|Infants in this arm will be given a placebo powder from a capsule that will be indistinguishable from the active study drug.
62412266|NCT01582074||Cases|women with breast cancer
62586094|NCT03356080|EXPERIMENTAL|DLAAG|"All patients receive 1-2 cycles of induction chemotherapy,that is DLAAG,which is expected to be 6 weeks/cycle,including decitabine,cytarabine, all-transretinoic acid,and Granulocyte Colony-Stimulating Factor(G-CSF).~patients with CR after the first course of induction therapy (DLAAG) will continue to receive 1 cycle of consolidation therapy, while those with therapy failure will continue the second course of induction therapy. If CR is not achieved, quit the study.~Patients who achieve CR after induction therapy will be in accordance with the guidelines, such as the proposed active treatment of allogeneic hematopoietic stem cell transplantation"
62586095|NCT06289478|EXPERIMENTAL|Retrograde Intraarticular Injection via Drain Tube|Tranexamic acid will be injected retrograde to the joint via drain tube after surgical wound closure
62794055|NCT02737475|EXPERIMENTAL|Part 7: Dose Safety and Expansion|"* BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals~* Enrollment is closed for this arm"
62794056|NCT02737475|EXPERIMENTAL|Part 8: Dose Exploration|"* BMS-986178/Nivolumab with tetanus vaccine at specified doses and interval~* Enrollment is closed for this arm"
62794057|NCT02737475|EXPERIMENTAL|Part 9: Dose Exploration|"* BMS-986178/Nivolumab/DPV-001 vaccine/cyclophosphamide (cohort 1) at specified doses at specified intervals OR Nivolumab/DPV-001 vaccine/cyclophosphamide (cohort 2) at specified doses at specified intervals~* Enrollment is open for this arm \[Tumor type triple negative breast cancer (TNBC)\]"
62794058|NCT02643238|EXPERIMENTAL|Group A - Blind|Subjects will be trained to ambulate through a 40-foot obstacle course by the occupational therapy colleagues at Akron Children's Hospital after which they will be scored on their performance while using the BrainPort® system.
62794059|NCT02643238|ACTIVE_COMPARATOR|Group C - Control|Subjects will be trained to ambulate through a 40-foot obstacle course by the occupational therapy colleagues at Akron Children's Hospital after which they will be scored on their performance while using the BrainPort® system.
62794060|NCT00991939|EXPERIMENTAL|High dose pulse dexamethasone|
62794061|NCT00991939|ACTIVE_COMPARATOR|Standard prednisone therapy|
62586096|NCT06289478|EXPERIMENTAL|Topical Soaking of Tranexamic Acid|Tranexamic acid will be placed to soak the intramedullary canal of the femur and surgical area after sheath closure for 5 minutes and completely remove by sunction
62022224|NCT05093517|EXPERIMENTAL|Glucagon Receptor Agonist (GRA) REMD-477 group|Participants are assigned to a 12 week treatment of REMD-477
62022225|NCT05093517|PLACEBO_COMPARATOR|Placebo group|Participants are assigned to a 12 week course of placebo for REMD-477
62218225|NCT01085968|ACTIVE_COMPARATOR|Control Subjects|Age matched controls who undergo to PC-based neurorehabilitation intervention. This intervention will train research subjects to improve movement initiation in response to visual stimuli.
62412267|NCT01582074||Controls|Matched women without breast cancer
62412268|NCT05021315|EXPERIMENTAL|Iodine group|50 women who received preoperative vaginal cleansing with 10% povidone-iodine.
62412269|NCT05021315|NO_INTERVENTION|Control group|50 women who did not receive preoperative vaginal cleansing even with tap water.
62412270|NCT03162120|ACTIVE_COMPARATOR|Ranolazine plus Metoprolol Combination|Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
62586097|NCT06289478|PLACEBO_COMPARATOR|Standard procedure (placebo)|Standard wound irrigation
62586098|NCT05173831|EXPERIMENTAL|Two Sessions of MDMA-assisted therapy|Two MDMA-assisted Therapy Sessions with 120 mg midomafetamine HCl and optional supplemental dose of 60 mg 1.5 to 2 hours later
62586099|NCT05535075|ACTIVE_COMPARATOR|Standard of Care Vancomycin treatment|Vancomycin standard-of-care dosing and therapeutic drug monitoring (TDM), according to institutional guidelines during 20 day study period
62586100|NCT05535075|EXPERIMENTAL|Vancomycin model-informed precision dosing|Area Under the Concentration-time curve ((AUC)/Minimal Inhibitory Concentration (MIC)-based model-informed precision dosing of vancomycin using a dosing calculator during 20 day study period
62794062|NCT04279535|EXPERIMENTAL|ascorbic acid|Participants applied topical solution of ascorbic acid twice daily for 8 weeks
62794063|NCT04279535|ACTIVE_COMPARATOR|Imiquimod|Participants applied 5% imiquimod cream topically 5x/week
62819397|NCT02187848|EXPERIMENTAL|SAR408701 Expansion Cohort colorectal cancer (CRC)|Administered intravenously at the maximum tolerated dose (MTD), once every 2 weeks, to patients with colorectal cancer
62819398|NCT02187848|EXPERIMENTAL|SAR408701 Expansion Cohort non-squamous NSCLC|Administered intravenously at the MTD, once every 2 weeks, to patients with carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expressing non-squamous non-small cell lung cancer (NSCLC) of at least 50% of tumor cells at or above 2+ intensity
62412271|NCT03162120|ACTIVE_COMPARATOR|FlecainidE pluS Metoprolol Combination|FlecainidE pluS Metoprolol Combination in in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
62412272|NCT01302639|EXPERIMENTAL|EGCG and resveratrol|
62412273|NCT01302639|EXPERIMENTAL|EGCG, resveratrol and genistein|
62412274|NCT01302639|PLACEBO_COMPARATOR|placebo|
62412275|NCT05927532|EXPERIMENTAL|Argyle Fistula Cannula Subjects|All subjects enrolled in the study and treated with the Argyle Safety Fistula Cannula with Anti-reflux Valve
62412276|NCT05451849|EXPERIMENTAL|Lymphodepletion followed by TC-510|Lymphodepletion (fludarabine and cyclophosphamide) followed by TC-510 T cells
62412277|NCT03840031|EXPERIMENTAL|Orange Fleshed Sweet Potato High Iron|Meal sequence B, OFSP High Fe
62412278|NCT03840031|ACTIVE_COMPARATOR|Orange Fleshed Sweet Potato Control|Meal sequence A, OFSP control
62022226|NCT03961594|OTHER|volume expansion in the ventilated patient|Including 51 patients, ventilated, under vasopressors suffering from septic shock. GLS, cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders. Patients with a 15% increase in cardiac output 20minutes after the end of volume expansion will be classified as persistent responders.
62218226|NCT05998161|EXPERIMENTAL|reviga + TAU|"Participants allocated to the intervention group will receive access to reviga in addition to treatment as usual (TAU).~reviga is a digital health application designed for individuals with stress and burnout, accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT). Topics addressed by reviga are relaxation, psychoeducation and exercises regarding relevant cognitions and behavior, acceptance, relationships, problem solving strategies, and positive psychology.~The program operates through interactive dialogues, which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days."
62218227|NCT05998161|NO_INTERVENTION|TAU|Participants allocated to the control group will receive access to treatment as usual (TAU).
62412279|NCT02435615|EXPERIMENTAL|Study group|There is one group of patients which are those presenting to the hospital with suspected clinical case of dengue fever for diagnosis. This group will have oral fluid collected via the SaniSal oral fluid collector and a pipette, and blood collected via venipuncture.
62412280|NCT01527942|EXPERIMENTAL|Arm 1 - Active Drug|Preoperative administration of 1,000 mg IV Acetaminophen will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
62412281|NCT01527942|PLACEBO_COMPARATOR|Arm 2 - Placebo|Preoperative IV Placebo (0.9 Sodium Chloride 100 ml) will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
62412282|NCT01905813|EXPERIMENTAL|INCB040093|
62412283|NCT01905813|EXPERIMENTAL|INCB040093 in combination with itacitinib (INCB039110)|
62412284|NCT01734421|OTHER|Control group|Habitual deshabituation in the control group following the guidelines of the primary health care institution.
62412285|NCT01734421|ACTIVE_COMPARATOR|Cell phone Aplication for Smarth Phone|Cell phone 6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation which includes mobile APPs application
62412286|NCT06703177|EXPERIMENTAL|Single group|
62412287|NCT06530706|EXPERIMENTAL|Experiment group|Esketamine 0.2mg/kg was given slowly after intubation, and then 0.1mg/kg/h was pumped continuously until the end of the operation. Patients received sufentanil based patient-controlled intravenous analgesia (PCIA) within 72 hours postoperatively, with sufentanil combined with esketamine 1mg/kg in a PCIA device.
62412288|NCT06530706|PLACEBO_COMPARATOR|Control group|Same volume of normal saline was given slowly after intubation, and then pumped continuously until the end of the operation. Patients received sufentanil based patient-controlled intravenous analgesia (PCIA) within 72 hours postoperatively, without esketamine in the PCIA device.
62586101|NCT04164108|EXPERIMENTAL|Intermittent feed participants|Patients admitted to medical ICU #1 (of 2 at our hospital) will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
62586102|NCT04164108|NO_INTERVENTION|Control participants|Patients admitted to the medical ICU #2 (of 2 at our hospital) will receive usual care.
62586103|NCT02156297||Induction Group|
62586104|NCT02156297||Consolidation Group|
62412289|NCT02845037|EXPERIMENTAL|2 mg or placebo|BIA 5-453 or placebo
62412290|NCT02845037|EXPERIMENTAL|10 mg or placebo|BIA 5-453 or placebo
62022227|NCT06576063|EXPERIMENTAL|Study group|Standard oral hygiene methods and adjuvant use of Lumoral Treatment device
62218228|NCT00817973|ACTIVE_COMPARATOR|Casein|
62218229|NCT00817973|ACTIVE_COMPARATOR|Whey|
62218230|NCT00817973|ACTIVE_COMPARATOR|Cod|
62218231|NCT00817973|ACTIVE_COMPARATOR|Gluten|
62218232|NCT06268080|EXPERIMENTAL|Light general anesthesia|Bispectral Index (BIS) of 55
62218233|NCT06268080|ACTIVE_COMPARATOR|Deep general anesthesia|Bispectral Index (BIS) of 40
62412291|NCT02845037|EXPERIMENTAL|20 mg or placebo|BIA 5-453 or placebo
62412292|NCT02845037|EXPERIMENTAL|50 mg or placebo|BIA 5-453 or placebo
62412293|NCT02845037|EXPERIMENTAL|100 mg or placebo|BIA 5-453 or placebo
62412294|NCT02845037|EXPERIMENTAL|200 mg or placebo|BIA 5-453 or placebo
62412295|NCT02845037|EXPERIMENTAL|400 mg or placebo|BIA 5-453 or placebo
62412296|NCT02845037|EXPERIMENTAL|600 mg or placebo|BIA 5-453 or placebo
62412297|NCT02845037|EXPERIMENTAL|900 mg or placebo|BIA 5-453 or placebo
62412298|NCT02845037|EXPERIMENTAL|1200 mg or placebo|BIA 5-453 or placebo
62586105|NCT02156297||Salvage Group|
62586106|NCT02156297||Maintenance Group|
62412299|NCT06652945|EXPERIMENTAL|Symptomatic uterine adenomyosis|Patients with symptomatic uterine adenomyosis
62586107|NCT02156297||Alleviatitive Group|
62586108|NCT04563741|EXPERIMENTAL|MOVE!+UP (intervention)|usual care enhanced with MOVE!+UP (intervention)
62586109|NCT04563741|ACTIVE_COMPARATOR|MOVE! (control condition)|usual care enhanced with MOVE! (control condition)
62586110|NCT02195622|OTHER|Lumenis VersaCut Morcellator|Lumenis VersaCut Morcellator will be utilized for prostate tissue morcellation
62586111|NCT02195622|OTHER|Wolf Piranha Morcellator|Wolf Piranha Morcellator will be utilized for prostate tissue morcellation
62586112|NCT03910452|EXPERIMENTAL|1|This is a single arm open-label pilot study.
62586113|NCT03871205|EXPERIMENTAL|Vaccinated group|Neoantigen loaded-DC vaccination will be performed with 6 doses in total, once per week, adjacent lymph-node injection.
62218234|NCT05220709|OTHER|Bio impedance spectroscopy in children scheduled for elective surgery under general anesthesia|All subjects receive bio impedance monitor measurements pre operatively and post operatively.
62022228|NCT06576063|ACTIVE_COMPARATOR|Control group|Standard oral hygiene methods
62412300|NCT03501017|EXPERIMENTAL|Intervention group|The 12-week physical activity program was implemented under the guidance of nurse, in outdoors with the group, 5 days a week with warm up and cooling down for 10 minutes and normal walking tempo at a moderate pace for 30-45 minutes (3-6 km/hour).
62412301|NCT03501017|ACTIVE_COMPARATOR|Control Group|As routine practice, a brochure provided from the Public Health Directorate on protection from CVD was delivered to the individuals in the control group.
62412302|NCT01826032|EXPERIMENTAL|CPAP|"Patients with CPAP treatment. Titration will be performed by polysomnography or automatic CPAP to determine the optimal treatment pressure.~This group will also be instructed in hygienic-dietary measures and sleep hygiene counselling."
62412303|NCT01826032|ACTIVE_COMPARATOR|Standard care for OSA|Sleep hygiene ( regular sleep schedule, avoid sedative drugs, alcohol and tobacco, physical exercise) and dietary counselling
62412304|NCT02105207|EXPERIMENTAL|Lung Ultrasound|In Patients allocated to this arm Lung ultrasound for detection of interstitial syndrome will be performed before chest radiography.
62412305|NCT02105207|EXPERIMENTAL|Chest Radiography|In Patients allocated to this arm chest radiography will be performed for the detection of indirect signs of pulmonary congestion/ADHF without ultrasound evaluation.
62412306|NCT03003793||Control group|Healthy control subjects
62022229|NCT02391402|EXPERIMENTAL|CABA|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
62218235|NCT04227704|PLACEBO_COMPARATOR|Control|Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection and 40-minute intravenous infusion of 0.9% sodium chloride.
62218236|NCT04227704|EXPERIMENTAL|Ketamine SC|Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection of 0.5 mg/kg of ketamine and a 40-minute intravenous infusion of 0.9% sodium chloride.
62218237|NCT04227704|EXPERIMENTAL|Ketamine IVI|Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection of 0.9% sodium chloride and a 40-minute intravenous infusion of 0.5 mg/kg ketamine.
62412307|NCT03003793||Atopic dermatitis/eczema group|Patients with atopic dermatitis
62412308|NCT04177472|EXPERIMENTAL|Obesity Prevention Group|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options.
62412309|NCT04177472|ACTIVE_COMPARATOR|Infant Safety and Injury Prevention Group|Parents will be provided with information about safe sleeping, car seats, baby-proofing, etc., delivered during virtual visits, participant binder and newsletter.
62433266|NCT01440478|EXPERIMENTAL|LY2140023 + sodium bicarbonate|4 g of sodium bicarbonate administered orally every 4 hours for 32 hours (totaling 9 doses) in combination with a single 80 mg dose of LY2140023 administered orally 18 hours after first dose of sodium bicarbonate (alkalized urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
62022230|NCT02391402|PLACEBO_COMPARATOR|TAU|"Treatment as Usual (TAU) is the usual care that patients would normally receive at the VA. TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
62022231|NCT01028209|EXPERIMENTAL|Assess [18F] PBR06 and PET imaging|
62022232|NCT02362880|ACTIVE_COMPARATOR|mutation carrier|
62433267|NCT01440478|EXPERIMENTAL|LY2140023|A single 80 mg dose of LY2140023 administered orally (normal urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
62022233|NCT02362880|SHAM_COMPARATOR|mutation non-carrier|
62022234|NCT03443466|EXPERIMENTAL|Epidural electrical stimulation (EES)|n=20
62022235|NCT03443466|ACTIVE_COMPARATOR|Loss of resistance (LOR)|n=20
62022236|NCT05266690|EXPERIMENTAL|Sequence 1|Roquette Glucidex 40 - Roquette Glucidex 2 - Pharmacosmos Dextran 10 - Promitor 70
62022237|NCT05266690|EXPERIMENTAL|Sequence 2|Roquette Glucidex 2 - Promitor 70 - Roquette Glucidex 40 - Pharmacosmos Dextran 10
62022238|NCT05266690|EXPERIMENTAL|Sequence 3|Promitor 70 - Pharmacosmos Dextran 10 - Roquette Glucidex 2 - Roquette Glucidex 40
62022239|NCT05266690|EXPERIMENTAL|Sequence 4|Pharmacosmos Dextran 10 - Roquette Glucidex 40 - Promitor 70 - Roquette Glucidex 2
62022240|NCT05216172|EXPERIMENTAL|AZD1656|AZD1656 100mg BD for 3 months
62218238|NCT01767480|EXPERIMENTAL|Higher-intensity RT group|All participants received a duration-matched intervention for 90-120 minutes/day, 5 days/week for 4 consecutive weeks. For the RT groups, they will receive RT training together with functional rehabilitation trainings. Within 1 training session, each patient in the higher-intensity RT group will use Bi-Manual-Tract to practice 400-600 repetitions of the mode 1 and 800-1000 repetitions of mode 2, totaling 1200-1600 repetitions, respectively for the forearm and the wrist movements. In addition, the patients will practice 100-200 repetitions in mode 3, if application.
62218239|NCT01767480|EXPERIMENTAL|Lower-intensity RT group|Patients in the lower-intensity RT received half the number of the repetitions per unit of time than patients in the higher-intensity RT group. Within 1 training session, patients in the lower-intensity RT group will practice 200-300 repetitions of the mode 1 and 400-500 repetitions of mode 2, totaling 600-800 repetitions, respectively for the forearm and the wrist movements. In addition, the patients will practice 50-100 repetitions in mode 3, if application.
62412310|NCT04177472|EXPERIMENTAL|Obesity Prevention Group + Food Boxes|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options. Parents will also be provided with grocery items (fruits, vegetables, meat) prior to each intervention visit to facilitate a healthy family diet.
62412311|NCT01683331|ACTIVE_COMPARATOR|Insulin treatment for hyperglycemia|Neutral Protamine Hagedorn (NPH) Insulin Titration Regimen, based on pre-dinner capillary blood glucose measurements (CPG) expressed in mg/dl; All NPH initiation doses and dose adjustments are presented in IU/day For pts. with CPG \> 240, NPH initiation: 14, dose increases by 4; For pts. with CPG \> 180 mg/dl, NPH initiation: 12, dose increases by 4; For pts. with CPG \> 140 mg/dl, NPH initiation: 10, dose increases by 4; For pts. with CPG \> 120 mg/dl, NPH initiation: 0, dose increases by 2; For pts. with CPG 100-119 mg/dl, NPH initiation: 0, maintain dose; For pts. with CPG 80-\<100 mg/dl, NPH initiation: 0, dose decrease by 4; For pts. with CPG 60-\<80 mg/dl, NPH initiation: 0, decrease by 8; For pts. with CPG \<60 mg/dl, NPH initiation: 0, ½ of previous dose.
62412312|NCT01683331|NO_INTERVENTION|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation.
62412313|NCT05859893|NO_INTERVENTION|No Intervention: Control|
62586114|NCT01421186|EXPERIMENTAL|Phase 1 dose escalation|"Part A: MOR03087 dose escalation; biweekly treatment~Part B: MOR03087 dose escalation; weekly treatment~Part C: MOR03087 dose escalation (weekly treatment) + dexamethasone~Part D: MOR03087 weekly treatment in combination with pomalidomide + dexamethasone~Part E: MOR03087 weekly treatment in combination with lenalidomide + dexamethasone~For all parts, patients will be treated until disease progression (PD) or until a maximum of 3 years after first treatment."
62586115|NCT01421186|EXPERIMENTAL|Phase 2a confirmatory cohorts|"Confirmatory cohorts of MOR03087 monotherapy (plus or minus dexamethasone), in combination with pomalidomide plus dexamethasone, and in combination with lenalidomide plus dexamethasone.~Following completion of Parts A, B, and C (dose escalation of MOR03087 biweekly and weekly schedules), the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen will be confirmed in a minimum of 6 subjects.~Following completion of Parts D (dose escalation of MOR03087 in combination with pomalidomide + dexamethasone) and E (dose escalation of MOR03087 in combination with lenalidomide + dexamethasone), the MTD and/or recommended dose in each part will be confirmed in a minimum of 6 subjects.~For all parts, patients will be treated until PD or until a maximum of 3 years after first treatment."
62819399|NCT02187848|EXPERIMENTAL|SAR408701 Expansion Cohort gastric adenocarcinoma|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing gastric adenocarcinoma
62022241|NCT05216172|PLACEBO_COMPARATOR|placebo|placebo 100mg BD for 3 months
62218240|NCT01767480|ACTIVE_COMPARATOR|Conventional rehabilitation (CR) group|The CR group will be designed to control for the duration of therapeutic activities. CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
62218241|NCT03661762||Healthy Volunteers|All trial participants are within this group. All trial participants will wear the CAVA device for up to 23 hours a day, for 30 days.
62022242|NCT00884481||Natalizumab|Participants with MS treated with Tysabri over 12 months
62022243|NCT00965523|EXPERIMENTAL|Eribulin Mesylate|
62022244|NCT04857359|EXPERIMENTAL|Dipraglurant TID|
62022245|NCT04857359|PLACEBO_COMPARATOR|Placebo TID|
62022246|NCT02800707|ACTIVE_COMPARATOR|Sucralose|Participants will be asked to consume 180 mg/day of sucralose (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 340 mg/day of sucralose (or 5.5 12-oz cans of sucralose-sweetened diet soda).
62022247|NCT02800707|ACTIVE_COMPARATOR|Stevia|Participants will be asked to consume 180 mg/day of stevia (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 800 mg/day of stevia (or about 12 cans of stevia-sweetened diet soda).
62022248|NCT01365000|EXPERIMENTAL|NKTR118 Formulation 1|Fasted
62022249|NCT01365000|EXPERIMENTAL|NKTR118 Formulation 2|Fasted
62022250|NCT01365000|EXPERIMENTAL|NKTR118 Formulation 3|Fasted
62022251|NCT01365000|EXPERIMENTAL|NKTR118 Formulation 1a|Fed
62022252|NCT01365000|EXPERIMENTAL|NKTR118 Formulation 3a|FED
62586116|NCT02064192||ICD Group (n=1500)|First ICD device implantation (after baseline assessments) is not part of this observational study and is carried out in the responsibility of the treating physician, all ICD-devices will undergo unique standard programming to ensure comparability of ICD shock events between patients.
62586117|NCT02064192||Control Group (n=750)|Patients who fulfill inclusion criteria but do not receive an ICD device will be followed as part of the Control Group
62022253|NCT06272734|EXPERIMENTAL|Reprieve System|Subjects will receive personalized and optimized diuretic and saline infusion using the study device during the course of the treatment.
62022254|NCT05511987|ACTIVE_COMPARATOR|Madela THOPAZ Suction Pump|Digital chest tube drainage systems utilize sensors to objectively quantify the size of air leaks as well as adjust the amount of suction applied to the pleural cavity in order to maintain a constant negative pressure(4). Studies in the adult population have showed that using a digital system allows for objective criteria regarding when it is safe to remove the chest tube and thus decreased time of chest tube drainage. This has also translated into decreased length of stay and cost(2, 6-8). Early data suggests that these same benefits may apply to pediatric patients, however a prospective randomized trial comparing the two systems has not been performed(9, 10).
62218242|NCT06124469||Benign lymph nodes|Categories UNN-RADS 1 and 2 (test negative)
62022255|NCT05511987|ACTIVE_COMPARATOR|Atrium Dry Suction Control Water Seal Chest Drain|there are several limitations to this analog system. First, although the system can manually be set to a certain negative pressure, the actual pressure experienced by the patient varies dependent on the amount of fluid in the tube and the level of the device relative to the patient(2). This leads to inconsistency of pleural pressure which has been associated with an increased incidence of prolonged air leak(2). Second, the analog system relies on a water chamber where bubbles are visualized to indicate an air leak. Air leaks are a common cause of increased duration of chest tube drainage and subsequent length of stay(3). There is high interobserver variability in the subjective measurement of air leaks when using the analog system thus exacerbating the amount of time the chest tube remains in the patient as well as the length of stay(4, 5).
62022256|NCT02824276|EXPERIMENTAL|Oral Opioid Medication|The primary study medication will be oxycodone, with morphine sulfate immediate release (MSIR) as a backup in case of side effects
62022257|NCT02824276|PLACEBO_COMPARATOR|Placebo Treatment|Placebo medications will be encapsulated in an opaque blinding capsule to ensure adequate blinding of study medications
62022258|NCT05413876||Men with classical Fabry disease|
62022259|NCT05413876||Women with classical Fabry disease|
62218243|NCT06124469||Metastatic lymph nodes|Categories UNN-RADS 3, 4, and 5 (test positive).
62218244|NCT06611228|EXPERIMENTAL|Intervention Group|"The interventions include:~* Physical Exercise: Tailored sessions with the VIVIFRAIL exercise protocol, monitored with accelerometers, and supported by a physical activity kit.~* Nutrition: Mediterranean diet with education on nutrient balance and avoiding ultra-processed foods.~* Health \& Sleep: Promotion of healthy habits, fall prevention, sleep hygiene, and targeted sleep disorder treatments.~* Polypharmacotherapy: Review and adjustment of medications as needed.~* Cognition: Cognitive rehabilitation using technology and educational videos.~* Environment: Adjustments to create an older-friendly Acute Unit, including modified routines and extended visiting hours."
62218245|NCT06611228|NO_INTERVENTION|Control Group|Centers randomized to the control group will follow usual care protocols. However, all participants in this group will receive standardized leaflets at discharge, providing physical, nutritional, and behavioral advice.
62218246|NCT01566253|EXPERIMENTAL|PCOA|The PCOA arm receiving oral self administered multimodal analgesic protocol (paracetamol, ketoprofen, morphine) by oral use.
62218247|NCT01566253|ACTIVE_COMPARATOR|Standard/ IV|The standard/IV arm will be received the analgesic treatment by intravenous use, administered by nursing staff.
62586118|NCT01581242|EXPERIMENTAL|A|
62586119|NCT01581242|EXPERIMENTAL|B|
62819400|NCT02187848|EXPERIMENTAL|SAR408701 Loading Dose Escalation cohorts (Escalation bis)|Loading dose escalation administered intravenously at first cycle, followed by MTD, once every 2 weeks
62022260|NCT05413876||Men with non-classical Fabry disease|
62022261|NCT05413876||Healthy controls|Age-, Sex-, BMI-matched controls
62022262|NCT02009176|EXPERIMENTAL|Laparoscop Anatomical Hepatectomy|Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy when necessary. The intraoperative ultrasound, hepatic segmental staining were used selectively.
62218248|NCT05408832|EXPERIMENTAL|Personalized Trial ABCCBA|Participants in Arm 1 will receive a Personalized Trial of the 3 stress management interventions in an ABCCBA treatment order, where A=mindfulness meditation, B=yoga, and C=brisk walking. Participants in this arm will be prompted to complete 30-minute stress management sessions during applicable treatment weeks. A link to the stress management video will be delivered via text 3 times per week to the participant during applicable intervention periods in the personalized trial arms. Participants will be limited to three views of study-provided stress management content each week.
62586120|NCT01581242|EXPERIMENTAL|C|
62819401|NCT02187848|EXPERIMENTAL|SAR408701 Expansion Cohort non-squamous NSCLC (Lung bis)|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing non-squamous NSCLC of at least 1% but below 50% of tumor cells at or above 2+ intensity
62819402|NCT02187848|EXPERIMENTAL|SAR408701 Expansion Cohort colorectal cancer (CRC-L)|Loading dose of determined MTD-L administered intravenously at first cycle, followed by MTD, once every 2 weeks
62022263|NCT02009176|ACTIVE_COMPARATOR|Laparoscope Aon-anatomical Hepatectomy|Total laparoscopic aon-anatomical hepatectomy were performed, combined with cholecystectomy when necessary. The intraoperative ultrasound or hepatic segmental staining will be used to ensure the tumour was completely resected.
62022264|NCT06063629|EXPERIMENTAL|Subcutaneous drain|The drain will be inserted into subcutaneous layer of the surgical wound. Redivac drain will be used in this study.
62022265|NCT06063629|OTHER|No drain|No drain will be inserted into the surgical wound in this arm.
62819403|NCT02187848|EXPERIMENTAL|SAR408701 Expansion Cohort small cell lung cancer (SCLC)|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing SCLC
62218249|NCT05408832|EXPERIMENTAL|Personalized Trial CBAABC|Participants in Arm 2 will receive a Personalized Trial of the 3 stress management interventions in a CBAABC treatment order, where A=mindfulness meditation, B=yoga, and C=brisk walking. Participants in this arm will be prompted to complete 30-minute stress management sessions during applicable treatment weeks. A link to the stress management video will be delivered via text 3 times per week to the participant during applicable intervention periods in the personalized trial arms. Participants will be limited to three views of the study-provided stress management content each week.
62218250|NCT05408832|ACTIVE_COMPARATOR|Standard Care|Participants in Arm 3 will receive Standard Care of the 3 stress management techniques (mindfulness meditation, yoga, and brisk walking). Participants will receive access to the same number of views of the mindfulness meditation, yoga, and brisk walking content given to participants randomized in Arm 1 and Arm 2. However, they will not be prompted to complete any session according to a randomization sequence. A link to the stress management video will be delivered via text 1 time per week to the participant. Participants will be limited to 36 total views of study-provided stress management content (12 total views per stress management technique).
62586121|NCT05579197|EXPERIMENTAL|Lower limbs robotic intervention|"The intervention administered in this arm is a lower limb robotic intervention using the device Myosuit. The intervention includes:~* An enrollment (session1), in which a clinical and psychological evaluation is performed for the assessment of the inclusion criteria~* A baseline evaluation (session2), in which a functional evaluation is performed both with and without the device~* Training sessions (sessions 3-9), these are the actual training sessions in which walking, sit to stand, balance and stairs climbing tasks are performed with the device on~* Final evaluation (session 10), in which a final functional, clinical, and psychological assessment is performed~The sessions are performed 3 times per week, with a duration of 45 minutes, with the expection of the assessement ones, session 1, 2 and 10, that have a duration of 1h, 2h and 3h, respectively."
62586122|NCT06366633|EXPERIMENTAL|Web-TIRELESS|An asynchronous web-based mind-body intervention focused on decreasing disability, pain, risky substance use, and related distress in patients with nontraumatic upper-extremity conditions and comorbid risky substance use.
62586123|NCT04762615||Patients with renal pathology treated with immunosuppressive drugs|Female in reproductive age suffering from renal disease that is or was previously treated with immunosuppressive drugs
62586124|NCT04762615||Patients with renal pathology without treatment|Control group
62218251|NCT03596866|EXPERIMENTAL|Brigatinib|Brigatinib 90 milligram (mg), tablets, orally, once daily 7 days, followed by Brigatinib 180 mg, tablets, orally, once daily for until objective disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), as assessed by the investigator, or intolerable toxicity.
62218252|NCT03596866|ACTIVE_COMPARATOR|Alectinib|Alectinib 600 mg, capsules, orally twice daily until objective disease progression per RECIST version 1.1, as assessed by the investigator, or intolerable toxicity.
62586125|NCT04762615||Patients after renal transplantation taking immunosuppressive drugs|Female in reproductive age after renal transplantation taking immunosuppressive drugs
62586126|NCT02036840||Penicillin allergy|
62586127|NCT06682819|OTHER|Two arms will be constituted according to gender and crossed according to OCT data|Considering the difference in NOHL prevalence in men and women, with a sex ratio of 7 men to 3 women, the metabolomic analysis data will be analyzed according to gender and OCT data.
62022266|NCT03865212|EXPERIMENTAL|Group A (VSV-IFNbetaTYRP1)|Patients receive recombinant vesicular stomatitis virus-expressing interferon-beta and tyrosinase related protein 1 IT and IV over 30-60 minutes 2-4 hours later on day 1.
62218253|NCT03842254|EXPERIMENTAL|Single arm|Single dose of erythropoietin 10,000 units to be administered subcutaneously at time of enrollment.
62218254|NCT03996343|EXPERIMENTAL|Endotracheal intubation|
62586128|NCT01359215||Treatment|Children who received an anesthetic prior to age 2
62586129|NCT01359215||Control|Children who have never been anesthetized
62586130|NCT04645901|EXPERIMENTAL|SYHA1805|Part 1: Subjects will receive a single dose of oral SYHA1805 tablets. Part 2: Subjects will receive single ascending doses of SYHA1805 tablets. Part 3: Subjects will receive a single dose SYHA1805 tablets in a fasted state and a single dose of SYHA1805 tablets after a high-fat, high-calorie meal, with sequence determined by randomization.
62586131|NCT04645901|PLACEBO_COMPARATOR|Placebo|Subjects will receive the matching placebo tablets.
62586132|NCT01220388|EXPERIMENTAL|L-lysine|11 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
62586133|NCT01220388|PLACEBO_COMPARATOR|placebo|11 days treatment with study drug, order of periods (L-lysine or placebo) being sorted out.
62586134|NCT00644176|EXPERIMENTAL|1|
62218255|NCT03996343|EXPERIMENTAL|Laryngeal mask airway|
62412314|NCT05859893|EXPERIMENTAL|Intervention|"Behavioral: Interactive livestreamed classical Turkish music sessions with a professional music band.~The sessions, which lasted approximately one and a half hours, twice a week, have been completed within one month."
62586135|NCT00644176|EXPERIMENTAL|2|
62218256|NCT04523389||colorectal cancer|
62412315|NCT03930901|OTHER|Intervention|Children in this group were examined for intestinal parasites and then treated accordingly. Then, health education learning package (HELP) was introduced to children in the selected schools. The package involved different items and activities during the study period, e.g. comic booklet on the intestinal parasitic infections, stand banners, posters, lectures, songs, drawing competition, puppet show, lectures, with a toolkit that involved soap, slipper (plastic clogs shoes), \& nail clipper).
62218257|NCT01453868|ACTIVE_COMPARATOR|Active non impact aerobics|This group will be performing a 12 week non impact aerobics program twice a week.
62218258|NCT01453868|ACTIVE_COMPARATOR|Control group: Passive lecture series|The control group will also be measured for balance and then attend a 12 week lecture series with no exercise. They will then also be remeasured post lectures series
62218259|NCT06048679|OTHER|main|
62218260|NCT01009151|EXPERIMENTAL|Heart Care Self Tracker|Web-based Home Tele-monitoring system
62218261|NCT01090479|NO_INTERVENTION|Control|This group will perform an ordinary shower the night prior and the morning of their scheduled surgery date.
62218262|NCT01090479|EXPERIMENTAL|2% Chlorhexidine cloth|This group will use the 2% chlorhexidine wipes the night prior as well as the morning of their surgery date.
62218263|NCT02610166|EXPERIMENTAL|Game|Access to the game.
62218264|NCT02610166|ACTIVE_COMPARATOR|Usual Care|Control group.
62218265|NCT03629327|ACTIVE_COMPARATOR|ASA 325mg|Daily uptake of 325mg ASA
62218266|NCT03629327|ACTIVE_COMPARATOR|No drug|no drug
62412316|NCT03930901|NO_INTERVENTION|Control|Children in this group were examined for intestinal parasites and then treated accordingly. They were follow up for 6 months.
62412317|NCT00618800|EXPERIMENTAL|Pharmacist Care|Pharmacist Intervention
62412318|NCT00618800|ACTIVE_COMPARATOR|Control|Written information only group
62412319|NCT01592968|EXPERIMENTAL|Arm I (SRS)|Patients undergo SRS on day 1.
62412320|NCT01592968|EXPERIMENTAL|Arm II (WBRT)|Patients undergo WBRT 5 days per week (7 days per week for inpatients) for 2 weeks.
62412321|NCT04509596|EXPERIMENTAL|daily dose of DZD1516|daily dose of DZD1516
62412322|NCT05752396||Chronic Pain - Localized|Patients with localized pain conditions (n=140)
62412323|NCT05752396||Chronic Pain - Overlapping|Patients with two or more pain conditions (n=140)
62412324|NCT05752396||Healthy Participants|Health Participants without a chronic pain condition (n=140)
62412325|NCT04311723|ACTIVE_COMPARATOR|Group I (conventional mechanical ventilation)|Patients receive anesthesia using a standard short breathing tube called LMA and then undergo standard of care bronchoscopy.
62586136|NCT02363413|ACTIVE_COMPARATOR|IniVAH|Initiation of the NIV in hospital : current care. 3 days hospitalization to start-up the NIV as usual.
62022267|NCT03865212|EXPERIMENTAL|Group B (VSV-IFNbetaTYRP1)|Patients receive recombinant vesicular stomatitis virus-expressing interferon-beta and tyrosinase related protein 1 IT and IV over 30-60 minutes 2-4 hours later on day 1. Cycle 1 continues for 28 days, with subsequent cycles repeating every 21 days in the absence of disease progression or unacceptable toxicity.
62218267|NCT03629327|ACTIVE_COMPARATOR|ASA 81mg|daily uptake of 81mg ASA
62218268|NCT01820585|PLACEBO_COMPARATOR|Placebo|Tablets
62412326|NCT04311723|EXPERIMENTAL|Group II (VESPA)|Patients receive anesthesia using a longer breathing tube called an endotracheal tube and then undergo standard of care bronchoscopy.
62412327|NCT04172727|ACTIVE_COMPARATOR|ultrasound guided transversalis fascia plane block|20 mL of 0.25% bupivacaine
62412328|NCT04172727|PLACEBO_COMPARATOR|ultrasound guided sham block|20 mL of saline
62412329|NCT01041807||All participants|Participants with hypertension treated with amlodipine/losartan(Cozaar XQ)
62412330|NCT06652685|EXPERIMENTAL|D5-PBCR(-)|On day five of IA induction, D5-PBCR will be tested according to protocol. For D5-PBCR (-) patients, no additional of venetoclax is needed.
62819404|NCT02187848|EXPERIMENTAL|SAR408701 Dose Escalation every 3 weeks cohort|Dose escalation administered intravenously, once every three weeks
62218269|NCT01820585|ACTIVE_COMPARATOR|ESL 400 mg|Eslicarbazepine acetate (BIA 2-093) tablets
62218270|NCT01820585|ACTIVE_COMPARATOR|ESL 800 mg|Eslicarbazepine acetate (BIA 2-093) tablets
62218271|NCT01820585|ACTIVE_COMPARATOR|ESL 1200 mg|Eslicarbazepine acetate (BIA 2-093) tablets
62412331|NCT06652685|EXPERIMENTAL|D5-PBCR(+)|On day five of induction, D5-PBCR will be tested according to protocol. D5-PBCR (+) patients, will receive induction therapy consisting of venentoclax combined with IA regimen.
62412332|NCT01803464|EXPERIMENTAL|Botox plus low-magnitude vibration|Cerebral palsy and Botox + vibration
62412333|NCT01803464|EXPERIMENTAL|Botox|Cerebral palsy and Botox
62412334|NCT01803464|NO_INTERVENTION|Cerebral palsy control|Cerebral palsy without treatment
62412335|NCT01803464|NO_INTERVENTION|Typically developing control|Typically developing
62412336|NCT04130594|EXPERIMENTAL|phase 1, vaccine half dose|half dose of BVRS-GamVac vaccine single administration
62412337|NCT04130594|EXPERIMENTAL|phase 1, vaccine full dose|full dose of BVRS-GamVac vaccine single administration
62412338|NCT04130594|EXPERIMENTAL|phase 2, vaccine selected dose|selected dose of BVRS-GamVac vaccine single administration
62412339|NCT04130594|PLACEBO_COMPARATOR|phase 2, placebo|placebo single administration
62022268|NCT05056103|OTHER|TrachFlush|
62022269|NCT00003498|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62218272|NCT06417580|PLACEBO_COMPARATOR|Negative Control Group|"A negative control group with gel without any active ingredient.~The protocol used for all groups will be the same: prophylaxis with an extra soft robinson brush and pumice stone, insertion of retractor thread number #000 in the gingival sulcus and then application and friction of the placebo gel with a microbrush applicator for 10 seconds, which will remain in contact with the tooth surface for 10 minutes, and the excess will be subsequently removed. Three desensitizing treatment sessions will be carried out, with an interval of 72 hours between each session."
62218273|NCT06417580|ACTIVE_COMPARATOR|Positive Control Group|"Potassium nitrate gel group that will serve as a positive control~The protocol used for all groups will be the same: prophylaxis with an extra soft robinson brush and pumice stone, insertion of retractor thread number #000 in the gingival sulcus and then application and friction of the potassium nitrate gel with a microbrush applicator for 10 seconds, which will remain in contact with the tooth surface for 10 minutes, and the excess will be subsequently removed. Three desensitizing treatment sessions will be carried out, with an interval of 72 hours between each session."
62218274|NCT06417580|EXPERIMENTAL|Experimental group|"Experimental group with 10% pregabalin gel.~The protocol used for all groups will be the same: prophylaxis with an extra soft robinson brush and pumice stone, insertion of retractor thread number #000 in the gingival sulcus and then application and friction of the pregabalin gel with a microbrush applicator for 10 seconds, which will remain in contact with the tooth surface for 10 minutes, and the excess will be subsequently removed. Three desensitizing treatment sessions will be carried out, with an interval of 72 hours between each session."
62218275|NCT06253598|EXPERIMENTAL|intervention arm|
62218276|NCT04244838|EXPERIMENTAL|MP-TKA group|20 patients candidates for cemented TKA with MP design for tri-compartment gonarthrosis will be recruited on indications of the surgeon and according to normal clinical practice at the Orthopedic and Traumatological Clinic 2nd of the Rizzoli Orthopedic Institute.
62218277|NCT05443152|EXPERIMENTAL|Experimental Arms|Prenatal attachment scale answered. In the first stage, pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care. The mother attachment scale was answered at least 1 month after the birth of the women.
62218278|NCT05443152|NO_INTERVENTION|No İntervention Arms|Prenatal attachment scale answered. The pregnant women continued to their routine prenatal care. No intervention was applied to the pregnant women in addition to their routine prenatal care.The pregnant women were called about whether continuing their routine care or having any problems during the research. The mother attachment scale was answered at least 1 month after the birth of the women.
62218279|NCT04535414|EXPERIMENTAL|1/ Arm 1|Bethesda protocol (investigational)with confocal endomicroscopy in assigned participants
62412340|NCT03519152|EXPERIMENTAL|study group one side|All patients were scheduled for open flap debridement surgery on at least two quadrants ≥1 weeks apart.One group will receive Low Dose Diclofenac tablets (25mg Diclofeanc and 325 mg paracetamol), BID for 3 days. The patients who are diagnosed with generalized moderate/severe chronic periodontitis will be included in study. For each quadrant, a flap was raised under local anesthesia (2% lignocaine with 1:80,000 epinephrine). In both the quadrants same technique of anesthesia will be employed. The location and the extent of surgery, volume of the local anesthesia given, and time required to perform the surgical procedure will be recorded in the patient file. Patients will be instructed to complete a pain diary chart for 3 days.
62412341|NCT03519152|PLACEBO_COMPARATOR|study group second side|Other group will receive Diclofeanc (50mg Diclofenac and 325mg paracetamol), BID for 3 days. The patients who are diagnosed with generalized moderate/severe chronic periodontitis were included in study. For each quadrant, aperiodontal flap was raised under local anesthesia (2% lignocaine with 1:80,000 epinephrine). In both the quadrants same technique of anesthesia will be employed. The location and the extent of surgery, volume of the local anesthesia given, and time required to perform the surgical procedure was recorded in the patient file. Patients were instructed to complete a pain diary chart for 3 days.
62412342|NCT05390853|EXPERIMENTAL|Active tDCS (A)|"Two daily tDCS sessions for 5 days a week, for 2 consecutive weeks, are carried out, simultaneously with the usual rehabilitation physiotherapy of the upper limbs.~Patients will receive the usual rehabilitation physiotherapy of the upper limbs at least in the 4 weeks before and in the 4 weeks after the tDCS treatment period too."
62586137|NCT02363413|EXPERIMENTAL|IniVAD|Initiation of the NIV at home : experimental care.
62586138|NCT02273375|EXPERIMENTAL|MEDI4736|MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier.
62819405|NCT06459817|EXPERIMENTAL|group 1|BB-02 therapy. 1h a day for 3 months
62819406|NCT06459817|EXPERIMENTAL|group 2|BB-02 therapy. 4h a day for 1 month
62819407|NCT03484130||High-Risk Normotensives|These high-risk normotensives are considered to be enriched for subclinical autonomous aldosterone secretion and have a high risk for developing incident hypertension
62819408|NCT05468814|EXPERIMENTAL|Z-plasty|It is a surgical technique in which a Z-shaped section of the transverse carpal ligament is performed, to later join both ends with a resorbable stitch.
62022270|NCT04121728|OTHER|Group Ginkgo-Placebo|Cross-over design: In Group Ginkgo-Placebo participants are allocated first to the IMP Symfona® during 6 months and after 2 months of wash-out period are allocated to the placebo for 6 months.
62022271|NCT04121728|OTHER|Group Placebo-Ginkgo|Cross-over design:In Group Placebo-Ginkgo participants are allocated first to the placebo during 6 months and after 2 months of wash-out period are allocated the IMP Symfona® for 6 months.
62218280|NCT04535414|ACTIVE_COMPARATOR|2/ Arm 2|Cambridge method (control) with confocal endomicroscopy in assigned participants
62218281|NCT01192464|EXPERIMENTAL|autologous CAR.CD30 EBV specific-CTLs|"Group One Dose (CTLs CAR.CD30) at Day 0: 2x10\^7 cells/m2~Group Two Dose (CTLs CAR.CD30) at Day 0: 5x10\^7 cells/m2~Group Three Dose (CTLs CAR.CD30) at Day 0: 1x10\^8 cells/m2"
62218282|NCT01871350|EXPERIMENTAL|Protein and Fish Oil|"Low Dose (FFM \<49kg): 30.00g milk protein + 12.75g maltodextrin and 6g fish oil~High dose (FFM \>49kg): 40.00g milk protein + 17.00g maltodextrin and 8g fish oil"
62412343|NCT05390853|PLACEBO_COMPARATOR|Sham tDCS (S)|"Two daily tDCS sessions for 5 days a week, for 2 consecutive weeks, are carried out, simultaneously with the usual rehabilitation physiotherapy of the upper limbs.~Patients will receive the usual rehabilitation physiotherapy of the upper limbs at least in the 4 weeks before and in the 4 weeks after the tDCS treatment period too."
62412344|NCT04881448|EXPERIMENTAL|Patients with chronic kidney disease - overall population|Patients with chronic kidney disease (CKD), including patients with non-diabetic chronic kidney disease (non-DKD) and diabetic kidney disease (DKD). Participants in this study did not receive any medication or study drug.
62412345|NCT00878735|EXPERIMENTAL|1|Zen meditation
62412346|NCT00878735|NO_INTERVENTION|2|No meditation (no intervention; keep regular activities) or a resting group (this group stays at the same place of the retreat group, but only to rest)
62218283|NCT01871350|EXPERIMENTAL|Protein|"Low Dose (FFM \<49kg): 30.00g milk protein + 12.75g maltodextrin and 6g olive oil~High dose (FFM \>49kg): 40.00g milk protein + 17.00g maltodextrin and 8g olive oil"
62218284|NCT01871350|PLACEBO_COMPARATOR|Placebo|"Low Dose (FFM \<49kg): 12.75g maltodextrin and 6g olive oil~High dose (FFM \>49kg): 17.00g maltodextrin and 8g olive oil"
62218285|NCT00558038|ACTIVE_COMPARATOR|1|
62412347|NCT01136629||Subjects with hyper-pigmented spots|Subjects age 21 to 80 year old, who have elected to undergo a plastic surgery will be enrolled. Subjects will be from Chinese, Malay, Indian or Caucasian ancestry. Subjects will be female or male with a hyper-pigmented spots.
62218286|NCT00558038|EXPERIMENTAL|2|
62218287|NCT03647488|EXPERIMENTAL|Run-in part: capmatinib + spartalizumab|Participants (enrolled in the run-in part) were treated with capmatinib 400 mg twice daily (BID) and spartalizumab 400 mg intravenously (i.v.) once every 28 days
62218288|NCT03647488|EXPERIMENTAL|Randomized part: capmatinib+spartalizumab|Participants (enrolled in the randomized part) treated with capmatinib 400 mg twice daily (BID) and spartalizumab 400 mg intravenously (i.v.) once every 28 days
62412348|NCT04730973|ACTIVE_COMPARATOR|Evolocumab|Subcutaneous evolocumab 140 mg will be administered every 2 weeks on top of optimal lipid-lowering therapy
62412349|NCT04730973|PLACEBO_COMPARATOR|Standard|No further treatment besides optimal lipid-lowering therapy will be administered
62412350|NCT05943158|EXPERIMENTAL|Myoinositol+folic acid group|This group is given myoinositol+folic acid (inofolic, ITF company, Italy) (myoinositol 4 gram+folic acid 400 micrograms)
62412351|NCT05943158|EXPERIMENTAL|Only folic acid group|This group is given only folic acid once a day (400 micrograms a day)
62218289|NCT03647488|ACTIVE_COMPARATOR|Randomized part: docetaxel|Participants (enrolled in the randomized part) treated with docetaxel 75mg/m2 i.v. following local guidelines as per standard of care and product labels once every 21 days
62218290|NCT04242251|NO_INTERVENTION|Usual Care|Management by primary oncologist. Referral to existing palliative care service initiated by primary oncologist if needed.
62022272|NCT04913857|EXPERIMENTAL|24-week SUDOKU Training Programme|"The SUDOKU training program include a 12-week face-to-face training session and a 12-week facilitated self-practice. The 12-week (60-minute sessions) training program will be evenly divided into 3 modules of increasing difficulty for the suboptimal cognitive function of the participants with MCI. As the use of T-code in solving the SUDOKU allows communicating the way a number is assigned to a box, participants are grouped into a small team of 3, so that they will work together during the tutorial practice.~Facilitated self-practice will last for another 12 weeks immediately after the group training session. The instructor will give them a workbook with 12 SUDOKU puzzles of increasing level of difficulty for completion. The instructor will encourage and facilitate their accomplishment by giving them guidance on the taught method through regular phone call. Solutions of the assigned puzzle and the T-code will be provided in the following week."
62586139|NCT02273375|PLACEBO_COMPARATOR|Placebo|PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier
62794064|NCT05421481|EXPERIMENTAL|intervention group|"In the first interview, the mobile phone contact information of the elderly will be obtained and planning will be made for the first home visit when appropriate. Physical activity education and health promotion during home visit brochure will be provided. A brochure containing healthy lifestyle habits, health responsibility, exercise, nutrition, oral hygiene and social support behaviors will be provided for general health promotion awareness. The Google Fit application, which is a mobile application, will be downloaded to the phones of the people and installed together, how to use the application will be explained and the application will be made. The group walk to be done. A reminder message will be sent by phone. Message content For your health, you should exercise at least 30 minutes a week for a total of 150 minutes. will be. Groups of five will be formed for the group walking, and it will be completed within seven days."
62794065|NCT05421481|NO_INTERVENTION|control group|There is no health-related practice in the pensioners' club. No intervention will be made in the control group. After the experimental group's attempts are completed, a home visit is planned for the control group, and it is planned to make physical activity training, brochure, google fit application installation attempts.
62794066|NCT03374371||S. epidermidis Infection (CASE)|Patients with confirmed infection at S. epidermidis
62022273|NCT04913857|ACTIVE_COMPARATOR|wait-list|wait-list comparison group will receive the same program upon completion of the 6-month posttest evaluation on study outcomes
62794067|NCT03374371||S. epidermidis Contamination (CONTROL)|Patients with confirmed contamination at S. epidermidis
62794068|NCT01862913|EXPERIMENTAL|Computer-assisted CBT|"* Usual medical treatment in accordance with a decision algorithm based on the Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile.~* Eight sessions of a computer-assisted cognitive-behavioral therapy. Trained psychologists administer this program in face to face meetings."
62794069|NCT01862913|ACTIVE_COMPARATOR|Usual care treatment|"- Usual psychological and medical treatment in accordance with a decision algorithm based on the Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile."
62794070|NCT04106518||cirrhosis|Patients with alcoholic liver disease without alcoholic hepatitis
62794071|NCT04106518||severe alcoholic hepatitis|Patients with severe alcoholic hepatitis ( Maddrey score ≥32)
62794072|NCT04106518||non-severe alcoholic hepatitis|Patients with non-severe alcoholic hepatitis (Maddrey score \<32)
62022274|NCT06634732||observational group|Subjectives will undergo abdominal ultrasound examination immediately after receiving an abdominal CT scan.after admission to the ICU.
62022275|NCT01637753|EXPERIMENTAL|Carmustine Sustained Release Implant|
62022276|NCT01637753|SHAM_COMPARATOR|Surgical control group|
62022277|NCT05917730||Experimental: Emotional Regulation and Interpersonal Abilities group Therapy (MERITA).|12 sessions of 75 minutes each and are carried out weekly. MERIT aims to improve emotional regulation, to cope with problems, promoting interpersonal skills and attachment security. Sessions will be lead by two psychologists with accredited experience in MERITA.
62794073|NCT02451020|EXPERIMENTAL|Altitude exposure|Stay at 3200 m for 3 weeks
62794074|NCT03589261|OTHER|MRI (magnetic resonance imaging)|Hepatic blood flow baseline will be measured using MRI. Fluid challenge of 500 ml of NaCl 0.9% will be administered during 10 minutes. Before and After fluid challenge, MRI will be performed to compare flow changes.
62022278|NCT05917730||Control: Treatment As Usual|The treatment as usual provided in children and adolescents who witnesses DV is mainly individual psychotherapy.
62022279|NCT01201525|EXPERIMENTAL|Surgical scar - part 1|Surgical scar - part 1
62022280|NCT01201525|PLACEBO_COMPARATOR|Surgical scar - part 2|Surgical scar - part 2
62218291|NCT04242251|EXPERIMENTAL|SPARKLE intervention group|Regular symptom monitoring and treatment of problems identified. Referral to existing palliative care services can also be initiated by the SPARKLE nurse if identified problems require follow up.
62586140|NCT03951974|EXPERIMENTAL|Experimental|Participants in the experimental group will receive training in utilizing social regulation of emotion strategies in an individualized format. They will meet with an interventionist for 5 weeks (1 in-person session and 4 telephone sessions) for 1-1.5 hours each week, and keep a journal documenting their emotion challenges and regulation strategy use.
62794075|NCT04679974|EXPERIMENTAL|MBCT treatment|Melodic-based communication treatment
62218292|NCT03281655|EXPERIMENTAL|Vulvovaginal atrophy|Postmenopausal sexually active women affected by vulvovaginal atrophy undergoing treatment (15 days, 1 application per day) with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
62794076|NCT02440243|ACTIVE_COMPARATOR|Patients active|Purethal Grass
62794077|NCT02440243|PLACEBO_COMPARATOR|Patients placebo|Placebo
62794078|NCT00943930||Marijuana-dependent volunteers|
62022281|NCT02343341|EXPERIMENTAL|Preschool Health Promotion Education Program|Children randomized to the intervention arm will receive a 4-month health promotion education program along with their parents/caregivers and teachers.
62022282|NCT02343341|OTHER|Control:Standard Curriculum|"The Standard curriculum control arm will receive the standard curriculum in their schools.~Children randomized to the control arm will receive the health promotion education program for 4 months after the intervention arm has completed it"
62022283|NCT04703881|EXPERIMENTAL|AYMES ActaGain|Patients of the intended target group (e.g. MUST score ≥ 1, with or at risk of disease related malnutrition) with an anticipated period of nutritional support ≥ 4 weeks will be changed / started on an equivalent prescription of 'AYMES ActaGain' for a period of 30 days.
62022284|NCT05034692|EXPERIMENTAL|Overlap group|Total laparoscopic with intracorporeal anastomosis by overlap method
62022285|NCT05034692|ACTIVE_COMPARATOR|Traditional group|Laparoscopic-assisted colectomy with extracorporeal anastomosis
62218293|NCT03363243|EXPERIMENTAL|STOP Therapy Treatment group|Self-regulation Treatment for Opioid addiction and Pain (STOP) is a 12-week, rolling entry group therapy protocol that underwent initial development in a previous K23 study. Treatment consists of weekly 90-minute CBT+SR (Self Regulation) treatment with skill building exercises for co-morbid opioid addiction and pain. STOP will be provided in lieu of TAU (Treatment as Usual) group therapy.
62218294|NCT03363243|ACTIVE_COMPARATOR|Treatment as usual (TAU) group|Psychotherapy for Addiction in conjunction with medication assisted treatment. Standard community treatment for opioid addiction consists of 90-minute weekly rolling entry addiction treatment for 12 weeks to allow for the learning and rehearsal of skills designed to reduce relapse.
62218295|NCT05023083||diseased individuals|post CABG patients will be included in the study to fill the tool
62794079|NCT05447208|EXPERIMENTAL|Treatment group|GH is supplemented during ovarian stimulation
62794080|NCT05447208|ACTIVE_COMPARATOR|Control group|GH is not supplemented during ovarian stimulation.
62794081|NCT03643458||Transfused infants|Preterm infants undergone red blood cell transfusion during hospital stay.
62794082|NCT02473900|EXPERIMENTAL|Sequence 1|HIP1403→HGP0919
62794083|NCT02473900|EXPERIMENTAL|Sequence 2|HGP0919→HIP1403
62794084|NCT01736670|EXPERIMENTAL|Acute Steroid Responsive dermatitis|10 patients with acute steroid-responsive dermatoses
62794085|NCT01736670|EXPERIMENTAL|Chronic Steroid Responsive Dermatits|10 patients with chronic steroid-responsive dermatoses
62794086|NCT01736670|ACTIVE_COMPARATOR|Control, Otherwise healthy|10 healthy controls
62412352|NCT01550354|ACTIVE_COMPARATOR|Propofol group|Intravenous administration of propofol 2 mg/kg before intubation
62586141|NCT03951974|OTHER|Control|Participants in the control group will not receive training in utilizing social regulation of emotion strategies. While they will still meet with the interventionist on the same schedule and for approximately the same length of time, they will simply be asked to report the emotion regulation strategies that they naturally employ. They will also keep a journal documenting their emotion challenges and regulation strategy use.
62586142|NCT06648356|ACTIVE_COMPARATOR|contract-relax proprioceptive neuromuscular facilitation (crPNF)|Participants in this group performed a stretching protocol using contract-relax proprioceptive neuromuscular facilitation (crPNF). The participants are placed in a long sitting position with maximum knee extension possible until a moderate-strong stretch sensation is felt, without pain. The stretch lasts for 20 seconds, followed by a maximal voluntary isometric contraction of the hamstrings for 5 seconds. Three stretch-contraction cycles are completed. One researcher maintains the stretch position, while a second researcher controls the stretching and contraction times.
62586143|NCT06648356|EXPERIMENTAL|Neuromuscular Electrical Stimulation (NMES + crPNF)|The participants follow the same stretching protocol but with neuromuscular electrical stimulation (NMES) added. Electrical stimulation (50Hz, 300 µs pulse width) is applied using an Enraf Nonius TensMed S82 device. Two 5x9 cm electrodes are placed on the hamstrings, and participants adjust the current to a moderate-strong, but painless, contraction. One researcher maintains the stretch, while another adjusts the current intensity and controls the timing of the stretching and contraction.
62218296|NCT05023083||healthy individuals|20 healthy individual will be included to solve questionnaire
62218297|NCT02842801|OTHER|Hip Manipulation|Hip manipulation: high velocity low amplitude thrust mobilization
62218298|NCT01096823|EXPERIMENTAL|Iyengar Yoga|
62218299|NCT01096823|NO_INTERVENTION|Waitlist Control|
62218300|NCT05326815||Osteopenia, no past medical therapy|Patients diagnosed with osteopenia on DEXA scan who have not been on any medical therapy in the past
62218301|NCT03218540|EXPERIMENTAL|SVV group|Fluid management protocol
62794087|NCT01750216||Cohort|
62794088|NCT06210048||Mild Primary Dysmenorrhoea|Consists of participants with mild dysmenorrhea according to VAS score
62794089|NCT06210048||Moderate Primary Dysmenorrhoea|Consists of participants with moderate dysmenorrhea according to VAS score
62412353|NCT01550354|ACTIVE_COMPARATOR|Alfentanil group|Intravenous administration of alfentanil 14 μg/kg before intubation
62412354|NCT01550354|ACTIVE_COMPARATOR|Rocuronium group|Intravenous administration of rocuronium 0.3 mg/kg before intubation
62586144|NCT06668168|PLACEBO_COMPARATOR|PLACEBO|
62218302|NCT03218540|ACTIVE_COMPARATOR|CVP group|Fluid management protocol
62218303|NCT04641377|EXPERIMENTAL|Multicomponent exercise intervention plus health education|The multicomponent training will be performed twice a week, on pre-established and non-consecutive days. The sessions will be held by video call (approximately 60 min) in small groups (maximum three participants) and will be taught by students of the Physical Education course, previously trained to carry out the intervention. The order of the multicomponent training will be: joint mobilization, aerobic stimulus, balance exercise, strength exercises and stretching of the main muscles used during the training session. Health education will also be carried out on one of the two days. The conversation on the topic of the week will take place during stretching.
62412355|NCT05174273|NO_INTERVENTION|Participants with a confirmed diagnosis of MDD receiving TAU|Eligible and consenting patients will be assigned 1:1 to receive either FMT from a healthy donor or continuing on their usual medication for MDD, i.e., treatment as usual (TAU). This arm will continue to receive their usual anti-depressant.
62794090|NCT06210048||Severe Primary Dysmenorrhoea|Consists of participants with severe dysmenorrhea according to VAS score
62794091|NCT00832416|EXPERIMENTAL|1 Tramadol Once A Day 100mg|
62586145|NCT06668168|ACTIVE_COMPARATOR|KETONE ESTER|
62794092|NCT00832416|EXPERIMENTAL|2: Tramadol Once A Day 200mg|
62794093|NCT00832416|EXPERIMENTAL|3: Tramadol Once A Day 300mg|
62218304|NCT04641377|ACTIVE_COMPARATOR|Health education|Once a week, participants in the health education group will be sent a message with a material with various topics related to the management of breast cancer diagnosis and physical activity. In addition, two days after this material is sent, members of ABRACE: Telehealth will have a conversation with the participants of this group, at a google meet of approximately 30 minutes, about the theme sent by message. The themes will be: depression, pain, fatigue, body image, symptoms in the arm and breast, vasomotor symptoms, neuropathy, arthralgia, sexual dysfunction, quality of life, physical activity and eating habits.
62794094|NCT00832416|EXPERIMENTAL|4: Placebo|
62794095|NCT06280508|EXPERIMENTAL|treatment arm|
62794096|NCT02951494|ACTIVE_COMPARATOR|AlterG Anti-gravity treadmill|cont. aerobic exercise training with lower body weight support
62794097|NCT02951494|NO_INTERVENTION|Exercise without body weight support|cont. aerobic exercise training without lower body weight support
62586146|NCT06668168|EXPERIMENTAL|KETOGENIC DIET|
62794098|NCT02694302|EXPERIMENTAL|Walkbot|Walkbot(robot assisted gait training) 30 minutes and conventional physical therapy 30 minutes each per day to be administered 5 times a week for 3 weeks.
62022286|NCT04474184|EXPERIMENTAL|Aim 1 (focus group)|Participants attend a focus group over 2 hours about endometrial cancer including knowledge of abnormal uterine bleeding, post-menopausal bleeding, risk factors, sources of medical information, barriers to seeking gynecologic care, and acceptance of tampon self-collection for endometrial cancer detection.
62022287|NCT04474184|EXPERIMENTAL|Aim 2 (vaginal kit)|Participants receive a tampon kit for collection of vaginal samples.
62218305|NCT01290029|EXPERIMENTAL|Cinacalcet|Participants received a single, oral dose of 0.25 mg/kg cinacalcet.
62794099|NCT02694302|ACTIVE_COMPARATOR|Conventional physical therapy|Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.
62022288|NCT05970393|EXPERIMENTAL|Experimental|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
62022289|NCT03854344|EXPERIMENTAL|Group 1|Liposomal Bupivicaine (266mg/20ml) will be diluted into Lactated Ringer solution (280 ml) and injected once intra-operatively subcutaneously before donor site harvesting
62022290|NCT03854344|ACTIVE_COMPARATOR|Group 2|Lidocaine (50 mg/50 ml) will be diluted into Lactated Ringer (1000ml) and injected once subcutaneously before donor site harvesting
62022291|NCT03854344|EXPERIMENTAL|Group 3|Subjects will receive regional anesthesia with a bupivacaine nerve block; either a fascia iliaca, lateral femoral cutaneous, or femoral nerve block based on the proposed donor site location
62586147|NCT06664619|EXPERIMENTAL|Fp/ABS eMDPI|Fluticasone propionate/albuterol sulfate multidose dry powder inhaler with electronic module
62586148|NCT06664619|ACTIVE_COMPARATOR|Fp eMDPI|Fluticasone propionate (Fp) dry powder inhaler with an integrated electronic module (eMDPI)
62586149|NCT06664619|ACTIVE_COMPARATOR|ABS eMDPI|Albuterol sulfate (ABS) dry powder inhaler with an integrated electronic module (eMDPI)
62586150|NCT06664619|PLACEBO_COMPARATOR|Placebo eMDPI|
62794100|NCT02446717|EXPERIMENTAL|Arm A|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
62022292|NCT05054023|ACTIVE_COMPARATOR|Piroxicam gel|50g tubes that contained 0.5% piroxicam. the gel was gently massaged in the injured site for 1 minute, 3 times a day for 7 days.
62022293|NCT05054023|ACTIVE_COMPARATOR|Soulagel®; Belpharma Tunisia|50 ml tubes that contained rosemary essential oil (Romarinus offienalus), mint essential oil, clove essential oil (Eugenda caryophyllus), harpgophytum natural extract (Harpagophytum procumbens), meadowsweet natural extract (Filipendula ulmaria), aqua, methyl salicylate, menthol, camphre, carbomer, triethanolamine, polysorbate-20, sodium polyacrylate, trideceth-6, methylchloroisothiazolinone, methylisothiazolinone , magnesim Chloride and magnesium nitrate. the gel was gently massaged in the injured site for 1 minute, 3 times a day for 7 days.
62022294|NCT05195411||Nephroblastoma with vena cava thrombosis|Children with nephroblastoma with vena cava thrombosis +/- atrial extension, cared between 1999 and 2019 in Parisian hospitals: Necker and Bicêtre.
62022295|NCT00824681|EXPERIMENTAL|1|Sound Of Family Together (S.O.F.T.) Music Program
62022296|NCT00824681|ACTIVE_COMPARATOR|2|Non-Therapy Related Activities (NTRA)
62022297|NCT02256501|EXPERIMENTAL|Mono Nunlear Cell (MNC)|The patients with idiopathic dilated cardiomyopathy who underwent intracoronary injection of autologous bone marrow-derived mononuclear cells .
62218306|NCT04041011|EXPERIMENTAL|1.Experimental: A (Part 1): Fluzoparib and SHR -1316|
62218307|NCT04041011|EXPERIMENTAL|2.Experimental: B (Part 1): Fluzoparib and SHR -1316|
62586151|NCT03404947|EXPERIMENTAL|Ethanol|Participants will ingest ethanol (in the form of 40% ethanol) at an ingestion rate of 0.1 grams/kg lean body mass/hour in a solution with water.
62794101|NCT02446717|EXPERIMENTAL|Arm B|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD plus ribavirin (RBV) for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
62794102|NCT02446717|EXPERIMENTAL|Arm C|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
62586152|NCT03404947|NO_INTERVENTION|No Ethanol|Participants will ingest a volume matched beverage of water only.
62586153|NCT05433532|EXPERIMENTAL|Azacitidine，Venetoclax，and Flumatinib Regimen|See Detailed Description.
62586154|NCT02237612|EXPERIMENTAL|Diagnostic (diffusion-weighted MRI)|Patients undergo diffusion-weighted MRI of the pelvis.
62586155|NCT01847781|ACTIVE_COMPARATOR|IgG-deficient patients|Prevenar13
62586156|NCT01847781|ACTIVE_COMPARATOR|Healthy controls|Prevenar13
62586157|NCT06513663|EXPERIMENTAL|Exercise Intervention|"Eligible and consented participants randomized to the exercise arm will work with an exercise trainer three times weekly for 12 weeks. Training sessions will be delivered virtually using HIPPA Complaint IU Health Zoom. These sessions will last 60 minutes and include cardiovascular exercise, resistance training, and balance or stretching exercise. The participants will be able to use any equipment they already have at home but will be provided a heart monitor and a set of resistance bands.~All sessions will have a moderate-intensity training goal, defined as 40-80% of heart rate reserve (HRR). Cardiovascular exercise will include any at-home equipment available to the participants or follow a Tabata-style program. Resistance training will include a full body workout, emphasizing all major muscle groups. Trainers will progress or regress intensity levels based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session."
62586158|NCT06513663|NO_INTERVENTION|Usual Care|Participants randomized to usual care arm will receive care per their treatment team. Usual care participants are encouraged to exercise but will not be provided components of the intervention. Participants in the usual care arm will be given usual care handouts at baseline.
62586159|NCT05070988||Rare diseases|Children and adult patients with rare diseases and followed at the Necker Enfant Malades Hospital, Paris
62586160|NCT00729222|PLACEBO_COMPARATOR|1|Placebo
62794103|NCT02446717|EXPERIMENTAL|Arm D|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks in HCV genotypes 1- or 4-6- infected participants with or without cirrhosis.
62794104|NCT02446717|EXPERIMENTAL|Arm E|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 16 weeks in HCV genotype 1- or 4-6- infected participants with or without cirrhosis.
62218308|NCT04041011|EXPERIMENTAL|3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion|
62412356|NCT05174273|ACTIVE_COMPARATOR|Participants with a confirmed diagnosis MDD who will receive FMT + TAU|Eligible and consenting patients will be assigned 1:1 to receive either FMT from a healthy donor or continuing on their usual medication for MDD, i.e., treatment as usual (TAU). This arm will be assigned to receive FMT provided by healthy donors.
62412357|NCT05174273|NO_INTERVENTION|Participants with a confirmed diagnosis of MDD + IBS assigned to continue with TAU|
62412358|NCT05174273|ACTIVE_COMPARATOR|Participants with a confirmed diagnosis of MDD + IBS assigned to receive FMT + TAU|
62412359|NCT05174273|NO_INTERVENTION|Participants with a confirmed diagnosis IBS only receiving TAU|
62586161|NCT00729222|EXPERIMENTAL|2|rolofylline
62586162|NCT04304482|EXPERIMENTAL|ANAVEX2-73 Active|ANAVEX2-73 liquid oral solution
62586163|NCT04304482|PLACEBO_COMPARATOR|ANAVEX2-73 Placebo|Placebo liquid oral solution
62586164|NCT06285994||HFJV|All patients who underwent bronchoscopy with the use of high frequency jet ventilation between January 1st 2019 and december 31st 2023.
62586165|NCT05794061||Patients|Patients with brain disorders
62218309|NCT00669682||Group A|The study group will include Class III to IV heart failure patients followed in the device clinic that have a chronically implanted (more than 90 days) Medtronic biventricular defibrillator with the ability to monitor intrathoracic impedance.
62412360|NCT05174273|NO_INTERVENTION|Healthy Controls|Data from healthy comparison (HC) participants will be drawn from another completed research study. Healthy comparison participants who will best match the patient population enrolled in the current trial and who consented to data sharing will be selected.
62412361|NCT06401317|EXPERIMENTAL|Saline Injection|A single injection of saline solution
62412362|NCT06401317|ACTIVE_COMPARATOR|Corticosteroid Injection|Usual care, consisting on a single injection of corticosteroids
62412363|NCT03388528|EXPERIMENTAL|Treatment Group|This is a single arm study where forty patients with a genetically or biochemically proven diagnosis of mitochondrial disease will be recruited from the mitochondrial CRESTA clinic and / or Medical Research Council Mitochondrial Disease Patient Cohort Study in Newcastle. All forty patients will be assessed prior to and following a 12 week low residue diet study intervention.
62412364|NCT01029769|ACTIVE_COMPARATOR|initial olanzapine|
62412365|NCT01029769|ACTIVE_COMPARATOR|initial amisulpride|
62586166|NCT05794061||Healthy controls|Neurologically Healthy Controls
62794105|NCT02780284|EXPERIMENTAL|Physical activity intervention|Subjects at higher risk of developing colorectal cancer will maintain the current level of activity during the first 4 weeks and exercise 150 minutes per week during the last 4 weeks. During the entire study, subjects will wear a Fitbit device on their wrist.
62794106|NCT03316144|EXPERIMENTAL|1 mg/kg Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg Q2w until disease progresses or unacceptable tolerability occurs
62794107|NCT03316144|EXPERIMENTAL|3 mg/kg Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
62412366|NCT01029769|ACTIVE_COMPARATOR|early responders|
62412367|NCT01029769|ACTIVE_COMPARATOR|early non-responders switched|
62412368|NCT01029769|ACTIVE_COMPARATOR|ealy non-responders non-switched|
62412369|NCT06650306||SCLs >10 years|high myopia patients who wear SCL more than 10 years before Small Incision Lenticule Extraction
62412370|NCT06650306||SCLs ≤10 years|high myopia patients who wear SCL for 10 years or less before Small Incision Lenticule Extraction
62412371|NCT06650306||NW|high myopia patients who have not worn SCLs before Small Incision Lenticule Extraction
62412372|NCT04089150|ACTIVE_COMPARATOR|Arm A|"* Option 1: fluorouracil(5-FU)/leucovorin/irinotecan/oxaliplatin (mFOLFIRINOX) (6 cycles)~* Option 2: gemcitabine + nab-paclitaxel (3 cycles)~* Resectable patients receive surgery 6 weeks post completion of initial chemotherapy~* Unresectable patients continue with ongoing chemotherapy (option 1 or option 2)~* Unresectable patients with locoregional progression or metastatic disease, chemotherapy treatment at the discretion of treating medical oncologist~* Adjuvant chemotherapy for resectable patients to begin within 8 weeks after surgery~* For patients who received option 1 chemotherapy: 12 weeks of mFOLFIRINOX~* For patients who received option 2 chemotherapy: 12 weeks of mFOLFIRINOX or 12 additional weeks of gemcitabine/capecitabine"
62794108|NCT03316144|EXPERIMENTAL|10 mg/kg Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 10mg/kg Q2w until disease progresses or unacceptable tolerability occurs
62794109|NCT05287828||Indicators validation - Group A|"This group is composed with the contrasted pre-op CT scan of the 40 patients recruited.~The classification criterion is contrasted CT scan."
62412373|NCT04089150|EXPERIMENTAL|Arm B|"* Option 1: fluorouracil(5-FU)/leucovorin/irinotecan/oxaliplatin (mFOLFIRINOX) (6 cycles)~* Option 2: gemcitabine + nab-paclitaxel (3 cycles)~* Stereotactic Radiotherapy (SBRT) to commence within 3 weeks of completing initial chemotherapy: 40 Gray (Gy) in 5 fractions over 2 weeks~* Resectable patients receive surgery 6 weeks post completion of initial chemotherapy~* Unresectable patients continue with ongoing chemotherapy (option 1 or option 2)~* Unresectable patients with locoregional progression or metastatic disease, chemotherapy treatment at the discretion of treating medical oncologist~* Adjuvant chemotherapy for resectable patients to begin within 8 weeks after surgery~* For patients who received option 1 chemotherapy: 12 weeks of mFOLFIRINOX~* For patients who received option 2 chemotherapy: 12 weeks of mFOLFIRINOX or 12 additional weeks of gemcitabine/capecitabine"
62412374|NCT04551027|EXPERIMENTAL|compensatory cognitive treatment|compensatory cognitive treatment intervention, focusing on learning cognitive strategies to overcome cognitive deficits.
62412375|NCT04551027|NO_INTERVENTION|control group|standard ambulatory treatment
62412376|NCT06652997|ACTIVE_COMPARATOR|Single oral administration of SPH3348 tablets under fasting condition|Single oral administration of SPH3348 tablets（480 mg） under fasting condition
62412377|NCT06652997|ACTIVE_COMPARATOR|Single oral administration of SPH3348 tablets under fed condition|Single oral administration of SPH3348 tablets（480 mg） under fed condition
62412378|NCT04995302|ACTIVE_COMPARATOR|Microneedling and Amnion Bilayer|Microneedling is a dermaroller procedure that uses small needles to prick the skin. Amnion bilayer is used as an additional therapy after microneedling therapy.
62412379|NCT04995302|PLACEBO_COMPARATOR|Microneedling|Microneedling is a dermaroller procedure that uses small needles to prick the skin.
62412380|NCT04352621|EXPERIMENTAL|Ketamine plus rTMS|Patients will be given a dose of ketamine followed by 6 weeks of rTMS treatment.
62218310|NCT03475277||Volunteers|"Participants will receive an IV infusion of ketamine (\~.05mg/kg and 0.5mg/kg) or placebo.~Ketamine is an FDA-approved dissociative anesthetic. The study doses are in the subanesthetic range. During the infusion, an ACLS-certified psychiatrist or anesthesiologist will provide continuous monitoring.~Afterwards, patients will be monitored on-site by an ACLS-certified MD or highly skilled research nursing staff, and an on-call emergency response team for 4 hours (ketamine's half-life is 15 min; 4 hrs= 16 half-lives)."
62218311|NCT04322877|EXPERIMENTAL|Body surface mapping and temporary pacing|Temporary pacing procedure with acute hemodynamic study and non-invasive body surface mapping.
62022298|NCT02256501|NO_INTERVENTION|Control|The patients with cardiomyopathy that are under observe during the study.
62218312|NCT04322877|EXPERIMENTAL|Catheter-based mapping and temporary pacing|Temporary pacing procedure with acute hemodynamic study and invasive catheter-based mapping.
62243297|NCT06493331|EXPERIMENTAL|Intervention|A workflow diagram will be created according to the gaps in the students' lesson plan, and the groups will create conversation circles and share communication under the leadership of two faculty members (Ö.K.S and E.C). The talking circle application will consist of four sessions. Each talking circle will last 90-120 minutes. At the end of the semester, the 'Therapeutic Communication Skills Scale for Nursing Students' will be administered to the students as a final test.
62412381|NCT05945849|EXPERIMENTAL|CD33KO-HSPC followed by CART33|All subjects will receive CD33KO-HSPC, followed by 1-3 CART-33 infusions
62412382|NCT06049355|EXPERIMENTAL|Arm I (Exercise Together exercise program)|Patients and partners undergo Exercising Together exercise program during radiation therapy on study. Patients also undergo collection of blood samples throughout the trial.
62412383|NCT06049355|ACTIVE_COMPARATOR|Arm II (educational material)|Patients and partners receive educational materials specific to exercise. Patients also undergo collection of blood samples throughout the trial.
62412384|NCT00391092|EXPERIMENTAL|1|
62412385|NCT00391092|ACTIVE_COMPARATOR|2|
62412386|NCT06004700|EXPERIMENTAL|Mobile Application|"This arm of the study will contain half the study population after randomization. The participants in this arm will receive the EHR integrated app and follow a 12-month interrupted time series analysis (ITSA) design.~n = 200"
62412387|NCT06004700|NO_INTERVENTION|Controls|"This arm of the study will contain half the study population after randomization. The participants in this arm will be from the same rheumatologists as the experimental participants and will be used as concurrent controls by accessing their data on visits from the EHR during the same time period.~n = 200"
62412388|NCT05281328|EXPERIMENTAL|CAM2029 once weekly|0.5 mL CAM2029 10 mg, subcutaneous (SC) injection, once weekly
62819409|NCT05468814|ACTIVE_COMPARATOR|Conventional|It is a surgical technique in which a complete section of the transverse carpal ligament is performed, without subsequent closure.
62022299|NCT03855722|EXPERIMENTAL|RIPC|RIPC will consist of setting a tourniquet to donor thigh and inflating it to 300mmHg four times 5 minutes with 5 minutes deflating in between each. RIPC-intervention will be performed twice: First after brain death and second time before procurement procedure.
62586167|NCT01908829|EXPERIMENTAL|Combination (solifenacin + mirabegron)|Participants received solifenacin 5 mg, mirabegron 25 mg and solifenacin 10 mg matching placebo once daily for the first 4 weeks of double-blind period. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron tablet was replaced by a 50 mg mirabegron tablet. Placebo was given for the 2 week single-blind safety follow-up period.
62412389|NCT05281328|EXPERIMENTAL|CAM2029 once every 2 weeks|0.5 mL CAM2029 10 mg, SC injection, every 2 weeks and 0.5 mL placebo, SC injection, once every 2 weeks (alternating with CAM2029 dosing)
62412390|NCT05281328|PLACEBO_COMPARATOR|Placebo|0.5 mL placebo, SC injection, once weekly
62022300|NCT03855722|SHAM_COMPARATOR|Sham-RIPC|Sham-RIPC will consist of setting a tourniquet to donor thigh without inflating it and keeping it in place for 35 min. Sham-RIPC-intervention will be performed twice: First after brain death and second time before procurement procedure.
62022301|NCT03585647||GA-group|Patients undergoing elective hip arthroplasty included in the GA-group received general anesthesia. GA was induced by intravenous fentanyl (1 mcg/kg) and propofol (2 mg/kg), followed by vecuronium bromide (0.1 mg/kg) to facilitate tracheal intubation, then GA was maintained using a 50% air/oxygen mixture and sevoflurane.The end-tidal concentration of sevoflurane was adjusted to maintain heart rate and blood pressure values within 20% of baseline. Mechanical ventilation was regulated to maintain the end-tidal carbon dioxide partial pressure ranging between 4.3 and 5.1 kilopascal.
62022302|NCT03585647||RA-group|"Patients undergoing elective hip arthroplasty included in the RA-group received regional anesthesia. Regional anaesthesia included continuous lumbar plexus block, performed by or under supervision of an experienced operator using a nerve stimulator (Stimulax, B. Braun) and Continued Peripheral Nerve Block Set.~A total dose of 20 ml of 0.5% Levobupivacaine was administered at the time of catheter placement. Dural puncture was performed at the L3-L4 interspace using a 25-Gauge whitaker spinal needle (Becton-Dickinson, New Jersey, USA) with the midline approach using 3 ml of 0.5% Levobupivacaine."
62022303|NCT03585647||IA-group|Patients undergoing elective hip arthroplasty included in the IA-group received integrated anesthesia. The patients received regional anaesthesia (lumbar plexus block + spinal anaesthesia) as described protocol. General anaesthesia was induced by propofol 1% and a laryngeal mask airway of appropriate size was inserted. General anaesthesia and mechanical ventilation were maintained as standard protocol.
62022304|NCT01049906|ACTIVE_COMPARATOR|Nerve stimulation and Ultrasound|
62022305|NCT01049906|ACTIVE_COMPARATOR|Ultrasound without nerve stimulation|
62022306|NCT05146791||Inlay Bristow Group|Inlay Bristow procedure
62022307|NCT05146791||Onlay Bristow Group|Onlay Bristow procedure
62022308|NCT02919852|OTHER|laparoscopic retrovesical colpopectinopexia|new operative technic
62022309|NCT03647514|EXPERIMENTAL|Abraxane Combined With Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
62243298|NCT06493331|NO_INTERVENTION|Control|No activity will be applied to control group students during the case collection process. At the end of the semester, the 'Therapeutic Communication Skills Scale for Nursing Students' will be administered as a final test to the students.
62022310|NCT01605045|EXPERIMENTAL|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique)versus
62022311|NCT01605045|ACTIVE_COMPARATOR|Standard technique|Coronary anatomy visualized and documented using cinematography alone (standard technique)
62022312|NCT05816421|EXPERIMENTAL|Affinity KEEP|"Affinity KEEP groups are tailored to meet a specific population's needs and are comprised of parents who all share a common interest, purpose, or key characteristic. The four types of Affinity KEEP groups for this study include:~* foster/kin parents of sexual and gender minority youth~* foster/kin parents of Native youth~* transracial placements where the youth and one or more parents are of a different race/ethnicity~* groups delivered in Spanish"
62022313|NCT05816421|ACTIVE_COMPARATOR|Non-Affinity KEEP|Parents attending a Non-Affinity KEEP group.
62243299|NCT01686360|NO_INTERVENTION|Control group 1: pre/post-test|Group receives pre and post test questions only.
62243300|NCT01686360|EXPERIMENTAL|Control group 2: tool and pre/post-test|Group receives decision tool without personalized information. (Behavioral: Decision Aid)
62586168|NCT01908829|ACTIVE_COMPARATOR|Solifenacin 5 mg|Participants received solifenacin 5 mg, mirabegron 25 mg matching placebo and solifenacin 10 mg matching placebo once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period
62819410|NCT05504070|EXPERIMENTAL|GSV/SSV|Incompetent Great and Small Saphenous Veins
62022314|NCT06077006||Research|Children between the ages of 6 and 18 years, diagnosed with Migraine, who are under follow-up at the Pediatric Neurology Clinic in Bnei Zion.
62022315|NCT06077006||Control|Children without Migraine, headache or other chronic diseases
62022316|NCT04762745|EXPERIMENTAL|Phase I, Cohort 1|The combination of bendamustine, 60mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).
62412391|NCT00646282|EXPERIMENTAL|Doxercalciferol|Stable kidney transplant recipients will receive Doxercalciferol
62412392|NCT00646282|NO_INTERVENTION|Control|Stable kidney transplant recipients will not receive any drug
62412393|NCT04639310|EXPERIMENTAL|XEN496|24-day dose titration period to a top dose of 21 mg/kg/day. Subjects continue at the top dose, or the highest tolerated dose up to the top dose, for 12-week maintenance period. If the subject does not immediately enter into the separate open-label extension (OLE) study, the maintenance period will be followed by a 15-day taper period.
62412394|NCT04639310|PLACEBO_COMPARATOR|Placebo|To maintain the blinded aspect of the study, subjects will be titrated on placebo over the 24-day period and remain at this dose for the 12-week maintenance period. If the subject does not immediately enter into the separate OLE study, the maintenance period will be followed by a 15-day taper period.
62412395|NCT00170456|ACTIVE_COMPARATOR|1|Low dose rPA vaccine regime 1
62218313|NCT03898037|EXPERIMENTAL|lifestyle intervention group|"Subjects will receive weight loss intervention under the guidance of a dietitian after assigned to lifestyle intervention group, including: restricted energy balanced diet, aerobic exercise, etc. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test oral glucose tolerance test (OGTT)/insulin resistance test(IRT)/HOMA, blood routine, liver and kidney function on the day of grouping and in the 4th week, the 8th week, the 12th week after grouping.~The aim is to lose 5-10% of the initial body weight. If the target was reached within 3 months, subjects will receive ovarian stimulation treatment in advance, otherwise treatment starts after 3 months. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos. The pregnancy and perinatal outcomes after transfer were followed up."
62218314|NCT03898037|EXPERIMENTAL|metformin intervention group|"Subjects will be given metformin intervention with a starting dose of 0.5g bid after assigned to metformin intervention group, and the dose will be adjusted by doctors according to the insulin level and adverse events. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and the 4th week, the 8th week, the 12th week after grouping.~The aim is to adjust insulin level to normal within 3 months. If the target was reached within 3 months, subjects will start to receive ovarian stimulation treatment in advance, Otherwise treatment starts after 3 months. All subjects are treated with the same procedures, including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up."
62218315|NCT03898037|EXPERIMENTAL|lifestyle combined with metformin intervention group|"Subjects will receive weight loss intervention and metformin intervention after assigned to lifestyle combined with metformin intervention group. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and in the 4th week, the 8th week, the 12th week after grouping.~The aim is to lose 5-10% of the initial body weight and adjust insulin level to normal within 3 months. If the target was reached within 3 months, subjects will receive ovarian stimulation treatment in advance, otherwise treatment starts after 3 months. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up."
62586169|NCT01908829|ACTIVE_COMPARATOR|Solifenacin 10 mg|Participants received solifenacin 5 mg matching placebo, mirabegron 25 mg matching placebo and solifenacin 10 mg once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period.
62243301|NCT01686360|EXPERIMENTAL|Gail score in a percentage format|Group receives Gail score in a percentage format. (Behavioral: Decision Aid)
62243302|NCT01686360|EXPERIMENTAL|Gail score in a frequency format|Group receives Gail score in a frequency format. (Behavioral: Decision Aid)
62022317|NCT04762745|EXPERIMENTAL|Phase I, Cohort 2|The combination of bendamustine, 70mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).
62412396|NCT00170456|ACTIVE_COMPARATOR|2|Low dose rPA vaccine regime 2
62412397|NCT00170456|ACTIVE_COMPARATOR|3|High dose rPA vaccine regime 1
62412398|NCT00170456|ACTIVE_COMPARATOR|4|High dose rPA vaccine regime 2
62412399|NCT05104450|EXPERIMENTAL|lifestyle intervention|The investigators will provide participants with the behavioral lifestyle intervention in addition to usual care.
62412400|NCT05104450|NO_INTERVENTION|usual care control|Participants in this arm will continue with usual care without the lifestyle intervention.
62412401|NCT03683121||the traditional follow-up group|The dose and notes for the use of the Non-selective beta blockers were informed during outpatient follow-ups for the patients with a history of esophageal variceal bleeding
62412402|NCT03683121||Non-traditional follow-up|The dose and notes for the use of the Non-selective beta blockers were informed during telephone or WeChat follow-ups for the patients with a history of esophageal variceal bleeding
62586170|NCT06661226|EXPERIMENTAL|Acceleration Drills|14 participants will be in experimental group A, giving them acceleration drill protocol for six weeks. Measure all values before giving them protocol and after protocol.
62586171|NCT06661226|EXPERIMENTAL|Change in Direction Drills|14 participants will be in experimental group B, giving them Change in direction drill protocol for six weeks. Measure all values before giving them protocol and after protocol.
62794110|NCT05287828||Indicators validation - Group B|"This group is composed with the non-contrasted CT scan of the 40 patients recruted.~This group is composed with pre-op non-contrasted CT scans to validate the possibility to use the device on the first scan realised on patient, when there is a suspicion of a disease. The classification criterion is non-contrasted CT scan."
62819411|NCT05504070|EXPERIMENTAL|IPV|Incompetent Perforator Veins
62022318|NCT04762745|EXPERIMENTAL|Phase I, Cohort 3|The combination of bendamustine, 80mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).
62412403|NCT03683121||Combine of Group1 and Group2|The dose and notes for the use of the Non-selective beta blockers were informed during outpatient follow-ups for the patients with a history of esophageal variceal bleeding,and the patients were followed up by telephone or WeChat again on the same day.
62022319|NCT04762745|EXPERIMENTAL|Phase II|The combination of MTD dosage of bendamustine with pomalidomide and dexamethasone will be administrated in an expanded relapsed or refractory multiple myeloma cohorts for 8 cycles, then under the combination of pomalidomide and dexamethasone as maintenance therapy until progression or intolerable toxicities.
62218316|NCT03898037|NO_INTERVENTION|routine clinical education group|Subjects will only accept clinical routine education after assigned to routine clinical education group. Subjects will measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and will start induced ovulation therapy after completing routine clinical examination. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up.
62412404|NCT01598740|EXPERIMENTAL|CLP with spironolactone|
62412405|NCT01598740|EXPERIMENTAL|CLP without spironolactone|
62218317|NCT06609395|EXPERIMENTAL|Brief online CBT targeting excessive worry|The treatment in this trial was based on an online CBT intervention developed by Wahlund et al. (2021) for dysfunctional worry during the COVID-19 pandemic. Originally designed for the Swedish population, the intervention was translated to English and adapted for Indian expatriates in Sweden, addressing broader global crises, including military conflicts and climate change.
62218318|NCT01452373|PLACEBO_COMPARATOR|Control (placebo)|
62586172|NCT06670508|ACTIVE_COMPARATOR|TAP Block|Group A, The patient was in the supine position then; the TAP block was given by a high frequency linear ultrasound transducer (Siemens acuson x300 3-5MHz ultrasound). After skin preparation and isolation, the transducer was placed 2 cm sub-xiphoid, then moved along the subcostal edge to identify the rectus abdominis muscle and the transversus abdominis then, a blunted tip, 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) was introduced in-plane 2-3 cm lateral to the transducer, under direct ultrasound visualization. After confirming the correct placement of the needle and the negative aspiration probe, the rest of the anaesthetic substance was injected along the subcostal line in the transversus abdominis plane 20 ml 0.25% bupivacaine on each side after aspiration to avoid intravascular placement, and the dissection of the plane was observed. The block was performed bilaterally.
62586173|NCT06670508|ACTIVE_COMPARATOR|ES Block|Group B, the patient was placed in the prone position. Then, the Erector Spinae block was given by same ultrasound transducer . It was sagittaly placed against the target vertebral level (T7 transverse process) in the prone position and moved in approximately 3-cm lateral to the spinous process.. The Erector Spinae muscle and transverse process was identified, and a same blunted tip , 20-gauge, short bevel needle was advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane. The block was performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally.
62586174|NCT02348645|ACTIVE_COMPARATOR|Decompression with fusion|Spinal decompression surgery with instrumented spinal fusion
62586175|NCT02348645|ACTIVE_COMPARATOR|Decompression alone|Midline-sparing spinal decompression alone
62586176|NCT02614742|ACTIVE_COMPARATOR|SFX-01|300mg bid for up to 28 days.
62022320|NCT03890341|EXPERIMENTAL|Drospirenone/Ethinylestradiol + Midazolam + JNJ-64530440|Participants will receive single oral dose of drospirenone/ethinylestradiol 3 milligram (mg)/0.02 mg (oral contraceptive \[OC\]) and midazolam 2 mg with under fed conditions (high fat meal) on Day 1 followed by JNJ-64530440 2,000 mg on Days 6 under fasted conditions ; JNJ-64530440 2,000 mg plus single oral dose of OC and midazolam 2 mg under fed conditions on Day 13; JNJ-64530440 2,000 mg once daily under fed conditions (standard meal) from Days 14 to 18; single oral dose of JNJ-64530440 2,000 mg plus single oral dose of OC and midazolam 2 mg on Day 19 under fed conditions (high fat meal); and JNJ-64530440 2,000 mg once daily under fed conditions (standard meal) on Days 20 to 22.
62586177|NCT02614742|PLACEBO_COMPARATOR|Placebo|300mg placebo bid for up to 28 days
62412406|NCT00006014|EXPERIMENTAL|Arm I|Patients receive SU5416 IV over 1 hour twice weekly. Courses repeat every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
62412407|NCT06283485||Male|"Phase 1: Creating artificial intelligence from ultrasound scans of 150 healthy volunteers Sonoanatomical PENG and Suprainguinal Fascia Iliaca Block pictures are taken as follows.~1) PENG (Pericapsular Nerve Group Block): Linear and convex probes will be used to collect images. No invasive procedures will be conducted on healthy subjects for sonoanatomical data. 150 healthy volunteers (75 women-75 males) will be ultrasounded.~1.2) Suprainguinal Fascia Iliaca Block: Linear probe images. No invasive procedures will be conducted on healthy subjects for sonoanatomical data. 150 healthy individuals (75 female-75 male) will be ultrasounded.~Phase 2: Smart Alfa Teknoloji San. and Tic. Inc. will use Nerveblox, an artificial intelligence system built using data from the first stage, in the second part of the study. First-stage artificial intelligence technology validation and accuracy study. The accuracy study will involve 40 healthy volunteers. 20 men and 20 women will be studied."
62586178|NCT00795080||1|Normal volunteers who do not have malformations in their cerebral spinal fluid (CSF)
62586179|NCT00795080||2|Patients with incidentally discovered Chiari 1 DVS malformation of the cerebral spinal fluid (CSF)
62586180|NCT00795080||3|Patients with known Chiari or any other CVJ malformations undergoing a workup prior to surgery. Research images will be added to the clinically ordered exams ordered at 3 months and 1 year after surgery.
62218319|NCT01452373|EXPERIMENTAL|DHEA + Acolbifene|
62794111|NCT05287828||Indicators validation - Group C|"This group is composed with the post-op contrasted CT scan of the 35 pathological patients listed above (25 AAA, 5 TAA, 5 JAA).~This last group is composed with post-op CT scans. These scans are realised in a purpose of follow-up. The classification criterion is post-op CT scan of patient with a AAA, TAA or JAA."
62794112|NCT05287828||Indicators validation - Group D|"This group is composed with the post-op non-contrasted CT scan of the 35 pathological patients above (25 AAA, 5 TAA, 5JAA).~To decrease risks for patients, practicians are doing more non-contrasted CT scan. Moreover, they still need the indicators to realize the follow-up of the patient after its surgery. This group is to evaluate the possibility for the software to analysis this type of scan. The classification criterion is post-op non-contrasted CT scan of patient with a AAA, TAA or JAA."
62794113|NCT05287828||Stent migration group|25 patients are added to the 25 patients treated with EVAR (25 AAA) recruted in part 1 in order to have more significative results.
62794114|NCT02607943|EXPERIMENTAL|Insulin Glargine|subcutaneous long acting basal insulin (insulin glargine) with added short acting regular insulin to correct hyperglycemic events
62794115|NCT02607943|ACTIVE_COMPARATOR|Regular Insulin|short acting regular insulin pre-meal with added NPH at bed time if start eating
62794116|NCT04713163||Health care or laboratory-based workers|Healthy individuals about to receive any approved COVID-19 vaccine
62218320|NCT00574873|EXPERIMENTAL|1|Bosutinib
62218321|NCT00574873|ACTIVE_COMPARATOR|2|Imatinib
62218322|NCT06589960|EXPERIMENTAL|Intervention|"* Health education~* Physical exercise"
62218323|NCT05192668|EXPERIMENTAL|Quiet time care|Reduce noise and centralize medical or nursing operations in the NICU
62586181|NCT04974151|ACTIVE_COMPARATOR|Amlodipine (5mg/d)|"Amlodipine 5mg x1 tablet + Amlodipine folic acid (dummy) x1 tablet + 5-MTHF (dummy) x2 tablets, taken orally, in the morning after waking up.~Amlodipine tablets, amlodipine folic acid placebos, and 5-MTHF placebos are provided in aluminum-plastic blister plate. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 50 plates, each plate includes a total of 8 tablets arranged as follows: amlodipine 5mg x2 tablets + amlodipine folic acid (dummy) x2 tablets + 5-MTHF (dummy) x4 tablets. Affixed to the package is the randomized treatment drug label (400 tablets/package, 4 tablets/day)."
62794117|NCT04713163||Outpatients|Outpatients about to receive any approved COVID-19 vaccine
62794118|NCT01709370|EXPERIMENTAL|Letrozole plus PD 0332991|Drug: Letrozole 2.5mg/d for 16 weeks before surgery plus PD 0332991 (CDK-4/6 inhibitor) 125 mg/d for 3 out of 4 weeks in repeated cycles for 16 weeks before surgery
62794119|NCT00881114|EXPERIMENTAL|Cetuximab|patients with 2 or fewer genetic variants will receive cetuximab
62794120|NCT00881114|EXPERIMENTAL|Cisplatin|Subjects with 3 to 8 genetic variants will receive cisplatin
62794121|NCT05870488|OTHER|Use of iFuse TORQ for SI Joint Fusion|Participants with SI joint dysfunction are treated with iFuse TORQ.
62794122|NCT01397461|EXPERIMENTAL|ozenoxacin 1% cream|1% cream
62218324|NCT05192668|NO_INTERVENTION|Routine nursing care|Perform routine nursing care for the VLBWIs in the NICU
62218325|NCT05333952|EXPERIMENTAL|Pulmonary vein isolation + Waveform Periodicity Group|Pulmonary vein isolation + Substrate ablation
62218326|NCT05333952|OTHER|Pulmonary vein isolation group|Pulmonary vein isolation (Conventional treatment)
62218327|NCT01757431|OTHER|ECULIZUMAB|
62794123|NCT01397461|PLACEBO_COMPARATOR|ozenoxacin placebo|cream
62794124|NCT01397461|ACTIVE_COMPARATOR|retapamulin 1% ointment|1% ointment
62794125|NCT03402035||Whole Blood|Subjects at enrolling centers that utilize whole blood for hemorrhagic shock
62794126|NCT03402035||Component Therapy|Subjects at enrolling centers that utilize component therapy for hemorrhagic shock
62794127|NCT05183438||patients with metachronous colorectal adenomas|
62794128|NCT05183438||patients without metachronous colorectal adenomas|
62218328|NCT00002768|EXPERIMENTAL|Autologous stem cell transplantation|Patients receive consolidation chemotherapy followed by autologous stem cell transplantation
62218329|NCT05970679|EXPERIMENTAL|DW1125|1 Ezetimibe/Atorvastatin 10/5 mg tablet orally once daily
62218330|NCT05970679|EXPERIMENTAL|DW1125A|1 Atorvastatin 5 mg tablet orally once daily
62218331|NCT05970679|PLACEBO_COMPARATOR|DW1125E|1 Ezetimibe 10mg tablet orally once daily
62218332|NCT05970679|PLACEBO_COMPARATOR|DW1125A-1|1 Atorvastatin 10mg tablet orally once daily
62218333|NCT00948766|EXPERIMENTAL|Rivastigmine 13.3 mg/24 h transdermal patch|In the core study, patients were titrated to the rivastigmine 13.3 mg/24 h dose in 2 steps. For Weeks 1-4, patients received rivastigmine 4.6 mg/24 h. For Weeks 5-8, patients received rivastigmine 9.5 mg/24 h and placebo. For Weeks 9-24, patients received rivastigmine 13.3 mg/24 h and placebo. In the extension study, all patients were switched to rivastigmine 9.5 mg/24 h for a 4-week titration period and were then titrated up to 13.3 mg/24 h for a further 20 weeks of treatment.
62794129|NCT01743443|EXPERIMENTAL|Sensitiviy|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
62218334|NCT00948766|ACTIVE_COMPARATOR|Rivastigmine 4.6 mg/24 h transdermal patch|In the core study, patients received rivastigmine 4.6 mg/24 h daily. For Weeks 1-4, patients received rivastigmine 4.6 mg/24 h. For Weeks 5-24, patients received rivastigmine 4.6 mg/24 h and placebo. No patients received this treatment in the extension study.
62586182|NCT04974151|EXPERIMENTAL|Amlodipine folic acid (5.8mg/d)|"Amlodipine folic acid 5.8mg x1 tablet + amlodipine (dummy) x1 tablet + 5-MTHF (dummy) x2 tablets, taken orally, in the morning after waking up.~Amlodipine folic acid tablets, amlodipine placebos, and 5-MTHF placebos are provided in aluminum-plastic blister plate. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 50 plates, each plate includes a total of 8 tablets arranged as follows: amlodipine folic acid 5.8mg x2 tablets + amlodipine (dummy) x2 tablets + 5-MTHF (dummy) x4 tablets. Affixed to the package is the randomized treatment drug label (400 tablets/package, 4 tablets/day)."
62794130|NCT05836168|ACTIVE_COMPARATOR|Probiotic|multi-strain probiotic mixture containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus salivarius W24, Lactococcus lactis W19 in a matrix of maize starch, maltodextrin, inulin, potassium chloride, rice protein, magnesium sulfate, fructooligosaccharides, amylases and mangane sulfate at a dose of 2 x 3g per day for 4 weeks.
62794131|NCT05836168|PLACEBO_COMPARATOR|Placebo|2 x 3g of a similar looking and tasting placebo per day for 4 weeks.
62794132|NCT03772262|EXPERIMENTAL|Control|Study subjects will be administered a single dose of midazolam syrup (2.5 mg), metformin solution (50 mg), furosemide solution (1 mg), and one rosuvastatin tablet (10 mg) by mouth. Plasma will be collected from 0-96 hours. Urine will be collected from 0-24 hours.
62794133|NCT03772262|EXPERIMENTAL|Treatment|Study subjects will be administered goldenseal 2 capsules (500 mg each) three times daily for 5 days. On day 6, subjects will be administered goldenseal 2 capsules (500 mg each), a single dose of midazolam syrup (2.5 mg), metformin solution (50 mg), furosemide solution (1 mg), and one tablet (10 mg) rosuvastatin. Goldenseal 2 capsules (500 mg each) will be administered approximately 4 and 8 hours later. Plasma will be collected from 0-96 hours. Urine will be collected from 0-24 hours.
62794134|NCT04034004|EXPERIMENTAL|Meditation|"Subjects will participate in four sessions (20 min/session) of mindfulness training. Participants will be taught that perceived sensory events are momentary and fleeting and require no further evaluation."
62794135|NCT04034004|EXPERIMENTAL|meditation|"Subjects will participate in four sessions (20 min/session) of mindfulness training. Participants will be taught that perceived sensory events are momentary and fleeting and require no further evaluation."
62794136|NCT06298136|EXPERIMENTAL|Online mindfulness-based intervention (MBI)|The research team have developed an online family MBI (arm 1) for parents and their children with ADHD. It integrates psychoeducation videos (each 3-7 minutes) with audio mindfulness exercises (each 5-15 minutes). The content includes: (1) mindfulness and attention, (2) mindfulness and physical sensation, (3) mindfulness and parental stress, and (4) mindfulness and parental self-care. The majority of the exercises in the first four modules are for parents, but five of them include guidance for child-parent mindfulness exercises. The fifth module targets children with ADHD and the length of video and audio of mindfulness exercises for children, each last 3-5 mins.
62794137|NCT06298136|ACTIVE_COMPARATOR|Psychoeducation|The psychoeducation program is based on the Parent Training for Child ADHD Program developed by Russell Barkley for children with ADHD and other behavioral disorders. It includes: (1) understanding ADHD symptoms, (2) general behavior management principles, (3) positive reinforcement and attending skills, (4) the use of a reward and token system, and (5) child problem-solving skills.
62794138|NCT03698227|EXPERIMENTAL|Study treatment|"* Olaratumab 20 mg/kg IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab IV on day 1 and day 8 of cycles 2-8.~* Plus dexrazoxane at a dose equal to 10 times the doxorubicin dose (mg/m2) IV on day 1 of each 21 day cycle for 8 cycles~* Plus doxorubicin 75 mg/m2 IV on day 1 of each 21 day cycle for 8 cycles~* Beginning with cycle 9, olaratumab maintenance monotherapy at 15 mg/kg IV on day 1 and day 8 of each subsequent 21 day cycle"
62794139|NCT03580681|EXPERIMENTAL|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
62794140|NCT03580681|PLACEBO_COMPARATOR|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
62794141|NCT02586623|EXPERIMENTAL|Open Label Period|Active droxidopa 100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally. During the Open Label Titration Period, patients will first receive 100 mg TID and their dose will be raised (in 100 mg increments) at subsequent visits until optimal dose is determined. During the Open Label Treatment Period, patients will receive active droxidopa100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally (equal to the patient's individual dose at the end of the Open-Label Titration Period).
62794142|NCT02586623|PLACEBO_COMPARATOR|Randomized Period|Active droxidopa 100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally (equal to patients individual dose at the end of the Open-Label Period) or matching placebo.
62794143|NCT05980585|EXPERIMENTAL|Study Group|The Study group will use the CPM device once daily (in the morning) for 60 days.
62794144|NCT03724929|EXPERIMENTAL|Ulcerative Colitis patients|"To determine if the best cut-off points of vedolizumab (VDZ) trough levels measured at W6 capable to identify UC patients who will achieve a clinical response at week 10 with VDZ and also the best cut-off points of VDZ trough levels measured at W14 capable to identify UC patients who will achieve a clinical remission to maintenance therapy with VDZ :~Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.~Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52, to evaluate treatment efficacy.~In cases of loss of response, rectosigmoidoscopy will be performed before and four weeks after optimization."
62218335|NCT06327581|EXPERIMENTAL|lactic acid group|· First group (A): 11 AA patients will be treated with MN combined with lactic acid solution 1%. Lactic acid solution 88% concentration PH (6.84), diluted with distilled water to have a final concentration of 1%
62022321|NCT03331120|ACTIVE_COMPARATOR|Control Group|"1--Control group~. Conventional treatment:~1. moist hot pack.~2. manual therapy.~3. Therapeutic Exercise.~4. Home program routine."
62022322|NCT03331120|EXPERIMENTAL|Study or Experimental Group|"2--Experimental or study group:~1. moist hot pack.~2. manual therapy.~3. Therapeutic Exercise.~4. Home program routine.~5. ambulatory mirror image functional re-training through wearing 3D adjustable cervical thoracic Posture Corrective orthosis (CTPCO) For 10 weeks(3Times/week for 20 minutes)."
62022323|NCT06300021|EXPERIMENTAL|Sequence capsule - ready to drink - sport bar - dairy analog - gummies - probiotic drink|Subjects receive Turmipure Gold® preparations in different food matrices in the following order: capsule - ready to drink - sport bar - dairy analog - gummies - probiotic drink
62022324|NCT06300021|EXPERIMENTAL|Sequence dairy analog - probiotic drink - ready to drink - gummies - capsule - sport bar|Subjects receive Turmipure Gold® preparations in different food matrices in the following order: dairy analog - probiotic drink - ready to drink - gummies - capsule - sport bar
62218336|NCT06327581|EXPERIMENTAL|vitamin d3|· Second group (B): 11 AA patients will be treated with MN combined with topical application of vitamin D3 (an aqueous preparation of cholecalciferol (Devarol® ampoule 200 000 IU/2 ml, Memphis, Egypt) (2.5 mg/ ml), The maximum total amount of vitamin D3 injected into a patient in every session will be 2.5 mg (1 ml)
62218337|NCT06327581|EXPERIMENTAL|triamcinolone acetonide group|· Third group (C): 11 AA patients will be treated with MN combined with triamcinolone acetonide injectable suspension (Epirelefan®, 40mg/ ml, Eipico, Egypt) (10 mg/ml) will be used in a dose of 0.1 ml/cm2 area
62218338|NCT06327581|EXPERIMENTAL|saline|· Fourth group (D): 11 AA patients will be treated with MN combined with normal saline 0.9%
62218339|NCT02750280|EXPERIMENTAL|Urinary Bladder matrix (UBM)|UBM covered with silicone foam dressing plus total contact cast
62218340|NCT02750280|ACTIVE_COMPARATOR|Standard Care|Silicone foam dressing plus total contact cast
62794145|NCT03309423||Respiratory disease|Patients with acute respiratory insufficiency admitted to the ICU and with pH \<7,35 or \>7,45
62794146|NCT03309423||Metabolic disease|Patients with acute metabolic disease admitted to the ICU and with pH \<7,35 or \>7,45
62794147|NCT03309423||Sepsis|Patients with acute sepsis admitted to the ICU and with pH \<7,35 or \>7,45
62794148|NCT02053636|EXPERIMENTAL|lucitanib|"Hard gelatine capsules of 2,5, 5 and 10 mg or film coated tablets of 5 and 7,5 mg.~5 to 10 mg orally on a daily basis until unacceptable toxicity according to the investigator, disease progression or withdrawal of consent"
62794149|NCT06051903|EXPERIMENTAL|Talar mobilization with movement|(group A) postmenopausal women who receive the talar mobilization with movement technique for knee joint , their age raged from 50-60 years (n= 20)
62022325|NCT06300021|EXPERIMENTAL|Sequence gummies - sport bar - probiotic drink - capsule - dairy analog - ready to drink|Subjects receive Turmipure Gold® preparations in different food matrices in the following order: gummies - sport bar - probiotic drink - capsule - dairy analog - ready to drink
62218341|NCT04831541|EXPERIMENTAL|68Ga-PSMA-11|Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
62022326|NCT06300021|EXPERIMENTAL|Sequence probiotic drink - gummies - dairy analog - sport bar - ready to drink - capsule|Subjects receive Turmipure Gold® preparations in different food matrices in the following order: probiotic drink - gummies - dairy analog - sport bar - ready to drink - capsule
62218342|NCT02247557|EXPERIMENTAL|Group A: Liposome encapsulated BoNT-A|Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
62218343|NCT02247557|EXPERIMENTAL|Group B: BoNT-A 200 U in Normal saline|BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation
62022327|NCT06300021|EXPERIMENTAL|Sequence ready to drink - dairy analog - capsule - probiotic drink - sport bar - gummies|Subjects receive Turmipure Gold® preparations in different food matrices in the following order: ready to drink - dairy analog - capsule - probiotic drink - sport bar - gummies
62218344|NCT02247557|PLACEBO_COMPARATOR|Group C: Normal saline|Normal saline (N/S) 50ml in single intravesical instillation
62022328|NCT06300021|EXPERIMENTAL|Sequence sport bar - capsule - gummies - ready to drink - probiotic drink - dairy analog|Subjects receive Turmipure Gold® preparations in different food matrices in the following order: sport bar - capsule - gummies - ready to drink - probiotic drink - dairy analog
62022329|NCT00548821|EXPERIMENTAL|2|ARM 2: Weekly cisplatin 40mg/m2, concurrent with radiotherapy.
62218345|NCT02806648|EXPERIMENTAL|Palbociclib|Palbociclib
62218346|NCT00872677||Dietitian-led counseling and Weight Watchers|Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.
62794150|NCT06051903|EXPERIMENTAL|Acupuncture for knee joint|(group B) postmenopausal women who receive acupuncture for knee joint (n= 20), their age ranged from 50-60 years
62794151|NCT03357562|EXPERIMENTAL|lung MRI|lung MRI without contrast injection
62794152|NCT02521922|EXPERIMENTAL|VSP Study Participants|Vital Signs Patch system study participants. Each study participant will receive the VSP System - NEHB Configuration and then the VSP System - PAL Configuration. Vital signs will be taken and adhesive will be assessed for each participant for each configuration.
62022330|NCT00548821|EXPERIMENTAL|1|ARM 1: 5-day 3 weekly cisplatin 20mg/m2 for 5 days, concurrent with radiotherapy
62218347|NCT00872677||Dietitian & Weight Watchers + Spirituality Counseling|Dietitian wkly for the 1st-3 months, every other week for the next 3 months and monthly thereafter; Spiritual counselor weekly in months 6-9, every other week in months 9-12 and monthly thereafter.
62218348|NCT04835337|EXPERIMENTAL|Air purifier|Participants in this group receive an intervention of real air purifiers placed in the indoor environment.
62218349|NCT04835337|SHAM_COMPARATOR|Control|Participants in this group receive an intervention of sham air purifiers, we just remove the filter in the purifiers, and the other treatments are the same as the real purification group.
62794153|NCT00005617|EXPERIMENTAL|Group A|No. DC: 10\^5 Route of Immunization: ID
62794154|NCT00005617|EXPERIMENTAL|Group B|No. DC: 10\^5 Route of Immunization: IV
62794155|NCT00005617|EXPERIMENTAL|Group C|No. DC: 10\^6 Route of Immunization: ID
62794156|NCT00005617|EXPERIMENTAL|Group D|No. DC: 10\^6 Route of Immunization: IV
62022331|NCT03032120|EXPERIMENTAL|Fresh orange juice|Intervention: The subjects drank 5 mL/kg body weight of fresh-squeezed orange juice (FOJ).
62218350|NCT04048421|EXPERIMENTAL|hvNOTES group|Participants will undergo hvNOTES radical colectomy.
62218351|NCT02810587||Topical antibiotics group|Those who receive topical antibiotics after intravitreous injection as home medication for 7 days.
62218352|NCT02810587||No topical antibiotics group|Those who does NOT receive topical antibiotics after intravitreous injection as home medication.
62412408|NCT06283485||Female|"Phase 1: Creating artificial intelligence from ultrasound scans of 150 healthy volunteers Sonoanatomical PENG and Suprainguinal Fascia Iliaca Block pictures are taken as follows.~1) PENG (Pericapsular Nerve Group Block): Linear and convex probes will be used to collect images. No invasive procedures will be conducted on healthy subjects for sonoanatomical data. 150 healthy volunteers (75 women-75 males) will be ultrasounded.~1.2) Suprainguinal Fascia Iliaca Block: Linear probe images. No invasive procedures will be conducted on healthy subjects for sonoanatomical data. 150 healthy individuals (75 female-75 male) will be ultrasounded."
62794157|NCT00005617|EXPERIMENTAL|Group E|No. DC: 10\^7 Route of Immunization: ID
62794158|NCT00005617|EXPERIMENTAL|Group F|No. DC: 10\^7 Route of Immunization: IV
62794159|NCT04531241|EXPERIMENTAL|Test/Control|Eligible subjects that are habitual wearers of daily disposable contact lenses in both eyes will be randomly assigned to sequence, Test/Control.
62794160|NCT04531241|EXPERIMENTAL|Control/Test|Eligible subjects that are habitual wearers of daily disposable contact lenses in both eyes will be randomly assigned to sequence, Control/Test.
62794161|NCT05981482||Stroke survivors|Individuals who have survived a stroke
62794162|NCT05650281||Patients|Patients with RRMS (2017 Mc Donald criteria) treated with highly active treatment in the first 5 years of symptoms onset, at least 1 year, with an EDSS below 4
62794163|NCT01979952|EXPERIMENTAL|Nintedanib|150 mg twice daily
62022332|NCT03032120|EXPERIMENTAL|Processed orange juice|Intervention: The subjects drank 5 mL/kg body weight of processed orange juice (POJ).
62218353|NCT03139669|EXPERIMENTAL|HPV home testing kit|The procedures will be recruitment of under-screened women in Health Districts 1, 2 and 3 of Southwest Virginia to complete HPV home testing using self-collection kits distributed by lay navigators. Regardless of HPV positivity, all women will be provided with information about cervical cancer screening (locations, cost, etc.), and will be encouraged to complete Pap screening by a clinician.
62218354|NCT02875886|ACTIVE_COMPARATOR|Diuretic treatment|Patients receive amiloride and hydrochlorothiazide
62218355|NCT02875886|ACTIVE_COMPARATOR|Low-sodium diet|Patients are put on a low-sodium diet (60 mmol/day)
62412409|NCT05205824|OTHER|Algorithm validation|all subjects will be measured with inertial measurement units while performing tasks like walking, standing and sitting.
62794164|NCT01979952|PLACEBO_COMPARATOR|Placebo|twice daily dosing
62794165|NCT04737018|EXPERIMENTAL|vibration program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation. The program will apply a frequency of 100 Hz, with an amplitude of 1 mm
62794166|NCT04737018|SHAM_COMPARATOR|sham program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation.
62794167|NCT06407050|EXPERIMENTAL|4-hr trial|Participants will go through a day of routine step counts and sleep hour monitor, 2 days of being physical active by taking ambulatory steps, 4 hours of physical inactivity intervention, and moderate intensity cycling, and 1 high fat tolerance test.
62794168|NCT06407050|EXPERIMENTAL|8-hr Trial|Participants will go through a day of routine step counts and sleep hour monitor, 2 days of being physical active by taking ambulatory steps, 8 hours of physical inactivity intervention, and moderate intensity cycling, and 1 high fat tolerance test.
62794169|NCT06407050|EXPERIMENTAL|12-hr Trial|Participants will go through a day of routine step counts and sleep hour monitor, 2 days of being physical active by taking ambulatory steps, 12 hours of physical inactivity intervention, and moderate intensity cycling, and 1 high fat tolerance test.
62022333|NCT03032120|EXPERIMENTAL|Control|The subjects drank 5 mL/kg body weight of control drink compounded by water mixed with sugars in a similar concentration of orange juices (5.2% of sucrose, 2.5% of fructose, 2.1% of glucose, 0.75% of citric acid, and malic acid 0.25%, flavored and colored with some drops of orange essence).
62794170|NCT04656457|ACTIVE_COMPARATOR|resistance exercises|Resistance exercises will be involved in this technique are for upper and lower limb (Exercise program including shoulder flexion, abduction and horizontal adduction, elbow extension and flexion, calf raise, leg extension and squatting) three times daily and five times per week. The 1 repetition maximum (1RM) is measured at baseline and following the intervention. Initially, participants will do two circuits using 50% of their 1RM and repeat them 10 times for the first and second weeks, progressing to two circuits, using 60% of their 1RM and repeat 10 times for the third and fourth weeks. In fifth and sixth weeks, participants will do three circuits using 60% of their 1RM and repeat 10 times. In the last 6 weeks, patients will do three circuits using 70% of their 1RM and repeat 10 times. Time of exercise equal time of rest
62794171|NCT04656457|ACTIVE_COMPARATOR|aerobic exercise|Aerobic training (AT) program of submaximal intensity will include a 45-minute session five times per week under the supervision of the researcher. Aerobic exercise will consist of three phases: warm-up, training and cool down. At the beginning of exercise session, subjects will have a ten-minute warm-up. The warm up protocol will be slowly running on treadmill. Then, the warm-up phase will be followed by the training phase. At baseline, the training phase will be commenced with two 30- minute running on treadmill at 50% of their maximal heart rate (MHR) in the first week and increased to 70% MHR by the final week of training. By the end of exercise session, subjects will have a five-minute cool down. The cool down protocol will be slowly running on treadmill. The vital measures such as HR and blood pressure was monitored before patient left the department (Dimeo et al.,2016), maximum heart rate will be calculated using the formula: (HR Max =220- age)
62022334|NCT01506739|ACTIVE_COMPARATOR|1|
62218356|NCT02923492|EXPERIMENTAL|In-person Therapy by ED Staff|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care delivered by ED staff in-person.
62218357|NCT02923492|EXPERIMENTAL|Remote Therapy by Research Staff|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care delivered remotely (over video) by research staff.
62218358|NCT02923492|NO_INTERVENTION|Comparison Group|This group will not receive an intervention, but did receive an informational pamphlet of resources in the area (enhanced usual care).
62218359|NCT05192941|EXPERIMENTAL|Inclisiran sodium 300 mg s.c. + open label rosuvastatin|"Participants will be randomized at the baseline visit (Day 1) to one of the following two double-blind treatment groups in a 1:1 ratio.~1. Inclisiran sodium 300 mg s.c.~2. Corresponding placebo~Open label study treatment rosuvastatin: all participants will receive rosuvastatin, starting at the lowest indicated dose and titrating up until they reach their individual LDL-C target or MTD, whichever occurs first."
62243303|NCT01686360|EXPERIMENTAL|Frequency + Average 50 year old|Group receives Gail score in a frequency format as well as information about risk of breast cancer for the average 50 year old woman. (Behavioral: Decision Aid)
62243304|NCT01686360|EXPERIMENTAL|Frequency + Mammography Data|Group receives Gail score in a frequency format as well as information about the risks of mammography. (Behavioral: Decision Aid)
62586183|NCT04974151|EXPERIMENTAL|Amlodipine folic acid (5.8mg/d) + 5-MTHF (0.4mg/d)|"Amlodipine folic acid 5.8mg x1 tablet + 5-methyltetrahydrofolate 0.2mg x2 tablets + amlodipine (dummy) x1 tablet, taken orally, in the morning after waking up.~Amlodipine folic acid tablets, 5-MTHF, and amlodipine placebos are provided in aluminum-plastic blister plate. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 50 plates, each plate includes a total of 8 tablets arranged as follows: amlodipine folic acid 5.8mg x2 tablets + amlodipine (dummy) x2 tablets + 5-MTHF, 0.2mg x4 tablets. Affixed to the package is the randomized treatment drug label (400 tablets/package, 4 tablets/day)."
62794172|NCT06090565|EXPERIMENTAL|Cefixime plus doxycycline|Single-dose cefixime 800 mg plus doxycycline 100 mg b.i.d. for 7 days
62794173|NCT06090565|ACTIVE_COMPARATOR|Ceftriaxone plus azithromycin|Single dose ceftriaxone 1 g plus single-dose azithromycin 2 g
62794174|NCT02517697|EXPERIMENTAL|Active drug|14 Nitrogen (N) Sodium Nitrite 40mg three times daily (TID)
62794175|NCT02517697|PLACEBO_COMPARATOR|Placebo|placebo capsules three time daily (TID)
62794176|NCT02759250|EXPERIMENTAL|adjuvant monotherapy|ARGX-110 5mg/kg once every three weeks for a maximum of 18 cycles
62794177|NCT02759250|EXPERIMENTAL|metastatic/recurrent monotherapy|ARGX-110 5mg/kg once every three weeks until disease progression
62794178|NCT02759250|EXPERIMENTAL|metastatic/recurrent combination therapy|ARGX-110 5mg/kg once every three weeks plus chemotherapy until disease progression. The choice of the chemotherapy agents is limited to: cisplatin, carboplatin, 5-fluorouracil, gemcitabine and paclitaxel.
62794179|NCT02134717|EXPERIMENTAL|sarcoidosis stage II|All subjects with active stage II sarcoidosis with or without skin disease will receive the drug maraviroc 300mg to be taken orally twice a day for 6 weeks duration.
62586184|NCT03807219|ACTIVE_COMPARATOR|Magnox Comfort|80 subjects will be on the Magnox Comfort arm.
62794180|NCT00620724|PLACEBO_COMPARATOR|A|Placebo three times daily
62794181|NCT00620724|EXPERIMENTAL|B|20 mg of slow-release Nifedipine three times daily
62022335|NCT01506739|ACTIVE_COMPARATOR|2|
62022336|NCT01506739|ACTIVE_COMPARATOR|3|
62022337|NCT03466580|EXPERIMENTAL|Intervention|('Standard' specialized palliative care +) The Carer Support Needs Assessment Tool (CSNAT) intervention.
62022338|NCT03466580|NO_INTERVENTION|Control|('Standard' specialized palliative care). No intervention offered.
62022339|NCT05369234|EXPERIMENTAL|Cohort 1--Arm 1|Aloe Vera Juice + Standard of Care Treatments Swish and spit ¼ cup (2 ounces) of 100% aloe vera juice 3 times per day, 7 days per week as first line treatment, standard of care agents added as needed
62218360|NCT05192941|PLACEBO_COMPARATOR|Corresponding placebo + open label rosuvastatin|"Participants will be randomized at the baseline visit (Day 1) to one of the following two double-blind treatment groups in a 1:1 ratio.~1. Inclisiran sodium 300 mg s.c.~2. Corresponding placebo~Open label study treatment rosuvastatin: all participants will receive rosuvastatin, starting at the lowest indicated dose and titrating up until they reach their individual LDL-C target or MTD, whichever occurs first."
62218361|NCT02187627|EXPERIMENTAL|Part 1: Tracer Selection|Participants will receive a single dose of one tracer on one occasion and a single dose of a different tracer after 7 to 14 days and will be followed for 7 to 14 days for safety. At the end of Part 1, one tracer with the best performance will be selected for further study in Part 2.
62218362|NCT02187627|EXPERIMENTAL|Part 2A: Test-Retest|Participants will receive a single dose of selected tracer from Part 1 on one occasion and then same tracer will be administered after 6 weeks. Participants will be followed for 7 to 14 days after last PET tracer administration for safety.
62586185|NCT03807219|PLACEBO_COMPARATOR|Placebo|80 subjects will be on the Placebo arm.
62586186|NCT00941499|EXPERIMENTAL|Group 1|HAI oxaliplatin in combination with HAI 5-fluorouracil and IV bevacizumab
62794182|NCT02770924|EXPERIMENTAL|AT LISA TRI TORIC|All patients will be undergo to phacoemulsification with IOL implantation bilateral
62794183|NCT02770924|EXPERIMENTAL|AT LISA TRI|All patients will be undergo to phacoemulsification with IOL implantation bilateral
62022340|NCT05369234|ACTIVE_COMPARATOR|Cohort 1--Arm 2|Standard of Care Treatments Use salt and baking soda rinses, Magic Mouthwash, Carafate, etc.
62022341|NCT05369234|EXPERIMENTAL|Cohort 2--Arm 1|Aloe Vera Juice + Standard of Care Treatments Drink ¼ cup (2 ounces) of 100% aloe vera juice 3 times per day, 7 days per week as first line treatment, standard of care agents added as needed
62022342|NCT05369234|ACTIVE_COMPARATOR|Cohort 2-- Arm 2|Standard of Care Treatments Use salt and baking soda rinses, Magic Mouthwash, Carafate, etc.
62022343|NCT05550246|EXPERIMENTAL|AtoOxy Predicted Responders|Participants will take Atomoxetine (80mg) and Oxybutynin (5mg) before bedtime for 3 nights. Half doses will be given on the first night.
62022344|NCT05550246|EXPERIMENTAL|AtoOxy Predicted Nonresponders|Participants will take Atomoxetine (80mg) and Oxybutynin (5mg) before bedtime for 3 nights. Half doses will be given on the first night.
62022345|NCT01785589|OTHER|coronary angiography-FFR-CZT|Patients who were referred to our cardiology department for stress-rest CZT SPECT for known or suspected CAD and submitted for a clinical reason to invasive coronary angiography within 2 month of the SPECT studies. for these patients, A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
62022346|NCT02194621|EXPERIMENTAL|Total Flavor Option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM (oral malodor) complex 1 ingredient - Total Flavor Option 1
62022347|NCT02194621|EXPERIMENTAL|Total Flavor Option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM (oral malodor) complex 2 ingredient. Total Flavor Option 2
62218363|NCT02187627|EXPERIMENTAL|Part 2B: Dosimetry|Participants will receive a single dose of selected tracer from Part 1 and will be followed for 7 to 14 days for evaluation of radiation dosimetry.
62218364|NCT03484273|EXPERIMENTAL|Full Compression|The LifeWrap compression garment will be fully secured with all straps.
62218365|NCT03484273|EXPERIMENTAL|Abdominal and Pelvic Compression|The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.
62218366|NCT03484273|EXPERIMENTAL|Lower Limb Compression|The Lifewrap compression garment calf and ankle straps only will be secured.
62586187|NCT00941499|EXPERIMENTAL|Group 2|HAI oxaliplatin in combination with IV 5-fluorouracil, leucovorin, bevacizumab, and cetuximab
62586188|NCT00941499|EXPERIMENTAL|Group 3|HAI oxaliplatin in combination with IV bevacizumab.
62586189|NCT00941499|EXPERIMENTAL|Group 4|HAI oxaliplatin in combination with IV bevacizumab and cetuximab.
62819412|NCT06306599|EXPERIMENTAL|Experiment|20 participants ultrasound scan five patients with thyroid nodules, and assess these nodules themselves, then with the AI-program, and at last they give a combined assessment.
62586190|NCT03636724|EXPERIMENTAL|Intervention group|Patients will receive the interventions on both PA and FVI simultaneously.
62586191|NCT03636724|NO_INTERVENTION|Waiting control group|Patients will not receive any supportive interventions on PA or FVI during the intervention period but will be provided with the same intervention at follow-up six-month after the intervention.
62412410|NCT03300726||MCI due to AD or mild AD dementia|The clinical diagnoses of amnestic MCI due to AD or mild AD dementia will be made according to standard clinical criteria as described by the National Institute of Aging -Alzheimer's Association Working Group and supported by CSF biomarker data for tau, p-tau181, and Aβ42. This includes evaluation for other systemic or neurological disorders which could account for the cognitive impairment, and inclusion of results from ancillary structural imaging (CT or structural MRI), neuro-psychometric testing, and FDG-PET imaging (when available) into the diagnostic scheme. All participants in this group will undergo clinical and cognitive evaluations, CSF analysis, and functional MRI during resting state and semantic memory tasks.
62794184|NCT00891228|PLACEBO_COMPARATOR|Testosterone Gel 10 g and Nestorone® 0 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
62218367|NCT03484273|NO_INTERVENTION|No Compression|None of the LifeWrap compression garment straps will be secured.
62218368|NCT04230291|OTHER|Verbal Consultation, then Written Action Plan|"CONTROL GROUP~1. Survey A~2. Routine clinic visit~3. Verbal consultation only~4. Survey B~5. Verbal consultation AND Written Action Plan~6. Survey C"
62218369|NCT04230291|EXPERIMENTAL|Written Action Plan|"INTERVENTION GROUP~1. Survey A~2. Routine clinic visit~3. Verbal consultation AND Written Action Plan~4. Survey C"
62218370|NCT00734097|EXPERIMENTAL|Nexium 40 mgs|
62218371|NCT05385432|EXPERIMENTAL|rabbit antithymocyte globulin (rATG)|The infusion of rATG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained. The recommended initial tacrolimus dose is Prograf® 0.1mg/kg/day twice day.
62218372|NCT05385432|ACTIVE_COMPARATOR|Basiliximab|The infusion of Basiliximab (Simulect® (20mg)) starts before the surgery on peripheral vein for 15 minutes and the second infusion at day 4.
62586192|NCT06172907|OTHER|Young Adults Coping with Cancer Together Intervention|Young adults with cancer and their partner-caregivers will attend dyadic virtual psychotherapy sessions lasting 45-60 minutes on a weekly basis for eight weeks.
62794185|NCT00891228|EXPERIMENTAL|Testosterone Gel 10 g and Nestorone® 8 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg NES mL gel) by pressing two times with 2 mL dispenser head.
62794186|NCT00891228|EXPERIMENTAL|Testosterone Gel 10 g plus Nestorone® Gel 12 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
62022348|NCT02194621|PLACEBO_COMPARATOR|Crest Toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste (currently marketed)
62794187|NCT01388907|EXPERIMENTAL|Prevadh film|Patient randomized in this arm have been treated with Prevadh film applied on the uterine surgical sites, at the end of the myomectomy surgery to prevent post-surgey adhesion formation.
62022349|NCT02981394||BMAC Group|Intervention Group
62022350|NCT03006406|ACTIVE_COMPARATOR|Long term GnRH-a for 1 month|patient in this group only receive GnRH-a 3.75 for 1 month
62218373|NCT00822523|EXPERIMENTAL|Botulinum toxin type A, 20 units|Single intramuscular (into extensor digitorum brevis muscle of the foot) dose of Botulinum toxin type A, 20 units
62218374|NCT00822523|EXPERIMENTAL|Botulinum toxin, type A, 2 units|Single intramuscular (into extensor digitorum brevis muscle of the foot) dose of Botulinum toxin type A, 2 units
62218375|NCT00822523|PLACEBO_COMPARATOR|Placebo|Saline, Single dose, Intramuscular injection into right EDB
62218376|NCT04325243|EXPERIMENTAL|study group|50 mg oral sildenafil citrate tablet
62218377|NCT04325243|PLACEBO_COMPARATOR|placebo group|placebo tablets of the same shape, color and size of sildenafil citrate tablets
62218378|NCT06083597||Chronic pelvic pain of venous origin|Women who are thought to have chronic pelvic pain of venous origin will be interviewed to determine the impacts of their pain on physical, social and emotional aspects of their health and well being.
62794188|NCT01388907|ACTIVE_COMPARATOR|Ringer solution|Patients randomized in the Ringer solution group have been treated with Ringer lactate solution directly applied to the uterine surgical sites at the end of the myomectomy surgery.
62218379|NCT06083597||Chronic pelvic pain of non-venous origin|Women who are thought to have chronic pelvic pain of a non-venous origin will be interviewed to determine the impacts of their pain on physical, social and emotional aspects of their health and well being. They will be asked of the concepts identified by the women with venous origin CPP apply to them and if the impacts of the pain are similar or differ.
62218380|NCT06610071|EXPERIMENTAL|Patients with DFSP in the first experimental group|The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group.
62218381|NCT06610071|EXPERIMENTAL|Patients with DFSP in the second experimental group|The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
62022351|NCT03006406|EXPERIMENTAL|patient in this group only receive GnRH-a 3.75 for 2 month|patient in this group only receive GnRH-a 3.75 for 2 month
62022352|NCT02683538|EXPERIMENTAL|Separable cluster electrode|radiofrequency ablation (RFA) using separable cluster electrode in switching monopolar mode.
62022353|NCT01772992|NO_INTERVENTION|Control group (iVCT)|Male couples randomized to the control group (iVCT) will each receive individual HIV counseling and testing, separately.These couples in the control group (iVCT) will return every 6 months, up to 18 months, for individual visits, in which they will have STI testing and repeat HIV testing. All follow-up visits will be conducted separately.
62218382|NCT06610071|NO_INTERVENTION|Patients with DFSP in the control group|
62586193|NCT00694473|EXPERIMENTAL|Freestyle Navigator|Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
62218383|NCT06610071|EXPERIMENTAL|Patients with sSCC in the first experimental group|The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group.
62218384|NCT06610071|EXPERIMENTAL|Patients with sSCC in the second experimental group|The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
62218385|NCT06610071|NO_INTERVENTION|Patients with sSCC in the control group|
62412411|NCT03300726||Normal controls|Normal cognition will be defined as cognitive performance on detailed neuropsychometric testing that falls within 1 SD of age-, gender-, and education-matched norms in all cognitive domains, and no subjective report of cognitive decline from an individual's baseline (i.e. CDR 0). All participants in this group will undergo clinical and cognitive evaluations, CSF analysis, and functional MRI during resting state and semantic memory tasks.
62586194|NCT03448575|SHAM_COMPARATOR|Control - Medication Alert Only|The control arm medication alert is a simple text pop-up in the EMR that will inform the prescriber of Choosing Wisely® recommendations developed the American Psychiatric Association regarding antipsychotic medication use in children and adolescents.
62586195|NCT03448575|EXPERIMENTAL|Intervention - Alert + CAP Review AND Enhanced BH Access|"The intervention alert prompts the prescriber to keep/remove the antipsychotic order, and/or order any study services: behavioral health navigation, expedited psychotherapy access, virtual consult with a child and adolescent psychiatrist (CAP). Passive case review by the study CAP will occur for all intervention arm cases. A virtual consult will be scheduled if the prescriber ordered it or the CAP needs to discuss the case. The CAP will provide the prescriber with a written summary of his/her review.~Following review by the CAP, a navigator reaches out to the eligible intervention arm patient/family to offer extra support. The navigator's role is to (a) provide extra support to facilitate access and engagement in appropriate psychosocial therapies; (b) coordinate short-duration bridging therapy sessions for teens/families not engaged in psychotherapy, when appropriate; and (c) keep the prescriber informed of any clinically relevant updates."
62794189|NCT05431478|OTHER|LID022821, then AOHP|Serafilcon A contact lenses worn during Period 1, with senofilcon A contact lenses worn during Period 2, as randomized. Each study lens type will be worn bilaterally (in both eyes) at least 10 hours per day for approximately 14 days. CLEAR CARE will be used for daily cleaning and disinfection. The serafilcon A contact lenses will be replaced with a fresh pair at the Week 1 follow-up visit.
62412412|NCT02918318|EXPERIMENTAL|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
62412413|NCT02918318|EXPERIMENTAL|Esketamine 28 milligram (mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
62412414|NCT02918318|EXPERIMENTAL|Esketamine 56 mg|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
62586196|NCT02287285|EXPERIMENTAL|Exendin9|Longitudinal study of insulin secretion and sensitivity in patients with type 2 diabetes before and after gastric bypass surgery.
62586197|NCT03633305|ACTIVE_COMPARATOR|Treatment as usual|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks
62586198|NCT03633305|EXPERIMENTAL|Online cognitive behavior therapy|Online CBT- Internet self-help program for insomnia with 6 cores
62586199|NCT03633305|EXPERIMENTAL|Treatment as usual + Online CBT|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks Online CBT- Internet self-help program for insomnia with 6 cores
62586200|NCT03633305|EXPERIMENTAL|Medication|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks (arms 1, 3, 4)
62586201|NCT03633305|EXPERIMENTAL|In-person cognitive behavior therapy|Face-to-face CBT- Face-to-face therapy with 3 to 4 individual sessions in a period of 6 to 8 weeks.
62586202|NCT03633305|NO_INTERVENTION|No additional treatment|
62586203|NCT04862923||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
62586204|NCT06665841||Trial volunteers|Trial volunteers refer to healthy individuals undergoing physical examinations at our hospital or recruited healthy university students.
62586205|NCT06665841||Cervical lesions|Patients with cervical lesions, including those with uterine fibroids, cervical cancer, endometrial cancer, and ovarian cancer.
62218386|NCT01728168||Atopic|Subjects with either documented allergy, neurodermatitis, allergic asthma, allergic rhinitis, and/or a positive atopic score based on the criteria of Erlangen (\>10 points).
62218387|NCT01728168||Non-atopic|Subjects without atopy.
62218388|NCT04907526|EXPERIMENTAL|Treatment Arm|Autologous (self) mononuclear cells derived from umbilical cord blood and that meet all release criteria are injected into the surface of the right heart muscle to achieve the target dose of 3 million cells per kilogram of body weight. This is a one time treatment at the time of Stage III Fontan surgery.
62218389|NCT04907526|NO_INTERVENTION|Control Arm|Control cohort not receiving the cell product, which will be enrolled and followed using the same inclusion/exclusion criteria and follow-up requirements as the treatment arm.
62218390|NCT02943811||MANIPULATOR|Patients who were operated for endometrial cancer by laparoscopy with the use of a uterine manipulator
62218391|NCT02943811||NO MANIPULATOR|Patients who were operated for endometrial cancer by laparoscopy without the use of a uterine manipulator
62218392|NCT04705103||initial|
62218393|NCT04705103||relapse|
62218394|NCT04705103||inactive|
62218395|NCT04223739|ACTIVE_COMPARATOR|Landiolol|Landiolol infusion starting at 2.5 µg/kg/min and titrating up to 80µg/kg/min with a heart rate goal of under 90 bpm.
62218396|NCT04223739|ACTIVE_COMPARATOR|Amiodarone|Amiodarone bolus of 5-7 mg/kg in 1 hour, followed by an infusion of 1g/day until conversion to sinus rhythm.
62412415|NCT02918318|EXPERIMENTAL|Esketamine 84 mg|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
62218397|NCT04330352|EXPERIMENTAL|"Mindfulness-based STOP touching your face intervention"|"Eligibility participants who are allocated to the intervention group will be required to find a time to monitor and record their behavior of hand-to-face contacts, including the frequency and length (in second) of face-touching in any of the mucosal area (eyes, nose, mouth) and nonmucosal area (ears, cheeks, chin, neck, forehead, hair) during a 60-minute period. Then, they will receive the online mindfulness-based STOP touching your face program. Each participant will be required to practice this technique until they feel confident and natural. The systematic review showed the efficacy of single session of brief MBIs, the average length was 15 minutes, ranged from less than 5 to 25 min. Thus, the requirement practice time will be at least 15 minutes (excluding the time of reading the text and the first time of listening to the audio). Later (at least 1-hour interval), they will be asked to self-monitor and report their one-hour face-touching behavior again."
62218398|NCT04330352|NO_INTERVENTION|Contron information intervention|"Participants who allocate to the control group will only receive information to thank them and encourage them to complete the study. They will receive STOP touching your face program after the end of this study. The repeat measurement of the face-touching behavior will be in at least 1-hour interval."
62586206|NCT06665841||persistent HPV infection|Persistent HPV infection refers to the infection by the same type of HPV for more than 12 months.
62586207|NCT06665841||Non-persistent HPV infection|Non-persistent HPV infection refers to the absence of HPV infection.
62586208|NCT06565104|ACTIVE_COMPARATOR|BWell4Life Control Arm|BWell4Life is a 4-week community health promotion program focused on lifestyle change through consumption of a healthy diet and being physically active through weekly educational sessions, setting specific, measurable, attainable, realistic, and timely (S.M.A.R.T.) goals for health behavior modification, and didactic content based on the American Heart Association (AHA) Life's Essential 8 framework. The two diet sessions include an overview of nutrition basics, examples of healthy dietary patterns and cooking methods to increase consumption of plant-based foods and healthy proteins and reduce intakes of red and processed meats, sugary foods, and sugar-sweetened beverages. The two physical activity sessions provide an overview of the physical activity guidelines and include 30-60 minutes of exercise. These sessions also address achieving and maintaining a healthy body weight. Participants will receive a Fitbit for self-monitoring and collecting sleep health and physical activity data.
62738659|NCT03832322||CO2 insufflation colonoscopy|During the first-pass colonoscopy, the procedure was performed in the usual fashion, with minimal CO2 insufflation to aid insertion. Cleaning of colon was predominantly performed during withdrawal. After the first complete withdrawal of the colonoscope, a second colonoscopic examination aided by CO2 insufflation during insertion and withdrawal was performed by the same endoscopist. The colonoscope was reinserted into the cecum as quickly as possible, and the entire colon was re-examined. Polyp resection was carried out during insertion and withdrawal of the first- and second-pass examinations.
62412416|NCT02424799|EXPERIMENTAL|Part A: Dose group 1|Subjects will be treated topically with 0.5 % GSK2646264 cream and placebo cream on an area of approximately 12 x 3 centimetre (cm) on the volar aspect of the arm which approximates to 0.2% total body surface area (BSA), on each arm. On Day 2 and Day 3 subjects will receive active treatment and placebo on the same arms as on Day 1, with the percentage BSA being 1% on Day 2 and 5% on Day 3.
62412417|NCT02424799|EXPERIMENTAL|Part A: Dose group 2|Subjects will be treated topically with 1 % GSK2646264 cream and placebo cream on the morning and evening of Day 1 starting at the final % BSA dosed at Day 3 in group 1 which is anticipated to be 5%. In dose group 2, the starting BSA will increase to 10% at Day 3 and then 20% by Day 5. Administration of the evening (PM) dose will be dependent on the data from Part A Dose group 1.
62412418|NCT02424799|EXPERIMENTAL|Part B|Cold urticaria subjects will receive treatment to 4 defined areas (right and left arms and legs). Subjects will be treated with maximum tolerated strength of GSK2646264 cream (0.5% or 1%) and placebo cream in morning or in morning and evening to 2 specified areas of \~5% BSA on the subject's legs for the CU assessment and to 2 specified areas of 0.2% BSA on the volar aspect of the arm. The maximum tolerated strength and evening dosing will be dependent on the data from the Part A
62412419|NCT02424799|EXPERIMENTAL|Part C|Chronic spontaneous urticaria subjects will be treated with the maximum tolerated strength of GSK2646264 cream from Part A (0.5% or 1%) and placebo cream onto defined areas (right and left arms and, legs and front torso) from Days 1 to 7. The total % BSA for an individual subject will be decided by the investigator prior to randomization. The maximum % BSA and the frequency of dosing will be decided after part A of the study.
62412420|NCT03144115|EXPERIMENTAL|oxytocin fertility|intranasal oxytocin administration (24IU) in women's fertility phase (LH\>40 mIU/ml)
62586209|NCT06565104|EXPERIMENTAL|Sleep2BWell Intervention Arm|Sleep2BWell is a 6-week program, which consists of the 4-wk BWell4Life program enhanced with two sleep health education and group coaching sessions and addressing structural barriers to healthy sleep in NYC (light, noise, and indoor air pollution). The sleep health education sessions will incorporate didactic content, engaging animated videos, group coaching, and an interactive Q\&A period. These sessions will incorporate techniques to establish regular bed and wake times, learn wind-down and wake-up routines, cope with stress through muscle relaxation and mindfulness techniques, and optimize the sleep environment. Participants will self-monitor using a Fitbit and will receive additional instruction on how to maximize health benefits of self-monitoring. They will also receive a sleep mask, ear plugs, a blue light blocker, and an indoor air purifier to address barriers to healthy sleep in the sleep environment.
62586210|NCT03999827|EXPERIMENTAL|Immediate Diet Group|Adhere to Low Glycaemic Index diet for 52 weeks, beginning immediately after randomisation.
62586211|NCT03999827|ACTIVE_COMPARATOR|Delayed Diet Group|Adhere to Low Glycaemic Index diet for 52 weeks, beginning 12 weeks after randomisation.
62794190|NCT05431478|OTHER|AOHP, then LID022821|Senofilcon A contact lenses worn during Period 1, with serafilcon A contact lenses worn during Period 2, as randomized. Each study lens type will be worn bilaterally (in both eyes) at least 10 hours per day for approximately 14 days. CLEAR CARE will be used for daily cleaning and disinfection. The serafilcon A contact lenses will be replaced with a fresh pair at the Week 1 follow-up visit.
62794191|NCT05651906||Donors|
62218399|NCT01875549|ACTIVE_COMPARATOR|Unilateral stent insertion group|the use of unilateral stent insertion in malignant hilar obstruction for using endoscopic retrograde cholangiopancreatography(ERCP)
62218400|NCT01875549|ACTIVE_COMPARATOR|Bilateral stent insertion group|the use of bilateral stent insertion in malignant hilar obstruction for using endoscopic retrograde cholangiopancreatography(ERCP)
62218401|NCT02309073||women with a regular indication for ART|In the present proposal we are aiming to include all normo-ovulatory women with a regular indication for ART.
62412421|NCT03144115|PLACEBO_COMPARATOR|placebos fertility|intranasal placebo administration (24IU) in women's fertility phase (LH\>40 mIU/ml)
62412422|NCT03144115|EXPERIMENTAL|oxytocin luteal|intranasal oxytocin administration (24IU) in women's luteal phase (LH\<30 mIU/ml)
62412423|NCT03144115|PLACEBO_COMPARATOR|placebos luteal|intranasal placebos administration (24IU) in women's luteal phase (LH\<30 mIU/ml)
62412424|NCT02866409|EXPERIMENTAL|Bupivacaine,dexmedetomidine scalp block|Bupivacaine (0.25%) and Dexmedetomedine (1 µg/kg). Maximum dose of bupivacaine kept \< 2 mg /kg for scalp block
62412425|NCT02866409|ACTIVE_COMPARATOR|bupivacaine dexmedetomidine infiltration|The incision site was infiltrated with 15-20 ml bupivacaine (0.25%) and dexmedetomedine (1 µg/kg). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.
62412426|NCT02866409|ACTIVE_COMPARATOR|bupivacaine infiltration|The incision site was infiltrated with 15-20 ml of bupivacaine (0.25%). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.
62586212|NCT00887783|EXPERIMENTAL|B: 66Gy/33F+Navelbine oral 150 mg q3w|"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).~Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization"
62586213|NCT00887783|ACTIVE_COMPARATOR|A: 60Gy/30F+Navelbine oral 150 mg q3w|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization
62586214|NCT03798470|EXPERIMENTAL|Cohort|Intervention with FAVOR peer recovery coaching. Patients identified in the ED as opioid overdose and enrolled in the current study.
62586215|NCT04708041|EXPERIMENTAL|Cohort 0: 1 Dose of 9vHPV Vaccine (previous 1-dose recipients)|10 to 15 year old girls and boys (who previously received 1 dose of 9vHPV vaccine) receive a second dose of 9vHPV vaccine at Day 1.
62794192|NCT05651906||Recipients|
62218402|NCT02309073||women undergoing donor insemination treatment|potential normal fertile control group
62412427|NCT04379102||IUD patients|80 patients who matched the inclusion criteria and received IUDs
62412428|NCT02799485|EXPERIMENTAL|Treatment (recombinant EphB4-HSA fusion protein)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1 and 15. Patients with disease progression after 2 or more courses who have not experienced toxicity may receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of further disease progression or unacceptable toxicity.
62794193|NCT03265236||Group1|Patients with early rheamatoid arthritis
62794194|NCT03265236||Group 2|patients with late rheamatoid arthritis
62794195|NCT03265236||Group 3|Healthy control
62794196|NCT02083536|EXPERIMENTAL|LDFWART + Docetaxel|"This study has 6 treatment cycles given at 3 weeks intervals ± 3 days. A cycle is defined as 1 treatment of morning Docetaxel and afternoon Low Dose Fractionated Whole Abdominal Radiation Therapy (LDFWART). The first day of the first treatment is designated study day 1."
62794197|NCT03054649|EXPERIMENTAL|Cohort 1|Study eye: Primary implantation of HMIOL system with toric optic and no intraoperative optic exchange
62794198|NCT03054649|EXPERIMENTAL|Cohort 2|Fellow eye: Primary implantation of HMIOL system with monofocal optic, followed by intraoperative optic exchange (toric or non-toric optic)
62586216|NCT04708041|EXPERIMENTAL|Cohort 1: 2 Doses of 9vHPV Vaccine Given 12 Months Apart|9 to 14 year old girls and boys receive a 2-dose regimen of 9vHPV vaccine at Day 1 and Month 12.
62218403|NCT04542161|ACTIVE_COMPARATOR|NAC 900mg/day|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 900mg/day caplets for a four week period
62218404|NCT04542161|ACTIVE_COMPARATOR|NAC 3600mg/day|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 3600mg/day caplets for a four week period
62794199|NCT02837029|EXPERIMENTAL|Treatment (yttrium Y 90 glass microspheres, nivolumab)|Patients receive yttrium Y 90 glass microspheres IA. Approximately 4 weeks after yttrium Y 90 glass microspheres treatment, patients receive nivolumab IV over 30-60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62794200|NCT01420926|EXPERIMENTAL|Arm A (decitabine)|"REMISSION INDUCTION THERAPY: Patients receive 20 mg/m\^2 decitabine IV over 1 hour QD on days 1-10. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving CR CRi proceed to continuation therapy. Patients achieving CR or CRi proceed to maintenance therapy.~CONTINUATION THERAPY: Patients receive 20 mg/m\^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive 20 mg/m\^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62218405|NCT04542161|PLACEBO_COMPARATOR|NAC 0mg/day (Placebo)|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 0mg/day (placebo) caplets for a four week period
62794201|NCT01420926|EXPERIMENTAL|Arm B (decitabine and bortezomib)|"REMISSION INDUCTION THERAPY: Patients receive 20 mg/m\^2 decitabine IV over 1 hour QD on days 2-11 and 1.3 mg/m\^2 bortezomib SC on days 1, 4, 8, and 11. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving CR or CRi proceed to continuation therapy. Patients achieving CR or CRi proceed to maintenance therapy.~CONTINUATION THERAPY: Patients receive 1.3 mg/m\^2 bortezomib SC on day 1 and 20 mg/m\^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive 1.3 mg/m\^2 bortezomib SC on day 1 and 20 mg/m\^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62794202|NCT04714008||Active gamblers in 2019/2020|Three panels of 40 000 gamblers active in 2019 and 2020, either in France or Sweden
62794203|NCT04714008||Newly registered gamblers in 2019 or 2020 (France and Sweden)|Six panels of 10 000 gamblers who newly registered either during the period of March-May 2019 or of March-May 2020, either in France or Sweden
62794204|NCT01440855|ACTIVE_COMPARATOR|CIS Fact Sheet (CIS: Cancer Information Service)|CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
62794205|NCT01440855|EXPERIMENTAL|Facing Forward booklet|NCI's Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
62794206|NCT05001204|EXPERIMENTAL|68Ga-NOTA-RM26 PET/CT|Patients underwent whole-body PET/CT scans at 30-90 minutes after intravenous injection of 55.5-148 MBq (1.5-4 mCi) of 68Ga-NOTA-RM26.
62794207|NCT05984043|EXPERIMENTAL|Biofeedback|
62794208|NCT05984043|OTHER|Waitlist|
62794209|NCT00646425|EXPERIMENTAL|1|Basiliximab
62794210|NCT00646425|PLACEBO_COMPARATOR|2|
62794211|NCT03734003|EXPERIMENTAL|Controllable infrared bioeffect system for cutaneous warts|"Controllable infrared bioeffect system at 44±2℃ for 30 mins on target lesion, at days of 1, 2, 3, 15, 16, 23, 30.~Common warts, plantar warts, and condyloma acuminata"
62218406|NCT04357444|EXPERIMENTAL|1: ILT101|ILT-101 in Subcutaneous route
62218407|NCT04357444|PLACEBO_COMPARATOR|2: Placebo Comparator|Placebo in subcutaneous injections every day during 10 days
62586217|NCT04708041|EXPERIMENTAL|Cohort 2: 2 Doses of 9vHPV Vaccine Given 24 Months Apart|9 to 13 year old girls and boys receive a 2-dose regimen of 9vHPV vaccine at Day 1 and Months 24.
62794212|NCT03734003|ACTIVE_COMPARATOR|Liquid nitrogen cryotherapy for cutaneous warts|Liquid nitrogen crytotherapy at days 1, 15, 30.
62218408|NCT01668901|EXPERIMENTAL|warfarin|medication
62794213|NCT03237793|ACTIVE_COMPARATOR|Fluorosed Group|45 patients for the fluorosis groupGROUP 1A: Patients with healthy fluorosed teeth receiving desensitising agent (potassium nitrate- RA Themoseal\*\*) treatment. (n=15) GROUP 1B: Patients with healthy fluorosed teeth receiving diode laser treatment$. (n=15) GROUP 1C: Patients with healthy fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA Thermoseal\*\*) treatment. (n=15)
62218409|NCT01668901|ACTIVE_COMPARATOR|aspirin|medication
62218410|NCT02209662|EXPERIMENTAL|APIC-PRP and Standard of Care|APIC-PRP
62218411|NCT02209662|PLACEBO_COMPARATOR|Placebo, Saline plus standard of care|Placebo, Saline plus standard of care
62243305|NCT01686360|EXPERIMENTAL|Frequency + Mortality Data|Group receives Gail score in a frequency format as well as information about mortality benefit of mammography. (Behavioral:Decision Aid)
62412429|NCT05725473|EXPERIMENTAL|Eso-Flip|Dilatation with Eso-Flip
62586218|NCT04708041|EXPERIMENTAL|Cohort 3: 2 Doses of 9vHPV Vaccine Given 36 Months Apart|9 to 12 year old girls and boys receive a 2-dose regimen of 9vHPV vaccine at Day 1 and Month 36.
62412430|NCT05917314|EXPERIMENTAL|Intervention Group (SlimBiotic Probiotic)|Participants will take 1 serving (1 capsule) per day.
62218412|NCT02093091|SHAM_COMPARATOR|Vitremer|Dental caries was removed from primary molars and was filled with the conventional filling material;Vitremer (n = 30). The right molars was always filled by Vitremer. A split-mouth design was used in the present clinical trial. Twenty nine children were involved in the present study and every one had one bilateral identical pair of carious molars except one child that had two identical pairs. This design was performed to enhance the accuracy of the present study.
62218413|NCT02093091|ACTIVE_COMPARATOR|Ketac Nano|Dental caries was removed from primary molars and was filled with the recent filling material; Ketac Nano (n=30). The left molars was always restored with Ketac Nano filling material.
62218414|NCT00833261|EXPERIMENTAL|Single Arm: Chemotherapy with Concurrent Radiation therapy|Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy intensity-modulated radiation therapy
62412431|NCT05917314|PLACEBO_COMPARATOR|Placebo Group|Participants will take 1 serving (1 capsule) per day.
62586219|NCT04708041|EXPERIMENTAL|Cohort 4: 2 Doses of 9vHPV Vaccine Given 60 Months Apart|9 to 10 year old girls and boys receive a 2-dose regimen of 9vHPV vaccine at Day 1 and Month 60.
62586220|NCT04708041|ACTIVE_COMPARATOR|Cohort 5: 3 Doses of 9vHPV Vaccine Given Over a 6-Month Period|16 to 26 year old young women receive 3 dose regimen of 9vHPV vaccine at Day 1, Month 2 and Month 6.
62586221|NCT06602908||Surgically and non-surgically treated patients with achilles tendon rupture|One hundred patients with surgically and non-surgically treated achilles tendon rupture referred to rehabilitation in the municipality of Copenhagen.
62586222|NCT02606942||Dancers with knee injury|A cohort of dancers with reported knee injury. Questionnaires, physical exam, US of the knee
62586223|NCT02606942||Dancers with no knee injury|A cohort of dancers without reported knee injury. Questionnaires, physical exam, US of the knee
62794214|NCT03237793|PLACEBO_COMPARATOR|Non Flourosed Group|45 patients for the non-fluorosis groupGROUP 2- Non Flourosed Group (n=45) GROUP 2A: Patients with healthy non fluorosed teeth receiving desensitising agent (potassium nitrate- RA Thermoseal\*\*) treatment. (n=15) GROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal\*\*) treatment. (n=15
62218415|NCT02997943|EXPERIMENTAL|Step 1: Optimal First Line Treatment|"Participants will first be randomized to an optimal first line treatment in order to compare APP vs. APP + coaching. Participants assigned to Step 1 treatment APP will receive a study-specific smartphone application. Participants assigned to Step 1 treatment APP + coaching will receive a study-specific smartphone application plus 12 weekly telephone coaching sessions."
62412432|NCT03725267|EXPERIMENTAL|Melatonin|Patients will receive 1 pill each day with 30 mg of Melatonin during polymyxin B treatment for a maximum of 14 days.
62586224|NCT02606942||Non-dancers athletes|A cohort of non-dancers athletes without knee injuries. Questionnaires, physical exam, US of the knee
62794215|NCT06114186|ACTIVE_COMPARATOR|control group|anticipate 20 CGM and 5 non-CGM user dyads in the control group
62794216|NCT06114186|EXPERIMENTAL|intervention group|anticipate 20 CGM and 5 non-CGM user dyads in the intervention group
62794217|NCT06532084|EXPERIMENTAL|Sorafenib prophylaxis|Sorafenib 200 mg bid for 168 days starting before day+100 after HCT
62412433|NCT03725267|PLACEBO_COMPARATOR|Placebo|Patients will receive 1 pill each day with Placebo during polymyxin B treatment for a maximum of 14 days.
62412434|NCT03121560|ACTIVE_COMPARATOR|Hysteroscopy|Women with ≥ 18 with abnormal bleeding (post-menopausal menorrhagia or metrorrhagia), managed at bleeding clinic. Each women will undergo an hysteroscopy and a hysterosonography and will be her own control.
62412435|NCT03121560|EXPERIMENTAL|Hysterosonography|Women with ≥ 18 with abnormal bleeding (post-menopausal menorrhagia or metrorrhagia), managed at bleeding clinic. Each women will undergo an hysteroscopy and a hysterosonography and will be her own control.
62586225|NCT04065451|EXPERIMENTAL|Epinephrine|Epinephrine in the submucosal injection fluid (1:200,000)
62586226|NCT04065451|NO_INTERVENTION|No epinephrine|Submucosal injection fluid without epinephrine
62586227|NCT03601312|ACTIVE_COMPARATOR|Treatment-As-Usual|Individuals receiving treatment as usual will be receiving exposure and response prevention (ERP), the standard of care for pediatric OCD.
62586228|NCT03601312|EXPERIMENTAL|OC-Go|Individuals in the OC-Go group will be receiving exposure and response prevention (ERP) augmented by the OC-Go application.
62794218|NCT06532084|NO_INTERVENTION|Observation|Usual care
62794219|NCT00921791|EXPERIMENTAL|Home Blood Pressure Monitoring|Automatic oscillometric device for blood pressure measurement at home plus usual care.
62794220|NCT00921791|EXPERIMENTAL|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists plus usual care.
62794221|NCT00921791|ACTIVE_COMPARATOR|Pharmaceutical care|Consultations with the pharmacists plus usual care.
62412436|NCT06651996|SHAM_COMPARATOR|one session of face-to-face telerehabilitation tutorial (OST)|Participants were assigned to receive either one session of face-to-face telerehabilitation tutorial (OST) and complete an 8-week home digital health program consisting of sensor-guided exercise therapy and knee pain self-care education. The primary outcome was short-term adherence as assessed by the Exercise Adherence Rating Scale (EARS) after 6 weeks of face-to-face therapy. Secondary measures included pain intensity, quadriceps strength, Kujala patellofemoral score, fatigue severity scale, and qualitative interviews affecting adherence.
62794222|NCT00921791|ACTIVE_COMPARATOR|Control|Usual care: participants are instructed to keep on their current antihypertensive medication and receive non-pharmacological recommendations for hypertension treatment.
62794223|NCT03811314|EXPERIMENTAL|Strength training|Muscle strength training programs
62218416|NCT02997943|EXPERIMENTAL|Step 2: Optimal Strategy to Address Nonresponse|Beginning at week 2, participants who are identified as treatment non-responders will be re-randomized in order to compare two strategies to address non-response: a modest step-up or vigorous step-up treatment augmentation tactic. Step 2 treatment strategy: modest step-up will include provision of an additional mHealth intervention component (push notifications). Step 2 treatment strategy vigorous step-up will include provision of an additional mHealth intervention component (push notifications), plus a traditional weight loss intervention component (coaching, meal replacements). Participants will continue to receive their first line treatment.
62218417|NCT05249868||SARS-CoV-2 Infection|"Confirmed SARS-CoV-2 infection diagnosed after 11 May 2020 and registered in electronic health records.~(positive confirmatory test on nucleic acid amplification (rRT-PCR) or having had symptoms for \<5 days is positive on a PRAg test)"
62218418|NCT05249868||NO SARS-CoV-2 Infection|No confirmed SARS-CoV-2 infection with diagnosis after 11 May 2020.
62218419|NCT02890212|EXPERIMENTAL|selenium|subjects resistant to treatment of major depression with sertraline who were randomized and ingest selenium pills (400 microgram) during six weeks
62218420|NCT02890212|PLACEBO_COMPARATOR|placebo|subjects resistant to treatment of major depression with sertraline who were randomized and ingest placebo pills
62218421|NCT02625688|PLACEBO_COMPARATOR|Early cord clamping|Cord clamping will be applied after 30 seconds post delivery.
62218422|NCT02625688|ACTIVE_COMPARATOR|Delayed cord clamping|Cord clamping will be applied after 3 minutes post delivery.
62412437|NCT06651996|EXPERIMENTAL|Three session of face-to-face telerehabilitation tutorials (TST)|Participants were assigned to receive 3 in-person remote rehabilitation coaching (TST) sessions and complete an 8-week home digital health program consisting of sensor-guided exercise therapy and knee pain self-care education. The primary outcome was short-term adherence as assessed by the Exercise Adherence Rating Scale (EARS) after 6 weeks of face-to-face therapy. Secondary measures included pain intensity, quadriceps strength, Kujala patellofemoral score, fatigue severity scale, and qualitative interviews affecting adherence.
62412438|NCT06651996|EXPERIMENTAL|Six session of face-to-face telerehabilitation tutorials (SST)|Participants were assigned to receive 6 in-person remote rehabilitation coaching (SST) sessions and complete an 8-week home digital health program consisting of sensor-guided exercise therapy and knee pain self-care education. The primary outcome was short-term adherence as assessed by the Exercise Adherence Rating Scale (EARS) after 6 weeks of face-to-face therapy. Secondary measures included pain intensity, quadriceps strength, Kujala patellofemoral score, fatigue severity scale, and qualitative interviews affecting adherence.
62794224|NCT03811314|EXPERIMENTAL|Aerobic training|Aerobic training programs
62794225|NCT03811314|EXPERIMENTAL|Isokinetic training|Isokinetic training
62794226|NCT03811314|EXPERIMENTAL|Isotonic training|Isotonic training
62794227|NCT01902329|EXPERIMENTAL|SGN-CD33A + HMA|SGN-CD33A with hypomethylating agent
62794228|NCT01902329|EXPERIMENTAL|SGN-CD33A Monotherapy|SGN-CD33A
62794229|NCT03948334|EXPERIMENTAL|ZPL389 30mg|30mg of ZPL389 + TCS and/or TCI for patients re-randomized from the core study (received placebo/ZPL389 3mg/ 10mg in the core study) and for patients continuing in the same arm from the core study
62412439|NCT01995058|EXPERIMENTAL|Cabozantinib arm 1|Subjects randomized to this arm will receive cabozantinb 40 mg daily with abiratarone and prednisone
62794230|NCT03948334|EXPERIMENTAL|ZPL389 50mg|50mg of ZPL389 + TCS and/or TCI for patients re-randomized from the core study (received placebo/ZPL389 3mg/ 10mg in the core study) and for patients continuing in the same arm from the core study
62794231|NCT04577469|EXPERIMENTAL|500 mg sulfadoxine / 25 mg pyrimethamine tablet|500 mg sulfadoxine / 25 mg pyrimethamine tablet will be administered once.
62794232|NCT04577469|ACTIVE_COMPARATOR|G-COSPE® tablets|G-COSPE® tablets (500 mg sulfadoxine / 25 mg pyrimethamine) will be administered once.
62794233|NCT01648972|EXPERIMENTAL|Gastrografin|
62794234|NCT01648972|PLACEBO_COMPARATOR|Placebo|
62794235|NCT02984917|EXPERIMENTAL|anterior transversalis fascia approach|Patients with inguinal hernia will undergo inguinal hernia repair via the anterior transversalis fascia approach.
62794236|NCT02984917|EXPERIMENTAL|preperitoneal space approach|Patients with inguinal hernia will undergo inguinal hernia repair via the preperitoneal space approach.
62412440|NCT01995058|EXPERIMENTAL|Cabozantinib arm 2|Subjects randomized to this arm will receive cabozantinib 20 mg daily with abiraterone and prednisone
62412441|NCT01995058|EXPERIMENTAL|Cabozantinib arm 3|Subjects randomized to this arm will receive cabozantinb 20 mg every other day with abiraterone and prednisone
62412442|NCT01995058|ACTIVE_COMPARATOR|Abiraterone only arm (4)|Subjects randomized to this arm will receive abiraterone with prednisone only
62586229|NCT04984226|EXPERIMENTAL|Sodium bicarbonate 16 weeks|Sodium bicarbonate will be dosed at 0.8meq per kilogram of ideal body weight daily (1meq is approximately 84mg). We will use the Devine formula to determine ideal body weight. Investigational Drug Services at both UC Davis and Vanderbilt will compound the sodium bicarbonate. Sodium bicarbonate 650 mg tablets will be over-encapsulated and matching placebo capsules will be prepared. Participants will be limited to a maximum of 9 capsules daily (maximum dose = 5850mg of sodium bicarbonate). Capsules will be dispensed to patients in two separate 8-week allotments. The dose will be rounded to the nearest whole capsule and depending on participant preference may be divided into portions taken twice or thrice daily. Given the high probability of interruption in sodium bicarbonate supply and availability, we may need to change brands of sodium bicarbonate intermittently.
62586230|NCT04984226|PLACEBO_COMPARATOR|placebo 16 weeks|Microcrystalline cellulose
62586231|NCT02332447|EXPERIMENTAL|NALOXONE|
62586232|NCT02332447|PLACEBO_COMPARATOR|PLACEBO|
62794237|NCT02039284|EXPERIMENTAL|SES group|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
62794238|NCT02039284|EXPERIMENTAL|VCT group|VCT group received the VCT training in addition to traditional rehabilitation.Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise.
62586233|NCT05577169|EXPERIMENTAL|Mind-body skills + diabetes education|"Participants randomly assigned to this arm will undergo 20-30 minutes discussing a predetermined diabetes topic followed by 20-30 minutes working on a mind-body skills component. This mind-body skills component will be a combination of deep breathing, self-reflection, and meditation techniques focused on self-awareness to calm the stress-response. Participants will be assigned homework designed to encourage practice of the learned skill."
62794239|NCT02039284|EXPERIMENTAL|VRCIT group|VRCIT group received the VRCIT training in addition to traditional rehabilitation.Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day.
62794240|NCT02039284|ACTIVE_COMPARATOR|traditional rehabilitation group|Shame control group received the shame SES and traditional rehabilitation programs.
62794241|NCT01919229|ACTIVE_COMPARATOR|Letrozole|Letrozole 2.5 mg alone once daily
62794242|NCT01919229|EXPERIMENTAL|LEE011 400 mg + letrozole|Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.
62794243|NCT01919229|EXPERIMENTAL|LEE011 600mg + letrozole|Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.
62794244|NCT02097030|ACTIVE_COMPARATOR|etafilcon A lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
62794245|NCT02097030|ACTIVE_COMPARATOR|nelfilcon A lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
62794246|NCT02097030|ACTIVE_COMPARATOR|filcon II 3 lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
62794247|NCT00036634|ACTIVE_COMPARATOR|Tenofovir DF|Participants received tenofovir DF 300 mg for 14 days
62794248|NCT00036634|EXPERIMENTAL|Tenofovir alafenamide 50 mg|Participants received tenofovir alafenamide 50 mg for 14 days
62794249|NCT00036634|EXPERIMENTAL|Tenofovir alafenamide 150 mg|Participants received tenofovir alafenamide 150 mg for 14 days
62794250|NCT03499314|EXPERIMENTAL|RS-tDCS Stimulation|20 times 20 minute stimulation session supervised by a study technician through a videoconferencing platform, VSee
62794251|NCT03499314|PLACEBO_COMPARATOR|Sham Stimulation|20 ×20-minute sessions sham tDCS
62794252|NCT03887273|EXPERIMENTAL|Q-Cells dose level 1|One time surgical transplantation of Q-Cells dose level 1 unilaterally into spinal cord demyelinated lesion
62794253|NCT03887273|EXPERIMENTAL|Q-Cells dose level 2|One time surgical transplantation of Q-Cells dose level 2 unilaterally into spinal cord demyelinated lesion
62412443|NCT06703827|EXPERIMENTAL|MCT group|"Online MCT group (10 sessions) will be delivered by colleague CBT therapist (with previous experience of delivering MCT group) and assistant psychologist/clinical associate psychological practitioner, where all professionals will receive appropriate training by chief investigator. The group will also have one expert patient who attended the previous pilot group (at The NHS Trust) and is willing to help conduct the current MCT training. All psychology staff have experience in delivering psychological therapies and working with psychosis.~The study will use qualitative data to refine the results of the quantitative findings by using follow-up semi-structured interviews to better understand the participants' experiences who had a minimum of 40% reduction of their persecutory delusions and/or cognitive biases and/or secondary measures (CHOICE and CORE-OM 34). The interviews will be conducted immediately post-intervention."
62412444|NCT06703827|NO_INTERVENTION|Treatment as Usual Group (TAU)|TAU group: Treatment as usual is the general treatment protocol for patients with first episode of psychosis in the Early Intervention in Psychosis Service, where most patients have antipsychotic medication and at least monthly contact with care coordinator, and at least 6 monthly outpatient appointment with a psychiatrist.
62794254|NCT03887273|EXPERIMENTAL|Q-Cells dose level 3|One time surgical transplantation of Q-Cells dose level 3 unilaterally into spinal cord demyelinated lesion
62794255|NCT03529968||Italian Siewert I-II adenocarcinoma|Patients with Siewert type I adenocarcinoma underwent subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Patients with Siewert type II adenocarcinoma underwent total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy. A right anterolateral thoracotomy and an upper midline laparotomy were performed as previously described. Lymphadenectomy included chest stations classified according to the AJCC TNM 7th edition (L/R = left/right; 3, 4R, 7, 2R, 8 and 9 and abdominal stations classified according to the Japanese Classification of Gastric Carcinoma (stations 1-12)
62794256|NCT03529968||Finnish Siewert I-II adenocarcinoma|All Siewert type I/II patients underwent minimally invasive esophagectomy and reconstruction with gastric tube. Laparoscopy and right-sided thoracoscopy in decubitus position were used as previously described. Thoracic lymphadenectomy consisted of stations 7-9 (AJCC TNM 7th edition) and abdominal stations 1-3 and 7-11 according to the Japanese Classification of Gastric carcinoma.
62218423|NCT02625688|ACTIVE_COMPARATOR|Cord milking|The baby will be placed below the level of the placenta, between the mother's thighs (during a vaginal delivery) or at the side of the mother swaddled in sterile towels (during a caesarian delivery).
62412445|NCT02215434|PLACEBO_COMPARATOR|Biolipid B2 (blanked/placebo)|"The study is a single-center, single-blind, placebo-controlled, parallel group trial.~It consists of a 4-week screening period plus a 12-week treatment phase. At the screening visit, all participants underwent a physical examination including vital signs and breast and pelvic examination.~They were randomly assigned in a 1:1 ratio to receive a transdermal vehicle biolipid B2 (identical placebo) provided by Evidence Pharmaceuticals Inc, SP,BRAZIL.~The testosterone and placebo emulsion were alcohol-free matrixes that were applied topically to the forearm daily for the period of 12 weeks."
62218424|NCT01851499|EXPERIMENTAL|Ultramicronized PEA (Normast)|"Normast is ultramicronized Palmitoylethanolamide (PEA) classified as Dietary foods for special medical purposes."
62218425|NCT01851499|PLACEBO_COMPARATOR|Microgranules|Same as Normast, without active component.
62218426|NCT00860847|ACTIVE_COMPARATOR|Aged Garlic Extract and Coenzyme Q10|"AGE (1200 mg) and CoQ10 (120 mg)~This is a combination of aged garlic extract and co-enzyme Q10"
62218427|NCT00860847|NO_INTERVENTION|Placebo|placebo pills will be given
62218428|NCT04871022|ACTIVE_COMPARATOR|Double layer unlocked uterine closer|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium and a second unlocked continuous suture that approximate the upper portion of the myometrium.
62218429|NCT04871022|EXPERIMENTAL|Purse uterine closer|Purse suture of the uterus with a first continuous purse suture of the deep portion of the myometrium and a second unlocked continuous suture including the remaining part of the myometrium
62218430|NCT02888873|ACTIVE_COMPARATOR|Charisma|applied randomly
62218431|NCT02888873|ACTIVE_COMPARATOR|Charisma classic|applied randomly
62218432|NCT03534401|NO_INTERVENTION|Standard Contraceptive Counseling|Providers at control clinics receive no additional training; clients receive standard contraceptive counseling services.
62218433|NCT03534401|EXPERIMENTAL|ARCHES Kenya Intervention in Contraceptive Counseling|Providers at intervention clinics receive training on ARCHES strategies integrated into contraceptive counseling; clients receive the ARCHES Kenya intervention integrated within standard contraceptive counseling services.
62218434|NCT05834881|EXPERIMENTAL|CM combined with Vocational/educational Coaching from Coaches without Lived Experience|This group will receive contingency management (CM) combined with vocational/educational coaching from paraprofessional coaches without lived experience in community settings.
62218435|NCT05834881|ACTIVE_COMPARATOR|CM combined with Vocational/educational Coaching from Coaches with Lived Experience|This group will receive contingency management (CM) combined with vocational/educational coaching from paraprofessional coaches with lived experience in community settings.
62218436|NCT05205187||Healthy group|Healthy people in the community.
62412446|NCT02215434|ACTIVE_COMPARATOR|Testosterone, Transdermal, Behavior|Testosterone 0.5%, daily, 3 months
62022354|NCT01772992|EXPERIMENTAL|Experimental group (CVCTPLUS)|Male couples randomized to the experimental group (CVCTPLUS) will each receive HIV counseling and testing as a couple. These couple will return for two additional visits that members of the control arm do not get, for two one-hour sessions of the Partner-STEPS. Couples in the experimental group (CVCTPLUS) at 8 and 10 weeks after the initial enrollment. They will also return every 6 months, up to 18 months, for visits in which they will be seen as a couple, in which they will have STI testing and repeat HIV testing. All follow-up visits will be conducted for the couples together.
62022355|NCT00438516|NO_INTERVENTION|1|Control group
62218437|NCT05205187||Non-Borrmann IV group|Patients with Borrmann types I, II and III gastric cancer.
62218438|NCT05205187||Borrmann IV group|Patients with Borrmann type IV gastric cancer.
62218439|NCT04840199|EXPERIMENTAL|Arm A: Letermovir|"Letermovir 480 mg will be administered by one of the following strategies:~* Letermovir 240 mg tablets administered orally as two tablets once daily with or without food.~* Letermovir 480 mg tablets administered orally as one tablet once daily with or without food.~Participants will be able to switch administration strategy during treatment duration based on availability of study supply."
62586234|NCT05577169|ACTIVE_COMPARATOR|Diabetes education alone|Participants randomly assigned to this arm will similarly undergo 20-30 minutes discussing the same predetermined diabetes topic as the intervention group.
62586235|NCT06667180|EXPERIMENTAL|Low-intensity TMS|This group will receive the real low-intensity TMS
62218440|NCT04840199|OTHER|Arm B: No anti-CMV treatment|
62218441|NCT01010191|EXPERIMENTAL|Cellulose pill|The active intervention is a sugar pill.
62218442|NCT01010191|NO_INTERVENTION|No treatment|The control arm is wait list control
62218443|NCT06097910||Observation|
62218444|NCT00561782||Group 1|Spinal cord injured with chronic central neuropathic pain.
62218445|NCT00561782||Group 2|Spinal cord injured without chronic central neuropathic pain.
62218446|NCT00561782||Group 3|Able-bodied without history of chronic pain of any type
62218447|NCT00561782||Group 4|Traumatically Brain Injured with a history of pain that onset after their TBI
62218448|NCT02259647|EXPERIMENTAL|Sorafenib +intravenous infusion ofVit K1|Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month
62794257|NCT05028335|OTHER|Group G1|Home bleaching treatment (Carbamide Peroxide (PC) 22%) + placebo gel
62218449|NCT02259647|ACTIVE_COMPARATOR|Sorafenib+Placebo|Sorafenib 400 mg twice daily + Intravenousinfusion of placebo daily for 6 days, followed by oral placebo twice daily till 3month
62412447|NCT01351194|EXPERIMENTAL|RFA group|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
62412448|NCT01351194|EXPERIMENTAL|HR group|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
62412449|NCT02317523|EXPERIMENTAL|Behavioral Activation|Behavioral Activation (BA) emphasize self-monitoring as an aid for increasing one's engagement in self-reinforcing activities while simultaneously reducing negative avoidant coping responses. The intervention consists of 6 total face-to-face sessions lasting 60 minutes each.
62412450|NCT02317523|ACTIVE_COMPARATOR|Information and Support|Information and Support (IS) consists of providing education on Alzheimer's disease, coping with specific stresses prevalent in caregiving, and community-based services available for caregivers. Caregivers choose information most relevant to their current circumstances, and can discuss this with their counselor during the sessions. In addition, the IS condition encompasses elements of supportive therapy including empathy and active listening. The intervention consists of 6 total face-to-face sessions lasting 60 minutes each.
62412451|NCT00679094|EXPERIMENTAL|Arm I|Participants receive a single dose of oral BBIC or placebo, as an orange juice suspension, immediately followed by consumption of a defined low-fat breakfast. Participants continue to consume a low-fat diet for the next 48 hours and then resume their normal diet.
62218450|NCT05303259|EXPERIMENTAL|HNC patients with radiation-induced brain injury.|Bevacizumab 2.5mg/kg， q2w，4 cycles.
62218451|NCT05303259|NO_INTERVENTION|HNC patients without brain injury after radiotherapy.|No treatment.
62412452|NCT02163278|EXPERIMENTAL|DBPR108|
62412453|NCT02163278|PLACEBO_COMPARATOR|matching placebo|
62412454|NCT00056537|EXPERIMENTAL|1|
62412455|NCT04419701|EXPERIMENTAL|periarticular infiltration group|will receive intraoperative periarticular infitration consisting of 89.5 mL of normal saline, 20 mL of 5% bupivacaine and 0.5 mL of adrenaline (4.5 ugm/ml) with a concentration 1:220000 (total volume: 110 mL)
62412456|NCT04419701|EXPERIMENTAL|genicular nerve block group|will receive ultrasound guided genicular nerve block at three nerves, i.e., superomedial, superolateral, and inferomedial genicular nerves consisting of 15 ml bupivacaine 0.25% with adrenaline 2.5 µg/ml with a concentration 1:400000 in the immediate postoperative period.
62412457|NCT06651723|EXPERIMENTAL|Electric brushes|The participants will use an electric soft brush (test).
62586236|NCT06667180|PLACEBO_COMPARATOR|Sham low-intensity TMS|This group will receive the simulation of the low-intensity TMS
62738660|NCT06311955|EXPERIMENTAL|Study arm|The patients will receive 72GyE per 18 fractions of carbon ion radiotherapy. Patients with thymus cancer should be combined with platinum-based regimen (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin; paclitaxel combined with cisplatin or cisplatin / carboplatin / loplatin / nedaplatin; docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.
62738661|NCT06659185|EXPERIMENTAL|Carbohydrate mouth rinsing|Carbohydrate mouth rinsing for 20 seconds with 25 ml of 6.4% maltodextrin
62738662|NCT06659185|PLACEBO_COMPARATOR|placebo|Mouth rinsing for 20 seconds with 25 ml of water
62022356|NCT00438516|EXPERIMENTAL|2|Nurse home visitation
62022357|NCT00875953|ACTIVE_COMPARATOR|Standard dissection|standard neck dissection technique: scalpel and cautery.
62738663|NCT05171374||Adjuvant cohort|Patients with resectable stage III melanoma, reciveng dabrafenib and trametinib in adjuvant settings
62738664|NCT05171374||Metastatic cohort|Patients with unresectable stage IIIC/D or stage IV melanoma, reciveng dabrafenib and trametinib in metastatic settings
62738665|NCT02024425|ACTIVE_COMPARATOR|Functional bioactive supplement|The functional bioactive supplement is composed of antioxidant extracted from rosemary, oligosaccharides derived from lactulose and bioactive peptides. It will be used for obese and overweight treatment
62794258|NCT05028335|EXPERIMENTAL|Group G2|Home bleaching treatment (Carbamide Peroxide (PC) 22%) + 1.5% Potassium Oxalate gel
62794259|NCT04800601|EXPERIMENTAL|Experimental group|
62794260|NCT04800601|ACTIVE_COMPARATOR|Control group|
62794261|NCT02722200|EXPERIMENTAL|Intravenous glucocorticoids|Subjects in the glucocorticoids arm will receive an infusion of hydrocortisone overnight in the research unit prior to fMRI testing on either the first or second visit.
62794262|NCT02722200|PLACEBO_COMPARATOR|Intravenous saline|Subjects in the saline arm will receive an infusion of saline overnight in the research unit prior to fMRI testing on either the first or second visit.
62794263|NCT01456169|ACTIVE_COMPARATOR|Azilsartan medoxomil 40 mg|Azilsartan medoxomil 40 mg and placebo to chlorthalidone combination tablets, orally, once daily for up to 8 weeks.
62794264|NCT01456169|EXPERIMENTAL|Azilsartan medoxomil + chlorthalidone 40/12.5 mg|Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.
62794265|NCT01456169|EXPERIMENTAL|Azilsartan medoxomil + chlorthalidone 40/25 mg|Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.
62218452|NCT03698812||CTL group|control group
62218453|NCT03698812||EXP group|Colonoscope
62794266|NCT01199809|EXPERIMENTAL|1|
62218454|NCT05128383|EXPERIMENTAL|Dupilumab Subcutaneous Injection|"600 mg at initial visit and 300mg every 2 weeks until week 22~Each subject will receive 600mg of Dupilumab at baseline visit and 300mg of Dupilumab as a subcutaneous injection every 2 weeks for a total of 9 doses over 22 weeks."
62218455|NCT03039101|EXPERIMENTAL|Montelukast|Subjects take 1 montelukast 10mg tablet orally, daily and effect on nasal allergen challenge (based on results of epicutaneous skin testing) induced recruitment of cd49d neutrophils in the peripheral blood and nasal lavage determined at 1 week
62412458|NCT06651723|ACTIVE_COMPARATOR|Manual brushes|The participants will use a soft manual brush (control).
62794267|NCT01199809|PLACEBO_COMPARATOR|2|
62022358|NCT00875953|EXPERIMENTAL|Harmonic Scalpel|Harmonic scalpel used in neck dissection.
62022359|NCT05123248|EXPERIMENTAL|Blinded Group|Participants in the blinded group will be wearing the sensor for 14 days without a reader. After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.
62218456|NCT03039101|PLACEBO_COMPARATOR|Placebo|Subjects take 1 placebo oral pill, daily and effect on nasal allergen challenge (based on results of epicutaneous skin testing) induced recruitment of cd49d neutrophils in the peripheral blood and nasal lavage determined at 1 week.
62218457|NCT01873560||FFRpost|High FFRpost group and low FFRpost group were defined according to the optimal cut-off value for predicting clinical outcome.
62412459|NCT03374566||Screened patients|Immunodeficiency screening: Heparinized peripheral blood is obtained from patients with severe EBV infections for immunological function assays and genetic analysis, when current screening is performed after parents' information and consent.
62794268|NCT00756431|ACTIVE_COMPARATOR|Screw without HA Coating (Hiploc)|
62794269|NCT00756431|EXPERIMENTAL|Screw with HA Coating (Hiploc)|
62794270|NCT03782363|EXPERIMENTAL|Autologous CIK Dose level 1|autologous CIK at dose level 1
62794271|NCT03782363|EXPERIMENTAL|Autologous CIK Dose level 2|autologous CIK at dose level 2
62794272|NCT03782363|EXPERIMENTAL|Autologous CIK Dose level 3|autologous CIK at dose level 3
62794273|NCT03782363|EXPERIMENTAL|Autologous CIK Dose level 4|autologous CIK at dose level 4
62794274|NCT04875052|ACTIVE_COMPARATOR|Standard ACL Rehabilitation|Patients will complete a 20-week supervised, progressive rehabilitation protocol directed by physical therapists at 1 of 3 participating clinics. While the specific rehabilitation exercises and techniques used for a given patient may vary depending on clinician preference/experience and patient responsiveness and progress, the general rehabilitation protocol will be standardized and follow current best practices emphasizing restoration of early weight bearing, range of motion, quadriceps function, balance, and neuromuscular control consistent with the Multicenter Orthopaedics Outcomes Network (MOON) rehabilitation protocol.
62794275|NCT04875052|EXPERIMENTAL|Whole Body Vibration|Patients will perform standard rehabilitation for the first month post-ACLR. At 1 month they will continue with standard rehabilitation, but will also be exposed to whole body vibration at the beginning of each session prior to rehabilitation exercises in an effort to enhance their efficacy.
62412460|NCT06079437|EXPERIMENTAL|experimental group|Heart rate, maximum isometric muscle strength, Soleus H-reflex, M-wave, and V-wave measurements were taken in three consecutive periods. First-period maximal isometric contraction; second-period maximal isometric contraction + cold pressure test; third-period maximal isometric contraction + Cheering
62412461|NCT05272267|ACTIVE_COMPARATOR|AI-assisted|AI-assisted models providing diagnosis and prognostic information
62412462|NCT05272267|PLACEBO_COMPARATOR|Usual care|usual care without AI-assisted models providing diagnosis and prognostic information
62794276|NCT04875052|EXPERIMENTAL|Local Muscle Vibration|Patients will perform standard rehabilitation for the first month post-ACLR. At 1 month they will continue with standard rehabilitation, but will also be exposed to local muscle vibration at the beginning of each session prior to rehabilitation exercises in an effort to enhance their efficacy.
62794277|NCT00001393||African descent controls|Controls; adult healthy volunteers of African descent without kidney disease
62794278|NCT00001393||African-Americans with FSGS|African-American patients with idiopathic or HIV-associated collapsing glomerulopathy
62794279|NCT00001393||African-Americans with HIV|Hyper-normal controls; adult African-Americans with HIV and without kidney disease
62794280|NCT00001393||European and Asian descent controls|Controls; healthy volunteers of European or Asian descent without kidney disease
62794281|NCT00001393||Kidney donors|People donating kidneys at NIH
62794282|NCT00001393||Other patients with idiopathic FSGS|Patients of other areas of descent with idiopathic FSGS
62794283|NCT00001393||Relatives of patients with familial FSGS|Relatives of patients with familial FSGS
62794284|NCT00001393||Tamils|Adults with Tamilian descent
62794285|NCT05171673|EXPERIMENTAL|Investigational|LicartTM topical system application once per day for a maximum of 14 days or until pain resolution, whichever occurs first.
62022360|NCT05123248|EXPERIMENTAL|Unblinded Group|Participants in the non-blinded group are required to wear the sensor for 14 days with an open reader. The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.
62022361|NCT02331134|OTHER|Melanoma, head and neck|10 μg/kg/day of Filgrastim will be given subcutaneously for 4 days
62794286|NCT04472299|EXPERIMENTAL|Experimental|Participants in this group will receive the intervention.
62794287|NCT04472299|NO_INTERVENTION|Control|Participants in this group will receive no intervention.
62794288|NCT03189160|EXPERIMENTAL|PEG-rhGH low dose|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
62794289|NCT03189160|EXPERIMENTAL|PEG-rhGH high dose|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
62022362|NCT03832946|EXPERIMENTAL|A. GB0139 3 mg once a day|Inhalation of GB0139
62022363|NCT03832946|PLACEBO_COMPARATOR|B. Placebo once a day|Inhalation of Placebo
62022364|NCT06331221|NO_INTERVENTION|Control Condition|5-minute rest period.
62412463|NCT00391118|EXPERIMENTAL|A (Part A)|"Enzastaurin: 1125 milligram (mg) loading dose then 500 mg oral tablet, daily for six 21-day cycles or up to 3 years~Carboplatin: Area under the concentration time curve (AUC) 5 intravenous (IV), every (q) 21 days for six 21-day cycles~Paclitaxel:175 milligrams/square meter (mg/m²) IV, q21 days for six 21-day cycles"
62412464|NCT00391118|PLACEBO_COMPARATOR|B (Part B)|"Carboplatin: AUC5 IV, q21 days for six 21-day cycles~Paclitaxel: 175 mg/m², IV, q21 days for six 21-day cycles~Placebo: oral tablet"
62794290|NCT03189160|NO_INTERVENTION|Non-treatment control group|
62794291|NCT04701190|ACTIVE_COMPARATOR|Noradrenaline 0.05/10|"Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.~The noradrenaline bolus dosage of 10 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely. After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.05 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
62412465|NCT02539472|EXPERIMENTAL|investigation|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
62022365|NCT06331221|ACTIVE_COMPARATOR|Quadriceps_Concentric|40 consecutive maximal concentric contractions of quadriceps at 30º/s
62022366|NCT06331221|ACTIVE_COMPARATOR|Quadriceps_Eccentric|40 consecutive maximal eccentric contractions of quadriceps at 30°/s
62022367|NCT06331221|ACTIVE_COMPARATOR|Hamstrings_Concentric|30 consecutive maximal concentric contractions of hamstrings at 30º/s
62022368|NCT06331221|ACTIVE_COMPARATOR|Hamstrings_Eccentric|30 consecutive maximal eccentric contractions of the hamstrings at 30º/s
62022369|NCT01734512|EXPERIMENTAL|Everolimus|Everolimus tablet will be taken daily by mouth with water. Twenty-eight days will constitute one course and subsequent courses will immediately follow with no break in the administration of the drug. Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Patients will also be provided with a drug diary for everolimus. The maximum time on study is 24-months, but if there is no disease progression or adverse events, the patient may speak with a doctor about continuing the treatment off-study.
62022370|NCT00931177||Dehydrated children|children with dehydration
62586237|NCT06057324|EXPERIMENTAL|Multi-component intervention groups|"Multi-component intervention with non-invasive approaches:~-Digital interactive tools (AI-based Apps): They will consist of a combination of two Artificial Intelligence (AI) Apps that will be used by parents to empower them in their daily dietary choices for children's dietary plan.~- Educational materials (Mediterranean-based diet toolkit) and activities: The toolkit will include a set of specific games and activities for kids designed to facilitate the ''learning through playing'' approach improving their understanding of different nutrition themes. The educational activities will be co-designed and carried out by adolescents outside of school hours.~- Healthy plant-based snacks: They will be adapted to children's nutritional requirements and to be consumed in-between time on a daily basis. Based on local and traditional products for each country including vegetables, fruits, legumes, seeds and nuts as main ingredients."
62794292|NCT04701190|ACTIVE_COMPARATOR|Noradrenaline 0.075/5|"Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.~The noradrenaline bolus dosage of 5 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely. After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.075 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
62794293|NCT04701190|ACTIVE_COMPARATOR|Noradrenaline 0.1/0|"Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.~After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.1 microgram/kg/minute without bolus dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
62794294|NCT06727383|EXPERIMENTAL|Cohort a|The collection of PBMCs will be performed during standard blood test procedures: 40 mL of PB will be collected in 8 EDTA tubes.
62794295|NCT06727383|EXPERIMENTAL|Cohort b|"The collection of CD34+ cells will be performed during HSC mobilization and staging bone marrow aspirations, as follows:~1. During standard HSC mobilization, 10 mL peripheral blood will be collected in two EDTA tubes from patients with \>20 CD34+ cells/mcL.~2. 5 mL of bone marrow will be collected in one EDTA tube during bone marrow aspiration performed in the context of standard diagnostic procedures."
62794296|NCT06727383|EXPERIMENTAL|Cohort c|The collection of CD34+ cells will be performed from a LP required in the context of standard therapeutic procedures
62218458|NCT05548140|EXPERIMENTAL|NOVEL MOTORIZED SPIRAL ENTEROSCOPY|This arm involves performance of spiral enteroscopy using a specialized enteroscope under general anaesthesia in patients who fulfill the inclusion criteria.
62218459|NCT05548140|ACTIVE_COMPARATOR|SINGLE BALLOON ENTEROSCOPY|This arm involves performance of single balloon enteroscopy using a specialized single balloon enteroscope in patients who fulfill inclusion criteria.
62218460|NCT01656733|EXPERIMENTAL|Nicotrol Inhaler|Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.
62218461|NCT01656733|PLACEBO_COMPARATOR|Placebo Inhaler|Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
62218462|NCT01045408|PLACEBO_COMPARATOR|Berry|
62218463|NCT01045408|PLACEBO_COMPARATOR|Placebo|
62218464|NCT05614986||Patients with Mild Cognitive Impairment Undergoing TAVR|Patients will be treated with standard of care. In addition, patients will complete the mini MoCA at 3 time points
62218465|NCT02949804||Smoker|Vasovagal tendency will be compared among smokers and non smokers
62218466|NCT02949804||Non-smokers|Vasovagal tendency will be compared among smokers and non smokers
62412466|NCT04218175|EXPERIMENTAL|neuromobilization stretching group|In the neuromobilization stretching group; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed.
62218467|NCT04639271|EXPERIMENTAL|Pyrotinib Plus Trastuzumab And Abraxane|Pyrotinib Plus Trastuzumab And Abraxane
62218468|NCT02882529|EXPERIMENTAL|Visible light exposure Green 30 lux|The participants will be exposed to green LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62586238|NCT06057324|NO_INTERVENTION|Control group|Families which will not follow any intervention; they will receive basic Mediterranean guidelines for parents and their children.
62794297|NCT02859103|ACTIVE_COMPARATOR|Treatment|Patients in this arm will receive treatment with desvenlafaxine for 8 weeks.
62794298|NCT02859103|NO_INTERVENTION|Healthy Control|Patients in this arm are healthy controls and will not receive any medication.
62794299|NCT02732964|NO_INTERVENTION|Control|baseline hemodynamics and anxiety screen; no music
62794300|NCT02732964|EXPERIMENTAL|Pandora Music|A study investigator will create a station in the Pandora® music application based on the patient's preferred music genre or artist.
62022371|NCT03365765|EXPERIMENTAL|mFOLFOX6 & apatinib|oxaliplatin 85mg/m2 intravenous infusion for 2 hours, intravenous infusion of leucovorin 400mg/m2 for 2 hours, intravenous infusion of 5- fluorouracil 400mg/m2, first days; 5- fluorouracil 2400mg/m2 continuous intravenous infusion for 46-48 hours, repeated 1 time every two weeks, a total of 12 cycles, 24 weeks. Patients also take apatinib, 1 time daily, 500mg each time, lasting 1 year, from the first chemotherapy of mFOLFOX6.
62586239|NCT01481662||retrospective|cases retrospectively reported the last 20 years
62794301|NCT02732964|EXPERIMENTAL|Mozart Music|A study investigator will turn on a playlist of pre-selected Mozart music.
62794302|NCT06727435|EXPERIMENTAL|non-sedation strategy|Patients eligible for this study will undergo non-sedation strategy, which continuous analgesia without sedation is performed with remifentanil. The remifentanil will be titrated (from 0.1µg/kg/min to 0.2ug/kg/min) every 10-15 minutes to achieve the goal for sedation (RASS score maintaining -2 to + 1). The patients in the non-sedation trial do not receive any sedatives but could receive bolus doses (2.5 or 5mg) of morphine for analgesia.
62794303|NCT02866227|EXPERIMENTAL|BV and/or VVC infection - Gel Treatment|Randomized 1:1 to gel nightly for 7 days. N = 40
62794304|NCT02866227|EXPERIMENTAL|BV and/or VVC infection - Vaginal Insert Treatment|Randomized 1:1 to insert nightly for 7 days. N = 40
62794305|NCT05195541|EXPERIMENTAL|Cohort A1|0.02mg/injection，2 injections
62022372|NCT03365765|ACTIVE_COMPARATOR|mFOLFOX6|oxaliplatin 85mg/m2 intravenous infusion for 2 hours, intravenous infusion of leucovorin 400mg/m2 for 2 hours, intravenous infusion of 5- fluorouracil 400mg/m2, first days; 5- fluorouracil 2400mg/m2 continuous intravenous infusion for 46-48 hours, repeated 1 time every two weeks, a total of 12 cycles, 24 weeks.
62022373|NCT01290367|EXPERIMENTAL|High Dose MPCs|Injection of High Dose MPCs with Hyaluronic Acid
62022374|NCT01290367|EXPERIMENTAL|Low Dose MPCs|Injection of Low Dose MPCs with Hyaluronic Acid
62794306|NCT05195541|EXPERIMENTAL|Cohort A2|0.04mg/injection，2 injections
62794307|NCT05195541|EXPERIMENTAL|Cohort B1|0.04mg/injection，4 injections
62022375|NCT01290367|SHAM_COMPARATOR|Saline injection|Injection of saline solution.
62022376|NCT01290367|PLACEBO_COMPARATOR|Hyaluronic acid injection|Injection of hyaluronic acid solution
62022377|NCT05947448||AZL-M single drug group|Azilsartan Medoxomil Potassium Tablet，80mg，tablet，QD，six months
62022378|NCT05947448||CCB single drug group|Nifedipine Controller-release Tablets，clinical maximum tolerated dose，tablet，QD，six months；or Levoamlodipine Maleate Table，clinical maximum tolerated dose，tablet，QD，six months； Doctor choose a medication that is more suitable for patient treatment.
62218469|NCT02882529|EXPERIMENTAL|Visible light exposure Green 120 lux|The participants will be exposed to green LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62412467|NCT04218175|EXPERIMENTAL|neuromobilization shifting group|In the neuromobilization shifting group, the subjects were brought to shoulder depression and 90 degrees of abduction while the dominant forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side. Thus, the participants performed median nerve shift.
62412468|NCT04218175|NO_INTERVENTION|Control Group|The dominant sides of the individuals are experimental sides and the other nondominant sides of the participants are control sides. And no intervention was made. All measurements were done bilaterally before and after.
62412469|NCT00397904|EXPERIMENTAL|Cetuximab, Cisplatin, and Irinotecan|Cetuximab will be combined with weekly irinotecan and cisplatin. Patients will receive cetuximab 400 mg/m2 on day 1, week 1. Following this loading dose, patients will receive weekly cetuximab 250 mg/m2 (day 8, 15, 22, etc.) until disease progression or unacceptable toxicity. Patients will continue to receive irinotecan and cisplatin weekly on day 1 and day 8, on an every 21 day cycle. The standard maximum doses are irinotecan 65 mg/m2 and cisplatin 30 mg/m2.
62412470|NCT05968924|EXPERIMENTAL|High risk Diabetic Foot Ulcer (DFU)|Podimetrics smart map
62412471|NCT00359359|EXPERIMENTAL|Sagopilone and cisplatin|The study drug sagopilone was administered in combination with a fixed dose of cisplatin
62794308|NCT05195541|EXPERIMENTAL|Cohort B2|0.075mg/injection，4 injections
62412472|NCT03083639|EXPERIMENTAL|Esomeprazole 40 mg Capsule + Esomeprazole 40 mg Tablet|Esomeprazole 40 mg, capsule, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg tablet, orally, once on Day 1 of Intervention Period 2.
62794309|NCT05195541|EXPERIMENTAL|Cohort C1|0.075mg/injection，6 injections
62794310|NCT05195541|EXPERIMENTAL|Cohort C2|0.15mg/injection，6 injections
62794311|NCT05195541|EXPERIMENTAL|cohort X1|0.04mg/injection，20 injections
62794312|NCT05195541|EXPERIMENTAL|cohort X2|0.075mg/injection，20 injections
62794313|NCT05195541|EXPERIMENTAL|cohort X3|0.15mg/injection，20 injections
62794314|NCT05195541|PLACEBO_COMPARATOR|cohort X|0.15mg of placebo /injection，20 injections
62794315|NCT01587040|EXPERIMENTAL|SAR245408: Monotherapy|Participants received SAR245408 400 milligrams (mg) once daily or at the established dose as monotherapy in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245408 were available (up to 1959 days).
62022379|NCT05947448||AZL-M + CCB drug group（Combined medication）|Nifedipine Controller-release Tablets，clinical maximum tolerated dose，tablet，QD，six months；and Levoamlodipine Maleate Table，clinical maximum tolerated dose，tablet，QD，six months； When the patient's upper pressure exceeds 160 Millimetre of mercury, the doctor will choose combination medication .CCB drug will be chosen either Nifedipine Controller-release Tablets or Levoamlodipine Maleate Table.
62218470|NCT02882529|EXPERIMENTAL|Visible light exposure Yellow 30 lux|The participants will be exposed to yellow LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62218471|NCT02882529|EXPERIMENTAL|Visible light exposure Yellow 120 lux|The participants will be exposed to yellow LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62218472|NCT02882529|EXPERIMENTAL|Visible light exposure Violet 30 lux|The participants will be exposed to violet LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62412473|NCT03083639|EXPERIMENTAL|Esomeprazole 40 mg Tablet + Esomeprazole 40 mg Capsule|Esomeprazole 40 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg capsule, orally, once on Day 1 of Intervention Period 2.
62412474|NCT04837274|PLACEBO_COMPARATOR|Placebo|Dextrose (480 mg)
62412475|NCT04837274|EXPERIMENTAL|Active|Tart Cherry (480 mg)
62412476|NCT05649423|EXPERIMENTAL|Postural drainage with percussion|Chest percussion is performed with cupped hands in an alternating rhythmic manner The force applied must be equal 8 weeks, 3 sessions per week , each session took about 30 minutes
62412477|NCT05649423|ACTIVE_COMPARATOR|Postural drainage|Postural drainage without Percussion Each position should be held for a minimum of five minutes Use pillows, foam wedges for comfort make position on patient back, side and stomach 8 weeks, 3 sessions of alternating positions per , each session took about 30 minutes
62412478|NCT05397119|EXPERIMENTAL|BW-1014: 25 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 25 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
62412479|NCT05397119|EXPERIMENTAL|BW-1014: 50 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 50 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
62412480|NCT05397119|EXPERIMENTAL|BW-1014: 100 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 100 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
62412481|NCT05397119|PLACEBO_COMPARATOR|rH5 (100 µg) control - pipette - IN|100 µg recombinant H5 antigen (without adjuvant) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
62412482|NCT05397119|SHAM_COMPARATOR|Saline (Placebo) - pipette - IN|Saline (negative control) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
62022380|NCT00931021|ACTIVE_COMPARATOR|Varenicline (Chantix)|
62022381|NCT00931021|ACTIVE_COMPARATOR|Nicotine Patch|
62218473|NCT02882529|EXPERIMENTAL|Visible light exposure Violet 120 lux|The participants will be exposed to violet LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62412483|NCT00606996|EXPERIMENTAL|IPT-G|Group Interpersonal Psychotherapy
62412484|NCT00606996|ACTIVE_COMPARATOR|PSYCHOED|Psychoeducation
62412485|NCT02453282|EXPERIMENTAL|Monotherapy|PD-L1 monoclonal Antibody monotherapy.
62412486|NCT02453282|EXPERIMENTAL|Combination Therapy|PD-L1+Tremelimumab combination therapy
62412487|NCT02453282|ACTIVE_COMPARATOR|Standard of Care|Standard of Care chemotherapy treatment
62412488|NCT05134740|EXPERIMENTAL|Experimental Arm|Patients receiving autologous TAA-specific cytotoxic CTLs
62412489|NCT02133911|NO_INTERVENTION|Controls|
62218474|NCT05080816|ACTIVE_COMPARATOR|Parenteral nutrition|Overnight infusion of parenteral nutrition. Supplied as all-in-one-bag format. Infusion rate of 0.2 g N/kg/day.
62218475|NCT05080816|ACTIVE_COMPARATOR|Enteral nutrition|Oral nutrition drink. 2 \* 200 ml on the night before operation. 1\* 200 ml on the morning of operation day.
62218476|NCT05080816|PLACEBO_COMPARATOR|control|Overnight infusion of crystalloid fluid (Ringer acetate) infused at the same rate (ml/kg) as intervention PN
62412490|NCT02133911|EXPERIMENTAL|Ranolazine|Initial dose is 375 mg bid. After 2 - 4 weeks the dose is increased to 500 mg bid and after another 2-4 weeks to 750 mg bid. In case of side effects the dose of the drug is to be decreased to the highest dose that the patient is still able to tolerate.
62412491|NCT01396499|EXPERIMENTAL|BKM120|Oral BKM120 starting dose 80 mg once daily.
62412492|NCT02861729|EXPERIMENTAL|Suprinity|Vita Suprinity® (VITA Zahnfabrik H. Rauter GmbH \& Co.KG- Germany) Zirconia reinforced lithium silicate PCRs
62412493|NCT02861729|ACTIVE_COMPARATOR|e.max|IPS-e.max® CAD (Ivoclar Vivadent AG, Schaan - Liechtenstein) lithium disilicate PCRs
62412494|NCT00646607|EXPERIMENTAL|A|FOLFOX-4 (infusional 5-Fluouracil, leucovorin and oxaliplatin) for 3 months or XELOX (capecitabine and oxaliplatin) for 12 weeks.
62412495|NCT00646607|ACTIVE_COMPARATOR|B|FOLFOX-4 (infusional 5-Fluouracil, leucovorin and oxaliplatin) for 6 months or XELOX (capecitabine and oxaliplatin) for 24 weeks.
62412496|NCT03466060|ACTIVE_COMPARATOR|etafilcon A|Eligible subjects were randomized to the etafilcon A lens in both eyes throughout the entire duration of the study.
62412497|NCT03466060|ACTIVE_COMPARATOR|senofilcon A|Eligible subjects were randomized to the senofilcon A lens in both eyes throughout the entire duration of the study.
62586240|NCT01481662||Prospective|"Diffusion tensor magnetic resonance imaging of the brain:~new cases prospectively reported"
62022382|NCT03351023||Nurses' Health Study II|Nurses' Health Study II, an ongoing cohort study of 116,430 female registered nurses in the US, aged 25-42 at enrollment in 1989. Participants have been followed by biennial mailed questionnaires that elicit updated information on diet, lifestyle, and various health outcomes; the follow-up rate over 26 years exceeds 90% of the eligible person-time.
62022383|NCT03129893||Patients intubated with uncuffed tracheal tubes|Portex uncuffed TT sizes selected according to local institutional guidelines. Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to institutional guidelines in uncuffed TTs.
62022384|NCT03129893||Patients intubated with cuffed tracheal tubes|Cuffed TT sizes selected as follows: ID 3.0 mm for birth (\>3 kg body weight) to \< 8 months; ID 3.5 mm for 8 to \< 12 months (Salgo, Schmitz et al. 2006). Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to the depth marking in cuffed TTs.
62412498|NCT03466060|ACTIVE_COMPARATOR|senofilcon C|Eligible subjects were randomized to the senofilcon C lens in both eyes throughout the entire duration of the study.
62412499|NCT05838352|EXPERIMENTAL|Telerehabilitation Group (TRG)|The group given physical activity and nutrition counseling for 2 months through telerehabilitation.
62412500|NCT05838352|ACTIVE_COMPARATOR|Conventional Rehabilitation Group (CRG)|The group who received conventional treatment and had no intervention, only pretest measurements
62412501|NCT05260307|OTHER|Experimental condition|Participants will be presented with sound stimuli under a number of experimental conditions that simulate different hearing-aid conditions.
62022385|NCT01098448|ACTIVE_COMPARATOR|Scaling and root planing|scaling and root planing as a solo therapy
62022386|NCT01098448|EXPERIMENTAL|Periodontal surgery|
62022387|NCT01098448|EXPERIMENTAL|systemic antibiotics|
62412502|NCT05517707||Nasogastric tube group|Neonates age 0-18 weeks post-partum at enrollment with gestational age \> 28 weeks will have the Gravitas Feeding Tube placed using standard technique. Tube placement will be verified by the institution standard of care. Study tubes are to remain in place up to 30 days.
62586241|NCT06238986||Observational|Patients undergo stool and blood sample collection, complete questionnaires, and have their medical records reviewed on study.
62022388|NCT01098448|EXPERIMENTAL|Local delivery of tetracycline|
62022389|NCT01098448|EXPERIMENTAL|local antibiotic and systemic antibiotics|
62022390|NCT01098448|EXPERIMENTAL|local antibiotics and surgery|
62022391|NCT01098448|EXPERIMENTAL|systemic antibiotics and surgery|
62022392|NCT01098448|EXPERIMENTAL|local and systemic antibiotics and surgery|
62586242|NCT02957968|EXPERIMENTAL|Cohort A: Triple Negative Breast Cancer (TNBC)|Triple Negative Breast Cancer (Cohort A): Decitabine IV over 60 minutes on 4 days and pembrolizumab IV over 30 minutes on days 8 and 22. Four cycles of dose-dense doxorubicin and cyclophosphamide (AC), followed by 12 doses of weekly paclitaxel and carboplatin.
62738666|NCT02024425|PLACEBO_COMPARATOR|Maltodextrin and saccharose|The control supplement is composed of maltodextrin and saccharose . It has no effect for obese and overweight treatment
62738667|NCT06049095|EXPERIMENTAL|LTG-001|Part A: Single-Ascending dose cohorts; relative bioavailability; food effect; Part B: Multiple-ascending dose cohorts
62022393|NCT04120506|EXPERIMENTAL|Rapid infusion of Vpriv|: Infusions at Baseline and during step-wise rate increases and End-of-study will be performed in the Shaare Zedek Medical Center (SZMC) by the Study Nurse who will monitor vital signs (see below) for a total of 8 visits at SZMC. Home therapy will be approved if the patient so desires for 5 infusions in Phase 1 and for the first 5 infusions in Phase 3. All routine hematological and biochemical tests will be performed in the SZMC clinical labs. Abdominal quantitative MR Imaging (MRI) for spleen and liver volumes will be performed at SZMC
62738668|NCT06049095|PLACEBO_COMPARATOR|Placebo|Part A: Single-Ascending dose cohorts; Part B: Multiple-ascending dose cohorts
62738669|NCT06292195||Cohort VitDTracking: Group 1- Pregnant women with vitamin D Sufficiency (≥30 ng/mL)|
62738670|NCT06292195||Cohort VitDTracking: Group 2 - Pregnant women with vitamin D Insufficiency (20-29 ng/mL)|
62738671|NCT06292195||Cohort VitDTracking: Group 3 - Pregnant women with vitamin D Deficiency (<20 ng/mL)|
62738672|NCT04960748|EXPERIMENTAL|intervention|7-sesson group intervention that uses dyadic instruction, role playing and group sharing and discussion to reduce internalized stigma, improve disclosure decision making and healthy living, and teach advocacy skills
62738673|NCT04960748|NO_INTERVENTION|wait-list control|Participants will not receive the intervention until all follow-up data has been collected.
62738674|NCT05755932|EXPERIMENTAL|Treatment A: HFO MDI|Test arm, 6 inhalations BID for 7 days
62738675|NCT05755932|ACTIVE_COMPARATOR|Treatment B: HFA MDI|Reference arm, 6 inhalations BID for 7 days
62738676|NCT04599803|EXPERIMENTAL|Arm 1|Participants told they may have Obstructive Sleep Apnea (OSA) and provided a home sleep test (HST)
62738677|NCT02552745||study group|parecoxib sodium was administered postoperatively
62738678|NCT02552745||control group|parecoxib sodium was not administered postoperatively
62738679|NCT00113633|NO_INTERVENTION|Control Subjects|These subjects will receive standard discharge instructions that recommend follow-up with a PCP within 3-5 days.
62738680|NCT00113633|EXPERIMENTAL|Intervention Subjects|As part of the intervention, the family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups. For children reporting persistent asthma symptoms, a letter will be given to the family to bring to their PCP stating that screening revealed symptoms that may require further treatment with controller medications. A mailed reminder to schedule a follow-up appointment will be sent to the family.
62738681|NCT05788419||examination group|Group of active hockey players
62738682|NCT05788419||control group|Group of athletes, non hockey players
62794316|NCT01587040|EXPERIMENTAL|SAR245408: Combination Regimen|Participants received SAR245408 400 mg once daily or at the established dose as combination regimen in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245408 were available (up to 1959 days). Commercially available drugs were used as combination medications with SAR245408 (depending on the parental study, the following drugs were used in combination with SAR245408: paclitaxel and carboplatin, letrozole, trastuzumab, paclitaxel and trastuzumab).
62218477|NCT00297232|EXPERIMENTAL|Natalizumab|300 mg intravenous (IV) infusions once every 4 weeks for up to 480 weeks
62218478|NCT05149053|EXPERIMENTAL|Food Supplement|Food supplement packet taken one per day preferably in the morning for 6 months.
62218479|NCT05149053|PLACEBO_COMPARATOR|Control|Placebo packet taken one per day preferably in the morning for 6 months.
62218480|NCT01763801|ACTIVE_COMPARATOR|P-Max group|Includes cases in which the catheter tip was considered correctly positioned when the Maximal P wave was obtained
62218481|NCT01763801|ACTIVE_COMPARATOR|P-Submax group|Includes cases in which the catheter tip was considered correctly positioned when the Submaximal P wave was obtained
62218482|NCT04847193|EXPERIMENTAL|Placebo|Participants receive a study drink supplemented with a placebo over a time period of 5 days.
62412503|NCT06396247|EXPERIMENTAL|Functional Activity Strength TRaining|Participants will perform 5 minutes of functional resistance training daily, supported by 24 video coaching sessions over 12 months.
62412504|NCT06396247|ACTIVE_COMPARATOR|Delayed Treatment|Participants will receive the intervention after 12 months.
62586243|NCT02957968|EXPERIMENTAL|Cohort B: HER2-negative hormone receptor-positive tumors|HER2-negative hormone receptor-positive tumors (Cohort B): Decitabine IV over 60 minutes on 4 days and pembrolizumab IV over 30 minutes on days 8 and 22. Four cycles of dose-dense doxorubicin and cyclophosphamide (AC), followed by 12 doses of weekly paclitaxel.
62586244|NCT02957968|EXPERIMENTAL|Cohort A2: Triple Negative Breast Cancer (TNBC) with Extended Pembrolizumab|Triple Negative Breast Cancer (Cohort A2). Decitabine IV over 60 minutes on 4 days and pembrolizumab IV over 30 minutes on days 8 and 22. Four cycles of dose-dense doxorubicin and cyclophosphamide (AC), followed by 12 doses of weekly paclitaxel and carboplatin, and pembrolizumab every 3 weeks.
62586245|NCT02780453|EXPERIMENTAL|Negative pressure dressing|Negative pressure dressing
62586246|NCT02780453|ACTIVE_COMPARATOR|Standard dressing|Standard wound dressing
62586247|NCT02064842|EXPERIMENTAL|TMC647055 150 mg or placebo + ritonavir (RTV)|Participants in Part 1 will receive a single oral dose of 150 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
62586248|NCT02064842|EXPERIMENTAL|TMC647055 450 mg or placebo + RTV|Participants in Part 1 will receive a single oral dose of 450 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
62794317|NCT01587040|EXPERIMENTAL|SAR245409: Monotherapy|Participants received SAR245409 50 mg twice daily or at the established dose as monotherapy in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245409 were available (up to 1917 days).
62218483|NCT04847193|EXPERIMENTAL|Xanthohumol|Participants receive a study drink supplemented with Xanthohumol over a time period of 5 days.
62218484|NCT04847193|EXPERIMENTAL|Iso-alpha acids|Participants receive a study drink supplemented with Iso-alpha acids over a time period of 5 days.
62218485|NCT04847193|EXPERIMENTAL|Xanthohumol/Iso-alpha acids|Participants receive a study drink supplemented with a combination of Xanthohumol and Iso-alpha acids over a time period of 5 days.
62218486|NCT01174732|EXPERIMENTAL|T1|A006 albuterol inhalation powder, 120 mcg/inhalation, 1 inhalation
62218487|NCT01174732|EXPERIMENTAL|T2|A006 albuterol inhalation powder 180 mcg/ inhalation, 1 inhalation
62218488|NCT01174732|EXPERIMENTAL|T3|A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations
62218489|NCT01174732|EXPERIMENTAL|T4|A006 albuterol inhalation powder 180 mcg/inhalation, 2 inhalations
62218490|NCT01174732|PLACEBO_COMPARATOR|P|Placebo, 2 inhalations
62218491|NCT01174732|ACTIVE_COMPARATOR|R1|Proventil 90 mcg/inhalation, 2 inhalations
62218492|NCT01174732|ACTIVE_COMPARATOR|R2|Proventil 90 mcg/inhalation, 4 inhalations
62218493|NCT03407560|EXPERIMENTAL|SintLife|Use of SintLife putty as bone substitute for spinal fusion in lumbar spine surgery for degenerative diseases.
62218494|NCT00069108|EXPERIMENTAL|XELOX|Participants received XELOX (oxaliplatin and capecitabine). Oxaliplatin was administered 130 mg/m\^2 intravenous (IV) infusion over 2 hours (every 3 weeks \[Day 1\]) before the first dose of capecitabine. Capecitabine was administered orally within 30 minutes after the end of a meal (breakfast and dinner) at a dose of 1000 mg/m\^2 twice-daily (equivalent to a total daily dose of 2000 mg/m\^2), with first dose the evening of Day 1 and last dose the morning of Day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) for up to 8 cycles (24-weeks).
62218495|NCT00069108|ACTIVE_COMPARATOR|FOLFOX-4|Participants received FOLFOX-4 (combination of oxaliplatin, leucovorin \[LV\] and 5-fluorouracil \[5-FU\] combination). Oxaliplatin was administered as an 85 mg/m\^2 IV infusion over 2 hours (on Day 1 only); with LV infusion as 200mg/m\^2 over 2 hours followed by 5-FU, given as 400mg/m\^2 bolus injection over 2-4 minutes, and then as a 600 mg/m\^2 continuous infusion over 22 hours. On Day 2, Leucovorin 200 mg/m\^2 (alone), followed by 5-FU 400 mg/m\^2 bolus injection over 2-4 minutes, and 5-FU 600 mg/m\^2 continuous infusion was repeated over 22 hours. It was (2-week cycles comprising 48 hours of infusion and 12 days of rest) for up to 12 cycles (24- weeks).
62218496|NCT01869127|NO_INTERVENTION|Control|Standard care
62218497|NCT01869127|EXPERIMENTAL|Shoes|Shoes
62586249|NCT02064842|EXPERIMENTAL|TMC647055 600 mg or placebo + RTV|Participants in Part 1 will receive a single oral dose of 600 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
62218498|NCT03573687|EXPERIMENTAL|RT on Fat Metabolism|Determine the extent to which a full-body acute RT protocol will affect intra-RT and post-RT SCAAT lipolytic rate, and post-RT whole-body substrate utilization in RT women compared to baseline measures (independent of Aims 2 and 3).
62412505|NCT00941681|EXPERIMENTAL|Cohort 1: MR 50 mg BID|Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.
62412506|NCT00941681|EXPERIMENTAL|Cohort 2: IR 37.5 mg TID|Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.
62412507|NCT00941681|EXPERIMENTAL|Cohort 3: MR 100 mg BID|Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days
62412508|NCT04969263|EXPERIMENTAL|BNT162b2 mRNA-based vaccine (Pfizer/BioNTech)|"The BNT162b2 mRNA-based vaccine was developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. Kidney transplant recipients who had a suboptimal antibody response to the standard two doses of vaccination with Pfizer/BioNTech will receive a third dose of the the same vaccine.~Administration: One dose administered intramuscularly, upper arm."
62412509|NCT04969263|EXPERIMENTAL|mRNA-1273 vaccine (Moderna)|"The mRNA-1273 vaccine was developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. Kidney transplant recipients who had a suboptimal antibody response to the standard two doses of vaccination with Moderna will receive a third dose of the same vaccine.~Administration: One dose administered intramuscularly, upper arm."
62412510|NCT04942964|EXPERIMENTAL|ASP0367: Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
62412511|NCT04942964|EXPERIMENTAL|ASP0367: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
62412512|NCT04942964|EXPERIMENTAL|ASP0367: Normal Hepatic Function|Participants with normal hepatic function will receive a single dose of ASP0367 under fasting conditions on day 1.
62412513|NCT05535842|EXPERIMENTAL|Intervention|Participants in the intervention group will use GLOW the conversational agent/app for 6 months in addition to their usual diabetes care offered by their attending doctor or endocrinologist.
62586250|NCT02064842|EXPERIMENTAL|Sequence 1 (Treatment A-B-C)|Participants in Part 2 will receive Treatment ABC in the following sequence - Treatment A: TMC435 150 mg once daily on Days 1 to 7; Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
62586251|NCT02064842|EXPERIMENTAL|Sequence 2 (Treatment B-C-A)|Participants in Part 2 will receive Treatment BCA in the following sequence - Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment A: TMC435 150 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
62586252|NCT02064842|EXPERIMENTAL|Sequence 3 (Treatment C-A-B)|Participants in Part 2 will receive Treatment CAB in the following sequence - Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment A: TMC435 150 mg once daily on Days 1 to 7; and Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
62586253|NCT02064842|EXPERIMENTAL|Sequence 4 (Treatment A-C-B)|Participants in Part 2 will receive Treatment ACB in the following sequence - Treatment A: TMC435 150 mg once daily on Days 1 to 7; Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
62794318|NCT01587040|EXPERIMENTAL|SAR245409: Combination Regimen|Participants received SAR245409 50 mg twice daily or at the established dose as combination regimen in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245409 were available (up to 1917 days). Commercially available drugs were used as combination medications with SAR245409 (depending on the parental study, the following drugs were used in combination with SAR245409: letrozole, temozolomide, rituximab, bendamustine and rituximab).
62022394|NCT04091399|EXPERIMENTAL|Patient cohort|Patients suffered from alveolar osteitis and treated using a Stomatological tamponade Contipro, composed of the Hyaluronic acid and Octenidine dihydrochloride. Firstly, the extraction wound had been irrigated with 2 ml of 3% solution of H2O2 to disinfect the site and then flushed by 2 ml of Aqua pro injectione to clear any remaining debris. After, the tested drug was applied into the extraction wound. This procedure was repeated on a daily basis for a maximum of 7 days or until the pain subsided below 20 mm and remained there for at least 2 days.
62022395|NCT06478927|EXPERIMENTAL|Palbociclib Group|Palbociclib capsules, oral, qd
62412514|NCT05535842|NO_INTERVENTION|Control|The control group will continue with their usual care, i.e., scheduled consultations with their diabetes team at TTSH and any consultations with healthcare professionals and diabetes education support received either during the consultations or during dedicated times if there are any. They will not be asked to use GLOW during the trial.
62412515|NCT03114527|EXPERIMENTAL|Dedifferentiated Liposarcoma Arm|Patients receive ribociclib orally at 300mg/day for 21 days of each 28 day cycle and everolimus 2.5mg orally on a continuous 28 day cycle.
62022396|NCT01646476|ACTIVE_COMPARATOR|Covered stent (Bona stent, pyloric/duodenal covered)|WAVE covered self-expandable metallic stent (BONASTENT, Standard Sci Tech, Ltd., Seoul, Korea)
62022397|NCT01646476|ACTIVE_COMPARATOR|Uncovered stent (Bona stent, pyloric/duodenal)|uncovered self-expandable metallic stent (BONASTENT, Standard Sci Tech, Ltd., Seoul, Korea)
62022398|NCT01627392|EXPERIMENTAL|Smoking abstinence|
62412516|NCT03114527|EXPERIMENTAL|Leiomyosarcoma Arm|Patients receive ribociclib orally at 300mg/day for 21 days of each 28 day cycle and everolimus 2.5mg orally on a continuous 28 day cycle.
62022399|NCT04937569|ACTIVE_COMPARATOR|Group 1: Ivermectin + standard treatment|Patients will receive 4-days course of Ivermectin 400 microgram/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast plus standard treatment (Azithromycin 500mg once daily for 5 days, Paracetamol 500mg every 8 hours, vitamin C 1gm once daily, Zinc 50 mg once daily, Lactoferrin 100mg sachets twice daily and prophylactic or therapeutic anticoagulation if D-dimer is elevated.
62022400|NCT04937569|OTHER|Group-2: Standard treatment only|This group will receive the standard treatment protocol as outlined above according to the Egyptian Ministry of Health protocol of treating cases with mild COVID-19.
62794319|NCT04376749||preterm infants received caffeine|preterm infants aged between 28 to 34 weeks gestational age who received caffeine therapy either for prophylaxis or treatment
62794320|NCT04376749||preterm infants received no caffeine|preterm infants aged between 28 to 34 weeks gestational age who received no caffeine therapy
62794321|NCT04968652||IBS-C Group|Result of ROME VI marked as 'IBS-C'.
62412517|NCT05217901|EXPERIMENTAL|14C-labeled ASP0367|Participants will receive a single oral dose of \[14C\]ASP0367 solution under fasting conditions on day 1.
62412518|NCT02723786|EXPERIMENTAL|GSK1070806 3 mg/kg IV|Subjects received a single dose of 3 milligram per kilogram (mg/kg) intravenous (IV) infusion of GSK1070806 administered prior to kidney allograft reperfusion. Subjects also received a combination immunosuppression comprized of basiliximab; mycophenolate mofetil (MMF) or aziothioprine; tacrolimus; and corticosteroids based on the clinical judgment of the investigator.
62412519|NCT03187899|SHAM_COMPARATOR|"Interscalene block plus sham"|"Patients in this group will receive a traditional interscalene block and a sham superficial plexus block with ropivacaine and 5-10cc of normal saline. N = 20"
62586254|NCT02064842|EXPERIMENTAL|Sequence 5 (Treatment B-A-C)|Participants in Part 2 will receive Treatment BAC in the following sequence - Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment A: TMC435 150 mg once daily on Days 1 to 7; and Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
62586255|NCT02064842|EXPERIMENTAL|Sequence 6 (Treatment C-B-A)|Participants in Part 2 will receive Treatment CBA in the following sequence - Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment A: TMC435 150 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
62586256|NCT04684459|EXPERIMENTAL|CAR-T cell therapy|Dual-targeting HER2 and PD-L1 CAR-T cell therapy
62794322|NCT04968652||Non IBS-C Group|Result of ROME VI marked as 'Non IBS-C'
62412520|NCT03187899|ACTIVE_COMPARATOR|Interscalene plus superficial plexus block|Patients in this group will receive a traditional interscalene block and a superficial plexus block with ropivacaine . N = 20
62794323|NCT05737654|EXPERIMENTAL|Augmented reality glasses group|Two days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
62022401|NCT06536062|EXPERIMENTAL|Monthly injection|The patients will recive 12 intravitreal injections in one eye and 12 sham injections in the other eye each month
62022402|NCT06536062|EXPERIMENTAL|Bimonthly injection|The patients will receive 6 intravitreal injections in one eye and 6 sham injections in the other eye each two months
62022403|NCT06536062|EXPERIMENTAL|Quarterly injection|The patients will receive 4 intravitreal injections in one eye and 4 sham injections in the other eye each three months
62412521|NCT03423914|EXPERIMENTAL|Writing Intervention Group|Expressive writing The participant will write four days about her deepest thoughts and feelings in relation to the experience of hospitalization of the premature newborn and how this experience is related to your current life and to your future.
62412522|NCT03423914|ACTIVE_COMPARATOR|Control Group|Only Writing The participants will write about situations not related to the subjective human experience of their preterm birth, but about general aspects.
62412523|NCT04776135|EXPERIMENTAL|MT-1186 orally|Subjects receive the edaravone oral suspension orally.
62794324|NCT05737654|NO_INTERVENTION|Control group|No intervention/application will be made to the children who will be included in the control group.
62794325|NCT01327599|EXPERIMENTAL|DUOTRAV®|Travoprost 0.004%+Timolol 0.5% ophthalmic solution, 1 drop to the study eye(s) once a day at 8:00 PM for 12 weeks
62794326|NCT02629120|ACTIVE_COMPARATOR|1|There is only one treatment arm for this study
62794327|NCT03570814|ACTIVE_COMPARATOR|Separate Administration|Standard administration of Albendazole/Ivermectin separated from administration of azithromycin
62794328|NCT03570814|EXPERIMENTAL|Co-administration|Combined administration of Albendazole/Ivermectin/Azithromycin at a single time point
62586257|NCT06683911||opioid free anaesthesia|"İnduction = 1 mg/kg lidocaine, 2-3 mg/kg propofol, 15 mg/kg magnesium, 1 mcg/kg dexmedetomidine (over 10 minutes), and a 0.6 mg/kg rocuronium.1 g acetaminophen, 4 mg ondansetron.~Blocks will include bilateral transverse thoracic muscle plane block and/or bilateral serratus anterior plane block with 0.5% bupivacaine (max 2 mg/kg) under ultrasound guidance.~Intravenous dexmedetomidine (0.1-1.4 mcg/kg/hr), lidocaine (0.5-1 mg/kg/hr), magnesium (1-10 mg/kg/hr), and propofol (1.5-12 mg/kg/hr) infusions will be adjusted based on hemodynamic parameters to achieve a target BIS value of 40-60.~if: heart rate \<80 and blood pressure \>140/90 mmHg, urapidil heart rate \>80 and blood pressure \>140/90 mmHg, esmolol heart rate \<50, atropine mean arterial pressure \<60 mmHg, ephedrine will be administered.~Local infiltration anesthesia will be administered through a catheter placed at the end of surgery, using bupivacaine at a concentration=2mg/ml and dosage=1.5 mg/kg/24 hours"
62586258|NCT06683911||opioid anaesthesia|"İnduction = 1 mcg/kg remifentanil and/or 1-5 mg fentanyl, 2-3 mg/kg propofol, intravenous 1 mg/kg lidocaine, 2-3 mg/kg propofol, and a 0.6 mg/kg rocuronium.1 g acetaminophen, 4 mg ondansetron.~Blocks will include bilateral transverse thoracic muscle plane block and/or bilateral serratus anterior plane block with 0.5% bupivacaine (max 2 mg/kg) under ultrasound guidance.~Intravenous remifentanil (0.02-2 mcg/kg/hr) and propofol (1.5-12 mg/kg/hr) infusions will be adjusted based on hemodynamic parameters to achieve a target BIS value of 40-60.~if: heart rate \<80 and blood pressure \>140/90 mmHg, urapidil heart rate \>80 and blood pressure \>140/90 mmHg, esmolol heart rate \<50, atropine mean arterial pressure \<60 mmHg, ephedrine will be administered.~Local infiltration anesthesia will be administered through a catheter placed at the end of surgery, using bupivacaine at a concentration=2mg/ml and dosage=1.5 mg/kg/24 hours"
62794329|NCT04882436||severe pneumonia|Patients with severe pneumonia
62586259|NCT04984369|EXPERIMENTAL|Never use other BRAF inhibitor therapy|Never use other BRAF inhibitor therapy
62794330|NCT01965730|ACTIVE_COMPARATOR|epsilon-aminocaproic acid (EACA)|75mg/kg loading dose with infusion 15mg/kg/hr
62794331|NCT01965730|EXPERIMENTAL|EACA|125mg/kg loading dose of EACA followed by an infusion of EACA at 25mg/kg/hr for length of cardiac surgery.
62218499|NCT03573687|EXPERIMENTAL|PRO Timing on Fat Metabolism|Assess the differences in overnight and next morning SCAAT lipolytic rate and next-morning whole-body substrate utilization compared to baseline between acute NP and DP consumption trials after a RT bout in RT women.
62794332|NCT02800499||KOCOSS|The KOrea COpd Subgroup Study team (KOCOSS) cohort is an ongoing, longitudinal, prospective, non-interventional observational study within the Korean COPD patients
62794333|NCT06299540||Group 1: Individual Physical Activity Intervention|Participants with chronic lymphocytic leukemia (CLL) will be invited to perform physical activity according to a predefined intervention program. This program includes walking and weekly remote adapted physical activity sessions (2 sessions per week, the duration and difficulty of which will be adapted by the adapted physical activity \[APA\] trainer according to the Participant's abilities).
62794334|NCT06299540||Group 2: Standard of Care|Participants with CLL will continue physical activity according to their lifestyle and the recommendations of the medical team.
62794335|NCT00824473|PLACEBO_COMPARATOR|1|Placebo
62794336|NCT00824473|ACTIVE_COMPARATOR|2|0.15% azelastine hydrochloride
62218500|NCT03573687|EXPERIMENTAL|PRO Timing on Markers of Fat Metabolism|Assess the differences in overnight and next morning metabolic biomarkers of fat metabolism compared to baseline between acute nighttime PRO (NP) consumption versus daytime PRO (DP) consumption trials after a RT bout in RT women.
62412524|NCT04776135|EXPERIMENTAL|MT-1186 via a nasogastric tube|Subjects receive the edaravone oral suspension via a nasogastric tube
62412525|NCT04132102|EXPERIMENTAL|Afatinib treatment group|This is an open-label, sing-arm phase IV clinical study
62586260|NCT04984369|EXPERIMENTAL|PD after other BRAF inhibitor therapy N=5~40|PD after other BRAF inhibitor therapy
62586261|NCT04984369|EXPERIMENTAL|SD but intolerant after other BRAF inhibitor therapy|SD but intolerant after other BRAF inhibitor therapy
62586262|NCT05140746|EXPERIMENTAL|PET/CT for prediction of NAC efficacy|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT will be scanned before, during or after NAC.
62586263|NCT02208284|EXPERIMENTAL|Cohort 1-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
62794337|NCT03057015|EXPERIMENTAL|Clonidine|50 mcg clonidine + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution
62412526|NCT00367601|EXPERIMENTAL|1|Bevacizumab + erlotinib; if no progressive disease observed, combination or single-agent treatment will continue until unacceptable toxicity or progressive disease.
62412527|NCT05104268|ACTIVE_COMPARATOR|Standard Therapy|Subjects will then be randomized into two groups. The Standard Therapy Group will continue their usual therapy with oral topical agents for oral mucositis.
62794338|NCT03057015|PLACEBO_COMPARATOR|Placebo|0.5 ml normal saline + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution
62794339|NCT04597385||Long-term Follow-Up|No intervention.
62794340|NCT06238778|EXPERIMENTAL|HDV Lispro (HDV-L)|Subjects in this arm will use degludec as their daily basal insulin, and HDV-lispro as their bolus insulin
62794341|NCT06238778|ACTIVE_COMPARATOR|Lispro (LIS)|Subjects in this arm will use degludec as their daily basal insulin and lispro as their bolus insulin
62794342|NCT05317663|EXPERIMENTAL|Waterpipe with Health Warning Label (HWL)|All participants will complete a lab visit where they will smoke waterpipe with HWL for up to 45 minutes.
62794343|NCT05317663|EXPERIMENTAL|Absence of Waterpipe without Health Warning Label (HWL)|All participants will complete a lab visit where they will smoke waterpipe without HWL for up to 45 minutes.
62794344|NCT06727123|EXPERIMENTAL|Motivational Interviewing|Motivational interviews will be conducted with diabetic patients for 6 months. Patients will be trained before starting the interviews.
62794345|NCT06727123|EXPERIMENTAL|Control|No application will be made. Routine follow-ups will be made.
62794346|NCT05293639|EXPERIMENTAL|Treatment Group|PFA ablation using a circular multi-electrode pulsed electrical field catheter and multichannel generator
62794347|NCT05304767|EXPERIMENTAL|Drug: KarXT|
62794348|NCT01361100|EXPERIMENTAL|Oncoral test|
62586264|NCT02208284|EXPERIMENTAL|Cohort 2-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
62218501|NCT04488627||Critically ill patients|Critically ill patients hospitalised in the intensive care unit indicated to echocardiographic examination.
62022404|NCT02370654|EXPERIMENTAL|Tai Chi|12 week Tai chi intervention, 3 sessions per week, 90 minutes per session
62022405|NCT02370654|ACTIVE_COMPARATOR|Conventional exercise|12 week conventional exercise intervention, 3 sessions per week, 90 minutes per session
62022406|NCT05168774|EXPERIMENTAL|Low Dose (20-30mg)|Subjects will receive daily subcutaneous (SC) dosing of Elamipretide (20-30 mg) for 52 weeks
62022407|NCT05168774|EXPERIMENTAL|High Dose (40-60 mg)|Subjects will receive daily subcutaneous (SC) dosing of Elamipretide (40-60 mg) for 52 weeks
62022408|NCT02133846|EXPERIMENTAL|TPI-287 low dose|2 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
62022409|NCT02133846|EXPERIMENTAL|TPI-287 moderate dose|6.3 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions).
62022410|NCT02133846|EXPERIMENTAL|TPI-287 high dose|20 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
62022411|NCT02133846|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
62022412|NCT05869812|EXPERIMENTAL|CaHMB+Vitamin D3-Active Experimental|Participants will consume 3 g HMB with 2000 IU Vitamin D3 per day, split into two doses daily for the duration of the study, beginning 2 weeks prior to their surgical date. The first dose will be consumed 60 minutes prior to any at- home or outpatient physical therapy session and a second will be consumed immediately following the session. If a treatment day does not include any rehabilitation session, the participant will consume one dose in the morning prior to food consumption and the second dose approximately 90 minutes later.
62412528|NCT05104268|EXPERIMENTAL|Bocaliner|Participants that are randomized to the Bocaliner Group will place Bocaliner™ inside of their mouth for 5 minutes and fill out the Initial Bocaliner™ Questionnaire. They will then continue all original therapy for oral mucositis, including oral topical treatments and general hygiene, and will place the Bocaliner™ device inside of their mouth and hold it in place up to 40 minutes as instructed after each topical treatment.
62412529|NCT05187507|OTHER|Children using fluoridated toothpaste|
62412530|NCT05187507|OTHER|Children using low- fluoridated toothpaste|
62586265|NCT02208284|EXPERIMENTAL|Cohort 3-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
62022413|NCT05869812|PLACEBO_COMPARATOR|Calcium Lactate-Control Placebo|Participants will consume inactive 510 mg Ca Lactate capsules per day, split into two doses daily for the duration of the study, beginning 2 weeks prior to their surgical date. The first dose will be consumed 60 minutes prior to any at- home or outpatient physical therapy session and a second will be consumed immediately following the session. If a treatment day does not include any rehabilitation session, the participant will consume one dose in the morning prior to food consumption and the second dose approximately 90 minutes later.
62022414|NCT06157931|EXPERIMENTAL|Resilient Student Training intervention (ReST)|Each participant will receive 3 intervention sessions over a 6-week period (1 individual 60-minute session and two 90-minute group-based sessions) delivered by the same interventionist. The specific skills, intervention protocol and intervention manual will be developed in the Phase 1. The skills and exercises will aim to address pertinent areas of needs relating to self-concept, emotional awareness, and maintaining relationships. The individual session will be conducted based on self-assessment results, identifying presenting concerns and goal planning. Group sessions will be gamified to enhance engagement and reward progress. The first group session will build on the individual session's content in a group setting, with the aim to learn from peers. The second group session aims to reinforce the principles and skills learned in the individual session and group session 1 and plan for the future.
62218502|NCT02433340|EXPERIMENTAL|ABT-122 120 mg EOW|All subjects receive open-label ABT-122 120 mg EOW subcutaneously, with the first dose administered at the last visit of Study M12-963 randomized controlled trial.
62218503|NCT05748223|EXPERIMENTAL|Mindfulness Group|The patients in this group received mindfulness meditation before dental implant surgery.
62218504|NCT05748223|NO_INTERVENTION|Conventional Group|The patients in this group did not receive mindfulness meditation before dental implant surgery.
62243306|NCT01686360|EXPERIMENTAL|Frequency + Avg 50 year old + Mamm Data + Mortality Data|Group receives Gail score in a frequency format as well as information about breast cancer risk for the average 50 year old woman, information about the risks of mammography, risk of breast cancer for the average 50 year old woman, and information about the mortality benefit associated with mammography. (Behavioral: Decision Aid)
62243307|NCT00460174|EXPERIMENTAL|Treatment Arm|Concurrent gemcitabine, bevacizumab, and radiation therapy
62243308|NCT04418544||Control|Do not test positive for COVID
62243309|NCT04418544||COVID-19 Positive|Test positive for Covid using swab test.
62412531|NCT05187507|EXPERIMENTAL|Children using Theobromine toothpaste (2%).|
62412532|NCT05187507|EXPERIMENTAL|Children using Theobromine toothpaste(4%)|
62412533|NCT05196802|EXPERIMENTAL|mHeart.4u|The mHEART.4U intervention includes the use of an online Clinical Decision Support System (CDSS) for remote patient monitoring. According to the patient needs and profile, the CDSS will suggest a monitoring plan for the patient. The mHEART.4U kit will include mobile apps and wearables, such as heart rate, blood pressure, peripheral oxygen saturation (SpO2), sleep and step trackers, symptoms, lifestyle self-monitoring tools, medication reminders or motivational resources. The intervention length will be 6 months and will take into account the most recent guidelines on Cardiac Rehabilitation.
62218505|NCT04679480|EXPERIMENTAL|Intervention|"Investigational product: a combination of an anti-PD1 antibody (Cemiplimab) and a HHI (Sonidegib).~Cemiplimab will be supplied as a liquid in a sterile, single-use 10 ml vial. Each vial will contain a volume of 7ml at a concentration of 50mg/ml. Cemiplimab will be prepared for infusion at the trial site and administered as a flat 350mg dose in 100ml sodium chloride 0.9% as an IV infusion over approximately 30 minutes (±10 minutes) in an outpatient setting. Each patient's dose will be administered as a flat 350mg dose in every 3 weeks, starting from week 2 of the trial.~The Hedgehog Inhibitor used for the trial will be Sonidegib. Sonidegib is a white 200mg capsule, orally administered once daily. Sonidegib will be administered in a 2 week cycle every 4 weeks (pulsed therapy: 2 weeks on, 2 weeks off), starting from week 0 of the trial."
62794349|NCT05516732||SNCA (Alpha-synuclein gene)|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
62218506|NCT05565027|ACTIVE_COMPARATOR|Pneumotachograph|The subject stood on the turntable of the instrument and grasped the postural fixator with both hands up. The subjects pinched their nose and breathed through the disposable filter mouthpiece connected to the pneumotachograph, taking care not to leak air at the corners of the mouth. The subjects were instructed to perform tidal breathing, deep inhalation, deep exhalation, etc., and to monitor lung volume by pneumotachograph.
62022415|NCT06157931|NO_INTERVENTION|Waitlist Control|The waitlist control group will not receive any additional support or interventions whilst waiting to receive the ReST intervention. These participants will be asked to report any psychological interventions or psychotropic medications that they have accessed outside of the trial whilst they are on the waiting list. Wait list control participants will be offered the ReST intervention following their 6-week follow-up assessment.
62218507|NCT05565027|EXPERIMENTAL|Dynamic digital radiography|The subject stood on the turntable of the instrument and grasped the postural fixator with both hands up. The subjects pinched their nose and breathed through the disposable filter mouthpiece connected to the pneumotachograph, taking care not to leak air at the corners of the mouth. The subjects were instructed to perform tidal breathing, deep inhalation, deep exhalation, etc., and to monitor lung volume by dynamic digital radiography analysis.
62218508|NCT04931082|ACTIVE_COMPARATOR|Probiotics|One capsule per day for 12 weeks
62218509|NCT04931082|PLACEBO_COMPARATOR|Placebo|One capsule per day for 12 weeks
62218510|NCT01912677|ACTIVE_COMPARATOR|Nifedipine|Women will receive an initial dose of oral nifedipine 10mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 10mg dose can be provided each hour for two additional doses (30 mg total).
62412534|NCT05196802|NO_INTERVENTION|Standard care|This arm will receive treatment and care according to the prevailing practice at each of the cardiac hospital units.
62412535|NCT01922635|OTHER|1|
62412536|NCT01544374|EXPERIMENTAL|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
62412537|NCT01544374|NO_INTERVENTION|Control- no intervention|Usual Care
62412538|NCT01900353|ACTIVE_COMPARATOR|horizontal brushing method|brushing methods
62412539|NCT01900353|ACTIVE_COMPARATOR|Vertical brushing method|brushing methods
62412540|NCT04898790|NO_INTERVENTION|Feedback for Preliminary Adaptation|Participants in Aim 1 will participate in qualitative interviews to obtain feedback on the CHAMPS-II intervention and survivorship education active control condition materials. Interviews will be with 1)adult participants 60+ years who have recently undergone HCT, 2)participants' care-partner, and 3)HCT team members.
62412541|NCT04898790|EXPERIMENTAL|Adapted CHAMPS-II intervention|"All participants in Aim 2 (preliminary testing) and Aim 3 (RCT) will participate in the CHAMPS-II physical activity program adapted to the HCT setting. Testing for outcome measures will be completed, and feedback on the intervention will be obtained via qualitative interviews from 1)adult participants 60+ years receiving HCT, 2)participants' care-partner, and 3)HCT team members.~Aim 3 participants will be randomized to either the immediate intervention (intervention then follow-up) or delayed intervention (wait period and then intervention)."
62412542|NCT05420636|EXPERIMENTAL|Iadademstat plus Paclitaxel|Iadademstat oralon a 5 day ON and 2-day OFF schedule every week plus Paclitaxel administered intravenously weekly on day 1, 8 and 15 on day 1 of a 21 day treatment cycle.
62412543|NCT04187469|EXPERIMENTAL|Regimen 1: 2HRM/4HR|Two month of chemotherapy with Moxifloxacin, Isoniazid and Rifampicin, followed by four month of Isoniazid and Rifampicin only.
62412544|NCT04187469|ACTIVE_COMPARATOR|Regimen 2: 2HRZE/4HR (control regimen)|Two month of chemotherapy with Isoniazid, Rifampicin, Pyrazinamide and Ethambutol, followed by four month of Isoniazid and Rifampicin only.
62412545|NCT05243810|EXPERIMENTAL|Intervention|A prospective, single-arm, repeated measures feasibility study will be coordinated on the use of EPC Silver Wound Gel in patients with diabetic foot ulcers and localized infections within an outpatient clinical setting, to determine the safety of EPC Silver Wound Gel on diabetic foot ulcerations and impact on wound infection classification, wound ecology, and immunological biomarkers, in conjunction with the standard of care, to clarify parameters for a potential future study.
62412546|NCT00317031|ACTIVE_COMPARATOR|1|Acamprosate
62412547|NCT00317031|ACTIVE_COMPARATOR|2|Naltrexone
62412548|NCT00317031|PLACEBO_COMPARATOR|3|Placebo
62794350|NCT05516732||Idiopathic Parkinson's Disease|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
62794351|NCT00852943||Patients|Subjects, ages birth to 99 years old, known to have or suspected of having an inherited disorder of allergic inflammation or mast cell homeostasis or activation, will be eligible for enrollment.
62794352|NCT02960607|EXPERIMENTAL|Icotinib|250mg, tid until disease progression or unacceptable toxicities occurred
62794353|NCT02779049||MAC-LD|patients with MAC-LD Do Blood examination
62794354|NCT02779049||Control|controls without NTM or tuberculosis infection Do Blood examination
62794355|NCT02779049||Tuberculosis infection|patients with tuberculosis infection which diagnosis by culture or typical pathology Do Blood examination
62218511|NCT01912677|EXPERIMENTAL|Methyldopa|Women will receive an initial dose of oral methyldopa 1000mg. No additional escalation in dose in the first 6 hours will be given.
62218512|NCT01912677|EXPERIMENTAL|Labetalol|Women will receive an initial dose of oral labetalol 200mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 200mg dose can be provided each hour for two additional doses (600 mg total).
62218513|NCT04898439|EXPERIMENTAL|Green school|The children from schools that are being greened will be investigated and compared to the control school. We will measure cognitive function, BMI, black carbon levels and emotional wellbeing.
62218514|NCT04898439|NO_INTERVENTION|control school|The children from schools that are not being greened will be investigated and used as a control group. We will measure cognitive function, BMI, black carbon levels and emotional wellbeing
62218515|NCT00493298||Tysabri|According to the local prescribing information
62218516|NCT03955523|EXPERIMENTAL|Single exercise bout trial|Exercise trial day: 30 min of continuous exercise at 60% VOpeak (or at the least 3 bouts of 10 min at 60% VO2peak separated by no more than 1 minute rest) - power output is set at that determined during the maximum test on the first visit, and adjusted accordingly if there is a deviation \>5% VO2peak for at least 3 minutes of exercise.
62412549|NCT03915041|EXPERIMENTAL|VR + active brain stimulation|Exposure to a virtual reality world with active transcranial electric stimulation
62412550|NCT03915041|SHAM_COMPARATOR|VR + sham brain stimulation|Exposure to a virtual reality world with sham transcranial electric stimulation
62794356|NCT02779049||MAC colonization|patients with MAC pulmonary colonization by American Thoracic Society guideline Do Blood examination
62794357|NCT06544616|EXPERIMENTAL|Arm A: JNJ-64042056|Participants will receive intramuscular (IM) injection of JNJ-64042056 from Week 0 until Week 180.
62794358|NCT06544616|PLACEBO_COMPARATOR|Arm B: Placebo|Participants will receive IM injection of placebo from Week 0 until Week 180.
62218517|NCT03955523|EXPERIMENTAL|Single diet trial|Diet trial day The protocol of the diet trial day is identical to that of the exercise trial day, except that exercise is substituted by asking the participant to eat a standardized breakfast meal that it is commonly consumed in a fast-food chain (i.e. cheese and egg McMuffin, double portion of hash browns and an orange pop).
62794359|NCT06446986||Study group|Patients with adolescent idiopathic scoliosis
62218518|NCT03955523|NO_INTERVENTION|Control (doing nothing)|Non-exercise trial day The protocol of the non-exercise trial day is identical to that of the exercise trial day, except that exercise is substituted by 30 min of quiet sitting in a lounge area (e.g. reading, working or watching a movie on an electronic device) without further engagement with other people.
62794360|NCT06446986||Control group|Age and sex matched healthy adolescent peers
62794361|NCT01094535|EXPERIMENTAL|Secretin|One-arm (open label): Synthetic Human Secretin. Patients will undergo four Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) evaluations.
62794362|NCT04047251|EXPERIMENTAL|Cohort 1: Treatment at Dose Level 1|FF-10850 Topotecan Liposome Injection, Dose Level 1 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
62794363|NCT04047251|EXPERIMENTAL|Cohort 2: Treatment at Dose Level 2|FF-10850 Topotecan Liposome Injection, Dose Level 2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
62794364|NCT04047251|EXPERIMENTAL|Cohort 3: Treatment at Dose Level 3|FF-10850 Topotecan Liposome Injection, Dose Level 3 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
62794365|NCT04047251|EXPERIMENTAL|Cohort E1: Treatment at Recommended Phase 2 Dose (RP2D)|For patients with advanced ovarian cancer: FF-10850 Topotecan Liposome Injection, RP2D administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
62218519|NCT03463161|EXPERIMENTAL|Acquired Resistance Group|"Participants that have benefited from prior treatment with immunotherapy. Defined as response to prior treatment and/or stable disease lasting at least 5 months and disease worsening seen on most recent imaging.~Participants will receive Pembrolizumab and Epacadostat."
62218520|NCT03463161|EXPERIMENTAL|Suboptimal Benefit Group|"Participants that have not benefited from prior treatment with immunotherapy. Defined as stable disease lasting at least 5 months or suboptimal response (11-49% shrinkage of tumors). Disease continues to be stable on most recent imaging.~Participants will receive Pembrolizumab and Epacadostat."
62243310|NCT03584971||female patients|women in fertility treatment according to Long GnRH Agonist Protocol
62243311|NCT03584971||control group|random sample of male students
62243312|NCT04328779|EXPERIMENTAL|multi-task overground walking training|The multi-task overground walking training group will undertake overground walking training while concurrently perform motor and cognitive tasks.
62794366|NCT04047251|EXPERIMENTAL|Cohort E5: Treatment at Recommended Phase 2 Dose (RP2D)|For patients with advanced Merkel cell carcinoma: FF-10850 Topotecan Liposome Injection, RP2D administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
62218521|NCT04609306|EXPERIMENTAL|Subjects getting 3% H2O2 applied to the incision|For the experimental cohort, a lap sponge soaked in 3% H2O2 will be applied to the incision and allowed to sit for 3 minutes. Following the 3 minutes, the sponge will be removed, the wound will be flushed with 100 mL of normal saline, and the exposed dermis will be swabbed and sent for culture.
62218522|NCT04609306|NO_INTERVENTION|Subjects not getting 3% H2O2 applied to the incision|In the control cohort, the dermis will be swabbed and sent for culture immediately after the skin incision is made and the knife is removed from the field.
62218523|NCT02848287|PLACEBO_COMPARATOR|Normal Saline|1\*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.
62218524|NCT02848287|EXPERIMENTAL|Ropivacaine|1\*2 gauze is soaked with 5 cc of 0.75% ropivacaine, applied in tonsillar fossae for 3 min, then removed.
62218525|NCT05519098||Inclusion group|"Patients referred for colonoscopy:~* ≥18 years old~* Consenting to participate~Exclusion criteria:~Endoscopists~* Employment or family member employed at Augere Medical AS~Patients:~* Severe comorbidity, NYHA III-IV~* Pregnancy~* Hospitalized patients~* Active inflammatory bowel disease~* Poor bowel preparation defined as Boston Bowel Preparation Score as ≤1 in any segment~* Absence or unable to provide consent~* Cecum not reached"
62412551|NCT05883527||Health and Care Professionals|GP's, nurses, social workers, mental health professionals, support workers, Independent mental capacity advocates (IMCA), and other HCP's working in GP surgeries and integrated social care hubs. Safeguarding leads in GP surgeries, social care organisations and other relevant organisations. Professionals from third-sector organisations who have previous experience of safeguarding.
62412552|NCT05883527||People Living with Dementia|Who have been involved in the safeguarding process and have capacity to consent.
62218526|NCT03261700|EXPERIMENTAL|RISE|This provider- administered brief- counseling intervention program will increase Women Veteran?s self- efficacy in addressing violence in their current or past relationships. The variable length (up to six- session) modular-based intervention aims at providing resources for WVs in the relevant domains of: 1) safety planning, 2) education on health effects of IPV, 3) improving coping and self- care and red flags, 4) enhancing social support, 5) making difficult decisions, and 5) connecting with resources.
62412553|NCT05883527||Paid carers of people living with dementia|Who have been involved in the safeguarding process.
62412554|NCT05883527||Family members of people living with dementia|Who have been involved in the safeguarding process.
62412555|NCT00803530|EXPERIMENTAL|1|"Loading phase (week 1): ATO 0.3 mg/Kg/die for 5 consecutive days.~* Subsequent phase (from week 2 to week 16): ATO 0.25 mg/kg twice a week (day 2 and 5 of every week).~* Ascorbic acid 1000 mg IV within 30 minutes after each arsenic trioxide infusion for 16 consecutive weeks."
62218527|NCT03261700|ACTIVE_COMPARATOR|Information and referral condition|This brochure-based intervention includes education about IPV, health effects of IPV, resources and referral options to address a wide-array of health and social issues associated with IPV, and safety planning. Participants randomized to this arm are offered resources and referrals to VA and community resources.
62218528|NCT04849494||Late preterm AGA infants/Group 1|According to the new BALLARD scoring system gestational age was 34-36 6/7 and those who were at the 10-90th percentile according to the Fenton growth curves
62218529|NCT04849494||Newborns with Intrauterine growth restriction/Group 2|Term or preterm infants below 10th percentile according to the values calculated according to Fenton growth curves
62412556|NCT05581797|EXPERIMENTAL|Psilocybin-assisted psychotherapy|Interpersonal Therapy integrated with psilocybin
62412557|NCT05859126|EXPERIMENTAL|Maternal Choline Supplementation 930 mg/d|Supplementation of 930 mg/d from early second trimester through birth. Offspring are followed for cognitive outcomes.
62412558|NCT05859126|ACTIVE_COMPARATOR|Maternal Choline Supplementation 480mg/d|Supplementation of 480 mg/d from early second trimester through birth.Offspring are followed for cognitive outcomes.
62794367|NCT03499093||Prosthetic patient with esthetic expectations|Prosthetic patients with esthetic expectations (PP-E, n=35), Patients seeking for restoration or replacement of anterior teeth, or expressing any esthetic expectation
62794368|NCT03499093||Prosthetic patients without esthetic expectations|Prosthetic patients without esthetic expectations (PP-NE, n=35) Patients pending restoration or replacement of posterior teeth (premolars and molars), expressing only functional expectation
62412559|NCT04950673||Subjects who had COVID-19 infection and recovered at 3 months|500 subjects who have had a history of COVID19 infection and recovered 3 months prior to the enrollment
62412560|NCT04950673||Subjects who never had COVID-19 infection|500 subjects who never had a history of COVID19 infection prior to the enrollment
62412561|NCT06650267|EXPERIMENTAL|Fathers for Change|
62794369|NCT03499093||Dental patient with esthetic concern|Dental patient with esthetic concern(C-E, n=35) Patient consulting for follow up, having crowns or removable denture replacing anterior teeth
62794370|NCT03499093||Dental patient without any esthetic concern|Dental patient without any esthetic concern (C-NE, n=35) Patient consulting for follow up, having no crown or removable denture replacing anterior teeth.
62022416|NCT00612612|EXPERIMENTAL|Treatment (obatoclax mesylate, fludarabine, rituximab)|"Patients receive obatoclax mesylate IV over 3 hours on days 1 and 3, fludarabine IV over 20-30 minutes on days 1-5, and rituximab IV over 4 hours on day 1 (days 1 and 3 of course 1 only). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo peripheral blood collection for correlative studies. Samples are analyzed for expression of pro- and anti-apoptotic Bcl-2 family members by western blot; apoptosis induction by measurement of lymphocyte count, Annexin V staining, and Caspase and PARP cleavage; activated Bax by immunoprecipitation; and Bax promoter polymorphism by PCR amplification and direct sequencing."
62794371|NCT05802043|EXPERIMENTAL|Cognitive Stimulating Interventions|The study interventions will be developed by the researchers based on review of the related literature and with reference to the CST manual (Spector, et al., 2006), and review on Cognitive Stimulation (Woods et al., 2012). The study subjects of group 1, the study group, will receive the proposed interventions, the cognitive stimulation interventions through small groups of study subjects receiving 12 sessions of group activities (2 sessions/week, approximately 45- 60 minutes/session). A group size of 6 to 8 will be conducted. The interventions group will be conducted in activity rooms within the elderl club. The study subjects group 2, the control group, will receive the routine activities of the elderly club. The researchers will provide the control group with written materials related the essential cognitive stimulation interventions after ending the implementation of the proposed interventions for the study group.
62794372|NCT05802043|ACTIVE_COMPARATOR|Routine Club care|The study subjects group 2, the control group, will receive the routine activities of the elderly club.The researchers will provide the control group with written materials related the essential cognitive stimulation interventions after ending the implementation of the proposed interventions for the study group,
62794373|NCT00171171|EXPERIMENTAL|Deferasirox|
62794374|NCT00974649|NO_INTERVENTION|Included in questionnaire study|
62794375|NCT06461832||Group 1|Patients who received general anesthesia and an epidural catheter.
62794376|NCT06461832||Group 2|Patients who received spinal anesthesia and an epidural catheter.
62794377|NCT06725524|EXPERIMENTAL|JMT601|"Subjects will receive JMT601 once a week. The first 4-week period is for DLT observation.~Dose escalation part will be carried out according to 3+3 dose-escalation design with up to 6 dose(0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 12 mg/kg and 20 mg/kg) escalation cohorts.~Dose expansion part will continue at the determined RP2D. Dose expansion part consists of two cohorts:~Cohort A: Subjects with CD20-positive diffuse large B-cell lymphoma, prior at least two lines of therapy.~Cohort B: Subjects with CD20-positive follicular lymphoma, prior at least two lines of therapy."
62794378|NCT00755495|EXPERIMENTAL|Ramelteon 8 mg QD and Doxepin 3 mg QD|
62022417|NCT04824313||COVID-CAVA PE|Patients with RT-PCR proven COVID-19 disease and CTA proven pulmonary embolism
62218530|NCT04849494||Control/Group 3|the healthy term (gestation week 38-42 weeks), AGA newborns, who born between January 2006 and December 2008
62412562|NCT06650267|ACTIVE_COMPARATOR|Individual Drug Counseling|
62412563|NCT04179578|ACTIVE_COMPARATOR|Crura|Closure of the diaphragmatic hiatus by a running suture alone
62586266|NCT04548115|EXPERIMENTAL|ARTISAN Condition|Participants assigned to this arm will engage in ARTISAN, a 5-weekly, 15-hour group-based arts and heritage intervention programme with specific intervention components including curated museum tours, facilitated storytelling and professionally-led art-making. The weekly intervention covers the five ARTISAN themes of national heritage, social bonds, adversity and resilience, dreams and aspiration, and community art exhibition.
62586267|NCT04548115|EXPERIMENTAL|Intergenerational Participatory Arts Condition|Participants assigned to this arm will engage in the participatory arts-making component of the ARTISAN Intervention framework. Youths and senior participants in this condition will engage in a 5-weekly, 5-hour, group-based professionally-led art-making that covers the five ARTISAN themes.
62586268|NCT04548115|EXPERIMENTAL|Intergenerational Art-space Condition|Participants assigned to this arm will engage in the cultural space component of the ARTISAN Intervention framework. Youths and senior participants in this condition will engage in a 5-weekly, 5-hour, group-based a group-based curated museum tour that covers the five ARTISAN themes.
62794379|NCT00755495|EXPERIMENTAL|Ramelteon 8 mg QD and Doxepin Placebo QD|
62022418|NCT04824313||COVID-CAVA non-PE|Patients with RT-PCR proven COVID-19 disease and no evidence of pulmonary embolism on CT
62022419|NCT01990053|EXPERIMENTAL|Beating the Blues|Beating the Blues plus helper support.
62022420|NCT01990053|NO_INTERVENTION|Waitlist Condition|Eight week waitlist condition group parallel to the immediate treatment condition with optional entrance into the Beating the Blues after the first eight weeks
62794380|NCT00755495|ACTIVE_COMPARATOR|Ramelteon Placebo QD and Doxepin 3 mg QD|
62794381|NCT00755495|PLACEBO_COMPARATOR|Placebo|
62794382|NCT01680666|ACTIVE_COMPARATOR|landmark guided|central line placement
62794383|NCT01680666|ACTIVE_COMPARATOR|ultrasound guided|central line placement
62022421|NCT04320680|OTHER|lupus cohort follow up|it is a descrption lupus patients study
62412564|NCT04179578|ACTIVE_COMPARATOR|Crura and lateral release|Closure of the diaphragmatic hiatus by a running suture and an incision of 4 cm of the left diaphragm (lateral release)
62586269|NCT04548115|EXPERIMENTAL|Inter-generational Storytelling Condition|Participants assigned to this arm will engage in the storytelling component of the ARTISAN Intervention framework. Youths and senior participants in this condition will be paired to engage in a 5-weekly, 5-hour, group-based guided storytelling activity that covers the five ARTISAN themes.
62586270|NCT04548115|EXPERIMENTAL|Control Condition|Participants assigned to this arm will engage in a 5-weekly, 5-hour, group-based physical activity session conducted in the community.
62022422|NCT01335711|EXPERIMENTAL|IMP_C/C IL28B|C/C IL28B subjects to whom IMP will be administrated prior to SOC
62022423|NCT01335711|ACTIVE_COMPARATOR|SOC_C/C IL28B|C/C IL28B subjects to whom only SOC will be administrated
62586271|NCT03530605|EXPERIMENTAL|Optune TTF Device|Optune TTF treatment
62586272|NCT03530605|NO_INTERVENTION|Historical matched control|age-matched historical controls
62022424|NCT01335711|EXPERIMENTAL|IMP_non-C/C IL28B|non-C/C IL28B subjects to whom IMP will be administrated prior to SOC
62022425|NCT01335711|ACTIVE_COMPARATOR|SOC_non-C/C IL28B|non-C/C IL28B subjects to whom only SOC will be administrated
62022426|NCT01136291|OTHER|physical exercise|exercise on obese and overweight pregnant women, routine prenatal care and nutritional counseling
62022427|NCT01136291|NO_INTERVENTION|no exercise|Routine prenatal care and nutritional counseling. No exercise
62218531|NCT03870347||Biliary Dilation Cohort|Patients referred for endoscopic evaluation of biliary dilation
62218532|NCT03981562|EXPERIMENTAL|1000 IU Vitamin D|
62218533|NCT03981562|EXPERIMENTAL|4000 IU Vitamin D|
62218534|NCT03981562|PLACEBO_COMPARATOR|Placebo|
62218535|NCT04280302|EXPERIMENTAL|Virtual reality based therapy|
62218536|NCT04280302|ACTIVE_COMPARATOR|Conventional Therapy|
62218537|NCT04072692|NO_INTERVENTION|1st part: The gliding properties of the tendons|No intervention. Subjects are measured by ultrasound under 5 different postures of the hand for forty minutes.
62218538|NCT04072692|NO_INTERVENTION|1st part: The gliding properties of the median nerve|No intervention. Subjects are measured by ultrasound under under 6 different postures of the wrist and hand and 5 different movement patterns of the wrist and hand for forty minutes.
62218539|NCT04072692|EXPERIMENTAL|2nd part: New hybrid rehabilitation strategy|"The program includes pre-test, 8 times training, post-test and follow-up test.~For pre-test, subjects perform the specific hand movement under different exerting force conditions and 4 different angles of phalangeal joints and be asked to do Phalen test, Grip strength test, Pinch test and SWMT test. It takes 40 minutes.~For post-test, the same procedure is repeated again after completing all training.~For follow-up, the same procedure is repeated again 6 months after completing all training.~After pre-test, 8 times hybrid rehabilitation training are asked. There are two times in a week, and all training will be completed in one month. Each time will take forty minutes."
62218540|NCT04072692|EXPERIMENTAL|2nd part: Traditional strategy|"The program includes pre-test, 8 times training, post-test and follow-up test.~For pre-test, subjects perform the specific hand movement under different exerting force conditions and 4 different angles of phalangeal joints and be asked to do Phalen test, Grip strength test, Pinch test and SWMT test. It takes 40 minutes.~For post-test, the same procedure is repeated again after completing all training.~For follow-up, the same procedure is repeated again 6 months after completing all training.~After pre-test, 8 times traditional rehabilitation training are asked. There are two times in a week, and all training will be completed in one month. Each time will take forty minutes."
62243313|NCT04328779|ACTIVE_COMPARATOR|multi-task treadmill walking|The multi-task treadmill walking training group will train the same set of motor and cognitive tasks while walking on the treadmill.
62412565|NCT03885648||Cases|Women's age will range 25-70 years. Cases will be women diagnosed and surgically intervened of breast cancer, stages I and II.
62412566|NCT03885648||Controls|Controls will be women surgically intervened of breast augmentation or reduction.
62412567|NCT05237674|EXPERIMENTAL|Intervention schools|School children exposed to 1-2 weekly sessions, a total of at least five hours pr week, of education outside the classroom.
62794384|NCT02489318|EXPERIMENTAL|Apalutamide plus ADT|Participants will receive apalutamide 240 milligram (mg) (4X 60 mg tablets) with ADT.
62022428|NCT05768308|EXPERIMENTAL|Internet CBT-UP intervention (iCBT-UP)|Patricipants in the experimental group will receive online cbt intervention for students with adjustment disorder (iCBT-UP).
62022429|NCT05768308|ACTIVE_COMPARATOR|Internet Progressive Muscle Realxation Training (iPMR)|Participants from the active control group will receive progressive muscle relaxation training (iPMR).
62022430|NCT05768308|NO_INTERVENTION|Waiting List|Participants from the waiting list condition will receive access to the choosen intervention after 6-weeks waiting period.
62022431|NCT00093145|EXPERIMENTAL|Albumin-bound paclitaxel, Carboplatin + Herceptin|Participants received albumin-bound paclitaxel, 100 mg/m\^2 weekly every 3 out of 4 weeks, carboplatin at an area under the curve (AUC) = 6 every 4 weeks and Herceptin weekly, 4 mg/kg the first week and 2 mg/kg on all subsequent weeks by intravenous (IV) infusion for up to 6 cycles in the absence of disease progression or intolerable toxicity. Participants could continue treatment with chemotherapy beyond 6 cycles at the discretion of the investigator, but Herceptin therapy was to continue to be administered weekly (2 mg/kg) until intercurrent illness, disease progression, unacceptable toxicity, patient withdrawal or administration of any non-protocol anti-cancer treatment.
62022432|NCT04258696|ACTIVE_COMPARATOR|Gingival retraction by ultrapak retraction cord|
62022433|NCT04258696|EXPERIMENTAL|Gingival retraction by diode laser|
62022434|NCT01881308|ACTIVE_COMPARATOR|Stable dose TNF inhibitor|Stable dose TNF inhibitor. Any co-medication with synthetic DMARDs kept stable.
62022435|NCT01881308|EXPERIMENTAL|Stepdown and withdrawal of TNF inhibitor|Half-dose of TNF inhibitor for the first four months, thereafter withdrawal of TNF inhibitor. Any co-medication with synthetic DMARDs kept stable.
62022436|NCT01881308|ACTIVE_COMPARATOR|Stable dose synthetic DMARD|Stable dose of synthetic DMARDs, either monotherapy or combination therapy.
62586273|NCT06141122|EXPERIMENTAL|The booklet group|The research protocol was explained during the colonoscopy appointment, and patients, when they agreed to follow their diet according to the recipe booklet, were accepted as part of the patient intervention group.
62218541|NCT04072692|NO_INTERVENTION|3rd part: The effect of carpal tunnel release|"No intervention. The program includes pre-test, post-test and two times follow-up tests.~For pre-test, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands before carpal tunnel release surgery. It takes 40 minutes.~For post-test, subjects perform the functional assessment of both hands one week after carpal tunnel release surgery. It takes 20 minutes.~For first follow-up, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands one month after carpal tunnel release surgery. It takes 40 minutes.~For second follow-up, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands two month after carpal tunnel release surgery. It takes 40 minutes."
62794385|NCT02489318|EXPERIMENTAL|Placebo plus ADT|Participants will receive matching Placebo with ADT.
62794386|NCT02318342|EXPERIMENTAL|Pre-existing bioprosthetic aortic valve|Patients with a history of surgical or transcatheter valve replacement with bioprosthetic valves undergo cardiac contrast CT imaging and transthoracic echocardiography to evaluate structural and functional integrity of the aortic valves. Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
62218542|NCT04072692|EXPERIMENTAL|3rd part: Wearable anti-bowstringing orthosis (WABO)|"The program includes pre-test, post-test and two times follow-up tests.~For pre-test, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands before carpal tunnel release surgery. It takes 40 minutes.~Subjects wear WABO in the morning and a splint at night within a week after carpal tunnel release surgery.~For post-test, subjects perform the functional assessment of both hands with and without wearing WABO and a splint one week after carpal tunnel release surgery. It takes 40 minutes.~From the third weeks after carpal tunnel release surgery, subjects wear WABO only in the morning.~For first follow-up, the same procedure in pre-test is repeated again one month after carpal tunnel release surgery. It takes 40 minutes.~For second follow-up, the same procedure in pre-test is repeated again two month after carpal tunnel release surgery."
62218543|NCT05128461|EXPERIMENTAL|Exercise Group|The group will receive modified-Constraint Induced Movement Therapy via telerehabilitation and a home exercise program.
62218544|NCT05128461|ACTIVE_COMPARATOR|Control group|The group only will be given a home exercise program.
62586274|NCT06141122|NO_INTERVENTION|control|The control group consists of patients who prepared for colonoscopy with the standard low-residue diet list without being given a recipe booklet.
62586275|NCT05377281|EXPERIMENTAL|Implantation of peripheral nerve tissue|Bilateral deployment of peripheral nerve tissue to the substantia nigra.
62022437|NCT01881308|EXPERIMENTAL|Synthetic DMARD dose reduction|Half-dose synthetic DMARDs (monotherapy or combination therapy) for the first 12 months of the study. Patients classified as non-failures are re-randomized at 12 months to either continue half-dose synthetic DMARD(s) or withdraw all DMARD(s).
62022438|NCT01881308|OTHER|ARCTIC follow-up|Patients are treated according to the ARCTIC treatment schedule based on disease activity.
62022439|NCT02582905|PLACEBO_COMPARATOR|Placebo|Matching placebo given beginning at 1 capsule twice daily (BID) increasing to 2 capsules BID at week 1, 3 capsules BID at week 2, and 4 capsules BID at weeks 3-12.
62022440|NCT02582905|EXPERIMENTAL|Citicoline|Citicoline will be given beginning at 250 mg BID with an increase to 500 mg BID at week 1, 750 mg BID at week 2, and 1000 mg BID at weeks 3-12.
62022441|NCT02582905|EXPERIMENTAL|Pregnenolone|Pregnenolone will be given beginning at 50 mg BID with an increase to 100 mg BID at week 1, 150 mg BID at week 2, and 250 mg BID at weeks 3-12.
62022442|NCT04896489|EXPERIMENTAL|hydrocortisone|Participants receive hydrocortisone (20mg)
62022443|NCT04896489|PLACEBO_COMPARATOR|placebo|Participants receive placebo.
62586276|NCT02783729|EXPERIMENTAL|Lemborexant 5 milligrams (mg)|Participants will receive one lemborexant 5 mg tablet and one zolpidem-matched placebo tablet each night
62794387|NCT00933322|ACTIVE_COMPARATOR|ruminant TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter containing ruminant TFA and with 15-20g rape oil for balancing the essential fatty acids.
62218545|NCT01990729||ARTRA|Patients with low back pain treated with ARTRA.
62218546|NCT05417022||Diamondback 360TM orbital atherectomy system|
62243314|NCT04328779|ACTIVE_COMPARATOR|traditional rehabilitation|Traditional rehabilitation group will train strength, balance, and gait.
62243315|NCT06734598|EXPERIMENTAL|Botox injection|
62794388|NCT00933322|ACTIVE_COMPARATOR|industrial TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter containing TFA from PHVO and with 15-20g rape oil for balancing the essential fatty acids.
62243316|NCT06734598|PLACEBO_COMPARATOR|Normal Saline Injection|
62243317|NCT01882218|ACTIVE_COMPARATOR|Standard treatment|Standard liver surgery and post-operative treatment
62022444|NCT04121598||Normal Weight Control|Adolescents with a BMI percentile under 85%.
62022445|NCT04121598||Overweight/Obese Control|Adolescents with a BMI percentile at 85% or higher.
62022446|NCT04121598||Overweight/Obese Experimental|Adolescents with a BMI percentile at 85% or higher, who report loss of control eating episodes.
62022447|NCT01777919|EXPERIMENTAL|Temozolomide+Disulfiram/copper|"Disulfiram/copper combination will be started on the 5th postoperative day and before the initiation of the standard radiochemotherapy (fractionated irradiation with a total dose of 60 Gy with concomitant 75 mg/m2 body surface temozolomide each day, including weekends, during irradiation). After completion of the radiation therapy patients will receive maintenance temozolomide 150-200 mg/m2 body surface on Days 1-5 every 28 days for 6 months. Daily administration of disulfiram and copper will take place for the whole study period.~NOTE: Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
62586277|NCT02783729|EXPERIMENTAL|Lemborexant 10 mg|Participants will receive one lemborexant 10 mg tablet and one zolpidem-matched placebo tablet each night
62794389|NCT00933322|PLACEBO_COMPARATOR|without TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter without TFA and with 15-20g rape oil for balancing the essential fatty acids.
62412568|NCT05237674|NO_INTERVENTION|Waiting control schools|The waiting control schools will receive the two-day training course on EOtC one year later immediately after post measurements are conducted.
62022448|NCT06384677|OTHER|M-Tapa + IV PCA applied group|After appropriate skin disinfection, the transversus abdominis, internal oblique and external oblique muscles were determined with a high-frequency linear probe (Esaote) at the costochondral angle in the sagittal plane under ultrasound guidance at the 10th costal border. A 21-G, 80-mm peripheral block needle was placed in the cranial direction using the in-plane technique, the needle tip did not exceed the cranial edge of the 10th costal cartilage, and 20 ml of 0.25% bupivacaine was applied to the lower surface of the chondrium on both sides, right and left. .
62794390|NCT05516758|EXPERIMENTAL|Peresolimab Dose 1|Participants will be given peresolimab by subcutaneous injection.
62412569|NCT05156164|EXPERIMENTAL|Kinesio-taping Group|"Conventional rehabilitative treatment (consisting in two treatments per day of 40 minutes each) plus a bi-weekly treatment focused on the joint complex of the shoulder plus Kinesio-taping (KT) treatment.~The Kinesio-taping treatment consists in 4 applications of KT on the affected shoulder to be held for 5 days a week, followed by 2 days of rest to safeguard skin integrity before a further application.~5 KT strips with graded tensions will be placed on the following muscles:~1. supraspinatus with a tension of 70%.~2. infraspinatus with a tension of 70%. 3,4,5) deltoid (3 strips, 50% of tension) A sixth application with a tension of 90% originates at the level of the anterior face of the humeral head and it ends to the lower corner of the scapula."
62412570|NCT05156164|SHAM_COMPARATOR|Control Group|"Conventional rehabilitative treatment (consisting in two treatments per day of 40 minutes each), plus a bi-weekly treatment focused on the joint complex of the shoulder, plus shame KT treatment.~- The CG will undergo a KT application on the deltoid but without support function with the same frequency and duration as the experimental group (shame-application)."
62412571|NCT02866695|OTHER|Open label treatment|All patients will be treated with ingenol mebutate gel 0.015%. There is no placebo or comparator for this study. The investigator will identify the patient's treatment area at Baseline, and provide a detailed application instruction sheet. The first dose will be applied in clinic under the supervision of the investigator.
62412572|NCT03855462|EXPERIMENTAL|MCT oil injection|"The patient treatment is the classical surgical procedure which is used for retinal detachment with silicon oil medium-chain triglycerides (MCT) as tamponade agent :~* Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous.~* MCT ablation after 4 to 6 weeks (after effective retinopexy)"
62022449|NCT06384677|OTHER|IV PCA applied group|In the IV PCA group, the surgeon performed local infiltration with 40 mL of 0.25% bupivacaine around the incisions. All patients were provided postoperative analgesia with intravenous patient-controlled analgesia (IVHKA). When pain was expressed by the patient, the patient pressed a button and the IV HKA pump was programmed to deliver a 1 ml bolus dose with a 10-minute lockout interval and no background infusion allowed. Each 1 ml of IVHKA solution contains 1 mg of morphine.
62022450|NCT05009563|EXPERIMENTAL|Inpatients with RT-PCR proven SARS-CoV-2 infection|Inpatients with real-time reverse-transcriptase polymerase chain reaction (RT-PCR) proven SARS-CoV-2 infection of the Department of Pulmonology of Semmelweis University who will undergo whole-body FDG-PET/CT
62412573|NCT02466776|ACTIVE_COMPARATOR|Stainless steel staples|Patients in this arm will receive stainless steel staples for skin closure at time of cesarean delivery (CD).
62412574|NCT02466776|ACTIVE_COMPARATOR|Absorbable subcuticular Suture|Patients will receive absorbable subcuticular suture for skin closure at time of cesarean delivery (CD).
62412575|NCT03312881||neuropathic pain|Children with clinical diagnosis of neuropathic pain. Interventions: patient reported outcome measures, quantitative sensory testing, neuroimaging
62022451|NCT05009563|ACTIVE_COMPARATOR|patients undergoing FDG-PET/CT for oncological indication|Age- and gender-matched group of patients undergoing FDG-PET/CT for oncological indication in the same time period
62022452|NCT01823744|EXPERIMENTAL|micronutrient supplementation|"All the enrolled subjects will recieve orally, onca a day, during school days a chocolate bar including vitamins and minerals.~The micronitrient supplementation will be consumed over 6 weeks, 5 days/week."
62022453|NCT01692704|EXPERIMENTAL|HAI with FUDR & systemic cisplatin and gemcitabin|FUDR: 0.2mg/kg/day continuously i.a. for 14 days Cisplatin: 25mg/m2 i.v. Gemcitabin: different doses according to dose level 600, 800, or 1000 mg/m2 i.v.
62412576|NCT03312881||non-neuropathic pain|Children with clinical diagnosis of non-neuropathic pain. Interventions: patient reported outcome measures
62412577|NCT06061848|ACTIVE_COMPARATOR|SLIT|Sublingual immunotherapy timothy pollen 75000 SQ-T 1 daily for 3 years
62794391|NCT05516758|EXPERIMENTAL|Peresolimab Dose 2|Participants will be given peresolimab by subcutaneous injection.
62794392|NCT05516758|EXPERIMENTAL|Peresolimab Dose 3|Participants will be given peresolimab by subcutaneous injection.
62794393|NCT05516758|ACTIVE_COMPARATOR|Placebo|Participants will be give placebo by subcutaneous injection.
62794394|NCT03353480|OTHER|Reference|250mg Azithromycin tablet manufactured at Pfizer Barceloneta, Puerto Rico, US
62218547|NCT00600886|EXPERIMENTAL|Pasireotide LAR|Patients in this arm received Pasireotide LAR 40 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 20 or 60 mg, respectively. Patients who responded to Pasireotide LAR (i.e. the randomized treatment) at the end of the core (Month 12), continued Pasireotide LAR treatment in the extension. Patients who did not respond to Pasireotide LAR at the end of the core (Month 12) were allowed to switch to receive Octreotide LAR in the extension.
62794395|NCT03353480|EXPERIMENTAL|Experimental|250mg Azithromycin tablet manufactured at Pfizer Dalian, China
62794396|NCT05672706||CFR and IMR group|
62218548|NCT00600886|ACTIVE_COMPARATOR|Octreotide LAR|Patients in this arm received Octreotide LAR 20 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 10 or 30 mg, respectively. Patients who responded to Octreotide LAR (i.e. the randomized treatment) at the end of the core (Month 12) continued Octreotide LAR treatment in the extension (up to 2 years of treatment). Patients who did not respond to Octreotide LAR at the end of the core (Month 12) were allowed to switch to receive Pasireotide LAR in the extension.
62218549|NCT01094210||G1|500 ppm F Test Toothpaste
62218550|NCT01094210||G2|1100 ppm F Control Toothpaste
62586278|NCT02783729|ACTIVE_COMPARATOR|Zolpidem tartrate|Participants will receive one zolpidem 6.25 mg tablet and one lemborexant-matched placebo tablet each night
62586279|NCT02783729|PLACEBO_COMPARATOR|Placebo|Participants will receive one zolpidem-matched placebo tablet and one lemborexant-matched placebo tablet each night
62586280|NCT06445322||Prescreening Group|The prescreening study consists of genetic and visual assessments and will require at least 1 onsite visit. All clinical assessments performed are for the purpose of determining research eligibility for ACDN-01 clinical trials.
62586281|NCT05093504|SHAM_COMPARATOR|Control|Standard of care with Sham set-up
62586282|NCT05093504|EXPERIMENTAL|DrugSorb-ATR Intervention|Standard of care + DrugSorb-ATR system
62794397|NCT03954080|EXPERIMENTAL|ISS|
62022454|NCT05443035|EXPERIMENTAL|Antimicrobial PDT and Papacarie Deproteination Group|The participants will receive selective chemical-mechanical removal of carious dentinal tissue around the walls of the cavity using a curette, followed by the application of antimicrobial PDT and deproteination with Papacárie DuoTM.
62022455|NCT05443035|EXPERIMENTAL|Antimicrobial PDT group and deproteination with NaClO 5% group|The participants will receive selective removal of carious dentinal tissue using a curette, followed by application of antimicrobial PDT and deproteination with NaClO 5%.
62218551|NCT01694173|EXPERIMENTAL|Stem cell therapy - SPD artery|Stem cells will be infused into the superior pancreaticoduodenal artery.
62218552|NCT01694173|ACTIVE_COMPARATOR|Stem cell therapy - splenic artery|Stem cells will be infused into the splenic artery.
62218553|NCT01694173|ACTIVE_COMPARATOR|Stem cell therapy-intravenous|Stem cells will be given intravenously.
62218554|NCT01694173|PLACEBO_COMPARATOR|Normal saline placebo -sham procedure|Sham procedure with infusion of normal saline.
62218555|NCT04191473|EXPERIMENTAL|group P|
62218556|NCT04191473|OTHER|group C|
62218557|NCT05951985|EXPERIMENTAL|HIFT Exercise|In this single group design, all participants will be provided with up to two years of twice weekly supervised group exercise.
62586283|NCT03010150||Observational (blood tests, questionnaires)|Participants provide blood samples prior to and at the 6-month visit after receiving radiation therapy. Participants also complete questionnaires either at home, in clinic, or via internet over 30 minutes prior to receiving radiation therapy and within 14 days of blood sample collection.
62586284|NCT05403853|EXPERIMENTAL|Monitoring of Diabetes Mellitus|Venous blood draw of up to 24ml and up to 4 fingersticks
62586285|NCT05407870|ACTIVE_COMPARATOR|Propofol|induction - 0.5mg/kg Propofol maintenance - 0.25mg/kg Propofol
62586286|NCT05407870|EXPERIMENTAL|Etomidate|induction - 0.25mg/kg Propofol + 0.05mg/kg Etomidate maintenance - 0.05mg/kg Etomidate
62586287|NCT06613633||third-generation EGFR-TKI monotherapy|
62586288|NCT01671995|EXPERIMENTAL|Nurse monitored heart failure program|To assess whether a nurse monitored management programme at the hospital outpatient clinic would improve quality of life, as compared to standard primary health care.
62794398|NCT02489539|EXPERIMENTAL|Short Neck Substudy|Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation ≤ 60˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
62794399|NCT02489539|EXPERIMENTAL|High Neck Angulation Substudy|Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation \> 60˚ and ≤ 90˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
62794400|NCT00821496|EXPERIMENTAL|Oral Contraceptive|
62794401|NCT01098227||RSV positive subjects|Subjects admitted to Winthrop University Hospital with lower viral respiratory infection and RSV positive status by DFA and/or Viral culture
62794402|NCT01098227||RSV negative subjects|Subjects admitted to Winthrop University Hospital with a lower viral respiratory infection and RSV status negative by DFA and viral culture. these subjects may be positive for other viruses detected by DFA or viral culture (Adenovirus, Influenza A or B, Metapneumovirus or parainfluenza) or not
62794403|NCT01098227||Control group|Children in the same age range without respiratory conditions and who are well enough to perform the test from the out patient setting
62794404|NCT06725420|EXPERIMENTAL|local steroid injection|The group of patients who were injected with ultrasound-guided in-plane steroid and local anesthetic injection + wrist splint
62218558|NCT02679027|ACTIVE_COMPARATOR|Easy intubation|Intubation difficulty score \<5
62412578|NCT06061848|ACTIVE_COMPARATOR|ILIT + Vitamin D|Intramuscular injection of kolecalciferol 100000 IU followed by intralymphatic immunotherapy with 3 monthly injections of grass pollen allergen 1000 SQ-U.
62412579|NCT06061848|ACTIVE_COMPARATOR|ILIT + placebo|Intramuscular injection of saline solution followed by intralymphatic immunotherapy with 3 monthly injections of grass pollen allergen 1000 SQ-U.
62412580|NCT01626794|EXPERIMENTAL|VARIVAX™ VEP|
62412581|NCT01626794|ACTIVE_COMPARATOR|VARIVAX™ 2007 Process|
62412582|NCT01591499|EXPERIMENTAL|BIOFINITY® MF - AIR OPTIX® AQUA MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
62412583|NCT01591499|ACTIVE_COMPARATOR|BIOFINITY® MF - PUREVISION® MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
62412584|NCT04394572||colorectal cancer|Patients with and without colorectal cancer
62794405|NCT06725420|EXPERIMENTAL|intramuscular steroid injection|The group of patients who received an intramuscular (gluteal) steroid and local anesthetic injection + wrist plint
62022456|NCT05443035|EXPERIMENTAL|Control group|The participants will receive selective removal of carious dentinal tissue using a curette.
62218559|NCT02679027|ACTIVE_COMPARATOR|Difficult intubation|Intubation difficulty score \>5
62218560|NCT00641901||Observation|Pregnant women with gingivitis
62218561|NCT03966768|EXPERIMENTAL|Duramesh suturable mesh for laparotomy closure|Patients undergoing a midline laparotomy for trauma or emergency surgery will be closed with Duramesh suturable mesh.
62218562|NCT03966768|EXPERIMENTAL|Conventional suture closure for laparotomy closure|Patients randomized to conventional laparotomy closure will be closed using size 1 slowly-absorbing polydiaxonone (PDS) single strand or looped suture, based on surgeon preference.
62218563|NCT03966768|EXPERIMENTAL|Open abdomen group closed in delayed fashion with Duramesh|Patients undergoing delayed primary closure of an open abdomen will also be studied. 20 study patients undergoing delayed primary closure of an open abdomen will be closed with Number 1 or Number 2 Duramesh
62218564|NCT02865837|EXPERIMENTAL|ARM 1|
62218565|NCT02168829|ACTIVE_COMPARATOR|Rivaroxaban|Rivaroxaban 15 mg daily
62412585|NCT01615757|EXPERIMENTAL|Arm B, Ara-c - 12 gm/m2|Arm B will receive HIDAC at 12 gm/m2/cycle for 3 cycles , i.e. 2 gm/m2 BD , Day 1,3,5
62412586|NCT01615757|ACTIVE_COMPARATOR|Arm A. Ara-c 18 gm/m2|Arm A will receive HIDAC at 18 gm/m2/cycle for 3 cycles , i.e. 3 gm/m2 BD , Day 1,3,5
62412587|NCT02689986|EXPERIMENTAL|Treatment arm|Bendamustine, Rituximab
62794406|NCT06725420|EXPERIMENTAL|Wrist splint|The group of patients who received only a nighttime wrist splint
62218566|NCT02168829|ACTIVE_COMPARATOR|Acetylsalicylic acid (ASA)|ASA 75-160 mg daily (if intolerant to ASA, no antiplatelet therapy will be prescribed)
62218567|NCT00602940|EXPERIMENTAL|1|Active acupuncture treatment
62218568|NCT00602940|SHAM_COMPARATOR|2|Sham acupuncture treatment
62218569|NCT04638595||Normative|50 neurotypical pediatric subjects
62218570|NCT05462158|EXPERIMENTAL|Available for Members-Text|"Participants will receive a text message that says, Two common kidney tests have been made available for members. By taking them, you could stay ahead of any problems and keep enjoying life. Schedule a doctor visit today to ask about them."
62218571|NCT05462158|EXPERIMENTAL|Checked Health-Text|"Participants will receive a text message that will say, Have you checked your kidney health recently? By taking two common kidney tests, members can stay ahead of any problems and keep enjoying life. Schedule a doctor visit today to ask about them."
62218572|NCT05462158|EXPERIMENTAL|No Text Message|Participants in this group will not receive a text message at all
62218573|NCT06324604|PLACEBO_COMPARATOR|Cohort A1S - Healthy Volunteers|Cohort A1S (n = 6): MTX-101, Dose level 1 IV or Placebo IV, Single dose
62218574|NCT06324604|PLACEBO_COMPARATOR|Cohort A2S - Healthy Volunteers|Cohort A2S (n = 6): MTX-101, Dose Level 2 IV or Placebo IV, Single dose
62412588|NCT03503201|ACTIVE_COMPARATOR|treatment|patients receive chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) for 2 months before Intracytoplasmic sperm injection cycle
62412589|NCT03503201|NO_INTERVENTION|No treatment|patients will not receive chromium supplementation before Intracytoplasmic sperm injection cycle
62794407|NCT04392154|EXPERIMENTAL|Lebrikizumab Q2W (Open-Label) from Parent Study|Participants assigned to lebrikizumab Q2W (once every 2 weeks) arm will receive investigational product Q2W by subcutaneous (SC) injection.
62794408|NCT04392154|EXPERIMENTAL|Lebrikizumab Q2W (Blinded) from Parent Study|Participants assigned to lebrikizumab Q2W arm will receive investigational product Q2W by SC injection. Some participants will receive loading doses.
62218575|NCT06324604|PLACEBO_COMPARATOR|Cohort A3S - Healthy Vounteers|Cohort A3S (n = 6): MTX-101, Dose Level 3 IV or Placebo IV, single dose
62794409|NCT04392154|EXPERIMENTAL|Lebrikizumab Q2W (Open-Label Addendum)|Participants enrolling in Open-Label Addendum will receive lebrikizumab Q2W by SC injection after loading doses.
62218576|NCT06324604|PLACEBO_COMPARATOR|Cohort A4S - Healthy Volunteers|Cohort A4S (n =6): MTX-101, Dose Level 4 IV or Placebo IV, single dose
62218577|NCT06324604|PLACEBO_COMPARATOR|Cohort A5Sa - Healthy Volunteers|Optional Cohort A5Sa (n = 6): MTX-101, Dose level 6 IV or Placebo IV, Single Dose
62794410|NCT04392154|EXPERIMENTAL|Lebrikizumab Q4W|"Participants assigned to lebrikizumab Q4W (once every 4 weeks) arm will receive investigational product Q4W by SC injection.~Intervention assigned: Lebrikizumab balanced with Placebo to maintain the blind between treatment arms."
62794411|NCT04392154|EXPERIMENTAL|Lebrikizumab Q4W (Open-Label Extension Addendum)|Participants enrolling in Open-Label extension addendum will receive lebrikizumab Q4W by SC injection.
62794412|NCT04392154|EXPERIMENTAL|Lebrikizumab Q8W (Open-Label Extension Addendum)|Participants enrolling in Open-Label extension addendum will receive lebrikizumab Q8W by SC injection.
62218578|NCT06324604|PLACEBO_COMPARATOR|Cohort A6M - Healthy Volunteers|Cohort A5M (n=8): MTX-101,Dose Level 4 IV or Placebo IV, dosed on Days 1 and 22 for a total of 2 doses
62794413|NCT04392154|EXPERIMENTAL|Lebrikizumab Q2W (Open-Label Extension Addendum)|Participants enrolling in Open-Label extension addendum will receive lebrikizumab Q2W by SC injection.
62794414|NCT04407988|EXPERIMENTAL|Pyrotinib plus Letrozole|
62794415|NCT04519502||Randomly Selected Delivery Dates 2019|Women who deliver at one of the MFMU Network hospitals on randomly selected days between March 1 and December 31, 2019.
62218579|NCT06324604|PLACEBO_COMPARATOR|Cohort A7M - Healthy Volunteers|Cohort A6M (n = 6): MTX-101, Dose Level 5 IV or Placebo IV, dosed on Days 1 and 22 for a total of 2 doses
62218580|NCT06324604|PLACEBO_COMPARATOR|Cohort A7Ma - Healthy Volunteers|Optional Cohort A6Ma (n = 6): Dose Level 6 IV or Placebo IV, dosed on Days 1 and 22 for a total of 2 doses
62218581|NCT06324604|PLACEBO_COMPARATOR|Cohort B8 - Celiac Disease or Type 1 Diabetes Patients|"* Dose Group 1 (n = 6): MTX-101 Dose Level 4 IV Day 1, placebo IV Day 22~* Dose Group 2 (n = 6): Placebo IV Day 1, MTX-101 Dose Level 3 IV Day 22"
62218582|NCT06324604|PLACEBO_COMPARATOR|Cohort B9 -Celiac Disease or Type 1 Diabetes Patients|Dose Group 1 (n = 6): MTX-101 Dose Level 5 IV Day 1, placebo IV Day 22 Dose Group 2 (n = 6): Placebo IV Day 1, MTX-101 Dose Level 5 IV (or the maximum tolerated dose in Part A MAD) Day 22
62218583|NCT06324604|PLACEBO_COMPARATOR|Cohort A5Sa -Healthy Volunteers|Optional Cohort A5Sa (n = 6): MTX-101, up to Dose Level 6 IV or Placebo IV, Single Dose
62218584|NCT04673253|ACTIVE_COMPARATOR|Passive leg raise|group for passive leg raise
62412590|NCT02610842|EXPERIMENTAL|Handbook group|"Patients will receive a home based program named Hands on - a hand care guide in Systemic Sclerosis which includes a handbook with instructions about the disease and hand exercises. Patients will be asked to follow the program instructions and carry out the exercises daily during the following 12 weeks."
62412591|NCT01851343|EXPERIMENTAL|1|All patients will receive the same treatment
62412592|NCT05125822|EXPERIMENTAL|Meal Replacement and Lifestyle Therapy|Participants in this study will have an 8-week meal replacement therapy period in which they are asked to reduce their BMI by 5% by following a prescribed eating regimen consisting of meal replacement shakes and/or frozen meals for breakfast and lunch. For dinner they will consume a pre-packaged frozen entree to be consumed with two servings of fruit and three servings of vegetables per day. Participants will also have lifestyle/behavioral modification counseling every 2 weeks throughout the entire study.
62794416|NCT04519502||Randomly Selected Delivery Dates 2020|Women who deliver at one of the MFMU Network hospitals on randomly selected days between March 1 and December 31, 2020
62794417|NCT04519502||Confirmed COVID-19 Infections|Women with confirmed COVID-19 infection between March 1, 2020 and December 31, 2020 and who delivered on or before December 31, 2020.
62794418|NCT03736941|EXPERIMENTAL|Patients with venous leg|"After inclusion, the medical device Venotrain® Ulcertec will be prescribed according to the indications supported by the Health Insurance and used according to the recommendations of the manufacturer. Follow-up visits are scheduled at 4, and 16 weeks (± 1 week) as well as an end-of-study visit, not later than 20 weeks after enrollment or in case of premature termination. follow-up.~During the various visits, clinical data will be collected in the patient's medical file as well as the answers to the questionnaires."
62794419|NCT06406023|EXPERIMENTAL|Instrument assisted soft tissue mobilization|"IASTM with Graston tool along with conventional treatment in first 6 sessions. Apply hot pack for 10 mins on low back as passive warm up then AROM's of Hip (5 reps x 2 sets each) will be performed. Apply Graston tool at 30-60 degrees angle along the length of following muscles Piriformis, Gluteus medius and Hamstrings after applying emollient for 40-120 seconds.~Piriformis stretch, SLR, Sciatic nerve stretch (3 reps x 20 sec hold x 2 sets/3 days/week for 2 weeks).~Only Conventional protocol will be followed for remaining 6 sessions. 3 days/ week for 2 weeks. Hot pack will be applied for 10 minutes on low back followed by Strengthening exercises of Hip abductors (Hip abduction with band in sitting, standing, side-lying hip raise), and hip extensors (Gluteal bridges, Prone hip extension, Prone hams curl). (5 reps x 2 sets each/3 days/week for 2 weeks)."
62412593|NCT04206436||on CFTR|For patients on or near time of initiation CFTR modulator therapy
62218585|NCT04673253|PLACEBO_COMPARATOR|Control|
62218586|NCT03056027||Group Open|Patient submitted to open inguinal hernia repair
62218587|NCT03056027||Group extraperitoneal laparoscopic|Patients submitted to total extraperitoneal laparoscopic inguinal hernia repair
62218588|NCT01886378|EXPERIMENTAL|UX007|UX007 dosing titrated to a target dose of 25-35% of total caloric intake or maximum tolerated dose. Participants are followed to evaluate the effects of UX007 over 24 weeks (Treatment Period), then continued treatment in the Extension Period for an additional 54 weeks for a total of 78 weeks of treatment.
62218589|NCT05834439|EXPERIMENTAL|Experimental group|Experimental group
62022457|NCT01173393|NO_INTERVENTION|Standard Treatment|"For patients randomised to hospital cooling:~* LMA/ Intubation and ventilation with 100% oxygen~* Measure temperature using tympanic probe and record~* Insert IV line and administer drugs as per protocol~* Fluid challenge with standard temperature saline only as per current guideline (suspected hypovolemia)~* Post resuscitation: midazolam 1-5 mg only to maintain LMA/ intubation as needed.~* Pancuronium 8 mg only if intubation unable to be maintained with midazolam.~After arrival at the Emergency Department, all patients receive standard care."
62022458|NCT06046313|EXPERIMENTAL|treatment group|Acute Myeloid Leukemia Myelodysplastic Syndrome
62586289|NCT01671995|ACTIVE_COMPARATOR|Standard primary health care|To assess whether a nurse monitored management programme at the hospital outpatient clinic would improve quality of life, as compared to standard primary health care.
62794420|NCT06406023|OTHER|Conventional Treatment|"Only conventional treatment will be given in this group. Stretching exercises for 6 sessions and strengthening exercises for remaining 6 sessions.~For first 6 sessions, hot pack will be applied for 10 minutes on low back. AROM's of Hip (5 reps x 2 sets each/ 3 days/week for 2 weeks). Piriformis stretch 3 reps x 20 sec hold x 2 sets/ 3 days/week for 2 weeks. SLR (5reps x 10 sec hold x 2 sets/ 3 days/ week for 2 weeks). Sciatic nerve stretch (5 reps x 10 sec hold x 2 sets/ 3 days/ week for 2 weeks).~In next 6 sessions, strengthening exercises will be performed after applying hot pack on low back for 10 minutes in each session. Hip abductors strengthening (Hip abduction with band in sitting, standing, side-lying hip raise) 5reps x 2 sets each/ 3 days/ week for 2 weeks, and hip extensors (Gluteal bridges, Prone hip extension, Prone hams curl). (5 reps x 2 sets each/ 3 days/ week for 2 weeks).~SLR (5 reps x 10 sec hold x 2 sets 3 days/ week for 2 weeks)."
62794421|NCT05079828|ACTIVE_COMPARATOR|Arm 1|Patients receive first a PET/CT with 68Ga-PSMA-11 and a second PET/CT with 18F-PSMA-1007
62794422|NCT05079828|ACTIVE_COMPARATOR|Arm 2|Patients receive first a PET/CT with 18F-PSMA-1007 and a second with 68Ga-PSMA-11
62794423|NCT01110356|EXPERIMENTAL|Ferinject|
62794424|NCT01110356|PLACEBO_COMPARATOR|Saline|
62794425|NCT01012258|EXPERIMENTAL|Cetuximab|All eligible subjects will receive cetuximab treatment only during week 1 of the treatment course and concomitant cetuximab and boost radiotherapy (RT) during week two to week seven of the treatment course
62794426|NCT02557737|EXPERIMENTAL|Ultrasonography direct-guidance|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
62794427|NCT02557737|EXPERIMENTAL|Electric stimulation|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Electric stimulation
62794428|NCT02557737|ACTIVE_COMPARATOR|Surface anatomy landmark|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.
62794429|NCT01721226|SHAM_COMPARATOR|Control Arm|Participants in the Control Arm will receive standard discharge services according to the standards of care for that facility. In addition, participants in this arm will view an educational video on opiate overdose prevention. Study participants in the Control Arm will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
62022459|NCT04446663|EXPERIMENTAL|Toripalimab+induction chemotherapy +CCRT|"Patients will receive induction chemotherapy with Albumin-bound paclitaxel (260 mg/m2, d1 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiotherapy.~Then patients will receive definitive intensity-modulated radiotherapy (IMRT) of ≥66 Gy（2-2.2Gy/fx）.Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT .~Toripalimab 240mg will be given every 3 weeks for 6 cycles, started on day 1 of induction chemotherapy"
62022460|NCT04446663|ACTIVE_COMPARATOR|induction chemotherapy +CCRT|"Patients will receive induction chemotherapy with Albumin-bound paclitaxel (260 mg/m2, d1 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiotherapy.~Then patients will receive definitive intensity-modulated radiotherapy (IMRT) of ≥66 Gy（2-2.2Gy/fx）.Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT ."
62218590|NCT05834439|OTHER|Control group|Control group
62218591|NCT00712673|EXPERIMENTAL|Lixisenatide (Morning Injection)|2-step initiation morning regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
62218592|NCT00712673|EXPERIMENTAL|Lixisenatide (Evening Injection)|2-step initiation evening regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
62218593|NCT00712673|PLACEBO_COMPARATOR|Placebo (Morning Injection)|2-step initiation morning regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
62794430|NCT01721226|EXPERIMENTAL|CARE tool and cell phone/text messaging|The Intervention Arm will complete the CARE tool device, a technology based HIV-counseling tool, and will receive text message reminders about HIV medical appointments and the importance of taking HIV medications. Study participants in this arm will be followed after release/study enrollment, just like participants in the Control Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
62586290|NCT05178992|EXPERIMENTAL|Socially Assistive Robot Activity|Participants will attend two sessions per week and interact with the robot. Four weeks with a humanoid robot and four weeks with a dog robot. Participants can continue to join other activities held within the facility.
62794431|NCT02008344|ACTIVE_COMPARATOR|favipiravir|Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
62794432|NCT02008344|PLACEBO_COMPARATOR|placebo|Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
62218594|NCT00712673|PLACEBO_COMPARATOR|Placebo (Evening Injection)|2-step initiation evening regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
62794433|NCT04574401|EXPERIMENTAL|Dose escalation|Dose-cohort escalation of a single intravenous injection of IS-002 at four different dose levels
62586291|NCT05178992|ACTIVE_COMPARATOR|Usual Activity Program|Participants will attend at least two sessions per week at activities held within the facility. They will not be exposed to the robot activities.
62794434|NCT01915173|EXPERIMENTAL|Supplement + Expanded Interview|Supplement, 2 tablets sublingually 3 times a day for 2 weeks.
62794435|NCT01915173|PLACEBO_COMPARATOR|Placebo + Standard Interview|Placebo, 2 tablets sublingually 3 times a day for 2 weeks.
62794436|NCT01915173|EXPERIMENTAL|Supplement + Standard Interview|Supplement, 2 tablets sublingually 3 times a day for 2 weeks.
62218595|NCT05422404|EXPERIMENTAL|Chronic GERD patient reciving Anti-Reflux Mucosal Ablation|150 chronic GERD patients will be enrolled from our outpatient clinic. The inclusion criteria are as following: 20-75 years of age, history of GERD over 1 year, who had received daily PPIs or H2 antagonists over 6 month for GERD treatment, and having persistent typical GERD symptoms (acid reflux sensation or heartburn) or atypical GERD symptoms (hoarseness, cough, acid related chest pain, laryngitis) when off PPI or H2 antagonists therapy, defective gastroesophageal Defective junction reciving Anti-Reflux Mucosal Ablation.
62218596|NCT05422404|ACTIVE_COMPARATOR|Chronic GERD patient reciving Anti-Reflux Mucosectomy|150 chronic GERD patients will be enrolled from our outpatient clinic. The inclusion criteria are as following: 20-75 years of age, history of GERD over 1 year, who had received daily PPIs or H2 antagonists over 6 month for GERD treatment, and having persistent typical GERD symptoms (acid reflux sensation or heartburn) or atypical GERD symptoms (hoarseness, cough, acid related chest pain, laryngitis) when off PPI or H2 antagonists therapy, defective gastroesophageal Defective junction reciving Anti-Reflux Mucosectomy
62412594|NCT04206436||Controls|controls will be patients not eligible for available treatment
62794437|NCT01915173|PLACEBO_COMPARATOR|Placebo + Expanded Interview|Placebo, 2 tablets sublingually 3 times a day for 2 weeks.
62794438|NCT06263478|EXPERIMENTAL|Axatilimab Dose|Axatilimab at the protocol-defined dose.
62794439|NCT03718767|EXPERIMENTAL|1/Nivolumab|IV nivolumab
62794440|NCT03670563|EXPERIMENTAL|Exercise 1|Short foot exercise protocol instructed utilizing verbal instruction, passive modeling, active-assisted modeling, and active modeling.
62794441|NCT03670563|ACTIVE_COMPARATOR|Exercise 2|Short foot exercises plus NMES. Short foot exercise protocol instructed utilizing verbal instruction, passive modeling assisted by neuromuscular electric stimulation (NMES), active-assisted modeling assisted by neuromuscular electric stimulation, and active modeling.
62794442|NCT03670563|NO_INTERVENTION|Control|No exercise intervention; continue normal physical activity, but do not start any new exercise programs
62794443|NCT03874117|OTHER|Twice weekly hemodialysis|Participants will undergo hemodialysis twice per week.
62412595|NCT05351437|ACTIVE_COMPARATOR|MTx-COVAB36|Cohort 1 - 100 mg IV dose Cohort 2 - 500 mg IV dose Cohort 3 - 1000 mg IV dose Cohort 4 - 2000 mg IV dose MTx-COVAB36 will be administered as a single dose intravenously.
62412596|NCT05351437|PLACEBO_COMPARATOR|Placebo|Placebo (0.9% NaCl) will be administered as a single dose intravenously.
62412597|NCT05552430|EXPERIMENTAL|Skills-Based VR|Participants will complete daily skills-based Virtual Reality (VR) sessions for 8 weeks (an average of 6 minutes per day) to determine the feasibility of at-home VR technology to aid the recovery of acute orthopedic musculoskeletal injuries. The VR device software is equipped with pain-specific treatment modules (e.g., Pain Education, Relaxation/Interoception, Mindful Escapes, and Pain Distraction Games) derived from evidence-based principles of cognitive behavioral therapy (CBT), mindfulness, and pain neuroscience education.
62412598|NCT02545868|EXPERIMENTAL|Group A: OCR + Vaccines|Participants will receive dual infusion of OCR 300 milligrams (mg) on Day 1 and then on Day 15, and then participants will further receive immunization course (TT-containing adsorbed vaccine, 23-PPV either unboosted or boosted with 13-PCV, influenza vaccine, and repeated administration with KLH) at 12 weeks post-OCR treatment until Week 24. Participants who complete the 24-week immunization study period will have the option for retreatment with a single infusion of 600 mg OCR on Day 169 and subsequent single infusions (600 mg OCR) at intervals of 24 weeks. Participants who have received one or more infusions of OCR will enter the 48-week safety follow-up period.
62586292|NCT00535782|EXPERIMENTAL|TCZ + MTX|Participants received 8 mg/kg tocilizumab (TCZ) by intravenous infusion (IV) every 4 weeks plus methotrexate (MTX) 7.5-25 mg (oral or parenteral) weekly for the first 24 weeks. From Week 24 to Week 104, participants received open-label TCZ 8 mg/kg every 4 weeks plus 7.5-25 mg MTX weekly.
62794444|NCT03874117|OTHER|Thrice weekly hemodialysis|Participants will undergo hemodialysis three times per week.
62794445|NCT01014182||Early PCI|Routine invasive strategy with early PCI performed in STEMI patients within 24 hours from successful fibrinolysis
62794446|NCT01014182||Standard Therapy|Standard therapy in STEMI patients with fibrinolysis and/or conventional ischaemic-guided therapy.
62794447|NCT01404780|EXPERIMENTAL|The GlideScope (GVL)|
62794448|NCT01404780|ACTIVE_COMPARATOR|Macintosh direct laryngoscope (MDL)|
62794449|NCT00323648|EXPERIMENTAL|postoperatively antibiotics|
62794450|NCT05541679|EXPERIMENTAL|Group A|
62794451|NCT05541679|EXPERIMENTAL|Group B|
62794452|NCT02964000|ACTIVE_COMPARATOR|Low level 1 Watt|"The Phoenix Thera-Lase System will be on 1 watt while retaining appropriate blinding of both the operator and the patient.~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.~Each treatment session will last for 20-40 minutes."
62022461|NCT04989998|EXPERIMENTAL|Hip7 Software on Kick/ CORI platforms|Subjects will receive total hip arthroplasty surgery using Hip7 on Kick or CORI platform utilizing R3 Polarstem implants.
62586293|NCT00535782|PLACEBO_COMPARATOR|Placebo + MTX|Participants received placebo intravenous infusion (IV) every 4 weeks plus methotrexate (MTX) 7.5-25 mg (oral or parenteral) weekly for the first 24 weeks. From Week 24 to 104, participants received open-label tocilizumab (TCZ) 8 mg/kg every 4 weeks plus 7.5-25 mg MTX.
62022462|NCT04989998|ACTIVE_COMPARATOR|Conventional procedures with standard, manual instrumentation and digital templating techniques|Subjects will receive total hip arthroplasty surgery using conventional procedures with standard instrumentation and digital templating techniques utilizing R3 Polarstem implants.
62586294|NCT04810000||Group A|Group A ( Tourniquet release before wound closure and hemostasis ensured )
62586295|NCT04810000||Group B|Group B ( Tourniquet release after wound closure )
62586296|NCT06097923|EXPERIMENTAL|Active fluid management with BIA monitoring|For assessment of fluid status, a commercial portable BIA device (InBody M20®, InBody Corp., Seoul, Korea) was measured. Baseline BIA data were collected at the time of ICU admission, and BIA measurements were performed daily for 3days for all participants. The participants in active fluid management with BIA monitoring arm received fluid supplementation targeting specific range of ECW ratio by BIA (0.390-0.406). If a patient with dehydrated status indicated by the ECW ratio was less than 0.390, a bolus infusion was performed using 250ml of crystalloid fluid (PlasmaLyte). If a patient with overhydrated status indicated by the ECW ratio was more than 0.406, 10mg of furosemide was administered. Changes in the ECW ratio were measured at one hour after initial intervention for fluid adjustment, and the investigators determined whether additional intervention was needed according to results of changes. These processes continued until the ECW ratio was within the normal range (0.390-0.406).
62794453|NCT02964000|EXPERIMENTAL|Phoenix Thera-Lase System 42|"The Phoenix Thera-Lase System will be on 42 watts while retaining appropriate blinding of both the operator and the patient.~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.~Each treatment session will last for 20-40 minutes."
62022463|NCT05164510|EXPERIMENTAL|ct-DNA test in MPC|treatment according to ct-DNA results:For Patients with abnormal gene changes of corresponding targeted drugs are recommended to use corresponding targeted therapy or immunotherapy drugs;For Patients without abnormal gene changes of corresponding targeted drugs, Treatment of Physician's Choice (TPC) is recommended.
62794454|NCT02964000|EXPERIMENTAL|Phoenix Thera-Lase System 74|"The Phoenix Thera-Lase System will be on 74 watts while retaining appropriate blinding of both the operator and the patient.~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.~Each treatment session will last for 20-40 minutes."
62022464|NCT01360359|EXPERIMENTAL|Core Stabilization|"8-week core stabilization program in 3 stage that emphasizes use of specific local trunk stabilizing muscles to restore active control and stability to the trunk.~8-week exercise program, 1-2 sessions/ week, 30-60 minute sessions"
62022465|NCT01360359|ACTIVE_COMPARATOR|Trunk Motion and Fitness|"8-week exercise program in 3 stages emphasizing spine motion, general trunk flexibility and strengthening and cardiovascular fitness.~8-week exercise program, 1-2 sessions/ week, 30-60 minute sessions"
62022466|NCT01836692|EXPERIMENTAL|Thoracic radiotherapy|Intensity Modulated Radiotherapy treatment (delivered twice daily on consecutive weekdays over 4.5 weeks)
62022467|NCT05800522|ACTIVE_COMPARATOR|Control group|Various active treatments implemented in Norwegian frontline services. Treatments will include different measures varying in scope and intensity including eclectic counselling and other systematic and evidence-based interventions.
62022468|NCT05800522|EXPERIMENTAL|Intervention group|Transdiagnostic and preventive parent training intervention, Supportive parents - coping kids (SPARCK)
62022469|NCT01218646|EXPERIMENTAL|Group 1: Investigational Quadrivalent Influenza Vaccine|Participants will receive a dose of Investigational Quadrivalent Inactivated Influenza Vaccine
62022470|NCT01218646|EXPERIMENTAL|Group 2: Investigational Trivalent Influenza Vaccine|Participants will receive a dose of Investigational Trivalent Inactivated Influenza Vaccine
62412599|NCT02545868|OTHER|Group B: Vaccines (Optional OCR in Extension)|Participants will receive immunizations (TT-containing adsorbed vaccine, 23-PPV, influenza vaccine, and repeated administration with KLH) on Day 1 until Week 12 of the immunization period.
62412600|NCT03979339|EXPERIMENTAL|blood sample collection|For all participants whatever the group Groups 0 and 4: Healthy volunteers Group1: Metastatic HER2-positive breast cancer Group 2: Advanced CA-125 positive ovarian cancer Group 3: Metastatic PSA-positive castrate-resistant prostate cancer Participants will receive the following interventions because they are enrolled in the study: blood sample collection of 32mL (4x8mL in EDTA tubes)
62022471|NCT01218646|ACTIVE_COMPARATOR|Group 3: Licensed 2010-2011 Trivalent Influenza Vaccine|Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
62022472|NCT01218646|ACTIVE_COMPARATOR|Group 4: Licensed 2010-2011 Trivalent Influenza Vaccine|Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
62022473|NCT00845910|EXPERIMENTAL|1|
62022474|NCT04905680|NO_INTERVENTION|Control group|The health screening before the study and at the end of study will collect anthropometric data (height, weight, waist and hip circumference), blood pressure data, and blood samples (for testing of HbA1c, fasting blood glucose, fasting insulin and lipid profile). Individuals are provided with an educational brochure upon receiving their screening results. Participants will then go through a baseline lifestyle tracking session using a study-issued smartphone and smartwatch, pre-installed with certain study applications. For participants in the control arm, there is no health coaching or study activities until the end of the study, where individuals will attend a 20- to 30-minute session with a coach to have their baseline lifestyle tracking results explained to them and receive personalised suggestions on lifestyle modifications.
62412601|NCT02139930|ACTIVE_COMPARATOR|Normal Nicotine Control Group|These subjects will smoke normal nicotine content Spectrum brand cigarettes for 20 weeks.
62412602|NCT02139930|EXPERIMENTAL|Immediate Nicotine Reduction Group|This group will immediately be switched to smoking very low nicotine content (VLNC) Spectrum brand cigarettes. They will smoke these cigarettes for 20 weeks.
62412603|NCT02139930|EXPERIMENTAL|Gradual Nicotine Reduction Group|This group will smoke progressively lower nicotine content Spectrum brand cigarettes for a period of one month each until they end up smoking the same VLNC cigarettes as the immediate reduction group.
62794455|NCT02630472|EXPERIMENTAL|Quinine Sulfate|"Each study participant randomized into the experimental arm will receive 28 tubes with 1mg/ml (6 mls total) of quinine sulfate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be supplied in light-protected tubes. Patients will apply 3 mls of quinine sulfate to each nostril twice per day. Thus the patients will be exposed to a maximum of 12mls or 12.0 mg of quinine per day.~The Investigational Drug Service (IDS) will prepare and record the distribution of the irrigant. The Clinical Research Coordinator or Clinical Research Nurse will pick up the solutions and will demonstrate the application to the subject. The application of the solution is exactly the same as if the study subject were to irrigate with regular saline as part of their daily regimen for chronic rhinosinusitis."
62218597|NCT03744104|EXPERIMENTAL|Quadrivalent influenza vaccine|Quadrivalent influenza vaccine(containing 2 subtypes of B lineage)
62218598|NCT03744104|ACTIVE_COMPARATOR|Trivalent influenza vaccine A|Trivalent influenza vaccine (containing B/Victoria lineage)
62218599|NCT03744104|ACTIVE_COMPARATOR|Trivalent influenza vaccine B|Trivalent influenza vaccine (containing B/Yamagata lineage)
62218600|NCT06138314|ACTIVE_COMPARATOR|Control group|The control group will perform a physical exercise program twice a week for a period of 8 weeks.
62218601|NCT06138314|EXPERIMENTAL|Experimental group|The experimental group will perform the same physical exercise program performed by participants in the control group, in addition to neural mobilization techniques twice a week for a period of 8 weeks.
62218602|NCT04625387|EXPERIMENTAL|Dry Needle plus exercise|Group A received Dry Needling along with exercise having 25 individuals. Treatment lasted four weeks duration, twice a week.
62218603|NCT04625387|EXPERIMENTAL|Dry Needling alone|Group B received Dry Needling alone having 25 individuals. Treatment lasted four weeks duration, twice a week.
62218604|NCT00431080|EXPERIMENTAL|1|FEC -\> TXT
62412604|NCT04043052|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Evaluation of depression and anxiety disorders at 3 and 6 months post-stroke using psychological and functional examination
62412605|NCT04043052|EXPERIMENTAL|EMA intervention assocuated to Treatment As Usual (EMA-TAU)|Evaluation of depression and anxiety disorders at 3 and 6 months post-stroke using psychological and functional examination in addition with Ecological Momentary Assessment (EMA) evaluation.
62218605|NCT00431080|EXPERIMENTAL|2|FEC -\> TXL
62412606|NCT05080218|EXPERIMENTAL|Treatment Interruption - UPA|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
62412607|NCT05080218|NO_INTERVENTION|Treatment Continuation|Treatment Continuation of All Immunomodulatory Therapy at the time of COVID Vaccine Booster
62218606|NCT06063018|EXPERIMENTAL|RC48 + Tislelizumab|Durg：RC48: intravenous drip, 2mg/kg, D1, repeated once every 2 weeks. Durg ：Tislelizumab: intravenous drip, fixed dose 600 mg, D1, repeated once every 6 weeks.
62218607|NCT03955796|EXPERIMENTAL|RayOne Hydrophobic Aspheric|Patient will receive the hydrophobic IOL during cataract surgery
62218608|NCT03955796|EXPERIMENTAL|RayOne Aspheric|Patient will receive the non-hydrophobic IOL during cataract surgery
62218609|NCT02903264||GDM group|Gestational diabetes mellitus patients under treatment of an endocrinologist
62412608|NCT05080218|EXPERIMENTAL|Treatment Interruption - ABA|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
62412609|NCT05080218|EXPERIMENTAL|Treatment Interruption - TOF|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
62412610|NCT05080218|EXPERIMENTAL|Treatment Interruption - SEC|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
62412611|NCT05080218|EXPERIMENTAL|Treatment Interruption - TNFi SQ|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
62412612|NCT05080218|EXPERIMENTAL|Treatment Interruption - CAN|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
62218610|NCT02903264||Control|Healthy non-pregnant females
62218611|NCT05820165||CVOD-WS|Cerebral Venous Outflow Disturbance with symptoms such as tinnitus cerebri，somnipathy ，anxiety ，depression and cognitive decline
62218612|NCT05820165||CVOD-WOS|Cerebral Venous Outflow Disturbance without symptoms such as tinnitus cerebri，somnipathy ，anxiety ，depression and cognitive decline
62218613|NCT05820165||HC|Healthy control
62218614|NCT01644279||Young|Young (age 20-35 years old)
62218615|NCT01644279||Old high-functioning|Old high-functioning (age 70-99 years old)
62218616|NCT01644279||Old low-functioning|Old low-functioning (age 70-99 years old)
62243318|NCT01882218|EXPERIMENTAL|Galactose|Standard liver surgery with direct peritoneal resuscitation with galactose after surgery.
62243319|NCT02131909|EXPERIMENTAL|mirror therapy|5 sessions mirror therapy 15 minutes per week for 5 weeks
62412613|NCT05080218|EXPERIMENTAL|Treatment Interruption - BAR|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
62794456|NCT02630472|PLACEBO_COMPARATOR|Placebo|"The placebo arm will be spiked with Sucrose Octaacetate which has a bitter taste, but does not stimulate sinonasal nitric oxide production.~Each study participant will receive 28 tubes with 0.5mg/ml sucrose octaacetate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be supplied in light-protected tubes.~The placebo arm will mirror the experimental arm exactly, except for the treatment solution contained in the vials."
62794457|NCT04724915|EXPERIMENTAL|Robot-assisted TKA|Patients undergoing TKA with the assistance of robot technology.
62794458|NCT04724915|ACTIVE_COMPARATOR|Conventional TKA|Patients undergoing TKA with manual instrumentarium
62218617|NCT04989465|EXPERIMENTAL|Experimental Group|450 Participants (including 150 subjects aged 2\~17 years, 150 subjects aged18\~60 years and 150 subjects aged 61years and older ) received one dose of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd will be collected venous blood about 3.0\~3.5 ml.
62218618|NCT04989465|PLACEBO_COMPARATOR|Control Group|150 Participants (including 50 subjects aged 2\~17 years, 50 subjects aged18\~60 years and 50 subjects aged 61years and older ) received one dose of 23-valent pneumococcal polysaccharide vaccine manufactured by Chengdu Institute of Biological Products will be collected venous blood about 3.0\~3.5 ml.
62218619|NCT00309959|EXPERIMENTAL|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive ABI-007 IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62218620|NCT02762149|ACTIVE_COMPARATOR|0.1ms pulse width|The nerve stimulator will be connected to the epidural catheter through an adapter, which will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle. All patients will have the trans-catheter electric stimulation test (TCEST) performed with both a 1 ms pulse width and 0.1 ms pulse width and the order of administration will be randomized.
62412614|NCT05080218|EXPERIMENTAL|Treatment Interruption - IXE|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
62412615|NCT06436469|OTHER|Mindfulness interventions|The intervention involves participation in a structured Mindfulness-Based Stress Reduction (MBSR) program. Participants engage in a series of sessions over a four week period. During these sessions, participants learn and practice mindfulness techniques such as deep breathing and body scans.
62412616|NCT03130777|EXPERIMENTAL|TPVR - Main Cohort|Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using Commander Delivery System.
62412617|NCT03130777|EXPERIMENTAL|TPVR - PDS Registry|Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using Pulmonic Delivery System (PDS).
62412618|NCT00738244||1|Normal hearing listeners
62412619|NCT00738244||2|Listeners with mild-to-moderate sensorineural hearing loss
62412620|NCT02379650|EXPERIMENTAL|Hydroxychloroquine (HCQ)|Subjects in the experimental arm will take 400 mg hydroxychloroquine pills every day, starting before they get pregnant and continuing until 36 weeks of pregnancy or until the pregnancy is over.
62794459|NCT02915263|PLACEBO_COMPARATOR|0.9% Sodium Chloride|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The placebo will consist of 0.9% Sodium Chloride per day over 5 days. Participants who are randomized to placebo will receive the same volume as they would if they were randomized to IVIG (i.e.: as if receiving IVIG at 2gm/kg) through a peripheral IV line.
62794460|NCT02915263|EXPERIMENTAL|IGIV-C|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The treatment will consist of IVIG administered at 2 grams/kg divided over 5 days, with a follow up treatment 3 weeks (+/-3 days) later of IVIG 1gram/kg administered over 2 day (or placebo).
62794461|NCT04770116|EXPERIMENTAL|Intervention group|Participants in this group will receive all-night auditory stimulation during sleep over one week using a portable, in-home device (MHSL-SleepBand).
62412621|NCT02379650|PLACEBO_COMPARATOR|Placebo|Subjects in the experimental arm will take placebo pills every day, starting before they get pregnant and continuing until 36 weeks of pregnancy or until the pregnancy is over.
62412622|NCT06653595|NO_INTERVENTION|CONTROL GROUP|The Control Group receives the usual intervention from the health center, that consists in breastfeeding support in the NICU 1 time/week until hospital discharge.
62412623|NCT06653595|EXPERIMENTAL|EXPERIMENTAL GROUP|The Experimental Group receives the PAP-LM programme.
62412624|NCT00120380|ACTIVE_COMPARATOR|Aerosolized Iloprost|
62412625|NCT00120380|PLACEBO_COMPARATOR|Bosentan monotherapy|
62412626|NCT05755399|EXPERIMENTAL|Experimental group|Participants scheduled for brain surgery
62794462|NCT04770116|SHAM_COMPARATOR|Control group|Participants in this group will receive sham-stimulation, i.e. the device will be applied (biosignals will be recorded), but no tones will be played.
62794463|NCT01284023||Controls|Uninjured volunteers
62022475|NCT04905680|EXPERIMENTAL|Experimental group|The activities during health screening before the study and at the end of study is similar to the control. Individuals are provided with an educational brochure upon receiving their screening results. Participants will then go through a baseline lifestyle tracking session using a study-issued smartphone and smartwatch, pre-installed with certain study applications, which will be used for the lifestyle tracking sessions. The experimental arm will go through 4 additional lifestyle tracking sessions (i.e., total of 5 including baseline), of which 1 will include Continuous Glucose Monitoring (CGM) tracking. For this CGM tracking session, participants will receive real-time feedback through the study applications, which will display the CGM trace. The data collected during the lifestyle tracking sessions will be discussed with the participants during 3 face-to-face coaching and 2 tele-coaching sessions, where the participants will develop and implement lifestyle change action plans.
62022476|NCT05294640|EXPERIMENTAL|Bacteriostatic Saline as Local Anesthesia|Patients receiving bacteriostatic saline as local anesthesia for in-office minor eyelid procedures at University of California, San Francisco Medical Center, Oculoplastics department
62022477|NCT05294640|ACTIVE_COMPARATOR|Lidocaine with Epinephrine as Local Anesthesia|Patients receiving lidocaine with epinephrine as local anesthesia for in-office minor eyelid procedures at University of California, San Francisco Medical Center, Oculoplastics department
62022478|NCT03424876||Arm A|Imatinib 400 mg/day or 600mg/day, and within 6 weeks after surgery, continuous treatment was not tolerated until tumor progression, recurrence or adverse reactions were not tolerated.
62022479|NCT03424876||Arm B|Sunitinib 37.5 mg/day, continuous taking, or 50 mg/day (4/2), began within 6 weeks after surgery, and was continuously administered until tumor progression, recurrence or adverse reactions were not tolerated
62022480|NCT02323594|EXPERIMENTAL|Group 1: Daclatasvir|Single oral dose of Daclatasvir (DCV) tablet and single oral dose of DCV pediatric chewable tablet
62022481|NCT02323594|EXPERIMENTAL|Group 2: Daclatasvir|Single oral dose of Daclatasvir (DCV) pediatric chewable tablet and single oral dose of DCV pediatric chewable tablet
62022482|NCT02323594|EXPERIMENTAL|Group 3: Asunaprevir|Single oral dose of Asunaprevir (ASV) tablet, single oral dose of ASV pediatric chewable tablet and single oral dose of ASV pediatric chewable tablets
62022483|NCT02323594|EXPERIMENTAL|Group 4: Daclatasvir|Single oral dose of Daclatasvir (DCV) tablet and single oral dose of DCV tablets
62022484|NCT06148129|ACTIVE_COMPARATOR|Study group|
62022485|NCT06148129|NO_INTERVENTION|Excluded Patients|
62022486|NCT06300541||1) IBD conventional treatment,|Medical therapy
62022487|NCT06300541||2) Colectomy|Surgical treatment
62022488|NCT00975234|EXPERIMENTAL|Skeletal myoblasts|Patients who are receiving skeletal myoblasts
62412627|NCT05474794|EXPERIMENTAL|Subepithelial lesions|"Patients with subepithelial lesions of the gastrointestinal (GI) tract (GISTs or leiomyomas) at EUS evaluation.~Two interventions: EUS-DFI examination for the detection of slow flow vascularization in SELS. Then, CE-EUS for diagnosis confirmation."
62412628|NCT06247579|NO_INTERVENTION|The control group|The control group, consisting of resident physicians, will use non-disposable plastic tableware (NDPT) provided by hospital canteens for two months.
62022489|NCT00975234|PLACEBO_COMPARATOR|Placebo|Revascularisation surgery
62022490|NCT01471002|EXPERIMENTAL|Renal cancer without nephrectomy|patients with renal cancer that cannot be offered a partial nephrectomy
62022491|NCT01034124|PLACEBO_COMPARATOR|Water|
62412629|NCT06247579|EXPERIMENTAL|The exposure group|The exposure group, also comprising resident physicians, will use disposable plastic tableware (DPT) made of polystyrene, provided by the same hospital canteens for two months
62412630|NCT04928794|OTHER|Peripheral Nerve Block with 2 Techniques|
62412631|NCT03914469|NO_INTERVENTION|Waitlist Control Group|The waitlist control group will continue with management of chronic back pain and depression per usual care. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant. Subjects randomized to the waitlist control group will be offered the same intervention once the active intervention group has completed the active sessions and assessments.
62412632|NCT03914469|EXPERIMENTAL|Behavioral Intervention Group|For participants assigned to the intervention arm, trained health coaches will deliver the intervention via telephone. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant.
62412633|NCT04686968|EXPERIMENTAL|Greenhouse group|Patients underwent greenhouse technique：The high-strength suture was passed through the tendon using Mason-Allen method, and then Crimson duvet procedure was performed on the foot print area from the articular surface of the humeral head to the apex of the greater tubercle. Immediately after this procedure, a lateral row anchor was used.
62412634|NCT04686968|ACTIVE_COMPARATOR|Vent group|The three-line anchor suture method is the same as before, the position is between the apex of the greater tubercle and the articular surface. After the rotator cuff is sutured, the bone bed beyond the suture point to the outer edge of the greater tubercle is opened with 2.0mm Kirschner wire every 5mm ( Crimson duvet), 1cm in depth, about 6 in total.
62412635|NCT00816166|EXPERIMENTAL|Stent Group|"Medical therapy + PHAROS Vitesse neurovascular stent (Stent Group)"
62412636|NCT00816166|ACTIVE_COMPARATOR|Medical Therapy Group|"Medical therapy alone (Medical Therapy Group)"
62412637|NCT00755573|ACTIVE_COMPARATOR|Pregabalin|Pregabalin 300 mg - 600 mg BID
62412638|NCT00755573|PLACEBO_COMPARATOR|Placebo|Placebo arm
62412639|NCT03958877|EXPERIMENTAL|BIIB017 (peginterferon beta-1a)|Participants will receive subcutaneous (SC) injection of BIIB017 (peginterferon beta-1a) 63 microgram (μg) on Day 1, followed by 94 μg at Week 2, followed by 125 μg at Week 4, and then 125 μg SC injection every 2 weeks up to Week 96 in Part 1 of the study. Eligible participants who enter optional Part 2 of the study will receive 125 μg SC injections of BIIB017 every 2 weeks for 96 Weeks.
62412640|NCT03958877|ACTIVE_COMPARATOR|Avonex|Participants will receive Avonex (interferon beta type 1a) starting at a dose of 7.5 μg on Day 1, followed by an increase of 7.5 μg each week for 3 weeks, followed by 30 μg intramuscular (IM) injections every week up to Week 96 in Part 1 of the study. Eligible participants who enter optional Part 2 of the study will receive 125 μg SC injections of BIIB017 every 2 weeks for 96 Weeks.
62412641|NCT01939470||Native American Women|Native American Women over the age of 50 yrs
62412642|NCT01761617|ACTIVE_COMPARATOR|Yoga Class Twice Per Week|Participants attend two hatha yoga classes each week for 12 weeks.
62412643|NCT01761617|ACTIVE_COMPARATOR|Yoga Class Once per Week|Participants attend one hatha yoga class each week for 12 weeks.
62412644|NCT04268394|EXPERIMENTAL|Part 1: CC-99677 with Methotrexate and Sulfasalazine|Fixed-sequence involving CC-99677 + Methotrexate 7.5 mg and sulfasalazine 1000 mg
62412645|NCT04268394|EXPERIMENTAL|Part 2: CC-99677 with Itraconazole and Rifampin|Fixed-sequence involving CC-99677 + Rifampin 600 mg and Itraconazole 200 mg
62412646|NCT04268394|EXPERIMENTAL|Part 3: CC-99677, Midazolam, Digoxin, Metformin, Rosuvastatin|Fixed-sequence involving CC-99677 + Midazolam 2 mg, Digoxin 0.25 mg, Metformin 500 mg, and Rosuvastatin 10 mg.
62412647|NCT06576752|EXPERIMENTAL|Home care|Follow-up and management of HF medications at home visits after 1, 2, 3 and 6 weeks performed by telecommunication led by HF nurses in close communication with physician at the institution. Around week 2 a single visit to the primary care physician's office is required.
62412648|NCT06576752|ACTIVE_COMPARATOR|Hospital care|Follow-up and management of HF medications provided by specialists at the participating institutions' outpatient clinics after 1, 2, 3 and 6 weeks. (Same as the high-intensity arm in STRONG-HF)
62412649|NCT06402890|EXPERIMENTAL|Resistance training with hydrolyzed collagen in health, active, middle-aged men|Middle-aged, trained males completed 12-weeks of a supervised, progressive resistance training programme while consuming 30 g of hydrolyzed collagen or a calorie matched placebo beverage.
62412650|NCT06402890|EXPERIMENTAL|Resistance training with hydrolyzed collagen in healthy, active, middle-aged women|Middle-aged, trained females completed 8-weeks of a supervised, progressive resistance training programme while consuming 30 g of hydrolyzed collagen or a calorie matched placebo beverage
62412651|NCT04071457|NO_INTERVENTION|Study Entry / Screening|Study entry/screening to follow patient until Maintenance.
62412652|NCT04071457|ACTIVE_COMPARATOR|Arm 1: Lenalidomide|Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 2 years from starting treatment.
62412653|NCT04071457|EXPERIMENTAL|Arm 2: Lenalidomide + Daratumumab/rHuPH20|Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 2 years from starting treatment. Plus Daratumumab/rHuPH20 1800 mg/30,000 units D1, 8, 15, 22 q 28 days for 2 cycles, then D 1 and 15 q 28 days for cycles 3-6 then D1 q 28 days for subsequent cycles for up to 2 years from starting treatment.
62412654|NCT04071457|ACTIVE_COMPARATOR|Arm 1a: Continue Lenalidomide|MRD+ or MRD- and randomized to Arm 1a: Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 7 years from starting treatment.
62412655|NCT04071457|NO_INTERVENTION|Arm 1b: Stop Lenalidomide|MRD- and randomized to Arm 1b: Discontinue protocol therapy.
62412656|NCT04071457|ACTIVE_COMPARATOR|Arm 2a: Continue Lenalidomide + Daratumumab/rHuPH20|MRD+ or MRD- and randomized to Arm 2a: Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 7 years from starting treatment. Plus Daratumumab/rHuPH20 1800 mg/30,000 units D1, 8, 15, 22 q 28 days for 2 cycles, then D 1 and 15 q 28 days for cycles 3-6 then D1 q 28 days for subsequent cycles for up to 7 years from starting treatment.
62412657|NCT04071457|NO_INTERVENTION|Arm 2b: Stop Lenalidomide + Daratumumab/rHuPH20|MRD- and randomized to Arm 2b: Discontinue protocol therapy.
62218621|NCT02762149|ACTIVE_COMPARATOR|1ms pulse width|The nerve stimulator will be connected to the epidural catheter through an adapter, which will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle. All patients will have the trans-catheter electric stimulation test (TCEST) performed with both a 1 ms pulse width and 0.1 ms pulse width and the order of administration will be randomized.
62218622|NCT04678999|EXPERIMENTAL|Tai Chi|The intervention will delivered via a secure Zoom video platform. One of two Tai Chi instructors will teach each of the classes. Tai Chi instructors will be selected prior to study start on the basis of familiarity with our previous Tai Chi protocols and experience working with OA patients.
62412658|NCT02766686|EXPERIMENTAL|Radiotherapy with protons|Proton radiotherapy 74-80 Gray equivalent (GyE), 2Gy per fraction, 5 fractions peer week
62412659|NCT02766686|ACTIVE_COMPARATOR|Radiotherapy with photons|Photon-Intensity-Modulated Radiation Therapy (IMRT) without lymph drainage vessels, 74-80 Gy, 2Gray (Gy) per fraction, 5 fractions peer week
62412660|NCT02766686|OTHER|Radiotherapy with photons with lymph drainage vessels|Photon-IMRT with lymph drainage vessels, 74-80 Gy, 2Gy per fraction, 5 fractions peer week
62412661|NCT05393765|EXPERIMENTAL|experimental|"Experimental: Intervention group Yönetebilirim Before the initiation of the program, patients who visit the outpatient clinic will be evaluated according to the inclusion-exclusion criteria, their consent will be obtained, and pre-tests will be administered. Then, randomization will be performed and participants will be assigned to the experimental and control groups. Participants in the experimental group will be registered on the web-based program. The individuals in the experimental group will use Yönetebilirim for 8 weeks as of the time the program is put into use. Yönetebilirim consists of modules and consultancy services. Participants will be able to watch informative videos as much as they want for 8 weeks and receive consultancy service if they wish."
62218623|NCT04678999|EXPERIMENTAL|Wellness Education|At each session, a variety of health professionals will provide a didactic lesson on a topic relating to knee OA. An informational brochure on knee OA education is presented to all participants during the first session. Each session will last 60 minutes including a 10-minute instructor-led program of stretching or flexibility exercises via a zoom platform.
62218624|NCT02407301||Laryngeal function in cough|cough airflow measure, vocal tasks, true vocal fold movement, spirometry test, and maximum expiratory pressure (MEP) assessment will be performed in this group.
62218625|NCT03073954|ACTIVE_COMPARATOR|Working memory training|Working memory training that increases with difficulty if participants answer two subsequent questions correctly, and standardised healthy lifestyle coaching.
62794464|NCT03760523|EXPERIMENTAL|Minnelide Dose Escalation|A 3+3 design will be used. The first 3 patients will be treated at dose level 1. If none experience a Dose Limiting Toxicity (DLT), the next 3 patients will be treated at dose level 2. If a DLT is observed in 1 out of 3 patients at dose level 1, up to an 3 more patients will be enrolled and treated at that dose level. If 2 patients at dose level have DLTs, dosing will be lowered to dose level -1 (.5 mg daily, taken orally). If 2 or more of the up to 6 patients at any dose level have DLTs, the preceding dose will be declared the Maximum Tolerated Dose (MTD). If more than 1 DLT occurs at Dose Level -1, the investigators will consider stopping the study. Once the MTD has been established, an additional 10 patients will be enrolled at this level to better characterize safety and tolerability.
62218626|NCT03073954|SHAM_COMPARATOR|Sham working memory training|Working memory training that does not increase in difficulty, and standardised healthy lifestyle coaching.
62218627|NCT04493502|EXPERIMENTAL|LY3041658|Participants received 600 mg LY3041658 administered intravenously (IV) once every 2 weeks (Q2W).
62218628|NCT04493502|PLACEBO_COMPARATOR|Placebo|Placebo administered IV. Participants will switch to 600 mg LY3041658 administered IV after week 16.
62218629|NCT01008319|ACTIVE_COMPARATOR|Traditional Administration|The traditional approach to ovulation induction with clomiphene citrate involves administration of 50mg/day for five days (starting on cycle day 3, 4, or 5). If ovulation does not occur then a progestin is prescribed to induce menses (which occurs within one week of stopping the progestin) and then a higher dose of medication is used in the next cycle.
62218630|NCT01008319|EXPERIMENTAL|Stair-Step Administration|The stair-step protocol the dose of clomiphene citrate would be increased without administering progestin and inducing a period. This would eliminate the days of progestin (10 days) and the waiting for the period (usually 3 to 7 days) and finally waiting to start clomiphene citrate on cycle day 3 at the earliest (3 more days) for a total of up to 20 days difference for the 100 mg dose of clomid. If they did not ovulate on 100mg, then the process repeats and another 20 days before they start 150mg. Therefore, the time to ovulation and pregnancy may be reduced, and hopefully pregnancy, by using the stair-step protocol. This method utilizes ultrasound monitoring for follicle development before increasing the dose of clomiphene citrate.
62218631|NCT02876159|EXPERIMENTAL|Vaccination Naïve|Participants who have received an influenza vaccine in 2 or less of the past 5 years will receive the FDA-approved 2016-2017 influenza vaccine.
62218632|NCT02876159|EXPERIMENTAL|Vaccination Experienced|Participants who have received an influenza vaccine at least 3 of the past 5 years will receive the FDA-approved 2016-2017 influenza vaccine.
62243320|NCT02131909|PLACEBO_COMPARATOR|bimanual rehabilitation exercises|5 sessions control therapy 15 minutes per week for 5 weeks
62412662|NCT05393765|NO_INTERVENTION|Control|The control group will receive standard care without any intervention. The group will not receive any other intervention.
62412663|NCT03980561|EXPERIMENTAL|Varenicline|2 mg daily
62412664|NCT03980561|PLACEBO_COMPARATOR|Placebo|2 mg daily
62412665|NCT06649864|EXPERIMENTAL|Liver Transplant|Subjects with liver disease with planned living donor liver transplantation
62022492|NCT01034124|ACTIVE_COMPARATOR|Cranberry juice|
62794465|NCT06499285|EXPERIMENTAL|Experimental: KER-050 (N=150)|KER-050 will be administered subcutaneously every 4 weeks. The Primary Phase of the Double-Blind Treatment Period will last 24 weeks. Based on the outcome of the MDS Disease Assessment approximately 24 calendar weeks after Cycle 1 Day 1, participants will either continue in the Secondary Phase or be discontinued from treatment. During the Secondary Phase of the Double-Blind Treatment Period, all participants will continue to receive the same double-blind treatment they received during the Primary Phase, which will last 24 weeks. The second MDS Disease Assessment should be completed approximately 48 calendar weeks after C1D1 to determine whether the participant will enter the Extension Phase or be discontinued from treatment. During the Extension Phase of the Double-Blind Treatment Period, all participants will continue to receive the same double-blind treatment that they received during the Primary and Secondary Phases.
62794466|NCT06499285|PLACEBO_COMPARATOR|Placebo Comparator (N=70)|Placebo will be administered subcutaneously every 4 weeks. The Primary Phase of the Double-Blind Treatment Period will last 24 weeks. Based on the outcome of the MDS Disease Assessment approximately 24 calendar weeks after Cycle 1 Day 1, participants will either continue in the Secondary Phase or be discontinued from treatment. During the Secondary Phase of the Double-Blind Treatment Period, all participants will continue to receive the same double-blind treatment they received during the Primary Phase, which will last 24 weeks. The second MDS Disease Assessment should be completed approximately 48 calendar weeks after C1D1 to determine whether the participant will enter the Extension Phase or be discontinued from treatment. During the Extension Phase of the Double-Blind Treatment Period, all participants will continue to receive the same double-blind treatment that they received during the Primary and Secondary Phases.
62218633|NCT00510640|EXPERIMENTAL|Sunitinib|Sunitinib will be administered orally daily for 4 weeks followed by a 2-week rest; the daily starting dose will be 50 mg with a provision for dose reduction based on tolerability. All patients will receive repeated cycles until disease progression or occurrence of severe toxicity.
62794467|NCT02531893||Irritable youth|Participants meet full DMDD criteria for IBT and either full DMDD or one of two core DMDD criteria for CBT.
62794468|NCT00214539|EXPERIMENTAL|Treatment|Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
62794469|NCT00214539|ACTIVE_COMPARATOR|Control|Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
62794470|NCT02497729|NO_INTERVENTION|Sniffing Position, No Checklist|Patient in the sniffing position without the use of a written checklist
62218634|NCT05697952|EXPERIMENTAL|E1K 1,200 ㎍/joint|Injected 1,200 ㎍/joint/3 mL on target lesion
62412666|NCT05286931|EXPERIMENTAL|N. gonorrhea (gyrA wildtype) -Ciprofloxacin Treatment Arm|Participants who are N. gonorrhea (NG) positive and gyrA WT, will receive ciprofloxacin 500 mg PO x 1.
62022493|NCT03344991|ACTIVE_COMPARATOR|Cardboard Cot Care|Stable infant will be transferred to cardboard cot, lined with reflective film for duration of hospital stay following weaning from radiant warmer. Infant's axillary temperature will be taken at 1 hour, 6 hours, 24 hours after being placed in the cot or crib, and then once every 24 hours until discharge.
62022494|NCT03344991|PLACEBO_COMPARATOR|Open Crib|Stable infant will be transferred to standard of care open crib for duration of hospital stay following weaning from radiant warmer. Infant's axillary temperature will be taken at 1 hour, 6 hours, 24 hours after being placed in the cot or crib, and then once every 24 hours until discharge.
62022495|NCT04912505|EXPERIMENTAL|Single arm|Sequential variations of daily aspirin intake time
62218635|NCT05697952|EXPERIMENTAL|E1K 2,400 ㎍/joint|Injected 2,400 ㎍/joint/3 mL on target lesion
62218636|NCT05697952|PLACEBO_COMPARATOR|Placebo|Injected 3ml of saline on target lesion
62243321|NCT06735846|EXPERIMENTAL|Demax Guide Wire|The objectives of this study are to confirm the safety and performance of the Guide Wire when used in patients with peripheral vasculature or coronary vasculature disease.
62243322|NCT05274802|EXPERIMENTAL|Part A1 (Single dose): Cohort A: ALS-4 25mg|Single dose of ALS-4 or placebo before Breakfast
62243323|NCT05274802|EXPERIMENTAL|Part A1 (Single dose): Cohort B: ALS-4 50mg|Single dose of ALS-4 or placebo before Breakfast
62243324|NCT05274802|EXPERIMENTAL|Part A1 (Single dose): Cohort C: ALS-4 100mg|Single dose of ALS-4 or placebo before Breakfast
62243325|NCT05274802|EXPERIMENTAL|Part A1 (Single dose): Cohort D: ALS-4 200mg|Single dose of ALS-4 or placebo before Breakfast
62243326|NCT05274802|EXPERIMENTAL|Part A1 (Single dose): Cohort E: ALS-4 300mg|Single dose of ALS-4 or placebo before Breakfast
62022496|NCT04155931||body temperature measurement|The investigators planned to perform prospectively in 80 children with ASA I according to the American Society of Anesthesia (ASA) Anesthesia Risk Scale between 6 months and 7 years of age in both sexes who underwent inguinal hernia, undescended testes and hydrocele surgery
62412667|NCT03763539|ACTIVE_COMPARATOR|Ultraslow shock wave lithotripsy (SWL)|"SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes.~The rest of the session at 22kv (full power)."
62412668|NCT03763539|ACTIVE_COMPARATOR|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
62412669|NCT06651203||Patients with clinical features consistent with erythrodermic cutaneous T cell lymphoma (CTCL)|at initial diagnosis assessment
62412670|NCT06651203||Patients previously diagnosed with Sézary syndrome (SS) and followed at Saint-Louis hospital|
62412671|NCT00661960|NO_INTERVENTION|1|HIV Negative volunteers
62412672|NCT00661960|ACTIVE_COMPARATOR|2|HIV-Positive volunteers taking raltegravir in combination with two other nucleoside reverse transcriptase inhibitors (NRTI) medications
62412673|NCT00661960|ACTIVE_COMPARATOR|3|HIV-Positive volunteers taking efavirenz or any other non-nucleoside reverse transcriptase inhibitors (NNRTI) in combination with two other nucleoside reverse transcriptase inhibitor (NRTI) medications
62412674|NCT06163209||Suspected nasal fracture|Patients with a history of recent nasal trauma.
62412675|NCT06650683|EXPERIMENTAL|With Hospitalisation at Home (HAH)|families living in Marseille, whose parents will be able to return home under the supervision of nursery nurses from the pediatric HAH.
62412676|NCT06650683|NO_INTERVENTION|Without Hospitalisation at Home (HAH)|Families living outside Marseille whose parents will have to carry out nursings at home independently, without the help of pediatric HAH.
62412677|NCT02187939|ACTIVE_COMPARATOR|Summer wellness program - nutrition & physical activity|The GROOVE condition uses conventional means to address health-related activities and content within the context of a science museum summer enrichment program. The emphasis is on nutrition, physical activity, and healthy lifestyle.
62412678|NCT02187939|EXPERIMENTAL|Summer program plus virtual world technology|The GROOVE+ condition enhances the conventional approach to address health-related activities and content within the context of a science museum summer enrichment program by employing technology and a 3-D virtual world as a key educational strategy. The emphasis is on nutrition, physical activity, and healthy lifestyle.
62794471|NCT02497729|ACTIVE_COMPARATOR|Sniffing Position, Checklist|Patient in the sniffing position with the use of a written checklist
62243327|NCT05274802|EXPERIMENTAL|Part A2 (Single dose): Cohort F: ALS-4 50mg|Dose three separate times in crossover fashion: (1) fasted morning dose; (2) fed morning dose; (3) fasted evening dose
62243328|NCT05274802|EXPERIMENTAL|Part B (Multiple dose): Cohort AA: ALS-4 50mg|Multiple dose of ALS-4 or placebo up to two times daily
62243329|NCT05274802|EXPERIMENTAL|Part B (Multiple dose): Cohort BB: ALS-4 100mg|Multiple dose of ALS-4 or placebo up to two times daily
62243330|NCT05274802|EXPERIMENTAL|Part B (Multiple dose): Cohort CC: ALS-4 200mg|Multiple dose of ALS-4 or placebo up to two times daily
62243331|NCT00730431|EXPERIMENTAL|IDX184 5 mg|Healthy participants will be administered a single 5 mg dose of IDX184.
62243332|NCT00730431|EXPERIMENTAL|IDX184 10 mg|Healthy participants will be administered a single 10 mg dose of IDX184.
62243333|NCT00730431|EXPERIMENTAL|IDX184 25 mg|Healthy participants will be administered a single 25 mg dose of IDX184.
62243334|NCT00730431|EXPERIMENTAL|IDX184 50 mg|Healthy participants will be administered a single 50 mg dose of IDX184.
62243335|NCT00730431|EXPERIMENTAL|IDX184 75 mg|Healthy participants will be administered a single 75 mg dose of IDX184.
62243336|NCT00730431|EXPERIMENTAL|IDX184 100 mg|Healthy participants will be administered a single 100 mg dose of IDX184.
62243337|NCT00730431|PLACEBO_COMPARATOR|Placebo|Healthy participants will be administered placebo matching IDX184.
62243338|NCT05943535|PLACEBO_COMPARATOR|Placebo|Matching placebo inhaled using an ultrasonic nebulizer QID
62243339|NCT05943535|EXPERIMENTAL|Inhaled Treprostinil|Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.
62243340|NCT05905393|EXPERIMENTAL|preoperative stimulation of the efferent loop with GABA before ileostomy closure surgery|Preoperative stimulation of the distal limb of the ileostomy loop with GABA was performed during the 5 days prior to surgery every day. During the process and after it, the patient himself registers the appearance of symptoms after each stimulation session: abdominal pain, emission of gas and stool. Sterile Foley catheter No.14 Ch connected to an infusion set was introduced through the defunctioned bowel to allow the slow infusion, for 10-20 minutes, of a solution with 3000 mg of GABA diluted in 100 ml of 0.9% physiological saline. Each preparation was made under sterile conditions and maintaining the cold chain.
62243341|NCT05905393|SHAM_COMPARATOR|control group was stimulated without giving any substance|"Control group was stimulated without giving any substance. During the process and after it, the patient himself registers the appearance of symptoms after each stimulation session: abdominal pain, emission of gas and stool.~After 5 stimulation sessions, reconstructive surgery was performed within the following 24 h."
62243342|NCT00785824||1 A-A Breastfeeding Mothers|Group 1: Postpartum African-American breastfeeding women at 6-8 weeks post childbirth, and again at 12-14 weeks post childbirth
62243343|NCT00785824||2 - AA Bottlefeeding Mothers|Group 2: Postpartum African-American bottlefeeding women at 6-8 weeks post childbirth and again at 12-14 weeks post childbirth.
62412679|NCT05427214|EXPERIMENTAL|Halcyon 4.0 imaging|Patients planning to receive radiation therapy to the head and neck/brain, thorax, abdomen, or pelvis will undergo imaging on the Halcyon 4.0 system. Patients will return for a minimum of 2 sessions over 9 weeks, with a cumulative total of 10 images being collected.
62022497|NCT04706234||Multiple System Atrophy|Patients diagnosed will probable or possible MSA according to the 2nd criteria for the diagnosis of MSA (Gilman 2008) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).
62022498|NCT04706234||progressive supranuclear palsy|Patients diagnosed will probable or possible Progressive Supranuclear Palsy or (PSP) related 4repeat tauopathies according to the Movement Disorders Society diagnostic criteria (Höglinger 2017) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).
62022499|NCT04706234||Parkinson Disease|Patients diagnosed will Parkinson's disease according to the Movement Disorders Society diagnostic criteria (Postuma 2015) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).
62022500|NCT05372601|EXPERIMENTAL|Relax+|Relax+ consists of a powder containing a blend of two prebiotics.
62022501|NCT05372601|PLACEBO_COMPARATOR|Placebo|The placebo contains maltodextrin.
62022502|NCT02707055|EXPERIMENTAL|PF-05190457, then placebo|Participants with alcohol use disorder received PF-05190457 100 mg twice a day for a maximum of 14 days followed by a minimum of 2-day washout period, then placebo twice a day for a maximum of 14 days.
62412680|NCT04650178||Observational (questionnaire, quality of life)|Patients complete an online questionnaire over 15 minutes about their experiences regarding the COVID-19 pandemic including testing, risks of exposure, whether people they know have acquired COVID-19, as well as questions on how the pandemic has impacted their quality of life.
62412681|NCT05652491||Control|Subjects who are not diagnosed with IBD
62412682|NCT05652491||IBD Patients|New onset, treatment-naive pediatric IBD patients
62412683|NCT04469868|EXPERIMENTAL|No opioids prescriptions at discharge|Patients will receive non-opioid analgesia, mostly over the counter, medications such as acetaminophen or ibuprofen. Opioids may be prescribed if the patients experience break through pain and call the office.
62412684|NCT01187615|EXPERIMENTAL|Arm 1|
62794472|NCT02497729|ACTIVE_COMPARATOR|Head of Bed Up, No Checklist|Patient with the head of bed up and without the use of a checklist
62794473|NCT02497729|ACTIVE_COMPARATOR|Head of Bed Up, Checklist|Patient with the head of bed up and with the use of a checklist
62794474|NCT05408390|EXPERIMENTAL|Low physical and energy density|
62022503|NCT02707055|PLACEBO_COMPARATOR|Placebo, then PF-05190457|Participants with alcohol use disorder received placebo twice a day for a maximum of 14 days followed by a minimum of 2-day washout period then PF-05190457 100 mg twice a day for a maximum of 14 days.
62022504|NCT04056806|EXPERIMENTAL|Group A|receiving terlipressin 2mg bolus on enrollment followed by 1mg per 6 hours. Both Terlipressin infusion and Ceftriaxone continue till 48 hours after endoscopic therapy
62022505|NCT04056806|ACTIVE_COMPARATOR|Gruoup B|receiving terlipressin 2mg bolus instituted on enrollment followed by 1mg per 6 hours. Ceftriaxone 1gm intravenously dose of ceftriaxone 1gm at 24 h interval. Both Terlipressin infusion and Ceftriaxone continue till 5 days after endoscopic therapy.
62218637|NCT04147117|EXPERIMENTAL|Pessary Group|"A pessary certified is inserted through the vagina with the woman in recumbent position and is placed around the cervix.~Correct placement of the pessary is assessed by ultrasound. Patients on the pessary group are specially awarded about adverse symptoms and the need of immediate report in case of pain, bleeding and symptomatic contractions.~The pessary is not removed when symptoms of infection occur after pessary insertion, but appropriate treatment is given.~The pessary is removed at 37 weeks of pregnancy. Indications for pessary removal before 37 weeks are: active vaginal bleeding, premature labor not responding to tocolysis or severe patient discomfort."
62412685|NCT01187615|EXPERIMENTAL|Arm 2|
62794475|NCT05408390|EXPERIMENTAL|High physical and low energy density|
62794476|NCT05408390|EXPERIMENTAL|Low physical and high energy density|
62794477|NCT05408390|EXPERIMENTAL|High physical and energy density|
62794478|NCT04811846|ACTIVE_COMPARATOR|TURBT (Transurethral Resection of Bladder Tumor)|For patients undergoing bipolar transurethral resection, bladder tumor is resected in a piecemeal manner.
62794479|NCT04811846|ACTIVE_COMPARATOR|PKVB (Plasma Kinetic Vaporization of Bladder Tumor)|For patients undergoing bipolar plasma kinetic vaporization of bladder tumor, bladder tumor is vaporized.
62794480|NCT03712683|EXPERIMENTAL|Sub clinical hypothyroid women|"Levothyroxine sodium(Euthyrox 50µg and 25 µg MerckSerono) treatment was initiated and the women were followed in a combined clinic of endocrinologist and Gynecologist.~2.5 µg of Thyroxine daily was prescribed to women with TSH more than 2.5 mIU/L. Women with TSH more than 4mIU/L were given 50 µg daily . When pregnancy was confirmed Thyroxine was continued till 13 weeks gestation ."
62794481|NCT06196346|EXPERIMENTAL|Experimental: Main group|The group underwent 16 sessions of supportive-expressive psychotherapy (Luborsky et al., 1995)
62218638|NCT04147117|NO_INTERVENTION|Control group|Current management for the follow-up of these women in the PBPC.
62218639|NCT02415452||Acute Coronary Syndrome (ACS) patients|Acute coronary syndrome (ACS) patients who underwent coronary angiography ,drug-eluting stent (DES) implantation, and eye fundus examination.
62218640|NCT04364243|EXPERIMENTAL|Patients exercise|Low back pain patients Next to basic medical physical training therapy group A receive a home exercising programme which involves 10 exercises for 2 minutes each with the Valedo training system.
62586297|NCT06097923|EXPERIMENTAL|Conventional fluid management without BIA monitoring|"For assessment of fluid status, a commercial portable BIA device with 5-kilohertz, 50-kilohertz, and 250-kilohertz alternating current (InBody M20®, InBody Corp., Seoul, Korea) was measured. Baseline BIA data were collected at the time of ICU admission. Thereafter, BIA measurements were performed daily for 3 days for all participants.~The participants in conventional fluid management without BIA monitoring arm underwent conventional fluid management without specific targets of ECW ratio by BIA."
62794482|NCT06625905||Myofascial/musculoskeletal pain group (active myofascial trigger points)|This group comprises individuals who present with myofascial and/or musculoskeletal pain, with the presence of at least one myofascial trigger point (MTrP) classified as active. Active MTrPs are characterized by the following criteria: a palpable taut band within the muscle, a hypersensitive spot within the band, and the reproduction of the patient's pain upon palpation. The selection of participants for this group will focus on individuals exhibiting active MTrPs in gastrocnemius medialis muscle.
62794483|NCT06625905||Control group (participants without pain, latent or no myofascial trigger points)|The control group consists of individuals who do not present with any musculoskeletal pain or dysfunction. These participants may or may not exhibit latent MTrPs. Latent MTrPs are defined as palpable taut bands and hypersensitive spots within the muscle that do not reproduce the patient's pain but may cause discomfort when palpated. Participants in this group will be recruited based on their lack of musculoskeletal complaints.
62794484|NCT03692559|EXPERIMENTAL|full sterile dressing|Patients receive full sterile dressing
62794485|NCT03692559|NO_INTERVENTION|usual standard care|Patients receive usual standard care
62794486|NCT05024734|EXPERIMENTAL|Epirubicin|"Patients in that PDOs show highest response to this drug in-vitro will be treated with Epirubicin.~If no significant drug selection can be performed in-vitro, Epirubicin will be the default for instillation."
62218641|NCT04364243|NO_INTERVENTION|Patients control|Low back pain patients Group B will receive basic medical physical training therapy
62218642|NCT04364243|EXPERIMENTAL|Non-patients exercise|non-patients Groups C will receive a home exercising programme which involves 10 exercises for 2 minutes each with the Valedo training system.
62412686|NCT06257511|EXPERIMENTAL|Non Technical Skills for Cardiac Surgery (NOTSCS) intervention group|These are the members of the cardiac surgical teams who will be trained in the non-technical skills.
62218643|NCT04364243|NO_INTERVENTION|Non-patients control|non-patients Group D will receive no intervention
62218644|NCT01035073|EXPERIMENTAL|Duloxetine|
62218645|NCT01219868|EXPERIMENTAL|Physician-nurse team|
62218646|NCT03727555|EXPERIMENTAL|Lentivirus-mediated delivery of ABCD1 to the CNS.|Intracerebral injection with lentiviral TYF-ABCD1 vector carrying the functional gene
62218647|NCT05734898|EXPERIMENTAL|rrAML|
62218648|NCT02622009||COPD I|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE I
62218649|NCT02622009||COPD II|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE II
62218650|NCT02622009||COPD III|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE III
62218651|NCT02622009||NONSMOKERS|BRONCHOSCOPIC PROCEDURE IN NONSMOKERS
62218652|NCT02622009||CURRENT OR EXSMOKERS|BRONCHOSCOPIC PROCEDURE IN CURRENT OR EXSMOKERS
62218653|NCT02140281|EXPERIMENTAL|Sequence 1 (Treatment A/B)|Subjects will be randomised to receive Treatment A in Period 1 followed by Treatment B in period 2
62586298|NCT06682208|ACTIVE_COMPARATOR|ES Catheter|Hospital procedure for ES catheters will be followed for postoperative pain.
62794487|NCT05024734|EXPERIMENTAL|Mitomycin|Patients in that PDOs show highest response to this drug in-vitro will be treated with Mitomycin.
62794488|NCT05024734|EXPERIMENTAL|Gemcitabine|Patients in that PDOs show highest response to this drug in-vitro will be treated with Gemcitabine.
62794489|NCT05024734|EXPERIMENTAL|Docetaxel|Patients in that PDOs show highest response to this drug in-vitro will be treated with Docetaxel.
62218654|NCT02140281|EXPERIMENTAL|Sequence 2 (Treatment B/A)|Subjects will be randomised to receive Treatment B in Period 1 followed by Treatment A in period 2
62218655|NCT03867032|EXPERIMENTAL|Cochlear implant users|The group will receive auditory training (psychophysical), and will be evaluated for speech recognition to determine the effect of training.
62218656|NCT02984202|EXPERIMENTAL|Safety/Efficacy|Patients will be implanted with the AMI and evaluated for safety and efficacy over a 2-year period. The placement of the AMI array into the inferior colliculus will also be evaluated.
62218657|NCT00542243|ACTIVE_COMPARATOR|Finasteride|"The recommended dosage of PROSCAR© is one 5 mg tablet daily with or without food. If a tablet is missed at its usual time, an extra dose should not be taken. The next dose should be taken as usual.~PROSCAR© 5 mg tablets are blue, apple-shaped; film coated with the code MSD 72 on one side and PROSCAR on the other. They will be provided in bottles of 35 tablets."
62218658|NCT00542243|PLACEBO_COMPARATOR|Placebo|Patient will receive a placebo comparator each day for 6 months.
62218659|NCT00688103|ACTIVE_COMPARATOR|ETN Alone|etanercept (25mg, twice/week, s.c.)
62218660|NCT00688103|ACTIVE_COMPARATOR|ETN+MTX|etanercept (25mg, twice/week, s.c.) combined with methotrexate (6-8mg/week)
62218661|NCT04271631|NO_INTERVENTION|Control|Received conventional education group
62218662|NCT04271631|EXPERIMENTAL|Intervention 1|Received conventional education group and Mobile Application-Based Diabetes Education
62218663|NCT04271631|EXPERIMENTAL|Intervention 2|Received Mobile Application-Based Diabetes Education and Health Coaching
62218664|NCT05712707|EXPERIMENTAL|BXCL501 (180 micrograms)|The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.
62218665|NCT05712707|EXPERIMENTAL|BXCL501 (240 micrograms)|The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.
62412687|NCT06257511|NO_INTERVENTION|Control group|These are members of the cardiac surgical teams who will not participate in the intervention.
62412688|NCT03252015|EXPERIMENTAL|Probe Drug Cocktail (Cohort 1a)|Probe Drug Cocktail administered orally on Day -3.
62412689|NCT03252015|EXPERIMENTAL|200 milligrams (mg) Lasmiditan+Probe Drug Cocktail (Cohort 1)|200 mg lasmiditan administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7.
62794490|NCT04269213|EXPERIMENTAL|Treatment (CPX-351)|"INDUCTION: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity.~RE-INDUCTION: Patients who do not achieve remission receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Beginning 5-8 weeks after the start of the last induction, patients who achieve CR receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 45 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity."
62218666|NCT05712707|ACTIVE_COMPARATOR|Lofexidine (Positive Control)|The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.
62218667|NCT05712707|PLACEBO_COMPARATOR|Placebo|The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.
62218668|NCT05502367|EXPERIMENTAL|Cohort A1: Single and multiple doses of ABI-2280|
62218669|NCT05502367|EXPERIMENTAL|Cohort A2: Multiple doses of ABI-2280|
62218670|NCT05502367|EXPERIMENTAL|Cohort A3: Multiple doses of ABI-2280|
62218671|NCT05502367|EXPERIMENTAL|Cohort A4: Multiple doses of ABI-2280|
62218672|NCT05502367|EXPERIMENTAL|Cohort A5: Multiple doses of ABI-2280|
62218673|NCT05502367|EXPERIMENTAL|Cohort A6: Multiple doses of ABI-2280|
62218674|NCT05502367|EXPERIMENTAL|Cohort A7: Multiple doses of ABI-2280|
62218675|NCT05502367|EXPERIMENTAL|Cohort A8: Intermittent multiple doses of ABI-2280|
62218676|NCT05502367|EXPERIMENTAL|Cohort A9: Multiple doses of ABI-2280|
62218677|NCT04447664|EXPERIMENTAL|Telemedicine arm|
62218678|NCT04447664|NO_INTERVENTION|Control arm|
62218679|NCT02814084|ACTIVE_COMPARATOR|Bilateral Internal Mammary Artery grafts|Standard care wound dressings used as part of coronary artery bypass graft operation
62412690|NCT03252015|PLACEBO_COMPARATOR|Placebo+Probe Drug Cocktail (Cohort 1b)|Placebo administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7.
62794491|NCT05179239|EXPERIMENTAL|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102|
62794492|NCT05179239|EXPERIMENTAL|SHR-1701 + paclitaxel + cisplatin/carboplatin ± BP102|
62218680|NCT02814084|EXPERIMENTAL|Prevena|Prevena dressing used as part of coronary artery bypass graft operation.
62218681|NCT04783831||Biodegradable stent|
62218682|NCT04783831||Non-biodegradable stent|
62218683|NCT04062487|EXPERIMENTAL|Lumbar pedicle screws implantation of traditional procedure|traditional method of lumbar pedicle screws implantation
62218684|NCT01191502||TECNIS MULTIFOCAL (TMF) INTRAOCULAR LENS|
62218685|NCT01191502||CRYSTALENS HD (CHD) INTRAOCULAR LENS|
62218686|NCT05803655|ACTIVE_COMPARATOR|36-Hour Group|"The women randomized to this group will undergo oocyte pick-up procedure 36 hours after the injection of the ovulation triggering agent.~The choice for ovulation trigger agent is at the discretion of the treating physician. The intervention is not the drug but the interval."
62412691|NCT03252015|EXPERIMENTAL|400 mg Lasmiditan (Cohort 2a)|400 mg lasmiditan administered orally for 7 days.
62794493|NCT05179239|PLACEBO_COMPARATOR|Placebo + paclitaxel + cisplatin/carboplatin ± BP102|
62794494|NCT00785980|ACTIVE_COMPARATOR|Quinine Sulfate|Baseline quinine sulfate pharmacokinetics
62794495|NCT00785980|EXPERIMENTAL|Quinine Sulfate with Ciprofloxacin|Quinine sulfate pharmacokinetics in the presence of steady state ciprofloxacin
62794496|NCT00307905|ACTIVE_COMPARATOR|A|TRAUMEEL S
62022506|NCT06532487|EXPERIMENTAL|Critical Time Medical-Legal Partnership Intervention|Patients receiving care at an intervention health center will (a) be screened for health-harming legal needs. Those who meet eligibility criteria will be offered the opportunity to meet with a lawyer to review and explain their legal risks, rights, and remedies, (b) will be provided direct legal representation to mitigate or eliminate those legal needs, and (c) will consent to tracking of legal case management activity and outcomes and health outcomes in ways that accord with patient autonomy/consent, study expectation.
62022507|NCT06532487|NO_INTERVENTION|Control|"Patients receiving care at a health center in the control arm of the study in the control or no intervention arm of the study will (a) be screened for health-harming legal needs. Those who meet eligibility criteria will (b) be provided basic legal information and referral to legal aid, and (c) will consent to tracking of legal and health outcomes in ways that accord with patient autonomy/consent, study expectation."
62022508|NCT04602624|EXPERIMENTAL|SAGE-718|Participants received SAGE-718 3 mg oral tablets, once daily in the morning for 14 days.
62022509|NCT02578394|ACTIVE_COMPARATOR|Group A|Anakinra 100mg and Placebo Depo-Medrone
62022510|NCT02578394|ACTIVE_COMPARATOR|Group B|Depo-Medrone 120mg and Placebo (Anakinra)
62022511|NCT00353704|ACTIVE_COMPARATOR|Pregabalin|150 mg Pregabalin per orally about one hour before surgery
62022512|NCT00353704|PLACEBO_COMPARATOR|Placebo|One capsule of saccharose (placebo) was administered orally about one hour before surgery.
62022513|NCT01022814||Pregnant woman|
62022514|NCT01641887||GERD patients|Patients who have GERD will be recruited for this study.
62022515|NCT05907369|EXPERIMENTAL|aEC/ stDCS|Participants in this group receive active EC training but sham tDCS.
62022516|NCT05907369|ACTIVE_COMPARATOR|sEC/atDCS|Participants in this group receive active tDCS training but sham EC training.
62022517|NCT05907369|EXPERIMENTAL|aEC/atDCS|Participants in this group receive both active EC training and active tDCS.
62218687|NCT05803655|EXPERIMENTAL|38-Hour Group|"The women randomized to this group will undergo oocyte pick-up procedure 38 hours after the injection of the ovulation triggering agent.~The choice for ovulation trigger agent is at the discretion of the treating physician. The intervention is not the drug but the interval."
62218688|NCT04767139||pre-intervention group|mothers included for the pre-intervention assessment of contraceptive prevalence rate in the selected health centers
62218689|NCT04767139||post intervention group|mothers included for the post-intervention assessment of contraceptive prevalence rate in the selected health centers
62218690|NCT06088147|ACTIVE_COMPARATOR|Group 1= Methotrexate|After microneedling, we will apply methotrexate topically (25 mg/ml) on half of the scalp at a dose of 0.02ml/cm2 with a maximum of 0.1-0.2 ml (2,5-5 mg) and rub it gently. The patient will take a session every 2 weeks for 12 weeks, on the same patient on the other patch or half of the scalp according to the pattern.
62218691|NCT06088147|EXPERIMENTAL|Group2=Triamcinilone|we will use Triamcinolone acetonide 40 mg/1ml after microneedking at dose 5mg/ml concentration;1/8/ 1:7 dilution session every 3 weeks for 12 weeks. then after 12 weeks of treatment we will follow up our patients after discontinuing therapy for other 12 weeks and evaluate.
62218692|NCT05607537|EXPERIMENTAL|Part 1: E7386 40 mg Tablet + (14C)E7386|Participants will be administered a single oral dose of E7386 40 mg tablet on Day 1 followed by an intravenous infusion containing a microdose solution of \[14C\]E7386 (100 mcg) with not more than (NMT) 7.4 kilobecquerel (kBq) (0.20 microcurie \[mcCi\]), starting approximately 25 minutes post oral dose administered as 5 milliliter (mL) over 5 minutes to coincide with the time at which the highest drug concentration occurs (tmax) for E7386 after an oral dose.
62218693|NCT05607537|EXPERIMENTAL|Part 2: (14C)E7386 40 mg Capsule|Participants will be administered a single oral dose of E7386 40 mg capsule radiolabeled with approximately 2.96 megabecquerel (MBq) (80 mcCi) (14C)E7386 (final dose to depend on the specific activity of \[14C\]E7386) in the morning on Day 1 after an overnight fasting.
62218694|NCT00555724|EXPERIMENTAL|BIIB022|
62218695|NCT05514041|EXPERIMENTAL|OC-01 (varenicline solution) nasal spray 0.03 mg|Subjects will be randomized 1:1 to be treated with the agent delivered as a 0.05 mL intranasal spray in each nostril at the following formulations
62412692|NCT03252015|EXPERIMENTAL|Placebo (Cohort 2b)|Placebo administered orally for 7 days.
62412693|NCT03465982|ACTIVE_COMPARATOR|Standard Interval Time Arm|Minimally invasive surgery after 8 weeks from chemoradiation treatment
62794497|NCT00307905|PLACEBO_COMPARATOR|B|placebo remedy
62794498|NCT06727409|EXPERIMENTAL|Finerenone on top of maximal tolerated RASi and stable SGLT2i therapy|pre and post Finerenone treatment evaluation
62022518|NCT05907369|SHAM_COMPARATOR|sEC/stDCS|Participants in this group receive the sham EC training and also sham tDCS.
62022519|NCT01468402||Magnetic Resonanse Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroid, and their location in the myometrium was classified. Perfusion and the characterization of the T2 signal were also evaluated.
62022520|NCT05219318|EXPERIMENTAL|Treatment pause|Treatment pause for 12 months
62022521|NCT05219318|ACTIVE_COMPARATOR|Treatment continuation|Treatment continuation regimens with PD-1/PD-L1 ICI + VEGFR-TKI until disease progression or unacceptable toxicity
62022522|NCT03257982|EXPERIMENTAL|BCI-FES hand therapy|BCI-FES hand therapy sessions (set up and use of system)
62022523|NCT03125668|EXPERIMENTAL|Intervention Group|At the hospitalization, patients receive the educational program (Power Point®Slides, booklets and orientation) about the use of warfarin. After hospital discharge they receive a telephone follow-up (five calls) and two Face to face counseling.
62218696|NCT05514041|PLACEBO_COMPARATOR|Placebo nasal spray (OC-01 Vehicle Nasal Spray)|Subjects will be randomized 1:1 to be treated with the agent delivered as a 0.05 mL intranasal spray in each nostril at the following formulations
62412694|NCT03465982|ACTIVE_COMPARATOR|Delayed Interval Time Arm|Minimally invasive surgery after 12 weeks from chemoradiation treatment
62412695|NCT05266131||OSA0HT0|without OSA or hypertension (OSA0HT0)
62412696|NCT05266131||OSA1HT0|OSA without hypertension (OSA1HT0)
62586299|NCT06682208|ACTIVE_COMPARATOR|Intercostal Nerve Cryoablation (INC)|Hospital procedure for intercostal nerve cryoablation will be followed for postoperative pain.
62586300|NCT04189939||subjects with treatment-resistant depression|approximately 48 subjects with treatment-resistant depression will undergo (1) clinical assessments, (2) perform a computer-based decision-making task while (3) their brain activity is monitored using a 3T MRI scanner.
62022524|NCT03125668|ACTIVE_COMPARATOR|Control Group|At the hospitalization, patients receive the educational program (Power Point®Slides, booklets and orientation) about the use of warfarin. After hospital discharge they receive two face to face counseling.
62022525|NCT02789787||Maxillary protraction|Early adolescents (11 - 14 yrs) with cleft lip and palate and Cl III malocclusion
62022526|NCT02789787||Orthognathic surgery|Late adolescents to young adults (16-21 years) with cleft lip and palate and Cl III malocclusion
62022527|NCT00214136|EXPERIMENTAL|1|prostate radiation to 70Gy, lymph nodes to 56Gy
62022528|NCT05409443|ACTIVE_COMPARATOR|Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA)|"N-SIJRFA - using a bipolar palisade technique to create a continuous strip lesion."
62022529|NCT05409443|ACTIVE_COMPARATOR|Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)|C-SIJRFA - using conventional monopolar periforaminal technique
62412697|NCT05266131||OSA0HT1|hypertension without OSA (OSA0HT1)
62412698|NCT05266131||OSA1HT1|with OSA and hypertension (OSA1HT1)
62412699|NCT00444873|EXPERIMENTAL|28 day dose interval|
62412700|NCT00444873|EXPERIMENTAL|42 day dose interval|
62412701|NCT00444873|EXPERIMENTAL|56 day dose interval|
62412702|NCT06282029|EXPERIMENTAL|Intervention arm|Group therapy
62586301|NCT04189939||healthy subjects|approximately 48 healthy subjects will undergo (1) clinical assessments, (2) perform a computer-based decision-making task while (3) their brain activity is monitored using a 3T MRI scanner.
62586302|NCT04189939||subjects with non treatment-resistant depression|approximately 48 subjects with non-treatment-resistant depression will undergo (1) clinical assessments, (2) perform a computer-based decision-making task while (3) their brain activity is monitored using a 3T MRI scanner.
62586303|NCT06512207|ACTIVE_COMPARATOR|Conventional Treatment Group|40 cases in this group to receive the standard conventional treatment (Chemotherapy + PD-1 Monoclonal Antibody)
62022530|NCT04634201|EXPERIMENTAL|Experimental group|
62022531|NCT04634201|SHAM_COMPARATOR|control group|
62022532|NCT00613951|EXPERIMENTAL|SIAC 30 (B)|
62022533|NCT00613951|EXPERIMENTAL|SIAC 45 (B)|
62022534|NCT00613951|ACTIVE_COMPARATOR|BIAsp 30|
62022535|NCT01542775|PLACEBO_COMPARATOR|Control|
62022536|NCT01542775|ACTIVE_COMPARATOR|Exercise|
62218697|NCT05513157||Chronic stroke patients with knee hyperextension|Chronic stroke patients with a maximum knee extension angle of less than 0 degrees in movement analysis
62218698|NCT05513157||Chronic stroke patients without knee hyperextension|Chronic stroke patients with a maximum knee extension angle greater than 0 degrees in movement analysis
62218699|NCT06440135|EXPERIMENTAL|Ziftomenib|"Participants will begin treatment 30 to 90 days after allo-HCT and only after disease remission is confirmed, and treatment will continue for up to 12 months. All participants will receive ziftomenib. Participants will undergo allo-HCT as a part of their standard care.~Participants will undergo the following procedures:~* Screening~* Allo-HCT (standard care), including pre and post-treatment as a part of standard care~* 30 - 90 days after allo-HCT, participants will take the study drug orally once per day for up to 12 28-day cycles~* End of treatment visit~* Follow-up data will be collected every 3 months for 24 months from the start of treatment"
62794499|NCT05463081|EXPERIMENTAL|Genitourinary disorder|"Participants with:~* stress urinary incontinence,~* mixed urinary incontinence with a predominance of the stress component,~* genitourinary menopausal syndrome,~* dystrophic and atrophic processes in the genital area,~* scleroatrophic changes in the urogenital region.~Laser treatment of the vagina, vulva, and paraurethral region with Magic Gyno laser. In total, three procedures will be performed with an interval of 4 weeks.~During the procedure, the following sequence of actions will be performed:~1. st Stage - vaginal processing with a conical mirror handpiece,~2. nd Stage - vaginal processing with a corner mirror handpiece,~3. d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece."
62218700|NCT03866473|EXPERIMENTAL|Photobiomodulation (PBM)|670nm wavelength device twice a day for 90 seconds through 4 months. At the 4-month visit, participants who have not already received alternative treatments for DME will return the original device and receive the alternative treatment group device (i.e. the sham group will receive an active treatment device and the active treatment group will receive a sham device).
62218701|NCT03866473|SHAM_COMPARATOR|Placebo|Broad spectrum light device twice a day for 90 seconds through 4 months. At the 4-month visit, participants who have not already received alternative treatments for DME will return the original device and receive the alternative treatment group device (i.e. the sham group will receive an active treatment device and the active treatment group will receive a sham device)
62218702|NCT01045343|ACTIVE_COMPARATOR|Control Arm|
62218703|NCT01045343|EXPERIMENTAL|Integrated Diagnostics Arm|
62218704|NCT00598273|EXPERIMENTAL|Peginesatide 0.025 mg/kg|
62218705|NCT00598273|EXPERIMENTAL|Peginesatide 0.04 mg/kg|
62412703|NCT05014139|EXPERIMENTAL|Enfortumab vedotin: Dose escalation cohort|During the induction phase, participants will receive enfortumab vedotin once a week for 6 weeks. During the maintenance phase, participants will receive enfortumab vedotin once a month for 9 doses.
62412704|NCT05014139|EXPERIMENTAL|Enfortumab vedotin: Dose expansion cohort|During the induction phase, participants will receive enfortumab vedotin once a week for 6 weeks. During the maintenance phase, participants will receive enfortumab vedotin once a month for 9 doses.
62218706|NCT00598273|ACTIVE_COMPARATOR|Darbepoetin Alfa|
62412705|NCT03790020|ACTIVE_COMPARATOR|transversus abdominis plane Block|Transversus abdominis plane block (10 cc / 10 cc, 0.5% bupivacaine to the right and left transversus abdominis muscle regions) will be applied.
62412706|NCT03790020|ACTIVE_COMPARATOR|TROCHAR SITES LOCAL ANESTHETIC INJECTION|local anesthetic injection (6 cc to subxiphoid and infraumbilical trocar sites, 4 cc instead of 2 cc, 0.5% bupivacaine solution to be applied)
62218707|NCT01058031|EXPERIMENTAL|Arm 1|MBSR
62218708|NCT01986673|EXPERIMENTAL|5% Sildenafil Cream (SST-6006)|5% Sildenafil Cream
62218709|NCT01986673|ACTIVE_COMPARATOR|Oral Sildenafil 50 mg|Oral Sildenafil 50 mg
62218710|NCT02011373|EXPERIMENTAL|IFABOND|
62218711|NCT05413109|EXPERIMENTAL|Coronary-CT|Patients with PAH, asymptomatic for angina, with a PA trunk diameter ≥ 4 cm that undergo a coronary-CT scan examination
62218712|NCT05142852|EXPERIMENTAL|Extracorporeal shock wave therapy|The participants in the experiment group received 5 consecutive sessions of ESWT for 5 minutes. Treatment parameters for the shock wave therapy group were set similar to a previous study (Devrimsel et al., 2013) 2000 shock waves with 1.6 bar intensity and 16 Hz frequency were applied for five sessions using the Swiss DolorClast Master (EMS, Nyon, Switzerland). All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
62218713|NCT05142852|ACTIVE_COMPARATOR|Conventional physiotherapy|The participants in the control group received 5 sessions of conventional physical therapy intervention for 5 minutes. The control group intervention consists of a 1-minute friction massage over the common extensor tendon of the elbow, followed by 3 minutes therapeutic ultrasound with a frequency of 1.5 Hz, and a 1-minute ice massage over the common extensor tendon of the elbow. All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
62412707|NCT03790020|ACTIVE_COMPARATOR|INTRAPERİTONEAL LOCAL ANESTHETIC SPREADING METHOD|Intraperitoneal direct vision of the appendix excision area-periappendiciall area under the direct injection of local anesthetic spraying process (percutaneous method injected into the periappendicial area 1: 1 diluted with 20 cc SF, 20 cc 0.5% bupivacaine solution total 40 cc spraying will be applied.
62412708|NCT03790020|NO_INTERVENTION|CONTROL GROUP|group will be the control group and any of these methods will not be applied,
62412709|NCT02218515|OTHER|Open Flap Debridement|Open Flap Debridement (Control Group)
62022537|NCT04345848|EXPERIMENTAL|Therapeutic anticoagulation|Participants will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or intravenous unfractionated heparin, from admission until the end of hospital stay or clinical recovery.
62218714|NCT01140698||Term and preterm newborn infants|5 infants of each gestational age of 24-42 weeks
62218715|NCT06074276|EXPERIMENTAL|Almonds|Consumption of almonds 5 times per week
62218716|NCT06074276|PLACEBO_COMPARATOR|Control Snack|Consumption of protein and calorie matched non-nut-based food 5 times per week
62218717|NCT01981395|EXPERIMENTAL|Treatment regimn 1|150 mg Fenobam Orally - once
62218718|NCT01981395|PLACEBO_COMPARATOR|Treatment Regimen 2|Placebo orally - once
62218719|NCT02538159|EXPERIMENTAL|Experimental CVC|CVC insertion Non-tunneled Central venous catheter insertion
62218720|NCT02538159|EXPERIMENTAL|Experimental PICC|PICC insertion Peripherally inserted catheter
62218721|NCT04466995|EXPERIMENTAL|laparoscopic gynecologic surgery|25 laparoscopic surgery to endotracheal cuff pressure 5., 15., 30., 45. min will be measured, values will be recorded
62218722|NCT04466995|OTHER|laparotomic gynecologic surgery|25 laparotomic surgery to endotracheal cuff pressure 5., 15., 30., 45. min will be measured, values will be recorded
62412710|NCT02218515|EXPERIMENTAL|Enamel Matrix Derivative|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)
62412711|NCT02218515|EXPERIMENTAL|Enamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
62412712|NCT03253159|EXPERIMENTAL|Hypnosis group|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room
62412713|NCT03253159|NO_INTERVENTION|Control group|No special preparation before intravenous general anesthesia induction in the operative room
62412714|NCT01502267|NO_INTERVENTION|Group 1|This group will not receive IVIG and B cell depleting agents
62412715|NCT01502267|EXPERIMENTAL|Group 2|This group will receive IVIG and B cell depleting agents
62412716|NCT02159534|EXPERIMENTAL|Primebrain|"' Stimulation ' Infants group will receive Primebrain stimulation whose items were selected according to a Delphi process and discussed at the European Academy of Childhood Disability (2013).~This sensorimotor stimulation programme is administered at home by parents (trained and monitored by a physical therapist), once a day between term-age and 6 months of corrected age.~In addition, these infants undergo systematic monitoring for preterm and infants born with low birth weight as organized in Belgium ( INAMI convention )."
62412717|NCT02159534|OTHER|usual care|"Infants in the comparison group receive usual care for preterm and infants born with low birth weight as organized in Belgium ( INAMI convention )."
62412718|NCT06702267||cord/placenta from women given birth|One single group is included in the study for the investigation of the PICO70 and safePICO syringes.
62412719|NCT06271798|EXPERIMENTAL|Group A (Resistive exercise group):|They will receive life style modification advice, in addition to performing resistive exercise three times per week for six weeks.
62412720|NCT06271798|EXPERIMENTAL|Group B (Aerobic exercise group):|They will receive the same life style modification advice, in addition to performing aerobic exercise three times per week for six weeks.
62412721|NCT06538402|EXPERIMENTAL|10 cm|Ileal reservoir length of 10 cm
62412722|NCT06538402|ACTIVE_COMPARATOR|15 cm|Ileal reservoir length of 15 cm
62412723|NCT04511975|EXPERIMENTAL|IBI188 + azacitidine|Participants will receive IBI188 in combination with azacitidine
62412724|NCT04757896|ACTIVE_COMPARATOR|Costoclavicular block lateral aproach|An 80-100 mm needle will be directed from the lateral to the medial with the ultrasound guided in-plane technique and the blockage procedure will be completed by injecting
62412725|NCT04757896|ACTIVE_COMPARATOR|Costoclavicular block medial aproach|An 80-100 mm needle will be directed from the medial to the lateral with the ultrasound guided in-plane technique and the blockage procedure will be completed by injecting
62412726|NCT03244722|OTHER|Obese - Very low energy diet (VLED)|Participants will adopt a very-low energy diet
62412727|NCT03244722|OTHER|Obese - Standard of care (SOC)|Participants will receive the standard of care for obese women looking to become pregnant.
62218723|NCT02930031|EXPERIMENTAL|n-acetylcysteine|orally in three daily dosages, at 20 mg/kg/day, daily for eight days after exercise
62218724|NCT02930031|ACTIVE_COMPARATOR|Placebo|orally in three daily dosages, content: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder
62218725|NCT01049217|EXPERIMENTAL|Active drug|
62412728|NCT03244722|OTHER|Lean - Standard of care (SOC)|Participants will receive the standard of care for lean women looking to become pregnant.
62412729|NCT02666768|EXPERIMENTAL|gamma interferon-1b|Gamma interferon-1b 100 mcg subcutaneous (SC) 3 times weekly for 12 months
62412730|NCT00350818|EXPERIMENTAL|Azacitidine|Azacitidine after Allogeneic Transplantation
62412731|NCT04462354|ACTIVE_COMPARATOR|Pancreatogastric anastomosis.|
62412732|NCT04462354|EXPERIMENTAL|Blumgart Anastomosis|
62412733|NCT05053750|EXPERIMENTAL|Paclitaxel|
62412734|NCT05053750|EXPERIMENTAL|Bevacizumab|
62412735|NCT06568406|EXPERIMENTAL|Scheduled Physiotherapy (Intervention)|The mothers in the group A will be referred to the physiotherapist's office at predetermined intervals (intervention group) compared to the current care system.
62412736|NCT06568406|ACTIVE_COMPARATOR|Standard Care (Control)|The mothers included in the group B will undergo standard care in the established manner at the Department of Obstetrics and Gynecology of the Faculty Hospital in Brno, which consists of routine treatment of the perineum and inspection of the perineum by a doctor that by rule occurs the 3rd day after delivery and by the end of the hospitalization
62412737|NCT01518296|EXPERIMENTAL|Patients referred to urodynamic test|Patients that are referred to urogynecology and the pelvic reconstruction unit undergoes a physical gynecological examination and a urodynamic test, During which the degree of pelvic organs prolapse is evaluated with full and empty bladder.
62218726|NCT01049217|PLACEBO_COMPARATOR|Control|
62218727|NCT04545229|EXPERIMENTAL|Active VR-PAT|Active VR-based Pain Alleviation Tool (VR-PAT) group played smart phone VR-PAT during the burn dressing changes.
62412738|NCT00795379|EXPERIMENTAL|IE|Participants will complete an at home four-week, intervention targeting their negative cognitions triggered by physical sensations. The goal of IE is to purposefully induce bodily sensations related to autonomic arousal so that participants can learn that those sensations are not harmful. IE and Cognitive restructuring have been found to be superior to progressive muscle relaxation as a way to avoid aversive autonomic sensations.
62412739|NCT00795379|NO_INTERVENTION|2|waitlist control
62412740|NCT06126523|ACTIVE_COMPARATOR|ESWT once|A single session of rESWT will be applied on the same day after BTX-A injection.
62218728|NCT04545229|EXPERIMENTAL|Passive VR-PAT|Passive VR-based Pain Alleviation Tool (VR-PAT) group watched smart phone VR-PAT games without interaction during the burn dressing changes.
62218729|NCT04545229|NO_INTERVENTION|Standard Care Control|Standard care control group used regular distraction such as background music or no distraction.
62218730|NCT06181760|ACTIVE_COMPARATOR|Fenretinide 300 mg/m2|Single oral dose of fenretinide, 300 mg/m2
62218731|NCT06181760|ACTIVE_COMPARATOR|Fenretinide 600 mg/m2|Single oral dose of fenretinide, 600 mg/m2
62218732|NCT06181760|ACTIVE_COMPARATOR|Fenretinide 900 mg/m2|Single oral dose of fenretinide, 900 mg/m2
62412741|NCT06126523|ACTIVE_COMPARATOR|ESWT twice|A total of 2 sessions of rESWT will be applied on the same day after BTX-A injection and on the 7th day after BTX-A.
62412742|NCT06126523|SHAM_COMPARATOR|Sham ESWT|A single session of placebo rESWT will be applied after BTX-A injection.
62412743|NCT06379139||BIOPAVIR 2 cohort|Adult critically ill patients (\> 18 years of age) exposed to endotracheal tube for at least two calendar days
62412744|NCT04981782||healthy subjects|"No intervention~Infants will be measured at different time points. At the age of 3,4,6 and 9 months."
62412745|NCT04981782||torticollis group|"No intervention~Infants will be measured at their visit to a Chiropractor. Before and after treatment."
62412746|NCT02701049|OTHER|SO/GI Collection|Methods to collect SO/GI information in the ED
62412747|NCT06464536|EXPERIMENTAL|Compression group|Participants in the intervention group wear surgical gloves at each taxane administration. The intervention will start 30 minutes before the infusion, continue during the infusion, and last until 30 minutes after the infusion ends. Glove size will be measured on both hands before the first use, following the European standard for medical gloves. The gloves will be worn half a size (0.5) smaller than the appropriate size on both hands. With the help of talcum powder, a second glove of the same size will be worn over the first glove on both hands. After selecting the glove size, the compression strength of the two overlapping gloves will be measured once using a pressure measuring device (PicoPress (c)). The PicoPress(c) device (Microlab Elettronica, Italy) is already in use to measure the pressure of compression bandages. The target range for compression pressure is between 23-32 mmHg (compression class 2) (RAL Deutsches Institut für Gütesicherung und Kennzeichnung e. V., 2008).
62412748|NCT06464536|SHAM_COMPARATOR|Control group|Participants in the control group will wear two non-compressing surgical gloves of their appropriate size on both hands during each administration of taxanes. The intervention will begin 30 minutes before the infusion, continue during the infusion, and last until 30 minutes after the infusion ends. After selecting the glove size, the compression strength of the two overlapping gloves will be measured once using a pressure measuring device (PicoPress(c)) to verify the pressure. The target range is below 3 mmHg. Measurements with the pressure sensor will be repeated as needed with gloves half a size larger to ensure a low pressure level of less than 3 mmHg.
62412749|NCT01578018|OTHER|Lung Cancer|Diagnostic
62218733|NCT06181760|PLACEBO_COMPARATOR|Placebo|Single oral dose of placebo capsules
62218734|NCT01455805|ACTIVE_COMPARATOR|Minuteman Fusion Implant|Minuteman™ interspinous interlaminar fusion Implant (interspinous interlaminar fusion device) which gained CE Mark approval in May 2011
62218735|NCT01455805|OTHER|Surgical decompression|Surgical decompression refers to the following operations Laminectomy, Foraminotomy, Discectomy or any other surgical procedure that the clinician feels is relevant for the decompression of lumbar spinal stenosis.
62218736|NCT03837210|EXPERIMENTAL|Test Drug|This group is treated with Herbal formulation.
62412750|NCT01578018|OTHER|Lung Disease|Diagnostic
62412751|NCT06467305|EXPERIMENTAL|Altered auditory feedback + cTBS to auditory cortex|Participants will perform learning tasks while receiving altered auditory feedback.This procedure will be repeated on day 2. cTBS will be applied to the left hemisphere auditory cortex following learning. Participants then leave the laboratory and return 24 hours later to assess retention of learning.
62412752|NCT06467305|EXPERIMENTAL|Altered auditory feedback + cTBS to somatosensory cortex|Participants will perform learning tasks while receiving altered auditory feedback.This procedure will be repeated on day 2. cTBS will be applied to the left hemisphere somatosensory cortex following learning. Participants then leave the laboratory and return 24 hours later to assess retention of learning.
62218737|NCT03837210|ACTIVE_COMPARATOR|Control Drug|This group is treated with Quintuple therapy
62218738|NCT01027182|NO_INTERVENTION|Raltegravir|
62218739|NCT04259944|EXPERIMENTAL|Liquid Biopsy-Guided Adjuvant Treatment|"A post-surgical LB executed 2-4 weeks after surgery will guide a Molecular Adjuvant treatment:~* ctDNA+ patients: CAPOX for 3 months~* ctDNA- patients: capecitabine (CAPE) for 6 months. LB after 1 cycle and if found ctDNA+ will be switched to CAPOX.~A post-Molecular Adjuvant treatment LB will be performed and instruct subsequent treatment:~* ctDNA+/+ patients: up-scale to a Molecular Metastatic treatment with FOLFIRI for 6 months or until radiological progression or toxicity;~* ctDNA-/+ patients: up-scale to a Molecular Metastatic treatment with CAPOX for 6 months or until radiological progression or toxicity. LB after 3 months at the end of treatment and in case of positivity switch to FOLFIRI.~* ctDNA+/- patients: de-escalate treatment to CAPE for 3 months. 3 LB performed within 3 months and in case of positivity switch to FOLFIRI.~* ctDNA-/- patients: interventional follow-up comprising 2 further LB and in case of positivity switch to CAPOX treatment."
62218740|NCT02090036|ACTIVE_COMPARATOR|artemether-lumefantrine+placebo|In the artemether-lumefantrine arm, the first dose of artemether-lumefantrine will be administered concomitantly with a single-dose placebo. A volume of normal saline will be measured based on weight bands and then will be given to patients.
62218741|NCT02090036|EXPERIMENTAL|artemether-lumefantrine+primaquine|All the recruited patients will be treated with a six doses, 3 days artemether-lumefantrine treatment regimen. However, patients randomized to the artemether-lumefantrine+primaquine arm will be given 0.25 mg/kg single-dose primaquine concomitantly with artemether-lumefantrine first dose.
62586304|NCT06512207|EXPERIMENTAL|Conventional Treatment Combined with Leuprolide Group|40 cases in this group to receive the standard conventional therapy (Chemotherapy + PD-1 Monoclonal Antibody) combined with Leuprorelin acetate, 3.75 mg
62586305|NCT05845762||Response|1000mg i.v. per day
62586306|NCT05845762||Non-response|1000mg i.v. per day
62218742|NCT01242826|EXPERIMENTAL|A|
62218743|NCT03769662|EXPERIMENTAL|High dose from study XT-150-1-0201|Open label administration of the highest dose in the earlier study, in which all doses were well tolerated
62218744|NCT02938091|EXPERIMENTAL|High-fat diet|The dietary intervention was designed as a typical Western diet (39% total fat, 14% saturated fat, 12% monounsaturated fat, 9.6% polyunsaturated fat, 42% carbohydrate, 8.8 grams fiber/1000 kcal)
62412753|NCT06467305|EXPERIMENTAL|Altered auditory feedback + cTBS to motor cortex|Participants will perform learning tasks while receiving altered auditory feedback.This procedure will be repeated on day 2. cTBS will be applied to the left hemisphere motor cortex following learning. Participants then leave the laboratory and return 24 hours later to assess retention of learning.
62412754|NCT06467305|EXPERIMENTAL|Altered auditory feedback + cTBS to motor cortex control zone|Participants in a control condition will undergo the same procedures using cTBS to a motor cortex control zone in the right hemisphere (associated with the hand muscle first dorsal interosseous). cTBS will be applied following learning and subjects will return 24 hours later to test for retention. This control condition is included as a test for non-specific effects of cTBS stimulation.
62412755|NCT06467305|EXPERIMENTAL|Unaltered auditory feedback + cTBS to auditory cortex|Participants will perform learning tasks while receiving unaltered auditory feedback.This procedure will be repeated on day 2. cTBS will be applied to the left hemisphere auditory cortex following learning. Participants then leave the laboratory and return 24 hours later to assess retention of learning. If the effects of cTBS are specific to learning, no effect should be observed in these control conditions.
62412756|NCT06467305|EXPERIMENTAL|Unaltered auditory feedback + cTBS to somatosensory cortex|Participants will perform learning tasks while receiving unaltered auditory feedback.This procedure will be repeated on day 2. cTBS will be applied to the left hemisphere somatosensory cortex following learning. Participants then leave the laboratory and return 24 hours later to assess retention of learning. If the effects of cTBS are specific to learning, no effect should be observed in these control conditions.
62586307|NCT06667258||Healthy|Volunteers who have not been diagnosed with any heart rhythm problems, or patients whose heart rhythm issues are not showing up at the time of recruitment.
62586308|NCT06667258||Arrhythmia patients|Patients who have been previously diagnosed with an abnormal heart rhythm and are showing signs of it when they join the study.
62586309|NCT05139602|EXPERIMENTAL|Main Study: Lutikizumab Dose A|Lutikizumab Dose A every week
62586310|NCT05139602|EXPERIMENTAL|Main Study: Lutikizumab Dose B|Lutikizumab Dose B every other week
62586311|NCT05139602|EXPERIMENTAL|Main Study: Lutikizumab Dose C|Lutikizumab Dose C every other week
62586312|NCT05139602|PLACEBO_COMPARATOR|Main Study: Placebo|Placebo every week
62794500|NCT05463081|EXPERIMENTAL|Relaxation of vagina|"Participants with:~* prolapse of the genitals I-II degree,~* vaginal relaxation syndrome,~* postpartum recovery,~* sexual dysfunctions,~* restoration of tone, turgor and tissue density of the urogenital area (Intimate rejuvenation, correction of age-related changes),~* preoperative preparation for genital prolapse surgery and postoperative rehabilitation.~Laser treatment of the vagina, vulva, and paraurethral region with Magic Gyno laser. In total, three procedures will be performed with an interval of 4 weeks.~During the procedure, the following sequence of actions will be performed:~1. st Stage - vaginal processing with a conical mirror handpiece,~2. nd Stage - vaginal processing with a corner mirror handpiece,~3. d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece."
62794501|NCT03295760||Children with cyclic vomiting syndrome|Children followed at Children's Hospital of Nancy treated with Q10 coenzyme for cyclic vomiting syndrome
62794502|NCT06600321|EXPERIMENTAL|Monotherapy: Dose Escalation|Patients will be administered multiple doses of ALN-BCAT.
62794503|NCT06600321|EXPERIMENTAL|Monotherapy: Dose Expansion|Patients will be administered multiple doses of ALN-BCAT.
62218745|NCT02938091|EXPERIMENTAL|Low-fat diet|The dietary intervention consisted of a Hispanic diet (20% total fat, 5.5% saturated fat, 9.6% monounsaturated fat, 3.7% polyunsaturated fat, 61% carbohydrate, 13.7 grams fiber/1000 kcal). The diet was comprised of typical foods and recipes resembling a traditional Caribbean Hispanic diet and differed from the Western diet in four primary ways: 1) more fruits and vegetables, 2) more beans (e.g. mixed dishes to reduce serving size of white rice while increasing legumes), 3) emphasis on reduced-fat dairy products (e.g., 1% fat milk), and 4) lower total fat and lower animal and hydrogenated fat.
62218746|NCT04072042|EXPERIMENTAL|VEGFR SNP-Positive Sarcoma Arm|"In this arm, patients with VEGFR2-604 A\>G single nucleotide polymorphism (SNP) were recruited for the efficacy analysis.~Biomarker positive patients will receive Apatinib 250mg tablet by mouth, bid. Biomarker negative patients are treated with the same regimens as a non-comparative, non-randomized, pragmatic control without a pre-specified sample size."
62243344|NCT00785824||3 - AA Normal Controls|Group 3: Normal African-American non-pregnant controls who are age-matched to Group 1
62586313|NCT05139602|EXPERIMENTAL|Sub-study: Group 1|Period 1: Lutikizumab Dose A every week. Period 2: Lutikizumab Dose A every week.
62586314|NCT05139602|EXPERIMENTAL|Sub-study: Group 2|Period 1: Lutikizumab Dose A every week. Period 2: Lutikizumab Dose A every other week.
62586315|NCT01259804|EXPERIMENTAL|Peanut immunotherapy|Peanut flour
62586316|NCT01867710|EXPERIMENTAL|AA + prednisone 5 mg twice daily|Abiraterone acetate in combination with prednisone 5 mg twice daily
62586317|NCT01867710|EXPERIMENTAL|AA + prednisone 5 mg once daily|Abiraterone acetate in combination with prednisone 5 mg once daily dose
62586318|NCT01867710|EXPERIMENTAL|AA + prednisone 2.5 mg twice daily|Abiraterone acetate in combination with prednisone 2.5 mg twice daily
62586319|NCT01867710|EXPERIMENTAL|AA + dexamethasone 0.5 mg once daily|Abiraterone acetate in combination with dexamethasone 0.5 mg once daily
62586320|NCT06665646|EXPERIMENTAL|Group 1- Study Vaccine|MOSAICO study products
62794504|NCT06600321|EXPERIMENTAL|Combination Therapy: Dose Escalation|Patients will be administered multiple doses of ALN-BCAT in combination with pembrolizumab.
62218747|NCT04072042|EXPERIMENTAL|CSF1-Positive Sarcoma Arm|"In this arm, patients with CSF1-positivity were recruited for the efficacy analysis. CSF1-positivity is defined as CSF1 copy number amplification and/or CSF1 expression ≥ 30% by immunohistochemistry (IHC) in the sarcoma tumor specimen according to the institutional pathological review.~Biomarker positive patients will receive Apatinib 250mg tablet by mouth, bid. Biomarker negative patients are treated with the same regimens as a non-comparative, non-randomized, pragmatic control without a pre-specified sample size."
62794505|NCT06600321|EXPERIMENTAL|Combination Therapy: Dose Expansion|Patients will be administered multiple doses of ALN-BCAT in combination with pembrolizumab.
62794506|NCT05699824|EXPERIMENTAL|Carvedilol at Day2 + Standard Medical Treatment|"Arm A- Carvedilol will be initiated on day 2, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.~All patients to receive Inj. Terlipressin, 1 mg at 4 hours along with standard management for acute variceal bleed as per institutional protocol"
62794507|NCT05699824|ACTIVE_COMPARATOR|Carvedilol at Day6 + Standard Medical Treatment|"Arm B- Carvedilol will be initiated on day 6, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.~All patients to receive Inj. Terlipressin, 1 mg at 4 hours along with standard management for acute variceal bleed as per institutional protocol"
62794508|NCT00625079|PLACEBO_COMPARATOR|Pre-transplant placebo|There are two placebo comparators.... one for the group of patients with resting PAH and another for the group of patients with exercise PAH
62794509|NCT00625079|EXPERIMENTAL|Pre-transplant sildenafil|There are two active comparators, one group with resting PAH and another with exercise PAH, both receiving drug.
62022538|NCT04345848|ACTIVE_COMPARATOR|Prophylactic anticoagulation|Participants will be treated with prophylactic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or unfractionated heparin, from admission until the end of hospital stay or clinical recovery. If hospitalized in the intensive care unit, they will receive an augmented thromboprophylaxis regimen as standard of care.
62022539|NCT00057915|EXPERIMENTAL|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
62022540|NCT06044298||Gastrointestinal procedural sedation|Investigators will include in our study patients aged 60 and over who have been evaluated in the pre-anesthesia clinic for procedures such as endoscopy, colonoscopy, ERCP, PEG, EUS, and ESD, and who have received sedation by an anesthesiologist. Patients will be assessed for frailty prior to the procedure; during and after the procedure, respiratory monitoring (SpO2, capnography) will be closely observed, and they will be contacted by phone three days later.
62022541|NCT01547650||SIADH, CSWS, CDI, PP, DIH, HF|CSWS (cerebral salt wasting syndrome), SIADH (syndrome of inappropriate ADH) , CDI (central diabetes insipidus), PP (primary polydipsia), DIH (drug-induced hyponatremia), HF (heart failure with hyponatremia)
62022542|NCT00834457|ACTIVE_COMPARATOR|2A|co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg po(Trizivir)one tablet twice daily(BID)for 96 weeks
62022543|NCT00834457|ACTIVE_COMPARATOR|2B|co-formulated abacavir 600mg/3TC 300mg orally (as Kivexa) one tablet daily plus fixed dose lopinavir 133.3mg/ritonavir 33.3mg orally (as Aluvia) four tablets daily for 96 weeks
62022544|NCT03450551|EXPERIMENTAL|Twin Block|61 patients will receive the Twin Block appliance (one of the three appliances being studied)
62022545|NCT03450551|ACTIVE_COMPARATOR|Herbst|61 patients will receive the Herbst appliance (one of the three appliances being studied)
62022546|NCT03450551|ACTIVE_COMPARATOR|Frog distalising appliance|61 patients will receive the Frog distalising appliance (one of the three appliances being studied)
62022547|NCT05651477||Doctor|Doctors of the Emergency department conduct questionnaires about occupational, mental, physical factors on their health.
62022548|NCT05651477||Nurses|Nurses of the Emergency department conduct questionnaires about occupational, mental, physical factors on their health.
62022549|NCT02239510|ACTIVE_COMPARATOR|Senna|1 capsule (50 mg) Senna daily for 12 weeks
62022550|NCT02239510|ACTIVE_COMPARATOR|Linzess|1 capsule (145 mcg) once daily for 12 weeks
62022551|NCT06529653|OTHER|intervention group|the group using an autogenous bone wedge harvested from the chin interpositioned between split cortices in the anterior maxilla to manage the horizontal deficiency of the ridge.
62022552|NCT06529653|OTHER|control group|the group used mixed autogenic and xenogenic bone particles that interposed between split cortices in anterior maxilla to manage the horizontal deficiency of the ridge
62022553|NCT02069600|ACTIVE_COMPARATOR|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure is a device that apply a positive pressure in the airway to avoid its collapse during sleep during three months in this study
62022554|NCT02069600|NO_INTERVENTION|No intervention|No intervention. No placebo is used. Control group without CPAP treatment during three months
62022555|NCT02899728|EXPERIMENTAL|Arm I (chemotherapy, cediranib maleate, olaparib)|"Patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~Patients in Arm I who have stable disease, partial, or a complete response are randomized to receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to receive maintenance therapy.~MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.~NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with cediranib maleate and olaparib upon disease progression at the treating investigator's discretion."
62218748|NCT05002829|EXPERIMENTAL|Restricted Post-Operative Antibiotics Group|"Participants undergoing standard of care (SOC) with simple appendicitis will not receive post-operative antibiotics.~Participants undergoing standard of care with complicated (gangrenous or perforated) appendicitis will receive up to 24 hours of SOC post-operative antibiotics."
62218749|NCT05002829|ACTIVE_COMPARATOR|Liberal Post-Operative Antibiotics Group|"Participants undergoing standard of care with simple appendicitis will receive 24 hours of post-operative SOC antibiotics~Participants undergoing standard of care with complicated (gangrenous or perforated) appendicitis will receive 4 days of post-operative SOC antibiotics."
62218750|NCT04984434|EXPERIMENTAL|Experimental: Single Arm|
62586321|NCT06665646|PLACEBO_COMPARATOR|Group 2- Placebo|MOSAICO placebo
62586322|NCT05935644|EXPERIMENTAL|ORCHID Group|Participants in the ORCHID group will receive an online intervention that improves depressive symptoms and positive affect (emotions) for clinic-based persons living with HIV, for up to 6 months.
62586323|NCT02954692|EXPERIMENTAL|Insulin glargine (U300)|Insulin glargine (U300) will be administered daily through subcutaneous injection, and thereafter, dose will be titrated weekly (preferably 3-4 days) as needed. Background non-insulin anti-diabetic drugs approved for use in combination with insulin according to local labelling, will be permitted, with the exception of Thiazolidinediones (TZDs), which must be stopped at the time of basal insulin initiation.
62586324|NCT04056845|EXPERIMENTAL|Knee brace group|Patients in this group will receive a valgus knee brace (Medex K39-OA Corrector), to be worn for at least four hours a day, during the study period, on top of the presrciption of physiotherapy and oral analgesic (diclofenac and panadol).
62586325|NCT04056845|ACTIVE_COMPARATOR|Control Group|Patients in this group will receive physiotherapy and oral analgesic (diclofenac and panadol).
62586326|NCT03589326|EXPERIMENTAL|Cohort A: Ponatinib 30 milligram (mg)|Ponatinib 30 mg, tablets, orally, once daily (QD), with vincristine 1.4 mg/m\^2 (max 2 mg) intravenous (IV), on Days 1 and 14 and dexamethasone 40 mg (\<60 years \[yrs\]) and 20 mg (≥60 yrs), orally, once on Days 1 to 4, Days 11 to 14 for up to 3 cycles (each cycle=28 days) in induction phase (reduced dose of ponatinib 15 mg upon achievement of MRD-negative CR at end of induction) followed by ponatinib last induction phase dose with cytarabine, 1000 mg/m\^2 as 2-hour IV infusion (\<60 yrs) and 250 mg/m\^2 (≥60 yrs) every 12 hours, IV on Days 1, 3, 5 of Cycles 2,4,6 and methotrexate, 1000 mg/m\^2 (\<60 yrs) and 250 mg/m\^2 (≥60 yrs), IV infusion, on Day 1 of cycles 1, 3, 5 in consolidation phase followed by ponatinib last consolidation phase dose with vincristine 1.4 mg/m\^2 (max 2 mg), IV, on Day 1 and prednisone 200 mg (\<60 yrs), 100 mg (≥60-69 yrs) and 50 mg(≥70 yrs) on Days 1 to 5 for up to 11 cycles in maintenance phase up to data cut-off date: 12 August 2022.
62586327|NCT03589326|ACTIVE_COMPARATOR|Cohort B: Imatinib 600 mg|Imatinib 600 mg, tablets, orally, QD, with vincristine 1.4 mg/m\^2 (max 2 mg), IV, on Days 1 and 14 and dexamethasone 40 mg (\<60 yrs) and 20 mg (≥60 yrs), orally, once on Days 1 to 4 and Days 11 to 14 in each 28-day cycle for up to 3 cycles in the induction phase followed by imatinib 600 mg, tablets, orally, QD, with cytarabine, 1000 mg/m\^2 every 12 hours as a 2-hour-IV infusion (\<60 yrs) and 250 mg/m\^2 every 12 hours (≥60 yrs), IV on Days 1, 3, and 5 of each 28-day even cycles (Cycles 2, 4, and 6), and methotrexate, 1000 mg/m\^2 (\<60 yrs) and 250 mg/m\^2 (≥60 yrs), IV infusion, on Day 1 of each 28-day odd cycles (Cycle 1, 3, and 5) in consolidation phase followed by imatinib 600 mg, tablets, orally, QD, along with vincristine 1.4 mg/m\^2 (max 2 mg), IV, on Day 1 and prednisone 200 mg (\<60 yrs), 100 mg (≥60-69 yrs) and 50 mg (≥70 yrs) on Days 1 through 5 in each 28-day cycle up to 11 cycles in maintenance phase up to data cut-off date: 12 August 2022.
62586328|NCT03518619|EXPERIMENTAL|PFIcope+EMI|This will include: 1) an in-person personalized feedback session to present normative information and feedback on problems associated with drinking to cope, to discuss the individual's use of alcohol to cope, and to generate relapse prevention coping skills messages to be used in the EMI text intervention; 2) EMA to monitor affect and intention to drink after discharge; 3) tailored text messages (EMI) based on EMA responses (i.e., individualized coping skills messages when individuals report negative affect and intention to drink); and 4) additional EMA to monitor coping skills usage, alcohol use, and drinking to cope.
62586329|NCT06667843|EXPERIMENTAL|Intervention|Standard follow-up at respective Healthy Lives Center with the addition of a digital therapeutic app with a full lifestyle program, including daily logging, tasks, articles and general information and possibility for digital communication with their healthcare provider.
62586330|NCT06667843|EXPERIMENTAL|Control|Standard follow-up at respective Healthy Lives Center, including daily logging in the digital therapeutic app.
62586331|NCT01376986|EXPERIMENTAL|Activation|All those determined fit for service or who are granted postponement will be included in the activation intervention. The physical activation intervention will be implemented between the call-up and start of military service. The activation group utilises an ICT platform that will be developed.
62586332|NCT01376986|NO_INTERVENTION|control|no access to the activation platform
62586333|NCT02751450|EXPERIMENTAL|Stannous Fluoride dentifice|Participants will apply (under supervision) a pea-sized dose of experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm) to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted
62586334|NCT02751450|OTHER|Sodium Monofluorophosphate dentifrice|Participants will apply (under supervision) a pea-sized dose of dentifrice containing Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted.
62412757|NCT06467305|EXPERIMENTAL|Unaltered auditory feedback + cTBS to motor cortex|Participants will perform learning tasks while receiving unaltered auditory feedback.This procedure will be repeated on day 2. cTBS will be applied to the left hemisphere motor cortex following learning. Participants then leave the laboratory and return 24 hours later to assess retention of learning. If the effects of cTBS are specific to learning, no effect should be observed in these control conditions.
62412758|NCT06467305|EXPERIMENTAL|Unaltered auditory feedback + cTBS to motor cortex control zone|Participants in a control condition will undergo the same procedures using cTBS to a motor cortex control zone in the right hemisphere (associated with the hand muscle first dorsal interosseous). cTBS will be applied following learning and subjects will return 24 hours later to test for retention. This control condition is included as a test for non-specific effects of cTBS stimulation. If the effects of cTBS are specific to learning, no effect should be observed in these control conditions.
62412759|NCT00110084|EXPERIMENTAL|Nab-paclitaxel/Gemcitabine|
62794510|NCT00625079|NO_INTERVENTION|Pre-transplant no PAH-specific therapy|this group of patients has no evidence for either resting or exercise PAH but will be followed without specific drug intervention
62218751|NCT01164644|ACTIVE_COMPARATOR|Arnica Montana|The subject will take twelve pills by mouth three times a day over four days.
62218752|NCT01164644|PLACEBO_COMPARATOR|Placebo|The subject will take twelve pills by mouth three times a day over four days.
62218753|NCT02055196|EXPERIMENTAL|Treatment (neuronal stem cells, irinotecan hydrochloride)|Patients receive carboxylesterase-expressing allogeneic neural stem cells via intracerebral catheter on day 1 of week 1; weeks 1 and 3, weeks 1, 2, and 3; or weeks 1, 2, 3, and 4. Patients also receive irinotecan hydrochloride IV over 90 minutes on day 3 of week 1; weeks 1 and 3, weeks 1, 2, and 3; or weeks 1, 2, 3, and 4. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62218754|NCT03700112|EXPERIMENTAL|JUUL Virginia Tobacco flavored 5.0% ENDS|"Administration of JUUL Virginia Tobacco flavored 5.0% ENDS product consumed using 10 puffs delivery method~Administration of JUUL Virginia Tobacco flavored 5.0% ENDS product consumed Ad-libitum delivery method"
62412760|NCT03338907|EXPERIMENTAL|Oxycarbon (5% CO2 + 95% O2)|Patients will be mechanical ventilated with Oxycarbon (5%CO2 +95% O2) after normocapnia is reached until FeO2 is stable for at least 1 min ≥ 80%. At timepoint 1 immediately prior apnea NIRS and vital parameters will be registered and an bloodsample will be drawn.
62412761|NCT03338907|PLACEBO_COMPARATOR|Control (95% O2)|"Same procedure as arm active comparator"
62412762|NCT05874518|EXPERIMENTAL|Experimental group|"Ask the patient to empty the bladder, and take supine position. Take guanyuan, zhongji, bilateral Tianshu, zigong, guilai, sanyinjiao, Taixi, zusanli, hegu points. Select 0.3mm×40mm fine needles. After conventional disinfection, the needle is 0.5-1 inch deep. Then the 1.5 cm moxa cones were inserted into the tail of the needle of the bilateral sanyinjioa and zusnli points for moxibustion. At the same time, electroacupuncture therapy was used. Select the density wave and set the time for 25 minutes.~Generally, the patient feels comfortable as moderate, so that the patient feel acid, distension, heat or local muscles for rhythmic contraction. After treatment, first reduce the power to zero value, turn off the power supply, then remove the electrode clip from the needle handle, and pull out the fine needle stabbed into the tissue. Treatment begins on the 5th day of the menstrual cycle, qd (once a day), usually for 6-8 consecutive days, and continuing to the day of ovulation."
62412763|NCT05874518|ACTIVE_COMPARATOR|Control group|Treatment was started on day 5 of the menstrual cycle. Letrozole tablets were given at 2.5mg (Jiangsu Hengrui Pharmaceutical Co., Ltd., H19991001, 2.5mg per tablet), po (oral), qd, for 5-7 consecutive days. When the diameter of follicles reaches 18mm, Chorionic gonadotrophin is given at 5000u (Lizhu Group Lizhu Pharmaceutical Factory, Chinese medicine H44020668, 5000u per branch), with intramuscular injection, qd, to promote follicle discharge. Patients were also instructed to have sexual intercourse on the same day and on day 2.
62412764|NCT06652594|EXPERIMENTAL|Eye Education Intervention|Doctors and nurses will educate parents about eye health in response to their child's myopia progression at baseline, 1 month, 3 months, 6 months.
62218755|NCT03700112|EXPERIMENTAL|PMI iQOS Heat sticks|"Administration of PMI iQOS Heat sticks - Regular consumed using 10 puffs delivery method~Administration of PMI iQOS Heat sticks - Regular consumed ad-libitum delivery method"
62412765|NCT06652594|EXPERIMENTAL|Control|Parents in the control group will not receive eye health education information from doctors and nurses.
62412766|NCT02332655|EXPERIMENTAL|Cannabidiol|All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis. The drug will be taken for 48 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of epilepsy in patients with Sturge-Weber syndrome.
62412767|NCT06648499||Pediatric-Onset Multiple Sclerosis Group|Individuals in the POMS group will be evaluated in terms of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue.
62794511|NCT04115631|EXPERIMENTAL|Arm A (bendamustine, rituximab, cytarabine)|Patients receive bendamustine IV on days 1 and 2 and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients receive rituximab IV on day 1 and cytarabine IV every Q12 hours on days 1 and 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
62794512|NCT04115631|EXPERIMENTAL|Arm B (acalabrutinib, bendamustine, rituximab, cytarabine)|Patients receive PO BID on days 1-28, bendamustine IV on days 1 and 2, and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients receive acalabrutinib PO BID on days 1-7 and 22-28, rituximab IV on day 1, and cytarabine IV Q12 hours on days 1 and 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
62218756|NCT03700112|EXPERIMENTAL|Reynolds VUSE Solo ENDS - Original|"Administration of Reynolds VUSE Solo ENDS - Original consumed using 10 puffs delivery method~Administration of Reynolds VUSE Solo ENDS - Original consumed using ad-libitum delivery method"
62218757|NCT03700112|EXPERIMENTAL|Imperial MyBlu ENDS - Original|"Administration of Imperial MyBlu ENDS - Original consumed using 10 puffs delivery method~Administration of Imperial MyBlu ENDS - Original consumed using ad-libitum delivery method"
62218758|NCT03700112|EXPERIMENTAL|Altria MarkTen ENDS - Bold Classic|"Administration of Altria MarkTen ENDS - Bold Classic consuming using 10 puffs delivery method~Administration of Altria MarkTen ENDS - Bold Classic consuming using ad-libitum delivery method"
62218759|NCT03700112|EXPERIMENTAL|MLV PHIX ENDS - Original Tobacco|"Administration of MLV PHIX ENDS - Original Tobacco consumed using 10 puffs delivery method~Administration of with MLV PHIX ENDS - Original Tobacco consumed using ad-libitum delivery method"
62218760|NCT03700112|EXPERIMENTAL|NJOY Daily EXTRA ENDS - Rich Tobacco|"Administration of NJOY Daily EXTRA ENDS - Rich Tobacco consumed using 10 puffs delivery method~Administration of NJOY Daily EXTRA ENDS - Rich Tobacco consumed using delivery method and ad-libitum"
62412768|NCT06648499||Healthy Controls|Individuals in the control group will be evaluated in terms of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue.
62412769|NCT05007106|EXPERIMENTAL|Pembrolizumab/Vibostolimab Co-Formulation|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion every 3 weeks (Q3W) up to 35 cycles.
62586335|NCT05782361|EXPERIMENTAL|Part A- Escalation|"The safety run-in part of the study will enrol 6-12 patients. Tepotinib will be given to patients daily for three weeks. After thee weeks, patients will be given pembrolizumab immunotherapy on a 21-day cycle along side tepotinib daily.~Dose de-escalation of Tepotinib only will be performed in in Part A.. Should dose level 1 (500mg OD) be deemed non-tolerable by the SRC then a single dose de-escalation to dose level -1 (250mg OD) may be performed. Alternative dosing schedules may be explored. Recruitment into Part A will be staggered such that at least 7 days elapse between treatment of the 1st and 2nd patient of each dose level. In the dose confirmation phase, the study will first evaluate the dose level 1 with 3 patients, expanding to a maximum of 6 evaluable patients. If needed, a maximum of 6 patients will be evaluate in the dose level -1.~Recruitment to this arm is closed."
62586336|NCT05782361|EXPERIMENTAL|Part B- Expansion|"The expansion part of the study will enrol 13-26 patients with NSCLC and MET exon 14 skipping mutations. The combination of tepotinib and pembrolizumab will be tested throughout this part of the study. The first cycle will test the safety run-in of tepotinib followed by the introduction of combination with pembrolizumab from cycle 2 onwards.~Recruitment to this arm is open."
62586337|NCT00776295|EXPERIMENTAL|adeno virus vectored p53|Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes
62586338|NCT05857930|EXPERIMENTAL|OM-85|Patients will receive OM-85 capsules as a treatment for 6 months and will be under observation for 6 months.
62586339|NCT05857930|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo capsules as a treatment for 6 months and will be under observation for 6 months.
62586340|NCT01578473|ACTIVE_COMPARATOR|Vitamin D and E|Oral Vitamin D and E alone in men with penile curvature due to PD.
62586341|NCT01578473|ACTIVE_COMPARATOR|Testosterone Pellets and Vitamin D and E|Testosterone in combination with oral Vitamin D an E supplementation in men with penile curvature due to PD.
62586342|NCT04476953|EXPERIMENTAL|Treatment Group|Subjects will receive treatment drug Fisetin
62586343|NCT04476953|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive placebo
62586344|NCT06086210|ACTIVE_COMPARATOR|Low-level laser therapy group|Low-level laser therapy was applied to the patients with the elbow at 45° flexion, creating a total of 5 areas by drawing 2 cm intervals 4 cm below the elbow and 6 cm above the elbow. The patients in the group used the elbow rest splint throughout the night during the treatment.
62794513|NCT04115631|EXPERIMENTAL|Arm C (acalabrutinib, bendamustine, rituximab)|Patients receive acalabrutinib PO BID on days 1-28, bendamustine IV on days 1 and 2, and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62794514|NCT01391624|EXPERIMENTAL|Omega 3|The group was treated with omega 3 fatty acids for 2 months.
62794515|NCT01391624|PLACEBO_COMPARATOR|Placebo|The group received paraffin with dye in order to mimic the visual aspects of omega 3 fatty acid capsules.
62586345|NCT06086210|SHAM_COMPARATOR|Sham group|Sham group was applied with a laser probe by the elbow in 45° flexion, creating a total of 5 areas by drawing 2 cm intervals 4 cm below the elbow and 6 cm above the elbow. The patients in the group used the elbow rest splint throughout the night during the treatment.
62586346|NCT06285214|EXPERIMENTAL|V117957|
62794516|NCT05007756|EXPERIMENTAL|Ultraviolet B (UVB) Challenge|Participants will receive UVB (various doses) for minimal erythema dose (MED) assessment at baseline following which there will be washout period. Participants will then receive a single dose of UVB challenge dermally through Lumera Phototherapy System on Day 1, twice (2\*) the MED at the challenge site with no UVB exposure at the contralateral control site.
62794517|NCT06124963|EXPERIMENTAL|WX390 + Toripalimab|Participants will receive WX390 continuous oral dosing (0.9 mg once a day) and Toripalimab fixed dose (240 mg, intravenous, Day 1, every 3 weeks).
62794518|NCT00242541|EXPERIMENTAL|Octreotide acetate|
62794519|NCT05396911|EXPERIMENTAL|UP2UTobacco|Youth Brief Tobacco Intervention
62794520|NCT05396911|NO_INTERVENTION|No Treatment Control|
62794521|NCT00773513|ACTIVE_COMPARATOR|Erythropoiesis Stimulating Agents|Participants will receive reference ESA according to approved label. The approved reference ESA compounds in the study will be darbepoetin alfa, epoetin alfa and epoetin beta.
62412770|NCT05007106|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg via IV infusion Q3W up to 35 cycles.
62794522|NCT00773513|EXPERIMENTAL|Methoxy Polyethylene Glycol-Epoetin Beta|Participants not currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta iv or sc once every 2 weeks for correction of renal anemia (target Hb 10-12 g/dL). Once corrected and in participants currently being treated with an ESA, methoxy polyethylene glycol-epoetin beta will be administered once monthly.
62586347|NCT06285214|PLACEBO_COMPARATOR|Placebo|
62586348|NCT03651427|EXPERIMENTAL|Transgender Women|"Transgender women who already completed GAS or that agreed to start gonadotropin release hormone analogue to suppress endogenous sex hormones.~If the participants were using CSHT in the moment of the study assignment, they were asked to stop hormones for 30 days to evaluate the impact of hypogonadism in the brain.~After this first assessment, they received prescriptions for Estradiol (equine conjugated oestrogen, or estradiol valerate, or topic 17-beta estradiol formulations) for 60 days, and the impact of CSHT was evaluated again to compare to washout condition."
62586349|NCT06537999|PLACEBO_COMPARATOR|Placebo|
62586350|NCT06537999|EXPERIMENTAL|DNTH103 low dose Q2W|
62586351|NCT06537999|EXPERIMENTAL|DNTH103 high dose Q2W|
62586352|NCT06682052|NO_INTERVENTION|Control group|"After obtaining the consent of the women, the Personal Information Form and the State Anxiety Inventory (STAI) will be filled out and prepared for the examination. The examination table is a stirrup table suitable for examination in the lithotomy position. It can be adjusted according to the height of the woman. When the women are taken to the examination table, a cover will be placed to protect privacy. No intervention other than routine application will be made to the women in the control group. After the Pap smear test is completed, the State Anxiety Inventory (STAI) and the Visual Analog Scale (VAS) will be applied."
62586353|NCT06682052|EXPERIMENTAL|Group to be applied anti-stress ball|"After the women's consent is obtained, the Personal Information Form and State Anxiety Inventory (STAI) will be filled out and prepared for the examination. The examination table is a stirrup table suitable for examination in the lithotomy position. It can be adjusted according to the woman's height. When the women are taken to the examination table, a cover will be placed to protect privacy.~The women will be given a round, silicone, medium-sized and medium-hard anti-stress ball, and they will be told how to use the stress ball, and they will be asked to squeeze the anti-stress ball throughout the examination, allowing the patients to rest occasionally as they wish. The women will be told to count to 3 as they squeeze the anti-stress ball, then to relax the stress ball and repeat this process.~After the Pap smear test is completed, the State Anxiety Inventory (STAI) and the Visual Analog Scale (VAS) will be applied."
62586354|NCT01303406|PLACEBO_COMPARATOR|Placebo|"Following the body weight, patients will be allocated to one of the following regimen:~Placebo Patients \< 45 kg - 3 tablets 3 times a day with meals~Placebo Patients \> 45 kg - 5 tablets 3 times a day with meals"
62586355|NCT01303406|EXPERIMENTAL|idebenone|"Following the body weight, patients will be allocated to one of the following regimen:~Idebenone Patients \< 45 kg - 3 tablets 3 times a day with meals~Idebenone Patients \> 45 kg - 5 tablets 3 times a day with meals"
62586356|NCT06640257|EXPERIMENTAL|SHR-1314 injection|
62586357|NCT06640257|PLACEBO_COMPARATOR|placebo|
62586358|NCT01762202|EXPERIMENTAL|Study therapy|
62586359|NCT03723161||Treatment|Bone Anchored Hearing surgery using a BHX implant manufactured by Oticon Medical
62586360|NCT05800730|EXPERIMENTAL|refined carbohydrate breakfast (Breakfast A)|white bread (50g) + milk powder (25g)
62586361|NCT05800730|EXPERIMENTAL|whole grain breakfast (Breakfast B)|plain oats (35g) + milk powder (25g)
62586362|NCT05800730|EXPERIMENTAL|Energy-restricted diet|
62586363|NCT05800730|EXPERIMENTAL|time-restricted diet|
62586364|NCT02358096|EXPERIMENTAL|ASP8232|ASP8232 administered once daily
62586365|NCT02358096|PLACEBO_COMPARATOR|Placebo|Placebo administered once daily
62586366|NCT05832905||Experiment (observational) group with Mobile and Wearable-assisted Case Management (MCM)|MCM involves the integration of mobile technology, such as smartphones and wearable devices, to supplement TAU. This approach is designed to provide additional support and monitoring to patients through the use of mobile applications and remote contact with healthcare professionals. In this study, MCM was implemented alongside TAU, with patients receiving pharmacotherapy, CBT, and mobile-assisted case management services. The MCM component consisted of regular contact with case managers via telephone and a dedicated mobile application.
62586367|NCT05832905||Control group (TAU)|TAU refers to the standard care provided to patients with panic disorder, which typically includes a combination of pharmacotherapy and psychological or behavioral treatment. In the context of this study, TAU consisted of pharmacological interventions, such as prescribing anxiolytic or antidepressant medications, and psychological interventions, primarily Cognitive Behavioral Therapy (CBT). The administration of TAU was conducted by qualified healthcare professionals who followed established clinical guidelines and treatment protocols to ensure the appropriate management of panic disorder symptoms.
62412771|NCT05007106|EXPERIMENTAL|Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 20 mg once daily (qd) up to 45 cycles.
62412772|NCT05007106|EXPERIMENTAL|Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 12 mg (body weight \[BW\] ≥60 kg) or lenvatinib 8 mg (BW \<60 kg) qd up to 45 cycles
62412773|NCT05007106|EXPERIMENTAL|Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W, plus 5-fluorouracil (5-FU), plus Cisplatin as background therapy.
62586368|NCT02910700|EXPERIMENTAL|Arm A (NDT, CLOSED)|Patients receive nivolumab IV over 30 minutes on day 1, dabrafenib PO BID on days 1-28, and trametinib PO QD on days 1-28. Cycles repeats every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
62586369|NCT02910700|EXPERIMENTAL|Arm B (NT, closed to accrual)|Patients receive nivolumab IV over 30 minutes on day 1 and 15, and trametinib PO QD on days 1-28. Cycles repeats every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
62586370|NCT02910700|EXPERIMENTAL|Arm C (NEB)|Patients receive nivolumab IV over 30 minutes on day 1 and 15, encorafenib PO QD on days 1-28, and binimetinib PO BID on days 1-28. Cycles repeats every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
62586371|NCT06142643|EXPERIMENTAL|Device under investigation|
62218761|NCT03700112|EXPERIMENTAL|Altria Marlboro combustible cigarette - Red|Administration of Altria Marlboro combustible cigarette - Red consumed using 10 puffs delivery method Administration of Altria Marlboro combustible cigarette - Red consumed using ad-libitum delivery method
62218762|NCT02842827|EXPERIMENTAL|Cohort 1a: bomedemstat 0.75 mg/kg/day|Participants receive bomedemstat 0.75 mg/kg/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
62218763|NCT02842827|EXPERIMENTAL|Cohort 1b: bomedemstat 1.5 mg/kg/day|Participants receive bomedemstat 1.5 mg/kg/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
62412774|NCT05007106|EXPERIMENTAL|Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus paclitaxel as background therapy until meeting discontinuation criteria.
62218764|NCT02842827|EXPERIMENTAL|Cohort 1c: bomedemstat 3 mg/kg/day|Participants receive bomedemstat 3 mg/kg/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
62412775|NCT05007106|EXPERIMENTAL|Pembrolizumab/Vibostolimab Co-Formulation + Gemcitabine/Cisplatin|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus gemcitabine (until disease progression or unacceptable toxicity) and cisplatin (up to 8 cycles) as background therapy.
62412776|NCT05007106|EXPERIMENTAL|Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus carboplatin, paclitaxel, and bevacizumab as local standard of care (SOC) background therapy.
62412777|NCT05007106|EXPERIMENTAL|Pembrolizumab/Vibostolimab Co-Formulation + Capecitabine/Oxaliplatin|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus capecitabine and oxaliplatin as background therapy.
62412778|NCT05428059|EXPERIMENTAL|application group|In addition to standard care, training and consultancy will be provided with a mobile application.
62218765|NCT02842827|EXPERIMENTAL|Cohort 1d: bomedemstat 6 mg/kg/day orally|Participants receive bomedemstat 6 mg/kg/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
62218766|NCT02842827|EXPERIMENTAL|Cohort 1x3: bomedemstat 3 mg/kg/day orally plus tretinoin 45 mg/m^2 /day3|Participants receive bomedemstat 3 mg/kg/day orally plus tretinoin 45 mg/m\^2/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
62412779|NCT05428059|NO_INTERVENTION|control group|Standard care will be given
62218767|NCT02842827|EXPERIMENTAL|Cohort 1x6: bomedemstat 6 mg/kg/day plus tretinoin 45 mg/m^2/day|Participants receive bomedemstat 6 mg/kg/day orally plus tretinoin 45 mg/m\^2/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
62218768|NCT02842827|EXPERIMENTAL|Cohort 3x: bomedemstat 6 mg/kg/day plus tretinoin 45 mg/m^2/day|Participants receive bomedemstat 6 mg/kg/day orally plus tretinoin 45 mg/m\^2/day orally in 21-day cycles consisting of 14 days of treatment and 7 days of rest. Participants will receive up to 2 cycles (21-day cycles) for up to a total of up 42 days (28 days on treatment).
62412780|NCT03323359|EXPERIMENTAL|Hemopatch 45x90 mm - CE 0297 Class III|Hemopatch + Common surgical techniques
62412781|NCT03323359|OTHER|Standard Surgery Technique|Common surgical techniques
62412782|NCT01836094|EXPERIMENTAL|Methylene Blue|Methylene Blue, 280mg, oral, one time
62412783|NCT01836094|PLACEBO_COMPARATOR|Placebo|FD\&C Blue No. 2 (food dye), oral, one time
62218769|NCT02842827|EXPERIMENTAL|Cohort 4x: bomedemstat 6 mg/kg/day plus tretinoin 45 mg/m^2/day|Participants receive bomedemstat 6 mg/kg/day orally for 21 days plus tretinoin 45 mg/m\^2/day orally in 28-day cycles consisting of 21 days of treatment and 7 days of rest. Participants will receive at least 1 cycle (28-day cycles) and will receive subsequent cycles at the discretion of the investigator.
62218770|NCT04565847|ACTIVE_COMPARATOR|Healthy Control - Active Arm|Healthy Controls Mannitol-Induced Cough Challenges on Visit 2 to determine elligibility (cough response). Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively. Nebulized salbutamol (5mg/mL) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4.
62794523|NCT05755139|EXPERIMENTAL|IPL with smart diagnostic handpiece|"Standard IPL module which has FDA clearance (K083733) for a wide range of indications including vascular and pigmented lesions. The Universal IPL handpiece (HP) operates at a spectrum of 400-1,200 nm with 7 different cut-off filters and 2 different notch filters that can be easily inserted into the handpiece to treat different conditions.~The SMART Camera is a novel add-on skin diagnostic (SD) tool. The SD module includes a proprietary spectral camera embedded in a handpiece, and proprietary computer vision-based algorithms designed to process the spectral information and to determine the skin attributes and optimal treatment IPL preset."
62794524|NCT04895241|EXPERIMENTAL|Litifilimab High Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive high dose of litifilimab, subcutaneously (SC) every 4 weeks (Q4W), up to Week 48 with an additional dose at Week 2.
62022556|NCT02899728|EXPERIMENTAL|Arm II (chemotherapy, cediranib maleate, olaparib)|"Patients receive treatment as in Arm I and also receive cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28."
62022557|NCT05954897|EXPERIMENTAL|Experimental group|
62218771|NCT04565847|PLACEBO_COMPARATOR|Healthy control - Placebo Arm|Healthy Controls Mannitol-Induced Cough Challenges on Visit 2 to determine elligibility (cough response). Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively. Nebulized 0.9% Saline given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4.
62218772|NCT04100031|EXPERIMENTAL|BCL group|
62794525|NCT04895241|EXPERIMENTAL|Litifilimab Low Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive low dose of litifilimab, SC Q4W, up to Week 48 with an additional dose at Week 2.
62022558|NCT02308033|ACTIVE_COMPARATOR|Metronidazole vaginal gel|One applicator full at bedtime
62022559|NCT02308033|PLACEBO_COMPARATOR|Gel vehicle|One applicator full at bedtime
62218773|NCT04100031|ACTIVE_COMPARATOR|control group|
62433268|NCT05751083|EXPERIMENTAL|brisk walk+ low intensity aerobic exercises group|"this group will perform the following exercises Brisk Walking Protocol~The brisk walking protocol will consist of :~1. 10 min of warm-up period with flexibility exercises of the knees, hips and back~2. 30 min of walking~3. 5 min of cool down.~General flexibility Exercises Protocol Chair Sitting exercise Standing Balance Exercises"
62433269|NCT05751083|ACTIVE_COMPARATOR|brisk walk group|"this group will perform the following exercises Brisk Walking Protocol~The brisk walking protocol will consist of :~1. 10 min: warming up of the knees, hips and back by flexibility exercises~2. 30 min of walking~3. 5 min of cool down."
62433270|NCT02880163|EXPERIMENTAL|ResQFoam|ResQFoam in-vivo expandable foam
62794526|NCT04895241|PLACEBO_COMPARATOR|Placebo|Participants who are receiving background nonbiologic lupus SOC therapy will receive litifilimab-matching placebo, SC Q4W, up to Week 48 with an additional dose at Week 2.
62794527|NCT04869540|ACTIVE_COMPARATOR|Usual care|Families randomized to this arm will receive the usual care by providers trained in the 'Got Transition' toolkit and that have access to web-based transition resources.
62794528|NCT04869540|EXPERIMENTAL|Usual care + PSE|Families randomized to this arm will receive the usual care by providers trained in the 'Got Transition' toolkit and that have access to web-based transition resources and will also receive a family-based problem solving eduction (PSE) intervention.
62794529|NCT00855816|EXPERIMENTAL|Breathing training|relaxation training
62794530|NCT00855816|NO_INTERVENTION|Treatment as usual|treatment as usual
62794531|NCT05973760||Hypertensive|Men or women previously diagnosed with hypertension
62794532|NCT05973760||Non-hypertensive|Men or women not previously diagnosed with hypertension
62794533|NCT01142882|ACTIVE_COMPARATOR|Traditional Prevention|educator-delivered, small-group HIV \& disease prevention education
62794534|NCT01142882|EXPERIMENTAL|Web-based Prevention|self-directed, interactive \& customized web-based HIV \& disease prevention education
62022560|NCT02258477|ACTIVE_COMPARATOR|Sequence 1 (D-B-A-C)|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
62022561|NCT02258477|ACTIVE_COMPARATOR|Sequence 2 (A-D-C-B)|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
62218774|NCT03539887|EXPERIMENTAL|Intranasal ketamine|Intranasal ketamine
62218775|NCT03539887|PLACEBO_COMPARATOR|Placebo|non-active placebo
62218776|NCT01424449|EXPERIMENTAL|no treatment|Aripiprazole is a D2/D3 antagonist registered in the UK for use in the treatment of schizophrenia. It allows the highest clinically acceptable blockade of central D2/D3 receptors and will allow us to examine the amount of displaceable binding in the brain - a proposed reference tissue for \[11C\]PHNO.
62794535|NCT05984680|OTHER|Aim A - Participants and Providers|Arm A will use the user-centered design process to survey pulmonology content experts, oncology providers, and patients and interview a smaller subset. Specifically, we will measure the perceived efficacy of various components of COPD management using a survey of patients with thoracic cancer and oncology providers.
62794536|NCT05984680|OTHER|Arm B - Participants only COPD Care Pathway|Investigators will use the COPD care pathway developed by Arm A as the intervention in single-arm pilot study to test its feasibility and other implementation outcomes.
62794537|NCT05663203|EXPERIMENTAL|Supportive care (CRCWeb intervention)|Patients and caregivers attend a CRCweb intervention over 8 weeks. Patients and caregivers complete interviews and surveys throughout the trial.
62794538|NCT00930384||Psoriasis group|All adult patients fulfilling inclusion criteria will be considered as cases in which psoriasis is detected and diagnosed by our principal investigator based on the clinical criteria accepted by American Academy of Dermatology. They will have an abdominal ultrasound performed by a radiologist to assess for the presence of nonalcoholic fatty liver disease. They will be referred to the research clinic to have a blood drawn.
62022562|NCT02258477|ACTIVE_COMPARATOR|Sequence 3 (C-A-B-D)|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
62022563|NCT02258477|ACTIVE_COMPARATOR|Sequence 4 (B-C-D-A)|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
62412784|NCT05744388|ACTIVE_COMPARATOR|Stylet shape modification group|"Endotracheal tube diameter size 7.5 mm and disposable rigid blade size 3 for the female patients and ETT diameter size 8.00 mm and disposable rigid blade size 4 for the male patients will be prepared. The under surface of the blade will be lubricated by soluble jelly, taking care not to touch the camera source of light.~The stylet will be more obtuse angle than the standard shape. The stylet will be lubricated also before being fitted inside the endotracheal tube. The blade will be introduced inside the mouth midline, the tube will be held from the upper third and introduced in the midline also sliding over the blade and introduced inside the glottis. Once the tip of the tube introduced inside the glottis, the stylet will be removed and the tube will be advanced more inside the trachea. The equality of air entry will be assessed by the stethoscope and the tube will by fixed by adhesive tape after inflating the cuff."
62412785|NCT05744388|NO_INTERVENTION|Standard shape of the stylet group|The second group will be a control group, they will be handled by the standard shape of the stylet and the blade without lubrication.
62412786|NCT06455774|EXPERIMENTAL|Group1- Exercise and Wearable Postural Feedback Devices Group|Participants will wear the postural feedback device for 8 weeks, 3 days a week during their desk work (6-8 hours) and will be included in an exercise program including 30 minutes of stretching and strengthening exercises for the cervical region. Exercises will be performed 3 days a week for 30 minutes and will be supervised by a physiotherapist one day a week.
62412787|NCT06455774|EXPERIMENTAL|Group2- Exercise Group|Participants will receive an exercise program consisting of stretching and strengthening exercises for the cervical region. Exercises will be performed 3 days a week for 30 minutes and will be supervised by a physiotherapist one day a week. Patients will be followed up with an exercise diary.
62412788|NCT06539689|EXPERIMENTAL|Sperstent® peripheral spot stent system|subjects using the Sperstent® peripheral spot stent system
62412789|NCT06539689|ACTIVE_COMPARATOR|Everflex® self-expanding peripheral stent system|subjects using the Everflex® self-expanding peripheral stent system
62218777|NCT04788381||Participants with CRC or lung cancer was performed unexpected operation|This is an observational study; thus, no intervention or treatment is required by the protocol. During the study, enrolled patients may be eligibled if bevacizumab was discontinued within 6 weeks prior to unexpected operation.
62218778|NCT04001543|EXPERIMENTAL|Immunomodulating oral supplementation|"The immunomodulating oral supplementation compound (Oral Impact®) contains 334kcal/bag and 18.1g of proteins, as well as immunomodulatory nutrients such as L-Arginine, RNA and omega-3.~Each bag of product containing powder (74g/bag) will be diluted in 250 millilitres of water by the patients and drunk at home. Three doses will be drunk at home by the patients daily, during the 5 days before each chemotherapy cycle."
62218779|NCT04001543|ACTIVE_COMPARATOR|Sip feed control|"The control has the same formula to that of the Oral Impact®, but not enriched with specific nutrients: it is an isocaloric isonitrogenous control.~Each bag of product containing powder (74g/bag) will be diluted in 250 millilitres of water by the patients and drunk at home. Three doses will be drunk at home by the patients daily, during the 5 days before each chemotherapy cycle."
62218780|NCT06337084|EXPERIMENTAL|MNPR-101-DFO*-89Zr Single Infusion and PET/CT Imaging|Participants receive a single injection of MNPR-101-DFO\*-89Zr on Day 1 with administered activity between 37-74 MBq (or 1-2 mCi). PET/CT imaging will occur post-infusion at 2 h (Day 1), once on Days 3-5, and once on Days 7-10.
62412790|NCT06569017|EXPERIMENTAL|1) Artificial intelligence supported working group|Pregnant women in the artificial intelligence-supported study group were aged 32-37. Starting from the first week of pregnancy, a mobile breastfeeding consultancy application supported by IOS and Android will be installed on smart phones.
62412791|NCT06569017|NO_INTERVENTION|3) Observation group|32-37 in the observation group. A breastfeeding education booklet will be given to primiparous pregnant women at the gestational age.
62794539|NCT00930384||Control group|For every case an age, sex and body mass index (BMI range - kg/m2) matched control will be selected from the same dermatologic/radiologic clinic. The controls will be invited to voluntarily participate and informed consent will be obtained for performing ultrasonography and analytical tests to ensure the absence of manifest hepatic disease.
62794540|NCT04330963||Hypersomnolence group|All patients referred to the outpatient clinic/sleep center for investigation due to complaints for excessive daytime sleepiness (EDS) and/or Hypersomnia (H) and/or suspected central disorder of hypersomnolence (CDH)
62412792|NCT06569017|EXPERIMENTAL|2)Nurse-led online breastfeeding counseling group|32-37. Primiparous pregnant women at the gestational age will be offered 1.5 hours of breastfeeding counseling by one of the researchers, between the 32nd and 37th weeks of pregnancy, with the participation of small groups of five pregnant women in each interactive session.
62412793|NCT04401709|EXPERIMENTAL|Gemcitabine/Capecitabine|gemcitabine1,000 mg/m2 over 30 min D1, D8, D15 capecitabine 1660 mg/m2, D1-21
62412794|NCT04401709|ACTIVE_COMPARATOR|Capecitabine|capecitabine 2,500 mg/m2 D1-14
62412795|NCT02890966|EXPERIMENTAL|Cohort 1|1mg SHR4640 or placebo
62412796|NCT02890966|EXPERIMENTAL|Cohort 2|2.5mg SHR4640 or placebo
62794541|NCT04330963||Healthy controls|Healthy control subjects without complaints of EDS and /or H.
62218781|NCT03812393|EXPERIMENTAL|Treatment|TNBC patients with HER2 signal positive are treated with neratinib for 3 weeks followed by 12 weeks of neratinib in combination with weekly paclitaxel and carboplatin
62794542|NCT04330963||SDB controls|Patients with EDS and diagnosis of severe sleep related breathing disorder (SBD) significantly improving with therapy.
62794543|NCT04330963||Pediatric Hypersomnolence group|Pediatric group aged 10-18. Same criteria for inclusion and exclusion apply as for the adult group.
62794544|NCT03974503|EXPERIMENTAL|Exposure, Relaxation, and Rescripting Therapy (ERRT)|Exposure, Relaxation, \& Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately one hour per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, sleep behavior modification, Progressive Muscle Relaxation, diaphragmatic breathing, exposure to the trauma-nightmare, rescription, and treatment maintenance planning.
62218782|NCT05497401|EXPERIMENTAL|treatment|
62218783|NCT05497401|PLACEBO_COMPARATOR|control|
62218784|NCT02469272|EXPERIMENTAL|Fecal Microbiota Transplantation|Intervention: standardized preparation of frozen fecal material from lean healthy donors Route: infused into the duodenum through the working channel of the instrument at upper endoscopy Dosing: 1 dose
62412797|NCT02890966|EXPERIMENTAL|Cohort 3|5mg SHR4640 or placebo
62218785|NCT00522873|EXPERIMENTAL|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 13 cycles (28 days per cycle).
62412798|NCT02890966|EXPERIMENTAL|Cohort 4|10mg SHR4640 or placebo
62412799|NCT02696304|OTHER|TBI for childhood leukemia|Patients with a metabolic syndrom who received TBI.
62586372|NCT03646526|EXPERIMENTAL|Fast group|"During the study session, healthy subjects will be administered a single dose of Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting） or Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） under fasting condition .~cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） or cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）"
62586373|NCT03646526|EXPERIMENTAL|Feeding group|"During the study session, healthy subjects will be administered a single dose of Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting） or Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） under feeding condition.~cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） or cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）"
62586374|NCT04055493|EXPERIMENTAL|Ribociclib plus ET|Ribociclib 600mg / day over 26 cycles + endocrine treatment of physician´s choice
62586375|NCT04055493|NO_INTERVENTION|Standard-of-care chemotherapy|Standard-of-care chemotherapy according to the clinical guidelines, e.g., of the Breast Committee of the German Gynecological Oncology Group (AGO), and regional prescribing information depending on patient's needs for 16-24 weeks,
62412800|NCT02696304|OTHER|No TBI for childhood leukemia|Patients with a metabolic syndrom without previousTBI
62586376|NCT02423031||Caregivers|caregivers of pediatric patients with cancer and other serious illnesses
62586377|NCT02423031||pediatric patients|pediatric patients with cancer and other serious illnesses
62586378|NCT01812317|ACTIVE_COMPARATOR|Real-fire training exercise|Subjects will undergo a 20 minute standardised training exercise in a fire simulation facility.
62586379|NCT01812317|SHAM_COMPARATOR|Sedentary training session|Subjects will undergo a training exercise where they will remain sedentary for 20 mins in an ambient temperature.
62586380|NCT02442570|ACTIVE_COMPARATOR|DC-TAB 7.5 mg|three intravenous injections of 7.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
62586381|NCT02442570|ACTIVE_COMPARATOR|DC-TAB 12.5 mg|three intravenous injections of 12.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
62586382|NCT02442570|ACTIVE_COMPARATOR|DC-TAB 17.5 mg|three intravenous injections of 17.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
62586383|NCT02442570|PLACEBO_COMPARATOR|placebo|three intravenous injections of placebo, 2 months apart
62586384|NCT04239963||Healthy Controls|Subjects who have no history of clinical depression or other psychological disorder
62586385|NCT04239963||Current MDD|Subjects experiencing a current episode of Major Depressive Disorder.
62586386|NCT03148392||Cryo Balloon Ablation|Arctic Front Advance Cryo Balloon: Mode of ablation determined based on patient and physician preference
62586387|NCT03148392||Radiofrequency Ablation|Contact Force Sensing Radiofrequency Catheter Ablation: Mode of ablation determined based on patient and physician preference
62218786|NCT00522873|ACTIVE_COMPARATOR|0.5mg NETA / 1.0mg E2 (Activella)|One capsule \[0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)\] per day taken orally for 13 cycles (28 days per cycle).
62218787|NCT05315765||Phase 1|Qualitative interviews with patients to generate thematic framework and questionnaire
62218788|NCT05315765||Phase 2|Face validity assessment of questionnaire
62412801|NCT03965507||The group with sacroiliac joint dysfunction|The patient with sacroiliac joint dysfunction in lumbar disc hernia
62412802|NCT03965507||The group without sacroiliac joint dysfunction|The patient without sacroiliac joint dysfunction in lumbar disc hernia
62433271|NCT03809013|EXPERIMENTAL|RC48-ADC|Participants will be treated with RC48-ADC 2.0 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
62412803|NCT04501159||End-stage renal disease (ESRD)|Patients with end-stage renal disease undergoing regular haemodialysis 3 times weekly.The investigation will measure cardiac output (CO), oxygen saturation (SaO2), arterial blood gases (ABG) and white blood cell (WBC) count during HD to assess changes in haemodynamics, pH, leukostasis and hypoxia. Patients undergoing regular HD will be recruited with arterial blood samples for gas analysis drawn over three consecutive HD treatments. Arterial samples will be taken at the start, 15 minutes and end of HD treatment for ABG and WBC analysis. Dialysis membrane, ultrafiltration volume, serum and dialysate bicarbonate levels will also be recorded. Regression analysis will be performed with pH, ABG and SaO2. A subset of patients will be used to assess an if cardiac output, WBC or pH better predicts PaO2 during HD.
62412804|NCT02384837||TCFA|EXCEL biodegradable polymer-coated sirolimus-eluting stent was implanted on lesions which include TCFA (\>=1)
62586388|NCT01146379|EXPERIMENTAL|Low Movement Dose, 3200 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
62794545|NCT03974503|ACTIVE_COMPARATOR|Sleep and Nightmare Management|This treatment protocol has amounts of therapist contact, handouts, and homework between sessions equivalent to those in ERRT. The protocol contains psychoeducation about sleep disturbances and trauma-related nightmares, including their distressing nature, chronicity, and impact on sleep and daytime functioning. Additionally, basic sleep behavior modification are presented. No nightmare content or rescripting will be explicitly discussed, and the diaphragmatic breathing techniques will be omitted from this protocol.
62794546|NCT04439539|EXPERIMENTAL|Cohort 1: Participants Enrolled Prior to Protocol Amendment 5 is in Effect|During the Induction phase, participants will receive JNJ-73763989 subcutaneously along with JNJ-56136379 tablet orally with NA (either tenofovir disoproxil or tenofovir alafenamide tablets orally) treatment. At the start of consolidation phase, participants will be randomized to receive PegIFN-alpha-2a subcutaneously in addition to JNJ-73763989 and JNJ-56136379 with NA in arm 1 and arm 2 (without PegIFN-alpha-2a). According to predefined criteria NA treatment may be continued during the follow up (FU) phase.
62794547|NCT04439539|EXPERIMENTAL|Cohort 2: Participants Enrolled After Protocol Amendment 5 is in Effect|Following implementation of protocol amendment- 5 and 6, all participants will receive JNJ-73763989 subcutaneously along with NA (tenofovir disoproxil tablets orally) for 36 weeks (induction phase). In the consolidation phase, participants will receive PegIFN-alpha-2a subcutaneously in addition to JNJ-73763989 and NA for 12 weeks. According to predefined criteria NA treatment may be continued during the follow up (FU) phase. JNJ-56136379 (JNJ-6379) was discontinued as per amendment 6 of the study.
62794548|NCT05871099|EXPERIMENTAL|Experimental group|Experimental group receive laparoscopic (robotic) D2 surgery plus HIPEC2 times plus systemic chemotherapy 6\~8 cycles.
62794549|NCT05871099|NO_INTERVENTION|Control group|Control group receive laparoscopic (robotic) D2 surgery + systemic chemotherapy 6-8 cycles
62794550|NCT03376737|EXPERIMENTAL|Apatinib + Pemetrexed|Apatinib + Pemetrexed
62794551|NCT00971074|EXPERIMENTAL|Hylan G-F 20|Single injection of Hylan G-F 20 into the affected knee.
62218789|NCT05315765||Phase 3|Completion of questionnaire to refine scale and item list
62218790|NCT00461032|EXPERIMENTAL|1|montelukast
62412805|NCT02384837||NO-TCFA|EXCEL biodegradable polymer-coated sirolimus-eluting stent was implanted on lesions which is not include TCFA
62412806|NCT03607552||Phase 1: Pilot Study Phase|Optimize DWI sequences to maximize spatial resolution, reduce distortion, and increase lesion contrast.
62794552|NCT00971074|SHAM_COMPARATOR|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
62794553|NCT05939362|EXPERIMENTAL|patient with early onset Alzheimer's disease|
62794554|NCT02645292|EXPERIMENTAL|1 mile Walk using treadmill|Walking for 1 mile on treadmill (American Motion Fitness, 8800D) as fast as participant can, without any inclination
62218791|NCT00461032|PLACEBO_COMPARATOR|2|Placebo
62218792|NCT06212401|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine in a 2 ml ampule of 100 ug/ml diluted in 18 ml of normal saline, making a total volume of 20 ml.
62412807|NCT03607552||Phase 2: Development Phase|Develop interpretation tools to optimize diagnostic performance for detecting cx on DWI.
62412808|NCT03607552||Phase 3: Reader Performance Phase|Test the performance of the optimized DWI approach for detecting clinically and mammographically-occult cancer in women with dense breasts.
62412809|NCT02773641|ACTIVE_COMPARATOR|Botulinum Toxin Type A|50 Allergan units (0.5 ml) injected in m bulbocavernosus twice with 3 months in between treatments
62412810|NCT02773641|PLACEBO_COMPARATOR|Sterile saline solution|0.5 ml of sterile saline injected in m bulbocavernosus twice with 3 months in between treatments
62412811|NCT05925309|ACTIVE_COMPARATOR|Antibiotics group|Basic treatment + Prophylactic oral antibiotics
62794555|NCT02645292|EXPERIMENTAL|Stair Climbing|30 meters of vertical distance to be covered (14 flights of stairs with a total of 154 steps)
62794556|NCT06669117|EXPERIMENTAL|VERT-002|"Part 1: Dose escalation (Phase Ia): VERT-002 will be administered via intravenous (IV) infusion every 2 weeks. 4 provisional doses are planned. An alternative regimen may be tested informed by the emerging data~Part 2a: Preliminary Activity Assessment (Phase Ib): One dose \& schedule selected from Part 1~Part 2b: Dose range optimization (Phase Ib): 2 or 3 doses \& schedule selected from Part 1: From the lower limit \[Optimal Biologically Active Dose (OBD)\] \& upper limit \[Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) if MTD is not reached\]~Part 3: Dose Expansion at RP2D (Phase II): To be defined later on"
62794557|NCT06587490|EXPERIMENTAL|SABR+SOC|stereotactic ablative radiotherapy (SABR) plus standard of care (SOC) cancer therapy
62794558|NCT06587490|NO_INTERVENTION|SOC|standard of care (SOC) cancer therapy
62794559|NCT06260800||CEQ Validation|In initial assessment, EQ-5D-5L and HADS questionnaires were completed. After sessions 1 and 2, CEQ and WAI-S were filled. Finally, EQ-5D-5L was completed before the fourth session.
62794560|NCT02354014|EXPERIMENTAL|TMC207/Background Regimen (BR)|There will be 4 age-based cohorts. Participants will be enrolled concurrently in Cohorts 1 and 2 followed by sequential enrollment of Cohorts 3, 4. Cohort 1: \>= 12 to \< 18 years: bedaquiline (TMC207) tablet orally as 400 mg, once daily(qd),for first 2 weeks, followed by TMC207, 200 mg 3 times per week (tiw) for 22 weeks; Cohort 2: \>=5 to \<12 years: TMC207 tablet given orally as 200 mg, qd, for first 2 weeks, followed by TMC207, 100 mg, tiw for 22 weeks. Cohort 3: \>=2 to \<5 years: TMC207 8 milligram per kilogram (mg/kg) qd for the first 2 weeks, followed by TMC207 4 mg/kg tiw for 22 weeks. Cohort 4: 0 months to \<2 years: TMC207 dose will be selected based on the results from the previous cohorts 1, 2 and 3. TMC207 will be given in combination with Background Regimen for Multidrug Resistant Tuberculosis (MDR-TB) according to WHO/National Tuberculosis Program (NTP) guidelines/current standard of care.
62794561|NCT04770038||Patient Group|56 BPD patients
62794562|NCT04770038||Control Group|31 Healthy participants
62218793|NCT06212401|ACTIVE_COMPARATOR|Ketofol|2 ml ketamine (50mg/ml) and 10 ml of propofol 1% (10mg/ml) diluted in 8 ml of normal saline. This mixture was 20 ml each, making 5mg/ml of ketamine and propofol.
62412812|NCT05925309|EXPERIMENTAL|Non-antibiotics group|Basic treatment
62586389|NCT01146379|EXPERIMENTAL|Medium Movement Dose, 6400 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
62794563|NCT06674525|EXPERIMENTAL|626 Group S1 for subcutaneous injection|dose level 1 of 626
62022564|NCT05715580|ACTIVE_COMPARATOR|Intervention group|The nursing intervention will consist of providing information to the patient with a KT about the importance of following the prescribed therapeutic regimen, at the same time the information they may have about healthy lifestyle habits will be expanded, with special emphasis on those areas in which there has been detected, through the administered questionnaires, a lack of adherence.
62794564|NCT06674525|EXPERIMENTAL|626 Group S2 for subcutaneous injection|dose level 2 of 626
62794565|NCT06674525|EXPERIMENTAL|626 Group S3 for subcutaneous injection|dose level 3 of 626
62794566|NCT06674525|EXPERIMENTAL|626 Group S4 for subcutaneous injection|dose level 4 of 626
62794567|NCT06674525|EXPERIMENTAL|626 Group S5 for subcutaneous injection|dose level 5 of 626
62022565|NCT05715580|PLACEBO_COMPARATOR|Control group|The control group will be informed of the same aspects following the usual clinical practice, which consists of providing the information in the immediate post-transplant period, and resolving any doubts that the patient may have during the subsequent time.
62218794|NCT05995327||spine degenerative disease|patients with spine degenerative disease
62218795|NCT05995327||spine tumor|patients with spinal tumors
62218796|NCT05995327||spine deformity|patients with spinal deformity
62412813|NCT01585896|EXPERIMENTAL|Self-help group|The facilitated self-help group, which represents an empirically supported intervention for hoarding (Frost et al., 2011).
62412814|NCT04243655|EXPERIMENTAL|Hemoperfusion treatment with HA 330-II|Hemoperfusion treatment with HA 330-II, one unit for 2-4 hours treatment, for 3 consecutive days along with SMT as per patients requirement.
62218797|NCT05995327||spine fracture|patients with spine fracture
62218798|NCT03192657|EXPERIMENTAL|Basiliximab group|"1. Basiliximab: 20mg injection each time at day1 and day5, respectively. The first administration should be within 8 weeks after disease onset.~2. Calcineurin inhibitors: cyclosporin A 3-5mg/kg/d or tacrolimus 0.05-0.10mg/kg/d.~3. Steroids: 1mg/kg/d, calculated with prednisone."
62218799|NCT03192657|ACTIVE_COMPARATOR|control group|"1. Calcineurin inhibitors: cyclosporin A 3-5mg/kg/d or tacrolimus 0.05-0.10mg/kg/d.~2. Steroids: 1mg/kg/d, calculated with prednisone."
62412815|NCT04243655|ACTIVE_COMPARATOR|Standard medical treatment (SMT)|SMT as per patients requirement- Management of cerebral edema/intracranial hypertension: prophylactic antibiotics, administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure, volume replacement and pressor support (noradrenaline, doubutamine, dopamine) as needed, NAC and correction of metabolic parameters.
62433272|NCT03426319||Primary adrenal insufficiency|Patients with primary adrenal insufficiency on hormone replacement therapy with hydrocortisone.
62794568|NCT06674525|EXPERIMENTAL|626 Group S6 for subcutaneous injection|dose level 6 of 626
62794569|NCT03545438|PLACEBO_COMPARATOR|cohort 1|LIB003 dose 1 SC
62794570|NCT03545438|PLACEBO_COMPARATOR|cohort 2|LIB003 dose 2 SC
62794571|NCT03545438|PLACEBO_COMPARATOR|cohort 3|LIB003 dose 4 SC
62794572|NCT03545438|PLACEBO_COMPARATOR|cohort 4|LIB003 dose 4 SC
62794573|NCT03545438|PLACEBO_COMPARATOR|cohort 5|LIB003 dose 5 SC
62794574|NCT03545438|PLACEBO_COMPARATOR|cohort 6|LIB003 dose 4 IV
62794575|NCT03545438|PLACEBO_COMPARATOR|cohort 7|LIB003 dose 5 IV
62022566|NCT06210256|EXPERIMENTAL|the unidirectional valve group|In the unidirectional valve group, as soon as disinfection and draping began, the lumen of the Y-connector to the non-ventilated lung was clamped and the unidirectional valve device was fastened to the bronchoscope port of the tracheal lumen to initial the one-lung ventilation.
62022567|NCT06210256|ACTIVE_COMPARATOR|the closed lumen group|In the closed lumen group, as soon as disinfection and draping began, the lumen of the Y-connector to the non-ventilated lung was clamped, and the bronchoscope port of the tracheal lumen was sealed off from the atmosphere until pleural opening. When the pleura opened, the bronchoscope port opened to the air for 30 seconds before closing once more until the one-lung ventilation was completed.
62218800|NCT05921825||Non survivors group|At 28 day, patients were divided into Non survivors group and Survivors group.
62412816|NCT06650241|EXPERIMENTAL|Behavioral therapy|Behavioral Therapy Group: Children were rewarded with their favorite candy or toys as positive reinforcement when they refrained from sucking their lower lip. When they exhibited lip-sucking behavior, corresponding punishments were applied (e.g., being prohibited from watching cartoons for 1 hour or from playing with toys) as negative reinforcement. At night, bitter nail polish or substances with unpleasant smells were applied to the lower lip as aversive stimuli. Patients attended follow-up appointments monthly.
62412817|NCT06650241|EXPERIMENTAL|Maxillary lip bumper appliance|Lip Bumper Therapy Group: The treatment involved placing arrow-shaped clasps and interproximal hooks on the maxillary molars, with a double-curved labial bow positioned on the labial side of the upper anterior teeth. A lip bumper wire was soldered at the position of the maxillary central incisors. The lip bumper wire should reach the mandibular vestibular groove to support the lower lip without obstructing the natural labial adjustment of the lower anterior teeth. Patients were required to wear the appliance at all times except during meals and oral hygiene activities. Monthly follow-up appointments were conducted, during which the double-curved labial bow could be adjusted to retract the upper anterior teeth.
62412818|NCT06650241|EXPERIMENTAL|Twin-block|Modified Twin-Block Therapy Group: Initially, occlusal reconstruction was performed, with the combined forward movement of the mandible and vertical dimension being less than 10 mm. The standard criteria were an incisal edge-to-edge bite of the upper and lower anterior teeth, with the vertical opening in the posterior region exceeding the resting occlusal gap by 2-3 mm. Patients were required to wear the appliance at all times except during meals and oral hygiene activities. Monthly follow-up appointments included progressive grinding of the maxillary occlusal pads. If discrepancies in arch width occurred, expansion therapy was implemented.
62412819|NCT03184376|EXPERIMENTAL|Prebiotic|Prebiotic oligofructose (Orafti P95, Beneo-Orafti Inc., Tienen, Belgium) taken 8g orally per day for 12 weeks followed by 16g per day for 24 weeks.
62412820|NCT03184376|PLACEBO_COMPARATOR|Placebo|Placebo maltodextrin (isocaloric to prebiotic) taken 3.3g orally per day for 12 weeks followed by 6.6g per day for 24 weeks.
62412821|NCT04692103|EXPERIMENTAL|Diagnostic (F-18 FES PET/CT)|Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.
62412822|NCT05978817|EXPERIMENTAL|Damon Ultima brackets|Damon Ultima brackets
62412823|NCT05978817|EXPERIMENTAL|conventional Roth appliance|conventional Roth appliance
62412824|NCT04338256||Students enrolled in the Wellness Course|Students in this group are enrolled in the Wellness Course for the Spring 2020 or Fall 2020 semesters
62412825|NCT04338256||Controls|Students in this group are enrolled at study sites during the Spring 2020 or Fall 2020 semesters, but are not enrolled in the Wellness Course
62586390|NCT01146379|EXPERIMENTAL|High Movement Dose, 9600 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
62586391|NCT01146379|EXPERIMENTAL|Individual Maximum High Movement Dose|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
62022568|NCT02825394||apixaban initiation|N=20
62022569|NCT02825394||apixaban on-treatment|N=20
62022570|NCT02825394||dabigatran initiation|N=20
62022571|NCT02825394||dabigatran on-treatment|N=20
62022572|NCT02825394||rivaroxaban initiation|N=20
62022573|NCT02825394||rivaroxaban on-treatment|N=20
62022574|NCT02825394||edoxaban initiation|N=20
62022575|NCT02825394||edoxaban on-treatment|N=20
62022576|NCT03060941|EXPERIMENTAL|Group 1|Physical activity education
62022577|NCT03060941|EXPERIMENTAL|Group 2|Physical activity education and facility access
62218801|NCT05921825||Survivors group|At 28 day, patients were divided into Non survivors group and Survivors group.
62218802|NCT01165931|EXPERIMENTAL|Arm 1|
62243345|NCT03057314|EXPERIMENTAL|Amorphous calcium carbonate|"The investigation product will include:~1. ACC tablets, containing 200 mg elemental calcium~2. 1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension"
62243346|NCT01864772|EXPERIMENTAL|Carbo, 5FU, Cetuximab|"6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity"
62243347|NCT01430806|OTHER|Dronedrone Arm|
62412826|NCT06358157|EXPERIMENTAL|Ladera LBC System|The Ladera LBC System will be used in all participants enrolled in the study
62022578|NCT03060941|EXPERIMENTAL|Group 3|Physical activity education and supervised exercise sessions
62412827|NCT06150872|EXPERIMENTAL|Photochemical tissue passivation group|Photochemical tissue passivation of a saphenous vein graft
62022579|NCT03060941|EXPERIMENTAL|Group 4|Physical activity education and self-monitoring (Fitbit)
62022580|NCT03060941|EXPERIMENTAL|Group 5|Physical activity education and active living counseling
62412828|NCT06150872|NO_INTERVENTION|Standard of care group|Standard of care treatment of a saphenous vein graft
62412829|NCT04677907|ACTIVE_COMPARATOR|Cemented knee replacement|total knee replacement with cemented modular knee replacement as per current standard for total knee replacements.
62586392|NCT02497963|EXPERIMENTAL|Foreskin Graft-Tubularized Incised Plate|Group of patients with primary hypospadias undergoing Foreskin Graft Tubularized Incised Plate Urethroplasty. The surgery involves making an incision on the midline of the urethral plate, graft inner foreskin, and create a new urethra on a urethral catheter.
62794576|NCT03545438|PLACEBO_COMPARATOR|cohort 8|LIB003 dose 3 SC - statin treated
62794577|NCT03545438|PLACEBO_COMPARATOR|cohort 9|LIB003 dose 4 SC - statin treated
62022581|NCT03060941|EXPERIMENTAL|Group 6|Physical activity education, facility access, and supervised exercise sessions
62412830|NCT04677907|EXPERIMENTAL|Uncemented knee replacement|total knee replacement with uncemented modular knee replacement, which is CE certified and accepted in the field.
62412831|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 1|
62412832|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 2|
62412833|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 3|
62412834|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 4|
62412835|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 5|
62412836|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 6|
62412837|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 7|
62412838|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 8|
62412839|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 9|
62412840|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 10|
62412841|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 11|
62412842|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 12|
62412843|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 13|
62794578|NCT02246959|NO_INTERVENTION|Control Arm|Arm 1 will be the Control arm, in which participants receive electronic pill bottles for their statin medication but are not enrolled in the sweepstakes.
62794579|NCT02246959|EXPERIMENTAL|Process Arm|Arm 2 will be a Process incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication.
62794580|NCT02246959|EXPERIMENTAL|Outcome Arm|Arm 3 will be an Outcome incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group may receive incentives if they lower their LDL.
62022582|NCT03060941|EXPERIMENTAL|Group 7|Physical activity education, facility access, and self-monitoring (Fitbit)
62022583|NCT03060941|EXPERIMENTAL|Group 8|Physical activity education, facility access, and active living counseling
62022584|NCT03060941|EXPERIMENTAL|Group 9|Physical activity education, supervised exercise sessions, and self-monitoring (Fitbit)
62022585|NCT03060941|EXPERIMENTAL|Group 10|Physical activity education, supervised exercise sessions, and active living counseling
62412844|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 14|
62412845|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 15|
62412846|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 16|
62412847|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 17|
62412848|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 18|
62412849|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 19|
62412850|NCT05958979|EXPERIMENTAL|E-cigarette e-liquid 20|
62412851|NCT05413395|EXPERIMENTAL|Protocol|"Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation with a modified plant oil (Activated Oil, AO) applied to designated target lesion sites and non-lesion sites (study sites) twice per day for 14 days, followed by a 7-day regression durability period during when no product is applied."
62433273|NCT02162030|OTHER|Full ACT|Acceptance and Commitment Therapy
62794581|NCT02246959|EXPERIMENTAL|Process Plus Outcome Arm|Arm 4 will be a process plus outcome incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication and receive additional incentives for lowering their LDL cholesterol.
62794582|NCT01675518|EXPERIMENTAL|Part-1 dose 1|
62243348|NCT05440643|EXPERIMENTAL|Part 1: Cohort 1|Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
62412852|NCT05413395|ACTIVE_COMPARATOR|Control|"Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation amended with deionized water to match the colloidal oatmeal concentration of the Protocol arm applied to designated target lesion sites and non-lesion sites (study sites) twice per day for 14 days, followed by a 7-day regression durability period during when no product is applied."
62412853|NCT04466436||CABG group|
62412854|NCT04466436||spine group|
62412855|NCT05345418|EXPERIMENTAL|Umbilical Cord-Derived Mesenchymal Stem Cell, then Placebo (group A)|"Cohort 1 will receive two single intravenous dose of UC MSCs of 1.5 million cells per kilogram body weight on their Study Month 0, and Study Month 3.~- Each treatment period was separated by a 4 - week washout to allow the effective systemic elimination of the UC MSCs before subsequent treatment initiation"
62412856|NCT05345418|ACTIVE_COMPARATOR|Placebo, then Umbilical Cord-Derived Mesenchymal Stem Cell (group B)|Cohort 2 will receive two single intravenous dose of UC MSCs of 1.5 million cells per kilogram body weight on their Study Month 7, and Study Month 10
62412857|NCT06466057|EXPERIMENTAL|Metacognitive Therapy|Intervention using metacognitive therapy, with sessions set for 8-15 weeks of 1-2 weekly psychotherapeutic dialogue.
62412858|NCT06466057|PLACEBO_COMPARATOR|Control Condition|Do not receive any additional psychotherapy in addition to conventional treatment.
62412859|NCT00244881|EXPERIMENTAL|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
62412860|NCT01293682|EXPERIMENTAL|Calcitriol|Calcitriol 45mcg/week
62412861|NCT05804123|PLACEBO_COMPARATOR|Control - Acute rhinosinusitis (ARS) subgroup|"The Control - ARS subgroup receives the routine treatment and uses 0.9% NaCl physiological saline:~Routine treatment (at the Thai Binh Medical University Hospital) is as follows:~* Oral-administrative antibiotics: Augmentin (Amoxicillin and Acid Clavulanic).~* Oral-administrative expectorant: Acetylcysteine~* Nasal- spraying decongestant: Xylometazoline (Otrivin®)"
62412862|NCT05804123|EXPERIMENTAL|Navax - Acute rhinosinusitis (ARS) subgroup|"Navax - ARS subgroup receives the routine treatment and uses NaCl 0.9% plus B. subtilis and B. clausii at 5 billion Colony Forming Units (CFU)/5 mL (LiveSpo® Navax):~Routine treatment (at the Thai Binh Medical University Hospital) is as follows:~* Oral-administrative antibiotics: Augmentin (Amoxicillin and Acid Clavulanic).~* Oral-administrative expectorant: Acetylcysteine~* Nasal- spraying decongestant: Xylometazoline (Otrivin®)"
62412863|NCT05804123|PLACEBO_COMPARATOR|Control - ARS accompanied by the AOM (ARS & AOM) subgroup|"The Control - ARS \& AOM subgroup receives the routine treatment and uses 0.9% NaCl physiological saline:~Routine treatment (at the Thai Binh Children's Hospital) is as follows:~* Oral-administrative antibiotics: Augmentin (Amoxicillin and Acid Clavulanic). Or injection or infusion-administrative antibiotics such as Imetoxim (Cefotaxime).~* Antibiotic ear drops: Ciprofloxacin~* Nasal- spraying decongestant: Xylometazoline (Otrivin®)"
62412864|NCT05804123|EXPERIMENTAL|Navax - ARS accompanied by the AOM (ARS & AOM) subgroup|"Navax - ARS \& AOM subgroup receives the routine treatment and uses NaCl 0.9% plus B. subtilis and B. clausii at 5 billion CFU/5 mL (LiveSpo® Navax):~Routine treatment (at the Thai Binh Children's Hospital) is as follows:~* Oral-administrative antibiotics: Augmentin (Amoxicillin and Acid Clavulanic). Or injection or infusion-administrative antibiotics such as Imetoxim (Cefotaxime).~* Antibiotic ear drops: Ciprofloxacin~* Nasal- spraying decongestant: Xylometazoline (Otrivin®)"
62412865|NCT01583400|ACTIVE_COMPARATOR|RESPECT-D|The RESPECT-D Model: Collaborative Care depression treatment within primary care including care manager
62412866|NCT01583400|EXPERIMENTAL|RESPECT-D-E|RESPECT-D-E: Collaborative Care depression treatment within primary care including care manager plus on-line coaching, education and symptom, side effect and, medication adherence tracking with the digital health coaching program for depressive symptoms.
62412867|NCT04955210||Severe infection|Children with severe infection in PICU
62412868|NCT05669924|EXPERIMENTAL|Methylphenidate|
62794583|NCT01675518|EXPERIMENTAL|Part-1 dose 2|
62794584|NCT01675518|EXPERIMENTAL|Part-1 dose 3|
62794585|NCT01675518|EXPERIMENTAL|Part-1 dose 4|
62412869|NCT05669924|PLACEBO_COMPARATOR|Placebo|
62794586|NCT01675518|EXPERIMENTAL|Part-1 dose 5|
62794587|NCT01675518|EXPERIMENTAL|Part-1 dose 6|
62022586|NCT03060941|EXPERIMENTAL|Group 11|Physical activity education, self-monitoring (Fitbit), and active living counseling
62794588|NCT01675518|PLACEBO_COMPARATOR|Part-1 placebo|
62794589|NCT01675518|EXPERIMENTAL|Part-2 fed|
62794590|NCT01675518|EXPERIMENTAL|Part-2 fasted|
62794591|NCT03263624|EXPERIMENTAL|Group (A)|fractional carbon dioxide laser plus tazarotene 0.1% cream
62794592|NCT03263624|ACTIVE_COMPARATOR|Group (B)|Tazarotene Cream 0.1%
62794593|NCT05683834|PLACEBO_COMPARATOR|Control|The placebo will be delivered intramuscularly into the deltoid muscle at Days 0, 30, and between 60 and 90. Each dose will consist of 0.4mL normal saline.
62022587|NCT03060941|EXPERIMENTAL|Group 12|Physical activity education, facility access, supervised exercise sessions, and self-monitoring (Fitbit)
62022588|NCT03060941|EXPERIMENTAL|Group 13|Physical activity education, facility access, supervised exercise sessions, and active living counseling
62022589|NCT03060941|EXPERIMENTAL|Group 14|Physical activity education, facility access, self-monitoring (Fitbit), and active living counseling
62243349|NCT05440643|EXPERIMENTAL|Part 1: Cohort 2|Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
62243350|NCT05440643|EXPERIMENTAL|Part 1: Cohort 3|Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
62243351|NCT05440643|EXPERIMENTAL|Part 1: Cohort 4|Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
62243352|NCT05440643|EXPERIMENTAL|Part 1: Cohort 5|Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
62794594|NCT05683834|EXPERIMENTAL|Interventional|The gp350-Ferritin vaccine will be delivered intramuscularly into the deltoid muscle at Days 0, 30, and between 60 and 90. Each vaccine dose will consist of 50 micrograms of EBV gp350-Ferritin combined with 49 micrograms of Matrix-M1 adjuvant.
62218803|NCT01850277|EXPERIMENTAL|Rhythm control|"In this group a strategy to restore and maintain SR, including amiodarone and an external electrical cardioversion (EEC), is implemented. A procedure of AF ablation is possible but not obligatory.~At baseline, patients assigned to the group undergo a standard 12-lead ECG, a 6-minute walk test (6MWT), a cardiopulmonary exercise test(CPX), an echocardiography(ECHO), a standard device control; a serum thyroid -stimulating hormone (TSH) level is assessed and patients fill the Minnesota Living With Heart Failure Questionnaire (MLHFQ). Control visits are performed every 3 months including a 12-lead ECG measurement and a device control. On the visits in the 3rd and 12th month an ECHO, a CPX, a 6MWT are performed and a MLHFQ is filled; control TSH levels are assessed every 6 months."
62218804|NCT01850277|ACTIVE_COMPARATOR|Rate control|"In the latter group a pharmacotherapy to slow and control ventricular rate by means of pharmacotherapy and an atrio-ventricular junction ablation (AVJA) is implemented.~At baseline, each patient assigned to the rate control group undergoes a standard 12-lead ECG, a 6MWT, a CPX, an ECHO, a standard device control and a serum TSH level assessed. Moreover, the patient fills the Minnesota Living With Heart Failure Questionaire (MLHFQ). The control visits are performed for one year, every 3 months including a standard 12-lead ECG measurement and standard control of the device. On the visits in the 3rd and 12th month additionally an ECHO, a CPX, a 6MWT are performed and a MLHFQ is filled. The control TSH levels are assessed every 6 months."
62218805|NCT03061071|EXPERIMENTAL|Randomized to SPT First: APAP Second|Randomized to order of treatment (SPT first or APAP first) for a total of 6 weeks home use with each treatment.
62218806|NCT03061071|EXPERIMENTAL|Randomized to APAP First: SPT Second|Randomized to order of treatment (APAP first or SPT first) for a total of 6 weeks home use with each treatment.
62412870|NCT06652425|EXPERIMENTAL|Low temperature (16°C) group|Subjects in exposure group will be exposed to low temperature (16°C) for about 2 hours in a chamber.
62794595|NCT04487080|EXPERIMENTAL|Treatment Arm A (Open-label): Amivantamab and Lazertinib|Participants will receive amivantamab 1050 milligram (mg) intravenously (IV) for body weight less than (\<) 80 kilogram (kg) and 1400 mg for body weight greater than or equal to (\>=) 80 kg in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2), and then every 2 weeks in subsequent cycles. Lazertinib will be administered 240 mg (80\*3) orally once daily.
62218807|NCT03251391|EXPERIMENTAL|Cardiac Rehabilitation Group|Participants randomized to this group will undergo cardiac rehabilitation program.
62218808|NCT03251391|ACTIVE_COMPARATOR|Control Group|Participants randomized to this group will receive care for their condition, conventional therapy, that they would normally receive.
62412871|NCT06652425|EXPERIMENTAL|Moderate temperature (22°C) group|Subjects in exposure group will be exposed to moderate temperature (22°C) for about 2 hours in a chamber.
62794596|NCT04487080|ACTIVE_COMPARATOR|Treatment Arm B (Double-blind): Osimertinib+Placebo Lazertinib|Participants will receive osimertinib 80 mg orally once daily plus matching placebo of lazertinib 240 mg (80\*3) orally once daily.
62794597|NCT04487080|EXPERIMENTAL|Treatment Arm C (Double-blind): Lazertinib+Placebo Osimertinib|Participants will receive lazertinib 240 mg (80\*3) orally once daily plus matching placebo of osimertinib 80 mg orally once daily.
62794598|NCT05421013|EXPERIMENTAL|STP705 30ug|STP705 will be administered once weekly for 6 weeks
62794599|NCT05421013|EXPERIMENTAL|STP705 60ug|STP705 will be administered once weekly for 6 weeks
62794600|NCT05421013|EXPERIMENTAL|STP705 90ug|STP705 will be administered once weekly for 6 weeks
62794601|NCT06577597|EXPERIMENTAL|GSK3923868|Participants from Chinese, Japanese and European ancestries will receive single dose of GSK3923868.
62794602|NCT06577597|PLACEBO_COMPARATOR|Placebo|Participants from Chinese, Japanese and European ancestries will receive single dose of placebo.
62794603|NCT05476783|EXPERIMENTAL|TB006 4000 mg|TB006 4000 milligram (mg) via a 1-hour continuous intravenous (IV) infusion will be administered once every 28 day
62794604|NCT02784171|ACTIVE_COMPARATOR|Arm A - Cisplatin/Pemetrexed|Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles
62794605|NCT02784171|ACTIVE_COMPARATOR|Arm B - Cisplatin/Pemetrexed/Pembrolizumab|Pembrolizumab 200 mg\* IV Day 1 over 30 min every 21 days for a total of 2 years Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles
62586393|NCT02497963|ACTIVE_COMPARATOR|Tubularized Incised Plate|Group of patients with primary hypospadias undergoing Tubularized Incised Plate Urethroplasty. The surgery involves making an incision on the midline of the urethral plate, and create a new urethra on a urethral catheter.
62412872|NCT03107416|EXPERIMENTAL|Bumetanide|Three escalating doses of bumetanide will be used: 0.01 mg/kg (level 1), 0.02 mg/kg (level 2) and 0.04 mg/kg (level 3) in a standard 3+3 design. Starting with level 1, three patients will first be enrolled at each level.
62022590|NCT03060941|EXPERIMENTAL|Group 15|Physical activity education, supervised exercise sessions, self-monitoring (Fitbit), and active living counseling
62218809|NCT04369716|ACTIVE_COMPARATOR|Whole fruit 1|Oranges
62412873|NCT02591173|EXPERIMENTAL|Angiotensin-(1-7)|Patients will receive an intravenous infusion of five ascending doses of Angiotensin-(1-7). The doses are: 1, 2, 4, 8 and 16 ng/kg/min. Each dose will be maintained for 10 minutes, for a total of 50 minutes.
62412874|NCT02591173|PLACEBO_COMPARATOR|Saline|Patients will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will be maintained for 50 minutes.
62412875|NCT01205373|EXPERIMENTAL|BI 671800 high dose|Oral drinking solution
62218810|NCT04369716|ACTIVE_COMPARATOR|Whole fruit 2|Apples
62586394|NCT00621868|EXPERIMENTAL|1|Lowest dose
62586395|NCT00621868|EXPERIMENTAL|2|Low-middle dose
62022591|NCT03060941|EXPERIMENTAL|Group 16|Physical activity education, facility access, supervised exercise sessions, self-monitoring (Fitbit), and active living counseling
62022592|NCT00268749|EXPERIMENTAL|1|
62412876|NCT02238639|EXPERIMENTAL|Active search for pulmonary embolism|All included patients will undergo D-dimer testing. A negative plasma highly sensitive D-dimer value (defined as a D-dimer level below the manufacturers assay threshold) will rule out pulmonary embolism, and no further examination will be performed. For patients with a positive D-dimer value, a multidetector computed tomographic pulmonary angiography (MDCT) will be performed.
62022593|NCT04410692|NO_INTERVENTION|Control|Participants' COVID-19 predictions are elicited via a survey
62022594|NCT04410692|EXPERIMENTAL|Treatment|Participants' COVID-19 predictions are elicited via a prediction market
62218811|NCT04369716|EXPERIMENTAL|Juice 1 + pomace|Orange Juice + orange pomace
62412877|NCT02238639|NO_INTERVENTION|Standard management|All included patients will undergo standard clinical management of their exacerbations, as deemed appropriate by the attending physician.
62022595|NCT05662501|EXPERIMENTAL|Subjects receiving the Pleioflow-RF device|Subjects receiving the Pleioflow-RF device in conjunction with IABP
62218812|NCT04369716|EXPERIMENTAL|Juice 2 + pomace|Apple Juice + apple pomace
62412878|NCT03779282||control|pediatric patients undergoing outpatient strabismus surgery, and not receiving ketodex
62412879|NCT03779282||study|pediatric patients undergoing outpatient strabismus surgery, and receiving ketodex
62412880|NCT03311217|EXPERIMENTAL|Intervention group|Healthy retail strategies will be implemented in tribally owned convenience stores in these communities. Specific strategies include pricing discounts, promotional signage, incorporation of new product, and placement of healthier items on shelves.
62586396|NCT00621868|EXPERIMENTAL|3|High-middle dose
62412881|NCT03311217|NO_INTERVENTION|Control group|No intervention will be implemented in the stores in the control communities.
62433274|NCT02162030|OTHER|Modified ACT|Acceptance and Commitment Therapy
62586397|NCT00621868|EXPERIMENTAL|4|Highest dose
62586398|NCT00621868|PLACEBO_COMPARATOR|5|placebo
62586399|NCT05551754|ACTIVE_COMPARATOR|ketone supplement|Subjects will drink single dose of ketone supplement 25g
62586400|NCT05551754|PLACEBO_COMPARATOR|Placebo beverage|Subjects will drink single dose of placebo beverage that will look and taste the same as ketone supplement.
62586401|NCT05334342|EXPERIMENTAL|Low-GI Diet|Low Glycemic Index Diet
62022596|NCT03736525|EXPERIMENTAL|Design For Wellness (DWELL)|Intervention participants will: 1) consume scientific evidence and practical solutions of how to design the home environment for wellness; 2) be part of a community which encourage participants engagement; 3) be empowered to read and control cues in the environment by developing skills.
62022597|NCT03736525|OTHER|Wait list control group|After the close of the study, we will open the Facebook group to all, and wait list control group participants can receive a delayed form of the intervention, which includes: 1) consume scientific evidence and practical solutions of how to design the home environment for wellness; 2) be part of a community which encourage participants engagement; 3) be empowered to read and control cues in the environment by developing skills.
62022598|NCT06243653||HFrEF|Patients with heart failure with reduced ejection fraction (HFrEF) without significant coronary artery disease (non-ischemic cardiomyopathy)
62218813|NCT04369716|ACTIVE_COMPARATOR|Juice 1 alone|Orange Juice
62218814|NCT04369716|ACTIVE_COMPARATOR|Juice 2 alone|Apple Juice
62218815|NCT01671254|ACTIVE_COMPARATOR|FishOil + placebo|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and placebo capsule
62218816|NCT01671254|EXPERIMENTAL|FishOil + CBE75|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and citrus bioflavonoids+vitamin E (CBE)(75 mg/capsule/day)
62218817|NCT01671254|EXPERIMENTAL|FishOil + CBE150|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and CBE (150 mg/capsule/day)
62586402|NCT05334342|ACTIVE_COMPARATOR|High-GI Diet|High Glycemic Index Diet
62586403|NCT06668792|EXPERIMENTAL|BCD-248|
62586404|NCT00565643|EXPERIMENTAL|HA-CMC Group|Hyaluronic Acid-Carboxymethylcellulose placed as an adhesion barrier
62586405|NCT00565643|PLACEBO_COMPARATOR|Routine Closure Group|Routine Closure without placement of an adhesion barrier
62794606|NCT02784171|ACTIVE_COMPARATOR|Arm C - Pembrolizumab (Phase II only)|Pembrolizumab 200 mg\* IV 30 min Day 1 every 21 days for a total of 2 years
62412882|NCT06111131|ACTIVE_COMPARATOR|Ancora-SB Overtube|Enteroscopy with Ancora-SB Balloon Overtube
62022599|NCT03877367|EXPERIMENTAL|Upper Extremity Group, Day 1|"Day 1: This group will receive a pre-test, upper extremity intervention, and post-test.~Day 2: This group will receive a pre-test, lower extremity intervention, and post-test."
62022600|NCT03877367|EXPERIMENTAL|Lower Extremity Group, Day 2|"Day 1: This group will receive a pre-test, lower extremity intervention, and post-test.~Day 2: This group will receive a pre-test, upper extremity intervention, and post-test."
62022601|NCT03174977|EXPERIMENTAL|18F-Raltegravir|
62412883|NCT06111131|ACTIVE_COMPARATOR|Olympus ST-SB1 Overtube|Enteroscopy with Olympus ST-SB1 Overtube
62412884|NCT06271109||laparoscopic Anatomical liver resection|
62412885|NCT06271109||laparoscopic Non Anatomical liver resection|
62412886|NCT05324254|EXPERIMENTAL|Heavier blanket|A heavier blanket will be worn overnight for 3 months. Blanket weight cannot be disclosed without unblinding participants.
62412887|NCT05324254|EXPERIMENTAL|Lighter blanket|A lighter blanket will be worn overnight for 3 months. Blanket weight cannot be disclosed without unblinding participants.
62412888|NCT05324254|NO_INTERVENTION|Waitlist control|No blanket will be provided until the end of the study; participants will sleep with their normal bedding.
62022602|NCT04218019|EXPERIMENTAL|Early Tumor Treating Fields (TTFields, Optune®) treatment|TTF will be started together with hypofractionated radiotherapy (+/- 5 days) with or without Temozolomide (according to the standard and local physician's decision). Chemoradiotherapy with temozolomide and hypofractionated radiotherapy is regarded as standard therapy and not part of the intervention. In case of chemoradiotherapy temozolomide will be applied according to the standard of the participating trial center. Use of antiemetic and infection prophylaxis will be at the discretion of the investigator.
62412889|NCT02765139|EXPERIMENTAL|EMAP Treatment|Engaging Men through Accountable Practice: 30 communities are matched into 15 pairs on a set of socio-demographic characteristic and within each pair, 15 treatment sites are randomly selected. Within each treatment community, all adult men (20+ years old) are eligible to participate in the EMAP intervention. A random draw of 50 participants determines who will participate in EMAP in case more than 50 eligible men express interest.
62794607|NCT04227093|ACTIVE_COMPARATOR|Acetazolamide|Acetazolamide will be prescribed in unembellished white capsules of 250 mg. The drug will be administered twice daily in the morning and evening (approximately one hour before bedtime). The total treatment length will amount to 16 weeks. In case of side effects hampering treatment adherence, the daily dosage will be reduced to a single evening dose of 250 mg.
62218818|NCT02197559||BMS group, DES group|All the participants in this group will be performed with bare-metal stents or drug -eluting stents
62243353|NCT05440643|EXPERIMENTAL|Part 2: Cohort 6|Adults - UDR with once daily peanut SLIT-tablet
62243354|NCT05440643|EXPERIMENTAL|Part 2: Cohort 7|Adolescents - UDR with once daily peanut SLIT-tablet
62243355|NCT05440643|EXPERIMENTAL|Part 2: Cohort 8|Children - UDR with once daily peanut SLIT-tablet
62412890|NCT02765139|OTHER|Control|In the 15 control sites, the male participants will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
62412891|NCT03668379|ACTIVE_COMPARATOR|Behavioral Activation Therapy|"During the initial stage treatment, the active comparator arm is the behavioral activation (BAT) program intervention. BAT is informed by behavioral theory and has been shown to be a highly efficacious treatment for depression. A total of five, 1-hour sessions will be delivered every two weeks. During Session 1, the focus will be on providing an introduction to BAT, as well as building confianza (mutual trust) between the patient and provider. Sessions 2 \& 3 will review the initial session, introduce high value activities and barriers to BAT protocols. Sessions 4 \& 5 will review progress, challenges \& maintenance strategies."
62412892|NCT03668379|EXPERIMENTAL|Behavioral Activation Therapy & mHealth|"During the initial stage treatment, the experimental arm will deliver a BAT program identical to the active comparator arm, as well as a mobile health (mHealth) component in the form of one-way and two-way SMS text-messages. Direct personalized text-messages will be delivered twice a week to facilitate engagement with the BAT intervention activities. One-way messages will be sent as appointment and BAT adherence reminders. Two-way messages will be sent once a week during a set block of protected hours, creating a mobile drop-in clinic where messages can be sent and received."
62412893|NCT03092115|EXPERIMENTAL|HIV medication adherence app|Youth in this arm will receive a medication adherence application to help them remember to take their HIV treatment medication (antiretroviral therapy) as a supplement to current HIV standard of care.
62412894|NCT01389700|EXPERIMENTAL|SAR279356 dose 1|SAR279356 dose 1, single administration
62412895|NCT01389700|EXPERIMENTAL|SAR279356 dose 2|SAR279356 dose 2, single administration
62412896|NCT01389700|PLACEBO_COMPARATOR|Placebo|Matching placebo, single administration
62412897|NCT06222502|EXPERIMENTAL|Planning, Reminders, and Micro-Incentives|
62412898|NCT06222502|ACTIVE_COMPARATOR|Health Education|
62794608|NCT04227093|PLACEBO_COMPARATOR|Placebo|The placebo regimen will be identical.
62794609|NCT05590728|EXPERIMENTAL|T1|Subjects 18 to 45 years of age to receive 30 mg/kg apramycin dose administered intravenously (IV) in a forearm vein over 30 min (+/- 5 min) using a syringe or infusion pump. 0.5 h (+/- 5 min) after dosing a single bronchoscopy with bronchoalveolar lavage (BAL) will be performed to analyze concentration of apramycin in BAL. N=4
62794610|NCT05590728|EXPERIMENTAL|T2|Subjects 18 to 45 years of age to receive single 30 mg/kg apramycin dose administered intravenously (IV) in a forearm vein over 30 min (+/- 5 min) using a syringe or infusion pump. 2 h (+/- 5 min) after dosing a single bronchoscopy with bronchoalveolar lavage (BAL) will be performed to analyze concentration of apramycin in BAL. N=4
62218819|NCT02769403|EXPERIMENTAL|Treatment|Participants will use HeartMath EmWave Pro for at least one 5-minute session daily, Monday through Friday. The treatment participants will use it daily for all 12 weeks, and will have the added component of weekly visits for the first 6 weeks of the study from the study team. The weekly visits is focused on reinforcing accountability and achievement of coherence. The participants will also complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance. Participants' blood pressure and heart rate will be collected at those three time points. Additionally, information about participants' use of HeartMath EmWave Pro, sick days, and patient satisfaction will be collected after week 12.
62022603|NCT04218019|ACTIVE_COMPARATOR|Late TTF treatment|Patients will be treated with hypofractionated radiotherapy with or without temozolomide (according to the local standard and physician's decision). Radiotherapy and treatment with temozolomide is regarded as standard therapy and not part of the intervention. In case of chemoradiotherapy temozolomide will be applied according to the standard of the participating trial center. Use of antiemetic and infection prophylaxis will be at the discretion of the investigator. Late TTFields treatment will start 4 weeks after the end of radiotherapy.
62022604|NCT00522249|EXPERIMENTAL|1|One cycle of the combination therapy will be 42 days (6 weeks). All patients will receive PEG-Intron given subcutaneously on Day 1 each week. Patients will receive Sunitinib orally on Days 1-28 of each cycle. Patients will receive Tarceva orally on Days 1-42.
62794611|NCT05590728|EXPERIMENTAL|T3|Subjects 18 to 45 years of age to receive single 30 mg/kg apramycin dose administered intravenously (IV) in a forearm vein over 30 min (+/- 5 min) using a syringe or infusion pump. 4 h (+/-10 min) after dosing a single bronchoscopy with bronchoalveolar lavage (BAL) will be performed to analyze concentration of apramycin in BAL. N=4
62412899|NCT04929834|EXPERIMENTAL|Experimental group|All patients will receive the experimental emollients during 3 weeks.
62022605|NCT02077023||Asymptomatic Carotid Artery Disease, AF|
62412900|NCT06653452|EXPERIMENTAL|18F-FDG PET/CT and PET/MR, 68Ga-FAPI-04 PET/CT and PET/MR|After patient enrollment, 68Ga-FAPI-04 PET/CT and PET/MR examinations are performed. Within 1 week before and after the examination, PET/CT and PET/MR is also performed in patients.
62412901|NCT03140527|ACTIVE_COMPARATOR|SAD HV PTI-801 Active - Complete|The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
62412902|NCT03140527|PLACEBO_COMPARATOR|SAD HV PTI-801 Placebo - Complete|The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
62412903|NCT03140527|ACTIVE_COMPARATOR|MAD HV PTI-801 Active - Complete|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
62022606|NCT04102501|EXPERIMENTAL|RT001|"* 9 capsules daily (8.64 g total dose) given as 3 capsules three times a day (TID) with meals for the first month of treatment.~* Six capsules daily (5.76 g total dose) given as 3 capsules (BID) with breakfast, and 3 capsules with dinner after the first month of treatment"
62022607|NCT04102501|PLACEBO_COMPARATOR|Placebo|"* 9 capsules daily (8.64 g total dose) given as 3 capsules three times a day (TID) with meals for the first month of treatment.~* Six capsules daily (5.76 g total dose) given as 3 capsules (BID) with breakfast, and 3 capsules with dinner after the first month of treatment"
62022608|NCT04735133|EXPERIMENTAL|intervention grpup|pNPWT device was placed in the pNPWT group for seven days. The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI.
62218820|NCT02769403|ACTIVE_COMPARATOR|Control|Participants will use HeartMath EmWave Pro for at least one 5-minute session daily, Monday through Friday. The control participants will use it daily only for weeks 7-12. The participants will also complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance. Participants' blood pressure and heart rate will be collected at those three time points. Additionally, information about participants' use of HeartMath EmWave Pro, sick days, and patient satisfaction will be collected after week 12.
62218821|NCT05515003|EXPERIMENTAL|Education group|Individualized patient education
62412904|NCT03140527|PLACEBO_COMPARATOR|MAD HV PTI-801 Placebo - Complete|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
62433275|NCT02103322|EXPERIMENTAL|Imatinib Mesylate Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.
62022609|NCT04735133|NO_INTERVENTION|control group|"The wound of the control group was covered with a sterile gauze dressing. After the wound was left closed for 48 hours in the clinical routine, the surgical site was left open, supporting healing. Therefore, the dressing of the control group was removed after 48 hours, and the wound was left open.~The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI."
62022610|NCT03734224|ACTIVE_COMPARATOR|Group1: Adhesix|This group gets the Adhesix mesh in a normal open hernia operation.
62412905|NCT03140527|ACTIVE_COMPARATOR|FE HV PTI-801 Active - Complete|Following the conclusion of SAD groups and after sufficient review of study data and approval by the SRC, a third set of healthy adult subjects will participate in the Food Effect cohort. Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
62022611|NCT03734224|ACTIVE_COMPARATOR|Group 2: Progrip|This group gets the Progrip mesh in a normal open hernia operation.
62022612|NCT01954706|EXPERIMENTAL|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
62412906|NCT03140527|ACTIVE_COMPARATOR|DDI HV PTI-801 Active - Complete|Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
62022613|NCT01954706|ACTIVE_COMPARATOR|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
62218822|NCT05515003|NO_INTERVENTION|Control group|No training will be provided
62218823|NCT01135537|EXPERIMENTAL|Thymoglobulin|Thymoglobulin 7.5 mg/kg/course prior to HSCT
62022614|NCT03403725|EXPERIMENTAL|MEN1309 (Step 1-Solid Tumors)/(Step 2-NHL)|"Step1: Accelerated Titration Design with 1 single pt per cohort and double dose level per cohort until grade ≥ 2 drug related toxicity. Then, study reverts to 3+3 design. Any cohort in which 1 pt experiences a DLT (along ATD or 3+3) will be expanded up to 6 pts.~Step2: MTD defined in Step 1, 3 MEN1309 dose levels will be tested (MTD-2, MTD-1, and MTD), with 6 pts per each dose level. A further MTD-3 level will be explored if 2 DLTs occur at the MTD-2 dose level."
62218824|NCT02390245|EXPERIMENTAL|Phase 1: Telemedicine Screening Participants|Participants across the Philadelphia, PA region were invited to participate in free eye screenings at primary care physician offices or health centers. Screenings included images of optic nerve and macula using non-contact, autofocus, hand-held fundus cameras (Volk Optical, Mentor, Ohio, USA) and measuring Intraocular Pressure (IOP) in millimeters of mercury (mm Hg) with non-contact rebound tonometers TA01I (ICare, Helsinki, Finland).
62218825|NCT02390245|EXPERIMENTAL|Phases 2 and 3: Enhanced Intervention Group|"From eye screening results (visit 1), Phase 2 includes participants requiring further evaluation received comprehensive eye exam to confirm diagnosis (visit 2). Following confirmation diagnosis, patients were randomized to the Enhanced Intervention Group and were referred to a general ophthalmologist for follow-up eye care. Patient navigation and a social worker and referred to a general ophthalmologist close to the current health center or primary care physician office where they received the non dilated eye exam. Prior to all follow-up visits, patients in the Enhanced Intervention Group were provided a scheduled appointment and received a personal phone call reminding them to attend. Patients received necessary interpretation services and educational materials.~Phase 3. Includes following this group over a 5 year period for adherence to eye care."
62218826|NCT02390245|EXPERIMENTAL|Phases 2 and 3: Usual Care Group|"From eye screening results (visit 1), Phase 2 includes participants requiring further evaluation received comprehensive eye exam to confirm diagnosis (visit 2). Following confirmation diagnosis, patients were randomized to the Usual Care Group and were referred to a general ophthalmologist for follow-up eye care. These patients were scheduled for their initial follow-up visit based on the recommendations of our study physicians so the research team was able to track outcomes. This group represents a realistic choice currently available for patients. Practice patterns vary depending on the resources, staff time, and services available within each local ophthalmology practice.~Phase 3. Includes following this group over a 5 year period for adherence to eye care."
62433276|NCT02103322|ACTIVE_COMPARATOR|Gleevec Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.
62022615|NCT05294757|NO_INTERVENTION|Hospital control|Hospital control cohort: Participants will be consecutively recruited from the scheduled patient list of the frailty unit, day hospital, and the outpatient clinic of the Geriatrics Department of Hospital 2. After obtaining informed consent, baseline study variables will be collected. Patients will be followed-up for a 16-week period, under usual care. After the follow-up period, baseline evaluation will be repeated.
62433277|NCT02023502||stress urinary incontinence|Patients presenting with stress urinary incontinence according to the inclusion and exclusion criteria
62794612|NCT05590728|EXPERIMENTAL|T4|Subjects 18 to 45 years of age to receive single 30 mg/kg apramycin dose administered intravenously (IV) in a forearm vein over 30 min (+/- 5 min) using a syringe or infusion pump. 8 h (+/- 15 min) after dosing a single bronchoscopy with bronchoalveolar lavage (BAL) will be performed to analyze concentration of apramycin in BAL. N=4
62586406|NCT05193617|EXPERIMENTAL|GP combine with Penpulimab and anlotinib neoadjuvant therapy+CCRT+Penpulimab adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on days 1,8) , cisplatin (80mg per square meter on day 1), penpulimab (200mg, day1), and anlotinib (10mg days 1-14) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1, D22, D43 of RT) ,then followed by adjuvant therapy with penpulimab (200mg) every three weeks for a maximum of nine cycles after radiotherapy.
62586407|NCT05193617|ACTIVE_COMPARATOR|GP combine with Penpulimab neoadjuvant therapy+CCRT+Penpulimab adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on days 1,8) , cisplatin (80mg per square meter on day 1), penpulimab (200mg, day1) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1, D22, D43 of RT) ,then followed by adjuvant therapy with penpulimab (200mg) every three weeks for a maximum of nine cycles after radiotherapy.
62022616|NCT05294757|EXPERIMENTAL|Exercise|Elderly people without muscle problems participating in the exercise program to see improvements in their muscle mass levels and quality
62022617|NCT05294757|NO_INTERVENTION|Primary care Control|Primary care cohort: Participants will be consecutively recruited from the scheduled patient list of the Primary Care Units. After informed consent acquisition, baseline study variables will be collected. Patients will be followed-up during one year, under usual care. After the one-year follow-up, the baseline evaluation will be repeated.
62218827|NCT05397834|EXPERIMENTAL|Test|Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals
62218828|NCT05397834|ACTIVE_COMPARATOR|Reference|FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK
62218829|NCT06078865||Subjects|Subjects implanted with the shoulder replacement medical devices manufactured by FX Shoulder Solutions
62218830|NCT06121167||study group|patients with acute kidney injury
62218831|NCT06121167||control group|patients who do not develop acute kidney injury
62218832|NCT03876860|ACTIVE_COMPARATOR|Standard Dilator|Participants in control arm (active comparator) will receive standard vaginal dilator with standard set of instructions for dilator use, including both verbal and written instructions. Recommended dilator use is three-times weekly for ten minutes
62218833|NCT03876860|EXPERIMENTAL|Silicone Dilator|Participants in experimental arm will receive standard vaginal dilator with addition of silicone ring with standard set of instructions for dilator use, including both verbal and written instructions. Recommended dilator use is three-times weekly for ten minutes
62218834|NCT03590405|EXPERIMENTAL|uterus transplantation|uterus transplantation from living donor with the donor being close relative
62218835|NCT02699086|EXPERIMENTAL|Low dose + Low dose|1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 + 28 days
62218836|NCT02699086|EXPERIMENTAL|Low dose + High dose|1 PDC-1421 Capsule for 28 days + 2 PDC-1421 Capsules for 28 days, trice daily, p.o. after meals
62218837|NCT05675787|EXPERIMENTAL|Experimental group|MPA + Atorvastatin
62218838|NCT05675787|NO_INTERVENTION|Control groups|MPA
62218839|NCT05342506|EXPERIMENTAL|Cohort 1|Study subjects: Patient with cervical carcinoma
62022618|NCT05694624||Sepsis patients|Patients admitted to the intensive care unit with sepsis diagnosed or suspected
62218840|NCT05342506|EXPERIMENTAL|Cohort 2|Study subjects: Patient with ovarian cancer
62218841|NCT05342506|EXPERIMENTAL|Cohort 3|Study subjects: Patient with malignant trophoblastic tumor
62218842|NCT03599973|OTHER|Patient|One-arm study, where all patients are given the same standard fluidotherapy and anesthetic conditions to compare measures of Aortic VTI before and after the IV fluid.
62218843|NCT01819259|ACTIVE_COMPARATOR|ADHD Nonsmokers|All participants will be non-smokers defined as never having smoked an entire cigarette and no tobacco use in the past 3 years. The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
62218844|NCT01819259|ACTIVE_COMPARATOR|Non-ADHD Nonsmokers|All participants will be non-smokers defined as never having smoked an entire cigarette and no tobacco use in the past 3 years. The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
62218845|NCT00560066|EXPERIMENTAL|cTIV|Subjects received one vaccination of cell culture-derived influenza vaccine
62412907|NCT03140527|PLACEBO_COMPARATOR|DDI HV PTI-801 Placebo - Complete|Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
62022619|NCT05694624||Surgical patients|Previously healthy patients who are operated for colon cancer with laparoscopic technique.
62022620|NCT02007486||Heart Failure: NYHA functional class I|Ambulatory and clinically-stable patients with New York Heart Association Functional Class I heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of \<45%.
62022621|NCT02007486||Heart Failure: NYHA functional class II|Ambulatory and clinically-stable patients with New York Heart Association Functional Class II heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of \<45%.
62022622|NCT02007486||Heart Failure: NYHA functional class III|Ambulatory and clinically-stable patients with New York Heart Association Functional Class III heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of \<45%.
62022623|NCT02007486||Healthy Control Subjects|Healthy, sedentary, non-smoking, age- and sex-matched control subjects.
62022624|NCT02722889||Healthy controls|Healthy control patients
62412908|NCT03140527|ACTIVE_COMPARATOR|MAD Cohort 1-3 CF PTI-801 Active - Complete|Adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
62412909|NCT03140527|PLACEBO_COMPARATOR|MAD Cohort 1-3 CF PTI-801 Placebo - Complete|Adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
62412910|NCT03140527|ACTIVE_COMPARATOR|Cohort 4 CF PTI-801 Active co-admin PTI-808 Active - Complete|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
62412911|NCT03140527|PLACEBO_COMPARATOR|Cohort 4 CF PTI-801 Placebo co-admin PTI-808 Placebo- Complete|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
62412912|NCT03140527|ACTIVE_COMPARATOR|Cohort 5 CF PTI-801 Active co-admin with PTI-808 Active|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 5. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
62412913|NCT03140527|PLACEBO_COMPARATOR|Cohort 5 CF PTI-801 Placebo co-admin with PTI-808 Placebo|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 5. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
62412914|NCT03140527|ACTIVE_COMPARATOR|Cohort 6 CF PTI-801 Active|Adult subjects diagnosed with CF currently on stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD.
62412915|NCT03140527|PLACEBO_COMPARATOR|Cohort 6 CF PTI-801 Placebo|Adult subjects diagnosed with CF currently on stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD.
62412916|NCT04116359|EXPERIMENTAL|Non-BRD4 exploratory cohort (molibresib, cisplatin, etoposide)|Patients receive molibresib besylate PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may receive molibresib besylate, etoposide phosphate and cisplatin as in Phase I and II Cohort at the discretion of the principal investigator.
62586408|NCT05418582|EXPERIMENTAL|DZD9008 and itraconazole|Subjects in arm 1 will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with itraconazole after the wash-out period.
62586409|NCT05418582|EXPERIMENTAL|DZD9008 and carbamazepine|Subjects in arm 2 will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with carbamazepine after the wash-out period.
62794613|NCT05590728|EXPERIMENTAL|T5|Subjects 18 to 45 years of age to receive single 30 mg/kg apramycin dose administered intravenously (IV) in a forearm vein over 30 min (+/- 5 min) using a syringe or infusion pump. Cohort T5 will be enrolled after plasma and lung apramycin concentrations and preliminary PK data analysis are completed in cohorts T1-T4 24 h (+/- 1 h) after dosing a single bronchoscopy with bronchoalveolar lavage (BAL) will be performed to analyze concentration of apramycin in BAL. N=4
62794614|NCT06590467||Amplatzer|"* ASO: ≥50 cases/year~* ASD-MF: ≥50 cases/year~* ADO: ≥50 cases/year~* ADO II: ≥50 cases/year~* Piccolo: ≥50 cases/year~* MuVSD: Up to 50 cases/year~* PI-VSD: Up to 50 cases/year~* Talisman/TDS: ≥100 cases/year~* TorqVue Delivery Systems Group 1 (ATV/ITV/EITV/TV2): 250 cases/year across different occluders~* TorqVue Delivery Systems Group 2 (TVLP/TVLPC): 100 cases/year across different occluders~* SB II:100 PFO cases/year \& 100 ASD cases/year~* GW: 200 cases/year"
62022625|NCT02722889||Type A dissection|Patients with proven type A dissection,
62022626|NCT03612193||Study A: Chronic >1 year|
62022627|NCT03612193||Study A: Acute <1 year|
62022628|NCT03612193||Study A: Household Control|
62022629|NCT03612193||Study B: Newly Diagnosed <6 months|
62022630|NCT03612193||Study B: Household Controls|
62022631|NCT02349958|OTHER|Ovarian peritoneal|CDDP Cisplatin 75 mg/m2 @T0 Ovarian peritoneal fallopian tube Uterine
62022632|NCT02349958|OTHER|Appendix Psuedomyxoma|MMC Mitomycin 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0 Appendix Psuedomyxoma colorectal small bowel
62022633|NCT02349958|OTHER|Gastric and Pancreato-biliary|MMC Mitomycin + CDDP Cisplatin 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0
62022634|NCT02349958|OTHER|Mesothelioma and Sarcoma|CDDP Cisplatin + Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
62022635|NCT00006172|ACTIVE_COMPARATOR|bright light box|60 min light therapy shortly after awakening
62218846|NCT00560066|ACTIVE_COMPARATOR|TIV|Subjects received one vaccination of egg-derived influenza vaccine
62412917|NCT04116359|EXPERIMENTAL|Phase I and II cohort (molibresib, etoposide, cisplatin)|Patients receive molibresib besylate PO QD on days 1-14 (may switch to days 1-21 after completion of etoposide and cisplatin cycles). Patients also receive etoposide phosphate IV over 60 minutes on days 1-3 and cisplatin IV over 60 minutes on day 1 of cycles 1-4. Treatments repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of cycle 4, patients may receive etoposide phosphate and cisplatin for up to 8 cycles total in the absence of disease progression or unacceptable toxicity at the investigator's discretion.
62412918|NCT03700515|PLACEBO_COMPARATOR|Placebo|Saline infusion
62218847|NCT01732159|EXPERIMENTAL|Administration of the checklist|Patients will be contacted by phone for administration of the checklist
62218848|NCT01732159|NO_INTERVENTION|No contact by phone|Patients who will not be contacted by phone
62218849|NCT04132531||Normal weight control|Individuals who are generally healthy and have a body mass index less than 25 kg/m\^2.
62218850|NCT04132531||Bariatric Surgery Group|Individuals electing to undergo bariatric surgery (generally with a body mass index between 35 and 40 kg/m\^2 with an additional co-morbidity such as type 2 diabetes, or individuals with a body mass index greater than 40 kg/m\^2) and who are willing to participate for 2 visits, one before and one after surgery. The intervention in this group is bariatric surgery.
62218851|NCT01245985|EXPERIMENTAL|treatment arm|patients receive induction chemotherapy with TPF for a maximum of 3 cycles followed by radioimmunotherapy with cetuximab as intensity-modulated radiotherapy (IMRT) plus carbon ion boost
62218852|NCT00194987|EXPERIMENTAL|IVIG x 2|IVIG 2 g/kg/wk divided into 2 infusions per week for women with a fetus affected by FNAIT
62794615|NCT06590467||Cardiac Surgery|"It is anticipated that approximately 830 subjects implanted with at least one applicable Abbott surgical tissue heart valve (THV) will be enrolled and followed for 10 years.~* Approximately 225 subjects receiving Epic Plus mitral valves~* Approximately 150 subjects receiving Epic Plus aortic valves~* Approximately 170 subjects receiving Epic Plus Supra aortic valves~* Approximately 285 subjects receiving Epic Max aortic valves"
62794616|NCT06114888|EXPERIMENTAL|MeMed BV|
62218853|NCT00194987|EXPERIMENTAL|IVIG x 1 + prednisone|IVIG 1 g/kg/wk in 1 infusion per week + prednisone 0.5 mg po daily for women with a fetus affected by FNAIT
62586410|NCT05326178|EXPERIMENTAL|General information about depression|Exposure to general information about depression
62586411|NCT02482714|EXPERIMENTAL|Rehab Institute|This group will do some physical activity in a specialized institute
62794617|NCT06114888|ACTIVE_COMPARATOR|Usual Care|
62022636|NCT00006172|ACTIVE_COMPARATOR|high-output negative ion generator|60 min high-density exposure shortly after awakening
62022637|NCT00006172|PLACEBO_COMPARATOR|low-output negative ion generator|60 min low-density exposure shortly after awakening
62022638|NCT00931151|EXPERIMENTAL|Casein|Protein source in the high fat meal is casein
62412919|NCT03700515|EXPERIMENTAL|EPO|Erythropoetin infusion (9 IU/kg)
62022639|NCT00931151|EXPERIMENTAL|Milk soluble protein|Protein source in the high fat meal are milk soluble protein
62022640|NCT00931151|EXPERIMENTAL|Alpha lactalbumin|Protein source in the high fat meal is alpha-lactalbumin
62218854|NCT03787056|OTHER|Cancer patients|420 patients affected by different types of cancer and treated in a curative or a palliative intent. In total 17 cohorts will be open, including: breast cancer, head and neck carcinomas, renal cell carcinoma, prostate carcinoma, lung carcinoma, hepatocellular carcinoma, colorectal carcinoma, thyroid cancer, pancreatic adenocarcinoma, ovarian adenocarcinoma, glioblastoma, endometrial adenocarcinoma, bladder carcinoma, oesophago-gastric carcinoma, B-cell lymphoma, gastric carcinomas. Patients enrolled in curative intent treatment cohorts will never have been previously treated for their cancer. Patients enrolled in non-curative intent treatment cohorts will have never been treated for their metastatic cancers previously, or have developed advanced/metastatic diseases as relapses of localized cancers previously treated with curative intent therapeutic strategies. Other cohort will be open (stability cohorts) : nychtemer cohort and post-operative kinetic cohort.
62218855|NCT04829500|NO_INTERVENTION|Pre-Intervention Baseline Collection Phase|All sites will start with a baseline collection phase without exposure to the intervention, consistent with the stepped wedge cluster randomized trial design. A sequential randomized crossover to the intervention (MAP-VA) will be assigned, which cannot be reversed once it has been introduced.
62243356|NCT05440643|EXPERIMENTAL|Part 2: Cohort 9|Highly sensitized Adults/Adolescents - UDR with once daily peanut SLIT-tablet
62243357|NCT05440643|EXPERIMENTAL|Part 2: Cohort 10|Highly sensitized Children - UDR with once daily peanut SLIT-tablet
62412920|NCT03700515|EXPERIMENTAL|EPO II|Erythropoetin infusion (20 IU/kg)
62412921|NCT02536625||Everolimus|Immunomonitoring
62412922|NCT02080273|PLACEBO_COMPARATOR|Colgate Cavity Protection toothpaste|Brush whole mouth 2x/day with Colgate Cavity Protection toothpaste. This study treatment is currently marketed/sold in Poland
62412923|NCT02080273|ACTIVE_COMPARATOR|Colgate Total toothpaste|Brush whole mouth 2x/day with Colgate Total toothpaste . This study treatment is currently marketed/sold in Poland
62586412|NCT02482714|ACTIVE_COMPARATOR|Club structure|This group will do some physical activity in a club.
62586413|NCT05296668|EXPERIMENTAL|Cuffed ETT group|(group C) to receive a cuffed ETT for airway management.
62586414|NCT05296668|ACTIVE_COMPARATOR|Uncuffed ETT group|(group U) to receive an uncuffed ETT for airway management.
62412924|NCT02080273|ACTIVE_COMPARATOR|Parodontax|Brush whole mouth 2x/day with Parodontax toothpaste. This study treatment is currently marketed/sold in Poland.
62022641|NCT04719585|EXPERIMENTAL|Experimental: Duloxetine group|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
62586415|NCT05030753|EXPERIMENTAL|iSIPsmarter|iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.
62586416|NCT05030753|ACTIVE_COMPARATOR|Patient Education (PE)|he PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
62586417|NCT04381689|EXPERIMENTAL|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
62022642|NCT04719585|ACTIVE_COMPARATOR|Active comparator: Opioid group|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
62022643|NCT00610051|ACTIVE_COMPARATOR|trial arm|6 months central continuous infusion with Alp_1 by infusion pump.
62022644|NCT00610051|PLACEBO_COMPARATOR|Placebo arm|6 months central infusion with NS by infusion pump with exact infusion rat as trial arm.
62586418|NCT04381689|ACTIVE_COMPARATOR|GSK PFS|Fluarix Tetra Pre-filled Syringe
62586419|NCT04591886|EXPERIMENTAL|mind. body. voice.|The 10-week mind. body. voice. program
62794618|NCT06335784|ACTIVE_COMPARATOR|Sleep Hygiene (SH)|Participants will receive 4 weekly individual sessions of standardized instructions on sleep hygiene, that they will be asked to apply every day for 4 weeks. Each session will consist of providing patients with advice to help their sleep without any CBT-I or other complementary medicine components. They will also have an odorless diffuser being diffused at the end of each weekly individual session and during the night.
62586420|NCT04591886|NO_INTERVENTION|Control|Assessment-only control
62022645|NCT03790982|PLACEBO_COMPARATOR|Placebo of AD-35 60mg /AD-35 30mg|Placebo of AD-35 60 mg Placebo of AD-35 30mg x two tablets, once daily in the first 26 weeks (oral), then AD-35 30mg +Placebo of AD-35 30mg, once daily in the second 26 weeks (oral)
62022646|NCT03790982|PLACEBO_COMPARATOR|Placebo of AD-35 60mg /AD-35 60mg|Placebo of AD-35 60 mg Placebo of AD-35 30mg x two tablets, once daily in the first 26 weeks (oral), then AD-35 30mg x two tablets, once daily in the second 26 weeks (oral)
62022647|NCT03790982|EXPERIMENTAL|AD-35 30 mg+Placebo of AD-35 30 mg|AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, once daily for 52 weeks (oral)
62022648|NCT03790982|EXPERIMENTAL|AD-35 60 mg|AD-35 60 mg AD-35 30 mg× two tablets, once daily for 52 weeks (oral)
62022649|NCT06387043|EXPERIMENTAL|Balance Games with Virtual Reality Glasses|Individuals with MS in the first group will play balance games with virtual reality glasses for 15 minutes. Three different progressive games will be determined according to the functional level of the individual. Each game offers different gradually increasing difficulty levels and time options.
62412925|NCT06620016||A|Small testicular mass suitable for testis sparing surgery.
62412926|NCT06620016||B|Retroperitoneal post-chemotherapy residual mass suitable for retroperitoneal lymph node dissection.
62412927|NCT06651528|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Traditional in-prison SUD treatment
62586421|NCT05801289|ACTIVE_COMPARATOR|Group Q|will receive 25 mg quetiapine at night of surgery and 25 mg daily for 7 days postoperative
62586422|NCT05801289|NO_INTERVENTION|Group C|will receive placebo alone
62586423|NCT01524549||WT for CYP2J2*7 and heterozygous for EPHX2 K55R|SNP
62586424|NCT01524549||WT for CYP2J2*7 and homozygous for EPHX2 K55R|SNP
62586425|NCT01524549||WT for EPHX2 K55R and heterozygous for CYP2J2*7|SNP
62586426|NCT01524549||WT for EPHX2 K55R and homozygous for CYP2J2*7|SNP
62586427|NCT01524549||WT for EPHX2 K55R and WT for CYP2J2*7|SNP
62586428|NCT05905523||3 year old participants|"In this study, your child will be asked to do the following things:~1. Play a drawing game on a tablet~2. Copy shapes using a pencil in a paper booklet~3. Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development"
62022650|NCT06387043|EXPERIMENTAL|Balance Exercises with Stroboscopic Glasses|Individuals with MS in the second group will be given balance exercises with stroboscopic glasses for 15 minutes. Exercises will be selected in accordance with the functional level of the individual and will progress according to the individual's condition. In each session, 3-5 different exercises will be performed, taking into account the functional status of the individual.
62022651|NCT06387043|EXPERIMENTAL|Balance Exercises with Visual-Based Metaphor Training|"Individuals with MS in the third group will be given balance exercises simultaneously with metaphor training using various visuals for 15 minutes. The images will be projected on the screen in front of the individuals and the individuals will be given the command: Imagine the movement you are doing as in the image. Meanwhile, reinforcers deemed necessary will be used by the researcher physiotherapist to increase the patient's participation and motivation. Static balance exercises in the program will be performed first on stable surfaces and then on unstable surfaces. In each session, 3-5 different exercises will be performed, taking into account the functional status of the individual. The difficulty levels of the exercises will progress by adjusting according to the functional status of the individual."
62412928|NCT06651528|EXPERIMENTAL|TBRI alone|Treatment as usual and the adapted version of TBRI for adult women
62412929|NCT06651528|EXPERIMENTAL|Re-entry Recovery Support|Treatment as usual, the adapted TBRI, and on-going re-entry recovery support with the Safe Support Person (SPP).
62412930|NCT06542523||WIFI stage 1 with type 1 foot arch|
62022652|NCT06387043|ACTIVE_COMPARATOR|Traditional Balance Exercises|Individuals with MS in the fourth group will be given balance exercises for 15 minutes under the supervision of a researcher physiotherapist. Exercises will be selected in accordance with the functional level of the individual and will progress according to the individual's condition. In each session, 3-5 different exercises will be performed, taking into account the functional status of the individual.
62022653|NCT04023006||Edentulous Patients|The investigational device is part of a treatment concept for edentulous patients of all ages, gender and races. The incidence for tooth loss has not declined over years, and the prevalence for edentulism is significantly higher for adults 50 years and older. For this descriptive two-part survey, no minimum number of patients is defined, but to achieve a reasonable subject number, a minimum of five (5) patients will be enrolled, i.e. 10 dentures will be fabricated within this study.
62412931|NCT06542523||WIFI stage 2 with type 1 foot arch|
62412932|NCT06542523||WIFI stage 3 with type 1 foot arch|
62412933|NCT06542523||WIFI stage 1 with type 2a foot arch|
62412934|NCT06542523||WIFI stage 2 with type 2a foot arch|
62412935|NCT06542523||WIFI stage 3 with type 2a foot arch|
62412936|NCT06542523||WIFI stage 1 with type 2b foot arch|
62794619|NCT06335784|EXPERIMENTAL|Imagery Rescripting (IR)|Participants will receive 4 weekly individual sessions of IR. The IR technique consists of imagining a negative memory or image as vividly as possible, and of transforming it into a positive one. An odorless diffuser will be presented while imagining the positive imagery generated during IR. During 4 weeks, patients of this group will practice IR at home, every day in bed and have the same odorless diffuser being diffused during the night.
62794620|NCT06335784|EXPERIMENTAL|Targeted Memory Reactivation (TMR)|Participants will receive 4 weekly individual sessions of IR, at the end of which, a chosen odor will be presented while imagining the positive imagery generated during IR. During 4 weeks, patients of this group will practice IR at home every day in bed and have the same odor being diffused during the night.
62794621|NCT06335784|ACTIVE_COMPARATOR|Odor Alone (OA)|Participants will have a chosen odor diffused during the night for 4 weeks and will receive 4 weekly individual sessions of standardized instructions on sleep hygiene, that they will be asked to apply every day for 4 weeks. The chosen odor will be diffused at the end of each weekly individual session.
62794622|NCT03466411|EXPERIMENTAL|Phase 2 (GALAXI 1): Group 1 (Guselkumab)|Participants will receive guselkumab (Dose 1) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) phase and continue to receive guselkumab.
62412937|NCT06542523||WIFI stage 2 with type 2b foot arch|
62412938|NCT06542523||WIFI stage 3 with type 2b foot arch|
62412939|NCT06542523||WIFI stage 1 with type 3a foot arch|
62412940|NCT06542523||WIFI stage 2 with type 3a foot arch|
62412941|NCT06542523||WIFI stage 3 with type 3a foot arch|
62412942|NCT06542523||WIFI stage 1 with type 3b foot arch|
62412943|NCT06542523||WIFI stage 2 with type 3b foot arch|
62412944|NCT06542523||WIFI stage 3 with type 3b foot arch|
62412945|NCT06565741|ACTIVE_COMPARATOR|Endoscopic Prostate Enucleation Using Moses 2.0 Technology|Pulse modulation technology in Moses 2.0 applied to Holmium Laser Endoscopic Prostate (MoLEP).
62412946|NCT06565741|ACTIVE_COMPARATOR|Endoscopic Prostate Enucleation Using the New Thulium Fiber Laser|Thulium Fiber laser to endoscopic prostate enucleation (ThuFLEP).
62412947|NCT03522155|EXPERIMENTAL|Intervention Arm|"Intervention: (1) Subjects will be provided with patient-specific LE estimates, (2) counseling physicians will receive talking points to assist in meaningful communication of life expectancy, and (3) subjects will complete a computer-based conjoint analysis exercise prior to counseling."
62412948|NCT03522155|NO_INTERVENTION|Standard-of-care Arm|Patients in the standard-of-care arm will not receive an intervention and will receive the usual standard of care for treatment counseling.
62412949|NCT01003470|EXPERIMENTAL|acupuncture|
62412950|NCT01003470|ACTIVE_COMPARATOR|rehabilitation|
62412951|NCT01003470|ACTIVE_COMPARATOR|acupuncture and rehabilitation|
62412952|NCT00002949|EXPERIMENTAL|Arm A|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2), Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy) Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
62412953|NCT01854125|ACTIVE_COMPARATOR|autologous bone marrow mesenchymal stem cells transplantation|Every patient is given 1x106 MSCs per kg infused via liver artery
62412954|NCT01854125|ACTIVE_COMPARATOR|mesenchymal stem cells transplantation|autologous bone marrow mesenchymal stem cells transplantation
62412955|NCT01854125|EXPERIMENTAL|stem cells transplantation|autologous bone marrow mesenchymal stem cells transplantation
62022654|NCT02239523|ACTIVE_COMPARATOR|Letter Group|Patients will be given discharge letter that includes recommendation to discuss further testing and treatment with their primary care physician.
62022655|NCT02239523|EXPERIMENTAL|Intervention Group|Patients will be given a pamphlet about osteoporosis and importance of treatment, have a bone density test (DEXA) arranged, be given a specific medication recommendation and monthly followup phone calls.
62022656|NCT05056350|OTHER|Assessment of the feasibility and impact of a back-to-work support program|questionnaires, back to work coaching
62022657|NCT05209893|EXPERIMENTAL|Telerehabilitation (TR)|The TR group will be followed up through the application within the 8-week home exercise program.
62412956|NCT00662974|EXPERIMENTAL|A|parturients during the second stage of labor massaged by Wheat Germ Oil
62586429|NCT05905523||4 year old participants|"In this study, your child will be asked to do the following things:~1. Play a drawing game on a tablet~2. Copy shapes using a pencil in a paper booklet~3. Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development"
62412957|NCT00662974|EXPERIMENTAL|B|parturients during the second stage of labor massaged by almond oil
62586430|NCT05905523||5 year old participants|"In this study, your child will be asked to do the following things:~1. Play a drawing game on a tablet~2. Copy shapes using a pencil in a paper booklet~3. Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development"
62794623|NCT03466411|EXPERIMENTAL|Phase 2 (GALAXI 1): Group 2 (Guselkumab)|Participants will receive guselkumab (Dose 3) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
62794624|NCT03466411|EXPERIMENTAL|Phase 2 (GALAXI 1): Group 3 (Guselkumab)|Participants will receive guselkumab (Dose 4) by intravenous (IV) infusion, followed by guselkumab (Dose 5) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
62794625|NCT03466411|ACTIVE_COMPARATOR|Phase 2 (GALAXI 1): Group 4 (Ustekinumab)|Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE and continue to receive ustekinumab.
62794626|NCT03466411|EXPERIMENTAL|Phase 2 (GALAXI 1): Group 5 (Placebo/Ustekinumab)|Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (Ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
62022658|NCT05209893|ACTIVE_COMPARATOR|Paper Based Rehabilitation (PBR)|The PBR group will be followed up through the paper instruction within the 8-week home exercise program.
62022659|NCT01889420|EXPERIMENTAL|Combination therapy|Pomalidomide: 1 tablet orally, daily for 21 days of a 28 day cycle (dose per cohort) Everolimus: 1 tablet orally for 21 days of a 28 day cycle (dose as per cohort) Dexamethasone 40 mg (20 mg \>75yrs) orally, days 1, 8,15, 22 of a 28 day cycle
62022660|NCT05239091|EXPERIMENTAL|Dextrose prolotherapy|:%15 dextrose prolotherapy injection will be applied to trigger point
62022661|NCT05239091|ACTIVE_COMPARATOR|Lidocaine|%2 lidocaine injection will be applied to trigger point
62022662|NCT05287867|EXPERIMENTAL|Platelet treatment|A series of two treatments spaced 4 weeks apart that include platelet-rich plasma (PRP). platelet lysate (PL), and platelet poor plasma (PPP).
62412958|NCT02102217|EXPERIMENTAL|Precious arm|Postoperative controls according to the PRECious protocol, which entails standardized measurement of CRP levels on postoperative day three, four and five. If CRP levels exceed 140 mg/l additional CT-scan imaging will be conducted.
62412959|NCT02102217|NO_INTERVENTION|Control|Standard postoperative controls. Additional testing will only be conducted on demand.
62794627|NCT03466411|EXPERIMENTAL|Phase 3 (GALAXI 2 and 3): Group 1 and Group 2 (Guselkumab)|Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
62794628|NCT03466411|ACTIVE_COMPARATOR|Phase 3 (GALAXI 2 and 3): Group 3 (Ustekinumab)|Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE phase and continue to receive ustekinumab.
62022663|NCT05287867|SHAM_COMPARATOR|Sham procedure|A series of two sham procedures spaced 4 weeks apart.
62022664|NCT05571943|EXPERIMENTAL|Difamilast Ointment 1%|A thin layer of Difamilast applied to affected areas twice daily (morning and evening, approximately 12 hours apart)
62022665|NCT01476215|EXPERIMENTAL|Fast dissolution suspension|
62022666|NCT01476215|EXPERIMENTAL|Medium dissolution suspension|
62412960|NCT06689917|EXPERIMENTAL|JY231 injection for the treatment of relapsed or refractory B cell lympho Early exploratory clinica|JY231 Injection for the Treatment of relapsed or refractory B cell lymphoma/ leukemia subjects who meet the inclusion criteria will receive intravenous JY231. JY231 infusion will produce CAR-T cells in the body.
62412961|NCT03683719|EXPERIMENTAL|Delgocitinib cream 1 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
62412962|NCT03683719|EXPERIMENTAL|Delgocitinib cream 3 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
62412963|NCT03683719|EXPERIMENTAL|Delgocitinib cream 8 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
62412964|NCT03683719|EXPERIMENTAL|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
62412965|NCT03683719|PLACEBO_COMPARATOR|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 16 weeks.
62412966|NCT05219513|EXPERIMENTAL|Parts I-III: Dose-escalation of RO7443904|The dose-escalation of RO7443904 and glofitamab will take place every three weeks (Q3W) with obinutuzumab pre-treatment.
62586431|NCT05905523||6 year old participants|"In this study, your child will be asked to do the following things:~1. Play a drawing game on a tablet~2. Copy shapes using a pencil in a paper booklet~3. Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development"
62412967|NCT05219513|EXPERIMENTAL|Part IV: Dose-expansion of RO7443904|Part IV of this study will evaluate selected dose levels of RO7443904 in combination with glofitamab from Parts I-III in a Q3W regimen with obinutuzumab pre-treatment.
62412968|NCT01638260|PLACEBO_COMPARATOR|Liraglutide|Subjects will inject liraglutide once daily for 26 weeks
62022667|NCT01476215|EXPERIMENTAL|Slow dissolution suspension|
62022668|NCT01476215|ACTIVE_COMPARATOR|Marketed suspension|
62022669|NCT05869305|EXPERIMENTAL|whey protein isolate group|Whey protein isolate is contained in the sachet.
62022670|NCT05869305|EXPERIMENTAL|isolated soy protein group|Isolated soy protein, pea protein isolate, and brown rice protein are contained in the sachet.
62022671|NCT05869305|EXPERIMENTAL|placebo group|Base powder without proteins is contained in the sachet
62022672|NCT04257318|EXPERIMENTAL|Vibrating Relaxation Tool|Use of a Vibrating Relaxation Tool in case of pain during pregn
62022673|NCT05806762||Sepsis Patients Discharged From the Hospital|We aim to apply a wearable biopatch to sepsis patients discharged from the hospital to determine if the additional data afforded by the biopatch can improve prediction of readmissions.
62794629|NCT03466411|EXPERIMENTAL|Phase 3 (GALAXI 2 and 3): Group 4 (Placebo/Ustekinumab)|Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
62794630|NCT02968342|EXPERIMENTAL|Vaginal progesterone 8%|Vaginal progesterone application 8%
62022674|NCT03517644|EXPERIMENTAL|Deceptive Placebo (DP)|After pretreatment heat pain assessment, participants are informed that they are about to receive an effective analgesic cream. In fact, they receive a placebo cream. Next, the posttreatment pain assessment is conducted.
62022675|NCT03517644|EXPERIMENTAL|OLP with Hope (OLP Hope)|After pretreatment heat pain assessment, participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, using verbal instructions, the investigator aims to induce hope among the participants that the cream could have a positive effect. Next, the posttreatment pain assessment is conducted.
62022676|NCT03517644|EXPERIMENTAL|OLP with Expectations (OLP Expectation)|After pretreatment heat pain assessment, participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, using verbal instructions, the investigator aims to raise expectations among the participants that the cream will have a positive effect. Next, the posttreatment pain assessment is conducted.
62218856|NCT04829500|EXPERIMENTAL|MAP-VA Intervention|Montessori approaches to person-centered care (MAP-VA) introduces practical strategies that frontline staff can use for successful engagement of residents through retained abilities such as implicit learning, procedural memory, reading abilities. Staff training provides practice with: 1) pre-developed activities and templates, 2) a simple reading assessment to inform development of external cues; and 3) identifying opportunities for increased independence and resident contribution to community routines. Staff are also introduced to concrete strategies that improve dignity, control, and independence.
62412969|NCT01638260|ACTIVE_COMPARATOR|Liraglutide and NEAT|Subjects will inject liraglutide once daily and combine this treatment with activating lifestyle, by increasing NEAT.
62412970|NCT01940276|EXPERIMENTAL|Abiraterone Acetate and Prednisone|abiraterone acetate will be administered by the patient at a dose of 1000mg orally once daily with prednisone 5 mg BID in 4-week cycles
62218857|NCT01970631|NO_INTERVENTION|Usual Care|Participants randomized to the Usual Care group will receive the current standard post-operative TKR care.
62412971|NCT00136565|EXPERIMENTAL|Experimental|Velcade, Doxorubicine, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
62794631|NCT02968342|PLACEBO_COMPARATOR|Placebo|Oral multivitamin supplement
62794632|NCT03081884|EXPERIMENTAL|FACBC PET-CT Imaging|Individuals who have been diagnosed with primary prostate carcinoma and do not have definitive findings of systemic metastasis with conventional imaging will have a whole body FACBC PET-CT scan.
62794633|NCT02346461|ACTIVE_COMPARATOR|Cohort A|6 subjects on Cohort A will receive oral ManNAc 3 g twice daily (6 g/day) for 7 days and, if safe, continue on 6 g twice daily (12 g/day) for the remainder of the study.
62794634|NCT02346461|ACTIVE_COMPARATOR|Cohort B|6 subjects on Cohort B will receive oral ManNAc 6 g twice daily (12 g/day) for the duration of the study.
62022677|NCT03517644|EXPERIMENTAL|Control|After pretreatment heat pain assessment, this group does not receive an intervention targeting pain sensation prior to the posttreatment pain assessment.
62022678|NCT05404529|EXPERIMENTAL|Moderate Hepatic Function|Participants will receive a single dose of tavapadon, 0.5 milligrams (mg) or 0.25 mg tablet based on tolerability, on Day 1.
62022679|NCT05404529|EXPERIMENTAL|Mild Hepatic Function|Participants will receive a single dose of tavapadon, 0.5 mg or 0.25 mg tablet based on tolerability, on Day 1.
62022680|NCT05404529|EXPERIMENTAL|Normal Hepatic Function|Participants will receive a single dose of tavapadon, 0.5 mg or 0.25 mg tablet based on tolerability, on Day 1.
62412972|NCT00637598|EXPERIMENTAL|Tomosynthesis scans|This is a case-only study with only one group/cohort. All women receive both mammography and tomosynthesis imaging.
62412973|NCT00337155|EXPERIMENTAL|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 1|25 kBq/kg b.w., 3 times at 6 week intervals
62412974|NCT00337155|EXPERIMENTAL|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 2|50 kBq/kg b.w., 3 times at 6 week intervals
62412975|NCT00337155|EXPERIMENTAL|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 3|80 kBq/kg b.w., 3 times at 6 week intervals
62412976|NCT05193435|EXPERIMENTAL|Pelvic floor exercise group|Pelvic floor exercises for muscle fiber types I and II will performed 3 days a week for 8 weeks
62412977|NCT05193435|ACTIVE_COMPARATOR|Stabilization exercise group|Lumbar spinal stabilization exercises will performed 3 days a week for 8 weeks
62412978|NCT06537583|EXPERIMENTAL|Low Level Tragus Stimulation Group|Participant will undergo low level tragus stimulation using Parasym Device
62412979|NCT06537583|SHAM_COMPARATOR|Sham Control Group|Participant will have Parasym Device implanted in their tragus without any active stimulation from the device
62412980|NCT02823587|EXPERIMENTAL|Bronchiectasis Pulmonary Rehabilitation|The volunteers will receive supervised physical training twice a week and will be instructed to adopt a routine of home exercises, for 12 weeks.
62412981|NCT02823587|EXPERIMENTAL|Healthy Pulmonary Rehabilitation|In this arm, the volunteers healthy will receive supervised physical training twice a week and will be instructed to adopt a routine of home exercises, for 12 weeks.
62412982|NCT02823587|SHAM_COMPARATOR|Bronchiectasis Group Control|The volunteers with bronchiectasis will be informed only about the benefits of physical activities
62412983|NCT02823587|SHAM_COMPARATOR|Healthy Group Control|Volunteers healthy will be informed only about the benefits of physical activities
62022681|NCT03547661|NO_INTERVENTION|Treatment as Usual|The treatment as usual (TAU) group will control for regression to the mean, spontaneous remission, natural course of disease, and the participants-provider interaction. Participants of the TAU group are allowed to continue their usual medication intake, given they are already on a stable dose (at least 30 days of intake) and the medication is not listed in the exclusion criteria.
62412984|NCT06445725|EXPERIMENTAL|Acceptance Based Coping (ABaCo) Skills Training|Participant-patients will receive care as usual in the Nosotros Promotores program at University Health Robert B Green Campus Family Health Center, including standardized procedures (e.g., home visits, phone calls and in-clinic visits), along with this protocol - individual telephone-delivered ABaCo skills intervention delivered by one Promotor/a for 10 weeks (6 weeks plus booster at 10 weeks).
62794635|NCT03420547|EXPERIMENTAL|Intervention group|Group of participants receiving the RISE intervention
62412985|NCT01689922||AlterG and Physical therapy|2) Standard postoperative rehabilitation program with addition of lower body positive pressure (LBPP) treadmill training
62412986|NCT01689922||Control group|1) Standard postoperative rehabilitation program
62412987|NCT04846075||Ramadan Group|Diurnal fasting and spiritual practices. Operationally assessed by the level of compliance to Sawm, Salat, and Zakat.
62412988|NCT03972709|EXPERIMENTAL|Galegenimab Q4W|Participants will receive galegenimab every 4 weeks (Q4W). After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT04607148 (GR42558) and receive open-label galegenimab injections.
62412989|NCT03972709|SHAM_COMPARATOR|Sham Control Q4W|Participants will receive Sham-control Q4W. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT04607148 (GR42558) and receive open-label galegenimab injections.
62412990|NCT03972709|EXPERIMENTAL|Galegenimab Q8W|Participants will receive galegenimab every 8 weeks (Q8W). After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT04607148 (GR42558) and receive open-label galegenimab injections.
62412991|NCT03972709|SHAM_COMPARATOR|Sham Control Q8W|Participants will receive Sham-control Q8W. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT04607148 (GR42558) and receive open-label galegenimab injections.
62412992|NCT05910580|EXPERIMENTAL|Screening, Brief Intervention, and Referral to Treatment (SBIRT)|Patients at study clinics who are randomized to receive the Screening, Brief Intervention, and Referral to Treatment (SBIRT) intervention, which is delivered in-person and through telemedicine.
62412993|NCT05910580|NO_INTERVENTION|Usual Care|Patients at study clinics who are randomized to receive usual care. None of the clinic sites have implemented standardized screening, brief intervention, or referral to treatment components. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.
62412994|NCT00668369|EXPERIMENTAL|1|Liver transplant recipients with HCV infection fulfilling inclusion criteria.
62412995|NCT06653790|EXPERIMENTAL|Intervention arm|The psychosocial stimulation will be offered in two phases: in-patient (at stabilization unit) and after discharge patient will be referred to out-patient (at outpatient therapeutic centre) and developmental out-patient. The sessions with development paediatrician and team will be held every week lasting for about 20-40 min in the presence of the caregiver. The intervention includes auditory, tactile and visual stimulation, hand-eye coordination, and different types of sensory-motor training that included fine and gross motor activities. The guiding principle will be to enhance a child's holistic development-cognitive, language, physical, and social-in an integrated manner by using age-appropriate play materials, cultural tools, and resources.
62412996|NCT06653790|NO_INTERVENTION|Control|The control arm will be given no intervention except standard treatment
62412997|NCT02677337|NO_INTERVENTION|No intervention|
62586432|NCT05905523||7 year old participants|"In this study, your child will be asked to do the following things:~1. Play a drawing game on a tablet~2. Copy shapes using a pencil in a paper booklet~3. Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development"
62586433|NCT06343402|EXPERIMENTAL|Cohort 1a - Dose Escalation/Dose Finding Monotherapy|Participants enrolled in this cohort will receive BBO-8520 (different dose levels will be evaluated) once a day (QD) as monotherapy
62412998|NCT02677337|OTHER|Educational Program|chart abstraction will be conducted post education intervention component.
62433278|NCT02023502||healthy controls|healthy women with the same inclusion and exclusion criteria as the case group, except for stress urinary incontinence
62433279|NCT05760378|EXPERIMENTAL|A|Famitinib in Combination With Camrelizumab and TPC
62586434|NCT06343402|EXPERIMENTAL|Cohort 1b - Dose Escalation/Dose Finding Combination Therapy|Participants enrolled in this cohort will receive BBO-8520 (different dose levels will be evaluated) once a day (QD) in combination with pembrolizumab infusion (IV)
62218858|NCT01970631|ACTIVE_COMPARATOR|Motivational Interviewing (MI)|Participants randomized to the MI Intervention group will receive up to 14 telephone calls from a Health Educator for 9 months post-TKR.
62243358|NCT05440643|EXPERIMENTAL|Part 3: Maintenance A|UDR A + maintenance dose A
62433280|NCT05760378|ACTIVE_COMPARATOR|B|Combination With Camrelizumab and TPC
62586435|NCT06343402|EXPERIMENTAL|Cohort 2a - Dose Expansion Monotherapy|Participants enrolled in this cohort will receive BBO-8520 once a day (QD) as monotherapy
62794636|NCT03420547|NO_INTERVENTION|Standard Care (waitlist)|Group receiving no intervention in first 6 weeks.They will have the option of participating in the RISE program after their second assessment at week 6.
62243359|NCT05440643|EXPERIMENTAL|Part 3: Maintenance B|UDR B + maintenance dose B
62218859|NCT01970631|ACTIVE_COMPARATOR|Financial Incentives (FI)|Participants randomized to the FI Intervention group will receive financial incentives for completing physical activity logs weekly/bi-weekly and achieving pre-specified physical activity goals over the course of the study.
62586436|NCT06343402|EXPERIMENTAL|Cohort 2b - Dose Expansion Combination Therapy|Participants enrolled in this cohort will receive BBO-8520 once a day (QD) in combination with pembrolizumab infusion (IV)
62218860|NCT01970631|ACTIVE_COMPARATOR|Motivational Inverterviewing (MI) + Financial Incentives (FI)|Participants randomized to the FI + MI Intervention group will receive financial incentives for completing physical activity logs weekly/bi-weekly and achieving pre-specified physical activity goals as well as receive up to 14 telephone calls from a Health Educator for 9 months post-TKR.
62412999|NCT05373017|EXPERIMENTAL|DANE Recovery Model|The delivery of the model will occur in five phases that correspond to the known stages of recovery after surgery. During the acute stage (0 - 1 month after surgery), participants will undergo the initial case review and two initial virtual visits, and the development of the recovery care plan. During the recovery (2 - 6 months after surgery) and maintenance (7-12 months after surgery) stages, the participants will undergo the interaction phase of the DANE Recovery Model.
62413000|NCT05373017|OTHER|Usual Care|Participants will receive the usual rehabilitation and post-operative care.
62413001|NCT02952300|EXPERIMENTAL|neolix|single full rotation file (Neolix ® Neolix ,France) the first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani Inc., Japan). is passively fit in the canal (most of the canals) , but in case of K-file (Mani Inc., Japan) size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length of the canal
62433281|NCT01771861||Seriously injured or potentially seriously injured patients|
62586437|NCT05615363|EXPERIMENTAL|OPC 131461 10mg group|OPC-131461 5 mg tablet ｘ 2
62586438|NCT05615363|EXPERIMENTAL|OPC 131461 5mg group|OPC-131461 5 mg tablet and placebo tablet
62218861|NCT02843893|OTHER|Intubated and Mechanically Ventilated Patients|Intubated and Mechanically Ventilated Patients receiving by continuous intravenous an hypnotic sedation (midazolam or propofol) associate with a morphine type drug (fentanyl, sufentanil, rémifentanil, or morphine) since at least 6 hours and for a predictable duration over 24 hours.
62586439|NCT05615363|EXPERIMENTAL|OPC 131461 2mg group|OPC-131461 1 mg tablet ｘ 2
62586440|NCT05615363|EXPERIMENTAL|OPC 131461 1mg group|OPC-131461 1 mg tablet and placebo tablet
62218862|NCT03028038|EXPERIMENTAL|Platelet Rich Plasma|Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.
62586441|NCT05615363|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62586442|NCT06684912|NO_INTERVENTION|CONTROL|A non-exercise condition.
62586443|NCT06684912|EXPERIMENTAL|High intensity interval exercise (HIIE)|The HIIE was comprised of 1 min exercise bouts at 90% of oxygen uptake (V̇O2) reserve interspersed by 1 min active recovery bouts at 60% V̇O2 reserve (1:1).
62586444|NCT06684912|EXPERIMENTAL|Moderate-intensity exercise (MICE)|MICE at 60% V̇O2 reserve with the duration adjusted to each participant so that each participant achieved the target energy expenditure.
62586445|NCT02068963||Study Population|
62586446|NCT03335228|EXPERIMENTAL|Eclipse Easy Spin for PRP Treatment|Assessing the safety and efficacy of platelet rich plasma for treating frontal fibrosing alopecia. This will be accomplished by the production of platelet rich plasma by the Eclipse Easy Spin centrifuge. Subjects will receive treatment once a month for 6 months. Platelet rich plasma will be administered via injections into the affected areas of the scalp.
62586447|NCT04563871|EXPERIMENTAL|80mg Osimertinib|One tablet of 80mg Osimertinib for oral administration per day
62586448|NCT02381730|EXPERIMENTAL|Aflibercept|
62738683|NCT05033587|EXPERIMENTAL|AK105 injection with anlotinib and radiotherapy|"AK105 200mg intravenously (IV) on day 1 of each 21-day cycle until disease progression or treatment intolerance, the dose can not be adjusted.~Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.~The conventional radiotherapy regimen delivered 2.0Gy once a day, five days a week to a total dose of 60Gy."
62738684|NCT04431843|EXPERIMENTAL|Spirulina maxima extract|Spirulina maxima extract for 1.5 g/day
62738685|NCT04431843|PLACEBO_COMPARATOR|Placebo|Spirulina maxima extract for 0 g/day
62738686|NCT01308814|PLACEBO_COMPARATOR|Placebo|Placebo patches for 12 months and placebo pills for 12 days every 2 months.
62738687|NCT01308814|EXPERIMENTAL|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months and oral micronized progesterone (200 mg/day) for 12 days every two months.
62794637|NCT06104904|EXPERIMENTAL|Managing Anxiety in Pediatric Primary Care (MAPP)|Participants receive approximately 4 sessions of a primary care provider-delivered intervention for reducing youth anxiety symptoms based on exposure therapy.
62794638|NCT06104904|PLACEBO_COMPARATOR|Enhanced Usual Care (EUC)|Participants receive a list of resources on how to reduce anxiety (e.g., videos, books, etc.).
62738688|NCT06071793|EXPERIMENTAL|All participants|Patients to receive mobility interventions from trained family members
62738689|NCT03248531|EXPERIMENTAL|Bimekizumab|Subjects will receive one Bimekizumab loading dose 1 and several Bimekizumab dose 2 applications.
62738690|NCT03248531|ACTIVE_COMPARATOR|Adalimumab|Subjects will receive one Adalimumab loading (dose 1) and several Adalimumab dose 2 and dose 3 applications.
62738691|NCT03248531|PLACEBO_COMPARATOR|Placebo|Subjects will receive several placebo applications to keep the blinding.
62794639|NCT04047628|EXPERIMENTAL|AHSCT|"AHSCT: Myeloablative and Immunoablative therapy followed by Autologous Hematopoietic Stem Cell Transplantation~Participants will undergo:~1. Mobilization and graft collection: mobilization of peripheral blood stem cells (PBSC) with cyclophosphamide, filgrastim, and dexamethasone. The autologous graft will be collected by leukapheresis and cryopreserved.~2. Conditioning: high dose myeloablative and immunoablative conditioning with a six-day BEAM chemotherapy and rabbit anti-thymocyte globulin regimen will be initiated ≥30 days after cyclophosphamide mobilization.~3. Autologous cryopreserved graft infusion: the cryopreserved peripheral blood stem cells (PBSC) graft will be thawed and infused the day following completion of the conditioning regimen. Each bag will be thawed and infused according to institutional standards consistent with the Foundation for the Accreditation of Cellular Therapy (FACT) guidelines. Participants will receive prednisone following graft infusion."
62022682|NCT03547661|ACTIVE_COMPARATOR|Integrative Open-Label Placebo|"The intervention will encompass an integrative administration of P-Dragees rosa Lichtenstein, which are pink placebo dragées without any active ingredient. Each dragée contents the following substances: lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; highly dispersed silicon dioxide; white clay, macrogol glycerolhydroxy stearate (Ph. Eur.); Arabic gum; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); erythrosine; aluminium salt (E 127); calcium carbonate; sucrose; glucose syrup; maize starch; macrogol 6000.~All participants will be informed that the administered dragées are placebo dragées and participants will be instructed to take two dragées a day for six weeks. (Amendment regarding dosage since 08/18)"
62218863|NCT03028038|EXPERIMENTAL|No Platelet Rich Plasma|No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.
62218864|NCT04672226|EXPERIMENTAL|PDE MAX|PDE MAX will be prescribed by the study dietitian based on the patient's individual requirement.
62794640|NCT04047628|ACTIVE_COMPARATOR|Best Available Therapy (BAT)|Participants randomized to BAT: Best available therapy will be selected by the Site Investigator from: Cladribine (Mavenclad®), natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), ublituximab (BRIUMVI™), rituximab (Rituxan®), or ofatumumab (Arzerra®) (after approval by the FDA for relapsing MS).
62794641|NCT02855268|EXPERIMENTAL|Placebo/Lademirsen|Participants received subcutaneous (SC) doses of placebo (matched to lademirsen) every week (QW) during the 48 weeks of double blind (DB) treatment period. Participants who received placebo and completed DB treatment period entered in open-label extension (OLE) treatment period and received lademirsen at a dose of 110 milligrams (mg) QW for an additional 48 weeks (i.e., up to Week 96).
62794642|NCT02855268|EXPERIMENTAL|Lademirsen/Lademirsen|Participants received SC doses of lademirsen 110 mg QW during the 48 weeks of DB treatment period. Participants who completed DB treatment period entered in OLE treatment period and continued the same lademirsen treatment in OLE period for an additional 48 weeks (i.e., up to Week 96).
62218865|NCT06609915|EXPERIMENTAL|Intervention group|Supraglottic, superimposed high frequency jet ventilation using the Monsoon 4 (Thora Tech GmbH, Giessen, Germany) with initial 1.0 FiO2 reduced to 0.3 during laser surgery
62218866|NCT06609915|ACTIVE_COMPARATOR|Control group|high-flow oxygen (up to 70 L/min FiO2 1.0) via nasal cannula with the Optiflow (Fisher \& Paykel Healthcare, Auckland, New Zealand) with initial 1.0 FiO2 reduced to 0.3 during laser surgery
62218867|NCT02022189||Dent Disease patients|Patients with diagnosed Dent Disease
62218868|NCT01815138|EXPERIMENTAL|hCG given at time of GnRHa trigger|"Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger.~Placebo administered 35 hours after GnRH agonist trigger"
62218869|NCT01815138|ACTIVE_COMPARATOR|hCG given 35 hours after GnRHa trigger|"Placebo administered at the time of GnRH agonist trigger~Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger."
62218870|NCT04133051|ACTIVE_COMPARATOR|Quadratus Lumborum Block|17 cases will be subjected to bilateral Ultrasound-guided Quadratus lumborum block through bilateral catheter insertion for perioperative analgesia.
62218871|NCT04133051|ACTIVE_COMPARATOR|Epidural Analgesia|17 cases will be subjected to epidural catheter insertion for perioperative analgesia (as a control group).
62218872|NCT02980731|EXPERIMENTAL|Venetoclax|Venetoclax was administered orally once daily (QD) for a planned duration of up to 2 years or until disease progression; median time on treatment was 127 weeks. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
62218873|NCT02866136|OTHER|(IV)Intravenous chemotherapy, laser diode|"Group 1 - Multicentric non randomised, phase II study for patients with retinoblastoma (unilateral group A,B according to age, group C according to the age and the vitreous seeding or bilateral groups A,B and C excluding the bilateral groups D or patients with bilateral macular threat).~Treatment by chemoreduction (VP16, carboplatin) followed by Carboplatin + laser day 1 (chemothermotherapy) without laser treatment at day 8 (decreasing laser sessions) combined to local treatments from third course (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan)."
62218874|NCT02866136|OTHER|(IA) Intraarterial Melphalan|"Group 2 - Multicentric non randomised, phase II study for the patients with bilateral very asymmetric disease (group D retinoblastoma on one of the eye, and the other amenable to a local treatment without chemotherapy) or unilateral presentation group D and groups B/C according to the age and vitreous seeding.~Treatment by Melphalan chemotherapy administered by superselective catheterization of the ophthalmic artery and combined to local treatments (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan)."
62218875|NCT02866136|OTHER|(IV-PM) Intravenous 3 drugs chemotherapy|Group 3 - Multicentric non randomised, phase II study for the patients with bilateral group D retinoblastoma or with a group D retinoblastoma on the only remaining eye. Treatment by 6 cycles of three drugs (VP16, carboplatin, vincristin) regimen combined to local treatments from the third cycle (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan).
62218876|NCT02689518|OTHER|Treatment - On-Label|On-label intravitreal aflibercept (Eylea) injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks (2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months
62218877|NCT05900700|EXPERIMENTAL|eYST website|
62218878|NCT00795613|EXPERIMENTAL|PET pos|Patients With Interim Pet Positive Proceed To Escalated Beacopp Regimen
62218879|NCT00795613|OTHER|PET negative|Patients With Interim-Pet Negative Continue The Conventional ABVD Regimen
62794643|NCT02883374|EXPERIMENTAL|Chidamide|Patients of advanced cephalic and cervical adenocystic carcinoma are given Chidamide 30mg,biw, then the efficacy and safety will be accessed.
62022683|NCT03547661|ACTIVE_COMPARATOR|Open-Label Placebo|"The intervention will encompass an administration of P-Dragees rosa Lichtenstein, which are pink placebo dragées without any active ingredient. Each dragée contents the following substances: lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; highly dispersed silicon dioxide; white clay, macrogol glycerolhydroxy stearate (Ph. Eur.); Arabic gum; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); erythrosine; aluminium salt (E 127); calcium carbonate; sucrose; glucose syrup; maize starch; macrogol 6000.~All participants will be informed that the administered dragées are placebo dragées and participants will be instructed to take two dragées a day for six weeks. (Amendment regarding dosage since 08/18)"
62022684|NCT05877729|ACTIVE_COMPARATOR|Standard of Care Arm|The Standard of Care (SOC) arm will include the current care delivery model: regularly scheduled visits with a healthcare provider and lab testing every 3-6 months or more/less frequently depending on the individual's HIV health outcomes (e.g., VL suppression) . At each assessment, the investigators will review participant responses to examine acute need for referral for medical, psychological, or substance use services. In between assessments, researchers will also do monthly check-ins to improve retention and check contact information.
62022685|NCT05877729|EXPERIMENTAL|Intervention Arm: Video-Counseling+app|The video-counseling+app arm will receive 12 brief weekly counseling sessions (given over 16 weeks) with a social worker, along with access to the WYZ app to use based on their needs. After 16 weeks, participants receive another assessment and based on VL, those in the video-counseling+app arm will be categorized as intervention responders or non-responders (responder= virologically suppressed; non-responder= virologically unsuppressed. Responders in video-counseling+app arm will continue to use the app only. Non-responders in the intervention arm will continue with intensified video-counseling+app for 16 more weeks.
62022686|NCT04405024|OTHER|Hepatitis C testing|"If the patient is included in the study, HCV serology (2 x 5 ml tubes) will be taken at the time of admission as part of the routine entry assessment.~These two tubes will be used for HCV screening. The patient is informed of the HCV serology result during hospitalization by an investigator."
62022687|NCT05774808||Aortic valve surgery only|
62022688|NCT05774808||Aortic valve + mitral valve surgery|
62022689|NCT00855829|ACTIVE_COMPARATOR|Miniature Actilady device active|one miniature Actilady device tested for all patients during a 4 months period. The device is active in 3 months out of the 4, and the patients are blinded to the action of the device (sham comparator).
62413002|NCT02952300|ACTIVE_COMPARATOR|wave one|single reciprocating file (Wave One ® Dentsply , Switzerland) the canal preparation is done by primary file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani Inc., Japan) is passively fit in the canal ( most of canals ) , but in case of K-file (Mani Inc., Japan) size 20 loose in the canal so we choose large large file size 40 taper 8% either of them to the full working length of the canal
62586449|NCT06682195|EXPERIMENTAL|Neoadjuvant chemotherapy combined with Toripalimab|"1, Neoadjuvant Chemotherapy Phase Combined with Toripalimab~1. First Phase of Neoadjuvant Chemotherapy: Epirubicin + Cyclophosphamide + Toripalimab. Administered intravenously: 100 mg/m² Epirubicin + 600 mg/m² Cyclophosphamide + 240 mg Toripalimab, every 3 weeks for a total of 6 weeks.~2. Second Phase of Neoadjuvant Chemotherapy: Albumin-bound Paclitaxel + Toripalimab. Administered intravenously: 260 mg/m² Albumin-bound Paclitaxel + 240 mg Toripalimab, every 3 weeks for a total of 6 weeks.~2, Receive Breast Cancer Radical Surgery After 4 Cycles of Neoadjuvant Chemotherapy 3, Postoperative Adjuvant Therapy~1. If pathology indicates pCR: Continue immunotherapy, administering 240 mg Toripalimab intravenously every 3 weeks for a total of 1 year.~2. If pathology indicates non-PCR: Continue postoperative adjuvant chemotherapy combined with Toripalimab.~4, Perform Gene Testing on Biopsy Tissue Before Treatment, and Collect Blood Samples for ctDNA Testing Before and After Treatment."
62022690|NCT00855829|SHAM_COMPARATOR|Miniature Actilady device not active|Sham Comparator: one miniature Actilady device tested for all patients during a 4 months period. The device is active in 3 months out of the 4, and the patients are blinded to the action of the device (sham comparator).
62022691|NCT05363033||one group|Using a one-group pretest-posttest design
62022692|NCT03457259|ACTIVE_COMPARATOR|Midline|Pt. will receive midline catheters. The outcomes will be registered and some patients will be examined once weekly for thrombosis with ultrasound.
62022693|NCT03457259|ACTIVE_COMPARATOR|Conventional|Pt. will receive the conventional treatment (PVC and/or PICCline/CVC). The outcomes will be registered.
62022694|NCT04193813||POAF|
62022695|NCT04193813||Non POAF|
62022696|NCT00382343|EXPERIMENTAL|sulfamethoxazole/trimethoprim|Antibiotic prophylaxis with sulfamethoxazole/trimethoprim \[1-2 mg/kg trimethoprim and 5-10 mg/kg sulfamethoxazole once daily\]; in case of intolerance (leucopoenia) and for children younger than 6 months: nitrofurantoin \[2 mg/kg once daily\]
62022697|NCT00382343|NO_INTERVENTION|No prophylaxis|
62022698|NCT02232529|EXPERIMENTAL|Part 1: MIN-101|"MIN-101~modified release formulation (MR),single oral dose between 16 and 64 mg"
62022699|NCT02232529|EXPERIMENTAL|Part 2: MIN-101 low dose|"MIN-101~single daily oral dose, low dose MR formulation, from Day 1 to Day 7"
62022700|NCT02232529|PLACEBO_COMPARATOR|Part 2: placebo|"placebo MIN-101~daily oral dose from Day 1 to Day 7"
62022701|NCT02232529|EXPERIMENTAL|Part 2: MIN-101 high dose|"MIN-101~single daily oral dose, low dose MR formulation, from Day 1 to Day 7"
62022702|NCT04296565|OTHER|Usual Care|Usual Care condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff.
62218880|NCT02073747|PLACEBO_COMPARATOR|Normal Saline Control Group|Control group will be administered a one hour normal saline inhaled treatment.
62218881|NCT02073747|ACTIVE_COMPARATOR|Albuterol Trial Group|Trial group to be administered one hour treatment of ten milligrams of inhaled albuterol
62218882|NCT02677480|ACTIVE_COMPARATOR|Test group, probiotic tablets and gel|Test group, probiotic tablets and gel: tablets with probiotic bacteria (10exp8/tablet) and pH-rising components and gel (with probiotic bacteria and pH-rising components) in trays on the teeth once a week.
62022703|NCT04296565|EXPERIMENTAL|WATER+CT|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
62413003|NCT02245997|EXPERIMENTAL|patients with high-risk neuroblastoma|Patients undergo external beam radiation therapy using IMRT or proton beam RT twice daily for 5-6 weekdays (10-12 treatments). Patients will be evaluated by physical exams, CT scan or MRI of the primary site, and MIBG at, 6, 12, 18 and 24 months (+/- 6 weeks).
62218883|NCT02677480|PLACEBO_COMPARATOR|Placebo group, placebo tablets and gel|Placebo group, placebo tablets and gel: placebo tablets without probiotic bacteria and pH-rising components and gel (with no probiotic bacteria but with pH-rising components) in trays on the teeth once a week.
62218884|NCT05636423||Italian physiotherapists|The survey will take place through the administration of a questionnaire accessible via the website of the Italian Physiotherapy Association (AIFI), the Scientific Association of reference for the physiotherapists, registered since 2020 in the list of Scientific Societies recognized by the Italian Health Ministry.
62243360|NCT05440643|PLACEBO_COMPARATOR|Part 3: Placebo|Placebo UDR + placebo maintenance
62413004|NCT05567562|EXPERIMENTAL|COPD Cases: Dual antiplatelet therapy first, then placebo|Dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) will be given for 2 weeks, followed by 2 weeks without intervention, then 2 weeks of placebo
62586450|NCT02900560|ACTIVE_COMPARATOR|Cohort 1|CC-486 100 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
62586451|NCT02900560|ACTIVE_COMPARATOR|Cohort 2|CC-486 100 mg twice a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
62218885|NCT04914299|EXPERIMENTAL|A novel mobile-App based intervention|"An App-based positive intelligence intervention consisting of 6 weeks of weekly videos and support group sessions, and 6 weeks of daily App-guided practices."
62413005|NCT05567562|PLACEBO_COMPARATOR|COPD Cases: Placebo first, then dual antiplatelet therapy|Placebos for each therapy (2 pills) will be given for 2 weeks, followed by 2 weeks without intervention, then 2 weeks of dual antiplatelet therapy
62413006|NCT05567562|ACTIVE_COMPARATOR|Controls: Dual antiplatelet therapy first, then placebo|Dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) will be given for 2 weeks, followed by 2 weeks without intervention, then 2 weeks of placebo
62413007|NCT05567562|PLACEBO_COMPARATOR|Controls: Placebo first, then dual antiplatelet therapy|Placebos for each therapy (2 pills) will be given for 2 weeks, followed by 2 weeks without intervention, then 2 weeks of dual antiplatelet therapy
62586452|NCT02900560|ACTIVE_COMPARATOR|Cohort 3|CC-486 300 mg once a day, 14 days on and 14 days off combined with Pembrolizumab 200 mg IV every 21 days
62586453|NCT02900560|ACTIVE_COMPARATOR|Cohort 4|CC-486 300 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
62586454|NCT00502892|EXPERIMENTAL|Topotecan + Ifosfamide + Carboplatin|
62586455|NCT03637140|EXPERIMENTAL|Order A|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
62586456|NCT03637140|EXPERIMENTAL|Order B|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
62586457|NCT02208713|EXPERIMENTAL|Stem cell recipient|The patients with FSHD who underwent muscle derived stem cell and Adipose derived mesenchymal stem cell with intramuscular injection.
62022704|NCT02012374|EXPERIMENTAL|"Intensive Language Action Therapy (constrained)"|Following a phase of baseline pre-treatment testing, speech therapy sessions take place 5 days/week for 3 hours per session during two consecutive weeks. Spoken responses are explicitly modeled and encouraged during therapy. Following the intensive 2-week treatment, participants are trained in using individualized home practice programs on iPads. They practice approximately daily for six months, checking in weekly with an SLP via videoconferencing software and return for probes monthly. Six months post-treatment testing will take place following completion of the home practice phase and again at 12 months post-treatment.
62586458|NCT05473572|EXPERIMENTAL|Children who stutter|Measuring stuttering severity and cortical auditory evoked potentials in a group of children who stutter then they will receive fluency shaping exercises for a period range from 2-4 months. Reassessment of cortical auditory evoked potentials and stuttering severity after the specified period
62586459|NCT05473572|NO_INTERVENTION|children who do not stutter|Measuring cortical auditory evoked potentials as a comparison group
62022705|NCT02012374|EXPERIMENTAL|Unconstrained Intensive Language Action Therapy|Following a phase of baseline pre-treatment testing, speech therapy sessions take place 5 days/week for 3 hours per session during two consecutive weeks. All communicative responses are encouraged during therapy. Following the intensive 2-week treatment, participants are trained in using individualized home practice programs on iPads. They practice approximately daily for six months, checking in weekly with an SLP via videoconferencing software and return for probes monthly. Six months post-treatment testing will take place following completion of the home practice phase and again at 12 months post-treatment.
62022706|NCT02807948|OTHER|Pacemaker, ICD, or CRT device patients|Subjects who need a non-thoracic clinically indicated scan
62022707|NCT00592995|PLACEBO_COMPARATOR|1|
62022708|NCT00592995|ACTIVE_COMPARATOR|2|
62218886|NCT04914299|ACTIVE_COMPARATOR|Standard of Care|Standard prenatal care and follow up
62218887|NCT00551265|EXPERIMENTAL|Arm I|Patients undergo delayed-type hypersensitivity (DTH) skin testing with oregovomab and a standard anergy panel (i.e., mumps, Candida, and tetanus toxoid) on day 0 (at baseline) and at week 14. The skin test response is measured 48 hours later. Patients receive cyclophosphamide IV on day 6 and oregovomab IV over 20 minutes on day 9 or 10. Patients then receive oregovomab alone at weeks 6 and 10 and then every 12 weeks for up to 2 years (10 doses) in the absence of disease progression or unacceptable toxicity.
62218888|NCT00551265|ACTIVE_COMPARATOR|Arm II|Patients undergo DTH skin testing and receive oregovomab as in arm I.
62413008|NCT05164562||type 1 diabetes|"type 1 diabetes group: patients with type 1 diabetes"
62413009|NCT03335839|EXPERIMENTAL|Intracoronary tPA 10 mg|
62413010|NCT03335839|EXPERIMENTAL|Intracoronary tPA 20 mg|
62413011|NCT03335839|PLACEBO_COMPARATOR|Placebo|saline
62586460|NCT04698538|NO_INTERVENTION|Educational Materials|Caregivers in this arm will receive intervention material, but no coaching. The material consists of a self-guided module introducing caregivers to the developmental concepts of joint engagement, social communication, and play.
62586461|NCT04698538|EXPERIMENTAL|JASPER intervention|The caregivers randomized to intervention, will meet twice a week with UCLA staff to do session planning one day and JASPER remote, live coaching another day. The caregivers are expected to meet with the UCLA team twice a week.
62586462|NCT05331443||participents who has the intention to fast Ramadan|subjects with at least two cardiovascular risk factors according to Framingham classification or with out any risk .
62586463|NCT03183089|EXPERIMENTAL|Active|
62586464|NCT03183089|ACTIVE_COMPARATOR|Active Comparator|
62586465|NCT06683118|EXPERIMENTAL|experimental group|
62433282|NCT05769088|EXPERIMENTAL|Multi-Ingredient Pre-Workout Supplement|"A 60 g dose of a commercially available preworkout supplement providing 159 kcal including carbohydrates 15 g, essential amino acids 12 g, citrulline 3.5 g, Arginine, 3.5 g Taurine 1 g, L-Tyrosine~1 g, yerba mate 0.3 g and caffeine 0.4 g. With 350 ml of water."
62586466|NCT06683118|ACTIVE_COMPARATOR|control group|
62586467|NCT02404688|EXPERIMENTAL|Active THC and Placebo Ethanol|
62586468|NCT02404688|EXPERIMENTAL|Active THC and Active Ethanol|
62586469|NCT02404688|EXPERIMENTAL|Placebo THC and Active Ethanol|
62586470|NCT02404688|PLACEBO_COMPARATOR|Placebo THC and Placebo Ethanol|
62586471|NCT04432831|EXPERIMENTAL|Faricimab PTI|
62413012|NCT06379984|EXPERIMENTAL|Rapid outpatient low-dose initiation|Participants randomized to low-dose initiation will be instructed to arrive to the research unit without withdrawal. Participants with COWS \<4 will be admitted to the research unit to begin induction. They will be administered 0.5, 0.5, 1, 1, 1, 4, and then 8 mg as sublingual buprenorphine films with doses scheduled every 2 hours. They will then continue 8-12mg twice daily as maintenance treatment.
62022709|NCT02289391|PLACEBO_COMPARATOR|non-asthma group|"* Non-asthma history~* Infusion of normal saline(1μg/kg) at 10 minutes before anesthesia induction.~* Infusion of normal saline at 0.4μg•kg-1•h-1during anesthesia maintenance.~* Stop infusion of normal saline at 10 minutes before the end of surgery."
62586472|NCT01461317|EXPERIMENTAL|Etrolizumab|Etrolizumab 100 milligrams (mg) subcutaneous (SC) administration every 4 weeks during the treatment period of up to 240 weeks.
62586473|NCT04099368|EXPERIMENTAL|Auditory|Group receives training on listening to musical pitch differences between sounds as the first component of a crossover trial. The intervention is the listening exercises. Exercises are completed daily as 30-minute sessions for 4 weeks. Hearing assessment outcomes of speech comprehension in background noise and of musical pitch sensitivity are conducted at baseline and at midpoint and endpoint.
62022710|NCT02289391|EXPERIMENTAL|Dexmedetomidine A|"* With a history of asthma~* Infusion of dexmedetomidine(1μg/kg) at 10 minutes before anesthesia induction.~* Infusion of dexmedetomidine at 0.4μg•kg-1•h-1during anesthesia maintenance.~* Stop infusion of dexmedetomidine at 10 minutes before the end of surgery."
62022711|NCT02289391|EXPERIMENTAL|Dexmedetomidine B|"* With a history of asthma~* Infusion of dexmedetomidine(1μg/kg) at 10 minutes before anesthesia induction.~* Infusion of dexmedetomidine at 0.7μg•kg-1•h-1during anesthesia maintenance.~* Stop infusion of dexmedetomidine at 10 minutes before the end of surgery."
62022712|NCT02289391|PLACEBO_COMPARATOR|Control group|"* With a history of asthma~* Infusion of normal saline(1μg/kg) at 10 minutes before anesthesia induction.~* Infusion of normal saline at 0.4μg•kg-1•h-1during anesthesia maintenance.~* Stop infusion of normal saline at 10 minutes before the end of surgery."
62022713|NCT02863562|EXPERIMENTAL|Group 1|"This group included 16 subjects. They received kinesio taping for both ankle joints and and performed proprioceptive exercises.~Proprioceptive exercises were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed. Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training."
62218889|NCT00294203|ACTIVE_COMPARATOR|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
62218890|NCT00294203|PLACEBO_COMPARATOR|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
62586474|NCT04099368|ACTIVE_COMPARATOR|Visual|Group receives training on visual differences between objects on a computer screen as the first component of a crossover trial. This is a control measure for the auditory training exercises. Exercises are completed daily as 30-minute sessions for 4 weeks. Hearing assessment outcomes of speech comprehension in background noise and of musical pitch sensitivity are conducted at baseline and at midpoint and endpoint.
62218891|NCT03948165||Distal Radial Approach|Distal transradial access will be performed on patients above 18 years of age, undergoing diagnostic and/or therapeutic coronary angiography, with palpable pulse at the level of the radial fossa, and these patients will be also subjected to the following tests: Allen maneuver and Barbeau maneuver; a positive Allen test was indication to perform the transradial access, while a type D Barbeau test will be a contraindication for it.
62218892|NCT02954965|EXPERIMENTAL|Reward|A brief, phone-administered intervention designed to help graduate students increase the number of pleasant and rewarding activities in their daily lives.
62433283|NCT05769088|PLACEBO_COMPARATOR|Maltodextrin Supplement|A isoenergetic Maltodextrin supplement will be administered as placebo. With 350 ml of water.
62433284|NCT00185211|EXPERIMENTAL|Initial IFNB-1b (Interferon beta-1b)|Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
62433285|NCT00185211|EXPERIMENTAL|Initial Placebo|Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
62433286|NCT00946465|EXPERIMENTAL|1|Ramipril 10 Capsule (Sandoz)
62586475|NCT06683014|EXPERIMENTAL|Open-Label MDMA|Participants will receive one dose of open-label 3,4-methylenedioxymethamphetamine (MDMA).
62586476|NCT03473028|ACTIVE_COMPARATOR|transabdominal ultrasound|400 obese female undergo transabdominal ultrasound guided embryo transfer
62586477|NCT03473028|ACTIVE_COMPARATOR|transvaginal group|400 obese female undergo transvaginal ultrasound guided embryo transfer
62586478|NCT04859790|ACTIVE_COMPARATOR|Active SCAR Intervention|In this arm, participants will complete baseline measures, receive the SCAR intervention, and complete follow-up measures one month following the intervention.
62586479|NCT04859790|NO_INTERVENTION|Waitlist Control|Participants assigned to the waitlist control condition will complete baseline measures and measures one month following their baseline appointment. After they complete the follow-up measures, they will be offered the SCAR intervention.
62586480|NCT01468259|EXPERIMENTAL|Normal renal function|16 subjects with normal renal function (eGFR greater than 90 mL/min/1.73m²)
62586481|NCT01468259|EXPERIMENTAL|Mild RD|Eight (8) with mild (60 less than eGFR less than 89 mL/min/1.73m²)
62586482|NCT01468259|EXPERIMENTAL|Moderate RD|Eight with moderate (30 less than eGFR less than 59 mL/min/1.73m²),
62586483|NCT01468259|EXPERIMENTAL|Severe RD|Eight with severe (15 less than eGFR less than 29 mL/min/1.73m²)
62586484|NCT01468259|EXPERIMENTAL|End Stage Renal Disease|Eight with ESRD (eGFR \< 15 mL/min/1.73m² and requiring hemodialysis)
62022714|NCT02863562|EXPERIMENTAL|Group 2|"This group received placebo kinesio taping for ankle joint (no tension) and performed proprioceptive exercises.~Proprioceptive exercises were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed. Kinesio taping technique was used on both ankles on the first day of training in the same way as before but with no tension. It was removed on the second day of training."
62022715|NCT02863562|EXPERIMENTAL|Group 3|This group received kinesio taping for ankle joint. Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training.
62022716|NCT02394743||eGFR > 90|group whose eGFR is more than 90
62022717|NCT02394743||60 < eGFR <90|group whose eGFR is between 60 and 90
62413013|NCT06379984|ACTIVE_COMPARATOR|Standard initiation|"Participants randomized to standard induction will be instructed to arrive to the research unit with mild withdrawal and to have abstained from opioids for at least 8 hours, per ASAM Guidelines. Participants with COWS 4 or higher on initial assessment will be admitted to the research unit to begin induction.~Standard initiation will follow guidelines from the 2020 Focused Update of the ASAM National Practice Guidelines. Once participants have had at least 8 hours of abstinence and have reached COWS \>11, they will be given 2 mg sublingual buprenorphine, followed 2 hours later by 2 mg, followed 2 hours later by 4 mg, followed 2 hours later by 8 mg. They will then continue 8-12 mg twice daily as maintenance treatment."
62413014|NCT00665366|PLACEBO_COMPARATOR|Placebo + valproate or lithium|Participants randomly received placebo (1:1 to study drug) as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks.
62022718|NCT02394743||eGFR < 60|group whose eGFR is less than 60
62022719|NCT06215846|EXPERIMENTAL|BioTTT001 injection|BioTTT001 is administered as a single Intratumoral injection. The dose groups to be infusion were 5×10\^9 viral particle (VP) ,5×10\^10 VP and 5×10\^11 VP based on the 3+3 dose escalation principle.
62022720|NCT05718765|SHAM_COMPARATOR|Usual care with sham intervention|Patients in the control group received usual care with sham exercise.
62022721|NCT05718765|EXPERIMENTAL|PACES intervention|PACES includes an exercise perception intervention and an exercise intervention, which lasts for 12 weeks and is carried out simultaneously.
62433287|NCT00946465|ACTIVE_COMPARATOR|2|Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)
62586485|NCT03376256|EXPERIMENTAL|Phase A - Thoracic ES with LOR|Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until loss of resistance (LOR) is perceived to identify the thoracic epidural space (ES). The Compuflo Epidural Instrument will be used to record pressure readings. The thoracic epidural procedure will then continue per standard of care.
62586486|NCT03376256|EXPERIMENTAL|Phase B - Thoracic ES with Compuflo|Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until the Compuflo Epidural Instrument indicates that pressure has decreased. The loss of resistance technique will then be used to identify the thoracic epidural space. The thoracic epidural procedure will then continue per standard of care.
62022722|NCT05883306|EXPERIMENTAL|[14C]LXI-15028(n=6-8)|Subjects will receive a single oral dose of \[14C\]LXI-15028 suspension under the fasted state .
62022723|NCT02167022|EXPERIMENTAL|Intense Physiotherapy (Group 1)|30 minutes each of physical and occupational therapy each weekday for 12 weeks (intense physiotherapy) followed by the same therapies administered once a week for 36 weeks (the current standard of care).
62022724|NCT02167022|EXPERIMENTAL|Delayed Intense Physiotherapy (Group 2)|30 minutes each of physical and occupational therapy once a week for 36 weeks (the current standard of care) followed by the same therapies administered each weekday for 12 weeks (intense physiotherapy).
62586487|NCT00206687|EXPERIMENTAL|Arm 1|
62022725|NCT01043874|EXPERIMENTAL|Nilotinib|400 mg BID
62022726|NCT03171233|ACTIVE_COMPARATOR|Group mobilization with movement|Techniques to improve ankle mobility that possibily will to cause changes in the biomechanical motion of the lower limb. The patient does the movement actively, but is assisted by the therapist to mobilize.
62022727|NCT03171233|ACTIVE_COMPARATOR|Group Self mobilization with movement|Techniques to improve ankle mobility that possibily will to cause changes in the biomechanical motion of the lower limb. The patient performs the movement and the mobilization in an independently way without receiving help from the therapist
62022728|NCT02053233|EXPERIMENTAL|Walkbot group|The Walkbot group received conventional physical therapy (session I for 40 min/day) companied with Walkbot training (session II for 30 min/day) 5 days a week for 4 weeks, 40 session in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks.
62022729|NCT02053233|PLACEBO_COMPARATOR|control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
62586488|NCT00206687|SHAM_COMPARATOR|Arm 2|
62586489|NCT03397108||Women with IBD|This group is composed of breastfeeding women aged over 18 years and in their first 4-month postpartum period, who are diagnosed with Crohn's disease or Ulcerative Colitis.
62586490|NCT03397108||Healthy breastfeeding women|This group is composed of healthy breastfeeding women aged over 18 years and in their first 4-month postpartum period.
62022730|NCT03994861|ACTIVE_COMPARATOR|Patients with musculoskeletal disorders|Patients with either shoulder pain, knee pain, hip pain, low back pain, pelvic pain or neck pain as their primary pain complaint, lasting for 6 weeks or longer
62586491|NCT02046395|OTHER|Washout Period for 30 days|In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure. The goal for their blood pressure will be set at \< 140/90 mm/Hg. The washout period will last for four weeks at the end of which the patient will enter the test period.
62586492|NCT03682861|PLACEBO_COMPARATOR|Placebo|Placebo flavored drink similar to treatments but with no energy will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
62794644|NCT05639257|ACTIVE_COMPARATOR|Lamotrigine|"An escalation phase of 28 days:~- tablet Lamotrigine 25 mg once daily in 14 days followed by 50 mg once daily in 14 days.~A treatment phase of 30 days:~- tablet Lamotrigine 100 mg, once daily in 10 days, twice daily in 10 days, followed by third daily in 10 days."
62794645|NCT05639257|ACTIVE_COMPARATOR|Namuscla|"A placebo phase of 28 days:~- tablet placebo 25 mg once daily in 14 days followed by 50 mg once daily in 14 days.~A treatment phase of 30 days:~- tablet Namuscla 167 mg, once daily in 10 days, twice daily in 10 days, followed by third daily in 10 days."
62794646|NCT06725498|EXPERIMENTAL|RT + IAC + Anti-PD-1 antibody|"Patients must undergo Multi-Disciplinary Treatment evaluation after receiving 3 cycles of neoadjuvant therapy (Tislelizumab-jsgr combined with platinum-based chemotherapy).~For operable patients, Radical surgery followed by adjuvant standard (chemo)radiotherapy plus Tislelizumab-jsgr (Q3W 17 cycles).~For inoperable patients, Intra-arterial Chemotherapy concurrent with Radical radiotherapy followed by Tislelizumab-jsgr (Q3W 17 cycles)."
62794647|NCT02822898|ACTIVE_COMPARATOR|Isotonic Maintenance Fluid|Isotonic Maintenance Fluid
62794648|NCT02822898|ACTIVE_COMPARATOR|Hypotonic Maintenance Fluid|Hypotonic Maintenance Fluid
62413015|NCT00665366|ACTIVE_COMPARATOR|Aripiprazole + valproate or lithium|Participants randomly received aripiprazole as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks. Aripiprazole was provided in 5-, 10-, or 15-mg oral tablets and administered at a starting dose of 5 mg per day for Week 1. For Weeks 2 through 3, the dose was titrated up to 10 mg per day, and for Weeks 4 through 6, the dose increased to 15 mg per day. Flexible doses of either 15 or 30 mg per day were administered for Weeks 7 through 12. If participants were unable to tolerate the dose of 15 mg per day of study drug, the dose was decreased to 10 mg per day for Weeks 7 through 12.
62413016|NCT05496634|EXPERIMENTAL|Exercise Group|An informative presentation will be made emphasizing the importance of physical activity during the pandemic process. Individuals in the exercise group also participated in pilates sessions that lasted 50 minutes, 2 days a week for 8 weeks.
62413017|NCT05496634|EXPERIMENTAL|Control Group|An informative presentation will be made emphasizing the importance of physical activity during the pandemic process.
62413018|NCT06649695|EXPERIMENTAL|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
62586493|NCT03682861|EXPERIMENTAL|Carbohydrate drinks|Sweet corn derived starch mixed in water at three different concentrations (6%, 12% and 18%) will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
62794649|NCT03918421||Immunogloblin M-anti myelin-associated-glycoprotein neuropathy|Patient group (25 subjects) presenting with an Immunogloblin M-anti myelin-associated-glycoprotein peripheral neuropathy
62413019|NCT03332394||Healthcare Professionals|Includes nurses, physicians, and allied health professionals who care for patients on the 6NW (Respirology ward) of the General campus at TOH who have implemented and worked with the COPD care pathway during the study duration.
62413020|NCT03332394||COPD Patients|Adult patients admitted to the 6NW (Respirology ward) of the General campus at TOH with a primary diagnosis of acute exacerbation of COPD (AECOPD). The diagnosis is based on the admitting physician's assessment of the patient in the emergency room.
62413021|NCT05471518||Pre-menopausal women with CKD|Age 18-44 years CKD stage 3-4 (eGFR 15-59 ml/min/1.73m2)
62413022|NCT05471518||Post-menopausal women with CKD|Age 55-75 years CKD stage 3-4 (eGFR 15-59 ml/min/1.73m2)
62794650|NCT00742183|EXPERIMENTAL|Mepilex® Ag|"Mepilex® Ag consists of a Safetac® soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film. Mepilex® Ag is an antimicrobial soft silicone foam dressing that absorbs exudate and maintains a moist wound environment.~Mepilex® Ag contains silver sulphate that releases silver ions to inactivate a wide range of wound related pathogens (bacteria and fungi), shown in vitro. By reducing the number of microorganisms, Mepilex® Ag may also reduce odour."
62794651|NCT00742183|ACTIVE_COMPARATOR|Silvadene® Cream 1%|Silvadene® Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second-and third-degree burns.
62794652|NCT00511134|EXPERIMENTAL|Zyban + Lunesta|Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + Lunesta (3 mg qd x 6 weeks)
62794653|NCT00511134|PLACEBO_COMPARATOR|Zyban + Placebo|Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + placebo (1 pill per day x 6 weeks)
62413023|NCT05471518||Pre-menopausal healthy women|Age 18-44 years Regular menstrual cycle (25-35 d)
62218893|NCT02954965|EXPERIMENTAL|Approach|A brief, phone-administered intervention designed to help graduate students block procrastination and avoidance and to approach important activities they are currently avoiding.
62413024|NCT05471518||Post-menopausal healthy women|Age 55-75 years
62413025|NCT06420726|EXPERIMENTAL|Exercise + Creatine|3 days a week of resistance exercise for 10-weeks + 5g day of creatine monohydrate supplementation
62413026|NCT06420726|PLACEBO_COMPARATOR|Exercise + Placebo|3 days a week of resistance exercise for 10-weeks + 5g day of placebo (dextrose supplementation
62413027|NCT02108132|EXPERIMENTAL|Cellular therapy|Cellular therapy : injection of mesenchymal stem cells subjected to hepatogenic induction
62413028|NCT05419635|EXPERIMENTAL|Arm A: Child-Pugh A|Participants with mildly impaired hepatic function (Child-Pugh A)
62413029|NCT05419635|EXPERIMENTAL|Arm B: Child-Pugh B|Participants with moderately impaired hepatic function (Child-Pugh B)
62413030|NCT05419635|EXPERIMENTAL|Arm C: Normal hepatic (Matched A and B)|Participants with normal hepatic function matched to Arm A and B
62022731|NCT03994861|SHAM_COMPARATOR|Healthy controls|Age- and gender-matched healthy controls (without musculoskeletal pain)
62218894|NCT02954965|NO_INTERVENTION|Monitoring|Participants will monitor their current behaviors, mood, and burnout with no directed intervention to change behavior
62218895|NCT05378230|EXPERIMENTAL|Probiotic mixture|Arm that received Lactobacillus plantarum mixture (CECT 7527, CECT 7528 and CECT 7529)
62413031|NCT04962958|EXPERIMENTAL|HAIC+Donafenib|Donafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
62413032|NCT02008552|OTHER|Mediagene|Sampling blood
62413033|NCT00857922||Neurosurgical patient|Neurosurgical patient of the Mischer Neuroscience Institute, 18 years and over
62413034|NCT00857922||Family members|Family members of specific vascular, trauma, brain tumor and functional disorder cohorts
62413035|NCT06568588|EXPERIMENTAL|First four months with Sb (Group A)|Children that receive Sb supplements in the initial 4 months of the study.
62413036|NCT06568588|EXPERIMENTAL|Last four months with Sb (Group B)|Children that receive Sb supplements in the final 4 months of the study.
62413037|NCT00605397|EXPERIMENTAL|1|breast cancer pt receiving trastuzumab therapy will undergo two complete PET studies.
62413038|NCT00605397|EXPERIMENTAL|2|breast cancer pt receiving trastuzumab therapy will undergo one complete PET studies
62794654|NCT03550274|EXPERIMENTAL|App-based exercise rehabilitation|Persons with Acute lateral ankle sprain (\<48 hours) evaluated by a relevant health specialist in the hospital Emergency Department.
62794655|NCT05919888|NO_INTERVENTION|No skin incision preparation|"All patients will receive standard pre-operative prophylactic antibiotics. Participants will all receive the same preoperative external skin preparation with Hibiclens (chlorhexidine) and ChloraPrep (2% chlorhexidine gluconate / 70% isopropyl alcohol solution) prior to draping. Intra-operative irrigation will be standardized with Irrisept (chlorhexidine gluconate 0.05% in sterile water).~The control group will receive no dermal layer skin preparation. At the time of the surgery, after the skin incision has been made with a skin knife, the dermal layer will not be prepped with an agent."
62022732|NCT01977911|EXPERIMENTAL|Tissue engineered airway construct|"Stem cell based tissue engineered partial laryngeal implants:~The final experimental product is a highly tested, recellularised, stem cells based tissue engineered product (airway construct) for operative partial laryngeal implantation into patients with severe laryngotracheal stenosis"
62022733|NCT01285375|ACTIVE_COMPARATOR|CDC graft perfusion|Flushing of kidney allografts prior to transplantation with UW-solution containing CDC
62022734|NCT01285375|SHAM_COMPARATOR|Sham perfusion|
62022735|NCT06497257||Group of high-frequency smartphone users|Male and female subjects, who are high-frequency smartphone users at least for two years before the study.
62022736|NCT06497257||Group of low-frequency smartphone users|Male and female subjects, who are low-frequency smartphone users.
62586494|NCT00585832|EXPERIMENTAL|DASH-4-Teens Intervention|DASH-4-Teens Intervention is described in detail in Couch, SC et al. Hypertension 2021: 77:241-251.
62586495|NCT00585832|OTHER|Routine Care|Routine Care is described in detail in Couch, SC et al. Hypertension 2021: 77:241-251.
62586496|NCT04365504||Osteoporotic|Post menopausal females with Lumbar T score \<-2.5 as determined by dual energy X ray absorbitometry
62022737|NCT04979819|EXPERIMENTAL|Multiple Sclerosis|Patients with multiple sclerosis will perform the UULEX and fill in the other mentioned parameters. Validity and reliability of the UULEX will be measured.
62586497|NCT04365504||Osteopenic|Post menopausal females with Lumbar T score -1 to -2.5 as determined by dual energy X ray absorbitometry
62586498|NCT04365504||Normal|Post menopausal females with T score \>-1 as determined by dual energy X ray absorbitometry
62586499|NCT04954794|EXPERIMENTAL|TACE in combination with Sintilimab plus a bevacizumab biosimilar|
62586500|NCT02565849||Control group|Recruited volunteers aged above 18 years with no history of smoking or hospitalization in the last three months without cardiac dysfunction, orthopedic or lung.
62586501|NCT02565849||Sickle Cell Anemia normal spirometry|Recruited patients aged above 18 years with no history of smoking or hospitalization in the last three months, ability to independent ambulation and spirometry tests and plethysmography with normal medical report.
62794656|NCT05919888|ACTIVE_COMPARATOR|Povidone-iodine|"At the time of the surgery, after the skin incision has been made, the dermal layer be prepped with povidone-iodine.~Drug: povidone-iodine Dose: swabstick Administration: swab the incision Frequency: once"
62586502|NCT02565849||Sickle Cell Anemia spirometry abnormal|Recruited patients aged above 18 years with no history of smoking or hospitalization in the last three months, ability to independent ambulation and spirometry tests and plethysmography with altered medical report.
62586503|NCT06683547|ACTIVE_COMPARATOR|Ketone Monoester (KET)|"Ketone monoester supplement: (R)-3-hydroxybutyl (R)-3-hydroxybutyrate dosed based on participants' body weight (0.36g/kg body weight).~The nutritional beverage will be consumed twice: 30 minutes prior to the exercise workout (t = -60 min) and immediately following the completion of the exercise protocol (t = 0 min)."
62586504|NCT06683547|PLACEBO_COMPARATOR|Placebo drink|Flavoured water. Participants will consume this beverage twice: 30 minutes prior to the exercise workout (t = -60 min) and immediately following the completion of the exercise protocol (t = 0 min).
62586505|NCT06066437|EXPERIMENTAL|LeadIn: Treatment with 177Lu rhPSMA-10.1|Participants will receive 177Lu rhPSMA-10.1 alone.
62599956|NCT03384784|PLACEBO_COMPARATOR|Placebo first|"This is a crossover study such that all participants receive both placebo and galantamine. Participants were randomized to receive galantamine first and placebo second. Timepoints Week 0 through Week 12 represent the first period and Weeks 16 through 28 represent the second period.~Placebo ingredients will be purchased, encapsulated, and packaged into blister packs by the IDS at the University of Pennsylvania. Both active medication and placebo will look identical.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take galantamine during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by galantamine during the second medication period."
62794657|NCT05919888|EXPERIMENTAL|SURGX Wound Gel|At the time of the surgery, after the skin incision has been made, the dermal layer be prepped with SURGX Wound Gel. SURGX wound gel is a topical antiseptic gel agent to be used on surgical incisions to prevent bacterial infection.
62794658|NCT06128369|EXPERIMENTAL|OCS-01|dexamethasone ophthalmic suspension,1.5% \[15 mg/mL\]
62794659|NCT06128369|PLACEBO_COMPARATOR|Vehicle ophthalmic suspension|Vehicle of OCS-01
62794660|NCT00733915|EXPERIMENTAL|Single arm|Cohort of total knee replacements with LCS Complete knee implants
62794661|NCT01770574|EXPERIMENTAL|ReproBone|calcaneal lengthening
62794662|NCT01770574|ACTIVE_COMPARATOR|Autologous bone graft|calcaneal lengthening
62794663|NCT06727149|EXPERIMENTAL|Control Group (Standard Procedure)|
62794664|NCT06727149|EXPERIMENTAL|Virtual Reality Group|
62794665|NCT05509803|EXPERIMENTAL|PE Audit and Feedback Intervention|Schools in this arm will receive a PE audit and feedback tool delivered by the school district's teacher on special assignment for PE, which will consist of an audit of the school's existing PE program; Feedback on ways to improve the PE program; and technical assistance to help improve the PE program.
62218896|NCT04659577|EXPERIMENTAL|internet based CBT|all patients will be offered active treatment via internet based CBT
62794666|NCT05509803|NO_INTERVENTION|PE Support as Usual|Schools in this arm will receive district-level support for PE as is typically provided by the school district.
62794667|NCT02771717|EXPERIMENTAL|Budesonide (Pulmicort)|Low dose inhaled corticosteroid.
62794668|NCT02771717|PLACEBO_COMPARATOR|Placebo - dummy inhaler|Placebo - dummy inhaler
62599957|NCT00220324|EXPERIMENTAL|Arm 1|
62022738|NCT03815071|EXPERIMENTAL|ips-nsc treatment group|
62218897|NCT02133118||Patients on metformin mono-therapy who receive add-on|
62218898|NCT04762121||Patients requiring intravenous catheter insertion|Adults (\>18 years old) who require intravenous catheter insertion for their operation/procedure
62218899|NCT00226837|PLACEBO_COMPARATOR|1|0% nitrous oxide
62218900|NCT00226837|ACTIVE_COMPARATOR|2|33% nitrous oxide
62794669|NCT05759858||Patients with hepatocellular carcinoma confirmed by pathology.|Patients with hepatocellular carcinoma confirmed by pathology.
62794670|NCT04243993|OTHER|Bio-MA|Calcium silicate cement containing calcium chloride accelerator
62218901|NCT00226837|ACTIVE_COMPARATOR|3|66% nitrous oxide
62218902|NCT02760277|EXPERIMENTAL|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
62218903|NCT02760277|EXPERIMENTAL|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
62794671|NCT04243993|OTHER|ProRoot MTA|Calcium silicate cement without calcium chloride accelerator
62794672|NCT05904574||A|The patients who underwent tru-cut biopsy with the coaxial technique and applied an autologous blood patch.
62794673|NCT05904574||B|The patients whose true-cut biopsy with coaxial technique was taken and autologous blood patch was not applied.
62794674|NCT01908530|EXPERIMENTAL|Microprobe Glucose Sensor Phase 1|The microprobe array continuous glucose sensor will be applied to healthy volunteers for 6 hours
62218904|NCT02760277|EXPERIMENTAL|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
62794675|NCT01908530|EXPERIMENTAL|Microprobe Glucose Sensor Phase 2|The microprobe array continuous glucose sensor will be applied to healthy volunteers for 24 hours
62794676|NCT01908530|EXPERIMENTAL|Microprobe Glucose Sensor Phase 3 and 4|The microprobe array continuous glucose sensor will be applied to participants with type 1 diabetes
62794677|NCT04844502|NO_INTERVENTION|Control Group|Frequent life activities.
62794678|NCT04844502|EXPERIMENTAL|Intervention Group|Protocol of physical exercises
62794679|NCT05727813|EXPERIMENTAL|cryoablation|"We will enroll women with a biopsy-proven diagnosis of early-stage breast cancer (T1 N0), not eligible for neo-adjuvant therapy, scheduled to breast surgery (mastectomy or nodulectomy), who have given the informed consent for the study.~We will recruit 20 women who will undergo cryoablation."
62022739|NCT02389543|EXPERIMENTAL|A: Selinexor (1x/week), Lenalidomide, & Dexamethasone|Lenalidomide will be dosed initially at 15 mg daily, and if that dose is tolerated per dose-limiting toxicity (DLT criteria,) it will be increased to 25 mg for that arm. Selinexor will be started at 80 mg (\~45 mg/m2) once weekly in combination with dexamethasone 40 mg once weekly with each dose of selinexor. If the selinexor 80 mg dose is tolerated per DLT criteria, the dose will be increased to 100 mg (\~60 mg/m2) and evaluated for MTD, tolerability and efficacy.
62218905|NCT02760277|EXPERIMENTAL|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
62218906|NCT03620331|ACTIVE_COMPARATOR|Non Surgical + Surgical|Non surgical approach (NS) followed by surgical treatment (S) of peri-implantitis
62218907|NCT03620331|EXPERIMENTAL|Immediate Surgery|Direct surgical approach (S), without a previous non surgical approach
62794680|NCT05727813|NO_INTERVENTION|no cryoablation|The results will be compared with those obtained from a control group of 20 women, who will follow the same therapeutic pathway for the treatment of breast cancer without performing cryoablation.
62794681|NCT05433155|ACTIVE_COMPARATOR|Videolaryngoscopy|Nasotracheal intubation performed with the Storz C-Mac Video Laryngoscope
62794682|NCT05433155|ACTIVE_COMPARATOR|Direct Laryngoscopy|Nasotracheal Intubation performed with the standard clinical direct blades
62794683|NCT03605108|ACTIVE_COMPARATOR|Probiotic|"• Probiotic fomula per capsule:~2 Billion CFUs HU36 - 30 mg HU58 - 20 mg Bacillus clausii -25 mg Bacillus coagulans 10B - 35 mg Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose."
62586506|NCT06668441|EXPERIMENTAL|Teneplase assisted dissolution of blood clot therapy|After CT reexamination 6 hours after surgery, the calculated injection amount of teneplase (teneplase injection amount = volume of hematoma × concentration of ascending drug) was diluted to 1ml with sterile injection water, and injected into the stereotaxically planned puncture path according to the location and size of the hematoma in turn. 0.5ml normal saline was used to flush the pipeline, and the drainage tube was fixed and closed for 2 hours. After the medication has fully acted with the hematoma mass, the drainage tube is re-opened to allow gravity drainage. CT examination was performed at 24 hours, 48 hours, 72 hours and 96 hours. Continuation or termination of the trial based on CT results at 24 hours, 48 hours, 72 hours, 96 hours: Teneplase was discontinued when the surgical goal defined by the test was achieved (residual hematoma ≤10ml), or new blood events occurred (compared with the previous time point CT, a CT value of \> 72Hu and a volume of \> 6ml of the space found in an
62586507|NCT06523569|NO_INTERVENTION|Usual Care (Control)|Participant will receive usual care.
62794684|NCT03605108|PLACEBO_COMPARATOR|Placebo|Rice flour only
62794685|NCT00988013|EXPERIMENTAL|IM-TMI (3Gy)|Patients will receive 3Gy per day for 1 day (total of 3Gy).
62022740|NCT02389543|EXPERIMENTAL|B: Selinexor (2x/week), Lenalidomide, & Dexamethasone|Lenalidomide will be dosed initially at 15 mg daily, and if that dose is tolerated per DLT criteria, it will be increased to 25 mg for that arm. Selinexor will be started at 60 mg (\~35 mg/m2) twice weekly in combination with dexamethasone 20 mg twice weekly with each dose of selinexor; dexamethasone 20 mg will also be given, without selinexor, on Days 22 and 24. If the selinexor 60 mg dose is tolerated per DLT criteria, the dose will be increased to 80 mg (\~45 mg/m2) and evaluated for MTD, tolerability and efficacy.
62022741|NCT02039505|PLACEBO_COMPARATOR|Induction Phase: Cohort 1, Placebo|Vedolizumab placebo-matching, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.
62022742|NCT02039505|EXPERIMENTAL|Induction Phase: Cohort 1, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2, and 6 in the induction phase.
62022743|NCT02039505|EXPERIMENTAL|Induction Phase: Cohort 2, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 in the induction phase.
62022744|NCT02039505|EXPERIMENTAL|Maintenance Phase: Placebo|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive placebo in maintenance phase.
62022745|NCT02039505|EXPERIMENTAL|Maintenance Phase: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive vedolizumab in maintenance phase.
62218908|NCT04895137|EXPERIMENTAL|mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations|mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations in patients with local advanced microsatellite stability colon and upper rectum cancer
62586508|NCT06523569|EXPERIMENTAL|Bundled digital health intervention|Participant will be enrolled in a remote patient monitoring program (Omron) and receive a subscription to a mobile health lifestyle change application (Noom) alongside usual care.
62794686|NCT00988013|EXPERIMENTAL|IM-TMI (6Gy)|Patients will receive 3Gy per day for 2 days (for a total of 6Gy).
62586509|NCT04075266|EXPERIMENTAL|Cohort 1|Participants with a body weight from \>/= 25 kg to \< 40 kg (with at least 2 participants with a body weight from \>/= 25 kg to \</= 35 kg) will receive 300 milligram (mg) ocrelizumab
62794687|NCT00988013|EXPERIMENTAL|IM-TMI (9Gy)|Patients will receive 3Gy per day for 3 days (for a total of 9Gy).
62794688|NCT00988013|EXPERIMENTAL|IM-TMI (12Gy)|Patients will receive 3Gy per day for 4 days (for a total of 12Gy).
62794689|NCT02837458|EXPERIMENTAL|High-Frequency|"Transcutaneous application of high frequency electrical current over the arm for a 30 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
62794690|NCT02837458|SHAM_COMPARATOR|Sham Stimulation|Electrodes are placed over the arm for a 30 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
62794691|NCT02396212|EXPERIMENTAL|Canakinumab|All patients received canakinumab (ACZ885) as open-label study medication. Patients were administered canakinumab 4 mg/kg every 4 weeks. The maximal total single dose of canakinumab allowed was 300 mg.
62794692|NCT06727097||Stroke Survivors|First ever clinical stroke (ischemic, supratentorial, and unilateral)
62586510|NCT04075266|EXPERIMENTAL|Cohort 2|Participants with a body weight \>/= 40 kg (with at least 2 participants with a body weight \>/= 40 kg but \</= 50 kg) will receive 600 mg ocrelizumab
62586511|NCT04075266|EXPERIMENTAL|Cohort 3 (optional)|Based on PK, PD, safety, and tolerability data analyses of Cohorts 1 and 2, additional participants with a body weight from \>/= 25 kg to \< 40 kg may be enrolled and receive another dose level of ocrelizumab
62586512|NCT04075266|EXPERIMENTAL|Cohort 4 (optional)|Based on PK, PD, safety, and tolerability data analyses of Cohorts 1 and 2, additional participants with a body weight \>/= 40 kg may be enrolled and receive another dose level of ocrelizumab
62586513|NCT01423643||Main cohort|Adults infected with both HIV and Hepatitis C
62586514|NCT01423643||Control Group|Adults at risk for liver disease, but not infected with both HIV and Hepatitis C
62794693|NCT06088979|EXPERIMENTAL|TOUR006 - 20 MG|In part A of the study, participants will receive a total of three 20 mg subcutaneous injections: 1 injection every 8 weeks (Day 1, Week 8, Week 16) followed by treatment in part B of the study based on proptosis response and rescue therapy use.
62794694|NCT06088979|EXPERIMENTAL|TOUR006 - 50 MG|In part A of the study, participants will receive a total of three 50 mg subcutaneous injections: 1 injection every 8 weeks (Day 1, Week 8, Week 16) followed by treatment in part B of the study based on proptosis response and rescue therapy use.
62794695|NCT06088979|PLACEBO_COMPARATOR|Placebo|In part A of the study, participants will receive a total of three Placebo subcutaneous injections: 1 injection every 8 weeks (Day 1, Week 8, Week 16) followed by treatment in part B of the study based on proptosis response and rescue therapy use.
62794696|NCT05006261|EXPERIMENTAL|Tele-Tai Chi|Tele-Tai Chi intervention
62022746|NCT02039505|PLACEBO_COMPARATOR|Maintenance Phase: Placebo continuation|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved clinical response at Week 10 received placebo in maintenance phase without randomization.
62022747|NCT02039505|EXPERIMENTAL|Open-Label Cohort: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 in open-label cohort.
62022748|NCT06329635|EXPERIMENTAL|Intrathecal Treatment Group|The participants in the IT treatment group will be treated with intrathecal nicardipine injection through EVD or LP draining catheter.
62218909|NCT00841555|EXPERIMENTAL|Hypofractionation Radiotherapy+Temozolomide|Patients will receive temozolomide PO daily for 5 weeks. Beginning week 1 after initiation of temozolomide therapy, patients undergo HIMRT times a week for a total of 15 fractions.
62218910|NCT04642872|EXPERIMENTAL|infant cimt|
62218911|NCT04642872|ACTIVE_COMPARATOR|Infant BIT|
62218912|NCT04642872|ACTIVE_COMPARATOR|Infant CIMT/BIT|
62022749|NCT06329635|SHAM_COMPARATOR|Control Group|The participants of the control group will receive no intrathecal nicardipine injection through EVD or LP draining catheter.
62022750|NCT01388387|EXPERIMENTAL|Tacrolimus pharmacokinetics|
62022751|NCT04620473|EXPERIMENTAL|Anlotinib+Capeox|neoadjuvant treatment with Anlotinib hydrochloride combined with Capeox
62022752|NCT04620473|ACTIVE_COMPARATOR|Capeox|neoadjuvant treatment with Capeox
62022753|NCT01243450|ACTIVE_COMPARATOR|Active generic|Treatment of acne for 12 weeks with generic tretinoin
62022754|NCT01243450|PLACEBO_COMPARATOR|Placebo|Treatment of acne for 12 weeks with Placebo
62218913|NCT04642872|ACTIVE_COMPARATOR|Conventional Therapy|
62218914|NCT01777451||Neurofibromatosis 1|"All patients diagnosed with neurofibromatosis type 1. GROUP 1:ADDITIONAL IMAGING OR SURGERY There will be patients with high-risk neurofibromas (potential malignant). These patients will underwent additional examinations or surgery (outside this study). Follow-up MRI within 2 years (study MRI )~GROUP 2:~No suspicious lesions at MRI. Follow-up within 2 years(Study MRI)."
62218915|NCT01262677|EXPERIMENTAL|pregabalin CR 330 mg|
62586515|NCT06682351|EXPERIMENTAL|Mediterranean Diet/GLP1a/Metformin|"1. 16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat.~2. 3 months washout~3. 16 weeks using GLP1 agonist: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.~4. 3 months washout~5. 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week."
62218916|NCT01262677|EXPERIMENTAL|pregabalin CR 165 mg|
62218917|NCT01262677|PLACEBO_COMPARATOR|Placebo|
62243361|NCT06690138|EXPERIMENTAL|Treatment A|Participants will receive a single oral dose of Divarasib on Day 1.
62243362|NCT06690138|EXPERIMENTAL|Treatment B|Participants will receive Itraconazole twice a day (BID) on Day 1 and once a day (QD) from Day 2 to Day 13. Participants will receive Divarasib in combination with Itraconazole on Day 5.
62243363|NCT00823303|EXPERIMENTAL|Paricalcitol|titrated to achieve 40-60% PTH suppression
62243364|NCT00823303|ACTIVE_COMPARATOR|Calcitriol|titrated to achieve 40-60% PTH suppression
62243365|NCT04136184|ACTIVE_COMPARATOR|Inotersen|Participants received inotersen, 300 milligrams (mg), subcutaneously (SC), once weekly up to Week 34. After Week 35 assessment, participants received eplontersen, 45 mg, SC, once every 4 weeks starting from Week 37 up to Week 81.
62243366|NCT04136184|EXPERIMENTAL|Eplontersen|Participants received eplontersen, 45 mg, SC, once every 4 weeks up to Week 81.
62794697|NCT05523817|EXPERIMENTAL|DLPFC Salience network target|iTBS delivered four times daily to an individually defined salience network representation in left dorsolateral prefrontal cortex (DLPFC).
62794698|NCT05523817|EXPERIMENTAL|DLPFC Control network target|iTBS delivered four times daily to an individually defined control network representation in left dorsolateral prefrontal cortex (DLPFC).
62218918|NCT01249989|EXPERIMENTAL|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
62794699|NCT05523817|EXPERIMENTAL|DLPFC Default network A target|iTBS delivered four times daily to an individually defined default network A representation in left dorsolateral prefrontal cortex (DLPFC).
62218919|NCT01249989|EXPERIMENTAL|Simultaneous MBC Condition|Participants in the simultaneous condition will target FV+, Sed- and PA+ simultaneously. Participants will wear accelerometers and enter diet and sedentary activity 5 days/week on their Smartphone. All 3 goal thermometers will be activated from the outset of prescription (FV, Sed, PA). In week 1-2, participants will close 1/3 of the gap between their baseline FV, Sed, and PA behavior and their goals. In week 3-4 participants will close 2/3 of the gap, and 100% of their goals in weeks 5-6. Participants will maintain their target behaviors for FV, Sed and PA through week 12.
62243367|NCT06734416||group 1|patients with Acute Coronary Syndrome , this group will be sub classified into: Non-ST-elevation myocardial infarction (NSTEMI) ST-elevation myocardial infarction (STEMI) Unstable angina
62243368|NCT06734416||group 2|apparently healthy patients will be included in this study as a control group for comparison
62243369|NCT05767866|EXPERIMENTAL|Part 1: Dose Escalation Component|In dose-escalation phase, previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 50, 100, 150, 200 to 250 mg/day (3+3 design).
62413039|NCT05359341|ACTIVE_COMPARATOR|Sitagliptin 50 mg twice daily|sitagliptin 50 mg is added for 12 weeks to T2DM not controlled with diet, exercise and metformin with or without other oral antidiabetic drugs.
62586516|NCT06682351|EXPERIMENTAL|Metformin/Mediterranean Diet/GLP1a|"1. 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.~2. 3 months washout~3. 16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat.~4. 3 months washout~5. 16 weeks using GLP1 agonist: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols."
62243370|NCT05767866|EXPERIMENTAL|Part 2: Expansion Cohort 1|In dose-escalation phase, previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 50mg/day and who have no active, measurable central nervous system (CNS) metastases.
62794700|NCT05523817|EXPERIMENTAL|dmPFC Default network B target|iTBS delivered four times daily to an individually defined default network B representation in left dorsomedial prefrontal cortex (DMPFC).
62794701|NCT05523817|EXPERIMENTAL|vmPFC limbic-reward network target|iTBS delivered four times daily to an individually defined reward network representation in left ventromedial prefrontal cortex (vMPFC).
62794702|NCT05523817|SHAM_COMPARATOR|SHAM stimulation|SHAM iTBS delivered four times daily to an individually defined SHAM region in left dorsolateral prefrontal cortex (DLPFC).
62794703|NCT06725238||Group I : patients presented with DFUs.|Participants who were referred to the consultant clinics at the Shar hospital were included if they had (i) a history of T2D irrespective of antidiabetic medicines or (ii) clinical and laboratory evidence of diabetic foot ulcers.
62794704|NCT06725238||Group II: patients who had T2D without DFUs|The participants have no previous history of diabetic foot ulcer or amputation. There were managed with oral anti-diabetes or occasionally with short term insulin therapy
62794705|NCT04466852|ACTIVE_COMPARATOR|cardio-relay Family Clinic|Patients discharged from a Rio de Janeiro municipality hospital and identified as belonging to a Family Clinic randomized to cardio-share receive instruction for telemedicine consultations. These are based on their own devices, when available, or provided by their local community agents associated in the study.
62794706|NCT04466852|NO_INTERVENTION|control Family Clinic|Patients discharged from a Rio de Janeiro municipality hospital and identified as belonging to a Family Clinic randomized to the control group or belonging who consent to participate in follow-up
62794707|NCT04953130|EXPERIMENTAL|Male vaccination + national HPV vaccination programme|Single dose of the 4-valent HPV vaccine (Gardasil®; Merck \& Co.) offered to all eligible boys aged 14 to 18 years in the 13 intervention communities. Girls aged 14 years are offered 2 doses of Gardasil® through the Tanzanian national HPV vaccine programme
62794708|NCT04953130|ACTIVE_COMPARATOR|National HPV vaccination programme only|Girls aged 14 years are offered 2 doses of Gardasil® through the Tanzanian national HPV vaccine programme
62794709|NCT04354324|EXPERIMENTAL|The test group|Oral administration of 30mci once on an empty stomach.
62794710|NCT04354324|ACTIVE_COMPARATOR|The control group|Oral administration of 100mci once on an empty stomach.
62794711|NCT05337800|EXPERIMENTAL|stress management program|
62794712|NCT05337800|NO_INTERVENTION|Control|
62022755|NCT01243450|ACTIVE_COMPARATOR|Brand|Treatment of acne over 12 weeks with tretinoin Brand
62022756|NCT05400096|EXPERIMENTAL|CFT based online group intervention|The group will consist of 12 weekly 1.15h long online sessions.
62794713|NCT03797846|ACTIVE_COMPARATOR|Corneal Suture|intraoperative fixation with the suture in clear cornea qualified to the combined glaucoma surgery
62794714|NCT03797846|ACTIVE_COMPARATOR|Muscle Suture|intraoperative fixation with the bridle suture for superior rectus muscle qualified to the combined glaucoma surgery
62794715|NCT06108154|EXPERIMENTAL|Educational interventional Arm.|Interventional arm received educational supportive breastfeeding and hand on training session on Latch techniques according to UNICEF guideline.
62218920|NCT01249989|ACTIVE_COMPARATOR|Stress Management Control|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
62794716|NCT06108154|NO_INTERVENTION|Control routine hospital care Arm.|Control. No interventions receive hospital routine care
62218921|NCT01976117|EXPERIMENTAL|enose|
62022757|NCT03291444|EXPERIMENTAL|CAR-T cells combined with peptide specific dendritic cell|CAR-T cells combined with Eps8 peptide specific dendritic cell,or CAR-T cells combined with WT1 peptide specific dendritic cell
62218922|NCT03037073|ACTIVE_COMPARATOR|Group D|35 patients will receive duloxetine (Cymbalta; Eli Lilly \& Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
62218923|NCT03037073|ACTIVE_COMPARATOR|Group C|35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
62218924|NCT02341131|EXPERIMENTAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy -Frontal/Executive Program (Delahunty)- (Wykes \& Reeder, 2005)
62218925|NCT02341131|ACTIVE_COMPARATOR|Psychoeducation|Symptom Management Module from the University of California. Liberman \& Kopelowicz (1995)
62218926|NCT02341131|NO_INTERVENTION|Healthy Controls|No intervention
62218927|NCT01015859|NO_INTERVENTION|DDD long AV delay|Pacemaker is programmed in DDD mode with long AV delay (250 msec)
62218928|NCT01015859|ACTIVE_COMPARATOR|AAI SafeR|Pacemaker is programmed in AAI SafeR mode
62218929|NCT00847925|OTHER|A|50ng Avotermin/100ul
62218930|NCT00847925|OTHER|B|20ng Avotermin/100ul
62218931|NCT00847925|OTHER|C|5ng Avotermin/100ul
62413040|NCT05359341|ACTIVE_COMPARATOR|Empagliflozin 12.5 twice daily|Empagliflozin 12.5 mg is added for 12 weeks to T2DM not controlled with diet, exercise and metformin with or without other oral antidiabetic drugs.
62413041|NCT05359341|ACTIVE_COMPARATOR|Sitagliptin 50 mg + empagliflozin 12.5 mg|empagliflozin 12.5 mg is added to the patients with HbA1c 7-10 % of sitagliptin 50 mg group for another 12 weeks.
62413042|NCT05359341|ACTIVE_COMPARATOR|Empagliflozin 12.5 + sitagliptin 50mg|sitagliptin 50 mg is added to the patients with HbA1c 7-10 % of empagliflozin 12.5 mg group for another 12 weeks.
62794717|NCT06468995|ACTIVE_COMPARATOR|Hospital arm|CAB 600mg +RPV 900mg q2M IM administration and follow-up in hospital
62794718|NCT06468995|EXPERIMENTAL|Home arm|CAB 600mg +RPV 900mg q2M IM administration and follow-up at home
62794719|NCT00318799|EXPERIMENTAL|Arm 1|
62794720|NCT00318799|ACTIVE_COMPARATOR|Arm 2|
62794721|NCT00856765|EXPERIMENTAL|1|Drug eluting balloon followed immediately by implantation of bare metal stent
62794722|NCT00856765|ACTIVE_COMPARATOR|2|Drug eluting stent
62794723|NCT00856765|ACTIVE_COMPARATOR|3|Bare metal stent
62794724|NCT03818035|EXPERIMENTAL|Part 1: Guselkumab|Participants in group 1 (Part 1) will receive 100 milligram (mg) guselkumab subcutaneously (SC) at Weeks 0, 4, 12 and 20.
62022758|NCT03291444|ACTIVE_COMPARATOR|Chimeric antigen receptor T cells|After pretreatment, chimeric antigen receptor T cells will be transfused.
62022759|NCT02255110|EXPERIMENTAL|TH-302 and doxorubicin|
62022760|NCT05937438|EXPERIMENTAL|Experimental Arm|Esophagectomy+postoperative radiotherapy+immunotherapy
62794725|NCT03818035|EXPERIMENTAL|Part 2: Guselkumab q8w and Guselkumab q16w|Eligible participants from Part 1 will continue to participate in Part 2. Participants (super responder \[SRe\]) with a Psoriasis Area and Severity Index (PASI) score = 0 at weeks 20 and 28 will be randomized to guselkumab 100 mg every 8 weeks (q8w) (group 2a) or guselkumab 100 mg q16w (group 2b), at weeks 28 to 60. Group 2b will receive placebo injection at weeks 28, 44 and 60 to keep the comparison double blind. Participants losing control of disease (PASI score \>5) during study Part 2 (until week 60), will enter the re-treatment arm (group 2d) and receive guselkumab 100mg q8w (at re-treatment week 0), followed by administration at re-treatment-weeks 8 and 16.
62794726|NCT03818035|EXPERIMENTAL|Part 2: Guselkumab q8w|Participants (Non SRe) in group 2c with a PASI score greater than (\>) 0 at week 20 and/or 28 will continue to receive guselkumab 100 mg q8w until week 60.
62218932|NCT00847925|OTHER|D|100ng Avotermin/100ul
62218933|NCT00847925|OTHER|E|500ng Avotermin/100ul
62218934|NCT00847925|OTHER|F|0.25ng Avotermin/100ul
62218935|NCT00847925|OTHER|G|1ng Avotermin/100ul
62218936|NCT00847925|OTHER|H|20ng Avotermin/100ul
62022761|NCT05937438|OTHER|Controlled Arm|Esophagectomy+postoperative radiotherapy
62022762|NCT04916639|EXPERIMENTAL|Active group|Physiomer®, undiluted seawater nasal spray
62218937|NCT00847925|OTHER|I|50ng Avotermin/100ul
62218938|NCT00376831|ACTIVE_COMPARATOR|0|fentanyl
62218939|NCT00376831|ACTIVE_COMPARATOR|1|ketamine
62413043|NCT04868877|EXPERIMENTAL|Part 2 NSCLC Second-line or more harboring EGFR exon 20 Insertion|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D).
62586517|NCT06682351|EXPERIMENTAL|GLP1a/Metformin/Mediterranean Diet|"1. 16 weeks using GLP1 agonist: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.~2. 3 months washout~3. 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.~4. 3 months washout~5. 16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat."
62586518|NCT04756193||Asymptomatic/Mild COVID-19 Group|50 confirmed COVID-19 patients who showed no or only mild respiratory/GI symptoms (not admitted to the hospital at all)
62022763|NCT04916639|NO_INTERVENTION|control group|
62413044|NCT04868877|EXPERIMENTAL|Part 2 NSCLC Second-line or more harboring cMet exon 14 skipping mutation|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D).
62586519|NCT04756193||Moderate COVID-19 Group|50 confirmed COVID-19 patients who were able to maintain oxygen saturation above 92% (or above 90% for patients with chronic lung disease) with up to 4 L/min oxygen via nasal prongs (admitted to the hospital, but never to the ICU and no obvious cardiac complications during the stay)
62022764|NCT02806739|EXPERIMENTAL|Soy Group (Soy Protein + Isoflavones)|"Intervention: Soy-based whole foods containing about 25 grams of soy protein and 60-75 mg isoflavones.~Intervention group will consume soy foods containing about 25 grams of soy protein and 60-75 mg isoflavones per day, from 16th gestational week to birth. Examples of soy foods that contain 25 grams of soy protein and 60-75mg isoflavones include: 2 cups of soy milk, or 12 ounces tofu, or a half cup of soy nuts. Women in the Soy Group will be instructed by a registered dietitian how to incorporate the soy foods into their daily diet."
62022765|NCT02806739|PLACEBO_COMPARATOR|Control Group (Minimize Soy Intake)|Control Group will avoid soy supplements and minimize intake of soy foods.
62022766|NCT05026957|ACTIVE_COMPARATOR|Control group|Participating in regular cardiac rehabilitation
62586520|NCT04756193||Severe COVID-19 Group|50 confirmed COVID-19 patients who had oxygen saturation lower than 92% at rest and PaO2/FiO2 between 200 and 300 (High-flow oxygen group, mostly in the ICU, and may have some cardiac complications)
62022767|NCT05026957|EXPERIMENTAL|Intervention|Participating in regular cardiac rehabilitation + using the shared-decision making application
62022768|NCT05003817|EXPERIMENTAL|LV-unloading|Participants in the elective unloading (intervention) group will have a percutaneous left ventricular unloading device (pLVAD) inserted at the start of the procedure, before the coronary intervention. Maximal support will be provided throughout the procedure, following which support will be weaned and the device removed should the patient remain haemodynamically stable.
62218940|NCT04049734|ACTIVE_COMPARATOR|patients received the oral losartan|50 patients with obstructive jaundice indicated for ERCP and received oral losartan 1 hour before ERCP as a prophylaxis of post-ERCP pancreatitis
62218941|NCT04049734|NO_INTERVENTION|patients didn't receive the oral losartan|50 patients with obstructive jaundice indicated for ERCP and didn't receive any prophylactic drugs
62218942|NCT02093559|EXPERIMENTAL|Brief Counseling Intervention|The brief counseling intervention will utilize MI and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address HIV risk behaviors and determine readiness for change in substance use.
62794727|NCT03818035|EXPERIMENTAL|Part 3: Guselkumab Withdrawal|Participants from groups 2a and 2b with a PASI score \<3 at week 68 will be included in Part 3 (group 3a and 3b) and be withdrawn from guselkumab. Study visits will be conducted every 12 weeks until week 220 (follow-up). Participants with fluctuating disease (PASI score greater than or equal to \[\>=\] 3) at week 68 or PASI \>5 (participants losing control of disease) at any visit during part 3 after week 68 will get an opportunity to enter the re-treatment-arm (group 3c) in which participants will receive three guselkumab injections of 100 mg q8w.
62022769|NCT05003817|NO_INTERVENTION|Standard of Care|Participants in the control arm will receive the planned high-risk percutaneous coronary intervention as is the current standard of care without elective left ventricular unloading. Alternative mechanical circulatory support devices (such as the intra-aortic balloon pump (IABP) or extracorporeal membrane oxygenation (ECMO) will only be permitted in case of complications.
62022770|NCT05879744|EXPERIMENTAL|Part A Dose Escalation|Patients with R/R B-NHL treated with CLN-978 in dose escalation cohorts
62022771|NCT05879744|EXPERIMENTAL|Part B Dose Expansion|Patients with R/R DLBCL, R/R FL and other R/R B-NHL treated with CLN-978 at a dose selected from the Part A Dose Escalation arm.
62022772|NCT01019330||Femoral|Subjects receiving femoral artery cardiac catheterization
62218943|NCT02093559|NO_INTERVENTION|Control Group|The control group will have access to brochures and be offered referral to services requested. SFDPH Community Behavioral Health Services (CBHS) provides immediate access to substance abuse treatment in San Francisco, including office- and clinic-based methadone and buprenorphine treatment. Given the pilot nature of this study, the control group will not be a full attention control; we will account for an attention effect due to assessment alone.
62218944|NCT04498338|EXPERIMENTAL|Neural mobilization and conventional physical therapy|Neural mobilization combined with conventional physical therapy program (Transcutaneous electrical nerve stimulation (TENs) and exercise program) were performed three times/week for 6 successive weeks.
62218945|NCT04498338|ACTIVE_COMPARATOR|Conventional physical therapy program|Conventional physical therapy program (Transcutaneous electrical nerve stimulation (TENs) and exercise program) was performed three times/week for 6 successive weeks.
62218946|NCT00950326|ACTIVE_COMPARATOR|B1-Physio|In Group B1, patients will be given physiotherapy of the hip or knee joint three times a week
62413045|NCT04868877|EXPERIMENTAL|Part 2 Selected solid tumors with or without an EGFR or cMet alteration|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D).
62586521|NCT04756193||Critical COVID-19 Group|50 confirmed COVID-19 patients who had PaO2/FiO2 less than 200 or required mechanical ventilation (in the ICU, need mechanical ventilation and more likely to have cardiac complications)
62022773|NCT01019330||Radial|Subjects receiving radial artery cardiac catheterization
62022774|NCT03141502|EXPERIMENTAL|Skin Stretching Device (SSD)|the wound is primarily closed by aid of the SSD after necessary surgical debridement.
62794728|NCT04046900|ACTIVE_COMPARATOR|Vaginal microbiome transplant|Women in this group will be randomized to receive two doses of vaginal fluid from a healthy donor
62218947|NCT00950326|EXPERIMENTAL|A1 Hydro|In this group patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region.
62218948|NCT00950326|ACTIVE_COMPARATOR|C- Hydro & Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
62413046|NCT04868877|EXPERIMENTAL|Part 2 NSCLC First-line harboring EGFR sensitizing mutations|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D) and Osimertinib orally once daily starting at a dose of 80mg.
62413047|NCT04868877|EXPERIMENTAL|Part 2 NSCLC Second-line or more, osimertinib resistant (combo with osimertinib)|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D) and Osimertinib orally once daily starting at a dose of 80mg.
62413048|NCT04868877|EXPERIMENTAL|Part 2 NSCLC Second-line or more, osimertinib resistant (combo with chemotherapy)|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D) and chemotherapy every three weeks per standard of care according to local guidance.
62413049|NCT04868877|EXPERIMENTAL|Part 2 NSCLC Third-line or more, osimertinib resistant, platinum resistant (combo with chemotherapy)|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D) and chemotherapy every three weeks per standard of care according to local guidance.
62413050|NCT00242567|EXPERIMENTAL|Early Group|Zoledronic acid 4 mg i.v. infusion every 4 weeks, commencing at Baseline.
62413051|NCT00242567|EXPERIMENTAL|Delayed group|Zoledronic acid 4 mg i.v. infusion every 4 weeks, commencing no sooner than 12 months after their baseline visit, and not until they have had three rises in PSA level from Baseline, one of which must be a least 10 ng/mL greater than the baseline Serum Prostate-specific Antigen (PSA) level.
62413052|NCT06537778|EXPERIMENTAL|atosiban|
62413053|NCT06537778|PLACEBO_COMPARATOR|normal saline|
62413054|NCT05800327|EXPERIMENTAL|LVL162 group|Levilimab 162 mg SC QW plus placebo starting from Week 0.
62413055|NCT05800327|EXPERIMENTAL|LVL324 group|Levilimab 324 mg SC Q2W plus placebo starting from Week 0.
62413056|NCT05800327|EXPERIMENTAL|LVL648 group|levilimab 648 mg IV Q4W plus placebo starting from Week 0.
62794729|NCT04046900|PLACEBO_COMPARATOR|Saline placebo|Women in this group will be randomized to receive two doses of sterile saline
62794730|NCT06490133|PLACEBO_COMPARATOR|Placebo|Capsules containing placebo.
62413057|NCT02069145|EXPERIMENTAL|Drug: OMP-54F28, with Sorafenib|
62413058|NCT06535828||AI and mechanic modeling|Participants with advanced/unresectable stage III or metastatic HR+ breast cancer with progression on a CDK4/6i and an AI will be eligible for study participation. The key action in this study will be the acquisition and analysis of tumor and blood for selection of standard of care systemic therapy. Tumor and blood will also be obtained at the time of disease progression to provide critical data for reverse translational model building. This will also provide insight into mechanisms of resistance for the administered standard of care therapy that can be used for future models to optimize selection of next-line therapy.
62413059|NCT02860039|EXPERIMENTAL|Group 1 - High Dose TIV|Patients receive HD-TIV intramuscularly (IM) on day 0 and day 28.
62413060|NCT02860039|ACTIVE_COMPARATOR|Group 2 - Standard Dose QIV|Patients receive standard dose QIV IM on day 0 and day 28.
62413061|NCT03587740|EXPERIMENTAL|T-DM1|T-DM1 will be administered every 3 weeks intravenously, with 21 consecutive days defined as a treatment.
62413062|NCT01444469|EXPERIMENTAL|Azithromycin (Zithromax)|500 mg of azithromycin (2×250mg capsules)
62413063|NCT01444469|PLACEBO_COMPARATOR|Placebo|Placebo
62413064|NCT03264001|EXPERIMENTAL|Diet-induced negative energy balance|For the diet-induced negative energy balance arm, the three trials will include one control trial (isocaloric diet; zero energy balance) and two trials of progressively increasing negative energy balance induced by calorie restriction (20% and 40% reduction of daily energy needs for weight maintenance). With respect to physical activity, all diet trials will be performed under resting conditions.
62794731|NCT06490133|EXPERIMENTAL|Polyhpenol extract|Capsules containing the experimental polyhpenol to be assayed
62794732|NCT02891395|EXPERIMENTAL|open-label|"Induction phase: Imatinib mesylate - starting with 100 mg/day with increase of 100 mg/day each other week up to maximum tolerable dose or 400 mg/day whichever occurred first. For the responders and in absence of toxicity, the treatment will be maintained up to one year.~Salvage phase:~Nilotinib - starting with 200 mg/day with increase of 200 mg/day each other week up to maximum tolerable dose or 800 mg/day whichever occurred first. In absence of toxicity, the treatment will be maintained up to one year."
62794733|NCT03728010||One-Lung Ventilarion|Thoracic surgery cases with one-lung ventilation strategy.
62794734|NCT06576076|EXPERIMENTAL|Cannabis Abstinence (CB-Abst)|Those randomized to the abstinence condition will be asked to stop using cannabis for eight weeks. They will participate in a contingency management protocol, which uses an escalating remuneration schedule to incentivize abstinence. Abstinence is confirmed biochemically via progressively decreasing values of creatinine-adjusted THCCOOH.
62794735|NCT06576076|NO_INTERVENTION|Cannabis Monitoring (CB-Mon)|Those randomized to the monitoring condition will be asked to make no changes to their cannabis use frequency or dose for the duration of the eight week study.
62022775|NCT03141502|ACTIVE_COMPARATOR|Skin Grafting (SG)|the wound is primarily closed by the technique of skin grafting after necessary surgical debridement.
62022776|NCT00745017|EXPERIMENTAL|1|
62022777|NCT00745017|EXPERIMENTAL|2|
62022778|NCT00745017|EXPERIMENTAL|3|
62413065|NCT03264001|EXPERIMENTAL|Exercise-induced negative energy balance|For the exercise-induced negative energy balance arm, the three trials will include one control trial (rest; zero energy balance) and two trials of progressively increasing negative energy balance induced by aerobic exercise (20% and 40% reduction of daily energy needs for weight maintenance); with respect to caloric intake, all exercise trials will be performed under isocaloric conditions.
62218949|NCT00994682|ACTIVE_COMPARATOR|Pioglitazone|After all patients receive dietary counseling at the research unit (CTSA), patients with prediabetes or type 2 diabetes mellitus (T2DM) and NASH will be started on pioglitazone (or placebo) in a randomized, double-blind,placebo-controlled study design. Pioglitazone will be given at 30 mg/day for the first 2 months and titrated to 45 mg/day thereafter (if well tolerated).
62022779|NCT02324491|EXPERIMENTAL|ZGN-440 Injectable Suspension (1.2mg)|ZGN-440 for Injectable Suspension
62218950|NCT00994682|PLACEBO_COMPARATOR|Placebo|After dietary counseling to all patients at the research unit (CTSA), patients with prediabetes or type 2 diabetes mellitus (T2DM) and NASH will be started on pioglitazone (or placebo) in a randomized, double-blind,placebo-controlled study design. Pioglitazone will be given at 30 mg/day for the first 2 months and titrated to 45 mg/day thereafter (if well tolerated).
62218951|NCT00434213|EXPERIMENTAL|Methylphenidate Transdermal System|To characterize the dermal reactions seen with the use of DAYTRANA
62218952|NCT05664867|EXPERIMENTAL|MGT (Mainstream Genetic Testing) Model|The mainstream genetic testing (MGT) model of cancer genetic services involves a non-genetics healthcare provider, such as the primary care provider, who engages patients in the counseling, consenting, and ordering of genetic testing. The provider/care team discloses the genetic test results and refers patients for genetic counseling only when genetic test results are abnormal. By eliminating the pre- and post-test counseling visits with a genetics provider, the MGT model has the potential to provide scalable access to genetic services.
62413066|NCT05923320|EXPERIMENTAL|experimental group -assigned intervention|The experimental group was given training on infancy vaccines and breastfeeding. The times of the trainings are determined based on the Postpartum Care Management Guide of the Ministry of Health. In the hospital on the first day after birth, 2-7. days and 30-42. Three days in total, trainings were given on breastfeeding and childhood vaccinations by making home visits. The training content has been prepared by taking into account the Ministry of Health Breastfeeding Guide (5) and the Ministry of Health's vaccination calendar and the Primary Care Vaccine Guide. The trainings will be given to the puerperant women individually. About 30 minutes of training will be given and their questions, if any, will be answered.
62413067|NCT05923320|NO_INTERVENTION|control grouup|no training was given to the control group
62413068|NCT06568471|EXPERIMENTAL|HST101(Lerodalcibep)|300 mg subcutaneously Q4W
62413069|NCT06568471|PLACEBO_COMPARATOR|Placebo|subcutaneously Q4W
62413070|NCT00890409|NO_INTERVENTION|Normothermia|Rectal temperature was maintained at 36.0-37.5 degree C.
62413071|NCT00890409|EXPERIMENTAL|Hypothermia|The group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
62413072|NCT05736809|EXPERIMENTAL|Low-Dye taping|out of 21 participants 7 will be included in the study design as an experimental group using low-dye taping in acute stage
62413073|NCT05736809|ACTIVE_COMPARATOR|Plantar fascia stretching|out of 21 participants 7 will be included in the study design as an active participants group using plantar fscia stretching in acute stage
62413074|NCT05736809|PLACEBO_COMPARATOR|Sham taping|out of 21 participants 7 will be included in the study design as an active participants group using plantar fscia stretching in acute stage
62413075|NCT06567431||Alzheimer's disease|Patients diagnosed with Alzheimer's disease (AD), either MCI, mild or moderate dementia.
62022780|NCT02324491|EXPERIMENTAL|ZGN-440 Injectable Suspension (1.8mg)|ZGN-440 for Injectable Suspension
62022781|NCT02324491|PLACEBO_COMPARATOR|Placebo|ZGN-440 Placebo for Injectable Suspension
62022782|NCT05996354|EXPERIMENTAL|Intervention arm|Concave Supra-arch Branched stent-graft system
62022783|NCT02548962|EXPERIMENTAL|Phase 1: Dose Finding|Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO
62413076|NCT06567431||Cognitive impairment due to non-Alzheimer's disease|Patients diagnosed with one of the following dementia disorders: Dementia with Lewy Bodies (DLB), Frontotemporal dementia (FTD), vascular dementia (VaD) and Normal pressure hydrocephalus (NPH).
62413077|NCT06567431||Controls|Patients who have undergone a diagnostic work-up in a memory clinic, but no neurodegenerative or other neurological disease was found, serve as control group.
62586522|NCT04756193||Control Group|50 age and sex-matched controls from our hospital admission database
62022784|NCT02548962|EXPERIMENTAL|Phase 2: Treatment Arm A|Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO
62022785|NCT02548962|EXPERIMENTAL|Phase 2: Treatment Arm B|Placebo PO+ Pomalidomide PO+ Dexamethasone PO
62022786|NCT04269772|EXPERIMENTAL|Community treatment Adherence at Re-Entry (CARE)|"CARE will begin within the 2 months before prison release, and will continue for 6 months after re-entry. CARE will be comprised of: a) 3 individual sessions with the CARE counselor; b) 1 optional family/significant other (SO) session; and c) 11 brief (15-20 min) follow-up telephone contacts with prisoners and their SO over the first 6 months post-release.~The CARE intervention will incorporate motivational strategies from existing interventions (e.g., Acceptance and Commitment Therapy) in order to clarify values and goals to enhance motivation for community treatment engagement and behavior change. CARE will also integrate bipolar disorder psychoeducation and strategies from existing models of intervention for BD (e.g., McMaster Model of Family Functioning) that are designed to improve family communication, social support, and problem-solving around BD illness management over this vulnerable transition period."
62022787|NCT04269772|OTHER|Treatment As Usual (TAU)|Treatment As Usual (TAU) consists of unrestricted treatment provided by prison and community providers, as part of routine care in the criminal justice re-entry context. Study staff will provide no additional treatment in this arm.
62022788|NCT05749913||Normal|"1. Participants living in the community.~2. No vision or hearing impairment.~3. No severe depression, or other neurological/mental disorders affecting cognitive function."
62022789|NCT05749913||Subjective Cognitive Decline, SCD|"1. The Montreal Cognitive Assessment (MoCA) score \>22~2. Use two questions to screen: Compared with the previous situation, do you have memory problems?, Has your family or relatives ever thought that you have memory problems compared with the previous situation?, the answer to both questions is yes.~3. Geriatric Depression Scale-Short Form (GDS-S) score \<8"
62413078|NCT02032446|EXPERIMENTAL|Umbilical Cord Mesenchymal stromal cells (UC-MSC)|"Pentostatin will be given by intravenous infusion at a dose of 1 mg/m2 for 3 consecutive days. Thereafter, three Umbilical Cord Mesenchymal stromal cells (UC-MSC) infusions will be given at weekly interval starting from day 5. We will follow a dose escalating programme with progressively increasing doses of cells until the maximally tolerated dose (MTD) is achieved.~The dose escalating design will be characterised by the administration of 1x106 /kg UC-MSC per dose per three doses for the first three patients (total up to 3x106/kg). The second three patients will receive 2x106/kg UC-MSC per dose per three doses (total up to 6x106/kg). The third three patients will receive 3x106/kg UC-MSC per dose per three doses (total up to 9x106 cells/kg).~Since three dosages of cells are programmed for each group of 3 patients, a minimum of 9 patients should be studied, unless unacceptable acute infusion related toxicity is observed."
62586523|NCT04062344||Short oral drug provocation test|Minors performing a short (1-4 days) drug provocation test
62586524|NCT04062344||Prolonged oral drug provocation test|Minors performing a prolonged (5-8 days)drug provocation test
62794736|NCT06576076|NO_INTERVENTION|Pre-intervention Pooled Groups (EMA Phase 1 Only)|All enrolled participants will participate in approximately two weeks of EMA data collection prior to being randomized and starting intervention procedures to characterize mood during baseline use as usual (CB-Abst or CB-Mon).
62022790|NCT05749913||Mild Cognitive Impairment, MCI|"1. MCI diagnosed by neurologists or psychiatrists: the diagnosis of MCI is mainly in accordance with the revised consensus version of the diagnostic criteria (Winblad et al., 2004), that is, memory function score is 1.5 standard deviations below the value for age- and education-related norms on the third edition of Wechsler Memory Scale.~2. MoCA: with a range of scores of 17-23(\>17 , \<23) (Trzepacz et al., 2015)~3. Geriatric Depression Scale-Short Form (GDS-S) score \<8"
62022791|NCT05749913||Mild Dementia|"1. has met the criteria of dementia~2. at the early stages"
62022792|NCT03112044|EXPERIMENTAL|HCV+ lung transplant to HCV- recipients|HCV+ donor lungs will be treated with Normothermic Ex Vivo Lung Perfusion (EVLP) in order to reduce viral load and minimize risk of HCV transmission. Patients who become viremic defined as at least two consecutive positive samples will receive sofosbuvir/velpatasvir 400 mg/100 mg (Epclusa) for 12 weeks.
62022793|NCT02754167|EXPERIMENTAL|PRS-080#022-DP|Hepcidin antagonist, single administration, ascending doses
62022794|NCT02754167|PLACEBO_COMPARATOR|PRS-080-Placebo#001|Comparator treatment, single administration
62022795|NCT05173519|ACTIVE_COMPARATOR|Omnibond topical skin adhesive|
62218953|NCT05664867|ACTIVE_COMPARATOR|SOC (Standard of Care) Model|The enhanced standard of care model (SOC+) is the current referral model of cancer genetic services delivery with an enhancement to include screening for and resources to address health literacy. This model begins with a health care provider's recognition, identification and then referral of a patient to a genetic counselor where genetic testing takes place if appropriate. This model is time- and resource- intensive and may not be scalable.
62218954|NCT00903682|EXPERIMENTAL|etravirine|etravirine (ETR TMC125) 400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
62413079|NCT03870061|NO_INTERVENTION|Control|
62586525|NCT05717062|EXPERIMENTAL|Varespladib Intravenous Form (IV) + Varespladib Oral tablet (LY315920) + SOC|Participants will receive intravenous (IV) infusion of varespladib at dose of 0.45 milligrams per kilogram per hour (mg/kg/hr) for six hours. This infusion will continue until when the participant meets clinical criteria for transition to oral drug, -If criteria are met, they will be transitioned to varespladib-methyl (initial dose of 500 mg) then continued oral dosing q12 (once every 12 hours) of 250 mg for the remainder of the study period. Participants that do not meet the criteria for transitioning to the oral drug will remain on the IV infusion at 0.45 mg/kg/hr (along with SOC) and assessed twice a day until they meet criteria for transition to oral drug.
62022796|NCT05173519|ACTIVE_COMPARATOR|Dermabond topical skin adhesive|
62022797|NCT05451303||Oral Squamous Cell Carcinoma (OSCC)|OSCC case cohort will consist of patients with Oral Squamous Cell Carcinoma (all stages, locations), recruited from secondary care.
62022798|NCT05451303||OroPharyngeal Cancer (OPC)|OPC case cohort will consist of patients with OroPharyngeal cancer (all stages, locations), recruited from secondary care.
62022799|NCT05451303||Oral Potentially Malignant Disease (OPMD)|"OPMD cohort will consist of patients with both potential malignancies or benign conditions including, but not limited to:~* Dysplasia~* Hyperplasia~* Leukoplakia~* Erythroplasia~* Lichenoid lesions~* Actinic Keratosis~* Lichenoid reaction~* Aphthous ulcer/ Canker Sores~* Gingival enlargement (side effect)~* Lichen planus~* Keratosis~* Inflammatory reaction~* Cheek bites"
62218955|NCT00903682|ACTIVE_COMPARATOR|efavirenz|efavirenz (EFV) 600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
62218956|NCT04535804|ACTIVE_COMPARATOR|Aspirin group|100 mg of low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
62413080|NCT03870061|EXPERIMENTAL|Treatment|This arm receives the full New Incentives' conditional cash transfer program (All Babies Are Equal Initiative).
62794737|NCT05534399|EXPERIMENTAL|Sparing antibiotic strategy|No antibiotic therapy will be administered during the peri-operative period
62794738|NCT05534399|SHAM_COMPARATOR|Peri-operative antibiotic strategy|"Recommendations - An antibiotic therapy will be administered during the peri-operative period.~The antibiotic will be selected according to the type of bacteria isolated and the antibiotic susceptibility testing, and started two days before and pursued until two days following intra-vesical BoNTA injections"
62794739|NCT04516109|ACTIVE_COMPARATOR|Arthrosocpic labral repair|Patients undergoing arthroscopic labral repair with the use of the modified hip capsule slotted cannula.
62794740|NCT04516109|ACTIVE_COMPARATOR|Arthroscopic bone grafting|Patients undergoing arthroscopic bone grafting of subchrondral cyst with the use of the modified bone graft delivery tool set and modified hip capsule slotted cannula.
62586526|NCT05717062|ACTIVE_COMPARATOR|Placebo Intravenous (IV) + Placebo Oral + SOC|Participants will receive intravenous (IV) infusion of placebo matched to varespladib for six hours. This infusion will continue until the participant meets clinical criteria for transition to oral drug. If criteria are met, they will be transitioned to the oral placebo then continued oral dosing for the remainder of the study period. Participants that do not meet the criteria for transitioning to the oral drug will remain on the IV infusion (along with SOC) and assessed twice a day until they meet criteria for transition to oral drug.
62022800|NCT05451303||Cancer-free|Cancer free control cohort will be matched with cases. Participants will be recruited following clinical adjudication with self-reported confirmation of no cancer and from primary care facilities.
62022801|NCT02330835|EXPERIMENTAL|In the Driver's Seat|Treatment materials. In the Driver's Seat: A Roadmap to Managing Student Behavior on the Bus is a comprehensive multimedia program that guides transportation departments in creating and maintaining a safe, responsible, and positive environment on the school bus through effective student behavior management. The program includes three components: 1) In the Driver's Seat: Transportation Supervisor Program for transportation department administrative staff, 2)In the Driver's Seat: Group Lessons DVD for Drivers. The DVD-based curriculum is designed to be facilitated by a transportation supervisor or driver trainer in groups and 3)In the Driver's Seat: Bus Driver Program. This CD-ROM-based program for bus drivers.
62218957|NCT04535804|PLACEBO_COMPARATOR|placebo group|100 mg of placebo was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
62218958|NCT03368638|EXPERIMENTAL|Intervention|
62218959|NCT06459739|EXPERIMENTAL|sacralESPB|Sacral ESPB group
62218960|NCT06459739|NO_INTERVENTION|Control|
62413081|NCT02960724|EXPERIMENTAL|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before surgery and compared with the histological findings to evaluate uPAR PET/CT in staging of oral cancer and oropharyngeal cancer.
62413082|NCT02263846||Postmenopausal group|Patients at the age ≥ 60 years with more than one year of menopause, or patients having undergone bilateral oophorectomy.
62413083|NCT02263846||Premenopausal group|Patients with regular menses during recent 3 months and having never received luteinizing hormone-releasing hormone analogue therapy.
62413084|NCT06422949|EXPERIMENTAL|Hilotherm® Cooling treatment|Cooling treatment with Hilotherm® at hands and feet level
62413085|NCT01884194||Retinoblastoma patients|patients with diagnosed retinoblastoma
62413086|NCT01884194||non-retinoblastoma patients|aged matched control cohort without the diagnosis of ocular or brain tumor
62218961|NCT00825825|ACTIVE_COMPARATOR|Escitalopram|One week of escitalopram at 10 mg followed by one week at 20 mg in healthy volunteers.
62218962|NCT00825825|ACTIVE_COMPARATOR|Citalopram|One week of citalopram at 20 mg followed by one week at 40 mg in healthy volunteers.
62218963|NCT00825825|PLACEBO_COMPARATOR|Placebo|Two weeks of placebo in healthy volunteers.
62218964|NCT02046889|EXPERIMENTAL|Intervention group|The intervention group or experimental group will receive the bicycle training intervention during the first year of the study. The intervention is a 5 day/75 minutes per day bicycle training intervention which used specialized instruction and adapted equipment to teach independent bicycle riding skills to youth aged 9-18 years with autism spectrum disorder and Down syndrome.
62218965|NCT02046889|NO_INTERVENTION|Control group|The control group will not receive the intervention during the first year of the study. Instead, this group will receive a delayed intervention during the second year of the study, after pre-post effects have been evaluated.
62413087|NCT01607398|EXPERIMENTAL|ADOAIR250|ADOAIR 250mcg inhalations, twice daily, from week0 - 12
62413088|NCT01607398|PLACEBO_COMPARATOR|Placebo|Placebo inhalation, twice daily, from week0 -12
62413089|NCT04551859|OTHER|Sacrospinofixation|After accepting the surgeon's proposal to perform a sacrospinofixation to treat the pelvic organ prolapse, participation in this study will be proposed to the patient. It will not change the management or the course of the surgery
62218966|NCT05729971||with NGT|In these patients, the nasogastric tube remains after surgery. It was removed after x-ray test.
62218967|NCT05729971||noNGT|In these patients, NGT was removed at the end of surgery.
62413090|NCT03287908|EXPERIMENTAL|AMG 701|
62413091|NCT03287908|EXPERIMENTAL|AMG 701 + Pomalidomide|
62413092|NCT03287908|EXPERIMENTAL|AMG 701 + Pomalidomide + Dexamethasone|
62413093|NCT05406310||Ablation-Index guided ablation group|This is the prospective study group that will undergo persistent atrial fibrillation ablation guided by Ablation Index.
62413094|NCT05406310||High-power, short-duration ablation Group|This is another prospective group of patients who will undergo persistent atrial fibrillation ablation by high-power, short-duration using QDOT Micro catheter.
62413095|NCT05217537|EXPERIMENTAL|Cohort 1 (adolescents)|12 to \< 18 years of age
62413096|NCT05217537|EXPERIMENTAL|Cohort 2 (children)|8 to \< 12 years of age
62586527|NCT05987007|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy for Insomnia|Participants assigned to the CBTI treatment group will receive 8 weeks of weekly telehealth sessions with a masters-level therapist. Each session is approximately 50 minutes in duration.
62586528|NCT05987007|ACTIVE_COMPARATOR|Acoustic Slow-Wave Activity Enhancement|Participants assigned to the SWAE group will be instructed to use the Dreem2 headband at least four nights out of seven nights of the week.
62586529|NCT05667363|EXPERIMENTAL|Digital Intervention|Accept metered-dose inhaler medication treatment equipped with digital therapeutics consist of smartphone app and intelligent medication recorder. The intelligent medication recorder can automatically record medication using data and reminds patients through the app. Patients can also record their symptom on the app for doctors to monitor.
62586530|NCT05667363|NO_INTERVENTION|Usual use|Accept regular metered-dose inhaler medication treatment.
62413097|NCT05138614|EXPERIMENTAL|Full MISSION|CTI + DRT + PS + MOUD
62413098|NCT05138614|EXPERIMENTAL|CTI & DRT|CTI + DRT + MOUD
62413099|NCT05138614|EXPERIMENTAL|CTI & PS|CTI + PS + MOUD
62413100|NCT05138614|EXPERIMENTAL|DRT & PS|DRT + PS + MOUD
62413101|NCT05138614|OTHER|MOUD only|MOUD
62586531|NCT05371015|EXPERIMENTAL|quadratus lumborum nerve block group with injection of local anesthetic (Ropivacaine)|The subjects would have quadratus lumborum nerve block group with injection of local anesthetic (Ropivacaine) after vaginal delivery.
62794741|NCT06727045|EXPERIMENTAL|Intervention Group|"Questionnaire and Hemodialysis Comfort Scale Version-II (HDKS-II) were applied to the patients. Patients were randomised to groups. A literature review was conducted for the frequency and number of mandalas to be applied to the patients in the intervention group, and mandalas were applied during eight hemodialysis sessions every other day. Mandala painting was done approximately 30 minutes after the start of HD treatment, considering the art therapist's suggestion and the symptoms that may develop during HD. Each mandala painting was performed with a structured and different mandala pattern. In the study, a booklet called the Mandala Booklet consisting of eight structured mandala patterns with round shapes and containing general information about mandalas was used. The patients in the intervention group were informed face to face about the content of the booklet. At the end of the 17th day, the Hemodialysis Comfort Scale-Version II was applied to the group again."
62794742|NCT06727045|NO_INTERVENTION|Control Group|Questionnaire and Hemodialysis Comfort Scale Version-II (HDKS-II) were applied to the patients. Randomization of the patients to the groups was done by a statistician other than the researcher with a computer program (www.randomizer.org) and was done by taking into account age, gender and comfort scale scores. No application was made to the patients in the control group. The booklet was given to the patients in the control group after the mandala coloring was completed. At the end of the 17th day, Hemodialysis Comfort Scale-Version II was applied to the group again.
62794743|NCT01708317|OTHER|ACASI|The group of patients that agreed to participate in the study and answer questions on our Audio-enhanced Computer-Assisted Self-Interview (ACASI)
62794744|NCT06402123|EXPERIMENTAL|Placebo then Zagociguat 15mg|Participants first receive placebo once a day for 12 weeks. Then after a 4 week washout, they receive zagociguat 15 mg once a day for 12 weeks.
62794745|NCT06402123|EXPERIMENTAL|Zagociguat 15mg then Placebo|Participants first receive zagociguat 15 mg once a day for 12 weeks. Then after a 4-week washout, they receive placebo once a day for 12 weeks.
62794746|NCT06402123|EXPERIMENTAL|Placebo then Zagociguat 30mg|Participants first receive placebo once a day for 12 weeks. Then after a 4-week washout, they receive zagociguat 30 mg once a day for 12 weeks.
62413102|NCT00580931|EXPERIMENTAL|1|Subjects will receive experimental drug in a blinded fashion.
62413103|NCT00580931|PLACEBO_COMPARATOR|2|Identical in size, shape and color to experimental drug.
62413104|NCT03682211|EXPERIMENTAL|Active Intranasal Fentanyl|Subjects will receive 50 μg/ml intranasal fentanyl citrate and a placebo matched to intravenous morphine (1 ml water for injection) at time 0
62413105|NCT03682211|ACTIVE_COMPARATOR|Active IV Morphine|Subjects will receive 10 mg/ml intravenous morphine sulphate and a placebo matched to intranasal fentanyl (2 ml water)
62413106|NCT03305159|ACTIVE_COMPARATOR|Control (Povidone Iodine)|Patients to receive povidone iodine for the surgical preparation of the vagina.
62413107|NCT03305159|EXPERIMENTAL|Intervention (4% Chlorhexidine gluconate)|Patients to receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
62413108|NCT03352804||Patients hospitalized in internal medicine ward|Patients included are patients hospitalized in internal medicine ward.
62413109|NCT00596973|EXPERIMENTAL|Ileal transposition with SG|Procedure: Surgical Treatment
62413110|NCT04145973||recurrence and metastasis|breast cancer patients with recurrence and metastasis after surgery
62413111|NCT03365869|ACTIVE_COMPARATOR|Sirolimus|Add sirolimus according to the protocol. Sirolimus active: 2mg po. QD
62413112|NCT03365869|PLACEBO_COMPARATOR|placebo|sirolimus placebo: 2mg po. QD
62218968|NCT02167737|EXPERIMENTAL|Bedside Decision Aid Group|This arm will include study participants who are randomized to the group utilizing the bedside decision aid, which has hospital staff arrange fall-risk reduction interventions (e.g., home safety checks, exercise programs, vision checks, etc.).
62022802|NCT02330835|ACTIVE_COMPARATOR|School bus driver training videos|Control materials. Bus drivers in the control condition viewed two linear videos on study computers. In Session 1 of the intervention, Control drivers viewed School Bus Driving, Part 1, 2nd Edition, © 1991, AIMS Media, 23-minute linear video showing defensive driving techniques. In Session 2, Control drivers viewed Decide Smart, Arrive Safe, © 2005, Operation Lifesaver, Inc., a video about school bus safety at railroad crossings produced in conjunction with the National Association of State Directors of Pupil Transportation services. Supervisors in the control condition received no materials until completing the study (waitlisted).
62413113|NCT03901352|EXPERIMENTAL|Mirogabalin|"The patients with creatinine clearance (CLcr) ≥ 60 mL/min: Mirogabalin 20 mg or 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose.~The patients with creatinine clearance (CLcr) 30 to \< 60 mL/min: Mirogabalin 10 mg or 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose"
62218969|NCT02167737|ACTIVE_COMPARATOR|Control Arm|"Participants in the control/comparator arm will experience the same study procedures with the exception of not using the Bedside Decision Aid and instead being given the Centers for Disease Control (CDC) brochure, What You Can Do to Prevent Falls, and arranging for their own fall prevention strategies."
62022803|NCT04448184|NO_INTERVENTION|Prophylactic Platelet Transfusion|Patients allocated to the prophylactic platelet transfusion group will receive a platelet transfusion when the measured platelet count is less than 10 x 109/L.
62218970|NCT05011773|EXPERIMENTAL|Deep brain stimulation|"All patients have already undergone deep brain stimulation. Results compared on and off stimulation."
62218971|NCT01119105|EXPERIMENTAL|BC-3781 dose 100mg|
62218972|NCT01119105|EXPERIMENTAL|BC-3781 dose 150mg|
62218973|NCT01119105|ACTIVE_COMPARATOR|Vancomycin|
62218974|NCT01940185||LINX device|Patients implanted with the LINX® Reflux Management System.
62218975|NCT04925687|EXPERIMENTAL|Intravitreal autologous CD34+ cells|Intravitreal injection of autologous CD34+ cells harvested from bone marrow under GMP conditions
62218976|NCT04458129|EXPERIMENTAL|Polyethylene glycol treatment|Study participants will take a 3-month laxative treatment with polyethylene glycol for 3 months.
62218977|NCT05802225|EXPERIMENTAL|BCD-178 group|Neoadjuvant therapy stage (6 cycles, 18 weeks): BCD-178, Trastuzumab, Docetaxel, Carboplatin; Surgical treatment; Adjuvant therapy stage (up to 12 months of HER2-targeted therapy in total): BCD-178, Trastuzumab
62218978|NCT05802225|ACTIVE_COMPARATOR|Perjeta Group|Neoadjuvant therapy stage (6 cycles, 18 weeks): Perjeta, Trastuzumab, Docetaxel, Carboplatin; Surgical treatment; Adjuvant therapy stage (up to 12 months of HER2-targeted therapy in total): BCD-178, Trastuzumab
62413114|NCT03901352|PLACEBO_COMPARATOR|Placebo|Placebo (14-weeks)
62413115|NCT00517868|OTHER|Crossover|Placebo Treatment on Visit 1 followed by URG101 Treatment on Visit 2
62413116|NCT00517868|OTHER|Crossover 2|URG101 Treatment on Visit 1 followed by Placebo Treatment on Visit 2
62413117|NCT04438980|EXPERIMENTAL|Methylprednisolone Arm|Standard of care plus Methylprednisolone
62413118|NCT04438980|PLACEBO_COMPARATOR|Placebo Arm|Standard of care plus placebo
62413119|NCT05910840|EXPERIMENTAL|Support-t plus usual diabetes care|Access to the Support-t online training and peer support platform in addition to usual diabetes care for 18 months. Support-t contains 3 components: 1) Educational material, 2) News blog and 3) Patients' discussion forum. Health care providers from the pediatric diabetes clinics will receive Support-t training and will be encouraged to recommend the Support-t platform during routine care with their patients from the active arm.
62413120|NCT05910840|NO_INTERVENTION|Usual diabetes care only|Usual diabetes care for 18 months, which consists of visits with their health care provider and ad-hoc diabetes education with nurses and dietitians. Health care providers from the pediatric diabetes clinics will be instructed not to discuss or refer to the Support-t platform with patients from the control arm. Control arm participants will have the option to use the Support-t platform after the 18-month study.
62586532|NCT05371015|PLACEBO_COMPARATOR|quadratus lumborum nerve block with normal saline|The subjects would have quadratus lumborum nerve block with normal saline after vaginal delivery.
62218979|NCT04715243|OTHER|control|Face-mask NIV is the standard of care
62218980|NCT04715243|ACTIVE_COMPARATOR|intervention 1|High flow nasal cannula
62218981|NCT04715243|ACTIVE_COMPARATOR|Intervention 2|Helmet NIV
62218982|NCT05144126|EXPERIMENTAL|i-Factor Arm|All patients undergoing spine fusion surgery will be treated with i-FACTOR
62218983|NCT03568396||Pupillometry|The relationship between the target effect site concentration of remifentanil and the pupil diameter and reactivity in response to a standard noxious stimulus.
62218984|NCT03576170|ACTIVE_COMPARATOR|aromatherapy-scent|
62413121|NCT05262894|EXPERIMENTAL|Breathing in the snow|Breathing in the snow using a specially designed apparatus and measuring the respiratory gases distribution in snow.
62586533|NCT05139303|EXPERIMENTAL|MAD therapy|An NOA® appliance (Orthoapnea S.L., Malaga, Spain) was custom made for each participant at 50% from maximum protrusion.
62218985|NCT03576170|ACTIVE_COMPARATOR|aromatherapy-touch|
62794747|NCT06402123|EXPERIMENTAL|Zagociguat 30mg then Placebo|Participants first receive zagociguat 30 mg once a day for 12 weeks. Then after a 4-week washout, they receive placebo once a day for 12 weeks.
62218986|NCT03576170|NO_INTERVENTION|wait-list control|
62586534|NCT06684132|EXPERIMENTAL|IMT group|High intensity intermittent inspiratory muscle training (H-IMT) will be applied. This training will be performed with Power breath (POWERbreathe Classic Light Resistance, PowerBreath, IMT Technologies Ltd, Birmingham, UK) respiratory muscle training device. The H-IMT will be performed in seven sets of three-minute cycles consisting of two minutes of training followed by one minute of rest in the training workload. Each session will consist of 14 minutes of loading and seven minutes of rest for a total of 21 minutes.
62586535|NCT06684132|OTHER|Exercise group|Stretching exercises for pectoral muscles, neck muscles and back muscles, strengthening exercises for upper extremity and back muscles and posture exercises will be applied.
62586536|NCT03606304|EXPERIMENTAL|Problem-solving therapy|The intervention is based on an established PST protocol for medical patients, with an additional focus on HF to link depressed mood to impaired HF self-care. Seven steps are included: 1) select and define the problem; 2) establish realistic and achievable goals for problem resolutions; 3) generate multiple solution alternatives (brainstorming); 4) implement decision-making guidelines (pros and cons); 5) evaluate and choose the solutions; 6) implement the preferred solution(s); and 7) evaluate the outcome.
62586537|NCT06666049||Treatment with GLP-1 agonists|Patients undergoing treatment with GLP-1 agonists, from any geographical area, who choose to undergo scheduled and/or urgent surgery under general anesthesia and/or sedation at our hospital over a two-year period (2024-2025).
62586538|NCT03867201|EXPERIMENTAL|Erenumab|Administered by pre-filled syringe
62586539|NCT03867201|PLACEBO_COMPARATOR|Placebo|Administered by pre-filled syringe
62586540|NCT04797299||Single Arm Cohort|Evaluating the risk of Local Recurrence (LR) in a group of women postulated to be at low risk of LR following Breast Conserving Surgery alone defined by a combination of clinicopathological factors and Oncotype DX DCIS score.
62794748|NCT06123078|NO_INTERVENTION|Control group|treatment as usual
62794749|NCT06123078|EXPERIMENTAL|Experimental group|CaCBT
62794750|NCT03894618|EXPERIMENTAL|SL-279252|Intravenous administration; Two possible dosing schedules for SL-279252 may be evaluated
62022804|NCT04448184|EXPERIMENTAL|Prophylactic Tranexamic Acid|Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.
62218987|NCT05769569|EXPERIMENTAL|Antiretroviral therapy + Investigational Products|Active Group (ART with the addition of VRC07-523LS, PGDM1400LS and N-803 in combination with Ad26.Mos4.HIV, MVA-BN-HIV, A244d11 gp120 and ALFQ vaccination)
62218988|NCT05769569|ACTIVE_COMPARATOR|Antiretroviral therapy only|Control Group (continue only with ART without further interventions)
62218989|NCT02728869|EXPERIMENTAL|Heat Stable Rotavirus (HSRV) Vaccine|25 healthy adults who will be administered a single dose of test HSRV vaccine
62218990|NCT02728869|PLACEBO_COMPARATOR|Placebo for Heatstable Rotavirus vaccine|25 healthy adults who will be administered a single dose of placebo
62413122|NCT03394404|EXPERIMENTAL|ECG-I mapping and PVI|ECG-I mapping and PVI
62586541|NCT06682676|EXPERIMENTAL|chronic rhinitis|Nasal ventilation tests were performed indoors at a temperature of (24±5) °C and a humidity of (70±10) %. Using acoustic rhinometry and rhinomanometry, total nasal volume, minimum cross-sectional area and total nasal resistance at 75Pa were recorded.Cold and dry air nasal provocation test usually requires nasal inhalation of 0°C-5°C, relative humidity \&lt; 10% cold air at a flow rate of 26L/min. The nasal symptom rating questionnaire and visual analogue scale were completed before and after the CDA test
62586542|NCT06682676|EXPERIMENTAL|Healthy Volunteers|Nasal ventilation tests were performed indoors at a temperature of (24±5) °C and a humidity of (70±10) %. Using acoustic rhinometry and rhinomanometry, total nasal volume, minimum cross-sectional area and total nasal resistance at 75Pa were recorded.Cold and dry air nasal provocation test usually requires nasal inhalation of 0°C-5°C, relative humidity \&lt; 10% cold air at a flow rate of 26L/min. The nasal symptom rating questionnaire and visual analogue scale were completed before and after the CDA test
62794751|NCT04293185|EXPERIMENTAL|bb1111|"Subjects will receive treatment with a single dose of Drug Product manufactured with autologous CD34+ hematopoietic stem cells collected by plerixafor mobilization and apheresis, transduced with BB305 lentiviral vector (LVV) encoding the human beta-A-T87Q globin gene.~Plerixafor mobilization and apheresis will also be used for collection of rescue cells."
62794752|NCT00730808|EXPERIMENTAL|Test|Oral nutritional supplement: assignment according to consecutive random numbers.
62022805|NCT04504045|EXPERIMENTAL|Metformin|Patients will receive metformin 1000-2000 mg daily for 12 weeks.
62413123|NCT03902249|ACTIVE_COMPARATOR|Dexamethasone group|Patients who received 0.15mg/kg of Dexamethasone in 8ml of saline
62413124|NCT03902249|PLACEBO_COMPARATOR|Placebo group|Patients who received the same volume of saline as the study group (8ml)
62413125|NCT06501131|EXPERIMENTAL|full spectrum light group|Subjects were asked to stay in a resting state for 5 minutes in a dark room, then turn on the full-spectrum light and adapt to the light environment for 5 minutes, and then take measurements for 5 minutes. After wash-out in the dark room for 5 minutes, change the light to ordinary LED lamp and repeat the above test steps for measurement.
62413126|NCT06501131|EXPERIMENTAL|ordinary LED light group|Subjects were asked to stay in a resting state for 5 minutes in a dark room, then turn on the ordinary LED lamp and adapt to the light environment for 5 minutes, and then take measurements for 5 minutes. After wash-out in the dark room for 5 minutes, change the light to full-spectrum light and repeat the above test steps for measurement.
62413127|NCT03819465|EXPERIMENTAL|A1|Durvalumab
62413128|NCT03819465|EXPERIMENTAL|A2|Durvalumab + danvatirsen
62413129|NCT03819465|EXPERIMENTAL|A3|Durvalumab + oleclumab
62413130|NCT03819465|EXPERIMENTAL|A4|MEDI5752
62794753|NCT00730808|PLACEBO_COMPARATOR|Control|Assignment according to consecutive random numbers.
62794754|NCT06514885|EXPERIMENTAL|SDF group|Participants of SDF group will be applied with SDF before placement of root caries restoration
62218991|NCT02728869|EXPERIMENTAL|Heat Stable Rotavirus Vaccine|25 healthy infants who will be administered 3-doses of test HSRV vaccine spaced at 4-week intervals
62794755|NCT06514885|PLACEBO_COMPARATOR|Control group|Participants of control group will be applied with placebo (tonic water) before placement of root caries restoration
62794756|NCT05766826|EXPERIMENTAL|Treatment Arm|After enrollment over a phone call, they receive a SMS text message with an ID number to receive their coupons at the health facility. Those coupons can be used to redeem WaterGuard 150mL dilute chlorine. Participants in this group will receive a packet of coupons that ensure a monthly supply of a150ml bottle of dilute chlorine solution for at least the next 12 months. These coupons are redeemable in health facilities and other sites registered for the study.
62218992|NCT02728869|ACTIVE_COMPARATOR|RotaTeq|25 healthy infants who will be administered 3-doses of comparator Rotateq® vaccine spaced at 4-week intervals
62218993|NCT05479201||Children 4-8 years of age|
62218994|NCT04025346|ACTIVE_COMPARATOR|Capsimax|
62413131|NCT03819465|EXPERIMENTAL|B1|Durvalumab + Investigator's choice of chemotherapy
62413132|NCT03819465|EXPERIMENTAL|B2|Durvalumab + Investigator's choice of chemotherapy + danvatirsen
62413133|NCT03819465|EXPERIMENTAL|B3|Durvalumab + investigator's choice of chemotherapy + oleclumab
62413134|NCT03819465|EXPERIMENTAL|B4|MEDI5752
62413135|NCT03819465|EXPERIMENTAL|A5|AZD2936
62413136|NCT03819465|EXPERIMENTAL|B5|AZD2936 + chemotherapy
62413137|NCT03447470|EXPERIMENTAL|Monotherapy RXC004 - Module 1|Patients will be given RXC004 at a specified dose level and reviewed for Dose Limiting Toxicities. Once the DLT period is complete RXC004 will be given at a higher dose until MTD is reached.
62413138|NCT03447470|EXPERIMENTAL|Combination RXC004 plus Nivolumab - Module 2|Patients will be given RXC004 at specific doses in combination with a standard dose of Nivolumab and reviewed for Dose Limiting Toxicities. Once the DLT period is complete, RXC004 will be given at a higher dose until MTD is reached.
62413139|NCT03447470|EXPERIMENTAL|Intermittent schedules of monotherapy RXC004 - Module 3|Patients will be given RXC004 at specific doses. One group will be treated for 4 days, followed by 3 days off; repeated weekly for 21 days. A second group will be treated for 2 weeks at the same dose, followed by 1 week off for 21 days.
62586543|NCT05094674|OTHER|Participants who require a diagnostic or screening COVID-19 RT-PCR test|Participants who require a diagnostic or screening COVID-19 RT-PCR test, presenting at Tameside and Glossop Integrated Care NHS Foundation Trust aged 18 years or over
62218995|NCT04025346|PLACEBO_COMPARATOR|Placebo|
62218996|NCT06079125|EXPERIMENTAL|Posterior fossa decompression with duraplasty|The bone is removed from the suboccipital region of the skull and Cervical 1 lamina so the constricting epidural band can be resected. Then, the dura is opened. Microsurgical dissection is performed and the dura is sewn closed.
62218997|NCT06079125|EXPERIMENTAL|PFDD with tonsillar resection/reduction|The bone is removed from the suboccipital region of the skull and Cervical 1 lamina so the constricting epidural band can be resected. Then, the dura is opened and herniated tonsil will be manipulated. Microsurgical dissection is performed and the dura is sewn closed.
62218998|NCT05800418|EXPERIMENTAL|Ramucirumab injection|8mg/kg, Single intravenous infusion
62218999|NCT05800418|ACTIVE_COMPARATOR|Cyramza|8mg/kg, Single intravenous infusion
62413140|NCT02173132|ACTIVE_COMPARATOR|acetyl-L-carnitine|2 g acetyl-L carnitine twice a day for 90 days
62586544|NCT06411730|EXPERIMENTAL|Cohort 1A|
62219000|NCT02641574||previous 1|women who have had in their past one cesarean section
62219001|NCT02641574||previous 2|women who have had in their past 2 cesarean sections
62219002|NCT02641574||previous 3|women who have had in their past 3 cesarean sections
62219003|NCT02641574||previous 4|women who have had in their past 4 cesarean sections
62219004|NCT06609317|EXPERIMENTAL|Device Arm|Participants in this arm will use a digital therapeutic motion-based device for postpartum pelvic floor muscle training
62219005|NCT05163782|EXPERIMENTAL|People with foot drop|People with left or right foot drop
62219006|NCT00729079|ACTIVE_COMPARATOR|1|Subject will be randomly assigned to work with providers at Clinton Medical Associates
62413141|NCT02173132|PLACEBO_COMPARATOR|sugar pill|Placebo twice a day for 90 days
62413142|NCT05671991|EXPERIMENTAL|Empagliflozin or Placebo in Acute|Acute phase: Participants will receive 25 mg empagliflozin once on Day 0 or Day 7. Participants receive empaglifozin or placebo on Day 0. On Day 7, they will be crossed over to the alternate treatment.
62413143|NCT05671991|ACTIVE_COMPARATOR|Empagliflozin in Chronic|Chronic phase: On day 8, all participants will receive 10 mg empagliflozin 10 mg x 8 weeks
62413144|NCT01901939|EXPERIMENTAL|exercise|daily bedside tailored low intensity pedaling exercise
62219007|NCT00729079|ACTIVE_COMPARATOR|2|Subjects will be randomly assigned to work with providers at 1655 Elmwood AVe, Suite 125
62219008|NCT04835077|EXPERIMENTAL|Structured Aerobic Exercises|"Following the training on aerobic exercise content and effectiveness;~1. First Week; participants 5 minutes warm-up, 20 minutes of aerobic exercise with 60-70% of maximum heart rate, and 5 minutes of cool down.~2. In the following weeks, the aerobic exercise duration of all participants will be increased by 5 minutes compared to the previous week.~3. The duration of the sessions in the 7th and 8th weeks will progressively progress to 40 minutes and the intensity to 75-80% of the maximum heart rate."
62243371|NCT05767866|EXPERIMENTAL|Part 2: Expansion Cohort 2|In dose-escalation phase, previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 100mg/day and who have no active, measurable central nervous system (CNS) metastases.
62413145|NCT00952432|ACTIVE_COMPARATOR|ACUPUNCTURE|ACUPUNCTURE
62413146|NCT00952432|ACTIVE_COMPARATOR|MEDICATION|Carbamazepine
62413147|NCT04109768|EXPERIMENTAL|Hands on Nutrition Education|Nutrition and activity intervention to improve behaviors pre to post
62586545|NCT06411730|EXPERIMENTAL|Cohort 1B|
62586546|NCT06411730|EXPERIMENTAL|Cohort 1C|
62794757|NCT05766826|EXPERIMENTAL|Control Arm|After enrollment over a phone call, they will not be contacted.
62794758|NCT01693536|EXPERIMENTAL|Lifestyle counselling|"Three dietician visits focussed on education to find food with sodium less than 120mg/100gms.~Two physiotherapist visits focussed on teaching personalised sustainable practical exercise."
62794759|NCT01693536|NO_INTERVENTION|Control|Control group was offered free skin cancer check and wait listed for the same lifestyle counselling after the six months of the study.
62794760|NCT06457867|EXPERIMENTAL|microfragmented adipose tissue|microfragmented adipose tissue loaded on bovine graft on ridge preservation
62794761|NCT06457867|ACTIVE_COMPARATOR|bovine graft|bovine graft only on ridge preservation
62794762|NCT05838157||Girls and women aged 16 to 40 years who receiving at least one dose of HPV vaccination|Girls and women aged 16 to 40 years who receiving HPV vaccination ( including 2vHPV、4vHPV、9vHPV) in Cancer Prevention Center, Sun Yat-sen University Cancer Center during April 10th 2023 to April 30th 2023.
62219009|NCT04835077|EXPERIMENTAL|Postural Stabilization Exercises|"Exercises; It will consist of postural exercises to be done in prone, supine, side lying, crawling, sitting and standing positions. All exercises will be done in 2 sets per day, the number of repetitions will be determined individually and progressed.~1. Breathing exercises~2. Four-way stretching and strengthening of the neck muscles~3. Shoulder girdle stretching and strengthening exercises~4. Hip flexors, hamstring, itb, lumbar extensor stretching and strengthening~5. Lying down exercises in the crawling position~6. Shuttle movement~7. Plank movement~8. Toe taps~9. Bridging~10. Straight leg lift~11. Straight leg raises in side-lying~12. Prone knee flexion"
62794763|NCT02509923|EXPERIMENTAL|1|3-way cross-over, Z-215 10 mg/day / Z-215 20 mg/day / Rabeprazole Sodium 10 mg/day
62219010|NCT04835077|NO_INTERVENTION|Control|The individuals without any treatment will continue their normal lives and will be included in the study as a control group. Exercise will be given after 8 weeks.
62219011|NCT06301425|EXPERIMENTAL|Intervention group|According to the MFC MRD status after the first consolidation (MRDcon1), the MRDcon1 positive patients were categorized into high-risk group (i.e., risk stratification). All the patients in high-risk group who fulfilled all inclusion/exclusion criteria were randomly assigned in a 1:1 ratio to receive a second consolidation therapy (intervention group) or receive allo-HSCT directly (control group).
62219012|NCT06301425|ACTIVE_COMPARATOR|Control group|According to the MFC MRD status after the first consolidation (MRDcon1), the MRDcon1 positive patients were categorized into high-risk group (i.e., risk stratification). All the patients in high-risk group who fulfilled all inclusion/exclusion criteria were randomly assigned in a 1:1 ratio to receive a second consolidation therapy (intervention group) or receive allo-HSCT directly (control group).
62219013|NCT00828477|ACTIVE_COMPARATOR|1|Xibrom (bromfenac)
62219014|NCT00828477|ACTIVE_COMPARATOR|2|Nevanac (nepafenac)
62219015|NCT03694275|EXPERIMENTAL|Soticlestat Dup 15q|Soticlestat tablets twice daily (BID) orally or via gastrostomy tube (G-tube)/ percutaneous endoscopic gastrostomy (PEG) tube, BID. Participants with Dup 15q weighing \<60 kg at Baseline received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
62413148|NCT02756169|EXPERIMENTAL|Intervention|One workshop during pregnancy Support for breastfeeding at immediate postpartum Telephonic support after delivery
62794764|NCT02509923|EXPERIMENTAL|2|3-way cross-over, Z-215 20 mg/day / Z-215 40 mg/day / Rabeprazole Sodium 20 mg/day
62794765|NCT02509923|EXPERIMENTAL|3|3-way cross-over, Z-215 20 mg/day (before breakfast) / Z-215 20 mg/day (after breakfast) / Rabeprazole Sodium 10 mg/day (after breakfast)
62219016|NCT03694275|EXPERIMENTAL|Soticlestat CDD|Soticlestat tablets BID orally or via G-tube/ PEG tube, BID. Participants with CDD weighing \<60 kg at Baseline received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
62219017|NCT06610149|EXPERIMENTAL|Probiotic|8-week treatment period with a probiotic mixture (Lactobacillus paracasei 101/37 LMG P-17504, Lactobacillus plantarum 14D CECT 4528, Bifidobacterium breve Bbr8 LMG P-17501, Bifidobacterium breve BL10 LMG P-17500, and Bifidobacterium animalis ssp. lactis Bi1 LMG P-17502)
62219018|NCT05734469|OTHER|Popliteal sciatic nerve block|A local anesthetic solution of 30ml of ROPIVACAINE 0,5% (4mg/kg maximum) will be used for the popliteal sciatic nerve block (popliteal sciatic, saphenous) by real-time ultrasound guidance (associated with a standardized general anesthesia)
62413149|NCT02756169|NO_INTERVENTION|Control|Standar procedures of neonatal and pregnancy health care at the clinics or hospitals.
62413150|NCT02591602|EXPERIMENTAL|CASI|Teleradiology service for patients residing at home or in nursing homes
62413151|NCT02591602|NO_INTERVENTION|CONTROLLI|X-ray hospital department
62413152|NCT04831502|EXPERIMENTAL|Sequence 1: TAK 906 50 mg (Treatment A+Treatment B+Treatment A+Treatment B+Treatment C)|Participants will receive TAK-906 50 milligram (mg) as Treatment A (TAK-906 capsule) and Treatment B (TAK-906 tablet) under fasted conditions and Treatment C (TAK-906 tablet) under fed conditions, orally, once on Day 1 of Periods 1 to 5. A washout interval of at least 3 days will be maintained between each Treatment Period.
62586547|NCT06411730|EXPERIMENTAL|Cohort 2A|
62794766|NCT02820454|EXPERIMENTAL|AGuIX and radiotherapy|"Patients receive a single intravenous injection of AGuIX on day 1. Then patients undergo a whole brain radiation therapy, 5 days a week in weeks 1-2. The first radiotherapy session will be performed 4 hours after AGuIX injection.~Five dose escalation cohorts : 15 mg/kg, 30mg/kg, 50mg/kg, 75mg/kg and 100 mg/kg"
62794767|NCT04685265|ACTIVE_COMPARATOR|anle138b|150 mg and higher dosage
62794768|NCT04685265|PLACEBO_COMPARATOR|Placebo|Matching placebo dosage
62794769|NCT06291480|EXPERIMENTAL|Music Therapy + Care as Usual|9 music therapy sessions within 2-5 weeks during stroke rehabilitation, in addition to care as usual.
62794770|NCT06291480|NO_INTERVENTION|Care as Usual|2-5 weeks of care as usual, without music therapy
62794771|NCT05676112||Nintedanib new users|
62794772|NCT05676112||Pirfenidone new users|
62794773|NCT05676112||no drug-treated users|subjects who did not receive nintedanib, pirfenidone
62219019|NCT05734469|OTHER|Ankle block|A maximum solution of 15ml of ROPIVACAINE 0. 5%( 4mg/kg maximum) for the ankle block (saphenous, superficial peroneal, deep peroneal and tibial nerves) by real-time ultrasound guidance (associated with a standardized general anesthesia)
62794774|NCT02667132||medical treatment|In this study, patient's data will be retrospectively obtained by recording the data in patients' files and electronic records. The data includes the determined parameters by the study group of GM and the data will be recorded in an excel file that includes specific columns of the following entries: patients' age, diagnosis, secondary disease, diagnosis methods, treatments, recurrence, the risk factors that may cause the disease (smoking, using oral contraceptive, breast infection etc.). antibiotic, immunosuppressive drugs, methotrexate
62794775|NCT02667132||surgical treatment|lumpectomy, mastectomy, abscess drainage
62794776|NCT02667132||surgical+medical treatment|first medical, after surgical treatment or first surgical, after medical treatment
62794777|NCT02315313||group1|RHR≤60bpm
62794778|NCT02315313||group2|RHR 61-70bpm
62794779|NCT02315313||group3|RHR 71-80bpm
62219020|NCT05749484||NCRT+TME|Neoadjuvant chemoradiotherapy (NCRT) and total mesorectal excision (TME) Interventions
62413153|NCT04831502|EXPERIMENTAL|Sequence 2: TAK-906 50 mg (Treatment B+Treatment A+Treatment B+Treatment A+Treatment C)|Participants will receive TAK-906 50 mg as Treatment B (TAK-906 tablet) and Treatment A (TAK-906 capsule) under fasted conditions and Treatment C (TAK-906 tablet) under fed conditions, orally, once on Day 1 of Periods 1 to 5. A washout interval of at least 3 days will be maintained between each Treatment Period.
62413154|NCT00769132|EXPERIMENTAL|A|ER niacin/laropiprant + Placebo to laropiprant
62413155|NCT00769132|ACTIVE_COMPARATOR|B|ER niacin + Placebo to laropiprant
62413156|NCT00769132|EXPERIMENTAL|C|laropiprant + Placebo to ER niacin/laropiprant
62413157|NCT00769132|PLACEBO_COMPARATOR|D|Placebo
62413158|NCT03094949|ACTIVE_COMPARATOR|Partial Nephrectomy|a kind of operation for renal tumor
62413159|NCT03094949|EXPERIMENTAL|microwave ablation|a kind of minimally invasive therapy by using microwave device for renal tumors
62586548|NCT06411730|EXPERIMENTAL|Cohort 2B|
62586549|NCT06411730|EXPERIMENTAL|Cohort 2C|
62586550|NCT06411730|EXPERIMENTAL|Cohort 2D|
62794780|NCT02315313||group4|RHR \>80bpm
62586551|NCT06411730|EXPERIMENTAL|Cohort 3A|
62219021|NCT00760773|EXPERIMENTAL|1|
62586552|NCT06411730|EXPERIMENTAL|Cohort 3B|
62219022|NCT00760773|EXPERIMENTAL|2|
62219023|NCT00760773|PLACEBO_COMPARATOR|3|
62413160|NCT00573118||1|The study group included 49 patients with a previous history of one or more of the following pregnancy complications: preeclampsia (n = 17), severe IUGR (n = 13), IUFD (n = 14) or placental abruption (n = 5).
62413161|NCT00573118||2|The control group included 49 healthy women who delivered during the study period, who did not smoke during pregnancy and in whom pregnancy and delivery were uneventful
62413162|NCT06124846|NO_INTERVENTION|control|Age- and sex-matched adolescents with no lifetime history of cannabis use will also complete the protocol.
62413163|NCT06124846|EXPERIMENTAL|CB-Abst|adolescents ages 15-18 years old with CUD use randomized to CB-Abst
62586553|NCT03884569||Patients treated with CLET|"Previously treated with CLET patients are included retrospectively, as the follow-up procedure is already stablished in our centre, and patients treated following standard care or through drugs-in-special-situation request in Spain prospectively. Patients are not treated to be included in the study, only the follow-up variables are taken into account."
62794781|NCT05270837|EXPERIMENTAL|Pegvaliase|
62794782|NCT05270837|OTHER|Drug: Diet Only|Participants will be managing their PKU with diet alone. Participants in the diet-only control arm will be required to maintain and adjust dietary and medical protein food intake through Week 72, initiating pegvaliase treatment beginning Week 73 and, from Weeks 73 through 215.
62794783|NCT02152709|EXPERIMENTAL|10µg/0.5ml hepatitis B vaccine|3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number: YHB2008063S1.
62794784|NCT02152709|ACTIVE_COMPARATOR|5µg/0.5ml hepatitis B vaccine|3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number:20080603.
62794785|NCT01597336|ACTIVE_COMPARATOR|Saline only flush of abscess|Saline alone used to flush abscess
62219024|NCT05817552||CBCT|Casts STLs generated from CBCT planmeca Pro Max
62219025|NCT05817552||Intraoral Scanner|Casts STLs generated from intraoral scanner Haron from 3DISC
62219026|NCT05817552||Desktop Optical Scanner|Casts STLs generated from desktop optical scanner Medit T710
62219027|NCT04073459|EXPERIMENTAL|L dose of Hexavalent|Low dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib)
62219028|NCT04073459|EXPERIMENTAL|M dose of Hexavalent|Middle dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib)
62586554|NCT03561376|OTHER|Single arm - split scar study|Surgical closures, at least 4.5cm in length, will be split and zinc oxide ointment applied to half and petrolatum ointment to the other half
62586555|NCT05674123|EXPERIMENTAL|Device Feasibility (Flex Robotic System)|Patients undergo resection with Flex Robotic System on study. Patients also undergo colonoscopy with or without rectal endoscopic ultrasound at screening.
62586556|NCT05476627||Hypertension Group|
62586557|NCT05476627||Diabetes Group|
62586558|NCT05476627||Hyperuricemia|
62586559|NCT05476627||Obesity|
62586560|NCT01623401|EXPERIMENTAL|TR-701 FA|TR-701 FA 200 mg oral once daily
62586561|NCT03718481||Surgical Trainees|Trainee membership of the Association of Surgeons in Training (ASiT) in the UK and the Republic of Ireland
62794786|NCT01597336|EXPERIMENTAL|Saline plus tPA flush of abscess|Saline plus tPA used for abscess flush
62794787|NCT06206161|ACTIVE_COMPARATOR|IPO, CLIN|Standard brief intervention eligibility criteria involving indicated prevention (i.e., brief interventions delivered to high-risk drinkers only). BIs delivered by standard SBIRT workforce involving school nursing or clinical staff.
62794788|NCT06206161|EXPERIMENTAL|IPO, CLIN+PARA|Standard brief intervention eligibility criteria involving indicated prevention (i.e., brief interventions delivered to high-risk drinkers only). BIs delivered by expanded SBIRT workforce involving school nursing or clinical staff and trained paraprofessionals.
62794789|NCT06206161|EXPERIMENTAL|SIP, CLIN|Expanded brief intervention eligibility criteria involving selective prevention in addition to indicated prevention (i.e., brief interventions delivered to current drinkers with and without risky alcohol use). BIs delivered by standard SBIRT workforce involving school nursing or clinical staff.
62794790|NCT06206161|EXPERIMENTAL|SIP, CLIN+PARA|Expanded brief intervention eligibility criteria involving selective prevention in addition to indicated prevention (i.e., brief interventions delivered to current drinkers with and without risky alcohol use). BIs delivered by expanded SBIRT workforce involving school nursing or clinical staff and trained paraprofessionals.
62794791|NCT02470520||AKI without CRRT|Patients with AKI who are not treated with continuous renal replacement therapy
62794792|NCT02470520||AKI with CRRT|Patients with AKI who are treated with continuous renal replacement therapy
62794793|NCT06727175||before non-invasive neuromodulation therapy|evaluation results before non-invasive neuroregulation therapy
62794794|NCT06727175||after non-invasive neuromodulation therapy|evaluation results after six-month non-invasive neuroregulation therapy
62794795|NCT04557813||IC before start of any treatment|Informed consent (IC) before start of any treatment after diagnosis of NTRK fusion-positive cancer. All data after diagnosis of NTRK fusion-positive cancer are collected prospectively.
62794796|NCT04557813||IC after start of any treatment|IC after start of any treatment after diagnosis of NTRK fusion-positive cancer. Data after study inclusion are collected prospectively and retrospectively.
62794797|NCT04557813||Deceased patients|Patients deceased prior to study inclusion (no IC required). All data are collected retrospectively.
62794798|NCT05092945|ACTIVE_COMPARATOR|Subject with Type 2 Diabetes- cold exposure|3-hour cold exposure: Protocol B
62794799|NCT05092945|EXPERIMENTAL|Subject with type 2 Diabetes- cold exposure and nicotinic acid|3-hour cold exposure with oral nicotinic acid: Protocol A
62794800|NCT05092945|ACTIVE_COMPARATOR|Subject without Type 2 Diabetes- cold exposure|3-hour cold exposure: Protocol B
62794801|NCT05092945|EXPERIMENTAL|Subject without type 2 Diabetes- cold exposure and nicotinic acid|3-hour cold exposure with oral nicotinic acid: Protocol A
62794802|NCT04131179|EXPERIMENTAL|Youth culturally adapted therapy (Y-CMAP)|Youth Culturally adapted manual assisted (Y-CMAP) psychological therapy
62794803|NCT04131179|NO_INTERVENTION|Treatment as Usual|"TAU will be standard routine care delivered by local medical, psychiatric and primary care services according to clinical judgement. A record will be kept of any treatment received by each participant.~Assessment will be done at 3rd,6th,9th and 12 month after randomization along with TAU"
62794804|NCT02362464|EXPERIMENTAL|Long Term T-cell Receptor Alternate Reading Frame Protein (TARP) Peptide Vaccinations|Intradermally given vaccine given at weeks 3, 6, 9, 12, 15 and 24.
62794805|NCT01462240||1 - LPS Flex Pororus Femoral Components|Patients suffering from severe knee pain and disability.
62794806|NCT06088719||axillary surgery group|this group of patients had axillary surgery for axilla staging
62022806|NCT06533163|EXPERIMENTAL|Device use|"This investigation will employ an individualized dose-time-escalation approach starting each patient at a low dose and escalating the dose within the same patient.~For each patient, the device will be used for 2 hours daily during the first two weeks. After this period, the duration will increase to 4 hours per day for the next two weeks, eventually reaching a maximum of 6 hours per day. 6 hours will then be used for the remainder of the time until the device is no longer required for use per protocol requirements.~Dose adjustments may also be made based on MRI findings, specifically addressing swelling, pseudoprogression, imaging criteria violations, and other special cases; however, Investigators are encouraged to guide patients back to the optimal 6-hour duration, considering safety and tolerability. It is anticipated that some patients will require less than 6 hours of treatment on a long-term basis. Consultation with the PI should occur in such cases."
62413164|NCT06124846|EXPERIMENTAL|CB-MON|adolescents ages 15-18 years old with CUD use randomized to CB-Mon
62413165|NCT01371006|EXPERIMENTAL|BI201335 low dose Efavirenz|low dose Efavirenz
62413166|NCT01371006|EXPERIMENTAL|BI201335 high dose Efavirenz|normal dose Efavirenz
62413167|NCT05941845|EXPERIMENTAL|6-month interferon alfa treatment|
62413168|NCT06650202|OTHER|Group 1- Training and Assessments|10 SCI participants with an scES implant that will receive 40-60 TPAD training sessions with stimulation and 5 assessments with and without stimulation.
62413169|NCT06650202|NO_INTERVENTION|Group 2- Assessments Only|10 SCI participants with an scES implant that will receive 4 assessments with and without stimulation.
62413170|NCT03073291|EXPERIMENTAL|Responsible Marijuana Vendor Training|The TrainToTend online responsible marijuana vendor training teaches responsible sales practices in five modules: Module 1, The Laws; Module 2, ID Checking; Module 3, Health Effects; Module 4, Customer Service, and Module 5, Rules of the Trade. The training content will be conveyed using online educational activities providing application and feedback such as in tabs with appropriate graphics and interactive simulations where users apply the skill and receive informative/corrective feedback.
62413171|NCT03073291|NO_INTERVENTION|Usual and Customary Sales Practices Training|Usual and customary training in retail sales practices delivered to employees at retail recreational marijuana stores by store managers. Some retail stores in Colorado may receive responsible marijuana vendor training of some type from another state-approved training provider. Thus, we consider the outlets in the control group to have usual and customer sales training but not to be entirely untrained.
62794807|NCT06088719||no axillary surgery group|this group of patients had no axillary surgery for axilla staging
62794808|NCT06279377|EXPERIMENTAL|Stabilization Exercise Group|"In the stabilization exercise group, in addition to those performed in the standard exercise group, training of deep neck flexor muscles with stabilizers and dynamic stabilization exercises will be applied.~Stabilizer Pressure Biofeedback unite, elastic resistance bands and elastic balls will be used in the stabilization exercise program.~Exercises performed with an elastic resistance band will be started in the 4th week, and exercises performed with an elastic ball will be started in the 6th week, depending on the suitability of the patient."
62413172|NCT06536595||Study group|got diagnosed scleroderma
62586562|NCT03520153||FD/MAS with diabetes mellitus|"Fibrous Dysplasia/McCune-Albright Syndrome with diabetes mellitus.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
62586563|NCT03520153||FD/MAS without diabetes mellitus|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
62586564|NCT03520153||FD/MAS without diabetes and without IPMN|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus and without intraductal papillary mucinous neoplasms.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
62413173|NCT06213441|EXPERIMENTAL|arm trained with pecha kucha|Before the patient is discharged from the clinic, the data collection form and scales will be administered to the patient (pre-test). Pecha kucha (PK) training presentation will be shown to the patient via mobile phone before the patient leaves the clinic and will also be shared via WhatsApp via the phone numbers they use. While the PK training presentation is approximately 5-7 minutes, the time to fill out the scales is approximately 10-15 minutes. 4 weeks after the training, the scale will be administered to the participants again via an online survey (posttest).
62413174|NCT06213441|NO_INTERVENTION|control arm|The data collection form and scales will be applied to the patient before the patient is discharged from the clinic (pre-test). Routine training is provided by the wound and stoma care nurse before the patient is discharged from the clinic. The scale will be administered to the patient again via an online survey 4 weeks after discharge (posttest).
62413175|NCT03731117|EXPERIMENTAL|FST|FUROSEMIDE STRESS TEST
62413176|NCT05054621|EXPERIMENTAL|Heterologous group|1st dose AZD1222, 2nd dose MVC-COV1901
62413177|NCT05054621|ACTIVE_COMPARATOR|Homologous group (control)|1st dose AZD1222, 2nd dose AZD1222
62413178|NCT02395601|EXPERIMENTAL|CPI-1205|
62413179|NCT06389825|EXPERIMENTAL|Canada's Food Guide principles (CFG diet)|During 28 days, participants will receive de CFG diet. The CFG diet emphasizes low intakes of red and processed meats and high intakes of minimally processed plant foods with water as the drink of choice, as per Canada's Food Guide. The number of portions of protein foods, whole-grains, fruits and vegetables to be served daily reflects the recommended ¼-¼-½ proportions. Regarding protein quality, vegetable proteins are served more often than animal proteins as stated in Canada's Food Guide. Weekly, red meat is served once, two days are meatless, and one day is free of animal products.
62586565|NCT03520153||FD/MAS without diabetes and with IPMN|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus and with intraductal papillary mucinous neoplasms.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
62586566|NCT03520153||Healthy Controls|Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test.
62586567|NCT05972486|EXPERIMENTAL|Muse-S headband system for management of sleep disturbances|Study participants will receive a new Muse-S headband system at study entry and will be asked to utilize it daily for a minimum of 10 minutes day for a period of 6 months (24 weeks). Three of the seven sessions per week will specifically be asked to be mind meditation.
62794809|NCT06279377|ACTIVE_COMPARATOR|Standard Exercise Group|"On the day they will be discharged from the hospital, cervical normal joint movement, patient and posture training will be given.~Then the exercise program will begin and the first session will be held. Patients will be given a 5-minute warm-up program before starting the exercise and a 5-minute cool-down program at the end of the exercise.~Cervical flexion, extension, lateral flexion and rotation movements will be performed within the scope of the warm-up and cool-down program. Then, posture exercises and neck exercises with elastic resistance band will be performed."
62794810|NCT01011543|ACTIVE_COMPARATOR|Endoscopic approach|CT thorax is done in all patients to localize the exact anatomical site of the disease. This evaluation is followed by fluoroscopy-guided bronchoscopy for BAL (bronchoalveolar lavage) and TBB (transbronchial biopsies). A sputum sample immediately after the endoscopy will be collected if possible.
62794811|NCT01011543|ACTIVE_COMPARATOR|Induced sputum|Sputum induction after administration of 6-8 mL 3% NaCl aerosol by an ultrasonic nebulizer; sputum will be collected 15-30 minutes after administration of the aerosol. This process will be done twice in every patient.
62794812|NCT03634163|EXPERIMENTAL|Immediate|Quality of Life Assessment plus facilitated implementation of neighbourhood exchange and personal care support
62433288|NCT04655482|EXPERIMENTAL|Treatment arm|"Patients treated with aflibercept (2.0ml/0.05cc) using treat-and-extend regimen.~Three monthly loading injections followed by proactive treatment using treat-and-extend regimen. Extension of injection interval by 2 weeks. The maximum injection interval was set as 16 weeks."
62794813|NCT03634163|ACTIVE_COMPARATOR|Delayed|Quality of Life Assessment
62794814|NCT04236752|EXPERIMENTAL|Single arm radiotherapy|HDR Brachytherapy Boost of 15Gy to the prostate followed by Stereotactic Ablative Body Radiation (SBRT) 25 Gy in 5 fractions, once weekly to prostate, SVs and pelvic lymph nodes + 6-18 months of ADT
62794815|NCT01174121|EXPERIMENTAL|1/CD8+ Enriched TIL (CLOSED)|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young CD8+ enriched TIL + high-dose aldesleukin (CLOSED)
62433289|NCT02625415|EXPERIMENTAL|Vitamin B6|Topical application of B6 cream to the hand or/and feet 1-2 ml applied to the hand or /and feet three times a day for 4 weeks.
62586568|NCT05654870|EXPERIMENTAL|Valbenazine|Valbenazine once daily
62586569|NCT05654870|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62219029|NCT04073459|EXPERIMENTAL|H dose of Hexavalent|High dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib).
62413180|NCT06389825|EXPERIMENTAL|Standard North American diet (NAD diet)|During 28 days, participants will receive de NAD diet. The NAD diet reflects current dietary intakes of the French-Canadian adult population in terms of foods, nutrients, and diet quality, as characterized in recent surveys conducted in an age- and a sex-representative sample of adults from the Province of Quebec. Intakes of minimally processed fruits and vegetables will be low; animal proteins, mostly red and processed meats, will be consumed more often than vegetable proteins; grains will be mostly refined; and ready-to-eat/ready-to-heat foods and sugary beverages will be served daily.
62586570|NCT05780177|EXPERIMENTAL|BBTI|Participants in this arm will receive 4 sessions (20-60 minutes) of a brief behavioral treatment for insomnia (BBTI). Relaxation techniques are not a component of BBTI.
62586571|NCT05780177|ACTIVE_COMPARATOR|PMRT|Participants in this arm will receive 4 sessions (20-60 minutes) of progressive muscle relaxation training (PMRT).
62219030|NCT04073459|ACTIVE_COMPARATOR|Pentavalent+IPV|Co-administration of EupentaTM Inj and Imovax Polio
62219031|NCT04918446|EXPERIMENTAL|T-POSE|Technology based brief educational intervention for hospitalized patients that will be discharged with an opioid prescription.
62219032|NCT04918446|OTHER|Usual Care|Standard discharge instructions provided.
62219033|NCT00876577||Group 1|
62219034|NCT03592810||ECPR|All patients who received ECMO placement during cardiopulmonary resuscitation (ECPR)
62219035|NCT03831373|EXPERIMENTAL|Upper-limb-focused resistance training|
62413181|NCT06568627|ACTIVE_COMPARATOR|EscharEx (EX-03)|"EX-03 is the code name of the third generation of EscharEx investigational medicinal product (IMP) formulation. A sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb ), the active pharmaceutical ingredient (API), that is blended with excipients.~EX-03 5% powder, should be diluted with Water for Injection (WFI) prior usage."
62413182|NCT06568627|PLACEBO_COMPARATOR|Placebo|"Placebo (Gel Vehicle, hydrogel) contains the same excipients as in EX-03, without the API.~Placebo powder, should be diluted with Water for Injection (WFI) prior usage."
62413183|NCT03141346|ACTIVE_COMPARATOR|Control|A control health education program to promote general health and safety
62413184|NCT03141346|EXPERIMENTAL|Sugar Reduction Program Only|A health education program that focuses on sugar reduction
62413185|NCT03141346|EXPERIMENTAL|Sugar Reduction Program & Water Delivery|A health education program that focuses on sugar reduction and provides home bottled water delivery
62413186|NCT05353816|EXPERIMENTAL|Corheart 6 LVAS|Corheart 6 Left Ventricular Assist System (Corheart 6 LVAS) to be used on patients with end-stage heart failure.
62586572|NCT06431607|EXPERIMENTAL|Flu mRNA_YA_Group 1|Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
62586573|NCT06431607|EXPERIMENTAL|Flu mRNA_YA_Group 2|Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
62219036|NCT03831373|EXPERIMENTAL|Lower-limb-focused resistance training|Lower-limb-focused resistance training with elastic bands.
62219037|NCT03831373|ACTIVE_COMPARATOR|Stretching exercise|Stretching exercise program in a sitting position.
62219038|NCT04988867|EXPERIMENTAL|Drug - trofinetide|Oral dose of trofinetide
62219039|NCT06083779||Patients with endometrial cancer|the 108 patients with early to mid-stage endometrial cancer, more than 50% were in FIGO stages I/II.
62219040|NCT06083779||healthy people|108 healthy people
62586574|NCT06431607|EXPERIMENTAL|Flu mRNA_YA_Group 3|Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
62219041|NCT00808054|EXPERIMENTAL|Glucose and EMLA|Received glucose oral and topical EMLA
62219042|NCT00808054|EXPERIMENTAL|Glucose and placebo|Received glucose and no EMLA
62219043|NCT00808054|EXPERIMENTAL|Oral placebo and EMLA|Received oral placebo and EMLA
62219044|NCT02884895|EXPERIMENTAL|Intubating laryngeal Tube Suction|Intubating laryngeal Tube Suction
62219045|NCT02884895|ACTIVE_COMPARATOR|Direct Laryngoscopy|Direct Laryngoscopy
62219046|NCT00659178|EXPERIMENTAL|SB-485232 plus pegylated liposomal doxorubicin|Subjects will receive one dose of pegylated liposomal doxorubicin on Day 1 plus two doses of SB-485232 on Day 3 and Day 9 in each cycle.
62219047|NCT04874285|NO_INTERVENTION|control group|Women with risk factors for abortion, treated with progesterone
62219048|NCT04874285|EXPERIMENTAL|study group|Women with risk factors for abortion, treated with progesterone and a dietary supplement containing hyaluronic acid, alpha-lipoic acid, vitamin D and vitamin B6
62219049|NCT01157676|ACTIVE_COMPARATOR|Open cystectomy|Open cystectomy performed using an incision made just above or at the level of umbilicus to the pubic symphysis.
62219050|NCT01157676|ACTIVE_COMPARATOR|Robotic assisted radical cystectomy|Robotic assisted Radical Cystectomy (RARC) is accomplished by a robot assisted laparoscopic approach.
62219051|NCT03517033|EXPERIMENTAL|Test|Torrent's Nebivolol Tablets 20 mg
62219052|NCT03517033|ACTIVE_COMPARATOR|Reference|Forest Pharmaceuticals Inc's Bystolic Tablets 20 mg
62413187|NCT06651710|NO_INTERVENTION|Placebo|
62586575|NCT06431607|EXPERIMENTAL|Flu mRNA_YA_Group 4|Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
62586576|NCT06431607|ACTIVE_COMPARATOR|YA_Active Comparator Group 1|Eligible participants receive 1 dose of an active comparator at Day 1 intramuscularly.
62586577|NCT06431607|EXPERIMENTAL|Flu mRNA_OA_Group 1|Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
62586578|NCT06431607|EXPERIMENTAL|Flu mRNA_OA_Group 2|Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
62586579|NCT06431607|EXPERIMENTAL|Flu mRNA_OA_Group 3|Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
62586580|NCT06431607|EXPERIMENTAL|Flu mRNA_OA_Group 4|Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
62586581|NCT06431607|ACTIVE_COMPARATOR|OA_Active Comparator Group 2|Eligible participants receive 1 dose of an active comparator at Day 1 intramuscularly.
62586582|NCT06431607|EXPERIMENTAL|Flu mRNA_YA_Group 5|Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
62586583|NCT06431607|ACTIVE_COMPARATOR|YA_Active Comparator Group 3|Eligible participants receive 1 dose of an active comparator at Day 1 intramuscularly.
62586584|NCT06431607|EXPERIMENTAL|Flu mRNA_OA_Group 5|Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
62586585|NCT06431607|ACTIVE_COMPARATOR|OA_Active Comparator Group 4|Eligible participants receive 1 dose of an active comparator at Day 1 intramuscularly.
62586586|NCT05294692|EXPERIMENTAL|Financial Health Incentives|"After registration, users were instructed to (a) enable step count tracking and (b) 'carry their phone' as much as possible over a five-day baseline period. After the five-day baseline period, participants earned FIs in the form of 'points' ($0.10 USD per day) for reaching personalized daily step goals (calculated using the median step count during baseline). Points could be redeemed for movie tickets and gym passes. Daily step count goals were reassessed weekly and new step goals (past 30-day median) were introduced to each user on Sunday night over the 12-week intervention period. Users could also complete 2-4 health knowledge questionnaires or surveys per week for points (\~$0.25 USD per quiz); this served as an educational feature covering healthy eating and meeting PA guidelines (in line with the National Health Service (NHS), Live Well guidelines)."
62586587|NCT03551717||High cardiovascular risk patients|Adult patients hospitalized in the Cardiology Department of the University Hospital of Dijon Burgundy for acute coronary syndrome, patients between D1 and D5 of acute coronary syndrome, who can be moved for an ophthalmology consultation where the retinal imaging is done (heart monitoring in the presence of an experienced cardiologist if necessary)
62586588|NCT03551717||Low cardiovascular risk patients|"Adult patients recruited in the Ophthalmology Department of the University Hospital of Dijon Burgundy following a standard consultation for cataract surgery.~The age balance of the patients included in the two groups will be checked regularly."
62794816|NCT01174121|EXPERIMENTAL|2/Unselected TIL (CLOSED)|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young unselected TIL + high-dose aldesleukin (CLOSED)
62794817|NCT01174121|EXPERIMENTAL|3/Unselected TIL + Pembro Prior to Cells|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young unselected TIL + high-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeks following cell infusion
62794818|NCT01174121|EXPERIMENTAL|4/Unselected TIL + Pembro at POD|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young unselected TIL + high-dose aldesleukin + pembrolizumab within 4 weeks of progressive disease for up to 8 doses every 3 weeks
62413188|NCT06651710|EXPERIMENTAL|Zynamite® soluble 100mg|
62413189|NCT06651710|EXPERIMENTAL|Zynamite® soluble 150mg|
62413190|NCT01232075|EXPERIMENTAL|Extended letrozole regimen|
62413191|NCT01232075|ACTIVE_COMPARATOR|Clomiphene citrate regimen|
62413192|NCT06380101|EXPERIMENTAL|Nonessential Amino Acid Restriction (NEAAR) Medical Food|This is a single arm study in which all subjects will receive NEAAR medical food.
62413193|NCT06561698|EXPERIMENTAL|Dual therapy|
62413194|NCT06561698|EXPERIMENTAL|Minocycline bismush quadruple therapy|
62413195|NCT00489008|EXPERIMENTAL|Cohort 1|Stereotactic Body Radiation Therapy (SBRT) Stage I NSCLC
62413196|NCT00489008|EXPERIMENTAL|Cohort 2|Stereotactic Body Radiation Therapy (SBRT) Selective Stage II NSCLC
62413197|NCT00489008|EXPERIMENTAL|Cohort 3|Stereotactic Body Radiation Therapy (SBRT) Isolated Peripheral Lung Recurrent NSCLC
62413198|NCT01607580|EXPERIMENTAL|low-dose glucocorticoid|drug
62413199|NCT01607580|OTHER|no intervention after transplant|
62413200|NCT02555254|EXPERIMENTAL|Low speed of rewarming|Patients will be placed in targeted temperature controlled at 33°C for 24 hours. Then, intervention will be proceeded after randomization: slowly rewarmed (0.25°C/h) to targeted temperature controlled at 37°C for 24 hours.
62413201|NCT02555254|EXPERIMENTAL|Fast speed of rewarming|Patients will be placed in targeted temperature controlled at 33°C for 24 hours. hen, intervention will be proceeded after randomization: fastly rewarmed (0.50°C/h) for targeted temperature controlled at 37°C for 24 hours.
62413202|NCT04253028|EXPERIMENTAL|Subjects with NERv's Inline Device Attached|This arm contains subjects which will have NERv's Inline Device attached to their peritoneal drain after bariatric surgery (this includes: Roux-en-Y Gastric Bypass (RYGBP), Sleeve Gastrectomy (SG), Gastric Plication and Duodenal Switch).
62413203|NCT00864084|EXPERIMENTAL|Pulmonary rehabilitation|People with respiratory disease
62413204|NCT01845194|EXPERIMENTAL|Drug application|"Two treatment periods:~Treatment period 1:~three sequential oral and i.v. doses of 5 mg Metoprolol, 50 mg Talinolol, 2.5 mg Torsemide, 0.2 mg Midazolam and 50 mg Caffeine. At least 1 week of wash out between drug application~Treatment period 2:~combined application of a single oral dose of 2.5 mg Talinolol, 0.25 mg Torsemide, 5 mg Pravastatin, 1 mg Midazolam and 5 mg Codeine.~Treatment period 2 may take place after or before treatment period 1 with a time interval of at least 1 week"
62433290|NCT02625415|PLACEBO_COMPARATOR|Placebo|Topical application of B6 Placebo cream to the hand or/and feet 1-2 ml applied to the hand or /and feet three times a day for 4 weeks.
62586589|NCT06668324||ofatumumab|
62586590|NCT06668324||ocrelizumab SC formulation|
62794819|NCT00125957|EXPERIMENTAL|Wellbutrin first, then Placebo|Subjects randomly assigned to the Wellbutrin then Placebo group will receive 100mg BID of Wellbutrin at the first visit following intake (Week 0).Subjects will be increased to 150mg Wellbutrin BID at Week 1 unless moderate/severe side effects are reported. If subject and rater classify 1+ symptom as severe or 2+ symptoms as moderate, subject will continue on 100mg of bupropion qAM. If subject and rater classify 1+ symptom as moderate or 2+ mild as moderate, subject will continue on Wellbutrin 100mg BID. At Week 4, subjects will cross-over to placebo and will continue to take placebo until Week 8.
62794820|NCT00125957|EXPERIMENTAL|Placebo first, then Wellbutrin|Subjects randomly assigned to the Placebo then Wellbutrin group will receive placebo until Week 4 when they will cross-over to active drug. At Week 4, subjects will be assigned 100mg Wellbutrin BID. At Week 5, Subjects will be increased to 150mg Wellbutrin BID unless moderate/severe side effects are reported. If subject and rater classify 1+ symptom as severe or 2+ symptoms as moderate, subject will continue on 100mg of Wellbutrin qAM. If subject and rater classify 1+ symptom as moderate or 2+ mild as moderate, subject will continue on bupropion 100mg BID. Subject will continue on the assigned dosage until Week 8 of study.
62794821|NCT04561258|EXPERIMENTAL|Low Dose Cohort|A single infusion of ≥1x10e8 and \<1x10e9 genetically modified T cells.
62794822|NCT04561258|EXPERIMENTAL|High Dose Cohort|A single infusion of ≥1x10e9 and \<5x10e9 genetically modified T cells.
62794823|NCT03507673||Progynova/Dydrogesterone|
62794824|NCT03507673||Spontaneous cycle|
62794825|NCT03507673||Progynova/Crinone|
62413205|NCT04995510||Chronic Obstructive Pulmonary Disease Group|Individuals diagnosed with chronic obstructive pulmonary disease by ''Bolu Abant Izzet Baysal University'' Faculty of Medicine, Department of Chest Diseases and referred to the Physiotherapy and Rehabilitation Department of Bolu Abant Izzet Baysal University Health Sciences Faculty
62794826|NCT03507673||Others Medication|
62794827|NCT05870423|EXPERIMENTAL|PRRT + olaparib 100mg q.d.|administration of the standard therapy of 7.4GBq 177lu-dotatate with the additional study medication olaparib 100mg q.d.
62794828|NCT05870423|EXPERIMENTAL|PRRT + olaparib 100mg b.i.d.|administration of the standard therapy of 7.4GBq 177lu-dotatate with the additional study medication olaparib 100mg b.i.d.
62794829|NCT05870423|EXPERIMENTAL|PRRT + olaparib 200mg b.i.d.|administration of the standard therapy of 7.4GBq 177lu-dotatate with the additional study medication olaparib 200mg b.i.d.
62794830|NCT05870423|EXPERIMENTAL|PRRT + olaparib 300mg b.i.d.|administration of the standard therapy of 7.4GBq 177lu-dotatate with the additional study medication olaparib 300mg b.i.d.
62794831|NCT04979676|EXPERIMENTAL|Cognitive Therapy|Experimental group subjected to active individual psychotherapy based on developing skills relating to flexibility of attention, which in turn sustains adolescents adopting a more realistic perspective on social events and acting based on external (and not only internal) social information. Assessed weekly during the intervention period on symptom change. Also assessed at pre-intervention, post-intervention (i.e., 10 to 12 weeks later), 12-weeks follow, and 24-weeks follow-up.
62794832|NCT04979676|EXPERIMENTAL|Compassion-focused Therapy|Experimental group subjected to active individual psychotherapy based on developing skills relating to flexibility of attention, which in turn sustains adolescents adopting a more realistic perspective on social events and acting based on external (and not only internal) social information. Assessed weekly during the intervention period on symptom change. Also assessed at pre-intervention, post-intervention (i.e., 10 to 12 weeks later), 12-weeks follow, and 24-weeks follow-up.
62794833|NCT04979676|EXPERIMENTAL|Acceptance and Commitment Therapy|Experimental group subjected to active individual psychotherapy based on developing skills for acceptance, defusing, and focusing on the present moments, which in turn sustain acting in social events in line with ones valued actions instead of prioritizing the avoidance of negative internal experiences). Assessed weekly during the intervention period on symptom change. Also assessed at pre-intervention, post-intervention (i.e., 10 to 12 weeks later), 12-weeks follow, and 24-weeks follow-up.
62794834|NCT04979676|PLACEBO_COMPARATOR|Waiting-list control|Group of participants with a main dignosis os social anxiety disorder not subjected to any psychological intervention within the current trial. Assessed at time 0, then at time 1 ten to twelve weeks after time 1, then again at time 3 twelve weeks later, and then again at time 4 another twelve weeks later (i.e., 24 weeks after time 1).
62794835|NCT00813189|EXPERIMENTAL|1 : early start (GH treatment) group|in the early start group, patients were treated with growth hormone for one year immediately after randomisation
62794836|NCT00813189|NO_INTERVENTION|2 :delayed start (GH treatment) group|in the delayed start group patients took GH treatment for 1 year , 6 months after randomisation
62219053|NCT02388854||Endometriosis|Sardinian Women with diagnosis of endometriosis
62794837|NCT01180686|ACTIVE_COMPARATOR|Multiple thrust Impulse instrument|This instrument automatically delivers 12 thrusts at the same intensity over the joint involved.
62794838|NCT01180686|ACTIVE_COMPARATOR|Single impulse Activator IV instrument|This is a manual spring loaded device that delivers one thrust to the joint involved
62413206|NCT04995510||Healthy Group|Volunteer healthy individuals with similar demographic characteristics and without any diagnosed disease will be recruited
62413207|NCT00631709|EXPERIMENTAL|1|Pacemaker Patients
62413208|NCT00860054|EXPERIMENTAL|Medium Phytosterols|Diets with daily 400 mg of phytosterols
62794839|NCT04585841|EXPERIMENTAL|Intervention group|Cancer patients receiving cannabidiol
62794840|NCT04585841|NO_INTERVENTION|Control group|Cancer patients not receiving cannabidiol
62219054|NCT02388854||Controls|Healthy blood Sardinian donors
62219055|NCT05973695|ACTIVE_COMPARATOR|Group A: Clamshell Exercise|Group A will be treated with baseline treatment and clamshell exercises. Lie on your side with your knees slightly bent and with one leg on top of the other. Keep your feet together and lift your top knee until its parallel with your hip. Lower your knee back to the initial position, repeat, and then switch sides. In 1st week 1 sets 10 repetitions. In 2nd week 2 sets of 10 repetitions. In 3rd and 4th week and onwards 3 sets of 10 repetitions.
62413209|NCT00860054|EXPERIMENTAL|High Phytosterols Diet|Diet with 2000 mg of daily phytosterols
62413210|NCT00860054|PLACEBO_COMPARATOR|Low Phyto Diet|Diet with less than 100 mg of daily phytosterols
62413211|NCT04795973|EXPERIMENTAL|time-restricted fasting for 4 weeks|
62794841|NCT05952557|ACTIVE_COMPARATOR|Arm A: standard endocrine therapy of investigator´s choice ± abemaciclib|standard endocrine therapy of investigator's choice (aromatase inhibitors \[AI; exemestane, letrozole, anastrozole\] or tamoxifen) ± abemaciclib
62794842|NCT05952557|EXPERIMENTAL|Arm B: camizestrant ± abemaciclib|camizestrant ± abemaciclib
62794843|NCT02316496|EXPERIMENTAL|open label , single arm|cetuximab - irinotecan until progression or unacceptable toxicity
62794844|NCT03319004|EXPERIMENTAL|Compare bispectral index and phase lag entropy|
62794845|NCT02682667||1/Cohort 1|Patients with cancer or a premalignant condition or at risk of cancer from an immunodeficiency
62794846|NCT05899400||Study Group|400 Male and Female Ugandan Africans
62413212|NCT04795973|EXPERIMENTAL|5:2 regimen for 4 weeks|
62413213|NCT01407107|EXPERIMENTAL|Nitroglycerin|Dose escalation trial of Nitroglycerin
62413214|NCT06019533|EXPERIMENTAL|LVDS|
62413215|NCT01231880|EXPERIMENTAL|Four monthly IPT|IPT give once a school term (every four months)
62413216|NCT01231880|EXPERIMENTAL|Monthly IPT|IPT given every month
62413217|NCT01231880|PLACEBO_COMPARATOR|Placebo|No active drug in the placebo
62413218|NCT03973723||Patients with NPC after treatment|All patients with NPC without distant metastases who receiving adequate RT dose
62794847|NCT03407755|ACTIVE_COMPARATOR|Air|Intraocular 100% atmospheric air (anterior chamber).
62794848|NCT03407755|EXPERIMENTAL|SF6|Intraocular 20% sulphur hexaflouride (anterior chamber).
62413219|NCT03372772|NO_INTERVENTION|Control group|Control group - patients with only levothyroxine therapy
62413220|NCT03372772|EXPERIMENTAL|Intervention group|Intervention Group- Patients with levocarnitine supplementation in addition to levothyroxine therapy
62413221|NCT00703261|ACTIVE_COMPARATOR|10 mg Atorvastatin|10 mg atorvastatin + placebo
62413222|NCT00703261|ACTIVE_COMPARATOR|80 mg Atorvastatin|80 mg atorvastatin + placebo
62413223|NCT06292728|EXPERIMENTAL|Treatment|
62413224|NCT05591404|EXPERIMENTAL|Film + TSST|Nature Film + Trier Social Stress Test (TSST)
62413225|NCT05591404|NO_INTERVENTION|Film Only (No-TSST)|Nature Film Only
62413226|NCT06702098|EXPERIMENTAL|Cell therapy group|Intravenous infusion of iNK cells is given to the subject, 5\*108 to 1\*109 cells/dose, two doses per week, a total of 8 doses. And then 1\*109 cells/dose, one doses every 4 weeks , a total of 5 doses.
62413227|NCT03328286|EXPERIMENTAL|Weekly group meeting w/psychotherapist|All the participants fulfilling the eligibility criteria are asked to take part in an additional Intervention. The Intervention is a weekly group Meeting with a psychotherapist to discuss issues or Problems the Group members have
62413228|NCT04285983||Trelagliptin 25 mg|Trelagliptin 25 milligrams (mg) tablet, orally, once weekly for up to 12 months. Participants received interventions as part of routine medical care.
62794849|NCT06725550|EXPERIMENTAL|Needling Acupuncture - 5 weeks|Needling acupuncture treatment will last 30 minutes per session and will be administered two times per week for 5 weeks. Each subject will receive one course of treatment which contains 10 treatment sessions.
62794850|NCT06725550|EXPERIMENTAL|Laser Acupuncture - 5 weeks|Laser acupuncture treatment will also last 30 minutes per session and will be administered two times per week for 5 weeks. Each subject will receive one course of laser acupuncture treatment which contains 10 treatment sessions.
62794851|NCT06725550|EXPERIMENTAL|Needling Acupuncture - 12 weeks|Needling acupuncture treatment will last 30 minutes per session and will be administered once per week for 12 weeks. Each subject will receive one course of treatment which contains 12 treatment sessions.
62413229|NCT06105008|EXPERIMENTAL|Disitamab Vedotin + Toripalimab|Disitamab Vedotin（RC48-ADC）with Toripalimab （JS001）arm
62413230|NCT06105008|ACTIVE_COMPARATOR|Disitamab Vedotin|Disitamab Vedotin（RC48-ADC） arm
62413231|NCT00764127||Obese Control|
62413232|NCT00764127||Normal Control|
62413233|NCT00764127||OVERWEIGHT ADOLESCENT PATIENTS UNDERGOING BARIATRIC SURGERY|
62413234|NCT01394120|EXPERIMENTAL|Tarteted Therapy|
62413235|NCT01394120|ACTIVE_COMPARATOR|Standard Chemotherapy|
62413236|NCT04935931|EXPERIMENTAL|Pilot|Pre/post fMRI
62413237|NCT05927194|EXPERIMENTAL|Using the Connect|Using The Connect (UTC) is a game-based learning program designed for middle school-aged youth (ages 9-15 or grades 6-8) consisting of four games played in a facilitated environment, and one take-away activity. The goals of the program include:To be a vehicle that encourages community sharing of healthy teen behavior. To facilitate safe connections between youth and adults in their community. To empower youth to lead healthy sexual lives. The four games each focus on specific health content or skills including growth and development, accessing information, positive communication, and decision-making. Each of the four games is intended to be played for a total of 90 minutes, split up into sessions of 30 minutes per game. When combining all gameplay sessions, along with the instructions for the take-away activity and program wrap-up activity, organizations will dedicate approximately 8 hours to the program.
62794852|NCT06725550|EXPERIMENTAL|Laser Acupuncture - 12 weeks|Laser acupuncture treatment will also last 30 minutes per session and will be administered once per week for 12 weeks. Each subject will receive one course of laser acupuncture treatment which contains 12 treatment sessions.
62794853|NCT05730413|ACTIVE_COMPARATOR|Once Daily Regimen|Patients who take bisoprolol 5 mg per day.
62794854|NCT05730413|EXPERIMENTAL|Twice Daily Regimen|Patients who take bisoprolol 2.5 mg twice per day.
62794855|NCT05721170|ACTIVE_COMPARATOR|Beta-blockers continuation|Patients assigned in the beta-blockers continuation arm will be receiving per os beta blocker medication for at least 72 hours before TAVI without interruption after it.
62794856|NCT05721170|ACTIVE_COMPARATOR|Beta-blockers interruption|Patients assigned to interrupt the beta-blockers treatment will abstain from beta blockers for at least 7 days after TAVI.
62413238|NCT05927194|NO_INTERVENTION|Business as Usual|Participants will not receive the Using the Connect curriculum.
62022807|NCT05631067|EXPERIMENTAL|BP monitoring arm|Participants will be adults \>18 years of age admitted for delivery with a diagnosis of HDP (i.e., chronic hypertension, gestational hypertension, preeclampsia, eclampsia, the HELLP syndrome, or chronic hypertension with superimposed preeclampsia) per the American College of Obstetricians and Gynecologists Criteria.
62413239|NCT05880537||Open Label|Open Label for subjects with End-Stage Renal Disease
62586591|NCT03443622|EXPERIMENTAL|SC-43 100 mg/day|SC-43 Oral Solution (100 mg/ml), 1 ml by mouth, q.d. for 28 days
62586592|NCT03443622|EXPERIMENTAL|SC-43 200 mg/day|SC-43 Oral Solution (100 mg/ml), 2 ml by mouth, q.d. for 28 days
62022808|NCT05631067|ACTIVE_COMPARATOR|Control arm|Control participants will be adults \>18 years of age with an uncomplicated pregnancy and delivery, and without a diagnosis of HDP.
62794857|NCT01540357|ACTIVE_COMPARATOR|Mindfulness-based therapy|Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
62022809|NCT02888405|EXPERIMENTAL|High-carbohydrate diet|Single day of 9 g/kg body weight consumption of carbohydrate. Isocaloric to very low-carbohydrate condition.
62413240|NCT05636475|EXPERIMENTAL|Manuel hand massage group|According to the hand massage training received, the patient coming out of the surgery is in diamond shape for ten minutes for each hand.
62413241|NCT05636475|EXPERIMENTAL|machine-based hand massage|The pressure setting of the machine is made according to the manual massage application method. In manual massage and machine massage, machine adjustments are made to keep the temperature and pressure difference as low as possible. A hand massage is done for ten minutes for each hand.
62794858|NCT01540357|ACTIVE_COMPARATOR|Treatment after waiting time|Treatment was performed after completion of the active arm.
62794859|NCT05712720|EXPERIMENTAL|Group 1 - 50 mg RZ402|
62794860|NCT05712720|EXPERIMENTAL|Group 2 - 200 mg RZ402|
62794861|NCT05712720|EXPERIMENTAL|Group 3 - 400 mg RZ402|
62794862|NCT05712720|PLACEBO_COMPARATOR|Group 4 - Placebo|
62794863|NCT01950403|EXPERIMENTAL|Arm I (linaclotide acetate)|Participants receive linaclotide acetate PO QD on days 1-7.
62794864|NCT01950403|PLACEBO_COMPARATOR|Arm II (placebo)|Participants receive placebo PO QD on days 1-7.
62794865|NCT06113211|ACTIVE_COMPARATOR|Narcotic Postoperative Pain Control|Standard of care control group given standard opioid pain control regimen.
62413242|NCT05636475|NO_INTERVENTION|Control group|The control group will be treated only according to the clinical analgesia protocol.
62413243|NCT03157934||Primary CSC (Comprehensive Stroke center) admission|Patients with primary admission to endovascular-ready hospital (comprehensive stroke center)
62413244|NCT03157934||Primary non-CSC (non-Comprehensive Stroke Center) SU (Stroke Unit) admission|Patients with primary admission to non-endovascular-ready hospital with (regional/local) stroke unit
62413245|NCT03157934||Non-acute stroke hospital admission|Patients with primary admission to non-acute stroke-ready hospital
62413246|NCT01759056|ACTIVE_COMPARATOR|AVX 470|AVX 470 0.2 g(Cohort 1), 1.6 g (Cohort 2) and 3.5 g (Cohort 3) will be administered daily for 28 days
62586593|NCT03443622|EXPERIMENTAL|SC-43 400 mg/day|SC-43 Oral Solution (100 mg/ml), 4 ml by mouth, q.d. for 28 days
62586594|NCT03443622|EXPERIMENTAL|SC-43 600 mg/day|SC-43 Oral Solution (100 mg/ml), 6 ml by mouth, q.d. for 28 days
62586595|NCT03443622|EXPERIMENTAL|SC-43 900 mg/day|SC-43 Oral Solution (100 mg/ml), 9 ml by mouth, q.d. for 28 days
62794866|NCT06113211|EXPERIMENTAL|Nonnarcotic Postoperative Pain Control|Experimental group given nonopioid pain control regimen.
62794867|NCT01637155|EXPERIMENTAL|Cholecalciferol|
62022810|NCT02888405|EXPERIMENTAL|Very low-carbohydrate diet|Single day of 1 - 1.5 g/kg body weight consumption of carbohydrate. Isocaloric to high-carbohydrate condition.
62022811|NCT05263388|EXPERIMENTAL|REKOVELLE (Follitropin Delta)|
62586596|NCT03443622|EXPERIMENTAL|SC-43 1200 mg/day|SC-43 Oral Solution (100 mg/ml), 12 ml by mouth, q.d. for 28 days
62586597|NCT02126423||1st intravitreal injection|Conjunctival and nasopharyngeal swabs are obtained from each treatment-naive patient receiving their 1st intravitreal injection
62413247|NCT01759056|PLACEBO_COMPARATOR|Placebo|Placebo will be administered daily for 28 days as a comparator with AVX-470 (all dose groups)
62413248|NCT01814917|EXPERIMENTAL|MCI-196 (Flexible dose)|MCI-196 BSA eq 3g, 6g, 9g, 12g or 15g
62413249|NCT01814917|ACTIVE_COMPARATOR|CBPB|Calcium-based P binder
62413250|NCT03635060|ACTIVE_COMPARATOR|Dorsal Bridge Plating|The intervention is surgery with dorsal distraction plating with or without any additional fragment specific fixation.
62413251|NCT03635060|ACTIVE_COMPARATOR|Volar Locking Plating|The intervention is surgery with open reduction and internal fixation with non-spanning fixation.
62413252|NCT05555745|EXPERIMENTAL|Audio-based behavioral activation intervention|This intervention consists of two audio-based sessions delivered one week apart. The first session lasts approximately 30 minutes, and the second session lasts approximately 15 minutes. The sessions are audio recordings. The first session introduces behavioral activation and provides instruction for how to schedule and engage in positively reinforcing activities. The second session recaps the principles of behavioral activation and guides participants through methods of troubleshooting. After each session, participants are asked to create an activity schedule for the coming week. Then, each day in the week following each session, participants receive an email with a survey asking them to report on their activity and mood in the previous day.
62413253|NCT05555745|ACTIVE_COMPARATOR|Audio-based self-monitoring intervention|This intervention consists of two audio-based sessions delivered one week apart. The first session lasts approximately 30 minutes, and the second session lasts approximately 15 minutes. The sessions are audio recordings. The first session introduces information about emotion and provides instruction for how to track emotion using self-monitoring. The second session provides more information about emotion and recaps instructions for self-monitoring. Each day in the week following each session, participants receive an email with a survey asking them to report on their mood in the previous day.
62413254|NCT06566976|EXPERIMENTAL|Prehabilitation|Subjects randomized to the prehabilitation group will undergo 6 weeks of individualized exercise therapy, including a 1-week ramp-up period (3 sessions) conducted at the VAPAHCS rehabilitation facility. Subjects will then exercise primarily at home, with an in-clinic exercise session repeated weekly for the duration of their participation. These sessions will be individualized based on tolerance and in accordance with standardized guidelines, but will generally consist of 45-60 min of supervised exercise that combines aerobic and resistance training, including warm-up and cool-down. Throughout the study, subjects will be asked to perform 30 minutes of daily unsupervised aerobic exercise of their choice, with an emphasis on improving walking performance at home. Guidelines for patient monitoring, safety, and prescription outlined by the American Heart Association, American College Sports Medicine, and American Association of Cardiovascular and Pulmonary Rehabilitation will be followed.
62413255|NCT06566976|ACTIVE_COMPARATOR|Rehabilitation|Subjects randomized to the rehabilitation group will initiate exercise sessions approximately 2-weeks following endovascular intervention as outlined in guidelines for PAD. Patient stability and wound patency will be paramount considerations prior to a patient beginning the rehabilitation program. Similar to prehabilitation, subjects will undergo a 1-week, 3 session familiarization period conducted at the VAPAHCS rehabilitation facility, then return once weekly for in-clinic supervised sessions. The weekly in-person visits will be conducted at the rehabilitation center to monitor and encourage compliance, review activity questionnaires, download accelerometry data, and address any clinical concerns. Similar to participants in the prehabilitation group, the 6-week rehabilitation period will be individualized and follow standardized guidelines designed for rehabilitation in patients with PAD.
62413256|NCT06566976|EXPERIMENTAL|Prehabiliation and Rehabilitation|Subjects randomized to the prehabilitation and rehabilitation group will undergo both the 6 weeks of prehabilitation pre-operative and 6 weeks of rehabilitation post-operative as described in their respective arm descriptions.
62413257|NCT04220073|EXPERIMENTAL|JS005|
62413258|NCT04220073|PLACEBO_COMPARATOR|placebo|
62413259|NCT04257773|EXPERIMENTAL|Immediate Treatment|Participants in this group will receive treatment/intervention immediately.
62413260|NCT04257773|EXPERIMENTAL|Delayed Treatment|Participant in this group will receive treatment/intervention 2-week later.
62413261|NCT03353415|OTHER|Masked CGM Wear (Phase 1)|Each participant will wear the Dexcom CGM for two sequential phases. During the first phase, participants will not be able to read the sensor glucose levels (masked).
62413262|NCT03353415|EXPERIMENTAL|Unmasked CGM Wear (Phase 2)|In the second phase, participants will be able to read the sensor glucose levels (unmasked). Frequency of hypoglycemia will be compared between the two phases of the study.
62413263|NCT04736316|EXPERIMENTAL|Early CCLAD|Early community client-led ART delivery groups
62413264|NCT01360021|ACTIVE_COMPARATOR|1 Symbicort/inhaler|Symbicort BA MDI 2x160/4.5 μg twice daily
62413265|NCT01360021|ACTIVE_COMPARATOR|Symbicort/inhaler|Symbicort AC pDMI 2x160/4.5 μg twice daily
62413266|NCT01360021|ACTIVE_COMPARATOR|Budesonide/inhaler|Budesonide AC pMDI 2x160 μg twice daily
62413267|NCT06554678|EXPERIMENTAL|Transnasal humidified rapid insufflation ventilatory exchange（THRIVE） group|
62794868|NCT06547450|EXPERIMENTAL|5-session UP condition|In both conditions, the contents of the UP manual were worked following the 2nd edition of the UP manual (Barlow et al., 2018). In the 5-session version, modules 1 (Motivation for change and commitment to treatment) and 8 (Achievement, maintenance, and relapse prevention) were removed and modules 6 and 7 (interoceptive and emotional exposure) were combined. The sessions were group sessions, 2 hours long and weekly.
62794869|NCT06547450|ACTIVE_COMPARATOR|8-session UP condition|In both conditions, the contents of the UP manual were worked following the 2nd edition of the UP manual (Barlow et al., 2018). In the 8-session UP condition, each of the original 8 treatment modules was worked on per week. The sessions were group sessions, 2 hours long and weekly.
62794870|NCT00913419|EXPERIMENTAL|1|Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories
62794871|NCT00913419|ACTIVE_COMPARATOR|2|Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp \& Dohme
62794872|NCT06137976|EXPERIMENTAL|Gastric decompression|Placement of the nasogastric or orogastric tube will occur after intubation while surgeons are scrubbing and out of the room to maintain blinding. At the end of surgery, the nasogastric or orogastric tube will be removed prior to removal of the surgical drapes to ensure the surgeon remains blinded. Patients will then be returned to routine post-operative care as otherwise planned or necessitated by surgery.
62586598|NCT02126423||>20 intravitreal injections|Conjunctival and nasopharyngeal swabs are obtained from each patient with \>20 intravitreal injection therapies.
62586599|NCT05525403|EXPERIMENTAL|Low Fatigue Exercise|Participants will complete a single leg knee extension exercise with weight until they report a fatigue level = 3/10 on the Borg Rating of Perceived Exertion. Participants will complete three sets.
62794873|NCT06137976|NO_INTERVENTION|No gastric decompression|No placement of gastric decompression tube.
62794874|NCT04305366||Head and Neck Cancers|This study will target patients with a diagnosis squamous cell carcinoma in the head and neck. In addition, this study will also target patients undergoing tonsillectomy or sleep surgery as the control group. This study will aim to enroll an equal number of patients into both the study group and control group. However, this will be dependent on patient encounters within the adult ENT clinic.
62794875|NCT06726746|EXPERIMENTAL|intervention by using the Fractional CO2 laser|". Using the following settings with the internal handpiece: square pattern with Deep Mode, fractional density of 5% and energy level of 50 mJ and fluence of 283 J/cm2. The handpiece will be inserted into the vagina (up to 10 cm) The handpiece will be positioned with contact to the vagina and will be rotated to apply 12 pulses at each 1-cm marking (application of laser energy at 3-10-cm depths) until the distal end of the vaginal probe reaches the introitus.~The laser application will be performed on an outpatient basis without local anesthesia in outpatient clinic."
62022812|NCT05263388|ACTIVE_COMPARATOR|GONAL-F (Follitropin Alfa)|
62022813|NCT03883672|EXPERIMENTAL|hematopoietic stem cell transplantation|Personality and transactional factors involved in the process and outcomes of hematopoietic stem cell transplantation
62022814|NCT04088981|ACTIVE_COMPARATOR|Low-fat, vegan diet|For a 22-week period, participants will be asked to follow a low-fat vegan diet which consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. In choosing grain products and starchy vegetables (e.g., bread, potatoes), participants will be encouraged to select those retaining their natural fiber and having a glycemic index \<70, using tables standardized to a value of 100 for glucose.
62413268|NCT06554678|ACTIVE_COMPARATOR|conventional oxygen mask group|
62794876|NCT00584519||500 patients|Patients with diagnosis of schizophrenia, schizophreniform or schizoaffective disorder (DSM-IV TR) with BMI (body mass index) more or equal to 25 Kg/m2
62022815|NCT04088981|ACTIVE_COMPARATOR|Portion-controlled diet|For a 22-week period, participants will be asked to follow a portion-controlled diet which will include individualized diet plans that reduce daily energy intake by 500 kcal for overweight participants, and keep carbohydrate intake reasonably stable over time. It will derive 50% of total energy from carbohydrates, 20% from protein, and less than 30% from fat (≤7% saturated fat), with less than 200 mg/day of cholesterol/day.
62219056|NCT05973695|ACTIVE_COMPARATOR|Group B: Gluteal Bridge exercise|Group B will be treated with baseline treatment and Gluteal Bridge exercises. Start flat on your back with your legs bent at a 90-degree angle and feet placed flat on the ground. Make sure your toes are turned outward at 45-degree angles and your knees are facing in the same direction as your toes. Drive down through your feet and push your hips up. You should feel this variation fatiguing the outer portion of your thighs. Make sure you keep your knees over your toes throughout the entire movement. Don't let them move forward over the toes. In a controlled motion, let your hips sink back down toward the ground. This completes 1 repetition. Perform 3 sets of 15 repetitions, or 3 rounds of a 30-second hold.
62219057|NCT02112747|NO_INTERVENTION|Arm 1: website access only|There is no intervention with this arm. Completion of the website is part of enrollment.
62413269|NCT03052374|NO_INTERVENTION|Control Group|Mothers will receive standard care such as referral to psychotherapy (intervention mothers will have the same access) over the same length of time.
62794877|NCT03502447|EXPERIMENTAL|TearCare|TearCare subjects will receive TearCare thermal treatment followed by manual clearing of the meibomian glands.
62022816|NCT06098521|EXPERIMENTAL|CONSENT and Follow-up|The therapy in the CONSENT program will be delivered twice a week (total time 12 ± 2 weeks), with measurement after 16±2 weeks. Participants in this arm will have a follow-up period of 16±2 weeks.
62219058|NCT02112747|EXPERIMENTAL|Arm 2: patient navigator|"The intervention consists of participants receiving the services of a patient navigator to address individual barriers to adhering to the personal prescription for colon and rectal cancer screening."
62794878|NCT03502447|ACTIVE_COMPARATOR|Warm Compress & Lid Massage|Subjects will perform warm compress and lid massage at home daily.
62794879|NCT03146546||Sepsis|Patients with sepsis as defined by the Sepsis-3 criteria
62794880|NCT03146546||Control|Patients without sepsis, as defined by the Sepsis-3 criteria
62794881|NCT04721210|EXPERIMENTAL|Frequency of 1 Hz|continuous stimulation with a frequency of 1 Hz, 2000 pulses, 10 days-daily;
62413270|NCT03052374|EXPERIMENTAL|VID-KIDS Intervention Program Group|RN review photos of infant engagement/disengagement cues. NCAST Teaching Activity, mothers asked to perform task advanced for infant's level, recorded. 1st-View, no feedback, mothers reveal infant cues. RN records infant/mother's response, later discussion. 2nd, RN and mother co-view interaction with time for replay/review parts of sensitivity and responsiveness. RN feedback: praising desired maternal behaviours; information on infant cues; maternal response to infant distress; and use of cognitive growth fostering language. 3rd, all concepts discussed in past views, use positive reinforcement to affirm aspects of sensitivity, useful feedback for areas of growth. Post-Debrief, RN and mother discuss interests of the mother. Mothers encouraged to note infants' engagement/disengagement cues.
62413271|NCT01382680|ACTIVE_COMPARATOR|Classic guidewires|Conventional guidewires used in combination as preferred by the investigating ERCP specialist
62413272|NCT01382680|ACTIVE_COMPARATOR|New guidewire (G240)|Primary use of the new guidewire (G240)
62586600|NCT05525403|EXPERIMENTAL|High Fatigue Exercise|Participants will complete a single leg knee extension exercise with weight until they report a fatigue level = 8/10 on the Borg Rating of Perceived Exertion. Participants will complete three sets.
62586601|NCT05525403|ACTIVE_COMPARATOR|Quiet Rest|Participants will rest quietly for two minutes, three sets.
62794882|NCT04721210|EXPERIMENTAL|Frequency of 10 Hz|continuous stimulation with a frequency of 10 Hz-10 seconds with a pause of 50 seconds, 2000 pulses, 10 days-daily;
62794883|NCT04721210|PLACEBO_COMPARATOR|Continuous stimulation placebo|continuous stimulation placebo
62794884|NCT04661007|EXPERIMENTAL|Part 1 : tafasitimab monotherapy|Dose-finding to evaluate the safety and tolerability and to determine the RP2Ds of single-agent tafasitamab in Japanese participants with NHL. Part 1 consists of 1 group (Group 1) to evaluate weight-based doses of tafasitamab.
62794885|NCT04661007|EXPERIMENTAL|Part 2 : tafasitamab combination therapy|tafasitamab will be combined with lenalidomide (Group 3) or parsaclisib (Group 4a) in R/R DLBCL participants or lenalidomide plus R-CHOP (Group 5) in previously untreated DLBCL participants. Modified tafasitamab dosing when combined with lenalidomide (Group 2) in participants with R/R DLBCL will be evaluated to determine the recommended clinical dose. The dose of tafasitamab will be based on the weight-based RP2D that is deemed safe and tolerable in Part 1.
62794886|NCT04661007|EXPERIMENTAL|Part 3 : Dose Expansion of tafasitamab +parsaclisib|tafasitamab in combination with parsaclisib will be further evaluated in Group 4b at RP2D determined in Part 2
62794887|NCT04661007|EXPERIMENTAL|Part 4: tafasitamab combination therapy|tafasitamiab in combination with lenalidomide will be further evaluated in Group 6 at RP2D determined in Part 2.
62022817|NCT06098521|EXPERIMENTAL|Waiting list and CONSENT|Participants will be on waiting list for 16±2 weeks. After waiting list participants are offered the CONSENT program including therapy delivered twice a week (total time 12 ± 2 weeks), with measurement after for 16±2 weeks.
62022818|NCT05497843|EXPERIMENTAL|Chiauranib capsule|Patients take chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression
62022819|NCT03663075|EXPERIMENTAL|Group 1|This group will receive the intervention Group information (GI).
62219059|NCT02112747|NO_INTERVENTION|Arm 3: genetic counseling|There is no intervention in this arm. Patients diagnosed as positive for Lynch Syndrome use genetic counseling to discuss medical and family history and genetic risk of CRC, including genetic factors such as DNA mismatch repair genes, autosomal dominant inheritance, cancer risks associated with LS, screening recommendations, and genetic testing. There is no intervention. This is standard care.
62219060|NCT02112747|EXPERIMENTAL|Arm 4:Gen. counselor & patient navigator|Participants diagnosed positive for Lynch syndrome use genetic counseling as in Arm 3 and in addition receive the services of a patient navigator to address individual barriers to adhering to the CRC screening recommendations.
62219061|NCT03329274||Patients with Erdheim-Chester Disease and Other Histiocytoses|
62794888|NCT04046146|EXPERIMENTAL|NIR-ICG MRL|We may ask healthy subjects to return for up to four injection sessions for the study. The first injection session will consist of intradermal injection of ICG into the webspaces of the hand as done in our previous studies followed by NIR camera imaging. The second session will consist of intradermal gadolinium injection and intravenous (IV) iron contrast agent followed by MRI imaging approximately 1 week after the first session. The third session will occur at minimum eight weeks later and entail intra-articular ICG injection in order to evaluate drainage via the lymphatics. The MCP joints will be identified in the non-dominant hand and injected with ICG. Approximately one week later, the fourth session will compromise of intra-articular gadolinium injection and IV iron contrast to confirm lymphatic drainage. The MCP joints of the non-dominant hand will again be identified and injected with gadolinium.
62219062|NCT06079541|EXPERIMENTAL|JMKX003142 SAD experimental group|Participants will be randomized into 7 cohorts to receive single oral dose of JMKX003142 on Day 1. The doses in each cohort will be escalated based on the safety and pharmacokinetics (PK) / Pharmacodynamics (PD) data of the previous cohort.
62219063|NCT06079541|EXPERIMENTAL|JMKX003142 MAD experimental group|Participants will be randomized into 3 cohorts to receive orally once -daily of JMKX003142 for 7 consecutive days. The second cohort will be escalated based on the safety and pharmacokinetics (PK)/ Pharmacodynamics (PD) data of the previous cohort.
62413273|NCT04874701|EXPERIMENTAL|Capsimax|
62413274|NCT04874701|PLACEBO_COMPARATOR|Placebo|Placebo, 2 capsules per day, for 12 weeks
62413275|NCT05246150||infants receiving nursing care|
62586602|NCT01932710|EXPERIMENTAL|White Blood Cell Transfusion|Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment is tolerated. Patient receives a transfusion every 3-4 days (at least 2 a week) for up to 6 weeks.
62794889|NCT04220554|EXPERIMENTAL|Intervention group|"Intervention group:~All participants will be instructed how to use of the medication according to the fingertip unit for topical steroids. All participants will be prescribed topical drugs based on shared decision between the prescriber and patient. The topical drugs will be either moderate corticosteroids (clobetasone-17-butyrate or hydrocortisone-17-butyrate), potent corticosteroids (betamethasone-17-valerate and betamethasone, mometasone furoate, fluocinolone acetonide or fluocinonide), very potent corticosteroids (clobetasol propionate), corticosteroids with antimicrobials (betamethasone and clioquinol, betamethasone and fusidic acid or fluocinolone acetonide and clioquinol), corticosteroid with calcipotriol or calcipotriol cream.~During the study period, a nurse or pharmaconomist will deliver;~* Improved support and instructions to the patients~* Patients will receive a diary and access to more consultations."
62794890|NCT04220554|NO_INTERVENTION|Non-intervention group|"All participants will be instructed how to use of the medication according to the fingertip unit for topical steroids. All participants will be prescribed topical drugs based on shared decision between the prescriber and patient. The topical drugs will be either moderate corticosteroids (clobetasone-17-butyrate or hydrocortisone-17-butyrate), potent corticosteroids (betamethasone-17-valerate and betamethasone, mometasone furoate, fluocinolone acetonide or fluocinonide), very potent corticosteroids (clobetasol propionate), corticosteroids with antimicrobials (betamethasone and clioquinol, betamethasone and fusidic acid or fluocinolone acetonide and clioquinol), corticosteroid with calcipotriol or calcipotriol cream."
62022820|NCT03663075|EXPERIMENTAL|Group 2|This group will receive the intervention Group information (GI) followed by Structured person-centered support (PCS)
62219064|NCT06079541|EXPERIMENTAL|JMKX003142 FE experimental group|Participants will receive 2 Sequence regimens, with a washout period between treatments.
62219065|NCT06079541|EXPERIMENTAL|Placebo in Cohorts 1 to 7|Participants in Cohorts 1 to 7 will receive single oral dose of matching placebo on Day 1.
62219066|NCT06079541|EXPERIMENTAL|Placebo in 3 Cohorts|Participants in 3 Cohorts will receive orally once -daily of matching placebo for 7 consecutive days.
62219067|NCT01900197||Iron deficiency anemia|Patients with iron deficiency anemia treated on the doctor's discretion with 10% Iron Isomaltoside 1000 (Monofer®) as standard treatment according to current practice
62413276|NCT00822601|EXPERIMENTAL|1|
62413277|NCT00822601|PLACEBO_COMPARATOR|2|
62413278|NCT05887752|EXPERIMENTAL|Standard rehab plus 20-session Hunova rehabilitation|"Patients will receive the Standard rehabilitation for a period of 4 weeks.~In the same 4 weeks and days, the Hunova® rehabilitation (20 sessions in total) will also be administered."
62413279|NCT05887752|OTHER|Standard rehab plus 10-session, delayed, Hunova rehabilitation|"Patients will receive the Standard rehabilitation for a period of 4 weeks.~During the last 2 weeks, in the same days, the Hunova® rehabilitation (10 sessions in total) will be also administered."
62413280|NCT02192307|EXPERIMENTAL|potassium oxalate gel|Professional application
62413281|NCT02192307|ACTIVE_COMPARATOR|Potassium oxalate liquid|Professional application
62413282|NCT01020695||PTSD veterans|18 PTSD veterans
62413283|NCT01020695||controls|20 controls
62413284|NCT03253666||Nurses' Health Study|"See Detailed Description"
62413285|NCT03253666||Health Professionals Follow-Up Study|"See Detailed Description"
62413286|NCT02534467|EXPERIMENTAL|Montelukast-Standard|8 weeks of montelukast and standard therapy crossing over to 8 weeks of only standard therapy
62413287|NCT02534467|ACTIVE_COMPARATOR|Standard-Montelukast|8 weeks of standard therapy only crossing over to 8 weeks of montelukast and standard therapy
62413288|NCT06650072|ACTIVE_COMPARATOR|Palatal Micro Connective Tissue Graft|A mucogingival surgery where a connective tissue graft harvested from the palate is divided in multiple micro connective tissue grafts and placed on a recipient site prepared for modified coronally advanced tunnel and sutured to cover multiple adjacent gingival recession defects.
62219068|NCT01127893|EXPERIMENTAL|Tanezumab 10 mg|
62219069|NCT01127893|EXPERIMENTAL|Tanezumab 5 mg|
62413289|NCT06650072|EXPERIMENTAL|Tuberosity Micro Connective Tissue Graft|A mucogingival surgery where a connective tissue graft harvested from the maxillary tuberosity is divided in multiple micro connective tissue grafts and placed on a recipient site prepared for modified coronally advanced tunnel and sutured to cover multiple adjacent gingival recession defects.
62413290|NCT03724591|EXPERIMENTAL|a high ligation of IMA|total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery
62413291|NCT03724591|ACTIVE_COMPARATOR|a low ligation of IMA|total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
62413292|NCT05598619|EXPERIMENTAL|Low dose|Daily dose of 80 mg Vitamin C (Ascorbic acid) once a day for 12 weeks
62413293|NCT05598619|EXPERIMENTAL|Mid dose|Daily dose of 200 mg Vitamin C (Ascorbic acid) once a day for 12 weeks
62413294|NCT05598619|EXPERIMENTAL|High dose|Daily dose of 500 mg Vitamin C (Ascorbic acid) once a day for 12 weeks
62413295|NCT05598619|PLACEBO_COMPARATOR|Placebo|One capsule of 570 mg (consisting microcrystalline cellulose) once a day for 12 weeks
62413296|NCT04794049|EXPERIMENTAL|Experiment cohort|4-6 hours before colonoscopy, patients in experiment cohort began to drink the first 150ml lactulose and half hour later, drink other 150ml lactulose dissolved in 1.5 L of water at a rate of 250ml every 15 minutes.
62413297|NCT04794049|ACTIVE_COMPARATOR|Control cohort|The participants in control cohort began to drink the first 2 L of PEG at 7:00-9 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
62413298|NCT05366725||Adult patients with locally advanced or metastatic urothelial cancer|
62413299|NCT06531343|EXPERIMENTAL|LDCT scan and simultaneous [18F]FDG PET/CT on new-generation long axial field of view scanner|
62413300|NCT06531343|ACTIVE_COMPARATOR|low LDCT only|
62413301|NCT00576849|EXPERIMENTAL|A|Total balanced volume replacement regimen consisting of a balanced HES 130/0.42 plus a balanced crystalloid
62413302|NCT00576849|ACTIVE_COMPARATOR|B|Conventional volume replacement strategy consisting of 6% HES 130/0.4 prepared in saline solution plus Ringer's lactate
62586603|NCT02792192|EXPERIMENTAL|Cohort 1A: Atezolizumab (BCG-unresponsive NMIBC)|Participants will receive atezolizumab 1200 mg IV infusion q3w, for a maximum of 32 doses or 96 weeks of therapy, whichever comes first.
62794891|NCT04249817|EXPERIMENTAL|Video conferencing with extended role practitioner|Participant goes to Ontario Telemedicine site for follow-up. At site, participant will get a physical assessment by an extended role practitioner and then will connect to their rheumatologist by videoconferencing for completion of follow-up.
62794892|NCT04249817|NO_INTERVENTION|Usual care|Participant goes to their rheumatologist's clinic for follow-up, including physical assessment by their rheumatologist, as they would normally.
62219070|NCT01127893|EXPERIMENTAL|Tanezumab 2.5 mg|
62219071|NCT05823831||Healthcare workers group|Children of healthcare worker mothers were grouped as the Healthcare workers group. Doctors, nurses, and paramedics are considered as healthcare workers.
62219072|NCT05823831||Non-healthcare worker group|Children of mothers from other occupations were grouped as Non-healthcare workers group
62219073|NCT04417322||Control|Observation of serum A.actinomycetemcomitans levels and correlation of plasma A.actinomycetemcomitans levels
62413303|NCT01845181|PLACEBO_COMPARATOR|Dose Level I - Group A - Placebo|2 capsules of placebo
62413304|NCT01845181|EXPERIMENTAL|Dose Level II - Group B - Active|20 mg: 1 capsule of 20 mg PBF-680
62413305|NCT01845181|PLACEBO_COMPARATOR|Dose Level II - Group B - Placebo|1 capsule of placebo
62413306|NCT01845181|EXPERIMENTAL|Dose Level I - Group A - Active|10 mg: 2 capsules of 5 mg PBF-680
62413307|NCT01845181|EXPERIMENTAL|Dose Level III - Group C - Active|40 mg: 2 capsules of 20 mg PBF-680
62413308|NCT01845181|PLACEBO_COMPARATOR|Dose Level III - Group C - Placebo|2 capsules of placebo
62219074|NCT04417322||Periodontitis|Observation of serum A.actinomycetemcomitans levels and correlation of plasma A.actinomycetemcomitans levels
62219075|NCT01678105|EXPERIMENTAL|Dovitinib|Dovitinib 500 mg PO OD (5 days on, 2 days off); Each cycle = 28 days
62219076|NCT01277900||Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
62413309|NCT01845181|EXPERIMENTAL|Dose Level IV - Group D - Active|60 mg: 3 capsules of 20 mg PBF-680
62413310|NCT01845181|PLACEBO_COMPARATOR|Dose Level IV - Group D - Palcebo|3 capsules of placebo
62413311|NCT06701916|NO_INTERVENTION|Control group|Usual Care. Participants allocated to the control group will not receive any additional intervention. They will receive standard care for the outpatient management of their Heart Failure, based on the recommendations of the European Society of Cardiology guidelines for the follow-up of heart failure patients.
62413312|NCT06701916|EXPERIMENTAL|Intervention group.|The Person-Centred Care intervention will be delivered for 3 months on top of usual care.
62413313|NCT00685711|PLACEBO_COMPARATOR|1|Placebo intradermal n = 2 with each dose level of Cat-PAD.
62413314|NCT00685711|EXPERIMENTAL|2|Intradermal injection of increasing single doses of Cat-PAD (0.03, 0.3, 3, 12 nmol) n = 6 per dose level. Based on review of blinded LPSR, an additional dose of Cat-PAD between 0.03 and 12 nmol may be administered to an additional cohort of 6 subjects.
62413315|NCT00685711|PLACEBO_COMPARATOR|3|Placebo subcutaneous n = 2 with each dose level of Cat-PAD.
62413316|NCT00685711|EXPERIMENTAL|4|Subcutaneous injection of increasing single doses of Cat-PAD (0.03, 0.3, 3, 12, 20 nmol) n = 6 per dose level. Based on review of blinded LPSR, an additional dose of Cat-PAD between 0.03 and 20 nmol may be administered to an additional cohort of 6 subjects.
62413317|NCT06565585||Low-risk Glans-sparing surgery patients|Patients with lower-risk tumors who underwent glans-sparing surgery defined as circumcision, wide local excision, laser ablation, glans resurfacing and partial glansectomy.
62794893|NCT04208555|EXPERIMENTAL|Boric acid vaginal suppository|
62794894|NCT04208555|ACTIVE_COMPARATOR|Terconazole vaginal suppository|
62794895|NCT00636285|PLACEBO_COMPARATOR|1|Placebo
62219077|NCT04729686|ACTIVE_COMPARATOR|Pericapsular Nerve Block Group|Pericapsular Nerve Block targets the anterior hip capsule by blocking the articular branches of the femoral nerve and accessory obturator nerve.
62413318|NCT06565585||High-risk glansectomy patients|Patients who underwent total glansectomy due to higher risk tumors resulting in a complete removal of all the glandulopreputhial epithelium.
62413319|NCT02973178|OTHER|Usability|Evaluate and validate the user-interface of the Scanadu Urine Device by the intended users for human factors and user interface of the Scanadu Urine Device.
62413320|NCT02973178|ACTIVE_COMPARATOR|Method Comparison|"Evaluate and validate the clinical performance of the Scanadu Urine Device in the hands of intended users as compared to:~* The visual read of chemical test strips performed by lab technicians utilizing the Siemens Multistix® 10SG technology (K905396),~* Scanadu Urine Device tests performed by lab technicians."
62413321|NCT02973178|OTHER|Reproducibility|Evaluate the reproducibility in the hands of the lay-users after repeated testing of samples with known test levels.
62413322|NCT03828344|EXPERIMENTAL|hUC-MSC treatment|BX-U001 (hUC-MSC suspension) will be tested at dose of 0.75 or 1.5×10\^6 cells/kg of body weight via a single IV infusion using a blood transfusion kit.
62413323|NCT03828344|PLACEBO_COMPARATOR|Placebo control|The control arm will be given placebo which contains the same cell suspension solution but without cells. Placebo will be given the same way as BX-U001 via a single IV infusion using a blood transfusion kit.
62586604|NCT02792192|EXPERIMENTAL|Cohort 1B: Atezolizumab + BCG (BCG-unresponsive NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. Optional BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
62794896|NCT00636285|EXPERIMENTAL|2|BSYX-A110, Dosed intravenously, 3mg/kg
62413324|NCT04819932|EXPERIMENTAL|group1|subject take DWC202008 and DWC2020091 on a fasted condition, and after wash out period, take DWJ1451 with on a fasted condition
62794897|NCT00636285|EXPERIMENTAL|3|BSYX-A110, Dosed intravenously, 10mg/kg
62794898|NCT00779493|ACTIVE_COMPARATOR|A|Curcumin 900mg twice daily by mouth
62022821|NCT03663075|EXPERIMENTAL|Group 3|This group will receive the intervention Structured person-centered support (PCS)
62022822|NCT03663075|NO_INTERVENTION|Group 4|This is a control group.
62413325|NCT04819932|EXPERIMENTAL|group2|subject take DWJ1451 on a fasted condition, and after wash out period, take DWC202008 and DWC202009 with on a fasted condition
62794899|NCT00779493|PLACEBO_COMPARATOR|B|Placebo capsule to be made by Swanson Vitamins to simulate the capsule.
62022823|NCT02250404||Ancillary-Correlative (molecular profile)|Previously collected tissue samples are analyzed via RNA sequencing and DNA methylation at baseline. Patients also undergo collection of tissue samples for analysis at relapse.
62022824|NCT06535126|EXPERIMENTAL|Healthy Volunteers|The drug administration scheme involves vaginal administration of one suppository (CanProFem-AK, 100 mg). The total duration of participation in a study is one day.
62022825|NCT01103206|EXPERIMENTAL|Control group|Parathyroid hormone suppression tests using successively (each test will be separate for a two week period) an intravenous calcium loading or cinacalcet will be performed in a group of 12 healthy volunteers.
62022826|NCT01103206|EXPERIMENTAL|Primary hyperparathyroidism dose I|Parathyroid hormone suppression test using the first dose of cinacalcet in patients with primary hyperparathyroidism.
62219078|NCT04729686|ACTIVE_COMPARATOR|Fascia Iliaca Nerve Block Group|Fascia Iliaca Nerve Block targets the space between the iliacus muscle and the fascia that overlies it (fascia iliaca), within which the femoral nerve and lateral femoral cutaneous nerve (LFCN) course.
62413326|NCT05692739|EXPERIMENTAL|Insulin|Topical insulin 1UI/ml 4 times a day
62413327|NCT05692739|ACTIVE_COMPARATOR|Cyclosporin|Cyclosporin 0,05% every 12 hours
62413328|NCT05692739|PLACEBO_COMPARATOR|Artificial tears|Artificial tears 4 times a day
62413329|NCT03896373||Lupus erythematosus|Patients with inactive lupus erythematosus, active lupus erythematosus or newly diagnosed
62413330|NCT01260194|EXPERIMENTAL|1|
62413331|NCT06335511||Decompression|microsurgical decompression (MiD)
62413332|NCT06335511||Fusion|decompression and instrumented fusion (MiD + F)
62413333|NCT00924573|EXPERIMENTAL|1|"Metformin on top of glimepiride~Twice a day with 2-6 mg of daily dose for glimepiride and 500-750mg of daily dose for metformin for 24 weeks"
62794900|NCT01383226|OTHER|Thoracic endosonography|Thoracic endosonography, either endobronchial or esophageal ultrasound controlled needle aspiration, is a minimally invasive diagnostic technique.
62794901|NCT04747899|ACTIVE_COMPARATOR|Traditional physical therapy|Traditional physical therapy ,Hot Pack, Muscle Stretching and Posture correction
62794902|NCT04747899|EXPERIMENTAL|Positional Release Technique|Experimental group is given Positional Release Technique along with the hot pack, muscle stretching and posture correction.
62219079|NCT02145234|EXPERIMENTAL|SAD Panel 1:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
62794903|NCT00016328|EXPERIMENTAL|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes once weekly for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62794904|NCT05661604||Participants at High Risk for Poor Outcomes From a Respiratory Infection|Data will be collected for participants at high risk for poor outcomes from a respiratory infection. The duration of participation per participant will be up to 12 months.
62794905|NCT02613585|EXPERIMENTAL|Permethrin Impregnated Clothing|Uniforms and work clothing (including pants, shorts, shirts, socks, and hats) treated with long-lasting permethrin by Insect Shield.
62219080|NCT02145234|EXPERIMENTAL|SAD Panel 2:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
62219081|NCT02145234|EXPERIMENTAL|SAD Panel 3:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
62219082|NCT02145234|EXPERIMENTAL|SAD Panel 4:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
62219083|NCT02145234|EXPERIMENTAL|SAD Panel 5:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
62219084|NCT02145234|EXPERIMENTAL|MAD Panel 1:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 multiple subcutaneous administrations weekly"
62413334|NCT00924573|PLACEBO_COMPARATOR|2|"Placebo on top of glimepiride~Twice a day with 2-6 mg of daily dose for glimepiride and 2-3 tablets of placebo for 24 weeks"
62413335|NCT04966117|EXPERIMENTAL|Risk-Guided DMP|The intervention is a 12 month disease management program after hospital discharge for coronary artery disease that is overseen by a cardiac nurse.
62413336|NCT04966117|ACTIVE_COMPARATOR|Usual Care|Usual care patients will receive standard cardiology care.
62219085|NCT02145234|EXPERIMENTAL|MAD Panel 2:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
62413337|NCT00559975|ACTIVE_COMPARATOR|1|
62413338|NCT00559975|ACTIVE_COMPARATOR|2|
62413339|NCT00559975|EXPERIMENTAL|3|
62413340|NCT00559975|EXPERIMENTAL|4|
62794906|NCT02613585|NO_INTERVENTION|Untreated Clothing|Uniforms and work clothing sent to Insect Shield, washed and refolded (no permethrin applied).
62794907|NCT03539718|EXPERIMENTAL|cases|Cases, taurolidine heparin 500 will be used at end of session
62219086|NCT02145234|EXPERIMENTAL|MAD Panel 3:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
62219087|NCT02145234|EXPERIMENTAL|MAD Panel 4:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
62219088|NCT02145234|EXPERIMENTAL|MAD Panel 5:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administration every 2 weeks~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
62219089|NCT02145234|EXPERIMENTAL|MAD Panel 6:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
62219090|NCT02145234|EXPERIMENTAL|MAD Panel 7:BMS-986089/Placebo|"BMS-986089 a single subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 a single subcutaneous administration every 2 weeks"
62794908|NCT03539718|ACTIVE_COMPARATOR|control|Controls, Heparin Sodium 5000 will be given at end of session
62219091|NCT00712998||1|Twenty subjects receiving health check program without X-ray computed tomography examination will be included as the control group.
62219092|NCT00712998||2|Twenty subjects receiving health check program including X-ray computed tomography examination of lung will be included as the treatment group-1.
62219093|NCT00712998||3|Twenty subjects receiving health check program including X-ray computed tomography examination of heart will be included as the treatment group-2.
62413341|NCT00559975|EXPERIMENTAL|5|
62413342|NCT00049010|EXPERIMENTAL|Group 1|"Melastatin mRNA expression is determined by in situ hybridization using tissue from primary tumor and lymph nodes. Tissue is also examined by immunohistochemical staining using antibodies to S-100 and MART-1. Patients do not receive the results of these tests nor do the results influence individual therapy.~Patients are followed every 4 months for 3.5 years."
62413343|NCT01906931|EXPERIMENTAL|Portable Oxygen Concentrator first|
62413344|NCT01906931|ACTIVE_COMPARATOR|Portable oxygen cylinder first|
62413345|NCT06653348|EXPERIMENTAL|intervention|Intervention group will be treat with ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 30 days. Then ticagrelor 60 mg BID and ASA 80 mg daily until the end of month 3.
62413346|NCT06653348|ACTIVE_COMPARATOR|comparator|Comparator group will be treat with ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 30 days. Then ASA 80 mg daily until the end of month 3.
62433291|NCT01559961|EXPERIMENTAL|TTI-1612|Single intravesical 30-minute treatments with escalating doses of TTI-1612.
62433292|NCT00652379|EXPERIMENTAL|1|Co-treatment with Pegvisomant (15-30 mg twice a week) and a 50 percent reduced somatostatin-analog dose
62433293|NCT00652379|ACTIVE_COMPARATOR|2|Somatostatin analog, unaltered dosage
62433294|NCT01098240|EXPERIMENTAL|Active Treatment|CP-601,927
62433295|NCT01098240|PLACEBO_COMPARATOR|Placebo|Placebo
62433296|NCT00355069|EXPERIMENTAL|1|Received the Basic Pediatric Chronic Care Model AND the Medication Assessment Prompt AND family education
62794909|NCT06425991|EXPERIMENTAL|Arm A: Pre-change Teclistamab|Participants will receive teclistamab monotherapy (made from the pre-change manufacturing process) for all step-up and treatment doses until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent to treatment, or end of the study, whichever occurs first.
62794910|NCT06425991|EXPERIMENTAL|Arm B: Post-change Teclistamab|Participants will receive teclistamab monotherapy (made from the post-change manufacturing process) for all step-up and treatment doses until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent to treatment, or end of the study, whichever occurs first.
62413347|NCT01023815|EXPERIMENTAL|Group A -Once-a-day regimen|"Everolimus: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole daily dose of everolimus was taken in the morning, at the same time of the CsA and steroid dosing. At the Rand+1W visit, the everolimus dose was adjusted to reach and maintain everolimus blood levels between 5 and 8 ng/mL until end of Month 12.~Cyclosporine: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole cyclosporine daily dose was taken in the morning. The dose was then adjusted to maintain C2 levels between 350 and 700 ng/mL.~Prednisone: In patients randomized to Group A before Amendment 1 approval, the dose of prednisone was kept stable at 5 mg/day in the morning."
62022827|NCT01103206|EXPERIMENTAL|Primary hyperparathyroidism dose II|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
62022828|NCT01143259|PLACEBO_COMPARATOR|300 mg Polyethylene|
62413348|NCT01023815|EXPERIMENTAL|Group B - Steroid Withdrawal group|"Everolimus: after randomization the everolimus dose was adjusted, if necessary, to maintain a C0 within 6-10 ng/mL until M12.~Cyclosporine:after randomization the cyclosporine dose was adjusted to maintain CsA C2 levels within 300-500 ng/mL until M12.~Prednisone: starting from Visit 5 (day 90 ± 28 days), oral prednisone was tapered until complete stop. It was recommended to taper prednisone by 1 mg/week until complete stop in 5 to 6 weeks."
62413349|NCT01023815|ACTIVE_COMPARATOR|Group C - Standard twice-a-day group|"Everolimus: after randomization the everolimus dose was adjusted, if necessary, in order to maintain a C0 within 6-10 ng/mL until M12.~Cyclosporine: after randomization the cyclosporine dose was gradually adjusted to reach and maintain C2 blood levels of 200-450 ng/mL between Month 6 and Month 12.~Prednisone: the dose of prednisone was kept stable at 5 mg/day in the morning."
62022829|NCT01143259|ACTIVE_COMPARATOR|Alvimopan|
62022830|NCT01538017|ACTIVE_COMPARATOR|Collagenase injection|Injection of collagenase obtained from Clostridium Histolyticum in contracture string
62022831|NCT01538017|ACTIVE_COMPARATOR|Percutaneous needle fasciotomy|PNF ad modum Lermusiaux and Debeyre
62022832|NCT04812353|OTHER|Foot and ankle arthrodesis or osteotomy|Patients who underwent a foot- or ankle reconstruction surgery using the Io-Fix system
62219094|NCT05131568|EXPERIMENTAL|Thermal insulation system|"experimental: layered thermal insulation system~The system was applied in the upper body to the entrance of the operating room and remained until the exit of the same room.~The test included the evaluation of temperature, tremors and the visual perception of thermal comfort in 6 moments (T1 - reference temperature - at the entrance of the anesthetic induction room, T2 - at the entrance to the operating room, T3, T4 and T5 - fifteen , thirty and forty-five minutes after the start of surgery, and T6 - leaving the operating room)"
62219095|NCT05131568|NO_INTERVENTION|Forced air active warming|Control: the same procedures as in the experiment group, were carried out in the control group, except for the intervention.
62219096|NCT03699826|EXPERIMENTAL|Active TMS|Active TMS stimulation administered for tinnitus symptoms (no sham stimulation).
62413350|NCT01023815|EXPERIMENTAL|Not Randomized Population (NRP)|"NRP defined in whom a renal transplantation was performed, received at least one dose of study drug (everolimus) but who did not qualify for randomization at Visit 5, Day 90. This group was addressed as not randomized patients (NRP) and described with respect to baseline characteristics, treatment and outcome variables."
62413351|NCT06367998|EXPERIMENTAL|Pregabalin group|
62413352|NCT06367998|NO_INTERVENTION|Control group|
62433297|NCT00355069|EXPERIMENTAL|2|Received the Basic Pediatric Chronic Care Model AND the Medication Assessment Prompt but NOT family education
62794911|NCT05059509|EXPERIMENTAL|FB825|One dose FB825, 5mg/kg, by 1 hour IV infusion on Day 1
62794912|NCT04515901|EXPERIMENTAL|SPGB|Via a soft tip 20-gauge long IV catheter attached to a 3 mL syringe will be filled with 2 mL of 2% viscous lidocaine. The 2% viscous lidocaine will be administered according to the method of Barre.
62022833|NCT03936244|ACTIVE_COMPARATOR|M-TURP|The M-TURP procedure requires the use of a resectoscope (Olympus or Storz, 26Ch), camera system and irrigation fluid (Glycine 1.5%, Baxter). The system consists of a generator unit (ForceTriadTM, Medtronic) and a stainless steel loop with an electrical current running through the loop used to cut (120W) prostate tissue and cauterize (80W). Prostate tissue is cut away in small pieces and removed at the end of the procedure using an Ellik evacuator
62794913|NCT04515901|PLACEBO_COMPARATOR|Placebo|It will be adminstered the same as the experimental arm but with methylcellulose and cherry flavouring to match odour and taste.
62794914|NCT06726720||Cohort 1 - Resectable|Ambispective, observational, study of patients with non-small cell lung cancer initiating approved drugs developed by AZ or as part of an AZ alliance in resectable NSCLC
62794915|NCT06726720||Cohort 2 - Unresectable|Ambispective, observational, study of patients with non-small cell lung cancer initiating approved drugs developed by AZ or as part of an AZ alliance in Unresectable NSCLC
62794916|NCT06726720||Cohort 3 - Metastatic|Ambispective, observational, study of patients with non-small cell lung cancer initiating approved drugs developed by AZ or as part of an AZ alliance in Metastatic NSCLC
62794917|NCT03792256|EXPERIMENTAL|Treatment (Palbociclib)|Patients receive Palbociclib 50 mg/m\^2 (starting dose with maximum dose of 100 mg) PO (or via NG-tube) once daily on Days 1-21; Intrathecal cytarabine (IT ARAC) age-based dosing on Day 1, Doxorubicin 60 mg/m\^2 IV push or infusion over 1-15 min on Day 4; Prednisone or prednisolone 40 mg/m\^2 PO divided BID or TID on days 4-31; Vincristine 1.5 mg/m\^2 (maximum dose 2 mg) IV push or mini-bag per institutional policy on days 4, 11, 18, and 25; and Pegaspargase 2500 IU/m\^2 IV over 1-2 hours on Days 5, and 18. If CNS3 leukemia is present, patients receive Intrathecal Triple Therapy (ITT) age-based dosing on days 4, 11, 18, and 25. Patients known to be CNS3 at study entry may receive ITT on Day 1 rather than IT ARAC. If CNS1 and 2 leukemia present, patient receive Methotrexate (IT MTX) age-based dosing on Days 18 and 32. Treatment will be given for one cycle, 32 days, in the absence of disease progression or unacceptable toxicity.
62794918|NCT02031263|EXPERIMENTAL|thermoplasty group|Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
62022834|NCT03936244|EXPERIMENTAL|PK-TURP|The PK-TURP procedure requires the use of a resectoscope (Storz, 26Ch), camera system and irrigation fluid (NaCl 0.9%, Baxter). The system consists of a generator unit (PlasmaKineticTM Superpulse de Gyrus, ACMI) and a platinum-iridium superloop with an electrical current running through the loop used to cut (180W) prostate tissue and cauterize (100W). Prostate tissue is cut away in small pieces and removed at the end of the procedure using an Ellik evacuator
62413353|NCT04798027|EXPERIMENTAL|Sentinel Cohort: SARS-CoV-2 Vaccine Ultra Low dose|Participants received two intramuscular (IM) injections of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Vaccine ultra-low dose on Day 1 and at Day 22, respectively.
62413354|NCT04798027|EXPERIMENTAL|Sentinel Cohort: SARS-CoV-2 Vaccine Low dose|Participants received two IM injections of SARS-CoV-2 Vaccine low dose on Day 1 and at Day 22, respectively.
62413355|NCT04798027|EXPERIMENTAL|Sentinel Cohort: SARS-CoV-2 Vaccine Medium dose|Participants received two IM injections of SARS-CoV-2 Vaccine medium dose on Day 1 and at Day 22, respectively.
62022835|NCT03691805|ACTIVE_COMPARATOR|anodal tDCS over rDLPFC|Participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal Cortex (DLPFC).
62022836|NCT03691805|SHAM_COMPARATOR|sham tDCS|Participants will receive sham tDCS (transcranial direct current stimulation) of the DLPFC.
62794919|NCT02345473||Cystectomy patients|Arm of patients undergoing radical cystectomy for bladder cancer providing peripheral blood samples for detection of circulating cancer cells
62794920|NCT02345473||Healthy volunteers|Arm of healthy subjects not undergoing radical cystectomy providing peripheral blood samples for detection of circulating cancer cells
62794921|NCT04683848|EXPERIMENTAL|MT-3921|Intravenous (IV)
62022837|NCT01891825|ACTIVE_COMPARATOR|Pecutaneous AF ablation|Percutaneous catheter ablation of atrial fibrillation
62022838|NCT01891825|ACTIVE_COMPARATOR|Surgical AF ablation|Minimally invasive thoracoscopic surgical ablation of atrial fibrillation
62219097|NCT06046950|EXPERIMENTAL|DAS28CRP-LDA|Arm that is allocated to strive for DAS28CRP low disease activity (LDA)
62219098|NCT06046950|EXPERIMENTAL|SDAI-remission|Arm that is allocated to strive for SDAI-remission
62219099|NCT04392401||Cohort|Patients over 18 years with a confirmed diagnosis of COVID 19 hospitalized in intensive care unit
62219100|NCT03298243|EXPERIMENTAL|Stroke Cohort - Progressive Training|Aim 1 intervention: Vibrotactile stimulation. Progressive training from simple to more complex reaching task using vibrotactile feedback to guide performance
62219101|NCT03298243|EXPERIMENTAL|Stroke Cohort - Whole Task Training|Aim2 intervention: Vibrotactile stimulation. Training on only the more complex reaching task using vibrotactile feedback to guide performance
62219102|NCT01263665|EXPERIMENTAL|25cm Gore VIABAHN|25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface
62219103|NCT05151705|EXPERIMENTAL|Treatment group A: HR17031 injection|
62219104|NCT05151705|EXPERIMENTAL|Treatment group B: HR17031 injection|
62219105|NCT05151705|EXPERIMENTAL|Treatment group C: HR17031 injection|
62219106|NCT00803751|EXPERIMENTAL|Truview intubation|Receive laryngoscopy with Truview first and is immediately followed by laryngoscopy and intubation with Macintosh
62219107|NCT00803751|ACTIVE_COMPARATOR|Macintosh intubation|Macintosh blade will be used first followed by laryngoscopy and intubation with the truview
62794922|NCT04683848|PLACEBO_COMPARATOR|Placebo|Intravenous (IV)
62794923|NCT06725576||Ablation Group|Patients in this group received ablation therapy for low-risk papillary thyroid carcinoma. The ablation method used was microwave ablation (MWA), with ablation performed under ultrasound guidance. Patients were informed of the potential risks and benefits of ablation, and follow-ups were conducted at regular intervals using thyroid ultrasound and contrast-enhanced ultrasound to evaluate treatment efficacy and disease progression.
62794924|NCT06725576||Surgery Group|Patients in this group underwent surgical treatment for low-risk papillary thyroid carcinoma. The surgery performed was partial or total thyroidectomy, based on the patient's condition and preferences. Patients were informed of the risks, including potential complications such as hypothyroidism, recurrent laryngeal nerve injury, and hypoparathyroidism. Follow-ups were conducted using thyroid ultrasound and clinical assessments to monitor for recurrence and evaluate postoperative recovery.
62794925|NCT02353715||Enzalutamide|Subjects will be administered enzalutamide per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
62413356|NCT04798027|EXPERIMENTAL|FEC Cohort 1: SARS-CoV-2 Vaccine Ultra Low dose|Participants received a single IM injection of SARS-CoV-2 Vaccine ultra-low dose on Day 1.
62413357|NCT04798027|EXPERIMENTAL|FEC Cohort 1: SARS-CoV-2 Vaccine Low dose|Participants received a single IM injection of SARS-CoV-2 Vaccine low dose on Day 1.
62413358|NCT04798027|PLACEBO_COMPARATOR|FEC Cohort 1: Placebo|Participants received a single IM injection of placebo matched to SARS-CoV-2 Vaccine on Day 1.
62413359|NCT04798027|EXPERIMENTAL|FEC Cohort 2: SARS-CoV-2 Vaccine Ultra Low dose|Participants received two IM injections of SARS-CoV-2 Vaccine ultra-low dose on Day 1 and at Day 22, respectively.
62413360|NCT04798027|EXPERIMENTAL|FEC Cohort 2: SARS-CoV-2 Vaccine Low dose|Participants received two IM injections of SARS-CoV-2 Vaccine low dose on Day 1 and at Day 22, respectively.
62413361|NCT04798027|PLACEBO_COMPARATOR|FEC Cohort 2: Placebo|Participants received two IM injections of placebo matched to SARS-CoV-2 Vaccine on Day 1 and at Day 22, respectively.
62413362|NCT00636922|EXPERIMENTAL|Everolimus with 5-azacitidine|Everolimus increasing oral doses days 5-21 each cycle 5-azacitidine 75mg sub cutaneously 7 doses in 21 days
62413363|NCT02297724||all subjects|For all subjects, administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan. Data collection will start about 10 min before the administration of oxygen, and last throughout the oxygen exposure, then continue for about 10 min after oxygen exposure for each subject.
62413364|NCT05925049||Cohort 1: Naive Participants|Per standard of care, participants with MS enrolled in selected MS registries, who are natalizumab-naïve and other MS mAb-therapy-naive will receive natalizumab 300 mg, SC injection according to decision of the treating physician.
62413365|NCT05925049||Cohort 2: Natalizumab Experienced|Per standard of care, participants with MS enrolled in selected MS registries, who have previously received natalizumab IV will be switched from natalizumab IV to SC administration to receive natalizumab 300 mg, SC injection according to decision of the treating physician.
62413366|NCT00331929|EXPERIMENTAL|A|Cohort of school children that evaluated with questionnaire and spirometry with MINATO 500 JAPAN spirometer
62413367|NCT05761522||Patients with septic shock for 24 hours or more|Adult patients suffering from septic shock, after 24 hours of their diagnosis. Presenting with Mean arterial pressure (MAP)\<65 mmHg or the target MAP For whom the physician in charge decided to increase the norepinephrine dose
62413368|NCT04611555||CI users|
62413369|NCT01148628|EXPERIMENTAL|RAD 001 in combination with CaelyxTM|"RAD001 will be given p.o. at increasing doses (no intra-patient)and CaelyxTM will be administered i.v. at a fixed dose.~At each dose level 3 to 6 patients will be entered, according to toxicities observed; the first 3 patients can be treated simultaneously; subsequent patients can be treated after the first 3 have been observed for at least one cycle (4 weeks).~The dose escalation process will be discontinued once the MTD has been achieved and the RD will be evaluated in a subsequent expansion part of the study."
62413370|NCT06653660||peripubertal children|Children born from a mother whose pregnancy was included in the Timoun cohort (2004 -2007).
62413371|NCT04695210|EXPERIMENTAL|Virtual Peer-to-Peer Support|"Those participants randomised to the intervention arm will have access to a 12-week virtual peer-to-peer support programme which entails:~1. weekly audio, video, or text private messaging with a peer supporter;~2. synchronous weekly discussion forum attended by peer supporters and family caregiver participants moderated by the research team. These forums will discuss specific topics (e.g. caregiver self-care, the emotional impact of caregiving). Ask the expert forums will be moderated by clinical experts every 6 weeks (meaning all participants will have access to 2 ask the expert sessions);~3. asynchronous discussion forums in which participants can post questions; and~4. access to informational resources."
62794926|NCT02353715||Abiraterone|Subjects will be administered abiraterone acetate per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
62794927|NCT02353715||Sipuleucel-T|Subjects will be administered sipuleucel-T per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
62794928|NCT02728453|EXPERIMENTAL|Empagliflozin|25 mg/d empagliflozin + matching glimepiride placebo for 24 weeks.
62794929|NCT02728453|ACTIVE_COMPARATOR|Glimepiride|2 or 4 mg/d glimepiride+ matching empagliflozin placebo for 24 weeks.
62794930|NCT05233033|EXPERIMENTAL|Phase 1a Dose Escalation|
62794931|NCT05233033|EXPERIMENTAL|Phase 1b Dose Expansion MYD88MT|KT-413 given at the RP2D identified in Phase 1a Dose Escalation in patients with MYD88 mutant DLBCL.
62794932|NCT05233033|EXPERIMENTAL|Phase 1b Dose Expansion MYD88WT|KT-413 given at the RP2D identified in Phase 1a Dose Escalation in patients with MYD88 wild type DLBCL.
62794933|NCT04936633|NO_INTERVENTION|No intervention by medical staff|The patients who start FSGM and receive general education on FSGM only.
62794934|NCT04936633|EXPERIMENTAL|Intervention by medical staff based on a cloud system|The patients who start FSGM and receive general education on FSGM and remote intervention based on a cloud system.
62219108|NCT02325479|EXPERIMENTAL|Group A|After scheduled oocyte pick up, a mock embryo transfer will be done using labotec catheter (Labotec, Gottingen Germany), and an injection of Enaoxaprin sodium (LMWH) (Clexane® Sanofi S.A Paris, France) will be given intrauterine in group A patients, 500 IU of LMWH which is 5mg, in 0.05 ml.
62794935|NCT01855659||COPD patients|Patients who are stratified in the subgroups of COPD based on the severity: stages II, III, IV
62794936|NCT04440748|EXPERIMENTAL|Experimental Group|Participants in the experimental group will perform additional high-intensity therapy on the T-Chair 2.0, which is a newly developed non-CE-marked prototype to train trunk control and sitting balance. This they will do in addition to their normal rehabilitation program.
62022839|NCT02804958||STEMI treated with primary PCI|Patients diagnosed with acute ST-segment elevation myocardial infarction and treated with primary percutaneous coronary intervention were consecutively registered.
62219109|NCT02325479|PLACEBO_COMPARATOR|Group B|The control arm (group B) will be injected intrauterine with similar volume of tissue culture media (G.2 plus ref. 10132, Vitrolife)
62219110|NCT05373823|EXPERIMENTAL|Enhance MSS using multi-level stakeholder collaboration (Mo.1-15)|Enhancements of MSS to increase intervention effects - theory - based strategies (PHM), (BCT)
62413372|NCT04695210|NO_INTERVENTION|Control|Those participants randomised to the control arm will receive usual care which comprises self-directed access to the MND Association Visitors programme and MND Association educational resources via their website.
62413373|NCT05121688|EXPERIMENTAL|Tele-physiotherapy group|"Allocated participants to intervention group will receive 18 Tele-physiotherapy sessions (three sessions per week, with 30 min. of duration) during six weeks. In this sessions, participants will carry out a tele-face-to-face multimodal physical therapy program based on health education, respiratory exercises, physical training exercises, aerobic exercises and functional mobility.~This group will receive conventional medical care too."
62413374|NCT05121688|ACTIVE_COMPARATOR|Control group|"No Physical therapy intervention. Allocated participants to control group will receive one consultation session by the physiotherapist, but will not received any physical Therapy treatment. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking. Conventional medical care will be provided.~In the control group, the same measurements will be made at the same times as the subjects in the intervention group. Once the study is finished, the researcher agrees to carry out the intervention to the patients in the control group."
62794937|NCT04440748|ACTIVE_COMPARATOR|Control Group|Participants in the control group will execute their normal rehabilitation program.
62413375|NCT03690206|EXPERIMENTAL|Glepaglutide SC injections twice weekly|Intervention: Glepaglutide
62413376|NCT03690206|EXPERIMENTAL|Glepaglutide SC injections once weekly and placebo once weekly|Intervention: Glepaglutide
62794938|NCT03565536|EXPERIMENTAL|Nexavar neoadjuvant treatment group|"After the patient had diagnosed as anaplastic thyroid cancer, Nexavar was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.~operation for possible surgical treatment,with complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.~then External radiation therapy after surgery."
62794939|NCT06025539|EXPERIMENTAL|Animal-assisted resilience training|12 sessions of group-based, animal-assisted resilience training.
62219111|NCT05373823|EXPERIMENTAL|Involves the longitudinal RCT comparing behavioral outcomes and effectiveness (Mo.16 -60)|RCT of enhanced MSS testing effectiveness (thorough SSE, sun protection behavior Involves the longitudinal RCT comparing behavioral outcomes and effectiveness of enhanced MSS versus an educational webpage on SSE as well as new recurrences/melanomas
62219112|NCT05373823|ACTIVE_COMPARATOR|Aim 3: Assess implementation outcomes, identify factors relevant for future scale-up (Mo.17-60)|Assessment of implementation outcomes and key contextual factors from the perspective of multi - level stakeholders
62413377|NCT03690206|PLACEBO_COMPARATOR|Placebo SC injections twice weekly|Intervention: Placebo
62413378|NCT05738083||aneurysmal subarachnoid hemorrhage|primary subarachnoid hemorrhage caused by intracranial ruputured aneurysm
62413379|NCT06279273|ACTIVE_COMPARATOR|real tDCS|
62413380|NCT06279273|SHAM_COMPARATOR|sham tDCS|
62413381|NCT04945980|EXPERIMENTAL|Low-MUFA ground beef|Participants consumed ground beef low in monounsaturated fatty acids.
62413382|NCT04945980|EXPERIMENTAL|High-MUFA ground beef|Participants consumed ground beef high in monounsaturated fatty acids.
62413383|NCT05691218|ACTIVE_COMPARATOR|Control - Standard Nebulization|
62413384|NCT05691218|EXPERIMENTAL|A-Vibrating mesh Nebulization|
62794940|NCT04515758|EXPERIMENTAL|Exercise and Cognitive Training|Each participant (in a group setting) completes 30 minutes of cognitive training and 1 hour of exercise two days/week.
62794941|NCT04515758|ACTIVE_COMPARATOR|Exercise Training Only|Each participant (in a group setting) completes 1 hour of exercise two days/week (separate days than the experimental group).
62413385|NCT05691218|EXPERIMENTAL|B-Vibrating mesh Nebulization and High-flow nasal cannula heated and humidified oxygen|
62794942|NCT06385483|EXPERIMENTAL|Treatment (afatinib)|Patients receive afatinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients may also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
62413386|NCT03088280|EXPERIMENTAL|3mg/kg Group|Patients will received Thymoglobuline 3mg/Kg (reduced dose)
62794943|NCT06548100|EXPERIMENTAL|mibavademab|Patients switching from at least 6 months of therapy with metreleptin to mibavademab.
62794944|NCT03335774|ACTIVE_COMPARATOR|Hydrocortisone Acetate Suppository, 25 mg|One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
62794945|NCT03335774|PLACEBO_COMPARATOR|Placebo (Vehicle) Suppository|One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
62794946|NCT06500988|EXPERIMENTAL|Corrie Virtual Atrial Fibrillation Management Program|Multicomponent virtual atrial fibrillation management program
62794947|NCT06500988|NO_INTERVENTION|Usual Care|Receives usual care. Usual care is defined as care according to the patients care team's standard practice
62794948|NCT06726161|EXPERIMENTAL|Dose Escalation, Dose Expansion|
62794949|NCT04014465||patients with radiotherapy|The patients of lung cancer or esophagueal cancer, who received definitvie RT, should included in this Cohort.
62794950|NCT03477396|EXPERIMENTAL|Treatment (ribociclib, aromatase inhibitor)|Participants receive ribociclib orally PO QD on days 1-21 and aromatase inhibitor per treating investigator's discretion. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62794951|NCT05090891|EXPERIMENTAL|Group A: INCB000928|Participants will receive INCB000928 for 24 weeks (double-blind period). Participants who complete the double-blind period will continue into open-label extension period for an additional 52 weeks.
62794952|NCT05090891|PLACEBO_COMPARATOR|Group B: Placebo followed by INCB000928|Participants will receive placebo for 24 weeks (double-blind period). Participants who completed the double-blind period will receive INCB000928 in the 52 week open-label extension period.
62794953|NCT01156103|EXPERIMENTAL|SCORES|America SCORES, Bay Area, after-school program
62413387|NCT03088280|ACTIVE_COMPARATOR|6mg/kg Group|Patients will received Thymoglobuline 6mg/Kg (standard dose)
62413388|NCT04285736|EXPERIMENTAL|Group A Ivabradine Group|
62413389|NCT04285736|ACTIVE_COMPARATOR|Group B Control Group|
62413390|NCT04637217||Control|
62413391|NCT04637217||Diabetes mellitus without Diabetic Retinopathy|
62413392|NCT04637217||Diabetes mellitus with Diabetic Retinopathy|
62413393|NCT06651879|EXPERIMENTAL|Two views ultrasound technique|: the ultrasound examiner will use the difficult airway examination by sonography (DARES) protocol in which involves only two views of the upper airway: the thyrohyoid and the suprahyoid views. Measurements selected for this protocol include the DSE, HMD, HMDR1, HMDR2, and tongue thickness, which cover all three domains of TTD, APD, and OSD
62413394|NCT06651879|ACTIVE_COMPARATOR|Five views ultrasound technique|The thicknesses of the anterior neck soft tissues will be measured by systematic examination includes five views: 1) Suprahyoid View .2) Thyrohyoid view; will be used to visualize epiglottis and pre -epiglottic space(PES).3) Thyroid view; for vocal cord visualization.4) Cricothyroid view .5) Suprasternal view From the previous views the following will be measured: tongue volume (TV ) ANS-H: anterior neck skin thickness at hyoid; TMD: thyromental distance; ANS-E: anterior neck skin thickness at epiglottis; ANS-VC: anterior neck skin thickness at vocal cords; SD: subglottic diameter PreE: pre epiglottic space; aVF: anterior vocal folds; pVF: posterior vocal folds; mVF: midpoint of anterior , posterior vocal folds , and diameter of the transverse tracheal air shadow in the subglottic area . The following will be calculated PreE/aVF, PreE/mVF , PreE/pVF and PreE/E-VC. That will be in addition to detection of any abnormalities in the airway
62413395|NCT05801094|EXPERIMENTAL|QL1604|
62433298|NCT00355069|EXPERIMENTAL|3|Received the Basic Pediatric Chronic Care Model AND family education but NOT the Medication Assessment Prompt
62794954|NCT01156103|NO_INTERVENTION|Usual care|Standard after-school programming
62794955|NCT01645254|EXPERIMENTAL|Argemone mexicana|"Argemone mexicana is traditional medicinal plant known as having an antimalarial activity.~The aerial part of this plant is used. The decoction of the powder of the plant will be used."
62794956|NCT04994756||Stroke|
62794957|NCT04994756||Thrombectomy|
62794958|NCT04994756||Aneurysm|
62794959|NCT05730036|EXPERIMENTAL|Linvoseltamab|Randomization 1:1
62794960|NCT05730036|ACTIVE_COMPARATOR|Elotuzumab/Pomalidomide/Dexamethasone (EPd)|Randomization 1:1
62794961|NCT06097663|EXPERIMENTAL|Treatment Sequence 1|Treatment Sequence 1
62794962|NCT06097663|EXPERIMENTAL|Treatment Sequence 2|Treatment Sequence 2
62794963|NCT06097663|EXPERIMENTAL|Treatment Sequence 3|Treatment Sequence 3
62794964|NCT06097663|EXPERIMENTAL|Treatment Sequence 4|Treatment Sequence 4
62794965|NCT06097663|PLACEBO_COMPARATOR|Treatment Sequence 5|Treatment Sequence 5
62794966|NCT02021643|EXPERIMENTAL|Sofosbuvir+RBV+PEG 12 weeks|Participants with genotype 1 or 6 will receive sofosbuvir+RBV+Peg-IFNα-2a for 12 weeks.
62794967|NCT02021643|EXPERIMENTAL|Sofosbuvir+RBV 12 weeks|Participants with genotype 1, 2 or 6 will receive sofosbuvir+RBV for 12 weeks.
62794968|NCT02021643|EXPERIMENTAL|Sofosbuvir+RBV 16 weeks|Participants with genotype 1, 6 will receive sofosbuvir+RBV for 16 weeks.
62413396|NCT05591547|EXPERIMENTAL|IMRT/VMAT-Based Accelerated Partial Breast Irradiation|Patients will be treated with a novel IMRT/VMAT-based accelerated partial breast irradiation regimen.
62413397|NCT01510587|EXPERIMENTAL|4-Health Educational curriculum|Parents participate in 10 face-to-face educational sessions delivered by Extension Agents at individual county locations over a 8-month period (fall to spring).
62413398|NCT01510587|ACTIVE_COMPARATOR|Healthy Living Information|Participants receive 10 mailed packets of written information derived from USDA's MyPlate website on approximately the same schedule as meetings of the experimental group.
62413399|NCT05472363|EXPERIMENTAL|Non-Stroke Subjects|Subjects will receive up to 30 minutes of focal simulation with either TMS or tDCS administered to one brain location within standard safety protocols
62586605|NCT02792192|EXPERIMENTAL|Cohort 2: Atezolizumab + BCG (BCG-relapsing NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. During BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
62586606|NCT02792192|EXPERIMENTAL|Cohort 3: Atezolizumab + BCG (BCG-naive NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. During BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
62586607|NCT02515383||Part 1 (MDASI questionnaire, interview)|Patients complete the MDASI questionnaire and then complete a cognitive debriefing interview regarding its comprehensibility, the acceptability of each item, and whether any important symptoms are missing from the questionnaire.
62586608|NCT02515383||Part 2 (MDASI questionnaires, interview)|Patients complete the MDASI questionnaire twice (1-7 days apart). Approximately 1 week after beginning standard of care treatment, patients complete the MDASI questionnaire at 4 additional time points, each 1 week apart. Patients may also complete a cognitive debriefing interview regarding its comprehensibility, the acceptability of each item, and whether any important symptoms are missing from the questionnaire.
62586609|NCT06114459|EXPERIMENTAL|Chlorhexidine|Postoperative disinfection
62586610|NCT06114459|EXPERIMENTAL|Sodium Chloride|Postoperative disinfection
62586611|NCT01224093||First line|
62586612|NCT01224093||Relapsed/refractory|
62586613|NCT05872555||Patients with psychiatric diagnosis/prescribed psychiatric medications|"1. Diagnosed with schizophrenia/schizoaffective disorder/bipolar disorder/depression/dementia/diagnosed with other psychiatric disorders, or not diagnoses with any disorder, and registered in the Clalit database.~2. First exposure to antipsychotics/antidepressants/benzodiazepines/mood stabilizers above the age of 16 years, regardless of the presence of having a psychiatric diagnosis. We will include patients treated with these medications also if they do not have a psychiatric diagnosis.~3. Prescription of these psychiatric medications between 2001-2024"
62586614|NCT05872555||Control individuals|"1. The control groups will differ according to the analysis performed, and will be clearly described in the publication.~2. Depending on the analysis, will not include person prescribed antipsychotics, antidepressants, benzodiazepines, mood stabilizers.~3. Matched for age, sex and socio-economic status and other potential confounders, depending on the disease studied."
62586615|NCT02804139|ACTIVE_COMPARATOR|Standard care|Standard Care after C-section with no additional physical therapy.
62586616|NCT02804139|EXPERIMENTAL|Standard care plus physical therapy|Subjects attend 1 to 2 physical therapy sessions per week for 6 weeks beginning 8-10 weeks post-C section. The physical therapy program includes scar management, core retraining, and lumbar and pelvic joint mobilization
62586617|NCT05283148|OTHER|SCD Bone Pain Study Cohort|Prospective cohort of 50 adults with sickle cell disease (SCD) undergoing research DXA scan to assess bone mineral density and thoracolumbar morphometry for vertebral fracture analysis
62794969|NCT02021643|EXPERIMENTAL|Sofosbuvir+RBV 24 Weeks|Participants with genotype 1, 3, or 6 will receive sofosbuvir+RBV for 24 weeks.
62794970|NCT06007820|EXPERIMENTAL|Large Volume Thoracocentesis|Group 1 - on-demand therapeutic thoracocentensis
62794971|NCT06007820|ACTIVE_COMPARATOR|Pigtail Catheter|Group 2 - small volume frequent thoracocentesis using PCD
62794972|NCT01458483|EXPERIMENTAL|Baroreceptor Stimulation|
62219113|NCT06487611|EXPERIMENTAL|A humanoid social robot|Project team will set up a physical robot at their homes. Each participant will be given a protocol to engage with different features of the robot every day. Participants are asked to complete the assigned daily tasks at their own homes
62794973|NCT03655561||Confirmed Lassa fever cases|Participants with a clinical presentation consistent with acute Lassa virus disease and a positive result for Lassa specific RT-PCR obtained before or after inclusion
62794974|NCT03655561||Non-Lassa cases (controls)|Participants with a clinical presentation consistent with acute Lassa virus disease but subsequently found to have a negative result for Lassa specific RT-PCR
62794975|NCT06264011|EXPERIMENTAL|Salaat|The salaat consists of praying the Duha prayer, an optional superogatory prayer that typically occurs in the early morning, to control for differences in timing and duration of prayer. The Duha is completed between the dawn and noon prayers and consists of four cycles of prayer as well as Qur'an recitation and supplication throughout the four positions. The salaat condition includes four cycles with four different positions during each cycle (standing with bowing at a 90-degree angle with both hands covering the knees, standing again briefly with arms at the sides, prostrating with forehead, hands, knees, and feet touching the ground, followed by sitting with knees bent under the torso, prostrating, and sitting again).
62219114|NCT06487611|NO_INTERVENTION|Control|
62219115|NCT05421611|EXPERIMENTAL|SII-YFV|"Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos~Diluent: 0.5 mL of sterile water for injection"
62219116|NCT05421611|ACTIVE_COMPARATOR|STAMARIL|"Live attenuated Yellow Fever Virus (17D-204 Strain) not less than 1000 IU/dose produced in specified pathogen-free chick embryos~Solvent: Sodium Chloride 2.0 mg; Water for injections up to 0.5 mL"
62219117|NCT05332145|EXPERIMENTAL|Intervention development and testing|"Phase 1 participants (N=12) will complete the MAP to Health online interview and rate the ease of use, usefulness, intention to use, and theoretical fidelity of the intervention.~Phase 2 participants (N=35) will participate in a proof-of-concept pilot trial via a double-pretest single group design. Participants will complete a 4-week pretest monitoring period and an 8-week pilot trial of the intervention, with assessments of Self-Determination Theory mechanisms and meaning salience at pretest (-4 weeks), baseline (0 weeks), midpoint (4 weeks) and posttest (8 weeks). In addition, participants will wear accelerometers to assess physical activity during the 12 week period."
62219118|NCT01741896|ACTIVE_COMPARATOR|RIPC|Patients in the RIPC arm will undergo a period of upper limb ischaemic preconditioning before their contrast enhanced CT scan. The RIPC stimulus involves four cycles of ischaemia/reperfusion (5 minutes of blood pressure cuff induced upper limb ischaemia with 3 minutes reperfusion). This will start at a time of 30 - 40 minutes before the administration of contrast. The cuff is inflated to 15mmHg above systolic pressure at each inflation.
62219119|NCT01741896|NO_INTERVENTION|Control arm|Patients in the control arm will undergo no extra intervention.
62219120|NCT02076438|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62219121|NCT02076438|EXPERIMENTAL|Probiotics|Lactobacillus Rhamnosus GG 10 billion cfu BID
62413400|NCT05472363|EXPERIMENTAL|Stroke Subjects|Subjects will receive up to 30 minutes of focal stimulation with either TMS or tDCS administered to one brain location within standard safety protocols
62413401|NCT03835312|EXPERIMENTAL|Interventional|Sequential transplantation of umbilical cord blood stem cells and islet cells
62413402|NCT04800822|EXPERIMENTAL|PF-07284892 monotherapy|Monotherapy dose escalation of PF-07284892 in participants with ALK- or ROS1-positive non-small cell lung cancer (NSCLC), B-type Raf proto-oncogene V600E mutation colorectal cancer (CRC), or RAS- mutant, NF1-mutant or BRAF class 3-mutant solid tumors
62413403|NCT04800822|EXPERIMENTAL|PF-07284892 in combination with lorlatinib (Part 2)|Combination dose escalation of PF-07284892 in combination with lorlatinib in participants with ALK- or ROS1-positive NSCLC
62794976|NCT06264011|SHAM_COMPARATOR|Counting|"The counting condition will include the same physical component as the salaat condition. This will include 4 cycles of movement through the four different positions (i.e., standing, bowing at a 90-degree angle with both hands covering the knees, standing again briefly with arms at the sides, prostrating with forehead, hands, knees, and feet touching the ground, followed by sitting with knees bent under the torso, prostrating, and a final sitting position in cycles two and four. The counting condition will include replacing Qur'anic recitation and subsequent supplications throughout the prayer by counting one one-thousand, two one-thousand, three one-thousand, etc. throughout the duration of time typically required to perform the full salaat."
62219122|NCT02880384|EXPERIMENTAL|FilmArray LRTI v.2.0 IUO Panel|Patients will provide sputum or sputum equivalent for FilmArray LRTI v.2.0 IUO Panel testing.
62219123|NCT04004936|ACTIVE_COMPARATOR|Active Feedback|EQUIPPED with active provider feedback, implementing one-to-one (1:1) in-person academic detailing from a professional colleague that includes in-person audit, feedback, and peer benchmarking and provide on-site expertise.
62219124|NCT04004936|ACTIVE_COMPARATOR|Passive Feedback|EQUIPPED with passive provider feedback, implementing monthly provider feedback via an electronic dashboard with audit, feedback and peer benchmarking.
62413404|NCT04800822|EXPERIMENTAL|Expansion Phase (Cohort 1)|PF-07284892 + lorlatinib in participants with ALK+ NSCLC with prior lorlatinib
62413405|NCT04800822|EXPERIMENTAL|Expansion Phase (Cohort 2)|PF-07284892 + lorlatinib in participants with ALK+ NSCLC with no prior lorlatinib
62413406|NCT04800822|EXPERIMENTAL|Expansion Phase (Cohort 3)|PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC with prior BRAF inhibitor (BRAFi) plus epidermal growth factor receptor inhibitor (EGFRi)
62794977|NCT02442440|EXPERIMENTAL|anisodamine group|administration of the drug
62219125|NCT04326595|ACTIVE_COMPARATOR|surgical termination|
62219126|NCT04326595|ACTIVE_COMPARATOR|medical termination|
62219127|NCT02609347|EXPERIMENTAL|Manual Therapy Group|Participants in the manual therapy group will receive 3 treatment sessions of joint mobilization based on the physical therapist's clinical decision making.
62219128|NCT02609347|SHAM_COMPARATOR|Control Group|Participants in the control group will receive a sham manual therapy treatment consisting of soft tissue mobilization and Grade I mobilizations at the proximal tib/fib joint.
62219129|NCT02733055|EXPERIMENTAL|subjects|participant undergoing posturographic evaluation
62413407|NCT04800822|EXPERIMENTAL|Expansion Phase (Cohort 4)|PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC with no prior BRAFi plus EGFRi
62413408|NCT04800822|EXPERIMENTAL|Expansion Phase (Cohort 5)|PF-07284892 + binimetinib in participants with RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumors who have received prior standard of care (SOC)
62413409|NCT04800822|EXPERIMENTAL|PF-07284892 in combination with encorafenib and cetuximab (Part 2)|Combination dose escalation of PF-07284892 in combination with encorafenib and cetuximab in participants with BRAF V600E mutant CRC
62022840|NCT00919269||Ancillary-Correlative (specimen collection)|Surgical tissue, bone marrow, and blood specimens are collected at diagnosis (initial or relapse) and, if applicable, at the development of a second primary tumor. Specimens are used for research purposes. A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute.
62413410|NCT04800822|EXPERIMENTAL|PF-07284892 in combination with binimetinib (Part 2)|Combination dose escalation of PF-07284892 in combination with binimetinib in participants with Ras-mutant, NF-1 mutant or BRAF class 3 -mutant solid tumors
62219130|NCT02234648|PLACEBO_COMPARATOR|Placebo|The PLA supplement consisted of a commercially available, less than 5% fruit, cordial (Protein - Trace, Carbohydrate 260 mg•mL-1, Sodium 0.02 mg•mL-1, Fibre-Trace and Anthocyanins-Trace for colour), mixed with water, whey protein isolate (Arla Foods Ltd., Leeds, UK) and maltodextrin (MyProtein Ltd., Northwich, UK) until matched for carbohydrate and calorie content of the MC.
62794978|NCT02442440|NO_INTERVENTION|control group|these arm do not use anisodamine, other resuscitation protocol is as usual.
62022841|NCT03176160||Patients receiving palliative regimen consisting of LITT|Patients with WHO grade IV malignant glioma who are approved for and receive the LITT (Laser Interstitial Thermal Therapy) procedure
62022842|NCT05793905|EXPERIMENTAL|Buffered lidocaine|Inferior alveolar nerve block with buffered anesthetic solution (2% lidocaine with 1/80000 adrenaline mixed with sodium bicarbonate 8.4%)
62022843|NCT05793905|OTHER|Lidocaine 2%|"Control group:~Inferior alveolar nerve block with anesthetic solution (Lidocaine 2% with adrenaline 1.80000)."
62022844|NCT01828502|EXPERIMENTAL|Active Intervention|Those randomized to the active intervention will receive education about secondhand smoke exposure and feedback using the cotinine test strip.
62022845|NCT01828502|OTHER|Education only|Those randomized to the education only group will receive only the education about secondhand smoke exposure.
62022846|NCT01140035|EXPERIMENTAL|Intensive insulin therapy|"Intensive insulin therapy with goal of glucose \< 150 mg/dl~Control group with standard insulin therapy with goal of glucose 180 mg/dl"
62219131|NCT02234648|ACTIVE_COMPARATOR|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency cherry (MC) juice mixed with 100mL of water. Independent analysis of MC (Atlas Biosciences, 2010) provided the following compositional data; Fat 0.028 mg•mL-1, Protein 31.47 mg•mL-1, Carbohydrate 669.4 mg•mL-1, Cholesterol \< 0.01 mg•mL-1, Sodium 0.691 mg•mL-1, Calcium 0.137 mg•mL-1 and Iron 0.026 mg•mL-1. Additionally, according to the manufacturers guidelines (Cherry Active, Hanworth, UK),
62586618|NCT06541379||Transradial Amputees Using Myoelectric Prosthesis|"The Standardized Mini Mental Test (SMMT) will be used to assess the cognitive status of individuals, the Beck Depression Inventory (BDI) to assess depression symptoms, the Movement Imagery Questionnaire-3 to assess motor imagery ability, the Mental Chronometry Test (MKT) to measure motor imagery time, the mobile application called Orientate to assess hand mental rotation task performance, the Box and Block Test to assess gross motor dexterity and functionality, the Jebsen Taylor Hand Function Test (JTEFT) to assess fine and gross motor functions of the hand, the Disabilities of the Arm Shoulder and Hand (DASH) for upper extremity functional assessment, the Modified Functional Reach Test (MFUT) to measure the dynamic balance of the trunk and the Joint Position Sense measurement to assess proprioceptive sense."
62413411|NCT01262391|EXPERIMENTAL|AD-PED 2.5 mg|Male and female adolescents aged 12 to less than 18 years old who receive pediatric equivalent dose (PED) of 2.5 mg of solifenacin succinate.
62413412|NCT01262391|EXPERIMENTAL|AD-PED 5 mg|Male and female adolescents aged 12 to less than 18 years old who receive PED of 5 mg of solifenacin succinate.
62794979|NCT03342534|ACTIVE_COMPARATOR|Anodal tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the contralesional supraorbital front of the patient.
62794980|NCT03342534|ACTIVE_COMPARATOR|High definition (HD) anodal tDCS|A single HD anode is placed over the primary motor cortex of the stroke affected hemisphere, 4 HD cathodes are placed over the affected hemisphere around the anode.
62794981|NCT03342534|ACTIVE_COMPARATOR|Bihemispheric tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the primary motor cortex of the contralesional hemisphere.
62022847|NCT02410395|ACTIVE_COMPARATOR|Conventional technique|Closure of the uterotomy with a conventional two-layer technique
62022848|NCT02410395|EXPERIMENTAL|Modified technique|Closure of the uterotomy with a modified two-layer technique
62022849|NCT06393062|EXPERIMENTAL|Gram staining|Gram staining of post-puncture urine in percutaneous nephrolithotomy
62022850|NCT06393062|NO_INTERVENTION|control|non-intervention percutaneous nephrolithotomy
62022851|NCT06390735|EXPERIMENTAL|Mommy ReachOut intervention|The intervention group will receive the Mommy ReachOut intervention, which is a web-based psychoeducation, consisting of a total of 4 sessions to be released over a 2-week period. Two sessions will be released each week, with each session consisting of readable mental health information and videos. Content for this intervention was based on previous reviews, previous intervention studies and the Diagnostic and Statistical manual of mental health disorders (DSM-5). Session content included basic information about antenatal depression, shared antenatal depression experiences, issues around stigma towards antenatal depression, and local resources available for antenatal women with depression in Eswatini.
62022852|NCT06390735|NO_INTERVENTION|waitlist control|Participants in the control group will have access to the active treatment after completing the 6-week waiting period. Once the control participants complete the 1-month follow-up assessment, they will receive a website link to access the complete Mommy ReachOut intervention.
62219132|NCT04307771|EXPERIMENTAL|m-health application|a mobile app designed to send reminders for brushing and give information on maintaining oral health
62413413|NCT01262391|EXPERIMENTAL|AD-PED 10 mg|Male and female adolescents aged 12 to less than 18 years old who receive PED of 10 mg of solifenacin succinate.
62022853|NCT03155750|EXPERIMENTAL|Zero Time Exercise training|Subjects in this group will attend two 2-hour ZTEx training lessons. Each subject will receive a handout and an exercise log. The handout includes a picture-illustrating ZTEx step-by-step protocol. The exercise log is for them to record their time spending on performing the ZTEx every day during the 8-week study period.
62022854|NCT03155750|ACTIVE_COMPARATOR|sleep hygiene education|Subjects in this group will receive two 2-hour lessons of sleep hygiene education delivered by a registered nurse.
62794982|NCT03342534|SHAM_COMPARATOR|Sham tDCS|The electrodes are placed as in one of the active arms, but only a ramp up current is applied during 30 seconds and then switched off. This induces similar sensations for the patients, but no change in excitability.
62219133|NCT04307771|OTHER|Leaflet|This is the control arm. An educational leaflet for maintaining oral hygiene will be given to participants in this arm
62794983|NCT04218409|ACTIVE_COMPARATOR|oxycodone (5mg) + intranasal oxytocin (48 IU)|Combined effects of oxycodone and oxytocin
62022855|NCT00734305|EXPERIMENTAL|Dose Escalation|Cohorts of escalating doses of MM-121 administered IV QW to determine MTD or RP2D + expansion cohort at MTD/RP2D
62219134|NCT05966597|EXPERIMENTAL|Written persuasive leaflet|Participants will receive a written persuasive leaflet in addition to the standard referral leaflet.
62219135|NCT05966597|SHAM_COMPARATOR|Standard referral leaflet|Participants will receive a standard referral leaflet.
62794984|NCT04218409|ACTIVE_COMPARATOR|Oral oxycodone (5mg) + intranasal placebo|Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo
62794985|NCT04218409|ACTIVE_COMPARATOR|oxytocin+placebo|Separate effects of oxytocin. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo
62794986|NCT04218409|SHAM_COMPARATOR|placebo+placebo|Serves as the control
62219136|NCT01299870|ACTIVE_COMPARATOR|AED treatment plus placebo|
62794987|NCT04218409|ACTIVE_COMPARATOR|Oral oxycodone (2.5mg) + intranasal oxytocin (48 IU)|Combined effects of oxycodone and oxytocin
62794988|NCT04218409|ACTIVE_COMPARATOR|Oral oxycodone (2.5mg) + intranasal placebo|Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo
62219137|NCT01299870|EXPERIMENTAL|Keishibukuryogan|
62022856|NCT04031339||Patients diagnosed with thyroid cancer|Patients with histologically-confirmed diagnoses of papillary, follicular, Hürthle, poorly differentiated, anaplastic, or medullary thyroid cancer
62022857|NCT02695238|EXPERIMENTAL|prophylactic manual rotation group|During persistent occipital posterior presentation during the second stage of labor, prophylactic manual rotation will be performed.
62022858|NCT02695238|NO_INTERVENTION|No prophylactic manual rotation group|During persistent occipital posterior presentation during the second stage of labor, expectant management for delevery will be performed
62219138|NCT02786550|EXPERIMENTAL|Botulinum Toxin|"Immediately after lower blepharoplasty surgery 3 injections of 2.5U of botulinum toxin over lateral part of orbicularis oculi muscle.~Intervention: Botulinum toxin injection"
62219139|NCT02786550|PLACEBO_COMPARATOR|Normal saline|"Immediately after lower blepharoplasty surgery 3 injections of same amount of normal saline over lateral part of orbicularis oculi muscle.~Intervention: Normal saline injection"
62219140|NCT04109924|EXPERIMENTAL|Treatment (irinotecan, bevacizumab, TAS-102)|Patients receive irinotecan IV over 90 minutes and bevacizumab IV over 10 minutes on days 1 and 15. Patients also receive trifluridine and tipiracil hydrochloride PO BID on days 2-6 and 16-20. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62243372|NCT05767866|EXPERIMENTAL|Part 2: Expansion Cohort 3|In dose-escalation phase, previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 150mg/day and who have no active, measurable central nervous system (CNS) metastases.
62794989|NCT04142294|EXPERIMENTAL|4 g / day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 4 g/day.
62794990|NCT04142294|EXPERIMENTAL|8 g / day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 8 g/day
62794991|NCT04142294|EXPERIMENTAL|12 g /day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 12 g/day
62794992|NCT04142294|EXPERIMENTAL|16 g /day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 16 g/day. The 16 g /day dose will be administered if no adverse effects are observed for doses 4-12 g/day
62794993|NCT06029049|EXPERIMENTAL|Modified Time Principle Induction (MTPI) with rocuronium|
62794994|NCT06029049|ACTIVE_COMPARATOR|RSI with succinylcholine|
62794995|NCT01565681|EXPERIMENTAL|Arm A: ASKP1240 lowest dose|
62794996|NCT01565681|EXPERIMENTAL|Arm B: ASKP1240 second lowest dose|
62794997|NCT01565681|EXPERIMENTAL|Arm C: ASKP1240 third lowest dose|
62794998|NCT01565681|EXPERIMENTAL|Arm D: ASKP1240 fourth lowest dose|
62794999|NCT01565681|EXPERIMENTAL|Arm E: ASKP1240 fifth lowest dose|
62795000|NCT01565681|EXPERIMENTAL|Arm F: ASKP1240 middle dose|
62795001|NCT01565681|EXPERIMENTAL|Arm G: ASKP1240 sixth highest dose|
62795002|NCT01565681|EXPERIMENTAL|Arm H: ASKP1240 fifth highest dose|
62795003|NCT01565681|EXPERIMENTAL|Arm I: ASKP1240 fourth highest dose|
62795004|NCT01565681|EXPERIMENTAL|Arm J: ASKP1240 third highest dose|
62795005|NCT01565681|EXPERIMENTAL|Arm K: ASKP1240 second highest dose|
62795006|NCT01565681|EXPERIMENTAL|Arm L: ASKP1240 highest dose|
62795007|NCT01565681|PLACEBO_COMPARATOR|Arm M: Placebo|Sodium Chloride solution
62795008|NCT00627250|EXPERIMENTAL|A|Amantadine 100 mg every morning and 12 noon
62795009|NCT00627250|PLACEBO_COMPARATOR|B|Placebo tablet every morning and 12 noon
62219141|NCT04334200|EXPERIMENTAL|Cultivate yourself: support for caregivers of dementia persons|There will be six sessions (1 or 2 session per week). The duration of each session will be 1.5-2 hours per session. The contents include: introduction on dementia, caregivers' role, how to communicate with dementia persons, tips on caregiving, stress and emotional management. The training content has been verified by one social worker, family caregivers of individuals living with dementia and a teacher who teach Chinese, Chinese history and culture in the secondary school in Hong Kong. No adverse comments are received from them.
62795010|NCT05054426|EXPERIMENTAL|intravenous MTX|intravenous methotrexate at a dose of 1g/m2 for 4 courses
62413414|NCT01262391|EXPERIMENTAL|CH-PED 2.5 mg|Male and female children aged 5 to less than 12 years old who receive PED of 2.5 mg of solifenacin succinate.
62795011|NCT05054426|EXPERIMENTAL|intrathecal MTX|intrathecal methotrexate 10mg at a time for 4 courses
62795012|NCT06726187||1|Adults with autism spectrum disorder
62795013|NCT06726187||2|The relative of the adult with autism spectrum disorder
62219142|NCT05378971|EXPERIMENTAL|experimental group|Primary MM patients started maintenance therapy after 3 months of ASCT or after maximum efficacy was achieved with induction and consolidation therapy. All patients will receive pomalidomide 1 mg daily on days 1 through 21 of each 28-day cycle.
62795014|NCT02132819|PLACEBO_COMPARATOR|Feeding During Transfusion|The feeding process will be continued during the transfusion
62219143|NCT00979810|EXPERIMENTAL|18F-FLT PET scan|This is a pilot study intended to collect preliminary data on 15 patients diagnosed with untreated high-grade glioma who are scheduled to undergo surgical resection.
62219144|NCT06392074|EXPERIMENTAL|MB04 (etanercept biosimilar)|1 mL pre-filled single-use syringe containing 50 mg (50mg/mL) of etanercept
62219145|NCT06392074|ACTIVE_COMPARATOR|US licensed Enbrel (etanercept)|1 mL pre-filled single-use syringe containing 50 mg (50mg/mL) of etanercept
62219146|NCT06392074|ACTIVE_COMPARATOR|EU sourced Enbrel (etanercept)|1 mL pre-filled single-use syringe containing 50 mg (50mg/mL) of etanercept
62219147|NCT06016959|EXPERIMENTAL|Individualised dietetic advice|Participants will receive 5 sessions receiving individualised nutritional counselling advice from a registered dietitian.
62413415|NCT01262391|EXPERIMENTAL|CH-PED 5 mg|Male and female children aged 5 to less than 12 years old who receive PED of 5 mg of solifenacin succinate.
62413416|NCT01262391|EXPERIMENTAL|CH-PED 10 mg|Male and female children aged 5 to less than 12 years old who receive PED of 10 mg of solifenacin succinate.
62795015|NCT02132819|ACTIVE_COMPARATOR|witholding feeds|At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded
62795016|NCT01440088|EXPERIMENTAL|TH-302 in Combination with Doxorubicin|
62795017|NCT01440088|ACTIVE_COMPARATOR|Doxorubicin|
62795018|NCT03818191|ACTIVE_COMPARATOR|Acamprosate|"All participants will be randomized to receive acamprosate or placebo in a double-blinded placebo-controlled trial.~The most common side effect associated with acamprosate use is diarrhea, which occurs in approximately 16% of patients. Other frequently occurring side effects include asthenia, nausea, pruritus, and flatulence, headache, abdominal pain, flu syndrome, edema, weight gain, and myalgia."
62795019|NCT03818191|PLACEBO_COMPARATOR|Placebo|All participants will be randomized to receive acamprosate or placebo in a double-blinded placebo-controlled trial.
62413417|NCT05923333|ACTIVE_COMPARATOR|B. infantis Rosell®-33|Participants will receive 8 x 109 CFU B. infantis Rosell®-33 per dose (single microbial active ingredient) and carrier material (maltodextrin) for 28 days from day 1-3 of life.
62413418|NCT05923333|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo (containing all materials besides B. infantis Rosell®-33) for 28 days from day 1-3 of life.
62433299|NCT00355069|PLACEBO_COMPARATOR|4|Received the Basic Pediatric Chronic Care Model only (NO Medication Assessment Prompt and NO family education)
62433300|NCT04590469|EXPERIMENTAL|WHELD training/virtual coaching programme supported with digital resources|WHELD training/virtual coaching programme supported with digital resources
62795020|NCT06345547||Child A|"The impact of sarcopenia in patients with cirrhosis may also be influenced by sex, severity of hepatic dysfunction, and etiology of cirrhosis. For this reason we aim for an homogeneous population, with a balanced distribution over the Child Pugh classification with a homogeneous population of at least 50%.~Child A patients still have a good hepatic function."
62795021|NCT06345547||Child B|Child B patients have a moderately impaired hepatic function.
62219148|NCT06016959|PLACEBO_COMPARATOR|Diet sheet|Participants will receive a diet sheet around poor appetite.
62219149|NCT04021550|EXPERIMENTAL|Combined Treatment|Subjects will be given 80 mg/day Telmisartan + 600 mg/day Alpha-Lipoic Acid. Subjects will also be prescribed CPAP therapy by their physician. Subjects will be instructed to use their CPAP device according to their physician's guidelines.
62219150|NCT04021550|PLACEBO_COMPARATOR|Placebo Control|Subjects will be given placebo capsules. Subjects will also be prescribed CPAP therapy by their physician. Subjects will be instructed to use their CPAP device according to their physician's guidelines.
62219151|NCT03972085|EXPERIMENTAL|Group 1|Patient received neural gliding exercises in addition electrotehrapy sessions.
62413419|NCT06039007|EXPERIMENTAL|7-DAY FMD|The 7-DAY FMD by L-Nutra is a low-calorie and low-protein diet that provides all the necessary micronutrients to prevent malnutrition. This medically-designed dietary kit supplies food for 7 days, with Day 1 providing 1100 kcal, while days 2 to 5 provide 800 kcal per day. The diet consists of ingredients that are Generally Regarded As Safe (GRAS), selected for their fasting mimicking properties. Patients will take the 7-DAY FMD once every 60 days.
62413420|NCT01033513||Literature Only (Control)|The participants on this arm served as the control group. Five types of literature were mailed to the participants in the literature only arm. A letter was included with the materials thanking participants for their participation, requesting that the participants read the literature, and encouraging them to contact the RDs with any questions. The Clinical Study Manager's telephone number was provided for questions about diet or lifestyle changes. The RDs documented all contacts with participants on a phone summary. Other than the delivery of literature and responses to specific questions asked by the participant or the participant's primary caregiver through telephone calls, the RDs had no further interaction with the participant until the conclusion of the participant's trial period.
62433301|NCT04590469|NO_INTERVENTION|Treatment as Usual|Usual Best practice
62586619|NCT06541379||Control Healthy Group|"The Standardized Mini Mental Test (SMMT) will be used to assess the cognitive status of individuals, the Beck Depression Inventory (BDI) to assess depression symptoms, the Movement Imagery Questionnaire-3 to assess motor imagery ability, the Mental Chronometry Test (MKT) to measure motor imagery time, the mobile application called Orientate to assess hand mental rotation task performance, the Box and Block Test to assess gross motor dexterity and functionality, the Jebsen Taylor Hand Function Test (JTEFT) to assess fine and gross motor functions of the hand, the Disabilities of the Arm Shoulder and Hand (DASH) for upper extremity functional assessment, the Modified Functional Reach Test (MFUT) to measure the dynamic balance of the trunk and the Joint Position Sense measurement to assess proprioceptive sense."
62219152|NCT03972085|ACTIVE_COMPARATOR|Group 2|Patient received only electrotherapy sessions
62433302|NCT03047954|EXPERIMENTAL|Broncho-Vaxom|1 capsule (3.5 mg) per day, administered over 9 months
62586620|NCT05911646|EXPERIMENTAL|OSA-18 Case Group|"Case group participants will be given the OSA-18 survey at the start of their consultation. OSA-18 is an 18-item questionnaire that collects information about 5 subscales that are considered to be elements in quality of life: sleep disturbance, physical symptoms, emotional symptoms, daytime function, and caregiver concerns. The score is calculated that ranges from 18 (no impact on quality of life) to 126 (major negative impact).~Upon completion of OSA-18, scores are tabulated and relayed to families through a decisional aid. The score and the aid, which explains treatment options, risks and benefits will be used to guide discussion throughout the consultation.~After the consultation is complete and the provider leaves the room, families will be given a decisional conflict scale survey. All surveys will remain anonymous by using a unique study identifier. Forms will be placed in a locked box by parents prior to departure from the exam room."
62795022|NCT06345547||Child C|Patients with Child C have an advanced hepatic dysfunction, within this group we will also look at patients with acute on chronic liver failure.(ACLF)
62795023|NCT04140630||E-cigarette users and bystanders|Households with one e-cigarette user (adult (18 years old and above); e-cigarette exclusive user for at least 1 month; daily use of e-cigarettes inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of any tobacco products or e-cigarettes) and one bystander cohabiting with the user
62433303|NCT03047954|PLACEBO_COMPARATOR|Placebo|Matching placebo capsule
62219153|NCT04495101|EXPERIMENTAL|Prolastin 120 mg/kg + Standard Medical Treatment|Subjects will receive Prolastin, two intravenous infusion (IV) doses of 120 milligram per kilogram (mg/kg), based upon the subject's body weight, on Day 1 and Day 8. Subjects will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
62219154|NCT04495101|ACTIVE_COMPARATOR|Standard Medical Treatment|Subjects will receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
62219155|NCT05146180|EXPERIMENTAL|Parametric positron emission computed tomography|
62219156|NCT03394001|ACTIVE_COMPARATOR|Lidocaine Hydrochloride|Wound infiltration with Lidocaine
62219157|NCT03394001|ACTIVE_COMPARATOR|Ketorolac tromethamine|Wound infiltration with Ketorolac
62219158|NCT05110027|EXPERIMENTAL|Period 1: Enpatoran + [14C]enpatoran microtracer|
62219159|NCT05110027|EXPERIMENTAL|Period 2: Enpatoran + [14C]enpatoran microdose|
62219160|NCT03042897|EXPERIMENTAL|Supportive Care (exercise and diet)|Patients undergo aerobic exercise thrice weekly over 95 minutes for up to 16 weeks. Patients also undergo multi-lifestyle interventions based on the DASH diet once weekly over 1 hour for up to 16 weeks.
62219161|NCT04897750|EXPERIMENTAL|Active|a target dose of intranasal sufentanil 0,5 mcg/kg + ketamine 0,5 mg/kg, (2-4 puffs) and an additional dose if needed as premedication before placement of a PVC for induction of anaesthesia.
62586621|NCT05911646|ACTIVE_COMPARATOR|Control Group|"During the consultation, families will be given a printed form, decisional aid, which is given to families to explain treatment options as well as their risks and benefits. The consultation will proceed as normal according to standard of care with the aid being used to guide conversation.~After the consultation is complete and the provider leaves the room, families will be given a decisional conflict scale survey to complete. All surveys will remain anonymous and only a unique study identification number will be placed on the surveys to correctly match each survey. Forms will be placed in a locked box by parents prior to departure from the exam room."
62219162|NCT06476613|EXPERIMENTAL|Permissive hypotension Intervention|In addition to the regular care provided to cardiac surgery patients, those in the permissive hypotension intervention arm will have a MAP target \> 60mmHg.
62219163|NCT06476613|NO_INTERVENTION|Standard of Care|Patients randomized to the standard of care arm will receive the regular care provided to cardiac surgery patients.
62219164|NCT00687687|EXPERIMENTAL|Pacitaxel/Carboplatin/Iniparib|Participants will be administered pacitaxel, carboplatin and BSI-201 (Iniparib) in 21 day treatment cycles. Treatment will continue until disease progression or adverse effects prohibit further therapy.
62219165|NCT00218660|EXPERIMENTAL|1|Nal + BRENDA
62219166|NCT00218660|PLACEBO_COMPARATOR|2|Placebo + BRENDA
62219167|NCT00218660|EXPERIMENTAL|3|Nal + CBT
62586622|NCT05114005|EXPERIMENTAL|Tango|The intervention will consist of 16 Argentine Tango (Tango) sessions, adapted for neurorehabilitation per Hackney and Earhart (2010). Delivered over 8 weeks at a frequency of 2x per week and duration of 1 hour per session, this program teaches the basics steps of partnered Tango dance.
62219168|NCT00218660|PLACEBO_COMPARATOR|4|Placebo + CBT
62219169|NCT05294601|ACTIVE_COMPARATOR|HIIG Group|General nutritional recommendations will be suggested in an initial consultation with weekly telephone follow-up. The high intensity children's games program for 12 weeks, . In this group the activities will include 3 weekly sessions. . The games last 6 minutes with a 2 minute break, four games per session; which is the one established for children of these ages according to the cited authors. The session is divided into 5 minutes of warm-up, 36 minutes of intervention and 8 minutes of cool-down. The intensity varies between 85-95% of HR max. According to the equation of Tanka et., Al. HR max = 208-0.7 x age
62243373|NCT05767866|EXPERIMENTAL|Part 3: ExTension Cohort 4|In dose-extension phase, previously treated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 150mg/day and who have no active, measurable central nervous system (CNS) metastases.
62243374|NCT05767866|EXPERIMENTAL|Part 3: ExTension Cohort 5|In dose-extension phase, previously treated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 200mg/day and who have no active, measurable central nervous system (CNS) metastases.
62243375|NCT05767866|EXPERIMENTAL|Part 3: ExTension Cohort 6|In dose-extension phase, previously untreated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 200mg/day and who have no active, measurable central nervous system (CNS) metastases.
62243376|NCT05767866|EXPERIMENTAL|Part 3: ExTension Cohort 7|In dose-extension phase, previously treated patients with EGFR rare mutation （G719X、L861Q、S768I etal.)were enrolled. YK-029A was given at doses of 150mg/day and who have no active, measurable central nervous system (CNS) metastases.
62243377|NCT05767866|EXPERIMENTAL|Part 3: ExTension Cohort 8|In dose-extension phase, previously treated patients with EGFR rare mutation （G719X、L861Q、S768I etal.)were enrolled. YK-029A was given at doses of 200mg/day and who have no active, measurable central nervous system (CNS) metastases.
62243378|NCT05767866|EXPERIMENTAL|Part 3: ExTension Cohort 9|In dose-extension phase, previously untreated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 150mgBID and who have no active, measurable central nervous system (CNS) metastases.
62243379|NCT02341703|ACTIVE_COMPARATOR|letrozole-metformin group|"this group will receive letrozole 2.5 mg daily from day 3 of the cycle and for 5 days + metformin 500 mg three times daily from the first day of the cycle and continuous for three months unless pregnancy occurred. treatment will continue for 3 cycles unless pregnancy occurred.~for this group: transvaginal ultrasound will monitor follicular enlargement laboratory investigations in the form of day 3 FSH, LH, TSH and serum testosterone will be done day 12 E2 day 21 serum progesterone"
62243380|NCT02341703|ACTIVE_COMPARATOR|letrozole-metformin-pioglitazone group|"this group will receive letrozole 2.5 mg daily from day 3 of the cycle and for 5 days + (metformin 850 mg + pioglitazone 15 mg) once daily from the first day of the cycle and for 10 days. treatment will continue for 3 cycles unless pregnancy occurred.~for this group: transvaginal ultrasound will monitor follicular enlargement laboratory investigations in the form of day 3 FSH, LH, TSH and serum testosterone will be done day 12 E2 day 21 serum progesterone"
62243381|NCT01104142||MDI|Subject on multiple Daily Injections
62243382|NCT01104142||CSII|Subjects on Continuous Subcutaneous Insulin Infusion
62243383|NCT04452903|EXPERIMENTAL|Reassurance intervention|The physiotherapist in the intervention group (n=15) will participate in a 3-hour communication skill workshop, followed by a month-long period to assimilate and implement the new set of skills, with supervision available by phone from the trainers.
62243384|NCT04452903|NO_INTERVENTION|Control|The physiotherapist in the control group (n=15) receives no training.
62243385|NCT00912652|EXPERIMENTAL|High Intensity Lifestyle Intervention|High intensity group will receive 48 sessions of lifestyle intervention over a two-year period
62243386|NCT00912652|EXPERIMENTAL|Mod. Intensity Lifestyle Intervention|Moderate intensity group will receive 32 sessions of lifestyle intervention over a two-year period.
62243387|NCT00912652|EXPERIMENTAL|Low Intensity Lifestyle Intervention|Low intensity group will receive 16 sessions of lifestyle intervention over a two-year period.
62219170|NCT05294601|ACTIVE_COMPARATOR|MIIG Group|: The interventions will be carried out by a graduate in physical education, recreation and / or sports and the main researcher. General nutritional recommendations will be suggested in an initial consultation with weekly telephone follow-up. The medium intensity physical activity program for 12 weeks (28). Medium intensity activities are very similar to those taught in physical education class. In this group the activities will include 3 weekly sessions, with six episodes of 10 min at 65% to 85% of maximum heart rate (HRmax) separated by 5 min of recovery.
62219171|NCT05294601|NO_INTERVENTION|Control Group|In this group, measurements will be made before, during and after the study. Neither medium nor high intensity interventions will be carried out in order to generate comparisons, control biases and confounding and interaction variables. However, the interventions that have been most beneficial in the intervention groups. It could be implemented in this study once the analysis between groups has been completed, according to the recommendations and follow-up by the ethics committee.
62219172|NCT02478710|PLACEBO_COMPARATOR|Aerosolized Placebo|Placebo tobramycin 0.5 mL 0.9% normal saline q.12h. Placebo vancomycin 0.5 mL 0.9% normal saline q.8h.
62219173|NCT02478710|EXPERIMENTAL|Aerosolized Tobramycin or Vancomycin|Aerosolized tobramycin 300 mg diluted in 5 mL 0.9% normal saline q.12h. Aerosolized vancomycin 125 mg diluted in 5 mL 0.9% normal saline q.8h.
62219174|NCT03750045|EXPERIMENTAL|Experimental group|For the tests, the volunteers used the access device (Leap Motion) and a computer that were previously installed. The intervention was composed by 8 sessions of 15 minutes each, where the volunteers used a virtual environment attached it to a Leap Motion, which is a sensor that allows to capture the movements that are produced by the hands and reproduce them in a computer through a 3D virtual environment in order to stimulate the execution of their finer movements. The strength (Jamar) and motor coordination (wooden box) evaluations were made in the first, fourth and eighth sessions with the objective of checking the gain progression or not of motion coordination and grip strength.
62219175|NCT06610123|EXPERIMENTAL|Genotype AA - Male - Caffeine|
62219176|NCT06610123|EXPERIMENTAL|Genotype AC or CC - Male - Caffeine|
62219177|NCT06610123|PLACEBO_COMPARATOR|Genotype AA - Male - Placebo|
62219178|NCT06610123|PLACEBO_COMPARATOR|Genotype AC or CC - Male - Placebo|
62219179|NCT06610123|EXPERIMENTAL|Genotype AA - Female - Caffeine|
62586623|NCT05114005|ACTIVE_COMPARATOR|Home Exercise (HEX)|The control group will consist of an evidence-based, structured home exercise program (HEX) based on the 8 week intervention described by Zimmer et al (2018) and recommended by physical therapists specializing in BC within our organization. This program consists of information on neuropathy and fall prevention combined with a schedule of 1 hr training (i.e., endurance, resistance, and sensorimotor) performed 2x per week
62219180|NCT06610123|EXPERIMENTAL|Genotype AC or CC - Female - Caffeine|
62219181|NCT06610123|PLACEBO_COMPARATOR|Genotype AA - Female - Placebo|
62586624|NCT06348797|EXPERIMENTAL|α-PD-L1/4-1BB DLL3 CAR-T (BHP01) Treatment|The Patients enrolled will be sequentially assigned to the corresponding dose level, BHP01 was administered intravenous infusion at different cell dose levels. The patients were received multiple-dose infusion according to investigator's evaluation.
62586625|NCT05508035|EXPERIMENTAL|sacubitril / valsartan|sacubitril / valsartan 200 mg twice a day PLUS placebo for ramipril 5 mg twice a day
62219182|NCT06610123|PLACEBO_COMPARATOR|Genotype AC or CC - Female - Placebo|
62219183|NCT03356626|EXPERIMENTAL|ULTRACISION Harmonic Scalpel|Patients group randomized to use ULTRACISION Harmonic Scalpel when receives laparoscopic gastrectomy
62219184|NCT03356626|EXPERIMENTAL|Ligasure Maryland|Patients group randomized to use Ligasure Maryland when receives laparoscopic gastrectomy
62219185|NCT03356626|EXPERIMENTAL|Thunderbeat|Patients group randomized to use Thunderbeat when receives laparoscopic gastrectomy
62219186|NCT05688345|ACTIVE_COMPARATOR|Remimazolam|Maintenance doses of remimazolam is administered for sedation
62219187|NCT05688345|ACTIVE_COMPARATOR|Propofol|Propofol is administered for sedation through target-controlled infusion
62219188|NCT05688345|ACTIVE_COMPARATOR|Dexmedetomidine|Loading and maintenance doses of dexmedetomidine are administered for sedation
62219189|NCT00369473|EXPERIMENTAL|1|350
62219190|NCT00369473|EXPERIMENTAL|2|350
62219191|NCT01394822||Ultrasound results reported|
62586626|NCT05508035|ACTIVE_COMPARATOR|ramipril|ramipril 5 mg twice a day PLUS placebo for sacubitril / valsartan 200 mg twice a day
62586627|NCT05296343||Adolescents and young adults|Boys and girls from 15 to 25 years old admitted to an Emergency Department (ED) following a suicidal act or considered as such by the medical team
62219192|NCT01394822||Ultrasound results NOT reported|
62219193|NCT03271554||Alectinib|Participants with ALK-positive, locally advanced or metastatic non-small cell lung cancer, who are treated with alectinib in accordance with local clinical practice and local labeling, are observed in this study.
62219194|NCT04733521|EXPERIMENTAL|NSCLC|
62219195|NCT04733521|EXPERIMENTAL|BTC|
62219196|NCT02984293|ACTIVE_COMPARATOR|Atorvastatin|The participants will receive atorvastatin (80 mg) orally once daily for 28 days.
62219197|NCT02984293|PLACEBO_COMPARATOR|Placebo|The participants will receive matched placebo orally once daily for 28 days.
62219198|NCT05690724|EXPERIMENTAL|Mitocholine™|Mitocholine™ is a novel formulation of three nutrients choline, succinic acid, and nicotinamide (a vitamin B3)
62219199|NCT05690724|PLACEBO_COMPARATOR|Placebo|The Placebo product will be identical in appearance and taste to the investigational product
62219200|NCT02383056|SHAM_COMPARATOR|Sham Group (Group 1)|This group will receive 4 sessions of Omnilux sham light, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
62586628|NCT05296343||Parents|One or the two parents of the included adolescents and young adults
62219201|NCT02383056|EXPERIMENTAL|Treatment group (Group 2)|This group will receive 4 treatment sessions with Omnilux 633nm LED, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
62586629|NCT05296343||Healthcare professionals|Professionals working in one emergency departments of the inclusion centers and who usually take care of suicidal adolescents and young adults
62586630|NCT02698657|EXPERIMENTAL|ASP5094 Dose Escalation|Three sequential cohorts will receive increasing intravenous doses of ASP5094. After all subjects in a cohort have completed study procedures the overall safety and tolerability of the dose will be determined after evaluation of the safety data. If there are no events which meet the stopping criteria, the next sequential cohort will begin enrollment while the current subjects continue through the third dose and the remainder of the study.
62586631|NCT02698657|PLACEBO_COMPARATOR|Placebo Dose Escalation|Three sequential cohorts will receive increasing intravenous doses of Placebo. After all subjects in a cohort have completed study procedures the overall safety and tolerability of the dose will be determined after evaluation of the safety data. If there are no events which meet the stopping criteria, the next sequential cohort will begin enrollment while the current subjects continue through the third dose and the remainder of the study.
62586632|NCT06684002|EXPERIMENTAL|Pilates training|The Pilates exercise program will be conducted for eight weeks, two days per week, with each session lasting 40 minutes.
62586633|NCT06684015||Intratechal morphine|Addition of intrathecal morphine as an adjuvant to local anesthesia in routine spinal anesthesia application and multimodal analgesia applications
62586634|NCT06684015||Erector spinae plane block|Application of erector spinae plane block and multimodal analgesia applications at the end of the operation after routine spinal anesthesia application
62586635|NCT05704348|ACTIVE_COMPARATOR|No gastropexy|Sleeve gastrectomy without gastropexy.
62586636|NCT05704348|EXPERIMENTAL|Gastropexy|Sleeve gastrectomy with gastropexy
62586637|NCT03813836|EXPERIMENTAL|pembrolizumab + best supportive care|Best supportive care and pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
62586638|NCT06185049|EXPERIMENTAL|PROCARE+ (Core intervention with add-on modules) and two booster sessions, at 6 and 12 months|In addition to core UP-A preventive intervention, PROCARE + will apply an innovative personalized medicine approach by adding specific modules according to the risk factor evidenced by adolescents. Different modules will be suited for the stratified groups in a more personalized format. Add-on young-focused modules would include: rejection, bullying/cyberbullying, addictions, healthy lifestyle habits, exam stress management, ecoanxiety, parental expressed emotion. Two booster sessions would be included (at 6 and 12 months).
62795024|NCT04140630||Conventional cigarette smokers and bystanders|Households with one smoker (adult (18 years old and above; manufactured cigarette exclusive smoker for at least 6 months; daily smoking inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of tobacco products or e-cigarettes) and one bystander cohabiting with the smoker
62219202|NCT02875808||patients|patients with an external ventricular drainage
62219203|NCT03350373|EXPERIMENTAL|Fasted dosing followed by fed dosing|Dosing of FYU-981 in the fasted state followed by fed dosing
62219204|NCT03350373|EXPERIMENTAL|Fed dosing followed by fasted dosing|Dosing of FYU-981 in the fed state followed by fasted dosing
62219205|NCT00556387|PLACEBO_COMPARATOR|1|Placebo Group receiving Saline Infusion.
62219206|NCT00556387|EXPERIMENTAL|2|Case Group receiving Ketamine infusion.
62219207|NCT04695912|OTHER|Initial activity tracker with feedback followed by control period|Initial activity tracker with feedback followed by control period
62433304|NCT05900609|EXPERIMENTAL|Fiber arm|"Subjects receive dietary guidelines, to increase their fiber intake. Additionally, during the last 6 weeks of the intervention period subjects receive a study product containing 8,5 grams fiber per day.~Additionally, subjects receive general guidelines about the effect of nutrition on the gut microbiome."
62219208|NCT04695912|OTHER|Initial control period followed by activity tracker with feedback|Initial control period followed by activity tracker with feedback
62433305|NCT05900609|EXPERIMENTAL|Fermented food arm|"Subjects receive dietary guidelines, to increase their intake of fermented foods.~Additionally, during the last 6 weeks of the intervention period subjects receive a study product of 17 millilitres concentrated kombucha per day.~Additionally, subjects receive general guidelines about the effect of nutrition on the gut microbiome."
62219209|NCT02781844|EXPERIMENTAL|A/B or B/A|Participants will be randomized to either receive 25 microgram (mcg) rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 25mcg rhPTH(1-84) BID with no calcium for treatment period 2
62219210|NCT02781844|EXPERIMENTAL|C/B or B/C|Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 2
62433306|NCT05900609|PLACEBO_COMPARATOR|Control|"Subjects receive general guidelines about the effect of nutrition on the gut microbiome.~Additionally, during the last 6 weeks of the intervention period subjects receive a placebo product of 10 grams maltodextrin per day."
62433307|NCT01689974|OTHER|Arm A: Ipilimumab|Ipilimumab administered alone Day 4, 25, 46, and 67
62586639|NCT06185049|EXPERIMENTAL|PROCARE+ (Core intervention with add-on modules) and a booster session at 6 months.|In addition to core UP-A preventive intervention, PROCARE + will apply an innovative personalized medicine approach by adding specific modules according to the risk factor evidenced by adolescents. Different modules will be suited for the stratified groups in a more personalized format. Add-on young-focused modules would include: rejection, bullying/cyberbullying, addictions, healthy lifestyle habits, exam stress management, ecoanxiety, parental expressed emotion. A booster sessions would be included at 6 months.
62795025|NCT04140630||Heated tobacco product users and bystanders|Households with one user of the heated tobacco product, HTP (adult (18 years old and above; • HTP exclusive user for at least 1 month; daily use of HTP inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of tobacco products or e-cigarettes) and one bystander cohabiting with the user
62795026|NCT04140630||Non-smokers and non-users (control)|Smoke free households (participants should be adult (18 years old and above), non e-cigarette user (never or former e-cigarette user \>1 month), non-user of any kind of tobacco product (never or former user \>1 month), and other household members should not be users of tobacco products or e-cigarettes
62219211|NCT02781844|EXPERIMENTAL|D/E or E/D|Participants will be randomized to either receive 25mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 25mcg rhPTH(1-84) twice daily with calcium for treatment period 2
62795027|NCT02293798|EXPERIMENTAL|SERI|Subjects receiving SERI for mastopexy
62795028|NCT00546546|NO_INTERVENTION|control = conventional treatment|conventional treatment: use of immunosuppressants only if steroid dependency or chronic active disease
62795029|NCT00546546|EXPERIMENTAL|Immunossuppresive treatment|Switch to different immunosuppresive treatment in case of relapse.
62795030|NCT02392572|EXPERIMENTAL|Arm A (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO once every 3 weeks. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62795031|NCT02392572|EXPERIMENTAL|Arm B (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO once every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62219212|NCT02781844|EXPERIMENTAL|F/E or E/F|Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with calcium for treatment period 2
62219213|NCT04201782||Cohort 1|Long-term follow-up of HIV-infected subjects who received SB-728-T or SB-728mR-T in a previous trial.
62795032|NCT02392572|EXPERIMENTAL|Arm C (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO on the first two consecutive days of every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62219214|NCT06434896|EXPERIMENTAL|ctDNA-based treatment group|Patients randomized to the ctDNA-based treatment group will have their post-surgery samples analysed directly after informed consent for MEDOCC-CrEATE. Results are reported to the treating physician and patients. All patients with detectable ctDNA are considered high risk stage 2 patients and will be offered adjuvant chemotherapy for 3 months (4 cycles CAPOX) according to routine clinical practice. Patients with undetectable ctDNA will receive routine follow-up at the surgical department.
62795033|NCT02392572|EXPERIMENTAL|Arm D (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62219215|NCT06434896|NO_INTERVENTION|Standard of care group|The treating physician and patient are not informed about the ctDNA result and these patients will receive routine follow-up at the surgical department.
62219216|NCT02592408|ACTIVE_COMPARATOR|Pf: ASP|In falciparum patients (Pf): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP)
62795034|NCT02392572|EXPERIMENTAL|Arm E (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO twice weekly. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62219217|NCT02592408|ACTIVE_COMPARATOR|Pv: ASP + 14DPQ on day 2|In vivax patients (Pv): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and 14 days of primaquine (14DPQ) starting on day 2
62795035|NCT01887132|EXPERIMENTAL|Open-Label Donepezil|
62795036|NCT01887132|EXPERIMENTAL|Donepezil - Blinded|
62795037|NCT01887132|PLACEBO_COMPARATOR|Placebo|
62219218|NCT02592408|ACTIVE_COMPARATOR|Pf: ASP + SDPQ|In falciparum patients (Pf): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and a single dose of primaquine (SDPQ) on day 2
62795038|NCT04881617|EXPERIMENTAL|Lexical Retrieval Treatment|
62795039|NCT04881617|EXPERIMENTAL|Script Training|
62219219|NCT02592408|ACTIVE_COMPARATOR|Pv: ASP + 14DPQ on day 42|In vivax patients (Pv): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and 14 days of primaquine (14DPQ) starting on day 42
62795040|NCT02756676|EXPERIMENTAL|Rehabilitative treatment (MIRT)|Rehabilitative treatment MIRT consist in daily sessions of: motor treatment, occupational therapy and language speech therapy
62795041|NCT01464177|ACTIVE_COMPARATOR|Stereotactic hypofractionated RT 5x5Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* the dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization."
62795042|NCT01464177|EXPERIMENTAL|Stereotactic hypofractionated RT 5x7Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* the dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization."
62022859|NCT00765908|EXPERIMENTAL|A|Patients undergoing elective PCI will be randomised to 90 second balloon inflations rather than the standard less than 30 second inflations in order to induce peri-ischaemic conditioning.
62219220|NCT00189488|EXPERIMENTAL|Palifermin|Palifermin 60 μg/kg administered daily on 3 consecutive days prior to the day of start of the conditioning regimen and 180 μg/kg administered once prior to transplant and at least 96 hours from last palifermin dose of 60 μg/kg. Participants received conditioning therapy starting at least 24 hours after the last 60 μg dose of palifermin. Allogeneic stem cell transplant occurred on Day 0. Methotrexate dosing began at least 24 hours after the 180 μg/kg dose of palifermin on Days 1, 3, 6 and (planned) 11 administration (toxicity allowing) at doses of 15, 10, 10 and 10 mg/m\^2 respectively.
62243388|NCT00912652|ACTIVE_COMPARATOR|Health Education Control|Health education control group will receive 16 sessions of health education related to diet and exercise over a two-year period.
62795043|NCT01025063||Lucentis (PRN group)|
62243389|NCT06390319|EXPERIMENTAL|Patients with T-ALL (except ETP or near-ETP)|"All eligible patients receive intervention according to the Detailed Description section with the following:~Induction: Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Dasatinib, IT MHA~Early Post Induction: Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, IT MHA, Methotrexate, Dasatinib, Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol~Maintenance: Mercaptopurine, Methotrexate, Nelarabine, Cyclophosphamide, Cytarabine, Dexamethasone, Vincristine, Dasatinib, IT MHA, Thioguanine"
62243390|NCT06390319|EXPERIMENTAL|Patients with ETP or near-ETP ALL or MPAL|"All eligible patients receive intervention according to the Detailed Description section with the following:~Induction: Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Venetoclax, IT MHA~Early Post Induction: Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, IT MHA, Methotrexate, Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Venetoclax~Maintenance: Mercaptopurine, Methotrexate, Nelarabine, Cyclophosphamide, Cytarabine, Dexamethasone, Vincristine, IT MHA, Thioguanine"
62586640|NCT06185049|EXPERIMENTAL|PROCARE+ (Core intervention with add-on modules) without booster sessions|In addition to core UP-A preventive intervention, PROCARE + will apply an innovative personalized medicine approach by adding specific modules according to the risk factor evidenced by adolescents. Different modules will be suited for the stratified groups in a more personalized format. Add-on young-focused modules would include: rejection, bullying/cyberbullying, addictions, healthy lifestyle habits, exam stress management, ecoanxiety, parental expressed emotion. Only follow-up would be conducted up to 12 months.
62795044|NCT01025063||Lucentis (3 Injections over three months)|
62795045|NCT01025063||PDT (Reduced Fluence) and Lucentis|
62586641|NCT04847284|EXPERIMENTAL|Single arms|To determine the efficiency and safety of IORT with low-energy photons to the cavity after resection of brain metastases
62586642|NCT06598202|EXPERIMENTAL|Exosomes group|Patients in this arm will receive exosomes derived from human umbilical cord blood mesenchymal stem cells as a nasal drop, administered once daily, twice a week, for a total of two weeks.
62586643|NCT06598202|PLACEBO_COMPARATOR|Exosomes placebo group|Patients in this arm will receive a placebo nasal drop mimicking exosomes derived from human umbilical cord blood mesenchymal stem cells, administered once daily, twice a week, for a total of two weeks.
62586644|NCT04867707|EXPERIMENTAL|Zanamivir treatment|Study participants will receive 5 days of treatment with a zanamivir inhaler.
62586645|NCT05118776|EXPERIMENTAL|ASC40|ASC40 tablets 100mg/m\^2 and bevacizumab 10mg/kg.
62586646|NCT05118776|PLACEBO_COMPARATOR|Placebo|Placebo and bevacizumab 10mg/kg.
62586647|NCT05474170|EXPERIMENTAL|AHA --> ERC|This group will first apply the AHA resuscitation sequence, then the ERC one
62022860|NCT00765908|ACTIVE_COMPARATOR|B|Control group. These patients will have a standard procedure with balloon inflations of 30 seconds or less as per standard.
62586648|NCT05474170|ACTIVE_COMPARATOR|ERC --> AHA|This group will first apply the ERC resuscitation sequence, then the AHA one
62586649|NCT03615144|ACTIVE_COMPARATOR|Melphalan/Thiotepa/Clofarabine|Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
62586650|NCT03615144|ACTIVE_COMPARATOR|Melphalan/Thiotepa/ Fludarabine|Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
62795046|NCT04303572|EXPERIMENTAL|Eloctate ITI plus Emicizumab|Arm A: Eloctate 100 IU/kg every other day by intravenous infusion plus Emicizumab 1.5 mg/kg subcutaneously (following 3 mg/kg/wk x 4 induction) in children and adults with severe hemophilia A and anti-FVIII inhibitor, continued up to 48 weeks.
62795047|NCT04303572|ACTIVE_COMPARATOR|Eloctate ITI|Arm B: Eloctate 100 IU/kg every other day by intravenous infusion in children and adults with severe hemophilia A and anti-FVIII inhibitor, continued up to 48 weeks.
62586651|NCT01493284|EXPERIMENTAL|Transfemoral Access|Transfemoral Access for transcatheter aortic valve implant
62586652|NCT03181269|EXPERIMENTAL|Intervention education|Participants will receive the intervention education and data recording package.
62586653|NCT03181269|PLACEBO_COMPARATOR|Placebo education|Participants will receive the placebo educational and data recording package.
62795048|NCT04789915|ACTIVE_COMPARATOR|Memantine + aripiprazole|"Tablet memantine or placebo will be initiated at 10mg/day for 1 week, hereafter the dose will be increased to 20mg/day until end of trial. The tablets will be identical and be provided in 10mg tablets or 20 mg tablets. (12 weeks of treatment).~Tablet aripiprazole will be administered in doses starting at 5-10 mg/day. Doses will be increased slowly according to effect and side effects up to 30 mg/day."
62413421|NCT01033513||Meals Only|Participants in the meals only arm received a pre-intervention assessment (but no nutrition counseling). The RDs gave the participants in the meals only arm a phone number and encouraged them to phone with questions or problems, especially problems associated with the meals. Subsequently, the meals only participants received seven diagnosis-appropriate therapeutic meals a week, delivered once per week. The meals were specially designed to address the participants' medical diagnoses. They were developed using the ADA MNT protocols for caloric and nutrient content requirements for individuals with the specified diagnoses, in addition to meeting AoA Nutrition Program dietary requirements. The meals were provided primarily in frozen form. However, some shelf-stable and refrigerated components were also included. In conformance with AoA regulations, appropriate meals were also offered to the spouse of any participant receiving a therapeutic meal.
62586654|NCT06334328|EXPERIMENTAL|Virtual reality based mindful movement therapy|"Participants will be asked to complete 12 VR-MMT sessions over a 6-week period, with two 30-minute sessions per week.~Each session will be comprised of a guided warm-up (5 min, pre-recorded video played on the computer monitor) followed by a VR module with a head-mounted display (HMD) on (20 min). The VR module includes both structured and freestyle dance/movement guided by the therapist's prompts that are pre-recorded. Sessions will end with a closing routine (5 min, including guided breathing, stretching, and meditation) in order to assist participants to transition back to the real environment."
62586655|NCT03154463|ACTIVE_COMPARATOR|TAP blocks|TAP group was received TAP block using ultrasound as a guide and injected on three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points)
62586656|NCT03154463|ACTIVE_COMPARATOR|continuous epidural infusion|Epidural group received epidural regional anesthesia in sitting position, with epidural regimen of 0.25% bupivacaine without any adjuvant
62586657|NCT04058652|EXPERIMENTAL|TENS therapy|the first step would be to administer the biologic medication in one thigh without the use of TENS therapy. Biologic medications are administered in two doses, with one in each thigh. Administering the first biologic medication injection is done to establish a control, or baseline, for how painful the injection experience is. The second step would be a study team member applying two to four TENS unit pads (made of adhesive gel) to the skin of subject's other thigh approximately two centimeters from the site where injection of the biological medication takes place. There will be no extra injection of biologic medication during this procedure. The prescribed dose will be used one time, split into two legs (which is the standard protocol for administration). The device will be turned on during the injection of the medication. Immediately after both steps, the subject will be given a brief survey to determine your pain level. The subject's involvement would last roughly 10-15 minutes.
62586658|NCT01763580|EXPERIMENTAL|Tacrolimus with low-dose corticosteroid|Oral
62586659|NCT01763580|ACTIVE_COMPARATOR|High-dose corticosteroid alone|Oral
62586660|NCT02809079|EXPERIMENTAL|Mycophenolate mofetil plus prednisone|Mycophenolate mofetil 500mg Bid and prednisone 10mg Qd
62586661|NCT06058442|EXPERIMENTAL|NORTASE®|
62586662|NCT06058442|PLACEBO_COMPARATOR|Placebo|
62795049|NCT04789915|PLACEBO_COMPARATOR|Placebo + aripiprazole|"Coated placebo tablets will be provided to match memantine. Placebo equivalent of 10mg/day for 1 week, hereafter the dose will be increased to 20mg/day until end of trial. (12 weeks of treatment).~Tablet aripiprazole will be administered in doses starting at 5-10 mg/day. Doses will be increased slowly according to effect and side effects up to 30 mg/day."
62795050|NCT06230224|EXPERIMENTAL|Odronextamab|Participants will receive odronextamab monotherapy.
62795051|NCT06230224|ACTIVE_COMPARATOR|Standard Of Care|Participants will receive salvage therapy (ifosfamide, carboplatin, etoposide ± rituximab \[ICE ± R\], or dexamethasone, cisplatin, cytarabine ± rituximab \[DHAP ± R\], or gemcitabine, dexamethasone, cisplatin ± rituximab \[GDP ± R\]) and continue with autologous stem cell transplant (ASCT) following a complete response (CR)/partial response (PR).
62586663|NCT05578716|EXPERIMENTAL|Study formula 1|Formula-fed intervention group randomised to one of two study formulae
62586664|NCT05578716|EXPERIMENTAL|Study formula 2|Formula-fed intervention group randomised to one of two study formulae
62586665|NCT05578716|NO_INTERVENTION|Standard formula|Formula-fed control group randomised to standard formula
62586666|NCT05578716|NO_INTERVENTION|Breast feeding|Reference group with exclusively breast-fed infants
62586667|NCT03643601||Non-Dialysis (ND) Patients|For the ND patients, data are captured on each clinic visit during the course of the year (2-4 times per year), the last available record for 2015 will be used.
62586668|NCT03643601||Dialysis (DD) Patients|For the DD patients, data are input from a randomly selected visit to the hospital in September to October 2015; the evaluation will be based on this record.
62586669|NCT03169075|EXPERIMENTAL|ARM A: A|Supervised physical exercise programs (SPEP)
62586670|NCT03169075|ACTIVE_COMPARATOR|ARM B: B|Adapted physical activity (APA)
62586671|NCT03626363|EXPERIMENTAL|Mindfulness-Based Stress Reduction|An 8-week program specifically designed to improve mindfulness and to reduce stress.
62586672|NCT03626363|ACTIVE_COMPARATOR|Stress Management Education|An 8-week program specifically designed to provide education about stress responses in humans, and as an active control for Mindfulness-Based Stress Reduction studies.
62586673|NCT05201963|NO_INTERVENTION|Group 1 control group|Control group will recive only IV Opioids
62586674|NCT05201963|EXPERIMENTAL|Group 2 ((Serratus Anterior Plane Block SAPB))|Patients will receive Ultrasound guided Serratus Anterior Plane Block with injection of 30 ml levobupivacaine 0.25%
62586675|NCT05201963|EXPERIMENTAL|Group 3 ((Erector Spinae Plane Block ESB))|Patients will receive Ultrasound guided erector spinae plane block with injection of 30 ml levobupivacaine 0.25%.
62795052|NCT05479240|EXPERIMENTAL|short-range radiotherapy sequential Tislelizumab combined with chemotherapy|
62795053|NCT05479240|EXPERIMENTAL|short-range radiotherapy combined with chemotherapy|
62413422|NCT01033513||MNT Only|The participants in this arm received MNT from the project RDs, who employed the Hyperlipidemia Medical Nutrition Therapy MNT Protocol, developed by ADA (2002). Because ADA had not finalized MNT protocols for hypertension, the RDs followed the protocol for hyperlipidemia for participants diagnosed with either hyperlipidemia or hypertension, with adjustments, as appropriate, to benefit those individuals who were diagnosed with hypertension.All MNT sessions were in the participants' homes, and if a caregiver was required for the individual to participate in the project, every effort was made to include this person in the MNT sessions. The MNT intervention took place over at least three sessions, and, in conformance with the ADA protocol, each participant received individualized counseling and education.
62795054|NCT00687804|EXPERIMENTAL|Ranibizumab 0.5 mg|"Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA \> 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Patients also received sham laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
62022861|NCT03727204||Aarhus University Hospital|100 patients undergoing on-pump cardiac surgery at Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand
62022862|NCT03727204||Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand|50 patients undergpoing on-pump cardiac surgery at at Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand
62022863|NCT04071002|ACTIVE_COMPARATOR|surgical group|distal radius fractures that treated volar plate
62022864|NCT04071002|ACTIVE_COMPARATOR|conservative group|distal radius fractures that treated plaster of paris
62022865|NCT03251469|ACTIVE_COMPARATOR|Group 1|intravenous tranexamic acid, 15mg/kg, preoperatively, single dose
62022866|NCT03251469|PLACEBO_COMPARATOR|Group 2|Intravenous normal saline, 100mg, preoperatively, single dose
62022867|NCT01907451||The control group|"will receive support traditional10 hours per week: techniques called neuro-facilitators"
62022868|NCT01907451||test group|enjoy the same support as control group at 7 hours week, coupled with a personalized retraining effort ergometer for 3 hours per week: after a 5 minute warm to 50% of Heart Rate Maximum (HRmax) of the initial test effort (TE), continuous work of 20 minutes at an intensity corresponding to 70% HRmax, followed by a recovery period of 5 min between active 40 and 50% of maximum heart rate (5 times per week).
62022869|NCT06237283|EXPERIMENTAL|Early shower|Start shower after drain removal
62022870|NCT06237283|NO_INTERVENTION|Late shower|Start shower after wound stitches are removed
62022871|NCT06288815|EXPERIMENTAL|Oral fluid|"* NPO (8hr for food, 2hr for water)~* Intraoperative IV fluid at least 1 liter~* Post operative (Off IV fluid, allow oral fluid as protocol at least 24hr)"
62022872|NCT06288815|ACTIVE_COMPARATOR|IV fluid|"* NPO (8hr for food, 2hr for water)~* Intraoperative IV fluid at least 1 liter~* Post operative (IV fluid as protocol at least 24hr, allow oral fluid as usual)"
62022873|NCT03314987|ACTIVE_COMPARATOR|intervention group|Each participant will be given a daily oral dose of 2 grams of carnosine for 12 weeks
62022874|NCT03314987|PLACEBO_COMPARATOR|placebo group|Each participant will be given a daily oral dose of 2 grams of placebo for 12 weeks
62022875|NCT00968669|EXPERIMENTAL|MEDI528 30 mg|MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
62022876|NCT00968669|EXPERIMENTAL|MEDI528 100 mg|MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
62022877|NCT00968669|EXPERIMENTAL|MEDI528 300 mg|MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
62022878|NCT00968669|EXPERIMENTAL|Placebo|Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
62022879|NCT01076400|EXPERIMENTAL|Part 1: adavosertib + topotecan/cisplatin|Part 1: Dose escalation study. adavosertib capsules will be administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3 . Cisplatin will be administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.
62586676|NCT06665633|OTHER|Treatment of U.S. Veterans with mild traumatic brain injury with hyperbaric oxygen therapy|Pilot Study - A total of 40 HBOT treatments at 1.5 atmospheres absolute (ATA) for a dive time of 60 minutes, twice a day Monday through Friday. The treatments were separated by an air break of 4 hours on the same day. Measurements of the effectiveness of HBOT in mTBI done before and after HBOT.
62586677|NCT04959201|EXPERIMENTAL|NMDAE plus Antioxidant agent (AO)|An NMDA enhancer plus a drug with antioxidant property
62022880|NCT01076400|EXPERIMENTAL|Part 2: adavosertib + topotecan/cisplatin|Part 2: adavosertib capsules will be administered at the dose determined in Part 1 twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3. Cisplatin will be administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.
62022881|NCT01076400|PLACEBO_COMPARATOR|Part 2: Placebo to adavosertib + topotecan/cisplatin|Part 2: Placebo to adavosertib capsules will be administered twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3. Cisplatin will be administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.
62022882|NCT02306915|EXPERIMENTAL|lipegfilgrastim 30|
62022883|NCT02306915|EXPERIMENTAL|lipegfilgrastim 60|
62022884|NCT02306915|EXPERIMENTAL|lipegfilgrastim 100|
62022885|NCT00882674|EXPERIMENTAL|1|
62022886|NCT02641548|EXPERIMENTAL|Silicone sock+heel cream|Every evening a cream (Footmender, Auxilum Cura Innovatio, Dublin, Ireland, European Patent 2522342) is applied to the feet and a sock of silicone is used every night.
62022887|NCT02641548|ACTIVE_COMPARATOR|Heel cream|Every evening a cream (Footmender, Auxilum Cura Innovatio, Dublin, Ireland, European Patent 2522342) is applied to the feet
62022888|NCT05571917|EXPERIMENTAL|ACT + MBRP Intervention|The ACT + MBRP group will follow a manualized clinical protocol. Treatment will include 12 weekly, virtual group-based sessions, each lasting 90 minutes. Group sizes will range from three to ten participants. All sessions will be audio recorded for fidelity. Over the course of the group meetings, participants identify areas of meaningful functioning that have been adversely impacted by pain, learn methods to enhance pain willingness in the service of these meaningful areas, and practice present-focused awareness skills. Group sessions include discussions of the impact of pain and distress avoidance, identifying alternatives to this avoidance and establishing plans for behavior change, demonstration and role-playing exercises, and homework assignments. Participants are provided with a treatment manual to help guide and inform practice outside of group sessions.
62219221|NCT00189488|PLACEBO_COMPARATOR|Placebo|Placebo to palifermin 60 μg/kg administered daily on 3 consecutive days prior to the day of start of the conditioning regimen and placebo to palifermin 180 μg/kg once prior to transplant and at least 96 hours from previous placebo to palifermin 60 μg/kg dose. Participants received conditioning therapy starting at least 24 hours after the last 60 μg/kg dose of placebo to palifermin. Allogeneic stem cell transplant occurred on Day 0. Methotrexate dosing began at least 24 hours after the dose of placebo to palifermin 180 μg/kg on Days 1, 3, 6 and (planned) 11 administration (toxicity allowing) at doses of 15, 10, 10 and 10 mg/m\^2 respectively.
62219222|NCT00366002|EXPERIMENTAL|1|Darifenacin
62219223|NCT01849627|EXPERIMENTAL|Low-ED|This condition will focus lowering on the energy density of the diet of the diet. This prescription does not include goals for any other nutrients, thus there are no energy goals.
62219224|NCT01849627|EXPERIMENTAL|Energy Balance|This condition will focus have an energy balance prescription. Participants will be asked to consume a daily energy intake at estimated energy needs for weight loss maintenance.
62413423|NCT01033513||Meals and MNT|The participants assigned to the MNT plus meals arm received both of the interventions, as described above.
62413424|NCT01833897|EXPERIMENTAL|Ketamine and DCS treatment|Standard of Care: Subjects will receive treatment with either quetiapine, olanzapine-fluoxetine, or lurasidone. If after about 2 week, subjects are symptomatic, subjects will receive infusion of ketamine hydrochloride (0.5 mg/kg). After the ketamine phase, subject who show improvement will begin an 8-week treatment of oral D-cycloserine.
62413425|NCT04951817|EXPERIMENTAL|Ga68-PSMA ligand|Glass vial with 5\~20 mCi(185-740 MBq) of 68Ga-PSMA ligand in ≤10% EtOH with aqueous sterile water for injection solution (approximately 15.5 mL), ≧ 0.33 mCi/mL @ EOS。
62219225|NCT06179784|EXPERIMENTAL|Exposure in vivo|The goal of the exposure in vivo treatment module is the correction of irrational, fearful beliefs regarding movements, a reduction of avoidance behaviours and hence a facilitation of activity levels. This will be done by carrying out feared, avoided movements and seeking out avoided situations and places. Exemplary units are the development of a movement hierarchy and protocols for exposure exercises.
62413426|NCT03797378|EXPERIMENTAL|eM2M|Participants in the eM2M arm will participate in an intervention that involves three 60-minute M2M sessions per week for 12 weeks. All sessions are delivered remotely in real-time through videoconferencing technology. At the beginning and end of each session, vital signs (heart rate, blood pressure and peripheral capillary oxygen saturation) are obtained from participants. Participants rate perceived exertion, pain, and fatigue level on a log. Participants set weekly exercise goals and expectations at first session of each week. Participants also record daily activities using a provided log.
62413427|NCT03797378|NO_INTERVENTION|Waitlist Control|Participants in the waitlist control arm are instructed to maintain their usual activities during the 12-week intervention period and are asked to record their activities on a provided log.
62795055|NCT00687804|EXPERIMENTAL|Ranibizumab 0.5 mg + laser|"Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA \> 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Patients also received active laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
62795056|NCT00687804|ACTIVE_COMPARATOR|Laser|"Laser photocoagulation treatment was administered on Day 1 and at intervals of at least 3 months, if deemed necessary by the physician. Patients also received monthly sham intravitreal injection in the study eye for 3 consecutive months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA \> 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
62219226|NCT06179784|EXPERIMENTAL|Relaxation|Goal of the relaxation treatment module is the reduction of stress and tension, which will be achieved applying relaxation techniques such as Progressive Muscle Relaxation (PMR), breathing techniques, and imaginary methods.
62586678|NCT04959201|PLACEBO_COMPARATOR|NMDAE plus Placebo|An NMDA enhancer plus Placebo
62586679|NCT01253551|EXPERIMENTAL|001|Treatment sequence AB Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6 with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10 with a morning dose of raltegravir and a morning and afternoon dose of telaprevir on Day 11.
62586680|NCT01253551|EXPERIMENTAL|002|Treatment sequence BA Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6 with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10 with a morning dose of raltegravir and a morning and afternoon dose of telaprevir on Day 11.
62795057|NCT06176768|EXPERIMENTAL|LY3972406 Dose 1|Participants will receive an oral dose of LY3972406
62219227|NCT06179784|EXPERIMENTAL|Activity and Rest|The treatment module activity and rest is based on pacing and pursues the goal to balance active and resting phases. For overly active patients, the module will consist of implementing breaks and resting phases, while for overly resting patients the module will consist of graduated activity build-up. Acitivity protocols, plans, and exercises will be used.
62795058|NCT06176768|EXPERIMENTAL|LY3972406 Dose 2|Participants will receive an oral dose of LY3972406
62795059|NCT06176768|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62219228|NCT06179784|EXPERIMENTAL|Cognitive Coping with Pain|Goal of the treatment module cognitive coping with pain is the reduction of rigid, dysfunctional thought patterns by flexibilising them and implement functional thought patterns instead. It includes classical methods such as cognitive restructuring as well as meta-cognitive or defusion techniques.
62413428|NCT02099929|EXPERIMENTAL|Coffee with Sugar|300mL of Coffee with 30g of Sugar
62413429|NCT02099929|EXPERIMENTAL|Coffee without Sugar|300mL of Coffee without Sugar
62413430|NCT02099929|EXPERIMENTAL|Decaffeinated Coffee without Sugar|300mL of Decaffeinated Coffee without Sugar
62413431|NCT02099929|SHAM_COMPARATOR|Water with Sugar|300mL of Water with 30g of Sugar
62413432|NCT02099929|SHAM_COMPARATOR|Water without Sugar|300mL of Water without Sugar
62586681|NCT05896150|EXPERIMENTAL|Intercostal cryoanalgesia AND single-injection paravertebral block|"* Videothoracoscopic-guided single-injection paravertebral block at T5 with 0.4 mL/kg of Bupivacaine 0.5% with adrenalin 5 mcg/mL (maximum 40 mL) at the beginning of surgery~* Cryoanalgesia 5 cm lateral to the neuraxial, on the inferior costal border, CO2 at (-)50C to (-)70C for 2 minutes, repeated on 7 costal levels (T3-T9), after the lung resection and before chest closure."
62586682|NCT05896150|ACTIVE_COMPARATOR|Single-injection paravertebral block|-Videothoracoscopic-guided single-injection paravertebral block at T5 with 0.4 mL/kg of Bupivacaine 0.5% with adrenalin 5 mcg/mL (maximum 40 mL) at the beginning of surgery
62795060|NCT03257033|EXPERIMENTAL|IA Therapy|IA Treatments with 1,000 mg/m2 gemcitabine administered through RenovoCath every other week for a maximum of 8 treatments for approximately 16 weeks.
62586683|NCT03384836|EXPERIMENTAL|Treatment (propranolol hydrochloride, pembrolizumab)|Patients receive propranolol hydrochloride PO BID and pembrolizumab IV over 30 minutes of day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
62413433|NCT04842448|EXPERIMENTAL|Hyperbaric oxygen treatment|HBO2 240 kPa, 90 min, maximum 10 treatments
62586684|NCT01851382||Cohort 1|Healthy volunteers.
62586685|NCT06685328|EXPERIMENTAL|minimal posterior pole vitrectomy|Patients undergo minimal posterior pole vitrectomy with tearing of the internal limiting membrane and its folding to cover the macular hole, injection of perfluorocarbon liquid to isolate the balanced salt solution, injection of sodium hyaluronate gel under the perfluorocarbon liquid to cover the folded internal limiting membrane, replacement of the perfluorocarbon liquid and filling of the vitreous cavity with the balanced salt solution and postoperative supine position for 24 hours.
62022889|NCT05571917|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|The Enhanced Usual Care (EUC) condition will supplement standard practices within the study sites related to chronic pain and OUD education. Participants randomized to the EUC condition will receive a brochure (in-person, via email, or via text message) with a list of chronic pain treatment resources, signs and management of opioid overdose including naloxone, and overdose prevention, and will encouraged to schedule an appointment with a clinical provider if they would like to discuss any current or past symptoms. In addition to receiving the brochure, EUC condition participants will meet with a therapist remotely for approximately 15 minutes for a descriptive overview of the brochure. In this session, the therapist will point out the resources in the brochure and read the helpful tips out loud to the participant. This session will be audio recorded for fidelity.
62586686|NCT06685328|OTHER|conventional vitrectomy|Patient undergo conventional vitrectomy with tearing of the inner limiting membrane and flipping to cover the macular hole, gas-liquid exchange and sterile air to fill the vitreous cavity, keeping standard prone position for three days postoperatively.
62022890|NCT00724971|EXPERIMENTAL|Inotuzumab Ozogamicin + Rituximab|
62413434|NCT04842448|PLACEBO_COMPARATOR|Sham treatment|Air 134-120 kPa, 90 min, maximum 10 treatments
62022891|NCT06297538|EXPERIMENTAL|gamma transcranial alternating current stimulation|
62022892|NCT06297538|SHAM_COMPARATOR|sham transcranial alternating current stimulation|
62413435|NCT03074916||DIP arthroplasty|
62586687|NCT06666582||Patients who received paclitaxel - ramucirumab as second-line treatment|Patients with unresectable or metastatic, locally advanced adenocarcinoma of the stomach, gastroesophageal junction, or distal esophagus who had been treated at Departments of Medical Oncology affiliated with the Hellenic Cooperative Oncology Group (HeCOG). All patients had received second-line treatment for advanced disease with paclitaxel and ramucirumab, for at least two months.
62586688|NCT06666582||Patients who received other regimens as second-line treatment|patients with unresectable or metastatic, locally advanced adenocarcinoma of the stomach, gastroesophageal junction, or distal esophagus who had been treated at Departments of Medical Oncology affiliated with the Hellenic Cooperative Oncology Group (HeCOG). All patients had received second-line treatment for advanced disease based on international/national guidelines, except from paclitaxel and ramucirumab. All other regimens, combinations of drugs as well as monotherapy, were accepted. Patients were included in the analysis if they have received at least two months of second-line treatment.
62022893|NCT01267123|EXPERIMENTAL|Trendelenburg position|The endoscopist places the patient in 15° Trendelenberg position immediately prior to the initiation of the colonoscopy.
62022894|NCT01267123|OTHER|Standard care|The patient will have colonoscopy in the standard horizontal position
62022895|NCT03871647||POAF group|Patients who will experience AF at any time during the first six days after the operation.
62022896|NCT03871647||Non POAF group|Patients with a sinus rhythm during the first six days after the operation.
62413436|NCT03074916||DIP arthrodesis|
62413437|NCT00463385|EXPERIMENTAL|Prednisone|"Participants received oral prednisone from Day 1-28 of each 28-day cycle for up to 3 cycles (84 days), 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day, and pomalidomide placebo tablets on Days 1-28 for up to 12 cycles in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants were discontinued from the study."
62413438|NCT00463385|EXPERIMENTAL|Pomalidomide|"Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and prednisone placebo tablets on Days 1-28 for the first 3 cycles in the Double-Blind Treatment Phase.~After the completion of Cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
62586689|NCT06668545||Group 1:|Patients with preeclampsia
62586690|NCT06668545||Group 2:|Patients without preeclampsia
62586691|NCT05144308|EXPERIMENTAL|Patients operated with a TECNIS® Eyhance Toric II 1-piece posterior chamber lens|For at least one eye : Planned cataract surgery with placement of a TECNIS® Eyhance Toric II 1-piece posterior chamber lens
62022897|NCT02114892|EXPERIMENTAL|Resveratrol|Resveratrol capsules, 500 mg, three times per day before meals during 90 days
62022898|NCT02114892|PLACEBO_COMPARATOR|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals during 90 days
62022899|NCT04064281|EXPERIMENTAL|the healthy Cantonese diet|Based on the typical Cantonese diet, the healthy Cantonese diet is developed according to the DASH diet and the balanced dietary pattern of the Chinese Dietary Guidelines 2016. In this diet, the main nutrients, dietary fiber, sodium, calcium, magnesium and potassium are set to achieve the healthy goal. Compared with the typical Cantonese diet, the healthy Cantonese diet is increased in fruit, vegetables, low-fat dairy products, whole grains, nuts and seeds, and reduced in salt, oil and sweets.
62219229|NCT06179784|EXPERIMENTAL|Attention Control|The goal of the treatment module attention control is to enable patients to willingly draw their attention towards other entities as their pain or perceive their pain in a non-judgmental way, thus improve their coping strategies and enhance functioning levels. Exemplary units are the anti-pain diary or the distraction alphabet.
62219230|NCT06179784|EXPERIMENTAL|Activating Resources|The goal of the activating resources module is relief and a balance between unpleasant perceptions as pain and pleasent experiences. This will be achieved by reactivating lost resources and implementing new ones, e.g. social networks or hobbies. Exemplary units are the positive diary or focusing on healthy bodyparts.
62219231|NCT06179784|EXPERIMENTAL|Acceptance|Goal of the acceptance module is the flexibilisation of thought patterns by regaining mental resources through givign up inner resistance against the pain. Patients will be supported in developing an accepting attitude towards their suffering using working units like the monster by the wayside or concluding a peace treaty with oneself.
62219232|NCT06179784|EXPERIMENTAL|Values and Values-based Action|Goal of the treatment module values and values-based action is enhancing satisfaction with life and regaining action control. Patients will learn about their personal values and how they can align their actions with them. Exemplary units are sorting values, a value diary, or looking back on one's life.
62219233|NCT06179784|EXPERIMENTAL|Sleep|Goal of the treatment module sleep is enhancing the subjective sleep quality and increase the feeling of recovery. Patients will learn about sleep hygiene, stimulus control, and imaginary techniques such as the inner feel-good place.
62219234|NCT06179784|EXPERIMENTAL|Selfcompassion|Goal of the selfcompassion treatment module is the development of a benevolent, loving, and kind attitude towards oneself and one's suffering in order to enhance wellbeing and feelings of self-worth. Exemplary units are the selfcompassion break, writing a letter to oneself, or changing perspective.
62219235|NCT05055557||ARDS group|"1.85 years≥Age≥18 years. 2.Moderate-to-severe ARDS, defined by the ARDS Definition Task Force in the Berlin definition (partial pressure of arterial oxygen \[PaO2\]:FiO2 ratio ≤200 mmHg with a PEEP ≥5 cmH2O).~3.Diagnosis of ARDS less than 72 hours. 4.Just observation"
62219236|NCT05055557||Critically ill patients without ARDS group|Unstable vital signs, rapid changes in the condition, unstable function of more than two organ systems (excluding the respiratory system), decline or failure, the development of the disease may endanger the life of the patient.
62219237|NCT05055557||healthy adult group|Healthy adults, voluntarily join the study.
62219238|NCT04158232|ACTIVE_COMPARATOR|Blood clotting protocol for pulp regeneration|pulp regeneration for mature teeth using blood clotting protocol
62219239|NCT04158232|EXPERIMENTAL|platelet rich fibrin for pulp regeneration|pulp regeneration for mature teeth using platelet rich fibrin (PRF)
62219240|NCT00730275|EXPERIMENTAL|Sitagliptin 50 mg|Participants were randomized to sitagliptin 50 mg
62413439|NCT00463385|EXPERIMENTAL|Pomalidomide 2 mg + Prednisone|"Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
62022900|NCT04064281|PLACEBO_COMPARATOR|the typical Cantonese diet|The typical Cantonese diet is a diet of what many Cantonese eat. In this diet, the main nutrients, dietary fiber, sodium, calcium, magnesium and potassium are set at the average dietary intake levels in Guangdong.
62413440|NCT00463385|EXPERIMENTAL|Pomalidomide 0.5 mg + Prednisone|"Participants received 0.5 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 0.5 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
62022901|NCT01547572|EXPERIMENTAL|Study group|The study group will get a video and leaflet on enhanced recovery.
62022902|NCT01547572|NO_INTERVENTION|Control group|The control group will receive a leaflet only.
62022903|NCT00389935|EXPERIMENTAL|Treatment|
62022904|NCT05267301|EXPERIMENTAL|AlmgaPL|New consumers of iwi self-elected to start taking 2 capsules a day with 1000 mg of AlmegaPL, containing 250 mg of eicosapentaenoic acid (EPA), 150 mg polar lipids and 15 mg chlorophyll.
62219241|NCT00730275|EXPERIMENTAL|Sitagliptin 100 mg|Participants were randomized to sitagliptin 100 mg
62219242|NCT00730275|EXPERIMENTAL|Sitagliptin 200 mg|Participants were randomized to a single dose of sitagliptin 200 mg
62219243|NCT00730275|PLACEBO_COMPARATOR|Placebo to sitagliptin|Participants were randomized to matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg
62219244|NCT04019223||anti-tissue transglutaminase group|serum IgA-tissue transglutaminase antibody (tTG) was analyzed in serum using a quantitative automated ELISA method by means of a commercially available detection kit using recombinant human tTG as antigen recommended cut-off by the manufacturer \> 8 U/mL).
62413441|NCT00491322|EXPERIMENTAL|Ergocalciferol group|Ergocalciferol 50000 international units once a week for 12 weeks
62413442|NCT00491322|PLACEBO_COMPARATOR|Ergocalciferol Placebo group|Matching placebo once a week for 12 weeks
62795061|NCT03257033|ACTIVE_COMPARATOR|IV Therapy|IV gemcitabine and nab-paclitaxel will be administered for 16 weeks on days 1, 8, and 15 of a 28 day cycle. Nab-paclitaxel will be administered intravenously following pre-medication at a dose of 125 mg/m2 over 30 minutes followed by an infusion of gemcitabine at a dose of 1000 mg/m2 over 30 minutes.
62022905|NCT03981003||MS Patients|
62022906|NCT04494412|EXPERIMENTAL|Hospitalized neonates and infants with influenza infection|Preterm neonates and infants who have reached Post-Menstrual Age (PMA) of at least 28 weeks and have a confirmed complicated influenza infection will be included. Participants will receive daily IV infusion of zanamivir for up to 5 days. This initial 5-day treatment course may be extended for up to 5 additional days if clinical symptoms, participant characteristics or virological tests warrant further treatment. The initial dose of IV zanamivir will be determined by PMA/corrected age and body weight. The maintenance dose and interval between the initial dose and subsequent twice-daily maintenance dose will be further determined by Principal Investigator based on renal function.
62413443|NCT06136676|EXPERIMENTAL|Heart-centred spiritual meditation|Intervention 1: Christian contemplation and Intervention 2: Islamic contemplation
62413444|NCT06136676|ACTIVE_COMPARATOR|Mindfulness Meditation (MBRS)|Intervention 3: Mindfulness Meditation (MBRS)
62413445|NCT06136676|NO_INTERVENTION|Waitlist control|No Intervention: Participants in this condition will not receive any intervention and the outcome measures will be only collected at time points T1 and T2. After T2 testing, they will be given access to either the Christian or Islamic intervention.
62795062|NCT00795236|NO_INTERVENTION|Observational|Observe to determine free-running versus entrained status.
62795063|NCT00795236|EXPERIMENTAL|Melatonin|Subjects with free-running rhythms will take melatonin.
62795064|NCT06725316|NO_INTERVENTION|control group|Women in the control group will receive routine care in the hospital. Vital signs assessment form will be used to evaluate vital signs and development of complications in the first 8 hours of the postoperative period. The 'Mcgill Pain Scale Short Form' form will be used to evaluate the pain of the patients and the pain of the patient will be evaluated 4 times in total, at two, four, six and eight hours post-op.
62795065|NCT06725316|EXPERIMENTAL|Experimental Group|"The women in the experimental group will be taught 4-7-8 breathing exercises before the operation. After making sure that they perform these exercises correctly, the training will be terminated. In order to perform the 4-7-8 exercise correctly and easily, an audible second counting application will be installed on the participants' phones and an hourly reminder alarm will be set. Participants will perform the first exercise with the postoperative nurse and the following exercises by themselves. Participants will be asked to do the exercise four times every hour for the first 8 hours postoperatively.~Vital signs assessment form will be used to evaluate vital signs and development of complications in the first 8 hours postoperatively. The 'Mcgill Pain Scale Short Form' form will be used to evaluate the pain of the patients and the patient's pain will be evaluated 4 times in total, at two, four, six and eight hours post-op."
62795066|NCT03261609||Extremely preterm (EPT)|"All adults born at gestational age (GA) \<29 wks at CHU Sainte-Justine (CHUSJ), the Royal Victoria Hospital (RVH), and the Jewish General Hospital (JGH), Montreal, in 1987-97.~Inclusion criteria: (a) Birth at GA\<29 wks, (b) age 18-29 years at the time of assessment (age of peak human physiological function).~Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion. In case of twins (or +), if both fulfil inclusion criteria, only one will selected (random) to participate to the study."
62795067|NCT03261609||Term or controls|"Same-sex friends identified by EPT subject who have accepted to be contacted. Inclusion criteria: (a) Birth at GA ≥37 wks, (b) born in Quebec, to account for health care access during pregnancy and throughout infancy/childhood, (c) birth date within 2 years of index case, (d) age 18-29 years at the time of assessment, (e) same self-reported race as preterm participant.~Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion."
62795068|NCT01187628|EXPERIMENTAL|Arm 1|
62795069|NCT03610191||Surgery|Patients aged over 18 scheduled for elective cardiac surgery under CPB and general anesthesia. This group will later be divided in to two sub groups based on their neuropsychological battery tests results before surgery and one day before discharge. Blood sample will be collected before, immediately after surgery and at 24h after surgery for serum biomarker tests: MD2, CysC as well as DNA methylation markers of neural system origin.
62795070|NCT03610191||non-surgical control|Age and sex matched volunteers from the community were included for neuropsychological battery tests and set as controls for the diagnosis of POCd in surgical patients.
62795071|NCT05307692|EXPERIMENTAL|Seltorexant|Participants will receive single oral dose of seltorexant 20 milligrams (mg) tablet once daily from Day 1 to Day 42.
62795072|NCT05307692|PLACEBO_COMPARATOR|Placebo|Participants will receive single oral dose of matching placebo tablet once daily from Day 1 to Day 42.
62022907|NCT03616210|EXPERIMENTAL|Protective ventilation|Protective ventilation strategy (tidal volume of 6 to 7 ml.kg-1 of predicted body weight and PEEP of 6 to 8 cmH2O)
62413446|NCT00006092|EXPERIMENTAL|Arsenic Trioxide Treatment|Patients receive arsenic trioxide IV over 2-3 hours daily for 28 days. Patients who respond may receive a second course of therapy beginning 28 days from the last dose of the first course.
62413447|NCT02392559|PLACEBO_COMPARATOR|Placebo|Matching subcutaneous injection every 4 weeks (QM)
62413448|NCT02392559|EXPERIMENTAL|EvoMab 420 mg QM|Evolocumab subcutaneous injection QM
62413449|NCT02578043|EXPERIMENTAL|Clindamycin and BPO Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% applied to the face once daily for 84 days.
62413450|NCT02578043|ACTIVE_COMPARATOR|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) applied to the face once daily for 84 days.
62413451|NCT02578043|PLACEBO_COMPARATOR|Placebo|Placebo (vehicle of the test product) applied to the face once daily for 84 days.
62413452|NCT00390572|EXPERIMENTAL|Sleep Specialty Consultation|Participants randomized to receive a one-time sleep consultation at beginning of study
62413453|NCT00390572|NO_INTERVENTION|Treatment as Usual|Participants randomized to receive a one-time sleep consultation after completing study procedures (after 10 month study wait-list period).
62413454|NCT05644899||SMA patients|51 adults with a genetically confirmed diagnosis of SMA (13 SMA type 2, 38 SMA type 3) treated with nusinersen. The technique used was based on the anesthesiologist's preference.
62413455|NCT05288452|EXPERIMENTAL|Arm 1|Digital coaching+ Food delivery+ RPM
62413456|NCT05288452|ACTIVE_COMPARATOR|Arm 2|Digital coaching
62795073|NCT04223713|EXPERIMENTAL|TriRec|Trileaflet Reconstruction of the Aortic Valve
62795074|NCT04223713|EXPERIMENTAL|Aortic valve replacement|Biological prosthesis, Device: Edwards Perimount
62413457|NCT05288452|ACTIVE_COMPARATOR|Arm 3|Digital coaching+ Food delivery
62413458|NCT05288452|ACTIVE_COMPARATOR|Arm 4|Digital coaching+ RPM
62413459|NCT05288452|ACTIVE_COMPARATOR|Arm 5|Food delivery+ RPM
62413460|NCT05288452|ACTIVE_COMPARATOR|Arm 6|The participant's will not receive any Intervention
62413461|NCT05288452|ACTIVE_COMPARATOR|Arm 7|Food delivery
62413462|NCT05288452|ACTIVE_COMPARATOR|Arm 8|RPM
62413463|NCT02384239|EXPERIMENTAL|Palbociclib 100mg and, fulvestrant or tamoxifen|Palbociclib dose 100mg, and either fulvestrant (500 mg IM on days 1 and 15 in the first 28 days, then every 28 days thereafter) or tamoxifen (20 mg PO daily by physician choice)
62413464|NCT02384239|EXPERIMENTAL|Palbociclib 125mg and, fulvestrant or tamoxifen|Palbociclib dose 125mg and either fulvestrant (500 mg IM on days 1 and 15 in the first 28 days, then every 28 days thereafter) or tamoxifen (20 mg PO daily by physician choice)
62413465|NCT04591327||general anesthesia|
62413466|NCT04591327||spinal anesthesia|
62219245|NCT04019223||biopsy group|upper gastrointestinal endoscopic examination will be done and the jejunal histopathological examinations will be done at the Histopathology Laboratory. The features consistent with CD included: hyperplasia of crypts, atrophy of villous, and increase of intraepithelial lymphocytes.Duodenal samples will be processed using haematoxylin/eosin staining and CD3 immunophenotyping. The number of intra-epithelial lymphocytes (IEL), the architecture of villi, and the inflammatory cell infiltration of the lamina propria will be assessed. Histopathological changes will be classified according to the Marsh-Oberhuber criteria.Lymphocytic enteropathy (Marsh 1 lesion) was defined as 25 or more IEL per 100 epithelial nuclei, and normal villous architecture.
62413467|NCT04794725|OTHER|Blood Sampling|blood samples from venepuncture (10mL)
62586692|NCT05483998|EXPERIMENTAL|Part A: Single Ascending Dose (SAD)|Part A will be comprised of up to 50 participants over 5 cohorts of 10. Each participant will receive a single oral dose of TLC-2716 or placebo at different dose levels (1 cohort per dose level).
62586693|NCT05483998|EXPERIMENTAL|Part B: Multiple Ascending Dose (MAD)|Part B will be comprised of up to 50 healthy participants over 5 cohorts of 10. Each participant will receive 14 oral doses of TLC-2716 or placebo over 14 days (given once daily) at different dose levels (1 cohort per dose level).
62586694|NCT05483998|EXPERIMENTAL|Part C: Adaptive SAD and/or MAD|Part C is an adaptive style where the dosing level is a single- or multiple-ascending dose design. Based on safety and pharmacokinetic data from Parts A and B, doses for Part C will be chosen. Part C will be comprised of up to 50 participants over 5 cohorts of 10. Each participant will receive an oral dose of TLC-2716 or placebo at different dose levels (1 cohort per dose level).
62586695|NCT05034861|EXPERIMENTAL|cCTG|cCTG group, that will undergo a following process: EFW and Doppler assessment biweekly, and instead of additional weekly Doppler-only assessment, the patients will be provided with an electronic cCTG device at no cost (Carebits). Women will be asked to apply Carebits device at least twice weekly for at least 30 minutes (e.g. Mondays-Thursdays) with minimum 72 hours interval in case of 2 sessions per week. The trace will be examined by an independent centre, available 24 hours daily. The person examining the trace is trained or already specialized in Obs\&Gynae. In case of situation requiring medical intervention, the patient will be immediately contacted by phone and advised to self-refer to the nearest Antenatal Unit. In case of normal trace, a full report will follow within 30 minutes after last reading of the trace.
62795075|NCT00676013|EXPERIMENTAL|Alloderm, Integra, Homograft, Autograft|Burn debridement and grafting using interventions of 1) AlloDerm, 2) Integra, 3) Homograft and 4) Autograft on four separate sites on each patient
62022908|NCT03616210|NO_INTERVENTION|Conventional ventilation|Conventional mechanical ventilation (tidal volume between 9 to 10 ml.kg-1 of predicted body weight and PEEP between 3 and 5 cmH2O)
62433308|NCT01689974|OTHER|Arm B: Ipilimumab and Radiation|Radiation Therapy and Ipilimumab. Radiation treatment is administered for 5 fractions (sessions) over 1 week. On Day 4 treatment with Ipilimumab begins and continues on Days 25, 46, and 67.
62433309|NCT06312085|EXPERIMENTAL|Endofill arm|Endofill arm- This arm will receive the novel obturation material after root canal preparation and success of root canal treatment will be measured after 12 months
62433310|NCT01281878|EXPERIMENTAL|Pyridoxal-phosphate|Treatment with pyridoxal-phosphate in increasing dosages every six weeks starting with 5mg/kg body weight up to 20 mg/kg body weight. treatment duration 24 weeks
62022909|NCT02580149|ACTIVE_COMPARATOR|Ticagrelor|Loading dose of 180 mg on day one, followed by a regular intake (90 mg twice daily) for 14 days
62022910|NCT02580149|ACTIVE_COMPARATOR|Clopidogrel|Loading dose of 600 mg on day one, followed by a regular intake (75 mg once daily) for 14 days
62022911|NCT02073968|EXPERIMENTAL|Treatment (PET-adjusted IMRT, carboplatin, paclitaxel)|"RADIOTHERAPY: Patients undergo PET-adjusted IMRT or proton beam radiation therapy five days a week for 5 weeks.~CONCURRENT CHEMOTHERAPY: Patients receive carboplatin IV over 3 hours and paclitaxel IV over 1 hour once weekly for 6 weeks beginning week 1 of thoracic radiotherapy.~CONSOLIDATION CHEMOTHERAPY: Beginning approximately 4-6 weeks after the completion of all radiation therapy and when esophagitis and chemotherapy-induced neuropathy are grade 1 or less, ANC \> 1500, and platelet count \> 100,000, patients may receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Treatment may repeat every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity at the discretion of the treating physicians."
62022912|NCT06290362|NO_INTERVENTION|Control|Any intervention applied. Following the completion of the research, the need for psychosocial support among the control group participants was assessed, and it was found that none of the students in the control group required such support.
62022913|NCT06290362|EXPERIMENTAL|Cognitive Behavioural Theory-based group consultation|"Cognitive Behavioural Theory-based group consultation was given to the intervention group through an Instagram as online social media platform. This approach has been developed with the philosophy of Cognitive Behavioral Theory (Eskin, 2009). For three days a week over eight weeks of intervention conducted with synchronized psychoeducation sessions, online posts, surveys, personal sharing messages, and group interaction tools.~1. Introduction and warm-up,~2. Problem orientation-identifying the problem,~3. Identifying prior problems-Which one I want to start?~4. Recognizing the losses caused by problems and complaints,~5. Setting reachable and realistic goals,~6. Generating alternatives-What can I do?~7. Regulating emotions,~8. Experimenting and exploring. Sessions were completed in approximately one hour as semi-structured interactive group training according to group dynamics."
62022914|NCT02427529|EXPERIMENTAL|HCG Group|This group received daily subcutaneous injections of Human Chorionic Gonadotropin while eating a very low calorie diet of 500 calories per day.
62022915|NCT02427529|PLACEBO_COMPARATOR|Saline/Placebo|This group received daily subcutaneous injections of saline while eating a very low calorie diet of 500 calories per day.
62413468|NCT01017731|EXPERIMENTAL|IMC-1121B|"Active-control participants (first 16 participants) will receive one dose of moxifloxacin orally 7 days before the first treatment with ramucirumab. All participants will undergo triplicate electrocardiogram (ECG) tests (consisting of three individual ECGs performed consecutively within a period of 4 minutes) and vital signs at various times over the trial period.~For Cycle 1, all participants will also receive 2 infusions of diphenhydramine before ramucirumab therapy (the first infusion is 1 day before therapy and the second infusion is 15 minutes before therapy). For Cycles 2, 3, and 4, all participants will receive diphenhydramine 15 minutes before ramucirumab therapy. For Cycle 5 and beyond, diphenhydramine infusions before ramucirumab therapy are at the investigator's discretion. Ramucirumab \[10 milligrams per kilogram (mg/kg)\] intravenously over 60 minutes, once every 3 weeks for minimum of 9 weeks without a break in between."
62413469|NCT06566248|EXPERIMENTAL|Part A: TQA3810 tablets+NUC|Part A: TQA3810 tablets+NUC：A total of 4 dose groups were set up, which were respectively TQA3810 tablets 0.1mg once a day, 0.2mg once every two days, 0.3mg twice a week and 0.2mg once a day combined with oral nucleoside (acid) drugs (NUC) group for 24 weeks.
62413470|NCT06566248|PLACEBO_COMPARATOR|Part A: Placebo+NUC|Part A: Placebo+NUC: Placebo combined with oral nucleoside (acid) drugs (NUC) group was treated for 24 weeks.
62413471|NCT00171899|EXPERIMENTAL|STI571|
62022916|NCT05453474|EXPERIMENTAL|WGA|DNA from the cells are amplified by whole genome amplification prior to genetic testing.
62022917|NCT05453474|NO_INTERVENTION|No-WGA|DNA from the cells are tested directly without whole genome amplification
62219246|NCT03690232|EXPERIMENTAL|Glucose group|The glucose group underwent 3 sessions of 6cc 25% glucose injection with a 2-week interval between each treatment
62219247|NCT03690232|ACTIVE_COMPARATOR|hyaluronic acid group|The HA group was administered intra-articular HA ((Hyruan Plus® , average MW 3000 kD; LG Life Sciences Ltd, Korea)) for sessions with a 1-week interval between each treatment.
62219248|NCT05486962||Remote Patient Monitoring|Patients undergoing elective abdominal surgery will be asked to use a wearable activity tracker, vivosmart®HR by Garmin, pre and post-operatively to help remotely monitor health metrics. Data collected through the Garmin device will be reviewed to assess compliance and improvement in activity. Aggregate data will be analyzed to assess feasibility and effectiveness of this device in improving patient recovery.
62219249|NCT04695431||Patients from the BLU-285-2101 and BLU-285-2202 studies|Patients with advanced systemic mastocytosis who received treatment with avapritinib as part of the BLU-285-2101 and BLU-285-2202 studies
62413472|NCT06622824|EXPERIMENTAL|Arm A|KX-826 0.5% BID
62795076|NCT01496469|EXPERIMENTAL|Febuxostat 80 mg QD|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks.
62022918|NCT02302261||Status Asthmaticus|Any patient presenting to the ED with status asthmaticus.
62022919|NCT03650205|ACTIVE_COMPARATOR|Ivabradine|Patients will receive ivabradine just before anthracycline chemotherapy, 5 mg per oral twice daily, until one month after the last chemotherapy session.
62022920|NCT03650205|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo just before anthracycline chemotherapy, one capsule per oral twice daily, until one month after the last chemotherapy session.
62022921|NCT03305679|EXPERIMENTAL|Direct provisional technique|Patients here will be subjected to the direct provisional technique
62022922|NCT03305679|ACTIVE_COMPARATOR|Indirect Provisional technique|Patients here will be subjected to the indirect provisional technique
62022923|NCT02013765|EXPERIMENTAL|Trastuzumab Monotherapy|Participants received an initial dose of trastuzumab 4 milligrams per kilogram (mg/kg) intravenously (IV) on Day 1, followed by weekly doses of 2 mg/kg IV beginning on Day 8 and continuing for up to 37 weeks.
62219250|NCT04695431||External Control Group|Patients with advanced systemic mastocytosis that received best available therapy
62413473|NCT06622824|EXPERIMENTAL|Arm B|KX-826 1.0% BID
62795077|NCT01496469|PLACEBO_COMPARATOR|Placebo QD|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
62795078|NCT05121948|EXPERIMENTAL|Phase 1a Cohort 1 - 10 mg|10 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
62586696|NCT05034861|ACTIVE_COMPARATOR|Doppler|Doppler group, that will undergo a standard process of antenatal care in case of FGR. The EFW and CTG STV will be assessed biweekly. In case of positive end-diastolic flow in UA, Doppler assessment (MCA PI, UA PI, DV PI, Ut PI) will be provided on a weekly basis. In case of deterioration to AEDF/REDF, further management will depend on clinical situation and the patient will be excluded from the study group (applies to both arms).
62586697|NCT01877967|EXPERIMENTAL|Intervention|This group will intake the recommended daily amount of the food supplement VSL#3 (two sachets of the supplement in powder form) every day for twelve weeks. The two sachets will either be taken together or one in the morning and one in the evening.
62586698|NCT01877967|PLACEBO_COMPARATOR|Placebo|This group will intake two sachets (2x4.4g) of a placebo each day for 12 weeks. The placebo is in the same powdered form as the food supplement taken by the intervention group. The two sachets will either be taken together or one in the morning and one in the evening.
62795079|NCT05121948|EXPERIMENTAL|Phase 1a Cohort 2 - 20 mg|20 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
62795080|NCT05121948|EXPERIMENTAL|Phase 1a Cohort 3 - 40 mg|40 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
62795081|NCT05121948|EXPERIMENTAL|Phase 1a Cohort 4 - 75 mg|75 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
62795082|NCT05121948|EXPERIMENTAL|Phase 1a Cohort 5 - 125 mg|125 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
62413474|NCT06622824|PLACEBO_COMPARATOR|Arm C|Matching Vehicle
62413475|NCT06651177|EXPERIMENTAL|Tirzepatide|Tirzepatide is available in single dose vials at six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg/0.5 mL. A study MC will administer the once-weekly SQ dose of tirzepatide. Consistent with tirzepatide's prescribing guidelines, participants will be initiated at a once-weekly SQ dose of 2.5 mg/week with a dose increase to 5mg/week at week 5. Consistent with tirzepatide's prescribing information, once the participant has received 5 mg/week for 4 weeks they are eligible for a dose increase if needed.
62795083|NCT05121948|EXPERIMENTAL|Phase 1a Cohort 6 - 150 mg|150 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
62022924|NCT02882802|EXPERIMENTAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.
62413476|NCT06651177|PLACEBO_COMPARATOR|Placebo|"A matched placebo (containing saline) will be created for use in the trial. A study MC will administer the once-weekly SQ dose of saline. The process for deciding on dose increases will be the same for placebo and tirzepatide"
62413477|NCT03099655|EXPERIMENTAL|Attain Stability Quad Lead|Attain Stability Quad Lead (Model 4798) - Single arm study.
62586699|NCT06667661|EXPERIMENTAL|12-Week Intervention|"Participants in the intervention group will receive access to the Shining Star mobile health application for 12 weeks. The app provides weekly lessons and behavior-related goals focused on improving adherence to the 24-Hour Movement Guidelines (physical activity, screen time, and sleep). Parents will receive concise messages (less than 500 characters) through the app, along with links to additional resources, gamification elements, and behavior trackers. Participants and participants will also complete physical activity and sleep assessments using accelerometers and questionnaires at baseline, Week 6, and Week 12."
62586700|NCT06667661|NO_INTERVENTION|Wait-list Control|Participants in the wait-list control group will receive no intervention during the initial 12 weeks. They will complete the same assessments (physical activity, screen time, sleep, motor skills, and cognition) at baseline, Week 6, and Week 12. After the 12-week period, they will be granted access to the Shining Star mobile app and receive all lessons and resources provided to the intervention group.
62586701|NCT05944783|ACTIVE_COMPARATOR|Liteda®|Dasatinib 100 mg tablets Lab. Tecnofarma Colombia S.A.S. Liteda®
62413478|NCT02704988|ACTIVE_COMPARATOR|Colon Cancer - Carnoy|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
62586702|NCT05944783|ACTIVE_COMPARATOR|Sprycel®|Dasatinib 100 mg tablets Lab. Bristol-Myer Squibb Sprycel®
62586703|NCT00972556|EXPERIMENTAL|GMTA|
62586704|NCT00972556|ACTIVE_COMPARATOR|20% FC|
62586705|NCT03745976||Group 1|a new long-term total articular prosthesis follow-up strategy by simple questionnaire and radiography (questionnaire and Xray for all patients)
62586706|NCT05427487|EXPERIMENTAL|Part 1a|IVX037 administered intratumorally, 1, 2 or 3 doses q2wks, Day 1, 15 and 29.
62586707|NCT05427487|EXPERIMENTAL|Part 1b|IVX037 administered intratumorally 3 doses q2wks, for up to 7 doses. Sintilimab administration will commence on Study Day 8 and be administered every three weeks (Q3wks) at 200 mg/dose through to Study Day 344.
62586708|NCT06170658|EXPERIMENTAL|Test Lenses, Then Control Lenses|Participants will wear the Test Lenses in both eyes for one week and then cross over to the Control Lenses in both eyes for one week.
62586709|NCT06170658|EXPERIMENTAL|Control Lenses, Then Test Lenses|Participants will wear the Control Lenses in both eyes for one week and then cross over to the Test Lenses in both eyes for one week.
62586710|NCT00511082|EXPERIMENTAL|Treatment group|
62586711|NCT04735692|PLACEBO_COMPARATOR|Periodontitis quadrant Scaling root planing|Patients undergo non surgical quadrant scaling and root planing performed per quadrant
62586712|NCT04735692|ACTIVE_COMPARATOR|Periodontitis full mouth scaling root planing|Patients undergo non surgical full mouth scaling and root planing
62586713|NCT04580693||Healthy Volunteers/Control|Age and body surface area (BSA) matched volunteers who are sedentary or normally active. Normally active is defined as less than 5 hours of exercise per week. Healthy volunteer subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
62795084|NCT05121948|EXPERIMENTAL|Phase 1b Cohort 7 - Dose 1 Chosen for Expansion|XX mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
62413479|NCT02704988|ACTIVE_COMPARATOR|Colon Cancer - GEWF|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
62433311|NCT02357550|PLACEBO_COMPARATOR|Control|Saline infusion. FDG-PET Scan. O2-PET scan. H2O-PET scan Muscle biopsy
62586714|NCT04580693||Hypertrophic Cardiomyopathy/HCM|HCM subjects are patients that are age and BSA-matched with the athletes who then have an established clinical diagnosis of HCM without left ventricular (LV) outflow tract obstruction. There can be no anticipated changes to baseline exercise program (if any) over the study period. HCM subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
62586715|NCT04580693||Endurance Athletes|Official participation in a collegiate athletic varsity rowing team OR participation in competitive endurance athletics. Competitive endurance athletics is defined as greater than or equal to 10 hours of exercise training per week with the majority dedicated to endurance activities such as cycling, rowing, or running. Endurance athlete subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
62586716|NCT05491200|EXPERIMENTAL|Prasugrel-based short DAPT|Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy for 11 months.
62586717|NCT05491200|ACTIVE_COMPARATOR|Prasugrel based standard DAPT|Prasugrel-based DAPT for 1 year
62586718|NCT05491200|EXPERIMENTAL|OCT guided non-culprit lesion|Complete revascularization of non culprit lesions guided by OCT
62586719|NCT05491200|ACTIVE_COMPARATOR|Angio guided non-culprit lesion|Complete revascularization of non culprit lesions guided by Angio
62586720|NCT04965155|EXPERIMENTAL|Isatuximab-Dexamethasone|Isatuximab-Dexamethasone pre and post transplant in relapsed multiple myeloma patients.
62586721|NCT04884360|EXPERIMENTAL|Group A: Olaparib tablets 300 mg oral twice daily (n=238).|Participants in Group A will receive olaparib tablets taken orally at a dose of 300 mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator, whichever is earlier, and as long as in the investigator's opinion they are benefiting from treatment and do not meet any other discontinuation criteria.
62586722|NCT04884360|PLACEBO_COMPARATOR|Group B: Placebo tablets 300 mg oral twice daily (n=118)|Participants in Group B will receive matching placebo tablets taken orally at a dose of 300 mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator, whichever is earlier, and as long as in the investigator's opinion they are benefiting from treatment and do not meet any other discontinuation criteria.
62586723|NCT03421145|EXPERIMENTAL|3M™ Oral Rinse|Subjects assigned to the Experimental Oral Rinse ('Plaque control device) will swish a volume of 15 mL of the Experimental Rinse for 30 seconds followed by expectoration, twice a day (morning and evening), after brushing teeth, for the 6-month duration of the study. They will use the dosing cup provided by the study team to ensure that the proper dose of rinse is used. Subjects will be instructed not to eat or drink for 30 minutes after using the rinse and to complete the subject daily diary.
62795085|NCT05121948|EXPERIMENTAL|Phase 1b Cohort 8 - Dose 2 Chosen for Expansion|XX mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
62795086|NCT04187495|EXPERIMENTAL|MAX-40279-01|
62586724|NCT03421145|PLACEBO_COMPARATOR|Vehicle Control Oral Rinse|Vehicle control oral rinse (no active ingredient). Subjects assigned to the Placebo Comparator will swish a volume of 15 mL of the Placebo Comparator rinse for 30 seconds followed by expectoration, twice a day (morning and evening), after brushing teeth, for the 6-month duration of the study. They will use the dosing cup provided by the study team to ensure that the proper dose of rinse is used. Subjects will be instructed not to eat or drink for 30 minutes after using the rinse and to complete the subject daily diary.
62586725|NCT03421145|ACTIVE_COMPARATOR|PerioShield™ Oral Health Rinse|Active control predicate device oral rinse ('Plaque control agent') Subjects assigned to the Active Comparator will swish a volume of 10 mL of the Active Comparator rinse for 30 seconds followed by expectoration, twice a day (morning and evening), after brushing teeth, for the 6-month duration of the study. They will use the dosing cup provided by the study team to ensure that the proper dose of rinse is used. Subjects will be instructed not to eat or drink for 30 minutes after using the rinse and to complete the subject daily diary.
62586726|NCT03421145|SHAM_COMPARATOR|Water|Water sham control oral rinse (not a Plaque control agent) Subjects assigned to the Sham Comparator will swish a volume of 15 mL of the Sham Comparator rinse for 30 seconds followed by expectoration, twice a day (morning and evening), after brushing teeth, for the 6-month duration of the study. They will use the dosing cup provided by the study team to ensure that the proper dose of rinse is used. Subjects will be instructed not to eat or drink for 30 minutes after using the rinse and to complete the subject daily diary.
62586727|NCT06277960|EXPERIMENTAL|percutaneous intramyocardial septal radiofrequency ablation system|
62586728|NCT06523231|EXPERIMENTAL|low dose|Participants receive 2 low-dose administrations of the investigational product
62586729|NCT06523231|EXPERIMENTAL|high dose|Participants receive 2 high-dose administrations of the investigational product
62586730|NCT06523231|OTHER|Control|Participants receive 2 administrations of MenACWY
62586731|NCT05449496|NO_INTERVENTION|Control|
62586732|NCT05449496|EXPERIMENTAL|Intervention|
62586733|NCT05804019|NO_INTERVENTION|Usual Care Group (Control)|Approximately 100 participants will be included and cluster randomized by nursing home (n= 3) to either 12 months of nutritional and physical intervention or 12 months of usual care (control). Usual Care Group will receive the usual care at the control nursing homes (n=3)
62586734|NCT05804019|EXPERIMENTAL|Nutritional and Physical Intervention Group (Intervention Group)|Approximately 100 participants will be included and cluster randomized by nursing home (n= 3) to either 12 months of nutritional and physical intervention or 12 months of usual care (control). The Nutritional and Physical Intervention Group will receive nutritional and physical interventions collaboratively defined by residents, relatives, care staff, and nursing home management during the PDSA workshops.
62795087|NCT00871338|EXPERIMENTAL|GSK2197870A Group|Subjects aged between and including 6 and 12 weeks of age at the time of first vaccination received 3 doses of GSK2197870A vaccine at Months 0, 1 and 2, 2 doses of Prevenar™ vaccine at Months 0 and 2 and a booster dose of Menitorix™ vaccine at Month 10. All vaccines were administered intramuscularly. GSK2197870A and Menitorix™ vaccines were administered in the right upper anterolateral thigh and Prevenar™ vaccine in the left upper anterolateral thigh.
62795088|NCT00871338|ACTIVE_COMPARATOR|Pediacel Group|Subjects aged between and including 6 and 12 weeks of age at the time of first vaccination received 3 doses of Pediacel™ vaccine at Months 0, 1 and 2, 2 doses of Prevenar™ vaccine at Months 0 and 2, 2 doses of Menjugate™ vaccine at Months 1 and 2 and a booster dose of Menitorix™ at Month 10. All vaccines were administered intramuscularly. Pediacel™ and Menitorix™ vaccines were administered in the right upper anterolateral thigh and Prevenar™ vaccine in the left upper anterolateral thigh and Menjugate™ vaccine in the left lower anterolateral thigh.
62795089|NCT05993923||Control group|Classical management in the digestive surgery department
62795090|NCT05993923||GPOU group|Treatment is carried out in Peri-Operative Geriatrics Unit to optimize specific geriatric care
62219251|NCT03995693|EXPERIMENTAL|Concentric cycling with placebo ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of CONCENTRIC cycling on a recumbent ergometer at the same VO2. A PLACEBO solution (water with a non-caloric sweetener) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
62433312|NCT02357550|EXPERIMENTAL|Hyperketonaemia|Ketone infusion. FDG-PET Scan. O2-PET scan. H2O-PET scan Muscle biopsy
62795091|NCT05809843||rype 1 diabetc patients with artificial pancreas device|
62795092|NCT05809843||healthy patients matched age and sex without diabetes and ocular disease|
62795093|NCT06165042|EXPERIMENTAL|Glass hybrid restorative system|(Equia Forte, GC Europe, Leuven, Belgium)
62795094|NCT06165042|EXPERIMENTAL|Fluoride varnish + Glass hybrid restorative|Fluoride varnish (SDI Riva Star)+ Glass hybrid restorative (Equia Forte, GC Europe, Leuven, Belgium)
62433313|NCT05093179|EXPERIMENTAL|Deep tissue massage group|"The one session of deep tissue massage was performed. The patient's positions were changed depending on the specificity of used techniques.~The following techniques were used:~* Shifting the rectus abdominis m.,~* Stretching of the fascia within the costal arches,~* trigger points compression (30-60 s).~* Stretching of the chest fascia, superficially with forearm or fingertips on intercostal muscles,~* filleting the pectoral muscles,~* hook and stretch with the proximal phalanges of the fingers 2-4 and the forearm~* filleting between the pectoral muscles and the deltoids,~* Releasing the lateral edge of the scapula using the fingers and stretching the tissues, Releasing the medial edge of the scapula using the fingers and the weight of the patient,~* hook and stretch of the trapezius muscle,~* Subsequently, the patient took a prone position.~* Stretching of the levator scapulae and supraspinatus muscles using the fist, forearm and elbow were performed."
62433314|NCT05093179|ACTIVE_COMPARATOR|Classic massage group|The one session of classic massage was performed. The massage was performed with moderate force. The entire procedure took about 15-20 min. The sequence of standard classic massage techniques was used in standard way and patterns.
62413480|NCT02704988|ACTIVE_COMPARATOR|Rectal Cancer - Carnoy|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
62413481|NCT02704988|ACTIVE_COMPARATOR|Rectal Cancer - GEWF|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
62413482|NCT02217657|ACTIVE_COMPARATOR|operator informed to contact force|Thermocool Smart Touch Catheter, operator informed to contact force (Biosense Webster)
62413483|NCT02217657|EXPERIMENTAL|operator blinded to contact force|Thermocool Smart Touch catheter, operator blinded to contact force information (Biosense Webster)
62413484|NCT02437175|PLACEBO_COMPARATOR|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
62413485|NCT02437175|EXPERIMENTAL|Trace elements|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
62413486|NCT02772003|EXPERIMENTAL|Treatment (INO-8000, INO-9012, EP)|Patients receive INO-8000 IM and DNA plasmid encoding interleukin-12 INO-9012 IM (dose levels 2-4) followed by EP at day 0 and at weeks 4, 12, and 24.
62413487|NCT06541691|EXPERIMENTAL|Enteric-coated aspirin (+/- hybrid strategy)|81 mg enteric-coated aspirin (+/- a hybrid strategy to mitigate the cardiovascular adverse effects of the air pollution)
62413488|NCT06541691|ACTIVE_COMPARATOR|Plain aspirin (+/- hybrid strategy)|81 mg plain aspirin (+/- a hybrid strategy to mitigate the cardiovascular adverse effects of the air pollution)
62413489|NCT06541691|EXPERIMENTAL|Hybrid strategy (with enteric-coated or plain aspirin)|A hybrid strategy to mitigate the cardiovascular adverse effects the air pollution, composed of one-page educational flashcard, cell phone text messages alerting participants on polluted days, recommending them to stay indoors or wear KN-95 facemasks provided by the study team in case of necessary outdoor activity, and recommendation to consume citrus fruits on polluted days.
62413490|NCT06541691|NO_INTERVENTION|Usual care (with enteric-coated or plain aspirin)|No active strategy (usual care) without any clear recommendations related to air pollution; only a control card will be shared with the patients randomized to the usual care
62413491|NCT05990608||Group I|Healthy Children
62413492|NCT05990608||Group II|Children with DMD
62413493|NCT01830712||Chart review|
62413494|NCT06357208|EXPERIMENTAL|Breathing Control and Retention|Breathing Control and Retention
62413495|NCT06357208|NO_INTERVENTION|Usual follow-up|the patient come at the begin of the study and come back after one month
62413496|NCT04747912|EXPERIMENTAL|Treatment Arm - Induction/Consolidation Phase - All Participants|"All participants in this arm will receive the same first round of treatment as part of induction/consolidation therapy. This treatment will use inotuzumab ozogamicin combined with anti-cancer drugs. The additional treatment that participants receive after this first round of treatment will vary based on the participant's response to induction therapy. This phase of treatment will last for 60 days. All participants in this arm will receive the following treatment:~Treatment Course I (Induction Phase, 28 days):~* Dasatinib 140mg daily continuous~* Dexamethasone 10mg/m\^2 PO or IV Days 1-7 and Day 15-Day 22~* InO 0.8mg/m2 Day 8; 0.5mg/m2 D15, 0.5mg/m2 Day 22~* Intrathecal methotrexate 15mg Day 1, Day 28~Treatment Course II (Consolidation Phase, 28 days):~* Dasatinib 140mg daily continuous~* InO: If in CR/CRi 0.5mg/m2 Day 1, Day 8, Day 15; If not in CR/CRi 0.8mg/m2 on Day 1, 0.5mg/m2 Day 8 and Day 15~* Intrathecal methotrexate 15mg Day 1, Day 28"
62413497|NCT04747912|EXPERIMENTAL|Treatment Arm - Interim/Maintenance Phase - Participants in CMR|"This study arm is for participants who no longer show any detectable signs of BCR-ABL1 (a cancer-causing gene) in response to the previous phase of induction/consolidation treatment (also known as being in complete molecular remission or CMR). Participants in this arm will receive 3 courses of interim/maintenance treatment using dasatinib combined with other anti-cancer drugs. Inotuzumab ozogamicin will be added during the fourth course of treatment. These treatments will be given in 28-day and 84-day cycles.~If the participant achieves complete molecular remission (no signs of BCR-ABL gene) after 60 days (or more) of treatment, then the treating physician may take the participant off the study for allogenic stem cell transplantation surgery.~If the participant does not undergo allogeneic stem cell transplantation after achieving complete molecular remission, they will complete 3 additional courses of maintenance treatment."
62413498|NCT04747912|EXPERIMENTAL|Treatment Arm - Interim/Maintenance Phase - Participants Not in CMR|"This study arm is for participants whose cancer responded to induction/consolidation treatment, but still shows detectable signs of BCR-ABL1 (a cancer-causing gene), so they are not in complete molecular remission. Participants in this arm will receive 3 courses of treatment using ponatinib combined with other anti-cancer drugs. Inotuzumab ozogamicin will be added during the 4th treatment course. These treatments will be given in 28-day and 84-day cycles.~If the participant achieves complete molecular remission (no signs of BCR-ABL gene) after 60 days (or more) of treatment, the treating physician may take the participant off the study for allogenic stem cell transplantation surgery.~If the participant does not undergo allogeneic stem cell transplantation after achieving complete molecular remission (CMR), they will complete 3 additional courses of maintenance treatment.~If the participant doesn't achieve CMR after 4th treatment course, they will be removed from the study."
62413499|NCT02002949|EXPERIMENTAL|Short daily hemodialsysis|Short Daily Hemodialysis (SDHD) - 5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
62022925|NCT02882802|ACTIVE_COMPARATOR|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
62413500|NCT02002949|ACTIVE_COMPARATOR|Conventional hemodialysis|Conventional Hemodialysis (CHD) - 3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
62022926|NCT04596566|OTHER|CD-TDI|Therapeutic diet Intervention ( CD-TDI )Group : Patients receiving CD-TDI will be offered patient-centered counseling for 12 weeks by a Registered Dietitian (RD) trained in the CD-TDI protocol with the goals of (a) identification and treatment of malnutrition if present, (b) targeted treatment of macro- and micronutrient deficiencies using whole foods;(c) increasing adherence to CD-TDI (d) multivitamin adherence and (e) reduced exposure to dietary antigens (e.g., maltodextrin, carrageenan, other food additives). They will receive a5 face-to-face appointment every 3 weeks with the study RD, and all other weekly appointments, which are 8 in number will be completed by phone.
62022927|NCT04596566|NO_INTERVENTION|Conventional management|Conventional Management (Control) Group: CM patients will meet with the RD at baseline, week 7 and week 13 to complete their 24HR food recall twice on different days of the week, followed by a phone few days after the visit to complete the second part of the recall. They will be advised to follow their habitual diet and will be offered the dietary intervention at 14 weeks if they are still experiencing a disease flare
62413501|NCT01708694|PLACEBO_COMPARATOR|Placebo Starch|Yogurt with about 45 g/day of placebo starch (amylopectin).
62022928|NCT01408589|PLACEBO_COMPARATOR|Sugar Pill|
62022929|NCT01408589|EXPERIMENTAL|Atomoxetine 40 mg|
62413502|NCT01708694|EXPERIMENTAL|Experimental Starch|Yogurt with about 45 g/day of slowly digestible starch (amylose).
62795095|NCT02641028|EXPERIMENTAL|CERC-501|Administered orally once daily, 15mg daily, 8 days.
62795096|NCT02641028|PLACEBO_COMPARATOR|Placebo|Administered orally daily, 8 days.
62795097|NCT00934219|ACTIVE_COMPARATOR|High dose Lovaza|Lovaza 4 g twice a day, if not effective then 4 g 3 times a day
62795098|NCT00934219|ACTIVE_COMPARATOR|Standard Dose|2 g twice a day
62795099|NCT05263557|EXPERIMENTAL|DHEA|Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited and randomised.
62795100|NCT05263557|EXPERIMENTAL|11KA4|Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited and randomised.
62022930|NCT01408589|EXPERIMENTAL|Atomoxetine 60 mg|
62022931|NCT01408589|EXPERIMENTAL|Atomoxetine 80 mg|
62413503|NCT06111794|EXPERIMENTAL|REACH TBI|Participants will receive the REACH TBI psychoeducational intervention.
62413504|NCT06111794|ACTIVE_COMPARATOR|Waitlist Control|Participants will receive the REACH TBI psychoeducational intervention.
62795101|NCT04107532|OTHER|Virtual Reality Therapy for Acrophobia|There were a total of 5 treatments in the VR treatment group, followed by cliffs, cliffs, cliffs, single-plank bridges, and high-altitude rescues. The difficulty of the scene increased in turn. The frequency of treatment twice a week, about 30 minutes each time, fills in the motion sickness questionnaire before and after each treatment to understand the safety of VR treatment. In the course of treatment, physiological data such as skin electricity, skin temperature, heart rate, and blood volume were measured, and the state of the subjects was objectively evaluated. At the same time, every two minutes, participants were asked about sud values and recorded.
62022932|NCT00780091||1|classical monitoring strategy
62022933|NCT00780091||2|optimized monitoring strategy
62413505|NCT02751372|EXPERIMENTAL|BAY 987517|All subjects are patched .
62413506|NCT04856488|EXPERIMENTAL|Iodine Potassium Iodide solution|Participants receive Iodine Potassium Iodide solution oral drops 3 times per day for 10 Days prior to thyroidectomy in addition to standard preoperative treatment
62413507|NCT04856488|NO_INTERVENTION|No intervention|Participants continue with standard preoperative treatment
62413508|NCT02972086|EXPERIMENTAL|Parent|Parent of a child who is a patient at the NYU Bellevue Attention Deficit Hyperactivity Disorder (ADHD) Clinic
62413509|NCT03530007|ACTIVE_COMPARATOR|normal saline|patients received normal saline for prevention of shivering during spinal anesthesia
62413510|NCT03530007|ACTIVE_COMPARATOR|ondansetron 4MG|patients received 4 mg of ondansetron for prevention of spinal shivering
62413511|NCT03530007|ACTIVE_COMPARATOR|ondansetron 8MG|patients received 8 mg of ondansetron for prevention of spinal shivering
62413512|NCT05428267|EXPERIMENTAL|Patients on the liver transplant list for cirrhosis.|Prevalence of sexual dysfunction before and after LT
62795102|NCT04107532|OTHER|Imagination Exposure Therapy for Acrophobia|The imaginary exposure treatment program is to convert the five scenes of VR exposure treatment through language, guide the subjects through the guidance language, guide the subjects to expose, and achieve the purpose of adaptation. Both treatment groups were required to collect scales and nuclear magnetic data before, after and after six months of follow-up.
62795103|NCT00226811|EXPERIMENTAL|A|50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
62795104|NCT04418258|EXPERIMENTAL|Capillary Aspiration Endoscopy Catheter group|Small intestine aspirate suction was carried out with a capillary aspiration endoscopy catheter
62795105|NCT04418258|ACTIVE_COMPARATOR|Aspiration endoscopy catheter group|Small intestine aspirate suction was carried out with an aspiration endoscopy catheter
62795106|NCT02347839|EXPERIMENTAL|Intervention group|Gefitinib-surgery-gefitinib. Induction gefitinib therapy was given for 8 weeks. Patients' resectability was assessed after 8-week gefitinib. Adjuvant gefitinib was given within 3-6 weeks after surgery until progression or unacceptable toxic effects.
62795107|NCT03259087|EXPERIMENTAL|Part 1: Mild Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
62795108|NCT03259087|EXPERIMENTAL|Part 1: Moderate Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
62795109|NCT03259087|EXPERIMENTAL|Part 1: Severe Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
62795110|NCT03259087|EXPERIMENTAL|Part 1: Healthy Participants|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
62795111|NCT03259087|EXPERIMENTAL|Part 2: End-stage Renal Disease Undergoing Hemodialysis|End-stage renal disease (ESRD) participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after hemodialysis (HD) in Period 1 and just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.
62413513|NCT01009073|EXPERIMENTAL|Arm A (ABT-263 and erlotinib)|
62413514|NCT01009073|EXPERIMENTAL|Arm B (ABT-263 and irinotecan)|
62413515|NCT01009073|EXPERIMENTAL|Arm C (ABT-263 monotherapy)|
62413516|NCT02024386|EXPERIMENTAL|Riociguat 0.5 mg|Riociguat 0.5 mg tablets, one-time oral dose of 0.5 mg
62413517|NCT02024386|EXPERIMENTAL|Riociguat 1.0 mg|Riociguat 0.5 mg tablets, one-time oral dose of 1.0 mg
62413518|NCT02024386|NO_INTERVENTION|Control arm|No drug
62413519|NCT06632990|EXPERIMENTAL|50 mg Active once daily|
62413520|NCT06632990|EXPERIMENTAL|50 mg Active twice daily|
62413521|NCT06632990|EXPERIMENTAL|100 mg Active twice daily|
62795112|NCT06284772||FINRISK 2002 re-examination cohort|All still-living FINRISK 2002 participants (\~6000) were invited do participate in a re-examination \>20 years after the initial fecal sampling. 2500 took part in the study.
62795113|NCT06284772||FINRISK 2002 re-examination health examination|The \~800 still-living participants from the Turku and Loimaa area were asked to participate in a health examination. 269 individuals took part in the health examination.
62795114|NCT00604630|PLACEBO_COMPARATOR|placebo|50ml 0.9% NaCL
62413522|NCT06632990|EXPERIMENTAL|Reference drugs cocktail|midazolam, caffeine and dextromethorphan will be administered orally
62413523|NCT06646003||stroke group|patients with chronic stroke
62413524|NCT00638339||1|critically ill patients undergoing invasive mechanical ventilation in medical ICU and CCU
62413525|NCT00638339||2|critically ill patients undergoing noninvasive mechanical ventilation in medical ICU and CCU
62413526|NCT01525407|EXPERIMENTAL|Supportive care (donor statin treatment)|Donors receive atorvastatin calcium PO beginning on day -14 and continuing until the last day of stem cell collection.
62413527|NCT02496442|ACTIVE_COMPARATOR|using Aqueduct|Patients passing procedures with Aqueduct
62413528|NCT02496442|NO_INTERVENTION|Not using Aqueduct|Patients passing the standard procedures
62413529|NCT05459077|OTHER|Aim 3B|This aim will evaluate the feasibility and acceptability of the adapted health care delivery intervention to improve anti-hypertensive medication adherence and blood pressure control in persons living with HIV at 24 weeks.
62413530|NCT02148835|ACTIVE_COMPARATOR|Triomeg|Sausage: Triomeg
62413531|NCT02148835|PLACEBO_COMPARATOR|Control sausage|Sausage: Control
62413532|NCT06652139|EXPERIMENTAL|selinexor combined with BEAM pretreatment regimen|Patients in this arm will receive selinexor combined with BEAM (carmustine, etoposide, cytarabine and melphalan) as pretreatment regimen of ASCT.
62413533|NCT06652139|ACTIVE_COMPARATOR|BEAM pretreatment regimen|Patients in this arm will receive BEAM (carmustine, etoposide, cytarabine and melphalan) as pretreatment regimen of ASCT.
62413534|NCT06700538|EXPERIMENTAL|Part 1: ARO-INHBE|ARO-INHBE in single (Day 1) or multiple (Days 1 and 29) ascending doses
62413535|NCT06700538|PLACEBO_COMPARATOR|Part 1: Placebo|Placebo in single (Day 1) or multiple (Days 1 and 29) matching doses
62413536|NCT06700538|EXPERIMENTAL|Part 2: ARO-INHBE + Tirzepatide|ARO-INHBE at selected dose on Days 1 and 29 plus weekly doses of tirzepatide (2.5 to 5 mg) up to Day 169
62413537|NCT06700538|PLACEBO_COMPARATOR|Part 2: Placebo + Tirzepatide|Placebo dose on Days 1 and 29 plus weekly doses of tirzepatide (2.5 to 5 mg) up to Day 169
62413538|NCT05550025|EXPERIMENTAL|TACE combined with Apatinib and Camrelizumab|TACE（transcatheter arterial chemoembolization） combined with Apatinib and Camrelizumab
62586735|NCT04152772|ACTIVE_COMPARATOR|Active during extinction learning / Sham during consolidation|Active tDCS stimulation will be applied during the extinction learning phase. Sham tDCS stimulation will be applied during the consolidation phase.
62586736|NCT04152772|ACTIVE_COMPARATOR|Sham during extinction learning / Active during consolidation|Sham tDCS stimulation will be applied during the extinction learning phase. Active tDCS stimulation will be applied during the consolidation phase
62413539|NCT06540820||patients with pituitary disorders|
62413540|NCT06540820||patients without pituitary disorders|
62413541|NCT06652776||COPD patients|All patients with a functionally confirmed diagnosis of COPD
62413542|NCT06344858||Ketamine|"In the preoperative room a vein of the forearm with preriferic access #18 will be established for the administration of general intravenous anesthesia and intraoperative fluids.~In the operating room, after routine monitoring (Heart Rate, Non-Invasive Blood Pressure, Oxygen Saturometry), the sensor of the Nociception Analgesia Index (ANI) monitor will be installed from the right chest to the left 5th intercostal space.~Wait XX time for calibration and capture of the electrocardiographic signal. The ANI value shall initially be measured and shall be considered as the reference value.~Inject 0.1 mg/kg of ketamine (1 mg/ml) once, then inject 5 ml of physiological saline at the same rate.~The time from ketamine administration until the ANI index rose above 50 (minimum appropriate nociception value) shall be recorded every 6 seconds."
62413543|NCT00567086|PLACEBO_COMPARATOR|A|
62586737|NCT04152772|SHAM_COMPARATOR|Sham during extinction learning / Sham during consolidation|Sham tDCS stimulation will be applied during both the extinction learning phase and the consolidation phase.
62586738|NCT04015921||Inpatients|Patients admitted with various psychiatric disorders
62795115|NCT00604630|ACTIVE_COMPARATOR|verum|erythropoietin alfa 40,000 IU iv in 50ml 0.9% NaCl
62795116|NCT01220739|SHAM_COMPARATOR|IV tPA + Sham Transcranial Laser Therapy|Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by sham transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset.
62795117|NCT01220739|ACTIVE_COMPARATOR|IV tPA +Transcranial Laser Therapy|Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset.
62413544|NCT00567086|EXPERIMENTAL|B|
62413545|NCT00567086|EXPERIMENTAL|C|
62413546|NCT00567086|EXPERIMENTAL|D|
62413547|NCT03312764|EXPERIMENTAL|Online Diabetes Prevention Program|Participants will receive access to a 12-month online diabetes prevention program modeled after the CDC DPP curriculum. Participants in the online program receive paced curriculum, access to a live health coach, interactive group message forums, and connected weight scale and activity monitoring devices.
62413548|NCT03312764|ACTIVE_COMPARATOR|Enhanced Standard Care|All participants randomized to the standard-care/control group (SC) will be offered the opportunity to attend a single 90-minute diabetes prevention class with a trained health professional (MPH, RD, or related advanced degree). The class will focus on healthful eating based on the current MyPlate recommendations, guidance on gradual increases in moderate intensity physical activity, and action planning to be shared with friends and/or family. Control participants will also be given the opportunity to participate in the online digital intervention upon completion of the 12-month follow-up assessment.
62413549|NCT05950828|EXPERIMENTAL|SkillTalk|Participants will receive one week of access to SkillTalk, a subscription-based microskills video training library designed to enhance the skills of high school sex educators to implement the frequently used core components of sexual and reproductive health (SRH) curricula.
62413550|NCT05950828|NO_INTERVENTION|Business as usual|"Control group will receive business as usual."
62413551|NCT04999592|ACTIVE_COMPARATOR|No prophylaxis (placebo)|"Standard care without antibiotic prophylaxis and treatment of infection if clinically warranted.~Administer antibiotics in response to infection."
62413552|NCT04999592|EXPERIMENTAL|Prophylaxis|Antibiotic prophylaxis for 3 days. Antibiotic prophylaxis with Ceftriaxone 2 gm IV q12h for 3 days.
62586739|NCT04015921||Age-matched control group|
62586740|NCT06683651|EXPERIMENTAL|STN1013800 ophthalmic solution|0.1% STN1013800 ophthalmic solution administered once daily
62795118|NCT04266132|ACTIVE_COMPARATOR|Retrolamianar block (RLB)|General anaesthesia will be induced.Ultrasound-guided RLB will be performed under strict aseptic precautions with patient in the lateral position.The anesthetic solution will be injected.
62022934|NCT06257147|PLACEBO_COMPARATOR|Group 1 wards (physician education)|For Group 1 wards, physician education will be provided. All physicians treating patients in general medical wards will undergo a training session at the start of the study. Education content includes latest evidence on short-course antibiotic therapy and criteria for de-escalation to oral antibiotics for BSI-E. The educational materials will be prepared by Infectious Diseases physicians, and will be presented during one of the monthly departmental meetings, which routinely involve physician education. Ample time will be provided for answering questions from physicians. During the study period, the same material will be presented to new medical staff joining the department. The educational materials will be sent to all physicians in the department regardless of their attendance of the meeting. Patients will receive standard of care.
62022935|NCT06257147|ACTIVE_COMPARATOR|Group 2 wards (physician education + paper reminder)|For Group 2 wards, physician education will be provided as in Group 1. A paper reminder will be attached in the medical records of all consecutive patients on the first working day after Enterobacterale is isolated from blood culture. The reminder documents (1) the clinical and host criteria that should be considered for prescribing short-course antibiotic therapy, and (2) options of oral antibiotics to complete the treatment course. These recommendations are based on results of the trials demonstrating non-inferiority of short-course and oral-switch therapy for BSI-E.
62413553|NCT02511873|EXPERIMENTAL|Fycompa|Fycompa dose is chosen based on tolerability and efficacy. 2mg to 8mg daily for 6 weeks then washed out.
62413554|NCT02511873|PLACEBO_COMPARATOR|Placebo|Inactive ingredient equal to 2mg tablets
62413555|NCT06244095|EXPERIMENTAL|Perturbation Therapy|Perturbation Therapy will be given to this group.
62413556|NCT06244095|ACTIVE_COMPARATOR|Trunk Control Therapy|Trunk control activities will be given to this group.
62413557|NCT01097759||LigaSure|LigaSure is a vascular sealing device that can seal the hemorrhoidal plexus during hemorrhoidectomy (surgery)
62413558|NCT01097759||Stapler|Circular stapler that removes excess loose tissue above the anus and interrupts the blood supply during hemorrhoidal surgery
62413559|NCT01965431|EXPERIMENTAL|BI 207127 + Faldaprevir|Tablets/capsules
62413560|NCT01965431|ACTIVE_COMPARATOR|Moxifloxacin (Avalox®)|Tablets
62795119|NCT04266132|ACTIVE_COMPARATOR|Ilioinguinal nerve block (INB)|General anaesthesia will be induced. Ultrasound-guided INB will be performed under strict aseptic precautions with patient in the supine position.The anesthetic solution will be injected.
62795120|NCT03370718|EXPERIMENTAL|Treatment (cabozantinib)|Patients receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
62795121|NCT03567876|EXPERIMENTAL|V-RBAC (RBAC followed by Venetoclax)|"Induction phase: RBAC --\> up to 6 cycles for low risk (LR) patients and up to 4 cycles for high risk (HR) patients.~Patients proceeding to Venetoclax treatment will receive consolidation with single agent Venetoclax 800 mg/die x 4 28d cycles (with initial ramp-up dose) of each consolidation cycle. Consolidation will be followed by maintenance with single agent Venetoclax 400 mg/die (V maint ) for a total of 2 years (4 months consolidation+20 months maintenance)."
62795122|NCT01766180|NO_INTERVENTION|Placebo / Placebo|In this control group, subjects receives placebo supplement pills without Fruitflow or ResVida ingredients.
62795123|NCT01766180|ACTIVE_COMPARATOR|Fruitflow-II / Placebo|In this group subjects receive Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for resVida.
62795124|NCT01766180|ACTIVE_COMPARATOR|Placebo / resVida|In this group subjects receive resVida daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for Fruitflow-II.
62795125|NCT01766180|ACTIVE_COMPARATOR|Fruitflow-II / resVida|In this group subjects receive resVida and Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient.
62586741|NCT06683651|PLACEBO_COMPARATOR|STN1013800 ophthalmic solution Liquid Base, without STN1013800|STN1013800 ophthalmic solution Liquid Base, without STN1013800 administered once daily
62586742|NCT03304665||Healthy Volunteers|Healthy Volunteers
62586743|NCT06684028|EXPERIMENTAL|68Ga-FAPI-JNU|68Ga-FAPI-JNU is administered through a superficial vein on the back of the hand. A PET/CT scan was performed approximately 1 hour after injection
62413561|NCT01965431|EXPERIMENTAL|BI 207127 placebo + Faldaprevir placebo|Tablets/capsules
62413562|NCT02472431|EXPERIMENTAL|ADRC injection|
62413563|NCT03231423|EXPERIMENTAL|DRAIN PLACEMENT|Effects of drainage
62413564|NCT03231423|NO_INTERVENTION|DRAIN NOT PLACED|Effects of not using drain
62413565|NCT01948011|EXPERIMENTAL|Racecadotril 10mg suspension|single oral dose
62413566|NCT01948011|EXPERIMENTAL|Racecadotril 30mg suspension|single oral dose
62413567|NCT01948011|EXPERIMENTAL|Racecadotril 60mg suspension|single oral dose
62413568|NCT01948011|ACTIVE_COMPARATOR|Racecadotril 60mg granules|single oral dose
62413569|NCT02662556|EXPERIMENTAL|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg
62413570|NCT00863239|EXPERIMENTAL|1|Locteron™ (controlled-release interferon alpha 2b) 320 µg as biweekly subcutaneous injection
62413571|NCT00863239|EXPERIMENTAL|2|Locteron™ (controlled-release interferon alpha 2b) 480 µg as biweekly subcutaneous injection
62413572|NCT00863239|EXPERIMENTAL|3|Locteron™ (controlled-release interferon alpha 2b) 640 µg as biweekly subcutaneous injection
62413573|NCT00863239|ACTIVE_COMPARATOR|4|PEG-Intron™ (12 kDalton pegylated interferon alpha 2b) 1.5 µg/kg body weight weekly subcutaneous injection
62586744|NCT02433821|EXPERIMENTAL|Pilates Group|The group will realize 2 classes per week, lasting one our, of Pilates under supervision of a trained instructor. The training program will last 3 months.
62022936|NCT06257147|ACTIVE_COMPARATOR|Group 3 wards (multifaceted antibiotic stewardship intervention)|Group 3 wards will receive a multifaceted antibiotic stewardship intervention. Physician education will be provided as in Group 1. All consecutive patients fulfilling inclusion and exclusion criteria for study eligibility will be assessed by an Antibiotic Stewardship team. A trained nurse will first assess the patients for clinical and host criteria to determine eligibility for short-course antibiotic therapy. The antibiotic susceptibility test results and the prescribed antibiotics treatment will be reviewed. An Infectious Diseases physician will subsequently make written recommendations for the duration and choice of antibiotic therapy, and provide an appointment within 2 weeks after hospital discharge to review patients' clinical condition when indicated.
62022937|NCT06347419||Idiopathic scoliosis|The study group for this research comprises patients diagnosed with idiopathic scoliosis, a condition characterized by abnormal lateral curvature of the spine of unknown cause.
62022938|NCT05425004|EXPERIMENTAL|Cabozantinib|Participants will self-administer cabozantinib 60 mg at the same time daily by mouth on a continuous 28-day schedule. Participants will continue to take this medication as long as they are deriving benefit from it without significant treatment-related toxicities.
62022939|NCT04756219|EXPERIMENTAL|Contact Video|Participants randomized to this group will watch a video of a person talking about his recovery after attempting suicide.
62413574|NCT04764669|EXPERIMENTAL|DLB Without Amyloid Copathology|Participants with DLB (without amyloid copathology) will receive E2027 50 milligram (mg) capsules, orally, once daily up to 12 weeks.
62022940|NCT04756219|EXPERIMENTAL|Contact Text|Participants randomized to this group will read a personal story of a person who survived a suicide attempt.
62022941|NCT04756219|EXPERIMENTAL|Education Video|Participants randomized to this group will watch a video of a psychiatrist presenting facts about suicide and suicide prevention.
62022942|NCT04756219|EXPERIMENTAL|Education Text|Participants randomized to this group will read a text containing facts about suicide and suicide prevention.
62022943|NCT04756219|PLACEBO_COMPARATOR|Control Contact|Participants randomized to this group will read a personal story of a person who survived a heart attack.
62022944|NCT04756219|PLACEBO_COMPARATOR|Control Education|Participants randomized to this group will read a text containing facts about heart-attacks and their prevention.
62219252|NCT03995693|EXPERIMENTAL|Concentric cycling with glucose ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of concentric cycling on a recumbent ergometer at the same VO2. A GLUCOSE solution (glucose with a trace amount of 13C) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
62219253|NCT03995693|EXPERIMENTAL|Eccentric cycling with placebo ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of ECCENTRIC cycling on a recumbent ergometer at the same VO2. A PLACEBO solution (water with a non-caloric sweetener) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
62413575|NCT04764669|EXPERIMENTAL|DLB With Amyloid Copathology|Participants with DLB (with amyloid copathology) will receive E2027 50 mg capsules, orally, once daily up to 12 weeks.
62219254|NCT03995693|EXPERIMENTAL|Eccentric cycling with glucose ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of ECCENTRIC cycling on a recumbent ergometer at the same VO2. A GLUCOSE solution (glucose with a trace amount of 13C) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
62219255|NCT00818532||1|Measurement device
62219256|NCT04054700|EXPERIMENTAL|distal upper rehabilitation robot|experimental group that applied the distal upper rehabilitation robot
62219257|NCT04054700|OTHER|proximal upper rehabilitation robot|control group that applied the proximal upper rehabilitation robot
62413576|NCT04764669|EXPERIMENTAL|PDD Without Amyloid Copathology|Participants with PDD (without amyloid copathology) will receive E2027 50 mg capsules, orally, once daily up to 12 weeks.
62413577|NCT04764669|EXPERIMENTAL|PDD With Amyloid Copathology|Participants with PDD (with amyloid copathology) will receive E2027 50 mg capsules, orally, once daily up to 12 weeks.
62413578|NCT01410565|ACTIVE_COMPARATOR|Apaziquone|
62413579|NCT01410565|PLACEBO_COMPARATOR|Placebo|Placebo
62022945|NCT05778305|ACTIVE_COMPARATOR|Dexmedetomidine group|patients will have loading Dexmedetomidine( 1ug/kg) over 10 minutes followed by continuous infusion of (0.5ug/kg/hr) from the initiation of anaesthesia up to extubation in the ICU. Patients will not be extubated until completely awake and have no sign of arrhythmias and bleeding
62413580|NCT06576830|ACTIVE_COMPARATOR|Short acting opioids: Fentanyl/Hydromorphone|Per Routine Care
62022946|NCT05778305|PLACEBO_COMPARATOR|control group|patients will receive the same volume of 0.9% saline infusion as loading and maintenance infusion.
62022947|NCT04410432||Patient|Patient hospitalized with SARS-Cov2 infection proven by virological sampling.
62413581|NCT06576830|ACTIVE_COMPARATOR|Long acting opioid: Methadone|"Initial Dosing: 0.15 mg/kg age-ideal body weight in children age 3 - \< 12 years and 0.2 mg/kg age-ideal body weight in adolescents age 12 - 17 years.~Dose escalation (possible, based on interim analysis): 0.2 mg/kg age-ideal body weight in children age 3 - \< 12 years and 0.25 mg/kg age-ideal body weight in adolescents age 12 - 17 years."
62413582|NCT06648473|EXPERIMENTAL|Magnetic Resonance Imaging (MRI) Scan|Subjects will begin the MRI with T1-pre, T2w, and volumetric 3D Fluid Attenuated Inversion Recovery (FLAIR) images being obtained. The subject will be brought out of the MRI magnet and moved into a seated position and will then have a standard Brain Tumor Imaging Protocol MRI scan.
62413583|NCT05146700|EXPERIMENTAL|Restrictive oxygen|"- Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94% either using no supplemental oxygen, a nasal cannula, a non-rebreather mask or manual/mechanical ventilation (intubated trial participants)~and~- Only trial participants receiving an FiO2 = 0.21 can saturate \>94%~Pre-oxygenation as usual prior to intubation is permitted"
62413584|NCT05146700|ACTIVE_COMPARATOR|Liberal oxygen|"- 15 L O2/min flow for non-intubated trial participants in the pre-hospital phase, the trauma bay and during intrahospital transportation. In the operating room, intensive care unit, post-anesthesia care unit and ward the flow can be reduced to ≥12 L O2/min if the arterial oxygen saturation is ≥98%~or~- FiO2 = 1.0 for intubated trial participants in the pre-hospital phase, the trauma bay and during intrahospital transportation. In the operating room, intensive care unit, post-anesthesia care unit and ward the FiO2 can be reduced to ≥0.6 if the arterial oxygen saturation is ≥98%"
62022948|NCT00733265|EXPERIMENTAL|AZD6140|
62022949|NCT01389908|EXPERIMENTAL|schizophrenia|schizophrenia or schizoaffective patients
62022950|NCT01407861|ACTIVE_COMPARATOR|Relaxation training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
62022951|NCT01407861|ACTIVE_COMPARATOR|Aerobic endurance training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
62022952|NCT05289102|EXPERIMENTAL|Two postpartum visits.|Group 1 serves as an intervention group (experimental). All enrolled women in the intervention group were in connection with the inclusion given two pre-booked postpartum care visits. One early at 3 weeks postpartum, and one later at 7 weeks postpartum.
62022953|NCT05289102|ACTIVE_COMPARATOR|One postpartum visit.|Group 2 serves as a control group (active comparator). All enrolled women in the control group were in connection with the inclusion given one pre-booked postpartum care visit at 7 weeks postpartum according to the traditional postpartum care.
62022954|NCT00059475|EXPERIMENTAL|Adj-2 MART-1: 27-35|melanoma antigen recognized by T-cells (MART)-1:27-35 peptide every three weeks for four cycles (Arm I).
62413585|NCT00187174|EXPERIMENTAL|Phase 1|
62022955|NCT00059475|EXPERIMENTAL|Adj-2 HD IL-2 after MART-1: 27-35|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm I (Arm IA)
62413586|NCT06647693|EXPERIMENTAL|First cohort|These participants begin the intervention after 6 sessions
62413587|NCT06647693|EXPERIMENTAL|Second cohort|These participants enter the intervention after 9 baseline sessions
62413588|NCT06647693|EXPERIMENTAL|Third cohort|These participants enter the intervention after 12 baseline sessions (and 3 sessions post-hurricane Helene)
62413589|NCT06179290|EXPERIMENTAL|Study Product A: Ploom HTP Menthol HTS; MX3 (681)|Subjects in A arm (Group 1 Menthol) will be required to smoke Ploom HTP Menthol HTS; MX3 (681) study product at least 5 times per day ad libitum from 07:00 through 23:00. There will be 60 subjects assigned to this arm with a randomization ratio of 2.
62022956|NCT00059475|EXPERIMENTAL|Adj-2 27-35 (27L) MART-1 (Mod9mer) peptide Q3wks x 4|27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide every three weeks for four cycles (Arm II).
62022957|NCT00059475|EXPERIMENTAL|Adj-2 HD IL-2 after 27-35 (27L): MART-1 (Mod9mer)|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm II (Arm IIA)
62022958|NCT00059475|EXPERIMENTAL|Adj-2 MART-1: 26-35 (27L) (Mod10mer) peptide Q3wks x 4|melanoma antigen recognized by T-cells (MART)-1:26-35(27L) peptide every three weeks for four cycles (Arm III).
62022959|NCT00059475|EXPERIMENTAL|Adj-2 HD IL-2 after MART-1: 26-35 (27L) (Mod10mer)|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm III (Arm IIIA)
62022960|NCT00059475|EXPERIMENTAL|Adj-2 27-35 (27L): MART-1 + gp100: 209-217 (210M) Q3wks x 4|27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide plus the gp100:209-217(210M) peptide emulsified together every three weeks for four cycles (Arm IV).
62022961|NCT00059475|EXPERIMENTAL|Adj-2 HD IL-2 after 27-35 (27L): MART-1 + gp209-2M|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm IV (Arm IVA)
62022962|NCT00623220|EXPERIMENTAL|A|O2 and N2O
62022963|NCT00623220|ACTIVE_COMPARATOR|B|O2 only
62022964|NCT06670404||Vertebroplasty cohort|Patients with vertebral compression fractures treated with vertebroplasty
62022965|NCT02076464|EXPERIMENTAL|StudentBodies - Eating Disorders|Participants will participate in the StudentBodies - Eating Disorders program
62022966|NCT02076464|NO_INTERVENTION|Usual Care|Participants will be referred to treatment per protocol at students' corresponding college's mental health services center
62413590|NCT06179290|NO_INTERVENTION|Study Product B: Continue Smoking (menthol)|Subjects in B arm (Group 1 Menthol) will continue to smoke their menthol UBCC ad libitum from 07:00 through 23:00. There will be 60 subjects assigned to this arm with a randomization ratio of 2.
62413591|NCT06179290|ACTIVE_COMPARATOR|Study Product C: Smoking Abstinence (menthol)|Subjects in C arm (Group 1 Menthol) will remain abstinent from cigarette smoking for the duration of the study during both the confinement and ambulatory phases. There will be 30 subjects assigned to this arm with a randomization ratio of 1.
62795126|NCT02053090|ACTIVE_COMPARATOR|Group Education with Stretching|"Group Education with Stretching will receive 10 small group educational classes at the Oregon Health \& Science University (OHSU), based on the book Fibromyalgia (Biographies of Disease). Each chapter of Fibromyalgia covers different aspects of the disease and its treatment including global, economic, and risk statistics; a timeline of key events in the study of fibromyalgia; common symptoms and diagnostic indicators; natural history of fibromyalgia; pharmacologic and non-pharmacologic treatments; associated disorders and syndromes; and impact of fibromyalgia at home, in the workplace and in society at large. Participants will be informed that they should not start additional treatments until the end of the study and complementary and alternative treatments won't be covered until the last session. Participants will also receive a digital video disk (DVD) covering stretching appropriate for fibromyalgia patients and will be asked to incorporate the DVD over the next 10 weeks."
62795127|NCT02053090|EXPERIMENTAL|Group Acupuncture|20 treatments in 10 weeks will include individualized acupuncture in a group setting, dietary and lifestyle recommendations each based on the Traditional Chinese Medicine diagnosis (zhang fu) at the time of the visit.
62022967|NCT04268017|EXPERIMENTAL|Healthy volunteer|
62022968|NCT02811237|OTHER|HESTIA group|
62795128|NCT02526628||Testosterone naïve KS|Men with Klinefelter syndrome without testosterone treatment. After initial examination standard treatment with testosterone will be effectuated according to current guidelines.
62795129|NCT02526628||Testosterone treated KS|Men with Klinefelter syndrome receiving testosterone treatment
62795130|NCT02526628||Controls 1|Matched healthy male controls for testosterone naive KS
62795131|NCT02526628||Controls 2|Matched healthy male controls for testosterone treated KS
62795132|NCT05733156|EXPERIMENTAL|SBRT + LDRT|
62795133|NCT02134444|EXPERIMENTAL|Experimental Group|Experimental group will receive the assigned intervention which is a game-based rehabilitation program delivered at home.
62795134|NCT02134444|ACTIVE_COMPARATOR|Control group|Control group will receive a vestibular rehabilitation program which will include the Herdman gaze stabilization exercises and balance training program.
62022969|NCT02811237|OTHER|sPESI group|
62413592|NCT06179290|EXPERIMENTAL|Study Product D: Ploom HTP Tobacco HTS; R8 (120)|Subjects in D arm (Group 2 Non-menthol) will be required to smoke Ploom HTP Tobacco HTS; R8 (120) study product at least 5 times per day ad libitum from 07:00 through 23:00. There will be 60 subjects assigned to this arm with a randomization ratio of 2.
62413593|NCT06179290|NO_INTERVENTION|Study Product E: Continue Smoking (non-menthol)|Subjects in E arm (Group 2 Non-menthol) will continue to smoke their non-menthol UBCC ad libitum from 07:00 through 23:00. There will be 60 subjects assigned to this arm with a randomization ratio of 2.
62413594|NCT06179290|ACTIVE_COMPARATOR|Study Product F: Smoking Abstinence (non-menthol)|Subjects in F arm (Group 2 Non-menthol) will remain abstinent from cigarette smoking for the duration of the study during both the confinement and ambulatory phases. There will be 30 subjects assigned to this arm with a randomization ratio of 1.
62413595|NCT04292756|ACTIVE_COMPARATOR|Triamcinolone Acetonide 40 mg|Arm 1
62795135|NCT01588561|ACTIVE_COMPARATOR|Intravenous Nicotine (1.5 mg/70 kg)|Participants are given a siingle infusion of nicotine (1.5 mg/70 kg), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans
62795136|NCT01588561|PLACEBO_COMPARATOR|Saline - placebo|Participants are given physiological saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans
62795137|NCT05971069|EXPERIMENTAL|Group1|Entire fluorescence defect on the Lt. lobe of liver → Preservation of the aberrant left hepatic artery
62022970|NCT02343458|EXPERIMENTAL|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
62795138|NCT05971069|EXPERIMENTAL|Group2|Partial fluorecence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
62795139|NCT05971069|EXPERIMENTAL|Group3|No fluorescence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
62022971|NCT02343458|EXPERIMENTAL|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
62022972|NCT02343458|EXPERIMENTAL|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
62022973|NCT02343458|PLACEBO_COMPARATOR|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
62022974|NCT01844323|ACTIVE_COMPARATOR|Treatment A|treatment A, reference, 20 micron palbociclib and lubrication level 1
62022975|NCT01844323|ACTIVE_COMPARATOR|Treatment B|treatment B, test, 50 micron palbociclib and lubrication level 1
62022976|NCT01844323|ACTIVE_COMPARATOR|Treatment C|treatment C, test, 20 micron palbociclib and lubrication level 2
62022977|NCT01844323|ACTIVE_COMPARATOR|Treatment D|treatment D, test, 20 micron palbociclib and lubrication level 3
62022978|NCT05363345|EXPERIMENTAL|Vortic Catch V basket catheter|Common bile duct stones (≧ 10 mm) are removed by using Vortic Catch V basket catheter following endoscopic papillary large balloon dilation.
62413596|NCT04292756|ACTIVE_COMPARATOR|Triamcinolone Acetonide 4 mg|Arm 2
62795140|NCT04659616|EXPERIMENTAL|Treatment (cytarabine, daunorubicin, pemigatinib)|"INDUCTION: Patients receive cytarabine IV on days 1-7, daunorubicin IV on days 1-3, and pemigatinib PO QD on days 8-21 in the absence of disease progression or unacceptable toxicity. Patients with hematologic count recovery (assessed between days 25-42) after induction proceed to consolidation therapy. Patients undergo ECHO during screening and as clinically indicated on study. Patients undergo blood sample collection and bone marrow aspirate and biopsy during screening and cycle 11 day 21 on study.~CONSOLIDATION: Patients receive high dose cytarabine IV BID on days 1, 3, and 5 of each cycle, and pemigatinib PO QD on days 8-21 of each cycle. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression of unacceptable toxicity. Patients undergo ECHO as clinically indicated and blood sample collection and bone marrow biopsy and aspirate at the end of consolidation."
62795141|NCT05987696|EXPERIMENTAL|CD33/CLL1 dual CAR-NK cell|CLL1/CD33 dual CAR-NK cell therapy in Adult subjects with r/r AML
62795142|NCT05987696|EXPERIMENTAL|CD33 CAR-NK cell|CD33 CAR-NK cell therapy in Adult subjects with r/r AML
62795143|NCT05987696|EXPERIMENTAL|super NK cell|super NK cell therapy in Adult subjects with AML MRD
62795144|NCT02442024|EXPERIMENTAL|Modified diet|This group will follow a modified diet over a period of two months.
62795145|NCT02442024|ACTIVE_COMPARATOR|Standard diet|This group will follow a standardized diet over a period of two months.
62795146|NCT02491983|ACTIVE_COMPARATOR|Arm A|Combination of Palbociclib and Letrozole
62795147|NCT02491983|EXPERIMENTAL|Arm B|Combination of Palbociclib and Fulvestrant
62795148|NCT00612755|EXPERIMENTAL|1|Peginterferon alfa-2a 180 mcg/week + 1000-1200 mg/day ribavirin during 24 weeks
62795149|NCT00612755|NO_INTERVENTION|2|
62795150|NCT03441061|EXPERIMENTAL|Treatment (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 1 hour on days 1 and 8. Treatment repeats every 21-28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62022979|NCT05363345|ACTIVE_COMPARATOR|ordinary basket catheter|Common bile duct stones (≧ 10 mm) are removed by using ordinary basket catheter following endoscopic papillary large balloon dilation.
62413597|NCT03889197|NO_INTERVENTION|Control|Standard of care sodium supplementation as directed by the medical care team
62433315|NCT01315483|EXPERIMENTAL|Low fat, high carb weight loss diet|Ornish-like weight loss dietary pattern
62433316|NCT01315483|EXPERIMENTAL|Low carb, high fat weight loss diet|South-Beach-like weight loss diet pattern
62795151|NCT00910780|ACTIVE_COMPARATOR|Staying on Risperdal|
62795152|NCT00910780|ACTIVE_COMPARATOR|Risperdal switched to Abilify|
62795153|NCT00910780|ACTIVE_COMPARATOR|Staying on Zyprexa|
62795154|NCT00910780|ACTIVE_COMPARATOR|Zyprexa switched to Abilify|
62795155|NCT05142605|EXPERIMENTAL|Cohort 1: Meaning-Centered Grief Therapy (MCGT)|Participants will receive the MCGT intervention for approximately 4 months or longer as needed.
62795156|NCT05142605|ACTIVE_COMPARATOR|Group 2: Supportive Psychotherapy (SP)|Participants will receive the SP intervention for approximately 4 months or longer as needed.
62795157|NCT05142605|ACTIVE_COMPARATOR|Group 3: Enhanced usual care (EUC)|Participants will receive EUC for approximately 4 months or longer as needed.
62795158|NCT03009422|EXPERIMENTAL|Treatment|CO2 fractional laser with local application of Pentostam
62795159|NCT03009422|ACTIVE_COMPARATOR|control|Intra-lesinal Pentostam injedction
62795160|NCT05832879|EXPERIMENTAL|OUD Telehealth Platform|Participants will be assigned to receive the OUD Telehealth Platform, which will be delivered remotely by research staff.
62795161|NCT03786536|EXPERIMENTAL|Treatment|All volunteers will receive the same treatment
62586745|NCT02433821|NO_INTERVENTION|Control group|The patients will keep the drug treatment and will be keep in a waiting list. After the 180 days of study the will be invited to realize the Pilates training.
62795162|NCT05648292||Clinical group|45 individuals with relapsing-remitting multiple sclerosis
62795163|NCT05648292||Control group|45 individuals with no chronic disease, matched in age, gender and level of education
62413598|NCT03889197|ACTIVE_COMPARATOR|Sodium supplementation algorithm|Beginning on the 14th -16th postnatal day and continuing until 36 weeks postmenstrual age, infants randomized to the algorithm will have a spot urine sodium concentration determined every two weeks and sodium supplementation provided according to the algorithm.
62413599|NCT02352207||identification of a pulmonary malformation in the fetus|pregnant women referred to a prenatal Center, because of the identification of a pulmonary malformation in the fetus
62413600|NCT00576875||Depressed|Older individuals with major depression
62413601|NCT00576875||Non-depressed|Older individuals without major depression
62413602|NCT04376073|EXPERIMENTAL|Treatment group|"Niraparib 300mg(Body Weigh ≥77 kg)/200mg (Body Weigh \<77 kg) po QD day1\~21, Anlotinib 12mg po QD day1\~14.~Starting dose of anlotinib changed to 10mg from 2020-11-13."
62795164|NCT04728386|EXPERIMENTAL|curcumin irrigant|final flush root canal irrigation with 5 ml curcumin solution
62795165|NCT04728386|EXPERIMENTAL|sodium hypochlorite|final flush root canal irrigation with 5 ml sodium hypochlorite
62795166|NCT05303623|EXPERIMENTAL|Conventional Physiotherapy|"In the intensive care unit and who had mechanical ventilation for more than 48 hours and who were extubated. Medical, physical and respiratory examination in this group Physical Function Test in Intensive Care (PFIT), maximum inspiratory mouth pressure and maximum expiratory mouth pressure, Medical Research Council Muscle Strength Test and diaphragmatic function with B mode and M mode ultrasonographic assessment.~In this group will apply only conventional physiotherapy. Conventional physiotherapy to contain breathing and,thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization. Conventional physiotherapy apply for 5 days after extubation period 1 time a day."
62022980|NCT04287933|ACTIVE_COMPARATOR|Drain|
62022981|NCT04287933|NO_INTERVENTION|No drain|
62022982|NCT00686400||1: FE|FE = first episode schizophrenia
62243391|NCT06390319|EXPERIMENTAL|Patients with T-LLy|"All eligible patients receive intervention according to the Detailed Description section with the following:~Induction: Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Bortezomib, IT MHA~Early Post Induction: Cyclophosphamide, Cytarabine, Mercaptopurine, IT MHA, Methotrexate, Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Bortezomib~Maintenance: Mercaptopurine, Methotrexate, Cyclophosphamide, Cytarabine, Dexamethasone, Vincristine, IT MHA, Thioguanine"
62413603|NCT06701903|EXPERIMENTAL|ITI-1284 10mg|ITI-1284 10 mg tablet, taken once daily, sublingual administration.
62022983|NCT00686400||2: CO|CO = age and gender-matched control subjects
62022984|NCT02169934|EXPERIMENTAL|Radiolabeled TRV130|
62022985|NCT03701555|EXPERIMENTAL|Part 1, Cohort 1A-1 to 1D-1 Healthy Participants|A single dose of PvP001 placebo, PvP001 100 mg, PvP001 300 mg, or PvP001 900 mg will be administered in ascending order to healthy participants in Cohorts 1A-1, 1B-1, 1C-1, and 1D-1.
62022986|NCT03701555|EXPERIMENTAL|Part 1, Cohort 1E-1 Healthy Participants|A single dose of the maximum feasible dose (MFD) of PvP002 will then be administered to healthy participants in Cohort 1E-1.
62022987|NCT03701555|EXPERIMENTAL|Part 1, Cohort 1A-2 - 1D-2 Celiac Disease (CeD)|A single dose of PvP001 placebo, PvP001 100 mg, PvP001 300 mg, or PvP001 900 mg will be administered in ascending order to participants with CeD in Cohorts 1A-2, 1B-2, 1C-2, and 1D-2.
62022988|NCT03701555|EXPERIMENTAL|Part 1, Cohort 1E-2 CeD|A single dose of the MFD of PvP002 will then be administered to participants with CeD in Cohort 1E-2.
62022989|NCT03701555|EXPERIMENTAL|Part 2, Cohort 2A - Cohort 2C Healthy Participants|Participants will be blinded to the PvP001 dose (placebo or MTD of PvP001) and will also receive MTD of PvP001 following 7 days of PPI treatment.
62022990|NCT03701555|EXPERIMENTAL|Part 2, Cohort 2D Healthy Participants|Participants will receive PvP001 placebo or MFD of PvP001.
62243392|NCT05251623|EXPERIMENTAL|pedometer|walking with pedometer
62243393|NCT05251623|NO_INTERVENTION|control|no intervention
62243394|NCT04728126||Study group|Female health-care givers aged 45 to 64 years. The study participants will be recruited from UMC (Clinical Academic Department (CAD) of Women's Health, Pediatric Clinical Academic Department, Republic Diagnostic Center (RDC) and National Center for Children's Rehabilitation (NCCR)), Nur-Sultan, Kazakhstan.
62243395|NCT01252810|EXPERIMENTAL|GE 145 320mg I/ml injection|
62243396|NCT01252810|ACTIVE_COMPARATOR|Iopamidol 370mg I/ml injection|
62243397|NCT04048980|NO_INTERVENTION|Control Group|Patients with dementia or cognitive impairment and femur fracture receiving the traditional care in traumatology units.
62243398|NCT04048980|EXPERIMENTAL|Experimental Group|Patients with dementia or cognitive impairment and femur fracture receiving an intervention in traumatology units.
62243399|NCT01068392|EXPERIMENTAL|OXP|Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2HR D1 Prednisolone 100mg/Day D1-D5 Every 3 weeks Maximum 6 cycles of treatment will be given for this study. Subjects will be treated for at least 1 cycle and to a maximum of 6 cycles unless there is documented disease progression, unacceptable adverse events or withdrawal of consent.
62413604|NCT06701903|EXPERIMENTAL|ITI-1284 20mg|ITI-1284 20 mg tablet, taken once daily, sublingual administration.
62413605|NCT06701903|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet, taken once daily, sublingual administration
62413606|NCT00232245|EXPERIMENTAL|Fish oil|Patients prescribed 6g/day of fish oil containing total 1.8 g of EPA+DHA in a 1.5:1 ratio
62413607|NCT00232245|NO_INTERVENTION|Control|No fish oil exposure
62413608|NCT00124579|EXPERIMENTAL|bortezomib with thalidomide and dexamethasone|bortezomib with thalidomide and dexamethasone
62413609|NCT00672308|EXPERIMENTAL|1|Benefiber (25 g/L)
62413610|NCT00672308|EXPERIMENTAL|2|Benefiber (50 g/L)
62413611|NCT00672308|EXPERIMENTAL|3|the reduced-osmolarity WHO-ORS without Benefiber.
62413612|NCT00552812|EXPERIMENTAL|Stent therapy of aortic coarctation|Stenting of aortic coarctation
62795167|NCT05303623|EXPERIMENTAL|Conventional Physiotherapy + inspiratory muscle training|"Physical ,medical and respiratory examination in this group Physical Function Test in Intensive Care (PFIT), maximum inspiratory mouth pressure and maximum expiratory mouth pressure, Medical Research Council Muscle Strength Test and diaphragmatic function with B mode and M mode ultrasonographic assessment. In this group, inspiratory muscle training will be applied in addition to conventional physiotherapy.~Inspiratory muscle training apply for 5 days after extubation period. Inspiratory muscle training will be given with a threshold loading by giving resistance at 30-40% of the maximum inspiratory pressure measurement obtained. The subjects in this group will be given inspiratory muscle training 4 sets with 6-10 breaths per set, 1-2 minutes between each set once a day in addition to conventional physiotherapy."
62413613|NCT01285388|EXPERIMENTAL|MB12066 10mg|
62413614|NCT01285388|ACTIVE_COMPARATOR|MB12066 30mg|
62219258|NCT03623373|EXPERIMENTAL|Bendamustine/Rituximab/Acalabrutinib/Cytarabine|"* Patients will receive (6) 28 day cycles~* Cycles 1-3 will consist of bendamustine on Days 1 and 2, rituximab on Day 1, and acalabrutinib twice per day (BID) on Days 1 through 28.~* Cycles 4-6 will consist of rituximab on Day 1, cytarabine every 12 hours on Days 1 and 2, acalabrutinib BID on Days 1 through 7 and 22 through 28 (one week on, two weeks off, one week on), and growth factors as per institutional standard~* After Cycle 6, patients will undergo leukapheresis"
62219259|NCT04096053|EXPERIMENTAL|TEACHH|The training workshop is designed as a 3-hour session for care providers. The training will be delivered by trans women. During this training, we plan to have providers: 1) discuss human rights for trans women; 2) teach providers about common words with which to discuss gender identity and expression, and develop a basic understanding of trans healthcare, HIV prevention, and HIV treatment, and how these types of healthcare affect trans women living with and affected by HIV; 3) discuss what it means to be trans-affirming in their work and how they can make their organizations more trans- affirming; and 4) have participants complete a case study to apply what they have learned to practice. These case studies will address issues affecting trans women who are immigrants/newcomers, trans women who are living with HIV, and trans women who experience other vulnerabilities.
62219260|NCT01756768|EXPERIMENTAL|Radio-labeled Dose Arm|
62022991|NCT03701555|EXPERIMENTAL|Part 2, Cohort 2E Healthy Participants|Participants will receive PvP002 placebo or MFD of PvP002.
62219261|NCT05857982|EXPERIMENTAL|MDD group|Dexamethasone 20 mg/d, on the same day of daratumumab injection; Mitoxantrone hydrochloride liposome injection: 20 mg/m2, d1; Daratumumab: 16 mg/Kg, once a week for the first 8 weeks; then changed to once every two weeks; Each cycle is 4 weeks long and the maximum number of cycles is 6.
62219262|NCT03103451|EXPERIMENTAL|Cohort 1|"This cohort includes 3 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
62219263|NCT03103451|EXPERIMENTAL|Cohort 2|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
62219264|NCT03103451|EXPERIMENTAL|Cohort 3|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
62219265|NCT03103451|EXPERIMENTAL|Cohort 4|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
62219266|NCT03103451|EXPERIMENTAL|Cohort 5|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
62219267|NCT03103451|EXPERIMENTAL|Cohort 6|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
62219268|NCT03103451|EXPERIMENTAL|Cohort 7|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
62413615|NCT01285388|ACTIVE_COMPARATOR|MB12066 100mg|
62413616|NCT01285388|ACTIVE_COMPARATOR|MB12066 150mg|
62413617|NCT01285388|ACTIVE_COMPARATOR|MB12066 200mg|
62413618|NCT01285388|PLACEBO_COMPARATOR|placebo|
62795168|NCT05303623|EXPERIMENTAL|Healthy Subject|In the group consisting of healthy volunteers, which will be taken to determine the normative values of the outcome measurements for diaphragmatic tissue Doppler imaging and ultrasonographic evaluation, 2 sessions a day with a threshold-loaded inspiratory muscle training device, starting at 30% of the MIP value, 5 days a week for 4 weeks. Inspiratory muscle training will be performed in 4 sets, 6-8 breaths in each set and 2 minutes rest between sets. In the second evaluation to be made after the inspiratory muscle training, the above-mentioned evaluations and measurements will be repeated.
62795169|NCT02240641||hypertension treatment strategies|
62219269|NCT00824447|PLACEBO_COMPARATOR|Placebo control|Placebo control
62219270|NCT00824447|ACTIVE_COMPARATOR|Grass pollen extract, twice weekly|Grass pollen extract, 9,500 BU, given twice weekly
62795170|NCT06393972|EXPERIMENTAL|Tofacitinib|Tofacitinib in patients with glucocorticoid resistant ICIs-related myocarditis
62795171|NCT03874572|EXPERIMENTAL|Allogeneic mesenchymal stem/stromal cell therapy|Treatment with intra-glandular Injections of allogeneic adipose derived stem cells
62022992|NCT03701555|EXPERIMENTAL|Part 2, Cohort 2F- Cohort 2H Healthy Participants|Participants will receive the PvP001 placebo and either 300 mg or 600 mg of PvP001.
62219271|NCT00824447|ACTIVE_COMPARATOR|Grass pollen extract daily|Grass pollen extract, 9,500 BU, given daily
62413619|NCT05516498|EXPERIMENTAL|Part A: Treatment Group 1|Participants will receive once daily dose of placebo matching zibotentan capsule + placebo matching dapagliflozin tablet for 6 weeks.
62413620|NCT05516498|EXPERIMENTAL|Part A: Treatment Group 2|Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 6 weeks.
62413621|NCT05516498|EXPERIMENTAL|Part B: Treatment Group 1|Participants will receive once daily dose of placebo matching zibotentan capsule + placebo matching dapagliflozin tablet for 16 weeks.
62413622|NCT05516498|EXPERIMENTAL|Part B: Treatment Group 2|Participants will receive once daily dose of placebo matching zibotentan capsule + dapagliflozin tablet for 16 weeks.
62413623|NCT05516498|EXPERIMENTAL|Part B: Treatment Group 3|Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 16 weeks.
62413624|NCT05516498|EXPERIMENTAL|Part B: Treatment Group 4|Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 16 weeks.
62413625|NCT05516498|EXPERIMENTAL|Part B: Treatment Group 5|Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 16 weeks.
62433317|NCT01315483|NO_INTERVENTION|Control|Usual care
62413626|NCT06224764|OTHER|Mother and Father questionnaires|Mother and Father questionnaires (on paper or by phone) and data collectionon newborns weighing less than 2 kilos (at discharge from birth to 11 months)
62413627|NCT06499935|EXPERIMENTAL|Rigid Taping Group|A single application of tape will be fastened to the fibula's lateral malleolus, extended beneath the foot, and crossed the medial foot at the calcaneus and navicular tuberosity. After that, it will wrapped around the fibular and tibial shafts and passed across the anterior part of the ankle. The tape will be applied similarly to the other application, with 1.5 inches of overlap between the strips.
62413628|NCT06499935|EXPERIMENTAL|Kinesio Taping Group|Elastic kinesiology tape will be employed in this investigation. Patients will be comfortably positioned on a table raised sufficiently so that their feet couldn't contact the ground. At the hindfoot, a 2-inch, 25-centimeter strip will be applied, stretching it seventy-five percent from the middle third of the medial tibia to the fibula (lateral malleolus), around the calcaneus. Applying the strip in the maximally supinated position while going in the direction mentioned will allow the foot to eventually reach its maximum dorsal flexion. The interior aspect of the tibial bone and fibula will then wrapped
62413629|NCT06499935|SHAM_COMPARATOR|Sham Taping Group|There are two steps to Sham taping: The internal malleolus is the starting point of the first stage, which extends to the lower limb's inner middle point. The second stage starts at the external malleolus and extends to the lower limb's outer middle point.
62413630|NCT04166877|EXPERIMENTAL|Magnesium Group|The magnesium group arm will receive a 40 mg/kg IBW (maximum 4 g) bolus of intravenous magnesium sulfate, followed by a continuous infusion of 0.5 g/hr for a total of 24 hours.
62022993|NCT03701555|EXPERIMENTAL|Part 2, Cohort 2I and Cohort 2J Healthy Participants|Participants will receive the PvP001 placebo and 900 mg of PvP001.
62795172|NCT06160011|EXPERIMENTAL|Intervention Group Electrical Dry Needling amd Physiotherapy|The intervention group will receive a treatment composed by electrical dry needling and conventional physiotherapy treatment
62795173|NCT06160011|ACTIVE_COMPARATOR|Intervention Group Dry Needling amd Physiotherapy|This group will receive a treatment composed by dry needling and conventional physiotherapy treatment
62795174|NCT06160011|PLACEBO_COMPARATOR|Control Group|Control group will receive conventional physiotherapy treatment
62022994|NCT03701555|EXPERIMENTAL|Part 3, Cohorts 3A and 3B Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 with pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
62022995|NCT03701555|EXPERIMENTAL|Part 3, Cohorts 3C and 3D Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
62022996|NCT03701555|EXPERIMENTAL|Part 3, Cohorts 3E and 3F Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution after an approximately 50 milliliter (mL) portion of a standardized 1 gm gluten-containing study meal.
62413631|NCT04166877|PLACEBO_COMPARATOR|Control Group|The control arm will receive the same volume and rate of saline as if they were in the experimental group.
62413632|NCT06197698|OTHER|18F-FDG PET is used as an imaging marker of gut microbiota composition evaluation in PD patients|We will investigate the correlation between 18F-FDC PET bowel uptake and dopamine transporter changes in patients with PD.
62413633|NCT05648097|NO_INTERVENTION|Standard of Care|Patients exposed to a patient with COVID-19 isolated at the site - standard of care
62413634|NCT05648097|ACTIVE_COMPARATOR|Baldachin-Intervention|Patients exposed to a patient with COVID-19 isolated at the site - under Baldachin
62413635|NCT02186470|EXPERIMENTAL|Treatment (image-guided intensity-modulated APBI)|Patients undergo image-guided intensity-modulated APBI twice daily (BID) in the prone position over a period of 5-10 days for a total of 10 treatment. Within 4-6 weeks post-APBI, patients undergo lumpectomy.
62795175|NCT04976686|EXPERIMENTAL|All study participants|All participants will undergo sample collection during their regular diet and after modification of their diet to a low carbohydrate diet
62022997|NCT03701555|EXPERIMENTAL|Part 3, Cohorts 3G and 3H Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution before a standardized gluten-free study meal followed approximately 30 minutes later by a standardized 1 gm gluten-containing study meal.
62022998|NCT03701555|EXPERIMENTAL|Part 4, Cohorts 4A and 4B Healthy Participants|Participants will receive multiple dose of PvP003 placebo and 600 mg of PvP003.
62022999|NCT03701555|EXPERIMENTAL|Part 3, Cohorts 3I and 3J Healthy Participants|Participants will receive single dose of PvP003 placebo and 150 mg of PvP003 without pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
62023000|NCT00954369|EXPERIMENTAL|[F-18]W372|Approximately twenty (20) adult subjects including ten (10) healthy volunteers and ten (10) high probability AD subjects, as defined by protocol criteria
62023001|NCT01564225|EXPERIMENTAL|EDI200|
62023002|NCT05995912|EXPERIMENTAL|Etoricoxib-Tramadol|Etoricoxib-Tramadol 120mg/100mg tablet, once-daily, for 3 days
62023003|NCT05995912|ACTIVE_COMPARATOR|Naproxen + Tramadol|Naproxen 220 mg tablet + Tramadol 50 mg capsule, twice a day, for 3 days.
62023004|NCT00353275|OTHER|1|Strict glycemic control with a blood glucose target range of 80-110 mg/dL
62023005|NCT00353275|OTHER|2|Conventional glycemic control with blood glucose target range of 110-140 mg/dL
62023006|NCT01188239||HIGH 6wks LOW 6wks NICOTINE|"Well characterized group of 100 regular smokers experimenting the E-Cigarette loaded with ORIGINAL 7.4 mg nicotine cartridges for 6 weeks followed by CATEGORIA 5.2 mg nicotine cartridges for a further 6 weeks (high and low nicotine group)."
62795176|NCT03310814|EXPERIMENTAL|Personalized nutrition intervention|Participant receives gene-test results plus personalized nutrition information from a registered dietician
62795177|NCT03310814|PLACEBO_COMPARATOR|Usual nutrigenomics intervention|Participant receives usual nutrigenomics intervention (direct-to-consumer)
62795178|NCT05175586|EXPERIMENTAL|Group 1|15 patients in the experimental group of percutaneous neuromodulation together with orthopaedic manual therapy (Maitland and Mulligan)
62795179|NCT05175586|ACTIVE_COMPARATOR|Group 2|15 patients in the experimental group of orthopaedic manual therapy (Maitland and Mulligan).
62795180|NCT06172647||Active Microscopic Colitis (MC) patients|
62795181|NCT06172647||Chronic watery diarrhoea patients|
62795182|NCT06172647||Patients with Advanced Colon Adenomas|
62795183|NCT06172647||Healthy controls|
62219272|NCT00824447|ACTIVE_COMPARATOR|Increased dose of grass pollen extract|Increased dose of grass pollen extract, 19,000 BU, given daily
62219273|NCT05339984|EXPERIMENTAL|Hepatectomy|Liver resection group
62219274|NCT05339984|EXPERIMENTAL|Liver Transplantation|Liver Transplantation group
62219275|NCT05339984|EXPERIMENTAL|Portal vein embolization|Portal vein embolization group
62219276|NCT02619981|ACTIVE_COMPARATOR|Father present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , Father present
62219277|NCT02619981|ACTIVE_COMPARATOR|Mother Present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , Mother present
62219278|NCT02619981|ACTIVE_COMPARATOR|Both parents present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , both parents present
62219279|NCT04064593|EXPERIMENTAL|Polygraphy|
62219280|NCT01234077|NO_INTERVENTION|ECG recording|In-laboratory vs. in-home recordings
62219281|NCT05660460|OTHER|Socially vulnerable individuals in contact with a mobile clinic|After obtaining informed consent, a project nurse in the mobile clinic reviews the online-questionnaire with the participant and performs a lung function examination requiring the individual to blow into a plastic tube. If the participant is identified as having obstructive reduction of lung function, they are offered a referral and patient support to a local pulmonary medicine department or GP for further investigation - regardless of whether or not they have a diagnosed or undiagnosed lung disease. In addition, participants are questioned about their motivation for smoking cessation and are informed of the options for this (in hospital and/or referral to the municipality).
62413636|NCT03662711|ACTIVE_COMPARATOR|Long-acting beta-agonist (LABA) or LABA/LAMA|long-acting bronchodilator agents (LABD, LAMA or LABA/LAMA) but no inhaled steroids plus usual care for comorbidities
62413637|NCT03662711|EXPERIMENTAL|Long-acting muscarinic antagonist (LAMA) and/or LABA plus ICS|Bronchodilator agents LAMA and/or LABA with inhaled steroids plus usual care for comorbidities
62413638|NCT05338671|ACTIVE_COMPARATOR|2% Lidocaine 1:100,000 epinephrine|Participants in this arm will receive an inferior alveolar nerve block with 1 cartridge (1.8 mL) of 2% Lidocaine 1:100,000 epinephrine following endodontic treatment.
62413639|NCT05338671|ACTIVE_COMPARATOR|0.5% bupivicaine 1:200,000 epinephrine|Participants in this arm will receive an inferior alveolar nerve block with 1 cartridge (1.8 mL) of 0.5% bupivicaine 1:200,000 epinephrine following endodontic treatment.
62586746|NCT04878484|EXPERIMENTAL|Cohort 1: TCRT-ESO-A2: 0.3 × 1010 TCRT-ESO-A2 cells * ±30%|Subjects will be evaluated for DLTs up to 28 days post-TCRT-ESO-A2 infusion. Enrollment into a dose level will be suspended if two of no more than six subjects at a dose level experience dose-limiting toxicity. Prior to increasing the dose, a cohort management meeting will be held after the final enrolled subject has been followed for up to28 days. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor. At each cohort, there will be at least 7 days between infusion of each subject in the cohort.
62795184|NCT04987502|EXPERIMENTAL|Virtual reality treatment|Virtual reality immersion with 3D audio and visual rendering (8 weekly sessions)
62795185|NCT04987502|ACTIVE_COMPARATOR|Standard treatment|Counselling Relaxation techniques Sound enrichment
62795186|NCT06722677|EXPERIMENTAL|VNS group|Active VNS paired with rehabilitation
62795187|NCT06722677|ACTIVE_COMPARATOR|Control group|Sham VNS paired with rehabilitation
62795188|NCT03805789|EXPERIMENTAL|AAT (low dose)|Open label. Alpha-1 antitrypsin (AAT) is a lyophilized product for intravenous administration
62023007|NCT01924325|ACTIVE_COMPARATOR|Dual-antiplatelet Therapy|Receiving a 75 mg dose of clopidogrel and 75mg dose of aspirin from day 1 to day 21, with placebo apixaban twice daily
62023008|NCT01924325|EXPERIMENTAL|Apixaban 2.5mg|Receiving a 2.5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from day 1 to day 21
62023009|NCT01924325|EXPERIMENTAL|Apixaban 5mg|Receiving a 5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from day 1 to day 21
62023010|NCT01575340|EXPERIMENTAL|fish oil encapsuled|will receive the supplementation of 2 g / day of fish oil encapsulated for 9 weeks
62023011|NCT01575340|NO_INTERVENTION|without supplementation|not will receive supplementation or encapsulated fish oil or placebo
62023012|NCT01973790|EXPERIMENTAL|Z-338|100mg TID
62023013|NCT03152305||Women with menstrual migraine|Womens presenting with regular menstrual migraine treated with triptans will be included in the study.
62023014|NCT03152305||Matched control|The potential variations will be compared to the measures done on matched healthy women outside and during menses.
62023015|NCT04020120||ADHD in professional activity|Adult ADHD patients in active employment at the time of inclusion or who were in employment within 3 months prior to inclusion
62023016|NCT04369027||preload responders|patients who increase their delta VTI by more than 10% during PLR
62023017|NCT04369027||preload unresponders|patients who do not increase their delta VTI by more than 10% during PLR
62023018|NCT00799812|EXPERIMENTAL|CHG Swabstick (3 @ once)|Chlorhexidine gluconate (CHG) 2% w/v CHG/isopropyl alcohol (IPA) 70% v/v - 3 swabsticks applied @ same time
62413640|NCT05458895|EXPERIMENTAL|High concentration free-base nicotine (5%), Tobacco flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
62413641|NCT05458895|EXPERIMENTAL|High concentration nicotine salt (5%), Tobacco flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
62413642|NCT05458895|EXPERIMENTAL|High concentration free-base nicotine (5%), Menthol flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
62795189|NCT03805789|EXPERIMENTAL|AAT (medium dose)|Open label. AAT is a lyophilized product for intravenous administration
62795190|NCT03805789|EXPERIMENTAL|AAT (high dose)|Open label. AAT is a lyophilized product for intravenous administration
62795191|NCT03805789|EXPERIMENTAL|AAT (selected dose from open-label)|Double-blind. AAT is a lyophilized product for intravenous administration
62023019|NCT00799812|EXPERIMENTAL|CHG Swabstick sequential|Chlorhexidine gluconate (CHG) 2% w/v and isopropyl alcohol (IPA) 70% v/v - 3 swabsticks applied sequentially
62023020|NCT00799812|ACTIVE_COMPARATOR|Hibiclens|Chlorhexidine gluconate (CHG) 4% w/v in an aqueous base
62219282|NCT06610916|EXPERIMENTAL|Reinforced Communautary Support Program (PARC)|"Participants will complete the initial self-questionnaire collecting baseline socio-demographic, clinical characteristics, and all intermediate effectiveness outcome criteria before. Concurrently with their participation in the program, they will complete various intermediate effectiveness evaluation questionnaires (after) at 3 months (end of PARC) and 6 months (Post-PARC). Healthcare professionals running the PARC program will also complete questionnaires related to implementation indicators throughout the patients' course (Adoption, Implementation, Maintenance).~Qualitative interviews will be conducted with patients and relevant healthcare professionals to explore barriers and drivers to the optimal deployment of the PARC program and to examine each of the Reach, Adoption, Implementation, Maintenance indicators through an organizational approach"
62219283|NCT01963923|EXPERIMENTAL|Rehabilitation Group|The rehabilitation group must complete at least 16 sessions of the Pulmonary Rehabilitation Program
62219284|NCT01963923|NO_INTERVENTION|Control Group|The control group must complete only the outcome measures and continue with their clinical routine as specified by their physicians.
62023021|NCT00799812|PLACEBO_COMPARATOR|Sterile water swab (3 @ once)|Sterile swabstick wetted with sterile deionized water - 3 swabsticks applied at the same time.
62795192|NCT03805789|PLACEBO_COMPARATOR|Placebo|Albumin solution administered intravenously
62795193|NCT06046729|EXPERIMENTAL|Eltrekibart Dose 1|Eltrekibart will be given subcutaneously (SC).
62795194|NCT06046729|EXPERIMENTAL|Eltrekibart Dose 2|Eltrekibart will be given SC.
62795195|NCT06046729|EXPERIMENTAL|Eltrekibart Dose 3|Eltrekibart will be given SC.
62023022|NCT00799812|PLACEBO_COMPARATOR|Sterile water swabstick (sequential)|Sterile swabstick wetted with sterile water--3 swabsticks applied sequentially.
62023023|NCT01311986||Patients with atopic dermatitis|
62023024|NCT01311986||Patients with nummular eczema|
62023025|NCT01311986||Normal control|
62023026|NCT02652728|EXPERIMENTAL|Drug administration|Enalapril Orodispersible Minitablet (ODMT), 0.25 mg or 1 mg, administered 1x/day or 2x/day for up to 8 weeks
62219285|NCT04238273||HHHFNC|it included 63 preterm neonates on Heated, Humidified High Flow Nasal Cannula, of which 35 preterm underwent functional echocardiography, transcranial ultrasonography Doppler applied to the anterior cerebral artery and assessment of pre-prandial superior mesenteric artery velocity and volume of blood flow with Doppler sonography. All of which done while on non invasive ventilation and after weaning.
62795196|NCT06046729|PLACEBO_COMPARATOR|Placebo|Placebo will be given.
62795197|NCT04601896||Live patients admitted for Refractory Cardiac Arrest with ECMO|
62795198|NCT04601896||Live patients quality of life admitted for Refractory Cardiac Arrest without ECMO|
62795199|NCT04403451|EXPERIMENTAL|Phase 1/Cohort 1|True North Love Notes, Financial Stability, Jobs
62023027|NCT03415620|EXPERIMENTAL|Music listening|"Phase 1: Before and after surgery, 300 patients will be offered an ipod with earphone, in which the ipod is equipped with saved playlist of different music genres to select from pre-determined lists of music of different genres or patient choice. Patient will choose the desired playlist and listen to the music for about 30 minutes. Hospital Anxiety and Depression Scale (HADS) score, pain scores, analgesia usage, patient satisfaction, and quality of life measurement will be collected. Analysis of the type of music, duration of music listening, and the genre chosen will be analysed.~Phase 2: One hundred and ten women undergoing Caesarean delivery assigned to experimental (music listening) group will listen to the music before, during and after surgery. Pain and psychological assessments and demographic data collection will be conducted before and after surgery."
62023028|NCT03415620|NO_INTERVENTION|No Music Listening|Phase 2: Patients assigned to this group (n=55) will only have pain, psychological assessments and demographic data collection conducted before and after surgery.
62023029|NCT01390012|ACTIVE_COMPARATOR|Dexamethasone oral|
62795200|NCT04403451|EXPERIMENTAL|Phase 2/Cohort 2|True North Love Notes, Financial Stability, Jobs
62795201|NCT04403451|EXPERIMENTAL|Phase 3/Cohort 3|True North Love Notes, Financial Stability, Jobs
62795202|NCT04688749||Healthy Control|Individuals without skin damage (melanoma, BCC, SCC, etc)
62023030|NCT01390012|ACTIVE_COMPARATOR|Dexamethasone intravenous|
62023031|NCT02754635|ACTIVE_COMPARATOR|Induction of labour|Induction of labour at 38-39 weeks
62023032|NCT02754635|ACTIVE_COMPARATOR|Expectant management|Expectant management until 41 weeks.
62795203|NCT04688749||Skin lesion|Individuals diagnosed with confirmed skin damage by Dermatologists
62795204|NCT06009094|EXPERIMENTAL|VC005 Low Dose groups|
62795205|NCT06009094|EXPERIMENTAL|VC005 median-A Dose groups|
62795206|NCT06009094|EXPERIMENTAL|VC005 median-B Dose groups|
62795207|NCT06009094|EXPERIMENTAL|VC005 high Dose groups|
62023033|NCT01895504|EXPERIMENTAL|ColoAssist|Screening colonoscopy with a new colonoscope with gradual stiffness
62023034|NCT01895504|ACTIVE_COMPARATOR|MEI|Screening colonoscopy with colonoscopes compatible with and guided by MEI
62795208|NCT06009094|PLACEBO_COMPARATOR|VC005 Placebo groups|
62795209|NCT06091735|EXPERIMENTAL|Magnesium sulfate sodium potassium solution group|Magnesium sulfate sodium potassium solution group: 3L magnesium sulfate sodium potassium oral concentrated solution. At 18:00 1d before the inspection, dissolve a package of contents into 200ml with water, and drink 250ml of water every half hour after that, drinking a total of 6 cups (that is, 1.5L); On the day of the examination (6 hours before the colonoscopy) repeat the same medication as the previous evening.
62023035|NCT01123759|ACTIVE_COMPARATOR|Tilapia|Subjects are fed 6 oz tilapia once a week for 3 months
62023036|NCT01123759|ACTIVE_COMPARATOR|Salmon|Subjects fed 6 oz salmon once a week for 3 months
62023037|NCT05483426|OTHER|Interviews|semi-directive interview
62795210|NCT06091735|EXPERIMENTAL|Magnesium sulfate sodium potassium solution group + linaclotide group|Magnesium sulfate sodium potassium solution + linaclotide group: 3L sodium magnesium sulfate potassium oral concentrated solution + linaclotide 290μg. One tablet of linalotide was taken orally at 18:00 one day before the examination, and then two packets of contents were dissolved into 300ml with water 6 hours before the colonoscopy. After that, 500ml of water was drunk every half hour, for a total of 6 cups.
62219286|NCT04238273||NCPAP|it included 60 preterm neonates on Nasal Continuous Positive Airway Pressure, of which 35 preterm underwent functional echocardiography, transcranial ultrasonography Doppler applied to the anterior cerebral artery and assessment of pre-prandial superior mesenteric artery velocity and volume of blood flow with Doppler sonography. All of which done while on non invasive ventilation and after weaning.
62795211|NCT06091735|PLACEBO_COMPARATOR|PEG (Compound polyethylene glycol electrolyte powder) group|PEG (Compound polyethylene glycol electrolyte powder) group: 3LPEG. At 18:00 1d before the inspection, dissolve a package of contents into 200ml with water, and drink 250ml of water every half hour after that, drinking a total of 6 cups; On the day of the examination (6 hours before the colonoscopy) repeat the same medication as the previous evening.
62795212|NCT03329092|EXPERIMENTAL|Aztreonam-Avibactam ± Metronidazole|All patients randomised to this arm will receive ATM-AVI; all patients with cIAI will receive MTZ for anaerobic cover
62795213|NCT03329092|ACTIVE_COMPARATOR|Meropenem ± Colistin|All patients randomised to this arm will receive MER; addition of COL will be at investigator's discretion in line with local practice
62795214|NCT02298400|ACTIVE_COMPARATOR|Acuvue®Oasys® Lenses(senofilcon A)|Acuvue® Oasys® Lenses (senofilcon A) contact lenses
62795215|NCT02298400|ACTIVE_COMPARATOR|Bausch + Lomb PureVision (balafilcon A)|30-Day Bausch + Lomb PureVision (balafilcon A) contact lenses
62795216|NCT02298400|ACTIVE_COMPARATOR|Clariti® 1-Day (Somofilcon A)|Clariti® 1-Day (Somofilcon A) contact lenses
62795217|NCT05989880|EXPERIMENTAL|SafeLM as a supraglottic airway device with video capability|
62795218|NCT05989880|EXPERIMENTAL|SafeLM as a supraglottic airway device without video capability|
62795219|NCT05989880|EXPERIMENTAL|SafeLM as a conduit for intubation using an endotracheal tube with video capability|
62795220|NCT05989880|EXPERIMENTAL|SafeLM as a conduit for intubation using a bougie with video capability|
62795221|NCT05314998|EXPERIMENTAL|Test Arm A: mFOLFIRINOX or Gem/Cap according to transcriptomic treatment specific signature|mFOLFIRINOX-therapy (5-FU, Folinic Acid, Irinotecan, Oxaliplatin) according to individual transcriptomic treatment specific signature or Gem/Cap-therapy (Gemcitabine and Capecitabine) according to individual transcriptomic treatment specific signature
62795222|NCT05314998|ACTIVE_COMPARATOR|Control Arm B: mFOLFIRINOX or Gem/Cap according to standard clinical criteria|mFOLFIRINOX-therapy (5-FU, Folinic Acid, Irinotecan, Oxaliplatin) according to standard clinical criteria or Gem/Cap-therapy (Gemcitabine and Capecitabine) according to standard clinical criteria
62795223|NCT02259465|ACTIVE_COMPARATOR|Oligofructose|Participants will be asked to follow the low FODMAP diet for a week, supplementing the diet with oligofructose, 7grams twice daily
62795224|NCT02259465|PLACEBO_COMPARATOR|Maltodextrin|Participants will be asked to follow the low FODMAP diet for a week, supplementing the diet with maltodextrin, 7grams twice daily
62023038|NCT01509859|ACTIVE_COMPARATOR|PFNA|"these patients will be treated with synthes PFNA device"
62023039|NCT01509859|ACTIVE_COMPARATOR|INTERTAN|"these patients will be treated with Smith\&Nephew INTERTAN device"
62219287|NCT03638973|EXPERIMENTAL|Biopsy with Er: YAG|Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser under previous local anesthesia
62219288|NCT03638973|ACTIVE_COMPARATOR|Biopsy with Scalpel|Biopsies taken with Er: YAG are compared with biopsies taken with a scalpel in patients with lichenoid or leukoplakic changes of the oral mucosa.
62795225|NCT01070173||Short Stature|Poor linear growth
62795226|NCT01070173||Poor Weight Gain (Failure-To-Thrive)|Poor Weight Gain
62795227|NCT01070173||Isolated Gastrointestinal Symptoms|No growth symptoms
62795228|NCT05142826|ACTIVE_COMPARATOR|School as Usual|School procedures as typically used and implemented.
62795229|NCT05142826|EXPERIMENTAL|Immediate Relative Age Effect Intervention|Relative age effect intervention administered in the Fall in school.
62795230|NCT05142826|EXPERIMENTAL|Delayed Relative Age Effect Intervention|Relative age effect intervention administered after the Winter break in school.
62795231|NCT05649800||Healthy|Healthy adults ages over 65 years
62795232|NCT05649800||Stroke|Stroke patients aged over 65 years
62795233|NCT05649800||Dementia|Dementia patients aged over 65 years
62795234|NCT05649800||Depression|Depression patients aged over 65 years
62795235|NCT05649800||Delirium|Delirium patients aged over 65 years
62795236|NCT03970941||CERAMENT|Patients having a septic pseudarthrosis managed with two-stage treatment (Masquelet Technique) with CERAMENT®.
62795237|NCT03970941||NO CERAMENT COMPARATIVE COHORT|Patients having had a septic pseudarthrosis managed with two-stage treatment (only Masquelet Technique) without CERAMENT®.
62023040|NCT05706727|EXPERIMENTAL|Mephentermine ( M group)|Group M
62795238|NCT03148041|ACTIVE_COMPARATOR|intensive health education program|Participants in the intervention group will have an intensive health education program of the introductory lecture and brochures about stroke as well as they fill up the questionnaire at baseline. At week 6 and 12 of the study the participants will only fill up the questionnaire.
62795239|NCT03148041|PLACEBO_COMPARATOR|routine care|Participants in the control group will have a routine care of different lecture and brochures than the intervention group as well as they fill up the questionnaire at baseline. At week 6 and 12 of the study the participants will only fill up the questionnaire.
62795240|NCT00940901|EXPERIMENTAL|sildenafil|Participants assigned to this arm were given sildenafil 50 mg tablet daily for 16 weeks.
62795241|NCT00940901|PLACEBO_COMPARATOR|placebo|Participants assigned to this arm were given a placebo pill for the first 8 weeks, and then Sildenafil 50 mg for weeks 9-16.
62795242|NCT01518374|EXPERIMENTAL|Florbetapir-PET Scans|
62795243|NCT06654752|EXPERIMENTAL|Immediate Antibiotics|Increased airway clearance plus early initiation of oral antibiotics
62795244|NCT06654752|EXPERIMENTAL|Tailored Therapy|Increased airway clearance alone, with addition of oral antibiotics for worsening symptoms or failure to improve
62795245|NCT01824550|EXPERIMENTAL|home-based exercise training condition|Home based endurance exercise training
62795246|NCT01824550|NO_INTERVENTION|attention control condition|Attention control condition - home based flexibility training
62795247|NCT00955396|OTHER|Period 1|
62795248|NCT00955396|OTHER|Period 2|
62023041|NCT05706727|EXPERIMENTAL|Phenylephrine ( P group )|Group P
62023042|NCT00752375|ACTIVE_COMPARATOR|A|Eligible children will be randomized to antibiotic prophylaxis. Children under 3 months will receive amoxicillin 10mg/kg once per day. Children \>3months will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component). Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day.
62023043|NCT00752375|PLACEBO_COMPARATOR|B|Eligible children will then be randomized to placebo.
62023044|NCT01303627|ACTIVE_COMPARATOR|ultiva,remifentanil,opioid,analgesic|Remifentanil:1.5ng/ml remifentanil infusion maintained at the end of the surgery
62795249|NCT02595424|EXPERIMENTAL|Arm A (capecitabine, temozolomide)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62795250|NCT02595424|ACTIVE_COMPARATOR|Arm B (cisplatin, carboplatin, etoposide)|Patients receive cisplatin IV on days 1-3 or carboplatin IV on day 1. Patients also receive etoposide IV on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62795251|NCT06141863||Group 1|no disability and mild disability
62795252|NCT06141863||Group 2|moderate and severe disability
62795253|NCT06340945|EXPERIMENTAL|ultrasound-guided thermal ablation|
62023045|NCT01303627|NO_INTERVENTION|control|Control:Remifentanil stopped at the end of the surgery
62023046|NCT05377177|EXPERIMENTAL|Bilateral aTBS|Patients will receive Bilateral accelerated theta-burst stimulation bilaterally for 5 consecutive days, with a total of 10 hours a day. treatment will be 10min with 50min of breaks in between the 10 sessions.
62433318|NCT05509634|EXPERIMENTAL|Treatment group A|HR20013 for injection + simulant of fosaprepitant dimeglumine for injection + simulant of palonosetron hydrochloride injection + dexamethasone
62795254|NCT01009684||DNG/EV|Users of the oral contraceptive containing Dienogest and Estradiol valerate
62795255|NCT01009684||Other OCs|Users of oral contraceptives (OCs) containing other progestins and estrogens
62795256|NCT01015781|EXPERIMENTAL|Arm 1|Progressive Tinnitus Management
62795257|NCT01015781|OTHER|Arm 2|Wait List Control
62795258|NCT04184297||Subjects initiated with Tiotropium and Olodaterol (Tio+Olo)|
62795259|NCT04184297||Subjets initiated with LABA/LAMA/ICS|Long-acting beta2/ Long-acting muscarinic antagonists/Inhaled corticosteriods
62795260|NCT03018691|EXPERIMENTAL|0.3% OPA-15406 Ointments|Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.
62795261|NCT03018691|EXPERIMENTAL|1% OPA-15406 Ointments|Subjects were treated with assigned 1% OPA-15406 ointment twice daily.
62795262|NCT03018691|PLACEBO_COMPARATOR|Placebo Ointments|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
62795263|NCT03928795||neonates with acute acidosis|neonates with Cord blood gases measured immediately after birth inferior to 7.15
62795264|NCT03928795||neonates with a normal ph|neonates with Cord blood gases measured immediately after birth of at least 7.15
62795265|NCT03077919|ACTIVE_COMPARATOR|Stellate Ganglion Block (SGB)|7-10 mL 0.5% ropivacaine injected under ultrasound visualization ventral to right longus coli muscle (around and into the ventral fascia) and into the longus coli immediately dorsal to the presumed ventral fascia, at the level of the C6 anterior tubercle (landmarks for stellate ganglion).
62795266|NCT03077919|SHAM_COMPARATOR|Sham Treatment|1-2 mL preservative-free normal saline, injected under ultrasound visualization anterolateral to right anterior tubercle of C6.
62795267|NCT06726629||Patients|
62795268|NCT04678752|ACTIVE_COMPARATOR|Standard of Care|Each primary care provider will administer weight loss care per their standard practice.
62795269|NCT04678752|EXPERIMENTAL|PATHWEIGH|A weight management care path that support primary care both through the EHR and training for the clinicians.
62023047|NCT05377177|ACTIVE_COMPARATOR|Unilateral aiTBS|Patients will receive unilateral accelerated theta-burst stimulation to the left side for 5 consecutive days, with a total of 10 hours a day. treatment will be 10min with 50min of breaks in between the 10 sessions. There will be a right DLPFC sham component to this treatment arm for all treatment sessions.
62023048|NCT02523534|EXPERIMENTAL|Recurrence Mapping|Participant undergoing their first ablation that fit our inclusion/exclusion criteria will undergo new atrial fibrillation mapping techniques to help identify the sources of atrial fibrillation. The participant will have an MRI and ECG prior to a clinically indicated ablation.
62023049|NCT04209660|EXPERIMENTAL|recurrent/metastatic adenoid cystic carcinoma (R/M ACC)|"All eligible patients will undergo informed consent and screening for trial enrollment.~Enrolled patients will receive a starting lenvatinib dose of 20mg daily taken orally and pembrolizumab 200mg intravenously every 3 weeks (1 cycle=3 weeks)"
62795270|NCT04523207|EXPERIMENTAL|Apalutamide + Androgen Deprivation Therapy (ADT)|In the main study, participants will receive apalutamide 240 milligram (mg) once daily orally along with ADT for 12 cycles (Each cycle is of 28 days). Participants who enrolled in the sub-study will receive apalutamide 240 mg once daily along with relugolix (a type of ADT) 120 mg once daily following a loading dose of 360 mg relugolix orally. Sub-study participants will be receiving relugolix up to Day 28 after which they will be transitioned into the main study from Cycle 2 Day 1 and will continue to receive conventional or oral ADT.
62795271|NCT00112372|EXPERIMENTAL|Ridaforolimus|10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.
62586747|NCT04878484|EXPERIMENTAL|Cohort 2: TCRT-ESO-A2: 1.0 × 1010 TCRT-ESO-A2 cells ±30%|Subjects will be evaluated for DLTs up to 28 days post-TCRT-ESO-A2 infusion. Enrollment into a dose level will be suspended if two of no more than six subjects at a dose level experience dose-limiting toxicity. Prior to increasing the dose, a cohort management meeting will be held after the final enrolled subject has been followed for up to28 days. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor. At each cohort, there will be at least 7 days between infusion of each subject in the cohort. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor.
62023050|NCT04209660|EXPERIMENTAL|recurrent/metastatic non-ACC salivary gland cancers (R/M SGC).|"All eligible patients will undergo informed consent and screening for trial enrollment.~Enrolled patients will receive a starting lenvatinib dose of 20mg daily taken orally and pembrolizumab 200mg intravenously every 3 weeks (1 cycle=3 weeks)"
62023051|NCT04180826||Stenosis|Patients with stenosis
62023052|NCT04180826||No stenosis|Patients without stenosis
62023053|NCT01744236|EXPERIMENTAL|Liraglutide (main study, long-term intervention)|This arm (n=20) will receive liraglutide 1.8mg and sitagliptin-placebo during 12 weeks
62023054|NCT01744236|EXPERIMENTAL|Sitagliptin (main study, long-term intervention)|This arm (n=20) will receive sitagliptin 100mg and liraglutide-placebo during 12 weeks
62586748|NCT04878484|EXPERIMENTAL|Cohort 3: TCRT-ESO-A2 : 3.0 × 1010 TCRT-ESO-A2 cells ±30%|Subjects will be evaluated for DLTs up to 28 days post-TCRT-ESO-A2 infusion. Enrollment into a dose level will be suspended if two of no more than six subjects at a dose level experience dose-limiting toxicity. Prior to increasing the dose, a cohort management meeting will be held after the final enrolled subject has been followed for up to28 days. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor. At each cohort, there will be at least 7 days between infusion of each subject in the cohort.
62586749|NCT01319474|OTHER|Ultrasound for suspected DVT|Enrolled subjects suspected to have deep vein thrombosis undergo whole-leg compression ultrasound. Those with a normal result undergo clinical follow-up for thrombotic outcomes over the following three months.
62795272|NCT05880381|EXPERIMENTAL|Virtual Reality Group|Patients allocated to the treatment group will undergo an intervention that comprises 3 weekly sessions of 60 minutes for 4 weeks with the VR prototype.
62023055|NCT01744236|PLACEBO_COMPARATOR|Placebo (main study, long-term intervention)|This arm (n=20) will receive liraglutide-placebo and sitagliptin-placebo during 12 weeks
62023056|NCT01744236|EXPERIMENTAL|Exenatide (main study, acute intervention)|Prior to the 12-week intervention study, a GLP-1 receptor agonist (exenatide) will be administered intravenously (n=30).
62795273|NCT05880381|OTHER|Control Group|The participants allocated to this group will do the formal standard care provided by the Gynecology- Obstetric service.
62795274|NCT04067258||Beta-Thalassemia group|Patients suffering from beta thalassemia major or intermedia will be included in this group
62795275|NCT04067258||Control group|Healthy age and sex matched volunteers will be included in this group
62023057|NCT01744236|PLACEBO_COMPARATOR|Placebo (main study, acute intervention)|Prior to the 12-week intervention study, placebo will be administered intravenously (n=30).
62023058|NCT01744236|OTHER|Acute MRI intervention study|In a subset of 12 patients with type 2 diabetes, a crossover trial with acute infusion of exenatide and placebo is performed. This is done prior to the 12-week intervention study.
62219289|NCT00192647|EXPERIMENTAL|PEG-IFN alfa-2a+Ribavirin - Induction Treatment|Participants will receive 12 weeks of induction therapy with PEG-IFN alfa-2a (Pegasys), 360 micrograms (mcg) subcutaneous (SC) once weekly, along with ribavirin, 1000 or 1200 milligrams (mg) orally daily in divided doses. Thereafter, the dose of PEG-IFN alfa-2a will be reduced to 180 mcg SC once weekly and the ribavirin dose maintained for the remaining 36 weeks of treatment.
62219290|NCT00192647|EXPERIMENTAL|PEG-IFN alfa-2a+Ribavirin - Standard Treatment|Participants will receive 48 weeks of standard therapy with PEG-IFN alfa-2a, 180 mcg SC once weekly, along with ribavirin, 1000 or 1200 mg orally daily in divided doses.
62413643|NCT05458895|EXPERIMENTAL|High concentration nicotine salt (5%), Menthol flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
62795276|NCT00200720|EXPERIMENTAL|Atkins Diet|Participants randomized to this arm will consume a low carbohydrate diet as described by Dr. Robert Atkins in his book: Dr. Atkins' New Diet Revolution New York: Avon Books, 2002.
62795277|NCT00200720|ACTIVE_COMPARATOR|DASH Diet|Participants randomized to this arm will consume the Dietary Approaches to Stop Hypertension (DASH) diet as described here: http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/new_dash.pdf
62795278|NCT04995523|EXPERIMENTAL|Dose Escalation Part A: Checkpoint inhibitor (CPI) experienced Non-small Cell Lung Cancer (NSCLC)|Rilvegostomig Intravenous (IV) monotherapy
62795279|NCT04995523|EXPERIMENTAL|Dose Expansion Part B: CPI experienced NSCLC|Rilvegostomig IV monotherapy
62795280|NCT04995523|EXPERIMENTAL|Dose Expansion Part C: CPI Naive NSCLC|Rilvegostomig IV monotherapy
62023059|NCT01744236|OTHER|Pilot-study|In 10 healthy obese subjects, a crossover trial with acute infusion of exenatide, placebo and L-NMMA is performed.
62795281|NCT04995523|EXPERIMENTAL|Dose Expansion Part D: CPI Naive NSCLC|Rilvegostomig IV monotherapy
62023060|NCT03498534|ACTIVE_COMPARATOR|Patients with a -TST|In all patients with a negative TST test, Isoniazid 300 mg per day will be administered for 6 months
62023061|NCT03498534|ACTIVE_COMPARATOR|Patients with a +TST|In patients with a +TST test researchers will test for HIV, hepatic function and we will take a chest x-ray. Isoniazid 300 mg per day will be administered for 6 months
62023062|NCT03498534|ACTIVE_COMPARATOR|HIV positive patients|The researchers will test hepatic function and take a chest x-ray. Isoniazid 300 mg per day will be administered for 6 months
62219291|NCT01405326|EXPERIMENTAL|Adalimumab|Adalimumab treatment for 6 months
62219292|NCT01405326|PLACEBO_COMPARATOR|Pacebo|Corresponding placebo for active treatment group
62219293|NCT03838887||control group|"Pregnant women:~1. Age between 18-35 years~2. Parity: primigravidas and multiparas.~3. Have no history of preeclampsia or eclampsia.~4. Have no history of chronic hypertension.~5. Not diabetic.~6. Not have antiphospholipid syndrome.~7. Not have autoimmune disease such as SLE"
62795282|NCT04995523|EXPERIMENTAL|Dose Expansion Part E: treatment Naive Squamous NSCLC|Rilvegostomig IV monotherapy
62795283|NCT05574010|EXPERIMENTAL|Cohort 1 in Part A|All eligible Part A participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 1
62795284|NCT05574010|EXPERIMENTAL|Cohort 2 in Part A|All eligible Part A participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 2
62219294|NCT03838887||High risk group|"Pregnant women with:~1. History of preeclampsia -Eclapmsia~2. Chronic hypertension~3. Diabetic~4. Antiphospholipid syndrome.~5. Autoimmune syndrome such as SLE."
62219295|NCT01164904|EXPERIMENTAL|Experimental|Ten escalating dose levels of AMG 181 administered as a single dose SC or IV in healthy volunteers and SC in subjects with mild-to-moderate ulcerative colitis.
62219296|NCT05601154|ACTIVE_COMPARATOR|Crest Cavity Protection|Crest Cavity Protection toothpaste (1,100 ppm F) will be used to brush teeth, followed by a mouth rinse with tap water
62413644|NCT05458895|EXPERIMENTAL|Low concentration free-base nicotine (1%), Tobacco flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
62413645|NCT05458895|EXPERIMENTAL|Low concentration nicotine salt (1%), Tobacco flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
62023063|NCT02083523|ACTIVE_COMPARATOR|Motivational Interview|The Motivational Interview, or MI, (15-30 minutes) was provided after initial substance use disorder assessments but prior to treatment admission. I twas facilitated by a computer generated report and included: an orientation to the session, discussion of the participants' strengths, an agenda setting procedure, a review of concerns, and a session summary. Therapists conveyed empathy, used reflective listening, tried to elicit and reinforce change talk elements, and elicited action steps from the participants.
62219297|NCT05601154|ACTIVE_COMPARATOR|Crest Cavity Protection followed by Act Mint Fluoride Rinse|Crest Cavity Protection toothpaste (1,100 ppm F) will be used to brush teeth, followed by a mouth rinse with Act Mint Fluoride Rinse (226 ppm)
62795285|NCT05574010|PLACEBO_COMPARATOR|Group 1 in Part B and Part C|All eligible Part B and Part C participants will receive 3 intravenous (IV) infusions of placebo
62795286|NCT05574010|EXPERIMENTAL|Group 2 in Part B and Part C|All eligible Part B and Part C participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 3
62219298|NCT05601154|ACTIVE_COMPARATOR|Colgate PreviDent 5000+|Colgate PreviDent 5000+ (5,000 ppm F) will be used to brush teeth, followed by a mouth rinse with tap water
62413646|NCT05458895|EXPERIMENTAL|Low concentration free-base nicotine (1%), Menthol flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
62795287|NCT05574010|EXPERIMENTAL|Group 3 in Part B and Part C|All eligible Part B and Part C participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 4
62413647|NCT05458895|EXPERIMENTAL|Low concentration nicotine salt (1%), Menthol flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
62413648|NCT04037683||MOLI participants pre IOL|Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) after recruitment to MOLI RCT but prior to the start of the induction of labour (IOL) process
62795288|NCT05574010|EXPERIMENTAL|Group 4 in Part B and Part C|All eligible Part B and Part C participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 5
62023064|NCT02083523|ACTIVE_COMPARATOR|MI with Normative Feedback|The Motivational Interview with Normative Feedback, or MI + NF, condition/intervention included all procedures described for the MI condition. Additionally, in the MI + NF condition/intervention, the participants' days of marijuana and alcohol use were compared to two sets of norms ( age specific or level of care specific) available for treatment attending youth. Therapists used whichever norm provided a greater contrast with participants' use.
62219299|NCT05601154|EXPERIMENTAL|Colgate PreviDent 5000+ followed by Act Mint Fluoride Rinse|Colgate PreviDent 5000+ (5,000 ppm F) will be used to brush teeth, followed by a mouth rinse with Act Mint Fluoride Rinse (226 ppm)
62795289|NCT00109824|EXPERIMENTAL|Arm I|Patients receive decitabine IV over 1 hour on days 1-5 or 1-10. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62219300|NCT03410368|EXPERIMENTAL|autologous natural killer cells|Infusion of 1-2×10\^9 NK cells every 14 days in the absence of progression or unacceptable toxicity until the 6 courses of treatment.
62219301|NCT03410368|NO_INTERVENTION|routine follow-up|According to present guideline, no special treatment is advised for patients with SCLC after first-line therapy.They will be followed-up regularly.
62219302|NCT00819390|EXPERIMENTAL|A: Chloroquine then Placebo for Off-ART Participants|Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
62219303|NCT00819390|EXPERIMENTAL|B: Placebo then Chloroquine for Off-ART Participants|Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
62219304|NCT00819390|EXPERIMENTAL|C: Chloroquine then Placebo for On-ART Participants|Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
62413649|NCT04037683||MOLI participants post IOL (misoprostol/misoprostol)|Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) 12 women post IOL with misoprostol/misoprostol Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) 12 women post IOL with misoprostol/oxytocin
62413650|NCT04037683||MOLI participants post IOL (misoprostol/oxytocin)|Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) 12 women post IOL with misoprostol/oxytocin
62023065|NCT02252055|EXPERIMENTAL|ATDC Treatment|"ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation.~Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus, as detailed below :~Prednidolone :~* D 0: 500 mg IV~* D 1: 125 mg IV~* D 2 to 14: 20.0 mg/d~* Wk 3 to 4: 15.0 mg/d~* Wk 5 to 8: 10.0 mg/d~* Wk 9 to 12: 5.0 mg/d~* Wk 13 to 14: 2.5 mg/d~* Wk 15 to End:Cessation~MMF (or biologic equiv.):~* D -7 to -2: 500 mg/d (250mg 2x/d)~* D -1 to 14: 2000 mg/d~* Wk 3 to 36: 1000 mg/d~* Wk 37 to 40: 750 mg/d~* Wk 41 to 44: 500 mg/d~* Wk 45 to 48: 250 mg/d~* Wk 49 to End:Cessation Note : MMF tapering will only happen if the 36-week protocol biopsy shows no signs of subclinical rejection and there is evidence of declining renal function or if the clinician has any other concern about MMF dose reduction.~Tacrolimus :~* ≤ 48 h pre-Tx to D 14: 3-12 ng/ml~* Wk 3 to 12: 3-10 ng/ml~* Wk 13 to 36: 3-8 ng/ml~* Wk 37 to End: 3-6 ng/ml"
62413651|NCT04037683||Staff focus group pre and during MOLI recruitment|"A focus group in each of the 2 recruitment sites before the start of the MOLI trial (n=2) A focus group in each of the 2 recruitment sites and with each cadre of staff during the MOLI trial (n=8)~* Research assistants~* Residents~* Consultants~* Midwives"
62413652|NCT03489239|EXPERIMENTAL|Single Arm|SingleArm: TAF 25 mg
62413653|NCT03724422|NO_INTERVENTION|Control|This group will receive the standard of care treatment for their distal humerus fracture only.
62413654|NCT03724422|EXPERIMENTAL|Intervention|This group will receive the prophylactic radiation therapy in addition to the standard of care treatment of their distal humerus fracture.
62219305|NCT00819390|EXPERIMENTAL|D: Placebo then Chloroquine for On-ART Participants|Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
62795290|NCT00109824|EXPERIMENTAL|Arm II|Patients receive decitabine as in stage 1 and valproic acid PO TID on days 5-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62219306|NCT06532370|EXPERIMENTAL|Contingency Managment|Participants are allowed to complete CM three times per week for the maximum of 12-weeks. At the six- and 12-week time points, participants will complete the Treatment Effectiveness Assessment (TEA) with study personnel.
62023066|NCT00666510||Bronchospasm|Patients who presented bronchospasm during anesthesia induction
62023067|NCT00666510||Asthma|Patients who presented bronchospasm during anesthesia induction and were identified as asthmatics
62023068|NCT00666510||Control|Patients who were submitted to anesthesia induction and showed no complications
62023069|NCT02855060|EXPERIMENTAL|Pelvic Binder|Commercially available device used to stabilize the pelvis
62023070|NCT02855060|NO_INTERVENTION|No Binder|Standard of care
62023071|NCT01687517|EXPERIMENTAL|Patient|90 patients suffering from sarcoidosis
62219307|NCT03258684|ACTIVE_COMPARATOR|vitamin C、hydrocortisone、thiamine|Intravenous vitamin C (1.5 g every 6 h for 4 days or until ICU discharge), hydrocortisone (50 mg every 6 h for 7 days or until ICU discharge followed by a taper over 3 days), as well as intravenous thiamine (200 mg every 12 h for 4 days or until ICU discharge).
62413655|NCT00511329|EXPERIMENTAL|Somatropin|
62219308|NCT03258684|PLACEBO_COMPARATOR|normal saline|Normal saline 500ml every day for 4 days，then 200ml every day for 3 days.
62219309|NCT04324203|EXPERIMENTAL|Experimental group|Three-dimensional Virtual Reality and Horticultural Therapy
62413656|NCT02933216||VR|The CSD patients are received treatment of vaginal repair.
62795291|NCT05865470|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Smoked Cannabis (0 mg THC) Oral placebo (0 mg THC)
62795292|NCT05865470|EXPERIMENTAL|Experimental: Low strength cannabis|Smoked Cannabis (10 mg THC) Oral placebo (0 mg THC)
62795293|NCT05865470|EXPERIMENTAL|Experimental: Higher strength cannabis|Smoked Cannabis (20 mg THC) Oral placebo (0 mg THC)
62795294|NCT05865470|EXPERIMENTAL|Experimental: Low strength oral THC|Smoked Cannabis (0 mg THC) Oral THC (10 mg THC)
62219310|NCT04324203|NO_INTERVENTION|Control group|No intervention
62795295|NCT05865470|EXPERIMENTAL|Experimental: Higher strength oral THC|Smoked Cannabis (0 mg THC) Oral THC (20 mg THC)
62795296|NCT00550407|PLACEBO_COMPARATOR|Placebo|
62795297|NCT00550407|ACTIVE_COMPARATOR|BW430C(lamotrigine)|
62795298|NCT00669708|ACTIVE_COMPARATOR|1|ph5 Eucerin Lotion with cooling compound
62795299|NCT00669708|PLACEBO_COMPARATOR|2|ph5 Eucerin Lotion
62023072|NCT01687517|ACTIVE_COMPARATOR|Volunteer|100 volunteers
62219311|NCT00768079|PLACEBO_COMPARATOR|Placebo|A single dose of placebo matched to benralizumab (MEDI-563) intravenous infusion over at least 30 minutes on Day 0.
62219312|NCT00768079|EXPERIMENTAL|Benralizumab 0.3 mg/kg|A single dose of benralizumab (MEDI-563) 0.3 milligram per kilogram (mg/kg) of body weight intravenous infusion over at least 30 minutes on Day 0.
62219313|NCT00768079|EXPERIMENTAL|Benralizumab 1.0 mg/kg|A single dose of benralizumab (MEDI-563) 1.0 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.
62219314|NCT02461043|EXPERIMENTAL|Arm A|chemotherapy and radiotherapy
62219315|NCT02461043|ACTIVE_COMPARATOR|Arm B|radiotherapy
62413657|NCT02933216||hysteroscope + laparoscope|The CSD patients are received treatment of hysteroscopic combined with laparoscopic excision.
62413658|NCT04678700|EXPERIMENTAL|Experimental groupe|"Intervention; 10 sessions telematics. Before starting and at the end of the respiratory physiotherapy program, the patient complete an online form which includes a quality of life questionnaire, an effort dyspnea questionnaire and an anxiety questionnaire.~The intervention of the following study follow the recommendations of chest physiotherapy in the management of the patient post covid-19 (1)(17).~Pre-session; respiratory frequency, dyspnea, oxigenation level are taken. Breathing techniques;~* Abdominal-diaphragmatic breathing(1)(16). (10 times).~* Costal expansion exercises with flexion and abduction of the upper limbs. (10 times)(1).~* Self-passive stretching of the ribcage and neck muscles, accessory to inspiration(25)(26).~* Jacobson's progressive relaxation(27). Post-session, respiratory frequency and the Borg's dyspnea index/ oxigenation level."
62413659|NCT04678700|OTHER|control groupe|The control group will complete the same questionnaires before and after the intervention, which will give us an idea of whether our intervention has had any improvement. In order for all patients to be able to receive the therapy if they want to. The control group will be on the waiting list to perform the sessions.
62413660|NCT02919033|PLACEBO_COMPARATOR|Usual care (UC)|Patients are managed by their PCPs at the registered CHCs as usual.
62219316|NCT01809496|ACTIVE_COMPARATOR|Informational counseling, patient only|The purpose of this experimental group is to evaluate the effectiveness of informational counseling alone. This type of counseling is considered the standard of care in audiologic practice. Patients in this will review this material in detail with a member of the study team for approximately 30 minutes at the second visit. Spouses in this experimental group will be will review material regarding VA services with a member of the study team for about 30 minutes.
62413661|NCT02919033|EXPERIMENTAL|Self-management|"* BP tele-monitor \& App based self-management supports~* Patient proficiency training"
62795300|NCT00946790|EXPERIMENTAL|1|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)
62413662|NCT02919033|EXPERIMENTAL|PCTM intervention|"* BP tele-monitor \& App-based self-management supports~* Patient proficiency training~* PCP \& cardiologist training of using Web-based analytics~* Proactive and interactive care by PCPs and cardiologists"
62413663|NCT00633295|EXPERIMENTAL|nilotinib|
62413664|NCT06701747||High-dose group|Receive RBCs transfusion over 1600mL
62413665|NCT06701747||No-high-dose group|Receive RBCs transfusion under 1600mL
62413666|NCT04642131|EXPERIMENTAL|Personalized insoles|Personalized insoles without supplementation
62413667|NCT04642131|EXPERIMENTAL|Caffeine supplementation|Standard insoles with caffeine supplementation (3mg/kg)
62413668|NCT04642131|PLACEBO_COMPARATOR|Control condition|Standard insoles without supplementation
62586750|NCT05584540|EXPERIMENTAL|UNTIRE App|"At baseline meeting participants will answer questionnaires and be introduced and instructed on self-managed use of Untire app treatment program.~Participants will then have check in meetings assessing app usage and progress on weeks 4, 8 and 12 post baseline, then a final check-in 6 months post baseline."
62795301|NCT00946790|ACTIVE_COMPARATOR|2|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)
62795302|NCT06630117|EXPERIMENTAL|Dose Escalation Panel A|Participants 18 to 49 years old will be randomized to receive low dose of V330 or placebo via intramuscular injection on Day 1 and Day 57.
62795303|NCT06630117|EXPERIMENTAL|Dose Escalation Panel B|Participants 18 to 49 years old will be randomized to receive medium dose of V330 or placebo via intramuscular injection on Day 1 and Day 57.
62795304|NCT06630117|EXPERIMENTAL|Dose Escalation Panel C|Participants 18 to 49 years old will be randomized to receive high dose of V330 or placebo via intramuscular injection on Day 1 and Day 57.
62795305|NCT06630117|EXPERIMENTAL|Dose Expansion Panel D|Participants 18 to 49 years old will be randomized to receive a dose less than or equal to high dose V330 or placebo via intramuscular injection on Day 1.
62023073|NCT05903274|EXPERIMENTAL|JSP191|This study will explore up to 5 ascending dose levels (Cohorts 1, 2, 3, 4, and 5) and subjects will receive JSP191 on Day 1 on each 8-week cycle for 4 consecutive cycles.
62023074|NCT06298006||PASC24 study participants|100 patients with residual cognitive and psychiatric symptoms after COVID-19 infection who undergo follow-up.
62023075|NCT01584063|NO_INTERVENTION|Control|These women received general information about pregnancy and the postpartum period and tips for stress management. This information was delivered during 3 group meetings during pregnancy and 1 group meeting postpartum by trained staff from a local community mental health agency.
62023076|NCT01584063|EXPERIMENTAL|MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
62795306|NCT06630117|EXPERIMENTAL|Dose Expansion Panel E|Participants 18 to 49 years old will be randomized to receive a dose less than or equal to high dose V330 or placebo via intramuscular injection on Day 1.
62795307|NCT06630117|EXPERIMENTAL|Dose Escalation Panel F|Participants 60 to 79 years old will be randomized to receive low dose of V330 or placebo via intramuscular injection on Day 1.
62023077|NCT05548790|EXPERIMENTAL|Group 1|Group 1: patients were given information via silent video with subtitle (5-minute)
62023078|NCT05548790|EXPERIMENTAL|Group 2|Group 2: patients were given information via video with background audio (5-minute 34-second)
62023079|NCT05548790|EXPERIMENTAL|Group 3|Group 3: patients were given written information brochure
62023080|NCT05548790|EXPERIMENTAL|Group 4|Group 4: patients were given information verbally
62023081|NCT00207441|EXPERIMENTAL|Arthritis self management program|
62023082|NCT00207441|EXPERIMENTAL|Chronic Disease Self Management Program|
62219317|NCT01809496|EXPERIMENTAL|Informational Counseling, couples|The purpose of this experimental group is to evaluate the influence of spousal involvement when receiving informational counseling. In this manner, both patients and spouses are presented with the same information regarding hearing loss and hearing aids. Couples in this experimental group will be given the same information that the patients in the first group were given. At the second visit, couples in this group will review this information together with a member of the research team for approximately 30 minutes.
62413669|NCT03387267|OTHER|single-arm Dysphagia Detection System|An operationally seamless single-arm, prospective, multicenter, single-blinded for central outcomes assessors trial to test DDS in assessing swallowing safety and efficiency in patients at risk of oropharyngeal dysphagia.
62433319|NCT05509634|ACTIVE_COMPARATOR|Treatment group B|simulant of HR20013 for injection + fosaprepitant dimeglumine for injection + palonosetron hydrochloride injection + dexamethasone + simulant of dexamethasone
62433320|NCT00245622|EXPERIMENTAL|Tovaxin Autologous T cell vaccine|2.0 mL subcutaneous formulated with 30-45 million autologous myelin reactive T cells
62023083|NCT05858528||Observational|No intervention in this study
62023084|NCT01850160|EXPERIMENTAL|GROUP A: Valsartan plus Chlorthalidone|GROUP A: Combination therapy of Valsartan plus Chlorthalidone. Valsartan 80 mg/Chlorthalidone 12,5 mg. Once daily during 12 weeks.
62795308|NCT06630117|EXPERIMENTAL|Dose Escalation Panel G|Participants 60 to 79 years old will be randomized to receive medium dose of V330 or placebo via intramuscular injection on Day 1.
62795309|NCT06630117|EXPERIMENTAL|Dose Escalation Panel H|Participants 60 to 79 years old will be randomized to receive high dose of V330 or placebo via intramuscular injection on Day 1.
62413670|NCT05722275||Peking University Cancer Hospital & Institute|Peking University Cancer Hospital \& Institute collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
62413671|NCT05722275||Zhenjiang First People's Hospital|Zhenjiang First People's Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
62023085|NCT01850160|EXPERIMENTAL|GROUP B: Valsartan|GROUP B: Treatment with Monotherapy. Valsartan 80 mg. Once daily during 12 weeks.
62433321|NCT00245622|PLACEBO_COMPARATOR|Placebo|2.0 mL subcutaneous injections without autologous myelin reactive T cells
62433322|NCT01745471||PCOS group|12 women with Polycystic Ovary Syndrome (PCOS) as defined by NIH criteria
62433323|NCT01745471||Pear shapes|12 with an android pattern as defined by a waist-to-hip greater than 0.85
62795310|NCT06630117|EXPERIMENTAL|Dose Expansion Panel I|Participants 60 to 79 years old will be randomized to receive a dose less than or equal to high dose V330 or placebo via intramuscular injection on Day 1.
62795311|NCT06630117|EXPERIMENTAL|Dose Expansion Panel J|Participants 60 to 79 years old will be randomized to receive a dose less than or equal to high dose V330 or placebo via intramuscular injection on Day 1.
62795312|NCT01844336|EXPERIMENTAL|PBASE system 1.1 + CT100 (active treatment)|
62795313|NCT01844336|PLACEBO_COMPARATOR|PBASE system 1.1 + CT100 (placebo treatment)|
62795314|NCT05708495|ACTIVE_COMPARATOR|Group 1|
62795315|NCT05708495|EXPERIMENTAL|Group 2|
62795316|NCT02171442|EXPERIMENTAL|BIBR 953 ZW Intravenously|
62795317|NCT02171442|ACTIVE_COMPARATOR|BIBR 1048 Oral Solution|
62795318|NCT03415945|EXPERIMENTAL|CRT implantation|In cardiac resynchronization therapy (CRT), biventricular pacing is performed by pacing the right ventricle (RV) and epicardium of the left ventricular (LV) posterolateral wall.
62795319|NCT06706219|EXPERIMENTAL|Sacituzumab tirumotecan (SKB264) in combination with pembrolizumab|
62023086|NCT01850160|EXPERIMENTAL|GROUP C: Chlorthalidone|GROUP C: Treatment with Monotherapy. Chlorthalidone 12,5 mg. Once daily during 12 weeks.
62586751|NCT03636204|EXPERIMENTAL|AL001|Up to six single ascending doses of AL001
62586752|NCT03636204|PLACEBO_COMPARATOR|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects
62023087|NCT01346891||Hyponatremia Group (Cases)|Patients over 21 years old, with confirmed antecedent of thiazide-induced hyponatremia who required hospitalization with a serum sodium concentration lower than 125 meq/L.
62795320|NCT03206801|EXPERIMENTAL|Intervention|Participants with high urine CXCL10 randomized to the Intervention Arm will undergo a kidney transplant biopsy to check for rejection. Biopsy-proven subclinical rejection will be treated per study protocol.
62795321|NCT03206801|NO_INTERVENTION|Control|Participants with high urine CXCL10 randomized to the Control Arm will continue routine post-transplant surveillance with serum creatinine and proteinuria; serial urine samples will continue to be collected and analyzed (blinded), but not used to direct care.
62023088|NCT01346891||Good Thiazide Tolerance (Controls)|Patients over 21 years old, who have consumed thiazide diuretics for more than 2 years, with a serum sodium concentration persistently over 135 meq/L.
62023089|NCT00499187||Fanconi Cases|This cohort enrolled participants with evidence of protocol-defined Fanconi syndrome (confirmed creatinine clearance decline and evidence of proximal tubulopathy).
62023090|NCT00499187||Control Cases|This cohort enrolled participants with no evidence of protocol-defined Fanconi syndrome.
62023091|NCT02298218|EXPERIMENTAL|Meloxicam|The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
62023092|NCT02298218|NO_INTERVENTION|No intervention|During 6 months, without meloxicam, the maintenance will be decided by the comparison of liver stiffness score comparing the intervention group.
62023093|NCT01855009|ACTIVE_COMPARATOR|MannaBears|Subjects will take 4 MannaBears daily
62023094|NCT01855009|ACTIVE_COMPARATOR|MannaBears, AlgaeCal Calcium, Vitamin D3|Subjects will take 4 MannaBears daily and 3 Calcium/Vit D capsules (2 with breakfast and 1 with dinner or vice-versa) daily
62023095|NCT01855009|ACTIVE_COMPARATOR|MannaBears, Calcium Carbonate, Vitamin D3|Subjects will take 4 MannaBears daily and 3 Calcium/Vit D capsules (2 with breakfast and 1 with dinner or vice-versa) daily
62023096|NCT04108312||Autism Spectrum Disorders|
62586753|NCT05311839|EXPERIMENTAL|Thera band exercises group|received graded Thera band exercises for 5 days per week for eight weeks in addition to the conventional physical therapy program.
62586754|NCT05311839|EXPERIMENTAL|conventional physiotherapy program group|received a conventional physical therapy program.
62795322|NCT03354273|EXPERIMENTAL|1|Flurpiridaz PET MPI (following off-study SPECT MPI)
62795323|NCT01933490|OTHER|a high carbohydrate test meal (control condition)|a high carbohydrate test meal (control condition)
62795324|NCT01933490|ACTIVE_COMPARATOR|high carbohydrate test meal after pre-treatment|a high carbohydrate test meal after pre-treatment with rapid acting aspart insulin (insulin condition)
62795325|NCT01933490|ACTIVE_COMPARATOR|high fructose low glucose test meal|high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal (fructose condition)
62795326|NCT02791230|EXPERIMENTAL|Tafamidis|Active treatment - 61 mg or if not available, tafamidis megulmine 80 mg
62795327|NCT06508463|EXPERIMENTAL|Group E (VSV-IFNβ-NIS, ipilimumab, cemiplimab) - Peripheral T-cell lymphoma (PTCL) only|PTCL patients receive VSV-IFNβ-NIS IV over 30 minutes on day 1, ipilimumab IV over 30 minutes on day -3 and cemiplimab IV over 30 minutes on day -3 in the absence of disease progression or unacceptable toxicity. Patients undergo SPECT, CT scan, PET scan throughout the study. Patients may undergo tumor biopsy, bone marrow biopsy and blood sample collection throughout the study.
62413672|NCT05722275||The First Affiliated Hospital of Zhengzhou University|The First Affiliated Hospital of Zhengzhou University collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
62413673|NCT05722275||Nanfang Hospital of Southern Medical University|Nanfang Hospital of Southern Medical University collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
62413674|NCT05722275||Guizhou Provincial People's Hospital|Guizhou Provincial People's Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
62023097|NCT04108312||Typical Control|
62023098|NCT03562715||Control group|Blood samples were collected from 100 control with normal pregnancies. Thirty fresh umbilical cord samples of women with healthy pregnancies (n=15) were retrieved during caesarean deliveries and umibilical cord mesenchymal stem cells (UCMSCs) were isolated from Wharton jelly.
62023099|NCT03562715||Preeclampsia group|Blood samples were collected from 100 patients with PE. Thirty fresh umbilical cord samples of PE patients (n=15) were retrieved during caesarean deliveries and UCMSCs were isolated from Wharton jelly.
62023100|NCT01899924|EXPERIMENTAL|Event Related Potentials|
62023101|NCT01019655|EXPERIMENTAL|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
62023102|NCT01019655|NO_INTERVENTION|Control|No intervention other than usual care at the study site
62413675|NCT05722275||Henan Cancer Hospital|Henan Cancer Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
62795328|NCT06508463|EXPERIMENTAL|Group E (VSV-IFNβ-NIS, ipilimumab, cemiplimab) - PTCL Expansion Cohort|PTCL patients receive VSV-IFNβ-NIS IV over 30 minutes on day 1, ipilimumab IV over 30 minutes on day -3 and cemiplimab IV over 30 minutes on day -3 in the absence of disease progression or unacceptable toxicity. Patients undergo SPECT, CT scan, PET scan throughout the study. Patients may undergo tumor biopsy, bone marrow biopsy and blood sample collection throughout the study.
62795329|NCT05865522|EXPERIMENTAL|Trapezius Massage Group|"The patients inTrapezius Group will be given classical massage to the trapezius muscle for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.~Patients in trapezius groups will be questioned about their pain with VAS once a week throughout the study. Pain follow-up of the patients in trapezius massage will be performed 48 hours after the massage."
62413676|NCT05722275||Yunnan Cancer Hospital|Yunnan Cancer Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
62586755|NCT06683716|ACTIVE_COMPARATOR|Training in presence|The instructor teaches the trainee in physical presence during the ERCP
62795330|NCT05865522|EXPERIMENTAL|Foot Massage Group|"The patients in Foot Group will be given foot massage for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.~Patients in foot groups will be questioned about their pain with VAS once a week throughout the study. Pain follow-up of the patients in Foot Massage Group will be performed 48 hours after the massage."
62023103|NCT04425226|EXPERIMENTAL|Pembrolizumab plus Lenvatinib|Participants receive intravenous (IV) pembrolizumab at 200 mg on Day 1 of each 21-day cycle. Number of cycles: until \>42 days before liver transplantation or unacceptable toxicity develops. Patients receive Lenvatinib 8-12mg(basing on weight), once a day, oral at least 38 days of each 6 weeks cycle until \>7 days before liver transplantation.
62023104|NCT04425226|NO_INTERVENTION|Comparator|Participants are advised to stay as healthy as possible and wait regularly
62413677|NCT05722275||Guangdong Provincial People's Hospital|Guangdong Provincial People's Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
62413678|NCT05722275||Guangzhou Medical University|Affiliated Cancer Hospital and Institute of Guangzhou Medical University collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
62795331|NCT05865522|NO_INTERVENTION|Control Group|Patients in Control Group will not receive massage. Patients in control groups will be questioned about their pain with VAS once a week throughout the study.
62023105|NCT05794867||Patients were randomly allocated in one of two groups each group contain 100 patients.|Group A considered control group. Those patients weaned from the ventilator by the conventional criteria of weaning
62023106|NCT05794867||100 patients|group B weaned from the ventilator by the ultrasound criteria of weaning. All patients weaned from both groups followed for six days for signs of failure of weaning ,signs of post-extubation respiratory failure. And number of patients who were re-ventilated and who discharged from ICU in both groups recorded and compared.
62219318|NCT01809496|EXPERIMENTAL|Patient Centered Counseling,patient only|In order to assess the effects of enhanced patient-centered counseling (PCC), the patients assigned to this group will meet together with either Dr. Lewis or the Research Audiologist for approximately 30 minutes of counseling. In addition to the PCC techniques used in audiology, this counseling also will involve the core components of motivational interviewing. These principles and methods will be used to allow the patient to clearly express his/her expectations of, concerns about, and motivations for hearing-aid use. The spouses in this experimental group will be given information regarding VA services. This material will be reviewed with a member of the research team for about 30 minutes at the second visit.
62795332|NCT01908452|EXPERIMENTAL|vitamin B6 (pyridoxine)|The 150 participating subjects will be randomized into 2 groups: 75 patients will receive vitamin B6 (1200 mg/day) and 75 patients will receive placebo, each for 12 weeks in a double-blind mode
62795333|NCT01908452|PLACEBO_COMPARATOR|placebo|The 150 participating subjects will be randomized into 2 groups: 75 patients will receive vitamin B6 (1200 mg/day) and 75 patients will receive placebo, each for 12 weeks in a double-blind mode
62795334|NCT00096434|EXPERIMENTAL|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62219319|NCT01809496|EXPERIMENTAL|Patient Centered Counseling, couples|In order to assess the influence of the spouse on the enhanced PCC process, the couples assigned to this group will meet together with either Dr. Lewis or the Research Audiologist for approximately 30 minutes of counseling. This counseling will be conducted with both the patient and the spouse together, giving both partners time to express their thoughts.
62795335|NCT00988988|ACTIVE_COMPARATOR|Steroid Cream|1% steroid cream
62795336|NCT00988988|ACTIVE_COMPARATOR|AGEE cream|AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled
62795337|NCT00988988|ACTIVE_COMPARATOR|placebo|inactive cream
62023107|NCT04413604|EXPERIMENTAL|YCM Group (1- <3) Years old|2 servings / day of the investigational (test) young children's milk (YCM) for 16 weeks
62413679|NCT05722275||Fujian Medical University Union Hospital|Fujian Medical University Union Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
62586756|NCT06683716|EXPERIMENTAL|Telemedical training|The instructor teaches the trainee telemedically by using smartglasses during the ERCP
62586757|NCT03365635|EXPERIMENTAL|Genotype 1a -Rx naive -no NS5A polymorph|Genotype 1a - treatment naive without NS5A polymorphism - Drug Intervention : Oral administration Elbasvir (50mg)/Grazoprevir (100mg) one tablet per day for 12 weeks
62795338|NCT05286502||Adults 18 years old or older|
62795339|NCT04094857|EXPERIMENTAL|HBN-1 Plus Standard of Care|Subjects will receive an intravenous loading dose of HBN-1 followed by a 12 hour maintenance infusion plus standard of care targeted temperature management
62795340|NCT04094857|NO_INTERVENTION|Standard of Care|Subjects will receive standard of care targeted temperature management only
62413680|NCT05722275||Shanxi Province Cancer Hospital|Shanxi Province Cancer Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
62413681|NCT05722275||Sun Yat-sen University|Sun Yat-sen University collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
62413682|NCT05722275||Scientific Institute San Raffaele|Scientific Institute San Raffaele collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
62413683|NCT06644729||Cohort 10 years after surgery|Cohort of 733 participants will be invited to a 10 year follow up and will be evaluated with patient reported outcome measurements and x-ray.
62413684|NCT00915980||Patients without diabetes undergoing gastric bypass|
62413685|NCT05286580|EXPERIMENTAL|Intervention|o Sequential deployment of standardized M\&M toolkit at a regional M\&M conference.
62413686|NCT06260007|EXPERIMENTAL|Tribulus terrestris 94mg|
62413687|NCT06260007|EXPERIMENTAL|Tribulus terrestris 280mg|
62413688|NCT06260007|EXPERIMENTAL|Tribulus terrestris 250mg|
62413689|NCT06260007|PLACEBO_COMPARATOR|Placebo|
62413690|NCT06130839|EXPERIMENTAL|perturbation based training|"1. Stretching of the erector spinae,~2. latissimus dorsi, gluteus Medius, gluteus minimums, and gluteus maximus (knee to chest) Pelvic Bridging Exercises~3. Strengthening Exercises of latissimus dorsi muscle~4. Pelvic Bridging Exercises include the gluteus maximus and quadriceps~5. Rocker board:~Trunk control exercises on Rocker Board in standing position first in medio-lateral direction for 10 min and then in anterio-posterior direction for 10 min with breaks in between."
62413691|NCT06130839|EXPERIMENTAL|bobath based training|"1. Stretching of the latissimus dorsi muscle~2. Functional use and strengthening of the latissimus dorsi.~3. Functional strengthening of abdominal and oblique abdominal muscles~4. Placing exercises to facilitate trunk extension~5. Rotations and counter-rotations (right and left) of the hips with the trunk extended Training of lumbar spine stabilizers~Functional reach of shoulder, anterior, right, and left sides."
62413692|NCT05336318|EXPERIMENTAL|Intervention group|
62413693|NCT05336318|NO_INTERVENTION|Control group|
62413694|NCT03763708|EXPERIMENTAL|Spinal Cord Stimulation|Each subject will be programmed to different settings.
62413695|NCT05025774||Case|Adolescent or young adult acute lymphoblastic leukemia survivor, OR living with chronic lung disease of prematurity, OR living with heart transplant
62413696|NCT05025774||Control|14-25 years old healthy individuals who are ambulatory without assistance. We may enroll younger subjects but we wish to subjects to match our patient population
62433324|NCT01745471||Apple shapes|12 will have a gynoid pattern as defined by a waist-to-hip ratio less than 0.78
62433325|NCT03558997|EXPERIMENTAL|Placebo|Participants received placebo matched to Dupilumab and placebo matched to Timothy grass subcutaneous immunotherapy (SCIT) every 2 weeks (Q2W) for 16 weeks. Both placebo doses were administered with a gap of 1 or 7 days.
62586758|NCT03365635|EXPERIMENTAL|Genotype 1a, Rx naive + NS5A polymorph|Genotype 1a - treatment naiive with NS5A polymorphism - Oral administration of Elbasvir/Grazoprevir one tablet daily and ribavirin (200 mg) daily for 16 weeks weeks
62586759|NCT03365635|EXPERIMENTAL|Genotype 1b - Rx naive|Genotype 1b-treatment naive - Oral administration of Elbasvir/Grazoprevir one daily for 12 weeks
62586760|NCT03365635|EXPERIMENTAL|Genotype 1a/1b -prior INF or NS3/4A|Genotype 1a or 1b - prior treatment with INF or HCV NS3/4A protease inhibitor - oral administration of Elbasvir/Grazoprevir and ribavirin each once daily for 12 weeks
62795341|NCT04331717|EXPERIMENTAL|Diet and exercise with BAE|After enrollment in the clinical trial, all men will be enrolled in diet and exercise counseling through the weight management program for a total of 4 weeks. If participants lose \>5 pounds of total body weight from weight management alone in the first 4 weeks, these participants will be excluded from study and will not undergo BAE but will be encouraged to continue with weight management. Those still enrolled will undergo BAE. Within 7 days of BAE, men will be given ADT (lupron subcutaneous injection).
62795342|NCT04513912|EXPERIMENTAL|Seltorexant|Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182.
62219320|NCT02782546|EXPERIMENTAL|Recipient|"* Standard of care reduced conditioning regimen on Day -1~* Graft cell infusion on Day 0~* Post-transplant cyclophosphamide on Days +3 and +4~* GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD~* G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines~* The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes.~* ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses"
62219321|NCT02782546|EXPERIMENTAL|Donor|"* Donors will receive subcutaneous G-CSF from Day -4 till Day 0 and undergo 20L apheresis per institutional guidelines.~* Two consecutive days for collection are allowed in case of the target CD34+ cell dose being less than the target 4 x106/kg-bw from the first day of collection.~* On Day +6 (one day before the planned CIML NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard 20-L apheresis over 4-5 hours from the same haploidentical related donor that provided the HCT graft."
62586761|NCT03365635|EXPERIMENTAL|Genotype4 - treatment naive|(e) Genotype 4 - treatment naive - oral administration of Elbasvir/Grazoprevir one daily for 12 weeks
62586762|NCT03365635|EXPERIMENTAL|Genotype 4- prior treatment|Genotype 4 -prior treatment - oral administration of Elbasvir/Grazoprevir and ribavirin each once per day for 16 weeks
62586763|NCT06585254|EXPERIMENTAL|#1: Patient controlled|Patient will ramp up current intensity until uncomfortable, then ratchet back to what is comfortable and press button. Patient is to do this daily for 35 minutes for 6 weeks.
62586764|NCT06585254|EXPERIMENTAL|#2: Device Controlled|Patients will ramp up current intensity until uncomfortable, then ratchet back to what is comfortable and press button. The device has software embedded in it that is used to arrive at a personalized way of stimulating the vagus nerve. At this level, the device stimulus will not be sensed by the patient. Patient is to do this daily for 35 minutes for 6 weeks.
62586765|NCT03200730|EXPERIMENTAL|Family Dignity Intervention group|"A standard framework of 12 FDI questions is given to patient-family dyads in the intervention group during baseline to provides them with the opportunity to think about their responses. During the intervention interview scheduled 2-3 days later, the FDI therapist follows that dyad's cues, help them to organize their thoughts, facilitate disclosure of cherished memories, and encourage the expression of appreciation. The interview is be recorded, quickly transcribed verbatim then edited into a coherent narrative. A second review session is arranged to review and finalize the edited transcript with the dyads. Once the legacy documents are ready, a final family sharing session is arranged for the dyads to share and read this document to each other and their loved ones."
62586766|NCT03200730|NO_INTERVENTION|Control group|Patient-family dyads in the control group have at least four interviews with a designated member of the research team via psychosocial home visits. Completing the assessments and taking part in the interviews provides them with the opportunity to share their feelings and emotions along their illness trajectory. The extent to which they feel sharing is therapeutic is explored in the interview.
62219322|NCT04858087||All students|All participating students were screened for Pf infection using malaria rapid diagnostic tests (mRDTs) and treated if positive. All were followed 1, 2, and 6 weeks after screening-and-treatment.
62586767|NCT03126162|EXPERIMENTAL|Bladder Backfilled group|Subjects randomized to the bladder backfilled group (Group A) will have 200 mL of normal saline instilled into their bladders prior to removal of the foley catheter. The foley catheter will subsequently be removed
62586768|NCT03126162|PLACEBO_COMPARATOR|Control group|Subjects randomized to the control group (Group B) will just have their foley catheters removed at the end of the surgery. This is routinely done post-operatively after routine gynecologic surgery.
62023108|NCT04413604|NO_INTERVENTION|Observation Group (1-<3) Years old|Habitual diet, consume the same regular foods and drinks as the children would normally
62023109|NCT06024304|ACTIVE_COMPARATOR|Trigen InterTan|Patients in this arm will be implanted with the cephalomedullary nail Trigen InterTan manufactured by Smith \& Nephew.
62219323|NCT04688502|EXPERIMENTAL|high intensity interval training wearing a face mask|high intensity interval training wearing a face mask
62413697|NCT02463058|EXPERIMENTAL|Research arm|"10 young and healthy civilian volunteers will participate in this study. The subjects will undergo 5 experiment days:~1. Recruitment , medical examination and VO2max test.~2. Acclimatization day by performing moderate exercise protocol under hot and humid climate.~3. 3 days of performing moderate exercise under hot and humid conditions protocol, each day dressed with different protective garment:~   1. Protective garment in current use + NBC mask.~  2. The new BC protective undergarment + standard combat uniforms~  3. The new BC protective undergarment + standard combat uniforms + NBC mask"
62413698|NCT01806259|EXPERIMENTAL|ketorolac 30 mg|Active drug to be compared with placebo
62413699|NCT01806259|PLACEBO_COMPARATOR|NaCl 0.9% 3mL|Placebo looking like the Active drug
62413700|NCT06128278|EXPERIMENTAL|(1) S-equol, (2) Placebo|This is a randomized, placebo-controlled, crossover study. Participants in one arm will receive S-equol (one visit) and then placebo (the other visit).
62413701|NCT06128278|EXPERIMENTAL|(1) Placebo, (2) S-equol|This is a randomized, placebo-controlled, crossover study. Participants in one arm will receive placebo (one visit) and then S-equl (the other visit).
62795343|NCT04513912|ACTIVE_COMPARATOR|Quetiapine Extended-Release (XR)|Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability.
62219324|NCT04688502|ACTIVE_COMPARATOR|high intensity interval training wearing no face mask|high intensity interval training wearing no face mask
62023110|NCT06024304|ACTIVE_COMPARATOR|Synthes TFNA|Patients in this arm will be implanted with the single-screw device TFNA manufactured by DePuy Synthes.
62219325|NCT04688502|EXPERIMENTAL|continuous exercise training wearing a face mask|continuous exercise training wearing a face mask
62219326|NCT04688502|ACTIVE_COMPARATOR|continuous exercise training wearing no face mask|continuous exercise training wearing no face mask
62219327|NCT03404687||Patients with adnexal masses|
62413702|NCT06395584|ACTIVE_COMPARATOR|Light therapy group|Participants will be asked to use two different colours of light for 1-2 hours/day in a dark room in their home for 20 weeks. They will first use a white light for 10 weeks, followed by a green light for 10 weeks. They will be asked to complete daily pain diaries and a series of 3 MRI brain scans.
62413703|NCT06395584|NO_INTERVENTION|No light therapy group|Participants will not receive light intervention but will be asked to complete daily pain diaries and a series of 3 MRI brain scans.
62413704|NCT06317870|EXPERIMENTAL|PENG group|Pericapsular nerve group block
62023111|NCT06189040|ACTIVE_COMPARATOR|BNT162b2 regular schedule|day 0: intramuscular administration of BNT162b2 (30µg) day 28: intramuscular administration of BNT162b2 (30µg)
62219328|NCT02374671|EXPERIMENTAL|Implantation-Non-Randomized|Subjects are not participants in the randomized sub-study. VisAbility micro inserts surgically implanted in the eye(s) after enrollment and meeting inclusion/exclusion criteria.
62219329|NCT02374671|EXPERIMENTAL|Implantation-Randomized|Subjects are participants in the randomized sub-study. Subjects were randomized to the Immediate Treatment group. VisAbility micro inserts surgically implanted in the eyes. Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria.
62219330|NCT02374671|NO_INTERVENTION|Deferred Implantation-Randomized|Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria. Subjects were randomized to the Deferred Treatment group are observed for 6 months. Upon completion of the observation follow-up, subjects can opt to have VisAbility micro inserts surgically implanted in the eye(s) and become part of the overall study experimental group.
62413705|NCT06317870|ACTIVE_COMPARATOR|ITM group|intrathecal morphine injection
62413706|NCT01438346|ACTIVE_COMPARATOR|Substance Abuse Education (SED)|The Substance Abuse Education (SED) group will serve as the control intervention in which participants will receive instruction on a variety of topics included in the substance abuse treatment program curriculum. These will include, but are not limited to, information about anger management, smoking cessation, women's issues, and stress management, and approaches to help reduce cravings. Each week the TAU group will meet and a House of Hope (HOH) clinical staff member will discuss the above and related issues and how these may help individuals deal with their substance abuse and related psychological issues.
62433326|NCT03558997|EXPERIMENTAL|Dupilumab|Participants received placebo matched to SCIT and subcutaneous (SC) injections of Dupilumab at a loading dose of 600 milligrams (mg) on Day 1, followed by a 300 mg for Q2W for 16 weeks. Both placebo matched to SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.
62023112|NCT06189040|EXPERIMENTAL|BNT162b2 + mRNA-1273 schedule|day 0: intramuscular administration of BNT162b2 (30µg) day 28: intramuscular administration of mRNA-1273 (100µg)
62023113|NCT06189040|EXPERIMENTAL|BNT162b2 + ChAdOx1-S schedule|day 0: intramuscular administration of BNT162b2 (30µg) day 28: intramuscular administration of ChAdOx1-S \[recombinant\] (not less than 2.5x10\^8 infectious units)
62219331|NCT00267904|EXPERIMENTAL|Healthy Volunteer for Banana|Ingestion of a single banana
62023114|NCT06189040|EXPERIMENTAL|BNT162b2 low dose schedule|day 0: intramuscular administration of BNT162b2 (20µg) day 28: intramuscular administration of BNT162b2 (20µg)
62023115|NCT06189040|EXPERIMENTAL|BNT162b2 long-interval schedule|day 0: intramuscular administration of BNT162b2 (30µg) day 84: intramuscular administration of BNT162b2 (30µg)
62023116|NCT06189040|EXPERIMENTAL|BNT162b2 intradermal schedule|day 0: intradermal administration of BNT162b2 (6µg) day 28: intradermal administration of BNT162b2 (6µg)
62219332|NCT00267904|EXPERIMENTAL|Healthy Volunteer for Coffee|Ingestion of caffeinated coffee on one day and decaffeinated coffee on another day
62413707|NCT01438346|EXPERIMENTAL|Mind-body Bridging (MBB)|Participants in the experimental Mind-Body Bridging (MBB) group, in addition to their usual treatment for substance abuse, will additionally receive instruction on the basics of MBB, and will learn MBB techniques to help deal with their cravings and comorbid psychological conditions. A workbook will be incorporated into the curriculum to provide MBB participants with daily exercises and activities to help facilitate adherence to the MBB program.
62413708|NCT02780115|EXPERIMENTAL|Cohort 1: Vehicle Control|Vehicle dosed in both eyes administered once daily during office visits 1 through 5.
62413709|NCT02780115|EXPERIMENTAL|Cohort 2: AGN-199201 Dose A and AGN-190584 Dose A|Fixed combinations of AGN-199201 Dose A and AGN-190584 Dose A dosed in both eyes administered once daily during office visits 1 through 5.
62413710|NCT02780115|EXPERIMENTAL|Cohort 3: AGN-199201 Dose B and AGN-190584 Dose B|Fixed combinations of AGN-199201 Dose B and AGN-190584 Dose B dosed in both eyes administered once daily during office visits 1 through 5.
62413711|NCT02780115|EXPERIMENTAL|Cohort 4: AGN-199201 Dose C and AGN-190584 Dose C|Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in both eyes administered once daily during office visits 1 through 5.
62413712|NCT02780115|EXPERIMENTAL|Cohort 5: Vehicle, AGN-199201 Dose C and AGN-190584 Dose C|Dominant eye dosed with Vehicle. Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in nondominant eye. Treatment administered once daily during office visits 1 through 5.
62413713|NCT05784363|EXPERIMENTAL|NT 201|Single NT 201 injection treatment.
62413714|NCT05784363|PLACEBO_COMPARATOR|Placebo|Single placebo injection treatment.
62413715|NCT03359473|EXPERIMENTAL|Male subjects receiving GSK2881078-Cohort 1|Male subjects between the age of 50 and 75 years will be administered GSK2881078 at a dose of 2 mg once daily by the oral route.
62413716|NCT03359473|PLACEBO_COMPARATOR|Male subjects receiving Placebo-Cohort 1|Male subjects between the age of 50 and 75 years will be administered GSK2881078 matching placebo once daily by the oral route.
62413717|NCT03359473|EXPERIMENTAL|Female subjects receiving GSK2881078-Cohort 2|Post-menopausal female subjects between the age of 50 and 75 years will be administered GSK2881078 at a dose of 1 mg once daily by the oral route.
62023117|NCT06189040|ACTIVE_COMPARATOR|mRNA-1273 regular schedule|day 0: intramuscular administration of mRNA-1273 (100µg) day 28: intramuscular administration of mRNA-1273 (100µg)
62413718|NCT03359473|PLACEBO_COMPARATOR|Female subjects receiving Placebo-Cohort 2|Post-menopausal female subjects between the age of 50 and 75 years will be administered GSK2881078 matching placebo once daily by the oral route.
62023118|NCT06189040|EXPERIMENTAL|mRNA-1273 low dose schedule|day 0: intramuscular administration of mRNA-1273 (50µg) day 28: intramuscular administration of mRNA-1273 (50µg)
62413719|NCT01502800|EXPERIMENTAL|Part 1 (ARQ 761)|"ARQ 761 (beta lapachone) will be given once a week. The same dose of ARQ761 each week for 4 weeks (1 cycle = 28 days). The total infusion time will be one (1) hour.~Beginning dose level will be 195 mg/m2 and will increase until the maximum tolerated dose is defined. Seven dose levels that may be administered:~1-195 mg/m2 2-390 mg/m2 3-450 mg/m2 4-550 mg/m2 5-660 mg/m2 6-800 mg/m2 7-1000 mg/m2"
62413720|NCT01502800|EXPERIMENTAL|Part 2 Arm A|"The same dose of ARQ761 will be given each week for 8 weeks. The total infusion time will be 2 or 3 hours.~Beginning dose level will be 390 mg/m2."
62413721|NCT01502800|EXPERIMENTAL|Part 2 Arm B|"ARQ 761 (beta lapachone) will be given bi-weekly for 8 weeks. The total infusion time may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
62413722|NCT01502800|EXPERIMENTAL|Part 2 Arm C|"ARQ 761 (beta lapachone) will be given 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
62413723|NCT03334942|EXPERIMENTAL|CFTSI|Youth and caregivers randomized to the Violence Intervention Program (VIP) and Child and Family Traumatic Stress Intervention (CFTSI) arm will receive 5 to 8 CFTSI sessions with a trained clinician and be enrolled in VIP. VIP is the standard clinical service offered to assault injured patients treated in the CHOP ED. Participants in this arm will also complete follow-up assessments approximately 4 and 10 months following the ED visit.
62413724|NCT03334942|NO_INTERVENTION|Violence Intervention Program|Youth and caregivers randomized to the VIP-only condition will complete a baseline assessment prior to randomization and then be enrolled in the Violence Intervention Program (VIP). VIP is the standard clinical service offered to assault injured patients treated in the CHOP ED. Participants in this arm will also complete follow-up assessments approximately 4 and 10 months following the ED visit.
62795344|NCT04970654|EXPERIMENTAL|Somapacitan weekly|participants will receive once-weekly somapacitan for 52 weeks
62219333|NCT00267904|EXPERIMENTAL|Healthy Volunteer for Olive|Ingestion of olives
62219334|NCT00267904|NO_INTERVENTION|Healthy Volunteer for Quality Control Plasma|Arm venous blood is drawn via an indwelling i.v. catheter from HVs to obtain quality control plasma
62219335|NCT00267904|EXPERIMENTAL|Healthy Volunteer for Temp. Manip.|Manipulation of temperature at skin of the back
62219336|NCT02730637|NO_INTERVENTION|Standard care|Patients with elevated biomarkers receive a standard treatment.
62219337|NCT02730637|ACTIVE_COMPARATOR|Interventional care|Patients in the interventional population receive an early nephrologist consultation which deliberates with attending doctor on preventing measures according to AKI-KDIGO recommendations.
62219338|NCT05320432|EXPERIMENTAL|Transcutaneous electrical nerve stimulation (TENS)|Prior to the procedure, the patient will have two sets of two self-adhesive electrodes placed parallel to the spinal cord at the T10-L1 and S2-S4 levels for TENS administration. For participants randomized to the experimental group, the non-blinded study coordinator will turn on the TENS unit 5 minutes prior to the procedure and monitor stimulating frequency level (80-100 Hz and pulse duration of 400 microseconds; intensity or frequency will be monitored to be administered to a non-painful level).
62219339|NCT05320432|SHAM_COMPARATOR|Sham|For the participants randomized to sham, the same placement of electrodes will occur, but the unit will not be delivering electrical stimulation.
62219340|NCT02130921|NO_INTERVENTION|Control|Community Health Workers (CHWs) in the control group will be invited to one group lecture didactically reviewing medical ethics, and the attending CHWs will be requested to pay a home visit to participating IDUs and FMs after the lecture.
62219341|NCT02130921|EXPERIMENTAL|Intervention|"Intervention for CHWs: 3 sessions will cover the understanding stigma and its impact, self-protection and universal precaution adherence, effective communication with patients and family members, and motivational enhancement for behavioral change.~Intervention for IDUs: CHWs who participate in the intervention will be required to conduct 3 individual sessions with participating IDUs covering the following topics: physical health, risk reduction behaviors, mental health, and community integration.~Intervention for FMs: CHWs who participate in the intervention will be required to conduct 2 group sessions with participating FMs covering the following topics: healthy family routine, coping with caregiver burdens, enhance family relationships, support positive behavior change."
62219342|NCT02097901|EXPERIMENTAL|Microfracture|Rotator Cuff Repair AND Microfracture at rotatorcuff footprint
62413725|NCT01224769||bendamustine +/- rituximab|
62413726|NCT06542224|EXPERIMENTAL|deep brain stimulation|
62413727|NCT04138173|EXPERIMENTAL|Tele coaching group|Coaching with daily interaction with the coaching application, based on an adaptive physical activity goal
62413728|NCT04138173|NO_INTERVENTION|Usual care group|Usual care
62413729|NCT04471792|EXPERIMENTAL|Creatine monohydrate|Creatine Monohydrate will be given at a 5 day loading period (10g/day) followed by a maintenance phase (5 g/day). The objectives of the current trial are to investigate if creatine supplementation plus muscle stretching improves 6-minute walking distance and muscle oxygenation in patients with peripheral artery disease.
62413730|NCT04471792|PLACEBO_COMPARATOR|Cellulose|These participants will consume a fiber supplement in place of creatine monohydrate at a matched dose with muscle stretching.
62413731|NCT02342574|EXPERIMENTAL|A active|Six subjects receiving F901318 1.5 mg/kg intravenously for eight days
62413732|NCT02342574|PLACEBO_COMPARATOR|A placebo|Two subjects receiving F901318 placebo intravenously for eight days
62413733|NCT02342574|EXPERIMENTAL|B active|Six subjects receiving F901318 3 mg/kg intravenously for eight days
62413734|NCT02342574|PLACEBO_COMPARATOR|B placebo|Two subjects receiving F901318 placebo intravenously for eight days
62413735|NCT02342574|EXPERIMENTAL|C active|Six subjects receiving F901318 4 mg/kg intravenously for eight days
62413736|NCT02342574|PLACEBO_COMPARATOR|C placebo|Two subjects receiving F901318 placebo intravenously for eight days
62413737|NCT02342574|EXPERIMENTAL|D1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
62413738|NCT02342574|PLACEBO_COMPARATOR|D1 placebo|Two subjects receiving F901318 placebo intravenously for one day
62413739|NCT02342574|EXPERIMENTAL|E1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
62413740|NCT02342574|PLACEBO_COMPARATOR|E1 placebo|Two subjects receiving F901318 placebo intravenously for one day
62413741|NCT02342574|EXPERIMENTAL|F1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
62023119|NCT03574792|ACTIVE_COMPARATOR|Arm I (gabapentin, methadone, oxycodone)|Participants receive gabapentin PO daily or TID. Participants may also receive methadone PO TID and oxycodone PO every 8 hours as needed. Treatment continues for up to 12 months in the absence of disease progression or unacceptable toxicity.
62413742|NCT02342574|PLACEBO_COMPARATOR|F1 placebo|Two subjects receiving F901318 placebo intravenously for one day
62023120|NCT03574792|EXPERIMENTAL|Arm II (gabapentin, methadone, oxycodone, venlafaxine)|Participants receive gabapentin, methadone, and oxycodone as in Arm I and venlafaxine PO BID or venlafaxine hydrochloride extended release daily for up to 12 months in the absence of disease progression or unacceptable toxicity.
62413743|NCT02342574|EXPERIMENTAL|D2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
62413744|NCT02342574|PLACEBO_COMPARATOR|D2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
62413745|NCT02342574|EXPERIMENTAL|E2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
62413746|NCT02342574|PLACEBO_COMPARATOR|E2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
62413747|NCT02342574|EXPERIMENTAL|F2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
62413748|NCT02342574|PLACEBO_COMPARATOR|F2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
62413749|NCT03632837|EXPERIMENTAL|Treatment|Inclusion of an extracorporal in line adsorbing cartridge for 48h (with a cartridge exchange at 24h) post establishing ECMO in addition to standard post resuscitation intensive care
62413750|NCT03632837|NO_INTERVENTION|Control|ECMO and standard post resuscitation intensive care without any additional module in extracorporal circulation
62413751|NCT01281176|EXPERIMENTAL|Arm I (high- and low-dose vorinostat and carboplatin)|Patients receive high-dose vorinostat PO QD on days 1-3 and low-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive high-dose vorinostat PO QD on days 1-3 and carboplatin IV over 30 minutes on day 3 of all subsequent courses.
62413752|NCT01281176|EXPERIMENTAL|Arm II (high- and low-dose vorinostat and carboplatin)|Patients receive high-dose vorinostat and low-dose vorinostat as in Arm I. After 5 days, patients receive lower-dose vorinostat PO QD on days 1-3 and carboplatin IV over 30 minutes on day 3.
62413753|NCT01281176|EXPERIMENTAL|Arm III (low- and high-dose vorinostat and carboplatin)|Patients receive low-dose vorinostat PO QD on days 1-3 and high-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive vorinostat and carboplatin as in Arm I.
62023121|NCT05262153|NO_INTERVENTION|Periodontally healthy|
62023122|NCT05262153|ACTIVE_COMPARATOR|Periodontitis III-C|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
62023123|NCT05262153|ACTIVE_COMPARATOR|Periodontitis III-C Smoking|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
62023124|NCT01798550|EXPERIMENTAL|Reduced Dose (0.8 mg/kg)|Enoxaparin 0.8 mg/kg (using total body weight) twice daily
62023125|NCT01798550|ACTIVE_COMPARATOR|Standard Dose (1 mg/kg)|Enoxaparin 1 mg/kg (using total body weight) twice daily
62219343|NCT02097901|ACTIVE_COMPARATOR|NO microfracture|Rotator cuff reinsertion without microfracture
62413754|NCT01281176|EXPERIMENTAL|Arm IV (low- and high-dose vorinostat and carboplatin)|Patients receive low-dose vorinostat and high-dose vorinostat as in Arm III. After 5 days, patients receive vorinostat and carboplatin as in Arm II.
62413755|NCT01281176|EXPERIMENTAL|Arm V (low- and mid-dose vorinostat and paclitaxel)|Patients receive low-dose vorinostat PO QD on days 1-3 and mid-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive mid-dose vorinostat PO QD on days 1-3 and paclitaxel IV over 3 hours on day 3.
62413756|NCT01281176|EXPERIMENTAL|Arm VI (mid- and low-dose vorinostat and paclitaxel)|Patients receive mid-dose vorinostat PO QD on days 1-3 and low-dose vorinostat PO QD on days 8-10. After 5 days, patients receive vorinostat and paclitaxel as in Arm V.
62413757|NCT01254357||YA Burned Subjects|Any person between the years of 19-30 years old treated for a burn injury, having incurred within past 12 months.
62413758|NCT01912547||Blood draw for TEG analysis|TEG analysis of blood from patients at different points in time
62413759|NCT01311505|ACTIVE_COMPARATOR|A|Test
62413760|NCT01311505|ACTIVE_COMPARATOR|B|Reference
62413761|NCT06412666|EXPERIMENTAL|Aficamten|Participants in this arm will receive a single daily oral dose of aficamten with dose levels (5 mg to 20 mg) guided by echocardiography assessments, for 12 weeks during the double-blinded period, and then for another 52 weeks during the open-label extension period.
62413762|NCT06412666|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive placebo for 12 weeks during the double-blinded period, and then will receive aficamten for 52 weeks during the open-label extension period.
62413763|NCT03360721|EXPERIMENTAL|Treatment (abiraterone acetate, apalutamide, prednisone)|Participants receive abiraterone acetate PO once daily QD, apalutamide PO QD, and prednisone PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62413764|NCT01555242|EXPERIMENTAL|Aneustat (OMN54)|
62413765|NCT06106282||Observational|Patients attend a 2-day treatment program and complete questionnaires on study. Patients also have their medical records reviewed on study.
62413766|NCT04873830|EXPERIMENTAL|Group I (VCMX)|includes 10 patients where implant placement will be performed followed by volume stable collagen matrix placement to augment the buccal defect.
62413767|NCT04873830|EXPERIMENTAL|Group II (control)|Will include 10 patients where implant placement will be performed followed by connective tissue grafting to augment the buccal defect.
62413768|NCT04027907||T2DM|
62413769|NCT04027907||healthy controls|
62795345|NCT04970654|ACTIVE_COMPARATOR|Norditropin® daily|Participants will receive Norditropin® daily for 52 weeks
62413770|NCT04387487|EXPERIMENTAL|Video Group|"Video Group~multimedia video information of 4.5 mins regarding procedure, indication and complications related to spinal anesthesia will be shown to patients in intervention group , patient will be allowed to ask questions."
62413771|NCT04387487|NO_INTERVENTION|non video group|patients in control group will be given verbal information regarding procedure, indication and complication, patient will be allowed to ask questions.
62413772|NCT06699290||Clear aligner therapy group|
62586769|NCT06668766|ACTIVE_COMPARATOR|4.78 cm Long Peripheral Intravenous Catheter|The BD Insyte Autoguard 4.78 cm 18- or 20-gauge needle with self-retraction is currently approved for use by the FDA and by Albany Medical center. The long PIV will be placed using standard aseptic technique (e.g., chlorhexidine prep, sterile gloves, sterile ultrasound probe cover and gel). Once the target vessel is identified, an ultrasound image of the vessel will be captured and recorded with the subject's study ID number in the comments section of the QPATH worksheet to allow for vessel depth and size measurement. Operators will be instructed to use standard techniques in US-guided vascular access.
62586770|NCT06668766|EXPERIMENTAL|10 cm Single Lumen Midline Catheter|The BD Powerglide Pro Midline catheter is currently approved for use by the FDA and by Albany Medical Center. This 18-gauge or 20-guage MC is distinct in that it is a standard 10-cm, does not require premeasurement or trimming of the catheter prior to placement, and features an accelerated Seldinger technique, meaning that it has a built-in deployable internal wire system. Additionally, because it is only 10-cm, it does not require a confirmatory chest x-ray prior to use. The provider will use standard aseptic technique for placing the MC (e.g., chlorhexidine prep, sterile probe cover and gel). Once the target vessel is identified, an ultrasound image of the vessel will be captured and recorded with the subject's study ID number from the randomization packet to allow for vessel depth and size measurement.
62219344|NCT06441500|EXPERIMENTAL|Kindergarten children|Children aged 3-5 years, enrolled in kindergartens. The pathfinder sampling technique has been used to obtain a representative sample. As suggested by the WHO, this survey design is suitable for collection of data for planning purposes and monitoring of oral health programmes in all countries regardless of the level of disease, availability of resources or complexity of care. Clinical examinations will be performed using ICDAS criteria by calibrated medical staff from each partner university. Caries incidence rate will be calculated on each tooth as the unit of analysis and evaluated using a multi-step approach: net increment for caries severity using ICDAS calculated at each follow-up examinations; Events defined as a new lesion or as the sum of the Δ-caries changes of status recorded at the baseline, at interim, and at the last examination. The number of events will be appraised by subtracting the number of caries-free teeth at last examination from those at baseline.
62413773|NCT06699290||Conventional fixed therapy group|
62413774|NCT00557700|PLACEBO_COMPARATOR|2|Administration of placebo
62413775|NCT00557700|EXPERIMENTAL|1|Administration of inhaled tiotropium bromide
62413776|NCT06701123|NO_INTERVENTION|No Intervention : Control Group Access to uMAT-R but did not engage|No Intervention : Control Group Access to uMAT-R but did not engage
62413777|NCT06701123|EXPERIMENTAL|Experimental : Experimental Group A- Mobile App with Coaching Feature|Access to a coached program on uMAT-R App
62586771|NCT05511467|EXPERIMENTAL|stroke group|
62219345|NCT02388243|EXPERIMENTAL|Brief Intervention in Public Clinic|Written information after screening; 15 minutes or so brief intervention at recruitment with follow-up visit of about the same length after one month; in public clinic.
62219346|NCT02388243|ACTIVE_COMPARATOR|Screening results in Public Clinic|Written information after screening; No brief intervention; in public clinic.
62413778|NCT02030509||New diagnosed patients of head and neck cancer|New diagnosed patients of head and neck cancer
62413779|NCT02030509||Old diagnosed head and neck cancer patients|
62413780|NCT06653712||Healthy controls|Healthy participants between 10 and 25 years of age. We plan to recruit 5 to 10 participants per age group.
62586772|NCT05511467|EXPERIMENTAL|control group|
62413781|NCT03529045||VNS Therapy|Any approved VNS Therapy System (according to local regulations) may be used in this registry.
62413782|NCT01876082|EXPERIMENTAL|PAZOPANIB|"Pazopanib~* 800 mg per day~* oral administration~* at least 1 hour before or 2 hours after a meal,~* until disease progression or for 12 months maximum"
62413783|NCT01876082|ACTIVE_COMPARATOR|Vinblastine and Methotrexate|vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
62413784|NCT00648583|EXPERIMENTAL|1|Ondansetron Tablets 24 mg
62413785|NCT00648583|ACTIVE_COMPARATOR|2|Zofran® Tablets 24 mg
62586773|NCT06424171||Athletes with atrial fibrillation without diagnosed stroke.|
62586774|NCT06424171||Athletes without atrial fibrillation.|
62586775|NCT06424171||Athletes with atrial fibrillation and a diagnosed stroke.|
62586776|NCT06424171||Healthy, non-athlete controls.|
62413786|NCT05058027|ACTIVE_COMPARATOR|GUARDIX-SG®|Treat GUARDIX-SG 6g prefilled syringe after surgery
62413787|NCT05058027|EXPERIMENTAL|Medicurtain®|Treat Medicurtain® 5ml prefilled syringe after surgery
62413788|NCT03813160|EXPERIMENTAL|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily
62413789|NCT03813160|EXPERIMENTAL|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily
62413790|NCT03813160|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo twice daily
62413791|NCT05924464|EXPERIMENTAL|Intervention arm|Group preconception care
62413792|NCT05924464|NO_INTERVENTION|Control arm|Usual care (completion of questionnaires only)
62413793|NCT05335096|EXPERIMENTAL|Intervention group|
62413794|NCT05335096|ACTIVE_COMPARATOR|TAU group|
62586777|NCT02339480|NO_INTERVENTION|Healthy volunteers|Healthy volunteers'hypothalamus picture of fMRI will compare with Obesity group' , no intervention and remaining unchanged lifestyle.
62586778|NCT02339480|ACTIVE_COMPARATOR|Obesity group|An intervention group of patients is put on a waiting list for massage therapy.Observing the Curative effect and hypothalamus picture of fMRI compare with healthy volunteers
62023126|NCT02283814|EXPERIMENTAL|Group A BIA 2-093 + Topamax|"Group A~* Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;~* Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days~* Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg for two consecutive days~* Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg (morning) + 100mg (evening) for two consecutive days~* Treatment 4: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200 mg for fifteen consecutive days"
62023127|NCT02283814|EXPERIMENTAL|Group B BIA 2-093 + Topamax|"* Pre-treatment: 100 mg once daily dose of TPM administered for two consecutive days;~* Pre-treatment 2: 100 mg twice daily dose of TPM administered for two consecutive days;~* Treatment: 200 mg once daily dose of TPM administered for four consecutive days;~* Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 600 mg and TPM 200 mg for two consecutive days~* Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200mg for seventeen consecutive days"
62219347|NCT02388243|EXPERIMENTAL|Brief Intervention in Private Clinic|Written information after screening; 15 minutes or so brief intervention at recruitment with follow-up visit of about the same length after one month; in private clinic.
62219348|NCT02388243|ACTIVE_COMPARATOR|Screening results in Private Clinic|Written information after screening; No brief intervention; in private clinic.
62413795|NCT02216214|PLACEBO_COMPARATOR|Placebo|Participants received placebo to match mirabegron at an initial dose of 25 mg and may have been increased to 50 mg of matching placebo based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.
62023128|NCT01979653|EXPERIMENTAL|dexmedetomidine alone|dexmedetomidine 0.5 mcg/kg for 10 min + normal saline (volume-matched) bolus + dexmedetomidine 0.2-0.4 mcg/kg/hr infusion
62219349|NCT02876276|ACTIVE_COMPARATOR|HA filler group|6 weeks after the initial therapy, patients were scheduled for the procedure.16 Local Anesthetic solution (2% Lignocaine HCl with adrenaline 1:80000) was administered.17 About 0.2 ml of a commercially available hyaluronic acid based gel was injected 2-3 mm coronal to the apical tip of the receded interdental papilla . Injections were performed using 23 gauge X 25mm intraoral injection needles . The concentration of HA gel used was 20 mg/ml.6 The area was gently massaged to ensure that the filler was uniformly distributed. Care was taken to fill each papilla to full correction (100% of defect). After the treatment the individual patient syringes were capped and stored in a refrigerator with patient names and details. The needle was discarded. Patients were seen three weeks after the initial treatment and if augmentation was still deemed necessary, another injection of 0.2ml was injected up to three times
62219350|NCT02876276|PLACEBO_COMPARATOR|saline filler group|with saline same protocol was performed as mentioned in test group
62219351|NCT05849831||Adult critically ill septic patients|
62413796|NCT02216214|EXPERIMENTAL|Mirabegron|Participants received mirabegron at an initial dose of 25 mg and may have been increased to 50 mg mirabegron after 4 weeks or 8 weeks based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.
62413797|NCT06531109||Alopecia Areata (AA) patients treated with ritlecitinib|
62413798|NCT01807910|EXPERIMENTAL|Fructose|Participants will receive fructose (3g/kg/day) for 2 weeks.
62413799|NCT01807910|ACTIVE_COMPARATOR|Glucose|Participants will receive glucose (3g/kg/day) for 2 weeks.
62413800|NCT05433376|EXPERIMENTAL|IVL group|
62413801|NCT04692753||Pre-intervention|baseline data prior to training and education of health care workers. Intervention: intensive training and education of workers for maintenance of venous access devices.
62586779|NCT00697125|ACTIVE_COMPARATOR|Group A|
62586780|NCT00697125|EXPERIMENTAL|Group B|
62413802|NCT04692753||Post intervention|observation after training and education of health care workers
62413803|NCT06650475|ACTIVE_COMPARATOR|Low pressure|Group L will undergo laparoscopy under low pressure (8-10mm Hg).
62413804|NCT06650475|SHAM_COMPARATOR|Standart Pressure|Standard pressures (12-16 mmHg) are used in laparoscopic surgery for patients in Group S.
62413805|NCT03029559|EXPERIMENTAL|IH + ITL|Subjects will be exposed to a session of Intermittent hypoxia (IH) (45 minutes, 2 minutes of hypoxia alternating with 1 minute of hyperoxia) followed by 5 sets of Inspiratory threshold loading (ITL) at 80%MIP (10 breaths per set).
62586781|NCT00697125|EXPERIMENTAL|Group C|
62586782|NCT06666192|OTHER|Phase I, Planning Phase (MLI material, focus group, interview)|Providers and community members review MLI materials and participate in focus groups and interviews to discuss challenges to being screened, what community members know about cancer and screening and what should be included in a program to increase screening over 30-60 minutes on study. A clinic champion will be identified during the interview to lead, advise, and oversee the implementation of the MLI at their clinic location.
62795346|NCT00018889||1|Patients age 2 years and older with a clinical or suspected diagnosis of movement disorder
62795347|NCT02436616||EEG monitoring|All subjects enrolled in this observational study will undergo EEG monitoring using the microEEG device.
62586783|NCT06666192|ACTIVE_COMPARATOR|Phase II, Arm I (Health Clinics)|The clinic champion coordinates planning sessions, staff training, and overall implementation and planning for the MLI within each health clinic. Health clinics may integrate new activities into usual clinic processes such as the use of the EHR to identify age-eligible patients in need of breast, cervical and/or CRC screening, reminder systems built into the EHR that can be sent to both providers and patients for screening and follow-up, and EHR information alerts for providers about patients who have positive FITs or a positive Pap test or mammogram on study. Additionally, health clinics may incorporate risk assessments (via paper or within the EHR) for all patients eligible for breast, cervical and/or CRC screening, promote screening via web-based or health portal messaging, promote annual wellness visits (during which screening should be discussed), and offer incentives for completing needed cancer screening on study.
62586784|NCT06666192|ACTIVE_COMPARATOR|Phase II, Arm II (Health Care Providers)|Providers participate in educational sessions that include self-administered pre-test surveys and discussions that assess screening knowledge, beliefs, attitudes, and practices, over one hour on study. Providers may also undergo coaching calls and one-on-one discussions to help tailor information and its delivery to the needs of providers and practices and are taught how to use clinic-based scheduling and reminder systems to help facilitate screening and follow-up actions.
62586785|NCT06666192|ACTIVE_COMPARATOR|Phase II, Arm III (Patients)|Patients receive educational materials about screening and screening recommendations via mail and during in-person visits, and a web link for the developed small media website on study. Patients participate in discussions about screening and are offered any test for which they are not up to date and appropriate follow-up is conducted by designated staff on study. Patients who choose to undergo testing and receive a positive result receive a letter from the clinic and a call from the designated clinic staff member on study.
62586786|NCT06666192|ACTIVE_COMPARATOR|Phase II, Arm IV (Community)|Community receive educational materials (e.g., posters) and outreach activities to promote screening (e.g., health fairs, farmers' markets, inflatable colon tours, community seminars) and receive access to a CHW for one-on-one education about screening on study.
62586787|NCT06666192|EXPERIMENTAL|Phase III and IV, Arm V (MLI Early Wave)|Participating clinics and communities participate in the MLI early (years 2-3) for up to 30 months.
62586788|NCT06666192|EXPERIMENTAL|Phase III and IV, Arm VI (MLI Delayed Wave)|Participating clinics and communities participate in the MLI 12 months later (years 3-4) for at least 12 months.
62795348|NCT04041154|EXPERIMENTAL|Cognitive Fatigue|We will use a behavioral intervention. Participants will perform a cognitively demanding task, repeatedly, to induce cognitive fatigue.
62795349|NCT04041154|EXPERIMENTAL|Physical Fatigue|We will use a behavioral intervention. Participants will perform a physically demanding task (grip force exertion task), repeatedly, to induce cognitive fatigue.
62795350|NCT04041154|EXPERIMENTAL|Rewarding Stimuli|We will use a behavioral intervention. Reward-associated stimuli will be used to study how reward-induced changes in motivational state influence effort choices.
62795351|NCT06474637|EXPERIMENTAL|Single Arm|
62795352|NCT01385657|EXPERIMENTAL|Placebo|Placebo (for Dupilumab) as a single subcutaneous (SC) injection on Day 1, 8, 15, and 22
62413806|NCT03029559|EXPERIMENTAL|Intermittent hypoxia (IH)|Subjects will only be exposed to a session of intermittent hypoxia.
62413807|NCT03029559|EXPERIMENTAL|Sham IH + ITL|Sham Intermittent Hypoxia + Inspiratory threshold loading (ITL) subjects will be exposed to a single 45-minute session of sham IH (normoxia). This will consist of the subject breathing room air (FiO2=21%) through a 4 way valve connected to the hypoxicator. Exposure to normoxia will be followed by 5 sets of ITL at 80%MIP (10 breaths per set).
62413808|NCT03029559|SHAM_COMPARATOR|Sham IH|Sham intermittent hypoxia subjects will be exposed to a single 45-minute session of sham IH alone.
62413809|NCT04000997||Failure group|Patients with a failure extubation
62413810|NCT04000997||Success group|Patients with a successful extubation
62413811|NCT05292339|ACTIVE_COMPARATOR|Triamcinolone injection to the shoulder, elbow, wrist, or hand|Participants will receive the triamcinolone injection solutions in a standard fashion. Injections will be performed using the treating physician's standard technique.
62413812|NCT05292339|ACTIVE_COMPARATOR|Ketorolac injection to the shoulder, elbow, wrist, or hand|Participants will receive the Ketoralac injection solutions in a standard fashion. Injections will be performed using the treating physician's standard technique.
62413813|NCT05358795|EXPERIMENTAL|Family Connections Intervention Arm|The intervention group sessions aim to 1) improve understanding of HIV among AYA and caregivers; 2) help AYA develop strategies for healthy living (e.g. ART adherence); 3) build AYA capacity to make informed decisions about their sexual and reproductive health; 4) build the capacity of caregivers to support AYA; and 5) help AYA develop life skills to communicate their HIV diagnosis effectively and to plan for their futures. Participants attend group sessions, with caregivers and AYA typically separated for sessions and then brought together sometimes during and sometimes at the end of the sessions, to share information and skills learned. The in-person group intervention will be held twice per month over a period of an estimated 6 months for a total of 10 sessions. Trained facilitators will deliver the intervention at the clinics. Health clinic staff will be available as technical experts to answer clinical questions.
62413814|NCT05358795|NO_INTERVENTION|Standard of Care Comparison|The control group will receive the standard of care during the study for AYA living with HIV in these public health care facilities and communities. The 20 facilities included in the research have been trained to operate under the standard protocols endorsed by the Zambia Ministry of Health. There can be variations in how these standards are adhered to and if special programming is provided for youth, such as youth group meetings and special youth clinic hours. Standard of care services per the 2020 Zambia Consolidated Guidelines include routine clinical care for HIV treatment including laboratory testing (CD4, VL tests); adherence counseling, with enhanced adherence counseling for clients with unsuppressed viral loads; multi-month dispensing of ART including differentiated service delivery for stable clients; screening and treatment of sexually transmitted infections (STIs); prevention and screening for opportunistic infections; and clinical monitoring of kidney and liver function.
62413815|NCT02230228|EXPERIMENTAL|ALK-001 capsules|
62413816|NCT05937230||Drug-coated balloon|Paclitaxel coated balloon
62413817|NCT05937230||Drug-eluting stent|Second-generation eluting stents
62795353|NCT01385657|EXPERIMENTAL|Dupilumab 150 mg|Dupilumab 150 mg as a single SC injection on Day 1, 8, 15, and 22
62586789|NCT06666621|OTHER|Single arm study: endogenous opioid blockade|"This is a single group study. The participants will undergo two sequential experimental conditions: saline infusion and naloxone infusion.~Participants will be identified as candidates for standard of care lumbar medial branch block, consented, and enrolled. Baseline demographics and patient reported clinical measures will be collected.~All participants will have IV placed, undergo standard of care lumbar medial branch block, wait 20 minutes, then have their response to procedure assessed. Then normal saline will be infused through the IV over several minutes, 10 minutes will pass, and response to procedure re-assessed. Then naloxone will be infused through the IV over several minutes, 10 minutes will pass, and response to procedure re-assessed for a final time. IV will then be removed.~Participants will then follow standard of care clinical practice for second lumbar medial branch block and lumbar medial branch radiofrequency neurotomy treatment."
62586790|NCT05349981|EXPERIMENTAL|Lyric self-replacement|This cohort of experienced Lyric patients are required to meet the candidacy criteria to be eligible for the self-replacement procedure. They will also be required to demonstrate proficiency with the self-replacement procedure before proceeding with independent self-replacement.
62586791|NCT05875779|EXPERIMENTAL|Peer-led vaccine education intervention|Parents randomized to peer-led vaccine education intervention.
62586792|NCT05875779|NO_INTERVENTION|Usual Care|Parents randomized to usual care.
62586793|NCT03815799|EXPERIMENTAL|Erector Spinae Plane Block Group|"Procedure:~In addition to routine standard perioperative and postoperative analgesic protocol participants will recieve erector spinae block under ultrasound guidence after the strict aseptic precautions."
62586794|NCT03815799|SHAM_COMPARATOR|Control|Routine standard perioperative and postoperative analgesic protocol will be given.
62023129|NCT01979653|EXPERIMENTAL|dexmedetomidine + midazolam|normal saline (volume-matched) for 10 min + midazolam 0.2 mg/kg bolus + dexmedetomidine 0.2-0.4 mcg/kg/hr infusion
62413818|NCT02206100|EXPERIMENTAL|Cohort 1|100 mg PER977 (10 subjects); the dose may be repeated two (2) times after an approximate one (1) hour interval for a maximum total of three (3) doses
62413819|NCT02206100|EXPERIMENTAL|Cohort 2|200 mg PER977 (10 subjects); the dose may be repeated once at approximately one hour for a maximum total of two (2) doses
62413820|NCT02206100|EXPERIMENTAL|Cohort 3|300 mg PER977 (10 subjects); the dose may be repeated once at approximately one hour after the initial dose for a maximum of total of two (2) doses
62586795|NCT00719238|EXPERIMENTAL|1|
62586796|NCT00719238|ACTIVE_COMPARATOR|2|
62586797|NCT04783441|ACTIVE_COMPARATOR|Continuous glucose monitoring (CGM)|Those in the intervention arm will wear a continuous glucose monitoring device. They only need to perform blood glucose fingersticks if the CGM transmission is lost for a prolonged period of time or in cases of hypo- or hyperglycemia when symptoms don't align with blood glucose readings.
62586798|NCT04783441|PLACEBO_COMPARATOR|Self monitoring of blood glucose (fingersticks)|The control arm will remain on standard-of-care SMBG while the intervention arm will use their CGM. The control arm utilizing SMBG will be required to have at minimum 4 glucose checks per day.
62586799|NCT06667570|EXPERIMENTAL|SALFOAM 3%|Participants in this group will receive a saline wash, followed by an injection of polidocanol 3% foam using the Tessari method, and extrinsic compression with Lidstop® over the treated vein. This is followed by the application of elastic compression stockings (20-30 mmHg) for 72 hours.
62586800|NCT06667570|ACTIVE_COMPARATOR|Tessari Method|Participants in this group will receive the conventional Tessari method of polidocanol 3% foam injection, followed by compression with a dental roll and elastic compression stockings (20-30 mmHg) for 24 hours.
62586801|NCT01413750|EXPERIMENTAL|Arm I (paclitaxel, carboplatin, vorinostat)|Patients receive paclitaxel IV over 3 hours, and carboplatin IV over 30 minutes on day 0. Patients also receive vorinostat PO once daily on days -2 to 2.
62795354|NCT01385657|EXPERIMENTAL|Dupilumab 300 mg|Dupilumab 300 mg as a single SC injection on Day 1, 8, 15, and 22
62795355|NCT01804881|EXPERIMENTAL|Lifestyle counseling|Group program using Craving Change(tm) material was the intervention for dietary counseling, 6 group sessions
62023130|NCT05007457|EXPERIMENTAL|Experimental Group|telerehabilitation
62023131|NCT05007457|ACTIVE_COMPARATOR|Control group|Standard treatment
62023132|NCT06489548|ACTIVE_COMPARATOR|Arm A: This cohort of subjects will receive 100µg/dosing day vs. placebo throughout the study.|This group will receive a nasal spray three times a week for two weeks, followed by a one-week rest. That cycle will occur three more times for a total of three months of drug intervention.
62413821|NCT02206100|EXPERIMENTAL|Cohort 4|4 x 25 mg PER977 (10 subjects); study drug will be administered every 30 minutes for a total of 4 doses (cumulative dose of 100 mg PER977)
62413822|NCT06541002|EXPERIMENTAL|SHIFT Intervention Group|SHIFT is a self-administered, multi-component digital application for HCT survivors, incorporating several features to promote engagement and health behavior change, and includes gamification strategies, videos of HCT survivors, intimacy exercises, and optional content.
62413823|NCT06541002|ACTIVE_COMPARATOR|Enhanced Usual Care Group|Patients assigned to enhanced usual care group will not receive access to the SHIFT application. They will meet with their HCT clinician and maybe referred to specialist care at the patients' request or at the discretion of the HCT clinician.
62413824|NCT01212926|EXPERIMENTAL|analysis of myocardial deformation in 2D strain|
62586802|NCT01413750|ACTIVE_COMPARATOR|Arm II (paclitaxel, carboplatin, placebo)|Patients receive paclitaxel and carboplatin as in arm I. Patients also receive placebo PO once daily on days -2 to 2.
62586803|NCT03977753|EXPERIMENTAL|2LVERU®/2LVERU® JUNIOR|Group N°1: 2LVERU® or 2LVERU® JUNIOR treatment (6 months of treatment)
62586804|NCT03977753|PLACEBO_COMPARATOR|Placebo|Group N°2: Placebo treatment (6 months of treatment)
62586805|NCT03396315|ACTIVE_COMPARATOR|alendronate|Subjects will receive oral alendronate
62586806|NCT03396315|ACTIVE_COMPARATOR|zoledronic acid|Subjects will receive zoledronic acid
62795356|NCT01804881|PLACEBO_COMPARATOR|Wait list control|Wait list, offered group program using Craving Change(tm) material at end of study
62795357|NCT04146545|EXPERIMENTAL|Cases|"Community Rx-Dementia CRxD Caregiver Resources"
62795358|NCT04146545|NO_INTERVENTION|Control|Usual Standard Care
62795359|NCT05073926||Persons with latent tuberculosis treated with 4 months rifampicin|Oral rifampicin 10 mg/kg (max 600mg) once daily during 4 months
62023133|NCT06489548|ACTIVE_COMPARATOR|Arm B: This cohort of subjects will receive 50µg/dosing day vs. placebo throughout the study.|This group will receive a nasal spray three times a week for two weeks, followed by a one-week rest. That cycle will occur three more times for a total of three months of drug intervention.
62219352|NCT01261637|EXPERIMENTAL|0.25% Ropivicaine|0.25% ropivicaine (maximum 1.5mg/kg)
62219353|NCT01261637|PLACEBO_COMPARATOR|Placebo|20ml saline
62413825|NCT02406937|EXPERIMENTAL|Feihe New Formula|Oral intake of Feihe new formula with hydrolyzed protein supplied by Arla Foods Ingredients.
62219354|NCT01810601|EXPERIMENTAL|Ultrasound guided embryo transfer|GnRh, HMG, HCG, Progesterone 45 patients had ultrasound guided embryo transfer during ICSI
62219355|NCT01810601|PLACEBO_COMPARATOR|clinical touch technique|GnRh, HMG, HCG, Progesterone 45 patients had embryo transfer using clinical touch technique during ICSI
62219356|NCT06208098|EXPERIMENTAL|Salivary cortisol dosage|saliva sample (1 ml) at 8 \& 9 h \& at T30
62413826|NCT02406937|ACTIVE_COMPARATOR|Feihe Stage 1 Formula|Oral intake of Feihe stage 1 formula
62219357|NCT02547259|EXPERIMENTAL|schizophrenic pain words test|schizophrenic will have memory test with pain words on computer
62219358|NCT02547259|EXPERIMENTAL|schizophrenic negative words test|schizophrenic will have memory test with negative words on computer
62413827|NCT02406937|PLACEBO_COMPARATOR|Breast Feeding|Oral intake of breast milk
62413828|NCT02251431|EXPERIMENTAL|Exenatide-extended release|Exenatide-extended release (BYDUREON™) 2 mg subcutaneously once per week x 38 weeks
62413829|NCT02251431|PLACEBO_COMPARATOR|Placebo|Matching placebo subcutaneously once per week x 38 weeks
62413830|NCT00005009|EXPERIMENTAL|Varivax®|0.5 mL of Varivax administered subcutaneously in the right upper arm (deltoid region).
62413831|NCT02843529|EXPERIMENTAL|Prodromal AD (MCI)|"Altoida: neuropsychological, MRI, EEG and CSF biomarkers~MCI participants will undergo at baseline and every 6 months a neurological examination and a neuropsychological assessment. Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
62413832|NCT02843529|EXPERIMENTAL|Preclinical AD (cognitively normal)|"Altoida: neuropsychological, MRI, EEG and CSF biomarkers~Cognitively normal participants at risk will undergo at baseline and every 6 months a neurological examination and a neuropsychological assessment. Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
62413833|NCT06568848|EXPERIMENTAL|Exp Group|
62413834|NCT06568848|ACTIVE_COMPARATOR|Control Group|
62413835|NCT05292781|EXPERIMENTAL|CHOICES|Experimental arm: receives the web-based reproductive education for individuals with sickle cell disease or sickle cell trait
62795360|NCT05073926||Persons with latent tuberculosis treated with 6-9 months isoniazide|Oral isoniazide 5 mg/kg (max 300mg) once daily in combination with 40mg vitamin B6 (pyridoxin) during 6-9 months
62795361|NCT05043753|NO_INTERVENTION|Control group: Symphysis fundal height measurement|Screening for fetal growth abnormalities is performed by certified nurse midwives (CNMs) using symphysis fundal height (SFH)
62219359|NCT02547259|OTHER|Healthy volunteer pain words test|Healthy volunteer will have memory test with pain words on computer
62219360|NCT02547259|OTHER|Healthy volunteer negative words test|Healthy volunteer will have memory test with negative words on computer
62219361|NCT01330173|EXPERIMENTAL|Treatment (vismodegib)|Patients receive vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity.
62219362|NCT05841732|OTHER|Usual Care|"Participants allocated to the usual care group will be informed that they can access their GP in the usual way (GPs consultation, pain medication, referral for other treatments/ services) and that they should contact their GP if their condition worsens. In addition, they will receive a minimal educational intervention focused on symptom management and promotion of physical activity (stay active)."
62413836|NCT05292781|SHAM_COMPARATOR|eBook (electronic-Book)|Control arm with eBook education focused on sickle cell disease and sickle cell trait.
62413837|NCT05029167|ACTIVE_COMPARATOR|Restrictive PaO2 and low normal MAP|Patients receiving PaO2 9-10 kPa (68-75 mmHg) and MAP 63 mmHg during targeted temperature management (36 hours) after OHCA.
62413838|NCT05029167|ACTIVE_COMPARATOR|Restrictive PaO2 and high normal MAP|Patients receiving PaO2 9-10 kPa (68-75 mmHg) and MAP 77 mmHg during targeted temperature management (36 hours) after OHCA.
62413839|NCT05029167|ACTIVE_COMPARATOR|Liberal PaO2 and low normal MAP|Patients receiving PaO2 13-14 kPa (98-105 mmHg) and MAP 63 mmHg during targeted temperature management (36 hours) after OHCA.
62413840|NCT05029167|ACTIVE_COMPARATOR|Liberal PaO2 and high normal MAP|Patients receiving PaO2 13-14 kPa (98-105 mmHg) and MAP 77 mmHg during targeted temperature management (36 hours) after OHCA.
62413841|NCT02886494|ACTIVE_COMPARATOR|BAC treatment|BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
62413842|NCT02886494|PLACEBO_COMPARATOR|Matched vehicle|Matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
62413843|NCT01414062|ACTIVE_COMPARATOR|Arm A|Participants receiving written dietary recommendations for breast cancer survivors (control arm)
62413844|NCT01414062|EXPERIMENTAL|Arm B|Participants attending Cocinar Para Su Salud Program held over a 12-week period
62413845|NCT04461431|EXPERIMENTAL|Knee joint lateral reconstruction group|
62413846|NCT04622540|EXPERIMENTAL|Experimental group|Application of external biliary drainage
62413847|NCT04622540|NO_INTERVENTION|Control group|Conventional duct-to-duct anastomosis (with or without internal stent)
62413848|NCT04426552|EXPERIMENTAL|Dexmedetomidine|have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI
62413849|NCT04426552|ACTIVE_COMPARATOR|Sevoflurane|(sevoflurane) will be preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation
62413850|NCT05808699||Fundus camera image|Subjects imaged with a fundus camera
62586807|NCT01004640||Group 1|"Peripheral blood samples and bone marrow aspirates are collected at baseline and at 3, 6, and 9 months after starting therapy. If patient continues to receive protocol treatment after 9 months, additional peripheral blood samples are collected every 6 months and bone marrow aspirates are taken annually. In the event of disease progression (blast crisis), an additional peripheral blood sample and bone marrow aspirate are collected.~Samples are examined by quantitative Southern blot analysis with probes to BCR, quantitative reverse transcriptase-polymerase chain reaction analysis for BCR/ABL fusion transcripts, and cytogenetic analysis."
62413851|NCT00626574|ACTIVE_COMPARATOR|A|Group A will receive Procrit® intravenous injections (40,000U) once daily for 3 days (Study Days 1, 2, and 3). The first dose of Procrit® will be given within 36 hours of the initial SAH event / symptoms and immediately before the vascular clipping procedure.
62413852|NCT00626574|PLACEBO_COMPARATOR|B|Group B will receive Saline intravenous injections once daily for 3 days (Study Days 1, 2, and 3).
62586808|NCT06234462|ACTIVE_COMPARATOR|Standard of Care|Participants in this arm will receive current standard of care for PASC symptoms which may include: PT, OT, SLP, provider counseling, and/or pharmacologic interventions for targeted symptom management.
62023134|NCT03885193||HMS plus group|HMS plus device is employed to assess anticoagulation and ensure adequate heparin and protamine dosing during cardiopulmonary bypass (CPB).
62023135|NCT03885193||ACT plus group|ACT plus device is employed to assess anticoagulation and ensure adequate heparin and protamine dosing during cardiopulmonary bypass (CPB).
62023136|NCT06336070|EXPERIMENTAL|Exercise group|Two cohorts of both healthy postmenopausal women and women free of postmenopausal breast cancer recurrence. Each of the groups will be split into two different exercise programmes. Both programmes, High Intensity Interval Training (HIIT) programme (metabolic power training) and Muscle Power Intervention (MPI) programme will consist of 8 weeks.
62023137|NCT06336070|NO_INTERVENTION|Control group|Two cohorts of both healthy postmenopausal women and women free of postmenopausal breast cancer recurrence.
62023138|NCT03783923|EXPERIMENTAL|Deflazacort|Participants will receive deflazacort 0.6 milligrams per kilograms per day (mg/kg/day) orally. The dose could be reduced in case of tolerability issues. Any participant assigned to placebo prior to the Version 4.0 amendment (prior to or after 01 February 2020) will have the option to be consented under Version 4.0 and will be switched to deflazacort for 26 weeks treatment. Any participant assigned to deflazacort prior to the Version 4.0 amendment (prior to 01 February 2020) will have the option to re-consent under Protocol Version 4.0 and continue for an additional 26 weeks treatment. Any participant assigned to deflazacort prior to the Version 4.0 amendment (after 01 February 2020) will have the option to re-consent under Protocol Version 4.0 at their Week 13 Visit and continue treatment until Week 26. Any new participant enrolled until 31 May 2020 will receive deflazacort for 26 weeks.
62023139|NCT03748498|EXPERIMENTAL|laser group|Low level laser was applied for 60 second per tooth using Nd-YAG laser.
62219363|NCT05841732|EXPERIMENTAL|MyBack|Patients in the MyBack group will participate in a patient-centred, tailored exercise programme informed by a behavioural change approach in addition to receiving usual care. The MyBack intervention programme will consist of 12 bi-weekly sessions (60 minutes each) over 6 weeks complemented by 12 exercise sessions to be carried out autonomously by the participants over the following 6 weeks
62219364|NCT02652923|EXPERIMENTAL|Part 1 - volunteers|Subdermal low (1.0 ml) or high (2.0 ml) dose injection of the ultrasound contrast agent Sonazoid divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock) around a 2 cm in diameter region in the mid-upper outer quadrant of the left breast, followed a week later by the other dose injected in the same fashion into the right breast.
62219365|NCT02652923|EXPERIMENTAL|Part 2 - patients|Subdermal injection of the ultrasound contrast agent of Sonazoid divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock) around the breast cancer. Subjects will receive an injection of either a low (1.0 ml) or a high (2.0 ml) dose of Sonazoid depending on the outcome of the Part 1 safety and tolerability study.
62219366|NCT04619940|EXPERIMENTAL|iHandy application|The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.
62219367|NCT04619940|ACTIVE_COMPARATOR|Standard goniometer|While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.
62413853|NCT06702150|EXPERIMENTAL|Changing the nursing care model to the primary nursing model|Inpatient unit where the primary nursing model has been implemented.
62413854|NCT06702150|NO_INTERVENTION|Standard of care|In this unit there was no change in the model of nursing care; the model used was the individualized care model. In this model, each nurse is responsible for the whole care of a group of patients on one working day and may or may not be given responsibility for the same patients on subsequent days. The patients who agreed to participate in the study completed the same questionnaires and at the same frequency as the patients in the intervention unit.
62023140|NCT03748498|PLACEBO_COMPARATOR|placebo group|The same procedures as in the laser group were performed, been completed but the laser was not activated in this group.
62219368|NCT06116864|EXPERIMENTAL|Endocuff + GI Genius|Endocuff is a polyp-detecting colonoscope attachment device. GI Genius is and Computer-Aid Detection (CADe) system to detect polyps
62219369|NCT06116864|ACTIVE_COMPARATOR|GI Genius|GI Genius is and Computer-Aid Detection (CADe) system to detect polyps
62219370|NCT03068065|ACTIVE_COMPARATOR|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
62413855|NCT06642350|EXPERIMENTAL|Whole-body electromyostimulation|WB-EMS 1.5x 20 min/week for 10 weeks
62413856|NCT06642350|ACTIVE_COMPARATOR|Medical training therapy (MTT)|MTT 2x 45 min/week for 10 weeks
62219371|NCT03068065|ACTIVE_COMPARATOR|Metformin|the dosage of merformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
62219372|NCT03068065|ACTIVE_COMPARATOR|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of \<7.0 mmol/L
62219373|NCT01830959|EXPERIMENTAL|Roflumilast|Roflumilast
62219374|NCT01830959|PLACEBO_COMPARATOR|Placebo|Placebo
62413857|NCT06652191|EXPERIMENTAL|The test group:Direct catheterization with non-dilation|Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, place the catheter into the vessel directly along the guide wire without using an dilator to expand the skin
62413858|NCT06652191|ACTIVE_COMPARATOR|The control group: Catheterization after expanding the skin with a dilator|Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, after the skin is expanded with a dilator, the catheter is inserted into the vessel along the guide wire
62413859|NCT06566443|EXPERIMENTAL|Honokiol|Approximately, 15 patients will be enrolled in the study. They will take the study drug, honokiol, for 2 weeks prior to the surgery. The primary endpoint will be the maximum tolerated dose (MTD) of honokiol and this will be determined using Bayesian Optimal Interval Design (BOIN)
62413860|NCT03759301|ACTIVE_COMPARATOR|Growth Hormones Somatropin Recombinant|Growth hormone (Somatropin) 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup for the treatment group which consists of 70 women.
62413861|NCT03759301|PLACEBO_COMPARATOR|Placebo saline solution|Control group consisting of 70 women who will receive subcutaneous placebo injection in the same dosing as the treatment group
62413862|NCT02380716|EXPERIMENTAL|GORE® Ascending Stent Graft|Treatment with the GORE® Ascending Stent Graft
62413863|NCT06538571|EXPERIMENTAL|NIRS use|Patients will have renal near infrared spectroscopy recorded in clinic.
62413864|NCT06298487|OTHER|PTE group|Group composed of patients who have already taken part in at least 3 Patient Therapeutic Education (PTE) workshops at the Maison de Prévention de la Santé et d'Accompagnement Therapeutique (MPSAT)
62219375|NCT06372873||Group I|mild-strain injury of ATFL
62219376|NCT06372873||Group II|partial ligament tears of ATFL
62219377|NCT06372873||Group III|complete rupture of ATFL
62219378|NCT06372873||Group IV|avulsed fractures
62219379|NCT00398554|EXPERIMENTAL|VECOPA|dose and time intensified consoloditation chemotherapy cycle
62219380|NCT00262951|EXPERIMENTAL|Pancreatic Adenocarcinoma Patients|Pancreatic Adenocarcinoma Patients treated with chemotherapy regimen and radiation (and or surgery).
62219381|NCT01627977|EXPERIMENTAL|Dye of Lutein/Zeaxanthin/Brilliant Blue|during the surgery will be evaluated if the dye is suitable for dyeing the internal limiting membrane as well as the epiretinal membrane
62219382|NCT02440451|EXPERIMENTAL|Neurofeedback using BCI|16 (13 + 3 in case of dropoffs) ASD subjects
62219383|NCT06243393|EXPERIMENTAL|Sacituzumab Govitecan (SG)|Treatment with Sacituzumab Govitecan (SG) .
62219384|NCT06243393|ACTIVE_COMPARATOR|Physicians Choice (PhC).|Treatment according to oncologic guidelines.
62413865|NCT06298487|OTHER|Control group|Group made up of patients on the waiting list for Patient Therapeutic Education (PTE) workshops at the Maison de Prévention de la Santé et d'Accompagnement Thérapeutique (MPSAT)
62023141|NCT02121847|EXPERIMENTAL|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily and carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
62413866|NCT05888649||Cluster 1|Communities highly affected and impacted by EVD
62219385|NCT01182467||Crohn's disease|Patients will receieve Radiation: PET-CT scan
62219386|NCT05277103|EXPERIMENTAL|Stay-Play-Talk with iPad Intervention|Peers without disabilities will be taught to be active communication partners using an iPad with voice output app as a speech-generating device, then paired up to play with one child with ASD for 16 sessions over 8 weeks. Focal child behaviors are assessed in different pre-treatment contexts (i.e., eye tracking, structured play, and naturalistic classroom settings), and rate of communication will be collected to predict gains children make in social communication with peers after treatment.
62219387|NCT00946231||Heart Failure|Subjects admitted to the hospital with decompensated heart failure.
62413867|NCT05888649||Cluster 2|Communities not highly affected and impacted by EVD
62795362|NCT05043753|EXPERIMENTAL|intervention group: Symphysis fundal height measurement and point of care ultrasound.|Screening for fetal growth abnormalities is performed by certified nurse midwives (CNM) using symphysis fundal height (SFH) and point of care ultrasound to measure the fetal abdominal circumference (POC-US-AC)
62795363|NCT04190901|EXPERIMENTAL|Simulated Black Male Physician|Participants are randomized to view the clinical vignette with a simulated Black Male physician.
62795364|NCT04190901|EXPERIMENTAL|Simulated Black Female Physician|Participants are randomized to view the clinical vignette with a simulated Black Female physician.
62795365|NCT04190901|EXPERIMENTAL|Simulated White Male Physician|Participants are randomized to view the clinical vignette with a simulated White Male physician.
62795366|NCT04190901|EXPERIMENTAL|Simulated White Female Physician|Participants are randomized to view the clinical vignette with a simulated White Female physician.
62219388|NCT01030406|ACTIVE_COMPARATOR|40/0mg taken first|8x oxycodone/niacin 5/0mg tablets
62219389|NCT01030406|ACTIVE_COMPARATOR|80/0mg taken first|8x oxycodone/niacin 10/0mg tablets
62219390|NCT01030406|EXPERIMENTAL|40/240mg taken first|8x oxycodone/niacin 5/30mg tablets
62219391|NCT01030406|EXPERIMENTAL|80/480mg taken first|8x oxycodone/niacin 10/60mg tablets
62413868|NCT05888649||Cluster 3|Communities receptive to EVD vaccination
62413869|NCT05888649||Cluster 4|Communities resistance to EVD vaccination
62413870|NCT05258500|EXPERIMENTAL|Ghostly|The first arm consists of a strength training program incorporated in the Ghostly game that will be given to the patient to be completed without supervision of the therapist as an added exercise program to their conventional therapy.
62413871|NCT05258500|EXPERIMENTAL|Blood flow restriction and Ghoslty|The second intervention arm incorporates blood flow restriction into the conventional therapy using the Smart Cuffs PRO system (Smart Tools, USA). Additionally, these participants will receive additional exercises added to their conventional therapy using the Ghostly game
62413872|NCT05258500|ACTIVE_COMPARATOR|Control|The control group will not be given the Ghostly game as additional exercises to complete after their conventional therapy, but will receive instructions for a strength training program targeting the same muscles as both intervention groups.
62586809|NCT06234462|EXPERIMENTAL|Standard of Care + Amantadine|Participants in this arm will review standard of care and amantadine.
62795367|NCT03052244|EXPERIMENTAL|intervention tDCS+VI|The anode will be placed over C3-C4 (EEG 10/20 system) to target M1 and the cathode over the contralateral supraorbital area. The stimulation will apply to the hemisphere which contralateral to the more painful hemi body. 2mA will be delivered over 20 min via neuroConn DC stimulator combined with video presenting walking legs. A total of 10 sessions (5 per week) will be administrated at the same manner.
62023142|NCT01736826||Group P: pregnancy w/complications|"The patient is pregnant and has complications typical of placental vascular disease (preeclampsia, eclampsia, HELLP syndrome, retro-placental hematoma, in utero fetal death) or venous thromboembolism (deep vein thrombosis, pulmonary embolism).~100 patients will be included.~Interventions to be administered: Bloodwork, baseline"
62219392|NCT01030406|PLACEBO_COMPARATOR|0/0mg taken first|Placebo
62219393|NCT00468104|ACTIVE_COMPARATOR|Alteplase, Placebo- intapleural instillation|Either 25 mg of Alteplase or Placebo instilled daily. Response to therapy after three days. cross over to the other drug if no response was noted.
62219394|NCT00468104|ACTIVE_COMPARATOR|Placebo, Alteplase -2nd arm|If the first arm fails then the 2nd arm ( cross over to either Placebo or Alteplase not used in the first arm) instilled intrapleurally daily for three days
62219395|NCT03058029|EXPERIMENTAL|Gelesis200|Gelesis200: Three (3) Gelesis200 capsules (2.10 gram (g)) two (2) times per day (id est (i.e.), lunch and dinner)
62219396|NCT03058029|PLACEBO_COMPARATOR|Placebo|Placebo: Three (3) placebo capsules two (2) times per day (i.e., lunch and dinner)
62219397|NCT03925545|EXPERIMENTAL|Unilateral|Implantation with the FluidVision AIOL in one eye during cataract surgery. Only one eye was treated.
62586810|NCT04373811||Principal cohort|"Quality of life, autonomy and survival will be assessed at one year on 50 patients.~Safety of early mobilization in post-ICU setting and Medical Reasearch Council (MRC) sum score will be assessed during hospitalization."
62219398|NCT03925545|EXPERIMENTAL|Contralateral|Implantation with the FluidVision AIOL in the first eye during cataract surgery, followed by implantation with the AcrySof IQ monofocal IOL in the fellow eye during a subsequent cataract surgery
62586811|NCT04373811||Lung cohort|Lung Ultrasound will be carried out on the first 38 patients of the principal cohort.
62219399|NCT03075410|EXPERIMENTAL|Cohort 1- GSK3036656 in Part A|During Part A (Cohort 1), Subjects will receive a single dose of GSK3036656 in the morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. The total daily dose for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The starting dose in Part A will be 5 mg and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
62219400|NCT03075410|PLACEBO_COMPARATOR|Cohort 1- Placebo in Part A|During Part A (Cohort 1), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. Placebo for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
62586812|NCT04373811||Muscle cohort|Muscle Ultrasound will be carried out on the first 27 patients of the principal cohort.
62219401|NCT03075410|EXPERIMENTAL|Cohort 2- GSK3036656 in Part A|During Part A (Cohort 2), Subjects will receive a single dose of GSK3036656 in morning on Day 1 in each period after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. The total dose for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The dose will be selected on basis of safety, tolerability and PK data from the previous treatment period or cohort and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
62219402|NCT03075410|PLACEBO_COMPARATOR|Cohort 2- Placebo in Part A|During Part A (Cohort 2), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. Placebo for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
62219403|NCT03075410|EXPERIMENTAL|Cohort 3- GSK3036656 in Part B|During Part B (Cohort 3), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from Part A. Subjects will be followed up to 2 weeks from the last dose.
62219404|NCT03075410|PLACEBO_COMPARATOR|Cohort 3- Placebo in Part B|During Part B (Cohort 3), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
62433327|NCT03558997|EXPERIMENTAL|SCIT|Participants received SCIT titrated up to a 4000 bioequivalent allergy unit (BAU) for 8 weeks followed by maintenance dose of 4000 BAU for following 8 weeks and SC injections of placebo matched to Dupilumab Q2W for 16 weeks. Both SCIT and placebo matched to Dupilumab doses were administered with a gap of 1 or 7 days.
62586813|NCT02464774|EXPERIMENTAL|Breast-Conserving Therapy|"1. Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.~2. Within 4-8 weeks after surgery, patients receive adjuvant chemotherapy as follows:~   TC for stage I: Docetaxel 75 mg/m + Cyclophosphamide 600 mg/m, cycled every 21 days for 4 cycles.~   TAC for stage II: Docetaxel 75 mg/m + Doxorubicin 50 mg/m + Cyclophosphamide 500 mg/m, cycled every 21 days for 6 cycles.~3. Within 4-8 weeks after completion of chemotherapy, patients undergo radiation therapy as follows:~N0: Radiation therapy to whole breast (+boost to tumor bed). N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes."
62586814|NCT02464774|ACTIVE_COMPARATOR|Mastectomy|"1. Patients undergo mastectomy (MT) with surgical axillary staging.~2. Within 4-8 weeks after surgery, patients receive adjuvant chemotherapy as follows:~TC for stage I: Docetaxel 75 mg/m + Cyclophosphamide 600 mg/m, cycled every 21 days for 4 cycles.~TAC for stage II: Docetaxel 75 mg/m + Doxorubicin 50 mg/m + Cyclophosphamide 500 mg/m, cycled every 21 days for 6 cycles."
62586815|NCT03921840|EXPERIMENTAL|Intervention|Based on the self-efficacy theory, participants in the intervention arm will receive personalized, circadian-based activity guidelines, a 2-hour in person education session, real time physical activity self-monitoring, interactive prompts, biweekly phone consultation with the research team, and financial incentives for achieving weekly physical activity goal.
62586816|NCT03921840|PLACEBO_COMPARATOR|Control|The control group will receive general education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life program book from the National Institute on Aging.
62586817|NCT02950766|EXPERIMENTAL|Neovax in Combination with Ipilimumab|"Patients will undergo surgery with the intent to resect the primary kidney tumor~Neovax is a combination of Poly-ICLC and Neoantigen Peptides~Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22~* In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20~Ipilimumab will be injected within 1 cm of each NeoVax administration"
62586818|NCT02950766|EXPERIMENTAL|NeoVax alone|"Patients will undergo surgery with the intent to resect the primary kidney tumor~Neovax is a combination of Poly-ICLC and Neoantigen Peptides~Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22~* In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20)"
62586819|NCT06547008|EXPERIMENTAL|Army-SPRING|Army-SPRING includes a package of implementation options to support implementation of ASIST
62795368|NCT03052244|SHAM_COMPARATOR|tDCS Sham+VI Sham|The stimulation will be turned on for only short duration (up to 30 sec), the video film will contains graphical illustrations or nature movie without human movement.
62795369|NCT06511102|EXPERIMENTAL|Intervention arm|In the intervention arm, participants are instructed to use ChatGPT for assistance to complete an analytical writing task.
62795370|NCT06511102|NO_INTERVENTION|Control arm|In the control arm, participants are instructed to complete an analytical writing task independently without access to any technology assistance.
62795371|NCT03718026||Patients with Multiple Sclerosis|"* The timed 360° turn test~* Berg Balance Scale~* Timed Up and Go test~* Functional Reach Test~* One-leg stance test~* Four square step test"
62795372|NCT03718026||Healthy Controls|-The timed 360° turn test
62795373|NCT00581581||1|Randomized to cooling (original randomized clinical trial): All children, now 6-8 years old who were randomized to cooling in the original trial were included in this arm. Cooling was achieved via the CoolCap system (Olympic Medical/Natus Corporation) in these babies.
62795374|NCT00581581||2|Randomized to standard care (original randomized clinical trial): All children, now 6-8 years old, who were treated using the standard of care at the time (normal temperature) were included in this arm. Infants' temperatures were monitored per standard of care. Most infants were cared for on an open wamer that was servo-controlled to normal body temperature (37 C) or in a standard bassinette.
62795375|NCT04981379|ACTIVE_COMPARATOR|Hydroxychloroquine + Favipiravir|Hydroxychloroquine 2x200 mg 5 days and favipiravir 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days)
62795376|NCT04981379|ACTIVE_COMPARATOR|Favipiravir + Placebo (Hydroxychloroquine)|Favipiravir 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days) + Placebo (Hydroxychloroquine ) 2x200 mg (5 days)
62413873|NCT04607772|EXPERIMENTAL|Arm A: Selinexor with Bendamustine and Rituximab (S-BR))|Participants will receive a dose of 40 or 60 or 80 milligrams (mg) of selinexor oral tablets on Days 1, 3, and 8 for Cycle 1 to 6 (each cycle consists of 21 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an intravenous (IV) dose of bendamustine 90 milligram per square meter (mg/m\^2) on Days 1 and 2 and IV dose of rituximab 375 mg/m\^2 on Day 1 during primary treatment for Cycle 1 to 6.
62413874|NCT04607772|EXPERIMENTAL|Arm B: Selinexor with Polatuzumab Vedotin and Rituximab (S-PR)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 3, and 8 for Cycle 1 to 6 (each cycle consists of 21 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of polatuzumab vedotin 1.8 milligram per kilogram (mg/kg) and IV dose of rituximab 375 mg/m\^2 on Day 1 during primary treatment for Cycle 1 to 6.
62413875|NCT04607772|EXPERIMENTAL|Arm C: Selinexor, Polatuzumab Vedotin, Bendamustine, Rituximab (S-PBR)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 3, and 8 for Cycle 1 to 6 (each cycle consists of 21 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of polatuzumab vedotin 1.8 mg/kg and IV dose of rituximab 375 mg/m\^2 on Day 1, and IV dose of bendamustine 90 mg/m\^2 on Days 1 and 2 during primary treatment for Cycle 1 to 6.
62413876|NCT04607772|EXPERIMENTAL|Arm D: Selinexor, Rituximab, Gemcitabine, Oxaliplatin (S-R-GemOx)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1 and 3 for Cycle 1 to 6 (each cycle consists of 14 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m\^2, IV dose of gemcitabine 1000 mg/m\^2, and Oxaliplatin IV dose of 100 mg/m\^2 on Day 1 during primary treatment for Cycle 1 to 6.
62413877|NCT04607772|EXPERIMENTAL|Arm E: Selinexor with Ibrutinib and Rituximab (S-IR)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 6 during primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2-4) during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m\^2 on Day 1, and ibrutinib oral dose of 420 or 560 mg once daily on Day 1 to 28 during primary treatment for Cycle 1 to 6. Participants will also receive ibrutinib oral dose of 420 mg once daily at all dose levels during continuous treatment.
62433328|NCT03558997|EXPERIMENTAL|Dupilumab + SCIT|Participants received SC injections of Dupilumab at a loading dose of 600 mg on Day 1, followed by 300 mg Q2W for 16 weeks and SCIT titrated up to 4000 BAU for 8 weeks followed by maintenance dose of 4000 BAU for following 8 weeks. Both SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.
62586820|NCT06547008|PLACEBO_COMPARATOR|Risk Reduction Group (Control)|Risk Reduction Group is a mandated training from National Guard Service members
62413878|NCT04607772|EXPERIMENTAL|Arm F: Selinexor with Lenalidomide and Rituximab (S-LR)|Participants will receive a dose of 40 or 60 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 6 during primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2) during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m\^2 on Day 1, and lenalidomide oral dose of 20 mg once daily on Days 1 to 21 during primary treatment for Cycle 1 to 6. Participants will also receive lenalidomide oral dose of 20 mg on Days 1 to 21 at all dose levels during the continuous treatment.
62413879|NCT04607772|EXPERIMENTAL|Arm G: Selinexor with Lenalidomide and Tafasitamab (S-LT)|Participants will receive a dose of 40 or 60 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 12 during primary treatment and 40 (dose level 1) then 60 mg (dose level 2) during continuous treatment (each cycle consists of 28 days). During the primary treatment, participants will also receive lenalidomide oral dose of 25 mg once daily on Days 1 to 21, and tafasitamab IV dose of 12 mg/kg on Days 1, 8, 15, and 22 for Cycle 1 to 3 and Days 1 and 15 for Cycle 4 to 12. Participants will also receive an IV dose of tafasitamab 12 mg/kg on Days 1 and 15 for all dose levels during the continuous treatment.
62586821|NCT03346681|EXPERIMENTAL|NAC and albuterol|The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).
62586822|NCT03346681|NO_INTERVENTION|Albuterol|Albuterol will be administered via nebulization every six hours.
62023143|NCT01736826||Group T1: Healthy volunteers|"Healthy volunteers with no history of chronic or neoplastic disease.~30 healthy volunteers will be included.~Interventions to be administered: Bloodwork, baseline"
62023144|NCT01736826||Group T2: Pregnancy, no complications|"Pregnant patients with no identifiable pregnancy complications, and no history of chronic or neoplastic disease.~50 pregnant volunteers will be included.~Interventions to be administered: Bloodwork, baseline"
62023145|NCT01736826||Group T1x: 15 Healthy volunteers|"15 Healthy volunteers selected from group T1 (the first 15). These patients will have 2 additional months of follow up.~Interventions to be administered: Blood work, Months 1 \& 2"
62219405|NCT03075410|EXPERIMENTAL|Cohort 4- GSK3036656 in Part B|During Part B (Cohort 4), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
62586823|NCT02206581||young healthy adult athletes|Hydration Monitor measurement of the ultrasound velocity and measures of hydration status including urine specific gravity, plasma and urine osmolality in male and female young adults after undergoing 3% acute dehydration and a 2-hr rehydration period
62586824|NCT03764826|EXPERIMENTAL|CAABT|CAABT(Cochleural Alternating Acoustic Beam Therapy) is an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
62586825|NCT03764826|ACTIVE_COMPARATOR|TMT|TMT(tinnitus masking therapy) is a traditional tinnitus intervention. The masking sound is mainly white noise, and the intensity just covers tinnitus.
62219406|NCT03075410|PLACEBO_COMPARATOR|Cohort 4- Placebo in Part B|During Part B (Cohort 4), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
62219407|NCT03075410|EXPERIMENTAL|Cohort 5- GSK3036656 in Part B|During Part B (Cohort 5), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
62586826|NCT06447597|EXPERIMENTAL|B007|
62586827|NCT06447597|PLACEBO_COMPARATOR|Placebo|
62586828|NCT06682546|EXPERIMENTAL|ET-26 0.6 mg group|0.6mg/kg
62586829|NCT06682546|EXPERIMENTAL|ET-26 0.8mg group|0.8mg/kg
62023146|NCT01736826||Group T2x: 15 Pregnancy, no complications|"15 patients selected from group T2 (the first 15); these patients will have 7 months of follow up during pregnancy.~Interventions to be administered: Bloodwork, Months -1 to -6"
62023147|NCT03697291|EXPERIMENTAL|PS wire|self-invented iECG wire
62023148|NCT03697291|ACTIVE_COMPARATOR|Certodyn|Commercially available iECG system - Certodyn
62586830|NCT06682546|ACTIVE_COMPARATOR|Etomidate group|0.3mg/kg
62795377|NCT04981379|ACTIVE_COMPARATOR|Hydroxychloroquine + Placebo (Favipiravir)|Hydroxychloroquine 2x200 mg (for 5 days) + placebo (favipiravir) 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days)
62586831|NCT06665854|EXPERIMENTAL|Rhythmic Song Group|The rhythmic song group will ring a bell when starting to stimulate the baby, and will code the baby's movements as present/absent via the mobile application; then it will sing a rhythmic song and code the baby's movements as present/absent via the mobile application again.
62023149|NCT05707234|ACTIVE_COMPARATOR|Control Group|"During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.~Patients randomized to the control group will undergo perioperative anesthesia according to the current standards of care, without the addition of the VR headset or headphones."
62586832|NCT06665854|EXPERIMENTAL|Rhythmic Instrument Group|The Rhythmic Instrument Group will ring a bell when starting the application to stimulate the baby, and will code the baby's movements as present/absent via the mobile application; then they will play a rhythmic instrument and code the baby's movements as present/absent via the mobile application again.
62219408|NCT03075410|PLACEBO_COMPARATOR|Cohort 5- Placebo in Part B|During Part B (Cohort 5), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
62586833|NCT06665854|PLACEBO_COMPARATOR|Control Group|The control group will ring a bell to warn the baby, they will code the baby's movements as present/absent via the mobile application again, and they will only rest.
62586834|NCT03644485|EXPERIMENTAL|Standard Prograf group|Participants received from day 1 tacrolimus immediate-release formulation (Prograf) 0.1 - 0.15 milligrams/kilograms/day (mg/kg/day) orally at 12-hour interval (twice daily 1 hour before meal or 2 hours after meal) for approximately 1 month. At 1 month after Kidney transplant, Prograf was converted to Advagraf on a 1:1 (mg: mg) total daily dose basis. The Advagraf was administered orally once daily in the morning, 1 hour before the breakfast; the whole blood target trough level for Advagraf was maintained as 6 - 12 nanograms/milliliter(ng/mL) within months 2 to 3, and 6 - 8 ng/mL within months 4 to 6.
62586835|NCT03644485|EXPERIMENTAL|Delayed Prograf group|Participants received from day 3 to 5 Prograf 0.1 - 0.15 mg/kg/day orally at 12-hour interval (twice daily 1 hour before meal or 2 hours after meal) for approximately 1 month. At 1 month after Kidney transplant, Prograf was converted to Advagraf on a 1:1 (mg: mg) total daily dose basis. The Advagraf was administered orally once daily in the morning, 1 hour before the breakfast; the whole blood target trough level for Advagraf was maintained as 6 - 12 ng/mL within months 2 to 3, and 6 - 8 ng/mL within months 4 to 6.
62586836|NCT02797457|OTHER|Allograft|Bilateral allograft of the hands and forearms.
62586837|NCT02797457|OTHER|Prostheses|Prosthetic forehands
62586838|NCT04004455||Childhood cancer|Children with an established cancer diagnosis (any type) between 8-18 years old that are currently being treated for cancer (not necessarily hospitalized) in the University Hospital Brussels or Ghent.
62586839|NCT04004455||Healthy controls|Healthy children between 8-12 years old, selected based on age and sex.
62586840|NCT05261724||Patients with primary brain tumors|
62586841|NCT05261724||Patients with secondary brain tumors|
62586842|NCT06244212|ACTIVE_COMPARATOR|Demonstration|Observe a live demonstration instructing how to dispense 1 fingertip unit (FTU) of medication (triamcinolone cream) per 1% body surface area
62586843|NCT06244212|EXPERIMENTAL|Mobile Application|Additional mobile application that provides instructions to apply the medication (triamcinolone cream)
62586844|NCT06244212|OTHER|Written/verbal instructions only|Standard of care written/verbal instructions only
62586845|NCT04168827||Relatives of severe traumatized child|Relatives of a child who has been hospitalized in intensive care of Necker hospital following a severe trauma
62586846|NCT06544135||FLIR thermal imaging group|Temperature measurements will be taken of the lower limb using the FLIR camera and correlated with other aspects of each patient.
62586847|NCT02693106|EXPERIMENTAL|Ketogenic potential|"Each participant has to go through a total of 8 visits, each visit corresponding to a standardize breakfast taken alone (control visit) or with one of the dietary supplements evaluated followed by a period of 4-hour with multiple blood sampling.~Intervention 1: Control; no supplement Intervention 2: 5 g of leucine Intervention 3: 3.6 g of butyrate Intervention 4: 7.2 g of butyrate Intervention 5: 5 g of octanoate Intervention 6: 10 g of octanoate Intervention 7: 1.95 g of carnitine Intervention 8: 65 g of butter fraction rich in MCT"
62586848|NCT02740868|ACTIVE_COMPARATOR|Healthy|Healthy Participants ages 8 and older. Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane). Participants will undergo magnetic resonance imaging and lung clearance index.
62586849|NCT02740868|ACTIVE_COMPARATOR|Cystic Fibrisos|Participants with cystic fibrosis ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane). Participants will undergo magnetic resonance imaging and lung clearance index.
62795378|NCT04981379|PLACEBO_COMPARATOR|Placebo (Favipiravir) + Placebo (Hydroxychloroquine)|Placebo (favipiravir) 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days) + Placebo (Hydroxychloroquine) 2x200 mg (5 days)
62795379|NCT05289986|EXPERIMENTAL|immediate switch arm|"Experimental arm (baseline visit switch group, N=30): One DOR/TDF/3TC tablet taken orally once daily for 48 weeks.~Virally suppressed participants on a stable combined ART regimen will be randomised (1:1) to an immediate switch to 3TC/TDF/DOR (immediate switch arm, N=30) for the duration of the 48-week study, or to maintaining their current cART followed by a switch to 3TC/TDF/DOR from week 24-48 (delayed switch arm, N=30). Participants will be monitored for the length of the study (48 weeks) plus a 30-day follow-up period."
62795380|NCT05289986|ACTIVE_COMPARATOR|delayed switch arm|"Control arm (deferred switch group, N=30): Participants will continue their current triple cART regimen for 24 weeks, and then switched to taking one TDF/3TC/DOR tablet orally once daily (24 -48 weeks).~Virally suppressed participants on a stable combined ART regimen will be randomised (1:1) to an immediate switch to 3TC/TDF/DOR (immediate switch arm, N=30) for the duration of the 48-week study, or to maintaining their current cART followed by a switch to 3TC/TDF/DOR from week 24-48 (delayed switch arm, N=30). Participants will be monitored for the length of the study (48 weeks) plus a 30-day follow-up period."
62795381|NCT06169449|EXPERIMENTAL|Weight management Group|Patients in the weight management group used a weight management model that included diet, exercise, accompany and refresh.
62023150|NCT05707234|EXPERIMENTAL|VRH Group|"They will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli.~During the whole procedure, an anesthesiologist will perform the usual cares, including closely monitoring, and will administrate intravenous sedation (midazolam) when necessary (see sedation protocol in the previous section)."
62413880|NCT04607772|EXPERIMENTAL|Arm H: Selinexor with Venetoclax (S-V)|Participants will receive 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 8 and 15 for Cycle 1 to 6 of primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2-5) during continuous treatment (28 days per cycle). Participants who received 40 and 60 mg of selinexor during primary treatment will also receive oral dose of venetoclax 200 mg on Days 1 to 7 then 400 mg on Days 8 to 28 for Cycle 1; 400 mg daily for Cycle 2 to 6. Participants who received 60 and 80 mg of selinexor during primary treatment will also receive venetoclax 400 mg orally on Days 1 to 7 then 600 mg on Days 8 to 28 for Cycle 1; 600 mg daily for Cycle 2 to 6. Participants who received 80 mg selinexor during primary treatment will also receive venetoclax 400 mg orally on Days 1 to 7, then 600 mg from Days 8 to 14, then 800 mg from Day 15 to 28 for Cycle 1; 800 mg daily for Cycle 2 to 6. Participants during continuous treatment will also receive venetoclax 400 mg orally daily.
62413881|NCT06371911|EXPERIMENTAL|Cureety telemonitoring|The digital telemonitoring platform, Cureety, has been designed to facilitate the monitoring of signs and symptoms of treatment-specific AEs and disease progression. The platform integrates Cureety TechCare, a CE marked algorithm that is a class I medical device
62795382|NCT06169449|OTHER|Control Group|Patients in the control group underwent routine care for self-weight management.
62795383|NCT01639053||Gel Participants|
62795384|NCT01639053||Control Participants|
62795385|NCT06419712|EXPERIMENTAL|Daily Vitamin D Supplementation Group|This arm of the study involves daily administration of vitamin D to participants, with the dosage adjusted based on body weight and initial vitamin D levels, aiming to achieve and maintain optimal serum vitamin D levels
62795386|NCT06419712|EXPERIMENTAL|Weekly Bolus Vitamin D Supplementation Group|This arm of the study involves administering a weekly bolus dose of vitamin D, equivalent to the total daily dose accumulated over the week, to investigate the efficacy of this regimen in improving vitamin D levels and reducing post-COVID-19 symptoms.
62795387|NCT05975645|EXPERIMENTAL|TQB2618 injection +Penpulimab injection+ Anlotinib Hydrochloride Capsules|Intravenous infusion of TQB2618 Injection 1200mg and Penpulimab Injection 200mg on 1st day, combining with Anlotinib capsules 10mg given orally in fasting conditions once daily in each 21-day cycle. (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
62795388|NCT01543074|PLACEBO_COMPARATOR|BSE placebo & garlic oil placebo|Two BSE placebo capsules and one garlic oil placebo capsule per day for seven days
62795389|NCT01543074|ACTIVE_COMPARATOR|garlic oil plus BSE placebo|one garlic oil capsule plus 2 BSE placebo capsules per day for seven days
62795390|NCT01543074|ACTIVE_COMPARATOR|BSE plus garlic oil placebo|two BSE capsules plus one garlic oil placebo capsule per day for seven days
62795391|NCT01543074|ACTIVE_COMPARATOR|BSE & Garlic Oil|two BSE and one garlic oil capsule per day for seven days
62795392|NCT06259669||Infants of women exposed to ruxolitinib cream during pregnancy|
62413882|NCT06371911|ACTIVE_COMPARATOR|OPTIMA or equivalent programs|"The programs consist of three stages:~1. The medical team make structured telephone calls with patients 2 to 3 days before the planned administration of injectable treatment. Adverse events and other relevant data are collected.~2. Patients undergo biological tests within 48 hours of the appointment and the results are sent by the laboratory to the centre.~3. Then, the physician assesses the data and decides whether to anticipate and validate the prescription of injectable treatments."
62413883|NCT02758509||PEG/RBV|Pegylated interferon alfa-2a 180 microg/week plus ribavirin 800-1200 mg during 48 weeks according to routine practice and European Guidelines (EASL recommendations 2011)
62413884|NCT02758509||PEG/RBV+BOC or TVR|Boceprevir 800 mg/8h or Telaprevir 750 mg/8h plus Pegylated interferon alfa-2a 180 microg/week plus ribavirin 800-1200 mg during 48 weeks according to routine practice and European Guidelines (EASL recommendations 2014)
62795393|NCT06259669||Infants of women not exposed to ruxolitinib cream during pregnancy|
62795394|NCT02529163|ACTIVE_COMPARATOR|Late-life Schizophrenia ICP|"The Late-Life Schizophrenia ICP arm will follow a medication algorithm composed of 3 trials and titration schedule with prompts.~First trial is Risperidone (2- 4mg daily).~Second trial: Quetiapine (100 - 400mg daily) OR Aripiprazole (100 - 200mg daily) OR OR Ziprasidone (80mg daily) OR Loxapine (100mg daily)~Third trial: Clozapine (450mg daily) or Olanzapine (20mg daily)~If non compliant depot preparation of: Paliperidone (50 - 150mg monthly), Risperidone (12.5 - 50mg q 2 weeks), Flupentixol (10 - 20mg q 2-3 weeks) or Aripiprazole ( up to 400mg monthly)~Prompts will be given to for non-pharmacological interventions such as:~* metabolic monitoring~* skin hygiene~* pain management~* nutritional counseling~* counseling"
62023151|NCT01958151||Sedated colonoscopy|"Planned colonoscopies for screening under propofol sedation titrated to reach a bispectal index value of 60.~Anxiety levels are assessed before the procedure with State-Trait Anxiety Inventory Scores."
62219409|NCT03075410|EXPERIMENTAL|Cohort 6- GSK3036656 in Part B|During Part B (Cohort 6), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
62413885|NCT02758509||IF-DAAs|"Interferon-free direct-acting antiviral combinations according to routine practice and European Guidelines (EASL recommendations 2015)~* Fixed-dose combination of sofosbuvir (400 mg) and ledipasvir (90 mg) daily +/- ribavirin 12-24 weeks~* Fixed-dose combination of ombitasvir (75 mg), paritaprevir (12.5 mg) and ritonavir (50 mg) in one single tablet (two tablets once daily) and dasabuvir (250 mg) (one tablet twice daily) with ribavirin 800-1200 mg 12 weeks (Genotype 1b) or 24 weeks (genotype 1a)~* Daily sofosbuvir (400 mg) and daily simeprevir (150 mg) +/- ribavirin 12-24 weeks~* Daily sofosbuvir (400 mg) and daily daclatasvir (60 mg) +/- ribavirin 12-24 weeks"
62413886|NCT01166074||SCIG|
62413887|NCT02208934|EXPERIMENTAL|PBF-999 (5 mg)|5 mg of PBF-999
62413888|NCT02208934|EXPERIMENTAL|PBF-999 (10 mg)|10 mg of PBF-999
62795395|NCT02529163|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|The TAU will not receive any prompts to follow a specific treatment. The TAU group will be treated according to the current standard of care by the treating physician. They will have an opportunity to be offered the same non-pharmacological interventions seen with the ICP group but at the discretion of the treating physician. Pharmacological interventions will include an anti-psychotic medication that is selected at the discretion of treating physician with no set titration schedule or timeline to meet a maximum dosage. Max dosage will be decided by the treating physician.
62795396|NCT05335876|EXPERIMENTAL|Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec|Patients who received OAV101 IT or OAV101 IV in clinical trials (COAV101A12306, COAV101B12301 and COAV101B12302)
62219410|NCT03075410|PLACEBO_COMPARATOR|Cohort 6- Placebo in Part B|During Part B (Cohort 6), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
62795397|NCT02068794|EXPERIMENTAL|Treatment (MV-NIS infected mesenchymal stem cells)|"Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IP over 30 minutes on day 1 of cycle 1 and MV-NIS infected MSC (if MSC are not available, MV-NIS may be given alone) IP over 30 minutes of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~Additionally, patients undergo ECHO or MUGA prior to registration and blood sample collection, chest X-ray, SPECT/CT, CT or MRI throughout the study."
62023152|NCT06532110||Chronic gastrointestinal disorders|A cohort of 260 patients (150 diagnosed with IBD, 40 with IBS, 30 with celiac disease, 10 with MC, 10 with functional diarrhea and 30 non-disease controls) of either sex between 18 and 75 years of age consulting to either the GI Clinical Investigation, the Endoscopy Unit (McMaster University)
62023153|NCT04095377||healthy|
62023154|NCT04095377||CVA|
62023155|NCT04095377||Hammorhage|
62219411|NCT01049932|EXPERIMENTAL|All subjects|TMC278LA 600mg injected intramuscularly (i/m)
62219412|NCT00116883|EXPERIMENTAL|Arm 1|
62219413|NCT06231654|EXPERIMENTAL|patents|the child will be placed in a dedicated, quiet, well-lit office with their parents. The following data are then collected: sex, age, phototype according to Fitzpatrick's classification. The child sits in a chair facing a camera connected to a laptop running Caducy® Medical Device software. At the same time, and following the usual procedure, three ECG electrodes will be positioned on the patient.
62219414|NCT02686684||Dimethyl Fumarate|MS patients who started treatment with dimethyl fumarate
62219415|NCT02686684||Healthy Control|
62219416|NCT01417650|ACTIVE_COMPARATOR|laser|In this group, the 890 nm diode laser (Mustang 2000+,Russia) will be used with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
62413889|NCT02208934|EXPERIMENTAL|PBF-999 (20 mg)|20 mg of PBF-999
62413890|NCT02208934|EXPERIMENTAL|PBF-999 (40 mg)|40 mg of PBF-999
62219417|NCT01417650|PLACEBO_COMPARATOR|placebo|In this group the low power laser will be applied with minimal dose that is very lower than the threshold necessary for therapeutic effects.
62413891|NCT02208934|PLACEBO_COMPARATOR|Placebo|Placebo for the 5, 10, 20 and 40 mg dose
62413892|NCT04969991|EXPERIMENTAL|Varespladib: 250 mg QD + Placebo + placebo|For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning. In order to maintain the blind, they will also take 1 placebo tablet in the afternoon and 1 placebo tablet in the evening.
62023156|NCT04095377||TBI|
62023157|NCT04095377||Concussion|
62023158|NCT04095377||Fibromyalgia|
62413893|NCT04969991|EXPERIMENTAL|Varespladib: 250 mg BID + placebo|For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning and in the evening. In order to maintain the blind, they will also take 1 placebo tablet in the afternoon.
62413894|NCT04969991|EXPERIMENTAL|Varespladib: 250 mg TID|For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning, in the afternoon, and in the evening.
62413895|NCT04969991|PLACEBO_COMPARATOR|Placebo|For 7 days, and in addition to institutional standard of care, participants will take 1 placebo tablet in the morning, in the afternoon, and in the evening.
62413896|NCT04969991|EXPERIMENTAL|Varespladib: 250mg BID (Part 2 of trial)|Dose chosen for Part 2 was twice a day dosing. For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning, and in the evening.
62219418|NCT06610552|EXPERIMENTAL|Intervention - Powerly|Participants in the intervention group will complete baseline questionnaires and receive instructions on how to download Powerly. They will use the app daily for 28 days, at least once per day, and will be invited to complete the questionnaires again, and once more six weeks postpartum.
62219419|NCT06610552|NO_INTERVENTION|Care as usual|Participants in the CAU group will complete baseline questionnaires and be informed that they will receive access to Powerly six weeks postpartum. They will be invited to complete the questionnaires again 28 days later, and once more six weeks postpartum.
62219420|NCT03916939|EXPERIMENTAL|Osteopathy|osteopathic treatment
62413897|NCT04969991|PLACEBO_COMPARATOR|Placebo (Part 2 of trial)|For 7 days, and in addition to institutional standard of care, participants will take 1 placebo tablet in the morning, and in the afternoon.
62413898|NCT06566352|EXPERIMENTAL|laparoscopic myomectomy with temporary bilateral uterine artery occlusion|laparoscopic myomectomy with temporary bilateral uterine artery occlusion
62219421|NCT03916939|PLACEBO_COMPARATOR|simulated osteopathy|simulated osteopathic treatment
62219422|NCT02570685|EXPERIMENTAL|Reflective Interpersonal Gratitude|An interpersonal gratitude journal, designed to foster gratitude for one's existing social relationships, by writing and reflecting on people and positive daily encounters for which one is grateful.
62219423|NCT02570685|EXPERIMENTAL|Reflective-Behavioral Gratitude|An interpersonal gratitude journal, designed to foster gratitude for one's existing social relationships, by writing and reflecting on people and positive daily encounters for which one is grateful. In addition participants are asked to choose a friend express this gratitude to them at the end of each week.
62413899|NCT06566352|EXPERIMENTAL|Laparoscopic myomectomy with intramyometrial injection of diluted epinephrine|Laparoscopic myomectomy with intramyometrial injection of diluted epinephrine
62413900|NCT06566352|EXPERIMENTAL|traditional laparoscopic myomectomy|traditional laparoscopic myomectomy
62023159|NCT04095377||ABD|
62023160|NCT04095377||ADHD|
62023161|NCT04095377||MCI|
62023162|NCT04095377||DEMENTIA|
62219424|NCT02570685|ACTIVE_COMPARATOR|Neutral Control Journal|Write about and reflect on things that occurred over the course of the day.
62219425|NCT03141723|ACTIVE_COMPARATOR|KMC & WHO protocol (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
62219426|NCT03141723|ACTIVE_COMPARATOR|KMC & WHO protocol (1-24 hours)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
62219427|NCT03141723|EXPERIMENTAL|KMC, WHO protocol & bag (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
62219428|NCT03141723|EXPERIMENTAL|KMC, WHO protocol & bag (1-24 hours|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
62219429|NCT06068595|OTHER|Patients|Patient with musculoskeletal anomalies
62219430|NCT04772482||All Participants|All participants will undergo path testing to determine skin sensitivity to certain compounds.
62219431|NCT02262247||Transoral Visualization & Access|Subjects ≥ 22 yrs requiring transoral procedures
62219432|NCT01467726|EXPERIMENTAL|Dose regimen 1|Varied doses
62413901|NCT04556877||Intraabdominal pressure under 12 mmHg|Patients with intraabdominal pressure under 12 mmHg
62413902|NCT04556877||Intraabdominal pressure between 12-20 mmHg|Patients with intraabdominal pressure between 12-20 mmHg
62413903|NCT04556877||Intraabdominal pressure over 20 mmHg|Patients with intraabdominal pressure over 20 mmHg
62413904|NCT04875637|OTHER|MEMR Diagnostic Evaluation|Middle Ear Muscle Reflex using wideband acoustic reflectance to assess hearing status.
62413905|NCT03829527|EXPERIMENTAL|Psychotherapy|
62413906|NCT00003786|EXPERIMENTAL|Arm A|MGI-114 (11mg/m2/day x 5 days every 28 days)
62219433|NCT01467726|EXPERIMENTAL|Dose regimen 2|Varied doses
62219434|NCT01467726|EXPERIMENTAL|Placebo|Matching placebo
62219435|NCT01018303|EXPERIMENTAL|Antioxidant-enriched multivitamin supplement|
62219436|NCT01744392|EXPERIMENTAL|education intervention|The intervention provides a personalized Meducation calendar to all patients enrolled in the study (identified in package as Example Calendar). The Meducation Calendar will include medications for diabetes (sugar), high blood pressure, cholesterol, heart medications and blood thinning medications. The medication calendars contains the following for each medication 1) the name, 2) the time of day, including a pictorial display, it should be taken 3) the number of times each day to take the medication, and 4) the indication for the medication.
62795398|NCT03660761|EXPERIMENTAL|apatinib 500mg|
62795399|NCT04254484|EXPERIMENTAL|SIESTA Rehab|"Stroke floor on which nurses will be receiving training (SIESTA Rehab Education) on how to minimize nighttime disruptions and batching overnight tasks to preserve sleep for patients hospitalized on that floor. Stroke patients admitted to the SIESTA Rehab Unit will be screening for sleep disordered breathing using ApneaLink.~Patients hospitalized on this unit will be approached for consent to wear sensors and actigraphy watches during the hospital stay and after discharge."
62795400|NCT04254484|NO_INTERVENTION|Control Unit|"Patients on this unit will receive usual care for stroke patients as outlined by SRALab. including routine nursing care without any intervention to promote sleep like SIESTA and routing sleep disorders screenings based on clinician judgement.~Patients hospitalized on this unit will also be approached for consent to wear sensors and actigraphy watches during the hospital stay and after discharge."
62795401|NCT06727006||Patients with acute large vessel occlusion stroke undergoing rescue stenting|
62219437|NCT02850484|ACTIVE_COMPARATOR|Reference 1 Symbicort Inhaler 160/4.5μg|Reference 1: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
62219438|NCT02850484|EXPERIMENTAL|SYN010 HFA Inhaler|SYN010 HFA (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
62413907|NCT00602927|PLACEBO_COMPARATOR|Placebo|
62413908|NCT00602927|ACTIVE_COMPARATOR|Varenicline|
62413909|NCT05297149|EXPERIMENTAL|hippotherapy group|Participants that are performed hippotherapy
62795402|NCT03282890|EXPERIMENTAL|CHRP-BB|Patients assigned to the CHRP-BB will receive a weekly HIV risk reduction and PrEP adherence group level intervention led by two facilitators trained and supervised by the PI, a licensed clinical psychologist. It is a substantially shortened version of the comprehensive Holistic Health Recovery Program (HHRP)-based interventions that have been identified as demonstrating evidence of effectiveness in two randomized clinical trials. The CHRP-BB, which includes four 50-minute groups (1 group per week), will contain only content that relates explicitly to drug- or sex-related HIV risk reduction and PrEP adherence. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
62219439|NCT02850484|ACTIVE_COMPARATOR|Reference 2 Symbicort Inhaler 160/4.5μg|Reference 2: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
62413910|NCT05297149|ACTIVE_COMPARATOR|Control group|Participants that are performed home exercise program
62413911|NCT03545360|EXPERIMENTAL|Treatment Group|Treated group of subjects, serves as its own control
62586850|NCT02740868|ACTIVE_COMPARATOR|Asthma|Participants with asthma ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane). Participants will undergo magnetic resonance imaging and lung clearance index.
62586851|NCT06140758|ACTIVE_COMPARATOR|Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice|
62795403|NCT03282890|NO_INTERVENTION|Control Condition|The time-and-attention-matched control condition for the proposed research will be a time and contact-matched, non-contaminating support group for individuals in recovery modeled after similar groups offered in the community. There will be no overlap between the content of the comparison intervention and experimental intervention although the basic structure will be the same. Thus, each participant will be asked to attend four 50-minute weekly group sessions led by two trained facilitators. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
62795404|NCT02920749|OTHER|Sevoflurane group A|Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture.
62023163|NCT04095377||COGNITIVE IMPAIRMENT|
62219440|NCT04664543|ACTIVE_COMPARATOR|3 days of low residue diet|Currently participants in the colorectal cancer screening program follow a 3 days low residue diet before colonoscopy. This is the active comparator arm of this study.
62219441|NCT04664543|EXPERIMENTAL|Free diet|Participants assigned to this arm are NOT instructed to follow any kind of restriction in the diet before colonoscopy.
62219442|NCT02825862|NO_INTERVENTION|Replication group|Replication group - this group will complete the entire questionnaire, in order to replicate the findings of O'Carroll et al (2011)
62219443|NCT02825862|ACTIVE_COMPARATOR|Omit affective attitudes|Omitting affective attitudes The intervention is the omission of all questions on affective attitudes. This group will complete a similar questionnaire to the replication group, with the same number of questionnaire items, but affective attitudes will be omitted. Dummy questions (e.g. about politics) will be substituted for these deleted questions.
62413912|NCT03494673||Control|Normal controls without headaches will undergo BOLD MRI with prospective CO2 targeting
62413913|NCT03494673||Migraineurs|Patients diagnosed with migraine based on the ICHD-3 beta will undergo BOLD MRI with prospective CO2 targeting
62413914|NCT03780452||Tibiotalocalcaneal arthrodesis with DynaNail|Tibiotalocalcaneal arthrodesis with a novel dynamic compression intramedullary nail
62413915|NCT01615900|OTHER|Teleconsultation|
62413916|NCT01615900|OTHER|Standard consultation|
62413917|NCT05244109|EXPERIMENTAL|NSAIDs|Patients responding to any class of NSAIDs and unlikely to initiate biotherapy
62413918|NCT05244109|EXPERIMENTAL|Anti-TNF antibody|Patients requiring the introduction of biotherapy according to current recommendations and randomized to the anti-TNF treatment arm
62413919|NCT05244109|EXPERIMENTAL|Anti-IL17 antibody|Patients requiring the introduction of biotherapy according to current recommendations and randomized to the anti-IL-17 treatment arm
62586852|NCT06140758|ACTIVE_COMPARATOR|Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice|
62219444|NCT02825862|ACTIVE_COMPARATOR|Omit negatively-worded items|Omitting negatively-worded affective attitudes. This intervention is the omission of a subset of negatively-worded affective attitudinal items. This group will complete a similar questionnaire to the replication group, with the same number of items, but all negatively-worded affective attitudes will be omitted. Dummy questions (e.g. about politics) will be substituted for these deleted questions.
62219445|NCT04193124||Prolonged vasospasm|Adult patients with a diagnosis of subarcnoid hemorrhage CT scan or presence of blood in the cerebrospinal fluid were incorporated. Patients with vasospasm were followed daily with transcranial doppler. Prolonged vasospasm was defined for patients who persisted with vasospasm after day 21 of cerebral bleeding.
62219446|NCT04029194|EXPERIMENTAL|Treatment|
62219447|NCT04029194|NO_INTERVENTION|Control|
62586853|NCT06140758|SHAM_COMPARATOR|Toms of Maine 0 ppm Fluoride Dentifrice|
62586854|NCT06140758|ACTIVE_COMPARATOR|Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice|
62219448|NCT00619333|OTHER|1|
62586855|NCT06140758|ACTIVE_COMPARATOR|1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice|
62586856|NCT06140758|ACTIVE_COMPARATOR|1100 ppm (0.454% Stannous fluoride) Dentifrice|
62219449|NCT01559779||Normal glucose tolerance|Morbidly obese subjects with normal glucose tolerance undergoing gastric bypass surgery
62219450|NCT02845362|EXPERIMENTAL|Dysphagia assessment|
62219451|NCT06062290||neonates|birth to \<28 days
62219452|NCT06062290||infants|28 days to ≤3 months
62219453|NCT06062290||toddlers|\>3 months to ≤2 years
62023164|NCT04095377||COGNITIVE DECLINE|
62219454|NCT06062290||children|\>2 years to \<5 years
62219455|NCT05939141||OLE Subjects|adult OSA patients with and without complete concentric collapse of the soft palate who have successfully been implanted with the Genio IS in a Nyxoah sponsored Clinical Investigation and having the device in-situ at the time of enrollment (with therapy activated or de-activated).
62219456|NCT03170349|EXPERIMENTAL|Edwards PASCAL Transcatheter Mitral Valve Repair System|
62219457|NCT00714545|NO_INTERVENTION|prospective study|This study is a prospective study of patients treated at Scripps Clinic with intracoronary brachytherapy for recurrent restenosis within drug-eluting stents. Beta irradiation with a 40-mm strontium/yttrium-90 source. No placebo will be used in this trial.
62586857|NCT05081479|EXPERIMENTAL|Participants with Lymphoma, Cohort 1|The first dose escalation cohort in the study will be treated at 25% of that target dose level
62219458|NCT05979350|ACTIVE_COMPARATOR|Standard care group|Endotracheal aspirates, blood samples, urine samples, and nasopharyngeal swabs were obtained from the patients as soon as possible after ICU admission. Bacterial culture was performed, with the use of standard techniques, on blood samples and endotracheal aspirates. Urine antigen detection was performed for detection of L. pneumophila and S. pneumoniae. A PCR assay was performed on nasopharyngeal swabs for the detection of influenza A and B viruses and SARS-CoV-2 viruses. Fungal or mycobacterial detections, and whether to use multiplex PCR for pathogen detection, such as the FilmArray system, were determined at the discretion of the physicians.
62219459|NCT05979350|EXPERIMENTAL|mNGS group|Subjects assigned to the mNGS group will receive etiology work-up followed the protocol used in the standard care group and additional mNGS testing for two specimen of mini-bronchoalveolar lavage and one specimen of blood samples retrieved at the same time of standard work-up.
62413920|NCT02779686||ARMD Free|Patient free of ARMD on clinical examination
62413921|NCT02779686||ARMD Positive|Patients with evidence of ARMD on clinical examination
62413922|NCT00532779|EXPERIMENTAL|NB16|Naltrexone SR 16 mg/Bupropion SR 360 mg /day with ancillary therapy
62413923|NCT00532779|EXPERIMENTAL|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg /day with ancillary therapy
62413924|NCT00532779|PLACEBO_COMPARATOR|Placebo|Placebo with ancillary therapy
62586858|NCT05081479|EXPERIMENTAL|Participants with Lymphoma, Cohort 2|The second cohort in the study will be treated at 50% of that target dose level
62795405|NCT02920749|OTHER|Sevoflurane group B|Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
62795406|NCT02920749|OTHER|Propofol group C|During anaesthesia TIVA was applied with a protocol (6 to 8 mg/kg/h propofol).
62023165|NCT04095377||MS|
62219460|NCT06322979|ACTIVE_COMPARATOR|MTA group|After the endodontic procedure, MTA will be placed into the apical 4 mm of the root canals. then a moist cotton pellet will be placed and the access cavity will be restored with GIC. Next day, GIC and the cotton pellet will be removed the coronal and middle third of the root canal will be filled with gutta-percha. The coronal restoration will be completed with GIC, composite.
62413925|NCT01074853|EXPERIMENTAL|Propranolol|Chronic dose escalation of propranolol over period of 6 to 8 weeks.
62413926|NCT01074853|PLACEBO_COMPARATOR|Placebo|Matched placebo used for dose escalation period of 6 to 8 weeks
62413927|NCT02991651|EXPERIMENTAL|Dose Level 1|IRX4204 5 mg/day PO + erlotinib 100 mg/day PO
62413928|NCT02991651|EXPERIMENTAL|Dose Level 2|IRX4204 5 mg/day PO + erlotinib 150 mg/day PO
62413929|NCT02991651|EXPERIMENTAL|Dose Level 3|IRX4204 10 mg/day PO + erlotinib 150 mg/day PO
62413930|NCT00572468|ACTIVE_COMPARATOR|Simvastatin|Twenty-two men will be on the Statin arm and take 40 mg of simvastatin.
62413931|NCT00572468|PLACEBO_COMPARATOR|Placebo|Twenty-two men will be on the placebo arm.
62413932|NCT00713830|EXPERIMENTAL|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
62413933|NCT00713830|PLACEBO_COMPARATOR|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
62413934|NCT01578603|EXPERIMENTAL|sugar substituted chewing gum A|
62413935|NCT01578603|EXPERIMENTAL|Sugar substituted chewing gum B|
62586859|NCT05081479|EXPERIMENTAL|Participants with Lymphoma, Cohort 3|The third cohort in the study will be treated at 100% of that target dose level only if no DLTs are seen at lower doses.
62586860|NCT02987374|OTHER|2011-2012 Fluzone IIV3 (IM)|Seasonal trivalent flu vaccine: NDC No 49281-011-50
62795407|NCT02920749|OTHER|Propofol group D|Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
62219461|NCT06322979|EXPERIMENTAL|Premixed Bioceramic Putty group|After the endodontic procedure, Premixed Bioceramic Putty (Well-Root™ PT) will be placed into the apical 4mm of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha. The coronal restoration will be completed with GIC, composite.
62219462|NCT01358487|ACTIVE_COMPARATOR|Online self-help mood management course|Online self-help mood management course based on cognitive behavioral therapy and social cognitive theory, plus automated online follow ups using email reminders and incentives for completing follow-ups
62219463|NCT01358487|EXPERIMENTAL|Online self-help course plus live follow-up if needed|Intervention and automated follow ups with incentives as in the active comparator condition. The experimental procedure is adding live phone follow-ups if participant does not complete online assessment surveys at 1, 3, and 6 months in response to automated emails.
62219464|NCT01119599|EXPERIMENTAL|Treatment (RO4929097, surgery, radiation therapy)|See Detailed Description.
62219465|NCT03861208|EXPERIMENTAL|diet|high fiber high protein foods served in childcare centers are offered for meals and snacks
62219466|NCT03861208|OTHER|usual diet|foods representing the usual diet in childcare centers are offered for meals and snacks
62219467|NCT02703051|EXPERIMENTAL|GMI-1271|GMI-1271
62795408|NCT06419088|OTHER|individualized education group|received individualized educational interventions utilizing audiovisual materials
62795409|NCT06419088|NO_INTERVENTION|standard education group|only routine preoperative education
62219468|NCT02703051|ACTIVE_COMPARATOR|Filgrastim|Filgrastim
62219469|NCT02703051|EXPERIMENTAL|GMI-1271 with Filgrastim|GMI-1271 with Filgrastim
62219470|NCT02439047|EXPERIMENTAL|Biological samples collection|"-Peritoneal samples : will be collected during abdominal surgery~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum~-Adipose tissue samples : will be collected during surgery for breast reconstruction"
62219471|NCT03715179||Standard of Care|Individuals living with an ostomy and their caregivers. Participants use their own ostomy pouching systems per their clinician's standard of care
62219472|NCT03188393|EXPERIMENTAL|Diagnostic (biopsy of breast)|After completion of neoadjuvant therapy, patients undergo stereotactic biopsy of breast tumor any time prior to breast conserving surgery. Patients then undergo breast conserving surgery as per standard of care. Patients may also undergo postoperative radiation therapy per standard of care or adjuvant therapy at the investigator's discretion.
62219473|NCT04504604|ACTIVE_COMPARATOR|Cholangiocarcinoma|Eligible patients that present with Cholangiocarcinoma.
62023166|NCT04000165|EXPERIMENTAL|AG-348 in participants with Sickle Cell Disease|Intra-patient dose escalating study, starting with 5 mg twice a day, increasing to 20 mg twice a day, to maximum 50 mg or 100 mg twice a day. Dosing period is every 2 weeks at each dose level. Dose taper will start on Day 42 (50 mg) or Day 56 (100 mg) with dose reduced over 12 to 15 days.
62219474|NCT04504604|ACTIVE_COMPARATOR|Cancer of Unknown Primary (CUP)|Eligible patients with cancer of unknown primary site (CUP).
62219475|NCT04504604|ACTIVE_COMPARATOR|Other remaining rare cancers (solid tumors & lymphomas)|Eligible patients that meet the definition of rare cancers (incidence of less than 6 per 100,000 in the United States).
62219476|NCT00950586|EXPERIMENTAL|Cohort 1|14 days dosing
62219477|NCT00950586|EXPERIMENTAL|Cohort 2|Single dose followed by 14 days repeat dosing
62795410|NCT05233618|EXPERIMENTAL|Tagraxofusp (escalating doses)|IV tagraxofusp on days 1-3 of cycles 1-4 and days 1-2 of additional cycles for up to 9 cycles (some participants could receive more if considered in their best interest)
62219478|NCT00950586|EXPERIMENTAL|Cohort 3|Up to 28 days repeat dosing with drug interaction
62219479|NCT04866251|ACTIVE_COMPARATOR|Healthy young subject|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
62219480|NCT04866251|ACTIVE_COMPARATOR|Healthy older subjects|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
62795411|NCT04070989|EXPERIMENTAL|Posterior Approach|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem implanted via the posterior approach
62219481|NCT04866251|ACTIVE_COMPARATOR|Acute stroke patients|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
62219482|NCT04866251|ACTIVE_COMPARATOR|Patients with Parkinson´s Disease|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
62219483|NCT04866251|ACTIVE_COMPARATOR|Patients with Multiple Sclerosis|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
62795412|NCT04070989|EXPERIMENTAL|Lateral Approach|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem implanted via the lateral approach
62795413|NCT04070989|EXPERIMENTAL|Anterior Approach|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem implanted via the anterior approach
62586861|NCT06307470|EXPERIMENTAL|EMBRACE Group|"Immediately following consent, participants randomized to the EMBRACE Group will begin with the EMBRACE intervention. Participants will meet with a registered nurse certified in sexuality and sex education for 8 sessions every two weeks depending on scheduling. Each of the 8 sessions will last between 60 - 90 minutes. By session 2, participants will receive vaginal rehydration (Hyalo-Gyn suppositories), vaginal dilation (CalExotics Dr. Berman Dilator), and vaginal lubrication (Good Clean Love BioNude). These products will be mailed to participants at no cost to the participants.~Participants will complete baseline measures, immediately following the intervention, and six weeks after the last session. Participants will be compensated for their time with a total up to $150."
62586862|NCT06307470|ACTIVE_COMPARATOR|Delayed EMBRACE Group|"After consenting, participants randomized to the Delayed EMBRACE Group will begin with the EMBRACE intervention 16 weeks after enrollment. Participants will meet with a registered nurse certified in sexuality and sex education for 8 sessions every two weeks depending on scheduling. Each of the 8 sessions will last between 60 - 90 minutes. By session 2, participants will receive vaginal rehydration (Hyalo-Gyn suppositories), vaginal dilation (CalExotics Dr. Berman Dilator), and vaginal lubrication (Good Clean Love BioNude). These products will be mailed to participants at no cost to the participants.~Participants will complete baseline measures, immediately following the intervention, and six weeks after the last session. Participants will be compensated for their time with a total up to $150."
62023167|NCT02995967|ACTIVE_COMPARATOR|Botulinum toxin A alone group|Just the intradetrusor injection of 100 units of botulinum toxin A alone
62219484|NCT04866251|ACTIVE_COMPARATOR|Patients with Myasthenia gravis|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
62219485|NCT04866251|ACTIVE_COMPARATOR|Geriatric patients|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
62413936|NCT04431622|EXPERIMENTAL|Effects of hearing aid algorithms|Neural processing and cognitive effort will be assessed in individuals who listen to stimuli generated with linear and fast-acting compression hearing aid algorithms and with actual hearing aids.
62219486|NCT03268525|ACTIVE_COMPARATOR|Study|Marcaine 0.5 % Injectable Solution will be injected before incision, and in a systematic fashion as a modified paracervical block. First, 2 ml will be injected through the vaginal fornices at 03.00, 06.00, 09.00, and 12.00 hours at 2 cm depth. Thus, 8 ml will be systematically injected around the cervical circumference before incision. In addition, 1 ml of the solution will be injected in each resection line (sacro-uterine and cardinal ligaments), adding up to a total of 10 ml. In case of performing additional anterior/ posterior colporrhaphy, additional solution of Marcaine 0.25%will be prepared: 5 ml of the solution will be injected to the cutting line of the anterior/ posterior vaginal wall, respectively, prior to incision.
62413937|NCT05610813|EXPERIMENTAL|Test intervention: VER-01|VER-01 will be administered twice daily to patients randomized to treatment arm VER-01.
62413938|NCT05610813|ACTIVE_COMPARATOR|Comparative intervention: Opioid therapy (with an authorised and marketed opioid, ATC code N02A)|Opioids will be administered according to the SmPC to patients randomized to treatment arm opioid therapy.
62413939|NCT05301894|EXPERIMENTAL|NBI-827104|NBI-827104 administered orally
62795414|NCT01308697|ACTIVE_COMPARATOR|Operative|Operative intervention
62795415|NCT01308697|ACTIVE_COMPARATOR|Non Operative Treatment|Non Operative management
62795416|NCT04927065|EXPERIMENTAL|Part A.1: mRNA-1273.211 50 μg|Participants will receive 1 intramuscular booster dose of 50 micrograms (μg) of mRNA-1273.211 on Day 1.
62795417|NCT04927065|EXPERIMENTAL|Part A.1: mRNA-1273.211 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.211 on Day 1.
62795418|NCT04927065|EXPERIMENTAL|Part B: mRNA-1273 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273 on Day 1.
62795419|NCT04927065|EXPERIMENTAL|Part C: mRNA-1273.617.2 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.617.2 on Day 1.
62795420|NCT04927065|EXPERIMENTAL|Part C: mRNA-1273.617.2 50 μg|Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.617.2 on Day 1.
62795421|NCT04927065|EXPERIMENTAL|Part D: mRNA-1273.213 50 μg|Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.213 on Day 1.
62795422|NCT04927065|EXPERIMENTAL|Part D: mRNA-1273.213 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.213 on Day 1.
62219487|NCT03268525|PLACEBO_COMPARATOR|Control|Sodium Chloride 0.9% will be injected before incision, and in a systematic fashion as a modified paracervical block. First, 2 ml will be injected through the vaginal fornices at 03.00, 06.00, 09.00, and 12.00 hours at 2 cm depth. Thus, 8 ml will be systematically injected around the cervical circumference before incision. In addition, 1 ml of the solution will be injected in each resection line (sacro-uterine and cardinal ligaments), adding up to a total of 10 ml. In case of performing additional anterior/ posterior colporrhaphy, additional solution of Sodium Chloride 0.9% will be prepared: 5 ml of the solution will be injected to the cutting line of the anterior/ posterior vaginal wall, respectively, prior to incision.
62219488|NCT03756129|EXPERIMENTAL|MIJ821 low dose weekly|Infusion. MIJ821 low dose weekly - 0.16 mg/kg
62413940|NCT06649799|EXPERIMENTAL|LenSx|
62413941|NCT06649799|PLACEBO_COMPARATOR|Z8|
62433329|NCT03244995|EXPERIMENTAL|Group I (CBMB program)|Patients undergo CBMB program consisting of 4-5 deep-breathing and meditation exercise sessions over 60 minutes and 2 weekly telephone calls over 15 minutes for 6 weeks. Patients also complete questionnaires regarding health, mood, sleeping habits, relationship, health care, work productivity, and quality of life.
62433330|NCT03244995|ACTIVE_COMPARATOR|Group II (waitlist control)|Patients complete questionnaires as in Group I. Patients may undergo CBMB program after completion of study.
62795423|NCT04927065|EXPERIMENTAL|Part E: mRNA-1273.213 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.213 on Day 1.
62795424|NCT04927065|EXPERIMENTAL|Part F Cohort 1: mRNA-1273.529 50 μg|Participants will receive 1 intramuscular first booster dose of 50 μg of mRNA-1273.529 on Day 1.
62795425|NCT04927065|EXPERIMENTAL|Part F Cohort 2: mRNA-1273.529 50 μg and mRNA-1273 50 μg|Participants will receive 1 intramuscular second booster dose of 50 μg of mRNA-1273.529 or mRNA-1273 enrolled sequentially (after receiving a primary series of mRNA-1273 and a single booster dose of mRNA-1273 50 μg) on Day 1.
62586863|NCT06070870|EXPERIMENTAL|Patient Navigation|Centralized patient navigators will be trained to help patients navigate the clinical, logistical, and financial aspects of LCS. Navigators employ case management approaches based on social work principles. The experience of patient navigation will be tailored to the individual participant
62586864|NCT04871711|EXPERIMENTAL|Delgocitinib cream 20 mg/g|Twice-daily topical application for 16 weeks
62219489|NCT03756129|EXPERIMENTAL|MIJ821 low dose bi-weekly|Infusion. MIJ821 low dose bi-weekly - 0.16 mg/kg
62219490|NCT03756129|EXPERIMENTAL|MIJ821 high dose weekly|Infusion. MIJ821 high dose weekly - 0.32 mg/kg
62413942|NCT01064869|EXPERIMENTAL|Psycho-educational intervention|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~1. A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~2. Motivational interviewing based on stages of change model to encourage change and adherence~3. Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
62413943|NCT01064869|NO_INTERVENTION|usual care|Standard asthma management
62413944|NCT02001038||Orthopaedic surgeons|Orthopaedic surgeons who perform surgical procedures for foot deformities in CMT patients at participants centres.
62413945|NCT02815189|EXPERIMENTAL|Post operative Pain after a RCT|Ibuprofen for Post operative pain. Take 400 mg taken a week after. Incidence of flare ups after a single vs multiple visits root canal treatments.
62586865|NCT04871711|PLACEBO_COMPARATOR|Cream vehicle|Twice-daily topical application for 16 weeks
62586866|NCT01713114|EXPERIMENTAL|Low carbohydrate|
62586867|NCT01713114|EXPERIMENTAL|Moderate carbohydrate|
62586868|NCT01713114|EXPERIMENTAL|Higher Carbohydrate|
62586869|NCT01713114|PLACEBO_COMPARATOR|Meal Skipping|
62586870|NCT05725291|EXPERIMENTAL|AMT-116 Dose Escalation|
62586871|NCT02211638||Candesartan Cilexetil tablets (2 to 12 mg)|Candesartan Cilexetil tablets (2 to 12 mg), orally, once daily for up to 3 months
62586872|NCT01910545|EXPERIMENTAL|OTS167IV|single arm
62586873|NCT06682130|EXPERIMENTAL|Glofitamab bridging ASCT Regimen|After at least second-line treatment, patients will be divided into three groups based on their disease status: Group A includes patients with partial response (PR) or ctDNA positivity who plan to receive ASCT or Glofitamab (specification: 10 mg per tube; dosage: 2.5 mg on day 8) as a bridge to ASCT; Group B includes patients with complete response (CR) and ctDNA negativity who will proceed directly to ASCT; Group C includes patients with stable or progressive disease (SD/PD) who will be assessed after two cycles of Glofitamab (Specification: 10mg per tube;Dosage: cycle 1: 2.5mg d8；10mg d15；cycle 2: 30mg d21). Those achieving PR will undergo ASCT, those with CR can choose ASCT or continue Glofitamab, and those with SD/PD will be removed from the group.
62795426|NCT04927065|EXPERIMENTAL|Part G: mRNA-1273.214 50 μg|Participants will receive 1 intramuscular second booster dose of mRNA-1273.214 50 μg on Day 1.
62795427|NCT04927065|EXPERIMENTAL|Part A.2: mRNA-1273.214 50 μg|Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.214 on Day 1.
62795428|NCT04927065|EXPERIMENTAL|Part H: mRNA-1273.222 50 μg|Participants will receive 1 intramuscular second booster dose of 50 μg of mRNA-1273.222 on Day 1.
62219491|NCT03756129|EXPERIMENTAL|MIJ821 high dose bi-weekly|Infusion. MIJ821 high dose bi-weekly - 0.32 mg/kg
62219492|NCT03756129|PLACEBO_COMPARATOR|Placebo weekly|Infusion. Placebo weekly
62219493|NCT03756129|ACTIVE_COMPARATOR|Ketamine 0.5 mg/kg weekly|Infusion. Ketamine 0.5 mg/kg weekly
62219494|NCT04463966|ACTIVE_COMPARATOR|Study|Tranexamic acid 1 gm (100 mg/ml) slowly intravenous infusion during delivery ( administered over 10 minutes at 1 ml/minute) .
62219495|NCT04463966|NO_INTERVENTION|Control|control group will not be given tranexamic acid
62219496|NCT02355080|EXPERIMENTAL|On-site bundled rapid HIV/HCV testing|Participants will receive the on-site bundled rapid HIV/HCV testing intervention. In the intervention group, all patients will receive an offer to participate in rapid HIV/HCV testing. Those who accept this offer will: receive pre-test information about testing procedures and education, be tested, receive results during the same visit as testing, and be provided post-test counseling and support services by trained test counselors. Patients with a preliminary positive (i.e., reactive) HIV and/or HCV test result(s) will be actively linked immediately to a health care provider for further evaluation and confirmatory HIV and/or HCV RNA testing.
62413946|NCT02815189|EXPERIMENTAL|Flare up|Acetaminophen 325 mg for Flare Up. Taken second day after. Incidence of Post operative pain after root canal treatment in one vs two visits.
62413947|NCT03920527|ACTIVE_COMPARATOR|Six months|Six months of itraconazole
62413948|NCT03920527|EXPERIMENTAL|12 months|12-months of itraconazole
62413949|NCT03916692|EXPERIMENTAL|Standard Process - glucose balance|Standard Process - glucose balance formula (200 kcal)
62413950|NCT03916692|EXPERIMENTAL|Energy smart Carbohydrate blend|Energy smart carbohydrate blend (50 grams, 200 kcal)
62413951|NCT03916692|ACTIVE_COMPARATOR|Liquid Dextrose Control|Liquid dextrose solution in the form of TRUTOL ® Glucose Tolerance Test Beverage (50 grams, 200 kcal)
62413952|NCT00345969|ACTIVE_COMPARATOR|Transdermal Testosterone gel (1%)|Transdermal testosterone 1% gel (Androgel) provided as 2.5 gm and/or 5 gm gel packets with dose titration and monthly dose adjustments to achieve and maintain serum total testosterone level between 500-900 mg/dL. Gel to be applied daily by participants. Participants are blinded to the contents of the gel packets. Participants in this arm also perform supervised exercise training for 6 months.
62413953|NCT00345969|PLACEBO_COMPARATOR|Placebo gel|Inactive topical gel identical in appearance to the active medication, provided in packets identical to the packaging for the active medication. Gel to be applied daily by participants. Participants are blinded to the contents of the gel packets. Participants in this arm also perform supervised exercise training for 6 months.
62413954|NCT06701084|EXPERIMENTAL|Genomic Sequencing|All enrolled infants receive the intervention (genomic sequencing, including rapid genome sequencing). Comprehensive genomic analyses will be performed to identify genetic diagnoses. Genetic results will be returned to families and infants will be followed until 2.5 years old to evaluate the impact of genetic diagnosis using quantitative validated outcome measures and qualitative parent interviews.
62219497|NCT02355080|ACTIVE_COMPARATOR|Standard of care (SOC)|Participants will receive the standard of care (SOC) at the study sites. The SOC entails venipuncture whole blood HIV testing + venipuncture whole blood HCV testing. Blood draws are sent to an external laboratory for processing, and patients must return for test results in another visit. Patients may not receive pre-test information or results and post-test counseling, especially if non-reactive or negative test result(s). Reflex testing is not standard practice, therefore some patients may require another visit and blood draw for confirmatory HIV and/or HCV RNA testing. Linkage to care in the SOC is accomplished by referral to a health care provider, either within the participating substance use disorder treatment organization or passive referral to other health facilities.
62413955|NCT05742607|EXPERIMENTAL|IPH5201 + durvalumab + standard chemotherapy|"Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy.~Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab."
62219498|NCT02734927|ACTIVE_COMPARATOR|schizophrenia group|Schizophrenia patients suffering
62219499|NCT02734927|SHAM_COMPARATOR|control group|subjects showing no psychological or neurological disorder
62219500|NCT04971681|EXPERIMENTAL|Low frequency repetitive transcranial magnetic stimulation (rTMS)|Low frequency repetitive transcranial magnetic stimulation (rTMS)
62219501|NCT04971681|SHAM_COMPARATOR|Sham rTMS Stimulation|Sham rTMS Stimulation
62219502|NCT06235944|EXPERIMENTAL|Caudal block|Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume 1ml/ kg max 20 ml via Ultrasound Guided caudal Block.
62219503|NCT06235944|EXPERIMENTAL|Sacral erector spinae|Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume of 1 ml/ kg maximum 20ml divided in both sides via ultrasound guided sacral erector spinae plain block (ESPB).
62219504|NCT04108052|OTHER|Low dose CT scanner and Ultra low dose CT Scan|Thoracic low dose CT acquisition and Thoracic ultra-low dose CT acquisition
62219505|NCT02849522||PAE patients|Men who have undergone PAE and are in the UK ROPE Register
62219506|NCT02849522||Comparator treatment patients|Men who have undergone TURP, Open Prostatectomy or laser ablation/enuclation of the prostate, and are on the UK ROPE Register.
62219507|NCT03129139|EXPERIMENTAL|Regimen A (monotherapy)|Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day off schedule. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.
62795429|NCT04927065|EXPERIMENTAL|Part J: mRNA-1273.815 or mRNA-1273.231|Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.815 or 50 ug of mRNA-1273.231 on Day 1.
62219508|NCT03129139|EXPERIMENTAL|Regimen B (combination)|MinnelideTM Capsules will be given orally once daily x 21 days in combination with protein-bound paclitaxel given intravenously on days 1, 8 and 15 in patients with pancreas and breast cancer. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.
62413956|NCT06566625||Observational cohort|"Inclusion criteria:~≥18 years of age Suspected NSTEMI (signs and symptoms suggest of ACS with initial ECG showing no ST-elevation) Planned ICA where CMR can be performed without delaying ICA Able to provide written informed consent~Exclusion criteria:~Contraindications for CMR examination with gadolinium contrast (claustrophobia, eGFR \<30ml/min/1.73m2, contrast allergy, and non-MRI compatible implants) Arrythmias which hinder CMR examination Previous CABG Hemodynamic instability Myocardial infarction \<6 months prior to inclusion"
62413957|NCT04040738|ACTIVE_COMPARATOR|Upper extremity surgery under general anaesthesia|Fentanyl 2 mcg/kg iv, propofol 2 mg/kg iv induction, 1MAC sevoflurane maintenance
62413958|NCT04040738|ACTIVE_COMPARATOR|Upper extremity surgery under regional anaesthesia|Bupivacaine brachial plexus block 0.4 ml/kg of 0.33% solution
62413959|NCT05887518|EXPERIMENTAL|EXPERIMENTAL GROUP|"In addition to the routine treatment and care practices of the operating theatre, the patients included in the study group will wear antiembolytic socks and warming socks to be developed with wearable technology. After the antiembolitic socks are put on the patients in the ward, the socks to be developed with wearable technology will be put on the study group before they are sent to the operating theatre and will be removed one day after the operation.~The socks to be used in the research (heating socks developed with wearable technology will be developed by the researchers and patent application will be made.~The application of socks to be developed with wearable technology in the research will be applied to all patients by the same executive. Verbal and written consent will be obtained from the patient/relative before the start of the study."
62219509|NCT03129139|EXPERIMENTAL|Regimen C (monotherapy in Gastric Cancer)|Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days. Minnelide™ Capsules should be given with the patient in a fasting state.
62586874|NCT04114331|EXPERIMENTAL|Manual therapy and exercise|"The intervention (3 times a week for 4 weeks, for a total of 12 sessions) consisted primarily of manual therapy (soft tissue and joint mobilization) followed by therapeutic exercises (muscular control and coordination).~Manual therapy:~Joint mobilizations (Grades I-V) to cervical spine, thoracic spine and ribs Soft tissue mobilization to the pectoralis, scaleni, upper traps, thoracolumbar fascia, erector spinae, and suboccipital musculature~Therapeutic exercises:~Strengthening of mid and lower traps, lats, glut med, and glut max. Active \& passive stretching of thoracic and lumbar rotation, hip flexors, and plantarflexors.~The treating therapists agreed on a protocol with treatment individualized to each patient."
62795430|NCT06465004|ACTIVE_COMPARATOR|Animal-based A|A commercially available high protein drink, based on animal proteins (Fresubin Protein Energy)
62795431|NCT06465004|ACTIVE_COMPARATOR|Animal-based B|A homemade drink containing animal-based proteins, using a specific animal-based protein isolate mix.
62433331|NCT03483181||Orthopedic surgery patient records|Medical records from patients aged 18 years or older with orthopedic surgeries during the hospitalization
62795432|NCT06465004|ACTIVE_COMPARATOR|Plant-based A|A homemade drink containing plant-based proteins, formulated to have the same macronutrient content as the animal-based drinks.
62023168|NCT02995967|EXPERIMENTAL|Hydrodistention group|Hydrodistention at a pressure of 80 cm H2O for 5 minutes, prior to the intradetrusor injection of 100 units of botulinum toxin A
62023169|NCT01732367|ACTIVE_COMPARATOR|Lamivudine plus adefovir|Continue lamivudine/adefovir add on treatment (standard treatment)
62023170|NCT01732367|EXPERIMENTAL|Tenofovir|Switch from lamivudine/adefovir add on treatment to tenofovir monotherapy
62219510|NCT01375231|ACTIVE_COMPARATOR|Measured Resection of patellofemoral joint|The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
62413960|NCT05887518|NO_INTERVENTION|CONTROL GROUP|"In the control group, the same looking sock will be worn before the patient is sent to the operating theatre and will be removed one day after the operation.~The sock to be used in the research will be developed by the researchers and a patent application will be made.~Verbal and written consent will be obtained from the patient/relative before the start of the study. The data obtained from the patients will be recorded in the Introductory Characteristics Form and Hypothermia Monitoring Form before the TUR. The application of socks to be developed with wearable technology will be carried out in accordance with the following application steps."
62586875|NCT06459050|EXPERIMENTAL|Dominant Limb Conditioning Activity|Each participant performed a single-leg drop jump for both the dominant and non-dominant limbs before and after completing the CA.
62586876|NCT06459050|EXPERIMENTAL|Non-dominant Limb Conditioning Activity|Each participant performed a single-leg drop jump for both the non-dominant and non-dominant limbs before and after completing the CA.
62795433|NCT04503265|EXPERIMENTAL|AMXI-5001 Treatment|Single Arm Study, all participants will receive AMXI-5001.
62795434|NCT06727279|EXPERIMENTAL|plant-based meat analog|Patients with non-alcoholic fatty liver disease will receive iso-caloric diet with modified fat and protein content: 18.8 g/day animal proteins a day will be substituted by 13.0 g/day vegetable protein; 6.0 g/day animal fat will be substituted by 19.1 g/day vegetable fat. This modification undermines substitution of a portion of meat product made of standard (animal) meat (cutlet or schnitzel) by plant-based analog, based on soy-bean source. The taste will be masked by natural food flavoring (taste of chicken).
62795435|NCT06727279|PLACEBO_COMPARATOR|Control - standard iso-calorie diet|Iso-calorie diet (based on resting energy expenditures measurements) is provided to subjects with non-alcoholic fatty liver disease
62023171|NCT01592708|ACTIVE_COMPARATOR|Antiemetic anesthesia protocol|Scopolamine 1.5 milligram(mg) patch Propofol infusion remifentanil infusion 250mg erythromycin po for 2 doses Solumedrol 0.625mg IV droperidol 4mg IV Ondansetron Ketorolac 30mg IV ibuprofen 600mg po q6h Fentanyl Hydrocodone/Tylenol po
62219511|NCT01375231|ACTIVE_COMPARATOR|Measured resection of patella|The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
62219512|NCT06611319|EXPERIMENTAL|Abbreviated lenght of thromboprophylaxis|Rivaroxaban from day 3-10; Placebo from day 11-35 after surgery
62413961|NCT05635760|EXPERIMENTAL|Group-based Parent-implemented Social Communication Training|Eight parents learning in a group format and will be taught by a speech therapist online.
62586877|NCT00713141||1|Early breast cancer
62586878|NCT01003483|EXPERIMENTAL|Orlistat|The dose of 120 mg orlistat was taken three times daily and the dose remained constant throughout the study period.
62023172|NCT05515302|EXPERIMENTAL|Experimental Group|The experimental group consists of 50 Participants as per the inclusion criteria. The Audio clips will be administered to the experimental group.
62413962|NCT05635760|ACTIVE_COMPARATOR|Self-learning-based Parent-implemented Social Communication Training|Parents will learn the same materials without the guidance of a therapist.
62413963|NCT01742390|EXPERIMENTAL|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
62413964|NCT01742390|ACTIVE_COMPARATOR|risperidone or paliperidone|Stay on risperidone (RIS) or paliperidone (PALI)
62433332|NCT04405193|EXPERIMENTAL|Treatment|2 capsules, each containing 600 mg N-acetylcysteine administered once daily every morning.
62433333|NCT04405193|PLACEBO_COMPARATOR|Placebo|2 capsules of matching placebo administered once daily every morning
62586879|NCT01003483|EXPERIMENTAL|Metformin|The dose of metformin was increased step - wise, from 500 mg once daily for the first week to 500 mg twice daily for the next week, and to 500 mg three times daily for the remaining study period .
62586880|NCT04408742||females with Multiple Sclerosis|patients with a confirmed diagnosis of MS according to the McDonald criteria, physician-administered Expanded Disability Status Scale (EDSS) range of 1-3.5, having regular menstrual cycle (between 21-35 days), and cognitive levels to give history and following the instructions
62586881|NCT06138262|EXPERIMENTAL|health promotion education about preconception nutrition|
62586882|NCT04793009||mesh group|patients undergoing abdominoperineal resection with end colostomy and implantation of a prophylactic, funnel-shaped, intraperitoneal mesh
62586883|NCT04793009||no-mesh group|patients undergoing abdominoperineal resection with end colostomy without implantation of a prophylactic, funnel-shaped, intraperitoneal mesh
62586884|NCT03050736|EXPERIMENTAL|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 20 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
62586885|NCT03745287|EXPERIMENTAL|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Subjects will receive a single infusion of CTX001 through a central venous catheter.
62586886|NCT02357160|EXPERIMENTAL|Choice|Patients given choice over artwork on wall
62586887|NCT02357160|ACTIVE_COMPARATOR|No choice|Patients not given choice over artwork on wall
62795436|NCT02968368|EXPERIMENTAL|Oral ferric maltol|30mg capsules BID
62795437|NCT02968368|PLACEBO_COMPARATOR|Oral placebo|Matching placebo capsules BID
62023173|NCT05515302|NO_INTERVENTION|Control Group|The control group will not receive the intervention but will receive treatment as usual.
62219513|NCT06611319|ACTIVE_COMPARATOR|Standard of care|Rivaroxaban from day 3-35 after surgery
62219514|NCT02476279|EXPERIMENTAL|Indomethacin alone|Indomethacin 100 mg rectally immediately after ERCP
62219515|NCT02476279|ACTIVE_COMPARATOR|Indomethacin+pancreatic stent|Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement
62219516|NCT05216887|ACTIVE_COMPARATOR|Aducanumab IV|Participants will receive a single weight-based dose of aducanumab via IV infusion on Day 1.
62219517|NCT05216887|EXPERIMENTAL|Aducanumab SC|Participants will receive 2 fixed doses of aducanumab via SC injection on Days 1 and 15.
62586888|NCT02357160|PLACEBO_COMPARATOR|No artwork|Patients not receiving any artwork on wall
62586889|NCT06072209|EXPERIMENTAL|Behavioral Activation|14 days of daily excercises
62586890|NCT06072209|EXPERIMENTAL|Mindfulness and Gratitude|14 days of daily excercises
62795438|NCT06493058|EXPERIMENTAL|Intervention group|In our study, the babies in the study group were given the supine, right lateral and left lateral positions (12×1), which are used in nursing care practices in the clinic after extubation, in addition to the supine, right lateral and left lateral positions (12×1), the prone position was given twice a day for 2×2 hours twice a day within 48 hours after extubation, with the head on the midline of the neck and the head facing to the right or left side.
62795439|NCT06493058|NO_INTERVENTION|Control group|Babies in the control group did not receive any treatment.
62413965|NCT04602208||Focal HIFU for primary localized prostate cancer|Between November 2009 and December 2016, at Edouard Herriot Hospital (Lyon, France), 146 consecutive patients were treated with focal HIFU for primary localized prostate cancer. Focal therapy was offered for low or intermediate risk disease (inclusion criteria: one tumor localized by systematic and targeted biopsies based on MRI findings, Gleason ≤7). Treatment failure was defined as local or systemic salvage treatment, a positive biopsy Gleason score of 7 or greater in-field or out-of-field in nontreated patients, prostate cancer metastasis or prostate cancer specific death.
62795440|NCT01416948|PLACEBO_COMPARATOR|Sugar Pill|
62219518|NCT05330312|EXPERIMENTAL|Part 1 - Digital cognitive behavioral therapy|4 weeks digital cognitive behavioral therapy.
62219519|NCT05330312|NO_INTERVENTION|Part 2 - Control group|No intervention
62219520|NCT05330312|EXPERIMENTAL|Part 2 - Digital cognitive behavioral therapy|9 weeks digital cognitive behavioral therapy
62219521|NCT01498029|ACTIVE_COMPARATOR|Randomized to Microfracture|This group of patients who have been randomised to receive microfracture procedure will be the control group for this study
62219522|NCT01498029|EXPERIMENTAL|Randomized to CAIS|This group of patients who have been randomised to receive the CAIS procedure will be the experimental group for this study
62219523|NCT00646633|ACTIVE_COMPARATOR|Acupuncture & educ|Patients will receive a total of 8 acupuncture treatments. In each of the first four sessions, they will also receive patient education.
62219524|NCT00646633|NO_INTERVENTION|2. Standard care|Patients in the control arm will continue to receive standard care from their physician.
62413966|NCT00447265|EXPERIMENTAL|Etanercept|Participants in this group will self-administer 50 mg etanercept injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).
62413967|NCT00447265|PLACEBO_COMPARATOR|Placebo|Participants in this group will self-administer 50 mg placebo injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).
62433334|NCT03793075|PLACEBO_COMPARATOR|Propofol group (P)|The maintenance of anesthesia , patient will receive sevoflurane 1%-2.5% with intravenous infusion of propofol 17 mcg /kg/min and 0.5 mg/kg fentanyl will be given if the heart rate or mean blood pressure increased by 30 % or more from the basal readings
62586891|NCT06072209|EXPERIMENTAL|Combination: Behavioral Activation and Mindfulness and Gratitude|14 days of daily excercises
62586892|NCT06072209|NO_INTERVENTION|Waitlist control group|Will receive the intervention (combination) after two weeks of intervention time of the other groups.
62586893|NCT05265923|EXPERIMENTAL|CM310|CM310, 600mg for the initial dose, and 300mg for subsequent doses, subcutaneous injection (SC), every 2 weeks (Q2W)
62795441|NCT01416948|ACTIVE_COMPARATOR|Galantamine|
62795442|NCT01416948|EXPERIMENTAL|Methylphenidate|
62219525|NCT06202586|EXPERIMENTAL|Received low FiO2|Patients undergoing elective thoracic surgery were treated with 30% FiO2 after pulmonary reexpansion following one-lung ventilation and 2-hour postoperative.
62219526|NCT06202586|ACTIVE_COMPARATOR|Received high FiO2|Patients undergoing elective thoracic surgery were treated with 80% FiO2 after pulmonary reexpansion following one-lung ventilation and 2-hour postoperative.
62219527|NCT00000145|EXPERIMENTAL|1|Antioxidants
62219528|NCT00000145|EXPERIMENTAL|2|Zinc
62219529|NCT00000145|EXPERIMENTAL|3|Antioxidants and zinc
62219530|NCT00000145|NO_INTERVENTION|4|
62219531|NCT00972205|EXPERIMENTAL|Paclitaxel and CBT-1|
62219532|NCT04982237|EXPERIMENTAL|AK104+chemotherapy± bevacizumab|AK104 in combination with cisplatin or carboplatin and paclitaxel± bevacizumab
62219533|NCT04982237|PLACEBO_COMPARATOR|Placebo+chemotherapy± bevacizumab|Placebo in combination with cisplatin or carboplatin and paclitaxel± bevacizumab
62219534|NCT06196632||"de novo strategy-HBeAg positive"|HBeAg positive patients treated with simultaneous administration of NA and Peg-IFN
62219535|NCT06196632||"de novo strategy-HBeAg negative"|HBeAg positive patients treated with simultaneous administration of NA and Peg-IFN
62795443|NCT04142801|EXPERIMENTAL|MeMo group|MeMo group: experimental: regular use at home of the Memo web application In the Memo group patients were instructed on how to use the application, and allowed to train for 12 weeks. It was also explained that this training needed to be done regularly on a basis of 4 sessions of 30 minutes each per week.
62219536|NCT06196632||"add-on strategy-HBeAg positive"|HBeAg positive patients treated with NA followed by addition of Peg-IFN.
62219537|NCT06196632||"add-on strategy-HBeAg negative"|HBeAg negative patients treated with NA followed by addition of Peg-IFN.
62219538|NCT00790816|EXPERIMENTAL|Group 1|Study Drug
62219539|NCT00790816|EXPERIMENTAL|Group 2|Study Drug
62433335|NCT03793075|ACTIVE_COMPARATOR|Ketamine group ((K)|The maintenance of anesthesia , patient will receive sevoflurane 1%-2.5% with intravenous infusion of ketamine 5 mcg /kg/min and 0.5 mg/kg fentanyl will be given if the heart rate or mean blood pressure increased by 30 % or more from the basal readings
62795444|NCT04142801|PLACEBO_COMPARATOR|Control group|Regular follow up at the memory center without cognitive training
62795445|NCT00410956|EXPERIMENTAL|UNRESECTABLE PRIMARY HEPATIC MALIGNANCY|All patients enrolled in the study will receive HAI FUDR (0.16 mg/kg X pump volume / pump flow rate), Dexamethasone (1 mg/m2/day) and IV Bevacizumab at 5mg/kg. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days post surgical placement of HAI pump; patients will receive their first treatment with Bevacizumab no sooner than 28 days post surgical placement of HAI pump.
62795446|NCT02175017|EXPERIMENTAL|ONO-4538 for squamous non-small-cell lung cancer (NSCLC)|In each treatment cycle, patients received an intravenous infusion of nivolumab (ONO-4538) at a dose of 3 mg/kg every 2 weeks for 6 weeks. Changes in dose were not allowed. Radiological assessments (computed tomography/ magnetic resonance imaging) were conducted every 6 weeks. Patients entered subsequent treatment cycles unless they met discontinuation criteria, including disease progression, unacceptable adverse events, and consent withdrawal. Patients who were discontinued for any of these reasons entered the follow-up phase.
62795447|NCT02175017|EXPERIMENTAL|ONO-4538 for non-squamous non-small-cell lung cancer (NSCLC)|In each treatment cycle, patients received an intravenous infusion of nivolumab (ONO-4538) at a dose of 3 mg/kg every 2 weeks for 6 weeks. Changes in dose were not allowed. Radiological assessments (computed tomography/ magnetic resonance imaging) were conducted every 6 weeks. Patients entered subsequent treatment cycles unless they met discontinuation criteria, including disease progression, unacceptable adverse events, and consent withdrawal. Patients who were discontinued for any of these reasons entered the follow-up phase.
62795448|NCT06344299||group of undergoing radical surgery|Elderly patients diagnosed with resectable PDAC underwent radical surgery.
62795449|NCT06344299||group of abandoning radical surgery|Elderly patients diagnosed with resectable PDAC abandoned radical surgery, the reasons of treatment abandonment included surgeons didn't recommend surgery for their elderly patients and patients chose to refuse surgery.
62219540|NCT04130763|EXPERIMENTAL|FMT Capsule in Combination with Anti-PD-1 Therapy|FMT Capsule in Combination with Anti-PD-1 Therapy
62219541|NCT02617303|EXPERIMENTAL|OTAGO'S program arm|Patients meeting the inclusion criteria will be randomly assigned to the experimental group. They will receive OTAGO'S exercise program during three months, followed by adherence phase. Falls and fractures will be quarterly followed during 15 months.
62219542|NCT02617303|ACTIVE_COMPARATOR|CONTROL GROUP|Patients meeting the inclusion criteria will be randomly assigned to the control group. Normal medical treatment will be provided by family physicians and nurses. Falls and fractures will be quarterly followed during 15 months.
62219543|NCT05180929|EXPERIMENTAL|Dual-M1 tDCS|In the M1- dual tDCS montage, the anodal electrode will be placed above ipsilesional M1 and the cathode will be positioned over contralesional M1.
62219544|NCT05180929|EXPERIMENTAL|a-tDCS over contralesional PMC|In the anodal-tDCS for PMC, the anodal electrode will be placed over the contralesional PMC. The PMC is defined as being 2.5 cm anterior to the M1. The cathodal electrode will be positioned over the contralateral suborbital region
62219545|NCT05180929|SHAM_COMPARATOR|Sham tDCS|For sham stimulation, there is no particular electrode configuration to be followed, thus, 6 participants will receive sham stimulation with the configuration will be used in group A, and 5 participants will receive sham stimulation with the configuration will be used in group B. By pressing the sham button, the current will automatically ramped up over 10 sec. till reaching 1 mA, then it will be decreased gradually over 30 seconds till turning off the apparatus. This is to ensure the typical initial itching sensation
62219546|NCT06399133|NO_INTERVENTION|Control Group|Patients in the CG received routine postoperative clinical interventions.
62219547|NCT06399133|EXPERIMENTAL|Study Group|Patients in the SG received a care package including warm water intake, abdominal massage, and a high-fiber diet.
62433336|NCT01458119|EXPERIMENTAL|Migalastat|Migalastat 150-mg capsule taken orally QOD. The median duration of exposure was 23.5 m.
62433337|NCT03437460|ACTIVE_COMPARATOR|Ibuprofen 600mg|Treatment group participants receive a single 600 mg of over-the-counter ibuprofen.
62023174|NCT04307719||Mexican Jewish Community|Sample of Patients from the Mexican Jewish Community to be subjected to genetic testing
62219548|NCT04500795|EXPERIMENTAL|Embolization Group|Patients with residual or recurrent haematoma (higher than 10mm thickness of haematoma at any dimension) following prior surgical evacuation of haematoma will be admitted to the Embolization Group and undergo embolization of MMA. Serial CT scans will be taken at times of presentation of the residual or recurrent haematoma, 1-day, 1-week, 1-month, 3-month, and 6-month following embolization. Size of haematoma will be measured for comparison to the Control Group. Clinical examinations will be done at the same setting.
62413968|NCT04793152|EXPERIMENTAL|Vancomycin targeting trough of 10 to 15mg/L|"If the patient has not received intravenous vancomycin yet, a loading dose of 25mg/kg (maximum 2g) will be given if the patient is severely ill at the discretion of the physician and pharmacist. The initial dose is 15mg/kg with a maximum dose of 2g. The frequency would be based on creatinine clearance (CrCl) as per the Cockcroft-Gault equation: Q8H if CrCl is \>100mL/min, Q12H if CrCl is 50-100mL/min, Q24H if CrCl is 30- 49mL/min, and Q48H if CrCl is \<30mL/min. Pharmacists can change the initial dose at their own discretion.~Trough level will be done 30 minutes before the 4th dose. For Q48H dosing, a trough level will be done before the second dose. Vancomycin dosing will be adjusted to target trough level of 10 to 15mg/L. If not at target, the pharmacist will adjust the dose based on an assumption of linear pharmacokinetics. Trough will be remeasured before the fourth dose of the new regimen."
62413969|NCT04793152|ACTIVE_COMPARATOR|Vancomycin targeting AUC of 400 to 600|"The initial intravenous vancomycin dosing is the same as described above for the trough group.~The AUC target will be 400 to 600, which assumes a MIC of 1ug/mL by broth microdilution.~After the first non-loading dose of vancomycin, patients will have vancomycin level 30 minutes before the next dose. As per the pharmacist's discretion, patient may have an additional vancomycin level one hour after infusion of vancomycin for more accurate estimates. A pharmacist will use a Bayesian software to estimate the AUC and the optimal dose."
62413970|NCT04095975|ACTIVE_COMPARATOR|Baking Soda|Subjects randomized to baking soda will be provided instructions for using baking soda to provide 40 mEq alkali, to be accomplished by dissolving ¼ teaspoon baking soda in water or other beverage (any amount) in the morning on an empty stomach and ½ teaspoon baking soda in water or other beverage again at bedtime, also on an empty stomach.
62413971|NCT04095975|ACTIVE_COMPARATOR|LithoLyte|Subjects randomized to LithoLyte® will be provided 40 mEq of alkali in the form of LithoLyte® and advised to take 20 mEq twice daily according to package instructions, once in morning and once at bedtime; no requirements about proximity to meals are necessary.
62413972|NCT06566430|EXPERIMENTAL|PrEP My Way intervention|"PrEP My Way is an intervention that involves peer-delivery of a kit containing PrEP and other sexual health services. Participants will be offered PrEP (if HIV-negative) per a point-of-care test, pregnancy testing, vaginal swabs for gonorrhea and chlamydia testing, condoms, and/or self-injection medroxyprogesterone, as desired.~Prior to randomization, participants will decide which form of PrEP they would like to take (oral FTC/TDF, dapivirine ring, injectable cabotegravir) and adherence support."
62795450|NCT05171192|EXPERIMENTAL|CMAP Plus LTP added to TAU|"C-MAP is a manual assisted intervention based on the principles of CBT which is focused on evaluation of the self-harm attempt, crisis skills, problem solving and basic cognitive techniques to manage emotions, negative thinking, and relapse prevention strategies. As family conflicts are a common issue with this group one session is focused on the use of culturally sensitive training in assertiveness and conflict management. The LTP is a community-based parenting intervention designed to deal with early child development. The central feature of the LTP intervention is a pictorial calendar devised for parents which depicts eight successive stages of child development from birth to 3 years along with illustrations of parent-child play and other activities that promote parental involvement, learning, and attachment.~This will be added to Treatment as Usual"
62795451|NCT05171192|NO_INTERVENTION|TAU alone|TAU alone will include routine follow up by Community Health Workers (CHWs) in Pakistan. Their work includes assisting with all aspects of maternal, new-born and childcare. Participants in treatment as usual arm will receive routine care.
62795452|NCT06367348|NO_INTERVENTION|Control Comparison|Standard of care, e.g. regular HIV care plus brief advice on alcohol use
62413973|NCT06566430|EXPERIMENTAL|PrEP My Way intervention without STI testing|"PrEP My Way is an intervention that involves peer-delivery of a kit containing PrEP and other sexual health services. Participants will be offered PrEP (if HIV-negative) per a point-of-care test, pregnancy testing, condoms, and/or self-injection medroxyprogesterone, as desired.~Prior to randomization, participants will decide which form of PrEP they would like to take (oral FTC/TDF, dapivirine ring, injectable cabotegravir) and adherence support."
62586894|NCT05265923|PLACEBO_COMPARATOR|Placebo|"Double blind treatment period : Placebo~Maintenance treatment period : CM310, 600mg for the initial dose, and 300mg for subsequent doses, subcutaneous injection (SC), every 2 weeks (Q2W)"
62795453|NCT06367348|EXPERIMENTAL|Mlambe Intervention|A couples-based intervention to reduce problematic drinking and improve economic and HIV outcomes.
62795454|NCT04367831|EXPERIMENTAL|Intervention arm: intermediate-dose anticoagulation|"If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily or unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1-0.3 U/mL.~If eGFR \<30 mL/min or acute kidney injury or CRRT: Unfractionated heparin infusion at 10 units/kg/hour (minimum 500 units/hour if CRRT) with goal anti-Xa 0.1-0.3 U/mL"
62023175|NCT04777682|OTHER|single arm|A single-arm, open, single-center (hospital-based) prospective interventional study to compare intestinal ultrasound versus double balloon enteroscopy in diagnosis of malabsorption syndrome
62023176|NCT06463015|OTHER|pulsed radiofrequency group|posterior tibial nerve pulsed radiofrequency for painful DPNP
62023177|NCT04755595|EXPERIMENTAL|Facial aesthetic treatment|Study participants will receive all three injectables: Botox Cosmetic (onabotulinumtoxinA), Juvéderm Voluma XC (hyaluronic acid gel filler), and Juvéderm Volbella XC (hyaluronic acid gel filler) during a single procedure, with an optional touch-up treatment at 2 weeks.
62023178|NCT04603989|EXPERIMENTAL|HNC042|HNC4042 for injection,freeze-dried powder,multiple ascending doses, Intravenous route
62023179|NCT04603989|PLACEBO_COMPARATOR|Placebo|Placebo, multiple ascending doses, Intravenous route
62795455|NCT04367831|ACTIVE_COMPARATOR|Control arm: prophylaxis|"Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):~If eGFR ≥30 mL/min (stable kidney function):~1. BMI \< 40 kg/m2: Enoxaparin 40 mg SC daily~2. BMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h~3. BMI \> 50 kg/m2: Enoxaparin 60 mg SC q12h~If eGFR \< 30 mL/min or acute kidney injury:~1. 50-120 kg: Unfractionated heparin 5000 units SC q8h~2. \>120 kg: Unfractionated heparin 7500 units SC q8h~If CRRT: Unfractionated heparin infusion pre-filter at 500 units/hour"
62023180|NCT03595345||Training set|2200 HCC cases from East and West centres enlisted for LT and then delisted or transplanted
62219549|NCT04500795|NO_INTERVENTION|Control Group|All symptomatic patients (headache unresponsive to analgesic or neurological deficits including focal neurological deficits, deteriorated consciousness, headache, seizures, and other signs or symptoms suggestive of SDH as the cause) will undergo haematoma evacuation either by burr-hole drainage or craniotomy. Their response to treatment, neurological status, and CT scans will be monitored. Asymptomatic patients will be monitored radiologically (CT) every 2-4 weeks. The decision for surgical evacuation of haematoma will be based on CT findings (increasing haematoma size) and presentation of symptoms or neurological deficits. They remain in the control group should they refuse embolization of MMA. The size of haematoma will be measured continuously based on CT scans taken at times of presentation, 1-day, 1-week, 1-month, 3-month, and 6-month post-op. Size of haematoma, residual or recurrent will be measured for comparison to the Embolization Group.
62219550|NCT05074797||covid not diabetic with AKI|AKI in pt with covid_19 not diabetic
62219551|NCT05074797||AKI in covid_19 in diabetic|AKI in covid_19 in diabetic pt
62219552|NCT05074797||covid_19 in diabetic|covid_19 in diabetic without AKI
62413974|NCT06566430|EXPERIMENTAL|Enhanced standard of care|Prior to randomization, participants will decide which form of PrEP they would like to take (oral FTC/TDF, dapivirine ring, injectable cabotegravir).
62586895|NCT02726906|EXPERIMENTAL|Moderate-aerobic walking|Participants will complete a 6-month home-based moderate-aerobic walking program of 150 minutes per week with the assistance of an interventionist.
62586896|NCT02726906|PLACEBO_COMPARATOR|Healthy Living Education|Participants will receive monthly topics on healthy living lifestyles for self-paced reading over 6 months with the assistance of an interventionist.
62586897|NCT06665074|EXPERIMENTAL|Aggressive Subjects|Subjects with Intermittent Explosive Disorder (IED)
62586898|NCT06665074|OTHER|Non-Aggressive Subjects|Subjects without IED
62586899|NCT06506955|EXPERIMENTAL|TAS-120 (futibatinib) monotherapy|TAS-120 tablets, oral, cycle length is defined as per antecedent study design
62795456|NCT00921349|EXPERIMENTAL|Ligation+Nadolol|"Multi-ligators were applied. Patients received regular ligation treatment at an interval of 3-4 weeks until variceal obliteration.~Intervention; ligation of varices plus beta blockers (Nadolol)."
62795457|NCT00921349|ACTIVE_COMPARATOR|Nadolol only|
62795458|NCT01062152|EXPERIMENTAL|Revlimid® in Combination with Telintra ®|Lenalidomide (Revlimid®) followed by Telintra® until MDS progression or lack of efficacy.
62795459|NCT02566317|ACTIVE_COMPARATOR|Move|A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace.
62795460|NCT02566317|EXPERIMENTAL|Stand & Move|Move intervention (A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace) plus the installation of a sit-stand workstation.
62023181|NCT03595345||West validation set|630 HCC cases from a Western centre enlisted for LT and then delisted or transplanted
62023182|NCT03595345||East validation set|300 HCC cases from a Eastern centre enlisted for LT and then delisted or transplanted
62023183|NCT00434057|OTHER|Biopsied Pigmented Skin Lesions|Pigmented skin lesions for which clinical management was prospectively determined to be biopsy of the lesion in toto
62023184|NCT05578404|PLACEBO_COMPARATOR|Control Group|50 patients will receive the standard conventional therapy in addition to a placebo for 4 months.
62219553|NCT00106418|EXPERIMENTAL|Romidepsin|13 mg/m\^2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
62219554|NCT02170818|EXPERIMENTAL|Educational Workshop on Speaking-Up|Educational Workshop on Speaking-Up Before Simulated Case
62219555|NCT02170818|SHAM_COMPARATOR|Unrelated Education|Unrelated Education (CPR) before simulated case (Educational Workshop on Speaking-up after case and debriefing)
62413975|NCT05276869||group A|from 3 to 7 years included 36 patients
62413976|NCT05276869||group B|from 8 to 16 years included 17 patients
62413977|NCT00337727|OTHER|1|Arm 1: Day 1: aprepitant 125 mg capsule; ondansetron 8 mg capsule prior to chemotherapy and 1 8mg capsule 12 hrs after first dose; dexamethasone 12 mg tablets + 2 dexamethasone Pbo tablets. Day 2: Aprepitant 80 mg capsule; Ondansetron 8 mg capsule every 12 hours Day 3: Aprepitant 80 mg capsule Ondansetron 8 mg capsule every 12 hours.
62586900|NCT06506955|EXPERIMENTAL|TAS-120 (futibatinib) combination therapy with fulvestrant|TAS-120 tablets in combination with fulvestrant, oral, cycle length is defined as per antecedent study design
62586901|NCT05698979|EXPERIMENTAL|drug administration|Botox Injection
62586902|NCT06682611|EXPERIMENTAL|SYHA1813 single agent or in combination with different regimens|Cohorts 1-4 are SYHA1813 combined with different regimens. Cohorts 5-8 are SYHA1813 monotherapy.
62586903|NCT06682611|ACTIVE_COMPARATOR|Control group|The cohort 7 control group is Everolimus. The cohort 8 control group is Regorafenib.
62586904|NCT02048098|ACTIVE_COMPARATOR|Buccal misoprostol|400 µg buccal misoprostol per 3 hours
62413978|NCT00337727|OTHER|2|Arm 2: Day 1: Aprepitant 125 mg Pbo capsule; Ondansetron 8 mg capsule prior to chemotherapy and 8 mg capsule 12 hours after first dose; Dexamethasone 20 mg tablets. Day 2: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours; Day 3: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours. 3 Day treatment period Optional cycle 2 is being offered to patients. Optional cycle 2 will substitute aprepitant with fosaprepitant dimeglumine 115 mg or Pbo on day 1. All other dosing regimen will remain the same as cycle 1.
62413979|NCT06701773||Intraprosthetic thrombus Group|presence of intraprosthetic thrombus according to the postoperative CTA
62413980|NCT06701773||Non-intraprosthetic thrombus Group|absence of intraprosthetic thrombus according to the postoperative CTA
62023185|NCT05578404|ACTIVE_COMPARATOR|Vit D Group|50 patients were given the standard conventional therapy plus cholecalciferol. Cholecalciferol was given as a high oral loading dose of 300,000 IU followed by a daily oral dose of 800 IU for 4 months.
62586905|NCT02048098|ACTIVE_COMPARATOR|vaginal misoprostol|400 µg vaginal misoprostol per 3 hours
62795461|NCT04628429||Episodic Migraine|All patients who have been diagnosed with migraine without aura or migraine with aura according to the diagnostic criteria of the International Classification of Headache Disorders, third edition (ICHD-3) and have been unsuccessfully treated with first-line prophylactic medication
62023186|NCT00408993|EXPERIMENTAL|Duloxetine|60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)
62023187|NCT00408993|PLACEBO_COMPARATOR|Placebo|Placebo every day (QD), by mouth (PO) for 12 weeks
62413981|NCT02143479||1:early conversion from Prograf® to Advagraf®|patients converted from Prograf® to Advagraf® in the first 3 months after transplantation
62795462|NCT04628429||Chronic Migraine|All patients who have been diagnosed with chronic migraine (≥15 headache days per month 8 of which with migrainous features) according to the diagnostic criteria of the International Classification of Headache Disorders, third edition (ICHD-3) and have been unsuccessfully treated with first-line prophylactic medication
62023188|NCT03906058|EXPERIMENTAL|Anlotinib|
62023189|NCT03660683|EXPERIMENTAL|Group A Dapa|Dapagliflozin 10 mg + Saxagliptin Placebo
62023190|NCT03660683|ACTIVE_COMPARATOR|Group B DapaSaxa|Dapagliflozin 10mg + Saxagliptin 5mg
62795463|NCT04628429||Healthy Control|Controls must be healthy (free of any diagnosed chronic disease, acute infection requiring medication, family history or personal history of migraine), chosen to be as similar as possible to migraine patients, in terms of age and sex.
62795464|NCT02579967|EXPERIMENTAL|1/ IOC Arm-Closed with amendment L (07/05/2019)|Immunosuppression Only Conditioning Arm
62023191|NCT03660683|PLACEBO_COMPARATOR|Placebo|Placebo Oral Tablet
62413982|NCT02143479||2:late conversion from Prograf® to Advagraf®|patients converted from Prograf® to Advagraf® between 3 months and one year after transplantation
62413983|NCT05718505|ACTIVE_COMPARATOR|SmartPill Monitoring System|"The SmartPill GI Monitoring System (Medtronic) offers a method for measuring gastric emptying time (GET), small bowel transit time (SBTT), colonic transit time (CTT), small bowel large bowel transit time (SLBTT) and whole gut transit time (WGTT) with a single test, which can be used as an aid for the diagnosis of both gastroparesis and slow transit constipation.~The SmartPill System measures pH, temperature and pressure. It is approved for use in the measurement of GI transit times by the FDA."
62413984|NCT05718505|EXPERIMENTAL|Atmo Motility Gas Capsule System|"The Atmo Motility Gas Capsule System (Atmo Biosciences) offers a novel method for measuring GET, SBTT, SLBTT, CTT and WGTT. This device measures temperature, relative humidity, hydrogen concentration and carbon dioxide concentration, along with indicators of fermentation activity, capsule tumble and antenna reflectance as it transit through the GI tract.~It has the added benefit of recording information on the fermentation and gas profiles within the GI tract."
62413985|NCT02670356|EXPERIMENTAL|Fish oil|fish oil, 1500 mg/day, EPA:DHA ratio of 4:1, each capsule containing 750 mg total EPA+DHA, 2 capsules/day for 10 weeks
62413986|NCT02670356|EXPERIMENTAL|krill oil|krill oil, 300 mg/day, each capsule containing 74 mg total EPA+DHA , 1 capsule/day for 10 weeks
62586906|NCT06169592||liver transplant group|
62795465|NCT02579967|EXPERIMENTAL|2/ RIC Arm - Closed with Amendment L (07/05/2019)|Reduced Intensity Conditioning Arm
62795466|NCT02579967|EXPERIMENTAL|3/ MAC Arm-Closed with amendment L (07/05/2019)|Myeloablative Conditioning Arm
62795467|NCT02579967|EXPERIMENTAL|4/ RIC-MMF Arm|Reduced Intensity Conditioning with MMF duration de-escalation design
62795468|NCT02579967|NO_INTERVENTION|5/ Donor Arm|Donor
62023192|NCT00919282|EXPERIMENTAL|Gemcitabine/folinic acid/5-FU|Gemcitabine 1g/m² 5-FU 750mg/m² FS 500 mg/m²
62023193|NCT04119284|EXPERIMENTAL|Anterior Vertebral Tethering|Anterior Vertebral Tether Vertebral body tethering done through anterior spine surgery under anesthesia.
62023194|NCT06103981||Group A|About 88 patients having pneumonia and developed acute liver injury That need observation of the outcome and hospital stay to evaluate acute liver injury impact
62795469|NCT02579967|EXPERIMENTAL|6/ RIC-SHORT Arm|Reduced Intensity Conditioning with shortened duration and dose-reduced PTCy
62795470|NCT06725303|EXPERIMENTAL|Excimer light|Light energy
62795471|NCT06725303|ACTIVE_COMPARATOR|Blue light|Light energy
62795472|NCT02673463|EXPERIMENTAL|Spironolactone|Spironolactone 25 mg once daily for 2 years
62795473|NCT02673463|PLACEBO_COMPARATOR|Placebo|Matched placebo once daily for 2 years
62795474|NCT00981461|ACTIVE_COMPARATOR|LLT Device 2009 9 Beam|HairMax LaserComb
62023195|NCT06103981||Group B|About 88 patients having pneumonia but did not develop acute liver injury that need observation of the outcome and hospital stay
62023196|NCT02384148||Healthy|Healthy volunteers with no inflammation diseases, no neoplasia, no allergy to lidocaine.
62023197|NCT02384148||Type 2 diabetic non obese|Type 2 diabetic patients with HbA1c\>6.5%, body mass index 19-30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
62219556|NCT01659853|EXPERIMENTAL|Overall Study|"In this crossover study of CD07805/47 gel 0.5%/CD07805/47 Vehicle and azelaic acid gel 15%, 70 subjects were randomly assigned to treatment sequence.~During Period 1 (15 days), 35 subjects received topical CD07805/47 gel 0.5% in the morning and topical CD07805/47 gel vehicle in the evening, and 35 received topical azelaic acid gel twice daily according to FDA approved prescribing information. Subjects crossed over to the other treatment in Period 2 (15 days)."
62413987|NCT02708940|ACTIVE_COMPARATOR|Usual care|Control arm - these patients will get usual care as part of the PHP and IOP programs at UCLA. They will not receive mobile support messages.
62413988|NCT02708940|ACTIVE_COMPARATOR|Participatory technology development|Intervention - Patients will have access to a website that allows them to co-create mobile support messages with their therapist to support their care as part of the PHP and IOP programs at UCLA.
62413989|NCT04624256|EXPERIMENTAL|Treatment (radiotherapy, genomic DNA testing)|Patients undergo SBRT per standard of care, then undergo collection of cheek swab and blood samples for the analysis of germline biomarkers. Afterwards, patients and their physicians engage in discussion about which form of radiotherapy to proceed with. Based on the decision, patients predicted to be at low risk of toxicity with SBRT continue to receive SBRT over 14 days while patients predicted to be at high risk of toxicity with SBRT will be counseled to undergo either conventionally fractionated radiotherapy over 63-70 days, moderate hypofractionated radiotherapy over 28-35 days, or may opt to still receive SBRT over 14 days per standard of care.
62413990|NCT03574623|EXPERIMENTAL|CCFES|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses an electrical stimulator and surface electrodes placed over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. During the lab visits, participants in the CCFES group will use CCFES to assist hand opening during occupational therapy task practice. During their home sessions, participants in the CCFES group will use CCFES to perform hand opening exercise.
62413991|NCT03574623|ACTIVE_COMPARATOR|cNMES|Cyclic Neuromuscular Electrical Stimulation (cNMES) uses an electrical stimulator and surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation to open the weak hand. The stimulation automatically turns on and off causing the weak hand to open repetitively for several seconds at a time. During the lab visits, participants in the cNMES group will receive occupational therapy task practice. During their home sessions, participants in the cNMES group will use cNMES to perform hand opening exercise.
62413992|NCT03574623|ACTIVE_COMPARATOR|Task Oriented Therapy|Task Oriented Therapy (TOT) focuses on practicing using the weak hand to practice activities of daily living tasks. During the clinic visits, participants in the TOT group will receive occupational therapy task practice. During their home sessions, participants in the TOT group will practice using their hand to complete a list of tasks given to them by the therapist to ensure that the participant receives a high dose of task practice.
62586907|NCT03098654|EXPERIMENTAL|Enhanced Intervention|"Members will have DM and HTN managed at the CTC together with their HIV care. Interventions include:~1. Community mobilization activities to inform community members of available services~2. Support at the local health center to aid clinicians in managing uncontrolled cases of DM and HTN, including training for clinical staff, glucometers/test strips, and BP monitors.~3. HIV counseling and serial rapid HIV testing~4. Blood glucose and blood pressure testing~5. DM/HTN medications as needed~6. Personalized diet and lifestyle counseling for all participants with elevated glucose or BP that includes education, dietary assessment and recommendations, advice on physical activity, and the need to regularly monitor their glucose/BP."
62586908|NCT03098654|NO_INTERVENTION|Control|Members in the control arm will receive community-level rapid HIV testing at the CTCs, which is the standard of care. HIV testing performed by the CTC is according to the National HIV Testing Algorithm (serial rapid testing using Determine HIV 1/2 and Uni-Gold HIV 1/2) which follows Tanzanian and international (WHO/CDC) standards for provision of HIV counseling and testing. Those who test positive for HIV will be referred to the CTC for the standard Tanzanian level of HIV care, which includes counseling and ART medication managed at the CTCs.
62795475|NCT00981461|SHAM_COMPARATOR|control device|control device
62795476|NCT01632020|PLACEBO_COMPARATOR|Placebo|Placebo 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
62023198|NCT02384148||Type 2 diabetic obese|Type 2 diabetic patients with HbA1c\>6.5%, body mass index \>30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
62023199|NCT02384148||obese|Obese non diabetic patients with HbA1c\<6.5%, body mass index \>30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
62219557|NCT01451216||ABI 50-70 y|patients suffering from acquired brain injury aged 50-70 years old
62433338|NCT03437460|PLACEBO_COMPARATOR|Prenatal vitamins|The placebo group participants receive a single dose of a pre-natal multivitamin.
62219558|NCT01451216||ABI 25-50y|Patients suffering from acquired brain injury aged 25-50 years oled
62219559|NCT03468205||Main Cohort|Main cohort of patients meeting all of the eligibility criteria enrolled through newspaper adds, flyers and via non personal recruitment.
62586909|NCT01116648|EXPERIMENTAL|Arm I (cediranib maleate and olaparib)|Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo CT or MRI as well as blood sample collection on the trial. Patients may also optionally undergo a tissue biopsy on the trial.
62413993|NCT03032575|OTHER|sample size 100|Study Design: This is a prospective observational cohort of Thai MSM who initiated ART at the time of AHI, defined as the first 30 days after HIV acquisition (Fiebig stages 1 through 5). Volunteers will be examined at baseline to determine the prevalence of HPV infection and HSIL at HIV diagnosis. They will then be followed longitudinally for new incidence of HPV and HSIL, as well as progression or regression of existing lesions.
62586910|NCT01116648|ACTIVE_COMPARATOR|Arm II (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo CT or MRI as well as blood sample collection on the trial. Patients may also optionally undergo a tissue biopsy on the trial.
62795477|NCT01632020|ACTIVE_COMPARATOR|Metformin|Metformin 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
62795478|NCT05042583|EXPERIMENTAL|experimental group|The experimental group was injected with 0.5% ropivacaine 6ml
62413994|NCT01177735|EXPERIMENTAL|Pomalidomide|
62413995|NCT06701513||Participants that have initiated deucravacitinib treatment|
62795479|NCT05042583|PLACEBO_COMPARATOR|Control group|control group was injected with 6ml normal saline.
62219560|NCT03468205||Subgroup|Smaller group of patients, meeting eligibility criteria for the main study, enrolled through clinical visits. These patients will be followed more closely and also be recorded in a logbook in order for later review. Some of the participants in this group will be interviewed in a semi-qualitative interview about their experiences of breathlessness.
62219561|NCT04490590|EXPERIMENTAL|Chidamide+ Etoposide capsule|"Chidamide: 30mg, twice a week(BIW), PO.~Etoposide capsule:50mg, quaque die （QD）, PO, d1-10，21days for one cycle. Patients receive the other treatment of chidamide and etoposide capsule, and those who have achieved PD(progressive disease) will give the other treatment."
62219562|NCT03312452|EXPERIMENTAL|Infusion pump group|Study subjects assigned to this group will receive intravenous fluid via an infusion pump (Hospira plum pump) during their surgery.
62219563|NCT03312452|ACTIVE_COMPARATOR|Gravity drip group|Study subjects assigned to this group will receive intravenous fluid via a gravity drip device during their surgery.
62219564|NCT03471351|EXPERIMENTAL|Tenalisib+Pembrolizumab|Participants receive Tenalisib in escalating doses Orally BID and pembrolizumab as a fixed dose intravenously (IV) in Escalation and Expansion.
62219565|NCT04727268||Group 1|"Retrospective data regarding genetic information will be collected from participants' medical records.~Deep phenotyping of participants will also be completed."
62413996|NCT00213629|OTHER|no arm|no arm
62413997|NCT04625634|EXPERIMENTAL|Consecutive work|Subjects will complete 2 consecutive days of simulated firefighting tasks in the heat. The simulated work consists of 20 minutes of simulated structural work in a hot environment, followed by 20 minutes of seated rest in a temperate room, mimicking a typical recovery period in structural firefighting. Subjects then re-enter the environmental chamber and complete 23 minutes of simulated overhaul work in a temperate environment.
62413998|NCT03259646|EXPERIMENTAL|Universal Education|Train providers to integrate screening, universal education, trauma informed counseling, and mobile health (mHealth) technology through the myPlan app safety decision aid in collaboration with local IPV programs as well as the integration of documentation and quality improvement templates and measures into clinical settings.
62586911|NCT06653465|EXPERIMENTAL|intravenous aceteminophen group|50 ml contains 500 mg of acetaminophen will be administered for the first dose when the surgical suture begin at the end of surgery and thereafter repeated every 6 hours for the following 7 doses using automatic intravenous pump (4g acetaminophen diluted with 0.9% saline to 400 ml), and every bolus of 50 ml will be finished within 10 minutes.
62795480|NCT03097965|ACTIVE_COMPARATOR|DIET|"* High Phyto-PRO food plan~* Physical activity~* Cognitive behavioral program"
62795481|NCT03097965|EXPERIMENTAL|PROGRAM|"* High Phyto-PRO food plan~* Physical activity~* Cognitive Behavioral Program~* Protein Shakes~* Phytosterols supplement~* Berberine supplement~* Anti-oxidant supplement~* Probiotic supplement~* Fish Oil supplement~* Multiple Vitamin/Multiple Mineral supplement"
62795482|NCT00622505|EXPERIMENTAL|Zoledronic acid|Participants received 4 milligrams (mg) or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes, every 4 weeks or every 12 weeks for up to 96 weeks based on the participants most recent urine N-telopeptide of type 1 collagen (NTx) measurement (greater than or equal to \[≥\] 50 nanomoles per millimoles \[nmol/mmol\] creatinine or \<50 nmol/mmol creatinine, respectively).
62795483|NCT01111435||Individuals with Multiple Sclerosis|
62795484|NCT06725758|EXPERIMENTAL|ODM-212|ODM-212 5mg and/or 40mg tablets
62586912|NCT06653465|PLACEBO_COMPARATOR|saline placebo group|50 ml 0.9% saline will be administered for the first dose placebo when the surgical suture begin at the end of surgery and thereafter repeated every 6 hours for the following 7 doses using automatic intravenous pump (400ml 0.9% saline without acetaminophen), and every bolus of 50 ml will be finished within 10 minutes.
62413999|NCT03259646|NO_INTERVENTION|Standard Practice|Standard clinical practice
62795485|NCT03275285|EXPERIMENTAL|Isatuximab + Carfilzomib + Dexamethasone (IKd)|Isatuximab (intravenous) on day 1, 8, 15 and 22 of 1st cycle, then on day 1 and 15 of subsequent cycles in combination with carfilzomib (intravenous) on day 1, 2, 8, 9, 15 and 16 + dexamethasone (intravenous or by mouth \[po\]) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle.
62414000|NCT03190707|EXPERIMENTAL|Intervention|The intervention consists of three key components aiming at promoting a better attachment between child and mother/parents and through that giving the child the best possible beginning of life. The three components aim at: 1) detecting ill-being in vulnerable pregnant woman and initiation of potential treatment, 2) strengthening knowledge sharing and organizing the course for the families across the sectors, 3) strengthening parenting skills.
62586913|NCT00726765||Referral Strategy 1|"Patient meets at least one of the following three criteria:~1. Inflammatory back pain~2. Human leukocyte antigen B27 (HLA-B27)~3. Sacroiliitis demonstrated by imaging (X-ray, magnetic resonance imagining \[MRI\], bone scan \[if previously available\])"
62586914|NCT00726765||Referral Strategy 2|"Patient meets at least two of the following six criteria:~1. Inflammatory back pain~2. HLA-B27~3. Sacroiliitis (on imaging)~4. Family history of AS~5. Good response of back pain to nonsteroidal anti-inflammatory drugs (NSAIDs)~6. Known Extra Articular Manifestations (Uveitis, Iridocyclitis, Psoriasis, Inflammatory Bowel Disease)"
62586915|NCT06405828|EXPERIMENTAL|ACCESS Supportive Care|Participants randomized to the intervention arm (n=30) will be connected to the navigator to with the ACCESS Supportive care
62586916|NCT06405828|PLACEBO_COMPARATOR|Attention Control|Participants randomized to the attention control arm (n=30) will be connected with an unblinded RC .
62795486|NCT03275285|ACTIVE_COMPARATOR|Carfilzomib + Dexamethasone (Kd)|Carfilzomib (intravenous) on day 1, 2, 8, 9, 15, 16 + dexamethasone (intravenous or po) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle.
62795487|NCT01815827|ACTIVE_COMPARATOR|Caucasian Healthy volunteers|
62795488|NCT01815827|EXPERIMENTAL|Japanese Healthy volunteers|
62795489|NCT03636789|EXPERIMENTAL|Neurological consultation group|
62795490|NCT04966507|ACTIVE_COMPARATOR|Listerine Cool Mint Antiseptic Mouthwash|Daily use of an antibacterial mouthwash (Listerine Cool Mint Antiseptic Mouthwash) during the 12-week follow-up period.
62414001|NCT03190707|NO_INTERVENTION|Control|The existing practice for psychosocial vulnerable pregnant women on Gentofte-Herlev Hospital, Denmark, will be offered for women allocated to the control group. The control group will be measured at the same follow-up periods as the intervention group.
62586917|NCT02219789|EXPERIMENTAL|Treatment (alisertib, fulvestrant)|Patients receive fulvestrant IM on day 1 (days 1 and 15 of course 1 only) and alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62795491|NCT04966507|PLACEBO_COMPARATOR|Biotene Oral Rinse|Daily use of a placebo mouthwash with no known antibacterial qualities (Biotene Oral Rinse) during the 12-week follow-up period.
62795492|NCT06725381|EXPERIMENTAL|Dose escalation|
62219566|NCT01952353|EXPERIMENTAL|Preoperation TACE arm|In the preoperative TACE arm (Arm 2), patients underwent TACE followed by surgical resection. Preoperative TACE sessions were repeated once at 4-week intervals unless patients showed either PD or PVTT PD. Then, the patients were prepared for surgical resection, with the exception of those with unresectable disease after TACE For patients who had unresectable disease after TACE, plans for surgical resection were abandoned and the subsequent treatment course was determined by his/her attending oncologist
62219567|NCT01952353|ACTIVE_COMPARATOR|Resection arm|Liver resection Plus Thrombectomy
62219568|NCT02679508|EXPERIMENTAL|Vonoprazan group|Vonoprazan 20 mg administered orally once daily in the healing phase + vonoprazan 10 mg (as the initial dose and adjusted to vonoprazan 10 mg or 20 mg) administered orally once daily in the maintenance phase
62219569|NCT02679508|ACTIVE_COMPARATOR|Lansoprazole group|Lansoprazole 30 mg administered orally once daily in the healing phase + lansoprazole 15 mg (as the initial dose and adjusted to lansoprazole 15 mg or 30 mg) administered orally once daily in the maintenance phase
62586918|NCT02640404|EXPERIMENTAL|Menactra® Vaccine (9 to 23 Months)|Participants (infants and toddlers) received 2-dose series of study vaccine with 3-month interval (first dose at Day 0 and second dose 3 months after dose 1).
62586919|NCT02640404|EXPERIMENTAL|Menactra® Vaccine (2 to 55 Years)|Participants (children, adolescents and adults) received 1 dose of study vaccine at Day 0.
62586920|NCT03379753|EXPERIMENTAL|Intervention group|Those patients randomized to intervention group will be exposed to the diad of music and positive images in a private hospital room in addition to receiving standard care.
62586921|NCT03379753|NO_INTERVENTION|Control group|Those patients randomized to control group will receiving standard care in a private hospital room with an un-modified post operative environment.
62795493|NCT04837573|EXPERIMENTAL|Group 1 Intervention, Weeks 1-8|During Weeks 1-8, Group 1 receives the Intervention and Group 2 receives no treatment.
62795494|NCT04837573|ACTIVE_COMPARATOR|Group 2 Intervention, Weeks 9-16|During Weeks 9-16, Group 2 receives the Intervention and Group 1 receives no treatment.
62795495|NCT03291717|EXPERIMENTAL|Bridging Community Gaps Photovoice (BCGP)|The BCGP program is a 6-month photovoice-based intervention to help individuals with psychiatric disabilities enhance their community participation.
62586922|NCT02627326|ACTIVE_COMPARATOR|Group 1|Interventions done in 30 patients and included conventional endodontic treatment (ET) and periodontal surgery . After 3 months of completion of endodontic therapy without using 2%chlorhexidine gluconate gel intracanal medicament , periodontal surgery in the form of open flap debridement (OFD) was performed.
62795496|NCT03291717|NO_INTERVENTION|Services as Usual|Individuals in this group continue with their regular mental health services with no additional intervention.
62795497|NCT05565703|EXPERIMENTAL|Intervention Group|This group is randomly selected from the Acute care for elders unit and receives a one hour intervention with the PARO robotic seal two days in a row during their hospital stay.
62219570|NCT01319084||ARMES group|Surgeons who watch Tilepro program before da Vinci Robotic Surgery.
62219571|NCT01319084||normal group|Surgeons who do not watch Tilepro program before da Vinci Robotic Surgery.
62414002|NCT04874311|EXPERIMENTAL|Experimental Arm A: treatment by bintrafusp alfa combined with doxorubicin|Soft-tissue sarcoma patients with an inflammed tumor will be treated with bintrafusp alfa combined with doxorubicin for 6 cycles, followed by bintrafusp alfa maintenance
62586923|NCT02627326|ACTIVE_COMPARATOR|Group 2 Chlorhexidine|Interventions done in 30 patients and included intracanal medicament . After biomechanical preparation of root canal, 2%Chlorhexidine gluconate gel as an intracanal medicament was placed in root canal from pulp chamber to apex for 3 months (replacing every month). After 3 months,periodontal surgery in the form of open flap debridement (OFD) was performed in the respective tooth and medicament was changed and placed further for 3 months (replacing every month). Obturation was done after 3 months of OFD.
62586924|NCT06151704|EXPERIMENTAL|True high intensity laser therapy on lumbar region, sciatic, tibial, and peroneal nerves|The laser scanner, 50 cm from the skin, will target the area from the 12th ribs to the upper iliac crest, 4.2 cm lateral to the spine. The sciatic, tibial, and peroneal nerves will also be irradiated.
62586925|NCT06151704|SHAM_COMPARATOR|Deactivated high intensity laser therapy, an audio device will mimic the laser's operational sound|the laser will remain deactivated, and an audio device will generate a simulation of the operational sound of the device. The subject will also participate in the same foundational treatment regimen involving motor control exercises as the intervention group.
62586926|NCT01151202|EXPERIMENTAL|AG NPP709 syrup|AG NPP709 contains Ivy leaf extract and coptis rhizoma extract
62586927|NCT01151202|ACTIVE_COMPARATOR|Ivy leaf extract syrup|
62586928|NCT04486053||Patients with flexor tendon injury|Patients between the ages of 6-18 who have applied to orthopedics emergency department due to hand injury and have been operated with flexor tendon injury, for the last 3 years, were retrospectively scanned from hospital record. Eligible patients for the study were informed about the study by telephone and requested to come hospital for further evaluations including sensory, motor and functional assessments.
62219572|NCT01001559||Deplin + antidepressant|Deplin in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)
62219573|NCT01001559||Antidepressant alone|SSRI or SNRI alone
62023200|NCT05248893|EXPERIMENTAL|AGN-151586|Participants will receive 5 intramuscular injections in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may receive up to 2 additional cycles of open-label treatments.
62219574|NCT02947087|ACTIVE_COMPARATOR|Prolastin-C|Subjects will be given Prolastin-C intravenously at 60mg/kg weekly for 4 weeks.
62219575|NCT02947087|PLACEBO_COMPARATOR|Placebo|Subjects will be given Saline weekly for 4 weeks.
62219576|NCT01781507|EXPERIMENTAL|Cetirizine|Cetirizine 10 mg orally once a day
62414003|NCT04874311|OTHER|Standard Arm B: treatment by doxorubicin|Soft-tissue sarcoma patients with an inflammed tumor will be treated with doxorubicin for 6 cycles
62586929|NCT01826890|EXPERIMENTAL|NAVA technology|Following randomisation, a NAVA catheter will be introduced. The Electrical Activity of the Diaphragm (EAdi) will be viewed primarily to ensure a minimum level of diaphragm activation during the weaning phase. NAVA mode suitability/safety assessments will be conducted in all patients prior to the first initiation of the NAVA mode. The NAVA preview function on the Maquet Servo-i ventilators will be used to transfer from the previous mode to the NAVA mode, and the assessment will last for a maximum of 30 minutes. We are recommending the use of the NAVA ventilation mode during the weaning period. Following the commencement of weaning, sedation holds and spontaneous breathing trials will be conducted according to local protocols.
62023201|NCT05402267||OA: OME-Adenoid group|Patients who meet the follow inclusion criteria will be considered eligible as the OME-Adenoid (OA) group
62414004|NCT04874311|EXPERIMENTAL|Experimental Arm C: treatment by bintrafusp alfa combined with doxorubicin|Soft-tissue sarcoma patients with a cold tumor will be treated with bintrafusp alfa combined with doxorubicin for 6 cycles, followed by bintrafusp alfa maintenance
62414005|NCT04874311|OTHER|Standard Arm D: treatment by doxorubicin|Soft-tissue sarcoma patients with a cold tumor will be treated with doxorubicin for 6 cycles
62023202|NCT05402267||CA: Control-Adenoid group|Patients who meet the follow inclusion criteria will be considered eligible as the Control-Adenoid (CA) group
62219577|NCT01781507|PLACEBO_COMPARATOR|Sugar pill|This will be the placebo arm
62219578|NCT03476707||Anemic|People with a preoperative hematocrit less than 0.39
62219579|NCT03476707||Non-anemic|People with a preoperative hematocrit greater than or equal to 0.39
62219580|NCT00492362|ACTIVE_COMPARATOR|A|Ergometer during hemodialysis
62219581|NCT00492362|ACTIVE_COMPARATOR|B|Pedometer use outside of hemodialysis
62219582|NCT01049295|EXPERIMENTAL|oil fish pearls|patients with invasive breast cancer who received 640 mg oil fish pearls 3 times a day
62219583|NCT01049295|PLACEBO_COMPARATOR|placebo|patient with invasive breast cancer who received corn oil pearls as placebo 3 times a day
62219584|NCT00195091|EXPERIMENTAL|Tetrathiomolybdate (TM)|"Induction period - TM 40 mg is administered three x per day with meals and TM 60 mg at bedtime for a total of 4 doses (180 mg) per day.~Maintenance Period - Total TM dose per day will be in 20 mg increments to tailor the therapy to individualized patient needs to maintain the Cp level at 5-17mg/dL. Thus all dose modifications will be dependent on individual patient Cp levels. TM 40 mg p.o. BID with meals and TM 20 mg at bedtime. Subjects who have no evidence of disease (NED) and are receiving a benefit of TM can continue taking the drug for up to 120 months."
62414006|NCT03584035|EXPERIMENTAL|Sensory motor integration group|Sensory-motor integration exercises with 3 progressive steps, 30 minutes per sessions, 3 sessions per week for 6 weeks.
62414007|NCT03584035|ACTIVE_COMPARATOR|Conventional group|Conventional exercises include simple passive and active exercises and lower extremities strengthening exercises for balance and ambulation. The exercise session will last 30 minutes for 3 sessions per week. The total intervention period is 6 weeks.
62795498|NCT05565703|ACTIVE_COMPARATOR|Attention Control Group|This group is randomly selected from the Acute Care for Elders unit and receives a one hour visit from the Researcher or research assistant two days in a row.
62023203|NCT05402267||CO: Control-OME group|Patients who meet the follow inclusion criteria will be considered eligible as the Control-OME (CO) group
62023204|NCT05402267||control group|Patients without OME and adenoid hypertrophy will be considered eligible as the control group
62795499|NCT04789876|EXPERIMENTAL|App Intervention Group (AIG)|Phosphate mobile app for 12 weeks.
62414008|NCT06115707|ACTIVE_COMPARATOR|The lying flat group|Patients in lying flat intervention to be nursed lying flat (0°-10°) after endovascular therapy is made and to remain in this position for 72 hours.
62586930|NCT01826890|NO_INTERVENTION|Standard Care|A NAVA catheter will be inserted following randomisation. The NAVA capabilities of the ventilator will be disabled. Patients will be ventilated according to local weaning protocol as per current standard care with either Pressure Support, Synchronised Intermittent Mandatory Ventilation, Volume Controlled Ventilation, Pressure Controlled Ventilation or Pressure Regulated Volume Controlled Ventilation. Following the commencement of weaning, sedation holds and spontaneous breathing trials will be conducted according to local protocols.
62586931|NCT03845582|EXPERIMENTAL|ALK-001|Capsule
62795500|NCT04789876|ACTIVE_COMPARATOR|Dietitian Intervention Group (DIG)|One-off 45-minute dietary counselling delivered by a dietitian at the baseline of the study.
62795501|NCT02956694|EXPERIMENTAL|Professional training|Professional e-learning program on shared decision making including two components: (1) a self-directed e-learning activity on shared decision making, lasting about 1 hour, that participants could complete in several sittings; and (2) five evidence summaries named Decision Boxes (DBs).
62023205|NCT06428747||30 filtered backed RBCs.|detection of micro-particles.
62023206|NCT06428747||30 non-filtered backed RBCs.|detection of micro-particles
62023207|NCT00659269|ACTIVE_COMPARATOR|Multivitamin (MV)|1 multivitamin pill will be taken orally, daily starting on the first day of chemotherapy and continuing for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts)
62023208|NCT00659269|EXPERIMENTAL|Multivitamin + Vitamin B12 + Vitamin B6|"1 multivitamin pill will be taken orally, daily starting on the first day of chemotherapy and continuing for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts).~The patient will also take the following, starting on the first day of chemotherapy:~1. pyridoxine 50 mg three times per day, orally and continue for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts)~2. Vitamin B12 one mg injected intramuscularly, every 3 or 4 weeks, depending on the timing of the chemotherapy for 4 doses."
62023209|NCT06247176|EXPERIMENTAL|Autism Spectrum Disorder Habituation Group|This will be the group of subjects with Autism and sensory over-responsivity. This group will go through a mock-MRI, a pre-habituation MRI, the habituation protocol in virtual reality, and a post-habituation MRI.
62414009|NCT06115707|EXPERIMENTAL|The head elevation group|Patients in the sitting up intervention should be nursed with their head elevated (30°-40°) by raising the head of the bed (or using extra pillows or wedges) after undergoing endovascular therapy, and to remain in this position for 72 hours.
62414010|NCT03356834|EXPERIMENTAL|TDF switch to TAF|Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Tenofovir Alafenamide(TAF) 25mg daily
62414011|NCT03356834|ACTIVE_COMPARATOR|Maintaining on TDF|Maintaining on Tenofovir Disoproxil Fumarate(TDF) 300mg daily
62414012|NCT01518465|EXPERIMENTAL|Arm I (5000 IU dalteparin)|Patients receive a prophylactic dose of dalteparin SC on days 1-28; lenalidomide PO on days 1-21; and low-dose dexamethasone PO on days 1, 8, 15, and 22.
62586932|NCT03845582|PLACEBO_COMPARATOR|Placebo|Capsule
62795502|NCT06439277|EXPERIMENTAL|Tirzepatide|Participants will receive tirzepatide subcutaneously (SC).
62795503|NCT06439277|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo SC.
62795504|NCT05956899|EXPERIMENTAL|Group A|Group A will receive a stat dose of IV palonosetron 1.5mcg/kg prior to commencement of general anaesthesia.
62795505|NCT05956899|ACTIVE_COMPARATOR|Group B|Group B will receive a stat dose of IV ondansetron 0.15mg/kg at the start of wound closure.
62795506|NCT00585520|ACTIVE_COMPARATOR|PG|
62795507|NCT00585520|PLACEBO_COMPARATOR|PLA|
62795508|NCT01186991|EXPERIMENTAL|Onartuzumab + Bevacizumab + Paclitaxel|Participants will receive treatment with onartuzumab, bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable drug-related toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
62795509|NCT01186991|EXPERIMENTAL|Onartuzumab + Placebo + Paclitaxel|Participants will receive treatment with onartuzumab, placebo matching to bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
62795510|NCT01186991|ACTIVE_COMPARATOR|Placebo + Bevacizumab + Paclitaxel|Participants will receive treatment with placebo matching to onartuzumab, bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
62586933|NCT06666348|EXPERIMENTAL|Mirdametinib + IV Vinblastine|Patients will receive oral mirdametinib twice daily (continuous) at a fixed dose (2mg/m2 PO BID, rounded to the nearest 1mg (capsules) or nearest 0.5 mg (dispersible tablets), up to a maximum of 4 mg BID) for a total of 13 cycles. Each cycle will last 28 days.
62586934|NCT06569706|EXPERIMENTAL|Nipple-Sparing Mastectomy, with immediate breast reconstruction|20 patients female with breast cancer will have a Nipple-Sparing Mastectomy, with immediate breast reconstruction
62586935|NCT06664138|OTHER|Group Etomidate & Remimazolam|Patients will receive both etomidate and remimazolam once each to compare their effects while minimizing individual differences in response to the medications. Group E will use etomidate first, followed by remimazolam in the subsequent session.
62586936|NCT06664138|OTHER|Group Remimazolam & Etomidate|Patients will receive both etomidate and remimazolam once each to compare their effects while minimizing individual differences in response to the medications. Group R will use remimazolam first, followed by etomidate in the subsequent session.
62586937|NCT04782895|EXPERIMENTAL|Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) group|Subjects would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .
62023210|NCT06247176|ACTIVE_COMPARATOR|Neurotypical Habitation Group|This will be the group of subjects who are neurotypical peers. This group will go through a mock-MRI, a pre-habituation MRI, the habituation protocol in virtual reality, and a post-habituation MRI.
62414013|NCT01518465|EXPERIMENTAL|Arm II (200 IU/kg dalteparin)|Patients receive a therapeutic dose of dalteparin SC on days 1-21 and lenalidomide PO and low-dose dexamethasone PO as in Arm I.
62586938|NCT04782895|ACTIVE_COMPARATOR|Gardasil®9 group|Subjects would receive 3 doses of 270μg/0.5ml Gardasil®9 .
62795511|NCT05813964|ACTIVE_COMPARATOR|Event-driven PrEP with TDF/FTC|Participants randomly assigned to the event-driven TDF/FTC arm will be instructed to take a loading dose of two single tablets containing coformulated TDF/FTC (300/200mg) 2 to 24 hours before sexual intercourse, followed by a third pill 24 hours after the first drug intake and a fourth pill 24 hours later. In case of daily sexual intercourses, they will be instructed to take one pill per day until the last sexual intercourse, then to take the two post-exposure pills.
62795512|NCT05813964|EXPERIMENTAL|Event-driven PrEP with TAF/FTC|Participants randomly assigned to the event-driven TAF/FTC arm will be instructed to take one single tablet containing coformulated TAF/FTC (25/200mg) with or without food 2 to 24 hours before sexual intercourse followed by a second pill 24 hours after the first drug intake. In case of daily sexual intercourses, they will be instructed to take one pill per day until the last sexual intercourse and then a last pill 24 hours later.
62795513|NCT01581398|EXPERIMENTAL|A1(Genotype2/3)|Ypeginterferon alfa-2b 180μg/week, in combination with Ribavirin 800mg/day
62586939|NCT05284448|EXPERIMENTAL|Pentoxifylline Group|25 patients will receive pentoxifylline (Trental SR®) 400 mg three times daily with their standard therapy for 6 months.
62586940|NCT05284448|NO_INTERVENTION|Control Group|25 patients will receive their standard therapy only
62586941|NCT06684418||Retrospective Cohort|"Enrolling about 5,000 early-stage NSCLC patients from January 2018 to June 2024 across 25 centers in China, data including chest CT scans and clinicopathological parameters will be used to train and validate the AI model. Patients will be divided into high-risk and low-risk groups based on the model's risk score, and clinical benefits of treatments like lymph node dissection, adjuvant therapy, and SBRT will be analyzed."
62586942|NCT06684418||Prospective Cohort|Enrolling 1,000 patients from November 2024 to October 2025, this cohort will prospectively validate the AI model's performance and explore the biological basis of metastasis by analyzing pathological tissues, RNA sequencing, and tumor immune microenvironment characteristics.
62586943|NCT01214369|ACTIVE_COMPARATOR|X-tip intraosseous injection|
62795514|NCT01581398|ACTIVE_COMPARATOR|A2(Genotype 2/3)|Pegasys 180μg/week, in combination with Ribavirin 800mg/day
62795515|NCT01581398|EXPERIMENTAL|B1(Non-genotype 2/3)|Ypeginterferon alfa-2b 180μg/week, in combination with Ribavirin 1000-1200mg/day based on body weight
62795516|NCT01581398|ACTIVE_COMPARATOR|B2(Non-genotype 2/3)|Pegasys 180μg/week, in combination with Ribavirin 1000-1200mg/day based on body weight.
62795517|NCT06108219|EXPERIMENTAL|Experimental (Cohort A)|Patients who meet the entry criteria for study CORT118335-862 (Cohort A) will be enrolled to receive 100 mg of miricorilant, twice a week for 48 weeks.
62795518|NCT06108219|PLACEBO_COMPARATOR|Placebo (Cohort A)|Patients who meet the entry criteria for study CORT118335-862 (Cohort A) will be enrolled to receive a matching placebo twice a week for 48 weeks.
62795519|NCT06108219|PLACEBO_COMPARATOR|Placebo (Cohort B)|Patients who meet the entry criteria for study CORT118335-862 (Cohort B) will be enrolled to receive a matching placebo twice a week for 24 weeks.
62023211|NCT06311123||patients with active ulcerative colitis|patients with active ulcerative colitis starting ozanimod therapy
62023212|NCT03073889|EXPERIMENTAL|Block|Scalp nerve block with 10ml solution of 0.75% ropivacaine before skin incision, n=15
62586944|NCT01214369|ACTIVE_COMPARATOR|PDL injection|
62586945|NCT04655092|EXPERIMENTAL|P1101 (Ropeginterferon alfa-2b)|Conventional treatment based on phlebotomies, lowdose aspirin (acetylsalicylic acid, 75-150 mg/day) plus the subcutaneous administration of pegylated prolineinterferon alpha-2b (P1101, Ropeginterferon alfa-2b) once every 2 weeks.
62795520|NCT06108219|EXPERIMENTAL|Experimental (Cohort B)|Patients who meet the entry criteria for study CORT118335-862 (Cohort B) will be enrolled to receive 100 mg of miricorilant, twice a week for 6 weeks. Dose will be escalated to 200 mg of miricorilant, twice a week for 18 weeks.
62795521|NCT01034930|ACTIVE_COMPARATOR|Retentive Anchors|23 patients will receive as retention system for overdentures Retentive Anchors (Straumann).
62795522|NCT01034930|ACTIVE_COMPARATOR|Magnets|23 patients will receive Magnets (Straumann) as retention system for overdenture.
62795523|NCT01034930|ACTIVE_COMPARATOR|Locator System|23 patients will receive Locator System (Straumann) as retention for the mandibular overdenture.
62023213|NCT03073889|ACTIVE_COMPARATOR|Infiltration|Scalp infiltration with 10ml solution of 0.75% ropivacaine before incision, n=15
62023214|NCT03073889|NO_INTERVENTION|Control|the control group has no treatment, n=15
62414014|NCT04918095||Moderate-Severe COPD|COPD patients diagnosed GOLD 2- 3, C- D for moderate-severe, poorly controlled
62586946|NCT03251261||Specimen collection|
62414015|NCT02705417||Group A|Patients in whom selection of vascular access relied upon physical examination and medical history, during pre-operative surgical assessment
62795524|NCT05898126|EXPERIMENTAL|Renin-guided hemodynamic management|We will measure serum renin values every six hours. If the measured renin concentration increases by more that 20% compared with the last value, the target mean arterial pressure (MAP) will be elevated to 75-80 mmHg. If the subsequent renin level is still rising, the target MAP will be further raised to 85-90 mmHg and the addition of inotropes will be considered. If the first subsequent renin level decreases or increases by ≤20%, the target MAP will be kept at 75-80 mmHg. If the renin level at the subsequent measurement after reaching the highest step of management protocol is still increasing, a failure of the intervention will be declared, the target MAP will return to 65-70 mmHg. If renin level further decreases or increases ≤20% for two consecutive measurements, we will downgrade the target MAP to the previous step.
62795525|NCT05898126|SHAM_COMPARATOR|Usual care|Patients in the usual care group will be managed according to standard of practice at each participating center.
62795526|NCT01646281|ACTIVE_COMPARATOR|Flecainide|Patients randomized to flecainide will receive a 10-minute infusion of 2 mg/kg (maximal 150 mg) flecainide. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
62795527|NCT01646281|ACTIVE_COMPARATOR|Vernakalant|Patients randomized to vernakalant will receive a 10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
62795528|NCT04726722|EXPERIMENTAL|Design of the CBT treatment content|Patient determined CBT content (i.e. person-centered) vs. therapist determined I-CBT content
62414016|NCT02705417||Group B|Patients who underwent vascular mapping using color Doppler Ultrasonography in addition to physical examination and history during pre-operative evaluation.
62414017|NCT04779242|EXPERIMENTAL|Omadacycline|Omadacycline 100 mg IV; Omadacycline 300 mg PO (2 x 150 mg tablets); QD Dosing; 7-10 day duration.
62414018|NCT04779242|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin 400 mg IV; Moxifloxacin 400 mg tablets; QD Dosing; 7-10 day duration
62414019|NCT05438199|EXPERIMENTAL|apparatus use|"All participants will use the apparatus following the same procedures. They will weigh themselves on a scale located in the bathroom, use the apparatus with or without hats (hats refer to a plastic container used to catch stool/urine that needs to be placed between the toilet rim and the toilet seat and discarded after each use) and weigh themselves after using the toilet."
62414020|NCT02141438||Radium-223 dichloride (Xofigo, BAY88-8223)|Single-arm cohort observational study with CRPC patients with bone metastasis treated with Radium-223.
62795529|NCT04726722|EXPERIMENTAL|Control of support and feedback|Patient-controlled support and feedback (person-centred) vs. therapist -controlled.
62795530|NCT05594719|EXPERIMENTAL|Light group 1|Sun-like spectrum, color temperature of 5000K, shorter-wavelength dominant;
62795531|NCT05594719|PLACEBO_COMPARATOR|Light group 2|Sun-like spectrum, color temperature of 5000K, wavelength proportion similar to the sunlight
62795532|NCT05594719|EXPERIMENTAL|Light group 3|Sun-like spectrum, color temperature of 5000K, longer-wavelength dominant.
62795533|NCT02021669|EXPERIMENTAL|Omega-3 supplement|Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks
62795534|NCT02021669|PLACEBO_COMPARATOR|Placebo|Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
62795535|NCT02545218|ACTIVE_COMPARATOR|Perineorraphy.|Secondary surgical repair of the perineal body. Operation is performed by a urogynecologist in an operation theater in local anesthesia. The operation aims to re-create the anatomy in the injured perineum using 2-4 sutures.
62795536|NCT02545218|ACTIVE_COMPARATOR|Pelvic floor exercise.|Tutored pelvic floor exercise. A trained physio therapist evaluate the pelvic floor musculature and helps the patient to perform proper pelvic floor exercises using biofeedback. The patient receives a training scheme and meets the therapist regularly every second week during 4 months.
62795537|NCT01432392||1|
62795538|NCT05173896|EXPERIMENTAL|Tadalafil|Oral tadalafil (20 mg) capsules once daily for three months.
62414021|NCT03191435|EXPERIMENTAL|Inspiratory muscle training|Patients will perform the inspiratory muscle training using a load moderate of 30% of maximal inspiratory pressure (MIP 30%).
62414022|NCT03191435|PLACEBO_COMPARATOR|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a load of 2% of maximal inspiratory pressure (MIP 2%).
62414023|NCT05891496|EXPERIMENTAL|Study intervention period 1|Participants will receive either semaglutide or placebo matched to semaglutide once-weekly subcutaneous (s.c.) injections for 12 weeks as an add on therapy to standard of care. Participants initially received 0.25 milligram (mg) once weekly and the dose was then escalated once in 4 weeks until the maintenance dose (1.0 mg) was reached: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 12).
62414024|NCT05891496|PLACEBO_COMPARATOR|Study intervention period 2|All participants will receive 1.0 mg semaglutide s.c. injections once weekly for 52 weeks during study intervention period 2 as an add-on therapy to standard of care. Participants randomised to semaglutide s.c. 1.0 mg during study intervention period 1 remained on 1.0 mg target maintenance dose for 52 weeks from weeks 12-64. Participants initially randomised to placebo during study intervention period 1 will receive semaglutide s.c. in dose escalation fashion for 8 weeks (0.25 mg from weeks 12-16 and 0.5 mg from weeks 16-20) followed by a maintenance period from weeks 20-64 at dose 1.0 mg.
62414025|NCT00157573|EXPERIMENTAL|GM-CSF, Sargramostim Cohort 1|GM-CSF, Sargramostim 250 μg/m\^2 subcutaneous injection daily on days 1 to 14 in a 28-day cycle until disease progression or unacceptable toxicity for a median of 3 cycles.
62795539|NCT05173896|PLACEBO_COMPARATOR|Placebo|Oral placebo capsules once daily for three months.
62795540|NCT01880658|EXPERIMENTAL|Capecitabine|Patients undergo R0-R1 resection and receive adjuvant chemotherapy FOLFOX or Capox for no less than 4 months. Radiotherapy may be applied for patients with rectal cancer if clinicians suspect that is necessary. Then patients receive oral capecitabine for 12 months maintenance.
62414026|NCT00157573|EXPERIMENTAL|GM-CSF, Sargramostim Cohort 2|GM-CSF, sargramostim 150 μg/m\^2 subcutaneous injection daily for 28 days in a 28-day cycle until disease progression or unacceptable toxicity fora median of 3 cycles. GM-CSF, sargramostim dose escalation was permitted up to 250 μg/m\^2 per day if applicable based on toxicity and white blood cell count.
62414027|NCT04243005|ACTIVE_COMPARATOR|Conventional surgery|Aim of gross total resection (i.e. removal of contrast enhancing tumor) according to institutional practice. No limit in use of technical adjuncts in this arm.
62414028|NCT04243005|EXPERIMENTAL|Supramarginal surgery|Aim of supramarginal resection, where a margin of at least 10 mm is considered feasible prior to surgery. The resection is guided by the T2 volume (i.e. zone of edema) where removal of as much as possible of this zone (or beyond) is attempted as long as considered safe
62795541|NCT04890470|EXPERIMENTAL|oxytocin group|subjects with oxytocin treatment
62414029|NCT04469322|EXPERIMENTAL|Pharmacogenetic Test Guided|Treating physician for this group receives a detailed pharmacogenetic report for the patient, prioritizing 53 psychoactive medications into 4 use categories: preferential use, use as directed, may have significant limitations, and may have severe adverse reactions.
62795542|NCT04890470|EXPERIMENTAL|vasopressin group|subjects with vasopressin treatment
62795543|NCT04890470|PLACEBO_COMPARATOR|placebo group|subjects with placebo treatment
62795544|NCT06280716|EXPERIMENTAL|Lebrikizumab every 2 weeks (Q2W)|"Induction Period (Baseline-Week 16):~Two subcutaneous (SC) injections of lebrikizumab as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14. Induction period includes mono cohort with only lebrikizumab and combo cohort where lebrikizumab is in combination with TCS treatment."
62795545|NCT06280716|EXPERIMENTAL|Lebrikizumab every 4 weeks (Q4W)|"Maintenance Period (Week 16-Week 52):~Treatment from Week 16 to Week 52 is based on re-randomization of responders (from lebrikizumab Q2W arm) in the Induction Period. Participants re-randomized to the Lebrikizumab Q4W arm receive one lebrikizumab injection Q4W from Week 16 until Week 48."
62586947|NCT06194851|EXPERIMENTAL|Brief Cognitive Behavioral Conjoint Therapy for PTSD plus Intranasal Oxytocin|Couples will receive Brief Cognitive-Behavioral Conjoint Therapy (bCBCT) weekly. Prior to each session, the veteran participant will self-administer intranasal oxytocin.
62414030|NCT04469322|SHAM_COMPARATOR|Treatment As Usual|Treating physician receives a sham report listing the names of all drugs and treats patients according to standard of care.
62414031|NCT06516133|ACTIVE_COMPARATOR|Conventional radiotherapy with conventional margins w or w/o chemotherapy|Complete the full course of radiotherapy using the original treatment plan. PTV margin: 3mm.
62795546|NCT06280716|EXPERIMENTAL|Lebrikizumab every 8 weeks (Q8W)|"Maintenance Period (Week 16-Week 52):~Treatment from Week 16 to Week 52 is based on re-randomization of responders (from lebrikizumab Q2W arm) in the Induction Period. Participants re-randomized to Lebrikizumab Q8W arm receive one lebrikizumab injection Q8W, with one placebo injection 4 weeks after each lebikizumab injection from Week 16 until Week 48."
62795547|NCT06280716|EXPERIMENTAL|Escape Arm (Lebrikizumab Q2W)|"Maintenance Period (Week 16-Week 50):~Participants who require rescue treatment for atopic dermatitis (AD) during the Induction Period, or are non-responders at Week 16, will be eligible for treatment in an Escape Arm where participants will receive open label lebrikizumab Q2W from Week 16 through Week 50. In addition, participants who do not maintain an acceptable response during the Maintenance Period (have an EASI score \<50% of baseline), will be eligible for the Escape Arm."
62795548|NCT06280716|PLACEBO_COMPARATOR|Placebo|"Induction Period (Baseline-Week 16):~Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14. Induction period includes mono cohort with only Placebo and combo cohort where Placebo is given in combination with topical corticosteroid (TCS) treatment.~Maintenance Period (Week 16-Week 52):~Participants of responders at Week 16 will receive single injection of placebo every 4 weeks (Q4W) from Week 16 until Week 48."
62795549|NCT02795585||QFR group|Patients with stable angina pectoris and indication for FFR.
62795550|NCT04385186|EXPERIMENTAL|Convalescent plasma+Support treatment selected by the hospital|Participants will receive two doses of ABO - Rh compatible inactivated convalescent plasma, each one of 200 mililiters (mL), with a 24-hour interval via transfusion, for a final volume of 400 mL, meanwhile they continue to receive the supportive treatment chosen by the hospitals, according to each institutional protocol.
62795551|NCT04385186|ACTIVE_COMPARATOR|Support treatment selected by the hospital|The best support treatment selected by the hospital, according to each institutional protocol. Due to the ongoing development of knowledge of pathophysiology and scientific evidence of the available alternatives, it will be selected at the time of treatment.
62795552|NCT06411574|NO_INTERVENTION|Standard of care|Only the GES test result will be used to guide treatment as part of standard of care.
62795553|NCT06411574|EXPERIMENTAL|BSGM-guided care|Both the GES and BSGM test results will be used to guide treatment.
62795554|NCT03811171|EXPERIMENTAL|Treatment|The arm receives the investigational Break Wave procedure.
62795555|NCT00655616|ACTIVE_COMPARATOR|1|The active comparator arm consists of Flixotide® (fluticasone propionate) via accuhaler (Diskus) dry powder inhaler device as per current inhaled steroid dose plus oral montelukast
62795556|NCT00655616|PLACEBO_COMPARATOR|2|The placebo comparator arm consists of Seretide® (salmeterol plus equivalent dose of fluticasone) via accuhaler dry powder inhaler device as per current inhaled steroid dose plus placebo for montelukast
62795557|NCT04030975||interview|emergency physicians
62795558|NCT06725134|ACTIVE_COMPARATOR|Control|Standard-of-care basic behavior guidance during local anesthesia
62414032|NCT06516133|EXPERIMENTAL|Radiotherapy with smaller margin and online adaptive radiotherapy w or w/o chemotherapy|"Throughout the course of radiotherapy, the treatment plan is adjusted online based on the anatomical and dosimetric changes in the target volumes and organs at risk of the patients.~PTV margin: smaller."
62414033|NCT02033382||Healthy Controls|Age and gender matched healthy controls
62586948|NCT06194851|PLACEBO_COMPARATOR|Brief Cognitive Behavioral Conjoint Therapy for PTSD plus Intranasal Placebo|Couples will receive Brief Cognitive-Behavioral Conjoint Therapy (bCBCT) weekly. Prior to each session, the veteran participant will self-administer intranasal placebo solution.
62586949|NCT00680901|EXPERIMENTAL|CapeOx plus Lapatinib|CapeOx plus Lapatinib
62586950|NCT00680901|PLACEBO_COMPARATOR|CapeOx plus Placebo|CapeOx plus Placebo
62795559|NCT06725134|EXPERIMENTAL|Therapy dog presence|Therapy dog present during local anesthesia administration
62586951|NCT06293508|NO_INTERVENTION|Control Arm|Participants do not receive any message throughout the study period.
62795560|NCT00369577|PLACEBO_COMPARATOR|Inhaled Placebo|Inhaled Staccato Placebo, single dose
62586952|NCT06293508|EXPERIMENTAL|Experimental Arm 1|Participants in this group will receive a message on a weekly basis throughout the intervention period, which is 6 months, via WhatsApp.
62795561|NCT00369577|EXPERIMENTAL|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, single dose
62795562|NCT00369577|EXPERIMENTAL|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, single dose
62219585|NCT02289092|EXPERIMENTAL|Family Check-Up Intervention|Prior to the feedback session, trained clinicians will observe family interactions by reviewing the video-taped observations and questionnaires filled out by parents. Therapists then use this data to inform the intervention process and provide feedback to parents based on norms for this age period. Feedback sessions will include a discussion of goal attainment and plans to achieve goals, with specific attention to the parent's role in supporting positive behavior. Options for obtaining goals are based on the literature about empirically supported interventions for this age group and include (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
62219586|NCT02289092|NO_INTERVENTION|Control|Control families will receive services as usual that are being provided to the families within their school
62219587|NCT01683656|ACTIVE_COMPARATOR|ER Niacin/laropipant|ER niacin/laropiprant 1g/20 mg for the first 4 weeks and 2g/40mg from week 5 to the end of the study.
62219588|NCT01683656|PLACEBO_COMPARATOR|ER Niacin/laropipant Placebo|ER niacin/laropiprant placebo p.m.
62219589|NCT03012698|EXPERIMENTAL|RMS treatment|
62219590|NCT01581138|EXPERIMENTAL|12 week treatment|
62219591|NCT01581138|EXPERIMENTAL|16 week treatment|
62219592|NCT03891693|EXPERIMENTAL|Passeo-18 Lux and SUPERA® stent|Target lesion will be treated with Passeo-18 Lux Drug Eluting Balloon and SUPERA® stent during angioplasty
62414034|NCT02033382||Patients|Participants diagnosed with Schizophrenia, schizophreniform disorder, or schizoaffective disorder, depressed type that are naive to anti-psychotic treatment.
62414035|NCT05230160|EXPERIMENTAL|Intervention Group|The IF group will fast for 16 consecutive hours on 6 days per week with an 8-hour eating window (e.g., eat from 10 a.m. to 6 p.m.). The IF group will consume their habitual diet in terms of food choices and energy intake, but only during the 8-hour and full-day non-fasting periods. An RD will meet virtually with participants in the IF group at baseline to teach them the fasting protocol and how to manage energy intake and hunger, as well as to reinforce the requirement to not change habitual dietary practices. The research coordinator will call patients every two weeks to assess for changes in medications, compliance with the fasting protocol, and symptoms (assessed monthly) using the modified HBI.
62414036|NCT05230160|NO_INTERVENTION|Standard Medical Care Group|The control group will continue with their habitual dietary pattern. The research coordinator will call patients at baseline and every two weeks to assess for changes in medications and symptoms (assessed monthly) using the modified HBI.
62414037|NCT04507646|EXPERIMENTAL|True auricular acupuncture|Effective auricular acupuncture
62795563|NCT04457063|EXPERIMENTAL|penetrating keratoplasty|A prospective non-comparative non-randomized clinical study which was conducted on 12 eyes of 8 patients 4 males and 4 females who underwent PKP for keratoconus, and then toric ICL was implanted after minimum of one year with stable refraction
62795564|NCT03030118|ACTIVE_COMPARATOR|Hydroxychloroquine|Hydroxychloroquine will be administered as a once daily dose of 200 or 400 mg, based on the patient's weight. Treatment will be for 96 weeks.
62023215|NCT05217732|EXPERIMENTAL|Single dose of ZX-7101A treatment A|Administrated as a single oral dose in healthy subjects
62023216|NCT05217732|EXPERIMENTAL|Single dose of ZX-7101A treatment B|Administrated as a single oral dose in healthy subjects
62219593|NCT04826861|OTHER|Intervention for overweight pregnant women|Intervention will be delivered during antenatal visits in maternity care
62219594|NCT02059785|EXPERIMENTAL|Pinocembrin for Injection|40mg /60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day
62219595|NCT02059785|PLACEBO_COMPARATOR|placebo|60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day
62219596|NCT01611805|EXPERIMENTAL|GSK1605786 250mg|Opaque Swedish orange body and cap.
62219597|NCT01611805|PLACEBO_COMPARATOR|Placebo|Opaque Swedish orange body and cap.
62219598|NCT01611805|EXPERIMENTAL|GSK1605786 500mg|Opaque Swedish orange body and cap.
62219599|NCT01611805|EXPERIMENTAL|GSK1605786 1000mg|Opaque Swedish orange body and cap.
62219600|NCT01611805|EXPERIMENTAL|GSK1605786 500mg in fed|Opaque Swedish orange body and cap.
62219601|NCT01775150|EXPERIMENTAL|health education|health education via text messaging
62219602|NCT01775150|NO_INTERVENTION|no health education|no health education via text messaging
62219603|NCT05803031|EXPERIMENTAL|Group I (Test group)|Eleven patients with localized periodontitis, receiving full mouth non-surgical periodontal debridement followed by local delivery of tea tree oil gel as an adjunctive treatment.
62414038|NCT04507646|SHAM_COMPARATOR|Sham auricular acupuncture|Ineffective auricular acupuncture
62414039|NCT03785652|EXPERIMENTAL|LY03005 extended-release tablets|LY03005 extended-release tablets at 4 doses 40 mg, 80mg, 120mg or 160mg
62414040|NCT03785652|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62433339|NCT03437460|NO_INTERVENTION|Control group|Control-group participants are not provided with any treatment and they are fully informed regarding their treatment status.
62586953|NCT06293508|EXPERIMENTAL|Experimental Arm 2|Participants in this group will receive a message on a weekly basis throughout the intervention period, which is 6 months, via WhatsApp.
62023217|NCT05217732|EXPERIMENTAL|Single dose of ZX-7101A treatment C|Administrated as a single oral dose in healthy subjects
62586954|NCT00225225|ACTIVE_COMPARATOR|fixed calorie (500 kcal) Reduction|
62586955|NCT00225225|PLACEBO_COMPARATOR|Control (no diet change)|
62586956|NCT03244540|EXPERIMENTAL|PCA|Subarchnoid anesthesia with bupivacaine PCA with morphine in the PACU
62414041|NCT00903409|EXPERIMENTAL|"Simvastatin + Lovaza® (Non-switchers)"|"Open label Simvastatin + Lovaza® (omega-3-acid ethyl esters) NOTE: this group was originally assigned to Simvastatin + Lovaza® in the double-blind trial, hence in this open-label extension, they are termed Non-switchers"
62414042|NCT00903409|EXPERIMENTAL|"Simvastatin + Lovaza® (Switchers)"|"Open label Simvastatin + Lovaza® (omega-3-acid ethyl esters) NOTE: this group was originally assigned to Simvastatin + placebo in the double-blind trial, hence in this open-label extension, they are termed Switchers"
62414043|NCT06402513|EXPERIMENTAL|Ravagalimab|Participants will receive 2 (SC) subcutaneous injections of Ravagalimab via Pre-Filled Syringe at Day 1 and followed for 85 days
62414044|NCT03465072|EXPERIMENTAL|Exercise training|8 Weeks exercise training 3x per week 30-40 minutes per session
62414045|NCT02484131|EXPERIMENTAL|Educational materials/mail|Participants in this group will receive educational materials by mail on the first day of the follow-up period.
62414046|NCT02484131|EXPERIMENTAL|Educational materials/participant choice|Participants in this group will receive educational materials by participant choice on the first day of the follow-up period.
62414047|NCT02484131|NO_INTERVENTION|Control|Participants in this group will not receive any educational materials during hte follow-up period. Educational materials will be sent by mail after the completion of this study.
62023218|NCT05217732|EXPERIMENTAL|Single dose of ZX-7101A treatment D|Administrated as a single oral dose in healthy subjects
62414048|NCT04356196|EXPERIMENTAL|Verapamil group|45 patients will receive 80 mg oral verapamil 3 hours pre-operative
62414049|NCT04356196|EXPERIMENTAL|Bisoprolol group|45 patients will receive Bisoprolol 5mg PO 3 hours preoperative
62414050|NCT04356196|EXPERIMENTAL|placebo group|45 patients will receive placebo tablet PO 3 hours preoperative .
62414051|NCT06565377|EXPERIMENTAL|Multimodal biopsychosocial teleprehabilitation (BPS-teleprehab)|see intervention description
62414052|NCT06565377|ACTIVE_COMPARATOR|Best-evidence prehabilitation advice (control)|see intervention description
62023219|NCT05217732|EXPERIMENTAL|Single dose of ZX-7101A treatment E|Administrated as a single oral dose in healthy subjects
62023220|NCT05217732|EXPERIMENTAL|ZX-7101A food effect|Administered as a selected, single oral dose of ZX-7101A in fasting state and non-fasting (with food) state.
62414053|NCT00518011|EXPERIMENTAL|Erlotinib + Gemcitabine|Participants received Erlotinib 150 mg/day orally as a continuous schedule with Gemcitabine 1000 (mg/m\^2)/day, IV on Days 1, 8, 15 and every 4 weeks for 6 cycles.
62414054|NCT00518011|ACTIVE_COMPARATOR|Gemcitabine|Participants received Gemcitabine 1000 (mg/m\^2)/day, IV on Days 1, 8, 15 and every 4 weeks for 6 cycles.
62414055|NCT02601326|ACTIVE_COMPARATOR|Laparoscopic ventral mesh Rectopexy|Fixation of the rectum to the sacrum using laparoscopy and mesh
62414056|NCT02601326|ACTIVE_COMPARATOR|delorme's procedure|excision of excess rectal mucosa under spinal anesthesia then plication of the rectal muscles with vicryl 2/0 sutures
62414057|NCT01481961|EXPERIMENTAL|rTMS arm|
62414058|NCT06034301|NO_INTERVENTION|MEMS Cap Only|"If the participant is randomized to the control group, they will:~1. receive a brief education session and be handed a flyer about the importance of medication adherence~2. receive a MEMS cap and be given instructions on how to use it with their blood pressure medication"
62414059|NCT06034301|ACTIVE_COMPARATOR|Medication Reminder App + MEMS Cap|Intervention group that will be shown how to use the mobile phone medication reminder app and be given assistance downloading and setting it up on their personal phone.
62414060|NCT06098131|EXPERIMENTAL|Sliding Technique Group|Participants in the sliding technique group first adopted the SSP. The therapist main-tained the head in a less flexed and closer to neutral position. During this process, they performed full dorsiflexion of the foot, ensuring that the movements allowed the nerve to glide through its pathway rather than creating significant tension
62414061|NCT06098131|EXPERIMENTAL|Tension Technique Group|Participants in the tensioner technique group first adopted the SSP, then proceeded to enhance neural tension by simultaneously fully dorsiflexing the foot and fully flexing the cervical spine forward, thereby increasing tension throughout the nerve pathway. The technique is applied dynamically with relaxation intervals to prevent any potential negative effects on neural vasculature
62414062|NCT06098131|NO_INTERVENTION|Control Group|In this group the participants will be requested to position themselves on the plinth in supine line position. All participants in this group will not receive any intervention and they will be instructed to remain in this position for 20 minutes.
62414063|NCT04574037||follow up of stroke patients with a upper limb deficit|Usual follow up of stroke patients with a upper limb deficit
62795565|NCT03030118|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo will be administered as one or two capsules as a single daily dose, based on the patient's weight. Treatment will be for 96 weeks.
62795566|NCT06143267|EXPERIMENTAL|Infusion of NST or placebo at different blood glucose levels|In a randomized, double-blind crossover design, participants will undergo six experimental days with controlled plasma glucose levels, consisting of two euglycemic, two hyperglycemic (around 8mmol/l), and two hypoglycemic (around 2.5mmol/l) days, with each pair of similar days involving the administration of either saline (placebo) or NST.
62414064|NCT03889925|EXPERIMENTAL|Autologous conditioned plasma group|Participants in this group will receive a three-injection series of autologous conditioned plasma over the course of 3 consecutive weeks.
62023221|NCT04510064|EXPERIMENTAL|Treatment group|Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every two weeks, and HER-2 positive patients were added with Herceptin therapy. Camrelizumab 200mg on day 1, albumin bound paclitaxol 125mg/m² on day 1,oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² on day 1, and 5-FU 2600 mg/m² as 24-h infusion on day 1.Herceptin 6mg/Kg at the first time, followed by 4mg/Kg if needed.The efficacy of therapy was evaluated every 3 treatment cycles. If the tumor can be R0 resected after 6-9 cycles, then proceeded to surgery. After the operation, patients continued to receive the prior immunotherapy totally to 12 cycles or to the disease progressed or intolerable toxicity.
62414065|NCT03889925|EXPERIMENTAL|Autologous conditioned plasma with hyaluronic acid group|Participants in this group will receive a two-injection series of autologous conditioned plasma and hyaluronic acid (Hymovis, Fidia Pharmaceuticals) and a third injection on the third week of autologous conditioned plasma.
62023222|NCT06529666|ACTIVE_COMPARATOR|Comparison Arm|Residents in comparison arm receive a core foundation course and will take part in all 3 assessments (including 3 surveys and 2 video communication assessments) over the course of 18 months.
62023223|NCT06529666|EXPERIMENTAL|Intervention Arm|Residents in the intervention arm will receive (in addition to the core foundation course) 6 email modules and practice video communication assessments on weight management counseling. They will also attend 2 educational session and take part in all 3 assessments (including 3 surveys and 2 video communication assessments) over the course of 18 months.
62414066|NCT04522271|ACTIVE_COMPARATOR|Resistant Starch|Once daily oral consumption of 7.5 g/m2 of an individually optimized resistant starch for approximately 5 months
62414067|NCT04522271|PLACEBO_COMPARATOR|Placebo|Once daily oral consumption of a food-grade cornstarch that is readily digestible for approximately 5 months
62414068|NCT05451407|EXPERIMENTAL|TQB2618 injection combined with Toripalimab injection|TQB2618 injection combined with Toripalimab injection，21 days as a treatment cycle.
62414069|NCT06561334||Spasmodic Dysphonia patients|Adults diagnosed with Spasmodic Dysphonia who have received at least one botulinum toxin injection.
62414070|NCT06124534|EXPERIMENTAL|Blistim System|Occipital Nerve Stimulation using the BliStim Occipital Nerve Stimulator
62414071|NCT06537531||Patients|Patients from any geographical area of the Iberian Peninsula who decide to undergo scheduled surgery at our hospital during a period of 6 months (2024-25).
62414072|NCT03992261|EXPERIMENTAL|Halobetasol Propionate Foam|2 weeks of application, 2 times daily
62414073|NCT06351540|PLACEBO_COMPARATOR|0 mg THC|Inhaled Cannabis - 0 mg THC
62795567|NCT05564455|ACTIVE_COMPARATOR|SRK-T Formula for Prediction of refraction|To compare post-operative refractive outcome with Sanders Retzlaff Kraff theoretical (SRK T) and Kane formulae for intraocular lens (IOL) power calculation in cataract patients
62795568|NCT05564455|ACTIVE_COMPARATOR|Kane Formula for Prediction of refraction|To compare post-operative refractive outcome with Sanders Retzlaff Kraff theoretical (SRK T) and Kane formulae for intraocular lens (IOL) power calculation in cataract patients
62023224|NCT04121104|EXPERIMENTAL|SCS off|
62023225|NCT04121104|EXPERIMENTAL|SCS on|
62023226|NCT02863991|EXPERIMENTAL|375 mg ONC201|Patients received 375 mg ONC201 once every week in combination with dexamethasone.
62414074|NCT06351540|EXPERIMENTAL|5 mg THC|Inhaled cannabis - 5 mg THC
62414075|NCT06351540|EXPERIMENTAL|30 mg THC|Inhaled cannabis - 30 mg THC
62414076|NCT06627894|EXPERIMENTAL|Intervention - Internet Cognitive-Behavioral Therapy (CBT) for Depression|Participants will complete nine 45-minute sessions of an internet CBT for depression called Good Days Ahead (GDA; MindStreet, Inc.) with 20 minutes of therapist assistance per session on the phone over six months.
62414077|NCT06627894|ACTIVE_COMPARATOR|Active Control - Depression Education, Symptom Monitoring, and Usual Care|Participants will review nine 45-minute segments of depression education material on their own with 20 minutes of therapist assistance per segment on the phone over six months. They will also have access to and could receive current depression care in the targeted healthcare systems.
62023227|NCT02863991|EXPERIMENTAL|625 mg ONC201|Patients received 625 mg ONC201 once every week in combination with dexamethasone.
62023228|NCT03989817|ACTIVE_COMPARATOR|VIP|To investigate the role of VIP on cranial hemodynamic and headache in healthy volunteers.
62023229|NCT03989817|PLACEBO_COMPARATOR|Saline|To investigate the role of saline on cranial hemodynamic and headache in healthy volunteers.
62414078|NCT03026842|EXPERIMENTAL|Decitabine|Six cycles of decitabine IV over one hour at 20 mg/m2/day for 5 days, every 6 weeks
62586957|NCT03244540|EXPERIMENTAL|TAP|"Subarchnoid anesthesia with bupivacaine TAP (transversus abdominis plane block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.~PCA with morphine in the PACU"
62023230|NCT06635356||The frequency and change of sarcopenia in patients undergoing knee arthroplasty|Sarcopenia frequency and changes will be investigated in women and men between the ages of 50 and 75 who will undergo knee prosthesis surgery, with follow-ups to be performed before the operation, in the first month and in the third month after the operation.
62795569|NCT03231007||Innovators|Maternity units that implemented the Care Bundle to the highest level (according to an NHS survey in 2015) are categorised as 'Innovators'.
62795570|NCT03231007||Early Adopters|Maternity units that implemented the Care Bundle to the second-highest level (according to an NHS survey in 2015) are categorised as 'Early Adopters'.
62795571|NCT03231007||Late Adopters|Maternity units that implemented the Care Bundle to the third-highest level (according to an NHS survey in 2015) are categorised as 'Late Adopters'.
62795572|NCT03231007||Low Adopters|Maternity units that implemented the Care Bundle to the fourth-highest level (according to an NHS survey in 2015) are categorised as 'Low Adopters'.
62795573|NCT06039995|EXPERIMENTAL|(Adjuvant Oral Care) Intervention Group|This group represents the intervention arm of the study. Patients in this arm receive a combination of interventions, including Chlorhexidine mouthwash, toothbrushing, and the application of moisturizing gel on the interior and exterior surfaces of the oral cavity. This group is the focus of the study's investigation to determine the effectiveness of adjuvant oral care in reducing the incidence of Ventilator-Associated Pneumonia (VAP) and improving patient outcomes.
62219604|NCT05803031|PLACEBO_COMPARATOR|Group II (Control group)|Eleven patients with localized periodontitis, receiving full mouth non-surgical periodontal debridement only.
62414079|NCT03026842|ACTIVE_COMPARATOR|Conventional chemotherapy|Four cycles of conventional chemotherapy for 5 days, every 12 weeks. conventional chemotherapy includes in: DA regimen: Daunorubicin 45 mg/m2/day for 3 days, cytarabine 100 mg/m2/day for 5 days; MA regimen: Mitoxantrone 8 mg/m2/day for 3 days, cytarabine 100 mg/m2/day for 5 days; AA regimen: Aclacinomycin 20 mg/day for 5 days, cytarabine 100 mg/m2/day for 5 days.
62414080|NCT05026749|PLACEBO_COMPARATOR|Control Group|
62414081|NCT05026749|ACTIVE_COMPARATOR|AZM 20mg/kg Treatment Group|
62414082|NCT06409325|EXPERIMENTAL|the MST group|MST was conducted at 100 Hz and 100% output using a pulse width of 350 μs and a peak intensity of the magnetic field at 3.0 Tesla. The duration of magnetic stimulation was titrated using a 10-second train duration, starting from 2 seconds and increasing by 4 seconds in subsequent sessions, up to a maximum of 10 seconds (i.e., 200-1,000 pulses per session). In cases of poor seizure quality (\<15 s), the stimulation duration increment was set to 6 seconds in the next session. If no seizures were elicited, an additional 10-second stimulation was administered immediately. Subsequent MST treatments were maintained at a 10-second duration for a total of 1000 pulses.
62414083|NCT06409325|ACTIVE_COMPARATOR|the ECT group|For ECT, the pulse width of the electrical stimulus was set to 0.5 ms. The initial energy dosage was determined based on the patient's age, with subsequent sessions increasing by 5% increments. In cases of inadequate seizure duration (\<25 s), the maximum dosage was administered in the following session. If no seizures were induced, the maximum dosage was administered immediately.
62795574|NCT06039995|ACTIVE_COMPARATOR|(Traditional Oral Care) Control Group|This group represents the control arm of the study. Patients in this arm receive traditional oral care, which involves the use of 0.2% Chlorhexidine mouthwash only.
62795575|NCT05026359|EXPERIMENTAL|Bilateral ankle coordination training group|Exercise training of bilateral ankle coordination training group consisted of 30 minutes of bilateral ankle coordination training 3 days per week for 4 weeks (total 12 sessions)
62795576|NCT05026359|NO_INTERVENTION|General rehabilitation intervention group|Exercise training of walking and balance training consisted of 30 minutes of general rehabilitation intervention group 3 days per week for 4 weeks (total 12 sessions)
62795577|NCT06713330|OTHER|SSC|Experimental: 3M Stainless Steel Crowns. In this split-mouth design, subjects were randomly assigned to receive SSC in the left or right side of the mouth.
62795578|NCT06713330|EXPERIMENTAL|BioFLX Crown|Experimental: BioFLX Crowns. In this split-mouth design, subjects were randomly assigned to receive BioFLX crowns on the side opposite of the 3M Stainless Steel Crowns.
62795579|NCT04236388|ACTIVE_COMPARATOR|Dietary Ketone|Participants will consume three daily ketone drinks (one before each meal) for 2 weeks.
62795580|NCT04236388|PLACEBO_COMPARATOR|Placebo|Participants will consume three daily placebo drinks (one before each meal) for 2 weeks. .
62023231|NCT00374842|EXPERIMENTAL|GSK1247446A Formulation 1 Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the GSK1247446A vaccine adjuvanted with a full dose of adjuvant at Day 0. The adjuvanted GSK1247446A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62023232|NCT00374842|EXPERIMENTAL|GSK1247446A Formulation 2 Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the GSK1247446A vaccine adjuvanted with a half dose of adjuvant at Day 0. The adjuvanted GSK1247446A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62219605|NCT00518466|EXPERIMENTAL|treatment 1|"One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Days 4 - 21 of Period 2."
62414084|NCT02714140|EXPERIMENTAL|Group A: More preferred Existing + Common|Group A participants will be offered the common option and 3 currently available testing options that are targeted at the distribution of preferences among participants.
62414085|NCT02714140|EXPERIMENTAL|Group B: More preferred Enhanced + Common|"Group B participants will be offered the common option and 3 preference-informed enhanced testing options, which include combinations of features that may not yet be available in the study area."
62414086|NCT02714140|ACTIVE_COMPARATOR|Group C: Less preferred + Common|Group C participants will be offered the common option and 3 predicted less-preferred options. With the common option being the best option in Group C, this group is effectively a non-PB-HCT comparison group.
62414087|NCT00740532||Observation|Breast cancer patients treated with Herceptin-based therapy
62219606|NCT00518466|EXPERIMENTAL|treatment 2|"Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~One 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsules at Hour 0 on Days 4, 5, and 6 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules (Cardinal) and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2."
62023233|NCT00374842|ACTIVE_COMPARATOR|Fluarix Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62023234|NCT01473654|EXPERIMENTAL|ADAPT tool|prediabetes counseling using ADAPT tool
62023235|NCT01473654|NO_INTERVENTION|Control|
62219607|NCT00518466|EXPERIMENTAL|treatment 3|"Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsule at Hour 0 on Days 4, 5, and 6 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2."
62219608|NCT00518466|EXPERIMENTAL|treatment 4|"Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate IR tablet at Hour 0 on Days 1, 2, and 3 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and two 25 mg topiramate IR tablets at Hour 0 on Days 4, 5, and 6 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and three 25 mg topiramate IR tablets at Hour 0 on Days 7, 8, and 9 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Days 10 - 21 of Period 2."
62219609|NCT02838927||Hypoparathyroidism|No intervention.
62219610|NCT04242953|EXPERIMENTAL|SCO-120|
62219611|NCT04242953|PLACEBO_COMPARATOR|Matching Placebo|
62219612|NCT04284215|EXPERIMENTAL|Albumin paclitaxel|"Albumin paclitaxel 40mg/m2/week was injected into normal saline at the same time as radiotherapy, once a week. Cisplatin 75 mg/m2 was given intravenously for 2-3 days , carboplatin 300 mg/m2 and 2 days. (Because toxicity and heart problems can replace DDP)\] Repeat every cycle (21-28 days/cycle, minimum 2 cycles).~Three-dimensional radiotherapy:~intensity-modulated radiotherapy (IMRT) or rotational intensity-modulated radiation therapy (VMAT) segmented dose: primary focus and mediastinal metastatic lymph nodes; segmented mode: continuous accelerated hypersegmentation; Dose: DTGTV: \> 60 Gy"
62219613|NCT04284215|ACTIVE_COMPARATOR|Paclitaxel|"Paclitaxel 175 mg/m2 was injected into saline solution on the first day. Cisplatin 75 mg/m2 was given intravenously for 2-3 days , carboplatin 300 mg/m2 and on the second day. (Because toxicity and heart problems can replace DDP)\]Repeated every cycle (21-28 days/cycle, minimum 2 cycles).~Three-dimensional radiotherapy:~intensity-modulated radiotherapy (IMRT) or rotational intensity-modulated radiation therapy (VMAT) segmented dose: primary focus and mediastinal metastatic lymph nodes; segmented mode: continuous accelerated hypersegmentation; Dose: DTGTV: \> 60 Gy"
62414088|NCT01301378|ACTIVE_COMPARATOR|KeraSys Tissue Patch Graft|20 patients needing a Molteno 3 glaucoma drainage shunt implant will receive the KeraSys patch graft
62414089|NCT01301378|ACTIVE_COMPARATOR|Tutoplast tissue patch graft|20 patients need Molteno 3 glaucoma drainage surgery will receive tutoplast patch graft
62414090|NCT03925116|NO_INTERVENTION|usual care|"women who present for birth control to the gynecology office will see their physician in the usual fashion for review, counseling and contraception decision/initiation.~Follow up phone call will be done at 2 weeks, 3, 6 and 12 months to discuss contraception initiation and continuation."
62586958|NCT03244540|EXPERIMENTAL|QLB|"Subarchnoid anesthesia with bupivacaine QLB (quadratus lumborum block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.~PCA with morphine in the PACU"
62586959|NCT05538975|EXPERIMENTAL|Group A|home based plan of aerobic exercises, strengthening exercises of upper and lower limbs and huffing and coughing
62586960|NCT05538975|PLACEBO_COMPARATOR|Group B|Supervised aerobic exercises, strengthening exercises of upper and lower limbs and huffing and coughing
62586961|NCT06258720|EXPERIMENTAL|Lu AF82422 Dose Level 1|Participants will receive a single intravenous (IV) infusion of Lu AF82422
62586962|NCT06258720|EXPERIMENTAL|Lu AF82422 Dose Level 2|Participants will receive a single IV infusion of Lu AF82422
62433340|NCT03338049|OTHER|Veran System|Staged biopsy sampling methodology. If lymph node staging is negative, EMN-bronchoscopy will be performed. If EMN-bronchoscopy is negative, EMN-TTNA will be performed
62586963|NCT06685692|EXPERIMENTAL|ADX-629 (125 mg twice daily)|
62586964|NCT06685692|EXPERIMENTAL|ADX-629 (250 mg twice daily)|
62586965|NCT04649840||COVID-19 moderate|moderate COVID-19 associated pneumonia
62414091|NCT03925116|EXPERIMENTAL|Contraceptive pathway|"Women who present for birth control to the gynecology office will be recognized by the front desk and offered a tablet which which will:~1. collect relevant medical history~2. provide educational material on birth control options~3. provide a link to bedsider.com for further information~They will then discuss the tablet information/history with the medical assistant, who will answer any remaining questions. They will then see the physician/APN.~Follow up phone call will be done at 2 weeks, 3, 6 and 12 months to discuss contraception initiation and continuation."
62023236|NCT05031910|EXPERIMENTAL|Arm I (VR/3D-CEPs, standard treatment)|Prior to surgery (day 0-13), patients undergo virtual reality 3D tumor resection via VR/3D-CEPs. Patients' pre-surgical CT scans are reviewed per standard of care. Patients then undergo surgical resection on day 14-29 and a 3D model of true tumor is created and imported into the virtual reality environment.
62023237|NCT05031910|ACTIVE_COMPARATOR|Arm II (standard treatment)|Prior to surgery (day 0-13), patients' pre-surgical CT scans are reviewed per standard of care. Patients then undergo surgical resection on day 14-29.
62023238|NCT03269812|EXPERIMENTAL|laparoscopic operated group|Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
62414092|NCT02815540|OTHER|Heart Function and Dysautonomia|This study looks at participants already receiving CBD from the state of MN. We are not providing the CBD. We are looking at heart function with ECGs and Holter monitoring before and after CBD is taken by the participant. We are also looking at dysautonomia signs and symptoms and seizure frequency before and after CBD is taken by the participant.
62414093|NCT02694393|EXPERIMENTAL|sodium nitrite|Inhalation of 46 or 80 mg of sodium nitrite twice daily for four weeks
62414094|NCT01953731|EXPERIMENTAL|Single-Arm Fixed-Sequence|Subjects will receive two different interventions in fixed-sequence two-period study. In the first period the subjects will receive a single-dose of palbociclib. In the second period, subjects will receive 12 days of rifampin and a single dose of palbociclib on day 8. In both periods, subjects will undergo pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
62414095|NCT03479515||Formerly-Premature Toddlers|Data will be used to create and evaluate predictive equation
62414096|NCT01002118|PLACEBO_COMPARATOR|Placebo|4 capsules inert oil Placebo each day for 16 weeks
62414097|NCT01002118|ACTIVE_COMPARATOR|Omega-3 Fatty Acid Ethyl Esters|4 capsules Omega-3 Fatty Acid Esters each day for 16 weeks
62414098|NCT04062643||Patients with obesity|Obesity in those with BMI ≥30 kg/m2
62414099|NCT04062643||Patients without obesity|Normal weight was considered in the patients with BMI \<30 kg/m2
62414100|NCT01923961|EXPERIMENTAL|HDF NaCl, Then HD, Then Standard Pre-HDF|Participants first receive hemodiafiltration with infusion of 5 M NaCl for 4 hours. After a washout period of 1 week, they then receive 4 hours of bicarbonate hemodialysis. After another washout period of 1 week, they reveive 4 hours of standard predilution hemodiafiltration.
62414101|NCT01923961|EXPERIMENTAL|HD, Then Standard Pre-HDF, Then HDF NaCl|Participants first receive bicarbonate hemodialysis for 4 hours. After a washout period of 1 week, they then receive 4 hours of standard predilution hemodiafiltration. After another washout period of 1 week, they reveive 4 hours of hemodiafiltration with infusion of 5 M NaCl.
62414102|NCT01923961|EXPERIMENTAL|Standard Pre-HDF, Then HDF NaCl, Then HD|Participants first receive standard predilution hemodiafiltration for 4 hours. After a washout period of 1 week, they then receive hemodiafiltration with infusion of 5 M NaCl 4 hours of. After another washout period of 1 week, they reveive 4 hours of bicarbonate hemodialysis.
62023239|NCT03269812|EXPERIMENTAL|non laparoscopic operated group|Under general anesthesia ,abdominal exploration ,removal of a ganglionic part by soav ,duhamel procedures and trans-anal pull through procedures.
62023240|NCT05399498|EXPERIMENTAL|Experimental: Psilocybin|Single 25 mg capsule oral dose of psilocybin
62023241|NCT00759109|EXPERIMENTAL|Arm A - PegIntron|Participants randomized to Arm A received peginterferon α-2b (PegIntron), 50 μg, weekly, subcutaneously (SC), for a period of 3 years.
62023242|NCT00759109|OTHER|Arm B - Control|Participants randomized to Arm B were under observation and received no treatment.
62023243|NCT03047447|EXPERIMENTAL|Ketogenic group|10-week diet with controlled glycemic indices provided for ketogenic group. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
62023244|NCT03047447|ACTIVE_COMPARATOR|Exercise group|Exercise group maintained normal diet for 10-weeks and exercised 3-5 days per week. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
62023245|NCT03047447|ACTIVE_COMPARATOR|Non-exercise|Non-exercise group maintained normal diet for 10-weeks with no exercise. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
62023246|NCT03297879|EXPERIMENTAL|exenatide group|The drug-naïve, overweight or obese patients with newly diagnosed T2D
62023247|NCT03297879|ACTIVE_COMPARATOR|metformin group|The drug-naïve, overweight or obese patients with newly diagnosed T2D
62023248|NCT03175653|EXPERIMENTAL|Arm A - Oxycodone Pill A|Participants in this study arm will receive a prescription for a lower number oxycodone (oxycodone A) pills for post-cesarean pain control.
62414103|NCT06652633|EXPERIMENTAL|Previously treated participants with GLPG CAR T-cell therapy|All participants who have been treated with a Galapagos CAR T-cell therapy
62414104|NCT01445236|EXPERIMENTAL|Weaning patients|
62414105|NCT04410627|NO_INTERVENTION|Standard of Care|
62414106|NCT04410627|EXPERIMENTAL|Standard of Care + HoPE|
62414107|NCT02152930|ACTIVE_COMPARATOR|Supervised Exercise Therapy|Standard treatment: Supervised Exercise Therapy during 12 weeks
62414108|NCT02152930|NO_INTERVENTION|Controlled group|
62586966|NCT04649840||COVID-19 severe|severe COVID-19 associated pneumonia
62586967|NCT01082211|EXPERIMENTAL|Partial Breast Re-Irradiation|Partial Breast Re-Irradiation (PBrI) 3D-Conformal External Beam 1.5 Gy x 15 (BID) to 45 Gy Total
62023249|NCT03175653|ACTIVE_COMPARATOR|Arm B - Oxycodone Pill B|Participants in this study arm will receive a prescription for a higher number of oxycodone (oxycodone B) pills for post-cesarean pain control.
62795581|NCT04345562|ACTIVE_COMPARATOR|Back and forth pattern|Abdominal skin prep using ChloraPrep 2 x 26 mL single use applicators. The first applicator will be applied to the skin prep over the suspected skin incision site for 30 sec - the first applicator will then be used in a back and forth pattern work up towards the upper edge of the surgical field. The first applicator will then be discarded. The second applicator will then again start at the expected site of the incision and again working inferiority until the lower edge of the surgical field is reached.
62219614|NCT03603249|EXPERIMENTAL|Clopidogrel and Trimetazidine Arm|Patients on DAPT for at least 6 months will be tested for platelet function testing with the P2Y12 VerifyNow assay at baseline. The patients will then undergo at least a 2-week course of Trimetazidine 35 mg/q12h, followed thereafter by platelet function testing.
62414109|NCT01248000||classical Hodgkin lymphoma|All cases of classical Hodgkin lymphoma diagnosed between 2006 and 2008 in the province of Modena, Reggio Emilia, Parma and Ferrara will be considered eligible for this study.
62414110|NCT06649734||Expert Panel|An international expert panel of at least 35 to 40 healthcare professionals representing ICU-nurses, respiratory therapists (or comparable version, based on local implementation), physiotherapists, ICU-physicians and pulmonologists with expertise in the field of invasively ventilated ICU-patients.
62414111|NCT05927207|EXPERIMENTAL|TRIP App|Both groups will be assessed at baseline on the outcome measurements, after which the immediate intervention group will begin the 6-week intervention
62414112|NCT05927207|NO_INTERVENTION|Waitlist control|Both groups will be assessed at baseline on the outcome measurements, after which the the waitlist control group will receive usual care in the following six weeks. Afterwards, the waitlist control group will complete outcome assessment once again, before receiving the 6-week intervention
62414113|NCT04048473||MUH (Mansoura University Hospital)|enrolled 127 patients in outpatient pain clinic The health service quality was assessed using Patient Satisfaction Questionnaire Short Form (PSQ-18) (ranging from strongly agree = 1, agree = 2, uncertain = 3, disagree = 4 and strongly disagree = 5). Also the treatment satisfaction using The Pain Treatment Satisfaction Scale (PTSS) was evaluated (ranging from 0 = dissatisfied to 100 = satisfied)
62414114|NCT04048473||Ocmu (Oncology center Mansoura University)|enrolled132 patients in outpatient pain clinic The health service quality was assessed using Patient Satisfaction Questionnaire Short Form (PSQ-18) (ranging from strongly agree = 1, agree = 2, uncertain = 3, disagree = 4 and strongly disagree = 5).Also the treatment satisfaction using The Pain Treatment Satisfaction Scale (PTSS) was evaluated (ranging from 0 = dissatisfied to 100 = satisfied)
62414115|NCT04469465|EXPERIMENTAL|Danicopan + C5 Inhibitor|Participants will receive danicopan, in addition to their C5 inhibitor therapy, for 24 weeks (12 weeks in Treatment Period 1, followed by 12 weeks in Treatment Period 2).
62414116|NCT04469465|PLACEBO_COMPARATOR|Placebo + C5 Inhibitor|Participants will receive placebo, in addition to their C5 inhibitor therapy, for 12 weeks during Treatment Period 1. At Week 12, participants randomized to receive placebo will be switched to danicopan for an additional 12 weeks (Treatment Period 2).
62414117|NCT06653283||60 patients with RRMS and 44 age- and sex-matched healthy controls|A total of 104 participants, including 44 healthy controls (HCs) and 60 patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) based on the 2017 revised McDonald criteria (Thompson AJ), were enrolled for this study. To be included, they had to be (1) right-handed, (2) ≥ 18 years old, (3) relapse- and steroid-free for at least 1 month before MRI acquisition, (4) conducting a stable disease-modifying treatment for at least 3 months. The exclusion criteria were as follows: (1) sleep disorder or taking medication for sleep, (2) a history of stroke, epilepsy, head trauma, and cerebral small vessel diseases, (3) neuropsychological or psychiatric disorders, (4) neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease. 44 age- and sex-matched HCs without neurological and psychological symptoms or a history of neuropsychological disorders were also included in the study.
62414118|NCT06650293|EXPERIMENTAL|Group-A|Neonates receive phototherapy plus vitamin D
62414119|NCT06650293|NO_INTERVENTION|Group-B|Neonates will receive only phototherapy
62586968|NCT04218864|EXPERIMENTAL|Strength for U in Relationship Empowerment (SURE)|Theory-driven and derived from empirical support
62586969|NCT04218864|ACTIVE_COMPARATOR|Attention, time, and information matched control|Well-validated
62586970|NCT06622668|EXPERIMENTAL|Arm 1|
62586971|NCT04265430|EXPERIMENTAL|Cohort I (MRI after radiation therapy)|Patients may receive a contrast agent IV and then undergo an MRI over 45-60 minutes at baseline, 3-5 weeks after starting standard of care radiation therapy, and then at 2 months, 6 months, 12 months, and 3 years after completing radiation therapy.
62586972|NCT04265430|EXPERIMENTAL|Cohort II (MRI after surgery)|Patients may receive a contrast agent IV and then undergo an MRI over 45-60 minutes at baseline, and at 5-10 weeks and 12 months after standard of care surgery.
62795582|NCT04345562|ACTIVE_COMPARATOR|Circular pattern|Abdominal skin prep using ChloraPrep 2 x 26 mL single use applicators. The first applicator will be applied to the skin over the suspected skin incision site for 30 sec - the applicator will then be moved in a circular pattern moving outwards form the incision site until approximately half of thee surgical field is cleaned. The second applicator will then be used to complete the surgical prep until the entire surgical field is prepped in accordance with the package instructions.
62795583|NCT01890837|EXPERIMENTAL|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID/3 times per day (15g/day)
62795584|NCT01890837|PLACEBO_COMPARATOR|Placebo|Placebo TID
62795585|NCT05616481|ACTIVE_COMPARATOR|Laparoscopic Burch|The original procedure will be performed
62586973|NCT05967832|EXPERIMENTAL|Patients with type 1 narcolepsy|Patients with type 1 narcolepsy
62586974|NCT05967832|ACTIVE_COMPARATOR|Healthy volunteers|
62795586|NCT05616481|ACTIVE_COMPARATOR|Laparoscopic modefied Burch procedur (TOT-like)|Sutures on the pubocervical fascia are placed at the level of the attachment of the arcus tendinous fascia pelvis and the pubourethral ligament.
62219615|NCT04618445||Undergraduate students|prevalence of TMD among undergraduate students
62219616|NCT02747641|OTHER|treatment|only one arm
62023250|NCT02009475|ACTIVE_COMPARATOR|Continues aerobic training|Treadmill or exercise bike training with target heart rate of 50-70% of the heart rate reserve (or 50-60% of the peak VO2 reserve). Overall 45 minutes of exercise (including the 5-10 minute warm-up period).
62219617|NCT04738227|EXPERIMENTAL|Low level Laser Therapy Group|"Laser therapy will be performed with a continuous wave diode laser device previously calibrated by the manufacturer.~6 points that will be the skin overlying the right hand side parotid gland and 3 points on the skin overlying the location of the right hand side submandibular gland).~Following are the parameters which will be employed for the laser:~Wavelength - 635nm (visible spectrum), Output power 100 milliwatt, Mean dose per point - 3 J/cm2 , Irradiation time per point 15 s Energy per point 3 J Energy per session 60 J , Laser spot tip will be 0.08cm2 Two laser sessions will be done each week, during 12 weeks, which will bring the total number of laser sessions to All the major salivary glands will be treated with the tip of the laser hand-piece in contact with patients tissues.~A sum total of 22 points will receive LLLT per session involving all three major salivary glands."
62219618|NCT00178126|ACTIVE_COMPARATOR|Segmented Foam Cushion|Receive seating assessment, wheelchair and seat cushion representing the standard of care in nursing homes
62414120|NCT06523400|PLACEBO_COMPARATOR|Placebo|0 mg (matching sachet volumes to low, medium and high dose active drug)
62414121|NCT06523400|ACTIVE_COMPARATOR|Mexiletine prolonged-release (PR)|Mexiletine PR 167 mg (mexiletine HCl 200 mg) Mexiletine PR 333 mg (mexiletine HCl 400 mg) OR Mexiletine PR 500 mg (mexiletine HCl 600 mg)
62219619|NCT00178126|EXPERIMENTAL|Skin Protection Cushion|Receive seating assessment, wheelchair and cushion meeting CMS code for Skin Protection Wheelchair Cushion
62414122|NCT06652347|EXPERIMENTAL|Early Sharing Arm|early sharing of GA and OFS results to participants
62414123|NCT06652347|NO_INTERVENTION|Delayed Sharing Arm|delayed sharing of GA and OFS results to participants
62586975|NCT06268340|EXPERIMENTAL|Intervention|ECochG monitored CI surgery incl. corrective action guide
62023251|NCT02009475|EXPERIMENTAL|Interval Exercse Training|Bouts of high intensity interval treadmill or exercise bike training, comprising of 85-95% of the heart rate reserve (or 80-90% of the peak VO2 reserve), for the duration of 4 minutes, separated by periods of low intensity activity until the heart rate reaches 50% of the peak heart rate. This set will be repeated 3 times.
62023252|NCT05473195|EXPERIMENTAL|Arm 1|BVL-GSK098 9 mg once daily (OD) plus ethionamide 250 mg OD (b9Eto250)
62023253|NCT05473195|ACTIVE_COMPARATOR|Arm 2|Isoniazid 300 mg po OD (INH)
62023254|NCT05473195|EXPERIMENTAL|Arm 3|BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125)
62023255|NCT05473195|EXPERIMENTAL|Arm 4|BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250)
62414124|NCT03004963|ACTIVE_COMPARATOR|clinical group|evaluate the volume status just according to clinical indexes in this group.
62414125|NCT03004963|EXPERIMENTAL|clinical and BCM group|Both body composition monitor (BCM) and clinical indexes are used to evaluate the volume status of patients in this group.
62414126|NCT03956901|EXPERIMENTAL|Liberal Fluid Management|liberal fluid management: 500 ml bolus crystalloid after 4-8 ml/kg/h infusion during surgery total amount of crystalloid volume of fluid infused during gycnecologcy l surgery fluid infused during whole procedure 4-8 ml/kg/h infusion during surgery If MAP \<65 mmHg or \<30%of basal value, infuse 250 ml cyristaloid/Gelofusine bolus and 5 mcg efedrin If MAP\>65 mmHg no intervention
62586976|NCT06268340|ACTIVE_COMPARATOR|Control|Routine CI surgery without ECochG monitoring
62586977|NCT02282046||non-diabetic group|patients without diagnosed type 2 diabetes, having an HbA1c level below 6.0%
62586978|NCT02282046||type 2 diabetes group|patients diagnosed with type 2 diabetes of over 1 year duration.
62414127|NCT03956901|EXPERIMENTAL|pvi guided fluid management|"GDFM Group: 500 ml bolus crystalloid after~2 ml \\ kg crystalloid infusion to be started~If PVI \<13 MAP is \<65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.~PVI \<13 MAP\> 65 mmHg to continue fluid infusion If PVI\> 13 MAP \<65 mmHg, 250 ml bolus crystalloid \\ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI \<13.~PVI\> 13 MAP \<65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl \<13."
62414128|NCT06346197|EXPERIMENTAL|Experimental arm|Patients treated with Botensilimab + Balstilimab
62586979|NCT05715242|EXPERIMENTAL|Condition 1|Calorie Goal (easier) + Step Goal (easier) + Eating Window Goal (easier) + Red Zone Food Goal (easier)
62795587|NCT05700877|EXPERIMENTAL|CAC-based treatment|"Patients randomized to CAC-based treatment, will be stratified into low- or high-risk patients (defined by CAC score=0 or ≥ 100), and hence, allocated to two parallel l clinical studies.~High-risk patients (CAC≥ 100) in the CAC-based treatment group will be included in a study in which they will receive information on CAC-score, mandatory treatment with dapagliflozin and semaglutide (both study drugs), and advise on further multifactorial treatment of blood lipid levels, blood pressure and antithrombotic therapy.~Low-risk patients (CAC=0) will be included in a study in which they will receive information on CAC-score and advise on how multifactorial treatment may be de-intensified."
62219620|NCT03745261|EXPERIMENTAL|YCC capsule+conventional medicine|Patients in this group will be given Yong Chong Cao (YCC) capsule and conventional medicine based on the classes of medications recommended by 2017 GOLD and Chinese Treatment Guidelines for COPD,which are Group A patients: Salbutamol (Ventolin®),Group B and Group C patients: Tiotropium Bromide (Spiriva®),Group D patients: Salmeterol / fluticasone (Seretide®).
62414129|NCT06346197|ACTIVE_COMPARATOR|Standard arm|"o FOLFOX\*, IV, Q2W + Nivolumab 240mg, IV, Q2. \*FOLFOX = oxaliplatin 85 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 400 mg/m2 administered IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours daily or per local standard on Days 1 and 2 of each treatment cycle, every 2 weeks. Premedication is not usually required in the first cycle. For subsequent cycles, adequate premedication may be administrated per local standard.~OR~* XELOX\*, IV, Q3W + Nivolumab (360 mg, IV, Q3W). XELOX = Oxaliplatin 130mg/m² IV on Day 1 of each treatment cycle + capecitabine 1000mg/m² orally twice daily on Days 1 to 14 of each treatment cycle, every 3 weeks~* Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression."
62414130|NCT05786794|EXPERIMENTAL|Rural Clinic Hearing Healthcare Patient Navigation Program|This arm will involve pilot testing of the Patient Navigation Program with adults in rural primary care clinics
62414131|NCT01700907|ACTIVE_COMPARATOR|group DES|The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.
62219621|NCT03745261|EXPERIMENTAL|BL capsule + conventional medicine|Patients in this group will be given Bailing (BL) capsule and conventional medicine based on the classes of medications recommended by 2017 GOLD and Chinese Treatment Guidelines for COPD, which are Group A patients: Salbutamol (Ventolin®),Group B and Group C patients: Tiotropium Bromide (Spiriva®),Group D patients: Salmeterol / fluticasone (Seretide®).
62219622|NCT04092361||anisometropic amblyopia|
62219623|NCT04092361||strabismic amblyopia|
62219624|NCT04092361||deprivational amblyopia|
62219625|NCT03254485|EXPERIMENTAL|IW-1973 High Dose|
62219626|NCT03254485|PLACEBO_COMPARATOR|Placebo|Placebo to match experimental drug
62219627|NCT04748874|EXPERIMENTAL|Immediate mNC-FET|In the immediate arm, patients undergo mNC-FET in the menstrual cycle immediately following oocyte retrieval and failed fresh embryo transfer or freeze-all.
62414132|NCT01700907|ACTIVE_COMPARATOR|group SEVO|The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
62414133|NCT02350439|EXPERIMENTAL|Adenosine intravenous infusion at 200μg/Kg/min|Fractional flow reserve assessment under Adenosine intravenous infusion at 200μg/Kg/min
62219628|NCT04748874|NO_INTERVENTION|Postponed mNC-FET|Standard procedure where mNC-FET is performed at least one full menstrual cycle after failed fresh embryo transfer or freeze-all cycle.
62795588|NCT05700877|OTHER|Standard treatment|Patients randomized to standard treatment and their primary physician are not informed about the screening findings. Patients are encouraged to follow contemporary diabetes guidelines at the time of inclusion. This information will be given in a written letter within a week of randomization.
62219629|NCT03695237|EXPERIMENTAL|Leuprolide Acetate (LA)|Participants received leuprolide acetate (LA) 45 mg every 6 months administered as an intramuscular injection for up to 144 weeks.
62219630|NCT01681888|EXPERIMENTAL|Surface EMG Biofeedback|
62219631|NCT04157374|EXPERIMENTAL|EXPERIMENTAL GROUP|AOT and Active exercises
62219632|NCT04157374|ACTIVE_COMPARATOR|Control group|Active exercises
62219633|NCT02004353||Cochlear® Hearing Implants, hearing loss|Implanted Adolescents and Adults with permanent hearing loss
62219634|NCT01847300|EXPERIMENTAL|cSBI-M|Participants in this group will complete the cSBI-M screening and brief intervention program
62219635|NCT01847300|NO_INTERVENTION|Treatment as Usual|Participants in this group will receive treatment as usual.
62586980|NCT05715242|EXPERIMENTAL|Condition 2|Calorie Goal (easier) + Step Goal (easier) + Eating Window Goal (easier) + Red Zone Food Goal (harder)
62586981|NCT05715242|EXPERIMENTAL|Condition 3|Calorie Goal (easier) + Step Goal (easier) + Eating Window Goal (harder) + Red Zone Food Goal (easier)
62586982|NCT05715242|EXPERIMENTAL|Condition 4|Calorie Goal (easier) + Step Goal (easier) + Eating Window Goal (harder) + Red Zone Food Goal (harder)
62795589|NCT06081387|EXPERIMENTAL|Vitamin D treatment and training|Subjects are type 2 diabetic patients on vitamin D treatment that will recieve a sarcoplasma stimulating training program. This program will run for 16 weeks and three sessions a week. This exercise plan is designed in three 5-week periods and a familiarization week session. In the first intervention week, the movements are as follows: 4 sets of eight repetitions with 20 seconds interval of rest between sets will be performed, with 60% of maximum repetitions. In the second week, with increasing intensity, the exercise will be performed with 60% 1RM. The third week, each movement will be performed in 5 sets with 6 repetitions with 20 seconds of rest between Hursts as an interval with 60% of maximum repetitions.
62023256|NCT05473195|EXPERIMENTAL|Arm 5|BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)
62023257|NCT05473195|EXPERIMENTAL|Arm 6|Ethionamide 250 mg po OD (Eto250)
62795590|NCT06081387|ACTIVE_COMPARATOR|No vitamin D and training|This will include type 2 diabetic patients not being treated with vitamin D. Sarcoplasm stimulating training system will be performed. This program will run for 16 weeks and three sessions a week. This exercise plan is designed in three 5-week periods plus a familiarization session. In the first week of intervention, the movements are as follows: 4 sets of eight repetitions with 20 seconds interval of rest between sets will be performed, with 60% of maximum repetitions. In the second week, with increasing intensity, the exercise will be performed with 60% 1RM. The third week, each movement will be performed in 5 sets with 6 repetitions with 20 seconds of rest between Hursts as an interval with 60% of maximum repetitions.
62414134|NCT05553028|EXPERIMENTAL|Robot assisted surgery|Patient operated for thoracic and/or lumbar spine arthrodesis with robot assistance Mazor
62414135|NCT05553028|ACTIVE_COMPARATOR|Conventional surgery|Patient operated for thoracic and/or lumbar spine arthrodesis with conventional surgery
62414136|NCT06696534|OTHER|FIT/FOBT population|Average-risk population undergoing FIT/FOBT within the colorectal cancer screening programme.
62414137|NCT01984970||videolaryngoscope|The patients received videolaryngoscope for double-lumen tube intubation
62586983|NCT05715242|EXPERIMENTAL|Condition 5|Calorie Goal (easier) + Step Goal (harder) + Eating Window Goal (easier) + Red Zone Food Goal (easier)
62795591|NCT06081387|NO_INTERVENTION|Vitamin D treatment and no traininig|Subjects are type 2 diabetic patients on vitamin D treatment. In this group, no exercise program will be performed.
62795592|NCT06081387|NO_INTERVENTION|No Vitamin D and no training|Subjects are type 2 diabetic patients with no vitamin D treatment and no exericse program
62795593|NCT06727071|OTHER|Wearable Sensor Arm|The intervention is the hyperglycemic clamp. All participants will complete the clamp.
62795594|NCT04587050||Cohort 1: Women with HIV sexually active|Women with perinatally acquired HIV aged 18 or over who are sexually active
62795595|NCT04587050||Cohort 2: Women with HIV not sexually active|Women with perinatally acquired HIV aged 18 or over who are not sexually active
62795596|NCT06122506|EXPERIMENTAL|Intervention|Laparoscopic cerclage
62795597|NCT06122506|EXPERIMENTAL|Control|Vaginal cerclage
62023258|NCT05473195|EXPERIMENTAL|Arm 7|Ethionamide 750 mg po given in a single or divided dose daily (Eto750)
62795598|NCT03194126|EXPERIMENTAL|Mifepristone + Misoprostol OR oxytocine + laminaria|
62795599|NCT03194126|OTHER|Mifepristone + Misoprostol OR oxytocine|
62795600|NCT03777059|PLACEBO_COMPARATOR|Placebo|Placebo-matching atogepant tablets orally once daily for 12 weeks.
62795601|NCT03777059|EXPERIMENTAL|Atogepant 10 mg|Atogepant 10 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
62795602|NCT03777059|EXPERIMENTAL|Atogepant 30 mg|Atogepant 30 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
62795603|NCT03777059|EXPERIMENTAL|Atogepant 60 mg|Atogepant 60 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
62795604|NCT06098937|EXPERIMENTAL|Kalifilcon A Daily Disposable Toric|Kalifilcon A Daily Disposable Toric
62795605|NCT06098937|ACTIVE_COMPARATOR|Total1 for Astigmatism|Total1 for Astigmatism
62795606|NCT06098937|ACTIVE_COMPARATOR|Precision1 for Astigmatism|Precision1 for Astigmatism
62023259|NCT05724186|EXPERIMENTAL|Test myopia control lenses (CSL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
62023260|NCT06234345|EXPERIMENTAL|Fluticasone Propionate 250 mcg/Formoterol Fumarate dihydrate 12 mcg/Glycopyrronium Bromide 25 mcg|Fluticasone Propionate 250 mcg/Formoterol Fumarate dihydrate 12 mcg/Glycopyrronium Bromide 25 mcg in the pharmaceutical form of hard capsule with powder for inhalation - 1 capsule per inhalation twice a day
62023261|NCT06234345|ACTIVE_COMPARATOR|Trimbow® (Beclomethasone 100 mcg/Formoterol 6 mcg/Glycopyrronium 12.5 mcg)|Beclomethasone Dipropionate 100 mcg/Formoterol Fumarate dihydrate 6 mcg/Glycopyrronium Bromide 12.5 mcg in pharmaceutical form aerosol solution in pressurized metered dose device (pMDI) for inhalation (Trimbow® - Chiesi Farmacêutica Ltda.) - 2 triggering twice a day
62414138|NCT01487018|EXPERIMENTAL|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
62414139|NCT01487018|ACTIVE_COMPARATOR|Traditional Surgery|To compare with the experimental arm.
62414140|NCT04751786|EXPERIMENTAL|PRECIOUS-01|Eligible subjects will receive three i.v. infusions of PRECIOUS-01 at a 3-weekly interval in three dose-finding cohorts (low: 0.4 mg/kg, intermediate: 0.8 mg/kg, and high: 1.6 mg/kg fixed doses). Subjects will be monitored for safety and the occurrence of Dose-Limiting Toxicities (DLTs). A 3+3 design is used for the dose escalation steps. Three subjects will be enrolled sequentially per cohort. If the maximum tolerated dose (MTD) is not reached in the planned dose escalation cohorts, the RP2D will be based on the observed safety and immune modulatory activity as pharmacodynamic parameter supporting the RP2D. The sample size is based on the determination of the MTD/RP2D. In order to collect sufficient information regarding changes in immune related parameters as readout for pharmacodynamics of the particles, it is planned to extend the two highest dosing cohorts to a total of six subjects or to extend the highest dosing cohort to a total of nine subjects, depending on observed toxicity
62586984|NCT05715242|EXPERIMENTAL|Condition 6|Calorie Goal (easier) + Step Goal (harder) + Eating Window Goal (easier) + Red Zone Food Goal (harder)
62586985|NCT05715242|EXPERIMENTAL|Condition 7|Calorie Goal (easier) + Step Goal (harder) + Eating Window Goal (harder) + Red Zone Food Goal (easier)
62586986|NCT05715242|EXPERIMENTAL|Condition 8|Calorie Goal (easier) + Step Goal (harder) + Eating Window Goal (harder) + Red Zone Food Goal (harder)
62414141|NCT02554331|EXPERIMENTAL|Patients RBD|Patients RBD subject to FP-CIT single-photon emission computed tomography and Neuropsychological evaluation and Gait recording with sensors
62586987|NCT05715242|EXPERIMENTAL|Condition 9|Calorie Goal (harder) + Step Goal (easier) + Eating Window Goal (easier) + Red Zone Food Goal (easier)
62586988|NCT05715242|EXPERIMENTAL|Condition 10|Calorie Goal (harder) + Step Goal (easier) + Eating Window Goal (easier) + Red Zone Food Goal (harder)
62414142|NCT02554331|OTHER|controls healthy volunteers|controls healthy volunteers subject to Neuropsychological evaluation and Gait recording with sensors
62414143|NCT02989259|EXPERIMENTAL|apatinib|apatinib 500mg p.o. qd
62586989|NCT05715242|EXPERIMENTAL|Condition 11|Calorie Goal (harder) + Step Goal (easier) + Eating Window Goal (harder) + Red Zone Food Goal (easier)
62586990|NCT05715242|EXPERIMENTAL|Condition 12|Calorie Goal (harder) + Step Goal (easier) + Eating Window Goal (harder) + Red Zone Food Goal (harder)
62586991|NCT05715242|EXPERIMENTAL|Condition 13|Calorie Goal (harder) + Step Goal (harder) + Eating Window Goal (easier) + Red Zone Food Goal (easier)
62586992|NCT05715242|EXPERIMENTAL|Condition 14|Calorie Goal (harder) + Step Goal (harder) + Eating Window Goal (easier) + Red Zone Food Goal (harder)
62795607|NCT06098937|ACTIVE_COMPARATOR|MyDay Toric|MyDay Toric
62795608|NCT06726967||Adults|Patients with thyroid function tests (thyroid-stimulating hormone (TSH), free T3 (fT3), free T4 (fT4)), thyroid antibodies (anti-Tg, anti-TPO), and 25(OH) vitamin D levels
62795609|NCT03384368|PLACEBO_COMPARATOR|Screw-Distraction (SD) group|six pedicle screws were implanted firstly, then distraction was achieved.
62414144|NCT03449420||Post Partum Hemorrhage|Patients presenting with a post partum hemorrhage. A thromboelastography analysis is realized at discretion of the anesthesiologist in charge
62023262|NCT01153633|ACTIVE_COMPARATOR|Prontosan Wound Solution and Gel|Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel. Secondary dressing to be a semi occlusive dressing. Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)
62414145|NCT00632476|PLACEBO_COMPARATOR|A|Participants will receive a placebo capsule throughout pregnancy.
62414146|NCT00632476|ACTIVE_COMPARATOR|B|Participants will receive a vitamin C capsule throughout pregnancy.
62414147|NCT00632476|NO_INTERVENTION|C|A group of non-smoking pregnant women will not receive placebo or vitamin C.
62414148|NCT03701516|EXPERIMENTAL|TEST/CONTROL|Subjects between the ages of 18 and 70 years of age and are habitual wearers of daily disposable contact lens wearers will be randomly assigned to the Test/Control sequence.
62586993|NCT05715242|EXPERIMENTAL|Condition 15|Calorie Goal (harder) + Step Goal (harder) + Eating Window Goal (harder) + Red Zone Food Goal (easier)
62586994|NCT05715242|EXPERIMENTAL|Condition 16|Calorie Goal (harder) + Step Goal (harder) + Eating Window Goal (harder) + Red Zone Food Goal (harder)
62586995|NCT04982211|EXPERIMENTAL|Propranolol and standard trauma memory reactivation group|Oral propranolol will be administered 60 minutes prior to writing (Treatment 1) or reading aloud a trauma narrative.
62586996|NCT04982211|PLACEBO_COMPARATOR|Placebo and standard trauma memory reactivation group|Oral placebo will be administered 60 minutes prior to writing (Treatment 1) or reading aloud a trauma narrative.
62586997|NCT04982211|ACTIVE_COMPARATOR|Propranolol and mismatch trauma memory reactivation group|Oral propranolol will be administered 60 minutes prior to a memory reactivation procedure involving variations in the contexts where the trauma memory reactivations occur.
62586998|NCT04982211|PLACEBO_COMPARATOR|Placebo and mismatch trauma memory reactivation group|Oral placebo will be administered 60 minutes prior to a memory reactivation procedure involving variations in the contexts where the trauma memory reactivations occur.
62795610|NCT03384368|EXPERIMENTAL|Distraction-Screw (DS) group|four pedicle screws were implanted firstly, then distraction was achieved, two additional screws were introduced at the fracture level at last.
62795611|NCT05283421|ACTIVE_COMPARATOR|Active estrogen|Will receive pretreatment with vaginal application of estrogen 30 microgram (three tablets) once a day for 14 days.
62795612|NCT05283421|PLACEBO_COMPARATOR|Placebo|Will receive pretreatment with vaginal application with no estrogen (three tablets) once a day for 14 days.
62414149|NCT03701516|EXPERIMENTAL|CONTROL/TEST|Subjects between the ages of 18 and 70 years of age and are habitual wearers of daily disposable contact lens wearers will be randomly assigned to the Control/Test sequence.
62586999|NCT00845208|ACTIVE_COMPARATOR|Case Management|
62587000|NCT00845208|EXPERIMENTAL|Network Support|12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
62587001|NCT00845208|EXPERIMENTAL|Network Support + Contingency Mgmnt|12 weekly sessions intended to help patients change their social networks to be more supportive of abstinence. Contingency management component added to reinforce efforts to make network changes.
62587002|NCT06667882|ACTIVE_COMPARATOR|Conventional thrombolysis group|A fixed dose of rtPA will be delivered, preferably with coagulation monitoring. The rtPA dose is 0.6 mg/kg over 15 minutes (with a maximum dose of 50 mg) for circulatory collapse, and 100 mg over 2 hours for circulatory instability that persists despite circulatory support
62795613|NCT02564458|EXPERIMENTAL|Interval Exercise Training/Motivational Accelerometry (IET/MA)|All patients on the experimental arm receive the intervention of 5-12 weeks of pre-transplant IET, motivational accelerometry via the FitBit Surge, pre- and post-fitness assessments, and periodic quality of life and symptom surveys.
62795614|NCT02564458|NO_INTERVENTION|Normal Standard of Care (control)|All patients on the control arm participate in the pre- and post-fitness assessment, are given the FitBit Surge without the motivational component, and are also given periodic quality of life and symptom surveys.
62795615|NCT06726356|NO_INTERVENTION|Group A|based on conventional clinical treatment including anti-infective and expectorant therapy.
62795616|NCT06726356|OTHER|Group B|Bronchoalveolar lavage with saline on the basis of conventional clinical treatment, with a volume of 90 ml per target lung lobe, up to a maximum of 2 lobes, and a total volume of up to 180 ml.
62023263|NCT01153633|PLACEBO_COMPARATOR|Normal Saline and Placebo Gel|Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel. Secondary dressing to be a semi occlusive dressing. Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)
62023264|NCT03778736|EXPERIMENTAL|Cumulase denudation|
62023265|NCT03778736|NO_INTERVENTION|Hyaluronidase denudation|
62414150|NCT00958698|EXPERIMENTAL|Arm I (nurse-assisted intervention module)|Patients are given password-protected access to their own web-based message board to communicate with a research nurse. The nurse leads patients through WRITE Symptoms? intervention module, with personalized support and advice. The nurse will encourage the patient to try new selected strategies, continue with effective strategies, and work with local health care providers in an ongoing process to improve symptom management.
62795617|NCT06726356|EXPERIMENTAL|Group C|Bronchoalveolar lavage with acetylcysteine solution in combination with saline on the basis of conventional clinical treatment, with a volume of 90 ml per target lung lobe, up to a maximum of 2 lobes, and a total volume of up to 180 ml.
62023266|NCT02950493|OTHER|Single group, one arm study group|Compare echocardiograph imaging efficacy of active Definity or Lumason (perflutren lipid microsphere) with compressed Definity or Lumason.
62023267|NCT03895710||Sleep-deprived group|i. Self-reported time in bed (period from bedtime to get-up time) during school days of \<8 hours per day ii. Self-perceived insufficient sleep during school days
62414151|NCT00958698|EXPERIMENTAL|Arm II (self-directed intervention module)|Patients are given password-protected access to an interactive web-based computer program that will lead them through a modified WRITE Symptoms? intervention module (comprising the same elements as in arm I) without guidance and individualized recommendations from a nurse. Patients work through 3 selected symptoms using the WRITE Symptoms? intervention module over approximately 4 weeks. The program will generate an encouragement for the patient to try new selected strategies, continue with effective strategies, and continue the new approach to symptom management with local health care providers in an ongoing process to improve symptom management.
62414152|NCT00958698|ACTIVE_COMPARATOR|Arm III (standard care from local provider)|Patients are given password-protected access to online questionnaires. Patients are prompted monthly to complete online questionnaires. Patients receive standard symptom management from their local health care providers.
62414153|NCT05071235|PLACEBO_COMPARATOR|CG (control group) + dressing|The group will receive placebo LLLT (low-level laser therapy) application associated with Helianthus annuus oil dressing.
62414154|NCT05071235|ACTIVE_COMPARATOR|LG1 (LLLT group 1) + dressing|The group will receive application of LLLT (low-level laser therapy) Gallium Arsenide (GaAs) 904 nm 10 J/cm² associated with Helianthus annuus oil dressing.
62795618|NCT01509755|PLACEBO_COMPARATOR|Placebo|
62795619|NCT01509755|EXPERIMENTAL|0.045 mg|
62795620|NCT01509755|EXPERIMENTAL|0.225 mg|
62795621|NCT01509755|EXPERIMENTAL|0.45 mg|
62795622|NCT01509755|EXPERIMENTAL|0.60 mg|
62795623|NCT01509755|EXPERIMENTAL|0.75 mg|
62795624|NCT01509755|ACTIVE_COMPARATOR|Glim|
62023268|NCT03895710||Normal sleep group|i. Self-reported time in bed during school days of \>=8 hours per day ii. Self-perceived sufficient sleep during school days
62023269|NCT03359980|EXPERIMENTAL|treated patients|Treated with Fecal Microbiota Transfer (FMT)
62023270|NCT05029648||Cohort|Simple cohort
62023271|NCT02773589|EXPERIMENTAL|Peroral endoscopic myotomy|
62414155|NCT05071235|ACTIVE_COMPARATOR|LG2 (LLLT group 2) + dressing|The group will receive application of LLLT (low-level laser therapy) Gallium Arsenide (GaAs) 904 nm 8 J/cm² associated with Helianthus annuus oil dressing.
62414156|NCT05071235|ACTIVE_COMPARATOR|LG3 (LLLT group 3) + dressing|The group will receive application of LLLT (low-level laser therapy) Gallium Arsenide (GaAs) 904 nm 4 J/cm² associated with Helianthus annuus oil dressing.
62795625|NCT01687296|EXPERIMENTAL|fluticasone Nebules/placebo tablet|2×0.5mg/2ml twice daily neblulized/placebo tablet, oral, once daily
62795626|NCT01687296|ACTIVE_COMPARATOR|oral prednisone/placebo inhalation solution|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) / placebo inhalation solution nebulized twice daily
62795627|NCT02618902|EXPERIMENTAL|tolerogenic dendritic cells (tolDC)|Each vaccine (5x106, 10x106 , or 15x106cells in 500 µL NaCl 0.9% solution supplemented with 5% human albumin) will be administered through intradermal injection at 5 sites (100 µL/site) in the subclavicular region (5-10 cm from the cervical lymph nodes). Injection sites will alternate between left and right sides.
62414157|NCT06000839|EXPERIMENTAL|CELLBOOSTER® Lift|
62414158|NCT00288106||Long Term Follow-Up|Follow-up data collection study for men who developed prostate cancer after participation in SWOG-9217 (PCPT)
62795628|NCT02459444|EXPERIMENTAL|IMT group and physiotherapy|Inspiratory muscle training with POWERBREATHE an approximate load of 50 % of MIP , for 1 set of 30 breaths twice a day, 7 days a week for 4 weeks ( total 56 sessions). Associated with physiotherapy program.
62795629|NCT02459444|PLACEBO_COMPARATOR|Sham IMT group|Inspiratory muscle training with the same device in the experimental group , however without charge , for 1 set of 30 breaths twice a day, 7 days a week for 4 weeks ( total 56 sessions). Associated with physiotherapy program.
62795630|NCT06121089|ACTIVE_COMPARATOR|Laparoscopy ileocecal resection with extended D3 lymphadenectomy.|Ileocecal resection with extended D3 lymphadenectomy.
62414159|NCT06566222||NAT+High|
62795631|NCT06121089|EXPERIMENTAL|Laparoscopy right hemicolectomy with D3 lymphadenectomy.|Right hemicolectomy with D3 lymphadenectomy
62795632|NCT06725277||IV Ketamine|Patients taking IV ketamine
62795633|NCT06725277||Spravato|Patients taking Spravato, an intranasal form of ketamine
62795634|NCT01217463|ACTIVE_COMPARATOR|Trafermin 0.01% spray|
62795635|NCT01217463|PLACEBO_COMPARATOR|Matching placebo spray|
62795636|NCT00389493|ACTIVE_COMPARATOR|1|Participants will receive treatment with risperidone
62795637|NCT00389493|ACTIVE_COMPARATOR|2|Participants will receive exposure and ritual prevention therapy (EX/RP)
62023272|NCT05761431|EXPERIMENTAL|5 mg cohort|Subjects will be randomly assigned 4:1 to single dose of either SYHX2008（octreotide long-acting injection) or placebo at dose of 5 mg (8 active : 2 placebo).
62023273|NCT05761431|EXPERIMENTAL|10 mg cohort|Subjects will be randomly assigned 4:1 to single dose of either SYHX2008 or placebo at dose of 10 mg (8 active : 2 placebo).
62023274|NCT05761431|EXPERIMENTAL|20 mg cohort|Subjects will be randomly assigned 4:1 to single dose of either SYHX2008 or placebo at dose of 20 mg (8 active : 2 placebo).
62023275|NCT05761431|EXPERIMENTAL|30 mg cohort|Subjects will be randomly assigned 4:1 to single dose of either SYHX2008 or placebo at dose of 30 mg (8 active : 2 placebo).
62023276|NCT05761431|EXPERIMENTAL|Octreotide long-acting release ( Sandostatin LAR®) 20 mg cohort|Subjects will be treated with single dose of octreotide long-acting release ( Sandostatin LAR®) at dose of 20 mg.
62023277|NCT05761431|EXPERIMENTAL|Sandostatin® 0.1mg cohort|Subjects will be treated with single dose of Sandostatin® at dose of 0.1mg.
62219636|NCT06481644||Pediatric critical illness|All admissions to the pediatric ICU of participant hospitals without restriction to age, gender or race/ethnicity. Patients who have previously consented under the Singapore Pediatric Intensive Care Registry (SG-PedIC) under a similar single-center study protocol which started from 2020 will also be included.
62023278|NCT02672046||Patients with knee injuries|Patients referred to assessment at the Clinic of Sports Injuries
62414160|NCT06566222||NAT+Low|
62414161|NCT06566222||PAT+High|
62414162|NCT06566222||PAT+Low|
62023279|NCT05750381|ACTIVE_COMPARATOR|Study Group A: Blis Q24 balm (Active)|Group A: Probiotic Micrococcus luteus Q24 balm (dose: 1e7 colony forming units per application)
62023280|NCT05750381|PLACEBO_COMPARATOR|Study Group B: Placebo balm (without Blis Q24)|Group A: Placebo balm
62023281|NCT05516199|EXPERIMENTAL|Antenatal breastmilk expression|Breastfeeding consultation with trained midwife in week 33 + antenatal breastmilk expression from week 34
62414163|NCT05343247||Children with AI|
62414164|NCT05343247||Healthy controls with gender-age match|
62414165|NCT00396318|EXPERIMENTAL|Tenecteplase|
62414166|NCT04382599|EXPERIMENTAL|Added sugar warning message|"Message displayed on warning labels is: WARNING: High in added sugar."
62414167|NCT04382599|EXPERIMENTAL|Weight gain warning message|"Message displayed on warning labels is: WARNING: Excess consumption of drinks with added sugar contributes to weight gain."
62414168|NCT04382599|EXPERIMENTAL|Type 2 diabetes warning message|"Message displayed on warning labels is: WARNING: Excess consumption of drinks with added sugar contributes to type 2 diabetes."
62414169|NCT04382599|EXPERIMENTAL|Heart damage warning message|"Message displayed on warning labels is: WARNING: Excess consumption of drinks with added sugar contributes to heart damage."
62023282|NCT05516199|OTHER|Control|Breastfeeding consultation with trained midwife in week 33
62023283|NCT06372093|EXPERIMENTAL|Enable reliable measurement of bilirubin levels in the blood of newborns|to enable reliable measurement of bilirubin levels in the blood of newborns independent of skin color
62023284|NCT05561959|EXPERIMENTAL|Phonophoresis Group|Phonophoresis with topical glyceryl trinitrate traditional therapy three times a week for four week
62414170|NCT04382599|ACTIVE_COMPARATOR|Neutral message|"Message displayed on control label is: Please refrain from littering."
62023285|NCT05561959|ACTIVE_COMPARATOR|Eccentric exercises Group|eccentric exercises three times a week for four weeks
62023286|NCT00111657|EXPERIMENTAL|pegloticase|"All study participants received intravenous pegloticase at dose of 8 mg, administered every 21 days for a maximum of 5 doses.~There was no control group for this open label study."
62023287|NCT00010218|EXPERIMENTAL|karenitecin|"Patients receive karenitecin IV over 60 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease after 6 courses may receive 2 additional courses beyond best response.~Patients are followed every 3 months for 1 year and then every 6 months thereafter."
62023288|NCT03043612|EXPERIMENTAL|Ureteral Study Stent|Commercially available Cook Sof-Flex® Double Pigtail Ureteral Stent that is coextruded with an alpha-blocker medication
62023289|NCT03043612|ACTIVE_COMPARATOR|Ureteral Control Stent|Commercially available Cook Sof-Flex® Double Pigtail Ureteral Stent
62023290|NCT04107090|EXPERIMENTAL|US guided lung recruitment|Group A: it included 22 patients on whom the recruitment manoeuvre was applied guided by lung ultrasonography.
62023291|NCT04107090|OTHER|Non US guided lung recruitment|Group B: it included 22 patients on whom the recruitment maneuver was not ultrasound guided. This is considered the control group.
62023292|NCT06390410|EXPERIMENTAL|Moderate Hepatic Impairment|
62023293|NCT06390410|EXPERIMENTAL|Healthy Volunteer|
62023294|NCT06390410|EXPERIMENTAL|Mild Hepatic Impairment|
62414171|NCT06347549||Healthy adults|Participants ≥18 years of age with normal health will be recruited in this study.
62414172|NCT06242977|EXPERIMENTAL|Intervention arm - EMLA cream|This arm will receive EMLA cream 30 minutes prior to their procedure, applied to the scrotum. The patient is blinded to which cream they have received and this cream is removed prior to entering the procedural suite.
62414173|NCT06242977|PLACEBO_COMPARATOR|Control arm - Control cream|This arm will receive lotion cream 30 minutes prior to their procedure, applied to the scrotum. The patient is blinded to which cream they have received and this cream is removed prior to entering the procedural suite.
62587003|NCT06667882|EXPERIMENTAL|ClotPro-controlled variable dose of thrombolytic treatment.|A variable dose will be delivered, according to ClotPro EX, IN, AP, FIB, ECA, RVV, TPA results. The starting rtPA dose is 0.15-0.04 mg/kg in bolus, the starting maintaining dose for the first lysis hour the same. ClotPro tests is made in every 1 h treatment. The maintaining rtPA dose if it is needed, will be increased, till EX, IN, ECA efficient lysis could be detected. On the other hand the reduction of the maintaining dose was permitted based on FIB MCF alarming decline. The thrombolysis treatment is stopped if the circulatory instability and/or circulatory support ceased. Based on FIB MCF results fibrinogen concentrate coadministration on safety reason is permitted.
62587004|NCT02401516|ACTIVE_COMPARATOR|Reprogramming Insoles|EG - experimental group. Subjects will be subjected to the use of insoles with the artifact in the postural reprogramming insole that emits a electrogalvanic stream. Volunteers of this research must use the insole for at least 12 hours a day and have usage control through a daily chart.
62587005|NCT02401516|PLACEBO_COMPARATOR|Neutral Insoles|CG - control group. Subjects will be subjected to the use of insoles likewise the ones used by EG, but instead the artifact in the postural reprogramming insole made of metal, will be made of cork.
62587006|NCT04701229||normal karyotype|control group
62587007|NCT04701229||del5q-RBM22neg-SLU7neg|this group is characterized by its karyotype. It presents a 5q deletion, a loss of RBM22, a loss of SLU7.
62587008|NCT04701229||del5q-RBM22neg-SLU7pos|this group is characterized by its karyotype. It presents a 5q deletion, a loss of RBM22 but no loss of SLU7
62587009|NCT04701229||del5q-RBM22pos-SLU7neg|this group is characterized by its karyotype. It presents a 5q deletion, and no loss of RBM22, but a loss in SLU7
62219637|NCT02414932|EXPERIMENTAL|Ketamine|Ketamine (ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland)) will be made up as a 50 ml colourless saline solution and administered as a slow infusion over 40 minutes using an intravenous infusion pump. A course of up to four once-weekly infusions will be administered. Infusions will be discontinued by the Anaesthetist if there are persisting haemodynamic changes (i.e. heart rate \>110/minute or systolic/diastolic blood pressure (BP) \>180/100 or \>20% increase above pre-infusion BP for more than 15 minutes) that do not respond to beta-blocker therapy.
62219638|NCT02414932|ACTIVE_COMPARATOR|Midazolam|Midazolam (0.045 mg/kg; Roche Products Ireland Ltd) will be made up as a 50 ml colourless saline solution and administered as a slow infusion over 40 minutes using an intravenous infusion pump. A course of up to four once-weekly infusions will be administered.
62587010|NCT04701229||del5q-RBM22pos-SLU7pos|this group is characterized by its karyotype. It presents a 5q deletion, and no loss of RBM22 nor SLU7
62587011|NCT06370728|EXPERIMENTAL|Orforglipron + Carbamazepine|Single dose of orforglipron along with twice-daily dose of carbamazepine administered orally
62795638|NCT00389493|PLACEBO_COMPARATOR|3|Participants will receive treatment with the placebo
62023295|NCT04975568|EXPERIMENTAL|Therapeutic Exercise Controlled Through App With face-to-face|3 months treatment using app for HTEP and 6 people therapeutic exercise group every 15 days
62587012|NCT06594146|EXPERIMENTAL|Group 1|CM313 injection and placebo
62587013|NCT06594146|EXPERIMENTAL|Group 2|CM313 injection and placebo
62795639|NCT03171337|EXPERIMENTAL|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory, twice 1 week for 4 weeks，fMRI will be used to detect the cerebral function changes
62795640|NCT03171337|ACTIVE_COMPARATOR|Fu's subcutaneous needling (FSN)|FSN at the points related with CTTH, twice 1 week for 4 weeks, fMRI will be used to detect the cerebral function changes.
62023296|NCT04975568|ACTIVE_COMPARATOR|Therapeutic Exercise Controlled Through App|3 months treatment using app for HTEP
62795641|NCT03171337|SHAM_COMPARATOR|Sham acupuncture|Streitberger placebo needles at nonacupoint for CTTH, twice 1 week for 4 weeks,fMRI will be used to detect the cerebral function changes.
62795642|NCT01695434||Copaxone MRI|Patients with relapsing-remitting multiple sclerosis who take Copaxone will have a MRI.
62023297|NCT06358482|EXPERIMENTAL|A Digital|oscillating-rotating electric toothbrush group
62023298|NCT06358482|ACTIVE_COMPARATOR|B Manual|manual toothbrush group
62219639|NCT04950829|ACTIVE_COMPARATOR|Conventional brackets|Patients will receive an orthodontic treatment using conventional brackets until achieving appropriate alignment of the upper anterior teeth.
62219640|NCT04950829|EXPERIMENTAL|Self-ligating brackets|Patients will receive an orthodontic treatment using self-ligating brackets until achieving appropriate alignment of the upper anterior teeth.
62587014|NCT06594146|EXPERIMENTAL|Group 3|CM313 injection and placebo
62587015|NCT04053712|PLACEBO_COMPARATOR|Single-hormone|FiAsp (R) - Saline
62587016|NCT04053712|ACTIVE_COMPARATOR|Dual-hormone|FiAsp(R) - GlucaGen(R)
62587017|NCT01704651|EXPERIMENTAL|Alvimopan|Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative. Drug was continued for duration of hospital stay, but did not exceed 7 days.
62587018|NCT01704651|PLACEBO_COMPARATOR|Placebo|Perioperative administration of placebo, at same dosing interval as study drug.
62587019|NCT05764616|EXPERIMENTAL|RECTUS group|Patients will receive General Anesthesia combined with bilateral parasternal block and rectus sheath block
62023299|NCT05228613|EXPERIMENTAL|Vaccine Candidate Formula A|2 doses of vaccine candidate formula A administered with 28 days interval (0.5 mL per dose)
62023300|NCT05228613|EXPERIMENTAL|Vaccine Candidate Formula B|2 doses of vaccine candidate formula B administered with 28 days interval (0.5 mL per dose)
62587020|NCT05764616|ACTIVE_COMPARATOR|CONTROL group|Patients will receive General Anesthesia combined with bilateral parasternal block and infiltration of drainage exits sites with local anesthetic
62587021|NCT06313398|EXPERIMENTAL|RBC survival in patients with SCD|RBC lifespan, determined by the mean number of days from biotin-labeled RBC infusion until biotin-labeled RBCs are below limit of detection, in patients with inherited hemoglobinopathies prior to and post initiation of disease modifying therapy or HSCT
62587022|NCT06287632|EXPERIMENTAL|Recruitment and ITP-CPAP|Recruitment maneuver followed by CPAP set to intrathoracic pressure (ITP)
62795643|NCT01695434||Healthy Controls MRI|Subjects who are otherwise healthy, without neurological disorders, will have a MRI.
62795644|NCT02363621|ACTIVE_COMPARATOR|Ranibizumab 0.3 Intravitreal injection|Intravitreal injection of Ranibizumab 0.3 mg once
62795645|NCT02363621|ACTIVE_COMPARATOR|Aflibercept 2.0 mg intravitreal injection|Intravitreal Aflibercept 2.0 mg once
62795646|NCT05189119||LVFgroup|patients with AECOPD and left ventricular failure
62219641|NCT04950829|EXPERIMENTAL|3- Self-Ligating brackets with fapless corticotomy|Patients will receive an orthodontic treatment using self-ligating brackets with corticotomy until achieving appropriate alignment of the upper anterior teeth.
62587023|NCT06287632|ACTIVE_COMPARATOR|Standard CPAP|CPAP set to home level of CPAP (if known) or CPAP set to standard levels (8-10 cmH20)
62587024|NCT06287632|PLACEBO_COMPARATOR|Atmospheric pressure|Breathing without CPAP
62219642|NCT03545503|ACTIVE_COMPARATOR|Etomidate|Etomidate will be dosed once at a standard of 0.3 mg/kg via IV Push
62219643|NCT03545503|ACTIVE_COMPARATOR|Ketamine|Ketamine will be dosed once at a standard 2 mg/kg via IV Push
62219644|NCT02670759|EXPERIMENTAL|Paravertebral analgesia|A paravertebral nerve block will be performed under ultrasound guidance by the anaesthesiologist prior to the induction of general anesthesia. A catheter will be inserted and a continuous infusion of bupivacaine will be administered.
62587025|NCT04060277|EXPERIMENTAL|Arm I (letermovir, Triplex)|Patients receive letermovir per SOC on days 7-100 and multi-peptide CMV-modified vaccinia Ankara vaccine IM on days 100 and 128 post-HCT.
62587026|NCT04060277|ACTIVE_COMPARATOR|Arm II (letermovir, placebo)|Patients receive letermovir per SOC on days 7-100 and placebo IM on days 100 and 128 post-HCT.
62587027|NCT04755413|EXPERIMENTAL|Optimization Group|Participants with CAD and a BRS greater than 0 who are randomized to the Optimization Group have treatment goals that include achieving LDL-C\<70 mg/dL, hemoglobin A1c \<7%, blood pressure \<130/80 mmHg, smoking cessation, at least 30 minutes of moderate-intensity aerobic activity 5 days a week and weight loss to body mass index \<30 kg/m2. To achieve these goals, both pharmacological and lifestyle interventions will be considered and individualized for each patient.
62587028|NCT04755413|ACTIVE_COMPARATOR|Usual Care Group|Participants with CAD and a BRS greater than 0 who are randomized to the usual care group will receive standard of care therapy prescribed by their primary care physician and/or cardiologist. Patients and their physicians will be informed that their BRS is ≥1 and they have been randomized to the usual care group.
62587029|NCT04755413|OTHER|Registry Group|Participants with BRS of 0 at baseline and after 3 months will undergo follow-up including measurements of BRS at the time-points specified for the randomized subjects and also for adverse events. Laboratory results and questionnaire data will be obtained on the phone.
62219645|NCT02670759|ACTIVE_COMPARATOR|Intercostal analgesia|An intercostal nerve block using a single dose of bupivacaine will be performed by the surgeon at the end of surgery before skin closure.
62587030|NCT02511392|ACTIVE_COMPARATOR|Group 1: Real rTMS-1 Hz|Included 15 patients, they received 1 Hz rTMS with intensity of 100% of the RMT continuous with total 2000 applied in 200 trains, each of 10 pulses, with 5 seconds intertrain interval
62219646|NCT04556721|EXPERIMENTAL|Sugammadex|After surgery and general anesthesia, a clinically-appropriate dose of Sugammadex will be utilized to reverse the rocuronium neuromuscular blockade. Either 2 mg/kg or 4 mg/kg dosing will be used based on the level of neuromuscular blockade at the time of reversal. Administer as single IV bolus injection infused over 10 seconds into existing IV line. Dose is based on actual body weight (mg/kg).
62219647|NCT04073251|EXPERIMENTAL|KalobaTuss children|KalobaTuss children syrup 5 ml for 4 times a day supplied for 8 consecutive days.
62219648|NCT04073251|PLACEBO_COMPARATOR|Placebo|Placebo syrup 5 ml for 4 times a day supplied for 8 consecutive days.
62219649|NCT04610541|EXPERIMENTAL|Remdesivir-HU|"Day 1 - single loading dose of remdesivir-HU 200 mg given by intravenous infusion~• Day 2 onwards - 100 mg given once daily by intravenous infusion."
62587031|NCT02511392|ACTIVE_COMPARATOR|Group 2: Real rTMS-10 Hz|Included 15 patients, they received 10 Hz rTMS with intensity of 100% of the RMT applied in 10 trains, each of them 200 pulses, with 20 seconds intertrain interval
62795647|NCT05189119||non LVF group|patients with AECOPD and whithout left ventricular failure
62795648|NCT05123599|EXPERIMENTAL|JNJ-73763989 plus JNJ-64300535 plus Nucleos(t)ide Analogs (NAs)|Participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks (q4w), NA (either Entecavir monohydrate \[ETV\], Tenofovir disoproxil or Tenofovir alafemide \[TAF\]) oral tablets once daily (qd) and JNJ-64300535 intramuscular (IM) injection q4w. From day 187, participants will receive treatment with NA oral tablets qd up to Week 36.
62219650|NCT04877730|EXPERIMENTAL|FCL (Fully Closed Loop)|Closed-loop control without meal anticipation module without meal bolus
62219651|NCT04877730|EXPERIMENTAL|FCL+ (Fully Closed Loop with meal anticipation)|Closed-loop control with meal anticipation module without meal bolus
62219652|NCT04877730|EXPERIMENTAL|HCL (Hybrid Closed Loop)|Closed-loop control without meal anticipation module with meal bolus
62219653|NCT05576753|EXPERIMENTAL|Patient|Patients scheduled for robot assisted laparoscopic preperitoneal repair (vTAPP: ventral transabdominal preperitoneal hernia repair) of a midline ventral hernia
62219654|NCT02244645|OTHER|Passive modality control group|Passive modality control group will receive regular 40-minutes rehabilitation twice a week for 3 months.
62219655|NCT02244645|EXPERIMENTAL|Yoga treatment group|Yoga treatment group will receive regular 60-minutes yoga classes twice a week for 4 months.
62219656|NCT01271491||Cases|Children hospitalized in the ICU with bronchiolitis
62587032|NCT02511392|SHAM_COMPARATOR|Group 3: Sham rTMS|Included 15 patients; they received the same number of pulses 2000 pulse applied in 200 trains, each of 10 pulses, with 5 seconds intertrain interval, but coil was placed over the same area but perpendicular to the scalp.
62587033|NCT02809547|ACTIVE_COMPARATOR|In Clinic monitoring|70 method comparison patients who represent a C-reactive protein (CRP) reference range and have retrievable study outcome measures will have a whole blood sample and DBSS taken at recruitment and at a routine six week review.
62219657|NCT01271491||Controls|Children hospitalized in the general ward with bronchiolitis
62795649|NCT04182841|OTHER|RheOx Treatment|RheOx is a CE-marked device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
62219658|NCT06262074|EXPERIMENTAL|Group-1 (Structured Exercise Program)|Patients undergo structured exercise sessions lasting 30 minutes, encompassing activities such as range of motion, flexibility exercises, strength training, balance exercises, and aerobic exercises, with designated intervals between each session.
62219659|NCT06262074|OTHER|Group-2 (Non-Structured Exercise Program)|Patients are provided with a simple exercise routine that lacks a structured format.
62219660|NCT02442336|EXPERIMENTAL|My Journey AHead|Several internet modules will be developed to address mouth and swallowing concerns, oral care, healthy eating, speech problems, coping with cancer, pain management, and physical therapy.
62219661|NCT04218045|ACTIVE_COMPARATOR|Laparoscopic sleeve gastrectomy group|The group of morbidly obese patients undergoing laparoscopic sleeve gastrectomy
62219662|NCT04218045|EXPERIMENTAL|SASI bypass group|The group of morbidly obese patients undergoing laparoscopic single- anastomosis sleeve ileal bypass (the new procedure being evaluated)
62587034|NCT02809547|EXPERIMENTAL|At Home monitoring|30 Prospective patients will provide (i) one whole blood sample and one set of dried blood spot samples (DBSS) at recruitment, (ii) a set of DBSS once a week for six weeks from recruitment, with a matched whole blood sample at six week appointment, (iii) two extra sets of DBSS to be taken during a flare and 24 hours after (iv) 6 prospective patients will have daily hand movement data collected for 5 minutes on each occasion using a provided data glove.
62795650|NCT04212598|EXPERIMENTAL|Definitive concurrent chemoradiotherapy or radiotherapy arm|Patients who completed concurrent chemoradiotherapy standard dose would received the Sintilimab as a consolidate therapy for one year.
62414174|NCT00742859|EXPERIMENTAL|Arm 1: Betrixaban|Betrixaban, 40 mg, orally, once daily for at least 3 months.
62414175|NCT00742859|EXPERIMENTAL|Arm 2: Betrixaban|Betrixaban, 60 mg, orally, once daily for at least 3 months
62795651|NCT01698502||Trained|Healthy, Endurance trained (Maximal oxygen uptake (VO2max), ml\*min-1\*kg-1\>60), 20-30 year, BMI: 18,5-25kg/m2, males.
62795652|NCT01698502||Untrained|Healthy, sedentary (Maximal oxygen uptake (VO2max), ml\*min-1\*kg-1\<50), 20-30 year, BMI: 18,5-25kg/m2, males.
62795653|NCT00684775|NO_INTERVENTION|Work Plus Naltrexone Prescription|Participants could work and earn vouchers but did not to take Vivitrol Injections to work and earn vouchers.
62795654|NCT00684775|EXPERIMENTAL|Work Plus Naltrexone Contingency|Participants could work and earn vouchers and had to take Vivitrol Injections to work and earn vouchers: employment-based reinforcement.
62795655|NCT02475278|EXPERIMENTAL|NoV Vaccine|Norovirus GI.1/GII.4 bivalent Virus-Like Particle (VLP) vaccine (NoV Vaccine) (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminum hydroxide), intramuscular (IM) injection, once on Day 1.
62219663|NCT05004571|PLACEBO_COMPARATOR|Placebo|"Matched placebo control 10 mg capsules or 20 mg capsules totaling 20 mg, 40 mg, 80 mg, or 120 mg will be given once orally to placebo subjects in the SAD portion of the study.~10 mg capsules or 20 mg capsules totaling 20 mg, 40 mg, 80 mg, or 120 mg will be given once daily for 14 days orally to placebo subjects in the SAD portion of the study."
62219664|NCT05004571|EXPERIMENTAL|Study drug EQU-001|"10 mg capsules or 20 mg EQU-001 capsules totaling 20 mg, 40 mg, 80 mg, or 120 mg will be given once orally to active-treatment subjects in the SAD portion of the study.~10 mg capsules or 20 mg EQU-001 capsules totaling 20 mg, 40 mg, 80 mg, or 120 mg will be given once daily for 14 days orally to active treatment subjects in the SAD portion of the study."
62219665|NCT03581825|EXPERIMENTAL|Test/Control|Myopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Test/Control. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
62414176|NCT00742859|EXPERIMENTAL|Arm 3: Betrixaban|Betrixaban, 80 mg, orally, once daily for at least 3 months
62414177|NCT00742859|ACTIVE_COMPARATOR|Arm 4: Warfarin|Warfarin will be prescribed by investigators according to the standard of care.
62414178|NCT04762771|ACTIVE_COMPARATOR|Active|Hospitalized covid-19 patients treated with colchicine plus current care per institution treating physicians.
62414179|NCT04762771|NO_INTERVENTION|Control|Hospitalized covid-19 patients treated with current standard of care (per institution treating physicians) alone.
62414180|NCT02566967|OTHER|open label|open label use of tofacitinib at either 5 mg bid or 10 mg bid delending on treat to target goal
62414181|NCT06540833|EXPERIMENTAL|ITI-1284|
62414182|NCT06540833|PLACEBO_COMPARATOR|Placebo|
62414183|NCT01570998|EXPERIMENTAL|Treatment (IORT)|Patients undergo IORT in a single fraction over 15-40 minutes at the time of standard of care lumpectomy.
62414184|NCT03778190|EXPERIMENTAL|Magnet|The physician will attempt to remove the corneal foreign body using an eye magnet for these patients.
62414185|NCT00090337|EXPERIMENTAL|Arm I|Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks.
62414186|NCT00090337|ACTIVE_COMPARATOR|Arm II|Patients undergo standard of care for 4 weeks.
62414187|NCT06218030|EXPERIMENTAL|L-methylfolate arm|Oral administration of L-methylfolate 15 mg per day for 8 weeks.
62587035|NCT02057484||Organ transplant patients treated with Advagraf|To evaluate long-term graft survival in patients treated with Advagraf
62795656|NCT02418052|EXPERIMENTAL|neck flexion group|Patients who fixed in neck flexion position after MIE
62795657|NCT02418052|NO_INTERVENTION|control group|Patients without posture intervention after MIE
62414188|NCT00447694|EXPERIMENTAL|deferasirox every day for 77 weeks|Participants received Deferasirox 30 milligrams per kilogram per day (mg/kg/day) orally once daily (OD), 30 minutes before breakfast, preferably around the same time every morning if possible. Deferasirox tablets were dropped into water or orange juice, or apple juice and stirred until completely dispersed. For doses less than 1 gram (g), tablets were dissolved in at least 100 milliliter (mL) of liquid; for doses of 1 to 3 g, tablets were dissolved in at least 200 mL. After tablets were fully disintegrated, the liquid was promptly consumed.
62414189|NCT06652048|EXPERIMENTAL|Furmonertinib 160mg QD|All patients enrolled into this group will receive furmonertinib 160mg p.o qd.
62414190|NCT06652048|EXPERIMENTAL|Furmonertinib 240mg QD|All patients enrolled into this group will receive furmonertinib 240mg p.o qd.
62414191|NCT06652048|EXPERIMENTAL|Furmonertinib 160mg QD plus Chemotherapy|All patients enrolled into this group will receive furmonertinib 160mg furmonertinib p.o qd plus chemotherapy\[(carboplatin AUC 5 / cisplatin 75mg/m2+ pemetrexed 500mg/m2) every 21 days ×4 cycles + pemetrexed 500mg/m2 every 21 days maintenance\]
62414192|NCT04803773|EXPERIMENTAL|Experimental Arm|
62795658|NCT02678351|EXPERIMENTAL|68Ga-PSMA PET/MRI|Patients receive 68Ga-PSMA-11 IV. Patients then undergo PET/MRI after 45 minutes of administration of radiopharmaceutical injection.
62795659|NCT00082407|EXPERIMENTAL|Exenatide Arm|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks
62795660|NCT00082407|ACTIVE_COMPARATOR|Biphasic Insulin Aspart Arm|subcutaneous injection, twice daily; titration to target blood glucose level
62023301|NCT05228613|EXPERIMENTAL|Vaccine Candidate Formula C|2 doses of vaccine candidate formula C administered with 28 days interval (0.5 mL per dose)
62587036|NCT02640950|EXPERIMENTAL|Open-Label TMS|Active Transcranial Magnetic Stimulation
62587037|NCT01532791||mtDNA mutation|m.3243 A\>G carriers and their maternal relatives Other mutations in the mitochondrial genome may be included
62795661|NCT06139406|EXPERIMENTAL|Part 1: Dose escalation|Participants will receive one cycle of TCE monotherapy (step up to target dose) with either JNJ-80948543 or JNJ-75348780 followed by initiation of combination therapy with JNJ-87801493 one week later.
62023302|NCT05228613|EXPERIMENTAL|Vaccine Candidate Formula D|2 doses of vaccine candidate formula D administered with 28 days interval (0.5 mL per dose)
62414193|NCT06346756|EXPERIMENTAL|G-aenial A'CHORD universal composite|
62414194|NCT06346756|EXPERIMENTAL|Tetric Prime universal composite|
62414195|NCT06346756|EXPERIMENTAL|Filtek Ultimate universal composite|
62414196|NCT06346756|EXPERIMENTAL|G-aenial Universal Injectable composite|
62414197|NCT05161884||Preclinical Study group|n=10 Landrace pigs The aim of the pre-clinical study was to assess the accuracy of BOLD-T2 MRI in acute systemic hyper- and hypoxemia in a porcine model in contrast to cardiac catheterization.
62414198|NCT05161884||Validation Study group|"n=25 The patients have an indication for a right heart catheter examination. This is a routine diagnostic examination that is performed on these patients.~Compared to the clinical routine, an additional MRI measurement will be performed. The measurement will be performed before the cardiac catheterization.~For the MRI examination, the patient/subject is placed in a magnetic resonance imaging machine. The MRI examination initially includes approximately 15 minutes of standard images for orientation and determination of function, morphology, and tissue characteristics. This is followed by images to determine oxygen saturation in the ventricles (approximately 5 minutes).~If a CMR examination is already planned for a patient for other reasons, this will only be extended by the recordings for the determination of oxygen saturation (approx. 5 minutes) at the time of study inclusion.~During the MRI measurements, patients will also perform a stepper stress test."
62414199|NCT05161884||Pulmonary Hypertension group|n=25 patients with pulmonary hypertension (definition: pulmonary arterial pressure (PAP) above 25 mmHg)
62414200|NCT05161884||Valvular heart disease group|n=25 patients with valvular heart disease (at least moderate)
62414201|NCT05161884||Ischemic cardiomyopathy group|n=25 patients with ischemic cardiomyopathy
62414202|NCT05161884||HFpEF group|n=25 patients with HFpEF (heart failure with preserved ejection fraction, definition: EF over 50%, heart failure symptoms, elevated NT-proBNP over 400pg/ml)
62414203|NCT06236334|EXPERIMENTAL|Lifestyle intervention|The intervention will be a twelve week lifestyle intervention (live and online)
62587038|NCT01532791||Control|controls (people not maternally related to mutation carriers) Preference is for married in relatives
62587039|NCT04649788|ACTIVE_COMPARATOR|Ultrasound-guided axillary vein access|This group of patients will receive the cardiac implantable electronic device with ultrasound-guided axillary venous access.
62587040|NCT04649788|ACTIVE_COMPARATOR|Cephalic vein access|This group of patients will receive the cardiac implantable electronic device with cephalic venous access.
62587041|NCT03305458|ACTIVE_COMPARATOR|Treatment as usual|Trauma Focused Cognitive Behavioral Therapy
62587042|NCT03305458|EXPERIMENTAL|Tablet-Facilitated TF-CBT|Standard treatment with the addition of in-treatment/session iPad activities
62795662|NCT06139406|EXPERIMENTAL|Part 2:Dose expansion|Participants with specific B-cell NHL histologies will receive recommended phase 2 regimen (RP2R) of JNJ-87801493 with TCE as determined in Part 1.
62414204|NCT06576167|EXPERIMENTAL|Wedge 1|The earliest group to implement the IMPROVE intervention ( in 4-9 study months).
62414205|NCT06576167|EXPERIMENTAL|Wedge 2|Following the wedge 1 group, the wedge 2 group started the intervention in the study months 7-12.
62795663|NCT01363089|EXPERIMENTAL|Ketorolac tromethamine|
62795664|NCT01363089|EXPERIMENTAL|Oxymetazoline hydrochloride|
62023303|NCT05228613|ACTIVE_COMPARATOR|Active Control|2 doses of active control administered with 28 days interval (0.5 mL per dose)
62414206|NCT06576167|EXPERIMENTAL|Wedge 3|The wedge 3 group started the intervention in the study months 10-15.
62414207|NCT02556528|EXPERIMENTAL|Health Coaching|
62587043|NCT06414109|EXPERIMENTAL|BREATHE-Migraine|Participants will receive 6 weekly 1-hour sessions of a remotely-delivered mindfulness-based intervention in a group setting.
62587044|NCT04979780||Cancer patients with acute venous thromboembolism (VTE)|Cancer-associated thrombosis (CAT) patients treated with Rivaroxaban or any DOAC (Direct Oral Anticoagulants) or LMWH (Low molecular weight heparin).
62587045|NCT00059891|EXPERIMENTAL|Anal Sphincter Prosthesis|All patients will follow a common treatment algorithm. Anorectal reconstruction with the ABS neosphincter device will be a staged surgical approach. Routine postoperative testing will then be performed at 6 months (+/- 8 weeks) and 12 months (+/- 8 weeks), following ileostomy reversal which we have designated as time zero. Postoperative testing will include completion of a series of questionnaires.
62587046|NCT03907527|EXPERIMENTAL|Treatment (PRGN-3005 UltraCAR-T cells) IP Administration|Patients receive autologous PRGN-3005 UltraCAR-T cells via IP administration with or without lymphodepleting chemotherapy.
62795665|NCT00123318|EXPERIMENTAL|1|Single-arm, non-randomised feasibility study to evaluate new regimen of adjuvant chemoradiotherapy (Epirubicin, Cisplatin, 5-Fluorouracil + radiotherapy)
62795666|NCT00747084|EXPERIMENTAL|Arm 1: Study Treatment|Study Treatment: warm water loading of the sigmoid colon and warm water irrigation for dealing with colonic spasms.
62219666|NCT03581825|EXPERIMENTAL|Control/Test|Myopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Control/Test. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
62023304|NCT03087266|EXPERIMENTAL|Full- Mouth Scaling and Root Planing|FM-SRP Non-surgical periodontal treatment will be performed in all dentition within 24 hours.
62219667|NCT05576259|EXPERIMENTAL|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for social anxiety, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
62414208|NCT02079389|ACTIVE_COMPARATOR|Lap+Lus|"The included patients randomly assigned either to the department's standard laparoscopic (Lap) surgery or standard laparoscopic surgery (lap) plus a LUS examination.~In the intervention arm the intra-abdominal conditions are also assessed by laparoscopy, but then supplemented with a LUS examination of the primary tumor, liver and retroperitoneum.~All the included patients are getting a CT scan of the abdomen after 3 months."
62219668|NCT05576259|NO_INTERVENTION|Waitlist|Participants in the waitlist condition will be offered the intervention directly after post-test.
62219669|NCT02575859|EXPERIMENTAL|Adjuvant HIPEC|Adjuvant HIPEC will be performed simultaneously with primary tumor resection in patients undergoing curative surgery for primary colorectal cancer associated with risk factors for the development of metachronous peritoneal metastases.
62219670|NCT02575859|NO_INTERVENTION|Matched control|"Comparable controls will be retrospectively selected from patients undergoing curative surgery for colorectal cancer at the National Cancer Institute (Milan, Italy) during the same period.~Every single control patient will be matched with a.patient in HIPEC group according to the following criteria: i) risk-factor for metachronous PM (minimal synchronous PM vs. ovarian metastases vs. pathological tumor \[pT\] stage (pT4a/b); ii) pathological node (pN) stage (pN0 vs. pN1/2); iii) grading (well/moderately vs. poorly differentiated); iv) histological subtype (adenocarcinoma vs. mucinous/signet ring cell carcinoma); v) sex; vi) age (+/-5 years). The investigators will be blinded to patient outcomes during the process."
62219671|NCT03573583|EXPERIMENTAL|Resistance Training group (RT)|The resistance training intervention will include a full body, resistance training performed three days per week.The intensity, volume, tempo, and progression will be based on the Federal Physical Activity guidelines
62219672|NCT03573583|ACTIVE_COMPARATOR|Successful Aging|The comparator group will meet for stretching and health education classes every 2-5 weeks up to 7 total visits.
62795667|NCT00747084|NO_INTERVENTION|Arm 2: Control Treatment|Control Treatment: no water loading and waiting for spasms to subside.
62795668|NCT04353739|EXPERIMENTAL|Immediate Treatment (IT)|This small RCT will contain two arms, with participants randomly assigned to either the immediate treatment group (IT Group) or the delayed treatment group (DT Group).
62023305|NCT03087266|ACTIVE_COMPARATOR|Quadrant Scaling and Root Planing|"Q-SRP Non-surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed with one week interval. In each appointment only a quadrant of the dentition will be instrumented."
62795669|NCT04353739|ACTIVE_COMPARATOR|Delay Treatment (DT)|This small RCT will contain two arms, with participants randomly assigned to either the immediate treatment group (IT Group) or the delayed treatment group (DT Group).
62587047|NCT03907527|EXPERIMENTAL|Treatment (PRGN-3005 UltraCAR-T cells) IV Administration|Patients receive autologous PRGN-3005 UltraCAR-T cells via IV administration with or without lymphodepleting chemotherapy.
62795670|NCT06471218|EXPERIMENTAL|Treatment A:SHR-1918/SHR-1918 Placebo|
62795671|NCT06471218|EXPERIMENTAL|Treatment B:SHR-1918/SHR-1918 Placebo|
62023306|NCT06025955|EXPERIMENTAL|minimally invasive non surgical therapy|Experimental sites designated to receive non-surgical treatment will be submitted to careful subgingival debridement using curettes and ultrasonic device using 3.5 x magnification.
62023307|NCT06025955|ACTIVE_COMPARATOR|open flap debridement|Surgical technique will be used and the full-thickness flap will be minimally elevated. The granulation soft tissue will be dissected with a blade and carefully removed with curettes.
62023308|NCT02045758|EXPERIMENTAL|TAP20-C|TAP20-C
62219673|NCT01588483||giant cell arteritis|patients with biopsy and/or scintigraphy proven GCA
62587048|NCT03748810||Triple OADs failure|Empagliflozin or dapagliflozin as an add-on drug for inadequately controlled T2D patients who are already receiving a regimen of three distinct OADs, including metformin, glimepiride and dipeptidyl peptidase 4 (DPP4) inhibitors.
62587049|NCT02720263|EXPERIMENTAL|Double-Blind ASP4345 Multiple Dose Levels|ASP4345 will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, ASP4345 will be administered under fasting conditions. On days 2-6 and 8-13, ASP4345 will be administered under fed conditions.
62795672|NCT05039957|ACTIVE_COMPARATOR|A|
62795673|NCT05039957|EXPERIMENTAL|B|
62795674|NCT04661982||Observational (long term follow-up)|Patients undergo long term follow-up and complete questionnaires.
62795675|NCT06222580|EXPERIMENTAL|Treatment (SNDX-5613 and gilteritinib)|Patients receive SNDX-5613 PO BID and gilteritinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and aspiration, and blood sample collection throughout the study.
62795676|NCT02379169|EXPERIMENTAL|Sea buckthorn & lutein|Sea buckthorn oil complemented with lutein. Dose: 2 g/day as capsules taken twice/day for 6 months
62795677|NCT02379169|PLACEBO_COMPARATOR|Placebo|Triglycerides of medium-chain fatty acids. Dose: 2 g/day as capsules taken twice/day for 6 months
62795678|NCT04880096||chronic pain patients|All adult patients followed-up in participating pain clinics
62795679|NCT06087224|EXPERIMENTAL|Teleneonatology group|Study eligible neonates cared for by the community hospital team with telemedicine consultation by a neonatologist from the regional neonatal intensive care unit (NICU).
62023309|NCT02045758|ACTIVE_COMPARATOR|Fingerstick|Fingerstick
62023310|NCT00930111|ACTIVE_COMPARATOR|2 weeks|Attending physicians are physician-of-records for traditional inpatient ward team (housestaff and medical students) for 2 weeks.
62023311|NCT00930111|PLACEBO_COMPARATOR|4 weeks|Attending physicians are physician-of-records for traditional inpatient ward team (housestaff and medical students) for 4 weeks.
62219674|NCT05161728|EXPERIMENTAL|PSMA response evaluation arm|PSMA-PET/CT response evaluation, 2 months after starting hormonal therapy, 2 months after starting upfront therapy
62219675|NCT02279628|EXPERIMENTAL|Continuous wound infiltration alone|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 1 ml sodium chloride 0.9% (without morphine). Patient will then receive a continuous wound infiltration of ropivacaine 0.2% 8 ml/H via a preperitoneal catheter.
62219676|NCT02279628|ACTIVE_COMPARATOR|Intrathecal moprhine alone|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 0.1mg morphine. Patient will then receive a continuous wound infiltration of sodium chloride 0.9% 8 ml/H via a preperitoneal catheter.
62219677|NCT02279628|EXPERIMENTAL|Intrathecal morphine&wound infiltration|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 0.1mg morphine. Patient will then receive a continuous wound infiltration of ropivacaine 0.2% 8 ml/H via a preperitoneal catheter.
62219678|NCT00629733|EXPERIMENTAL|Ro-14|
62414209|NCT02079389|NO_INTERVENTION|laparoscopic examination (Lap)|"The included patients randomly assigned either to the department's standard laparoscopic (Lap) surgery or standard laparoscopic surgery (lap) plus a LUS examination.~In the standard arm (Lap) the conditions at the abdomen is only assessed by laparoscopy immediately prior to the resection.~All the included patients are getting a CT scan of the abdomen after 3 months."
62414210|NCT06248671|ACTIVE_COMPARATOR|Atorvastatin 40mg|Each participant in this arm will receive 40mg atorvastatin once daily for 84 days.
62414211|NCT06248671|ACTIVE_COMPARATOR|Atorvastatin 20mg|Each participant in this arm will receive 20mg atorvastatin once daily for 84 days.
62587050|NCT02720263|PLACEBO_COMPARATOR|Double-Blind Placebo Multiple Dose|Matching placebo capsules will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, matching placebo capsules will be administered with food. On days 2-6 and 8-13, matching placebo will be administered under fed conditions.
62219679|NCT02585232|ACTIVE_COMPARATOR|Care Consultation (CC)|"Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment - much like an interview guide - which then immediately shapes development of concrete action plans."
62219680|NCT02585232|EXPERIMENTAL|Care Consultation + Counseling (CC+C)|Care Consultation + Counseling (CC+C): is consistent with the original CC protocol in that the therapist partners with each dyad in a patient-centered way to prioritize unmet needs as identified during the CC initial assessment. Once this phase has been completed, typically within the first 2 sessions, the CC+C therapist will determine when to initiate counseling sessions targeting 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.). The counseling component of the CC+C intervention incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework.
62414212|NCT06248671|PLACEBO_COMPARATOR|Placebo|Each participant in this arm will receive placebo once daily for 84 days.
62414213|NCT06410859|EXPERIMENTAL|Botulinum Toxin Type A for Injection(5U/site）|5U/site
62414214|NCT06410859|EXPERIMENTAL|Botulinum Toxin Type A for Injection（2.5U/site）|2.5U/site
62414215|NCT06410859|EXPERIMENTAL|placebo|0U/site
62414216|NCT06567665|EXPERIMENTAL|Leucine supplementation between meals|Volunteers will take leucine supplements between breakfast and lunch, between lunch and dinner, and between dinner and supper.
62587051|NCT02720263|EXPERIMENTAL|Open-Label ASP4345|ASP4345 will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, ASP4345 will be administered with food. On days 2-6 and 8-13, ASP4345 will be administered under fed conditions. This is an optional cohort where subjects will be enrolled to further characterize pharmacodynamics in the event a higher sample size is necessary to determine changes in electrophysiological biomarkers.
62219681|NCT03756987|EXPERIMENTAL|ESPB group|Patient will receive a single shot of Ropivacaine injection 0.5% 25 mL injected at the erector spinae plane.
62414217|NCT06567665|EXPERIMENTAL|Leucine supplementation with meals|Volunteers will take leucine supplements with breakfast, with lunch and with dinner.
62414218|NCT06214780||Type 1 diabetes patients|Adult patients treated with advanced hybrid closed-loop in Castilla-La Mancha during summer 2023.
62414219|NCT01527786|EXPERIMENTAL|SNRI treatment|Participants are undergoing pharmacotherapy treatment with Desvenlafaxine (SNRI).
62414220|NCT06566547|EXPERIMENTAL|GR1803|
62414221|NCT01327989||Solitaire™ FR device|Eligible subjects treated with the Solitaire™ FR device.
62414222|NCT04051840|EXPERIMENTAL|ClinOleic group|Patients will be grouped to ClinOleic-based lipid parenteral nutrition regimen using ClinOleic or Structolipid-based lipid parenteral nutrition regimen using Structolipid. From day 0 to day 5, patients will not to receive any food or liquid oral or enteral nutrition. The goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid. The weight of patient calculated as ideal body weight. The patients will be allowed water based on the clinical judgment of the Investigator. From day 6 through the remainder of the study treatment period, liquid oral or enteral nutrition could be added to the study treatment. The intent is to supply the total calculated daily nutritional requirement with study treatment plus liquid oral or enteral nutrition. Liquid oral or enteral nutrition will be increased daily, as tolerated by the patient, with a concurrent reduction in study treatment, while still supplying the calculated daily nutritional requirement.
62414223|NCT03246321|EXPERIMENTAL|repetitive ePIPAC-OX|
62414224|NCT03883789||Normal pregnancies|Participants who have normal uncomplicated pregnancies
62414225|NCT03883789||Pregnancies with complications|Participants who undergo pregnancy with liver disease or develop liver disease or other conditions
62795680|NCT06087224|NO_INTERVENTION|Control group|Study eligible neonates cared for by the community hospital team per the site's usual practice of care.
62023312|NCT04475744|NO_INTERVENTION|Control arm|POI women radomized to control arm will undergo a 3-month follow up for: AFC, AMH, FSH and E2 determinations.COS will be initiated if growing antral follicles detected. In the second phase, POI women allocated to control group after completed the follow up period will undergo the 4-step ASCOT technique, as described in the previous phase but only one ovary will be injected, then they will undergo a 6-month follow up period as described above.
62023313|NCT04475744|EXPERIMENTAL|4-step ASCOT arm|POI women randomized to the 4-step ASCOT technique will receive a direct ovarian injection of G-CSF mobilized and activated PRP. For each patient, both ovaries will be directly injected with the G-CFS activated PRP (4-step ASCOT). Follow up (AFC, AMH, FSH and E2 determinations) will be developed for 6 months and COS initiated if growing antral follicles detected.
62219682|NCT03756987|PLACEBO_COMPARATOR|Control Group|Patient will receive a single shot of normal saline 25 mL injected at the erector spinae plane.
62219683|NCT00574756|OTHER|1|Active drug for 2 weeks, then washout period for 2 weeks, then placebo for 2 weeks
62414226|NCT03107442|EXPERIMENTAL|Exercise|12-weeks aerobic exercise intervention
62414227|NCT03107442|NO_INTERVENTION|Control|Usual care, with recommendations for a healthy lifestyle.
62414228|NCT05501002|EXPERIMENTAL|Device Arm|The Device Arm receives the eShunt® Implant
62414229|NCT03310606|OTHER|Peritonitis|"Patient received for antibiotic treatment a B lactam according to French recommendation :~* type of antibiotic : cefotaxime or ceftriaxone or piperacilline/tazobactam or imipenem~* dose : cefotaxime 2g / cetriaxone 2g / piperacilline 4g / imipenem 1g"
62414230|NCT03112707|EXPERIMENTAL|Study arm|1023 real world high-bleeding risk (HBR) patients with coronary artery disease (stable as well as acute coronary syndromes) who qualify for percutaneous coronary interventions will be included in the study.
62414231|NCT01224418|EXPERIMENTAL|Tacrolimus group|
62414232|NCT00265239|ACTIVE_COMPARATOR|1|Edaravone Group
62587052|NCT02250482|EXPERIMENTAL|Optivate®|Optivate® (Human Coagulation Factor VIII)
62023314|NCT05626829|EXPERIMENTAL|Tranilast|concurrent Tranilast 100mg 3 times per day
62023315|NCT03673436||Patients with low back pain|Cohort of 200 low back pain patients, 18 years+, who have been undergoing a lumbar spinal fusion
62023316|NCT04080973|EXPERIMENTAL|osteopenic patients|patients with a kidney stone and osteopenic changes.
62023317|NCT05868083|EXPERIMENTAL|SNC-109 CAR-T Cells|After the operation and pre-infusion evaluation, SNC-109 CAR-T Cells will be evaluated.
62023318|NCT00418392|EXPERIMENTAL|Minocycline group|After successful simple aspiration, minocycline pleurodesis will be performed.
62023319|NCT00418392|PLACEBO_COMPARATOR|Control group|After successful simple aspiration, nothing will be performed.
62219684|NCT00574756|OTHER|2|Placebo for 2 weeks, then washout for 2 weeks, then ranolazine for 2 weeks
62414233|NCT00265239|NO_INTERVENTION|2|Placebo Group
62414234|NCT06389240||6 weeks post-operatively early weight bearing|Full weight bearing will be allowed 6 weeks post-operatively. Gait analyses is carried out on when full weight-bearing is allowed.
62414235|NCT06389240||10 weeks post-operatively weight bearing (standard of care)|Full weight bearing will be allowed 10 weeks post-operatively. Gait analyses is carried out on when full weight-bearing is allowed.
62414236|NCT04256135|EXPERIMENTAL|Experimental mobilization: Mulligan|Mobilization will be performed while the patient actively performs knee flexion and/or extension depending on the patient's painful or limited movements. Three series of ten repetitions will be performed.
62414237|NCT04256135|ACTIVE_COMPARATOR|Control mobilization: AP Maitland|The joint mobilization, will be carried out in the knee with both hands, with displacement of the tibia from the front to the back of the femur in an oscillatory way without pain, will be carried out in blocks of 2 minutes with rests of 30 seconds with a duration of about 6 minutes.
62587053|NCT02103192|EXPERIMENTAL|Control plus low level nutrient fortification|Control plus low level nutrient fortification
62587054|NCT02103192|EXPERIMENTAL|Control plus increasing level nutrient fortification|Control plus increasing level nutrient fortification
62587055|NCT02103192|PLACEBO_COMPARATOR|Caffeine-free, carbonated soft drink|Caffeine-free, carbonated soft drink
62587056|NCT03184194|EXPERIMENTAL|Nivolumab-daratumumab|daratumumab 16 mg/kg: 8 times once weekly, then 8 times every 2 weeks; then every 4 weeks; nivolumab: 240 mg every 2 weeks during first 6 cycles, followed by 480 mg every 4 weeks
62795681|NCT00532688|EXPERIMENTAL|1|5 patients: 28 days of n-acetylcysteine (in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period.
62795682|NCT00532688|PLACEBO_COMPARATOR|2|28 days of oral distilled water (5ml) (in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to intervention (N-acetylcysteine 500mg oral bd) for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
62219685|NCT05102721|EXPERIMENTAL|Experimental|Single arm, all patients serially enrolled to combination doses of Avelumab and Pepinemab
62219686|NCT01638234|PLACEBO_COMPARATOR|Starch pill|
62219687|NCT01638234|EXPERIMENTAL|Melatonin|
62219688|NCT05201118|EXPERIMENTAL|CT103A combined with Selinexor|All subjects will be assigned to two Selinexor dose groups of 20 mg/week and 40 mg/week after receiving a single dose infusion of CT103A.
62219689|NCT04896151|ACTIVE_COMPARATOR|Standard MMPI|Participants will be instructed to complete the MMPI-2-RF-EX and other measures under standard conditions (e.g., to not simulate underreporting of suicide risk).
62219690|NCT04896151|EXPERIMENTAL|Simulation MMPI|Participants will be instructed to conceal current suicide risk when completing the MMPI-2-RF-EX and other measures.
62219691|NCT03118986|ACTIVE_COMPARATOR|Olanzapine|Standard antiemetics plus olanzapine
62219692|NCT03118986|PLACEBO_COMPARATOR|Placebo Oral Tablet|Standard antiemetics plus placebo
62219693|NCT00551590|PLACEBO_COMPARATOR|1|placebo PO (placebo control for sitagliptin) for three days. Saline IV (placebo control for exendin(9-39) on two consecutive study days.
62219694|NCT00551590|EXPERIMENTAL|2|Sitagliptin 100 mg PO for three days. Saline IV (placebo control for exendin(9-39)) on two consecutive study days
62219695|NCT00551590|EXPERIMENTAL|3|Sitagliptin 100 mg PO for three days. Exendin(9-39) IV on two consecutive study days.
62587057|NCT03184194|EXPERIMENTAL|Nivolumab-daratumumab with cylclophosphamide|daratumumab 16 mg/kg: weekly for 8 weeks, then Q2W for 16 weeks, ten Q4W thereafter; nivolumab: 240 mg every 2 weeks during first 6 cycles, followed by 480 mg every 4 weeks; low-dose cyclophosphamide 50mg daily on days 1-28 of each 28-day cycle;
62795683|NCT02851706||First cohort Patients (Person with the disease)|Patients with tumors of the central nervous system (CNS) who appear to be probable candidates for future protocol entry, have disease manifestations that are of unique scientific interest, importance, and/or educational value, or who have understudied tumors with unknown or unclear natural history. Patients with known genetic syndromes at high risk of developing CNS cancers will also be evaluated.
62414238|NCT02964910|EXPERIMENTAL|the chronic Hepatitis B patients|Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
62414239|NCT02964910|ACTIVE_COMPARATOR|the healthy volunteer|Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
62414240|NCT01591902|EXPERIMENTAL|EGRIFTA Treatment Grop|Sterile, lyophilized, nonpyrogenic powder containing tesamorelin acetate with mannitol as excipient
62414241|NCT01591902|PLACEBO_COMPARATOR|Placebo|Placebo-controlled
62414242|NCT05559242|EXPERIMENTAL|Anlotinib Hydrochloride Capsules|Anlotinib hydrochloride capsules, 12mg, 1 time in total
62414243|NCT06162117||Traumatic meniscus tear|Patients with traumatic meniscus tears will be enrolled in this study
62414244|NCT01807780|OTHER|single arm :vaccinated|military personnel vaccinated with multiple vaccines and monitored about safety, immunogenicity and efficacy
62414245|NCT00363428|PLACEBO_COMPARATOR|Control|Receive standard care and educational material on exercise and lifestyle choices of well-being
62414246|NCT00363428|EXPERIMENTAL|Lifestyle intervention|
62414247|NCT02007512|EXPERIMENTAL|Enzalutamide & exemestane|Enzalutamide 160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food and exemestane 50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) once daily after food.
62414248|NCT02007512|ACTIVE_COMPARATOR|Placebo & exemestane|Placebo and exemestane 25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet without placebo after unblinding) once daily after food.
62414249|NCT03540446|EXPERIMENTAL|Standard stimulation|Group A will be treated with First Relief Treatment at standard stimulation.
62414250|NCT03540446|EXPERIMENTAL|sweep stimulation|Group B will be treated with First Relief Treatment at sweep stimulation.
62414251|NCT03540446|EXPERIMENTAL|Placebo|Group C will be treated with First Relief Treatment, receiving a placebo.(dummy device with no electrical stimulation)
62414252|NCT06030947|ACTIVE_COMPARATOR|Connective Tissue Graft|A mucogingival surgery where a conventional connective tissue graft harvested from the palate is placed on a recipient site prepared for modified coronally advanced tunnel and sutured to cover multiple adjacent gingival recession defects.
62414253|NCT06030947|EXPERIMENTAL|Micro Connective Tissue Graft|A mucogingival surgery where multiple micro connective tissue graft harvested from the palate are placed on a recipient site prepared for modified coronally advanced tunnel and sutured to cover multiple adjacent gingival recession defects.
62587058|NCT03159234|OTHER|Diabetic pregnant women|
62414254|NCT04166851|EXPERIMENTAL|Open contest messages|Participants will view the top PrEP-promotion messages developed via an open contest.
62795684|NCT02851706||Second cohort Caregivers (Informants)|Caregivers will be defined as anyone who patients identify as an unpaid close friend or family member who knows them well and who is involved with their day-to-day care.
62219696|NCT00551590|PLACEBO_COMPARATOR|4|placebo PO (placebo control for sitagliptin) for three days. Exendin(9-39)IV on two consecutive study days.
62219697|NCT00543712|EXPERIMENTAL|PRO95780|
62587059|NCT05712629|ACTIVE_COMPARATOR|Responden Intervention|Arm 1 (Interventional) : Respondent has given bread with composit flour and vla with dadiah. pregnant women received 1 pieces bread containing 50 gram provide total fat 4 gram, protein 5 gram, carbohydrate 23.8 gram, Fe 2 mg, 2150 kcal and vla dadiah containing 30 gram provide 308 kcal.
62795685|NCT06538116|EXPERIMENTAL|Mevidalen (high dose)|Mevidalen high dose administered orally.
62795686|NCT06538116|EXPERIMENTAL|Mevidalen (low dose)|Mevidalen low dose administered orally.
62795687|NCT06538116|PLACEBO_COMPARATOR|Placebo|Placebo administered orally.
62795688|NCT01866358|PLACEBO_COMPARATOR|Umbilical vein infusion|using umbilical vein infusion for resucitation
62795689|NCT01866358|EXPERIMENTAL|Intraosseous infusion|using intraosseous infusion for resucitation
62219698|NCT00982995|EXPERIMENTAL|Palonosetron|Palonosetron 0.25 mg I.V. bolus
62219699|NCT04441060|EXPERIMENTAL|distress intervention subject group|Distress intervention program will be developed, and applied to the subject group, and they will be assessed before and after the intervention program with several tools.
62219700|NCT04441060|NO_INTERVENTION|distress intervention control group|No intervention will be applied to the control group. They will be assessed before and after the intervention program with same tools with subject group.
62219701|NCT06037473||growth hormone deficiency(GHD)|Growth hormone deficiency (GHD) is a rare and treatable condition that causes short height in children and metabolic issues in adults.
62795690|NCT06322888|EXPERIMENTAL|Arm A: Exercise Intervention|"Participants will be randomized and will complete:~* Baseline study visit with assessments, breast biopsy, and blood draw.~* Exercise program for 12 weeks 3x weekly and exercise logs. Additional blood draw after first exercise session.~* End of study visit with assessments, breast biopsy, and blood draw."
62795691|NCT06322888|NO_INTERVENTION|Arm B: Waitlist Control|"Participants will be randomized and will complete:~* Baseline study visit with assessments, breast biopsy, and blood draw.~* End of study visit with assessments, breast biopsy, and blood draw.~* Participants will be offered a complimentary 12-week exercise program after completing the study."
62219702|NCT06037473||Idiopathic short stature (ISS)|Idiopathic short stature is a condition in which the height of the individual is more than 2 SD below the corresponding mean height for a given age, sex and population, in whom no identifiable disorder is present.
62219703|NCT06037473||small for gestational age (SGA)|Small for gestational age (SGA) is defined as a birth weight of less than 10th percentile for gestational age.
62219704|NCT06037473||Turner Syndrome (TS)|Turner syndrome, a condition that affects only females, results when one of the X chromosomes (sex chromosomes) is missing or partially missing.
62219705|NCT06037473||others|others who with the height of the individual is more than 2 SD below the corresponding mean height for a given age, sex and population.
62219706|NCT04902508|EXPERIMENTAL|Explicit Master Plus No Additional Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Mastery and receives no additional treatment."
62219707|NCT04902508|EXPERIMENTAL|Explicit Master Plus Explicit Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Mastery and receives 32 additional sessions of explicit treatment."
62219708|NCT04902508|EXPERIMENTAL|Explicit Master Plus Implicit Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Mastery and receives 32 sessions of implicit treatment."
62219709|NCT04902508|EXPERIMENTAL|Explicit Non-Master Plus Explicit Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Non-Mastery and receives 32 additional sessions of explicit treatment."
62219710|NCT04902508|EXPERIMENTAL|Explicit Non-Master Plus Implicit Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Non-Mastery and receives 32 sessions of implicit treatment."
62219711|NCT04902508|EXPERIMENTAL|Implicit Master Plus No Additional Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Mastery and receives no additional treatment."
62219712|NCT04902508|EXPERIMENTAL|Implicit Master Plus Implicit Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Mastery and receives 32 additional sessions of implicit treatment."
62219713|NCT04902508|EXPERIMENTAL|Implicit Master Plus Explicit Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Mastery and receives 32 sessions of explicit treatment."
62414255|NCT04166851|ACTIVE_COMPARATOR|Social marketing messages|Participants will view the PrEP-promotion messages developed via social marketing.
62414256|NCT03872622|OTHER|CD patients|New onset Crohn's disease patients
62414257|NCT03872622|OTHER|Healthy controls|Patients' family members and healthy subjects undergoing colonoscopy for non-research purposes
62795692|NCT03856216|EXPERIMENTAL|Group I (inotuzumab ozogamicin, chemotherapy, transplant)|See Detailed Description.
62414258|NCT03507608|EXPERIMENTAL|flutamide|50mg flutamide prior to brachytherapy and prostatic biopsy
62795693|NCT03856216|EXPERIMENTAL|Group II (inotuzumab ozogamicin, chemotherapy, transplant)|See Detailed Description.
62795694|NCT05184634|ACTIVE_COMPARATOR|Working group|The data of the control group will be compared with the data of the study group.
62219714|NCT04902508|EXPERIMENTAL|Implicit Non-Master Plus Implicit Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Non-Mastery and receives 32 additional sessions of implicit treatment."
62795695|NCT05184634|ACTIVE_COMPARATOR|Control Group|The data of the study group will be compared with the data of the control group.
62414259|NCT03507608|PLACEBO_COMPARATOR|placebo|placebo prior to brachytherapy and prostatic biopsy
62414260|NCT04361552|EXPERIMENTAL|Arm I (tocilizumab, standard of care)|Patients receive tocilizumab IV every 12 hours for up to 3 doses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care.
62414261|NCT04361552|ACTIVE_COMPARATOR|Arm II (standard of care)|Patients receive standard of care.
62414262|NCT03878056||Transvaginal mesh|Vaginal surgery (UpholdTM Lite Vaginal Support, Boston Scientific)
62414263|NCT03878056||Robotic sacral colpopexy|Robotic surgery (Artisyn® Y-Shaped Mesh - Ethicon)
62414264|NCT06565520|EXPERIMENTAL|Transcranial Direct Current Stimulation (tDCS)|
62414265|NCT06565520|SHAM_COMPARATOR|Sham|
62795696|NCT02152306|EXPERIMENTAL|Fimasartan and Amlodipine|Combination of Fimasartan and Amlodipine
62219715|NCT04902508|EXPERIMENTAL|Implicit Non-Master Plus Explicit Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Non-Mastery and receives 32 sessions of explicit treatment."
62219716|NCT03361280|EXPERIMENTAL|Atenolol|Atenolol (50 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
62219717|NCT03361280|EXPERIMENTAL|Bisoprolol|Bisoprolol (5 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
62414266|NCT04736576|OTHER|Group 1|Palbociclib plus endocrine therapy
62414267|NCT04736576|OTHER|Group 2|Endocrine monotherapy
62414268|NCT02393066|ACTIVE_COMPARATOR|propofol|these patients are sedated with propofol infusion during ICU admission
62795697|NCT02152306|ACTIVE_COMPARATOR|Fimasartan|Fimasartan Monotherapy
62587060|NCT05712629|PLACEBO_COMPARATOR|Responden Placebo|Arm 2 (Placebo) : Respondent has given bread with original flour (wheat flour) and vla original without dadiah. pregnant women received 1 pieces bread containing 50 gram and vla containing 30 gram.
62587061|NCT06665087|EXPERIMENTAL|CGA cohort|all patients will receive Ultrafractionated Radiotherapy (RT) and Comprehensive Geriatric Assessment (CGA) Guided systemic treatment. All patients will receive Ultrafractionated RT and PD-1 antibody. Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed, with/without targeted therapy, and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, with/without targeted therapy, and BSC.
62587062|NCT06665087|OTHER|external control cohort|external control from real word, data of patients with the same baseline characteristics from the same period and the same institute will be prospectively collected.
62587063|NCT01570972|OTHER|MFG and GCBT|There is a single arm for this study. All participants will be able to participate in MFG and GCBT
62587064|NCT05127304||Tiotropium bromide/Olodaterol (TIO/OLO)|Chronic Obstructive Pulmonary Disease (COPD) patients with ≥30 consecutive days with TIO/OLO initiated during the patient identification period of 01 June 2015 to 30 November 2019 and ≥40 years of age as of the year of the index date. The index date was the date of the TIO/OLO pharmacy claim that started the ≥30 consecutive days with the medication.
62219718|NCT03361280|EXPERIMENTAL|Metoprolol|Metoprolol (50 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
62219719|NCT03361280|EXPERIMENTAL|Carvedilol|Carvedilol (6.25 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
62219720|NCT03318042|EXPERIMENTAL|Child-teenagers-walnuts-pomegranate|Intake of walnuts or pomegranate juice for 3 days
62219721|NCT02978573|EXPERIMENTAL|Cartiva|Cartiva Synthetic Cartilage Implant
62219722|NCT00785993|ACTIVE_COMPARATOR|Control Group|Fresh donor oocytes
62219723|NCT00785993|EXPERIMENTAL|Group I|vitrified donor oocytes
62414269|NCT02393066|ACTIVE_COMPARATOR|dexmedetomidine|these patients are sedated with dexmedetomidine infusion during ICU admission
62414270|NCT06562075|OTHER|Investigational Medical Device|All eligable subjects desiring correction of their jawline profile will receive intradermal injection of Decoria Intense Strong on either one or both sides of the face (including or not including the chin).
62795698|NCT04291859|EXPERIMENTAL|Lu AF28996|"Participants in Part A will receive ascending oral doses of Lu AF28996 OD for 14 days in all OD cohorts, followed by down-titration as per Investigator's judgement. For the BID Cohort A1, participants will receive Lu AF28996 BID for 24 days, followed by down-titration as per Investigator's judgement. For the BID Cohort A2, participants will receive Lu AF28996 BID for 39 days, followed by down-titration as per Investigator's judgement.~Participants in Part B (Cohorts B1, B2, and B3) will receive Lu AF28996 BID for 41 days, followed by down-titration as per Investigator's judgement"
62219724|NCT04837820|EXPERIMENTAL|Acupuncture|The intervention will consist of 10 acupuncture sessions over 10 weeks using the standardized, semi-fixed protocol.
62219725|NCT04837820|PLACEBO_COMPARATOR|Sham Acupuncture (SA)|The intervention will consist of 10 acupuncture sessions over 10 weeks using the standardized, semi-fixed protocol.
62219726|NCT04837820|EXPERIMENTAL|Wait-List Control|During the 26-week waiting period, the CRC will contact patients in the WLC group at the same frequency as the acupuncture groups with respect to data collection. Patients in the WLC group will continue to receive their standard medical care as prescribed by their oncologists/primary care physicians. WLC patients will be compensated with real acupuncture treatments after Week 26 (end of study).
62219727|NCT01026285||antipsychotic treatment|Risperidone Long-Acting injectable or oral antipsychotics According to label
62219728|NCT04133506||acute eczema|acute eczema patients with eczema \<72 hours no drugs
62219729|NCT04133506||chronic eczema|chronic eczema with eczema \> 72 hours no drugs
62219730|NCT04133506||allergic contact dermatitis|allergic contact dermatitis with a clear allergen identified no drugs
62219731|NCT04133506||psoriasis patients|patients with plaque psoriasis no drugs
62219732|NCT04133506||healthy volunteers|dithranol or DNCB (used to induce irritant or allergic eczema used safely in similar research studies for decades) aspirin to half the group to assess the effects on downstream mediators
62219733|NCT05026346||Healthy|Healthy subjects, wothout shoulder pathology
62219734|NCT05026346||Rotator cuff tears|Patients after arthroscopic reconstruction of rotator cuff
62219735|NCT06446622|EXPERIMENTAL|Young Adults|Young Adults between 20-40 years of age.
62219736|NCT04569643||Main|Patients with cerebral small vessel disease and periodic limb movement index equal or more than 15 movements per hour of sleep.
62219737|NCT04569643||Control|Patients with cerebral small vessel disease and periodic limb movement index less than 15 movements per hour of sleep.
62414271|NCT02015286||Growth Disorders|
62414272|NCT06700902|EXPERIMENTAL|Taking Action Intervention Condition|Participants in the experimental condition will participate in the Taking Action intervention.
62414273|NCT06700902|NO_INTERVENTION|Information Only Control Condition|"Participants in the information only control condition will not participate in any intervention but will be given access to a resource entitled, A Practical Guide for People with Disabilities Who Want to Go to College."
62587065|NCT05127304||Fluticasone furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)|Chronic Obstructive Pulmonary Disease (COPD) patients with ≥30 consecutive days with FF/UMEC/VI initiated during the patient identification period of 01 June 2015 to 30 November 2019 and ≥40 years of age as of the year of the index date. The index date was the date of the FF/UMEC/VI pharmacy claim that started the ≥30 consecutive days with the medication.
62587066|NCT03719248|ACTIVE_COMPARATOR|HTEA Group + N(LVMI)+ AVR alone(n=10)|HTEA Group + N(LVMI)+ AVR alone(n=10)
62587067|NCT03719248|ACTIVE_COMPARATOR|HTEA Group + ↑ (LVMI)+ AVR alone(n=10)|HTEA Group + ↑ (LVMI)+ AVR alone(n=10)
62587068|NCT03719248|ACTIVE_COMPARATOR|HTEA Group + N(LVMI)+ AVR + CABG(n=10)|HTEA Group + N(LVMI)+ AVR + CABG(n=10)
62795699|NCT05948631|EXPERIMENTAL|MISC|Mediational Intervention for Sensitizing Caregivers (MISC): a program for mother and children where mothers become sensitized to the impact of their behavior on their children with the aim of improving quality caregiving and child outcomes.
62795700|NCT05948631|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as Usual in the rehousing program. Mothers receive support in a domestic violence rehousing program to find work and housing.
62795701|NCT05582993|EXPERIMENTAL|Cohort 1: Participants With Age >=12 to <18 years|Participants with age greater than or equal to (\>=) 12 to less than (\<) 18 years who have received on-demand (OD) therapy or prophylactic treatment with a pdVWF product will receive rVWF with an initial dose selected within the range of 40 to 60 international units per kilogram (IU/kg) rVWF, intravenous infusions, twice-weekly for 12 months. Participants may receive rVWF with or without ADVATE intravenous infusions, when indicated (as deemed necessary for breakthrough bleeding episode treatment and perioperative bleeding management).
62795702|NCT05582993|EXPERIMENTAL|Cohort 2: Participants With Age >=6 to <12 years|Participants with age \>=6 to \<12 years who have received OD therapy of VWF product or prophylactic treatment with a pdVWF product will receive rVWF with an initial dose selected within the range of 40 to 60 IU/kg rVWF, intravenous infusions, twice-weekly for 12 months. Participants may receive rVWF with or without ADVATE intravenous infusions, when indicated (as deemed necessary for breakthrough bleeding episode treatment and perioperative bleeding management).
62795703|NCT05582993|EXPERIMENTAL|Cohort 3: Participants With Age <6 years|Participants with age \<6 years who have received OD therapy of VWF product or prophylactic treatment with a pdVWF product will receive rVWF with an initial dose selected within the range of 40 to 60 IU/kg rVWF, intravenous infusions, twice-weekly for 12 months. Participants may receive rVWF with or without ADVATE intravenous infusions, when indicated (as deemed necessary for breakthrough bleeding episode treatment and perioperative bleeding management).
62219738|NCT01518933|EXPERIMENTAL|Silibilin (Legalon-SIL)|20 mg/kg Silibinin (Legalon SIL) ,as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
62414274|NCT01033175|OTHER|COPD patients with ACD|"In the 1st part of this clinical study the prevalence ACD in COPD subjects will be estimated in a consecutive population of COPD subjects who will visit the hospital's pulmonary clinics as outpatients. During the first visit, subjects will give a detailed medical history and will undergo clinical examination and pulmonary function testing 15 minutes post-bronchodilation. Eligible patients will then undergo peripheral venous blood analysis. The first 30 COPD subjects from the population described above, fulfilling the criteria of ACD will constitute the first arm (group of cases).ACD is defined by low Hb levels (men: \<13 mg/dl, women: \<12 mg/dl), no other cause of anemia present, normal or increased serum ferritin and decreased total iron binding capacity."
62414275|NCT01033175|OTHER|COPD patients without ACD|"Thirty matched patients with COPD without ACD from the initial cohort will constitute the second arm (the controls)"
62795704|NCT00458120|EXPERIMENTAL|1|Participants previously vaccinated with rDEN4delta30 will receive one subcutaneous vaccination (10\^3 dose of vaccine) of rDEN1delta30 vaccine into the deltoid region of either arm.
62795705|NCT00458120|EXPERIMENTAL|2|Participants previously vaccinated with rDEN4delta30 will receive one subcutaneous vaccination (10\^3 dose of vaccine) of rDEN2/4delta30(ME) into the deltoid region of either arm.
62795706|NCT00458120|EXPERIMENTAL|3|Participants previously vaccinated with rDEN2/4delta30(ME) will receive one subcutaneous vaccination (10\^3 dose of vaccine) of rDEN1delta30 vaccine into the deltoid region of either arm.
62795707|NCT00458120|EXPERIMENTAL|4|Participants previously vaccinated with rDEN1delta30 will receive one subcutaneous vaccination (10\^3 dose of vaccine) of rDEN2/4delta30(ME) vaccine into the deltoid region of either arm.
62795708|NCT00458120|PLACEBO_COMPARATOR|5|One subcutaneous vaccination with placebo into the deltoid region of either arm.
62795709|NCT03545074|EXPERIMENTAL|Mindfulness Spanish|The MAPs program was developed at UCLA (Winston \& Smalley, 2010 and Lopez-Maya, 2016) and provides experiential training in mindfulness-based practices, including mindfulness meditation. UCLA-certified instructors delivered the interventions. Active program components include sitting and walking meditations, body scan and loving-kindness meditation. Participants were provided with audio CDs or digital downloads to complete their daily meditation assignments. Sessions were held once per week for 2 hours per session over a period of six consecutive weeks. Home practice assignments consist of daily mindfulness exercises starting with 5 minutes daily, progressing to 20 minutes daily by the end of the program.
62219739|NCT01518933|PLACEBO_COMPARATOR|Saline|Placebo (saline), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
62219740|NCT00536302|EXPERIMENTAL|1|Collagen Hydrolysate
62219741|NCT00536302|PLACEBO_COMPARATOR|2|
62219742|NCT04628351|EXPERIMENTAL|Bladder Training|"Patients in the structured bladder training group were trained on lifestyle changes (nutrition, fluid management, exercise), pelvic floor muscle exercises and bladder control techniques."
62219743|NCT04628351|NO_INTERVENTION|Control Group|Routine patient training was given to the patients in the control group by a nurse working in the clinic.
62414276|NCT02682069|EXPERIMENTAL|All patients|There is one arm to this study and all patients will undergo the same procedures. The test of this technology is on a per wound basis where bacteria will fluoresce red and samples will be obtained from the discrete red locations. Microbiology results indicating the presence or absence of bacteria will be correlated to the fluorescence signal in the fluorescent images.
62414277|NCT03829020|EXPERIMENTAL|Treatment (metformin, nelfinavir)|Patients receive metformin hydrochloride PO on days 1-14, nelfinavir mesylate PO BID on days 1-14, and bortezomib SC on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62414278|NCT03022799|EXPERIMENTAL|KM-819|Each cohort consists of 8 subjects; 6 subjects will receive planned dose of KM-819 and 2 subjects will receive placebo.
62414279|NCT03022799|PLACEBO_COMPARATOR|Placebo|Each cohort consists of 8 subjects; 6 subjects will receive planned dose of KM-819 and 2 subjects will receive placebo.
62219744|NCT05526079|EXPERIMENTAL|Watchful Waiting|"Six cycles of FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) will be administered every two weeks according to protocol. After a 3 week recovery period, this will be followed by conventional concurrent radiation and 5FU/capecitabine.~Patients will be re-staged two to three weeks after completion of induction FOLFOX therapy to ensure no disease progression. The patients will be re-staged again at least 7-11 weeks post completion of nCRT. Patients with restaging results showing either complete or near complete response, will be allocated to watchful waiting."
62219745|NCT03341689|EXPERIMENTAL|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
62219746|NCT03341689|EXPERIMENTAL|Placebo/High Dose Psilocybin|Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
62219747|NCT03341689|EXPERIMENTAL|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
62219748|NCT03341689|EXPERIMENTAL|High Dose Psilocybin/Placebo|Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.
62219749|NCT03398213|EXPERIMENTAL|Acupuncture|Acupuncture for treatment of COPD exacerbation + standard conventional care for COPD exacerbation
62219750|NCT03398213|SHAM_COMPARATOR|Sham procedure|Ear stimulation with plaster + standard conventional care for COPD exacerbation
62219751|NCT03398213|NO_INTERVENTION|Standard care|Standard conventional care for COPD exacerbation
62219752|NCT01493232|EXPERIMENTAL|Denture, edentulous patient, treatment|Dentures with different type of occlusion
62219753|NCT01493232|EXPERIMENTAL|Denture, Edentulous patient, treatment|Dentures with different type of occlusion
62219754|NCT01975870|EXPERIMENTAL|intervention group|use of application on smartphone for lifestyle counseling
62219755|NCT01975870|NO_INTERVENTION|control group|no use of application on smartphone
62219756|NCT01244854|OTHER|Arm 1|Enhanced Usual Care; patients receive care as usual, with additional mailings on wellness newsletter topics
62219757|NCT04298021|EXPERIMENTAL|AZD6738 + Durvalumab|"* Durvalumab 1500 mg iv on D1~* AZD6738 240 mg bid on D15-D28 Every 4 weeks C1D1 dose of durvalumab will be delivered, and AZD6738 of 240 mg bid will be dosed at D15-D28. Every cycle consists of 4 weeks."
62219758|NCT04298021|EXPERIMENTAL|AZD6738 + Olaparib|"* AZD6738 160 mg qd on D1-D7~* Olaparib 300 mg bid on D1-D28 Every 4 weeks Every cycle consists of 4 weeks. AZD6738 of 160 mg qd will be administered on D1-D7. Olaparib will be delivered as 300 mg bid dose on D1-D28."
62219759|NCT05202639||Continuation of pregnancy|The parents who have chosen to continue pregnancy will be asked to complete a questionnaire.
62219760|NCT05202639||Medical termination of pregnancy|The parents who have chosen to terminate pregnancy will be asked to complete a questionnaire.
62219761|NCT01474434|EXPERIMENTAL|Pradigastat (LCQ908) followed by placebo|Pradigastat 80 mg (4 x 20-mg tablets) loading dose daily for three days followed by pradigastat 20 mg (2 x 10-mg tablets) daily for two days followed by a 30-day washout period in between followed by 5-day placebo treatment
62219762|NCT01474434|EXPERIMENTAL|Placebo followed by pradigastat (LCQ908)|Placebo (5-day treatment period) followed by a 30-day washout period followed by pradigastat 80 mg (4 x 20-mg tablets) loading dose daily for three days followed by p20 mg (2 x 10-mg tablets) daily for two days
62219763|NCT03254342||Major depressive disorder|There is no intervention/treatment in this study.
62219764|NCT03254342||Non-depressed individuals|There is no intervention/treatment in this study.
62219765|NCT00456677|EXPERIMENTAL|Minocycline|Addition of minocycline 150 mg po twice daily to current asthma treatment regimen.
62219766|NCT00456677|PLACEBO_COMPARATOR|Placebos|Addition of placebo capsules po twice daily to current asthma treatment regimen
62587069|NCT03719248|ACTIVE_COMPARATOR|HTEA Group +↑ (LVMI)+ AVR + CABG(n=10)|HTEA Group +↑ (LVMI)+ AVR + CABG(n=10)
62219767|NCT06067061|EXPERIMENTAL|Atezolizumab plus RP1 (Immulytic™) oncolytic immunotherapy|Atezolizumab IV q2w RP1 (Immulytic™) by imaging-guided intra-tumor (IT) route.
62219768|NCT02891408|EXPERIMENTAL|Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg|Participants with mild hepatic impairment will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
62219769|NCT02891408|EXPERIMENTAL|Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg|Matched normal hepatic function participants to mild hepatic impairment participants will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
62587070|NCT03719248|NO_INTERVENTION|Control(GA) Group+ N(LVMI)+ AVR alone(n=10)|Control(GA) Group+ N(LVMI)+ AVR alone(n=10)
62587071|NCT03719248|NO_INTERVENTION|Control(GA) Group+ ↑ (LVMI)+ AVR alone(n=10)|Control(GA) Group+ ↑ (LVMI)+ AVR alone(n=10)
62219770|NCT02891408|EXPERIMENTAL|Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg|Participants with moderate hepatic impairment will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
62219771|NCT02891408|EXPERIMENTAL|Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg|Matched normal hepatic function participants to moderate hepatic impairment participants will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
62219772|NCT02891408|EXPERIMENTAL|Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg|Participants with severe hepatic impairment will receive a single dose of firsocostat 5 mg (1 × 5 mg capsule).
62219773|NCT02891408|EXPERIMENTAL|Cohort 3 (Normal Hepatic Function) Firsocostat 5 mg|Matched normal hepatic function participants to severe hepatic impairment participants will receive a single dose of firsocostat 5 mg (1 × 5 mg capsule).
62219774|NCT02891408|EXPERIMENTAL|Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg|Participants with mild hepatic impairment will receive a single dose of fenofibrate 48 mg (1 × 48 mg tablet).
62587072|NCT03719248|NO_INTERVENTION|Control(GA) Group+ N(LVMI)+ AVR + CABG(n=10)|(GA) Group+ N(LVMI)+ AVR + CABG(n=10)
62587073|NCT03719248|NO_INTERVENTION|Control(GA) Group+↑ (LVMI)+ AVR + CABG(n=10)|Control(GA) Group+↑ (LVMI)+ AVR + CABG(n=10)
62795710|NCT03545074|EXPERIMENTAL|Mindfulness English|The MAPs program was developed at UCLA (Winston \& Smalley, 2010) and provides experiential training in mindfulness-based practices, including mindfulness meditation. UCLA-certified instructors delivered the interventions. Active program components include sitting and walking meditations, body scan and loving-kindness meditation. Participants were provided with audio CDs or digital downloads to complete their daily meditation assignments. Sessions were held once per week for 2 hours per session over a period of six consecutive weeks. Home practice assignments consist of daily mindfulness exercises starting with 5 minutes daily, progressing to 20 minutes daily by the end of the program.
62219775|NCT02891408|EXPERIMENTAL|Cohort 4 (Normal Hepatic Function) Fenofibrate 48 mg|Matched normal hepatic function participants to mild hepatic impairment participants, will receive a single dose of fenofibrate 48 mg (1 × 48 mg tablet).
62219776|NCT03524053|EXPERIMENTAL|Exercise induced bronchoconstriction|An exercise challenge will then be performed according to international guidelines. The exercise will consist of 8 minutes of cycling on a cycle ergometer while breathing medical grade dry air from a reservoir (Douglas bag) via a two-way non-rebreathing valve. The workload will be increased progressively over the first 2 minutes, and will then be maintained for 6 minutes at a target workload (in Watts) of \[53.76 \* measured forced expiratory volume in 1 sec (FEV1)-11.07\].
62219777|NCT03524053|ACTIVE_COMPARATOR|Inhibited EIB|An exercise challenge will then be performed according to international guidelines. The exercise will consist of 8 minutes of cycling on a cycle ergometer while warm-humid air from a reservoir (Douglas bag) via a two-way non-rebreathing valve. The workload will be increased progressively over the first 2 minutes, and will then be maintained for 6 minutes at a target workload (in Watts) of \[53.76 \* measured forced expiratory volume in 1 sec (FEV1)-11.07\].
62219778|NCT03524053|NO_INTERVENTION|Control|Participants will attend the laboratory but no exercise trial will be performed.
62219779|NCT04955444|NO_INTERVENTION|Historical control group|The historical control group underwent a thyroidectomy or parathyroidectomy procedure prior to implementation of the quality improvement bundle.
62219780|NCT04955444|EXPERIMENTAL|Post-implementation group|The post-implementation group will have a thyroidectomy or parathyroidectomy procedure after bundle implementation and will receive care that is enhanced by the quality improvement bundle.
62219781|NCT03417895|EXPERIMENTAL|A (SHR-1210+Apatinib)|SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
62219782|NCT03417895|EXPERIMENTAL|B (SHR-1210+Apatinib)|SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD (5 Days on, 2 Days off)
62219783|NCT03417895|EXPERIMENTAL|C (SHR-1210+Apatinib)|SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD (7 Days on, 7 Days off)
62219784|NCT00294918|EXPERIMENTAL|Serostim® (1 mg)|
62414280|NCT03853980|EXPERIMENTAL|Rotational fractional resection (RFR)|Single treatment of skin resection (removal of loose skin)
62414281|NCT00836238||Questionnaire + Fall Risk Assessment|Physical Function Interview + Physical Function Tests + Symptom Assessment Interview
62219785|NCT00294918|EXPERIMENTAL|Serostim® (2 mg)|
62219786|NCT00294918|EXPERIMENTAL|Serostim® (4 mg)|
62414282|NCT03823859||Healthy volunteers|"* Blood sampling (fT3, fT4, TSH, Lipids, Glucose, HbA1c)~* Indirect calorimetry~* Dual energy X-ray Absorptiometry (DXA)"
62414283|NCT03823859||Patients with thyroid dysfunction|"Patients with Primary hypothyroidism newly diagnosed, Primary hypothyroidism substituted, hyperthyroidism, secondary hypothyroidism~* Blood sampling (fT3, fT4, TSH, Lipids, Glucose, HbA1c)~* Indirect calorimetry~* Dual energy X-ray Absorptiometry (DXA)"
62414284|NCT06703437|EXPERIMENTAL|Long-acting neuraxial blockade|Long-acting neuraxial blockade at the time of prostate biopsy by periprostatic injection of Dehydrated alcohol + lidocaine.
62414285|NCT06529250|EXPERIMENTAL|intermediate-dose HAD regimen|Patients received intermediate-dose HAD regimen. When patients reach complete remission (CR) after the induction therapy, 3 courses of the high-dose cytarabine regimen (3g/m2 q12h, 3 days) are used. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment. When patients do not achieve CR after the induction therapy, reinduction therapy with IAC (IDA 10mg/m2 for 3 days, cytarabine 100mg/m2 for 7 days, cyclophosphamide 350mg/m2 d2, d5) regimen is used. Patients who still do not achieve CR after reinduction therapy will be removed from the group.
62414286|NCT06529250|ACTIVE_COMPARATOR|conventional treatment|Patients were treated with 3+7 induction regimen (IA or DA). When patients reach complete remission (CR) after the induction therapy, 3 courses of the high-dose cytarabine regimen (3g/m2 q12h, 3 days) are used. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment. When patients do not achieve CR after the induction therapy, reinduction therapy with IAC (IDA 10mg/m2 for 3 days, cytarabine 100mg/m2 for 7 days, cyclophosphamide 350mg/ m2 d2, d5) regimen is used. Patients who still do not achieve CR after reinduction therapy will be removed from the group.
62414287|NCT02599350||1|Patients receiving mechanical ventilation
62219787|NCT02677454|EXPERIMENTAL|Flash Glucose Monitor|"Each patient with Type 1 diabetes will have a subcutaneous tissue FGM sensor inserted. The sensor will produce a maximum of 1440 tissue fluid glucose measurements per 24 hours and 20160 measurements during the 14 day study. The FGM data (Abbott Freestyle Libre) will be compared to the time-matched reference blood glucose measurements.~Each ambulatory patient will sample capillary blood with the HemoCue meter and measure the concentration of glucose 6 to 10 times per day for 14 days. The concentration of finger-stick capillary blood glucose will be measured using the self-monitoring blood glucose (SMBG) hemocue meter in their daily living. The subjects will record SMBG, in a written diary. Subjects will dose insulin according to their routine methods throughout the 14 day study."
62414288|NCT02539979|ACTIVE_COMPARATOR|IV Paracetamol|Patients will receive 1gram of IV paracetamol mixed in 100ml infused over 15 minutes. The patients will undergo radiofrequency lesioning of two consecutive levels of lumbar facets under fluoroscopic guidance
62795711|NCT03545074|ACTIVE_COMPARATOR|Health Education Spanish|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general. Similar interventions have been described elsewhere (Black, et al., 2014; Irwin, et al., 2014). A trained health educator provided videos and didactic presentations on topics such as: stress, sleep hygiene, diet \& nutrition, sexuality, mental health and substance abuse. The health education condition resembled the MAPs intervention in terms of duration, group format and support, attention and participant expectancy regarding health benefits.
62414289|NCT02539979|PLACEBO_COMPARATOR|IV Placebo (Normal Saline)|Patients will receive 100ml of normal saline infused over 15 minutes. The patients will undergo radiofrequency lesioning of two consecutive levels of lumbar facets under fluoroscopic guidance
62795712|NCT03545074|ACTIVE_COMPARATOR|Health Education English|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general. Similar interventions have been described elsewhere (Black, et al., 2014; Irwin, et al., 2014). A trained health educator provided videos and didactic presentations on topics such as: stress, sleep hygiene, diet \& nutrition, sexuality, mental health and substance abuse. The health education condition resembled the MAPs intervention in terms of duration, group format and support, attention and participant expectancy regarding health benefits.
62795713|NCT06069336|ACTIVE_COMPARATOR|Hypertonic saline|3% hypertonic saline (NEBU-dose hypertonic). The treatment will be delivered through nebulisation using oxygen with 5 litres of O2 flow, or through a compressed air-driven jet nebuliser, every 6 hours for three times daily with a night break, until discharge.
62795714|NCT06069336|PLACEBO_COMPARATOR|Normal saline|0,9% normal saline (NEBU-dose isotonic).The treatment will be delivered through nebulisation using oxygen with 5 litres of O2 flow, or through a compressed air-driven jet nebuliser, every 6 hours for three times daily with a night break, until discharge.
62795715|NCT00001595||Patients with pituitary tumors or hypothalmic defects|Patients with pituitary tumors or hypothalmic defects
62795716|NCT02370420|EXPERIMENTAL|Unique application of PRP|Patients will be applied a unique application of platelet-rich plasma for knee osteoarthritis, and will be given rehabilitation exercises at home
62795717|NCT02370420|ACTIVE_COMPARATOR|Triple application of PRP|Patients will be applied a triple application of platelet-rich plasma for knee osteoarthritis, with a interval of two weeks between each, and will be given rehabilitation exercises at home
62414290|NCT04078893|NO_INTERVENTION|control group|
62414291|NCT04078893|EXPERIMENTAL|on need group|
62414292|NCT04078893|EXPERIMENTAL|communication group|
62414293|NCT05566730|EXPERIMENTAL|CT-MICART App|Participants in this arm will receive daily EMAs for 6 weeks.
62414294|NCT04708782|PLACEBO_COMPARATOR|Placebo|Matching placebo inhaled using an ultrasonic nebulizer QID
62587074|NCT02114450|EXPERIMENTAL|Robot-assisted Rehabilitation|Participants will receive Robot-assisted training with the H2 lower limb powered exoskeleton. They will perform walking and other lower limb exercises (as applicable) while wearing the H2 lower limb powered exoskeleton. Training will involve 3 sessions per week for 4 weeks, each lasting about 1.5 hours.
62587075|NCT02114450|ACTIVE_COMPARATOR|Supervised motor practice|Participants in this group will perform walking and other lower limb exercises (as applicable) under the supervision of a research physical therapist. Training will be for 3 sessions per week for 4 weeks, each session lasting about 1.5 hours.
62587076|NCT05161208|EXPERIMENTAL|OC-01 (varenicline 0.6mg/ml) nasal spray|Intranasal delivery of OC-01 nasal spray twice daily (BID)
62587077|NCT05161208|PLACEBO_COMPARATOR|Placebo (vehicle) nasal spray|Intranasal delivery of placebo vehicle nasal spray twice daily (BID)
62587078|NCT01270464|PLACEBO_COMPARATOR|Placebo|Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses.
62414295|NCT04708782|EXPERIMENTAL|Inhaled Treprostinil|Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.
62414296|NCT03911882||Celergen Administration|The food supplement Celergen was administered to fibromyalgia patients following a protocol of a daily intake for the period of a total of 3 months (90 days)
62414297|NCT06565533|EXPERIMENTAL|Retrogressive imagery (RETI)|RETI protocol was implemented over eight weeks, gradually simplifying the imagery script to focus on essential aspects of the free-throw (FT) shooting technique.
62414298|NCT06565533|EXPERIMENTAL|Virtual Reality (VR)|Using Virtual Reality (VR) technology, participants are fully immersed in an intense basketball game experience.
62414299|NCT05673915|EXPERIMENTAL|tDCS Treatment A (Low Amplitude)|Subjects with focal epilepsy that is not well-controlled on anti-seizure medications will receive 2 different treatments periods, each lasting 2 months, of transcranial direct current stimulation (tDCS). The initial treatment stimulation will be completed during the first 2-months.
62414300|NCT05673915|EXPERIMENTAL|tDCS Treatment B (High Amplitude)|Subjects with focal epilepsy that is not well-controlled on anti-seizure medications will receive 2 different treatments periods, each lasting 2 months, of transcranial direct current stimulation (tDCS). The last treatment stimulation will be completed during the following 2-months.
62414301|NCT06406894|EXPERIMENTAL|superficial back line relaxation|suboccipital muscle inhibition, cranial cervical flexion exercise
62587079|NCT01270464|EXPERIMENTAL|Reslizumab - 0.3 mg/kg|0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses
62587080|NCT01270464|EXPERIMENTAL|Reslizumab - 3.0 mg/kg|3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses.
62587081|NCT04275921|EXPERIMENTAL|Study participants cohort I|3 stage III NSCLC patients receiving radiotherapy will be imaged, each for a single MRI session using TWIST and HASTE sequences.
62587082|NCT04275921|EXPERIMENTAL|Study participants cohort II|12 patients will be imaged, each for two MRI sessions taking place during the radiotherapy schedule and separated by at least a week.
62587083|NCT06282224|EXPERIMENTAL|surgery with AR-integrated endoscope|Performing endoscopic transnasal skull base surgery with AR-integrated endoscope
62587084|NCT06682312||Pediatrics|Participants aged 3-12 years
62795718|NCT02114606|EXPERIMENTAL|EoE Patients|Patients who have been diagnosed with EoE as per recent guidelines will be enrolled. Samples will be obtained using the Cytosponge™ Cell Collection Device (Cytosponge) prior to participants' routine endoscopy with biopsy.
62795719|NCT00940758|EXPERIMENTAL|PEP02|
62795720|NCT00592488|OTHER|A|Placebo for first 6 hours then Acetyl-L-Carnitine (ALC) for 12 hours
62219788|NCT02907645|EXPERIMENTAL|Local educational|Adult patients in this arm receive educational information regarding influenza vaccination based on local data
62219789|NCT02907645|EXPERIMENTAL|National educational|Adult patients in this arm receive educational information regarding influenza vaccination based on national data
62219790|NCT02907645|NO_INTERVENTION|Usual care|No educational information other than provided as usual care by health care providers
62219791|NCT06137326|EXPERIMENTAL|Pulsed Electromagnetic Field Therapy|
62414302|NCT06406894|ACTIVE_COMPARATOR|Conventional physical therapy|hot packs, muscle stretching exercise of lowerlimb ( Pelvic bridging, knee to chest, Cat and camel stretch)
62795721|NCT00592488|OTHER|B|Acetyl-L-Carnitine (ALC) for first 12 hours then placebo for next 6 hours
62414303|NCT04671329|OTHER|Affirm Contrast Biopsy|Women 40 years of age or older recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities
62414304|NCT01169831|EXPERIMENTAL|Sedentary Older Adults|
62219792|NCT06137326|ACTIVE_COMPARATOR|Laser Acupuncture|
62219793|NCT01660581|EXPERIMENTAL|CD133+|intramyocardial injection (electromechanical mapping based) of autological CD133+ cells, isolated from bone marrow
62219794|NCT01660581|PLACEBO_COMPARATOR|Placebo|intramyocardial injection (electromechanical mapping based) of placebo - 0,9% NaCl plus 0,5% solution of patients' serum
62414305|NCT01169831|EXPERIMENTAL|Older Endurance Athletes|
62414306|NCT01501071|EXPERIMENTAL|esophageal calibration|Esophageal calibration tube was applied to this group of patients during laparoscopic Nissen fundoplication operation
62587085|NCT06682312||Adults|Participants aged 12-85 years
62587086|NCT06685471|EXPERIMENTAL|Simulation-Based Training Program Effect on Pediatric Nurses' Knowledge and Performance|Simulation-Based Training Program
62587087|NCT06685471|NO_INTERVENTION|traditional method|traditional method program
62587088|NCT03494400|EXPERIMENTAL|Presential Aerobic Training with Hormone Therapy|A group of women with breast cancer who use Tamoxifen or Aromatase Inhibitor and will perform presential aerobic training.
62587089|NCT03494400|ACTIVE_COMPARATOR|Presential Aerobic Training without Breast Cancer|A group of women without breast cancer who use Aromatase Inhibitor and will perform presential aerobic training.
62587090|NCT03494400|EXPERIMENTAL|Home-based Aerobic Training with Hormone Therapy|A group of women with breast cancer who use Tamoxifen or Aromatase Inhibitor and will perform home-based aerobic training.
62587091|NCT03494400|ACTIVE_COMPARATOR|Home-based Aerobic Training without Breast Cancer|A group of women without breast cancer who use Aromatase Inhibitor and will perform aerobic training home-based.
62587092|NCT06599502|EXPERIMENTAL|Module 1 Part A. Dose Escalation|AZD0022 monotherapy
62587093|NCT06599502|EXPERIMENTAL|Module 1 Part B. Dose Optimisation|AZD0022 monotherapy
62587094|NCT06599502|EXPERIMENTAL|Module 1 Part C. Potential Efficacy Expansion|AZD0022 monotherapy
62587095|NCT06599502|EXPERIMENTAL|Module 1 Part B. Food Effect Cohort|AZD0022 monotherapy
62795722|NCT04541030||GPS Cohort 1|Samples and images from up to 277 evaluable patients diagnosed with NCCN low or intermediate risk prostate cancer, Gleason \<= 7, managed with RP, and mpMRI within 6 months prior to prostatectomy
62795723|NCT03316638|EXPERIMENTAL|W0101 - Cohort A1|This is a 14 days treatment cycle cohort in a 2 weeks schedule
62219795|NCT02486276|ACTIVE_COMPARATOR|Sumatriptan|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg
62219796|NCT02486276|PLACEBO_COMPARATOR|Placebo|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placebo
62219797|NCT03397732||Aorto-bifemoral bypass|Patients scheduled for elective aorto-bifemoral bypass surgery by vascular surgeons and consented to participate in the study.
62219798|NCT03397732||Aorta stentgraft|Patients scheduled for elective aorta stentgraft implantation by vascular surgeons and consented to participate in the study.
62219799|NCT06054282|EXPERIMENTAL|Intervention|"Patients and caregivers will use the Ready for Tonsillectomy mobile application on their mobile devices as they prepare for and recover from surgery, in addition to standard care. Individual families will receive a phone call for enrollment/verbal informed consent at least 2 weeks before the scheduled surgery, likely around the time of the clinic visit when surgery is scheduled. Participants assigned to the intervention arm will download the mobile application at this time. They will be able to access the application as often as desired in the weeks leading up to surgery and afterward."
62219800|NCT06054282|NO_INTERVENTION|Control|Families will receive standard care (standard educational handouts and preoperative consults).
62414307|NCT01501071|NO_INTERVENTION|Control|Standard Laparoscopic Nissen fundoplication without esophageal calibration
62414308|NCT06470087|OTHER|SOC and Type-I Collagen-based Skin Substitute|Arm 1 -The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
62795724|NCT03316638|EXPERIMENTAL|W0101 - Cohort A2|This is a 21 days treatment cycle cohort in a 3 weeks schedule
62795725|NCT03316638|EXPERIMENTAL|W0101 - Expansion Phase|Will be initiated after completion of cohorts A1 and A2
62219801|NCT04949347||Glycerin-preserved, human-donor, cornescleral patch grafts|Consecutive glaucoma patients who had undergone glaucoma drainage device implantation using glycerin-preserved, human-donor, cornescleral patch grafts
62219802|NCT02721667|NO_INTERVENTION|Enhanced Usual Care|"Participants receive a home BP monitor, are taught how to measure home BP and are encouraged to take BP readings to appointments with their providers. In addition, they will be reminded to perform a home BP series each quarter for study outcome purposes, which will encourage self-monitoring.~Home BP readings will be teletransmitted for data collection purposes but neither participants nor providers will have access to the these readings. High BP levels that trigger safety alerts to research personnel are the only exception - participants and their primary care providers will be made aware of these."
62219803|NCT02721667|ACTIVE_COMPARATOR|Telemonitoring and Case Management|"Home BP series mean, trends and individual readings will be generated for use by the case manager. Participants in this arm will each be assigned a pharmacist case manager who holds full prescribing privileges and who will:~1. Administer health behaviour modification counselling, teach BP self-monitoring, and monitor medication adherence;~2. Review telemonitored health portal BP summaries and make medication regimen adjustments according to guideline-concordant study protocol;~3. Fax a summary of these adjustments to the participant's primary care provider (to make them aware of treatment changes); and~4. Facilitate communication between participants and providers."
62219804|NCT03386825||Regorafenib_DoT<4 months|DoT \< 4 months
62219805|NCT03386825||Regorafenib_4 months ≤ DoT < 12 months|4 months ≤ DoT \< 12 months
62219806|NCT03386825||Regorafenib_DoT ≥ 12 months|DoT ≥ 12 months
62414309|NCT06470087|OTHER|SOC and Human Amnion/Chorion Membrane|Arm 2: The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
62414310|NCT03862807|EXPERIMENTAL|Patisiran|Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.
62414311|NCT03296059|EXPERIMENTAL|RBC transfusion with conventional treatment|Besides conventional treatment,neonates diagnosed with ARDS is treated with RBC transfusion.
62414312|NCT03296059|ACTIVE_COMPARATOR|conventional treatment|neonates diagnosed with ARDS is treated with conventional treatment.
62414313|NCT05907044|ACTIVE_COMPARATOR|RQ3013|C-3013B-202211005, Alpha/Beta, mRNA 30μg dose
62587096|NCT06599502|EXPERIMENTAL|Module 2 Part A. Dose Escalation|AZD0022 in combination with Cetuximab
62587097|NCT06599502|EXPERIMENTAL|Module 2 Part B. Dose Optimisation|AZD0022 in combination with Cetuximab
62219807|NCT02341027|ACTIVE_COMPARATOR|Levonorgestrel (LNG) implants immediately postpartum|LNG contraceptive implants provided within 5 days of delivery
62219808|NCT02341027|ACTIVE_COMPARATOR|Levonorgestrel (LNG) implants 6 weeks postpartum|LNG contraceptive implants provided 6-8 weeks postpartum
62414314|NCT05907044|EXPERIMENTAL|RQ3025|INDA-3025TB-20221002, Alpha/Beta + Omicron BA.2/4/5, mRNA 30μg dose
62219809|NCT04852367|ACTIVE_COMPARATOR|Arm A (Doxorubicin)|a single intravenous dose of Doxorubicin, 50 mg/ m2 in 250 mL of normal saline or 5% dextrose over a 30-min infusion is delivered as per local practice.
62414315|NCT05907044|EXPERIMENTAL|RQ3027|IND-3027TB-202304001, Alpha/Beta + Omicron XBB.1.5, mRNA 30μg dose
62414316|NCT06567730|EXPERIMENTAL|Ni-ti closed Coil spring|For canine retraction, Ni-Ti closed-coil springs will be randomly allocated to the right and left quadrants of both arches
62414317|NCT06567730|ACTIVE_COMPARATOR|Elastomeric power chain|For canine retraction, elastomeric power chains will be randomly allocated to the right and left quadrants of both arches
62414318|NCT04785651|EXPERIMENTAL|Tranexamic arm|Patients in this arm will undergo to a tibial osteotomy in combination with the anti-fibrinolytic agent Tranexamic acid.
62414319|NCT04785651|OTHER|control arm|Patients in this arm will undergo to a tibial osteotomy without the use of Tranexamic acid
62587098|NCT06599502|EXPERIMENTAL|Module 2 Part C. Potential Efficacy Expansion|AZD0022 in combination with Cetuximab
62587099|NCT04613141|SHAM_COMPARATOR|Mobility-plus|"Mobility-plus is a pseudo placebo comparator program using non-slip socks, a low intensity paper-based exercise program and health information specific to Parkinson's Disease."
62587100|NCT04613141|EXPERIMENTAL|WalkingTall-PD|WalkingTall-PD is a novel neuro-rehabilitation program delivered through a tablet/smart phone and smart garments (socks, insoles or ankle bands) for people with Parkinson's disease that aims to improve mobility and reduce falls. WalkingTall-PD combines a variety of PD-specific rhythmic stimuli (auditory, visual and haptic cues) which are synchronised with high intensity stepping, walking and balance training.
62587101|NCT06484452||Test Group 1|"* M1131A (989803205831)~* M1191T (989803128591)~* M1191BL (989803144381) for endpoint analysis~* M1193A (989803205881)"
62587102|NCT06484452||Test Group 2|"* M1194A (989803205891)~* Alar (989803205381)~* M1191BL (989803144381) as an internal reference only"
62587103|NCT06484452||Test Group 3|"* EX-Alar on Nasal Ala (Experimental)~* EX-Alar on Ear (Experimental)~* M1191BL (989803144381) as an internal reference only"
62795726|NCT06312202||Fatal drowning|This group of patients experienced a drowning incident defined as the process of experiencing respiratory impairment from submersion or immersion in liquid and died within 30 days after the incident as a consequence of the submersion injury.
62795727|NCT06312202||Non-fatal drowning|This group of patients experienced a drowning incident defined as the process of experiencing respiratory impairment from submersion or immersion in liquid and survived until 30 days after the incident.
62795728|NCT05566028|EXPERIMENTAL|Expermental group 1|Pateints assigned to this group are treated with D150, D759 and D745 formulation I
62587104|NCT06484452||Test Group 4|"* M1133A (989803205851)~* EX-M1133A (Experimental)~* M1196T (989803205911)~* EX-M1196T (Experimental)~* M1191BL (989803144381) as an internal reference only (optional)"
62219810|NCT04852367|EXPERIMENTAL|Arm B (ThermoDox + Focused Ultrasound)|under general anaesthetic, patients receive FUS, which is moved through the target tumour volume to raise the bulk tumour temperature above the thermal release threshold. At presumed target temperature, a single intravenous dose of ThermoDox®, 50 mg/ m2 in 250 mL of normal saline or 5% dextrose over a 30-min infusion is delivered concurrently to FUS, in line with the pharmacy manual provided by the manufacturer. FUS will continue following infusion, for no longer than two hours from infusion commencing.
62219811|NCT02513719||XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
62219812|NCT00559611|EXPERIMENTAL|Endobronchial Ultrasound vs. Mediastinoscopy|"Endobronchial Ultrasound - A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.~Mediastinoscopy - Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS."
62219813|NCT00802698|EXPERIMENTAL|Group 1|
62795729|NCT05566028|EXPERIMENTAL|Experimental group 2|Pateints assigned to this group are treated with D150, D759 and D745 formulation II
62219814|NCT05757284||patients with unilateral or bilateral, primary or secundary LLL|
62587105|NCT05599139|OTHER|Low iodine diet|Patients recieve a low iodine diet. Consecutive iodine uptake measurements will be made before and after starting this low iodine diet. This study is constructed of only one study arm, and patients will be compared to themselves.
62587106|NCT01604980|EXPERIMENTAL|Protein Intakes|subjects will recieve differnt levels of protein intakes varying from 0.2 to2.0g/kg/day.
62795730|NCT05566028|PLACEBO_COMPARATOR|Placebo group|Pateints assigned to this group are treated with D150, D759 and D745 placebo
62023320|NCT04302792|NO_INTERVENTION|Stage 1: Interviews and focus group sessions|"Group A: Cancer patients (requiring or have required texture-modified foods and/or experiencing or have experienced taste\&smell alterations in the last 12 months) will be required to attend a one-hour online interview.~Group B: Relatives of cancer patients (requiring texture-modified foods and/or experiencing taste\&smell alterations) will be required to attend a 2-hour online focus group session.~Group C: Healthcare professionals with a minimum of a year's experience with oncological patients that require texture-modified foods and/or have taste \& smell alteration will be required to attend a 2-hour online focus group session.~A food diary will be given to Group A and B to complete for 7-days prior to their session. Topics to be discussed during the interview and the focus group sessions will include the food requirements of cancer patients, the barriers of the current food products, possible solutions to these requirements if any and their expectations towards new food solutions."
62023321|NCT04302792|EXPERIMENTAL|Stage 2: Texture-modified foods for cancer patients|The study will involve conducting a tasting trial over a 2-weeks period where participants will be required to consume a maximum of three 3D printed texture-modified food based on the findings from Stage 1 and evaluate the food product by completing a structured questionnaire. Key questions areas covered by the questionnaire include appetite, sensory characteristics of the product (taste, flavour, mouthfeel/texture and smell), liking and acceptability, purchase intent and best place to buy the products; questions will involve rating scales as well as qualitative comments.
62023322|NCT04302792|EXPERIMENTAL|Stage 3: Taste-optimised foods for cancer patients|The study will involve conducting a home test over a one-month period where participants will be required to consume taste-optimised products based on the findings from Stage 1 and evaluate the food product by completing a structured questionnaire. Key questions areas covered by the questionnaire include appetite, sensory characteristics of the product (taste, flavour, mouthfeel/texture and smell), liking and acceptability, purchase intent and best place to buy the products; questions will involve rating scales as well as qualitative comments.
62023323|NCT04015193||Full responders|Full responders: no signs or symptoms of Raynaud's phenomenon (RP) in Raynaud condition score, no RP during cooling-recovery experiment.
62023324|NCT04015193||Partial responders|Partial responders: at least 25% reduction in Raynaud condition score and finger ischemia time during cooling and recovery.
62219815|NCT05757284||healthy controls|
62219816|NCT00811304||US group|All patients admitted to the labor and delivery suite who request an epidural for labor analgesia.
62219817|NCT00756691||1|First 5 consecutive 18F-FAZA avid subjects that undergo up to 5 PET scans, 13 blood and 2 urine samples over 4.5 hours
62219818|NCT00756691||2|Next 5 consecutive 18F-FAZA avid subjects that undergo up to 4 PET scans, 8 blood and 2 urine samples over 5.5 hours
62219819|NCT06074029|EXPERIMENTAL|Immunotherapy cohort|Patients who were administered with immunotherapy
62219820|NCT02859324|EXPERIMENTAL|CC-122 with Nivolumab|CC-122 orally 5/7 days with nivolumab Intravenously (IV) 3mg/kg every 2 weeks. Cohorts of up to 6 subjects per dose level until Recommended Phase 2 dose (RP2D).
62219821|NCT06145191|EXPERIMENTAL|Tranexamic acid|
62219822|NCT06145191|EXPERIMENTAL|Adrenaline|
62219823|NCT06145191|PLACEBO_COMPARATOR|Placebo|
62219824|NCT06576661|ACTIVE_COMPARATOR|URS WITH INTRARENAL PRESSURE MONITORING VISIBLE|In Arm 1, participants will undergo URS with real-time IRP monitoring visible to surgeons using the LithoVue Elite™. Participants will be scheduled to undergo URS per standard of care. All follow-up visits will be scheduled per standard of care.
62795731|NCT03502473|EXPERIMENTAL|One pass/no treatment arm|One random flank will be treated with UltraShape Power device with one pass or remained as a control (no treatment)
62795732|NCT03502473|EXPERIMENTAL|Multiple passes treatment arm|Second flank will be treated with UltraShape Power device with multiple passes.
62795733|NCT04950530|EXPERIMENTAL|Arm 1|"Biktarvy - one tablet once daily, orally administered for the first 28 days of the study.~No treatment for the last 44 days of the study."
62023325|NCT04015193||Non-responders|Non-responders: no or less than 25% reduction in Raynaud condition score and/or finger ischemia time during cooling and recovery.
62023326|NCT03567226|EXPERIMENTAL|Intervention Group|The intervention group will be enrolled into a WeChat Group to receive reminders to exercise and health education materials.
62023327|NCT03567226|ACTIVE_COMPARATOR|Control Group|Controls will receive a handout telling them to increase walking and that walking may be helpful for the eye at the return visit.
62587107|NCT03805984|EXPERIMENTAL|INO-4500 Group A|Participants will receive 1 ID injection of 1 mg/dose INO-4500 followed by EP using the CELLECTRA® 2000 device
62023328|NCT04161911||Advanced Hepatocellular Carcinoma (aHCC) cohort|aHCC cohort selected from the Flatiron Health Oncology electronic health record (EHR) data from January 2011 to the most recent data available. The index date will be defined as the start of second or third line nivolumab therapy for aHCC between January 1, 2011 and the most recent data available.
62023329|NCT02233660|EXPERIMENTAL|Physical Therapy Group.|The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.
62023330|NCT02233660|ACTIVE_COMPARATOR|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
62023331|NCT01213017|EXPERIMENTAL|Certolizumab pegol|
62023332|NCT04629794|ACTIVE_COMPARATOR|Demineralized Bone Matrix|Prospective cohort subjects undergoing deformity correction surgery that receive Demineralized Bone Matrix (DBM).
62023333|NCT04629794|ACTIVE_COMPARATOR|Bone Morphogenic Protein|Retrospective cohort subjects that underwent deformity correction surgery and received Bone Morphogenic Protein (BMP).
62023334|NCT01932164|EXPERIMENTAL|cleft lip and palate|5 Patients with cleft unilateral lip and palate that have already performed the alignment of dental arches through the recommended orthodontic treatment will be selected to be submited to alveolar bone tissue engineering surgery
62587108|NCT03805984|PLACEBO_COMPARATOR|Placebo Comparator Group A|Participants will receive 1 ID injection of 1 mg/dose placebo followed by EP using the CELLECTRA® 2000 device
62023335|NCT02546752|EXPERIMENTAL|THEO Video Arm|"THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). Two programs have been developed. Parents/guardians of children who have not received the first HPV vaccine, will first assess whether the family has already decided in favor of the HPV vaccine or if they would like more information. The parent/guardian will be shown a video specific to where they are in the decision-making process. After completion, the THEO system will then ask the parent/guardian a series of Post Video questions. Parents/guardians of children who have received the first or second vaccine in the series, will emphasize the need to make the first vaccine count. Pre and post video questions have been developed."
62023336|NCT02546752|NO_INTERVENTION|Usual Care Arm|This arm will receive usual care.
62414320|NCT01155258|EXPERIMENTAL|Arm I|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and vinorelbine ditartrate IV over 5-10 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62023337|NCT03599063|EXPERIMENTAL|Cohort 1|Single subcutaneous administration of PF-06946860 at planned dose level 0.1 mg, or placebo
62023338|NCT03599063|EXPERIMENTAL|Cohort 2|Single subcutaneous administration of PF-06946860 at planned dose level 0.3 mg, or placebo
62023339|NCT03599063|EXPERIMENTAL|Cohort 3|Single subcutaneous administration of PF-06946860 at planned dose level 1 mg, or placebo
62023340|NCT03599063|EXPERIMENTAL|Cohort 4|Single subcutaneous administration of PF-06946860 at planned dose level 3 mg, or placebo
62023341|NCT03599063|EXPERIMENTAL|Cohort 5|Single subcutaneous administration of PF-06946860 at planned dose level 10 mg, or placebo
62023342|NCT03599063|EXPERIMENTAL|Cohort 6|Single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo
62023343|NCT03599063|EXPERIMENTAL|Cohort 7|Single subcutaneous administration of PF-06946860 at planned dose level 100 mg, or placebo
62023344|NCT03599063|EXPERIMENTAL|Optional: Cohort 8|Optional: single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo in healthy Japanese subjects
62414321|NCT05682352|EXPERIMENTAL|LEO 158968 Single Ascending Dose (SAD) Cohorts|Participants will receive a single dose of LEO 158968 or matching placebo via an intravenous (IV) infusion or subcutaneous (SC) injection. The dose of LEO 158968 will be increased per cohort.
62414322|NCT05682352|EXPERIMENTAL|LEO 158968 Multiple Ascending Dose (MAD) Cohorts|Participants will receive 5 once weekly (QW) doses of LEO 158968 or matching placebo via a SC injection.
62414323|NCT03538314|EXPERIMENTAL|Experimental Treatment|UV1/GM-CSF
62414324|NCT01637207|EXPERIMENTAL|palpation|
62414325|NCT01637207|EXPERIMENTAL|ultrasound|
62414326|NCT04708626||Extended Cohort: Patients tested for any neuronal antibody in the Swedish population|All patients tested for any neuronal antibody in serum or CSF between 2015 and 2019 in Sweden.
62414327|NCT04708626||Core Cohort: Patients with a positive neuronal antibody test belonging to the Uppsala-Örebro region|All patients belonging to the Uppsala-Örebro health care region (a region in the middle of Sweden with a population of approximately 2.1 million), that tested positive for any neuronal antibody in serum or cerebrospinal fluid between 2015-2019.
62414328|NCT06219135||contamination|Patients with a positive blood culture due to contamination microorganism
62414329|NCT06219135||Bacteraemia|This group includes all adults and children with a positive blood culture due to pathogen microorganism
62414330|NCT02191930|EXPERIMENTAL|B-CAP|Patients with ECOG of 2 or less (3 or less if caused by HL) and CIRS-G score of 6 or less (overall) and 3 or less per organ system receive 6 cycles of B-CAP (Brentuximab vedotin, cyclophosphamide, doxorubicine, predniso(lo)ne). Cycle length is 21 days
62795734|NCT04950530|EXPERIMENTAL|Arm 2|No treatment for the first 28 days of the study. Biktarvy - one tablet once daily, orally administered for the last 28 days of the study (day 44-72).
62795735|NCT06726369|EXPERIMENTAL|MK-6204 (SKB535) for Injection|Several dose levels of MK-6204 (SKB535) for Injection are planned and administered every 3 weeks.
62023345|NCT02775383||Longitudinal|Participants with MDS, MDS/MPN overlap disorder, AML \<30% blasts without core binding factor or acute promyelocytic leukemia, ICUS, or at risk based on select karyotypic or genetic abnormalities
62023346|NCT02775383||Cross-sectional|Participants who do not have MDS, MDS/MPN overlap disorder, or ICUS and have the baseline visit only
62023347|NCT03495024|OTHER|Smoking cessation with varenicline|FDA-approved indication of varenicline for smoking cessation
62795736|NCT00801216|EXPERIMENTAL|High-dose sequential chemoimmunotherapy|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 \& 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
62795737|NCT06726759||50 males|50 males with FHP and their BMI was between 20 and 25 kg/m2 ang ranged between 18 and 25 years
62795738|NCT06726759||50 females|females with forward head posture and their BMI was between 20 and 25 kg/m2 and their age ranged between 18 and 25 years
62795739|NCT06628219|EXPERIMENTAL|Free Tissue Transfer, Therapeutic Lymphatic Surgery, Prophylactic Lymphatic Surgery Participants|
62795740|NCT06529913|EXPERIMENTAL|Allergic contact dermatitis to metals|Patients with allergic contact dermatitis due to metal exposure (nickel, cobalt, chromium, palladium, molybdenum, aluminium, and copper).
62795741|NCT06529913|EXPERIMENTAL|Systemic allergic syndromes to metals|Patients with systemic allergic syndrome due to metal exposure (nickel, cobalt, chromium, palladium, molybdenum, aluminium, and copper).
62795742|NCT06529913|EXPERIMENTAL|Healthy volunteers|Healthy volunteers without metal exposure (nickel, cobalt, chromium, palladium, molybdenum, aluminium, and copper).
62795743|NCT06141707||OSA group|This group will include 66 parents in charge of participants with SRBDs.
62795744|NCT06141707||reliability group|To test the reliability of the Arabic Pediatric Sleep Questionnaire (APSQ); 33 parents in charge will be randomly selected among the 66 parents in charge of subjects with SRBDs in OSA group.
62795745|NCT06141707||control group|control group will include 66 children with no OSA
62795746|NCT01078610||Psoriatic arthritis patients|
62795747|NCT05896527|EXPERIMENTAL|Treatment Group 1: DC-806 Dose A|
62795748|NCT05896527|EXPERIMENTAL|Treatment Group 2: DC-806 Dose B|
62795749|NCT05896527|EXPERIMENTAL|Treatment Group 3: DC-806 Dose C|
62795750|NCT05896527|EXPERIMENTAL|Treatment Group 4: DC-806 Dose D|
62795751|NCT05896527|PLACEBO_COMPARATOR|Treatment Group 5: Placebo|
62795752|NCT05583916|OTHER|Lung Cancer Patients|Patients with stage I or II primary lung cancer or pulmonary metastasis scheduled to undergo surgery.
62795753|NCT04302220||high myopia|Population who have high myopia.
62795754|NCT05818683|EXPERIMENTAL|JNJ-78278343 + Combination agent: Part 1 (Dose Escalation) and Part 2 (Dose Expansion)|Participants will receive JNJ-78278343 and combination agent (cetrelimab, cabazitaxel, docetaxel, apalutamide, enzalutamide, Darolutamide, abiraterone acetate plus prednisone) during Part 1 (dose escalation). The dose of JNJ-78278343 will be escalated sequentially until a recommended phase 2 regimen (RP2R). Participants will receive JNJ-78278343 and combination agent treatment at the putative RP2R in Part 2 (dose expansion).
62795755|NCT06680817||Cohort 1: Faricimab for nAMD|
62795756|NCT06680817||Cohort 2: Faricimab for DME|
62795757|NCT03045523|EXPERIMENTAL|GLPG2222 Dose 1|
62795758|NCT03045523|EXPERIMENTAL|GLPG2222 Dose 2|
62795759|NCT03045523|PLACEBO_COMPARATOR|Placebo|
62795760|NCT05340738|ACTIVE_COMPARATOR|LyssnCBT|Therapists will use the LyssnCBT tool with clients for recording and session-sharing functionalities. Therapists and supervisors will also have access to LyssnCBT features like speech-to-text transcription, annotation tools, and AI-generated metrics.
62795761|NCT05340738|NO_INTERVENTION|SAU (services-as-usual)|Therapists will use the LyssnCBT tool with clients for recording and session-sharing functionalities. No other LyssnCBT features will be available for therapist or supervisor review.
62795762|NCT06727448||Patients|French patients indicated for 14-day actimetry for chronic insomnia or circadian rhythm disorders
62795763|NCT02858310|EXPERIMENTAL|Arm 1: Phase I|Non-myeloablative, lymphocyte depleting preparative regimen, followed by E7 TCR Cells at escalating doses, followed by aldesleukin
62023348|NCT00809757|EXPERIMENTAL|1|90 ug Levalbuterol (2 actuations)
62023349|NCT00809757|ACTIVE_COMPARATOR|2|0.31 ug Levalbuterol UDV TID
62023350|NCT00809757|PLACEBO_COMPARATOR|3|Placebo
62023351|NCT05436574|OTHER|Before/after study|Before/after study to measure the effects of the implementation of a dance therapy activity on the quality of life of the elderly population
62795764|NCT02858310|EXPERIMENTAL|Arm 2: Phase II|1 x 10 e11 E7 Cells that was determined in Phase I + aldesleukin
62795765|NCT04914533|EXPERIMENTAL|Intervention Arm|Luminance Red Treatment Arm
62795766|NCT06127589|EXPERIMENTAL|Brief cessation advice + Nicotine replacement Therapy + Instant Messaging + Financial Incentives|Participants will receive a special designed evidence-based intervention using health advice, behavioral and pharmacological support, mobile health technologies, and awareness building (highlight harms) based on the biofeedback results of SHS exposure in the child. A selected sample of 50 families will receive environmental assessment-derived intervention, including results interpretation and health advice, which will be provided via phone calls for the 50 families within 1 week after the data collection.
62023352|NCT05343871|EXPERIMENTAL|Priming Group 1: Sinovac Prime, AZD1222 ½ dose (Brazil only)|
62023353|NCT05343871|ACTIVE_COMPARATOR|Priming Group 1: Sinovac Prime, AZD1222 full dose (Brazil only)|
62023354|NCT05343871|EXPERIMENTAL|Priming Group 1: Sinovac Prime, BNT162b2 1/3 dose|
62587109|NCT03805984|EXPERIMENTAL|INO-4500 Group B|Participants will receive 2 ID injections of 1 mg/dose INO-4500 followed by EP using the CELLECTRA® 2000 device
62023355|NCT05343871|EXPERIMENTAL|Priming Group 1: Sinovac Prime, BNT162b2 1/2 dose|
62023356|NCT05343871|ACTIVE_COMPARATOR|Priming Group 1: Sinovac Prime, BNT162b2 full dose|
62023357|NCT05343871|ACTIVE_COMPARATOR|Priming Group 1: Sinovac Prime, Sinovac full dose|
62023358|NCT05343871|EXPERIMENTAL|Priming Group 2: AZD1222 Prime, AZD1222 ½ dose (Brazil only)|
62587110|NCT03805984|PLACEBO_COMPARATOR|Placebo Comparator Group B|Participants will receive 2 ID injections of 1 mg/dose placebo followed by EP using the CELLECTRA® 2000 device
62587111|NCT01108341|EXPERIMENTAL|Bendamustine and Ofatumumab|There are 6 planned and 2 optional 28-day cycles in which participants are administered both bendamustine and ofatumumab in the following doses: Bendamustine administered at 90 mg/m\^2 intravenously (iv) on study days 1 and 2. Ofatumumab administered at 300 mg iv on day 1 and 1000 mg iv on day 8 of cycle 1. Ofatumumab administered at 1000 mg iv on day 1 of all additional cycles.
62219825|NCT06576661|NO_INTERVENTION|URS WITHOUT INTRARENAL PRESSURE MONITORING VISIBLE|In Arm 2, participants will undergo URS LithoVue Elite™ without the real-time IRP monitoring information visible to the surgeon. Participants will be scheduled to undergo URS per standard of care. All follow-up visits will be scheduled per standard of care.
62219826|NCT02215382|ACTIVE_COMPARATOR|sugammadex|
62219827|NCT02215382|ACTIVE_COMPARATOR|neostigmine + atropine|
62023359|NCT05343871|ACTIVE_COMPARATOR|Priming Group 2: AZD1222 Prime, AZD1222 full dose (Brazil only)|
62023360|NCT05343871|EXPERIMENTAL|Priming Group 2: AZD1222 Prime, BNT162b2 1/3 dose|
62023361|NCT05343871|EXPERIMENTAL|Priming Group 2: AZD1222 Prime, BNT162b2 1/2 dose|
62023362|NCT05343871|ACTIVE_COMPARATOR|Priming Group 2: AZD1222 Prime, BNT162b2 full dose|
62219828|NCT01313247|PLACEBO_COMPARATOR|Placebo pills|Placebo tablets resembling paracetamol 500 mg are given as alternative 2 tablets 4 times daily
62219829|NCT01313247|ACTIVE_COMPARATOR|oral paracetamol 4 g daily|Patients are given 2 tablets of 500 mg paracetamol on a regular basis 4 times daily
62587112|NCT05282225|EXPERIMENTAL|MI-SP +supportive Texts + monitoring (Sequence A)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group A: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of supportive Texts and monitoring post discharge.
62587113|NCT05282225|EXPERIMENTAL|MI-SP + monitoring (Sequence D)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group D: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of monitoring post discharge.
62023363|NCT05343871|EXPERIMENTAL|Priming Group 3-B: BNT162b2 Prime, AZD1222 ½ dose (Brazil only)|
62023364|NCT05343871|ACTIVE_COMPARATOR|Priming Group 3-B: BNT162b2 Prime, AZD1222 full dose (Brazil only)|
62023365|NCT05343871|EXPERIMENTAL|Priming Group 3-B: BNT162b2 Prime, BNT162b2 1/3 dose (Brazil only)|
62023366|NCT05343871|EXPERIMENTAL|Priming Group 3-B: BNT162b2 Prime, BNT162b2 1/2 dose (Brazil only)|
62023367|NCT05343871|ACTIVE_COMPARATOR|Priming Group 3-B: BNT162b2 Prime, BNT162b2 full dose (Brazil only)|
62023368|NCT05343871|EXPERIMENTAL|Priming Group 3-P: Natural Infection Prime, BNT162b2 1/3 dose (Pakistan only)|
62023369|NCT05343871|EXPERIMENTAL|Priming Group 3-P: Natural Infection Prime, BNT162b2 1/2 dose (Pakistan only)|
62023370|NCT05343871|ACTIVE_COMPARATOR|Priming Group 3-P: Natural Infection Prime, BNT162b2 full dose (Pakistan only)|
62023371|NCT01764100|EXPERIMENTAL|Mesenchymal Stromal Cells (MSC)|Intravenous injections for a dose of 1 ± 0.5 x 106 MSC/kg recipient body weight
62023372|NCT03094689|NO_INTERVENTION|Control group|
62023373|NCT03094689|EXPERIMENTAL|Immersion group|They will be immersed in a barrel of 200 liters of water (without ice) at room temperature, according to local conditions of temperature and humidity (Natal county - RN). They will be immersed to the height of the iliac crests for 10 minutes.
62023374|NCT03094689|EXPERIMENTAL|Cold water immersion group|They will be immersed in a barrel of 200 liters of ice water at an average temperature of 10 ° C for 10 minutes. They will be immersed to the height of the iliac crests.
62023375|NCT06425393|NO_INTERVENTION|H. pylori positive subjects|The H. pylori infected subject is responsible for providing details of the number of household members, family structure, family history of gastric diseases, family economy, living conditions, family hygiene and living habits. Patients also need to provide personal information including HKID, ethnicity.
62023376|NCT06425393|EXPERIMENTAL|H. pylori positive subjects' household members|The household members of the index subjects will be invited to complete a questionnaire which includes the baseline demographics, past medical history, personal hygiene and living habits. Also, they will be received urea beath test (UBT). Referral will be given to those positive result household members.
62219830|NCT01501682||primary suture|operated with primary suture
62219831|NCT01501682||other mesh|operated with insertion of another mesh
62219832|NCT01501682||ventralex|operated with insertion of ventralex mesh
62219833|NCT04924842||Children|Hospitalized children, 0 to 17 years of age, 30 subjects, consecutive sample survey, recruitment in quotas of five age ranges.
62219834|NCT04924842||Adults|Hospitalized adults, 18 years and above, 60 matched subjects
62219835|NCT04889105|OTHER|Performance evaluation|Preliminary performance evaluation to refine the Smart MOVE! intervention.
62587114|NCT05282225|EXPERIMENTAL|MI-SP + supportive Texts + monitoring + portal follow-up for non-responders (Sequence B).|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group B: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of supportive Texts and monitoring post discharge in addition to the portal follow-up for non-responders.
62023377|NCT01903655|OTHER|patients with a first episode of major depressive disorder|a group of patients with a first episode of major depressive disorder according to DSM-IV-TR including depressive episodes with melancholic features
62414331|NCT02191930|EXPERIMENTAL|Brentoximab Vedotin only|Patients with CIRS-G score of 7 ore more receive Brentuximab Vedotin as single agent therapy for up to 16 cycles. Cycle length is 21 days
62414332|NCT04924738||MOZART_SG|Women treated for hyperglycemia in pregnancy. Observational data are to be collected at follow-up visits during pregnancy, at delivery and postpartum.
62587115|NCT05282225|EXPERIMENTAL|MI-SP + supportive Texts + monitoring + booster call for non-responders (Sequence C)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group C: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of supportive Texts and monitoring post discharge in addition to the booster call for non-responders.
62023378|NCT01903655|OTHER|patients with recurrent depressive disorder|a group of patients with recurrent depressive disorder according to DSM-IV-TR including depressive episodes with melancholic features (at least three episodes of depression)
62023379|NCT01903655|OTHER|control group|patient with no depressive disorder during the study period and no psychiatric history
62414333|NCT06058598|EXPERIMENTAL|Intervention Group|Group performing exercise training and receiving standard care
62587116|NCT05282225|EXPERIMENTAL|MI-SP + monitoring + portal follow-up for non-responders (Sequence E)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group E: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of monitoring post discharge in addition to the portal follow-up for non-responders.
62023380|NCT06535672|EXPERIMENTAL|Kamishibai Diabetes Education|"Patients in the intervention group will receive diabetes education using the Kamishibai method. This method involves interactive storytelling tailored to the cognitive and sensory development of children aged 8-12. Training will be conducted over 3 days, with 3 sessions each day.~Patients will attend training daily without hospitalization. Training includes interactive storytelling using the Kamishibai method, designed to be engaging and suitable for children aged 8-12.~After the training, participants will complete the Diabetes Knowledge Level Evaluation Form, the PedsQL 3.0 Quality of Life Scale, and the Kamishibai Training Feedback Form. Filling out the forms will take approximately 30 minutes.~Follow-up information and checks will be provided every 3 months."
62414334|NCT06058598|EXPERIMENTAL|Control Group|Group receiving lifestyle counseling and receiving standard care
62587117|NCT05282225|EXPERIMENTAL|MI-SP + monitoring + booster call for non-responders (Sequence F)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group F: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of monitoring post discharge in addition to the booster call for non-responders.
62587118|NCT01399047|ACTIVE_COMPARATOR|Mycophenolate Mofetil|
62587119|NCT01399047|PLACEBO_COMPARATOR|Placebo liquid|
62023381|NCT06535672|EXPERIMENTAL|Routine diabetes education|"Patients in the control group will receive routine diabetes education as per standard hospital procedures. This training will also occur over 3 days, with 3 sessions per day.~Training involves a PowerPoint presentation and a whiteboard, based on the Ministry of Health Childhood Diabetes Education guide.~The language used will be simple and understandable for children. The training will be interactive, encouraging feedback and questions. Participants will fill out the Diabetes Knowledge Level Evaluation Form, PedsQL 3.0 Quality of Life Scale, and Routine Education Feedback Form after the training.~Filling out the forms will take approximately 30 minutes. Follow-up information and checks will be provided every 3 months."
62023382|NCT04877301|EXPERIMENTAL|Ultrasound guidance|Ultrasound guidance used to facilitate insertion of PIV catheter.
62587120|NCT05184569|EXPERIMENTAL|Verdiperstat|Verdiperstat 2 tablets twice daily (600mg total daily) by mouth for 24 weeks.
62587121|NCT05184569|PLACEBO_COMPARATOR|Placebo|Placebo 2 tablets twice daily by mouth for 24 weeks.
62023383|NCT04877301|ACTIVE_COMPARATOR|Non-ultrasound guidance|Ultrasound guidance will not be used for insertion of PIV catheter.
62023384|NCT00216151|ACTIVE_COMPARATOR|A|Patients will be randomly assigned by study number to receive 4mg of zoledronic acid every three months.
62414335|NCT01692470||rilpivirine hydrochloride|Patients will be taking 1 tablet of 25 mg rilpivirine hydrochloride is administered once daily orally in combination with other anti-retroviral (ARV) medications.
62414336|NCT03037918|EXPERIMENTAL|Treatment Group|"Participants will receive 2 x 65mL doses of Yakult light per day, for 28 days.~Participants will consume a high-fat (65% of kilocalories) high-calorie (150% of requirements) diet from day 21 to day 28."
62414337|NCT03037918|NO_INTERVENTION|Control Group|Participants will consume a high-fat (65% of kilocalories) high-calorie (150% of requirements) diet from day 21 to day 28.
62587122|NCT05516524|EXPERIMENTAL|HSAT prior to clinical sleep study|Participants will be randomized to undergo HSAT before receiving their clinical, in-lab polysomnography
62587123|NCT05516524|ACTIVE_COMPARATOR|PSG first Participants will be random|Participants will be randomized to undergo HSAT after receiving their clinical, in-lab polysomnography.
62587124|NCT02944552|EXPERIMENTAL|low dose group|Patients in the low dose group administrated bicyclol tablet 25mg orally, three times daily for 4-8 weeks.
62587125|NCT02944552|EXPERIMENTAL|high dose group|Patients in the high dose group administrated bicyclol tablet 50mg orally, three times daily for 4-8 weeks.
62587126|NCT02944552|ACTIVE_COMPARATOR|positive drug control group|Patients in the positive drug control group administrated polyene phosphatidylcholine capsule 456mg orally, three times daily for 4-8 weeks.
62587127|NCT05103280|EXPERIMENTAL|Progressive improvement in walking performance|A total of ten patients with peripheral artery disease will be enrolled for this arm and wear the assistive tennis shoes for three-months as an intervention.
62587128|NCT04880707|ACTIVE_COMPARATOR|Twin Block with Local Anesthetic|Following lower third molar extraction under intravenous sedation, the patient randomized to this arm with receive the Twin block local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine, on the day after extraction, if the patient has pain greater than or equal to 5 on 10 in their jaw-closer muscles (Numerical Pain rating scale).
62023385|NCT00216151|NO_INTERVENTION|B|Patients will be randomly assigned by study number to observation only.
62795767|NCT06127589|ACTIVE_COMPARATOR|Brief cessation advice (AWARD) + Waitlist for same intervention|"Participants in the control group will receive the same AWARD brief advice model, self-help booklet at baseline, and financial incentives for validated abstinence at 3- and 6-month follow-up. After the 6-month follow-up, participants who continued to smoke will receive the remaining intervention components: 1-week sampling of NRT and 3 months instant messaging chat-based personalized psychosocial and behavioural counselling for quitting. Participants who validated abstinence at the 12 months or actively engaged in mobile Health counselling will also receive the financial incentives of HK$ 500 and HK$ 200, respectively (waitlist control).~Similar to the Intervention group, environmental assessment derived intervention, including results interpretation and health advice, will be provided via phone calls for the 50 families within 1 week after the data collection."
62795768|NCT02098798||HD|High Definition Colonoscopy alone
62795769|NCT02098798||HD + iSCAN|HD colonoscopy + iSCAN
62795770|NCT02098798||HD + Dye|High definition colonoscopy + dye spraying chromoendoscopy
62023386|NCT02139501|EXPERIMENTAL|rhTPO, 300Units/kg ,daily for 14 consecutive days|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,daily for 14 consecutive days
62023387|NCT02139501|EXPERIMENTAL|rhTPO, 300Units/kg ,one times every other day for 7 times|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,one times every other day for 7 times.
62023388|NCT02139501|EXPERIMENTAL|rhTPO, 300Units/kg ,daily for 7 consecutive days|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,daily for 7consecutive days.
62795771|NCT05287646|ACTIVE_COMPARATOR|Suction Suspension First|The residual limb will be imaged during dynamic activities while participants use suction suspension first, then while participants use elevated vacuum suspension. Dynamic stereo x-ray will take place 4-weeks after socket fitting.
62795772|NCT05287646|ACTIVE_COMPARATOR|Elevated Vacuum Suspension First|The residual limb will be imaged during dynamic activities while participants use elevated vacuum suspension first, then while participants use suction suspension. Dynamic stereo x-ray will take place 4-weeks after socket fitting.
62795773|NCT01484535|OTHER|Ankle aspiration|ankle aspiration
62795774|NCT01484535|PLACEBO_COMPARATOR|placebo procedure|placebo procedure
62795775|NCT00137241||Group 1|
62795776|NCT06518161|OTHER|Voluntary|Subjects undergoing scheduled surgery in the operating room at Nantes University Hospital, requiring general anesthesia with placement of an endotracheal intubation tube for invasive mechanical ventilation.
62795777|NCT00799435|NO_INTERVENTION|1|Participants will receive usual care for 12 weeks. The care will be dictated by the primary physician and/or diabetologist caring for the participant. Efforts will be made to ensure that all participants receive standard measures as indicated by guidelines, with a particular emphasis on blood pressure control and glucose control.
62795778|NCT00799435|EXPERIMENTAL|2|Participants will receive exenatide for 12 weeks.
62795779|NCT02305212|EXPERIMENTAL|Cogmed|Cogmed is a cognitive rehabilitation protocol designed to improve working memory. The Cogmed sessions are on a computer at home for 30-40 min per day, 5 days per week for 5 weeks.
62023389|NCT06283004|ACTIVE_COMPARATOR|Level walking|It will walk at a 0-degree slope (0) throughout the research.
62219836|NCT04889105|ACTIVE_COMPARATOR|Smart MOVE!|Participants will be enrolled in the multi-component Smart MOVE! intervention for 12 weeks.
62219837|NCT04889105|PLACEBO_COMPARATOR|Usual care|Participants will receive general walking advice for 12 weeks.
62219838|NCT02250092|ACTIVE_COMPARATOR|tDCS/CIMT|Intervention Group will receive 20 minutes of 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT.
62795780|NCT02305212|NO_INTERVENTION|Wait list|
62795781|NCT05100914|EXPERIMENTAL|Couple-based family nursing|Women and their spouses were provided couple-based family nursing based on dignity and respect, information sharing, participation and collaboration for 30-60 minutes with couple-based interviews for arm rehabilitation. Arm rehabilitation begins within 48 hours postoperatively, and each movement should be incrementally increased in terms of exertion and repetition until the patient reaches 10 repetitions, 2-3 times daily, for one month.
62795782|NCT05100914|ACTIVE_COMPARATOR|Treatment as usual|All women in the control group received hospital standard operative care, and couples attended a routine, 30-60-minute presentation about rehabilitation after breast surgery without any specific couple-based dyad interview.
62795783|NCT06726980|PLACEBO_COMPARATOR|group I|patients will receive infused IV 0.9 % saline
62795784|NCT06726980|EXPERIMENTAL|Study group II|patients will receive 5 % dextrose infusion
62219839|NCT02250092|PLACEBO_COMPARATOR|tDCS sham/CIMT|Placebo Group will receive 20 minutes of sham 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT.
62414338|NCT01419028||Patients with perinatal and/or infantile onset HPP|Patients with a confirmed diagnosis of perinatal or infantile onset hypophosphatasia (HPP)
62414339|NCT04496765||< 40 years|Patients with rectal cancer ageing 40 years or less
62414340|NCT04496765||> 40 years|Patients with rectal cancer ageing more than 40 years
62023390|NCT06283004|EXPERIMENTAL|Downhill walking|It will walk at a 10-degree downhill slope (-10) throughout the research.
62414341|NCT05918952||Testing Group|1-health COVID-19 test and Video
62414342|NCT05918952||Non-Testing Group|
62414343|NCT05655494|EXPERIMENTAL|Stand-alone Portal|The standard of care condition will include a portal that provides patients with access to existing online cancer clinical trial resources in one location. This includes links to pages with basic information about cancer clinical trials, ongoing studies, enrollment opportunities for existing institutional research registries, and contact information for study coordinators.
62795785|NCT06726980|EXPERIMENTAL|Study group III|patients will receive 10 % dextrose infusion (25gm/ 250 mL)
62795786|NCT04071769|EXPERIMENTAL|Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF)|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments
62587129|NCT04880707|PLACEBO_COMPARATOR|Twin Block with sterile normal saline|Following lower third molar extraction under intravenous sedation, the patient randomized to this arm with receive the Twin block using sterile normal saline, on the day after extraction, if the patient has pain greater than or equal to 5 on 10 in their jaw-closer muscles (Numerical Pain rating scale).
62587130|NCT02787421|EXPERIMENTAL|Functional Rhinoplasty|Participants undergoing functional rhinoplasty for nasal valve compromise and obstruction at the Emory Aesthetics Center.
62795787|NCT05999266||Rheumatoid Arthritis Patients with Knee Pain|In patients with knee pain, the cartilage thickness measurement of the knee joint will be measured from 3 points by ultrasound. At the same time, Quadriceps and Hamstring muscle thickness measurements of the patients will be made from the midpoints where the muscle thickness is the highest.
62795788|NCT05999266||Rheumatoid Arthritis Patients without Knee Pain|In patients without knee pain, the cartilage thickness measurement of the knee joint will be measured from 3 points by ultrasound. At the same time, Quadriceps and Hamstring muscle thickness measurements of the patients will be made from the midpoints where the muscle thickness is the highest.
62795789|NCT02468726|EXPERIMENTAL|NER1008|Use of NER1008 enema for bowel cleansing
62795790|NCT02468726|ACTIVE_COMPARATOR|Fleet|Use of Fleet enema for bowel cleansing
62795791|NCT05246800|EXPERIMENTAL|Experimental group|a structured 8-week mHealth mindfulness program.
62795792|NCT05246800|NO_INTERVENTION|Control group|The control group was suggested to read the information about stress and burnout on the website of the TV-programme.
62795793|NCT06140173|EXPERIMENTAL|Contrast group (CG)|
62587131|NCT03489707|EXPERIMENTAL|Home-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.
62795794|NCT06140173|ACTIVE_COMPARATOR|Traditional group (TG)|
62795795|NCT06472115|EXPERIMENTAL|Active treatment|Eligible participants that enroll will received 16 week parent based intervention for insistence on sameness
62795796|NCT05677282|EXPERIMENTAL|Rifaximin with loperamide|
62795797|NCT05677282|ACTIVE_COMPARATOR|Azithromycin mg with loperamide|
62795798|NCT04366661|EXPERIMENTAL|screening|Participants undergo low dose CT of the chest
62795799|NCT02995317||Fall accidents|
62795800|NCT02598297|ACTIVE_COMPARATOR|Ruxolitinib|Two tablets of ruxolitinib 5 mg were administered orally twice per day.
62795801|NCT02598297|PLACEBO_COMPARATOR|Ruxolitinib Placebo|Two tablets of 5mg placebo were administered orally twice per day.
62795802|NCT05455476|EXPERIMENTAL|CBT for Loneliness|CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth more centrally focused addressing factors contributing to loneliness and social isolation.
62023391|NCT06283004|EXPERIMENTAL|Uphill walking|It will walk at a 10-degree uphill slope (+10) throughout the research.
62023392|NCT05045521|EXPERIMENTAL|plyometric warm up group|set of active exercises used as warm up protocol.
62023393|NCT05045521|EXPERIMENTAL|resistance warm up group|warm up protocol on treadmill wearing weighted jacket
62023394|NCT05045521|ACTIVE_COMPARATOR|control|warm up protocol on treadmill without weights
62023395|NCT06268912|EXPERIMENTAL|Cold Mepivacaine|Mepivacaine 3% at 5ºC
62023396|NCT06268912|ACTIVE_COMPARATOR|Mepivacaine at room temperature|Mepivacaine 3% at room temperature
62795803|NCT05455476|ACTIVE_COMPARATOR|CBT for Chronic Pain|CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth broadly focused on increasing quality of life despite being in pain.
62414344|NCT05655494|EXPERIMENTAL|Portal with Virtual Community Health Educator (vCHE)|The virtual community health educator condition will provide all information in standard of care with the addition of a virtual community health educator. Patients will have the opportunity to choose which virtual community health educator will provide digital navigation. The choices will include at least four English-speaking and four Spanish-speaking virtual community health educators representing different genders and racial/ethnic backgrounds.
62414345|NCT02783508|ACTIVE_COMPARATOR|IV Meperidine|Intravenous injection of meperidine 50mg given in 100cc NaCl 0.9% over 10 minutes. Repeated doses (if needed) will be given in intervals of 2 hours minimum until a maximum of 4 doses.
62414346|NCT02783508|ACTIVE_COMPARATOR|Inhaled Nitrous Oxide|Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, the parturient will be advised not to breath through the mask.
62414347|NCT05460377|ACTIVE_COMPARATOR|IMBCAMS Sabin IPV full dose at 14 weeks and 9 months|Participants will receive two full doses of Sabin IPV intramuscularly at 14 weeks and 9 months produced by Institute of Medical Biology Chinese Academy of Medical Sciences, Kunming (IMBCAMS).
62414348|NCT05460377|ACTIVE_COMPARATOR|IMBCAMS Sabin IPV fractional dose at 14 weeks and 9 months|Participants will receive two fractional (1/5) doses of Sabin IPV intradermally at 14 weeks and 9 months produced by Institute of Medical Biology Chinese Academy of Medical Sciences, Kunming (IMBCAMS).
62414349|NCT05460377|ACTIVE_COMPARATOR|BIBP Sabin IPV full dose at 14 weeks and 9 months|Participants will receive two full doses of Sabin IPV intramuscularly at 14 weeks and 9 months produced by Beijing Bio Institute Biological Products (BIBP).
62414350|NCT05460377|ACTIVE_COMPARATOR|BIBP Sabin IPV fractional dose at 14 weeks and 9 months|Participants will receive two fractional (1/5) doses of Sabin IPV intradermally at 14 weeks and 9 months produced by Beijing Bio Institute Biological Products (BIBP).
62414351|NCT05043779|OTHER|Preoperative Awake Airway Nasoendoscopy|only one arm
62414352|NCT03273010|EXPERIMENTAL|Periacryl group|Periacryl, a tissue adhesive, was applied on wound surfaces to achieve haemostasis
62414353|NCT03273010|ACTIVE_COMPARATOR|Control group|Free gingival graft was harvested from palatal region and left to heal without applying periacryl.
62414354|NCT05131282||PE group|Women with a confirmative diagnosis of PE
62414355|NCT05131282||Normal pregnancy group|Normal pregnant women
62414356|NCT05131282||Preterm PE group|Women with a confirmative diagnosis of Preterm PE
62414357|NCT03761121|EXPERIMENTAL|Primary Testing Group|"* This scan is in the same imaging session as the participant's scheduled clinical MRI and is no longer 15 minutes~* Wave-CAIPI will be use to enable a 40-60 s acquisition per contrast at 0.9-mm isotropic resolution~* Wave-CAIPI will be used to acquire a 4-echo GE-SE time-series at 1.5-mm isotropic resolution"
62414358|NCT03761121|EXPERIMENTAL|Software Testing Group|"* Participants will receive hour research-only scan~* Wave-CAIPI will be use to enable a 40-60 s acquisition per contrast at 0.9-mm isotropic resolution~* Wave-CAIPI will be used to acquire a 4-echo GE-SE time-series at 1.5-mm isotropic resolution"
62414359|NCT03286595|EXPERIMENTAL|Early Psychosis (EP)|EP participants will be individuals who are either a) at clinical high risk (CHR) for developing psychosis and/or bipolar disorder, or b) First Episode Psychosis (FEP) participants meeting criteria for schizophreniform disorder, schizophrenia, schizoaffective disorder or another psychotic, non-schizophrenia diagnosis including those with bipolar disorder.
62414360|NCT03286595|EXPERIMENTAL|Clinicians|Clinicians/treatment team members who are providing treatment services to the EP participants at one of the three early psychosis clinics.
62414361|NCT00537056|EXPERIMENTAL|F-18 FDG PET/CT and DCE MRI|FDG PET CT F-18 Fluoro-deoxi-glucose: 15 mCi iv Gadolinium-DTPA: 0.1 mmol/kg Sunitinib: 50 mg/day po
62414362|NCT06567405|EXPERIMENTAL|group I: dermapen and topical ascorbic Acid|12 individuals who have orthodontically induced gingivitis will be treated with dermapen and topical ascorbic Acid
62414363|NCT06567405|ACTIVE_COMPARATOR|group II: mechanical periodontal treatment|12 individuals who have orthodontically induced gingivitis will receive mechanical periodontal treatment only
62414364|NCT00880867|EXPERIMENTAL|Poly-ICLC|Poly-ICLC plus low dose local radiation.
62414365|NCT01870921|EXPERIMENTAL|Ticargrelor|90 mg/tablet, 1 tablet bid
62414366|NCT04479943|NO_INTERVENTION|Pre-intervention/control|160-200 older adult patients (age 65 or older) will be recruited on four units across two hospitals (two units per hospital) over 6-8 months prior to implementation of the unit-based MOVIN intervention.
62587132|NCT03489707|ACTIVE_COMPARATOR|Clinic-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.
62587133|NCT06215989|EXPERIMENTAL|Colchicine group|Patients are randomized within 48 hours after diagnosis of ACS, and on the day of randomization, eligible patients undergo standard treatment plus colchicine (0.5mg qd from 1st month to 12th month).
62414367|NCT04479943|EXPERIMENTAL|Post-intervention|160-200 older adult patients (age 65 or older) will be recruited on four units across two hospitals (two units per hospital) over 6-8 months after MOVIN has been implemented on the unit.
62414368|NCT04479943|EXPERIMENTAL|Nurses|Nurses will complete surveys and provide qualitative data to assess barriers to implementation
62587134|NCT06215989|PLACEBO_COMPARATOR|Placebo group|Patients are randomized within 48 hours after diagnosis of ACS, and on the day of randomization, eligible patients undergo standard treatment plus placebo (1 tablet qd from 1st month to 12th month).
62219840|NCT04002401|EXPERIMENTAL|Axicabtagene Ciloleucel and Rituximab Combination|Participants will receive rituximab 375 mg/m\^2, once on Day -5 along with conditioning chemotherapy (fludarabine 30 mg/m\^2 over 30 minutes and cyclophosphamide 500 mg/m\^2 over 60 minutes) once on Days -5 to -3, followed by axicabtagene ciloleucel 2 x 10\^6 anti-cluster of differentiate 19 (CD19) chimeric antigen receptor (CAR) T cells/kg once on Day 0 and additional rituximab 375 mg/m\^2 of 5 doses, once every 28 days starting from Day 21 up to Day 133.
62795804|NCT05461391||Study Group|Participants who got COVID-19.
62587135|NCT04786223|OTHER|C-11 ER176 PET/CT|C-11 ER176 is an investigational radiopharmaceutical that will be produced under cGMP in the Mayo Clinic Cyclotron Facility. The imaging agent (C-11 ER176) will be administered on an outpatient basis. It will be administered at a single time IV prior to the PET imaging.
62023397|NCT03598491||Iohexol|Iohexol was applied in video-fluoroscopic-swallowing study
62795805|NCT05461391||Control Group|Healthy participants
62219841|NCT04028089|EXPERIMENTAL|Diet Modification Group|
62587136|NCT06058520|EXPERIMENTAL|MMT group|patients with HS randomized to receive MTT
62587137|NCT06058520|PLACEBO_COMPARATOR|Placebo group|patients with HS randomized to receive placebo treatment
62023398|NCT03598491||Barium|Barium was applied in video-fluoroscopic-swallowing study
62023399|NCT05077267|EXPERIMENTAL|ABNCoV2 100ug single dose|ABNCoV2 100ug single dose. Intervention type: Biological/Vaccine
62023400|NCT05077267|EXPERIMENTAL|ABNCoV2 50ug single dose|ABNCoV2 50ug single dose. Intervention type: Biological/Vaccine
62219842|NCT04028089|OTHER|Regular Diet Group|
62219843|NCT05619029||Positive|chest radiographs with the specific target radiologic findings (Atelectasis, Calcification, Cardiomegaly, Consolidation, Fibrosis, Mediastinal Widening, Nodule/Mass, Pleural Effusion, Pneumoperitoneum, Pneumothorax)
62219844|NCT05619029||Negative|chest radiographs with no target radiologic findings
62219845|NCT04011943|EXPERIMENTAL|Participants with bowel diseases|Treatment by transplantation of fecal microbiota
62023401|NCT05077267|EXPERIMENTAL|ABNCoV2 100ug two doses|ABNCoV2 100ug two doses 4 weeks apart. Intervention type: Biological/Vaccine
62023402|NCT05490667|EXPERIMENTAL|Anlotinib|Anlotinib combined with chemotherapy for desmoid tumors
62219846|NCT04011943|EXPERIMENTAL|autologous transplantation of fecal microbiota - healthy|Healthy volunteers will receive autologous transplantation of fecal microbiota (capsules)
62219847|NCT04011943|EXPERIMENTAL|Both autologous and heterologous transplantation - healthy|Healthy volunteers will receive both autologous and heterologous transplantation (capsules)
62219848|NCT04011943|PLACEBO_COMPARATOR|placebo capsules - healthy|Healthy volunteers will receive placebo capsules
62219849|NCT02819362||Prospective cohort - MRI|Patients with pathological nipple discharge
62795806|NCT01136408|EXPERIMENTAL|Dabigatran etexilate 220 mg daily|Dabigatran etexilate 110 mg capsule, twice a day, oral administration
62795807|NCT01136408|EXPERIMENTAL|Dabigatran etexilate 300 mg daily|Dabigatran etexilate 150 mg capsule, twice a day, oral administration
62795808|NCT01136408|ACTIVE_COMPARATOR|Warfarin|Dose-adjusted warfarin based on target INR values
62795809|NCT06262100|OTHER|Carragelose|Treatment with Carragelose containing eye drops
62795810|NCT02772744||Group 1: Easy to treat group|"* Treatment naïve~* Total serum bilirubin ≤ 1.2 mg/dl~* Serum albumin ≥ 3.5 g/dl~* International normalized ratio ≤ 1.2~* Platelet count ≥ 150000 mm3~This group will be receiving Sofosbuvir + daclatasvir for 12 weeks."
62795811|NCT02772744||Group 2: Difficult to treat group|"* Peg interferon treatment experienced.~* Total serum bilirubin ≥ 1.2 mg/dl~* Serum albumin ≤ 3.5 g/dl~* International normalized ratio ≥ 1.2~* Platelet count ≤ 150000 mm3~This group will be receiving Sofosbuvir + daclatasvir + ribavirin for 12 weeks."
62795812|NCT02772744||Group 3: Sofosbuvir resistant cases|This is the group of patients who failed in previous Sofosbuvir treatment regiment. This group will be receiving Sofosbuvir + daclatasvir + ribavirin for 24 weeks.
62023403|NCT02331992|EXPERIMENTAL|Positive airway pressure adherence program|Participants will be enrolled in the automated adherence program and will receive supportive messages while they use CPAP as prescribed by their healthcare provider. These messages are designed to aid the participant towards therapy adherence.
62023404|NCT02912533|EXPERIMENTAL|JR-131|
62023405|NCT05430412|EXPERIMENTAL|Adacolumn|"Adacolumn is a non-pharmacological treatment which reduces the inflammation by removing specifically targeted white blood cells from the blood circulation. The Adacolumn is designed to be used in combination with the Adamonitor and its Adastand, and the Adacircuit. The column has a capacity of 335 mL and is filled with cellulose acetate beads of 2 mm in diameter as the column adsorptive leukocytapheresis carriers. The carriers are bathed in 130 mL of sterile saline until use when the column is primed with additional sterile saline and then with heparinized saline prior to use.~Patients will receive 10 sessions with Adacolumn. It would be reduced between 5 - 10, according to the patient´s response and following PI valuation. Patients will receive Adacolumn with IFX for that period of time.~Patients will have received previously IFX for 12-16 weeks. visits will be conducted every week, for the application of Adacolumn."
62023406|NCT02605057|EXPERIMENTAL|LEO 80185 gel|LEO 80185 gel will be allocated to 7 different test sites on each subject
62023407|NCT02605057|EXPERIMENTAL|Dovobet Ointment|Dovobet Ointment will be allocated to 7 different test sites on each subject
62023408|NCT02564198|EXPERIMENTAL|Ramucirumab|"(Part A-Non-CNS Solid Tumors) Escalating doses of 8 milligrams per kilogram (mg/kg) or 12 mg/kg Ramucirumab administered as an intravenous infusion every 2 weeks (Q2W) with 3 doses per 42 day cycle.~(Part B-CNS Tumors) Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle."
62023409|NCT04434404|PLACEBO_COMPARATOR|control group|33, patients in the control group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 without cardioprotective agents
62414369|NCT03413722||Conversion Group|Kidney transplant recipients at the University of Kansas Medical Center (KUMC) who are currently on tacrolimus (CNI), and will be undergoing conversion to Everolimus + low dose CNI. Potential participants will be asked to participate in the study after the decision to convert CNI to Everolimus + low dose CNI has been made.
62414370|NCT03413722||Control Group|Kidney transplant recipients at KUMC on tacrolimus (CNI). These will be patients not planning to undergo any change in immunosuppression.
62414371|NCT04117048|EXPERIMENTAL|At home INR measurement with LabPad®|All at home INR measurements will be performed with the LabPad® point-of-care
62414372|NCT06701552||A Group of 266 young adult Egyptian patients|Patients will be examined for prevalence of molar incisor hypomineraliztion and its correlation to caries incidence
62414373|NCT06623006|NO_INTERVENTION|Control group|The control group will be receive usual care they have been getting. At the end of the intervention, they will be provided with a leaflet that contains messages that was included in the mhealth intervention.
62023410|NCT04434404|ACTIVE_COMPARATOR|L-carnitine group|25 patients received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine
62023411|NCT04434404|ACTIVE_COMPARATOR|Silymarin group|25 patients received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin140 mg
62023412|NCT06104735|EXPERIMENTAL|All participants|Each participant will undergo varying conditions in separate phases to determine optimal: Pairing interval; Frequency; Number of bouts, Inter-bout spacing, and the order of SCAP when given in conjunction with task-oriented hand exercise.
62023413|NCT02614976|NO_INTERVENTION|Control|No padding before application of blood pressure cuff
62414374|NCT06623006|EXPERIMENTAL|Intervention|The intervention group will receive a text-based mhealth (text messages) in addition to standard care which they are used to receiving.
62023414|NCT02614976|EXPERIMENTAL|Padding|Padding before application of blood pressure cuff
62023415|NCT00736996|EXPERIMENTAL|Pioglitazone|"Pioglitazone~30 - 45mg tablet daily for 6 months"
62414375|NCT03505606|ACTIVE_COMPARATOR|Control|Visual acuity tests on control participants
62414376|NCT03505606|EXPERIMENTAL|Strabismic/mixed amblyopes|Visual acuity tests on strabismic/mixed amblyopic participants.
62414377|NCT03505606|EXPERIMENTAL|Anisometropic amblyopes|Visual acuity tests on anisometropic amblyopic participants.
62587138|NCT04678232|EXPERIMENTAL|receive PATH therapy|PATH includes six 60-90 min, weekly sessions, with two booster sessions for partial responders. Session 1 provides the PATH rationale and a review of life events (PATH of life: negative and positive). A rationale for an explicit focus on positive events/emotions will be provided. Sessions 2-4 focus on a verbal narrative of the destabilizing life event, reminiscence and processing of a major positive life event, and real-life practice to enact what was taught. Sessions 5 focuses on constructive processing and provides opportunity for integration and consolidation of learning. Session 6 focuses on future negative and positive events to promote application of new learning and resilience. Booster sessions focus on positive and negative life events since the last session and adaptive processes (constructive processing, approach, and reward). All sessions will include cultivation and elaboration of positive emotions to promote engagement and to build on the benefits of positive emotions.
62587139|NCT03902184|EXPERIMENTAL|Cohort 1: Relapsed/refractory Sezary Syndrome|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
62587140|NCT03902184|EXPERIMENTAL|Cohort 2: Stage IB-IV Mycosis Fungoides, KIR3DL2 expressing|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
62023416|NCT00736996|ACTIVE_COMPARATOR|Endurance Exercise Training|Endurance Exercise Training (EET) Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
62023417|NCT00736996|PLACEBO_COMPARATOR|Placebo|Placebo matching tablet sugar pill daily for 6 months
62587141|NCT03902184|EXPERIMENTAL|Cohort 3: Stage IB-IV Mycosis Fungoides,KIR3DL2 non-expressing (closed)|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
62587142|NCT03902184|EXPERIMENTAL|Cohort All comers: Stage IB-IV Mycosis Fungoides,KIR3DL2 expressing and non-expressing|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
62587143|NCT04088071||Patients with atrial fibrillation|Subjects with symptomatic PAF or PsAF who, in the opinion of the investigator, are candidates for ablation for AF, age 18 years or older, and are able and willing to comply with all pre-, post-, and follow-up testing and requirements.
62587144|NCT06529731|EXPERIMENTAL|IFN-γ + DLI|"ACTIMMUNE® (IFN-γ-1b) at a dose of 50 mcg/m\^2 (All participants will receive a 4-week period of IFN-γ monotherapy with ACTIMMUNE 100 mcg 3 times a week. This dose and schedule will be continued for 4 additional weeks and then tapered to 100 mcg weekly for an additional 4 weeks)~DLI at a dose of 10\^7 CD3+ cells/kg (DLI doses will be given pending clinical assessment for disease, graft versus host disease (GVHD) and peripheral blood donor chimerism the week prior to DLI. Second DLI dose is only offered to subjects with residual disease not requiring cytotoxic therapy and without GVHD)"
62587145|NCT05450354||Patients|Alive patients between the ages of 9 and 15 included at the time of their hospitalization at the Necker Enfants Malades Hospital following a serious suicide attempt that took place after January 1, 2016 and at least one of the two parents of the patient, to answer to the study questionnaires.
62587146|NCT05450354||Control patients|Patients aged 9 to 15 years hospitalized at the Necker-Enfants Malades hospital at time of the study for a non-serious suicide attempt and at least one of the two parents of the patient.
62587147|NCT05669508|EXPERIMENTAL|Treatment Arm|Participants will receive closed-loop transcutaneous spinal cord stimulation via the RISES-T System while completing functional task practice in occupational therapy sessions.
62023418|NCT06039748||AngioQFA|
62023419|NCT06634667|EXPERIMENTAL|The experimental cohort|third-generation EGFR-TKI combined with anlotinib
62414378|NCT05193331|EXPERIMENTAL|DQS group|Participants in DQS group will be administered one drop of 3% DQS (Diquas, Santen Pharmaceutical Co., Ltd., Osaka, Japan) six times per day for 4 weeks (28 days).
62414379|NCT04229758|EXPERIMENTAL|1 week|Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
62414380|NCT04229758|EXPERIMENTAL|2 weeks|Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
62414381|NCT04229758|EXPERIMENTAL|4 weeks|Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
62414382|NCT06538714|EXPERIMENTAL|MIIT|12-week supervised exercise program consisting of moderate -intensity interval training (MIIT)
62587148|NCT05667116||EVUSHELD arm|3,000 Individuals given EVUSHELD for pre-exposure prophylaxis
62023420|NCT04547972|ACTIVE_COMPARATOR|Higher-load limbs|This treatment arm will have participants performing resistance training with loads of \~80% of an individuals one-repetition maximum. Each participant will have one arm and one leg assigned to this condition.
62414383|NCT06538714|ACTIVE_COMPARATOR|MIIT+ HIIT|12-week supervised exercise program consisting of moderate-intensity interval training (MIIT) (6-week) and high-intensity interval training (HIIT) (6-week).
62414384|NCT06538714|PLACEBO_COMPARATOR|Control group No training|
62587149|NCT05667116||Concurrent Control arm|3,000 individuals eligible for EVUSHELD pre-exposure prophylaxis but did not receive Evusheld
62587150|NCT06363110||Adult patients initiating vericiguat|Adult patients initiating vericiguat in the US. Retrospective single-arm cohort analysis using HealthVerity Heart Failure (HF) dataset licensed by Bayer.
62023421|NCT04547972|ACTIVE_COMPARATOR|Lower-load limbs|This treatment arm will have participants performing resistance training with loads of \~30% of an individuals one-repetition maximum. Each participant will have one arm and one leg assigned to this condition.
62414385|NCT05416125|PLACEBO_COMPARATOR|Lifestyle therapy plus placebo|Individuals randomized to this arm will receive lifestyle therapy plus placebo for 24 weeks.
62414386|NCT05416125|ACTIVE_COMPARATOR|Lifestyle therapy plus lisdexamfetamine|Individuals randomized to this arm will receive lifestyle therapy plus lisdexamfetamine for 24 weeks.
62414387|NCT06460298|EXPERIMENTAL|Dose Escalation|"Experimental: Dose Escalation ProAgio Dose Levels (DL) 1,2,3,4 ProAgio combined with Gemcitabine is administered to study participants by intravenous injections on days 1, 8, 15, every 4-week Cycle.~Other Names:~ACT50, and Gemcitabine"
62795813|NCT03084692|EXPERIMENTAL|Therapeutic Yoga and Resistance Exercise|The individuals with lung cancer and their caregivers will participate in a combined intervention of yoga and resistance exercise for 8-week, two times/week. The dyad will attend a one-hour resistance exercise intervention at the start of the week and a one-hour yoga class with a break of one day between both interventions. The resistance exercise training will involve one-on-one personal exercise session, while the yoga intervention will be offered in a class setting. The participants will be allowed to make up for any missed resistance exercise session based on the available time. Pamphlets will be given demonstrating breathing exercises, meditation, postures, and core resistance exercises to facilitate programming.
62795814|NCT06236919|EXPERIMENTAL|VR cognitive training|The VR cognitive training group will engage in a subset of six games with adaptive difficulty, designed to target specific cognitive functions.
62795815|NCT06236919|ACTIVE_COMPARATOR|VR nature-exposure relaxation group|The control group will be immersed in VR nature-based content and perform relaxation exercises.
62795816|NCT06725966|ACTIVE_COMPARATOR|Conventional Epley maneuver|Participants will be advised to perform Brandt-Daroff exercises at home twice daily for 8 weeks. An MRI of the inner ear and posterior cranial fossa will also be requested. If the exercises are ineffective, repositioning maneuvers using a mechanized chair will be repeated biweekly until symptom resolution.
62795817|NCT06725966|EXPERIMENTAL|Personalized Epley maneuver|Participants will perform Brandt-Daroff exercises at home twice daily for 8 weeks. An MRI will be conducted, and based on the images, a personalized mathematical model will be created to modify the angles of the repositioning maneuver. If the exercises are ineffective, the personalized maneuver will be performed using a mechanized chair.
62795818|NCT06444581|EXPERIMENTAL|Group experimental|"Super Skills intervention group: multimedia material version~The Super Skills program will be administered following the manual of the intervention by a trained therapist, as described in the section of intervention/ treatment and will be enriched with multimedia material that the implementer will project at various moments of the sessions.~Super Skills Structured and manualized intervention with a manual for the therapist and a workbook for the children. The intervention will be administered by Super Skills-trained clinical psychologists. Sessions will take place once a week for twelve weeks, with each session lasting approximately fifty minutes. The program includes emotional education and social skills training. These contents are learned through playful exercises, activities, readings and role-playing. The intervention modality will be face-to-face."
62795819|NCT06444581|NO_INTERVENTION|Group without any intervention|Participants in the wait-list group will receive no psychological intervention during the twelve-week duration of the Super Skills program. Families will be informed that children in this group will receive the intervention once the posttest is completed.
62795820|NCT01366482|EXPERIMENTAL|Drug-eluting balloon|Subjects are randomized to have a lesion treated with a paclitaxel-coated balloon Intervention: Cotavance Drug-Eluting Balloon
62219850|NCT03177499|EXPERIMENTAL|Single arm study|"Patients will receive CT angiography, Doppler ultrasound, invasive PPG, and vePPG per protocol.~Intervention: Procedure: Invasive PPG"
62414388|NCT06460298|EXPERIMENTAL|Dose Expansion|"Participants will receive ProAgio at the objective response rate (ORR) combined with Gemcitabine is administered to study participants by intravenous injections on days 1, 8, 15 every 4-week Cycle.~Other Names:~ACT50, and Gemcitabine"
62587151|NCT05861492|ACTIVE_COMPARATOR|FDDA Group|Fatigue anamnesis was done with the help of the Fatigue Differential Diagnosis Aid.
62795821|NCT01366482|EXPERIMENTAL|Plaque excision + drug-eluting balloon|Subjects are randomized to have a lesion treated with plaque excision (PE) followed by treatment with a paclitaxel-coated balloon Intervention: SilverHawk/TurboHawk + Cotavance Drug-Eluting Balloon
62795822|NCT01366482|EXPERIMENTAL|Severely Ca++ Group|Subjects with a severely calcified lesion will be assigned to a non-randomized arm and treated with plaque excision followed by a drug-eluting balloon Intervention: SilverHawk/TurboHawk + Cotavance Drug-Eluting Balloon
62795823|NCT05733442|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|The TAU condition will entail the current CNHS MAT program for OUD.
62795824|NCT05733442|EXPERIMENTAL|CHaRRM-CN|The CHaRRM-CN condition comprises changes and additions to TAU codesigned with a community advisory board and taking into account suggestions from MAT patients and community members impacted by OUD with the goal of improving MAT retention in culturally aligned and community-driven ways.
62795825|NCT04198792||ECPR patients|Patients that is put om ECMO during cardiac arrest
62795826|NCT04198792||ECMO patients, non-ECPR|Patients that is put on ECMO due to circulatory failure but not cardiac arrest
62795827|NCT05030207|EXPERIMENTAL|Real-Time Gated 4DCT and Conventional 4DCT|During the simulation (radiotherapy planning) session, the participant will undergo both the experimental 'Real-Time Gated 4DCT' and standard 'Conventional 4DCT'.
62795828|NCT03739710|EXPERIMENTAL|Part 1: Participants receiving feladilimab and ipilimumab|
62795829|NCT03739710|EXPERIMENTAL|Part 1: Participants receiving dostarlimab plus GSK4428859A/EOS884448/belrestotug|
62795830|NCT03739710|EXPERIMENTAL|Part 1: Participants receiving dostarlimab plus GSK4428859A/EOS884448/belrestotug plus GSK6097608|
62795831|NCT03739710|ACTIVE_COMPARATOR|Part 2: Participants receiving SoC: docetaxel|
62795832|NCT03739710|EXPERIMENTAL|Part 2: Participants receiving feladilimab and docetaxel|
62414389|NCT01523301|EXPERIMENTAL|Rotigotine|Rotigotine, daily doses, treatment group
62414390|NCT01523301|PLACEBO_COMPARATOR|Placebo|Placebo, daily doses, placebo group
62414391|NCT02093650|ACTIVE_COMPARATOR|Black cohosh extract|black cohosh extract 80 mg daily
62414392|NCT02093650|PLACEBO_COMPARATOR|Placebo|Matching placebo
62414393|NCT05649059|ACTIVE_COMPARATOR|Cannabidiol|300mg Cannabidiol (3mL Epidiolex), oral, single-dose
62414394|NCT05649059|PLACEBO_COMPARATOR|Placebo|Placebo (3mL sesame seed oil), oral, single-dose
62414395|NCT03544567|EXPERIMENTAL|Oraxol|Oraxol will be administered once daily for 3 consecutive days every week from Weeks 1 through 25. Subjects who do not have documented disease progression by the end of the Treatment Period will be eligible to receive therapy in the Treatment Extension Period; additional doses of Oraxol may be administered from Week 26 onwards. Subjects may receive Oraxol until they meet 1 of the criteria for withdrawal from the study.
62023422|NCT02552836|EXPERIMENTAL|Interpersonal Psychotherapy (IPT)|Patients assigned to IPT will receive 12 sessions of individual therapy of approximately 50 minutes duration. Therapy will be manualized and slightly adapted to meet the needs of patients with Parkinson's Disease. Therapy focuses on one of four interpersonal events that are linked with onset or maintenance of depression (role transition, role disputes, unresolved grief, and interpersonal deficits).
62023423|NCT02552836|ACTIVE_COMPARATOR|Supportive Psychotherapy (SP)|Patients assigned to SP will receive 12 sessions of individual therapy of approximately 50 minutes duration. SP strives to create a supportive therapeutic relationship by emphasizing non-specific therapeutic interactions and techniques. Therapy will be manualized,
62023424|NCT04546087|EXPERIMENTAL|Ultrasound|Ultrasound measurements of the cricothyroid membrane.
62023425|NCT03011216|EXPERIMENTAL|Adaptive emotional cognitive control training|"Adaptive emotional n-back task: On each trial of this task, participants are presented with an emotional facial expression. Participants have to indicate whether the emotion presented in the current trial is the same as n trials back. In order to train participants at their individual ability level, the n-level varies by trial block based on participants' performance on the previous block.~The adaptive emotional n-back task is assumed to train the ability to continuously update emotional material in working memory."
62023426|NCT03011216|ACTIVE_COMPARATOR|Placebo training|"Adaptive non-emotional feature match task: On each trial of this task, participants are presented with two panels containing 8-12 shapes each. Participants are asked to compare the two panels and decide whether or not they are identical. The panels contain a minimum of 8 shapes and a maximum of 12 shapes, depending on participants' performance on the previous block.~The adaptive non-emotional feature match task is assumed to train the speed of responding (involving processes like visual search and concentration). It does not trait working memory updating."
62023427|NCT01645709|EXPERIMENTAL|Verapamil|Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.
62023428|NCT01645709|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.
62414396|NCT00869726|EXPERIMENTAL|Dirucotide|
62414397|NCT00869726|PLACEBO_COMPARATOR|Placebo|
62587152|NCT05861492|NO_INTERVENTION|Non-FDDA group|Fatigue anamnesis was done without the help of the Fatigue Differential Diagnosis Aid.
62587153|NCT01364688|EXPERIMENTAL|Treatment|oral alfacalcidol
62587154|NCT01364688|NO_INTERVENTION|Control|No drug
62219851|NCT00057629|ACTIVE_COMPARATOR|1 Prolonged Exposure|Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.
62219852|NCT00057629|ACTIVE_COMPARATOR|2 Individual and group therapy|"TUGT (Treatment as usual group therapy - used in Study 1), delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is no formal, structured format for these groups; counselors are sensitive to the participants' needs and follow their lead re content covered in discussions and exercises.~Supportive counseling (SC - study 2): individual therapy delivered in 10 weekly, 90 minute sessions. Therapist helps patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these."
62219853|NCT00094354||1|HIV-infected FPDs
62219854|NCT00094354||2|Family members of HIV-infected FPDs
62219855|NCT00094354||3|Local healthcare workers
62219856|NCT00094354||4|Villagers not related to an HIV-infected individual
62219857|NCT03117231|EXPERIMENTAL|Active tDCS|Subjects will undergo low-intensity transcranial electrical stimulation for 20 minutes.
62219858|NCT03117231|SHAM_COMPARATOR|Sham tDCS|Subjects will undergo low-intensity transcranial electrical stimulation for 20 minutes.
62414398|NCT02428491|EXPERIMENTAL|DTaP-IPV-HB-PRP~T Vaccine|All participants will receive 3 doses of 0.5 mL DTaP-IPV-HB-PRP\~T combined vaccine, intramuscularly, at 2, 3 and 4 months of age (primary series), followed by a booster dose approximately 12 months after the completion of the primary series (at 16 to 17 months of age).
62414399|NCT06567184|EXPERIMENTAL|Strong Hearts Urban|A 12-week multi-level intervention targeting behavior modification, nutrition education, strength training, aerobic exercise, and stress reduction activities
62414400|NCT02962115|EXPERIMENTAL|Decision Aid Invitation|Electronic invitation to complete a web-based lung cancer screening decision aid
62414401|NCT04499391|EXPERIMENTAL|ECHO plus|Nursing homes in this arm will receive the intervention via real-time, interactive videoconferencing using Zoom at no cost to participants. Sessions will be 90 minutes in duration and held weekly for 6 months (25 sessions total) at regularly scheduled times. Participants in this arm will receive a 2 month (8 sessions total) refresher course in Fall 2021. Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation
62587155|NCT04824794|EXPERIMENTAL|GEN3014|"Experimental: GEN3014 Participants in Dose Escalation phase with~* Relapsed or refractory myeloid myeloma (RRMM)~* R/R acute myeloid leukemia (AML)~Participants in Expansion Part A with~* RRMM (anti-CD38 mAb-naïve)~* RRMM (anti-CD38 mAb-refractory)~* R/R diffuse large B-cell lymphoma (DLBCL)~* R/R AML~Participants in Expansion Part B with~• RRMM (anti-CD38 mAb-naïve)"
62587156|NCT04824794|ACTIVE_COMPARATOR|Daratumumab|"Participants in Expansion Part B with~- RRMM (anti-CD38 mAb-naïve)"
62219859|NCT01993173|EXPERIMENTAL|ADACEL Vaccine Group|Children, adolescents and adults randomized to receive a single booster dose of ADACEL (Tdap vaccine)
62219860|NCT01993173|ACTIVE_COMPARATOR|Local DT/Td Vaccine Group|Participants randomized to receive either a single booster dose of local DT vaccine (children aged 4 through 11 years) or local Td vaccine (adolescents and adults aged 12 through 64 years)
62219861|NCT02807103|EXPERIMENTAL|Rituximab with FFS=0|"All patients in the rituximab group will receive corticosteroids with a predefined tapering schedule similar to the conventional therapy group.~Patients with FFS=0 will receive 1 gram of rituximab at day 1 and day 15 as induction treatment"
62219862|NCT02807103|PLACEBO_COMPARATOR|Conventional therapy with FFS=0|"All patients will receive corticosteroids with a predefined tapering schedule similar to the experimental group.~Patients with FFS=0 will receive placebo-rituximab at day 1 and day 15."
62219863|NCT02807103|EXPERIMENTAL|Rituximab with FFS≥1|"All patients in the rituximab group will receive corticosteroids with a predefined tapering schedule similar to the conventional therapy group.~Patients with FFS≥1 will receive a total of 9 pulses :~* 1 gram of rituximab at day 1 and day 15 as induction treatment~* placebo-cyclophosphamide at days 1, 15, 29, 50, 71, 92, 113, 134 and 155.~Maintenance therapy by azathioprine will be started at day 180 according to the standard of care of these patients, as recommended by the French Vasculitis Study Group."
62219864|NCT02807103|ACTIVE_COMPARATOR|Conventional therapy with FFS≥1|"All patients will receive corticosteroids with a predefined tapering schedule similar to the experimental group.~Patients with FFS≥1 will receive intravenous pulses of cyclophosphamide for a total of 9 pulses: 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.~Maintenance therapy by azathioprine will be started at day 180 according to the standard of care of these patients, as recommended by the French Vasculitis Study Group."
62219865|NCT00417105||1|hemodialysis twice weekly 4 hours
62219866|NCT00417105||2|nocturnal dialysis twice weekly 8 hours
62219867|NCT00417105||3|nocturnal hemodialysis, 8 hours every other night
62219868|NCT00417105||4|nocturnal hemodialysis, 8 hours, six times per week
62219869|NCT06419478||postoperative symptoms|Investigation of postoperative symptoms in eligible patients undergoing liver resection at two time points
62219870|NCT05902156|EXPERIMENTAL|DiaPaDeSS intervention group|DiaPaDeSS will be introduced to participants with type 2 diabetes during face-to-face interviews. The DiaPaDeSS intervention group will have access to all the contents of the DiaPaDeSS, which includes the patient education information about type 2 diabetes, self-management practice tasks (daily, weekly, quarterly), type 2 diabetes patient education program according to DiaPaDeSS algorithms, and measurement questionnaires. During the follow-up period, the participants in the DiaPaDeSS intervention group will take DiaPaDeSS messages once a week and be reminded to use the education program. The DiaPaDeSS will be asked to use it for three months on daily and weekly inputs. During the follow-up period, the participants can contact the researcher via 24/7 on the DiaPaDeSS. Participants in the DiaPaDeSS intervention group will also receive routine patient education and hospital follow-ups.
62414402|NCT04499391|ACTIVE_COMPARATOR|ECHO|Nursing homes in this arm will receive the intervention via real-time, interactive videoconferencing using Zoom at no cost to participants. Sessions will be 90 minutes in duration and held weekly for 6 months (25 sessions total) at regularly scheduled times. Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation
62414403|NCT02397083|EXPERIMENTAL|Arm I (LIUD)|Patients continue treatment with the LIUD for up to 9 months in the absence of disease progression or unacceptable toxicity.
62414404|NCT02397083|EXPERIMENTAL|Arm II (LIUD, everolimus)|Patients continue treatment with the LIUD and receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.
62414405|NCT03427788|EXPERIMENTAL|Verum|Study group 1-11 of BAY2328065 (increasing dose levels for study group 2-11)
62414406|NCT03427788|PLACEBO_COMPARATOR|Placebo|Study group 1-11 of Placebo
62414407|NCT03992612|OTHER|control group|The patients received usual medical care.
62414408|NCT03992612|EXPERIMENTAL|MBPM- Minfulness- Based Pain Management|"Psychological intervention with 8 group sessions ( 8 -10 subjects) with a duration of 2 and a half hours per session and a weekly periodicity (total hours 1080).~It is centered on training on the awareness of physical, cognitive and emotional sensations, and the attentional processes to become an observer of one's own thoughts and emotions. With the aim to provide greater flexibility to manage pain"
62414409|NCT05036447|EXPERIMENTAL|DM1-Ex|Moderate-heavy resistance exercise of one leg in DM1-patients
62414410|NCT05036447|NO_INTERVENTION|DM1-Rest|Control leg (i.e. no exercise) in DM1-patients
62414411|NCT05036447|EXPERIMENTAL|Ctrl-Ex|Moderate-heavy resistance exercise of one leg in healthy participants
62414412|NCT05036447|NO_INTERVENTION|Ctrl-Rest|Control leg (i.e. no exercise) in healthy participants
62414413|NCT05157529|EXPERIMENTAL|Aquablation|The participant will undergo aquablation procedure for Benign Prostate Hypeplasia (BPH) treatment using the AQUABEAM Robotic System and Ultrasound Accessories
62023429|NCT00094380|EXPERIMENTAL|Dose-escalation portion: Low dose CTLA4-IgG4m (RG2077)|Three patients will receive a single intravenous infusion of 0.2 mg/kg CTLA4-IgG4m following the scheduled cyclophosphamide infusion on the same day. If one or more dose-limiting toxicities (CTC grade 3 or higher adverse event in the first 28 days after CTLA4-IgG4m administration that is possibly, probably, or definitely related to CTLA4-IgG4m (RG2077)). are observed, enrollment in the trial will be suspended pending DSMB review. If no dose-limiting toxicity is observed in the 0.2mg/kg dose, three patients will receive a single intravenous infusion of 2 mg/kg of CTLA4-IgG4m following the scheduled cyclophosphamide infusion on the same day. If one or more dose-limiting toxicities are observed, enrollment will be suspended pending review by the Data Safety and Monitoring Board (DSMB).If no dose-limiting toxicity is observed in the 2 mg/kg dose, treatment of patients with 10 mg/kg of CTLA4-IgG4m in combination with cyclophosphamide will proceed.
62587157|NCT06310551|EXPERIMENTAL|Formulation A SC Group|Participants receive a Formulation A starting dose of VH4524184 LAI subcutaneously (SC).
62587158|NCT06310551|EXPERIMENTAL|Formulation B SC Group|Participants receive a Formulation B starting dose of VH4524184 LAI subcutaneously.
62023430|NCT00094380|EXPERIMENTAL|Part IIA: CTLA4-IgG4m|Participants randomized to the CTLA4-IgG4m Arm will receive a single intravenous infusion of 10 mg/kg CTLA4-IgG4m (RG2077) following the scheduled cyclophosphamide infusion on the same day
62023431|NCT00094380|EXPERIMENTAL|Part IIA: Control Group|Participants randomized to the control group will not receive treatment with CTLA4-IgG4m (RG2077); these participants will undergo all study evaluations with the exception of the CTLA4-IgG4m (RG2077) pharmacokinetic evaluations and immunogenicity evaluations.
62219871|NCT05902156|ACTIVE_COMPARATOR|Control Group|DiaPaDeSS will be introduced to participants with type 2 diabetes in the control group during face-to-face interviews. The control group will have access to only these fields self-management practice tasks (daily, weekly, quarterly), and measurements questionnaires. The diabetes patient education brochure of the Ministry of Health will be sent to the phones of the active control group in pdf format. Participants in the DiaPaDeSS group will also receive routine patient education and routine hospital follow-up during the three-month follow-up period..
62219872|NCT02190045|EXPERIMENTAL|Wii-Fit program|Wii-Fit exercises will be adminstered for 45 minutes 3 days a week for 8 weeks
62219873|NCT02190045|PLACEBO_COMPARATOR|Cognitive remediation program|Cognitive remediation exercises will be adminstered for 45 minutes 3 days a week for 8 weeks
62219874|NCT01276938|ACTIVE_COMPARATOR|IORT 21 Gy|Single fraction 21 Gy Intraoperative Radiation Therapy for breast tumors with diameter between 10 and 25 mm
62219875|NCT01276938|EXPERIMENTAL|IORT 18 Gy|Single fraction 18 Gy Intra Operative Radiation Therapy in breast tumors smaller than 10 mm.
62587159|NCT06310551|EXPERIMENTAL|Formulation C SC Group|Participants receive a Formulation C starting dose of VH4524184 LAI subcutaneously. This intervention is optional and initiated only if Formulation B is poorly tolerated.
62587160|NCT06310551|EXPERIMENTAL|Formulation A IM Group|Participants receive a Formulation A starting dose of VH4524184 LAI intramuscularly (IM).
62587161|NCT06310551|EXPERIMENTAL|Formulation B IM Group|Participants receive a Formulation B starting dose of VH4524184 LAI intramuscularly (IM).
62023432|NCT05647447|EXPERIMENTAL|Pilot Trial: Osanetant 28 Days|Osanetant 200 mg orally, twice per day for 28 days.
62414414|NCT06568445|EXPERIMENTAL|maintenance at initial treatment sequential as-needed therapy group|budesonide 160 µg-formoterol 4.5 µg (Symbicort 160/4.5) ®）, administered as one inhalation twice daily for maintenance for 4 weeks, sequential as-needed therapy for symptom relief to 24-week (no more than 8 inhalations per day).
62219876|NCT04251507|EXPERIMENTAL|Virtual Reality Goggles|Patients randomized to the intervention group will undergo their procedure as standard of care but will wear the Oculus Go Goggles and experience a virtual reality simulation. The simulation is a non-interactive polar theme video.
62219877|NCT04251507|NO_INTERVENTION|Control|Patients randomized to the control group will undergo their procedure as standard of care without the use of virtual reality goggles.
62219878|NCT04812275|ACTIVE_COMPARATOR|Non absorbable suture|Wound closure with non absorbale suture. Dimension and brand at the discretion of the surgeon.
62219879|NCT04812275|EXPERIMENTAL|Absorbable suture|Wound closure with absorbale suture. Dimension and brand at the discretion of the surgeon.
62219880|NCT00911937|EXPERIMENTAL|Fesoterodine|
62219881|NCT00911937|PLACEBO_COMPARATOR|Placebo|
62219882|NCT05631470||Enrolled|Participants with ICAS will be scheduled for both MR screening and pressure-wire-based FFR measurement.
62414415|NCT06568445|ACTIVE_COMPARATOR|As-needed therapy group|Inhaled budesonide-formoterol as needed when symptoms are present (Symbicort 160/4.5) ®），no more than 8 inhalations per day, continuous to 24-week.
62795833|NCT04915729|EXPERIMENTAL|Tenecteplase treatment group|Chinese patients with AIS were screened (visit 1) and randomised (visit 2a) when admitted. Patients received a single dose of tenecteplase, 0.25 mg/kg via intravenous (iv) bolus no later than 4.5 hours (h) after symptom onset. Visits on Day 1 consisted of two further visits (Visit 2b and Visit 2c) that were performed 1 h and 2 h after the start of the treatment. Visits 3 to 5 for continuous follow-up were performed on day 2, 8 and 30 after the start of the treatment. Treated patient performed a 90-day follow-up visit after the treatment to complete the study.
62795834|NCT04915729|ACTIVE_COMPARATOR|Alteplase active control group|Chinese patients with AIS were screened (visit 1) and randomised (visit 2a) when admitted. Patients received a single dose of alteplase, 0.9 mg/kg, 10% via intravenous (iv) bolus and the remaining 90% of the total dose administered as an iv infusion over 1 h no later than 4.5 hours (h) after symptom onset. Visits on Day 1 consisted of two further visits (Visit 2b and Visit 2c) that were performed 1 h and 2 h after the start of the treatment. Visits 3 to 5 for continuous follow-up were performed on day 2, 8 and 30 after the start of the treatment. Treated patient performed a 90-day follow-up visit after the treatment to complete the study.
62023433|NCT02505932||Arthroscopic Latarjet procedure|arthroscopic approach (set Depuy-Mitek, Raynham, MA)
62023434|NCT02505932||Mini-open Latarjet procedure|mini-open approach (set Arthrex, Naples, FL)
62023435|NCT01141361||Peripheral arterial disease patients|Patients with a peripheral arterial disease, defined by an ankle to brachial index below 0.90
62023436|NCT03300388|PLACEBO_COMPARATOR|Control|Dietary advice for a healthy diet supplemented with placebo (olive oil).
62023437|NCT03300388|EXPERIMENTAL|Omega-3|Dietary advice for a healthy diet supplemented with DHA-rich dietary supplement (providing 1.650 mg/day of DHA).
62219883|NCT05293483||COVID-19|
62219884|NCT05293483||non-COVID-19|
62219885|NCT01546636|PLACEBO_COMPARATOR|Hypocapnic group|Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
62219886|NCT01546636|ACTIVE_COMPARATOR|Normocapnic group|Patients will be ventilated to an ETCO2 of 40-42 mm Hg
62023438|NCT03300388|EXPERIMENTAL|Resistance Training|Dietary advice for a healthy diet supplemented with placebo (olive oil) and moderate resistance training program.
62023439|NCT03300388|EXPERIMENTAL|Omega-3 + Resistance Training|Dietary advice for a healthy diet supplemented with a DHA-rich dietary supplement (providing 1.650 mg/day of DHA) and moderate resistance training program.
62219887|NCT01048554|OTHER|Temozolomide/Bevacizumab|Patients will be treated with a combination of temozolomide at 75 mg/m2/day for six continuous weeks, followed by a two-week rest period and bevacizumab 10 mg/kg every 2 weeks without interruption. Cycles will be repeated every 8 weeks. Patients will be restaged every 8 weeks.
62219888|NCT01959997|ACTIVE_COMPARATOR|Redo PVI|Therapeutic anticoagulation will be required for at least 3 weeks prior to ablation. An MRA will be performed to define cardiac and PV anatomy. Standard ablation technique will be employed. After gaining venous access, double transseptal puncture will be performed to permit left atrial access, guided by intracardiac ultrasound. A circular mapping catheter will be placed in each PV and any reconnections will be ablated by delivery of RF energy. Confirmation of re-isolation of all PVs will be performed at the conclusion of the procedure.
62414416|NCT01184781|OTHER|A|On the same patient, we compare both methods (video-colonoscopy vs capsule endoscopy)
62414417|NCT05860049|ACTIVE_COMPARATOR|Conventional physiotherapy + Core stability|They received conventional physical therapy and core stability for 4 weeks.
62414418|NCT05860049|EXPERIMENTAL|Conventional physiotherapy + Core stability + Instrument assisted soft tissue mobilization (IASTM)|They received conventional physical therapy, core stability, and IASTM technique for 4 weeks.
62587162|NCT06310551|EXPERIMENTAL|Multiple doses Group|VH4524184 LAI formulations administered SC or IM as single doses that achieve adequate PK exposure targets, may be evaluated for safety and tolerability as multiple doses.
62587163|NCT01651520|EXPERIMENTAL|Relapsing patients < 5 years|Relapsing patients \< 5 years
62587164|NCT01651520|EXPERIMENTAL|relapsing patients < 10 years|relapsing patients \< 10 years
62795835|NCT02957734|EXPERIMENTAL|LAVA Ultimate restorations|For rehabilitation of the severely worn teeth, teeth are prepared (based on Minimal Invasive procedures), scanned using an intra-oral 3D-scanner (TrueDef, 3M), a digital wax-up model is made and finally restorations are milled from a pre polymerized block of resin (LAVA Ultimate). These indirect restorations are then adhesively cemented on the teeth (Relyx Ultimate, 3M). Teeth on which no indirect restoration could be made/designed a direct composite restoration was made using Filtek Supreme XTE in combination with Scotchbond Universal. Furthermore, all anterior veneer restorations are made of direct composite restorations (Filtek Supreme XTE in combination with Scotchbond Universal).
62414419|NCT03576794|ACTIVE_COMPARATOR|Leflunomide treatment|Patients will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27. During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day in order to prevent early drug withdrawal due to side effects. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
62414420|NCT03576794|PLACEBO_COMPARATOR|Placebo control|Patients will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27. During the first 2 weeks after randomization patients will receive placebo 20 mg every other day in order to prevent early drug withdrawal due to side effects. After 2 weeks placebo will be increased to 20 mg once daily and this therapy will be continued during 12 months.
62414421|NCT01757873|EXPERIMENTAL|Z160|375 mg BID
62023440|NCT03074422|EXPERIMENTAL|Hypsnosis|During the fixation of the stereotactic frame, a single hypnosis session is performed by a certified senior anesthesiologist. Blood pressure, heart rate and respiratory rate are continuously monitored by the mean of a regular scope. Pain perceived during and after the procedure is quantifies by the mean of the Visual Analogue Scale (VAS) questionnaire. An open, standardized question will be asked to participants concerning feelings and thoughts about the frame fixation. Answers will be audio recorded. A standardized perceived distress questionnaire (PDI-13) will be performed.
62414422|NCT01757873|PLACEBO_COMPARATOR|Placebo|matching placebo control
62023441|NCT03074422|NO_INTERVENTION|Control|Local anesthesia after clear and complete information of the procedure given the day prior to the surgery. In order to determine the pain perceived during the procedure, a VAS questionnaire will be used, directly after the frame disposal. The rest of the procédure is similar to the hypnosis group.
62023442|NCT00618514|ACTIVE_COMPARATOR|1|Bright Tip Laser Fiber - FDA-cleared study device
62023443|NCT00618514|ACTIVE_COMPARATOR|2|Standard bare tip Laser Fiber - Any commercially available laser device (the control)
62023444|NCT03171025|EXPERIMENTAL|Nivolumab, all patients|
62023445|NCT03706599|EXPERIMENTAL|Fever therapeutic education session|Therapeutic education session on fever
62023446|NCT03706599|PLACEBO_COMPARATOR|Control therapeutic education session|Control therapeutic education session (on household accidents)
62023447|NCT06634511|EXPERIMENTAL|Core stability exercise group|Group A: core stability exercise group:15 Patients assigned to this group will undergo a core stability exercises.2times per week /8weeks.in addition to traditional physical therapy program
62023448|NCT06634511|EXPERIMENTAL|aerobic exercise group|Group B:(aerobic exercise group) 15 patients will receive aerobic exercise in the form of treadmill for 30 minutes2 session per week/8 weeks
62414423|NCT06006169|EXPERIMENTAL|Study treatment|Participants receive BL-B01D1, SI-B003 or BL-B01D1 + SI-B003 therapy in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
62795836|NCT06018948|ACTIVE_COMPARATOR|Dexmedetomidine 0.6 group|patients will receive a bolus dose of 1µg/kg dexmedetomidine15 minute after endotracheal intubation over 10 minutes followed by continuous infusion of 0.6 mic/kg/hour for one hour.
62795837|NCT06018948|ACTIVE_COMPARATOR|Dexmedetomidine 0.3group|patients will receive a bolus dose of 1µg/kg dexmedetomidine 15 minute after endotracheal intubation over 10 minutes followed by continuous infusion of 0.3 mic/kg/hour for one hour.
62795838|NCT06018948|PLACEBO_COMPARATOR|Control group|Patients will receive comparable volume of normal saline (0.9%) 15 minute after endotracheal intubation.
62587165|NCT01651520|EXPERIMENTAL|primary progressive patients < 10 years|primary progressive patients \< 10 years
62587166|NCT01651520|OTHER|healthy volunteers|healthy volunteers
62587167|NCT02266719|EXPERIMENTAL|Fenestrated CMD cohort|Patients enrolled in this arm will be implanted with the custom made fenestrated device. The device is aimed to treat complex abdominal aortic aneurysms including juxtarenal, suprarenal and type IV thoracoabdominal aneurysms.
62587168|NCT02266719|EXPERIMENTAL|Type I - III TAAA cohort|Patients enrolled in this arm will be implanted with the custom made/ off-the-shelfp branched devices. The device is aimed to treat type I-III TAAAs.
62587169|NCT02266719|EXPERIMENTAL|Arch cohort|Patients enrolled in this arm will be implanted with patient-specific stent-grafts with one to three inner branches or a scallop.
62587170|NCT05838365|EXPERIMENTAL|Immediate loading zirconia implant|Loading of zirconia dental implant within 7 days after implant placement
62587171|NCT05838365|ACTIVE_COMPARATOR|Delayed loading zirconia implant|Loading of zirconia dental implants after at least 2 months of healing
62795839|NCT04438317|ACTIVE_COMPARATOR|Seldinger Technique|Small bore chest tubes inserted by Seldinger technique. A needle is inserted into the intercostal space, and the aspiration of a fluid allows the confirmation the correct position, possibly after ultrasound tracking. A metal guidewire is inserted through the needle, which is then removed. A dilator is then inserted on the metal guidewire to dilate the skin and the subcutaneous tissues. The chest tube is finally inserted on the guide, which is finally removed, and the chest tube is connected to the aspiration system after fixation to the chest wall.
62414424|NCT05013749|ACTIVE_COMPARATOR|Hysterectomy|Hysterectomy: An incision will be made above the level of the placenta, delivering the newborn. Uterotonics will be administered, and spontaneous delivery of the placenta will be awaited using gentle traction. The absence of spontaneous separation of the placenta will confirm the diagnosis of PAS, the patient will undergo to hysterectomy. The complete removal of the uterus will be attempted, including the cervix, the duration of the intervention and intraoperative blood loss will be recorded, as well as the damage to organs neighboring the uterus. In this arm of the study, to hysterectomy will be performed in 100% of patients
62023449|NCT06634511|EXPERIMENTAL|traditional physical therapy group|Group C(conventional group): 15 patients will receive Infrared radiation (using BL 220 Infrared lamp, MT03009201 model) for 15 minutes, Transcutaneous Electrical Nerve stimulation (using model DX66053, pain modulation mode) for 10 minutes, Participants were treated twice weekly
62023450|NCT06535217||DGF|patients occured delayed graft function after liver transplantation
62219889|NCT01959997|ACTIVE_COMPARATOR|PVI + RDN|"All patients who are randomized to Group II will undergo redo PVI exactly as described above.~At the conclusion of PVI, RDN will be performed. Real-time 3-dimensional aorta-renal artery maps will be constructed with the use of the same navigation system and catheter used for PVI after femoral artery access. Both mapping and ablation will performed under the same modified sedation. RF ablations of 8 to 10 watts will be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium, for 2 min, and up to 6 lesions (separated by ≥ 5 mm). Lesions will be made both longitudinally and rotationally within each renal artery. To confirm renal denervation, high-frequency stimulation (HFS) will be used before the initial and after each RF delivery within the renal artery. RDN will be considered to have been achieved when the sudden increase of blood pressure (≥ 15 mm Hg from invasive arterial monitoring) is absent."
62219890|NCT02217124|EXPERIMENTAL|Apple group|twenty four participants will be randomly selected for the apple group, in which they will receive 37.5 grams equal to 120kcal of dried apples twice a day for eight weeks. This snack of apples will be eaten once between breakfast and lunch and once between lunch and dinner and both will be consumed with an eight ounce bottle of water.
62219891|NCT02217124|PLACEBO_COMPARATOR|Muffin control|twenty four participants will be randomly selected to make up the muffin control group, in which one 120kcal muffin control snack will be consumed twice each day for eight weeks. The muffin control will be consumed one between breakfast and lunch and one between lunch and dinner, each snack will be consumed with an eight ounce bottled water.
62219892|NCT04054518|EXPERIMENTAL|Durvalumab|1500 mg durvalumab (MEDI4736) via IV infusion Q4W \<\<for up to a maximum of 12 months (up to 13 doses/cycles) with the last administration on week 48\>\> or \<\<until confirmed disease progression\>\> unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
62219893|NCT06605495|ACTIVE_COMPARATOR|Chinese Medicine External Treatment Group|
62587172|NCT04370756|ACTIVE_COMPARATOR|Ex only|Participants will perform 8 weeks of supervised exercise training (EX).
62587173|NCT04370756|EXPERIMENTAL|EX + BR|Participants will perform 8 weeks of supervised exercise training (EX) plus pre-exercise consumption of beetroot juice (BR).
62219894|NCT06605495|EXPERIMENTAL|Chinese Medicine Internal Treatment Group (Oral Herbal Medicine)|
62587174|NCT06288360|EXPERIMENTAL|Neoadjuvant chemotherapy plus camrelizumab (NACI)|Patients first received one cycle of platinum-based doublet priming chemotherapy. After 3 weeks, participants received two cycles of the PD-1 inhibitor camrelizumab combined with chemotherapy every 3 weeks. Patients with stable disease or progressive disease received concurrent chemoradiotherapy, and patients with a complete response or partial response proceeded to radical surgery.
62414425|NCT05013749|ACTIVE_COMPARATOR|Partial myometrial resection|Partial myometrial resection: The technique described by Palacios-Jaraquemada et al5. will be followed. Briefly, the uterus will be dissected to free it from the posterior wall of the bladder to the cervix. The vesicouterine vessels will be ligated and the parametrial space will be visualized. The hysterotomy will be performed in the upper segment, immediately above the area of invasion of the myometrium. The entire invaded myometrium and the entire placenta will be removed. The uterus will repair itself in one or two layers. Intrauterine balloon tamponade will be used if indicated.
62219895|NCT06605495|ACTIVE_COMPARATOR|Western medicine treatment group|
62023451|NCT06535217||non-DGF|patients NOT occured delayed graft function after liver transplantation
62023452|NCT04459611|EXPERIMENTAL|sintilimab+chemotherapy(2 cycles of neoadjuvant chemotherapy)|Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the second dose of sintilimab; Followed by 2 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.
62219896|NCT05790577|ACTIVE_COMPARATOR|Metformin 30% and 2% Nicotinamispde|Metformin 30% plus Nicotinamide 2% in the reatment of Melasma
62219897|NCT05790577|ACTIVE_COMPARATOR|Kligman formula|Kligman formula in the treatment of Melasma
62587175|NCT02115581|EXPERIMENTAL|Coenzyme Q10|"Known cases of idiopathic dilated cardiomyopathy who received supplementation of coenzyme Q10 as a part of their medical regimen.~Dosage administered: 2 milligram/kilogram/day in 2 or 3 divided doses, these being increased to the maximum dose of 10 milligram/kilogram/day according to tolerance or the appearance of sideeffects."
62795840|NCT04438317|ACTIVE_COMPARATOR|Surgical-like Technique|Large bore chest tube inserted by surgical-like technique. Progressive chest wall dissection is conducted with appropriate instruments (scissors, scalpel, clamps...) by a non-surgeon physician. Large bore drain with rigid introductor is blindly inserted in the pleural cavity, secured to the chest wall with suture fixation and further connection to the aspiration system.
62795841|NCT02828475||CALYPSO-augmented|Patients' postoperative care will be augmented with the CALYPSO platform.
62219898|NCT05462886|EXPERIMENTAL|Masimo INVSENSOR00057|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive Masimo INVSENSOR00057 device.
62795842|NCT02828475||Historical Control|Patients' postoperative care was performed using standard practice, before adopting the CALYPSO platform
62795843|NCT03357536|EXPERIMENTAL|Patients with Listeriosis|"Patients with Listeriosis.~Human biological samples :~* Blood sample~* Skin biopsy~* Saliva"
62795844|NCT03357536|EXPERIMENTAL|Volunteers related with patients with Listeriosis|"Volunteers related with patients with Listeriosis.~Human biological samples :~* Blood sample~* Skin biopsy~* Saliva"
62795845|NCT01107314||trauma patient|SBP less than 90mmHg
62219899|NCT03420170|EXPERIMENTAL|Graded Exercise Integrated Education|"The graded exercise (8 weeks)~1. Strengthening exercise~2. Aerobic Exercise~Educational session to increase exercise self-efficacy and physical activity level (16 weeks)"
62219900|NCT03420170|ACTIVE_COMPARATOR|Conventional physical therapy|Normal routine of physical therapy (8 weeks)
62219901|NCT00670345|EXPERIMENTAL|1|Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
62219902|NCT00670345|PLACEBO_COMPARATOR|2|Patients belonging to the control group will receive the same volume of saline infusions.
62219903|NCT05868902||Negative Cardiac PET|Participants without clinical significant findings for coronary ischemia on cardiac PET scan.
62219904|NCT05868902||Positive Cardiac PET|Participants with findings indicative of coronary ischemia on cardiac PET scan.
62219905|NCT01800032||Plexiform Neurofibroma|NF1 associated plexiform neurofibroma
62587176|NCT02115581|PLACEBO_COMPARATOR|Placebo|known cases of idiopathic dilated cardiomyopathy who received placebo
62587177|NCT04898764|NO_INTERVENTION|Healthy Volunteers|This study arm will only participate in part A of the study (Characterisation study) and thus will not receive the study drug. A maximum of 35 healthy volunteers will be included in this study arm.
62795846|NCT02246907|NO_INTERVENTION|Control Group|The control group will receive standard of care which includes recreational therapy and standard encouragement.
62795847|NCT02246907|OTHER|Exercise|Participants in this arm will receive standard of care plus exercise for the duration of their inpatient stay for induction chemotherapy.
62795848|NCT01441804|EXPERIMENTAL|24-Week treatment group|Genotype 1 chronic hepatitis C patients with IL28B CC Polymorphism and rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 20 weeks
62795849|NCT01441804|ACTIVE_COMPARATOR|48-Week treatment group|Genotype 1 chronic hepatitis C patients with IL28B CC Polymorphism and rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 44 weeks
62219906|NCT01800032||Optic Glioma|NF1 associated optic glioma
62219907|NCT00974376|EXPERIMENTAL|Gabapentin 1200mg/day|1200mg/day of gabapentin for 12 weeks given in conjunction with 12 weeks of manual-guided behavioral counseling.
62219908|NCT00974376|PLACEBO_COMPARATOR|Placebo|1200mg/day of placebo for 12 weeks given in conjunction with 12 weeks of manual-guided behavioral counseling.
62219909|NCT01458431|EXPERIMENTAL|Levobupivacaine|Continuous levobupivacaine subfascial infusion
62219910|NCT01458431|PLACEBO_COMPARATOR|NaCl|Continuous NaCl subfascial infusion
62219911|NCT00950794|ACTIVE_COMPARATOR|Hokunalin(tulobuterol) tape|Hokunalin(tulobuterol) tape: long-acting Beta2-agonist
62219912|NCT00950794|EXPERIMENTAL|Salmeterol(408DP-02)|Salmeterol(408DP-02)：long-acting Beta2-agonist
62219913|NCT00159133|EXPERIMENTAL|1|Early intervention with benzodiazepines in case of prodromal symptoms of an impending relapse
62219914|NCT00159133|ACTIVE_COMPARATOR|2|Early intervention with antipsychotics in case of prodromal symptoms of an impending relapse
62219915|NCT03732404|EXPERIMENTAL|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrin; 240 mOsm/L) in a dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
62219916|NCT03732404|PLACEBO_COMPARATOR|Placebo|The control group will receive plain water with the same volume and timing of treatment
62219917|NCT01415362|ACTIVE_COMPARATOR|Active tDCS|The subject will receive sessions of active tDCS remotely triggered by the EEG monitoring system each time seizure activity is detected during the 24-hour period.
62414426|NCT02392975|EXPERIMENTAL|Fast magnetic resonance imaging (Fast MR)|All subjects will undergo fast MR in addition to Computerized Tomography (CT) (the current criterion standard). Fast MR will be interpreted independently for research purposes by 2 blinded radiologists. Consensus interpretation will be compared to the clinical reading of the CT.
62414427|NCT02866370|EXPERIMENTAL|Nintedanib|Nintedanib (BIBF1120) 200mg twice daily PO, continuously
62414428|NCT02866370|ACTIVE_COMPARATOR|Chemotherapy|"Ovarian Cancer Patients:~Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days Topotecan (4mg/m2) IV Day 1, 8, 15 every 28 days~Endometrial Cancer Patients:~Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days Doxorubicin IV (60mg/m2) every 21 days~Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
62414429|NCT05917938|EXPERIMENTAL|Participants With Normal Hepatic Function|Participants with normal hepatic function will receive a single subcutaneous dose of 30 milligram (mg) of NNC0194-0499 on Day 1.
62414430|NCT05917938|EXPERIMENTAL|Participants With Mild Hepatic Impairment|Participants with mild hepatic impairment (Child Pugh Grade A) will receive a single subcutaneous dose of 30 mg of NNC0194-0499 on Day 1.
62414431|NCT05917938|EXPERIMENTAL|Participants With Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Grade B) will receive a single subcutaneous dose of 30 mg of NNC0194-0499 on Day 1.
62219918|NCT01415362|SHAM_COMPARATOR|Sham tDCS|The subject will receive sessions of sham tDCS remotely triggered by the EEG monitoring system each time seizure activity is detected during the 24-hour period.
62219919|NCT00370682|EXPERIMENTAL|T-DEN F17|Full Dose (0.5 mL) 0 and 6 months
62219920|NCT00370682|EXPERIMENTAL|T-DEN F19|Full Dose (0.5 mL) at 0 and 6 months
62219921|NCT00370682|PLACEBO_COMPARATOR|Placebo Comparator|0.5 mL sterile buffer at 0 and 6, subcutaneous injection
62219922|NCT06577285|ACTIVE_COMPARATOR|Intervention group I|Patients in the intervention group I will take zinc gluconate 50 mg (Now food company) 1 per day to increase zinc level with phytase supplement 176mg (800FTU) (Goodphyte company) 2 tablets per day to give the maximum absorption of zinc, both supplements will be given for 4 days before botulinum toxin injections.
62219923|NCT06577285|ACTIVE_COMPARATOR|Intervention group II|Patients in the intervention group II will take zinc gluconate 50 mg (Now food company) 1 per day to increase zinc level, 4 days before botulinum toxin injections.
62219924|NCT06577285|NO_INTERVENTION|Control group|Patients in the control group will receive the Botulinum toxin injections only.
62414432|NCT05917938|EXPERIMENTAL|Participants With Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Grade C) will receive a single subcutaneous dose of 30 mg of NNC0194-0499 on Day 1.
62219925|NCT05670015|ACTIVE_COMPARATOR|Glaucoma suspect group|Cases diagnosed as glaucoma suspect
62795850|NCT01574235||Curative or prophylactic Nivestim® treatment for FN|
62587178|NCT04898764|EXPERIMENTAL|Patients with long-term use of nasal decongestants|"A maximum of 100 patients with long-term use of nasal decongestants will be included in this study arm, for part A of the study (Characterisation study).~The investigators will consecutively recruit patients from part A (Characterisation study) into part B of the study (Intervention study) until a total of 35 patients completed all study-related visits of part B. During the intervention study, patients with long-term use of nasal decongestants will administer Mometasone furoate intranasally, two doses (50µg/actuation) in each nostril, twice daily (total daily dose of 400µg) during a 12 week period."
62023453|NCT04459611|EXPERIMENTAL|sintilimab+chemotherapy(3 cycles of neoadjuvant chemotherapy)|Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the third dose of sintilimab; Followed by 1 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.
62023454|NCT00366626|EXPERIMENTAL|1.|Naltrexone one capsule a day
62023455|NCT00366626|PLACEBO_COMPARATOR|2|One capsule a day match to naltrexone
62023456|NCT05013892|EXPERIMENTAL|NTS-WBRT (normal tissue sparing whole brain radiation therapy) + Memantine|"Participants will be randomly assigned to NTS-WBRT (normal tissue sparing whole brain radiation therapy) administration group and receive:~* NTS-WBRT for 5 days (Monday-Friday) for either 2 or 3 weeks.~* Memantine per standard of care, 1-2x daily for up to 24 weeks Specific participant administration schedules will be determined by study doctor"
62023457|NCT06350019|EXPERIMENTAL|Cases with erectile dysfunction of vascular origin|Penile revascularization surgery was performed in cases with erectile dysfunction of vascular origin. Penile color Doppler ultrasonography, corpus cavernosum electromyography and cavernosometry tests were performed on all cases in the preoperative period and at the 3rd postoperative month. Penile computed tomography angiography was performed at the 3rd postoperative month.
62587179|NCT01840150|EXPERIMENTAL|Treatment (NA-NOSE breath test)|Patients undergo breath sample collection for the NA-NOSE breath test at baseline (2 pre-treatment samples), and post-treatment samples at regularly scheduled follow up visits, for 2 years in the absence of disease progression.
62023458|NCT02536508|EXPERIMENTAL|BGF MDI (PT010) 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) (PT010, BGF MDI)
62023459|NCT02536508|EXPERIMENTAL|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate (GFF) metered dose inhaler (MDI) (PT003, GFF MDI)
62219926|NCT05670015|ACTIVE_COMPARATOR|Post-refractive surgery group|Cases had undergone refractive surgery
62219927|NCT06495372|EXPERIMENTAL|Experimental group|
62795851|NCT06513169|EXPERIMENTAL|Group 1: LEE|
62023460|NCT02536508|EXPERIMENTAL|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate (BFF) metered dose inhaler (MDI) (PT009, BFF MDI)
62023461|NCT05203029|EXPERIMENTAL|Aerobic exercises|The warm-up for 5 minutes; stretching exercises include stretching the neck to the sides, stretching the muscles of the shoulder girdle, back, and legs for 10 minutes; resistance exercises for 15 minutes, which will initially be applied in a light and weight-bearing manner, and in each session, according to the patient's progress, using free lightweights; light aerobic exercise for 10 minutes standing, sitting and lying down by controlling patients' heartbeat; cool down for 5 minutes.
62219928|NCT06495372|PLACEBO_COMPARATOR|control group|
62219929|NCT02047331|ACTIVE_COMPARATOR|group PI|group PI were performed periarticular drug injection during surgery.
62795852|NCT06513169|NO_INTERVENTION|Group 2: no LEE|
62795853|NCT03877211|EXPERIMENTAL|Cochlear implant users|Adult cochlear implanted patients wearing an Oticon Medical/Neurelec device will have speech audiometry test in noise, psychophysical tuning curves in forward masking and Electrically-evoked Auditory Brainstem Response (EABR) measurement
62795854|NCT03877211|ACTIVE_COMPARATOR|Normal-hearing subjects|Normal-hearing subjects will have speech audiometry test in noise, psychophysical tuning curves in forward masking, auditory canal examination and tonal audiometry
62795855|NCT00217217|EXPERIMENTAL|Active EEP-MRSI treatment|20 minutes of active treatment with theEcho-Planar Magnetic Resonance Imaging (EP-MRSI)
62795856|NCT00217217|SHAM_COMPARATOR|Sham comparator EP-MRSI|Sham treatment (20 minutes) with the Echo-Planar Magnetic Resonance Imaging (EP-MRSI).
62414433|NCT06362369|EXPERIMENTAL|Dose Escalation - Open Label Phase 1b|Alintegimod dose escalation, 3 cohorts Alintegimod monotherapy 1 cycle Alintegimod + Ipilimumab - 4 cycles Nivolumab - 11 cycles
62023462|NCT05203029|EXPERIMENTAL|Laughter yoga|Breathing techniques for 20 minutes including deep breathing, diaphragmatic breathing, tap on immune-boosting centers like thymus; laughter concert for 20 minutes such as laughter for no reason, childish movements, release the inner child; and laughter meditation for 5 minutes.
62023463|NCT05203029|ACTIVE_COMPARATOR|Yoga|Meditation and deep breathing for 10 minutes; physical posture for 15 minutes; 15 minutes relaxation exercises; and 5 minutes mindfulness practices.
62414434|NCT05760924|ACTIVE_COMPARATOR|Cardiac Resynchronization Therapy with Biventricular Pacing|Patients who are non-responders to biventricular cardiac resynchronization therapy (CRT) with indications to CRT devices with defibrillator function (CRT-D) or CRT-D leads replacement. CRT-D or CRT-D leads replacement will be performed in this group of patients.
62587180|NCT06566521|EXPERIMENTAL|TPVB group|After surgery and before extubation, the patient was positioned in an upper lateral position on the affected side. For patients in the TPVB group, an ultrasound high-frequency linear array probe was used to perform a mid-sagittal scan at the T8-9 spinous process interspace on the affected side. The probe was moved to visualize the T8-9 transverse process and pleura. Using the out-of-plane needling technique, the needle was inserted between the costotransverse ligament and the pleura in the paravertebral space adjacent to the thoracic vertebra. After confirmation of no blood or cerebrospinal fluid return, 30 mL of 0.5% ropivacaine hydrochloride was injected. Under ultrasound guidance, the spread of the medication and downdraft of the pleura could be observed.
62587181|NCT06566521|NO_INTERVENTION|control group|The patients in the control group did not undergo the nerve block procedure.
62023464|NCT02300883||no treatment|no treatment
62023465|NCT01813500||IBD Patients|Subjects with Crohn's Disease or Ulcerative colitis. IBD patients will be asked to provide a blood and stool sample.
62023466|NCT01813500||Control Subjects|Subjects without Crohn's Disease or Ulcerative Colitis. Controls will also be asked to provide a blood and stool sample.
62219930|NCT02047331|ACTIVE_COMPARATOR|group FI|group FI were performed fascia iliaca block before surgery
62219931|NCT04181684|EXPERIMENTAL|Experimental: LITT with Hypofractionated radiation therapy|Laser interstitial thermal therapy (LITT) followed by hypo-fractionated radiation therapy, 35Gy/10 fractions.
62587182|NCT05564195||Patients undergoing elective surgery with a duration of > 60 minutes|Participants included will be patients undergoing planned non-cardiac surgery with general anesthesia that are \>60 years of age, have a Mini-mental state examination score of \>24, are able to speak Swedish and does not suffer from uncorrected severe visual or auditory disorder, disease of the central nervous system, psychiatric diseases including alcoholism or drug dependence, current motor impairment in dominant hand, or colour-blindness.
62587183|NCT05856786||Ocular parameters|Patients aged 19 years or more who are scheduled to undergo refractive surgery will be included in the study. OCT will be performed at baseline (before surgery), 1 day after surgery and 1 week after surgery. Each patient will be tested 3 times.
62219932|NCT01962415|EXPERIMENTAL|UCBT:transfusion dependent anemias or increased rejection risk|Day -21 to -19: Alemtuzumab + Hydroxyurea; Day -18 to -10: Hydroxyurea; Day -9 to -5: Fludarabine + Hydroxyurea; Day -4 to -3: Melphalan; Day -2: Thiotepa; Day -1: Rest; Day 0: Transplant
62219933|NCT01962415|EXPERIMENTAL|BMT, PBSCT and not transfusion dependent UCBT|Start of conditioning to Day -15: Hydroxyurea; Day -14 to -13: Alemtuzumab + Hydroxyurea; Day -12 to -10: Hydroxyurea; Day -9 to -5: Fludarabine + Hydroxyurea; Day -4 to -3: Melphalan; Day -2: Thiotepa; Day -1: Rest; Day 0: Transplant
62219934|NCT05916339|ACTIVE_COMPARATOR|Stage 1 - Stimulant|"This proposed naturalistic, pragmatic clinical trial does not involve investigational drugs. Sequential, multiple assignment randomized trial (SMART) pragmatic clinical trial.~Stage 1 - randomization to either Amphetamine (AMP) or Methylphenidate (MPH). The specific medication prescribed by the physician will be determined by discussion between physician and parent / caregiver and review of the subject's insurance coverage. Subjects will receive their medication from their pharmacy."
62219935|NCT05916339|ACTIVE_COMPARATOR|Stage 2 - Alpha-2 Agonist or Alternate Stimulant|"Stage 2 - randomization to either Alpha-2 Agonist or other stimulant not randomized to in Stage 1: Amphetamine (AMP) or Methylphenidate (MPH).~(frequency, dosage, format, and duration dependent on participant and study doctor discussion)."
62587184|NCT00513383|EXPERIMENTAL|Part A|Determine the best dosing of panitumumab, chemotherapy and radiation.
62587185|NCT00513383|EXPERIMENTAL|Part B|Determine the best dosing of induction chemotherapy combined with panitumumab prior to receiving panitumumab and chemoradiotherapy.
62587186|NCT02012790|EXPERIMENTAL|Diet A|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
62587187|NCT02012790|EXPERIMENTAL|Diet B|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
62587188|NCT02012790|ACTIVE_COMPARATOR|Diet C|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
62587189|NCT05406115|EXPERIMENTAL|Part A: Single Ascending Dose Cohorts|Participants in 4 cohorts will receive either AMG 786 or placebo in Single Ascending Doses.
62023467|NCT03112616||Left-brain damaged chronic patients|
62023468|NCT03112616||Right-brain damaged chronic patients|
62023469|NCT04577144||Individuals who participated in the RECOVER study|Individuals who enrolled in the Remission from Chronic Opioid Use-Studying Environmental and Socio-Economic Factors on Recovery (RECOVER) study. Individuals who received at least one injection in a SUBLOCADE Phase III program were eligible to participate in the original study.
62587190|NCT05406115|EXPERIMENTAL|Part A: Food Effect Cohort|Participants in the food effect cohort (FEC) will receive 1 of 2 AMG 786 in 1 of two sequences. Participants in Sequence 1 will receive a dose of AMG 786 on day 1 under fed conditions followed by a 10-day washout period and another dose of AMG 786 on day 11 under fasted conditions. Participants in Sequence 2 in the FEC cohort will receive the first dose on day 1 under fasted conditions and the second dose on day 11 under fed conditions.
62795857|NCT04533529|EXPERIMENTAL|Seltorexant|Participants will receive seltorexant tablet orally once daily, from Day 1 to Day 42 in double blind (DB) treatment phase. Eligible participants who will enter the open label (OL) treatment phase will receive seltorexant tablet daily from OL baseline until the end of phase/ early withdrawal (EW) visit (Up to 1 Year).
62795858|NCT04533529|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo tablet orally once daily, from Day 1 to Day 42 in double blind (DB) treatment phase.
62023470|NCT05710068|EXPERIMENTAL|Conventional therapy with RF microneedle|Half face Oral tranexamic acid combined with triple combination cream with RF microneedle
62023471|NCT05710068|ACTIVE_COMPARATOR|Conventional therapy|Half face Oral tranexamic acid combined with triple combination cream
62023472|NCT06280365|EXPERIMENTAL|MWM group|Participants in group 2 will receive MWM technique treatment 3 times a week for 4 weeks. The patient should lie face down with a pillow over the knee and the physiotherapist should stand on the contralateral side for the application. The physiotherapist passes the belt around the waist to the patient's tibia edge. The knee is stabilized with one hand while the leg is supported with the other hand. The knee is moved medially without applying too much force through the belt and the patient is asked to stretch. If there is no pain, the movement is indicated. If pain occurs during the movement, the same procedure is performed for the lateral side by changing the position. It is important that the arch remains horizontal and does not cause rotation of the hip. The movement will be repeated 3 times at the point where there is no pain.
62023473|NCT06280365|NO_INTERVENTION|Control Group|"Participants in group 1 will receive conservative treatment 3 times a week for 4 weeks. Conservative treatment includes hot packs and traditional transcutaneous electrical nerve stimulation (TENS), an electrotherapy.~All participants in the study will receive 20 minutes of hot pack application to the knee area each session by a physiotherapist. All participants in the study will receive TENS for 20 minutes each session from the physiotherapist, who will place personalized electrodes around the knee joint and adjust the current to the level the person can tolerate."
62023474|NCT05046457|EXPERIMENTAL|3mg BCX supplement|One 3mg BCX capsule + one placebo capsule to be taken once per day for 8 weeks
62414435|NCT05760924|EXPERIMENTAL|Cardiac Resynchronization Therapy with Left Bundle Branch Pacing|Patients who are non-responders to biventricular cardiac resynchronization therapy (CRT) with indications to CRT devices with defibrillator function (CRT-D) or CRT-D leads replacement. CRT-D or CRT-D leads replacement with the new lead implantation to the left bundle branch and inactivation of conventional right and left ventricular pacing will be performed in this group of patients.
62587191|NCT05406115|EXPERIMENTAL|Part B: Multiple Ascending Dose Cohorts|Participants in 4 cohorts will receive either AMG 786 or placebo in Multiple Ascending Doses.
62795859|NCT06553495|EXPERIMENTAL|intertransverse nerve block|To study the analgesic effect of intertransverse nerve block after endoscopic hepatectomy
62795860|NCT06553495|PLACEBO_COMPARATOR|paravertebral nerve block|To study the analgesic effect of paravertebral nerve block after endoscopic hepatectomy
62795861|NCT01922271|EXPERIMENTAL|NVA237 followed by tiotropium|Period 1: NVA237 plus placebo to tiotropium on day 1, followed by a 7 day washout. Period 2: tiotropium plus placebo to NVA237 on day 8. Salbutamol was used as rescue medication.
62795862|NCT01922271|EXPERIMENTAL|Tiotropium followed by NVA237|Period 1: tiotropium plus placebo to NVA237 on day 1, followed by a 7 day washout. Period 2: NVA237 plus placebo to tiotropium on day 8. Salbutamol was used as rescue medication.
62219936|NCT06609798||Adult patients during the period of weaning from mechanical ventilation|"Adult patients (age ≥18 years) who have been on invasive mechanical ventilation via an endotracheal tube for at least 48 hours and are eligible to begin a spontaneous breathing trial in T-tube mode will be included.~Cardiac, diaphragmatic, and pulmonary ultrasound measurements will be performed between 20 and 30 minutes after the start of the spontaneous breathing trial. The ultrasound sequence includes: 1) modified Lung Ultrasound Score (LUS), 2) left ventricular systolic function assessed by MAPSE, 3) right ventricular systolic function assessed by TAPSE, 4) left ventricular diastolic function via E/e' ratio, 5) diaphragmatic excursion, and 6) diaphragmatic thickening fraction."
62219937|NCT04482686|EXPERIMENTAL|Active Arm|Patients will be treated with a combination of Ivermectin, Doxycycline, Zinc, Vitamin D3 and Vitamin C
62587192|NCT02239133|EXPERIMENTAL|ProVATE vaginal pessary|"The ProVATE device is a disposable, single-use, vaginal pessary for the management of Pelvic Organ Prolapse (POP). The ProVATE device is similar to other ring pessaries currently on the market. Its features allow for easy and comfortable insertion and removal by the user herself at her home environment. The ProVATE device is provided in six (6) different sizes and is intended for prescription use only."
62795863|NCT05176236|EXPERIMENTAL|Pictographic group|Participants received the pictographic handouts on tracheostomy care
62795864|NCT01041313|ACTIVE_COMPARATOR|Opiate Naive|Subjects who have not taken opiate medication in previous 6 weeks before surgery
62795865|NCT01041313|ACTIVE_COMPARATOR|Opiate tolerant|Subjects who have taken opiate medications for the 6 weeks before surgery
62023475|NCT05046457|EXPERIMENTAL|6mg BCX supplement|Two 3mg BCX capsules to be taken once per day for 8 weeks
62023476|NCT05046457|PLACEBO_COMPARATOR|0mg BCX supplementation|Two placebo capsules to be taken once per day for 8 weeks
62023477|NCT05213845|OTHER|Patients with chronic low back pain|
62023478|NCT04336202|OTHER|External beam radiotherapy + Endorectal brachytherapy|In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
62023479|NCT05842057|EXPERIMENTAL|Membrane Arm: dHACM Group|Participants will undergo standard of care robot-assisted radical prostatectomy (RARP) surgery and the dehydrated Human Amnion Chorion Membrane (dHACM) membrane placed after removal of the prostate. Participants will be in the group for approximately 12 months.
62023480|NCT05842057|OTHER|Control Arm: No dHACM Group|Participants will undergo standard of care RARP surgery but will have no dehydrated Human Amnion Chorion Membrane (dHACM) placed after removal of the prostate. Participants will be in the group for approximately 12 months.
62023481|NCT05780645|EXPERIMENTAL|Cohort 1|"Regimen A: Participants will receive Dose B (3 x Dose A) ALXN2050 IR Tablet orally under fasted conditions.~Regimen B: Participants will receive Dose C ALXN2050 MR Prototype Tablet orally under fasted conditions.~Optional Regimens C, D, E, and F"
62414436|NCT05760924|EXPERIMENTAL|Cardiac Resynchronization Therapy with Combined Left Bundle Branch and Left Ventricular Pacing|Patients who are non-responders to biventricular cardiac resynchronization therapy (CRT) with indications to CRT devices with defibrillator function (CRT-D) or CRT-D leads replacement. CRT-D or CRT-D leads replacement with the new lead implantation to the left bundle branch and inactivation of conventional right ventricular pacing will be performed in this group of patients.
62414437|NCT03026868|EXPERIMENTAL|quadrilateral surface plate|The fragments of the acetabulum were fixed with novel quadrilateral surface plate through Stoppa approach.
62023482|NCT05780645|EXPERIMENTAL|Cohort 2|"Regimen G: Participants will receive Dose B (3 x Dose A) ALXN2050 IR Tablet orally under fasted conditions.~Regimen H: Participants will receive Dose C ALXN2050 MR Prototype Mini-Tablet orally under fasted conditions.~Optional Regimens: I, J, K, and L"
62023483|NCT02040597|EXPERIMENTAL|CHF5993 pMDI|CHF 5993 pMDI (Beclometasone/Formoterol/Glycopyrrolate 100/6/25 mcg) 4 inhalations
62219938|NCT04482686|PLACEBO_COMPARATOR|Placebo|Placebo and Vitamin D3, Vitamin C, and Zinc
62219939|NCT04602273||High Risk MDS|New diagnosed patients treated with Azacitidine 75 mg/sqm SC QD on a 28 days based cycles (both 7-0-0 and 5-0-2 regimens are allowed) until disease progression, unacceptable toxicity, death or investigator decision
62219940|NCT02614417||Polysomnography|Patients undergo an one-night in-hospital polysomnography to diagnose sleep-disordered breathing
62219941|NCT00297336||001|
62219942|NCT05816265|EXPERIMENTAL|IV Iron Infusion Group|Subjects will receive iron infusion 1 week after enrollment. Dosage of iron will be at discretion of physicians
62414438|NCT01388101|EXPERIMENTAL|LECT2 detection|single-arm study: Electrosensing antibody probing system(e-AB sensor)
62414439|NCT01396980||dialysis patients|dialysis patients, stabil, dialysis dependancy for more than 3 months, with adequate access
62414440|NCT06599047||Non-Obese Group (Lean)|Healthy participants without obesity
62414441|NCT06599047||Bariatric Patients without Diabetes|Participants with obesity undergoing bariatric surgery
62414442|NCT06599047||Bariatric surgery patients with diabetes|Participants with diabetes undergoing bariatric surgery
62414443|NCT05339542|EXPERIMENTAL|Platelet rich plasma group|"platelet rich plasma (PRP) will be produced through whole blood centrifuge using a specific methodology in a strict aseptic setting. Then, blood will be collected and mixed with anticoagulant and Citrate-phosphate-dextrose adenine in a 10 volume blood to 1 volume anticoagulant ratio. The blood will be centrifuged for 10 minutes at 1000 rpm. Afterward, the plasma will be transferred to a new glass tube and centrifuged for 15 minutes at 3000 rpm. At the bottom of the tube, platelets will form a pellet. Finally, pure platelet-rich plasma will be obtained at a concentration of up to four times higher than baseline. Prior to the injection, calcium gluconate will be combined with PRP (at a ratio of 0.3 ml ca gluconate/ml PRP).~The injection will be done once."
62414444|NCT05339542|ACTIVE_COMPARATOR|Methylprednisolone group|"2 ml methylprednisolone acetate 40mg/ml (total 80mg methylprednisolone acetate) together with 1 ml lidocaine 2% (total 3 ml solution) will be directly injected under ultrasound guidance to the plantar fascia.This group serves as active comparative group.~The injection will be done once."
62219943|NCT05816265|NO_INTERVENTION|Control Group|Subjects will not receive iron replacement infusion.
62219944|NCT05318547|EXPERIMENTAL|standard-gamble technique|"Participants will be asked to imagine a scenario in which they are experiencing one of the 4 described conditions in the long-term. They will declare their preference between (a) keeping this long-term condition as is, or using a painless hypothetical cure that is associated with some risk of death, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision whether to take the treatment or not. The utility will be calculated as 1 - the obtained risk of death of the point of equipoise. Health states will be evaluted in different orders across participants.~The elicitation of health state utilites by the standard-gamble technique is further clarified."
62219945|NCT05318547|EXPERIMENTAL|time trade-off technique|Participants will be asked to declare their preference between 50 years of life with the symptoms of 1 of the conditions, or 50-X years without these symptoms, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision on the preference of the 2 choices. The utility will be calculated as the 50-x/50 obtained at this point of equipoise. Health states will be evaluted in different orders across participants.
62219946|NCT02857569|EXPERIMENTAL|Experimental IT Arm|"* ipilimumab: 0.3mg/kg IT injection every 3 weeks until complete response, eradication of all injectable sites, disease progression or toxicity, for a maximum of 4 doses (to compare back to back to IV standard of care and marketing authorization).~* nivolumab: 1mg/kg, IV injection every 3 weeks during IT ipilimumab treatment period and 3mg/kg, IV injection every 2 weeks after IT ipilimumab treatment interruption. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient for a maximum of 12 months."
62219947|NCT02857569|ACTIVE_COMPARATOR|Standard Arm|"* ipilimumab: 3mg/kg, IV injection every 3 weeks for a maximum of 4 doses as per standard of care and marketing authorization.~* nivolumab: 1mg/kg, IV injection every 3 weeks during IV ipilimumab treatment period and 3mg/kg, IV injection every 2 weeks after IV ipilimumab treatment interruption. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient for a maximum of 12 months."
62219948|NCT05074927|OTHER|Cohort|All patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France)
62219949|NCT02192125|EXPERIMENTAL|REWIRE-System|The training system consists of a so-called Tymoplate® (Tyromotion, Austria), a medical device class 1 with CE certification and approval by the FDA for use in neurorehabilitation after stroke. The Tymoplate® is connected to a computer and allows by means of a base plate with integrated pressure sensors and custom-developed training software different postural biofeedback exercise.
62219950|NCT06233825|EXPERIMENTAL|Nutritional Intervention|5 g omega-3 fatty acids (3.75 g eicosapentaenoic acid \[EPA\] + 1.25 g docosahexaenoic acid \[DHA\]) per day for 6 weeks, starting 4 weeks before and continuing 2 weeks after surgery, plus 40 g (2 x 20 g) of EAA per day, starting 1 week before and continuing 2 weeks after surgery.
62219951|NCT06233825|PLACEBO_COMPARATOR|Placebo Control|5 g safflower oil per day for 6 weeks, starting 4 weeks before and continuing 2 weeks after surgery, plus 40 g (2 x 20 g) of NEAA per day, starting 1 week before and continuing 2 weeks after surgery.
62219952|NCT02802254|EXPERIMENTAL|Pedometer+physical-activity-feedback|At cardiac consultation patients receive a patient-targeted individual physical-activity-feedback.
62219953|NCT02802254|ACTIVE_COMPARATOR|Pedometer-only|Patients use a Pedometer in order to measure their daily step number
62219954|NCT01134120|EXPERIMENTAL|LY2784544|
62023484|NCT06536283||Opiophobia in Postsurgical Adults|Participants that agree to take part in this study, partiicpants will have a virtual visit, via Zoom, about 7 days after you are discharged from the hospital. The visit will take about 20 minutes, and you will meet with a member of the research team to complete several questionnaires.
62023485|NCT03691038|ACTIVE_COMPARATOR|Pregabalin 75mg bid|The patients who were prescribed according to the conventional flexible dose regimen
62023486|NCT03691038|EXPERIMENTAL|pregabalin 25mg,50mg|The patients who were prescribed according to the new flexible dose regimen.
62414445|NCT06253585|EXPERIMENTAL|EHR Alert|Enrolled patients who are classified to Group D by the algorithm will be randomized within the electronic health record to the intervention arm.
62414446|NCT06253585|ACTIVE_COMPARATOR|Standard of Care|Enrolled patients who are classified to Group D by the algorithm will be randomized within the electronic health record to usual care.
62414447|NCT06702475||pregnant with pre-eclampsia at altitude (Cohort 1)|"Pregnant women at High Country Obstetric Clinic in Summit County Colorado (about 9000 ft.) who develop pre-eclampsia.~Home sleep testing with Watch PAT-one will be done soon after diagnosis of pre-eclampsia.~Up to 20 in this cohort"
62414448|NCT06702475||healthy pregnant women at altitude (Cohort 2)|"Pregnant healthy women at High Country Obstetric Clinc in Summit County Colorado will also be studied with the Watch PAT-one home sleep test..~Up to 20 will be chosen to match the subjects, 1 by 1, in cohort 1, regarding gestational time of the home sleep test, and match age, pre-pregnant BMI, and race as best as available of the volunteered subjects. Up to another 20 pregnant healthy women at altitude may be recruited, not matching a subject in cohort 1, to have Watch PAT-one home sleep testing in the 33rd to 34th week of pregnancy."
62414449|NCT06702475||healthy pregnant women at sea level (Cohort 3)|Up to 40 healthy pregnant women at sea level, in vicinity of Baltimore, will be recruited to have Watch PAT-one home sleep testing, matching the subjects in cohort 2 regarding gestational time of testing, Race, Age and pre-pregnant BMI as best as available.
62414450|NCT06319573|ACTIVE_COMPARATOR|Standard Counseling|Patients in this group will be counseled as per standard care during their second consultation. They will be asked to complete an anonymous online validated questionnaire (see below) to assess their responses to the anonymous online questionnaire after consultation.
62414451|NCT06319573|EXPERIMENTAL|Counseling Supported by Univfy® Report|Patients in this group will be counseled with the Univfy® PreIVF report during their second consultation. They will also be asked to fill out the same anonymous online questionnaire.
62219955|NCT03518827||Athletes|For Asymmetry measurement, the group will consist of 200 athletes of different sports (the proportion not strictly predefined) - track and field, racket sports, ball sports, other team sports, swimming, running, cycling, dancing, ice skating, etc.
62795866|NCT04400565|EXPERIMENTAL|Recovery group|The recovery program has 2 phases and consists of 20 classes, 1.5 hour per class and one class per week. We will introduce concepts of recovery and personal strengths in phase 1. Then, we will help participants to set goals and implement their plans in phase 2. Participants will fill out all questionnaires during the recruitment meeting.They will fill out the same questionnaires plus the course satisfaction survey in the end of phase 1 and 2. Six months later, participants will receive a follow-up interview and fill out the questionnaires again.
62795867|NCT04400565|NO_INTERVENTION|Control group|The control group will receive a spiritual book and complete the questionnaires at the same time as the recovery group.
62219956|NCT03095001|EXPERIMENTAL|Intraperitoneal bevacizumab+ carboplatin|"Intraperitoneal administration: intraperitoneal bevacizumab plus carboplatin every 3 weeks for 4-6 cycles~Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles"
62219957|NCT03095001|ACTIVE_COMPARATOR|Intraperitoneal carboplatin|"Intraperitoneal administration: intraperitoneal carboplatin every 3 weeks~Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles"
62795868|NCT04270708|EXPERIMENTAL|Dexmedetomidine|Intranasal Dexmedetomidine 3mcg/kg
62795869|NCT04270708|ACTIVE_COMPARATOR|Triclofos|Oral Triclofos Sodium 50mg/kg
62795870|NCT06364228|PLACEBO_COMPARATOR|Intranasal Spray Placebo|Nasal Spray of placebo liquid solution as 2 puffs of daily dose (every morning) for 3 weeks. fMRI scan pre and post-administration.
62795871|NCT06364228|ACTIVE_COMPARATOR|Oxytocin Intranasal Spray 12 International Unit (IU)|Nasal spray of Oxytocin 12 International Unit (12IU) liquid solution as 2 puffs of daily dose (every morning) for 3 weeks. fMRI scan pre and post administration.
62795872|NCT06364228|ACTIVE_COMPARATOR|Oxytocin Intranasal Spray 24 International Unit (IU)|Nasal spray of Oxytocin 24 International Unit (12IU) liquid solution as 2 puffs of daily dose (every morning) for 3 weeks. fMRI scan pre and post administration.
62795873|NCT01453010|EXPERIMENTAL|8 individual case reviews|SaeboFlex Self-directed training
62795874|NCT02326597|ACTIVE_COMPARATOR|Standard Practice|Participants will receive education regarding treatment consideration from their healthcare provider/team as per standard practice (usual care).
62795875|NCT02326597|EXPERIMENTAL|Standard Practice + Decision Aid|Participants will receive standard of care teaching and discussion in addition to web-based decision aid tool access.
62414452|NCT02046239|OTHER|Staple Group|Staple Group: At the end of the operation, the skin will be closed using stainless steel staples, which is standard clinical practice at St. James's University Hospital. Approximately ten days after the operation, the staples will be manually removed; this is normally performed by the patients GP.
62414453|NCT02046239|EXPERIMENTAL|Suture Group|Suture Group: At the end of the operation, the skin will be closed using absorbable surgical suture. Manual removal of this suture is not required because the thread is self-absorbable.
62795876|NCT02306798|EXPERIMENTAL|Formulation D|TP05
62795877|NCT06725784|EXPERIMENTAL|ReHandyBot|The therapy sessions with ReHandyBot (e.g., frequency, duration) will be scheduled based on the therapist's instruction and may vary between patients, depending on their specific needs.
62795878|NCT06726096|EXPERIMENTAL|Injection of recombinant humanized monoclonal antibody against interleukin-6 receptor6mg/kg|
62795879|NCT06726096|PLACEBO_COMPARATOR|placebo control|
62219958|NCT00095420|EXPERIMENTAL|1|Participants with autism will receive social skills training targeting children with autism
62219959|NCT00095420|EXPERIMENTAL|2|Participants without autism will receive social skills training to increase acceptance of peers with autism
62219960|NCT00095420|EXPERIMENTAL|3|Participants with and without autism will receive a combination treatment of social skills/education about autism
62219961|NCT00095420|ACTIVE_COMPARATOR|4|Participants with and without autism will receive usual training provided by their school district
62219962|NCT03196154||Metformin|Patients who are on either metformin 2g per day or metformin extended release 2g per day. Subject will be required to fast overnight. Fasting insulin levels and plasma drug levels will be measured.
62795880|NCT06726096|ACTIVE_COMPARATOR|Tocilizumab Injection8mg/kg|
62795881|NCT03943641||Population-based|Population-based cohort of participants registered with a SAIL-contributing practice.
62795882|NCT01810003|EXPERIMENTAL|High DHA|High DHA supplementation (3g/day)
62795883|NCT01810003|EXPERIMENTAL|High EPA|EPA supplementation (3g/day)
62795884|NCT01810003|PLACEBO_COMPARATOR|Placebo|Placebo (3g corn oil/day)
62795885|NCT01428908|EXPERIMENTAL|children group A|600 children aged 2-5 years old, will be vaccinated on day0
62795886|NCT01428908|EXPERIMENTAL|infants group A|600 infants aged 6-23 months old, will be vaccinated on day0, 28
62795887|NCT01428908|ACTIVE_COMPARATOR|children group B|600 children aged 2-5 years old, will be vaccinated on day0
62795888|NCT01428908|ACTIVE_COMPARATOR|infants group B|600 infants aged 6-23 months old, will be vaccinated on day0, 28
62795889|NCT01438658||All|A cohort of all the patients.
62795890|NCT03742973|EXPERIMENTAL|Baricitinib Cohort A|Participants received 2 milligram (mg) of Baricitinib tablet orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.
62795891|NCT03742973|PLACEBO_COMPARATOR|Placebo Cohort A|Participants received placebo orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.
62795892|NCT03742973|EXPERIMENTAL|Baricitinib Cohort B|Participants received 4 mg of Baricitinib orally once a day for 12 weeks. Cohort B was planned, but due to enrollment futility, the strategic decision was made to terminate the study.
62795893|NCT03742973|PLACEBO_COMPARATOR|Placebo Cohort B|Placebo administered orally. Cohort B was planned, but due enrollment futility, the strategic decision was made to terminate the study.
62795894|NCT00554450|EXPERIMENTAL|Arm 1|50 mg single dose
62795895|NCT00554450|EXPERIMENTAL|Arm 2|20 mg up to 7 days
62219963|NCT03196154||Metformin + Gliclazide|Patient who are on both metformin 2g per day or metformin extended release 2g per day and gliclazide 320mg per day or gliclazide modified release 120mg per day. Subject will be required to fast overnight. Fasting insulin levels and plasma drug levels will be measured.
62795896|NCT05314465|EXPERIMENTAL|Median nerve mobilization|Experimental arm given Median nerve mobilization for 12mins 3sets for 3mins each with 1 minute interval in between for 5times a week for 4weeks
62795897|NCT06725602|ACTIVE_COMPARATOR|TQ1 (CAT)|Application of CAT tourniquet
62795898|NCT06725602|ACTIVE_COMPARATOR|TQ2 (T-APH)|Application of T-APH tourniquet
62795899|NCT06725602|ACTIVE_COMPARATOR|TQ3 (SOF)|Application of SOF tourniquet
62795900|NCT01870115|PLACEBO_COMPARATOR|Fiber pill|2 plant fiber pills taken p.o. (by mouth) nightly for one year
62795901|NCT01870115|ACTIVE_COMPARATOR|strontium/melatonin/Vitamins K2 and D3|2 pills taken p.o. (by mouth) nightly for one year. Each pill contains strontium citrate (225 mg), melatonin (2.5 mg), Vitamin K2 (MK7) (30 mcg) and Vitamin D3 (1000 IU)
62795902|NCT02563236|EXPERIMENTAL|Parabolic flight and Augmented Reality interface alignments|
62795903|NCT00380731|EXPERIMENTAL|1|Participants will receive immediate cognitive behavioral therapy
62795904|NCT00380731|EXPERIMENTAL|2|Participants will receive cognitive behavioral therapy with a 16-week delayed start
62795905|NCT06514547|EXPERIMENTAL|Pneumococcal Vaccination|All participants will receive a pneumococcal vaccine.
62795906|NCT03275324||Enrolled patients|Surgical patients meeting enrollment criteria
62795907|NCT03271502|EXPERIMENTAL|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
62795908|NCT03271502|ACTIVE_COMPARATOR|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
62219964|NCT01134536|EXPERIMENTAL|Tapentadol Oral Solution (OS)|
62219965|NCT02121301|EXPERIMENTAL|Low Dose SkQ1|Drug: Low Dose 0.155µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
62414454|NCT05560230|EXPERIMENTAL|Clonidine|A 100 ml isotonic saline will be mixed with 1 ml clonidine (150 μg). The blinded 100 ml bag including isotonic saline and clonidine 150 μg will be infused over 5-10 min., immediately after intubation.
62219966|NCT02121301|EXPERIMENTAL|High Dose SkQ1|Drug: High Dose 1.55µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
62219967|NCT02121301|PLACEBO_COMPARATOR|Placebo (vehicle)|Drug: Placebo (vehicle) ophthalmic solution administered twice daily for 28 days
62219968|NCT01587391|EXPERIMENTAL|BI 163538 XX|1 single dose per subject as oral solution
62414455|NCT05560230|PLACEBO_COMPARATOR|Isotonic saline|A 100 ml isotonic saline will be mixed with 1 ml isotonic saline. The blinded 100 ml bag including isotonic saline will be infused over 5-10 min., immediately after intubation.
62414456|NCT01016158|EXPERIMENTAL|umbilical cord serum eyedrops|patients with recurrent corneal erosions were treated with 20% umbilical cord serum eye drops 3 to 4 times a day in addition to artificial tears
62219969|NCT01587391|PLACEBO_COMPARATOR|Placebo to BI 163538 XX|1 single dose per subject as oral solution
62219970|NCT04393753|EXPERIMENTAL|domatinostat and avelumab|Single arm study of Domatinostat tablets in combination with avelumab infusion
62219971|NCT00621361|EXPERIMENTAL|1|
62414457|NCT04294290|EXPERIMENTAL|hCT-MSC infusion|
62414458|NCT00564486|PLACEBO_COMPARATOR|IV Placebo 100 ml|IV Placebo 100 ml dosed every every 6 hours for 24 hours (4 doses total).
62414459|NCT00564486|PLACEBO_COMPARATOR|IV Placebo 65 ml|IV Placebo 65 ml dosed every every 4 hours for 24 hours (6 doses total).
62414460|NCT00564486|EXPERIMENTAL|IV Acetaminophen 1 gm|IV Acetaminophen 1 gm dosed every every 6 hours for 24 hours (4 doses total).
62414461|NCT00564486|EXPERIMENTAL|IV Acetaminophen 650 mg|IV Acetaminophen 650 mg dosed every every 4 hours for 24 hours (6 doses total).
62414462|NCT05589649|EXPERIMENTAL|Erector spinae plane block|Ultrasound-guided erector spinae plane block
62414463|NCT05589649|EXPERIMENTAL|Paravertebral|Ultrasound-guided thoracic paravertebral block
62414464|NCT05141045|EXPERIMENTAL|omega-3 PUFA supplement|omega-3 PUFA supplement, 3.0 grams per day
62414465|NCT05141045|PLACEBO_COMPARATOR|placebo|safflower oil, 3.0 grams per day
62414466|NCT06702280|EXPERIMENTAL|IgY Supplement|Participants will ingest the IgY supplement on a daily basis
62414467|NCT03827460|EXPERIMENTAL|Free access alcohol self-administration|During the 2.5-hour free-access self-administration sessions, the participant may choose to complete a task for an alcohol or water reward. Interventions include Abstinence from Alcohol and Usual Drinking
62414468|NCT03827460|EXPERIMENTAL|Clamped alcohol exposure|A battery of behavioral tasks will be administered to participants before, and at the beginning and end of a 3 hour clamped exposure to alcohol (fixed at 80 mg/dL). EEG will be recorded throughout to assess event related potentials associated with task performance. Interventions include Abstinence from Alcohol and Usual Drinking.
62414469|NCT03827460|NO_INTERVENTION|2 year followup|Participants from both Arm 1 and Arm 2 will be surveyed every 2 months for alcohol consumption for 2 years following the Experimental phase. Interventions include Abstinence from Alcohol and Usual Drinking.
62414470|NCT06184373||Participants|Participants will be recruited at 6-8 weeks postpartum; at that appointment, CGMs will be placed. After wearing the CGM, participants will fill out surveys regarding their experience. At 10-12 weeks postpartum, they will complete the standard of care OGTT as well as complete an interview regarding their experience. At 12 months postpartum, they will complete a blood test to check their hemoglobin A1c.
62414471|NCT04473339|EXPERIMENTAL|HRR mt 1|Patients are HRR mutated type, will undergo CRS plus HIPEC and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.
62414472|NCT04473339|EXPERIMENTAL|HRR mt 2|Patients are HRR mutated type, will undergo CRS and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.
62414473|NCT04473339|EXPERIMENTAL|HRR wt 3|Patients are HRR wild type, will undergo CRS plus HIPEC and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.
62414474|NCT04473339|EXPERIMENTAL|HRR wt 4|Patients are HRR wild type, will undergo CRS and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.
62414475|NCT03843307|EXPERIMENTAL|Electrical stimulation|
62795909|NCT06726304|EXPERIMENTAL|Baby Carrier Intervention Group|Participants and their babies will be visited twice by trained research staff in their home. Once at the beginning of the study (at 8 weeks postpartum) and for a second time at the end of the study (at 16 weeks postpartum). During the first visit, mothers will choose between two soft ergonomic baby carriers and be given instructions regarding the expected frequency and length of usage. Maternal sensitivity will be observed during a 15-minute free play session of the mother-baby dyad. During the second home visit, inter-personal neural synchrony in mother-baby dyads will be assessed during a joint attention task (9 minutes). Participants will also be interviewed about their lived experiences with babywearing and increased physical contact with their baby (30-40 minutes). Finally, participants will complete questionnaires about mother-infant bonding, depression and anxiety symptoms, and rate the burden of the protocol.
62795910|NCT06726304|NO_INTERVENTION|Waitlist Control Group|"The waitlist control group will be assessed using the same measures as the intervention group (described above) except for the open-ended interview questions about their lived experiences with regular babywearing and increased physical contact with their baby.~At the end of the second home visit, all waitlist control participants will be offered to choose between the same two ergonomic baby carrier models as the intervention group, and will be provided with the same instructions regarding the recommended frequency and length of use as intervention group participants at the beginning of the study."
62795911|NCT02934165|EXPERIMENTAL|Family Safety 123|Parents viewed a website with videos on child injury prevention strategies and received emails for 30 days inviting them to view additional videos.
62795912|NCT02934165|ACTIVE_COMPARATOR|AAP TIPP sheets|Parents viewed online injury prevention materials developed by the American Academy of Pediatrics and had continuing access to these materials for 30 days.
62795913|NCT05413408|EXPERIMENTAL|education and contact to change participants stigma towards schizophrenia|The intervention consists of three phases, including investigative learning activity (this section will last about one week), higher-order thinking activity (this section will last about two hours), collaborative activity (this section will last about two hours). Both the intervention group and the control group will be interns in the hospital simultaneously. The study outcomes include nursing students' knowledge, attitude, and behavioral intentions regarding stigma towards schizophrenia. The intervention effect will be evaluated by the researcher, comparing results between and within the two groups from baseline (T0) to immediately after first and second session intervention (T1), immediately after third session intervention (T2), and three months follow-up (T3).
62219972|NCT00621361|ACTIVE_COMPARATOR|2|Etoposide + Cisplatin
62219973|NCT05773144|SHAM_COMPARATOR|Attention control|Static stretching
62587193|NCT06134856|EXPERIMENTAL|Intervention|"Subjects assigned to the intervention group will then receive a talocrural joint high velocity, low amplitude thrush mobilization/manipulation. Standardized technique for this procedure involves the subject long-sitting with their back supported on the treatment table. The provider will then passively dorsiflex and evert the ankle to the point at which a joint tension end-feel is obtained.~A small amplitude of movement is rapidly provided by the provider in a caudal direction. The provider may attempt up to three treatment thrust impulses, or until an audible cavitation is heard, indicating joint movement. Even without an audible cavitation, no more than three impulses will be provided. Some research in other body regions indicates that treatment effect is present even in those with whom audible joint cavitation is not noted."
62219974|NCT05773144|EXPERIMENTAL|75 min/wk aerobic exercise|Aerobic exercise at a dose of 75 minutes per week
62219975|NCT05773144|EXPERIMENTAL|150 min/wk aerobic exercise|Aerobic exercise at a dose of 150 minutes per week
62219976|NCT05773144|EXPERIMENTAL|225 min/wk aerobic exercise|Aerobic exercise at a dose of 225 minutes per week
62219977|NCT05773144|EXPERIMENTAL|300 min/wk aerobic exercise|Aerobic exercise at a dose of 300 minutes per week
62414476|NCT02926053|EXPERIMENTAL|Patient group|"All patients receive the same treatment.~Surgical removal of tumor tissue for T cell production, which takes 4-6 weeks, is performed initially.~All patients are hospitalized during treatment (one week in advance of the T cell product being ready and for approximately 3 weeks in total) and receive treatment only once.~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine on day -7 to day -1.~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 5. Interleukin-2 is administered as high-dose i.v. bolus every eight hour starting approximately 6 hours after TIL infusion and for up to 5 days (maximum of 15 doses)."
62414477|NCT06568497|EXPERIMENTAL|Dairy|A food containing dairy cheese
62414478|NCT06568497|EXPERIMENTAL|Non-Dairy|A food containing vegan alternative to cheese
62587194|NCT06134856|SHAM_COMPARATOR|Control|Subjects in the control group will receive 1 minute of passive ankle movement into ankle dorsiflexion. The researcher will not move the subjects ankle into a point where tissue stretch/tension is perceived. This will serve as an appropriate sham treatment since it still involves the subjects perception of treatment and includes the hands-on element of manual therapy, without the use of any tissue intervention which would theoretically effect change.
62219978|NCT06124911|EXPERIMENTAL|Maximal-intent Resistance Training - 3x5 (MI3x5)|The max-intent group were instructed and encouraged to deliberately commit to exerting maximal effort and force during the concentric phase of the leg press with the intention of achieving the greatest velocity possible. This group completed 3 sets of 5 repetitions at 60% one-repetition maximum.
62219979|NCT06124911|EXPERIMENTAL|Maximal-intent Resistance Training - 5x5 (MI5x5)|The max-intent group were instructed and encouraged to deliberately commit to exerting maximal effort and force during the concentric phase of the leg press with the intention of achieving the greatest velocity possible. This group completed 5 sets of 5 repetitions at 60% one-repetition maximum.
62587195|NCT06683664|EXPERIMENTAL|Integrated health service delivery for very young adolescents|The intervention will be implemented in 90 non-randomly selected health facilities and their catchment areas located in the North and Far North Regions of Cameroon. In intervention areas, the intervention (a complex, supply- and demand-side implementation model with the primary objective of increasing access to HPV vaccination and other health services for very young adolescents girls and boys \[aged 9-13 years\]) will be developed in the study's phase 1, a rapid formative phase. It is anticipated that the intervention will include supply- and demand-side components, such as household mobilization by community health workers engaged through the exiting Programme d'Accès aux Services de Santé de la Reproduction (PASSR), strengthened linkages between households and health facilities, and routinized HPV and adolescent health service delivery within communities.
62587196|NCT06683664|NO_INTERVENTION|Standard of care|90 non-randomly selected health facilities and their catchment areas supported by the Programme d'Accès aux Services de Santé de la Reproduction (PASSR) have been selected as concurrent comparison areas. These sites will conduct HPV vaccination (and other other adolescent health service delivery) through the standard-of-care procedures.
62795914|NCT05413408|ACTIVE_COMPARATOR|Participants reading a book about schizophrenia knowledge|The control group only has one session and will be given a book of schizophrenia knowledge, and they will be asked to finish reading it in four weeks.
62219980|NCT06124911|EXPERIMENTAL|Controlled-tempo Resistance Training - 3x5 (CT3x5)|The controlled-tempo group followed a metronome for both eccentric and concentric phases of the leg press with the intention of maintaining a steady three-second concentric and three-second eccentric. This group completed 3 sets of 5 repetitions at 60% one-repetition maximum.
62414479|NCT06568497|EXPERIMENTAL|Conrtol|A control treatment in the form of food
62795915|NCT06395038|ACTIVE_COMPARATOR|Abatacept plus Aldesleukin every 4 weeks|Subcutaneous abatacept (125 mg) followed by five-day-courses of IL-2 (1MUI/day) every four weeks will be administered for a total of 21 weeks
62795916|NCT06395038|ACTIVE_COMPARATOR|Abatacept plus Aldesleukin every 2 weeks|Subcutaneous abatacept (125 mg) followed by five-day-courses of IL-2 (1MUI/day) every two weeks will be administered for a total of 21 weeks
62795917|NCT02664506|EXPERIMENTAL|Word repetition after a tiem delay|People with Aphasia and Short-Term Memory impairment will receive a behavioral treatment: Word repetition after a time delay. This is the intervention: repetition of words after a 5 or 10 second delay.
62795918|NCT06726460||Group 1: Nova Group|This group involves the use of the Nova Stat Profile pHOx Ultra Analyzer System for measuring serum and whole blood samples. The results obtained from Nova will be compared with those obtained from P1.
62795919|NCT06726460||Group 1: P1 Group|This group involves the use of the novel POCT dry electrolyte analysis system P1 for measuring serum and whole blood samples. The results obtained from P1 will be compared with those obtained from Nova.
62795920|NCT03664232|EXPERIMENTAL|JNJ-42165279|Participants will self-administer 25 milligram (mg) JNJ-42165279 tablets orally twice daily for 12 weeks.
62795921|NCT03664232|PLACEBO_COMPARATOR|Placebo|Participants will self-administer matching placebo tablets orally twice daily for 12 weeks.
62219981|NCT06124911|EXPERIMENTAL|Controlled-tempo Resistance Training - 5x5 (CT5x5)|The controlled-tempo group followed a metronome for both eccentric and concentric phases of the leg press with the intention of maintaining a steady three-second concentric and three-second eccentric. This group completed 5 sets of 5 repetitions at 60% one-repetition maximum.
62219982|NCT06414837|EXPERIMENTAL|Treatment group A: HR091506 tablets + placebo of febuxostat tablets|
62219983|NCT06414837|ACTIVE_COMPARATOR|Treatment group B: febuxostat tablets + placebo of HR091506 tablets|
62219984|NCT02717351|EXPERIMENTAL|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62219985|NCT03029221||Marriage & Relationship Ed Skills-Couples|This group will receive the PREP 8.0 curriculum developed by PREP. In Years 2-5, 4 7-week class series will be held each year in Clearfield and Centre Counties (PA); 32 adults will be served each year. In Year 1, 8 adults will be served. Couples will receive 11 hours of curriculum instruction. This group will also receive two 30-minute presentations on available financial management, and job and career advancement services through two partnering organizations (CareerLink and Central PA Community Action, Inc.). Participants will also have access to optional parenting skills training provided by CAS (i.e., Triple P - Positive parenting Program). Referrals to community agencies based on individual/family needs will be provided by participant's case managers, as needed.
62219986|NCT03029221||Marriage & Relationship Ed Skills-Individuals|This group will receive the Within My Reach curriculum developed by PREP. In Years 2-5, 4 9-week class series will be held each year in Clearfield and Centre Counties (PA); 32 adults will be served each year. In Year 1, 8 adults will be served. Participants will receive 15 hours of curriculum instruction. This group will also receive two 30-minute presentations on available financial management, and job and career advancement services through two partnering organizations (CareerLink and Central PA Community Action, Inc.). Participants will also have access to optional parenting skills training provided by CAS (i.e., Triple P - Positive parenting Program). Referrals to community agencies based on individual/family needs will be provided by participant's case managers, as needed.
62219987|NCT03029221||Pre-Marital Ed and Marriage Skills|This group will receive healthy marriage and relationship education to pre-marital couples using Within Our Reach 8 Hours curriculum developed by PREP. In Years 2-5, 9 10-hour weekend workshops will be held each year in nine central PA counties; 72 adults will be served each year. In Year 1, 24 adults will be served.
62219988|NCT03029221||Marriage Enhancement and Marriage Skills|This group will receive healthy marriage and relationship education to married couples using Within Our Reach 8 Hours curriculum developed by PREP. In Years 2-5, 9 12-hour weekend workshops will be held each year in nine central PA counties; 174 adults will be served each year. In Year 1, 60 adults will be served.
62219989|NCT00440999|EXPERIMENTAL|pyronaridine artesunate|The tablet strength is 180:60 mg oral PA plus chloroquine-placebo. Depending on their body weight, patients receive 1 to 4 tablets once a day, for 3 days. The actual dose-level range covered by this regimen is 7.2: 2.4 mg/kg to 13.8:4.6 mg/kg pyronaridine artesunate.
62219990|NCT00440999|ACTIVE_COMPARATOR|chloroquine|"The tablet strength is 155 mg oral chloroquine plus PA-placebo.~Patients receive:~For adults: 620 mg (i.e. 4 tablets) on Days 0 and 1 and 310 mg (i.e. 2 tablets) on Day 2. For children: 10 mg/kg on Days 0 and 1 and 5 mg/kg on Day 2."
62414480|NCT04645927|PLACEBO_COMPARATOR|Placebo control beverage group|The placebo will be provided in the same unmarked plain packages and contain the same constituents, but without flax (control packages contain oat fiber and milk). For 180 days (6 months) participants will consume 2 servings of 330 ml of placebo beverage (i.e. normal fiber beverage; control) per day.
62219991|NCT05812833|EXPERIMENTAL|Participating in online training and providing active consultancy|Online training will be given to mothers, and then the web link will be shared and online counseling will be given every week. Mothers will be followed for 3 months
62219992|NCT05812833|NO_INTERVENTION|Control|Will receive routine maintenance of the institution
62219993|NCT03913780|ACTIVE_COMPARATOR|Group 1 (Medical record)|For group 1, participants do not have intervention as groups 2 and 3. This group consists of reviewing the medical history of the year 2000 to determine the variables of the study and then compare them with groups 2 and 3. This group of participants they were from the year 2000 and whose information will be strictly taken from their medical history was based on initial training with warm-up and walking, after that, aerobic training was performed from 50 to 70% of their maximum heart rate and they finished their session training with breathing exercises, coordination, balance and walking.
62219994|NCT03913780|EXPERIMENTAL|Group 2: Aerobic exercise + Strength training in MMSS|"For group 2, participants begin their training with warm-up and walking, after that, performed aerobic exercise in endless band and elliptical bike more strength exercises for upper limbs with dumbbells, multi-strength equipment and Theraband.~The prescription of aerobic exercise was given from 50 to 70% of your maximum heart rate and for strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale."
62414481|NCT04645927|EXPERIMENTAL|Experimental flax beverage group|Flax beverage (30 gr daily, oral) is presented in liquid form in plain unmarked packages. For 180 days (6 months) participants will consume 2 servings of 330 ml of flax beverage (treatment group; 30 gms flax/day beverage) per day.
62414482|NCT05267639|NO_INTERVENTION|Comparator Baseline|The subject will wear their usual Microprocessor Knee (MPK) for 3 months, as well as in the lab to complete outcome measures.
62414483|NCT05267639|EXPERIMENTAL|Power Knee|The subject will wear the Ossur PK in place of their usual MPK for 3 months, as well as in the lab to complete outcome measures.
62414484|NCT04527549|EXPERIMENTAL|Arm A (dabrafenib, trametinib, hydroxychloroquine)|Patients receive dabrafenib mesylate PO BID, trametinib dimethyl sulfoxide PO QD, and hydroxychloroquine sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62414485|NCT04527549|ACTIVE_COMPARATOR|Arm B (dabrafenib, trametinib, placebo)|Patients receive dabrafenib mesylate PO BID, trametinib dimethyl sulfoxide PO QD, and placebo PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62587197|NCT04687072|EXPERIMENTAL|Efgartigimod PH20 SC|Patients receiving efgartigimod PH20 SC treatment
62587198|NCT04687072|PLACEBO_COMPARATOR|Placebo PH20 SC|Patients receiving placebo PH20 SC treatment
62414486|NCT04082533|ACTIVE_COMPARATOR|Stiffness Intravenous Hydrocortisone|Total knee replacement patients with preoperative knee stiffness (defined as flexion \< 100 degrees or extension lag \> 10 degrees) receive 3 doses of 100mg intravenous hydrocortisone every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
62587199|NCT01296945|ACTIVE_COMPARATOR|Kiosk|
62587200|NCT01296945|ACTIVE_COMPARATOR|Paper|
62587201|NCT01296945|ACTIVE_COMPARATOR|Kiosk PLUS paper|
62587202|NCT01296945|ACTIVE_COMPARATOR|kiosk PLUS web|
62219995|NCT03913780|EXPERIMENTAL|Group 3: Aerobic exercise + Strength training in MMII|"For group 3, participants begin their training with warm-up and walking, after that, performed aerobic exercise in endless band and elliptical bike more the strength training for lower limbs with theraband, multi-strength equipment and exercises for activation of the sole-twin pump.~The prescription of aerobic exercise was given from 50 to 70% of your maximum heart rate and for strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale."
62587203|NCT04881695||Patients|Women aged 18-26 years with congenital (Turner syndrome or other determined or undetermined genetic cause) or acquired (post-therapeutic)
62587204|NCT04881695||Controls|Women aged 18-26 years who do not have a condition that compromises their fertility
62587205|NCT02025140|ACTIVE_COMPARATOR|: This group consisted of 30 patients.|The traditional IANB injection was given according to the standard technique (Evers and Haegerstam 1981). From everyday practice, it is known that the present operator takes approximately 60 to 90 seconds to give a mandibular block
62587206|NCT02025140|EXPERIMENTAL|30 IANB with Computer controlled|The IANB injection was given by a computer- regulated device performed with the STA system. The IANB injection was given according to the manufacturer's instruction (the model was used is the STA Single Tooth Anesthesia System produced by Milestone Scientific, Livingston, NJ).
62795922|NCT04977713|EXPERIMENTAL|Acupressure group|In the acupressure uterine contractions were checked before the care application began. Acupressure was applied when the women's cervical dilation reached 4-5 cm, 6-7 cm and 8-10 cm. This method was applied 18 times during uterine contractions. The application stopped at the end of each contraction and resumed once another contraction started. No application was performed between contractions.
62023487|NCT02973958|ACTIVE_COMPARATOR|No ketorolac|15 mg/kg oral dose of acetaminophen is administered prior to surgery. General anesthesia will be induced with sevoflurane via facemask. After establishing venous access, a laryngeal mask will be inserted, and anesthesia maintained with 1 minimum alveolar anesthetic concentration (MAC) of sevoflurane in oxygen/air 50/50 mixture. The DPNB nerve block is done using a 23 GA needle inserted below the Buck fascia. Once the needle tip is positioned appropriately and after a negative aspiration test, 0.2mL/kg (maximum 10mL) of 0.25% bupivacaine is injected in small aliquots, with intermittent aspiration throughout. In all patients, skin incision is performed at least 5 min after placement of the nerve block. Patients will be advised to take ibuprofen and acetaminophen post-operatively as needed.
62023488|NCT02973958|EXPERIMENTAL|Peri-operative ketorolac|Exactly same as the no ketorolac group except at the beginning of the circumcision, once the patient is asleep, patients in the perioperative ketorolac group will also receive a 0.5 mg/kg intravenous dose of ketorolac.
62023489|NCT03752164|EXPERIMENTAL|Yoga and Mindfulness|An intervention consisting of one session lasting 30 minutes where a certified yoga instructor teaches the children gentle yoga and mindfulness skills.
62219996|NCT02805881|EXPERIMENTAL|Neurolief System treatment|Treatment with the Neurolief system will be applied by the subject at his home and/or surrounding daily during a period of six weeks
62414487|NCT04082533|PLACEBO_COMPARATOR|Stiffness Intravenous Placebo|Total knee replacement patients with preoperative knee stiffness (defined as flexion \< 100 degrees or extension lag \> 10 degrees) receive 3 doses of matched volume diluent every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
62023490|NCT02736084|EXPERIMENTAL|Positive Psychology|"The Positive Psychology intervention consists of 7 exercises that will be completed by the participant with the guidance of a trainer.~Exercises:~Gratitude for positive events Using personal strengths Gratitude letter Enjoyable and meaningful activities Recalling past success Performing acts of kindness Repeating one of the previous exercises."
62023491|NCT04853004||Study cohort|Personnel in health and care in Stockholm County, who have previously participated in a study where data on sick leave, SARS-Cov2 infections and SARS-CoV2 antibody levels were collected and documented form the study cohort.
62023492|NCT06191705||Individuals with Arm, Shoulder or Hand pain /symptoms.|
62023493|NCT03593668|ACTIVE_COMPARATOR|Metformin|Metformin Hydrochloride Tablet 500mg po by month,three times a day for 12 weeks
62023494|NCT03593668|ACTIVE_COMPARATOR|Benaglutide|Benaglutide Injection 0.2mg, iH,po, three times a day for 3 12 weeks
62219997|NCT02116673|OTHER|Control|The control arm receives usual care discharge instructions.
62219998|NCT02116673|EXPERIMENTAL|Cognitive rest|The intervention is providing discharge instructions instructing cognitive rest and graduated return to usual activities in patients whom have experienced minor traumatic brain injury.
62219999|NCT01028027|EXPERIMENTAL|Loteprednol and tobramycin|Loteprednol etabonate and tobramycin ophthalmic suspension
62220000|NCT01028027|ACTIVE_COMPARATOR|Tobramycin and dexamethasone|Tobramycin and dexamethasone ophthalmic suspension
62414488|NCT04082533|ACTIVE_COMPARATOR|Non-stiff Intravenous Hydrocortisone|Total knee replacement patients without preoperative knee stiffness (defined as flexion \< 100 degrees or extension lag \> 10 degrees) receive 3 doses of 100mg intravenous hydrocortisone every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
62023495|NCT06434701|EXPERIMENTAL|Severe acute COVID-19 infection|Nasopharyngeal swab sampling for COVID-19
62220001|NCT01957449|ACTIVE_COMPARATOR|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
62220002|NCT01957449|PLACEBO_COMPARATOR|Sugar Pill|Placebo by mouth given daily throughout hospitalization for up to 12 months
62220003|NCT01390077|EXPERIMENTAL|Nitisinone|all subjects will receive open-label nitisinone
62220004|NCT02381600|EXPERIMENTAL|Intervention group- vitamin D|Include patients aged 65 years and older that are found to have below-normal serum levels of vitamin D on routine laboratory testing. After providing informed consent (the study was submitted for approval by the Ethics Committee of the Clalit Health Services) eligible subjects will undergo cognitive and affective assessment
62220005|NCT02847247|EXPERIMENTAL|CCRE|20,000 EU of CCRE (Clinical Center Reference Endotoxin)
62220006|NCT02645227|ACTIVE_COMPARATOR|Group 1|Open flap debridement (OFD)
62220007|NCT02645227|ACTIVE_COMPARATOR|Group 2|OFD with Platelet rich fibrin (PRF)
62414489|NCT04082533|PLACEBO_COMPARATOR|Non-stiff Intravenous placebo|Total knee replacement patients without preoperative knee stiffness (defined as flexion \< 100 degrees or extension lag \> 10 degrees) receive 3 doses of matched volume diluent every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
62023496|NCT04101799|EXPERIMENTAL|Intervention|Participating in the For our children's sake intervention, 10 group sessions, 2 hours each
62220008|NCT02645227|ACTIVE_COMPARATOR|Group 3|OFD with PRF and 1.2% Rosuvastatin
62220009|NCT06219369|ACTIVE_COMPARATOR|Group T|Group T patients who underwent TPVB
62220010|NCT06219369|ACTIVE_COMPARATOR|Group S|Group S patients who underwent SPSIPB
62220011|NCT01692899||Etanercept|Etanercept: administered as first line biotherapy in RA during the period of the study
62220012|NCT01692899||Adalimumab|Adalimumab: administered as first line biotherpy in RA during the period of the study
62220013|NCT01692899||Infliximab|Infliximab: administered as first line biotherpy in RA during the period of the study
62587207|NCT02025140|EXPERIMENTAL|consisted of 30 periodontal anesthesia|The interligamental injection was given by computer- regulated device performed with the STA system.
62587208|NCT03669055|EXPERIMENTAL|Pre-operative and post operative Magnetic Resonance Imaging|Realization of an angio-MRI with 4D phase contrast sequence before and after the endovascular treatment of the aortic dissection
62587209|NCT03356639|EXPERIMENTAL|ASP6981 50 mg, then matching Placebo|Participants in Sequence AB will first receive ASP6981 capsules orally (50 mg) during period 1. After a 14-day washout period, participants receive matching placebo during period 2. Participants will receive ASP6981 capsules or matching placebo capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, ASP6981 or matching placebo will be administered under fasting conditions.
62220014|NCT02731183|EXPERIMENTAL|FMT|Patients included will receive standard FMT, and then will be followed up for 8 weeks.
62414490|NCT03803514||Treated group (rEPO)|"Patients with ESRD in HD, and medical indication of recombinant EPO for management of anemia (Hb \< 10 g/dL). Ambulatory hemodialysis 3 times per week.~Recombinant beta-epoetin (Recormon) will be used, according to current recommendations.~Clinical and laboratory data will be obtained before and during the study. The primary outcome (changes of plasma intact FGF23) will be measured during the follow-up, up to 12 weeks."
62795923|NCT04977713|EXPERIMENTAL|Shower Group|The shower group, uterine contractions were checked before the care application began. A shower was applied when the women's cervical dilation reached 4-5 cm, 6-7 cm and 8-10 cm. This method was applied 18 times during uterine contractions. The application stopped at the end of each contraction and resumed once another contraction started. No application was performed between contractions.
62414491|NCT03803514||Control group|"Patients with ESRD and HD, without medical indication of recombinant EPO (Hb \> 10 g/dL). Ambulatory hemodialysis 3 times per week.~Follow-up for 3 months, similar than rEPO group. Clinical and laboratory data will be obtained before and during the study, similar periods than rEPO group.~The primary outcome (changes of plasma FGF23) will be measured every 2 week during the evaluation period."
62414492|NCT02560207|ACTIVE_COMPARATOR|Intermittent cefotaxime|Cefotaxime 1 gram (1000 mg) is to be administered 4 times daily for 4 days
62414493|NCT02560207|EXPERIMENTAL|Continuous cefotaxime|After a 1 gram (1000 mg) Cefotaxime loading dose, Cefotaxime 4 gram (4000 mg) is to be administered as a continuous infusion in 24h for 4 days .
62414494|NCT03009591|EXPERIMENTAL|Expermiental group|All patients included in the experimental group should be on prophylactic treatment with FVIII / FIX concentrates. Likewise, the factor should be administered on the same day that they receive each of the fascial therapy treatment sessions. Each session will last approximately 50 minutes, with three physiotherapy sessions taking place over a period of 3 weeks. The treatment program includes 11 maneuvers that must be administered bilaterally:
62414495|NCT03009591|NO_INTERVENTION|Control group|Subjects included in the control group will not receive physical therapy through fascial therapy and will continue with their usual routine of physical activity and exercise, and with the same pharmacological treatment regimen with FVIII / FIX. At the end of the study period the intervention will be applied under the same conditions as the experimental group, analyzing the overall sample at the end of the study.
62414496|NCT04645342|EXPERIMENTAL|Baylis Versacross RF wire|Device: Baylis Versacross radiofrequency wire
62587210|NCT03356639|EXPERIMENTAL|Matching Placebo, then ASP6981 50 mg|Participants in Sequence BA will first receive matching placebo capsules orally during period 1. After a 14-day washout period, participants receive ASP6981 capsules (50 mg) during period 2. Participants will receive matching placebo or ASP6981 capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, matching placebo or ASP6981 will be administered under fasting conditions.
62795924|NCT04977713|NO_INTERVENTION|Control group|The women in the control group underwent routine hospital care. They were administered neither pharmacological nor nonpharmacological methods to reduce labour pain.
62795925|NCT06467916|EXPERIMENTAL|Intervention|anticipatory guidance, brief behavioral intervention, or referral to community mental health provider
62795926|NCT06467916|NO_INTERVENTION|Control|usual care
62795927|NCT06726031|NO_INTERVENTION|control group|Participants in this group will not undergo VR glasses application during transradial coronary angiography.
62023497|NCT04101799|ACTIVE_COMPARATOR|Control|Participating in everyday activities that may include parenting activities in the control prisons
62220015|NCT05976893|EXPERIMENTAL|the PCSK9 inhibitor plus statin therapy|Patients with very high risk of ASCVD and cancer are treated with moderate intensity statin daily and evolocumab (420 mg) every 4 weeks throughout the study period.
62220016|NCT05976893|OTHER|the statin alone therapy|Patients with very high risk of ASCVD and cancer are treated with moderate intensity statin daily throughout the study period.
62220017|NCT02319759|EXPERIMENTAL|Guselkumab|Participants will receive guselkumab 100 milligram (mg) subcutaneous injection (injected under the skin by way of a needle) at Weeks 0, 4, 12, 20, 28, 36, and 44, and placebo for guselkumab at Week 24 to maintain the blind. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
62023498|NCT03812458|EXPERIMENTAL|Guidance|The intervention group will consist of the relatives who will receive a printed brochure and are encouraged to visit a website with detailed information and with simple language regarding the ICU environment (treatments, care, alarms, multidisciplinary team) and the characteristics of critically ill patients (organ dysfunction, prognosis, palliative care, organ dysfunction).
62220018|NCT02319759|EXPERIMENTAL|Placebo|Participants will receive placebo for guselkumab at Weeks 0, 4, 12, and 20, and guselkumab 100 mg subcutaneous injection at Weeks 24, 28, 36, and 44. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
62220019|NCT04290936|EXPERIMENTAL|Arm 1|NUC-naïve patients will be randomization into Tenofovir Alafenamide(TAF) treatment.
62220020|NCT04290936|PLACEBO_COMPARATOR|Arm 2|NUC-naïve patients will be randomization into placebo arm.
62414497|NCT04645342|ACTIVE_COMPARATOR|Baylis RF Needle|Device: conventional Baylis radiofrequency needle
62414498|NCT04024852|NO_INTERVENTION|Control group|The control group did daily mild exercise (walking) outdoors for 30 minutes, for maximum 70 days.
62414499|NCT04024852|OTHER|Intervention group|When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes. Total study period lasted for maximum 70 days.
62795928|NCT06726031|ACTIVE_COMPARATOR|VR Glass Group|Participants in this group will use VR glasses during transradial coronary angiography. With the help of VR glasses, patients will be shown visuals based on nature and listen to calming sounds.
62414500|NCT06321042||Patient treated with PS Link Symphoknee prosthesis and Orthokey perseus alignment device|
62414501|NCT02657746|NO_INTERVENTION|usual care|Usual care comprises existing services for hypertension control in the community without any additional training
62795929|NCT06725407||Group 1|Cesarean section
62795930|NCT01609114||control groups|chemotherapy (C/T) is applied in the morning. After 4-6 hrs, RT is delivered (according to the clinical practice).
62795931|NCT01609114||experimental groups|RT is delivered in the morning. After 4-6 hrs, C/T is applied.
62795932|NCT01854580||Integrated care|Insured people in the Techniker Krankenkasse that are registered in the integrated care project.
62795933|NCT01854580||Control group|Insured people in the Techniker Krankenkasse that are not registered in the integrated care project.
62023499|NCT03812458|NO_INTERVENTION|Control|The families who will not receive the brochure and are not encouraged to visit the website.
62220021|NCT04290936|ACTIVE_COMPARATOR|Arm 3|NUCs-treated patients will be switched to Tenofovir Alafenamide(TAF) treatment.
62220022|NCT02793076|EXPERIMENTAL|Bollywood Dance|Bollywood dance is a routine that doubles as both physical and mental exercise.
62414502|NCT02657746|EXPERIMENTAL|multi-component interventions|: The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
62414503|NCT03049371|OTHER|sample size 100|24 post-op and 100 pre- non- and post-op TGW Study participants need to be of Thai nationality, at least 18 years old, male at birth and self-identify as post-op TGW for participation in study. Signed informed consent is required for study participation
62414504|NCT05572814|NO_INTERVENTION|Usual Care|Teaching - CardioSmart Resources + Clinician Education
62414505|NCT05572814|ACTIVE_COMPARATOR|Decision Support|Technology - Facilitated Solution (Existing Team)
62795934|NCT04314986|EXPERIMENTAL|AR882 (Dose A)|
62795935|NCT04314986|EXPERIMENTAL|AR882 (Dose B)|
62795936|NCT04314986|EXPERIMENTAL|AR882 (Dose C)|
62795937|NCT04314986|EXPERIMENTAL|AR882 (Dose D)|
62795938|NCT04314986|PLACEBO_COMPARATOR|Placebo|
62795939|NCT05185726|EXPERIMENTAL|Mini-KIDS|Mini-KIDS is a direct treatment based on principles of stuttering modification, with pseudo-stuttering, that is, deliberate stuttering, as one of the main components. The program for 4-6-year old children consists of four stages: Stage 1 = desensitization, Stage 2 = modification, Stage 3 = identification and Stage 4 = generalization. The program for 2-4-year old children does not include stage 3. Speech therapist and parent(s) are the speech model for the child. They add normal dysfluencies to their speech. Later on in treatment and if necessary, children learn to recognise and alter their stuttering moments.
62795940|NCT05185726|EXPERIMENTAL|Social-Cognitive Behaviour Treatment|The social cognitive behaviour therapy contains 5 treatment phases: (1) conditioning speaking activities, (2) cognitive training focused on emotions, (3) cognitive training focused on cognitions, (4) emotional training and (5) skill training (Boey, 2010). This treatment is not directed at the speech of the children, but rather at the cognitive and emotional aspects that surround the stuttering.
62023500|NCT01181921|EXPERIMENTAL|Galantamine|
62023501|NCT01196975|EXPERIMENTAL|GSK2282512A 1 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62023502|NCT01196975|EXPERIMENTAL|GSK2282512A 2 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62023503|NCT01196975|EXPERIMENTAL|GSK2282512A 3 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62023504|NCT01196975|ACTIVE_COMPARATOR|Victoria Strain FluLaval Group|Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62414506|NCT05572814|ACTIVE_COMPARATOR|Referral|Teams - Protocol-Supported Team, (Virtual GDMT Team)
62414507|NCT04335292|EXPERIMENTAL|Treatment Arm|"First-line treatment = osimertinib, 80 mg, oral, daily; Second-line treatment = platinum (carboplatin or cisplatin) + pemetrexed chemotherapy, prescribed as per institutional standards; Third-line treatment = osimertinib rechallenge, 80 mg, oral, daily.~Patients may enter the study at first-line treatment, second-line treatment, or third-line treatment. This is dependent on meeting the eligibility criteria."
62414508|NCT01789515||rectal cancer|Low Anterior Resection for Rectal Cancer
62414509|NCT04205292|ACTIVE_COMPARATOR|Dilatation and Evacuation (D&E)|Women in this group will receive an in-patient treatment with Dilatation and Evacuation (D\&E) after two doses of Methotrexate .
62414510|NCT04205292|EXPERIMENTAL|hysteroscopic surgery|Women in this group will receive hysteroscopic surgery after two doses of Methotrexate .
62023505|NCT01196975|ACTIVE_COMPARATOR|Yamagata Strain FluLaval Group|Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62023506|NCT04558957|EXPERIMENTAL|FLEBOGRIF|Interventions will be performed using Flebogrif catheter.
62023507|NCT01191489|EXPERIMENTAL|High Flow Conditioned Oxygen Therapy in high risk patients|
62023508|NCT01191489|ACTIVE_COMPARATOR|Non-invasive mechanical ventilation in High Risk Patients|
62023509|NCT01191489|EXPERIMENTAL|High Flow Conditioned Oxygen Therapy in Low Risk Patients|
62023510|NCT01191489|ACTIVE_COMPARATOR|Conventional Oxygen Therapy in Low Risk Patients|
62023511|NCT04336215||Healthcare Workers|546 HCW with high intensity direct patient care from two RBHS-affiliated academic hospitals: Robert Wood Johnson University Hospital (New Brunswick, NJ) and University Hospital (Newark, NJ) and Rutgers School of Dental Medicine (Newark, NJ).
62414511|NCT02242331||essential hypertension patients|
62414512|NCT04679233|EXPERIMENTAL|Arm 1: Intervention Arm|Arm 1 will receive the aerobic prescription exercise intervention. As this is a feasibility and safety study, there will not be a second arm.
62414513|NCT04849858|ACTIVE_COMPARATOR|Bupivacaine TAP Block|The first 15 patients enrolled will receive perioperative plain bupivacaine TAP blocks.
62023512|NCT04336215||Non-Healthcare Workers|283 non-healthcare workers (NHCW) from Rutgers faculty, postdoctoral students, students, other trainees, administrators, and staff who do not have patient contact.
62023513|NCT00437489|ACTIVE_COMPARATOR|Control|
62023514|NCT00437489|EXPERIMENTAL|Experimental|
62023515|NCT00003457|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62023516|NCT05387291|EXPERIMENTAL|Nursing Intervention|The intervention group will undergo an education program related to the circumcision process for the child's relatives/guardians.
62023517|NCT05387291|OTHER|Usual intervention|The control group will receive the usual intervention of the center.
62023518|NCT02328664|OTHER|Flexible sigmoidoscopy or colonoscopy|Subjects will undergo these investigation to take biopsies from the polypectomy scar.
62023519|NCT04251468|OTHER|GEPII|All patients who completed the study.
62023520|NCT03335358|EXPERIMENTAL|Positive Psychology Intervention|Participants complete baseline assessments and receive a 20min training on the positive psychology activities. They are instructed to engage in at least 2 positive psychology activities alone and at least 2 as a couple each week for 8 weeks. Self-administered activities include expressing gratitude, practicing acts of kindness, focusing on the positive, fostering relationships, working toward a goal, spirituality, savoring. Post-intervention and 3-month follow-up assessments are completed.
62023521|NCT03335358|OTHER|Waitlist control|Participants complete a baseline assessment and are waitlisted for 4-6 weeks. They then complete another assessment, receive the 20min training on activities, and then complete the 8-week self-administered intervention (same as the experimental arm). Post-intervention and 3-month follow up assessments are also completed.
62414514|NCT04849858|ACTIVE_COMPARATOR|Liposomal Bupivacaine TAP Block|After enrolling all 15 participants in the first arm, the next 15 patients enrolled will receive perioperative single-dose Liposomal Bupivacaine TAP blocks.
62414515|NCT04849858|ACTIVE_COMPARATOR|Liposomal Bupivacaine TAP Block with Re-dosing|After enrolling all 30 patients in the first two arms, the final 15 patients enrolled will receive perioperative Liposomal Bupivacaine TAP blocks followed by redosing of the TAP blocks in 48-60 hours.
62795941|NCT05185726|ACTIVE_COMPARATOR|Lidcombe Program|The Lidcombe Program (LP) is an operant program that directly provides verbal feedback to the child's stutter-free speech (mainly) and the child's stuttering (occasionally). The program comprises two stages: Stage 1 in which (near) zero levels of stuttering are achieved and Stage 2 in which the achieved (near) zero levels of stuttering are maintained for a long period of time. The LP usually takes between 11 to 23 (60-minute) treatment sessions to achieve the goals of Stage 1, i. e. (near) zero levels of stuttering.
62023522|NCT01296568|EXPERIMENTAL|LY2603618|"Single 250 milligram (mg) intravenous dose of LY2603618 containing carbon-14-labeled LY2603618 (\[\^14C\]LY2603618).~After the completion of a minimum 7-day washout period, participants may receive additional doses of LY2603618 in combination as follows:~* Gemcitabine 1000 milligrams per square meter (mg/m\^2) on Days 1, 8, and 15 with 230 mg LY2603618 being administered on Days 2, 9 and 16 of a 28-day cycle OR~* Pemetrexed 500 mg/m\^2 on Day 1 and 275 mg LY2603618 on Day 2 of a 21-day cycle~Participants will be allowed to continue to receive the combination therapy until fulfilling one of the criteria for discontinuation, such as unacceptable toxicity or disease progression."
62795942|NCT05376631|ACTIVE_COMPARATOR|Group Five|For emergence from general anesthesia, a fresh gas flow of 5 L/min is used.
62795943|NCT05376631|EXPERIMENTAL|Group Ten|For emergence from general anesthesia, a fresh gas flow of 10 L/min is used.
62023523|NCT04177511|EXPERIMENTAL|Transcutaneous auricular vagus nerve stimulation|"A 30-minute session twice a day during 3 months of transcutaneous auricular vagus nerve stimulation using the TENS Eco Plus.~Standard treatment will be continued by the patients of this arm."
62023524|NCT04177511|NO_INTERVENTION|Standard treatment|Patients of this arm will continue their standard treatment.
62414516|NCT03586986||FDR with abnormal brain MRI|First degree relatives fulfilling lesions disseminated in space on MRI
62414517|NCT03586986||FDR with normal brain MRI|First degree relatives not fulfilling lesions disseminated in space on MRI
62414518|NCT03586986||Non-FDR|Age and sex-matched controls to FDRs noted above
62414519|NCT02976389|EXPERIMENTAL|$40/month|Financial incentives: Participants will be randomized to receive $40/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
62414520|NCT02976389|ACTIVE_COMPARATOR|$20/month|Financial Incentives: Participants will be randomized to receive $20/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
62795944|NCT05563415|OTHER|Medicare AWV Toolkit|This is a stepped-wedged study. All practices will receive the intervention.
62220023|NCT05722574|ACTIVE_COMPARATOR|Information Only Control Condition|The information only control condition is designed to mimic relationship education that could be easily found online by adolescents. This condition does not teach romantic competence skills such as insight, communication/mutuality, or emotion regulation skills; rather, it focuses on educating subjects about the healthy and unhealthy signs of a romantic relationship. In addition, this condition is designed to control for nonspecific aspects of the intervention, such as engaging in an online program and taking time to reflect on one's relationships.
62220024|NCT05722574|EXPERIMENTAL|Romantic Competence Intervention|The Romantic Competence Single-Session Intervention provides adolescents with the opportunity to learn one of three relational skills online: (1) Insight, the ability to understand what one needs in relationships and act in alignment with one's needs, (2) Communication, the capacity to listen to others and express one's needs effectively, and (3) Stay vs. Go, the ability to reflect and make difficult decisions in relationships. Adolescents are presented with the opportunity to choose which module they would like to complete. Each module has the following components: psychoeducation, a personalized action plan, and practice overcoming barriers.
62795945|NCT04662359|OTHER|Ultrasound Assessment of Rheumatoid Arthritis Severity|All patients will receive an ultrasound scan to assess the severity of their arthritis. This scan will then be placed in their medical record to allow their rheumatologist to utilize the scan when making treatment recommendations.
62220025|NCT03562650|EXPERIMENTAL|Safety Behavior Fading|Participants are asked to pick their three most common safety behaviors from a list and then receive texts every other day for a month reminding them to fade those behaviors.
62795946|NCT05271916|EXPERIMENTAL|Combined treatment group|Dacomitinib+Anlotinib: Patients will be treated with combined Dacomitinib and Anlotinib.
62220026|NCT03562650|ACTIVE_COMPARATOR|Present Centered|Participants receive texts every other day for a month asking them to try to focus on the present that day.
62220027|NCT04100577|EXPERIMENTAL|TNT PISP intervention|Participants in TNT PISP intervention group will come to once monthly educational support group sessions and will be additionally enrolled in the community based doula program where they will receive 1 on 1 doula and lactation support throughout their pregnancy, delivery, and postpartum period. They will receive prenatal care clinical visits on their own with their prenatal care provider. In phase 2 of the study, participants will be offered on site prenatal care once per month.
62220028|NCT04100577|NO_INTERVENTION|Control|Participants in control group will have no enhanced prenatal care support. They will attend visits on their own with their prenatal care provider and participation in this research study will not interfere with the prenatal care.
62220029|NCT00892073|EXPERIMENTAL|Diazoxide and Metformin Therapy|
62414521|NCT02976389|ACTIVE_COMPARATOR|$10/month|Financial Incentives: Participants will be randomized to receive $10/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
62414522|NCT05051384|EXPERIMENTAL|Intraocular tumor|New sonographic software technique on ultrasonography to detect low-vascular flow inside intraocular tumors
62795947|NCT05271916|ACTIVE_COMPARATOR|Dacomitinib monotherapy group|Dacomitinib: Patients will be treated with Dacomitinib.
62414523|NCT06568770|OTHER|GROUP S-FICB|Suprainguinal Facia iliaca Block
62795948|NCT04119180|EXPERIMENTAL|Sedation|The child receives sedatives approved for use in an outpatient setting, directed by a doctor, to accomplish the dental treatment.
62220030|NCT00153881|EXPERIMENTAL|1|Docetaxel/Carboplatin every 3 weeks for 2 cycles then concommitant chemotherapy and radiation Docetaxel weekly for 5 doses without premedication, then Capecitabine will be given orally, one dose prior to each fraction or irradiation (28 cycles).
62220031|NCT03770533|OTHER|MR-proADM guided|
62414524|NCT06568770|OTHER|GROUP-PENG|Pericapsular Nerve Group Block
62795949|NCT04119180|OTHER|Control|The child does not receive sedatives. As s/he exhibits negative behavior for the dental procedure, s/he will be restrained by a family member and dental team.
62220032|NCT03770533|NO_INTERVENTION|Standard Care|
62220033|NCT02590705|EXPERIMENTAL|Group 1|surface anesthesia with lidocaine
62220034|NCT02590705|NO_INTERVENTION|Group 2|no anesthesia
62220035|NCT03323073|ACTIVE_COMPARATOR|Bipolar disorder type I or II|a single resting state fMR for patients with bipolar disorder type I or II with acute depressive state
62220036|NCT03323073|ACTIVE_COMPARATOR|Unipolar disorder|a single resting state fMR for patients with monopolar disorder with acute depressive state
62220037|NCT03323073|OTHER|Healthy volunteers|a single resting state fMRI for subjects without psychiatric disorders assessed by the SCID
62220038|NCT01183234|EXPERIMENTAL|SPD544 (Equasym XL)|
62220039|NCT01183234|EXPERIMENTAL|Methylphenidate hydrochloride (Metadate CD )|
62220040|NCT03531385||Behcet|Patients diagnosed with Behcet disease
62220041|NCT03531385||Healthy controls|Individuals without any chronic disease
62414525|NCT06670105|EXPERIMENTAL|Glofitamab|Participants will enter a screening period to determine eligibility for the study
62414526|NCT01618201||50 subjects with migraine without aura|Inflammation Migraine Headache
62414527|NCT01618201||50 subjects with migraine with aura|Inflammation Migraine Headache
62220042|NCT06476756|EXPERIMENTAL|ACTIVE CYCLE OF BREATHING TECHNIQUE|Group A: combine effects of ACBT and Buteyko techniques will be performed first 3days of cardiac rehab phase 1.
62414528|NCT01618201||50 subjects with tension headache and cluster headache|Inflammation Migraine Headache
62414529|NCT01618201||50 healthy subjects|Inflammation Migraine Headache
62414530|NCT04181697||PwH A|People with Haemophilia (PwH) A, moderate or severe.
62414531|NCT04181697||Controls|Demographically and seasonally matched non-haemophilia controls.
62414532|NCT03800134|EXPERIMENTAL|Arm 1: Durvalumab with platinum-based chemotherapy|"Patients will receive durvalumab 1500 mg in combination with platinum-based chemotherapy every 3 weeks for up to 4 cycles prior to surgery, followed by durvalumab 1500 mg monotherapy every 4 weeks for up to 12 cycles after surgery unless disease is deemed unresectable, disease recurrence, or unacceptable toxicity~The platinum-based chemotherapy will be based on tumour histology and Investigator discretion:~* cisplatin with pemetrexed~* carboplatin with pemetrexed~* carboplatin with paclitaxel~* cisplatin with gemcitabine (or carboplatin with gemcitabine for patients who have comorbidities or who are unable to tolerate cisplatin per the investigator's judgment)"
62433341|NCT03542318||Active group (Experimental)|Total of 60 patients were enrolled. All patients were referred for PR from the outpatient clinics of the local general hospital. Pulmonary fibrosis was confirmed through a high resonance computed tomography scan and pulmonary function testing. Participants who required modifications to their drug therapy due to exacerbations were excluded from the study. Each participant was classified according to the modified Medical Research Council dyspnoea scale
62795950|NCT01200368|EXPERIMENTAL|1|Experimental
62795951|NCT01200368|ACTIVE_COMPARATOR|2|Active comparator
62795952|NCT01200368|ACTIVE_COMPARATOR|3|Active comparator
62220043|NCT06476756|EXPERIMENTAL|Buteyko techniques|Group B: effect of buteyko techniques will be performed first three days of cardiac rehab phase 1.
62220044|NCT05354765|EXPERIMENTAL|"first type, called A Cohorts"|"The first type, called A Cohorts, corresponds to indications for which the treatment induces a high response rate (\>30%). These patients will have a lymphapheresis before and during treatment with immunotherapy. In addition, a blood sample in CellSave® tubes (15mL) will be taken at baseline and three weeks, and EDTA tubes (15mL) will be taken at baseline, 3 weeks after treatment start and at progression."
62795953|NCT05575362|EXPERIMENTAL|Epley Manuver group|Group A is Experimental group will receive Epley's maneuver and Cawthorne Cooksey exercise for two weeks.
62795954|NCT05575362|ACTIVE_COMPARATOR|half somersault group|Group B is Control group will receive Half somersault maneuver and Cawthorne Cooksey exercise for two weeks.
62795955|NCT04311255|ACTIVE_COMPARATOR|intercostal group|group of patient receiving inrercostal nerve block as analgesia
62795956|NCT04311255|ACTIVE_COMPARATOR|pecs group|group of patient receiving pectoralis nerve block as analgesia
62795957|NCT03988764||Antibody-negative|"Patient has been found negative for at least three T1D antibodies.~The investigators will proceed with whole exome sequencing"
62795958|NCT03988764||Antibody-positive|"Patient has been found to be positive for at least one T1D autoantibody.~No further studies will be performed as part of the main study."
62795959|NCT05830370||case|patients complaining of symptoms of IBS fulfilling the Rome criteria , such as abdominal discomfort, diarrhea, and constipation, bloating with any age \& sex groups from different locations.
62795960|NCT05830370||control|healthy individuals not suffering from IBS symptoms such as abdominal discomfort, diarrhea, and constipation, bloating.
62023525|NCT03895060|EXPERIMENTAL|autogenous ring blockls with GBR covered by collagen membrane|Vertical and horizontal ridge augmentation using autogenous onlay ring blocks combined with simultaneous guided bone regeneration using native collagen membrane in atrophic anterior maxilla.
62023526|NCT03091751|EXPERIMENTAL|BeneFIX|BeneFIX is a recombinant FIX provided in a vial containing 100 IU/mL lyophilized nonacog alfa accompanied with solvent for reconstitution and injection.
62023527|NCT02796326|EXPERIMENTAL|Dilatation|Patients undergoing tracheal dilatation with the study device
62023528|NCT06636500|EXPERIMENTAL|CG001419|Part A: Single ascending dose cohorts; food effect cohort; Part B: Multiple ascending dose cohorts
62023529|NCT06636500|PLACEBO_COMPARATOR|Placebo|Part A: Single ascending dose cohorts; Part B: Multiple ascending dose cohorts
62023530|NCT00775918|EXPERIMENTAL|1|Doxycycline monohydrate 100mg tablets of Ranbaxy
62023531|NCT00775918|ACTIVE_COMPARATOR|2|Adoxa ® 100 mg tablets of Bradley Pharmaceuticals Inc
62023532|NCT05575947||robotic-assisted|"Robotic-assisted cases converted to open will be part of the robotic cohort.~Comparison of the following safety and effectiveness related surgical outcomes across robotic-assisted and laparoscopic cohorts:~Safety Related Outcomes~1. Intraoperative Complication Rates~2. Transfusion Rates~3. 30-Day Post-Operative Complication Rates~4. 30-Day Readmission Rates~5. 30-Day Reoperation Rates~6. 30-Day Mortality~Effectiveness Related Outcomes~1. Conversion Rate to Open Surgery~2. Operative Time~3. Length of Hospital Stay"
62023533|NCT05575947||laparoscopic|"Laparoscopic cases converted to open will be part of the laparoscopic cohort.~Comparison of the following safety and effectiveness related surgical outcomes across robotic-assisted and laparoscopic cohorts:~Safety Related Outcomes~1. Intraoperative Complication Rates~2. Transfusion Rates~3. 30-Day Post-Operative Complication Rates~4. 30-Day Readmission Rates~5. 30-Day Reoperation Rates~6. 30-Day Mortality~Effectiveness Related Outcomes~1. Conversion Rate to Open Surgery~2. Operative Time~3. Length of Hospital Stay"
62023534|NCT05794854|EXPERIMENTAL|abdominal aerobic endurance exercise|Subjects were combining treadmill running at 70% HRmax (27 minutes) with 4x4minutes (30-40% maximal strength, 1RM) of torso rotation and abdominal crunches (57 minutes), 4 d per wk for 10 weeks
62023535|NCT05794854|ACTIVE_COMPARATOR|Control group|Subjects performed only treadmill running (45 minutes) at 70% HRmax for 4 d per week for 10 weeks.
62023536|NCT05412862|EXPERIMENTAL|Positive Psychology + Motivational Interviewing|Each week, participants in the PP-MI intervention group will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. Each phone session will include PP and goal setting portions. In the PP portion, the study trainer will (a) review the week's PP exercise, (b) discuss the rationale of the next week's PP exercise through a guided review of the PP-MI manual, and (c) assign the next week's PP exercise. In the goal-setting portion, the trainer will (a) review the participant's physical activity goal from the prior week, (b) discuss techniques for improving physical activity (e.g. tracking activity), and (c) help the participant to set a physical activity goal for the next week. Participants also will receive supplemental text messages throughout the 12 weeks of the intervention and during the initial follow-up period (Week 13-24).
62023537|NCT05412862|NO_INTERVENTION|Treatment as Usual|Participants in the treatment as usual (TAU) arm will not receive any specific intervention, though they will be free to receive any post-ACS treatment.
62023538|NCT04444154|ACTIVE_COMPARATOR|Control group|oral hygiene advice given orally
62795961|NCT02426840|EXPERIMENTAL|High dose vitamin D and calcium|Fixed-dose combination (FDC) of 1,500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3, administered orally twice daily plus vitamin D2 (20,000 IU/cap) administered once weekly (a total of 1,200 mg of elemental calcium and 3,200 IU of vitamin D daily)
62023539|NCT04444154|ACTIVE_COMPARATOR|Group with active participation|oral hygiene advice given orally and demonstration of brushing methods in the sink with active participation
62220045|NCT05354765|EXPERIMENTAL|"second type, called B Cohorts"|"The second type, called B Cohorts, corresponds to indications for which a role of the immune system is suspected. Only the so-called informative patients (responders or surprising evolution) will have one lymphapheresis during treatment. The lymphapheresis will be performed between 8 weeks and 18 months after the start of treatment and depending on the clinical course determined by the clinicians in consultation with at least one immunologist (Olivier Lantz, Emanuela Romano, Cécile Alanio, Marion Alcantara)."
62795962|NCT02426840|ACTIVE_COMPARATOR|Normal dose vitamin D and calcium|Fixed-dose combination (FDC) of 1,500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3, administered orally twice daily (a total of 1,200 mg of elemental calcium and 400 IU of vitamin D daily)
62795963|NCT03741582||Control - San Cristobal|"1021 individuals located in an area with no access to the intervention (TransMicable). The control area was defined by a 800-meter buffer around each projected station of the car, San Cristobal was an area with a projected but non financed Cable Car."
62795964|NCT03741582||Intervention - Ciudad Bolviar|1031 individuals who live in the area of influence of TransMiCable. The area of influence of TransMiCable was defined by a 800-meter radial buffer around each station of the cable car.
62795965|NCT01571752||CMU|Current marijuana users
62795966|NCT01571752||Cohort 1 - NIH Negative|HIV negative adults
62795967|NCT01571752||Cohort 1- HIV Positive|HIV positive adults
62795968|NCT01571752||Cohort 2 Seeds-Wave 0|HIV positive adults
62795969|NCT01571752||Cohort 2 Wave 1|HIV negative adults or HIV positive adults
62795970|NCT01571752||Cohort 2 Wave 2|HIV negative adults or HIV positive adults
62795971|NCT01571752||COSU|Current opioid/stimulant users
62795972|NCT01571752||COSU-NTS|Non-treatment seekers
62795973|NCT01571752||COSU-TS|Treatment seekers
62795974|NCT01571752||NDU|Non-drug-users
62023540|NCT04444154|EXPERIMENTAL|Group with video and quizz|oral hygiene advice given orally and an additional appointment between the device bonding appointment and the first check-up. This is a 15-minute session dedicated to teaching oral hygiene. This session will include watching of an educational video followed by a quiz, as well as the application of the methods taught in the sink (using plate developer and the Oral B electric toothbrush with special orthodontic head).
62023541|NCT03102099||contrast-enhanced ultrasound group|The contrast-enhanced ultrasound(CEUS)patients will undergo biopsy with contrast-enhanced ultrasound guidance.
62023542|NCT03102099||conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
62023543|NCT02751281|ACTIVE_COMPARATOR|pneumatic percutaneous nephrolithotomy|pneumatic percutaneous nephrolithotomy is type of surgery in treatment of kidney stone
62023544|NCT02751281|ACTIVE_COMPARATOR|Ultra-sonic percutaneous nephrolithotomy|Ultra-sonic percutaneous nephrolithotomy is type of surgery in treatment of kidney stone
62023545|NCT05528081||Persons with migraine disease|Persons diagnosed with migraine based on the third edition of the International Classification of Headache Disorders (ICHD-3) and underwent baseline 3-tesla MRI
62023546|NCT05528081||Persons with medication-overuse headache|Persons diagnosed with MOH based on the ICHD-3 and underwent baseline 3-tesla MRI
62023547|NCT05528081||Healthy controls|Healthy individuals with no history of primary or secondary headache based on the ICHD-3 and underwent baseline 3-tesla MRI
62023548|NCT00559559|OTHER|Control Group|Patient Notifier turned OFF
62023549|NCT00559559|EXPERIMENTAL|Treatment group|Patient Notifier turned ON
62023550|NCT03357601|EXPERIMENTAL|High Intensity Interval Training|six 20 second bouts of high intensity interval exercise (HIIT) separated by 2 minutes of active recovery with 3 minutes and warm up and cool down on the treadmill, three times per week for five weeks
62023551|NCT03357601|EXPERIMENTAL|MCEET|14 minutes of Moderate Endurance Training with 3 minutes and warm up and cool down on the treadmill, three times per week for five weeks
62023552|NCT01100164|EXPERIMENTAL|eszopiclone 3 mg|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
62023553|NCT01100164|ACTIVE_COMPARATOR|zopiclone 7,5mg|Zopiclone once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
62023554|NCT01165281|EXPERIMENTAL|001|R331333 (referred to as JNS024 ER or CG5503) One 25 mg to 200 mg capsule twice daily for 4 weeks.
62023555|NCT01165281|ACTIVE_COMPARATOR|002|Oxycodone CR One 5 mg to 40 mg capsule twice daily for 4 weeks.
62414533|NCT03800134|PLACEBO_COMPARATOR|Arm 2: Placebo with platinum-based chemotherapy|"Patients will receive placebo in combination with platinum-based chemotherapy every 3 weeks for up to 4 cycles prior to surgery, followed by placebo monotherapy every 4 weeks for up to 12 cycles after surgery unless disease is deemed unresectable, disease recurrence, or unacceptable toxicity~The platinum-based chemotherapy will be based on tumour histology and Investigator discretion:~* cisplatin with pemetrexed~* carboplatin with pemetrexed~* carboplatin with paclitaxel~* cisplatin with gemcitabine (or carboplatin with gemcitabine for patients who have comorbidities or who are unable to tolerate cisplatin per the investigator's judgment)"
62795975|NCT01571752||Unclassified|
62023556|NCT05711069|ACTIVE_COMPARATOR|Core Stability Exercise Program Group|23 Football players from Gönyeli Futbol Akademisi voluntarily will participate in the study. Subjects will include to study if they fulfil criteria. Athletes will involve 8 Weeks core stability exercise program. During this process they will continue to attend routine football training program. After 8. Weeks assessments will be repeated.
62023557|NCT05711069|OTHER|Routine Football Training Program Group|22 Football players from Gönyeli Futbol Akademisi voluntarily will participate in the study. Subjects will include to study if they fulfil criteria. Kicking velocity, run speed and agility performance will evaluate and athletes will continue to attend football training program. After 8 Weeks assessments will be repeated.
62023558|NCT04098692|EXPERIMENTAL|Single-Arm: Derazantinib (Part 1 and Part 2)|"* Part 1: 300 mg Derazantinib oral administration followed by 100 μg \[14C\]-Derazantinib intravenous microdose~* Part 2: 300 mg \[14C\]-Derazantinib oral administration"
62414534|NCT02790619|ACTIVE_COMPARATOR|Meditation and Active Stimulation 1|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.Participant will then receive 20 minutes of tDCS with Anode over F8 and cathode over left supraorbital area with 1 milliamp(mA) stimulation with intervention administration delivered by tDCS via Chattanooga Ionto Iontophoresis System-Phoresor.
62795976|NCT06654440|EXPERIMENTAL|Single Group|
62795977|NCT02289638|EXPERIMENTAL|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
62023559|NCT03952247|EXPERIMENTAL|Single Use Bronchoscopy|optical guidance of percutaneous tracheotomy is done by single use bronchoscopy
62023560|NCT03952247|ACTIVE_COMPARATOR|Conventional Multi Use Bronchoscopy|optical guidance of percutaneous tracheotomy is done by conventional multi use bronchoscopy
62023561|NCT05950802|NO_INTERVENTION|Cyclophosphamide and fludarabine, standard dose|Fludarabine 30mg/m2 Cyclophosphamide 500mg/m2 Days -4, -3, -2
62023562|NCT05950802|EXPERIMENTAL|Cyclophosphamide and fludarabine, standard dose with radiation|Fludarabine 30mg/m2 Cyclophosphamide 500mg/m2 Days -6, -5, -4, and 2 Gy in 2 Fractions Days -3, -2
62023563|NCT05950802|EXPERIMENTAL|Cyclophosphamide (intermediate dose) and fludarabine|Fludarabine 30mg/m2 Cyclophosphamide 750mg/m2 Days -4, -3, -2
62023564|NCT05950802|EXPERIMENTAL|Cyclophosphamide (intermediate dose) and fludarabine with radiation|Fludarabine 30mg/m2 Cyclophosphamide 750mg/m2 Days -6, -5, -4, and 2 Gy in 2 Fractions Days -3, -2
62023565|NCT04425083||Polycystic Ovary Syndrome|Polycystic Ovary Syndrome women
62023566|NCT04425083||control|non- Polycystic Ovary Syndrome women
62023567|NCT02280603|EXPERIMENTAL|DA-4001C|DA-4001C is administered
62023568|NCT02280603|ACTIVE_COMPARATOR|5% minoxidil|5% minoxidil is administered
62023569|NCT04092426||patients with keratoconus|"patients with keratoconus attending refractive surgery centers in Assiut will be subjected to the following :-~1. Full history and clinical evaluation.~2. collection of individual data ( residency , occupation , special habbit , chronic illness )~3. Analysis of results to assess prevelance of keratoconus and its distribution geographically in Assiut"
62023570|NCT01817205|OTHER|TACE with Hyperthermia treatment|Interventions: TACE to all liver lesions and two sessions of systemic hyperthermia performed at 24 hours and 48 hours respectively after TACE.
62414535|NCT02790619|ACTIVE_COMPARATOR|Meditation and Active Stimulation 2|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.Participant will then receive 20 minutes of tDCS with Anode over F8 and cathode over left supraorbital area with 2 mA stimulation with intervention administration delivered by tDCS via Chattanooga Ionto Iontophoresis System-Phoresor.
62414536|NCT02790619|SHAM_COMPARATOR|Meditation and Sham Stimulation|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.The participants in the sham study will receive Sham tDCS (no stimulation) with Anode over F8 and cathode over left supraorbital area with intervention administration delivered by Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor
62587211|NCT03356639|EXPERIMENTAL|ASP6981 135 mg, then matching Placebo|Participants in Sequence CD will first receive ASP6981 capsules orally (135 mg) during period 1. After a 14-day washout period, participants receive matching placebo during period 2. Participants will receive ASP6981 capsules or matching placebo every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, ASP6981 or matching placebo will be administered under fasting conditions.
62587212|NCT03356639|EXPERIMENTAL|Matching Placebo, then ASP6981 135 mg|Participants in Sequence DC will first receive matching placebo capsules orally during period 1. After a-14 day washout period, participants receive ASP6981 (135 mg) during period 2. Participants will receive matching placebo or ASP6981 capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, matching placebo or ASP6981 will be administered under fasting conditions.
62587213|NCT06647524|EXPERIMENTAL|THC then Placebo|Participants in this arm will receive THC then placebo in a 2-session per subject double-blind, random assignment, placebo-controlled counterbalanced design. (Participants randomized to receive THC in the first session will receive placebo at the 2nd session.) Sessions will be scheduled at least one week apart. Tasks tapping each of the major cognitive memory-related domains will be performed in the MRI scanner, to reveal the relevant underlying circuitry and its disruption by drug using functional MRI.
62587214|NCT06647524|PLACEBO_COMPARATOR|Placebo then THC|Participants in this arm will receive placebo then THC in a 2-session per subject double-blind, random assignment, placebo-controlled counterbalanced design. (Participants randomized to receive placebo in the first session will receive THC at the 2nd session.) Sessions will be scheduled at least one week apart. Tasks tapping each of the major cognitive memory-related domains will be performed in the MRI scanner, to reveal the relevant underlying circuitry and its disruption by drug using functional MRI.
62587215|NCT05887271|EXPERIMENTAL|Low calorie meal replacement plan (MRP) arm|The MRP comprises of 3-4 meals a day (850kcal/day) supplied by Counterweight. Participants will be supported by professional research dieticians, and a study clinician. Participant health and medications will be monitored throughout the study.
62587216|NCT05887271|ACTIVE_COMPARATOR|Guideline driven care with attention control arm|Dietary advice to participants will be given in line with NICE guidelines for cardiovascular risk modification. Heart failure specific advice on exercise will be given in line with guidelines. Health advice will be reinforced at regular 4-weekly phone calls.
62023571|NCT05006365|EXPERIMENTAL|Transcranial Pulse Stimulation|Investigators will use a single-blind randomized controlled trial design with two-armed repeated measures. The trial design complies with the Consolidated Standards of Reporting Trials (CONSORT) statement. The first arm is the Intervention Group (Transcranial Pulse Stimulation) (TPS group)
62414537|NCT06306573||Primary Cohort|The Primary Cohort will include NYHA Class II heart failure subjects receiving a CardioMEMS PA Sensor implant in the commercial setting.
62414538|NCT06306573||Full Cohort|The Full Cohort will include both NYHA Class II and Class III heart failure subjects receiving a CardioMEMS PA Sensor implant in the commercial setting.
62587217|NCT06020612||Presence of desmoplasia|Tumors with presence of desmoplasia according to the predefined definition.
62587218|NCT06020612||Absence of desmoplasia|Tumors in absence of desmoplasia according to the predefined definition.
62587219|NCT04980820|EXPERIMENTAL|FFP2|This arm starts with a FFP2 mask and switches to a FFP3 mask.
62587220|NCT04980820|EXPERIMENTAL|FFP3|This arm starts with a FFP3 mask and switches to a FFP2 mask.
62795978|NCT02289638|EXPERIMENTAL|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
62795979|NCT02527590|EXPERIMENTAL|patient with neuropathic pain with allodynia|
62220046|NCT05617482|ACTIVE_COMPARATOR|Ultrasound guided ilioinguinal, iliohypogastric TAP block|In ilioinguinal-iliohypogastric block group, the probe will be placed medial to the lateral one-third of the line joining the umbilicus and the anterior superior iliac spine (ASIS). The anterior superior iliac crest, iliacus muscle, internal oblique, transverses abdominis, and the ILIH nerves between them will be identified. After appreciating the sonoanatomy, the ILIH nerve will be approached with the 23-gauge Quincke spinal needle through in-plane technique and 10 ml of 0.25% bupivacaine will be injected all around and the drug spread will be appreciated.
62795980|NCT02527590|EXPERIMENTAL|healthy volunteers|
62220047|NCT05617482|ACTIVE_COMPARATOR|Ultrasound guided transversus abdominis plane block|The transducer will be placed at between the lower rib margin and the iliac crest, the 23-gauge Quincke spinal needle needle passed through the external oblique and internal oblique muscle till reaching the transversus abdominis sheet. 20 ml of 0.25% bupivacaine will be injected
62795981|NCT05494606||Participants receiving upadacitinib|Participants receiving upadacitinib for moderate to severe Ulcerative colitis (UC) in real-world practice.
62795982|NCT06411873|PLACEBO_COMPARATOR|Control Group|The patients included in the control group received the customary protein amount and were fed a standard formula (Pediacomplete, Abbot, Indonesia)
62795983|NCT06411873|EXPERIMENTAL|Intervention Group|The patients included in the intervention group received the same formula like control group with the addition of modular protein supplement PURO ISOPRO WPI Whey Isolate PLAIN, Puro Pure Nutrition, Sukoharjo, Indonesia (BPOM : MD 862312050010)
62795984|NCT03386721|EXPERIMENTAL|Cohort A (Part I)|Checkpoint Inhibitor (CPI)-Naïve Participants with non-small-cell lung cancer (NSCLC) who have not received CPI therapy previously will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: collection of fresh tumor biopsies (at baseline and on-treatment) will be optional.
62795985|NCT03386721|EXPERIMENTAL|Cohort B (Part I)|CPI-Experienced Participants (NSCLC) who have received CPI therapy previously will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.
62220048|NCT05617482|ACTIVE_COMPARATOR|Ultrasound guidedQuadratus lumborum block|The transducer will be placed at the level of the anterosuperior iliac spine and will move cranially until the 3 abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border was visualized (hook sign), leaving underneath the internal oblique muscle, like a roof over the quadratus lumborum muscle. The probe will be tilted down to identify a bright hyperechoic line that corresponded with the middle layer of he thoracolumbar fascia. The needle (21 gauge) will be inserted in plane from anterolateral to posteromedial. The optimal point of injection for the QL block will be determined over the lumbar interfacial triangle using hydrodissection.
62220049|NCT05451914|EXPERIMENTAL|My Diabetes Care|Patients have access to an existing patient web portal (i.e., Epic's MyChart) embedded with My Diabetes Care.
62220050|NCT05451914|NO_INTERVENTION|Usual Care|Patients will have access to an existing patient web portal (i.e., Epic's MyChart) NOT embedded with My Diabetes Care (i.e., usual care)
62414539|NCT03278639|EXPERIMENTAL|Rhythmic auditory stimulation|Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by music therapists board-certified in RAS.
62414540|NCT03278639|ACTIVE_COMPARATOR|Kinesiology|Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by board-certified kinesio therapists. The objectives of the training sessions will match those of RAS.
62414541|NCT00068770|ACTIVE_COMPARATOR|p450 ( +EIASD)|"on p450 inhibitor (Patients taking anttiseizure drugs that are known to induce the hepatic drug-metabolizing enzymes - including phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine)~celecoxib and radiation therapy will be adminstered with this arm"
62414542|NCT00068770|ACTIVE_COMPARATOR|nonp450 (-EIASD)|"not on p450 inhibitor (Patients either NOT taking anti-seizure drugs or ones that are known to not significantly influence the hepatic drug-metabolizing enzymes - including gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine,topiramate, zonisamide and filbamate.~celecoxib and radiation therapy will be adminstered with this arm"
62414543|NCT02550509|EXPERIMENTAL|patients with hemiplegia after stroke|ultrasound echogenicity paraclinical assessment and elastography to patients with hemiplegia following stroke with an indication of injection of botulinum toxin into the triceps sural
62414544|NCT03033069|EXPERIMENTAL|Brexpiprazole + Sertraline|Participants were administered oral brexpiprazole initial dose of 0.5 milligram (mg)/day plus sertraline initial dose of 50 mg/day. The dose was up titrated to brexpiprazole maximum dose of 3 mg/day and sertraline maximum dose of 200 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received sertraline matching placebo based on dose titration/adjustment up to Week 12.
62414545|NCT03033069|EXPERIMENTAL|Brexpiprazole|Participants were administered oral brexpiprazole initial dose of 0.5 mg/day The dose was up titrated to brexpiprazole maximum dose of 3 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received sertraline matching placebo up to Week 12.
62023572|NCT05006365|ACTIVE_COMPARATOR|Waitlist Control Group|Second arm is the waitlist control group.
62795986|NCT03386721|EXPERIMENTAL|Cohort C (Part I)|"This is a mandatory biopsy cohort based on the treatment's safety and preliminary activity analysis to enroll CPI-Naive Participants. Participants (NSCLC) will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
62795987|NCT03386721|EXPERIMENTAL|Cohort D Arm I (Part I)|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel.~Participants will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
62795988|NCT03386721|EXPERIMENTAL|Cohort D Arm 2 (Part I)|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel.~Participants will receive simlukafusp alfa intravenous (IV) infusion once in 3 weeks (Q3W) up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q3W at a dose of 1200 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
62023573|NCT01952912|ACTIVE_COMPARATOR|PkEP|
62795989|NCT03386721|EXPERIMENTAL|Cohort D Arm 3 (Part I)|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel will receive a single-agent gemcitabine or vinorelbine as per approved protocol.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
62795990|NCT03386721|EXPERIMENTAL|Cohort E Arm I (Part II)|"This cohort will enroll participants (NSCLC) with High-Tumor PD-L1 Expression who have not received any prior systemic therapy. Participants will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
62023574|NCT01952912|ACTIVE_COMPARATOR|OP|
62587221|NCT06303570|EXPERIMENTAL|CBL-514 injection|Eligible participants will receive CBL-514 administered in doses ranging from 1 mL to a maximum of 20 mL per lipoma, with treatments scheduled at intervals of approximately 4 weeks, up to 5 treatments.
62795991|NCT03386721|EXPERIMENTAL|Cohort E Arm 2 (Part II)|"This cohort will enroll participants (NSCLC) with High-Tumor PD-L1 Expression who have not received any prior systemic therapy. Participants will receive simlukafusp alfa IV infusion in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
62795992|NCT03386721|EXPERIMENTAL|Cohort F (Part I)|"CPI-experienced, docetaxel naive participants (NSCLC) who experienced disease progression during or following treatment with a platinum - containing regimen. Participants will receive combination of simlukafusp alfa and atezolizumab in a Q3W schedule. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.~Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional."
62023575|NCT05783180|EXPERIMENTAL|Treatment|Sesderma LACTYFERRIN™ Forte (64mg/20ml, TID) and Sesderma ZINC Defense™ (20mg/20ml QD) + SOC (N=20).
62023576|NCT05783180|PLACEBO_COMPARATOR|Control|Placebo +SOC (N=20)
62023577|NCT02612012||Axillary radiotherapy|
62023578|NCT03942718|NO_INTERVENTION|Control group|Participants will obtain no exercise program. After 12 weeks, the patients in the control group will be invited to participate in the training group.
62023579|NCT03942718|EXPERIMENTAL|Aerobic exercise group|Participants will obtain aerobic exercise only.
62023580|NCT03942718|EXPERIMENTAL|Anaerobic exercise group|Participants will obtain aerobic and anaerobic exercise respectively
62023581|NCT06634043|ACTIVE_COMPARATOR|Control group|Coronally Advanced Tunel + ADM (Novomatrix®)
62023582|NCT06634043|EXPERIMENTAL|test group|Coronally Advanced Tunel + ADM (Novomatrix®) + L-PRF
62023583|NCT05255016|SHAM_COMPARATOR|Standard of care + Sham CXL + Artificial Tears|Standard-of-care treatment and Sham CXL and administration of artificial tears.
62023584|NCT05255016|EXPERIMENTAL|Standard of care + CXL + Riboflavin 0.25% TE Solution|Standard of care treatment and the experimental combination product. The PXL Platinum 330 Illumination System is a portable electronic medical device. The device's light emitting diode (LED) is used to deliver a metered dose of UV-A light to a targeted treatment area for illuminating the cornea during corneal collagen CXL. The riboflavin solution is an isotonic (0.9%) sodium chloride solution containing 0.25% riboflavin, 1% hydroxypropylmethylcellulose, and 0.007% benzalkonium chloride, adjusted to a pH of 7.0, and packaged in 2 mL sterile syringes for topical ophthalmic use.
62023585|NCT02519504||Duarte galactosemia|Pediatric subjects with Duarte galactosemia will undergo direct assessments of cognitive skills (memory, executive function, and auditory processing), communication processes (speech and language), physical development (including motor skills, coordination, and occurrence of tremors), and social-emotional development.
62023586|NCT02519504||Control|Pediatric subjects without Duarte galactosemia will undergo direct assessments of cognitive skills (memory, executive function, and auditory processing), communication processes (speech and language), physical development (including motor skills, coordination, and occurrence of tremors), and social-emotional development.
62023587|NCT00680407|EXPERIMENTAL|silymarin 420 mg|420 mg Legalon (silymarin) three times daily
62023588|NCT00680407|EXPERIMENTAL|silymarin 700 mg|700 mg of Legalon (silymarin) three times daily
62795993|NCT03386721|EXPERIMENTAL|Cohort G (Part III)|CPI-naïve SCC of the head and neck (SCCHN) (20 response-evaluable participants), mandatory biopsies. Participants in cohort G Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
62795994|NCT03386721|EXPERIMENTAL|Cohort H (Part III)|Previously treated, CPI-experienced squamous cell carcinoma head and heck cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort H Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
62795995|NCT03386721|EXPERIMENTAL|Cohort I (Part III)|Previously treated, CPI-naïve squamous esophageal cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort I Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
62795996|NCT03386721|EXPERIMENTAL|Cohort J (Part III)|Previously treated, CPI-naïve squamous cervical cancer (20 response evaluable participants): mandatory biopsy. Participants in cohort J Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
62795997|NCT03386721|EXPERIMENTAL|Cohort K (Part III)|CPI-naïve SCC of the head and neck (SCCHN) (20 response-evaluable participants), mandatory biopsies. Participants in cohort K Part III will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
62795998|NCT03386721|EXPERIMENTAL|Cohort L (Part III)|Previously treated, CPI-experienced squamous cell carcinoma head and neck cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort L Part III will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
62023589|NCT00680407|PLACEBO_COMPARATOR|Placebo|Placebo (lactose pill)
62023590|NCT06635239|EXPERIMENTAL|Single-arm intervention|Co-creation with women with breast cancer, their families, and healthcare professionals of a MOOC aimed at women with breast cancer; and evaluation of the MOOC's effectiveness and acceptability.
62587222|NCT06303570|PLACEBO_COMPARATOR|0.9% Sodium Chloride|Eligible participants will receive 0.9% Sodium Chloride administered in doses ranging from 1 mL to a maximum of 20 mL per lipoma, with treatments scheduled at intervals of approximately 4 weeks, up to 5 treatments.
62220051|NCT02891837|EXPERIMENTAL|L-citrulline|"* Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;~* Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;~* Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~* 9 mg/kg/hr continuous infusion for up to 48 hours."
62220052|NCT02891837|PLACEBO_COMPARATOR|Placebo|"* Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;~* Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;~* Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~* 9 mg/kg/hr continuous infusion for up to 48 hours."
62414546|NCT03033069|ACTIVE_COMPARATOR|Sertraline|Participants were administered oral sertraline initial dose of 50 mg/day. The dose was up titrated to sertraline maximum dose of 200 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received brexpiprazole matching placebo and sertraline matching placebo based on dose titration/adjustment up to Week 12.
62414547|NCT03033069|PLACEBO_COMPARATOR|Placebo|Participants received oral brexpiprazole matching placebo tablet and oral sertraline matching placebo capsules up to Week 12.
62587223|NCT04121156|ACTIVE_COMPARATOR|2 milli Amp dose of HD-tDCS treatment|2 milli Amp dose of HD-tDCS treatment for for 25 minutes, once working day for 2 weeks, total 10 sessions
62587224|NCT04121156|SHAM_COMPARATOR|Sham (placebo) dose of HD-tDCS treatment|Sham (placebo) dose of HD-tDCS treatment for 25 minutes, once working day for 2 weeks, total 10 sessions
62795999|NCT03386721|EXPERIMENTAL|Cohort M (Part III)|Esophageal SCC participants will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
62796000|NCT03386721|EXPERIMENTAL|Cohort N (Part III)|Cervical SCC participants will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
62796001|NCT06726005|EXPERIMENTAL|Functional appliance group|Upon diagnostics, functional appliance Twin block will be proposed to the participants for one year.
62796002|NCT00602420|EXPERIMENTAL|Naproxen|Patients receive oral naproxen twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.
62796003|NCT00602420|PLACEBO_COMPARATOR|Placebo|Patients receive an oral placebo twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.
62796004|NCT04104607|EXPERIMENTAL|CC-1 therapy|Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation. In case of clinical benefit, additional cycles with a total of up to six are possible.
62796005|NCT05609435|EXPERIMENTAL|REASSURE Follow Up care|
62796006|NCT05609435|NO_INTERVENTION|Usual Follow Up Care|
62796007|NCT03117855|EXPERIMENTAL|Treatment (capecitabine, yttrium Y-90 radioembolization)|Patients undergo yttrium Y 90 resin microspheres radioembolization over 60-90 minutes on day 1. Patients receive capecitabine PO BID on days 1-14.
62587225|NCT02821013|ACTIVE_COMPARATOR|Arm 1: Intermittent PD-1 Inhibitor therapy|Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.
62414548|NCT06146543|EXPERIMENTAL|neurology patients|Patients coming to the neurology clinic for lumbar puncture.
62414549|NCT06146543|NO_INTERVENTION|Control|The scale will be applied to the same patient group before and after lumbar puncture without intervention.
62414550|NCT06599658|EXPERIMENTAL|Group 1|Covid-19 booster every 3 months and Inactivated influenza vaccine (IIV) at baseline
62587226|NCT02821013|ACTIVE_COMPARATOR|Arm 2: Continuous PD-1 Inhibitor therapy|Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.
62587227|NCT02510963|EXPERIMENTAL|Tenofovir 24 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 24 weeks of gestation to 1 month postpartum
62796008|NCT06709443||PPIA: children anesthetized in the presence of parents|PPIA: Children induced during the presence parents to assess the level of anxiety while aneshetizing.
62796009|NCT06709443||Control group|Control Group: children induced without the parental presence to assess level of anxiety during anesthitizing.
62023591|NCT05951322|EXPERIMENTAL|Shockwave therapy|"All patients were received (ESWT) at sitting position, exposed the affected shoulder, the shoulder adducted and elbow extended and the shock wave applicator was directed in most tender point near the insertion of rotator cuff at greater tuberosity under the acromion \[23\].~The treatment area was prepared with a coupling gel to minimize the loss of shockwave at the interface between applicator tip and skin.~Each patient was received (6000 shocks,21000 shock/ session, 3 session 2 weeks apart, energy flux density 0.22 mJ/mm2, energy level 5-7, pulse rate 160/min., 2-3Hz)"
62220053|NCT04595318|EXPERIMENTAL|Standard clinical care first, followed by standard clinical care and varenicline|"Four weeks of standard clinical care (SCC) in an outpatient substance use disorder treatment program. SCC includes individual counseling, at least once a month, that uses motivational and cognitive behavioral strategies, may address cannabis or tobacco use, and is delivered by trained substance use disorder treatment counselors; and medications for opioid use disorder (MOUD).~This is followed by four weeks of SCC plus varenicline treatment (SCC and VT). Varenicline treatment included a gour-week supply of standard doses: 0.5mg for the first three days, 0.5mg twice a day for the following four days, and 1 mg twice a day for the remaining 21 days."
62587228|NCT02510963|EXPERIMENTAL|Tenofovir 28 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 28 weeks of gestation to 1 month postpartum
62023592|NCT05951322|ACTIVE_COMPARATOR|Phonophoresis|Pagani ultrasound apparatus 200 cosistts of multi frequency head(1 and 3 MHz), surface area 4 cm², continuous and pulsed mode, main voltages: 100-240-VAC.50/60Hz.
62587229|NCT02510963|ACTIVE_COMPARATOR|Tenofovir 32 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 32 weeks of gestation to 1 month postpartum
62220054|NCT04595318|EXPERIMENTAL|Standard clinical care and varenicline first, followed by standard clinical care|"Four weeks of standard clinical care (SCC) plus varenicline treatment (SCC and VT). SCC includes individual counseling, at least once a month, that uses motivational and cognitive behavioral strategies, may address cannabis or tobacco use, and is delivered by trained substance use disorder treatment counselors; and medications for opioid use disorder (MOUD).Varenicline treatment included a gour-week supply of standard doses: 0.5mg for the first three days, 0.5mg twice a day for the following four days, and 1 mg twice a day for the remaining 21 days.~This is followed by four weeks of SCC in an outpatient substance use disorder treatment program, as described above."
62220055|NCT03138772||Healthy Controls|No intervention. Only monitoring LCI
62220056|NCT03138772||Cystic Fibrosis Patients|No intervention. Only monitoring LCI
62023593|NCT04262999||drug sodium valproate|individuals on antiepileptic drug sodium valproate for at least 1 year at the time of participation of the study.
62587230|NCT00685724|EXPERIMENTAL|1|Following 2 sessions of MET intervention received by all patients, patients in Condition 1 receive no further intervention.
62587231|NCT00685724|EXPERIMENTAL|2|Patients in Condition 2 will receive 8 sessions of the CBT (Cognitive Behavioral Therapy) intervention.
62587232|NCT00685724|EXPERIMENTAL|3|Patients in Condition 3 will receive 8 sessions of CBT plus aftercare treatment.
62587233|NCT02219581|PLACEBO_COMPARATOR|Placebo|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of placebo intravenously in addition to a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty. The first dose of placebo will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
62796010|NCT05178199|EXPERIMENTAL|Remote Psychological Support Group|The study will invite nurses through QR code on line, and assess their background, self-efficacy, fear of COVID-19, psychological distress, and quality of life by questionnaires first. Then four evacuation acute wards (A, B, C, and D) will be randomly allocated, and the two wards will be drawn out as experimental group ward. Each group will be followed for 2 months and their outcomes will be assessed at 3 time points: baseline (pre-RPSG) (T0), and 4 (T1), 8 (T2) weeks after-RPSG, T0-T2, respectively.
62023594|NCT04262999||drug levetiracetam|individuals on antiepileptic drug levetiracetam monotherapy for at least 1 year at the time of participation of the study.
62023595|NCT04262999||drug sodium valproate + levetiracetam|individuals on antiepileptic drug sodium valproate + levetiracetam combination therapy for at least 1 year at the time of participation of the study.
62023596|NCT04262999||control group|systemically healthy individuals
62220057|NCT06610058|EXPERIMENTAL|IASTM First|This arm of the study received IASTM treatment on the first day and the wait/control on the second day of the study
62220058|NCT06610058|EXPERIMENTAL|Wait/control First|This arm of the study waited (was the control) on the first day and received IASTM treatment on the second day of the study.
62414551|NCT06599658|EXPERIMENTAL|Group 2|Covid-19 booster every 3 months and IIV at 1 month
62414552|NCT06599658|EXPERIMENTAL|Group 3|Covid-19 booster every 6 months and IIV at baseline
62414553|NCT06599658|EXPERIMENTAL|Group 4|Covid-19 booster every 6 months and IIV at 1 month
62414554|NCT00868816|EXPERIMENTAL|1|12 cycles of oxaliplatine based adjuvant chemotherapy
62414555|NCT00868816|ACTIVE_COMPARATOR|2|8 cycles of oxaliplatine based adjuvant chemotherapy
62414556|NCT01537809|ACTIVE_COMPARATOR|D3 600 IU/ daily|Subjects randomized to 600 IU/day of vitamin D3 taken orally for six months.
62414557|NCT01537809|ACTIVE_COMPARATOR|D3 1000 IU/ daily|Subjects randomized to 1000 IU/day of vitamin D3 taken orally for six months.
62414558|NCT01537809|ACTIVE_COMPARATOR|D3: 2000 IU/daily|Subjects randomized to 2000 IU/day of vitamin D3 taken orally for six months.
62414559|NCT06204848|EXPERIMENTAL|Imaging using the SVO-ID|Patients will have their eyes imaged with the SVO-ID as part of a study visit.
62414560|NCT03455530|EXPERIMENTAL|Intervention Group|The intervention group will receive the IH-enhanced CHW intervention before (\~3 months) the other arm (Delayed Intervention Group).
62414561|NCT03455530|OTHER|Delayed Intervention Group|The delayed intervention group will receive the IH-enhanced CHW intervention after (\~3 months) the other arm (Intervention Group).
62414562|NCT04475731|EXPERIMENTAL|Experimental arm|"MRD+ Ph+ ALL adult patients will receive Ponatinib x 4 weeks x 3 courses; +/-Concomitant chemotherapy (according to hematologic status).~Patients will receive the study drug until disease relapse or progression."
62220059|NCT03606668|EXPERIMENTAL|People with Multiple Sclerosis (PwMS) and Chronic Pain|"Participants with MS will only be able to receive eight treatment sessions in this study group and will complete their treatment over four weeks. Two treatments sessions must be completed each week (of the four weeks) and separated by at least one day.~Participants will attend a baseline visit with assessment and training procedures and receive their first treatment immediately after all baseline assessments. Participants will then complete the remaining seven treatment sessions over four weeks. At the final treatment session, participants will repeat assessments. One week following the final treatment session, participants will be asked to return to clinic to complete assessments once more to test cumulative benefits one week following treatment end."
62220060|NCT05612152|ACTIVE_COMPARATOR|Referral to Quitline|Patients who indicate they are ready to quit in the next 30 days are offered an electronic referral to the state quitline for tobacco cessation services.
62220061|NCT05612152|EXPERIMENTAL|Choose2Quit|Patients who indicate they are ready to quit in the next 30 days are offered an electronic referral to the Choose2Quit tobacco treatment navigator who walks the patient through choices for tobacco cessation counseling, tobacco cessation medications and other supports (e.g. texting, apps) and facilitates placing referrals, orders and providing information.
62220062|NCT01981473||etanercept|Participants currently receiving etanercept treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
62220063|NCT01981473||adalimumab|Participants currently receiving adalimumab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
62220064|NCT01981473||infliximab|Participants currently receiving infliximab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
62220065|NCT04658238||Dry eye disease|Patients with dry eye disease
62220066|NCT04658238||Healthy controls|Healthy controls without dry eye disease
62220067|NCT06248333|EXPERIMENTAL|Active Stimulation|After randomization, participants will undergo STN-DBS ON in the 3-month blinded phase (Month 2 to Month 5) with the individual stimulation parameters determined in the parameter determination period, then continue to receive stimulation for the remainder of the study.
62220068|NCT06248333|SHAM_COMPARATOR|Sham Stimulation|After randomization, participants will undergo STN-DBS OFF in the 3-month blinded phase (Month 2 to Month 5) with 0mA current, then the stimulator will be turned on with individual stimulation parameters and left on for the remainder of the study.
62220069|NCT00670839|ACTIVE_COMPARATOR|A|GenHevac-B 20 microgram intramuscular use at M0, M1 and M6
62220070|NCT00670839|EXPERIMENTAL|B|GenHevac-B 40 microgram intramuscular use at M0, M1 and M6
62220071|NCT03062579|EXPERIMENTAL|ACTEMRA® (Tocilizumab)|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible.
62414563|NCT02446496|EXPERIMENTAL|Group A|Subjects will receive a single oral dose of cefadroxil tablet manufactured by GSK under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of cefadroxil tablet manufactured by NP under fasting condition in treatment period 2
62220072|NCT04814641||Infants with hypophosphatemia|Infant less than 3 months with severe bronchiolitis admitted in a pediatric intensive care unit, with hypophosphatemia in the first 5th days
62220073|NCT04814641||Infants without hypophosphatemia|Infant less than 3 months with severe bronchiolitis admitted in a pediatric intensive care unit, without hypophosphatemia
62220074|NCT01052103|EXPERIMENTAL|LY2140023|40 mg/day, given orally twice daily (BID) as a 20-mg tablet. LY2140023 dosage was adjustable from 10 mg to 40 mg BID.
62220075|NCT01052103|PLACEBO_COMPARATOR|Placebo|Placebo tablets to match LY2140023 tablets
62220076|NCT01391039|EXPERIMENTAL|Contrast perfusion and elastography arm|Intravenous injection of microbubble contrast agent and elastography
62220077|NCT02632162||cardiac surgery|active Group screening
62220078|NCT02632162||orthopedic surgery|control Group screening
62220079|NCT03801473|EXPERIMENTAL|robot assisted training (RAT)|RoboGait which is an automated locomotor therapy system was used for treating RAT group. The system composed of a robotic lower extremity orthosis, adjustable dynamic gait support, synchronized treadmill and biofeedback utilities
62220080|NCT03801473|ACTIVE_COMPARATOR|conventional training (CT)|Participants in CT group had physiotherapist assisted walking exercises on the parallel bars and on the ground with aids/cane, tripod or walker.
62220081|NCT02743026|EXPERIMENTAL|Intervention|participants will complete the FOXY intervention
62220082|NCT03444350|ACTIVE_COMPARATOR|Control group|SRP plus placebo
62220083|NCT03444350|EXPERIMENTAL|Gaseous ozone group|SRP plus gaseous ozone \[1 W (100 mJ, 10 Hz)\]
62220084|NCT01675479|EXPERIMENTAL|wavefront-guided LASIK|
62220085|NCT02084173|OTHER|MET|Motivational Enhancement Therapy (MET)
62220086|NCT02084173|OTHER|MET + CRA|Motivational Enhancement Therapy (MET) with subsequent add-on The Community Reinforcement Approach (CRA)
62220087|NCT01075802|EXPERIMENTAL|Tamoxifen|Dose escalation of tamoxifen in patients with low endoxifen levels
62220088|NCT00559390||Pre-PCOS|First degree relatives, either sisters or daughters, of women with Polycystic Ovary Syndrome.
62220089|NCT00559390||Controls|Sisters and daughters of women who do not have PCOS
62220090|NCT01367977||Ehlers-Danlos patients|Patients with diagnosed or suspected Classic or Hypermobile Ehlers-Danlos Syndrome
62023597|NCT00004010|EXPERIMENTAL|BEACOPP therapy|"Patients receive 4 cycles of BEACOPP therapy. Drugs utilized in this regimen include Bleomycin (B), Etoposide (E), Doxorubicin (A), Cyclophosphamide (C), Vincristine (O), Prednisone (P) and Procarbazine (P). Each cycle lasts 21 days and is characterized by intravenous pulses of Etoposide (Days 0-2), Doxorubicin (Day 0), Cyclophosphamide (Day 0), Bleomycin (Day 7), Vincristine (Day 7). Seven days of oral procarbazine (Days 0-6) and 14 days of oral prednisone (Days 0-13) are given during each cycle.~Growth factor support with Filgrastim (G-CSF) is given by subcutaneous injection daily beginning Day 8. Response will then be determined and stratification for further treatment."
62023598|NCT03846843|EXPERIMENTAL|OCR-002 - Treatment A|A single 5 g oral dose of OCR-002 oral solution administered under fasting conditions
62023599|NCT03846843|EXPERIMENTAL|OCR-002 - Treatment B|A single 5 g oral dose of OCR-002 oral solution administered under fed conditions
62023600|NCT03846843|EXPERIMENTAL|OCR-002 - Treatment C|A single 5 g intravenous dose of OCR-002 solution infused over 1 hour under fasting conditions
62220091|NCT02369640|EXPERIMENTAL|Error-avoidance training|Study group 1: Error-avoidance training (Focusing on achieving the highest possible metrics score by avoiding errors).
62220092|NCT02369640|EXPERIMENTAL|Error-management training|Study group 2: Error-management training (Focusing on making errors and thinking of them in a positive way).
62220093|NCT05569772|ACTIVE_COMPARATOR|semaglutide|semaglutide SC once weekly, up titration over 2 month period to 1mg/week (0.25mg once weekly, after 4 weeks 0.5mg once weekly and after 8 weeks the maintenance dose of 1mg once weekly), treatment duration of max. 3 years
62220094|NCT05569772|PLACEBO_COMPARATOR|placebo|placebo SC once weekly, the same dose-escalation regimen, using matching injections, treatment duration of max. 3 years
62414564|NCT02446496|EXPERIMENTAL|Group B|Subjects will receive a single oral dose of cefadroxil tablet manufactured by NP under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of cefadroxil tablet manufactured by GSK under fasting condition in treatment period 2
62414565|NCT03639584||Group 1|Patients admitted to ICU less than 48 hours and the anticipated stay is less than 5 days. Take blood sample on the day of enrollment.
62796011|NCT05178199|ACTIVE_COMPARATOR|Mindfulness through audio and video|The study will invite nurses through QR code on line, and assess their background, self-efficacy, fear of COVID-19, psychological distress, and quality of life by questionnaires first. Then four evacuation acute wards (A, B, C, and D) will be randomly allocated, and the two wards will be drawn out as experimental group ward. Each group will be followed for 2 months and their outcomes will be assessed at 3 time points: baseline (pre-RPSG) (T0), and 4 (T1), 8 (T2) weeks after-RPSG, T0-T2, respectively.
62023601|NCT03846843|EXPERIMENTAL|OCR-002 - Treatment D|A single 5 g oral dose of OCR-002 oral solution administered under fasting conditions following discontinuation of lactulose
62220095|NCT03618368|EXPERIMENTAL|Blinded THERANOVA-500 dialyzer|This group of 25 subjects is dialyzed with masked THERANOVA-500 dialyzer enabling Expanded Hemodialysis (HDx) therapy.
62414566|NCT03639584||Group 2|Patients admitted to ICU less than 48 hours and the anticipated stay is longer than 5 days. Take blood sample on the day of enrollment, 7th, 14th, 21st, and 28th. Stop blood sample once exit.
62414567|NCT03639584||Group 3|Patients admitted to ICU 3\~7 days. Take blood sample on the day of enrollment.
62414568|NCT03639584||Group 4|Patients admitted to ICU 8\~14 days. Take blood sample on the day of enrollment.
62796012|NCT01002651|EXPERIMENTAL|Wheat Bran Extract (high dose)|
62796013|NCT01002651|EXPERIMENTAL|Wheat Bran Extract (low dose)|
62796014|NCT01002651|PLACEBO_COMPARATOR|placebo|
62796015|NCT05120414|ACTIVE_COMPARATOR|Control|patients in control group did balance exercises for period of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly.) The exercises included standing with feet together, Standing in Tandem position, Standing eye open to eye closed, multidirectional functional reach during standing, March in place and walk sideways.
62023602|NCT03846843|EXPERIMENTAL|OCR-002 - Treatment E|6 g OCR-002 per day (2 tablets TID for 6 g total daily dose)
62023603|NCT03846843|EXPERIMENTAL|OCR-002 - Treatment F|12 g OCR-002 per day (4 tablets TID for 12 g total daily dose)
62023604|NCT03846843|EXPERIMENTAL|OCR-002 - Treatment G|21 g OCR-002 per day (7 tablets TID for 21 g total daily dose)
62023605|NCT01459276|EXPERIMENTAL|FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μg HA of seasonal A/H1N1, A/H3N2 and B influenza antigens
62023606|NCT01459276|ACTIVE_COMPARATOR|FLUVALAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μg HA of seasonal A/H1N1, A/H3N2 and B influenza antigens
62023607|NCT01269892|OTHER|lactose-free milk|it is kind of nutritional regime
62023608|NCT01269892|OTHER|conventional milk|it is kind of nutritional regime
62220096|NCT03618368|PLACEBO_COMPARATOR|Blinded REVACLEAR-400 dialyzer|This group of 25 subjects is dialyzed with masked REVACLEAR-400 dialyzer enabling conventional hemodialysis (HD).
62220097|NCT03618368|EXPERIMENTAL|Unblinded THERANOVA-500 dialyzer|This group of 10 subjects is dialyzed with unmasked THERANOVA-500 dialyzer which enables Expanded Hemodialysis (HDx) therapy.
62414569|NCT03639584||Group 5|Patients admitted to ICU 15\~28 days. Take blood sample on the day of enrollment.
62414570|NCT04372810|EXPERIMENTAL|Intervention Group|Intervention group, assessed on day 1, then underwent manual manipulation intervention and were reevaluated post-intervention and again evaluated on the 7th post-treatment day and received preventive guidance at the end of the experiment (follow-up).
62414571|NCT04372810|SHAM_COMPARATOR|Sham Group|Sham group, evaluated on day 1 and day 7, and received preventive diabetes guidance at the end of the experiment (follow-up).
62414572|NCT00919165||control and study group|severe carotid artery stenosis in asymptomatic patients defined as greater than 80% stenosis angiographically or greater than 400 cm/sec peak systolic velocity on carotid doppler evaluation
62587234|NCT02219581|EXPERIMENTAL|Dexamethasone 10 mg|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of 10 mg dexamethasone. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting. Additionally, subjects will also receive a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty.
62587235|NCT02219581|EXPERIMENTAL|Dexamethasone 20 mg|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of 20 mg dexamethasone. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting. Additionally, subjects will also receive a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty.
62587236|NCT06452147|EXPERIMENTAL|Nerve block + standard anesthesia protocol|(described in detail in sub-trial protocol 1)
62220098|NCT03618368|PLACEBO_COMPARATOR|Unblinded REVACLEAR-400 dialyzer|This group of 10 subjects is dialyzed with unmasked REVACLEAR-400 dialyzer which enables conventional hemodialysis (HD).
62796016|NCT05120414|EXPERIMENTAL|Experimental|Experimental group received ankle strategy exercises in addition to balance exercises for a period of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly). Ankle strategy exercises included raising and lowering heels and forefeet, heel to toe walking, stepping up and down and right and left and diagonal inclination of body during standing.
62796017|NCT02486536|ACTIVE_COMPARATOR|Group A|Fast for 12h before the examination and take 8ml of Simethicone Emulsion (Berlin-Chemie, Germany, containing 40 mg simethicone in 1mL emulsion) with 250ml water 30min before capsule ingestion.CE are performed with the Pillcam SB2 capsule endoscopy system (Given Imaging Co. Ltd., Yoqnem, Israel).
62796018|NCT02486536|ACTIVE_COMPARATOR|Group B|the same as protocol A plus 1L Polyethylene glycol 11-12h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
62796019|NCT02486536|ACTIVE_COMPARATOR|Group C|the same as protocol A plus 2L Polyethylene glycol 10-12h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
62023609|NCT04798781|EXPERIMENTAL|telatinib + Keytruda|
62220099|NCT06610877|EXPERIMENTAL|To determine the most effective stimulation parameters for DRTT LIFU neuromodulation.|Investigators will record wrist accelerometer signals while participants maintain standardized postures that maximally elicit their tremor before, during, and after delivering LIFU stimulation.
62414573|NCT05166369|EXPERIMENTAL|Intervention targeted to healthcare providers (paediatricians, nurses and pharmacists) (ITHP)|"Professionals in the PC centres allocated to this group will receive a complex intervention, delivered remotely, which will include the following components:~i) Web based training that will include: communication skills training and optimal management of acute non-complicated RTI, including a specific training on delayed antibiotic prescription.~ii) By-monthly feedback about the rate of antibiotic prescription and consumption for RTI, center level and individual pediatrician level (information automatically gathered from electronic health records)."
62414574|NCT05166369|EXPERIMENTAL|Intervention targeted to parents (ITP)|PC centres allocated to this group will display posters and flyers to inform parents and/or caregivers about a mobile app. It will provide detailed information about respiratory tract infections and optimal use of antibiotics. The app will include information that will be of use before the consultation, but it will also allow the patient to interact with the physician during the consultation, potentially improving share decision-making. Importantly, the app will allow tailoring the guidance provided according to the type of infection or number of days with symptoms. The app will be accessible through an app store or directly using a QR (quick response) code to facilitate uptake. Professionals in the primary care centres allocated to this group will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI, at center level and individual pediatrician level (information automatically gathered from electronic health records).
62414575|NCT05166369|EXPERIMENTAL|Intervention targeted to patients and/or patient´s parents and to the healthcare providers (ITHP*P)|Centres allocated to this group will receive the two interventions described above (intervention targeted to parents plus intervention targeted to providers).
62587237|NCT06452147|EXPERIMENTAL|Intravenous infusion of lidocaine + standard anesthesia protocol|(described in detail in sub-trial protocol 2)
62587238|NCT06452147|NO_INTERVENTION|Standard anesthesia protocol|(If an intervention was found to be effective in the interim analysis, the executive committee will decide whether to add it to the standard anesthesia protocol.)
62587239|NCT06664775|EXPERIMENTAL|TachoSil|
62587240|NCT06664775|ACTIVE_COMPARATOR|Surgicel Original|
62796020|NCT02486536|ACTIVE_COMPARATOR|Group D|Group D: the same as protocol A plus 1L Polyethylene glycol 3-4h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
62796021|NCT02486536|ACTIVE_COMPARATOR|Group E|Group E: the same as protocol A plus 2L Polyethylene glycol 2-4h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
62023610|NCT01410838|PLACEBO_COMPARATOR|Broth- NaCl|Sodium chloride containing broth matched for sodium content to the MSG broth
62023611|NCT01410838|ACTIVE_COMPARATOR|Broth- MSG|MSG containing broth with the same sodium content as the placebo comparator.
62023612|NCT04265079|EXPERIMENTAL|Added weight to hand|
62023613|NCT02525107|EXPERIMENTAL|SCD patients on Hydroxyurea|Omega-3 capsules \[750 mg\], 4 capsules a day for 52 weeks. \[Each capsule will contain 417.9mg Docosahexaenoic acid \[DHA\], 50.8 mg Eicosapentaenoic acid \[EPA\] and 11.9mg Arachidonic acid \[AA\] and 1000 IU Vitamin E\]
62023614|NCT02525107|EXPERIMENTAL|SCD patients not on Hydroxyurea|Dietary Supplement: Placebo \[730 mg\], 4 capsules a day for 52 weeks.\[Each capsule will contain 538.2mg Oleic Acid \[OA\] and 1000 IU Vitamin E\]
62587241|NCT06016634|EXPERIMENTAL|Alendronate group|Single-arm prospective cohort of 24 adult with SCD
62796022|NCT05784545|PLACEBO_COMPARATOR|Placebo|
62796023|NCT05784545|EXPERIMENTAL|Blueberry Supplementation|
62796024|NCT00180388|EXPERIMENTAL|Endoscopic vein harvesting|Harvesting of vein for coronary artery bypass grafting using endoscopy to visualize the vein
62796025|NCT00180388|ACTIVE_COMPARATOR|Open Vein harvesting|Harvesting of vein for coronary artery bypass grafting without endoscopy
62220100|NCT04973904|EXPERIMENTAL|PD-1+Paclitaxel+Cisplatin+Bevacizumab|"Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W)~Paclitaxel 175mg/m2 IV every 3 weeks (Q3W)~Cisplatin 50mg/m2 (Q3W)~Bevacizumab 7.5mg/kg IV every 3 weeks (Q3W)"
62220101|NCT00538200|OTHER|1|Dietary Advice
62220102|NCT00538200|OTHER|2|Supplements
62220103|NCT05574491|EXPERIMENTAL|Super Skills for Life intervention group: traditional version|The Super Skills for Life program will be administered following the manual of the intervention by a trained therapist, as described in the section of intervention/treatment.
62220104|NCT05574491|EXPERIMENTAL|Super Skills for Life intervention group: computerized version|"The Super Skills for Life program will be administered in-person as well by a trained therapist, as described in the section of intervention treatment.~The therapist will use the multimedia presentation of the program's contents as a tool for the better development of the sessions. The digital version of the program consists of an animation whose characters narrate examples that help the children better understand the contents. The therapist will have a password assigned to each child, and it will be the therapist who will guide the sessions and select the contents of the digital presentation that correspond to each session. The web address to access the programme is https://www.superskillsonline.com/."
62220105|NCT05511961|EXPERIMENTAL|Intervention arm|Immediate referral to local budget and debt counselling service and a copy of 'Your child, your money', a financial guidance book for new parents
62220106|NCT05511961|ACTIVE_COMPARATOR|Waitlist-control arm|Immediately given a copy of 'Your child, your money' book, and referral to local budget and debt counselling service after a period of 3 months
62220107|NCT04042493|EXPERIMENTAL|Connect for Health Program|
62220108|NCT01039792|PLACEBO_COMPARATOR|Placebo|Placebo
62220109|NCT01039792|EXPERIMENTAL|Active|Active Methyl B12
62220110|NCT01414504|ACTIVE_COMPARATOR|Neonatal PCV + PPV 9 months|Group 1: Children receiving 7VPCV at 0-1-2 months of age and PPV at 9 months of age
62220111|NCT01414504|ACTIVE_COMPARATOR|Infant PCV + PPV at 9 months|Group 2: Children receiving 7VPCV at 1-2-3 months of age and PPV at 9 months of age
62414576|NCT05166369|NO_INTERVENTION|Control group|The centers allocated to this arm of the study will continue with their usual care. To avoid a potential Hawthorne effect (observer effect) these centers will not be informed about their participation as controls.
62587242|NCT02383368|EXPERIMENTAL|ASP4132 dose escalation|"Subjects will receive a single dose of the study drug on Day -4 (Single-Dose Period), followed by PK sampling prior to Multiple-Dose Period where they will receive the same dose as they received in the Single-Dose Period on one of four schedules:~Continuous - daily dosing for 28 days, Intermittent: Schedule A: 3 days on / 4 days off; Schedule B: 1 days on / 6 days off; Schedule C: 3 days on / 11 days off."
62587243|NCT02383368|EXPERIMENTAL|ASP4132 dose expansion|Subjects in Part 2 will be treated with ASP4132 at the MTD and dosing schedule identified from Part 1.
62587244|NCT03721055|EXPERIMENTAL|4-[18F]Fluoroglutamine|Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-\[18F\]Fluoroglutamine IV and 60 minutes after injection, undergo 4-\[18F\]Fluoroglutamine PET/CT before the start of therapy.
62220112|NCT01414504|ACTIVE_COMPARATOR|No PCV + PPV at 9 months|Group 3: Children who only received PPV at 9 months of age
62220113|NCT01414504|ACTIVE_COMPARATOR|Control|Group 4: Children who have not received any previous pneumococcal vaccine
62414577|NCT06701877|EXPERIMENTAL|COSP Intervention Group|The intervention group will participate in the COS-P program in addition to TAU. Foster carers will be assigned to groups of 8 to 10 participants and will attend sessions in dedicated training facilities.
62587245|NCT01023256|EXPERIMENTAL|Group 1: MOR103, experimental|Biological: MOR103 0.3 mg/kg or placebo
62587246|NCT01023256|EXPERIMENTAL|Group 2: MOR103, experimental|Biological: MOR103 1.0 mg/kg or placebo
62587247|NCT01023256|EXPERIMENTAL|Group 3: MOR103, experimental|Biological: MOR103 1.5 mg/kg or placebo
62587248|NCT01692249|EXPERIMENTAL|immediate spa therapy|group (A) received immediate spa treatment, with 18 days of therapy over 3 weeks; The standardized shoulder therapy program was designed by experienced spa therapy physicians. Spa mineral water and treatments are approved and controlled by the French authorities. Spa treatment included: bubble buses at 36°C for 15 minutes, applications of mineral matured mud at 45°C to the shoulder for 20 minutes, mineral hydrojet sessions at 39°C for 7 minutes and general mobilization in a collective mineral water pool at 35°C for 20 minutes supervised by a registered physiotherapist.
62587249|NCT01692249|NO_INTERVENTION|control group|in group (B), spa therapy was delayed for 6 months (control group).
62220114|NCT04884412|EXPERIMENTAL|PARKEO 2 targeting with asleep deep brain stimulation procedure|Participant with parkeo 2 targeting procedure
62220115|NCT04884412|ACTIVE_COMPARATOR|Usual DBS procedure|Participant with usual targeting and surgery
62220116|NCT01767532|EXPERIMENTAL|A(reference)/B(test)|initial administration of reference and cross-over to test
62220117|NCT01767532|EXPERIMENTAL|B(test)/A(reference)|initial administration of test and cross-over to reference
62220118|NCT02372136|EXPERIMENTAL|Individualized and Optimized Nutrition|Individualized nutrition Optimized nutrition
62220119|NCT02372136|OTHER|Optimized Nutrition|Optimized nutrition
62220120|NCT02317133||HSP: acute episode|"Patients in this group are going through an acute episode of Henoch Schönlein Purpura.~Intervention: Blood samples Intervention: Stool samples"
62220121|NCT02317133||HSP: remission|"Patients in this group have had Henoch Schönlein Purpura in the past but currently have no symptoms.~Intervention: Blood samples Intervention: Stool samples"
62587250|NCT06683053|EXPERIMENTAL|Empagliflozin 10 mg|In this group the patients will receive the medication empagliflozin 10 mg
62587251|NCT06683053|EXPERIMENTAL|Empagliflozin 25 mg|In this group the patients will receive the medication empagliflozin 25 mg.
62220122|NCT02317133||Control group|"Control patients recruited from elective surgery candidates at the participating hospitals.~Intervention: Blood samples Intervention: Stool samples"
62587252|NCT02594904|EXPERIMENTAL|G-6-PD normal group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
62023615|NCT01184014|EXPERIMENTAL|Experimental group|a study-specific steroid (NPH) dosing algorithm plus standard recommended care. The intervention is Neutral Protamine Hagedorn (NPH) insulin plus complete insulin orders (CIO).
62220123|NCT04262752|EXPERIMENTAL|chronically constipated people|Adults with chronic constipation due to either neurogenic bowel dysfunction (NBD) as consequence of a neurogenic condition such as Multiple sclerosis or Parkinson Disease, or to unkwon origin (Idiopathic No-NBD)
62220124|NCT04230603|EXPERIMENTAL|Hyperspectral imaging|diagnostic hyperspectral imaging of the human tissue an correlation with local blood parameters and local pathological examination
62220125|NCT04204603|PLACEBO_COMPARATOR|Placebo|
62220126|NCT04204603|EXPERIMENTAL|CKD-506 Dose A|
62220127|NCT04204603|EXPERIMENTAL|CKD-506 Dose B|
62220128|NCT04204603|EXPERIMENTAL|CKD-506 Dose C|
62220129|NCT01854853|EXPERIMENTAL|STYLE Brazil|STYLE-BRazil Multifamily Group HIV/STI Prevention intervention
62220130|NCT01854853|ACTIVE_COMPARATOR|Health Promotion|Health Promotion Intervention - Adolescents only
62587253|NCT02594904|EXPERIMENTAL|G-6-PD mild deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
62587254|NCT02594904|EXPERIMENTAL|G-6-PD moderate deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
62220131|NCT01079663|EXPERIMENTAL|Chlorhexidine chip (Periochip®)|PerioChip®, consisting of 2.5 mg Chlorhexidine Gluconate PerioChips were inserted only to target pockets whose pocket depth (PD) at Baseline visit (Week 0), Week 2, Week 4, Week 6, Week 8, Week 12 and Week 18 was ≥ 6 mm
62220132|NCT01079663|PLACEBO_COMPARATOR|Placebo chip|Placebo Chip Placebo Chips were inserted only to target pockets whose pocket depth (PD) at Baseline visit (Week 0), Week 2, Week 4, Week 6, Week 8, Week 12 and Week 18 was ≥ 6 mm
62220133|NCT05368467||1|All consecutive consenting patients diagnosed with PH according to specific hemodynamic criteria at participating institutions.
62220134|NCT02876822|EXPERIMENTAL|Vitamin D|Enrolled subjects will receive one observed oral vitamin D dose (based on current vitamin D status and rounded to the nearest 5000IU) within 2 weeks prior to their HSCT.
62220135|NCT05470673|EXPERIMENTAL|Alveolar ridge preservation using demineralized dentin combined with I-PRF + metronidazole|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft then inserted in the extraction socket and covered then suturing
62220136|NCT05470673|ACTIVE_COMPARATOR|Alveolar ridge preservation using autogenous demineralized dentin graft alone|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and inserted in the extraction socket and covered then suturing
62587255|NCT02594904|EXPERIMENTAL|G-6-PD sever deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
62587256|NCT05437861|NO_INTERVENTION|Treatment as usual|
62796026|NCT04992663|EXPERIMENTAL|Intervention group (VR-group)|"The participants randomised into this group are offered the BirthVR intervention during Labour.~The VR group receives a VR information moment during labour and the possibility to exercise with the VR glasses and they receive VR during labour from the moment they are in active labour and use VR as much as they prefer. After labour, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated and participants receive the WDEQ-B questionnaire and PROM and PREM (ICHOM; T3, T4, T5).~As soon as VR does not serve as adequate pain relief during labour and a women requests additional pain medication this will be offered according to local protocol."
62796027|NCT04992663|NO_INTERVENTION|Care as usual group|Patients randomised to the care as usual group will be offered pain medication during labour according to the local protocol, and on maternal request only. Postpartum participants receive the WDEQ-B questionnaire and PROM and PREM (ICHOM; T3, T4, T5)
62220137|NCT02368678|ACTIVE_COMPARATOR|Scaling and Root Planning (SRP)|Scaling and root planing (SRP) (n=15): the traditional mechanical periodontal therapy consisting of quadrant-wise (30 min. per quadrant) scaling and root planning performed at weekly sessions (one or two weeks of interval between session) and completed within 2 months.
62220138|NCT02368678|ACTIVE_COMPARATOR|Full Mouth Scaling (FMS)|Full mouth scaling (FMS) (n=15): the alternative mechanical periodontal therapy consisting of full-mouth scaling and root planning completed in a single stage within 24 hours; i.e two sessions (60 min. per session) in two consecutive days.
62587257|NCT05437861|EXPERIMENTAL|Brief Intervention|
62587258|NCT06666790|NO_INTERVENTION|Clinical assessment only|Lesions assessed as clinically suspicious by primary care investigator who make diagnostic and management decision to biopsy without ESS device output
62587259|NCT06666790|EXPERIMENTAL|Clinical assessment with device output|Lesions assessed as clinically suspicious by primary care investigator who make diagnostic and management decision to biopsy with ESS device output
62587260|NCT06115395|ACTIVE_COMPARATOR|(Group 1) 25 (H. NIV): Hypoxemic patients{hypoxemic NIV group}|who will undergo fiber-optic bronchoscopy under non- invasive ventilation and conventional oxygen therapy
62220139|NCT04401501|EXPERIMENTAL|Manual Therapy + Exercise Group|Combination of manual therapy and exercises for cervicogenic headache
62220140|NCT04401501|ACTIVE_COMPARATOR|Exercise Group|Only exercises for cervicogenic headache
62023616|NCT01184014|ACTIVE_COMPARATOR|Control group|the standard recommended care (Methodist Hospital Complete Insulin Orders)
62023617|NCT03736200|ACTIVE_COMPARATOR|Exergaming 1/day|Post stroke group that received 4 weeks of intensive therapy. (1/day)
62023618|NCT03736200|ACTIVE_COMPARATOR|physiotherapy|Post stroke group that received 4 weeks of traditional physiotherapy.
62023619|NCT03736200|ACTIVE_COMPARATOR|Exergaming 2/day|Post stroke group that received 4 weeks of intensive therapy. (2/day)
62023620|NCT01271335|EXPERIMENTAL|Collagenase (MZ-004)|Local intra-coronary administration of MZ-004 at or into the CTO
62023621|NCT06417281|EXPERIMENTAL|5 Aminolevulinic Acid|This is an single arm study.
62023622|NCT05378945|EXPERIMENTAL|OC-01|
62023623|NCT05378945|PLACEBO_COMPARATOR|Placebo|
62587261|NCT06115395|ACTIVE_COMPARATOR|(Group 2) 25 (H. conv.): Hypoxemic patients{hypoxemic conventional group }|who will undergo conventional fiber-optic bronchoscopy under conventional oxygen therapy without non- invasive ventilation
62587262|NCT06115395|ACTIVE_COMPARATOR|(Group 3) 25 (N.H.NIV): Non- hypoxemic patients{non-hypoxemic NIV group}|who will undergo fiber-optic bronchoscopy under non- invasive ventilation and conventional oxygen therapy
62220141|NCT03404453||Paediatric patients at preanaesthetic visi|Difficult airway incidence and prediction:Paediatric patients at preanaesthetic visit scheduled for surgery under general anaesthesia
62220142|NCT03294148|EXPERIMENTAL|Placebo|The open-label placebo treatment the investigators will use is based on past open-label placebo trials (Kam-Hansen et al., 2014; Kaptchuk et al., 2010; Kelley et al., 2012). Prior to treatment administration, patients will view a brief (\~3 min) video summarizing scientific findings regarding the therapeutic power of placebo treatments. The video will describe established findings regarding placebo and suggest that placebos may still work even when patients know the treatment is a placebo. The video will state that believing in the placebo is not necessary, and the investigators ask only that patients keep an open mind. Patients will then receive a subcutaneous injection of 1ml medical grade saline into the lower back. The injection will be administered near the location of the pain, as specified by the participant. The investigators will use a standard needle used in subcutaneous injections of 27 gauge with a length from 1in to 1.5in.
62414578|NCT06701877|ACTIVE_COMPARATOR|Waitlist control group|Waitlist control groupe will continue to receive Treatment as Usual (TAU), which consists of Psycho-Educational Support (PSE) provided by Child Protection Services. PSE typically involves home visits, educational and psychological support for foster carers and/or children in placement, and efforts to support and monitor contact between children and their birth families. The control group will be placed on a waiting list to receive the COS-P program as part of continuing education at a later date.
62414579|NCT06313294|EXPERIMENTAL|App Group|In this group the patients will use the app for asking about related to pain, patient satisfaction and another complications.
62414580|NCT06313294|ACTIVE_COMPARATOR|Telephone interview group|In this group the patients will receive the calling by one member of the healthcare team asking items related to pain, patient satisfaction and another complications.
62587263|NCT06115395|ACTIVE_COMPARATOR|(Group 4) 25(N.H. conv.): Non- hypoxemic patients{non-hypoxemic conventional group}|who will undergo conventional fiber-optic bronchoscopy under conventional oxygen therapy without non- invasive ventilation
62587264|NCT03926052|ACTIVE_COMPARATOR|LDX|
62587265|NCT03926052|PLACEBO_COMPARATOR|Placebo|
62587266|NCT00877071|EXPERIMENTAL|LC Drug Eluting Bead, Regional Chemoembolization|Use of LC Drug-Eluting Beads for chemoembolization will provide a method for downstaging patients with hepatocellular carcinoma which is not amenable to surgical resection or local ablative therapy to liver transplant eligibility
62587267|NCT04182204|EXPERIMENTAL|Pola-R-GemOx (Stage 1)|Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) for a maximum dose of 240 mg per cycle (mg/cycle) administered intravenously (IV) and rituximab 375 milligrams per square meter (mg/m\^2) administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\^2 administered IV and oxaliplatin 100 mg/m\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration.
62587268|NCT04182204|EXPERIMENTAL|Pola-R-GemOx (Stage 2)|Participants will receive polatuzumab vedotin 1.8 mg/kg for a maximum dose of 240 mg/cycle administered IV and rituximab 375 mg/m\^2 administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\^2 administered IV and oxaliplatin 100 mg/m\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration.
62587269|NCT04182204|ACTIVE_COMPARATOR|R-GemOx (Stage 2)|Participants will receive rituximab 375 mg/m\^2 administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\^2 administered IV and oxaliplatin 100 mg/m\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration.
62587270|NCT01636154|NO_INTERVENTION|The basic treatment|Comply to the Chinese guidelines of acute ischemic stroke in 2010
62587271|NCT01636154|OTHER|Clearing heat|Treat with KDZ injection on the basis of the basic treatment
62587272|NCT01636154|OTHER|Promoting blood circulation|Treat with Xueshuantong injection on the basis of the basic treatment
62023624|NCT04066218||age 15-19|The investigators plan to complete 24 interviews with 12 in the age 15-19 cohort.The investigators will also ensure that at least 8 people from each sex are included in this study.
62023625|NCT04066218||age 20-24|The investigators plan to complete 24 interviews with 12 in the age 20-24 cohort. The investigators will also ensure that at least 8 people from each sex are included in this study.
62023626|NCT02817789|ACTIVE_COMPARATOR|Standard group|154 patients
62587273|NCT01636154|EXPERIMENTAL|Clearing heat & Promoting blood circulation|Treat with both KDZ injection and Xueshuantong injection on the basis of the basic treatment
62587274|NCT06560216|NO_INTERVENTION|Control|Frozen-thawed sperm suspension without apigenin supplementation in freezing medium
62414581|NCT05823194|OTHER|Fertility spared gynecologic cancer diagnosed women|Participants recruited from a tertiary care hospital, and women diagnosed with gynecological malignancies (e.g. cervical, ovarian, endometrial cancer) who underwent fertility-sparing surgery between 2010 and 2022.
62433342|NCT03542318||Inactive control group|A total of 60 patients were enrolled in a control group. All were referred for PR from the outpatient clinics of the local general hospital. In this group patients who requested not to carry out the intervention but participate in the investigations were enrolled. Each participant was classified according to the modified Medical Research Council dyspnoea scale, and placed in one of 5 categories (0 to 4) according to self-perceived breathlessness during daily activities
62433343|NCT05466513|EXPERIMENTAL|Experimental Group|Facial tactile stimulation was applied for 2 minutes.
62587275|NCT06560216|EXPERIMENTAL|Apigenin|Frozen-thawed sperm suspension with apigenin 0.2 mM supplementation in freezing medium
62587276|NCT05111600|EXPERIMENTAL|Treatment|After confirmation of eligibility criteria and ICF signature, subject undergoes to skin biopsy for collection of autologous epidermal cells to be used to produce IMP under GMP process. Approximately 2 months later, IMP is transplanted on selected area.
62587277|NCT06684288|EXPERIMENTAL|Access flap surgery group|Quadrants in participants requiring periodontal surgery were randomly assigned to access flap surgery sites. Following local anesthesia, a mucoperiosteal flap was elevated and handled with microsurgical instruments (blades, scalpel, needle holder, scissors, and tweezers; Carl Martin GmbH, Solingen, Germany) in accordance with the simplified papilla preservation flap (SPPF) technique.
62587278|NCT06684288|NO_INTERVENTION|Control group|untreated sites
62587279|NCT00217893|EXPERIMENTAL|1|Combination of counseling, cotinine feedback, and contingent incentives.
62587280|NCT00217893|ACTIVE_COMPARATOR|2|Usual education program
62587281|NCT04948541|EXPERIMENTAL|treatment|
62023627|NCT02817789|EXPERIMENTAL|Ticagrelor group|154 patients
62023628|NCT01181934|EXPERIMENTAL|001|A643 (nicotine) 1mg oromucosal nicotine spray- three times daily during each treatment period
62023629|NCT01181934|EXPERIMENTAL|002|A643 (nicotine) 2mg oromucosal nicotine spray- three times daily during each treatment period
62023630|NCT01181934|PLACEBO_COMPARATOR|003|placebo placebo - three times daily during each treatment period
62023631|NCT02613481|OTHER|Poly-L-Lactic Acid (Sculptra) injection|Poly-L-Lactic Acid (Sculptra) injection for all enrolled subjects
62587282|NCT04948541|EXPERIMENTAL|no treatment|
62587283|NCT03880968||inactive - half dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who achieved inactive disease (ASDAS\<1.3, group A) at week 12 and assigned to sequential tapering group (A1).
62587284|NCT03880968||inactive - discontinuation|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who achieved inactive disease (ASDAS\<1.3, group A) at week 12 and then assigned to discontinuation group (A2).
62587285|NCT03880968||low disease activity - half dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS\<2.1, group B) and designated to sequential tapering group (B1).
62587286|NCT03880968||low disease activity - full dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS\<2.1, group B) and designated to delayed tapering group (B2) with extra 12 weeks of full dose ETN.
62587287|NCT03880968||low disease activity - discontinuation|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS\<2.1, group B) and designated to discontinuation group (B3).
62414582|NCT02611531|EXPERIMENTAL|Video Module Education (VME)|The RE will provide participants with a tablet device and will demonstrate how to access VME and complete the pre/post e-learning assessments. The RE will provide technical support but will neither participate directly in the education nor help with the self-assessments. The participants will first complete the pre-assessment e-learning tool on the tablet. They will then watch the video instruction that will provide a complete demonstration with verbal instructions on correct inhaler technique. Next the participants will complete the post-assessment e-learning tool. Based on participants' performance, they will be directed to further tailored video-instruction. The cycle of self-assessment and video instruction will continue until sufficient mastery has been achieved.
62414583|NCT02611531|ACTIVE_COMPARATOR|Teach-To-Goal (TTG)|Participants assigned to the TTG condition will be provided with an intensive, iterative education and evaluation strategy that consists of the following steps.
62414584|NCT05984329||Tonic then Burst DR(TM)|Tonic Motor Cortex Stimulation (MCS) for 3 months then Burst DR(TM) MCS for 3 months
62414585|NCT05984329||Burst DR(TM) then tonic|Burst DR(TM) MCS for 3 months then tonic MCS for 3 months
62587288|NCT05721872|EXPERIMENTAL|Combination of D-isoascorbic acid (D-VC) with arsenic trioxide (ATO)-Phase 1|"Participants will receive single intravenous administration as monotherapy of D-isoascorbic acid (D-VC) with dose escalation (0.05, 0.1, 0.2 g/kg/day) and with arsenic trioxide (ATO).~Patients who have satisfactorily tolerated the study drug in combination with arsenic trioxide (ATO) in a phase I study are transferred to a phase II clinical trial."
62587289|NCT05721872|EXPERIMENTAL|Combination of D-isoascorbic acid (D-VC) with arsenic trioxide (ATO)-Phase 2|After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I.
62587290|NCT05721872|ACTIVE_COMPARATOR|Standard therapy (FOLFOX/FOLFIRI)-Phase 2|"Drug: FOLFOX/FOLFIRI regimen FOLFOX - oxaliplatin 85mg/m2 1 day, Leucovorin 200mg/m2 IV 2h, 1, 2 days, 5 - Fluorouracil 400mg/m2 IV bolus, 1, 2 days, 5 - Fluorouracil 600mg/m2 IV 22h, 1, 2 days~FOLFIRI - Irinotecan 180 mg/m2 IV, Leucovorin 400 mg/m2 IV, Fluorouracil bolus 400 mg/m2 IV, Fluorouracil infusional 2400 mg/m2 IV. Courses are held every 2 weeks"
62587291|NCT03283293|EXPERIMENTAL|Target volume delineation after NACT|
62587292|NCT03973918|EXPERIMENTAL|Treatment Cohort 1 AA & GBM|"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle~Research Bloods"
62587293|NCT03973918|EXPERIMENTAL|Treatment Cohort 2 anaplastic PXAs|"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle~Research Bloods"
62587294|NCT03973918|EXPERIMENTAL|Surgical Arm|"Pre-op -14 days: Encorafenib 450mg QD and Binimetinib 45mg BID last dose of both drugs 2hrs prior to surgery~Tumor; research blood; CSF samples~post surgery: Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle"
62587295|NCT03973918|EXPERIMENTAL|Treatment Cohort 3 Other Tumors|"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle~Research Bloods"
62587296|NCT03562286|EXPERIMENTAL|Experimental Fetoscopy|All participants will undergo fetoscopic repair of open spina bifida
62414586|NCT02341872|NO_INTERVENTION|Control|The investigators won't do any application , the oral hygiene konwledge will be given only.
62587297|NCT04092673|EXPERIMENTAL|Part 1: Sequential escalation (Completed)|eFT226 administered IV weekly in 21-day cycles; dose escalated in sequential cohorts after subjects enrolled in a given cohort have completed DLT evaluation period.
62587298|NCT04092673|EXPERIMENTAL|Part 2: Cohort Expansion, Monotherapy, NSCLC, KRAS (EMNK)|Cohort EMNK
62587299|NCT04092673|EXPERIMENTAL|Part 2: Cohort Expansion, Monotherapy, Breast, FGFR (EMBF)|Cohort EMBF
62587300|NCT04092673|EXPERIMENTAL|Part 2: Cohort Expansion, Monotherapy, Breast, HER2 (EMBH)|Cohort EMBH
62587301|NCT04092673|EXPERIMENTAL|Part 2: Cohort Expansion, Combination, Breast, Fulvestrant (ECBF)|Cohort ECBF; Combination therapy partner administered per SOC at the approved dose.
62023632|NCT04046874|OTHER|Usual Care|All patients were referred for the study by their General Practitioner (GP). GPs were encouraged to assess and treat their patients as usual and make all the referrals they think are appropriate for their patients.
62587302|NCT04092673|EXPERIMENTAL|Part 2: Cohort Expansion, Combination, NSCLC, Sotorasib (ECNS)|Cohort ECNS; Combination therapy partner administered per SOC at the approved dose.
62587303|NCT04092673|EXPERIMENTAL|Part 2: Cohort Expansion, Combination, Breast, Fulvestrant+Abemaciclib (ECBF+A)|Cohort ECBF+A; Combination therapy partner administered per SOC at the approved dose.
62587304|NCT04092673|EXPERIMENTAL|Part 2: Cohort Expansion, Combination, Breast, Trastuzumab (ECBT)|Cohort ECBT; Combination therapy partner administered per SOC at the approved dose.
62414587|NCT02341872|ACTIVE_COMPARATOR|Fluoride + Calcium varnish|The investigators will do fluoride+ calcium varnish( Clinpro White Varnish) application on white spot lesions.
62796028|NCT05949268||Patients with gastrointestinal bleeding undetected in gastroscopy and colonoscopy|Gastrointestinal bleeding in the small bowel.
62796029|NCT06333665||Coe-T2DM group|There was a definitive diagnosis of type 2 diabetes mellitus before surgery
62796030|NCT06333665||No-T2DM group|There was no clear diagnosis of type 2 diabetes mellitus before surgery
62414588|NCT02341872|EXPERIMENTAL|Polipeptide solution|The investigators will do polipeptide ( Curodont Repair) solution application on white spot lesions.
62414589|NCT02341872|EXPERIMENTAL|Fluoride + calcium + polipeptide|The investigators will do polipeptide ( Curodont Repair) solution and fluoride + calcium varnish (Clinpro White Varnish) application on white spot lesions.
62414590|NCT05645016|EXPERIMENTAL|Adapted Comprehensive Overdose Education and Skills Training (COEST)|
62414591|NCT03387735|PLACEBO_COMPARATOR|Treatment as usual (TAU) + Internet|Patients will be given access to helpful websites such as National Institute on Aging.
62796031|NCT06693089|EXPERIMENTAL|Experimental: MIT-ED|"Participants will receive 1 or 2 preliminary sessions focused on typical elements of Cognitive Behavioral Therapy for Eating Disorders, including psychoeducational training on eating behaviors, an introduction to tools such as monitoring forms, weight charts, and assessments of eating behaviors like physical exercise, body checking, and episodes of binging, purging, and starvation. Before treatment starts, patients meet with a dietitian to develop a nutritional plan that normalizes calorie intake, which will be reviewed throughout treatment. After these sessions, participants will receive up to 40 weekly individual sessions.~Given the inclusion of underweight patients, the protocol developed by Fioravanti and colleagues (2023) required adaptations, such as considering the effects of malnutrition on cognitive and organic functioning and extending psychotherapy for up to 40 sessions."
62414592|NCT03387735|EXPERIMENTAL|Treatment as usual (TAU) + ElderTree|Patients will be given access to the ElderTree website for 12 months which provides tools, motivation, and social support to help them manage their specific set of chronic conditions and communicate with peers and their primary care physician.
62414593|NCT01735864|ACTIVE_COMPARATOR|Indirubin 200 μg/g|per gram of ointment contains 200 μg of indirubin
62414594|NCT01735864|ACTIVE_COMPARATOR|Indirubin 100 μg/g|per gram of ointment contains 100 μg of indirubin
62414595|NCT01735864|ACTIVE_COMPARATOR|Indirubin 50 μg/g|per gram of ointment contains 50 μg of indirubin
62414596|NCT01735864|ACTIVE_COMPARATOR|Indirubin 10 μg/g|per gram of ointment contains 10 μg of indirubin
62414597|NCT06015711|EXPERIMENTAL|Maxigesic group|Administration of Maxigesic before surgery start.
62587305|NCT04092673|EXPERIMENTAL|Part 1a: Dose Escalation, Combination, Breast|eFT226 administered IV weekly in 21-day cycles. Fulvestrant will also be given. Dose escalations per protocol.
62587306|NCT04092673|EXPERIMENTAL|Part 1b Dose Escalation, Combination, Breast|eFT226 administered IV every other week in 14-day cycles. Fulvestrant will also be given. Dose escalations per protocol.
62796032|NCT02511002||1|Post influenza infection
62796033|NCT06457789|EXPERIMENTAL|Dual T cell PET imaging|Patients will receive PET imaging with two different T-cell targeting tracers.
62023633|NCT04046874|OTHER|Stratified Model of Care|A subgrouping tool helps guide clinical decision-making about treatment and onward referral (Start Back Screening Tool). Patients in each subgroup (low, medium or high risk of chronicity) are then managed according to a targeted treatment system of increasing complexity.
62023634|NCT04864808|EXPERIMENTAL|Behavioral Parenting Training|
62023635|NCT03586635||Patients with Multiple Sclerosis|
62414598|NCT06015711|NO_INTERVENTION|Control group|Administration of normal saline before surgery start.
62587307|NCT04092673|EXPERIMENTAL|Part 2 Cohort Expansion, Combination, Breast, Fulvestrant, Cyclin D1|ECBF-D1; Combination therapy partner administered per SOC at the approved dose.
62414599|NCT01959659||Cohort|
62414600|NCT06539208|EXPERIMENTAL|YOLT-201|
62414601|NCT06649825|EXPERIMENTAL|Vitamin B1|
62414602|NCT05287802|ACTIVE_COMPARATOR|Biodex Training (BT) group|Biodex Balance System features a platform that can move simultaneously in the anteroposterior (AP) or medio-lateral (ML) direction in 12 different levels of stability within a 20-degree range of inclination, as well as a locked position for static environments. For this platform, 1 represents the least stable level and 12 represents the most stable level. Interactive, game-like training modes are provided with the on-screen grid and score-keeping functions. Patients in the BT group performed exercises with the Balance SystemTM SD once a day, three days a week for 10 weeks under the physicians' supervision. Furthermore this group received closed kinetic chain exercises (CKCE) in addition to their own exercise program, which was applied in exactly the same way. The CKCE were performed in three sets of 10 repetitions with five seconds rest between each exercise. The exercises consisted of mini-squats, wall sits, and lunges.
62433344|NCT05466513|NO_INTERVENTION|Control Group|No intervention was applied.
62433345|NCT02431481|EXPERIMENTAL|Normal renal function|Normal renal function; matched demography to renal impariment cohorts
62433346|NCT02431481|EXPERIMENTAL|Severe renal impairment|Severe decrease in GFR (15-29 ml/min)
62433347|NCT02431481|EXPERIMENTAL|End Stage Renal Disease|End stage renal disease not on dialysis; GFR \<15 ml/min
62433348|NCT02431481|EXPERIMENTAL|Mild renal impairment|Mild decrease in GFR (60-89 ml/min)
62587308|NCT01744184|ACTIVE_COMPARATOR|Midazolam|"midazolam sedation combined with pharyngeal anaesthesia~Participants randomized to receive midazolam will have an intravenous cannula sited and, following the administration of xylocaine throat spray as above, will be put into the left lateral position. They will then be given up to 5mg midazolam as appropriate to achieve conscious sedation as for standard protocol in endoscopy."
62587309|NCT01744184|EXPERIMENTAL|Entonox|"Entonox combined with pharyngeal anaesthesia.~Pharyngeal anaesthesia, given as 8-16 sprays of xylocaine to the pharynx; 3 minutes will be given to allow the pharynx to become anaesthetized.~Participants randomized to receive Entonox will be given the 50:50 nitrous oxide:oxygen mix via a mouthpiece with a demand valve system, once in position for the procedure. Inhalations will be given for 3-5 minutes (or until the participant feels adequately sedated) measured using a stopwatch. Oxygen will be given at 2 litres per minute via nasal cannulae during the procedure, (standard care for sedated procedures). The endoscopist will then proceed to intubate the cricopharynx and perform the procedure in the standard manner."
62587310|NCT06685601|ACTIVE_COMPARATOR|active stimulation|During the active stimulation condition, participants will receive a single session of tPBM intervention, lasting 12 minutes.
62587311|NCT06685601|SHAM_COMPARATOR|sham stimulation|During the sham stimulation condition, participants will receive the same intervention with identical target areas and wavelength, but only for the first and last 30 seconds of the session.
62023636|NCT04844281|EXPERIMENTAL|Daily Disposable Toric Contact Lens|All subjects are fit into Precision1® toric contact lenses. Subjects are requested to wear the lenses for a total of two weeks.
62587312|NCT04821453|PLACEBO_COMPARATOR|Conventional Flow Triggered Mechanical Ventilation (CMV)|Subjects will be ventilated with conventional mechanical ventilation with data collected for the 5 day time frame to compare to the experimental arm
62587313|NCT04821453|EXPERIMENTAL|Neurally Adjusted Ventilatory Assist (NAVA)|Subjects will be ventilated on neurally adjusted ventilatory assist (NAVA) mode with data collected for the 5 day time frame to compare with placebo arm
62796034|NCT03261388||ABLE POWER Program|Participants on the Activity-Based Locomotor Exercise Program (ABLE) waitlist will be enrolled prior to beginning the ABLE program. This waiting period will allow outcomes to be compared (in the same participant) before receiving the intervention and after receiving the intervention.
62796035|NCT05767840|EXPERIMENTAL|mgGap-IG|MhGap-IG intervention to be delivered to depression and self-harm cohorts
62220143|NCT03294148|EXPERIMENTAL|Psychotherapy|Psychotherapy will consist of one initial medical history session with Co-I Schubiner, followed by twice weekly 50 minute psychotherapy sessions for 4 weeks with a therapist, for a total of 9 sessions maximum. The purpose of the initial medical history session is to help evaluate the likelihood that the patient's back pain is caused by structural conditions in the back. Dr. Schubiner will then speak with patients for a 1 hour session in which he collects their medical history and discusses different possible causes of their back pain with them. This session will be conducted by phone, by HIPAA-compliant Zoom, or by another HIPAA-compliant videoconferencing technology in consultation with the OIT team at Dr. Schubiner's hospital.
62433349|NCT02431481|EXPERIMENTAL|Moderate renal impairment|Moderate decrease in GFR (30-59 ml/min)
62587314|NCT04286789|EXPERIMENTAL|ORTD-1-Low Dose|5.6 mg/0.45 mL of active study drug
62587315|NCT04286789|PLACEBO_COMPARATOR|Vehicle Control -Low Dose|Vehicle (Identical formulation without the active DP)
62796036|NCT05833438|EXPERIMENTAL|VEN+AZA-5|Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)
62796037|NCT01066728|ACTIVE_COMPARATOR|Theophylline|Oral loading dose of 6 mg per kilogram of body weight of theophylline followed by a maintenance dose of 2 mg per kilogram every 8 hours plus room air by nasal prongs at 0.5 l/min for 3 days.
62796038|NCT01066728|EXPERIMENTAL|CO2 inhalation|Equivalent loading and maintenance volume of oral normal saline plus CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
62796039|NCT05081895||Respiratory failure|
62796040|NCT00853866|EXPERIMENTAL|RBX + tDCS|reboxetine + tDCS verum
62796041|NCT00853866|ACTIVE_COMPARATOR|RBX + sham stimulation|reboxetine + sham tDCS
62023637|NCT02958644|EXPERIMENTAL|Synbiotics|Synbiotics - 12g / day fructo-oligosaccharide and probiotics supplemented orally for 90 days.
62023638|NCT02958644|PLACEBO_COMPARATOR|Placebo|"Placebo - polydextrose 12g /day supplemented orally for 90 days.~The study supplements are packed in identical envelopes containing either 12g of oral powder fructo-oligosaccharide and probiotics or placebo to be diluted in water. The powder and the solution were identical in appearance, taste, and smell."
62023639|NCT01834820|EXPERIMENTAL|Epinephrine and Dexamethasone|First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes. And one treatment of nebulized dexamethasone every 24h for three days.
62023640|NCT01834820|EXPERIMENTAL|Hypertonic Saline 3%|3 treatments of nebulized HS 3% 4ml in first day of treatment with interval 20 minutes And one treatment of nebulized HS 3% 4ml every 24 hours for 3 days
62023641|NCT01834820|ACTIVE_COMPARATOR|Normal Saline 0.9%|3 treatments of nebulized Normal Saline 0.9% 4ml in first day of treatment with interval 20 minutes. And one treatment of nebulized Normal Saline 0.9% 4ml every 24 hours for 3 days
62023642|NCT00178490|EXPERIMENTAL|1|Children with high blood pressure who will receive treatment for high blood pressure
62023643|NCT00178490|NO_INTERVENTION|2|Children with normal blood pressure who will undergo no treatment
62587316|NCT04286789|EXPERIMENTAL|ORTD 1-High Dose|22.5 mg/1.8 mL of active study drug
62587317|NCT04286789|PLACEBO_COMPARATOR|Vehicle Control -High Dose|Vehicle (Identical formulation without the active DP)
62433350|NCT03940326|EXPERIMENTAL|Levetiracetam|
62433351|NCT03940326|ACTIVE_COMPARATOR|Valproate|
62023644|NCT05392634|ACTIVE_COMPARATOR|Amoxicillin/ Cefuroksim|standard antibiotic prophylaxis 24 hours
62023645|NCT05392634|EXPERIMENTAL|Meropenem|preventive antibiotic therapy within 5 days from the date of the skin incision
62220144|NCT03294148|NO_INTERVENTION|Waitlist|Wait-listed patients will be asked not to change their treatment regime for the 4 weeks in between their two fMRI sessions. Wait-listed patients in the placebo injection arm will be offered the opportunity to receive the placebo treatment (optional). Waitlisted participants in the psychotherapy arm will be given a copy of Dr. Schubiner's book and free access to his online self-help program (optional to accept these).
62220145|NCT01946438|EXPERIMENTAL|Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)|Participants age 18 to \< 65 years randomized to receive a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)
62414603|NCT05287802|ACTIVE_COMPARATOR|Classical balance training group (CT group)|Patients in the CT group completed the exercise program once a day and three days a week during the 10-week period under the physicians' supervision. The exercises consisted of standing on one leg, tandem walking (heel-to-toe), balance board exercises, Romberg exercise, backward walking, and side-to-side stepping exercises. The total duration of these exercises was 20-30 minutes. Furthermore this group also received CKCE in addition to their own exercise program, which was applied in exactly the same way. The CKCE were performed in three sets of 10 repetitions with five seconds rest between each exercise. The exercises consisted of mini-squats, wall sits, and lunges.
62414604|NCT05287802|ACTIVE_COMPARATOR|Control group|Isometric home exercises, which can be considered the most basic and feasible strengthening program, were selected to compare the effects they had when added to the intervention groups and administered alone. All patients in the study performed isometric exercises for the quadriceps and hamstrings at home once a day, three days a week for 10 weeks. The exercises were performed as 10 repetitive cycles of six-second contractions and two-second rest periods. All patients were given a daily exercise chart to mark the home program, and adherence to the exercises was monitored weekly by telephone call.
62414605|NCT05814510|EXPERIMENTAL|School staff|School staff in a K-8 school participating in Asthma CHAMPS
62414606|NCT05814510|EXPERIMENTAL|Children with asthma|Aged 5-13 and enrolled in Baltimore City Public School participating in Asthma CHAMPS
62414607|NCT05814510|EXPERIMENTAL|Caregivers of children with asthma|Caregiver of a child with asthma that is aged 5-13 enrolled in a Baltimore City Public School participating in Asthma CHAMPS
62414608|NCT03187873|EXPERIMENTAL|Chama cha MamaToto|Women attending chamas will meet twice per month, receive social and health education from CHVs and participate in a savings/loans program.
62414609|NCT03187873|NO_INTERVENTION|Control|The CHVs in the control group will be given refresher training on health roles they are supposed to play according to the standard MOH activities
62414610|NCT04959708|ACTIVE_COMPARATOR|Control group|Participants in the control group will have the same exposure in time as the intervention group and will be asked to maintain their lifestyle during the whole study and to refrain from starting any new regular physical activity. In case they can not maintain the same lifestyle during the study period, they will be asked to inform the researchers at any of the assessments.
62220146|NCT01946438|EXPERIMENTAL|Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)|Participants age 18 to \< 65 years randomized to receive a dose of Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation)
62220147|NCT01946438|EXPERIMENTAL|Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)|Participants age ≥ 65 years randomized to receive a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)
62220148|NCT01946438|EXPERIMENTAL|Elderly Fluzone® High-Dose, Influenza Vaccine (Group 4)|Participants age ≥ 65 years randomized to receive a dose of Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
62220149|NCT02436590|ACTIVE_COMPARATOR|Active PEMF|Subjects have a 2 out of 3 chance to get the active device which emits a Pulsed Electromagnetic Field (PEMF) from the Physio-Stim Model 3315OA device. Double blind randomization
62220150|NCT02436590|PLACEBO_COMPARATOR|Control/no PEMF|Subjects have a 1 out of 3 chance of getting the control/placebo device which does not emit Pulsed Electromagnetic Field (PEMF) from the Physio-Stim Model 3315A device. Double blind randomization
62220151|NCT04292184|ACTIVE_COMPARATOR|UW (perfusion solution) + sodium thiosulfate (STS)|We will flush the deceased donor kidney with UW (perfusion solution) + sodium thiosulfate (STS)
62414611|NCT04959708|EXPERIMENTAL|Intervention group|The intervention group will consist of the Ínsula method. Insula method will be developed twice a week for 12 weeks online form through videoconference platform. The intervention will consist of twelve individual treatments. Insula method consists of the facilitation and activation of self-regulation resources, relational regulation through breathing, movement, contact, sensory stimulation and posture
62414612|NCT01607866|EXPERIMENTAL|Quadrant parotidectomy|Patients in this arm will receive excision of the parotid gland quadrant harboring the tumor
62414613|NCT01607866|ACTIVE_COMPARATOR|Superficial parotidectomy|Patients in this group will receive superficial parotidectomy
62414614|NCT06496711|OTHER|Cancer Patients and Parents of Cancer Patients|Children: Age 5-12 years Parents of children with cancer Teenager: Age 13-17 years Parents of teenager with cancer AYAs: Adolescence and young adults: Age 18-39 years Adults: \> 40 years
62796042|NCT00853866|ACTIVE_COMPARATOR|PLC + tDCS|placebo drug + verum tDCS
62796043|NCT00853866|SHAM_COMPARATOR|PLC + sham stimulation|placebo drug + sham tDCS
62796044|NCT00997802|OTHER|CT colonography and optical colonoscopy|
62587318|NCT02278120|EXPERIMENTAL|Ribociclib + NSAI/tamoxifen + goserelin|Ribociclib 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
62587319|NCT02278120|PLACEBO_COMPARATOR|Placebo + NSAI/tamoxifen + goserelin|"Placebo daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days).~Participants were unblinded once the final OS analysis was conducted and after the implementation of protocol amendment 6 (16-Jul-2019) and were given the option to crossover to treatment with ribociclib +NSAI/tamoxifen + goserelin."
62587320|NCT05519228||ToggleLoc 2.9 mm soft tissue device|Patients who already received the ToggleLoc 2.9 mm soft tissue device in the elbow. No additional surgery will be performed.
62587321|NCT06024473|NO_INTERVENTION|Standard Treatment|This arm will be followed without intervention
62587322|NCT06024473|ACTIVE_COMPARATOR|rTMS|This group will be randomized to receive rTMS treatment
62587323|NCT06024473|EXPERIMENTAL|rTMS+iVCT|This group will be randomized to receive rTMS and iVCT treatment
62587324|NCT01872598|EXPERIMENTAL|Masitinib escalating dose|Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment
62587325|NCT01872598|EXPERIMENTAL|Masitinib fixed dose (4.5 mg/kg/day)|Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily.
62587326|NCT01872598|EXPERIMENTAL|Masitinib fixed dose (3.0 mg/kg/day)|Participants receive masitinib at 3.0 mg/kg/day, given orally twice daily.
62587327|NCT01872598|PLACEBO_COMPARATOR|Placebo (escalating dose)|Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment
62587328|NCT01872598|PLACEBO_COMPARATOR|Placebo (fixed dose)|Participants receive fixed dose placebo, given orally twice daily
62023646|NCT02893722|EXPERIMENTAL|atosiban|"Give drugs 30 minutes before the start of the embryo transfer. First step: give a 37.5 mg Atosiban (Ferring, Germany) to take 0.9 ml, that is, 6.75 mg, conduct intravenous injection in one minute.~Second step: for the remaining 4.1 ml, namely 30.75 mg, dilute to 41 ml, use the venous pump to adjust to 24 ml/h, infuse for 1 hour, namely 18 mg.~Third step: for the remaining 17 ml, use the venous pump to adjust to 8 ml/h, infuse 2.1 hours, namely 12.75 mg. Total administration time is 3 hours, total dose is 37.5 mg."
62587329|NCT06549413||Observational|Patients receive 18F-FSPG IV and undergo a PET/CT scan. During week 3 of standard of care radiation therapy, patients receive 18F-FSPG and undergo a second PET/CT scan on study.
62587330|NCT00896181|EXPERIMENTAL|Chemoradiation for Nasopharyngeal Carcinoma|"INDUCTION THERAPY: Patients receive docetaxel intravenously (IV) over 60 minutes on Day 1; cisplatin IV over 1 to 3 hours (or carboplatin IV over 30 minutes) on Day 1; and fluorouracil IV continuously over 24 hours on Days 1 to 5. Each cycle is 21 days, with treatment consisting of up to 3 cycles in the absence of disease progression or unacceptable toxicity.~CONCURRENT CHEMO-RADIOTHERAPY: Beginning within 3 to 6 weeks after initiating the last course of induction chemotherapy, patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily for 6.5 to 7 weeks. Patients also receive cisplatin IV over 1 hour (or carboplatin IV over 30 minutes) once weekly in weeks 1 to 6 in the absence of disease progression or unacceptable toxicity."
62414615|NCT06213961|EXPERIMENTAL|arm trained with pecha kucha|Before basic life support training is given to students, an introductory characteristics form and basic life support skill questions will be applied (pre-test). Skill questions will be administered immediately after the PK training presentation, which includes basic life support skills, is given to the students (Posttest 1), and 4 weeks later.
62587331|NCT06102382|EXPERIMENTAL|Norepinephrine (0.1)|An intravenous bolus dose of norepinephrine (5 µg) followed by infusion of 0.1 µg/kg/min till 5 minutes after delivery of the fetus.
62587332|NCT06102382|ACTIVE_COMPARATOR|Norepinephrine (0.075)|An intravenous bolus dose of norepinephrine (5 µg) followed by infusion of 0.075 µg/kg/min till 5 minutes after delivery of the fetus.
62796045|NCT05548946|OTHER|General population|In this group, younger adults (18-64) and older (from 65 and older) from the general population are included. The participants fill in questionnaires.
62023647|NCT02893722|PLACEBO_COMPARATOR|0.9% salain|intravenous injection of 0.9% saline in one minute before transfer. Then use the same dose of normal saline for intravenous infusion to set the same infusion rate with experimental group, complete the infusion in 3 hours.
62587333|NCT06038058|EXPERIMENTAL|BRY812|
62587334|NCT02229279|ACTIVE_COMPARATOR|Teleconsulting|Teleconsulting
62587335|NCT02229279|NO_INTERVENTION|No Teleconsulting|
62587336|NCT02050919|EXPERIMENTAL|Treatment (sorafenib, chemotherapy, radiation, surgery)|Patients receive sorafenib tosylate PO QD on days 1-71 and 85-155, epirubicin hydrochloride IV over 3-5 minutes, and ifosfamide IV over 90 minutes on days 15-17, 36-38 (ifosfamide only), 57-59, 99-101, 120-122, and 141-143. Patients undergo EBRT on days 36-45 and surgical resection on day 78. Patients with positive margins, undergo EBRT boost on days 91-98.
62587337|NCT06665815||Negative result at the autoantibodies screening test|"1. Participants without positive autoantibodies will not be confirmed or referred to follow up~2. Participants with only one positive autoantibody, will be referred to perform regular follow up as part of routine medical care according to the international consensus guidelines published in July 2024"
62587338|NCT06665815||Positive result at the autoantibodies screening test|"Participants with two or more positive autoantibodies:~1. will be invited to perform a confirmation test as part of the study~2. If confirmed as having pre-symptomatic type 1 diabetes (T1D) (stages 1 / 2), participants will be referred to complete an educational program emphasizing on DKA prevention and to perform regular follow-up according to the international consensus guidelines published in July 2024, as part of routine medical care"
62587339|NCT06682871|ACTIVE_COMPARATOR|Arm T: Transversus Abdominis Plane (TAP) blocks with bupivacaine|Infants of mothers who received 4-Quadrant TAP block after inactive elective spinal cesarean section (25 patients)
62587340|NCT06682871|ACTIVE_COMPARATOR|Arm E : Epidural Analgesia with bupivacaine|Infants of mothers who received Epidural analgesia after inactive elective spinal cesarean section (25 patients)
62414616|NCT06213961|NO_INTERVENTION|control arm|Before basic life support training is given to students, an introductory characteristics form and basic life support skill questions will be applied (pre-test). Immediately after the traditional powerpoint training presentation, which includes basic life support skills, is given to the students (Posttest 1), the skill questions will be administered again 4 weeks later.
62587341|NCT06682871|ACTIVE_COMPARATOR|Arm M: Iv Multimodal Analgesia with paracetamol or tramadol|Infants of mothers who received Multimodal intravenous analgesia after inactive elective spinal cesarean section (25 patients)
62220152|NCT04292184|NO_INTERVENTION|UW (perfusion solution)|Kidney will be flushed with UW (perfusion solution) which is the normal standard of care.
62414617|NCT04839133|OTHER|Feasibility study group|
62587342|NCT02562222|EXPERIMENTAL|anodal tDCS on M1|anodal tDCS on left primary motor cortex
62587343|NCT02562222|EXPERIMENTAL|cathodal tDCS on M1|cathodal tDCS on left primary motor cortex
62414618|NCT06519266|ACTIVE_COMPARATOR|IPI3/NIVO1|Patients will be treated with 4 cycles of intravenous (i.v.) infusion with ipilimumab 3mg/kg and nivolumab 1mg/kg q3w followed by continued i.v. nivolumab 480mg q4w up to 1 year
62587344|NCT02562222|EXPERIMENTAL|anodal tDCS on V1|anodal tDCS on visual cortex
62220153|NCT03367390|EXPERIMENTAL|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
62220154|NCT02418676|EXPERIMENTAL|Gel with HPβCD-I complex|A quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
62587345|NCT02562222|EXPERIMENTAL|cathodal tDCS on V1|cathodal tDCS on visual cortex
62587346|NCT02562222|EXPERIMENTAL|anodal tDCS on M1 and cathodal on V1|dual tDCS - anodal tDCS on left primary motor cortex and cathodal on visual cortex
62220155|NCT02418676|ACTIVE_COMPARATOR|Gel with insulin|A quantity of 5 grams of gel with insulin was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
62796046|NCT05548946|OTHER|Clinical Population|In this group, in- and outpatients from the clinical population are included. This are older adults, from the age of 65 with varying psychological pathologies (such as anxiety disorders, mood disorders, substance use disorders, developmental disorders, personality pathology, grief, trauma-related disorders, psychosocial problems, psychosis and schizophrenia-related disorders and somatic disorders). The patients fill in questionnaires and a randomly selected smaller group of patients will conduct a clinical interview.
62796047|NCT00398567|EXPERIMENTAL|Part 1 - dose level 1 (160 mg)|All subjects receiving HKI-272 dose level 1 in combination with trastuzumab
62220156|NCT02418676|PLACEBO_COMPARATOR|Control gel|A quantity of 5 grams of gel without active was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
62414619|NCT06519266|EXPERIMENTAL|PHP + IPI1/NIVO3|Patients will be treated with two cycles of PHP (CHEMOSAT® Hepatic Delivery System for Melphalan) six weeks apart, followed by two cycles of i.v. ipilimumab 1mg/kg and nivolumab 3mg/kg q3w, followed by continued i.v. nivolumab 480mg q4w up to 1 year
62414620|NCT04921384|EXPERIMENTAL|Eptinezumab 300 mg|300 mg eptinezumab by intravenous (IV) infusion.
62414621|NCT04921384|EXPERIMENTAL|Eptinezumab 100 mg|100 mg eptinezumab by IV infusion.
62414622|NCT04921384|PLACEBO_COMPARATOR|Placebo|Placebo by IV infusion.
62414623|NCT03372395|OTHER|Group 1|Standard treatment plus short-term (3 months) vaginal Lactobacillus rhamnosus BMX 54 implementation
62587347|NCT02562222|EXPERIMENTAL|cathodal tDCS on M1 and anodal on V1|dual tDCS - cathodal tDCS on left primary motor cortex and anodal on visual cortex
62587348|NCT02562222|SHAM_COMPARATOR|sham tDCS|sham tDCS
62587349|NCT05945615|EXPERIMENTAL|Oxymetazoline 0.1% ophthalmic drops|Patients will use once daily in affected eye. Drops are provided in single use vials.
62587350|NCT05945615|PLACEBO_COMPARATOR|Preservative free lubricating drops|Patients will use once daily in affected eye. Drops are provided in single use vials.
62587351|NCT06110754|EXPERIMENTAL|I-STRONG for SCD|Adolescents with sickle cell disease and their parents participating in a multi-component intervention that includes mind-body, cognitive-behavioral, and neuromuscular movement training.
62796048|NCT00398567|EXPERIMENTAL|Part 1 - dose level 2 (240 mg)|All subjects receiving HKI-272 dose level 2 in combination with trastuzumab
62796049|NCT00398567|EXPERIMENTAL|Part 2 - expanded MTD cohort|All subjects receiving HKI-272 in combination with trastuzumab
62796050|NCT06726083|EXPERIMENTAL|Nutrition Intervention|Weekly virtual live group sessions led by a trained study team member will be held twice weekly for 1 hour/week over 12 weeks using a HIPAA compliant online platform. The first class of each week will include the teaching kitchen cooking demonstration (\~30 min) and the remainder of the class will focus on dietary education. The second class each week will provide an opportunity for group discussion to have Veterans share to their peers about how they used the weekly produce
62414624|NCT03372395|EXPERIMENTAL|Group 2|Standard treatment plus long-lasting (6 months) Lactobacillus rhamnosus BMX 54 administration
62414625|NCT03911817|NO_INTERVENTION|IV vasopressor|Will receive IV vasopressor infusion only
62414626|NCT03911817|ACTIVE_COMPARATOR|Midodrine|Will receive midodrine in addition to IV vasopressor infusion
62587352|NCT06440356|EXPERIMENTAL|Treatment protocol|"In the first group, a NGD laser with dual wavelength, infrared and LED features, operating at a depth of 50 mm, which can be applied regionally, was used.~In the second group, a neodymium-doped yttrium aluminium garnet laser was used. After the laser unit has been switched on, the LLLT preset has been selected.~Patients in the third group received emission-free laser treatment. In the same procedure with the Nd:YAG laser, a placebo treatment was performed with the device on, laser beams visible but not active."
62220157|NCT05319301|EXPERIMENTAL|Patients with hypopituitarism|A single dose of melatonin administration
62220158|NCT05319301|ACTIVE_COMPARATOR|Healthy controls|A single dose of melatonin administration
62220159|NCT03402815|EXPERIMENTAL|A|Patients received Maraviroc 300 mg/day in addition to current ART for 24 weeks. At the end of the first 24-week period patients were switched to ART with no additional treatment.
62587353|NCT02522156|EXPERIMENTAL|Looming Vulnerability Induction|"Four audiotape-guided imagery exercises, each lasting about 3 minutes:~* Conveyor Belt: Places the participants in a dimly-lit factory, in which they are being carried along faster and faster on a conveyor belt as they smoke. This conveyor belt is described as ultimately leading to the diagnosis of lung cancer.~* Office Building: Places participants in an office all alone, watching calendar pages fly off the wall. As participants smoke and time progresses, participants are meant to feel their lungs withering away and their heart beat becoming weaker and weaker.~* Train Tracks: Set in the open plains on top of a set of railroad tracks. As participants smoke, a train heading directly towards them gains speed.~* Clock Ticking: In this timing exercise, participants are instructed to imagine terrible health consequences related to smoking coming closer and closer to them as they smoke. Participants are asked to keep track of time for a period of three minutes."
62587354|NCT02522156|PLACEBO_COMPARATOR|Control|"Four audiotape-guided imagery exercises, as follows:~* Escalator (parallel to conveyor belt above): Takes place in an empty mall in the morning. The participants imagine they are slowly and steadily being carried by the escalator until they reach the top.~* Metro (parallel to office building): Involves riding public transportation while reading a magazine, steadily flipping the pages.~* Driving (parallel to Train Tracks): Involves driving a car. The car in this case moves steadily with no traffic hindrances that would cause a reduction of speed.~* Human Clock (parallel to Clock Ticking): Another timing exercise. In this case, the participants receive instruction to pretend they are a human clock."
62414627|NCT03001427|EXPERIMENTAL|Structured center-based lifestyle intervention|The Structured center-based Lifestyle Intervention (C-LIFE) will include individualized plans for the DASH diet, weight management, and aerobic exercise.
62414628|NCT03001427|EXPERIMENTAL|Standard education and physician advice|The Medical Management with Standardized Education and Physician Advice (SEPA) will consist of encouragement to achieve an ideal body weight and engage in exercise as part of routine counseling in primary care, but no special program will be delivered to enhance the participants' ability to comply with these recommendations.
62220160|NCT03402815|EXPERIMENTAL|B|Patients received ART with no additional treatment for 24 weeks. At the end of the first 24-week period patients were switched to Maraviroc 300 mg/day in addition to current ART.
62414629|NCT05922592|EXPERIMENTAL|The sinus membrane will be elevated by using balloon technique with simultaneous Implant placement.|
62414630|NCT05922592|EXPERIMENTAL|The sinus membrane will be elevated by using Densah burs with simultaneous Implant placement|
62414631|NCT03463759||Recurrent Low Back Pain Patients|Participants experiencing a current episode of their recurrent non-specific low back pain at the time of recruitment.
62220161|NCT05370001|NO_INTERVENTION|Routine procedure - use of ETT size 9|When using HFJV in liver tumour ablation procedures for optimizing surgical conditions, an ETT size 9 is routinely being used in our department.
62220162|NCT05370001|EXPERIMENTAL|Experimental group - use of ETT size 8|In this arm an endotracheal tube of size 8 will be used. This is one size smaller than is routine when HFJV is being used for liver tumour ablation procedures in our department. Worth to note is that an endotracheal tube of size 8 is routine in all other surgical procedures, in men, during general anaesthesia.
62220163|NCT02143752||Mindfulness|Smokers enter a Mindfulness Training for Smokers course
62220164|NCT02143752||Quit Line|Smokers attempt smoking cessation with the help of the Wisconsin Tobacco Quit Line
62220165|NCT03316300|EXPERIMENTAL|NT-501|Test product
62414632|NCT03463759||Healthy Volunteers|Participants matched in age and gender to one of the recurrent low back pain patients, with no significant past low back pain, chronic pain or other relevant medical disorders.
62796051|NCT06726083|ACTIVE_COMPARATOR|Contact Control|Weekly virtual live group health education sessions led by staff will be held for two hours/week over 12 weeks. We will enroll up to 15 participants into each virtual class cohort and run multiple different group sessions for a total sample size of 90 participants. The content follows the LIFE study structured successful aging health education curriculum80,81 which was designed to increase self-efficacy and empower older Veterans to take control of their own healthcare. Topics focus on a broad range of healthy aging, such as importance of sleep, safe travel, goal setting, self-care, and common comorbidities
62023648|NCT03867734|EXPERIMENTAL|2g Aztreonam|Subjects to receive 2g Aztreonam IM for the treatment of gonorrhea
62023649|NCT05377398|EXPERIMENTAL|1) Intervention group|"Participants in this arm will be offered~1. a digital individual-level intervention (Bit Habit) \&~2. group-based or individual-level healthy lifestyle and green power intervention~3. a mini-intervention for substance use if their level of substance use is above certain risk level."
62220166|NCT03316300|SHAM_COMPARATOR|Sham|A sham surgical procedure was performed to mimic the implant procedure; there was no comparator product.
62414633|NCT06537323|OTHER|Femoral nerve block with0.25% bupivacaine|Femoral nerve block with0.25% bupivacaine guided by ultrasound.
62414634|NCT06537323|OTHER|PENG block with0.25% bupivacaine|PENG block with0.25% bupivacaine guided by ultrasound
62220167|NCT04910607||Patient|Participating patients will be recruited from the Specialised Obesity Centres =CSO (CHU and Follow-up and rehabilitation care (SSR), as well as patient associations) to fill in a questionnaire and take part in an interview (varied panel representative of the target population in terms of place of residence, socio-professional category, sex and age).
62414635|NCT06537323|OTHER|Preoperative IV fentanyl|Preoperative IV fentanyl 100microgram
62796052|NCT01871519|OTHER|Balloon Kyphoplasty|This group of patients will be treated with balloon kyphoplasty in the treatment of painful, acute VCFs associated with either osteoporosis or cancer.
62023650|NCT05377398|NO_INTERVENTION|2) Control group|"The control group is assumed to continue with current health information and national recommendations for healthy lifestyle and use of services as usual."
62023651|NCT02199847|EXPERIMENTAL|Pharmaton® Caplets|
62023652|NCT02199847|PLACEBO_COMPARATOR|Placebo|
62414636|NCT02414165|EXPERIMENTAL|Toca 511/Toca FC|"Resection followed by administration of 4 mL Toca 511 (vocimagene amiretrorepvec). Toca 511 is administered by injection into the wall of the subject's tumor resection cavity on Day 1 (approximately 40 injections of 0.1 mL)~Toca FC is an extended-release formulation of flucytosine. Toca FC will be administered at 220 mg/kg/day orally for 7-day courses beginning at least 6 weeks after resection and repeated approximately every 6 weeks."
62796053|NCT05841875|EXPERIMENTAL|Intervention group - C reactive protein|"For patients in the intervention group, attending physicians will be encouraged to follow an algorithm that uses clinical variables and serum CRP levels to guide the duration of antibiotic therapy. The peak CRP is defined as the highest value recorded within the first 72 hours of treatment.~Antibiotic therapy discontinuation will be encouraged under the following conditions:~If the peak CRP is below 100 mg/L: Consider stopping antibiotics when CRP falls below 35 mg/L, with a minimum treatment duration of 3 days.~If the peak CRP is above 100 mg/L or the patient meets criteria for sepsis or septic shock: Consider stopping antibiotics when CRP has decreased by 50%, after a minimum of 5 days.~If the patient does not meet the CRP criteria: Antibiotic discontinuation will be recommended after 5-7 days, provided there is clinical improvement."
62023653|NCT04845958||Pediatric Patients with Unexplained Enlarged Spleen|
62023654|NCT02525133|EXPERIMENTAL|XaraColl|3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose
62433352|NCT03759769|EXPERIMENTAL|simulator|Practice at home all activities of the wheelchair simulator, at least 20 minute per session, at least one session every second day
62433353|NCT03759769|ACTIVE_COMPARATOR|control|Practice on a computer video game, at least 20 minute per session, at least one session every second day
62023655|NCT02525133|PLACEBO_COMPARATOR|Placebo|3 placebo implants
62023656|NCT03793192|EXPERIMENTAL|PACE2 Intervention|All participants will receive usual healthcare as per their treating medical team and carry a pedometer for recording of physical activity. In addition, participants randomized to the PACE2 intervention will receive written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
62023657|NCT03793192|NO_INTERVENTION|Enhanced Usual Care|All participants will receive usual healthcare as per their treating medical team and carry a pedometer for recording of physical activity.
62023658|NCT01527201|EXPERIMENTAL|Treatment Group|Worn out cartilage will be surgically treated.
62023659|NCT01527201|NO_INTERVENTION|Control Group|Worn out cartilage will be observed, but will not be treated surgically.
62023660|NCT02369029|EXPERIMENTAL|Arm 1|To determine maximum tolerated dose (MTD) of BAY 1238097
62023661|NCT05665218||patients undergoing right heart catheterization|
62220168|NCT04910607||Professional|Medical and paramedical staff involved in the partner CSOs will also be asked to participate in a semi-structured interview.
62220169|NCT05244915|EXPERIMENTAL|Experimental|Participants will receive a geriatric assessment which consists of validated questionnaires that are used to assess health status of older adults with cancer. Based on participant responses, tailored recommendations will be provided.
62220170|NCT04705207|EXPERIMENTAL|reflexology massage|foot reflexology massage
62220171|NCT04705207|PLACEBO_COMPARATOR|sham massage|traditional foot massage
62220172|NCT00936741|EXPERIMENTAL|Mifepristone|Mifepristone 300mg to 1200mg once daily
62433354|NCT06355960|ACTIVE_COMPARATOR|group A|Dexmedetomidine (Precedex) loadings of 1 μg/kg than continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
62220173|NCT01633918|EXPERIMENTAL|Internet-supported FeetEnergy approach|Schools which integrate Internet-supported approach with two home works in three health education lessons on physical activity
62220174|NCT01633918|ACTIVE_COMPARATOR|Usual health education|Schools which follow their usual practices in carrying out health education classes on physical activity
62220175|NCT01739816|NO_INTERVENTION|Control group|Patients get no intervention at study start, but only at study end after seven months.
62220176|NCT01739816|ACTIVE_COMPARATOR|Intervention group|At the beginning and at the end of the study, this group receives a pharmacist's led medication review focusing on daily medicines use (= Polymedication Check).
62220177|NCT01739816|OTHER|Observational arm|If participants after recruitment violate inclusion criteria (e.g. change from autonomous medication management to external home care) or insists on intervention despite being randomised to control group or patient condition forces pharmacist to provide a PMC.
62414637|NCT02414165|ACTIVE_COMPARATOR|Lomustine, Temozolomide, or Bevacizumab|"Investigator selects one of the following:~Bevacizumab: Beginning 6 weeks after tumor resection, bevacizumab will be administered by IV infusion at 10 mg/kg and repeated every 2 weeks. Refer to the prescribing information and to institutional guidelines for details on the administration procedure.~Lomustine: Beginning 6 weeks after tumor resection, lomustine will be administered as a single oral dose of 110 mg/m2 and repeated every 6 weeks. Refer to the prescribing information and to institutional guidelines for details regarding the administration procedure.~Temozolomide: Beginning 6 weeks after tumor resection, temozolomide will be administered per 1 of 2 options:~* at a dose of 50 mg/m2 PO once daily continuously, or~* at an initial dose of 150 mg/m2 IV or PO once daily for 5 consecutive days per 28-day treatment cycle that may be raised to 200 mg/ m2 once daily for 5 consecutive days in the following 28-day treatment cycles"
62414638|NCT06567275|EXPERIMENTAL|erector spinae plane block|Ultrasound-guided erector spinae plane block will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%).
62414639|NCT06567275|EXPERIMENTAL|serratus anterior plane block|Ultrasound-guided serratus anterior plane block will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%).
62414640|NCT01658215|OTHER|Sequence 1|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days.~Each patch will be applied for 24 hours."
62414641|NCT01658215|OTHER|Sequence 2|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days.~Each patch will be applied for 24 hours."
62414642|NCT05872451|EXPERIMENTAL|Current intensity|"1. An I-gel mask is inserted for the mechanical ventilator of the patient who is sedated with propofol.~2. For the ultrasound-guided obturator nerve (ON) block, and needle tip gradually advanced to the anterior branch of the ON. The current intensity for the stimulation of ON starts at 1.0 mA (using the sequential electrical nerve stimulation mode), and the needle is advanced gradually to the location where the contraction of the adductor longus muscle (ALM) occurs at 0.3-0.5 mA.~3. After fixing the needle in that position, measure the current intensity.~4. Then, rocuronium (0.6 mg/kg) is administered under quantitative neuromuscular-blockade monitoring.~5. When the train-of-four count becomes 0, the current intensity is increased until the contraction of the ALM occurs.~6. The current intensity is measured when the contraction of the ALM occurs."
62414643|NCT00896038|EXPERIMENTAL|Aprepitant|Following a 1-week placebo lead-in period subjects were given 125 mg of Aprepitant orally daily for 21 days
62414644|NCT00896038|PLACEBO_COMPARATOR|Placebo|Subjects received oral placebo during the 1-week placebo lead-in and then daily for 21 days
62220178|NCT05900362|EXPERIMENTAL|Interventional|All patients receive the VitalCare platform with a tablet computer, an Eko Duo device, a weight scale, a blood pressure cuff, a pulse oximeter
62414645|NCT02822612||Retinal Disease|Fifteen subjects with retinal disease. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
62414646|NCT02822612||Glaucoma|Fifteen subjects with glaucoma. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
62414647|NCT02822612||Strabismus|Fifteen subjects with strabismus. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
62414648|NCT02822612||Healthy volunteers|Fifteen healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
62414649|NCT03533335|ACTIVE_COMPARATOR|Chlorhexidine spray|0.2% chlorhexidine oral spray, once daily
62220179|NCT02272088|EXPERIMENTAL|physical activity-moderate|participants will be walking during 60 minutes in a moderate pace
62414650|NCT03533335|EXPERIMENTAL|Chlorine Dioxide spray|0.1% pH-balanced chlorine dioxide oral spray, once daily
62414651|NCT03533335|PLACEBO_COMPARATOR|Sterile water spray|Placebo
62414652|NCT01164137|EXPERIMENTAL|Medication Reconciliation Intervention|Participants receiving a pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at identifying and correcting medication discrepancies.
62414653|NCT01164137|NO_INTERVENTION|Medication Reconciliation Non-Interven.|Participants not receiving a pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at identifying and correcting medication discrepancies.
62414654|NCT00986609|EXPERIMENTAL|Arm I|Patients receive MUC-1 peptide vaccine subcutaneously and poly-ICLC vaccine intramuscularly in weeks 0, 4, 8, 12, 52, and 56, in the absence of disease progression or unacceptable toxicity. Patients may receive additional vaccines in weeks 34 and 38 if anti-MUC1 immunity falls below the two-fold enhancement from baseline
62220180|NCT02272088|EXPERIMENTAL|intense physical activity|participants will be running during 60 minutes in na intense pace.
62220181|NCT05871567||group 1 or MSS|colorectal cancers (CRCs) with stable microsatellite
62220182|NCT05871567||group 2 or MSI|colorectal cancers (CRCs) with unstable microsatellite
62796054|NCT05841875|NO_INTERVENTION|Control group: Best practice|"For patients in the control group, the attending physician will be encouraged to determine the duration of antimicrobial therapy based on the best available evidence, taking into account the most likely infectious focus and the patient's clinical response. These recommendations will be guided by international society guidelines and established best practices for antibiotic therapy.~Additionally, it is recommended that CRP monitoring in the control group be discontinued after 72 hours of antibiotic therapy, as this period is considered sufficient for using CRP as a biomarker to assist in diagnosing the infectious condition."
62796055|NCT04843436|EXPERIMENTAL|Robotic Assisted Microsurgery|Patients who meet the eligibility criteria for the study and undergo a microsurgical reconstruction using the Symani System according to its indications for use.
62796056|NCT01668225||G-CSF FIV nat|Patient following a natural In Vitro Fecondation cycle
62796057|NCT06727370||patients diagnosed with lung cancer|patients diagnosed with lung cancer (both SCLC and NSCLC)
62796058|NCT05428631|EXPERIMENTAL|CARDIOMEMS(TM) HF device|Renal failure patients testing the CARDIOMEMS(TM) HF device
62796059|NCT06227234|EXPERIMENTAL|LV - DC - AT|Order: LifeVac then Dechoker then Abdominal Thrusts
62796060|NCT06227234|EXPERIMENTAL|LV - AT - DC|Order: LifeVac then Abdominal Thrusts then Dechoker
62796061|NCT06227234|EXPERIMENTAL|DC - AT - LV|Order: Dechoker then Abdominal Thrusts then LifeVac
62796062|NCT06227234|EXPERIMENTAL|DC - LV - AT|Order: Dechoker then LifeVac then Abdominal Thrusts
62220183|NCT03671694|ACTIVE_COMPARATOR|laser treatment|Erbium-YAG laser treatment to the vagina
62796063|NCT06227234|EXPERIMENTAL|AT - LV - DC|Order: Abdominal Thrusts then LifeVac then Dechoker
62796064|NCT06227234|EXPERIMENTAL|AT - DC - LV|Order: Abdominal Thrusts then Dechoker then LifeVac
62220184|NCT03671694|PLACEBO_COMPARATOR|sham treatment|sham treatment with laser placebo
62220185|NCT03482401|EXPERIMENTAL|Polyphenol group|Patients consumed a polyphenol-rich dietary supplement (commercial lemon, orange, pomegranate, olive, grape, cocoa, curcuma and broccoli extracts), mainly rich in simple phenolics such as hydroxytyrosol and the polyphenols procyanidins, hesperidin, eriocitrin, curcumin, resveratrol, punicalagin and ellagic acid. Cocoa extract also contains the methylxanthines theobromine and caffeine.
62220186|NCT03482401|NO_INTERVENTION|Control group|Participating patients did not consume the supplement but provided biological samples to the trial
62414655|NCT02136615||overweight and obese male volunteers|BMI between 23-40 kg/m2
62796065|NCT05206812|EXPERIMENTAL|durvalumab|The operable non-small cell lung carcinoma patients (resectable stage IIA\~IIIB)
62796066|NCT05901636|EXPERIMENTAL|INFLUENZA G1 mHA Dose Level 1|Participants will receive single intramuscular (IM) injection of INFLUENZA G1 mHA Dose level 1 on Days 1 and 57 in Cohort 1.
62796067|NCT05901636|EXPERIMENTAL|INFLUENZA G1 mHA Dose Level 1 along with Al(OH)3|Participants will receive single IM injection of INFLUENZA G1 mHA Dose level 1 with Aluminum Hydroxide (Al\[OH\])3 adjuvant on Days 1 and 57 in Cohort 1.
62796068|NCT05901636|PLACEBO_COMPARATOR|Placebo|Participants will receive IM injection of placebo on Days 1 and 57 in Cohorts 1 and 2.
62796069|NCT05901636|EXPERIMENTAL|INFLUENZA G1 mHA Dose Level 2|Participants will receive single IM injection of INFLUENZA G1 mHA Dose level 2 on Days 1 and 57 in Cohort 2.
62796070|NCT05901636|EXPERIMENTAL|INFLUENZA G1 mHA Dose Level 2 along with Al(OH)3|Participants will receive single IM injection of INFLUENZA G1 mHA Dose level 2 with Al(OH)3 adjuvant on Days 1 and 57 in Cohort 2.
62796071|NCT05901636|EXPERIMENTAL|INFLUENZA G1 mHA Dose Level 2 + Placebo|Participants will receive single IM injection of INFLUENZA G1 mHA Dose level 2 on Day 1 and placebo on Day 57 in Cohort 2.
62220187|NCT04317677|OTHER|Babies hospitalized in the pediatric sleep unit|
62220188|NCT06611124|OTHER|k -wires|fixation of hand metacarpals fractures with k-wire 2 arms
62220189|NCT06611124|OTHER|k -wire|fixation of hand metacarpals fractures with k-wire 2 arms
62220190|NCT06205537|PLACEBO_COMPARATOR|Oral Liquid Supplement (ONS) Group A|One 8 oz. serving
62220191|NCT06205537|EXPERIMENTAL|Oral Liquid Supplement (ONS) Group B|One 8 oz. serving
62220192|NCT03888989|OTHER|Study Phase|Participants will be given the current year's quadrivalent inactivated influenza vaccine (IIV)
62796072|NCT05901636|EXPERIMENTAL|INFLUENZA G1 mHA Dose Level 2 along with Al(OH)3 + Placebo|Participants will receive single IM injection of INFLUENZA G1 mHA Dose level 2 with Al(OH)3 adjuvant on Day 1 and placebo on Day 57 in Cohort 2.
62796073|NCT03892746|ACTIVE_COMPARATOR|Active tDCS + task oriented practice|
62796074|NCT03892746|SHAM_COMPARATOR|Sham tDCS + task oriented practice|
62796075|NCT01688375|EXPERIMENTAL|Ursodeoxycholic acid|Ursodeoxycholic acid administration UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
62587355|NCT04562129|EXPERIMENTAL|Treatment|HD IL2 (600,000 units/kg/dose IV) will be given during week 1 of the 2 initial cycles or each course. Ipilimumab will be given concurrently at the low dose of 1 mg/kg during week one of the 2 initial cycles of each course for up to 2 doses, total. Nivolumab will be given on during week one of the 3rd cycle of each course. No systemic treatment will be administered during the 4th cycle. Patients without evidence of disease progression (RECIST v.1.1) or limiting toxicities will be offered additional courses of treatment for up to a maximum of 3 courses, total.
62796076|NCT06558838|EXPERIMENTAL|Study Drug (acyclovir-penciclovir cream)|Patients will treat herpes simplex eruption with active study drug.
62796077|NCT06558838|ACTIVE_COMPARATOR|Active Comparator (Abreva)|Patients will treat herpes simplex eruption with Abreva.
62796078|NCT01082692|EXPERIMENTAL|3mg DNA/dose|Subjects will receive a 4 dose series of PENNVAX-B containing 3mg of DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8 and Week 16.
62796079|NCT02068625|EXPERIMENTAL|Treatment|Patients getting perioperative oral treatment with rasagiline (1mg daily) for 7 days
62796080|NCT02068625|PLACEBO_COMPARATOR|Control|Patients getting perioperative oral treatment with placebo for 7 days
62796081|NCT02071199|EXPERIMENTAL|Low dose 0.3X ACCS|20 microliters of 0.3X ACCS per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
62796082|NCT02071199|EXPERIMENTAL|High dose 1X ACCS|20 microliters of 1X ACCS per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
62796083|NCT02071199|PLACEBO_COMPARATOR|Normal saline|20 microliters of saline placebo per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
62796084|NCT02871635|EXPERIMENTAL|BI 695501|
62796085|NCT02871635|ACTIVE_COMPARATOR|HUMIRA + BI 695501|
62796086|NCT06725992|ACTIVE_COMPARATOR|A group|"Period 1 : Ilaprazole 10mg 2Tab, one a day~Period 2 : IY-NS250 1Tab, one a day"
62796087|NCT06725992|ACTIVE_COMPARATOR|B group|"Period 1 : IY-NS250 1Tab, one a day~Period 2 : Ilaprazole 10mg 2Tab, one a day"
62796088|NCT00476827|ACTIVE_COMPARATOR|Bevacizumab / Capecitabine|Bevacizumab 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle.
62796089|NCT00476827|ACTIVE_COMPARATOR|Bevacizumab / Docetaxel|Docetaxel (taxotere) 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
62796090|NCT00476827|ACTIVE_COMPARATOR|Bevacizumab /Irinotecan (Camptosar®, CPT-11)|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
62796091|NCT00476827|ACTIVE_COMPARATOR|Bevacizumab / Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
62796092|NCT00476827|ACTIVE_COMPARATOR|Bevacizumab /Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle.
62796093|NCT00476827|ACTIVE_COMPARATOR|Bevacizumab / Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.
62023662|NCT03219983|ACTIVE_COMPARATOR|Interscalene Block|Ultrasound guided interscalene catheter will be placed and a 30 ml .5% ropivacaine will be given pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score \> 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
62023663|NCT03219983|ACTIVE_COMPARATOR|Deep soft tissue/surgical site injection|A total volume of 100ml will be comprised of 60ml of 0.9% normal saline + 20ml 0.5% bupivacaine + 20ml liposomal bupivacaine will be injected into the deep soft tissue using an 18 or 20 gauge needle prior to or after prosthesis insertion
62220193|NCT06302517|NO_INTERVENTION|non-BIS-guided group (group C)|The depth of anesthesia was not monitored in the non-BIS-guided group (group C).
62220194|NCT06302517|EXPERIMENTAL|BIS-guided group (group B)|The BIS-guided group (group B) underwent intraoperative monitoring of BIS anesthesia depth
62220195|NCT06387368|EXPERIMENTAL|Huaier treatment group|The subjects received a combination of Huaier granules and capecitabine regimen.The subject takes Huaier granules orally, 10g once, three times a day; take capecitabine 1250mg/m\^2 orally , twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.
62220196|NCT06387368|ACTIVE_COMPARATOR|Control group|The subjects received the capecitabine monotherapy regimen. The subjects take capecitabine orally, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day for 1-14 days, once every 3 weeks.
62220197|NCT00893984|EXPERIMENTAL|Nebivolol|Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
62220198|NCT02704468||CAVI and FGF-21|renal transplant patients for more than 1 month measured FGF-21 and CAVI
62220199|NCT01220193||Normal cornea|
62220200|NCT01220193||Post laser refractive surgery|
62220201|NCT01220193||Cornea pathology|
62220202|NCT01220193||Cataract surgery|
62220203|NCT00743301|ACTIVE_COMPARATOR|Olive oil|
62220204|NCT00743301|EXPERIMENTAL|Palm olein|
62220205|NCT00743301|ACTIVE_COMPARATOR|Lard|
62220206|NCT01981772|EXPERIMENTAL|buffered lidocaine|administration of 4% buffered lidocaine with 1:100,000 epinephrine
62220207|NCT01981772|ACTIVE_COMPARATOR|nonbuffered lidocaine|administration of 4% lidocaine with 1:100,000 epinephrine
62414656|NCT04520711|EXPERIMENTAL|CDX-1140 + TCR-T + Pembro|Patients will receive CDX-1440, TCR-T, and pembrolizumab.
62414657|NCT02334839||Preeclampsia|women with diagnosed preeclampsia
62414658|NCT02334839||gestational hypertension|women with diagnosed gestational hypertension without preeclampsia
62414659|NCT02334839||healthy|women without gestational hypertension or preeclampsia
62414660|NCT06704139|EXPERIMENTAL|group 1|Fifty patients will receive intrathecal morphine
62220208|NCT00294515|EXPERIMENTAL|Valganciclovir up to 100 days|Valganciclovir for up to 100 days post kidney transplant
62414661|NCT06704139|EXPERIMENTAL|group 2|Fifty patients will receive intrathecal morphine and fentanyl
62414662|NCT00806416|EXPERIMENTAL|Sequence 1|alendronate/vitamin D combination then alendronate
62414663|NCT00806416|EXPERIMENTAL|Sequence 2|alendronate then alendronate/vitamin D combination
62414664|NCT00806416|EXPERIMENTAL|Sequence 3|alendronate/vitamin D combination then vitamin D
62220209|NCT00294515|ACTIVE_COMPARATOR|Valganciclovir up to 200 days|Valganciclovir for up to 200 days post kidney transplant
62220210|NCT06180018|EXPERIMENTAL|cases|Using interrupted sutures
62220211|NCT03910686|PLACEBO_COMPARATOR|Regular treatment (symptomatic treatment) with blank TMS|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation
62220212|NCT03910686|ACTIVE_COMPARATOR|Regular treatment (RT) with blank TMS and CBT|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation and cognitive behavioral therapy
62220213|NCT03910686|ACTIVE_COMPARATOR|RT with right DLPFC hf-rTMS|Regular treatment with right dorsolateral prefrontal cortex (DLPFC) high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
62220214|NCT03910686|ACTIVE_COMPARATOR|RT with right DLPFC hf-rTMS and CBT|Regular treatment with right DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
62220215|NCT03910686|ACTIVE_COMPARATOR|RT with left DLPFC hf-rTMS|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
62414665|NCT00806416|EXPERIMENTAL|Sequence 4|vitamin D then alendronate/vitamin D combination
62023664|NCT04434040|EXPERIMENTAL|Atezolizumab and Sacituzumab govitecan|"Patients will receive the following treatment:~Atezolizumab and Sacituzumab govitecan treatment will continue for 6 cycles (18 total weeks).~* Atezolizumab intravenously (IV) at a pre-determined dose on day 1 in a 21-day cycle~* Sacituzumab govitecan: intravenously (IV) at a pre-determined dose on days 1 and 8 in a 21-day cycle"
62220216|NCT03910686|ACTIVE_COMPARATOR|RT with left DLPFC hf-rTMS and CBT|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
62220217|NCT03354091|EXPERIMENTAL|Intervention|Patient education program and the use of an Fitbit where the users can monitore their activity and receive minor feedback regarding physical activity.
62220218|NCT03354091|NO_INTERVENTION|Control|Patient education program only.
62220219|NCT02873091|ACTIVE_COMPARATOR|CEI|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil. The basal infusion of CEI: 10 ml/h, beginning immediately after the initial dose
62220220|NCT02873091|ACTIVE_COMPARATOR|PIEB 1|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil.The basal infusion of PIEB1: 5 ml per 30 min, beginning 30 min after the initial dose
62414666|NCT01294709|EXPERIMENTAL|Telcagepant/ Placebo|Participants receive single oral dose of 600 mg (two 300 mg capsules or two bioequivalent 280 mg tablets) or 900 mg telcagepant (three 300 mg capsules) in Period 1 and single oral dose of two capsules or tablets of placebo for telcagepant (or three capsules of placebo for telcagepant) in Period 2 of the crossover. Each treatment period is separated by a washout of 96-240 hours.
62414667|NCT01294709|EXPERIMENTAL|Placebo/Telcagepant|Participants receive single oral dose of two capsules or tablets of placebo for telcagepant (or three capsules of placebo for telcagepant) in Period 1 and a single oral dose of 600 mg (two 300 mg capsules or two bioequivalent 280 mg tablets) or 900 mg telcagepant (three 300 mg capsules) in Period 2 of the crossover. Each treatment period is separated by a washout of 96-240 hours.
62414668|NCT05724875|EXPERIMENTAL|Arm A: FLASH RT|
62414669|NCT05724875|ACTIVE_COMPARATOR|Arm B: Conventional RT|
62220221|NCT02873091|ACTIVE_COMPARATOR|PIEB 2|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil. The basal infusion of PIEB2: 10 ml per 60 min, beginning 60 min after the initial dose
62220222|NCT01128816|NO_INTERVENTION|Standard HF therapy|Subjects will receive optimal standard therapy for heart failure conforming to national guidelines as determined by the referring cardiologist
62220223|NCT01128816|ACTIVE_COMPARATOR|Standard therapy for HF + ASV|Subjects will receive treatment with Adaptive Servo Ventilation in addition to optimal standard therapy for heart failure conforming to national guidelines, as determined by the referring cardiologist
62220224|NCT06378268|ACTIVE_COMPARATOR|Progestins Primed Ovarian stimulation group|PPOS group: Recombinant FSH 150-300 IU/day will start from day 2 to day 4 of menstruation. The initial FSH dose will be chosen based on age, anti-Müllerian hormone (AMH) level, antral follicle count (AFC), and body mass index (BMI). The FSH dosage will be fixed during ovarian stimulation. Dydrogesterone (Duphaston, Abbott, USA) 20mg/day will start on the day of gonadotropin injection to the oocyte maturation trigger night.
62220225|NCT06378268|ACTIVE_COMPARATOR|GnRH antagonist group|GnRH antagonist group: Recombinant FSH 150-300 IU/day will be given from day 2 to day 4 of menstruation. The initial FSH dose will be chosen based on age, anti-Müllerian hormone (AMH) level, antral follicle count (AFC), and body mass index (BMI). The FSH dosage will be fixed during ovarian stimulation. Cetrorelix (Cetrotide, Merck, Germany) 0.25mg/day will be given from day 5 of stimulation by the oocyte maturation trigger day.
62220226|NCT02824081|OTHER|Depressive patients|Blood samples (inflammatory biomarkers and genetic purpose) on depressive patients with or without story of suicidal behavior
62220227|NCT03191500|EXPERIMENTAL|steerable catheter|to study the safety and efficacy of a steerable catheter in the treatment of peripheral vascular disease
62220228|NCT00190749|EXPERIMENTAL|Olanzapine|
62220229|NCT00190749|ACTIVE_COMPARATOR|Risperidone|
62220230|NCT05609110|ACTIVE_COMPARATOR|RIC group|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
62414670|NCT05905809|EXPERIMENTAL|Group I with UniRelieverTM offloading brace|"Patients wearing the UniRelieverTM offloading brace (THUASNE):~For intervention group I, in addition to the usual care described above for the control group, patients will wear the studied UniRelieverTM offloading brace."
62414671|NCT05905809|EXPERIMENTAL|Group II with Unloader One® X brace|"Patients wearing the Unloader One® X brace (Össur):~For intervention group II, in addition to the usual care described above for the control group, patients will wear the Unloader One® X brace by Össur"
62414672|NCT05905809|NO_INTERVENTION|Group III without orthosis|"Patients wearing no orthosis:~In the control group, usual care is defined by:~* buffer heel and/or~* insoles and/or~* outer edge raisin and/or~* walking stick and/or~* physiotherapy and/ or~* analgesics oral and local depending on the patient's needs."
62414673|NCT04425642|EXPERIMENTAL|Glucose/Amino acids|Patients who will require nutritional support will receive parenteral nutrition consisting of glucose and amino acids according age and weight
62414674|NCT04425642|EXPERIMENTAL|Glucose/Amino acids/Lipids|Patients who will require nutritional support will receive parenteral nutrition consisting of glucose, amino acids and lipid emulsions according age and weight
62433355|NCT06355960|ACTIVE_COMPARATOR|group B|Dexmedetomidine (Precedex) loadings of 0.5 μg/kg then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
62587356|NCT06662448|EXPERIMENTAL|Home-based Repetitive Transorbital Alternating Current Stimulation (rtACS)|Participants will undergo 30 stimulation sessions. The first two sessions will be administered in the office, the first one the day after the subjects' baseline visit and the second one 48 hours after the first intervention. Then subjects will conduct 28 at-home intervention sessions taking place every other day over the course of 8 weeks.
62023665|NCT02021279|EXPERIMENTAL|MatriStem Pelvic Floor Matrix|surgical mesh device
62023666|NCT02021279|ACTIVE_COMPARATOR|Native Tissue Repair|suture repair
62023667|NCT02997566||Autistic Disorder|Age: 3 to 14 years-old Gender: male and female Autism Spectrum Disorder
62023668|NCT02997566||Typical|Age: 3 to 14 years-old Gender: male and female Typical
62023669|NCT04943289|EXPERIMENTAL|DUOC-01|Intrathecal Infusion of DUOC-01 and hydrocortisone. Cohort 1: 10 million cells Cohort 2: greater than 10 to 25 million cells Cohort 3: greater than 25 to 50 million cells
62220231|NCT05609110|PLACEBO_COMPARATOR|Sham RIC group|Sham remote ischemic conditioning (Sham RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
62220232|NCT02238054||ABSORB BVS|All patients with a coronary angioplasty procedure and the implantation of at least one ABSORB BVS
62220233|NCT02938026|NO_INTERVENTION|Control|Usual care
62220234|NCT02938026|EXPERIMENTAL|Telephone intensive lifestyle counseling|Telephone intensive lifestyle counseling
62220235|NCT02938026|EXPERIMENTAL|Bariatric surgery|Bariatric surgery
62220236|NCT00446992|EXPERIMENTAL|Open Trial Group|The patients were newly diagnosed with psychosis and were recruited at their first clinical contact for psychosis.
62220237|NCT03216421|OTHER|Low/Intermediate Grade DCIS|Subjects with Low/Intermediate Grade DCIS will complete quality of life questionnaires before and after the IORT.
62796094|NCT06349382|EXPERIMENTAL|OCHL group|"Approximately 25 patients will receive a high-carbohydrate beverage in the evening before surgery and two hours before the induction of anesthesia.~Intervention: carbohydrate-rich beverage~Glucose and insulin values will be assessed from the peripheral venous or arterial blood samples (from the arterial cannula postoperatively), taken at four-time points. Other parameters of insulin resistance (HOMA-IR, HOMA-ISI, and HOMA-β) will be calculated based on the values of fasting insulin and fasting glucose for each of four time points.~The subjective well-being variables will be evaluated in the morning before the surgery, 6-12 hours after the surgery, and 24 hours after the surgery."
62220238|NCT03216421|OTHER|High Grade DCIS|Subjects with High Grade DCIS will complete quality of life questionnaires before and after the IORT.
62220239|NCT02799901|EXPERIMENTAL|Patient|patient with Advanced melanoma
62220240|NCT02328339|EXPERIMENTAL|Black tea|Approximately 400 mg total polyphenols in 240 ml hot water (loading dose; 2 hours before the start of measurements; t=0) and 130 mg total polyphenols in 120 ml hot water (maintenance dose just before start of the measurements; t=120 min)
62220241|NCT02328339|PLACEBO_COMPARATOR|Placebo|Caramel colour, maltodextrin and tea flavour in 240 ml hot water (2 hours before the start of measurements; t=0) and 120 ml hot water (maintenance dose just before start of the measurements; t=120 min)
62220242|NCT03834038|EXPERIMENTAL|Open Label Lyophilized Fecal Microbiota Transplantation|Eligible participants with history of recurrent or refractory CDI
62220243|NCT02700477|ACTIVE_COMPARATOR|Fenugreek seed extract|Fenugreek seeds extract 500 mg capsule twice a day for 12 weeks
62220244|NCT02700477|PLACEBO_COMPARATOR|Placebo|Placebo capsule containing Dicalcium Phosphate 500mg, BD
62220245|NCT01724073|EXPERIMENTAL|Leafy vegetable-fish sauce|one meal per day, 6 days a week, with leafy vegetable-fish sauce + tô, a local cereal-based paste
62220246|NCT01724073|EXPERIMENTAL|Leafy vegetable-fish/liver sauce|one meal per day, 6 days a week, 5 days with leafy vegetable-fish sauce + tô, 1 day with leafy vegetable-liver sauce + tô
62220247|NCT01724073|EXPERIMENTAL|Misola|one meal per day, 6 days a week, with gruel prepared with the fortified Misola flour
62414675|NCT03054168|EXPERIMENTAL|Old Testosterone trained|"8 old participants (65-75 years old) who will receive resistance exercise training and Testosterone (Sustanon 250: 250 mg every 2wks)~Drug name: Sustanon 250 Generic Name: Testosterone Proprietary Name: N/A Formulation: 250mg of Testosterone in 1ml volume Dose: 250mg of testosterone Frequency: every 2 weeks Route: intramuscular injection"
62414676|NCT03054168|PLACEBO_COMPARATOR|Old Placebo trained|8 old participants (65-75 years old) who will receive resistance exercise training and Placebo every two weeks.
62414677|NCT03054168|EXPERIMENTAL|Young Zoladex trained|"8 young participants (18-30 years old) who will receive resistance exercise training and Testosterone inhibitor (3.6mg Zoladex subcutaneous injection, one time over the study)~Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single injection one time over the study. Route: Subcutaneous injection (abdomen) performed by clinician."
62414678|NCT03054168|PLACEBO_COMPARATOR|Young placebo trained|8 young participants (18-30 years old) who will receive resistance exercise training and placebo, one time over the study.
62414679|NCT02131831||cirrhosis|
62220248|NCT01724073|NO_INTERVENTION|no test food|control group receiving no test food
62414680|NCT05520060|EXPERIMENTAL|experimental|The experimental group will be placed in continuous midwifery care. The continuous and supportive care stages to be presented at birth are planned within the framework of Kolcaba's comfort theory. According to this theory, interventions will be applied according to the physical, psychospiritual, environmental and sociocultural comfort needs of women.
62414681|NCT05520060|PLACEBO_COMPARATOR|Control|The experimental group will be placed in routine midwifery care.
62587357|NCT02422966|EXPERIMENTAL|Paracetamol|Paracetamol intravenous solution 15 mg/kg (corresponding to 1.5 ml/kg) per dose every 6 hours for 3 days, for a total amount of 12 doses.
62587358|NCT02422966|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen intravenous solution at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 5 mg/kg at 48 h.
62587359|NCT04850261|ACTIVE_COMPARATOR|Intervention A: hCG injection|Ovulation induction by subcutaneous injection of 5.000 IU hCG
62220249|NCT06216873||multiple trauma|multiple trauma patients sent to emergency room for further evaluation are included
62220250|NCT05765162||All patients form age 18 and above|All patients form age 18 and above
62220251|NCT00805181||Acute uncomplicated pyelonephritis|
62220252|NCT02108990|EXPERIMENTAL|Acetaminophen 1000mg|Acetaminophen 1000mg capsule orally three times a day
62220253|NCT04593927||Mayzent|Patients administered Mayzent by prescription
62220254|NCT01177982|ACTIVE_COMPARATOR|Usual RBT (t-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club
62220255|NCT01177982|EXPERIMENTAL|Reduced RBT (r-RBT)|Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social Club Job Club
62220256|NCT01177982|EXPERIMENTAL|Abbreviated RBT (a-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation
62220257|NCT01177982|ACTIVE_COMPARATOR|Enhanced RBT (e-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club Recovery housing CAP short term housing admission Recovery sponsor
62220258|NCT01177982|ACTIVE_COMPARATOR|Early compliant t-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social club Job club
62220259|NCT01177982|ACTIVE_COMPARATOR|Early non-compliant t-RBT|t-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club e-RBT: Recovery housing CAP short term housing admission Recovery sponsor
62220260|NCT01177982|EXPERIMENTAL|Early compliant r-RBT|a-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation r-RBT: Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
62220261|NCT01177982|EXPERIMENTAL|Early non-compliant r-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social Club Job Club
62220262|NCT05907109|EXPERIMENTAL|Intervention|Remotely monitored parent-mediated hybrid home and clinic based multidisciplinary Early Intervention protocols.
62414682|NCT04041063|EXPERIMENTAL|Nerve transfer + robotic training|Participants will receive nerve transfer surgery at Massachusetts General Hospital in Boston, MA. One year after the surgery, participants will receive six weeks of upper limb robotic training at the Burke Neurological Institute in White Plains, NY.
62414683|NCT04041063|ACTIVE_COMPARATOR|Nerve transfer + delayed robotic training|Participants will receive nerve transfer surgery at Massachusetts General Hospital in Boston, MA. One year + six weeks after the surgery, participants will receive six weeks of upper limb robotic training at the Burke Neurological Institute in White Plains, NY.
62414684|NCT02107768|EXPERIMENTAL|Exercise recommendation|Patients randomized to the control group receive general advice for physical training and activity but no specific training or other rehabilitation efforts
62414685|NCT02107768|EXPERIMENTAL|Aerobic exercise|"The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added. The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20, Rate of Perceived Exertion (Borg 's RPE scale)~Two fitness goals was to be achieved during the training session:~1. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.~2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) .Which corresponds to 85% of maximum heart rate."
62414686|NCT06196970|EXPERIMENTAL|Baseline warmup along with Pilate exercises|Pilate exercises: Group A perform Pilates exercises for 6 weeks. In the initial stage of training Pilates exercises with lo intensity then we proceeded gradually with high intensity. Pilates was performed for core strengthening and dynamic balance Pelvic curl, The hundred, Side plank with 4-5 rep, 30 sec hold and 3 sets with each exercise.
62414687|NCT06196970|EXPERIMENTAL|: Baseline physical therapy treatment along with burpees exercises|Burpees Exercises: Group B perform Burpees exercises for 6 weeks. In initial weeks of training Burpees exercises with low intensity then we proceeded gradually with high intensity exercises. Burpees was performed for core strengthening and dynamic balance .10 to 15 repetition ,3 sets with rest interval of 10 sec after each set of exercises
62414688|NCT05813275|EXPERIMENTAL|AD109|AD109
62414689|NCT05813275|PLACEBO_COMPARATOR|Placebo|Placebo
62414690|NCT06650553|EXPERIMENTAL|Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study|In patients with AA undergoing hematopoietic stem cell transplantation, the feasibility of the umbilical cord blood combined with haploidentical transplantation scheme is assessed by comparing it with sibling fully matched transplantation using a non-inferiority analysis method (with the time of neutrophil engraftment after transplantation as the primary efficacy indicator). At the same time, indicators such as the time of platelet engraftment, infection incidence (including CMV, EBV incidence), acute/chronic GvHD incidence, transplant-related mortality (TRM), event-free survival (EFS), and overall survival (OS) are monitored to evaluate the safety and effectiveness of this scheme.
62414691|NCT05508321|EXPERIMENTAL|Patients with confirmed or suspected telomeropathy|Patients with idiopathic pulmonary fibrosis, adult or pediatric medullar dysplasia or myelodysplasia, unexplained liver cirrhosis or unexplained liver regenerative nodular hyperplasia.
62414692|NCT05508321|OTHER|Controls|Age and sex-matched control participants
62414693|NCT05144958||Totally thoracoscopic LAAO - ATRICLIP|In this group, LAA will be sealed using the epicardial thoracoscopic approach with the ATRICLIP device.
62414694|NCT05144958||Percutaneous LAAO - WATCHMAN|In this population, LAA will be occluded using an endocardial totally-percutaneous approach with the WATCHMAN device.
62414695|NCT05144958||Hybrid- minimally invasive LAAO - LARIAT|In these patients, LAA will be closed using a hybrid, combined endo- and epicardial approach using the LARIAT system.
62414696|NCT00457431|NO_INTERVENTION|Control|Standard therapy as used in the hospital's ICU
62414697|NCT00457431|ACTIVE_COMPARATOR|Hypothermia|Standard therapy as used in the hospital's ICU plus Hypothermia
62414698|NCT06393907|EXPERIMENTAL|Hemostatic forceps|Hemostatic forceps will be used for control bleeding with electrocautery unit setting: 80 W, effect 4, soft coagulation mode for 1-2 seconds.
62414699|NCT06393907|ACTIVE_COMPARATOR|Bipolar electrocautery probes|Bipolar electrocautery probes will be used for control bleeding with electrocautery unit setting: effect 2, soft coagulation bipolar mode for 8-10 seconds.
62414700|NCT01267968|EXPERIMENTAL|Cohort 1|GSK2251052 1500 mg Single dose (i.v., 60 min)
62414701|NCT01267968|EXPERIMENTAL|Cohort 2|GSK2251052 1500 mg IV q12h x 5 doses infused over 60 minutes
62414702|NCT03299218|NO_INTERVENTION|Control|Receiving current Government of Punjab health services
62414703|NCT03299218|EXPERIMENTAL|Cash-based transfers|Cash-based transfers only by BISP
62023670|NCT00709384|EXPERIMENTAL|Prophylactic intervention|"We performed a prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone). Conduction times between electrodes placed on both sides of the lesions are measured on the second postoperative day. Coronary angiography and electrophysiology study using an electroanatomic mapping system to assess conduction across the line and to try to induce atrial flutter are performed three month after the operation.~There is only an intervention arm, no control arm"
62414704|NCT03299218|EXPERIMENTAL|Cash with SBCC|Cash-based transfers and Social \& behaviour change communication (SBCC)
62414705|NCT03299218|EXPERIMENTAL|Cash with SNF (Wawamum)|Cash-based transfers and SNF (Wawamum)
62414706|NCT03299218|EXPERIMENTAL|Cash,SNF (Wawamum) & SBCC|Cash-based transfers, SNF (Wawamum) and SBCC
62414707|NCT05958238|EXPERIMENTAL|AR/VR group|Students in EG recieved a 2-hour AR/VR training for elderly oral healthcare at 2-week and 4-week follow-ups.
62414708|NCT05958238|ACTIVE_COMPARATOR|Traditional teaching group|Students in the CG received thirty minutes oral care training class with same teaching content in AR/VR-based training system by well-trained oral hygienist.
62414709|NCT06060496|EXPERIMENTAL|Active cTBS and sham cTBS|There is only one arm in this study and all participants in this arm will receive 2 interventions: active and sham cTBS in a within subject blinded fashion. They will first receive active cTBS and then sham cTBS, separated by four weeks to minimize carryover effects.
62414710|NCT04413357|ACTIVE_COMPARATOR|Balanced Nutritional Drink|The study interventions contain protein, carbohydrate and fat and are intended for use as Supplemental Nutrition.
62414711|NCT04413357|ACTIVE_COMPARATOR|Balanced Nutritional Drink - DMA|The study interventions contain protein, carbohydrate and fat and are intended for use as retail Supplemental Nutrition for people living with diabetes.
62414712|NCT04413357|ACTIVE_COMPARATOR|Balanced Nutritional Drink - DMB|The study interventions contain protein, carbohydrate and fat and are intended for use as Supplemental Nutrition for people living with diabetes.
62414713|NCT02086968|ACTIVE_COMPARATOR|Injectafer|2 doses of Injectafer, at 15 mg/kg for a maximum single dose of 750 mg given on Days 0 and 7 for a total of up to 1500 mg
62414714|NCT02086968|ACTIVE_COMPARATOR|Ferrous Sulfate tablets|Oral Ferrous Sulfate at 325 mg (1 tablet) three times a day for 28 days
62587360|NCT04850261|EXPERIMENTAL|Intervention B: nasal application of Nafarelin|Ovulation induction by nasal application of 200 microgram Nafarelin
62587361|NCT06408857|EXPERIMENTAL|Part A: Cohort 1a (Healthy Adults): 300 milligrams (mg) MAM01 subcutaneously (SC)|Participants will receive MAM01.
62220263|NCT05907109|NO_INTERVENTION|Control Group - Standart of Care|"* The control group receives basic guidelines on child development, nutrition, and breastfeeding provided by the Brazilian Ministry of Health, in addition to standard of care cardiac pediatric follow-up visits.~* Infants will receive outcome developmental evaluations within a 42-month follow-up clinic."
62587362|NCT06408857|EXPERIMENTAL|Part A: Cohort 1b (Healthy Adults): 300 mg MAM01 intramuscularly (IM)|Participants will receive MAM01.
62587363|NCT06408857|EXPERIMENTAL|Part A: Cohort 1c (Healthy Adults): 2000 mg MAM01 intravenously (IV)|Participants will receive MAM01.
62796095|NCT06349382|NO_INTERVENTION|Control group|"Approximately 25 patients in the no-intervention (control) group will be fasted from midnight until surgery.~Glucose and insulin values will be assessed from the peripheral venous or arterial blood samples (from the arterial cannula postoperatively), taken at four-time points. Other parameters of insulin resistance (HOMA-IR, HOMA-ISI, and HOMA-β) will be calculated based on the values of fasting insulin and fasting glucose for each of four time points.~The subjective well-being variables will be evaluated in the morning before the surgery, 6-12 hours after the surgery, and 24 hours after the surgery."
62796096|NCT01434849|EXPERIMENTAL|Timolol|Application of 1-2 drops of Timolol maleate 0.5% ophthalmic aqueous solution to hemangioma twice daily.
62796097|NCT01434849|PLACEBO_COMPARATOR|Placebo|Application of 1-2 drops of placebo gel twice daily to hemangioma.
62023671|NCT05763134||weaning failure|Unstable patient without mechanical ventilator support within 48 hours
62414715|NCT02998645|EXPERIMENTAL|Eltrombopag + cyclosporine|Participants received eltrombopag (orally, 150 mg once daily for non-Asian participants / 100 mg once daily for participants of Asian ancestry) in combination with cyclosporine (orally, 10.0 mg/kg/day in divided doses every 12 hours) for up to 6 months. Thereafter, responders at Month 6 were treated with cyclosporine until Month 24
62414716|NCT03969979||testis with epididymo-orchitis|The patients' previously inflamed testis with epididymo-orchitis
62414717|NCT03969979||healthy testis|The patients' non inflamed testis
62587364|NCT06408857|EXPERIMENTAL|Part B: Cohort 2a (Healthy Younger Children): 190 mg MAM01 or placebo SC|Participants are randomized in 3:1 ratio (MAM01 : PBO)
62023672|NCT05763134||weaning success|Stable patient for more than 48 hours without mechanical ventilator support
62023673|NCT04989764||perioperative chemotherapy vs. adjuvant therapy in gastric ca patients|
62023674|NCT04989764||perioperative chemotherapy group vs. adjuvant chemotherapy group|
62023675|NCT05890183|EXPERIMENTAL|Randomization to Combined Cognitive Training and Exercise (CT&E)|"The primary interventions for this arm of the protocol are Cognitive Training and Exercise sessions. The Cognitive Training will be conducted in a group format using Zoom videoconferencing, with participants logging into their individual Posit Science cognitive training accounts.~The Aerobic Exercise Program will consist of a physical exercise intervention of 150 minutes/week of moderate aerobic activity, over 4 days, including two group sessions (45 min duration) and two individual sessions (30 min duration in the heart rate zone), for 6 months. After the first 6 months, the group sessions will be once a week with the continuing goal of 150 minutes/week of moderate exercise."
62220264|NCT02030301|EXPERIMENTAL|VCL-HB01, 0.25-mL dose|VCL-HB01, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses
62220265|NCT02030301|PLACEBO_COMPARATOR|PBS, 0.25-mL dose|PBS, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses
62220266|NCT02030301|EXPERIMENTAL|VCL-HB01, 0.5-mL dose|VCL-HB01, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses
62220267|NCT02030301|PLACEBO_COMPARATOR|PBS, 0.5-mL dose|PBS, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses
62587365|NCT06408857|EXPERIMENTAL|Part B: Cohort 2b (Healthy Younger Children): 225 mg MAM01 or placebo SC|Participants were randomized in 3:1 ratio (MAM01 : PBO)
62587366|NCT06408857|EXPERIMENTAL|Part B: Cohort 3a (Healthy Infants): 150 mg MAM01 or placebo SC|Participants are randomized in 3:1 ratio (MAM01 : PBO)
62220268|NCT02030301|EXPERIMENTAL|VCL-HB01, 1-mL dose|VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 3 doses
62587367|NCT06408857|EXPERIMENTAL|Part B: Cohort 4a (Healthy Infants): 100 mg MAM01 or placebo SC|Participants are randomized in 3:1 ratio (MAM01 : PBO)
62587368|NCT06408857|EXPERIMENTAL|Part B: Cohort 4b (Healthy Infants): 150 mg MAM01 or placebo SC|Participants are randomized in 3:1 ratio (MAM01 : PBO)
62220269|NCT02030301|EXPERIMENTAL|VCL-HM01, 1-mL dose|VCL-HM01, 1-mL dose by intramuscular injection once every 28 days for 3 doses
62587369|NCT06408857|EXPERIMENTAL|Part B: Cohort 4c (Healthy Infants): 150 mg MAM01 or placebo IM|Participants are randomized in 3:1 ratio (MAM01 : PBO)
62587370|NCT06408857|EXPERIMENTAL|Part B: Cohort 4d (Healthy Infants): 150 mg MAM01 or placebo IV|Participants are randomized in 3:1 ratio (MAM01: PBO)
62414718|NCT01829490|EXPERIMENTAL|Starter Group|The first six volunteers will receive one dose of 5x10\^9vp of ChAdOx1 85A intramuscular injection.
62414719|NCT01829490|EXPERIMENTAL|Group A|12 subjects will receive one dose of 2.5x10\^10vp of ChAdOx1 85A intramuscular injection.
62414720|NCT01829490|EXPERIMENTAL|Group B|12 subjects will receive one dose of 2.5x10\^10vp of ChAdOx1 85A by intramuscular injection, followed by a boost dose of 1x10\^8pfu of MVA85A by intramuscular injection 56 days later.
62433356|NCT06355960|ACTIVE_COMPARATOR|group C|Dexmedetomidine (Precedex) loadings of 0.25 μg/kg(group C) then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
62796098|NCT06418594|EXPERIMENTAL|Adebrelimab+Apatinib+Etoposide|"Adebrelimab: 1200mg， ivgtt，administered on the first day of each cycle, with a cycle of 21 days.~Apatinib: 250 mg, oral, once daily, continuous use, with a cycle of 21 days.~Etoposide: 50mg/day, oral, administered on days 1-14 of each cycle, with a cycle of 21 days."
62796099|NCT04328740|EXPERIMENTAL|TP-1454|Flat dose once or twice daily
62796100|NCT05274958|EXPERIMENTAL|Initial PROM plus monthly PROM plus educational video|These patients receive usual care plus monthly PROMs and educational video(s) while on the waitlist
62220270|NCT02030301|PLACEBO_COMPARATOR|PBS, 1-mL dose|PBS, 1-mL dose by intramuscular injection once every 28 days for 3 doses
62220271|NCT00851838|EXPERIMENTAL|PD solution|
62414721|NCT01829490|EXPERIMENTAL|Group C|12 subjects will receive two doses of 2.5x10\^10vp of ChAdOx1 85A by intramuscular injection at day 0 and day 28, followed by a boost dose of 1x10\^8pfu of MVA85A by intramuscular injection at day 119.
62414722|NCT03086642|EXPERIMENTAL|T-Vec|All enrolled patients will receive a test dose of talimogene laherparepvec (10\^6 plaque forming units (PFU)/ml) on day 1, followed by treatment doses at escalating concentrations weeks 4, 7, and 10. A biopsy will be obtained during each scheduled endoscopy prior to talimogene laherparepvec injection.
62587371|NCT01914146|OTHER|Before Initiation of Insulin Therapy|Study sessions will occur before the initiation of insulin therapy (no insulin). Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
62796101|NCT05274958|NO_INTERVENTION|Usual Care|Patients will complete the initial bundle of PROMs, then no further PROMs while they remain on the waitlist
62023676|NCT05890183|ACTIVE_COMPARATOR|Cognitive Training and Healthy Living Group (CT&HLG)|"The primary interventions for this arm of the protocol are Cognitive Training and the Healthy Living Group. The Cognitive Training will be conducted in a group format using Zoom videoconferencing, with participants logging into their individual Posit Science cognitive training accounts.~The participants in this arm will also participate in a Healthy Living Group, which is a didactic, educational and interactive group that is designed to offer very useful information and discussion of topics that are relevant to a healthy lifestyle. It includes manualized modules devoted to wellness, nutrition, insight, recovery, independent living, social skills, and hobbies. It meets 2 times/week for 6 months and then once a week for the next 6 months."
62796102|NCT05205291||Parkinson's disease patients|18 patients with Parkinson's disease who will undergo clinical assessment, and PET/MR imaging of TSPO using the tracer \[11C\]PBR28 before and four hours after administration of LPS (1 ng/Kg)
62220272|NCT03770910|PLACEBO_COMPARATOR|Placebo+placebo|Saline infusions
62220273|NCT03770910|ACTIVE_COMPARATOR|GIP+placebo|GIP(1-42), receptor agonist
62220274|NCT03770910|EXPERIMENTAL|GIP+dose 1|GIP(1-42) and lowest dose of GIP(3-30)NH2
62220275|NCT03770910|EXPERIMENTAL|GIP+dose 2|GIP(1-42) and dose of GIP(3-30)NH2
62220276|NCT03770910|EXPERIMENTAL|GIP+dose 3|GIP(1-42) and dose of GIP(3-30)NH2
62220277|NCT03770910|EXPERIMENTAL|GIP+dose4|GIP(1-42) and highest dose of GIP(3-30)NH2
62414723|NCT01291186|EXPERIMENTAL|BPV6NO|
62414724|NCT01291186|EXPERIMENTAL|BPV7NO|
62414725|NCT01291186|EXPERIMENTAL|BPV8NO|
62414726|NCT01291186|EXPERIMENTAL|BPV9NO|
62220278|NCT01535560|EXPERIMENTAL|AL-60371|AL-60371, 0.3% otic suspension, 4 drops in the affected ear(s) twice daily for 7 days
62220279|NCT01535560|PLACEBO_COMPARATOR|Vehicle|AL-60371 Vehicle, 4 drops in the affected ear(s) twice daily for 7 days
62220280|NCT00618982|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006)|Intrapatient dose escalation of sorafenib from 400 mg orally twice daily (bid) for the first cycle, 600 mg bid for the second cycle and 800 mg bid until disease progression, unacceptable toxicity or withdrawal of consent. Dose reductions due to toxicities were allowed.
62220281|NCT02948023|NO_INTERVENTION|Standard Surgical therapy|Includes the control group that fulfills the inclusion criteria
62220282|NCT02948023|ACTIVE_COMPARATOR|Ex-vivo cultivated limbal stem cell pool|0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
62220283|NCT03727438|EXPERIMENTAL|Tele-Self CBTI|Tele-Self CBTi is a telephone-based CBT insomnia intervention
62220284|NCT03727438|ACTIVE_COMPARATOR|Health Education Control|The Health Education is an active control arm
62414727|NCT01291186|EXPERIMENTAL|BPV10NO|
62414728|NCT01291186|EXPERIMENTAL|BPV11NO|
62414729|NCT01291186|ACTIVE_COMPARATOR|BPV6O|
62414730|NCT01291186|ACTIVE_COMPARATOR|BPV7O|
62796103|NCT05205291||Healthy controls|6 healthy controls who will undergo clinical assessment, and PET/MR imaging of TSPO using the tracer \[11C\]PBR28 before and four hours after administration of LPS (1 ng/Kg)
62796104|NCT06060067|EXPERIMENTAL|Cohort 1: ≥18 to ≤60 Age Group: TDV|
62796105|NCT06060067|PLACEBO_COMPARATOR|Cohort 1: ≥18 to ≤60 Age Group: Placebo|
62796106|NCT06060067|EXPERIMENTAL|Cohort 2: ≥4 to <18 Age Group: TDV|
62796107|NCT06060067|PLACEBO_COMPARATOR|Cohort 2: ≥4 to <18 Age Group: Placebo|
62587372|NCT01914146|OTHER|After Initiation of Insulin Therapy|Study session will take place 2-4 weeks after the initiation of insulin therapy. Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
62587373|NCT03854370|EXPERIMENTAL|Baby shampoo|Baby shampoo used for surgical site prep
62587374|NCT03854370|ACTIVE_COMPARATOR|Peridex (Chlorhexidine)|Peridex used for surgical site prep
62796108|NCT06726473||Group 1: ABL90 Group|Blood gas and biochemical measurements are performed using the ABL90 blood gas analyzer. The results will be compared with those from the EG-i30 analyzer.
62796109|NCT06726473||Group 2: EG-i30 Group|Blood gas and biochemical measurements are performed using the EG-i30 blood gas analyzer. The results will be compared with those from the ABL90 analyzer.
62220285|NCT03122600||vascular surgery group|Elderly patients undergoing vascular surgery in the lower half of the body
62220286|NCT06246266|EXPERIMENTAL|Helfer Skin Tap Technique group|Mechanical stimulation given with the Helfer Skin Tap technique during intramuscular vaccine administration will distract the baby's attention.
62220287|NCT06246266|EXPERIMENTAL|ShotBlocker Technique group|"During intramuscular vaccine administration to babies, the injection ShotBlocker Technique will be applied using the ShotBlocker tool (a tool with a U appearance, with blunt but not pointed protrusions)."
62220288|NCT01915472|EXPERIMENTAL|IMMU 130|
62220289|NCT01621737|EXPERIMENTAL|Oxytocin: Low Dose|42 IU BID for the six weeks
62220290|NCT01621737|EXPERIMENTAL|Oxytocin: High Dose|84 IU BID for six weeks
62220291|NCT01621737|PLACEBO_COMPARATOR|Placebo|
62220292|NCT03954795|ACTIVE_COMPARATOR|Group 1: TAP Block|TAP Block performed from the petit triangle ( anterior axillary line and iliac crest.)
62414731|NCT01291186|ACTIVE_COMPARATOR|BPV8O|
62220293|NCT03954795|ACTIVE_COMPARATOR|Group 2: OSTAP Block|Modified TAP (OSTAP) block performed from the medial of linea semilunaris applying local anesthetic to the area between xiphoid and anterior iliac crest.
62220294|NCT03954795|NO_INTERVENTION|No Block|No interventions
62414732|NCT01291186|ACTIVE_COMPARATOR|BPV9O|
62414733|NCT01291186|ACTIVE_COMPARATOR|BPV10O|
62220295|NCT04694443|ACTIVE_COMPARATOR|Study group|The study group will receive the multidisciplinary tele-health intervention plus standard medical care
62220296|NCT04694443|PLACEBO_COMPARATOR|Control group|The control group will receive the best standard medical care
62220297|NCT00539565|ACTIVE_COMPARATOR|A|oral corticosteroids
62220298|NCT00539565|PLACEBO_COMPARATOR|B|as for active regimen
62220299|NCT03887078|EXPERIMENTAL|A. Presurgery Noom Bariatric + Augmentation Noom Bariatric|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention responsive individuals will be randomized post-surgery to Noom Bariatric augmentation.
62220300|NCT03887078|EXPERIMENTAL|B. Presurgery Noom Bariatric + Augmentation Standard Care|"Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention responsive individuals will be randomized post-surgery to usual care in which participants are free to seek any assistance for their bariatric post-surgery care during the study period."
62220301|NCT03887078|EXPERIMENTAL|C. Presurgery Noom Bariatric + Augmentation Noom Bariatric|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention non-responsive individuals will be randomized post-surgery to Noom Bariatric augmentation.
62220302|NCT03887078|EXPERIMENTAL|D. Presurgery Noom Bariatric + Augmentation Standard Care|"Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention non-responsive individuals will be randomized post-surgery to usual care in which participants are free to seek any assistance for their bariatric post-surgery care during the study period."
62414734|NCT01291186|ACTIVE_COMPARATOR|BPV11O|
62433357|NCT02868281|EXPERIMENTAL|Subjects recruited at ACT centers|For the subjects who will be recruited in the ACT centers, they will be treated based on the ACT score. If ACT score are = 25 for \>=3 months then step-down the treatment; if ACT score \>=20, \<25 or ACT=25 for \<3 months then there will be no change and if ACT score less than (\<=) 19 then step-up the treatment.
62587375|NCT03854370|ACTIVE_COMPARATOR|TechniCare (chloroxynel)|TechniCare used for surgical site prep
62587376|NCT03854370|ACTIVE_COMPARATOR|Betadine (Povidone- iodine)|Betadine used for surgical site prep
62796110|NCT01450761|EXPERIMENTAL|Ipilimumab+Etoposide+Cisplatin/Carboplatin|"Ipilimumab: IV solution, Intravenous (IV), 10 mg/kg, Once every 3 weeks for 4 doses, then every 12 weeks, Until progression of disease or unacceptable toxicity, or until the maximum treatment period of 3 years is reached~Etoposide: IV solution, IV, 100 mg/m2, Days 1-3 every 3 weeks, 4 cycles~Cisplatin: IV solution, IV, 75 mg/m2, Once every 3 weeks, 4 doses~Carboplatin: IV Solution, IV, Area Under the Curve (AUC) 5, Once every 3 weeks, 4 doses"
62414735|NCT03285152|EXPERIMENTAL|Ketogenic Diet (KD)|The KD cohort will receive a rotating 7 day meal plan prepared by the Clinical Translational Science Center (CTSC) at Weill Cornell Medical Center (WCMC) with weekly food pick-up. The meal plan will provide a 3:1 fat to net carbohydrate ratio and calories for weight maintenance (30kcals /kg for a BMI\< 30kg/ m2 and 25 kcal/kg for a BMI.30 kg/ m2.
62587377|NCT00112528|EXPERIMENTAL|gemcitabine + bevacizumab + oxaliplatin|"Patients receive gemcitabine IV over 100 minutes and bevacizumab IV over 30-90 minutes on days 1 and 15. Patients also receive oxaliplatin IV over 120 minutes on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses of therapy beyond CR.~After completion of study treatment, patients are followed every 3-6 months for up to 5 years."
62796111|NCT01450761|PLACEBO_COMPARATOR|Placebo matching Ipilimumab+Etoposide+Cisplatin/Carboplatin|"Placebo matching Ipilimumab: IV solution, IV, 0 mg/kg, Once every 3 weeks for 4 doses, then every 12 weeks, Until progression of disease or unacceptable toxicity, or until the maximum treatment period of 3 years is reached~Etoposide: IV solution, IV, 100 mg/m2, Days 1-3 every 3 weeks, 4 cycles~Cisplatin: IV solution, IV, 75 mg/m2, Once every 3 weeks, 4 doses~Carboplatin: IV Solution, IV, Area Under the Curve (AUC) 5, Once every 3 weeks, 4 doses"
62796112|NCT06725745||People with spina bifida|People with spina bifida are approached through representative organizations by email to complete a digital survey at 1 timepoint.
62220303|NCT03887078|EXPERIMENTAL|E. Pre-surgery Standard Care + Augmentation Noom Bariatric|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care responsive individuals will be randomized post-surgery to Noom Bariatric augmentation."
62220304|NCT03887078|NO_INTERVENTION|F. Pre-surgery Standard Care + Augmentation Standard Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care responsive individuals will be randomized post-surgery to usual care."
62220305|NCT03887078|EXPERIMENTAL|G. Pre-surgery Standard Care + Augmentation Noom Bariatric|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care non-responsive individuals will be randomized post-surgery to Noom Bariatric augmentation."
62220306|NCT03887078|NO_INTERVENTION|H. Pre-surgery Standard Care + Augmentation Standard Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care non-responsive individuals will be randomized post-surgery to usual care."
62220307|NCT03614637||Cannabis User Group|Forty eight participants who are regular Cannabis users with a self-reported frequency of at least once weekly over the past 6 months of screening visit.
62220308|NCT03614637||Non-Cannabis User Group|Twenty four participants who self-report no Cannabis use in the past 6 months of screening visit and fewer than 10 times during their lifetime
62414736|NCT03285152|ACTIVE_COMPARATOR|Standard Diet (SD)|Patients randomized to the SD group will consume their normal diet plan. They will meet with the dietitian from the CTSC at WCMC weekly and receive standard nutritional counseling from the CTSC. Average intake will be documented through analyzing a 3 day intake pre and post the 4 week period.
62414737|NCT02135276|EXPERIMENTAL|End stage renal disease (ESRD) subjects|A single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes
62414738|NCT02135276|EXPERIMENTAL|Normal healthy subjects|A single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes
62414739|NCT06316960|EXPERIMENTAL|Relapsed/Refractory CBF-AML with KIT mutation|The relapsed/refractory patients will receive a combination treatment of decitabine/azacitidine+ IdAG (idarubicine + cytarabine + granulocyte stimulating factor)regimen along with avapritinib. CBF-AML with KIT mutated patients with molecular relapse after hematopoietic stem cell transplantation may receive avapritinib combined with demethylating agents or interferon or donor lymphocyte infusion without low-dose chemotherapy. The dose of avapritinib will start at 50mg/m2/d, and if platelets stabilize at 50 ×10\^9/L and neutrophils stabilize above 1.0 ×10\^9/L after one week, the dose can be increased to 100mg/m2/d, with a maximum daily dose of 100mg. Avapritinib should be discontinued in the presence of febrile neutropenia or active infection, and avapritinib can be resumed once the infection is controlled, with each treatment cycle not exceeding 28 days.
62414740|NCT04559373|EXPERIMENTAL|Virtual Reality and Field Practice Training (VRFT)|Participants will engage in a 4-week VRFT intervention that comprises of 1-hour training sessions, 3 times/week.
62587378|NCT03438604|OTHER|Donepezil TDS with Heat Applied|Corplex Donepezil TDS 5 mg/day with heat applied
62220309|NCT02261259|EXPERIMENTAL|Immediate treatment|This arm receives osteopathic manipulative treatment shortly after enrollment
62587379|NCT03438604|OTHER|Donepezil TDS without Heat|Corplex Donepezil TDS 5 mg/day with no heat applied
62587380|NCT03438604|OTHER|Donepezil TDS Extension Study with Heat|Corplex Donepezil TDS 5 mg/day with heat. Two skin sensors will be placed underneath the TDS and adjacent to the TDS.
62587381|NCT06682377|EXPERIMENTAL|No touch RFA with dual switching monopolar + bipolar mode|
62796113|NCT05698277||Cases|Singleton pregnancies affected by congenital heart disease
62796114|NCT05698277||Controls|Singleton healthy pregnancies
62796115|NCT06540144|EXPERIMENTAL|rozanolixizumab|Study participants will receive pre-defined doses of rozanolixizumab. Each treatment cycle in each Treatment Period (TP) consists of 6 subcutaneous (sc) administrations of rozanolixizumab at 1-week intervals. Each Treatment Period will be initiated upon the discretion of the Investigator based on the medical needs of the study-participant.
62796116|NCT06533579|EXPERIMENTAL|Group 1/Group 2/Group 3/Group 4|
62023677|NCT06532955|EXPERIMENTAL|Lymphaticovenous anastomosis using Microsure Motion Stabilizer|Patients in this group undergo robot-assisted lymphaticovenous anastomosis at one or more locations on the affected arm. The procedure is performed under local anesthesia. Incisions are made at the sites where lymphatic vessels are obstructed, ensuring no harm to the viable part of the lymphatic system. The location(s) are determined prior to surgery using ICG lymphography. LVA(s) are made in the subdermal plane with the aid of a surgical microscope. Generally, 1 to 4 LVAs are made. The LVAs are madeusing a surgical microscope and the operation takes approximately 240 minutes.
62023678|NCT06532955|ACTIVE_COMPARATOR|Lymphaticovenous anastomosis|Patients in this group undergo lymphaticovenous anastomosis at one or more locations on the affected arm. The procedure is performed under local anesthesia. Incisions are made at the sites where lymphatic vessels are obstructed, ensuring no harm to the viable part of the lymphatic system. The location(s) are determined prior to surgery using ICG lymphography. LVA(s) are made in the subdermal plane with the aid of a surgical microscope. Generally, 1 to 4 LVAs are made. The LVAs are madeusing a surgical microscope and the operation takes approximately 90 minutes.
62220310|NCT02261259|EXPERIMENTAL|Delayed treatment|This arm receives osteopathic manipulative treatment approximately 4 weeks after enrollment
62220311|NCT02261259|NO_INTERVENTION|Healthy control (no neck pain)|In this arm, healthy controls are tested at baseline.
62587382|NCT06229288|EXPERIMENTAL|Amoxicillin|"Amoxicillin is an antibiotic treatment approved in France and in many countries.~The investigational medicinal products (IMPs) are:~- Amoxicillin capsules : Formulated as a 500 mg capsules for PO administration (commercially available). Description in IMP file.~Amoxicillin capsules contain compendial excipients listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15- 25°C.~- Amoxicillin IV vials : Formulated as a 1000 mg vial for IV administration (commercially available). Description in IMP file.~Amoxicillin IV vials contain compendial excipient listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15-25°C."
62796117|NCT04967196|EXPERIMENTAL|Cohort A (ipilimumab DC and IV, nivolumab) CLOSED|Patients receive ipilimumab intra-lymphatically via DoseConnect™ on day 1 of cycle 1 and IV over 30 minutes on day 1 of cycles 2-4. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo lymphatic imaging with ICG prior to treatment start and blood sample collection throughout the study. (CLOSED TO ENROLLMENT)
62796118|NCT04967196|EXPERIMENTAL|Cohort B (Ipilimumab DC and nivolumab IV)|Patients receive ipilimumab intra-lymphatically via DoseConnect™ and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study and may optionally undergo lymphatic imaging with ICG prior to treatment start.
62796119|NCT05088057|EXPERIMENTAL|Camrelizumab+Chemotherapy|"PD-1+AC-T: Participants receive Camrelizumab Q3W + doxorubicin Q3W + cyclophosphamide Q3W for 4 cycles, followed by Camrelizumab Q3W + docetaxel Q3W for 4 cycles as neoadjuvant therapy prior to surgery,followed by 9 cycles of Camrelizumab Q3W as adjuvant therapy post-surgery.~PD-1+TA: Participants receive Camrelizumab Q3W for 8 cycles , docetaxel Q3W + doxorubicin Q3W for 4 cycles as neoadjuvant therapy prior to surgery,followed by 9 cycles of Camrelizumab Q3W as adjuvant therapy post-surgery."
62796120|NCT02203994|EXPERIMENTAL|extracorporeal shock wave therapy (ESWT)|"one-time treatment of the spastic muscle/ spastic muscles (adductor muscles and/ or M. triceps surae) with extracorporeal shock wave therapy (device: Duolith® SD 1 T-Top (Storz Medical AG, Tägerwilen, Switzerland))"
62796121|NCT05763576|EXPERIMENTAL|RO7565020|
62796122|NCT05763576|PLACEBO_COMPARATOR|Placebo|
62796123|NCT04320355|EXPERIMENTAL|Soft tissue manual therapy|The researcher student will place the gloves with the force sensor on the thumb of her right and left hand. She will evaluate the Caesarean section scar and identify the most rigid scar areas when compression is applied. On these identified areas, the researcher student will apply the manual therapy procedure described in the independent variable (compression + shear) section. This procedure will be applied to all identified rigid areas of the Caesarean section scar.This procedure will last 10 minutes (approximately 2 minutes per rigid area). After this time, the researcher-student will remove the force sensor and leave the room.
62220312|NCT01337583|EXPERIMENTAL|Dapivirine|Vaginal ring containing 25mg of dapivirine
62220313|NCT01337583|PLACEBO_COMPARATOR|Placebo Ring|Vaginal ring containing no drug substance
62220314|NCT03217682|EXPERIMENTAL|Music Therapy|Music therapy twice a week for two weeks, each session lasting approximately 45 min-1 hr
62220315|NCT03217682|EXPERIMENTAL|Massage Therapy|Massage therapy twice a week for two weeks, each session lasting approximately 45 min-1 hr
62220316|NCT02869854|ACTIVE_COMPARATOR|PAP only|This group will follow the referral scheme for three months, and after this period they will leave new blood samples and answer surveys. They will get a new PAP with follow up after another 3 months.
62220317|NCT02869854|ACTIVE_COMPARATOR|Mindfulness only|Mindfulness. This group will receive a group course in mindfulness during 8 weeks once a week, and with 20 minutes of daily personal training. Three and six months after inclusion they will answer a new set of surveys and fasting blood samples.
62433358|NCT02868281|ACTIVE_COMPARATOR|Subjects recruited in the control centers|For subjects who will be recruited in the control centers, they will be treated based on doctor's subjective judgment.
62220318|NCT02869854|EXPERIMENTAL|Combination of the two groups|Mindfulness and physical activity prescription. This group will get a combination of the two other groups. PAP will be prescribed during the first meeting and another one after 3 months. During the first 8 weeks once a week they will participate in a mindfulness training group and also preform 20 minutes of daily training. The same surveys as the other groups and fasting blood samples
62220319|NCT05233332|EXPERIMENTAL|phase IIa: HL-085 in Subjects With BRAF V600E-Mutated CRC|12mg BID HL-085
62220320|NCT05233332|EXPERIMENTAL|phase IIa: HL-085+Vemurafenib in Subjects With BRAF V600E-Mutated CRC|12mg BID HL-085+720mg BID Vemurafenib
62220321|NCT05233332|EXPERIMENTAL|phase IIa: HL-085+Vemurafenib in Subjects With RAS or other BRAF-Mutated or MEK1/2-Mutated CRC|12mg BID HL-085+720mg BID Vemurafenib
62220322|NCT05233332|EXPERIMENTAL|phase IIb: HL-085+Vemurafenib in Subjects With BRAF V600E-Mutated CRC|12mg BID HL-085+720mg BID Vemurafenib
62220323|NCT04288609|EXPERIMENTAL|Intendu FBT inpatient|Motion Based Cognitive Video Games Software
62220324|NCT04288609|ACTIVE_COMPARATOR|paper and pencil tasks|paper and pencil tasks
62220325|NCT04467528|EXPERIMENTAL|Electroacupuncture combined with conventional drug therapy|"Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial~For participants with abdominal distension:~Electroacupuncture will be applied to the acupoints (LI4, PC6, ST36, SP6) 30min~For participants with post-operative ileus:~Electroacupuncture will be applied to the acupoints (LI4, SJ6, ST36, ST37) 30min~32# acupuncture needle used and twice daily for three days"
62414741|NCT01964391|EXPERIMENTAL|Trastuzumab|In adjuvant setting trastuzumab will be administered in the following treatment regimens: (a) trastuzumab following surgery, chemotherapy (neo-adjuvant or adjuvant) and radiotherapy (if applicable); (b) trastuzumab following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel; (c) trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. In neo-adjuvant setting, trastuzumab will be administered in combination with neo-adjuvant chemotherapy followed by adjuvant trastuzumab, for locally advanced (including inflammatory) breast cancer or tumors greater than (\>) 2 centimeters (cm) in diameter.
62414742|NCT01211873|EXPERIMENTAL|Dotarem (gadoterate meglumine )|Dotarem and Magnevist were randomised as 2:1 ratio for adult patients.
62414743|NCT01211873|ACTIVE_COMPARATOR|Magnevist (gadopentetate dimeglumine)|Dotarem and Magnevist were randomised as 2:1 ratio
62023679|NCT00506961|ACTIVE_COMPARATOR|1|10 mg rosuvastatin for 4 weeks followed by 20 m rosuvastatin for another 8 weeks
62023680|NCT00506961|ACTIVE_COMPARATOR|2|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
62414744|NCT01211873|EXPERIMENTAL|Dotarem 2 (gadoterate meglumine )|Pediatric patients were assigned to Dotarem group only.
62796124|NCT03372967||Comprehensive Vaccination History Review|Patients who receive a comprehensive vaccination history review at a participating pharmacy site will be eligible to: a) receive a vaccination forecast review, b) be evaluated for unmet vaccination needs, c) receive patient education, and d) have vaccination needs met.
62220326|NCT04467528|ACTIVE_COMPARATOR|Conventional drug therapy|"Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial"
62414745|NCT05939713||VSD subjects|Patients with a confirmed diagnosis of Ventricular Septal Defect (VSD) and implanted with the Cera VSD occluder as per IFU instructions
62414746|NCT01243866|EXPERIMENTAL|Early treatment|comprehensive dental treatment
62414747|NCT01243866|NO_INTERVENTION|Regualr treatment|Regular treatment consisted of children who would be on a waiting list for regular dental treatment at KFAFH for at least 8 months
62414748|NCT05589246|NO_INTERVENTION|control|intraoperative cryoanalgesia of intercostal nerves with multimodal analgesia
62414749|NCT05589246|EXPERIMENTAL|intervention|regional analgesia (ESP block) with intraoperative cryoanalgesia of intercostal nerves and multimodal analgesia
62414750|NCT01493583||severely obese women|
62414751|NCT01493583||Women after Roux-en Y gastric bypass surgery|Women recruited for this group had undergone Roux-en Y gastric bypass surgery at least one year before. In this women measurement of brain activity and gastrointestinal and metabolic response took place between 13 and 106 month after surgery.
62414752|NCT01493583||lean women|
62414753|NCT03474952|EXPERIMENTAL|Remote ischemic preconditioning (RIPC)|Intervention is remote ischemic preconditioning (RIPC) consists of 4 cycles of 5-min ischemia (using pneumatic cuff pressure of 200 mmHg) and subsequent 5-min reperfusion applied to upper arm.
62414754|NCT03474952|SHAM_COMPARATOR|Control (Sham-RIPC)|Intervention is Sham-RIPC (ischemia pressure \< 10 mmHg) applied to upper arm.
62796125|NCT02591108|EXPERIMENTAL|Safety and Efficacy|Parallel treatment; use of standard TOF peripheral Stimulator to Novel Train of Four Device
62023681|NCT01617629|EXPERIMENTAL|Cvac Treatment Group|Participants received Epithelial Mucin Surface Antigen 1 (MUC1) Dendritic Cell Vaccine (Cvac) treatment.
62023682|NCT06306534|EXPERIMENTAL|Insert Array Into Auditory Nerve|
62023683|NCT01722591|EXPERIMENTAL|Cardiapex device|Use of the Cardiapex device in the context of transapical TAVI procedures
62023684|NCT01813240|EXPERIMENTAL|Minocycline, Spinal Tumor patients, quality of life|
62023685|NCT01813240|EXPERIMENTAL|Minocycline, Trauma patuents, quality of life|
62220327|NCT00345293|EXPERIMENTAL|DC/PC3 vaccine|3 subcutaneous injections of ex vivo-generated autologous dendritic cell vaccine: 1) pulsed with apoptotic PC3 cells; 2) pulsed with apoptotic PC3-M1 cells, and 3) pulsed with keyhole limpet hemocyanin (KLH, control antigen)
62220328|NCT02533531|EXPERIMENTAL|1-Lead Outpatient Telemetry|1-Lead Outpatient Patch study participants. Patients assigned to outpatient telemetry monitoring will receive the 1-Lead patch upon discharge from hospital inpatient status. ECG data will be submitted by the 1-lead patch to a central database.
62023686|NCT01813240|PLACEBO_COMPARATOR|Placebo, Trauma patients, quality of life|
62023687|NCT01813240|PLACEBO_COMPARATOR|Placebo, Spinal cord tumors, quality of life|
62220329|NCT01254240|EXPERIMENTAL|UVA/B phototherapy treatment|UVA/B phototherapy units, stand alone cabins, patients undress, step in the cabin and receive treatment in a duration of seconds to minutes. The noticable difference between the UVA/B and UVB treatment is only in the settings of the cabin.
62023688|NCT00899223||Group 1|Previously untreated patients on a CALGB treatment protocol for leukemia (acute or chronic) or myelodysplasia are eligible. Patients must be registered to CALGB 9665 prior to receiving any therapy for their disease.
62220330|NCT01254240|ACTIVE_COMPARATOR|UVB phototherapy treatment|UVB phototherapy units, stand alone cabins, patients undress, step in the cabin and receive treatment in a duration of seconds to minutes. The noticable difference between the UVA/B and UVB treatment is only in the settings of the cabin.
62220331|NCT06611371|EXPERIMENTAL|Group 1; GBS-06 (Low)|Participants will receive a single 0.5mL dose of IVT GBS-06 Formulation 1 (low dose polysaccharide concentration) administered by intramuscular injection to the non-dominant deltoid muscle on Day 1.
62220332|NCT06611371|EXPERIMENTAL|Group 2; GBS-06 (Mid)|Participants will receive a single 0.5mL dose of IVT GBS-06 Formulation 2 (mid-dose polysaccharide concentration) administered by intramuscular injection to the non-dominant deltoid muscle on Day 1.
62220333|NCT06611371|EXPERIMENTAL|Group 3; GBS-06 (High)|Participants will receive a single 0.5mL dose of IVT GBS-06 Formulation 3 (high dose polysaccharide concentration) administered by intramuscular injection to the non-dominant deltoid muscle on Day 1.
62220334|NCT06611371|PLACEBO_COMPARATOR|Group 4; Placebo|Participants will receive a single 0.5mL dose of 0.9% sodium chloride placebo administered by intramuscular injection to the non-dominant deltoid muscle on Day 1.
62220335|NCT05253820|EXPERIMENTAL|distal radial approach group|subjects randomized to experimental group were underwent coronary diagnosis and intervention via distal radial approach
62220336|NCT05253820|ACTIVE_COMPARATOR|conventional radial access group|subjects randomized to active comparator group were underwent coronary diagnosis and intervention via conventional radial approach
62220337|NCT03946579|OTHER|Patient treated by adjuvant therapy|Self questionnaires of sexual health and quality of life (FSFI, QLQ-C30, BR23, ELD 15, HADS, GDS 15, BIS, FACIT)
62220338|NCT03035201||Cocoa extract + multivitamin (MTV)|2 capsules containing 500 mg/d cocoa extract; daily MTV
62220339|NCT03035201||Cocoa extract + multivitamin placebo|2 capsules containing 500 mg/d cocoa extract; daily MTV placebo
62220340|NCT03035201||Cocoa extract placebo + multivitamin|Cocoa extract placebo (2 capsules/d); daily MTV
62220341|NCT03035201||Cocoa extract placebo + multivitamin placebo|Cocoa extract placebo (2 capsules/d); daily MTV placebo
62220342|NCT05087979|EXPERIMENTAL|Intervention|An investigational device will be used to hold patient's head and airway in a stable position.
62220343|NCT05087979|NO_INTERVENTION|Standard of care|Pillows and towels will be used to hold patient's head and airway in a stable position.
62220344|NCT06147050|EXPERIMENTAL|Metformin|"Drug: Metformin~* Patients assigned to the metformin arm will receive a 500-mg dose of metformin extended-release formulation twice daily for a period of 30 days~* 500 mg extended-release tablet (Twice Daily)~* Participants will be randomised in a 1:1 ratio to receive 1 dose of Metformin or Placebo on same day as randomisation"
62220345|NCT06147050|PLACEBO_COMPARATOR|Placebo Control|"Other: Placebo control~• Participants will be randomised in a 1:1 ratio to receive 1 dose of Metformin or Placebo on same day as randomisation"
62220346|NCT01939665|EXPERIMENTAL|Irreversible electroporation|Single arm study: Percutaneous irreversible electroporation of locally advanced pancreatic carcinoma
62220347|NCT00682773|NO_INTERVENTION|1|Usual care, no educational intervention.
62220348|NCT00682773|EXPERIMENTAL|2|Usual care, nursing home nursing staff receive educational intervention on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
62220349|NCT05145309|EXPERIMENTAL|Potassium Magnesium Citrate (KMgCit) first then Placebo|Patients will be asked to take KMgCit ( Sterling Pharmaceutical Services) first for 4 weeks. The content of each sachet will be dissolved in 250 ml water and will be drunk with breakfast and again with dinner during the KMgCit Phase, to deliver 40 meq K, 20 meq Mg and 74 meq citrate per day. Then, subjects will be asked to take Placebo packaged in an identical sachet by dissolving in 250 ml water and drink it with breakfast and again with dinner for 4 weeks
62220350|NCT05145309|EXPERIMENTAL|Placebo first then KMgCit|Patients will be asked to take Placebo packaged in an identical sachet by dissolving in 250 ml water and drink it with breakfast and again with dinner for 4 weeks. Then, subjects will be asked to take KMgCit (Sterling Pharmaceutical Services, Dupo, IL) after dissolving in 250 ml water and drink it with breakfast and again with dinner for 4 weeks
62023689|NCT05786924|EXPERIMENTAL|Phase 1 Dose Escalation|BDTX-4933 will be administered at escalating dose levels until the maximum tolerated dose (MTD) is reached and the preliminary recommended Phase 2 dose (RP2D) is determined.
62023690|NCT05786924|EXPERIMENTAL|Phase 1 Dose Expansion|BDTX-4933 will be administered at the RP2D.
62023691|NCT05528120|EXPERIMENTAL|KG|
62023692|NCT05528120|EXPERIMENTAL|GK|
62796126|NCT02591108|ACTIVE_COMPARATOR|Microstim|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
62023693|NCT06387251|OTHER|Protein Powder|Participants in Group A used the green powder supplement, probiotic supplement and protein Powder.
62796127|NCT05659927|EXPERIMENTAL|MG-ZG122 first dose group|4 cases in the 52.5 mg dose group (2 cases of placebo, 2 cases of experimental drug)
62220351|NCT03553680|EXPERIMENTAL|Emotion-Focused CBT|Ten CBT sessions with a therapist.
62220352|NCT03553680|NO_INTERVENTION|Wait List|Three visits for assessments only over the same time period of the Experimental Arm.
62220353|NCT05416190|OTHER|Group/Cohort 1 :|Notion of the presence of lupus anticoagulant (according to ISTH criteria) and whose last test was positive
62220354|NCT05416190|OTHER|Group/Cohort 2:|Without a previous thrombosis and considered healthy on the basis of the interview and clinical examination. Without coagulation disease.
62220355|NCT06479642|ACTIVE_COMPARATOR|3 nerves protocol|tradiational the three-nerve genicular RF Group (3RFG),
62414755|NCT04682977|EXPERIMENTAL|IPROACTIF|10 weekly sessions. First two sessions focus on comprehensive assessment of physical and executive functioning, assessment of home safety and accessibility, assessment of ADL/IADL competence and performance in context; information in these areas is used by the interventionist to collaboratively identify three patient-centered goals. Goal planning is followed by 10 treatment sessions. Treatment sessions focus on chronic disease education, problem solving issues related to disease management by modifying daily routines, recommendations for embedding physical activity in everyday tasks, and environmental modifications or activity adaptations to increase ADL/IADL independence.
62414756|NCT04682977|OTHER|Usual care|Participants in the control group will receive usual services which might include primary care and prescription medications for chronic disease management.
62414757|NCT00518531|OTHER|Treatment Sequence B|When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment Sequences. Subjects randomized to treatment sequence B will receive 70 mg oral alendronate QW for 1-year (Treatment period 1) followed by denosumab 60 mg Q6M SC for 1 year (Treatment Period 2).
62220356|NCT06479642|ACTIVE_COMPARATOR|4 nerves protocol|targeting the intermedius genicular nerve in addition to traditional genicular nerves four-nerve genicular RF Group (4RFG),
62414758|NCT00518531|OTHER|Treatment Sequence A|When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment sequences. Subjects randomized to treatment sequence A will receive 60 mg denosumab Q6M SC for 1-year (Treatment period 1) followed by oral alendronate 70 mg QW for 1 year (Treatment period 2).
62414759|NCT00197561|ACTIVE_COMPARATOR|Selenium|Selenium (200 ug as selenomethionine)
62414760|NCT00197561|PLACEBO_COMPARATOR|Placebo|Placebo
62414761|NCT02263118|EXPERIMENTAL|Uni-directional SMS|Participants in this group received breastfeeding promoting messages based on the MAMA (http://www.mobilemamaalliance.org/) breastfeeding database. Individuals could only receive text messages.
62414762|NCT02263118|EXPERIMENTAL|Virtual communities|Participants were made part of virtual communities in which could exchange about infant's health as groups, via SMS, following the SHM Foundation's (http://www.shmfoundation.org/) m-health methodology.
62414763|NCT02263118|EXPERIMENTAL|Hybrid setup|Participants were made part of virtual communities in which they could exchange about infant's health as groups, via SMS. Additionally, a health professional was included in the virtual community.
62414764|NCT02263118|EXPERIMENTAL|Control group|Individuals were given a feature phone (simple mobile phone)
62414765|NCT06341413|EXPERIMENTAL|Stimulation mode first|During one week, the SmartSleep device will be set to stimulation mode.
62796128|NCT05659927|EXPERIMENTAL|MG-ZG122 second dose group|10 cases in the 105 mg dose group (2 cases of placebo, 8 cases of experimental drug)
62796129|NCT05659927|EXPERIMENTAL|MG-ZG122 third dose group|10 cases in the 210 mg dose group (2 cases of placebo, 8 cases of experimental drug)
62023694|NCT06387251|OTHER|All-in-one Meal Powder|Participants in Group B used the green powder supplement, probiotic supplement and All-in-one Meal Powder.
62023695|NCT02475408|EXPERIMENTAL|Interventional Study Arm|In the presence of a significant right coronary artery stenosis, catheter-based occlusion of the right IMA distal to the take-off of the pericardio-phrenic branch is performed at baseline using a dedicated occlusion device (Amplatzer vascular plug).
62023696|NCT02977546||Heart Failure|Patients with chronic heart failure NYHA \>= 2 based on a reduced left ventricular ejection fraction (LV-EF \<= 45%). All patients receive pulmonary artery catheterization and noninvasive pulse contour Analysis.
62023697|NCT03950193||premature child|Premature children evaluated during their 24 months follow up consultation
62023698|NCT00731315|EXPERIMENTAL|Treatment Group 1 - uncomplicated UTI|Would receive computer-assisted treatment for a uncomplicated UTI.
62220357|NCT01893294|EXPERIMENTAL|Treatment (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IT on day 1. Within 33 hours, patients receive standard chemotherapy comprising fluorouracil IV on days 1, 8, 15, 22, 29, and 36 and undergo standard radiation therapy 5 days a week for 6 weeks.
62796130|NCT05659927|EXPERIMENTAL|MG-ZG122 forth dose group|10 cases in the 420 mg dose group (2 cases of placebo, 8 cases of experimental drug)
62796131|NCT06726863|EXPERIMENTAL|Treatment Period 1: Vamifeport IR Formulation Dose Level 1|Participants will receive multiple doses of Vamifeport Immediate-release (IR) formulation at Dose level 1.
62587383|NCT06229288|ACTIVE_COMPARATOR|Amoxicillin/clavulanate|"Amoxicillin/clavulanate is recommended by French and European guidelines for the treatment of patients aged 65 years or older, and hospitalized in a non-ICU ward, as reported above.~The active comparators (IMPs) are:~- Amoxicillin/clavulanate tablets: Formulated as a tablet for PO administration (commercially available). Description in IMP file. Tablets contain 500 mg of amoxicillin trihydrate and 62.5 mg of clavulanate. Amoxicillin/clavulanate tablets contain compendial excipients listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15-25°C.~- Amoxicillin/clavulanate vials Vials contain 1000 mg of amoxicillin and 200 mg of clavulanate. Description in IMP file.~Amoxicillin/clavulanate vials contain compendial excipients listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15-25°C"
62023699|NCT00731315|ACTIVE_COMPARATOR|Control Group 1|Qualified for expedited treatment for uncomplicated cystitis but would receive usual care in the Emergency Department of Community Health Center.
62023700|NCT00731315|EXPERIMENTAL|Treatment Group 2 - Complicated Cystitis|Would receive expedited treatment for complicated cystitis with longer antibiotic course than the simple UTI patients.
62414766|NCT06341413|SHAM_COMPARATOR|Sham mode first|During one week, the SmartSleep device will be set to sham.
62414767|NCT01570127|EXPERIMENTAL|Individualized Acupuncture|The patients in this group received individualized acupuncture prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on the pattern diagnosis, which is an unique diagnosis system of Oriental Medicine.
62414768|NCT01570127|EXPERIMENTAL|Standardized Acupuncture|The patients in this group received standardized acupuncture treatment using the same acupuncture points, applied by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on literature review of RCTs.
62414769|NCT01570127|SHAM_COMPARATOR|Sham acupuncture|Non-penetrating acupuncture device, Park-sham acupuncture, was applied to the patients. The appearance of the acupuncture is same but the needles do not penetrate the skin.
62414770|NCT01570127|NO_INTERVENTION|Waiting|No interventions were applied to the patients in this group. Only assessments were made at each visit.
62414771|NCT04426188|SHAM_COMPARATOR|Without mouthguard|Heading series without mouthguard from machine-projected soccer balls at standardized speeds
62587384|NCT04010903|EXPERIMENTAL|HEALTHY SUBJECTS|SUBJECTS WITH BMI\<27 and HOMA\<4
62023701|NCT00731315|ACTIVE_COMPARATOR|Control Group 2|Qualified for expedited treatment for complicated cystitis treatment but would receive usual care in the clinic or emergency department.
62414772|NCT04426188|EXPERIMENTAL|With mouthguard|Heading series with mouthguard from machine-projected soccer balls at standardized speeds
62414773|NCT06109402|EXPERIMENTAL|Perioperative immunotherapy|In this arm, patients will receive neoadjuvant immunochemotherapy and adjuvant immunotherapy.
62023702|NCT05008510|EXPERIMENTAL|Sabizabulin Monotherapy|Subjects in the Sabizabulin Treated Group will receive sabizabulin 32 mg each day by mouth until disease progression confirmed by BICR is observed.
62414774|NCT06109402|EXPERIMENTAL|Adjuvant immunotherapy|In this arm, patients will receive adjuvant immunochemothrapy and immunotherapy
62414775|NCT06373978|ACTIVE_COMPARATOR|Diclofenac|50mg
62414776|NCT06373978|ACTIVE_COMPARATOR|Tramadol|50mg
62587385|NCT04010903|EXPERIMENTAL|OVERWEIGHT NON INSULINRESISTANT PATIENTS|SUBJECTS WITH BMI\>27 and HOMA\<4
62587386|NCT04010903|EXPERIMENTAL|OVERWEIGHT INSULINRESISTANT PATIENTS|SUBJECTS WITH BMI\>27 and HOMA\>4
62796132|NCT06726863|EXPERIMENTAL|Treatment Period 2: Vamifeport PR1 Dose Level 2|Participants will receive multiple doses of Vamifeport Prolonged-release formulation 1 (PR1) at Dose level 2.
62220358|NCT05600296|ACTIVE_COMPARATOR|Ilioinguinal/iliohypogastric nerve block (IINB)|evaluate the postoperative analgesic effects with using ultrasound-guided ilioinguinal/iliohypogastric nerve block (IINB) in children scheduled for elective open inguinal herniotomy.
62220359|NCT05600296|ACTIVE_COMPARATOR|IINB+ Spermatic cord block|evaluate the postoperative analgesic effects with using ultrasound-guided IINB + spermatic cord block (SCB) in children scheduled for elective open inguinal herniotomy.
62220360|NCT02711969|EXPERIMENTAL|Apatinib mesylate|
62023703|NCT05008510|EXPERIMENTAL|Sacituzumab govitecan-hziy/Sabizabulin Combination|Subjects in the Sacituzumab govitecan-hziy /Sabizabulin Combination Treated Group will receive sabizabulin 32 mg each day by mouth and Sacituzumab govitecan-hziy at the FDA approved dose and dosage regimen for mTNBC until disease progression confirmed by BICR is observed.
62796133|NCT06726863|EXPERIMENTAL|Treatment Period 2: Vamifeport PR2 Dose Level 2|Participants will receive multiple doses of Vamifeport Prolonged-release formulation 2 (PR2) at Dose level 2.
62220361|NCT06293703|EXPERIMENTAL|aRYGB|BP and roux limb lengths measuring 30% and 15% respectively of patient's total small bowel length.
62796134|NCT06726863|EXPERIMENTAL|Treatment Period 3: Vamifeport PR1 Dose Level 3|Participants will receive a single dose of Vamifeport PR1 at Dose level 3.
62796135|NCT06726863|EXPERIMENTAL|Treatment Period 3: Vamifeport PR2 Dose Level 3|Participants will receive a single dose of Vamifeport PR2 at Dose level 3.
62796136|NCT06726863|EXPERIMENTAL|Treatment Period 4: Vamifeport PR1 Dose Level 3|Participants will receive a single dose of Vamifeport PR1 at Dose level 3.
62023704|NCT05008510|ACTIVE_COMPARATOR|Sacituzumab govitecan-hziy Monotherpy|Subjects in the Control Treated Group will receive Sacituzumab govitecan-hziy intravenous infusion of 10 mg/kg in accordance with the FDA approved use and dosage regimen for mTNBC until disease progression confirmed by BICR is observed.
62023705|NCT00177229|NO_INTERVENTION|A|Enhanced usual care: 2 free, individual consultations with a nutritionist over first 6 months. Medical monitoring throughout study period.
62023706|NCT00177229|EXPERIMENTAL|B|
62220362|NCT06293703|ACTIVE_COMPARATOR|sRYGB|Standard fixed-length RYGB
62220363|NCT04362384|EXPERIMENTAL|Vitamin E ovules|Endoanal Vitamin E ovules will be prescriped during 14 days
62220364|NCT04362384|ACTIVE_COMPARATOR|Prednisolone ointment|Endoanal Prednisolone ointment will be prescriped during 14 days
62220365|NCT05073666||pulmonary embolism|Patients with a recent pulmonary embolism event will be followed for 6 months and will benefit of routine tests (Lung scintigraphy, venous echo doppler, d- dimers measurement) in order to determine chronic thrombo-embolic disease prevalence and its risk factors.
62220366|NCT04897906|EXPERIMENTAL|Experimental group|Experimental group; It is the group that will be given mother and neonatal care education.
62220367|NCT04897906|NO_INTERVENTION|Control Group|Control group; It is the group in which no intervention will be made other than data collection.
62220368|NCT02109315|EXPERIMENTAL|Liraglutide endovenous 6 mg|Liraglutide endovenous de 0.6 mg. one time a day
62023707|NCT01807273||Hemiplegic subjects|60 hemiplegic outpatients walking test
62023708|NCT06057246|EXPERIMENTAL|Men and post-menopausal women with type 2 diabetes on treatment with diet or diet plus metformin|Each participant will undergo anthropometrics and blood pressure measurements, bioimpedance analysis, indirect calorimetry, administrations of questionnaires for the evaluation of lifestyle habits, 7 days continuous glucose monitoring in parallel with diet, physical activity and sleep monitoring, and standard mixed-nutrient meals at home; a subgroup of 60 participants will undergo venous blood sampling for biochemical determinations before and after a standard mixed-nutrient meal.
62023709|NCT00698568|EXPERIMENTAL|Group A|
62023710|NCT00698568|PLACEBO_COMPARATOR|Group B|
62023711|NCT06458361||Anastomotic Leakage|Anastomotic Leakage in the first month after surgery
62023712|NCT06458361||non-anastomotic Leakage|non-anastomotic Leakage in the first month after surgery
62220369|NCT02109315|EXPERIMENTAL|Vitamine C|C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
62220370|NCT02391779|EXPERIMENTAL|BeneFlax® + walking training (Dash)|BeneFlax (0.8 g, twice a day) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
62220371|NCT02391779|PLACEBO_COMPARATOR|Placebo + walking training (Dash)|Placebo (whey powder isocaloric to BeneFlax) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
62220372|NCT02391779|EXPERIMENTAL|BeneFlax® + flexibility training (Dash)|BeneFlax (0.8 g, twice a day) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
62414777|NCT06373978|SHAM_COMPARATOR|Acetaminophen|1000mg
62414778|NCT03101215|PLACEBO_COMPARATOR|Placebo|glucose drink (100g) with placebo tablets
62414779|NCT03101215|ACTIVE_COMPARATOR|phosphorus|Glucose drink (100g) with phosphorus tablets (400 mg of phosphorus)
62414780|NCT06702826|EXPERIMENTAL|Cadonilimab combined with SRS|Eligible subjects were treated with stereotactic radiotherapy for brain metastases plus Cadonilimab followed by maintenance therapy with Cadonilimab alone
62414781|NCT02830724|EXPERIMENTAL|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-hCD70 CAR transduced PBL + high-dose aldesleukin
62414782|NCT02830724|EXPERIMENTAL|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-hCD70 CAR transduced PBL + high-dose aldesleukin
62414783|NCT00544713|EXPERIMENTAL|Carboxymethylcellulose and Glycerin based artificial tear|Carboxymethylcellulose and Glycerin based artificial tear
62414784|NCT00544713|ACTIVE_COMPARATOR|Carboxymethylcellulose based artificial tear|Carboxymethylcellulose based artificial tear
62433359|NCT01956227|EXPERIMENTAL|Home-based Exercise|Participants will be taught a series of exercises targeting balance and lower limb strength in four instructional sessions. They will be asked to complete exercises 3 times a week for 12 weeks. Exercise compliance will be recorded with a diary.
62220373|NCT02391779|SHAM_COMPARATOR|Placebo + flexibility training (Dash)|Placebo (whey powder isocaloric to BeneFlax) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
62796137|NCT06726863|EXPERIMENTAL|Treatment Period 4: Vamifeport PR2 Dose Level 3|Participants will receive a single dose of Vamifeport PR2 at Dose level 3.
62796138|NCT02277444|EXPERIMENTAL|Golimumab + Methotrexate|Participants will receive 80 milligram per meter square (mg/m\^2) as an intravenous (IV) infusion at Weeks 0, 4, and every 8 weeks thereafter up to Week 244, along with commercial methotrexate (MTX) weekly through Week 28 at the same Body Surface Area (BSA)-based dosage (10 to 30 mg/m\^2 per week for participants with BSA less than \[\<\] 1.67 meter square (m\^2), or minimum of 15 mg/week for participants with BSA greater than or equal to \[\>=\] 1.67 m\^2) as at the time of study entry. At Week 252, participants who meet the criteria for the optional Extended Treatment Period (ETP) may continue treatment with golimumab 80 mg/m\^2 every 8 weeks after completion of the Week 252 assessments.
62796139|NCT01569620|ACTIVE_COMPARATOR|Culturally targeted print materials|Best clinical practices plus culturally print materials
62023713|NCT00058266|EXPERIMENTAL|Group A|Patients receive oral genistein once daily for 1-2 months, undergo radical prostatectomy, and then continue oral genistein once daily for 1-2 months afterward (for a total of 3 months of therapy).
62023714|NCT00058266|EXPERIMENTAL|Group B|Patients undergo radical prostatectomy. Beginning 1 month after surgery, patients receive genistein as in arm I for 3 months.
62796140|NCT01569620|ACTIVE_COMPARATOR|Standard print materials|Best clinical practices plus standard print materials
62796141|NCT01569620|ACTIVE_COMPARATOR|Best clinical practices alone|Best clinical practices alone: This intervention arm includes best clinical practices (or standard/usual care at MSSM) and no additional print materials.
62796142|NCT05958849|EXPERIMENTAL|Prospective Research|"Soventinib in combination with solutumab and tegeo dosing regimen:~* Soventinib: 200 mg orally, within 1 hour of breakfast, administered once daily as a continuous dose, d1-d21, every 3 weeks in treatment cycles~* Slulizumab: 300 mg administered intravenously, d1, every 3 weeks for one treatment cycle.~* Tegeo: 40-60 mg/dose administered twice daily, d1-d14, continuously (dosing based on body surface area (BSA): 40 mg/dose for BSA ≤ 1.25 m2; 50 mg/dose for 1.25 ≤ BSA \< 1.5 m2 and 60 mg/dose for BSA ≥ 1.5 m2), every 3 weeks for one treatment cycle. Dose adjustments, including suspension, dose reduction, or permanent discontinuation, were allowed as required by the protocol."
62220374|NCT00514891|ACTIVE_COMPARATOR|1|Vitamin A supplementation
62414785|NCT05268718|EXPERIMENTAL|Nanogel photothermal therapy|After the subjects were enrolled in the study, the eyes were coated with Au-Ag-Cu2O nano-gel once (the concentration was 26.4μg/mL, the dosage was suitable to cover the ulcer surface evenly, and the dosage was recorded). Combined with mdl-n-808-10w near-infrared laser (China changchun new industry photoelectric technology) combined with photothermal therapy (laser wavelength 808 nm, power 1.5W/cm2, temperature controlled at 40℃, lasting 10min)
62796143|NCT05054998|EXPERIMENTAL|Diagnostic (fludeoxyglucose F-18, PET/MRI)|Patients receive fludeoxyglucose F-18 IV over approximately 1 minute and undergo a PET/MRI scan over 70 minutes. Within 5 hours of receiving fludeoxyglucose F-18, patients undergo a repeat PET/MRI scan over 30 minutes. Scans take place within 2 weeks before scheduled surgery and within 4-6 weeks after radiation treatment.
62796144|NCT04198480|EXPERIMENTAL|JMT103|Eligible subjects will receive JMT103 at a dose of 2 mg/kg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 2 mg/kg SC on study days 8 and 15.
62796145|NCT04519463|EXPERIMENTAL|Xylocaine|30 patients who receive Xylocaine 10% nasal spray
62796146|NCT04519463|PLACEBO_COMPARATOR|Saline|30 patients who receive saline nasal spray
62796147|NCT01726582|EXPERIMENTAL|Milestones related to therapy|"Milestone 1: Targeted chemotherapy prior to surgery: 8 weeks targeted chemotherapy; restaging.~Milestone 2: Before surgery: Chemoradiotherapy (cRXT); restaging Milestone 3: Before surgery: 8 weeks targeted chemotherapy; restaging; chemoradiotherapy (cXRT); restaging.~Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery: 8 weeks FOLFIRINOX (standard chemotherapy); restaging; standard chemoradiotherapy (cXRT); restaging.~Milestone 5: After surgery: 8 weeks targeted chemotherapy; restaging; chemoradiotherapy (cXRT); restaging.~Milestone 6: Gemcitabine after surgery: 8 weeks standard Gemcitabine (chemotherapy); restaging; chemoradiotherapy (cXRT); restaging.~Milestone 7: After surgery: chemoradiotherapy (cXRT); restaging. Milestone 8: Gemcitabine after surgery: 8 weeks Gemcitabine (chemotherapy); restaging; 8 weeks Gemcitabine (chemotherapy); restaging.~Milestone 9: No additional therapy after surgery. Milestone 10: After surgery no additional treatment."
62796148|NCT02949999|EXPERIMENTAL|0.25mg/kg voclosporin|0.25mg/kg voclosporin BID.
62796149|NCT02949999|EXPERIMENTAL|0.5mg/kg voclosporin|0.5mg/kg voclosporin BID
62023715|NCT04040127|EXPERIMENTAL|Cord blood stem cells|cord blood stem cells from Invitrx
62023716|NCT04040127|PLACEBO_COMPARATOR|0.9% sodium chloride (saline)|canal will be rinsed by saline solution.
62414786|NCT05268718|ACTIVE_COMPARATOR|Voriconazole eye drops|Voliconazole eye drops (once in half an hour) were also used in the control group.
62023717|NCT03448549|EXPERIMENTAL|Group A (TGOP-OX)|Colorectal cancer patients p-staged III are randomized and assigned with TGOP-OX (Tegafur，gimeracil and oteracil potassium+Oxaliplatin) as adjuvant chemotherapy.
62023718|NCT03448549|ACTIVE_COMPARATOR|Group B (XELOX)|Colorectal cancer patients p-staged III are randomized and assigned with XELOX (Xeloda+Oxaliplatin) as adjuvant chemotherapy.
62023719|NCT05378711|EXPERIMENTAL|Fluoxetine|Children will receive an introductory dose and therapeutic dose of fluoxetine at various time points in the study. Onset of fluoxetine is determined by assignment to a pre-determined randomized treatment schedule.
62220375|NCT00514891|PLACEBO_COMPARATOR|2|Placebo
62220376|NCT02866500|EXPERIMENTAL|oral cancer|
62220377|NCT02647567|EXPERIMENTAL|Caffeine Intake|The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
62220378|NCT02647567|PLACEBO_COMPARATOR|Placebo Intake|The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
62414787|NCT05268718|PLACEBO_COMPARATOR|Normal saline|Normal saline eye drops (once in half an hour) were also used in the control group.
62796150|NCT02949999|EXPERIMENTAL|1.0mg/kg voclosporin|1.0mg/kg voclosporin BID
62796151|NCT02949999|EXPERIMENTAL|1.5mg/kg voclosporin|1.5mg/kg voclosporin BID
62023720|NCT05257525|OTHER|Univentricular physiology|Neonates with univentricular physiology
62023721|NCT05257525|OTHER|Biventricular physiology|Neonates with biventricular physiology
62023722|NCT01946711|EXPERIMENTAL|Buparid; Treatment A|Buparid 1 mg budesonide/2 ml nebuliser solution
62023723|NCT01946711|ACTIVE_COMPARATOR|Budes; Treatment B|Budes® Nasal Spray 50 µg budesonide/pump
62023724|NCT01704339|EXPERIMENTAL|QUTENZA|Single treatment with QUTENZA (topical capsaicin 8%) transdermal patch
62023725|NCT02176889|EXPERIMENTAL|Lactospore|One tablet once daily, 30 minutes before a meal, preferably in the morning for 30 days
62023726|NCT02176889|PLACEBO_COMPARATOR|Placebo|One tablet once daily, 30 minutes before a meal, preferably in the morning, for 30 days.
62796152|NCT02949999|PLACEBO_COMPARATOR|Placebo voclosporin|placebo BID
62023727|NCT02405286||Upeer gastrointestinal bleeding|"* Adult Egyptian patients.~* Patients with acute upper G.I hemorrhage.~* Informed consent."
62023728|NCT03792594||Bone marrow concentration group|The patients receive arthroscopic repair with bone marrow concentration.
62023729|NCT03792594||Historical control group|The patients receive arthroscopic repair only
62220379|NCT03592901||BPA Patients|Participants that are receiving brachial plexus anesthesia for a previously planned shoulder surgery.
62796153|NCT02914405|EXPERIMENTAL|Treatment|"The dose and schedule of 131-I mIBG will be constant, and the doses of ch14.18/ CHO and Nivolumab determined by cohort:~* Cohort I: 3 mg/kg Nivolumab (100% adult dose). No ch14.18/CHO. (3-6 patients)~* Cohort II: 50mg/m2/cycle ch14.18/CHO (50% established Long Term Intervention (LTI) dose) and 3 mg/kg Nivolumab (100% adult dose) (3-6 patients)~* Cohort III: 100mg/m2/cycle ch14.18/CHO (100% established LTI dose) and 3 mg/kg Nivolumab (100% adult dose) (initial 3-6 patients, expanded to 15 patient cohort if tolerated)"
62796154|NCT00363636|EXPERIMENTAL|1|
62796155|NCT00363636|ACTIVE_COMPARATOR|2|
62796156|NCT04201106|NO_INTERVENTION|Control|In the control group, the participants will not be taking any placebos or undergoing any other study-related treatments.
62023730|NCT05719974|EXPERIMENTAL|criterion-based rehabilitation protocol|
62023731|NCT05719974|ACTIVE_COMPARATOR|conventional physical therapy program|
62023732|NCT02646423|EXPERIMENTAL|Prior CD Decision App (PCDDA)|Women who are randomized to PCDDA will be provided access to a tablet which they can use to view the Prior CD Decision App at their own pace. The research assistant will print a summary of the participant's predicted likelihood of a vaginal delivery (VBAC) if she undergoes a trial of labor (TOLAC), as well as her answers to the values clarification exercises, that she can review and share with whomever she chooses, including her provider.
62220380|NCT02343874||Alcohol consumption|"Patients over 17 years old with alcohol consumption registered in the electronic medical record (31st December 2012).~No intervention is going to be administered but exposure to alcohol will be analysed"
62220381|NCT03677765|ACTIVE_COMPARATOR|Infraclavicular group|In the infraclavicular group, subclavian venous catheterization using ultrasonography is performed beneath the clavicle.
62220382|NCT03677765|ACTIVE_COMPARATOR|Supraclavicular group|In the supraclavicular group, subclavian venous catheterization using ultrasonography is performed over the clavicle.
62414788|NCT02880722||IBS patients|IBS according to Rome IV criteria.
62587387|NCT03473639|EXPERIMENTAL|Entinostat and Capecitabine|"Dose escalation of the combination of entinostat and capecitabine in MBC patients. This dose will be given to MBC patients and to BC patients with residual invasive disease after neoadjuvant chemotherapy and surgery.~The dose combinations include:~Combination 1: 3 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 2: 5 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 3: 3 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine Combination 4: 5 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine~If a participant experiences unacceptable side effects, he or she will receive the next lowest dose combination. If he or she is on Combination 1, he or she will stop study treatment."
62587388|NCT01242202|EXPERIMENTAL|ASP group|Concomitant administration of ASP1941 and α- glucosidase inhibitor
62587389|NCT03025308|EXPERIMENTAL|Blinded Phase: Filgotinib 200 mg|Filgotinib 200 mg plus placebo to match (PTM) filgotinib 100 mg for up to 6 years
62587390|NCT03025308|EXPERIMENTAL|Blinded Phase: Filgotinib 100 mg|Filgotinib 100 mg plus PTM filgotinib 200 mg for up to 6 years
62587391|NCT03025308|EXPERIMENTAL|Open Label Phase: Filgotinib 200 mg|Filgotinib 200 mg for up to 6 years
62587392|NCT03025308|EXPERIMENTAL|Open Label Phase: Filgotinib 100 mg|Filgotinib 100 mg for up to 6 years
62220383|NCT01545323|EXPERIMENTAL|One 20cm2/10cm2 autologous skin sheet graft|Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
62587393|NCT02949193|EXPERIMENTAL|evogliptin|evogliptin 5mg qd add-on to metformin
62587394|NCT02949193|ACTIVE_COMPARATOR|sitagliptin|sitagliptin 100mg qd add-on to metformin
62587395|NCT00621166|OTHER|1|generic lopinavir/ritonavir
62587396|NCT06429228|EXPERIMENTAL|Catheter removal in postoperative day I|
62587397|NCT06429228|EXPERIMENTAL|Catheter removal in postoperative day II|
62220384|NCT04393337|EXPERIMENTAL|Gestational Age Chart Method|In this method, the endotracheal tube insertion depth is obtained from the gestational age chart provided in the 7th edition textbook of neonatal resuscitation program (adapted from Kempley et al. PubMed identifier number: 18372092)
62220385|NCT04393337|ACTIVE_COMPARATOR|Nasal-Tragus Length Method|In this method, the endotracheal tube insertion depth is calculated based on the formula-the distance from nasal septum tip to ear tragus+1 cm
62220386|NCT01778257|EXPERIMENTAL|Mate extracts group|Mate extract(3150 mg/day)for 12 weeks
62414789|NCT02880722||Healthy control group|Healthy volunteers without abdominal complaints fulfilling Rome IV criteria for IBS.
62414790|NCT04395040||Patients|Elderly patients with digestive cancer or breast cancer.
62414791|NCT04770194|EXPERIMENTAL|Cohort 1: 200mg SP-8008 Prototype Capsule A|Treat 200 mg SP-8008 Prototype Capsule A or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
62414792|NCT04770194|EXPERIMENTAL|Cohort 2: 400mg SP-8008 Prototype Capsule A|Treat 400 mg SP-8008 Prototype Capsule A or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
62414793|NCT04770194|EXPERIMENTAL|Cohort 3: 800mg SP-8008 Prototype Capsule A|Treat 800 mg SP-8008 Prototype Capsule A or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
62220387|NCT01778257|PLACEBO_COMPARATOR|Placebo group|Placebo (3150 mg/day) for 12 weeks
62414794|NCT04770194|EXPERIMENTAL|Cohort 4: 800 mg SP-8008 Prototype Capsule B|Treat 800 mg SP-8008 Capsule B or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
62414795|NCT04770194|EXPERIMENTAL|Cohort 5: 1200 mg SP-8008 Prototype Capsule B|Treat 1200 mg SP-8008 Capsule B or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
62587398|NCT05238025|EXPERIMENTAL|Group 1: Single dose MVA-BN-RSV|Single dose (Week 0): MVA-BN-RSV virus with a titer of at least 3x10E8 Inf.U/0.5mL (intramuscular vaccination)
62220388|NCT06283368||Benign Thyroid Pathologies|Nodular Goiter Graves Diseases Tocsic Thyroid Nodular Disease
62414796|NCT04770194|EXPERIMENTAL|Cohort 6: 1800 mg SP-8008 Prototype Capsule B|Treat 1600 mg SP-8008 Capsule B or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
62433360|NCT01956227|EXPERIMENTAL|Education|Participants will attend 4 education sessions focusing on interaction of beliefs, behaviors and symptoms on falls. They will be taught self-management principles to modify their fall risk.
62433361|NCT01956227|EXPERIMENTAL|Exercise plus education|Participants will attend 2 instructional exercise sessions as well as 2 education sessions. Participants will be asked to complete exercises at home 3 times per week and engage in behavior to minimize fall risk.
62587399|NCT05238025|EXPERIMENTAL|Group 2: Single dose Placebo|Single dose of TBS (intramuscular injection; 0.5mL)
62587400|NCT00421018|SHAM_COMPARATOR|Symptom-guided group|Anti-inflammatory treatment is guided conventionally according to symptoms and beta-2-agonist use.
62587401|NCT00421018|ACTIVE_COMPARATOR|FeNO-guided group|Anti-inflammatory treatment is guided according to the level of exhaled nitric oxide
62587402|NCT04016038||QualiPas Observational|Prospective qualitative study through a participant observation procedure with 8 care teams practicing within Palliative Care Units, Palliative Care Mobile Team or Territorial Palliative Care Team.
62220389|NCT06283368||Thyroid Cancer Cases|Papillary Thyroid Carcinoma Medullary Thyroid Carcinoma Hurthle Cell Carcinoma Anaplastic Thyroid Carcinoma
62220390|NCT02164123|EXPERIMENTAL|Spinal mobilization|20 subjects will be randomized to this arm. A postero-anterior (PA) mobilization, to the fourth thoracic vertebra will be applied, for 3 sets of one minute. The subject will be comfortable prone lying.
62220391|NCT02164123|ACTIVE_COMPARATOR|Spinal Mobilization II|20 subjects will be randomized to this arm. A postero-anterior (PA) mobilization, to the fourth thoracic vertebra will be applied, for 3 sets of one minute, but in this case, the subject will be seated, in a position that influence the sympathetic trunk, at the thorax.
62433362|NCT01956227|NO_INTERVENTION|Control|Participants will not receive any treatment.
62796157|NCT04201106|EXPERIMENTAL|Open Label Placebo Group with Rationale|
62796158|NCT04201106|ACTIVE_COMPARATOR|Open Label Placebo Group without Rationale|
62220392|NCT02164123|PLACEBO_COMPARATOR|Placebo|20 subjects will be randomized to this arm. Only manual contact will be applied, without any oscillation. The subject will be comfortable prone lying. The intervention time is the same of the other arms.
62220393|NCT03561831|ACTIVE_COMPARATOR|propofol group|patients who anesthesized by propofol
62220394|NCT03561831|ACTIVE_COMPARATOR|sevoflurane group|patients who anesthesized by sevoflurane
62220395|NCT02865980|EXPERIMENTAL|inflammation|The effect of washing with betadine and clove extract on incidence of inflammation place logging shaldon catheter in the hemodialysis patients
62220396|NCT02865980|EXPERIMENTAL|infection|The effect of washing with betadine and clove extract on incidence of infection place logging shaldon catheter in the hemodialysis patients
62220397|NCT01946763|NO_INTERVENTION|safety of Anesthesia|No pre operative education
62220398|NCT01946763|EXPERIMENTAL|Behavioral : pre operative education|Behavioral pre operative education
62220399|NCT02372500|EXPERIMENTAL|Chewing gum|Patients will chew sugar free gum three times a day
62220400|NCT02372500|NO_INTERVENTION|Control|Normal post operative care
62220401|NCT03383926|EXPERIMENTAL|Group 1|Suture confection of theTobacco-pouch of 4.5cm from the anal margin.
62220402|NCT03383926|EXPERIMENTAL|Group 2|Suture confection of theTobacco-pouch of 6cm from the anal margin.
62220403|NCT01893125|EXPERIMENTAL|CNV2197944|CNV2197944 75mg tid 21 days
62220404|NCT01893125|PLACEBO_COMPARATOR|Placebo|Placebo 1 cap tid 21 days
62220405|NCT02341859|ACTIVE_COMPARATOR|stenfilcon A and delefilcon A|Participants randomized wear the stenfilcon A and the delefilcon A contralaterally.
62220406|NCT02341859|ACTIVE_COMPARATOR|stenfilcon A and narafilcon A|Participants randomized wear the stenfilcon A and the narafilcon A contralaterally
62220407|NCT01315587|ACTIVE_COMPARATOR|intermittent theta burst stimulation|
62220408|NCT01315587|ACTIVE_COMPARATOR|repetitive Transcranial Magnetic Stimulation|
62414797|NCT04843501|EXPERIMENTAL|CATCH My Breath (CMB) program for E-cigarette prevention among adolescents|The CMB curriculum is divided into four developmentally appropriate e-cigarette lessons (approximately 20-30 minutes each) for middle school aged youth (6th - 8th grade). A variety of educational strategies are used and include cooperative learning groups, large group discussions, interviews, role-play, media, reports, and goal setting. CMB will provide study materials to teachers and schools through a state-of-the art online delivery portal. A site-based management team will oversee program implementation. Teachers will be trained via webinar. Project staff will visit all participating schools to assemble and train the CATCH site-based management team, and answer questions about the study. Teachers in CMB intervention schools will be provided with CMB-specific training for implementing the lessons with fidelity through a one-hour live webinar with Dr. Kelder, which will be offered at multiple times to accommodate teaching schedules.
62414798|NCT04843501|ACTIVE_COMPARATOR|Texas Education Agency required tobacco prevention program|The TEA tobacco prevention program is a state-supported program that meets the mandates of the state. It includes online lessons and support materials.
62414799|NCT06181136|EXPERIMENTAL|Cohort A1|Participants with MPS IIIA
62220409|NCT01315587|PLACEBO_COMPARATOR|Sham TMS|
62414800|NCT06181136|EXPERIMENTAL|Cohort A2|Participants with MPS IIIA
62414801|NCT06181136|EXPERIMENTAL|Cohort A3|Participants with MPS IIIA
62414802|NCT06181136|EXPERIMENTAL|Cohort B1|Participants with MPS IIIA
62414803|NCT06181136|EXPERIMENTAL|Cohort B2|Participants with MPS IIIA
62414804|NCT00527527|ACTIVE_COMPARATOR|1|8 flexion distraction visits
62414805|NCT00527527|ACTIVE_COMPARATOR|2|12 flexion distraction visits
62414806|NCT00527527|ACTIVE_COMPARATOR|3|18 flexion distraction visits
62023733|NCT02646423|NO_INTERVENTION|Usual Care - No App|Women randomized to the Usual Care - No App group will simply continue with usual care.
62220410|NCT05249439|EXPERIMENTAL|I-SatPro|Patients in the I-SatPro group will attend I-SatPro patient group sessions and follow the I-SatPro weight loss programme
62220411|NCT05249439|ACTIVE_COMPARATOR|Control|Patients in the control group will attend NHS Tier 3 patient group sessions and follow the NHS Tier 3 weight loss programme
62220412|NCT05712473||Cohort 1|Patients who are newly diagnosed with prostate cancer (and have suspected metastases) and have not yet initiated any prostate cancer treatment and are referred to undergo PYLARIFY PET
62220413|NCT05712473||Cohort 2:|Patients who have previously received treatment for prostate cancer and are referred to undergo PYLARIFY PET or have received PYLARIFY PET for suspected recurrence of prostate cancer (based on an elevated PSA) within 60 days of consent to enroll in the registry
62220414|NCT03929172|EXPERIMENTAL|AAVLP-HPV Vaccine Arm|Subjects will receive a total of 3 vaccinations: a prime on Day 1, and boosts on Day 57 (± 2 days) and Day 180 (± 1 week).
62220415|NCT03929172|PLACEBO_COMPARATOR|Placebo Arm|Subjects will receive a total of 3 vaccinations: a prime on Day 1, and boosts on Day 57 (± 2 days) and Day 180 (± 1 week).
62220416|NCT02447172|EXPERIMENTAL|Gentamicin sponge group|Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
62220417|NCT02447172|PLACEBO_COMPARATOR|Placebo sponge group|Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
62220418|NCT02447172|NO_INTERVENTION|No sponge group|Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
62220419|NCT00434005|EXPERIMENTAL|Diesel Exhaust|
62220420|NCT00434005|SHAM_COMPARATOR|Filtered Air|
62220421|NCT03273361|EXPERIMENTAL|Seated|Participants completed work tasks while seated.
62220422|NCT03273361|EXPERIMENTAL|Low Intensity Pedaling|Participants completed work tasks while pedaling at a low intensity.
62220423|NCT03273361|EXPERIMENTAL|Low-Moderate Intensity Pedaling|Participants completed work tasks while pedaling at a low-moderate intensity.
62220424|NCT05924308|SHAM_COMPARATOR|control group|
62220425|NCT05924308|EXPERIMENTAL|treatment group|
62414807|NCT00527527|PLACEBO_COMPARATOR|4|8 placebo control visits
62796159|NCT04708834|EXPERIMENTAL|Troriluzole (BHV-4157)|200 mg daily first 2 weeks, 280 daily for following 46 weeks
62796160|NCT06177600|OTHER|Deferred Access|Deferred access participants will be given usual care and gain access to the digital app at 6 months. Usual care consists of access to published resources and community support organizations, if available. The list of resources will include contact information for a suicide prevention hotline.
62023734|NCT05388903|EXPERIMENTAL|DS-2325a SC|Participants who will be randomized to receive DS-2325a as a fixed dose subcutaneous (SC) injection (starting dose 30 mg).
62220426|NCT02143297||SAHS negative|Subjects derived to the sleep unit due to suspicion of suffering from sleep apnea which finally do not have the disease according to standard PSG
62220427|NCT02143297||SAHS positive|Subjects derived to the sleep unit due to suspicion of suffering from sleep apnea which finally have the disease according to standard PSG
62220428|NCT00712946||1|Arteriosclerosis obliterans patients undergoing elective vascular surgery
62220429|NCT00712946||2|Healthy age-matched volunteers
62220430|NCT03362047|EXPERIMENTAL|Riciguat Group|15 PAH patients will be administered Riciguat according to standard of care. RV function will be evaluated 90 mintutes after first medication intake and 12 weeks after first medication intake.
62414808|NCT04853888|OTHER|Intervention group|"* A quasi-experimental design was selected to more closely approximate service delivery models in agencies that do not typically employ control groups.~* Given promising findings (from seven ATTACH™ pilot studies), a randomized controlled trial design, even employing wait-list controls was deemed unacceptable and even unethical by patients, health care professionals and health system administrators in engagement activities surrounding the preparation of this proposal."
62796161|NCT06177600|EXPERIMENTAL|Immediate Access|Immediate access participants will have access to a digital app, plus usual care, after enrollment and the deployment of the app. Usual care consists of access to published resources and community support organizations, if available. The list of resources will include contact information for a suicide prevention hotline.
62023735|NCT05388903|PLACEBO_COMPARATOR|Placebo SC|Participants who will be randomized to receive placebo as a subcutaneous (SC) injection.
62023736|NCT05388903|EXPERIMENTAL|DS-2325a IV|Participants who will be randomized to receive DS-2325a as a fixed dose intravenous (IV) infusion (starting dose 100 mg).
62023737|NCT05388903|PLACEBO_COMPARATOR|Placebo IV|Participants who will be randomized to receive placebo as an intravenous infusion.
62023738|NCT01919099||Post-transplant|Patients receiving allogenic stem cell transplants at the NIH CC
62023739|NCT00504829|EXPERIMENTAL|LCP-AtorFen|LCP-AtorFen 40/100mg fixed-dose combination tablet of 40mg atorvastatin and 145mg fenofibrate for treatment of mixed dyslipidemia
62220431|NCT03362047|EXPERIMENTAL|Macitentan Group|15 PAH patients will be administered Macitentan according to standard of care. RV function will be evaluated 90 mintutes after first medication intake and 12 weeks after first medication intake.
62220432|NCT00081497|EXPERIMENTAL|Fabrazyme 1.0 mg/kg every 2 weeks|This is an open-label extension study to AGAL-008-00 (NCT00074984) and all patients received Fabrazyme treatment.
62220433|NCT04353973|EXPERIMENTAL|ARM A|"Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing).~Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing)."
62433363|NCT02264457|OTHER|First eye closed loop haptic|subjects implanted with the Closed loop haptic during first eye surgery and the plate haptics toric intraocular lens during second eye surgery
62433364|NCT02264457|OTHER|First eye plate haptic|subjects implanted with the plate haptic toric during first eye surgery and the closed loop haptic toric intraocular lens during second eye surgery
62023740|NCT00504829|ACTIVE_COMPARATOR|atorvastatin|atorvastatin 40mg tablet (Lipitor), as an adjunct to diet and exercise for treatment of mixed dyslipidemia
62023741|NCT00504829|ACTIVE_COMPARATOR|fenofibrate|fenofibrate 145mg tablet (Tricor), as an adjunct to diet and exercise for treatment of mixed dyslipidemia
62023742|NCT06525181|ACTIVE_COMPARATOR|Standard weekly symptom assessment by physicians|
62023743|NCT06525181|EXPERIMENTAL|AI-assisted symptom intake|
62023744|NCT04329104|EXPERIMENTAL|Dose-escalation study: Arm 1: 5 mg/kg of CIS43LS|Participants receive 5 mg/kg of CIS43LS as one time intravenous infusion on Day 0.
62220434|NCT04353973|EXPERIMENTAL|ARM B|"Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing).~Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention."
62220435|NCT04353973|EXPERIMENTAL|ARM C|"Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention.~Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing)."
62220436|NCT04353973|EXPERIMENTAL|ARM D|"Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention.~Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention."
62433365|NCT03853083|EXPERIMENTAL|Hypoxi Equipment|
62023745|NCT04329104|EXPERIMENTAL|Dose-escalation study: Arm 2: 10 mg/kg of CIS43LS|Participants receive 10 mg/kg of CIS43LS as one time intravenous infusion on Day 0.
62023746|NCT04329104|EXPERIMENTAL|Dose-escalation study: Arm 3: 40 mg/kg of CIS43LS|Participants receive 40 mg/kg of CIS43LS as one time intravenous infusion on Day 0.
62796162|NCT04862247|EXPERIMENTAL|Imaginal Exposure Condition|Participants will complete one phone session including education about the treatment followed by four online sessions of imaginal exposure across a one month time period. Each session is separated by 1 week.
62220437|NCT02257567|EXPERIMENTAL|Arm A (Phase II Randomization): Polatuzumab+BR in FL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
62220438|NCT02257567|ACTIVE_COMPARATOR|Arm B (Phase II Randomization): BR in FL|Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with FL.
62220439|NCT02257567|EXPERIMENTAL|Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
62414809|NCT06593366|ACTIVE_COMPARATOR|Fecal Microbiota Transplant|Banked donor stools that have been previously screened, prepared and frozen per previous protocols will be used to prepare all oral FMT capsules (OFC) through the laboratory of a collaborator. Recipients will receive OFC (two capsules, twice a day, twice per week) prepared from a single donor throughout their 8-week treatment course, to support assessment of FMT engraftment in recipients; this totals to 64 capsules across the duration of the study. Each OFC will contain approximately 15.0g of dried healthy donor stool contained within a size 00 gelatin capsule.
62023747|NCT04329104|EXPERIMENTAL|Efficacy study: Arm 1: 10 mg/kg of CIS43LS|Participants receive 10 mg/kg of CIS43LS as one time intravenous infusion on Day 0.
62023748|NCT04329104|EXPERIMENTAL|Efficacy study: Arm 2: 40 mg/kg of CIS43LS|Participants receive 40 mg/kg of CIS43LS as one time intravenous infusion on Day 0.
62023749|NCT04329104|PLACEBO_COMPARATOR|Efficacy study: Arm 3: Placebo|Participants receive placebo as one time intravenous infusion on Day 0.
62023750|NCT01794325|ACTIVE_COMPARATOR|Trans-radial access|Coronary angiography performed through trans-radial access
62023751|NCT01794325|ACTIVE_COMPARATOR|Trans-femoral access|Coronary angiography performed through trans-femoral access
62023752|NCT02937246|EXPERIMENTAL|the intervention group|Partial covered double bare metal stent
62023753|NCT02937246|ACTIVE_COMPARATOR|the control group|Uncovered double bare metal stent
62220440|NCT02257567|ACTIVE_COMPARATOR|Arm D (Phase II Randomization): BR in DLBCL|Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with DLBCL.
62220441|NCT02257567|EXPERIMENTAL|Arm E (Phase II Expansion): Polatuzumab+BG in FL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
62220442|NCT02257567|EXPERIMENTAL|Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
62220443|NCT02257567|EXPERIMENTAL|Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
62220444|NCT02257567|EXPERIMENTAL|Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
62433366|NCT03853083|ACTIVE_COMPARATOR|Recumbent Bicycle|
62433367|NCT03807882|EXPERIMENTAL|Test group|Bilateral Maintenance ECT (B/L M-ECT)
62587403|NCT04016038||QualiPas clinical interview|Qualitative study retrospective research interviews with the doctor and another carer involved in the care of the patient, and close relatives of patients who had sedated before their death. The interviews will be based on 50 cases of patients who have been sedated.
62587404|NCT04016038||QualiPas Focus|Qualitative study by group focus group interviews with clinical teams participating in the project.
62796163|NCT04862247|ACTIVE_COMPARATOR|Writing and Thinking Condition|Participants will complete one phone session including education about the treatment followed by four online sessions of a writing and thinking intervention across a one month time period. Each session is separated by 1 week.
62220445|NCT02257567|EXPERIMENTAL|Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
62220446|NCT02257567|EXPERIMENTAL|Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
62796164|NCT05706571|NO_INTERVENTION|control grup (skill laboratory)|The control group of the study: The control group of the study; Students will be formed from students whose school number has a single last digit. The experimental 1 group and control group of experimental 2 groups of the study consist of the same group. Before the theoretical lecture of the pediatric patient end-of-life care module of nursing students teaching with augmented reality and the Benner model, students will be pre-tested. After the pre-test, students are taught on a virtual case in the last hours and days of life; Theoretical lecture will be given by the researcher in the form of a PowerPoint presentation, which will last 60 minutes, using question-answer, discussion, and commentary methods. A final test will be given at the end of the course.
62023754|NCT04644328|EXPERIMENTAL|High-Intensity Treatment Arm|"Treatment: Individuals received approximately 3 Facebook ads over a 2-week period. Each ad contained a short video recorded by a physician using a script that discusses staying safe during the holidays by considering not traveling and using a mask when appropriate.~Randomization to treatment: The 13 states which centrally report COVID-19 cases at the ZCTA level contained 829 counties. At Thanksgiving, 9 counties were excluded due to data limitations. At Christmas, 62 counties were excluded due to data limitations and potential negative impacts in rural, conservative areas resulting from polarization in the wake of the 2020 presidential election. Approximately half of the counties were randomized to high-intensity treatment with the remaining randomized to low-intensity treatment. In high-intensity counties, 3/4 of ZCTAs were treated (i.e., Facebook users in those ZCTAs received ads) and 1/4 were not. In low-intensity counties, 1/4 of ZCTAs were treated and 3/4 were not."
62220447|NCT02257567|EXPERIMENTAL|Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL|In this New Formulation (NF) cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
62220448|NCT02257567|EXPERIMENTAL|Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL|In this NF cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
62220449|NCT00699894|EXPERIMENTAL|1|aprepitant 40 mg + normal saline IV
62220450|NCT00699894|ACTIVE_COMPARATOR|2|placebo PO + ondansetron 4 mg IV
62220451|NCT02232607|EXPERIMENTAL|Lacidipine, low dose|
62414810|NCT06593366|PLACEBO_COMPARATOR|Placebo|Matching oral placebo capsules (OPC) containing methylcellulose will be identical in terms of size, colour, taste, and dosing. Participants will be asked to take the Placebo treatment capsules twice a day for two days per week for a duration of eight weeks (total 64 capsules).
62414811|NCT03348319||Cadaver organs|
62414812|NCT02594384|EXPERIMENTAL|Continuous monotherapy|All patients will take LAM-002A two times daily by mouth every day until cancer progression or intolerability.
62414813|NCT02594384|EXPERIMENTAL|Intermittent monotherapy|All patients will receive LAM-002A at escalating dose levels two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
62414814|NCT02594384|EXPERIMENTAL|LAM-002A + rituximab|All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab 375 mg/m2 by vein every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions)
62220452|NCT02232607|EXPERIMENTAL|Lacidipine, medium dose|
62220453|NCT02232607|EXPERIMENTAL|Lacidipine, high dose|
62220454|NCT02232607|ACTIVE_COMPARATOR|Placebo|
62220455|NCT04806217|EXPERIMENTAL|¨Patients with multiple sclerosis|"Patients :~* With multiple sclerosis~* Aged of 18 and over~* Recruited during their consultation in the adult outpatient unit or neurological unit or during a hospitalization."
62587405|NCT03247153|EXPERIMENTAL|Corticosteroid Therapy Patients|Corticosteroid therapy patients will be examined by echocardiography before, during and after receiving treatment
62587406|NCT02402257||Traditionally-trained|Patients who undergo CVC procedures by traditionally-trained providers who have not undergone simulation-based mastery learning. This could be retrospective (before the study started) or at a site where the training was not implemented.
62587407|NCT02402257||CVC Train the Trainer|Patients who undergo CVC procedures by providers who have participated in simulation-based mastery learning.
62587408|NCT05458219|EXPERIMENTAL|Phase 1a|"Phase 1a Dose Escalation: IBI343 will be administered intravenously (IV) at different dose levels following accelerated titration for the first 2 dose levels and traditional 3+3 dose escalation design for following levels.~Phase 1a Dose Optimization: IBI343 will be administered in parallel cohorts (randomized 1:1 ratio) to determine the optimal dose for the PDAC indication across China, Australia and the US (n=30-40). Dose levels 4.5mg/kg and 6mg/kg will be studied.~Phase 1a Dose Expansion: IBI343 will be administered at dose levels which is equal or lower than MTD. Each dose level contains no more than 60 subjects (including subjects in dose escalation)."
62220456|NCT06609564|EXPERIMENTAL|Inspiratory Muscle Training|Inspiratory muscle training in addition to convantional chest physiotherapy
62414815|NCT02594384|EXPERIMENTAL|LAM-002A + atezolizumab|All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
62796165|NCT05706571|EXPERIMENTAL|experimental group1 (Benner model)|Experiment 1 Group of the Research With the Benner model, it is planned to create the pediatric end-of-life care module for nursing students in the Fall Term of the 2023-2024 Academic Year, with an estimated 140 students enrolled in the Istanbul Medipol University Faculty of Health Sciences Nursing Department Child Health and Diseases Nursing Course. The enrolled students will form the novice nurse group according to the Benner model of the research. A pre-test will be done before the theoretical lesson is given to the novice nurse group of the research.
62796166|NCT05706571|EXPERIMENTAL|experimental group2 (augmented reality mobile application)|Application of the Research to the Experimental Group 2 Experiment 2 group of the research; In the Fall Term of the 2023-2024 Academic Year, an estimated 140 students will be enrolled in the Istanbul Medipol University Health Sciences Faculty Nursing Department Child Health and Diseases Nursing Course. The 3rd group of the study will be pre-tested before the theoretical lecture of the Pediatric Patient End-of-Life Care Module with the augmented reality method and Benner model. At the end of the pre-test, students will be given a theoretical lecture.
62220457|NCT06609564|EXPERIMENTAL|Convational Chest Physiotherapy|Diaphragm breathing, costal expansion exercises, postural drainage, effective coughing, in-bed range of motion exercises, and mobilization
62220458|NCT00628576|ACTIVE_COMPARATOR|1|UFH: patients treated with unfractionated heparin
62220459|NCT00628576|EXPERIMENTAL|2|FH: patients treated with low-molecular-weight (fractionated) heparin
62220460|NCT03368339|ACTIVE_COMPARATOR|PR013 topical Ophthalmic Drops (0.045%)|topical Ophthalmic Drops (0.045%)
62220461|NCT03368339|ACTIVE_COMPARATOR|PR013 topical Ophthalmic Drops (0.06%)|topical Ophthalmic Drops (0.06%)
62220462|NCT03368339|PLACEBO_COMPARATOR|Vehicle|Placebo
62414816|NCT00326339|EXPERIMENTAL|1|R788 50 mg PO bid
62587409|NCT05458219|EXPERIMENTAL|Phase 1b|Phase 1b Dose Extension: IBI343 will be administered at RP2D.
62220463|NCT01880528|EXPERIMENTAL|Arm I (lisinopril)|Beginning within 7 days of beginning radiation therapy, patients receive lisinopril PO QD on days 1-7.
62587410|NCT06665438|EXPERIMENTAL|group of control (C)|receive 18 ml of normal saline only and serve as the control group.the normal saline will injected in the knee joint by the surgeon through the arthroscope after completing the procedure
62220464|NCT01880528|PLACEBO_COMPARATOR|Arm II (placebo)|Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD on days 1-7.
62220465|NCT06116955||S-M group|Midazolam combines with sufentanil to titrate to moderate sedation for bronchoscopy.
62220466|NCT06116955||S-M-P group|Midazolam and sufentanil combine with low-dose propofol to titrate to deep sedation for bronchoscopy.
62220467|NCT06116955||S-R group|Remazolam combines with sufentanil to titrate to moderate sedation for bronchoscopy.
62220468|NCT06116955||S-R-P group|Remazolam and sufentanil combine with low-dose propofol to titrate to deep sedation for bronchoscopy.
62220469|NCT04232059|ACTIVE_COMPARATOR|Group 1: hyperventilation|• Group 1: hyperventilation (ETco2 25-30 mm Hg) for 20 minutes that will start immediately after skin incision followed by normoventilation (ETco2 31-35 mm Hg) for another 20 minutes.
62414817|NCT00326339|EXPERIMENTAL|2|R788 100 mg PO bid
62414818|NCT00326339|EXPERIMENTAL|3|R788 150 mg PO bid
62414819|NCT00326339|PLACEBO_COMPARATOR|4|Placebo PO bid
62414820|NCT02619370|EXPERIMENTAL|Intervention|Play 'My Gift of Grace,' a conversation card game for 4-6 players (the game consists of 20 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues); all game sessions will be audio recorded and transcribed.
62220470|NCT04232059|ACTIVE_COMPARATOR|Group 2: normoventilation|• Group 2: normoventilation (ETco2 31-35 mm Hg) for 20 minutes immediately after skin incision followed by hyperventilation (ETco2 25-30 mm Hg) for another 20 minutes.
62220471|NCT01096654|ACTIVE_COMPARATOR|CT-scan|In this group treatment will be based on the outcome of the CT-scan only. Patients will be treated by adrenalectomy (Adx) if an unilateral lesion is visible on the CT-scan and the contralateral gland is normal. If bilateral lesions, bilateral enlargement or symmetric normal adrenal glands are present patients will be treated by the mineralocorticoid receptor antagonist (MRA)
62587411|NCT06665438|EXPERIMENTAL|groups of Bupivacaine (B)|The 18ml 0.25% bupivacaine will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure
62587412|NCT06665438|EXPERIMENTAL|groups of dexmedetomidine (D)|Dexmedetomidine 1 μg/kg will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure.
62587413|NCT02779764|EXPERIMENTAL|ASP1517 Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
62587414|NCT01451970|OTHER|High Monounsaturated Fat Diet|Subjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated.
62587415|NCT01451970|OTHER|High Saturated Fat Diet|Subjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
62414821|NCT02619370|ACTIVE_COMPARATOR|Control|"Review and discuss a brochure on ACP called Advance Care Planning: Tips from the National Institute of Aging. Discussion will be prompted by the researcher asking participants to discuss the information they've just read with the group. However, there will not be a formal structure to this discussion."
62414822|NCT06184659|EXPERIMENTAL|Meropenem|Participants in the experimental intervention arm will receive 1 g of IV meropenem three times daily administered according to usual clinical practice (i.e., intermittent-, prolonged-, or continuous infusion) until discharge from the participating site, death, or termination of empirical antibiotic therapy (including initiation of definitive treatment).
62587416|NCT06661590|EXPERIMENTAL|Dietician|
62587417|NCT02741440||Affected Participants|Twenty-five (25) participants with molecularly-confirmed SCA7
62587418|NCT06683963|NO_INTERVENTION|Control - usual care|Business as usual in community hospital, no added device intervention
62796167|NCT06652958|EXPERIMENTAL|Arm A, Cohort 1|Healthy adult participants receive a single dose of VH4527079 Dose 1 (lowest dose) by IV infusion.
62414823|NCT06184659|ACTIVE_COMPARATOR|Piperacillin/Tazobactam|Participants in the control arm will receive 4/0.5 g of intravenous piperacillin/tazobactam four times daily administered according to usual clinical practice (i.e., intermittent-, prolonged-, or continuous infusion) until discharge from the participating site, death, or termination of empirical antibiotic therapy (including initiation of definitive treatment).
62414824|NCT03337776|ACTIVE_COMPARATOR|WhatsApp message|WhatsApp messages will be sent to invite subjects to participate CRC screening
62414825|NCT03337776|ACTIVE_COMPARATOR|Telephone call|Telephone call will be made to invite subjects to participate CRC screening
62414826|NCT00057330|EXPERIMENTAL|Herpes Simplex Virus Group|Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus (HSV) vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.
62587419|NCT06683963|EXPERIMENTAL|Intervention - Rebee|Addition of Rebee device during and after community hospital stay
62587420|NCT02145442|EXPERIMENTAL|Obex|Obex®, two oral sachets daily during three months.
62587421|NCT04259931||No relapses|Patients with clostridium difficile infections without relapses
62587422|NCT04259931||Relapsing patiens|Patients with clostridium difficile infections with relapses
62796168|NCT06652958|EXPERIMENTAL|Arm A, Cohort 2|Healthy adult participants receive a single dose of VH4527079 Dose 2 (low dose) by IV infusion.
62414827|NCT00057330|EXPERIMENTAL|Havrix Group|Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.
62796169|NCT06652958|EXPERIMENTAL|Arm A, Cohort 3|Healthy adult participants receive a single dose of VH4527079 Dose 3 (mid-low dose) by IV infusion.
62796170|NCT06652958|EXPERIMENTAL|Arm A, Cohort 4|Healthy adult participants receive a single dose of VH4527079 Dose 4 (mid-high dose) by IV infusion.
62414828|NCT02010307|EXPERIMENTAL|aggressive periodontitis|25 patients with aggressive periodontitis blood extraction
62414829|NCT02010307|EXPERIMENTAL|chronic periodontitis|25 patients with chronic periodontitis blood extraction
62414830|NCT02010307|EXPERIMENTAL|healthy|25 healthy periodontal patients blood extraction
62587423|NCT01430988||Head Injured Group|Subjects who are suspected of a traumatically induced structural brain injury and/or clinical manifestations of functional brain injury, as a result of insult to the head from an external force, e.g., the head being struck by an object, the head striking an object, the head being exposed to forces generated from a blast or explosion, and/or the brain undergoing an acceleration/deceleration movement without direct external trauma to the head will be recruited from patients who enter the Emergency Department at hospitals that are participating as clinical sites for this study
62796171|NCT06652958|EXPERIMENTAL|Arm A, Cohort 5|Healthy adult participants receive a single dose of VH4527079 Dose 5 (high dose) by IV infusion.
62796172|NCT06652958|EXPERIMENTAL|Arm A, Cohort 6|Healthy adult participants receive a single dose of VH4527079 Dose 6 (max dose) by IV infusion.
62796173|NCT06652958|EXPERIMENTAL|Arm A, Cohort 7|Healthy adult participants receive a single dose of VH4527079 Dose 1 (lowest dose) by SC injection.
62796174|NCT06652958|EXPERIMENTAL|Arm B, Cohort 8|Healthy adult participants receive three doses of VH4527079 dose that is selected in Arm A, by IV infusion, separated by a time interval.
62023755|NCT04644328|NO_INTERVENTION|Low-Intensity Control Arm|"Control: Individuals did not receive ads containing short physician-recorded videos.~Randomization to treatment: The 13 states which centrally report COVID-19 cases at the ZCTA level contained 829 counties. At Thanksgiving, 9 counties were excluded due to data limitations. At Christmas, 62 counties were excluded due to data limitations and potential negative impacts in rural, conservative areas resulting from polarization in the wake of the 2020 presidential election. Approximately half of the counties were randomized to high-intensity treatment with the remaining randomized to low-intensity treatment. In high-intensity counties, 3/4 of ZCTAs were treated (i.e., Facebook users in those ZCTAs received ads) and 1/4 were not. In low-intensity counties, 1/4 of ZCTAs were treated and 3/4 were not."
62220472|NCT01096654|ACTIVE_COMPARATOR|Adrenal Vein Sampling|"This group will be treated according to the results of the adrenal vein sampling only. Adrenal vein sampling will be performed under the continuous infusion of ACTH (adrenocorticotropic hormone). A cortisol ratio ≥ 3 between the adrenal vein and the inferior vena cava is set as the criterium for successful cannulation. The criterium for lateralization is a aldosterone/cortisol ratio ≥ 4 between the adrenal veins and a lower aldosterone/cortisol ratio in the contralateral adrenal vein than in the inferior vena cava.~If AVS fails patients will be treated according to the CT-findings as described in the group with CT-scan only. Patients with a successful AVS will be treated by Adrenalectomy if unilateral production of aldosterone is shown. If no unilateral aldosterone production is present, i.e. the aldosterone/cortisol ratio is less than 4, patients will be treated by MRA."
62220473|NCT03989661||Test group|This group corresponds to patients who had undergone preoperative embolization (with resorbable material) before myomectomy.
62220474|NCT03989661||Control group|This group corresponds to patients with myomectomy without embolization.
62220475|NCT04899141||Coronary Artery Disease|
62220476|NCT02335931||Charcot foot|Patients with Charcot foot and diabetes mellitus 1 or 2
62220477|NCT02335931||No charcot foot|patients with diabetes mellitus type 1 or 2
62220478|NCT03226951|EXPERIMENTAL|Subtherhold 532 nm laser|Applying 532nm subtherhold laser with 5% duty cycle using high density low intensity protocol at the area of non central clinical significant macular edema
62220479|NCT02704663|EXPERIMENTAL|Transumbilical route|Transumbilical removal of benign adnexal masses via laparoscopy.
62220480|NCT02704663|ACTIVE_COMPARATOR|Lateral abdominal route|Lateral transabdominal removal of benign adnexal masses via laparoscopy.
62220481|NCT00910689|PLACEBO_COMPARATOR|1|Optimal Acute Therapy plus Beta Blocker Placebo
62220482|NCT00910689|ACTIVE_COMPARATOR|2|Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)
62220483|NCT00910689|ACTIVE_COMPARATOR|3|Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker placebo
62414831|NCT06423937|EXPERIMENTAL|Advanced non-MSI-H left-sided colorectal cancer|Advanced non-MSI-H left-sided colorectal cancer with liver metastasis after first-line standard treatment failure
62220484|NCT00910689|ACTIVE_COMPARATOR|4|Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)
62220485|NCT02220231|EXPERIMENTAL|capnothorax group|After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
62220486|NCT01759576|EXPERIMENTAL|Group 1 (normal kidney function)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
62220487|NCT01759576|EXPERIMENTAL|Group 2 (mild kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
62220488|NCT01759576|EXPERIMENTAL|Group 3 (moderate kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
62220489|NCT01759576|EXPERIMENTAL|Group 4 (severe kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
62414832|NCT06423937|EXPERIMENTAL|Advanced non-MSI-H right-sided colorectal cancer|Advanced non-MSI-H right-sided colorectal cancer with liver metastasis after first-line standard treatment failure
62587424|NCT01430988||Normal Control Group|A normal control group will be recruited for comparison and will consist of Emergency Department patients who have sustained an injury but do not exhibit any trauma above the clavicle and no history of Road Traffic Accident requiring an ED visit or TBI within the past one (1) year, and no primary complaint of syncope.
62587425|NCT01430988||Head Injured Control Group|A 'head injured' control group will be recruited and will consist of Emergency Department patients who are suspected or who have sustained a head injury but do not report or manifest symptoms, e.g. facial lacerations and/or whiplash.
62796175|NCT06652958|EXPERIMENTAL|Arm B, Cohort 9|Participants with HIV receive three doses of VH4527079 dose that is selected in Arm A, by IV infusion, separated by a time interval.
62023756|NCT00673049|EXPERIMENTAL|Arm A|"The CP 751,871 treatment in combination with erlotinib will be given in three week cycles.~CP 751,871 (20 mg/kg) + erlotinib (150 mg/day) CP 751,871 will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter."
62220490|NCT01759576|EXPERIMENTAL|Group 5 (hemodialysis)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1 following completion of hemodialysis. Approximately 10 days later, each volunteer will receive another single dose of canagliflozin before hemodialysis begins.
62220491|NCT05198011|EXPERIMENTAL|3D mandibular ridge augmentation|
62220492|NCT05198011|ACTIVE_COMPARATOR|Conventional mandibular ridge augmentation|
62220493|NCT02349373|ACTIVE_COMPARATOR|Preconditioning running|An 8 week preconditioning period. The variables of interest are running distance and running intensity: running speed \>80% VO2max (maximal oxygen uptake).
62414833|NCT02949219|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62587426|NCT03703011|EXPERIMENTAL|Interventional|Subjects aged \>70 years, hospitalized in the rehabilitation geriatric ward in the Paul Brousse hospital, France, able to walk 10 meters, ready to be discharged, and a Mini mental state examination ≥ 20/30
62796176|NCT01818596|EXPERIMENTAL|E/C/F/TAF|Participants will receive E/C/F/TAF for 144 weeks. Following Week 144, in countries where E/C/F/TAF is not available (except for the United Kingdom), participants will be given the option to continue in the study and receive E/C/F/TAF for another 48 weeks, or until the product becomes available through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever comes first.
62796177|NCT05864326|EXPERIMENTAL|Warm group|The Balloon Catheter will be filled with heated saline water up to 40° C
62796178|NCT05864326|ACTIVE_COMPARATOR|Room temperature group|the Balloon Catheter will be filled with saline water at room temperature.
62796179|NCT02506634||Participants with upper gastrointestinal symptoms|Participants are stratified at baseline based on their main upper gastrointestinal symptoms and then evaluated for GERD using different methods (i.e., reflux esophagitis on endoscopy or positive acid exposure time (AET) on reflux monitoring). Patients would then be given Esomeprazole MUPS（ Multiple Unit Pellet System）20 mg bid for evaluating the ability of the PPI Test for GERD. According to the guidelines, the duraion of PPI treatment was 4 weeks and 8 weeks for endoscopy negative patients and patients has reflux esophagitis, respectively.
62796180|NCT02458573|EXPERIMENTAL|continuous epidural analgesia group|
62796181|NCT02458573|ACTIVE_COMPARATOR|continuous intravenous analgesia group|
62220494|NCT02349373|ACTIVE_COMPARATOR|Follow-up period|"The Volume group progress 23% in total weekly running distance in the last adaptation week in the prior 4 week block.~The Intensity group progress 23% in weekly distance of running above 80% VO2 max (maximal oxygen uptake), based on the distance of running above 80% VO2max in the last adaptation week in the prior 4 week block."
62220495|NCT01321320|EXPERIMENTAL|Active stimulation|This group will receive active muscle stimulation for 1 week to the quadriceps muscle - the leg will be randomly assigned.
62220496|NCT05391737||patients with SIPE|"Adult patients (age ≥18 years) with SIPE-diagnosis during Vansbrosimningen and peripheral oxygen saturation ≤95%. SIPE-diagnosis based on pulmonary edema on lung ultrasound."
62220497|NCT05391737||control group|"Swimmers completing Vansbrosimningen without respiratory symptoms or signs of pulmonary edema on lung ultrasound. Matched to patients with SIPE for age and gender."
62220498|NCT02863497|ACTIVE_COMPARATOR|Mindfulness Intervention|For those randomly selected to receive mindfulness-based sex therapy, they will be asked to participate in four sessions of group therapy, over a period of 2 months. Sessions will occur in a conference room at St. Paul's Hospital. Part of the protocol of the Mindfulness - based sex therapy is that they will have a diary to be filled in. This diary will not be collected at the end of the therapy, as it is for the participant to keep. The group facilitators will be collecting session attendance.
62220499|NCT02863497|NO_INTERVENTION|No Intervention|For those who are not in the intervention group they will simply be asked to fill the initial questionnaire and the 3 month post questionnaire. They will not participate in any other questionnaires.
62220500|NCT05560347|EXPERIMENTAL|Experimental Group|Hot water will be applied to the participants in the experimental group at the 2nd and 6th hours postoperatively. During the hot water application, the feet of the individual will be immersed in the hot water application device and kept in the device for 20 minutes. At the end of the 20th minute, the feet of the individual will be removed from the device and dried with a towel for 10 minutes and the application will be completed. The data will be obtained by using the Introductory Information Form, Visual Analog Scale (VAS), Postpartum Comfort Scale and Post Cesarean Patient Evaluation Form.
62220501|NCT05560347|NO_INTERVENTION|Control Group|Routine care will be given to the control group
62220502|NCT05468359|OTHER|Treatment|All participants will receive Atezolizumab, Bevacizumab,Sorafenib and cyclophosphamide until maximum tolerated dose is reached.Tolerability will be defined after completion of Course 1. Part 2 will begin once the recommended phase 2 dose (RP2D) is determined.
62220503|NCT00329511|ACTIVE_COMPARATOR|A|methyldopa
62220504|NCT00329511|ACTIVE_COMPARATOR|B|clonidine patch
62220505|NCT04703738|ACTIVE_COMPARATOR|Control|Soft tissue flap + Connective Tissue Graft
62796182|NCT03725384|EXPERIMENTAL|Ferrous Sulfate and Vitamin C every other day|Ferrous sulfate 300mg tablet and vitamin C 500mg tablet taken by mouth every other day for 12 weeks
62796183|NCT03725384|ACTIVE_COMPARATOR|Ferrous Sulfate and Vitamin C daily|Ferrous sulfate 300mg tablet and vitamin C 500mg tablet taken by mouth every day for 12 weeks
62796184|NCT05234957|ACTIVE_COMPARATOR|Group 1|Symmetric bilateral lateral rectus recession (S-BLR). The amount of bilateral lateral rectus recession is equally divided between both eyes.
62796185|NCT05234957|ACTIVE_COMPARATOR|Group 2|Asymmetric bilateral lateral rectus recession (A-BLR). The amount of bilateral lateral rectus recession is asymmetrically divided between both eyes, with 2mm more recession in the non-dominant eye.
62796186|NCT03214354|EXPERIMENTAL|Non-myeloablative conditioning|Non-myeloablative conditioning
62796187|NCT04494620|NO_INTERVENTION|Control Arm|Standard of Care
62796188|NCT04494620|ACTIVE_COMPARATOR|Intervention Arm|Visual Inspection of Oral Cavity for Precancers and Cancer
62796189|NCT06357039||Female|Participants aged 18-65 who identify as female for biological
62796190|NCT06357039||Male|Participants aged 18-65 who identify as male for biological
62796191|NCT03335410||shoulder surgery|18-85 years, undergoing day case shoulder surgery during 15th Sept- 15th Oct 2017, possibility to e-mail and an internet connection, understands Finnish,
62796192|NCT03343626|PLACEBO_COMPARATOR|Flavivirus-naïve Cohort: Placebo|Placebo injection, intramuscular (IM), once on Day 1 (first dose) and Day 29 (second dose).
62796193|NCT03343626|EXPERIMENTAL|Flavivirus-naïve Cohort: PIZV 2 mcg (Low Dose)|PIZV 0.5 mL, 2 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
62796194|NCT03343626|EXPERIMENTAL|Flavivirus-naïve Cohort: PIZV 5 mcg (Medium Dose)|PIZV 0.5 mL, 5 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
62796195|NCT03343626|EXPERIMENTAL|Flavivirus-naïve Cohort: PIZV 10 mcg (High Dose)|PIZV 0.5 mL, 10 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
62796196|NCT03343626|PLACEBO_COMPARATOR|Flavivirus-primed Cohort: Placebo|Placebo injection, IM, once on Day 1 (first dose) and Day 29 (second dose).
62796197|NCT03343626|EXPERIMENTAL|Flavivirus-primed Cohort: PIZV 2 mcg (Low Dose)|PIZV 0.5 mL, 2 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
62796198|NCT03343626|EXPERIMENTAL|Flavivirus-primed Cohort: PIZV 5 mcg (Medium Dose)|PIZV 0.5 mL, 5 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
62796199|NCT03343626|EXPERIMENTAL|Flavivirus-primed Cohort: PIZV 10 mcg (High dose)|PIZV 0.5 mL, 10 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
62796200|NCT03590314|EXPERIMENTAL|Experimental group|The experimental group was treated using a robot assisted arm training, Armotion (Reha Technology, Olten, Switzerland).
62796201|NCT03590314|ACTIVE_COMPARATOR|Control group|The control group was treated using a conventional training, without end effector robot.
62796202|NCT06723665|EXPERIMENTAL|18F-PSMA-1007|"Subjects: Patients with suspected or diagnosed prostate cancer, or biochemical recurrence of prostate cancer.~Over 40 years old (including 40 years old); Informed consent and access to follow-up; To exclude patients who are difficult to receive further diagnosis and treatment because of their serious condition.~PSMA PET/CT was reviewed 7 days and 3 months after surgery. All patients were followed up once every 3 months to understand the progression and survival of the lesions."
62796203|NCT06723665|ACTIVE_COMPARATOR|18F-FDG|The corresponding patients underwent PSMAPET/CT examination within one week before and after routine 18F-FDGPCT/CT imaging (control examination). PCT/CT whole body scan was performed 45min-1h after intravenous injection of the developer, and the image processing was as usual.
62796204|NCT05919511||At risk for GVHD|Equal or Greater than 18 years old post alloSCT
62796205|NCT01131910|EXPERIMENTAL|Vaccination against TBE|"Less than 60 years old: Two doses of TBE- vaccine separated by a month and a third dose 12 months after the first dose~60 years and above: Three doses, given at 0+1+3 months and a 4 th dose 12 months after the first dose"
62796206|NCT03420872||Subset from PROGRESS cohort|Participants included children 4-6 years of age from mother-child pairs in the Programming Research in Obesity, Growth Environment and Social Stress (PROGRESS) prospective birth cohort in Mexico City
62796207|NCT01940757|EXPERIMENTAL|Cohort 1 (25 Necator americanus Hookworm Larvae)|A dose of 25 Necator americanus Hookworm Larvae, administered via a sterile absorbent pad fixed with a transparent adhesive dressing for at least 1 hour.
62796208|NCT01940757|EXPERIMENTAL|Cohort 2 (50 Necator americanus Hookworm Larvae)|A dose of 50 Necator americanus Hookworm Larvae, administered via a sterile absorbent pad fixed with a transparent adhesive dressing for at least 1 hour.
62023757|NCT00673049|ACTIVE_COMPARATOR|Arm B|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food)
62220506|NCT04703738|EXPERIMENTAL|Test|Soft tissue flap + Geistlich Fibro-Gide®
62796209|NCT01940757|EXPERIMENTAL|Cohort 3 (75 Necator americanus Hookworm Larvae)|A dose of 75 Necator americanus Hookworm Larvae, administered via a sterile absorbent pad fixed with a transparent adhesive dressing for at least 1 hour.
62796210|NCT00986843|EXPERIMENTAL|HM30181AK tablet + Irinotecan tablets|HM30181AK tablet + Irinotecan tablets
62796211|NCT05697341|ACTIVE_COMPARATOR|Ultra-Mini-PCNL Group (A)|In The Ultra-Mini-percutaneous nephrolithotomy group, a 5 Fr open-ended ureteral catheter was introduced and a retrograde pyelogram was performed in the Lithotomy position after the induction of general anesthesia. Patients were then repositioned to the prone position. Ultra-mini-PCNLs were done in a prone position by a single consultant. The desired calyx was punctured with a Cook diamond tip 18G puncture needle under fluoroscopy guidance using standard bull's eye technique. Single tract dilatation with One Step Dilator (11Fr), with central channel for guide wires with its Operating Sheath (Storzz Dilator and Operating Sheaths for MIP XS) under fluoroscopy guidance. Storzz Nephroscope for MIP XS / S along with Swiss Lithoclast master pneumatic lithotripter with 1/0.8 mm probe was used for stone fragmentation. Stone fragments are flushed out on rapid removal of the endoscope, due to a 'vortex' effect and with wash through the operating sheath using a 6 Fr. nelaton catheter.
62796212|NCT05697341|ACTIVE_COMPARATOR|Stented SWL Group (B)|In the stented ESWL group, a 5 Fr open-ended ureteral catheter was introduced in the renal pelvis, and a retrograde pyelogram was performed in the Lithotomy position after the induction of general anathesia. JJ is applied either 5-26 or 5-28 accorging to the patient. Extracorporeal shock wave lithotripsy ESWL was administered with an electromagnetic shockwave lithotripter (Siemens electromagnetic lithotripters devices). Patients were positioned supine with the shock head from the back. Fluoroscopy was used for the localization and monitoring of stone fragmentation. All patients received shocks at a frequency of 60/min. An average of approximately 2500-3000 shocks was targeted in all patients.
62023758|NCT04307212|ACTIVE_COMPARATOR|Trained|Participants who have been CrossFit training at least 3 times per week for the previous 3 months. These individuals will be invited in person to participate in the study.
62220507|NCT00913237|EXPERIMENTAL|1|Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)
62220508|NCT00913237|ACTIVE_COMPARATOR|2|Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)
62220509|NCT01347801|PLACEBO_COMPARATOR|2C - 1|TNF and OGTT and saline
62220510|NCT01347801|ACTIVE_COMPARATOR|2C - 2|TNF and OGTT and GLP-1
62220511|NCT01347801|PLACEBO_COMPARATOR|2C - 3|TNF and IVGTT and saline
62796213|NCT05373862|EXPERIMENTAL|Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter|Participants with cardiac arrhythmias/ablation history who are scheduled to have a clinically-indicated catheter mapping and ablation procedure of arrhythmia management for atrial and ventricular procedures will be using multi-electrode mapping catheter.
62023759|NCT04307212|ACTIVE_COMPARATOR|Untrained|Nonactive/non--exercise trained participants who have participated in any type of exercise no more than 2 times per week for the past 3 months. These individuals will be recruited from the general public.
62220512|NCT01347801|ACTIVE_COMPARATOR|2C - 4|TNF and IVGTT and GLP-1
62220513|NCT01347801|PLACEBO_COMPARATOR|2A-1|Saline infusion and OGTT
62796214|NCT06627283|ACTIVE_COMPARATOR|IMT|
62796215|NCT06627283|ACTIVE_COMPARATOR|EMT|
62220514|NCT01347801|PLACEBO_COMPARATOR|2A-2|Saline and IVGTT
62796216|NCT06627283|SHAM_COMPARATOR|Sham|
62796217|NCT06627283|NO_INTERVENTION|Control|
62220515|NCT01347801|ACTIVE_COMPARATOR|2A-3|TNF and OGTT
62796218|NCT04486378|EXPERIMENTAL|RO7198457|Participants will receive a recommended dose of RO7198457.
62796219|NCT04486378|OTHER|Observational Group|Observational group will undergo watchful waiting, which is the standard of care in this setting.
62796220|NCT04486378|EXPERIMENTAL|Biomarker Cohort|
62796221|NCT04486378|EXPERIMENTAL|Exploratory Cohort|
62796222|NCT04486378|EXPERIMENTAL|Colorectal Liver Metastasis (CLM) Cohort|
62796223|NCT06726252|EXPERIMENTAL|Validation of OUFR using wire-based FFR measurement as the gold standard|Participants undoing anticipated percutaneous coronary intervention will be performed wire-based FFR measurement and intravascular imaging, including IVUS and integrated OCT-IVUS using a single catheter, to assess the sensitivity, specificity and oter performance measures of OUFR, using wire-based FFR as the gold standard.
62796224|NCT05658588|EXPERIMENTAL|Hemoperfusion and CKRT in pediatric septic shock|Hemoperfusion with Cytosorb in combination with CKRT
62220516|NCT01347801|ACTIVE_COMPARATOR|2A-4|TNF and IVGTT
62220517|NCT01347801|EXPERIMENTAL|1C|OGTT and corresponding IVGTT
62220518|NCT01181323|EXPERIMENTAL|Group 1: LAIV|0.2 ml of Live attenuated influenza vaccine (LAIV), Flumist® given intranasally (IN) and 0.5 ml of placebo given intramuscularly (IM) injection administered to 120 maternal subjects.
62220519|NCT01181323|EXPERIMENTAL|Group 2: TIV|0.5 ml of Inactivated Trivalent Influenza Vaccine (TIV), Fluzone® given intramuscularly (IM) and 0.2 ml of placebo given intranasally (IN) administered to 120 maternal subjects.
62220520|NCT03594604|EXPERIMENTAL|Norethindrone|Delaying menstruation using Norethindrone 5mg three times daily in women who desire postponement of their period for social or personal reasons.
62220521|NCT03594604|ACTIVE_COMPARATOR|Oral Contraceptive Pills|Women who desire postponing their periods are typically treated with oral contraceptive pills, the current standard of care.
62796225|NCT04273893|EXPERIMENTAL|SBRT Additional treatment planning dose optimization|Lung SBRT 50-60Gy in 5 fractions with standard of care planning and additional treatment planning dose optimization criteria to minimize decrease in lymphocyte count beyond dosimetric criteria from RTOG 0915/0813 SBRT trials.
62796226|NCT04273893|ACTIVE_COMPARATOR|SBRT with standard of care planning only|Lung SBRT 50-60Gy in 5 fractions with standard of care planning (no additional dose optimization beyond SOC)
62796227|NCT02223338|ACTIVE_COMPARATOR|Ciprofloxacin|"Ciprofloxacin:~Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These patients must have been instructed to use post-injection topical ciprofloxacin 0.3% 4x daily for 3 days. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops."
62796228|NCT02223338|ACTIVE_COMPARATOR|Standard Aseptic Technique|"Standard Aseptic Technique:~Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These injections must have been given with povidone-iodine only applied to the injection site and conjunctival fornix prior to injection, but no post-injection antibiotics were given. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops."
62023760|NCT01908777|EXPERIMENTAL|high dose chemo w/asct + maintenance txt|High dose chemotherapy (Carmustine), VP-16 (etoposide, Vepesid®), Cytarabine (Ara-C), Melphalan (Alkeran)with autologous stem cell transplant followed by maintenance therapy with Romidepsin (Istodax)
62023761|NCT02763384|EXPERIMENTAL|Arm 1: BL-8040 and Nelarabine|"* Cycle 1: BL-8040 subcutaneous daily from Day 1 to Day 6 and nelarabine intravenously over 2 hours on Days 2, 4, and 6~* Cycles 2-4: BL-8040 subcutaneous daily from Day 1 to Day 5 and nelarabine intravenously over 2 hours on Days 1, 3, and 5~* Treatment may be repeated every 21 days for up to 4 cycles"
62023762|NCT02359669|ACTIVE_COMPARATOR|Growing up milk (GUM)|GUM associated with StimuLearn intervention.
62023763|NCT02359669|PLACEBO_COMPARATOR|Skimmed Milk|Control group given skimmed milk without StimuLearn intervention.
62220522|NCT06610422||Inactive stage|patients diagnosed as SLE and lupus nephritis (inactive stage)
62220523|NCT06610422||Active stage|patients diagnosed as SLE and lupus nephritis (active stage)
62414834|NCT06594289|NO_INTERVENTION|Control group|Group A (Pringle method + restricted fluid management + use of vasoactive drugs by anesthesiologists) : The means of use and anesthetic drugs in this group were all conventional technical means without special intervention, so it was the control group.
62796229|NCT01151371|EXPERIMENTAL|narafilcon B daily disposable 4 weeks|narafilcon B soft contact lenses worn daily on a daily disposable/replacement schedule, for 4 weeks
62220524|NCT06610422||Control|patients control group not SLE
62220525|NCT06609447|EXPERIMENTAL|VSL#3 combine with Vedolizumab Arm|"Treatment with probiotic VSL#3 combined with vedolizumab; Subjects will receive two sachets daily of VSL#3, each containing 450 billion bacteria (totaling 900 billion bacteria per day), for 14 weeks.~Vedolizumab will be administere as per clinical practice with the following schedule: 300 mg ev at 0, 2 and 6, 14 weeks."
62220526|NCT06609447|PLACEBO_COMPARATOR|Placebo combine with Vedolizumab Arm|Treatment with placebo combined with vedolizumab; Subjects will receive two sachets daily of Placebo for 14 weeks. Vedolizumab will be administere as per clinical practice with the following schedule: 300 mg ev at 0, 2 and 6, 14 weeks.
62220527|NCT01912560|EXPERIMENTAL|CAT-2003 or Placebo Dose 1|Daily for 28 days in patients with moderate hypertriglyceridemia
62414835|NCT06594289|EXPERIMENTAL|Observation group|Group B (Pringle method +IVC flow limiting and blocking method + open fluid intake during operation; Observation group: Patients in this group did not use anesthesia related drugs to control CVP, so they should strictly communicate with the anesthesiologist, and achieve homogeneity in the use of vasoactive drugs and narcotic drugs.
62414836|NCT04125160||Type 2 diabetes and peritoneal dialysis|Case group with type 2 diabetes undergoing peritoneal dialysis for at least 3 months.
62796230|NCT01151371|ACTIVE_COMPARATOR|nelfilcon A daily disponsable 1 week|nelfilcon A soft contact lenses worn daily on a daily disposable/replacement schedule, for 1 week
62796231|NCT01151371|ACTIVE_COMPARATOR|lotrafilcon B daily wear, monthly replacement, 4-weeks|lotrafilcon B soft contact lenses worn daily on a 1-month replacement schedule, for 4 weeks
62796232|NCT06725485|EXPERIMENTAL|Low-Dose Lidocaine Infusion|Low-dose lidocaine infusion 10-30 mcg/kg/min administered within 1 hour of ICU admission.
62796233|NCT02781220||Qualifying participants|All consented IDEAS trial participants will have additional data collected: visual and semi-quantitative software aided amyloid PET scan interpretation, care partner questionnaires and documented provider diagnosis, diagnostic confidence, and management plan following the IMPACT design
62796234|NCT06040099|EXPERIMENTAL|Yttrium 90 glass microspheres TARE in combination with Durvalumab and Bevacizumab|Participants will undergo Yttrium 90 glass microspheres TARE according to the dosimetry recommendation.
62587427|NCT02023411|ACTIVE_COMPARATOR|teriparatide|10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive 20 microgram of teriparatide , subcutaneous between 8-9 p.m., daily.
62796235|NCT06462183|EXPERIMENTAL|Dose escalation|RGT-61159 in escalating doses
62796236|NCT06462183|EXPERIMENTAL|Dose expansion Cohort A|Dose optimization; RGT-61159, 2 doses, randomized allocation
62023764|NCT05450432|OTHER|Ketamine and Esketamine Treatment|All study subjects will receive intravenous (IV) ketamine and intranasal (IN) esketamine treatment.
62023765|NCT02956330||CLS1003-201|Those subjects whose parent study primary investigator has access to their medical records, following exit from CLS1003-201.
62023766|NCT00680316|EXPERIMENTAL|Dornase alfa|
62023767|NCT00680316|PLACEBO_COMPARATOR|Placebo|
62023768|NCT01329029|ACTIVE_COMPARATOR|Roflumilast|concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
62220528|NCT01912560|EXPERIMENTAL|CAT-2003 or Placebo Dose 2|Daily for 28 days in patients with moderate hypertriglyceridemia
62220529|NCT01912560|EXPERIMENTAL|CAT-2003 or Placebo Dose 3|Daily for 28 days in patients with moderate hypertriglyceridemia
62220530|NCT01912560|EXPERIMENTAL|CAT-2003 or Placebo Dose 4|Daily for 28 days in patients with hypercholesterolemia who are on a statin
62220531|NCT04750785||All Participants|Participants who have been diagnosed with CHM will be enrolled.
62220532|NCT06078137|EXPERIMENTAL|Intervention Group|Patients randomized to intervention receive both usual Patient reported outcome measure (PROM) and new PROMs strategy (on the technology platform for English speakers and on REDCap/Qualtrix for Spanish Speakers) done after rooming.
62220533|NCT06078137|NO_INTERVENTION|Control group|Patients go through the registration process which includes PROMs completion using Ipads. Enrolled in the room at the end of the visit.
62414837|NCT04125160||Type 2 diabetes and eGFR above 60ml/min|Control group with type 2 diabetes and no nephropathy (defined as eGFR above 60ml/min and UACR below 300mg/g).
62414838|NCT04344782|EXPERIMENTAL|Bevacizumab|
62414839|NCT04344782|NO_INTERVENTION|Standard of Care|
62414840|NCT04056091|EXPERIMENTAL|Back rub stimulation|
62796237|NCT06462183|EXPERIMENTAL|Dose expansion Cohort B|Simon's 2 stage, RGT-61150 at optimized dose from Part A
62796238|NCT05681065|NO_INTERVENTION|Control group|Standard practice. Patients will receive the usual clinical care based on the transmission of information and advice, and review according to the Clinical Practice Guidelines corresponding to the various chronic diseases presented by the patient.
62796239|NCT05681065|EXPERIMENTAL|Intervention Group|Standard practice. Patients will receive the usual clinical care based on the transmission of information and advice, and review according to the Clinical Practice Guidelines corresponding to the various chronic diseases presented by the patient. In addition, these participants will be provided with the TeNDER technological tool. The TeNDER intervention consists of the use of the TeNDER technological tool. It is a web application that integrates all the functionalities of the biosensors to facilitate patient self-monitoring, caregiver care and monitoring and management in the daily work of health professionals.
62796240|NCT02534363|ACTIVE_COMPARATOR|Aripiprazole & cognitive battery|Aripiprazole 5-30 mg/day. Cognitive battery at baseline and at 1 year.
62796241|NCT02534363|ACTIVE_COMPARATOR|Quetiapine & cognitive battery|Quetiapine 100-600 mg/day. Cognitive battery at baseline and at 1 year.
62796242|NCT02534363|ACTIVE_COMPARATOR|Ziprasidone & cognitive battery|Ziprasidone 40-160 mg/day. Cognitive battery at baseline and at 1 year.
62796243|NCT02327676|EXPERIMENTAL|naive child CHB group|200 patients take generic emtricitabine capsule(200 mg one time per day) for 48 weeks
62796244|NCT02782286|ACTIVE_COMPARATOR|Ketorolac|The patients randomised to this arm will receive 30 mg intravenous ketorolac.
62796245|NCT02782286|ACTIVE_COMPARATOR|Morphine|The patients randomised to this arm will receive 0,1 mg/kg intravenous morphine.
62796246|NCT03374579|EXPERIMENTAL|CO2 gap|The patients will receive fluid bolus and observe changes in co2 gap and gap/ ratio in them.
62796247|NCT03162822|ACTIVE_COMPARATOR|Cognitive Intervention|The cognitive intervention has parents come up with reasons why their children do things they don't like, until they come up with benign attributions for those behaviors.
62796248|NCT03162822|ACTIVE_COMPARATOR|Behavioral Intervention|The behavioral intervention has the parents develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
62796249|NCT03162822|ACTIVE_COMPARATOR|Interpretation Bias Intervention|"The Interpretation Bias intervention has parents look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
62023769|NCT01329029|PLACEBO_COMPARATOR|Placebo|concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
62414841|NCT04056091|ACTIVE_COMPARATOR|Foot flicks stimulation|
62414842|NCT02394379||Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
62587428|NCT02023411|PLACEBO_COMPARATOR|placebo|10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive placebo , subcutaneous between 8-9 p.m. , daily.
62796250|NCT03162822|ACTIVE_COMPARATOR|Evaluative Conditioning Intervention|The Evaluative Conditioning intervention presents parents with pictures of ambiguous child faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., sweet; cooperative).
62796251|NCT02035527|EXPERIMENTAL|Treatment (sorafenib tosylate, docetaxel, and cisplatin)|Patients receive sorafenib tosylate PO BID on days 1-14 of course 0. Beginning in course 1, patients receive sorafenib tosylate PO BID on days 1-21, docetaxel IV over 1 hour on day 1, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity.Correlative studies will be performed and a total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
62023770|NCT03557437|ACTIVE_COMPARATOR|Triple Therapy|Esomeprazole 20mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
62023771|NCT03557437|EXPERIMENTAL|Bismuth Plus Triple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
62023772|NCT04231630|OTHER|Observational Case|1 infant will be enrolled as an observational case. Will receive an exclusive human milk diet at home.
62023773|NCT02488434|ACTIVE_COMPARATOR|fertile chip|sperm selection by using fertile chip and conventional methods
62023774|NCT02488434|NO_INTERVENTION|classical ICSI procedure|unexplained infertile couples who will be undertaken intracytoplasmic sperm injection (ICSI) for fertilisation
62023775|NCT05599594|EXPERIMENTAL|Neroli oil|Neroli oil improves the quality of life by reducing premenstrual symptoms with relaxing and calming effect.
62023776|NCT05599594|EXPERIMENTAL|Lemongrass oil|Lemongrass oil improves the quality of life by reducing premenstrual symptoms with relaxing and calming effect.
62220534|NCT00134745|ACTIVE_COMPARATOR|4 mg estradiol|
62414843|NCT06326112|EXPERIMENTAL|Active deresuscitation|"* Fluid minimization: clinical and research teams will review all intravenous orders and attempt to reduce fluids to 10-15 ml/hr.~* Active deresuscitation:~* Administer bolus furosemide 0.5 mg/kg bid or tid~* Target daily negative fluid balance as follows:~Calculated positive balance:~\< 3 liters -600 - -800 ml/24 hours 3-6 liters 0.8 - 1.2 liters/24 hours 6- 10 liters 1.2 - 2.0 liters/24 hours \>10 liters \>2.0 liters/24 hours~* If bolus furosemide fails to achieve these goals, results in hypotension or tachycardia, or at the discretion of the attending intensivist, start furosemide infusion titrated on an hourly basis to achieve above goals~* If single agent ineffective, consider addition of metolazone"
62414844|NCT06326112|NO_INTERVENTION|Usual care|Care at the discretion of the attending team.
62796252|NCT00924196||Biologic parents of children and adults with NFI|Biologic parents of children and adults with NFI will be evaluated at one time point, using a Neuropsychological Test Battery and QOL Assessment. Closed to enrollment
62796253|NCT00924196||Children and adults with NFI|Children and adults with NFI whose tumor and non tumor related manifestations will be longitudinally evaluated. Closed to enrollment
62796254|NCT00924196||Unaffected siblings of children and adults with NFI|Unaffected siblings of children and adults with NFI will be evaluated at one time point using a Neuropsychological Test Battery and QOL Assessment. Closed to enrollment
62023777|NCT04106999|PLACEBO_COMPARATOR|Placebo|Normal Saline will be infused as per the protocol
62587429|NCT06308302|EXPERIMENTAL|Group A|Group A (Inspiratory Muscles Training +Aerobic Interval Training)
62796255|NCT04182815||Robotic assisted bronchoscopy|Robotic assisted bronchoscopy procedures will be performed using the Monarch platform.
62220535|NCT00134745|PLACEBO_COMPARATOR|2 mg estradiol|
62220536|NCT03102645|EXPERIMENTAL|Imipramine first|A: Imipramine Hydrochloride 25 MG x2 B: Placebo Oral Tablet x2
62414845|NCT04059861|OTHER|ultrasound assisted resection|resection of tongue cancer will be done with assistance of ultrasound to visualise the deep margin.
62414846|NCT05266807|EXPERIMENTAL|SoC + oral Fecal Microbiota Transplantation|Antibiotic (vancomycin 125 mg 4 times daily or fidaxomicin 200 mg 2 times daily, as initially prescribed per SoC) for 10 days, followed 12h to 4 days later by one oral FMT (20 capsules administered at D1 and 20 capsules at D2), and a second oral FMT if CDI is severe.
62414847|NCT05266807|ACTIVE_COMPARATOR|SoC|Antibiotic (vancomycin 125 mg 4 times daily or fidaxomicin 200 mg 2 times daily, as initially prescribed per SoC) for 10 days.
62796256|NCT06655155|EXPERIMENTAL|Efgartigimod PH20 SC|Participants receiving efgartigimod PH20 SC
62796257|NCT06655155|PLACEBO_COMPARATOR|Placebo PH20 SC|Participants receiving placebo PH20 SC
62796258|NCT05720390|ACTIVE_COMPARATOR|Quinine only|In this arm, participants will receive a 10 ml intragastric bolus of 300 mg quinine followed 30 min later by 100 ml intragastric bolus of control for L-leucine.
62796259|NCT05720390|ACTIVE_COMPARATOR|L-leucine only|In this arm, participants will receive a 10 ml intragastric bolus of control for quinine followed 30 min later by 100 ml intragastric bolus of 5 g L-leucine.
62023778|NCT04106999|EXPERIMENTAL|Intervention group|Dexmedetomidine will be infused as per the protocol
62220537|NCT03102645|EXPERIMENTAL|Placebo first|A: Placebo Oral Tablet x2 B: Imipramine Hydrochloride 25 MG x2
62220538|NCT05223777|ACTIVE_COMPARATOR|KINCISE|The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument. As such, the focus of the study does not relate to the safety and efficacy of the device, which has already been established. Instead, the current IRB proposal investigates whether there are long-term benefits to patient outcomes that differ between KINCISE-guided versus mallet THA.
62414848|NCT06653478||Lung cancer group|Participants with lung cancer/pulmonary nodules
62414849|NCT06653478||Stomach cancer group|Participants with Stomach cancer/Stomach lesion
62414850|NCT06653478||Colorectal cancer group|Participants with Colorectal cancer/Colorectal lesion
62414851|NCT06039293|EXPERIMENTAL|Intervention|Participants will receive 10 cognitive behavioral therapy sessions and 6 physical activity sessions over 12 weeks. Participants in this group will also be assigned exercise goals. Exercise goals will be adapted to accommodate the physical and medical restrictions of older adults with type 2 diabetes. Exercise goals consistent with our prior trials will be used using a stepwise approach starting with 100 minutes of aerobic activity in week 1, 125 minutes in week 2 and 150 minutes in weeks 3 through 12. Exercise prescriptions will be based on the results obtained from the 6 Minute Walk Test obtained at baseline
62414852|NCT06039293|OTHER|Control|"Participants in the control group will receive enhanced usual care and will not take part in cognitive behavioral therapy sessions or exercise sessions. The EUC group will receive the American Diabetes Association Diabetes Basics web series (one video per week for 10 weeks) or Diabetes Basics handouts sent via mail."
62587430|NCT06308302|EXPERIMENTAL|Group B|Group B (Expiratory Muscles Training +Aerobic Interval Training)
62587431|NCT00756236|EXPERIMENTAL|M-Group|Patients were randomly assigned to Metoprolol Group. The drug was dispensed in 60ml \& 5ml syringes of 0.9% NaCl and 1mg/ml Metoprolol. Investigators and patients were blinded to the group assignment.
62587432|NCT00756236|EXPERIMENTAL|E-Group|Patients were randomly assigned to Esmolol Group. The drug was dispensed in 60ml \& 5ml syringes of 0.9% NaCl and 10mg/ml Esmolol. Investigators and patients were blinded to the group assignment.
62587433|NCT00756236|PLACEBO_COMPARATOR|P-Group|Patients were randomly assigned to this group. Patients received 0.9% NaCl only. To maintain the blind, 0.9% NaCl was also dispensed in 60ml \& 5ml syringes.
62023779|NCT04361357|EXPERIMENTAL|Experimental group|whey protein powder was added on the basis of standardized enteral nutrition preparation.
62023780|NCT04361357|NO_INTERVENTION|Control group|standardized enteral nutrition preparation only.
62023781|NCT04279808|EXPERIMENTAL|measured distance|"In the modified Seldinger's maneuver, after guide-wire insertion into the right internal jugular vein, we will measure the distance between the skin puncture site and the outside of anterior wall of the jugular vein. Next, we will insert the dilator on the guidewire by the measured length."
62220539|NCT05223777|PLACEBO_COMPARATOR|Traditional Mallet|A traditional mallet will be used during surgery in this group.
62587434|NCT06668727|EXPERIMENTAL|Group 1|Participants (n=4), will be enrolled in Group 1 (HepB mAb19 3 mg/kg or placebo, single dose) and randomized 3:1 to HepB mAb19 or placebo with each participant being dosed at least 72 hours apart. Following enrollment and administration of study drug in the first two participants, the Protocol Safety Review Team (PSRT) will review available safety data (including safety labs) and only following this review and in the absence of dose limiting toxicities (DLT), the remaining two participants in Group 1 will be enrolled and randomized to HepB mAb19 or placebo.
62023782|NCT04279808|NO_INTERVENTION|conventional method|"In the modified Seldinger's maneuver, after guide-wire insertion into the right internal jugular vein, we will insert the dilator on the guidewire as commonly used method of the practitioners."
62023783|NCT03524404|EXPERIMENTAL|Diabetes Prevention Program (DPP)|Live stream the first six sessions of the Diabetes Prevention Program (DPP) curriculum to Senior Planet on a weekly basis, The webinars will be about 1 hour long, led by a certified DPP educator, and live-streamed to the senior center. Participants will have weekly weigh-ins and meet with a research assistant led focus group following two out of the six sessions to discuss program acceptability.
62220540|NCT02946190|EXPERIMENTAL|Arm 1: Pertagen® aP + Td-pur®|BioNet-Asia recombinant acellular Pertussis vaccine (Pertagen®) given simultaneously with Td-pur® vaccine (Novartis/GSK) intramuscularly as a single dose on Day 0
62587435|NCT06668727|EXPERIMENTAL|Group 2|Participants (n=4), will be enrolled in Group 2 (HepB mAb19 10 mg/kg or placebo, single dose) and randomized 3:1 to HepB mAb19 or placebo with each participant being dosed at least 72 hours apart.
62587436|NCT06668727|EXPERIMENTAL|Group 3|Participants (n=4), will be enrolled in Group 2 (HepB mAb19 30 mg/kg or placebo, single dose) and randomized 3:1 to HepB mAb19 or placebo with each participant being dosed at least 72 hours apart.
62414853|NCT02263677|EXPERIMENTAL|Sitagliptin|60 day supply of 100mg Sitagliptin
62587437|NCT06668727|EXPERIMENTAL|Group 4|Participants (n=18) will enroll in Group 4 in an open-label fashion and will receive the MTD. Enrollment in Group 4 will begin after all 4 participants enrolled in the preceding dose group reach at least 28 days, none of the dose escalating halting criteria outlined above occur, and following review of available safety data by the PSRT
62587438|NCT04778943||oblique lateral interbody fusion (OLIF)|Patients with lumbar spinal stenosis undergoing oblique lateral interbody fusion (OLIF)
62023784|NCT01060865|EXPERIMENTAL|Aliskiren|only one arm with the experimental drug \[aliskiren\]
62587439|NCT04778943||minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)|Patients with lumbar spinal stenosis undergoing minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)
62587440|NCT03831360|EXPERIMENTAL|Hatha Yoga|12 weeks of hatha yoga
62587441|NCT03831360|EXPERIMENTAL|Group CBT|12 weeks of group CBT
62023785|NCT01995123|EXPERIMENTAL|Behavioral Activation Therapy|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding. In addition, this arm will receive standard smoking cessation therapy, nicotine patch, and either nicotine gum or nicotine lozenge.
62023786|NCT01995123|ACTIVE_COMPARATOR|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health. In addition, this arm will receive standard smoking cessation therapy, nicotine patch, and either nicotine gum or nicotine lozenge.
62220541|NCT02946190|ACTIVE_COMPARATOR|Arm 2: Boostrix® dTpa|Licensed Tetanus-diphtheria (reduced dose)-acellular Pertussis vaccine (Boostrix® dTpa; GSK) given intramuscularly as a single dose on Day 0
62587442|NCT02735512||Group I|Patients without cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and 4 months.
62220542|NCT04802616|EXPERIMENTAL|Polyvalent mechanical bacterial lysate|Treatment over 3 successive months with one daily sublingual tablet (7 mg of bacterial lysate) over 10 days followed by 20 days of rest.
62220543|NCT04802616|PLACEBO_COMPARATOR|Placebo|Treatment over 3 successive months with one daily sublingual tablet over 10 days followed by 20 days of rest.
62220544|NCT03212989|EXPERIMENTAL|VOR + HXTC arm|"This is an open label single arm study. All eligible participants receive the following interventions:~* Step 2 - Single dose of Vorinostat (VOR) 400 mg PO~* Step 4 - Vorinostat (VOR) 400 mg PO every 72 hrs x 10 doses and 2 HXTC infusions~* Step 5 - Vorinostat (VOR) 400 mg PO every 72 hrs x 10 doses and 2 HXTC infusions"
62220545|NCT05367115||Familial Amyloidotic Polyneuropathy|The Familial Amyloidotic Polyneuropathy patients are validated in the catastrophic illness certification.
62220546|NCT05367115||Osteogenesis imperfecta|The Osteogenesis imperfecta patients are validated in the catastrophic illness certification.
62220547|NCT05367115||(Acute Hepatic) Porphyria|The (Acute Hepatic) Porphyria patients are validated in the catastrophic illness certification.
62414854|NCT05844826|EXPERIMENTAL|Single Arm|Participant swallows and retrieves capsule in stool. Intestinal fluid samples collected by SIMBA capsules from the MS and HC participants, along with a fecal and blood samples, will be used for gut microbiome, viral and metabolomic analysis.
62414855|NCT00216073|ACTIVE_COMPARATOR|1|Capecitabine + Oxaliplatin + trastuzumab. Patients must be HER2 positive.
62414856|NCT05165173|EXPERIMENTAL|Intervention|Based on estimated glomerular filtration rate (eGFR) and vitamin D levels, participants will be placed into the nanoparticle group.
62587443|NCT02735512||Group II|Patients with localized bladder cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and within 4 weeks after cystectomy.
62220548|NCT05999695|EXPERIMENTAL|self-management interventions|"self-management interventions: According to the results of literature search and based on the theory of self-efficacy, the intervention measures of the self-management program were designed.~regular care:regular care"
62220549|NCT05999695|ACTIVE_COMPARATOR|regular care|regular care
62220550|NCT02851641||Nasolacrimal duct obstruction|
62220551|NCT00201890|EXPERIMENTAL|1|Standard of Care plus Lymphatic massage (Decongestive Lymphatic Therapy)
62220552|NCT00201890|NO_INTERVENTION|2|Standard of Care
62220553|NCT00618618|EXPERIMENTAL|Deoxycholic Acid Injection 0.2 mL/0.7 cm|Participants received deoxycholic acid administered in 0.2 mL injections, 0.7 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
62796260|NCT05720390|ACTIVE_COMPARATOR|Quinine + L-leucine|In this arm participants will receive a 10 ml intragastric bolus of 300 mg quinine followed 30 min later by 100 ml intragastric bolus of 5 g L-leucine.
62220554|NCT00618618|PLACEBO_COMPARATOR|Placebo 0.2 mL/0.7 cm|Participants received placebo administered in 0.2 mL injections, 0.7 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
62220555|NCT00618618|EXPERIMENTAL|Deoxycholic Acid Injection 0.2 mL/1.0 cm|Participants received deoxycholic acid administered in 0.2 mL injections, 1.0 cm apart, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
62220556|NCT00618618|PLACEBO_COMPARATOR|Placebo 0.2 mL/1.0 cm|Participants received placebo administered in 0.2 mL injections, 1.0 cm apart, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
62220557|NCT00618618|EXPERIMENTAL|Deoxycholic Acid Injection 0.4 mL/1.0 cm|Participants received deoxycholic acid administered in 0.4 mL injections, 1.0 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
62220558|NCT00618618|PLACEBO_COMPARATOR|Placebo 0.4 mL/1.0 cm|Participants received placebo administered in 0.4 mL injections, 1.0 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
62220559|NCT01791036|EXPERIMENTAL|Adductor Canal Block Group|Adductor Canal Block
62587444|NCT02735512||Group III|Patients with metastatic cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and within 4 weeks after completion of 4 courses of systemic chemotherapy.
62587445|NCT02015416|EXPERIMENTAL|IDC-G305|NY-ESO-1 recombinant protein together with GLA-SE
62220560|NCT01791036|ACTIVE_COMPARATOR|Femoral Nerve Block Group|Femoral Nerve Block
62220561|NCT00513604|EXPERIMENTAL|Cohort 1 - NMA, TIL, aldesleukin|"Cohort 1 - Nonmyeloablative (NMA), tumor infiltrating lymphocytes (TIL), \& high dose (HD) aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by bulk young tumor infiltrating lymphocytes and high dose aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m\^2 intravenous (IV) daily x 5 days. Bulk young TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 1 = unselected TIL"
62220562|NCT00513604|EXPERIMENTAL|Cohort 2 - NMA, CD4+ TIL, aldesleukin|"Cohort 2 - Nonmyeloablative (NMA), cluster of differentiation 4 (CD4+) depleted tumor infiltrating lymphocytes (TIL), aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by CD4+ depleted tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m\^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 2 = CD4+ depleted (selected) TIL"
62220563|NCT00513604|EXPERIMENTAL|Cohort 3 - NMA, total body irradiation|"Cohort 3 - Nonmyeloablative (NMA), total body irradiation (TBI):~Nonmyeloablative chemotherapeutic conditioning regimen and 2 gray units (Gy) of total body irradiation followed by cluster of differentiation 4 (CD4+) depleted tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m\^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL 2Gy (gray units) of total body irradiation (TBI) twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute using a linear accelerator in Radiation Oncology Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 3 = CD4 + depleted (selected) TIL + 600Gy radiation"
62220564|NCT00513604|EXPERIMENTAL|Cohort 4 - NMA, young TIL, aldesleukin|"Cohort 4 - Nonmyeloablative (NMA), tumor infiltrating lymphocytes (TIL), aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by bulk young tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m\^2 intravenous (IV) daily x 5 days. Bulk young TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 4 = unselected TIL - it is the SAME as cohort 1"
62414857|NCT05165173|ACTIVE_COMPARATOR|Comparator|Based on the estimated glomerular filtration rate (eGFR) and vitamin D levels, participants will be placed into the microparticle group.
62414858|NCT01125007|ACTIVE_COMPARATOR|toothbrush|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
62587446|NCT01585753||Arm 1|NRTI and PI
62587447|NCT01585753||Arm 2|Maraviroc + PI
62587448|NCT01585753||Arm 3|maraviroc + NRTI
62587449|NCT01866657|EXPERIMENTAL|Intervention cohort|Open cerebral oximetry monitoring; observed desaturations will be treated with an intervention algorithm including increase FiO2, head/neck repositioning,vasoconstrictor agents, IV fluid bolus, increase ETCO2, additional anesthesia, RBC transfusion.
62023787|NCT02507089|EXPERIMENTAL|Intervention|In this arm, the participants will receive access to a password protected website that features tailored information and educational materials on sleep health and the signs of sleep disorders such as obstructive sleep apnea (OSA). There will be both text-based information on sleep health and OSA, and also videos depicting narrative stories about patients who have been diagnosed with OSA and sought treatment.
62023788|NCT02507089|ACTIVE_COMPARATOR|Control|In this arm, participants will receive access to generic sleep educational materials that do not feature linguistic or cultural tailoring to the target population. This arm will include access to the same general information (materials on sleep health, sleep disorder signs and symptoms) but be intended for a general audience.
62023789|NCT05153434|EXPERIMENTAL|ARD-101|First week 400 mg of ARD-101 twice daily, second week 600 mg of ARD-101 twice daily, third week 800 mg of ARD-101 twice daily, fourth week 800 mg of ARD-101 twice daily.
62023790|NCT00059813|EXPERIMENTAL|Treatment (recombinant interferon alfa, oblimersen sodium)|Patients receive oblimersen IV continuously on days 1-7 and interferon alfa subcutaneously on days 4, 6, 8, 10, and 12 of course 1 and on days 1, 3, 5, 8, 10, and 12 of all subsequent courses. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive an additional 2 courses past CR.
62023791|NCT05648591|EXPERIMENTAL|Iloperidone|Open-label iloperidone
62023792|NCT01462994|NO_INTERVENTION|Single arm|
62023793|NCT03022851|EXPERIMENTAL|Occlutech AFR Device|Patients who will get the AFR Device implantation
62023794|NCT06296173|EXPERIMENTAL|Open lung extubation|Before emergence from anesthesia, the patient will be positioned at 30 degrees, and oropharyngeal secretions will be suctioned. Anesthetic gas or intravenous agents will be stopped. Oxygen levels will be set to 50% with a fresh gas flow of at least 10 L/min. Ventilation mode will switch to pressure support adjusted to achieve similar volumes as controlled ventilation. PEEP levels will remain unchanged, while the minimum respiratory rate will decrease by 4 breaths/min. The inspiratory flow for triggering will be set at 2 L/min.
62023795|NCT06296173|ACTIVE_COMPARATOR|Conventional extubation|Before emergence from anesthesia, the patient will be kept supine and oropharyngeal secretions will be suctioned. Anesthetic gas or IV agents will be stopped. Oxygen concentration will be inscreased to 100% with a fresh gas flow ≥10 L/min. The ventilator will be halted, APL valve opened to atmosphere, and the patient manually ventilated with the reservoir bag until spontaneous breathing resumes, followed by manual assistance as deemed necessary by the anesthesiologist.
62023796|NCT01173848|ACTIVE_COMPARATOR|Vitamin D2|Patients randomized to take vitamin D2
62023797|NCT01173848|ACTIVE_COMPARATOR|Vitamin D3|Patient's randomized to take Vitamin D3
62023798|NCT04057495|PLACEBO_COMPARATOR|no mango intake|No mango consumption on the study visit
62023799|NCT04057495|EXPERIMENTAL|white bread with same amount of calorie as mango|White bread consumption on the study visit
62023800|NCT04057495|EXPERIMENTAL|mango consumption|mango consumption on the study visit
62023801|NCT02433353|EXPERIMENTAL|EMDR + Venlafaxine XR|Participants will receive 12 one-hour sessions of EMDR while taking venlafaxine XR 150mg or 225mg for the duration of the 6 month study.
62023802|NCT02433353|PLACEBO_COMPARATOR|EMDR + Placebo|Participants will receive 12 one-hour sessions of EMDR while taking placebo 150mg or 225mg for the duration of the 6 month study.
62023803|NCT06533982|EXPERIMENTAL|High intensity interval exercise session|"Performed on an ergometer, the intensity of the session is adapted to the participant's physical capacity, initially assessed by the VO2max test at baseline.~The session begins with a 5-minute warm-up at 50% of maximum aerobic power (MAP). The exercise then consists of 2 sets of 12 repetitions of 15 seconds each at 100% of MAP and 15 seconds of passive recovery. 2-minute of passive recovery is recommended between the two sets. The session ends with 5-minute of recovery at 50% of MAP."
62023804|NCT06533982|EXPERIMENTAL|Isometric neuromuscular exercise session|"Performed with a handgrip (K-Force grip, KINVENT), the intensity of the session is adapted to the participant's capacity, initially assessed by the isometric maximal voluntary force (MVF) measurement at the beginning of the session.~The session consists of 4 repetitions of 2 minutes at 30% of the isometric MVF, separated by 1 minute recovery."
62220565|NCT00513604|EXPERIMENTAL|Cohort 5 - NMA, CD4+TIL, HD aldesleukin|"Cohort 5 - Nonmyeloablative (NMA), cluster of differentiation 4 (CD4+) tumor infiltrating lymphocytes (TIL), high dose (HD) aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by CD4+ depleted tumor infiltrating lymphocytes and high dose aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m\^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 5 = CD4 + depleted TIL - it is the SAME as cohort 2"
62587450|NCT01866657|NO_INTERVENTION|Blinded cerebral oximetry monitoring|These subjects will have continous cerebral oximetry monitoring like the experimental cohort but the values will be blinded to all clinicians and research staff. There will be no cerebral desaturation interventions in this group because the clinicians will not be aware of a desaturation as the monitor's output is blinded in this group.
62796261|NCT05720390|PLACEBO_COMPARATOR|Control|In this arm, participants will receive a 10 ml intragastric bolus of control solution followed 30 min later by 100 ml intragastric bolus of control solution.
62023805|NCT06533982|NO_INTERVENTION|Control session|Participants are seated for 30 minutes.
62023806|NCT06232408|EXPERIMENTAL|RP-1664|
62023807|NCT05704959|OTHER|Measurement|
62023808|NCT06635343|EXPERIMENTAL|CPRP Group|In the CPRP group, a chest physiotherapy program was given by the physiotherapist 5 days a week, for 8 weeks, including respiratory control, diaphragmatic breathing, thoracic expansion exercises, and physical activity recommendations, to be applied once a day.
62023809|NCT06635343|EXPERIMENTAL|Experimental Inspiratuar Muscle Training Group|The experimental group underwent inspiratory muscle training (IMT) with an inspiratory muscle training device 5 days a week for 8 weeks.
62023810|NCT00318006|ACTIVE_COMPARATOR|Spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
62587451|NCT05326828||ICM group|Patients eligible for ICM implantation for screening of atrial fibrillation
62220566|NCT01771640|EXPERIMENTAL|stem cell reciepient|The patients with ALS that underwent mesenchymal stem cell transplantation
62220567|NCT03429231||Active Group|Women who are taking coenzyme Q and who will continue taking it for 3 months
62220568|NCT03429231||Control Group|Women who are not taking coenzyme Q and who will not take it in the next 3 months
62220569|NCT02510209|EXPERIMENTAL|Teen Outreach Program|
62220570|NCT02510209|NO_INTERVENTION|Control|Business as usual.
62220571|NCT04845243|OTHER|Emotion recognition training|All participants have to complete the online emotion recognition training E.V.A. as well as the pre- and post training tasks: GERT and social decision making task.
62220572|NCT01493843|EXPERIMENTAL|Arm A: 340 mg pictilisib + CP|Participants with advanced (Stage IV) or recurrent squamous NSCLC will be administered 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P).
62220573|NCT01493843|PLACEBO_COMPARATOR|Arm B: Placebo + CP|Participants with advanced (Stage IV) or recurrent squamous NSCLC will be administered placebo corresponding to 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm A during the first 4 cycles with carboplatin + paclitaxel or after chemotherapy has been completed (Cycle \>/= 5).
62220574|NCT01493843|EXPERIMENTAL|Arm C: 340 mg pictilisib + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P) plus bevacizumab (B).
62220575|NCT01493843|PLACEBO_COMPARATOR|Arm D: Placebo + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered placebo corresponding to 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm C during the first 4 cycles with carboplatin + paclitaxel + bevacizumab or after chemotherapy has been completed (Cycle \>/= 5).
62220576|NCT01493843|EXPERIMENTAL|Arm E: 260 mg pictilisib + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered 260 mg pictilisib plus carboplatin (C) plus paclitaxel (P) plus bevacizumab (B).
62220577|NCT01493843|PLACEBO_COMPARATOR|Arm F: Placebo + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered placebo corresponding to 260 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm E during the first 4 cycles with carboplatin + paclitaxel + bevacizumab or after chemotherapy has been completed (Cycle \>/= 5).
62220578|NCT02262091|PLACEBO_COMPARATOR|Placebo group|
62796262|NCT04502563|EXPERIMENTAL|Active arm|Subjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.
62796263|NCT04502563|SHAM_COMPARATOR|Control|Subjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.
62220579|NCT02262091|EXPERIMENTAL|Food fibers|
62220580|NCT05164029||ART couples|Couples in reproductive age undergoing ART treatment
62220581|NCT05164029||natural pregnancy couples|Couples who get pregnant naturally
62220582|NCT04310098||CADASIL patients|
62220583|NCT04310098||Asymptomatic carriers of CADASIL|
62220584|NCT04310098||Relatives of CADASIL patients and carriers|
62220585|NCT04310098||Unrelated healthy controls|
62220586|NCT03947190|EXPERIMENTAL|Group 1|Group 1 adults (n=20) will be receiving, 4 weeks apart, three doses of 10µg R21 /50µg Matrix M vaccine, and a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge.
62220587|NCT03947190|EXPERIMENTAL|Group 2|Group 2 adults (n=20) will be receiving 5x10\^10 vp ChAd63 ME-TRAP and 2x10\^8 pfu MVA ME-TRAP vaccines, 8 weeks apart, and then a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge, 4 weeks later.
62220588|NCT03947190|EXPERIMENTAL|Group 3|Group 3 adults (n=10) will be receiving, 4 weeks apart, three doses of 10µg R21 /50µg Matrix M vaccine, and a CHMI intravenously (DVI) by inoculation of 3,200 PfSPZ Challenge.
62220589|NCT03947190|EXPERIMENTAL|Group 4|Group 4 adults (n=14) will be the control group receiving no vaccine, only a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge.
62220590|NCT01296789|ACTIVE_COMPARATOR|Tissue perfusion guided protocol|Active comparator group, where parameters of tissue perfusion are used to guide hemodynamic therapy
62220591|NCT01296789|OTHER|Usual Care|Usual Care
62220592|NCT05342025|EXPERIMENTAL|PNF group|PNF will be applied to the trunk and upper extremities combined with breathing, 3 times a week, 1 hour a day for 6 weeks. The physiotherapist will apply pressure and stretches to the chest wall and diaphragm for 20 seconds by giving verbal commands to the patient for the inspiration/expiratory phases. The physiotherapist will apply patterns over the 2nd and 3rd ribs in a bilateral anterior manner including intercostal stretches.
62220593|NCT05342025|ACTIVE_COMPARATOR|Control Group|"Individuals in this group will be taught breathing exercises (diaphragmatic breathing, thoracic expansion, pursed-lip breathing, and respiratory control) after the assessments, and they will be informed about performing breathing exercises for 15 minutes a day, every day of the week. Patients will be asked to keep a treatment diary to control regular breathing exercises. Individuals will be re-evaluated after 2 months."
62220594|NCT06406842|EXPERIMENTAL|The autoregulation group|In the autoregulation group, anesthesiologist will maintain that the cerebral oxygen index value below 0.3. If cerebral oxygen index exceeds the threshold, Norepinephrine or Phenylephrine will be infused continuously, or arterial partial pressure of oxygen or arterial partial pressure of carbon dioxide will be adjusted to increase regional cerebral oxygen saturation.
62220595|NCT06406842|NO_INTERVENTION|The routine group|In the routine group, the screen of the collection monitor will be covered by a black cloth . Anesthesiologist will not have access to the patient's cerebral oxygen index value. Anesthesiologist will strive to maintain mean arterial pressure within a ± 20% range of their baseline mean arterial pressure. Outside of this range, the same vasoactive drugs will be employed for modulation.
62220596|NCT01460173|OTHER|Normal subjects|
62220597|NCT01460173|OTHER|OSA Patients|
62414859|NCT01125007|EXPERIMENTAL|medium toothbrush|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
62587452|NCT05326828||Non-ICM group|Patients ineligible for ICM implantation due to 1) refusal, 2) contraindication, or 3) clear underlying cause of MINOCA before ICM implantation.
62587453|NCT05672628|EXPERIMENTAL|Oculus VR|
62023811|NCT00318006|EXPERIMENTAL|Irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
62023812|NCT05843968|EXPERIMENTAL|Rituximab|2 doses of rituximab 375 mg/m\^2 (Maximum 500mg/day)at 6 months intervals
62023813|NCT05843968|ACTIVE_COMPARATOR|Mycophenolate Mofetil|MMF 20\~30mg/kg/day，BID
62023814|NCT01858662|ACTIVE_COMPARATOR|oxaliplatin +leucovorin L+5FU+ cetuximab|oxaliplatin +leucovorinL+5-Fluorouracile +cetuximab+'Metastases Resection ( multiple steep surgery possible)
62023815|NCT01858662|ACTIVE_COMPARATOR|Irinotecan+ + leucovorinL +5-Fluorouracil +cetuximab|Irinotecan+ + leucovorinL +5-Fluorouracile + cetuximab +'Metastases Resection ( multiple steep surgery possible)
62023816|NCT00723775|OTHER|Part 1|GSK706769 new vs. current formulation; GSK706769 alone vs. GSK706769 plus Kaletra
62023817|NCT00723775|OTHER|Part 2|GSK706769 alone for 10 days; GSK706769 + Kaletra for 14 days
62023818|NCT05839769||carpal tunnel syndrome in third trimester pregnant women|pregnant women who has CTS
62220598|NCT01380015|PLACEBO_COMPARATOR|Placebo Control|Participants will consume two cups of commercial spearmint tea per day (300 mL in the morning and 300 mL in the evening, providing a total of approximately 20 mg of rosmarinic acid per day) for a total of 4 months.
62023819|NCT05839769||healthy pregnant women in third trimester|
62023820|NCT02571452|EXPERIMENTAL|Brief Behavioral Treatment for Insomnia|Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
62220599|NCT01380015|EXPERIMENTAL|Experimental|Participants will consume two cups of a high rosmarinic acid spearmint tea per day (300 mL in the morning and 300 mL in the evening, providing a total of approximately 300 mg of rosmarinic acid per day) for a total of 4 months.
62220600|NCT06093776||Case Series|Prospective: Case Series The investigators will complete ioveraº system training (i.e., cadaveric demonstration) and work with our local surgical team to develop an effective procedure. The technique will then be refined and considered fully developed with three consecutive successful placements. Data reporting to the sponsor will occur once data for the first five successful interventions and the subsequent 14-day follow-ups are completed. Adverse event reporting to the IRB will occur in accordance with GCP standards. Due to the small sample size and short duration, patients lost to follow-up will be an indication for additional enrollment. No more than 10 total subjects will be enrolled.
62220601|NCT01418989|EXPERIMENTAL|1|
62220602|NCT01418989|EXPERIMENTAL|2|
62220603|NCT02501915|EXPERIMENTAL|Kinesio Taping (GROUP A)|Received the application of KT from muscle Origin to Insertion
62220604|NCT02501915|EXPERIMENTAL|Kinesio Taping (GROUP B)|received the application of KT from muscle Insertion to Origen
62220605|NCT03435354|EXPERIMENTAL|Intervention|Physical activity counselling during cardiac clinic visit with additional supports for community physical activity and access to a kinesiologist.
62220606|NCT03435354|NO_INTERVENTION|Usual Care|Cardiac clinic visit with usual care but no physical activity counselling
62414860|NCT06652308||Multiple Sclerosis Patients with Mood Disorders|
62414861|NCT06173713|OTHER|Emphasys Hip Solutions|Emphasys Acetabular Shell, Emphasys AOX Polyethylene Liner, Articul/eze 12/14 metal head and Emphasys fem. stem
62414862|NCT04475536||Coronary Artery Disease (CAD)|
62414863|NCT00178763|EXPERIMENTAL|1|All protocol subjects are treated with fever-range whole-body thermal therapy combined in an optimized schedule with cisplatin + gemcitabine + metronomic low-dose interferon-alpha
62414864|NCT06425601|EXPERIMENTAL|Silicone (SIL) group|For postoperative pleural space drainage a silicone coaxial drain of size French 24 (Redax Coaxial Drain, Redax S.p.A., Poggio Rusco Mantova, Italy) was used
62587454|NCT03377270|EXPERIMENTAL|RST|Respiratory Swallow Training Arm
62587455|NCT03377270|NO_INTERVENTION|Standard of Care|Standard of Care Arm
62587456|NCT00675428|EXPERIMENTAL|Natalizumab 300 mg|Intravenous (IV) infusions of natalizumab 300 mg once every 28 days for 6 months.
62587457|NCT00675428|EXPERIMENTAL|Natalizumab 450 mg|Intravenous (IV) infusions of natalizumab 450 mg once every 28 days for 6 months.
62587458|NCT03783403|EXPERIMENTAL|CC-95251|
62587459|NCT03783403|EXPERIMENTAL|CC-95251 in combination with rituximab|
62587460|NCT03783403|EXPERIMENTAL|CC-95251 in combination with cetuximab|
62796264|NCT06726239|NO_INTERVENTION|No Intervention|Demographic characteristics and trait anxiety levels of patients who accept the study will be measured preoperatively. On postoperative day 1, physiologic parameters, state anxiety and pain levels will be measured in the adult cardiovascular surgery service and physiologic parameters and pain levels will be measured again after 30 minutes. According to the clinical procedure, physiological parameters, state anxiety and pain levels will be measured 15 minutes after the patients are mobilized. The scales will be administered once on postoperative day 1 and twice on postoperative day 2 at 6-hour intervals. In addition, it was stated that the smart wristband should be worn on the arm of the patients during the 1st and 2nd postoperative days to monitor the frequency and duration of mobilization.
62796265|NCT06726239|EXPERIMENTAL|Experimental|Demographic characteristics and trait anxiety levels of the patients who accept the study will be measured preoperatively. Progressive relaxation exercises will be explained preoperatively. On postoperative day 1, physiologic parameters, state anxiety and pain levels will be measured in the adult cardiovascular surgery service. After the measurement, progressive relaxation exercises will be applied for 20 minutes with the researcher. Physiologic parameters and pain levels will be measured and checked 5 minutes after the exercise. According to the clinical procedure, physiological parameters, state anxiety and pain levels will be measured 15 minutes after the patients are mobilized, and the scales will be administered once on postoperative day 1 and twice at 6-hour intervals on postoperative day 2. It was also stated that a smart wristband should be worn on the arm of the patients on postoperative days 1 and 2 to monitor the frequency and duration of mobilization.
62796266|NCT05947864|EXPERIMENTAL|Allo-HSCT recipients|Adult recipients of allogenic hematopoietic stem cell transplantation, eligible for live-attenuated vaccines, i.e. who are more than 24 months after their HSCT, without GVHD and more than 3 months after cessation of any immunosuppressant treatment
62796267|NCT05947864|PLACEBO_COMPARATOR|Healthy volunteers (HV)|Healthy adults with a history of measles (=convalescents) or vaccinated with two doses of MMR in the past (=vaccinated)
62796268|NCT04249843|EXPERIMENTAL|Phase 1a: Dose Escalation|BGB-3245 administered orally (PO)
62796269|NCT04249843|EXPERIMENTAL|Phase 1b, Group 1: Dose Expansion|BGB-3245 administered orally (PO)
62796270|NCT05276817|SHAM_COMPARATOR|Perio maint. then sham laser|
62796271|NCT05276817|EXPERIMENTAL|Perio maint. then medicament|
62796272|NCT05276817|EXPERIMENTAL|Perio maint. then diode laser 1|
62796273|NCT05276817|EXPERIMENTAL|Perio maint. then diode laser 2|
62796274|NCT06019455||Observational group|Patients undergoing definitive radiochemotherapy ± immunotherapy will be assessed about the level of participation in their medical processes.
62796275|NCT00746863|EXPERIMENTAL|1|Patients randomized to this arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
62796276|NCT00746863|NO_INTERVENTION|2|Patients assigned to this arm will have the mid-urethral sling placed via the suprapubic approach in the standard fashion with no injection of Marcaine into the retropubic space.
62414865|NCT06425601|ACTIVE_COMPARATOR|PVC group|For postoperative pleural space drainage a standard polyvinyl chloride drain of size French 24 (Argyle, Covidien, Mansfield, USA) was used
62414866|NCT02183701|EXPERIMENTAL|Telmisartan|4 weeks placebo run-in, 6-weeks fixed dose period
62796277|NCT06725043|ACTIVE_COMPARATOR|Active|Therapeutic ultrasound (1 MHz) Pulsed mode at bilateral acupuncture points of PC6, PC7, BL60 andKI1
62587461|NCT02778074|EXPERIMENTAL|Internet Cognitive Behavioural Therapy|Participants will perform a nine-week tailored I-CBT program developed to fit CVD patients. The program consists of psychoeducation, relaxation, problem-solving and behavioral activation.
62587462|NCT02778074|PLACEBO_COMPARATOR|Moderated discussion forum|In this arm the participants are allocated to a non mandatory discussion forum for nine weeks. Evert week will participants discuss issues regarding their CVD. Themes discussed are suggested by the study team, and a new theme is added every week. A moderator from the study group act as a supervisor and checks that issues discussed are ok. After the nine week discussion forum the participants are offered the nine week CBT program.
62587463|NCT05567211|NO_INTERVENTION|Control group|Will receive basic recommendations from the World Health Organization on healthy eating and physical activity.
62414867|NCT02183701|ACTIVE_COMPARATOR|Losartan + Hydrochlorothiazide|4 weeks placebo run-in, 6-weeks fixed dose period (Losartan 50 mg / HCTZ 12.5 mg)
62023821|NCT02571452|ACTIVE_COMPARATOR|Progressive Muscle Relaxation|Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
62220607|NCT01051830|EXPERIMENTAL|Interdisciplinary group|Diabetes intervention and rehabilitation program. The rehabilitation program includes geriatric consultation, the rehabilitation program (interventions to improve ROM, muscle strength and endurance, proprioceptive enhancement, balance capacity, aerobic and anaerobic capacity, flexibility, and body composition), and discharge-planning services. The DM intervention includes: dietary and DM education, blood pressure control, dyslipidemia management, a glycemic treatment regimen, and exercises.
62587464|NCT05567211|PLACEBO_COMPARATOR|Control group with free use of the virtual platform|The athletes, in addition to the recommendations indicated in the previous point, will have access to the virtual platform designed to voluntarily record the parameters they consider appropriate.
62587465|NCT05567211|ACTIVE_COMPARATOR|Intervention group with Mediterranean diet and physical exercise planning|They will receive nutritional plans adapted to their energy expenditure and based on Mediterranean diet. The physical exercise intervention will be based on 3 weekly sessions of 50 minutes of combined resistance and strength, deferred.
62587466|NCT05567211|ACTIVE_COMPARATOR|Intervention group with red berries and physical exercise planning|They will also receive personalized nutritional plans with a diet rich in antioxidants obtained from red berries and the same physical exercise intervention as in the Mediterranean diet intervention group.
62587467|NCT05607680|PLACEBO_COMPARATOR|Placebo|Placebo,SC,once a week for 48 weeks
62587468|NCT05607680|EXPERIMENTAL|IBI362 4 mg|2 mg,SC,once a week for 4 weeks 4 mg,SC,once a week for 44 weeks
62587469|NCT05607680|EXPERIMENTAL|IBI362 6 mg|2 mg,SC,once a week for 4 weeks 4 mg,SC,once a week for 4 weeks 6 mg,SC,once a week for 40 weeks
62587470|NCT06684236|EXPERIMENTAL|Acupoint stimulation|transcutaneous electrical acupoint stimulation is one of the many forms of acupuncture, and is a distinctive part of Chinese medicine that has been practiced in China for thousands of years. It is employed by placing electrodes on acupoint and electrical stimulation is given after anesthetic induction to the end of the surgery
62220608|NCT01051830|NO_INTERVENTION|Control group|Routine care
62220609|NCT01575028|ACTIVE_COMPARATOR|Local anesthetic infiltration injection|Patients will receive local anesthetic infiltration injected at the surgical site by the surgeon at the end of surgery.
62220610|NCT01575028|EXPERIMENTAL|Transversus abdominis plane (TAP) block|Patients will receive a transversus abdominis plane (TAP) block.
62220611|NCT04952454|ACTIVE_COMPARATOR|External DCR|Patients treated with External DCR for functional epiphora
62220612|NCT04952454|ACTIVE_COMPARATOR|Endonasal DCR|Patients treated with Endonasal DCR for functional epiphora
62587471|NCT06684236|SHAM_COMPARATOR|Control|"Electrodes are placed on same acupoints as the experimental group, and will receive the optimal intensity test before the anesthesia induction, but no electrical stimulation is given during the operation"
62220613|NCT04952454|ACTIVE_COMPARATOR|Transcanalicular DCR|Patients treated with Transcanalicular DCR for functional epiphora
62220614|NCT05415943|EXPERIMENTAL|Women at high risk of breast cancer|Women with a confirmed diagnosis of breast cancer by thick-needle biopsy and known HER2 receptor expression status, referred for surgical treatment.
62220615|NCT05813639|EXPERIMENTAL|Lumbar medial branch cryoablation|Lumbar medial branch cryoablation Procedure lumbar medial branch cryoablation Decreasing the electrode temperature to - 85 C for 120 seconds in two cycles. Follow-up: before the procedure, 3 months, 6 months, 12 months, and 24 months after the procedure Repeated cryoablation ablation procedures are allowed (when VAS will be =/\> 4 ) Procedure/Surgery: Lumbar medial branch cryo ablation neurotomy A procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
62414868|NCT02934568|EXPERIMENTAL|LEE011|All patients in all combinations with LEE011 will be entered in one arm.
62414869|NCT05804201|OTHER|HOT Giobor|EUS-guided hepatico-gastrostomy would be performed with Niti-S HOT Giobor (Taewoong Medical, Gyeonggi-do, Korea), a novel device designed for hepatico-gastrostomy.
62414870|NCT05015803|EXPERIMENTAL|CBTi with Application|Device-based intervention facilitation and clinician interfacing for Cognitive Behavioral Therapy for Insomnia (CBTi).
62414871|NCT05015803|ACTIVE_COMPARATOR|CBTi|Standard CBTi delivered via video conferencing \[Zoom Health\].
62414872|NCT05015803|ACTIVE_COMPARATOR|Sleep Hygiene|Treatment as usual: Sleep hygiene education and training.
62587472|NCT02137850|EXPERIMENTAL|50 EDs (exposure days)|
62023822|NCT06535685|EXPERIMENTAL|Romiplostim group|Romiplostim group
62023823|NCT05861674|EXPERIMENTAL|HH-003 (20mg/kg)+TAF|Subjects will receive HH-003 20 mg/kg Q2W intravenously and TAF 25 mg QD orally during 48-week treatment period, and receive TAF 25 mg QD orally during 24-week follow-up period.
62587473|NCT05335395|EXPERIMENTAL|SUNRISE clusters|SUNRISE campaign broadcast through local radio stations plus broadcasting as usual
62023824|NCT05861674|EXPERIMENTAL|HH-003 (10mg/kg)+TAF|Subjects will receive HH-003 10 mg/kg Q2W intravenously and TAF 25 mg QD orally during 48-week treatment period, and receive TAF 25 mg QD orally during 24-week follow-up period.
62414873|NCT06405087|EXPERIMENTAL|Treatment Cohort: Vedolizumab 108 mg PFS+AI|Vedolizumab 108 mg, PFS+AI, subcutaneously, once every two weeks (Q2W) to the participants weighing greater than or equal to (\>=) 30 kg and once every four weeks (Q4W) to the participants weighing \>=10 to less than (\<) 30 from Day 1 up to Week 120, until participant withdraws from the study, or until vedolizumab SC is commercially available for pediatric indication in the participant's country or other drug access programs become available, or the sponsor decides to close the study, whichever occurs first.
62414874|NCT06405087|EXPERIMENTAL|Treatment Cohort: Vedolizumab 108 mg PFS+NSD|Vedolizumab 108 mg, PFS+NSD, subcutaneously, Q2W to the participants weighing \>=30 kg and Q4W to the participants weighing \>=10 to \<30 from Day 1 up to Week 120, until participant withdraws from the study, or until vedolizumab SC is commercially available for pediatric indication in the participant's country or other drug access programs become available, or the sponsor decides to close the study, whichever occurs first.
62587474|NCT05335395|NO_INTERVENTION|Control clusters|Local radio stations broadcast as usual
62587475|NCT02697890|ACTIVE_COMPARATOR|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|"Interventions:~Procedure: Ridge preservation procedure"
62587476|NCT02697890|EXPERIMENTAL|FDBA (MinerOss®) + Mucograft® seal|"Interventions:~Device: Mucograft® seal Procedure: Ridge preservation procedure"
62587477|NCT06290843||Scoliosis|Children with idiopathic scoliosis
62587478|NCT06290843||Control|Children without idiopathic scoliosis
62587479|NCT01921790|EXPERIMENTAL|Avastin+ GemAOD|Avastin+ GemAOD means Avastin Combined With Gemcitabine, Oxaliplatin, Pegaspargase and Dexamethasone
62587480|NCT05927350||Survey|Participants will complete a one-time survey asking about sociodemographics, pediatric research participation, experience with research, gender minority stress and resilience, vaccine hesitancy, medical mistrust, and connectedness to the LGBT community
62587481|NCT03104439|EXPERIMENTAL|Nivolumab+Ipilimumab|"* Nivolumab will be administered intravenously 3 times per cycle~* Ipilimumab will be administered intravenously once per cycle~* Radiation Therapy will be administered per hospital standard"
62414875|NCT06405087|OTHER|Observational Cohort: Early Terminated Participants From Parent Study|Participants who receive any dose of vedolizumab SC during the parent study VedolizumabSC-3003 (NCT06100289) and are not eligible for the treatment cohort of this extension study (that is, participants who early terminated from parent study VedolizumabSC-3003 \[NCT06100289\] or did not achieve clinical response in the parent study or who received corticosteroids in the last 4 weeks of the parent study) will only be observed in the observational cohort of this study and will not receive any dose of the vedolizumab SC in this cohort.
62587482|NCT00863473|NO_INTERVENTION|Conservative /Physiotherapy|Active training protocol with instructed physiotherapy and self excercises
62587483|NCT00863473|ACTIVE_COMPARATOR|Surgery with LCP T plate|Surgical treatment with interlocking plate
62587484|NCT06665165|EXPERIMENTAL|Active Treatment: AMX0114|AMX0114 will be administered once every 4 weeks by intrathecal bolus injection for a total of up to 4 doses. Treatment will be administered on Day 1, followed by repeat dosing every 4 weeks at approximately Day 29, Day 57 and Day 85.
62587485|NCT06665165|PLACEBO_COMPARATOR|Placebo|Placebo drug will be administered once every 4 weeks by intrathecal bolus injection for a total of up to 4 doses. Treatment will be administered on Day 1, followed by repeat dosing every 4 weeks at approximately Day 29, Day 57 and Day 85.
62587486|NCT02858336|ACTIVE_COMPARATOR|Control|All participants will receive the NEA availability to act as their own control to the experimental DEA intervention.
62023825|NCT05861674|OTHER|TAF|Subjects will receive TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period.
62587487|NCT02858336|EXPERIMENTAL|Experimental|All participants will be in the experimental arm and receive the DEA intervention.
62023826|NCT04708873|EXPERIMENTAL|High Intensity Interval Training Group|Participants in this group will initially undergo continuous aerobic training to achieve a baseline fitness level, after which HIIT and resistance training will be employed. Warm-up period will be followed by 4 bouts of 4-minute interval treadmill running and stationary bike cycling at 80-95% of the measured HR reserve, interspersed with active recovery phase at 55-70% HRR. After this resistance exercises will be performed in a circuit fashion for strengthening the upper limbs, lower limbs and trunk. The session will be ended with a 5-7 minute cool-down period
62023827|NCT04708873|ACTIVE_COMPARATOR|Moderate Intensity Continuous Training Group|Participants in this group will also initially undergo continuous aerobic training to achieve a baseline fitness level, after which the intensity will be increased to moderate continuous training achieving 55-70% of HRR. Every session will be preceded by appropriate warm-up and end with cool down.
62023828|NCT05710523|EXPERIMENTAL|I-ACE training|Participants will receive twenty-two sessions on the non-pharmacological therapies' methodology and on awareness of body language.
62414876|NCT05643118|EXPERIMENTAL|Part A 100 μg/eye/50 μL|study eye treated with 100 μg (94.3 μg free acid) of OLX10212
62414877|NCT05643118|EXPERIMENTAL|Part A 250 μg/eye/50 μL|study eye treated with 250 μg (235.8 μg free acid) of OLX10212
62587488|NCT06665061|EXPERIMENTAL|PCV|After intubation under anesthesia, mechanical ventilation is performed in the pressure control ventilation (PCV) mode.
62587489|NCT06665061|EXPERIMENTAL|VCV|After intubation under anesthesia, mechanical ventilation is performed in the volume control ventilation (VCV) mode.
62587490|NCT06665061|EXPERIMENTAL|PRVC|After intubation under anesthesia, mechanical ventilation is performed in the pressure-regulated volume control (PRVC) mode.
62587491|NCT01279395||naproxen|Patients age 40-70 who fulfill the American College of Rheumatology (ACR) criteria for a diagnosis of primary osteoarthritis are considered eligible. This group has been prescribed naproxen (1000 mg/day) for a minimum of two weeks.
62796278|NCT06725043|PLACEBO_COMPARATOR|Experime|Placebo Therapeutic ultrasound at bilateral acupuncture points of PC6, PC7, BL60, and KI1
62796279|NCT03496675|OTHER|Standard care|Participants receive standard care as locally available. The components of standard care are recorded.
62220616|NCT05813639|EXPERIMENTAL|Lumbar medial branch RF neurotomy|Lumbar medial branch RF neurotomy Procedure lumbar medial branch RF neurotomy: Raising the temperature of the tip of the electrode to 85 C for 120 seconds. RF generator. Follow-up: before the procedure, 3 months, 6 months, 12 months, and 24 months after the procedure. Repeated cryoablation ablation procedures are allowed (when VAS will be \> 4 )
62220617|NCT05813639|EXPERIMENTAL|Lumbar fazet joint decapsulation|Lumbar facet joint decapsulation through an endoscopic approach
62414878|NCT05643118|EXPERIMENTAL|Part A 500 μg/eye/50 μL|study eye treated with 500 μg (471.5 μg free acid) of OLX10212
62414879|NCT05643118|EXPERIMENTAL|Part A 750 μg/eye/50 μL|study eye treated with 750 μg (707.3 μg free acid) of OLX10212
62414880|NCT05643118|EXPERIMENTAL|Part A 950 μg/eye/50 μL|study eye treated with 950 μg (895.9 μg free acid) of OLX10212
62414881|NCT05643118|EXPERIMENTAL|Part B 750 μg/eye/50 μL|study eye treated with a total of 3 intravitreal injections of 750 μg (707.3 μg free acid) of OLX10212 each 28 days apart
62587492|NCT01279395||diclofenac|Patients age 40-70 who fulfill the ACR criteria for a diagnosis of primary osteoarthritis. The group consists of patients who have been prescribed diclofenac (150 mg/day)for a minimum of two weeks.
62587493|NCT01279395||celecoxib|Patients age 40-70 who fulfill the ACR criteria for a diagnosis of primary osteoarthritis are considered eligible. This group has been prescribed celecoxib (200 mg/day) for a minimum of two weeks.
62220618|NCT00658684|EXPERIMENTAL|Fesoterodine fumarate|
62220619|NCT02822144|EXPERIMENTAL|general anesthesia|General anesthesia with etomidate, succinylcholine, propofol and remifentanil
62220620|NCT02822144|EXPERIMENTAL|sedation|Sedation with remifentanil and local anesthesia with lidocaine
62220621|NCT01524601|EXPERIMENTAL|Rosuvastatin|Rosuvastatin treatment for 4 weeks
62220622|NCT02570932|EXPERIMENTAL|Autologous Mesenchymal Bone Marrow Cell|"All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow expanded Stem Cell (CME)~Pharmaceutical form: Suspension in autologous plasma cell Route of administration: Intrathecal in subarachnoid space by lumbar puncture. Dose: Total dose of 300 x 106 CME, given in 3 injections of 100 x 106 CME, at intervals of 3 months between each administration."
62220623|NCT03383315|EXPERIMENTAL|Group 1|Intravenous tramadol 50mg + intravenous metoclopramide 10mg
62220624|NCT03383315|ACTIVE_COMPARATOR|Group 2|Intravenous tramadol 50mg + placebo (normal saline)
62414882|NCT05643118|EXPERIMENTAL|Part B 950 μg/eye/50 μL|study eye treated with a total of 3 intravitreal injections of 950 μg (895.9 μg free acid) of OLX10212 each 28 days apart
62414883|NCT05634629|ACTIVE_COMPARATOR|Anterior Lamellar Recession|
62414884|NCT05634629|ACTIVE_COMPARATOR|Bilamellar Tarsal Rotation|
62414885|NCT03015207|EXPERIMENTAL|NNC0194-0499|Injected s.c. /subcutaneously (under the skin)
62414886|NCT03015207|PLACEBO_COMPARATOR|Placebo|Injected s.c. /subcutaneously (under the skin)
62414887|NCT06653400|PLACEBO_COMPARATOR|Lidocaine alone|Paracervical block will be performed with just lidocaine
62414888|NCT06653400|EXPERIMENTAL|Lidocaine plus ketorolac|Paracervical block will be performed with lidocaine plus ketorolac
62414889|NCT00834288|EXPERIMENTAL|1: 1x200 mg Tramadol HCl OAD tablet daily|
62414890|NCT00834288|ACTIVE_COMPARATOR|2: 1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly|
62414891|NCT01097369||Anti-rasburicase antibodies|
62414892|NCT05855473|EXPERIMENTAL|Semi-permanent needle|Five sessions of unilateral auricular acupuncture were applied alternately to the right and left ears, once a week, to the intensive care nurses in the semi-permanent needle group. Semi-permanent needles placed on the acupuncture points of the nurses' ears remained for one week with adhesive tapes. In the sessions in the following weeks, semi-permanent needles were replaced with new ones. Shen men (TF4), Sympathetic (AH6a), Lung, Liver (CO12) Kidney point (CO10) were applied to five specific points in the ear in accordance with the NADA protocol.
62414893|NCT05855473|EXPERIMENTAL|Seed|Five sessions of unilateral auricular acupuncture were applied alternately to the right and left ears, once a week, to the intensive care nurses in the seed group. Seeds placed on the acupuncture points of the nurses' ears remained for one week with adhesive tapes. In the sessions in the following weeks, seeds were replaced with new ones. The seed group was asked to apply pressure on the bands three times a day, 15 times each time. Shen men (TF4), Sympathetic (AH6a), Lung, Liver (CO12) Kidney point (CO10) were applied to five specific points in the ear in accordance with the NADA protocol.
62414894|NCT05855473|NO_INTERVENTION|Control|This group received no intervention.
62414895|NCT06452797|NO_INTERVENTION|Usual Prognostic Approach|Participants will make form a prognosis using their usual approach
62414896|NCT06452797|EXPERIMENTAL|ProVent-14 Guided Prognostic Approach|Participants will be asked to form a prognosis after being provided the patient's ProVent-14 score and its meaning
62414897|NCT06091527|EXPERIMENTAL|Yoga practice|Yoga practice groups
62414898|NCT06091527|ACTIVE_COMPARATOR|Education|Education module group
62414899|NCT01268683|EXPERIMENTAL|Glyburide for Injection|This arm is administered a glyburide bolus followed by continuous infusion of glyburide for 72 hours
62414900|NCT04384731|EXPERIMENTAL|Surfactant arm|patient receiving the surfactant
62587494|NCT02913404|EXPERIMENTAL|ACL Reconstruction|"Surgical Protocol~Standard single bundle anatomic ACL reconstruction will be performed for all subjects. Quadrupled hamstring tendon will be used with cortical fixation on femur and tibia."
62220625|NCT03207009|EXPERIMENTAL|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product (autologous CD34+ cell-enriched population that contains cells transduced with LentiGlobin BB305 lentiviral vector encoding human βA-T87Q-globin)
62220626|NCT02112032|EXPERIMENTAL|Dose Level 1|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 1 µg/kg every week by subcutaneous injection for up to 2 years
62796280|NCT03496675|EXPERIMENTAL|Group Music Therapy (GMT)|"GMT is provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.~In line with usual practice, and as appropriate in local contexts, residents of a unit allocated to GMT may be divided into smaller groups (e.g. around 5 participants)."
62023829|NCT05710523|ACTIVE_COMPARATOR|Standard non-pharmacological therapies (NPT) training|Participants will receive twelve sessions on the non-pharmacological therapies' methodology.
62220627|NCT02112032|EXPERIMENTAL|Dose Level 2|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 2 µg/kg every week by subcutaneous injection for up to 2 years
62220628|NCT02112032|EXPERIMENTAL|Dose Level 3|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 3 µg/kg every week by subcutaneous injection for up to 2 years
62220629|NCT00057174|OTHER|Arm 1|
62220630|NCT01474928|EXPERIMENTAL|Group 2: community video group|In each community intervention group two subject viewed the patient role played community video
62220631|NCT01474928|EXPERIMENTAL|Group three: both videos group|In each community intervention group three subject viewed two videos (the patient role played community and physician-led knowledge videos)
62220632|NCT01474928|ACTIVE_COMPARATOR|Group four: pamphlet group|In each community intervention group four subject read an educational pamphlet only - act as active comparator group
62414901|NCT04384731|NO_INTERVENTION|Control arm|patient not receiving the surfactant
62220633|NCT01474928|EXPERIMENTAL|Group one: knowledge video group|In each community intervention group one subject viewed the physician-led knowledge video
62220634|NCT01435733||Parents of children with ASD|Parents with one or more children diagnosed with Autism Spectrum Disorder
62220635|NCT05564416|EXPERIMENTAL|Arm I (erdafitinib)|Patients receive erdafitinib orally (PO). Patients undergo collection of blood and computed tomography (CT)/magnetic resonance imaging (MRI) at various time points throughout the trial and colposcopy at baseline.
62220636|NCT05564416|EXPERIMENTAL|Arm II (erdafitinib, atezolizumab)|Patients receive erdafitinib PO and atezolizumab intravenously (IV). Patients undergo collection of blood and CT/MRI at various time points throughout the trial and colposcopy at baseline.
62220637|NCT03085615|EXPERIMENTAL|100%NRG|Patient will receive the enteral nutrition product Jevity 1.5 starting at 20mL per hour and increasing by 20mL every four hours until a goal rate delivering 25-30kcals/kg is achieved. If feeding is interrupted, flow rate will be adjusted to compensate for nutritional loss.
62414902|NCT01910701|EXPERIMENTAL|Family Spirit Intervention|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
62414903|NCT01609127|EXPERIMENTAL|Tesetaxel every 3 weeks|Tesetaxel 27 mg/m2 orally on Day 1 in a 21-day cycle
62414904|NCT01609127|EXPERIMENTAL|Tesetaxel weekly|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 in a 28-day cycle
62796281|NCT03496675|EXPERIMENTAL|Recreational Choir Singing (RCS)|"RCS is provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.~RCS may be conducted in larger groups (e.g. with all residents of the unit in one group)."
62220638|NCT03085615|ACTIVE_COMPARATOR|40%NRG|Patient will receive the enteral nutrition product Jevity 1.5 starting at 20mL per hour and increasing by 20mL every four hours until a goal rate delivering 12-14 kcals/kg is achieved. If feeding is interrupted, flow rate will be adjusted to compensate for nutritional loss.
62220639|NCT04617977|EXPERIMENTAL|Parent-child I-BMS intervention group|Children with eczema and their parent caregivers will attend the six sessions simultaneously in a parallel group format. Parent caregivers will attend the parents group in the first 2.5 hours; while children will attend the children group in the first 2.5 hours. Both parents and children will later reunite in the joint group in the final 0.5 hours.
62220640|NCT04617977|EXPERIMENTAL|Parent only I-BMS intervention group|Only parent caregivers of children with eczema will attend the six sessions. The content of the 2.5-hour parents group will be the same as the one in Arm 1 (Parent-child I-BMS intervention group), with an additional 0.5 hour of reflective discussion among group members. The children group will simultaneously attend a group activity class in a separate room for 3 hours.
62414905|NCT01609127|ACTIVE_COMPARATOR|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 in a 21-day cycle
62414906|NCT04476459|EXPERIMENTAL|camrelizumab in combination with apatinib|Apatinib should be given at a fixed time. On the day of camrelizumab infusion, Apatinib should be taken 30 minutes after the end of camrelizumab infusion
62414907|NCT00683046|EXPERIMENTAL|Drug Intervention|
62220641|NCT04617977|ACTIVE_COMPARATOR|Parent only health education active control group|Only parent caregivers of children with eczema will attend the six sessions. Each session consists of teaching in the first 2.5 hours and Q\&A in the final 0.5 hour. The children group will simultaneously attend a group activity class in a separate room for 3 hours.
62414908|NCT06566859||M-TAPA Block|Patients who have standard anesthesia are randomized with the research randomizer application while under anesthesia and M-TAPA block is applied under ultrasound guidance in the preoperative period. For the block, 50 mg of 0.25% bupivacaine and 100 mg lidocaine are injected, totaling 20cc.
62414909|NCT06566859||ESP Block|Patients who have standard anesthesia are randomized with the research randomizer application while under anesthesia and ESP block is applied under ultrasound guidance in the preoperative period. For the block, 50 mg of 0.25% bupivacaine and 100 mg lidocaine are injected, totaling 20cc.
62414910|NCT01889927|NO_INTERVENTION|Group 1: Control|Control Group (Arm 1): Children randomised to the control group will receive 24-months of current model of specialist CF care.
62796282|NCT03496675|EXPERIMENTAL|GMT + RCS|Group Music Therapy and Recreational Choir Singing are both provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.
62796283|NCT06526988|NO_INTERVENTION|Usual Care|Patients will receive care as usual.
62796284|NCT06526988|EXPERIMENTAL|EPIC-HF Patient-facing Tool|Patients will receive the patient engagement video and HeartMeds Guide checklist electronically about 2-7 days and 0-1 days prior to their next clinic appointment after enrollment.
62414911|NCT01889927|ACTIVE_COMPARATOR|Group 2: Exercise Intervention|Intervention group (Arm 2): Children randomised to the intervention group will receive 24-months of current model of specialist CF care PLUS a weekly structured, individually prescribed and personally supervised exercise intervention at a local fitness facility or at school.
62414912|NCT02502084|EXPERIMENTAL|3NT flexible endoscope|Evaluation of 3NT flexible endoscope in terms of access and evaluation of the nasal anatomy
62414913|NCT00684437|EXPERIMENTAL|Factual Gain-Framed|Smoking Risk Message - Factual Gain-Framed (FGF)
62796285|NCT06526988|EXPERIMENTAL|PROMPT-HF Clinician-facing Alert|Clinicians will receive tailored electronic health record (EHR) alerts recommending guideline-directed medical therapy (GDMT) in eligible patients with HFrEF during outpatient visits.
62796286|NCT06526988|EXPERIMENTAL|Both (EPIC-HF and PROMPT-HF Interventions)|Patients will receive the patient engagement video and HeartMeds Guide checklist electronically about 2-7 days and 0-1 days prior to their next clinic appointment after enrollment, and clinicians will receive tailored electronic health record (EHR) alerts recommending guideline-directed medical therapy (GDMT) in eligible patients with HFrEF during outpatient visits.
62796287|NCT05838768|EXPERIMENTAL|A: HRO761 single agent|phase Ib (Dose finding (Escalation and Optimization) and expansion)
62796288|NCT05838768|EXPERIMENTAL|B: HRO761 + pembrolizumab|phase Ib (Dose escalation and expansion)
62796289|NCT05838768|EXPERIMENTAL|C: HRO761 + irinotecan|phase Ib (Dose escalation and expansion)
62796290|NCT02118974|EXPERIMENTAL|Robot-assisted|Robot-assisted hysterectomy
62796291|NCT02118974|EXPERIMENTAL|Laparoscopic Hysterectomy|Laparoscopic Hysterectomy
62414914|NCT00684437|EXPERIMENTAL|Factual Loss-Framed|Smoking Risk Message - Factual Loss-Framed (FLF)
62414915|NCT00684437|EXPERIMENTAL|Emotional Gain-Framed|Smoking Risk Message - Emotional Gain-Framed (EGF)
62414916|NCT00684437|EXPERIMENTAL|Emotional Loss-Framed|Smoking Risk Message - Emotional Loss-Framed (ELF)
62414917|NCT01972607|NO_INTERVENTION|CONTROL|This group will receive the same treatment of the experimental group after the test-retest measurements.
62414918|NCT01972607|EXPERIMENTAL|EXERCISE|This group will receive the treatment with aerobic exercise training
62414919|NCT06124326|EXPERIMENTAL|Premenstrual Syndrome Supplement|"During the first menstrual cycle, participants will take the supplement as needed (pro re nata) when they feel symptoms of PMS, such as cramping or bloating.~For the second and third menstrual cycles, Participants will take 2 capsules per day with water for 1 week, starting 4 days before their menstrual cycle and finishing on Day 3 of their cycle."
62414920|NCT06565598|NO_INTERVENTION|Traditional robot-assisted transabdominal radical nephrectomy|Radical nephrectomy was performed through traditional robot-assisted transabdominal approach
62796292|NCT03828617|EXPERIMENTAL|20vPnC Lot 1|20vPnC Lot 1
62796293|NCT03828617|EXPERIMENTAL|20vPnC Lot 2|20vPnC Lot 2
62796294|NCT03828617|EXPERIMENTAL|20vPnC Lot 3|20vPnC Lot 3
62796295|NCT03828617|ACTIVE_COMPARATOR|13vPnC|13vPnC
62796296|NCT05432401|EXPERIMENTAL|T cell injection targeting FLT3 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1.0 × 10\^8, 2.0 × 10\^8 and 4.0 × 10\^8 CAR-T groups in order of sequence. And the subjects will be administered once.
62796297|NCT06410014||Participating patients|All patient who have consented to participate in the study
62796298|NCT06725056|EXPERIMENTAL|group of participants|Sequentially performing DS-MCE and EGD examinations on AUGIB patients with stable hemodynamics, using EGD as the gold standard to evaluate the sensitivity of DS-MCE in diagnosing upper gastrointestinal bleeding lesions and active bleeding.
62796299|NCT06337695|EXPERIMENTAL|Vedolizumab|Participants receive 300 mg vedolizumab IV at weeks 0, 3, 6, 14, and 22.
62796300|NCT06337695|PLACEBO_COMPARATOR|Placebo|Participants receive 300 mg placebo IV at weeks 0, 3, 6, 14, and 22.
62414921|NCT06565598|NO_INTERVENTION|Traditional laparoscopic transabdominal radical nephrectomy|Traditional laparoscopic radical nephrectomy was performed
62414922|NCT06565598|EXPERIMENTAL|Single-layer robot-assisted transperitoneal retroperitoneal tubeless radical nephrectomy|Through a single-level surgical approach, surgical robot-assisted transperitoneal retroperitoneal radical nephrectomy was performed.
62414923|NCT04228081||UTI Positive|"In phase I of the study testing residual urine samples the aim is to include at least 50 positive samples from each bacterial species known to be commonly associated with urinary tract infections. We selected 2000 positive urines to enable capturing enough of these organisms in the development process.~For phase II of the study, the same number of positive samples in order to include all common species causing urinary tract infection. The number of negative samples included is reduced to 1000.~Phase 3 - approximately one third of all urine sample submitted will be positive for a uropathogen. Sample size of 3000 we expect 1000 these to be culture positive. We expect most uropathogens occurring at a frequency of 5% or more will be included with sufficient numbers in the validation process."
62414924|NCT04228081||UTI Negative Control|2000 negative urine samples are being run as controlled to ensure the false positivity rate is low.
62796301|NCT06137586|EXPERIMENTAL|Infusion of GIP[1-42], GIP[1-30] or placebo|This is a single arm study. All participants will go through all five experimental days in a randomized order. The interventions are A) 4pmol/kg/min GIP\[1-42\] B) 8pmol/kg/min GIP\[1-42\] C) 4pmol/kg/min GIP\[1-30\] D) 8pmol/kg/min GIP\[1-30\] E) Saline (placebo)
62414925|NCT06469736|SHAM_COMPARATOR|Standard of Care Ureterorenoscopy|Arm A) Standard procedure ( URS) for the removal of kidney stones using URS
62414926|NCT06469736|ACTIVE_COMPARATOR|Standard of Care Ureterorenoscopy with MediNik|Arm B) Standard procedure (URS) for the removal of kidney stones using URS in combination with the mediNiK®
62414927|NCT01277107|EXPERIMENTAL|Zaleplon AP formulation|Gastric Retentive Dual Release Zaleplon (Zaleplon AP)
62414928|NCT01277107|PLACEBO_COMPARATOR|Placebo|Identical placebo capsule
62414929|NCT06653088|EXPERIMENTAL|Intervention group with Physical Education program|A four-month intervention will be implemented, led by the PE teacher, with three sessions per week. These sessions will last 45 minutes each (Koolwikh et al., 2023), divided into 5 minutes of warm-up, 35 minutes of intervention content, and 5 minutes of return to calm. The program content of the intervention group will contemplate a warm-up with several activities, such as dancing or games. The intervention part will be composed of circuit-based exercises with several stations and games involving locomotion skills, namely run, gallop, slide, skip, jump, hop, etc.; games that integrate manipulative skills, such as throwing, catching, kicking, punting, striking, rolling and bouncing/dribbling; balance games involving swinging, turning, pulling, etc. Games involving perceptual motor skills, such as body schema, laterality, temporality, and spatiality, and games focused on PA. The return to calm will include activities such as yoga, meditation, and flexibility.
62414930|NCT06653088|NO_INTERVENTION|Control group without programmed PE classes|The control group will continue with their normal activity; however, they will receive the same training after the intervention, so it can also be implemented in their preschools if they wish so (Engel et al., 2022; Santos et al., 2016).
62414931|NCT05186727|ACTIVE_COMPARATOR|Researcher-Group|Education delivered in a group session by a member of the research team
62414932|NCT05186727|ACTIVE_COMPARATOR|Research-One on One|Education delivered telephonically one-on-one by a member of the research team
62414933|NCT05186727|ACTIVE_COMPARATOR|Patient Ambassador-Group|Education delivered in a group session by a Patient Ambassador (a peer mentor)
62023830|NCT05710523|NO_INTERVENTION|As usual control group|Participants will continue the usual care activities and non-pharmacological interventions already in use in the Nursing Homes without participating in the training.
62023831|NCT02465229|EXPERIMENTAL|Diagnostic methods of indeterminate biliary stricture|
62023832|NCT00898677|EXPERIMENTAL|1|rizatriptan 5 mg
62023833|NCT00898677|EXPERIMENTAL|2|rizatriptan 10 mg
62023834|NCT00898677|ACTIVE_COMPARATOR|3|sumatriptan 100 mg
62023835|NCT00898677|PLACEBO_COMPARATOR|4|placebo
62414934|NCT05186727|ACTIVE_COMPARATOR|Patient Ambassador- One on One|Education delivered telephonically one-on-one by a Patient Ambassador (peer mentor)
62414935|NCT02995928|EXPERIMENTAL|Decompressive craniectomy|Decompressive craniectomy and best medical treatment
62414936|NCT02995928|ACTIVE_COMPARATOR|Control|Only best medical treatment. Decompressive craniectomy is employed only if intracranial pressure \>25 mm Hg for 1-12 hours to keep the patients safe.
62414937|NCT06567782|EXPERIMENTAL|Dostarlimab plus CAPEOX|Participants will receive dostarlimab plus CAPEOX (chemotherapy).
62414938|NCT06567782|ACTIVE_COMPARATOR|CAPEOX|Participants will receive CAPEOX (chemotherapy).
62414939|NCT00123110|EXPERIMENTAL|1|metformin pill plus placebo injection
62414940|NCT00123110|EXPERIMENTAL|2|leuprolide injection plus placebo pill
62414941|NCT00123110|PLACEBO_COMPARATOR|3|placebo pill plus placebo injection
62796302|NCT04899336|EXPERIMENTAL|ExPEC9V|Participants will receive a single intramuscular (IM) injection of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) on Day 1.
62414942|NCT05434767|ACTIVE_COMPARATOR|Standard rehabilitation program|
62414943|NCT05434767|EXPERIMENTAL|Mobile application|
62414944|NCT02325401|EXPERIMENTAL|Metformin with Chemoradiation|Metformin administered orally daily to start one week prior to Cisplatin and Radiation Therapy. Metformin dose is escalating.
62414945|NCT01198990|EXPERIMENTAL|Group 1|"Subjects in will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.~eating/physical activity/positive affect/self-affirmation group."
62414946|NCT01198990|EXPERIMENTAL|Group 2|"Subjects will be randomized to the small change eating strategy and a physical activity goal.~eating/physical activity group. No intervention, just the eating strategy and physical activity components."
62023836|NCT03818373|OTHER|Patients with univentricular congenital heart disease|Patients 8 years old or more with functionally univentricular congenital heart disease
62414947|NCT04476654|NO_INTERVENTION|Fact Sheet Arm|Komen print materials about genetic counseling and testing will be given to women.
62587495|NCT02913404|EXPERIMENTAL|ACL Recon. extra-articular-tenodesis|"Surgical Protocol~Standard single bundle anatomic ACL reconstruction will be performed for all subjects. Quadrupled hamstring tendon will be used with cortical fixation on femur and tibia. ACL-R+EAT will be performed as described by Marcacci with doubled hamstring tendon left attached at the pes anserinus, an anatomic tibial tunnel, staple fixation in the over the top position, routing of the graft superficial to the LCL, and staple fixation at Gerdy's tubercle. Concomitant tears to the menisci and their roots will be repaired as indicated."
62587496|NCT06078267|EXPERIMENTAL|Study Group|"The study group will use the CardioPulmonary Management (CPM) device daily for 6 months (beginning at visit 1 and ending at visit 2). The ADI (Analog Devices, Inc) triaging team will monitor the CPM device data and call the patient as indicated by the data.~The ADI care team will then forward the device data and patient symptomology collected to the patient's care team where that team will device if intervention is necessary. The patient's care team will also have access to view device data at any time using the CPM website."
62023837|NCT04783753|EXPERIMENTAL|EDP-514 and Itraconazole interaction (Part 1)|
62587497|NCT06078267|NO_INTERVENTION|Control Group|The control group will not receive a device and will continue their normal standard of care.
62023838|NCT04783753|EXPERIMENTAL|EDP-514 and Carbamazepine interaction (Part 2)|
62796303|NCT04899336|PLACEBO_COMPARATOR|Placebo|Participants will receive a single IM injection of matching placebo on Day 1.
62220642|NCT04447846|EXPERIMENTAL|Cannabidiol/ Epidiolex|All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis. The drug will be taken for 24 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of cognitive impairments in patients with Sturge-Weber syndrome.
62796304|NCT02999906|PLACEBO_COMPARATOR|Placebo|Matching placebo (sugar pill)
62796305|NCT02999906|ACTIVE_COMPARATOR|Active|Oral treprostinil sustained release tablet
62796306|NCT03791970|EXPERIMENTAL|DCB for post-dilation|DCB was used for post-dilation after stent placement. The DCB for post-dilation in this study is Orchid 035 DCB Catheter.
62796307|NCT03791970|ACTIVE_COMPARATOR|POBA for post-dilation|POBA was used for post-dilation after stent placement. POBA Catheter for post-dilation in this study can be Mustang, Dorado or others balloon catheters.
62220643|NCT00968227|EXPERIMENTAL|Transfusion|
62414948|NCT04476654|ACTIVE_COMPARATOR|YouTube Video Arm|Participants in this arm will receive the culturally tailored video either via a Youtube link or a DVD.
62414949|NCT01827085||Macintosh laryngoscope|Patients will be intubated with a conventional Machintosh laryngoscope
62414950|NCT01827085||Videolaryngoscope|Intubation with Stortz video laryngoscope
62414951|NCT06652386|EXPERIMENTAL|Telemedicine Group|"* Nursing-led lactation support via secure video conferencing platforms (e.g., Zoom for Healthcare).~* Scheduled sessions at postpartum days 1, 3, 7, and 14.~* Additional support available upon request."
62414952|NCT06652386|NO_INTERVENTION|In-Person Group|"* Nursing-led lactation support at the hospital bedside and during follow-up clinic visits.~* Scheduled sessions at postpartum days 1, 3, 7, and 14."
62796308|NCT00001350||1|ALPS patients and relatives of all ages
62796309|NCT04322188||group 1|Patients in Cohort A were treated with siltuximab after the use of continuous positive airways pressure (CPAP) or non-invasive ventilation (NIV). Patients in Cohort B were treated after intubation
62796310|NCT04322188||Group 2|The control cohort will include all the patients with pneumonia/ARDS in need of non-invasive ventilation (CPAP or NIV) or intubation and not receiving experimental treatments in the ReCOVID-19-2020
62796311|NCT03494296||Open, multi-center, prospective|All enrolled and relapsed patients received D-COP regimen chemotherapy
62796312|NCT01646086|EXPERIMENTAL|weekly weight tracking|12 month behavioral weight loss intervention
62796313|NCT01646086|ACTIVE_COMPARATOR|daily weight tracking|12 month behavioral weight loss intervention
62796314|NCT01646086|ACTIVE_COMPARATOR|no weight tracking|12 month behavioral weight loss intervention
62796315|NCT06091150|EXPERIMENTAL|Patients with direct carotid cavernous fistula|Endovascular management using coils , detachable balloons or embolizing agents
62796316|NCT06106802|EXPERIMENTAL|single arm|"Patients will be treated with Lazertinib + tepotinib based on the MET FISH results.~Lazertinib 240mg daily Tepotinib 500mg daily"
62796317|NCT01264406||Exercise Group (20 KKW)|Exercise group will obtain 20 KKW, perform in 4-5 sessions per week for approximately 50-70 minutes per session.
62796318|NCT01264406||Exercise Group (8 KKW)|One exercise group will obtain 8KKW (kcal/kg/week) over 3-4 sessions per wee, which will result in each session lasting approximately 30 minutes
62796319|NCT01264406||Control group|This group will be instructed to maintain their baseline level of exercise.
62023839|NCT04783753|EXPERIMENTAL|EDP-514 and Quinidine interaction (Part 3)|
62023840|NCT00710424|EXPERIMENTAL|Sativex|
62023841|NCT00710424|PLACEBO_COMPARATOR|Placebo|
62023842|NCT03023891|EXPERIMENTAL|Prednisone|"Each participant will received a single dose of oral 60 mg of prednisone~Visit 1: Baseline Oral Glucose Tolerance Test (OGTT) and White Blood Count (WBC) count Visit 2: Prednisone 60mg oral at 7am, OGGT and WBC count at 4 to 8 hours post drug"
62023843|NCT04358445|NO_INTERVENTION|Historical control group|The patients were treated by aneurysm clipping in our hospital in the previous nine months, and normal saline (0.9% Sodium Chloride Injection) had applied as intraoperative perfusion solution in operation of the historical control group. All of the 35 patients selected should meet the inclusion and exclusion criteria of this study.
62023844|NCT04358445|EXPERIMENTAL|MACSF group|Use Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) in the operation, and the remaining treatments should strictly follow the guidelines as same as the historical control group.
62414953|NCT06269965|EXPERIMENTAL|Regeneten® Arm|Arthroscopic shoulder repair, in double row, with complete coverage of the foot print and addition of Regeneten®
62414954|NCT06269965|NO_INTERVENTION|Witness Arm|Arthroscopic shoulder repair, in double row, with complete coverage of the foot print
62796320|NCT04083365|EXPERIMENTAL|CAPECITABINE + concomitant RT + Durvalumab|After careful staging, patients will be initiated to a standard concomitant chemoradiation therapy with 825 mg/m2 twice daily capecitabine every day for 5 weeks and 5040 cGy radiotherapy for 5 days per week for 5 weeks. At the end of treatment patients will undergo a lesion biopsy. One week after the end of CT/RT patients will be treated with 1500 mg IV Q4W durvalumab for 3 administrations. From week 9 to 10 after neoadjuvant therapy will be performed re-staging with CT and MRI scan. Surgery will be performed at week 10-12 from the end of CT/RT and the surgical piece will be analyzed
62414955|NCT02206256|ACTIVE_COMPARATOR|Low calorie diet|Low calorie diet 2 weeks pre-operatively
62414956|NCT02206256|ACTIVE_COMPARATOR|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
62796321|NCT01954095||Group 1: No prior preterm birth & normal cervix length|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had one or more term births (no prior preterm births) and have a normal cervical length (\> 25 mm). These women will serve as gestational age controls for all groups.
62414957|NCT06318091|ACTIVE_COMPARATOR|platelet poor plasma gel group|in this group, plasma gel will be injected intradermally in the dark circles.
62414958|NCT06318091|ACTIVE_COMPARATOR|nanofat group|in this group, nanofat will be injected intradermally and subcutaneously in the dark circles
62796322|NCT01954095||Group 2: No prior preterm birth & short cervix length|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have no prior preterm births and have a short cervical length (20mm or less). These women may receive treatment (e.g. vaginal progesterone, cerclage, pessary, NSAIDs, or a combination thereof) or no treatment.
62796323|NCT01954095||Group 3: Prior preterm birth, normal cervix length, 17-OHPC|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had prior preterm birth, have a normal cervical length and will receive 17-OHPC treatment.
62796324|NCT01954095||Group 4: Prior preterm birth, normal cervix length, no treat|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had prior preterm birth, have a normal cervical length, and will not receive any treatment. These women will serve as controls for Group 3.
62796325|NCT04783909||PEX|42 eyes with PEX syndrome and coexisting cataract
62023845|NCT02555046|NO_INTERVENTION|General Anaesthesia|EVAR-treatment is preformed with the patient in General Anaesthesia
62023846|NCT02555046|EXPERIMENTAL|Local Anaesthesia|EVAR-treatment is preformed with the patient in Local Anesthesia
62023847|NCT03985618|ACTIVE_COMPARATOR|Randomized Caesarean section|Randomized to planned pre-labour Caesarean section
62023848|NCT03985618|ACTIVE_COMPARATOR|Randomized Induction of Labour|Randomized to planned induction of labour
62414959|NCT04317664|NO_INTERVENTION|Control Group|The Control Group will have the in-vehicle device installed in the teen's car, but all feedback features will be disabled.
62414960|NCT04317664|EXPERIMENTAL|Feedback Only Group|The Feedback Only Group will have the in-vehicle devices in the teen's car and download the smartphone app on the teen's smartphone. Researchers will provide instructions on how teens can review their driving data. Teens will also receive biweekly cumulative driving reports.
62414961|NCT04317664|EXPERIMENTAL|Feedback and Parent Communication Group|The Feedback and Parent Communication Group will have the in-vehicle devices in the teen's car and download the smartphone app on the teen's smartphone. Researchers will provide instructions on how teens and parents can review their driving data. The parent will also receive communication training on how to motivate their teen to adopt safe driving habits via online modules and a video call with a motivational interviewing professional. A second booster session will also occur two months after the initial training. Both teens and parents will receive a biweekly cumulative driving report.
62414962|NCT03458910|EXPERIMENTAL|HRV-increase group|Half of the participants will be randomly assigned to this group who will undergo daily practice to increase their heart rate variability (HRV).
62414963|NCT03458910|EXPERIMENTAL|HRV-decrease group|Half of the participants will be randomly assigned to this group who will undergo daily practice to decrease their HRV and heart rate.
62587498|NCT05231772|EXPERIMENTAL|Probiotics|Patients in the Test arm will receive Saccharomyces boulardii (Saccharomyces), (Enterol), Biocodex Ltd, France, registration number LP-000622 from 21.09.2011 at a dose of 250 mg 2 times a day for 3 months.
62796326|NCT04783909||Control|38 eyes with cataract only
62796327|NCT03010033|NO_INTERVENTION|regular care|\[Control group\] preoperative treatment: smoking cession, aerosol inhalation for expectorant and antiasthmatic, anti-infection therapy if necessary and regular rehabilitation-propaganda; postoperative treatment: regular postoperative treatment (anti-infection, pain control, oxygen Inhalation aerosol inhalation for expectorant and antiasthmatic), patting back (3 times/day, 15min/time) and early ambulation unless serious patients.
62796328|NCT03010033|EXPERIMENTAL|pulmonary rehabilitation|\[Study group\] preoperative treatment: smoking cession, aerosol inhalation for expectorant and antiasthmatic, anti-infection therapy if necessary, regular rehabilitation-propaganda and interventional pulmonary rehabilitation (preoperative part); postoperative treatment: regular postoperative treatment (anti-infection, pain control, oxygen Inhalation aerosol inhalation for expectorant and antiasthmatic), patting back (3 times/day, 15min/time), early ambulation unless serious patients and interventional pulmonary rehabilitation (postoperative part).
62023849|NCT03985618|ACTIVE_COMPARATOR|Preference Caesarean section|Preference for planned pre-labour Caesarean section
62023850|NCT03985618|ACTIVE_COMPARATOR|Preference Induction of Labour|Preference for planned Induction of Labour
62023851|NCT02752620|EXPERIMENTAL|Osteopathic Manipulative Treatment|"We selected two types of osteopathic techniques for this study:~Technical articulation: rhythmic technique with low speed in which the goal is the full gain range of motion.~Myofascial techniques (Neuromuscular): techniques involving lateral stretching, linear, deep pressures and pulls of the origins and insertions aiming at a myofascial relaxation.~Sacroiliac articulatory technique; Dorsal articulatory technique; Lumbar paraspinal muscles stretching technique; Lumbar myofascial technique (inhibitory)."
62023852|NCT02752620|ACTIVE_COMPARATOR|Exercise Therapy|"2 types of therapeutic exercises techniques were used:~* Stabilization exercises~* Stretches~Stabilization exercises:~Bridge on the ball 10 - 15 sec Side plank 10 - 15 sec Front board 10 - 15 sec active mobilization lumbopelvic 3 x 6 rep Squats with the ball on the wall 3 x 8 rep~Static-passive stretch (2 x 30 sec):~Paraspinal; Abdominals; Quadratus lumborum; Hip extenders; Hip flexors; Hip abductors; Hip adductors."
62023853|NCT02186951|EXPERIMENTAL|Amoxicillin clavulanic acid|Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
62023854|NCT02186951|PLACEBO_COMPARATOR|Placebo|Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
62023855|NCT04134663|EXPERIMENTAL|vasoconstrictor + intranasal oxytocin group|subjects receive the vasoconstrictor followed by oxytocin
62023856|NCT04134663|ACTIVE_COMPARATOR|vasoconstrictor's placebo + intranasal oxytocin group|subjects receive the vasoconstrictor's placebo followed by oxytocin
62023857|NCT04134663|PLACEBO_COMPARATOR|vasoconstrictor + intranasal oxytocin placebo group|subjects receive the vasoconstrictor followed by intranasal oxytocin's placebo
62023858|NCT05469568|EXPERIMENTAL|Circuit training and telerehabilitation|The experimental group will participate in a 12-week rehabilitation program, including training once a week. After the end of this outpatient program, participants will gain access to a mobile application in which participants will record all their physical activities.The mobile application will also include a library of exercises taught during the outpatient program so patients can practice them at home.
62220644|NCT05727345|ACTIVE_COMPARATOR|Interscalene|Right after general anesthesia induction and patient intubation, the patient will be placed in the semi-sitting position. Following sterile skin preparation, an interscalene block will be performed by the same anaesthesiologist under ultrasound guidance with an in-plane posterior approach approximately between C6-C7 nerve roots through a 22-gauge 50-mm insulated stimulating needle (StimuPlex Nanoline, Braun). Neurostimulation with an initial current of 0,5 mA, pulse width of 100ms, and a frequency of 2 Hz will be used as protection for intraneural injection, once the needle tip is in proximity to the brachial plexus. 15 mL local anesthetic solution (0.375 % bupivacaine anesthetic solution of 10 mL and 2 % lidocaine anesthetic solution of 5 mL) will be observed to disperse within the interscalene space.
62587499|NCT05231772|PLACEBO_COMPARATOR|Placebo|Patients in the Placebo arm will receive the placebo at a dose of 250 mg 2 times a day for 3 months.
62023859|NCT05469568|SHAM_COMPARATOR|Usual Care|Patients have usual care and usual information about importance of regular movement activities and recommendation of proper exercises. Patients don't visit ambulatory rehabilitation program and they don't have access to an application
62023860|NCT06163105|EXPERIMENTAL|Meibomian gland expression (MGX)|"* In-office MGX every 2 weeks~* Lid hygiene at home once daily for 12 weeks~* Preservative-free artificial tears (0.18% sodium hyaluronate) 4 times daily for 12 weeks"
62023861|NCT06163105|NO_INTERVENTION|Control group|"* Lid hygiene at home once daily for 12 weeks~* Preservative-free artificial tears (0.18% sodium hyaluronate) 4 times daily for 12 weeks"
62023862|NCT01289067|OTHER|Satraplatin, Single Arm|
62414964|NCT03840473|EXPERIMENTAL|MET+ICT+Conventional intervention|Hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) followed by ICT (90-second hold-time) and MET (5-second hold-time, 3-second relaxation by exhalation while reaching the new barrier).
62414965|NCT03840473|EXPERIMENTAL|MET+Conventional Intervention|Hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) followed by MET (5-second hold-time, 3-second relaxation by exhalation while reaching the new barrier).
62414966|NCT03840473|ACTIVE_COMPARATOR|Conventional Intervention|Received hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) only.
62414967|NCT05782140||Mayo Clinic Rochester Surgical Patients|Mayo Clinic Watch Device
62587500|NCT05744960|EXPERIMENTAL|HPV vaccine communication training.|Staff in clinics randomized to this arm will receive an intervention called Announcement Approach Training (AAT). This training is designed to improve communication about HPV vaccination.
62587501|NCT05744960|EXPERIMENTAL|HPV vaccine communication training and clinic-level financial incentive program|Staff in clinics randomized to this arm will receive the Announcement Approach Training and a clinic-level financial incentive program with a monthly data feedback report to increase HPV vaccine uptake.
62587502|NCT03631914|ACTIVE_COMPARATOR|Active needle tip tracking|A needle tip tracking system is used when performing an ultrasound guided infraclavicular brachial plexus block.
62796329|NCT03029910|EXPERIMENTAL|Cryotherapy and eccentric exercise|
62796330|NCT03029910|EXPERIMENTAL|Vibration and eccentric exercise|
62023863|NCT01274546||"In Office"|These subjects will come into the office to perform the consenting process, and complete all evaluations required at the only visit in the study.
62796331|NCT03029910|NO_INTERVENTION|Control|
62796332|NCT00237497|EXPERIMENTAL|Ramelteon 8 mg QD|
62023864|NCT01274546||"Telephone Arm"|These subjects will be consented over the phone and give a verbal consent to participate. They will complete all aspects of the study over the phone except for the knee society score evaluation and the x-ray.
62796333|NCT00237497|ACTIVE_COMPARATOR|Zopiclone 7.5 mg QD|
62023865|NCT01886976|EXPERIMENTAL|anti-CD138 CAR T cells|Patients receive anti-CD138-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
62796334|NCT00237497|PLACEBO_COMPARATOR|Placebo QD|
62414968|NCT04365907|EXPERIMENTAL|Omarigliptin 12.5 mg|Drug: Omarigliptin 12.5 mg Once weekly new anti-diabetic drug approved only in Japan Other Name: Zafatek tablets
62796335|NCT05392309|EXPERIMENTAL|Manual ankle rocking training|Group will receive manual ankle rocking training with lower limb exercise and core strengthening of trunk
62796336|NCT05392309|ACTIVE_COMPARATOR|conventional|Group will receive lower limb exercises and core strengthening of trunk. Sessions will be 4 days in a week
62796337|NCT02052752|EXPERIMENTAL|Test Product|Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
62796338|NCT02052752|ACTIVE_COMPARATOR|Vehicle gel|The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
62796339|NCT02052752|PLACEBO_COMPARATOR|Positive control|A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
62796340|NCT03434548||Cohort 1|Healthy controls. Multi-modal MRI imaging.
62023866|NCT05020483|EXPERIMENTAL|FEIBA Group|Pediatric patients ≤15 kg of weight, undergoing cardiac surgery with cardiopulmonary bypass will receive activated prothrombin complex concentrate (aPCC) FEIBA to be incorporated into standard treatment of post-bypass coagulopathic bleeding.
62414969|NCT05136859|EXPERIMENTAL|preserve|preserve the perivascular fat of the target cephalic vein
62414970|NCT05136859|NO_INTERVENTION|remove|remove from perivascular fat of the target cephalic vein
62414971|NCT00935415|ACTIVE_COMPARATOR|Montelukast|capsules prepared in blindness
62414972|NCT00935415|PLACEBO_COMPARATOR|Placebo|matched placebo
62414973|NCT06702137|ACTIVE_COMPARATOR|Experimental Condition|Active sessions will last 1 hour each. The following parameters will be used for electric stimulation: low frequency (20 Hz), low current intensity (2 mA), with a small pulse width of 25-170 microseconds. These parameters were previously found to be safe in human studies. Based on the clinical exam of each patient, the spastic muscles will be targeted. EXOPULSE Mollii Suit is used for the activation of weak muscles or relaxation of spastic muscles mediated by a physiological reflex mechanism referred to as reciprocal inhibition. By sending an electrical signal to an antagonistic muscle, the spastic muscle will subsequently relax.
62587503|NCT03631914|OTHER|Inactive needle tip tracking|No needle tip tracking system is used when performing an ultrasound guided infraclavicular brachial plexus block.
62796341|NCT03434548||Cohort 2|"People with Huntington's (without symptoms, early disease stage, and later disease stage), and healthy controls~People with HD divided in groups according to disease stage:~* Without symptoms (approximately HD-ISS stage 0 or 1)~* Early disease (approximately HD-ISS stage 2)~* Later disease stage (approximately HD-ISS stage 3)"
62796342|NCT01615016|EXPERIMENTAL|MISurf|Minimally Surfactant application via small tube inserted into the trachea under CPAP therapy without formal intubation and without mechanical ventilation
62796343|NCT01615016|ACTIVE_COMPARATOR|InSurE|Surfactant application via Intubation - Surfactant Application - Extubation sequence
62796344|NCT00807352||level 2|Patients triaged level 2
62587504|NCT06667999|OTHER|Albumin domain|Adult patients with shock in the intensive care unit will be randomised to an albumin arm to receive any albumin solution or in the no use of albumin arm not to receive albumin solutions.
62587505|NCT05269706|EXPERIMENTAL|Standard Meal|Participants taking a standard meal.
62023867|NCT05020483|PLACEBO_COMPARATOR|Placebo Group|Pediatric patients ≤15 kg of weight, undergoing cardiac surgery with cardiopulmonary bypass will receive a placebo to be incorporated into standard treatment of post-bypass coagulopathic bleeding.
62587506|NCT05269706|EXPERIMENTAL|High Fat Meal|Participants taking a high fat meal.
62796345|NCT00807352||level 3|patients triaged level 3
62796346|NCT00807352||level 4|patients triaged level 4
62796347|NCT00807352||level 5|patients triaged level 5
62796348|NCT04859088|EXPERIMENTAL|Partial Enteral Nutrition|Patients allocated to Partial Enteral Nutrition study arm will be asked to replace 50% of their daily energy requirements with a proprietary formula (Modulen IBD, Nestle) for 6 weeks alongside standard care of treatment with adalimumab as induction therapy.
62220645|NCT05727345|EXPERIMENTAL|SHAC|Right after general anesthesia induction and patient intubation, the patient will be placed in the semi-sitting position with the arm in extension and abduction. Following sterile skin preparation, a SHAC block will be performed by the same anaesthesiologist under ultrasound guidance by visualization of the interfascial space between the deep lamina of the deltoid muscle fascia and the superficial lamina of the subscapularis fascia and glenohumeral pericapsular space. A 22-gauge 50-mm insulated stimulating needle (StimuPlex Nanoline, Braun) will be used to give 1-3 mL of 5% Dextrose for the correct location and then 15 mL local anesthetic solution will be divided into 7,5 mL (0.375 % bupivacaine 5 mL and 2 % lidocaine 2,5 mL) for each target points as interfascial space and pericapsular space.
62796349|NCT04859088|NO_INTERVENTION|Unrestricted diet|Patients allocated to unrestricted diet study arm will be asked to follow their normal diet for 6 weeks alongside standard care of treatment with adalimumab as induction therapy.
62796350|NCT00352924||Cohort of Agricultural Workers|Cohort of Agricultural Workers
62796351|NCT01324661|NO_INTERVENTION|Control|Individuals who receive the ball during a computerized ball tossing game about the same number of times as the other players in the game.
62796352|NCT01324661|OTHER|Ostracism|Participant would receive the ball of a ball-tossing game once or twice in the beginning and then never again for the duration of the game.
62796353|NCT05143034|EXPERIMENTAL|TCI66207 Essence|Essence
62796354|NCT05143034|PLACEBO_COMPARATOR|Placebo Essence|
62796355|NCT00250159||1/CAH Patients Managed at the NIH|Patients with Congenital Adrenal Hyperplasia (CAH).
62796356|NCT00250159||2/CAH Patients Managed by Outside Physicians|Patients with Congenital Adrenal Hyperplasia (CAH) followed by home physician post visit at NIH.
62796357|NCT00250159||3/Relatives of Patients|Relatives (mostly parents) of patients will be genotyped. This is often necessary to establish the genotype of the patient.
62796358|NCT00250159||4/FMPP Patients|Patients with Familial Male-Limited Precocious Puberty (FMPP).
62796359|NCT00250159||5/Patients with Androgen Excess of Unknown Etiology|Patients with Androgen Excess of Unknown Etiology followed by home physician post visit at NIH.
62796360|NCT06706141|EXPERIMENTAL|Experimental Group|The experimental group received various interventions such as group education based on the health belief model, individual counseling, and brochures on screening. The training was given by two study team members in the faculty's conference hall, in the form of a presentation, discussion, and question-answer sessions, with the experimental group divided into two groups, lasting approximately 90 minutes. It was completed in 3 sessions with breaks every 30 minutes. For training hours, free hours when students did not have classes were chosen. For each training group, a member of the study team first gave a presentation on breast cancer and breast screening behaviors and BSE (30 minutes). Then, a film was shown on the BSE practice recommended by the World Health Organization (20 minutes) and training was given on how to perform correct and effective BSE on the breast model (20 minutes).
62796361|NCT06706141|NO_INTERVENTION|Control Group|The intervention group within the control group received health education on early diagnosis and prevention of breast cancer once the program was finished for them and all data had been gathered for both groups.
62796362|NCT01578681|ACTIVE_COMPARATOR|Airway clearance, bronchiectasis|"The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist.~Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary."
62796363|NCT01578681|PLACEBO_COMPARATOR|bronchiectasis, stretching|"The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist.~Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary."
62220646|NCT00346671|PLACEBO_COMPARATOR|Supine Rest|30min supine rest listening to soft music
62414974|NCT06702137|SHAM_COMPARATOR|Control Condition|In the control condition, the patients will receive a sham stimulation, for which the control unit will be programmed to start stimulating for 1 minute then it will shut off. There is no risk related to the sham intervention since it consists of applying the same parameters used for the active session (low frequency: 20 Hz; current intensity: 2 mA; pulse width ranging from 25 to 170 µs) but for a shorter duration of time (1 minute instead of 1 hour).
62414975|NCT03486327|EXPERIMENTAL|0.03mL/kg Dose Group|A group of up to 8 subjects to receive a single dose of BR55 at 0.03mL/kg.
62414976|NCT03486327|EXPERIMENTAL|0.05mL/kg Dose Group|A group of up to 8 subjects to receive a single dose of BR55 at 0.05mL/kg.
62796364|NCT04758065|ACTIVE_COMPARATOR|1-Goup: Control group|Home-based cervical therapeutic exercise and manual therapy.
62796365|NCT04758065|EXPERIMENTAL|2-Group: Radial pressure waves Group|Home-based cervical therapeutic exercise, manual therapy, and radial pressure waves.
62796366|NCT03038295|EXPERIMENTAL|oral propranol group|"Enrolled preterm newborns will receive oral propranolol 0.25mg/kg daily(every 24 hours).~The treatment will be started as soon as the diagnosis of stage 1 or 2 ROP without plus is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days."
62796367|NCT03038295|PLACEBO_COMPARATOR|oral placebo group|Enrolled preterm newborns will receive oral normal saline 0.25mg/kg daily(every 24 hours) and other disposals will be done similarily to the oral propranol group.
62023868|NCT04666272||dabrafenib in combination with trametinib as adjuvant treatment|Patients will be treated according to the China package insert for dabrafenib and trametinib. The approved starting doses of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) will be used.
62220647|NCT00346671|SHAM_COMPARATOR|Sham Reiki|30 min intervention by sham practitioner
62023869|NCT01298791|EXPERIMENTAL|Provider sitting|Providers seated during communication through hospitalization
62023870|NCT01298791|EXPERIMENTAL|Provider standing (control)|Providers standing during communication through hospitalization
62023871|NCT01281358|EXPERIMENTAL|HOP-ON intervention|Participants will receive a CD-ROM (or DVD and booklet if no access to computer) highlighting motor skills which could be encouraged with premature infants
62023872|NCT01281358|ACTIVE_COMPARATOR|SMILES|Participants will received a CD-ROM (or DVD and booklet if no access to a computer) which contains information on interacting with their premature infant
62023873|NCT01153646|EXPERIMENTAL|Cohort 1: 1x10e9 and Cohort 2: 1x10e10 T cells per infusion|Group of patients receiving genetically modified T-cells
62023874|NCT01286259|EXPERIMENTAL|Intervention Arm|
62023875|NCT02187757|EXPERIMENTAL|PreLipid|Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90days along with lifestyle modification.
62220648|NCT00346671|EXPERIMENTAL|Reiki|30 min session with Reiki practitioner
62023876|NCT02187757|PLACEBO_COMPARATOR|Placebo 600 mg capsules|Placebo was given to patients twice daily 30 mins before food for 90 days along with lifestyle modification program.
62220649|NCT05126082|NO_INTERVENTION|Control|Providers and patients assigned to control arm clinics will engage in the current standard of care, without access to the PedsBP clinical decision support tool.
62796368|NCT03038295|EXPERIMENTAL|eye drop propranol group|"Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%). 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette,in each eye, four times daily (every 6 hours) .~The treatment will be started as soon as the diagnosis of stage 1 or 2 ROP without plus is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days."
62796369|NCT03038295|PLACEBO_COMPARATOR|eye drop placebo group|Enrolled preterm newborns will receive placebo as ophthalmic solution in the same way of eye drop propranolol and other disposals will be done similarily to the eye drop propranol group.
62023877|NCT01020721||Glaucoma|South korean patients with primary congenital glaucoma
62023878|NCT06634563|EXPERIMENTAL|mindfulness meditation|Twenty five women in study group will receive mindfulness meditation for 30 minutes in addition to mobile application-based brain training program (cognitive behavioral training) for 30 minutes day after day for 8 weeks
62414977|NCT03486327|EXPERIMENTAL|0.08mL/kg Dose Group|A group of 8 subjects to receive a single dose of BR55 at 0.08mL/kg.
62414978|NCT06014359|PLACEBO_COMPARATOR|Control group|Patients of this group will be Nebulized with 3 mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
62023879|NCT06634563|ACTIVE_COMPARATOR|cognitive behavioral training|Twenty five women in control group will receives mobile application-based brain training program (cognitive behavioral training) for 60 minutes day after day for 8 weeks.
62414979|NCT06014359|EXPERIMENTAL|Study group|Patients of this group will be Nebulized with Dexmedetomidine (1 mcg/kg) in 3mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
62414980|NCT04854707||Monoprotocols: follitropin alpha biosimilar only and antagonists/agonists of GnRH|The ovarian stimulation (OS) protocols included monotherapy protocols with using follitropin alpha biosimilar only and antagonists/agonists of of gonadotropin-releasing hormone (GnRH): ganirelix, cetrorelix, triptorelin, buserelin.
62023880|NCT04159688|EXPERIMENTAL|Alcohol Challenge|Alcohol Challenge, oral, targeting BAL of 60 mg/dL, Given once
62023881|NCT04607187||Normals, Dupuytren's subjects with and without treatment|Ultrasound analysis of patient receiving treatment for Dupuytren's
62220650|NCT05126082|EXPERIMENTAL|Low-Intensity Implementation|Providers and patients in the low-intensity arm will have access to the PedsBP clinical decision support tool and will receive standard training and training resources using the health systems standard training platform.
62220651|NCT05126082|EXPERIMENTAL|High-Intensity Implementation|Providers and patients in the high-intensity arm will have access to the PedsBP clinical decision support tool and will receive enhanced training and training resources, and regular feedback from the project team regarding CDS use rates.
62220652|NCT02105922|ACTIVE_COMPARATOR|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
62220653|NCT02105922|EXPERIMENTAL|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
62220654|NCT02105922|ACTIVE_COMPARATOR|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
62220655|NCT00731809|OTHER|1|PET CT
62220656|NCT06335277||Total Body Irradiation (TBI)|Patients treated at European Institute of Oncology with Total Body Irradiation (TBI)
62414981|NCT04854707||Mixed protocols: recombinant and urinary-derived gonadotropins and antagonists/agonists of GnRH|The OS protocols included: mixed protocols (recombinant with addition of urinary-derived gonadotropins) and antagonists/agonists of GnRH (ganirelix, cetrorelix, triptorelin, buserelin), where follitropin alpha biosimilar used for at least 5 days during OS.
62414982|NCT04854707||Monoprotocols: follitropin alpha biosimilar only and antagonists of GnRH|The OS protocols included: monotherapy protocols with using only follitropin alpha biosimilar and antagonists of GnRH.
62796370|NCT01488526|NO_INTERVENTION|Control arm: HBIG & vaccine for infants|Provide standard of care to mothers and standard immunoprophylaxis to their infants
62796371|NCT01488526|EXPERIMENTAL|TDF treatment arm|tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum for mothers and standard immunoprophylaxis to their infants
62796372|NCT01115673|EXPERIMENTAL|ACE-1000|1000 mg Acetaminophen Caplet
62796373|NCT01115673|ACTIVE_COMPARATOR|ACE-650|650 mg Acetaminophen Caplet
62796374|NCT01115673|PLACEBO_COMPARATOR|ACE-0|0 mg Acetaminophen Caplet
62796375|NCT05562323||MKP vaccination for pre-exposure prophylaxis (HIV positive)|HIV positive individuals who receive MKP vaccination for pre-exposure prophylaxis
62796376|NCT05562323||MKP vaccination for pre-exposure prophylaxis (seronegative individuals)|HIV seronegative individuals who receive MKP vaccination for pre-exposure prophylaxis
62587507|NCT05269875|OTHER|Advance care planning in heart failure patients|The patient and their closest relative will be offered a palliative care intervention by the Department of Cardiology.
62587508|NCT03799692|EXPERIMENTAL|Chemotherapy|Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, Carboplatin AUC=2, iv, d1, 8, 15, 4 cycles (21 days per cycle).
62796377|NCT05305560|EXPERIMENTAL|Active IMP|
62414983|NCT04854707||Monoprotocols: follitropin alpha biosimilar only and agonist of GnRH|The OS protocol included: monotherapy protocols with using only follitropin alpha biosimilar and agonists of GnRH.
62796378|NCT05305560|PLACEBO_COMPARATOR|Placebo|
62796379|NCT06726564|EXPERIMENTAL|MT027|
62796380|NCT03334032||Inpatient treatment for Anorexia nervosa|"Adolescents with anorexia nervosa assessed~1. at baseline: on admission to inpatient treatment~2. at follow-up: 6 months after admission on outpatient basis"
62796381|NCT03334032||Controls|Adolescent healthy and normal weight controls (matched for gender and age), assessed at one point of time
62796382|NCT01880177||Current smokers|Current smokers (\>10 pk yrs.)
62796383|NCT01880177||Ex-smokers|Ex-smokers with a history of \>10 pk yrs
62796384|NCT01880177||Never-smokers|Never-smokers, defined as ≤100 cigarettes/pipes/cigars over life
62796385|NCT06726213|EXPERIMENTAL|walk and talk group|Participants will participate in a walk and talk intervention once every two weeks for a 16-week period.
62796386|NCT06726213|NO_INTERVENTION|Control group|Participants will continue their usual treatments.
62796387|NCT02588261|EXPERIMENTAL|ASP8273|Participants received 300 mg of ASP8273 orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).
62414984|NCT04854707||The overall protocols|The OS protocols included: (1) Monoprotocols: follitropin alpha biosimilar only and antagonists/agonists of GnRH, (2) Mixed protocols: recombinant and urinary-derived gonadotropins and antagonists/agonists of GnRH
62796388|NCT02588261|ACTIVE_COMPARATOR|erlotinib or gefitinib|Participants received 150 mg of erlotinib or 250 mg of gefitinib orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).
62796389|NCT05919953|EXPERIMENTAL|Virtual reality and therapeutic education|"Multimodal tele-rehabilitation consisting of therapeutic education and immersive virtual reality neck exercises.~The duration of the intervention will be 6 weeks, including 5 virtual reality sessions (15-20 minutes per session, without supervision of the physiotherapist) and 1 teleconsultation session with a physiotherapist (30 minutes per session) per week.~In addition, participants will receive several brochures to read on their own (therapeutic education). These brochures will be discussed with the physiotherapist during the teleconsultations."
62796390|NCT00413218|EXPERIMENTAL|Isavuconazole (ISA)|Participants received 3 intravenous (IV) loading doses of 200 mg of isavuconazole on days 1 and 2, followed by an IV maintenance dose of 200 mg once daily from day 3 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV to oral therapy. Oral therapy consisted of 200 mg isavuconazole twice daily.
62414985|NCT05061459||Group1:|28 control
62796391|NCT00413218|ACTIVE_COMPARATOR|Caspofungin (CAS)/Voriconazole|Participants received 1 intravenous (IV) loading dose of 70 mg CAS on day 1, followed by an IV maintenance dose of 50 mg CAS from day 2 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV CAS to oral voriconazole comprising of a loading dose of 400 mg twice daily (BID) on the first day of oral therapy followed by standard dosing of 200 mg BID thereafter.
62796392|NCT04968912|PLACEBO_COMPARATOR|Group 1: Placebo|Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 22 along with standard of care treatments (\[including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues\], and/or one immunomodulator with or without low-dose glucocorticosteroids).
62414986|NCT05061459||Group 2:|68 T2DM patients
62587509|NCT01065376|EXPERIMENTAL|on the day of hCG|cabergoline administration for 8 days on the day of hCG.
62587510|NCT01065376|EXPERIMENTAL|on the day after oocyte retrieval|cabergoline administration for 8 days on the day after oocyte retrieval
62023882|NCT06634654|EXPERIMENTAL|Patients who undergo total total knee arthroplasty|The study population comprises 197 patients who require Total Knee Arthroplasty (TKA) due to symptomatic, end-stage knee osteoarthritis. Eligible participants are adults over the age of 18 years with functionally intact ligaments. Exclusion criteria include individuals with neurological or other conditions that affect their ability to participate in walking trials, those with inflammatory or infectious arthritis, previous significant knee surgeries such as articular fractures (excluding knee arthroscopy and meniscal surgery), and those with active tumors or who are pregnant. This population selection is aimed at assessing the efficacy of AI-integrated interventions in improving surgical outcomes and postoperative recovery in a homogeneous group affected by severe knee degeneration.
62023883|NCT06074094|EXPERIMENTAL|probiotic group|Healthy lifestyle habits and standard diet was recommended for participants ,Probiotic supplementation (Lacteol fort 10 billion) which contains culture medium and lactobacillus LS as active ingredients was administered in the form of oral sachets once daily for 12 weeks.
62220657|NCT00112047|ACTIVE_COMPARATOR|EFV+CBV|Participants in this group received EFV 600 mg once daily + Combivir (\[CBV\]; the fixed dose combination pill containing lamivudine 150 mg + zidovudine 300 mg) taken twice daily from the start of the study until Week 144. At Week 144 all participants who opted to roll over into the additional 96-week study extension received Atripla (\[ATR\]; the fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg) taken once daily until the end of the study (Week 240). At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.
62220658|NCT00112047|EXPERIMENTAL|EFV+FTC+TDF|Participants in this arm received 3 component drugs: efaviren (EFV; 600 mg) + emtricitabine (FTC; 200 mg) + tenofovir disoproxil fumarate (tenofovir DF \[TDF\]; 300 mg) as 3 separate pills once daily from the start of the study. At 96 weeks Truvada (\[TVD\] the fixed-dose combination pill containing FTC/TDF \[200/300 mg\] once daily) replaced the 2 component drugs FTC + TDF; participants continued to receive EFV 600 mg once daily. At Week 144 all participants who opted to roll over into the further 96-week study extension received ATR. At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.
62220659|NCT01175954|EXPERIMENTAL|Lacosamide Open-Label|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
62220660|NCT06401239||ARF Survivor-Care Partner Dyads|"The study will recruit 235 dyads of adult ARF survivors and care partners. The term care partner refers to an individual (e.g. family member or friend) that supports the survivor at home."
62414987|NCT06111781|ACTIVE_COMPARATOR|Stereotactic body radiotherapy|SBRT Though a range of doses are delivered nationally for IR prostate cancer, the most common regimen is 7.25 Gy- 8.00 Gy x 5 fractions, given over 2 weeks.
62414988|NCT06111781|ACTIVE_COMPARATOR|Relugolix and SBRT|SBRT and Relugolix SBRT along with 30 days of total relugolix (study drug) will be used. Relugolix starting 14 days to 17 days prior to the first treatment.
62796393|NCT04968912|EXPERIMENTAL|Group 2: Nipocalimab Dose 1|Participants will receive nipocalimab dose 1 IV q2w through Week 22 along with standard of care treatments (\[including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues\], and/or one immunomodulator with or without low-dose glucocorticosteroids).
62414989|NCT02552329|NO_INTERVENTION|Control group|Since no medication or other treatments are currently approved by Food and Drug Administration (FDA) for treatment of MCI, participants in the usual care group will not receive any form of treatment. They will receive an educational material about cognitive impairment. They will also be asked to maintain their daily routine.
62796394|NCT04968912|EXPERIMENTAL|Group 3: Nipocalimab Dose 2|Participants will receive nipocalimab dose 2 IV q2w through Week 22 along with standard of care treatments (\[including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues\], and/or one immunomodulator with or without low-dose glucocorticosteroids).
62796395|NCT04992871||Patient population|Children, adolescents and adults diagnosed with cerebral palsy who are born, treated or living in Switzerland
62796396|NCT01994616||keloid or hypertrophic scars|All patient including all skin types with keloid or hypertrophic disease receiving Intralesional Cryotherapy
62796397|NCT02426736|ACTIVE_COMPARATOR|Low dose intravenous dexamethasone|4 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
62796398|NCT02426736|ACTIVE_COMPARATOR|High dose intravenous dexamethasone|8 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
62414990|NCT02552329|EXPERIMENTAL|Tai Chi exercise group|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down.
62587511|NCT01071980|ACTIVE_COMPARATOR|Specific resistance training|3 x 20 min a week of specific resistance training for 20 weeks
62023884|NCT06074094|ACTIVE_COMPARATOR|standard treatment group|Healthy lifestyle habits and standard diet was recommended for participants ,
62023885|NCT04917679|EXPERIMENTAL|Combination group|Eltrombopag plus diacerein
62023886|NCT04917679|PLACEBO_COMPARATOR|Monotherapy group|Eltrombopag monotherapy
62414991|NCT06193044|EXPERIMENTAL|Amlodipine and Valsartan Tablets USP 10/160 mg, Then Exforge® 10/160 mg|Participants first received Amlodipine and Valsartan Tablet USP 10/160 mg 1 tablet (Test product) in a fasting state.After a washout period of 21 days, they then recieved Exforge® 10/160 mg tablet (Reference product) in a fasting state
62414992|NCT06193044|ACTIVE_COMPARATOR|Exforge® 10/160 mg, Then Amlodipine and Valsartan Tablets USP 10/160 mg|Participants first received Exforge® 10/160 mg tablet 1 tablet (Reference product) in a fasting state.After a washout period of 21 days, they then recieved Amlodipine and Valsartan Tablets USP 10/160 mg (Test product) in a fasting state.
62220661|NCT01149109|EXPERIMENTAL|lomustine (CCNU) + temozolomide (TMZ) and radiotherapy|60 Gy standard radiotherapy (RT, 30 x 2 Gy) Six 42-day courses of oral CCNU 100 mg/m2 (day 1) and oral TMZ 100 mg/m2 (day 2-6), first CCNU application during the first week of RT CCNU/TMZ and radiotherapy start 2-5 weeks after diagnosis (day of surgery for glioblastoma (GBM)). In courses 2-6, TMZ dose are adjusted according to the hematotoxicity observed in the previous course and can be increased stepwise up to 200 mg/m2/day
62414993|NCT05565105|EXPERIMENTAL|Regimen A: TBI/Thiotepa/Cyclophosphamide|"Patients in enrolled in Regimen A will receive the following:~* Total Body Irradiation (TBI), hyper-fractionated to a dose of 1320 cGy depending on age, stage of disease and requirement of general anesthesia with lung shielding~* Thiotepa, 5 mg/kg/day x 2 days via IV infusion over 4 hours daily or 10 mg/kg on one day~* Cyclophosphamide, 60 mg/kg/day x 2 days via IV infusion over 2 hours daily (or if cyclophosphamide is contraindicated, fludarabine at 25 mg/m\^2 x 5 days may be substituted)"
62414994|NCT05565105|EXPERIMENTAL|Regimen B: Busulfan/Melphalan/Fludarabine|"Patients in enrolled in Regimen B will receive the following:~* Busulfan, IV 0.8 mg/kg q6hours x 10 or 12 doses over 3 days, depending on the disease~* Melphalan, 70 mg/m\^2/day x 2 days via IV infusion over 30 minutes daily~* Fludarabine, 25 mg/m\^2/day x 5 days via IV infusion over 30 minutes daily"
62414995|NCT03255226|EXPERIMENTAL|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
62414996|NCT03278483|ACTIVE_COMPARATOR|Isoniazid|Diabetic patients with a positive TST of \>10mm, will be randomly assigned to receive treatment with isoniazid 300mg Oral Tablet daily plus pyridoxine 50mg daily for six months
62414997|NCT03278483|ACTIVE_COMPARATOR|Rifampin|Diabetic patients with a positive TST of \>10mm, who wil be randomly assigned to receive treatment with rifampin 600mg Oral Tablets daily for three months
62414998|NCT02516917|EXPERIMENTAL|Attention Training Technique (ATT)|Participants will receive 3-5 sessions of the ATT over a period of 3-5 weeks. A set of standardised instructions will be read to each participant and then they will engage in the procedure for a period of 12 minutes. Participants will listen to a set of auditory stimuli and follow the directions of the recording. This will ask them to focus their attention on selected sounds or spatial locations, switch attention between different sounds and locations, before allocating their attention to all sounds simultaneously. Participants will be given a recording of the ATT on a C.D and asked to practice this at least once before the second session.
62414999|NCT02031874||Miami Cohort|Measured vaccine response to H1N1 in HIV perinatally infected children
62220662|NCT01149109|ACTIVE_COMPARATOR|temozolomide and radiotherapy|60 Gy standard radiotherapy (RT, 30 x 2 Gy) and concomitant TMZ therapy (daily TMZ 75 mg/m2) starting with the first day of radiotherapy Six 28-day courses of TMZ (day 1-5) starting 4 weeks after completion of radiotherapy. In the first course TMZ is given at a dose of 150 mg/m2/day, in case no toxicity is observed, the 2nd course is applied at a daily dose of 200 mg/m2
62220663|NCT00767468|EXPERIMENTAL|Bilirubin Normal to 3x Upper Limit of Normal|
62415000|NCT00730067|EXPERIMENTAL|1|Sildenafil treatment
62415001|NCT00730067|PLACEBO_COMPARATOR|2|placebo
62415002|NCT06636682|EXPERIMENTAL|FK-PC101|Up to 7 doses of intradermal FK-PC101 vaccine
62796399|NCT02426736|ACTIVE_COMPARATOR|Low dose perineurial dexamethasone|4 milligrams dexamethasone administered once perineurally with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
62796400|NCT02426736|ACTIVE_COMPARATOR|High dose perineurial dexamethasone|8 milligrams dexamethasone administered once perineurally with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
62796401|NCT04112966|EXPERIMENTAL|Early Manual Lymph Drainage|14 sessions of manual lymphatic drainage technique in the three months following surgery and received health education on the prevention of lymphedema.
62220664|NCT00767468|EXPERIMENTAL|Bilirubin >3x to 6x Upper Limit of Normal|
62220665|NCT04939961|EXPERIMENTAL|Hericium erinaceus|8 gram of mushroom Hericium erinaceus (containing 5 milligram of erinacines) per day
62415003|NCT06636682|ACTIVE_COMPARATOR|Standard of Care|Standard of care, with possibility to cross-over to FK-PC101 vaccine should prostate cancer recur within 1 year of radical prostatectomy
62415004|NCT04718727|PLACEBO_COMPARATOR|Group 1|patients will receive oral placebo tablets one hour preoperatively
62415005|NCT04718727|ACTIVE_COMPARATOR|Group 2|patients will receive oral 5 mg Olanzapine tablets one hour preoperatively
62415006|NCT04718727|ACTIVE_COMPARATOR|Group 3|patients will receive oral 10 mg Olanzapine tablets one hour preoperatively
62415007|NCT04332874|EXPERIMENTAL|Participants with Sarcoma|Advanced/metastatic extremity sarcoma eligible for pembrolizumab and isolated limb infusion (ILI)
62415008|NCT05759988|EXPERIMENTAL|Outpatient cervical ripening with Foley|Cervical ripening will begin with a Foley balloon in the outpatient setting
62415009|NCT05759988|NO_INTERVENTION|Standard of care Inpatient cervical ripening|Cervical ripening will begin in the inpatient setting with Foley ballooon or other cervical ripening agent
62415010|NCT00160446|EXPERIMENTAL|1|
62415011|NCT00160446|EXPERIMENTAL|2|
62796402|NCT04112966|OTHER|Health education for lymphedema prevention|Only the health education for lymphedema prevention.
62796403|NCT03833024|ACTIVE_COMPARATOR|Venixxa|Micronized Purified Flavonoid Fraction (MPFF) for 6 months MPFF 500 mg, BID (morning and evening) for 6 months
62796404|NCT03833024|PLACEBO_COMPARATOR|Placebo|"Placebo for 6 months~1 Tablet, BID (morning and evening) for 6 months"
62796405|NCT03191266|ACTIVE_COMPARATOR|active rTMS|Active rTMS will receive an intermittent rTMS stimulation protocol.
62796406|NCT03191266|SHAM_COMPARATOR|sham rTMS|Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
62796407|NCT01486966|EXPERIMENTAL|Insulin detemir / IAsp|
62796408|NCT01486966|ACTIVE_COMPARATOR|insulin NPH|
62415012|NCT00160446|EXPERIMENTAL|3|
62415013|NCT00160446|PLACEBO_COMPARATOR|4|
62220666|NCT04939961|PLACEBO_COMPARATOR|Placebo capsule|8 gram of allergen free corn starch per day
62220667|NCT05681923||High-Risk Cohort|"High family risk cohort for recurrence of autism and other developmental disorders in siblings (have at least one child with a confirmed diagnosis of autism)~Specific to the High Risk cohort:~Clinical observations of the unborn child will be performed at 3 months, 6 months, 12 months, between 24 and 30 months, 36 months, between 60 and 66 months, and 72 months by psychologists or child psychiatrists in the participating hospitals. They will allow to evaluate the child's behaviors in the areas of communication and social interaction.~A video recording of the baby at 3 months of age will allow the analysis of the General Movements Assessment.~If genetic consultation is provided to the family as part of the routine care, the results will be collected and additional blood samples may be taken"
62220668|NCT05681923||Low Risk Cohort|Low family risk cohort for recurrence of autism and occurrence of other developmental disorders in siblings. The risk is comparable to the risk observed in the general population (do not have a child with autism, nor with other developmental disorders).
62220669|NCT04614454|EXPERIMENTAL|Experimental arm|Devices will be programmed by our study coordinator to provide a sham signal or the experimental signal. The location of the TENS electrodes will be determined by the location of the pain with the goal of placing the unit at the top of the dermatological level corresponding to the pain. The study coordinator will assist each subject to place the device appropriately. Treatment will be administered for 1 hour per day for 4 weeks.
62220670|NCT04614454|SHAM_COMPARATOR|Sham arm|The sham unit looks identical to the experimental unit. There may be a sensation experienced by subjects with the sham device but it does not deliver an electric current as the experimental units. The study coordinator will assist each subject to place the device appropriately. Treatment will be administered for 1 hour per day for 4 weeks.
62220671|NCT01776801|EXPERIMENTAL|Hydrocephalus|Patients suffering of hydrocephalus (cognitive impairment, gait disturbance, urinary incontinence and enlargement of the ventricles) require for clinical purpose infusion studies i.e. injection of mock cerebrospinal fluid (CSF) in the sub arachnoid space to artificially increase ICP. We aim at using infusion studies as a indirect tool to assess whether a moderate increase in ICP has any influence on haemodynamics.
62220672|NCT01853774|EXPERIMENTAL|Tailored Navigation|Participants will receive tailored navigation phone calls to assist them with barriers in making a clinic appointment or attending the clinic. The tailored navigation intervention protocol will be used to guide individuals from an especially hard-to-reach, multicultural, and underinsured population into primary care clinics and, subsequently, track the effects of this intervention through a clinic navigation program to complete Colorectal cancer screening.
62220673|NCT01853774|NO_INTERVENTION|Control|Participants in the control arm will receive phone calls to support data collection and tracking, but not receive tailored messages
62220674|NCT01413854|ACTIVE_COMPARATOR|diclofenac|
62220675|NCT01413854|PLACEBO_COMPARATOR|sugar pill|
62415014|NCT00461396||Group 1|
62220676|NCT01481298||LVNC|12 patients with left ventricular non-compaction cardiomyopathy
62220677|NCT01481298||HCM|10 patients with hypertrophic cardiomyopathy
62220678|NCT01481298||DCM|11 patients with dilatative cardiomyopathy
62220679|NCT01481298||controls|24 healthy controls
62220680|NCT00735020|EXPERIMENTAL|1|
62415015|NCT02651974|ACTIVE_COMPARATOR|Control condition|A control invitation letter similar to the previous standard (non-incentive) invitation with slight wording and grammatical improvements will be mailed to patients randomly assigned to this group.
62415016|NCT02651974|ACTIVE_COMPARATOR|Cost condition|A control invitation letter with the addition of one line informing participants of the average value of the KIT procedure will be mailed to patients randomly assigned to this group.
62415017|NCT02651974|ACTIVE_COMPARATOR|Cost/Future condition|An invitation letter with the average value of the KIT procedure and a sentence assuring participants that should a follow-up test be requested, it will also be provided free of charge will be mailed to patients randomly assigned to this group.
62415018|NCT01402193|ACTIVE_COMPARATOR|Study Arm|"Investigational treatment: Arimidex commenced before and continued during radiotherapy.~Interventions:~Drug: Pre-radiotherapy commencement of Arimidex Radiation: Radiotherapy"
62796409|NCT05401136||Participants|Consecutive people who use drugs and visit the addiction care centre
62796410|NCT03591562||COSYCONET COPD Subcohort|"MRI and CT of the lung will be performed in a multi-centre subcohort of 370 patients having already participated in the precursor trial  Image-Based Structural and Functional Phenotyping of the COSYCONET Cohort Using MRI and CT (MR-COPD), NCT 02629432."
62796411|NCT00250237|ACTIVE_COMPARATOR|A|Patients receiving blinded medication (Haloperidol or Placebo)
62220681|NCT00735020|ACTIVE_COMPARATOR|2|
62220682|NCT03733041|ACTIVE_COMPARATOR|rTMS|This group will be randomized to receive rTMS
62415019|NCT01402193|ACTIVE_COMPARATOR|Control Arm|"Standard Treatment: Arimidex delayed until 2 weeks after radiotherapy~Interventions:~Radiation: Radiotherapy Drug: Post radiotherapy commencement of Arimidex"
62415020|NCT01071083|ACTIVE_COMPARATOR|natalizumab|
62220683|NCT03733041|SHAM_COMPARATOR|Sham|This group will be randomized to receive sham treatment
62220684|NCT03733041|OTHER|No intervention|This group will receive no intervention
62220685|NCT03805620|ACTIVE_COMPARATOR|Phys Group|physical training group
62023887|NCT04389840|EXPERIMENTAL|Cohort 1 dociparstat|Subjects received 4 mg/kg of dociparstat administered as an intravenous (IV) bolus on Day 1, followed by 0.25 mg/kg/hr dociparstat by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 \[168 hours\]).
62023888|NCT04389840|PLACEBO_COMPARATOR|Cohort 1 placebo|Placebo IV bolus on Day 1, followed by Placebo by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 \[168 hours\])
62023889|NCT04389840|EXPERIMENTAL|Cohort 2 dociparstat|Subjects received 4 mg/kg of dociparstat administered as an intravenous (IV) bolus on Day 1, followed by 0.325 mg/kg/hr dociparstat by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 \[168 hours\]).
62023890|NCT04389840|PLACEBO_COMPARATOR|Cohort 2 placebo|Subjects received placebo IV bolus on Day 1, followed by placebo by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 \[168 hours\]).
62023891|NCT04389840|EXPERIMENTAL|Cohort 3 dociparstat|Subjects received 4 mg/kg of dociparstat administered as an intravenous (IV) bolus on Day 1, followed by 0.325 mg/kg/hr dociparstat by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 \[168 hours\]).
62023892|NCT04389840|PLACEBO_COMPARATOR|Cohort 3 placebo|Subjects received placebo IV bolus on Day 1, followed by placebo by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 \[168 hours\]).
62023893|NCT02024334|ACTIVE_COMPARATOR|leflunomide|leflunomide tablet: for patients less than 20 kg: 10 mg every 2 day, for patients 20 - 40 kg: 10 mg daily, for patients more than 40 kg: 20 mg daily.
62023894|NCT02024334|PLACEBO_COMPARATOR|placebo|placebo tablet for patients less than 20 kg: 10 mg every 2 day, for patients 20 - 40 kg: 10 mg daily, for patients more than 40 kg: 20 mg daily.
62023895|NCT01592435||Pred. & Invest.-All Study Participants|"Cedera AccuStitch Software is standard of care software currently used at sites.~Carestream DR LLI software is investigational software used for reconstruction."
62023896|NCT01217931|EXPERIMENTAL|Group 1|Pazopanib + possible Bevacizumab
62023897|NCT01217931|EXPERIMENTAL|Group 2|Pazopanib + possible Everolimus
62023898|NCT01217931|EXPERIMENTAL|Group 3|Everolimus + possible Bevacizumab
62023899|NCT01217931|EXPERIMENTAL|Group 4|Everolimus + possible Pazopanib
62023900|NCT01217931|EXPERIMENTAL|Group 5|Bevacizumab + possible Pazopanib
62023901|NCT01217931|EXPERIMENTAL|Group 6|Bevacizumab + possible Everolimus
62023902|NCT05103761|ACTIVE_COMPARATOR|Ketogenic diet|Diet administered to induce ketosis.
62023903|NCT05103761|PLACEBO_COMPARATOR|Low glycemic index treatment diet|Diet matched with a ketogenic diet with added carbohydrates to avoid ketosis.
62587512|NCT01071980|NO_INTERVENTION|Control|Control group
62587513|NCT06429969||IMH group|Participants diagnosed with idiopathic macular hole(IMH) requiring PPV were enrolled in the IMH group, and this group was a control group because the vitreous of IMH may be closest to normal and normal people do not undergo PPV. 100-250ul of vitreous fluid was collected intraoperatively for NMR analysis.
62023904|NCT02293187|ACTIVE_COMPARATOR|vitamin D3|Vitamin D3, 800 IU will be given initially; after 4 months if D level \< 70 nmol/L, increase dose to 1600 IU for remainder of study.
62023905|NCT02293187|PLACEBO_COMPARATOR|Placebo|Placebo, microcrystalline cellulose
62023906|NCT04598152|EXPERIMENTAL|Transcranial Direct Current Stimulation during fMRI|Each subject will undergo transcranial direct current stimulation twice while completing a task in the functional magnetic resonance imaging scanner.
62220686|NCT03805620|ACTIVE_COMPARATOR|Cog Group|cognitive training group
62587514|NCT06429969||DR group|In patients with a confirmed diagnosis of diabetic retinopathy (DR) and requiring PPV surgery, 100-250ul of vitreous fluid was collected intraoperatively for NMR analysis.
62220687|NCT03805620|EXPERIMENTAL|Phys-Cog Group|combined physical-cognitive training group
62415021|NCT01071083|PLACEBO_COMPARATOR|IV placebo|
62587515|NCT06429969||RD group|In patients with a confirmed diagnosis of retinal detachment (RD) and requiring PPV surgery, 100-250ul of vitreous fluid was collected intraoperatively for NMR analysis.
62587516|NCT06429969||IMM group|In patients with a confirmed diagnosis of idiopathic macular epiretinal membrane (IMM) and requiring PPV surgery, 100-250ul of vitreous fluid was collected intraoperatively for NMR analysis.
62587517|NCT06429969||RVO group|In patients with a confirmed diagnosis of retinal vein occlusion (RVO) and requiring PPV surgery, 100-250ul of vitreous fluid was collected intraoperatively for NMR analysis.
62023907|NCT05703282|EXPERIMENTAL|Renal Impairment 1|Test Drug: AD-104-A
62023908|NCT05703282|EXPERIMENTAL|Renal Impairment 2|Test Drug: AD-104-A
62023909|NCT05703282|EXPERIMENTAL|Renal Impairment 3|Test Drug: AD-104-A
62023910|NCT05703282|EXPERIMENTAL|Normal|Test Drug: AD-104-A
62023911|NCT00107419|EXPERIMENTAL|pemetrexed|pemetrexed
62023912|NCT02069054||Asthma|Patients with mild to moderate asthma diagnosed in accordance with GINA
62023913|NCT02069054||COPD|Patients with mild to moderate COPD diagnosed in accordance with GOLD
62023914|NCT02069054||Control|Healthy subjects
62023915|NCT00801827|EXPERIMENTAL|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET) scans of their brains using F-18 (fallypride), a dopamine type 2/3 (DA D2/3) receptor radioligand whose binding is sensitive to competition with endogenous dopamine, before and after the operation.
62023916|NCT01513850|EXPERIMENTAL|Hepabulin IV|
62220688|NCT03805620|NO_INTERVENTION|Con Group|educational control group
62415022|NCT01071083|ACTIVE_COMPARATOR|interferon β-1a, glatiramer acetate, or methylprednisolone|
62415023|NCT00572169|EXPERIMENTAL|VDTPACE|Velcade, Dexamethasone, Thalidomide, Cisplatinin, Adriamycin, Cyclophosphamide and Etoposide
62415024|NCT05954611|EXPERIMENTAL|GR2002 injection|GR2002 subcutaneous injection
62220689|NCT05747300|ACTIVE_COMPARATOR|MTA pulpotomy|Vital pulpotomy primary Molars using MTA
62796412|NCT00250237|PLACEBO_COMPARATOR|B|Patients receiving blinded medication (Haloperidol or Placebo)
62220690|NCT05747300|EXPERIMENTAL|Wellroot PT pulpotomy|Vital pulpotomy primary Molars using premixed bioceramic paste wellroot PT
62220691|NCT04621773||PGS(Preimplantation Genetic Screening)|patients with two times or more unexplained pregnancy loss, who wants to be pregnant via preimplantation genetic screening procedure
62796413|NCT03832335||Phakic group|21 eyehealthy individuals examined for baseline stereopsis and impact of aniseikonia on stereopsis. An non-invasive measurement.
62796414|NCT03832335||Cataract group|11 patients awaiting cataract surgery on both eyes. Measurement of baseline stereopsis and impact of artificial induced aniseikonia on stereopsis. A non invasive measurement that are repeated after dilatation of the eyes and again six weeks after surgery.
62796415|NCT00063778|EXPERIMENTAL|1 x 10^4 IU dose|Vaccine dose of 1 x 10\^4 IU per injection
62220692|NCT04621773||SP(spontaneous pregnancy )|patients with two times or more unexplained pregnancy loss, who wants to be pregnant via spontaneous pregnancy.
62220693|NCT00632437||Speckle-Contrast Imaging|
62220694|NCT04771754|EXPERIMENTAL|Arm 1|"* Dolutegravir - 50 mg once daily, orally administered for the first 28 days of the study.~* No treatment for the last 44 days of the study."
62220695|NCT04771754|EXPERIMENTAL|Arm 2|"* No treatment for the first 28 days of the study.~* Dolutegravir - 50 mg once daily, orally administered for the last 28 days of the study (day 44-72)."
62220696|NCT01723254|EXPERIMENTAL|PF-06444753|
62796416|NCT00063778|EXPERIMENTAL|1 x 10^5 IU dose|Vaccine dose of 1 x 10\^5 IU per injection
62796417|NCT00063778|PLACEBO_COMPARATOR|Placebo|
62796418|NCT05937061||Milk allergy|Children with milk allergy.
62796419|NCT05937061||Egg Allergy|Children with egg allergy
62220697|NCT01723254|EXPERIMENTAL|PF-06444752|
62220698|NCT01723254|PLACEBO_COMPARATOR|Placebo|Intramuscular
62023917|NCT04324684||Covid19 pneumonia with comorbidities|"Patients with pneumonia from Covid 19 with at least one of the following comorbidities:~1. Hypertension~2. Obesity and/or type 2 diabetes~3. Cardiovascular disease~4. Chronic obstructive lung disease"
62220699|NCT02691533|EXPERIMENTAL|ω3 PUFA(10% Omegavan 100 ml)|
62023918|NCT04324684||Covid2 pneumonia without comorbidities|Without any of the following comorbidities
62220700|NCT02691533|EXPERIMENTAL|ω6 PUFA (20% Intralipid 50 ml)|
62220701|NCT02691533|PLACEBO_COMPARATOR|Placebo Arm|No Lipid Emulsion will be given in this arm
62220702|NCT04007341|NO_INTERVENTION|Saline group|Patients in the saline group were infused with an identical volume of normal saline.
62220703|NCT04007341|EXPERIMENTAL|Dexmedetomidine group|Patients in the dexmedetomidine group were infused with a loading dose of dexmedetomidine (1.0 mcg/kg over 10 min) and were thereafter infused at a rate of 0.5 mg/kg/h.
62220704|NCT05396482||Patients with vestibular migraine and their relative|
62220705|NCT02764216|EXPERIMENTAL|EMI group|Elective mucosal irradiation
62220706|NCT02951364||LDV/SOF|Adult Korean participants and pediatric Korean participants aged 12 to \<18 years with genotype 1, 2, 4, 5, and 6 chronic HCV infection who are initiating commercial Harvoni regimen
62220707|NCT03074890|EXPERIMENTAL|Intervention (cases)|Intervention: Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC:FFP:PLT) and conventional coagulation tests guiding further resuscitation with blood products and procoagulant factors
62220708|NCT03074890|NO_INTERVENTION|No Intervention (control))|all patients with massive haemorrhage in which the massive transfusion protocol didn´t apply
62415025|NCT05954611|PLACEBO_COMPARATOR|placebo|placebo subcutaneous injection
62023919|NCT01131312|EXPERIMENTAL|Cytology|Referred to colposcopy if cytology is high grade
62023920|NCT01131312|EXPERIMENTAL|Human Papillomavirus (HPV)|Referred to colposcopy if cytology is high grade or HPV +
62220709|NCT04793841||General population|sexually experienced adults (aged 18 or above) of the randomly selected household
62220710|NCT04793841||men who have sex with men|men who have sex with men aged 18 or above and normally living in Hong Kong
62220711|NCT04095481||Obalon NTS|Patients who commercially purchased the NTS Compatible Obalon Balloon System
62415026|NCT00677170|EXPERIMENTAL|1|MLN4924
62415027|NCT04668326|ACTIVE_COMPARATOR|Manual Standing Wheelchair|Mobile in seated position; Not mobile in standing position
62023921|NCT01131312|EXPERIMENTAL|Colposcopy|All refer to colposcopy
62023922|NCT01259713|EXPERIMENTAL|Liposomal amphotericin B|Liposomal amphotericin B 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
62023923|NCT01259713|PLACEBO_COMPARATOR|Placebo|Placebo to match liposomal amphotericin B twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
62023924|NCT02998242|ACTIVE_COMPARATOR|RT alone|symptomatic bony metastatic site(s) receive SBRT less than 5 fractions
62023925|NCT02998242|EXPERIMENTAL|RT with apatinib|selected dose administered PO during and after SBRT
62023926|NCT01086657|EXPERIMENTAL|Group 1|Inactivated H5N1 Vaccine at Enrollment and inactivated H5N1 Vaccine at Week 24
62023927|NCT01086657|EXPERIMENTAL|Group 2|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 4
62023928|NCT01086657|EXPERIMENTAL|Group 3|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 8
62023929|NCT01086657|EXPERIMENTAL|Group 4|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 12
62023930|NCT01086657|EXPERIMENTAL|Group 5|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 16
62023931|NCT01086657|EXPERIMENTAL|Group 6|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 24
62220712|NCT06610409||SLE patients|
62220713|NCT06610409||Healthy controls|
62220714|NCT01274845|OTHER|Heliox|
62220715|NCT04630392|EXPERIMENTAL|Intervention Group|There are two intervention groups: treadmill walking only, whole-body vibration plus treadmill walking.
62220716|NCT05522621|EXPERIMENTAL|TJAOA102|Once enrolled, participants will be administrated TJAOA102 and followed by a 3-month medication cycle. The usage of this herbal compound is to take orally twice a day(two sacks per). Add it to about 200ml warm water and take it half an hour before breakfast in the morning and half an hour before bedtime in the evening except menstrual period.
62220717|NCT01736865|PLACEBO_COMPARATOR|placebo|One placebo pill daily for 1 year
62220718|NCT01736865|ACTIVE_COMPARATOR|cholecalciferol|One cholecalciferol pill daily for 1 year
62220719|NCT01864954|EXPERIMENTAL|Enhanced Web+phone|Engaging and interactive website access plus phone calls from personal coach.
62415028|NCT04668326|EXPERIMENTAL|Mobile Manual Standing Wheelchair|Mobile in BOTH seated and standing positions
62415029|NCT01743664|EXPERIMENTAL|Eye Movement Desesitization Reprocessing|The EMDR protocol follows procedures and phases described by Shapiro (1996). This is a complex treatment that incorporates many different interventions in order to recall trauma-related memories and to subdue them. EMDR processing consists of attending to oscillatory stimulation presented in a visual, auditory or tactile modalities, such as moving the finger from side to side across the patient's visual field or presenting an alternating tapping on the hands alternatively. Eye movements are the most commonly used external stimulus, but if the patient has problems with this kind of stimulation, such as headaches or sensomotor deficits, the therapist chooses tapping as an alternative form of oscillatory stimulation with equivalent therapeutic efficacy.
62796420|NCT05937061||Peanut allergy|Children with peanut allergy
62796421|NCT05937061||Control group|Patients withhout food allergy (bee venom or drug allergy).
62220720|NCT01864954|ACTIVE_COMPARATOR|Basic Static Web|Static website access only, only introductory call.
62220721|NCT05615493|ACTIVE_COMPARATOR|Group I|Will receive rESWT once weekly for one month
62415030|NCT01743664|ACTIVE_COMPARATOR|relaxation|Relaxation sessions will include diaphragmatic breathing, progressive muscle relaxation, visualisation, and rapid relaxation.
62796422|NCT04508426|EXPERIMENTAL|Mass Balance|
62023932|NCT06530316||None MTC|DTC, PDTC and ATC patients with RET fusions.
62220722|NCT05615493|SHAM_COMPARATOR|Group II|Will receive Sham rESWT once weekly for one month
62220723|NCT00472160|EXPERIMENTAL|1|Non Invasive Ventilation
62220724|NCT00558259|EXPERIMENTAL|dabigatran etexilate 150 mg BID|Patient to receive dabigatran etexilatate capsules 150 mg twice daily
62220725|NCT00558259|PLACEBO_COMPARATOR|matching placebo twice daily (BID)|Patient to receive dabigatran extexilate matching placebo capsules twice daily
62220726|NCT05442996|EXPERIMENTAL|HLX35+HLX10|Subjects will receive HLX35 in combination with HLX10 therapy, every 2 weeks as one treatment cycle.
62220727|NCT02013960|EXPERIMENTAL|Laminaria|cytotec and laminaria
62220728|NCT02013960|ACTIVE_COMPARATOR|Cytotec|Cytotec only
62220729|NCT06545838||Septic group|Patients with sepsis or septic shock
62415031|NCT05264623|EXPERIMENTAL|TENEO 317 Model 2 excimer laser|
62415032|NCT05285943|ACTIVE_COMPARATOR|Betamethasone cream|Patients will apply Betamethasone Valerate 0.1% cream to the irradiated area twice a day.
62415033|NCT05285943|ACTIVE_COMPARATOR|Olive oil cream|Patients will apply prepared Olive Oil cream to the irradiated area twice a day.
62415034|NCT05285943|PLACEBO_COMPARATOR|Base cream|Patients will apply prepared base cream to the irradiated area twice a day.
62433368|NCT03807882|ACTIVE_COMPARATOR|Control group|Clozapine monotherapy. Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients
62415035|NCT02741609|EXPERIMENTAL|Early/Late Stage Lyme disease|Have early Lyme disease based on the following criteria: Signs, symptoms and clinical history consistent with early stage Lyme disease. Subjects must have a physician-diagnosed erythema migrans (EM) rash and should have systemic symptoms indicative of disseminated infection. Symptoms may include fever, headache, fatigue, myalgias, arthralgias, and stiff neck. Paired acute and convalescent titers will be drawn (first draw at time of initial visit and second draw 4 weeks later). Have late Lyme disease based on the following criteria: Signs, symptoms and clinical history consistent with late stage Lyme disease, including but not limited to disseminated rash, arthritis, meningitis, facial palsy, or carditis. Qualified subjects will be administered the Borrelia Diagnostic Test.
62220730|NCT01015560|EXPERIMENTAL|treatment|MLN1202 8mg/kg IV Days 1, 15, 29 given as 1 6 week cycle
62220731|NCT03915704|EXPERIMENTAL|Buzzy|Buzzy was placed 3-5 cm above the injection site 60 sec before the injection and used until the procedure was completed. The Buzzy application to all children in this group was done by the second researcher. After the injection, the ice pack was wiped with 70% alcohol and frozen again by freezing.
62220732|NCT03915704|EXPERIMENTAL|Shotblocker|ShotBlocker is a small, flat, yellow horseshoe-shaped plastic tool that is non-invasive, appropriate for every age group, does not have the characteristics of medication or adverse effects. ShotBlocker has short, blunt points that provide contact with skin on one side, and a hole that exposes the injection site in the middle of the tool. It is used by being held on the skin surface during injection. The pointed surface of the tool is placed on the administration area right before the injection
62220733|NCT03915704|EXPERIMENTAL|Control|No intervention was performed to reduce pain and fear in the control group.
62415036|NCT06007378|OTHER|Bupivacaine and ketamine|
62415037|NCT06007378|OTHER|Bupivacaine and transdermal fentanyl patch|
62220734|NCT03450187|ACTIVE_COMPARATOR|Cohort A|50 mg TP-271 q24 (n=6), a novel, broad-spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
62220735|NCT03450187|ACTIVE_COMPARATOR|Cohort B|100 mg TLP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
62220736|NCT03450187|ACTIVE_COMPARATOR|Cohort C|200 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
62220737|NCT03450187|ACTIVE_COMPARATOR|Cohort D|300 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
62220738|NCT03450187|ACTIVE_COMPARATOR|Cohort E|400 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
62415038|NCT06007378|OTHER|Bupivacaine|
62415039|NCT03401762|EXPERIMENTAL|Chronic stroke MCI Electromyogram (EMG) pairs|Decoupling 2 muscles at a time with MCI
62415040|NCT03401762|EXPERIMENTAL|Chronic stroke MCI EMG triplets|Decoupling 3 muscles at a time with MCI
62415041|NCT03401762|EXPERIMENTAL|Chronic stroke MCI while reaching|Decoupling muscles with MCI while reaching to targets
62415042|NCT03401762|SHAM_COMPARATOR|Chronic stroke Sham MCI|Sham control group
62415043|NCT03401762|EXPERIMENTAL|Acute stroke MCI|Decoupling muscles with MCI in acute stroke subjects
62415044|NCT03401762|SHAM_COMPARATOR|Acute stroke Sham MCI|Acute stroke subjects sham comparator
62415045|NCT05949658|EXPERIMENTAL|Sirolimus|1mg tablets of sirolimus that total the assigned dose
62415046|NCT05949658|EXPERIMENTAL|Everolimus|1mg tablets of everolimus that total the assigned dose
62415047|NCT01098058|EXPERIMENTAL|CBT plus treatment as usual|
62433369|NCT01722266|PLACEBO_COMPARATOR|Placebo|Daily Injection
62023933|NCT06530316||MTC|MTC patients with RET mutations
62023934|NCT06627504|EXPERIMENTAL|Sleep Health and Circadian Timing Intervention|Participants will be prescribed a sleep schedule that allows them to obtain at least 1h more time in bed compared to their typical school week schedule. In addition, participants will be provided with pharmaceutical-grade exogenous melatonin and instructed to take 500mcg 2 hours before their scheduled bedtime. They will also be asked reduce evening light exposure starting 2 hours before bedtime by limiting household lights and dimming electronics. In the mornings, participants will be exposed to bright light for 30 minutes after waking by wearing provided ReTimer light therapy glasses.
62023935|NCT06627504|NO_INTERVENTION|Typical Sleep|Participants will be asked to sleep on their usual schedule.
62023936|NCT04631822|ACTIVE_COMPARATOR|Dexamethasone, combined with bupivacaine for adductor canal block|"All patients will receive spinal anesthesia with 3 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position. Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention.~In this arm, patients will receive 20 ml mixture of 0.25% bupivacaine and 8 mg dexamethasone."
62415048|NCT01098058|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
62415049|NCT05354336|EXPERIMENTAL|SHR6390（100mg）|
62023937|NCT04631822|ACTIVE_COMPARATOR|Dexmedetomedine, combined with bupivacaine for adductor canal block|"All patients will receive spinal anesthesia with 3 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position. Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention.~In this arm, patients will receive 20 ml mixture of 0.25% bupivacaine and 0.5 Mg/kg dexmedetomidine."
62023938|NCT04631822|ACTIVE_COMPARATOR|control group|"All patients will receive spinal anesthesia with 3 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position. Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention.~In this arm, patients will receive 20 ml mixture of 0.25% bupivacaine with no additives"
62023939|NCT01359735|ACTIVE_COMPARATOR|HP802-247|allogeneic, growth arrested keratinocytes and fibroblasts: final concentration of 5.0 M cells/mL with a ratio of 1:9 keratinocytes:fibroblasts, applied weekly
62023940|NCT01359735|ACTIVE_COMPARATOR|Bacitracin Ointment|bacitracin antibiotic ointment
62023941|NCT01679535|EXPERIMENTAL|Intervention|nutrition and hygiene education by community health workers
62023942|NCT06184698|EXPERIMENTAL|Experimental Group|liposomal irinotecan+5-FU/LV+ bevacizumab q2w
62023943|NCT04442555|EXPERIMENTAL|3-Hydroxybutyrate treatment|HVMN Ketone Ester 0,5 g / kg
62220739|NCT04463368|EXPERIMENTAL|Arm A|Patients will be treated with IHP followed by 4 courses of ipilimumab 3mg/kg and nivolumab 1mg/kg every third week followed by continued nivolumab 480mg q4w up to 1 year.
62415050|NCT05354336|EXPERIMENTAL|SHR6390（125mg）|
62415051|NCT05354336|EXPERIMENTAL|SHR6390（150mg）|
62415052|NCT04203758|EXPERIMENTAL|Wholegrain rye products with a high content of dietary fiber|Cereal products based on wholegrain rye
62415053|NCT04203758|ACTIVE_COMPARATOR|Refined wheat products with a low content of dietary fiber|Cereal products based on refined wheat
62023944|NCT04442555|PLACEBO_COMPARATOR|Placebo Treatment|Maltodextrin-base isocaloric placebo
62023945|NCT06175819|EXPERIMENTAL|Manuka nanoformulation group|This group will apply Manuka honey ( MgO 850, UMF+20) nanoformulation on the face lesions 2 times daily for 28 days or cure of lesions (Arm 1)
62415054|NCT01230502|ACTIVE_COMPARATOR|Group 3: Donor Specific Regulation (DSR) -, standard of care|Subjects who test Donor Specific Regulation (DSR) negative will not be randomized to possible tacrolimus withdrawal, and will remain on standard of care immunosuppression.
62415055|NCT01230502|ACTIVE_COMPARATOR|Group 2 Donor Specific Regulation (DSR) +; standard of care|Subjects that are Donor Specific Regulation (DSR) positive and randomized (1:1) to Group 2 will remain on standard of care immunosuppression.
62433370|NCT01722266|ACTIVE_COMPARATOR|Liraglutide 1.8mg|Daily Injection
62433371|NCT01722266|ACTIVE_COMPARATOR|Liraglutide 1.2mg|Daily injections
62433372|NCT01722266|ACTIVE_COMPARATOR|Liraglutide 0.6 mg|Daily injection
62023946|NCT06175819|EXPERIMENTAL|Manuka honey gel group|This group will apply Manuka honey ( MgO 850, UMF+20) gel on the face lesions 2 times daily for 28 days or cure of lesions (Arm 2)
62023947|NCT06175819|ACTIVE_COMPARATOR|clindamycin commercial gel|This group will apply clindamycin commercial gel (Clindamycin 1%gel,European pharmaceuticals, Alex, Egypt) on the face lesions 2 times daily for 28 days or cure of lesions (Arm 3)
62023948|NCT01640158|EXPERIMENTAL|Experimental Treatment|Computerized plasticity-based adaptive cognitive training, up to 65 hours
62220740|NCT04463368|EXPERIMENTAL|Arm B|Patients will be treated with 1 course of ipilimumab 3mg/kg and nivolumab 1mg/kg followed by IHP after 3 weeks and then another 3 courses of ipilimumab 3mg/kg and nivolumab 1mg/kg every third week followed by continued nivolumab 480mg q4w up to 1 year.
62023949|NCT01640158|ACTIVE_COMPARATOR|Active Comparator|Commercially available computerized training, up to 65 hours
62023950|NCT06635564||Patients with functional liver disease undergoing liver surgery|This group consists of patients with liver disease undergoing elective liver surgery defined as one of the following invasive procedures a) liver resection (anatomic or non-anatomic segmental resection, right or left hepatectomy, right or left extended hepatectomy) or b) orthotopic liver transplantation.
62023951|NCT06635564||neurosurgical patients undergoing intracranial procedures|This group consists of patients who undergo elective neurosurgery e.g. tumor resection, aneurysm clipping or other intracranial procedures.
62220741|NCT02713282|EXPERIMENTAL|Paliperidone palmitate 3 month formulation (PP3M)|Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq.) up to 525 mg eq. based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
62220742|NCT01532895||Hydromorphone HCI OROS|
62220743|NCT01625585||Consecutive patients undergoing SBE for OGIB|
62433373|NCT06363201|EXPERIMENTAL|Ocoxin Oral Solution|Patients will receive one vial of Ocoxin® daily from the start of oncospecific therapy until two weeks after the end of therapy.
62220744|NCT01078220||3-Dose Safety Population (Primary)|Females between ages 9 to 26 at receipt of the first dose of GARDASIL who are members of the participating MCOs and have completed the 3-dose regimen of GARDSIL vaccination with 12 months.
62433374|NCT00472706|ACTIVE_COMPARATOR|1|Excision
62023952|NCT06635564||pregnant women undergoing cesarean section|This group consists of pregnant women undergoing elective cesarean section.
62023953|NCT04616651|ACTIVE_COMPARATOR|Pre-Chatbot survey arm|Participants will take the self-appraisal survey prior to interacting with the O2O program via the online Chatbot.
62023954|NCT04616651|EXPERIMENTAL|Post-Chatbot survey arm|Participants will take the self-appraisal survey after interacting with the O2O program via the online Chatbot. (This arm will also answer additional questions regarding participants' satisfaction with the O2O Chatbot.)
62023955|NCT00354354|EXPERIMENTAL|1|Combivent
62023956|NCT00354354|PLACEBO_COMPARATOR|2|Saline Solution (0.9% NaCl)
62023957|NCT05203419|EXPERIMENTAL|Part A: Cohort 1 - MHS552 low dose|Participants will receive MHS552 low dose once weekly subcutaneously for 4 weeks
62023958|NCT05203419|PLACEBO_COMPARATOR|Part A: Cohort 1, 2, 3 - Placebo|Participants will receive placebo once weekly subcutaneously for 4 weeks
62220745|NCT01078220||Pregnancy Safety Population|Females who received at least one dose of GARDASIL during pregnancy.
62023959|NCT05203419|EXPERIMENTAL|Part A: Cohort 2 - MHS552 medium dose|Participants will receive MHS552 medium dose once weekly subcutaneously for 4 weeks
62023960|NCT05203419|EXPERIMENTAL|Part A: Cohort 3 - MHS552 high dose|Participants will receive MHS552 high dose once weekly subcutaneously for 4 weeks
62415056|NCT01230502|EXPERIMENTAL|Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy|"Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy:~Subjects that are Donor Specific Regulation (DSR) positive and randomized (1:1) to Group 1 will begin a taper off tacrolimus for 6 months, after repeat DSR testing at 6 months subject will either discontinue tacrolimus if they remain DSR negative or remain at reduced dose if converted to DSR positive"
62415057|NCT02204527|EXPERIMENTAL|vitamin D3|supplementation of 100.000 IU of vitamin D3
62415058|NCT02204527|PLACEBO_COMPARATOR|Placebo pill|Placebo
62415059|NCT03265483|ACTIVE_COMPARATOR|Magnesium treatment|Participants will be assigned to magnesium glycinate
62796423|NCT01385709||Sertraline|Therefore, patients who are already taking psychotropic medications, and therefore are currently in treatment for a psychiatric illness, will be recruited. The specific psychiatric diagnoses anticipated in the subject pool include the conditions that sertraline is indicated to treat, including Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, and Social Anxiety Disorder. Patients must be female, between the ages of 18-40, taking either sertraline on a daily basis for at least one week. Exclusion criteria include 1) currently pregnant or breastfeeding, 2) concurrent use of any form of hormonal birth control, including oral contraceptive pills, Norplant or Depo-provera, 3) hepatic or renal disease, 4) irregular menstrual cycles.
62796424|NCT01385709||Lithium|Therefore, patients who are already taking psychotropic medications, and therefore are currently in treatment for a psychiatric illness, will be recruited. The specific psychiatric diagnoses anticipated in the subject pool include the conditions that lithium is indicated to treat, including Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, and Social Anxiety Disorder. Patients must be female, between the ages of 18-40, taking lithium on a daily basis for at least one week. Exclusion criteria include 1) currently pregnant or breastfeeding, 2) concurrent use of any form of hormonal birth control, including oral contraceptive pills, Norplant or Depo-provera, 3) hepatic or renal disease, 4) irregular menstrual cycles.
62796425|NCT06719804|EXPERIMENTAL|Open label single arm, drug propanolol|All subjects will receive the experimental drug
62796426|NCT01450865|EXPERIMENTAL|Placebo first|Volunteers receive placebo first and after a cross-over period of at least 7 days flupirtine second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention
62796427|NCT01450865|EXPERIMENTAL|Flupirtine first|Volunteers receive flupirtine first and after a cross-over period of at least 7 days placebo second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention
62796428|NCT00660465||A18|
62796429|NCT01800097|PLACEBO_COMPARATOR|placebo|placebo
62796430|NCT01800097|ACTIVE_COMPARATOR|Modafinil|Modafinil
62796431|NCT03222687|EXPERIMENTAL|therapy group|Immunosuppressive therapy included tacrolimus and prednisone.
62796432|NCT03415282|EXPERIMENTAL|Open-label treatment arm|Open-label treatment arm - patients will receive RVT-501 0.5% twice daily (BID) for 4 weeks.
62796433|NCT04017091|EXPERIMENTAL|VR Group|ABI Patients Twenty-one patients with ABI participated in this pilot study (Figure 1): 9 diagnosed with stroke (43%), 6 with TBI (29%), 2 with anoxic injury (10%), 3 with brain tumor (14%), and 1 with amyloid angiopathy (5%).
62796434|NCT04017091|NO_INTERVENTION|Control Group (Standard Care)|The 12 Controls were age- and gender-matched (and etiology when possible) patients who had previously received traditional neurorehabilitation and completed the same measures as the VR group prior to onset of the study, but they did not receive VR treatment.
62796435|NCT01553019|EXPERIMENTAL|1- R(0) negative|50.40 cobalt gray equivalent (CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
62796436|NCT01553019|EXPERIMENTAL|2- R(1) micro-positive|54.00 cobalt gray equivalent(CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
62796437|NCT01553019|EXPERIMENTAL|3- R(2) gross positive|59.40 cobalt gray equivalent (CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
62796438|NCT02650180|OTHER|Soberlink Cellular Device|Soberlink Cellular Device: a Breath Alcohol Analyzer
62023961|NCT05203419|EXPERIMENTAL|Part B: MHS552|Participants will receive MHS552 (dose to be determined) once weekly subcutaneously for 12 weeks
62023962|NCT05203419|PLACEBO_COMPARATOR|Part B: Placebo|Participants will receive placebo once weekly subcutaneously for 12 weeks
62023963|NCT01299493|EXPERIMENTAL|Interventional|Access to systems-level interventions to increase colorectal cancer screening.
62023964|NCT01299493|NO_INTERVENTION|Usual Care|Practices will receive access to intervention components after outcomes data collection is complete.
62023965|NCT04026100|EXPERIMENTAL|CTA101|
62023966|NCT00297817|EXPERIMENTAL|Arm 1: rMenB|
62023967|NCT00297817|EXPERIMENTAL|Arm 2: rMenB + OMV|
62023968|NCT00297817|PLACEBO_COMPARATOR|Arm 3: Placebo|
62023969|NCT01318889|EXPERIMENTAL|normal saline|mouth wash of normal saline ,three times a day, 10 cc each time
62023970|NCT03207529|EXPERIMENTAL|Treatment (alpelisib, enzalutamide)|Patients receive alpelisib PO and enzalutamide PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62023971|NCT05124457|EXPERIMENTAL|Insulin Detemir|Patients are to receive insulin detemir as long acting insulin to control blood sugars
62415060|NCT03265483|PLACEBO_COMPARATOR|Placebo|Participants will be assigned to placebo group
62433375|NCT00472706|ACTIVE_COMPARATOR|2|Photodynamic therapy
62796439|NCT02691559|ACTIVE_COMPARATOR|maternal inflammation group|Amniotic fluid analysis by blood gas device: evaluate the possible association between maternal inflammation and amniotic fluid pH two groups will be designed. One group will consist of infants born to mothers with infection/inflammation whereas the control group will consist of infants born to mothers without infection/inflammation. In all deliveries amniotic fluid will be taken and will be analyzed by blood gas device.
62796440|NCT02691559|ACTIVE_COMPARATOR|normal pregnancy group|Amniotic fluid analysis by blood gas device: The control group will consist of infants born to mothers without infection/inflammation. In all deliveries amniotic fluid will be taken and will be analyzed by blood gas device.
62796441|NCT06342518|EXPERIMENTAL|ESWT GROUP|"The ESWT group received radial ESWT on the painful lateral epicondyle once per week for a total of 3 sessions.~A wrist resting splint, wrist extensor strengthening and stretching exercises, and ice treatment were administered to both groups."
62796442|NCT06342518|SHAM_COMPARATOR|Sham-ESWT group|"The Sham-ESWT group received Sham radial ESWT on the painful lateral epicondyle once per week for a total of 3 sessions.~A wrist resting splint, wrist extensor strengthening and stretching exercises, and ice treatment were administered to both groups."
62023972|NCT05124457|ACTIVE_COMPARATOR|Insulin NPH|Patients are to receive insulin NPH as long acting insulin to control blood sugars
62796443|NCT02950480|EXPERIMENTAL|Zafirlukast|Zafirlukast
62796444|NCT02950480|OTHER|Standard of Care (no intervention)|Standard of Care (no intervention)
62796445|NCT05187078|EXPERIMENTAL|IUD placement with allis clamp|
62796446|NCT05187078|ACTIVE_COMPARATOR|IUD placement with single tooth tenaculum|
62796447|NCT06328673|EXPERIMENTAL|Module A Dose Escalation|Patients with advanced solid tumors enrolled in dose escalation cohorts treated with DM919
62796448|NCT06328673|EXPERIMENTAL|Module A Cohort Expansion|Patients with select solid tumor types enrolled in expansion cohorts treated with DM919 at a dose selected from the Module A Escalation arm
62796449|NCT06328673|EXPERIMENTAL|Module B Combination Therapy Dose Escalation|Patients with advanced solid tumors enrolled in dose escalation cohorts treated with DM919 in combination with pembrolizumab
62796450|NCT06328673|EXPERIMENTAL|Module B Combination Therapy Cohort Expansion|Patients with select tumor types enrolled in expansion cohorts treated with DM919 at a dose selected from the Module B Escalation arm, in combination with pembrolizumab
62796451|NCT01623544||Symbicort|BFC patients new to ICS/LABA combination therapy
62796452|NCT01623544||Advair|FSC patients new to ICS/LABA combination therapy
62796453|NCT04303559|ACTIVE_COMPARATOR|Eloctate|Arm A: Eloctate 65 IU/kg will be administered weekly by intravenous infusion in previously untreated children with severe hemophilia A beginning before the first bleed and continued up to 48 weeks.
62796454|NCT04303559|EXPERIMENTAL|Emicizumab|Arm B: Emicizumab 1.5 mg/kg will be administered weekly by subcutaneous injection (following 3 mg/kg/wk x4 induction) in previously untreated children with severe hemophilia A beginning before the first bleed and continue up to 48 weeks.
62796455|NCT04671264|EXPERIMENTAL|VC group|"Vibrating capsule (VC) was proposed and applied for the patent by professor Liao Zhuan from Changhai Hospital, developed and manufactured by the Ankon Medical Technology Co., Ltd. The system consisted of a vibrating capsule and an external configuration device (ECD). It's 26.7 mm in length, 11.8 mm in diameter and 4.5 + 0.5 g in weight.~Each VC has its own semiconductor chip with serial number in order to be recognized and controlled by ECD. VC can be stopped by ECD or mobile-phone application. There was a bidirectional radio frequency communication signal between VC and ECD. In addition, an application (APP) named VCP can be connected to ECD through smart phone to select mode and debug specific parameters for VC. The capsule can be activated by ECD, and then the vibration mode can be controlled by a configurator or an smartphone application."
62796456|NCT04671264|PLACEBO_COMPARATOR|Control group|The Intervention of control group were similar to VC group except the capsule function. Sham capsule we used in control group which had no function of vibrating.
62796457|NCT02275663|EXPERIMENTAL|Azacytidine plus FLAG|"Azacytidine 75 mg/m2 = mg IV in 100 ml Normal Saline (NS) over 30 minutes on days -5 t0 -1~G-CSF 5 mcg/kg subcut on days 0 to + 6~Fludarabine 30mg/m² in 100ml NS IV daily over 30min., on Days +1 to +5~Cytarabine 2gm/m² = 500ml NS IV daily over 4h, on Days +1 to +5 Start 4h after completion of fludarabine infusion."
62023973|NCT03697785|EXPERIMENTAL|Beacon Caresystem with weaning advice|Beacon care system set up to give weaning advice and options to accept or reject advice.
62023974|NCT03697785|OTHER|Beacon Caresystem for monitoring only|Beacon care system attached but only for data collection purposes. No advice will be given.
62220746|NCT01078220||Autoimmune Safety Population|Females who have received at least one dose of GARDASIL and have been members in the same MCO for at least 12 months prior to receiving their first dose of GARDASIL.
62220747|NCT01078220||Any Dose Safety Population (Secondary)|Females who have received at least one dose of GARDASIL and have been members in the same MCO for at least 12 months prior to receiving their first dose of GARDASIL.
62023975|NCT06403592||Observational cohort|ASA I-II patients scheduled for surgery under general anesthesia with a laryngeal airway mask
62220748|NCT02638077||Group 1|2000 DTC patients undergo the first-time thyroidectomy and identified as intermediate or high risk of recurrence will be recruited. Doctors can treat the patients based on disease conditions. Investigators will record data which are related to study endpoints.
62415061|NCT04070534|OTHER|PALS intervention|This arm will influence the development of a patient-directed education module using the Patient Activated Learning System (PALS)
62796458|NCT01314001|PLACEBO_COMPARATOR|Placebo (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks \& wear a placebo patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
62220749|NCT03283072|EXPERIMENTAL|Sequence 1|Intervention 1: 15 bouts of 2mins:1min hypoxia:hyperoxia Intervention 2: 15 bouts of 1mins:1min hypoxia:hyperoxia Intervention 3: 8 bouts of 2mins:1min hypoxia:hyperoxia 15 bouts of 1min:1min normoxia (sham)
62220750|NCT03283072|EXPERIMENTAL|Sequence 2|Intervention 2: 15 bouts of 1mins:1min hypoxia:hyperoxia Intervention 3: 8 bouts of 2mins:1min hypoxia:hyperoxia 15 bouts of 1min:1min normoxia (sham) Intervention 1: 15 bouts of 2mins:1min hypoxia:hyperoxia
62220751|NCT03283072|EXPERIMENTAL|Sequence 3|Intervention 3: 8 bouts of 2mins:1min hypoxia:hyperoxia 15 bouts of 1min:1min normoxia (sham) Intervention 1: 15 bouts of 2mins:1min hypoxia:hyperoxia Intervention 2: 15 bouts of 1mins:1min hypoxia:hyperoxia
62220752|NCT03283072|EXPERIMENTAL|Sequence 4|15 bouts of 1min:1min normoxia (sham) Intervention 1: 15 bouts of 2mins:1min hypoxia:hyperoxia Intervention 2: 15 bouts of 1mins:1min hypoxia:hyperoxia Intervention 3: 8 bouts of 2mins:1min hypoxia:hyperoxia
62220753|NCT05325801|EXPERIMENTAL|BMCA and GPRC5D dual target CAR-T cells （OriC321）|
62220754|NCT00688454||Pt with hypercholesteremia|Patients treated with CRESTOR because of hypercholesteremia
62220755|NCT03289429|EXPERIMENTAL|Atorvastatin|Atorvastatin and intravenous placebo
62220756|NCT03289429|EXPERIMENTAL|Magnesium sulfate|Magnesium sulfate and tablets placebo
62220757|NCT03289429|PLACEBO_COMPARATOR|Control|intravenous placebo and tablet placebo
62220758|NCT03108456|ACTIVE_COMPARATOR|Orbital Atherectomy (OA)|The Diamondback 360® Coronary Orbital Atherectomy System (OAS) will be used for orbital atherectomy (OA) vessel preparation prior to implantation of a drug-eluting stent.
62220759|NCT03108456|ACTIVE_COMPARATOR|Conventional Balloon Angioplasty|Coronary balloons cleared or approved for commercial use by the Food and Drug Administration will be used for conventional balloon angioplasty prior to implantation of a drug-eluting stent.
62220760|NCT04663724|EXPERIMENTAL|Experimental Computer-Based Treatment|A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.
62220761|NCT04663724|ACTIVE_COMPARATOR|Comparator Computer-Based Treatment|A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.
62415062|NCT06514586|ACTIVE_COMPARATOR|MenOxy|The investigational product will contain a Plastic tube containing 36 g of study product (gel) and a Vaginal calibrated plastic applicator for dose (1 ml) administration. The active constituent is oxytocin 600 IU/ml dissolved in a gel based on Hypromellose with a pH of 3.8.
62415063|NCT06514586|PLACEBO_COMPARATOR|Placebo|The placebo gel will match the IP gel (Hypromellose) with a pH of 3.8, without oxytocin.
62587518|NCT06411600|EXPERIMENTAL|Experimental arm|The experimental arm in the BRAVE protocol involves the administration of a combination therapy consisting of encorafenib, cetuximab, and bevacizumab. This arm is designed to evaluate the efficacy and safety of this combination in patients with metastatic colorectal cancer harboring the BRAF-V600E mutation who have experienced disease progression after one or two prior chemotherapy regimens. The primary objective is to assess the antitumor activity of the combination therapy, with secondary objectives including safety and tolerability assessments, as well as evaluations of progression-free survival, overall survival, and patient-reported outcomes.
62587519|NCT06411600|ACTIVE_COMPARATOR|Control arm|The control arm in the BRAVE protocol involves standard-of-care treatment, which may include various chemotherapy regimens or targeted therapies typically used for metastatic colorectal cancer. In this arm, patients receive the standard treatment without the addition of encorafenib, cetuximab, or bevacizumab. The purpose of the control arm is to provide a reference point for comparing the efficacy and safety of the experimental combination therapy. Patients in this arm may also undergo similar assessments for tumor response, survival outcomes, and adverse events to facilitate comparison with the experimental arm.
62587520|NCT01775982||Study population|"See inclusion and exclusion criteria.~Intervention: Psychiatric evaluation Intervention: Geriatric evaluation~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
62587521|NCT02073448|EXPERIMENTAL|GK530G|Fixed-dose combination gel of Adapalene and Benzoyl Peroxide
62587522|NCT02073448|ACTIVE_COMPARATOR|CD0271|Adapalene 01% Gel
62587523|NCT02073448|ACTIVE_COMPARATOR|CD1579|Benzoyl Peroxide 2.5% Gel
62587524|NCT04049383|EXPERIMENTAL|5 x 10^5 CAR-20/19-T cells/kg|The study will utilize a 3+3 dose escalation design in ALL followed by a six-patient expansion cohort.
62587525|NCT04049383|EXPERIMENTAL|1 x10^6 CAR-20/19-T cells/kg|The study will utilize a 3+3 dose escalation design in ALL followed by a six-patient expansion cohort.
62587526|NCT04049383|EXPERIMENTAL|2.5 x10^6 CAR-20/19-T cells/kg|The study will utilize a 3+3 dose escalation design in ALL followed by a six-patient expansion cohort.
62587527|NCT04049383|EXPERIMENTAL|Dose Expansion Phase|The study will utilize a 3+3 dose escalation design in ALL followed by a six-patient expansion cohort. Subjects will receive one of three dose levels. The dose expansion arm will be updated with the appropriate dose in the future based on the escalation results.
62587528|NCT02191722|EXPERIMENTAL|JIA patients|All participants will be evaluated before and after reading the comics booklet
62587529|NCT05670041|NO_INTERVENTION|Standard follow-up|
62587530|NCT05670041|EXPERIMENTAL|Intensified follow-up|Early, intensified follow-up after discharge from TAVI-procedure consisting of telephone consults and an additional visit to the outpaitent clinic.
62587531|NCT03613909|EXPERIMENTAL|All participants|At least 6 months experience with a Nucleus 24 series or later implant in at least one implanted ear and at least 3 months experience with the CP810,CP920 or CP910 sound processor.
62587532|NCT03417232|EXPERIMENTAL|Split Full Split Elevation of CAF|The central portion of the flap apical to the recession was elevated full thickness by the use of a small periostium elevator inserted into the probable sulcus
62587533|NCT03417232|SHAM_COMPARATOR|Split Elevation of CAF|The flap was fully elevated with a split thickness approach: the blade of the knife was inserted into the sulcus
62587534|NCT05525572|EXPERIMENTAL|Shockwave Therapy (SWT) + Platelet-Rich Plasma (PRP) Group|Participants will receive a combination of 5 weekly extracorporeal shockwave therapy sessions (SWT) and two sessions of autologous platelet-rich plasma (PRP) penile injection.
62796459|NCT01314001|ACTIVE_COMPARATOR|Varenicline (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take active varenicline pills daily for twelve weeks \& wear a placebo patch daily for eleven weeks.~When taking the active varenicline, subjects will follow the same treatment regimen per the manufacturer.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
62796460|NCT01314001|ACTIVE_COMPARATOR|Transdermal Nicotine (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks \& will wear an active transdermal nicotine patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~When wearing the active transdermal nicotine, subjects will follow the same treatment regimen per the manufacturer.~All subjects in this arm will receive smoking cessation counseling during their sessions."
62587535|NCT05499182||Teens|Teens are: 1) Male 2) Aged 13-17; 3) self-identified as Hispanic/Latino; 4) diagnosed with Major Depressive Disorder or Persistent Depressive Disorder/Dysthymia; and 5) referred to psychotherapy or prescribed medication for depression. Teens will be excluded if they are experiencing intense psychological distress or imminent thoughts of suicide.
62587536|NCT05499182||Parents|Parents will 1) Be parents or legal guardians of teens; and 2) Speak and read English or Spanish.
62587537|NCT05499182||Healthcare Providers|Healthcare providers will 1) Self-identify as regularly providing clinical care to Latino adolescents with depression; and 2) be in a role in which they can refer to or provide depression treatment.
62587538|NCT03677323|EXPERIMENTAL|Virtual reality|The virtual reality device will consist of the virtual reality headset and headphones for full immersion.
62587539|NCT03677323|ACTIVE_COMPARATOR|Drug sedation|The sedation group will benefit from drug sedation used in current practice, that is to say an association of Sufentanil, Droleptan and Propofol.
62220762|NCT06140654||Non-dental group|"62 non-seeking dental treatment subjects, aged 30-65 years, previously recruited within the general population from december 2017 to january 2018. Declared painful conditions including temporo-mandibular disorder, cephalalgia, oral or dental pain were initially considered as excluding conditions. Exclusion criteria also included diagnosis of acute orofacial disease (i.e. rhinitis) or sensory trouble (i.e. anosmia, dysgeusia) neither at the time of the experiment nor in the recent past, pregnancy, head and neck irradiation, eating disorders, enteral or parenteral feeding, and cognitive impairment or impaired communication.~They took part in an individual session with a dental practitioner of about 30-min during which food selectivity, medical history, and oral health status were assessed."
62220763|NCT06140654||Dental group|"63 patients recruited from September 2019 to December 2020 among patients seeking/pending dental treatment within the university dental clinic of the Rothschild hospital (AP-HP Sorbonne University, Paris, France). Inclusion criteria were: age between 35 and 65 years, literate French speakers, willing and able to complete the survey in a single setting. Patients suffering from cognitive impairment or impaired communication were excluded.~They took part in an individual session with a dental practitioner of about 30-min during which food selectivity, medical history, and oral health status were assessed."
62220764|NCT03422523|ACTIVE_COMPARATOR|Arm A Control|6 Cycles of R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) every 14 days.
62220765|NCT03422523|EXPERIMENTAL|Arm B Experimental|"1 Cycle of R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) followed by 5 cycles of R-GemOx with Atezolizumab every 14 days.~Followed by 8 maintenance cycles of Atezolizumab every 21 days."
62587540|NCT06587412|EXPERIMENTAL|Radial Shock Wave Treatment|Patients assigned to this group will receive three sessions. During each session, 2000 pulses will be administered using a radial shock wave generator, with a pressure of 2.5 bars and a frequency of 8 Hz.
62587541|NCT06587412|EXPERIMENTAL|Focal Shock Wave Treatment|Patients assigned to this group will receive three sessions. During each session, 2000 pulses will be delivered by a focal shock wave generator, with an energy flux density of 0.2 mJ/mm² and a frequency of 4 Hz.
62796461|NCT01314001|PLACEBO_COMPARATOR|Placebo (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks \& wear a placebo patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
62220766|NCT03191773|EXPERIMENTAL|Anti-CD19 CAR transduced T cells|Patients will receive a lymphodepleting preconditioning regimen with Fludarabine and Cyclophosphamide followed by anti-CD19 CAR-transduced T cells.
62220767|NCT05264389||Poly-Tape Device|Poly-Tape Device for Medial Patellofemoral Ligament (MPFL) Reconstruction
62415064|NCT05959668||Children, adolescents and young adults with cystinosis and their parents|"Depending on the patient's age, different HrQoL aspects are more relevant in cystinosis patients and their families. Therefore, a division based on age groups is needed to measure and interpret HrQoL measures successfully:~Age group stratification will include young patients aged 8-12, 13-17 and 18-26 for a self-reported version and children and adolescents aged 0-4, 5-7, 8-12, 13-17, 18-26 for a parent-reported version."
62415065|NCT06236126|ACTIVE_COMPARATOR|INTRADERMAL|Prior to insertion of the Tuohy epidural needle, each patient will receive an injection of 3 mL 1% lidocaine either intradermally (Group Intradermal).
62415066|NCT06236126|ACTIVE_COMPARATOR|SUBCUTANEOUS|Prior to insertion of the Tuohy epidural needle, each patient will receive an injection of 3 mL 1% lidocaine subcutaneously (Group Subcutaneous).
62415067|NCT02672488|EXPERIMENTAL|Sorafenib and Metformin|Sorafenib 400μg tablet by mouth and Metformin 500mg tablet by mouth with meal, twice per day
62415068|NCT02672488|ACTIVE_COMPARATOR|Sorafenib Alone|Sorafenib 400μg tablet by mouth, twice per day
62587542|NCT06587412|PLACEBO_COMPARATOR|Placebo Shock Waves|Subjects in this group will receive a placebo treatment with very low energy settings, designed to simulate therapy without offering real therapeutic effects. This group will receive 20 pulses per session, with an energy flux density of 0.08 mJ/mm².
62220768|NCT04091048||Primary Cohort|
62220769|NCT03302351|EXPERIMENTAL|Dexmedetomidine|1st group will include 30 patients will receive intravenous dexmedetomidine 1 mcg/kg.
62587543|NCT04794608|EXPERIMENTAL|HypnoVR Arm|During the three days of study in protector isolation, patients benefit from a 20-minute session of medical hypnosis in virtual reality.
62220770|NCT03302351|EXPERIMENTAL|Ketamine|2nd group will include 31 patients will receive intravenous ketamine 0.4 mg/kg.
62220771|NCT03302351|EXPERIMENTAL|Dexmetedomidine-Ketamine combination|3rd group will include 33 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg and low dose ketamine 0.25mg/kg.
62220772|NCT02194673|EXPERIMENTAL|Trans free palm margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
62220773|NCT02194673|EXPERIMENTAL|Interesterified palm based margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
62587544|NCT04794608|NO_INTERVENTION|Control Arm|During the three days of study in protector isolation, patients benefit from a 20-minute session of activity among those currently proposed in the service of hematology (reading, music, television).
62415069|NCT00798707|EXPERIMENTAL|Desvenlafaxine succinate sustained-release 25 mg|
62415070|NCT00798707|EXPERIMENTAL|Desvenlafaxine succinate sustained-release 50 mg|
62415071|NCT00798707|PLACEBO_COMPARATOR|Placebo|
62415072|NCT02507271|EXPERIMENTAL|Experimental Group|
62415073|NCT02507271|PLACEBO_COMPARATOR|Control Group|
62415074|NCT06059547|ACTIVE_COMPARATOR|Combination with Placebo|Placebo + Checkpoint Inhibitor nivolumab
62587545|NCT02856724|EXPERIMENTAL|Early amniotomy and PGE2|10 mg PGE2 vaginal ovul(Propess) Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
62023976|NCT05990062|EXPERIMENTAL|Verify performance gains for the innovative KSH system that can be delivered to Veterans. The new de|The investigators will perform several functional tests of the both the KSH system and the standard of care prosthesis: tensile static load bearing capacity before failure, test rowing ergometer 10-minute test before failure measured using strokes per minute, power in Watts, distance in meters, maximal force, and time before failure, range of motion in flexion/extension, and donning/doffing time.
62220774|NCT02194673|EXPERIMENTAL|IE soybean oil-based margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
62220775|NCT03933904|EXPERIMENTAL|Sirolimus|Oral sirolimus: For adults, loading dose of 5 mg/m\^2, rounded to the nearest mg, on day 1. For adults, starting on day 2, oral sirolimus daily at 2.5 mg/m\^2/day (rounded to the nearest mg), target trough level 10-15 ng/mL by HPLC, for 12 months. For children, 2 mg/m\^2/day, target trough level 5-15 ng/mL by HPLC.
62796462|NCT01314001|ACTIVE_COMPARATOR|Varenicline (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take active varenicline pills daily for twelve weeks \& wear a placebo patch daily for eleven weeks.~When taking the active varenicline, subjects will follow the same treatment regimen per the manufacturer.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
62796463|NCT01314001|ACTIVE_COMPARATOR|Transdermal Nicotine (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks \& will wear an active transdermal nicotine patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~When wearing the active transdermal nicotine, subjects will follow the same treatment regimen per the manufacturer.~All subjects in this arm will receive smoking cessation counseling during their sessions."
62220776|NCT01789736|EXPERIMENTAL|PG286|PG286 Ophthalmic Solution q.d. O.U.
62220777|NCT01789736|EXPERIMENTAL|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5% q.d. O.U.
62796464|NCT04713956|EXPERIMENTAL|G-CSF+DAC+BF|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo- HSCT, Granulocyte Colony-Stimulating Factor (G-CSF)+Decitabine+BF conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -6 to -3, Fludarabine (FLU) 30mg/m2/ day on days -7 to -3.
62796465|NCT04713956|ACTIVE_COMPARATOR|G-CSF+DAC+BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo- HSCT, Granulocyte Colony-Stimulating Factor (G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -7 to -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 to -2.
62220778|NCT01789736|ACTIVE_COMPARATOR|Travoprost 0.004%|Travoprost 0.004% q.d. O.U.
62220779|NCT05331677|EXPERIMENTAL|study group|
62587546|NCT02856724|ACTIVE_COMPARATOR|PGE2|10 mg PGE2 vaginal ovul(Propess)
62220780|NCT04326517||Emphysematous pyelonephritis|This is a single-group cohort study. A sub-classification will be used in order to differentiate patients that did not require intensive care, the ones who admitted to intensive care and mortality.
62796466|NCT06009835||Treatment group based on DOTr/DOTA detection result|Develop a final treatment plan based on DOTr/DOTA test results, MTB consultation expert opinions, and drug accessibility
62220781|NCT02033161|EXPERIMENTAL|Internet-delivered CBT|
62220782|NCT01297881||Caucasian outpatients with respiratory symptoms|all consecutive new Caucasian outpatients with respiratory symptoms like dyspnoea, cough, sputum but without diagnosis who are being examined for the first time.
62220783|NCT01681173|EXPERIMENTAL|Drink enriched in fibers|7,5g enriched fiber drinks, BID
62587547|NCT05477524|EXPERIMENTAL|VLA15 Lot 1 (3-dose primary vaccination series and booster dose)|Shot in the deltoid muscle (preferable in the nondominant arm)
62587548|NCT05477524|EXPERIMENTAL|VLA15 Lot 2 (3-dose primary vaccination series and booster dose)|Shot in the deltoid muscle (preferable in the nondominant arm)
62796467|NCT01862523|PLACEBO_COMPARATOR|diluent|diluent
62796468|NCT01862523|EXPERIMENTAL|capsaicin|capsaicin
62796469|NCT01862523|NO_INTERVENTION|control healthy volunteers|control healthy volunteers
62796470|NCT06466460|EXPERIMENTAL|Motion based intervention|To examine whether the activity of virtual cycling contributes to the improvement of quality of life for individuals with cognitive impairment
62796471|NCT06466460|NO_INTERVENTION|No intervention|no intervention for this group
62796472|NCT05552963|EXPERIMENTAL|Irreversible Electroporation (IRE) System|Participants with symptomatic drug refractory paroxysmal atrial fibrillation (PAF) and indicated for catheter ablation will be treated with the IRE system which includes multi-electrode circular IRE catheter and the multi-channel IRE generator.
62796473|NCT04851054||Patients after surgery for colon cancer with intention to cure|Patients with colon cancer admitted to the Colorectal Surgery Unit of the centers participating in the study, who will undergo elective surgical resection with potentially curative intention
62796474|NCT04444466|EXPERIMENTAL|UCB8600|Study participants randomized to this arm will receive various single doses and multiple doses of UCB8600 administered to various cohorts.
62796475|NCT04444466|PLACEBO_COMPARATOR|Placebo|Study participants randomized to this arm will receive various single doses and multiple doses of Placebo administered to various cohorts.
62796476|NCT03625284|EXPERIMENTAL|Fucovital|capsules of a dietary supplement rich with fucoxanthin from microalgae extract
62220784|NCT01681173|EXPERIMENTAL|Placebo drink|Placebo drink, BID
62587549|NCT05477524|EXPERIMENTAL|VLA15 Lot 3 (3-dose primary vaccination series and booster dose)|Shot in the deltoid muscle (preferable in the nondominant arm)
62587550|NCT05477524|PLACEBO_COMPARATOR|Placebo (3-dose primary vaccination series and booster dose)|Shot in the deltoid muscle (preferable in the nondominant arm)
62587551|NCT03492814|EXPERIMENTAL|Partial wound closure|3 sutures distal to second molar and leaving the vertical releasing incision open without any sutures.
62587552|NCT03492814|ACTIVE_COMPARATOR|Total wound closure|5 interrupted sutures with 2 sutures closing the vertical releasing incision and 3 sutures distal to second molar leading to a complete hermetic closure of the wound.
62587553|NCT05172440|EXPERIMENTAL|therapy group|Subjects received axitinib 5 mg bid, 12 weeks, and tislelizumab 200 mg on the first day of the first week, 4th week, 7th week, and 10th week, and intravenous infusion. With 21 days as a treatment cycle, 4 cycles of treatment, namely 12 weeks. Axitinib was discontinued for 12 weeks after the completion of treatment, and surgery was performed 7 days later.
62587554|NCT05347238||Dopamine Units|Units who have standardized their practice with the use of Dopamine as a first line agent.
62587555|NCT05347238||Norepinephrine Units|Units who have standardized their practice with the use of Norepinephrine as a first line agent.
62587556|NCT02912260|EXPERIMENTAL|MGL-3196|Study Drug
62587557|NCT02912260|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62415075|NCT06059547|EXPERIMENTAL|Combination with Visugromab/Verum|visugromab (CTL-002) + Checkpoint Inhibitor nivolumab
62587558|NCT03224611|NO_INTERVENTION|Control group|"The flexible LMA is inserted using index finger technique"
62796477|NCT03625284|PLACEBO_COMPARATOR|Placebo|capsules of an edible oil
62796478|NCT06727396|EXPERIMENTAL|CKD-508 dose level 1|Multiple dose of CKD-508 tablets
62796479|NCT06727396|EXPERIMENTAL|CKD-508 dose level 2|Multiple dose of CKD-508 tablets
62796480|NCT06727396|EXPERIMENTAL|CKD-508 dose level 3|Multiple dose of CKD-508 tablets
62220785|NCT04370548|EXPERIMENTAL|Clindamycin phosphate vaginal gel, 2%|
62220786|NCT04370548|PLACEBO_COMPARATOR|Placebo vaginal gel (Universal HEC Placebo Gel)|
62220787|NCT02245737|EXPERIMENTAL|Lanabecestat 20 milligrams (mg)|Lanabecestat 20 mg given orally once daily for 104 weeks.
62415076|NCT05959564|EXPERIMENTAL|Personalized Chatbot Condition|After reading a standard CDC HPV vaccine message, participants will interact with a chatbot designed to deliver personalized HPV vaccine messages (i.e., tailored to their personalities).
62415077|NCT05959564|EXPERIMENTAL|Non-Personalized Chatbot Condition|After reading a standard CDC HPV vaccine message, participants will interact with a chatbot designed to deliver HPV vaccine messages, which are not tailored to their personalities.
62796481|NCT06727396|EXPERIMENTAL|CKD-508 dose level 4|Multiple dose of CKD-508 tablets
62796482|NCT06727396|PLACEBO_COMPARATOR|Placebo|Multiple dose of placebo tablets
62796483|NCT04104737|EXPERIMENTAL|Spire Medical Health Tag|Spire Medical Health Tag is worn by all subjects The study is open label
62796484|NCT05367791|OTHER|POSTUR|Postural training only.
62796485|NCT05367791|OTHER|POSTUR + LV (localized vibration)|Postural training combined with localized vibration
62796486|NCT05367791|OTHER|POSTUR+SES (somatosensory electrical stimulation)|Postural training combined with somatosensory electrical stimulation
62796487|NCT05367791|OTHER|POSTUR+LV-SES|Postural training combined with somatosensory electrical stimulation and localized vibration
62796488|NCT01691157|ACTIVE_COMPARATOR|Usual physiotherapy without exercise|Will receive 6 sessions of modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
62587559|NCT03224611|ACTIVE_COMPARATOR|Light wand group|The flexible LMA is inserted using light wand as a stylet
62587560|NCT04757610|EXPERIMENTAL|0.5 mg ranibizumab with Standard Dosing 2.0 mg OPT-302|"0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals.~2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals."
62587561|NCT04757610|EXPERIMENTAL|0.5 mg ranibizumab with Extended Dosing 2.0 mg OPT-302|"0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals.~2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals, with sham intravitreal injection administered at visits when OPT-302 is not."
62796489|NCT01691157|EXPERIMENTAL|Exercise|Will receive an evidence based exercise protocol but no other physiotherapeutic modalities
62796490|NCT04276233|EXPERIMENTAL|Participants with severe eosinophilic asthma|Participants with severe eosinophilic asthma will receive Mepolizumab 100 mg subcutaneously into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses). Salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
62796491|NCT06514001|EXPERIMENTAL|AMDX-2011P 100 milligram|AMDX2011P 100 milligram (4 milliliter) single bolus injection intravenous for diagnostic review
62796492|NCT02842294||irinotecan based chemotherapy|patients having a 1st line doublet chemotherapy including irinotecan
62796493|NCT02842294||oxaliplatin based chemotherapy|patients having a 1st line doublet chemotherapy including oxaliplatin
62796494|NCT02842294||triplet chemotherapy|patient having a 1st line triplet chemotherapy including oxaliplatin / irinotecan this cohort was added while primary objective was to compare doublet chemotherapy
62796495|NCT02044055||Children born to HBV-HDV women|"Children born to HBV-HDV co-infected women will be checked for:~* HDV antibodies~* if positive, HDV RNA"
62796496|NCT06169553|EXPERIMENTAL|Intervention group|Participants in the IRIS program will be offered a one-stop, low-barrier combined care model to address their injection-related infections. Specific program components include: (1) Diagnosis and treatment of injection-related infections; (2) Substance use treatment (3) Peer support; and (4) Care coordination/systems navigation.
62796497|NCT04451941|EXPERIMENTAL|RecoveriX with individual EEG calibration|RecoveriX applied functional electrical stimulation (FES) according to individual brainwave by individual EEG calibration for 4 weeks
62796498|NCT04451941|SHAM_COMPARATOR|RecoveriX without individual EEG calibration|RecoveriX applied FES according to the brainwave of other subjects regardless of the individual brainwave for 4 weeks
62796499|NCT04724863|EXPERIMENTAL|Protocol|Each patient agreeing to participate in the study will be distributed in the protocol group and will receive an angioscan according to the protocol in pre-operative and at the usual post-operative check-up within 3 months after the operation. The usual procedure, foresees an angioscanner with injection of contrast product and the measurement of the images is performed during a deep breath. In order to obtain a complete respiratory cycle, the study procedure foresees in addition to the usual procedure, an image measurement during a deep exhalation.
62796500|NCT05062135|EXPERIMENTAL|Morphological analysis of endometrium|"PCOS: Seventeen PCOS subjects underwent two endometrial biopsies after the first P4-treated cycle, the first between days 5-9 of the cycle and the other between days 20-22 (i.e., under P4 treatment) of the cycle.~Controls: Thirteen ovulatory control women under two endometrial biopsies, performed after the first month of luteal P4 treatment, the first between days 5-9 and the second between days 20-22 of the cycle To quantify the parameters of interest, images were captured using a high-resolution camera (AxioCam-MCR, Carl Zeiss) adapted to a light microscope (Axiolab, Carl Zeiss) and adjusted with 40× objective lenses. The images were transmitted to a computer with AxioVision Rel 4.2 software (Carl Zeiss). For assessment of glandular and surface epithelial thickness, cell count, and counting newly formed blood vessels, ten images of each endometrial sample were made for each patient. For VEGF-C determination, the numerical density of blood vessels per mm2 was established"
62796501|NCT02472301|EXPERIMENTAL|Cowpeas|Cowpea supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
62796502|NCT02472301|EXPERIMENTAL|Common bean|Common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
62220788|NCT02245737|EXPERIMENTAL|Lanabecestat 50 mg|Lanabecestat 50 mg given orally once daily for 104 weeks.
62220789|NCT02245737|PLACEBO_COMPARATOR|Placebo|Placebo given orally once daily for 104 weeks.
62220790|NCT00324675|ACTIVE_COMPARATOR|Rosiglitazone|
62587562|NCT04757610|SHAM_COMPARATOR|0.5 mg ranibizumab with sham|"0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals.~Sham intravitreal injection administered at 4-weekly intervals."
62220791|NCT00324675|PLACEBO_COMPARATOR|placebo|
62220792|NCT01081054|OTHER|Ambulatory Treatment|Patients are treated ambulatory with oral antibiotic for 10 days; for the first five days these patients are contacted by telephone daily to progress oral intake.
62415078|NCT05959564|ACTIVE_COMPARATOR|No Chatbot Control Condition|Participants will read a standard CDC HPV vaccine message without interacting with any chatbot that delivers additional messages.
62023977|NCT05990062|EXPERIMENTAL|Verify functionality of the KSH system through testing with end-users.|The investigators will use System Usability Scale (SUS) to assess high usability with setup and operation of the device. The investigators will assess Comfort Scores (SCS), evaluate weight and correlate it with user satisfaction. The investigators will report selection outcome between new design and current design. The investigators will asses 1) functional status, (2) health- related quality of life, and (3) satisfaction with services and (4) device scores through the Orthotics and Prosthetics User Survey (OPUS).
62023978|NCT02311179|ACTIVE_COMPARATOR|Prosthesis, BoneMaster-Exceed cup|Prosthesis, BoneMaster-Exceed cup: A hemispheric joint cup of the type Exceed cup (Biomet) characterized by a porous surface of titanium plasma spray. The surface is coated with hydroxyapatite deposited electrochemically (BoneMaster)
62796503|NCT02472301|ACTIVE_COMPARATOR|Corn Soy Flour|Corn flour with 10% soy supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
62023979|NCT02311179|ACTIVE_COMPARATOR|Prosthesis Exceed cup without HA|Prosthesis Exceed cup without HA: A hemispheric joint cup of the type Exceed cup (Biomet) characterized by a porous surface of titanium plasma spray
62220793|NCT01081054|ACTIVE_COMPARATOR|Hospital treatment|Patients are hospitalized and treated with antibiotic, for the first days by endovenous antibiotic and with diet progression orally.
62023980|NCT05877001|EXPERIMENTAL|HAIC combined with Tislelizumab and Regorafenib|HAIC combined with Tislelizumab and Regorafenib until progression or death.
62220794|NCT01080833|ACTIVE_COMPARATOR|ERCP mechanical simulator practice|Trainees who are offered ERCP Mechanical Simulator (EMS) training in addition to routine training (study group)
62220795|NCT01080833|NO_INTERVENTION|No ERCP mechanical simulator practice|Trainees undergoing routine ERCP training only (control group).
62220796|NCT05961904|EXPERIMENTAL|Study group|Study group with receive orally breast milk
62220797|NCT05961904|NO_INTERVENTION|Control group|no intervention
62220798|NCT01226095||Osteoarthritic patients|Patients male or female, age ≥ 18 having clinical or radiological evidence of osteoarthritis
62220799|NCT02822313|EXPERIMENTAL|BAY987518|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62415079|NCT04222478|EXPERIMENTAL|Real Auriculotherapy|"Patients benefit from 3 sessions of auriculotherapy with semi-permanent needles on the 6 points according to the protocol of Alimi at one month intervals."
62415080|NCT04222478|SHAM_COMPARATOR|Sham Auriculotherapy|Patients are treated according to the same scheme as the experimental group but with semi-permanent needles positioned on non-specific points.
62415081|NCT02603536|EXPERIMENTAL|Vulnerable or pilot participant|"In addition to standard care, WelTel will send a weekly text message to participants in this arm for a one year period. Participants will be requested to respond to the outgoing message How are you? within 48 hours; they may respond that they are doing well or that they have a problem. A clinician will call to follow-up with all participants who respond indicating a problem or who do not respond within 48 hours."
62796504|NCT02034877|EXPERIMENTAL|1|
62796505|NCT01111617|EXPERIMENTAL|Real-Time fMRI|Real-Time fMRI
62023981|NCT01600300|PLACEBO_COMPARATOR|Sham|Treatment with inactivate Tesmac device
62023982|NCT01600300|ACTIVE_COMPARATOR|Tesmac|Treatment with active Tesmac device
62415082|NCT01652482|ACTIVE_COMPARATOR|FOLFIRI + Cetuximab|
62415083|NCT01652482|EXPERIMENTAL|FOLFIRI + MEHD7945A|
62415084|NCT06566560|OTHER|Intervention|
62415085|NCT00832286|EXPERIMENTAL|Cipro|At Week 12, subjects will receive a 3-day course of oral Ciprofloxacin 500 mg every 12h.
62796506|NCT05529693|EXPERIMENTAL|Bif-038 arm, high dose|Active trial product with minimum 10 billion CFU daily dose
62220800|NCT00740987|NO_INTERVENTION|1|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
62415086|NCT04509440|EXPERIMENTAL|Neural prolotherapy|Neural prolotherapy using isotonic dextrose 5% in water solution (about 3 ml). The injection was done using Lyftgot technique. The subcutaneous injections were done at sensory nerves fascial penetration points and tender areas around the anserine bursa anatomical region.
62023983|NCT01263743|EXPERIMENTAL|This is a single arm study|Relaxation Response training will be given to all participants
62023984|NCT00918294|EXPERIMENTAL|QuickOpt|QuickOpt is an optimization algorithm to program the AV, PV and VV delays
62415087|NCT04509440|ACTIVE_COMPARATOR|Corticosteroid group|Corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% ) (local anesthetic). They were given as a single local soft tissue injection at the point of maximal tenderness on the lower medial aspect of the knee region.
62415088|NCT03706209|EXPERIMENTAL|150 mg MP1032 bid|3 × 50 mg (150 mg) MP1032 plus 3 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
62415089|NCT03706209|EXPERIMENTAL|300 mg MP1032 bid|6 × 50 mg (300 mg) MP1032 hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
62415090|NCT03706209|PLACEBO_COMPARATOR|Placebo bid|6 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
62023985|NCT02621606|EXPERIMENTAL|Part 1, Healthy Participants|Healthy participants receive a single intravenous (IV) dose of \~370 megabecquerel (MBq) \[11C\]MK-6884 in Part 1 of the study.
62415091|NCT05131893||LuminalA|"1. tamoxifen (+ LHRH analogue for premenopausal participant)~2. non-steroidal aromatase inhibitor (+ LHRH analogue for premenopausal participant)~3. Non-steroidal aromatase inhibitor in non-resectable tumor (+ LHRH analogue in premenopausal participant) + CDK4 / 6 inhibitor"
62415092|NCT05131893||LuminalB (Her2 negative)|"1. 12 times weekly paclitaxel (80 mg / m˄2) followed by 4 times every 3 weeks epirubicin (E) (90-100 mg / m˄2) + cyclophosphamide (C) (600) (preferred)~2. 4x 3 weekly E (90-100mg / m˄2) + C (600mg / m˄2), then~   1. docetaxel (90-100 mg / m˄2) 4 times in every 3 weeks or~  2. 12x weekly paclitaxel (80mg / m˄2)~3. 4x every 2 weeks Epirubicin (E) (90-100mg / m˄2) + Cyclophosphamid (C) (600mg / m˄2), then~   1. 4 times every 2 weeks with paclitaxel (175 mg / m˄2) or~  2. 12x weekly paclitaxel (80mg / m˄2)~4. TC: docetaxel (75 mg / m˄2) + cyclophosphamide (600 mg / m˄2) every 21 days with GCSF prevention (6 cycles)"
62415093|NCT05131893||Her2 positive|"1. 4x 3 weeks E (90-100mg / m˄2) + C (600mg / m˄2), then~   1. 12 times weekly paclitaxel + trastuzumab (every week or 3 weekly) +/- pertuzumab (3 weekly) or~  2. 4x 3 weekly docetaxel (100mg / m˄2) + trastuzumab +/- pertuzumab~2. Docetaxel (75 mg / m˄2) + carboplatin (AUC6) + trastuzumab +/- pertuzumab 6 times every 3 weeks c) E (90-100mg / m˄2) + C (600mg / m˄2) 4x every 2 weeks, then 12 times weekly paclitaxel + trastuzumab (every week or 3 weekly) +/- pertuzumab (3 weekly)"
62796507|NCT05529693|EXPERIMENTAL|Bif-038 arm, low dose|Active trial product with minimum 1 billion CFU daily dose
62023986|NCT02621606|EXPERIMENTAL|Part 2, Healthy Elderly Participants|Healthy elderly participants receive two separate IV doses of \~370 MBq \[11C\]MK-6884 in Part 2 of the study. Administration of the two doses is separated by at least 3 hours.
62023987|NCT02621606|EXPERIMENTAL|Part 3, Participants with AD|Participants with AD receive a single IV dose of \~370 MBq \[11C\]MK-6884 in Part 3 of the study.
62023988|NCT03737370|EXPERIMENTAL|Dose escalation|"There are four dose cohorts (1, 1a, 2, 2a) in this arm and two dose levels of docetaxel (40mg/m\^2 \[level 1\] and 50mg/m\^2 \[level 2\]). Dosing of Radium 223 remains the same in all cohorts (55 KBq/kg given every 28 days for 6 cycles).~Maximum tolerated dose (MTD) of docetaxel will be assessed. MTD is defined as the highest dose-level, among those tested, associated with a rate of less than a 33% dose limiting toxicity (DLT)."
62023989|NCT03737370|EXPERIMENTAL|Dose expansion|If the maximum tolerated dose (MTD) of docetaxel is found in arm 1, this dose level will be expanded to include an additional 25 subjects to confirm the safety and explore the preliminary anti-cancer effect. If the MTD is not identified, the study will be stopped and the expansion cohort will not be accrued.
62415094|NCT05131893||Triple-negative breast cancer|"1. Paclitaxel (80 mg / m˄2) +/- carboplatin (AUC2) 12 times weekly, then E (90-100 mg / m˄2) + C (600 mg / m˄2) 4 times three weekly (preferred)~2. 4x every 3 weeks E (90-100mg / m˄2) + C (600mg / m˄2), then~   1. 4x docetaxel (90-100mg / m˄2) or~  2. 12x weekly paclitaxel (80mg / m˄2) +/- carboplatin (AUC2 )~3. 4x every 2 weeks E (90-100mg / m˄2) + C (600mg / m˄2), then~   1. 4 times every 2 weeks paclitaxel (175 mg / m˄2) or~  2. 12x weekly paclitaxel (80mg / m˄2) +/- carboplatin (AUC2)"
62796508|NCT05529693|PLACEBO_COMPARATOR|Placebo arm|Similar trial product, but without Bif-038 probiotic bacteria
62796509|NCT06149078||cases group|hyperurecemic
62796510|NCT06149078||control group|normal
62796511|NCT04522167|EXPERIMENTAL|FYB203 (Proposed aflibercept biosimilar)|Patients will receive intravitreal (IVT) injections of FYB203 as detailed in the protocol.
62796512|NCT04522167|ACTIVE_COMPARATOR|Eylea® (Aflibercept)|Patients will receive intravitreal (IVT) injections of Eylea® as detailed in the protocol.
62023990|NCT05348681|EXPERIMENTAL|RIST4721 400 mg|RIST4721 400 mg: 4 active (100 mg) tablets once daily for 12 weeks
62023991|NCT05348681|PLACEBO_COMPARATOR|Placebo|Placebo: 4 placebo tablets once daily for 12 weeks
62023992|NCT05669391|EXPERIMENTAL|Pharmacogenomics Group|
62796513|NCT00782717|EXPERIMENTAL|NEVANAC|One drop three times a day starting on the day prior to cataract surgery (Day -1) and continuing on the day of surgery (Day 0) and for 90 days thereafter.
62023993|NCT05669391|NO_INTERVENTION|Non Pharmacogenomics Group|
62023994|NCT01133652|ACTIVE_COMPARATOR|VeinViewer|The Veinviewer machine will be used to guide intravenous access.
62023995|NCT01133652|ACTIVE_COMPARATOR|Ultrasound|The Ultrasound will be used to guide intravenous access.
62023996|NCT01133652|ACTIVE_COMPARATOR|Conventional IV placement|IV will be placed using conventional technique
62023997|NCT02699281|EXPERIMENTAL|Ultra-micronized Palmitoylethanolamide|Ultra-micronized Palmitoylethanolamide 600 mg twice a day
62023998|NCT02699281|PLACEBO_COMPARATOR|Placebo|Placebo tab twice a day
62023999|NCT02397395|EXPERIMENTAL|Simeprevir Co-administered with Daclatasvir|All participants will receive Simeprevir (SMV) 150 milligram (mg) capsule co-administered with Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks. Participants should take the study drugs (SMV and DCV together) orally and once daily with food.
62220801|NCT00740987|EXPERIMENTAL|2|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
62415095|NCT05308654|EXPERIMENTAL|Part 1: Monotherapy Dose Escalation|Participants with relapsed or refractory (R/R) multiple myeloma (MM) will receive escalating doses of ABBV-453, until the maximum tolerated dose (MTD) is determined.
62796514|NCT00782717|PLACEBO_COMPARATOR|Nepafenac Vehicle|One drop three times a day starting on the day prior to cataract surgery (Day -1) and continuing on the day of surgery (Day 0) and for 90 days thereafter.
62796515|NCT01324791|ACTIVE_COMPARATOR|laparoscopic antireflux surgery|
62796516|NCT01324791|ACTIVE_COMPARATOR|endoscopic full-thickness-gastroplication|
62024000|NCT04283929|EXPERIMENTAL|Intervention 1 (Int1)|Facilities assigned to the enhanced package for Int1 will receive alerts and reminders to promote linkage of HIV positives from diagnosis to care.
62024001|NCT04283929|NO_INTERVENTION|Control 1 (Ctrl1)|Facilities assigned to the Ctrl1 will not receive any additional equipment, software tools, training or other forms of support.
62796517|NCT04423055|EXPERIMENTAL|COC users or new starts|Subjects will have an etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users. Women using COC for less than 1 month will be considered new starts.
62796518|NCT03128242|EXPERIMENTAL|oxytocin group|oxytocin treatment
62796519|NCT03128242|PLACEBO_COMPARATOR|placebo group|placebo treatment
62024002|NCT04283929|EXPERIMENTAL|Intervention 2 (Int2)|Randomise the Intervention 1 group into two additional arms: Intervention 2 (Int2) and Control (Ctrl2). Facilities assigned to Int2 will also receive alerts and reminders to improve lab reporting as part of their enhanced package.
62024003|NCT04283929|NO_INTERVENTION|Control 2 (Ctrl2)|Facilities assigned to the Ctrl2 will not receive any additional equipment, software tools, training or other forms of support to improve lab reporting as part of their enhanced EMR.
62220802|NCT02923687|ACTIVE_COMPARATOR|Buccal infiltration of Ketorolac|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, case group will receive a supplemental buccal infiltration of 30 mg/mL of Ketorolac tromethamine (Alborz-Darou Co. Qazvin, Iran).
62415096|NCT05308654|EXPERIMENTAL|Part 2: Arm 1|Participants will receive continuous doses of ABBV-453 in combination with dexamethasone in 28-day cycles.
62415097|NCT05308654|EXPERIMENTAL|Part 2: Arm 2|Participants will receive continuous doses of ABBV-453 in combination with daratumumab and dexamethasone in 28-day cycles.
62415098|NCT05308654|EXPERIMENTAL|Part 2: Arm 3|Participants will receive continuous doses of ABBV-453 in combination with daratumumab, lenalidomide, and dexamethasone in 28-day cycles.
62796520|NCT06726434|EXPERIMENTAL|CryoNeurotomy (CN)|Cryoneurotomy procedure
62796521|NCT06726434|ACTIVE_COMPARATOR|Surgical neurotomy (SN)|Surgical neurotomy procedure
62796522|NCT04372420|ACTIVE_COMPARATOR|RhBMP-2|RhBMP-2 belongs to TGF-β super family with osteoinductive property which is capable of promoting bone formation
62415099|NCT05308654|EXPERIMENTAL|Japan Cohort|Participants with R/R MM will receive escalating doses of ABBV-453, until the MTD is determined.
62796523|NCT04372420|PLACEBO_COMPARATOR|PLATELET RICH FIBRIN|Platelet rich fibrin(PRF) is a healing biomaterial with a great potential for bone and soft tissue regeneration, without any inflammatory reactions
62796524|NCT06227897|EXPERIMENTAL|Aumolertinib|Aumolertinib 110 mg once daily (110 mg per day) orally for 36 months.
62796525|NCT03133507|EXPERIMENTAL|Reapprasial Condition|Children in this condition will be instructed to think about how the procedure will help them become adjusted to cold weather.
62796526|NCT03133507|EXPERIMENTAL|Reassurance Condition|Children will receive empathic support from the experimenter.
62796527|NCT03133507|EXPERIMENTAL|Distraction Condition|Children in this condition will be instructed to focus their attention on a picture on a computer screen rather than on the pain.
62024004|NCT04283929|EXPERIMENTAL|Intervention 3 (Int3)|Randomise the Intervention 2 group into two additional arms: Intervention 3 (Int3) or Control (Ctrl3). Facilities assigned to Int3 will receive alerts and reminders to improve clinical response to the detection of treatment failure as part of their enhanced package.
62024005|NCT04283929|NO_INTERVENTION|Control (Ctrl3)|Facilities assigned to Ctrl3 will not receive alerts and reminders to improve clinical response to the detection of treatment failure as part of their enhanced package.
62024006|NCT02221115|OTHER|Google Glass|Investigators using Google Glass during clinic visit
62415100|NCT04749121|EXPERIMENTAL|Fit test|All the participants had to pass the initial fit test.After decontamination with UVC irradiation for 60 minutes.The protocol was conducted in accordance with the protocol from the OSHA respiratory protection standard , including the number, type, and duration of the exercise, and the seal checks in accordance with the manufacturer's instructions\[15\] 60 minutes, fit testing was conducted using qualitative fit test (Bittrex Solution aerosol)
62415101|NCT01307488|EXPERIMENTAL|ATV/r+3TC|Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
62415102|NCT01307488|ACTIVE_COMPARATOR|ATV/r+2 NRTIs|Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
62415103|NCT03601923|EXPERIMENTAL|Niraparib|"* Niraparib will be administered orally once daily~* Palliative radiation therapy to a small field \>1 week prior to Day 1 of study treatment"
62587563|NCT06667739|EXPERIMENTAL|IMPACT-L3|The experimental group will receive virtual peer health coaching (\~30 minutes weekly) delivered by a peer trainer over 8 weeks. Peer trainers with dysvascular LLA themselves will be matched to a participant based on gender and level of amputation. The peer will help participants set goals and create an action plan for physical activity. Peers will receive specialized training in brief action planning. Participants will have access to five web-based modules. Modules include content on benefits of physical activity, types of physical activity (strengthening, aerobic, balance, flexibility), intensity of activity (light, moderate, vigorous), and exercise safety. Participants will complete modules weekly at their own pace for the first 5 weeks. To support behaviour change, participants will be provided with a wearable to track their physical activity: an Apple Watch to be worn at the wrist of the non-dominant side.
62415104|NCT01506986|ACTIVE_COMPARATOR|H. pylori eradication treatment|Active treatment will consist of seven days of lansoprazole 30mg twice daily, clarithromycin 500mg twice daily and metronidazole 400mg twice daily.
62415105|NCT01506986|PLACEBO_COMPARATOR|Placebo H. pylori eradication treatment|Placebos to seven days of lansoprazole 30mg twice daily, clarithromycin 500mg twice daily and metronidazole 400mg twice daily.
62587564|NCT06667739|NO_INTERVENTION|Control|The control group will continue with their usual health care and be offered the intervention program at the end of the follow-up period (wait-list control).
62587565|NCT04964544|OTHER|Open Label, Single Arm Technology-Assisted Cholesterol Trial|Open Label Single Arm study in All-comers population who self-report having concern about high cholesterol or heart health
62587566|NCT04376944||Exposed group|Caregivers and agents working directly in COVID units compared to those living.
62587567|NCT04376944||Control group|caregivers anf agents working in services excluding the management of patients screened positive for Covid-19 infection
62587568|NCT01862263|EXPERIMENTAL|Vildagliptin|Vildagliptin 50 mg twice daily (bid) + Insulin 20 to 40 IU/day
62587569|NCT01862263|PLACEBO_COMPARATOR|Placebo|Insulin 20 to 40 IU/day + Vildagliptin Placebo twice daily (bid)
62796528|NCT05941234|OTHER|Patients cohort Fondazione Policlinico Gemelli|Collection of tumor and blood samples at T0 (surgery) and T1 (6 months follow-up) Tumor microenvironment and blood multi-omics analysis In-depth functional characterization of tumor microenvironment Cancer stem cells generation and drug testing Data integration by business intelligence and development of artificial intelligence-based prognostic markers
62024007|NCT02221115|NO_INTERVENTION|No Google Glass|Investigator will not be using Google Glass during clinic visit
62024008|NCT00233935|EXPERIMENTAL|Arm I (1 capsule)|Patients receive 1 capsule of defined green tea catechin extract PO BID for the next 6 months.
62415106|NCT03356769|EXPERIMENTAL|experimental：asprin & AEDS|Aspirin 5mg/kg，maximum 300mg; once a day plus AEDS
62024009|NCT00233935|EXPERIMENTAL|Arm II (2 capsules)|Patients receive 2 capsules of defined green tea catechin extract PO BID for the next 6 months.
62024010|NCT00233935|EXPERIMENTAL|Arm III (3 capsules)|Patients receive 3 capsules of defined green tea catechin extract PO BID for the next 6 months.
62024011|NCT00233935|PLACEBO_COMPARATOR|Arm IV (placebo)|Patients receive 1-3 capsules of placebo PO BID for the next 6 months.
62415107|NCT03356769|PLACEBO_COMPARATOR|control: placebo & AEDS|placebo 5mg/kg，maximum 300mg; once a day plus AEDS
62415108|NCT06540040|EXPERIMENTAL|Aquacel Ag|Participants in this group will receive Aquacel Ag, a Hydrofibre wound dressing consisting of non-woven sodium carboxymethylcellulose fibres integrated with ionic silver. This dressing is designed to provide a moist wound environment and has antimicrobial properties to help reduce the risk of infection. The dressing will be applied post-operatively and changed as per the standardized protocol.
62587570|NCT05247242|EXPERIMENTAL|Tarrant Community Fitness Program: LOF-VR|LOF-VR
62587571|NCT05247242|EXPERIMENTAL|Tarrant Community Fitness Program: VR-LOF|VR-LOF
62587572|NCT01005823|ACTIVE_COMPARATOR|LEO 29102 cream 0.3 mg/g|
62587573|NCT01005823|ACTIVE_COMPARATOR|LEO 29102 cream 1.0 mg/g|
62587574|NCT01005823|ACTIVE_COMPARATOR|LEO 29102 cream 2.5 mg/g|
62587575|NCT01005823|PLACEBO_COMPARATOR|LEO 29102 placebo cream|
62587576|NCT06144710|EXPERIMENTAL|SG301 SC|"Part A: Dose escalation of SG301 SC will be done in healthy volunteers at 1 mg/kg dose group and 2 mg/kg dose group.~Part B: Dose escalation of SG301 SC will be done in Systemic lupus erythematosus subjects in 4 dose groups, namely 2 mg/kg, 4 mg/kg, 8 mg/kg, and 12 mg/kg dose groups. 8 subjects will be randomized to SG301 SC injection in an 8:2 ratio at each dose group."
62587577|NCT06144710|PLACEBO_COMPARATOR|Placebo|Part B: Dose escalation of SG301 SC will be done in Systemic lupus erythematosus subjects in 4 dose groups, namely 2 mg/kg, 4 mg/kg, 8 mg/kg, and 12 mg/kg dose groups. 2 subjects will be randomized to SG301 SC injection in an 8:2 ratio at each dose group.
62587578|NCT04500483||Burn outpatients|Burn patients treated for minor burns in an outpatient setting
62587579|NCT04500483||ICU survivors|Critically ill patients who survived ICU stay and are admitted in a general ward
62024012|NCT00901290|EXPERIMENTAL|1|monophasic oral contraceptive
62415109|NCT06540040|EXPERIMENTAL|OPSITE|Participants in this group will receive OPSITE, a transparent waterproof cotton pad with a high Moisture Vapour Transmission Rate. This dressing is intended to provide a protective barrier while allowing moisture vapor to escape, helping to maintain an optimal wound healing environment. The dressing will be applied post-operatively and changed according to the standardized protocol.
62024013|NCT00901290|EXPERIMENTAL|2|AZD7325
62024014|NCT00775749|EXPERIMENTAL|1|The nicotine patch will be applied prior to surgery and remain on the right upper back for 24 hours.
62024015|NCT00775749|PLACEBO_COMPARATOR|2|The placebo patch has no active ingredients and the same inactive ingredients as the nicotine patch. It will be administered the same fashion as the nicotine patch.
62024016|NCT01391104|EXPERIMENTAL|Sildenalfil|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
62024017|NCT01391104|PLACEBO_COMPARATOR|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
62024018|NCT04307823|ACTIVE_COMPARATOR|Treadmill training group|Treadmill training according to American College of Sports Medicine's guidelines
62415110|NCT06540040|EXPERIMENTAL|MEPILEX POST OP BORDER|Participants in this group will receive MEPILEX POST OP BORDER, a 4-layer foam dressing with flex technology. This advanced dressing is designed to provide superior absorption and conformability, helping to manage exudate and protect the wound site. The dressing will be applied post-operatively and changed as per the standardized protocol.
62415111|NCT06540040|ACTIVE_COMPARATOR|Traditional Dressing|Participants in this group will receive traditional wound dressings consisting of gauze pieces, surgical pads, and porous paper adhesive strips. This type of dressing is commonly used in post-operative care to absorb exudate and protect the wound site. The dressing will be applied post-operatively and changed according to the standardized protocol.
62415112|NCT00203892|EXPERIMENTAL|A: CEA peptide 10mcg|Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
62796529|NCT02928575|EXPERIMENTAL|Sunitinib, Temozolomide and Radiation Therapy|Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
62796530|NCT05180383|EXPERIMENTAL|Mobile Application to Prevent Suicide (MAPS)|"Participants receiving MAPS will receive the Safety Planning Intervention (SPI) which will be uploaded into the smartphone app. They will be prompted four times per day to complete a brief ecological momentary assessment check-in inquiring about their cognitions, affect, and behavior, including suicidal thoughts and behaviors. Based on these responses, they will be provided with coping strategies from their safety plans and from a database of coping strategies created by study staff. They will also have access to emergency phone numbers, the coping strategies database, and can communicate with their study clinician through a text-like interface in the app. They will receive this intervention for one month."
62024019|NCT04307823|EXPERIMENTAL|Treadmill protocol and respiratory training group|Treadmill training, slow breathing training and incentive spirometry
62024020|NCT03870763|EXPERIMENTAL|Dimethyl Fumarate 240 mg|Participants will receive dimethyl fumarate 240 milligrams (mg) capsule twice daily (BID) orally and placebo subcutaneous (SC) injection every 2 weeks for up to 96 weeks (2 years).
62024021|NCT03870763|EXPERIMENTAL|Peginterferon Beta-1a 125 µg|Participants will receive peginterferon beta-1a 125 micrograms (µg) SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years).
62024022|NCT03870763|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years)
62415113|NCT00203892|EXPERIMENTAL|B: CEA peptide 100 mcg|Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
62796531|NCT06147141|EXPERIMENTAL|Online Peer Companion Intervention group (OPCI)|experimental group
62796532|NCT06147141|PLACEBO_COMPARATOR|Wait-List Group (WLG)|control group
62024023|NCT00993447|EXPERIMENTAL|CYD Dengue Vaccine Group|Sanofi pasteur's CYD Dengue vaccine group (Dengvaxia®)
62024024|NCT00993447|SHAM_COMPARATOR|Control Vaccine Group|
62024025|NCT06266923|EXPERIMENTAL|SPH6516 tablets|
62024026|NCT01579344|ACTIVE_COMPARATOR|Thyroid carcinoma, Radioactive iodine therapy|50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma undergoing radioactive iodine therapy
62024027|NCT01579344|NO_INTERVENTION|Thyroid carcinoma, without radioactive iodine therapy|50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma not undergone radioactive iodine therapy
62024028|NCT02235597||Patients and Staff of Community Clinics|Patients and Staff of Community Clinics who shared strategies and solutions to overcome barriers to accessing health care
62024029|NCT04700306|EXPERIMENTAL|Sophrology|the patient must make 8 visits with interviews and questionnaires, including 7 visits with a session of sophrology
62024030|NCT04700306|NO_INTERVENTION|Control|the patient must make 7 visits with interviews and questionnaires
62024031|NCT02600130|EXPERIMENTAL|Cohort 1|Cohort 1 (10 subjects) Target dose 20 million Longeveron Mesenchymal Stem Cells (LMSCs) via peripheral intravenous infusion.
62024032|NCT02600130|EXPERIMENTAL|Cohort 2|Cohort 2 (10 subjects) Target dose 100 million Longeveron Mesenchymal Stem Cells (LMSCs)via peripheral intravenous infusion.
62220803|NCT02923687|PLACEBO_COMPARATOR|Buccal infiltration of Normal saline|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the control group will receive normal saline as placebo.
62220804|NCT01425424|EXPERIMENTAL|Fasting glucose (blood sugar)|This group is associated with a diagnosis of prediabetes
62220805|NCT01425424|EXPERIMENTAL|Resting Blood pressure|This group is associated with a diagnosis of prehypertension.
62220806|NCT01425424|EXPERIMENTAL|Fasting Glucose & Resting Blood Pressure|coexisting prediabetes and prehypertension
62220807|NCT01788787||Texas Quitline|Patients interested in smoking cessation treatment by calling the Texas Quitline.
62220808|NCT01788787||Training Providers|Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians).
62024033|NCT02600130|PLACEBO_COMPARATOR|Cohort 3|Cohort 3 (5 subjects) Placebo (Plasmalyte A and 1% human serum albumin (HSA)) via peripheral intravenous infusion.
62220809|NCT01735851|ACTIVE_COMPARATOR|Thoracic epidural analgesia|Group 1 will receive a catheter congruent TEA. The epidural space will be identified using the loss of resistance technique. After a test dose to rule out intravascular and intrathecal placement of the catheterthe initial block will be made with 0.25% bupivacaine 5 mL followed by 3 mL aliquots administered every 5 minutes to establish a block between T8 and T12. An infusion will be started at 8 mL/hour with 0.1 % bupivacaine with 10microgram/mL of dilaudid and continued for 72 hours. Additional nurse administered boluses of 5-10mL of the standard solution will be allowed via the epidural catheter every 6hourly for poor pain control followed by an increase in the basal infusion rate up to a maximum of 14mL/hr. Patients will be allowed to self administer additional boluses of 3mL of the standard infusate every 20minutes (PCEA)
62220810|NCT01735851|EXPERIMENTAL|Bilateral Paravertebral block|Group 2 will have bilateral PVB catheters inserted using the ultrasound with patients prone. A high-frequency linear probe will used to visualize the transverse process, pleura and the internal intercostal membrane. A 17 guage Tuohy needle will be inserted to puncture the internal intercostal membrane. Injection of local anesthetic will push the pleura away, which will be the end point of needle position. A curved pigtail catheter will be inserted and further 5mL of local anesthetic will be injected while observing further movement of pleura. A similar procedure will be done on the contralateral side at the same level. Infusion of 0.2% ropivacaine will be continued for the next 72 hours. They will also receive IVPCA and additional nurse administered boluses of 5-10mL of ropivacaine 0.2% in the PVB every 6 hourly to the side of maximal pain.
62587580|NCT01089764|EXPERIMENTAL|Couplelinks.ca Intervention|Intervention arm - Couple participates in the Couplelinks.ca program.
62024034|NCT01691300|EXPERIMENTAL|ACT PET/CT|Dual-tracer ACT/FDG PET/CT and WB-DCE-MRI at baseline (pretreatment), post-induction and post-ASCT (if eligible)
62415114|NCT00203892|EXPERIMENTAL|C: CEA peptide 1000mcg|Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
62415115|NCT05570175|EXPERIMENTAL|intervention group|The intervention group received a mobile application RA joint protection and activity self-management program based on self-efficacy theory for 6 weeks.
62796533|NCT04781686|EXPERIMENTAL|First-line treatment|"First-line treatment: Apatinib plus Camrelizumab combined with Docetaxel and S1 for six cycles.~Maintenance treatment: Apatinib and Camrelizumab"
62796534|NCT06503666|EXPERIMENTAL|Zambian Informed Motivated Aware Responsible Adolescent Girls and Young Adults(ZAIMARA)|Intervention Arm
62220811|NCT05375851|EXPERIMENTAL|Digital Intervention|"The digital interventions will consist of two parts:~A) Psychoeducation videos: Five psychoeducation videos on mental health and GAD will be produced especially for the research to be watched by the patient between consultations. These videos will last approximately 3 minutes, will use animations and educational content. They will be available on +PSI app. The topics of the videos will be as follows: Normal Anxiety versus Pathological Anxiety; Sleep Hygiene; Healthy Eating and Mental Health; Physical Exercise and Mental Health; Excessive Consumption of Alcohol and Drugs.~B) GAD-7 Scale: The patient will be instructed to respond to the GAD-7 self-administered scale the day before their next scheduled appointment. This instrument will also be available free of charge on +PSI mobile app and will be used to guide clinical management.~The above digital interventions will be added to the usual GAD treatment."
62415116|NCT05570175|NO_INTERVENTION|control group|The control group received general information on rheumatoid arthritis care and follow-up.
62415117|NCT06446193|EXPERIMENTAL|The experimental group|NDTx-01 + TAU (Treatment-As-Usual)
62587581|NCT01089764|NO_INTERVENTION|No Intervention|Couple is waitlisted for participation in the Couplelinks.ca program.
62587582|NCT03444948|EXPERIMENTAL|3 radiofrequency ablation procedures|Subject will undergo 3 radiofrequency ablation procedures at 1 month intervals (EUS-RFA using Habib Tm as a probe)
62587583|NCT03444948|ACTIVE_COMPARATOR|standard medical care|Subject will receive standard medical care, including pain relief drugs
62587584|NCT03843749|EXPERIMENTAL|HER2-positive Metastatic Colorectal Cancar|
62024035|NCT06533241||pediatric patients less than 18 years' old who underwent renal biopsy|pediatric patients less than 18 years' old who underwent renal biopsy at Tanta University Hospital from 2012 to 2022.
62415118|NCT06446193|OTHER|The control group|TAU (Treatment-As-Usual)
62415119|NCT05037409|EXPERIMENTAL|PF-06823859 low|Participants will receive single intravenous infusion.
62415120|NCT05037409|EXPERIMENTAL|PF-06823859 high|Participants will receive single intravenous infusion.
62415121|NCT05037409|PLACEBO_COMPARATOR|Placebo|Participants will receive single intravenous infusion.
62415122|NCT02449109|NO_INTERVENTION|Control|Liver cancer patients never received any interventional therapy.
62415123|NCT02449109|EXPERIMENTAL|Nano drug|Liver cancer patients received nano drug interventional therapy using digital subtraction angiography（DSA）. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
62415124|NCT02449109|ACTIVE_COMPARATOR|Drug microspheres|Liver cancer patients received drug microspheres (HepaSphere Microspheres) interventional therapy using digital subtraction angiography（DSA）.
62415125|NCT06048718|EXPERIMENTAL|T-DXd|Patients will receive T-DXd at 5.4 mg/kg administered as an intravenous (IV) infusion every three-weeks (Q3W) until disease progression, unacceptable toxicity, death, or discontinuation from the study.
62587585|NCT06659783||Unselected acute UGIB adult patients admitted with overt signs of AUGIB or in-bleeder|40 hospitals receiving emergency admissions in the Guangdong-Hong Kong-Macao area in China are invited to participate in this study. Unselected acute UGIB adult patients (≥18 years old) admitted within a 2-month period in the second quarter of 2025 are identified. These patients are newly admitted patients from both the emergency department and clinics with overt signs of AUGIB, as well as patients who develop bleeding while hospitalized for other reasons.
62587586|NCT02476812|EXPERIMENTAL|Positive Piggy Bank|"Patients randomized to this group will meet with a research assistant who provides an overview of the intervention, explains the rationale for this treatment, and then gives the patients the instructions, piggy bank, and currency slips. Participants in this group will receive instructions. At the end of the monitoring period, 30 days, they are to close their account by opening the piggy bank and reviewing all of the slips of paper.~Study personnel will contact patients within 72 hours to answer questions. Participants will also be contacted at 30 days to let patients know that they should read all of their currency slips in one sitting. They are also told that the intervention part of the study is over and are asked they complete the follow up questionnaires. Then, study personnel will call again to let the participant know that the second set of questionnaires will be arriving by mail."
62796535|NCT06503666|EXPERIMENTAL|Health Promotion (HP)|Control Arm
62796536|NCT02668458|EXPERIMENTAL|NIV|NIV group, preoxygenation by NIV: pressure support set for an exhaled tidal volume of 6-8 ml / kg of ideal body weight, PEEP of 5 cm H2O and FiO2 at 100%.
62796537|NCT02668458|ACTIVE_COMPARATOR|HFNC|High-flow nasal canula oxygen therapy. NHFC group, preoxygenation by NHFC: oxygen flow rate of 60 L / min and 100% FiO2
62415126|NCT06073873||Participants with moderate to severe active ulcerative colitis treated with ozanimod|
62220812|NCT05375851|ACTIVE_COMPARATOR|Control|"The usual treatment will be standardized as follows:~Biweekly online consultations (via WhatsApp or Google Meet) previously scheduled, 20/30 minutes-long, with a trained psychiatrist.~The patient will receive only clinical, not psychotherapeutic treatment. The psychiatrist will be instructed to perform an assessment of symptoms, general guidelines on the pathology, use of medication when necessary.~The medication of choice, when necessary, will be fluoxetine, as it is the medication for the treatment of GAD available free of charge in our health system in Brazil."
62220813|NCT05270174||lncRNA-ELNAT1 high expression group|
62587587|NCT02476812|NO_INTERVENTION|Waitlist Control|The control group will serve to show the relative benefits of the Positive Piggy Bank intervention. Those in the control group who meet study criteria will also receive regular care after their epidural steroid injection (e.g., physician visits, medication maintenance, standard patient education). These patients will follow the same questionnaire follow up procedures as listed above including phone calls. The phone call at 72 hours will be to simply thank them for their participation in the study. At the end of the study period, approximately three months, Wait List control patients will also be offered the Positive Piggy Bank intervention along with the supportive phone calls. Should they choose to try the Positive Piggy Bank intervention, they will be required to return to the center to pick up supplies and receive instruction. They will also complete study questionnaires by mail at 30 days to assess intra-individual change.
62796538|NCT03826069|ACTIVE_COMPARATOR|Conventional Simulation Curriculum|Four, one-hour small-group sessions on the theory of colonoscopy including pathology, anatomy, and therapeutic technique. Following each session, a multiple choice test on topics covered will be administered. In addition, this group will be given a total of six hours of expert-assisted instruction on both the low-fidelity simulator (1 hour) and the high-fidelity VR simulator (5 hours). During the high-fidelity simulation, endoscopic procedures will be performed with instructor support. The difficulty of the therapeutic intervention (polypectomy) will rise after each successfully completed module. The last two hours of training on the high-fidelity simulator will consist of two integrated scenarios.
62220814|NCT05270174||lncRNA-ELNAT1 low expression group|
62220815|NCT03110185|OTHER|delirium|Patients in the cardiothoracic ICU diagnosed with postoperative delirium. Subjects will wear a diffuse optical tomography device in addition to the normal monitors. A non-contrast functional MRI will be performed.
62220816|NCT03110185|OTHER|no delirium|Patients in the cardiothoracic ICU not diagnosed with postoperative delirium. Subjects will be monitored in the same way as the delirium arm
62220817|NCT05774743|NO_INTERVENTION|Standard Consent|Participants will receive the standard anesthesia consent procedure without the use of the visual aid that is being used in this study.
62220818|NCT05774743|EXPERIMENTAL|Consent with Visual Aid|Participants will receive standard anesthesia consent procedure with the use of the visual aid that is being used in this study.
62220819|NCT03862001|EXPERIMENTAL|LungCARE Group|The intervention group will receive the LungCARE intervention
62220820|NCT03862001|NO_INTERVENTION|Comparison Group|The comparison group will receive usual care.
62220821|NCT00211185|EXPERIMENTAL|Denileukin diftitox in combination with CHOP|Unblinded denileukin diftitox at 18 micrograms/kilogram/day (ug/kg/d) was administered intravenously (IV) on Days 1 and 2 of each 21-day cycle. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) was administered on Day 3 of each 21-day cycle. On Day 4 of each 21-day cycle, pegfilgrastim (a granulocyte colony-stimulating factor (G-CSF)) was started as a prophylaxis to prevent neutropenia. After completion of two 21-day cycles, participants were evaluated for clinical response. Two 21-day cycles with denileukin and CHOP were repeated followed by response evaluations after each set of two 21-day cycles with intent to treat for 6 cycles, with a maximum of 8 cycles.
62220822|NCT04307420|EXPERIMENTAL|Sonic Fill Restoration|Using sonic activation system turns the highly filled sonic fill composite into a flowable which enables the material to rapidly fill the cavity effortlessly- greatly reducing procedure time.
62220823|NCT04307420|ACTIVE_COMPARATOR|Composite Resin Restoration|Direct composite restorations are the most requested and performed dental procedures. The incremental placement technique is the gold standard for posterior universal composite placement.
62220824|NCT00464009|ACTIVE_COMPARATOR|A|Group A practices (n=39) received didactic training and course materials in oral health screening, referral, counseling and application of fluoride varnish.
62220825|NCT00464009|ACTIVE_COMPARATOR|B|Group B practices (n=41) received the same as Group A and were offered weekly conference calls providing advice and support.
62220826|NCT00464009|ACTIVE_COMPARATOR|C|Group C practices (n=41) received the same as Group B and were also offered in-office follow-up visits providing hands-on advice and support.
62415127|NCT05972954|EXPERIMENTAL|Treatment with OMT-28|24mg OMT-28, oral capsule, for 12 weeks
62415128|NCT04432129|EXPERIMENTAL|IBBIS II|Integrated Mental Health Care and Vocational Rehabilitation
62415129|NCT04432129|ACTIVE_COMPARATOR|Service As Usual|Standard vocational rehabilitation and treatment
62587588|NCT02074098|EXPERIMENTAL|a 65 cm bed height|1) Bed height : approximately 65cm (Lowest)
62415130|NCT04631055|EXPERIMENTAL|DCB group|use intracranial drug coated balloon catheter made by Acotec Scientific Co.,Ltd.
62415131|NCT04631055|ACTIVE_COMPARATOR|Stent group|use the Intracranial Stent System made by MicroPort.
62415132|NCT05367934|EXPERIMENTAL|The Effect of Therapeutic Touch on Nursing Students on Perceived Stress and Stress Coping Behaviors|The nurses in the intervention group were given therapeutic touch for 15 minutes once a week for two weeks.
62415133|NCT05367934|OTHER|The Effect of Therapeutic Touch on Stress and Stress Coping Behaviors|No treatment was applied to the patients in the control group other than their routine care.
62587589|NCT02074098|EXPERIMENTAL|a 95cm bed height|2) Bed height : approximately 95cm (highest)
62024036|NCT01156701||Cohort1: Prophylaxis with untreated index|"Individuals are eligible to be included in the prophylaxis with untreated index cohort if they are at least 5 years old and have at least 6 months of continuous enrollment, and~1. Received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034), and~2. Have no diagnosis of influenza (ICD-9 487.xx) on the day of Relenza dispensing or in the 3 preceding days, and~3. A household member (index case) with the same family identifier code has had a medical visit (outpatient, inpatient or emergency room (ER) visit) in the 3 days preceding or the day of the Relenza dispensing with a diagnosis of influenza (ICD-9 487.xx), and~4. The household member (index case) has not received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
62587590|NCT03138031|EXPERIMENTAL|Percutaneous Ethanol Injection (PEI)|"Those participants receive percutaneous ethanol alcohol injection for the large and unresectable HCC. Absolute alcohol; weekly sessions; under close monitoring; maximum of 30 mls; no anaesthesia needed and a maximum pain score of 8 during the procedure. Postprocedure analgesia may be required."
62587591|NCT05781516|PLACEBO_COMPARATOR|Prednisolone monotherapy|Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months.
62587592|NCT05781516|EXPERIMENTAL|Prednisolone plus Baricitinib|Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months. Oral Baricitinib 2mg daily for 12 months.
62587593|NCT01115920|EXPERIMENTAL|Arm 1|Cohort 1, Dose 0.010 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
62587594|NCT01115920|EXPERIMENTAL|Arm 2|Cohort 2, Dose 0.025 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
62024037|NCT01156701||Cohort2: Prophylaxis with treated index|"Individuals are eligible to be included in the prophylaxis with treated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~1. Received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034), and~2. Have no diagnosis of influenza (ICD-9 487.xx) on the day of Relenza dispensing or in the 3 preceding days, and~3. A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) in the 3 days preceding or the day of the Relenza dispensing with a diagnosis of influenza (ICD-9 487.xx), and~4. The household member (index case) has received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
62220827|NCT04020354|EXPERIMENTAL|HABIT-ILE|Early HABIT-ILE (Hand and arm bimanual intensive therapy including lower extremities) will be applied over 2 weeks.
62415134|NCT04124900||patients at prostate cancer risk diagnosed|"The study is composed of one single subject cohort. After risk evaluation, prostate biopsies will be performed for diagnostic purposes on all recruited patients. The cases are sorted into two groups after diagnosis:~* Group 1: patients at prostate cancer risk diagnosed with significant prostate cancer after prostatic biopsy (Gleason \>6).~* Group 2: patients at prostate cancer risk diagnosed free of cancer after prostate biopsy. There will be a subdivision within this group in patients without significant prostate cancer ( No cancer o Non-significant prostate cancer (Gleason ≤6))."
62587595|NCT01115920|EXPERIMENTAL|Arm 3|Cohort 3, Dose 0.050 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
62587596|NCT01115920|EXPERIMENTAL|Arm 4|Cohort 4, Dose 0.100 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
62796539|NCT03826069|EXPERIMENTAL|Augmented Reality Group|This group will receive the same 4 hours of small group teaching and 6-hours of hands-on simulator training. The intervention is the augmented reality-based curriculum: (1) a brief explanation of the principles of AR and how it will be used during the VR simulations and (2) performance of the therapeutic procedure (polypectomy) as demonstrated by the real-time AR platform. Specific videos corresponding to the therapeutic intervention and pathology (e.g pedunculated vs non-pedunculated polyp) will be available every time a polypectomy is required. Each new module will come with increased technical challenges and will require adjustment to previously used technique by the learner. The last two hours of training on the high-fidelity simulator will consist of two integrated scenarios.
62796540|NCT01362829||Patients with severe sepsis|Patients who are admitted to medical ICU with severe sepsis
62796541|NCT04975776|EXPERIMENTAL|Sleep restriction therapy|Four group sessions delivered at the participants' primary health care centers once a week for 3 weeks and again after a 4-week pause. The first session will last for 2 hours and the other sessions for 1 hour.
62220828|NCT04020354|ACTIVE_COMPARATOR|Usual Care|A two weeks period of usual customary care
62220829|NCT06228118||Subjects enrolled in method comparison study only|
62796542|NCT04975776|ACTIVE_COMPARATOR|Sleep hygiene|Participants in the active comparator group will receive a brochure with sleep hygiene advice from the primary health care center at baseline.
62796543|NCT01359345|EXPERIMENTAL|A|The patients with renal failure in whom Gadollinume has being used
62220830|NCT06228118||Subjects enrolled in both the method comparison study and lay user study|
62220831|NCT03034538|ACTIVE_COMPARATOR|100mg|Zonegran 100mg
62220832|NCT03034538|ACTIVE_COMPARATOR|200mg|Zonegran 200mg
62220833|NCT03699085|EXPERIMENTAL|ED-LINC Intervention Condition|Patients in this arm will receive the ED-LINC intervention. Elements of ED-LINC are based on evidence-based treatments and are central components of collaborative care. ED-LINC will be supported by a novel Emergency Department Information Exchange (EDIE) technology platform that allows for the creation of ED care plans and electronic alerts and will assist in care coordination of this complex population.
62220834|NCT03699085|NO_INTERVENTION|Usual Care Condition|Patients in this arm may receive a spectrum of consulting services visits including social work services, psychiatric consultation, inpatient psychiatry consult, rehabilitation psychology consultation, addiction intervention services, pain team consultation services that include MD psychiatric and PhD psychologist providers, spiritual care or other consulting services which shall count as usual care.
62796544|NCT04015206|EXPERIMENTAL|IPT-G+UCT|10 sessions of Group Interpersonal therapy added to pharmacotherapy + clinical management plus one individual session pre-group and one session pos-group
62796545|NCT04015206|ACTIVE_COMPARATOR|Usual treatment (UCT)|Pharmacotherapy + Clinical management once a month
62220835|NCT02867878|EXPERIMENTAL|Adenosine|Patients in this arm will receive systemic infusion of adenosine at 140μg/kg/min for 3 minutes plus standard therapy according to current guidelines
62587597|NCT01115920|EXPERIMENTAL|Arm 5|Cohort 5, Dose 0.250 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
62587598|NCT00595985|EXPERIMENTAL|A|administer sorafenib 400mg bid until disease progression or intolerable toxicity or patients withdrawal of consent
62587599|NCT05787808|ACTIVE_COMPARATOR|Treatment 1|1000 mg Calcium tablets + 20µg vitamin D and optimal efficacy dose of Jarlsberg cheese
62587600|NCT05787808|ACTIVE_COMPARATOR|Treatment 2|1000 mg Calcium tablets + 20µg vitamin D
62024038|NCT01156701||Cohort3: No prophylaxis with untreated index|"Individuals are eligible to be included in the no prophylaxis with untreated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~1. Have not received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034) within 3 days following the date on which~2. A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) with a diagnosis of influenza (ICD-9 487.xx), and~3. The household member (index case) has not received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
62024039|NCT01156701||Cohort4: No prophylaxis with treated index|"Individuals are eligible to be included in the no prophylaxis with treated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~1. Have not received a dispensing of Relenza(HICL=020398 or HCPCS = G9018 or G9034) within 3 days following the date on which~2. A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) with a diagnosis of influenza (ICD-9 487.xx), and~3. The household member (index case) has received zanamivir (Relenza) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza"
62415135|NCT05063318|ACTIVE_COMPARATOR|Sequence TR|"Sequence 1 (TR)~* Cycle 1: Itraconazole + lurbinectedin 0.8 mg/m²~* Cycle 2: Lurbinectedin alone 3.2 mg/m²~* Cycle 3: Lurbinectedin alone 3.2 mg/m² (optional)~PART A The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m². In Part A, all patients will receive itraconazole plus lurbinectedin in Cycle 1 and lurbinectedin alone in Cycles 2 and 3 (this last cycle being optional).~PART B Randomization will apply for study Part B only. In Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A. In Part B, patients will be randomly assigned to the corresponding sequences."
62415136|NCT05063318|ACTIVE_COMPARATOR|Sequence RT|"Sequence 2 (RT):~* Cycle 1: Lurbinectedin alone 3.2 mg/m²~* Cycle 2: Itraconazole + lurbinectedin 0.8 mg/m²~* Cycle 3: Lurbinectedin alone 3.2 mg/m² (optional)"
62024040|NCT03354676||MetS+|Obese group with metabolic syndrome/Data processing from Patient Medical Files
62024041|NCT03354676||MetS-|Obese group without metabolic syndrome/Data processing from Patient Medical Files
62415137|NCT02025400|ACTIVE_COMPARATOR|Physical Therapy|This arm will receive the standard of care for orthopedic patients receiving a diagnosis and then a recommendation for outpatient physical therapy referral. They will follow through on the referral and attend physical therapy.
62415138|NCT02025400|EXPERIMENTAL|eRehab|This group will not go to formal therapy but receive Internet delivered patient education and exercise instruction. This group will then perform those exercises at home.
62415139|NCT01500434|EXPERIMENTAL|PROMUS Element|Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent
62587601|NCT03694964|EXPERIMENTAL|Supplementation with Citrulline|Patients will receive citrulline (ProteoCIT®) 10 mg by day during 45 days
62587602|NCT03694964|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo (one tablet by day) during 45 days
62587603|NCT02738255|ACTIVE_COMPARATOR|Polysomnogram With Varnum First, Regular Polysomnogram Second|Varnum mouthpiece, similar to a mouth tape with central opening on the first night, then a 1-week non-treatment period, then overnight sleep study with no mouthpiece.
62587604|NCT02738255|ACTIVE_COMPARATOR|Regular Polysomnogram First, Polysomnogram With Varnum Second|Baseline sleep study without Varnum mouthpiece on the first night, then a 1-week non-treatment period, then an overnight sleep study with Varnum mouthpiece on the second night.
62587605|NCT01532843|ACTIVE_COMPARATOR|PegIFN alfa-2b + nucleos(t)ide analogue|Peginterferon alfa-2b 1.5 μg/kg per week s.c. for 48 weeks in addition to standard nucleos(t)ide analogue treatment
62024042|NCT00974168|ACTIVE_COMPARATOR|A|Radiation Cumulative BED ≤ 100 Gy2
62024043|NCT00974168|ACTIVE_COMPARATOR|B|Cumulative BED ≤ 130 Gy2
62024044|NCT04622358|EXPERIMENTAL|AD-214-02/Rabeprazole|Period 1 : Test Drug(AD-214-02) Period 2 : Reference Drug(Rabeprazole)
62024045|NCT04622358|EXPERIMENTAL|Rabeprazole/AD-214|Period 1 : Reference Drug(Rabeprazole) Period 2 : Test Drug(AD-214-02)
62024046|NCT03021382||severity of calcification|All vessels were divided into tertile groups according to the severity of coronary calcification evaluated by the Agatston score.
62024047|NCT03021382||minimal lumen diameter (MLD) ≥1.0 mm|All lesions were divided according to an MLD ≥1.0 mm, and \<1.0 mm by OCT in order to isolate the lesions which an MLD below the OCT catheter size.
62024048|NCT00982670||Systemic lupus erythematosus|Patients should fulfill the diagnostic criteria of the 1997 American College of Rheumatology for systemic lupus erythematosus
62024049|NCT00982670||Normal control|Age- and sex-matched health volunteers will serve as controls.
62024050|NCT03750487|EXPERIMENTAL|e-screening & brief intervention (e-SBI)|A two-session (20 minutes each) computer-delivered screening and brief motivational intervention targeting alcohol and drug use. Computerized screening is conducted using the ASSIST. Session 1 of the BI includes personalized feedback, readiness to change interventions, and goal setting around substance use. Session 2 will contain motivational content reinforcing engagement in home visiting and information around other challenges mothers may experience including tobacco use, postpartum depression, and intimate partner violence.
62587606|NCT01532843|NO_INTERVENTION|Nucleos(t)ide analogue|Continuation of Nucleos(t)ide analogue mono-therapy
62587607|NCT05999617|EXPERIMENTAL|Intervention Group|Conventional rehabilitation (stretching, strengthening, balance) plus dual task exercise training (simple math during active stretching, carrying the ball without dropping child while on the balance pad) will be applied 3 days a week for 12 weeks. Interventions will be implemented individually. Patients will be evaluated before and 12 weeks after the interventions.
62587608|NCT05999617|ACTIVE_COMPARATOR|Control Group|Conventional rehabilitation program (stretching, strengthening, balance) will be employed.
62415140|NCT06333041|EXPERIMENTAL|Epidiolex (cannabidiol)|"Oral Epidiolex (cannabidiol) administered twice daily (BID) Week 1: 5 mg/kg/day BID Weeks 2-8: 10 mg/kg/day BID Weeks 9-16: 20 mg/kg/day BID~8-week washout; cross-over to placebo comparator starting on Week 24."
62415141|NCT06333041|PLACEBO_COMPARATOR|Placebo (PBO)|"Week 1: Dose escalate to maximum tolerated placebo dose Weeks 2-16: Maximum tolerated placebo dose~8-week washout; cross-over to Experimental group starting at week 24, following the same dose-escalation as the Experimental arm."
62796546|NCT03468244|EXPERIMENTAL|Personalized mRNA Tumor Vaccine|Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma
62796547|NCT02085694|EXPERIMENTAL|Lactobacillus brevis CD2 lozenges|
62796548|NCT04998955|EXPERIMENTAL|MST group|Exercise intervention, 20 supervised MST sessions
62796549|NCT04998955|NO_INTERVENTION|Control group|IRD patient controls
62796550|NCT05759494||A|50 patients before use rapid diagnostic test (multiplex PCR filmArray)
62796551|NCT05759494||B|50 patients after use rapid diagnostic test (multiplex PCR filmArray)
62796552|NCT04329910||Lean|BMI \< 25
62796553|NCT04329910||overweight|BMI 25 - 29.9
62796554|NCT04329910||class i obesity|BMI 30 -34.9
62796555|NCT04329910||class ii obesity|BMI 35 - 39.9
62587609|NCT04168502|EXPERIMENTAL|Experimental arm|"Induction:~Gemtuzumab 3 mg/m2 day 1,4,7 Daunorubicin 60 mg/m2 day 1-3 Cytosine arabinoside 200 mg/m2 day 1-7~Consolidation:~Gemtuzumab 3 mg/m2 day 1 Daunorubicin 50 mg/m2 day 4-6 Cytosine arabinoside 500 mg/m2 twice a day, day 1-6~Allogeneic transplantation or Autologous transplantation according to MRD level~clinical observation"
62587610|NCT05377957||Brachytherapy|Uveal melanoma patients treated with Ruthenium-106 plaque brachytherapy
62587611|NCT05377957||Proton therapy|Uveal melanoma patients treated with proton therapy
62796556|NCT04329910||class iii obesity|BMI \>= 40
62796557|NCT03263273|PLACEBO_COMPARATOR|Topical Vehicle Gel|Topical administration of vehicle gel. Regimen: Apply once daily, at bedtime to the face
62415142|NCT05385276|EXPERIMENTAL|Transverse supraumbilical incision|The skin incision will be performed as a straight transverse skin incision 3-5cm above the umbilicus after maximum retraction of the panniculus caudally using two towel clips, to facilitate the approach to the lower uterine segment.
62415143|NCT05385276|EXPERIMENTAL|Pfannenstiel Incision|The skin incision is a transverse upward concavity, typically initiated two finger breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm).
62415144|NCT01596088|EXPERIMENTAL|Drug: Dexrazoxane|"Dexrazoxane should be given once daily for 3 consecutive days. The dose is:~Day 1: 1000 mg/m2, Day 2: 1000 mg/m2, Day 3: 500 mg/m2 (body surface area)"
62587612|NCT05377957||Enucleation|Uveal melanoma patients treated with enucleation
62587613|NCT05948605|ACTIVE_COMPARATOR|Active Treatment|The Active Treatment will use a functional Stimulator system.
62587614|NCT05948605|SHAM_COMPARATOR|Sham Treatment|The Sham Treatment (Placebo) will use a functional Stimulator system, but will provide a treatment in a location that is believed to have no benefit or harm to the subject.
62796558|NCT03263273|ACTIVE_COMPARATOR|1% Topical Minocycline Gel|Topical administration of 1% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face
62796559|NCT03263273|ACTIVE_COMPARATOR|3% Topical Minocycline Gel|Topical administration of 3% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face
62796560|NCT01922141|EXPERIMENTAL|Aliskiren monotherapy|Aliskiren 150 mg, once a day, force titrated to Aliskiren 300 mg after 8 weeks in 50% of patients. Optional addition/titration of amlodipine 5 mg/10 mg and hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
62796561|NCT01922141|EXPERIMENTAL|Aliskiren dual therapy|Aliskiren 150 mg plus amlodipine 5 mg, once a day, force titrated to Aliskiren 300 mg plus amlodipine 5 mg after 8 weeks in 50% of patients. Optional titration of amlodipine 5 mg to 10 mg and optional addition/titration of hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
62796562|NCT01922141|ACTIVE_COMPARATOR|Ramipril monotherapy|Ramipril 5 mg, once a day, force titrated to Ramipril 10 mg after 8 weeks in 50% of patients. Optional addition/titration of amlodipine 5 mg/10 mg and hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
62796563|NCT06725511|ACTIVE_COMPARATOR|Opt-in Outreach|Outreach notifies those eligible that they are invited to join the program, as usual practice.
62796564|NCT06725511|EXPERIMENTAL|Opt-out Outreach|Outreach notifies those eligible that they are enrolled in the program and invited to begin their first session.
62796565|NCT05192993|EXPERIMENTAL|visual motor integration group|participants in the experimental group will receive visual motor integration program
62796566|NCT05192993|ACTIVE_COMPARATOR|Handwriting intervention group|participants in the experimental group will receive handwriting intervention program.
62415145|NCT01974869||Inflammatory bowel diseases-1|Treatment with anti-tumor necrosis factor alpha agents
62415146|NCT01974869||Inflammatory bowel diseases-2|Controls
62587615|NCT02251106|NO_INTERVENTION|-LBP/-Brace|Subjects in this arm did not have back pain nor did they wear brace (asymptomatic controls). Subjects had their spine function measured before and after a two week period.
62796567|NCT05192993|ACTIVE_COMPARATOR|visual motor integration and Handwriting intervention group|participants in the group will receive visual motor integration program and handwriting intervention program.
62796568|NCT03524014||HEV-infected patients with hepatitis|
62796569|NCT03524014||HEV-infected patients with neurological features|
62796570|NCT03524014||HEV-infected patients with kidney features|
62796571|NCT03123666|EXPERIMENTAL|Granulocyte/macrophage colony-stimulating factor (GM-CSF)|GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer OR Placebo for 7 days. Both the groups will receive standard medical care
62796572|NCT03123666|PLACEBO_COMPARATOR|Placebo|Placebo will be given identical to the interventional
62796573|NCT00860171|EXPERIMENTAL|Treatment (iodine I 131 monoclonal antibody B, autologous HCT)|Patients receive a dosimetric dose of iodine I 131 monoclonal antibody BC8 IV on day -20 and a therapeutic dose on day -11. Before day -20, patients may also receive up to 2 additional dosimetric doses of iodine I 131 monoclonal antibody BC8 IV approximately 1-2 weeks apart. Patients then undergo autologous stem cell transplantation on day 0.
62220836|NCT02867878|PLACEBO_COMPARATOR|Saline solution|Patients in this arm will receive systemic infusion of saline solution at 140μg/kg/min for 3 minutes plus standard therapy according to current guidelines
62796574|NCT06725888|EXPERIMENTAL|Vagitab-T plus metronidazole (the standard treatment for bacterial vaginosis).|"Vagitab-T for 3 monthly cycles In addition, metronidazole (the standard treatment for bacterial vaginosis) will be administered for seven days.~Vagitab -T: 1.1 g vaginal tablets; medical device class IIa, already CE marked. The product contains the following components:~tyndallized probiotic L. plantarum HA-119, lactic acid, and xylo-oligosaccharides, lauryl glucoside, and macrogol 3350~Metronidazole It is the treatment indicated for Bacterial Vaginosis by the 2021 CDC's Sexually Transmitted Infections Treatment Guidelines.~Metronidazole will be administered vaginally (as 500 mg vaginal ovules) or orally (as 500 mg tablets)"
62024051|NCT03750487|SHAM_COMPARATOR|Control|The control group will receive a similar 2-session brief motivational intervention. Session 1 focuses on nutrition and healthy eating, session 2 focuses on exercising while pregnant or in the postpartum period.
62024052|NCT04880551||COPD patients with a recent Spirometry|Patients that have a diagnosis of COPD and have completed a recent Pulmonary Function Test - Spirometry.
62024053|NCT01203189|ACTIVE_COMPARATOR|Shampoo Group|Subjects in the S group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.
62024054|NCT01203189|ACTIVE_COMPARATOR|Foam group|Subjects in the F group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.
62024055|NCT01203189|ACTIVE_COMPARATOR|Cross Over Group|apply ketoconazole 2% foam to scalp twice daily for four weeks. Subjects in the Shampoo group will be able to cross over into the Foam group if the TDSS score does not improve by 60% at the end of the four week treatment period using shampoo.
62024056|NCT02855905|EXPERIMENTAL|Coronary artery disease patients|Coronary artery disease patients are exposed to brief cold exposure (-15 C for 30 min) mainly subjected to facial region during which their cardiovascular responses are registered. Exposure was repeated 4 times: rest and exercise in 22 C and rest and exercise in -15 C.
62024057|NCT00985218|EXPERIMENTAL|experimental arm|Embryos cultured in SMART System
62024058|NCT00985218|ACTIVE_COMPARATOR|Control|Embryos cultured in microdrops in dishes
62024059|NCT01223313|EXPERIMENTAL|Woman's Condom|The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
62024060|NCT02167633|ACTIVE_COMPARATOR|Decompression surgery plus fractionated radiotherapy|
62220837|NCT01372098|EXPERIMENTAL|NFP + IPV intervention|The protocol for number and timing of visits will be the same for both NFP+IPVI and Standard Care, as follows: weekly for the first four visits, every other week for the remainder of the pregnancy, every week for six weeks in the postpartum and every other week until the infant is 21 months old after which it is once a month for the last three months. We recognize that the intervention might prompt the nurse and mother to alter the regular visit schedule if IPV is present.
62220838|NCT01372098|NO_INTERVENTION|NFP (standard care)|"The NFP nurses currently receive some training regarding IPV, but it is minimal. Between intake and when the child is 3 months and 12 months old, there is a brief instruction that the nurse assess for IPV. If the client acknowledges current abuse when completing the Abuse Assessment Screen, the nurse should assist her to evaluate threats to personal safety and make referrals as needed. There is a prompt to be mindful of client safety, and to make referrals as needed."
62220839|NCT02047864|EXPERIMENTAL|Creatine monohydrate|Creatine monohydrate to be given during a resistance training program
62415147|NCT06702449|EXPERIMENTAL|Part 1 Group A1/A2|Participants receive candidate UTI vaccine low dose formulation 1 or placebo on Day 1 and Day 61.
62587616|NCT02251106|ACTIVE_COMPARATOR|-LBP/+Brace|Intervention = Lumbar corset (Quickdraw, Aspen Medical Products) Subjects in this arm did not have back pain but wore a brace for a two week period (asymptomatic intervention). Subjects had their spine function measured before and after a two week period.
62796575|NCT03884790|EXPERIMENTAL|Surgical repair of long bone defects|The Patients in the study group will be surgically treated and the GreenBone Bone Substitute will be implanted
62024061|NCT02167633|EXPERIMENTAL|Radiosurgery|Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in one fraction to cover as large a fraction as possible the defined target volume
62220840|NCT02047864|PLACEBO_COMPARATOR|Sugar pill|Placebo to be given during a resistance training program
62415148|NCT06702449|EXPERIMENTAL|Part 1 Group B1/B2|Participants receive candidate UTI vaccine low dose formulation 2, or placebo on Day 1 and Day 61.
62415149|NCT06702449|EXPERIMENTAL|Part 1 Group C1/C2|Participants receive candidate UTI vaccine medium dose formulation 1, or placebo on Day 1 and Day 61.
62415150|NCT06702449|EXPERIMENTAL|Part 1 Group D1/D2|Participants receive candidate UTI vaccine medium dose formulation 2, or placebo on Day 1 and Day 61.
62796576|NCT05152108|EXPERIMENTAL|Stroke patients|Experimental group of stroke survivors for testing the feasibility of a BCI system
62024062|NCT06099171|EXPERIMENTAL|Oxygen-Ozone Therapy plus Cannabidiol and ß-Caryophyllene Patch|"The patients will undergo 8 session of oxygen-ozone therapy, 2 per week. In each session 10 cc of a gaseous mixture of oxygen-ozone (at a concentration of 10 μg of ozone per ml of oxygen) will be injected with 6 paravertebral injections.~For the fisrt 2 weeks of oxygen-ozone therapy patients will be asked to apply patches with local action based on Cannabidiol and ß-Caryophyllene for 8-24 hours/day for 5 days/week."
62024063|NCT06099171|ACTIVE_COMPARATOR|Oxygen-Ozone Therapy|The patients will undergo 8 session of oxygen-ozone therapy, 2 per week. In each session 10 cc of a gaseous mixture of oxygen-ozone (at a concentration of 10 μg of ozone per ml of oxygen) will be injected with 6 paravertebral injections.
62024064|NCT01308580|EXPERIMENTAL|Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m\^2 intravenous (IV) infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.
62024065|NCT01308580|EXPERIMENTAL|Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.
62024066|NCT06182865|EXPERIMENTAL|Ga-68 Dolacga Injection|Ga-68 Dolacga Injection, 2.0±1.0 mCi, single dose, iv bolus
62024067|NCT01623076||Neuromyelitis Optica Spectrum Disorder|Patients diagnosed with NMOSD based on revised diagnostic criteria. Seronegative, anti-AQP4 seropositive and ant-MOG seropositive patients will be included
62024068|NCT01623076||Transverse Myelitis and Optic Neuritis|Patients who have had one demyelinating event, not diagnosed with multiple sclerosis and whom are considered at risk for NMO or NMOSD.
62024069|NCT01623076||Healthy Controls|patients without a history of CNS inflammation
62796577|NCT03174366|EXPERIMENTAL|Intervention Group, receiving medication|Subjects in this group will be receiving medication (denosumab)
62796578|NCT03109639|ACTIVE_COMPARATOR|Group A|This group will undergo tissue acquisition using the conventional EUS-FNA needle followed by the experimental Acquire EUS- FNB needle
62024070|NCT01623076||Neuromyelitis Optica|patients diagnosed with NMO
62024071|NCT03600285|EXPERIMENTAL|TB1-K|TB1-K preservation arm
62024072|NCT02449538|EXPERIMENTAL|everolimus|everolimus 10 mg qd daily
62024073|NCT02078115||chronic kidney disease, hypertension|20 \<= age \< 75 years 15 \<= estimated glomerular filtration rate (GFR) \< 90
62024074|NCT03934502|EXPERIMENTAL|Evobrutinib: Treatment Sequence A, B, C, D|Participant will receive single oral dose of evobrutinib after an overnight fast of at least 10 hours (Treatment A) for 3 days, followed by within 30 minutes after start of a light meal (Treatment B) for 2 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days, followed by 2 hours after start of low-fat meal (Treatment D) for 2 days. There will be 48 hours washout period between each treatment period.
62024075|NCT03934502|EXPERIMENTAL|Evobrutinib: Treatment Sequence B, D, A, C|Participant will receive single oral dose of evobrutinib within 30 minutes after start of a light meal (Treatment B) for 3 days, followed by 2 hours after start of a low-fat meal (Treatment D) for 2 days, followed by after an oversight fast of at least 10 hours (Treatment A) for 2 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days. There will be 48 hours washout period between each treatment period.
62024076|NCT03934502|EXPERIMENTAL|Evobrutinib: Treatment Sequence C, A, D, B|Participant will receive single oral dose of evobrutinib 1 hour prior to a low-fat meal (Treatment C) for 3 days, followed by after an oversight fast of at least 10 hours (Treatment A) for 2 days, followed by 2 hours after start of a low-fat meal (Treatment D) for 2 days followed by within 30 minutes after start of a light meal (Treatment B) for 2 days. There will be 48 hours washout period between each treatment period.
62415151|NCT06702449|EXPERIMENTAL|Part 1 Group E1/E2|Participants receive candidate UTI vaccine high dose formulation 1, or placebo on Day 1 and Day 61.
62415152|NCT06702449|EXPERIMENTAL|Part 1 Group F1/F2|Participants receive candidate UTI vaccine high dose formulation 2, or placebo on Day 1 and Day 61.
62796579|NCT03109639|ACTIVE_COMPARATOR|Group B|This group will undergo tissue acquisition using the experimental Acquire EUS- FNB needle followed by the conventional EUS-FNA needle
62024077|NCT03934502|EXPERIMENTAL|Evobrutinib: Treatment Sequence D, C, B, A|Participant will receive single oral dose of evobrutinib 2 hours after start of a low-fat meal (Treatment D) for 3 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days, followed by within 30 minutes after start of a light meal (Treatment B) for 2 days, followed by after an overnight fast of at least 10 hours (Treatment A) for 2 days. There will be 48 hours washout period between each treatment period.
62024078|NCT02802345|EXPERIMENTAL|Nintedanib + placebo matching sildenafil|
62024079|NCT02802345|ACTIVE_COMPARATOR|Nintedanib + Sildenafil|
62024080|NCT02093299||Stroke|clopidogrel 75 mg
62220841|NCT04702542|EXPERIMENTAL|Enteral oxygen therapy for the improvement of children with chronic gastroduodenal pathology.|Enteral oxygen therapy is prescribed for children with chronic gastroduodenal pathology during the recovery period, after inpatient treatment, for 14 days, every day, in the form of an oxygen cocktail. An oxygen cocktail is prepared on the basis of a pharmaceutical product using herbal ingredients. The patient takes a 200 ml oxygen cocktail. using a small spoon, during the daytime.
62220842|NCT02366468|EXPERIMENTAL|Discretion of the investigator (DI)|ranibizumab 0.5 mg, after initial monthly treatment until maximum BCVA and no signs or no further change of disease activity, the investigator treated patients at their own discretion. There were no strict recommendations for retreatment or scheduling of upcoming visits.
62220843|NCT02366468|ACTIVE_COMPARATOR|Pro re nata (PRN)|ranibizumab 0.5 mg, after initial monthly therapy until maximum BCVA and no signs or no further improvement of disease activity, patients were monitored every month and retreated if any signs of disease activity occurred
62415153|NCT06702449|EXPERIMENTAL|Part 2 Group 1|Participants receive the candidate UTI vaccine highest tolerated dose (HTD) formulation 2, tested in Part 1 of the study, on Day 1 and Day 61.
62415154|NCT06702449|PLACEBO_COMPARATOR|Part 2 Group 2|Participants receive placebo on Day 1 and Day 61.
62415155|NCT05044637|EXPERIMENTAL|Primaquine (3.5mg x 7d)|Primaquine 7 days Standard blood schizontocidal therapy plus 7 days of unsupervised primaquine (3.5 mg/kg total dose) administered once per day (0.5 mg/kg OD).
62024081|NCT06370637|OTHER|Control Arm - Wound Management Program Nova Scotia|Participants will be directed to apply the standard of care cream liberally after each bowel movement after cleaning the area in their usual manner.
62024082|NCT06370637|EXPERIMENTAL|Intervention Arm - Wound Management Program Nova Scotia|Participants will be directed to apply the Cream D liberally after each bowel movement after cleaning the area in their usual manner.
62024083|NCT00850616|EXPERIMENTAL|1|MRKAd6 Trigene 0.5x10\^9 Ad6 vg
62024084|NCT00850616|EXPERIMENTAL|2|MRKAd6 Trigene 0.5x10\^10 Ad6 vg
62024085|NCT00850616|EXPERIMENTAL|3|MRKAd6 Trigene 0.5x10\^11 Ad6 vg
62024086|NCT00850616|EXPERIMENTAL|4|MRKAd5 Trigene 0.5x10\^10 Ad5 vg
62024087|NCT00850616|EXPERIMENTAL|5|MRKAd5 Trivalent 1.5x10\^10 Ad5 vg
62024088|NCT00850616|EXPERIMENTAL|6|MRKAd5+6 Trigene 1x10\^9 Ad vg
62024089|NCT00850616|EXPERIMENTAL|7|MRKAd5+6 Trigene 1x10\^10 Ad vg
62024090|NCT00850616|PLACEBO_COMPARATOR|8|Placebo
62024091|NCT03556657|EXPERIMENTAL|Music Therapy Group|Patient receives 6 sessions of music therapy with a board-certified music therapist. Patient will learn various music interventions for pain management that he/she will utilize at home.
62024092|NCT03556657|NO_INTERVENTION|Wait-List Control Group|Patient receives standard care alone. Patient will receive music therapy sessions following completion of the post-test.
62024093|NCT01389973|EXPERIMENTAL|Open-label: ustekinumab 90 mg|
62024094|NCT01389973|EXPERIMENTAL|Double-blind: ustekinumab 45 mg|
62024095|NCT01389973|EXPERIMENTAL|Double-blind: ustekinumab 90 mg|
62024096|NCT01389973|EXPERIMENTAL|Double-blind: ustekinumb 180 mg|
62415156|NCT05044637|ACTIVE_COMPARATOR|Primaquine (7.0mg x 7d)|Primaquine 7 days Standard blood schizontocidal therapy plus 7 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (1.0 mg/kg OD).
62415157|NCT05044637|ACTIVE_COMPARATOR|Primaquine (7.0mg x 14d)|Primaquine 14 days Standard blood schizontocidal therapy plus 14 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (0.5 mg/kg).
62415158|NCT04925479|EXPERIMENTAL|Asciminib|"This arm consists of 2 groups:~* The pediatric formulation group where the dose is based on body weight (1.3mg/kg BID or 2.6 mg/kg QD)~* The adult formulation group where participants will receive a flat dose of 40mg BID"
62415159|NCT06697483|OTHER|Lenalidomide|For patients with low-risk or intermediate-low risk and minimal residual disease negativity before maintenance
62024097|NCT01389973|PLACEBO_COMPARATOR|Double-blind: placebo|
62415160|NCT06697483|OTHER|Daratumumab and Lenalidomide|For patients with high-risk or intermediate-high risk OR minimal residual disease posivitity before maintenance
62024098|NCT01448746|EXPERIMENTAL|intermittent pneumatic compression|another arm include intermittent pneumatic compression plus low molecular weight heparin
62024099|NCT04950101|ACTIVE_COMPARATOR|HAS-N|In this arm the patient without HIV using PrEP will be included
62024100|NCT04950101|ACTIVE_COMPARATOR|HAS-P|In this arm the patient with HIV will be included
62024101|NCT04744363|EXPERIMENTAL|AVT04 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
62024102|NCT04744363|ACTIVE_COMPARATOR|US Stelara 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
62024103|NCT04744363|ACTIVE_COMPARATOR|EU Stelara 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
62024104|NCT02845908|EXPERIMENTAL|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. The combined chemotheraphy will be treated for 9 circle. then，the capetabine was allowed
62024105|NCT02845908|EXPERIMENTAL|FOLFOX plus PAC(ip)|The regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2) plus paclitaxel (80 mg/m2) intra-peritoneally.Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
62024106|NCT02845908|ACTIVE_COMPARATOR|FOLFOX|The FOLFOX regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
62024107|NCT05826236||Patients with knee osteoarthritis|Periarticular knee compression using a sphygmomanometer.
62024108|NCT05826236||Healthy subjects|Periarticular knee compression using a sphygmomanometer.
62024109|NCT06173219|EXPERIMENTAL|treatment group|The subjects will receive the combination therapy of SBRT, LDRT, PD-1/L1 inhibitor and GMCSF. The specific treatment regimen is as follows: (1) SBRT 8Gy×3f, (2) LDRT 2Gy ×3f, PD-1/L1 inhibitor, periodically, until the disease progresses or intolerable toxic side effects, (4) GM-CSF, 200ug/QD, subcutaneous injection, the first course of treatment for 7 days.
62024110|NCT06238323|EXPERIMENTAL|All participants|Participants will be young sexual minority men (YSMM) and providers from healthcare institutions working with YSMM.
62024111|NCT01760954|EXPERIMENTAL|Elagolix 150 mg QD|Participants received elagolix 150 mg tablets once a day (QD) for 6 months.
62024112|NCT01760954|EXPERIMENTAL|Elagolix 200 mg BID|Participants received elagolix 200 mg tablets twice a day (BID) for 6 months.
62024113|NCT01430494||No treatment|
62024114|NCT03399760|EXPERIMENTAL|i-PRF assisted upper canine retraction|I-PRF assisted upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
62024115|NCT03399760|EXPERIMENTAL|conventional upper canine retraction|Conventional upper canine retraction will be performed in the other side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
62024116|NCT00781560||1|patients being diagnosed as dyslipidemia but not receiving Crestor®
62024117|NCT00781560||2|hypercholesterolemia or mixed dyslipidemia and have been initiated treatment with Crestor®
62220844|NCT01764685|EXPERIMENTAL|Topiramate + Medical Management|Topiramate titrated up to 150 mg/day over 5 weeks then maintained for 6 weeks + Medical Management sessions for 15-25 minutes per study visit
62024118|NCT06365736|EXPERIMENTAL|Contemplative nature intervention|Participants will spend 30 minutes in nature per day for 10 times over 14 days. Participants will walk for 10 minutes and then choose a nice spot to sit for 10 minutes. During these minutes they will be asked to be silently present and observe trees, plants, flowers, or other aspects of nature and contemplate their connectedness to nature and their own awareness. Then walk back 10 minutes.
62024119|NCT06365736|ACTIVE_COMPARATOR|Walking in nature|Participants will be asked to walk for 30 minutes in nature per day for 10 times over 14 days without further instruction.
62024120|NCT06365736|NO_INTERVENTION|Waitlist|Participants will wait about 3 weeks and then receive the instruction of contemplative nature intervention.
62587617|NCT02251106|EXPERIMENTAL|+LBP/+Brace|Intervention = Lumbar corset (Quickdraw, Aspen Medical Products) Subjects in this arm had back pain and wore a brace for a two week period (symptomatic intervention). Subjects had their spine function measured before and after a two week period.
62024121|NCT06535438||The prognosis of cerebral hemorrhage is good at 90 days|
62024122|NCT06535438||The prognosis of cerebral hemorrhage is poor at 90 days|
62024123|NCT02277080||Opioid group|These patients should have been treated only with one opioid (morphine, oxycodone, fentanyl, methadone, hydromorphone, tapentadol or tramadol) for more than one month
62024124|NCT02277080||Control group|Chronic non-cancer pain patients not treated with analgesics
62024125|NCT01075074|ACTIVE_COMPARATOR|Ropivacaine 0.05%|Subject received a bilateral transversus abdominis plane block block using 15 cc of 0.5% ropivacaine on each side
62024126|NCT01075074|PLACEBO_COMPARATOR|Normal Saline|Subjects received a bilateral transversus abdominis plane block using 15 cc of sterile normal saline.
62024127|NCT01075074|ACTIVE_COMPARATOR|Ropivacaine 0.25%|Subjects received a bilateral transversus abdominis plane block using 15cc of 0.25% ropivacaine on each side
62024128|NCT01108640||Elective surgical patients|
62024129|NCT01108640||Massive resuscitation patients|
62024130|NCT01108640||surgical patients on pressors|
62415161|NCT03356366|EXPERIMENTAL|Principal study|Patients pathological process will be assessed using MRI 3T
62415162|NCT03356366|EXPERIMENTAL|Ancillary study 1|Patients pathological process will be assessed using MRI 1,5T
62415163|NCT03356366|EXPERIMENTAL|Ancillary study 2|Patients pathological process will be assessed using MRI 7T
62415164|NCT01341158|EXPERIMENTAL|Experimental arm|
62415165|NCT04946474|EXPERIMENTAL|Xingnaojing injection + Shuxuetong oral liquid|Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).
62587618|NCT02339350|NO_INTERVENTION|Rapid early responder group|"1. RER Consolidation BM exam on day 63: M1, M2 -\> IM M3 or residual CNS ds or Bx proven extramedullary ds - off protocol~2. RER Interim Maintenance #1~3. RER Delayed Intensification~4. RER Interim Maintenance #2~5. RER Maintenance (12 weeks=84 days)"
62587619|NCT02339350|EXPERIMENTAL|Slow early responder group|"Includes : SER, Testis(+), CNS 3, T-cell (non ETP), Initial PB WBC ≥ 100,000/μL~1. SER Consolidation~* Intrathecal triple chemotherapy at d0, 7, 14, 21 2. SER Interim Maintenance #1~* high dose methotrexate included~* Intrathecal triple chemotherapy at d0, 28 3. SER Delayed Intensification #1~* Intrathecal triple chemotherapy at d0, 28, 35 4. SER Interim Maintenance #2~* high dose methotrexate included~* Intrathecal triple chemotherapy at d0, 28 5. SER Delayed Intensification #2~* Intrathecal triple chemotherapy at d0, 28, 35 6. SER Maintenance~* Intrathecal triple chemotherapy at d0"
62024131|NCT02945865|EXPERIMENTAL|ITreatment arm: Pain Assessment|Pain assessment by Doloplus-2 pain scale regularly and additional pain assessment in situations where pain is suspected.
62587620|NCT00829140|PLACEBO_COMPARATOR|Placebo BID|
62024132|NCT02945865|NO_INTERVENTION|Control arm: No treatment|Treatment us usual
62024133|NCT04393701|EXPERIMENTAL|neonates tested in Normandie, France|All neonates will be tested in Normandie
62415166|NCT04946474|PLACEBO_COMPARATOR|Placebo group|Xingnaojing injection simulation agent + Naoxueshu oral liquid simulation agent treatment was given.
62415167|NCT04375735|EXPERIMENTAL|BLES treatment|For patients randomized to the treatment arm, exogenous BLES will be administered as soon as possible and within 48 hours of intubation. BLES will be administered daily for up to 3 doses, or until the patient is liberated from the ventilator.
62415168|NCT04375735|NO_INTERVENTION|Control|Patients will receive standard treatment and will not receive surfactant.
62587621|NCT00829140|EXPERIMENTAL|Lorcaserin 10mg BID|
62587622|NCT02458339|EXPERIMENTAL|Experimental|3 consecutive cycles of intraventricular methotrexate infusions into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle, each cycle will be of 4 weeks duration. During the first 3 weeks, methotrexate will be infused twice weekly on days 1 and 4 (+/- 2 days). The 4th week is a rest week.
62587623|NCT05195047|EXPERIMENTAL|Probiotics-Placebo-Placebo|1 week of consecutively consuming oral probiotics (1 time/day) followed by SARS-CoV-2 vaccination, then 2 weeks of consecutively consuming oral placebo (1 time/day).
62024134|NCT00395044|EXPERIMENTAL|Gabapentin|1200 mg/daily of Gabapentin
62024135|NCT00395044|PLACEBO_COMPARATOR|Placebo|1200mg/d of Placebo
62024136|NCT04388982|EXPERIMENTAL|MSCs-Exos Dosage 1|MSCs-Exos. low-dose group
62024137|NCT04388982|EXPERIMENTAL|MSCs-Exos Dosage 2|MSCs-Exos mid-dose group
62024138|NCT04388982|EXPERIMENTAL|MSCs-Exos Dosage 3|MSCs-Exos high-dose group
62024139|NCT02286544|ACTIVE_COMPARATOR|Salmonella typhi vaccine|0.5 mL Salmonella typhi vaccine
62024140|NCT02286544|EXPERIMENTAL|Salmonella typhi vaccine + oxygen|0.5 mL Salmonella typhi vaccine + 6l/min oxygen
62024141|NCT02286544|EXPERIMENTAL|S. typhi vaccine + oxygen + Atorvastatin|0.5 mL Salmonella typhi vaccine + 6l/min oxygen + 80mg Atorvastatin
62220845|NCT01764685|PLACEBO_COMPARATOR|Placebo Pill + Medical Management|Sugar pill with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit
62220846|NCT01258413|EXPERIMENTAL|Laparoscopic Radical Hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament are removed + pelvic lymphadenectomy
62220847|NCT01258413|ACTIVE_COMPARATOR|Abdominal radical hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament are removed + pelvic lymphadenectomy
62587624|NCT05195047|EXPERIMENTAL|Placebo-Probiotics-Placebo|1 week of consecutively consuming oral placebo (1 time/day) followed by SARS-CoV-2 vaccination, then consuming oral probiotics (1 time/day) for 1 week and placebo (1 time/day) for 1 week (1 time/day) respectively.
62220848|NCT00987454|ACTIVE_COMPARATOR|Erythropoietin|Epoetin alfa 40,000 international units will be given by subcutaneous injection to eligible patients, allocated to the treatment arm, on Study Days 1; 8 and15 during the intensive care unit stay.
62220849|NCT00987454|PLACEBO_COMPARATOR|Placebo|Sodium Chloride 0.9% in m/L will be given by subcutaneous injection to eligible patients, allocated to the placebo arm, on Study Days 1; 8 and15 during the intensive care unit stay.
62415169|NCT04188678|OTHER|Interventional Arm- Bone Marrow Transplant|"Study visits will include the performance of assessments prior to the start of conditioning chemotherapy and at 1 month and 6 months post-BMT. Assessments include:~1. Physical function assessments~2. questionnaires about general health and current health compared to health one year ago~3. assessments that measure cognition, attention and memory~4. assessments regarding personality and psychological and social stressors~5. Physiological measures including~   * blood tests- 160 mL of blood during evaluations, and 90mL of blood at the day 180 visit.~  * bone marrow aspirate collected during standard of care bone marrow biopsies pre-transplant and at day 180~  * Saliva collections pre-transplant~  * ACTH Stimulation Test~  * Oral Glucose Tolerance Test~  * Holter Monitor- to record hear rate variability~  * MRI pre-transplant and at Day 180 in a subset of 10 subjects"
62587625|NCT05195047|EXPERIMENTAL|Placebo-Placebo-Probiotics|1 week of consecutively consuming oral placebo (1 time/day) followed SARS-CoV-2 vaccination, then consuming oral placebo for 1 week (1 time/day) and probiotics for 1 week (1 time/day) respectively.
62587626|NCT05195047|PLACEBO_COMPARATOR|Placebo|1 week of consecutively consuming oral placebo (1 time/day) followed by SARS-CoV-2 vaccination, then 2 weeks of consecutively consuming oral placebo (1 time/day).
62587627|NCT05156762|EXPERIMENTAL|Bariatric surgery group|Participants randomized to the bariatric surgery arm will undergo either a laparoscopic sleeve gastrectomy or a laparoscopic gastric bypass to achieve a BMI ≤ 40 kg/m2.
62587628|NCT05156762|EXPERIMENTAL|Medical weight loss group|Participants randomized to the medical weight loss study arm will attempt to lose weight through diet, exercise, and potentially pharmacotherapy an effort to lower their BMI to ≤ 40 kg/m2.
62587629|NCT05156762|OTHER|"Usual Standard of Care"|"Patients randomized to the usual standard of care study arm will be counseled on the importance of losing weight to optimize their BMI and will be provided with referral information (name and clinic number) to either the bariatric surgery or medical weight loss clinics."
62587630|NCT04323488|EXPERIMENTAL|Lindamood-Bell Seeing Stars|Subjects receive reading instruction focusing on the building blocks of reading
62587631|NCT04323488|NO_INTERVENTION|Control|Subjects are followed longitudinally but do not receive intervention
62587632|NCT00078078||Methylmalonic Acidemia|Individuals with methylmalonic acidemia
62587633|NCT01999998|EXPERIMENTAL|Pilot|
62587634|NCT00531713|NO_INTERVENTION|1|Usual T4 dose is given
62587635|NCT00531713|ACTIVE_COMPARATOR|2|20 microgram of T3 is given and 50 microgram of T4 is withdrawn
62587636|NCT06665685|EXPERIMENTAL|Patient Group|Patients in this arm will wear the device, BioButton, continuous for 30 days as it collects physiologic and gait data, while receiving otherwise routine, standard of care.
62587637|NCT06665685|EXPERIMENTAL|Nurse Group|Nurses caring for patients wearing the device, BioButton, will assist in placing and removing the device. Otherwise, they will provide routine, standard of care to the enrolled patients to determine the overall feasibility of the device for clinical care providers.
62220850|NCT05425628|EXPERIMENTAL|Treatment with NeoChord Transcatheter Mitral Repair System|Implanting ePTFE sutures as artificial neochordae using NeoChord Transcatheter Mitral Repair System
62415170|NCT02096796||persons without arm pump|
62415171|NCT02096796||persons with arm pump|
62587638|NCT06264557|EXPERIMENTAL|Treatment group|"Device : SB-100~Cognitive training will be conducted once a day, and it will take 15 to 30 minutes.~It consists of cognitive training and educational videos."
62587639|NCT06264557|OTHER|Contol group|Educational book : book of education on daily rules for preventing dementia
62587640|NCT06667245||Patients > 18 years old who are going to be immunized against HZ|Patients \> 18 years old who are going to be immunized against HZ
62587641|NCT01554865|ACTIVE_COMPARATOR|conventional diet counselling|counselling given by dietician on diet modification and caloric restriction
62587642|NCT01554865|ACTIVE_COMPARATOR|partial meal replacement diet|calorie-restricted diet using 1-2 meal replacements
62587643|NCT06668129|EXPERIMENTAL|Back care intervention program|
62587644|NCT06668129|NO_INTERVENTION|Control condition|
62587645|NCT02524743|PLACEBO_COMPARATOR|Placebo (Group I)|"For pretreatment the patients were administered IV 5ml normal saline.~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
62220851|NCT00705861|PLACEBO_COMPARATOR|1|
62220852|NCT00705861|EXPERIMENTAL|2|
62415172|NCT02058368|EXPERIMENTAL|Arm 1|Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatin placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet once daily (OD) (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 dutasteride 0.5 milligram (mg) capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.
62220853|NCT02926404||Pediatric patients operated with Patient-specific rods|Patients with patient-specific rods (UNiD Rods) \<18Years old
62220854|NCT02926404||Adult patients operated with Patient-specific rods|Patients with patient-specific rods (UNiD Rods) \>18Years old
62220855|NCT01632982|OTHER|standard treatment|the standard drug counseling offered to patients in methadone maintenance treatment at the study site
62220856|NCT01632982|EXPERIMENTAL|Mobile Therapeutic System (MTS)|The Mobile Therapeutic System (MTS) is a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
62415173|NCT02058368|EXPERIMENTAL|Arm 2|Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatine placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet OD (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 placebo dutasteride 0.5mg capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.
62415174|NCT02512991||HEMS patients|Patients bound for Percutaneous Coronary Intervention (PCI) at the PCI centre at Copenhagen University Hospital, Rigshospitalet, and who were transported by Helicopter Emergency Medical Service (HEMS) in a 36-month period (May 1st 2010 - April 30th 2013).
62415175|NCT02512991||GEMS patients|Patients bound for Percutaneous Coronary Intervention (PCI) at the PCI centre at Copenhagen University Hospital, Rigshospitalet, and who were transported by Ground Emergency Medical Service in a 40-month period (January 1st 2010 - April 30th 2013).
62415176|NCT06538428||GBM group|58 primary GBM treatment-naïve Egyptian patients DNA methylation profiling for four genes (MGMT, NUPR1,NDRG2,and GLI1 gene) using EpiTect Methyl II (qPCR) system (Qiagen, Germany).
62415177|NCT06538428||NND group|DNA methylation profiling for four genes (MGMT, NUPR1,NDRG2,and GLI1 gene) using EpiTect Methyl II (qPCR) system (Qiagen, Germany).
62415178|NCT05562713|NO_INTERVENTION|Control (Arm #1)|CIC will be discussed with caretakers \& patients during their appointment and they will be given the instruction sheet to take home. They will not have a follow-up appointment scheduled. Research team will call them to check if the patient is able to perform CIC independently. If they can, a visit will be scheduled for them to demonstrate this in clinic.
62415179|NCT05562713|EXPERIMENTAL|Present Bias without Loss Aversion (Arm #2)|CIC will be discussed with caretakers \& patients during their appointment and they will be given the instruction sheet to take home. Child will receive a prize (\~$5-20 in value) for every CIC step completed. They will follow-up in clinic in 3 months (or earlier) to demonstrate their CIC ability. If they can demonstrate this ability, they will receive a large prize (\~$30-50 in value)
62415180|NCT05562713|EXPERIMENTAL|Present Bias with Loss Aversion (dependent on accrual) (Arm #3)|CIC will be discussed with caretakers \& patients during their appointment and they will be given the instruction sheet to take home. Child will pick a prize for every CIC step completed. They will follow-up in clinic in 3 months (or earlier) to demonstrate their CIC ability. All of the prizes that the child picked will be given only if fully-independent CIC is demonstrated.
62415181|NCT03231709|EXPERIMENTAL|Trelagliptin 100 mg + Alogliptin 25 mg|Trelagliptin preceding group (T-A group): Trelagliptin 100 mg, tablets, orally, once a week for 8 weeks, followed by alogliptin, 25 mg, tablets, orally, once a day for 8 weeks.
62415182|NCT03231709|EXPERIMENTAL|Alogliptin 25 mg + Trelagliptin 100 mg|Alogliptin preceding group (A-T group): Alogliptin, 25 mg, tablets, orally, once a day for 8 weeks, followed by trelagliptin, 100 mg, tablets, orally, once a week for 8 weeks.
62415183|NCT01777191|EXPERIMENTAL|80 mg Ixekizumab Auto-Injector|Ixekizumab administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection every 2 weeks (Q2W) at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection every 4 weeks (Q4W).
62415184|NCT01777191|EXPERIMENTAL|80 mg Ixekizumab Prefilled Syringe|Ixekizumab administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection Q2W at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection Q4W.
62415185|NCT06195267|EXPERIMENTAL|Sivelestat|
62415186|NCT06195267|SHAM_COMPARATOR|Blank control|The control group did not receive any intervention.
62415187|NCT05920031|EXPERIMENTAL|Cross-education training only|Participants will perform resistance exercises at 60% of their 1 repetition maximum (1RM) with the less affected limb.
62415188|NCT05920031|EXPERIMENTAL|Mirror therapy only|Participants will perform bilateral upper limb movements while observing the reflection of the less affected limb in a mirror.
62220857|NCT01632982|ACTIVE_COMPARATOR|mobile control|a mobile phone-based application that directs participants to the NIDA website's home page
62220858|NCT04967560|ACTIVE_COMPARATOR|DBS true-stimulation group|The electrical stimulation will be 'turned-on' immediately after programming in true-stimulation group.
62220859|NCT04967560|SHAM_COMPARATOR|DBS sham-stimulation group|The electrical stimulation will be 'turned-off' after programming in sham-stimulation group. The stimulation will begin until after completing three months of Y-BOCS and CGI assessments
62220860|NCT05130047|EXPERIMENTAL|Aldafermin (NGM282)|Aldafermin (NGM282) is an investigational medication. It is an engineered analog of FGF-19 which reduces synthesis of bile acids and diarrhea caused by elevated bile acids. Participants receive aldafermin (NGM282) 1 mg given by subcutaneous injection once daily for 28 days.
62415189|NCT05920031|EXPERIMENTAL|Combined cross-education and mirror therapy|Participants will perform resistance exercises with the less affected limb while observing its reflection in a mirror.
62415190|NCT05920031|ACTIVE_COMPARATOR|Conventional rehabilitation|Participants will receive conventional rehabilitation for post-stroke upper limb motor impairments.
62220861|NCT05130047|PLACEBO_COMPARATOR|Placebo|A placebo looks exactly like the study drug but contains no active ingredients. It is used to learn if the effects seen are truly from the study drug. Participants receive placebo solution matching aldafermin (NGM282) given by subcutaneous injection once daily for 28 days.
62415191|NCT05647694|EXPERIMENTAL|V-NAV users|Users who try the V-NAV for navigation tasks.
62220862|NCT04418570|EXPERIMENTAL|Cognitive remediation|"Computerized cognitive remediation through Neuropersonal Trainer software, 1.5 h per session twice a week for 12 weeks (36 h of total duration).~Participants will also attend the Early Intervention Service for Psychosis with visits by a psychiatrist, clinical psychologist, social worker, or nurse as scheduled."
62220863|NCT04418570|OTHER|Treatment as usual|Participants will attend the Early Intervention Service for Psychosis with visits by a psychiatrist, clinical psychologist, social worker, or nurse as scheduled.
62220864|NCT02502123||OnabotulinumtoxinA (BOTOX®)|Patients diagnosed with chronic migraine headache treated with BOTOX® as standard of care in clinical practice. No intervention was administered in this study.
62220865|NCT05712122|EXPERIMENTAL|stellat gagnliyon blockadge|Ultrasound-guided stellate ganglion blockade and for blockage, the solution was prepared by adding 8 mg dexamethasone, 40 mg lidocaine, and 10 mg bupivacaine to 10 mL with physiological saline.
62220866|NCT01047293|EXPERIMENTAL|All patients|All participants enrolled.
62220867|NCT03768583|EXPERIMENTAL|Group TSM ICT sneakers|"* ICT with sneaker~* five weeks~* twice a week~* half hour."
62220868|NCT03768583|EXPERIMENTAL|Group TSM ICT barefoot|"* ICT barefoot~* five weeks~* twice a week~* half hour."
62220869|NCT03768583|EXPERIMENTAL|Group TSM health barefoot|"* Health with sneaker~* five weeks~* twice a week~* half hour."
62415192|NCT02145000|EXPERIMENTAL|Rotavirus vaccine (BRV-PV)|Live attenuated bovine-human \[UK\] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine (BRV-PV) contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is in lyophilized form and supplied with 2.5 ml of citrate bicarbonate buffer that is added for reconstitution just before oral administration.
62415193|NCT02145000|PLACEBO_COMPARATOR|Placebo|Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
62415194|NCT05162326|EXPERIMENTAL|BC-101|BC-101 will be injected at the dose of 0.1 mL per linear centimeter along the nasolabial fold, up to 2 mL in total volume for each side of the nasolabial folds.
62415195|NCT05573646|EXPERIMENTAL|Dual-task training|Dual-task training group
62415196|NCT05573646|OTHER|Attention control|Attention control group
62415197|NCT05008419|EXPERIMENTAL|Discourse Treatment|Biweekly discourse treatment sessions.
62415198|NCT05008419|NO_INTERVENTION|Treatment as Usual|No treatment. Participants will engage in their usual care.
62415199|NCT05113277|EXPERIMENTAL|Tonic Immobility Psychoeducation (TIP)|Participants in the experimental condition will receive the TIP intervention.
62415200|NCT05113277|PLACEBO_COMPARATOR|Health Education Training (HET)|Participants in the control condition will receive the HET intervention.
62415201|NCT01062022|ACTIVE_COMPARATOR|Control - Standard of Care|Participation in the study will involve your child completing a questionnaire about (a) your family's background, descriptive information about people in your family, and previous major life events, (b) his/her current functioning, (c) his/her feelings before, during, and after the combat injury, and (d) his/her current social relationships and adjustment. Your child will be asked to complete the questionnaire during the baseline assessment, and at 6 months, 12 months, and 24 months after the original assessment.
62415202|NCT01062022|ACTIVE_COMPARATOR|FOCUS-CI|Those participants in the FOCUS-CI intervention will be part of a family skill-building/resiliency training program designed to provide information and skills training in a variety of forms, including clinician-led sessions, handouts, on-line training modules, and individual family care management. Study participation will also involve completing a questionnaire about (a) your family's background, descriptive information about people in your family, and previous major life events, (b) his/her current functioning, (c) his/her feelings before, during, and after the combat injury, and (d) his/her current social relationships and adjustment. Questionnaires will be completed during the baseline assessment, and at 6 months, 12 months, and 24 months after the baseline assessment.
62415203|NCT06172361|EXPERIMENTAL|Treatment group|Prednisone (or equivalent dose of methylprednisolone) + Tofacitinib
62415204|NCT06172361|ACTIVE_COMPARATOR|Positive control group|prednisone (or equivalent dose of methylprednisolone)
62220870|NCT03768583|EXPERIMENTAL|Group TSM health sneakers|"* Health barefoot~* five weeks~* twice a week~* half hour."
62220871|NCT05235230|EXPERIMENTAL|Test product (T) 25 mg Film Coated Tablets|Single oral dose of 25 mg tablet
62220872|NCT05235230|ACTIVE_COMPARATOR|Reference product (R) 25 mg Film Coated Tablets (first dose)|Single oral dose of 25 mg tablet
62220873|NCT05235230|ACTIVE_COMPARATOR|Reference product (R) 25 mg Film Coated Tablets (second dose)|Single oral dose of 25 mg tablet
62415205|NCT06566287|EXPERIMENTAL|Group A|
62415206|NCT06566287|ACTIVE_COMPARATOR|Group B|
62796580|NCT03066193|EXPERIMENTAL|Dronabinol and Palmitoylethanolamide|All participants will be titrated up on Dronabinol dose during the first week of the trial (2.5mg Dronabinol for 3 days and then 5mg Dronabinol for 4 days increasing to 10mg Dronabinol for the remainder of the trial). Dronabinol will only be increased to 10mg at the week 1 assessment if the subject is tolerating the 5mg dose of Dronabinol and the Dronabinol may be reduced based on patient side-effects. All participants will receive two 400mg tablets of PEA daily for the same 12 weeks that they receive the Dronabinol.
62796581|NCT03837145||Liver transplant recipients|Adult patients requiring elective post-operative ventilation after a living donor liver transplant receiving intravenous propofol infusion for sedation titrated to Bi-Spectral Index (BIS) score of 60-80,as per our institutional protocol.
62024142|NCT04517721|EXPERIMENTAL|Treatment group|"The 4C's-TBuRP for adult burn survivors comprises of two phases:~* Phase 1: Discharge planning/ preparation and day of discharge (Comprehensive assessment and evaluation, Education, guidance, and counselling, Treatment and procedures, Case management (referral for nursing follow-up), multi-disciplinary follow-up and Surveillance)~* Phase 2: Follow-up Phase (2 WeChat Telehealth, 6 structured telephone follow-ups and daytime patient/ family-initiated telephone service; home visit based on meeting criteria) over an 8-week follow-up with delivery of rehabilitation care across the spectrum by trained nurse case managers ongoing assessment, intervention using the Omaha System and delivery of evidence-based care."
62024143|NCT04517721|ACTIVE_COMPARATOR|Control group|Participants in the control group will receive the care at the discharge planning phase and thereafter continue to utilise the exiting service available at the hospital, that is, medical review in the hospital.
62415207|NCT06082609|ACTIVE_COMPARATOR|• Group 1 (Functional relining of processed RPD base at insertion)|"* After try in, a record base will be attached to the minor connectors and metal frameworks using 3D printed master cast.~* Registration of jaw relation.~* Mounting of master casts on articulator.~* Setting of artificial teeth according to lingualized occlusion principles.~* Try in of RPD.~* Flasking of RPD to obtain mandibular distal extension removable partial dentures.~* The finished removable partial denture is relined using the functional relining impression technique."
62415208|NCT06082609|ACTIVE_COMPARATOR|• Group 2 (Digitally obtained altered cast );|"1. Construction of custom tray on metal frame work.~2. Border molding of custom tray.~3. Selective pressure impression technique will be made.~4. Digital altered cast will be done according to J. Wu, Y. Cheng~5. 3D printing of altered master cast that will be used for completing the construction of RPD with the same steps of group (A) but without relining.~   * Finally the occlusion of dentures in the two groups will be verified before delivery."
62415209|NCT05439291|ACTIVE_COMPARATOR|Regular epilation regimen only|
62415210|NCT05439291|ACTIVE_COMPARATOR|Regular epilation regimen with surgical excision|
62415211|NCT06156761|EXPERIMENTAL|Experimental: 3-week arm|Patients will receive mitoxantrone hydrochloride liposome combined with capecitabine therapy in a 3-week treatment cycle.
62796582|NCT01460134|EXPERIMENTAL|Hematologic Malignancies (Dose Escalation)|B-Cell Enrollment COMPLETED T-Cell Enrollment COMPLETED
62796583|NCT01460134|EXPERIMENTAL|Solid tumors (Dose Escalation; COMPLETED)|
62796584|NCT01460134|EXPERIMENTAL|Solid Tumors (Expansion Phase; COMPLETED)|Several expansion cohorts of up to 15 patients each are planned, including melanoma and renal cell carcinoma.
62796585|NCT01460134|EXPERIMENTAL|Hematologic Malignancies (COMPLETED)|Several expansion cohorts of up to 15 patients each are planned, including Hodgkin lymphoma.
62796586|NCT03306940|PLACEBO_COMPARATOR|unilateral injection group|Patients of unilateral group were injected botulinum toxin type A to the affected hemiface.
62796587|NCT03306940|EXPERIMENTAL|bilateral injection group|Patients of bilateral group were injected botulinum toxin type A to the affected hemiface and normal hemiface. The intervention of the bilateral group was that the normal side was injected.
62796588|NCT06725095|PLACEBO_COMPARATOR|Placebo Comparator: non-surgical sub-marginal peri-implant instrumentation (NSPI) with placebo gel|Patients received a one-session of non-surgical sub-marginal peri-implant instrumentation (NSPI) with placebo
62796589|NCT06725095|ACTIVE_COMPARATOR|non-surgical sub-marginal peri-implant instrumentation (NSPI) with EMD|Patients received a one-session of non-surgical sub-marginal peri-implant instrumentation (NSPI) with EMD
62024144|NCT06170333|EXPERIMENTAL|8% sulphur and A. vera soap and ketoconazole 2% shampoo|"Twenty-one patients will be given the combination of 8% sulphur and A. vera soap applied to the entire body surface (excluding face), left on for five minutes and then washed off. This was applied twice daily for four weeks.~Along with the soap or placebo, patients will receive 2% ketoconazole shampoo, left on for five minutes and then washed off. This was applied thrice weekly for a week"
62220874|NCT01959334|ACTIVE_COMPARATOR|Glucagon IM|Glucagon dose of 1 milligram (mg) administered intramuscularly (IM).
62220875|NCT01959334|EXPERIMENTAL|Nasal Glucagon (NG|Nasal Glucagon (NG) doses of 3 mg administered intra-nasally.
62220876|NCT01157273||High Anxiety (HA) group|13 participants of both genders, 19-42 years old, with no history of psychiatric disorders and scores above 41 in STAI-Trait
62220877|NCT01157273||Low Anxiety (LA) group|11 participants of both genders, 19-42 years old, with no history of psychiatric disorders and scores below 41 in STAI-Trait
62220878|NCT02830971|OTHER|Clinical specific education|Providing clinical skills conditions
62220879|NCT05060978|ACTIVE_COMPARATOR|Watch your Weight During the Holidays Program|
62220880|NCT05060978|ACTIVE_COMPARATOR|Relative 5:2 Fasting|
62220881|NCT05060978|PLACEBO_COMPARATOR|Control Group|
62220882|NCT02977637|EXPERIMENTAL|Feraheme group|All patients enrolled in the study will receive Feraheme MRI/MRA to detect vascular malformations. Ferumoxytol in its standard concentration (510 mg in 17 cc) will be administered IV at 0.15-0.21 mg/kg prior to MRI/MRA.
62220883|NCT00588653|ACTIVE_COMPARATOR|1|All patients were to undergo all 4 diagnostic modalities, and each of these was compared to the consensus clinical diagnosis. Readers of each modality were blinded to the results of the other 3.
62220884|NCT02369146|EXPERIMENTAL|cohort 1|Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly
62220885|NCT02369146|EXPERIMENTAL|cohort 2|Subjects will receive 8 doses of the UB-421 by intravenous infusion at 25 mg/kg weekly
62220886|NCT04867928|EXPERIMENTAL|Venetoclax+azacitidine|subjects will receive treatment until alloSCT
62220887|NCT04452760|ACTIVE_COMPARATOR|Control group|Only testing sessions
62587646|NCT02524743|ACTIVE_COMPARATOR|Group II|"For pretreatment the patients were administered IV acetaminophen 50 mg~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
62587647|NCT02524743|ACTIVE_COMPARATOR|Group III|"For pretreatment the patients were administered IV acetaminophen 25 mg.~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
62796590|NCT05028452|OTHER|Internet based support|Internet based support for informal caregivers to individuals who are undergoing treatment for head and neck cancer.
62796591|NCT01673997|EXPERIMENTAL|Metoprolol Succinate ER Tablets, 200 mg|Metoprolol Succinate ER Tablets, 200 mg of Dr.Reddy's Laboratories Ltd
62796592|NCT01673997|ACTIVE_COMPARATOR|TOPROL-XL ER Tablets 200 mg|TOPROL-XL ER Tablets 200 mg of AstraZeneca
62796593|NCT04999995||HFrEF|Patients admitted with acutely decompensated HFrEF.
62024145|NCT06170333|ACTIVE_COMPARATOR|Bland soap and ketoconazole 2% shampoo|"Twenty-one patients will be given bland soap applied to the entire body surface (excluding face), left on for five minutes and then washed off. This was applied twice daily for four weeks.~Along with the soap or placebo, patients will receive 2% ketoconazole shampoo, left on for five minutes and then washed off. This was applied thrice weekly for a week."
62415212|NCT06156761|EXPERIMENTAL|Experimental: 4-week arm|Patients will receive mitoxantrone hydrochloride liposome combined with capecitabine therapy in a 4-week treatment cycle.
62796594|NCT04999995||HFpEF|Patients admitted with acutely decompensated HFpEF.
62024146|NCT03876041|ACTIVE_COMPARATOR|dexamethasone group|this group will receive Dexamethasone: 0.1 to 0.3 mg/kg as single intra-operative dose and blood samples will be obtained from central venous blood at following time points: immediately after insertion during anesthetic induction (T1), 48hrs post-operative (T2), 72hrs post-operative (T3).
62024147|NCT03876041|ACTIVE_COMPARATOR|methylprednisolone group|this group will receive Methylprednisolone: 5-10mg/kg as single intra-operative dose and blood samples will be obtained from central venous blood at following time points: immediately after insertion during anesthetic induction (T1), 48hrs post-operative (T2), 72hrs post-operative (T3).
62024148|NCT00737841|EXPERIMENTAL|A|Bifidobacterium breve
62415213|NCT02179385|EXPERIMENTAL|Health coaching|Patients receive health coaching via the phone, face to face or group support, according to patients' choice
62415214|NCT02179385|PLACEBO_COMPARATOR|Standard of Care|
62415215|NCT05537246||GROUP HT|In the preoperative evaluation, after arterial blood pressure measurement was made 3 times; Hypertension group was defined as the patients who did not use drugs that are effective on the cardiovascular system, whose SBP value was higher than 140 mmHg, or those who were diagnosed with hypertension and were using drugs with a SBP value higher than 140 mmHg.
62024149|NCT00737841|PLACEBO_COMPARATOR|B|Placebo
62024150|NCT06526572||symptomatic acute pulpitis|Patients with symptomatic acute pulpitis who are resistant to inferior alveolar nerve block (IANB)
62024151|NCT06381908|ACTIVE_COMPARATOR|Low-carbohydrate calorie-restriction|Minimum of 3 g carbohydrate/kg body weight/day and a \~1000 kcal calorie restriction
62796595|NCT04999995||Non-HF Dyspnea|Patients admitted with acute dyspnea without evidence of HF.
62796596|NCT03078556|EXPERIMENTAL|Treatment sequence A/B: Part 1|Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 1, B: DTG 3TC FDC formulation 1 tablet in Period 2.
62796597|NCT03078556|EXPERIMENTAL|Treatment sequence B/A: Part 1|Eligible subjects will be randomized in sequence B/A and will receive B: DTG 3TC FDC formulation 1 tablet in Period 1 and A: DTG 50 mg and 3TC 300 mg single entities in Period 2.
62796598|NCT03078556|EXPERIMENTAL|Subjects receiving high fat meal: Part 1|Eligible subjects will be administered single dose of DTG 3TC FDC formulation 1 tablet with high fat meal in Period 3 to study the effect of food on tablet.
62796599|NCT03078556|EXPERIMENTAL|Treatment sequence A/C: Part 2|Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 mg and 3TC 300 mg single entities in Period 1 and C: DTG 3TC FDC formulation 2 tablet in Period 2.
62796600|NCT03078556|EXPERIMENTAL|Treatment sequence C/A: Part 2|Eligible subjects will be randomized in sequence C/A and will receive C: DTG 3TC FDC formulation 2 tablet in Period 1 and A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 2.
62796601|NCT03078556|EXPERIMENTAL|Subjects receiving high fat meal: Part 2|Eligible subjects will be administered single dose of DTG 3TC FDC formulation 2 tablet with high fat meal in Period 3 to study the effect of food on tablet.
62796602|NCT02743013|ACTIVE_COMPARATOR|CHF 5993 100/6/12,5 pMDI|with/without Charcoal Block
62796603|NCT02743013|ACTIVE_COMPARATOR|CHF 5993 100/6/12,5 pMDI (replicate)|with/without Charcoal Block
62796604|NCT02743013|ACTIVE_COMPARATOR|CHF 5993 100/6/12,5 pMDI VHC|with/without Charcoal Block with Valved Holding Chamber
62796605|NCT02743013|EXPERIMENTAL|CHF 5993 100/6/12,5 DPI test 1|with/without Charcoal Block
62024152|NCT06381908|EXPERIMENTAL|Moderate-carbohydrate calorie-restriction|Maximum of 1 g carbohydrate/kg body weight/day and a \~1000 kcal calorie restriction
62220888|NCT04452760|EXPERIMENTAL|Progressive resistance training group|10-weeks of progressive resistance training group. Leg press, leg extension, calf raises, hip extension exercises.
62220889|NCT01442896||Primary Open Angle Glaucoma|"• Group A (diagnosis of primary open-angle glaucoma or pseudo-exfoliative glaucoma) - subjects with documented disease progression in the past and high IOP (IOP above target), disc hemorrhage, family history of glaucoma-related vision loss or thin central cornea (\<510um),~* Progression is confirmed with repeatable abnormal standard automated perimetry (SAP) or progressive glaucomatous optic neuropathy~* For patients that have had previous glaucoma surgery, they can be included if they have had documented glaucomatous progression post-surgery~* Best corrected visual acuity of 20/40 or better at enrollment"
62220890|NCT01442896||Healthy Individuals|"• Group B (healthy controls)- healthy subjects without any ophthalmic disease and an IOP \< 22mmHg~o Normal appearing optic disc and no evidence of optic disc damage"
62220891|NCT05246280|EXPERIMENTAL|Candidates for initiation of anti-TNFα bDMARD therapy|All subjects will be candidates for initiation of, or change to, a new anti-TNFα bDMARD for RA treatment.
62220892|NCT04027192|EXPERIMENTAL|Bridging part: intervention sequence ABC or BAC|10 healthy male participants will be randomly allocated to this arm. The study interventions will follow the sequence ABC or BAC: A: single dose of 50 mg BAY2328065 given as LSF in fasted state B: single dose of 50 mg BAY2328065 given as tablet in fasted state C: single dose of 50 mg BAY2328065 given as tablet in fed state (i.e. after a high caloric and high fat meal)
62220893|NCT04027192|EXPERIMENTAL|Multiple dose escalation part: dose 1|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day"
62220894|NCT04027192|EXPERIMENTAL|Multiple dose escalation part: dose 2|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
62220895|NCT04027192|EXPERIMENTAL|Multiple dose escalation part: dose 3|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
62220896|NCT04027192|EXPERIMENTAL|Multiple dose escalation part: dose 4|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
62220897|NCT04027192|EXPERIMENTAL|Multiple dose escalation part: dose 5|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by a treatment pause of 2 days followed by twice daily doses for 1 day followed by three times daily doses for 9 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
62220898|NCT00801931|EXPERIMENTAL|A: Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated total body irradiation (TBI) will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5 and-4, Cyclophosphamide on Days -3 and -2 and- rabbit antithymocyte globulin on Days -4, -3, -2 and -1.The double cord blood infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/mycophenolate mofetil (MMF).
62415216|NCT05537246||GROUP NORMO|As a result of 3 measurements and medical histories of the cases, those who did not use drugs effective on the cardiovascular system and whose SBP value was lower than 140 mmHg were called the normotensive group.
62415217|NCT05871853||Pre-implementation group|Women delivering during an eight month period, before the intervention is implemented.
62415218|NCT05871853||Post-implementation group|Women delivering during an eight month period, after the intervention is implemented.
62587648|NCT02524743|ACTIVE_COMPARATOR|Group IV|"For pretreatment the patients were administered IV lidocaine 20 mg~The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
62415219|NCT01247753|EXPERIMENTAL|Intervention|
62415220|NCT01247753|NO_INTERVENTION|Control|
62796606|NCT02743013|EXPERIMENTAL|CHF 5993 100/6/12,5 DPI test 2|with/without Charcoal Block
62796607|NCT03308006|EXPERIMENTAL|Stem cells therapy|
62024153|NCT06025331|EXPERIMENTAL|BIO-RSA|
62024154|NCT06025331|ACTIVE_COMPARATOR|RSA|
62024155|NCT04036916|EXPERIMENTAL|Virtual Reality Training (Experimental)|Participants will receive multi-modal sensorimotor training interventions, including activities training the vestibular system, oculomotor control and visual perception, neuromotor control and strengthening of the cervical spine, postural control/ balance exercises, and exercises integrating the use of multiple types of sensory information for controlled motor output, including speed and accuracy. Novel headset virtual reality (VR) games/activities; compliant balance surfaces; resistance bands/weight; and biofeedback devices will be utilized to deliver the training intervention. The exercises delivered at each intervention will be delivered in a group format, using a circuit of exercises that each athlete will complete in a session. Subsequent sessions will build upon previous sessions to work the sensorimotor control system in progressively more challenging and sport-specific scenarios. This present study will complete 12 sessions over 6 weeks.
62796608|NCT06162780||TEER group|Severe DMR patients of low to intermediate surgery risk who underwent TEER.
62796609|NCT00819936|EXPERIMENTAL|2|Backward walking,
62796610|NCT00819936|ACTIVE_COMPARATOR|1|Forward walking
62796611|NCT03158194|EXPERIMENTAL|CBT for anxiety-related asthma|Ten to twelve weekly sessions of CBT targeting enhanced function and decreased symptoms of anxiety.
62796612|NCT01243723|EXPERIMENTAL|Eductyl suppository|
62796613|NCT01243723|PLACEBO_COMPARATOR|Placebo suppository|
62796614|NCT01851629|EXPERIMENTAL|ADAPT Locomotor Training|Individuals receive 15 sessions of ADAPT-locomotor training for 3 weeks. During ADAPT-locomotor training, stepping in response to obstacles and walking challenges are practiced on a treadmill and overground.
62796615|NCT01851629|ACTIVE_COMPARATOR|Basic Locomotor Training|Individuals will receive 15sessions of the traditional form of basic locomotor training for 3 weeks. Repetitive stepping patterns are practiced on the treadmill and overground.
62024156|NCT04036916|NO_INTERVENTION|No Virtual Reality Training (Control)|True control.
62024157|NCT01851057|ACTIVE_COMPARATOR|Education Only|Education only arm (8 total sessions)
62024158|NCT01851057|EXPERIMENTAL|STAR: Education and Problem Solving|Problem-solving and education intervention (8 total sessions)
62024159|NCT04532697|ACTIVE_COMPARATOR|Chinese Medicine|Uncaria Rhynchophylla (Gou-Teng)
62024160|NCT04532697|PLACEBO_COMPARATOR|Placebo treatment|Placebo
62220899|NCT00801931|EXPERIMENTAL|B: Full intensity without TBI|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with double cord blood infusion on Day 0. Granulocyte-macrophage colony-stimulating factor (GM-CSF) hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
62220900|NCT00801931|EXPERIMENTAL|C: Moderate Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -8. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
62220901|NCT00801931|EXPERIMENTAL|D: Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -6. Patients will receive busulfan twice daily on Days -6, and-5; fludarabine on Days -6, -5, -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
62415221|NCT02425358|EXPERIMENTAL|BMC therapy within 24 hours|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 24 hours after successful primary PCI.
62415222|NCT02425358|EXPERIMENTAL|BMC therapy within 3-7 days|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 3-7days after successful primary PCI.
62415223|NCT02425358|EXPERIMENTAL|BMC therapy within 7-30 days|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 7-30days after successful primary PCI.
62415224|NCT02425358|ACTIVE_COMPARATOR|PCI only|Patients with acute myocardial infarction who were performed successful primary PCI.
62796616|NCT01851629|OTHER|Cross-Sectional Testing|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
62415225|NCT06568315|EXPERIMENTAL|Concurrent MMS / Calcium|Daily multiple micronutrient supplement (providing 30 mg iron) taken concurrently with daily calcium supplement (500 mg)
62415226|NCT06568315|ACTIVE_COMPARATOR|Separate MMS / Calcium|Daily multiple micronutrient supplement (providing 30 mg iron) taken separately from daily calcium supplement (500 mg)
62415227|NCT01064830|ACTIVE_COMPARATOR|topical cyclosporine suspension|apply 2 drops to 2 target nails under occlusion daily for 20 weeks
62415228|NCT01064830|PLACEBO_COMPARATOR|vehicle|apply to target nails daily under occlusion daily for 20 weeks
62796617|NCT03068702||African Canadians|African Canadians with sickle cell disease maculopathy diagnosed by OCTA.
62796618|NCT02245945|EXPERIMENTAL|TFV 1% gel|"Participants will be instructed to use TFV 1% vaginal gel according to the BAT 24 regimen (2 gel doses) at least twice per week, regardless of sexual frequency.~The BAT24 dosing regimen when used with sex is defined as one dose of gel within 12 hours before sex and a second dose of gel as soon as possible within 12 hours after sex and no more than two doses in a 24 hour period. Participants who do engage in sexual intercourse should use the BAT24 regimen with each sex act.~If used without sex, the BAT24 dosing regimen is defined as 2 doses of gel administered 2-24 hours apart, with no more than two doses in a 24 hour period."
62024161|NCT03787667||Patients with pathologically diagnosed colorectal cancer|Patients with pathologically diagnosed colorectal cancer
62024162|NCT04890340||Women in age 35 to 65 with suspected breast cancer|Women in age 35 to 65 with suspected breast cancer, previously untreated. Additionally, eligible patients should have appropriate mammography results, either breast ultrasound or breast MRI.
62024163|NCT04890340||Healthy Volunteers|Healthy woman in age 35 to 65.
62024164|NCT02052349|EXPERIMENTAL|Arm 1: ABT-333|A single centre, open-label, 4-treatment, 3-period, 4-sequence incomplete randomised, single dose crossover study in healthy subjects.
62024165|NCT04097132||ischemic stroke patients|all patient admitted with acute ischemic stroke either their ECG was AF or sinus rythm
62024166|NCT04665856|EXPERIMENTAL|Tiragolumab + Atezolizumab + Carboplatin and Etoposide|Induction treatment with tiragolumab plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with tiragolumab plus atezolizumab for 21-day cycles.
62024167|NCT04665856|PLACEBO_COMPARATOR|Placebo + Atezolizumab + Carboplatin and Etoposide|Induction treatment with placebo plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with placebo plus atezolizumab for 21-day cycles
62024168|NCT05799495|EXPERIMENTAL|Arm 1: low dose|
62024169|NCT05799495|EXPERIMENTAL|Arm 2: medium dose|
62024170|NCT05799495|EXPERIMENTAL|Arm 3: high dose|
62024171|NCT05799495|PLACEBO_COMPARATOR|Arm 4: Placebo|
62024172|NCT02584049|ACTIVE_COMPARATOR|Osteopathy|3 sessions of Osteopathic treatment in addition to the usual follow
62415229|NCT00318409|ACTIVE_COMPARATOR|Bupropion|buproprion XL 300mg daily
62415230|NCT00318409|PLACEBO_COMPARATOR|Placebo|placebo 300mg daily
62220902|NCT00801931|EXPERIMENTAL|E: Fanconi's Anemia|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and horse antithymocyte globulin on Days -5, -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
62220903|NCT00801931|EXPERIMENTAL|F: Regimen for non-malignant diseases|Patients will begin fosphenytoin or phenytoin prophylaxis on Day -10. Patients will receive busulfan on days -9, -8, -7 and -6, cyclophosphamide on days -5, -4, -3, and -2 and rabbit antithymocyte globulin on days -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
62220904|NCT05334251||general anesthesia group|Patients in this group will undergo open colon cancer surgery under general anesthesia. Epidural catheterization will be applied for postoperative analgesia.
62220905|NCT05334251||combined spinal-epidural anesthesia group|Patients in this group will undergo open colon cancer surgery under combined spinal-epidural anesthesia with ketofol sedation. Epidural catheterization will be applied for postoperative analgesia.
62220906|NCT00616057|PLACEBO_COMPARATOR|B|Maltodextrin, non digestible carbohydrate
62220907|NCT00616057|EXPERIMENTAL|A|fructans, non digestible carbohydrates fermented in the caeco-colon
62415231|NCT01898624||Betanis group|mirabegron treated group
62415232|NCT05694169|EXPERIMENTAL|Renal Autologous Cell Therapy (REACT)|Participants will receive 2 REACT injections separated by 6 months. All participants will be followed for 12 months post last supplemental REACT injection.
62415233|NCT00281827|EXPERIMENTAL|Treatment Arm|Chemotherapy treatment (carboplatin, gemcitabine and thalidomide) every 21 days for 3 courses.
62415234|NCT06561711|EXPERIMENTAL|Minocycline group A|Vonoprazan 20mg bid, Bismuth Potassium Citrate 300mg qid, Minocycline 50mg tid, Metronidazole 400mg tid
62024173|NCT02584049|SHAM_COMPARATOR|Sham osteopathy|3 sessions of Sham osteopathy treatment in addition to the usual follow
62415235|NCT06561711|EXPERIMENTAL|Minocycline group B|Vonoprazan 20mg bid, Bismuth Potassium Citrate 300mg qid, Minocycline 50mg bid, Metronidazole 400mg qid
62024174|NCT06535061|ACTIVE_COMPARATOR|control|Pacifiers suitable for the mouth diameter of all newborns were given. Heel blood was collected from the heel of the right foot of all newborns. The heel was stroked by hand before the procedure. Blood flow was accelerated.
62220908|NCT02455154|PLACEBO_COMPARATOR|Letrozole|"Early Breast Cancer patients receiving adjuvant endocrine therapy~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po."
62220909|NCT02455154|ACTIVE_COMPARATOR|Letrozole + Xinglinggubao|"Early Breast Cancer patients receiving adjuvant endocrine therapy plus Xianlinggubao~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po.~Xinglinggubao: 0.5g bid po"
62220910|NCT02455154|ACTIVE_COMPARATOR|Letrozole + Zhongyaofufang|"Early Breast Cancer patients receiving adjuvant endocrine therapyplus Zhongyaofufang (Traditional Chinses Medicine)~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po.~Zhongyaofufang: qow po"
62220911|NCT02901782|EXPERIMENTAL|Personalized titanium plate|Ten males and two females with a mean age of 22.8 years were recruited. They all had bone tumor around the knee.
62220912|NCT05764941||Observational Group|Patients receive initetamab combined with pyrotinib and vinorelbine after trastuzumab progression.
62220913|NCT02950064|EXPERIMENTAL|BTP-114|Intravenous (IV) treatment n 21-day cycles
62220914|NCT04866446||normal airway manikin with standard uniform|The participants will carry out intubation procedure using macintosh direct laryngoscope, GlideScope video laryngoscope, C-Mac video laryngoscope and Frova intubation catheter and laryngeal mask insertion using ProSeal LMA and I-gel LMA, respectively.
62415236|NCT06561711|EXPERIMENTAL|Minocycline group C|Vonoprazan 20mg bid, Bismuth Potassium Citrate 300mg qid, Minocycline 50mg bid, Metronidazole 400mg tid
62415237|NCT06561711|ACTIVE_COMPARATOR|Tetracycline group|Vonoprazan 20mg bid, Bismuth Potassium Citrate 300mg qid, Tetracycline 500mg qid, Metronidazole 400mg qid
62415238|NCT02312752|OTHER|Intra-epidermal stimulation|"A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds."
62415239|NCT02490215||ARDS, non-ARDS|patients with ARDS and patients without ARDS
62415240|NCT05204849|ACTIVE_COMPARATOR|Active irrigation and aspiration|Patients randomized to IRRAflow will receive a ventricular catheter with active irrigation and aspiration.
62587649|NCT02524743|ACTIVE_COMPARATOR|Group V|"For pretreatment the patients were administered IV lidocaine 40 mg.~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
62024175|NCT06535061|EXPERIMENTAL|intervention|White noise sound and pacifier implemented Group
62024176|NCT05140278|EXPERIMENTAL|1-step Artesunate parenteral arm|Argesun (Artesunate 60 mg)
62024177|NCT05140278|EXPERIMENTAL|2-step Artesunate parenteral arm|Artesun (Artesunate 60 mg)
62024178|NCT04561570||Study Group: Vivity ACRYSOF IQ IOL|Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
62024179|NCT04561570||Control Group: ACRYSOF IQ IOL|Control Group: Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
62024180|NCT01205685|EXPERIMENTAL|OSI-906 + Erlotinib + Letrozole + Goserelin|"* OSI-906 in a pill form, by mouth, twice a day (12 hours a part)~* Erlotinib in a pill form, by mouth, once a day~* Letrozole in a pill form, by mouth, once a day~* Goserelin, by injection once per month for women who are pre-menopausal"
62024181|NCT02405715|PLACEBO_COMPARATOR|Placebo Spray And Interpersonal Psychotherapy|Participants will receive 6 sprays of a placebo nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total).
62587650|NCT05278143||type1diabetes patients who use CGM|Males and females diagnosed with T1D, aged less than 18 years old who are currently under the care of the Unit of Endocrinology and Diabetes of Bambino Gesù Children's Hospital, Rome, Italy and who already use continuous glucose monitoring (CGM) systems are eligible to be involved in the study. Participants will wear an additional non-invasive wearable device, Medtronic Zephyr BioPatch, for recording physiological data for three days.
62587651|NCT04890236|EXPERIMENTAL|Treatment (duvelisib)|Patients receive duvelisib PO BID for 2 weeks prior to collection of CAR-T cells in the absence of disease progression or unacceptable toxicity. Patients then receive tisagenlecleucel via infusion.
62587652|NCT02179970|OTHER|Plerixafor (Mozobil)|Plerixafor (Mozobil), continuous 7 day IV infusion. Starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
62587653|NCT01478672|NO_INTERVENTION|Standard care|
62796619|NCT02245945|PLACEBO_COMPARATOR|hydroxyethylcellulose (HEC) placebo gel|"Participants will be instructed to use HEC placebo gel according to the BAT 24 regimen (2 gel doses) at least twice per week, regardless of sexual frequency.~The BAT24 dosing regimen when used with sex is defined as one dose of gel within 12 hours before sex and a second dose of gel as soon as possible within 12 hours after sex and no more than two doses in a 24 hour period. Participants who do engage in sexual intercourse should use the BAT24 regimen with each sex act.~If used without sex, the BAT24 dosing regimen is defined as 2 doses of gel administered 2-24 hours apart, with no more than two doses in a 24 hour period."
62796620|NCT01698814|EXPERIMENTAL|AL-4943A|AL-4943A Ophthalmic Solution, one drop instilled in both eyes once daily for up to 6 weeks
62796621|NCT01698814|PLACEBO_COMPARATOR|AL-4943A Vehicle|AL-4943A Ophthalmic Solution Vehicle, one drop instilled in both eyes once daily for up to 6 weeks
62796622|NCT02294058|ACTIVE_COMPARATOR|Interferon beta-1a|Participants received 30 µg interferon beta-1a by intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally once a day until the last participant had been treated for 12 months.
62796623|NCT02294058|EXPERIMENTAL|Ozanimod 0.5 mg|Participants received ozanimod 0.5 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.
62796624|NCT02294058|EXPERIMENTAL|Ozanimod 1 mg|Participants received ozanimod 1 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.
62796625|NCT06056661|EXPERIMENTAL|WMR group|Participants in this group will receive the WMR program for up to 5 weeks.
62796626|NCT05330208|EXPERIMENTAL|Group A|
62796627|NCT05330208|PLACEBO_COMPARATOR|Group B|
62024182|NCT02405715|EXPERIMENTAL|Oxytocin Spray And Interpersonal Psychotherapy|Participants will receive 6 sprays of a oxytocin nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total). Each spray will contain 4IU of oxytocin, for a total dose of 24IU.
62024183|NCT06615531||Single group study|Dr Joe Dispenza Week Long Advanced Retreat Attendees
62024184|NCT06052852|EXPERIMENTAL|Single agent BDC-3042|Escalating doses followed by expansion targeting advanced malignancies
62024185|NCT06052852|EXPERIMENTAL|Combination BDC-3042 plus cemiplimab|Escalating doses followed by expansion targeting advanced malignancies
62024186|NCT00525317|ACTIVE_COMPARATOR|Magnesium tablet suplementation (1)|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"
62024187|NCT00525317|PLACEBO_COMPARATOR|Placebo tablet suplementation (2)|Placebo (3 times daily for 2 weeks)
62024188|NCT02491320|EXPERIMENTAL|Pre-treatment acupuncture + letrozole|A 16 week acupuncture pretreatment followed by letrozole(LE). Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. All subjects will be requested to use contraception during the 16 week acupuncture pretreatment. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks. After 16 weeks of acupuncture treatment, LE will start on day 2-3 after a spontaneous period or after a withdrawal bleeding after progestin administration. The subjects will be instructed to have intercourse on a regular basis during the cycles.
62415241|NCT05204849|ACTIVE_COMPARATOR|Standard passive external ventricular drainage|Patients randomized to passive external ventricular drainage will receive a standard EVD.
62415242|NCT06652230|EXPERIMENTAL|Smile Arc Marginal Ridge Approach (SAMRA)|
62415243|NCT06652230|ACTIVE_COMPARATOR|MBT Chart Method|
62415244|NCT02244086|NO_INTERVENTION|bupivacaine 0.125%|administrate bupivacaine at 0.125% during initiation of effective labor work
62415245|NCT02244086|EXPERIMENTAL|bupivacaine 0.25%|Administrate bupivacaine at 0.25% during initiation of effective labor work One of the researchers selected from a randomized list containing pages in both groups with numbers ranging from 0001 to 0110 with 55 pages for each group and these selected folios prepared in sterile form and start the day in the morning, the amount of 10 10 ml syringes with foil for each mixture. The remaining samples were discarded if 10 analgesics are not achieved during the day, and the day new preparations were made.
62415246|NCT06550180|EXPERIMENTAL|Spinal anaesthesia group (S)|patient in S group They will receive 20 mg of 0.5% hyperbaric bupivacaine plus 25 microgram fentanyl.
62415247|NCT06550180|EXPERIMENTAL|Subcostal TAP block and spinal anaesthesia group (STAP)|Patients in STAP group will receive 20 ml of 0.25% isobaric bupivacaine for each side before spinal anaesthesia.
62415248|NCT02198209|OTHER|single arm|"Liraglutide (Victoza)~1. acute study: one injection of 0.6 mg s.c. before IVGTT~2. chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c)."
62024189|NCT02491320|ACTIVE_COMPARATOR|Letrozole|LE alone. LE will be started on day 3-5 after a spontaneous period or a withdrawal bleeding following progestin. The subjects will be instructed to have intercourse on a regular basis during the cycles.
62024190|NCT03713762|EXPERIMENTAL|Group 1 LB|Peribulbar block 1 was performed received 100 mg of lidocaine 5% and 15 mg of bupivacaine 0.5% for a total volume of the anesthetic mixture of 5 ml
62024191|NCT03713762|EXPERIMENTAL|Group 2 LBF|Peribulbar block 2 was performed received 100 mg of lidocaine 5%, 15 mg of 0.5% bupivacaine and 50 mcg of fentanyl citrate for a total volume of the anesthetic mixture of 6 ml.
62024192|NCT01146236|ACTIVE_COMPARATOR|Sutures|Orthopedic surgical wound closed with sutures
62024193|NCT01146236|ACTIVE_COMPARATOR|Staples|Orthopedic surgical wound closed with metallic staples
62024194|NCT05215574|EXPERIMENTAL|NGM831 Monotherapy Dose Escalation|Part 1a Single Agent Dose Escalation
62024195|NCT05215574|EXPERIMENTAL|NGM831 combination dose finding with pembrolizumab (KEYTRUDA®)|Part 1b NGM831 plus pembrolizumab (KEYTRUDA®)
62024196|NCT05215574|EXPERIMENTAL|NGM831 and NGM438 Combination Dose Finding with pembrolizumab (KEYTRUDA®)|Part 1c NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
62024197|NCT03096418|EXPERIMENTAL|Weekly Paclitaxel|"Paclitaxel 80 mg/m2 will be initiated as standard infusion on days 1, 8, 15 of a 21-day cycle.~Participants will continue with paclitaxel 80 mg/m2 for cycles 2-4 prior to surgery."
62024198|NCT06037759||Cases (N=50):|Patients with incident ESKD managed by HD (n=50)
62024199|NCT06037759||Controls (N=50)|Patients with Incident ESKD managed by PD (n=20) Patients with CKD stage 3-4 (not on dialysis) with hypertension as a key risk factor for CKD and CVD (n=30)
62024200|NCT05081414|EXPERIMENTAL|Intervention Group|Beyond the active comparator, this group will receive the PEAC-IC, as described previously.
62024201|NCT05081414|NO_INTERVENTION|Control Group|The Control Group will receive the usual care in the health care institution, which consists of guidance during hospital discharge and delivery of a discharge planning form and outpatient follow-up with medical and nursing consultations and exams when indicated.
62024202|NCT04818411|ACTIVE_COMPARATOR|Routine physical therapy treatment with the Stabilization exercises|Stabilization exercises
62024203|NCT04818411|EXPERIMENTAL|Routine physical therapy treatment + High-velocity thrust manipulation|High-velocity thrust manipulation
62415249|NCT03490539||azathioprine (AZT)|Patients with MG who are receiving azathioprine as part of routine clinical care
62415250|NCT03490539||mycophenolate mofetil (MMF)|Patients with MG who are receiving mycophenolate mofetil as part of routine clinical care
62024204|NCT05284968|EXPERIMENTAL|Cell injection|Cell injection
62024205|NCT02602301|ACTIVE_COMPARATOR|1|group A that included 109 women in whom labour was augmented by IV infusion of oxytocin using isotonic saline 0.9%,
62024206|NCT02602301|ACTIVE_COMPARATOR|2|group B that included 109 women in whom labour was augmented by IV infusion of oxytocin using glucose 5% .
62024207|NCT02602301|PLACEBO_COMPARATOR|3|Group C in which 109 women continued their labour course without any further augmentation.
62024208|NCT06221605|EXPERIMENTAL|Probiotic group|15B CFU/sachet/day, before meals; Compound Probiotics (Bifidobacterium animalis subsp. animalis BLa80、Bifidobacterium longum subsp. longum BL21、Lacticaseibacillus rhamnosus LRa05) Storage: store in a cool, dry place without sun exposure.
62024209|NCT06221605|PLACEBO_COMPARATOR|placebo|Maltodextrin, 1 sachet/day, before meals; Storage: store in a cool, dry place without sun exposure.
62024210|NCT04773587|EXPERIMENTAL|Roflumilast Cream 0.15%|Participants with mild to moderate AD apply roflumilast cream 0.15% QD for 4 weeks.
62415251|NCT03032237|EXPERIMENTAL|Protein-rich assortment|The intervention groups receives protein-rich meals and protein-rich dairy products.
62415252|NCT03032237|PLACEBO_COMPARATOR|Standard assortment|The control group receives standard meals and food products.
62415253|NCT00357708|EXPERIMENTAL|Treatment (decitabine, vorinostat)|"Patients receive decitabine IV over 1 hour on days 1-5 and oral vorinostat (SAHA) three times daily on days 6-19. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients receive escalating doses of decitabine and SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose."
62587654|NCT01478672|EXPERIMENTAL|Health coaching and and Life-long Monitoring|
62024211|NCT04773587|PLACEBO_COMPARATOR|Vehicle Cream|Participants with mild to moderate AD applied vehicle cream QD for 4 weeks.
62024212|NCT01595919|EXPERIMENTAL|1% Milk|
62024213|NCT01595919|EXPERIMENTAL|Regular Cola|
62024214|NCT01595919|EXPERIMENTAL|Diet cola|
62024215|NCT01595919|EXPERIMENTAL|Orange juice|
62024216|NCT01595919|PLACEBO_COMPARATOR|Water|
62024217|NCT00671281|EXPERIMENTAL|B|This group will be the experimental group which will receive tranexamic acid in oral form three days before and six days after surgery.
62024218|NCT00671281|PLACEBO_COMPARATOR|A|This will be the control group which will take the placebo medication for 3 days before and six days after their functional endoscopic sinus surgery (FESS).
62024219|NCT03791125|EXPERIMENTAL|Experimental|
62024220|NCT03791125|PLACEBO_COMPARATOR|Placebo|
62024221|NCT06636188|NO_INTERVENTION|Treatment-As-Usual Arm|Participants in the Treatment-As-Usual group will receive routine onsite nursing care in which the nurse discusses general knowledge of self-care behaviors regarding the management of radiotherapy-related side effects.
62024222|NCT06636188|EXPERIMENTAL|Digi-Coach Chatbot Arm|Participants in Digi-Coach Chatbot Arm will have access to the Digi-Coach chatbot in addition to usual care. The research nurse will provide training on how to use the chatbot.
62024223|NCT00375089||Group 1|Individuals with Prader-Willi syndrome.
62024224|NCT00375089||Group 2|Individuals with Early-onset Morbid Obesity
62024225|NCT00723177|PLACEBO_COMPARATOR|Placebo|This group will receive placebo drug
62024226|NCT00723177|EXPERIMENTAL|Low-dose AV411|This group will receive a low dose of AV411
62024227|NCT00723177|EXPERIMENTAL|High-dose AV411|This group will receive a high dose of AV411
62024228|NCT06669013|EXPERIMENTAL|Generalized / metastatic GD2-positive rhabdomyosarcoma|"Generalized / metastatic GD2-positive rhabdomyosarcoma after progression on 1st line of chemotherapy.~Chemotherapy options:~• CARBO(CARBOPLATIN) + ETO(ETOPOSIDE), IFO(IFOSFAMIDE) + ETO(ETOPOSIDE), CARBO(CARBOPLATIN) + IFO(IFOSFAMIDE) (rhabdomyosarcoma)~+ 6 consecutive cycles of dinutuximab beta immunotherapy"
62024229|NCT06669013|EXPERIMENTAL|Generalized / metastatic GD2-positive Ewing sarcoma|"Generalized / metastatic GD2-positive Ewing sarcoma after progression on 1st line of chemotherapy.~• ICE (IFOSFAMIDE+CARBOPLATIN+ETOPOSIDE), TEM(TEMOZOLOMIDE+IRINOTECAN), VCT(VINCRISTINE+CYCLOPHOSPHAN+TOPOTECAN), TC(CYCLOPHOSPHAN+TOPOTECAN), TT(TEMOZOLOMIDE+TOPOTECAN), GEM/TAX(GEMCITABINE+DOCETAXEL) (Ewing's sarcoma)~+ 6 consecutive cycles of dinutuximab beta immunotherapy"
62024230|NCT06669013|EXPERIMENTAL|Generalized / metastatic GD2-positive osteosarcoma|"Generalized / metastatic GD2-positive osteosarcoma after progression on 1st line of chemotherapy.~• ICE(IFOSFAMIDE+CARBOPLATIN+ETOPOSIDE), IE (IFOSFAMIDE+ETOPOSIDE), CARBOPLATIN+ ETOPOSIDE, Аi(DOXORUBICIN+IFOSFAMIDE), IFO(IFOSFAMIDE), GEM/TAX(GEMCITABINE+DOCETAXEL) (osteosarcoma)~+ 6 consecutive cycles of dinutuximab beta immunotherapy"
62024231|NCT01228162|EXPERIMENTAL|general anaesthesia|patients receiving general anaesthesia and rocuronium bromide for muscle relaxation
62220915|NCT04866446||normal airway manikin with personal protective equipment|The participants will carry out intubation procedure using macintosh direct laryngoscope, GlideScope video laryngoscope, C-Mac video laryngoscope and Frova intubation catheter and laryngeal mask insertion using ProSeal LMA and I-gel LMA, respectively.
62220916|NCT04866446||difficult airway manikin with standard uniform|The participants will carry out intubation procedure using macintosh direct laryngoscope, GlideScope video laryngoscope, C-Mac video laryngoscope and Frova intubation catheter and laryngeal mask insertion using ProSeal LMA and I-gel LMA, respectively.
62415254|NCT06395389|ACTIVE_COMPARATOR|Health Education (HealthEdu)|Brief intervention providing recommendations/advice for good sleep hygiene, nutrition and physical activity, stress, and relationships.
62415255|NCT06395389|EXPERIMENTAL|Values in Action (VIA)|Brief intervention providing personalized discussion of values/goals, reasons for cannabis use, and strategies to help live in line with values and achieve goals.
62024232|NCT01228162|ACTIVE_COMPARATOR|spinal anaesthesia|patients receiving spinal anaesthesia without muscle relaxation
62024233|NCT00016289|EXPERIMENTAL|Treatment (recombinant interleukin-12)|Patients receive interleukin-12 intraperitoneally once weekly. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease receive 2 additional courses.
62024234|NCT06531356|EXPERIMENTAL|cases|
62024235|NCT06531356|ACTIVE_COMPARATOR|control|
62024236|NCT01480700|EXPERIMENTAL|rich-eggs|subjects consume 2 eggs rich in lutein/zeaxanthin and DHA per day during 4 months
62024237|NCT01480700|ACTIVE_COMPARATOR|standard eggs|subjects consume 2 standard eggs per day
62024238|NCT04013542|EXPERIMENTAL|Treatment (nivolumab, ipilimumab, radiation therapy)|"CONCURRENT THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 30 minutes on day 1. Treatment with nivolumab repeats every 21 days for up to 8 cycles, and treatment with ipilimumab repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 1 day of starting nivolumab and ipilimumab, patients also undergo radiation therapy 5 days a week (Monday-Friday) over 6-7 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
62220917|NCT04866446||difficult airway manikin with personal protective equipment|The participants will carry out intubation procedure using macintosh direct laryngoscope, GlideScope video laryngoscope, C-Mac video laryngoscope and Frova intubation catheter and laryngeal mask insertion using ProSeal LMA and I-gel LMA, respectively.
62220918|NCT05769283|ACTIVE_COMPARATOR|Platelet Rich Plasma|Platelet Rich Plasma Injection
62220919|NCT05769283|PLACEBO_COMPARATOR|Saline|Placebo injection of saline
62220920|NCT05610332|EXPERIMENTAL|Immune activated experimental group|Albumin paclitaxel 260mg/m2, ivgtt, d1, d8 Carrelizumab: 200mg, ivgtt, d1, q3w
62415256|NCT06280066|EXPERIMENTAL|Children Intervention Group|Intervention Program Based on Strengthening Psychological Resilience for Children with Cystic Fibrosis and Their Mothers. The program will be implemented for 10 weeks, with a total of 10 sessions, 1 session per week (each session consists of 2 sessions).
62415257|NCT06280066|EXPERIMENTAL|Mothers Intervention Group|Intervention Program Based on Strengthening Psychological Resilience for Children with Cystic Fibrosis and Their Mothers. The program will be implemented for 10 weeks, with a total of 10 sessions, 1 session per week (each session consists of 2 sessions).
62415258|NCT06280066|NO_INTERVENTION|Children Controlled Group|No intervention.
62415259|NCT06280066|NO_INTERVENTION|Mothers Controlled Group|No intervention.
62024239|NCT05652751|PLACEBO_COMPARATOR|sham EA + placebo group|The sham EA intervention a is that the stimulator is connected to the needle handle on GV20 and GV26 without power for 40 min intervention,once a day for 4 weeks;The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks before the sham EA intervention.
62220921|NCT05610332|ACTIVE_COMPARATOR|Immune activated control group|Docetaxel 50mg/m2, ivgtt, d1, q14d; Oxaliplatin 85mg/m2, ivgtt, d1, q14d; Calcium folinate 200mg/m2, ivgtt, d1, q14d; 5-fluorouracil 2600mg/m2, 24h civ, d1, q14d
62220922|NCT05610332|EXPERIMENTAL|Immune silence experimental group|Carrelizumab: 200mg, ivgtt, d1, q3w Docetaxel 50mg/m2, ivgtt, d1, q14d; Oxaliplatin 85mg/m2, ivgtt, d1, q14d; Calcium folinate 200mg/m2, ivgtt, d1, q14d; 5-fluorouracil 2600mg/m2, 24h civ, d1, q14d
62220923|NCT05610332|ACTIVE_COMPARATOR|Immunosilent control group|Docetaxel 50mg/m2, ivgtt, d1, q14d; Oxaliplatin 85mg/m2, ivgtt, d1, q14d; Calcium folinate 200mg/m2, ivgtt, d1, q14d; 5-fluorouracil 2600mg/m2, 24h civ, d1, q14d
62220924|NCT04735328|OTHER|Intervention|"When clinics join the intervention, leaders will receive leadership training through the Leadership and Organizational Change for Implementation (LOCI) intervention.~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR and CT-PTSD)."
62220925|NCT03070951|EXPERIMENTAL|OBE2109 dose 1 (100mg) + Placebo Add-back|
62220926|NCT03070951|EXPERIMENTAL|OBE2109 dose 1 (100mg) + Add-back|
62415260|NCT02725840||Proton beam radiation therapy|The participants in this group will be receiving proton therapy of the affected breast and chest wall as part of their standard of care. In addition, a Computed Tomography (CT) Scan of the chest wall will be performed, and pulmonary function test (PFT).
62415261|NCT02725840||X-ray based radiation therapy|The participants in this group will be receiving X-ray radiation therapy of the affected breast and chest wall as part of their standard of care. In addition, a Computed Tomography (CT) Scan of the chest wall will be performed, and pulmonary function test (PFT).
62415262|NCT06652555||group 1|Baseline characteristics and information during loratinib treatment were collected
62415263|NCT05375968|ACTIVE_COMPARATOR|Changes in Splanchnic venous capacitance(SVC) before and after a 75-g oral glucose challenge|"To compare and measure changes in splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. between participants with POTS (Postural Tachycardia Syndrome) and Healthy Control group~Various GIP hormones especially GLP-1, GLP-2, glucagon, and other GI hormones before and after a 75-gram oral glucose at different timepoints through out 3 hours of the study visit"
62415264|NCT05375968|PLACEBO_COMPARATOR|Effect of GIP antagonist GIP(3-30)NH2 Vs Saline on splanchnic venous capacitance on POTS patients|"POTS patients who participated in Aim 1, will be and randomized to either saline versus GIP antagonist (GIP(3-30)NH2) in Visit 2.~The changes in their splanchnic venous capacitance and superior mesenteric arterial flow will be measured, before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr.~Notably, changes in venous capacitance will be assessed using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume."
62415265|NCT01834391||Geriatric Traumatic Injury|Geriatric trauma pateints being admitted to Saint Marys Hosptial.
62024240|NCT05652751|ACTIVE_COMPARATOR|EA + placebo group|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle will be inserted in GV20（Baihui) and the stainless needle will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day;The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks before the EA intervention."
62024241|NCT05652751|ACTIVE_COMPARATOR|sham EA + NGF group|The sham EA intervention a is that the stimulator is connected to the needle handle on GV20 and GV26 without power for 40 min intervention,once a day for 4 weeks;The 20ug nerve growth factor will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks before the sham EA intervention. Dose modification is not allowed for mNGF.
62415266|NCT04294498|EXPERIMENTAL|Durvalumab|Durvalumab
62024242|NCT05652751|ACTIVE_COMPARATOR|EA + NGF group|Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle will be inserted in GV20（Baihui) and the stainless needle will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness . Then, the needles are stimulated by using an acupuncture point nerve stimulator , 28 days as a course of treatment, once a day;The 20ug nerve growth factor will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks before the EA intervention. Dose modification is not allowed for mNGF.
62024243|NCT06412276|EXPERIMENTAL|Control|"Food menu typical for the out-of-home outlet with~* Product price promotions (25% off orders over £10)~* Bulk buy reductions (bundle options for reduced prices)~* Volume value pricing (increase in size for a disproportionately small increase in price)"
62024244|NCT06412276|EXPERIMENTAL|Product price reductions removed|Food menu without product price promotions
62220927|NCT03070951|EXPERIMENTAL|OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-back|
62220928|NCT03070951|EXPERIMENTAL|OBE2109 dose 2 (200mg) + Add-back|
62220929|NCT03070951|PLACEBO_COMPARATOR|Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-back|
62220930|NCT05559931|EXPERIMENTAL|Part A: Single Dose Active|Subjects will receive a single IV dose of DMT, administered as a bolus loading dose followed by a 6-h infusion. The starting dose will be 1.5 mg bolus, followed by a 0.105 mg/min infusion. Subsequent doses will be based on the safety and tolerability data from previous groups.
62220931|NCT05559931|PLACEBO_COMPARATOR|Part A: Single Dose Placebo|Subjects will receive a single IV dose of placebo, administered as a bolus loading dose followed by a 6-h infusion.
62024245|NCT06412276|EXPERIMENTAL|Bulk buy price reductions removed|Food menu without price decrease for bulk-buy items (i.e. bundles available but not at a decreased price)
62024246|NCT06412276|EXPERIMENTAL|Volume value pricing removed|For products on the food menu with size increases, increases in price will be made proportionate (as opposed to value)
62220932|NCT05559931|EXPERIMENTAL|Part B: Multiple Dose Active|Subjects will receive a total of 6 doses of DMT, given as a bolus loading dose, followed by a IV infusion over 6 h, on Days 1, 3, 5, 8, 10, and 12 of a 2-week treatment period. Dose to be determined from single dose phase.
62220933|NCT05559931|PLACEBO_COMPARATOR|Part B: Multiple Dose Placebo|Subjects will receive a total of 6 doses of placebo, given as a bolus loading dose, followed by IV infusion over 6 h, on Days 1, 3, 5, 8, 10, and 12 of a 2-week treatment period.
62220934|NCT00602563|EXPERIMENTAL|1 Attention Modification Program (AMP)|The AMP is a computer-delivered attention modification
62220935|NCT00602563|ACTIVE_COMPARATOR|Applied Relaxation (AR)|Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev \& Chambless, 2007)
62220936|NCT00602563|PLACEBO_COMPARATOR|Clinical monitoring control|participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions ; however, they will not be randomized to treatment until after the 3-month follow-up assessment. To control for the effects of psychoeducation, symptom monitoring, contact by project staff, and maturation effects, participants will be asked to complete pre-, mid- and post-assessments, and will be informed that they will receive treatment.
62220937|NCT00602563|EXPERIMENTAL|Combining the AMP and AR|Both AMP and AR
62220938|NCT05653570|ACTIVE_COMPARATOR|Ultrasound Guidance Only|
62220939|NCT05653570|EXPERIMENTAL|Electrical stimulation and Ultrasound Guidance|
62587655|NCT02935361|EXPERIMENTAL|Treatment (guadecitabine, atezolizumab)|Patients receive guadecitabine SC on days 1-5 and atezolizumab IV over 30-60 minutes on days 8 and 22. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
62796628|NCT06277063|EXPERIMENTAL|Acute exacerbation experimental group|VAS pain intensity will be assessed at the onset of headache, and patients will receive nVNS for half an hour within 20 minutes of the onset, and post-treatment evaluation results will be recorded immediately after treatment, 2 hours, 8-12 hours, 24 hours, and 36-48 hours. During the course of treatment and intervention, a 20-minute ECG closed-loop assessment test will be performed before admission and after return. The procedure included: 5 minutes of rest (i.e. no vagal stimulation), 10 minutes of vagal stimulation, 5 minutes of rest(5-10-5), a total of 20 minutes of ECG, and real-time extraction of heart rate and sex data. Neck electromyography before and after intervention was also used as an auxiliary indicator.
62796629|NCT06277063|SHAM_COMPARATOR|Acute exacerbation control group|VAS pain intensity will be assessed at the onset of headache, and patients will receive sham-nVNS for half an hour within 20 minutes of the onset, and post-treatment evaluation results will be recorded immediately after intervention, 2 hours, 8-12 hours, 24 hours, and 36-48 hours. During the course of intervention, a 20-minute ECG closed-loop assessment test will be performed before admission and after return. The procedure included: 5 minutes of rest (i.e. no vagal stimulation), 10 minutes of vagal stimulation, 5 minutes of rest, a total of 20 minutes of ECG, and real-time extraction of heart rate and sex data. Neck electromyography before and after intervention was also used as an auxiliary indicator.
62796630|NCT06277063|EXPERIMENTAL|Seizure prevention experimental group|The total course of intervention will be 8 weeks. Two 20-minute (5-10-5) closed-loop vagal - ECG/EMG measurements will be required before and after the intervention. Subjects will be required to keep a headache diary for 4 weeks at baseline before the intervention. The time of onset, duration, pain intensity (as measured by visual analogue scale (VAS)), accompanying symptoms, and medication use will be recorded. According to the randomized group, nVNS intervention will be carried out at home for 8 weeks, twice a day (7:00-8:00 in the morning and 19:00-20:00 in the evening). After the intervention, headache diary will be still needed to fill out, and the content will be the same as above. Headache diaries will be collected at 4-week intervals from week 4 to week 20.
62796631|NCT06277063|SHAM_COMPARATOR|Seizure prevention control group|The total course of intervention will be 8 weeks. Two 20-minute (5-10-5) closed-loop vagal - ECG/EMG measurements will be required before and after the intervention. Subjects will be required to keep a headache diary for 4 weeks at baseline before the intervention. The time of onset, duration, pain intensity (as measured by visual analogue scale (VAS)), accompanying symptoms, and medication use will be recorded. According to the randomized group, sham-nVNS intervention will be carried out at home for 8 weeks, twice a day (7:00-8:00 in the morning and 19:00-20:00 in the evening). After the intervention, headache diary will be still needed to fill out, and the content will be the same as above. Headache diaries will be collected at 4-week intervals from week 4 to week 20.
62220940|NCT01227382|OTHER|ERCP with Cholangiopancreatoscopy|The subjects who have been scheduled for an Endoscopic Retrograde Cholangiopancreatography (ERCP) with Cholangiopancreatoscopy for evaluation of a bile duct or pancreatic duct stricture sampling.
62220941|NCT00432666|EXPERIMENTAL|IncobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection"
62220942|NCT00432666|PLACEBO_COMPARATOR|Placebo|
62220943|NCT03774485||Healthy controls|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in healthy controls. The investigator does not change the routine medical care of study participants.
62587656|NCT05705193|EXPERIMENTAL|Computerized Cognitive Remediation|
62220944|NCT03774485||Crohn's disease (remission state)|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in subjects with Crohn's disease (remission state). The investigator does not change the routine medical care of study participants.
62024247|NCT06412276|EXPERIMENTAL|No price-based incentive|Food menus will be provided with no price-based incentives
62024248|NCT03870230|EXPERIMENTAL|POAG MD<10dB|patients with primary open angle glaucoma with MD in visual field less than or equal 10dB
62220945|NCT03774485||Crohn's disease (flare state)|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in subjects with Crohn's disease (flare state). The investigator does not change the routine medical care of study participants.
62220946|NCT02939612|EXPERIMENTAL|App for Stress management|Participants will get access to two modules per week for five weeks (total 10 modules). The app consists of stress management education, cognitive behavioral interventions and relaxation training exercises.
62220947|NCT02939612|NO_INTERVENTION|Waitlist control group|Participants will get treatment as usual during the study. After the one year study follow up they will receive the stress management app.
62220948|NCT03650309|EXPERIMENTAL|Deep Brain Stimulation|All patients will receive deep brain stimulation (DBS) targeting two brain areas involved in the pathophysiology of obesity. No other changes to pre-existing treatment will be made. This is the only arm in this experiment.
62220949|NCT04696380|EXPERIMENTAL|High nicotine, preferred flavor|Participants will sample their preferred flavored JUUL e-cigarette at 5% nicotine strength.
62220950|NCT04696380|EXPERIMENTAL|High nicotine, non-preferred flavor|Participants will sample their non-preferred flavored JUUL e-cigarette at 5% nicotine strength.
62220951|NCT04696380|EXPERIMENTAL|Low nicotine, preferred flavor|Participants will sample their preferred flavored JUUL e-cigarette at 3% nicotine strength.
62220952|NCT04696380|EXPERIMENTAL|Low nicotine, non-preferred flavor|Participants will sample their non-preferred flavored JUUL e-cigarette at 3% nicotine strength.
62220953|NCT01220427||Clinical high-risk prostate cancer, radical prostatectomy|
62415267|NCT05998031|EXPERIMENTAL|Active tDCS|AA neuroConn MR-safe 1x1 tDCS stimulator will be used to apply 12 minutes of 2.0 mA electrical current, with 30 seconds ramps up and 30 seconds ramps down. The electrical current will be applied by using two carbon rubber electrodes (one anode, one cathode) with added ten20 conductive paste. The electrode+paste will be affixed on the participant's scalp over the frontal cortices at F3 and F4 location (EEG 10-20 system). Inflow of current (anode) will occur at F4 location, and outflow of current will occur at F3 (cathode).
62415268|NCT05998031|PLACEBO_COMPARATOR|Sham tDCS|Sham stimulation will be performed with the same 1x1 device. Participants will receive 2 mA of direct current stimulation for 30 seconds with 30 seconds ramps up and down. This provides the tingling and prickling sensation on the scalp associated with tDCS while prevent delivering sufficient current (12 minutes) to penetrate the skull and stimulate the brain. Prep in sham conditions will be identical to active stimulation conditions. For each stimulation condition (active, sham), each participant will perform three runs of N-back working memory task (baseline/pre-stimulation, during stimulation, and after/post-stimulation) as detailed below. Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
62415269|NCT06461897|EXPERIMENTAL|Dupi-IR Cohort|Participants in this cohort will receive upadacitinib medium dose
62220954|NCT06474728|EXPERIMENTAL|Treatment with an Emollient Containing Postbiotic Saccharomyces and Lactobacillus|
62220955|NCT06474728|NO_INTERVENTION|Treatment without an Emollient Containing Postbiotic Saccharomyces and Lactobacillus|
62220956|NCT02413333|OTHER|Clear Care Plus, then PeroxiClear|Clear Care Plus contact lens solution in Period 1, followed by PeroxiClear contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual silicone hydrogel contact lenses for approximately 30 cleaning cycles.
62220957|NCT02413333|OTHER|PeroxiClear, then Clear Care Plus|PeroxiClear contact lens solution in Period 1, followed by Clear Care Plus contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual silicone hydrogel contact lenses for approximately 30 cleaning cycles.
62220958|NCT02173847|EXPERIMENTAL|Penetrating keratoplasty|Femtosecond laser sculptured anvil graft. Diode laser welding of the flap in its final position. 12 months follow up study
62415270|NCT06461897|EXPERIMENTAL|Randomized Cohort|Participants in the Randomized Cohort will be randomized to receive either medium dose upadacitinib daily adult equivalent dose, low dose upadacitinib daily adult equivalent dose or dupilumab every 2 weeks or 4 weeks (at the label-indicated dose and frequency).
62220959|NCT01322802|EXPERIMENTAL|Treatment (pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine)|Patients receive pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine ID monthly for 3 months.
62220960|NCT02376374|EXPERIMENTAL|10% OPV|In this arm, 10% of the households in this community will receive OPV.
62220961|NCT02376374|EXPERIMENTAL|30% OPV|In this arm, 30% of the households in this community will receive OPV.
62220962|NCT02376374|EXPERIMENTAL|70% OPV|In this arm, 70% of the households in this community will receive OPV.
62220963|NCT04973644|EXPERIMENTAL|Internet + Digital Hospital-remote home management mode|Remote monitoring devices+Internet management platform, dietary recommendations, exercise supervision, web education, information pushing, doctor-patient interaction.
62796632|NCT04526626|EXPERIMENTAL|High ligation and stripping|High ligation and stripping of long saphenous vein is the traditional standard procedure for the treatment of varicose veins
62796633|NCT04484818|ACTIVE_COMPARATOR|Arm A (ADT, placebo)|Patients receive goserelin acetate, leuprolide acetate, or triptorelin via injection every 3 months for 12 months (4 injections), every 4 months for 12 months (3 injections), or every month for 12 months (12 injections) in the absence of disease progression or unacceptable toxicity. Patients also receive a placebo four times daily (QID) for 52 weeks in the absence of disease progression or unacceptable toxicity.
62220964|NCT04973644|NO_INTERVENTION|the traditional management mode|Routine dietary and exercise recommendations, education as well as monitor in the clinic.
62220965|NCT04954404|EXPERIMENTAL|Transcatheter mitral valve repair/replacement|
62220966|NCT01423032|EXPERIMENTAL|Bendamustine|
62220967|NCT01423032|ACTIVE_COMPARATOR|Fludarabine|
62415271|NCT04461626||Persona fixed bearing knee system|Persona fixed bearing knee system (All patients will received Persona fixed bearing knee system)
62415272|NCT06701500||Alcohol Use Disorder (AUD) Group|Participants with alcohol use disorder (moderate to severe if no withdrawal symptoms)
62415273|NCT06701500||Control Group|Participants without SUD
62415274|NCT06567223|EXPERIMENTAL|Vibration Therapy|
62415275|NCT06567223|ACTIVE_COMPARATOR|Rhythmic auditory stimulation therapy.|
62220968|NCT01116102|EXPERIMENTAL|24 ga catheter, dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
62220969|NCT01116102|EXPERIMENTAL|24 ga catheter, no dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
62220970|NCT01116102|EXPERIMENTAL|24 ga catheter, dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
62587657|NCT06684561|EXPERIMENTAL|Arm 1|"All subjects will be instructed to change the investigational infusion sets (PIS) every 246 hours (10 days \& 6 hours) or at set failure. Each subject is required to wear the CGM device continuously.~defined as any one of the following: After completing 2 sets, the subjects have an optional office visit to download pump and CGM data and will continue to additional two wears. At day 40 or after using 4 completed wears of infusion sets (Note: early infusion set failure with wear time of \<6 hours due to insertion failure will be reported, yet not accounted as completed wear), the patients will return to a visit, download pump and CGM data, and end the study.~if study 1 is successful, participants will enter study 2; , the same study designed will be performed on the current on-market Extended infusion set (EIS) for comparison of clinical performance with the PIS, using the same cohort of pump users"
62220971|NCT01116102|EXPERIMENTAL|24 ga catheter, no dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
62220972|NCT01116102|EXPERIMENTAL|25 ga needle, dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
62220973|NCT01116102|EXPERIMENTAL|25 ga needle, no dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
62220974|NCT01116102|EXPERIMENTAL|25 ga needle, dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
62220975|NCT01116102|EXPERIMENTAL|25 ga needle, no dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
62220976|NCT00591370|EXPERIMENTAL|1 - Temozolomide (TMZ)|
62415276|NCT06398561|EXPERIMENTAL|Experimental: Active Patient Program intervention|The intervention consists of carrying out the six sessions of the Active Patient Program by peers. The sessions have a duration of 2 hours/week during 6 weeks. It is aimed at patients with a diagnosis of major depression and they will undergo 4 evaluations, one before, one at the end of the sessions and two more at 6 and 12 months after the end of the sessions.
62415277|NCT06398561|ACTIVE_COMPARATOR|Control: Use App COGITO|"the control consists of the regular use (30 minutes daily) of the COGITO App that will guide the participant in the performance of exercises to improve depressive symptomatology. The time of use is equivalent to the time invested in the sessions.~The same evaluations will be carried out as in the experimental group (previous evaluation, at the end of the sessions (6 weeks) and two more at 6 and 12 months after the end of the sessions."
62415278|NCT05469854|EXPERIMENTAL|Linaprazan glurate|Oral administration as a single dose of 300 mg, 600 mg, 200 mg, and a final dose level of maximum 400 mg.
62415279|NCT05469854|PLACEBO_COMPARATOR|Placebo|Oral administration as a singel dose
62415280|NCT04381468|EXPERIMENTAL|pepinemab 40mg/kg|The study drug, pepinemab, will be administered via monthly intravenous infusions.
62415281|NCT04381468|PLACEBO_COMPARATOR|Placebo|.A placebo control will be administered via monthly intravenous infusions.
62415282|NCT06565845||surgery group|The patients underwent surgery
62415283|NCT06565845||triple anti-tuberculosis drug therapy group|The patients were treated with triple anti-tuberculosis drugs
62587658|NCT05989074|EXPERIMENTAL|ALLEGRA|ALLEGRA Delivery System TF will be administered.Patient will receive Anticoagulation medication according to the site-specific standard of care
62415284|NCT06565845||combination therapy group|The patients were treated with surgery first, and then took triple anti-tuberculosis drugs after surgery
62415285|NCT00297882|ACTIVE_COMPARATOR|1 Artemether-Lumefantrine (AL)|Study group 1. Subjects in this group received treatment with Artemether-Lumefantrine. Children received 2 mg/kg Artemether and 12 mg/kg Lumefrantrine with milk twice daily (or every 12 hours for 3 days.
62415286|NCT00297882|ACTIVE_COMPARATOR|2 Amodiaquine-Artesunate (AQ-AS)|Study group 2. Subjects in this group received treatment with Amodiaquine-Artesunate. Children received a co-administered combination of 30 mg/kg Amodiaquine (AQ) plus 4 mg/kg Artesunate (AS) daily for 3 days.
62415287|NCT05145023||Development of the CARD-SARC (n=20)|"* Interviews: 6-20 participants (depending of data saturation) will be recruited using a convenience sampling strategy.~* Field-testing: 20 participants using a convenience/consecutive sampling strategy."
62220977|NCT03857074|EXPERIMENTAL|Open Label, Green Light Exposure|This is a single-center, open label, pilot feasibility study. Patients with epilepsy will be exposed to a narrow band of green light at low intensities (1-10 cd/m2). The investigators will record 30 minutes of scalp EEG prior to the light exposure and 30 minutes of scalp EEG recording post-light exposure. The number of epileptic spikes per minute at baseline will be compared to epileptic spike count per minute post-treatment, to determine whether green light exposure effectively decreases the number of epileptic spikes, in patients with ≥1 epileptic spike per minute at baseline.
62587659|NCT05989074|ACTIVE_COMPARATOR|Balloon-expandable TAVI|Patient will receive any kind of CE-marked balloon-expandable valve, and anticoagulation medication according to the site-specific standard of care
62587660|NCT04123535|EXPERIMENTAL|Undifferentiated Pleomorphic Sarcoma (UPS)|All enrolled participants will be scheduled to receive pre-operative MRgFUS with the ExAblate 2000/2100 MRgFUS system 1-4 weeks prior to surgical resection of their tumor or approximately 2 weeks after a pre-procedure biopsy of the metastatic tumor target depending on diagnosis at enrollment. For patients enrolled with metastatic disease, pre and post-MRgFUS biopsy samples will be obtained.
62220978|NCT03620370|EXPERIMENTAL|NBO group|Normobaric oxygen therapy is the delivery of high-flow oxygen (10L/min) via oxygen storage facemask. This therapy should start in the pre-hospital or emergency room as soon as possible (within 1 hours) after diagnosis of ischemic stroke and last for 4 hours. All participant will receive mechanical thrombectomy and a standard clinical therapy.
62220979|NCT03620370|NO_INTERVENTION|Control group|The participants receive mechanical thrombectomy therapy after diagnosed ischemic. All participants receive a standard clinical therapy.
62587661|NCT06585527|EXPERIMENTAL|TS-2021|30 eligible participants with recurrent malignant glioma will be intratumoral injected the TS-2021 oncolytic virus to study its safety and efficacy.
62220980|NCT02043964|EXPERIMENTAL|tears and cerebro-spinal fluid sampling|
62587662|NCT06667167|EXPERIMENTAL|Single Arm|Single Arm
62587663|NCT00771017|ACTIVE_COMPARATOR|Arm I|Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment comprising leuprolide acetate or goserelin intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
62587664|NCT00771017|EXPERIMENTAL|Arm II|Patients receive androgen ablation as in arm I. Patients receive GVAX prostate cancer vaccine (CG1940 and CG8711) intradermally (ID) on day 1. Beginning on day 1 of week 3, patients receive booster doses of CG1940 and CG8711 ID every 2 weeks for 24 weeks.
62220981|NCT06448832||Agenesis Group|Subjects with the presence of muscular agenesis of the plantar muscle and palmaris longus.
62587665|NCT03115138|OTHER|Patients with glial tumor|
62587666|NCT06152614|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|"Participants randomized to EUC will have access to existing usual primary care services. They will also be enrolled in Hypertension Self-Management Education and Support (SMES) class (Hypertension group), which is an existing CDC-endorsed program offered at Eskenazi Health to provide information and skills for managing hypertension (HTN). Classes are led by registered dietitians via Webex."
62220982|NCT06448832||Non-agenesis Group|Subjects without the presence of muscular agenesis of the plantar muscle and palmaris longus.
62220983|NCT01466933|EXPERIMENTAL|Community-based|Community trained peer educator delivers parenting sessions to mothers in the village on a monthly basis
62415288|NCT05145023||Validation of the CARD-SARC (n=100)|The CS-specialist centres (Barts Health NHS Trust and Royal Papworth Hospital NHS Foundation Trust) have a cohort of 60-70 potential candidates in each site. The estimated sample size for the Pilot-testing is 100 study participants, considering previous sarcoidosis studies including PROMs, with less than 10% population declining participation or failing to complete their questionnaires.
62587667|NCT06152614|EXPERIMENTAL|Food Delivery and Cooking PLUS Aerobic Training (FoRKS+)|"Participants randomized to FoRKS+ will attend weekly HTN SMES classes separately from EUC participants. SMES classes will include the EUC curriculum stated above and an introduction to the upcoming FoRKS+ intervention.~Following HTN SMES completion, FoRKS+ continues with home-delivered Mediterranean-style ingredient kits, food management lessons, and hands-on cooking classes in one's own kitchen. Classes are led by registered dietitians via Webex. Classes are held twice per week thru Week 12, then only once per week through Week 16. Intervention continues with aerobic exercise led by health coaches via Webex. Classes start in Week 13 with one session per week, increasing to two sessions per week in Weeks 17-28."
62587668|NCT03121196||deprived women|Two groups of women will be compared deprived women and non-deprived women
62796634|NCT04484818|EXPERIMENTAL|Arm B (ADT, darolutamide)|Patients receive goserelin acetate, leuprolide acetate, or triptorelin via injection every 3 months for 12 months (4 injections), every 4 months for 12 months (3 injections), or every month for 12 months (12 injections) in the absence of disease progression or unacceptable toxicity. Patients also receive darolutamide QID for 52 weeks in the absence of disease progression or unacceptable toxicity.
62796635|NCT04007263|PLACEBO_COMPARATOR|Placebo|Placebo intravenous infusion over 30 minutes, five days of once daily dosing
62796636|NCT04007263|EXPERIMENTAL|NP10679 25 mg|NP10679 25 mg intravenous infusion over 30 minutes, five days of once daily dosing
62220984|NCT01466933|ACTIVE_COMPARATOR|Government-based|Government community health workers, trained, deliver the intervention to mothers in the village
62220985|NCT01466933|NO_INTERVENTION|Control|Mothers receive the standard care which is a visit from the health worker
62415289|NCT06700408|EXPERIMENTAL|Dachaihu Decoction combined Erzhiwan with variation granules|Chinese medicine granules
62415290|NCT06700408|PLACEBO_COMPARATOR|Placebo granules|Placebo granules
62415291|NCT01977625|ACTIVE_COMPARATOR|Lisdexamfetamine|Lisdexamfetamine or Vyvanse
62415292|NCT01977625|PLACEBO_COMPARATOR|Sugar Pill|Placebo pill, capsules
62415293|NCT04280939|ACTIVE_COMPARATOR|spinal anesthetic without intrathecal narcotic|spinal anesthetic with standard painkillers without intrathecal narcotics
62415294|NCT04280939|EXPERIMENTAL|spinal anesthetic with morphine|spinal anesthetic with 100 micrograms of intrathecal morphine
62415295|NCT04280939|EXPERIMENTAL|spinal anesthetic with hydromorphone|spinal anesthetic with 20 micrograms of intrathecal hydromorphone
62220986|NCT00832182|EXPERIMENTAL|Insulin aspart and neutral protamine Hagedorn insulin|
62220987|NCT05004896|EXPERIMENTAL|Ketamine|Four infusions of ketamine will be administered over two weeks. The first two infusions will be dosed at 0.5mg/kg over a period of 40 minutes. For infusions 3 and 4, patients will be flexibly dosed between 0.5 mg/kg to 0.75 mg/kg, depending on clinical response to first two infusions.
62220988|NCT05004896|ACTIVE_COMPARATOR|Midazolam|Four infusions of midazolam will be administered over two weeks. The first two infusions will be dosed at 0.02mg/kg over a period of 40 minutes. For infusions 3 and 4, patients will be flexibly dosed between 0.02 mg/kg to 0.03 mg/kg, depending on clinical response to first two infusions.
62220989|NCT04059653|EXPERIMENTAL|Electrical stimulation|Neuromuscular electrical stimulation treatment
62220990|NCT04059653|ACTIVE_COMPARATOR|Treatment As Usual|Usual GP treatment
62220991|NCT00423930|EXPERIMENTAL|IMRT + cisplatin + bevacizumab|This is a single-institution phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab.
62220992|NCT02199704|OTHER|No control or comparison arm.|This case series study has no control or comparison arm. There is only one arm being evaluated (the self directed parenting intervention).
62220993|NCT05963139|ACTIVE_COMPARATOR|Group 1:10 ml %0,25 bupivacaine ıpack and 15 ml %0,25 bupivacaine adductor block|In this group,US guided IPACK block will be performed with 10 ml %0,25 bupivacaine and adductor block will be performed with 15 ml %0.25 bupivacaine using a 22 gauge 10 mm block needle.
62220994|NCT05963139|ACTIVE_COMPARATOR|Group 2:15 ml %0,25 bupivacaine ıpack and 15 ml %0,25 bupivacaine adductor block|In this group,US guided IPACK block will be performed with 15 ml %0,25 bupivacaine and adductor block will be performed with 15 ml %0.25 bupivacaine using a 22 gauge 10 mm block needle.
62220995|NCT05963139|ACTIVE_COMPARATOR|Group 3:20 ml %0,25 bupivacaine ıpack and 15 ml %0,25 bupivacaine adductor block|In this group,US guided IPACK block will be performed with 20 ml %0,25 bupivacaine and adductor block will be performed with 15 ml %0.25 bupivacaine using a 22 gauge 10 mm block needle.
62220996|NCT05963139|ACTIVE_COMPARATOR|Group 4:15 ml %0,25 bupivacaine adductor block and intravenous patient controlled analgesia|In this group adductor block will be performed with 15 ml %0.25 bupivacaine using a 22 gauge 10 mm block needle and postoperative patient controlled analgesia with morphine will be preferred for postoperative analgesia method.
62796637|NCT04007263|EXPERIMENTAL|NP10679 50 mg|NP10679 50 mg intravenous infusion over 30 minutes, five days of once daily dosing
62796638|NCT04007263|EXPERIMENTAL|NP10679 100 mg|NP10679 100 mg intravenous infusion over 30 minutes, five days of once daily dosing
62796639|NCT06172179||Sun Yat-sen memorial hospital|
62796640|NCT06172179||Second People's Hospital of Foshan City|
62220997|NCT00625248||no anthithrombotic|procedures where there were no antithrombotics
62220998|NCT00625248||Antithrombotic - continued|patients who are on antithrombotics
62220999|NCT00625248||Discontinued Antithrombotic|Patients who were on antithrombotics but have been discontinued
62221000|NCT01885520|EXPERIMENTAL|fasting condition|eperisone SR administrated under fasting condition
62415296|NCT06543056|EXPERIMENTAL|ES014|ES014 will be administered in patients with advanced solid tumors.
62415297|NCT03773393|EXPERIMENTAL|CK0801|All subjects will receive adoptive therapy with an infusion of unrelated cord blood-derived regulatory T cells: CK0801. Subjects will receive one intravenous dose of CK0801 (Treg cells) on study Day 0.
62415298|NCT01104935|EXPERIMENTAL|trastuzumab monotherapy|"H group (trastuzumab monotherapy group)~* Trastuzumab: 1-year treatment~* Loading dose, 8 mg/kg; from 2nd dose, 6 mg/kg; iv inj, qw, 18 times"
62415299|NCT01104935|ACTIVE_COMPARATOR|trastuzumab and chemotherapy|"H+CT group (combination therapy of trastuzumab and chemotherapy)~* Chemotherapy: 12 to 24 weeks~* Select chemotherapy from certain regimens (PTX, DTX, TC, AC, EC, FEC, CMF and TCb (CBDCA)) based on decision of a physician or a patient. Initiate administration of trastuzumab after completion of chemotherapy as a sequential combination. However, concomitant administration is allowed when combining trastuzumab with PTX, DTX and CMF. In cases of TCb (CBDCA), trastuzumab is used concomitant administration."
62415300|NCT05910450|EXPERIMENTAL|Clascoterone Part 1 and Part 2|Subjects treated for 12 months with Clascoterone 5% solution (both in double-blind Part 1 and in the single-blind Part 2 of the study)
62796641|NCT06172179||The Fifth People's Hospital of Nanhai District, Foshan City|
62796642|NCT01365364|ACTIVE_COMPARATOR|PLM group|Individuals with increased periodic leg movement index (\>5)
62796643|NCT01365364|ACTIVE_COMPARATOR|Non-PLM group|Individuals with PLM index \<5
62415301|NCT05910450|OTHER|Clascoterone Part 1 + Vehicle Part 2|Subjects treated for the first 6 months Part 1 in double-blind with Clascoterone 5% solution followed by 6 months Part 2 in the single-blind label with Vehicle
62587669|NCT03121196||non-deprived women|Two groups of women will be compared deprived women and non-deprived women
62587670|NCT01935856|EXPERIMENTAL|KHK7580|
62221001|NCT01885520|ACTIVE_COMPARATOR|Fed condition|eperisone SR administrated under fed condition
62221002|NCT05599503|EXPERIMENTAL|SimpleC Wellness Platform with Social Robot Interaction|Participants in the Social Robot condition will have access to personal media, reminders, televisit, messaging, news, and wellness programs in their own room via the Companion. Participants will also will have access to social and health reminders as well as social and wellness programs facilitated by a virtual robot agent in their own room via the Companion, social and health reminders as well as social and wellness programs facilitated by a physical robot in the community area and a staff member (likely the activity director).
62221003|NCT05599503|ACTIVE_COMPARATOR|SimpleC Wellness Platform|Participants in the SimpleC Wellness Platform condition will have access to personal media, reminders, televisit, messaging, news, and wellness programs in their own room via the Companion.
62796644|NCT00740584|EXPERIMENTAL|Open Label, only arm|3%w/w SPL7013 vaginal gel (VivaGel)
62796645|NCT06538155||Wearable device users|Healthy volunteers (every adult individual with no history of cardiovascular events willing to contribute to the project) and patients who experienced major cardiovascular events (i.e., myocardial infarction or cardiac arrest). Both groups must have worn a wearable device or used a smartphone able to collect healthcare data and biosignals.
62796646|NCT06538155||Patients with cardiac arrest|Adults resuscitated after cardiac arrest or during ongoing cardiopulmonary resuscitation (CPR).
62024249|NCT03870230|EXPERIMENTAL|POAG MD>10dB|patients with primary open angle glaucoma with MD in visual field more than 10dB
62221004|NCT05444959|EXPERIMENTAL|HMB supplementation|"The experimental procedure for each participant in this group includes a two 21-days periods HMB supplementation.~HMB will be administered in the form of blinded liquid containing 1 mL HMB free acid per 30 drops. The liquid HMB will be ingested with at least 100 mL of water. Each participant will ingest individualized dose of 90 mg HMB/kgFFM/day of liquid HMB free acid in a split dose per day. On training days in the S group during the first and the second period of supplementation and on training days in W group during the second period of supplementation the supplement will be taken before (half of the individual daily dose) and immediately after training session (second half of the individual daily dose), On rest days the supplements will be taken in the morning (half of the individual daily dose) and before bedtime (second half of the individual daily dose)."
62221005|NCT05444959|PLACEBO_COMPARATOR|Placebo treatment|"The experimental procedure for each participant in this group includes a two 21-days periods Placebo supplementation.~PLA (liquid placebo similar in appearance, taste and smell to HMB, but containing no HMB) will be placed in the blinded liquid form. PLA will be ingested with at least 100 mL of water. Each participant will ingest individualized dose of 90 mg PLA/kgFFM/day of liquid PLA in a split dose per day. On training days in the S group during the first and the second period of supplementation and on training days in W group during the second period of supplementation, the PLA will be taken before (half of the individual daily dose) and immediately after training session (second half of the individual daily dose), On rest days the PLA will be taken in the morning (half of the individual daily dose) and before bedtime (second half of the individual daily dose)."
62221006|NCT03494478|EXPERIMENTAL|Cohort group|All participants will have evaluations at inclusion and 12 months. Neuropsychological testing Actimetry Selfquestionnaires on emotional topics
62221007|NCT02877329|EXPERIMENTAL|Internet-delivered ACT|Guided Internet-delivered Acceptance and commitment therapy for 8 weeks
62221008|NCT02877329|NO_INTERVENTION|Wait list control|No treatment during 8 weeks
62221009|NCT05344781||ileostomy|Patients with ileostomy
62221010|NCT05344781||colostomy|Patients with colostomy
62415302|NCT05910450|OTHER|Vehicle Part 1 + Clascoterone Part 2|Subjects treated for the first 6 months Part 1 in double-blind with Vehicle followed by 6 months Part 2 in the single-blind label with Clascoterone 5% solution.
62415303|NCT05910450|PLACEBO_COMPARATOR|Vehicle Part 1 and Part 2|Subjects treated for 12 months with Vehicle (both in double-blind Part 1 and in the single-blind Part 2 of the study)
62415304|NCT04846920|EXPERIMENTAL|Belzutifan 160 mg BID|Participants will receive belzutifan 160 mg orally twice daily (BID). Treatment will continue until progressive disease or discontinuation.
62415305|NCT04846920|EXPERIMENTAL|Belzutifan 160 mg TID|Participants will receive belzutifan 160 mg orally three times daily (TID). Treatment will continue until progressive disease or discontinuation.
62415306|NCT04846920|EXPERIMENTAL|Belzutifan 200 mg TID|Participants will receive belzutifan 200 mg orally TID. Treatment will continue until progressive disease or discontinuation.
62415307|NCT04846920|EXPERIMENTAL|Belzutifan 120 mg QD|Participants will receive belzutifan 120 mg orally once daily (QD). Treatment will continue until progressive disease or discontinuation.
62415308|NCT03775577||HFpEF|Participants with Heart Failure with Preserved Ejection Fraction
62415309|NCT03775577||HFrEF|Participants with Heart Failure with Reduced Ejection Fraction
62415310|NCT03775577||Hypertensive Subjects|Participants with Hypertension
62415311|NCT03775577||Healthy Subjects|Participants without heart failure and without commodities
62796647|NCT06538155||Patients who received a CT scan|Adults who received a chest CT scan for any reasons.
62415312|NCT04746456||Menopausal women|Women will complete a series of questionnaires, including the VVAQ
62796648|NCT00240461|ACTIVE_COMPARATOR|1|200 mg COLD-fX Natural health products 2 times daily for six months
62796649|NCT00240461|ACTIVE_COMPARATOR|Arm 2|Arm 2 - 400 mg COLD FX Natural health product - 2 times daily for 6 months
62796650|NCT00240461|PLACEBO_COMPARATOR|3|Inactive crystalline substance. This is the placebo arm in which subject receive 200 mg of the placebo 2 times daily for 6 months. Placebo is an inactive crystalline substance.
62221011|NCT03977415||RA with no ILD|"Subjects diagnosed with RA less then 2 years and without a diagnosis of ILD, will complete 5 in-person study visits. Visits will be performed every 6 months for 18 months.~Study Assessments Include:~1. Medical history and Physical exams~2. Quality of Life Questionnaires~3. Collection of Sputum and Blood~4. Radiology (HRCT)~5. Lung Function Test"
62415313|NCT05519527|EXPERIMENTAL|Part 1 (dose escalation)|Participants of the first group will receive the lowest dose level. Participants of each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of STI-6129 is found.
62415314|NCT05519527|EXPERIMENTAL|Part 2 (dose expansion)|Participants will receive the dose of STI-6129 found in Part 1 of the study.
62415315|NCT05557968|ACTIVE_COMPARATOR|Conventional Therapy|"1. Active range of motion exercises.~2. Passive range of motion exercises~3. Balance exercises.~4. On-ground gait training without watching videos"
62415316|NCT05557968|EXPERIMENTAL|Action Observation Therapy (AO)|Conventional therapy in addition to observing images related to stair walking will be observed and physical training will performed to imitate tasks with a physical therapist. While observing the image, they will be instructed to think that their body was performing the movement of the image
62415317|NCT05484830|ACTIVE_COMPARATOR|Individualised HDR-approach|HMS Plus® Hemostasis Management System (Medtronic International, Tolochenaz, CH).
62796651|NCT05423314||control|patients operated for ACLR
62796652|NCT05423314||cold therapy|"patients operated for ACLR, and received a knee brace cold therapy to use it in the post op recovery rehabilitation, sent to patient's home directly during pre-op phase."
62796653|NCT01373658|EXPERIMENTAL|Yinyi stent|
62024250|NCT03870230|EXPERIMENTAL|NTG MD<10dB|patients with normal tension glaucoma with MD in visual field less than or equal 10dB
62024251|NCT03870230|EXPERIMENTAL|NTG MD>10dB|patients with normal tension glaucoma with MD in visual field more than 10dB
62024252|NCT03870230|EXPERIMENTAL|OHT|patients with ocular hypertension
62024253|NCT03870230|EXPERIMENTAL|controls|healthy, age and sex matched, control subjects
62024254|NCT04197947|EXPERIMENTAL|PD patient who have FoG|
62221012|NCT03977415||RA with ILD|"Patients diagnosed with RA less than 2 years, and clinically diagnosed with interstitial lung disease (ILD), will complete 5 in-person study visits. Visits will be performed every 6 months for 18 months.~Study Assessments Include:~1. Medical history and Physical exams~2. Quality of Life Questionnaires~3. Collection of Sputum and Blood~4. Radiology (HRCT)~5. Lung Function Test~6. Spirometry"
62415318|NCT05484830|ACTIVE_COMPARATOR|Conventional ACT-approach|ACT Hemostasis Management
62415319|NCT00722007|EXPERIMENTAL|Cormet Hip Resurfacing Post-PMA Group|hip resurfacing
62415320|NCT06700382||6-8 cycles full dose capecitabine|6-8 cycles of full dose capecitabine intensive therapy (1250mg/m2, BID,D1-D14,Q3W)
62221013|NCT01832285|EXPERIMENTAL|Fluvoxamine|Tablets of Fluvoxamine in dosage 100mg/day will be added to the treatment regimen and continued for 6 weeks
62415321|NCT06700382||1-year metronomic capecitabine|1-year capecitabine metronomic chemotherapy (650mg/m2,BID)
62415322|NCT06700382||no other chemotherapy|no other chemotherapy besides neoadjuvant therapy
62415323|NCT05638607|EXPERIMENTAL|Intensified occupational therapy|Two hours occupational therapy each weekday with specific focus on basic ADL
62415324|NCT05638607|ACTIVE_COMPARATOR|Usual care|Occupational therapist instruct nursing staff on how to assist patients with basic ADL
62415325|NCT00131573|EXPERIMENTAL|1|Stimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on.
62415326|NCT00131573|SHAM_COMPARATOR|2|No stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on.
62415327|NCT04661163|EXPERIMENTAL|Virtual reality avatar therapy|Patients will be offered seven individual sessions of virtual reality therapy and two booster sessions conducted by a skilled therapist. In the initial phase of treatment, the participants create a virtual avatar that corresponds to their visual perception of the source of their voice. The therapist initiates, encourages and supports a dialogue between the participant and the avatar by alternating between talking as the avatar and as a supportive therapist. The therapy sessions last 50 minutes of which around 15 minutes is spent in dialogue with the avatar. The remaining 30 minutes will be used on preparing the patient for the confrontation with the avatar, evaluating on the interaction with the avatar, and use general cognitive behavioral techniques to reduce the auditory hallucination. The treatment is conducted with the use of virtual reality, so the participant will wear VR headset during treatment and watch and talk with the avatar shown in front of him or her.
62415328|NCT04661163|NO_INTERVENTION|Supportive counselling (comparison group)|The control group is offered seven session with health professionals providing supportive counselling. This can (but does not necessarily) involve psychotherapy targeting auditory hallucinations.
62415329|NCT01876628|PLACEBO_COMPARATOR|Flucloxacillin and Placebo oral capsule|Intravenous or oral Flucloxacillin with a Placebo oral capsule
62415330|NCT01876628|ACTIVE_COMPARATOR|Flucloxacillin and Clindamycin|Intravenous or oral Flucloxacillin with Clindamycin oral capsule
62415331|NCT05149807|EXPERIMENTAL|SHR-1701 + Tegafur Gimeracil Oteracil Potassium and Oxaliplatin|
62415332|NCT05149807|PLACEBO_COMPARATOR|Placebo + Tegafur Gimeracil Oteracil Potassium and Oxaliplatin|
62415333|NCT02827188|EXPERIMENTAL|Treatment group|Subjects randomly assigned to this arm will train on the Mega Team video game.
62221014|NCT00969709|EXPERIMENTAL|1|40 mg Levomilnacipran ER capsules, low dose, oral administration, once daily.
62415334|NCT02827188|NO_INTERVENTION|Control-waitlist group|Subjects randomly assigned to this arm will be the wait-list group. They are allowed to play the video games that they usually play.
62415335|NCT03113201|EXPERIMENTAL|Collabri Flex|Collaborative care
62415336|NCT03113201|EXPERIMENTAL|Consultation-Liaison|Consultations with general practitioner
62415337|NCT06566924|EXPERIMENTAL|Traditional Training Group|Students in the control group were taken to the laboratory practice within one week after the training presentation. Students were expected to act in accordance with the skills of isolation precautions in line with the 'Sample Scenario'. The individual in this scenario was an individual who was diagnosed with Covid-19 and suffered from anxiety due to isolation and neglected some rules. The performance of the students was evaluated with the Skill Evaluation Form for Isolated Patient Care. The students were asked to fill out the 'Satisfaction Survey on Training Methods' at the end of the application. Their opinions and suggestions regarding the training they attended were also taken.
62415338|NCT06566924|EXPERIMENTAL|Training Group for Standardised Patient Simulation|One week after the training presentation, the experimental group was invited to the simulation training. Simulation training was carried out in a hospital environment. Materials to be used in standardised patient and isolated patient care were made available in the room. The students were introduced to the field, scenario information on the subject and general principle frameworks. Students were included in groups in the simulation training created in line with the 'Simulation Scenario'. The scenario was prepared in line with the Healthcare Simulation Standards of Best PracticeTM of the International Nursing Association for Clinical Simulation and Learning (INACSL) standards (31) and submitted for expert opinion.
62415339|NCT05179434|EXPERIMENTAL|Retrograde graft reperfusion|Kidney transplantation with retrograde venous reperfusion of renal graft followed by arterial reperfusion
62415340|NCT05179434|ACTIVE_COMPARATOR|conventional antegrade perfusion|Kidney transplantation with conventional arterial reperfusion of renal graft (without retrograde venous reperfusion)
62415341|NCT04840628|EXPERIMENTAL|neural respiratory drive|neural respiratory drive assessed by EMGdi recorded from a multipair esophageal electrode
62415342|NCT06701162|OTHER|TAP group|Uktrasound-guided TAP block
62221015|NCT00969709|EXPERIMENTAL|2|80 mg Levomilnacipran ER capsules, medium dose, oral administration, once daily dosing
62221016|NCT00969709|EXPERIMENTAL|3|120 mg Levomilnacipran ER capsules, high dose, oral administration, once daily dosing
62415343|NCT06701162|OTHER|IIIH block|Ultrasound-guided Ilio-inguinal Ilio-Hypogastric Block
62415344|NCT01048411|ACTIVE_COMPARATOR|Naja-comp.|s.c. injection of naja comp (homeopathic remedy) three times a week
62415345|NCT01048411|PLACEBO_COMPARATOR|Placebo|s.c. injection of placebo (NaCl-solution) three times a week
62415346|NCT03847428|EXPERIMENTAL|Arm A|Durvalumab 1120 mg (Q3W) + bevacizumab 15 mg/kg (Q3W)
62415347|NCT03847428|EXPERIMENTAL|Arm B|Durvalumab 1120 mg (Q3W) + bevacizumab placebo (Q3W)
62587671|NCT00287989|EXPERIMENTAL|150 PRE|Erlotinib 150mg on days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200 mg/m2
62221017|NCT00969709|PLACEBO_COMPARATOR|4|Matching placebo capsules, oral administration, once daily.
62415348|NCT03847428|PLACEBO_COMPARATOR|Arm C|Durvalumab placebo (Q3W) + bevacizumab placebo (Q3W)
62415349|NCT01856257|ACTIVE_COMPARATOR|Thymoglobulin®+tacrolimus+MMF|Induction with Thymoglobulin®, methylprednisolone, and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF)
62415350|NCT01856257|EXPERIMENTAL|Thymoglobulin®+belatacept+MMF|Induction with Thymoglobulin®, methylprednisolone, and maintenance with belatacept and mycophenolate mofetil (MMF)
62415351|NCT01856257|EXPERIMENTAL|Basiliximab+20 weeks of tacrolimus+MMF + belatacept|"Induction basiliximab and methylprednisolone, administration of NULOJIX® (belatacept) 24 hours post reperfusion (+/-12 hrs); maintenance immunosuppression with 1. )20 week course of Prograf® (tacrolimus) or equivalent 2.) CellCept® (mycophenolate mofetil- MMF), or Myfortic® (mycophenolate sodium), or equivalent.~Subjects participating in this arm may have tacrolimus reinstated, at a dose to be determined by the site investigator, if any of the following events occur: 1 - An acute rejection episode 2- Request of the subject or site Investigator."
62415352|NCT04980391|EXPERIMENTAL|RSV_MAT Group|Maternal participants randomized to the RSV_MAT Group received a single dose of the RSV MAT vaccine administered, between 24 and 36 weeks of gestation, at Day 1 in this study.
62415353|NCT04980391|PLACEBO_COMPARATOR|Control Group|Maternal participants randomized to the Control Group received a single dose of Placebo administered, between 24 and 36 weeks of gestation, at Day 1 in this study.
62415354|NCT04980391|NO_INTERVENTION|RSV_MAT Group-Infant|This group consisted of infants born to mothers (from RSV_MAT Group-Mother) who received a single dose of RSV MAT vaccine during pregnancy.
62415355|NCT04980391|NO_INTERVENTION|Control Group-Infant|This group consisted of infants born to mothers (from Control Group-Mother) who received a single dose of placebo during pregnancy.
62415356|NCT03857945|ACTIVE_COMPARATOR|Mobility Device Training Group|Patients receiving preoperative mobility device(s) training before surgery
62415357|NCT03857945|NO_INTERVENTION|No Mobility Device Training Group|Patients not receiving preoperative mobility device(s) training before surgery
62415358|NCT06562673|EXPERIMENTAL|IA cisplatin plus endostatin|Intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) combined with systematic chemotherapy
62587672|NCT00287989|EXPERIMENTAL|1,500 PRE|Erlotinib 1500mg on Days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200mg/m2
62587673|NCT00287989|EXPERIMENTAL|1,500 POST|Carboplatin AUC6, Paclitaxel 200 mg/m2 followed by Erlotinib 1500mg days 2 and 3.
62415359|NCT06535347|NO_INTERVENTION|Control|This arm will receive no intervention outside of usual care.
62415360|NCT06535347|EXPERIMENTAL|Experimental: Schedule Follow-Up Visit - 1 message|This arm will receive a text message (at 1 day post-ED discharge) and information added to the patient's after visit summary providing a number and patient portal hyperlink via which to schedule an ED follow-up appointment.
62415361|NCT06535347|EXPERIMENTAL|Experimental: Schedule Follow-Up Visit - 2 messages|This arm will receive text messages (at 1 day and 8 days post-ED discharge) and information added to the patient's after visit summary providing a number and patient portal hyperlink via which to schedule an ED follow-up appointment.
62415362|NCT03159000|EXPERIMENTAL|GONB of lidocaine/bupivacaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion bilaterally. The subject will remain in the office for 30 minutes after injection, and receive a questionnaire to be filled out at 10 and 30 minutes, and 2 and 24 hours post-injection. Subjects who are not improved after 2 hours will be allowed to use their abortive treatment.
62415363|NCT03159000|PLACEBO_COMPARATOR|Placebo injection of 1/3 saline|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion bilaterally. The subject will remain in the office for 30 minutes after injection, and receive a questionnaire to be filled out at 10 and 30 minutes, and 2 and 24 hours post-injection. Subjects who are not improved after 2 hours will be allowed to use their abortive treatment.
62415364|NCT03208218|EXPERIMENTAL|SYP-1512|Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)
62415365|NCT03208218|ACTIVE_COMPARATOR|Revlimid cap.|Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I\&II D1(crossover)
62415366|NCT06581250|NO_INTERVENTION|Control|
62415367|NCT06581250|ACTIVE_COMPARATOR|Reminder Messages|
62221018|NCT02415673|EXPERIMENTAL|NiTi Af 37ºC|Patients were treatment with fixed orthodontics appliance and arch wire. Two nickel-titanium alignment and leveling sequences were employed - NiTi archwire: 0.012 in and 0.019 X 0.025 in; and thermal activated NiTi archwires: 0.018 in and 0.016 X 0.022 in with different austenite finish temperatures (37ºC).
62415368|NCT06581250|ACTIVE_COMPARATOR|Walk-in Visits|
62415369|NCT06581250|ACTIVE_COMPARATOR|Motivation-enhanced Communication|
62587674|NCT03809767|EXPERIMENTAL|CS1003 monoclonal antibody|
62587675|NCT02726711|EXPERIMENTAL|Trimethaphan|"The investigator will measure cardiac output by studying the air the participant breathes in and out. The participant will also wear a facemask to apply a low air pressure to the airway.~After this, the trimethaphan infusion will begin with a small dose and the investigators increase at 1-2 minute intervals for up to five doses. The measurements will be collected again.~Next, a standard blood pressure cuffs will be wrapped around the participant's abdomen. the cuff will inflate to apply pressure for 5 - 15 minutes."
62587676|NCT02726711|PLACEBO_COMPARATOR|Placebo|"The investigator will measure cardiac output by studying the air the participant breathes in and out. The participant will also wear a facemask to apply a low air pressure to the airway.~After this, the placebo (saline) infusion will begin with a small dose and the investigators increase at 1-2 minute intervals for up to five doses. The measurements will be collected again.~Next, a standard blood pressure cuffs will be wrapped around the participant's abdomen. the cuff will inflate to apply pressure for 5 - 15 minutes."
62796654|NCT03226743|EXPERIMENTAL|Intervention Group|collaborative and stepped care model for depressive, anxiety, somatoform and/or alcohol abuse disorders within a multiprofessional network
62796655|NCT03226743|NO_INTERVENTION|Control Group|treatment as usual in German health care system
62221019|NCT02415673|EXPERIMENTAL|NiTi Af 35ºC|Patients were treatment fixed orthodontics appliance and arch wire. Two nickel-titanium alignment and leveling sequences were employed - NiTi archwire: 0.012 in and 0.019 X 0.025 in; and thermal activated NiTi archwires: 0.018 in and 0.016 X 0.022 in with different austenite finish temperatures (35ºC)
62221020|NCT03516929|ACTIVE_COMPARATOR|high risk group|history of stroke or TIA, carotid bruit, left main stem disease, other peripheral vascular disease
62221021|NCT03516929|SHAM_COMPARATOR|low risk group|No history or stroke,TIA. NO left main stem disease
62221022|NCT00623402|EXPERIMENTAL|A|
62221023|NCT03912246|EXPERIMENTAL|Healthy volunteers|"Human biological samples:~whole blood (serum or plasma, PBMCs, red blood cells), urine, feces, saliva, tears, mouth and skin swabs.~Bio-clinical data :~adjusted to the purpose of the searches will be collected"
62221024|NCT03912246|EXPERIMENTAL|Patients with neuro-meningeal infection|"Human biological samples:~Whole blood (serum or plasma, PBMCs, red blood cells), urine, feces, saliva, tears, mouth and skin swabs.~Extended collection of CSF~Bio-clinical data :~adjusted to the purpose of the searches will be collected"
62221025|NCT03718130|EXPERIMENTAL|Group 1: 0.6 mg HTNV - Intradermal (ID)|0.1 mL 6.0 mg/mL HTNV DNA + 0.1 mL 0.9% saline (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
62221026|NCT03718130|EXPERIMENTAL|Group 2: 3.0 mg HTNV - Intramuscular (IM)|0.5 mL 6.0 mg/mL HTNV DNA + 0.5 mL 0.9% saline (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
62221027|NCT03718130|EXPERIMENTAL|Group 3: 0.6 mg PUUV - Intradermal (ID)|0.1 mL 6.0 mg/mL PUUV DNA + 0.1 mL 0.9% saline (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
62415370|NCT06581250|ACTIVE_COMPARATOR|Reminder Messages & Walk-in visits|
62415371|NCT06581250|ACTIVE_COMPARATOR|Reminder Messages & Motivation-enhanced Communication|
62415372|NCT06581250|ACTIVE_COMPARATOR|Walk-in visits & Motivation-enhanced Communication|
62415373|NCT06581250|ACTIVE_COMPARATOR|Reminder Messages, Walk-in visits, & Motivation-enhanced Communication|
62587677|NCT06491654|EXPERIMENTAL|Lymphedema experimental|Subjects belonging to this group perform a 12-week supervised exercise. The patients will follow a moderate-to-high intensity strength exercise protocol, along with the application of a cohesive bandage (bandage will only be applied in subjects with Breast Cancer-Related Lymphedema, BCRL, and not in patients at risk).
62221028|NCT03718130|EXPERIMENTAL|Group 4: 3.0 mg PUUV - Intramuscular (IM)|0.5 mL 6.0 mg/mL PUUV DNA + 0.5 mL 0.9% saline (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
62221029|NCT03718130|EXPERIMENTAL|Group 5: 1.2 mg HTNV/PUUV (0.6 mg each) - Intradermal (ID)|0.1 mL 6.0 mg/mL HTNV DNA + 0.1 mL 6.0 mg/mL PUUV DNA (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
62221030|NCT03718130|EXPERIMENTAL|Group 6: 6.0 mg HTNV/PUUV (3.0 mg each) - Intramuscular (IM)|0.5 mL 6.0 mg/mL HTNV DNA + 0.5 mL 6.0 mg/mL PUUV DNA (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
62587678|NCT06491654|NO_INTERVENTION|Healthy control|Subjects belonging to this group perform a 1-week supervised exercise, following the same training protocol as experimental group (arm 1). This group will not receive cohesive compressive bandage.
62587679|NCT05570786|EXPERIMENTAL|Gestrinone|Subdermal implant-bioabsorbable gestrinone pellet (85 mg) All patients will undergo insertion of an intrauterine system of levonorgestrel release (Kyleena®) as a contraceptive method
62221031|NCT03801915|EXPERIMENTAL|Cohort 1 - Pre-operative Escalation Doses of MVT-5873 (HuMab-5B1)|Pre-operative escalation doses of MVT-5873, pancreatectomy or hepatectomy and post-operative MVT-5873 treatment
62221032|NCT03801915|EXPERIMENTAL|Cohort 2 - Pre-operative Recommended Dose (RD) of MVT-5873 (HuMab-5B1)|Pre-operative RD of MVT-5873, pancreatectomy or hepatectomy and post-operative MVT-5873 treatment
62221033|NCT02104050|PLACEBO_COMPARATOR|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
62415374|NCT06180174|EXPERIMENTAL|MC-1-50 cell preparation|Patients will be be treated with CD19 CAR- T cells
62415375|NCT02272972||Retrospective group|One x-ray image per patient is assessed by the surgeon. The surgeon undergoes an educational intervention (video/poster) and applies the achieved knowledge during the second assessment of the same image. The intervention is not administered to patients, only to an image.
62415376|NCT02272972||Prosp.group (Application of knowledge)|No direct intervention at the patient. The surgeon applies the achieved knowledge during the performance of the fluoroscopy in the operating room. This image is assessed.
62415377|NCT05410769|EXPERIMENTAL|PD patients|The intervention envisaged by the study takes place in the form of interviews, self-reports, and measurement of the heart rate variability.
62415378|NCT05410769|EXPERIMENTAL|patient's caregivers|The intervention envisaged by the study takes place in the form of interviews, self-reports, and measurement of the heart rate variability.
62415379|NCT05714150|EXPERIMENTAL|Balance Intervention|Participants with TBI history and without TBI history will both complete the same intervention.
62415380|NCT03257774|EXPERIMENTAL|Test of three new adhesive strips|"The subjects test three new adhesive strips~* adhesive strip A~* adhesive strip B~* adhesive strip C"
62415381|NCT06150001|PLACEBO_COMPARATOR|dilute with normal saline|Researchers will dilute rocuronium at a dose of 0.8mg/kg with 2mL of normal saline. The rocuronium mixture will be injected into participants intravenous catheter.
62221034|NCT02104050|EXPERIMENTAL|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
62221035|NCT00462332|EXPERIMENTAL|High risk patientes|Category of risk will be defined according to biological features.
62221036|NCT00462332|EXPERIMENTAL|Low risk patients|Category of risk will be defined according to biological features.
62221037|NCT04540250||Study group of Rheumatoid arthritis patients|RA patients receiving MTX as monotherapy were included in the study. Patients suffering from systemic disease known to cause oral manifestations; salivary gland diseases and malignancies were excluded.
62221038|NCT01340638|ACTIVE_COMPARATOR|Cookgas|This group will be assigned to use cookgas mask
62221039|NCT01340638|ACTIVE_COMPARATOR|LMA mask|This group will be assigned to use LMA mask
62415382|NCT06150001|ACTIVE_COMPARATOR|dilute with 2%lidocaine|Researchers will dilute rocuronium at a dose of 0.8mg/kg with 2mL of 2%lidocaine. The rocuronium mixture will be injected into participants intravenous catheter.
62415383|NCT06150001|EXPERIMENTAL|dilute with investigator's blood|Researchers will dilute rocuronium at a dose of 0.8mg/kg with 2mL of blood. The rocuronium mixture will be injected into participants intravenous catheter.
62415384|NCT03039517|EXPERIMENTAL|ACTitouch - ACT-Adaptive Compression Therapy|a dual treatment pneumatic compression device offering two operational modes: sustained compression mode and intermittent compression mode. The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
62415385|NCT03039517|EXPERIMENTAL|Standard Compression Stocking|The control group will receive care using elastic compression stocking.
62415386|NCT04208165|ACTIVE_COMPARATOR|Group P (ultrasound-guided PVB)|In group P, the patient is in sitting position, a linear transducer (6-15 MHz) placed just lateral to the spinous process. Once the transverse processes and ribs are identified, the transducer is moved slightly cauded into the intercostal space between adjacent ribs to identify the thoracic paravertebral space (PVS) and the adjoining intercostal space. The hyper echoic line of the pleura and underlying hyper echoic air artifacts move with respiration. The needle stimuplex needle will be inserted and 0.5- 1 ml local anesthetic injection administered to show the displacement of pleura downward followed by 15 cc bupivacaine 0.25% into each side the PVS. A pop often is felt as the needle penetrates the internal intercostal membrane. Intravascular injection will be eliminated by negative aspiration before injection. Local anesthetic (15- 20 ml) is slowly injected in small increments, avoiding forceful high-pressure injection to reduce the risk of bilateral epidural spread.
62415387|NCT04208165|ACTIVE_COMPARATOR|Group T (ultrasound-guided TAB)|In group T, Subcostal blockage will be done in plane technique with 22 G needle (BRAUN Stimuplex D Plus 0,71 50- 80 mm 22 G). The puncture area and the ultrasound probe will be prepared in an aseptic manner. The ultrasound probe is placed in a transverse plane to the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest. On each side, The rectus abdominis and underlying transverses abdominis muscles near the costal margin and xiphoid process will be identified. In-plane image will be obtained and the needle will be inserted through the rectus muscle 2-3 cm medial to the probe. Once the tip of the needle is visualized to be in the plane, 0.25% bupivacaine will be administered incrementally. The drug will be injected along the oblique subcostal line, extending inferolaterally from the xiphoid towards the anterior part of the iliac crest by multiple punctures; a total of 15 ml will be given on each side.
62415388|NCT01909752|EXPERIMENTAL|DRibble Vaccine Alone|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
62415389|NCT01909752|EXPERIMENTAL|DRibble vaccine with imiquimod|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4) and for four days following each vaccine cycle. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
62415390|NCT01909752|EXPERIMENTAL|DRibble vaccine with GM-CSF|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
62587680|NCT05570786|PLACEBO_COMPARATOR|Placebo|Subdermal implant-bioabsorbable placebo pellet (cholesterol) All patients will undergo insertion of an intrauterine system of levonorgestrel release (Kyleena®) as a contraceptive method
62587681|NCT04443062|EXPERIMENTAL|Interventional arm: 177Lu-PSMA radioligand therapy|2 (+2) cycles of 7.4 GBq 177Lu-PSMA 6 weeks in between
62221040|NCT05557227|EXPERIMENTAL|Galactose|30 g in 200 ml liquid
62587682|NCT04443062|NO_INTERVENTION|Standard of care|Deferred androgen deprivation therapy. However, the control arm can receive the study drug (177Lu-PSMA) in case of disease progression (defined in the study protocol).
62024255|NCT05531539|EXPERIMENTAL|Outpatient Respiratory patients|They were examined with spirometry, manual auscultation of the thorax and where necessary, with chest X-ray or CT scan. They wore the WELMO sensors vest for a period of 15-20 minutes during which they performed tidal and deep breathing, cough and spirometry maneuvers and changes of posture. At the end of the study, they were requested to fill in a questionnaire about comfort and usability of the vest.
62024256|NCT05531539|EXPERIMENTAL|Hospitalized Respiratory patients|They were examined with spirometry, manual auscultation of the thorax and where necessary, with chest X-ray or CT scan. They wore the WELMO sensors vest for a period of 15-20 minutes during which they performed tidal and deep breathing, cough and spirometry maneuvers and changes of posture. At the end of the study, they were requested to fill in a questionnaire about comfort and usability of the vest.
62024257|NCT05531539|EXPERIMENTAL|Critically ill Respiratory patients|They were examined with manual auscultation of the thorax and where necessary, with chest X-ray or CT scan. They wore the WELMO sensors vest for a period of 15-20 minutes during which the vest recorded the breathing provided by the mechanical ventilator.
62024258|NCT06122766||N-glycanase 1 (NGLY1) Deficiency|
62024259|NCT04944875|ACTIVE_COMPARATOR|Group I; group headphone|In the first group of the patients in the isolation group wear the headphones but do not listen to music during the procedure. Then patients were sedated by midazolam and propofol.
62024260|NCT04944875|ACTIVE_COMPARATOR|Group II; group music|"In the second group of the patients wear the headphones and listen to Vivaldi's The Four Seasons violin concertos by sound isolating headphones during the procedure.~Then patients were sedated by midazolam and propofol."
62024261|NCT04944875|ACTIVE_COMPARATOR|Group III; group maternal voice|In the third group of the patients wear the headphones and listen the maternal voice during the procedure.Then patients were sedated by midazolam and propofol.
62024262|NCT02430025||control subjects|people had no clinical history of cardiovascular diseases,no family history of premature cardiovascular diseases.
62415391|NCT05425823|EXPERIMENTAL|Education and message|"In Intervention Group 1, a face-to-face training session based on the Health Belief Model will be given once a week and SMS-based short messages will be sent to the spouse.~Vaccination rates of children in the intervention group-1 in the study at the end of the 1st, 6th and 12th months will be evaluated. Public Attitudes Towards Vaccination Scale-Health Belief Model sub-dimensions (severity, susceptibility, benefit, barrier, health motivation) scores of the intervention group-1 at the 1st, 6th, and 12th months after birth will be evaluated."
62415392|NCT05425823|EXPERIMENTAL|Education|"In Intervention Group 2, face-to-face training will be provided one day a week based on the Health Belief Model.~Vaccination rates of children in the intervention group-2 in the study at the end of the 1st, 6th and 12th months will be evaluated. Public Attitudes Towards Vaccination Scale-Health Belief Model sub-dimensions (severity, susceptibility, benefit, barrier, health motivation) scores of the intervention group-2 at the 1st, 6th, and 12th months after birth will be evaluated."
62415393|NCT05425823|NO_INTERVENTION|Standard Care Group|"Standard information about childhood vaccines will be provided to the Standard Care Group at the Family Health Care Center.~Vaccination rates of children in the Standard Care Group in the study at the end of the 1st, 6th and 12th months will be evaluated. Public Attitudes Towards Vaccination Scale-Health Belief Model sub-dimensions (severity, susceptibility, benefit, barrier, health motivation) scores of the Standard Care Group at the 1st, 6th, and 12th months after birth will be evaluated."
62024263|NCT02430025||coronary atherosclerosis|Subjects with CAD also had at least one \<50% stenotic lesion on coronary angiography.
62415394|NCT00795483|EXPERIMENTAL|1-ANNUAL|1. Zoledronic acid + Lifestyle modifications (experimental)
62415395|NCT00795483|OTHER|2-CONTROL|2. Lifestyle modifications (control)
62415396|NCT00795483|EXPERIMENTAL|3-BIENNIAL|3. Zoledronic acid + Lifestyle modifications (experimental)
62415397|NCT06569030|OTHER|Individuals with Adolescent Idiopathic Scoliosis Who Receive Spinal Orthosis|
62587683|NCT03299426|EXPERIMENTAL|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Children will receive a single 0.5-ml dose of Vi-TCV administered by the intramuscular route.
62587684|NCT03299426|ACTIVE_COMPARATOR|Meningococcal A Conjugate Vaccine (MCV-A)|Children will receive a single dose of MCV-A administered by the intramuscular route. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
62587685|NCT04764331|OTHER|Intervention|Caps will be provided for each subjects will use the cap once daily for10-minute treatment regimen
62587686|NCT04288687|OTHER|Niraparib Arm (only arm)|Niraparib 200 mg by mouth daily (2 x 100 mg pills) on a 28 day cycle
62587687|NCT06682013|EXPERIMENTAL|Virtual agent|
62587688|NCT06682013|ACTIVE_COMPARATOR|Human agent|
62587689|NCT00833482|ACTIVE_COMPARATOR|Voriconazole, 200 mg BID (EM)|
62587690|NCT00833482|ACTIVE_COMPARATOR|Atazanavir/Ritonavir, 300/100 QD (EM & PM)|
62221041|NCT05557227|EXPERIMENTAL|Lactose|30 g in 200 ml liquid
62221042|NCT05557227|EXPERIMENTAL|Dextrose|30 g in 200 ml liquid
62221043|NCT05557227|EXPERIMENTAL|Water|200 ml liquid sweetened
62221044|NCT05347043|EXPERIMENTAL|Intervention|All patients will undergo both the MoCA test and the standardized neuropsychological evaluation Montreal cognitive assessment and standardized neuropsychological evaluation (Test of Attentional Performance of Zimmermann and Fimm ; Wechsler Adult Intelligence Scale 4th version digit span ; Wechsler memory scale III, spatial span ; Wisconsin Card Scoring Test, GREFEX version ; Wechsler Adult Intelligence Scale 4th version block design ; Six elements test GREFEX version; free and cued selective reminding test, 16 items, B version ; Behavioral Rating Inventory of Executive Function ; Modified Fatigue Impact Scale)
62221045|NCT04971278||HealthFirst Intervention|Patients attributed to HealthFirst who will receive the intervention
62221046|NCT04971278||HealthFirst Control|Patients attributed to HealthFirst who will not receive the intervention
62221047|NCT04971278||Mortality Model Intervention|Patients who are identified as High Risk by the mortality predictive model and who receive the intervention.
62221048|NCT04971278||Mortality Model Control|Patients who are identified as High Risk by the mortality predictive model and who do not receive the intervention.
62221049|NCT02503189|EXPERIMENTAL|KCT-0809|
62221050|NCT02503189|PLACEBO_COMPARATOR|Placebo|
62024264|NCT02430025||stable coronary artery disease|Subjects with stable CAD had clinically established atherosclerotic vascular disease but had been stable for ≥3 months.
62024265|NCT02430025||acute coronary syndrome|Subjects with CAD also had at least one ≥50% stenotic lesion on coronary angiography or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting. All subjects with ACS exhibited acute ECG changes consistent with myocardial ischemia or elevated troponin levels. ACS was confirmed with urgent coronary angiography; all subjects had at least one ≥50% stenotic lesion with ruptured plaque or thrombus.
62024266|NCT04894253||Single group of 30 patients with systemic lupus|
62024267|NCT02872064|EXPERIMENTAL|Treatment with PDT|A single intravenous injection of Verteporfin (0.4mg/kg) will be administered, at least 60minutes and up to 90 minutes before laser activation. A 690nm red laser light will be delivered with a diffuser laser fibre inserted through the skin into the breast tissue, with light dose escalation after every three patients. All patients will have fixed dose of the photosensitizer but variable light dose.
62221051|NCT05497973|EXPERIMENTAL|eHealth ecosystem of stepped psychosocial care|"Patients will be monitored allowing the delivery of timely and personalized care via a 4-level program:~1. Screening and psychosocial monitoring through a mobile application where patients have a messaging system to contact their psychologist and reference nurse.~2. Psychoeducation and health education campus, where patients can consult videos and online resources developed by health professionals, containing scientifically validated information.~3. Psychosocial support community where patients can share doubts, fears, and experiences with other patients with advanced lung cancer. This private social network is monitored by team specialists when necessary.~4. Online group psychotherapy of 8 weekly sessions of 90 minutes based on Meaning-Centered Group Psychotherapy (MCGP; Breitbart et al., 2010). Patients at this level will be on a waiting list, so the pool starts when there are 4-8 users available."
62415398|NCT04184882|EXPERIMENTAL|ASP0367 group|Participants will be dosed investigational product (IP) at the low dose for 2 weeks and then at the high dose for 10 weeks with the total duration of 12 weeks in the DB part and OLE part, respectively.
62415399|NCT04184882|PLACEBO_COMPARATOR|Placebo to ASP0367 group|Participants will be dosed matching placebo in the DB part. In OLE part, participants will dosed IP at the low dose for 2 weeks and then at the high dose for 10 weeks with the total duration of 12 weeks.
62415400|NCT03712046|EXPERIMENTAL|Main arm|PET-CT imaging of the ankles and feet following injection of 18F-FDG
62415401|NCT05492877|PLACEBO_COMPARATOR|Placebo|Approximately 203 participants will be randomised to receive placebo.
62415402|NCT05492877|EXPERIMENTAL|Mitiperstat (AZD4831)|Approximately 203 participants will be randomised to receive mitiperstat (AZD4831).
62415403|NCT02292407|EXPERIMENTAL|LigaSure Precise instrument|ALND with use of LigaSure Precise instrument, closure of dead space, omission of a postoperative drain.
62415404|NCT02502565||Uric Acid Level|
62415405|NCT02204449|EXPERIMENTAL|Cardiac Rehabilitation Peer Mentorship|Trained cardiac rehabilitation (CR) peer mentors will visit cardiac inpatients in the hospital to provide patients with information on CR. During this visit the CR mentors will discuss the benefits of CR, stress the importance of getting a referral, and arrange a time to call the patient/participant at home to find out about their CR progress. One week post-discharge the peer mentor will mail a card to the patient to remind them of the planned call. Two weeks post-discharge the peer mentor will call the patient at home to determine if they were referred and if they are planning to attend CR. If any barriers are stated by patient the peer mentors will work with the patient to develop possible solutions. Patients can request up to two additional phone calls from the mentors.
62415406|NCT02204449|NO_INTERVENTION|Usual Care|Cardiac inpatients will not be visited by the cardiac rehabilitation (CR) peer mentor. They will instead receive usual care involving care from health care providers (i.e. nurses and doctors) as well as allied health professionals such as physiotherapists. In addition, some may be visited by general volunteer cardiac mentors.
62415407|NCT00480363|EXPERIMENTAL|1|Lenalidomide + Dexamethasone for 9 cycles and maintenance
62415408|NCT00480363|NO_INTERVENTION|2|Observation
62415409|NCT05631652|EXPERIMENTAL|PillSense System|All subjects were asked to swallow a PillSense Capsule, followed by the ingestion of autologous blood mixed with water, to verify the ability of the PillSense System to correctly identify blood.
62415410|NCT01244516|OTHER|galyfilcon A|Subjects that were randomized to receive the galyfilcon A lens with a base curve of 8.30 throughout the entire course of the study.
62415411|NCT01244516|OTHER|lotrafilcon B|Subjects that were randomized to wear lotrafilcon B lens throughout the course of the study.
62415412|NCT01244516|OTHER|comfilcon A|Subjects that were randomized to wear comfilcon A lens throughout the course of the study.
62415413|NCT05083559|EXPERIMENTAL|MPC AP system|Participants will use the MPC AP system for automated insulin delivery for a 9 hour study visit.
62415414|NCT05083559|EXPERIMENTAL|Robust R-AP system|Participants will use the Robust R-AP system for automated insulin delivery for a 9 hour study visit.
62415415|NCT06701032|EXPERIMENTAL|Cardiovascular rehabilitation program|
62415416|NCT05065957|EXPERIMENTAL|Phase IIa:Dose-Finding Stage|"Level -5: 20 mg D07001-softgel capsules plus 625 mg/m\^2 Xeloda (or 20/30/40 mg TS-1).~Level -4: 40 mg D07001-softgel capsules plus 625 mg/m\^2 Xeloda (or 20/30/40 mg TS-1).~Level -3: 60 mg D07001-softgel capsules plus 625 mg/m\^2 Xeloda (or 20/30/40 mg TS-1).~Level -2: 80 mg D07001-softgel capsules plus 625 mg/m\^2 Xeloda (or 20/30/40 mg TS-1).~Level -1 (starting dose): 100 mg D07001-softgel capsules plus 625 mg/m\^2 Xeloda (or 20/30/40 mg TS-1).~Level 1: 100 mg D07001-softgel capsules plus 800 mg/m\^2 Xeloda (or 30/40/50 mg TS-1).~Level 2: 100 mg D07001-softgel capsules plus 1000 mg/m\^2 Xeloda (or 40/50/60 mg TS-1)."
62415417|NCT05065957|ACTIVE_COMPARATOR|Phase IIb/III: Dose Expansion Stage|"ASC+ D07001-softgel capsules plus Xeloda (or TS-1)~ASC+mFOLFOX (5-FU+Oxalipatin+folinic acid)"
62415418|NCT05302037|EXPERIMENTAL|Dose-Escalation Arm|Four infusions of CTM-N2D at escalating doses: 1x10\^7, 1x10\^8, 3x10\^8 or 1x10\^9 per infusion at an interval of one infusion every 7 days.
62415419|NCT05302037|EXPERIMENTAL|Optimal Dose Arm|Four infusions of CTM-N2D at the optimal dose (expected to be 1x10\^9) at an interval of one infusion every 7 days.
62587691|NCT00833482|ACTIVE_COMPARATOR|Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)|
62587692|NCT00833482|ACTIVE_COMPARATOR|Voriconazole, 50 mg BID (PM)|
62587693|NCT00833482|ACTIVE_COMPARATOR|Atazanavir/ritonavir, 300/100mgQD+voriconazole, 50mgBID (PM)|
62587694|NCT06664047|ACTIVE_COMPARATOR|OTT ACLR|Patients in this group will undergo a reconstruction with the OTT technique which includes an intra-articular component and an extra-articular one, functioning as a LET.
62796656|NCT04459507||Participants With Palmoplantar pustulosis (PPP)|Participants treated with a new systemic therapy for their PPP, having had an inadequate response to a prior PPP therapy either as their first systemic therapy or as a switch from, or addition to, a previous systemic therapy will be observed. Participants will be treated in accordance with routine clinical practice in Japan in the outpatient specialist care setting. The primary data source for this study will be the medical records of each participant.
62796657|NCT04236362|EXPERIMENTAL|TQB2450+Anlotinib|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
62796658|NCT03959059|EXPERIMENTAL|PKP of traditional procedure|traditional method of PKP
62796659|NCT01558947|EXPERIMENTAL|chemotherapy with ECX|chemotherapy with ECX
62796660|NCT01558947|EXPERIMENTAL|chemotherapy with XP|chemotherapy with XP
62796661|NCT02768779||HIV negative and positive individuals|HIV Negative or HIV positive individuals, aged 18 years or older, who have been taking their ARV medication for at least 3 months and are adherent based on blood plasma HIV RNA of \<50 copies/mL or HIV negative status. Hair analysis.
62796662|NCT02733523|EXPERIMENTAL|"Program Sentirnos bien"|"The intervention Program Sentirnos bien is based around a group dynamic, held once a week during 3 months, aimed at:~1. Promoting the uptake of self-care healthy habits~2. Promoting social capital at individual level:~3. Promoting health literacy"
62796663|NCT02733523|NO_INTERVENTION|Control arm|The control arm will receive no intervention. Once the trial is finished, i.e. after the last follow-up evaluation, this arm will receive the intervention (waiting-list approach).
62796664|NCT03306992|EXPERIMENTAL|Personalized Exercise Program|
62796665|NCT03306992|NO_INTERVENTION|Standard of Care - No Exercise|
62796666|NCT06727136|EXPERIMENTAL|Part A: Cohort 1|Participants will receive TBP-PI-HBr, 900 milligrams (mg) tablets orally, as a single dose under fasted condition on Day 1.
62796667|NCT06727136|EXPERIMENTAL|Part A: Cohort 2 (Fasted/Fed)|Participants will receive TBP-PI-HBr, 1200 mg, tablets, orally, as a single dose under fasted and fed conditions on Day 1 and Day 3, as per the assigned crossover sequence.
62221052|NCT05497973|ACTIVE_COMPARATOR|Usual psychosocial care|This group will receive standard psychosocial care for cancer survivors at ICO Hospitalet center led by a clinical psychologist. It consists of 7 individual sessions of 45-60 minutes, scheduled every 2-3 weeks during 9 months and focused on emotional support and psychoeducation. Moreover, they will be offered the education materials from the 2nd step of the platform, as they are compiled in a website open to all patients and relatives.
62221053|NCT01280162|EXPERIMENTAL|3 day therapy|Total dose split over 3 days (3 tablets per day)
62221054|NCT01280162|EXPERIMENTAL|2 day therapy|Total dose split over 2 days (4.5 tablets per day)
62221055|NCT06433960||Cardiovascular sample group|Cardiac patients undergoing elective or urgent coronary artery bypass graft surgery and radial artery harvest in two Cardiothoracic hospitals.
62587695|NCT06664047|ACTIVE_COMPARATOR|ACLR LET|Patients in this group will undergo a reconstruction with the conventional ACL technique accompanied by a routine LET, obtained from the iliotibial band.
62221056|NCT00986973|EXPERIMENTAL|Sapropterin (KUVAN)|All subjects will receive Sapropterin (KUVAN) therapy at a dose of 20/mk/kg/day for four months.
62415420|NCT00819091|ACTIVE_COMPARATOR|BI 1356|5 mg orally (po) once daily
62587696|NCT02952846|NO_INTERVENTION|Before algorithm|Observational
62796668|NCT06727136|EXPERIMENTAL|Part B: Cohort 3|Participants will receive TBP-PI-HBr, 600 mg, orally as a single dose on Day 1, followed by 9 doses every 6 hours from Day 3 through Day 5. (first and ninth dose will be given under fasted conditions).
62796669|NCT06243640|EXPERIMENTAL|High-dose experimental group|Subjects took 120mg per day of Buagafuran capsules after breakfast and dinner for 8 weeks
62796670|NCT06243640|EXPERIMENTAL|Low-dose experimental group|Subjects took 60mg per day of Buagafuran capsules and Buagafuran capsules mimic after breakfast and dinner for 8 weeks
62796671|NCT06243640|PLACEBO_COMPARATOR|Placebo-Control group|Subjects took 0 mg per day Buagafuran capsules mimic after breakfast and dinner for 8 weeks
62796672|NCT05102864|ACTIVE_COMPARATOR|Active intermittent Theta Burst Stimulation|Participants will complete 10 daily sessions of active iTBS to the left dorsolateral prefrontal cortex
62796673|NCT05102864|SHAM_COMPARATOR|Sham intermittent Theta Burst Stimulation|Participants will complete 10 daily sessions of sham iTBS to the left dorsolateral prefrontal cortex
62221057|NCT03009760|EXPERIMENTAL|CJ-12420 50mg(HP-)|CJ-12420 50mg in H. pylori negative subject
62415421|NCT00819091|PLACEBO_COMPARATOR|Placebo|one tablet once daily
62587697|NCT02952846|EXPERIMENTAL|After algorithm|Algorithm for tapering of analgosedation
62587698|NCT04582929|EXPERIMENTAL|50 unit of Neubotulinum Toxin Type A (Neuronox)|50 unit of Neubotulinum Toxin Type A (Neuronox) injection for Cervical Dystonia in patient diagnosed with cervical dystonia according to clinical diagnosis
62587699|NCT04582929|EXPERIMENTAL|100 unit of Neubotulinum Toxin Type A (Neuronox)|100 unit of Neubotulinum Toxin Type A (Neuronox) injection for Cervical Dystonia in patient diagnosed with cervical dystonia according to clinical diagnosis
62796674|NCT04751318|EXPERIMENTAL|Duloxetine Test Produc|Participants will receive one capsule of the test formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a feeding condition.
62796675|NCT04751318|ACTIVE_COMPARATOR|Duloxetine Referent Product|Participants will receive one capsule of the marketed reference formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a feeding condition.
62796676|NCT01054456|EXPERIMENTAL|All Participants: Palonosetron 0.25 mg/5 mL|Participants will receive palonosetron 0.25 milligram (mg) per (/) 5 milliliter (mL) intravenous injection 30 minutes prior to receiving a low emetogenic chemotherapy (LEC) agent on Day 1.
62221058|NCT03009760|EXPERIMENTAL|CJ-12420 100mg(HP-)|CJ-12420 100mg in H. pylori negative subject
62221059|NCT03009760|EXPERIMENTAL|CJ-12420 50mg(HP+)|CJ-12420 50mg in H. pylori positive subject
62221060|NCT03009760|EXPERIMENTAL|CJ-12420 100mg(HP+)|CJ-12420 100mg in H. pylori positive subject
62587700|NCT03065959|EXPERIMENTAL|CK-2127107, then Placebo|Participants will first receive CK-2127107 tablets (twice daily) for 14 days. After a 14 day wash out period participants will then receive matching placebo.
62024268|NCT04092660|EXPERIMENTAL|Intervention Care Group|"The Intervention care group will receive the Mandibular Advancement Appliance (MAA) or the anti-snoring mouthguard. Additionally, they will also receive special support in the form of behaviour change interventions. The behavior change interventions consist of motivational interviewing, will be shown a video highlighting the negative consequences of sleep apnoea.~Booster calls at week 3,6, 18 and 12 for verbal encouragement and to resolve any technical problems with the device.~Participants will be asked to complete questionnaires regarding their personality, socio-economic status, social support and quality of sleep and life."
62796677|NCT05848895|EXPERIMENTAL|Osteopathic Manipulative Treatment|Patients will be treated once a week with OMT x 8 weeks
62796678|NCT05848895|ACTIVE_COMPARATOR|Standard of Care Repositioning|Patients will only receive repositioning only x 8 weeks and all parents will receive standardized materials to counsel/instruct on the repositioning
62024269|NCT04092660|ACTIVE_COMPARATOR|Standardized Care Group|"The standardized care group will only receive the Mandibular Advancement Appliance (MAA) or the anti-snoring mouthguard along with routine care and will be called for follow up at 3rd and 6th month of treatment to assess their use and to resolve any technical problems with the device.~Participants will be asked to complete questionnaires regarding their personality, socio-economic status, social support and quality of sleep and life at the initial visit and subsequent follow-up."
62024270|NCT06068686|EXPERIMENTAL|Vildagliptin|Group I (N=35) are patients who the endocrinologist prescribed them Vildagliptin 50mg /tab plus their Metformin 500mg /tab once daily for 12 weeks to control their blood sugar level.
62024271|NCT06068686|ACTIVE_COMPARATOR|Glimepiride|Group II (N=35) are patients who the endocrinologist prescribed them Glimepiride 3mg / tab plus Metformin 500mg /tab once daily for 12 weeks.
62024272|NCT01012882|EXPERIMENTAL|sublingual application of allergen extract|
62415422|NCT06146517|EXPERIMENTAL|Clevr Blends Arm|"Weeks 1-4: Participants will take one 6 oz serving daily of Clevr Blends Sleeptime 20 - 60 minutes before bed. The product comes with a scoop that measures 3 tsp. Participants should mix a full scoop with 6oz of water and froth using the frother that will be provided.~Weeks 5-8: Participants will take one serving daily of Clevr Blends Matcha, before 1pm. The product comes with a scoop that measures 3 tsp. Participants should mix a full scoop with 6oz of water and froth using the frother that will be provided.~Weeks 9-12: Participants will take one serving daily of Clevr Blends Chai, before 1pm. The product comes with a scoop that measures 3 tsp. Participants should mix a full scoop with 6oz of water and froth using the frother that will be provided."
62415423|NCT04044365||1/Project 1 Child/caregiver-proxy|Children age 5-7 with cGVHD and their caregiver, n=20 child/parent dyads
62415424|NCT04044365||2/Project 1 Child/caregiver-proxy|Children age 8-12 with cGVHD and their caregiver, n=35 child/parent pairs
62415425|NCT04044365||3/Project 1 Child/caregiver-proxy|Children age 13-17 with cGVHD and their caregiver, n=35 child/parent pairs
62415426|NCT04044365||4/Project 2 Child/caregiver-proxy|Children age 5-7 with cGVHD and their caregiver, n=40 child/parent pairs
62415427|NCT04044365||5/Project 2 Child/caregiver-proxy|Children age 8-12 with cGVHD and their caregiver, n=40 child/parent pairs
62415428|NCT04044365||6/Project 2 Child/caregiver-proxy|Children age 13-17 with cGVHD and their caregiver, n=40 child/parent pairs
62415429|NCT06536868|EXPERIMENTAL|ICI+EC/EP+TRT|Drug: Tislelizumab Drug: Carboplatin Drug: Etoposide Radiation: Radiation therapy Drug: Cisplatin
62415430|NCT06701942|EXPERIMENTAL|Multiple family group therapy intervention arm|"ALHIV and their families will be invited to participate in 16 program sessions, each lasting 90 minutes, and will be held on clinic days over a period of 14 weeks.~The MFG will combine group discussions and activities fostering support, learning and interaction both within the family and among families. The MFG intervention will be delivered by parent peers and community health workers trained by the study team"
62587701|NCT03065959|EXPERIMENTAL|Placebo, then CK-2127107|Participants will first receive Placebo tablets (twice daily) for 14 days. After a 14 day wash out period participants will then receive matching CK-2127107.
62587702|NCT04779528|EXPERIMENTAL|Group S|Patients will undergo fiberoptic intubation in supine position.
62587703|NCT04779528|EXPERIMENTAL|Group L|Patients will undergo fiberoptic intubation in lateral position.
62587704|NCT03054298|ACTIVE_COMPARATOR|Cohort 1|Single dose of 1-3x10\^7 huCARTmeso cells/m\^2
62587705|NCT03054298|ACTIVE_COMPARATOR|Cohort 2|Cyclophosphamide 1 gram/m\^2 administered 2-4 days prior to a single dose of 1-3x10\^7 huCARTmeso cells/m\^2
62587706|NCT03054298|ACTIVE_COMPARATOR|Cohort 3|PERMANENTLY CLOSED
62587707|NCT03054298|ACTIVE_COMPARATOR|Cohort 4|PERMANENTLY CLOSED
62024273|NCT01012882|PLACEBO_COMPARATOR|sublingual application of placebo|
62024274|NCT02792582|ACTIVE_COMPARATOR|Tumor-Surgery|"Participants who are eligible to undergo surgery to remove the tumor will proceed to surgery. If all tumor is removed, they will be followed over 5 years for outcome comparison to the other participant groups.~If the entire tumor is not removed by surgery, participants will receive 6 weeks of proton therapy. They will then be followed for 5 years to collect outcome data for comparison to the other participant groups."
62587708|NCT03054298|ACTIVE_COMPARATOR|Cohort 5|Single dose of 1-3x10\^7 huCART-meso cells/m\^2 day 0 by intrapleural infusion (IP) through an indwelling pleural catheter without any conditioning chemotherapeutic regimen.
62024275|NCT02792582|ACTIVE_COMPARATOR|Tumor-No Surgery|Participants whose tumor cannot be resected through surgery will receive 6 weeks of proton therapy. They will then be followed over 5 years for outcome comparison to the other participant groups.
62024276|NCT06319885|EXPERIMENTAL|Gain-framed|One daily text-message and weekly alcohol use assessment. The text-messages focus on the positive consequences of drinking less.
62415431|NCT06701942|NO_INTERVENTION|Control Arm|Clinic allocated to the control group will continue with treatment as usual. This group will not receive the MFGT until after the study period when they may be considered to also receive the intervention to ensure all participants eventually benefit from the program. Until then, the control group will receive the usual standard of care including adherence counselling, adherence support, health education and medical care.
62415432|NCT04666012|EXPERIMENTAL|Group 1: low dose|Subject will receive single dose of AdCLD-CoV19(2.5x10\^10VP) as intramuscular injection.
62415433|NCT04666012|EXPERIMENTAL|Group 2: middle dose|Subject will receive single dose of AdCLD-CoV19(5.0x10\^10VP) as intramuscular injection.
62587709|NCT03054298|ACTIVE_COMPARATOR|Cohort 6|Cyclophosphamide 1 gram/m\^2 administered 2-4 days prior to dose of 1-3x10\^7 huCART-meso cells/m\^2 via IV infusion on Day 0. This initial infusion may be followed by up to two additional IV infusions of huCART-meso cells at the same dose level, given approximately 21-42 days apart, if the subject meets eligibility to receive additional infusions. Cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells.
62024277|NCT06319885|EXPERIMENTAL|Loss-framed|One daily text-message and weekly alcohol use assessment. The text-messages focus on the negative consequences of a high alcohol-intake.
62024278|NCT06319885|EXPERIMENTAL|Static-tailored|One daily text-message and weekly alcohol use assessment. The text-messages are adapted to the participant's gender and to baseline information on (e.g.) participants' drinking patterns, social network, and self-efficacy. One message per week is adapted to the day on which the participants find it most challenging to reduce their drinking.
62024279|NCT06319885|EXPERIMENTAL|Adaptive-tailored|One daily text-message and weekly alcohol use assessment. The text-messages are adapted to the participant's gender and to baseline information on (e.g.) participants' drinking patterns, social network, and self-efficacy. One message per week is adapted to the day on which the participants find it most challenging to reduce their drinking. In addition, text messages are adapted to the weekly alcohol-assessment over time and participants can demand supportive Just-In-Time messages.
62221061|NCT06126731|EXPERIMENTAL|mCRPC patients dose with a combination of enzalutamide and antibiotics|"Phase I:~The evaluation of the safety and tolerability of the combinations of amoxicillin plus metronidazole, and ciprofloxacin plus vancomycin with enzalutamide.~Phase II:~Determination of the anti-tumour activity of the combinations of amoxicillin plus metronidazole, and ciprofloxacin plus vancomycin with enzalutamide."
62024280|NCT06319885|EXPERIMENTAL|Combined|This arm combines all features of the arms Adaptive-tailored and Gain-framed.
62024281|NCT06319885|NO_INTERVENTION|Assessment-only|The control group. Participants do only receive 4 questions on their alcohol intake once a week.
62024282|NCT03391648||Cesarean|
62221062|NCT05216432|EXPERIMENTAL|RLY-2608 for patients with unresectable or metastatic solid tumors|Multiple doses of RLY-2608 for oral administration.
62221063|NCT05216432|EXPERIMENTAL|RLY-2608 + fulvestrant combination for HR+ HER2- locally advanced or metastatic breast cancer|Oral dose of RLY-2608 in addition to fulvestrant as determined during Part 1 Dose Escalation.
62221064|NCT05216432|EXPERIMENTAL|RLY-2608+fulvestrant+palbociclib 125 mg for HR+ HER2- locally advanced or metastatic breast cancer|Oral dose of RLY-2608 in addition to fulvestrant and palbociclib 125mg as determined during Part 1 Dose Escalation.
62221065|NCT05216432|EXPERIMENTAL|RLY-2608+fulvestrant+ribociclib 400 mg for HR+ HER2- locally advanced or metastatic breast cancer|Oral dose of RLY-2608 in addition to fulvestrant and ribociclib 400mg as determined during Part 1 Dose Escalation.
62221066|NCT05216432|EXPERIMENTAL|RLY-2608+fulvestrant+ribociclib 600 mg for HR+ HER2- locally advanced or metastatic breast cancer|Oral dose of RLY-2608 in addition to fulvestrant and ribociclib 600mg as determined during Part 1 Dose Escalation.
62221067|NCT05018221|PLACEBO_COMPARATOR|Placebo (Double-Blind Period)|Placebo Vitamin K1 Placebo Magnesium Citrate Placebo Sodium Thiosulphate
62221068|NCT05018221|EXPERIMENTAL|Vitamin K1 (Double-Blind Period)|"Dose: 10mg Vitamin K1 capsules, administered 3 times per week following the subject's hemodialysis session.~* Placebo Magnesium Citrate~* Placebo Sodium Thiosulphate"
62221069|NCT05018221|EXPERIMENTAL|Magnesium Citrate (Double-Blind Period)|"Dose: 150mg Magnesium Citrate tablets, administered 3 times per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.~* Placebo Vitamin K1~* Placebo Sodium Thiosulphate"
62415434|NCT04666012|EXPERIMENTAL|Group 3: high dose|Subject will receive single dose of AdCLD-CoV19(1.0x10\^11VP) as intramuscular injection.
62415435|NCT04666012|EXPERIMENTAL|Group 4: selected dose|Subject will receive single dose of AdCLD-CoV19 as intramuscular injection.
62024283|NCT00147966|EXPERIMENTAL|ritxumab|all patients get treatment
62024284|NCT03203213|EXPERIMENTAL|Interventional arm|"* Sampling of a few additional drops of blood and sending this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient~* Oriented hair removal is also carried out if possible (small wick cut and not torn the size of a pencil mine of paper taken at the level of the occipital region). This technique has been used many times, and evaluates the previous consumption (memory consumption)~* A urine sample is taken if possible."
62024285|NCT00440765||001|bortezomib dose as determined (observational study) by treating physician
62024286|NCT04423965|EXPERIMENTAL|mFOLFOXIRI|Patients receive 6 cycles of mFOLFOXIRI
62024287|NCT04423965|EXPERIMENTAL|Chemoradiotherapy(CRT)|Patients receive standard chemoradiotherapy
62221070|NCT05018221|EXPERIMENTAL|Sodium Thiosulfate (Double-Blind Period)|"Dose: 25g Sodium Thiosulfate injection, administered intravenously 3 times per week, during the subject's last hour of hemodialysis.~* Placebo Vitamin K1~* Placebo Magnesium Citrate"
62221071|NCT05018221|ACTIVE_COMPARATOR|High Flux Hemodialysis|Hemodialysis using a high flux dialyser
62221072|NCT05018221|EXPERIMENTAL|Medium Cut-off Hemodialysis|Hemodialysis using a medium cut-off dialyser
62415436|NCT04666012|EXPERIMENTAL|Group 5: selected dose|Subject will receive single dose of AdCLD-CoV19 as intramuscular injection.
62415437|NCT06290622|EXPERIMENTAL|Dose Level Assignments|"Dose Level 1 Retifanlimab 375mg INCAGN02385 250mg INCAGN02390 200mg~Dose Level 2 Retifanlimab 500mg INCAGN02385 250mg INCAGN02390 200mg~Dose Level 3 Retifanlimab 750mg INCAGN02385 250mg INCAGN02390 200mg"
62415438|NCT05595161|EXPERIMENTAL|Intervention|Bright Bodies
62415439|NCT06411470||pancreatic cancer|Pathologic diagnosis of pancreatic ductal adenocarcinoma
62587710|NCT03054298|ACTIVE_COMPARATOR|Cohort 7|Cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day given over 3 days by IV infusion followed by a single dose of 1-3x10\^7 huCART-meso cells/m\^2 via intraperitoneal (i.p.) administration. Lymphodepleting chemotherapy will be scheduled such that the last day of chemotherapy is 3 days (+/- 1 day) prior to the infusion of huCART-meso cells. This initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart. The subject must meet eligibility to receive additional infusions. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of huCART-meso cells.
62587711|NCT06665152|EXPERIMENTAL|ProTaper Group|These patients underwent root canal treatment due to pain in their molar teeth. The file system used in this arm was ProTaper (Dentsply), a rotary file system that moves in a complete 360° rotation and prepares a root canal.
62587712|NCT06665152|ACTIVE_COMPARATOR|WaveOne Group|These patients underwent root canal treatment due to pain in their molar teeth. The file system used in this arm was WaveOne(Dentsply), a reciprocating file system that moves in 150° anticlockwise and 30° clockwise motion and prepares a root canal.
62024288|NCT03343262|EXPERIMENTAL|"ta-VNS yidan-pi"|"Device:ta-VNS \& Electro-acupuncture(yidan-pi auricular acupoints):2 times per day,2 days per week for 12 weeks"
62024289|NCT03343262|PLACEBO_COMPARATOR|"ta-VNS jian"|"Device:ta-VNS \& Electro-acupuncture(jian auricular acupoints):2 times per day,2 days per week for 12 weeks"
62221073|NCT04431700|EXPERIMENTAL|Anti-inflammatory whole food|Included food items will include a defined minimum diversity of fruits, vegetables, and nuts based on complementary phytonutrient contents, particularly those rich in phenolic compounds such as ellagitannins and sulforaphanes. Selected herbs (e.g., curcumin), fermented foods, fats (e.g., avocado), and oils (e.g., olive oil) will be permitted or encouraged. Recommended portions of complex carbohydrates (50% - 60%) and lean proteins (20% - 30%) will form the basis of weight-based caloric needs. The goal is to have 5 servings of vegetables, 2 fruits per day, and 5 vegetable color groups per week. Vegetables with high insoluble fiber content will be cooked instead of eaten raw.
62221074|NCT04431700|ACTIVE_COMPARATOR|Regular Diet|Patients in the control diet arm will be counseled to continue their regular diets and focus on recording all food intake.
62221075|NCT05303220|EXPERIMENTAL|Part 1 Treatment A|
62415440|NCT06411470||chronic pancreatitis|Diagnosis of CP defined as having obvious morphological features of CP (i.e., the presence of pancreatic calcifications on CT scan and/or magnetic resonance cholangiopancreatography)
62415441|NCT06411470||healthy people|Other benign disease populations without pancreatic lesions
62415442|NCT06703008|NO_INTERVENTION|PAC hemodynamic monitoring|Patients undergoing Liver Transplantation are monitored using the pulmonary artery catheter.
62024290|NCT05237622|OTHER|High Flow|Standard HighFlow therapy after weaning from continuous positive airway pressure therapy will be applied on different flow levels. Starting with a flow level of 8l/min, the flow-rates will be changed every 30 minutes subsequently from 8-6-4-2-4-6-8 l/min. Meanwhile, data lung volume changes will be measured using electrical impedance tomography.
62024291|NCT02604784|EXPERIMENTAL|cohort A|Cohort A: For patients that have indication for systemic therapy with standard chemotherapy. This cohort has a phase II design; the Objective Response Rate (ORR) will be evaluated according to the RECIST criteria (version 1.1) after 2 and 3 cycles of PIPAC with Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m2 ) or Oxaliplatin (92 mg/m2) according to the primary cancer, in association with standard systemic chemotherapy.
62221076|NCT05303220|EXPERIMENTAL|Part 1 Treatment B|
62221077|NCT05303220|EXPERIMENTAL|Part 1 Treatment C|
62221078|NCT05303220|EXPERIMENTAL|Part 1 Treatment D|
62587713|NCT00926848|EXPERIMENTAL|PaTH intervention group|"The PaTH intervention group for patients and partners consisted of participation in a structured and formal cardiac rehabilitation program:~* 18-36 exercise sessions~* 18 educational sessions. The intervention consisted of patients and partners participating together in a formal cardiac rehabilitation program when typically just patients participate. In addition, partners were asked to make the same healthy eating and exercise changes that patients did to meet guidelines for health."
62415443|NCT06703008|EXPERIMENTAL|TEE hemodynamic monitoring|Patients undergoing Liver Transplantation are monitored using Transesophageal echocardiography and blinded to the pulmonary artery catheter data (insertion of PAC for patient safety is still mandatory, unblinding is allowed if needed for management by the OR anesthesiologist in charge)
62415444|NCT06567418||intervention group|patients were treated with alirocumab 75mg combined with statin ± ezetimibe
62415445|NCT06567418||control group|patients were treated with statin ± ezetimibe only
62415446|NCT02030327||No trauma|n=5 patients
62415447|NCT02030327||trauma without organ dysfunction|n=40 patients
62587714|NCT00926848|ACTIVE_COMPARATOR|Usual care group|"The usual care group intervention for patients only consisted of participation in a structured and formal cardiac rehabilitation program:~* 18-36 exercise sessions and 18 educational sessions~Partners participated in the 18 educational sessions only."
62587715|NCT05250102|OTHER|Pulse oximeter sensor readings|Subjects who satisfy all of the inclusion criteria will be eligible to participate in the study, will receive intervention (the Masimo and Nellcor sensors, and their arterial blood sample will be taken in the normal course of care). This is a single arm study. Those who don't meet the inclusion/ exclusion criteria won't be eligible to participate.
62587716|NCT02659280|ACTIVE_COMPARATOR|Standard of Care Therapy|Home Health or Outpatient Physical therapy services (a minimum of 1x/week).
62587717|NCT02659280|EXPERIMENTAL|Adjunct Therapy|"Home Health or Outpatient Physical therapy services (a minimum of 1x/week) with an adjunct Home Exercise Program given up to 1x/wk via Store and Forward tele-health through the Hudl Technique app."
62587718|NCT05536024||glioma patients|This study includes the glioma patients aged over 18 years, receiving surgical resection or needle biopsy for the first time, and without any radiotherapy and/or chemotherapy prior to preoperative MRI scan. All included glioma patients were redefined or newly diagnosed according to the 2021 WHO of CNS classification.
62587719|NCT03847753||Danish population|The cohort includes all those born in Denmark between 1900-2015, and who resided there in the period of 2000-2016.Whether they received a diagnosis of one of the following mental disorders will be ascertained: Organic Disorders, Substance Use Disorders, Schizophrenia Disorders, Mood Disorders, Eating Disorders, Neurotic Disorders, Personality Disorders, Intellectual Disorders, Developmental Disorders, Behavioral Disorders The risk of receiving a later diagnosis of one of the following types of general medical conditions will then be estimated: Circulatory, Endocrine, Pulmonary and Allergy, Gastrointestinal, Urogenital, Musculoskeletal, Hematological, Cancer, Neurological
62587720|NCT03407157|EXPERIMENTAL|Intervention|Probiotic supplementation
62587721|NCT03407157|PLACEBO_COMPARATOR|Control|Placebo
62221079|NCT05303220|EXPERIMENTAL|Part 2 Treatment A|
62415448|NCT02030327||trauma with organ dysfunction|n=40 patients
62415449|NCT04311359||Group/Cohort|Brain Oedema induced by drugs reported to the FAERS database from inception till first quarter of 2019
62415450|NCT04546126|EXPERIMENTAL|Dexamethasone (Group 2)|"Participants will undergo an FNP-59 scan on day 0 in the am. Participants will then take~1 mg dexamethasone 2x a day for 3 days to suppress cortisol production. Participants will then have a second FNP-59 scan on day 4 in the am."
62415451|NCT04546126|EXPERIMENTAL|Cosyntropin (Group 3)|Participants will undergo an FNP-59 scan on day 0 in the am. On day 4 the participant will arrive for imaging. Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
62221080|NCT05303220|EXPERIMENTAL|Part 2 Treatment B|
62221081|NCT05303220|EXPERIMENTAL|Part 2 Treatment C|
62415452|NCT04546126|EXPERIMENTAL|Adrenal pathology (Group 4)|Whole-body PET/CT scans will be done on 4 patients at 1 hr and the other 4 patients at 6 hours. All the patients will have a whole-body PET/CT scan at 3 hours.
62415453|NCT06653686|ACTIVE_COMPARATOR|Febuxostat|
62415454|NCT06653686|EXPERIMENTAL|Hyperthermia combined with febuxostat|
62415455|NCT06070701|EXPERIMENTAL|SUPERFICIAL PARASTERNAL INTERCOSTAL PLANE BLOCK (SPIPB)|Following induction, ropivacaine 0.5% (1.5 mg/kg per each side) with dexamethasone 8mg/20ml is deposited under ultrasound guidance in the plane between the intercostal muscles and the pectoralis major muscles, targeting the anterior cutaneous branches of the intercostal nerves.
62415456|NCT06070701|ACTIVE_COMPARATOR|ERECTOR SPINAE PLANE BLOCK (ESPB)|Before induction, ropivacaine 0.5% (1.5 mg/kg per each side) with dexamethasone 8mg/20ml is deposited under ultrasound guidance between the transverse process of the 5th thoracic vertebra and the erector spinae muscle, targeting the dorsal and ventral rami of the spinal nerves.
62415457|NCT00136500||Individuals affected with ALS|This population be sporadic or familial ALS.
62415458|NCT00136500||Unaffected individuals from families in which the genetic cause of ALS is known|This population includes pre-symptomatic individuals at genetic risk for ALS or a related neurodegenerative disorder (i.e., FTD).
62415459|NCT00136500||Individuals affected with an ALS-related neurodegenerative disease|This would include FTD, MSP, IBMPFD, etc.
62415460|NCT00136500||Healthy controls|
62415461|NCT03943407|EXPERIMENTAL|Zyclara/vehicle|All subjects will be treated with Zyclara cream (Imiquimod 3.75%) and vehicle.
62415462|NCT03943407|EXPERIMENTAL|Zyclara/Doxepin|All subjects will be treated with the topical antihistamine cream (Prudoxin, containing 5% doxepin hydrochloride, Healthpoint, San Antonio, TX) or a placebo cream. After removal, subjects will be treated with Zyclara cream
62221082|NCT05303220|EXPERIMENTAL|Part 3 Treatment A|
62221083|NCT05303220|PLACEBO_COMPARATOR|Part 3 Treatment B|
62221084|NCT04025567|EXPERIMENTAL|1/Arm 1|Oral vancomycin
62415463|NCT03943407|EXPERIMENTAL|Zyclara/Histamine/Cowage|All subjects will be treated with Zyclara cream, vehicle cream, histamine and cowhage
62024292|NCT02604784|EXPERIMENTAL|cohort B|Cohort B: For patients that have not indication for systemic therapy with standard chemotherapy. This cohort has a phase I design; with a dose-escalation design the maximum tolerated doses and recommended doses of Cisplatin + Doxorubicin and Oxaliplatin (according to the pathology) administered through PIPAC in patients with peritoneal carcinomatosis will be evaluated.
62024293|NCT05449639|EXPERIMENTAL|Main group|A second no-random open interventional pilot study sponsored by Relief srl. The primary objectives of the study were to assess the safety and reproducibility of the implantation of the magnetic endo-urethral sphincter, if the procedure was well tolerated by the patients, and if possible irritation symptoms due to the device presence emerged in patients with severe stress urinary incontinence where standard medical treatments failed. The device will be implanted by endoscopic procedure by a standard resectoscope. Up to 20 patients of both gender affected by severe stress urinary incontinence will be involved in the study by means of prospective enrollment.
62024294|NCT00898716|EXPERIMENTAL|BMS-754807|
62024295|NCT06227000|EXPERIMENTAL|Living Longer and Stronger (LLS) intervention|
62024296|NCT06227000|ACTIVE_COMPARATOR|Control Group|
62024297|NCT01381172|EXPERIMENTAL|Treatment|The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.
62415464|NCT03943407|EXPERIMENTAL|Zyclara/L-menthol/trans-cinnamaldehyde|All subjects will be treated with Zyclara cream (Imiquimod 3.75%) and vehicle. After removal, subjects will be treated with L/menthol and trans-cinnamaldehyde
62415465|NCT06703580|ACTIVE_COMPARATOR|arm 40|
62587722|NCT03366766|EXPERIMENTAL|Cohort I (nivolumab, cisplatin, pemetrexed disodium)|Patients with non-squamous lung cancer receive nivolumab IV over 30 minutes, cisplatin IV over 60-120 minutes, and pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity
62024298|NCT01381172|OTHER|Control|The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.
62024299|NCT02090738|EXPERIMENTAL|Arm1|Treatment group
62024300|NCT02090738|ACTIVE_COMPARATOR|Arm2|Control group
62024301|NCT06496256|EXPERIMENTAL|Treatment Arms|Subjects will be injected Barrigel between the rectum and prostate bed using transrectal ultrasound for guidance.
62024302|NCT06496256|SHAM_COMPARATOR|Control Arm|Subjects randomized to the control group will not receive Barrigel but will have a Transrectal ultrasound probe inserted to simulate that aspect of the injection of Barrigel.
62415466|NCT06703580|ACTIVE_COMPARATOR|arm 50|this arm will include 50 patients who will receive intrathecal hyperbaric prilocaine 2% in the dose of 50 mg.
62415467|NCT06703580|ACTIVE_COMPARATOR|arm 60|this arm will include 50 patients who will receive intrathecal hyperbaric prilocaine 2% in the dose of 60 mg
62415468|NCT04669756|EXPERIMENTAL|A|ovariopexy for 2 days
62415469|NCT04669756|EXPERIMENTAL|B|ovariopexy for 4 days
62415470|NCT04669756|EXPERIMENTAL|C|ovariopexy for 6 days
62415471|NCT04669756|PLACEBO_COMPARATOR|D|Placebo Operation for 2 days
62415472|NCT05576597|EXPERIMENTAL|Butyrate supplement|2 capsules butyrate supplement (containing 1200 mg of butyric acid ) once a day for 12 weeks Drug: sodium butyrate
62415473|NCT06702397|ACTIVE_COMPARATOR|Microsurgical-assisted testicular sperm extraction (m-TeSE) - Group A|A longitudinal incision of 3cm was made along the scrotal raphe using a scalpel. Surgical dissection proceeded layer by layer. The testis was separated from the surrounding dartos and luxated outside the scrotal sac. A longitudinal incision was made in the tunica vaginalis to allow complete exposure of the tunica albuginea. Two Vicryl 2-0 traction sutures were placed 0.5 cm cranially and caudally to the testicular equatorial line, which was subsequently incised with a scalpel for 3/4 of the testicular circumference. In M-TESE, through the operating microscope, a direct examination of the testicular parenchyma was performed under magnification (20-25x). Multiple testicular specimens were excised. The same procedure is performed on the contralateral side, where instead of the operating microscope, the surgeon uses surgical loupes for magnification (3.5 - 5x).
62587723|NCT03366766|EXPERIMENTAL|Cohort I (nivolumab, cisplatin, gemcitabine hydrochloride)|Patients with squamous lung cancer receive nivolumab IV over 30 minutes on day 1, cisplatin IV over 60-120 minutes on day 1, and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
62024303|NCT05898542|EXPERIMENTAL|Nature-based therapy intervention group|Patients getting additional therapies outdoors
62024304|NCT05898542|NO_INTERVENTION|Control group|Patients getting additional rehabilitation tasks indoors
62024305|NCT02542748|EXPERIMENTAL|norepinephrine|norepinephrine is injected after spinal anesthesia
62024306|NCT02542748|OTHER|ephedrine|ephedrine is injected after spinal anesthesia
62024307|NCT06371794|OTHER|To characterize in detail and classify the DS phenotype|"Patients will be stratified according to the severity of epilepsy and cognitive impairment as follows:~i) Severely impaired with severe epilepsy (SISE); ii) Severely impaired with mild epilepsy (SIME); iii) Mildly impaired with severe epilepsy (MISE); iv) Mildly impaired with mild epilepsy (MIME). Mild epilepsy will be defined by: i) no history of myoclonic and/or absence seizure; ii) no history of status epilepticus; iii) seizure frequency less than weekly. Patients not fulfilling these criteria will be considered as having severe epilepsy. Cut-off for severe impairment will be defined as a z-score of more or less of -3 of adaptive behavioral or intellectual abilities scales (vineland, WISC or equivalent)."
62024308|NCT05809518|EXPERIMENTAL|Propofol Group|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group (Pr):~continuous infusion of propofol using a syringe pump at the dose of 1-1.5 mg / kg / h"
62024309|NCT05809518|EXPERIMENTAL|Dexmedetomidine group|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group Dexmedetomidine (Dx):~continuous infusion of Dexmedetomidine using a syringe pump at the dose of 0.5-1.0 mcg/ kg / h"
62024310|NCT05809518|EXPERIMENTAL|Dexmedetomidine and propofol group|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group DxPr:~continuous infusion of propofol using a syringe pump at the dose of 0.5-1.5 mg / kg / h and dexmedetomidine 0.2-0.7 mcg\\kg\\h"
62024311|NCT01094080|ACTIVE_COMPARATOR|standard infant formula|infants are fed a commercial formula during the first 4 month of life, according to protocol
62587724|NCT01883817|PLACEBO_COMPARATOR|Placebo|Corn/soy oil placebo capsules that are similar in shape and color to the DHA capsules given over 10 weeks
62587725|NCT01883817|EXPERIMENTAL|DHA Omega-3|Long-chain omega-3 fatty acid docosahexaenoic acid (DHA) at 1,200 mg/day, 600 mg twice daily for 10 weeks
62587726|NCT05481385|EXPERIMENTAL|Test preparation|Ezetimibe tablets: specification: 10mg; Package specification: 7 pieces / plate, 1 plate / box; Produced and provided by Changzhou Pharmaceutical Factory Co., Ltd.
62587727|NCT05481385|ACTIVE_COMPARATOR|Reference preparation|Ezetimibe Tablets Ezetrol ®; Specification: 10mg, packaging specification: 10 pieces / plate, 1 plate / box; Licensee: MSD Pharma (Singapore) PTE. Ltd
62587728|NCT06663202|EXPERIMENTAL|Fiber Retention Osseous Resective Surgery|Paramarginal incisions both on buccal and lingual/palatal sides with bone remodelling preserving the supracrestal fibers
62587729|NCT06663202|ACTIVE_COMPARATOR|Papilla preservation flap|Access flap for open flap debridement using intrasulcular incisions and papilla preservation approaches to preserve the entire interdental tissues
62587730|NCT06663202|ACTIVE_COMPARATOR|Conventional surgery|Access flap for open flap debridement using a conventional modified Widman flap procedure
62587731|NCT06661798|OTHER|Orthognathic surgery|Patients who have reached skeletal maturity, have skeletal Class II or Class III malocclusion, and are indicated for orthognathic surgery due to malocclusion complaints
62587732|NCT02537431|EXPERIMENTAL|Open-Label Burosumab Q4W|1.0 mg/kg burosumab monthly (Q4W), calculated based on baseline weight and up to a maximum dose of 90 mg.
62796679|NCT04733053|EXPERIMENTAL|Diet plus exercise|The initial physiotherapy consultation for participants in this group will last 75 minutes, with 30 minutes for the exercise component and 45 minutes for the diet component. Thereafter, consultations will last 50 minutes, with 20 minutes for the exercise component and 30 minutes for the diet component. The exercise component will be the same as that described for the exercise alone group.
62796680|NCT04733053|ACTIVE_COMPARATOR|Exercise|Physiotherapy consultations for participants in this group will last 30 minutes initially and then 20 minutes thereafter, consistent with clinical practice. Physiotherapists will prescribe 5-6 strengthening exercises from a pre-determined list to be performed at home three times/week, including two quadriceps exercises, one each for hip abductors, hamstrings and calf, and any other as appropriate and a personalised physical activity plan.
62796681|NCT01223729|EXPERIMENTAL|Acetyl-L-Carnitine|
62796682|NCT01223729|PLACEBO_COMPARATOR|placebo|
62796683|NCT03491514|EXPERIMENTAL|Test Granola|51 g of Test Granola
62796684|NCT03491514|PLACEBO_COMPARATOR|Control Granola|54.1 Control Granola
62796685|NCT05751837|EXPERIMENTAL|Treatment Arm|Injection of Lipopolysaccharide into one abdominal tumor
62024312|NCT01094080|EXPERIMENTAL|modified infant formula|infants are fed a modified infant formula (modified protein content and fatty acid pattern) during the first 4 month of life, according to protocol
62024313|NCT01094080|OTHER|breast milk|infants are breast fed
62024314|NCT04244461|EXPERIMENTAL|Personalized normative feedback|Personalized feedback about drinking behavior compared to peers
62796686|NCT02766868|EXPERIMENTAL|FACE-Flu/Bu/Cy|Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
62796687|NCT00482625|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.
62796688|NCT02404818||Survivors of Hodgkin's lymphoma|Cardiac Magnetic Resonance Imaging and Echocardiogram
62415474|NCT06702397|ACTIVE_COMPARATOR|Testicular sperm extraction performed with surgical loupes (l-TeSE) - Group B|A longitudinal incision of 3cm was made along the scrotal raphe using a scalpel. Surgical dissection proceeded layer by layer. The testis was separated from the surrounding dartos and luxated outside the scrotal sac. A longitudinal incision was made in the tunica vaginalis to allow complete exposure of the tunica albuginea. Two Vicryl 2-0 traction sutures were placed 0.5 cm cranially and caudally to the testicular equatorial line, which was subsequently incised with a scalpel for 3/4 of the testicular circumference. In M-TESE, through the operating microscope, a direct examination of the testicular parenchyma was performed under magnification (20-25x). Multiple testicular specimens were excised. The same procedure is performed on the contralateral side, where instead of the operating microscope, the surgeon uses surgical loupes for magnification (3.5 - 5x).
62415475|NCT00228878|EXPERIMENTAL|Effects of Pulsatile IV insulin on QoL|Effects of Pulsatile IV insulin on Diabetic Quality of Life
62415476|NCT05072145||Non-tele-ED hospital|Patients receiving care in an ED that does not provide any tele-ED service
62415477|NCT05072145||Tele-ED hospital|Patients receiving care in an ED that uses tele-ED services, but patient care did NOT utilize this service
62415478|NCT05072145||Tele-ED used|Patient care was provided through tele-ED services
62415479|NCT06023680|ACTIVE_COMPARATOR|Continuous sedentary reduction intervention|Structured intervention to progressively replace sedentary time with one daily 30-minute light-intensity walking bout
62415480|NCT06023680|ACTIVE_COMPARATOR|Bouted sedentary reduction intervention|Structured intervention to progressively replace sedentary time with three daily 10-minute light-intensity walking bouts
62415481|NCT04797637|EXPERIMENTAL|Treatment Group|Patients randomized to the treatment group will have the ABBy device applied by study personnel at the time of randomization, followed by a continuation of usual postoperative care.
62415482|NCT04797637|NO_INTERVENTION|Standard of Care|The control group will have postoperative care per usual care
62415483|NCT01348659|ACTIVE_COMPARATOR|7.2% NaCl/hydroxyethyl starch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) (Hyperhaes®, Fresenius Kabi)
62415484|NCT01348659|ACTIVE_COMPARATOR|0.9% NaCl|250 ml of NaCl 0.9% (Natriumklorid Braun 9 mg/ml)
62415485|NCT04782687|EXPERIMENTAL|Selinexor plus DRd|"1. Lenalidomide 15 mg orally on Days 1-21 of each 28-day cycle~2. Dexamethasone 40 mg on Days 1, 8, 15, 22 of each cycle. However, those \>75 years old may be administered a weekly dose of 20 mg dexamethasone.~3. Daratumumab 1800 mg subcutaneous injection once weekly in Cycles 1 and 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter.~4. Selinexor 60 mg on Days 1, 8, 15, of cycles 1-3, with a planned dose-reduction to 40 mg on Days 1, 8, 15 for cycles beyond 3. If patient was previously dose reduced prior to cycle 4, then at cycle 4 planned dose reduction, you will again decrease dose by 1 level."
62415486|NCT04390100|ACTIVE_COMPARATOR|PRF|PRF membrane is placed in the area where the free gingival graft was taken from the palate
62415487|NCT04390100|ACTIVE_COMPARATOR|hyaluronic acid|hyaluronic acid gel is placed in the area where the free gingival graft was taken from the palate and the patient is instructed to place the gel 3 times per day
62415488|NCT04390100|ACTIVE_COMPARATOR|Gel foam|Gel foam is placed in the area where the free gingival graft was taken from the palate
62415489|NCT02944097|EXPERIMENTAL|Vineatrol30 native powder|500 mg Vineatrol30 containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin
62415490|NCT02944097|EXPERIMENTAL|Vineatrol30 micelles|500 mg Vineatrol30 micelles containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin
62415491|NCT06388265|EXPERIMENTAL|Verbal and Written detailed information|The experimental group will receive verbal information about the procedure (exodontia of third molars) and additionally a trifold with detailed information about the surgical procedure.
62415492|NCT06388265|NO_INTERVENTION|Control|The control group will only receive verbal information about the surgical procedure.
62796689|NCT06725264|EXPERIMENTAL|Granuloma Annulare|Participants with GA will receive the TYK2 inhibitor deucravacitinib 6mg twice daily
62796690|NCT06725264|EXPERIMENTAL|Cutaneous Sarcoidosis|Participants with CS will receive the TYK2 inhibitor deucravacitinib 6mg twice daily
62796691|NCT01552135||Healthy|Healthy men above 50 years old
62796692|NCT03618420|OTHER|Clinical Investigation|All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.
62796693|NCT03191630|EXPERIMENTAL|Control|This arm includes participants randomized to the control group who will use activity trackers (Fitbits) only, and not receive the SystemCHANGE intervention.
62796694|NCT03191630|EXPERIMENTAL|Intervention|This are includes participants randomize to the intervention group who will receive the combination of the SystemCHANGE TM and activity tracker intervention
62024315|NCT04244461|NO_INTERVENTION|Control|Control participants will receive content similar in length but different in content from the PNF (i.e., non-drinking focused). These participants will receive information based on their actual and perceived behavior of playing video games, a strategy used in prior PNF work to balance attention to non-targeted behaviors.
62587733|NCT04310397|EXPERIMENTAL|Treatment (dabrafenib, trametinib, surgery, spartalizumab)|"NEOADJUVANT TREATMENT: Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo surgical resection of melanoma.~ADJUVANT TREATMENT OF pCR PATIENTS: Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeats every 28 days for 44 weeks in the absence of disease progression or unacceptable toxicity.~ADJUVANT TREATMENT OF NON pCR PATIENTS: Patients receive spartalizumab IV over 30 minutes on day 1, dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeats every 28 days for 44 weeks in the absence of disease progression or unacceptable toxicity."
62587734|NCT01881204|EXPERIMENTAL|Hesperidin and Calcilock|Subjects will consume 4 cookies containing Hesperidin and Calcilock.
62415493|NCT02704130|EXPERIMENTAL|TAE + MWA combination therapy|In patients randomized to receive the experimental therapy, transarterial embolization (TAE) treatments will be initiated within one week of randomization. Blunt embolization will be performed with LC beads with a maximum size of 700 µm. Microwave ablation (MWA) will be performed up to one month following randomization. The LC beads will be admixed with 8-15 mL of contrast and injected into the arterial branch at a rate of 1-2 mL/min. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request.
62415494|NCT02704130|ACTIVE_COMPARATOR|MWA monotherapy|Microwave ablation (MWA) will be performed up to one month following randomization. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request. All operative MWAs will be performed in a laparoscopic or robot-assisted laparoscopic setting. All ablations will be guided by intraoperative ultrasound. Ablations will be performed with a 2.45-GHz generator with a 1.8-mm-diameter transcutaneous antenna.
62415495|NCT06384898|EXPERIMENTAL|Tai Chi + Routine Care|The intervention will be delivered via a HIPAA-secure web-based video platform. All remote Tai Chi sessions will be 60 minutes, twice a week, for 3 months. All program components will use the Yang style Tai Chi, and every session will include warm up, review of principles, meditation with movement, breathing techniques and relaxation.
62415496|NCT06384898|NO_INTERVENTION|Routine Care|"Participants will be encouraged to continue their ongoing care for Knee OA by their providers. In addition, primary care providers and other participating clinicians in the health system will receive information from the study team on routine care or 2019 ACR Guideline-Based Care. At the end of the 12-month trial period, routine care participants will be offered access to recordings for the full 3-month Tai Chi program (24 sessions)."
62415497|NCT03020966|EXPERIMENTAL|Oral Tylenol|Patient group receiving 1000mg of oral acetaminophen and an intravenous placebo
62415498|NCT03020966|EXPERIMENTAL|Intravenous Tylenol|Patient group receiving 1000mg of intravenous acetaminophen and an oral placebo
62415499|NCT03284515||All women|Women who are between 16-32 weeks gestation and who have not previously received a pertussis vaccination in pregnancy.
62587735|NCT01881204|EXPERIMENTAL|Hesperidin|Subjects will consume 4 cookies containing Hesperidin, 552mg, daily
62587736|NCT01881204|PLACEBO_COMPARATOR|Control|Subjects will consume 4 cookies daily without Hesperidin or Calcilock.
62024316|NCT02181530||OZURDEX®|Retrospective data collection study of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) administered at least once in accordance with routine clinical practice. No treatment (intervention) is administered as part of this study.
62024317|NCT01141894|ACTIVE_COMPARATOR|Routine fluid treatment|Buffered Glucose 25 mg/ml 1ml/kg/h Ringer's Acetate 2 ml/kg/h and additionally as needed Voluven at the attending anaesthetist's discretion Phenylephrine 50 μg for correction of hypotension
62221085|NCT05366790|EXPERIMENTAL|CEASE Intervention arm|"The CEASE and CEASE-A interventions are tobacco and vaping cessation interventions delivered in pediatric practices, leveraging existing healthcare and community resources. They integrate evidence-based tobacco use screening and cessation assistance into routine visits to pediatric clinics. CEASE and CEASE-A are based on the 5A's model of smoking cessation: Ask about smoking, Advise to quit, Assess readiness to quit, Assist with a quit plan and Arrange follow-up. Given that CEASE and CEASE-A are one-time interventions, Arrange is removed, and the fourth step Assist is divided into two parts: a) providing phone/text/app quit support and b) providing NRT.~CEASE-A follows the same format at CEASE, but is modified slightly to address smoking and vaping in the adolescent target population"
62221086|NCT05366790|NO_INTERVENTION|Control: Usual care condition|The control condition will be care as is usually delivered in participating clinics with the possibility of receiving direct linkage with cessation services delivered via CEASE/CEASE-A at the end of the 6-month study period. Current practice does not include routine provision of assistance for parental/adolescent smoking or e-cigarette cessation (e.g., referral to quitlines, NRT prescription).
62587737|NCT03946449|EXPERIMENTAL|Fazirsiran (TAK-999, ARO-AAT) Cohort 1|"Administered on Day 1, Weeks 4 and 16 for a minimum of 3 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 12 additional doses."
62587738|NCT03946449|EXPERIMENTAL|Fazirsiran (TAK-999, ARO-AAT) Cohort 1b|"Administered on Day 1, Weeks 4 and 16, for a minimum of 3 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 12 additional doses."
62796695|NCT02544659|EXPERIMENTAL|pamidronate disodium|the patients will be administered intravenous pamidronate disodium
62796696|NCT03782701|ACTIVE_COMPARATOR|Lumify Eye Drop|Participants will be randomized to receive a single drop of Lumify to either the left or right eye.
62796697|NCT03782701|ACTIVE_COMPARATOR|Saline Solution Eye Drop|Participants will be randomized to receive a single drop of sterile balanced saline solution to either the left or right eye.
62024318|NCT01141894|EXPERIMENTAL|Goal directed haemodynamic treatment|Goal directed haemodynamic treatment Dobutamine 0.2-10 μg/kg/min Buffered Glucose 25 mg/ml 1ml/kg/h Ringer's Acetate 2 ml/kg/h Voluven 3 ml/kg as fluid challenge at the attending anaesthetist's discretion Phenylephrine 50 μg for correction of hypotension
62587739|NCT03946449|EXPERIMENTAL|Fazirsiran (TAK-999, ARO-AAT) Cohort 2|"Administered on Day 1, Weeks 4, 16, 28 and 40 for a minimum of 5 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 12 additional doses."
62587740|NCT02162719|EXPERIMENTAL|Ipatasertib + Paclitaxel|Participants randomised to receive paclitaxel 80 mg/m\^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
62587741|NCT02162719|PLACEBO_COMPARATOR|Placebo + Paclitaxel|Participants randomised to receive paclitaxel 80 mg/m\^2, intravenously on Days 1, 8, and 15 along with placebo matching ipatasertib, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
62796698|NCT03708978||mammography group|women who receives mammography because of suspected breast lesion(s)
62024319|NCT00337766|ACTIVE_COMPARATOR|Desmopressin (DDAVP)|
62024320|NCT00337766|PLACEBO_COMPARATOR|Placebo|
62024321|NCT06141135|EXPERIMENTAL|Experimental Arm - Transfer of Best Quality, Euploid Blastocyst|Transfer of best quality, PGTA normal (euploid) blastocyst.
62415500|NCT06703047|EXPERIMENTAL|All trans tretinoic acid+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)|
62587742|NCT05108298|EXPERIMENTAL|Intervention arm|5 domain-specific HRQOL measures
62587743|NCT05108298|OTHER|Control arm|5 pre-selected HRQOL measures
62587744|NCT03892382|ACTIVE_COMPARATOR|Active rTMS|10 hertz (Hz) rTMS will be administered over the left dorsolateral prefrontal cortex. Therapy will include 10 daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 120% of the resting motor threshold intensity will be elicited.
62587745|NCT03892382|SHAM_COMPARATOR|Sham rTMS|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
62587746|NCT05377554|EXPERIMENTAL|ALM-488-002a WLR only|Patients with a preoperative diagnosis of malignancy will be assigned to study ALM-488-002a. All patients will receive ALM-488 infusion. Intraoperative nerve visualization will be performed using WLR only.
62587747|NCT05377554|EXPERIMENTAL|ALM-488-002a WLR with FL Overlay|Patients with a preoperative diagnosis of malignancy will be assigned to study ALM-488-002a. All patients will receive ALM-488 infusion. Intraoperative nerve visualization will be performed using WLR with FL Overlay.
62587748|NCT05377554|EXPERIMENTAL|ALM-488-002b WLR only|Patients without a preoperative diagnosis of malignancy will be assigned to study ALM-488-002b. All patients will receive ALM-488 infusion. Intraoperative nerve visualization will be performed using WLR only.
62587749|NCT05377554|EXPERIMENTAL|ALM-488-002b WLR with FL Overlay|Patients without a preoperative diagnosis of malignancy will be assigned to study ALM-488-002b. All patients will receive ALM-488 infusion. Intraoperative nerve visualization will be performed using WLR with FL Overlay.
62587750|NCT06228352||Ulcerative colitis flare-up|Patient with ulcerative colitis, whatever the extent, except isolated proctitis (\<5 cm), diagnosed for more than 3 months, presenting with a flare of UC defined by a Pediatric Ulcerative Colitis Activity Index (PUCAI) score between 35 and 65.
62796699|NCT05825326||Patients diagnosed with Philadelphia-negative Myeloproliferative Neoplasms|
62796700|NCT01751100|ACTIVE_COMPARATOR|HIV Test Offer|Group 1 (Control) is the current standard of care in HIV testing. A trained counselor provides required information to obtain informed consent for HIV testing and provides rapid HIV testing on site.
62796701|NCT01751100|EXPERIMENTAL|General Health Screen Offer|In Group 2 (Intervention), a free general health screening is offered that may include a blood pressure check, blood glucose measurement, a Hepatitis C (HCV) test, and an HIV test.
62024322|NCT06141135|NO_INTERVENTION|Control Arm - Transfer of Untested, Best Quality Blastocyst|Transfer of Untested, Best Quality Blastocyst
62024323|NCT05588518|EXPERIMENTAL|test group-1- 10% propolis|10% propolis desensitizer, a pea-sized quantity was smeared over the test tooth. Subsequently, Iontophoresis was applied immediately. The desensitizing agent was administered at two intervals, immediately after oral prophylaxis and at the 14th-day visit.
62024324|NCT05588518|ACTIVE_COMPARATOR|test group -2- 2% sodium fluoride|2% sodium fluoride desensitizer, a pea-sized quantity was smeared over the test tooth. Subsequently, Iontophoresis was applied immediately. The desensitizing agent was administered at two intervals, immediately after oral prophylaxis and at the 14th-day visit.
62024325|NCT05588518|ACTIVE_COMPARATOR|test group-3- 1.23% acidulated phosphate fluoride|1.23% acidulated phosphate fluoride desensitizer, a pea-sized quantity was smeared over the test tooth. Subsequently, Iontophoresis was applied immediately. The desensitizing agent was administered at two intervals, immediately after oral prophylaxis and at the 14th-day visit.
62415501|NCT06703047|PLACEBO_COMPARATOR|Placebo+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)|
62415502|NCT06596382|ACTIVE_COMPARATOR|NAFLD with metabolic syndrome; intervention with tocotrienol rich-vitamin E|66 patient diagnosed with NALFD and associated with metabolic syndrome were given 100mg of tocotrienol rich-vitamin E for six months
62796702|NCT06725615|EXPERIMENTAL|Regular Umami exposure|The Regular Umami Exposure (RegularU) group (control) will receive the basic diet with added MSG, representing Dutch dietary intake levels of around the 50th percentile, which is about 20-25 mg/kg body weight.
62024326|NCT02805569|ACTIVE_COMPARATOR|Group A|articulating stylet
62024327|NCT02805569|ACTIVE_COMPARATOR|group C|conventional stylet
62024328|NCT05663047|EXPERIMENTAL|Prevent It 2.0|
62024329|NCT05663047|ACTIVE_COMPARATOR|Waitlist|
62024330|NCT01839734|EXPERIMENTAL|Lubiprostone|4 weeks of treatment with lubiprostone 24 mcg by mouth (PO) once-daily (Interventional Group)
62024331|NCT01839734|NO_INTERVENTION|No intervention|No intervention
62024332|NCT03216837|EXPERIMENTAL|Cathodal Transcranial direct current stimulation|Cathodal tDCS
62024333|NCT03216837|SHAM_COMPARATOR|Sham Transcranial direct current stimulation|Sham
62024334|NCT06635616||diuretics|patients prescribed diuretics for oral treatment admitted to emergency service with elevated blood pressure
62415503|NCT06596382|ACTIVE_COMPARATOR|NAFLD without metabolic syndrome; intervention with tocotrienol rich-vitamin E|66 patient diagnosed with NALFD without being associated with metabolic syndrome were given 50mg of tocotrienol rich-vitamin E for six months
62415504|NCT06596382|PLACEBO_COMPARATOR|NAFLD with metabolic syndrome; intervention with placebo|66 patient diagnosed with NALFD and associated with metabolic syndrome were given placebo for six months
62415505|NCT06596382|PLACEBO_COMPARATOR|NAFLD without metabolic syndrome; intervention with placebo|66 patient diagnosed with NALFD without being associated with metabolic syndrome were given placebo for six months
62415506|NCT02267759|EXPERIMENTAL|McGrath|Nasotracheal intubation was performed with McGrath videolaryngoscopy
62415507|NCT02267759|ACTIVE_COMPARATOR|Macintosh|Nasotracheal intubation was performed with Macintosh direct laryngoscopy
62415508|NCT06116994|ACTIVE_COMPARATOR|control group|In the control group, subjects will receive the buccal infiltration anesthesia using the traditional dental syringe.
62415509|NCT06116994|EXPERIMENTAL|Test group|Subjects in the test group will receive the buccal infiltration anesthesia with the camouflaged dental syringe.
62024335|NCT06635616||Beta Blockers|patients prescribed Beta Blockers for oral treatment admitted to emergency service with elevated blood pressure
62024336|NCT06635616||Calcium Channel Blockers|patients prescribed Calcium Channel Blockers for oral treatment admitted to emergency service with elevated blood pressure
62024337|NCT06635616||ACE (angiotensin converting enzyme) Inhibitors|patients prescribed ACE (angiotensin converting enzyme) Inhibitors for oral treatment admitted to emergency service with elevated blood pressure
62024338|NCT06635616||ARB( angiotensin receptor blockers)|patients prescribed ARB( angiotensin receptor blockers) for oral treatment admitted to emergency service with elevated blood pressure
62024339|NCT06635616||combination|patients prescribed combination agents for oral treatment admitted to emergency service with elevated blood pressure
62024340|NCT02317458|EXPERIMENTAL|Active arm|One arm with standard of care and C3BS-CQR-1 injection (treatment group) using intramyocardial catheter injection.
62415510|NCT06056063|EXPERIMENTAL|Evaluate the Halcyon 4.0 obtained CBCT in comparison to a CT SIM for radiotherapy dose planning|To evaluate the Halcyon 4.0 as a machine that will obtain CBCT that will be comparable to a CT simulator for radiotherapy treatment planning dose calculation. The novel CBCT images of subjects with malignancies from six disease sites obtained during the course of treatment for evaluation in place of the standard evaluation CBCT will be compared to their initial standard conventional CT simulation images used for treatment planning.
62024341|NCT02317458|SHAM_COMPARATOR|Control arm|One arm with standard of care undergoing a sham procedure (control group)using intramyocardial catheter injection. .
62024342|NCT03836053|EXPERIMENTAL|AMG 420|Single Arm Design
62024343|NCT03845608|EXPERIMENTAL|Pulmonary Recruitment Maneuver|Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity
62024344|NCT03845608|OTHER|Intraperitoneal Hydrocortisone|Drug Injection: 100mg of Hydrocortisone will be injected In the peritoneum
62024345|NCT03845608|NO_INTERVENTION|control group|In the controls, carbon dioxide will be removed by the traditional passive deflation of abdominal cavity.
62024346|NCT01134874|EXPERIMENTAL|Standard weight loss intervention|
62024347|NCT01134874|EXPERIMENTAL|Standard weight loss intervention plus technology|
62024348|NCT01134874|EXPERIMENTAL|Technology only|
62415511|NCT05354141|PLACEBO_COMPARATOR|Placebo|Normal saline 100 mL
62796703|NCT06725615|EXPERIMENTAL|High Umami exposure|the High Umami Exposure (HighU) will receive the basic diet with added MSG, representing Dutch intake levels of around the 90th percentile, which is about 50-55 mg/kg body weight.
62024349|NCT04855253|EXPERIMENTAL|Dose level 1 : E7777 at 5 mcg/kg|Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
62024350|NCT04855253|EXPERIMENTAL|Dose level 1 : E7777 at 7 mcg/kg|Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
62024351|NCT04855253|EXPERIMENTAL|Dose level 1 : E7777 at 9 mcg/kg|Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
62024352|NCT04855253|EXPERIMENTAL|MTD from phase 1|Single dose of E7777 (Maximum tolerated dose level identified in phase 1) given on Day -7 two days prior to the start of lymphodepleting chemotherapy
62024353|NCT00991926||orlistat plus normo-caloric diet|10 subjects received normo-caloric diet plus + orlistat (Xenical, Roche, UK) at a dose of 120 mg tid. The duration of follow-up was 10 days
62415512|NCT05354141|EXPERIMENTAL|Experimental Dose|Normal saline 85 mL and ExoFlo 15 mL
62024354|NCT00991926||normo-caloric diet|10 subjects received normo-caloric diet without the additional treatment. The duration of follow-up was 10 days
62024355|NCT02672904|ACTIVE_COMPARATOR|CO2 laser|Patients undergoing endoscopic treatment with CO2 laser
62024356|NCT02672904|ACTIVE_COMPARATOR|KTP laser|Patients undergoing endoscopic treatment with KTP laser
62024357|NCT01620892||Unicondylar knee replacement|This is a non-intervational, retrospective, observational study of a case series cohort of patients who received a particular surgical operation during a specified time period.
62024358|NCT00412087|EXPERIMENTAL|Cholecalciferol 2000 IU|Women at 12-16 weeks' gestation are enrolled into the study to receive 2000 IU/day vitamin D3 for one month. After the run-in dose, the subjects are randomized to one of two treatment groups: either 2000 or 4000 IU/day to be taken throughout pregnancy until delivery.
62415513|NCT06543498|ACTIVE_COMPARATOR|NCT and NFT|21 days of 1x capsule per day. Dosage 120mg.
62415514|NCT06543498|PLACEBO_COMPARATOR|Placebo|21 days of 1x placebo capsule per day
62415515|NCT03315871|EXPERIMENTAL|1/combination therapy (closed December 2018)|Prostvac + CV301+ MSB0011359C
62796704|NCT06725615|EXPERIMENTAL|Low Umami exposure|The Low Umami Exposure (LowU) group will receive the basic diet without added MSG.
62796705|NCT01004289|ACTIVE_COMPARATOR|Control|Primary angioplasty and stenting without additional intervention.
62587751|NCT06228352||Ulcerative colitis remission|Patient with ulcerative colitis, whatever the extent, except isolated proctitis (\<5 cm), diagnosed for more than 3 months and in clinical remission defined by a Pediatric Ulcerative Colitis Activity Index (PUCAI) score under 10.
62587752|NCT06228352||Controls|Paediatric patients (\<18 years) without chronic liver disease or chronic digestive disease (celiac disease, inflammatory bowel disease, chronic diarrhea) and hospitalized for an endoscopic examination to investigate abdominal pain, gastroesophageal reflux or polyposis.
62024359|NCT00412087|EXPERIMENTAL|Cholecalciferol 4000 IU|Women are randomized to one of 2 treatment groups: 2000 or 4000 IU vitamin D3/day
62024360|NCT02630212||Control|Chinese Han people undergoing coronary angiography in Qilu Hospital in corresponding period whose coronary arteries narrowing less than 50 percent.
62024361|NCT02630212||Aortic dissection|Chinese Han people diagnosed with aortic dissection in Qilu Hospital
62024362|NCT02513654|EXPERIMENTAL|Lamotrigine dispersible tablets 25mg, 50mg, 100mg|Each subjects will start dosing with lamotrigine 25mg dispersible tablet once daily at Day 1 and remain at this dose level for 2 weeks (Days1-14), then will be titrated to 50 mg once daily at Day 15 and last for weeks 3-4 (Days 15-28), and then titrated to 100 mg once daily at Day 29 during weeks 5-6 (Days 29-42).
62024363|NCT00949026|EXPERIMENTAL|A|
62415516|NCT03315871|EXPERIMENTAL|2/combination therapy + surveillance (closed)|Surveillance followed by Prostvac + CV301 then Prostvac + CV301 + MSB0011359C
62415517|NCT03315871|EXPERIMENTAL|3/combination vaccine therapy +/- surveillance|Surveillance as needed followed by Prostvac + CV301
62587753|NCT00792974||COPD by GOLD-criteria III and IV|
62587754|NCT06097624|EXPERIMENTAL|Exercise|The exercises will be applied three times a week for four weeks. Each exercise is going to start with 10 repetitions and 1 set in the first session, and the exercises will be revised at the beginning of each week. Resistance will gradually be increased, and after four weeks, 3 sets of 10 repetitions will be targeted.
62587755|NCT06097624|NO_INTERVENTION|Control|After a waiting period of four weeks, the participants will be contacted for reevaluation, and at the end of the assessment, an individual home exercise program will be created for them.
62796706|NCT01004289|EXPERIMENTAL|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion.
62796707|NCT01019070|ACTIVE_COMPARATOR|BMS-650032 in Child-Pugh A|
62415518|NCT01246297|OTHER|Control|Usual Care
62415519|NCT01246297|ACTIVE_COMPARATOR|Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of twice weekly exercise classes with an educational component.
62796708|NCT01019070|ACTIVE_COMPARATOR|BMS-650032 in Child-Pugh B|
62796709|NCT01019070|ACTIVE_COMPARATOR|BMS-650032 in Child-Pugh C|
62796710|NCT01019070|ACTIVE_COMPARATOR|BMS-650032 in Healthy Subjects|
62796711|NCT02669459|ACTIVE_COMPARATOR|LLETZ|LLETZ (Large Loop excision of the transformation zone) treatment conform current guidelines, which is also the current gold standard in the Netherlands
62796712|NCT02669459|OTHER|Imiquimod 5% cream|intervention group
62796713|NCT05605106||addict patients presenting with acute coronary syndrome|
62024364|NCT01970033|PLACEBO_COMPARATOR|Placebo|
62024365|NCT01970033|EXPERIMENTAL|SP2086 50 mg b.i.d|
62024366|NCT01970033|EXPERIMENTAL|SP2086 100 mg q.d.|
62024367|NCT03874000|EXPERIMENTAL|Sintilimab plus Metformin Hydrochloride|Patients receive metformin hydrochloride 500mg orally (PO) twice daily (BID). Patients also receive Sintilimab 200mg intravenously (IV) in 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.
62024368|NCT02673658|ACTIVE_COMPARATOR|Motor + problem solving|This method focuses on spontaneous movement (rather than facilitated movement). Self-initiated, functionally directed movement is emphasized. Intervention includes guidance and cues, which gently call the child's attention to the support surface, and a set-up of the environment for small increments of movement so that the child can solve a movement problem. Passive movements are not used. Each small increment of movement to advance sitting skill or other motor skills is paired with a specific object or toy that challenges a cognitive concept for spatial problem solving. In this approach, the parent will adjust toys and supports to encourage changes of position from sitting, to transitions in and out of sitting to crawling or standing, but will not assist the child physically.
62587756|NCT03362190|EXPERIMENTAL|Cohort 1|Zimura dosage 1 + Lucentis 0.5 mg
62587757|NCT03362190|EXPERIMENTAL|Cohort 2|Zimura dosage 2 + Lucentis 0.5 mg
62415520|NCT03059940|EXPERIMENTAL|Quitline (QL) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider. Participants given shared decision making and discussion about screening with the LDCT provider.~Participants referred to the Quitline for counseling and NRT (nicotine patch). Participants have 5 smoking cessation counseling sessions over the next 12 weeks."
62024369|NCT02673658|ACTIVE_COMPARATOR|Body weight support training|In this approach, infants will be supported physically by their parents to take steps, sit, crawl, or reach, in practice sessions focused simply on the motor skill. Toys or problem solving will not be part of this intervention, but the child will be assisted (lifted by the parent) through movement to improve strength and learn specific movements and new positions. The child will be able to perform as much of the movement as possible, but the parents will initiate the activity if the child does not initiate, and the parent will lift the child passively through the task if the child is unable to move.
62587758|NCT03362190|EXPERIMENTAL|Cohort 3|Zimura dosage 3 + Lucentis 0.5 mg
62587759|NCT03362190|EXPERIMENTAL|Cohort 4|Zimura dosage 4 + Lucentis 0.5 mg
62587760|NCT02053142|EXPERIMENTAL|Part 1 PK|400mg dose of acyclovir taken orally, followed by 2 ml blood plasma collection at 1,2,4,6 and 8 hours.
62587761|NCT02053142|ACTIVE_COMPARATOR|Acyclovir|400 mg Acyclovir three times daily for 5 days
62587762|NCT02053142|PLACEBO_COMPARATOR|Placebo|Placebo three times daily for 5 days
62587763|NCT00823043||Timolol hemihydrate|Subjects currently prescribed timolol hemihydrate 0.5% solution.
62587764|NCT00823043||Timolol maleate|Subjects currently prescribed timolol maleate in sorbate.
62587765|NCT03867487|EXPERIMENTAL|Study intervention|Empagliflozin 10 mg will be taken daily
62024370|NCT02639702|EXPERIMENTAL|Switch group|Participants will receive clozapine once daily at evening or bedtime throughout the study period. If a participant takes ≥200 mg of clozapine at a time other than evening/bedtime, half of this dose will be switched to an evening/bedtime regimen on day 0 (baseline), then another half dose will be switched on day 7 (week 1). Participants will receive placebo in place of the clozapine dose that was switched to evening/bedtime.
62024371|NCT02639702|NO_INTERVENTION|Maintenance group|Participants will continue to take clozapine twice daily throughout the study period.
62024372|NCT00659334|ACTIVE_COMPARATOR|1|Adults with brain tumor to receive Combidex infusion only
62024373|NCT00659334|ACTIVE_COMPARATOR|2|Adults with brain tumors to receive Combidex infusion and neurosurgery
62587766|NCT03867487|PLACEBO_COMPARATOR|Control arm|Placebo oral tablet will be taken daily
62587767|NCT01800643|OTHER|Orally Busulfan PK|Evaluate the Pharmacokinetics of orally busulfan
62587768|NCT01800643|OTHER|Intravenously Busulfan PK|Evaluate the Pharmacokinetics of intravenously busulfan
62587769|NCT03430479|EXPERIMENTAL|Cohort A|
62587770|NCT03430479|EXPERIMENTAL|Cohort B|
62796714|NCT05605106||non addict patients presenting with acute coronary syndrome|
62796715|NCT01988714|EXPERIMENTAL|(TCT) plus evidence-based SE|(TCT) plus evidence-based SE
62587771|NCT06666660|EXPERIMENTAL|Multivitamin/Mineral Supplement (MVM)|Participants in this arm will take 1.2g/day of MVM supplement from CENTRUM for 12 months.
62587772|NCT06666660|PLACEBO_COMPARATOR|Placebo|Participants in this arm will take 1.2g/day of placebo for 12 months.
62587773|NCT06387212|EXPERIMENTAL|DermaShine PRO negative microneedles instrument|
62587774|NCT01779310||Alzheimer's disease|Outpatients with clinically significant cognitive impairment per judgment of the participating physicians are enrolled.
62587775|NCT04024111|EXPERIMENTAL|KONTAKT(c)|A social skills group training
62587776|NCT04024111|ACTIVE_COMPARATOR|Art group|A social Art group
62796716|NCT01988714|PLACEBO_COMPARATOR|(CG) plus evidence-based SE|(CG) plus evidence-based SE
62796717|NCT04282668|EXPERIMENTAL|TAS1440|TAS1440 as a single agent administered once daily (QD) on specific days during each 28-day cycle in Part 1.
62221087|NCT02598024|EXPERIMENTAL|Narrative Exposure Therapy (NET-R)|Revised Narrative Exposure Therapy (NET-R) is a 4-session manual-based treatment, each session lasting 60-90-minutes, and first three sessions delivered daily and the last session after a gap of 1-2 days
62221088|NCT02598024|EXPERIMENTAL|Control Focused Behavioural Treatment|CFBT is an intervention to facilitate natural recovery process by restoring sense of control over anxiety, fear, or distress. For this study in Nepal, a monitoring session will be added to the one-session group CFBT used by Basoglu and Salcioglu (2011), and the revised CFBT would be delivered to groups of 20-30 survivors. Each treatment session would be delivered within 1- 2 hours (90 minutes on average), at the interval of two weeks.
62221089|NCT02598024|NO_INTERVENTION|Waiting List Control|The waiting list participants will receive the treatment of choice (NET-R or CBFT-R) after 3 months.
62221090|NCT02957526|EXPERIMENTAL|App|The web-based app will be used to ask participants about their aromatase inhibitor use in the previous 7 days and ask about treatment-related adverse symptoms, or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
62221091|NCT02957526|ACTIVE_COMPARATOR|Usual Care|Participants will have access to the web-based app, but will not receive reminders. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
62796718|NCT04282668|EXPERIMENTAL|TAS1440 + ATRA|TAS1440 administered QD on specific days during each 28-day cycle in combination with ATRA twice daily (BID) in Part 2.
62796719|NCT00829842|PLACEBO_COMPARATOR|1|Placebo
62796720|NCT00829842|EXPERIMENTAL|2|
62796721|NCT02595957||Cascade Testing|Family members of individuals who have received secondary genomic findings after exome/genome sequencing
62796722|NCT02595957||Secondary findings recipients|Individuals who have received secondary genomic findings after exome/genome sequencing
62796723|NCT06342908|EXPERIMENTAL|Treatment (PpDC vaccine, Poly ICLC)|Patients undergo leukapheresis 10 days prior to first injection. Patients then receive ppDC ID with poly ICLC IM in both arms Q2W for total 3 doses and then every 6 months for up to 3 doses. Patients undergo MRI throughout the trial. Patients also undergo blood sample collection throughout the trial in addition to stool sample collection during screening and on the trial.
62796724|NCT01051336|EXPERIMENTAL|TARIS Placebo|
62221092|NCT02097082|EXPERIMENTAL|STANZA Drug-eluting Resorbable Scaffold|Treatment of Superficial Femoral Artery (SFA) lesion with resorbable scaffold
62221093|NCT06169683|EXPERIMENTAL|Experienced Lyric Users|This cohort of participants is required to have Lyric hearing instrument experience, and they will be asked to wear Lyric for the duration of the study period and report on their experience.
62221094|NCT02673515|ACTIVE_COMPARATOR|Alternate day fasting|"Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum feed day with a 100% restriction fast day)."
62221095|NCT02673515|NO_INTERVENTION|control group|control group
62221096|NCT04702529|EXPERIMENTAL|Three treatments to hypertrophic scar with RAP device|RAP treatments will be administered to the scar every +/- 2 weeks for a total of 3 treatments
62796725|NCT01051336|SHAM_COMPARATOR|Sham Procedure|
62796726|NCT01961271|EXPERIMENTAL|Buprenorphine transdermal patch|Subjects will be on either 5mg, 10mg, 15mg, 20mg, 25mg, 30mg or 40mg doses for 17 weeks. Dose titration will occur every week for the first 6 weeks, and will be maintained for the next 11 weeks.
62221097|NCT02992821|EXPERIMENTAL|Bed-side pocket-size ultrasound|All participants will be examined bed-side by pocket size ultrasound for the assessment of the carotid arteries by junior doctors. All participants will then be examined by reference imaging in specific ultrasound laboratories with conventional high end equipment and new doppler techniques and when appropriate computer tomography or magnetic resonance imaging.
62796727|NCT04062591|ACTIVE_COMPARATOR|piroxicam|piroxicam group who received induction with piroxicam(0.4mg/kg) IM
62796728|NCT04062591|SHAM_COMPARATOR|placebo|saline IM in the same dose of piroxicam
62796729|NCT03170661|NO_INTERVENTION|Moderate neuromuscular block|Subjects will receive moderate neuromuscular block, aimed at 1-2 twitches train of four
62796730|NCT03170661|EXPERIMENTAL|Deep neuromuscular block|Subjects will receive deep neuromuscular block, aimed at 1-2 twitches post tetanic count
62796731|NCT04555460|ACTIVE_COMPARATOR|Decompressive surgery|Decompressive surgery was performed with a large hemicraniectomy that removed, ipsilateral to the stroke, a bone flap as large as possible including temporal, frontal, parietal, and some occipital squama.
62796732|NCT04555460|ACTIVE_COMPARATOR|Conservative medical therapy|Conservative medical therapy was based on published guidelines for the early management of patients with ischemic stroke. Administration of intravenous mannitol (0.25 to 0.5 g/kg) or furosemide was given only in patients whose condition was rapidly worsening because of brain edema, without additional recommendations on loading doses.
62024374|NCT00659334|OTHER|3|Adults with brain tumors to receive neurosurgery only (NO Combidex)
62024375|NCT00659334|ACTIVE_COMPARATOR|4|Children with brain tumors to receive Combidex only
62024376|NCT00659334|ACTIVE_COMPARATOR|5|Children with brain tumors to receive Combidex and neurosurgery
62024377|NCT00659334|OTHER|6|Children with brain tumors to receive neurosurgery only, NO Combidex
62024378|NCT00659334|ACTIVE_COMPARATOR|7|Adults with Inflammatory lesions (stroke or MS) to receive Combidex only
62024379|NCT06532669||Fetal period|from the formation of the fertilized egg until before birth, approximately 40 weeks
62024380|NCT06532669||Neonatal period|from the beginning of umbilical cord ligation after birth to 28 days
62024381|NCT06532669||Infancy period|after neonatal to 1 year of age.
62221098|NCT04331496|EXPERIMENTAL|Hypertonic solution|Hypertonic solution 4 ml 3% , for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow.
62024382|NCT06532669||Early childhood|from 1 year old to before 3 years old.
62024383|NCT06532669||Pre-school age|from three years old to six years old before entering primary school
62415521|NCT03059940|EXPERIMENTAL|Quitline-Rx (QL-Rx) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider.~LDCT provider and patient discuss options for pharmacotherapy.~Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks."
62415522|NCT03059940|EXPERIMENTAL|Integrated Care (IC) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider.~Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,"
62415523|NCT03121664|EXPERIMENTAL|Cohort 1|
62587777|NCT04817488||Prehospital emergency ultrasound with tele-supervision|Prehospital emergency ultrasound of patients with acute dyspnea will be performed with tele-supervision.
62796733|NCT02432417|NO_INTERVENTION|Standard|Radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 30 daily fractions of 2 Gray (Gy) or 33 daily fractions of 1.8 Gy to the tumor and surrounding margin in combination with TMZ 75 mg/m² Per os daily (po qd) and six adjuvant cycles of TMZ 150 - 200 mg/m² po qd.
62024384|NCT06532669||School age|from the age of 6 to the age of 12
62024385|NCT06532669||Puberty|from the age of 12 to the age of 18
62024386|NCT03726905|EXPERIMENTAL|respiratory muscles training|4 weeks guided respiratory muscles training followed by 12 weeks guided aerobic training - (treadmill walking)
62024387|NCT03726905|SHAM_COMPARATOR|sham respiratory muscles training|"4 weeks sham respiratory muscles training (THRESHOLD® IMT breathing trainer with 0 pressure level) followed by 12 weeks guided aerobic training - (treadmill walking)"
62221099|NCT04331496|ACTIVE_COMPARATOR|Physiological solution|Single-dose physiological saline serum (5 ml 0.9% NaCl), for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow.
62024388|NCT02524704||Healthy controls|Subjects between the ages of 2 and 21 with healthy lungs. Electrical impedance tomography data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, and during FEV1 and FEF 25-75 spirometry maneuvers for subjects over age 8.
62024389|NCT02524704||CF patients scheduled for a CT scan|Subjects with CF between the ages of 2 and 21 who are either clinically indicated for a CT scan of the lungs or are scheduled for a pulmonary CT scan as part of their routine care. Electrical impedance tomography data data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, during forced expiratory volume in 1 second (FEV1) and forced expiratory flow (FEF) 25-75 spirometry maneuvers for subjects over age 8, and immediately before or after pulmonary CT scanning.
62024390|NCT02524704||CF patients with pulmonary exacerbation|"Subjects with CF between the ages of 8 and 21 who are being started on intravenous (IV) antibiotics for a clinically diagnosed pulmonary exacerbation.~Electrical impedance tomography data data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, during FEV1 and FEF 25-75 spirometry maneuvers upon admission for a pulmonary exacerbation and following 7 to 14 days hospitalized treatment including IV antibiotics. Further data will be collected at the same time with CT scanning if the scan is part of the patient's standard of care."
62024391|NCT05525624|EXPERIMENTAL|Experimental|"TRAMPRE is an acronym that defines multimodal interventions discharge training. TRAMPRE will be applied to the participants in line with the Preterm Baby Care Guide at the discharge stage. Weekly telephone follow-up will be carried out for 12 weeks after discharge. Applications to be made to the initiative group are given below. Phone Follow-up/Interview: During the first 12 weeks following the discharge of the preterm baby, parents will be interviewed by phone at least once a week."
62221100|NCT06187194|EXPERIMENTAL|Enlarged tonsil(s) mass will be reduced by ENTire IRE System.|The bi-polar IRE System locally applies short, high-voltage (HV) pulses, increasing the permeability of tissue cells, creating non-thermal irreversible electroporation (NTIRE). The energy is transferred via bipolar forceps and causes irreversible cell membrane perforation and apoptosis. This results in tissue reduction within 2-4 weeks after treatment.
62415524|NCT01458860||GROUP A|patients had a CT
62415525|NCT01458860||GROUP B|patients with severe carotid artery stenosis
62587778|NCT04817488||Prehospital emergency ultrasound without tele-supervision|Prehospital emergency ultrasound of patients with acute dyspnea will be performed without tele-supervision.
62024392|NCT05525624|ACTIVE_COMPARATOR|Control Group|Participants in this group will be included in the routine neonatal clinic discharge training of the hospital where the research was conducted and no intervention will be applied.
62024393|NCT03651180||Amphilimus eluting stent|Diabetic patients treated with Cre8 Amphilimus eluting stent
62796734|NCT02432417|EXPERIMENTAL|Experimental arm|"Radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 30 daily fractions of 2 Gray (Gy) or 33 daily fractions of 1.8 Gy to the tumor and surrounding margin in combination with TMZ 75 mg/m² Per os daily (po qd) and six adjuvant cycles of TMZ 150 - 200 mg/m² po qd.~In addition this treatment will be combined with a daily intake of the recommended phase two dose (RPTD) of chloroquine (CQ)."
62024394|NCT03651180||Non Amphilimus eluting stent|Diabetic patients treated with any other drug eluting stent
62024395|NCT00874029|EXPERIMENTAL|Halt Procedure|In this single-arm study, subjects who have symptomatic uterine fibroids will have the Halt Procedure in which intra-abdominal ultrasound will guide RF ablation of uterine fibroids using the Halt System.
62024396|NCT00567242|EXPERIMENTAL|Word-finding with intention component|Treats word-finding (picture naming, category member generation) with an intention manipulation (complex left-hand movement to initiate word-finding trials)
62024397|NCT00567242|ACTIVE_COMPARATOR|Word-finding with no intention component|Word-finding trials similar to intention mediated treatment, but without intention manipulation
62024398|NCT04257370|EXPERIMENTAL|Kerecis™ Omega3 Wound|
62024399|NCT04257370|ACTIVE_COMPARATOR|Standard of care|
62024400|NCT03735550||Group A age: 18-49|Women aged 18-49 who had breast ultrasound performed with a result of BI-RADS 4b, 4c or 5. Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to breast ultrasound. The planned number of participants in the group: n=700 people.
62024401|NCT03735550||Group B age: 50 and above|Women aged 50 and above who had mammography and/or breast ultrasound performed (both examinations are obligatory, i.e. if the subject was recruited based on mammography, then ultrasound must be performed and vice-versa). Women were recruited if they had a result of BI-RADS 4, 4a, 4b, 4c or 5 on mammography or BI-RADS 4a, 4b, 4c or 5 on ultrasound. Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to the aforementioned techniques. The planned number of participants in the group: n=2100 people.
62221101|NCT01697215||Oral or nasal endotracheal intubation|Oral or nasal endotracheal intubation, anticipated to last at least 48 hours Adults that require ETT internal diameter sizes of 6.5 - 9.0 mm Subject must be at least 18 years old (no upper age limitation) English speaking patients/decision makers.
62796735|NCT06727201|ACTIVE_COMPARATOR|Ondansetron (Zofran)|Ondansetron will be given intravenously in a dose of 0.1mg/kg 10 minutes before spinal anaesthesia as single shot
62796736|NCT06727201|PLACEBO_COMPARATOR|Saline placebo|Normal saline will be administered by intravenous infusion 10 minutes before spinal anaesthesia
62796737|NCT03233113|ACTIVE_COMPARATOR|Exposure and response prevention|Exposure therapy with response prevention involves four hour-long individual sessions with a trained exposure therapist. Session 1 involves functional assessment, psychoeducation, presentation of the treatment rationale, and treatment planning. Sessions 2-4 involve a review of the model/treatment rationale, condition-specific reminders about how to prevent engaging in any safety behaviors during exposure, a 30-minute in-vivo exposure trial involving a live tarantula, and post-exposure processing. Session 4 also involves a discussion of relapse prevention strategies.
62024402|NCT03735550||Group C 18-49; 50 and above|"Subgroup C1 (n=100 people): women aged 18-49 years, who underwent breast ultrasound with a result of BI-RADS 1 or 2.~Sub-group C2 (n=100 people): women aged 50 and above, who had mammography or breast ultrasound performed; with a result of BI-RADS 1 or 2 (both examinations are obligatory, i.e. if the subject was recruited based on mammography, then ultrasound must be performed and vice-versa).~Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to the aforementioned techniques."
62024403|NCT04623294||Brain death patients for HLH Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ\[Hb\] and Δ\[HbO2\] time courses were collected by the NIRS instrument for hemodynamic parameter.
62024404|NCT04623294||Brain death patients for LHL Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ\[Hb\] and Δ\[HbO2\] time courses were collected by the NIRS instrument for hemodynamic parameter.
62796738|NCT03233113|EXPERIMENTAL|Exposure with judicious safety behaviors|Exposure therapy with judiciously used safety behaviors for spider phobia involves four hour-long individual sessions with a trained exposure therapist. Session 1 involves functional assessment, psychoeducation, presentation of the treatment rationale, and treatment planning. Sessions 2-4 involve a review of the model/treatment rationale, condition-specific reminders about how to strategically incorporate safety behaviors during exposure, a 30-minute in-vivo exposure trial involving a live tarantula, and post-exposure processing. Session 4 also involves a discussion of relapse prevention strategies.
62221102|NCT06277310|EXPERIMENTAL|3WP intervention|families of patients whose loved ones died in the ICU where the 3 Wishes Program has been implemented
62221103|NCT02686047|EXPERIMENTAL|the HYAJOINT Plus group|the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
62024405|NCT04623294||Deep coma patients for HLH Oxygen|Deep coma patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ\[Hb\] and Δ\[HbO2\] time courses were collected by the NIRS instrument for hemodynamic parameter.
62024406|NCT04623294||Deep coma patients for LHL Oxygen|Deep coma patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ\[Hb\] and Δ\[HbO2\] time courses were collected by the NIRS instrument for hemodynamic parameter.
62024407|NCT04623294||Healthy people for HLH Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ\[Hb\] and Δ\[HbO2\] time courses were collected by Optical monitor for hemodynamic parameter.
62024408|NCT04623294||Healthy people for LHL Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ\[Hb\] and Δ\[HbO2\] time courses were collected by Optical monitor for hemodynamic parameter.
62024409|NCT01560520||Accelerometer|
62221104|NCT02686047|ACTIVE_COMPARATOR|The Synvisc-One group|The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
62221105|NCT02015182||Blood sample for bupivicaine pharmacokinetics|Children undergoing TAP block will have blood sampled for bupivacaine pharmacokinetics
62221106|NCT06437587|EXPERIMENTAL|intervention group|Home-based rehabilitation appropriate technology (S-HRAT) training
62415526|NCT02618772|PLACEBO_COMPARATOR|Intranasal Saline|0.08ml/kg of saline to a maximum of 2ml intranasally with an atomizer MAD-300
62415527|NCT02618772|ACTIVE_COMPARATOR|Intranasal Midazolam|0.08ml/kg (0.4mg/kg of 5mg/ml IV solution) intranasal midazolam, to a maximum of 2ml (10mg), with an atomizer MAD-300
62415528|NCT02553005|SHAM_COMPARATOR|sham acupuncture|False acupuncture treatment using not acupuncture points
62415529|NCT02553005|EXPERIMENTAL|verum acupuncture|Real acupuncture treatment
62796739|NCT01702025|PLACEBO_COMPARATOR|Placebo|"Administer a single dose of placebo (yellow corn meal in a capsule, gelatin ) in Normoxic Conditions.~Following a minimum of 7 days a single dose placebo will be administered (yellow corn meal in a gelatin capsule) in Hypoxic conditions."
62024410|NCT03579979|EXPERIMENTAL|Self control|"During the operation, with the fluorescent molecular imaging instrument, the imaging agent (indocyanine green) is illuminated by the probe distance to the tissue surface 10-30cm, and is excited to produce the near infrared fluorescence of the specific wavelength (the human eye is not visible). The system uses a photoelectric coupler to collect the light of the specific spectrum, and the image is collected by the method of correction. The operation was performed to achieve real-time display of lesions.~The injection points were selected subcutaneously around the areola or the periphery of the tumor. 1% methylene blue 0.5ml was injected at each point, with a total of 2-3 points. Within 5 minutes, 2.5mg/ml ICG 0.5ml was injected at each point, with a total of 2-3 points."
62024411|NCT04502329|EXPERIMENTAL|IER|Intermittent Energy Restriction
62024412|NCT04502329|NO_INTERVENTION|CER|Continous Energy Restriction
62024413|NCT06226844||Control group : PEMA SHAM|Patients receiving the usual management
62024414|NCT06226844||Experimental group : PEMA BeatMove|Patients on rehabilitation using the BeatMove device
62024415|NCT05800392|EXPERIMENTAL|Experimental|DEC103: The participants will take 02 (two) pills of the sublingual formulation and 01 (one) pill of the oral one, 1 hour prior the IUD insertion.
62221107|NCT06437587|NO_INTERVENTION|control group|Routine discharge instructions
62415530|NCT02553005|NO_INTERVENTION|Control|
62415531|NCT06701448|OTHER|RBS group|Biopsy of peripheral pulmonary lesions using RBS
62415532|NCT06701448|OTHER|ENB group|Biopsy of peripheral pulmonary lesions using ENB
62415533|NCT06701448|OTHER|FB group|Biopsy of peripheral pulmonary lesions using FB
62415534|NCT00571909|EXPERIMENTAL|video thoracoscopic splanchnicectomy (VSPL)|
62024416|NCT05800392|PLACEBO_COMPARATOR|Placebo|PLACEBO DEC103: The participants will take 02 (two) pills of the placebo sublingual formulation and 01 (one) pill of the placebo oral one, 1 hour prior the IUD insertion.
62024417|NCT04936282|EXPERIMENTAL|Experimental|Normal treatment (Steroids, tacrolimus and mycophenolate) for first 90 days, then add Grafalon single-dose if borderline lesions are present in protocol biopsy (performed at third month post-transplantation).
62587779|NCT04101682|ACTIVE_COMPARATOR|Single Shot|Patients will receive an adductor canal block in the operating room postoperatively as single shot of 20-30cc bupivacaine
62587780|NCT04101682|ACTIVE_COMPARATOR|Continuous Block|Patients will have a catheter inserted into the adductor canal which will be attached up to a continuous infusion pump of bupivacaine that will have a set flow rate over the next couple days
62024418|NCT04936282|ACTIVE_COMPARATOR|Normal treatment|Normal treatment (Steroids, tacrolimus and mycophenolate) arm
62221108|NCT01607632|EXPERIMENTAL|loving-kindness meditation|
62796740|NCT01702025|ACTIVE_COMPARATOR|Aminophylline|"Administer a single dose of 400 mg Aminophylline (4-100 mg tablets) in Normoxic Conditions.~Following a minimum of 7 days administer a single dose of 400 mg Aminophylline (4-100 mg tablets) in Hypoxic conditions."
62796741|NCT01702025|ACTIVE_COMPARATOR|Methazolamide|"Administer a single dose of 250 mg Methazolamide (10-25 mg tablets) in Normoxic Conditions.~Following a minimum of 7 days administer a single dose of 250 mg Methazolamide (10-25 mg tablets) in Hypoxic conditions."
62796742|NCT01702025|ACTIVE_COMPARATOR|Aminophylline+Methazolamide|"Administer a single dose of 400 mg Aminophylline (4-100 mg tablets) + 250 mg Methazolamide (10-25 mg tablets) in Normoxic Conditions.(Aminophylline+Methazolamide)~Following a minimum of 7 days administer a single dose of 400 mg Aminophylline (4-100 mg tablets) + 250 mg Methazolamide (10-25 mg tablets) in Hypoxic conditions."
62024419|NCT05442580|EXPERIMENTAL|Cohort A Dose Level 1: Relapsed/Refractory Acute Myeloid Leukemia (AML)|Cohort A Dose Level 1: Adult patients ages ≥ 18 with acute myeloid leukemia (AML) who have not achieved remission after at least two lines of prior therapy will receive a single fixed dose of 3x10(6) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
62024420|NCT05442580|EXPERIMENTAL|Cohort A Dose Level -1 :Relapsed/Refractory Acute Myeloid Leukemia (AML)|Cohort A Dose Level -1: Adult patients ages ≥ 18 with acute myeloid leukemia (AML) will receive a single fixed dose of 7x10(5) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
62221109|NCT04771728|ACTIVE_COMPARATOR|Metronidazole vaginal|Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )
62796743|NCT03462719|EXPERIMENTAL|Treatment Arm A: Ibrutinib and Venetoclax (I+VEN)|Participants will initially receive ibrutinib (420 mg \[milligrams\]/day) for 3 cycles. Venetoclax dose ramp up (from 20 to 400 mg over 5 weeks) will begin at Cycle 4 and the combination of ibrutinib and venetoclax will be given for 12 cycles (each cycle is equivalent to 28 days). Participants who subsequently develop progressive disease may enter to Subsequent Therapy Phase to receive single-agent ibrutinib until disease progression or unacceptable toxicity.
62221110|NCT04771728|EXPERIMENTAL|Metronidazole vagianl and Probiotics(Umeta-mimi)|Metronidazole:Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) Probiotics:Oral Umeta-mimi( 5×109cfu per day,30 days）
62587781|NCT05210114|EXPERIMENTAL|Skin Hydration Sensor|
62587782|NCT05262309|EXPERIMENTAL|Pamrevlumab|
62587783|NCT05262309|NO_INTERVENTION|Standard of care|
62587784|NCT02780726|EXPERIMENTAL|ASP1517 Low Dose Group (ESA Untreated)|This group includes subjects who have not received Erythropoieses Stimulating Agents (ESAs). Study drug will be dosed three times weekly and dose adjustments will be made during the study.
62587785|NCT02780726|EXPERIMENTAL|ASP1517 High Dose Group (ESA Untreated)|This group includes subjects who have not received ESAs. Study drug will be dosed three times weekly and dose adjustments will be made during the study.
62221111|NCT03657654||Thyroidectomy|Patients that are clinically referred for a thyroidectomy for known or potential cancer.
62221112|NCT03657654||Other surgeries|Patients must be clinically referred for a surgery requiring intubation, but without risk to the laryngeal nerves or dissection adjacent to the larynx
62221113|NCT02029846|ACTIVE_COMPARATOR|Standard Treatment|A regimen with traditional drugs only
62221114|NCT02029846|EXPERIMENTAL|Incretin-based Treatment|A regimen including incretin-based drugs
62415535|NCT03444909|EXPERIMENTAL|cardiotocograph and Toconaute|monitoring with cardiotocograph and next with the Toconaute of Bioserenity
62415536|NCT03444909|EXPERIMENTAL|Cardiotocograph and Toconaute and Electrophysiological device|monitoring withardiotocograph and next with Toconaute and next with the electrophysiological device
62415537|NCT03444909|EXPERIMENTAL|Cardiotocograph and electrophysiological device|monitoring with the cardiotocograph and next with the electrophysiological device (Micromed)
62415538|NCT06569004|EXPERIMENTAL|IR beam used before peripheral intravenous catheter application on vein visibility|IR beam application
62415539|NCT06569004|NO_INTERVENTION|control|Only parenteral catheter application
62796744|NCT03462719|ACTIVE_COMPARATOR|Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb)|Participants will receive chlorambucil and obinutuzumab (G-Clb) for 6 cycles. Participants will receive obinutuzumab, 1000 mg intravenously (IV) on Days 1, 8 and 15 of Cycle 1, and on Day 1 of Cycles 2 to 6 and chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight, on Days 1 and 15 of Cycles 1 to 6. Participants who subsequently develop progressive disease may enter to Subsequent Therapy Phase to receive single-agent ibrutinib until disease progression or unacceptable toxicity.
62024421|NCT05442580|EXPERIMENTAL|Cohort A Dose Level 2 :Relapsed/Refractory Acute Myeloid Leukemia (AML)|Cohort A Dose Level 2: Adult patients ages ≥ 18 with acute myeloid leukemia (AML) will receive a single fixed dose of 7x10(6) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
62221115|NCT03780075|EXPERIMENTAL|1.11GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
62221116|NCT03780075|EXPERIMENTAL|2.00 GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 2.00 GBq (54 mCi) of 177Lu-EB-PSMA-617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
62221117|NCT03780075|EXPERIMENTAL|3.70GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
62221118|NCT04577547|EXPERIMENTAL|Dietary Guidelines (DGA) diet with weight loss (WL) & exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight loss with Physical Activity Guidelines for Americans (PAGA)-recommended exercise
62024422|NCT05442580|EXPERIMENTAL|Cohort A Dose Level 3 :Relapsed/Refractory Acute Myeloid Leukemia (AML)|Cohort A Dose Level 3: Adult patients ages ≥ 18 with acute myeloid leukemia (AML) will receive a single fixed dose of 3x10(7) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
62024423|NCT05442580|EXPERIMENTAL|Cohort B Dose Level 1: Multiple Myeloma (MM)|Cohort B Dose Level 1 - Adult patients ages ≥ 18 with Multiple Myeloma (MM) who have not achieved remission after at least two lines of prior therapy will receive a single fixed dose of 3x10(6) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
62221119|NCT04577547|EXPERIMENTAL|DGA diet with WL & no exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight loss with no exercise
62221120|NCT04577547|EXPERIMENTAL|DGA diet weight maintenance (WM) & exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight maintenance with PAGA-recommended exercise
62415540|NCT04141670|EXPERIMENTAL|Low dose group|Experimental: 120 mg S48168 (ARM210; 6 x 20 mg tablets) daily for 29 days
62415541|NCT04141670|EXPERIMENTAL|High dose group|Experimental: 200 mg S48168 (ARM210; 10 x 20 mg tablets) daily for 28 days (1 participant) or 29 days (3 participants)
62415542|NCT04983095|ACTIVE_COMPARATOR|Standard of Care|ADT+ARPI to all patients and local RT +/- pelvic fields to de novo patients
62415543|NCT04983095|EXPERIMENTAL|SBRT+Standard of Care|SBRT to all PSMA+ lesions in addition to SoC and salvage RT to the prostate bed +/- pelvic fields if recurrent post prostatectomy and PSMA-PET+ in the pelvis
62415544|NCT06471738|EXPERIMENTAL|Treatment (zanubrutinib, venetoclax, rituximab)|"stage I (cycles 1-3, every 4 weeks): zanubrutinib PO 160mg, BID; rituximab IV on day 1.~stage II (cycles 4-9, every 4 weeks): if complete response : zanubrutinib PO 160mg, BID; rituximab IV on day 1.~if no complete response : zanubrutinib PO160mg, BID; rituximab IV on day 1 and Venetoclax PO (100mg D1, 200mg D2, and 400mg D3 of cycle 4; 400mg QD)."
62415545|NCT04437407|OTHER|Control|The first night will be a control night with infrared video recording where only the Ajuvia sleep monitor is worn in passive mode so that each participant can act as her own control for comparison of treatment effect on outcomes.
62415546|NCT04437407|EXPERIMENTAL|PB2-1|During this night, the PB2-1 prototype will be worn with the Ajuvia in passive mode.
62415547|NCT04437407|EXPERIMENTAL|PB2-2|During this night, the PB2-2 prototype will be worn with the Ajuvia in passive mode.
62415548|NCT04437407|EXPERIMENTAL|PB2-3|During this night, the PB2-3 prototype will be worn with the Ajuvia in passive mode.
62415549|NCT04437407|EXPERIMENTAL|PB2-4|During this night, the PB2-4 prototype will be worn with the Ajuvia in passive mode.
62415550|NCT04437407|EXPERIMENTAL|PB2-5|During this night, the PB2-5 prototype will be worn with the Ajuvia in active mode.
62415551|NCT04686500|OTHER|Deep Inspiration Breath-hold (DIBH) Respiratory Motion|DIBH qualified patient will experience one high-resolution CT scan as SOC and additional 3 low resolution/lower dose CT scans to further investigate inter-DIBH patient surface and tumor position stability and repeatability
62415552|NCT04965896|PLACEBO_COMPARATOR|Control meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a snack with crackers and cheese. The meal is similar in energy and macronutrients to the test meal.
62415553|NCT04965896|EXPERIMENTAL|Nut meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a portion of 30g of nuts. The meal is similar in energy and macronutrients to the control meal.
62796745|NCT06726590||Polypharmacy|Patients taking many medications or medications with severe side effects
62221121|NCT04577547|EXPERIMENTAL|DGA diet WM & no exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight maintenance with no exercise
62221122|NCT04577547|EXPERIMENTAL|Western diet with WL & exercise|Western-type menu to provide a calorie level to promote weight loss with PAGA-recommended exercise
62221123|NCT04577547|EXPERIMENTAL|Western diet with WL & no exercise|Western-type menu to provide a calorie level to promote weight loss with no exercise
62221124|NCT04577547|EXPERIMENTAL|Western diet WM exercise|Western-type menu to provide a calorie level to promote weight maintenance with PAGA-recommended exercise
62221125|NCT04577547|EXPERIMENTAL|Western diet WM no exercise|Western-type menu to provide a calorie level to promote weight maintenance with no exercise
62221126|NCT00417261|EXPERIMENTAL|1|ATF936
62221127|NCT00417261|EXPERIMENTAL|2|AXT914
62221128|NCT00417261|PLACEBO_COMPARATOR|3|Placebo
62221129|NCT01410123|OTHER|Treatment as Usual (TAU)|
62221130|NCT01410123|OTHER|Integrated Stepped Care (ISC)|
62221131|NCT02253901|EXPERIMENTAL|TRUVADA with BILR 355 BS and ritonavir|
62221132|NCT02253901|ACTIVE_COMPARATOR|BILR 355 BS in combination with ritonavir|
62415554|NCT04225416||Hemodialysis patients|Patients undergoing hemodialysis
62415555|NCT04225416||Peritoneal dialysis patients|Patients undergoing peritoneal dialysis
62415556|NCT06332209|ACTIVE_COMPARATOR|Tele-TF-CBT|Trauma-Focused Cognitive Behavioral Therapy delivered via telehealth
62415557|NCT06332209|ACTIVE_COMPARATOR|Clinic-TF-CBT|Trauma-Focused Cognitive Behavioral Therapy delivered in clinic (in-person)
62796746|NCT01684202|EXPERIMENTAL|OPC-41061|
62221133|NCT04039477|EXPERIMENTAL|Arm A - KZR-616 30mg|KZR-616 30mg Subcutaneous (SC) injection weekly for 13 weeks
62415558|NCT01849029|EXPERIMENTAL|Cognitive Processing Theapy-Cognitive|Immediate group receives Cognitive Processing Therapy-Cognitive CPT-C intervention within one week of being consented into the study
62415559|NCT01849029|OTHER|Cognitive Processing Threapy-Cognitive|Wait list group: waits 6 weeks before receiving the Cognitive Processing Therapy-Cognitive (CPT-C) intervention. During this period no intervention is received
62415560|NCT06565754|ACTIVE_COMPARATOR|strengthening exercises group (SE Group)|"all patients will receive :~1. Isometric quadriceps exercise - 3 sets of 20 repetitions (5 s).~2. Straight leg raise (SLR) with 3 sets - 20 repetitions.~3. Short arc knee extension exercise - 3 sets of 20 repetitions.~4. Hip abduction from side lying - 3 sets of 20 repetitions."
62415561|NCT06565754|EXPERIMENTAL|BFRT plus strengthening exercises group (BFRT Group)|"all patients will receive the below exercises using BFR cuff :~1. Isometric quadriceps exercise - 3 sets of 20 repetitions (5 s).~2. Straight leg raise (SLR) with 3 sets - 20 repetitions.~3. Short arc knee extension exercise - 3 sets of 20 repetitions.~4. Hip abduction from side lying - 3 sets of 20 repetitions."
62415562|NCT01551329|EXPERIMENTAL|Drug: Ketamine|
62415563|NCT01188759|EXPERIMENTAL|Voriconazole and Anidulafungin Combination|Subjects in the combination arm will receive voriconazole and anidulafungin in combination for 2-4 weeks followed by voriconazole monotherapy to complete 6-12 weeks of therapy.
62415564|NCT01188759|ACTIVE_COMPARATOR|Voriconazole Monotherapy|Subjects in the monotherapy arm will receive voriconazole monotherapy for 6-12 weeks of therapy.
62415565|NCT06023953||Migraine with aura (MWA)|Patients with migraine who used the Nerivio device at least once and reported having aura in at least one treatment
62415566|NCT06023953||Migraine without aura (MWoA )|Patients with migraine who used the Nerivio device at least once and never reported having aura in any of their treatments
62415567|NCT04269746||Control group|The control population comprised normal healthy individuals.
62415568|NCT04269746||Precancerous group|patients with precancerous colorectal diseases
62796747|NCT06399289|EXPERIMENTAL|rIX-FP|Subjects will receive rIX-FP as an intravenous (IV) infusion for a minimum of 50 exposure days (EDs)
62221134|NCT04039477|EXPERIMENTAL|Arm B - KZR-616 45mg|KZR-616 30 mg SC injection weekly for 1 dose then 45mg weekly for 12 weeks.
62415569|NCT04269746||CRC group|patients with colorectal cancer
62415570|NCT02487979|EXPERIMENTAL|Treatment (glembatumumab vedotin)|Patients receive glembatumumab vedotin IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
62415571|NCT05471063|EXPERIMENTAL|ABCD treatment|In this single-arm research, patients were treated with ABCD 3.0-4.0 mg/kg/d (subject to adjustment, maximum dose not exceeding 6.0 mg/kg/d) combined with flucytosine 100 mg/kg/d for induction therapy of cryptococcal meningitis. The course of induction therapy is at least four weeks. Then, patients were treated with Fluconazole (400-600 mg/d) ± flucytosine (100 mg/kg/d) for consolidation therapy for at least 6 weeks.
62415572|NCT06564155||ankylosing spondylities patients|"detect level of IL33 in serum of AS patients~measure carotid intima media thickness by caroid dupex"
62415573|NCT06564155||control persons|"detect level of IL33 in serum of normal control group~measure carotid intima media thickness by caroid dupex"
62415574|NCT02232685|EXPERIMENTAL|Choline PET/CT|18F-Choline PET/CT
62415575|NCT04482101|EXPERIMENTAL|Ah-Plus sealer|"Root canal sealer which is a resin-based formula with excellent radiopacity , low shrinkage , low solubility and outstanding flow characteristics .~It features a 1:1 , paste-to-paste mixing system for fast , easy preparation and less waste . It is biocompatible and silver free ."
62415576|NCT04482101|EXPERIMENTAL|Endosequence BC sealer|"It is a root canal sealer which is premixed ready-to-use injectable bioceramic cement paste developed for permanent root canal filling and sealing applications.~It is insoluble , radiopaque and aluminum-free material based on calcium silicate composition , which requires the presence of water to set and hardens . It does not shrink during setting and demonstrate excellent physical properties ."
62415577|NCT04764825|EXPERIMENTAL|Methadone, induction|"Patients receive methadone 0.15-0.2 mg/kg ideal bodyweight 10 minutes prior to surgery start (Syringe A).~45 minutes before expected extubation patients will receive saline (syringe B)."
62415578|NCT04764825|EXPERIMENTAL|Methadone, end of surgery|Patients receive saline 10 minutes prior to surgery start (Syringe A). 45 minutes before expected extubation patients will receive methadone 0.15-0.2 mg/kg ideal bodyweight (syringe B).
62415579|NCT04764825|ACTIVE_COMPARATOR|Morphine|Patients receive saline 10 minutes prior to surgery start (Syringe A). 45 minutes before expected extubation patients will receive morphine 0.15-0.2 mg/kg ideal bodyweight (syringe B).
62415580|NCT03491800|OTHER|Question/Topic Prompt List|The Question/Topic Prompt List is provided to HF Patients and their family member (if applicable) for completion prior to being seen by the doctor.
62415581|NCT03417674|EXPERIMENTAL|Intervention group|Lifestyle intervention with meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
62415582|NCT03417674|NO_INTERVENTION|Control group|Routine care.
62221135|NCT04428073|EXPERIMENTAL|Low dose group|Subjects will receive 1.0 mL of low dose vaccine at week 0 and 2.
62221136|NCT04428073|EXPERIMENTAL|High dose group|Subjects will receive 1.0 mL of high dose vaccine at week 0 and 2.
62221137|NCT01666457||Pre-SOFFI infants|Infants discharged from the NICU prior to the implementation of the SOFFI infant driven feeding program with NICU staff.
62221138|NCT01666457||Post SOFFI infants|Subject infants discharged from the NICU at least 6 months after the implementation of the SOFFI infant driven feeding program and
62415583|NCT01881178|ACTIVE_COMPARATOR|Apricot|Supplement: Apricot Juice
62221139|NCT01015339|ACTIVE_COMPARATOR|Cisplatin plus capecitabine|
62221140|NCT01015339|EXPERIMENTAL|Paclitaxel plus Capecitabine|
62415584|NCT01881178|EXPERIMENTAL|Nopalea|Supplement: Nopalea
62796748|NCT02197702|PLACEBO_COMPARATOR|Placebo|2 ml identical placebo taken by mouth at baseline and 3.5 months.
62796749|NCT02197702|EXPERIMENTAL|Vitamin D|Vitamin D (100,000IU) given in a 2 ml oral dose at baseline and 3.5months.
62221141|NCT02437071|EXPERIMENTAL|Pembrolizumab Plus Radiotherapy|pembrolizumab plus RT in subjects with metastatic CRC who are undergoing RT as standard therapy
62221142|NCT02437071|EXPERIMENTAL|Pembrolizumab Plus Ablation|pembrolizumab plus ablation in subjects with metastatic CRC who are undergoing ablation as standard therapy
62415585|NCT03686124|EXPERIMENTAL|Dose Escalation A|Dose escalation of IMA203
62796750|NCT04428151|EXPERIMENTAL|Lenvatinib + Pembrolizumab|Participants will be treated with the combination of lenvatinib (once daily 20 mg oral dose) plus pembrolizumab (200 mg 30-minute intravenous (IV) infusion on Day 1 of each 21-day cycle for 35 cycles), until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met. Participants may receive up to an additional 17 cycles of pembrolizumab as Second Course treatment, with or without lenvatinib.
62796751|NCT04428151|ACTIVE_COMPARATOR|SOC Chemotherapy|Participants will be treated with investigator's choice of standard of care (SOC) chemotherapy (docetaxel, paclitaxel, cetuximab, or capecitabine) until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met.
62024424|NCT05442580|EXPERIMENTAL|Cohort B Dose Level -1: Multiple Myeloma (MM)|Cohort B Dose Level -1 - Adult patients ages ≥ 18 with Multiple Myeloma (MM) who have not achieved remission after at least two lines of prior therapy will receive a single fixed dose of 7x10(5) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
62221143|NCT03866161||CPAP group|Obstructive sleep apnea patients treated with continuous positive airway pressure
62221144|NCT06056167|EXPERIMENTAL|Degludec|
62221145|NCT05045508|EXPERIMENTAL|OC-01 (varenicline 0.6mg/ml) nasal spray|
62221146|NCT05045508|PLACEBO_COMPARATOR|Placebo (vehicle) nasal spray|
62221147|NCT03210584||Imaging measurements|All subject of the study have a knee osteoarthritis (OA) and are going to have a knee prosthetic surgery with cartilage excision. Multimodal evaluation is conducted on ex vivo human cartilage samples (2 samples per patient are selected : healthy and severely degraded).
62415586|NCT03686124|EXPERIMENTAL|Extension Cohort A|IMA203 at RP2D
62415587|NCT03686124|EXPERIMENTAL|Extension Cohort B|IMA203 at RP2D + nivolumab
62415588|NCT03686124|EXPERIMENTAL|Extension Cohort AA|IMA203 at anticipated final RP2D (flat dose)
62415589|NCT03686124|EXPERIMENTAL|Dose Escalation B|Dose escalation of IMA203CD8
62415590|NCT03686124|EXPERIMENTAL|Extension Cohort C|IMA203CD8 at dose levels confirmed to be safe
62415591|NCT03686124|EXPERIMENTAL|Extension Cohort D|IMA203CD8 at dose levels confirmed to be safe; without IL-2
62796752|NCT04428151|ACTIVE_COMPARATOR|Lenvatinib Monotherapy|Participants will be treated with lenvatinib monotherapy (once daily 24 mg oral dose) until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met.
62796753|NCT06554379||Periodontal health|It includes gingival healthy individuals without any periodontal disease.
62796754|NCT06554379||Gingivitis|It includes individuals with gingivitis.
62415592|NCT03686124|EXPERIMENTAL|Ovarian/Uterine|IMA203CD8 monotherapy at dose levels confirmed to be safe
62415593|NCT03686124|EXPERIMENTAL|Synovial Sarcoma|IMA203CD8 monotherapy at dose levels confirmed to be safe
62415594|NCT03686124|EXPERIMENTAL|Head and Neck, Lung, and Triple Negative Breast Cancer|IMA203CD8 monotherapy at dose levels confirmed to be safe
62024425|NCT05442580|EXPERIMENTAL|Cohort B Dose Level 2: Multiple Myeloma (MM)|Cohort B Dose Level 2 - Adult patients ages ≥ 18 with Multiple Myeloma (MM) who have not achieved remission after at least two lines of prior therapy will receive a single fixed dose of 7x10(6) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
62024426|NCT05442580|EXPERIMENTAL|Cohort B Dose Level 3: Multiple Myeloma (MM)|Cohort B Dose Level 3 - Adult patients ages ≥ 18 with Multiple Myeloma (MM) who have not achieved remission after at least two lines of prior therapy will receive a single fixed dose of 3x10(7) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
62024427|NCT03879018|EXPERIMENTAL|Reinforcement Training|Reach training with visual feedback. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed. During training the participant will reach a total of 400 times. For reinforcement training, participants will not see their hand or a cursor, but instead participants will receive target-specific binary feedback after each reach (i.e. based on running average of last 10 reaches to that target). Binary feedback indicates only whether the reach was successful or unsuccessful and provides no specific information about the location of the hand.
62221148|NCT03104491|EXPERIMENTAL|Inotuzumab Ozogamicin|"Phase I:~A maximum of 4 cycles will be allowed and doses will be adjusted in 0.1mg/m2 increments using a dose escalation scale depending on tolerability. Total range of dose levels for participants is 0.1-0.6mg/m\^2.~Phase II:~Participants will be enrolled until all Phase I participants have been followed and assessed for toxicity for at least 4 weeks after the fourth treatment dose of inotuzumab ozogamicin or 4 weeks after the participant goes off treatment, whichever comes first. Doses to be administered will be determined in the phase I portion of the study. The recommended phase 2 dose is 0.3mg/m2. Repeat cycles every 28 days for up to 4 cycles"
62415595|NCT01238523|EXPERIMENTAL|Long leg cast in full extension|Long leg cast in full extension with instructions to begin immediate weight bearing as tolerated on the injured extremity
62415596|NCT01238523|EXPERIMENTAL|Long leg cast with 45 degrees of flexion|Long leg cast with 45 degrees of flexion at the knee with instructions not to bear weight on the injured extremity
62415597|NCT04032522||Intervention Arm (A)|Half of the health facilities will implement the intervention package. All mothers will be tested using PoC-VL at delivery and all HIV-exposed infants will be offered PoC-EID at birth and week 4-8. Newborns found to be HIV-positive will be offered immediate ART. Neonatal ART initiation will be supported at birth by trained nurses/midwives, and approved and supervised by local doctors from the affiliated HIV CTC. Following ART initiation infants will be referred for consolidated ART management to their paediatric HIV clinic following local procedures. Newborns testing HIV-negative will be offered postnatal prophylaxis (PNP) or enhanced postnatal prophylaxis (ePNP), depending on clinical risk factors, the maternal VL and country guidelines. Mothers with HIV-RNA \>1000 copies/mL will receive immediate referral information for ART initiation if not on ART or enhanced ART counselling, with follow up virologic testing and switch of ART regimen as applicable at their local HIV clinic.
62415598|NCT04032522||Control Arm (B)|The other half of the health facilities will implement the standard of care (SoC). Enrolled mothers will not receive immediate PoC VL at delivery, but infants deemed to be at high risk using clinical criteria (e.g. no or late initiation of maternal ART) will be offered ePNP. EID testing will follow the national algorithm with testing at 4-8 weeks, followed by referral for immediate ART initiation for all HIV-infected infants. As PoC EID testing is expected to be nationally implemented on a programme level we will facilitate the availability of PoC testing at these sites.
62587786|NCT02780726|EXPERIMENTAL|ASP1517 ESAs Treated Group|This group includes subjects who have received ESAs. The treatment was converted from ESAs to study drug. Study drug will be dosed three times weekly and dose adjustments will be made during the study.
62415599|NCT03176511|EXPERIMENTAL|MOB+DTBC Group|A Matter of Balance plus Dual-Task Balance Challenge Group. Standardized MOB classes twice/week for 4 weeks, plus 15 minutes of DTBC each class. Each class is 2 hours 15 minutes.
62415600|NCT03176511|ACTIVE_COMPARATOR|MOB Group|A Matter of Balance Group. Standardized MOB classes twice/week for 4 weeks, plus 15 minutes of social time each class. Each class is 2 hours 15 minutes.
62587787|NCT00489086|OTHER|Tazarotene Cream|Open label
62587788|NCT04729179|EXPERIMENTAL|Cannabidiol|Participants will start with 10 mg of cannabidiol daily and the dose will be escalated every third day until the maximum dosage of 50 mg is reached (after two weeks). The participants be on the 50 mg dosage of cannabidiol for 24 weeks.
62587789|NCT04729179|PLACEBO_COMPARATOR|Placebo|Placebo is administered as tablets of 10 mg that are identical in appearance, taste, and smell to the Cannabidiol tablets.The participants will be on the 50 mg dosage of placebo for 24 weeks.
62024428|NCT03879018|EXPERIMENTAL|Standard Practice Training|Reach training with visual feedback. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed. During training the participant will reach a total of 400 times. For standard practice, participants will be able to see a cursor that represents the position of the hand at all times and try to make straight reaches to the targets. This type of feedback provided specific information about the location of the hand.
62221149|NCT01332773|EXPERIMENTAL|Artery first group|"The basic principle of the artery first approach is the early identification of the SMA at its origin at the aorta with the further resection then being guided by its anatomic course.~The dissection is carried cephalad along the aorta until the origin of the SMA is reached. The posterior and right aspect of the SMA is then dissected over a few centimeters. On the right side of the SMA a replaced or accessory right hepatic artery, if present, will be identified and preserved. This maneuver should be done, if infiltration of the SMA is suspected as the procedure can be terminated at this point. Once the situation at the SMA is assessed and resectability is confirmed resection will be done."
62221150|NCT01332773|ACTIVE_COMPARATOR|Conventional Group|A wide Kocher manoeuver is performed to fully mobilize the duodenum and the head of the pancreas. The colonic mesentery on the right side is separated from the anterior surface of the duodenum and the head of the pancreas. The size of the tumor and its relation to the superior mesenteric artery, the celiac trunk, the mesentery, the portal vein, and the superior mesenteric vein is assessed. If resectability is given a Kausch-Whipple's resection is performed.
62221151|NCT05449561||Discrete Choice qualitative interview|We will invite at least 20 participants with at least mild level of depressive symptoms to participate in individual interviews. The interviews will be in semi-structured format. Upon provision of informed consent and completion of demographics survey, we will ask respondents a single question of what matters to them when considering the use of psychotherapy, with adequate probes during the conversation. This will ensure uniformity of the topics to be discussed, and the level of digression allowed.
62221152|NCT02682745|EXPERIMENTAL|R-T1-T2|First period: administration of reference drug, Second period: administration of test drug l, Third period : administration of test drug ll
62221153|NCT02682745|EXPERIMENTAL|R-T2-T1|First period : administration of reference drug, Second period : administration of test drug ll, Third period : administration of test drug l
62221154|NCT02682745|EXPERIMENTAL|T1-T2-R|First period : administration of test drug l, Second period : administration of test drug ll, Third period : administration of reference drug
62221155|NCT02682745|EXPERIMENTAL|T1-R-T2|First period : administration of test drug l, Second period : administration of reference drug, Third period : administration of test drug ll
62796755|NCT01837277|EXPERIMENTAL|Dolutegravir|Intervention: Patients will receive ART regimen based on investigational drug Dolutegravir 50 mg QD + TDF 300 mg QD+ 3TC 150 mg BID
62024429|NCT05952505|EXPERIMENTAL|Group 1|immunized inactivated SARS-CoV-2 vaccine and varicella vaccine in day 0 followed by measles-mumps-rubella vaccine(MMR) in day 28.
62024430|NCT05952505|EXPERIMENTAL|Group 2|immunized varicella vaccine in day 0 followed by SARS-CoV-2 vaccine and MMR in day 28.
62024431|NCT05952505|ACTIVE_COMPARATOR|Group 3|immunized inactivated SARS-CoV-2 vaccine in day 0 followed by MMR and varicella vaccine in day 28.
62024432|NCT05273164|EXPERIMENTAL|Perceptual Discrimination Training|Training will involve Gabor patch and other visual stimuli discrimination exercises that focus on improving signal-to-noise resolution and attentional control with minimal working memory/cognitive control effects. On each training trial, participants are required to distinguish a target stimulus among a set of distractor stimuli. The similarity between target and distractors increases in level of difficulty based on an adaptive perceptual processing staircase function. Consecutive correct responses lead to increased modulation of the distractors to be more similar to the target, while 1 incorrect response drops the user to an easier level. Difficulty is adapted to maintain an 80% correct response rate. Each session will consist of 4 exercises requiring \~45 minutes. with 40 trials for each exercise.
62796756|NCT01837277|ACTIVE_COMPARATOR|Efavirenz|Intervention: Patients who received ART regimen based efavirenz (EFV 600 mg QD +TDF 300 mg QD+ 3TC 300 mg QD) for one year, befor the use of DTG as SOC for first-line therapy (historic controls)
62221156|NCT02682745|EXPERIMENTAL|T2-R-T1|First period : administration of test drug ll, Second period : administration of reference drug, Third period : administration of test drug l
62024433|NCT05273164|ACTIVE_COMPARATOR|Cognitive Control Training|"Training will involve maintaining accurate representations of cognitive context (the rule) in working memory during response selection. On each training trial, participants must observe stimuli, and hold the correct response context on-line in order to select the correct response from among the stimuli. Training is adaptive using a staircase function, such that two consecutive correct responses increases either the speed of stimuli presentation or the working memory load via an increased number of stimuli that are presented; one incorrect response reduces the cognitive load. Each session will consist of 45 exercises requiring \~45 minutes."
62221157|NCT02682745|EXPERIMENTAL|T2-T1-R|First period : administration of test drug ll, Second period : administration of test drug l, Third period : administration of reference drug
62587790|NCT02449304|EXPERIMENTAL|Endometrial Ablation (4th gen)|A single-centre uncontrolled observational study is proposed. All women presenting to the gynaecology outpatient clinic with heavy menstrual bleeding (HMB) in the absence of recognizable pelvic pathology, as determined by one or all of a normal pelvic ultrasound, hysteroscopy and / or endometrial biopsy, refractory to medical therapy that persists despite treatment with recommended pharmacological agents, who have no desire to preserve their fertility and are willing to have an endometrial ablation will be invited to participate. Eligible women with HMB will undergo RFA G4 endometrial ablation in either an inpatient or outpatient setting according to their preference.
62587791|NCT06684080|EXPERIMENTAL|Care bundle group|"1. Risk evaluation for PPH; 2. Reserve plan; 3.Assess blood loss using Estimated Blood Loss Form and amnion fluid collection drape; 4. Satisfy any of the following conditions: i. If the estimated blood loss reaches 500ml but is less than 1000ml, and any of the following abnormal indicators are present; ii. If the estimated blood loss reaches 1000ml, no other indicators need to be considered:~1. Lack of uterine contractions~2. Persistent bleeding~3. Shock index (heart rate/systolic blood pressure) was greater than 0.9 Initiate the following protocols①, ②, ③, ④~   * Administration of Oxytocin~     * Administration of Second-Line Medications for the Prevention of PPH ③Intravenous Fluid Replenishment~       * Multifaceted Treatment and multidisciplinary collaboration"
62796757|NCT05524779|EXPERIMENTAL|BTL-785-7 Treatment|Treatment of wrinkles with the BTL-785-7 applicator to the BTL-785F system.
62415601|NCT06542354|EXPERIMENTAL|Prehabilitation|6-week trimodel prehabilitation program consists of physical exercises, nutrition supplement and mental support for patients with rectal cancer during neoadjuvant chemotherapy before surgery. All patients will receive ERAS care pattern after surgery.
62415602|NCT06542354|NO_INTERVENTION|Standard care|Patients receive no specific interventions mentioned above during their neoadjuvant chemoradiotherapy. All patients undergoing primary leision resection will receive postoperative ERAS care.
62796758|NCT06727058|EXPERIMENTAL|Group 1: Low Dose Pandemic flu H5 mRNA vaccine|Participants will receive 2 injections of pandemic flu H5 mRNA vaccine 21 days apart (at Day 01 and Day 22)
62796759|NCT06727058|EXPERIMENTAL|Group 2: Medium Dose Pandemic flu H5 mRNA vaccine|Participants will receive 2 injections of pandemic flu H5 mRNA vaccine 21 days apart (at Day 01 and Day 22)
62796760|NCT06727058|EXPERIMENTAL|Group 3: High Dose Pandemic flu H5 mRNA vaccine|Participants will receive 2 injections of pandemic flu H5 mRNA vaccine 21 days apart (at Day 01 and Day 22)
62796761|NCT06727058|PLACEBO_COMPARATOR|Group 4: Placebo|Participants will receive 2 injections of placebo 21 days apart (at Day 01 and Day 22)
62796762|NCT04627363|EXPERIMENTAL|HAIC plus Bevacizumab and Toripalimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 6 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab, 240 mg intravenously every 3 weeks. Bevacizumab 15 mg/kg intravenously every 3 weeks.
62221158|NCT02183844|EXPERIMENTAL|Psychosocial Weight Intervention|Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
62796763|NCT03713281|EXPERIMENTAL|Test Lens|Subjects between the ages 40 to 70 years of age and who are adapted contact lens wearers with astigmatism in both eyes will be assigned to the same Test Lens according to the lens wear schedule.
62415603|NCT05517005|EXPERIMENTAL|Hype Bites Supplement|Participants will take the 2 chocolates each day, complete surveys at baseline, midpoint, and study conclusion, and take blood biomarker samples at baseline and conclusion
62415604|NCT04036786|EXPERIMENTAL|study gorup|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Sixty six pregnant participants with preeclampsia risk were included in the control group and 66 pregnant participants with preeclampsia risk were included in the intervention (exercise) group.
62024434|NCT04011150|EXPERIMENTAL|Variable volume Automated Mandatory Bolus (VVAMB)|The anaesthetic drug and pain medication are prepared in an epidural infusion pump with the VVAMB programme. The programme uses higher doses with lower frequency of medication (ropivacaine and fentanyl), and a patient control button for the patient to control the additional pain relief demands depending on the requirements during labour.
62024435|NCT04011150|ACTIVE_COMPARATOR|Automated mandatory bolus (AMB) of variable-frequency (VAMB)|The anaesthetic drug and pain medication are prepared in an epidural infusion pump with the VAMB programme. The programme uses lower doses with more frequency of medication (ropivacaine and fentanyl), and a patient control button for the patient to control the additional pain relief demands depending on the requirements during labour.
62024436|NCT04483479|EXPERIMENTAL|Active Treatment|Orally Administered ENT-01 25mg Tablet Once Daily (Dose dependent on ENT-01-030 dose level stratification)
62024437|NCT03431168|ACTIVE_COMPARATOR|Azithromycin/TMPS|"Azithromycin 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit.~TMPS double strength 1 tablet po daily."
62024438|NCT03431168|PLACEBO_COMPARATOR|Placebo/TMPS|"Azithromycin placebo 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit.~TMPS double strength 1 tablet po daily."
62024439|NCT05888376||Consecutive CKD including ESRD treatments|Consecutive retrospective treatments across all sites with a diagnosis of CKD, including ESRD
62024440|NCT05888376||Consecutive treatments with minimum hospital stay of 20 days|Consecutive retrospective treatments across all sites with a minimum hospital stay of days (excluding cases previously identified; may be acute or chronic disease)
62024441|NCT05888376||Consecutive acute/chronic kidney disease treatments|Consecutive retrospective treatments across all sites with acute or chronic disease (excluding cases previously identified)
62024442|NCT05883852|EXPERIMENTAL|Arm A：TCbHP|Docetaxel 75mg/m2 ivgtt d1+ carboplatin AUC=6 ivgtt d1+ trastuzumab first dose 8mg/kg (maintain 6mg/kg) d1 ivgtt d1+ Pertuzumab first dose 840mg (maintain 420mg) ivgtt d1, 3 weeks of treatment, a total of 6 courses. After the completion of chemotherapy, the dual-target therapy was continued for one year.
62024443|NCT05883852|ACTIVE_COMPARATOR|Arm B：EC-THP|Epirubicin 90 mg/m2 ivgtt d1+ cyclophosphamide 600 mg/m2 iv d1, 3 weeks of treatment, a total of 4 courses; Docetaxel 100mg/m2 ivgtt d1+ trastuzumab first dose 8mg/kg (maintenance 6mg/kg) d1 ivgtt d1+ pertuzumab first dose 840mg (maintenance 420mg) ivgtt d1, 3 weeks of treatment, a total of 6 courses. After the completion of chemotherapy, the dual-target therapy was continued for one year.
62024444|NCT02818738|EXPERIMENTAL|Levamisole Hydrochloride|Dosage : 5, 10, 25 et 50mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
62024445|NCT02818738|PLACEBO_COMPARATOR|Placebo|matching verum
62024446|NCT02632149|EXPERIMENTAL|Vagus nerve Stimulation is on|
62024447|NCT01194115|EXPERIMENTAL|Cephalexin and metronidazole|500 mg cephalexin per oral every 8 hours for total of 6 doses; 500 mg metronidazole per oral every 8 hours for total of 6 doses
62415605|NCT04036786|OTHER|control group|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Sixty six pregnant participants with preeclampsia risk were included in the control group and 66 pregnant participants with preeclampsia risk were included in the intervention (exercise) group.
62415606|NCT00901420||Prostatectomy|
62415607|NCT00901420||Prostatectomy After Radiation Therapy|
62415608|NCT04598009|EXPERIMENTAL|Treatment (binimetinib, imatinib)|Patients receive binimetinib PO BID on days 1-28 and imatinib PO QD on days 1-28. Cycles repeat every 28 days
62415609|NCT03065517|EXPERIMENTAL|VillageWhere App|Parent-youth dyads assigned to the VillageWhere condition will be asked to use the VillageWhere App that has been developed for this study. Parent and youth will be asked upload the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 12 week trial. The app is designed to be used several times throughout each day.
62024448|NCT01194115|PLACEBO_COMPARATOR|Placebo/standard of care|Placebo pills per oral every 8 hours for total of 6 doses
62024449|NCT01748916|EXPERIMENTAL|Papaya-Carrot-Tomato|Test meals were consumed in the following order: 1. Papaya 2. Carrot 3. Tomato.
62024450|NCT01748916|EXPERIMENTAL|Papaya-Tomato-Carrot|Test meals were consumed in the following order: 1. Papaya 2. Tomato 3. Carrot
62024451|NCT01748916|EXPERIMENTAL|Tomato-Papaya-Carrot|Test meals were consumed in the following order: 1. Tomato 2. Papaya 3. Carrot
62024452|NCT01748916|EXPERIMENTAL|Tomato-Carrot-Papaya|Test meals were consumed in the following order: 1. Tomato 2. Carrot 3. Papaya
62024453|NCT01748916|EXPERIMENTAL|Carrot-Papaya-Tomato|Test meals were consumed in the following order: 1. Carrot 2. Papaya 3. Tomato
62221159|NCT01567904|EXPERIMENTAL|Age group from 12 to 18 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
62221160|NCT01567904|EXPERIMENTAL|Age group from 6 to 12 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
62024454|NCT01748916|EXPERIMENTAL|Carrot-Tomato-Papaya|Test meals were consumed in the following order: 1. Carrot 2. Tomato 3. Papaya
62024455|NCT05846581||ESRD patients that require hemodialysis access through the GORE® ACUSEAL Vascular Graft.|"Patient population - patients with CKD in ESRD that require hemodialysis access through the GORE® ACUSEAL Vascular Graft.~Registry subject population - those patients with CKD in ESRD that require hemodialysis access through the GORE® ACUSEAL Vascular Graft meeting the inclusion and exclusion criteria will be eligible for screening for participation in this registry.~The registry has been designed with broad eligibility criteria to capture real-world GORE® ACUSEAL Vascular Graft use, for which the device is intended to be implanted. Only patients who meet all of the inclusion criteria and none of the exclusion criteria will be implanted.~No vulnerable populations are included in this registry."
62221161|NCT01567904|EXPERIMENTAL|Age group from 2 to 6 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
62415610|NCT03065517|PLACEBO_COMPARATOR|Attention-Control Placebo App|Parent-youth dyads assigned to the control condition will be asked to use a free placebo control app that is well-liked by parents and youth but void of content already part of an existing evidence-based treatment for youth with conduct problems (e.g., geolocation tracking). Parent and youth will be asked upload the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 12 week trial.
62587792|NCT06684080|NO_INTERVENTION|Usual care group|The usual care group does not receive a PPH risk assessment and estimates blood loss visually and used various interventions for postpartum hemorrhage in accordance with local or national guidelines.
62415611|NCT02989467|ACTIVE_COMPARATOR|Aprepitant|Subjects will receive one tablet daily for 5 consecutive days. On Day 1 subjects will take a 125mg tablet, on Days 2-5, subjects will take an 80 mg tablet.
62415612|NCT02989467|PLACEBO_COMPARATOR|Placebo|Subjects will receive one placebo tablet daily for 5 consecutive days.
62415613|NCT02755727|EXPERIMENTAL|Platelet Rich Plasma injection|"In the outpatient setting a sample of venous whole blood will be taken from the patient (40mls), from the antecubital fossa using standard phlebotomy techniques. The Angel™ system will be in the available also in the outpatient clinic and will be used to separate the blood to yield a PRP sample (approximately 15 minutes preparation time). The PRP sample is then injected into the common extensor origin.~2 injections will be used per patient over 2 weeks."
62587793|NCT02397122|EXPERIMENTAL|PRF+CAF+CTG|platelet-rich fibrin + coronally advanced flap + connective tissue graft
62587794|NCT02397122|ACTIVE_COMPARATOR|CAF+CTG|coronally advanced flap + connective tissue graft
62796764|NCT02290015|EXPERIMENTAL|true acupuncture|12 sessions of ACP treatment were performed twice a week. Before ACP was performed, patients were examined based on the diagnostic pattern of TCM. Then, the appropriate acupoints for treatment were selected according to the tinnitus-related syndrome. The experimental group was treated with true ACP (stimulating selected meridian points), and the control group was treated with sham-ACP (stimulating false meridian points). The patients were blinded to the identity of their treatment group. Disposable stainless steel ACP needles (0.25 x 30 mm, Dong Bang Acupuncture, Korea) were used in both groups. Needles were inserted manually at each meridian point, and the retention time was twenty minutes.
62796765|NCT02290015|SHAM_COMPARATOR|sham acupuncture|The control group was treated with sham-ACP (stimulating false meridian points). Disposable stainless steel ACP needles (0.25 x 30 mm, Dong Bang Acupuncture, Korea) were used. Needles were inserted manually at each false meridian point, and the retention time was twenty minutes.
62796766|NCT06420271|EXPERIMENTAL|Real|10 sessions of real 5Hz tACS with real iTBS + exergaming biofeedback, 5 times per weeks for two weeks.
62796767|NCT06420271|PLACEBO_COMPARATOR|Sham|10 sessions of sham 5Hz tACS with sham iTBS + exergaming biofeedback, 5 times per weeks for two weeks.
62796768|NCT04041271||Nonspecific chronic neck pain (NCNP) group|Subjects with nonspecific chronic neck pain will be included to perform clinical test and assess their jaw kinematics and muscle activation.
62796769|NCT04041271||Control group|Healthy control subjects will be included to compare the differences in jaw kinematics, muscle activation and clinical tests between healthy subjects and subjects with nonspecific chronic neck pain. Subjects in this group will received the same assessment as the NCNP group.
62796770|NCT03958357||Treatment arm|Single arm study, 40 participants will undergo brachytherapy with the Advanced Gynecological Applicator Venezia Configuration
62221162|NCT01567904|EXPERIMENTAL|Age group from 3 months to 2 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
62221163|NCT01567904|EXPERIMENTAL|Age group from birth to 3 (<) months|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
62221164|NCT02867579|OTHER|women with denial pregnancy|women with denial pregnancy
62221165|NCT02867579|OTHER|women without denial pregnancy|women without denial pregnancy
62221166|NCT03543657|EXPERIMENTAL|Molidustat group|Subjects in the molidustat group will receive molidustat and darbepoetin alfa placebo.
62221167|NCT03543657|ACTIVE_COMPARATOR|Darbepoetin alfa group|Subjects in the darbepoetin alfa group will receive molidustat placebo and darbepoetin alfa.
62221168|NCT00269360|EXPERIMENTAL|1|
62221169|NCT00269360|EXPERIMENTAL|2|
62221170|NCT00269360|ACTIVE_COMPARATOR|3|
62221171|NCT06300450|EXPERIMENTAL|Alert|Alert-based CDS will consist of an on-screen electronic alert that will notify the clinician that the patient has an indication for LDL-C-lowering therapy but is not prescribed any. The clinician will have the opportunity to proceed to an order template through which appropriate lipid-lowering can be prescribed. The clinician could also elect to learn more about current evidence-based recommendations for LDL-C lowering in the PAD population. Finally, the clinician could elect to proceed without ordering oral LDL-C-lowering therapy or reading evidence-based recommendations for LDL-C lowering but would have to provide a rationale for not doing so.
62221172|NCT06300450|NO_INTERVENTION|No Alert|No on-screen notification will be issued to the clinician
62221173|NCT03616977|EXPERIMENTAL|LY900014 U-200|Single subcutaneous (SC) dose of LY900014 U-200 in two of four study periods.
62221174|NCT03616977|EXPERIMENTAL|LY900014 U-100|Single SC dose of LY900014 U-100 in two of four study periods.
62221175|NCT06354231|EXPERIMENTAL|DV+Toripalimab|DV, 2.0 mg/kg, intravenously administered every 2 weeks; toripalimab, 3.0mg/kg, intravenously administered every 2 weeks;
62221176|NCT02907515|EXPERIMENTAL|cm-loc attachment|cm-loc attachment is a new attachment for dental implants and connect to the denture with resin matrix as housing
62221177|NCT02907515|ACTIVE_COMPARATOR|ball attachment|ball attachment is the most common attachment for dental implants and connect to the denture by nylon cap and metal housing
62221178|NCT03629639|EXPERIMENTAL|Metformin|the distributed subjects will be orally administered Metformin 500mg bid lasting for 12 weeks.
62221179|NCT03629639|PLACEBO_COMPARATOR|Placebo|the distributed subjects will be orally administered Metformin-like placebo 500mg bid lasting for 12 weeks.
62024456|NCT02099734||A: suspicion of germ cell tumor and/or a testicular mass|patients with testicular GCTs and non-GCT testicular tumors, extragonadal male GCTs, and female GCTs,
62415614|NCT02755727|ACTIVE_COMPARATOR|Open Surgical Release|Standardised surgical technique based on the Nirschl technique will be used. The patient will then have a small scar centred over the lateral epicondyle and the plane opened between ECRL (Extensor Carpi Radialis Longus) and EDC (Extensor Digitorum Communis) to expose the damaged ECRB (Extensor Carpi Radialis Brevis) tendon. The amount of abnormal tendon will be documented and excised. EDC will also be inspected and any abnormal tissue documented then excised. The footprint of the excised ECRB +/- EDC is cleared of soft tissue and the bone scored with an osteotome to promote bleeding. The interval is closed with suture material and the skin wound closed.
62415615|NCT05819645|EXPERIMENTAL|Early fluid intake|
62415616|NCT05819645|OTHER|Standard Delayed oral fluid|
62415617|NCT06496360||Case|
62587795|NCT06249347|EXPERIMENTAL|PROMISED|"Guided by a circular mapping catheter, all patients initially underwent wide-area circumferential pulmonary vein isolation (CPVI) using radiofrequency ablation catheter. If sinus rhythm was restored after performing the CPVI ablation, the ablation procedure would be stopped. If AF persisted, patients underwent linear ablation (roof linear ablation+anterior septal linear ablation+mitral isthmus linear ablation) using radiofrequency ablation catheter. Then, guided by left atrial appendage (LAA) angiography, the operators selected an appropriately sized left atrial appendage occlusion device according to the LAA size and morphology.~Interventions:~Procedure: CPVI+ roof linear ablation + anterior septal linear ablation + mitral isthmus linear ablation + Left atrial appendage closure (LAAC)"
62024457|NCT02099734||B: family members of Group A|relatives of patients with GCTs or testicular tumors
62024458|NCT02099734||C: healthy controls unrelated to Group A or B|healthy controls who are unrelated to Groups A or B and do not have a personal history of cancer nor a family history of GCT or non-GCT testicular tumors
62024459|NCT01233986||Case group - Large artery atherosclerosis|
62024460|NCT01233986||Control group-Small vessel occlusion|
62024461|NCT00736242||PEG-IFN alfa-2b + RBV|Participants received a combination of PEG-IFN alfa-2b plus RBV according to routine clinical practice and locally-approved product recommendations for a minimum of 12 weeks. No investigational medicinal product was provided by the sponsor.
62415618|NCT06496360||Control|
62415619|NCT04925622||Control|No symptoms of neurological condition
62415620|NCT04925622||Parkinson's disease|Parkinson's disease diagnosis
62024462|NCT01373086|EXPERIMENTAL|LFF269 low dose|LFF269 low dose + Matching Placebo to Eplerenone 50mg during 4 week double blind period
62024463|NCT01373086|EXPERIMENTAL|LFF269 high dose|LFF269 high dose + Matching Placebo to Eplerenone 50mg
62587796|NCT06249347|ACTIVE_COMPARATOR|CPVI and LAAC|"Guided by a circular mapping catheter, all patients initially underwent wide-area CPVI using radiofrequency ablation catheter. Then, guided by LAA angiography, the operators selected an appropriately sized left atrial appendage occlusion device according to the LAA size and morphology.~Interventions:~Procedure: CPVI and LAAC"
62587797|NCT06685705|EXPERIMENTAL|group 1|patients will receive 15 mg of 0.5% hyperbaric bupivacaine + 50 mg Magnesium sulfate intrathecally.
62415621|NCT04925622||Non-PD Movement disorder|Non-PD with other movement disorder such as progressive supranuclear palsy, multiple system atrophy, essential tremor, corticobasal degeneration, vascular Parkinsonism, or Parkinsonian syndromes
62415622|NCT06597006|EXPERIMENTAL|Inclisiran|Year 1 - inclisiran sodium subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium subcutaneous injection (given at Days 450 and 630)
62587798|NCT06685705|EXPERIMENTAL|group 2|patients will receive 15mg of 0.5% hyperbaric bupivacaine + 50 µg Neostigmine intrathecally
62024464|NCT01373086|ACTIVE_COMPARATOR|Eplerenone|Eplerenone 50mg twice daily + matching placebo of LFF269
62415623|NCT06597006|PLACEBO_COMPARATOR|Placebo|Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium subcutaneous injection (given at Days 360, 450, and 630)
62415624|NCT04578548|EXPERIMENTAL|GLPG2737 During DB + During OLE|Participants received 150 milligrams (mg) GLPG2737 capsules orally once daily for 52 weeks in the double-blind (DB) treatment period. Eligible participants were rolled over to an open-label extension (OLE) period to receive 150 mg GLPG2737 orally once daily for 52 weeks.
62587799|NCT06685705|EXPERIMENTAL|group3|patients will receive 15mg of 0.5% hyperbaric bupivacaine + 25µg of fentanyl intrathecally.
62024465|NCT01373086|PLACEBO_COMPARATOR|Placebo|Placebo of LFF269 high dose + Placebo of Eplerenone 50 mg
62024466|NCT00863850|EXPERIMENTAL|1|
62024467|NCT02488486|EXPERIMENTAL|Automated postoperative sedation|Postoperative sedation is provided automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 40 and 60.
62415625|NCT04578548|PLACEBO_COMPARATOR|Placebo During DB + GLPG2737 During OLE|Participants received placebo matched to GLPG2737 capsules orally once daily for 52 weeks in the DB treatment period. Eligible participants were rolled over to an OLE period to receive 150 mg GLPG2737 orally once daily for 52 weeks.
62415626|NCT01273584|ACTIVE_COMPARATOR|Metformin|"Tablet Metformin 500 mg, starting dose of 1 tablet twice a day with meals, gradually titrated upwards by 1 tablet every week to a maximum dose of 2 tablets three times a day.~Tablets started at recruitment and continued till the delivery of the baby"
62415627|NCT01273584|PLACEBO_COMPARATOR|Placebo|"Tablet Placebo 500 mg, starting dose of 1 tablet twice a day with meals, gradually titrated upwards by 1 tablet every week to a maximum dose of 2 tablets three times a day.~Tablets started at recruitment and continued till the delivery of the baby"
62587800|NCT03151616||No anticholinergic exposure|People with an anticholinergic risk scale score of 0
62587801|NCT03151616||Moderate anticholinergic exposure|People with an anticholinergic risk scale score of 1-2
62587802|NCT03151616||High anticholinergic exposure|People with an anticholinergic risk scale score of \>=3
62587803|NCT05797974|EXPERIMENTAL|Virtual coach|Participants will utilize the MyChart enabled virtual coach to aid preoperative weight loss.
62587804|NCT05797974|ACTIVE_COMPARATOR|Standard weight loss tools|Participants will not utilize the MyChart enabled virtual coach to aid preoperative weight loss, but instead use standard weight loss tools.
62796771|NCT05223868|EXPERIMENTAL|Group 1: JNJ-77242113 Dose 1 Once Daily (QD) and Placebo|Participants will receive JNJ-77242113 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
62796772|NCT05223868|EXPERIMENTAL|Group 2: JNJ-77242113 Dose 2 QD and Placebo|Participants will receive JNJ-77242113 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
62587805|NCT06664866|EXPERIMENTAL|Suspicious by EchoNet-LVH Algorithm|Each potential participant identified by automated AI-enhanced echocardiogram review will be chart reviewed by each site's CA experts for appropriateness of enrollment and clinican suspicion for CA. Based on the judgement of CA experts, potential participants that meet eligibility criteria will be called to be consented, followed in the study, and referred to see the CA expert.
62587806|NCT06684054||NAC group|Participants will receive 6 cycles of TEC/TAC neoadjuvant chemotherapy, and radical mastectomy after chemotherapy. Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study. 5ml peripheral venous blood will be collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.
62221180|NCT00660543|EXPERIMENTAL|Ferumoxytol|Patients receive ferumoxytol non-stoichiometric magnetite IV on day 2 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose). Ferumoxytol non-stoichiometric magnetite administration continues in the absence of unacceptable toxicity.
62415628|NCT00698607|EXPERIMENTAL|E6|Everolimus-eluting stent 6-month clopidogrel therapy
62796773|NCT05223868|EXPERIMENTAL|Group 3: JNJ-77242113 Dose 3 QD and Placebo|Participants will receive JNJ-77242113 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
62796774|NCT05223868|EXPERIMENTAL|Group 4: JNJ-77242113 Dose 1 Twice Daily (BID) and Placebo|Participants will receive JNJ-77242113 Dose 1 BID and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
62796775|NCT05223868|EXPERIMENTAL|Group 5: JNJ-77242113 Dose 3 BID and Placebo|Participants will receive JNJ-77242113 Dose 3 BID and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
62796776|NCT05223868|PLACEBO_COMPARATOR|Group 6: Placebo|Participants will receive placebo BID from Week 0 through Week 16.
62796777|NCT03523767|EXPERIMENTAL|Typhoid Vaccine, then Normal Saline|0.5 ml of S.typhi injection, then 0.5 ml of normal saline injection
62796778|NCT03523767|PLACEBO_COMPARATOR|Normal Saline, then Typhoid Vaccine|0.5 ml of normal saline injection, then 0.5 ml of S.typhi injection
62796779|NCT03513276|EXPERIMENTAL|Multimodal analgesia + Local Infiltration Anesthesia|100cc of 2% ropivacaine + Adrenaline 10mcg/ml + 20cc saline solution
62796780|NCT03513276|ACTIVE_COMPARATOR|Multimodal analgesia + saline solution|120cc of saline solution
62796781|NCT01130363||Fundic Gland Polyps on PPI|Patients found to have fundic gland polyps on endoscopic evaluation that have also been prescribed and regularly take a proton pump inhibitor.
62415629|NCT00698607|ACTIVE_COMPARATOR|S6|Sirolimus-eluting stent 6-month clopidogrel therapy
62415630|NCT00698607|EXPERIMENTAL|E12|Everolimus-eluting stent 12-month clopidogrel therapy
62415631|NCT00698607|ACTIVE_COMPARATOR|S12|Sirolimus-eluting stent 12-month clopidogrel therapy
62415632|NCT05503160|ACTIVE_COMPARATOR|Intervention|With validated questionnaires, patient reported outcome monitoring data on quality of life, distress and therapy-adherence are collected. In case of pathologic values, the attending breast center gets advised to intervene according to individual requirements.
62415633|NCT05503160|NO_INTERVENTION|Control|Standard of care
62415634|NCT00552682|EXPERIMENTAL|A|Duloxetine 60 mg, 1 tablet/day
62587807|NCT04073433|EXPERIMENTAL|MDMA-assisted therapy|One session of MDMA-assisted therapy with a dose of 120 mg midomafetamine HCl and optional supplemental dose of 60 mg 1.5 to 2 hours later
62587808|NCT03875274|PLACEBO_COMPARATOR|Ropivacaine group|Ropivacaine 0.375% 20 ml + Normal saline 2 ml via FICB
62796782|NCT01130363||Fundic Gland Polyp not on PPI|Patients found to have fundic gland polyps on endoscopic evaluation that have not been prescribed a proton pump inhibitor.
62415635|NCT00552682|NO_INTERVENTION|B|To continue with the antidepressive treatment if exist
62415636|NCT00535873|EXPERIMENTAL|Lenalidomide|Lenalidomide starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
62415637|NCT01904084|ACTIVE_COMPARATOR|Volar locked plating|One group with distal radius fracture is operated with Locking plate
62415638|NCT01904084|ACTIVE_COMPARATOR|Hoffman external fixator|One group with distal radius fracture is operated with Hoffman external fixator
62415639|NCT04635631|EXPERIMENTAL|talazoparib|1 mg QD
62415640|NCT01162993|EXPERIMENTAL|Spinal Cord Stimulation|Spinal cord stimulation
62415641|NCT01162993|NO_INTERVENTION|Treatment as usual|Treatment as usual
62415642|NCT05144477|EXPERIMENTAL|FAID Fear Intervention|Family members of CA patients assigned to intervention will receive the ICU diary.
62587809|NCT03875274|EXPERIMENTAL|Ropivacaine and morphine group|Ropivacaine 0.375% 20 ml + Morphine 2 ml via FICB
62587810|NCT05630040|EXPERIMENTAL|Non-invasive Vagus Nerve Stimulation|Participants in the Non-Invasive Vagus Nerve Stimulation arm will have devices calibrated to a therapeutic setting.
62587811|NCT05630040|SHAM_COMPARATOR|Sham Vagus Nerve Stimulation|"Participants in the sham VNS arm will be asked to use the VNS device daily on a sham setting for six weeks and will be given the opportunity to crossover into the active VNS arm once they have completed the sham arm."
62587812|NCT05051254|EXPERIMENTAL|Respiratory muscle impairment|Minor patients with primary or secondary impairment of respiratory muscles and followed at Necker Hospital
62796783|NCT01130363||Group 3 (Control Group)|Individuals who are prescribed proton pump inhibitor but are not found to have fundic gland polyps on endoscopic evaluation.
62796784|NCT02750488|EXPERIMENTAL|BAY987517|All subjects are patched with the same product
62796785|NCT01369784||refractory/relapsed LDCBG|patients with refractory/relapsed diffuse large B-cell lymphoma
62415643|NCT05144477|NO_INTERVENTION|Control condition - Usual Care|Family members of CA patients assigned to usual care will not receive the ICU diary.
62415644|NCT02341794|EXPERIMENTAL|Rosuvastatin|
62587813|NCT02905981|EXPERIMENTAL|Period 1: Iron Absorption Tests|During 3 consecutive weekly study visits, patients will receive Fer-In- Sol orally 3 milligram iron per kilogram (mg Fe/kg) body weight, Shohl's solution 0.67 millimoles per kilogram (mmol/kg) followed 5 - 15 minutes later by Fer-In- Sol orally 3 mg Fe/kg body weight, and Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight (respectively). All oral doses will be administered by study personnel at the research center. Blood tests will be conducted following each administration in order to measure iron absorption to see if patients qualify for Period 2.
62587814|NCT02905981|EXPERIMENTAL|Period 2: Dose Titration|Patients who qualified as 'Triferic responders' in Period 1 will participate in Period 2. Patients will be given oral Shohl's solution and Triferic to administer at home 3 times per day, with the dose being titrated higher or lower based on lab results. The initial dose will be the same as Period 1 (Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight) but may be adjusted during Period 2 based on lab results. Period 2 will involve 5 study visits, scheduled every 4 weeks. At the end of Period 2, blood tests will be performed to determine if patients qualify for Period 3.
62587815|NCT02905981|EXPERIMENTAL|Period 3: Hemoglobin Maintenance|Patients who qualified as 'hemoglobin responders' in Period 2 will participate in Period 3. Patients will continue to take Shohl's solution and Triferic at their titrated dose for an additional six months to confirm that their hemoglobin can be maintained over an extended period of time. The period will be comprised of 3 study visits, scheduled every 8 weeks.
62587816|NCT05771896|EXPERIMENTAL|Darolutamide with Radium-223|"Darolutamide:~Dosage:600mg Route: By mouth (PO) Frequency: Twice a day, throughout the duration of the study~Radium-223:~Dosage: 55 kBq/kg body weight or 1.49 microcurie/kg body weight Route: IV Frequency: Every 28+/-7 days, a maximum of 6 cycles"
62587817|NCT05771896|PLACEBO_COMPARATOR|Darolutamide with Placebo|"Darolutamide:~Dosage:600mg Route: By mouth (PO) Frequency: Twice a day, throughout the duration of the study~Placebo:~Dosage: 55 kBq/kg body weight or 1.49 microcurie/kg body weight Route: IV Frequency: Every 28+/-7 days, a maximum of 6 cycles"
62587818|NCT06360432|EXPERIMENTAL|M-health group|Participants in the M-health will receive an 8-week program consisting of personalized dietary modification program and group-based exercise training. Additionally, the m-health group will be instructed to use the EatWellLog app for daily diet self-management.
62587819|NCT06360432|SHAM_COMPARATOR|Control group|Participants in the Control group will receive an identical, 8-week program consisting of personalized dietary modification program and group-based exercise training without using the EatWellLog App.
62587820|NCT05928429|EXPERIMENTAL|arm A - interventional|Each patient in the experimental arm will wear glycerine-containing Elasto-Gel™ gloves and socks (Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA) over a disposable glove and sock liner secured by Velcro at the wrist and ankle on their hands and feet from 15 minutes before paclitaxel administration to 15 minutes after the infusion is complete (90 minutes in total).
62587821|NCT05928429|NO_INTERVENTION|arm B|Patients will receive planned paclitaxel chemotherapy without cryotherapy intervention.
62587822|NCT05542706|EXPERIMENTAL|Accompanying caregivers by paramedical team|
62587823|NCT05542706|NO_INTERVENTION|No dedicated accompanying by medical team|
62587824|NCT00746707|EXPERIMENTAL|1|use of octyl-2-cyanoacrylate adhesive glue for perineal tear grade 1 in 80 women
62587825|NCT00746707|ACTIVE_COMPARATOR|3|use of traditional suturing for perineal tear grade 1 in 50 women
62587826|NCT05156892|EXPERIMENTAL|Dose-escalation/ expansion|SUBA-itraconazole (oral 150mg twice daily) and escalating dose of Tamoxifen (oral once daily) then expansion cohort
62587827|NCT03457116|ACTIVE_COMPARATOR|NSAIDS|400mg of Ibuprofen
62587828|NCT03457116|ACTIVE_COMPARATOR|Opiates|Norco (hydrocodone 5mg- acetaminophen 325mg)
62587829|NCT06528925|EXPERIMENTAL|EXPERIMENTAL GROUP|After the forms are applied to the patients and recorded, it will be determined whether they will be in the study or control group according to the randomization schedule. Patients in the study group will be shown a video with virtual reality glasses during the procedure. Patients will be asked to wear a virtual reality goggle (VR Box Virtual Reality Headset 3D Vr Glasses V2.0 2020 model) that is compatible with a mobile phone (Xiaomi Redmi Note 8 Pro 2019 model) with android operating system and minimizes sound loss in the supine position. With the virtual reality glasses, nature landscapes with relaxing music background will be watched by adjusting the volume at the level desired by the patient. Virtual reality glasses will be applied during the urodynamics procedure. After the device is applied to each patient, it will be disinfected in accordance with the company's recommendation.
62587830|NCT06528925|NO_INTERVENTION|CONTROL GROUP|The control group will receive routine care.
62587831|NCT05655910|EXPERIMENTAL|Group 1 (Not malnourished) - 3 products per day|Patients assessed as well-nourished based on AND-ASPEN criteria and randomized to receive 3 Ensure Surgery Immunonutrition shake per day during the days from consent to LVAD implantation.
62587832|NCT05655910|EXPERIMENTAL|Group 1 (Not malnourished) - 1 product per day|Patients assessed as well-nourished based on AND-ASPEN criteria and randomized to receive 1 Ensure Surgery Immunonutrition shake per day during the days from consent to LVAD implantation.
62587833|NCT05655910|EXPERIMENTAL|Group 2 (at risk/malnourished)|Patients assessed as at risk for malnourishment or malnourished based on AND-ASPEN criteria automatically assigned to receive 3 Ensure Surgery Immunonutrition shake per day during the days from consent to LVAD implantation.
62587834|NCT04528212|EXPERIMENTAL|Group I|Glimepiride (4 mg) per Day
62221181|NCT00660543|ACTIVE_COMPARATOR|Gadoteridol|Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).
62587835|NCT04528212|EXPERIMENTAL|Group II|Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day
62587836|NCT04528212|EXPERIMENTAL|Group III|Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day
62587837|NCT01128998|EXPERIMENTAL|S-1 and Sorafenib|
62587838|NCT01703247|ACTIVE_COMPARATOR|PVI+LL|Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.
62587839|NCT01703247|ACTIVE_COMPARATOR|PVI+GP|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
62587840|NCT05774483|ACTIVE_COMPARATOR|Sentinel node biopsy|
62587841|NCT05774483|EXPERIMENTAL|Limited elective neck dissection|
62587842|NCT00872261||Proxy microbicide product|Use of vaginal lubricant as a proxy microbicide gel; use of multivitamin as proxy pre-exposure prophylaxis (PrEP) product
62587843|NCT00819598||SUSPECTED ARTERIAL DISEASE|
62433376|NCT01913873|EXPERIMENTAL|Cardiac biomarkers concentration changes|"In 2012 the Third Global MI Task Force has presented a third universal definition of MI implying that MI associated with CABG is arbitrarily defined by elevation of cardiac biomarkers values \> 10x99th percentile URL in patients with normal baseline cTn values (≤ 99th percentile URL), in addition with either (i) new pathological Q waves or new LBBB (left bundle branch block), or (ii) angiographic documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.~In this study we will measure the concentration changes over time of cardiac biomarkers (hs-cTN and CK-MB) and establish a threshold value for myocardial injury, diagnosed by ECG and approved -if necessary- by echocardiography."
62587844|NCT04444193|EXPERIMENTAL|Durvalumab and Lenvatinib|Combination therapy of Lenvatinib 80-120mg daily orally and durvalumab 1500mg by IV infusion every 4 weeks
62796786|NCT04891289|EXPERIMENTAL|HAI FUDR plus GemOx (Arm 1)|Surgical HAI pump placement. 2. HAI FUDR \[(0.12 mg/kg/day) x wt (kg) x (30ml) / pump flow rate \] and dexamethasone \[1 mg/day \* 30\] / pump flow rate \] on Day 1 of each cycle. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. 3. Gemcitabine (800 mg/m2 IV over 30 minutes) and oxaliplatin (85 mg/ m2 IV over 120 minutes on Days 1 and 15 of each cycle; however, for patients in Arm 1, initiation of systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first dose of systemic chemotherapy will be given on Cycle 1, Day 15, and then every 2 weeks thereafter.
62587845|NCT02799004||Patients in acute pain|
62587846|NCT03386253|EXPERIMENTAL|active tDCS|Participants receive active tDCS for five consecutive days before attempting to quit smoking
62587847|NCT03386253|SHAM_COMPARATOR|sham tDCS|Participants receive sham tDCS for five consecutive days before attempting to quit smoking
62587848|NCT06195839|EXPERIMENTAL|Immediate Financial Incentives for BP monitoring|"* instructions for participating in a 2-month remote patient monitoring program~* home blood pressure monitor and associated smartphone app, which includes a module for logging medication-taking~* wrist-worn sensor and associated smartphone app~* weekly adherence feedback to home blood pressure monitoring~* immediate financial incentives for home blood pressure monitoring distributed weekly"
62587849|NCT06195839|ACTIVE_COMPARATOR|Delayed Financial Incentives for BP monitoring|"* instructions for participating in a 2-month remote patient monitoring program~* home blood pressure monitor and associated smartphone app, which includes a module for logging medication-taking~* wrist-worn sensor and associated smartphone app~* weekly adherence feedback to home blood pressure monitoring~* delayed financial incentives for home blood pressure monitoring distributed at the end of the study"
62587850|NCT05440435||Center A|Study center A that observe cohort populations (sample size=400).
62587851|NCT05440435||Center B|Study center B that observe cohort populations (sample size=400).
62587852|NCT05440435||Center C|Study center C that observe cohort populations (sample size=400).
62587853|NCT05440435||Center D|Study center D that observe cohort populations (sample size=400).
62587854|NCT05440435||Center E|Study center E that observe cohort populations (sample size=400).
62587855|NCT01073228|ACTIVE_COMPARATOR|EVP-6124 0.3 mg|one 0.3 mg capsule every day for 183 days
62587856|NCT01073228|ACTIVE_COMPARATOR|EVP-6124 1 mg|one 1 mg capsule every day for 183 days
62587857|NCT01073228|ACTIVE_COMPARATOR|EVP-6124 2 mg|one 2 mg capsule every day for 183 days
62587858|NCT01073228|PLACEBO_COMPARATOR|Placebo|Placebo every day for 183 days
62587859|NCT05296044|EXPERIMENTAL|JT-003|Drug: JT-003
62587860|NCT05296044|PLACEBO_COMPARATOR|JT-003 Placebo|Drug: JT-003 Placebo
62587861|NCT00467727|EXPERIMENTAL|1|Phase Contrast Mammography Exam
62587862|NCT04546139||fast group|
62587863|NCT04546139||slow group|
62587864|NCT05331755||Severe T2 high asthma|"Included patients will have severe type 2 high asthma, are eligible for dupilumab conform EU label, minimally treated with high dose ICS and LABA and have:~* blood eosinophils 150 - 1500/mm2 OR~* FeNO \>20 ppb OR~* clinical significant inhalation allergy (+ sIgE positive) OR~* OCS dependency"
62796787|NCT04891289|ACTIVE_COMPARATOR|GemOx alone (Arm 2)|Gemcitabine (800 mg/m2 IV over 30 minutes) and oxaliplatin (85 mg/m2 IV over approximately 120 minutes) on Days 1 and 15 of each 28-day cycle.For patients in Arm 2, systemic therapy will be administered on Days 1 and Day 15 of each Cycle on a 28-day cycle basis, compromised of Gemcitabine and Oxaliplatin. If a patient randomized to Arm 2 has intrahepatic progression on any follow-up scan during study treatment, that patient will be eligible to crossover to Arm 1 and commence to pump placement surgery and HAI FUDR treatment. Patients with any extrahepatic progression will not be eligible to utilize the crossover arm. Arm 2 patients will have 28 days from date of the scan showing intrahepatic progression to proceed to the crossover arm.
62796788|NCT01311336|ACTIVE_COMPARATOR|Loratadine|Loratadine 10 mg once a day for 7 days beginning the day of pegfilgrastim treatment in patients with pegfilgrastim-induced back and leg pain during the previous treatment cycle
62796789|NCT01311336|PLACEBO_COMPARATOR|Placebo|Placebo once a day for 7 days beginning the day of pegfilgrastim treatment in patients with pegfilgrastim-induced back and leg pain during the previous treatment cycle
62796790|NCT00183326|EXPERIMENTAL|1|Participants will receive trauma-focused cognitive behavioral therapy
62587865|NCT06666894|EXPERIMENTAL|Intermittent fasting group|intermittent fasting time-restricted feeding (TRF) subjects consumed 100 % of their energy needs in an 8 hours period of time each day, with their caloric intake divided into three meals consumed at 1 p.m., 4 p.m., and 8 p.m. schedule (8-hr daily eating period, The remaining 16 hours per 24-hour period made up the fasting period)
62221182|NCT00660543|ACTIVE_COMPARATOR|Gadoteridol Leakage Corrected|Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).
62221183|NCT06609382||Obstructive hypertrophic cardiomyopathy who underwent septal myectomy|Patients who had at least one cardiac magnetic resonance examination before surgery.
62415645|NCT05237687|EXPERIMENTAL|Intervention|Patients will be randomized using age-based randomization to initial treatment with 0.5 mg sirolimus p.o. (orally) everyday vs standard of care. The medications would be dispensed from UT Southwestern Medical Center. To ensure patent's safety, all patients will be closely monitored. We will start with a 0.5 mg tablet- the smallest sirolimus dose available. Sirolimus level will be checked weekly in the first month to ensure we maintain a low goal (5-7) that will decrease the risk of developing side effects. In order to monitor study drug compliance, we will ask the patient to keep a pill diary. After the first month, the patient will have monthly blood work and monthly phone call to enquire about potential side effects. The patients will be followed in clinic in person every 3 months. Functional assessment will be obtained at baseline, 3 months 6 months 9 months and 1 year follow up. Completion of the 1-year treatment period will be followed by a follow-up phone call 1 month later.
62415646|NCT05237687|NO_INTERVENTION|Control|Interventions: standard of care Patients are not going to receive any additional intervention.
62415647|NCT03789162||Confirmed CRC with Residual Lesion|A diagnosis of CRC confirmed with a tissue biopsy or a colorectal lesion at least 1 cm in size suspicious for adenoma (including sessile serrated adenoma) or CRC on a pre-enrollment colonoscopy.
62587866|NCT06666894|ACTIVE_COMPARATOR|Diet group|the dietary approach to stop hypertension (DASH) subjects consumed 100 % of their energy needs divided into three meals consumed at 8 a.m., 1 p.m., and 8 p.m. (12-hr eating period).
62587867|NCT04457102|ACTIVE_COMPARATOR|Arm N°1 - Standard treatment-Breast DIBH|Patients will be treated during spontaneous breath hold wich is considered as the gold-standard radiotherapy treatment for left breast cancer.
62796791|NCT00183326|ACTIVE_COMPARATOR|2|Participants will receive child-centered supportive therapy
62796792|NCT02220829|ACTIVE_COMPARATOR|Preventive administration of Rapaflo|Rapaflo treatment will start on day one of radiation therapy (early administration- before symptoms onset) and continue for a total duration of 6 months: 8 mg daily during 4 months and 8 mg every other day for 2 months.
62796793|NCT02220829|OTHER|Standard care|Administration of alpha-blocker Rapaflo at the onset of symptomatic urinary problems caused by radiation therapy. 8 mg of Rapaflo is administered daily until disappearance of symptoms.
62796794|NCT02878317||Study 2 - Non randomised proof of principle study|Malnourished participants received individualized nutritional advice and support formulated and delivered by experienced dietitians consisting of food fortification recommendations and oral nutritional supplementation aiming to achieve estimated nutritional requirements (i.e. energy \[30-35 kcal/kg/day\] and protein intake \[1.1-1.2 g/kg/day\]). Food fortification involved enhancing the energy and protein content of meals and snacks without increasing the portion sizes of foods. Advice was individualized according to patient needs and food preferences. Oral nutritional supplements included Fortisip Compact (2.4 kcal/ml), Fortisip (1.5 kcal/ml) and Fortijuice (1.5 kcal/ml), as well as Renapro® shot and Fresubin® 5kcal Shot.
62221184|NCT01733173||mass in posterior fossa, either benign or malignant|A pilot study will be performed. We will perform fMRI and DTI in children before and after surgery for posterior fossa brain tumors. Each subject will receive the standard of care for their brain tumors in terms of surgical resection, radiation therapy and/or chemotherapy.
62221185|NCT04646954|EXPERIMENTAL|Study group|All eligible participants are included in the study group
62587868|NCT04457102|EXPERIMENTAL|Arm N°2 - Interventional -Breast MANIV DIBH|Irradiation will take place during DIBH induced by MANIV (Bellavista 1000, IMTMedical®) with SL mode. Oxygen will be added (FiO2 60%) to safely and easily prolong the DIBH duration up to 30 seconds to allow the complete delivery of a treatment beam.
62024468|NCT05774600|EXPERIMENTAL|SSW Works|SSW Works, is a virtual learning environment (VLE) for automated, comprehensive, on-demand, tailored distribution of the SSW program to private and public employers with outdoor workers. It will be delivered in both English and Spanish to managers and employees who work outdoors to reduce risk for skin cancer.
62024469|NCT05774600|ACTIVE_COMPARATOR|Minimal Information Control|Workplaces randomized to the control condition will receive a set of printed materials on occupational sun safety (1 mailing per year) as an attention control. These will include posters on personal protection and skin cancer incidence, risk assessment brochure, American Academy of Dermatology SPOT bookmark showing the ABCDEs of melanoma and skin self-examination, and a sun safety tip card from OSHA.
62024470|NCT00838344|NO_INTERVENTION|Usual care|Usual prescription refill system and pharmacy care.
62415648|NCT03300882||CMV+ First Lung Transplant Recipients|Participants enrolled in one of four North American sites in clinical research study CTOT-20 (Clinical Trials.gov ID: NCT02631720) who are cytomegalovirus positive by serology (e.g., CMV Recipient positive).
62587869|NCT04457102|EXPERIMENTAL|Arm N°3 - Interventional -Liver/Lung MANIV DIBH|Irradiation will take place during DIBH induced by the MANIV (Bellavista 1000, IMTMedical®) with SL mode. Oxygen will be added (FiO2 60%) to safely and easily prolong the DIBH duration up to 30 seconds to allow the complete delivery of a treatment beam \[13\]. Prior to treatment, a radio-opaque fiducial will be implanted in the tumor by an interventional radiologist, to facilitate the tumor position monitoring from onboard imaging. Residual tumor baseline shift and motion will thus be measured during beam delivery, and used to recompute the optimal safety margins that ensure an adequate dose coverage of at least 90% of tumors, according to literature recommendations \[24\]. We will also compare these safety margins computed under MANIV condition with those routinely applied in free-breathing condition to estimate the gain in terms of margin reduction.
62796795|NCT02878317||Historical control group from Study 1|Participants on dialysis with malnutrition taken from Study 1, who were seen by their usual dietitian once a month and received standard nutritional counselling.
62796796|NCT01124279|EXPERIMENTAL|AMG 853|
62796797|NCT05159466||Kidney transplant recipients|Up to 25 HIV-positive participants requiring kidney organ transplantation
62024471|NCT00838344|EXPERIMENTAL|Intervention|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
62024472|NCT03808662|EXPERIMENTAL|Arm 1: Early Stereotactic Body Radiotherapy/SBRT|SBRT to all oligoprogressive sites
62024473|NCT03808662|ACTIVE_COMPARATOR|Arm 2:Standard of Care|
62415649|NCT01387672|ACTIVE_COMPARATOR|Nitrol|Nitroglycerin Ointment 2% USP
62587870|NCT04457102|EXPERIMENTAL|Arm N°4 - Interventional -Liver/Lung MANIV VC|Patients will be ventilated by VC mode during their treatment. For each fraction, the treatment time, the number of reconstructions of the tracking model and the correlation errors of the model will be collected. The same information will be extracted from a matched retrospective cohort treated by tracking in spontaneous breathing.
62796798|NCT05159466||Kidney living donors|Up to 5 HIV-positive living donors will be enrolled.
62796799|NCT04515212|ACTIVE_COMPARATOR|Healthy Volunteers|
62796800|NCT04515212|EXPERIMENTAL|Traumatic Brain Injury Patients|
62796801|NCT06725810|EXPERIMENTAL|high-hemoglobin target group|Patients are managed to achieve and maintain hemoglobin target of 13 g/dl over 96 weeks.
62796802|NCT06725810|EXPERIMENTAL|low-hemoglobin target group|Patients are managed to achieve and maintain hemoglobin target of 11 g/dl over 96 weeks.
62796803|NCT05440734|EXPERIMENTAL|Melatonin|2 mg oral tablet, melatonin slow release formulation, 1x 60 min before bedtime for 15 days
62024474|NCT01387568|ACTIVE_COMPARATOR|group L|Lidocaine group
62024475|NCT01387568|PLACEBO_COMPARATOR|group P|Placebo group
62024476|NCT04771169|EXPERIMENTAL|Vestibular Training Group|This Group will receive vestibular Adaptation and Balance exercises
62024477|NCT04771169|ACTIVE_COMPARATOR|Virtual Reality Group|This Group will receive virtual reality training by using exergaming.
62024478|NCT02170168||Orkdal region patients|cancer patients participating in a integrated palliative care program for diagnostics, treatment, care and follow-up in and between hospital care and 13 municipalities
62796804|NCT05440734|PLACEBO_COMPARATOR|Placebo|2 mg oral tablet, 1x 60 min before bedtime for 15 days
62024479|NCT02170168||Romsdal county patients|control palliative care cancer patients in standard care, i.e. a local hospital in the county of Møre and Romsdal, Molde Hospital, and nine districts
62024480|NCT02170168||Orkdal region carers|carers of cancer patients participating in a integrated palliative care program for diagnostics, treatment, care and follow-up in and between hospital care and 13 municipalities
62024481|NCT02170168||Romsdal county carers|carers of cancer patients receiving standard care, i.e. in a local hospital in the county of Møre and Romsdal, Molde Hospital, and community care in nine districts
62024482|NCT02170168||Orkdal region health care providers|Health care providers for cancer patients participating in a integrated palliative care program for diagnostics, treatment, care and follow-up in and between hospital care and 13 municipalities
62024483|NCT02170168||Romsdal county health care providers|Health care providers for cancer patients receiving standard care, i.e. in a local hospital in the county of Møre and Romsdal, Molde Hospital, and community care in nine districts
62024484|NCT02461121|EXPERIMENTAL|MST（microtransplantation）|The microtransplantation conditioning regimen included high-dose Ara-C chemotherapy (2.0 to 2.5 g/m2 per 12 hours intravenously on days -4 to -2) followed by an infusion of HLA mismatched stem cell 24 hours (day 0) after the completion of cytarabine.
62415650|NCT01387672|ACTIVE_COMPARATOR|Nitro-Dur|Nitroglycerin Extended Release Patch 160mg
62415651|NCT01387672|ACTIVE_COMPARATOR|Nitrostat 1|Nitroglycerin 0.3mg Sublingual Tablet
62415652|NCT01387672|ACTIVE_COMPARATOR|Nitrostat 2|Nitroglycerin 0.6mg Sublingual Tablet
62415653|NCT01387672|ACTIVE_COMPARATOR|ISMO|Isosorbide Mononitrate 20mg Oral Tablet
62415654|NCT01387672|PLACEBO_COMPARATOR|Placebo|Placebo Ointment
62415655|NCT06446154|EXPERIMENTAL|Fruquintinib|Fruquintinib monotherapy
62221186|NCT04641871|EXPERIMENTAL|Sym021+Sym022 [ARM A] for BTC patients|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym022 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
62221187|NCT04641871|EXPERIMENTAL|Sym021+Sym023 [ARM B] for BTC patients|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
62221188|NCT04641871|EXPERIMENTAL|Sym021+Sym023+irrinotecan for BTC patients|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated. After another 30-minute post-dosing interval, irinotecan will be infused over 90 minutes.
62221189|NCT04641871|EXPERIMENTAL|Sym021+Sym023+irrinotecan for ESCC patients|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated. After another 30-minute post-dosing interval, irinotecan will be infused over 90 minutes.
62796805|NCT02962661|EXPERIMENTAL|Arm I (hMSCs IV)|Patients receive hMSCs IV over 10-20 minutes on days 1, 14, 21, and 28 and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.
62221190|NCT05879549|EXPERIMENTAL|Closed Chain Exercise Group|Closed kinetic chain exercises will be given under the supervision of a physiotherapist, 2 sessions a week for 12 weeks.
62415656|NCT05437718|OTHER|Group NB (thoracic paravertebral block Group)|Thoracic paravertebral block(TPVB) is performed 20 minutes before the ablation surgery began,30 mL of 0.375% ropivacaine was totally injected in T3-4 and T5-6 spinal segment（the block segment can be adjusted according to the tumor site) under the ultrasound guidance.
62796806|NCT02962661|EXPERIMENTAL|Arm II (hMSCs transendocardially)|Patients receive hMSCs transendocardially for a total of 15 injections and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.
62796807|NCT02962661|ACTIVE_COMPARATOR|Arm III (standard of care)|Patients receive standard of care treatment for heart failure.
62796808|NCT04146350|NO_INTERVENTION|Control|
62796809|NCT04146350|ACTIVE_COMPARATOR|PPV+/-Cat|
62796810|NCT04146350|ACTIVE_COMPARATOR|PPV+/-Cat+Gas|
62024485|NCT02461121|ACTIVE_COMPARATOR|NST（nonmyeloablative transplantation）|The NST（nonmyeloablative transplantation）conditioning regimen consisted of 30 mg/m2/d fludarabine for days -6 to -2, 1.5-2 mg/kg/d anti-lymphocyte globulin for days -5 to -2, 40 mg/kg/d cyclophosphamide for days -4 and -2 and 2.0-3.0 g/m2/d cytarabine for days -6 to -4，followed by an infusion of HLA matched stem cell after the completion of regimen. The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
62433377|NCT03555890|EXPERIMENTAL|Subjects of Group A: Part 1|Subjects in Group A will be randomized to receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine ODT 5 mg with 150 mL water in fasted state in Period 2.
62433378|NCT03555890|EXPERIMENTAL|Subjects of Group B: Part 1|Subjects in Group B will be randomized to receive levocetirizine ODT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 2.
62796811|NCT04146350|ACTIVE_COMPARATOR|PPV+ILM+/-Cat+/-Gas|
62796812|NCT04146350|ACTIVE_COMPARATOR|PPV+ILM+/-Cat+/-Oil|
62796813|NCT04146350|ACTIVE_COMPARATOR|PSR|
62796814|NCT04146350|ACTIVE_COMPARATOR|PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）|
62796815|NCT04146350|ACTIVE_COMPARATOR|Gas|
62796816|NCT05899140|OTHER|Standard of care|"Participants with skin and soft-tissue infections requiring systemic treatment (oral or intravenous). Treatment according to local guidelines = standard of care: usually an anti-staphylococcal penicillin with or without incision and drainage, as required.~Treatment can be with (local guidelines) cloxacillin (non-severe) po 500g QIDfor 5-7 days ceftriaxone (severe infections) 2g iv OD with step-down to cloxacillin po 500 mg QID for a total of 7 days"
62796817|NCT05899140|ACTIVE_COMPARATOR|Standard of care + clindamycin|"Participants with skin and soft-tissue infections requiring systemic treatment (oral or intravenous).~Addition of clindamycin: 10 mg/kg/dose QID iv (maximum 600mg QID iv) or oral clindamycin 450 mg TDS for adults for a total of 7 days from randomisation."
62024486|NCT06628206|EXPERIMENTAL|Rheumatoid arthritis|LPX-TI641 or Placebo
62221191|NCT05879549|EXPERIMENTAL|Proprioceptive Exercise Group|Proprioceptive exercises will be given under the supervision of a physiotherapist, 2 sessions a week for 12 weeks.
62221192|NCT05879549|NO_INTERVENTION|Control Group|No intervention will be applied.
62024487|NCT06628206|EXPERIMENTAL|Psoriatic Arthritis|LPX-TI641 or Placebo
62024488|NCT01186523|EXPERIMENTAL|400 kcal of exercise/session|400 kcal of exercise/session
62221193|NCT02539147||patients with severe sepsis|blood samples from patients with severe sepsis
62415657|NCT05678101|ACTIVE_COMPARATOR|TENS|"The Chattanooga Physio TENS (DJO Global, Vista, CA) will be applied with mixed burst / TENS alternated, which is a 30-minute long program where the stimulation frequencies of alternate in 3 second intervals, producing a combined stimulation of 80 Hz and 2 Hz. Two programs/sessions ('a' and 'b') will be applied in succession for a total of 60-minutes (one round). In total, each day will have 3 rounds.~The energy intensity level will firstly be adjusted for 80 Hz (TENS) until a tingling sensation is felt but no discomfort, and then the procedure will be repeat for 2 Hz.~The patient will use a pair of pants with integrated stimulation electrodes, to which the CE-marked TENS device (Chattanooga Physio, DJO Nordic, Malmö, Sweden) will be connected and used to provide pain relief, in addition to usual postoperative care.~The TENS device will be connected to the textile electrodes of the pants which are located 5cm in front and behind the hip incision dressing respectively."
62796818|NCT06618118|EXPERIMENTAL|Fosigotifator|Participants will receive fosigotifator.
62796819|NCT06618118|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo for fosigotifator.
62796820|NCT01907464|EXPERIMENTAL|Patients with anorexia nervosa|This arm is the experimental arm composed of patients
62796821|NCT01907464|ACTIVE_COMPARATOR|controls subjects|This arm is composed of healthy volunteers
62796822|NCT01359904|ACTIVE_COMPARATOR|high dialysate bath|additive is put in the dialysate to increase the concentration of glucose to 10mmol/l
62796823|NCT01359904|NO_INTERVENTION|Standard dialysate glucose concentration|Standard 5.5 mmol/L dialysate glucose concentration.
62415658|NCT05678101|SHAM_COMPARATOR|Control|The control group will also receive the TENS-pants described above with integrated stimulation electrodes, connected to TENS treatment. However, the TENS treatment to the control group will be set such that no electricity will be applied to the patient. In all other regards, the control group will follow the same protocol as the intervention group.
62796824|NCT05614037|EXPERIMENTAL|Felodipine Controlled Release Tablets|Test preparation (T) :Felodipine Controlled Release Tablets Specification: 5 mg Batch number: 22090301 Content: 100.8% Valid until: September 2024 Storage conditions: sealed, room temperature (10\~30℃) Manufacturer: Overseas Pharmaceuticals, Ltd. Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
62024489|NCT01186523|EXPERIMENTAL|600 Kcal of exercise/session|600 Kcal of exercise/session
62221194|NCT05887115|ACTIVE_COMPARATOR|Intervention (NFP)|In the standard NFP intervention, low-income pregnant women are recruited to voluntarily join the program through their 28th week of pregnancy. Enrolled women receive home visits from a nurse. The visits can occur in-person or via telehealth. In-person visits can occur in the client's home or in another community location agreed upon by the client and the nurse (such as a library or coffee shop). The typical schedule for visits is weekly during the first month after enrollment, every two weeks until the birth of the infant, weekly during the post-partum period, then every two to four weeks until child age two.
62024490|NCT01186523|EXPERIMENTAL|Control, no exercise|No exercise control group
62221195|NCT05887115|NO_INTERVENTION|Control|The control group will receive usual care for pregnant people, which may include home visiting services from another source other than NFP. Participants who are randomly selected to receive other services will be given information about other services for which they may qualify and information about how to access those services.
62415659|NCT01021696|NO_INTERVENTION|Treatment as usual|Control group
62415660|NCT01021696|ACTIVE_COMPARATOR|Paracetamol|Intervention group
62415661|NCT01021696|ACTIVE_COMPARATOR|Morphine|Intervention group, individual pain treatment
62415662|NCT01021696|ACTIVE_COMPARATOR|Buprenorphine plaster|Intervention group, individual pain treatment
62415663|NCT01021696|ACTIVE_COMPARATOR|Pregabalin|Intervention group, individual pain treatment
62796825|NCT05614037|ACTIVE_COMPARATOR|Felodipine Modified-release Tablets (trade name:plendil ®)|Reference preparation (R) : Felodipine Modified-release Tablets (trade name:plendil ®) Specification: 5 mg Batch number: 2204 a11 Content: 99.1% Valid until March 2025 Storage conditions: below 25℃ Manufacturer:AstraZeneca AB Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
62024491|NCT05956431|EXPERIMENTAL|Levosimendan group|The administration scheme of Levosimendan is continuous intravenous infusion at the rate of 0.05-0.2 μg/kg/min for 24 hours, and no load is given to reduce the risk of Hypotension.
62024492|NCT05956431|PLACEBO_COMPARATOR|Placebo group|The placebo group received continuous intravenous infusion of physiological saline at the rate of 0.05-0.2 μg/kg/min for 24 hours, while also receiving comprehensive cluster therapy with PCAS.
62024493|NCT00502125||Patients with oral lesions|
62024494|NCT00326378|ACTIVE_COMPARATOR|CCRT arm without consolidation chemotherapy|Docetaxel 20mg/m2 \& Cisplatin 20mg/m2 (D1,8,15,22,29,36) during radiotherapy
62024495|NCT00326378|EXPERIMENTAL|CCRT arm with consolidation chemotherapy|docetaxel 20mg/m2 \& cisplatin 20mg/m2 (D1,8,15,22,29,36) during radiotherapy, and followed by consolidation chemotherapy with 3-weekly docetaxel 35mg/m2 \& cisplatin 35mg/m2 (D1,8) every 3 weeks (#3).
62024496|NCT02671487|EXPERIMENTAL|Mind-Body Skills Groups|Mind-body skills groups will be administered for 2 hours once a week for 10 weeks and then once a month for 10 months.
62024497|NCT02671487|NO_INTERVENTION|Wait List Control|No intervention will be administered. Students will have the opportunity to receive the intervention at the end of the study.
62415664|NCT06416930|EXPERIMENTAL|Cadonilimab combined with chemotherapy|All subjects in the group will be treated with Cadonilimab plus gemcitabine / vinorelbine / pemetrexed once every three weeks.
62796826|NCT05213702|ACTIVE_COMPARATOR|Traditional free hand puncture for renal calyx access|For human PCNL, we target 60 cases of PCNL, 30 ANT-X puncture and 30 traditional free hand puncture performed by 4 urologic trainees(15 cases per urologic trainee).
62796827|NCT05213702|ACTIVE_COMPARATOR|RObotic ANT-X device puncture for renal calyx access|For human PCNL, we target 60 cases of PCNL, 30 ANT-X puncture and 30 traditional free hand puncture performed by 4 urologic trainees(15 cases per urologic trainee).
62796828|NCT03738488|EXPERIMENTAL|3D printing + images|Surgery planification with the combination of all the images available and a 3D biomodel printed from that images.
62796829|NCT03738488|ACTIVE_COMPARATOR|Images|Surgery planification with all the images available
62796830|NCT02363595||Papillary Microcarcinoma|This clinical trial protocol describes implementation of a prospective observation protocol to standardize data collection and obtain permission to collect samples of PMC tumors in a cohort of PMC patients being followed with active surveillance. This will allow PMC tumors to be accurately classified as either stable or progressive over time and used for comprehensive molecular profiling if surgical removal is required during follow-up
62796831|NCT06135974|PLACEBO_COMPARATOR|Placebo|Vaginal placebo tablet administered daily for 7 days starting after antibiotic treatment
62796832|NCT06135974|EXPERIMENTAL|LC106 7 days|Vaginal live biotherapeutic product with 6 strains of L. crispatus, administered daily for 7 days after antibiotic treatment
62796833|NCT06135974|EXPERIMENTAL|LC106 3 days|Vaginal live biotherapeutic product with 6 strains of L. crispatus, administered daily for 3 days after antibiotic treatment and packaged with 4 tablets of placebo to maintain masking (so a total of 7 tablets)
62796834|NCT06135974|EXPERIMENTAL|LC106 7 days, early start|Vaginal live biotherapeutic product with 6 strains of L. crispatus, administered daily for 7 days starting on the 3rd day of antibiotic treatment
62796835|NCT06135974|EXPERIMENTAL|LC115|Vaginal live biotherapeutic product with 15 strains of L. crispatus, administered daily for 7 days after antibiotic treatment
62796836|NCT01987102|EXPERIMENTAL|Cohort 1|"1 MAP cycle (incl. 2 HDMTX Courses using Calcium Folinate rescue 15mg/m2)~1 MAP cycle (incl. 2 HDMTX Courses using \[6R\] 5,10-methylenetetrahydrofolate rescue 15mg/m2)"
62796837|NCT01987102|EXPERIMENTAL|Cohort 2|"1 MAP cycle (incl. 2 HDMTX Courses using Calcium Folinate rescue 15mg/m2)~1 MAP cycle (incl. 2 HDMTX Courses using \[6R\] 5,10-methylenetetrahydrofolate rescue 7,5mg/m2 or 30mg/m2\*)~\*Dose will depend on outcome from Cohort 1"
62796838|NCT05894447|EXPERIMENTAL|Naptumomab estafenatox in combination with pembrolizumab preceded by Obinutuzumab|"The study will test two doses of NAP 5 µg/kg/day IV (Dose Level 1) and 10 µg/kg/day IV (Dose Level 2), in combination with a fixed dose of pembrolizumab (200mg IV every 3 weeks). NAP will be given on Days 1-4 of each 21 day cycle for 6 cycles. Pembrolizumab will be given on Day 2 of each 21-day treatment cycle for the first 6 cycles and then as monotherapy every 21 days for up to a total of 34 administrations. Two doses of Obinutuzumab 1,000 mg IV will be given before starting NAP and pembrolizumab on Days - 13 and -12.~Pembro 200 mg i.v. Day 2 of each 21-day treatment cycle for the first 6 cycles"
62796839|NCT04683029|EXPERIMENTAL|Group A: Guselkumab|Participants will receive intravenous (IV) injection of Guselkumab Dose 1 at Week 0, 4, and 8 followed by subcutaneous (SC) injection of Dose 2 Guselkumab every 4 weeks (Q4W) from Week 12 to Week 48 (end of maintenance phase). Participants will receive SC injection of Guselkumab Dose 2 and IV injection of placebo at long-term extension (LTE) Weeks 52, 56, and 60 followed by SC injection of Guselkumab Dose 2 Q4W from LTE Week 64 until Week 100.
62796840|NCT04683029|PLACEBO_COMPARATOR|Group B: Placebo|Participants will receive IV injection of matching placebo at Week 0, 4, and 8 followed by SC injection of matching placebo Q4W from Week 12 to Week 48 (end of maintenance phase). Participants will receive SC injection of Placebo and IV injection of Guselkumab Dose 1 at LTE Weeks 52, 56, and 60 followed by SC injection of Guselkumab Dose 2 Q4W from LTE Week 64 until Week 100.
62587871|NCT04457102|OTHER|Arm N°5 -Liver/Lung MANIV DIBH for PT|Data on tumor position and its residual motion from patients included in the arm n°3 will be used to compute the planned and in silico delivered dose distribution with PBS PT. The MIRO lab (UCLouvain - IREC) has developed comprehensive tools for simulating treatment delivery on patients CT images using the Monte Carlo dose engine MCsquare \[25\], coupled with log-file acquisitions \[26\]. In this way, we will be able to validate our approach in silico in collaboration with IBA, as a first step before conducting prospective trials for the clinical validation of this approach.
62796841|NCT05488457|EXPERIMENTAL|Oxytocin PK/PD Arm|Eligible subjects will receive a single, 1 IU bolus of deuterated oxytocin (d5OT) intra-operatively, followed by an infusion of standard therapeutic d0 oxytocin immediately after placental delivery.
62796842|NCT06260163|EXPERIMENTAL|Open-label Induction Phase: Guselkumab Intravenously (IV)|Participants will receive a guselkumab dose IV based on their body weight (BW) during the 12-week open-label induction phase.
62796843|NCT06260163|EXPERIMENTAL|Open-label Induction Phase: Guselkumab Subcutaneously (SC)|Participants will receive a guselkumab dose SC based on their BW during the 12-week open-label induction phase.
62796844|NCT06260163|EXPERIMENTAL|Double-blind Maintenance Phase: Guselkumab Dose Regimen 1|At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their BW up to Week 56.
62796845|NCT06260163|EXPERIMENTAL|Double-blind Maintenance Phase: Guselkumab Dose Regimen 2|At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their BW up to Week 56.
62796846|NCT06260163|EXPERIMENTAL|Open-label Maintenance Phase: Guselkumab SC|Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 56.
62221196|NCT02055781|EXPERIMENTAL|Pacritinib, Once Daily|Pacritinib 400 mg QD
62221197|NCT02055781|EXPERIMENTAL|Pacritinib, Twice Daily|Pacritinib 200 mg BID
62415665|NCT06488417|EXPERIMENTAL|Frankincense essential oil + boswellic acid supplement|Participants in this arm take two capsules of a frankincense essential oil + boswellic acid supplement daily for approximately 30 days.
62415666|NCT06488417|ACTIVE_COMPARATOR|Frankincense essential oil supplement|Participants in this arm take two capsules of a frankincense essential oil supplement daily for approximately 30 days.
62796847|NCT06440005|EXPERIMENTAL|Dose Escalation Phase|AGX-101, initial 90-minute IV infusion, second 60-minute IV infusion and 30 minute subsequent IV infusions on Day 1 of every 3-week cycle in Dose Escalation Phase. Dose escalation will be carried out in sequential cohorts of escalating doses.
62221198|NCT02055781|ACTIVE_COMPARATOR|Best Available Therapy|BAT includes any physician-selected treatment for myelofibrosis, such as approved JAK2 inhibitors administered according to package insert for patients with thrombocytopenia, and may include any treatment received before study entry.
62221199|NCT01805401|EXPERIMENTAL|Left OFC Group|Anode applied to the left OFC and cathode applied to the right OFC
62587872|NCT01356043|EXPERIMENTAL|Free combination of S-amlodipine and Telmisartan|Subjects received S-amlodipine 5mg and Telmisartan 80mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
62587873|NCT01356043|ACTIVE_COMPARATOR|S-amlodipine monotherapy|Subjects received S-amlodipine 5mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
62587874|NCT05335447|EXPERIMENTAL|Period 1 - Absolute Bioavailability|
62587875|NCT05335447|EXPERIMENTAL|Period 2 - Mass Balance|
62796848|NCT06440005|EXPERIMENTAL|Dose Expansion Phase|AGX-101, initial 90-minute IV infusion, second 60-minute IV infusion and 30 minute subsequent IV infusions on Day 1 of every 3-week cycle in Dose Escalation Phase. Dose expansion will be carried out with a selected dose and selected cancer type.
62796849|NCT02552134|EXPERIMENTAL|frequent participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence.
62796850|NCT02552134|EXPERIMENTAL|medium participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence
62796851|NCT02552134|EXPERIMENTAL|low participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence
62796852|NCT02552134|ACTIVE_COMPARATOR|recommendation to be active|"During the stay in the health care resort participants are introduced to be active in the future. They will receive a brochure Physical Activity: Health for all."
62796853|NCT01391663|EXPERIMENTAL|Alogliptin 12.5 mg QD|
62796854|NCT01391663|EXPERIMENTAL|Alogliptin 25 mg QD|
62796855|NCT01391663|EXPERIMENTAL|Alogliptin 50 mg QD|
62024498|NCT05527028|PLACEBO_COMPARATOR|Control group|Both groups will receive the standard care provided at the long-term care home. The intervention group will receive the addition of directed occupational therapy intervention provided by student occupational therapists for up to 30 minutes, five days a week. At present, no decisive evidence exists that this intervention being tested will be superior to the standard of care.
62024499|NCT05527028|EXPERIMENTAL|Intervention Group|Both groups will receive the standard care provided at the long-term care home. The intervention group will receive the addition of directed occupational therapy intervention provided by student occupational therapists for up to 30 minutes, five days a week. At present, no decisive evidence exists that this intervention being tested will be superior to the standard of care.
62221200|NCT01805401|EXPERIMENTAL|Right OFC Group|Anode applied to the right OFC and cathode applied to the left OFC
62221201|NCT01805401|SHAM_COMPARATOR|Sham tDCS|
62221202|NCT00386373|EXPERIMENTAL|Imatinib Mesylate|
62221203|NCT01859273|NO_INTERVENTION|Standard Care|Standard Care after kidney transplantation
62221204|NCT01859273|EXPERIMENTAL|mHealth|subjects provided with electronic medication tray, electronic blood pressure cuff, and a smart phone.
62221205|NCT01201265|EXPERIMENTAL|Overall Participants|Participants received a combination therapy of bevacizumab with gemcitabine plus carboplatin.
62221206|NCT03341767|EXPERIMENTAL|Clofazimine|Subjects \>/=50 kg: Clofazimine two 50mg gelatin capsules taken orally every 8 hours for 5 days Subjects \<50 kg: Clofazimine 50mg gelatin capsule taken orally every 8 hours for 5 days
62221207|NCT03341767|PLACEBO_COMPARATOR|Placebo|Placebo gelatin capsule(s) taken orally every 8 hours for 5 days.
62221208|NCT03341767|EXPERIMENTAL|Clofazimine, no diarrhea|Subjects \>/=50 kg: Clofazimine two 50mg gelatin capsules taken orally every 8 hours for 5 days Subjects \<50 kg: Clofazimine 50mg gelatin capsule taken orally every 8 hours for 5 days
62415667|NCT01376856||PET/CT and surgical biopsy group|person who performed PET/CT and surgical biopsy of mediastinal lymph node for diagnosis of primary lung cancer of metastatic lung cancer
62415668|NCT06375122||Cohort 1|Participants with Kaposi sarcoma
62587876|NCT06110806|EXPERIMENTAL|Mindfulness-based interoceptive exposure (MBIE)|Outpatient therapy for individuals with ARFID using mindfulness and exposures in a family-based therapy approach.
62796856|NCT03919357||Verbal|Passing of a specialized questionnaire on verbal disorders
62796857|NCT03919357||Non-verbal|Passing of a specialized questionnaire on non verbal disorders
62796858|NCT03919357||Attention|Passing of a specialized questionnaire on attention disorders
62796859|NCT03919357||Complaint about learning|Passing of a specialized questionnaire on learning disorders
62796860|NCT05590585|EXPERIMENTAL|dupilumab|Adolescents and adults will receive 1 of 2 dose regimens based on age and body weight
62796861|NCT02019511||High dose Steroid|"Patients scheduled for primary unilateral elective TKA Age \>17 years~none of the following contraindications for Methylprednisolone:~* Allergy against Methylprednisolone.~* Currently in systemic treatment with glucocorticoid~* Current gastric ulcer~* Insulin dependent diabetes mellitus~Citizens without Danish social security number are not eligible for this study as follow-up is not possible."
62796862|NCT02019511||Historical cohort|"Patients having primary unilateral elective TKA before initiation of Methylprednisolone as standard treatment~age \>17 years, Danish social security number~and none of the following at time of surgery:~* systemic treatment with glucocorticoid defined as: regular prescriptions on glucocorticoid within 2 months prior to surgery.~* gastric ulcer defined as: prescriptions on drugs used in triple therapy for Helicobacter Pylori infection or prescriptions on antiacids/proton pump inhibitors beginning 1 month before surgery~* Insulin dependent diabetes mellitus defined as: any prescriptions on insulin within 6 months prior to surgery"
62587877|NCT06299358|EXPERIMENTAL|Foot massage group|"Foot massage will be performed by the researcher for 10 minutes on two consecutive days a week in the infants' own homes. In foot massage, euphlorage, petrisage and friction techniques will be used in the appropriate order.~Infants in the foot massage group will be visited five times in total, two times each in the first encounter, first and second weeks. Related forms (Infantile colic and newborn comfort behavior scale) will be filled out by the researcher three times in total, once for the first encounter and once for each week. A total of two forms related to crying and sleep, one for each week, will be completed by the mother at the end of the study. The maternal state-trait anxiety scale will be completed twice, at the first encounter and at the end of the intervention."
62587878|NCT06299358|EXPERIMENTAL|Mother heart sound group|"For the group to listen to the mother's heart sounds, the heart sounds of the mothers of the babies will be recorded on an mp3 player in a quiet environment (in their own homes) with the help of hand-held doopes. The volume (65 decibels) and distance of the mp3 player will be determined by the researcher with the help of a decibel meter and the appropriate distance will be determined. The mother will play this sound to the infant for half an hour every day for two weeks, in coordination with the hours of the intervention in the other groups.~The infants in this group will be visited three times in total, once at the first encounter and once at the end of the first and second weekends, and the relevant forms (Infantile colic and newborn comfort behavior, state-trait anxiety scale) will be applied. Forms related to crying and sleep will be completed by the mother two times in total, one for each week."
62796863|NCT02019511||Procedures without Steroid|Patients scheduled for primary unilateral elective TKA and age \>17 years but who did not receive high dose Methylprednisolone regardless of reason.
62024500|NCT06572670|EXPERIMENTAL|Progressive relaxation exercise before coronary angiography|Patients in the intervention group will undergo progressive relaxation before undergoing angiography.
62024501|NCT06572670|NO_INTERVENTION|Control group|No application will be made to the control group before the procedure.
62024502|NCT03317704|ACTIVE_COMPARATOR|speed endurance training (SET)|Training 6 weeks 3 times pr. week
62221209|NCT03306459||1/PCOS|The authors will select 30 PCOS patients who met the more strict and conservative Rotterdam diagnostic criteria (Rotterdam phenotype A) which include the presence of oligo-anovulation (cycles lasting \>35 days or amenorrhea) and hyperandrogenemia /hyperandrogenism (hirsutism or obvious acne or pronounced alopecia). All patients should have bilateral polycystic ovaries morphology on ultrasound. Additionally, the authors have decided to enroll PCOS patients that are all without pregnancy desire at the moment they fill out the questionnaires, in order to control for the potential confounding role of infertility on psychological outcomes. Different pituitary, adrenal, ovarian, thyroid or metabolic diseases will be excluded
62221210|NCT03306459||2/CONTROL|The authors will enroll a control group of 30 women, age- matched with the PCOS women, from consecutive women controlled in the same outpatient clinic who met the following inclusion criteria: history of irregular menstrual cycle in absence of severe gynecologic and non-gynecologic diseases. This PCOS sample will be entirely constituted by women with no pregnancy desire; therefore, with the aim to limit the potential effect of the unfulfilled wish to conceive in the final results; additionally, infertile women will not admitted into the control group.
62796864|NCT01905878|EXPERIMENTAL|single dose DLBS1033|Before taking the drug, blood samples will be collected from subject to assess PAP complex level, serum creatinine, SGOT, SGPT, PT and aPTT. After that, subjects will instructed to take three tablets enteric coated of DLBS1033 in front of investigator. After take the medicine blood sample will be collected on 30 minute, 60 minute, 90 minute, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, and 24 hour to evaluate serial PAP complex. Subjects will undergo a clinical assessment including vital signs and the presence of adverse events at the time of blood sampling. On this trial, subjects are only permitted to eat food from investigator.
62024503|NCT03317704|NO_INTERVENTION|Controls|Asked to continue their usual life style
62024504|NCT03317704|ACTIVE_COMPARATOR|speed endurance training (SET) II|Training 6 weeks 3 times pr. week
62221211|NCT04682444|EXPERIMENTAL|Group 1 - Active Treatment|Patient who were randomized into Group 1 ingested Amizon tablets 0.5 g (2 tablets) after a meal, 3 times a day, for 7 days; each tablet contains 0.25 g of enisamium iodide.
62221212|NCT04682444|PLACEBO_COMPARATOR|Group 2 - Placebo|Patient who were randomized into Group 2 ingested placebo tablets after a meal, at the dose 0.5 g (2 tablets), 3 times a day, for 7 days.
62221213|NCT00292032||Cardiac Arrest Survivors or Post Mortem Unexplained Cardiac|Probands - Unexplained Cardiac Arrest Survivors and Post Mortem Unexplained Cardiac Arrest Cases
62024505|NCT02276482|EXPERIMENTAL|Tedizolid Phosphate|Tedizolid Phosphate IV and/or oral 200 mg once per day for 6 days. Participants with gram-negative wound infection may receive aztreonam (IV) and/or metronidazole (IV or oral).
62024506|NCT02276482|ACTIVE_COMPARATOR|Antibiotic comparator drug|IV and/or oral antibiotic comparator drug for 10 days. Participants with gram-negative wound infection may receive aztreonam (IV) and/or metronidazole (IV or oral).
62024507|NCT06108063|EXPERIMENTAL|Losartan (investigational)|Losartan 12.5 mg, PO, BID, for four weeks post-TKA surgery (on Days 1 through 28, starting the day after surgery).
62024508|NCT06108063|PLACEBO_COMPARATOR|Placebo (control)|Losartan Placebo 12.5 mg, PO, BID, for four weeks post-TKA surgery (on Days 1 through 28, starting the day after surgery).
62024509|NCT05061121|EXPERIMENTAL|sustained natural apophyseal glides|Investigate the short- and mid-term effects of Mulligan's SNAGs on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
62796865|NCT01905878|EXPERIMENTAL|steady state of DLBS1033|On day 1 blood samples will be collected to assess PAP complex level, serum creatinine, SGOT, SGPT, PT and aPTT. After that, subjects will instructed to take one tablet of DLBS1033 in front of investigator. Study drug packages (that consist of 8 tablets) will dispense to the subjects at day-1 and instructed to take the drug 3 times daily 30 minutes before meals. Subjects also will instructed to record any adverse events and concomitant medication prescribed in diary card. Subjects have to take the drug on 3 days (day 1, 2, and 3). On day 4, blood sample will be collected on 0 minutes, 30 minute, 60 minute, 90 minute, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, and 24 hour to evaluate serial PAP complex. Subjects will undergo a clinical assessment including vital signs and the presence of adverse events at the time of blood sampling. On this trial, subjects are only permitted to eat food from investigator.
62024510|NCT05061121|EXPERIMENTAL|Myofascial release|Investigate the short- and mid-term effects of Myofascial release on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
62024511|NCT05061121|EXPERIMENTAL|sustained natural apophyseal glides in addition to myofascial release|Investigate the short- and mid-term effects of Mulligan's SNAGs combined with Myofascial release on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
62024512|NCT00656838|ACTIVE_COMPARATOR|1|Patient has had PCP contact (letter, phone call, office visit, educational materials).
62024513|NCT00656838|NO_INTERVENTION|2|Usual Care
62221214|NCT00292032||First Degree Family Members|First Degree Family Members of those affected by Sudden Unexplained Cardiac Arrest
62796866|NCT05580081|EXPERIMENTAL|i-CAN|18 weeks of access to the online consulting platform
62024514|NCT03198000|EXPERIMENTAL|Formula # 13418-148|
62024515|NCT03198000|EXPERIMENTAL|Formula # 13418-158|
62024516|NCT03198000|ACTIVE_COMPARATOR|Control Formula # PF004390|
62024517|NCT03926507|EXPERIMENTAL|Diagnostic (fluciclovine F18 PET/CT)|Patients receive fluciclovine F18 IV and undergo 4 PET/CT scans over 10 minutes paired with standard of care MRI within 14 days prior to initial maximal tumor resection, within 7 days prior to initiation of radiation therapy, 28 days after the completion of radiation therapy, and 6 months after the completion of radiation therapy.
62024518|NCT06446037|EXPERIMENTAL|Interventional arm|All subjects will be instrumented with an electrode array on their forearms. The EMG signals detected by the electrodes will be fed into Phantom X hardware running the Phantom X algorithms. The algorithms will decode the EMGs signals and drive a desk mounted hand prosthesis.
62024519|NCT03039673|EXPERIMENTAL|low dose interleukin-2|"Patients randomized to this arm will receive subcutaneous injections of low-dose interleukin-2 in addition to oral Riluzole treatment.~Intervention: Riluzole Intervention: IL-2"
62221215|NCT02436473|EXPERIMENTAL|Test fluoride toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods
62415669|NCT00460421|EXPERIMENTAL|Palifermin Dose Escalation|A 3 dose escalation design. Sucessive cohorts of patient (9 patients per group) will each be administered Palifermin as an IV bolus injection (40, 60 or 80 µg) once daily for 3 consecutive days before the start of conditioning regimen (chemotherapy and total body irradiation) and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).
62796867|NCT05580081|NO_INTERVENTION|waitlist control|No offered support or consultation
62796868|NCT02416739|EXPERIMENTAL|Nicotinamide|"Nicotinamide with EGFR-TKI:~1. gefitinib (250mg tab) or erlotinib (150mg tab) - per oral, once a day~2. nicotinamide (500mg tab) - per oral, twice a day, until the event or censoring occurs"
62796869|NCT02416739|PLACEBO_COMPARATOR|Placebo|"Placebo tablet with EGFR-TKI:~1. gefitinib (250mg tab) or erlotinib (150mg tab) - per oral, once a day~2. placebo tablet - per oral, twice a day, until the event or censoring occurs"
62796870|NCT03507205||HOST-BIOLIMUS-Korea-3000|Active prospective registration of patients receiving biodegradable polymer-coated biolimus-eluting stents (BP-BES; Biomatrix, Biomatrix Flex, Nobori)
62221216|NCT02436473|PLACEBO_COMPARATOR|Fluoride free (0ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
62415670|NCT06556914||group albumin|The effect of albumin replacement on the measurements will be evaluated by calculating the ECHO findings, blood gas parameters and SOFA score of the study patients before and after albumin replacement. Oxygen delivery will be calculated 6 times in total for 3 days and the SOFA score will be calculated 3 times in total once a day.
62796871|NCT03507205||EXCELLENT-PRIME|Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents (DP-EES; Xience Prime)
62796872|NCT03507205||EXCELLENT Prospective cohort|Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents and sirolimus-eluting stents (Xience V/Promus; Cypher)
62796873|NCT03507205||HOST-RESOLINTE|Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES-RI; Resolute Integrity)
62796874|NCT03507205||RESOLUTE-Korea|Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES; Endeavor; Resolute)
62796875|NCT03500640|ACTIVE_COMPARATOR|DPP Plus 30-minute calls|Following the 6-month, 16-session, DPP core program, 30-minute group telephone calls will be implemented. Structured behavioral DPP maintenance sessions with a healthy aging focus occur once-per-month from months 7 to 12, and every-two-months from months 13 to 24.
62796876|NCT03500640|PLACEBO_COMPARATOR|DPP Minimal 15-minute calls|Following the 6-month, 16-session, DPP core program, 15-minute group telephone calls will be implemented. Social-support sessions occur once-per-month from months 7 to 12, and every-two-months from months 13 to 24.
62796877|NCT04585789|EXPERIMENTAL|Panel 1: JNJ-73763989+ NA|Ongoing and new participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks (last injection at Week 44) and nucleos(t)ide analog (NA) treatment (either entecavir \[ETV\], tenofovir disoproxil or tenofovir alafenamide \[TAF\] tablets) once daily up to 48 weeks. Participants may receive optional treatment with pegylated interferon alpha-2a (PegIFN-alpha-2a) after the Week 40 for a duration of either 12 or 24 weeks at the investigator's discretion. As per amendment-5, JNJ-56136379 is no longer included as part of the study intervention and all participants are counted as single arm in each panel.
62024520|NCT03039673|PLACEBO_COMPARATOR|Placebo|"Patients randomized to this arm will receive subcutaneious placebo injections (5% glucose water solution) in addition to oral Riluzole treatment.~Intervention: Riluzole Intervention: 5% glucose water solution"
62415671|NCT00335985|EXPERIMENTAL|1|
62415672|NCT00335985|PLACEBO_COMPARATOR|2|
62796878|NCT04585789|EXPERIMENTAL|Panel 2: JNJ-73763989+ NA|Ongoing and new participants will receive JNJ-73763989 SC injection once every 4 weeks (last injection at Week 44) and NA treatment (ETV, tenofovir disoproxil or TAF tablets) once daily up to 48 weeks. Participants may receive optional treatment with PegIFN-alpha-2a after the Week 40 for a duration of either 12 or 24 weeks at the investigator's discretion. As per amendment-5, JNJ-56136379 is no longer included as part of the study intervention and all participants are counted as single arm in each panel.
62796879|NCT03897673|EXPERIMENTAL|Early Iron|Children in the immediate iron group will receive iron syrup for the first three months (84 days) and placebo syrup for the fourth month.
62796880|NCT03897673|EXPERIMENTAL|Delayed Iron|Children in the delayed iron group will receive placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months.
62221217|NCT02436473|ACTIVE_COMPARATOR|Low dose fluoride (250ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
62024521|NCT01823094||Variability of measurements|variability of CTP measurements will be determined by repeating the CTP examination, and comparing the resultant blood flow estimates
62024522|NCT01823094||Treatment induced effects|The magnitude of treatment induced effects will be assessed by comparing tumor blood flow estimates before and after treatment
62221218|NCT02436473|ACTIVE_COMPARATOR|Fluoride (1150ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
62221219|NCT02252380|EXPERIMENTAL|Transcranial ExAblate System|Transcranial ExAblate System (MRgFUS)
62415673|NCT06700655|EXPERIMENTAL|Cornea limbal stem cell transplantation group|The corneal limbal tissue (2mm x 5mm) was harvested from the patient's healthy eye, and ex vivo amplification was performed to obtain an adequate quantity of transplantable corneal limbal stem cells The patient was followed up and re-examined for 2 years postoperatively.
62415674|NCT06700655|EXPERIMENTAL|Cornea limbal stem cell transplantation combined corneal stromal stem cell group|The corneal limbal tissue (2mm x 5mm) was harvested from the patient's healthy eye, and ex vivo amplification was performed to obtain an adequate quantity of transplantable corneal limbal stem cells and corneal stromal stem cells. The patient was followed up and re-examined for 2 years postoperatively.
62415675|NCT06700655|ACTIVE_COMPARATOR|Corneal transplantation group|The patient awaited allogeneic corneal donation and underwent corneal transplantation surgery. Postoperatively, the patient was followed up and re-examined for 2 years.
62415676|NCT04177173|EXPERIMENTAL|Simvastatin & Methotrexate|Methotrexate 10 mg once a week per oral for 6 months and Statins (Simvastatin) 20 mg once a day per oral
62221220|NCT02747199|ACTIVE_COMPARATOR|Coronary artery implanted with SYNERGY stent|One of the blocked coronary artery of a patient will received SYNERGY stent
62415677|NCT04177173|ACTIVE_COMPARATOR|Methotrexate|Methotrexate 10 mg once a week for 6 months
62221221|NCT02747199|ACTIVE_COMPARATOR|Coronary artery implanted with ABSORB scaffold|Another blocked coronary artery of the same patient will received ABSORB scaffold
62221222|NCT01796015|OTHER|For the 97 patients|"* day 0: ultrasound of ONSD (= 4 measurements: 1 transverse and 1 sagittal for each eye) + transcranial Doppler at T-15 (15 minutes before ICP measurement), within 1h following ICP measurement, and one more measurement is to be done if significant ICP variations are noticed (variation over 15 mmHg during at least 5 minutes)~* day 1: ONSD ultrasound + transcranial Doppler in the morning and one more measurement is to be done if significant ICP variations are noticed (variation over 15 mmHg during at least 5 minutes)~* days 2 and 3 : same as day 1~* when leaving the intensive care unit: Pediatric Overall Performance Category (POPC) scale"
62221223|NCT01796015|OTHER|For the control group|one single ONSD in addition to their usual care (4 measurements: 1 transverse and 1 sagittal for each eye) in the morning in absence of painful sensation
62221224|NCT01796015|OTHER|For the learning curve|minimum 15 ONSD ultrasounds will be performed by each of the 15 intensive care doctor or interns expected. One ONSD ultrasound corresponds to 2 measurements: 1 transverse and 1 sagittal. Each volunteer will have maximum 30 ONSD ultrasound measures over a 1 month period.
62415678|NCT05801107|EXPERIMENTAL|WX0593|60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 21-days cycle.
62415679|NCT01314859|EXPERIMENTAL|Nifedipine|"* Oral Treatment with Nifedipine capsules (10 mg)~  * Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).~ * Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.~* Maximum Duration of the treatment: 48 hours."
62415680|NCT01314859|ACTIVE_COMPARATOR|Atosiban|"* Intravenously Treatment with Atosiban (7.5mg/ml)~  * Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.~ * Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.~* Maximum Duration of the treatment: 48 hours."
62415681|NCT00825799||Major Depressive Disorder|Adults with major depressive disorder who are experiencing a current depressive episode.
62796881|NCT03897673|NO_INTERVENTION|Community Control Children|Healthy, non-anemic community children will be enrolled from the same households and villages as the children with malaria. They will not have ZPP tested or receive iron, but they will also be under the same illness surveillance as the children with malaria.
62796882|NCT06725563|EXPERIMENTAL|Endoscopically placed lumen-apposing metal stents for the treatment of IBD-strictures|Individuals will receive endoscopic lumen-apposing metal stents. The specific size of the stent used will depend on the length of the stricture. All LAMS placements are part of one arm.
62796883|NCT00377858|EXPERIMENTAL|Insulin Lispro Mid Mixture|Insulin lispro mid mixture (MM) up to three times a day (TID)
62221225|NCT02234687|PLACEBO_COMPARATOR|Placebo|Placebo, one dose
62221226|NCT02234687|EXPERIMENTAL|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
62415682|NCT00825799||Healthy controls|Individuals without any Axis I psychiatric diagnosis who are matched to depressed subjects by age and sex.
62415683|NCT05243134||Study Group|Patients with at least one type of anatomic deformity
62415684|NCT05243134||Control group|Patients without anatomic deformity
62415685|NCT04311411|EXPERIMENTAL|Tirzepatide|Participants received tirzepatide 5 milligrams (mg) once a week (QW) for Weeks 1 through 3 followed by tirzepatide 10 mg QW for Weeks 4 through 6 into the subcutaneous (SC) tissue of the abdominal wall.
62415686|NCT04311411|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered into the SC tissue of the abdominal wall.
62415687|NCT04311411|ACTIVE_COMPARATOR|Liraglutide|Participants received Liraglutide with step wise dose escalation regimen starting from 0.6 mg once daily (QD) for week 1 followed by 1.2 mg QD for week 2, 1.8 mg QD for week 3, 2.4 mg QD for Week 4 followed by 3 mg QD starting in Week 5 and maintained for 10 days administered into the SC tissue of the abdominal wall.
62415688|NCT02405494|OTHER|Beverage 1|Liquid foam consisting of 37 ml liquid with 73% overrun (total volume 65 ml).
62415689|NCT02405494|OTHER|Beverage 2|Liquid foam consisting of 37 ml liquid with 427% overrun (total volume 197 ml).
62415690|NCT02405494|OTHER|Beverage 3|Liquid foam consisting of 98 ml liquid with 73% overrun (total volume 169 ml).
62415691|NCT02405494|OTHER|Beverage 4|Liquid foam consisting of 98 ml liquid with 427% overrun (total volume 514 ml).
62415692|NCT02405494|OTHER|Beverage 5|Liquid foam consisting of 25 ml liquid with 250% overrun (total volume 88 ml).
62415693|NCT02405494|OTHER|Beverage 6|Liquid foam consisting of 110 ml liquid with 250% overrun (total volume 385 ml).
62024523|NCT01346657|EXPERIMENTAL|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects
62415694|NCT02405494|OTHER|Beverage 7|68 ml beverage consisting of 68 ml liquid with 0% overrun (total volume 68 ml).
62221227|NCT02234687|EXPERIMENTAL|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
62221228|NCT02884076||Symptomatic Hemorrhoid|Consecutive patients with symptomatic hemorrhoids presenting to our clinic
62221229|NCT05216497|EXPERIMENTAL|Ingavirin®, 90 mg capsules|Ingavirin®, 90 mg capsules will be administered on top of standard therapy: days 1-3: 180 mg (2 capsules once a day); days 4-7: 90 mg (1 capsule 1 time per day).
62221230|NCT05216497|PLACEBO_COMPARATOR|Placebo|Placebo capsules will be administered on top of standard therapy: days 1-3: 2 capsules once a day; days 4-7: 1 capsule 1 time per day.
62221231|NCT01536015|EXPERIMENTAL|Rotigotine|Rotigotine patch titrated from 4 mg/24 h - 8 mg/24 h or until effective or maximum dose is reached.
62415695|NCT02405494|OTHER|Beverage 8|Liquid foam consisting of 68 ml liquid with 500% overrun (total volume 405 ml).
62415696|NCT02405494|OTHER|Beverage 9|Liquid foam consisting of 68 ml liquid with 250% overrun (total volume 236 ml).
62796884|NCT00377858|ACTIVE_COMPARATOR|Insulin Glargine|Insulin glargine daily with insulin lispro at mealtime (up to 3 injections) as needed.
62796885|NCT02059798||Decompression of cervical myelopathy|JOA (Japanese Orthopaedic Association) Scores for cervical myelopathy Compliance Rigidity activity unit
62024524|NCT01017406|EXPERIMENTAL|Plantar fascia stretching exercise|Patient perform plantar fascia stretching 3 times per day
62024525|NCT01515085||biopsy proven glioma, no prior treatment|
62415697|NCT04543578||Patients unfit for Surgery with mild-moderate acute cholecyst|Conservative treatment (antibiotics, etc). EUS-guided gallbladder drainage will be considered in recurrent acute cholecystitis and in patients with no improvement in 48-72h after admission.
62415698|NCT04543578||Patients unfit for Surgery with severe acute cholecystitis|Percutaneous cholecystostomy or Endoscopic Ultrasound (EUS)-guided cholecystostomy (the latter is not 24/7 available). Palliative care may also be considered in patients with very serious conditions and low life expectancy.
62415699|NCT04543578||Patients suitable for Surgery with high and intermediate risk|"Admission in Gastroenterology Department. antibiotic treatment. Close follow-up of posible AC complications. Once choledocholithiasis is solved or ruled our, the patient will be considered for same-admission cholecystectomy or programmed cholecystectomy.~* High risk: Endoscopic Retrograde Cholangiopancreatography (ERCP) will be performed.~* Intermediate risk: EUS or Magnetic Resonance Cholangiopancreatography prior to consider ERCP."
62415700|NCT04543578||Patients suitable for Surgery with low risk|"Admission in Surgery Department. According to the AC severity:~* Mild-moderate AC: check de ASA/Charlson comorbidity index.~* ASA I-II/Charlson \<6: laparoscopic cholecystectomy~* ASA \> =III/Charlson \>=6: close follow-up 24-48h. Consider laparoscopic cholecystostomy (if no improvement is achieved)~* Severe AC: consider Intensive Care Unit admission. Percutaneous cholecystectomy."
62415701|NCT06702527||M-TEER patients|Patients with optimized guideline-directed medical therapy (GDMT) undergoing mitral transcatheter edge-to-edge repair (M-TEER, using the PASCAL system) for severe functional mitral regurgitation.
62796886|NCT04204707||Conservative surgery|
62796887|NCT04204707||Radical surgery (segmental resection)|
62796888|NCT05067387|PLACEBO_COMPARATOR|Placebo|Oral placebo; sesame and MCT oil
62796889|NCT05067387|EXPERIMENTAL|20 mg THC|THC suspended in sesame oil
62796890|NCT05067387|EXPERIMENTAL|20 mg CBD|CBD suspended in MCT oil
62024526|NCT05923281|EXPERIMENTAL|Treatment A|K-877 0.2 mg/day
62024527|NCT05923281|EXPERIMENTAL|Treatment B|K-877 0.4 mg/day
62024528|NCT05923281|PLACEBO_COMPARATOR|Control A|Placebo
62024529|NCT03936491|EXPERIMENTAL|Methylphenidate|The subjects will receive methylphenidate according to their clinical symptoms
62024530|NCT03936491|ACTIVE_COMPARATOR|Atomoxetine|The subjects will receive atomoxetine according to their clinical symptoms
62024531|NCT01295541||4 months of observation|CVICU
62024532|NCT06281691||Greenlandic citizens aged 18 years and above, referred for cystoscopy|Patients who have been referred for a cystoscopy will be invited to participate in the study. During their cystoscopy appointment, they will be asked to provide a urine sample for the Xpert bladder cancer detection test.
62796891|NCT05067387|EXPERIMENTAL|20 mg THC + 20 mg CBD|THC and CBD in sesame and MCT oil
62024533|NCT04132609|ACTIVE_COMPARATOR|Cognitive Bias Intervention|Complete cognitive bias intervention task during methadone clinic visit 3x/wk for 4 weeks.
62024534|NCT04132609|PLACEBO_COMPARATOR|Control|Complete standard attentional bias intervention task during methadone clinic visit 3x/wk for 4 weeks.
62024535|NCT05481021||Diabetes Specialist trainee Registrars/Middle grade working in UK|All doctors in in middle grade or similar rank who are in training as Diabetes Specialist trainee Registrars or non-trainee Middle grade doctors working in Diabetes/Endocrinology department in NHS Wales, NHS Scotland or Health and Social Care northern Ireland (health systems in all of UK)
62024536|NCT00614211|ACTIVE_COMPARATOR|1|Total Abdominal Radical Hysterectomy
62024537|NCT00614211|EXPERIMENTAL|2|Total Laparoscopic or Robotic Radical Hysterectomy
62024538|NCT02438449||Abdominal-based Autogenous Tissue (AAT)|The AAT-based breast reconstruction surgery will include any of the following techniques: pedicled transverse rectus abdominis myocutaneous (TRAM) flap, Free TRAM, muscle-sparting TRAM flap, deep inferior epigastric perforator (DIEP) flap, superficial inferior epigastric artery (SIEA) flap, and Rubens flap.
62415702|NCT04731909|EXPERIMENTAL|Toripalimab Combined With Anlotinib, Etoposide and Platinum|Toripalimab 240mg,d1,q3w+Anlotinib 12mg/d,d1-14,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 or Carboplatin AUC=5, d1, q3w,4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Toripalimab 240mg,d1,q3w+Anlotinib 12mg/d, was taken orally for 2 weeks and stopped for 1 week until the disease progressed.
62415703|NCT04923607|EXPERIMENTAL|TQC2731 injection(sc.) in healthy subjects|"For the single ascending dose (SAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of TQC2731(12mg、105mg、210mg、420mg、630mg) once.~For the multiple ascending dose (MAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of 420mg TQC2731 ."
62415704|NCT04923607|PLACEBO_COMPARATOR|Matching Placebo(sc.) in healthy subjects|"For the single ascending dose (SAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of matching placebo(12mg、105mg、210mg、420mg、630mg) once.~For the multiple ascending dose (MAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of 420mg matching placebo(12mg、105mg、210mg、420mg、630mg)."
62415705|NCT04923607|EXPERIMENTAL|TQC2731 injection(SAD,iv.)|Healthy subjects received 210mg TQC2731 intravenously (iv.) once.
62415706|NCT04923607|PLACEBO_COMPARATOR|Matching Placebo(SAD,iv.)|Healthy subjects received 210mg matching placebo intravenously (iv.) once.
62415707|NCT04923607|EXPERIMENTAL|TQC2731 injection(sc.) in asthma subjects|For the multiple ascending dose (MAD) portion of the study, asthma subjects received subcutaneous(sc.) injection of TQC2731(70mg、210mg、280mg) .
62024539|NCT02438449||Tissue Expander-Implants (TE/I)|The TE/I approach will include two-stage breast reconstruction surgery. In the initial stage, immediately after mastectomy and with or without sentinel node biopsy, an expander will be placed in the subpectoral plane and the defect closed. Two weeks after the surgery, the expansion of the TE will commence until the desired volume of the respective expander is achieved. The second stage will include removal of the TE and the placement of a permanent implant which may be either saline or gel. The delayed method will be similar to the immediate reconstruction with the exception of the incision, which will be relatively smaller as the mastectomy was performed previously with breast cavity being fully closed.
62024540|NCT04050592|OTHER|Group A, Abrupt Discontinuation|Women in group A will discontinue HT (estradiol, 2 mg daily) abruptly after study week 9 and will continue with placebo for study weeks 10-20.
62024541|NCT04050592|OTHER|Group B, Tapered Discontinuation|"Women in group B will discontinue HT (estradiol, 2 mg daily) gradually during study weeks 7-9, as follows:~* weeks 7-9: 1 mg estradiol daily for 10 days and then 1 mg estradiol every other day for 11 days.~* weeks 10-20: placebo"
62024542|NCT04050592|ACTIVE_COMPARATOR|Group C, Control Group|Women in Group C, the control group, will continue with HT (estradiol, 2 mg daily) throughout the whole study period of 20 weeks.
62024543|NCT05422118|ACTIVE_COMPARATOR|case|people who have spontaneous bacterial peritonitis
62024544|NCT05422118|ACTIVE_COMPARATOR|control|people who donot have spontaneous bacterial peritonitis
62024545|NCT04153370|ACTIVE_COMPARATOR|intubation time airtraq|inserting the device through the oral cavity till the visualization of the endotracheal tube passing through the vocal cords
62024546|NCT04153370|ACTIVE_COMPARATOR|intubation time glidescope|inserting the device through the oral cavity till the visualization of the endotracheal tube passing through the vocal cords
62024547|NCT04153370|ACTIVE_COMPARATOR|intubation time c-mac|inserting the device through the oral cavity till the visualization of the endotracheal tube passing through the vocal cords
62796892|NCT06725901|EXPERIMENTAL|Web-Based Application|"The intervention involves the use of the DIAGEN-IA platform, a diagnostic support application designed to assist in identifying pediatric neurological diseases with a genetic basis. DIAGEN-IA employs a Bayesian network model, integrating ontologies such as ORDO, HPO, and HOOM to link phenotypic characteristics entered by physicians with suggested diagnoses and recommended tests. Participating pediatric neurologists will receive training to use the application during the 6-month intervention phase.~The platform enables clinicians to input clinical data and complementary test results, generating a list of potential diagnoses and corresponding diagnostic tests. The results can be exported in PDF format for integration into the patient's medical record. Throughout the intervention, platform usage will be monitored, including login frequency, duration of use, and the number of evaluations performed."
62024548|NCT03867877|EXPERIMENTAL|Periodized Training with Motor Practice|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2s concentric and 3s eccentric for the strength day. 30-80% of subjects' maximal strength for the power day with high-speed concentric and 2 second eccentric contractions, and exercises that simulate activities of daily living for the motor practice day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
62024549|NCT03867877|EXPERIMENTAL|Simple Periodized Training|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day, with high speed concentric and 2 second eccentric contractions, and 60-75% of subjects' maximum strength for the hypertrophy day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down
62415708|NCT04923607|PLACEBO_COMPARATOR|Matching Placebo(sc.) in asthma subjects|For the multiple ascending dose (MAD) portion of the study, asthma subjects received subcutaneous(sc.) injection of matching placebo(70mg、210mg、280mg) .
62415709|NCT03770182|EXPERIMENTAL|Group A|"NEUROLITH~* Cycle 1: Active treatment~* Cycle 2: Sham treatment"
62415710|NCT03770182|EXPERIMENTAL|Group B|"NEUROLITH~* Cycle 1: Sham treatment~* Cycle 2: Active treatment"
62415711|NCT05362955|EXPERIMENTAL|5-FU Arm|intravaginal 2g 5-fluorouracil cream in every two weeks
62024550|NCT02352064|EXPERIMENTAL|PET-CT at day 150+/-15 days|Patient will have PET (18-FDG) following allogeneic stem cell transplantation
62221232|NCT01536015|PLACEBO_COMPARATOR|Placebo|Placebo patch.
62221233|NCT05909111|EXPERIMENTAL|MRI assessment during radiation therapy course|Patients perform on MRI every week during the 5-weeks treatment
62221234|NCT02996331|ACTIVE_COMPARATOR|2 hour arm|All participants in this arm are assigned a 2-hour repositioning interval.
62221235|NCT02996331|EXPERIMENTAL|3 hour arm|All participants in this arm are assigned a 3-hour repositioning interval.
62415712|NCT04672824|EXPERIMENTAL|ChAdOx1 RVF group 1|Participants will receive ChAdOx1 RVF 5 x 10\^9 vp, delivered intramuscularly
62415713|NCT04672824|ACTIVE_COMPARATOR|Control group|Placebo (Normal Saline), 0.5ml delivered intramuscularly
62415714|NCT04672824|EXPERIMENTAL|ChAdOx1 RVF group 2|Participants will receive ChAdOx1 RVF 2.5 x 10\^10 vp, delivered intramuscularly
62415715|NCT04672824|EXPERIMENTAL|ChAdOx1 RVF group 3|Participants will receive ChAdOx1 RVF 5 x 10\^10 vp, delivered intramuscularly
62415716|NCT00713765|EXPERIMENTAL|A|AZD3480 + Donepezil
62415717|NCT04992897||REN-Medication combinations|"all evaluable treatments.~'Treatment' defined as a REN treatment of at least 20 minutes (the nominal duration is 45 minutes).~'Evaluable treatment' defined as a treatment in which pain levels were reported at baseline and post 2 hours."
62024551|NCT03509935|EXPERIMENTAL|Intervention Ultrasound Group|"Patients will be submitted to Ultrasound protocol, namely:~1. In the first 6 to 12 hours of admission to ICU~2. Second US after 12-24 hours of inclusion.~3. Third US after 24-48 hours of inclusion.~Protocol:~* US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions.~* US inferior vena cava, collapsability or distensibility index according to the patient's conditions, in spontaneous or controlled ventilation, respectively.~* Cardiac US: subjective evaluation of contractility between normal, reduced or severely reduced.~The US findings will be communicated to the attending physicians who will conduct the patient, according to the protocol, recommending the administration of volume or not, and the use of vasopressors and/or inotropic drugs."
62024552|NCT03509935|NO_INTERVENTION|Control Group|Patients randomized to this group will receive care according to the indication of the attending physicians, composed mainly of intensive care physicians, without bedside US. Patients may be submitted to echocardiographic, abdominal and vascular examinations, among others, requested to ultrasound service, according to the indication.
62024553|NCT02942199|EXPERIMENTAL|MySafeRx Intervention|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. This arm represents MySafeRx using the MedicaSafe 3000 electronic pill dispenser.
62024554|NCT05476224||A history of asymptomatic/mildly symptomatic SARS-CoV2 infection|Participant with asymptomatic or mild symptomatic SARS CoV2 infection that did not require hospitalization at least 6 months prior to study inclusion
62024555|NCT05476224||A history of symptomatic SARS-CoV2 infection hospitalized at the CHU of Dijon outside the ICU|participant with symptomatic SARS CoV2 infection requiring conventional hospitalization at least 6 months prior to study inclusion
62024556|NCT05476224||A history of symptomatic SARS-CoV2 infection hospitalized in the ICU|participant with a symptomatic SARS CoV2 infection requiring an ICU hospitalization at least 6 months prior to study inclusion
62796893|NCT06128304|ACTIVE_COMPARATOR|Core Implementation Strategies|"Core Implementation Strategies~1. Ongoing consultation~2. Educational meetings~3. Strengthen referral system~4. Prepare patients to be active participants"
62024557|NCT05476224||No history of SARS-CoV2 infection matched on sex and age|participant with no evidence of SARS CoV2 infection and negative SARS-CoV2 serology
62024558|NCT05298176|EXPERIMENTAL|Patients with untreated EGFR positive NSCLC tumors|TKI-naïve advanced NSCLC patients, harboring a non-exon20insertion uncommon EGFR mutation, who are eligible for treatment with afatinib in 1st line
62024559|NCT05263531|EXPERIMENTAL|remote ischemic conditioning|Receiving remote ischemic conditioning (RIC) treatment with pressure set at 200 mmHg.
62024560|NCT05263531|SHAM_COMPARATOR|placebo remote ischemic conditioning|Receiving sham RIPC treatment with pressure set at 60 mmHg
62024561|NCT04489446|EXPERIMENTAL|Sildenafil|Patients allocated to this arm will receive Sildenafil 25mg every 8 hours orally for up to seven consecutive days.
62024562|NCT04489446|PLACEBO_COMPARATOR|Control|Patients allocated to this arm will receive a placebo that will be similar in form to sildenafil pills in the interventional arm. These doses will be scheduled every 8 hours and wil be administered orally por up to seven consecutive days.
62024563|NCT06015776||Men|Men who are undergoing cardiac surgery
62796894|NCT06128304|EXPERIMENTAL|Core+ Enhanced Implementation Strategies|"Includes all of the Core implementation strategies and adds:~5. Community engagement using Health Beginning Initiative Model~6. Smart Cards to facilitate patient engagement"
62024564|NCT06015776||Women|Women who are undergoing cardiac surgery
62024565|NCT01315548||Pancreatic adenocarcinoma|Patients diagnosed with solid pancreatic adenocarcinoma masses, with cytological / histologicalconfirmation
62024566|NCT01315548||Chronic pancreatitis|Patients diagnosed with solid pancreatic tumor masses with all the criteria fulfilled to exclude pancreatic cancer
62221236|NCT02996331|EXPERIMENTAL|4 hour arm|All participants in this arm are assigned a 4-hour repositioning interval.
62221237|NCT04838951|EXPERIMENTAL|Intervention arm|CADe system will be used during withdrawal phase of colonoscopy.
62796895|NCT03766126|EXPERIMENTAL|Treatment Arm|CART123 cells; cyclophosphamide; fludarabine
62221238|NCT04838951|NO_INTERVENTION|Control arm|Colonoscopy will be performed according to hospital protocol.
62415718|NCT04992897||Consistent efficacy|"all users that performed at least 2 evaluable treatments. In order to isolate the effect of REN treatments, this dataset considered only treatments where REN was used as a standalone treatment.~'Treatment' defined as a REN treatment of at least 20 minutes (the nominal duration is 45 minutes).~'Evaluable treatment' defined as a treatment in which pain levels were reported at baseline and post 2 hours."
62796896|NCT06204250|EXPERIMENTAL|Part 1 Single Ascending Dose: Cohorts 1 to 6|Participants will receive GS1-144 5 mg, 15 mg, 30 mg, 60 mg , 90 mg and 120mg tablets once on Day 1 in their respective Cohort in Part 1. 2 participants will receive placebo in each cohort.
62796897|NCT06204250|EXPERIMENTAL|Part 2 Multiple Ascending Dose: Cohorts 1 to 4|tablets once on Day 1 in their respective Cohort in Part 2. 2 participants will receive placebo in each cohort.
62796898|NCT06725693||Single Group Assignment|Each subject receive a single intravenous injection of 68Ga/18F-Exendin 4, and undergo PET/CT imaging within the specificed time.
62796899|NCT06726798|EXPERIMENTAL|Robotic ESD arm|
62796900|NCT05841537||Risankizumab|Participants will receive risankizumab as prescribed by their physician according to local label.
62796901|NCT06447415|EXPERIMENTAL|HRS-7450|
62796902|NCT06447415|PLACEBO_COMPARATOR|0.9% sodium chloride injection|
62024567|NCT05410574|EXPERIMENTAL|Children: Family-based Behavioral Weight Loss Treatment (FBT)|"* Traffic Light Eating Plan: All foods are assigned a color of the traffic light depending on their energy density \& nutritional quality. Participants are encouraged to set dietary goals to decrease the number of RED food servings consumed daily \& to increase the consumption of GREEN \& YELLOW foods.~* Traffic Light Activity Plan: Activities are assigned colors of the traffic light depending on intensity levels. Families are encouraged to increase time spent in GREEN activities and decreased RED activities.~* Behavior Change Strategies: Behavior modification will be fostered using several different strategies~* Social Facilitation: FBT emphasizes creating an ecology that supports long-term change, which includes modifying the family environment, reshaping peer networks, \& ensuring that there are community resources available to maintain change."
62024568|NCT05410574|EXPERIMENTAL|Caregivers: Family-based Behavioral Weight Loss Treatment (FBT)|"* Traffic Light Eating Plan: All foods are assigned a color of the traffic light depending on their energy density \& nutritional quality. Participants are encouraged to set dietary goals to decrease the number of RED food servings consumed daily \& to increase the consumption of GREEN \& YELLOW foods.~* Traffic Light Activity Plan: Activities are assigned colors of the traffic light depending on intensity levels. Families are encouraged to increase time spent in GREEN activities and decrease RED activities.~* Behavior Change Strategies: Behavior modification will be fostered using several different strategies~* Social Facilitation: FBT emphasizes creating an ecology that supports long-term change, which includes modifying the family environment, reshaping peer networks, \& ensuring that there are community resources available to maintain change."
62024569|NCT03207412|EXPERIMENTAL|Minimally invasive implantation|Patients receive minimally invasive implantation, and 200 million hAECs is implanted into bilateral ovarian tissue by Ultrasound-guided puncture.
62024570|NCT03207412|EXPERIMENTAL|Intravenous infusion|100 million hAECs is administered by intravenous infusion every 30 days, for 3 times.
62024571|NCT00952653|EXPERIMENTAL|DVS SR|
62221239|NCT02498431|EXPERIMENTAL|myocardial infraction|Patients with acute myocardial infraction who are admitted to the emergency department of 424 General Military Hospital before and after percutaneous coronary intervention and stent placement
62221240|NCT02498431|ACTIVE_COMPARATOR|coronary artery disease|Patients with coronary artery disease but not myocardial infraction who are being subjected to coronary angiography and percutaneous coronary intervention and stent placement
62221241|NCT02498431|ACTIVE_COMPARATOR|Control|Patients subjected to coronary angiography and found with no presence of coronary artery disease
62221242|NCT01996189|EXPERIMENTAL|Insulin|Arterial puncture with an insulin syringe followed by arterial puncture with standard needle.
62221243|NCT01996189|ACTIVE_COMPARATOR|Standard|Arterial puncture with standard needle followed by arterial puncture with insulin syringe.
62796903|NCT05877534|EXPERIMENTAL|Intervention|A 16 week period of exercise, supervised by a physiotherapist once a week. The exercise should be individually tailored from a programme based on a previous feasibility study. The program consist of exercises both to improve endurance and muscle strength. Progression and adjustments of time and position will be performed during the intervention period based any symptoms the participant exhibits. Progression should be halted if the participant experience PEM or other symptoms within \>24hours after last exercise. The participants will also recieve standard care during the intervention period. Standard care includes (but not restricted to) information about POTS and lifestyle changes that may effect the symptoms, advice about fluid intake and nutrition, compression garments, pharmacological interventions etc.
62415719|NCT04992897||Treatment intensity distribution|"all treatments.~'Treatment' defined as a REN treatment of at least 20 minutes (the nominal duration is 45 minutes)."
62415720|NCT04992897||Safety|all reported treatment/device-related adverse events (AEs) within the time period.
62415721|NCT06703775|EXPERIMENTAL|Low level laser therapy (LLLT) + Conventional physical therapy program|This group will be composed of 22 patients with shoulder dysfunction post liver donation. Patients will receive low level laser in addition to conventional physical therapy program. LLLT will be applied for 3 times a week for 4 consecutive weeks.
62796904|NCT05877534|NO_INTERVENTION|Control|Standard care during 16 weeks. Standard care includes (but not restricted to) information about POTS and lifestyle changes that may effect the symptoms, advice about fluid intake and nutrition, compression garments, pharmacological interventions etc.
62796905|NCT06020781|EXPERIMENTAL|Bupivacaine and Dexmedetomidine|Patients will receive ultrasound-guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% + 1 μg/kg dexmedetomidine.
62024572|NCT06050421|OTHER|Treatment as Usual (TAU)|The TAU condition will follow the standard treatment of the EDs Unit of the HSCSP for AN. This treatment consists of visits with a psychiatrist with a frequency decided according to the clinical situation and, in some cases, nursing follow-up and/or relapse prevention group that takes place twice per month
62221244|NCT03383120|EXPERIMENTAL|Laser|Mechanical debridement of the implant surface using an ultra-sonic device with saline irrigation and plastic curettes, followed by soft tissue curettage using a metallic curette. Adjunctive sub-mucosal diode laser application according to the instructions of the manufacturer (settings: 810 nm, 2.5 W, 50 Hz, 10 ms), 3x for 30 seconds, using a 400-µm thick fiber (Doctor Smile Wiser diode laser, Orcos Medical AG, Küsnacht, Switzerland), will be performed three times at one week intervals (days 0, 7, and 14).
62221245|NCT03383120|ACTIVE_COMPARATOR|Surgery|Active control includes mechanical debridement of the implant surface using an ultra-sonic device with saline irrigation and plastic curettes, followed by soft tissue curettage using a metallic curette at day 1. An open flap debridement procedure is performed at day 14 using normal saline for implant decontamination. Adjunctive systemic antimicrobials will be prescribed; Amoxi-mepha 500mg 3x/day and Metronidazole 500mg 3x/day, for 1 week. A chlorhexidine 0.2% mouth rinse will also be prescribed 2x/day for one week. Suture removal and prophylaxis are performed 7-10 days post-operatively.
62221246|NCT05420844|OTHER|Kintsugi|Enrolled participants who will be using the Kintsugi voice journaling phone application.
62221247|NCT03374527||Psoriasis|Patients with psoriasis vulgarism without clinical signs of PsA
62221248|NCT03374527||Psoriatic Arthritis (PsA)|Patients with a diagnosis of psoriatic arthritis and cutaneous psoriasis
62221249|NCT03374527||Control group|Healthy subjects
62415722|NCT06703775|EXPERIMENTAL|Neural mobilization techniques + Conventional physical therapy program|This group will be composed of 22 patients with shoulder dysfunction post liver donation. Patients will receive neural mobilization techniques in addition to conventional physical therapy program. Exercises will be applied for 3 times a week for 4 consecutive weeks.
62415723|NCT06703775|ACTIVE_COMPARATOR|Conventional physical therapy program|This group will be composed of 22 patients with shoulder dysfunction post liver donation. Patients will receive conventional physical therapy program. Exercises will be applied for 3 times a week for 4 consecutive weeks.
62796906|NCT06020781|ACTIVE_COMPARATOR|20 ml Bupivacaine without additives|Patients will receive ultrasound-guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% without additives.
62221250|NCT05174455|EXPERIMENTAL|Treatment (Niraparib)|Patients receive niraparib PO QD. Cycles repeat every 28 days for 15 months in the absence of disease progression or unacceptable toxicity.
62221251|NCT02818959|EXPERIMENTAL|Transcatheter Aortic Valve Replacement|In this study, transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial TAVR System, which is intended for use in subjects with severe aortic stenosis. The JenaValve replacement valve is placed inside the aortic valve by using a delivery system.
62221252|NCT03402490|EXPERIMENTAL|Motivational interviewing|Over a time span of 6 months, participants in the intervention group received up to 7 sessions of motivational counseling, lasting 15-30 minutes each, to enhance physical activity.
62221253|NCT03402490|NO_INTERVENTION|Usual care|Participants who served as controls received usual care.
62221254|NCT03723616|ACTIVE_COMPARATOR|Hookah Tobacco Smokers|Young adults, ages 18-34, who smoke hookah tobacco
62221255|NCT03723616|ACTIVE_COMPARATOR|Open to Smoking Hookah Tobacco|Young adults, ages 18-34, who do not smoke hookah tobacco but are open to trying
62221256|NCT01534377|EXPERIMENTAL|Interpersonal Psychotherapy|Adolescents will receive Interpersonal Psychotherapy for the treatment and prevention of depression.
62221257|NCT01534377|EXPERIMENTAL|Enhanced Care|Adolescents will receive the Enhanced care model or care that they would typically receive in community setting to treat and prevent depression.
62221258|NCT01383460|ACTIVE_COMPARATOR|G-CSF+EPO|
62221259|NCT01383460|PLACEBO_COMPARATOR|Placebo|
62221260|NCT02648490|EXPERIMENTAL|HLX07, in patients with solid cancers.|"Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive weekly infusion of assigned dose of HLX07. No intra-patient dose escalation is allowed.The proposed dose escalation sequence is 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg.~Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07, followed by dexamethasone 10 mg intravenous infusion for 10 minutes, and followed by diphenhydramine 30 mg intravenous infusion for 10 minutes. If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions."
62221261|NCT00697333|NO_INTERVENTION|A|Irradiation of all tumor manifestations detectable by CT and/or positron emission tomography using fluoro-deoxy-glucose including a part of eventual atelectasis and the whole affected lymph node stations by 60 - 74 Gy/2Gy) irradiation of elective lymph node stations up to 50 Gy/2 Gy
62221262|NCT00697333|EXPERIMENTAL|B|Irradiation of all tumor manifestations detectable by positron emission tomography using fluoro-deoxy-glucose including the whole affected lymph node stations by 60 - 74 Gy/2Gy
62433379|NCT03555890|EXPERIMENTAL|Subjects of Group C: Part 2|Subjects in Group C will be randomized to receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine ODT 5 mg without water in fasted state in Period 2.
62796907|NCT06020781|ACTIVE_COMPARATOR|30 ml bupivacaine without additives|Patients will receive ultrasound-guided Supraclavicular brachial plexus block with 30 ml bupivacaine 0.5% without additives as a control group.
62796908|NCT05810155||Time waiting for surgery|This group includes all patients with IBD who are waiting for elective surgery and was put on the waiting list 2017-2021 at Sahlgrenska University Hospital.
62796909|NCT05810155||Operated|This group includes patients with IBD who was operated with elective surgery 2017-2021 at Sahlgrenska University Hospital.
62796910|NCT06647069|EXPERIMENTAL|DL1 of DR-0201|Subjects in this arm will receive up to 6 months of dosing with dose level 1 of DR-0201
62796911|NCT06647069|EXPERIMENTAL|DL2 of DR-0201|Subjects in this arm will receive up to 6 months of dosing with dose level 2 of DR-0201
62221263|NCT04709315|ACTIVE_COMPARATOR|saline pretreatment/succinyl group (SS group).|patients receive pretreatment with 10 ml 0.9% saline over 10 minutes, and succinyl choline 1mg/ kg is the intubating muscle relaxant.
62221264|NCT04709315|EXPERIMENTAL|Dex pretreatment/ rocuronium group (DR group),|patients receive pretreatment with Dex 1 µg / kg in 10 ml 0.9% saline over 10 minutes and rocuronium 0.6 mg/kg is the intubating muscle relaxant.
62415724|NCT05641246|ACTIVE_COMPARATOR|Control Arm|"* Standard of care Urea-based cream (CARBAMIDE®) will be applied to hands and feet 2-3 times daily for 14 days starting from the first dose and cycle of Capecitabine (XELODA ®).~* Each Capecitabine (XELODA ®) cycle lasts for 21 days.~* Capecitabine (XELODA ®) dose :2g/m2 daily divided into 2 doses after breakfast and dinner for 14 days followed by 7 days Capecitabine free.~* Capecitabine (XELODA ®) dose will be modified according to treatment related side effects (26).~* This regimen will be repeated at each cycle of Capecitabine (XELODA ®) and lasts for 6 cycles (18 weeks) and preventive measures of Hand-foot syndrome will be applied (Avoid mechanical stress"
62433380|NCT03555890|EXPERIMENTAL|Subjects of Group D: Part 2|Subjects in Group D will be randomized to receive levocetirizine ODT 5 mg without water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 2.
62221265|NCT05983224|EXPERIMENTAL|Quercetin|The intervention group will receive two 500 mg quercetin tablets daily, after breakfast and lunch, for twelve weeks.
62221266|NCT05983224|PLACEBO_COMPARATOR|Placebo|The Placebogroup will receive Placebo tablets daily, after breakfast and lunch, for twelve weeks.
62221267|NCT00691327|EXPERIMENTAL|1|Primary reconstruction
62221268|NCT00691327|EXPERIMENTAL|2|Revision-reconstruction
62221269|NCT00691327|EXPERIMENTAL|3|Revision-augmentation
62221270|NCT00710853|EXPERIMENTAL|1|YiRen Qi gong weekly class for 8 weeks
62221271|NCT00710853|EXPERIMENTAL|2|Tai Chi weekly class for 8 weeks
62221272|NCT00710853|ACTIVE_COMPARATOR|3|Hatha yoga weekly class for 8 weeks
62415725|NCT05641246|ACTIVE_COMPARATOR|Intervention Arm|"* Standard of care Urea-based cream (CARBAMIDE®) will be applied to hands and feet twice daily for 14 days starting from the first dose and cycle of Capecitabine (XELODA ®).~* Each Capecitabine (XELODA ®) cycle lasts for 21 days.~* Capecitabine (XELODA ®) dose: 2g/m2 daily divided into 2 doses after breakfast and dinner for 14 days followed by 7 days Capecitabine free.~* Capecitabine (XELODA ®) dose will be modified according to treatment related side effects (26).~* This regimen will be repeated at each cycle of Capecitabine (XELODA ®) and lasts for 6 cycles (18 weeks) and preventive measures of Hand-foot syndrome will be applied (Avoid mechanical stress Plus~* Topical diclofenac (VOLTAREN®) Emulgel 1% 2-4g (2g = 4 fingertip Units (FTU)) twice daily 2 hours away from Urea-based cream (CARBAMIDE®) for 14 days starting from the first cycle and dose of Capecitabine.~* This regimen will be repeated at each cycle of Capecitabine (XELODA ®) and lasts for 6 cycles (18 weeks)."
62221273|NCT03143621|EXPERIMENTAL|Coffee|100 cc's of coffee administered three times per day until return to bowel function has been established.
62415726|NCT06095362|EXPERIMENTAL|Intervention group|
62415727|NCT04916067|EXPERIMENTAL|Intervention|Patients undergoing mesh implantation during ileostomy closure to reinforce the abdominal wall
62415728|NCT05986565|EXPERIMENTAL|Website treatment|This arm will receive access to the FMF teacher adapted website.
62415729|NCT05986565|ACTIVE_COMPARATOR|delayed treatment control|This arm will get the same intervention as the experimental arm delayed by 6 weeks.
62221274|NCT03143621|PLACEBO_COMPARATOR|Water|100 cc's of warm water administered three times per day until return to bowel function has been established.
62221275|NCT01236534|ACTIVE_COMPARATOR|Lubiprostone|
62415730|NCT05161546|EXPERIMENTAL|patients with bipolar disorder (BD)|"Electrophysiological recordings with ERG and EEG will be performed with a virtual reality headset after a standardized clinical evaluation (first visit).~Then, an actigraphic monitoring of 21 consecutive days will be carried out. At the end of this period a neuropsychological evaluation will be performed during a second visit.~Between day 23 and day 28 (after the second visit), patients will be offered to assess the retinal structure and microvascularization using Spectral Domain Optical Coherence Tomography (SD-OCT) and OCT-Angiography (OCT-A)."
62433381|NCT04128878||Atrial Fibrillation Cohort|Adult patients with known or new diagnosis of either paroxysmal or persistent atrial fibrillation seen at the electrophysiology outpatient clinic and admitted to the electrophysiology service for initiation of anti-arrhythmic medications (dofetilide or sotalol).
62796912|NCT06647069|EXPERIMENTAL|DL3 of DR-0201|Subjects in this arm will receive up to 6 months of dosing with dose level 3 of DR-0201
62221276|NCT01236534|PLACEBO_COMPARATOR|Sugar pill|
62221277|NCT03468231|ACTIVE_COMPARATOR|Sorafenib plus HAIC of FOLFOX|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin, Fluorouracil and Leucovorin
62221278|NCT03468231|EXPERIMENTAL|Sorafenbi plus HAIC of OXA|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin
62796913|NCT06647069|EXPERIMENTAL|DL4 of DR-0201|Subjects in this arm will receive up to 6 months of dosing with dose level 4 of DR-0201
62796914|NCT06647069|EXPERIMENTAL|DL5 of DR-0201|Subjects in this arm will receive up to 6 months of dosing with dose level 5 of DR-0201
62796915|NCT06647069|EXPERIMENTAL|DL6 of DR-0201|Subjects in this arm will receive up to 6 months of dosing with dose level 6 of DR-0201
62796916|NCT05013359||Adolescents Living with Obesity (ALwO)|Recruited from online, general population consumer panels
62221279|NCT01710891|ACTIVE_COMPARATOR|Direct Laryngoscopy|Patients will undergo their first intubation attempt with direct laryngoscopy using the CMAC device without video assistance. The video monitor with be covered with a hood.
62221280|NCT01710891|EXPERIMENTAL|CMAC|Patients will undergo their first intubation attempt using the CMAC videolaryngoscope using video assistance
62221281|NCT01220518|ACTIVE_COMPARATOR|CT-P13|infliximab
62221282|NCT01220518|ACTIVE_COMPARATOR|Remicade|infliximab
62796917|NCT05013359||Health Care Providers (HCPs)|HCPs treating adolescents who have obesity
62796918|NCT05013359||Caregivers|A parent or legal guardian of an adolescent with obesity
62221283|NCT00497185|OTHER|A|Mindfulness-Based Cognitive Therapy
62221284|NCT00497185|NO_INTERVENTION|B|Shared care: Treatment as usual augmented by psychiatric consultation intervention to optimise treatment in the present health care system.
62221285|NCT04678115|EXPERIMENTAL|MLP first, KTFS second|Participants in this arm will receive the MLP in the first period of the crossover and the KTFS in the second period.
62221286|NCT04678115|EXPERIMENTAL|KTFS first, MLP second|Participants in this arm will receive the KTFS in the first period of the crossover and the MLP in the second period.
62221287|NCT01581359|ACTIVE_COMPARATOR|GnRHa|Triptorelin acetate 3,75 mg subcutaneous injection administered on days 1, 28 and 56 after menstrual cycle.
62221288|NCT01581359|PLACEBO_COMPARATOR|Physiological serum|physiological serum subcutaneous injection with same delivery device and same volume that active comparator ) administered on days 1, 28 and 56 after menstrual cycle.
62221289|NCT04869228|EXPERIMENTAL|GT0918 in the treatment arm|GT0918 tablets : oral, 1 time / day, 2 tablets / time, after meals
62221290|NCT04869228|PLACEBO_COMPARATOR|Placebo in the placebo arm|placebo : oral, 1 time / day, 2 tablets / time, after meals
62221291|NCT04433702|EXPERIMENTAL|Experimental Eye|10 mmHg of negative pressure is applied to the periocular microenvironment. This is achieved by programming the Mercury™ Multi-Pressure Dial (MPD) such that only one goggle receives negative pressure.
62221292|NCT04433702|PLACEBO_COMPARATOR|Control Eye|The opposing eye serves as the intrasubject control for each participant. No negative pressure is applied to the periocular microenvironment. This is achieved by programming the Mercury™ Multi-Pressure Dial (MPD) such that the other goggle does not receive negative pressure.
62221293|NCT02594605|EXPERIMENTAL|Platelet Rich Fibrin|Platelet Rich Fibrin was applied with conventional flap surgery for treatment of periodontal bone loss in test group.
62221294|NCT02594605|ACTIVE_COMPARATOR|Conventional Flap Surgery|Platelet Rich Fibrin was not applied to control groups. Only conventional flap surgery was applied to control groups.
62221295|NCT00704379|PLACEBO_COMPARATOR|Placebo|Placebo will be given in a double blind fashion via an equal number of tablets (identical to the sertraline tablets) administered once daily.
62221296|NCT00704379|EXPERIMENTAL|Sertraline|Sertraline will be given in a double blind fashion via tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention.
62221297|NCT05324397|EXPERIMENTAL|Experimental: Treatment|Subjects will undergo treatment with the NEUROMARK System
62221298|NCT01322997|EXPERIMENTAL|Myomo + RTP|This group will be administered a regimen comprised of repetitive task specific practice (RTP) in conjunction with use of the robotic brace described elsewhere in this record.
62221299|NCT01322997|ACTIVE_COMPARATOR|Myomo|Patients in this group will only be administered the robotic brace described elsewhere in this record.
62221300|NCT01322997|ACTIVE_COMPARATOR|RTP only|Patients in this group will be administered repetitive task specific practice (RTP), emphasizing use of their affected arms during performance of valued, functional tasks.
62221301|NCT03768804|OTHER|SyncAV algorithm on|"Device randomised to have SyncAV on, with delta programmed to the value which gives the narrowest QRS duration at rest and pseudo left ventricular (LV) only pacing"
62221302|NCT03768804|OTHER|SyncAV algorithm off|"Device randomised to have SyncAV off, with a fixed sensed atrioventricular (AV) delay of 120ms or shorter if necessary to prevent fusion, and biventricular (BiV) pacing"
62221303|NCT02982460|EXPERIMENTAL|Isoinertial + eccentric exercise|The isoinertial training will be based on 4 sets of 8 maximal repetitions using a YoYo-Squat (YoYo Technology AB, Stockholm, Sweden). This exercise device use the inertia of a spinning flywheel (moment inertia = 0.11 kg m-2), offering resistance during coupled concentric and eccentric actions, and allows for high demanding to rotator cuff exercises while offering the possibility to perform with an eccentric overload.Two initial repetitions in any set were aimed at accelerating the flywheel, before executing the subsequent 8 actions at maximal effort. Eccentric exercise will based on a set of 4 exercise implicating abduction, lateral rotation, extension and flexion of the shoulder.
62221304|NCT02982460|ACTIVE_COMPARATOR|Eccentric exercise|Eccentric exercise will based on a set of 4 exercise implicating abduction, lateral rotation, extension and flexion of the shoulder. Participants will attend three appointments per week over three weeks. They will complete three sets of 10 repetitions, with the exercises progressed in difficulty at each appointment.
62221305|NCT03723876|ACTIVE_COMPARATOR|Intervention group|Twelve occasions of Basic body awareness therapy, administered once a week, alongside treatment as usual (such as structured everyday support, medicine, contact with social worker).
62796919|NCT02009488|EXPERIMENTAL|Canagliflozin (JNJ-28431754)|Each patient will receive canagliflozin 100 mg once daily during the first 4 weeks of the 25 weeks double-blind period, then the dose may be increased to 300 mg once daily, till the end of the period.
62221306|NCT03723876|NO_INTERVENTION|Control group|No extra intervention except treatment as usual.
62796920|NCT02009488|PLACEBO_COMPARATOR|Placebo|One placebo capsule taken orally (by mouth) once daily for approximately 28 days during the Pre-Treatment Run-In and the Baseline Periods, then during double-blind study for 178 days (approximately 24-25 weeks).
62796921|NCT01345188|ACTIVE_COMPARATOR|Ranolazine|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
62796922|NCT01345188|PLACEBO_COMPARATOR|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
62796923|NCT04372823||Comparison|Comparison children within family child care homes not exposed to policy/program
62796924|NCT04372823||Intervention|Intervention children within family child care homes exposed to policy/program
62796925|NCT02551263||Observational group|All patients will receive adequate treatment for breast cancer which selected by the primary physician after enrollment using the Japanese Breast Cancer Society Clinical Practice Guideline of Breast Cancer and the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Investigators at the investigational sites will enter patient data into an electronic data capture (EDC) system up to the third chemotherapy in the study.
62796926|NCT05027867|EXPERIMENTAL|Arm 1|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
62415731|NCT05161546|ACTIVE_COMPARATOR|healthy volunteers|"Electrophysiological recordings with ERG and EEG will be performed with a virtual reality headset after a standardized clinical evaluation (first visit).~Then, an actigraphic monitoring of 21 consecutive days will be carried out. At the end of this period a neuropsychological evaluation will be performed during a second visit."
62796927|NCT05027867|EXPERIMENTAL|Arm 2|KRT-232 180 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
62796928|NCT00451022||Cohort 1|Subjects previously participating in gene transfer or other immunotherapy studies at the NCI or extramural sites receiving therapeutic agents as part of a multi-site trial.
62796929|NCT03785704|EXPERIMENTAL|Xinmailong injection group|given 5 mg/kg of Xinmailong injection every cycle on d0, d1, d2, d3, d4 on the same chemotherapy regimen (EC-T) as those in the control group.
62415732|NCT03069365|EXPERIMENTAL|GLE/PIB for 8 weeks|HCV genotype 1,2,4-6 non-cirrhotic, treatment-naive or treatment-experienced; genotype 3 non-cirrhotic, treatment-naïve participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 8 weeks
62796930|NCT03785704|NO_INTERVENTION|control group|receive conventional EC-T regimen chemotherapy (Epirubicin 45mg/m2 d1, 2 + cyclophosphamide 600mg/ m2 d1, repeated every 14 or 21 days for 4 cycles, followed by paclitaxel 175 mg/m2 (or docetaxel 75 mg/m2) on day 1, repeated every 21 days for 4 cycles).
62024573|NCT06050421|EXPERIMENTAL|TAU + Radically Open Dialectical Behaviour Therapy (RO-DBT)|2. TAU + skills of the RO-DBT: In this treatment branch, a RO-DBT skills training therapy will be added to TAU. Treatment and therapists: RO DBT skills training consists of a 30-week intervention program in which a set of skills specifically designed to treat overcontrol are taught on an ongoing basis. The duration of each session is 2 hours. Table X provides an overall summary of each skill training session content. Detailed and extensive information about the treatment can be found elsewhere \[24\], \[34\]. Three clinical psychologists and one psychiatrist will conduct the treatment, all of whom have undergone extensive training in RO DBT. A maximum of two therapists will be in charge of each session, and the same two therapists will go throughout each group intervention. The team will be supervised by an approved RO DBT supervisor to improve therapeutic skills and ensure adherence to the protocol.
62415733|NCT03069365|EXPERIMENTAL|GLE/PIB for 12 weeks|HCV genotype 1,2,4-6 compensated cirrhosis, treatment-naive or treatment-experienced; genotype 3 compensated cirrhosis, treatment- naïve participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 12 weeks
62796931|NCT00287716|ACTIVE_COMPARATOR|2403 mg/day pirfenidone|Active arm 1, 2403 mg/day pirfenidone dose group.
62796932|NCT00287716|ACTIVE_COMPARATOR|1197 mg/day pirfenidone|Active arm 2, 1197 mg/day pirfenidone.
62796933|NCT00287716|PLACEBO_COMPARATOR|placebo|Placebo equivalent.
62796934|NCT03819049|EXPERIMENTAL|Cohort 1: ExPEC10V (Low Dose)|Participants will be randomized to receive a single intramuscular (IM) injection of low dose ExPEC10V on Day 1.
62796935|NCT03819049|EXPERIMENTAL|Cohort 1: ExPEC10V (Medium dose)|Participants will be randomized to receive a single IM injection of medium dose ExPEC10V on Day 1.
62796936|NCT03819049|EXPERIMENTAL|Cohort 1: ExPEC10V (High dose)|Participants will be randomized to receive a single IM injection of high dose ExPEC10V on Day 1.
62796937|NCT03819049|EXPERIMENTAL|Cohort 1: ExPEC4V|Participants will be randomized to receive a single IM injection of ExPEC4V on Day 1.
62796938|NCT03819049|EXPERIMENTAL|Cohort 1: Prevnar 13|Participants will be randomized to receive a single IM injection of Prevnar 13 on Day 1.
62796939|NCT03819049|EXPERIMENTAL|Cohort 2: ExPEC10V|Participants will be randomized to receive a single IM injection of selected dose of ExPEC10V on Day 1. The ExPEC10V dose used in Cohort 2 will be based on the primary analysis (Day 30) results of Cohort 1.
62796940|NCT03819049|PLACEBO_COMPARATOR|Cohort 2: Placebo|Participants will be randomized to receive a single IM injection of matching placebo on Day 1.
62796941|NCT06311578|EXPERIMENTAL|Part 1: Dose Escalation|Participants with advanced solid tumors will receive JNJ-87704916 alone and in combination with cetrelimab. Ascending dose levels will be sequentially tested.
62796942|NCT06311578|EXPERIMENTAL|Part 2: Dose Expansion|Part 2 will consist of two cohorts: Cohort A and Cohort B. Participants in both Cohorts with metastatic non-small cell lung cancer (NSCLC) will receive JNJ-87704916 in combination with cetrelimab at the dose identified in Part 1.
62796943|NCT02780492||Ambulant patients|A set of assessment tools (blood analyses, functional, respiratory, quality of life questionnaires, Dexa scan, MRI) will be performed.
62796944|NCT02780492||Non-ambulant patients|A set of assessment tools (blood analyses, functional, respiratory, quality of life questionnaires, Dexa scan, MRI) will be performed.
62796945|NCT02780492||Healthy volunteers and Disease controls|A set of assessment tools (upper limb function tests, MRI, blood analyses) will be performed
62024574|NCT06050421|OTHER|Healty controls|All controls will complete data collection notebook and will undergo the same neuroimaging acquisition. There will not be follow-up for this group.
62796946|NCT00649506|EXPERIMENTAL|1|Nitrofurantoin Macrocrystals 100 mg Capsules
62796947|NCT00649506|ACTIVE_COMPARATOR|2|Macrodantin® 100 mg Capsules
62415734|NCT03069365|EXPERIMENTAL|GLE/PIB for 16 weeks|HCV genotype 3 non-cirrhotic or with compensated cirrhosis, treatment-experienced participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 16 weeks
62796948|NCT03337334|OTHER|Non-Focused stimulation|Stimulation frequency is set similar to that of the tremor and the amplitude is set up to 2 mA peak amplitude (reduced if not uncomfortable). One 5\*5 cm2 square patch electrodes are placed over the Motor cortex and the Prefrontal cortex respectively and a common return electrode of 10\*10 cm2 over the ankle. Each subject follows three sessions of 12 min length each. During each session the tremor is measured while interleaving between Motor cortex stimulation, Prefrontal cortex stimulation and No stimulation. By the end of each session we get 4 min of Motor Cortex stimulation, 4 min of Prefrontal Cortex stimulation and 4 min of No stimulation.
62796949|NCT03337334|OTHER|Focused stimulation|Stimulation frequency is set similar to that of the tremor and the amplitude is set up to 5 mA peak amplitude (with the help of local anesthetic cream and amplitude is reduced if not uncomfortable). A set of 4\*1 gel-filled cup-electrodes is placed over each of motor cortex and the occipital cortex respectively. Each subject follows three sessions of 12 min length each. During each session the tremor is measured while interleaving between Motor cortex stimulation, Occipital cortex stimulation and No stimulation. By the end of each session we get 3 min of Motor Cortex stimulation, 3 min of occipital Cortex stimulation and 6 min of No stimulation.
62796950|NCT04320784|EXPERIMENTAL|Time restricted eating (TRE)|TRE group consumed 100% of its estimated daily energy needs in an 8-hour time window: from 10:00 AM to 6:00 PM
62024575|NCT06535412|EXPERIMENTAL|IMC-002 + SOC|
62024576|NCT06535412|PLACEBO_COMPARATOR|Placebo + SOC|
62024577|NCT01947881||Patients with DME|Patients with DME who need treatment with anti-VEGF injections of Lucentis.
62024578|NCT00905580|PLACEBO_COMPARATOR|Placebo|Patients receive oral Placebo 150 mg 1 hour prior to surgery, and 12 hours later
62024579|NCT00905580|EXPERIMENTAL|Pregabalin|Patients receive oral pregabalin 150 mg 1 hour prior to surgery, and 12 hours later
62024580|NCT02961972|PLACEBO_COMPARATOR|control group|Oral ingestion of placebo pills (maltodextrin) during three weeks
62024581|NCT02961972|EXPERIMENTAL|creatine supplementation|Oral supplementation with 5 g of monohydrate and micronized creatine during three weeks
62415735|NCT01054469|PLACEBO_COMPARATOR|TAP block with placebo|
62415736|NCT01054469|ACTIVE_COMPARATOR|TAP block with ropivacaine|
62415737|NCT02871466|EXPERIMENTAL|stem cells infusion|
62415738|NCT06539949|EXPERIMENTAL|Experimental|Subjects in the experimental group (RPM Group) will be admitted to the Tony Robbins Rapid Planning Method (RPM) virtually at no cost. RPM™ , developed by Tony Robbins, is a new system of thinking that is purported to help you align your daily actions with your life's purpose. During RPM, Tony will coach participants how to implement these life strategies.
62221307|NCT00996476|EXPERIMENTAL|TMC12/PR24 50 mg|Participants received TMC435 50 mg once daily with PegIFNa-2a and ribavirin (PR) for 12 weeks followed by PR until Week 24 Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \<1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
62024582|NCT04571346|ACTIVE_COMPARATOR|the classical TOT procedure|performing the trans-obturator procedure through the standard vertical incision
62024583|NCT04571346|EXPERIMENTAL|2 paramedian vertical incisions|performing the trans-obturator procedure through a new technique of 2 paramedian vertical incisions
62024584|NCT03397446|EXPERIMENTAL|Lisdexamfetamine dimesylate|A central nervous system stimulant, specifically, a prodrug of dextro-amphetamine
62024585|NCT05071001|EXPERIMENTAL|A|
62024586|NCT05071001|EXPERIMENTAL|B|
62024587|NCT06259968|EXPERIMENTAL|NMES+|Neuromuscular electrical stimulation with superimposed voluntary contraction
62024588|NCT06259968|ACTIVE_COMPARATOR|NMES|Neuromuscular electrical stimulation without voluntary contraction
62221308|NCT00996476|EXPERIMENTAL|TMC12/PR24 100 mg|Participants received TMC435 100 mg once daily plus PegIFNa-2a and ribavirin (PR) for 12 weeks followed by PR until Week 24. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \<1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
62221309|NCT00996476|EXPERIMENTAL|TMC24/PR24 50 mg|Participants received TMC435 50 mg once daily plus PegIFNa-2a and ribavirin (PR) for 24 weeks. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \<1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435, PR) at Week 24. All other participants continued PR until Week 48.
62221310|NCT00996476|EXPERIMENTAL|TMC24/PR24 100 mg|Participants received TMC435 100 mg once daily plus PegIFNa-2a and ribavirin (PR) for 24 weeks. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \<1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
62415739|NCT06539949|ACTIVE_COMPARATOR|Control|Subjects assigned to the control group, will not attend the event, but instead be required to regularly complete journaling involving a to-do-list of their weekly work tasks.
62221311|NCT00996476|EXPERIMENTAL|PR48 Control|Participants received PegIFNa-2a and ribavirin (PR) for 48 weeks (PR48 control group)
62415740|NCT06260683|EXPERIMENTAL|Arm I (PEC)|Participants receive PEC for 14 weeks, including a 2-week pre-switch period to become familiar with usage. Participants in all arms participate in discussions throughout the trial.
62796951|NCT04320784|ACTIVE_COMPARATOR|Control (CTRL)|CTRL group consumed 100% of its estimated daily energy needs in 3 meals between 7:00 AM and 9:00 PM
62796952|NCT00963586||HNC Maastricht|Patients treated for HNC in the University Hospital Maastricht/MAASTRO clinic, the Netherlands
62796953|NCT00963586||HNC Groningen|Patients treated for HNC in the University Medical Center Groningen, the Netherlands
62796954|NCT04661046|EXPERIMENTAL|TCM Syndrome Types|Traditional Chinese Medicine
62024589|NCT01283789|EXPERIMENTAL|Lapatinib and RAD-001|"RAD-001 will be administered orally as a once-daily dose of 5 mg (one 5 mg tablet) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD-001 in the morning, at the same time each day.~Lapatinib will be administered orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take lapatinib at bedtime, at the same time each day. Lapatinib should be taken by the patient in a fasting state."
62024590|NCT02863640||Exposed patients|Patients treated for Parkinson's disease with a cumulative dose of L-DOPA above the 59th percentile of the population
62024591|NCT02863640||Non exposed patients|Patients treated for Parkinson's disease with a cumulative dose of L-DOPA below the 41th percentile of the population
62221312|NCT02706899|EXPERIMENTAL|33A + azacitidine|Vadastuximab talirine plus azacitidine
62415741|NCT06260683|EXPERIMENTAL|Arm II (TEC)|Participants receive TEC for 14 weeks, including a 2-week pre-switch period to become familiar with usage. Participants in all arms participate in discussions throughout the trial.
62415742|NCT06260683|ACTIVE_COMPARATOR|Arm III (NRT)|Participants receive NRT (nicotine patches and lozenges) for 14 weeks, including a 2-week pre-switch period to become familiar with usage. Participants in all arms participate in discussions throughout the trial.
62415743|NCT04846049||Comprehensive Care|"Veterans with complex medical conditions that may need more help. This intervention will provide extra care coordination after a complete assessment of their health.~Research team will assess veteran's memory, physical function, strength, balance, and from there, find the areas they need the most help with and coordinate services at home. This is in addition to their regular primary care provider."
62415744|NCT04846049||Standard Care|Veterans receiving standard of care
62415745|NCT04141839|OTHER|Control|Delayed intervention: baseline and 3-month assessment prior to receiving the Safer Bars training.
62796955|NCT01550757|NO_INTERVENTION|Arm 1|Normal PACT Clinical Care
62796956|NCT01550757|EXPERIMENTAL|Arm 2|Normal PACT Clinical Care + Embedded Peer Mentor
62796957|NCT01550757|NO_INTERVENTION|Arm 3|Normal Homeless Oriented PACT Clinical Care
62796958|NCT01550757|EXPERIMENTAL|Arm 4|Normal Homeless Oriented PACT Clinical Care + Embedded Peer Mentor
62024592|NCT06668961|EXPERIMENTAL|Cohort A|Participants will receive treatment during the first cycle. Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62024593|NCT06668961|EXPERIMENTAL|Cohort B|Participants will receive treatment during the first cycle. Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62024594|NCT06646666|EXPERIMENTAL|ARTA-based Chemo-free bridging therapy to CAR-T and maintenance therapy post CAR-T|
62024595|NCT00796718|EXPERIMENTAL|Capecitabine|Capecitabine orally twice daily plus standard radiotherapy for 5 weeks, followed by surgery within 6 weeks after completion of treatment.
62024596|NCT02124642|ACTIVE_COMPARATOR|Folic acid, 400 mcg/day|A daily 400 microgram (mcg) dose of folic acid will be taken orally, along with the recommended intake for pregnancy of other vitamins, minerals and docosahexaenoic acid (DHA), beginning at enrollment until delivery. The 400 mcg dose approximates the current Recommended Dietary Allowance (RDA) for pregnant women of 600 mcg Dietary Folate Equivalents (400 mcg folic acid ≈ 600 mcg DFEs; conversion factor based on higher bioavailability of folic acid is: 1 mcg folic acid = 1.7 mcg DFE).
62024597|NCT02124642|EXPERIMENTAL|Folic acid, 800 mcg/day|A daily 800 microgram (mcg) dose of folic acid will be taken orally, along with the recommended intake for pregnancy of other vitamins, minerals and docosahexaenoic acid (DHA), beginning at enrollment until delivery. The 800 microgram dose, which is considerably higher than the current RDA, represents an amount commonly found in over-the-counter prenatal vitamin formulations.
62024598|NCT06264921|EXPERIMENTAL|Dose Escalation|Dose escalation will assess the safety, efficacy, and PK/PD data of oral dosing NKT3447 at increasing dosage levels to determine the MTD and/or preliminary RDEs.
62024599|NCT06264921|EXPERIMENTAL|Dose Expansion|Dose expansion will include 2 RDEs selected to determine the preliminary antitumor activity and the RP2D.
62024600|NCT06636630|EXPERIMENTAL|Double scleral flap|Double Flap Technique (Group A) A 360-degree peritomy will be performed to expose the underlying sclera. Following evisceration of the ocular contents, careful hemostasis will be achieved. Two muscular-tendinous flaps will be developed from the horizontal rectus muscles. These flaps will be dissected under minimal tension to preserve their vascular supply. The prepared flaps will be draped over the implant in a manner that the edges slightly overlap, ensuring complete coverage. The flaps will be sutured together using silk sutures, securing the implant in place.The conjunctiva will be meticulously closed over the muscle flaps with continuous absorbable sutures to enhance the healing process and minimize postoperative discomfort.
62221313|NCT02706899|ACTIVE_COMPARATOR|Placebo + azacitidine|placebo plus azacitidine
62415746|NCT04141839|EXPERIMENTAL|Intervention|This arm with consist of bars randomized to have the Safer Bars training on their premises attended by all their liquor serving staff with assessment directly before and after training (pre/post), and at 3 and 6 months post-training follow-up.
62415747|NCT05873075|EXPERIMENTAL|Study group|Patients received intravascular laser irradiation of blood for 20 days before IVF cycles
62221314|NCT00911287|EXPERIMENTAL|Single Arm|
62024601|NCT06636630|EXPERIMENTAL|Quadruple scleral flap|Quadruple flap technique involves creating four scleral flaps, which proponents argue provides a more robust framework for securing the implant. This technique is designed to enhance the integration of the implant with surrounding orbital structures, thereby potentially reducing the risk of exposure and improving cosmetic outcomes. The quadruple flap method is suggested to better preserve the orbital anatomy, allowing for superior distribution of volume and more natural prosthetic motility.
62024602|NCT01287585|EXPERIMENTAL|ADI-PEG 20|Arginine deiminase formulated with polyethylene glycol.
62024603|NCT01287585|PLACEBO_COMPARATOR|Placebo|an inert treatment with no therapeutic value.
62024604|NCT06318676|EXPERIMENTAL|Group A: Participants with severe renal impairment|
62024605|NCT06318676|EXPERIMENTAL|Group B: Participants with End Stage Renal Disease|
62024606|NCT06318676|EXPERIMENTAL|Group C: Participants with normal renal function|
62024607|NCT01540123|PLACEBO_COMPARATOR|Control|Sugar matched control containing no phytochemicals
62221315|NCT02274974|ACTIVE_COMPARATOR|lidocaine|20 ml of 2% lidocaine.
62221316|NCT02274974|EXPERIMENTAL|lidocaine and epinephrine.|20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000. I.e.: by adding 1/4 from ampoule of adrenaline 1mg./1ml to bottle of lidocaine Hydrochloric acid (HCL) 2% 50 ml(20mg/ml).
62221317|NCT05952687|EXPERIMENTAL|Dose Finding/Safety Phase|Patients with progressive/relapsed atypical teratoid/rhabdoid tumors (AT/RT) \& malignant rhabdoid tumors (MRT) or synchronous/metachronous AT/RT \&MRT
62221318|NCT05952687|EXPERIMENTAL|Expansion Phase: Stratum A|Patients with progressive/relapsed AT/RT
62415748|NCT05873075|NO_INTERVENTION|Control|No intervention before IVF cycles
62415749|NCT00503035|EXPERIMENTAL|Celecoxib|Celecoxib 400 mg orally twice daily for 6 months. Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure.
62415750|NCT06349408|EXPERIMENTAL|Open-label: IBI3001 monotherapy|
62415751|NCT04719728||pre lingual|aided response, speech perception threshold impedance telemetry electrically evoked action potential p1n1 cortical evoked potential
62221319|NCT05952687|EXPERIMENTAL|Expansion Phase: Stratum B|Patients with progressive/relapsed MRT
62221320|NCT05952687|EXPERIMENTAL|Expansion Phase: Stratum C|Patients with progressive/relapsed, synchronous/metachronous AT/RT \& MRT
62221321|NCT00832234|EXPERIMENTAL|BDR|
62221322|NCT00940732|EXPERIMENTAL|Destigmatisation and Mental Health Literacy|
62221323|NCT00940732|EXPERIMENTAL|Help-seeking list|
62221324|NCT00940732|EXPERIMENTAL|Feedback|
62221325|NCT00940732|NO_INTERVENTION|Control|
62221326|NCT02675127|EXPERIMENTAL|A Test|Test drug (Daktavira, European Egyptian Pharmaceutical Industries)1 tablet contains 60 mg Daclatasvir
62221327|NCT02675127|ACTIVE_COMPARATOR|B Reference|Reference drug (Daklinza, (Bristol-Myers Squibb Pharma, UK)) 1 tablet contains 60 mg Daclatasvir
62221328|NCT00267631||At Risk Body Weight|Children with a BMI greater and equal to 85%
62221329|NCT00267631||Normal Body Weight|Children with a BMI of 25 to 75%
62221330|NCT05358106|ACTIVE_COMPARATOR|AntiBKV neutralising antibody|AntiBKV infused i.v. over 30 minutes. Infusion parameters may be adjusted to bodyweight so that infusion rate does not exceed 60mg/kg per hour. AntiBKV will be administered as a single infusion in Part 1 or as 4 infusions administered 4 weeks apart in Part 2 (100, 500, 1000 or 2000 mg).
62221331|NCT05358106|PLACEBO_COMPARATOR|Placebo|Solution containing no active excipients, infused i.v. over 30 minutes as a single infusion in Part 1 or as 4 infusions administered 4 weeks apart in Part 2.
62221332|NCT03047304|OTHER|Women in risk for preterm labor|Women in risk for preterm labor treated with magnesium.
62221333|NCT02412839||Group 20-39|Patients aged from 20 to 39 years old. 30 males and 30 females.
62221334|NCT02412839||Group 40-59|Patients aged from 40 to 59 years old. 30 males and 30 females.
62415752|NCT04719728||post lingual|aided response, speech perception threshold speech in noise impedance telemetry electrically evoked action potential p1n1 cortical evoked potential
62796959|NCT06191393|EXPERIMENTAL|OTC Study|This OTC study will take place in simulated home environments which will be set up within or near clinical settings (e.g., urgent care facilities). The study will enroll symptomatic subjects only. Candidate samples will be self-collected by participants (or collected by a guardian for participants under the age of 14 years) and comparator samples will be collected by a healthcare practitioner with informed consent and Institutional Review Board (IRB) approval. Each sample will be coded for confidentiality.
62796960|NCT05049798||Cohort 1: Guselkumab|Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of Psoriatic Arthritis (PsA) who are starting guselkumab as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.
62221335|NCT02412839||Group 60-79|Patients aged from 60 to 79 years old. 15 males and 15 females.
62221336|NCT00352911|ACTIVE_COMPARATOR|VGX-410 (Mifepristone)|150mg twice daily of VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of VGX-410 for 14 days
62221337|NCT00352911|PLACEBO_COMPARATOR|Placebo for VGX-410 (Mifepristone)|150mg twice daily of placebo for VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of placebo for VGX-410 for 14 days
62221338|NCT04780477|EXPERIMENTAL|High Fiber Diet Featuring Legumes (HLD)|Participants randomized to the high fiber diet featuring legumes (HLD) will add approximately 30 grams of dietary fiber per day from legume dishes, ensuring a total intake of approximately 50 grams of dietary fiber per day.
62221339|NCT04780477|ACTIVE_COMPARATOR|Healthy American Diet Control Arm|Participants randomized to the healthy American diet control arm will receive pre-portioned meal replacement entrées with legumes replaced by lean chicken or meat.
62221340|NCT03500913||Adults with growth hormone deficiency|Subjects who present to the neuroendocrine unit at Columbia University Irving Medical Center (CUIMC) for therapy of GH deficiency or who are followed in the unit and have active GH deficiency and are planning to initiate a therapy.
62221341|NCT03500913||Control group|Healthy subjects matched to the GH deficiency subjects for age (+/- 5 years), gender and total fat mass (+/- 4%).
62221342|NCT02032979|EXPERIMENTAL|FSHD patient|
62221343|NCT02213341||Positive blood test to milk, egg, and/or peanut|Family history to atopy
62221344|NCT02213341||Negative blood test to allergy|A negative skin prick test to egg, milk, and peanut and a negative Immunoglobulin E (IgE) to egg, milk, and peanut.
62221345|NCT06408974|NO_INTERVENTION|Control group|will include 30 patients, will receive intrathecal bupivacaine 10mg , ,2mg morphine.
62221346|NCT06408974|ACTIVE_COMPARATOR|Ketamine group|will include 30 patients, will receive intrathecal bupivacaine 10 mg , ,2 mg morphine, ,1 mg/kg ketamine .
62221347|NCT06408974|ACTIVE_COMPARATOR|Dexamethasone group|will include 30 patients , will receive intrathecal bupivacaine 10 mg , ,2 mg morphine , intravenous dexamethasone 8mg .
62221348|NCT00918580|EXPERIMENTAL|1|
62221349|NCT03816267|ACTIVE_COMPARATOR|Nebulizer|Containing salbutamol
62221350|NCT03816267|EXPERIMENTAL|Metered Dose Inhaler and spacer|Containing Salbutamol
62221351|NCT05307211|ACTIVE_COMPARATOR|GROUP 1 (CIESI Only)|Only interlaminar epidural steroid injection will be administered to patients in this arm with the same method as in the other arms (one session, week 0). Staying active will be the only recommendation, and no exercise prescription will be provided.
62221352|NCT05307211|EXPERIMENTAL|GROUP 2 (CIESI plus NECK STABILIZATION EXERCISES)|After the interlaminar epidural steroid injection, the patients will be taken to an exercise program in the physical therapy unit, in the company of a physiotherapist, within 24 hours, within 72 hours at the latest.
62415753|NCT03415139||Arm 1 for MRD HCT Recipients|Patients undergo an Oral Glucose Tolerance Test (OGTT) and 1 hyperglycemic clamp will be performed on separate days prior to transplant and then each procedure will be repeated once between day+80 to day+100 (+/- 10 days) after transplant.
62415754|NCT03415139||Arm 2 for MRD HCT Recipients|Patients undergo 2 Oral Glucose Tolerance Test (OGTTs) (with and without GLP-1 analogue) will be performed on separate days prior to transplant and then each procedure will be repeated once between day+80 to day+100 (+/- 10 days) after transplant.
62415755|NCT03558607|EXPERIMENTAL|Experimental arm|
62024608|NCT01540123|EXPERIMENTAL|Berry drink standardised to contain 500mg of polyphenols|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
62024609|NCT02270320|NO_INTERVENTION|Control|Control group will receive a telephone consultation once every two weeks for 12 weeks.
62024610|NCT02270320|ACTIVE_COMPARATOR|Physical activity|Experimental group will receive a 60-minute 24 forms Yang-style Tai Chi Chuan exercise program, three times per week for 12 weeks.
62024611|NCT00872495||1|"Bladder Cancer Group:~Patients scheduled to have a cystectomy or cystoscopy of their bladder with possible removal or biopsy of bladder tumor or tissue.~Two urine samples collected at the time of the scheduled procedure:~One sample collected through voiding. The other sample collected from atheterized urine in the operating room. Additional urine samples may be collected at each follow up visit over two years. These samples will be obtained via voiding, standard urine sample collection."
62024612|NCT00872495||2|Control Group: Patients with no known evidence of bladder cancer. One urine sample will be collected through voiding, as with standard urine sample collection at the time of clinic visit.
62221353|NCT05307211|EXPERIMENTAL|GROUP 3 ( CIESI plus NECK and SCAPULAR STABILIZATION EXERCISES)|After the interlaminar epidural steroid injection, the patients will be taken to an exercise program in the physical therapy unit, in the company of a physiotherapist, within 24 hours, within 72 hours at the latest.
62415756|NCT03327532|EXPERIMENTAL|Patients hospitalized for acute heart failure|"One arm study.~Patients hospitalized for acute heart failure will undergo the following evaluations:~* Clinical examination centered on congestion~* Cardiopulmonary and peritoneal ultrasound~* Blood sample retrieved for biological assessment and biobanking~* Telephone interview"
62415757|NCT02306174|EXPERIMENTAL|Cognitive Rehabilitation and Exposure-based Class for Compulsi|"Cognitive training is to improve thinking by learning new skills and strategies. The class begins with cognitive training to increase ability to carry out the skills learned later in treatment.~Exposure therapy for discarding and acquiring helps to improve ability to make choices about possessions and learn to tolerate anxiety. Participants will face making difficult choices about items and potentially letting them go. Through repeated exposure to decisions about discarding and acquiring, distress about letting go or making choices about items will decrease over time."
62415758|NCT05573555|EXPERIMENTAL|ARV-471 in combination with Ribociclib|ARV-471 administered orally QD continuously and Ribociclib administered orally QD consecutively for 21 days followed by 7 days off treatment on 28-day cycles
62415759|NCT05968482|EXPERIMENTAL|AMZ001 Low dose|AMZ001 applied once daily for 7 consecutive days
62024613|NCT05914610|EXPERIMENTAL|Envolimab + fruquinitinib +SOX regimen|
62024614|NCT05914610|ACTIVE_COMPARATOR|SOX regimen|
62024615|NCT04584372|ACTIVE_COMPARATOR|High-nitrate (HI-NI) intervention|The 'active treatment' arm will involve daily consumption of 2×70 mL nitrate-rich (HI-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) over an intervention period of 4 weeks.
62415760|NCT05968482|EXPERIMENTAL|AMZ001 High dose|AMZ001 applied once daily for 7 consecutive days
62415761|NCT05968482|ACTIVE_COMPARATOR|Diclofenac Sodium 1% Gel|Reference product applied four-times daily for 7 consecutive days
62415762|NCT06704048|EXPERIMENTAL|Cardiac rehabilitation|"An intervention with physical exercise training within cardiac rehabilitation according to the SEPHIA and SWEDEHEART protocols is offered to a new group of patients, patients with infective endocarditis.~The intervention is studied with qualitative and quantitative methods on regard of the physical and health-related effects of rehabilitation, the adherence to the intervention and the health restoration in general. Patient's perspectives on rehabilitation and health restoration are given in interviews."
62415763|NCT06363591|OTHER|Wide - With wide local excision - Control group|Standard treatment with a wide local excision (i.e. reexcision of the diagnostic excision scar with a lateral clinical surgical margin of 10 mm and a deep clinical surgical margin down to the muscular fascia as recommended by the Swedish national guidelines).
62415764|NCT06363591|EXPERIMENTAL|Wise - Without wide local excision - Experimental group|No wide local excision.
62415765|NCT03378999|PLACEBO_COMPARATOR|Control|Placebo capsules containing microcrystalline cellulose
62415766|NCT03378999|EXPERIMENTAL|Rhodospirillum rubrum 0.25 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 0.25 gram/day
62024616|NCT04584372|PLACEBO_COMPARATOR|Low-nitrate (LO-NI) intervention|The placebo treatment arm daily consumption of 2×70 mL nitrate-depleted (LO-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) an intervention period of 4 weeks.
62024617|NCT04020510|ACTIVE_COMPARATOR|Standard Injections|For idiopathic overactive bladder, 100 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 20 sites with 0.5mL per injection along the posterior wall of the bladder above the trigone. For neurogenic overactive bladder, 200 units of onabotulinumtoxinA mixed in 30mL of injectable saline injected in 30 sites with 1mL per injection along the posterior wall of the bladder above the trigone.
62024618|NCT04020510|EXPERIMENTAL|Reduced Injections|"For idiopathic overactive bladder, 100 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 5 sites with 2mL per injection in an X configuration on posterior wall of the bladder above the trigone. For neurogenic overactive bladder, 200 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 5 sites with 2mL per injection in an X configuration on posterior wall of the bladder above the trigone."
62024619|NCT06459921|ACTIVE_COMPARATOR|FLOT+Sintilimab|Patients in the FLOT group received 4 cycles of standard FLOT chemotherapy, the FLOT chemotherapy cycle consists of: day 1: intravenous 5-FU 2600 mg/m² inserted through a peripherally inserted central catheter (PICC) for 24 hours intravenous folic acid 200 mg/m2 intravenous OXA 85 mg/m² intravenous TXT 50 mg/m². The next cycle of chemotherapy was repeated on day 15. Sintilimab: 200 mg every 3 weeks.
62024620|NCT06459921|EXPERIMENTAL|SOX+Sintilimab|Patients in the SOX group received 3 cycles of S-1 + OXA chemotherapy prior to radical gastrectomy.The SOX chemotherapy cycle consists of: day 1: intravenous OXA 130 mg/m² days 1-14: oral S-1 80 mg/m², 2 times/Day. Repeat next chemotherapy on day 22. Sintilimab: 200 mg every 3 weeks.
62024621|NCT02696317|OTHER|AO1D, then AO|Senofilcon A contact lenses with HydraLuxe™, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
62024622|NCT02696317|OTHER|AO, then AO1D|Senofilcon A contact lenses, followed by senofilcon A contact lenses with HydraLuxe™. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
62024623|NCT02395484||constipation|collect stool samples from constipation patients
62024624|NCT02395484||healthy controls|collect stool samples from healthy controls patients
62415767|NCT03378999|EXPERIMENTAL|Rhodospirillum rubrum 0.5 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 0.5 gram/day
62415768|NCT03378999|EXPERIMENTAL|Rhodospirillum rubrum 1.0 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 1.0 gram/day
62796961|NCT05049798||Cohort 2: Interleukin-17 inhibitor (IL-17i)|Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of PsA who are starting IL-17i as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.
62796962|NCT05666141|EXPERIMENTAL|PES stimulation in volunteers|10 volunteers will receive PES stimulation. For healthy volunteers, the study protocol includes 1 stimulation trial. Each stimulation trial consists of 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters, as reported by Fraser et al. (2003).
62796963|NCT05666141|SHAM_COMPARATOR|Sham treatment in volunteers|10 volunteers will receive Sham treatment. In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
62024625|NCT05494879|EXPERIMENTAL|microkinesitherapy treatment|"The study group received a single therapy session of microkinesitherapy. The entire procedure lasted about 10 minutes. Microkinesitherapy is based on locating information in the patient's body about previous traumas/traumas that have been experienced physically and emotionally, which the body could not eliminate. This information is interpreted on the body by sensitive tensions and called body scars and does not necessarily remain in the brain."
62024626|NCT01787526|ACTIVE_COMPARATOR|Oral Iron|oral iron in a corresponding dose of 10g (assuming an absorption of 10%, 100 capsules a 100mg iron each) taken over 8-12 weeks
62024627|NCT01787526|EXPERIMENTAL|Intravenous high dose iron|high dose intravenous iron (ferric carboxymaltose, 1000mg)
62024628|NCT01575847||Part I|"Part 1 will be a feasibility study conducted in the Emergency Department at UAMS and ACH. This Part will test the research use dipsticks and dipstick testing kit in subjects that are having APAP levels obtained as part of their medical evaluation.~Part 1 20 subjects~Part I~Inclusion Criteria:~Subject is 12-18 years of age. Subject has an APAP level ordered as part of clinical management.~Exclusion Criteria:~Previous recent history of APAP overdose in the previous 30 days."
62024629|NCT01575847||Part 2|"Part 2~Part 2 will be a non-intervention study in adults presenting to hepatology centers participating in the Acute Liver Failure Study Group (ALFSG). The dipstick will be tested in these subjects and the results will be compared to the HPLC-EC measurement of APAP protein adducts. The results of the dipstick testing will not be used for diagnosis or clinical decision-making.~Part 2 100 subjects~Part 2~Inclusion Criteria:~Subject is 18 years of age or older. Subject is enrolled in the ALFSG registry.~Exclusion Criteria:~None."
62024630|NCT04730297|ACTIVE_COMPARATOR|Paracetamol/codeine Group A|analgesic group preoperative oral dose of paracetamol 500 mg plus codeine 30 mg
62024631|NCT04730297|ACTIVE_COMPARATOR|Ibuprofen Group B|analgesic group preoperative oral dose of ibuprofen 400 mg
62024632|NCT04730297|PLACEBO_COMPARATOR|Placebo Group C|Placebo group preoperative placebo
62024633|NCT06057389|EXPERIMENTAL|Intervention group|Intervention group: an energy-restricted diet + aronia melanocarpa extract
62024634|NCT06057389|PLACEBO_COMPARATOR|Control group|control group: an energy-restricted diet + maltodextrin
62024635|NCT01925716|EXPERIMENTAL|Corn oil/olive oil|Corn oil 56 g per day for 21 days followed by olive oil 56 g for 21 days
62024636|NCT01925716|EXPERIMENTAL|Olive Oil/Corn Oil|olive oil, 56g per day for 21 days followed by corn oil, 56 g for 21 days
62024637|NCT00793208|EXPERIMENTAL|Vaccine|vaccine composed of lethally irradiated semi-allogeneic human fibroblasts transfected with genomic tumor DNA from the patient's own tumor
62024638|NCT06013176|NO_INTERVENTION|Usual practice|This arm will consist of encounter-based PRO monitoring, in which patients have an opportunity to complete PRO questionnaires via patient portal in advance of clinical encounters or via tablet during clinical encounters. While clinicians will be encouraged to view and discuss PROs with patients during clinical encounters, they will not be prompted to do so in real-time, nor will there be alerts for escalating symptoms.
62024639|NCT06013176|EXPERIMENTAL|Encounter-based PRO monitoring|Encounter-based PRO monitoring (usual practice) plus patient reminders and triage nurse alerts
62024640|NCT06013176|EXPERIMENTAL|Remote PRO monitoring|Remote PRO monitoring plus patient reminders and triage nurse alerts
62024641|NCT03267680|EXPERIMENTAL|Arm I (IRX-2)|Patients receive cyclophosphamide IV on day 1 and IRX-2 via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.
62415769|NCT05429632|EXPERIMENTAL|3mg mocravimod arm|3 mg of mocravimod orally once per day for 12 months
62415770|NCT05429632|EXPERIMENTAL|1mg mocravimod arm|1 mg of mocravimod orally once per day for 12 months
62221354|NCT05866731||Identical twins|60 identical twins (30 sets) will be enrolled. Participants will answer 15-20 minutes of questionnaires on demographics, lifestyle, medical history, and family history over Zoom or the phone with a study coordinator. Participants will then be mailed an iRhythm Zio XT heart rhythm monitor, or EKG, to apply and wear for a maximum of 2 weeks, as well as a DNA Genotek saliva collection kit to collect a small saliva sample. Participants will return the monitor and saliva sample to the study team, and will be reimbursed upon return. The study team is also requesting photo validation to verify twin status.
62221355|NCT05866731||Same-sex fraternal twins|60 same-sex fraternal twins (30 sets) will be enrolled. Participants will answer 15-20 minutes of questionnaires on demographics, lifestyle, medical history, and family history over Zoom or the phone with a study coordinator. Participants will then be mailed an iRhythm Zio XT heart rhythm monitor, or EKG, to apply and wear for a maximum of 2 weeks, as well as a DNA Genotek saliva collection kit to collect a small saliva sample. Participants will return the monitor and saliva sample to the study team, and will be reimbursed upon return. The study team is also requesting photo validation to verify twin status.
62221356|NCT00842985|OTHER|drug condition|Participants received each drug condition in sequential order across 4 test days. Not all participants received the interventions in the same order.
62221357|NCT01480219||Any Voriconazole|
62221358|NCT01480219||No Voriconazole|
62221359|NCT02244021|EXPERIMENTAL|BRENTUXIMAB VEDOTIN|1 arm for all patients
62796964|NCT05666141|EXPERIMENTAL|PES stimulation + PES stimulation in stroke patients|Max 8 patients will receive PES stimulation twice. For patients, the protocol thus includes 2 stimulation trails. Each stimulation trial consists of 3 PES sessions, so they receive 6 PES sessions in total. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters, as reported by Fraser et al. (2003).
62221360|NCT00636311|ACTIVE_COMPARATOR|1|IGEV regimen (Ifosfamide, Gemcitabine, Vinorelbine)
62221361|NCT00636311|EXPERIMENTAL|2|B-IGEV (Bortezomib + IGEV)
62415771|NCT05429632|PLACEBO_COMPARATOR|Placebo arm|placebo orally once per day for 12 months
62796965|NCT05666141|OTHER|PES stimulation + Sham treatment in stroke patients|Max 8 patients will receive PES stimulation and afterwards Sham treatment. During the first stimulation trial, they will receive 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters, as reported by Fraser et al. (2003). During the second stimulation trial, the same method and same device will be used. However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
62796966|NCT05666141|SHAM_COMPARATOR|Sham treatment + Sham treatment in stroke patients|Max 8 patients will receive Sham twice. In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
62024642|NCT03267680|ACTIVE_COMPARATOR|Arm II (placebo)|Patients receive cyclophosphamide IV on day 1 and placebo via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.
62024643|NCT01069783|EXPERIMENTAL|A3309 low dose|
62024644|NCT01069783|EXPERIMENTAL|A3309 high dose|
62024645|NCT01069783|PLACEBO_COMPARATOR|Placebo|
62024646|NCT05890053|EXPERIMENTAL|HSK16149 40mg BID|HSK16149 40mg , orally twice a day, treatment period; 52-weeks fixed dose.
62024647|NCT02500225|ACTIVE_COMPARATOR|Etomidate|0.2 mg/kg etomidate during anesthesia induction
62024648|NCT02500225|ACTIVE_COMPARATOR|8% sevoflurane|Sevoflurane 8% concentration during anesthesia induction
62221362|NCT00206661|EXPERIMENTAL|Arm 1|
62221363|NCT00206661|EXPERIMENTAL|Arm 2|
62221364|NCT02434068||stone residuals|all patients are going to be submitted to the same intervention: CT, US, KUB
62221365|NCT03411447|ACTIVE_COMPARATOR|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level \< 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
62415772|NCT04497571|EXPERIMENTAL|Piezoelectric osteotomy|Implant placement by piezoelectric osteotomy
62415773|NCT04497571|ACTIVE_COMPARATOR|Conventional drilling|Implant placement by conventional drilling
62024649|NCT04475601|EXPERIMENTAL|Enzalutamide+Standard of Care|Up to 5 days with 4x40 mg enzalutamide tablets orally once daily
62024650|NCT04475601|NO_INTERVENTION|Standard of Care|Standard of care
62796967|NCT05666141|EXPERIMENTAL|PES stimulation + PES stimulation in ICU patients|Max 20 patients will receive PES stimulation twice. For patients, the protocol thus includes 2 stimulation trails. Each stimulation trial consists of 3 PES sessions, so they receive 6 PES sessions in total. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters, as reported by Fraser et al. (2003).
62024651|NCT04570826|EXPERIMENTAL|Meditation program|The experimental group participated in the Meditation program during one month, eight sessions with a total of sixteen hours.
62221366|NCT03411447|ACTIVE_COMPARATOR|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
62221367|NCT02819830|EXPERIMENTAL|Intervention group|"Participants, who have been randomly assigned to the intervention group, will take part in a six-week supervised exercise training programme. This programme takes place in a rehabilitation gymnasium. The exercise programme consists of two group sessions per week (scheduled for evenings, after typical working hours, approximately 12 patients per session). Each session lasts for approximately 70 minutes and includes a 5 minute warm up, 30 minutes of aerobic cycling exercise, 30 minutes of strength training, and a 5 minute cool down.~Participants will also perform a 30 minute walk each weekend as part of the intervention."
62221368|NCT02819830|NO_INTERVENTION|Control group|Participants who have been randomly assigned to the control group will not undertake the exercise intervention. These participants are instructed to maintain their usual lifestyle.
62221369|NCT03562143|EXPERIMENTAL|Alternate-day iron supplementation|Patients taking iron supplementation given as 2 tabs of 325 mg ferrous sulfate (equivalent to 130 mg of elemental iron) for 6 weeks.
62221370|NCT03562143|ACTIVE_COMPARATOR|Daily iron supplementation|Patients taking iron supplementation given as 1 tab of 325 mg ferrous sulfate (equivalent to 65 mg of elemental iron) for 6 weeks.
62221371|NCT01632670|EXPERIMENTAL|Music therapy|The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
62221372|NCT01632670|NO_INTERVENTION|No music therapy|
62221373|NCT02412410|EXPERIMENTAL|Single|Single arm pilot study analyzing sleep data and calculated efficacy before and after fatigue avoidance education (comparator is same group after intervention)
62796968|NCT05666141|EXPERIMENTAL|Sham treatment + Sham treatment in ICU patients|Max 20 patients will receive Sham twice. In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
62796969|NCT06726200|EXPERIMENTAL|Injectable Buprenorphine|Long-Acting Injectable Buprenorphine administered after participants receive and tolerate a single 4/1 mg sublingual buprenorphine/naloxone dose
62024652|NCT04570826|ACTIVE_COMPARATOR|Scientific descriptions about meditation|The control group received scientific descriptions about meditation.
62024653|NCT05759598|OTHER|Control group (CTRL)|
62024654|NCT05759598|EXPERIMENTAL|Experimental group (RMT)|
62024655|NCT01559402|EXPERIMENTAL|Start O2 100% and CPAP 10, end O2 100%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with an inspiratory oxygen fraction(FIO2) of 1.0, supplied by a continuous positive airway pressure of 10 centimeters of water(cmH2O), during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 1.0 is used. The intervention associated with this arm is labeled CPAP and 100% oxygen.
62024656|NCT01559402|EXPERIMENTAL|Start O2 100% and CPAP 10, end O2 31%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with a FIO2 of 1.0, supplied by a continuous positive airway pressure of 10 cmH2O, during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 0.3 is used. The intervention associated with this arm is labeled CPAP and 31% oxygen.
62221374|NCT02918227|EXPERIMENTAL|Search retrograde ejaculation|Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
62415774|NCT06650254|NO_INTERVENTION|Control Group|The mothers in the control group will be followed in line with the hospital's routine health monitoring and information.
62796970|NCT06726200|ACTIVE_COMPARATOR|Sublingual Buprenorphine/Naloxone|Titration onto sublingual buprenorphine/naloxone (standard of care)
62796971|NCT06725368|EXPERIMENTAL|PCC|
62024657|NCT01559402|EXPERIMENTAL|Start O2 100% and CPAP 0, end O2 100%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with a FIO2 of 1.0, without a continuous positive airway pressure, during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 1.0 is used. The intervention associated with this arm is labeled No CPAP and 100% oxygen.
62221375|NCT05097222|EXPERIMENTAL|Active PBMT|Participants will receive 50minutes of PBMT, three times a week, for 8 weeks.
62221376|NCT05097222|SHAM_COMPARATOR|Sham PBMT|Participants will receive 50minutes of Sham PBMT, three times a week, for 8 weeks. The Sham device will appear to function like the treatment device without providing any power intensity (0% power). At 0% power, no light is emitted from the LEDs.
62221377|NCT00950274|ACTIVE_COMPARATOR|CD133+ autologous bone marrow stem cells|
62221378|NCT00950274|PLACEBO_COMPARATOR|Placebo|
62415775|NCT06650254|EXPERIMENTAL|Breastfeeding Support Program Structured According to Kolcaba's Comfort Theory|"Mothers who are on postpartum day 0 will be included in the Breastfeeding Support Program Structured According to Kolcaba's Comfort Theory in addition to the routine follow-up and training they can receive from the hospital."
62221379|NCT02708264|EXPERIMENTAL|Cervical Pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 36th week of pregnancy (or earlier if indicated)
62221380|NCT02708264|NO_INTERVENTION|No intervention|No pessary No pessary will be used. Subjects will receive standard obstetrical management
62221381|NCT05550701||SEER database|Data on CRC patients with synchronous liver metastasis (LM) were derived from the US Surveillance, Epidemiology, and End Results (SEER) between January 2010 and December 2017.
62796972|NCT05319353|EXPERIMENTAL|Cohort 1: Maribavir 400, 200 or 100 mg|Participants with greater than or equal to (\>=) 12 to less than (\<) 18 years of age will receive maribavir 400 milligrams (mg) (2\*200 mg tablets or powder for oral suspension) twice daily (BID) based on body weight \>= 25 kilogram (kg); or 200 mg tablet or powder for oral suspension BID based on body weight 14 to \< 25 kg; or 100 mg powder for oral suspension BID based on body weight 10 to \< 14 kg for up to 8 weeks treatment period (Day 1/Week 0 to Day 56/Week 8).
62796973|NCT05319353|EXPERIMENTAL|Cohort 2: Maribavir 400, 200 or 100 mg|Participants with \>= 6 to \< 12 years of age will receive maribavir 400 mg (2\*200 mg tablets or powder for oral suspension) BID based on body weight \>= 25 kg; or 200 mg tablet or powder for oral suspension BID based on body weight 14 to \< 25 kg; or 100 mg powder for oral suspension BID based on body weight 10 to \< 14 kg orally for up to 8 weeks treatment period (Day 1/Week 0 to Day 56/Week 8).
62796974|NCT05319353|EXPERIMENTAL|Cohort 3: Maribavir 400, 200, 100 or 50 mg|Participants with 0 to \< 6 years of age will receive maribavir 400 mg (2\*200 mg tablets or powder for oral suspension) BID based on body weight \>= 25 kg; or 200 mg tablet or powder for oral suspension BID based on body weight 14 to \< 25 kg; or 100 mg powder for oral suspension BID based on body weight 10 to \< 14 kg; or 50 mg powder for oral suspension BID based on body weight 7 to \< 10 kg; or 50 mg powder for oral suspension once daily (QD) based on body weight 5 to \<7 kg for up to 8 weeks treatment period (Day 1/Week 0 to Day 56/Week 8).
62221382|NCT05550701||Chinese cohort|Data on CRC patients with synchronous liver metastasis (LM) were derived from two Chinese tertiary centers: The Second Affiliated Hospital of Harbin Medical University and National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences \& Peking Union Medical College between January 2010 and December 2017.
62221383|NCT06414707|ACTIVE_COMPARATOR|Vonoprazan Group|included 160 patients received Vonoprazan 20 mg oral once daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for two weeks.
62221384|NCT06414707|ACTIVE_COMPARATOR|Pantoprazole Group|included 160 patients received Pantoprazole 40 mg oral twice daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for 14 days
62221385|NCT05239637|EXPERIMENTAL|Previous|Heparin stopped before ECMO decannulation
62221386|NCT05239637|EXPERIMENTAL|Afterwards|Heparin reduced after ECMO decannulation
62221387|NCT02617680|EXPERIMENTAL|desflurane - oxygen in air|The manufacturer recommended age-corrected end-tidal concentrations of desflurane in air should be set and achieved initially. Concentration of oxygen should be 50%.
62221388|NCT02617680|EXPERIMENTAL|desflurane - oxygen in nitric oxide|The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially.Concentration of oxygen should be 50%.
62221389|NCT05744752|OTHER|Group A|Control; Placebo 1ml NaCl 0.9% daily for 12 weeks
62221390|NCT05744752|ACTIVE_COMPARATOR|Group B|Pb Group; Lead acetate 19.5mg/kg b.w daily for 12 weeks
62221391|NCT05744752|EXPERIMENTAL|Group C|Pb + Allium sativum extract; Lead acetate 19.5mg/kg b.w followed by Allium sativum(AS) extract 500 mg/kg b.w daily for 12 weeks
62221392|NCT05744752|OTHER|Group D|CPb + Moringa oleifera extract; Lead acetate 19.5mg/kg b.w followed by Moringa oleifera extract 400mg/kg b.w daily for 12 weeks
62221393|NCT05744752|ACTIVE_COMPARATOR|Group E|Allium sativum extract; Allium sativum extract 500mg/kg b.w daily for 12 weeks
62221394|NCT05744752|EXPERIMENTAL|Group F|Moringa oleifera extract; Moringa oleifera extract 400mg/kg b.w daily for 12 weeks
62415776|NCT06650397|EXPERIMENTAL|Biofortified maize|Children consume biofortified maize that has been traditionally bred to have higher amounts of iron and zinc. Children consume the biofortified maize via 10-15 tortillas a day for 3 days.
62415777|NCT06650397|PLACEBO_COMPARATOR|Traditional Maize|Children consume traditional maize that has lower amounts of iron and zinc compared to the biofortified maize. Children consume the maize via 10-15 tortillas a day for 3 days.
62415778|NCT01644461|OTHER|Study Group|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
62221395|NCT01593332|ACTIVE_COMPARATOR|Rituximab|
62221396|NCT01593332|ACTIVE_COMPARATOR|Methotrexate|
62221397|NCT06470061|EXPERIMENTAL|Resveratrol, Quercetin, and Curcumin (RQC)|Resveratrol, Quercetin, and Curcumin (RQC) galactomannan formulations taken orally twice daily for 24 months.
62221398|NCT06470061|PLACEBO_COMPARATOR|Curcumin|Curcumin taken orally twice daily during the 7 days preceding each study visit in order to label retinal amyloid-β.
62221399|NCT04261998|EXPERIMENTAL|Service-learning group|Intervention group will perform a service-learning program with real patients with heart transplantation and coronary syndrome, and will have to perform a physical therapy program adapted to a real patient. Two meetings will be performed in order to establish groups, explain the project and search information based on evidence in scientific databases. In addition, three meetings with patients will be stated in order to establish the adapted program based on the real patient's needs and characteristics.
62415779|NCT02922036|EXPERIMENTAL|Treatment|WiSE System therapy ON with Guideline Directed Medical Therapy
62415780|NCT04757675|EXPERIMENTAL|0.3 SK iv|0.3 μg/kg intravenous injection s-ketamin
62415781|NCT04757675|EXPERIMENTAL|0.5 SK iv|0.5 μg/kg intravenous injection s-ketamin
62415782|NCT04757675|EXPERIMENTAL|2 SK in|2 μg/kg intranasal s-ketamin
62415783|NCT04757675|EXPERIMENTAL|1 SK in + 1 DEX in|1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine
62415784|NCT04757675|EXPERIMENTAL|0.5 SK in + 2 DEX in|0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine
62415785|NCT01132170|EXPERIMENTAL|Divalproex Sodium DR Tablets 500 mg|Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Laboratories Limited
62415786|NCT01132170|ACTIVE_COMPARATOR|Depakote DR 500 mg Tablets|Depakote DR 500 mg Tablets of Abbott Laboratories PR Ltd.,
62415787|NCT01887366|EXPERIMENTAL|TV-1380 150 mg|
62024658|NCT03524326|EXPERIMENTAL|Head and Neck Squamous or Cutaneous Squamous Cell Carcinoma|A 3+3 dose de-escalation design for three dose levels of lenvatinib combined with cetuximab will be used. A DLT will be defined as any toxicities of grade 3 or higher (per CTCAE v4 criteria) felt to be possibly, probably, or definitely related to lenvatinib, as well as grade 4 toxcities related to cetuximab, which occurs within 28 days following the first dose of lenvatinib in combination with cetuximab.
62024659|NCT03243526|PLACEBO_COMPARATOR|Central venous pressure group|fluid therapy to maintain CVP not 5 cmH2o
62024660|NCT03243526|EXPERIMENTAL|Pulse pressure variation|fluid therapy will be guided by PPV to be less than 14%
62415788|NCT01887366|EXPERIMENTAL|TV-1380 300 mg|
62796975|NCT01372566|EXPERIMENTAL|Platelet Rich Plasma|Concentrated blood platelets from subject will be injected multiple times into the superficial layer of either their arm (Part 1) or one side of their upper face and cheek (Part 2).
62024661|NCT03356912|ACTIVE_COMPARATOR|Cabazitaxel plus prednisone|Cabazitaxel 25 mg/m² intravenously (Day 1) every 3 weeks, plus prednisone 10 mg orally given daily. Premedication must be administered according to Cabazitaxel Package Insert.
62024662|NCT03356912|EXPERIMENTAL|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously (Day 1) every 3 weeks. Premedication must be administered according to Cabazitaxel Package Insert.
62024663|NCT06404580||R anastomosis|
62024664|NCT06404580||B-II-B anastomosis|
62024665|NCT02790385|EXPERIMENTAL|NPWT|subjects will undergo negative pressure wound therapy
62024666|NCT02790385|ACTIVE_COMPARATOR|Standard Gauze|standard method of using gauze and dressing will be utilized
62221400|NCT04261998|NO_INTERVENTION|Control group|Control group will perform a physical therapy program for heart transplantation and coronary syndrome, but without meeting real patients. One meeting will be performed in order to establish groups and search information based on evidence in scientific databases.
62221401|NCT03552432|EXPERIMENTAL|Alirocumab therapy group|start with alirocumab 75mg per 2weeks and rosuvastatin 10mg per day
62221402|NCT03552432|NO_INTERVENTION|standard statin therapy group|start with only rosuvastatin 10mg per day
62221403|NCT04579822||Pregnant women vaccinated with a QIV|Women aged 20-44 years who had received a QIV during their pregnancy between September 22, 2020, and April 30, 2021, under the national immunization program in South Korea.
62415789|NCT01887366|PLACEBO_COMPARATOR|Placebo|
62415790|NCT00625118||1|Children in receipt of a Hib containing vaccine at pre-school booster (3.5-6 years old).
62796976|NCT01372566|PLACEBO_COMPARATOR|Sterile Saline|Sterile saline will be injected multiple times into the superficial layer of either their arm (Part 1) or one side of their upper face and cheek (Part 2)that has not been injected with PRP.
62796977|NCT04528719|EXPERIMENTAL|Cohort 1: Dose A in Younger Adults|Single injection of Dose A of mRNA-1345 or matching-placebo on Day 1.
62796978|NCT04528719|EXPERIMENTAL|Cohort 2: Dose B in Younger Adults|Single injection of Dose B of mRNA-1345 or matching-placebo on Day 1.
62796979|NCT04528719|EXPERIMENTAL|Cohort 3: Dose B in Younger Adults|Three total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
62796980|NCT04528719|EXPERIMENTAL|Cohort 4: Dose C in Younger Adults|Single injection of Dose C of mRNA-1345 or matching-placebo on Day 1.
62221404|NCT04579822||Pregnant women unvaccinated with a QIV|Women aged 20-44 years who had not received a QIV during their pregnancy between September 22, 2020, and April 30, 2021, under the national immunization program in South Korea.
62738692|NCT00392834|EXPERIMENTAL|Regimen A (R-CODOX-M chemotherapy)|Patients receive rituximab IV and doxorubicin hydrochloride IV over 15 minutes on day 1, cyclophosphamide IV over 30-60 minutes on days 1 and 2, pegfilgrastim SC on day 3, vincristine IV on days 1 and 8, high-dose methotrexate IV over 2-4 hours on day 15, and leucovorin calcium IV beginning 24 hours after the start of methotrexate and continuing every 6 hours until level is adequate. Patients receive CNS prophylaxis of methotrexate IT, cytarabine IT, and hydrocortisone IT on day 1. Patients with high-risk disease receive an additional dose of cytarabine IT on day 3. Patients also receive G-CSF SC once daily on days 3-9. Once the methotrexate levels drops below 50 nmol/L, patients resume G-CSF SC once daily beginning on approximately day 18 and continuing until blood counts recover.
62796981|NCT04528719|EXPERIMENTAL|Cohort 5: Dose D in Children|Three total injections, 1 injection of either Dose D of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
62796982|NCT04528719|EXPERIMENTAL|Cohort 6: Dose G in Children|Three total injections, 1 injection of either Dose G of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
62024667|NCT02399267|ACTIVE_COMPARATOR|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
62024668|NCT02399267|EXPERIMENTAL|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
62221405|NCT05338489|EXPERIMENTAL|Selpercatinib - Part 1 Period 1|Selpercatinib administered orally.
62221406|NCT05338489|EXPERIMENTAL|Selpercatinib and Itraconazole - Part 1 Period 2|Selpercatinib and itraconazole administered orally.
62221407|NCT05338489|EXPERIMENTAL|Selpercatinib - Part 2 Period 1|Selpercatinib administered orally.
62221408|NCT05338489|EXPERIMENTAL|Selpercatinib and Rifampin - Part 2 Period 2|Selpercatinib and rifampin administered orally.
62221409|NCT02638480|NO_INTERVENTION|Control|The control subjects will be treated with only the current SOC including NSAIDs and physical therapy.
62221410|NCT02638480|EXPERIMENTAL|Experimental|The experimental subjects will be treated with current SOC and will also use a kneeMD splint 3 times a day for 20 minutes per session
62221411|NCT04694209|EXPERIMENTAL|Fixed implant supported prosthesis|the prosthesis is an all-on-four prosthesis composed of a hybrid prosthesis. a metal framework, acrylic resin denture base and acrylic resin teeth
62221412|NCT04694209|ACTIVE_COMPARATOR|Removable implant supported prosthesis|the prosthesis is an all-on-four prosthesis composed of a telescopic retained overdenture, both primary and secondary copings are custom made. the secondary copings are conncetd via a metal framework
62221413|NCT02428361|EXPERIMENTAL|Pouchitis patients receiving FMT|Pouchitis patients receiving biologically active human fecal material sourced from OpenBiome.The physician will administer 250 mL of the fecal suspension in aliquots of 50-60 mL through the endoscope. The material will be delivered to the most proximal point of insertion.
62415791|NCT02623530|ACTIVE_COMPARATOR|Control group|Control group: to implement educational intervention focusing on first aid for developing critical thinking (CT) skills and disposition, through the Problem Based Learning (PBL), not based on the Active Learning Model for Critical Thinking (MEAPC).
62415792|NCT02623530|EXPERIMENTAL|Experimental group|Experimental group: to implement educational intervention focusing on first aid for developing critical thinking (CT) skills and disposition, through the Problem Based Learning (PBL), based on the Active Learning Model for Critical Thinking (MEAPC).
62415793|NCT06013423|EXPERIMENTAL|Arm I (myeloablative UCBT)|See detailed description.
62415794|NCT06013423|EXPERIMENTAL|Arm II (myeloablative UCBT)|See detailed description.
62415795|NCT06212375|EXPERIMENTAL|All subjects|Within subject study design: All children receive the four possible combinations of interventions.
62415796|NCT01875419|EXPERIMENTAL|Patients tDCS|A group of 30 patients will receive active tDCS stimulation once a week for 8 weeks, immediately prior to CBT.
62415797|NCT01875419|SHAM_COMPARATOR|Patients - Sham|Another group of 30 patients will receive sham stimulation once a week during 8 weeks, immediately prior to CBT.
62415798|NCT03515889|EXPERIMENTAL|Ideal Protein Weight Loss Protocol|This arm will follow the Ideal Protein method as documented in the Ideal Protein Clinic Manual and in the Ideal Protein Coaches Manual.
62415799|NCT03515889|ACTIVE_COMPARATOR|Standard Weight Loss|This arm utilizes evidence-based, low fat, low calorie strategies that have been shown to be effective for long-term weight loss and weight loss maintenance.
62024669|NCT02399267|ACTIVE_COMPARATOR|PS SBTs|In the 'PS SBTs arm', RTs will conduct SBTs using only PS =\< 8 cm H2O with PEEP =\< 5 cm H2O. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
62024670|NCT02399267|ACTIVE_COMPARATOR|T-piece SBTs|In the 'T-piece SBTs arm', RTs will conduct SBTs using only T-piece. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
62221414|NCT00005829|EXPERIMENTAL|gemcitabine|Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 4 weeks for a minimum of 3 courses. Patients achieving clinical complete remission, complete remission, nodular partial remission, or partial remission following 3 courses of therapy, receive 2 additional courses of therapy. Patients achieving complete remission or further improvement following the 2 additional courses of therapy, receive another 2 courses of therapy. Patients are followed every 3 months until disease progression or relapse. Patients achieving complete remission are followed every 6 months for 1 year.
62221415|NCT03988920|EXPERIMENTAL|Tenapanor w/Sevelamer|Tenapanor will be administered QD or BID and sevelamer can be added to achieve desired serum phosphorus level
62221416|NCT03988920|EXPERIMENTAL|Sevelamer w/Tenapanor|Sevelamer will be administered QD, BID or TID and tenapanor will be added to achieve desired serum phosphorus level and sevelamer dose will be decreased as needed
62796983|NCT04528719|EXPERIMENTAL|Cohort 7: Dose A in Older Adults|Two total injections, 1 injection of either Dose A of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later. Participants will receive second booster injection of Dose A of mRNA-1345 at Month 24.
62024671|NCT06405373|EXPERIMENTAL|ReCharge|Participants randomized to ReCharge will participate in an emotions-focused intervention facilitated by a mental health professional.
62796984|NCT04528719|EXPERIMENTAL|Cohort 8: Dose B in Older Adults|Two total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later. Participants will receive second booster injection of Dose A of mRNA-1345 at Month 24.
62796985|NCT04528719|EXPERIMENTAL|Cohort 9: Dose C in Older Adults|Two total injections, 1 injection of either Dose C of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later. Participants will receive second booster injection of Dose A of mRNA-1345 at Month 24.
62796986|NCT04528719|EXPERIMENTAL|Cohort 10: Dose E in Older Adults|Two total injections, 1 injection of either Dose E of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later. Participants will receive second booster injection of Dose A of mRNA-1345 at Month 24.
62796987|NCT04528719|EXPERIMENTAL|Cohort 11: Dose F in Older Adults|Two total injections, 1 injection of either Dose F of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later. Participants will receive second booster injection of Dose A of mRNA-1345 at Month 24.
62796988|NCT04528719|EXPERIMENTAL|Cohort 12: Dose E in Women of Child-Bearing Potential|Single injection of Dose E of mRNA-1345 or matching-placebo on Day 1.
62024672|NCT06405373|EXPERIMENTAL|TakeCharge|Participants randomized to TakeCharge will participate in a problem-solving focused intervention facilitated by a diabetes care professional.
62796989|NCT04528719|EXPERIMENTAL|Cohort 13: Dose F in Women of Child-Bearing Potential|Single injection of Dose F of mRNA-1345 or matching-placebo on Day 1.
62796990|NCT04528719|EXPERIMENTAL|Cohort 14: Dose A in Women of Child-Bearing Potential|Single injection of Dose A of mRNA-1345 or matching-placebo on Day 1.
62221417|NCT01323647|EXPERIMENTAL|Group A|Subjects in this group will receive the GSK Biologicals' IPV vaccine at 18 months of age. Subjects will also receive a dose of DTPa/Hib (Infanrix+Hib) as part of the local standard of care.
62221418|NCT01323647|ACTIVE_COMPARATOR|Group B|Subjects in this group will receive only a booster dose of GSK Biologicals' DTPa/Hib vaccine (Infanrix+Hib) as part of the local standard of care and will not be associated with any study endpoint.
62221419|NCT04805229||Patients undergoing surgery|Retrospective cohort of patients who underwent surgery between 1/1/13 to 12/31/19 and were sampled from the Truven Health MarketScan Database.
62221420|NCT06095700|ACTIVE_COMPARATOR|Rib Resection Group|This arm undergoes first rib resection, as mentioned in the textbook.
62221421|NCT06095700|EXPERIMENTAL|Rib Avulsion Group|This group of patients undergo first rib avulsion
62221422|NCT03180177|EXPERIMENTAL|Experimental group|"1. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m\^2 and cisplatin 75 mg/m\^2 intraperitoneally in succession~2. 2 cycles of neoadjuvant chemotherapy: paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks~3. Interval debulking surgery~4. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m\^2 and cisplatin 75 mg/m\^2 intraperitoneally in succession~5. 2 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks"
62415800|NCT02547779|ACTIVE_COMPARATOR|0.9% Saline|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
62415801|NCT02547779|ACTIVE_COMPARATOR|Physiologically-balanced|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
62796991|NCT04528719|EXPERIMENTAL|Cohort 15: Dose B in Japanese Older Adults|Single injection of Dose B of mRNA-1345 or matching-placebo on Day 1.
62796992|NCT03325959|ACTIVE_COMPARATOR|Hyperbaric oxygen therapy|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes Crossover: After 3 months of either pharmaceuitical or HBOT, once the 2nd evaluation is completed, all patients in both groups will be offered to switch to the alternative treatment group.
62796993|NCT03325959|ACTIVE_COMPARATOR|Pharmacotherapy|"patients will be offered pharmacological treatment with one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg at bedtime while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning). After a period of 6 weeks patients will be evaluated and dose will be adjusted as necessary. Patients may also be switched from one medication to the other based according to clinical judgment.~Crossover: After 3 months of either pharmaceuitical or HBOT, once the 2nd evaluation is completed, all patients in both groups will be offered to switch to the alternative treatment group."
62415802|NCT04592731|EXPERIMENTAL|Gel containing Acetylated Natural Nucleotides|
62415803|NCT04592731|PLACEBO_COMPARATOR|Vehicle Gel|
62415804|NCT03109613|EXPERIMENTAL|Positive end-expiratory pressure (PEEP) level changes|Sequential changes in PEEP level within range of 4-8 cm H2O followed by measurement of V/Q mismatch at each level.
62024673|NCT06371885|ACTIVE_COMPARATOR|Shock wave therapy group|This group will be composed of twenty-six patients who will managed by shock wave therapy one session per week, each ESWT session will involve 2,000 pulses of the focus probe at 4-bar pressure and 5 Hz frequency for twelve weeks in addition to the traditional physical therapy in form of (10 minutes hot pack around wrist and forearm and 10 minutes of gentle stretching exercises for wrist joint, three sessions per week for twelve weeks.
62024674|NCT06371885|ACTIVE_COMPARATOR|Control group|This group will be composed of twenty-six patients who will only managed by the traditional physical therapy in form of (10 minutes hot pack around wrist and forearm and 10 minutes of gentle stretching exercises for wrist joint, three sessions per week for twelve weeks
62024675|NCT04545268|SHAM_COMPARATOR|Control group|
62221423|NCT03180177|ACTIVE_COMPARATOR|Control group|"1. 3 cycles of neoadjuvant chemotherapy: paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks~2. Interval debulking surgery~3. 3 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks"
62221424|NCT03439423||Patients who underwent EVAR|
62796994|NCT02754726|OTHER|single arm|open label using combination therapy
62796995|NCT04514822|OTHER|N0 stage|patients without malignant lymph nodes
62796996|NCT04514822|OTHER|Non-N0 stage|patients with malignant lymph nodes
62796997|NCT03267004|EXPERIMENTAL|Meal Order 1|Meal A will be served to participant in meal session 1 and Meal B in meal session 2.
62796998|NCT03267004|EXPERIMENTAL|Meal Order 2|Meal B will be served to participant in meal session 1 and Meal A in meal session 2.
62796999|NCT04579471||Transplanted patients|All patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven
62221425|NCT03686631|NO_INTERVENTION|Passive Arm|This arm uses a passive tracking device to assess the number of times a patient uses their prescribed incentive spirometer.
62221426|NCT03686631|EXPERIMENTAL|Smartphone Arm|This arm uses a smartphone connected device and smartphone application to remind and encourage patients to use the spirometer as well as track the number of times they utilize the spirometer.
62221427|NCT02666469|ACTIVE_COMPARATOR|Group A Hyperbaric Oxygen Therapy and Exercise Program|Group A: Hyperbaric Oxygen Therapy (HBOT) and Exercise with HBOT sessions for 90 minutes, once daily, 5 times a week for 8 consecutive weeks. HBOT will be provided with 100% oxygen at 2.0 ATA. Patients will exercise in the multiplace hyperbaric chamber while receiving hyperbaric oxygen.
62797000|NCT04579471||Transplanted patients with past SARS-CoV-2 infection|Transplanted patients with past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity
62797001|NCT04579471||Transplanted patients without past SARS-CoV-2 infection|100 transplanted patients without past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity and as control for the transplanted patients with WITH past SARS-CoV-2 infection
62797002|NCT05481775|EXPERIMENTAL|Experiment group|Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy
62797003|NCT05481775|ACTIVE_COMPARATOR|Control group|Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy
62797004|NCT02548208|ACTIVE_COMPARATOR|Verum focused extracorporeal shockwave therapy|Verum focused extracorporeal shockwave therapy is applied at 7 equidistant points, perpendicular to the belly of the biceps brachii muscle on a thought line between the radial tuberosity and the coracoid process (Dermagold120, Tissue Regeneration Technologies, Woodstock, Georgia, U.S.). Shock waves are generated by electrohydraulic mechanisms.
62797005|NCT02548208|SHAM_COMPARATOR|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy. The study personal is blinded to the applicators. All handling, adjustments and noises are thus same in this group.
62797006|NCT02548208|NO_INTERVENTION|Control|Control procedure stipulates participants to lay down on the same therapy table for 5 minutes receiving no intervention.
62797007|NCT02639299||Healthy volunteer|healthy, malaria-na(SqrRoot) ve US adults
62797008|NCT05404048|EXPERIMENTAL|PD-L1 PET-imaging|The main intervention of this study is 89Zr-atezolizumab PET-scan combined with a low-dose CT-scan. The PET/CT scan will be performed before infusion of CAR T-cell therapy. In patients with an end-of-treatment F-FDG positive PET-signal a second 89Zr-atezolizumab PET/CT-scan will be performed.
62797009|NCT01424501|EXPERIMENTAL|Group A|Subjects from TB-treated cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
62221428|NCT02666469|ACTIVE_COMPARATOR|Group B Exercise Program|Group B: Exercise Program in the hyperbaric medical unit without exposure to HBOT
62797010|NCT01424501|PLACEBO_COMPARATOR|Group B|Subjects from TB-treated cohort will receive 2 doses of physiological Saline.
62797011|NCT01424501|EXPERIMENTAL|Group C|Subjects from TB-treatment cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
62797012|NCT01424501|PLACEBO_COMPARATOR|Group D|Subjects from TB-treatment cohort will receive 2 doses of physiological Saline.
62797013|NCT01424501|EXPERIMENTAL|Group E|Subjects from TB-naive cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
62433382|NCT03197805|EXPERIMENTAL|Use of PAM 50 test in Her2 equivocal breast cancer patient|Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio \<2 and 4 ≤HER2 gene number copy \< 6) will be eligible for RNA genomic test (PAM 50 test).
62797014|NCT01424501|PLACEBO_COMPARATOR|Group F|Subjects from TB-naive cohort will receive 2 doses of physiological Saline.
62797015|NCT01301313|EXPERIMENTAL|Levosimendan|
62797016|NCT01301313|ACTIVE_COMPARATOR|Conventional intensified inotropic treatment|
62797017|NCT06280092|EXPERIMENTAL|AMSCs|A single dose of 5x10\^6 AMSCs will be resuspended in 1ml of LRS and infused via intraparenchymal at the time of DBS surgery
62024676|NCT04545268|EXPERIMENTAL|NMES group|
62221429|NCT01473446|NO_INTERVENTION|Control|Standard monitoring. Initial optimization of fluid status is performed by pulse, BP and anaesthesiologist assessment with Ringer acetate. Followed by an infusion of 10ml/kg/t Ringer acetate. Urinary output and blood pressure is used as a surrogate parameter: the infusion rate is increased by a fall in blood pressure or urine output \<0.5ml/kg/t. Bleeding replaced with HES 1:1, otherwise see table for fluid therapy page 9. Vasoactive agents (noradrenaline / phenylephrine) is given if the anesthesiologist considers this necessary. Postoperative give 1000ml Glucose 5%. HES or Ringer when low blood pressure, eventually noradrenaline as vasoactive agent.
62797018|NCT04358692|EXPERIMENTAL|Surgical Aortic Valve Replacement|Patients with aortic stenosis
62221430|NCT01473446|EXPERIMENTAL|Goal directed fluid therapy|
62221431|NCT00527592|EXPERIMENTAL|Travoprost|Travoprost assigned to one eye, with latanoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.
62024677|NCT04223102|OTHER|Tissue collection|Tissue collection
62221432|NCT00527592|ACTIVE_COMPARATOR|Latanoprost|Latanoprost assigned to one eye, with travoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.
62221433|NCT02772419|EXPERIMENTAL|benralizumab A|Subcutaneous (SC) administration
62221434|NCT02772419|EXPERIMENTAL|benralizumab B|SC administration
62221435|NCT02772419|PLACEBO_COMPARATOR|Placebo|Placebo SC administration
62221436|NCT02128542|EXPERIMENTAL|Sofosbuvir+RBV 12 weeks|Participants will receive sofosbuvir+RBV for 12 weeks.
62221437|NCT06312228|EXPERIMENTAL|Helper Skin Tap Technique Group|Before the vaccine injection, body weight, height and physiological parameters (pulse, blood pressure, SpO2, body temperature) were measured and behavioural pain responses were evaluated by the child, nurse and parent using the Wong-Baker pain scale and fear scale. Slow tapping was performed with rhythmic tapping movements on the left deltoid muscle where the vaccine will be administered to the children. When the needle was to be inserted into the deltoid muscle, the tapping was slightly increased and the needle entry was made with the same movement. After the vaccine injection was given, the needle was rapidly withdrawn from the muscle by increasing the tapping movements while the needle was withdrawn.
62415805|NCT04285892|EXPERIMENTAL|CAPA IVM|CAPA IVM is a 2-step In vitro Maturation system in which an additional culture step, in which the oocytes are kept in meiotic arrest by the presence of the C-type Natriuretic peptide (CNP) for 22-24 hours, is preceding the in vitro maturation step in which maturation medium is supplemented with amphiregulin (AREG). The 'IVM System' of Medicult-Origio is used as a base medium.
62415806|NCT04285892|NO_INTERVENTION|Standard IVM|The IVM is performed as a single step protocol in which oocytes are immediately exposed to in vitro maturation medium for 30 hours. This is the current standard procedure in the clinical practice using the commercially available 'IVM System' of Medicult-Origio. Standard IVM medium: 10% HSA + 75mIU/ml FSH + 100mIU/ml hCG
62415807|NCT04250818||Control Group|Patients with mTNBC who receive chemotherapy only
62797019|NCT04358692|OTHER|Reference|Coronary bypass patients without hypertrophic left ventricular remodeling or sequelae of myocardial infarction
62797020|NCT01128426||1|
62797021|NCT05597033|EXPERIMENTAL|Morning (AM)|Before 10 A.M.
62024678|NCT02595203|EXPERIMENTAL|Part A: Cohort 1|Participants receive a single intravenous (IV) dose of 240 mg/3.7 megabecquerel (MBq) of \[14C-pos 1\]-Debio 1450 BES solution.
62024679|NCT02595203|EXPERIMENTAL|Part A: Cohort 2|Participants receive a single oral dose of 240 mg/3.7 MBq of \[14C-pos 1\]-Debio 1450 BES solution.
62024680|NCT02595203|EXPERIMENTAL|Part B: Cohort 3|Participants receive a single oral dose of 240 mg Debio 1450/37 kilobecquerel (kBq) of \[14C-pos 25\]-Debio 1450 BES solution.
62024681|NCT03876067|EXPERIMENTAL|Ozone Group|in which Ozone will be added to cold blood cardioplegia
62797022|NCT05597033|EXPERIMENTAL|Evening (PM)|After 4 P.M.
62797023|NCT02331186||obese women who underwent bariatric surgery|obese women who underwent bariatric surgery
62024682|NCT03876067|PLACEBO_COMPARATOR|Control Group|: in which in which only cold blood cardioplegia
62024683|NCT01031147||Magnetic resonance angiography|Three-dimensional time-of-flight magnetic resonance angiography(3D-TOF-MRA) was used to detect the intracranial aneurysms in this study
62024684|NCT01438866|EXPERIMENTAL|Preventing occlusal caries|Comparing preventing effect of fissure sealants vs. fluoride varnish
62024685|NCT02966067|EXPERIMENTAL|Microneedle Device|Local Dental Anaesthetic Solution Delivery System: Microneedle device with an array of 2x3 pyramidal wet-etch silicone microneedles of 280µm height to inject anaesthetic solution.
62221438|NCT06312228|EXPERIMENTAL|Buzzy Group|Before the vaccine injection, body weight, height and physiological parameters (pulse, blood pressure, SpO2, body temperature) were measured and behavioural pain responses were evaluated by the child, nurse and parent using the Wong-Baker pain scale and fear scale. The ice pack previously removed from the deep freezer was kept at room temperature for 10 minutes and the hole in the ice pack wing was placed on the hook behind the Buzzy®. The Buzzy® was placed on the left arm deltoid muscle and activated and kept for 30 seconds. After 30 seconds, Buzzy® was pulled up 1 centimetre (cm) and the MMR vaccine injection was administered to the area corresponding to the left deltoid muscle. After the vaccine injection, Buzzy® was pulled to the injection site and kept for another 30 seconds.
62221439|NCT06312228|NO_INTERVENTION|Control Group|Before the vaccine injection, body weight, height and physiological parameters (pulse, blood pressure, SpO2, body temperature) were measured and behavioural pain responses were evaluated by the child, nurse and parent using the Wong-Baker pain scale and fear scale. MMR vaccine injection was routinely administered in the area corresponding to the left deltoid muscle without any intervention or application to the injection site.
62797024|NCT06725797|ACTIVE_COMPARATOR|GROUP A:wound hygiene with spa thermal sulphurous water delivered with pack on soaked gauzes|non woven gauzes will be soaked with sulphurous thermal water and positioned on the wound as packs for 20 minutes, at spring temperature (23°C).
62415808|NCT04250818||Experimental Group|patients with mTNBC who receive a combination of chemotherapy and Immunotherapy
62797025|NCT06725797|ACTIVE_COMPARATOR|GROUP B: limb full immersion in spa thermal sulphurous water|full wound immersion: the limb hosting the wound is located in a limb-sized tube filled with sulphurous water for 20 minutes at spring temperature (23°C).
62797026|NCT06360393||Severe asthma patients on biologics|Participants diagnosed with severe asthma using a biologic medication and medium or high dose ICS + LABA with or without LAMA and/or SABA via pMDI and spacer. Participants are being treated at one of the five severe asthma clinics in The Netherlands.
62797027|NCT05633472|EXPERIMENTAL|Experimental: Treatment group|Vitamin D (2000IU/day) for 6 months
62797028|NCT05633472|PLACEBO_COMPARATOR|Placebo Comparator: Control group|placebo
62797029|NCT05859074|EXPERIMENTAL|Dose Escalation Group|"MQ710~The dose levels will be escalated following a standard 3+3 dose escalation scheme."
62797030|NCT05859074|EXPERIMENTAL|Dose Expansion Group|"MQ710 + pembrolizumab~Approximately 8 patients will be recruited into the dose expansion group for monotherapy dosing of MQ710. Approximately 12 patients will be recruited for dosing at the MTD/maximally administered dose established in combination with pembrolizumab."
62797031|NCT04647240|ACTIVE_COMPARATOR|Dermacyte® Liquid (human amniotic fluid)|Dermacyte® Liquid (human amniotic fluid) solution 1.0mL to 2.0mL weekly
62797032|NCT04647240|PLACEBO_COMPARATOR|Placebo (0.9% saline)|Matching placebo solution 1.0mL to 2.0mL weekly
62797033|NCT01964963||Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 months. Participants will receive interventions as part of routine medical care.
62797034|NCT06319534|EXPERIMENTAL|Comprehensive rehabilitation+Stellate ganglion block|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 10 days.
62797035|NCT06319534|PLACEBO_COMPARATOR|Comprehensive rehabilitation+placebo|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 10 days.
62024686|NCT02966067|ACTIVE_COMPARATOR|30-gauge Short Hypodermic Needle|Local Dental Anaesthetic Solution Delivery System: Standard thirty-gauge short hypodermic needle to inject anaesthetic solution.
62024687|NCT01546194||Morning consent|Consent process consisting of information only provided on the morning of surgery
62024688|NCT01546194||Phone call and morning consent|Consent process consisting of information provided on the morning of surgery. In addition, a phone call on the day prior to surgery will be provided to subjects explaining that they will be approached about participation in a clinical research project
62024689|NCT03819335|ACTIVE_COMPARATOR|Standard care|Usual follow-up of diabetes type 1 with face-to-face visits
62024690|NCT03819335|EXPERIMENTAL|mySugr app|Telemedical assistance with mySugr app
62415809|NCT06425419|EXPERIMENTAL|Participants who received intravitreal topotecan|These are the patients who will be receiving intravitreally 20 micrograms of topotecan in a 1cc syringe during surgery, at the post-operative day 7 and at the post-operative day 28.
62415810|NCT06425419|NO_INTERVENTION|Participants who did not received intravitreal topotecan|These patients will not be receiving any intervention.
62797036|NCT01594229|EXPERIMENTAL|Arm 1|Non-Hodgkin's Lymphoma (NHL)
62797037|NCT06726070||Prostate Cancer|Prostate Cancer Patients
62797038|NCT06726070||Benign Prostatic Hyperplasia|Benign prostatic hyperplasia(BPH) patients
62797039|NCT06726070||Control|Healthy control
62797040|NCT05443256|EXPERIMENTAL|Theta Stim|To stimulate fMRI-informed individualized targets in dlPFC to diminish affective modulation of the RewP. Based on our working hypothesis, TMS Figure-8 coil stimulation should diminish affective modulation of RewP amplitude when compared to sham.
62797041|NCT05443256|SHAM_COMPARATOR|Sham Stim|Sham stimulation. The Reward Positivity should be unaffected.
62797042|NCT00889512|ACTIVE_COMPARATOR|Luveris Fixed dose|Participants in this arm will take Gonal F® and the same dose of Luveris® throughout the cycle. Their dose of Gonal F® will be adjusted throughout the cycle based on their response to the medication. The Luveris® dose will remain constant throughout.
62415811|NCT02374008|EXPERIMENTAL|Combined nerve block|Ropivacaine and Adrenalin, systemic Ketorolac and high dose Dexamethasone
62415812|NCT02374008|ACTIVE_COMPARATOR|Local infiltrationanalgesia|Ropivacaine, Adrenalin and Ketorolac combined with systemic high dose dexamethasone
62415813|NCT04365829|EXPERIMENTAL|Virtual reality|
62415814|NCT06696170|EXPERIMENTAL|CellFX nano-PFA Treatment Arm|CellFX nano-PFA 360 Endocardial Ablation Catheter System
62587879|NCT06299358|EXPERIMENTAL|Foot massage and mother heart sound group (mixed group)|For the group in which maternal heart sounds and foot massage will be applied, the heart sounds of the mothers of the babies will be recorded on an mp3 player in a quiet environment (in their own homes) with the help of hand-held doopes. The sound (65 decibels) and distance of the mp3 player will be determined by the researcher with the help of a decibel meter. The researcher will perform foot massage as in the massage group and the mother's heart sound will be played for a total of half an hour with the massage. The infants in this group will be visited five times in total, once in the first encounter and twice each in the first and second week, and the relevant forms (Infantile colic, neonatal comfort behavior scales will be applied 3 times for infants; state-trait anxiety scale will be applied twice for the mother, once at the beginning and twice at the end). A total of two forms related to crying and sleep will be completed by the mother, one for each week.
62024691|NCT04748354|ACTIVE_COMPARATOR|Usual Care|Clinical care provided by geriatricians. Each participant will see the geriatrician at baseline and 6 months.
62415815|NCT06319339|EXPERIMENTAL|Control: Vumerity intake, then Placebo|Participants will receive a single dose of VUMERITY (diroximal fumarate, 462mg). After a minimum period of 7 days, they will then receive a single dose of the placebo (microcrystalline cellulose, 462 mg).
62415816|NCT06319339|PLACEBO_COMPARATOR|Control: Placebo intake, then Vumerity|Participants will receive a single dose of placebo (microcrystalline cellulose, 462 mg). After a minimum period of 7 days, they will then receive a single dose of VUMERITY (diroximal fumarate, 462mg).
62415817|NCT06319339|EXPERIMENTAL|PAD: Vumerity intake, then Placebo|Participants with peripheral artery disease (PAD) will receive a single dose of VUMERITY (diroximal fumarate, 462mg). After a minimum period of 7 days, they will then receive a single dose of the placebo (microcrystalline cellulose, 462 mg).
62221440|NCT06265870|ACTIVE_COMPARATOR|Specific anthelminthic|"Participants were asked to provide stool samples for three consecutive days for testing through microscopy, culture, and PCR to detect parasites.~* This study will combine wet smear and Kato's thick smear methods, with duplicate samples collected from each stool specimen to maximize parasite detection. To ensure reliability, two experienced microscopists will independently examine all four slides, and an independent report generated. In cases of discrepant results, a third microscopist will arbitrate, and the final diagnosis determined by majority vote.~* Stool culture will look for Strongyloides stercoralis and hookworm larvae.~* Stool PCR: Targeted gene of 7 helminths will be amplified and detected by multiplex real-time PCR. The reaction will be dividing into three assays.~Following the analysis of the stool samples, participants will receive specific anthelminthic treatment tailored to the results of the stool tests."
62024692|NCT04748354|EXPERIMENTAL|Usual Care with Exercise|Clinical care provided by geriatricians. Each participant will see the geriatrician at baseline and 6 months. In addition, they will receive the Otago Exercise Program, an individualized and home-based program of progressive strength and balance training exercises delivered by a physical therapist.
62024693|NCT00746954|OTHER|Arm 1 BUS to PLA to ACET|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=3
62221441|NCT06265870|PLACEBO_COMPARATOR|Empirical anthelminthic|Participants will receive an empirical anthelminthic regimen consisting of albendazole 400 mg twice a day for seven consecutive days. Following this treatment, a follow-up complete blood count (CBC) will be requested to assess responsiveness.
62221442|NCT02910739|EXPERIMENTAL|Part I: MK-8931 40 mg in Moderate HI Participants|Single oral dose of MK-8931 40 mg tablet in participants with moderate HI in fasted state (Part I)
62221443|NCT02910739|ACTIVE_COMPARATOR|Part I: MK-8931 40 mg in Healthy Participants|Single oral dose of MK-8931 40 mg tablet in healthy matched participants in fasted state (Part I)
62024694|NCT00746954|OTHER|ARM 2 ACET to BUS to PLA|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=3
62024695|NCT00746954|OTHER|ARM 3 PLA to ACET to BUS|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=2
62024696|NCT01054729|EXPERIMENTAL|Sofosbuvir 100 mg+PEG+RBV|Participants received sofosbuvir 100 mg (1 x 100 mg tablet) and placebo to match sofosbuvir (3 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
62024697|NCT01054729|EXPERIMENTAL|Sofosbuvir 200 mg+PEG+RBV|Participants received sofosbuvir 200 mg (2 x 100 mg tablets) and placebo to match sofosbuvir (2 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
62024698|NCT01054729|EXPERIMENTAL|Sofosbuvir 400 mg+PEG+RBV|Participants received sofosbuvir 400 mg (4 x 100 mg tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
62024699|NCT01054729|ACTIVE_COMPARATOR|Placebo+PEG+RBV|Participants received placebo to match sofosbuvir (4 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
62024700|NCT06048523|OTHER|Patient cohort|Patients with a molecularly identified NGD (80 patients in total of which 15 with LP (Lumbar Puncture) and of which 30 with cutaneous biopsy)
62221444|NCT02910739|EXPERIMENTAL|Part II: MK-8931 40 mg in Mild HI Participants|Single oral dose of MK-8931 40 mg tablet in participants with mild HI in fasted state (Part II)
62024701|NCT06048523|OTHER|Control cohort|Patients control: 10 controls with lumbar puncture and 10 controls without LP (Lumbar Puncture)
62221445|NCT02910739|ACTIVE_COMPARATOR|Part II: MK-8931 40 mg in Healthy Participants|Single oral dose of MK-8931 40 mg tablet in healthy matched participants in fasted state (Part II)
62221446|NCT06306339|PLACEBO_COMPARATOR|Placebo infusion|Placebo + SOC
62221447|NCT06306339|EXPERIMENTAL|Burfiralimab(hzVSF-v13) 200mg IV infusion|Burfiralimab (hzVSF-v13) 200mg/dose + SOC
62221448|NCT06306339|EXPERIMENTAL|Burfiralimab(hzVSF-v13) 600mg IV infusion|Burfiralimab (hzVSF-v13) 600mg/dose + SOC
62221449|NCT01585987|EXPERIMENTAL|Arm A: Ipilimumab|Ipilimumab 10 mg/kg solution intravenously, 90 minute infusion, once every 3 weeks for 4 doses, then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)
62221450|NCT01585987|OTHER|Arm B: Best Supportive care (BSC)|BSC may include the continuation of the Fluoropyrimidine that was used during the lead-in chemotherapy, but no other systemic anti cancer therapy
62221451|NCT03254446|EXPERIMENTAL|TRC150094 45 mg|TRC150094 45 mg Tablet to be administered orally once a day for 50 weeks
62024702|NCT04191772|EXPERIMENTAL|MS - training goal 1|Persons with Multiple Sclerosis (PwMS) with a 'poor VO2max', a 'fair VO2max' with no running experience and a 'good VO2max' with no running experience (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the first training group will be trained to run continuously for 45 minutes.
62221452|NCT03254446|PLACEBO_COMPARATOR|Placebo|Matching Placebo Tablet to be administered orally once a day for 50 weeks
62221453|NCT01680484|ACTIVE_COMPARATOR|Bitter chocolate|50 grams Ülker Golden %70 bitter chocolate, İstanbul, Turkey
62221454|NCT01680484|ACTIVE_COMPARATOR|Orange juice|Ülker İçim Orange Juice 250 cc, İstanbul, Turkey
62221455|NCT01680484|NO_INTERVENTION|Control|Sit and rest
62221456|NCT04059003||Sensitivity group|100 patients will be assigned into sensitivity group according to the actual situation of them.
62221457|NCT04059003||Drug resistance group|100 patients will be assigned into drug resistance according to the actual situation of them.
62221458|NCT04496492|EXPERIMENTAL|Tocotrienol|Subjects receiveTocotrienol 200 mg/twice daily before surgery
62221459|NCT03854773|ACTIVE_COMPARATOR|Erector spinae block (Group ESPB)|In group A, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T5 transverse process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
62221460|NCT03854773|ACTIVE_COMPARATOR|Thoracal paravertebral block group (Group TPVB)|In group B, TPVB will be performed. US probe will be placed 2-3 cm laterally following the visualization T5 spinous process in sagittal orientation. The ribs and transverse processes will be visualized as hyperechoic structures. The costotransverse ligament will be visualized in the superior, and the pleura in the anterior region. Using in plane technique, the block needle will be inserted in the cranio-caudal direction until the costotransverse ligament will be passed. For confirmation of correct position of the needle, 5 ml saline will be injected. After the negative aspiration of cerebrospinal fluid, blood and air; 20 ml of 0.25% bupivacaine will be performed and it will be seen of moving downwards of the pleura during the injection
62221461|NCT03854773|OTHER|Control group (Group C)|Patients in control group will be only received fentanyl via a patient controlled analgesia (PCA) device.
62221462|NCT00596193||Group I|patients with normal or irreversible pulpitis teeth with capsaicin administered at increasing volumes.
62587880|NCT05829343||Robotic surgery group|Patients with diverticular disease resected with a robotic approach.
62587881|NCT05829343||Laparoscopic surgery group|Patients with diverticular disease resected with a laparoscopic approach.
62221463|NCT00596193||Group II|Patients with normal teeth only with capsaicin added at a specific volume only
62221464|NCT03373201|EXPERIMENTAL|Tasimelteon|
62221465|NCT03373201|PLACEBO_COMPARATOR|Placebo|
62587882|NCT03988881||1 PCI Group|Patients after acute myocardial infarction and at least one moderate stenosis on the non-culprit vessels with positive dobutamine stress echocardiography and positive Fractional Flow Reserve recieving revascularization (PCI or CABG) Drug: Standard of care after acute myocardial infarction
62587883|NCT03988881||Group 2 OMT group|Patients after acute myocardial infarction and at least one moderate stenosis on the non-culprit vessels with negative dobutamine stress echocardiography and negative Fractional Flow Reserve or the mismatching cases Standard of care after acute myocardial infarction
62587884|NCT06598462|EXPERIMENTAL|Solrikitug low dose|Solrikitug
62587885|NCT06598462|EXPERIMENTAL|Solrikitug mid dose|Solrikitug
62587886|NCT06598462|EXPERIMENTAL|Solrikitug high dose|Solrikitug
62221466|NCT01614431|EXPERIMENTAL|N acetyl cysteine|NAC will be given to cystinosis patients and we will observe the renal function status and a marker of oxidative stress (TBARS)
62587887|NCT06598462|PLACEBO_COMPARATOR|Placebo|Placebo
62587888|NCT02769949||Family members|Family members (adult and pediatric; affected and unaffected) may be enrolled for the purpose of determining the molecular lesion(s) responsible for genetic disorders.
62415818|NCT06319339|PLACEBO_COMPARATOR|PAD: Placebo intake, then Vumerity|Participants with peripheral artery disease (PAD) will receive a single dose of placebo (microcrystalline cellulose, 462 mg). After a minimum period of 7 days, they will then receive a single dose of VUMERITY (diroximal fumarate, 462mg).
62415819|NCT04305184|EXPERIMENTAL|Single Ascending Dose (SAD): 0.03 mcg|Participants received single dose of 0.03 microgram (mcg) ASP0598 Otic Solution into the affected ear on day 1 and returned to the investigative site for assessments on days 2, 3, 8, 15, 29, and 57 \[End of Study (EOS)\].
62415820|NCT04305184|EXPERIMENTAL|SAD: 0.15 mcg|Participants received single dose of 0.15 mcg ASP0598 Otic Solution into the affected ear on Day 1 and returned to the investigative site for assessments on days 2, 3, 8, 15, 29, and 57 (EOS).
62221467|NCT05015933|EXPERIMENTAL|Refill at home|Patients will have one pump refill at home instead of at the hospital.
62221468|NCT01619397|OTHER|Condom|Test condom with new Xanthan gum condom coating
62415821|NCT04305184|EXPERIMENTAL|SAD: 0.75 mcg|Participants received single dose of 0.75 mcg ASP0598 Otic Solution into the affected ear on day 1 and returned to the investigative site for assessments on days 2, 3, 8, 15, 29, and 57 (EOS).
62587889|NCT02769949||Genetic disorders|Participants with genetic disorders
62221469|NCT03284047|EXPERIMENTAL|2.5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:~1. 2.5 U~2. 5 U~3. 7.5 U"
62221470|NCT03284047|EXPERIMENTAL|5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:~1. 2.5 U~2. 5 U~3. 7.5 U"
62221471|NCT03284047|EXPERIMENTAL|7.5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:~1. 2.5 U~2. 5 U~3. 7.5 U"
62221472|NCT04320706|EXPERIMENTAL|Oral Oxytocin|Oxytocin orally (24 IU)
62221473|NCT04320706|PLACEBO_COMPARATOR|Oral Placebo|Placebo orally (identical ingredients, except the active agent)
62221474|NCT00359216|EXPERIMENTAL|Mometasone furoate nasal spray|
62587890|NCT05272761||Oronasal Route|Patients will sleep in the sleep lab for CPAP titration wearing a custom oronasal mask with 2 open oral and nasal compartments. The titration was split between the first half of the night and the second half. The titration will be started with the patient remaining for 90 minutes with the pressure he uses at home (supine position and in lateral decubitus), after a period of 90 minutes the patient will be titrated in order to abolish respiratory events in both positions of the body.
62221475|NCT00359216|PLACEBO_COMPARATOR|Placebo nasal spray|
62415822|NCT04305184|EXPERIMENTAL|SAD: 2.25 mcg|Participants received single dose of 2.25 mcg ASP0598 Otic Solution into the affected ear on day 1 and returned to the investigative site for assessments on days 2, 3, 8, 15, 29, and 57 (EOS).
62221476|NCT04068766|EXPERIMENTAL|Paracervical block with 5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
62221477|NCT04068766|PLACEBO_COMPARATOR|Paracervical block with normal saline|ck with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
62415823|NCT04305184|PLACEBO_COMPARATOR|SAD: Placebo|Participants received single dose of placebo matched to ASP0598 Otic Solution into the affected ear on day 1 and returned to the investigative site for assessments on days 2, 3, 8, 15, 29, and 57 (EOS).
62415824|NCT04305184|EXPERIMENTAL|Multiple Ascending Dose (MAD): 0.75 mcg|Participants received multiple doses of 0.75 mcg ASP0598 Otic Solution into the affected ear on days 1, 15 and 29 and returned to the investigative site for assessments on days 8, 15, 22, 29, 36, 57, and 85 (EOS).
62415825|NCT04305184|EXPERIMENTAL|MAD: 2.25 mcg|Participants received multiple doses of 2.25 mcg ASP0598 Otic Solution into the affected ear on days 1, 15 and 29 and returned to the investigative site for assessments on days 8, 15, 22, 29, 36, 57, and 85 (EOS).
62415826|NCT04305184|PLACEBO_COMPARATOR|MAD: Placebo|Participants received multiple doses of placebo matched to ASP0598 Otic Solution into the affected ear on days 1, 15 and 29 and returned to the investigative site for assessments on days 8, 15, 22, 29, 36, 57, and 85 (EOS).
62221478|NCT03704246|OTHER|Anti-PD-1|Anti-PD-1 monoclonal antibody HX008 injection with a dose of 200mg (intravenous infusion, every 3 weeks)
62221479|NCT01065844|EXPERIMENTAL|Nelfinavir|1250 mg Nelfinavir twice daily Monday-Sunday
62221480|NCT00662506|EXPERIMENTAL|Treatment (enzyme inhibitor therapy, chemotherapy, IMRT)|See Detailed Description
62415827|NCT04987307|EXPERIMENTAL|Arm A: Efavaleukin alfa|Efavaleukin alfa Dose 1 administered by SC injection once every two weeks (Q2W)
62797043|NCT00889512|EXPERIMENTAL|Luveris increasing dose|Patients assigned to this group will gradually reduce the Gonal F® dose while increasing the Luveris® dose during the cycle, which more closely mimics the natural menstrual cycle.
62797044|NCT03030417|EXPERIMENTAL|Treatment Arm - LMP744 (NSC 706744)|LMP744 (NSC 706744) will be administered intravenous (IV) over 1 hour on days 1-5 of each 28-day cycle.
62221481|NCT00518492|EXPERIMENTAL|Arm 1|Includes subjects from a trial involving experimental vaccine and an active comparator vaccine. Comparator is Twinrix (not a MnB vaccine) and thus is comparator for safety but not immunogencity
62221482|NCT01183260|EXPERIMENTAL|Trabecular Metal Revision Cup|Patients randomized to this arm will receive a trabecular metal revision component which does not have a titanium inner surface and requires a cemented highly crosslinked polyethylene liner.
62221483|NCT01183260|ACTIVE_COMPARATOR|Trabecular Metal Modular Cup|Patients randomized to this arm will receive a trabecular metal modular component which has a titanium inner surface and requires a non-cemented highly crosslinked polyethylene liner.
62221484|NCT02668484|EXPERIMENTAL|repositionable valve prosthesis|Lotus
62221485|NCT02668484|ACTIVE_COMPARATOR|balloon-expandable valve prosthesis|Sapien
62221486|NCT00901823|EXPERIMENTAL|Sequence 1|Single dose of low dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
62221487|NCT00901823|EXPERIMENTAL|Sequence 2|Single dose of high dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
62415828|NCT04987307|EXPERIMENTAL|Arm B: Efavaleukin alfa|Efavaleukin alfa Dose 2 administered by SC injection Q2W
62415829|NCT04987307|EXPERIMENTAL|Arm C: Efavaleukin alfa|Efavaleukin alfa Dose 3 administered by SC injection Q2W
62415830|NCT04987307|PLACEBO_COMPARATOR|Arm D: Placebo|Placebo Q2W
62415831|NCT04619472|EXPERIMENTAL|Radiofrequency Ablation (RFA)|The subjects will first undergo interventional bronchoscopy to reach the target lesion through the bronchial pathway. Then the lung lesions will be treated with radiofrequency ablation using the pulmonary radiofrequency ablation system and the disposable pulmonary radiofrequency ablation catheter.
62221488|NCT02516020|ACTIVE_COMPARATOR|Global|EmbryoSingle step culture medium Embryos are cultured in single step culture from day 1 to day 5 Other Name: Global medium (LifeGlobal)
62221489|NCT02516020|ACTIVE_COMPARATOR|Origio|Sequential media Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast) Other Name: Sequential Blast (Origio)
62221490|NCT06140706|EXPERIMENTAL|tSCS plus home tele-video support|Cervical transcutaneous spinal stimulation during home tele-video visits
62221491|NCT04138693|EXPERIMENTAL|Cohort 1: 2 x 2.0 g G-PUR® oral suspension|
62221492|NCT04138693|EXPERIMENTAL|Cohort 2: 1 x 2.0 g G-PUR® oral suspension|
62221493|NCT04138693|PLACEBO_COMPARATOR|Cohort 3: Placebo oral suspension|
62221494|NCT03580005|ACTIVE_COMPARATOR|Quillichew ERCT|Quillichew ERCT
62415832|NCT03717298|EXPERIMENTAL|Ocoxin-Viusid|It will be used at a rate of 60 ml daily (1 vial every 12 hours).
62415833|NCT04203888|OTHER|Massage|A licensed massage therapist will deliver 60-minute Swedish Massage in the participant's home, 2 times per week with at least 48-hours between massage sessions. Each massage arm will be 2 weeks in length, and consist of 4 total Swedish massages.
62415834|NCT04203888|OTHER|Yoga|"A certified yoga instructor will deliver 60-minute yoga instruction in the participant's home, 2 times per week with at least 48-hours between yoga session. Yoga sessions will be based on the yoga postures available in the appendix of the December 2005 Annals of Internal Medicine article, Comparing Yoga, Exercise, and a Self-Care Book for Chronic Low Back Pain (Sherman KJ et al., 2005). Each yoga arm will be 2 weeks in length, and consist of 4 total yoga sessions."
62797045|NCT06727422|EXPERIMENTAL|low dose for IBS-D|RNIB21 containing rifaximin 66mg + NAC 560mg three times a day
62797046|NCT06727422|EXPERIMENTAL|high dose for IBS-D|RNIB21 containing rifaximin 132mg + NAC 560mg three times a day
62415835|NCT04203888|NO_INTERVENTION|Usual Care|Participants will be instructed to abstain from any massage or yoga activity, and instructed to treat their chronic lower back pain as they normally would. Each usual care arm will be 2 weeks in length.
62221495|NCT03580005|PLACEBO_COMPARATOR|Placebo to match Quillichew ERCT|Placebo to match Quillichew ERCT
62221496|NCT05258045||SUV ratio of mediastinal blood pool to the lesion and SUV ratio of liver to lesion|Avidity of SUV of blood pool
62221497|NCT00757341|EXPERIMENTAL|SKI-606|
62797047|NCT06727422|PLACEBO_COMPARATOR|placebo|placebo three times a day
62797048|NCT01930942|EXPERIMENTAL|preoperative concurrent chemoradiation|Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
62797049|NCT04705246|EXPERIMENTAL|Psychoeducation|The goal of the psychoeducation session is to provide insight in the hyperacusis symptoms, take away the fear of external noises, and encourage exposure to noise.
62797050|NCT01299181|ACTIVE_COMPARATOR|Atorvastatin|Atorvastatin 80mg once daily
62797051|NCT01299181|PLACEBO_COMPARATOR|Placebo|Placebo
62797052|NCT04458909|EXPERIMENTAL|Arm I (nivolumab, gemcitabine, cisplatin / carboplatin)|Patients receive nivolumab IV over 30 minutes on day 1, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV over 30-60 minutes or carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 4 weeks, patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62221498|NCT06444230|EXPERIMENTAL|Neuro-developmental Physical Therapy+ Routine Physical Therapy|"* Protocol of 40 minutes focusing on gross motor functional movements including upright sitting at the table, walking, kneeling, running and stair climbing.~* Used a Neuro-developmental method to inhibit undesirable movement patterns and facilitate favorable movement patterns.~* Weight-bearing exercises that involved proprioceptive training while in various positions (such as quadruped, kneeling, half kneeling, and standing).~* Facilitating weight transfer forward, backward, and sideways during balancing reactions from various balance board postures"
62221499|NCT06444230|EXPERIMENTAL|Routine Physical therapy:|All children in this group received physical therapy of 40 minutes, 3 times per week for 12weeks, which included passive stretching with focus on diplegic limb 8 minutes, neck and trunk postural control for 8 minutes, strength training 8 minutes, ambulation and gait training for 8 minutes with 2 minutes rest interval between each set of exercise.
62221500|NCT06292962|EXPERIMENTAL|Group VTG|Group VTG will receive active non-invasive transcutaneous vagal nerve stimulation (tVNS)
62221501|NCT06292962|SHAM_COMPARATOR|Group STG|Group STG will receive Inactive sham stimulation
62221502|NCT02383004|EXPERIMENTAL|Acupuncture|"Same premedication, induction and maintenance protocol as the No Acupuncture (Standard of Care) group.~The intervention will be placement of 4 acupuncture needles. The needles will be placed after inhalational anesthesia induction and removed prior to leaving the operating room. A total of 4 needles will be placed, one in each wrist at the HT7 point and one in each ear at the shen men point."
62415836|NCT02297607|EXPERIMENTAL|Tube Feeding|Study subjects will continue to receive tube feedings (for at least 50% of caloric need) for 1-month post-operatively.
62797053|NCT04458909|ACTIVE_COMPARATOR|Arm II (gemcitabine, cisplatin / carboplatin)|Patients receive gemcitabine and cisplatin or carboplatin as in Arm I.
62221503|NCT02383004|NO_INTERVENTION|No Acupuncture (Standard of Care)|"If needed, the patient will receive a standard does of oral midazolam (0.5 mg /kg or less, up to 15mg) plus acetaminophen 12.5 mg/kg (V group). If the patient does not require premedication with midazolam, oral acetaminophen 12.5mg/kg will be given alone (NV group).~Induction of anesthesia by mask ventilation with sevoflurane in 50% nitrous oxide mixed with 50% oxygen. Sevoflurane will be incrementally titrated from 0% up to 8%. Nitrous oxide will be discontinued after induction. Anesthesia will be maintained with sevoflurane in an oxygen/air mixture. Sevoflurane concentration will be titrated to maintain the adequate depth of anesthesia. Prior to leaving the operating room, a dose of ketorolac 0.5mg/kg will be given intramuscularly."
62221504|NCT04684407|ACTIVE_COMPARATOR|calcium hydroxide|calcium hydroxide powder is mixed with normal saline and placed as intra-canal medication
62221505|NCT04684407|EXPERIMENTAL|Triple antibiotic paste|"Triple antibiotic paste (TAP)- combination of metronidazole,ciprofloxacin and minocycline mixed in a ratio of 1:1:1 .~TAP paste is combined with propylene glycol and placed as intra canal medication."
62221506|NCT06178081|ACTIVE_COMPARATOR|Clinical Healthy|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) salivary sample and gingival crevicular fluid will be taken from all individuals at the beginning of the study. IL-39 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample and gingival crevicular fluid will be collected from the clinically healthy group.
62221507|NCT06178081|EXPERIMENTAL|Periodontitis|Non-surgical periodontal treatment will be applied to individuals with periodontitis, clinical measurements, saliva collection and gingival crevicular fluid will be repeated 12 weeks after the treatment. IL-39 analysis will be performed by ELISA in saliva and gingival crevicular fluid of individuals. IL-39 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
62221508|NCT03605173|EXPERIMENTAL|free vitamin d|free vitamin is directly measured from blood serum using an ELISA kit
62221509|NCT03605173|EXPERIMENTAL|total vitamin d|Total vitamin d is measured routinely from blood serum
62221510|NCT01277393||Experimental Group|
62221511|NCT01277393||Control Group|
62221512|NCT00484458|EXPERIMENTAL|1|Wallis Stabilization System
62221513|NCT00484458|ACTIVE_COMPARATOR|2|Total Disc Replacement
62221514|NCT05105451||Patients in the control group were followed up without dNCR postoperatively.|If the MOCA or MMSE assessment all show a negative resluts at all time point.
62221515|NCT05105451||Patients in the case group were followed up with dNCR postoperatively.|If the MOCA assessment is positive at any time point after surgery, and there is a positive MMSE at any time point after surgery(no need for both MOCA and MMSE to be positive at the same time), it is defined as the occurrence of dNCR.
62221516|NCT06594783|ACTIVE_COMPARATOR|Carvedilol plus endoscopic variceal ligation|Take carvedilol every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol.
62221517|NCT06594783|PLACEBO_COMPARATOR|Carvedilol alone|Take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable).
62221518|NCT06609811|EXPERIMENTAL|The immediate vaccination group.|Participants are assigned to receive one dose of 0.2 mL of intranasal live attenuated influenza vaccine immediately (Day 0)
62221519|NCT06609811|EXPERIMENTAL|The delayed vaccination group|Participants are assigned to receive one dose of 0.2 mL of intranasal live attenuated influenza vaccine after a delay (Day 28).
62221520|NCT01553773|EXPERIMENTAL|Isoflavone|a gel with isoflavones (genistein 4%)
62221521|NCT01553773|EXPERIMENTAL|Estradiol|gel with 17-β estradiol 0.01%
62221522|NCT02592993|EXPERIMENTAL|PicoWay treatment to all subjects|Subjects in this study will receive up to six (6) treatments in 3-8 weeks interval, with the PicoWay device-fractional handpiece 532nm and/or 1064nm according to the study protocol. Subjects will be followed by phone 7 days post first treatment by study staff, and will return for two follow-up (FU) visits at the clinic at: 6 weeks and 12 weeks following the last treatment.
62221523|NCT04268290|EXPERIMENTAL|SILS plus one assistant ERAS|"Preoperative:~preadmission information, education, counseling, optimization ( breathing training), shortening fasting time and carbohydrate load~Intraoperative:~The intravenous fluid therapy is restricted. All patients undergo single incision plus one port laparoscopic surgery(SILS plus one).~A suitable warming device (such as forced-air heating blankets) and warmed intravenous fluids are been adopted routinely to keep body temperature~Postoperative:~multimodal analgesia (surgical site infiltration, a nonsteroidal anti-inflammatory drug, epidural analgesia) early oral intake and move. nasogastric tubes should not be used routinely. Nasogastric tubes inserted during surgery are been removed before reversal of an aesthesia."
62221524|NCT03866291||ESBL carrier|"This cohort is followed for a year with additional selective ESBL cultures after 1, 3, 6 and 12 months. In the end of the year a questionnaire is handed in to the study group.~Sera is donated after 4-6 weeks and in year."
62221525|NCT03866291||Non ESBL-carrier|No further rectal cultures. In the end of the year a questionnaire is handed in to the study group. Sera is donated after 4-6 weeks and in year.
62221526|NCT02641496|EXPERIMENTAL|CBT-OSA|CBT-OSA is a new cognitive behavioral therapy which focuses on changing behaviors and thoughts to help individuals adjust to using a CPAP machine.
62221527|NCT02641496|ACTIVE_COMPARATOR|Sleep Education|The Sleep Education treatment will include information, facts, and videos on sleep, cardiovascular disease, PTSD, and proper sleep hygiene.
62415837|NCT02297607|NO_INTERVENTION|Standard of Care|Tube feeding to continue in the hospital until the patient is taking adequate nutrition by mouth at post-op day #8, or upon discharge,
62433383|NCT04949867|ACTIVE_COMPARATOR|Dual-hormone Closed-loop|FiAsp® and GlucaGen®.
62415838|NCT06565910|EXPERIMENTAL|Liposomal Bupivacaine plus Bupivacaine Intervention|Participants in this arm will receive liposomal bupivacaine(LB) plus bupivacaine(B) as a local anesthetic for PENG block under ultrasound guidance. Liposomal bupivacaine plus bupivacaine is being investigated for its analgesic effect in postoperative pain management following hip replacement surgery. This arm aims to evaluate the analgesic efficacy, duration of pain relief, and safety profile of liposomal bupivacaine plus bupivacaine compared to the standard local anesthetic, ropivacaine. Participants in this arm will undergo hip replacement surgery under spinal anesthesia and will be assessed for pain relief, opioid analgesic consumption, and any associated complications at multiple time points within 72 hours after surgery.
62415839|NCT06565910|ACTIVE_COMPARATOR|Ropivacaine Intervention|Participants in this arm will receive ropivacaine (R) as a local anesthetic for the PENG block under ultrasound guidance. Ropivacaine, a routinely used local anesthetic in clinical practice, is being compared to liposomal bupivacaine plus bupivacaine to assess its analgesic effect in postoperative pain management following hip replacement surgery. This arm aims to evaluate the analgesic efficacy, duration of pain relief, and safety profile of ropivacaine in comparison to the investigational intervention, liposomal bupivacaine. Participants in this arm will undergo hip replacement surgery under spinal anesthesia and will be assessed for pain relief, opioid analgesic consumption, and any associated complications at multiple time points within 72 hours after surgery.
62415840|NCT04093479||BMI, oxytocin|Repeteadly blood samples will be taken
62415841|NCT06567366|EXPERIMENTAL|CAR T-cell therapy in combination with Glofitamab|"After undergoing leukapheresis, participants will receive treatment in the following procedure.~Bridging Phase:~All participants will receive two cycles of Glofitamab treatment. On Day 1 of Cycle 1, patients will receive 1000 mg of Obinutuzumab as pretreatment.~CAR-T Treatment Phase:~Participants will receive lymphodepletion therapy with the FLU/CY regimen on Day -5 through Day -3. Participants will receive the CAR T-cell infusion on Day 0.~Consolidation Phase:~Treatment based on the response assessment at Day 28 after CAR T-cell infusion: participants who attained complete response (CR) at Day 28 will not receive additional Glofitamab treatment, while those attained partial response (PR), stable disease (SD), or progressive disease (PD) will receive additional four cycles of Glofitamab."
62415842|NCT05347407||Control|Healthy Patients
62415843|NCT05347407||Parkinson's Disease|Patients diagnosed with Parkinson's disease
62415844|NCT05347407||At risk for PD|Defined as REM sleep behavior disorder, known genetic risk factor, and/or first degree relatives with PD
62415845|NCT05347407||Dementia with Lewy Bodies|Patients diagnosed with Dementia with Lewy Body Disease
62415846|NCT05347407||Multiple System Atrophy|Patients diagnosed with Multiple System Atrophy
62415847|NCT01830257|EXPERIMENTAL|sending message|The investigators would send the tip to the children's guardian
62415848|NCT04754425|EXPERIMENTAL|Treatment (erdafitinib, biospecimen collection)|Patients receive erdafitinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may also undergo collection of blood and bone marrow via biopsy and aspirates.
62415849|NCT03165630|NO_INTERVENTION|Group 1|Education or Control group.
62415850|NCT03165630|EXPERIMENTAL|Group 2|Transportation incentives
62415851|NCT03165630|EXPERIMENTAL|Group 3|Transportation and rehabilitation services incentives
62415852|NCT05957237||Subjects hospitalised with non-surgical complications after bariatric surgery (case)|
62415853|NCT05957237||Subjects with bariatric surgery without nonsurgical complications (control)|
62415854|NCT05957237||Subjects with obesity (control)|
62415855|NCT03642886|NO_INTERVENTION|Continued Strenuous Exercise|Continued strenuous athletics (no reduction in training volume) - athletes will be asked to document their activity and be fitted with an activity monitor during the run-in period and intervention period
62415856|NCT03642886|EXPERIMENTAL|Prescribed Detraining|"Detraining period of 8-weeks which is defined as:~1. a 75% decrease in the amount of exercise (from baseline)~2. a 50% decrease in the intensity of exercise as measured in METS (from baseline)~3. Mitchell Classification classes 1A, 2A, 2B of activity are permitted"
62415857|NCT03747094|ACTIVE_COMPARATOR|Fentanyl group|
62415858|NCT03747094|EXPERIMENTAL|Ketamine group|
62415859|NCT02388659||Brain MRI/MRS Patients|3 Tesla Scanning: MRI/MRS of glioma and non-glioma patients.
62415860|NCT04075656|EXPERIMENTAL|UrApp|Participants randomized to this study arm will use the UrApp mobile application for one year, in addition to receiving the standard of care.
62415861|NCT04075656|ACTIVE_COMPARATOR|Standard of Care|Participants randomized to this study arm will use receive the standard of care for one year.
62415862|NCT04369885|EXPERIMENTAL|Home Telemedicine Device|This arm will receive the intervention of the home telemedicine device for three months.
62415863|NCT03877848||ACS and Non-ACS|"DAPT will be stopped at 30 days in non-ACS subjects while at ACS Patients it may be maintained for up to 3 months. In patients with ACS or with an ischemic event during the first 30 days, DAPT may be continued at the discretion of the investigator. In ACS patients DAPT should be continued for a maximum of 3 months. For patients with recurrent ischemic events duration of DAPT therapy will be at the discretion of the investigator.~Patients receiving long-term oral anticoagulation with either a Vitamin K inhibitor or a NOAC/DOAC will receive either single antiplatelet therapy with clopidogrel, or DAPT for 30 days (triple therapy) followed by single antiplatelet therapy with clopidogrel. Clopidogrel (75 mg QD) will be given to these patients post procedure for 6 months in stable patients and 12 months in ACS patients."
62415864|NCT01968174||eyelid displacement|patients suffering from eyelid disposition due to ptosis, blepharochalasis and are registered for eyelid surgeries will be assigned for the study
62415865|NCT04794595||sepsis group with CBP|The child with sepsis should be treated with CBP， but could not receive this treatment for various reasons
62415866|NCT04794595||sepsis group without CBP|The child with sepsis should be treated with CBP and received this treatment
62433384|NCT04949867|PLACEBO_COMPARATOR|Single-Hormone Closed-loop|FiAsp® and isotonic saline.
62797054|NCT06726538|EXPERIMENTAL|MSC infusion group (Group A)|This clinical trial involves intravenous administration of MSCs at a dose of 10\^6 cells/kg, offering a non-rejection approach due to the autologous nature of the cells. These cells, surviving approximately 8 weeks in the body, secrete growth factors and cytokines to nourish cells, enhance vascular supply, and mitigate harmful inflammation, thereby countering cellular aging. Fifty female participants will be randomly assigned to two groups. Group A will receive mesenchymal stem cell (MSC) infusions twice: once at baseline and a second time three months later.
62221528|NCT04637854|EXPERIMENTAL|Operating Microscope.|"Surgical technique is the same used for extraction of the lower third molar. Patients will be enrolled (baseline) whenever sign their written informed consent to participate to the study, after having read and understand the informative pamphlet.~The intervention will be performed under local anesthesia (mepivacaine 20 mg/ml with adrenaline 1:100000) and by the use of microscope.~At the end of the surgical procedure, all patients will receive a 100mg Nimesulide cpr and apply the ice pack on the cheek.~At the end of each procedure will give post-operative instructions for all patients and prescribe an antiseptic therapy with chlorhexidine coll. 0.2% 3 times/ day for 10 days from the day following the intervention and anti-inflammatory therapy Nimesulide 100 mg cpr to take up to 2 times / day for up to 4 days.~Each patients will be recalled for follow-up visits at 7 days."
62221529|NCT04637854|ACTIVE_COMPARATOR|Surgical Loupes with coaxial illumination.|The same as above but the intervention will be performed with the use of surgical loupes
62221530|NCT04637854|ACTIVE_COMPARATOR|Naked Eye.|The same as above but the intervention will be performed at naked eyes
62221531|NCT03219515|EXPERIMENTAL|Gongjin-dan|Participants will be orally administered Gongjin-dan pills of 3.75g, 1 pill/day, 8 weeks (56 days).
62221532|NCT03219515|PLACEBO_COMPARATOR|placebo|Participants will be orally administered placebo pills of 3.75g, 1 pill/day, 8 weeks (56 days).
62587891|NCT05272761||Oral Route|"Group/Cohort Interventions Oronasal Route~Patients will sleep in the sleep lab for CPAP titration using a custom 2-compartment oronasal mask. In this titration, the nasal compartment will be closed and the patient will be titrated only through the oral route. The titration split between the first half of the night and the second half. The titration will be started with the patient staying for 90 minutes with the pressure used at home (during the supine position and lateral position), after the 90 minute period the patient will be titrated in order to abolish respiratory events in both positions of the body."
62587892|NCT04417803|OTHER|diffuse large B-cell lymphoma|
62587893|NCT04417803|OTHER|follicular lymphoma|
62587894|NCT04417803|OTHER|Hodgkin's lymphoma|
62221533|NCT01198756|EXPERIMENTAL|GSK2282512A 1 Group|Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62221534|NCT01198756|ACTIVE_COMPARATOR|Victoria strain Fluarix Group|Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62221535|NCT01198756|ACTIVE_COMPARATOR|Yamagata strain Fluarix Group|Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62221536|NCT01198756|EXPERIMENTAL|GSK2282512A 2 Group|Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants \<12 months of age.
62221537|NCT03143946|EXPERIMENTAL|Vitamin supplement and diet advice|Single arm. Patient be prescribed vitamin supplement if vitamin deficiencies are diagnosed and will get diet advice
62587895|NCT04611191|EXPERIMENTAL|Team Sports|Elderly men and women performing team sports in local sports clubs
62587896|NCT04611191|EXPERIMENTAL|Control|Elderly men and women continue their normal lifestyle
62221538|NCT01085266|EXPERIMENTAL|Dimebon (latrepirdine)|Patients receive dimebon 10mg orally 3 times per day for 1 week and 20 mg orally 3 times per day thereafter.
62221539|NCT03510585|EXPERIMENTAL|saline and sniffing|This RRC is the combination of positioning (laying down), sniffing (only one side), throat vibration and saline instillation. And then the other side.
62221540|NCT03510585|PLACEBO_COMPARATOR|sniffing|Pacient will be in a lay down condition and will perform sniffing with throat vibration several times each side (but with no saline instillation)
62433385|NCT04150783||Unilateral Cleft Lip Nasal Deformity (uCLND)|uCLND patients who are scheduled to undergo surgical treatment for nasal obstruction as standard of care.
62587897|NCT03611777||subjects with Pulmonary Disease, Chronic Obstructive|
62587898|NCT04466761|EXPERIMENTAL|Experimental: Cohort 1-4|60% of subjects per cohort will consume 30-90 grams of dietary supplement daily for 4 weeks, with each successive cohort dosage increasing according to a Fibonacci dose escalation.
62587899|NCT04466761|PLACEBO_COMPARATOR|Placebo: Cohort 1-4|40% of subjects per cohort will consume 30-90 grams of daily placebo for 4 weeks with each successive cohort dosage increasing in parallel to the experimental arm.
62587900|NCT06384976|EXPERIMENTAL|KYV-101 CAR-T cells with lymphodepletion conditioning|Dosing with KYV-101 CAR T cells
62587901|NCT06384976|ACTIVE_COMPARATOR|Anti- CD20 mAb|Dosing with anti-CD20 mAb
62797055|NCT06726538|NO_INTERVENTION|Control group (Group B)|25 participants in Group B will act as controls for 6 months.
62024703|NCT04191772|EXPERIMENTAL|HC - training goal 1|Healthy control (HC) persons with a 'poor VO2max', a 'fair VO2max' with no running experience and a 'good VO2max' with no running experience (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the first training group will be trained to run continuously for 45 minutes.
62024704|NCT04191772|EXPERIMENTAL|MS - training goal 2|PwMS with a 'fair VO2max' and running experience, a 'good VO2max and running experience', an 'excellent VO2max' and a 'superior VO2max' (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the second training group will be trained to run continuously for 75 minutes.
62221541|NCT01893931|PLACEBO_COMPARATOR|Satisfaction Survey|Within 1-3 days after ED discharge, patients will be called by a nurse to complete a brief satisfaction survey.
62221542|NCT01893931|ACTIVE_COMPARATOR|ED Discharge and Medication Call|Within 1-3 days after ED discharge, patients will receive a follow up phone call from a nurse to review discharge instructions, review medication instructions, and provide any necessary patient navigation.
62221543|NCT00196976|EXPERIMENTAL|GSK134612A Form1 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
62415867|NCT05657964||Gokhale ARM|Participants enrolled in the Gokhale Arm will be provided the Gokhale PostureTracker, a wearable posture monitoring sensor developed for interactive posture coaching, and a loaner smartphone with pre-installed App. Participants will be provided instruction to apply the sensor on their lumbar area and receive real-time visual feedback on their posture kinematic during the class. Participants can also perform normal daily activities while wearing the device. Data collected by the sensor will be sent to a HIPAA compliance server and shared with Stanford researchers.
62415868|NCT05657964||Physical Therapy ARM|Participants randomized into the standard care/physical therapy (PT) arm will similarly receive a standardized PT prescription during a 6-12 weeks period, meeting 1-2 times per week, to include posture education and training, therapeutic exercise instructions and development of an independent home exercise program.
62221544|NCT00196976|EXPERIMENTAL|GSK134612A Form2 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
62415869|NCT06651788|EXPERIMENTAL|Freeze spray group|Ethyl Chloride Usage Prior to Orthopaedic Injections
62415870|NCT06651788|PLACEBO_COMPARATOR|Placebo application of cold saline spray|Saline spray before injection
62415871|NCT06651788|NO_INTERVENTION|No spray prior to injection|No intervention before injection
62415872|NCT03079739||fractional flow reserve group|consecutive patients undergoing coronary artery angiography for established or suspected ischemic heart disease and receiving in at least one lesion FFR assessment
62415873|NCT05529641|EXPERIMENTAL|Combined diaphragmatic resistance training and cervical stabilization exercise group|Participants in this group will receive supervised cervical stabilization exercise and diaphragmatic resistance training as home grogram.
62415874|NCT05529641|ACTIVE_COMPARATOR|Cervical stabilization exercise group|Participants in this group will only receive supervised cervical stabilization exercise.
62415875|NCT06568835|EXPERIMENTAL|exercise group|"patients were asked to choose walking (no less than 8000 steps per day) or low-intensity aerobic exercise such as jogging, swimming, Tai Chi, etc., according to their own conditions, for no less than 30 minutes each time, at least 3 times per week, and the intensity of the exercise was determined by the need to increase the frequency and depth of breathing during the exercise, and it was appropriate to feel slightly tired but not exhausted (RPE score 12-16).~Exercise intensity should be at least 3 times a week, and the exercise intensity should be at a level that requires an increase in breathing rate and depth, allowing for dialogue and communication, slight sweating, and a feeling of being slightly tired but not exhausted (RPE score of 12 to 16)."
62415876|NCT06568835|NO_INTERVENTION|Control group|only receive conventional MHD treatment, no requirement for exercise.
62415877|NCT06138548|EXPERIMENTAL|Subchondral Insufficiency|Those who have subchondral insufficiency with tibial or femoral overload in the knee.
62415878|NCT05996601|EXPERIMENTAL|Intervention arm|All participants would undergo educational intervention by pharmacist.
62587902|NCT02320058|EXPERIMENTAL|Nivolumab and Ipilimumab|"Induction Phase: Nivolumab + Ipilimumab infusion intravenously~Maintenance Phase: Nivolumab infusion intravenously"
62587903|NCT06664944||Children 8-17 years old|Over 84% of children ages 8 and up have access to a mobile device (smartphone, tablet) and are active on social media. This study focuses on children ages 8-17 to better understand social media usage and how it relates to their mental well-being.
62024705|NCT04191772|EXPERIMENTAL|HC - training goal 2|HC with a 'fair VO2max' and running experience, a 'good VO2max and running experience', an 'excellent VO2max' and a 'superior VO2max' (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the second training group will be trained to run continuously for 75 minutes.
62024706|NCT04191772|NO_INTERVENTION|MS - sedentary control group|Twenty PwMS will receive no intervention, only usual care.
62024707|NCT04191772|NO_INTERVENTION|HC - sedentary control group|Twenty HC will receive no intervention, only usual care.
62024708|NCT02623673||bevacizumab plus dexamethasone 0.7mg|simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg
62221545|NCT00196976|EXPERIMENTAL|GSK134612A Form3 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
62797056|NCT05826067||patients with UTI or catheter (suprapubic, nephrostomy)|Patients with urinary tract infection caused by E. coli, with or without neurological disorders or patients that are planned to undergo the insertion of a suprapubic or nephrostomy catheter.
62797057|NCT05902598|EXPERIMENTAL|VSA001 25 mg|VSA001 25 mg every 3 months
62797058|NCT05902598|PLACEBO_COMPARATOR|VSA001 25 mg matching placebo|VSA001 25 mg matching placebo，every 3 months
62797059|NCT05902598|EXPERIMENTAL|VSA001 50 mg|VSA001 50 mg every 3 months
62797060|NCT05902598|PLACEBO_COMPARATOR|VSA001 50 mg matching placebo|VSA001 50 mg matching placebo，every 3 months
62797061|NCT05684068|EXPERIMENTAL|Gum Graft Placed on Denuded Bone|Subjects in this arm will have a free epithelialized gingival/mucosal graft (gum graft) placed on full thickness periosteal bed preparation where all of the tissue was removed (test group).
62797062|NCT05684068|ACTIVE_COMPARATOR|Gum Graft Placed on Split Thickness Periosteal Bed Preparation|Group B will have a free epithelialized gingival/mucosal graft (gum graft) on split thickness periosteal bed preparation where only a portion of the tissue was removed (control group).
62797063|NCT03896321|ACTIVE_COMPARATOR|Asprin|Patient will receive dual anti platelet asprin And clopidogrel
62797064|NCT03896321|ACTIVE_COMPARATOR|Clopidogrel|Patient will receive dual anti platelet asprin And clopidogrel
62797065|NCT03896321|ACTIVE_COMPARATOR|Warfarin|Patient will receive oral anticoagulation
62797066|NCT03896321|ACTIVE_COMPARATOR|Novel oral anticoagulant|Patient will receive oral anticoagulation
62797067|NCT06465433|EXPERIMENTAL|Tafasitamab Dose|Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.
62797068|NCT03784677|EXPERIMENTAL|Treatment (TRPV6 calcium channel inhibitor SOR-C13)|Patients receive TRPV6 calcium channel inhibitor SOR-C13 IV over 2 hours on days 1, 2, 8, 9, 15, 16, 22, and 23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62797069|NCT02509845|EXPERIMENTAL|Adolescent Safety Only Cohort|Prior to commencing enrollment of subjects 12-17 years of age in Study Arms 1 \& 2, a safety only cohort of 4 to 8 adolescent subjects will receive 4 administrations of C16G2 on Day 0.
62797070|NCT02509845|EXPERIMENTAL|Study Arm 1|Subjects will receive 2 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 1 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
62797071|NCT02509845|EXPERIMENTAL|Study Arm 2|Subjects will receive 4 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 2 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
62221546|NCT00196976|EXPERIMENTAL|GSK134612A Form4 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
62415879|NCT01906801|EXPERIMENTAL|Glucosamine sulfate & Diacerein|Glucosamine sulfate (sachet) 1500 mg and Diacerein 50 mg tablet by mouth once daily for 24 weeks
62415880|NCT01906801|ACTIVE_COMPARATOR|Glucosamine sulfate & Placebo|Glucosamine sulfate 1500 mg and Placebo (for Diacerein) 50 mg by mouth once daily for 24 weeks
62415881|NCT03586778|EXPERIMENTAL|MTEX-DN|dry needling, manual therapy, and therapeutic exercise
62415882|NCT03586778|ACTIVE_COMPARATOR|MTEX|manual therapy and therapeutic exercise
62024709|NCT01786694|EXPERIMENTAL|cma microdialysis catheter placement|At the end of the surgery the cma microdialysis catheter is placed near the anastomosis
62415883|NCT06700551|EXPERIMENTAL|Intervention group|In the intervention group, participants will receive interventions through the Zalo app on their mobile phones. Weekly, the investigator will send a topic for participants to learn about. Participants will have the opportunity to ask questions and share their feelings or experiences through the Zalo app.
62415884|NCT06700551|NO_INTERVENTION|Control group|Participants will receive usual care and will not receive any intervention
62433386|NCT04150783||Healthy Subjects|Existing data from healthy subjects with no prior symptoms of nasal obstruction used to create normative ranges for comparison to uCLND cohort.
62797072|NCT06577987|EXPERIMENTAL|Part 1 Dose Escalation and Part 2 Dose Expansion|
62797073|NCT05734755|EXPERIMENTAL|The COMB group|Participants in The COMB group will be grounded on the HAPA model and piloted by the team. It consists of three phases with 10 face-to-face hourly sessions nested with weekly telephone calls to enhance the participants' adherence to dietary behavioral change. And will be group-based, and offered weekly for about 60 minutes during the execution phase (a total 20 sessions from weeks 4-24). The combination of resistance and aerobic exercises can improve muscle quantity and strength as well as reduce body fat in people with sarcopenic obesity, and will be adopted in this study.
62797074|NCT05734755|EXPERIMENTAL|The EXER-only group|Participants in The EXER-only group will be group-based, and offered weekly for about 60 minutes during the execution phase (a total 20 sessions from weeks 4-24). The combination of resistance and aerobic exercises can improve muscle quantity and strength as well as reduce body fat in people with sarcopenic obesity, and will be adopted in this study.
62587904|NCT05160246|EXPERIMENTAL|taping group|Facilitation taping will be applied to the rectus femoris of patients with knee OA in the taping group.
62587905|NCT05160246|PLACEBO_COMPARATOR|placebo group|The patients with knee OA in the placebo group will be placed tape on the rectus femoris without any tension.
62415885|NCT05911763||Cohort A (Prophylactic treatment)|"All participants on efanesoctocog alfa prophylactic treatment fulfilling the overall study inclusion/exclusion criteria. The prophylactic cohort will include the following sub-cohorts:~Sub-cohort A1 (Joint imaging): Participants with severe hemophilia A and joint imaging by Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) or Joint Tissue Activity and Damage Exam (JADE) protocol performed within 6 months of initiating treatment with efanesoctocog alfa or within 3 months after initiating treatment with efanesoctocog alfa available.~Sub-cohort A2 (Children with no prior joint damage):Participants with severe hemophilia A who have no prior joint damage"
62221547|NCT00196976|ACTIVE_COMPARATOR|Control (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer's Meningitec™ conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
62587906|NCT05771324|EXPERIMENTAL|Baby-Led Weaning (BLW)|The group named for infants who received complementary feeding education with the BLW method and who were fed with the BLW method.
62587907|NCT05771324|EXPERIMENTAL|Traditional Complementary Feeding (TCF)|The group named for infants who received complementary nutrition education with the TCF method and who were fed with the TCF method.
62587908|NCT05287919|OTHER|Control group|Patients received the standard physical therapy (SPT) programme only (passive mobilization) twice a day.
62587909|NCT05287919|EXPERIMENTAL|Low-frequency NMES group|Patients submitted to low-frequency NMES and SPT twice a day.
62587910|NCT05287919|EXPERIMENTAL|Medium-frequency NMES group|Patients submitted to medium-frequency NMES and SPT twice a day.
62587911|NCT03190915|EXPERIMENTAL|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a bone marrow aspiration or biopsy at baseline, on day 28 of cycles 1 and 2, at all subsequent odd numbered cycles, and at end of treatment.
62587912|NCT05303766|EXPERIMENTAL|RFT group|The treatment of the patients in the radio frequency thermo-coagulation of the genicular nerves was conducted under the guidance of C-arm X-ray machine . The C-arm machine showed that the radiofrequency cannula needle was advanced percutaneously towards the periosteal areas connecting the shaft of the femur to bilateral epicondyles and the shaft of the tibia to the medial epicondyle while the lateral image showed that the depth of the needle insertion was about 50% of the diameter of the femur or tibia. The radiofrequency electrodes were connected and tested. These induced abnormal pain around the knee joint at 50 Hz and 0.1-0.3 V, but did not induce contraction of the muscles of the knee joint at 2 Hz and \> 2.0 V. The location of the needle tip was confirmed by the C-arm, and 0.5 mL of 1% lidocaine was used for local anesthesia. The temperature of RFT was increased gradually to 70°C for 180 seconds.
62587913|NCT05303766|EXPERIMENTAL|IAPRF group|The puncture site was selected in the middle of the medial or lateral edge of the patella. After local anesthesia was administered with 0.5% lidocaine, the radiofrequency cannula needle was inserted slowly between the patella and femoral condyles. The needle was gradually inserted into the joint cavity, and then a small volume of saline was administered using a syringe. If any resistance was encountered, which indicated that the needle tip was located in a ligament or tendon, the surgeon readjusted the needle tip until the injection proceeded without any significant resistance. After entering the joint cavity, the C-arm x-ray is used confirm that the cannula needle was located in the middle of the joint space. Subsequently, sensory stimulation using 50 Hz/2 Hz was performed at \> 2 V, to prevent inducing pain or muscle contraction. Then, an automatic PRF mode ≤ 45 V (≤ 42°C, 2 Hz, pulse width of 20 ms) was administered for 300 seconds.
62415886|NCT05911763||Cohort B (On-Demand treatment)|Participants receiving on-demand treatment with efanesoctocog alfa who fulfil the overall study inclusion/exclusion criteria
62587914|NCT05303766|EXPERIMENTAL|IAS group|The puncture procedure was similar to that for the IAPRF group. After the cannula needle was inserted to the articular cavity, 1 mL compound betamethasone (2 mg betamethasone sodium phosphate and 5 mg betamethasone dipropionate) was injected. Then, the needle was withdrawn, and the puncture site was dressed aseptically.
62587915|NCT06137742|EXPERIMENTAL|PF-07868489|single subcutaneous injection (Part A); 6 subcutaneous injections at regular intervals (Part B)
62587916|NCT06137742|PLACEBO_COMPARATOR|Placebo|single subcutaneous injection (Part A); 6 subcutaneous injections at regular intervals (Part B)
62797075|NCT05734755|EXPERIMENTAL|The IDBC-only group|Participants in The IDBC-only group will be grounded on the HAPA model and piloted by the team. It consists of three phases with 10 face-to-face hourly sessions nested with weekly telephone calls to enhance the participants' adherence to dietary behavioral change. And attend centre-based health talks about the management of different health issues with the exception of sarcopenic obesity.
62415887|NCT03890835|ACTIVE_COMPARATOR|Mineral Trioxide Aggregate (MTA)|
62415888|NCT03890835|EXPERIMENTAL|Biodentine|
62415889|NCT02204839|EXPERIMENTAL|Basal dose reduction|Total daily basal (Glargine, Lantus, Sanofi-Aventis, or Detemir, Levemir, Novo Nordisk) reduction of 20% versus normal basal dose.
62415890|NCT06703255|EXPERIMENTAL|Patients received HX301/+Temozolomide treatment at assigned dose level on a 4 weeks basis|
62415891|NCT03791255|EXPERIMENTAL|Resin Modified Calcium Silicate|light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
62415892|NCT03791255|ACTIVE_COMPARATOR|Light Cured Calcium Hydroxide|gold standard for pulp capping, It allows for the formation of a reparative dentine bridge through cellular differentiation, extracellular matrix secretion and subsequent mineralization.
62797076|NCT05734755|NO_INTERVENTION|The Control Group|Participants in The Control Group will attend centre-based health talks about the management of different health issues with the exception of sarcopenic obesity. As the purpose of the health talk is to control the group interactive effect in exercise training, the group size, and the frequency and the time of the health talks will be similar to those offered in the exercise programme for the COMB and EXER-only groups.
62024710|NCT02665000|EXPERIMENTAL|Study arm: Structured training programme|"The participants in study arm will undergo 5 days training program in laparoscopic appendectomy using the Box and Wet Trainer as intervention. Each training session will take up to 2 hours. The participant will then be exposed to the standard training in current practice over 5 supervised cases of laparoscopic appendectomy.~After the above training, they will be required to perform another 5 cases of laparoscopic appendectomy as performing surgeon under supervision by a trained surgeon. The operation will be recorded and graded based on a validated GOALS scoring system 6. The Primary Outcome will be the difference of the GOALS results between the 2 groups. Secondary outcomes will include OSAT score, patient outcome, residents' feedback score as well as conversion rates to open surgery."
62024711|NCT02665000|NO_INTERVENTION|Control arm: non-training|"Participant in study arm will not receive any additional training during the training week. The participant will then be exposed to the standard training in current practice over 5 supervised cases of laparoscopic appendectomy.~They will be required to perform another 5 cases of laparoscopic appendectomy as performing surgeon under supervision by a trained surgeon. The operation will be recorded and then graded based on a validated GOALS scoring system 6"
62024712|NCT04972500|EXPERIMENTAL|Pre-op|Nutricia Pre-op, 400 milliliters, per os
62024713|NCT04972500|NO_INTERVENTION|Control|No intervention
62024714|NCT05190081|EXPERIMENTAL|single-task training group|Tasks were completed separately in the single-task training group
62024715|NCT05190081|EXPERIMENTAL|dual-task training group|Tasks were completed at the same time in the dual-task training group
62024716|NCT05190081|NO_INTERVENTION|control group|No intervention was performed in the control group
62024717|NCT05897593|EXPERIMENTAL|Augmented Reality Delivered Therapy + Standard Clinical Care|The GlenXRose augmented reality therapies will be delivered to participants using a head-mounted device to allow acquired brain injury rehabilitation therapy and practice. Participants will also receive routine clinical care provided by clinicians.
62221548|NCT00196976|EXPERIMENTAL|GSK134612A Form1 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
62221549|NCT00196976|EXPERIMENTAL|GSK134612A Form2 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
62221550|NCT00196976|EXPERIMENTAL|GSK134612A Form3 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
62221551|NCT00196976|EXPERIMENTAL|GSK134612A Form4 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
62415893|NCT04889794|EXPERIMENTAL|Exposed FMGs to GPS intervention|Patients who are followed by FMGs exposed to the GPS intervention. They will receive the GPS intervention.
62415894|NCT04889794|NO_INTERVENTION|Non exposed FMGs to GPS intervention|Patients who are part of the FMGs not exposed to the GPS intervention. They will receive the usual care and services.
62797077|NCT02538601|EXPERIMENTAL|CBT-A|An 8-session, CBT-based group smoking cessation program (CBT-A) enhanced with transdiagnostic skills for the management of anxiety and fear-based avoidance behaviors.
62797078|NCT02538601|ACTIVE_COMPARATOR|CBT-S|An 8-session, CBT-based, traditional group CBT based smoking cessation program.
62221552|NCT00196976|ACTIVE_COMPARATOR|Control (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).
62415895|NCT02980029|EXPERIMENTAL|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme.
62415896|NCT02980029|PLACEBO_COMPARATOR|Placebo|Placebo
62415897|NCT05167396|EXPERIMENTAL|Healthy Controls (HC)|n=90
62415898|NCT05167396|EXPERIMENTAL|Clinical High Risk of Psychosis (CHRP)|n=30
62797079|NCT06725173||Patients with presumed germline retinoblastoma due to RB1 mutation|
62797080|NCT00700713|EXPERIMENTAL|One-Dose Menactra Group|Participants received one dose of Menactra® in Study MTA26
62797081|NCT00700713|EXPERIMENTAL|Two-Dose Menactra Group|Participants received two doses of Menactra® in Study MTA26
62797082|NCT00700713|ACTIVE_COMPARATOR|Menactra vaccine-naïve Group|Participants had never received Menactra® vaccine.
62797083|NCT01647841||Pregnant women and infants|HIV+ and HIV- pregnant women, HIV-exposed and HIV-unexposed infants, ARV-exposed and ARV-unexposed infants
62797084|NCT01255891|OTHER|Adjuvant|Adjuvant suppression plus radiation therapy
62415899|NCT05167396|EXPERIMENTAL|First Episode Psychosis (FEP)|n=30
62433387|NCT05649631|EXPERIMENTAL|Normal sodium diet(100mmol/d)|
62797085|NCT03986203|EXPERIMENTAL|Active|Subjects in this group will receive the active treatment for each daily treatment session.
62024718|NCT05897593|NO_INTERVENTION|Standard Clinical Care|Participants will receive routine clinical care provided by clinicians.
62797086|NCT03986203|SHAM_COMPARATOR|Sham|Subjects in this group will receive the sham treatment for each daily treatment session.
62024719|NCT01528228|ACTIVE_COMPARATOR|Structured TENS Therapy|This group will be given an active TENS unit to use.
62024720|NCT01528228|SHAM_COMPARATOR|Sham TENS Therapy|This group will receive a placebo TENS unit which has been functionally disabled to provide a short initial electrical impulse then cease delivering that impulse.
62024721|NCT01615029|EXPERIMENTAL|Daratumumab|Participants will receive daratumumab along with Lenalidomide and dexamethasone.
62415900|NCT06353113|EXPERIMENTAL|Down Dog Prenatal Yoga App|Prenatal yoga via Down Dog Prenatal Yoga Mobile App 20 minutes a day, 3 days per week, for 12 weeks.
62415901|NCT06063291|EXPERIMENTAL|Cohort 1|Cohort 1 will consist of 8 healthy subjects who will be randomised to receive a single oral dose of ID110521156 of placebo.
62415902|NCT06063291|EXPERIMENTAL|Cohort 2|Cohort 2 will consist of 8 healthy subjects who will be randomised to receive a single oral dose of ID110521156 of placebo.
62415903|NCT06063291|EXPERIMENTAL|Cohort 3|Cohort 3 will consist of 8 healthy subjects who will be randomised to receive a single oral dose of ID110521156 of placebo.
62415904|NCT06063291|EXPERIMENTAL|Cohort 4|Cohort 4 will consist of 12 healthy subjects who will receive a single oral dose of ID110521156 at fed state and fasted state each.
62415905|NCT05643625|EXPERIMENTAL|Pilates exercise and myofascial release group|In this study, pilates exercise and myofascial release technique will be applied for 8 weeks, 2 days a week. Participants will be evaluated at the beginning of the study, at the end of the first session and after 8 weeks.
62415906|NCT05643625|ACTIVE_COMPARATOR|Pilates Exercise|In this study, pilates exercise will be applied for 8 weeks, 2 days a week. Participants will be evaluated at the beginning of the study, at the end of the first session and after 8 weeks.
62415907|NCT05198349|EXPERIMENTAL|M1069|
62415908|NCT06702228||Familial pulmonary fibrosis group|Patients meeting the study inclusion criteria with an multidisciplinary team (MDT) diagnosis of a fibrotic interstitial lung disease, reporting one or more relatives with a fibrotic form of ILD
62415909|NCT06702228||Idiopathic pulmonary fibrosis group|Patients meeting the study inclusion criteria with an MDT diagnosis of IPF in accordance with consensus criteria, ATS, ERS, JRS, ALAT guidelines, without a family history of pulmonary fibrosis.
62415910|NCT06702228||Connective tissue disease related interstitial lung disease group|Patients meeting the study inclusion criteria who meet the American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis, scleroderma, Sjogren's syndrome, idiopathic inflammatory myopathy and systemic lupus erythematosus criteria
62415911|NCT06429033|EXPERIMENTAL|Treatment Group|A single dose of PEP (Purified Exosome Product) in Lactated Ringers at doses of 1 vial (75 mg) (Low Dose/Cohort 1) or 2 vials (150 mg) (Target Dose/Cohort 2) will be injected intradermally into the hypodermis of a 5 cm by 10 cm section of abdomen (to the right of the umbilicus) that is planned for removal during abdominoplasty surgery. The solution will be injected into the hypodermis in retrograde linear threads.
62415912|NCT06569160|OTHER|Active then sham|There are 2 follow-up periods in cross-over. The clusters will be with active UVGI devices during one period and with sham UV-filtered devices during the other.
62415913|NCT06569160|OTHER|Sham then active|There are 2 follow-up periods in cross-over. The clusters will be with active UVGI devices during one period and with sham UV-filtered devices during the other.
62024722|NCT06669637||Patients undergoing AF Ablation using TactiFlex catheter|patients undergoing de novo or redo AF ablation procedures using TactiFlex ablation catheter following patients up to 6 to 12 months follow up.
62024723|NCT05792553|EXPERIMENTAL|group I: bonded tongue tamers|25 cases with anterior open bite will be treated using bonded tongue tamers
62024724|NCT05792553|EXPERIMENTAL|group II: customized bonded spurs|25 cases with anterior open bite will be treated using customized bonded spurs
62415914|NCT06426186|EXPERIMENTAL|Right-stellate ganglion block|Right-stellate ganglion block was given 30 minutes before anesthesia induction
62415915|NCT06426186|NO_INTERVENTION|Blank control group|No treatment was given 30 minutes before anesthesia induction
62415916|NCT05632757|EXPERIMENTAL|Psychological assessments|
62415917|NCT00424632|EXPERIMENTAL|Single arm dose escalation|
62415918|NCT06700642|ACTIVE_COMPARATOR|Research Arm|Individuals in this arm were given individual education on rational drug use by the researcher at the first visit. 'Individual Training Presentation on Rational Drug Use' consisting of visual and written content was used for patient education intervention. After the education, 'Rational Drug Use Patient Brochure' was given to all participants in this arm.
62415919|NCT06700642|NO_INTERVENTION|Control Arm|No educational intervention was made in the control arm and no brochure was given at the first visit. In line with the principle of equality, participants in this arm were given a patient brochure at the end of the study.
62415920|NCT02618252|EXPERIMENTAL|Zonare|108 patients are randomized to receive the intervention of using ultrasound machine (Zonare ZS3 machine) for IV cannulation. These patients will first undergo IV cannulation with assistance of the ultrasound machine.
62415921|NCT02618252|EXPERIMENTAL|Veinviewer|108 Patients are randomized to receive the Intervention of using the Veinviewer Flex machine for IV cannulation. These patients will first undergo IV cannulation with assistance of the Veinviewer Flex machine.
62415922|NCT02525627|ACTIVE_COMPARATOR|Trident cup, X3 inserts, 28 mm head|Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
62415923|NCT02525627|ACTIVE_COMPARATOR|Trident cup, X3 inserts, 40 mm head|Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
62433388|NCT05649631|EXPERIMENTAL|Low sodium diet(50mmol/d)|
62024725|NCT05792553|ACTIVE_COMPARATOR|group III: conventional fixed palatal spurs|25 cases with anterior open bite will be treated using conventional fixed palatal spurs
62797087|NCT05050097|EXPERIMENTAL|Treatment Regimen A: Talquetamab + Carfilzomib|Participants assigned to Treatment regimen A will receive talquetamab subcutaneously (SC) in combination with carfilzomib as an intravenous (IV) infusion.
62024726|NCT05441930|EXPERIMENTAL|Levofloxacin Ocular Implant|Biphasic levofloxacin antibiotic implant
62024727|NCT05441930|ACTIVE_COMPARATOR|Control|Commercially available topical medications as per LEVO-CS102 Surgical Therapy Procedure.
62024728|NCT02393313|EXPERIMENTAL|Cataract surgery toric intraocular lens|Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
62024729|NCT03888573|ACTIVE_COMPARATOR|Stretch|Patients within Stretch Group will receive stretching protocols to the cervical musculature at the side of symptoms.
62024730|NCT03888573|ACTIVE_COMPARATOR|Traction|Patients within Traction Group will be treated with traction from 15-degree flexion, 30-degree lateral bending, and 15-degree rotation toward the painful side.
62221553|NCT00196976|EXPERIMENTAL|GSK134612A Form1 (T), Booster Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).
62221554|NCT00196976|ACTIVE_COMPARATOR|Control (T), Booster Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer's Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).
62221555|NCT00196976|EXPERIMENTAL|GSK134612A Form1 (C), Booster Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.
62433389|NCT05489679|EXPERIMENTAL|AC682|This arm will evaluate AC682 monotherapy administered in 28-day cycles. The participants will participate in this dose escalation arm.
62797088|NCT05050097|EXPERIMENTAL|Treatment Regimen B: Talquetamab + Daratumumab + Carfilzomib|Participants assigned to Treatment regimen B will receive talquetamab SC in combination with daratumumab SC and carfilzomib as an IV infusion.
62024731|NCT05043337|EXPERIMENTAL|Maternal voice|Recording the maternal voice in reading children's books, and recorded the sound for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group was explored maternal voice, which starts from 3 minutes before the procedure and ends ten minutes after the heel puncture.
62797089|NCT05050097|EXPERIMENTAL|Treatment Regimen C: Talquetamab + Lenalidomide|Participants assigned to Treatment regimen C will receive talquetamab SC in combination with lenalidomide orally.
62024732|NCT05043337|EXPERIMENTAL|Lullaby|The Brahms Lullaby recordings are compiled for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group was explored Brahms Lullaby, which starts from 3 minutes before the procedure and ends ten minutes after the heel puncture.
62024733|NCT05043337|EXPERIMENTAL|Maternal voice combined with lullaby|Recording the maternal voice in reading children's books and giving mother listening to the lullaby at the same time, and recorded the sound for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group was explored Maternal voice combined with Brahms lullaby, which starts from 3 minutes before the procedure and ends ten minutes after the heel puncture.
62024734|NCT05043337|NO_INTERVENTION|Control group|When the premature infants undergoing heel lance procedure , the control group was under routine care . Measuring with the Respiration , heart rate , oxygen saturation , and neonatal infant pain scale (NIPS ) were recorded 3 minutes before , during , 1st , 3rd , and 10th minutes after the heel lance puncture .
62024735|NCT01673633||SSc|Sacroiliitis
62221556|NCT00196976|ACTIVE_COMPARATOR|Control (C), Booster Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer's Meningitec™ conjugate vaccine, did not receive any booster vaccination.
62221557|NCT05977504|EXPERIMENTAL|Multi-Psychological Empowerment Courses|9 times online course and 3-days workshop for 6 months .
62415924|NCT04751435|EXPERIMENTAL|Breast,Ovarian, Prostate & Pancreatic Cancer|"There is no treatment or intervention for Phase 1 of this study. Participants will be asked to participate in a cognitive interview.~This section will be amended to include the Phase 2 intervention information once the Phase 1 portion of the study is complete. The Phase 1 materials developed, and results obtained, will directly be part of and inform the intervention for Phase 2.Phase 2: Following completion of Assessment #1, participants will be randomized to the standard-of-care arm or the LCAM intervention arm."
62415925|NCT02255773|OTHER|High-Fatigue Head and Neck (HNC) Cancer Survivors|Participants undergo assessment with three validated computerized tasks designed to measure the neurobehavioral domains of interest: the Effort Expenditure for Rewards Task (EEfRT), an associative learning task, and a set-switch task. Participants complete questionnaires assessing mood, somatic symptoms, and sleep quality, including the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), the Checklist Individual Strength (CIS), and others. A 10-mL blood sample drawn for assessment of inflammatory markers and COMT and DAT1 genotype.
62415926|NCT02255773|OTHER|Low-Fatigue Head and Neck (HNC) Cancer Survivors|Participants undergo assessment with three validated computerized tasks designed to measure the neurobehavioral domains of interest: the Effort Expenditure for Rewards Task (EEfRT), an associative learning task, and a set-switch task. Participants complete questionnaires assessing mood, somatic symptoms, and sleep quality, including the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), the Checklist Individual Strength (CIS), and others. A 10-mL blood sample drawn for assessment of inflammatory markers and COMT and DAT1 genotype.
62415927|NCT05794386|NO_INTERVENTION|PVI only group|Patients will receive PVI alone regardless of LVA burden.
62415928|NCT05794386|EXPERIMENTAL|Additional LA substrate modification group|Patients will receive PVI plus additional LA substrate modification according to their LVA burden.
62415929|NCT04934969|EXPERIMENTAL|Use of lavender and peppermint essential oils pre and post|passive inhalation of either peppermint and lavender essential oil with pre and post test measure
62415930|NCT05031286|EXPERIMENTAL|Experimental Arm|
62415931|NCT05484622|EXPERIMENTAL|Safety Lead-In Phase: Vorasidenib + Pembrolizumab|Participants will receive vorasidenib orally, once daily (QD) in combination with pembrolizumab 200 mg intravenous (IV) infusion, once every 3 weeks (Q3W) in each 21-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
62415932|NCT05484622|EXPERIMENTAL|Randomized Perioperative Phase: Vorasidenib + Pembrolizumab|Participants will receive vorasidenib recommended combination dose (RCD) determined in the Safety Lead-in phase, orally, QD from Day 1 to 28 in combination with pembrolizumab 200 mg IV infusion, Q3W on Days 1 and 22 of a 28-day cycle prior to surgery.
62415933|NCT05484622|EXPERIMENTAL|Randomized Perioperative Phase: Vorasidenib Only|Participants will receive vorasidenib orally, QD from Day 1 to 28 of a 28-day cycle prior to surgery.
62415934|NCT05484622|NO_INTERVENTION|Randomized Perioperative Phase: Untreated Control Group|Participants will not receive any treatment prior to surgery.
62415935|NCT03847532|OTHER|Patients with mutations in the MutYH-gene|Patients with established diagnosis of MutYH-associated polyposis with monoallelic and biallelic mutations in the MutYH-gene
62415936|NCT03847532|OTHER|Patients with multiple colon polyps|Number of polyps from 4+
62415937|NCT03847532|OTHER|Control sample|Patients who did not have colon polyps
62415938|NCT02277548|EXPERIMENTAL|Lyrica at 300 mg per day|
62415939|NCT02277548|PLACEBO_COMPARATOR|Placebo|
62415940|NCT05564494|ACTIVE_COMPARATOR|Bankart Repair|Arthroscopic Bankart repair procedures will be performed according to each individual surgeon's usual technique. Procedures will be performed with the patient in the lateral or beach-chair position. Repairs for associated or conjoined superior labral anterior-to-posterior (SLAP) tears will be documented and performed at the surgeon's discretion. Labral detachments will be repaired with the use of suture-anchor fixation and arthroscopic tying techniques. Either two or three suture anchors will be used. Capsular redundancy will be addressed with arthroscopic suture plication at the surgeon's discretion. Surgeons will mobilize the capsulolabral tissue as deemed necessary. Surgical time and video of the operation will be recorded, and photographs will be taken documenting any bone loss.
62024736|NCT01673633||Rheumatoid arthritis|Sacroiliitis
62024737|NCT01673633||Healthy controls|Sacroiliitis
62024738|NCT01323699|EXPERIMENTAL|Behavioral Therapy|
62221558|NCT05977504|NO_INTERVENTION|Control group|Participants in control group will receive usual course.
62221559|NCT05893628||study group|
62221560|NCT00641329|EXPERIMENTAL|1|
62221561|NCT00641329|PLACEBO_COMPARATOR|2|
62587917|NCT06180486|OTHER|Waitlist control: Receive MMI After 90 days|The waitlist control group will allow for comparison of those who had access to the mindfulness meditation intervention (MMI) prior to surgery to those who did not. This group will be given the mindfulness meditation intervention 90 days after their surgery when all study questionnaires are complete. Up until 90-days, they will be asked the same questionnaires as the intervention group aside from the MMI practice survey and the exit survey. They will then be given the exit survey 2 weeks after receiving the MMI. This is done to ensure that both groups receive the potential benefit of the teachings and to deter patient dropout for those interested in the study because of wanting to receive the mindfulness training.
62797090|NCT05050097|EXPERIMENTAL|Treatment Regimen D: Talquetamab + Daratumumab + Lenalidomide|Participants assigned to Treatment regimen D will receive talquetamab SC in combination with daratumumab SC and lenalidomide orally.
62797091|NCT05050097|EXPERIMENTAL|Treatment Regimen E: Talquetamab + Pomalidomide|Participants assigned to Treatment regimen E will receive talquetamab SC in combination with pomalidomide orally.
62797092|NCT05173883|EXPERIMENTAL|A cohort of CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml of CU-20401, 6 injections，0.04mg/ml（A1)，0.075mg/ml(A2)，0.15mg/ml(A3)
62797093|NCT05173883|EXPERIMENTAL|B cohort of CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml of CU-20401, 12 injections，0.075mg/ml（B1)，0.10mg/ml(B2)
62797094|NCT05173883|EXPERIMENTAL|C cohort and D cohort of CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml of CU-20401, 24 injections，0.075mg/ml（C1)，0.10mg/ml(C2)，0.12mg/ml(D2),
62797095|NCT05173883|PLACEBO_COMPARATOR|A cohort of placebo|Subcutaneous injection in the subcutaneous fat area，0.2ml of placebo, 1 injections，0.04mg/ml（A1)，0.075mg/ml(A2)，0.15mg/ml(A3)
62415941|NCT05564494|EXPERIMENTAL|Anatomic Glenoid Reconstruction|The surgical technique was the lateral decubitus all-arthroscopic anatomic glenoid reconstruction procedure for treatment of anterior shoulder instability as described by Wong et al. (2015). The procedure is done in a semi-lateral decubitus position that assists with optimal graft placement on the native glenoid. The investigators utilize the cannulated Bristow-Latarjet Instability Shoulder System (Depuy-Mitek, MA, USA). The surgical technique is identical to that of arthroscopic Bankart repair with one additional step. Prior to insertion of anchors, one additional medal portal is created for insertion of the bone graft. The distal tibia allograft is prepared; the cannulated guide is attached and advanced through the rotator interval and secured with two cannulated screws. Finally, the Bankart repair is performed above the graft. Surgical time and video of the operation will be recorded, and photographs will be taken documenting any bone loss.
62415942|NCT01661153||Cohort|
62415943|NCT05388201||FACEFIT|Participants will enter a chamber where they will undergo 3D facial scanning using a dedicated camera system and be trained to don a N95 respirator properly. The fitted filtering efficiency (FFE) of 4 types of face coverings: a N95 respirator, a KN95 respirator (with and without a clip), a surgical mask (with and without a clip), and a KF94 respirator (with and without a clip) will be tested using the OSHA quantitative fit testing protocol for filtering face pieces. Participants will measure their peak expiratory flow pre and post mask fit testing using a disposable peak flow meter.
62415944|NCT04613310|OTHER|Saliva and nasopharyngeal swabs|One patient will have 4 swabs taken, 2 saliva for PCR and RDT, 2 nasopharyngeal for PCR and RDT
62415945|NCT03899545|EXPERIMENTAL|Serratus Plane Block|Serratus plane block will be applied after induction of general anesthesia.
62415946|NCT03899545|ACTIVE_COMPARATOR|Serratus Plane Block plus Pectoral I block|Serratus plane plus pectoral I block will be applied after induction of general anesthesia.
62797096|NCT05173883|PLACEBO_COMPARATOR|B cohort of placebo|Subcutaneous injection in the subcutaneous fat area，0.2ml of placebo, 1 injections，0.075mg/ml（B1)，0.10mg/ml(B2)
62797097|NCT04520971|EXPERIMENTAL|780G closed-loop|780 closed-loop insulin delivery system
62797098|NCT04520971|ACTIVE_COMPARATOR|standard of care|standard of care treatment (continue with current treatment of insulin pump without closed-loop or multiple daily insulin injections).
62797099|NCT00570310|ACTIVE_COMPARATOR|A|Patients in Group A will remain on pregabalin (up to 600 mg/day po) treatment for the entire double-blind period.
62797100|NCT00570310|PLACEBO_COMPARATOR|B|Patients in Group B will be treated with placebo.
62797101|NCT05065788||2020 Lockdown period|Patients who access to Ophthalmological emergency service during lockdown period in 2020
62797102|NCT05065788||2019|Patients who access to Ophthalmological emergency service in 2019 definite periods
62797103|NCT01232322||Pulmicort Respules|Those with an exposure
62587918|NCT06180486|EXPERIMENTAL|Intervention: Receive MMI before their day of surgery|The intervention group will be given the mindfulness meditation intervention (MMI) 1 week prior to their day of surgery. Up until 90-days, they will be asked the same questionnaires as the waitlist control group, with the addition of the MMI practice survey and the exit survey.
62024739|NCT00512135|EXPERIMENTAL|IncobotulinumtoxinA (Xeomin) (20 units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
62024740|NCT06069492|ACTIVE_COMPARATOR|Standard-dose group|Consumes one serving containing 38 grams wheat pasta daily for 6 days every week
62024741|NCT06069492|ACTIVE_COMPARATOR|Low-dose group|Consumes one serving containing 5 grams wheat pasta and 33 grams gluten-free pasta daily for 6 days every week
62024742|NCT04396886|EXPERIMENTAL|Bintrafusp Alfa|Single group assignment of bintrafusp alfa in previously treated patients with recurrent and metastatic (R/M) nonkeratinizing nasopharyngeal carcinoma (NPC)
62415947|NCT03747939|EXPERIMENTAL|Apremilast 30 mg twice daily ± NSAIDs, ≤ 1 csDMARD|Subjects will take ORAL tables of apremilast for up to 48 weeks (30 mg twice daily). Subjects may also receive stable doses of background therapy (standard or care) with NSAIDs, glucorticosteroids and 1 csDMARD as permitted by protocol. After wk. 24, subjects may change the dose /type of permitted Psoriatic Arthritis medications
62587919|NCT04423770||U.S. dentists|Dentists in the United States
62587920|NCT04495985||Thyrogen (rh-TSH)|Group 1: Female patients prepared for radioactive iodine treatment by rh-TSH (Thyrogen)
62587921|NCT04495985||Withdrawal from thyroid hormone|Group 2: Female patients prepared for radioactive iodine treatment by withdrawal from thyroid hormones
62587922|NCT01181713||No Antibiotic|No prophylactic antibiotic post intravitreal injection
62024743|NCT02837744||Axiostat®|Size: 3.5 cm X 3.5 cm
62024744|NCT04993690|EXPERIMENTAL|Phase I Dose Escalation|Dose Escalation and determination of MTD; multiple dose levels of LP-168 to be evaluated
62024745|NCT04993690|EXPERIMENTAL|Phase I Dose Expansion A|CLL/SLL patients treated with prior regimens.
62024746|NCT04993690|EXPERIMENTAL|Phase I Dose Expansion B|CLL/SLL patients with no prior therapy.
62024747|NCT04993690|EXPERIMENTAL|Phase I Dose Expansion C|MCL patients treated with prior regimens.
62024748|NCT04993690|EXPERIMENTAL|Phase I Dose Expansion D|WM patients treated with prior regimens.
62024749|NCT04993690|EXPERIMENTAL|Phase I Dose Expansion E|MZL patients treated with prior regimens.
62587923|NCT01181713||Prophylactic Antibiotic|Group treated with 3 day course of prophylactic topic antibiotic, fourth generation fluoroquinolones, after each intravitreal injection
62587924|NCT01037595|EXPERIMENTAL|turmeric|turmeric 500 mg tid orally for 8 weeks
62797104|NCT01598909|ACTIVE_COMPARATOR|Arnica ointment|
62797105|NCT01598909|PLACEBO_COMPARATOR|Placebo ointment|
62797106|NCT01598909|NO_INTERVENTION|Control|
62797107|NCT05549830|EXPERIMENTAL|Intervention Group|"During the night before surgery and for the first 36 hours after surgery, the participants assigned to the intervention group will be placed in positions different from surgical positions.~After surgery the patient will be placed in a different position compared to during surgery, with repositioning being undertaken every two hours until the first 36th postoperative hour, and the development of pressure injuries will be evaluated at the 36th hour. If no pressure injury has developed in this period, the patient will be placed in the surgical position for a duration that will not exceed 30 minutes, and then repositioning will be applied at two-hour intervals. If pressure injuries have developed, different repositioning techniques will continue to be applied at two-hour intervals."
62024750|NCT00023829|EXPERIMENTAL|LH-RH agonist plus radiation therapy|Luteinizing hormone-releasing hormone (LH-RH) agonist x 2 years plus radiation therapy (RT) to 63.0 - 66.6 Gy
62024751|NCT00023829|ACTIVE_COMPARATOR|Radiation therapy alone|Radiation therapy alone to 63.0 - 66.6 Gy
62024752|NCT00023829|ACTIVE_COMPARATOR|LH-RH agonist alone|Luteinizing hormone-releasing hormone (LH-RH) agonist x 2 years
62587925|NCT01037595|PLACEBO_COMPARATOR|plasebo|placebo tid orally for 8 weeks
62587926|NCT00683124|EXPERIMENTAL|Losartan|Losartan administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 100 mg/day for adults and 1,6 mg/kg/die for children minor than 16 years.
62024753|NCT00150631|PLACEBO_COMPARATOR|active (candesartan)|12 mo treatment with candesartan
62024754|NCT00150631|PLACEBO_COMPARATOR|placebo|12 mo placebo treatment
62024755|NCT00738842|EXPERIMENTAL|1|
62024756|NCT00738842|PLACEBO_COMPARATOR|2|
62024757|NCT03197792|EXPERIMENTAL|Pulmonary endarterectomy patients|All patients
62024758|NCT04671862|EXPERIMENTAL|Photobiomodulation|"Parameters: combined 633nm and 870 nm @1000mW~* 1 Treatment pre radiotherapy~* 3 treatments weekly during radiotherapy"
62221562|NCT01074216|EXPERIMENTAL|vitamin D, vitamin D3|This is a Phase II study involving Stage IV colorectal cancer patients with serum vitamin D deficiency, to determine the ability to correct vitamin D deficiency and to maintain serum vitamin D levels (25-hydroxy vitamin D) once achieved.
62587927|NCT00683124|EXPERIMENTAL|Nebivolol|Nebivolol administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 10 mg/day for adults and 0,16 mg/kg/die for children minor than 16 years.
62587928|NCT00683124|EXPERIMENTAL|Losartan+Nebivolol|"Losartan administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 100 mg/day for adults and 1,6 mg/kg/die for children minor than 16 years.~Nebivolol administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 10 mg/day for adults and 0,16 mg/kg/die for children minor than 16 years."
62587929|NCT06666907|EXPERIMENTAL|AI smile design|Artificial intelligence digital smile designing software
62587930|NCT06666907|ACTIVE_COMPARATOR|Conventional smile design|Digital smile design software
62797108|NCT05549830|NO_INTERVENTION|Control Group|The control group will only receive routine care. The positions of the patients in this group will be monitored and recorded at two-hour intervals.
62024759|NCT03661853|ACTIVE_COMPARATOR|Control|This microintervention is intended to control for the effect of nonspecific therapy factors such as therapeutic alliance, time spent with a therapist, talking about alcohol, and/or effects related to assessment reactivity, and consists of 60 minutes of psycho-education on alcohol and drugs. The therapist will talk about historical and scientific information on different types of alcohol and drugs and will not overlap with CBT treatment. The participants will not be encouraged to personalize this information, make any behavioral changes, or do homework. The control does not have any active interventions that would specifically target or affect our outcome variables.
62221563|NCT00605215|PLACEBO_COMPARATOR|Placebo|Participants will receive 1 capsule of placebo matching to laquinimod orally once daily for 24 months.
62415948|NCT03747939|PLACEBO_COMPARATOR|Placebo|Subjects will take placebo for up to 24 weeks (twice daily). Subjects may also receive stable doses of background therapy ( standard of care) with NSAIDs, glucocorticosteroids and 1 csDMARD as permitted by protocol. After wk 24, subjects may change the dose /type of permitted PsA medications.
62415949|NCT05853237|EXPERIMENTAL|class IV group|start from day one surgery for 4 successive weeks, the goal in the phase I (1st 10 days after surgery) is decontamination, improve circulation, pain reduction \&wound healing acceleration The goal of phase II (next10 days till complete healing) is improve osteo-integration, pain reduction \& enhance superficial collagen production to decrease scarring. The parameters are: Power \> 500 mW; fluence 20 joule/ cm2 with (980, 915, 810 nm) and 5 joules/ cm2 by 650 nm; mode (continuous); hand piece radius = 2.5 cm; spot size (Area) = 5 cm; application by scanning not spotting to avoid thermal effect and time of session is 5- 10 minutes
62797109|NCT05120362|EXPERIMENTAL|Cream containing JAK Inhibitor|
62797110|NCT00970437|ACTIVE_COMPARATOR|CBASP|CBASP as the experimental intervention will follow a manual (McCullough, 2000; German version: Schramm et al., 2006). The approach is specifically tailored for the treatment of chronic forms of depression, particularly with early-onset by focusing on the problems resulting from an inhibition of maturation in early childhood and by using the therapeutic relationship in a personal, disciplined way as well as other specific techniques (e.g. Interpersonal Discrimination Exercise, Situation Analysis). CBASP integrates behavioural, cognitive, and interpersonal strategies.
62221564|NCT00605215|EXPERIMENTAL|Laquinimod|Participants will receive 1 capsule of laquinimod 0.6 mg orally once daily for 24 months.
62221565|NCT00605215|ACTIVE_COMPARATOR|Avonex®|Participants will receive an injection of Avonex® 30 micrograms (mcg) given intramuscularly (IM) once weekly for 24 months.
62221566|NCT05357430|EXPERIMENTAL|group D1(obese patient)|Administration of 0.3μg/kg of remifentanil in advance, then corresponding dose of remimazolam, according to the experimental results of the previous patient.
62415950|NCT05853237|EXPERIMENTAL|class IIIb|Use the same protocol as in HLLT with the same wave lengths but with low power Power = 200- 300 mW; fluence 20 joule/ cm2 with (980, 915, 810 nm) and 5 joules/ cm2 by 650 nm; mode (continuous); hand piece radius = 2.5 cm; spot size (Area) = 5 cm; application by spotting and time of session was 25- 30 minutes.
62415951|NCT05853237|ACTIVE_COMPARATOR|traditional wound care|According to the hospital protocol Irrigation of the wound by normal saline, betadine application, bivatracin spray and Change dressing daily to protect the wound from infection
62415952|NCT05894382|EXPERIMENTAL|Group A|Double Helix Design Defocus Lens Spectacle (RACE) for 2 years
62221567|NCT05357430|EXPERIMENTAL|group D2(non-obese patient)|Administration of 0.3μg/kg of remifentanil in advance, then corresponding dose of remimazolam, according to the experimental results of the previous patient.
62221568|NCT05357430|EXPERIMENTAL|group R|Administration of 0.3μg/kg of remifentanil in advance, then the calculated dose of remimazolam, according to calculated results from group D1 and D2
62221569|NCT05357430|EXPERIMENTAL|group C|Administration of 0.3μg/kg of remifentanil in advance, then 1.5-2mg/kg propofol.
62221570|NCT01870232|EXPERIMENTAL|US guided block|Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
62415953|NCT05894382|PLACEBO_COMPARATOR|Group B|"1. st year: single-vision spectacle lenses~2. nd year: double helix design defocus lens spectacle (RACE)"
62415954|NCT06694857|EXPERIMENTAL|Filler|HA Filler to jaw line
62415955|NCT06566950|EXPERIMENTAL|Low load-BFRt|70% of the arterial occlusion pressure and 30% of the maximum repetition rate
62415956|NCT06566950|SHAM_COMPARATOR|Sham Low load-BFRt|10% of the arterial occlusion pressure and 30% of the maximum repetition rate
62797111|NCT00970437|PLACEBO_COMPARATOR|SYSP|The comparator for CBASP is SYSP, a system of supportive psychotherapy, an active but less specific, manualized control treatment. SYSP - defined as non-interpersonal and non-cognitive-behavioral therapy - resembles supportive clinical management, client-centered therapy, counseling, and psychoeducation about depression. There is no specific explanatory mechanism for treatment effect offered to the patient and it does not focus on specific themes.
62415957|NCT06566950|ACTIVE_COMPARATOR|High load-Eccentric training|70% of the maximum repetition rate
62415958|NCT01922973||normal men and women|normal volunteers: young and older men and women studied under fed and fasting (62.5h) conditions with frequent blood sampling for ghrelin and related hormones
62415959|NCT05916378||Patients and Caregivers|We will survey 100 patients and 50 caregivers.
62797112|NCT03202563|EXPERIMENTAL|Gemigliptin 50mg|"the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total.~Drug: Gemigliptin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS)"
62797113|NCT03202563|ACTIVE_COMPARATOR|Dapagliflozin 10mg|"the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total.~Drug: Dapagliflozin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS)"
62797114|NCT05850520|EXPERIMENTAL|Higher Dose Regimen 1|Higher dose of aflibercept is administered with initial initiation doses intervals, followed by extension of treatment intervals and further adjustment of intervals according to treatment response.
62797115|NCT05850520|EXPERIMENTAL|Higher Dose Regimen 2|Higher dose of aflibercept is administered with initial initiation doses intervals, followed by extension of treatment intervals and further adjustment of intervals according to treatment response.
62797116|NCT05850520|ACTIVE_COMPARATOR|Standard of care|Aflibercept 2 mg is administered by standard treatment intervals, followed by adjustment of treatment intervals according to treatment response.
62587931|NCT06162715|EXPERIMENTAL|Tirzepatide Group|Participants in the TRZ cohort will initiate a standardized dose titration as described in the package insert. Participants will begin TRZ at 2.5 mg for four weeks and then increase by 2.5 mg every 4 weeks to a maximum dose of 15 mg. If subjects experience intolerable GI symptoms, they will be allowed to decrease to a lower dose by 2.5 mg for 2 weeks, at which point another attempt at an increased dose will be trialed. Should patients not tolerate a higher dose a second time, they will have the dose again lowered by 2.5 mg and kept at the lower dose for the remainder of the study, except for patients who do not tolerate two attempts at 5 mg. For patients who fail to titrate to at least 5 mg TRZ, a third attempt at an increased dose will be attempted 4 weeks after the second decrease in dose. These patients will then remain on 5 mg for the remainder of the intervention period. All participants receiving TRZ will be pooled in terms of outcomes measures.
62587932|NCT06162715|OTHER|Control - Standard of care Post-Gastric Bypass Surgery|Patients randomized to the control arm will receive the standard of care for weight maintenance after gastric bypass including dietary guidance provided by the Vanderbilt Surgical Weight Loss handbook.
62797117|NCT03035604||Nutritional geriatric assessment|Participants undergo nutritional geriatric assessment over 15 minutes in person or on the phone every 3 months for 12 months.
62024760|NCT03661853|EXPERIMENTAL|Functional Analysis|"Functional Analysis (FA) is a core intervention in Cognitive Behavioral Therapy (CBT) for AUD, and helps to break the chain of events (external and internal) that lead from cue (trigger) to alcohol use to consequences of use. The FA microintervention teaches the patient to think and behave in new, more controlled ways in response to triggers, to identify maladaptive, impulsive behavior chains and to replace them with more deliberate ones."
62024761|NCT03661853|EXPERIMENTAL|Cognitive Restructuring|"Cognitive Restructuring of Thoughts About Alcohol (CR) is a core technique in CBT to help patients identify automatic (habituated) thoughts that happen quickly and are often not noticed, and change automatic thoughts occurring in response to alcohol triggers."
62415960|NCT03288649||Anorexia nervosa|adolescents with anorexia nervosa (N=20 ?), their parents (N=20), their physicians (N=20)
62587933|NCT01758731|EXPERIMENTAL|Olaparib with C225 and Radiation Therapy|Patients will begin taking Olaparib at the assigned dose three days prior to their first Cetuximab infusion. Patients will receive an initial dose of Cetuximab, 400 mg/m², intravenously over 120 minutes on Day 1. The initial dose of C225 will precede the start of radiation by 5-7 days. All patients will receive RT to a total dose of 69.3 Gy in 33 fractions over 6½ weeks. Weekly C225 will be administered at 250 mg/m2 in combination with daily RT. Patients will be assigned to receive Olaparib (25, 50, 100 or 200 mg bid) in combination with RT and C225. Olaparib will be taken twice daily, beginning three days prior to first scheduled C225 infusion. A further dose level of 300mg or 400mg may be considered should the 200mg Olaparib dose be well tolerated in this C225/RT combination schedule.
62797118|NCT05184582|NO_INTERVENTION|Standard|Routine information on the benefit of physical activity
62797119|NCT05184582|EXPERIMENTAL|Intervention|High-intensity interval and strength training during neoadjuvant chemotherapy
62797120|NCT00806039|OTHER|1|Early renal involvement
62797121|NCT00806039|NO_INTERVENTION|2|control
62797122|NCT00855244|OTHER|BMT survivors|Diagnostic exams
62797123|NCT00765180|ACTIVE_COMPARATOR|2|The investigators evaluate beneficial effect of colonoscopy using narrow band imaging (NBI) for colorectal adenoma detection.
62797124|NCT00765180|EXPERIMENTAL|1|The investigators evaluate the beneficial effect of colonoscopy with a transparent retractable extension (TRE) device on colorectal adenoma detection rate.
62797125|NCT05963906||SCFI|SCFI participants will complete a survey once per week for three consecutive weeks. They will participate in training for the FoodImage app and deploy it the last two weeks of their study period. During these last two weeks, these participants will also have waste collected on designated days by a waste pickup contractor.
62797126|NCT02097693||dyston-dyskinetic cerebral palsy|Young patients with dyston-dyskinetic cerebral palsy who receive DBS in the GPi
62797127|NCT06039709|EXPERIMENTAL|Sonodynamic Therapy (5-ALA + LIFU)|Administration of SDT occurs 1-3 weeks prior to GBM resection
62797128|NCT00965250|EXPERIMENTAL|Thymoma|Patients will receive IMC-A12 at a dose of 20 mg/kg intravenously once every three weeks. The most common tumors of the thymus are thymomas (well differentiated neoplasms and moderately differentiated neoplasms) and thymic (poorly differentiated neoplasms) carcinomas.
62797129|NCT00965250|EXPERIMENTAL|Thymic Carcinoma|Patients will receive IMC-A12 at a dose of 20 mg/kg intravenously once every three weeks. The most common tumors of the thymus are thymomas (well differentiated neoplasms and moderately differentiated neoplasms) and thymic (poorly differentiated neoplasms) carcinomas.
62797130|NCT02934724||Vaccinated|"Women born in 1997, resident to Norway in 2009, vaccinated by the quadrivalent HPV vaccine.~Interventions:~* Self sample from vagina using Rover's Evalyn Brush~* Self sample from the oral cavity using COPAN's FloqSwab~* Questionnaire"
62797131|NCT02934724||Un-vaccinated|"Women born in 1997, resident to Norway in 2009, not vaccinated by the quadrivalent HPV vaccine~Interventions:~* Self sample from vagina using Rover's Evalyn Brush~* Self sample from the oral cavity using COPAN's FloqSwab~* Questionnaire"
62024762|NCT03661853|EXPERIMENTAL|Dealing with Cravings|Dealing with Cravings (DC) is designed to directly target the reward and arousal systems, helping the patient accept the nature of cravings as time limited and deflated by continued abstinence so that craving is no longer associated with urgency. DC also teaches skills to reduce cravings by conjuring images such as a spider floating in a glass of wine, or of older versions of oneself sitting alone and dejected in a bar. Distraction techniques and breathing skills to reduce physiological arousal occurring in response to alcohol cues are also taught.
62221571|NCT02274532|EXPERIMENTAL|Patient|Testing will include self-report questionnaires, assessments of activities of daily living (ADL) by an occupational therapist, and biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks. Motion will be recorded using sensors that are attached to the arm and SoftHand. During each session, videos will be obtained of the subjects performing tasks. The experimental data collections are organized into 5 Sessions, which will take place over the course of 1 week, scheduled by the subject's availability, with the option with patients for a 1-week period of take-home testing and associated pre- and post-assessments.
62221572|NCT02274532|OTHER|Control|Testing will include self-report questionnaires, assessments of activities of daily living (ADL) by an occupational therapist, and biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks. Motion will be recorded using sensors that are attached to the arm and SoftHand. During each session, videos will be obtained of the subjects performing tasks. The experimental data collections are organized into 4 Sessions, which will take place over the course of 1 week, scheduled by the subject's availability. Control subjects will participate in two sessions, including a pre- and post-training assessments.
62797132|NCT02396706|ACTIVE_COMPARATOR|Ivy Leaves Cough Liquid|Ivy Leaves Cough Liquid
62024763|NCT06534801|EXPERIMENTAL|Group I（Age < 65 years old)|We will use the sequential allocation designed by Dixon. Oxycodone will be administered intravenously 30min before the end of surgery. The initial oxycodone dose will be set to 0.1 mg/kg. A satisfactory or an unsatisfactory analgesic response of the previous patient determined, respectively, the relative 10% decrease or increase in the dose of oxycodone the next patient received in the same group. The patient before the first crossover point will be included as the first case for ED50 estimation in each group. The study will conducted until 7 crossover points have be collected .
62221573|NCT00574613|EXPERIMENTAL|1|
62221574|NCT00574613|PLACEBO_COMPARATOR|2|
62415961|NCT03288649||Anxiety based school refusal|adolescents with anxiety based school refusal (N=20 ?), their parents (N=20), their physicians (N=20)
62415962|NCT03288649||Depression|adolescents with depression (N=20 ?), their parents (N=20), their physicians (N=20)
62415963|NCT02501655|ACTIVE_COMPARATOR|Phase 1|Jet Nebulizer - control group
62415964|NCT02501655|EXPERIMENTAL|Phase 2|Mesh nebulizers
62797133|NCT02396706|PLACEBO_COMPARATOR|Placebo|Placebo
62797134|NCT04742452|ACTIVE_COMPARATOR|Superior Capsular Reconstruction|
62797135|NCT04742452|PLACEBO_COMPARATOR|Partial Rotator Cuff Repair|
62797136|NCT03827525||Cognitive and Behavioral Therapy|There is no group, the study will be based on single case method. The sudy concerns 5 patients with a Williams Syndrome
62024764|NCT06534801|EXPERIMENTAL|Group II(Age ≥65 years old)|We will use the sequential allocation designed by Dixon. Oxycodone will be administered intravenously 30min before the end of surgery. The initial oxycodone dose will be set to 0.1 mg/kg. A satisfactory or an unsatisfactory analgesic response of the previous patient determined, respectively, the relative 10% decrease or increase in the dose of oxycodone the next patient received in the same group. The patient before the first crossover point will be included as the first case for ED50 estimation in each group. The study will conducted until 7 crossover points have be collected .
62024765|NCT04575428|EXPERIMENTAL|Splanchnic nerve block|
62024766|NCT01751022|EXPERIMENTAL|Attain Performa LV Lead (Models 4298, 4398, 4598)|N/A: single arm study, separate analysis for each lead model (total of 3).
62221575|NCT04893265|ACTIVE_COMPARATOR|Text Messaging Only|Participants will receive a weekly SMS Text or instant message on a topic related to COVID-19 testing over 12 weeks. In addition, participants will receive as-needed messages on updates of COVID-19 testing related information. The messages will be responsive to the rapid evolving developments and changes related to COVID-19 testing guidelines. Some of the messages will include a link to allow participants to get to the entire message/information on the study website.
62221576|NCT04893265|EXPERIMENTAL|INFORMED|"Participants will receive a weekly SMS Text or instant message on a topic related to COVID-19 testing as described in the Text Messaging Only. In addition, participants will receive a Lay Health Worker (LHW) Educational Outreach Program, which includes 2 group sessions via video calls like Zoom or another video conferencing platform and 2 follow-up contacts via telephone, text or other media assignment."
62221577|NCT02932566|ACTIVE_COMPARATOR|Pirfenidone|Pirfenidone 801mg capsule by mouth, three times a day (target dose) for 12 months
62221578|NCT02932566|PLACEBO_COMPARATOR|Placebo|Placebo capsule by mouth, three times a day (target dose) for 12 months
62415965|NCT06422832|EXPERIMENTAL|Interventional group|In this group the respective algorithm will be activated and alerts will be sent according to its design
62415966|NCT06422832|NO_INTERVENTION|Control Group|The algorithm will not be activated and follow-up will continue as if the patient was not included in the study.
62415967|NCT00555399|EXPERIMENTAL|Ph I: Arm 1|Vorinostat plus isotretinoin
62415968|NCT00555399|EXPERIMENTAL|Ph I: Arm 2|Temozolomide plus isotretinoin
62415969|NCT00555399|EXPERIMENTAL|Ph I: Arm 3|Vorinostat plus isotretinoin plus temozolomide
62415970|NCT00555399|NO_INTERVENTION|Ph II: Arm 1|Non-Surgical
62415971|NCT00555399|OTHER|Ph II: Arm 2|Surgical Arm
62415972|NCT03981315||Lithogenic bile in symptomatic patient|Patients who are performed a cholecystectomy as a treatment of their gallbladder disease
62415973|NCT03981315||Lithogenic bile in asymptomatic patient|Patients who are performed a cholecystectomy for another reason (cancer, organ donation) and gall stones are found
62415974|NCT03981315||Non-lithogenic bile|Patients who are performed a cholecystectomy for another reason (cancer, organ donation) without gall stones
62415975|NCT03332212|EXPERIMENTAL|Cohort A (Empagliflozin + Placebo)|Heart Failure with Reduced Ejection Fraction
62415976|NCT03332212|EXPERIMENTAL|Cohort B (Empagliflozin + Placebo)|Heart Failure with Preserved Ejection Fraction
62415977|NCT01215955|EXPERIMENTAL|3 Day Algorithm|"Basal insulin glargine plus mealtime bolus insulin lispro titrated based on blood glucose readings from the past three days.~(Sites were assigned to Study A and Study B according to an allocation plan that was pre-specified before initiation of Study A and Study B)"
62587934|NCT02957435|EXPERIMENTAL|eplerenone|(Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
62024767|NCT04941300|OTHER|Mailed FIT Outreach|Primer, FIT Kit, Reminders, Abnormal FIT Follow-up
62415978|NCT01215955|EXPERIMENTAL|Daily Algorithm|"Basal insulin glargine plus mealtime bolus insulin lispro titrated based on blood glucose readings from the previous day.~(Sites were assigned to Study A and Study B according to an allocation plan that was pre-specified before initiation of Study A and Study B)"
62415979|NCT06702865||LP and LAAO|Patients indicated for combined leadless pacemaker and left atrial appendage occlusion will have combined procedure. Procedure will be performed with usual implantation techniques.
62415980|NCT04511923|NO_INTERVENTION|Standard Care|Standard care
62415981|NCT04511923|EXPERIMENTAL|Heparin|Standard care plus nebulised unfractionated heparin 25000 units every 6 hours for 10 days
62415982|NCT02641730|EXPERIMENTAL|Group 1|Participants will receive guselkumab 200 milligram (mg) at Week 0, 4, 12 and every 8 weeks thereafter through Week 60, and two syringes of placebo at Week 16 to maintain the blind.
62415983|NCT02641730|EXPERIMENTAL|Group 2|Participants will receive a syringe of guselkumab 100 mg and a syringe of placebo for guselkumab at Week 0, 4, 12 and every 8 weeks thereafter through Week 60, two syringes of placebo at Week 16 to maintain the blind.
62415984|NCT02641730|EXPERIMENTAL|Group 3|Participants will receive two syringes of placebo at Week 0, 4 and 12. At Week 16, placebo participants will be randomized in a 1:1 ratio to guselkumab mg arm (Group 3a) or 100 mg arm (Group 3b). Group 3a participants will receive guselkumab 200 mg at Week 16, 20 and every 8 weeks thereafter through Week 60. Group 3b participants will receive guselkumab 100 mg and a syringe of placebo at Week 16, 20 and every 8 weeks thereafter through Week 60.
62433390|NCT04651283|EXPERIMENTAL|Adaptive seating equipment group|Study group who received the same selected program for hand function on adaptive swiss ball seating
62433391|NCT04651283|ACTIVE_COMPARATOR|Traditional seat group|Control group who received a specially selected physical therapy program for hand function on a standard chair seating.
62587935|NCT03173690|EXPERIMENTAL|Intervention group|Receive medication reconciliation at the ICU, pluss medication reconciliation at the ward
62797137|NCT05112939|EXPERIMENTAL|Panel A: Rilpivirine (RPV) Long-acting (LA)|Participants will receive one dose of RPV LA (formulation 1) under different conditions (Treatment A and B) on Day 1.
62797138|NCT05112939|EXPERIMENTAL|Panel B: RPV LA|Participants will receive one dose of RPV LA (formulation 2) under different conditions (Treatment C and D) on Day 1.
62797139|NCT05112939|EXPERIMENTAL|Panel C: RPV LA|Participants will receive one dose of RPV LA (formulation 1) under different conditions (Treatment E and F) on Day 1, based on interim data of Panel A.
62797140|NCT05112939|EXPERIMENTAL|Panel D: RPV LA|Participants will receive one dose of RPV LA (formulation 2) under different conditions (Treatment G and H) on Day 1, based on interim data of Panel B.
62797141|NCT05112939|EXPERIMENTAL|Panel E: RPV LA + Cabotegravir (CAB) LA|Participants will receive one dose of RPV LA (formulation 1) with CAB LA (formulation 3) (Treatment I) on Day 1.
62797142|NCT06725914|EXPERIMENTAL|Implementation of paternal early kangaroo care transport|Early kangaroo care was administered immediately after delivery. The fathers were seated on a wheelchair for transportation from the gynecology operating room to the NICU. The newborn was then dressed in a diaper and hat. The preterm baby was laid naked on the father's bare chest in an upright position. Preterms were secured with a kangaroo care garment in the frog leg position in the prone position with the head turned to the side. The baby was covered with a blanket to prevent heat loss.
62797143|NCT06725914|NO_INTERVENTION|Control Group|The babies in the control group were transported to the NICU in the arms of the nurse after birth as in the clinical routine.
62797144|NCT06004986|ACTIVE_COMPARATOR|Dupilumab 300 mg q2w|Dupilumab s.c. 300 mg every 2 weeks for 24 weeks.
62221579|NCT02947893|PLACEBO_COMPARATOR|Group 1 (placebo)|Out of 42 total participants with mild to moderate AD (MMSE=17-24 inclusive) and their study partners that will be recruited and 1:1 randomized, 21 (twenty-one) will be assigned to group 1 and given 1 capsule of a placebo drug by mouth every day for the first 6 months followed by 2 capsules once daily for the subsequent 6 months, every time taken without a meal, for the total duration of the study for 12 months.
62415985|NCT04732728||LUX-Dx PERFORM Study Enrollment|"The first 227 subjects enrolled in the study belong to the Safety Cohort. The number of subjects is required to fulfill the sample size requirement of the primary safety endpoint. The Safety Cohort subjects are not required to participate in the Holter study. Once the Safety Cohort enrollment is completed, all subsequent subjects are required to participate in the Holter study. All subjects who participate in the Holter study belong to the Holter Cohort."
62415986|NCT06566807|EXPERIMENTAL|O2|
62415987|NCT05584839||carpal tunnel syndrome|"* Admitted to outpatient clinics with symptoms of CTS~* Findings of CTS in physical examination~* CTS diagnosis was confirmed by nerve conduction study~* KTS grade mild or moderate~* He has not received physical therapy for this reason in the previous 1 year~* No steroid injection and no treatment for neuropathic pain (pregabalin, gabapentin, etc.)"
62797145|NCT06004986|EXPERIMENTAL|Dupilumab 300 mg q3w|Dupilumab s.c. 300 mg every 3 weeks for 24 weeks.
62797146|NCT06004986|EXPERIMENTAL|Dupilumab 300 mg q4w|Dupilumab s.c. 300 mg every 4 weeks for 24 weeks.
62797147|NCT00835250|ACTIVE_COMPARATOR|Laparoscopy|Laparoscopic cholecystectomy
62797148|NCT00835250|EXPERIMENTAL|Transumbilical|Transumbilical endoscopic cholecystectomy
62024768|NCT04941300|NO_INTERVENTION|Usual Care|
62024769|NCT06525883||Group 1|upper cervical
62024770|NCT06525883||Group 2|lower cervical
62024771|NCT06525883||Group 3|thoracolumbar
62221580|NCT02947893|ACTIVE_COMPARATOR|Group 2 (treated)|Out of 42 total participants with mild to moderate AD (MMSE=17-24 inclusive) and their study partners that will be recruited and 1:1 randomized, 21 (twenty-one) will be assigned to group 2 treated with 1 capsule (150mg Nilotinib) once a day by mouth for the first 6 months followed by dose escalation to 2 capsules (300mg Nilotinib) once daily by mouth for the subsequent 6 months, every time taken without a meal, for the total study duration of 12 months.
62221581|NCT00351663|ACTIVE_COMPARATOR|IV by weight|intravenous dose of 0.5 mg/kg enoxaparin once daily
62221582|NCT00351663|ACTIVE_COMPARATOR|SC fixed dose|subcutaneous fixed dose of 40 mg enoxaparin once daily
62221583|NCT00351663|ACTIVE_COMPARATOR|SC by weight|subcutaneous dose of 0.5 mg/kg enoxaparin once daily
62221584|NCT06417567||experimental group|
62221585|NCT01683734||Renal Function Observation|
62797149|NCT00835250|EXPERIMENTAL|Transvaginal|Transvaginal endoscopic cholecystectomy
62024772|NCT00841581|EXPERIMENTAL|Lucentis|"All patients receive iL for for first 6 months of study. At 6 months - patients are classified as responders or non-responders. Responders receive iL PRN based on OCT,clinical exam etc. Non-responders are seen again at 12 months for repeat investigations."
62221586|NCT02891317||Cataract Surgery Only|Twenty-five participants with mild or moderate open angle glaucoma (OAG) controlled by medication with a visually significant cataract that meets clinical criteria for cataract surgery will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for cataract surgery only (Group 1) will be recruited to this group. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
62221587|NCT02891317||Cataract Surgery with iStent|Twenty-five participants with mild or moderate open angle glaucoma (OAG) that meets clinical criteria for cataract surgery with implantation of an iStent trabecular micro-bypass shunt will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for cataract surgery with iStent (Glaukos Corp., Laguna Hills, CA) implantation (Group 2) will be recruited to this group. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
62221588|NCT02891317||Glaucoma Drainage Device|Twenty-five participants with moderate or severe open angle glaucoma (OAG) that meets clinical criteria for implantation of a glaucoma drainage device (Group 3) will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for implantation of a glaucoma drainage device (Group 3) will be recruited to this group. There will be 25 participants in each of the groups. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
62221589|NCT02641860|OTHER|Mesenchymal progenitor cells Dosage 1|Mesenchymal progenitor cells low-dose group
62221590|NCT02641860|OTHER|Mesenchymal progenitor cells Dosage 2|Mesenchymal progenitor cells mid-dose group
62221591|NCT02641860|OTHER|Mesenchymal progenitor cells Dosage 3|Mesenchymal progenitor cells high-dose group
62221592|NCT02740374|EXPERIMENTAL|ROTEM|"ROTEM will be performed in patients with signs of clinically relevant bleeding and in whom blood transfusion is considered (Temp above 35 Celsius degrees; pH below 7.2; Cai above 4.6 mg/dL; Hb below 9g/dL, or below 10g/dL with anticipated greater blood loss) or at a fixed range every 2 hours or at Anesthesiologist criteria based on patient's clinical situation.~There will be also be performed standard of care test for this set of patients, as described for the CONTROL arm. ROTEM results will guide transfusion strategy."
62221593|NCT02740374|ACTIVE_COMPARATOR|CONTROL/STANDARD OF CARE|"If patients are randomized to standard coagulation tests (SCT), these will be performed according to Ohio State Wexner University Medical Center standard practices and attending's criteria, or at 2 hour intervals per protocol.~Standard of care tests include but are not limited to: hemoglobin, platelet count, fibrinogen concentration, INR, aPTT, and PT. These will be performed at fixed time points (preoperatively, every 2 hours intraoperatively, procedure completion, and 24 hours after procedure completion). Arterial blood gases will be performed repetitively intraoperatively at a fixed range every 1-hour or at attending's criteria, as well as any postoperative laboratory tests. SCT will guide transfusion management."
62221594|NCT02706132|EXPERIMENTAL|The MSCs group|The group of patients receive allogeneic MSCs therapies.
62221595|NCT05834777|EXPERIMENTAL|Icatibant|153 mL 0.9% saline bag containing 30 mg icatibant acetate (10 mg/ml) IV at each dialysis treatment for four weeks (12 hemodialysis sessions)
62221596|NCT05834777|PLACEBO_COMPARATOR|Placebo|153 mL 0.9% saline bag IV at each dialysis treatment at each dialysis treatment for four weeks (12 hemodialysis sessions)
62221597|NCT05932745|EXPERIMENTAL|Non-menthol, nicotine 59mg/ml (1)|Flavor without menthol with 59mg/ml nicotine
62221598|NCT05932745|EXPERIMENTAL|Low menthol, nicotine 59mg/ml (1)|Flavor with low menthol concentration with 59mg/ml nicotine
62415988|NCT02878239||Early OA|All patients (\>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with early knee osteoarthritis because their Kellgren-Lawrence Scores were Grade I.
62221599|NCT05932745|EXPERIMENTAL|High menthol, nicotine 59mg/ml (1)|Flavor with high menthol concentration with 59mg/ml nicotine
62221600|NCT05932745|EXPERIMENTAL|Non-menthol, nicotine 59mg/ml (2)|Flavor without menthol with 59mg/ml nicotine
62221601|NCT05932745|EXPERIMENTAL|Low menthol, nicotine 59mg/ml (2)|Flavor with low menthol concentration with 59mg/ml nicotine
62221602|NCT05932745|EXPERIMENTAL|High menthol, nicotine 59mg/ml (2)|Flavor with high menthol concentration with 59mg/ml nicotine
62221603|NCT05932745|EXPERIMENTAL|Non-menthol, nicotine 59mg/ml (3)|Flavor without menthol with 59mg/ml nicotine
62221604|NCT05932745|EXPERIMENTAL|Low menthol, nicotine 59mg/ml (3)|Flavor with low menthol concentration with 59mg/ml nicotine
62221605|NCT05932745|EXPERIMENTAL|High menthol, nicotine 59mg/ml (3)|Flavor with high menthol concentration with 59mg/ml nicotine
62221606|NCT05932745|EXPERIMENTAL|Non-menthol, nicotine 59mg/ml (4)|Flavor without menthol with 59mg/ml nicotine
62415989|NCT02878239||Moderate OA|All patients (\>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with moderate knee osteoarthritis because their Kellgren-Lawrence Scores were Grade II.
62415990|NCT02878239||Severe OA|All patients (\>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with moderate knee osteoarthritis because their Kellgren-Lawrence Scores were Grade III/IV.
62415991|NCT02878239||Asymptomatic Participants|The asymptomatic participants（\>35 years） has no history of knee pain, trauma, surgery, or obvious gait abnormalities. They are set as controls in the study.
62415992|NCT06399276|EXPERIMENTAL|Behavioral Weight Loss Focused on Intermittent Fasting|3-month integrated behavioral weight loss intervention with a dietary focus on intermittent fasting.
62587936|NCT03173690|OTHER|Control group|No intervention at the ICU, medication reconciliation at the ward
62221607|NCT05932745|EXPERIMENTAL|Low menthol, nicotine 59mg/ml (4)|Flavor low menthol concentration with 59mg/ml nicotine
62221608|NCT05932745|EXPERIMENTAL|High menthol, nicotine 59mg/ml (4)|Flavor high menthol concentration with 59mg/ml nicotine
62797150|NCT04106609|EXPERIMENTAL|Exercise Group|Patients will complete a 60-minute exercise session once per week for 12 weeks. The exercise sessions will be individualized to the patient's needs and fitness level by a trainer. A patient will work with the same trainer throughout the study, who will plan the patient's individualized exercise regimen, and who will provide one-on-one supervision for the duration of each 60-minute session. Each 60-minute session will include cardiovascular, strength, and flexibility training. The intensity level for the aerobic exercise ranges from 30-45% of the individual's predicted VO2max, controlled by heart monitors and lasting 30 min. Strength training will involve a full body workout, with emphasis on all major muscle groups and employing machines, free weights, and resistance tubing. Patients will complete 3 sets of 10 repetitions for each strength exercise. Flexibility training will involve static stretching of all major muscle groups for 15-20 seconds at the completion of each workout.
62221609|NCT05932745|EXPERIMENTAL|Non-menthol, nicotine 59mg/ml (5)|Flavor without menthol with 59mg/ml nicotine
62797151|NCT04106609|ACTIVE_COMPARATOR|Control Group|The control group will receive the current standard of care, which includes a resource guide with various options available to the cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.
62221610|NCT05932745|EXPERIMENTAL|Low menthol, nicotine 59mg/ml (5)|Flavor low menthol concentration with 59mg/ml nicotine
62797152|NCT00059345|EXPERIMENTAL|Arm 1: Acupuncture|Participants will receive acupuncture
62797153|NCT00059345|PLACEBO_COMPARATOR|Arm 2: Shallow needling|Participants will receive shallow needling on non-mederian points
62221611|NCT05932745|EXPERIMENTAL|High menthol, nicotine 59mg/ml (5)|Flavor high menthol concentration with 59mg/ml nicotine
62221612|NCT00589589|ACTIVE_COMPARATOR|A|
62221613|NCT01928251|EXPERIMENTAL|Informed early monetary incentive|Incentives of abstinence will be given to those who self-report abstinence for the past 7 days at 3-month follow-up and pass the 3-month biochemical validation (Exhaled carbon monoxide level \< 4 ppm, saliva cotinine level \< 10 ng/ml) (Group A-Q). Participants will be informed about the incentives through telephone follow-up at 1 week and 1 month. Those who have not quitted at 3 months (Group A-N) or those self-reported quitters who refuse to participate in biochemical validation will be informed again that they will be given the same incentive if they have quitted at 6 months and the quitting is validated.
62415993|NCT06442826|EXPERIMENTAL|True non-invasive auricular stimulation (TniAS)|Ear stimulation using true ear patches
62415994|NCT06442826|PLACEBO_COMPARATOR|Sham auricular stimulation (SAS)|Ear stimulation using sham ear patches
62415995|NCT06442826|NO_INTERVENTION|No-intervention group (NI)|Participants in the No-Intervention group (NI) will not receive any active intervention as part of the trial.
62415996|NCT00595127|EXPERIMENTAL|1|This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m\^2 dose \[intended specific activity of \~20 mCi/mg protein\] preceded by administration of 50mg/1.73m\^2 of unlabeled 8H9.
62415997|NCT03230695|ACTIVE_COMPARATOR|Active stimulation + robotic therapy|"Active transcranial direct current stimulation will be applied during 20 minutes prior to robotic training.~Number of interventions sessions: 1"
62415998|NCT03230695|SHAM_COMPARATOR|Sham stimulation + robotic therapy|"Sham transcranial direct current stimulation will be applied during 20 minutes prior to robotic training.~Number of interventions sessions: 1"
62415999|NCT05311215|EXPERIMENTAL|SL-1002|SL-1002 injectable solution, single dose
62416000|NCT05311215|PLACEBO_COMPARATOR|Matching placebo|Matching placebo injectable solution, single dose
62416001|NCT05510856|EXPERIMENTAL|Duloxetine|group 1
62416002|NCT05510856|EXPERIMENTAL|Gabapentin|group 2
62024773|NCT04511689||test group|bone grafting with gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene mixed with autobone
62024774|NCT04511689||control group|bone grafting with xenogenic deproteinized bone matrix mixed with autobone
62221614|NCT01928251|EXPERIMENTAL|Uninformed early monetary incentive|Incentives of abstinence will be given to those who self-report abstinence for the past 7 days and pass the 3-month biochemical validation (Group B-Q), but they will not be informed about the incentive at the 1-week and 1-month follow-up. Those who have not quitted at 3 months (Group B-N) or those self-reported quitters who refuse to participate in the biochemical validation will be informed that they will be given the same incentive if they have quitted at 6 months and the quitting is validated.
62221615|NCT01928251|NO_INTERVENTION|Uninformed late monetary incentive|Incentives for the self-reported and biochemically-validated abstinence at 6-month follow-up will be given after the 6-month biomedical validation. They would not be informed about the incentive at the 1-week, 1-month and 3-month follow-up. Group C also has two subgroups, those who have quitted at 3 months (Group C-Q) and those who have not (Group C-N).
62416003|NCT05510856|EXPERIMENTAL|Lacosamide|group 3
62416004|NCT06701968|EXPERIMENTAL|Healthy Nordic Diet|Dietary advice and provided with some key food items
62416005|NCT06701968|ACTIVE_COMPARATOR|Usual care|Dietary advice according to standard clinical care at the cardiology unit
62416006|NCT06121661|EXPERIMENTAL|APPRAISE cases|Trauma patients for which APPRAISE system was used
62416007|NCT03384407|EXPERIMENTAL|Open label|Red cell recovery/survival analysis of untreated and INTERCEPT treated RBC concomitantly
62416008|NCT05093374|EXPERIMENTAL|Cohort 1 - Quantitative|"Patients will undergo monthly follow-up visits including fluid quantification and will be retreated in case of active disease, which is defined as:~* reduction of 5 EDTRS letters or more related to any (suspected) neovascular activity compared to previous visit~* new sub-retinal hemorrhage~* increase \>50% in IRF volume in the central 1 mm compared to month 2~* increase \> 50 % in SRF volume in the central 1 mm compared to month 2~* in case of NO intra- and/or subretinal fluid (=less than 10nl) in visits 2 or 3, retreat if fluid in central 1mm ≥ 10nl~Presence/change of sub- and intraretinal fluid will be assessed objectively by AI software and the results will be provided during the visit to the investigator. The final decision for/against retreatment is always made by the discretion of the clinical investigator."
62416009|NCT05093374|ACTIVE_COMPARATOR|Cohort 2 - Qualitative|"Patients will undergo monthly follow-up visits. Treatment will be performed in case of active disease, which is defined as:~* reduction of 5 EDTRS letters or more related to any (suspected) neovascular activity~* new sub-retinal hemorrhage~* any fluid~In this cohort the amount of retinal fluid will not be assessed by AI software at the time of retreatment."
62587937|NCT04183413|NO_INTERVENTION|Standard of Care|Health services for diabetes and hypertension are provided as was the standard of care prior to the healthcare reform after the emergency decentralization motivated by the COVID-19 outbreak. Healthcare for diabetes and hypertension for complicated cases is provided through physician-led teams at hospitals and health centers. Healthcare for diabetes and hypertension for uncomplicated cases is provided at primary care clinics through nurses.
62221616|NCT04085965|EXPERIMENTAL|CAMP|Children randomized to CAMP were enrolled in the Boys and Girls Club Camp in one of two low-income Rhode Island communities in summer 2017 or 2018 for 7-weeks in 2017 and 8-weeks in 2018 due to a delayed end to the 2017 school year (i.e. snow days). Camp was offered daily from 8:30 to 4:30.
62587938|NCT04183413|EXPERIMENTAL|DSD|Clients are invited to participate in one of three Differentiated Service Delivery models tailored to their needs.
62587939|NCT04183413|EXPERIMENTAL|CDP|Health services for diabetes and hypertension are provided in the scope of outreach activities set up on a monthly basis in communities.
62587940|NCT02499653|EXPERIMENTAL|Psychological Intervention|In addition to the standard care, subjects are participating in a brief psychological support, which will include elements of psychological well-being's promotion and cognitive restructuring exercises (mindfulness).
62221617|NCT04085965|NO_INTERVENTION|Summer As Usual|Children randomized to the SAU group were asked to experience an unstructured summer as otherwise planned by their parent / guardian. They agreed to not attend structured summer programming (i.e. camp, summer school, or day care) for more than one week over the summer so as to provide an inactive control group for comparison to those in CAMP.
62587941|NCT02499653|ACTIVE_COMPARATOR|Videos|The subjects assigned in the Control Group watch some videos relating to the management of their disease.
62587942|NCT00954512|EXPERIMENTAL|Regimen A: FOLFIRI (± Cetuximab) + Robatumumab|Participants with colorectal adenocarcinoma receive FOLFIRI (Irinotecan 180 mg/m\^2+ folinic acid 400 mg/m\^2+ 5-fluorouracil \[5-FU\] 400 mg/m\^2 bolus followed by 2400 mg/m\^2 intravenous \[IV\] infusion over 46 hours) (± cetuximab initial dose of 400 mg/m\^2 IV followed by once-weekly doses of 250 mg/m\^2 IV) PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 2-week cycle.
62587943|NCT00954512|EXPERIMENTAL|Regimen B: Carboplatin + Paclitaxel + Robatumumab|Participants with non-small cell lung cancer receive carboplatin administered at an area under the curve (AUC) of 6 mg/mL/min IV PLUS paclitaxel 225 mg/m\^2 IV PLUS robatumumab 15 mg/kg IV on Day 1 of each 3-week cycle.
62024775|NCT01250860|SHAM_COMPARATOR|Control Group|Control DoboMed group - only specific active exercises: symmetrical positions for exercising; asymmetrical active movements; thoracic spine kyphotization; transverse plane derotation; apical area involvement; concave ribs mobilization; exteroceptive facilitation; respiration-directed movements of the thorax and spine; three-dimensional displacement of vertebra; active autocorrection.
62221618|NCT03168607|EXPERIMENTAL|FOLFIRI|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
62221619|NCT06234878|EXPERIMENTAL|Gait analysis|Gait analysis with the investigational and the reference devices
62221620|NCT05839015|EXPERIMENTAL|Intervention|"This is group wil use Eu + Compassivo app."
62221621|NCT05839015|NO_INTERVENTION|Control|This group will be made up of a waiting list.
62221622|NCT02290132||highly aggressive T cell tumors|The study is to research the outcome of Rabbit Anti-human Thymocyte Globulin (ATG)based myeloablative conditioning regimen after allo-HSCT in patients with highly aggressive T-cell tumors.
62416010|NCT04221204|EXPERIMENTAL|Open-Label, Dose-Escalation|"The starting dose in this dose-escalation study is 50 mg, and the preset 6 dose-escalation cohorts are 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg, respectively. This study adopts an i3+3 method for dose escalation.~All subjects in each cohort will receive a single oral dose of 3D185, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive daily doses (Once daily \[QD\], 28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first"
62416011|NCT04727580|EXPERIMENTAL|HSK7653 10 mg|
62587944|NCT00954512|EXPERIMENTAL|Regimen C: Epirubicin + Cisplatin + 5-FU + Robatumumab|Participants with gastric adenocarcinoma receive epirubicin 50 mg/m\^2 IV PLUS cisplatin 60 mg/m\^2 IV PLUS 5-FU 200 mg/m\^2/day administered via a 21-week continuous IV infusion PLUS robatumumab 15 mg/kg IV on Day 1 of each 3-week cycle.
62587945|NCT00954512|EXPERIMENTAL|Regimen D: Trastuzumab + Robatumumab|Participants with human epidermal growth factor receptor 2 positive (Her2+) breast cancer receive trastuzumab 4 mg/kg IV once every week PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle.
62587946|NCT00954512|EXPERIMENTAL|Regimen E: mTor Inhibitor (Everolimus) + Robatumumab|Participants with renal cell cancer receive mammalian target of rapamycin (mTor) inhibitor (everolimus) 10 mg orally once per day PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle.
62587947|NCT00954512|EXPERIMENTAL|Regimen F: Gemcitabine (± Erlotinib) + Robatumumab|Participants with pancreatic adenocarcinoma receive gemcitabine 1000 mg/m\^2 IV on Days 1, 8, 15, 22, 29, 36, and 43 in Cycle 1 and on Days 1, 8 and 15 in subsequent cycles (± erlotinib 100 mg per day orally) PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle. (Cycle 1 is 8 weeks.)
62587948|NCT00623935|EXPERIMENTAL|Fludarabine plus Busulfan (CR)|Patients in CR will receive a reduced intensity transplant regimen consisting of Fludarabine plus Busulfan (FluBu2).
62587949|NCT00623935|EXPERIMENTAL|Fludarabine plus Busulfan (PR)|Patients in PR will receive a full intensity transplant regimen consisting of Fludarabine plus Busulfan (FluBu4).
62587950|NCT03543969|EXPERIMENTAL|Arm A: BRAF-MEK Inhibitor Therapy|Participants will receive 450 mg Encorafenib daily, along with 45 mg Binimetinib twice daily and 240 mg Nivolumab IV every 2 weeks.
62587951|NCT03543969|ACTIVE_COMPARATOR|Arm B|Participants will receive 240 mg Nivolumab IV every 2 weeks
62797154|NCT00059345|OTHER|Arm 3: No Acupuncture or Placebo Treatment|Participants will receive usual care, no acupuncture or placebo acupuncture treatment.
62797155|NCT04346329|PLACEBO_COMPARATOR|Control|Controlled group with placebo medication similar to hydroxychloroquine (loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days)
62221623|NCT03231631|EXPERIMENTAL|Education plan and adherence to exercise|"* Educational talk about the importance of nutrition and exercise as an important strategy to change cardiovascular risk factors at the start of the study.~* It will be sent via text, whatsapp, and / or e-mail on a weekly basis three text messages that remind them of the importance of doing the exercise and how often they should do it, it will be a predetermined text."
62221624|NCT03231631|NO_INTERVENTION|Control|"The blood sample will be taken for the collection of serum HDL and the aerobic capacity test measured in MET will be recorded at the beginning of the study.~A survey will be conducted at week 12 of monitoring where adherence to exercise is measured during the 12-week study."
62221625|NCT03053154||Experimental group1|15 stroke patients with right side affection, their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
62221626|NCT03053154||Experimental group2|15 stroke patients with left side affection, their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
62221627|NCT03053154||Control group|15 Normal subjects without any diseases or dysfunctions , their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
62587952|NCT01585662|EXPERIMENTAL|Naso-pancreatic tube|The patients enrolled in this group will be treated with modified naso-pancreatic tube drainage method.
62587953|NCT01585662|EXPERIMENTAL|Stents|The patients enrolled this group will be treated by placing the stents (at least 2 stents) between gastric and pancreatic pseudocyst.
62587954|NCT06667713|EXPERIMENTAL|Intervention|ENTRUST intervention comprised of adapted SBIRT-T, economic strengthening and photovoice training
62587955|NCT06667713|ACTIVE_COMPARATOR|Waitlist Control|SBIRT-T only
62587956|NCT04630613||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and are classified as Class 1A, 1B, 1C, 1D and 1E.
62587957|NCT04660994||Therapeutic education|Children with disordered breathing requiring CPAP or NIV and followed-up by the pediatric non-invasive ventilation and sleep unit of Necker-Enfants Malades hospital.
62587958|NCT04660994||Therapeutic education and Yapouni educational game|Children with disordered breathing requiring CPAP or NIV and followed-up by the pediatric non-invasive ventilation and sleep unit of Necker-Enfants Malades hospital.
62587959|NCT03628131|EXPERIMENTAL|Pazopanib + conventional chemotherapy|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
62587960|NCT05926973||Before intervention|Standard care as per ALS guidelines prior to October 2021
62587961|NCT05926973||After intervention|Enhanced cardiac arrest management as per TVAA guideline from October 2021 onwards
62797156|NCT04346329|EXPERIMENTAL|treated|hydroxychloroquine with a loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days
62797157|NCT02041416||Group 1|REDCap and paper pencil
62797158|NCT02041416||Group 2|REDCap twice
62221628|NCT01383499|EXPERIMENTAL|Treatment A|patients inhale 2 puffs (low dose) once daily in the evening via Respimat inhaler
62587962|NCT04778462|EXPERIMENTAL|Extracorporeal shock wave|Extracorporeal shock wave group A consist of 15 subject will receive extracorporeal shock wave and conventional treatment for trigger points for two weeks four treatment sessions
62587963|NCT04778462|EXPERIMENTAL|High-power pain thershold ultrasound|High -power pain thershold group b consist of 15 subject will receive high power pain threshold ultrasound and conventional treatment for upper trapezius trigger points for two weeks four treatment session
62587964|NCT04778462|OTHER|Controlled group|controlled group consist of 15 subjects will receive conventional treatment for trigger point for two weeks
62587965|NCT04030390|EXPERIMENTAL|Physical Fatigue Condition|
62797159|NCT02041416||Group 3|Support Screen and paper pencil
62416012|NCT04727580|EXPERIMENTAL|HSK7653 25 mg|
62797160|NCT02041416||Group 4|Support Screen twice
62797161|NCT03535129|NO_INTERVENTION|Stage 1|Pilot portion to optimize intervention and achievecorrelational research aims
62797162|NCT03535129|EXPERIMENTAL|Stage 2|Main Clinical Trial with random assignment
62797163|NCT05639296||MSUS experts|Physicians with extensive experience with MSUS (performed more than 1000 examinations).
62797164|NCT04590560|NO_INTERVENTION|1-year screening interval|Women will follow the normal screening program (they will be invited to screen every year)
62221629|NCT01383499|EXPERIMENTAL|Treatment B|patients inhale 2 puffs (medium dose) once daily in the evening via Respimat inhaler
62221630|NCT01383499|EXPERIMENTAL|Treatment C|patients inhale 2 puffs (high dose) once daily in the evening via Respimat inhaler
62221631|NCT01383499|PLACEBO_COMPARATOR|Treatment D|patients inhale 2 puffs of placebo inhalation solution matching tiotropium once daily in the evening via Respimat inhaler
62416013|NCT04727580|PLACEBO_COMPARATOR|Placebo|
62587966|NCT04030390|PLACEBO_COMPARATOR|Control Condition|
62587967|NCT05449587||Primary /Revision Augmentation Cohort|Patients that underwent primary and/or revision augmentation from 3 years or more postoperatively.
62587968|NCT01421628|EXPERIMENTAL|exercise|
62797165|NCT04590560|EXPERIMENTAL|2-year screening interval|Women will be invited to screen every two years
62797166|NCT04590560|EXPERIMENTAL|3-tailored screening interval|the screening interval will be decided on the basis of breast density. Women with very dense breast (BI-RADS category D) will be referred to 1-year interval whereas women with less dense breast to 2-year interval (BI-RADS category A, B, C)
62797167|NCT03468868|ACTIVE_COMPARATOR|Facility-based rehabilitation|Participants will conduct the exercise program for people with MS in a facility, for example a gym, or rehabilitation center. They will receive coaching on site at the facility.
62797168|NCT03468868|ACTIVE_COMPARATOR|Telerehabilitation|Participants will conduct the exercise program for people with MS at home and receive coaching via phone or Skype sessions.
62797169|NCT06672549|EXPERIMENTAL|Orforglipron (ISA PW01)|Participants will receive orforglipron or placebo orally. Each ISA will detail the intervention specific.
62797170|NCT05244746|ACTIVE_COMPARATOR|Rectus sheath block|
62221632|NCT02275832|EXPERIMENTAL|Minoxidil|3% Minoxidil lotion is applied twice daily to the beard.
62221633|NCT02275832|PLACEBO_COMPARATOR|Placebo|Placebo is applied twice daily to beard.
62221634|NCT03454698|OTHER|Contol|"Usual care for patients in the CG is defined as follows: Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the wound expert according to the hospital's own standards. This standard corresponds to the one from the EWMA."
62221635|NCT03825926||Gestational Diabetes Mellitus|The diagnosis of GDM is based on a 75-g oral glucose tolerance test (OGTT) performed between 24 and 28 gestational weeks, according to the American diabetes association (ADA) criteria (fasting ≥ 5.1 mmol/L, 1 h ≥ 10.0 mmol/L, 2 h ≥ 8.5 mmol/L). Recruited patients were accepted the standard of treatment of GDM according to the American college of obstetricians and gynecologists (ACOG) practice bulletin on gestational diabetes mellitus.
62221636|NCT03825926||Non-Gestational Diabetes Mellitus|normal group
62221637|NCT04351737|EXPERIMENTAL|Pterygium patients|patients with bilateral pterytium
62797171|NCT05244746|PLACEBO_COMPARATOR|Control|
62221638|NCT04793659|EXPERIMENTAL|Oral Fasudil 90 mg/day|Subjects will receive a daily dose of 90 mg Fasudil for 42 days (open-label period 1). After Period 1 is complete, if the subject is a responder to Fasudil 90 mg/day, they will be randomized to either Fasudil 90 mg/day or a placebo for 6 weeks (double-blind period 1), then crossover to the other arm for 6 weeks (double-blind period 2).
62221639|NCT04793659|EXPERIMENTAL|Oral Fasudil 180 mg/day|If the subject is a not a responder in the open-label period 1 but tolerated Fasudil 90 mg/day, they will be escalated to Fasudil 180 mg/day (open-label period 2) for 42 days. If the subject is a responder to Fasudil 180 mg/day, they are randomized to either Fasudil 180 mg/day for 42 days or a placebo (double-blind period 1), then crossover to the other arm for 6 weeks (double-blind period 2).
62797172|NCT04656743|EXPERIMENTAL|intra-articular injection group|will receive ultrasound guided intraarticular injection consisting of 20 mL of 0.25% bupivacaine before surgical procedure. The surgical procedure will be started 30 min after intraarticular injection.
62797173|NCT04656743|EXPERIMENTAL|genicular nerve block group|will receive ultrasound guided genicular nerve block at three nerves, i.e., superomedial, superolateral, and inferomedial genicular nerves consisting of 15 ml bupivacaine 0.25% before surgical procedure. The surgical procedure will be started 30 min after genicular nerve block.
62797174|NCT06355453||Pregnant Woman Arm|Subjects will have Goldcrest patch and three Novii electrodes will be placed on the subjects abdomen.
62797175|NCT06355453||Non-Pregnant Woman Arm|Subjects will have Goldcrest patch and Novii Patch and electrodes will be placed on the subjects abdomen.
62221640|NCT04793659|PLACEBO_COMPARATOR|Oral Placebo|Placebo comparator arm to investigational drug (Fasudil 90 mg/day or 180 mg/day).
62221641|NCT04486326|EXPERIMENTAL|crofelemer|125mg bid
62221642|NCT04486326|PLACEBO_COMPARATOR|placebo|bid
62416014|NCT02023723|EXPERIMENTAL|Energy Drink|16oz original flavor energy drink consume 2 -16oz energy drinks within 60 minutes
62416015|NCT02023723|ACTIVE_COMPARATOR|Active Control|16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
62416016|NCT04657978||Substrate guided intervention arm|Participants recruited to the study will undergo High Density Wave Solution™ guided substrate mapping of the left atrium. Ablation will thereafter be performed to comprise wide area circumferential ablation of the pulmonary veins in pairs, followed by ablation of low voltage zones in the left atrium.
62416017|NCT02475161|EXPERIMENTAL|JNJ-42847922 Plus Rabeprazole|Participants will receive JNJ-42847922, 20 milligram (mg) on Day 1 and Day 6. Participants will receive rabeprazole 20 mg once daily from Day 2 to Day 6.
62416018|NCT01293786||Kidney transplant recipients|
62587969|NCT05405946|EXPERIMENTAL|Computerized Cognitive Remediation Intervention and Treatment as Usual (CCRT+TAU)|"Participants with a diagnosis of schizophrenia / schizoaffective disorder undergo Computerized CRT and the usual treatment.~Three evaluations are carried out, each one divided into two sessions: an evaluation before the start of treatment, a second evaluation after finishing the Computerized CRT (after 40 sessions), and a third evaluation (follow-up) 6 months after finishing the Computerized CRT."
62221643|NCT04041674|EXPERIMENTAL|Group 1 (T1): DNA + MVA + Placebo (IM)|"Participants will receive 3 mg of GEO-D02 DNA by intramuscular (IM) injection at Months 0 and 2.~Participants will also receive 1×10\^8 50% tissue culture infective dose (TCID50) of MVA/HIV62B plus placebo for B63521\^11 gp120 plus placebo for IHV01, each by IM injection at Months 4, 6, and 10."
62416019|NCT01293786||Chronic kidney disease|
62416020|NCT06696274||Hemodialysis patients|
62416021|NCT05519605||PTBD after failed ERCP|Patients with a distal malignant obstruction undergoing placement of a percutaneous transhepatic biliary drain after failed ERCP.
62416022|NCT05519605||EUS-BD after failed ERCP|Patients with a distal malignant obstruction undergoing EUS-guided biliary drainage after failed ERCP.
62416023|NCT05665530|EXPERIMENTAL|PRT2527 Monotherapy in Lymphoid Malignancies|PRT2527 will be administered by intravenous infusion once weekly at the dose level assigned during the dose escalation phase and at the defined RP2D dose for indication-specific cohorts during the dose confirmation phase.
62587970|NCT05405946|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|"Participants with a diagnosis of schizophrenia / schizoaffective disorder undergo the usual treatment.~Two evaluations will be carried out, also divided into two sessions: a first baseline evaluation and a second evaluation 5 months later, after receiving the usual treatment. After this second evaluation, the Computerized CRT is then started to guarantee ethics in all patients.~The evaluation is not carried out at 6 months since they will also have received the intervention."
62221644|NCT04041674|EXPERIMENTAL|Group 2 (T1): DNA + MVA + Placebo (SC)|"Participants will receive 3 mg of GEO-D02 DNA by IM injection at Months 0 and 2.~Participants will also receive 1×10\^8 TCID50 of MVA/HIV62B by IM injection plus placebo for B63521\^11 gp120 by subcutaneous (SC) injection plus placebo for IHV01 by SC injection at Months 4, 6, and 10."
62221645|NCT04041674|EXPERIMENTAL|Group 3 (T2): DNA + MVA + IHV01 + B63|"Participants will receive 3 mg of GEO-D02 DNA by IM injection at Months 0 and 2.~Participants will also receive 1×10\^8 TCID50 of MVA/HIV62B plus 150 mcg of B63521\^11 gp120 plus 150 mcg of IHV01, each by IM injection at Months 4, 6, and 10."
62416024|NCT05665530|EXPERIMENTAL|PRT2527/Zanubrutinib Combination in Lymphoid Malignancies|"PRT2527 will be administered by intravenous infusion once weekly at the dose level assigned during the dose escalation phase and at the defined RP2D dose for indication specific cohort during the dose confirmation phase.~Zanubrutinib will be administered orally as combination therapy once or twice daily."
62416025|NCT05665530|EXPERIMENTAL|PRT2527 Monotherapy in Myeloid Malignancies|PRT2527 will be administered by intravenous infusion once weekly at the dose level assigned during the dose escalation phase and at the defined RP2D dose for indication-specific cohorts during the dose confirmation phase.
62416026|NCT05665530|EXPERIMENTAL|PRT2527/Venetoclax Combination in Myeloid Malignancies|"PRT2527 will be administered by intravenous infusion once weekly at the dose level assigned during the dose escalation phase and at the defined RP2D dose for indication specific cohort during the dose confirmation phase.~Venetoclax will be administered orally as a combination therapy once daily."
62416027|NCT04439097|EXPERIMENTAL|Experimental Group|"Patients allocated to the intervention group will perform a MPEP during 6 months, with a frequency of 3 sessions per week, and approximately 45-50 minutes of duration each session. In addition, they will have a Mediterranean Diet.~The patients in the MPEP will be carried out in small groups of 5-8 people. Structure of sessions: 3 different parts: an initial warm-up, a main part and a final cool-down and relaxation."
62416028|NCT04439097|ACTIVE_COMPARATOR|Control Group|Participants allocated to the control group will receive usual care and continue with their life normally, without participating in a standardized exercise program. They will be instructed to maintain their current physical activity level.
62221646|NCT04041674|EXPERIMENTAL|Group 4 (T3): DNA + MVA +IHV01 + Placebo|"Participants will receive 3 mg of GEO-D02 DNA by IM injection at Months 0 and 2.~Participants will also receive 1×10\^8 TCID50 of MVA/HIV62B plus placebo for B63521\^11 gp120 plus 150 mcg of IHV01, each by IM injection at Months 4, 6, and 10."
62221647|NCT04041674|EXPERIMENTAL|Group 5 (T4): DNA + MVA +IHV01 (SC)+ B63 (SC)|"Participants will receive 3 mg of GEO-D02 DNA by IM injection at Months 0 and 3.~Participants will also receive 1×10\^8 TCID50 of MVA/HIV62B by IM injection plus 150 mcg of B63521\^11 gp120 by SC injection plus 150 mcg of IHV01 by SC injection at Months 4, 6, and 10."
62221648|NCT05569031|ACTIVE_COMPARATOR|venlafaxidine|venlafaxine 75-225 mg per day.
62221649|NCT05569031|ACTIVE_COMPARATOR|Lofixidine|Lofixidine 1.6 to 2.4 per day.
62221650|NCT06203015||MDD patients|patients diagnosed with MDD (according to the WHO's \[2019\] International Classification of Diseases and related health problems categorization of mental disorders), diagnosed by a psychiatrist; ≥18 years old
62221651|NCT06203015||Control group|Subjects who have not been diagnosed with any mental disorder in the past year; ≥18 years old
62221652|NCT02516475|ACTIVE_COMPARATOR|zinc sulfate|1 zinc sulfate capsule for 15 weeks
62221653|NCT02516475|PLACEBO_COMPARATOR|starch|1 corn starch capsule for 15 weeks
62416029|NCT02060227|ACTIVE_COMPARATOR|Arthroscopic Bankart repair|After the diagnostic arthroscopy is completed, any other pathology is documented. At least 3 anchors will be used for the bankart repair for repair of the labrum with an inferior to superior capsular shift. The suture anchors used will be at the discretion of the surgeon but will be of the screw-in variety. The sutures are passed through the labrum, and the labrum is tied to the glenoid rim after the bone is prepared in the standard fashion. The surgical times will be recorded on standardized forms.
62587971|NCT04563975|EXPERIMENTAL|Chemotherapy and programmed death 1 inhibitor|Docetaxel /nab-paclitaxel in combination with Toripalimabs
62587972|NCT03268200|EXPERIMENTAL|Case group|Each segment of colon (right colon, mid-colon, and left colon) was examined twice
62587973|NCT03268200|NO_INTERVENTION|Control group|Withdrawal time in the each segment of colon (right colon, mid-colon, and left colon) was about 2 minutes.
62221654|NCT05720845|ACTIVE_COMPARATOR|conventional mechanical ventilation|Conventional mechanical ventilation for General Anesthesia
62416030|NCT02060227|ACTIVE_COMPARATOR|Open Latarjet procedure|A deltopectoral approach is used. The coracoacromial ligament (CAL) is exposed and incised 1 cm from its coracoid attachment. Harvesting of a 2.5- to 3-cm coracoid graft allows use of 2 screws for fixation to the glenoid neck through a subscapularis-splitting approach. The stump of the CAL is repaired to the capsule with the arm positioned in neutral. The graft is placed in a extra-articular fashion with capsular closure to the native glenoid rim.
62587974|NCT03557216|EXPERIMENTAL|Complicated diverticulitis|Patients with complicated diverticulitis diagnosed by computed tomography. Colonoscopy, Fecal immunochemical and occult blood test (FIT) and fecal calprotectin test wil be performed.
62221655|NCT05720845|EXPERIMENTAL|VESPA|ventilatory strategy to prevent atelectasis for General Anesthesia
62221656|NCT02072915|EXPERIMENTAL|Suction|Suction will be applied to patients undergoing EUS-FNA
62221657|NCT02072915|NO_INTERVENTION|Without suction|No suction will be applied to patients undergoing EUS-FNA
62221658|NCT05402930|EXPERIMENTAL|Neoadjuvant chemotherapy|
62221659|NCT02593266|EXPERIMENTAL|Intervention Group|weekly sessions of PIP for depression.
62221660|NCT02593266|NO_INTERVENTION|Waiting list control group|This is treatment as usual.
62221661|NCT02304146||High ligation and stripping (surgery)|6-10 years post classical stripping of the great saphenous vein.
62221662|NCT02304146||Foam sclerotherapy|6-10 years post post ultrasound guided foam sclerotherapy of the great saphenous vein.
62587975|NCT03557216|EXPERIMENTAL|Uncomplicated diverticulitis|Patients with uncomplicated diverticulitis diagnosed by computed tomography. Colonoscopy, Fecal immunochemical and occult blood test (FIT) and fecal calprotectin test wil be performed.
62797176|NCT04245839|EXPERIMENTAL|Administration of JCAR017|"* Subjects will be treated with fludarabine IV (30 mg/m2/day for 3 days) and cyclophosphamide IV (300 mg/m2/day for 3 days) prior to JCAR017 infusion. Refer to the most recent package inserts for further details on administration of these agents.~* JCAR017 will be infused on Day 1 at a target dose of 100 × 10\^6 CAR-positive viable T cells (CAR+ T cells), 2 to 7 days after completion of LD chemotherapy. Each JCAR017 dose includes CD4+ CAR+ T cells and CD8+ CAR+ T cells."
62797177|NCT02073994|EXPERIMENTAL|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or Investigator discretion.
62797178|NCT04818970|EXPERIMENTAL|Phototherapy of narrow band ultraviolet Light B-Band NB-UVB|Daavlin Series 1 Phototherapy Unit that emits UVB light between 280nm and 320nm.
62221663|NCT04375761||SARS-CoV-2 Surveillance: Total Group|"Participants either currently or in the past, enrolled in National Institutes of Health (NIH)-funded cohort studies, and their families (household contacts).~Active surveillance for detection of SARS-CoV-2 for 6 months, beginning with enrollment. During surveillance, biological samples will be collected by the family at established intervals and symptom and exposure surveys will be completed at the time that biological samples are collected."
62221664|NCT04253080|NO_INTERVENTION|patients with primary thin melanoma < or = 1mm|patients with primary thin melanoma (Breslow thickness less than or equal 1 mm)
62221665|NCT04253080|NO_INTERVENTION|patients with primary thick melanoma > or = 3 mm|patients with primary thick melanoma (Breslow greater than or equal 3 mm)
62221666|NCT04253080|OTHER|patient with melanoma who received treatment|patient with melanoma (stages III or IV inoperable) and who received first line treatment with immunotherapy and / or targeted therapies
62221667|NCT02632032|OTHER|Insulin therapy and diabetes education|Children and adolescents living with type 1 diabetes already on insulin therapy received collective diabetes education during a five days camp.
62416031|NCT05303727|EXPERIMENTAL|Conditioning regimen for different sources of donors|There are 3 groups according to different sources of donor: (1) Cord blood HSCT: Flu+Bu+CTX+Topotecan (without ATG); (2) Peripheral blood HSCT or haploid bone marrow combined with peripheral stem cell transplantation: Flu+Bu+Melphalan+Antithymocyte globulin (ATG)+ Thiotepa (TT) or (3) Flu+Bu+Melphalan+ATG (applicable to peripheral stem cells or haploid bone marrow combined with peripheral stem cell transplantation for which TT cannot be used).
62416032|NCT04533165|EXPERIMENTAL|Virtual exercise program|This arm will receive the virtual exercise program.
62416033|NCT03056716|EXPERIMENTAL|Silastic drain|Placement of 19FR silastic drain as basal drain
62416034|NCT03056716|ACTIVE_COMPARATOR|Conventional drain|Placement of 32FR conventional drain as basal drain
62416035|NCT02061709|EXPERIMENTAL|Ragweed-SPIRE 1|Ragweed SPIRE regimen 1 given 2 weeks apart
62416036|NCT02061709|EXPERIMENTAL|Ragweed-SPIRE 2|Ragweed-SPIRE regimen 2 given 2 weeks apart
62416037|NCT02061709|EXPERIMENTAL|Ragweed-SPIRE 3|Ragweed-SPIRE regimen 3 given 2 weeks apart
62416038|NCT02061709|PLACEBO_COMPARATOR|Placebo|Placebo given 2 weeks apart
62416039|NCT05066347|NO_INTERVENTION|Usual care|Patients randomized to usual care will receive all care as prescribed by the discharging physician and there will be no study specific interventions. The current usual care varies from no outpatient monitoring to short-term Holter monitoring (24 hours to 72 hours).
62587976|NCT01065870|EXPERIMENTAL|Group I|Patients with only venous involvement Treated with 6 cycles og GTX and then surgery
62587977|NCT01065870|EXPERIMENTAL|Group II|Patients with arterial involvement and may have venous involvement with tumor treated with 6 cycles of GTX, thenb GX/RT and then surgery
62797179|NCT04818970|PLACEBO_COMPARATOR|Placebo - Light|Daavlin Series 1 Phototherapy Unit that does not emit UVB light between 280nm and 320 nm.
62797180|NCT04170543|EXPERIMENTAL|Group 1|MEDI3506 Dose 1 plus Dapagliflozin (Day 85 to Day 168).
62797181|NCT04170543|EXPERIMENTAL|Group 2|MEDI3506 Dose 2 plus Dapagliflozin (Day 85 to Day 168).
62416040|NCT05066347|EXPERIMENTAL|Prolonged 24/7 live outpatient cardiac rhythm monitoring|Patients randomized to the intervention arm will receive 24/7 live cardiac rhythm monitoring for 15 days. If a patient is randomized to the intervention arm and was prescribed outpatient cardiac monitoring such as Holter monitor, this will be replaced by the 24/7 live monitoring and will be applied either prior or within 24 hours of discharge from the ED.
62416041|NCT06497101|EXPERIMENTAL|Temperament Based Therapy with Support (TBT-S)|TBT-S in addition to treatment as usual
62416042|NCT06497101|NO_INTERVENTION|Treatment as Usual (TAU)|Treatment as Usual
62416043|NCT03162016|EXPERIMENTAL|Transplants of acellular matrix|
62416044|NCT03162016|ACTIVE_COMPARATOR|Transplants of connective tissue|
62416045|NCT01135901|EXPERIMENTAL|group programme|Group based behaviour change programme
62797182|NCT04170543|EXPERIMENTAL|Group 3|MEDI3506 Dose 3 plus Dapagliflozin (Day 85 to Day 168).
62797183|NCT04170543|EXPERIMENTAL|Group 4|MEDI3506 Dose 4 plus Dapagliflozin (Day 85 to Day 168).
62797184|NCT04170543|PLACEBO_COMPARATOR|Group 5|Placebo (volume matched) plus Dapagliflozin (Day 85 to Day 168).
62797185|NCT06725836|EXPERIMENTAL|Spinal Cord Stimulation|Patients with clinical presentations of complete and incomplete spinal cord injury.
62797186|NCT04809285|EXPERIMENTAL|Guardian™ Connect system, InPen™ Basal smart cap, and smart insulin pens|All subjects will wear the Guardian Connect system (real-time continuous glucose monitoring (CGM)) continuously and use smart insulin pens or insulin pens with smart caps for multiple daily injections and continue their standard therapy throughout the duration of the study.
62416046|NCT04383769||5,000 participants:|"2,500 are PLHIV receiving standard care in the hospital and 2,500 are PLHIV receiving care in DSD-ART model~Inclusion criteria:~1. Thai citizenship~2. Age ≥ 18~3. HIV positive~4. Received ART for at least 6 months at a participating hospital (Except for After hour ART clinic model that will allow participants who receive ART less than 6 months into service)~5. One of the following:~   1. Accept DSD-ART, OR~  2. Already receiving DSD-ART, OR~  3. Decline DSD-ART and will continue standard ART service at the hospital."
62416047|NCT05991492|ACTIVE_COMPARATOR|Web-based Cognitive Behavioral Therapy for Insomnia (wCBT-I) with general sleep education|
62797187|NCT04391114|ACTIVE_COMPARATOR|Traditional HoLEP|Holmium laser enucleation of the prostate (HoLEP), first reported by Fraundorfer et al in 1998, is a more recent step in the evolution of holmium laser prostatectomy. HoLEP is a safe and effective procedure which has demonstrated comparable results to Transurethral Resection of the Prostate (TURP) and open prostatectomy for patients with symptomatic enlarged prostate, with low morbidity and short hospital stay \[4\]. The improvement in outcome parameters is durable, and the late complications and reoperation rates reported are very low \[5\]. HoLEP is equally suitable for small, medium and larger prostate glands, with clinical outcomes that are independent of prostate size, unlike TURP. HOLEP offers patients the alterative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay \[6\].
62416048|NCT05991492|NO_INTERVENTION|General Sleep Education|
62416049|NCT02561728|EXPERIMENTAL|Plagiocephaly|Children with a misshaped head due to positioning. This is also known as flat head. Children with plagiocephaly will be treated with either the Hangar Helmet or the P-Pod helmet.
62416050|NCT02561728|EXPERIMENTAL|Craniosynostosis|Craniosynostosis occurs when one or multiple sutures fuse too early. Several sutures may be fused alone or in combination. An open or endoscopic surgical procedure to open the suture(s) is necessary to allow for normal brain growth and development. After surgery a cranial remolding helmet is used to direct skull growth. Children with craniosynostosis will be treated with either the Hangar Helmet or the P-Pod helmet
62416051|NCT02032823|EXPERIMENTAL|Olaparib|Olaparib tablets 300mg b.i.d. p.o.
62416052|NCT02032823|PLACEBO_COMPARATOR|Placebo|Placebo tablets b.i.d. p.o.
62416053|NCT06703151|EXPERIMENTAL|The experimental group will have (CMDs self-care) teaching material and a [Monopoly board game] plan|1st-5th month: Complete the assessment of self-care ability and biochemical indicators, introduce the (CMDs self-care) teaching material manual, and evaluate the case's referral treatment status from the institution, and provide answers to questions. Played the Monopoly board game 8 times: On average, each community has about 2-3 groups (a group of 4-7 people), each group has a leader (seed teacher) to provide CMDs health education Q\&A before each board game activity . The 6th month: Conduct self-care process assessment in each community. The 7th-12th month: Telephone visits are provided every 2 months (3 times in total), each case lasts 5-10 minutes each time.
62416054|NCT06703151|NO_INTERVENTION|Only follow the community screening abnormality handling process and accept the referral treatment|After completing the assessment of self-care ability and biochemical indicators, use the referral treatment and care model of the health center or cooperative hospital; provide self-care manuals to each community in the first to second months, and providing answers to questions (same as the experimental group); conduct self-care process assessments in each community in the 24th week
62416055|NCT04452097|EXPERIMENTAL|Phase 1 Low-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 0.5 million cells/kg in addition to standard of care treatment.
62416056|NCT04452097|EXPERIMENTAL|Phase 1 Middle-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1 million cells/kg in addition to standard of care treatment.
62416057|NCT04452097|EXPERIMENTAL|Phase 1 High-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1.5 million cells/kg in addition to standard of care treatment.
62416058|NCT04452097|EXPERIMENTAL|Phase 2a Treatment Group|Eligible subjects will receive a single infusion of hUC-MCS product at the selected dose from phase 1 in addition to standard of care treatment.
62416059|NCT04452097|PLACEBO_COMPARATOR|Phase 2a Control Group|Eligible subjects will receive a single infusion of placebo control and standard of care treatment.
62416060|NCT06137339|EXPERIMENTAL|Avocado Group|Participants will consume 1 avocado per day and receive education to maintain usual caloric intake for 12 weeks and participate in 4 study visits.
62416061|NCT06137339|NO_INTERVENTION|No Diet Modification Group|Participants will continue their normal dietary pattern for 12 weeks and participate in 4 study visits.
62416062|NCT06251024|EXPERIMENTAL|Group 1: RSV vaccine candidate|Participants will be enrolled in a 1:1 ratio to receive a single IM administration of the RSV vaccine candidate.
62416063|NCT06251024|PLACEBO_COMPARATOR|Group 2: placebo|Participants will be enrolled in a 1:1 ratio to receive a single IM administration of the placebo.
62416064|NCT00353782||Dyslipidemia|Dyslipidemia
62416065|NCT06703801||Patients at the Prince of Wales Hospital ambulatory cardiac clinic|Patients age \> 18 with echocardiographic confirmation of increased pulmonary pressure (eg. estimated RVSP \>40mmHg, evidence of RV dilatation etc) and able to attend at the Prince of Wales Hospital ambulatory cardiac clinic
62416066|NCT04579367||Bempedoic acid and/or fixed-dose combination with ezetimibe|Participants with primary hypercholesterolemia or mixed dyslipidemia who received bempedoic acid and/or its fixed-dose combination with ezetimibe.
62221668|NCT00201227|EXPERIMENTAL|Practice Change|Enhancement of primary care practice performance and practice guideline adherence
62221669|NCT00201227|NO_INTERVENTION|Control|Usual care
62587978|NCT05742009|EXPERIMENTAL|iCare ST500 vs GAT and iCare IC200|Measurement of intraocular pressure (IOP) with iCare ST500 compared to GAT and iCare IC200. Measurements will be performed in three categories: Low IOP (7 to 16 mmHg), Medium IOP (\>16 to \<23 mmHg), or High IOP (≥23 mmHg).
62797188|NCT04391114|ACTIVE_COMPARATOR|Top-Down HoLEP|"The Top-Down HoLEP technique is a novel technique which offers potential benefits to the Traditional HoLEP procedure, including decreased complexity, a reduced learning curve, with anticipated improved continence \[8\]. A variation of this method is also being explored in Japan (termed the en-bloc technique with anteroposterior dissection HoLEP) \[9\]. The main difference between the Top-Down and Traditional approach is that the direction of lateral dissection begins from upwards to downwards. This could help in avoiding the overtraction of the mucosal strip overlying the posterior urethral sphincter, which theoretically leads to a decrease in the incidence of postoperative stress incontinence. Moreover, using the Top-Down approach should lead to a decrease in the incidence of lost enucleation planes, which results in decreasing the intraoperative time and decreasing the number of cases required to master the HoLEP technique."
62221670|NCT06108960|EXPERIMENTAL|Proprioceptive neuromuscular facilitation|The patients will be positioned in supine lying and then contract relax will be performed on affected side of pelvis first in D1 pattern (anterior elevation and posterior depression) 3 times with 10 sec contractions and 5 sec relaxations in 1 set. Then in D2 pattern (posterior elevation and anterior depression) 3 times with 10 sec contractions and 5 sec relaxations in 1 set. 3 set of each diagonal pattern to be performed in 1 treatment session alternatively. Treatment will be given for a period of 4 days a week for 8 weeks
62221671|NCT06108960|EXPERIMENTAL|Pelvic stabilization exercises|All participants will receive training programs for the eight levels of training from static to dynamic conditions. The practiced therapy method will first taught by a physical therapist with a verbal explanation and visual aids (such as photographs) in each group. The therapist will supervise all stages of the exercise therapy to ensure the patients correctly performed the exercises. The supervised exercise intervention will be conducted 3 days a week for 8 weeks.
62221672|NCT01545154||Prostate Cancer|
62221673|NCT05442905|ACTIVE_COMPARATOR|Quadratus lumborum block group|will receive quadratus lumborum block the patient will be placed in lateral position, the probe will be placed on the crista iliaca anterior superior. After the external oblique, internal oblique, and transversus abdominis muscles will be seen, the probe will be moved to the posterior and the quadratus lumborum muscle will be observed. A 22-gauge, 80 mm insulated Quince-type needle (Uniplex; Pajunk, Geisingen, Germany) will be moved from the anterolateral plane to the posteromedial plane, and confirmation will be made using 0.5 mL/kg saline; after a negative aspiration, 0.7 mL/kg (0.25%) bupivacaine will be applied to the posterior of the quadratus lumborum muscle and the thoracolumbar fascia in between the quadratus lumborum and latissimus dorsi muscles.
62221674|NCT05442905|ACTIVE_COMPARATOR|Transversus abdominis block group|will receive TAP block with 0.7mL/kg of 0.25% bupivacaine under US guidance. A linear high frequency ultrasound probe (6-13 MHz) will be placed transversely in the mid axillary line between the iliac crest and the costal margin. The three layers of muscles, the external oblique, the internal oblique, and the transversus abdominis will be identified. Using the in-plane technique, needle will be inserted (from anterior to posterior direction) until the tip of the needle will reach between the internal oblique and the transversus abdominis. Hydro dissection with 1-2 mL saline will be done to separate the fascial layers. After the correct localization, 20 mL of the drug will beinjected with repeated aspiration to avoid the accidental intravascular injection.
62221675|NCT05442905|ACTIVE_COMPARATOR|Caudal block group|will receive caudal block with 1mL/kg of 0.25% bupivacaine, with children in left lateral position. with all aseptic measures caudal block will be performed using 25 G needle in left lateral decubitus position. Needle position will be confirmed by the pop felt during penetration of the sacrococcygeal ligament, further ensured by doing whoosh test using 0.5 mL of air injection 0.25% bupivacaine 1mL/kg will be administered after negative aspiration of blood and CSF. Intraoperative hemodynamic parameters will be recorded throughout the surgery at fixed intervals (at time of skin incision then after every 5 min till the end of surgery).
62221676|NCT04665999||Free-cycling females|Continuous glucose monitor (CGM) data will be collected for three (3) full menstrual cycles. At the end of data collection, data will be analyzed to track insulin sensitivity and glycemic variability changes across the menstrual cycle. Participants will be asked to record meals consumed and free-cycling females will be asked to confirm ovulation by means of study-provided ovulation kits. Participants will be asked to record dates of beginning of menses and ovulation. Participants will also be provide an activity tracker to wear during the duration of the trial.
62416067|NCT06703203|OTHER|≥60 years old age group (for phase Ⅰ)|There are 30 subjects in ≥60 years old age group, randomly assigned to the experimental group and the control group in a 2:1 ratio.
62416068|NCT06703203|OTHER|18-59 years old age group (for phase Ⅰ)|There are total 40 subjects in 18-59 age group. Among them, 30 subjects were randomly assigned to the experimental group and the control group in a 2:1 ratio. In addition, other 10 subjects aged 18-55 to receive the experimental vaccine as the serum calibration test population.
62416069|NCT06703203|OTHER|6-17 years old age group (for phase Ⅰ)|There are 30 subjects in 6-17 years old age group, randomly assigned to the experimental group and the control group in a 2:1 ratio.
62416070|NCT06703203|OTHER|2-5 years old age group (for phase Ⅰ/Ⅱ)|There are total 230 people in 2-5 years old age group. Among them, there were 30 subjects included in the phase Ⅰ clinical trial and were randomly assigned to the experimental group and the control group in a 2:1 ratio. And the other 200 people were included for phase Ⅱ and were randomly assigned to the experimental group and the control group in a 1:1 ratio.
62416071|NCT06703203|OTHER|13-23 months old age group (for phase Ⅰ)|There are 30 subjects in 13-23 months old age group, randomly assigned to the experimental group and the control group in a 2:1 ratio.
62416072|NCT06703203|OTHER|7-11 months old age group (for phase Ⅰ)|There are 30 subjects in 7-11 months old age group, randomly assigned to the experimental group and the control group in a 2:1 ratio.
62416073|NCT06703203|OTHER|3 months old age group (for phase Ⅰ)|There are 30 subjects in 3 months old age group, randomly assigned to the experimental group and the control group in a 2:1 ratio.
62416074|NCT06703203|OTHER|2 months old age group （for phase Ⅰ）|There are 30 subjects in 2 months old age group, randomly assigned to the experimental group and the control group in a 2:1 ratio.
62221677|NCT04665999||Females taking Monophasic contraception|Continuous glucose monitor (CGM) data will be collected for three (3) full menstrual cycles. At the end of data collection, data will be analyzed to track insulin sensitivity and glycemic variability changes across the menstrual cycle. Participants will be asked to record meals consumed and free-cycling females will be asked to confirm ovulation by means of study-provided ovulation kits. Participants will be asked to record dates of beginning of menses and ovulation. Participants will also be provide an activity tracker to wear during the duration of the trial.
62416075|NCT02810496|EXPERIMENTAL|patient|
62416076|NCT00364416||001|
62221678|NCT03143166|EXPERIMENTAL|All participants|Dabigatran etexilate given without rabeprazole and then Dabigatran etexilate given without rabeprazole.
62221679|NCT03674593|EXPERIMENTAL|Mitral valve chordae prosthesis|"Patients of this group receive mitral valve chordae replacement performed in five stages:~1. Measure the required length of the chordae.~2. Forming loops.~3. Fixation of the loop group to the papillary muscles.~4. Fixation of chordal loops to the free edge of the valve.~5. Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse."
62797189|NCT00342589||Healthy Volunteers|Individuals exposed to environmental or person-to-person sources of organisms, including healthy volunteers, health care professionals, patient families, or other patients in health care facilities
62797190|NCT00342589||Patients|Patients immunosuppressed with acute pneumonia and are undergoing or have undergone a clinically indicated procedure to obtain a respiratory sample for diagnostic purposes.
62416077|NCT05455411|EXPERIMENTAL|Group-based Parent-implemented Social Communication Training|A group-based parent-implemented social communication treatment program for up to 8 parents of children with autism spectrum disorder
62416078|NCT05455411|ACTIVE_COMPARATOR|Individual-based Parent-implemented Social Communication Training|An individual-based parent-implemented social communication treatment program for a parent of a child with autism spectrum disorder
62416079|NCT05314413|EXPERIMENTAL|Single Leg Immobilization - Males|Males will be subjected to 7-days of single-leg immobilization.
62797191|NCT00060632|EXPERIMENTAL|Cohort 1: Ridaforolimus 6.25 mg|
62416080|NCT05314413|EXPERIMENTAL|Single Leg Immobilization - Females|Females will be subjected to 7-days of single-leg immobilization.
62416081|NCT03664024|EXPERIMENTAL|Pembrolizumab Standard of Care|Participants will receive standard of care pembrolizumab combined with platinum-doublet chemotherapy for 4 cycles, then pembrolizumab plus pemetrexed maintenance for up to 31 additional cycles. The platinum doublet would be pemetrexed plus the investigator's choice of either cisplatin or carboplatin.
62416082|NCT04007406|EXPERIMENTAL|4 mg DP13 daily|DP13 for 8 weeks
62797192|NCT00060632|EXPERIMENTAL|Cohort 2: Ridaforolimus 12.5 mg|
62797193|NCT00060632|EXPERIMENTAL|Cohort 3: Ridaforolimus 25 mg|
62797194|NCT00060632|EXPERIMENTAL|Cohort 4: Ridaforolimus 50 mg|
62797195|NCT00060632|EXPERIMENTAL|Cohort 5: Ridaforolimus 100 mg|
62797196|NCT00060632|EXPERIMENTAL|Cohort 6: Ridaforolimus 75 mg|
62797197|NCT04234867|EXPERIMENTAL|Dapagliflozin - Stress|Administration of 10mg dapagliflozin oral for 5 days and one i.v. administration of 250µg ACTH (Synacthen)
62797198|NCT04234867|EXPERIMENTAL|Dapagliflozin and Placebo Stress|Administration of 10mg dapagliflozin oral for 5 days and one i.v. administration of Placebo matching Synacthen
62797199|NCT04234867|PLACEBO_COMPARATOR|Placebo Dapagliflozin and Stress|Administration of placebo oral for 5 days identical to dapagliflozin and one i.v. administration of 250µg ACTH (Synacthen)
62797200|NCT04234867|PLACEBO_COMPARATOR|Placebo Dapagliflozin and Placebo Stress|Administration of placebo oral for 5 days identical to dapagliflozin and one i.v. administration of Placebo matching Synacthen
62797201|NCT06725394||Group 1|Pregnant women
62416083|NCT04007406|EXPERIMENTAL|8 mg DP13 daily|DP13 for 8 weeks
62416084|NCT04007406|EXPERIMENTAL|12 mg DP13 daily|DP13 for 8 weeks
62416085|NCT06041516|EXPERIMENTAL|1/Arm1|ADCT-701 given as an IV infusion
62416086|NCT04777591|ACTIVE_COMPARATOR|Control - plain bupivacaine|Receives plain bupivacaine TAP block as part of multi-modal pain control intraoperatively
62416087|NCT04777591|EXPERIMENTAL|Experimental - Liposomal bupivacaine|Receives plain bupivacaine + liposomal bupivacaine TAP block as part of multi-modal pain control intraoperatively
62797202|NCT01568840|EXPERIMENTAL|Global Postural Reeducation Group|Global Postural Reeducation
62797203|NCT01568840|ACTIVE_COMPARATOR|Segmental Exercises Group|Segmental Exercises
62797204|NCT06433323||Treated group : Healthy female adults|
62797205|NCT03451851|EXPERIMENTAL|Part 1 Group 1: Guselkumab|Participants in Part 1a (age greater than or equal to (\>=) 12 - less than (\<) 18 years) will receive a weight-based dose of guselkumab subcutaneously (SC) at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of guselkumab until they lose \>=50% of their Week 16 PASI response, then they receive 1 dose guselkumab, followed by a dose 4 weeks later, and every 8 weeks (q8w) thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a placebo injection at Week 16 and continue to receive guselkumab q8w from Week 20 through Week 52. Participants who are eligible and willing to continue guselkumab may enter the Long Term Extension (LTE) Phase of the study. Part 1b (age \>= 6 - \<12 years) will follow the same dosing and commence after Part 1a data review.
62221680|NCT03674593|ACTIVE_COMPARATOR|Mitral valve chordae translocation|"The technique of translocation of secondary chordae:~The method consists essentially of three stages:~1. Selection of the secondary chordae.~2. Fixation of secondary chordae to the free edge of the valve.~3. Annuloplasty support ring and hydraulic test to confirm the absence of prolapse."
62416088|NCT02132936|EXPERIMENTAL|LEO 90100|LEO 90100 aerosol foam, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per can, applied once daily up to 12 weeks
62587979|NCT06667973|EXPERIMENTAL|Newly-diagnosed FLT3-positive Acute Myeloid Leukemia treated with gilteritinib|"Treatment consists in up to 2 induction cycles and up to 3 consolidation cycles:~Induction: Patients will receive Gilteritinib 120 mg QD p.o from day 6 to 26 (21 days), in combination with FLAI induction (fludarabine 30 mg/sqm from day 1 to 5, cytarabine 2000 mg/sqm from day 1 to 5, Idarubicine 10 mg/sqm on days 1, 3, 53).~Response will be assessed on day 28 with a bone marrow aspirate.~* In patients not achieving CR, the second induction cycle will be identical to Induction I.~* In patients achieving CR, a second induction cycle with ARA-C + IDA will be allowed (cytarabine 2000 mg/sqm from day 1 to 5, Idarubicine 10 mg/sqm on days 1, 3, 5), with the same schedule for Gilteritinib (day 6 to 26)~Up to 3 consolidation cycles consisting in high dose cytarabine (1500-3000 mg/sqm bid on days 1,3,5) or intermediate in combination with Gilteritinib 120 mg QD p.o from day 6 to 26 will be allowed.~Patients considered eligible may proceed to allo-HSCT at any time after day 28."
62587980|NCT06120569|EXPERIMENTAL|Soleus muscle exercise in diabetes|Soleus muscle decrease blood glucose
62587981|NCT06120569|EXPERIMENTAL|Decrease glucose level by soleus exercise|Soleus ms exercise in decrease blood glucose
62221681|NCT04470232||Patients with coxofemoral pathologies|"For the transcultural validation, a french version of the 2 self-assessment questionnaires, SUSHI-score and the HOOs-12 score will be produced.~For the psychometric validation, 120 patients with coxofemoral pathologies will pass the two questionnaires. The HAGOS (Hip and Groin Score) questionnaire will be also passed by the subject, for the convergent validity."
62221682|NCT01571401|EXPERIMENTAL|Supervised PA plus Exercise Counselling|Participants will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, this group will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at fitness centre. In order to achieve the physical activity guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed. In addition to the supervised sessions, traditional exercise counselling will be provided to teach proper technique, how to monitor intensity, and to progress PA safely and effectively to achieve the public health physical activity guidelines
62221683|NCT01571401|EXPERIMENTAL|Supervised PA plus behavioural counselling|"In addition to the same supervised PA sessions as the SPA group, participants in this group will receive six individual face-to-face behavioural counselling sessions with a physical activity specialist. These counselling sessions will be combined with the supervised PA sessions, and will be provided directly following the supervised PA session. Counselling strategies will be based on the TPB and will target the unique benefits of PA for kidney cancer survivors, strategies for making PA enjoyable, for overcoming barriers, for including social support from family and friends, time management, self-monitoring, goal setting, and planning."
62221684|NCT06526013|NO_INTERVENTION|Standard of care|Usual care according to current procedure (in patients with post acute coronary syndrome) regarding LDL target level adjustment
62221685|NCT06526013|EXPERIMENTAL|Cholesterol self-measurement|Training patients for self-monitoring of cholesterol, with independent monthly measurements and reporting of results to the study team, followed by prompt therapy adjustments
62221686|NCT06243861||kangaroo unit|
62221687|NCT06243861||postnatal care|
62221688|NCT05306405|ACTIVE_COMPARATOR|vaginal misoprostol|only vaginal misoprostol 25 μg tablets will be applied for induction of laour
62221689|NCT05306405|ACTIVE_COMPARATOR|combined vaginal misoprostol and estradiol|vaginal misoprostol 25 μg (Vagiprost) tablets with vaginal estradiol 150 ml cream will be applied for induction of laour
62221690|NCT06151223||Tier 1|"* Participants with Peutz-Jeghers syndrome and/or carriers of a germline CDKN2A mutation and/or hereditary pancreatitis with PRSS1 mutation and clinical history of pancreatitis(age ≥40 or 10 years younger than youngest affected blood relative)~* Carriers of a germline BRCA2, BRCA1, PALB2, ATM, MLH1, MSH2, or MSH6 gene mutation with at least one affected first-degree blood relative (age ≥45 or 10 years younger than youngest affected blood relative)~* At least one first-degree relative (FDR) with pancreatic cancer who in turn also has a first-degree relative with pancreatic cancer and/or at least two affected blood relatives on the same side of the family, of whom at least one is an FDR to the individual and/or at least three affected relatives on the same side of the family, of whom at least one is an FDR to the individual(age ≥50 or 10 years younger than youngest affected blood relative)"
62416089|NCT02132936|PLACEBO_COMPARATOR|Aerosol foam vehicle|Aerosol foam vehicle, 60 g per can, applied once daily for up to 12 weeks
62416090|NCT02132936|ACTIVE_COMPARATOR|Calcipotriol BDP gel|Calcipotriol BDP gel, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per bottle, applied once daily up to 12 weeks
62416091|NCT02132936|PLACEBO_COMPARATOR|Gel vehicle|Gel vehicle, 60 g per bottle, applied once daily up to 12 weeks
62587982|NCT06509958|EXPERIMENTAL|Dose 1|
62587983|NCT06509958|EXPERIMENTAL|Dose 2|
62587984|NCT06509958|ACTIVE_COMPARATOR|Ropivacaine Hydrochloride Injection|
62587985|NCT06243783|EXPERIMENTAL|Stress|Montreal Imaging Stress Test during each PET/MRI measurement and in-between
62797206|NCT03451851|PLACEBO_COMPARATOR|Part 1 Group 2: Placebo for Guselkumab|Participants in Part 1a (age \>= 12 - \<18 years) will receive placebo for guselkumab administered SC at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of study intervention until they lose \>=50% of their Week 16 PASI response, at which time they will receive a weight-based guselkumab SC dose, followed by a dose 4 weeks later, and q8w thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a weight-based guselkumab dose at Weeks 16 and 20, followed by q8w dosing thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE phase of the study. Part 1b (age \>= 6 - \<12 years) will follow the same dosing and commence after Part 1a data review.
62416092|NCT03286426|EXPERIMENTAL|Vision/Eye Screening|Image of back of each eye along with color vision and visual acuity assessment if able.
62797207|NCT03451851|ACTIVE_COMPARATOR|Part 1 Group 3: Etanercept|Participants in Part 1a (age \>= 12 - \<18 years) will receive weight-based etanercept dose up to 50 milligram SC weekly through Week 15. Participants who elect to continue in the study will receive a weight-based guselkumab dose at Weeks 20 and 24, followed by q8w dosing thereafter through Week 48. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE phase of the study. Part 1b (age \>= 6 - \<12 years) will follow the same dosing and commence after Part 1a data review.
62797208|NCT03451851|EXPERIMENTAL|Part 2: Guselkumab|Participants will receive a weight-based dose of open-label guselkumab SC at Weeks 0, 4 and q8w thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE of the study and continue to receive guselkumab at Week 52 and q8w thereafter.
62797209|NCT03668002|PLACEBO_COMPARATOR|Arteriovenous Fistula (AVF)|If the participant is randomized to the AVF arm of the trial, the surgeon will connect an artery to a vein in the upper extremity, without using artificial material as conduit.
62797210|NCT03668002|ACTIVE_COMPARATOR|Arteriovenous Graft (AVG)|If the participant is randomized to the AVG arm of the trial, the surgeon will place a synthetic graft connecting an artery and vein under the skin in an upper extremity.
62797211|NCT06017180|EXPERIMENTAL|Myofascial Release Group|54 healthy people playing volleyball will be included in our study and randomly divided into groups. In group I (myofascial release group), myofascial release will be applied to the shoulder and elbow region.
62797212|NCT06017180|SHAM_COMPARATOR|Control Group|54 healthy people playing volleyball will be included in our study and randomly divided into groups. The sham method will be applied to the shoulder and elbow region of group II (control group).
62797213|NCT06726317|EXPERIMENTAL|Intervention group receiving the novel early palliative care package|This group received the novel early palliative care intervention package
62797214|NCT06726317|NO_INTERVENTION|Control group|This group received only the existing standard care in the health system and did not receive any special intervention through this study
62797215|NCT06059404|NO_INTERVENTION|Meals only|"ARM 1: Meals only. Participants randomized to receive meals only will receive 14 frozen meals, delivered 1x/week, for 3-months. Participants will be provided with a menu of 40 meal options and instructions for how to select their meals and change weekly meal selections (if desired). Participants in this arm will also receive nutrition education and fall prevention handouts. Nutrition education handouts will indicate which of LifeCare Alliance's meals are considered to be heart healthy as well as diabetic-friendly. Participants will have the autonomy to select their own meals according to their preferences and their ability to self-manage their own health conditions (e.g., diabetes, cardiovascular disease). Fall prevention education handouts will provide guidance on how to reduce fall risk at home and modify the home environment to eliminate fall hazards."
62797216|NCT06059404|ACTIVE_COMPARATOR|Meals + registered dietitian services|"ARM 2: Meals + registered dietitian services. Participants randomized to receive meals + RD only will receive 14 frozen meals, delivered 1x/week, for 3-months. In addition to receiving nutrition education and fall prevention handouts, participants in this arm will have a telephone-based nutrition assessment completed by one of LifeCare Alliance's registered dietitians who will assign participants a nutrition diagnosis (e.g., overconsumption of carbohydrates) within 60 days of study enrollment."
62416093|NCT06632509||USGVAD|Patient who is a candidate for an ultrasound-guided vascular access device (USGVAD) placement procedure using SiteRite 9 System as assessed per their clinician(s)
62433392|NCT06069765|NO_INTERVENTION|Standard group|Children in this group will continue with their daily activities such as conventional physiotherapy and occupational therapy, even psychology, and their physical activities such as swimming or playing football.
62587986|NCT01182597|ACTIVE_COMPARATOR|IV PPI|Pantoprazole 3.3mg/hr for 72hrs
62797217|NCT06059404|ACTIVE_COMPARATOR|Meals + occupational therapy services|ARM 3: Meals + occupational therapy services. Participants randomized to this arm will receive 14 frozen meals, delivered 1x/week, for 3-months and be able to make weekly meal selections from LifeCare Alliance's full list of 40 meals. In addition to receiving nutrition education and fall prevention handouts, participants in this arm will be contacted (within 30 days of study enrollment) by one of Lifecare Alliance's occupational therapists to complete a phone screen to determine each participant's occupational therapy needs (e.g., home safety/fall risk hazards, need for durable medical equipment).
62797218|NCT06059404|EXPERIMENTAL|Meals + registered dietitian + occupational therapy services|ARM 4: Meals + registered dietitian services + occupational therapy services. Participants in this arm will receive 14 frozen meals, delivered 1x/week, for 3-months as well as the same nutrition education and fall prevention handouts as provided in Arms 1-3. Additionally, participants will receive the combination of dietitian and OT services as provided in Arms 2 and 3 and have the same autonomy to make their own weekly meal selections from a curated list provided by the dietitian.
62587987|NCT01182597|EXPERIMENTAL|Oral PPI|Lansoprazole (Takepron OD) 30mg PO q12h
62221691|NCT06151223||Tier 2|"* Individual with family history of PDAC in only one first degree relative (FDR); age ≥50 or 10 years younger than the affected first degree relative~* OR known BRCA2, BRCA1, PALB2, ATM, MLH1, MSH2, or MSH6 gene mutation; age \> 45 who do not meet tier 1 criteria."
62221692|NCT03606434|EXPERIMENTAL|Hypoxic Exposure|Men, and women in early or late follicular phase of menstrual cycle will be exposed to acute and intermittent hypoxic episodes.
62221693|NCT00681460|ACTIVE_COMPARATOR|1|gestational diabetes, insulin therapy
62416094|NCT05346939|EXPERIMENTAL|Senior high school athletes in Taiwan|"In the first year, the investigators would verify the relation between wearable device and motion analysis and its validity and reliability at stage I (n=15). And the investigators are going to observe the effect of dynamic taping in lower limb biomechanics of high-school soccer or basketball athletes (n=50) at stage II.~In the second year, the investigators would recruit high school soccer and basketball athletes to examine the effect of dynamic taping in lower limb biomechanics under fatigue (n=50)."
62416095|NCT01548573|EXPERIMENTAL|Tandem autologous stem cell transplant|"Induction: DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant 1: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide) Transplant 2: 8 weeks to 6 months after the first transplant, participants will have the second transplant Maintenance: Year 1- VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
62416096|NCT01788163|OTHER|Locally advanced/metastatic NSCLC pats.|Patients with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy)
62416097|NCT02636166|OTHER|Pregnancy test|"Clearblue investigational Pregnancy test~Clearblue Marketed pregnancy test~Professional pregnancy test"
62416098|NCT03475186|EXPERIMENTAL|Ramipril|Ramipril will be taken once daily by mouth. It will be titrated during the first 3 weeks of chemoradiation to the highest tolerable dose (2.5-5 mg). This dose will be taken each day until 4 months post-chemoradiation treatment (22 weeks).
62221694|NCT00681460|EXPERIMENTAL|2|gestational diabetes, metformin therapy
62221695|NCT03266705|EXPERIMENTAL|61 mgA tafamidis free acid soft gelatin capsule|
62587988|NCT00089778|EXPERIMENTAL|Grp A-Measurable metastatic disease (no immediate aldesleukin)|"Patients who do not need or are ineligible for treatment with interleukin-2 (IL-2) and patients who have previously had IL-2 therapy.~A3 FGF-5 (Fibroblast growth factor 5): 172-176/217-220 peptide - two 1 ml injections in the anterior thigh deep subcutaneous tissue within 2c of each other."
62587989|NCT00089778|EXPERIMENTAL|Grp B - Measurable metastatic disease that require aldesleukin|"Patients who require immediate treatment with IL-2. A2 FGF-5: 117-126 peptide + HD (high dose) IL-2 (prior cycle 1)- two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.~720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses)."
62221696|NCT03266705|EXPERIMENTAL|4x20 mg tafamidis meglumine soft gelatin capsule|
62221697|NCT02146326|ACTIVE_COMPARATOR|Motivational Interviewing-Mental Health Staff|
62221698|NCT02146326|ACTIVE_COMPARATOR|BREATHE-Mental Health Staff|
62221699|NCT02146326|ACTIVE_COMPARATOR|Motivational Interviewing-Clients|
62221700|NCT02146326|ACTIVE_COMPARATOR|BREATHE-Clients|
62221701|NCT01477554|NO_INTERVENTION|Control|Hospitals randomized to the control arm do not receive any intervention.
62221702|NCT01477554|EXPERIMENTAL|PRONTO training|PRONTO training is delivered to medical teams at hospitals randomized to this arm.
62221703|NCT06315504||Patients with de novo nephrotic syndrome|
62221704|NCT05100082||Cabozantinib 60 mg|Cabozantinib 60 milligrams (mg) tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
62221705|NCT03496831||Rheumatoid Arthritis|Registered in DANBIO with a diagnosis of M05.9, M06.0 or M06.9.
62797219|NCT05821244|EXPERIMENTAL|Morning Group|Participants must start their exercise between the hours of 5am and 10am.
62797220|NCT05821244|EXPERIMENTAL|Evening Group|Participants must start their exercise between the hours of 3pm and 8pm.
62797221|NCT02112617|EXPERIMENTAL|Proton Beam Radiation Therapy (PBRT)|Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
62221706|NCT03496831||Spondyloarthritis|Registered in DANBIO with a diagnosis of M45.9, M46.1, M46.8+M02.9, M46.8+M07.4, M46.8+M07.5 or M46.9.
62221707|NCT03496831||Psoriatic Arthritis|Registered in DANBIO with a diagnosis of M07.3 or M46.8+M07.2.
62416099|NCT01139801|ACTIVE_COMPARATOR|Oxytocin|Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.
62416100|NCT01139801|EXPERIMENTAL|Misoprostol|Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
62416101|NCT05409664|EXPERIMENTAL|webMFT|Survivors randomized to webMFT will receive the evidence-based intervention for moderate-to-vigorous physical activity (MVPA) promotion that consists of MVPA counseling matched to patients' motivational readiness, and self-monitoring of MVPA (via Fitbit Inspire 2). The goal for the 3-month program will be to gradually increase the amount of moderate-intensity aerobic exercise that is performed, to the current national recommendations of at least 150 minutes of MPVA per week. Our goal is to promote aerobic exercise that is safe and enjoyable, such as walking.
62416102|NCT05409664|ACTIVE_COMPARATOR|MVPA tracking|These survivors will be asked to self-monitor moderate-to-vigorous physical activity (MVPA) participation by wearing the Fitbit Inspire 2 each day over 12 weeks. This group will not receive the MVPA counseling from the coaches.
62416103|NCT06542887|EXPERIMENTAL|Black Seed Oil Group|
62416104|NCT06542887|ACTIVE_COMPARATOR|Controlled Group|
62416105|NCT06702605|EXPERIMENTAL|XNW5004|XNW5004 tablets Oral administration, twice daily, with a 28-day continuous dosing as one cycle.
62587990|NCT00089778|EXPERIMENTAL|Grp C - High-risk loco-regional disease|"Patients whose cancer has been surgically removed but who are at risk for recurrence and local disease and who are seeking experimental adjuvant therapy.~A2 FGF-5: 117-126 peptide (adjuvant); A3 FGF-5: 172-176/217-220 peptide (adjuvant)"
62587991|NCT04743193||sevoflurane 8 %|In the initial phase, after reaching 1 (MAK) level with 1lt / min fresh gas flow and 8% sevoflurane concentration, anesthesia maintenance will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC.
62587992|NCT04743193||sevoflurane 2.5 %|In the initial phase, after reaching 1 MAK level with 4 lt / min fresh gas flow and 2.5% sevoflurane concentration, anesthesia maintenance will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC.
62797222|NCT06725927|EXPERIMENTAL|Influenza vaccination|Vaccination pre-discharge in patients stabilized after heart failure exacerbation
62797223|NCT06725927|NO_INTERVENTION|Standard of care|
62797224|NCT03472950|EXPERIMENTAL|Ranolazine 500mg|Participants will take Ranolazine 500mg twice daily for up to 4 weeks.
62797225|NCT03472950|EXPERIMENTAL|Ranolazine 1000mg|Participants will take Ranolazine 1000mg twice daily for up to 4 weeks.
62416106|NCT06262490|ACTIVE_COMPARATOR|Control group A|They will receive traditional ultrasound therapy for six weeks
62416107|NCT06262490|EXPERIMENTAL|Study group B|They will receive the same traditional ultrasound therapy in addition to pelvic floor rehabilitation for six weeks
62416108|NCT06701487||Alcohol use disorder (AUD)|Participants with alcohol use disorder (moderate to severe if no withdrawal symptoms) and no other substance use disorder (SUD)
62433393|NCT06069765|EXPERIMENTAL|TUPEX group|Children in this group will continue with their daily activities and will add the TUPEX program during 8 weeks.
62797226|NCT06054607|PLACEBO_COMPARATOR|Low-amylose maize starch|Low-amylose maize starch (AMIOCA; Ingredion, Inc).
62797227|NCT06054607|ACTIVE_COMPARATOR|High-amylose maize starch+acetate/butyrate|High-amylose maize starch, (Hylon VII; Ingredion, Inc.) to which the SCFA acetate or butyrate has been chemically added.
62797228|NCT06281535|EXPERIMENTAL|Early loading group|The surgical treatment protocol entails atraumatic tooth extraction, fixture insertion and placement of the final restoration 2 months following implant placement.
62797229|NCT06281535|ACTIVE_COMPARATOR|Conventional loading group|The surgical treatment protocol entails atraumatic tooth extraction, fixture insertion and placement of the final restoration 3 months following implant placement.
62797230|NCT03251937|EXPERIMENTAL|Spinal Cord Stimulation|Spectra WaveWriter SCS System
62797231|NCT00932906|PLACEBO_COMPARATOR|Instructor based training; <21 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program \[ref; navragen bij Koen\] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
62797232|NCT00932906|PLACEBO_COMPARATOR|Instructor based training; 21-50 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program \[ref; navragen bij Koen\] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
62416109|NCT06701487||Alcohol use disorder (AUD) and Substance use disorder (SUD)|"Participants with Alcohol use disorder (AUD) and comorbid Substance use disorder (SUD) (moderate to severe cases without withdrawal symptoms) including:~Participants with alcohol use disorder (AUD) and/or cannabis use disorder and/or methamphetamine use disorder and/or amphetamine use disorder and/or cocaine use disorder."
62797233|NCT00932906|PLACEBO_COMPARATOR|Instructor based training; >50 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program \[ref; navragen bij Koen\] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
62416110|NCT06701487||Non-AUD Substance use disorder (SUD)|"Participants with substance use disorder (moderate to severe cases without withdrawal symptoms) without alcohol use disorder (AUD) including:~Participants with methamphetamine use disorder and/or cannabis use disorder and/or amphetamine use disorder and/or cocaine use disorder"
62416111|NCT06701487||Control group|Healthy participants without AUD or SUD
62416112|NCT00306137|EXPERIMENTAL|Arm 1|
62416113|NCT00306137|PLACEBO_COMPARATOR|Arm 2|
62416114|NCT06567483|EXPERIMENTAL|Predilution online hemodiafiltration|The dialysis mode will be set as predilution online hemodiafiltration for 8 weeks.
62416115|NCT06567483|ACTIVE_COMPARATOR|Hemodialysis|The dialysis mode will be set as conventional hemodialysis for 8 weeks.
62221708|NCT03237637|ACTIVE_COMPARATOR|Group A- Propranolol|Oral propranolol 1mg/kg/day as crushed tablets, in two divided doses, increased to 2mg/kg/day in two divided doses after 24 hours if tolerated well. Treatment will be stopped at complete clinical clearance of lesion (defined arbitrarily as \>90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier.
62416116|NCT06101719||Contrast Group|Inclusion criteria: children 1-20 years diagnosed with an adhesive small bowel obstruction by an attending pediatric surgeon and underwent a trial of nonoperative management (NOM) on hospital admission and received an enteral contrast challenge. Exclusion criteria included peritonitis, suspicion of incarcerated or internal hernia, active intra-abdominal malignancy, inflammatory bowel disease, \<4 weeks since the most recent abdominal operation,45 pneumatosis, pneumoperitoneum, or known contrast allergy. If the attending surgeon made the decision to take a child directly to the operating room (OR) with no attempt at NOM, these children were excluded. Children under one year of age were excluded as the rate of successful NOM is lower in this age group
62416117|NCT06101719||No Contrast group|Inclusion criteria: children 1-20 years diagnosed with an adhesive small bowel obstruction by an attending pediatric surgeon and underwent a trial of nonoperative management (NOM) on hospital admission and who did not receive an enteral contrast challenge. Exclusion criteria included peritonitis, suspicion of incarcerated or internal hernia, active intra-abdominal malignancy, inflammatory bowel disease, \<4 weeks since the most recent abdominal operation, pneumatosis, pneumoperitoneum, or known contrast allergy. If the attending surgeon made the decision to take a child directly to the operating room (OR) with no attempt at NOM, these children were excluded. Children under one year of age were excluded as the rate of successful NOM is lower in this age group
62416118|NCT05305079||ODD-AION|NA-AION patients with ODD aka. Optic disc drusen associated non-arteritic anterior ischemic optic neuropathy.
62416119|NCT05305079||nODD-AION|NA-AION patients without ODD aka Non-optic disc drusen associated non-arteritic anterior ischemic optic neuropathy.
62416120|NCT00761566|EXPERIMENTAL|1|
62416121|NCT00761566|EXPERIMENTAL|2|
62416122|NCT06538935|EXPERIMENTAL|Perioperative queue|"SBRT: SBRT: 8-30Gy/1-6F（dose is determined according to the tumor diameter）； Adbelimumab: 2-3 cycles of neoadjuvant therapy before surgery, 1200mg iv d1 q3w; Apatinib : D1-D21 : 250 mg, orally, qd; Before surgery, the patient's surgical pathology samples still need to be collected.~After surgery, patients would receive Adbelimumab and Apatinib as adjuvant therapy .No more than 17 cycles before and after surgery."
62433394|NCT02667496|EXPERIMENTAL|Leukine|"Administered SC in treatment cycles up to 24 weeks~Florbetapir administered for PET scans to examine baseline brain imaging pathology and changes on treatment."
62587993|NCT04837508|EXPERIMENTAL|MRG002|MRG002 will be administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle).
62416123|NCT06538935|EXPERIMENTAL|Conversion queue|SBRT: tumor thrombus dose 30Gy /5-6F; Primary tumor dose is referred to Perioperative queue; Adbelimumab: 1200mg iv d1 q3w; Apatinib : D1-D21 : 250 mg, orally, qd; Treatment continues till PD,death,intolerable toxicity,or meet the criteria for Successful transformation(the maximum duration of adbelizumab combined with Apatinib conversion therapy was 1 year).
62416124|NCT05968300|EXPERIMENTAL|INFORMED-Living Well|INFORMED-Living Well consists of two components: 1) LHW outreach support providing responsive education and support; and 2) a 6-week automated SMS text messaging. The LHW educational outreach component includes 2 small group educational sessions with 2-8 participants. Participants will also receive a weekly SMS Text or instant message on managing emotional wellness within and beyond the context of the COVID-19 pandemic over 6 weeks. In addition, participants will receive as-needed messages on updates of COVID-19 or other situations that may introduce new worries and tragic culturally-based traumatic events.
62797234|NCT00932906|EXPERIMENTAL|Video Skill Training; <21 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
62221709|NCT03237637|EXPERIMENTAL|Group B- Atenolol|Oral atenolol 0.5mg/kg as a single dose, increased to 1mg/kg as a single dose after 24 hours if tolerated well. Treatment will be stopped at complete clinical clearance of lesion (defined arbitrarily as \>90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier.
62587994|NCT06666478|EXPERIMENTAL|Exercise protocol at workspace|"The exercise protocol at Workspace begins in a sitting position with spinal mobility exercises that mobilize the hips, lumbar spine, thoracic spine, and cervical spine, accompanied by progressive activation of the peripheral joints in the upper limbs. This is followed by multiaxial functional exercises for the trunk and upper limbs, which combine various movements (e.g., lateral bending and twisting) that simulate the positions employees assume while working.~Subsequently, exercises are performed in an upright position, focusing on stretching and mobilizing the joints and nervous tissue to promote relaxation and release. Coordination, fluid movement, and controlled breathing are emphasized to help workers develop and maintain a stable core while on the job. These principles are essential for workers who are frequently exposed to stressors and physical exertion, as they seek to improve the quality of their movements-namely, smoothness, rhythm, and appropriate speed-while at work."
62416125|NCT05968300|ACTIVE_COMPARATOR|Text Messaging Only|Participants will have a 6-week SMS text messaging program identical to that received by the INFORMED-Living Well participants.
62797235|NCT00932906|EXPERIMENTAL|Video Skill Training; 21-50 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
62416126|NCT03925025|NO_INTERVENTION|Control|Standard therapy
62416127|NCT03925025|ACTIVE_COMPARATOR|Magnesium sulfate|Standard therapy plus magnesium sulfate
62416128|NCT03925025|ACTIVE_COMPARATOR|Nimodipine|Standard therapy plus nimodipine
62416129|NCT03681769|EXPERIMENTAL|Intermittent Theta Burst Stimulation (iTBS) to the left dlPFC|For intermittent theta burst stimulation (iTBS) (Aim 1), participants will receive 20 trains of stimulation over the dlPFC (middle frontal gyrus) (F3) (each train: 3 pulse bursts presented at 5 hertz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% resting motor threshold, MagPro; 600 pulses total) using a figure 8 coil (Coil Cool-B65 A/P).
62433395|NCT02667496|PLACEBO_COMPARATOR|Placebo|"Administered SC in treatment cycles up to 24 weeks~Florbetapir administered for PET scans to examine baseline brain imaging pathology and changes on treatment."
62221710|NCT01853644|EXPERIMENTAL|Treatment (Tivozanib)|Tivozanib 1.5mg orally given daily for 3 weeks with one week off to complete a 4 week cycle until disease progression or adverse effects prohibit further therapy
62433396|NCT05881200|EXPERIMENTAL|Magnetic mitohormesis|Treatment using the BIXEPS machine
62221711|NCT02657512|EXPERIMENTAL|Arm A|"* Period  rivaroxaban alone~* Washout period (at least 6 days)~* Period  rivaroxaban and activated charcoal 2 hours after rivaroxaban administration~* Washout period (at least 6 days)~* Period   rivaroxaban and activated charcoal 5 hours after rivaroxaban administration"
62433397|NCT01968681|EXPERIMENTAL|Alexandrite laser treatment|
62797236|NCT00932906|EXPERIMENTAL|Video Skill Training; >50 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
62797237|NCT00932906|EXPERIMENTAL|Video scenario training; <21 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
62797238|NCT00932906|EXPERIMENTAL|Video scenario training; 21-50 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
62797239|NCT00932906|EXPERIMENTAL|Video scenario training; >50 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
62797240|NCT00932906|EXPERIMENTAL|Video demonstration training; <21 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
62797241|NCT00932906|EXPERIMENTAL|Video demonstration training; 21-50 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
62221712|NCT02657512|EXPERIMENTAL|Arm B|". Period  rivaroxaban and activated charcoal 5 hours after rivaroxaban administration~* Washout period (at least 6 days)~* Period  rivaroxaban alone~* Washout period (at least 6 days)~* Period   rivaroxaban and activated charcoal 8 hours after rivaroxaban administration"
62797242|NCT00932906|EXPERIMENTAL|Video demonstration training; >50 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
62797243|NCT04951752||Hemicolectomy, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
62797244|NCT04951752||Hemicolectomy, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
62797245|NCT04951752||Nephrectomy, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
62797246|NCT04951752||Nephrectomy, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
62797247|NCT04951752||Percutaneous nephrolithotomy, Active treatment|1x30mL 0.75% Ropivacaine administered by way of transmuscular quadratus lumborum block
62416130|NCT03681769|SHAM_COMPARATOR|Sham iTBS to the left dlPFC|The MagVenture MagPro system has an integrated, active sham which passes current through two surface electrodes placed on the scalp. The electrodes will be placed on the left frontalis muscle for all sessions. A patient identification card will randomize participants to receive either real or sham stimulation. This system maintains blinding by a gyroscope in the coil which indicates to the clinical staff whether the coil should be rotated up or down for this participant once the card is entered into the machine. One side of the coil is active, the other is sham. The integrity of the double-blind procedure will be assessed by asking the patients and study personnel rate their confidence regarding whether they thought they received real or sham (scale 1-10).
62797248|NCT04951752||Percutaneous nephrolithotomy, Placebo treatment|1x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
62221713|NCT02657512|EXPERIMENTAL|Arm C|". Period  rivaroxaban and activated charcoal 2 hours after rivaroxaban administration~* Washout period (at least 6 days)~* Period   rivaroxaban and activated charcoal 8 hours after rivaroxaban administration~* Washout period (at least 6 days)~* Period  rivaroxaban alone"
62221714|NCT05955794|OTHER|patient group|500 (400 syndromic patients plus 100 non-syndromic controls matched for gender and age)
62221715|NCT05955794|OTHER|control group|500 (400 syndromic patients plus 100 non-syndromic controls matched for gender and age)
62797249|NCT04951752||Hysterectomy, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
62797250|NCT04951752||Hysterectomy, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
62797251|NCT04951752||Elective Caesarean section, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
62797252|NCT04951752||Elective Caesarean section, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
62221716|NCT05209763|ACTIVE_COMPARATOR|Standard rehabilitation|patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.
62797253|NCT06404138|EXPERIMENTAL|Intervention group|Receives 18 physiotherapy sessions at home over 6 weeks according to the Geriatric Activation program Pellenberg (GAPP, see intervention)
62797254|NCT06404138|OTHER|Control group|Older persons in the control group receive the standard of care, without any restrictions. This implies that some of the older persons in the control group could receive physical therapy, but the standard of care implies that although geriatricians regularly prescribe physical therapy the therapy is actually not started in most cases. Therefore, physical therapy will not often be delivered in the control group, and if it is delivered it will be less structured and at lower intensity and/or frequency. Moreover, physical therapy delivered to participants in the control group will not be supported by a targeted rehabilitation plan and a specific training for the therapists.
62221717|NCT05209763|EXPERIMENTAL|More intensive rehabilitation|"* patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.~* patient daily exercises using the rehabilitation device MOTOmed Letto 2 for a minimum of 5 days, maximum duration not limited, minimum duration of exercise 20 minuts once daily~* exercise duration will be recorded daily and total time (in hours) at the end of the hospital stay"
62416131|NCT03681769|EXPERIMENTAL|cTBS to the mPFC|For continuous theta burst stimulation (Aim 2), participants will receive 1 train of stimulation over the left frontal pole (FP1) (each train: 3 pulse bursts presented at 5 hertz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% resting motor threshold, MagPro; 600 pulses total) using a figure 8 coil (Coil Cool-B65 A/P). This protocol has been shown to attenuate the mPFC and striatum in cocaine dependent individuals in the past (61-63) and has been more effective than 1200 or 1800 pulses of cTBS in attenuating depression (The time between the end of the TBS procedures and the beginning of the behavioral assessments, as well as the scalp-to-cortex distance (which effects the actual TMS dose given to the cortex) will be compiled and used as covariates in subsequent analyses.
62587995|NCT06666478|NO_INTERVENTION|Control group|Description: Control group. No exercise intervention. A printed document containing general guidelines for pain management and prevention of pain will be provided, in accordance with international guidelines for non-pharmacological interventions in the prevention of chronic non-specific spinal pain, along with recommended exercises for posture improvement.
62221718|NCT05209763|ACTIVE_COMPARATOR|Standard nutrition|- nutrition determined by the attending physician according to recommendations for age, type of acute illness and comorbidities
62587996|NCT02096757|PLACEBO_COMPARATOR|Placebo|Pro-Omega Placebo soybean capsules; 4.4gm/day (Nordic Naturals, Watsonville, CA, USA) 2 weeks prior to surgery and continued for 4 weeks after.
62587997|NCT02096757|EXPERIMENTAL|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day (Nordic Naturals, Watsonville, CA, USA) 2 weeks prior to surgery and continued for 4 weeks after.
62587998|NCT04828226|EXPERIMENTAL|Intervention|"The study drug (clonidine 2 mcg/kg) is diluted in 100 ml sodium chloride 0.9 % by trained post-anaesthesia care staff not involved in the study.~At admission, electrocardiogram, non-invasive blood pressure and pulse oximetry is installed, a peripheral venous line established and supplemental oxygen applied.~The study drug will be given intravenously over 10 minutes at least 10 minutes before induction of anaesthesia.~Electroconvulsive therapy will be conducted according to hospital standard (Etomidate 0.2 mg/kg, Suxamethonium 1.0 mg/kg, isolated limb technique, THYMATRON® SYSTEM IV, Somatics Inc., Lake Bluf, Illinois, USA) adjusted to the patient's condition. Seizure quality will be assessed, prolonged seizure activity terminated with propofol 0.2 - 0.3 mg/kg. Severe agitation (Richmond Agitation and Sedation Score (RASS) \> 1) needing intervention will be treated with propofol or lorazepam. Patients will be assessed for delirium using CAM-ICU at 20 minutes after induction."
62416132|NCT03681769|SHAM_COMPARATOR|Sham cTBS to the mPFC|The MagVenture MagPro system has an integrated, active sham which passes current through two surface electrodes placed on the scalp. The electrodes will be placed on the left frontalis muscle for all sessions. A patient identification card will randomize participants to receive either real or sham stimulation. This system maintains blinding by a gyroscope in the coil which indicates to the clinical staff whether the coil should be rotated up or down for this participant once the card is entered into the machine. One side of the coil is active, the other is sham. The integrity of the double-blind procedure will be assessed by asking the patients and study personnel rate their confidence regarding whether they thought they received real or sham (scale 1-10).
62587999|NCT04828226|PLACEBO_COMPARATOR|Control|The placebo will be created by diluting 1ml of sodium chloride 0.9% in 100ml of sodium chloride in a sterile manner prior to application. The container will be identically labelled as the verum. The placebo will be applied by the same team members named above via the same route (intravenously), with the same speed and the same timing. All other parts of the procedure are identical as to the procedure described above.
62588000|NCT05794984||Targeted Focus Group Discussions and Cross-sectional questionnaire|57 people for targeted Focus Group Discussions 162 people for Cross-sectional questionnaire
62588001|NCT04253626|EXPERIMENTAL|Intravenous iron|Participants will receive 510mg intravenous iron ferumoxytol, with a maximum of 2 doses based on the baseline hemoglobin level. The ferumoxytol is administered as an infusion for approximately 15 - 30 minutes.
62588002|NCT04253626|ACTIVE_COMPARATOR|Oral iron|Participants will be prescribed 1-2 ferrous sulfate 325mg tablets by mouth (based on severity of anemia) until delivery. For standardization, the dosage is as follows based on severity: one ferrous sulfate tablet for women with baseline hemoglobin 9-11, and two ferrous sulfate tablets for hemoglobin \< 9.
62416133|NCT05328167|EXPERIMENTAL|Diagnostic (perflutren protein-type A microspheres, CEUS)|Patients receive perflutren protein-type A microspheres IV over 10 minutes and undergo ultrasound at 1 month before TARE, 1-4 hours, 1 week, and 2 weeks post-TARE.
62797255|NCT04807933|EXPERIMENTAL|Experimental group (BFB training)|The participants assigned to the experimental group will do the biofeedback training using the Emwave software during the intervention period (T2-T3). The biofeedback software (Emwave Pro®) includes a photoplethysmography sensor that can be positioned on the earlobe. The installation of the program and the explanations needed for using it, will be done during the second session (T2). According to the guidelines, a fractional training is proposed 5 minutes, 3 times a day for 24 days (T2-T3).
62221719|NCT05209763|EXPERIMENTAL|More intensive nutrition|"determined by the attending physician according to recommendations for age, type of acute illness and comorbidity~- in addition, the patient will be administered hydroxymethylbutyrate at a dose of 3 g/day and in case of hypovitaminosis D and serum Ca concentration up to 3.0 mmol/l, vitamin D will be administered at a dose of 3000 IU/day for 5 days"
62797256|NCT04807933|NO_INTERVENTION|Control group (no BFB training)|The participants assigned to the experimental group will not do a specific exercise during the intervention period (T2-T3).
62797257|NCT05349357|ACTIVE_COMPARATOR|Group A|TENS, Stretching exercises, ROM exercises Sliding neural mobilization to femoral, sciatic, tibial nerve
62797258|NCT05349357|ACTIVE_COMPARATOR|Group B|TENS, Stretching exercises, ROM exercises Tensioner neural mobilization to femoral, sciatic, tibial nerve
62797259|NCT03374787|EXPERIMENTAL|Fusion sound processor|The sound processor picks up the sound and transfer it to the implant that convert the sound to vibrations that are transmitted to the inner ear.
62797260|NCT05813457|EXPERIMENTAL|PRESTO program|"The PRESTO programs consists of an early identification program for First Episod Psychosis, called PRESTO (First Episodes Raise Awareness Treat Referral), including 3 complementary components:~* Information campaign for the general population~* Training of front-line actors~* Facilitating access to specialized care by setting up mobile teams made up of pivotal workers who provide the link between front-line actors and specialized psychiatric care"
62797261|NCT05813457|NO_INTERVENTION|Usual Care|No change in the conditions of referral of First Episod Psychosis (emergencies, hospitalizations, consultations)
62797262|NCT06472245|EXPERIMENTAL|Arm A: OSE2101|Unit dose: 1 mL corresponding to a total of 5 mg of the combination of peptides Mode/Route: Subcutaneous injection Regimen: One injection every three weeks for six cycles, then every eight weeks for the remainder of year one and, finally every twelve weeks until the end of second year.
62416134|NCT00185731|EXPERIMENTAL|80 mg Atorvastatin|Atorvastatin, 80 mg tablet, will be taken orally by the patient daily, beginning on study day 1.
62588003|NCT00004235|EXPERIMENTAL|irinotecan + docetaxel|"Patients receive irinotecan IV over 90 minutes followed by docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.~Patients achieving a complete response (CR) receive 2 additional courses after CR. Patients experiencing disease progression after a CR and 2 additional courses may be retreated with irinotecan and docetaxel. Dysphagia, anorexia, and swallowing ability are assessed before the first course of treatment and then at each tumor assessment.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
62797263|NCT06472245|ACTIVE_COMPARATOR|Arm B: Docetaxel|Unit dose: 75 mg/m2 Mode/Route: Intravenous infusion over 1 hour Regimen: One infusion every three weeks.
62797264|NCT06472245|OTHER|GenDx CDx Tedopi|System of qualitative companion diagnostic devices, consisting of a polymerase chain reaction (PCR) assay Amp-HLA-A-CDx Tedopi, a DNA library preparation assay, LFK-CDx Tedopi and the software NGSengine-CDx Tedopi.
62797265|NCT00657163|EXPERIMENTAL|1|fluoxetine
62797266|NCT00657163|PLACEBO_COMPARATOR|2|Placebo
62797267|NCT06085599|EXPERIMENTAL|Progressive relaxation exercise group|Sociodemographic information form, numerical pain scale and kinesiophobia scale were applied to the patients in the experimental group after liver transplantation. They were shown 15 minutes progressive relaxation exercises prepared by Mark Connelly and Jennifer Bickel on Youtube, and then the numerical pain scale and kinesiophobia scale were applied again.
62797268|NCT06085599|NO_INTERVENTION|Control group|No application other than clinical protocols was performed in the follow-up of the patient. In the control group, sociodemographic information form, kinesiophobia scale and numerical pain scale were applied after liver transplantation. No intervention was made. Then, the kinesiophobia scale and numerical pain scale were applied again.
62416135|NCT06652724|EXPERIMENTAL|Dynamic interpersonal therapy (DIT)|A total of 54 patients (18 FM, 18 CM, and 18 FibroMig) will receive a brief psychotherapy intervention of 16 sessions (one per week) for a total of 4 months.
62797269|NCT03439735|EXPERIMENTAL|Cohort A: Participants with untreated metastatic disease receiving ET and a CDK 4/6|Participants will undergo blood collection (intervention) at time of initiating treatment with endocrine therapy and palbociclib, at 4 weeks after initiating this treatment, and every 3-4 months while on treatment. If a participant progresses on this treatment, they will have a blood collection at that time.
62797270|NCT03439735|EXPERIMENTAL|Cohort B: Participants initiating a CDK 4/6 i after progression on ET.|Participants will undergo blood collection (intervention) at time of initiating treatment with endocrine therapy and palbociclib, at 4 weeks after initiating this treatment, and every 3-4 months while on treatment. If a participant progresses on this treatment, they will have a blood collection at that time.
62797271|NCT02649556|EXPERIMENTAL|THS 2.2|Ad libitum use of THS 2.2
62797272|NCT02649556|ACTIVE_COMPARATOR|CC|Ad libitum use of CC
62221720|NCT02956785|ACTIVE_COMPARATOR|Extension of propess+/-second propess|Women will have the initial slow-release Dinoprostone pessary left in place for six more hours (total of 30 hours in place) then removed followed by vaginal assessment 48 hours after the start of labour induction and insertion of a second slow-release pessary if required
62221721|NCT02956785|ACTIVE_COMPARATOR|Prostin|Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of quick-release Dinoprostone tablet (Prostin® 3 mg Dinoprostone vaginal tablet; Pfizer, UK) high in the posterior vaginal fornix immediately after removal of the slow-release pessary. The tablet will be left for 6 hours followed by vaginal reassessment and insertion of a second tablet if ARM is still not achievable.
62588004|NCT06682533||PPI-BID group|Standard dose of PPI bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid, tripotassium dicitrate bismuthate (DENOL) 300 mg bid 14 days
62588005|NCT06682533||Tegoprazan-BID group|Tegoprazan 50 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid, tripotassium dicitrate bismuthate (DENOL) 300 mg bid for 14 days
62588006|NCT06682533||PPI-QID group|Standard dose of PPI bid, amoxicillin 500 mg qid, clarithromycin 500 mg bid, tripotassium dicitrate bismuthate (DENOL) 300 mg bid 14 days
62588007|NCT06682533||Tegoprazan-QID group|Tegoprazan 50 mg bid, amoxicillin 500 mg qid, clarithromycin 500 mg bid,tripotassium dicitrate bismuthate (DENOL) 300 mg bid for 14 days
62588008|NCT02963428|NO_INTERVENTION|Standard of Care (SOC)|Participants will receive the usual standard of care which includes written educational materials as well as counseling by their obstetric care provider.
62221722|NCT02956785|ACTIVE_COMPARATOR|Dilapan-S|Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of 1-5 Osmotic cervical rods (Dilapan-S® Aquacryl hydrogel rod; HPSRx Enterprises, USA) by a senior obstetrician or a midwife into the cervical canal, immediately after removal of the slow-release pessary using a vaginal speculum and a holder. The rods will be left for 12-24 hours.
62221723|NCT04415723|EXPERIMENTAL|intervention group|supportive care management programme
62221724|NCT04415723|NO_INTERVENTION|control group|receive the usual care provided by the health care system of Cyprus
62221725|NCT01990118|ACTIVE_COMPARATOR|Neoral|Patients who continued to be treated with the drug Neoral.
62221726|NCT01990118|EXPERIMENTAL|Gengraf arm|Patients were randomly selected to be converted to 'Gengraf® capsule containing 25mg or 100mg cyclosporine'
62221727|NCT01560468|EXPERIMENTAL|ITX 5061|Subjects will receive ITX 5061 for 28 days beginning at the time of liver transplantation for hepatitis C virus. 300mg will be administered on the day of surgery and for one week post transplant, followed by 150mg for an additional 21 days.
62221728|NCT01629602|EXPERIMENTAL|vascularized nerve graft|The investigators combined the nerve branch with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
62221729|NCT06279026|EXPERIMENTAL|UTAA17 Injection|After signing informed consent, subjects will be screened according to inclusion/exclusion criteria. Successful subjects will receive 3E8 CAR+γδT, 5E8 CAR+γδT, 1E9 CAR+γδT, 5E9 CAR+γδT, 1E10 CAR+γδT cell transfusions in sequence, and each subject will receive only one dose.
62221730|NCT05414487||Ofatumumab|17 RMS patients and 17 NMOSD patients prescribed with Ofatumumab will be enrolled after informed consent.
62221731|NCT01543932|EXPERIMENTAL|Prasugrel standard dose|Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
62221732|NCT01543932|EXPERIMENTAL|high clopidogrel dose|Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 15 days and 30 days we will control the responsivness of the study drug.
62416136|NCT06652724|ACTIVE_COMPARATOR|technique of expressive writing (TSE)|A total of 54 patients (18 FM, 18 CM, and 18 FibroMig) will receive an expressive writing therapy intervention of 8 meetings (one every fortnight) for a total of 4 months.
62588009|NCT02963428|EXPERIMENTAL|Enhanced Care (EC)|"In addition to standard of care, the study participants will also receive:~i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy."
62588010|NCT06685042|EXPERIMENTAL|Anti-CD19 CAR T cell|"Single intravenous infusion of 1 x 106 /kg body weight CAR T cell (CD19-CAR_Lenti )"
62416137|NCT06652724|OTHER|treatment as usual (TAU)|A total of 54 patients (18 FM, 18 CM, and 18 FibroMig) will be part of the active control group, planned to monitor specific aspects of the psychotherapeutic intervention, which aims to equate a good standard of primary care.
62416138|NCT06703814|EXPERIMENTAL|Intraoperative flow-controlled ventilation FCV|Flow-controlled ventilation (FCV) differs from conventional ventilation modes in several key ways. Unlike pressure-controlled ventilation (PCV) and volume-controlled ventilation (VCV), FCV maintains a constant airflow during both the inspiration and expiration phases. This method generates smooth linear pressure variations by delivering a constant positive flow during inspiration and a constant negative flow during expiration, resulting in linearly changing airway pressures. Additionally, FCV operates without any interruptions in flow throughout the cycle. This consistent rate of pressure and volume change in the lungs, particularly the linear decrease in airway pressure during expiration, has been shown to improve lung recruitment. This approach may thus reduce the risk of pulmonary complications commonly associated with conventional ventilation modes.
62221733|NCT01543932|EXPERIMENTAL|Ticagrelor standard dose|Patient will be randomized to this intervention will receive in the first time ticagrelor and after 15 days and 30 days we will control the responsivness of the study drug.
62588011|NCT04454684|EXPERIMENTAL|AN-R: MDMA-assisted Psychotherapy|Three Experimental Sessions of MDMA-assisted psychotherapy. The first Experimental Session involves 80mg midomafetamine HCl followed by a supplemental half-dose of 40 mg midomafetamine HCl 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions involve a flexible dose of 80 or 120 mg midomafetamine HCl followed by a supplemental half-dose of 40 or 80 mg midomafetamine HCl, respectively, 1.5 to 2 hours later, unless contraindicated.
62588012|NCT04454684|EXPERIMENTAL|BED: MDMA-assisted Psychotherapy|Three Experimental Sessions of MDMA-assisted psychotherapy. The first Experimental Session involves 80mg midomafetamine HCl followed by a supplemental half-dose of 40 mg midomafetamine HCl 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions involve a flexible dose of 80 or 120 mg of midomafetamine HCl followed by a supplemental half-dose of 40 or 80 mg midomafetamine HCl, respectively, 1.5 to 2 hours later, unless contraindicated.
62588013|NCT04454684|EXPERIMENTAL|Caregivers: Psychotherapy|Psychotherapy alone
62797273|NCT01967563||overweight and class I obese adult male volunteers|Adult Male Subjects will be recruited to determine the effects on energy expenditure of transitioning from an energy-and macronutrient-balanced standard baseline diet to a eucaloric ketogenic diet
62797274|NCT06726109||vasodilator treated|patients treated with vasodilator therapy after admission for an ADHF episode
62024776|NCT01250860|EXPERIMENTAL|Experimental group|"Experimental DoboMed and Kaltenborn manual therapy. Suitable techniques were chosen according to manual examination: cervical spine; thoracic spine; lumbar spine; costovertebral articles; pelvis position. During the 15 sessions in group DK we used:derotational manual terapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method; the manual techniques used in continuation study were different from techniques in pilot study."
62024777|NCT01428960|EXPERIMENTAL|Palm Mid Fraction|
62221734|NCT03044925|EXPERIMENTAL|Remote magnetic navigation|Persistent atrial fibrillation ablation with remote magnetic navigation
62416139|NCT06703814|ACTIVE_COMPARATOR|Intraoperative pressure-controlled ventilation PCV|Pressure-controlled ventilation (PCV) is the standard of care in patients undergoing mechanical ventilation during general anesthesia in robot-assisted laparoscopic surgery. The operator sets the inspiratory pressure (rather than tidal volume as in VCV) and respiratory rate (along with FiO2, I:E ratio and PEEP). Typically, the pressure is titrated to achieve a targeted tidal volume.
62416140|NCT00018174|EXPERIMENTAL|1|
62416141|NCT00018174|PLACEBO_COMPARATOR|2|
62416142|NCT01306968|NO_INTERVENTION|Standard TBI Care|Routine post-concussive symptoms (PCS) care as practiced within Departments of Defense (DoD)
62416143|NCT01306968|EXPERIMENTAL|HBO2 Group|Routine PCS care supplemented with hyperbaric oxygen (HBO2) at the dose of 1.5 ATA for 60 minutes administered over 40 sessions given daily Monday through Friday
62797275|NCT06726109||Not vasodilator treated|Patients not treated with vasodilator therapy after admission for an ADHF episode
62797276|NCT01643382|EXPERIMENTAL|Tight glucose control|Patients randomized to the tight glucose control arm will be placed on an insulin infusion, or continuous low dose insulin drip.
62797277|NCT01643382|ACTIVE_COMPARATOR|Standard glucose control|Patients randomized to the standard glucose control group will be given subcutaneous doses of insulin every few hours based on their blood sugar.
62797278|NCT05128578|EXPERIMENTAL|LEAP Intervention Arm|Enrolled patients participated in weekly sessions led by a health coach to learn self-pain management tools and skills. There were 6 individual session and 6 optional group sessions. Participants also received an intervention manual with workbook activities they could complete.
62797279|NCT06487091||patients on Impella support|CS/CA patients that receive primary temporary mechanical circulatory support with an Impella device
62797280|NCT03551626|EXPERIMENTAL|Dabrafenib and trametinib combination therapy|Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for up to 12 months.
62797281|NCT06725979|ACTIVE_COMPARATOR|Rapid maxillary expansion group|expansion of the maxilla with hyrax expander
62024778|NCT01428960|EXPERIMENTAL|Shea Butter|
62024779|NCT01428960|EXPERIMENTAL|High Oleic Sunflower Oil|
62024780|NCT05629026|EXPERIMENTAL|primary lymphoedema|patients with primary lymphoedema
62024781|NCT05629026|EXPERIMENTAL|secondary lymphoedema|patients with secondary lymphoedema
62024782|NCT05054335|EXPERIMENTAL|Supportive care (walking function test, X-ray)|Patients undergo walking function assessment using optical motion capture and bi-plane dynamic X-ray imaging pre- and post-hemipelvectomy.
62024783|NCT05054335|NO_INTERVENTION|Retrospective Group|"1. Acquisition of pre- and post-operative MRI data of the pelvic region (when available) collected previously as part of standard clinical care~2. Acquisition of pre-operative CT data of the pelvic region (when available) collected previously as part of standard clinical care~3. Acquisition of Physical Therapy Assessment data collected previously by a physical therapist and/or physical therapist assistant under protocol PA12-1046"
62416144|NCT01306968|SHAM_COMPARATOR|Sham Group|Routine PCS care supplemented with an otherwise identical sham hyperbaric air exposure at 1.2 atmospheres absolute (ATA)
62416145|NCT01306968|NO_INTERVENTION|PTSD With no History of TBI|Subjects who have been diagnosed with PTSD but have no diagnosed or suspected brain injuries. This group does not receive HBO2.
62416146|NCT06701045||Elderly living in community|The inclusion criteria were domicile in Bandung City, able to mobilize without assistive devices, able to see and read and willing to participate in the study after informed consent.
62433398|NCT02888925|OTHER|Epilepsy|Patients do face specific tests during conventional pre-lobectomy intercritical assessment hospitalization (inclusion, day 0) and after 6 and 18 months from anterior temporal lobectomy
62797282|NCT06725979|NO_INTERVENTION|control|no need for the maxillary expansion
62797283|NCT02944279||Peking University Third Hospital|
62797284|NCT02944279||Beijing Friendship Hospital|
62024784|NCT03579459|ACTIVE_COMPARATOR|Clostridium difficile vaccine Lot 1|
62024785|NCT03579459|ACTIVE_COMPARATOR|Clostridium difficile vaccine Lot 2|
62024786|NCT03579459|ACTIVE_COMPARATOR|Clostridium difficile vaccine Lot 3|
62024787|NCT03579459|PLACEBO_COMPARATOR|Placebo|Normal saline solution (0.9% sodium chloride)
62221735|NCT03044925|ACTIVE_COMPARATOR|Cryoablation|Persistent atrial fibrillation ablation with cryoballoon
62221736|NCT03580668||B/F/TAF|Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) therapy in HIV-1 infected adults who initiate B/F/TAF therapy
62221737|NCT04281446|EXPERIMENTAL|G-FBM-CEN|Photobiomodulation application in women of endogenous cycle. Antares® equipment (IBRAMED, Amparo-SP, Brazil) will be used, by means of a cluster, with two wavelengths (13 LEDs of 630 nm, 300 mW + 13 LEDs of 850 nm, 500 mW), being its area of 80 cm² contact, acting 180 J of energy being applied at 15 points on each thigh - 9 in the anterior region and 6 in the posterior region, in addition to 2 points in the gastrocnemius.
62797285|NCT02944279||Beijing Shijitan Hospital|
62797286|NCT02944279||Beijing Xiyuan Hospital|
62797287|NCT02944279||China-Japan Friendship Hospital|
62797288|NCT01317251|EXPERIMENTAL|Control diet|Diet without dairy products
62797289|NCT01317251|EXPERIMENTAL|Milk diet|Diet with a high content of milk
62797290|NCT01317251|EXPERIMENTAL|Cheese diet|Diet with a high content of cheese
62588014|NCT05412290|EXPERIMENTAL|Consolidation Mosunetuzumab|Mosunetuzumab is a CD3xCD20 bispecific antibody administered intravenously in the consolidation setting after autologous stem cell transplant (autoSCT). Mosunetuzumab will be given in a step-up dosing schedule beginning on Day 49 after autoSCT on C1D1, C1D8, C1D15, and then Day 1 of all cycles thereafter. Patients will undergo PET-CT restaging around Day 100 post-autoSCT (approximately Cycle 3) and patients in complete response will continue mosunetuzumab for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients not in complete response will discontinue treatment and enter follow-up. All cycles are planned to be 21 days.
62588015|NCT05927740|OTHER|1 ( Hyperemesis gravidarum )|55 hyperemesis gravidarum patient (11-14th gestational week of pregnancy)
62588016|NCT05927740|OTHER|2( Control group)|55 healthy pregnant women (11-14th gestational week of pregnancy)
62024788|NCT06635460|NO_INTERVENTION|Control Group|Adolescents in this group will be followed up according to the routine follow-up program of pediatric endocrinology. Adolescents in the control group will not receive any intervention from the researcher during the study.
62588017|NCT05080114|EXPERIMENTAL|Modified technique (MT)|All the steps of the laparoscopic hysterectomy were performed according to conventional standard technique until the colpotomy step. Instead, the modified Bakay technique was used for later on.
62588018|NCT05080114|ACTIVE_COMPARATOR|Standard technique (ST)|The conventional standard total laparoscopic hysterectomy technique was used in this control group.
62588019|NCT02831010||encephalopathy of prematurity|infants with encephalopathy of prematurity showed on MRI at term-equivalent age
62797291|NCT03826186|ACTIVE_COMPARATOR|Traditional epidural group|The traditional approach to placing thoracic epidurals by loss-of-resistance technique using a ground glass syringe will be used in this group.
62797292|NCT03826186|EXPERIMENTAL|CompuFlo epidural group|This device (CompuFlo) will aid in correct placement of the epidural by electronically sensing pressure in real time and by providing a numerical value on a read out screen to determine a loss of resistance. There is also an audio signal that signals a loss of resistance.
62221738|NCT04281446|SHAM_COMPARATOR|G - Sham - CEN|"Sham Photobiomodulation (disabled) application in women of endogenous cycle.~The procedure and equipment will be the same as for the experimental groups, however no dosage will be applied:~Antares® equipment (IBRAMED, Amparo-SP, Brazil) will be used, by means of a cluster, with two wavelengths (13 LEDs of 630 nm, 300 mW + 13 LEDs of 850 nm, 500 mW), being its area of 80 cm² contact, with 0 J of energy being applied at 15 points on each thigh - 9 in the anterior region and 6 in the posterior region, in addition to 2 points in the gastrocnemius."
62416147|NCT02935946|NO_INTERVENTION|Room Temperature Swallows|"Once consented, each participant underwent a video fluoroscopic swallow study (VFSS). Each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder®) with an attached Similac® Infant Nipple and Ring. The swallows were assessed in real time for any swallowing dysfunction and saved electronically. These swallows were labeled RTS for room temperature swallows. If no swallow dysfunction was observed, the participant became ineligible and the study ended. If swallow dysfunction was observed, the participant became eligible to complete the other arms of the study."
62416148|NCT02935946|EXPERIMENTAL|Cold Liquid Swallows- 5|"Immediately following the RTS condition, a total of 5 swallows of Cold Liquid Barium was observed under fluoroscopy from an identical bottle and nipple. Images were saved electronically and labeled CS5 for cold swallows-5."
62797293|NCT02255227|ACTIVE_COMPARATOR|1 dose Prevenar13 and 1 dose PSV23|one dose of the polysaccharide vaccine, Prevenar 13 at M0 and one dose of polysaccharide vaccine, Pneumo 23 at M4
62416149|NCT02935946|EXPERIMENTAL|Cold Liquid Swallows- 10|"After 10 minutes of feeding a cold liquid, a total of 10 swallows of Cold Liquid Barium was observed under fluoroscopy from an identical bottle and nipple. Images were saved electronically and labeled CS10 for cold swallows-10."
62416150|NCT06282523|EXPERIMENTAL|Healthy Minds Program (HMP) - Awareness first|Participants will be assigned to use the HMP mobile app on symptoms of psychological distress, and will complete the Awareness module first.
62797294|NCT02255227|EXPERIMENTAL|2 doses Prevenar13 and 1 dose PSV23|one dose of the polysaccharide vaccine, Prevenar 13 at M0, one dose of the polysaccharide vaccine, Prevenar 13, at M2 and one dose of polysaccharide vaccine, Pneumo 23 at M4
62797295|NCT02506192|EXPERIMENTAL|Modified-Release Prednisone|Take oral tablets as directed (2x5mg) with food each evening at bedtime- approximately 10:00 pm
62797296|NCT02506192|PLACEBO_COMPARATOR|Placebo|Take oral tablets as directed (2x5mg) with food each evening at bedtime-approximately 10:00 pm
62588020|NCT02831010||no encephalopathy of prematurity|infants with no encephalopathy of prematurity showed on MRI at term-equivalent age
62588021|NCT03466203|EXPERIMENTAL|LLF580|LLF580 every 28 days \* 3
62588022|NCT03466203|PLACEBO_COMPARATOR|Placebo|Placebo to LLF580 every 28 days \* 3
62588023|NCT01860040|EXPERIMENTAL|Cisplatin and pemetrexed|Cisplatin on day 1 and pemetrexed on day 1, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
62797297|NCT02177188|EXPERIMENTAL|Haemorrhage simulation|
62221739|NCT02210143||AERSA-I gingival recession|The AERSA classification was developed based on 15 mm2 which is the lowest cut-off point and the group of AERSA ≤ 15 mm2 named as AERSA-I (low risk group)
62416151|NCT06282523|EXPERIMENTAL|Healthy Minds Research Platform (HMRP) - Awareness first|Participants will be assigned to use the HMRP web app on symptoms of psychological distress, and will complete the Awareness module first.
62588024|NCT01860040|EXPERIMENTAL|Cisplatin and gemcitabine|Cisplatin on day 1 and gemcitabine on days 1 and 8, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
62588025|NCT04661241|EXPERIMENTAL|Investigational Scan|The proposed sequence (\<15 minutes) will be added as a supplementary sequence only for the preoperative imaging if subjects agree to participate.
62588026|NCT04661241|ACTIVE_COMPARATOR|Current Clinical Practice|All patients will undergo a routine clinical preoperative MRI of the brain under general anesthesia to reduce movement artifacts.
62588027|NCT04287946|EXPERIMENTAL|Ablation|
62797298|NCT03740659|EXPERIMENTAL|Levofloxacin + Dexamethasone|"Levofloxacin 5 mg/ml + Dexamethasone 1 mg/ml (30 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery."
62588028|NCT05481125|EXPERIMENTAL|Clareon/Clareon Toric|Phacoemulsification surgery, followed by implantation with Alcon Clareon Aspheric Hydrophobic Acrylic IOL or Alcon Clareon Aspheric Hydrophobic Acrylic Toric IOL, as indicated. The second eye surgery is recommended to occur within 14 days after the 1st eye surgery.
62797299|NCT03740659|ACTIVE_COMPARATOR|Levofloxacin|"Levofloxacin 5 mg/ml (30 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery."
62797300|NCT03740659|ACTIVE_COMPARATOR|Dexamethasone|"Dexamethasone 1.14 mg/ml (26 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery."
62797301|NCT00801229|ACTIVE_COMPARATOR|Vyvanse|Patients may be randomized to the active comparator arm. Participants randomized to this arm will receive 30, 50, or 70mg Vyvanse daily.
62416152|NCT06282523|EXPERIMENTAL|HMP - Connection first|Participants will be assigned to use the HMP mobile app on symptoms of psychological distress, and will complete the Connection module first.
62416153|NCT06282523|EXPERIMENTAL|HMRP - Connection first|Participants will be assigned to use the HMRP web app on symptoms of psychological distress, and will complete the Connection module first.
62416154|NCT06024785|ACTIVE_COMPARATOR|Indication for decompression, randomization for decompression|microsurgical (i.e., the use of a microscope or magnifying glasses during decompression) lumbar laminotomy with partial removal of the medial facet joint by preserving the midline structures (supraspinous-interspinous ligament complex); approach: bilateral or ipsilateral with cross-over to the contralateral side
62416155|NCT06024785|EXPERIMENTAL|Indication for decompression, randomization for vertebropexy|decompression (see above) and additional stabilization of the spine with a ligament (for instance semitendinosus donor allograft), which connect the postoprior structures (Proc. Spinosus and/or Lamina) of the vertebrae . Situation-related application of laminar bands or analogous suture material (for instance FiberTape, Arthrex, Naples or Nile Band, K2M, Virginia)
62416156|NCT06024785|ACTIVE_COMPARATOR|Indication for fusion, randomization for fusion|decompression (see above) and posterolateral instrumented fusion (arthrodesis) with implantation of pedicle screws, titanium alloy rods across the level of listhesis, an intervertebral fusion device and local autograft as well as DBX (demineralized bone matrix) to improve bony fusion
62416157|NCT06024785|EXPERIMENTAL|Indication for fusion, randomization for vertebropexy|decompression (see above) and additional stabilization of the spine with a ligament (for instance semitendinosus donor allograft), which connect the postoprior structures (Proc. Spinosus and/or Lamina) of the vertebrae . Situation-related application of laminar bands or analogous suture material (for instance FiberTape, Arthrex, Naples or Nile Band, K2M, Virginia)
62416158|NCT01817764|EXPERIMENTAL|Umeclidinium/vilanterol Arm|The subjects will receive UMEC/VI 62.5/25 mcg, administered as one inhalation once-daily in the morning via the NDPI and placebo administered as one inhalation each morning and evening via ACCUHALER/DISKUS
62416159|NCT01817764|ACTIVE_COMPARATOR|Fluticasone propionate/salmeterol Arm|The subjects will receive FSC 250/50 mcg, administered as one inhalation each morning and evening via ACCUHALER/DISKUS and placebo administered once-daily in the morning via NDPI
62416160|NCT02531698|EXPERIMENTAL|Bivalent rLP2086|Bivalent rLP2086 (containing 60 μg each of a purified subfamily A and subfamily B rLP2086 protein, adsorbed to aluminum in a sterile buffered isotonic suspension) in a 0.5-mL dose for injection.
62416161|NCT02531698|OTHER|Licensed pediatric hepatitis A vaccine|
62416162|NCT06702423|EXPERIMENTAL|AI-based chatbot|A chatbot that was developed using information related to HPV vaccines from authoritative sources such as the Japanese Ministry of Health, Labour, and Welfare, World Health Organization, Centers for Disease Control and Prevention, and other reputable public health organizations and validated survey questions from published research.
62416163|NCT06702423|ACTIVE_COMPARATOR|Leaflet|A leaflet which is a publicly accessible HPV vaccination document prepared by the Ministry of Health, Labour, and Welfare.
62416164|NCT00759668|EXPERIMENTAL|SN60D3|AcrySof Natural ReSTOR Intraocular Lens (IOL) Model SN60D3
62416165|NCT00759668|ACTIVE_COMPARATOR|SN60AT|AcrySof Natural Monofocal Intraocular Lens (IOL) Model SN60AT
62416166|NCT06267781||aHSCT|n.10 patients with RRMS referred for pharmacological treatment with myeloablative autologous hematopoietic stem cell transplantation (aHSCT) according to clinical practice following the Italian pharmacological regulatory agency (AIFA) criteria and guidelines and recommendations from the European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)
62416167|NCT06267781||BCDT|n.10 patients with RRMS referred for pharmacological treatment with anti-CD20 monoclonal antibody (ocrelizumab or ofatumumab - B cell depleting therapies) according to clinical practice following the Italian pharmacological regulatory agency (AIFA) criteria.
62416168|NCT06267781||LEM|n.10 patients with RRMS referred for pharmacological treatment with anti-CD52 monoclonal antibody (alemtuzumab) according to clinical practice following the Italian pharmacological regulatory agency (AIFA) criteria.
62416169|NCT02487407|EXPERIMENTAL|ODM-109|ODM-109 capsules for oral administration
62416170|NCT02487407|PLACEBO_COMPARATOR|Placebo for ODM-109|Placebo ODM-109 capsules for oral administration
62416171|NCT05918055|EXPERIMENTAL|Phase I- Dose escalation of KPT-8602 for HR-MDS|Inqovi for 5 days, followed by escalating doses of KPT-8602
62416172|NCT05918055|EXPERIMENTAL|Phase II- Dose expansion for HR-MDS|Inqovi for 5 days, followed by RP2D/Phase II dose of KPT-8602
62416173|NCT06381401|ACTIVE_COMPARATOR|Bupivacaine 0.25%|Patients will receive superficial cervical plexus block using 0.25% bupivacaine (5ml of bupivacaine 0.5% + 5ml normal saline).
62416174|NCT06381401|ACTIVE_COMPARATOR|Bupivacaine 0.125%|Patients will receive superficial cervical plexus block using 0.125% bupivacaine (2.5ml of bupivacaine 0.5% + 7.5ml normal saline).
62433399|NCT02888925|OTHER|Control|Control individuals do face specific tests during inclusion visit (day 0) and after X months (X = time from day 0 and lobectomy of matched patient + 6 months)
62797302|NCT00801229|PLACEBO_COMPARATOR|Placebo|Patients may be randomized to the placebo comparator arm. Those randomized to this arm will receive 30, 50, or 70mg placebo daily.
62797303|NCT02682368||POCUSS Trial-1 Acute Biliary Disease|Patients with suspected biliary pathology which will undergo POCUS. The results will be compared to the subsequent findings by imagistic means or at time of surgery.
62797304|NCT02682368||POCUSS Trial-2 Acute Diverticulitis|Patients with suspected diverticulitis will undergo POCUS. The results will be compared to the subsequent findings by imagistic means or at time of surgery.
62797305|NCT02682368||Radiology Report|Departmental imaging and reports.
62797306|NCT02682368||Surgical diagnostic|Intraoperative findings of patients that undergo emergency surgery.
62797307|NCT00414141|EXPERIMENTAL|1|Grass MATA MPL
62797308|NCT00414141|PLACEBO_COMPARATOR|2|
62797309|NCT06726499|EXPERIMENTAL|spherical design|
62797310|NCT06726499|EXPERIMENTAL|Toric Design|
62797311|NCT06726330|EXPERIMENTAL|Fimbriectomy Followed by Delayed Oophorectomy (F-DO)|Participants in this arm will undergo fimbriectomy, a surgical procedure to remove the fimbrial end of the fallopian tubes, while preserving ovarian function. A delayed oophorectomy (removal of the ovaries) will be performed at menopause or later, based on individual timing and preferences. This approach aims to reduce the risk of advanced-stage tubo-ovarian or primary peritoneal carcinoma while minimizing the adverse effects of premature menopause.
62797312|NCT06726330|ACTIVE_COMPARATOR|Bilateral Salpingo-Oophorectomy (BSO)|Participants in this arm will undergo a bilateral salpingo-oophorectomy (BSO), the standard preventive surgical strategy, involving the removal of both fallopian tubes and ovaries. This procedure is performed around the recommended age of 40-45 years for women with BRCA1/2 mutations or similar high-risk genetic predispositions. The primary objective is to eliminate the risk of tubo-ovarian or primary peritoneal carcinoma, though it induces premature menopause.
62797313|NCT05693363|EXPERIMENTAL|18F-FDG AURA10 Specimen Imager|"* Intravenous injection of radiotracer (18F-FDG) (study-specific)~* Thoracic surgery (standard-of-care; not study-specific)~* High-resolution specimen imaging using the AURA10 PET-CT specimen imager (study-specific)~* Postoperative histopathological analysis of specimen (standard-of-care)"
62797314|NCT02641431|EXPERIMENTAL|mapping/ablation|Epicardial substrate identification consisted in mapping the entire RV epicardial surface under baseline conditions and after ajmaline infusion (1mg/kg in 5 minutes).We obtained 3 groups of RV epicardial maps using CARTO3 system: 1) bipolar/unipolar voltage map, 2) local activation time map (LAT), and 3) potential duration map (PDM), in which abnormal long-duration bipolar electrograms were defined as low-frequency (up to 100 Hz) prolonged duration (\> 200 ms) bipolar signals with delayed activity extending beyond the end of the QRS complex. Epicardial ablation was performed during sinus rhythm using a stepwise strategy in a descending order of abnormal potential duration as displayed on the map and beginning from the longest potentials.
62416175|NCT06594445|EXPERIMENTAL|Arm 1: Dose Level 1: 1.25 ug/kg/day|"GTB-3650 is administered during an inpatient stay by continuous infusion (CI) consisting of three consecutive 24 hour infusion bags over a 72 hour period. Each 72-hour infusion period is designated a block.~A 28-day treatment cycle consists of two blocks followed by approximately 18 days of no treatment. Prior to each block start, the patient must meet the safety criteria.GTB-3650 may continue for up to four treatment cycles total provided disease based response criteria is met and the patient is otherwise eligible to continue."
62416176|NCT06594445|EXPERIMENTAL|Arm 2: Dose Level 2: 2.5 ug/kg/day|"GTB-3650 is administered during an inpatient stay by continuous infusion (CI) consisting of three consecutive 24 hour infusion bags over a 72 hour period. Each 72-hour infusion period is designated a block.~A 28-day treatment cycle consists of two blocks followed by approximately 18 days of no treatment. Prior to each block start, the patient must meet the safety criteria.GTB-3650 may continue for up to four treatment cycles total provided disease based response criteria is met and the patient is otherwise eligible to continue."
62588029|NCT05481125|ACTIVE_COMPARATOR|Eyhance/Eyhance Toric|Phacoemulsification surgery, followed by implantation with TECNIS Eyhance IOL or TECNIS Eyhance Toric II IOL, as indicated. The second eye surgery is recommended to occur within 14 days after the 1st eye surgery.
62797315|NCT02414685|EXPERIMENTAL|intravenous chemotherapy|"TIP regimen:~* Paclitaxel 250 mg/ m2 iv on day 1~* Ifosfamide 1,2 g/ m2/ day iv x 5 days~* Cisplatin 20 mg/ m2/ day iv x 5 days"
62797316|NCT06609057|EXPERIMENTAL|Prevention (nutrition intervention)|Participants attend Cooking for Your Health in Southern New Mexico intervention sessions, consisting of 15-30 minutes of pre-work (watching an educational video and/or practicing a new culinary skill), 60 minutes of hands-on experiential cooking and culinary session in a teaching kitchen, and a 30 minute meal that includes group discussion of educational information, QW for 6 weeks.
62797317|NCT05663580||HIV-positive people virologically suppressed without resistance/failure to NNRTI and INI|Initial administration of two separate intramuscolar injection of cabotegravir 400mg/3mL and rilpivirine 600mg/3mL in opposite gluteal muscles, repeated one month later and then every two months.
62797318|NCT01466127|PLACEBO_COMPARATOR|Placebo|Matched nasal spray placebo.
62797319|NCT01466127|EXPERIMENTAL|Oxytocin|Liquid intranasal oxytocin administered in a nasal spray.
62797320|NCT01008072||without buprenorphine preparation|
62797321|NCT01008072||with buprenorphine preparation|
62797322|NCT06725355|EXPERIMENTAL|Sequence A|R-\>T R: IN-R00002 T: IN-G00002
62797323|NCT06725355|EXPERIMENTAL|Sequence B|T-\>R R: IN-R00002 T: IN-G00002
62416177|NCT06594445|EXPERIMENTAL|Arm 3: Dose Level 3: 5 ug/kg/day|"GTB-3650 is administered during an inpatient stay by continuous infusion (CI) consisting of three consecutive 24 hour infusion bags over a 72 hour period. Each 72-hour infusion period is designated a block.~A 28-day treatment cycle consists of two blocks followed by approximately 18 days of no treatment. Prior to each block start, the patient must meet the safety criteria.GTB-3650 may continue for up to four treatment cycles total provided disease based response criteria is met and the patient is otherwise eligible to continue."
62588030|NCT01579838|EXPERIMENTAL|Eculizumab|Eculizumab will be administrated according to known protocols.
62797324|NCT01405300|EXPERIMENTAL|Peanut|
62797325|NCT01405300|PLACEBO_COMPARATOR|Control|
62797326|NCT05849168|EXPERIMENTAL|Veterans with respiratory symptoms|
62797327|NCT00798525|ACTIVE_COMPARATOR|PR1|Patients treated with Argatroban (Argatra®), a direct thrombin inhibitor
62797328|NCT00798525|ACTIVE_COMPARATOR|PR2|Patients treated with Lepirudin (Refludan®), a direct thrombin inhibitor
62797329|NCT06646289|EXPERIMENTAL|Cohort 1|Participants will receive a dose of AAV5 hRKp.RPGR under the retina (low-dose or intermediate-dose) on Day 1 depending on the dosage administered in study MGT009 (NCT03252847) in the past. After receiving the treatment, participants will be assessed for safety.
62797330|NCT06646289|EXPERIMENTAL|Cohort 2|Participants will receive the treatment dose of AAV5 hRKp.RPGR under the retina (low-dose or intermediate-dose) on Day 1 in the second eye once the safety will be determined in Cohort 1.
62221740|NCT02210143||AERSA-II gingival recession|AERSA \> 15 mm2 named as AERSA-II (high risk group).
62797331|NCT06646289|OTHER|Cohort 3|The participants who are not willing to undergo surgery or are not eligible for surgery will be assessed in this cohort. They will be assessed yearly until 5 years after their initial eye surgery in previous study MGT009.
62797332|NCT02226718||questionnaire|Otitis patients and controls
62797333|NCT01013194|EXPERIMENTAL|Treated patients|Cirrhotic patients treated with Human Fetal Liver Cell Transplantation.
62221741|NCT02210143||Miller gingival recession|Gingival recessions classified according to Miller
62221742|NCT04303767|EXPERIMENTAL|Test (ART + CPP-ACP)|In this group, teeth selected will receive intervention with CPP-ACP and restorations with light cured Glass Ionomer restorations after excavating the carious lesions preserving the caries affected dentine using the ART
62797334|NCT01013194|NO_INTERVENTION|Control patients|Cirrhotic patients on Standard therapy.
62797335|NCT04963400||Patients with low disease severity|Hospitalized patients without a diagnosed or suspected cardiac disease and with an acute medical condition of low severity (e.g. patients with retinal detachment)
62221743|NCT04303767|ACTIVE_COMPARATOR|Control (ART)|in this group, teeth selected will receive restorations with light cured Glass Ionomer restorations after excavating the carious lesions preserving the caries affected dentine using the ART
62221744|NCT06610383||Group 1 (08:30 group (n=20))|Patients in this group will spit into 1.5 ml tubes at 08:30 in the morning before starting the impacted tooth surgery and 48 hours after the surgery, and these tubes will be stored in the refrigerator at -22 degrees. The samples in these tubes will then be examined with ELISA kits and the numerical data of adrenal glucocorticoids in the saliva will be obtained. The patients will fill out the Visual Analog Scale and OHIP-14 forms a total of five times: 6 hours, 24 hours, 48 hours, 72 hours and 7 days after the surgery.
62416178|NCT06594445|EXPERIMENTAL|Arm 4: Dose Level 4: 10 ug/kg/day|"GTB-3650 is administered during an inpatient stay by continuous infusion (CI) consisting of three consecutive 24 hour infusion bags over a 72 hour period. Each 72-hour infusion period is designated a block.~A 28-day treatment cycle consists of two blocks followed by approximately 18 days of no treatment. Prior to each block start, the patient must meet the safety criteria.GTB-3650 may continue for up to four treatment cycles total provided disease based response criteria is met and the patient is otherwise eligible to continue."
62433400|NCT03289637|EXPERIMENTAL|Active intervention|"In the group randomised to active treatment and with a screening level of 25-OH-vitamin D 25-50nmol/L an intervention with 1600IE daily of vitamin D will be given.~In those randomised to active treatment and with a screening level of 25-OH-vitamin D of \<25nmol/L, an intervention of 2400IE of vitamin D will be given."
62588031|NCT05262088||newborns|Assessment of the motor repertoire in children aged 0 to 5 months and its relationship with prenatal and perinatal factors and the results of neurological development in the second year of life.
62588032|NCT06614543|ACTIVE_COMPARATOR|The WLC program plus meal replacements|Participants will have a choice on what type of meal replacement they will consume each day (either a bar or a shake) and will record this in the product consumption log.
62588033|NCT06614543|NO_INTERVENTION|The WLC program only|
62588034|NCT04432714|EXPERIMENTAL|R2-DA-EPOCH|
62588035|NCT02779699|EXPERIMENTAL|AL2846|AL2846 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62797336|NCT04963400||Patients with medium disease severity|Hospitalized patients without a diagnosed or suspected cardiac disease and with an acute medical condition of medium severity (e.g. patients with an uncomplicated acute pancreatitis oder an acute exacerbation of a chronic inflammatory bowel disease)
62797337|NCT04963400||Patients with high disease severity|Hospitalized patients without a diagnosed or suspected cardiac disease and with an acute medical condition of high severity (e.g. patients with a proximal femoral fracture)
62797338|NCT02155777|NO_INTERVENTION|No intervention|No intervention.
62588036|NCT05918783|EXPERIMENTAL|Part A|"will be a monotherapy light dose escalation with single dose of Padeliporfin at light laser doses of 150, 250 and 400 mW/cm for 20 minutes.~Part A will proceed with light dose escalation and will continue until the maximum tolerated light dose (MTD) and/or recommended phase 2 dose (RP2D) is defined."
62588037|NCT05918783|EXPERIMENTAL|Part B|will be a dose expansion part at MTD/RP2D dose level identified in Part A to further assess the safety, tolerability, and treatment effect of the MTD and/ or RP2D
62797339|NCT02155777|ACTIVE_COMPARATOR|OrthoNovum 1/35|OrthoNovum 1/35
62221745|NCT06610383||Group 2 (15:30 group (n=20))|Patients in this group will spit into 1.5 ml tubes at 15:30 in the morning before starting the impacted tooth surgery and 48 hours after the surgery, and these tubes will be stored in the refrigerator at -22 degrees. The samples in these tubes will then be examined with ELISA kits and the numerical data of adrenal glucocorticoids in the saliva will be obtained. The patients will fill out the Visual Analog Scale and OHIP-14 forms a total of five times: 6 hours, 24 hours, 48 hours, 72 hours and 7 days after the surgery.
62221746|NCT05820477|EXPERIMENTAL|FAMS-T1D|"Participants will receive FAMS-T1D components (monthly phone coaching and text message support for goals) for 6 months. Support person will receive text messages that are tailored to the goal set by the person with type 1 diabetes.~All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes."
62221747|NCT05820477|PLACEBO_COMPARATOR|Digital resources for diabetes|Persons with type 1 diabetes will receive text messages as to how to access their HbA1c results and digital materials related to self-care behaviors for their diabetes. All support persons will receive digital materials about type 1 diabetes and how to provide helpful support to the person with diabetes.
62433401|NCT03289637|PLACEBO_COMPARATOR|Placebo|In the group randomised to placebo and with a screening level of 25-OH-vitamin D \<50 mol/L, the participants will be given placebo.
62433402|NCT02775227|EXPERIMENTAL|Hydrocortisone|
62433403|NCT02775227|ACTIVE_COMPARATOR|Pasireotide|
62797340|NCT06443190|EXPERIMENTAL|Indigenous Patient Navigator Support|"Participants will work with an Indigenous Patient Navigator (IPN) for up to 18 months. The IPN may have the following roles in supporting the youth +/- their caregiver in managing their healthcare and health condition:~* Spiritual: connect with community Elders, connect with cultural programs, arrange smudging and ceremony~* Physical: find housing, find a family doctor, arrange transportation, fill prescriptions, create a health passport~* Mental: arrange health benefits, schedule appointments, find employment, connect to community services~* Emotional: connect with peers, find mental health supports, support youth at appointments, communicate with youth's healthcare team"
62797341|NCT00242723||1/Cohort 1|Subjects with potentially malignant or suspicious lesions, or biopsy proven thoracic cancers or thoracic metastases from cancers of non-thoracic origin
62797342|NCT01153737|EXPERIMENTAL|manual therapy|
62797343|NCT01153737|ACTIVE_COMPARATOR|TENS|Electric Nerve Stimulation (TENS)
62797344|NCT01470456|EXPERIMENTAL|SAR3419 + Rituximab|Combined therapy will be administered intravenously for 8 doses in the absence of unacceptable toxicity, disease progression or withdrawal of consent.
62797345|NCT05661851|EXPERIMENTAL|Investigational product|Eligible subjects will be randomly assigned the investigational product to be used in both eyes for the duration of the study.
62797346|NCT05661851|ACTIVE_COMPARATOR|Control product|Eligible subjects will be randomly assigned the control product to be used in both eyes for the duration of the study
62797347|NCT04537026|EXPERIMENTAL|Transforaminal epidural Amniotic Fluid injection|"Using fluoroscopic guidance, a lumbosacral epidural injection will be performed. 2-5cc of 1% lidocaine will be injected into the skin and subcutaneous tissue to anesthetize the skin and subcutaneous structures over the site of planned entry to the neural foramen. A 22 or 25 g Whitacre needle (3.5-7) will be used to access the epidural space using the sub-pedicular or infraneural transforaminal approach, depending on individual anatomy at the discretion of the treating physician. Needle tip position will be confirmed using anterior-posterior and lateral fluoroscopic views as well as with injection of a standard 1-3 mL aliquot of omnipaque 180 (Iohexol) (GE Healthcare) contrast material during live fluoroscopy to confirm epidural flow of contrast and to rule out an intravascular injection. Then 3 mL of Amniotic Fluid will be injected through the spinal needle for unilateral symptoms, for a total injection volume of 3 mL in both groups."
62433404|NCT04149899|EXPERIMENTAL|Part 1 (Period 1): WB007 0.05%|WB007 0.05%, single dose to study eye on Day 1
62588038|NCT04028895|OTHER|Experimental|
62588039|NCT02372812|ACTIVE_COMPARATOR|group1|12 mg( 3 mls) of dexamethasone given 15 mins after induction of anesthesia
62588040|NCT02372812|PLACEBO_COMPARATOR|group2|3 mls of placebo( normal saline) given 15 mins after induction of anesthesia
62588041|NCT05898984|EXPERIMENTAL|single dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI (T)|CHF 5993 BDP/FF/GB 200/6/12.5 µg via pressurized metered dose inhaler: 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a total daily dose (TDD) of BDP/FF/GB: 800/24/50 µg.
62588042|NCT05898984|ACTIVE_COMPARATOR|single dose of CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI (R1)|CHF 5993 BDP/FF/GB 100/6/12.5 µg via pressurized metered dose inhaler: 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg.
62588043|NCT05898984|ACTIVE_COMPARATOR|Single dose of BDP HFA (QVAR REDIHALER®, BDP 80 μg) (R2)|BDP HFA (QVAR REDIHALER®, BDP 80 μg): pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve).
62588044|NCT03783585|EXPERIMENTAL|cognitive behavioral therapy for insomnia (CBT-I)|Participants randomized to this arm will participate in a 6-week web-based cognitive behavioral therapy for insomnia (CBT-I) program.
62588045|NCT03783585|EXPERIMENTAL|CBT-I + biweekly support|Participants randomized to this arm will participate in a 6-week web-based CBT-I program. In addition, biweekly support consisting of one-on-one, semi-structured, online video-chat sessions (via HIPAA-compliant Zoom) or phone calls will be conducted every other week.
62588046|NCT04793529|EXPERIMENTAL|Cholecalciferol injection|
62588047|NCT00536627|EXPERIMENTAL|1|Patients will receive 5 injections of DNA vaccine at weeks 0, 8, 16, 40, 44.
62588048|NCT00536627|NO_INTERVENTION|2|
62588049|NCT06111196|EXPERIMENTAL|BAT3306 injection|100mg/4ml,intravenous injection
62588050|NCT06111196|ACTIVE_COMPARATOR|KEYTRUDA® (EU-sourced)|100mg/4ml,intravenous injection
62221748|NCT03598010|EXPERIMENTAL|Lenodiar Pediatric in Acute/Prolonged Diarrhea|"LenoDiar Pediatric acts thanks to Actitan-F, a plant-based molecular complex resulting from Aboca research which reduces attacks of diarrhoea and normalises the consistency of stools, helping to rapidly restore a balanced intestinal function.~Actitan-F counteracts the inflammation of the intestinal mucous membrane, always present in the case of diarrhoea, through two action mechanisms:~* a protective action, achieved by forming a barrier-effect film to limit contact with microorganisms and irritants;~* an antioxidant action on the free radicals which counteracts the irritation of the mucous membrane."
62221749|NCT03598010|EXPERIMENTAL|Lenodiar Pediatric in Chronic Diarrhea|"LenoDiar Pediatric acts thanks to Actitan-F, a plant-based molecular complex resulting from Aboca research which reduces attacks of diarrhoea and normalises the consistency of stools, helping to rapidly restore a balanced intestinal function.~Actitan-F counteracts the inflammation of the intestinal mucous membrane, always present in the case of diarrhoea, through two action mechanisms:~* a protective action, achieved by forming a barrier-effect film to limit contact with microorganisms and irritants;~* an antioxidant action on the free radicals which counteracts the irritation of the mucous membrane."
62221750|NCT03147404|EXPERIMENTAL|Avelumab|Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
62221751|NCT03460691||Group 1|Group 1:patients who will undergo the bariatric surgery
62221752|NCT03536143|EXPERIMENTAL|Topical beremagene geperpavec|HSV1-COL7A1 vector (KB103)
62588051|NCT06665347|ACTIVE_COMPARATOR|Progressive muscle relaxation group|All participants in this group will receive progressive muscle relaxation for 8 weeks
62588052|NCT06665347|EXPERIMENTAL|Progressive muscle relaxation and Yoga group|All participants in this group will receive the same progressive muscle relaxation plus yoga for 8 weeks.
62588053|NCT06620731|EXPERIMENTAL|mild hepatic impairment group|participants with mild hepatic impairment(Child-Pugh A)
62588054|NCT06620731|EXPERIMENTAL|moderate hepatic impairment group|participants with moderate hepatic impairment (Child-Pugh B)
62588055|NCT06620731|EXPERIMENTAL|health volunteer group|Normal hepatic function
62588056|NCT06662409|EXPERIMENTAL|Nature-based healing meditation (NBHM) intervention|6 nature-based healing meditation (NBHM) auditory modules intervention
62588057|NCT03244631|ACTIVE_COMPARATOR|Lumbar Plexus Block|"A lumbar plexus 'nerve block' is a procedure in which local anesthetic (numbing medicine) is injected around a specific group of nerves to provide pain relief directly to the nerves supplying the area of the body undergoing surgery."
62588058|NCT03244631|ACTIVE_COMPARATOR|Pericapsular Injection|"The pericapsular injection is a procedure in which local anesthetic (numbing medicine) is injected around the hip joint to provide direct pain relief to the area undergoing surgery."
62588059|NCT03715972||Anemia Observation|The study will enroll 90 adult subjects with transfusion independent sickle cell disease (70 SS, 10 SC, 10 Sβ0) and 60 patients with transfusion-dependent sickle cell disease. It will also include 10 transfusion independent thalassemia patients and 20 transfusion dependent thalassemia patients. Diamox (acetazolamide) will be administered during MRI.
62221753|NCT03536143|PLACEBO_COMPARATOR|Placebo|Placebo
62221754|NCT00822211|EXPERIMENTAL|Vildagliptin Dose 1|
62221755|NCT00822211|EXPERIMENTAL|Vildagliptin Dose 2|
62221756|NCT00822211|PLACEBO_COMPARATOR|Placebo|
62433405|NCT04149899|EXPERIMENTAL|Part 1 (Period 2): WB007 0.15%|WB007 0.15%, single dose to study eye on Day 1
62588060|NCT03715972||Anemia Intervention|"Most patients will already be prescribed hydroxyurea as part of their standard of care. Since hydroxyurea could impact brain blood flow, there is also a small pilot study (20 patients, nonrandomized, open label) where MRI imaging will be performed prior to and following administration of hydroxyurea up to maximum tolerated dose.~non transfusion dependent sickle cell disease patients not already receiving hydroxyurea will be placed on hydroxyurea following their baseline exam and titrated to maximal tolerated dose. They will then undergo a repeat MRI within two months of reaching that dose and be given the option to continue on hydroxyurea or stop."
62588061|NCT03715972||Healthy Controls|40 control subjects recruited from first degree relatives of the sickle cell disease population. Diamox (acetazolamide) will be administered during MRI.
62588062|NCT04013360|ACTIVE_COMPARATOR|Breath Stacking|Instrument composed of a one-way valve coupled to a face mask to promote the accumulation of successive inspiratory volumes.
62588063|NCT04013360|ACTIVE_COMPARATOR|Expiratory Positive Airway Pressure|Therapeutic technique consisting of a face mask, a one-way valve and an expiratory resistor, responsible for resistance to expiratory flow, which will determine the level of pressure in the airway.
62588064|NCT06572748|OTHER|Assigned intervention|"During the first 10 weeks, the intervention group will undergo the 10-week programme in the Chef Anchor 3.0"
62588065|NCT06572748|OTHER|Assigned waitlist attention control|During the first 10 weeks, no activity for the waitlist control group. Then, from week 10 to 20, the waitlist control group will attend the same 10-week programme.
62588066|NCT06288841|PLACEBO_COMPARATOR|Ropivacaine injection group|
62588067|NCT06288841|EXPERIMENTAL|Bupivacaine liposomal low-dose group|
62588068|NCT06288841|EXPERIMENTAL|Bupivacaine liposomal medium-dose group|
62588069|NCT06288841|EXPERIMENTAL|Bupivacaine liposomal high-dose group|
62221757|NCT02854969|NO_INTERVENTION|epinephrine auto-injector|3 months using the epinephrine auto-injector alone, and after that 3 more months using the epinephrine auto-injector + medical device
62221758|NCT02854969|EXPERIMENTAL|epinephrine auto-injector + medical device|"Device: Anapphylaxis is a medical device with a case for an epinephrine autoinjector that connects via Bluetooth to a mobile application~3 months using the epinephrine auto-injector + medical device , and after that 3 more months using the epinephrine auto-injector alone"
62433406|NCT04149899|EXPERIMENTAL|Part 1 (Period 3): WB007 0.4%|WB007 0.4%, single dose to study eye on Day 1
62588070|NCT06665139||impigment|Patients diagnosed with impingement and meeting the criteria will be included,
62588071|NCT06665139||healty|the healthy group will consist of hospital staff who do not have shoulder pain and who are not diagnosed with a shoulder-related disease.
62588072|NCT01298869||Chronic kidney disease|Chronic kidney disease stage IV and V
62588073|NCT06666309|EXPERIMENTAL|Strengths Based Case Management - PrEP + Text Messaging|Two session Strengths-based Case Management intervention delivered by a peer support specialist to individual clients in the syringe service program
62797348|NCT04537026|ACTIVE_COMPARATOR|Transforaminal epidural dexamethasone injection|"Using fluoroscopic guidance, a lumbosacral epidural injection will be performed. 2-5cc of 1% lidocaine will be injected into the skin and subcutaneous tissue to anesthetize the skin and subcutaneous structures over the site of planned entry to the neural foramen. A 22 or 25 g Whitacre needle (3.5-7) will be used to access the epidural space using the sub-pedicular or infraneural transforaminal approach, depending on individual anatomy at the discretion of the treating physician. Needle tip position confirmed using anterior-posterior and lateral fluoroscopic views as well as with injection of a standard 1-3 mL aliquot of omnipaque 180 (Iohexol) (GE Healthcare) contrast material during live fluoroscopy to confirm epidural flow of contrast and to rule out an intravascular injection. 1 mL of dexamethasone sodium phosphate (10 mg/mL) combined with 2 mL of sterile water will be injected through the spinal needle for unilateral symptoms, for a total injection volume of 3 mL in both groups."
62797349|NCT02695251|EXPERIMENTAL|Low AGE meal|Renal functional parameters are measured at baseline and after a low AGE (eggs) meal
62797350|NCT02695251|EXPERIMENTAL|High AGE meal|Renal functional parameters are measured at baseline and after a high (mixed nuggets) AGE (eggs) meal
62797351|NCT04258826|EXPERIMENTAL|LY3154207|LY3154207 administered orally in one of two study periods.
62797352|NCT04258826|PLACEBO_COMPARATOR|Placebo|Placebo administered orally in one of two study periods.
62221759|NCT06223854|ACTIVE_COMPARATOR|Iodized salt|Refined iodized salt containing 35 ppm iodine as potassium iodate
62221760|NCT06223854|EXPERIMENTAL|Iodized salt with lower-dose folic acid fortification|Refined iodized salt containing 35 ppm iodine as potassium iodate and 33 ppm folic acid (to provide an estimated 200 microgram folic acid per day to women consuming the previously determined average amount of discretionary salt in the study communities)
62221761|NCT06223854|EXPERIMENTAL|Iodized salt with higher-dose folic acid fortification|Refined iodized salt containing 35 ppm iodine as potassium iodate and 99 ppm folic acid (to provide an estimated 600 microgram folic acid per day to women consuming the previously average amount of discretionary salt in the study communities)
62221762|NCT00790751|PLACEBO_COMPARATOR|placebo|
62221763|NCT00790751|EXPERIMENTAL|avanafil 50 mg|
62221764|NCT00790751|EXPERIMENTAL|avanafil 100 mg|
62221765|NCT00790751|EXPERIMENTAL|avanafil 200 mg|
62221766|NCT01046773|ACTIVE_COMPARATOR|Children with Crohn's disease less than 35 kg|These are children ages 8 to 18 years inclusive, with mild to moderately active Crohn's disease.
62221767|NCT01046773|ACTIVE_COMPARATOR|Children with Crohn's disease 35 kg or greater|These are children ages 8 to 18 years inclusive, with mild to moderately active Crohn's disease.
62221768|NCT03029351|EXPERIMENTAL|Exenatide extended release|Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.
62221769|NCT03029351|PLACEBO_COMPARATOR|Placebo|Placebo treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to Exenatide extended release.
62221770|NCT01326754|OTHER|Artemether-lumefantrine|
62221771|NCT01326754|OTHER|Artesunate-amodiaquine|
62433407|NCT04149899|EXPERIMENTAL|Part 2: WB007 0.15%|WB007 0.15%, dosed twice daily for 14 days
62433408|NCT04149899|EXPERIMENTAL|Part 2: WB007 0.4%|WB007 0.4%, dosed twice daily for 14 days
62588074|NCT06666309|ACTIVE_COMPARATOR|CDC-PrEP + Text Messaging|1 session PrEP education following CDC guidelines delivered to individual clients in the syringe service program
62588075|NCT06666309|EXPERIMENTAL|Strengths Based Case Management - PrEP + Text Messaging + Peer Transitional SBCM (T-SBCM)|SBCM-PrEP + Text Messaging no response by end of month 1, and randomized to rup to 2 sessions of post-linkage transitional SBCM delivered by a peer support specialist
62588076|NCT06666309|EXPERIMENTAL|Strengths Based Case Management - PrEP + Text Messaging + Mobile outreach|SBCM-PrEP + Text Messaging no response by end of month 1, and randomized to up to 2 sessions of post-linkage field session visits delivered by a peer support specialist
62588077|NCT06666309|OTHER|CDC-PrEP + Text Messaging + Peer Transitional SBCM (T-SBCM)|CDC-PrEP + Text Messaging; no response by end of month 1, and randomized to rup to 2 sessions of post-linkage transitional SBCM delivered by a peer support specialist
62588078|NCT06666309|OTHER|CDC-PrEP + Text Messaging + Mobile outreach|CDC-PrEP + Text Messaging no response by end of month 1, and randomized to up to 2 sessions of post-linkage field session visits delivered by a peer support specialist
62588079|NCT03378297|NO_INTERVENTION|Feasibility study cohort|
62588080|NCT03378297|EXPERIMENTAL|Metformin|850 mg
62588081|NCT03378297|EXPERIMENTAL|Acetylsalicylic acid|160 mg
62588082|NCT03378297|EXPERIMENTAL|Olaparib|300 mg x 2
62588083|NCT03378297|EXPERIMENTAL|Letrozol|2.5 mg
62588084|NCT06682884|EXPERIMENTAL|Lorlatinib as Neoadjuvant Treatment|These patients will receive lorlatinib neoadjuvant therapy for 6-8 weeks (determined by clinicians' decision based on clinical practice) and then underwent surgery
62588085|NCT05209776|EXPERIMENTAL|Patients|Carrier of a definite diagnosis of arrhythmogenic dysplasia of the right ventricle in line with the criteria of the Task Force 2010 (see Appendices), admitted for an electrical mapping of the right ventricle
62221772|NCT01326754|OTHER|Dihydroartemisinin-piperaquine|
62588086|NCT05209776|EXPERIMENTAL|Control case|Without heart disease, admitted for a Kent bundle ablation or endocavity procedure / Wolff-Parkinson-White syndrome or common flutter (in subjects in whom the same irrigated material will be used and for whom echocardiography will have excluded associated heart disease).
62588087|NCT06651827|EXPERIMENTAL|Dentin sensitivity was measured before and after treatment|Dentin sensitivity was measured using the Yeaple Probe and air stimulation tests before and after treatment
62588088|NCT06402448||group 1|one group containing 300 patients of muscle , joint and nerve pain.
62588089|NCT05709951|ACTIVE_COMPARATOR|Functional exercises|Piriformis stretching Cobra pose Sit up Bridging exercise
62221773|NCT02040584|EXPERIMENTAL|Minimisation of TAC|Treatment with rTAC+EVR+corticosteroids
62221774|NCT02040584|ACTIVE_COMPARATOR|TAC + MMF + corticosteroids|Treatment with TAC + MMF + corticosteroids
62221775|NCT01283477|EXPERIMENTAL|ACUPUNCTURE|
62221776|NCT01283477|SHAM_COMPARATOR|SHAM ACUPUNCTURE|
62221777|NCT03099746|EXPERIMENTAL|INVOLVE|"The first study condition, called Interactive Virtual Decision Support for End-of-Life and Palliative Care (INVOLVE) will consist of exposures to an avatar-based decision support technology that will be administered via tablet computer and allow SDMs opportunities to practice their communication and decision making skills through interactions with avatars that portray a decision coach and various healthcare providers."
62416179|NCT06594445|EXPERIMENTAL|Arm 5: Dose Level 5: 25 ug/kg/day|"GTB-3650 is administered during an inpatient stay by continuous infusion (CI) consisting of three consecutive 24 hour infusion bags over a 72 hour period. Each 72-hour infusion period is designated a block.~A 28-day treatment cycle consists of two blocks followed by approximately 18 days of no treatment. Prior to each block start, the patient must meet the safety criteria.GTB-3650 may continue for up to four treatment cycles total provided disease based response criteria is met and the patient is otherwise eligible to continue."
62416180|NCT06594445|EXPERIMENTAL|Arm 6: Dose Level 6: 50 ug/kg/day|"GTB-3650 is administered during an inpatient stay by continuous infusion (CI) consisting of three consecutive 24 hour infusion bags over a 72 hour period. Each 72-hour infusion period is designated a block.~A 28-day treatment cycle consists of two blocks followed by approximately 18 days of no treatment. Prior to each block start, the patient must meet the safety criteria.GTB-3650 may continue for up to four treatment cycles total provided disease based response criteria is met and the patient is otherwise eligible to continue."
62433409|NCT04149899|ACTIVE_COMPARATOR|Part 2: Timolol 0.5%|Timolol 0.5%, dosed twice daily for 14 days.
62588090|NCT05709951|ACTIVE_COMPARATOR|Core Stability Exercises|Pelvic bridging Plank Cat and camel Curl up
62221778|NCT03099746|EXPERIMENTAL|Informational Support|The second condition, called Informational Support (IS), will also be administered via tablet computers and expose SDMs to educational resources of INVOLVE without the experiential components.
62221779|NCT03099746|EXPERIMENTAL|Usual Care|The third condition, usual care (UC), will expose SDMs to the routine communication and decisional support practices provided by the healthcare team.
62221780|NCT04968808|ACTIVE_COMPARATOR|Staged in-hospital CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized in other day (during hospitalization) after percutaneous coronary intervention (PCI) for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
62588091|NCT05382091|EXPERIMENTAL|OLANI (naltrexone implant)|2 OLANI implants containing 60% naltrexone (3.6 g total NXT) administered at Day 0 with repeat dosing at Week 13 to 24
62588092|NCT05601323|EXPERIMENTAL|HIFU (High-Intensity Focused Ultrasound) + Chemotherapy|"HIFU treatment with Suizenji: up to 2 times per week (1 course) for pancreatic primary lesions; the second course should be at least 60 days apart, up to a maximum of 5 courses.~Chemotherapy (physician's choice): Nal-IRI/FL, mFOLFIRINOX or Gem/nab-PTX"
62588093|NCT05601323|ACTIVE_COMPARATOR|Chemotherapy|Chemotherapy (physician's choice): Nal-IRI/FL, mFOLFIRINOX or Gem/nab-PTX
62588094|NCT00392743||pet/spect scan|
62588095|NCT01024868||TAP block|Patients before undergoing laparoscopic or other abdominal surgery
62588096|NCT06475937|EXPERIMENTAL|DM001 administrated to subjects with advanced or metastatic solid tumors|An IV infusion of DM001 will be administrated approximately 30-60 min on Day 1 once Q3W
62588097|NCT01802736|ACTIVE_COMPARATOR|Standard Positive Prevention Counselling|"Standard positive prevention counseling which includes alcohol reduction and sexual risk behavior counseling provided in the clinic by the clinic medical counselors on the day of enrollment and at month 3 visit.~Although there is awareness of the need to engage and include PLWHA in HIV prevention, there are little practical efforts devoted towards this engagement even in developed countries. One of the major reasons is the lack of a well-defined standard positive prevention package that needs to be delivered to PLWHA. The approach proposed by Kennedy et al modified to suit the local setting and involves a simpler understandable classification of the goals, interventions and expected outcomes of the treatment."
62588098|NCT01802736|EXPERIMENTAL|Alcohol Motivational intervention counselling plus SPP|
62588099|NCT04004065|EXPERIMENTAL|Part A: Vesleteplirsen|Participants received escalating dose levels of vesleteplirsen, every 4 weeks, via intravenous (IV) infusion for up to 75 weeks during Part A. Once the doses have been selected for Part B, all participants who have completed Part A will transition to Part B.
62588100|NCT04004065|EXPERIMENTAL|Part B: Vesleteplirsen|Participants will receive vesleteplirsen at the doses selected based on data from Part A every 4 weeks, via IV infusion, for up to 5 years. This includes the participants who rollover from Part A, as well as the additional participants who will be enrolled at the beginning of Part B.
62588101|NCT01769508|EXPERIMENTAL|Combined Therapy|Combined Modality Treatment of Radiation therapy, 5-Fluorouracil, Oxaliplatin and Lapatinib followed by Surgery
62588102|NCT02793674|OTHER|Fisher & Paykel high flow nasal cannula|All participants in the study were on one or two high flow nasal cannula (HFNC) delivery systems. All were measured on the Fisher \& Paykel HFNC delivery system. The flow rate of the HFNC was adjusted to determine if there exists a change in their effort of breathing.
62221781|NCT04968808|EXPERIMENTAL|Immediate CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized immediately after percutaneous coronary intervention (PCI) for IRA (during index PCI). Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
62221782|NCT01152632|EXPERIMENTAL|specific points of Bladder meridian and Shanjiao meridian|In traditional Chinese acupuncture theory, Bladder meridian and Shanjiao meridian have been considered as the main pathological meridian location of migraine. Meanwhile, specific points on both meridians have been used widely in its treatment for a long time.
62416181|NCT06594445|EXPERIMENTAL|Arm 7: Dose Level 7: 100 ug/kg/day|"GTB-3650 is administered during an inpatient stay by continuous infusion (CI) consisting of three consecutive 24 hour infusion bags over a 72 hour period. Each 72-hour infusion period is designated a block.~A 28-day treatment cycle consists of two blocks followed by approximately 18 days of no treatment. Prior to each block start, the patient must meet the safety criteria.GTB-3650 may continue for up to four treatment cycles total provided disease based response criteria is met and the patient is otherwise eligible to continue."
62433410|NCT04744896|EXPERIMENTAL|cryolipolysis|3max cool shaping device is administered 3 times for each patient, one session every 6 weeks, each session is 40 minutes.
62221783|NCT01152632|EXPERIMENTAL|non-specific points of Bladder meridian and Shanjiao meridian|Non-specific points of Shaoyang meridians are also used in cure of migraine. It is conventionally thought to be less effective using non-specific points than specific ones.
62221784|NCT01152632|ACTIVE_COMPARATOR|specific points of Stomach meridian|Specific points of Stomache meridian for migraine were searched in Chinese ancient data. And this group is set to compare with specific points of Shaoyang meridians for their possible different brain networks.
62221785|NCT01152632|PLACEBO_COMPARATOR|non-acupoints|Three non-acupoints were chosen,two of which were located on the arm and one one the leg.
62221786|NCT01152632|NO_INTERVENTION|waiting list|
62221787|NCT00212160|EXPERIMENTAL|RYGB with omentectomy|Subjects undergoing RYGB will be randomized to also have the greater omentum removed at the time of surgery.
62221788|NCT00212160|NO_INTERVENTION|RYGB without omentectomy|Subjects undergoing RYGB will be randomized to NOT have the greater omentum removed at the time of surgery.
62221789|NCT00212160|NO_INTERVENTION|Normal body weight|Healthy normal weight subjects studied via hyperinsulinemic-euglycemic clamp to obtain reference values for insulin sensitivity and other metabolic parameters.
62221790|NCT00212160|NO_INTERVENTION|Tissue samples|Tissue samples (omental fat, subcutaneous fat, muscle,and blood)are obtained from subjects of varying weights during abdominal surgery in order to compare various parameters, including inflammation, oxidative stress, and gene expression, among tissues across weight classes.
62221791|NCT00597246|EXPERIMENTAL|1|
62221792|NCT02434497|EXPERIMENTAL|Single Arm|One treatment period for all patients (\<1 year and 10 months), with the possibility to up-titrate dose to 40 mg of rosuvastatin for non-Asian patients.
62797353|NCT06074562|EXPERIMENTAL|LY3556050 Dose 1|Participants will receive LY3556050 orally.
62797354|NCT06074562|EXPERIMENTAL|LY3556050 Dose 2|Participants will receive LY3556050 orally.
62797355|NCT06074562|EXPERIMENTAL|LY3556050 Dose 3|Participants will receive LY3556050 orally.
62433411|NCT04744896|EXPERIMENTAL|treadmill|aerobic training in form of high intensity interval training, three times per week for 3 weeks by treadmill(jkexer focus 8020A) each session is for 20 minutes.
62797356|NCT06074562|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo orally.
62797357|NCT04338308||SVG PCI|
62221793|NCT02174042|EXPERIMENTAL|Tangning Tongluo Capsule|Type 2 diabetes
62433412|NCT04744896|ACTIVE_COMPARATOR|treadmill+cryolipolysis|aerobic training 3 times per week and cryolipolysis once every 6 weeks
62588103|NCT02793674|OTHER|Vapotherm high flow nasal cannula|All participants in the study were on one or two high flow nasal cannula (HFNC) delivery systems. A subgroup was measured on the Vapotherm HFNC delivery system. The flow rate of the HFNC was adjusted to determine if there exists a change in their effort of breathing.
62588104|NCT03257852|EXPERIMENTAL|ASP5094 Group|To be intravenously administered ASP5094 in patients with rheumatoid arthritis (RA) treated with methotrexate.
62797358|NCT06725199||Healthy group|Blood and urine samples taken from completely healthy individuals will be examined.
62797359|NCT06725199||Fibromyalgia group|Blood and urine samples taken from individuals diagnosed with fibromyalgia will be examined
62797360|NCT06465511|EXPERIMENTAL|Supportive clinic|Patients randomized to the intervention arm will attend a 120-minute survivorship clinic in which each participant will be assessed by members of a multidisciplinary team comprising an oncology nurse practitioner, a dietitian, a cancer exercise specialist, and a counsellor.
62221794|NCT03309462|EXPERIMENTAL|Re-biopsy tissue sample|The gene testing of re-biopsy tissue sample diagnosed with NSCLC will be performed with NGS using Illumina Miseq squencer and Cobas.
62221795|NCT03309462|EXPERIMENTAL|Peripheral blood sample|The peripheral blood sample will be extracted with DNA and performed with NGS using Illumina Miseq squencer and ddPCR.
62221796|NCT01495832|EXPERIMENTAL|Pulse Group|The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
62221797|NCT01495832|ACTIVE_COMPARATOR|Control Group|The control group will consume comparator foods for 12 weeks.
62221798|NCT05615545||Cryoablation|Cryoablation of selected tumor lesions
62221799|NCT03952325|EXPERIMENTAL|Cohort 1, Arm A: Tesetaxel plus nivolumab|
62221800|NCT03952325|EXPERIMENTAL|Cohort 1, Arm B: Tesetaxel plus pembrolizumab|
62588105|NCT03257852|PLACEBO_COMPARATOR|Placebo Group|To be intravenously administered ASP5094 in patients with rheumatoid arthritis (RA) treated with methotrexate.
62588106|NCT06642207||group A|
62588107|NCT06642207||group B|
62797361|NCT06465511|ACTIVE_COMPARATOR|Control: Self-management|Patients randomized to the control group will be given a set of pamphlets explaining symptoms and describing skill-based self-management for symptom management and lifestyle recommendations.
62797362|NCT06105840|EXPERIMENTAL|Intervention Group|Groups assigned randomly using lottery draw number 1
62797363|NCT06105840|SHAM_COMPARATOR|Control Group|Groups assigned randomly using lottery draw number 2
62024789|NCT06635460|EXPERIMENTAL|Intervention Group|"Adolescents in this group will receive motivational interviewing and WhatsApp-based follow-up. Adolescents will be followed for 6 months. Online motivational interviewing sessions will occur once during the first 4 weeks. Meetings will then continue at 15-day intervals in the form of online motivational interview meetings and WhatsApp chats, respectively. Follow-up WhatsApp meetings will be held every 15 days for the next 3 months. The meetings will be conducted according to the Intervention Group Meeting Content prepared in accordance with the literature and expert opinion. The duration of the motivational meetings will be limited to 30-45 minutes in accordance with the literature. Blood glucose results, the lowest and highest values, and the reasons will be included in the content of patient follow-up, which will be conducted at intervals on the WhatsApp platform. Although the duration of written dialogues will vary among adolescents, it will be limited to an average of 2-10 min."
62024790|NCT05162820|EXPERIMENTAL|Smoker Solarplast|Smoker's assigned to solarplast
62221801|NCT03952325|EXPERIMENTAL|Cohort 1, Arm C: Tesetaxel plus atezolizumab|
62221802|NCT03952325|EXPERIMENTAL|Cohort 2: Tesetaxel|
62221803|NCT03952325|EXPERIMENTAL|Cohort 3: Tesetaxel|
62416182|NCT06372834|EXPERIMENTAL|piTBS (active, N=50)|The piTBS sessions will be delivered using the Magstim Rapid2 stimulator (Magstim Company, Ltd, Whitland, Wales, UK, SA340HR) with a 70-mm air-cooled figure-eight coil (Magstim D70 Air film coil). The piTBS protocol consists of 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) for 2 s at 8-s intervals for 60 cycles. A 2-s train of piTBS will be repeated every 10 s for a total of 1800 pulses per session. The intensity of stimulation will be set at 90% resting motor threshold (RMT), as measured from the right first dorsal interosseous muscle by a handheld 700-mm figure-of-eight coil (Magstim D70 alpha coil). The Beam F3 method will be used for coil positioning to target the left dorsolateral prefrontal cortex. The piTBS protocol will be scheduled for 3 sessions per working day for 2 weeks (i.e., a total of 30 sessions over 2 weeks). Three sessions of the piTBS per day will be separated by at least 60 mins.
62797364|NCT03461146|EXPERIMENTAL|MT-6548|
62797365|NCT02466932||Birth Weight|
62797366|NCT04066478|EXPERIMENTAL|Teatment|75mg Dehydroepiandrosterone once daily for minimum ten weeks prior to starting ovarian stimulation
62024791|NCT05162820|PLACEBO_COMPARATOR|Smoker Placebo|Smoker's assigned to placebo
62024792|NCT05162820|EXPERIMENTAL|Non-smoker Solarplast|Non-smoker assigned to solarplast
62416183|NCT06372834|SHAM_COMPARATOR|piTBS (sham, N=50)|The patients in the sham piTBS condition will receive the same piTBS regimen and exact positioning of the coil, but stimulations will be delivered using a commercial identical-looking figure-8 sham coil (Magstim D70 Air film sham coil) that can produce a similar sound and sensations but induce neither magnetic pulses nor current in the cortex.
62416184|NCT06480383|EXPERIMENTAL|ITI-1284 10mg|
62416185|NCT06480383|EXPERIMENTAL|ITI-1284 20mg|
62416186|NCT06480383|PLACEBO_COMPARATOR|Placebo|
62797367|NCT04066478|PLACEBO_COMPARATOR|Comaprator|75mg placebo once daily for minimum ten weeks prior to starting ovarian stimulation
62797368|NCT00439296|EXPERIMENTAL|Dose Level 1|"Treatment Dose of ABT-751 is 80 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
62797369|NCT00439296|EXPERIMENTAL|Dose Level 2|"Treatment Dose of ABT-751 is 100 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
62221804|NCT03971630|NO_INTERVENTION|Standard care group|These patients will be followed by standard protocol in the Unit of HMV of the University Hospital of Santa María- University Hospital Arnau de Vilanova.
62221805|NCT03971630|EXPERIMENTAL|MyVENT group|These patients will be followed up using the telemedicine (MyVENT System and APP)
62221806|NCT04822493|EXPERIMENTAL|Counseling Aid|"A. Complete the demographic questionnaire, the survey questions, and then complete the counseling aid. Receive standard counseling as part of routine prenatal care.~B. Prior to discharge after delivery, study personnel will administer the postpartum questionnaire via a mobile tablet. The questionnaire is programmed into the study application."
62797370|NCT00439296|EXPERIMENTAL|Dose Level 3|"Treatment Dose of ABT-751 is 125 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
62797371|NCT00439296|EXPERIMENTAL|Dose Level 4|"Treatment Dose of ABT-751 is 150 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
62221807|NCT04822493|NO_INTERVENTION|Standard Care|"A. Complete the demographic questionnaire and survey questions without watching the educational video. Receive standard counseling as part of routine prenatal care.~B. Prior to discharge after delivery, study personnel will administer the postpartum questionnaire via a mobile tablet. The questionnaire is programmed into the study application."
62416187|NCT05134727|EXPERIMENTAL|Part 1 (single ascending doses [SAD])|Healthy participants will be randomized to a single dose of AZD5055 or placebo.
62416188|NCT05134727|EXPERIMENTAL|Part 2 (multiple ascending doses [MAD])|Healthy participants will be randomized to repeated dosing with AZD5055 or placebo
62416189|NCT06317337|EXPERIMENTAL|focused ultrasound cavitation augmented with aerobic exercise|Ultrasound cavitation single session per week along with the Aerobic exercises. Aerobic Exercise was Treadmill walk for 30 min with moderate intensity
62416190|NCT06317337|ACTIVE_COMPARATOR|focused ultrasound cavitation|Ultrasound cavitation single session per week along with 6min walk test.
62416191|NCT06277778|EXPERIMENTAL|Taekwondo training with music therapy|the participating children will attend 20 sessions of Taekwondo training with the presence of music.
62416192|NCT06277778|SHAM_COMPARATOR|Taekwondo training alone|the participating children will attend 20 sessions of Taekwondo training alone.
62416193|NCT06703710|EXPERIMENTAL|Test group (JW2286)|Ethnicity: Korean or Caucasian
62416194|NCT06703710|PLACEBO_COMPARATOR|Placebo group (Placebo of JW2286)|Ethnicity: Korean or Caucasian
62416195|NCT06701344|EXPERIMENTAL|Go-CHOP|Golidocitinib 150mg qd plus Standard CHOP regimen
62797372|NCT00439296|EXPERIMENTAL|Dose Level 5|"Treatment Dose of ABT-751 is 175 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
62797373|NCT00439296|EXPERIMENTAL|Dose Level 0|"Treatment Dose of ABT-751 is 65 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
62797374|NCT00439296|EXPERIMENTAL|Dose Level -1|"Treatment Dose of ABT-751 is 50 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
62797375|NCT05560685|OTHER|Patient participants|Patients with risk factors for adjuvant endocrine therapy non-adherence or early discontinuation will complete patient-reported outcome (PRO) surveys via smart phone app at baseline and 2, 4, 8 and 12 weeks after adjuvant endocrine therapy initiation.
62797376|NCT05560685|OTHER|Team Member Participants|Feedback about the intervention will be obtained from patients and from members of the study teams and clinical teams caring for the patients who participate.
62797377|NCT01526213|OTHER|Sequence 1: Water, GFJ, FC-free GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
62221808|NCT03619070|EXPERIMENTAL|Lower load resistance training (LL)|In the LL group, postmenopausal women will perform the resistance training with moderate volume (i.e. three sets per exercise performed until or close to failure) and low load (i.e. 30% of 1RM)
62024793|NCT05162820|PLACEBO_COMPARATOR|Non-smoker Placebo|Non-smoker assigned to placebo
62416196|NCT00975338||Prospective LIFEspan|LIFEspan youths with Cerebral Palsy or Acquired Brain Injury
62416197|NCT00975338||Prospective Non-LIFEspan|LIFEspan youths with Spina Bifida
62416198|NCT00975338||Retrospective Non-LIFEspan|Non-LIFEspan youths with Cerebral Palsy or Acquired Brain Injury
62416199|NCT00975338||LIFEspan Staff|All staff affiliated with the LIFEspan model of linked transition care
62416200|NCT00975338||Caregivers|Parents of participating youths
62024794|NCT02451657||Cohort|
62221809|NCT03619070|EXPERIMENTAL|Higher load resistance training (HL)|In the HL group, postmenopausal women will perform the resistance training with moderate volume (i.e. three sets per exercise performed until or close to failure) and high load (i.e. 80% of 1RM)
62416201|NCT00716027|ACTIVE_COMPARATOR|1|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
62416202|NCT00716027|EXPERIMENTAL|2|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
62416203|NCT02790372|NO_INTERVENTION|Control nursing homes|Nursing homes carries out usual care
62416204|NCT02790372|ACTIVE_COMPARATOR|Intervention nursing homes|Nursing homes that carries out regularly case conferencing
62416205|NCT00720304|EXPERIMENTAL|oral erlotinib hydrochloride|
62416206|NCT05780515|EXPERIMENTAL|ANX009|Participants will receive repeat doses of ANX009 administered by subcutaneous (SC) infusion 3 times weekly during the approximate 3-week intervention period.
62588108|NCT03689374|EXPERIMENTAL|Semaglutide|"Run-in period (12 weeks): subjects will be treated with metformin and insulin glargine (IGlar) U100.~Treatment period: Participants who are not in glycaemic control (defined as HbA1c of more than or equal to 7.5% to less than or equal to 10%) after run-in will receive semaglutide for 52 weeks in addition to metformin and IGlar U100.~Metformin will be considered as background therapy during the trial."
62588109|NCT03689374|ACTIVE_COMPARATOR|Insulin aspart|"Run-in period (12 weeks): subjects will be treated with metformin and insulin IGlar U100.~Treatment period: Participants who are not in glycaemic control (defined as HbA1c of more than or equal to 7.5% to less than or equal to 10%) after run-in receive insulin aspart for 52 weeks in addition to metformin and IGlar U100.~Metformin will be considered as background therapy during the trial."
62797378|NCT01526213|OTHER|Sequence 2: Water, FC-free GFJ, GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
62797379|NCT01526213|OTHER|Sequence 3: GFJ, FC-free GFJ, Water|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
62797380|NCT01526213|OTHER|Sequence 4: GFJ, Water, FC-free GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
62797381|NCT01526213|OTHER|Sequence 5: FC-free GFJ, GFJ, Water|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
62416207|NCT05700942|EXPERIMENTAL|High Dose Intervention|tsDCS will be delivered to the lumbar region of the spinal cord during LT using a commercially available stimulation unit (Soterix Medical, Inc., New York, NY). tsDCS electrodes are comprised of a 10x5 cm carbon rubber electrode encased in a saline-soaked sponge. The anode electrode will be placed on the skin over the spinal processes of the 11th and 12th thoracic vertebrae, and the two cathode electrodes will be placed on each side of the umbilicus. For the high dose group, a standard dosage of 30 continuous minutes of 2.5 mA stimulus will be used.
62416208|NCT05700942|ACTIVE_COMPARATOR|Low Dose Intervention|tsDCS will be delivered to the lumbar region of the spinal cord during LT using a commercially available stimulation unit (Soterix Medical, Inc., New York, NY). tsDCS electrodes are comprised of a 10x5 cm carbon rubber electrode encased in a saline-soaked sponge. The anode electrode will be placed on the skin over the spinal processes of the 11th and 12th thoracic vertebrae, and the two cathode electrodes will be placed on each side of the umbilicus. The low dose condition will use an identical montage and stimulation arrangement, except the stimulation will be delivered briefly at the beginning and end of the stimulation period (30 seconds) with a three-second ramp.
62797382|NCT01526213|OTHER|Sequence 6: FC-free GFJ, Water, GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
62024795|NCT06444282|EXPERIMENTAL|Emergency Care Action Plan|An Emergency Care Action Plan (ECAP) is a brief, pre-populated summary of suggested emergency management for children with medical complexity, embedded in the electronic health record.
62416209|NCT04986488||Without delirium|
62416210|NCT04986488||With delirium|
62416211|NCT05341583|EXPERIMENTAL|Ensatinib|Ensatinib ( 225 mg, once daily), in accordance with the randomization schedule
62588110|NCT04128904|ACTIVE_COMPARATOR|Standard in vitro fertilisation (IVF)|"Oocytes are fertilised with standard IVF. For details please see Project Description."
62588111|NCT04128904|ACTIVE_COMPARATOR|Intracytoplasmic sperm injection (ICSI)|"Oocytes are fertilised with ICSI. For details please see Project Description."
62588112|NCT01177709|EXPERIMENTAL|Metformin|
62416212|NCT05341583|PLACEBO_COMPARATOR|Placebo|Placebo ( 225 mg, once daily), in accordance with the randomization schedule
62416213|NCT05552092|EXPERIMENTAL|Experimental|The patients with ASA class 1-2 (20-65 years old) who are undergoing elective surgery with supine or lithotomy position, without position change, scheduled to last more than 90 min.
62797383|NCT02109991|EXPERIMENTAL|CG-100 device|
62221810|NCT03619070|EXPERIMENTAL|Higher volume resistance training (HVHL)|In the HVHL group, postmenopausal women will perform the resistance training with high volume (i.e. six sets per exercise performed until or close to failure) and high load (i.e. 80% of 1RM)
62221811|NCT03619070|OTHER|Control group, (CG)|In CG, the postmenopausal women group will not perform exercise
62416214|NCT03858920||General Responder Cohort (GRC) WTC Responders|General Responder Cohort (GRC) and who have chosen to undergo annual medical monitoring and treatment of their WTC-related conditions at Mount Sinai's Irving J. Selikoff Center for Occupational and Environmental Medicine (SCOEM), which is directed by Dr. M. Crane
62024796|NCT06444282|NO_INTERVENTION|Standard Care|The current standard of care does not include emergency care planning.
62416215|NCT03858920||General Responder Cohort (GRC) Non WTC Responders|Members of the World Trade Center General Non Responder Cohort.
62416216|NCT06125886|EXPERIMENTAL|high risk population|The enrolled patients underwent simultaneous transvaginal ultrasound examination and microscale endometrial sampling biopsy.
62416217|NCT04818060||Low Risk of Motor Diagnosis|Approximately 52 participants who have a low probability of motor diagnosis based on the multivariate risk score.
62416218|NCT04818060||High Risk of Motor Diagnosis|Approximately 102 participants who have a high probability of motor diagnosis based on the multivariate risk score.
62416219|NCT04818060||Stage I or II Huntington's Disease|Approximately 52 participants who are living with diagnosed stage I or stage II Huntington's Disease.
62221812|NCT02373943|EXPERIMENTAL|β-carotene biofortified maize|Participants will ingest porridge bF: this will be the β-carotene fortified maize porridge where each 250 g will be made with 50 g of dry maize flour obtained from fortified corn seeds. The contents of β-carotene and other provitamin A carotenoids in this flour will be determined before preparing the porridges.
62416220|NCT04818060||Healthy Controls|Approximately 52 participants who are age-, ethnicity-, and education-matched healthy controls.
62416221|NCT02001285|EXPERIMENTAL|Double lumen tube|This arm contains patients who are needed endobronchial intubation with double lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.
62416222|NCT02001285|ACTIVE_COMPARATOR|single lumen tube|This arm contains patients who are needed endotracheal intubation with single lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.
62416223|NCT04800913|EXPERIMENTAL|Multimodal imaging|"Preoperative 2D/3D TOE AND MDCT for appendage characterisation and sizing~Operative 2D/3D TOE and fluoroscopy/angiography for guiding and checking the procedural events and success~Postoperative 2D/3D TOE and MDCT to assess the complications (peri-device leak, thrombus)"
62416224|NCT04800913|EXPERIMENTAL|Standard imaging|"Preoperative MDCT for appendage characterisation and sizing~Operative 2D/3D TOE and fluoroscopy/angiography for guiding and checking the procedural events and success~Postoperative 2D/3D TOE and MDCT to assess the complications (peri-device leak, thrombus)"
62416225|NCT04477785||Clinical Observation|In PPMI Clinical up to 4,500 participants will be enrolled and followed longitudinally once identified, over the course of 5-8 years.
62416226|NCT05680727|OTHER|real individualized resting state functional connectivity targeting|Participants in this group will receive aiTBS with neuronavigation to a treatment target identified with individualized resting state functional connectivity.
62416227|NCT05680727|OTHER|sham individualized resting state functional connectivity targeting|Participants in this group will receive aiTBS with neuronavigation to a treatment target identified with head measurements (i.e., Beam F3)
62416228|NCT04441203|NO_INTERVENTION|Control|Heart failure clinic follow up
62416229|NCT04441203|ACTIVE_COMPARATOR|CardioMems|The treatment group will be implanted with a CardioMEMS HF sensor and managed using remote access to hemodynamics compared to a non-implanted control group.
62221813|NCT02373943|ACTIVE_COMPARATOR|white maize supplemented with β-carotene|Participants will ingest porridge F: this will be also a β-carotene fortified maize porridge but in this case it will be made with 50 g of dry maize flour obtained from non fortified corn seeds and supplemented with a 500-1500 µg β-carotene reference dose. The exact dose of β-carotene that will be added to these porridges will be established according to the amount of β-carotene found in the flour used with porridges BF.
62416230|NCT01819389|EXPERIMENTAL|Imatinib and nilotinib combination|All patients will receive treatment as follows: imatinib 100 mg tablets, 200 mg daily for 6 months; and nilotinib 150 mg capsule, 300 mg daily for 6 months.
62416231|NCT06542003|EXPERIMENTAL|MGW Drum and Dance Group|Participants in the intervention group engage in a 10-week program that includes both drumming and dancing sessions. The group is further divided into two subgroups due to logistical reasons, with one subgroup attending five weeks of drumming sessions followed by five weeks of dancing sessions, and the other subgroup attending sessions in the opposite order. All participants in this arm participate in both drumming and dancing sessions.
62797384|NCT04295525|PLACEBO_COMPARATOR|Controls subjects placebo|Placebo mucoadhesive oral tablet
62797385|NCT04295525|EXPERIMENTAL|Controls subjects active Treatment|AqualiefTM 400 mg mucoadhesive oral tablet
62797386|NCT04295525|PLACEBO_COMPARATOR|Diseased subjects placebo|Placebo mucoadhesive oral tablet
62797387|NCT04295525|EXPERIMENTAL|Diseased subjects active Treatment|AqualiefTM 400 mg mucoadhesive oral tablet
62797388|NCT06002945||Neurological Outpatients|Participants in this group will be recruited from the outpatient clinical population at MGNet participating sites. Treating physicians will make the initial determination of patients' potential eligibility to participate in the study.
62024797|NCT05759234|EXPERIMENTAL|HS248 pieces|"dose escalation period： At this stage, it is planned that HS248 will adopt the traditional 3+3 method of increasing doses at four dose levels of 20 mg, 40 mg, 60 mg and 80 mg. All dosage components are divided into single administration stage and multiple administration stage. After 5 days of observation after single administration, it enters the stage of multiple administration. In the stage of multiple administration, HS248 is administered once a day (qd) for 28 days. a treatment cycle. 33 days after the first administration (the 5-day observation period in the single-administration phase and the first cycle in the multiple-administration phase) is the dose-limiting toxicity (DLT) observation period of this study"
62797389|NCT06671782|ACTIVE_COMPARATOR|control group (usual care)|Consented patients randomized to the control group will receive usual care at MSK. This will comprise standardized verbal (and sometimes also written) instructions about Kegel exercises from the nurse and/or urologist before the operation. All patients will complete the Prostate Quality of Life Survey at baseline and at 1.5, 3, and 6 months after radical prostatectomy (within ±2 weeks is considered acceptable to avoid protocol violations). This is part of the standard of care for patients undergoing prostatectomy.
62024798|NCT04944342||Individuals who have had COVID-19.|Individuals who have had COVID-19 and who treated by a standart medical treatment at home.
62221814|NCT02373943|SHAM_COMPARATOR|white maize|Participants will ingest porridge N which will be the control porridge and will be made with 50 g of dry maize flour obtained from non fortified corn seeds.
62221815|NCT00626132|EXPERIMENTAL|Eucommia|Eucommia capsules two orally three times a day for 2 weeks
62221816|NCT00626132|PLACEBO_COMPARATOR|1|
62024799|NCT04944342||Individuals who have not a COVID-19 illness history.|Individuals who have not a COVID-19 illness history.
62221817|NCT04669353|ACTIVE_COMPARATOR|Platelet Rich Plasma|In the operating room before the start of each procedure, approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate. After closure of the fascia and prior to skin closure, PRP was directly applied to the subcutaneous tissue of the wound site by using a sterile syringe.
62221818|NCT04669353|NO_INTERVENTION|control group|In the control group (group II), the patients did not receive topical treatment and the subcutaneous tissue was cleaned with normal saline before skin closure
62221819|NCT03451760|EXPERIMENTAL|Feru-guard|Over a 12 week period participants will take two 280 mg hard gel capsules of Feru-guard 100M per day (1 capsule am, 1 capsule pm). One capsule will be taken in the morning with a meal and one capsule will be taken in the afternoon with a meal. Each capsule contains 180.32 mg ferulic acid and 20.02 mg of Angelica archangelica. Total daily dose will be 560mg of Feru-guard 100M, with 360.64 mg of ferulic acid and 40.04 mg of Angelica archangelica.
62416232|NCT06542003|NO_INTERVENTION|No-treatment Control Group|"Participants in the control group do not participate in the drumming and dancing sessions. They represent normal student life. They only complete the same questionnaires at the same time points as the intervention group to serve as a baseline comparison for evaluating the impact of the interventions."
62797390|NCT06671782|EXPERIMENTAL|intervention group (PFME program with biofeedback)|Consented patients randomized to the intervention group will be referred to SPEAR Physical Therapy to undergo the study PFME training program. The team at SPEAR Physical Therapy regularly sees patients undergoing radical prostatectomy and is specially trained in PFME training for male patients. Patients in the intervention arm will undergo PFME training with a physical therapist 2 times before surgery (4-6 weeks \[in person\] and 3-4 weeks \[in person\], before surgery) (within ±1 week is considered acceptable to avoid protocol violations). Patients in the intervention group will also undergo 2 PFME training sessions after surgery (3 weeks and 1.5 months after surgery).
62797391|NCT02221674|EXPERIMENTAL|Tapentadol|Tapentadol 4 mg/mL immediate release oral solution, single dose post-operatively.
62797392|NCT06726421|EXPERIMENTAL|SBRT arm|Patients undergo SBRT to all metastatic sites in addition to standard systemic therapy. Patients should complete radiotherapy for all lesions within 6 months of enrollment, preferably within the first 3 months.
62797393|NCT06726421|ACTIVE_COMPARATOR|Control arm|Patients receive standard systemic therapy.
62797394|NCT05695599|EXPERIMENTAL|Whole body vibration|Participants will undergo a whole body vibration training
62221820|NCT03451760|PLACEBO_COMPARATOR|Placebo|Over a 12 week period participants will take two 280 mg hard gel capsules of a placebo per day (1 capsule am, 1 capsule pm). One capsule will be taken in the morning with a meal and one capsule will be taken in the afternoon with a meal.Total daily dosage will be 560mg of a maltodextrin, calcium stearate, and vanilla food flavor mixture.
62221821|NCT04850794|EXPERIMENTAL|Case A then Case B|Participant will first review and answer questions about Case A without using the tool. Then, they will use the tool to answer questions about case B.
62221822|NCT04850794|EXPERIMENTAL|Case B then Case A|Participant will first review and answer questions about Case B without using the tool. Then, they will use the tool to answer questions about case A.
62221823|NCT01207297|ACTIVE_COMPARATOR|TAC group|Oral tacrolimus (0.04-0.08 mg/kg/d) and prednisone for 12 months.
62221824|NCT01207297|ACTIVE_COMPARATOR|CYC group|Pulse cyclophosphamide (750mg/m2 per month for six months) and prednisone followed by azathioprine (50mg/day）for 6 months.
62221825|NCT05384405|ACTIVE_COMPARATOR|active stimulation|Active Intermittent theta burst stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 5 days.
62221826|NCT05384405|SHAM_COMPARATOR|Sham stimulation|Sham stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 5 days.
62221827|NCT01683929|ACTIVE_COMPARATOR|Oral glucose tolerance test|The participants will consume a beverage containing 75 gram glucose During the meeting, the participants will drink the sweetened drink followed by blood work, at 0, 30, 60, 120, 180 minutes. Also, they will record their macronutrient\\caloric consumption during the 24 hour following the test.
62797395|NCT05695599|NO_INTERVENTION|Control Group|Participants will not perform an intervention
62221828|NCT01683929|PLACEBO_COMPARATOR|Artificial sweetner|"participants will consume a beverage containing 0.42 gram artificial sweetener (Aspartame) During each meeting, the participants will drink the sweetened drink followed by blood work, at 0, 30, 60, 120, 180 minutes.~Also, they will record their macronutrient\\caloric consumption during the 24 hour following the test."
62221829|NCT03878251|OTHER|X fragile syndrome patients|
62221830|NCT03878251|OTHER|Angelman syndrome patients|
62416233|NCT05188287|EXPERIMENTAL|HealthyCells|"The HealthyCells app will have the following features:~Smoking status assessments with facial recognition: Participants will initiate a smoking status assessment and CO breath sample submission using the iCOquit® Smokerlyzer® TWICE per day. To verify the participant's identity while they complete their CO breath sample, we will use Microsoft Face API.~Daily step counter and sedentary behavior prompts: A Google OS smartwatch will be used to monitor participants' activity, and the HealthyCells app will deliver an activity prompt when they have been sedentary for 30 minutes, which will be experienced as noise and vibration on the phone and watch. Also, a text-based reminder message will appear on the phone and watch along with a personalized tip for reducing sedentary time.~Motivational messages for smoking cessation and physical activity. TWICE per day, the HealthyCells app will send messages to encourage users to remain quit and become more active."
62416234|NCT06649591||EC/aligned|Cohort with expert consensus aligned with actual treatment
62416235|NCT06649591||EC/unaligned|Cohort with expert consensus not aligned with actual treatment
62797396|NCT03516422|PLACEBO_COMPARATOR|STANDARD CARE GROUP|The subject positioned so absorbent pads are in position to catch irrigation solution. The saline bottle will be held 10-15 cm from wound bed, and squeezed to spray all surfaces of wound in a sweeping motion, from clean to dirty area of wound. Irrigation will be repeated as necessary to remove exudate, slough, and debris from the wound until the solution draining from the wound is clear. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into the wound cavity, undermining, or tunnel to fill the dead space without causing the wound to stretch or bulge or be packed tightly. Packing should be in contact with entire wound base and edges. Dressings changed once every 3 days by the patient's care provider.
62797397|NCT03516422|EXPERIMENTAL|ULTRASOUND DEBRIDEMENT GROUP:|Low-frequency ultrasound SonicOne O.R. (Misonix, New York, US) generates ultrasound waves with 22.5 kHz frequency. Each probe is attached to a set of irrigation solution (saline 0.9%), they transform electric energy into mechanical vibrations to induce tiny particles of water from irrigation fluid. Absorbent pads are positioned to catch excess saline. With SonicOne set at continuous mode with minimum pump flow, the debridement will begin at most distal aspect of ulcer with the hand piece in constant motion until entire ulcer surface has been debrided until as much necrotic tissue has been removed. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into wound cavity.
62221831|NCT03878251|OTHER|Rett syndrome patients|
62416236|NCT06649591||No EC|Expert panel recommended treatment did not achieve 80% agreement
62797398|NCT03789916|EXPERIMENTAL|DAPT|"Dual antiplatelet therapy: acetylsalicylic acid 100 mg/die + ticagrelor 90 mg bis in die"
62797399|NCT03789916|ACTIVE_COMPARATOR|SAPT|"Single antiplatelet therapy: acetylsalicylic acid 100 mg/die"
62797400|NCT06523894|EXPERIMENTAL|1 fraction SBRT|Treated volume up to 40 cc. Dose escalation from 21 Gy to 23 Gy to 25 Gy every 3 patients if no dose-limiting toxicity (DLT).
62797401|NCT06523894|EXPERIMENTAL|3 fractions SBRT|Treated volume up to 60 cc. Dose escalation from 11Gy/fraction to 13Gy/fraction to 14Gy/fraction every 3 patients if no dose-limiting toxicity (DLT).
62797402|NCT06523894|EXPERIMENTAL|5 fractions SBRT|Treated volume up to 110 cc. Dose escalation from 8Gy/fraction to 9Gy/fraction to 10Gy/fraction every 3 patients if no dose-limiting toxicity (DLT).
62024800|NCT02105506|EXPERIMENTAL|Tachosil patch|Tachosil patch (9.5 x 4.8 cm), containing human fibrinogen (5.5 mg/cm2) and human thrombin (2.0 IU/cm2), applied during surgery. Up to 7 patches per participant may be applied.
62221832|NCT03878251|OTHER|Patients with other genetic rare syndromes with intellectual d|
62221833|NCT05271552|EXPERIMENTAL|Cohort 1- 40 Micrograms|Sublingual film containing 40 Micrograms Dexmedetomidine
62221834|NCT05271552|EXPERIMENTAL|Cohort 2- 60 Micrograms|Sublingual film containing 60 Micrograms Dexmedetomidine
62221835|NCT05271552|PLACEBO_COMPARATOR|Placebo|Sublingual Placebo film
62221836|NCT00531102|EXPERIMENTAL|1|"Resuscitation will proceed as per standard of care and infants are only to receive respiratory support if they remain cyanotic despite 60 seconds of spontaneous regular respirations. All infants will have a pulse oximetry probe placed on the right hand (pre-ductal position) immediately after birth. Infants that meet the entry criteria will be randomized to resuscitation with one of two neonatal T-piece resuscitator circuits:~GROUP 1 - infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes."
62416237|NCT02469675|EXPERIMENTAL|All subjects|"All subjects undergo same full protocol, including different combinations of stimulation on different days:~Transcranial Magnetic Stimulation Cervical Transcutaneous Stimulation Median Nerve Stimulation"
62416238|NCT05681039|EXPERIMENTAL|Neoadjuvant and Adjuvant|
62416239|NCT05521958|OTHER|Acute tibial shaft or tibial plateau fractures without compartment syndrome|Patients with acute lower leg fractures who do not have clinical compartment syndrome.
62416240|NCT05521958|OTHER|Acute tibial shaft or tibial plateau fractures with compartment syndrome.|Patients with acute lower leg fractures with acute compartment syndrome.
62416241|NCT05521958|OTHER|Exertional compartment syndrome|Patients with a diagnosis of exertional compartment syndrome who are planning to undergo surgical procedure to release the compartment fascia will be recruited to participate prior to surgical intervention.
62024801|NCT02266628|EXPERIMENTAL|Treatment Group A|RSV-F vaccine (0.5mL Injection)
62221837|NCT00531102|ACTIVE_COMPARATOR|2|"Resuscitation will proceed as per standard of care and infants are only to receive respiratory support if they remain cyanotic despite 60 seconds of spontaneous regular respirations. Infants that meet the entry criteria will be randomized to resuscitation with one of two neonatal T-piece resuscitator circuits:~GROUP 2 - infants will receive 50% oxygen at a rate of 6 liters per minute continuously for at least 5 minutes using a modified neonatal T-piece resuscitator circuit that does not generate pressure. Fifty percent oxygen was chosen because it reflects the actual inspired oxygen concentration when 100% oxygen is blown towards the infant's face."
62797403|NCT05880303|EXPERIMENTAL|Nonsurgical periodontal therapy|Subjects in the IG will be given non-surgical periodontal treatment comprising of oral hygiene instructions, scaling and root surface debridement. Scaling will be carried out with ultrasonic scaler. For root surface debridement (for sites with PPD \>4mm), local anaesthetic will be administered and ultrasonic scaler and Gracey curettes will be used. The scaling and root surface debridement will be done in 2 sittings over 2 different days within a week. Oral hygiene instructions and additional supportive scaling and root surface debridement will be repeated at 3 months and 6 months if judged necessary (presence of sites with BOP and/or PPD ≥5mm).
62797404|NCT05880303|NO_INTERVENTION|Delayed treatment|Oral hygiene instructions at baseline and will be repeated at 3 months and 6 months. All subjects will receive scaling and root surface debridement at the end of the 6 month trial.
62221838|NCT00737373|EXPERIMENTAL|1|FLOT
62416242|NCT06123897||Individuals with schizophrenia|"Inclusion Criteria:~* 1.Clinical diagnosis of schizophrenia according to ICD-11.~* 2.Confirmation of the diagnosis of schizophrenia using the SCID-5-RV (DSM-5 Structured Clinical Interview for DSM-5 Disorders - Research Version).~Exclusion criteria:~* 1.Clinical diagnosis or SCID-5-RV assessment confirming neurodevelopmental disorders, bipolar and related disorders, substance use disorders (excluding alcohol and tobacco).~* 2.Presence of severe or acute physical illnesses, including traumatic brain injury, intracranial space-occupying or infectious diseases, acute cardiovascular diseases, acute respiratory system diseases, acute hematological disorders, etc.~* 3.Presence of clearly defined genetic diseases, including tuberous sclerosis, multiple sclerosis, Kleefstra syndrome, 22q11.2 deletion syndrome, Prader-Willi syndrome, Klinefelter syndrome (47,XXY), etc."
62797405|NCT00066677|EXPERIMENTAL|rhuMAB-VEGF|bevacizumab 10 mg/kg by intravenous infusion over 30-90 minutes once every 2 weeks until disease progression, unacceptable toxicity or patient preference.
62797406|NCT00066677|EXPERIMENTAL|rhuMAB-VEGF and Docetaxel|rhuMAB-VEGF,bevacizumab: 10 mg/kg by intravenous infusion over 30-90 minutes once every 2 weeks docetaxel, Taxotere: 35 mg/m2 given intravenously over 1 hour on days 1, 8, and 15 of each 28 day cycle. Treatment continued until evidence of disease progression, unacceptable toxicity, or patient preference.
62221839|NCT00737373|ACTIVE_COMPARATOR|2|FLO
62221840|NCT01442831|EXPERIMENTAL|Human ADME|
62221841|NCT02877966|EXPERIMENTAL|Arm A|Amixea- patented stoechiometrical mixture of EAA \& AA
62221842|NCT02877966|PLACEBO_COMPARATOR|Arm B|Placebo
62221843|NCT02120742|EXPERIMENTAL|Social Norming|"The first group will receive SMS message reminders framed as social norming (ie Most of your peers wear helmets)."
62221844|NCT02120742|EXPERIMENTAL|Fear Appeal|"The second group will receive SMS message reminders framed as fear appeals (ie Not wearing your helmet increases your chance of dying in an accident)."
62221845|NCT02120742|PLACEBO_COMPARATOR|Control|The third group will act as the control and receive texts that relate to general road safety, but not helmet use.
62221846|NCT02566343||COPD cohort|confirmed COPD: 240 patients with COPD confirmed by spirometry undergoing high-risk noncardiac major surgery in the University Medical Center Hamburg-Eppendorf will be included in this group.
62221847|NCT02566343||Control cohort|disproved COPD: 80 patients without COPD (clinical risk factors but negative spirometry) undergoing high-risk noncardiac major surgery will be included as a control group.
62221848|NCT02697994|EXPERIMENTAL|Sterile Water Injection|Participants randomised to the intervention group received 4 intracutaneous injections of 0.1 ml sterile water into the skin surrounding the Michaelis rhomboid over the sacral area.
62221849|NCT02697994|PLACEBO_COMPARATOR|Dry Injection|Participants in the control group received 4 dry injections in the same region using an insulin needle .
62221850|NCT02898415||Training set|Consecutive patients who underwent liver transplantation for HCC at Italian transplant centers
62024802|NCT02266628|PLACEBO_COMPARATOR|Treatment Group B|Saline Placebo (0.5mL Injection)
62221851|NCT03231501|EXPERIMENTAL|single arm|This is a single arm study. It is an open-label study. The intervention is eptinib succinate.
62221852|NCT00964587|ACTIVE_COMPARATOR|Usual Care|Packet of standard print patient education materials on CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA).
62221853|NCT00964587|EXPERIMENTAL|Self Study|One 90-minute educational session. Print materials and DVDs for self-study
62221854|NCT00964587|EXPERIMENTAL|Group Problem-Solving Training|One 90-minute education session. Group problem-solving training (eight, 90-minute sessions)
62221855|NCT00964587|EXPERIMENTAL|Individual Problem-Solving Training|One 90-minute education session. Individual problem-solving training (eight, 60-minute sessions)
62221856|NCT06271629||Insomnia Severity index Grade 0&1|administered the Insomnia Severity Index (Korean validated version) to patients with Low Anterior Resection Syndrome (LARS) and divided them into two groups based on the severity grade.
62221857|NCT06271629||Insomnia Severity index Grade 2&3|administered the Insomnia Severity Index (Korean validated version) to patients with Low Anterior Resection Syndrome (LARS) and divided them into two groups based on the severity grade.
62221858|NCT06015828|EXPERIMENTAL|lactoferrin group|Neonates will receive a daily dose of 150 mg/kg body weight per day (up to a maximum of 300 mg/day) of bovine lactoferrin and will be prepared for administration by addition by syringe of sterile water (4 mL) orally or through gavage feeding, once the infant's enteral feed volume is more than 12 mL/kg per day until 36 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer. (Asztalos.,et al 2020)
62221859|NCT06015828|NO_INTERVENTION|control group|Neonates will receive their routine feds and will not receive lactoferrin.
62221860|NCT00363909|EXPERIMENTAL|low-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in weeks 2-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
62221861|NCT00363909|EXPERIMENTAL|medium-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in week 2 and 2 tablets once daily in weeks 3-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
62024803|NCT03264872|EXPERIMENTAL|Peer-Enhanced Motivational Interviewing|Both dyad members, the target client and their peer support person, in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions with a trained counselor.
62024804|NCT03264872|OTHER|Waitlist Control|Delayed Treatment.
62221862|NCT00363909|EXPERIMENTAL|high-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in week 2, 2 tablets once daily in week 3, and 3 tablets once daily in weeks 4-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
62221863|NCT00363909|PLACEBO_COMPARATOR|placebo|"Patients receive 1-3 placebo tablets once daily in weeks 2-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
62221864|NCT01078454|EXPERIMENTAL|ARM A (Mel-Dex)|Patients receive melphalan 0.22 mg/kg orally (PO) and dexamethasone 40 mg PO on days 1-4 every 4 weeks. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
62221865|NCT01078454|EXPERIMENTAL|ARM B (B-Mel-Dex)|Patients receive melphalan 0.22 mg/kg PO and dexamethasone 40 mg PO on days 1-4 and bortezomib 1.3 mg/m\^2 intravenously (IV) on days 1, 4, 8, and 11 every 4 weeks. Treatment repeats every 4 weeks for 2 cycles. Patients then receive melphalan PO and dexamethasone PO on days 1-4 and bortezomib IV on days 1, 8, 15, and 22 every 5 weeks. Treatment repeats every 5 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62416243|NCT06123897||Healthy volunteers|"* Inclusion Criteria:~  1. Ages 13-60 years old.~ 2. Clinical diagnosis not meeting ICD-11 criteria for schizophrenia.~ 3. Diagnosis not meeting schizophrenia criteria confirmed using SCID-5-RV (DSM-5 Structured Clinical Interview for DSM-5 Disorders - Research Version).~* Exclusion criteria are the same as for the schizophrenia patient group."
62588113|NCT04229329|EXPERIMENTAL|Intervention|The patient hand will be restrained to a robotic arm AMADEO(TM) which enables the measurement and manipulation of forces at each finger individually. After appropriate calibration, the force measurements obtained from the robot will be used to move a cursor on the screen. The patient will be rewarded visually and auditory when a higher degree of finger individuation will be measured. Specifically, when the applied force of the instructed fingers hit the predefined force target and at the same, the force in the non-instructed fingers stay as low as possible
62797407|NCT05855772|EXPERIMENTAL|Extracorporeal shock waves therapy[ESWT] + posture corrective exercise programs[PCEP]|Before proceeding with the exercise, apply a radial-type Extracorporeal shock waves. This applies to the main muscles with TrP, the upper trapezius and Leavator scapulae muscle. It is conducted twice a week at 1000 impulse, 60 mJ/m (2), and 5 Hz frequencies. In addition, a posture correction exercise program will be conducted along with ESWT. Muscles such as weakened deep neck flexors, middle trapezius muscles, lower trapezius muscles, and serratus anterior muscles will undergo strengthening exercises, while muscles such as shortened and overactive upper trapezius muscle, Leavator scapulae muscle, and sternocleidomastoid muscle will apply relaxation stretching. This will be conducted privately at home by providing exercise leaflets, and will be conducted for a total of four weeks with a 30-minute program three times a week.
62024805|NCT02575599|ACTIVE_COMPARATOR|Lifestyle counselling|Intervention group: Eighty six adults with type 2 diabetes will be recruited from the general practices where the trained nurses in Guided self-determination programme are working.
62024806|NCT02575599|NO_INTERVENTION|Regular consultation|Control group: Eighty six adults with type 2 diabetes will be recruited from general practices with employed registered nurses without the Guided self-determination training.
62024807|NCT01735539|EXPERIMENTAL|Old Bolus|15g EAA bolus
62024808|NCT01735539|EXPERIMENTAL|Old Arginine|15g EAA Bolus supplemented with 3g Arginine
62024809|NCT01735539|EXPERIMENTAL|Young Bolus|15g EAA bolus
62221866|NCT05031663|EXPERIMENTAL|Almonds|The almond group will receive 15% of their daily energy intake in the form of almonds
62221867|NCT05031663|PLACEBO_COMPARATOR|Pretzel|The placebo group will receive an isocaloric carbohydrate based pretzel snack
62416244|NCT06359964|EXPERIMENTAL|TP BIospy without antibiotic prophylaxis|Transperineal Biopsy without antibiotic prophylaxis
62588114|NCT04229329|SHAM_COMPARATOR|Control|The patient hand will be restrained to a robotic arm AMADEO(TM) which enables the measurement and manipulation of forces at each finger individually. After appropriate calibration, the force measurements obtained from the robot will be used to move a cursor on the screen. The patient will be rewarded in a way that is unrelated to the degree of individuation. In other words, a successful trial considered when the applied force of the instructed fingers hits the predefined force target regardless of the force exerted in the non-instructed fingers.
62588115|NCT03196661|PLACEBO_COMPARATOR|H7N9 split influenza vaccine (15μg/dose)|"This group was divided into three subgroups according ages of subjects, the ages of those subjects are: 3 to 11(36 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines)，12 to 17(36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines)，≥18 (36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
62588116|NCT03196661|PLACEBO_COMPARATOR|H7N9 split influenza vaccine (30μg/dose)|"This group was divided into three subgroups according ages of subjects, the ages of those subjects are: 3 to 11(36 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines)，12 to 17(36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines)，≥18 (36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
62221868|NCT00650351|EXPERIMENTAL|1|Ciprofloxacin Extended-Release Tablets 1000 mg
62221869|NCT00650351|ACTIVE_COMPARATOR|2|Cipro® XR Tablets 1000 mg
62221870|NCT04940026|EXPERIMENTAL|SAR439859|Single oral dose of SAR439859 at Day 1 in fasted condition followed by intravenous administration of \[14C\]-SAR439859 microtracer 3 hours later, and single oral dose of \[14C\]-SAR439859 at Day 7 in fasted condition
62221871|NCT00798915|EXPERIMENTAL|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
62221872|NCT00798915|EXPERIMENTAL|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
62221873|NCT00798915|EXPERIMENTAL|Type 2 diabetes mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
62221874|NCT05790330||Severe eczema|Patients aged 12-18 who have been diagnosed with atopic eczema and require starting systemic therapy.
62221875|NCT05790330||Less severe eczema|Patients aged 12-18 who have been diagnosed with atopic eczema and require topical steroid therapy only.
62221876|NCT05790330||Healthy controls|Patients ages 12-18 who do not have atopic eczema.
62221877|NCT01921010|ACTIVE_COMPARATOR|Niaspan|Patients will be randomized to Niaspan 1.5 g/d in addition to usual care statin lipid lowering agents. The dose of Niaspan will be titrated over a 4-week period and then patients will remain on study drug for additional 12 weeks. The dose of statin will be adjusted in a blinded fashion in both groups at week 10 to similarly achieve a LDL-C of less than 100mg/dl.
62221878|NCT01921010|PLACEBO_COMPARATOR|Control|patients will be randomized to placebo 1.5 g/d in addition to usual care statin lipid lowering agents. The dose of placebo will be titrated over a 4-week period and then patients will remain on study drug for additional 12 weeks. The dose of statin will be adjusted in a blinded fashion in both groups at week 10 to similarly achieve a LDL-C of less than 100mg/dl.
62416245|NCT06359964|ACTIVE_COMPARATOR|TP BIospy with antibiotic prophylaxis|Transperineal Biopsy with antibiotic prophylaxis
62416246|NCT03308123||Health Care Professionals|Health care professionals
62416247|NCT03308123||Carers of hip-fracture patients with moderate/severe|Carers of hip-fracture patients with moderate/severe
62416248|NCT03308123||Discharged hip-fracture patient with memory difficulty|Discharged hip-fracture patient with memory difficulty
62221879|NCT03813420|OTHER|Physiotherapy students|"1. Pittsburgh Sleep Quality Index-PSQI:The sleep quality was evaluated through the Turkish version of the PSQI containing 19 self-rated questions searching the sleep quality during the previous month~2. International Physical Activity Questionnaire-IPAQ: The physical activity of the participants was assessed through the Turkish version of the International Physical Activity Questionnaire -Short Form (IPAQ-SF), which includes 6 questions searching the frequency (days per week) and duration (hours) of walking, as well as the intensity of physical activity in the last seven days.~3. Short Form-36-SF-36: The Turkish version of SF-36 was used to understand the health related quality-of -life (HRQOL) of the participants over the past four weeks in eight health concepts."
62221880|NCT05500443|EXPERIMENTAL|Active treatment|Tablets with vitamin k2 (Menaquinone-7 (MK-7)) 720 μg/day
62221881|NCT05500443|PLACEBO_COMPARATOR|Placebo|Tablets with placebo
62221882|NCT02176213|EXPERIMENTAL|Pomalidomide, Cyclophosphamide, Dexamethasone|Three oral drugs will be given in 28-day cycles: Pomalidomide 4 mg daily x 21 days; cyclophosphamide 50 mg BID x 21 days; and dexamethasone 40 mg weekly x 3 (20 mg weekly if the patient aged ≥ 75 years old)
62221883|NCT04025112|EXPERIMENTAL|Armeo|Patients group (54 patients) for robotic therapy.
62221884|NCT04025112|ACTIVE_COMPARATOR|Conventional|Patients group (54 patients) for conventional rehabilitation protocol.
62024810|NCT01735539|EXPERIMENTAL|Young Pulse|4 x 3.75g Mixed EAA Pulses
62024811|NCT01735539|EXPERIMENTAL|Old Pulse|4 x 3.75g Mixed EAA Pulses
62024812|NCT05385016|EXPERIMENTAL|Education Arm|Participants will attend weekly two hour small group instruction sessions. All sessions will have an education component, a hands-on nutrition/cooking lesson, and a group exercise session. Two health educators will be present during group sessions with one leading
62024813|NCT01490177|EXPERIMENTAL|One|
62024814|NCT04463641|EXPERIMENTAL|Axone 4LV Lead|Subjects implanted with the Axone 4LV Lead
62024815|NCT06534281|EXPERIMENTAL|BAO-G group|
62221885|NCT05730062|EXPERIMENTAL|SSRI 1 week following initiation oxycodone|Patients will be included day 4-10 following initiation of treatment with either Paroxetine, Sertraline, Escitalopram or Citalopram and will be administered oxycodone 10 mg IR
62416249|NCT06117111||Study group|Age: minimum of 18 years, Undergoing pancreatic or ENT tumour surgery, Ability to give informed consent, Volunteering to the study. Monitored in addition to standard monitoring using PaMo device.
62588117|NCT03196661|PLACEBO_COMPARATOR|H7N9 whole virus influenza vaccine (7.5μg/dose)|"This group was divided into two subgroups according ages of subjects, the ages of those subjects are: 12 to 17(54 subjects got inoculated test vaccines,18 subjects got inoculated reference vaccines)，≥18 (54 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
62024816|NCT00949247|EXPERIMENTAL|Docetaxel,Carboplatin,Trastuzumab and Bevacizumab|
62221886|NCT05730062|PLACEBO_COMPARATOR|SSRI 1 week following initiation placebo|Patients will be included day 25-45 following initiation of treatment with either Paroxetine, Sertraline, Escitalopram or Citalopram and and will be administered placebo comparator
62221887|NCT05730062|EXPERIMENTAL|SSRI 1 month following initiation oxycodone|Patients will be included day 25-45 following initiation of treatment with either Paroxetine, Sertraline, Escitalopram or Citalopram and and will be administered oxycodone 10 mg IR.
62024817|NCT04914572|EXPERIMENTAL|Therapeutic rainforest & MIndful walking|The first arm uses mindful walking through a 2km forest trail in Singapore. All Interventional and Control arms will conduct their walk between 8 am to 11 am for five occasions weekly. At the T1, participants will attend a Zoom orientation session to familiarize themselves with the route. During this session, participants will need to answer the self-report questionnaire and provide the first saliva sample for the baseline measurement. In T2, a pre-intervention and post-intervention saliva sample will be taken before the walk. This will follow by T3 the following week. At T4, participants will attend a 60 mins reflection session and answer the self-report questionnaire. On T5 and T6, the participants will continue with the therapeutic rainforest mindfulness walk. On T7, a pre-intervention and post-intervention saliva sample will be taken. On T8, participants will attend a 60 mins reflection session and answer the self-report questionnaire.
62024818|NCT04914572|EXPERIMENTAL|Therapeutic rainforest walk|The second arm of the intervention includes walking through a guided forest trail suggested by NParks Board. The collection of samples and answering of the self-report questionnaire will follow the same sequence as the 1st arm of the 3-arm RCT.
62221888|NCT05730062|PLACEBO_COMPARATOR|SSRI 1 month following initiation placebo|Patients will be included day 25-45 following initiation of treatment with either Paroxetine, Sertraline, Escitalopram or Citalopram and and will be administered placebo comparator.
62221889|NCT06610708|EXPERIMENTAL|Cardiac Prehabilitation for CTO Patients|This single arm involves a 6-month cardiac pre-habilitation program designed for patients with chronic total occlusions (CTO) who are referred for percutaneous coronary intervention (PCI). Participants receive personalized cardiac rehabilitation, which includes physical exercise, medical optimization, and lifestyle modifications. The program aims to improve functional capacity and overall health before PCI. Assessments will be conducted at the start, after 6 months, and one month post-PCI if performed, with ongoing virtual follow-up for 5 months if PCI is not needed.
62416250|NCT04484987|OTHER|TRE group|Time-restricted eating group
62416251|NCT04484987|OTHER|Control group|Time-unrestricted eating group
62416252|NCT04449354|OTHER|Quality of Life assessment|HidraWear AX Garment
62416253|NCT04265209|OTHER|SPECT and PET|\[123I\]-FP-CIT SPECT imaging procedure first, then \[18F\] LBT-999 PET Imaging procedure
62024819|NCT04914572|ACTIVE_COMPARATOR|Campus green walk|The control for this study includes guided casual walking around the campus green trial conducted at the same intervals as per the interventions. The collection of samples and answering of the self-report questionnaire will also follow the same sequence as the 1 arm of the 3-arm RCT.
62024820|NCT05063344||Sexually active persons who self-select for syphilis testing|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
62024821|NCT05063344||Expectant mothers|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
62416254|NCT04265209|OTHER|PET and SPECT|\[18F\] LBT-999 PET imaging procedure first, then \[123I\]-FP-CIT SPECT imaging procedure
62433413|NCT06293690|EXPERIMENTAL|SBRT combined with immunochemotherapy|Patients received preoperative neoadjuvant therapy: SBRT 12Gy on the first day, and Toripalimab (IV 240mg, q3W) combined with platinum-containing dual drugs on the second day. Two cycles in total.
62588118|NCT03196661|PLACEBO_COMPARATOR|H7N9 whole virus influenza vaccine (15μg/dose)|"This group was divided into two subgroups according ages of subjects, the ages of those subjects are: 12 to 17(54 subjects got inoculated test vaccines,18 subjects got inoculated reference vaccines)，≥18 (54 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
62024822|NCT05063344||Lay users|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years; 1/2 high risk sexual behavior and 1/2 low risk sexual behavior
62221890|NCT04906408|EXPERIMENTAL|Prevena|Patients will then be randomized to group A (Prevena™) or group B (Prineo™) or group C (Standard wound dressing) using a random number generator made in Microsoft Excel. They will be made aware of which group they are in after the consent and randomization process, in order for proper post-operative teaching during the pre-operative clinic visit. The principal investigator, co-investigators and operating room staff will be aware of which post-operative intervention is being used on the day of surgery.
62221891|NCT04906408|EXPERIMENTAL|Prineo|Patients will then be randomized to group A (Prevena™) or group B (Prineo™) or group C (Standard wound dressing) using a random number generator made in Microsoft Excel. They will be made aware of which group they are in after the consent and randomization process, in order for proper post-operative teaching during the pre-operative clinic visit. The principal investigator, co-investigators and operating room staff will be aware of which post-operative intervention is being used on the day of surgery.
62221892|NCT04906408|ACTIVE_COMPARATOR|Standard Dressing|Patients will then be randomized to group A (Prevena™) or group B (Prineo™) or group C (Standard wound dressing) using a random number generator made in Microsoft Excel. They will be made aware of which group they are in after the consent and randomization process, in order for proper post-operative teaching during the pre-operative clinic visit. The principal investigator, co-investigators and operating room staff will be aware of which post-operative intervention is being used on the day of surgery.
62416255|NCT06520358|ACTIVE_COMPARATOR|AIH + TST|Participants will complete a 5-day intervention blocks where they receive daily AIH followed by task specific airway protection training 60 minutes after the AIH exposure. Each exposure involves a 1-minute delivery of low oxygen (9-11% inspired O2), followed by a 1.5-min interval of room air breathing (21% O2). This method of waiting 45-60 minutes after the delivery of AIH and prior to engaging in task-specific training/rehabilitation enables sufficient time to increase brain derived neurotrophic factor (BDNF) following AIH, thereby augmenting the impact of task-specific training.
62416256|NCT06520358|SHAM_COMPARATOR|Sham AIH + TST|Participants will complete a 5-day intervention blocks where they receive sham AIH followed by task specific airway protection training 60 minutes after the AIH sham exposure. Sham AIH will be delivered using methods identical to AIH, except a normoxic gas mixture (\~21% O2) will be delivered. The gas mixture with normoxic air will effectively serve as a sham.
62416257|NCT06354959|NO_INTERVENTION|Control|Receive standard of care
62588119|NCT04888442|EXPERIMENTAL|pCAR-19B cells|Infusion of pCAR-19B cells by dose-escalating
62588120|NCT06667609||1|This is an observational study with no predefined treatments for the enrolled patients. Participants may receive any treatments in accordance with standard clinical practice, based on physicians' recommendations and patients' preferences.
62588121|NCT06472531|EXPERIMENTAL|phase I|"Experimental: INR101 PET/ CT~Drug: INR101."
62588122|NCT06472531|EXPERIMENTAL|phase II|"Experimental: INR101 PET/ CT~Interventions:~Drug: INR101"
62588123|NCT01844661|EXPERIMENTAL|CELYVIR|Patients will received weekly (n=6) IV infusion of Celyvir.
62024823|NCT06634888|EXPERIMENTAL|Right sides were randomly allocated to treatments with i-PRF|The amount of i-PRF was standardized as 2mL and was injected submucosal into the distobuccal and distopalatal side of the canine tooth (1mL for each side) under local anesthesia for pain control.
62588124|NCT04042350||CKD patients on dialysis|Data will be analyzed from CKD patients on dialysis that participated in the AURORA study.
62221893|NCT06414473|ACTIVE_COMPARATOR|Active Drug|Hemp supplement is a full spectrum CBD-rich formulation (\~10%) containing very low levels of THC (\<0.3%), along with all naturally occurring minor cannabinoids, terpenes, and essential oils from the plant extract.
62416258|NCT06354959|EXPERIMENTAL|Prehab|Complete an 8-week community based prehab program.
62416259|NCT01991184|EXPERIMENTAL|Dose-escalation|
62588125|NCT03578796||Persons with ALS|Persons With possible ALS-specific cognitive impairment will be tested With ECAS-N, MoCA, CDR and a questionnaire at 4 months (baseline) and 8 months (1. follow-up). Further evaluation will be with the questionnaire and CDR at each follow-up until 3 years or use of permanent ventilation support or Death. Information about use of advanced life-prolonging therapy will be collected from patient journal.
62588126|NCT03613649|EXPERIMENTAL|Treatment A|2 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72
62588127|NCT03613649|EXPERIMENTAL|Treatment B|4 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72
62221894|NCT06414473|PLACEBO_COMPARATOR|Vehicle Control|A medium chain triglyceride-based mixing agent blended with coconut oil will be used as the placebo.
62588128|NCT03613649|PLACEBO_COMPARATOR|Treatment C|Placebo for zoliflodacin administered orally on Day 1 of each dosing period, n=72
62588129|NCT03613649|ACTIVE_COMPARATOR|Treatment D|400 mg of moxifloxacin administered orally on Day 1 of each dosing period, n=72
62221895|NCT01714531|EXPERIMENTAL|Telephone-Based Goal Management Training|The GMT intervention targets cognitive deficits in executive functioning that impact a person's ability to carry out daily tasks. Participants learn how to recognize and stop absentmindedness and automatic pilot and how to reduce daily errors and 'slips' through goal setting. The telephone-based GMT condition includes 7 sessions delivered over the phone for 10 weeks.
62221896|NCT01714531|ACTIVE_COMPARATOR|Telephone-Based Attention-Control|The attention group receives an educational intervention that is matched to the GMT intervention in terms of session length and contact with the study therapist. The telephone-based attention condition includes 7 sessions delivered over 10 weeks. Sessions address education on brain function and cognitive principles of memory, attention, language, perception, and motor skills. Education on stress reduction, sleep hygiene, energy management, exercise, communication, and nutrition are also provided
62588130|NCT00136136||Normal healthy term newborn|Normal healthy term newborns
62588131|NCT00136136||Ill term newly born without brain damage|Ill term newly borns without brain damage
62588132|NCT00136136||Preterm newly born without brain damage|Preterm newly borns without brain damage
62221897|NCT01714531|NO_INTERVENTION|Usual Care Control|Participants in the control group will receive usual care as determined by the treating surgeon. Usual care may include referral to a physical therapist, occupational therapist, psychiatrist, and/or psychologist and utilization of health services will be recorded during follow-up assessments.
62221898|NCT02518737||GIP-receptor deficient|Persons with a mutation (Glu354Gln) causing their GIP-receptor to loose function.
62221899|NCT02518737||Controls|Matched controls, with a normal functioning GIP-receptor.
62588133|NCT06588751|ACTIVE_COMPARATOR|control group|After the surgery was completed, each patient received 3 mg of morphine IV and 8 mg of dexamethasone IV. Upon transfer to the intensive care unit, patients were administered 1 g of paracetamol IV three times a day and 20 mg of tenoxicam IV twice daily.
62588134|NCT06588751|OTHER|scalp block|After the surgical procedure, patients in Group S were placed in a semi-sitting position. Following skin antisepsis with 5% povidone-iodine, a sterile drape was applied. A circumferential scalp block with 2 cc of 0.25% bupivacaine was done on each of the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater occipital, and lesser occipital nerves that supply the forehead and scalp with sensory information. The procedure was performed bilaterally. The supratrochlear and supraorbital nerves were blocked at the brow, close to the upper middle edge orbit, and over the supraorbital notch that could be felt. The zygomaticotemporal nerve was blocked between the posterior edge of the zygomatic arch. The auriculotemporal nerve was blocked at the level of the tragus. The greater and lesser occipital nerves were blocked at the medial and lateral thirds of the superior nuchal line.
62024824|NCT06634888|PLACEBO_COMPARATOR|Left sides were randomly allocated to control sides.|The placebo was standardized as 2mL and was injected submucosal into the distobuccal and distopalatal side of the canine tooth (1mL for each side) under local anesthesia for pain control.
62588135|NCT05208528|EXPERIMENTAL|ES1 group|Participants treated with Bifidobacterium longum ES1 for 2 months.
62416260|NCT01861717|EXPERIMENTAL|Somatuline Depot Subcutaneous (SC)|Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.
62416261|NCT03506776|ACTIVE_COMPARATOR|Education Only Group|The education only group will receive foot self-management education.
62416262|NCT03506776|EXPERIMENTAL|Education and Thermometer Group|The intervention group will receive foot self-management education. Additionally, the intervention group will receive a Commercially Available Infrared Thermometer (CAIT). Education on use of the CAIT will be provided through demonstration using a foot model and CAIT.
62416263|NCT06539143|ACTIVE_COMPARATOR|GROUP A (Conscious Sedation)|30mg of pentazocine was given intravenously, over one minute and a latency period of about 2 minutes was allowed before starting the procedure for analgesic function to take effect.
62416264|NCT06539143|EXPERIMENTAL|GROUP B (The Paracervical Block)|Received 10 ml of 1% lidocaine, for the blocks with 4ml at 4 O' clock and 8 O'clock positions and 2 ml at the anterior cervical lip.
62588136|NCT05208528|EXPERIMENTAL|HT-ES1 group|Participants treated with heat treated version of ES1 for 2 months.
62588137|NCT05208528|PLACEBO_COMPARATOR|Control group|Participants treated with maltodextrin for 2 months.
62588138|NCT03349554|EXPERIMENTAL|"standardized meditation technique body-scan"|
62416265|NCT05643027|OTHER|INTERVENTION FOR AVOIDANCE-RELATED OPIOID MISUSE|Participants will participate in a six-session behavioral intervention, delivered by a licensed clinical psychologist.
62416266|NCT03881722|ACTIVE_COMPARATOR|thickened formula|
62221900|NCT01303731|ACTIVE_COMPARATOR|Standard dose Marcaine Spinal 0.5% Heavy|Standard group - will receive spinal anesthesia induced by Marcaine Spinal 0.5% Heavy 12.5 mg (2.5 ml).
62221901|NCT01303731|EXPERIMENTAL|Minidose of Marcaine Spinal 0.5% Heavy|Minidose group - will receive spinal anesthesia induced by Marcaine Spinal 0.5% Heavy 7.5 mg (1.5 ml) diluted in 0.75ml of patient's CSF (0.25 ml)with addition of Fentanyl 12.5 mcg (total 2.5 ml)
62416267|NCT03881722|EXPERIMENTAL|Mg alginate|
62416268|NCT05790200|EXPERIMENTAL|Cadonilimab (AK104) combined with chemotherapy|Cadonilimab (200 mg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy, Q3W, 4-6 cycles), every 3 weeks (21 days) is a treatment cycle
62416269|NCT04464382|EXPERIMENTAL|Outpatient appendectomy|"Patients with acute uncomplicated appendicitis that require emergency appendectomy. The intervention will be the classic.Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed.~Patients after surgery will go to the anesthetic recovery room without requiring hospital admission. The degree of satisfaction of the quality of the service and the care that must be completed before discharge and after surgery will be recorded.~1 phone review call will be made per month +/- 30 days in order to assess the safety and satisfaction of the procedure."
62588139|NCT05360160|EXPERIMENTAL|SNDX-5613|Capsules by mouth 2 times every day (about 12 hours apart).
62588140|NCT05360160|EXPERIMENTAL|Venetoclax|Tablets by mouth on Days 1-14 of each cycle.
62588141|NCT05360160|EXPERIMENTAL|ASTX727|Tablets by mouth on Days 1-5 of each cycle.
62588142|NCT00491309|ACTIVE_COMPARATOR|exercise training group|exercise and respiratory therapy with specific program for pulmonary hypertension (respiratory therapy, dumbbell training, ergometer training, mental training)
62588143|NCT00491309|NO_INTERVENTION|Control group without exercise training|continuation of sedentary lifestyle without advice for specific exercise training
62024825|NCT00581945|EXPERIMENTAL|Canakinumab|Participants received an initial dose of 1 mg/kg canakinumab (ACZ885) via intravenous infusion. Four weeks later, participants received a dose of 3 mg/kg canakinumab, and another dose of 3 mg/kg two weeks later. Thereafter, participants received doses of 6 mg/kg every four weeks until completion of the 45-week treatment period.
62024826|NCT00581945|PLACEBO_COMPARATOR|Placebo|Participants received a matching placebo intravenous infusion at weeks 1, 5, 7, and thereafter every four weeks until completion of the 45-week treatment period.
62024827|NCT02061384|EXPERIMENTAL|13-cis retinoic acid|20mg 13-cis retinoic acid twice daily (BID) with meals for 20 weeks
62024828|NCT02061384|EXPERIMENTAL|Calcitriol 0.25 mcg|oral calcitriol 025 mcg BID subjects 11-20 for 20 weeks
62024829|NCT01450358|ACTIVE_COMPARATOR|Pathogen detection by Multiplex PCR|Blood samples for cultures and Multiplex PCR will be collected before start the antibiotic therapy in patients with sepsis. Multiplex PCR will be immediately undertaken and its results will be reported to prompt medical researcher (6-12 hours).The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR.
62024830|NCT01450358|NO_INTERVENTION|Pathogen detection by blood culture|Blood samples for cultures and Multiplex PCR will be collected before start the antibiotic therapy in patients with sepsis. The results of multiplex PCR will be not informed to the medical researcher, being focused care as a result of blood culture (at least after 72 hours).
62024831|NCT05152693|EXPERIMENTAL|Low Variety Small Portion Without Beverage|Test meal with food components mixed together (low variety) with a small portion of food served without water
62024832|NCT05152693|EXPERIMENTAL|High Variety Small Portion Without Beverage|Test meal with food components separated on the plate (high variety) with a small portion of food served without water
62024833|NCT05152693|EXPERIMENTAL|Low Variety Small Portion With Beverage|Test meal with food components mixed together (low variety) with a small portion of food and water
62024834|NCT05152693|EXPERIMENTAL|High Variety Small Portion With Beverage|Test meal with food components separated on the plate (high variety) with a small portion of food and water
62221902|NCT04037267|EXPERIMENTAL|Endoscopic Treatment|Endoscopy was performed using a rigid endoscope. The hematoma was removed by a technique using irrigation and aspiration. The ventricular drainage catheter was placed on the surgical side. Six hours after surgery, we administered 20,000 U urokinase with 5 ml saline every 8 hours through the catheter and the catheter was closed for 1 hour to allow drug-clot interaction and then reopened to allow for gravitational drainage. Subsequent CT scans were done for any safety concern or every 24 hours. Administration of urokinase was stopped when the CT scans showed that the circulation of cerebrospinal fluid is unobstructed. When CT scans showed that the intracerebral hematoma was significantly reduced and the circulation of cerebrospinal fluid is unobstructed, the catheter could be clamped for 24 h. If there was no acute intracranial pressure increase, the catheter could then be removed.
62221903|NCT04037267|ACTIVE_COMPARATOR|EVD Treatment|The surgeons used a soft catheter to puncture in depth of about 5 cm. The next step was to fix the drainage catheter. Postoperative CT was done immediately to confirm positioning of the soft catheter and stability of the hematoma. Six hours or more after catheter placement, we administered 20,000 U urokinase with 5 ml saline every 8 hours and the catheter was closed for 1 h to allow drug-clot interaction and then reopened to allow for gravitational drainage. Subsequent CT scans were done for any safety concern or every 24 hours. Administration of urokinase was stopped when the CT scans showed that the circulation of cerebrospinal fluid is unobstructed. When CT scans showed that the intracerebral hematoma was significantly reduced and the circulation of cerebrospinal fluid is unobstructed, the catheter could be clamped for 24 h. If there was no acute intracranial pressure increase, the catheter could then be removed.
62221904|NCT00249002|EXPERIMENTAL|ABI-007|ABI-007 35 mg/m\^2 given intravenously (IV) into the arteriovenous (AV) graft within 96 hours after angioplasty, followed by repeat treatment during weeks 5, 13 and 21
62024835|NCT05152693|EXPERIMENTAL|Low Variety Large Portion With Beverage|Test meal with food components mixed together (low variety) with a large portion of food and water
62024836|NCT05152693|EXPERIMENTAL|High Variety Large Portion With Beverage|Test meal with food components separated on the plate (high variety) with a large portion of food and water
62024837|NCT01343056|ACTIVE_COMPARATOR|Office Staff follow up education|"A designee in the office staff shall be assigned to follow up with the patient for for behavioral goal setting attainment. The office staff will call patients monthly to monitor goal attainment. It will be suggested that they phone the participant monthly but researchers will observe how and if they provide follow up.~The intervention is the follow up goal attainment and office staff have been trained on elements of goal attainment."
62221905|NCT02142140|EXPERIMENTAL|Medication Monitoring & Case Management|All children entered into this study will be prescribed medication for their ADHD symptoms (usually a long-acting stimulant). Based on the individual needs of the child and family, they could receive the following interventions - Academic and organization skills, social skills training and parent training. Participants randomized to this group will meet with the study clinicians 4 times a year for medication monitoring and adjustment. This group will also receive a monthly call from a case manager who will explore the child's academic, social and emotional functioning. Depending on the needs of the child and family, the case manager may offer 1 to 5 intervention sessions with the child (e.g. social skills, anger management), the family (e.g. family counselling), and the school (e.g. consultation with the teacher).
62024838|NCT01343056|ACTIVE_COMPARATOR|Peer follow up education|"A person with diabetes trained as a peer shall meet the participant at their 6 week follow up visit and then call the participant monthly to monitor behavioral goal attainment.The intervention is the follow up goal attainment and peers have been trained on elements of goal attainment."
62588144|NCT01959763|EXPERIMENTAL|Weight loss counseling with ICT intervention|Cognitive behavioral therapy-based weight loss counseling program including 8 group visits. Participant have also persuasive ICT support.
62797408|NCT05855772|ACTIVE_COMPARATOR|posture corrective exercise programs[PCEP]|Only posture correction exercise programs are conducted. Muscles such as weakened deep neck flexors, middle trapezius muscles, lower trapezius muscles, and serratus anterior muscles will undergo strengthening exercises, while muscles such as shortened and overactive upper trapezius muscle, Leavator scapulae muscle, and sternocleidomastoid muscle will apply relaxation stretching. This will be conducted privately at home by providing exercise leaflets, and will be conducted for a total of four weeks with a 30-minute program three times a week.
62797409|NCT06726291|EXPERIMENTAL|antiemetic|Patients who will receive a fixed dose combination of netupitant and palonsetron, NEPA
62024839|NCT01343056|ACTIVE_COMPARATOR|Usual Care|ADA Recognition maintains the standard that a follow up to diabetes education must occur from 3-6 month post education. This one phone call will be made by the diabetes educator. The intervention is the diabetes educator making a phone call to the patient to ask how they are doing.
62024840|NCT01343056|ACTIVE_COMPARATOR|Educator support follow up|A diabetes educator will provide follow up support and make monthly call to the patient to ascertain behavioral goal setting attainment. The diabetes educator uses behavioral goal setting as an education intervention. The educator calls patient to determine goal attainment. That is the intervention.
62024841|NCT05489926|EXPERIMENTAL|Pamiparib|
62024842|NCT06168708|ACTIVE_COMPARATOR|Garamicin group|the participants in this arm will undergo TURP with addition of one ampoule of gentamicin 80 mg (2ml) /3L of irrigation solution (the first 9 Liters during resection and the first 6 Liters during post-operative irrigation)
62024843|NCT06168708|PLACEBO_COMPARATOR|control group|the participants in this arm will undergo TURP with addition of normal saline (2 ml) on the irrigation solution (placebo).
62024844|NCT06391112|NO_INTERVENTION|control group|Pregnant women in the control group will receive standard outpatient clinic treatment.
62433414|NCT06293690|OTHER|SBRT combined with immunotherapy|Patients received preoperative neoadjuvant therapy: SBRT 12Gy on the first day, and Toripalimab (IV 240mg, q3) on the second day. Two cycles in total.
62588145|NCT01959763|EXPERIMENTAL|Weigth loss counseling|Cognitive behavioral therapy-based weight loss counseling program including 8 group visits.
62024845|NCT06391112|EXPERIMENTAL|Experimental group|In the research, pregnant women in the Painting-Based Art Intervention group will be asked to imagine their own babies during the NST procedure and after imagining them, they will be asked to draw them in a drawing book.
62588146|NCT01959763|EXPERIMENTAL|ELVIRA-based weight loss counseling with ICT intervention|Weight loss counseling program based on 2 group visits of ELVIRA counseling method. Participant have also persuasive ICT support.
62588147|NCT01959763|EXPERIMENTAL|ELVIRA-based weight loss counseling|Weight loss counseling program based on 2 group visits of ELVIRA counseling method.
62588148|NCT01959763|EXPERIMENTAL|ICT-based weight loss counseling|ICT-based weight loss counseling program with 52 weekly tasks and information packages.
62588149|NCT01959763|EXPERIMENTAL|Control group|Usual care without any interventions.
62588150|NCT05040672||Group I|All volunteer male employees of Libbs Pharmaceuticals residing in all Brazilian regions will participate in this research.An online questionnaire will be applied to assess research subjects understanding of prostate cancer and health habits.
62588151|NCT00595738||Heart Failure Patients|Patients admitted with advanced heart failure for tailoring of heart failure therapy via placement of a pulmonary artery (PA) catheter. In our study, the patients will already have a PA catheter placed for clinical/treatment reasons when we approach them for the study.
62588152|NCT01928602|EXPERIMENTAL|Expressive Aphasia Group A|"1. Behavioral: TherAppy Language App~2. Behavioral: Mind-Games"
62221906|NCT02142140|ACTIVE_COMPARATOR|Community Follow-up Group|All children entered into this study will be prescribed medication for their ADHD symptoms (usually a long-acting stimulant). Based on the individual needs of the child and family, they could receive the following interventions - Academic and organization skills, social skills training and parent training. Families randomized to this group will be referred to their pediatricians or family physicians for medication follow-up and their local Community Health Clinic (CLSC) for other psychosocial interventions that may be required and available.
62416270|NCT04464382|ACTIVE_COMPARATOR|Hospitalization appendectomy|"Patients with acute uncomplicated appendicitis that require emergency appendectomy. The intervention will be the classic.Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed.~Patients after surgery will go to the anesthetic recovery room and then be admitted to hospital beds, to be discharged within approximately 12 hours.~1 phone review call will be made per month +/- 30 days in order to assess the safety and satisfaction of the procedure."
62416271|NCT03406611|ACTIVE_COMPARATOR|Pegtibatinase|
62416272|NCT03406611|PLACEBO_COMPARATOR|Placebo|
62416273|NCT05948917|EXPERIMENTAL|Behavioral: Mind-body Skills Groups|10 mind-body skills groups held once a week.
62416274|NCT06372145|EXPERIMENTAL|Tolebrutinib|"* Participants will receive OL tolebrunitib 60 mg once daily.~* RMS participants who are not eligible for OL tolebrutinib per Health Authority and/or ethics committee decisions on the study conduct (ie, partial hold on initiation of tolebrutinib) will continue their parent study treatment assignment as per their randomization from the parent study."
62416275|NCT06372145|ACTIVE_COMPARATOR|Teriflunomide|"* participants will receive teriflunomide 14 mg daily~* RMS participants who are not eligible for OL tolebrutinib per Health Authority and/or ethics committee decisions on the study conduct (ie, partial hold on initiation of tolebrutinib) will continue their parent study treatment assignment (either tolebrutinib or teriflunomide) as per their randomization from the parent study. If unblinded to teriflunomide parent study treatment assignment, these RMS participants will continue teriflunomide in the LTS17043 study."
62588153|NCT01928602|EXPERIMENTAL|Expressive Aphasia Group B|"1. Behavioral: Mind-Games~2. Behavioral: TherAppy Language App"
62588154|NCT05279235|EXPERIMENTAL|JT001& Favipiravir Placebo|JT001 (VV116):Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days Favipiravir placebo:Day 1: 1600mg, Q12H X 1 day; Day 2\~5: 600mg, Q12H X 4 days
62588155|NCT05279235|ACTIVE_COMPARATOR|Favipiravir & JT001 Placebo|Favipiravir:Day 1: 1600mg, Q12H X 1 day; Day 2\~5: 600mg, Q12H X 4 days JT001 (VV116) placebo:Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
62588156|NCT02587598|EXPERIMENTAL|Parts 1 and 2: INCB053914 100 mg QD|INCB053914 will be self-administered orally once a day in as a 100mg immediate release tablet as a monotherapy.
62221907|NCT02727062||OM Pain Smartphone Application|This study examines whether the smartphone OM Pain App is a feasible and valid tool to assess pain from radiation-induced oral mucositis.
62221908|NCT03170037|ACTIVE_COMPARATOR|Standard V-E ventilation technique|After induction of anesthesia subject will be ventilated using the standard V-E ventilation technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute, I:E ratio of 1:2, peak inspiratory pressure of 20cmH2O and no PEEP. If the subjects can be adequately ventilated, as defined by perceivable chest movement and end tidal CO2 during the first three breaths, ventilation will continue for total ten breaths.
62416276|NCT00003892|EXPERIMENTAL|ISIS 5132|ISIS 5132 x 21 days IV infusion
62416277|NCT04560452||Prostate cancer|according to the doctor's decision, have prescribed and agreed to start taking at least one dose of Olaparib
62416278|NCT04560452||Ovarian cancer|At least take one tablet of olaparib before enrolment for OC cohort
62416279|NCT06081946|EXPERIMENTAL|Sleep fragmentation|This subproject will be conducted in two sessions separated by three nights of sleep fragmentation. Each session will last approximately 2 hours. At the beginning of the first visit and after the last visit, 9 ml of blood will be drawn, and plasma will be isolated. After plasma isolation, the CRP concentration will be analyzed. In each forearm of the participant, a 4x4 cm area will be selected as Area of Interest (AOI). In these selected areas, itch will be induced in both sessions using histamine and cowhage and several tests will be conducted.
62416280|NCT04519294|ACTIVE_COMPARATOR|SURE|
62416281|NCT04519294|ACTIVE_COMPARATOR|Standard Ureteroscopy (Basketing)|
62416282|NCT03534635|EXPERIMENTAL|Pembrolizumab|"Pembrolizumab 200 mg will be administered intravenously every 3 weeks, for a maximum of 2 years, until progression, unacceptable toxicity, or withdrawal of consent, whichever happens first.~Patients may be treated for up to one year of additional treatment with pembrolizumab via the Second Course Phase, and according to defined criteria."
62416283|NCT01905007|ACTIVE_COMPARATOR|Defibrillation testing|Defibrillation testing at initial ICD implantation
62416284|NCT01905007|NO_INTERVENTION|No defibrillation testing|No defibrillation testing at initial ICD implantation
62416285|NCT06682949|EXPERIMENTAL|Sleep Extension|"Participants will review their baseline actigraphy data with a research team member and discuss sleep patterns. Participants will be given a sleep prescription, giving them specified sleep and wake times based on AASM guidelines. Participants and their parent will discuss stimulus control with team member. Participants will implement their sleep prescription for two weeks."
62588157|NCT02587598|EXPERIMENTAL|Parts 3 and 4: INCB053914 + Azacitidine|Azacitidine will be administered at a dose of 75 mg/m2 subcutaneously or via IV per day, as a combination therapy with INCB053914.
62588158|NCT02587598|EXPERIMENTAL|Parts 3 and 4: INCB053914 + I-DAC (Intermediate dose cytarabine)|I-DAC (intermediate dose cytarabine) will be administered at a dose of 1 g/m2 per day as an infusion as a combination therapy with INCB053914.
62588159|NCT02587598|EXPERIMENTAL|Parts 3 and 4: INCB053914 + Ruxolitinib|Ruxolitinib will be administered as an oral dose between 5 mg to 25 mg twice per day, as a combination therapy with INCB053914.
62588160|NCT02587598|EXPERIMENTAL|Parts 1 and 2: INCB053914 50 mg|INCB053914 will be self-administered orally twice day in as a 50mg immediate release tablet as a monotherapy.
62024846|NCT05634226|EXPERIMENTAL|Hands-free oral-positive pressure device (oPEP)|
62024847|NCT03346668|EXPERIMENTAL|Topical gabapentin|gabapentin 6% solution, 1mL applied twice daily for 12 weeks
62416286|NCT06682949|PLACEBO_COMPARATOR|Daytime Routine|Participants will review their daily routines with a research team member. With parent collaboration, they will agree to adjust a behavioral daytime routine to implement for the next two weeks.
62416287|NCT00038467|ACTIVE_COMPARATOR|B|
62416288|NCT00038467|EXPERIMENTAL|A|
62416289|NCT02957461||Injured and Matched Control Subject Pool|Injured subjects consist of athletes who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
62416290|NCT02957461||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) contact and non-contact athletes and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
62416291|NCT02115373|EXPERIMENTAL|Phase 1b: Tepotinib 300 mg|
62416292|NCT02115373|EXPERIMENTAL|Phase 1b: Tepotinib 500 mg|
62416293|NCT02115373|EXPERIMENTAL|Phase 2: Tepotinib 500 mg|
62416294|NCT01652872|ACTIVE_COMPARATOR|Hb-Based Titration Group|Participants received darbepoetin alfa as a subcutaneous (SC) injection once every 4 weeks (Q4W) for up to 96 weeks. The dose of darbepoetin alfa was titrated based on the Hb concentration on the date of the visit, the corresponding Hb rate of rise (ROR), and the previously assigned dose. Doses were reduced if Hb exceeded 10.5 g/dL or Hb ROR exceeded 1.0 g/dL/4W. When darbepoetin alfa therapy was withheld per the dosing algorithm, placebo was administered. The starting dose of darbepoetin alfa was 0.45 micrograms/kilogram (mcg/kg) and the protocol specified doses ranged from 10 to 300 mcg.
62416295|NCT01652872|EXPERIMENTAL|Fixed Dose Group|Participants received darbepoetin alfa as a SC injection Q4W at the same dose as assigned at the time of randomization for the duration of the 96 week treatment period. There was 1 exception to the fixed dose strategy: if the Hb was \> 12.0 g/dL, darbepoetin alfa therapy was withheld and placebo administered. Once the Hb fell to \< 10.0 g/dL, darbepoetin alfa therapy resumed at the same dose. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.
62416296|NCT02306018||EV1000™/volumeView™|
62416297|NCT05905874||AECOPD patients present with DVT and/or PTE|
62416298|NCT05905874||AECOPD patients absent with DVT and/or PTE|
62416299|NCT00499252|EXPERIMENTAL|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation (Abraxane®) IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62588161|NCT02587598|EXPERIMENTAL|Parts 1 and 2: INB053914 65 mg|INCB053914 will be self-administered orally twice day in as a 65mg immediate release tablet as a monotherapy.
62588162|NCT02587598|EXPERIMENTAL|Parts 1 and 2: INB053914 80 mg|INCB053914 will be self-administered orally twice day in as a 80mg immediate release tablet as a monotherapy.
62588163|NCT02587598|EXPERIMENTAL|Parts 1 and 2: INB053914 100 mg BID|INCB053914 will be self-administered orally twice day in as a 100mg immediate release tablet as a monotherapy.
62588164|NCT02587598|EXPERIMENTAL|Parts 1 and 2: INB053914 115 mg|INCB053914 will be self-administered orally twice day in as a 115mg immediate release tablet as a monotherapy.
62797410|NCT06389578|EXPERIMENTAL|Cohort 1|Participants will receive a single dose of lyophilized teprotumumab by subcutaneous (SC) administration on Day 1 followed by intravenous (IV) infusions of teprotumumab at the approved dosing regimen.
62797411|NCT06389578|EXPERIMENTAL|Cohort 2|Participants will receive a single high concentration formulation teprotumumab by SC administration on Day 1 followed by IV infusions of teprotumumab at the approved dosing regimen.
62024848|NCT01449305|EXPERIMENTAL|Nanoone Woman Underwear|"Nanoone negative ion of textiles, which is health material specifically designed for human body, in short distance and long time to produce negative ion, the human body really needed, it can neutralize free radical in the human body."
62024849|NCT01753193|EXPERIMENTAL|Anifrolumab|Participants will receive IV infusion of anifrolumab 1000 milligrams (mg) every 4 weeks (Q4W) from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter will receive 300 mg Q4W for up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
62024850|NCT01024387|EXPERIMENTAL|AMG 479|Patients receive AMG 479 at a dose of 18 mg/kg administered IV on day 1 (± 3 days) of every 3-week cycle. Treatment should continue until disease progression, unacceptable toxicity or withdrawal of consent.
62416300|NCT00433771|EXPERIMENTAL|WallFlex Biliary Fully Covered stent|Single arm, biliary stenting, using WallFlex Biliary Fully Covered stent
62416301|NCT05831787||Diagnosis of multiple myeloma and currently receiving active treatment for any phase of the disease|Diagnosis of multiple myeloma must meet the International Myeloma Working Group criteria.
62416302|NCT00693056|PLACEBO_COMPARATOR|1|
62416303|NCT00693056|EXPERIMENTAL|2|
62416304|NCT00693056|EXPERIMENTAL|3|
62416305|NCT00693056|EXPERIMENTAL|4|
62416306|NCT03138135|EXPERIMENTAL|Intervention|The Intervention group will receive the HOME Study intervention.
62416307|NCT03138135|ACTIVE_COMPARATOR|Control|The Control group will receive standard of care.
62588165|NCT04561557|EXPERIMENTAL|CAR T cells therapy，Dose level 1: 0.5 × 10^6 CAR-T cells/Kg|"The tolerability and safety of CT103A cells will be assessed in an initial dose of 0.5×10\^6 CAR-T cells/Kg and three subjects will be enrolled firstly. If no dose-limiting toxicity (DLT) occurs and at least one subject benefits from the treatment, there will be two options for the investigator based on the available data: 1) three more subjects will be enrolled in the 0.5 × 10\^6 CAR-T cells/Kg group and DLT will be evaluated in a total of six subjects; 2) another three subjects will be treated with 1 × 10\^6 CAR-T cells/Kg instead of 0.5 × 10\^6 CAR-T cells/Kg.~If DLT occurs in one of the first three subjects, three more subjects will be enrolled in this cohort to reach the total subjects of six."
62221909|NCT03170037|EXPERIMENTAL|Reversal V-E ventilation technique|After induction of anesthesia subject will be ventilated using the reversal V-E ventilation technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute, I:E ratio of 1:2, peak inspiratory pressure of 20cmH2O and no PEEP. If the subjects can be adequately ventilated, as defined by perceivable chest movement and end tidal CO2 during the first three breaths, ventilation will continue for total ten breaths.
62221910|NCT04675151|EXPERIMENTAL|Nyxol + Pilocarpine|1 drop of Nyxol (Treatment 1) and 1 drop of Pilocarpine (Treatment 2)
62588166|NCT04561557|EXPERIMENTAL|CAR T cells therapy，Dose level 2: 1 × 10^6 CAR-T cells/Kg|If neither DLT nor efficacy is shown in the first three subjects, the dose of CAR-T cells will be increased to 1 × 10\^6 CAR-T cells/kg to assess DLT.
62588167|NCT04561557|EXPERIMENTAL|CAR T cells therapy，Dose level 3: 0.25 × 10^6 CAR-T cells/Kg|If DLT occurs in two subjects, whether to test the safety and efficacy in 0.25 × 10\^6 CAR-T cells/kg group will be determined by the investigator based on the initial data of efficacy, PK and PD.
62588168|NCT06662526|EXPERIMENTAL|Trace lithium dose|This arm will consist of 125 participants, each receiving trace doses of lithium
62588169|NCT06662526|PLACEBO_COMPARATOR|Placebo|This arm will consist of 125 participants, each receiving placebo.
62588170|NCT05607004|EXPERIMENTAL|PK Cohort|"(Z)-endoxifen capsules orally once daily for 4 weeks. Initial (Z)-endoxifen dose evaluated will be 40 mg with an option to evaluate 20 mg or 80 mg.~The PK Cohort participants may extend treatment based on Ki-67% at Week 4.~If Ki-67 ≤ 10% at Week 4, participant will be offered option to continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days.~If Ki-67 \> 10% at Week 4, participant will be withdrawn and go on to surgery."
62797412|NCT01858363|EXPERIMENTAL|Paclitaxel-coated balloon|Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.
62024851|NCT02693990|EXPERIMENTAL|Grade II (Atypical) Meningiomas, STR|Patient will be treated at the starting dose of Intensity Modulated Proton Therapy (IMPT) which is pre-determined.
62024852|NCT02693990|EXPERIMENTAL|Grade III (Malignant) Meningiomas, GTR|Patient will be treated at a pre determined dose of Intensity Modulated Proton Therapy (IMPT) for the specific cohort.
62221911|NCT04675151|ACTIVE_COMPARATOR|Nyxol|1 drop of Nyxol (Treatment 1)
62221912|NCT04675151|ACTIVE_COMPARATOR|Pilocarpine|1 drop of Pilocarpine (Treatment 2)
62221913|NCT04675151|PLACEBO_COMPARATOR|Placebo|1 drop of Placebo (Treatment 1)
62221914|NCT03228602|ACTIVE_COMPARATOR|healthy subjects|
62221915|NCT03228602|EXPERIMENTAL|obese|
62221916|NCT03228602|EXPERIMENTAL|obese diabetic|
62416308|NCT06703749|EXPERIMENTAL|Treatment with BTL-899M|Four (4) BTL-899M treatments will be applied to the lower extremities.
62416309|NCT06703749|PLACEBO_COMPARATOR|Treatment with BTL-899M with intensities below therapeutic threshold|Four (4) BTL-899M treatments will be applied to the lower extremities, with intensities below therapeutic threshold
62416310|NCT01491737|EXPERIMENTAL|Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy|"Participants will receive pertuzumab in combination with trastuzumab plus aromatase inhibitor (AI) until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.~Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion."
62221917|NCT03228602|EXPERIMENTAL|obese diabetic who are going to be operated on|25 of a sleeve gastrectomy and 25 of a Y gastric bypass
62221918|NCT04326166||Group A|Patients who receive Double therapy or Insulin
62221919|NCT04326166||Group B|Patients who receive DPP-4 inhibitor
62221920|NCT04326166||Group C|Drug-naïve patients
62221921|NCT04221399|EXPERIMENTAL|DWP16001 Single dose|Single dose
62221922|NCT04221399|EXPERIMENTAL|DWP16001 Multiple dose|Up to 7 days
62221923|NCT04137094|EXPERIMENTAL|PHCI with HIV/HCV counselor|A persuasive health communication intervention will be performed by a community HIV/HCV test counselor
62221924|NCT04137094|EXPERIMENTAL|PHCI with ED Medical Staff|A persuasive health communication intervention will be performed by ED medical staff
62221925|NCT00647491|EXPERIMENTAL|20 mg|20 mg adalimumab eow
62221926|NCT00647491|EXPERIMENTAL|40 mg|40 mg adalimumab eow
62221927|NCT00647491|EXPERIMENTAL|80 mg|80 mg adalimumab eow
62221928|NCT00647491|PLACEBO_COMPARATOR|Placebo|Placebo eow
62416311|NCT01491737|ACTIVE_COMPARATOR|Arm B: Trastuzumab + AI +/- Chemotherapy|"Participants will receive trastuzumab plus aromatase inhibitor (AI) until predefined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.~Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion."
62416312|NCT03143205|EXPERIMENTAL|AWARENESS for sexual minorities|Group receives new CBT-based intervention
62416313|NCT03143205|ACTIVE_COMPARATOR|Writing tasks|Group receives writing-based sessions
62416314|NCT06651047||Patients with difficult-to-treat gram-negative infection treated with CAZ/AVI or CEF, ± FOS|All patients (any age) with infection due to a difficult-to-treat Gram-negative bacteria treated with CAZ/AVI alone, CEF alone, CAZ/AVI plus FOS, or CEF plus FOS
62797413|NCT01858363|PLACEBO_COMPARATOR|Bare balloon|Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.
62024853|NCT02693990|EXPERIMENTAL|Grade III (Malignant) Meningiomas, STR|Patient will be treated at a pre determined dose of Intensity Modulated Proton Therapy (IMPT) for the specific cohort.
62024854|NCT02095262|ACTIVE_COMPARATOR|STAR2|Reactive auditory training
62221929|NCT02674815|EXPERIMENTAL|Intervention|Patients within this arm will perform two weeks of high intensity interval training prior to colorectal/thoracic surgery. Exercise intensity will be 100% of the peak power output (PPO) during maximal cardiopulmonary exercise testing. Patients will exercise for 15 seconds at 100% PPO and rest for 15 seconds (passive) for 30 minutes or until exhaustion. This will be performed 5 days a week for 2 weeks.
62024855|NCT02095262|EXPERIMENTAL|Treasure Hunter|Interactive auditory training
62024856|NCT02095262|EXPERIMENTAL|Submarine|Interactive auditory training
62024857|NCT05696106||Patients initiating a biologic or immunosuppressive drug|"Patients initiating a biologic or immunosuppressive drug including small molecules for a first IMID (either IBD, inflammatory rheumatic diseases, or cutaneous psoriasis)~* Conventional immunosuppressive drug including immunomodulators (thiopurines) and csDMARDs (methotrexate)~* Anti-TNF (infliximab, adalimumab, golimumab, certolizumab, etanercept)~* Biologics targeting the IL-12/IL-23 pathways (ustekinumab, risankizumab, guselkumab)~* Biologics targeting the IL-6 pathways (tocilizumab, sarilumab)~* Biologics targeting the IL-17 pathways (secukinumab, ixékizumab, brodalumab)~* Biologics targeting cell adhesion, anti-integrins (vedolizumab)~* JAK inhibitors (tofacitinib, baricitinib, upadacitinib)"
62221930|NCT06594744|ACTIVE_COMPARATOR|Endoscopic variceal ligation|EVL will be performed and repeated every 3 to 4 weeks until the EVs are eradicated. Following this, patients will undergo regular upper gastrointestinal endoscopic surveillance, initially every three months for a total of two sessions, then every six months for a total of two sessions, and subsequently annually. If EVs are found to recur during surveillance, additional EVL will be performed every 3 to 4 weeks until the varices are again eradicated endoscopically.
62221931|NCT06594744|PLACEBO_COMPARATOR|Carvedilol|The initial dosage of carvedilol is set at 6.25 mg daily. In the absence of hypotension (systolic blood pressure \< 90 mmHg), bradycardia (resting heart rate \< 55 beats per minute), or other adverse effects, hospitalized patients may have their dosage increased to 12.5 mg daily after 3 days, while outpatient patients may increase their dosage to 12.5 mg daily after 7 days. This dosage represents the target dose for the trial.
62221932|NCT01009580|EXPERIMENTAL|IDegAsp BID|
62221933|NCT01009580|EXPERIMENTAL|BIAsp 30 BID|
62221934|NCT02878902||Before implementation|"Patients registered in monitoring French registry of renal patients Réseau Epidémiologie et Information en Néphrologie (REIN) from January 1, 2012 to December 31, 2013"
62797414|NCT03641170|EXPERIMENTAL|Experimental intervention|Fixed diet and physical activity.
62797415|NCT03641170|OTHER|Control intervention|Fixed diet and inactivity.
62797416|NCT02416596|EXPERIMENTAL|Group Undergoing Hysterosopy|This group will include 340 women with unexplained primary infertility undergoing their first trial of IVF/ICSI (intracytoplasmic sperm injection). This group will undergo hysteroscopy in the mid luteal phase of the proceeding cycle.
62797417|NCT02416596|NO_INTERVENTION|Group With No intervention|This group will include 340 women with unexplained primary infertility they will undergo their first trial of IVF/ICSI (intracytoplasmic sperm injection) without hysteroscopy in the mid Luteal phase of the proceeding cycle.
62221935|NCT02878902||Post implementation|"Patients registered in monitoring French registry of renal patients Réseau Epidémiologie et Information en Néphrologie (REIN) from January 1, 2014 to December 31, 2015"
62588171|NCT05607004|EXPERIMENTAL|Treatment Cohort Arm 1 Initial Regimen|"(Z)-endoxifen capsules orally once daily for 4 weeks. Dose will be based on the results of the PK Cohort.~If Ki-67 ≤ 10% at Week 4, continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days.~If Ki-67 \> 10% at Week 4, participant will be offered modified regimen or be withdrawn and go on to surgery."
62588172|NCT05607004|ACTIVE_COMPARATOR|Treatment Cohort Arm 2 Initial Regimen|"Exemestane 25 mg orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant approximately every 28 days.~If Ki-67 ≤ 10% at Week 4, continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days.~If Ki-67 \> 10% at Week 4, participant will be offered modified regimen or be withdrawn and go on to surgery."
62588173|NCT05607004|EXPERIMENTAL|Treatment Cohort Arm 1 Modified Regimen|"(Z)-endoxifen capsules orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant approximately every 28 days. (Z)-endoxifen dose will be based on the results of the PK Cohort.~If Ki-67 ≤ 10% after 4 weeks of modified regimen, continue on this treatment for up to 6 total treatment cycles/Week 24. Each cycle is 28 days.~If Ki-67 \> 10% after 4 weeks of modified regimen, participant will be withdrawn and go on to surgery."
62221936|NCT00998998|EXPERIMENTAL|1|6 or 12 month old infants with iron deficiency anemia assigned to receive home stimulation program via weekly home visits over 1 year
62221937|NCT00998998|ACTIVE_COMPARATOR|2|6 or 12 month old infants with iron deficiency anemia assigned to surveillance (weekly visits to monitor health and iron supplement) over 1 year
62588174|NCT05607004|EXPERIMENTAL|Treatment Cohort Arm 2 Modified Regimen|"(Z)-endoxifen capsules orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant approximately every 28 days. (Z)-endoxifen dose will be based on the results of the PK Cohort.~If Ki-67 ≤ 10% after 4 weeks of modified regimen, continue on this treatment for up to 6 total treatment cycles/Week 24. Each cycle is 28 days.~If Ki-67 \> 10% after 4 weeks of modified regimen, participant will be withdrawn and go on to surgery."
62588175|NCT05607004|EXPERIMENTAL|PK Cohort 80 mg|"(Z)-endoxifen 80 mg capsules orally once daily for 4 weeks.~The PK Cohort participants may extend treatment based on Ki-67% at Week 4.~If Ki-67 ≤ 10% at Week 4, participant will be offered option to continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days.~If Ki-67 \> 10% at Week 4, participant will be withdrawn and go on to surgery."
62588176|NCT05607004|EXPERIMENTAL|PK Cohort 80 mg + OFS|"(Z)-endoxifen 80 mg capsules orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant approximately every 28 days.~The PK Cohort participants may extend treatment based on Ki-67% at Week 4.~If Ki-67 ≤ 10% at Week 4, participant will be offered option to continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days.~If Ki-67 \> 10% at Week 4, participant will be withdrawn and go on to surgery."
62588177|NCT04270409|EXPERIMENTAL|Isatuximab, lenalidomide, and dexamethasone (ILd)|Participants will receive isatuximab \[intravenous (IV) administration\] in combination with lenalidomide \[per os (PO) administration\] and dexamethasone \[IV on Day 1 of Cycle 1 for participants receiving isatuximab IV only and PO otherwise for subsequent cycles\] for 24 cycles followed by isatuximab monotherapy for 12 cycles for a total duration of 36 cycles. 1 cycle = 28 days. Participants may receive other treatments as pre-medication.
62416315|NCT06651255|EXPERIMENTAL|Optimized management|systematic gastrointestinal and nasal endoscopic exploration, local endoscopic treatment whenever applicable,prophylaxis with stepwise dose escalation of VWF concentrate and use of antiangiogenic drugs in patients with severe GI angiodysplasia-related bleeding
62416316|NCT06651255|OTHER|Standard of care management|Standard of care management
62416317|NCT04720885||Patients with a placental remnant in medical history|
62221938|NCT00998998|EXPERIMENTAL|3|Nonanemic infants identified at 6 or 12 months assigned to receive home stimulation program via weekly home visits over 1 year
62221939|NCT00998998|ACTIVE_COMPARATOR|4|Nonanemic infants identified at 6 and 12 months assigned to surveillance (weekly visits to monitor health) over 1 year
62221940|NCT03809559||Biliary Conditions|Participants who have a history of a biliary tree related condition
62221941|NCT03809559||Liver conditions|Participants who have a history of a non-biliary tree related liver condition
62221942|NCT03809559||Healthy Volunteers|Participants who have do not have a diagnosed liver condition and are in general good health
62416318|NCT06703606|EXPERIMENTAL|MARSTACIMAB|Marstacimab 150 mg subcutaneous (SC) once weekly (QW)
62416319|NCT02621021|EXPERIMENTAL|1/ACT TIL|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin (IL-2)
62416320|NCT02621021|EXPERIMENTAL|2/ACT TIL + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin (IL-2) + pembrolizumab
62416321|NCT06362304|EXPERIMENTAL|intracranial tumor|
62416322|NCT05597514|ACTIVE_COMPARATOR|Tranditional model group|Received a regular learning
62416323|NCT05597514|EXPERIMENTAL|3D-printed presention group|Received a regular learning plus 3D printing model
62416324|NCT06159686|EXPERIMENTAL|hemp group|They was assigned to apply the hemp-containing cream.
62416325|NCT06159686|PLACEBO_COMPARATOR|Control group|They was assigned to apply the placebo cream.
62416326|NCT01473589|PLACEBO_COMPARATOR|Placebo|Administered once daily by subcutaneous (SC) injection for 6 months
62416327|NCT01473589|EXPERIMENTAL|Teriparatide|20 microgram (µg) administered once daily by SC injection for 6 months
62416328|NCT02405351|EXPERIMENTAL|Training Group|Participants will be 10 individuals post stroke, living in the community. The intervention, adaptive working memory training, is a dual n-back working memory task. This training will take place once for 30 minutes per day, 5 days a week for 6 weeks, with one week dedicated for familiarizing participants to the program in the very beginning (i.e., Week 1).
62416329|NCT06470737|EXPERIMENTAL|Healthy volunteers|
62416330|NCT06025786|EXPERIMENTAL|Districts with established and operational BNP implementation|The intervention arm consists of nine districts from four provinces and two regions of Pakistan where the Benazir Nashonuma Program (BNP) is operational, providing reproductive and healthcare services to pregnant women and their children under the age of two.
62416331|NCT06025786|NO_INTERVENTION|Districts without BNP implementation and functionality|The control arm comprises of nine districts where Benazir Nashonuma Program (BNP) has not been implemented. These districts are comparable to their respective intervention districts in terms of average maternal BMI and prevalence of stunting.
62221943|NCT00912301|EXPERIMENTAL|NaCDC 500 mg|Participants randomized to this arm received 500 mg NaCDC per day for 4 days.
62221944|NCT00912301|EXPERIMENTAL|NaCDC 1000 mg|Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.
62221945|NCT00912301|PLACEBO_COMPARATOR|Placebo|Participants randomized to this arm received a placebo capsule each day for 4 days.
62221946|NCT05941728|EXPERIMENTAL|Avocado|The experimental treatment will contain an avocado. Avocados will be consumed daily for 4 weeks.
62221947|NCT05941728|ACTIVE_COMPARATOR|Fiber + Oil|The active comparator will have a snack that mimics the fiber and fatty acid composition found in avocados and will be consumed daily for 4 weeks.
62221948|NCT05941728|SHAM_COMPARATOR|Standard American Diet|The sham comparator contains foods and beverages of a standard American diet and will be consumed daily for 4 weeks.
62416332|NCT01016431|EXPERIMENTAL|Rate adaptive|Patients will have their ICD programmed in a AAI-R mode, with peak atrial rate set at 85% of age-adjusted predicted maximal HR
62416333|NCT01016431|ACTIVE_COMPARATOR|Control|ICDs will be programmed in the usual VVI backup pacing mode at 40 bpm
62416334|NCT03637270|EXPERIMENTAL|PRO group|Participants in PRO group receive dietary supplementation with protein-rich supplements immediately before and after each exercise training session. The interventions include 30 training sessions.
62416335|NCT03637270|ACTIVE_COMPARATOR|CHO group|Participants in CHO group receive dietary supplementation with carbohydrate-rich supplements immediately before and after each exercise training session. The interventions include 30 training sessions.
62416336|NCT03695042|EXPERIMENTAL|BFR THEN without BFR|Will perform exercises with BFR at the first visit and without BFR at the second visit
62416337|NCT03695042|EXPERIMENTAL|Without BFR THEN with BFR|Will perform exercises without BFR at the first visit and with BFR at the second visit
62416338|NCT05795062||apixaban|Patients treated with apixaban
62416339|NCT05795062||warfarin|patients treated with warfarin
62416340|NCT06701851|EXPERIMENTAL|Patients|"We will conduct a study using functional MRI and EEG in this subgroup of at least 1 patient(s) with a PRRT2 mutation capable of triggering paroxysmal dyskinesia episodes. We will analyze of the activation of regions involved in the occurrence of abnormal movements during the prodromal phase, during which the acquisition is not affected by movements. We will also investigate the regions involved in judging control over action during phases where abnormal movements may occur before and after the dyskinetic episode.~Thus, each subject will serve as their own control across different conditions of the experimental paradigm."
62797418|NCT06422884|EXPERIMENTAL|ENV-101 Low Dose (IPF Population)|
62797419|NCT06422884|EXPERIMENTAL|ENV-101 Mid Dose (IPF Population)|
62024858|NCT03087591|EXPERIMENTAL|Treatment (APN401)|Patients receive siRNA-transfected peripheral blood mononuclear cells APN401 IV over 30 minutes on days 1, 29, and 57 in the absence of disease progression or unacceptable toxicity.
62024859|NCT00627705|ACTIVE_COMPARATOR|N-Acetyl Cysteine|active compound N-Acetyl Cysteine
62024860|NCT00627705|PLACEBO_COMPARATOR|Sugar pill|Placebo or sugar pill
62024861|NCT00931073|EXPERIMENTAL|Period 1|
62416341|NCT04904588|EXPERIMENTAL|Regimen A (MAC: busulfan and fludarabine, PBSC HCT)|"Patients receive:~* Busulfan (≥ 9 mg/kg total dose) IV or PO on days -6 to -3~* Fludarabine (150 mg/m2 total dose) IV on days -6 to -2~Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0."
62416342|NCT04904588|EXPERIMENTAL|Regimen B (MAC: Fludarabine and TBI; PBSC HCT)|"Patients receive:~* Fludarabine (90 mg/m2 total dose) IV on days -7 to -5~* Total body irradiation (TBI) (1200 cGy total dose) on days -4 to -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
62416343|NCT04904588|EXPERIMENTAL|Regimen C (RIC: Fludarabine and Busulfan; PBSC HCT)|"Patients receive:~* Fludarabine (120-180 mg/m2 total dose) IV on days -6 to -2~* Busulfan (less than or equal to 8 mg/kg PO or 6.4 mg/kg IV) on days -5 and -4~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
62416344|NCT04904588|EXPERIMENTAL|Regimen D (RIC: Fludarabine and Melphalan; PBSC HCT)|"Patients receive:~* Fludarabine (120-180 mg/m2 total dose) IV on days -7 to -3~* Melphalan (100-140 mg/m2) IV on day -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
62416345|NCT04904588|EXPERIMENTAL|Regimen E (NMA: Fludarabine, Cyclophosphamide, TBI; PBSC HCT)|"Patients receive:~* Fludarabine (150 mg/m2 total dose) IV on days -6 to -2~* Cyclophosphamide (29-50 mg/kg) IV on days -6 and -5~* TBI (200 cGy) on day -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
62416346|NCT04904588|EXPERIMENTAL|Regimen F (MAC: Busulfan and Cyclophosphamide; BM HCT)|"Patients receive:~* Busulfan (dosed by age and weight per institutional standards to target goal pharmacokinetic (PK) in range noted in protocol.) on days -6 to -3~* Cyclophosphamide (100 mg/kg total dose) IV on days -2 and -1~Patients receive a bone marrow (BM) graft infusion from a mismatched unrelated donor on Day 0."
62797420|NCT06422884|EXPERIMENTAL|ENV-101 High Dose (IPF Population)|
62797421|NCT06422884|PLACEBO_COMPARATOR|Placebo (IPF Population)|
62797422|NCT00834665|EXPERIMENTAL|hTERT/GM-CSF+PCV, T cell infusion|ARM A = hTERT/GM-CSF+PCV, T cell infusion
62797423|NCT00834665|EXPERIMENTAL|GM-CSF+PCV, T cell infusion,GM-CSF+PVC|ARM B GM-CSF+PCV, T cell infusion,GM-CSF+PVC
62024862|NCT00931073|EXPERIMENTAL|Period 2|
62024863|NCT00931073|EXPERIMENTAL|Period 3|
62024864|NCT01177111|EXPERIMENTAL|Sunflower seed Oil|
62024865|NCT01177111|ACTIVE_COMPARATOR|Mustard seed oil|
62024866|NCT05386160|ACTIVE_COMPARATOR|Cataract phacoemulsification combines Ranibizumab|0.05 ml of ranibizumab was injected into the vitreous immediately after the operation
62024867|NCT05386160|ACTIVE_COMPARATOR|Cataract phacoemulsification|0.05 ml of ranibizumab was injected into the vitreous immediately after the operation
62024868|NCT05531994|OTHER|TR|Administration order: montelukast sodium oral thin films with water, montelukast sodium chewable tablets with water.
62797424|NCT01946152|EXPERIMENTAL|Treatment (pomalidomide, dexamethasone, filgrastim-sndz)|"INDUCTION: Patients receive pomalidomide PO daily on days 1-21, dexamethasone PO on days 1, 8, 15, and 22, and filgrastim-sndz SC on days 22-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive lower-dose pomalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62797425|NCT02734745|EXPERIMENTAL|flash glucose monitoring|Patients will use a device: Freestyle Libre for 14 days
62221949|NCT02508246|EXPERIMENTAL|Treatment (WEE1 inhibitor MK-1, cisplatin, docetaxel, surgery)|Patients receive WEE1 inhibitor MK-1775 PO BID on days 2-4, 9-11, and 16-18, and day -7 prior to course 1, day 1 for PD assessment. Patients also receive cisplatin IV on days 1 (or up to two days after last dose of WEE1 inhibitor MK-1775 lead-in is completed), 8 (or 7 days after first chemotherapy dose), and 15, and docetaxel IV on days 1, 8, and 15. Patients experiencing progressive disease undergo surgical resection. Patients not deemed surgically resectable proceed to chemoradiation as clinically indicated. Patients experiencing stable disease or partial response may receive 2 additional courses of treatment every 28 days in the absence of disease progression or unacceptable toxicity.
62797426|NCT01436578||All Participants|All participants treated with posaconazole oral suspension during the pre-specified surveillance period.
62797427|NCT00672919|EXPERIMENTAL|Pioglitazone QD|(and stable statin therapy)
62221950|NCT06132243|EXPERIMENTAL|Test Group|Subjects in the first sequence of the first cycle were administered with a test formulation (T) of 50 mg of Jaktinib on an empty stomach, while subjects in the second sequence were administered with a reference formulation (R) of 50 mg of Jaktinib on an empty stomach. The reference formulation (R) or test formulation (T) was administered alternately in the next periods.
62221951|NCT06132243|ACTIVE_COMPARATOR|Reference Group|Subjects in the first sequence of the first cycle were administered with a test formulation (T) of 50 mg of Jaktinib on an empty stomach, while subjects in the second sequence were administered with a reference formulation (R) of 50 mg of Jaktinib on an empty stomach. The reference formulation (R) or test formulation (T) was administered alternately in the next periods.
62221952|NCT04538690|NO_INTERVENTION|Control Group|Age and sex matched non interventional, healthy control group
62797428|NCT06500117|EXPERIMENTAL|patient|
62797429|NCT03349658|ACTIVE_COMPARATOR|general anesthesia|Patients in this group were randomized to receive general anesthesia.
62797430|NCT03349658|ACTIVE_COMPARATOR|spinal anesthesia|Patients in this group were randomized to receive spinal anesthesia.
62797431|NCT05594862|ACTIVE_COMPARATOR|Lipogems|surgical drainage with cone fistulectomy + infiltration of micro-fractured autologous adipose tissue at the level of the internal orifice
62797432|NCT05594862|NO_INTERVENTION|Placebo|surgical drainage with cone fistulectomy + infiltration of physiological solution and suture point positioning at the internal orifice level
62797433|NCT01449006|NO_INTERVENTION|Standard of care HAART regimen|Participants randomised to this arm of the trial will remain on their usual prescribed HAART regimen.
62797434|NCT01449006|EXPERIMENTAL|Maraviroc|Participants randomised to this arm will remain on their usual prescribed HAART regimen, with the addition of Maraviroc. Maraviroc will be prescribed according to the Product Information Sheet, with consideration given to background therapy.
62024869|NCT05531994|OTHER|RT|Administration order: montelukast sodium chewable tablets with water, montelukast sodium oral thin films with water.
62024870|NCT01910519|EXPERIMENTAL|H5N1 vaccine plus AS03 adjuvant|"H5N1 vaccine plus AS03 adjuvant: Influenza A Vaccine with AS03 adjuvant~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant given 21 days apart (i.e., Administer day 1, booster at Day 21)."
62024871|NCT01910519|EXPERIMENTAL|H5N1 vaccine without adjuvant|"H5N1 vaccine without adjuvant: Influenza A Vaccine without AS03 adjuvant~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant given 21 days apart (i.e., Administer day 1, booster at Day 21)."
62024872|NCT01822860|PLACEBO_COMPARATOR|Placebo|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
62024873|NCT01822860|EXPERIMENTAL|Chlorthalidone 12.5 mg|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
62024874|NCT01822860|ACTIVE_COMPARATOR|Hydrochlorothiazide 25 mg|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
62588178|NCT04270409|ACTIVE_COMPARATOR|Lenalidomide and dexamethasone (Ld)|Lenalidomide \[PO administration\] in combination with dexamethasone \[PO administration\] for 24 cycles. 1 cycle = 28 days
62024875|NCT05447546|ACTIVE_COMPARATOR|1 mg HT-6184 QD|Cohort 1 - 6 subjects x 1 mg HT-6184 QD on Day 1
62024876|NCT05447546|PLACEBO_COMPARATOR|1 mg Placebo QD|Cohort 1 - 2 subjects x placebo, QD on Day 1
62416347|NCT04904588|EXPERIMENTAL|Regimen G (MAC: Cyclophosphamide and TBI; BM HCT)|"Patients receive:~* Cyclophosphamide (100 mg/kg total dose) IV on days -5 and -4~* TBI (1200 cGy total dose) on days -3, -2 and -1~Patients receive a BM graft infusion from a mismatched unrelated donor on Day 0."
62588179|NCT00462592|ACTIVE_COMPARATOR|1|montelukast - montelukast 5 mg ( \< 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening
62797435|NCT03147352||NSTI patients|NSTI is an infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection in subcutis, muscle and/or fascia and that spreads along tissue structures.
62797436|NCT03147352||Orthopaedic control patients|Elective orthopaedic control patients.
62797437|NCT04713306||Participants in the Swedish Neuro Register|Participants are patients with parkinsonian symptoms
62797438|NCT05467748|EXPERIMENTAL|combination of tulmimetostat and pembrolizumab|Enrolled patients will receive combination treatment for whole study duration (2 years). For first cycle, patient will start tulmimetostat one week prior to start every 3 week pembrolizumab intravenous infusion (pembrolizumab will be given day 8 only for the first cycle, rest of cycles will be day 1 of each cycle).
62797439|NCT05917613|EXPERIMENTAL|Intervention|Psychotherapy
62797440|NCT04311684||Patients with proteinuria|Patients with newly diagnosed glomerulonephritis with different range of proteinuria at the age between 18-65 years and estimated glomerular filtration rate (GFR) ≥60 ml/min will be included for urine protein measurements
62797441|NCT04311684||Healthy volunteers|Healthy men/women between age group 18-65 years will be included for urine protein measurements
62797442|NCT03980730|EXPERIMENTAL|Azeliragon|Azeliragon 5mg capsule administered orally, once daily for 6 months (Part 1) or 18 months (Part 2)
62797443|NCT03980730|PLACEBO_COMPARATOR|Placebo|Matching placebo capsule administered orally, once daily for 6 months (Part 1) or 18 months (Part 2)
62797444|NCT05924945|ACTIVE_COMPARATOR|Bridge™ active device|The active Bridge device delivers electrical stimulation to the cranial and occipital nerves.
62797445|NCT05924945|SHAM_COMPARATOR|Bridge™ sham device|The sham device has the same appearance and will require the same placement technique as the Bridge (active) device but will not deliver electrical impulses
62797446|NCT03897556|ACTIVE_COMPARATOR|High-dose|This arm consists of cancer survivors who receive two guarana energy bars to take per day for six weeks; one in the morning and one around lunch time.
62797447|NCT03897556|ACTIVE_COMPARATOR|Low-Dose|This arm consists of cancer survivors who receive one guarana energy bar to take per day for six weeks; one in the morning only.
62024877|NCT05447546|ACTIVE_COMPARATOR|2 mg HT-6184 QD|Cohort 2 - 6 subjects x 2 mg HT-6184 QD on Day 1
62024878|NCT05447546|PLACEBO_COMPARATOR|2 mg Placebo QD|Cohort 2 - 2 subjects x placebo, QD on Day 1
62024879|NCT05447546|ACTIVE_COMPARATOR|3 mg HT-6184 QD|Cohort 3 - 6 subjects x 3 mg HT-6184 QD on Day 1
62024880|NCT05447546|PLACEBO_COMPARATOR|3 mg Placebo QD|Cohort 3 - 2 subjects x placebo, QD on Day 1
62024881|NCT05447546|ACTIVE_COMPARATOR|4 mg HT-6184 QD|Cohort 4 - 6 subjects x 4 mg HT-6184 QD on Day 1
62221953|NCT04538690|EXPERIMENTAL|Exercise Group|Individuals who are taken part of shoulder exercises with painful shoulder disorders.
62433415|NCT02787226|ACTIVE_COMPARATOR|TSA - Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension for postoperative analgesia after total shoulder arthroplasty (TSA).
62024882|NCT05447546|PLACEBO_COMPARATOR|4 mg Placebo QD|Cohort 4 - 2 subjects x placebo, QD on Day 1
62024883|NCT05447546|ACTIVE_COMPARATOR|1 mg HT-6184 QD x 2 weeks|Cohort 5 - 6 subjects x 1 mg HT-6184 QD on Day 1-5, 8-12
62024884|NCT05447546|PLACEBO_COMPARATOR|1 mg Placebo QD x 2 weeks|Cohort 5 - 2 subjects x 1 mg placebo, QD on Day 1-5, 8-12
62024885|NCT05447546|ACTIVE_COMPARATOR|2 mg HT-6184 QD x 2 weeks|Cohort 6 - 6 subjects x 2 mg HT-6184 QD on Day 1-5, 8-12
62588180|NCT00462592|ACTIVE_COMPARATOR|2|budesonide - inhaled budesonide turbuhaler 200ug (\& matching placebo) taken 1 puff morning \& 1 puff evening.
62588181|NCT00462592|PLACEBO_COMPARATOR|3|placebo
62588182|NCT00462592|ACTIVE_COMPARATOR|4|montelukast budesonide combination - montelukast 5mg ( \< 15 years) or 10 mg (\& matching placebo)will be taken 1 tab in the evening together with inhaled budesonide turbuhaler 200 ug (\& matching placebo) taken 1 puff morning \& 1 puff evening.
62588183|NCT05091684|EXPERIMENTAL|Fibrinogen|Patients with refractory thrombocytopenia, following intensive chemotherapy, and presenting grade ≥ 2 hemorrhagic symptoms, will receive adjuvant fibrinogen administration and platelet transfusions.
62588184|NCT05828303|EXPERIMENTAL|Repotrectinib (TPX-0005)|Phase 1 Oral repotrectinib (TPX-0005) + cocktail drugs (metformin hydrochloride, digoxin, rosuvastatin calcium)
62588185|NCT04144348|EXPERIMENTAL|mRNA-1653, Adult participants|Participants will receive 1 of 2 doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57.
62588186|NCT04144348|EXPERIMENTAL|mRNA-1653 Pediatric participants|Participants will receive 1 of 2 possible doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57.
62221954|NCT02814539||congenital heart disease|children with severe congenital heart disease who undergo open heart surgery during infancy
62221955|NCT02814539||healthy controls|
62797448|NCT03897556|OTHER|Usual Care|This arm receives usual-care only as cancer survivors.
62797449|NCT02908906|EXPERIMENTAL|JNJ-63723283|In Part 1, the first cohort will receive JNJ-63723283 at a starting dose of 80 milligram (mg), intravenous (IV) every 2 weeks. JNJ-63723283 doses will be escalated following a modified Continual Reassessment Method (mCRM). Multiple doses, dose administration routes (subcutaneous \[SC\] or IV), and dose schedules may be explored. In Part 2, participants will receive JNJ-63723283 at the recommended Phase 2 dose (RP2D) determined in Part 1. In Part 3, participants will receive JNJ-63723283 to evaluate pharmacokinetic (PK), pharmacodynamic (PD) and safety. In Part 4, participants will receive JNJ-63723283 at the dose level determined in Part 3. Additional cohorts may be enrolled in Part 4.
62797450|NCT01653639|EXPERIMENTAL|Arm 1|
62797451|NCT01653639|EXPERIMENTAL|Arm 2|
62797452|NCT01684319|PLACEBO_COMPARATOR|Infant formula milk|Infant formula milk adapted to age of infant
62797453|NCT01684319|ACTIVE_COMPARATOR|Formula milk free of milk proteins|Milk-free formula milk adapted to age of infant
62797454|NCT04219241|EXPERIMENTAL|Cellavita-HD|The participants will receive a total of 12 intravenous administrations of 2x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 180 days (total of 4 cycles).
62797455|NCT02133898|OTHER|L-methyfolate|Single-arm open label administration of L-methylfolate 15mg once daily for 90 days
62797456|NCT06725251|EXPERIMENTAL|Dementia Participants and Care Partners|Dyads including a participant diagnosed with dementia and the care partner
62797457|NCT02115295|EXPERIMENTAL|Treatment (cladribine, cytarabine, idarubicin)|"INDUCTION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-5 and idarubicin IV over 30-60 minutes on days 1-3. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD on days 1-14. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-3 and idarubicin IV over 30-60 minutes on days 1-2. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity."
62221956|NCT06596447||Patients with Treatment Resistance OCD|
62221957|NCT04684394|EXPERIMENTAL|SoC + GEM103|Participants were administered SoC therapy defined as aflibercept (2 milligram \[mg\]/50 microliter \[mcL\]) first, followed by GEM103 (500 microgram \[mcg\]/50mcL) 15 minutes later. Administration occurred every other month (EOM) for a total of 6 doses during the 12-month study period.
62221958|NCT04684394|SHAM_COMPARATOR|SoC + Sham|Participants were administered SoC therapy defined as aflibercept (2mg/50mcL) first, followed by the Sham injection 15 minutes later. Administration occurred EOM for a total of 6 doses during the 12-month study period.
62221959|NCT06023563|EXPERIMENTAL|Virtual reality active video gaming|The participants in this group will engage in VR active gaming using Nintendo Switch Sports under supervision via Zoom, for 6 sessions over 2 weeks.
62221960|NCT06023563|ACTIVE_COMPARATOR|Standard balance exercises|The participants in this group will engage in standard physical therapy exercises for balance and walking under supervision via Zoom, for 6 sessions over 2 weeks.
62588187|NCT04144348|PLACEBO_COMPARATOR|Placebo, Adult participants|Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57.
62024886|NCT05447546|PLACEBO_COMPARATOR|2 mg Placebo QD x 2 weeks|Cohort 6 - 2 subjects x 2 mg placebo, QD on Day 1-5, 8-12
62221961|NCT00936273||Suspected sleep apnea syndrome|Outpatients with suspected sleep apnea syndrome, age \> 18 year
62221962|NCT02279394|EXPERIMENTAL|Elo / Len / Dex|"•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \& 15 Cycles 3-8~Other Name: HuLuc63~•Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24~Other Name: REVLIMID~•Drug: Dexamethasone 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8~Other Name: Decadron"
62221963|NCT02279394|EXPERIMENTAL|Elo / Len|"•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \& 15 Cycles 3-8~Other Name: HuLuc63~•Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24~Other Name: REVLIMID"
62221964|NCT06335602|EXPERIMENTAL|Laser Acupuncture Treat|Low level laser therapy to acupoints related to operation wound, before and after operation
62221965|NCT06335602|SHAM_COMPARATOR|Laser Acupuncture Sham|Low level laser therapy(with Sham device) to acupoints related to operation wound, before and after operation
62221966|NCT06335602|ACTIVE_COMPARATOR|Herbal packing|External application of herbal medicine packing around the operation wound, before and after operation
62588188|NCT04144348|PLACEBO_COMPARATOR|Placebo, Pediatric participants|Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57.
62588189|NCT02166411|EXPERIMENTAL|myomectomy using barbed sutures|.Myoma bed is sutured with barbed sutures
62588190|NCT02166411|ACTIVE_COMPARATOR|myomectomy using conventional sutures|Myoma bed is sutured with conventional sutures
62588191|NCT03994133||Daily Home Dialysis patients|Daily Home Dialysis patients with low-flow dialisate for more than 3 months in France
62588192|NCT03507764|NO_INTERVENTION|Control Group|"During the randomized study phase (6 months),subjects will perform their usual activity without access to the treadmill workstation in the dispatch center.~After six months, all subjects will continue to be assessed with free access to the treadmill workstation at the workplace."
62797458|NCT03047577|NO_INTERVENTION|Standard care arm|Treatment as usual and discussion according to the treating clinicians in the hospital
62797459|NCT03047577|OTHER|Intervention arm|Patients receive a brief intervention, including a short discussion, opportunity for an appointment with a social worker and written information about effects of alcohol on health and contact information for seeking additional support
62797460|NCT02872246|EXPERIMENTAL|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
62024887|NCT05447546|ACTIVE_COMPARATOR|3 mg HT-6184 QD x 2 weeks|Cohort 7 - 6 subjects x 3 mg HT-6184 QD on Day 1-5, 8-12
62221967|NCT00689585|PLACEBO_COMPARATOR|1|
62221968|NCT00689585|EXPERIMENTAL|2|
62221969|NCT04078633|EXPERIMENTAL|Normal Liquid Soap (250mL)|A normal hygiene kit will be distributed to the households. In addition, a liquid soap will be added to see the impact of having a liquid soap for hand washing on hygiene behaviors.
62221970|NCT04078633|EXPERIMENTAL|Bar soap (250gram)|A normal hygiene kit will be distributed to the households. In addition, a nice bar soap will be added to see the impact of having a nicer bar soap for hand washing on hygiene behaviors.
62797461|NCT03953469|NO_INTERVENTION|Placebo Group|"(a) Baseline blood pressure readings and one heart rate reading taken after at least 5 minutes of rest time without talking, eating, or caffeine consumption.~b) will be given 1/4 tsp of blackstrap molasses placebo. Subjects may not consume caffeine or eat food during this time.~(c) blood pressure readings and one heart rate will be taken 15 minutes after the baseline reading."
62221971|NCT04078633|EXPERIMENTAL|Mirror (50x30cm)|A normal hygiene kit will be distributed to the households. In addition, a mirror will be added to see the impact of having a mirror by the handwashing stand on handwashing behaviour. The mirror will have a plastic edge and be 30x 50cm in size.
62221972|NCT04078633|NO_INTERVENTION|Control|A normal hygiene kit will be distributed to the households. No additional interventions will be given.
62221973|NCT04078633|EXPERIMENTAL|Nurture story for hygiene promotion|Hygiene promoters will share a story of being a good parent through teaching their children to do hand washing with soap at critical times. A story about a good mother who every day reminds her child to wash her/his hands before eating or preparing food and after going to the toilet will be shared with participants. The story ends with the child growing up healthy, happy and with a good education. This story if belived to increae handwashing with soap in the household/
62024888|NCT05447546|PLACEBO_COMPARATOR|3 mg Placebo QD x 2 weeks|Cohort 7 - 2 subjects x 3 mg placebo, QD on Day 1-5, 8-12
62024889|NCT05447546|ACTIVE_COMPARATOR|4 mg HT-6184 QD x 2 weeks|Cohort 8 - 6 subjects x 4 mg HT-6184 QD on Day 1-5, 8-12
62024890|NCT05447546|PLACEBO_COMPARATOR|4 mg Placebo QD x 2 weeks|Cohort 8 - 2 subjects x 4 mg placebo, QD on Day 1-5, 8-12
62588193|NCT03507764|EXPERIMENTAL|Experimental Group|"During the randomized study phase, subjects will have an open access to the treadmill workstation with the indication to use it for at least one hour (continuous or split) on working days.~After six months, all subjects will continue to be assessed with free access to the treadmill workstation."
62024891|NCT01144312|EXPERIMENTAL|pharmacokinetics of fentanyl|
62588194|NCT04144582|EXPERIMENTAL|Sintilimab Combined With Docetaxel|Sintilimab Combined With Docetaxel for Metastatic or Non-driver Gene Mutation Non-small Cell Lung Cancer
62024892|NCT05413187|ACTIVE_COMPARATOR|Medical Grade Cannabis oil 30% CBD ,1.5% Δ9-THC|during phase 1; subjects will receive cannabis oil. They will receive treatment for twelve weeks, following a four-week washout period without any treatment. In the second phase, a crossover of trial arms will take place and patients who received cannabis oil will then receive placebo and vice versa. Clinical evaluation will take place after completing each phase.
62797462|NCT03953469|ACTIVE_COMPARATOR|Group II|"1. Baseline blood pressure readings and one heart rate reading taken after at least 5 minutes of rest time without talking, eating food, or caffeine consumption.~2. 15 minutes after examination - will be given 1/8 tsp (900mg) of Passiflora incarnata solid extract by Wise Woman Herbals mixed with 1/8 tsp of blackstrap molasses to mask the taste.~3. blood pressure readings and one heart rate will be taken 15 minutes after the baseline reading."
62024893|NCT05413187|PLACEBO_COMPARATOR|Olive oil and Chlorophyl|during phase 1; subjects will receive placebo. They will receive treatment for twelve weeks, following a four-week washout period without any treatment. In the second phase, a crossover of trial arms will take place and patients who received cannabis oil will then receive placebo and vice versa. Clinical evaluation will take place after completing each phase.
62221974|NCT04078633|EXPERIMENTAL|Comfort story for hygiene promotion|Hygiene promoters will deliver hygiene promotion through an activity that provoke the feeling of comfort by having clean hands. Hygiene promoters will deliver this intervention to up to 5 neighbor households at the time, sharing a story about a family that keeps good hygiene behaviors and therefore are clean, healthy and happy. This story is believed to encourage families to increase handwashing with soap in the household.
62797463|NCT01101789|ACTIVE_COMPARATOR|triclosan|triclosan-coated sutures
62221975|NCT04078633|NO_INTERVENTION|Education session for hygiene promotion|Hygiene promoters will deliver regular hygiene promotion activities; an educational message about disease transmission and how handwashing with soap can help protect against disease. This would include teaching participants about the benefits of handwashing with soap, such as reducing diarrhea incidence and preventing cholera.
62024894|NCT03787940|ACTIVE_COMPARATOR|Standard INH for Non-rapid acetylators|Participant with slow or intermediate acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with standard chemotherapy (3 months HRZE followed by 9 months HRE with standard dose isoniazid)
62221976|NCT04078633|EXPERIMENTAL|Hygiene Promotion Activity - Disgust|The activity will be delivered to a group of maximum 5 neighbouring households at the time. Hygiene promoters will use 5 buckets of clean water and place them in front of households. They will then ask a member of one of the households to rinse their hands in the first bucket. Some dirt will come of their hands. Then the participant rinses their hands again in bucket number 2, then 3 and then 4. Before the 5th bucket the participant receives a bar of soap to use when they rinse their hand. When they do the water will have a dirty colour as the dirt comes of their hands. This activity is believed to encourage handwashing with soap.
62416348|NCT06047249|NO_INTERVENTION|Coronary heart disease group|16SrDNA sequencing and ELISA test were carried out for patients over 50 years old who reported coronary atherosclerosis after coronary angiography or coronary angiography with CT examination to detect the abundance of Prevotella in their intestines, the concentration of 5-hydroxytryptamine, branched chain amino acids and lipopolysaccharide in their blood
62416349|NCT06047249|NO_INTERVENTION|Non coronary heart disease group|For patients over 50 years old who reported no coronary atherosclerosis after coronary angiography or CTA examination, 16SrDNA sequencing and ELISA tests were carried out to detect the abundance of Prevotella in the intestinal tract, the concentration of 5-hydroxytryptamine, branched chain amino acids and lipopolysaccharide in the blood
62433416|NCT02787226|ACTIVE_COMPARATOR|Reverse TSA - Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension for postoperative analgesia after reverse total shoulder arthroplasty (TSA).
62024895|NCT03787940|ACTIVE_COMPARATOR|Standard INH for rapid acetylators|Participant with rapid acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with standard chemotherapy (3 months HRZE followed by 9 months HRE with standard dose isoniazid )
62588195|NCT06044350|EXPERIMENTAL|Experimental group：BAT4406F|RCP：Intravenous infusion; Dosage:500mg/time; Time of administration:The drug was given at D 1 and D 182 respectively OLP：Intravenous infusion; Dosage:500mg/time; Time of administration: After D1 dosing, Every 6 months to 1 times
62588196|NCT06044350|ACTIVE_COMPARATOR|Control group：BAT4406F Placebos|RCP：Intravenous infusion; Dosage:500mg/time; Time of administration:The drug was given at D 1 and D 182 respectively OLP：Intravenous infusion; Dosage:500mg/time; Time of administration: After D1 dosing, Every 6 months to 1 times
62588197|NCT02976753||Elocta|Elocta will be prescribed and administered for prophylactic treatment of patients with haemophilia A according to usual clinical practice
62588198|NCT02976753||Conventional factor VIII product|Conventional factor VIII products will be prescribed and administered for prophylactic treatment of patients with haemophilia A according to usual clinical practice
62797464|NCT01101789|PLACEBO_COMPARATOR|control|sutures without triclosan-coating
62797465|NCT00699608|EXPERIMENTAL|Crossover|All subjects received all three treatments in a randomised order
62797466|NCT01928927|EXPERIMENTAL|Arm A: Telmisartan|
62797467|NCT01928927|NO_INTERVENTION|Arm B: No Study Drug|Participants received no study drug and followed the week 0-48 evaluation schedule.
62797468|NCT00687739|PLACEBO_COMPARATOR|1|GnRH agonist + placebo
62797469|NCT00687739|ACTIVE_COMPARATOR|2|GnRH agonist + placebo + exercise
62797470|NCT00687739|EXPERIMENTAL|3|GnRH agonist + Estradiol
62797471|NCT00687739|EXPERIMENTAL|4|GnRH agonist + Estradiol + exercise
62797472|NCT06726603||Women in BC conceiving by ART|Women in BC with in-province deliveries following pregnancies conceived by assisted reproductive technology occurring between March 1 2008 and April 31 2018 that resulted in singleton live birth or fetal death at \>20 weeks.
62797473|NCT06726603||Women in BC conceiving spontaneously|Women in BC with in-province deliveries following pregnancies conceived spontaneously occurring between March 1 2008 and April 31 2018 that resulted in singleton live birth or fetal death at \>20 weeks.
62797474|NCT06161129|NO_INTERVENTION|Control|Group of 50 participants (control) will receive glasses with clear lenses.
62797475|NCT06161129|ACTIVE_COMPARATOR|FL-41|Group of 50 participants will receive a glasses with an FL-41 filter.
62797476|NCT06161129|ACTIVE_COMPARATOR|BlueCut|Group of 50 participants will receive glasses with a Blue Cut filter.
62797477|NCT06161129|ACTIVE_COMPARATOR|500nm|Group of 50 participants will receive glasses with a below 500 nm filter
62024896|NCT03787940|EXPERIMENTAL|High dose INH for rapid acetylators|Participant with rapid acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with high dose isonized treatment (3 months HRZE followed by 9 months HRE with high dose isoniazid)
62588199|NCT04518098|EXPERIMENTAL|Intervention group|Participants in the IG will receive the STABLE intervention, which entails orientation, and undertaking a remotely delivered resistance and balance training regimen 3 times weekly for 3 months
62588200|NCT04518098|NO_INTERVENTION|Control group|Participants in the CG will not receive the intervention, and will be advised to carry out their usual daily activities.
62797478|NCT01337336||COPD patients with comorbid depression/anxiety|Patients aged 40 and over with COPD and comorbid depression/anxiety. Managed care enrolees (aged \>40 years) having newly initiated drug therapy with FSC or AC during the identification period (01/01/2004 to 06/30/2008) to treat COPD with a medical or pharmacy claim for depression before and 60 days post index date were the target population. The first fill date of FSC or AC was the index date.
62797479|NCT05491382|EXPERIMENTAL|Does muscle temperature influence heat loss responses independently from core and skin temperature?|The study will consist of three experimental trials, conducted in a randomized order, where participants will be required to run for one hour at \~60% of their maximal oxygen consumption on one of three different inclines: 1) flatland, 2) uphill, and 3) downhill. Environmental conditions will be maintained at 34°C/93°F and 20% relative humidity.
62797480|NCT05491382|EXPERIMENTAL|Does muscle temperature influence muscle blood flow independently from core and skin temperature?|Following the exercise protocol described above in Arm 1, the participants will then lay supine for one hour while their muscle and skin blood flow, as well as blood pressure are measured.
62797481|NCT05491382|EXPERIMENTAL|What factors contribute to exercise-induced skeletal muscle damage?|For those participants who additionally agree to participate in the muscle microdamage portion of the study, participants will be asked to return to the lab 24h and 48h post-trial. During these subsequent follow-up sessions, an additional blood sample will be drawn from the participants, the participants maximal voluntary contraction and muscle pain will be assessed, and they will be asked to fill out the muscle soreness scale.
62797482|NCT05519514|ACTIVE_COMPARATOR|Cortiment (Budesonide 9 mg prolonged release tablet)|
62797483|NCT05519514|EXPERIMENTAL|Budesonide 9 mg prolonged release tablet|
62797484|NCT05338034|EXPERIMENTAL|HPG1860 3 mg|20 subjects will be treated with HPG1860 3 mg once daily at a similar time with or without food.
62797485|NCT05338034|EXPERIMENTAL|HPG1860 5 mg|20 subjects will be treated with HPG1860 5 mg once daily at a similar time with or without food.
62797486|NCT05338034|EXPERIMENTAL|HPG1860 8 mg|20 subjects will be treated with HPG1860 5 mg once daily at a similar time with or without food.
62797487|NCT05338034|PLACEBO_COMPARATOR|Placebo|20 subjects will be treated with Placebo once daily at a similar time with or without food.
62797488|NCT01396213|EXPERIMENTAL|Larazotide Acetate 0.5 mg|larazotide acetate 0.5 mg capsules TID
62797489|NCT01396213|EXPERIMENTAL|Larazotide Acetate 1 mg|larazotide acetate 1 mg capsules TID
62797490|NCT01396213|EXPERIMENTAL|Larazotide Acetate 2 mg|larazotide acetate 2 mg capsules TID
62797491|NCT01396213|PLACEBO_COMPARATOR|Placebo|placebo capsules TID
62797492|NCT05062447||Adaptive emotions, non-metastatic disease|Participants who are categorized as having 'adaptive emotions' and have a non-metastatic disease
62797493|NCT05062447||Adaptive emotions, metastatic disease|Participants who are categorized as having 'adaptive emotions' and have a metastatic disease
62797494|NCT05062447||maladaptive emotions, non-metastatic disease|Participants who are categorized as having 'maladaptive emotions' and have a non-metastatic disease
62797495|NCT05062447||maladaptive emotions, metastatic disease|Participants who are categorized as having 'maladaptive emotions' and have a metastatic disease
62797496|NCT04171050|ACTIVE_COMPARATOR|Group 1: Local Anesthesia|Standard of care with local anesthesia used during surgery
62797497|NCT04171050|ACTIVE_COMPARATOR|Group 2: Local Anesthesia plus Pudendal Nerve Block|Pudendal Nerve Block (PNB) in addition to local anesthesia used during surgery
62433417|NCT02787226|ACTIVE_COMPARATOR|TSA - Continuous Perineural Ropivacaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine for postoperative analgesia after TSA.
62797498|NCT06725433|ACTIVE_COMPARATOR|Nissen fundoplication|Hiatal hernia repair and Nissen (posterior 360-degree) fundoplication
62797499|NCT06725433|EXPERIMENTAL|Dor fundoplication|Hiatal hernia repair and Dor (anterior 180-degree) fundoplication
62797500|NCT04958889||HIV+ adults with recent COVID-19 diagnosis|"Required study visits:~* Baseline questionnaire at enrollment or month 1.~* Follow up questionnaire at month 1 and month 4~* Height, weight, vital signs, and blood sampling at month 1 and month 4~Optional study visits:~• Follow up questionnaire at month 2, month 6, and month 12"
62024897|NCT03769623|EXPERIMENTAL|Biolimus|BA9 Drug-eluting Coronary Artery Balloon Catheter
62024898|NCT03769623|ACTIVE_COMPARATOR|Powerline|Balloon dilated catheter
62024899|NCT00841867||1|Subjects 18-80 years of age who have previously undergone partial pancreatectomy due to a benign lesion
62024900|NCT00841867||2|Healthy control subjects, 18-80 years of age, who have not had partial pancreatectomy.
62588201|NCT04482998||Steroids only - early|treatment was initiated within 7 days of acoustic trauma.
62024901|NCT02653521|EXPERIMENTAL|adaptive radiation therapy (ART)|40 patients treated with ART, using dose adaptation method to match the change of PTV and movement of OARs and achieve an optimal dose distribution using online CBCT images.
62024902|NCT02653521|NO_INTERVENTION|the control group|40 patients treated with original plan for full treatment course.
62024903|NCT01877447|EXPERIMENTAL|cathodal F4|"Transcranial Direct Current Stimulation~Cathodal tDCS over F4 (right dorsolateral prefrontal cortex) Anodal tDCS over the left deltoid (extra-cephalic) n=15"
62024904|NCT01877447|EXPERIMENTAL|Anodal F3|"Transcranial Direct Current Stimulation'~Anodal tDCS over F3 (right dorsolateral prefrontal cortex) Cathodal tDCS over the right deltoid (extra-cephalic) n=15"
62024905|NCT01709019|EXPERIMENTAL|Group A|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 \& Day 28)
62024906|NCT01709019|EXPERIMENTAL|Group B|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 \& Day 28)
62221977|NCT04078633|EXPERIMENTAL|Hygiene Promotion Activity - Comfort|The activity will be delivered to a group of maximum 5 neighbouring households at the time. Hygiene promoters will bring some food oil and ask participants to cover their hands in food oil. They will then ask the participants to cover their hands in turmeric powder. The participants will then be asked to wash their hands with water only. This will have little effect on the cleanliness of their hands. Then participants will be given a bar of soap. The participants will then be asked to wash their hands again. This will leave their hands nice comfortable and clean. They will experience the comfort of clean hands and the activity hope to increase regular handwashing.
62588202|NCT04482998||Early combined steroid and hyperbaric oxygen therapy|treatment was initiated within 7 days of acoustic trauma.
62588203|NCT04482998||Delayed combined steroid and hyperbaric oxygen therapy|treatment was initiated after 7 days of acoustic trauma.
62797501|NCT04958889||HIV- adults with recent COVID-19 diagnosis|"Required study visits:~* Baseline questionnaire at enrollment or month 1.~* Follow up questionnaire at month 1 and month 4~* Height, weight, vital signs, and blood sampling at month 1 and month 4~Optional study visits:~• Follow up questionnaire at month 2, month 6, and month 12"
62797502|NCT04958889||HIV+ adults with no history of COVID-19|"Required study visits:~* Baseline questionnaire at enrollment.~* Follow up questionnaire at enrollment and approximately 3 months after first follow up questionnaire.~* Height, weight, vital signs, and blood sampling at enrollment.~Optional study visits:~• Follow up questionnaire at 1, 5, and 11 months after first follow up questionnaire."
62024907|NCT01709019|EXPERIMENTAL|Group C|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 \& Day 28)
62024908|NCT01709019|EXPERIMENTAL|Group D|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 \& Day 28)
62024909|NCT01709019|PLACEBO_COMPARATOR|Group E|Placebo (Day 0 \& Day 28); Seasonal TIV (Day 28)
62024910|NCT01446380||Pseudoxanthoma elasticum|
62024911|NCT03399110|EXPERIMENTAL|XELOX for 4 months|Adjuvant chemotherapy with capecitabine and oxaliplatin after surgery (five 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 4 months or progress of disease
62416350|NCT06047249|EXPERIMENTAL|KAP group|Conduct a survey on the relationship between coronary heart disease and dietary patterns among hospitalized patients in the form of KAP Popular Science Research. After the survey, conduct scientific popularization of relevant knowledge, conduct a satisfaction questionnaire survey after surgery, and collect data on preoperative and postoperative examinations and laboratory tests
62588204|NCT04482998||Early sequential steroid followed by HBO therapy|treatment was initiated within 7 days of acoustic trauma.
62588205|NCT04482998||Delayed sequential steroid followed by HBO therapy|treatment was initiated after 7 days of acoustic trauma.
62588206|NCT04482998||Hyperbaric oxygen therapy only|
62588207|NCT04482998||No treatment|
62588208|NCT04482998||Steroid only - delayed|treatment was initiated after 7 days of acoustic trauma.
62588209|NCT06522945|ACTIVE_COMPARATOR|A: Mild Renal Impairment (GFR:60~89 mL/min)|A: TQD3524 2.5 mg/kg administered as a 90 minute infusion via infusion pump, single dose
62588210|NCT06522945|ACTIVE_COMPARATOR|B: Moderate Renal Impairment (GFR:30~59 mL/min)|B: TQD3524 2.5 mg/kg administered as a 90 minute infusion via infusion pump, single dose
62588211|NCT06522945|ACTIVE_COMPARATOR|C: Severe Renal Impairment (GFR:15~29 mL/min)|C: TQD3524 1.25 mg/kg administered as a 90 minute infusion via infusion pump, single dose
62588212|NCT06522945|ACTIVE_COMPARATOR|D: End-stage renal disease (patients undialyzed ) (GFR<15 mL/min)|D: TQD3524 1.25 mg/kg administered as a 90 minute infusion via infusion pump, single dose
62024912|NCT03399110|ACTIVE_COMPARATOR|XELOX for 6 months|Adjuvant chemotherapy with capecitabine and oxaliplatin after surgery(eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
62024913|NCT03116919|OTHER|Potato arm|One group will be fed an extra serving of boiled, baked or mashed potatoes daily for 1 week
62024914|NCT03116919|OTHER|Non-starchy vegetable|Then crossover to an extra serving of a non-starchy vegetable
62024915|NCT06349902||Positive HCV RNA, no sufficient previous course of DAA treatment.|Having a positive HCV RNA laboratory result and lacking a sufficient previous course of DAA treatment.
62797503|NCT04958889||HIV- adults with no history of COVID-19|"Required study visits:~* Baseline questionnaire at enrollment.~* Follow up questionnaire at enrollment and approximately 3 months after first follow up questionnaire.~Optional study visits:~• Follow up questionnaire at 1, 5, and 11 months after first follow up questionnaire."
62024916|NCT04749719|EXPERIMENTAL|DLPFC stimulation|F3-SO montage or OLE optimized with 2 mA stimulation for up to 30 min during memory and metamemory task.
62024917|NCT04749719|SHAM_COMPARATOR|Sham tDCS|F3-SO montage or OLE optimized with sham stimulation for up to 30 min during memory and metamemory task.
62024918|NCT01628276|EXPERIMENTAL|Rehab first|
62024919|NCT01628276|EXPERIMENTAL|Rehab Second|
62024920|NCT01628276|NO_INTERVENTION|Non Rehab|
62024921|NCT00174993|EXPERIMENTAL|Pioglitazone QD|
62416351|NCT06047249|SHAM_COMPARATOR|Non KAP group|Investigators will not conduct a survey on the relationship between coronary heart disease and dietary patterns among hospitalized patients, conduct science popularization, and conduct a satisfaction questionnaire survey after surgery
62416352|NCT03361332||Healthy subjects|
62024922|NCT00174993|PLACEBO_COMPARATOR|Placebo QD|
62024923|NCT00714168|ACTIVE_COMPARATOR|1|Participants will take part in a standard behavioral weight loss program.
62416353|NCT03361332||Patients with Gilles de la Tourette Syndrome|
62416354|NCT06319963|EXPERIMENTAL|Arm A : Refractory newly diagnosed|Refractory recurrent and/or metastatic cervical or oropharyngeal cancer that is not amenable to local therapy with curative intent (ie, surgery or radiation therapy with or without chemotherapy).
62797504|NCT01669317|EXPERIMENTAL|Cherry Juice Standardized|You will be given an 8-ounce glass of cherry juice to drink when you arrive at the Sleep Laboratory.
62797505|NCT01669317|PLACEBO_COMPARATOR|Artificial Cherry Juice|You will be given an 8-ounce glass of artificial cherry juice to drink when you arrive at the Sleep Laboratory.
62024924|NCT00714168|EXPERIMENTAL|2|Participants will take part in a stepped-care weight loss program.
62024925|NCT04929145||MICROMS|No intervention will be administered. Stool, hair, and blood samples will be collected at baseline and three months post baseline. Clinical follow-up will occur at year 1, 2, and 4.5 (neurological consultation) and in-between visits (regular follow-up).
62024926|NCT02265237|EXPERIMENTAL|Arm A|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 12 weeks for genotype 4 treatment-naïve or treatment-experienced with IFN/RBV.
62024927|NCT02265237|EXPERIMENTAL|Arm B|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 16 weeks for genotype 4 treatment-naive or treatment-experienced with IFN/RBV.
62024928|NCT02265237|EXPERIMENTAL|Arm C|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 24 weeks for genotype 4 treatment-naive and treatment-experienced with IFN/RBV.
62416355|NCT06319963|EXPERIMENTAL|Arm B : newly diagnosed locally advanced|Participants who have newly diagnosed locally advanced HPV-related oropharyngeal cancer (defined by AJCC 8th edition \[ie, T1-2N2-N3, T3-T4N0-N3\]) or cervical cancer (stages IB to IVA) that has never been treated with curative intent, and who are candidates to begin an SoC treatment (surgery, radiation therapy with or without chemotherapy).
62588213|NCT06522945|ACTIVE_COMPARATOR|E: End-stage renal disease (patients dialyzed) (GFR<15 mL/min)|E: TQD3524 1.25 mg/kg administered as a 90 minute infusion via infusion pump, single dose
62588214|NCT06522945|ACTIVE_COMPARATOR|F: Normal (GFR≥90mL/min)|F: TQD3524 2.5 mg/kg administered as a 90 minute infusion via infusion pump, single dose
62797506|NCT06129136|ACTIVE_COMPARATOR|Nature-based exposure by biodiversity component in lotion.|This group uses regularly the lotion with added natural biodiversity component. The component is mimicking natural exposure to Finnish forest soil and it contains high microbial diversity. The microbes are inactivated.
62797507|NCT06129136|PLACEBO_COMPARATOR|Placebo group using colored lotion.|This group uses regularly the same vehicle lotion than Nature exposure group, with the difference that the biodiversity component has been replaced with safe coloring ingredients to give the same brownish color than in the other group's lotion. Coloring ingredients are iron oxides that are common in foods and cosmetics: C.I.7791, C.I.77492, C.I. 774499.
62024929|NCT02265237|EXPERIMENTAL|Arm D|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 24 weeks for genotype 4 SOF/pegIFN/RBV or SOF/RBV treatment-experienced.
62024930|NCT02446808|EXPERIMENTAL|Intraoperative nerve monitoring|Patients for which intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
62416356|NCT00960687|EXPERIMENTAL|Fenofibric Acid (Fibricor™)|1 x 105 mg fenofibric acid (Fibricor™)tablet administered 30 minutes after the initiation of a standard breakfast.
62797508|NCT02784847|OTHER|treatment arm|pilot-study with single arm of 10 migraine patients treated for 3 months with triheptanoin 1mg/kg/day
62797509|NCT03923634|EXPERIMENTAL|Princess® RICH|"Eligible subjects will be injected with Princess® RICH (this is an open-label study).~Princess® RICH is injected into the lateral canthal lines and/or perioral rhytids."
62797510|NCT03812536|NO_INTERVENTION|SOC Voiding Protocol|Patients in the control group will follow the standard of care protocol and are required to void post anorectal surgery before being discharged home.
62024931|NCT03178552|EXPERIMENTAL|Cohort A: Alectinib 600 Milligrams (mg)|"This cohort includes participants with anaplastic lymphoma kinase (ALK) positive NSCLC. Participants will receive alectinib 600 mg orally twice in a day (BID) until disease progression, unacceptable toxicity, withdrawal of consent or death.~Enrollment to Cohort A is complete."
62416357|NCT00960687|EXPERIMENTAL|Fenofibrate (Tricor®)|1 x 145 mg fenofibrate (Tricor®) tablet administered 30 minutes after the initiation of a standard breakfast.
62416358|NCT05824975|EXPERIMENTAL|GI-102|Dose escalation: GI-102 intravenous (IV), multiple ascending doses Dose optimization: GI-102 intravenous (IV), sRP2D Dose optimization: GI-102 intravenous (IV), sRP2D-1 (or sRP2D+1)
62416359|NCT05824975|EXPERIMENTAL|GI-102 subcutaneous (SC)|Dose escalation: GI-102 subcutaneous (SC), multiple ascending doses Dose expansion: GI-102 subcutaneous (SC), sRP2D
62588215|NCT04447352|ACTIVE_COMPARATOR|Arm A - FLOT|"Patients randomized to treatment Arm A already received 3-6 cycles of FLOT in 2-week treatment cycles prior to undergoing surgery. Following surgery, patients will receive four further 2-week cycles FLOT. FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.~FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m²."
62024932|NCT03178552|EXPERIMENTAL|Cohort B: Dose Finding Phase (DFP) Alectinib|"This cohort includes participants with rearranged during transfection (RET) positive NSCLC. Participants may receive alectinib 900 or 1200 mg orally BID until disease progression, unacceptable toxicity, withdrawal of consent or death if the recommended phase 2 dose (RP2D) is not established in any other clinical study. Participants may receive 750 mg or 600 mg, if it is unsafe to pursue the higher starting dose.~Enrollment to Cohort B is complete."
62416360|NCT05824975|EXPERIMENTAL|GI-102 + doxorubicin|
62797511|NCT03812536|EXPERIMENTAL|No Void Intervention|Patients in the experimental group (No Void Intervention) will be discharged home without voiding spontaneously.
62797512|NCT02555176|EXPERIMENTAL|Low Carbohydrate Diet|Patients follow a normocaloric, low-carbohydrate diet for 10-28 days (from the time of cancer diagnosis to definitive surgical treatment).
62797513|NCT06726265|EXPERIMENTAL|efti + Standard of Care arm|Combination of efti, pembrolizumab (KEYTRUDA®) and histology-based platinum doublet chemotherapy
62797514|NCT06726265|PLACEBO_COMPARATOR|Placebo + Standard of Care arm|Combination of efti-matching placebo, pembrolizumab (KEYTRUDA®) and histology-based platinum doublet chemotherapy
62797515|NCT04883866|EXPERIMENTAL|Intervention Group|"Sending breastfeeding guidelines for premature babies to phones after the discharge procedure is completed.and implementing a Telephone Breastfeeding Support Program."
62797516|NCT04883866|EXPERIMENTAL|Control Group|Sending breastfeeding guidelines for premature babies to phones after the discharge procedure is completed.
62797517|NCT01650194|EXPERIMENTAL|Enzalutamide + Abiraterone + Prednisone|Participants received enzalutamide combined with abiraterone acetate once daily plus prednisone twice daily.
62797518|NCT01367834|EXPERIMENTAL|Growth Hormone|Subjects in the somatotropin (growth hormone, GH) arm will receive GH injections from 12-24 months of life.
62797519|NCT01367834|NO_INTERVENTION|Control|Subjects will receive no GH or placebo.
62416361|NCT05824975|EXPERIMENTAL|GI-102 + paclitaxel + bevacizumab|
62416362|NCT05824975|EXPERIMENTAL|GI-102 + eribulin|
62416363|NCT05824975|EXPERIMENTAL|GI-102 + trastuzumab deruxtecan (T-DXd)|
62416364|NCT05824975|EXPERIMENTAL|GI-102 + pembrolizumab|
62416365|NCT05042453||Hysteropexy using Splentis via vaginal route|Non-fertile women ≥ 18 years with uterine descent (POP-Q ≥ 2) which are study-independently scheduled for hysteropexy with Splentis
62416366|NCT05775237|EXPERIMENTAL|Curcumin Gummies|Curcumin Gummies contain energy, dietary fiber, sugar, total carbohydrate, protein, fat, and curcumin.
62416367|NCT05775237|EXPERIMENTAL|Vitamin C Gummies|Vitamin C Gummies contain Vitamin C and Zinc
62024933|NCT03178552|EXPERIMENTAL|Cohort B: Dose Expansion Phase (DEP) Alectinib|"This cohort includes participants with RET positive NSCLC. Participants will receive alectinib at the RP2D established in the DFP of Cohort B or a separate clinical study. Participants will continue receiving study treatment until disease progression, unacceptable toxicity, withdrawal of consent or death.~Enrollment to Cohort B is complete."
62024934|NCT03178552|EXPERIMENTAL|Cohort C: Atezolizumab 1200 mg|"This cohort includes participants with bTMB positive NSCLC. Participants will receive atezolizumab at a dose of 1200 mg administered by IV infusion every 21 days (Q21D) until disease progression, loss of clinical benefit, unacceptable toxicity, withdrawal of consent or death.~Enrollment to Cohort C is complete."
62024935|NCT03178552|ACTIVE_COMPARATOR|Cohort C: Pemetrexed, Cisplatin or Carboplatin|"This cohort includes participants with bTMB positive, non-squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Carboplatin at a dose of area under the concentration-time curve (AUC) of 5 or 6 IV or cisplatin at a dose of 75 milligrams per meter square (mg/m\^2) IV on Day 1 of each cycle combined with pemetrexed at a dose of 500 mg/m\^2 IV on Day 1 of each cycle. Pemetrexed may be continued as maintenance therapy every 21 days (Q21D) as per local standard of care.~Enrollment to Cohort C is complete."
62024936|NCT03178552|ACTIVE_COMPARATOR|Cohort C: Gemcitabine, Cisplatin or Carboplatin|"This cohort includes participants with bTMB positive, squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of every cycle and cisplatin 75 mg/m\^2 IV on Day 1 Q21D or gemcitabine 1000 mg/m\^2 IV on Days 1 and 8 of every cycle and carboplatin AUC 5 IV on Day 1 Q21D.~Enrollment to Cohort C is complete."
62024937|NCT03178552|EXPERIMENTAL|Cohort D: Entrectinib 600 Milligrams (mg)|"This cohort includes participants with c-ros oncogene 1 positive (ROS1+) NSCLC. Participants will receive entrectinib 600 mg orally once a day (QD) until disease progression, unacceptable toxicity, withdrawal of consent or death.~Enrollment to Cohort D is complete."
62024938|NCT03178552|EXPERIMENTAL|Cohort E: Atezolizumab, Vemurafenib, and Cobimetinib|"This cohort includes participants with BRAF V600 mutation. Participants will receive: atezolizumab 1680 mg IV Q4W after the run-in period; cobimetinib 60 mg orally (PO) QD on Days 1-21 of each cycle during the run-in and triple-combination periods; and vemurafenib 960 mg PO twice daily (BID) on Days 1-21 of the initial run-in period, then 720 mg PO BID on Days 1-22 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.~Enrollment to Cohort E is complete."
62024939|NCT03178552|EXPERIMENTAL|Cohort F: Atezolizumab, Bevacizumab, Carboplatin, and Pemetrexed|"This cohort includes participants with EGFR exon 20+ NSCLC. Participants will receive atezolizumab + bevacizumab + carboplatin + pemetrexed for 4 or 6 induction cycles (cycle = 21 days). After induction therapy, participants will continue maintenance treatment with atezolizumab + bevacizumab + pemetrexed until disease progression, unacceptable toxicity, withdrawal of consent, or death.~Enrollment to Cohort F is complete."
62797520|NCT01225094|EXPERIMENTAL|curcumin|Patients will take the study medication (500 mg x 4 capsules, twice daily \[BID\]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg., and then another 2000 mg dose 6 hours after the repair. Final dose (2000 mg)is administered morning after repair.
62024940|NCT03178552|EXPERIMENTAL|Cohort G: Divarasib or Docetaxel|"Experimental: Cohort G: GDC-6036 or Docetaxel This cohort includes participants with KRAS G12C mutation. Participants will receive GDC-6036 PO QD or IV docetaxel Q3W (75 mg/m\^2) until disease progression or unacceptable toxicity~New participants will no longer receive docetaxel."
62024941|NCT03178552|NO_INTERVENTION|Cohort Z: Natural History Cohort|Participants with genomic profiles of interest that are not enrolled in the other cohorts will enter into natural history follow-up.
62797521|NCT01225094|PLACEBO_COMPARATOR|placebo|The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.
62797522|NCT01949974|EXPERIMENTAL|Integral Attention Program (PAI)|"The key points of the PAI are:~* To assess and manage pain and other symptoms resulting from disease progression.~* To evaluate the information needs that may arise and to address them.~* To encourage patient and family adaptation to the situation of advanced disease and in the terminal phase of it.~* To provide guidance in decision-making while respecting patient autonomy.~* To establish a plan of care and treatment, adapted to the evolution and needs of the patient.~* To promote continuity of care."
62797523|NCT01949974|ACTIVE_COMPARATOR|Standard Palliative Chemotherapy and PAI|Standard palliative chemotherapy will be administered, depending on type of cancer, as well as PAI as been defined above.
62797524|NCT04577378|ACTIVE_COMPARATOR|13 cis retinoic acid doses orally|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus aerosolized Itraconzaole powder: single dose of 5mg/kg/day for 14 days
62797525|NCT04577378|SHAM_COMPARATOR|Aerosolized 13 cis retinoic acid|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Aerosolized Itraconzaole powder: single dose of 5mg/kg/day for 14 days
62797526|NCT04577378|NO_INTERVENTION|control|No intervention
62797527|NCT01814475|ACTIVE_COMPARATOR|A: Fludarabine + Busulphan|Conventional conditioning regimen with Fludarabine and Busulphan (Busilvex)for allogeneic stem cell transplantation in myelofibrosis
62797528|NCT01814475|EXPERIMENTAL|B: Fludarabine + Thiotepa|Reduced-intensity conditioning with Fludarabine and Thiotepa for allogeneic stem cell transplantation in myelofibrosis
62797529|NCT05167565|EXPERIMENTAL|Infants aged around 3 month|80 infants aged around 3 months will be included in this study up to around 12.5 months
62797530|NCT01150097|EXPERIMENTAL|Everolimus + reduced tacrolimus|Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.
62797531|NCT01150097|EXPERIMENTAL|Tacrolimus elimination|Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.
62797532|NCT01150097|ACTIVE_COMPARATOR|Tacrolimus control|Participants were maintained on a whole blood trough level of 6 - 10 ng/mL tacrolimus.
62797533|NCT06369974|EXPERIMENTAL|Intervention|Open Label
62221978|NCT04078633|NO_INTERVENTION|Education Hygiene Promotion Activity|Hygiene promoters will deliver regular hygiene promotion activities; an educational message about disease transmission and how handwashing with soap can help protect against disease. This would include teaching participants about the benefits of handwashing with soap, such as reducing diarrhea incidence and preventing cholera.
62221979|NCT04498091||A|Type 2 MI with COVID-19
62221980|NCT04498091||B|Type 2 without COVID-19
62221981|NCT04498091||C|Type 2 MI with pneumonia without COVID-19
62221982|NCT04498091||D|Type 2 MI without pneumonia and without COVID-19
62221983|NCT05014646|EXPERIMENTAL|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62221984|NCT04234854||Carotid Artery Stenting|Consecutive patients older than 18 yrs with symptomatic carotid artery stenosis qualified for endovascular revascularization.
62221985|NCT02588300|EXPERIMENTAL|Drug induced sleep endoscopy|Patients upper airway is assessed by drug induced sleep endoscopy
62221986|NCT03439254|EXPERIMENTAL|Obeticholic Acid (OCA) 10 mg|10 mg OCA for up to 18 months
62221987|NCT03439254|EXPERIMENTAL|Obeticholic Acid (OCA) 10 mg to 25 mg|10 mg OCA for the first 3 months and then may titrate up to 25 mg OCA for the remaining 15 months of the study
62221988|NCT03439254|PLACEBO_COMPARATOR|Placebo|Placebo for up to 18 months
62221989|NCT05959954||Carpal Tunnel Syndrome (CTS) Patients|Adults with clinical and electrodiagnostic evidence of carpal tunnel syndrome.
62221990|NCT03224351|PLACEBO_COMPARATOR|Part 1: Placebo|Participants received placebo matched to VX-659/TEZ/IVA in TC treatment period for 4 weeks and placebo matched TEZ/IVA in washout period for 4 days.
62221991|NCT03224351|EXPERIMENTAL|Part 1: VX-659/TEZ/IVA TC - Low Dose|Participants received VX-659 80 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
62221992|NCT03224351|EXPERIMENTAL|Part 1: VX-659/TEZ/IVA TC - Medium Dose|Participants received VX-659 240 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
62221993|NCT03224351|EXPERIMENTAL|Part 1: VX-659/TEZ/IVA TC - High Dose|Participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
62416368|NCT05775237|EXPERIMENTAL|Multivitamin Gummies|Multivitamin Gummies contain energy, dietary fiber, sugar, total carbohydrate, protein, fat, sodium, Vitamin C, Vitamin E, pantothenic acid, Zinc, iodine, Vitamin A, Magnesium, Folate, Vitamin D, Vitamin 12
62221994|NCT03224351|ACTIVE_COMPARATOR|Part 2: TEZ/IVA|Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
62221995|NCT03224351|EXPERIMENTAL|Part 2: VX-659/TEZ/IVA TC|Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
62416369|NCT06687434|EXPERIMENTAL|Accurate carb counting|Participants will use precise carb counting to manage their meals
62416370|NCT06687434|EXPERIMENTAL|Simplified qualitative meal-size estimation|Participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian assessment.
62024942|NCT06213025|EXPERIMENTAL|web-based Educational program|nurses who entered a web-based Educational program about elder abuse will demonstrate higher response and willingness to handle elderly abuse (high score in REAGERA-P scale) than those who not entered
62024943|NCT06213025|NO_INTERVENTION|nurses in control group|non intervention group
62024944|NCT05409417|EXPERIMENTAL|Tislelizumab Combined With chemotherapy|Tislelizumab Combined With XELOX and Bevacizumab or Tislelizumab Combined With FOLFOX and Cetuximab
62024945|NCT03032926||Open Trial|N/A - Open Trial
62797534|NCT03965494|EXPERIMENTAL|AXL inhibitor BGB324 then surgery|Participants receive AXL inhibitor BGB324 PO QD on days 1-5, then undergo surgery 3-6 hours after last dose. Within 45 days, participants receive AXL inhibitor BGB324 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62797535|NCT03965494|EXPERIMENTAL|Surgery then AXL inhibitor BGB324|Participants undergo surgery, then within 45 days receive AXL inhibitor BGB324 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62797536|NCT02495129|EXPERIMENTAL|VAY736 lower dose|12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
62797537|NCT02495129|EXPERIMENTAL|VA736 higher dose|12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
62797538|NCT05349630|PLACEBO_COMPARATOR|Healthy individuals - pre-iron|"Five healthy participants will be enrolled. Baseline echocardiography and exercise data prior to oral iron supplementation will be obtained as part of the parent study to this study (NCT05272514)."
62797539|NCT05349630|ACTIVE_COMPARATOR|Healthy individuals - post-iron|The same five healthy participants will complete echocardiography and exercise testing after taking 30 days of oral iron supplementation.
62416371|NCT06565832|ACTIVE_COMPARATOR|Virtual exercise testing via video link|The One-Minute Sit-to-Stand test and the Chester Step test will be completed via a video link call with the participant and the research team.
62797540|NCT03932695|ACTIVE_COMPARATOR|High dose Milk peptides|2800mg of whey protein hydrolysates single dose
62797541|NCT03932695|ACTIVE_COMPARATOR|Low dose Milk peptides|1400mg of whey protein hydrolysate Single dose and 6 weeks intervention
62797542|NCT03932695|PLACEBO_COMPARATOR|Placebo|maltodextrin
62797543|NCT02303093||Octagam|Patient receiving Octagam 5% or 10% IVIG
62797544|NCT02303093||Panzyga|Patient receiving panzyga
62797545|NCT03655041|EXPERIMENTAL|Beta-Alanine|6.4 g/day of beta-alanine for 24 weeks
62797546|NCT03655041|PLACEBO_COMPARATOR|Placebo|6.4 g/day of maltodextrin for 24 weeks
62797547|NCT01372969|EXPERIMENTAL|Cx601|
62024946|NCT05080764|EXPERIMENTAL|1h incubation BF-200 ALA|Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid) red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 1h incubation.
62024947|NCT05080764|EXPERIMENTAL|3h incubation BF-200 ALA|Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid) red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 3h incubation.
62024948|NCT05080764|PLACEBO_COMPARATOR|1h incubation vehicle|Topical application of vehicle to BF-200 ALA red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 1h incubation.
62024949|NCT05080764|PLACEBO_COMPARATOR|3h incubation vehicle|Topical application of vehicle to BF-200 ALA red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 3h incubation.
62024950|NCT03956498|OTHER|Patients with cervix or vaginal cancer|
62024951|NCT05923944|EXPERIMENTAL|Eco-Rescue - Attentional Control - intervention|The Eco-Rescue training intervention will be delivered through a dedicated video game installed on each participant's personal computer through the Steam platform, following a recommended training regimen of 30 minutes per day, 4 days per week for 6 weeks, for an expected total training duration of 12 hours.
62024952|NCT05923944|EXPERIMENTAL|Bejeweled 3 - Casual gaming - intervention|The Bejeweled 3 training intervention will be delivered through a dedicated video game installed on each participant's personal computer through the Steam platform, following a recommended training regimen of 30 minutes per day, 4 days per week for 6 weeks, for an expected total training duration of 12 hours.
62024953|NCT05923944|NO_INTERVENTION|No-training intervention|The No-training intervention group does not involve any specific training program. Instead, participants assigned to this group will receive weekly phone calls, similar to the other groups, to answer the same questions as the other groups concerning their mental and emotional states and maintain regular contact throughout the 6-week study duration.
62024954|NCT06128616|EXPERIMENTAL|ESWT Group|Patients treated by BoNT-A, intermittent SC and ESWT, whom received either PT or OT
62024955|NCT06128616|ACTIVE_COMPARATOR|Control Group|Patients treated by BoNT-A, and intermittent SC, whom received either PT or OT
62024956|NCT00968604|EXPERIMENTAL|BikDD Nanoparticle|BikDD Nanoparticle starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
62024957|NCT02160873|EXPERIMENTAL|chocolate milk|In this arm, subjects receive chocolate milk
62797548|NCT01564563|PLACEBO_COMPARATOR|Placebo|
62797549|NCT01564563|EXPERIMENTAL|Low dose|
62024958|NCT02160873|PLACEBO_COMPARATOR|flavor-matched placebo|In this arm, subjects receive a flavor-matched placebo
62797550|NCT01564563|EXPERIMENTAL|High dose|
62797551|NCT04907474|OTHER|1 Mist|One mist of tropicamide-phenylephrine fixed combination solution administered to each eye with the MAP Dispenser
62797552|NCT04907474|OTHER|2 Mists|Two mists of tropicamide-phenylephrine fixed combination solution administered to each eye with the MAP Dispenser
62024959|NCT06442436|EXPERIMENTAL|Panel A|Participants with moderate hepatic impairment will receive a single oral dose of 25 mg nemtabrutinib on Day 1.
62797553|NCT04406675|OTHER|Patients Amyotrophic Lateral Sclerosis|
62797554|NCT04406675|OTHER|Control subjects|
62416372|NCT06565832|ACTIVE_COMPARATOR|Face-to-Face exercise testing|The One-Minute Sit-to-Stand test and the Chester Step test will be completed face to face at a hospital appointment with the participant and the research team.
62416373|NCT06358859|EXPERIMENTAL|Intervention|The intervention involves regularly distributed fruit and vegetable produce boxes as well as nutrition education materials to the intervention group.
62416374|NCT06358859|NO_INTERVENTION|Control|The control group will receive produce boxes later, after they complete study activities.
62416375|NCT05658731|EXPERIMENTAL|Stratum A (new diagnosis, substructure informed radiation therapy)|Patients will undergo radiation therapy which has been planned according to dose constraints to specific brain substructures.
62797555|NCT02766712|EXPERIMENTAL|CA 1st Half of lesion|During each of the 15 pre-specified lesions, pacing will be initiated at a 500ms cycle length from a catheter in the coronary sinus or right ventricle prior to the start of the lesion. Pacing will be stopped at the halfway point (e.g. after 10 seconds for a 20-second lesion and after 15 seconds for a 30-second lesion). In the event that Wenckebach behavior is noted, pacing will be adjusted to a 550ms cycle length. In the event that Wenckebach behavior persists, the cycle length will be adjusted to 600ms. In the event that Weckebach behavior continues, the pacing catheter will be moved to the right ventricle, which and pacing will be performed at a 500ms cycle length. If Wenckebach behavior still persists, the patient will be withdrawn from the study.
62797556|NCT02766712|EXPERIMENTAL|CA 2nd Half of Lesion|During each of the 15 pre-specified lesions, pacing will be stopped at the halfway point (e.g. after 10 seconds for a 20-second lesion and after 15 seconds for a 30-second lesion). In the event that Wenckebach behavior is noted, pacing will be adjusted to a 550ms cycle length. In the event that Wenckebach behavior persists, the cycle length will be adjusted to 600ms. In the event that Wenckebach behavior persists, the pacing catheter will be moved to the right ventricle and pacing will be performed at a 500ms cycle length. If Wenckebach behavior still persists, the patient will be withdrawn from the study.
62797557|NCT04909866|EXPERIMENTAL|TACE+Lenvatinib+Camrelizumab|
62416376|NCT05658731|OTHER|Stratum B (patients ≥ 2 years after standard radiation therapy)|Patients who completed radiation therapy under standard planning procedures ≥ 2 years ago.
62416377|NCT05658731|OTHER|Stratum C (healthy controls matched to Stratum A)|Healthy patients who are matched to Stratum A patients
62416378|NCT06699771|EXPERIMENTAL|Phase 1a Dose Escalation and Phase 1b Dose Expansion|Dose Confirmation of GCC2005 in Relapsed or Refractory NK and T-cell Malignancies
62221996|NCT03224351|PLACEBO_COMPARATOR|Part 3: Placebo|Participants received placebo matched to VX-659/TEZ/VX-561 in TC treatment period for 4 weeks.
62221997|NCT03224351|EXPERIMENTAL|Part 3: VX-659/TEZ/VX-561 TC|Participants received VX-659 400 mg qd/TEZ 100 mg qd/VX-561 200 mg qd in TC treatment period for 4 weeks.
62221998|NCT03112564|OTHER|Sevoflurane 8% + Intravenous fentanyl|Avoidance of rocuronium/cisatracurium
62221999|NCT02813629|ACTIVE_COMPARATOR|SS-tDCS (active) plus PES (active)|tDCS plus PES (n=15).
62222000|NCT02813629|ACTIVE_COMPARATOR|SS-tDCS (active) plus PES (simulated)|tDCS plus PES (n=15).
62222001|NCT02813629|ACTIVE_COMPARATOR|SS-tDCS (simulated) plus PES (active)|tDCS plus PES (n=15).
62222002|NCT02813629|SHAM_COMPARATOR|SS-tDCS (simulated) plus PES (simulated)|tDCS plus PES (n=15).
62416379|NCT06463886|EXPERIMENTAL|STEP-AD|"Participants in this arm will receive the manualized 10 session behavioral medicine intervention titled Striving Towards EmPowerment and Medication Adherence. Participants will be in this group for a total of up to 1.5 years."
62416380|NCT06463886|ACTIVE_COMPARATOR|Enhanced treatment as usual|Participants in the comparison condition will also complete 10 in person sessions. The first session will consist of a session on healthy living with HIV. The remaining 9 sessions will consist of neutral (daily events) writing. Participants will be in this group for a total of up to 1.5 years.
62588216|NCT04447352|EXPERIMENTAL|Arm B - FLOT/HIPEC|"Patients randomized to treatment Arm B already received 3-6 cycles of FLOT in 2-week treatment cycles prior to undergoing surgery including Intraoperative Hyperthermic IntraPEritoneal Chemoperfusion (HIPEC) during gastric-/ esophagogastric resection using Cisplatin 75mg/m². Following surgery, patients will receive four further 2-week cycles FLOT. FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.~FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m²."
62416381|NCT05465044|EXPERIMENTAL|Twice-Weekly Hemodialysis|Twice-weekly hemodialysis with incremental crossover to thrice-weekly hemodialysis as indicated
62416382|NCT05465044|PLACEBO_COMPARATOR|Thrice-Weekly Hemodialysis|Outright thrice-weekly hemodialysis without option to switch to less frequent dialysis schedule
62588217|NCT02513498|EXPERIMENTAL|Treatment (ixazomib citrate)|Patients receive ixazomib citrate PO once weekly on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response, partial response, or stable disease may receive an additional 6 courses of ixazomib citrate.
62588218|NCT01937910|EXPERIMENTAL|Stroke Group|Participants in the stroke group will complete 10 training sessions of the TRAIT task.
62222003|NCT02813629|ACTIVE_COMPARATOR|SC-tDCS (active) plus PES (active)|tDCS plus PES (n=15).
62222004|NCT02813629|ACTIVE_COMPARATOR|SC-tDCS (active) plus PES (simulated)|tDCS plus PES (n=15).
62222005|NCT02813629|ACTIVE_COMPARATOR|SC-tDCS (simulated) plus PES (active)|tDCS plus PES (n=15).
62416383|NCT06149624|PLACEBO_COMPARATOR|control|participants randomized to control group
62416384|NCT06149624|EXPERIMENTAL|Intervention group|participants randomized to intervention group
62416385|NCT05109416|ACTIVE_COMPARATOR|Group A|Children will receive bupivacaine 0.5% ( 1 mg / kg ) ,divided in each side , by infiltration through anterior and posterior approaches to block glossopharyngeal nerve
62416386|NCT05109416|PLACEBO_COMPARATOR|Group B|Children will receive sterile saline 0.9 , 5 cm in each side , by infiltration through anterior and posterior approaches
62588219|NCT01937910|ACTIVE_COMPARATOR|Matched Healthy Control Group|Participants in the Matched Healthy Control group will complete 10 sessions of the TRAIT task
62588220|NCT05627674|ACTIVE_COMPARATOR|Usual Care|Annual lung cancer screening with low-dose computed tomography (LDCT) is currently recommended in the U.S. for at-risk patients. Tobacco treatment and cessation is recommended for patients who smoke.
62222006|NCT02813629|SHAM_COMPARATOR|SC-tDCS (simulated) plus PES (simulated)|tDCS plus PES (n=15).
62222007|NCT00825916|EXPERIMENTAL|High Dose|
62222008|NCT00825916|PLACEBO_COMPARATOR|Placebo|
62222009|NCT00825916|EXPERIMENTAL|Low Dose|
62222010|NCT04374851|EXPERIMENTAL|New Device|The new Hearing aid is essentially the same as the current device (i.e., hardware, use) but with an improved digital signal processing (DSP).
62222011|NCT04374851|ACTIVE_COMPARATOR|Current Device|The current device is the Hearing aid that is currently sold on the market. It is used as a normal Hearing aid that is worn daily to amplify sounds for Hearing-impaired people.
62416387|NCT03370393|EXPERIMENTAL|Pathways for African-Americans' Success|Subjects will complete a 6-week Pathways for African-Americans' Success (PAAS) intervention. This is a weekly, 1.5 hour/session, family intervention for 6 weeks.
62416388|NCT03370393|NO_INTERVENTION|Wait-list|Subjects will be on waiting list for active intervention and will receive the PAAS intervention at the end of the study (same as active intervention).
62416389|NCT03212443|SHAM_COMPARATOR|Group A|In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
62416390|NCT03212443|ACTIVE_COMPARATOR|Group B|In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
62588221|NCT05627674|EXPERIMENTAL|RiskProfile-Clin|RiskProfile-Clin is a clinically-informed risk feedback tool to activate cancer risk-reducing behaviors.
62588222|NCT05627674|EXPERIMENTAL|RiskProfile-Gen|RiskProfile-Gen is a genetically-informed risk feedback tool to activate cancer risk-reducing behaviors.
62588223|NCT02336360|EXPERIMENTAL|Urine Analysis|Urine will be collected from subjects administered flortaucipir in an Avid-sponsored study to determine the amount of radioactivity excreted in urine.
62588224|NCT03452488|PLACEBO_COMPARATOR|Placebo|Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
62588225|NCT03452488|EXPERIMENTAL|175mg BIO101|BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
62416391|NCT02803138||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablets; 1000 or 1200 mg divided twice a day) up to 24 weeks
62416392|NCT06416527|PLACEBO_COMPARATOR|Pompage and photobiomodulation (placebo)|(1) Pompage Group + photobiomodulation placebo (Control): Patients will receive treatment through the application of the pompage technique in the cervical region during 10 sessions performed 3 times per week, excluding weekends.
62416393|NCT06416527|EXPERIMENTAL|Pompage + photobiomodulation (Experimental)|(2) Pompage + photobiomodulation (PBM) Group (Experimental): Treatment will consist of 10 sessions in which the pompage technique will be applied associated with photobiomodulation in the form of LED cluster in the cervical region, performed 3 times per week, excluding weekends.
62797558|NCT01083823|ACTIVE_COMPARATOR|Self-reported mood swings|Participants who self-identify as experiencing severe mood swings that interfere with life.
62024960|NCT06442436|EXPERIMENTAL|Panel B|Healthy control participants will receive a single oral dose of 25 mg nemtabrutinib on Day 1.
62797559|NCT01083823|ACTIVE_COMPARATOR|Healthy|Participants who self-identify as not experiencing mood swings in the past or at present and who deny past / present problems with substance use.
62797560|NCT00437424|EXPERIMENTAL|1|
62024961|NCT00695331|EXPERIMENTAL|1|Titrated Oral Misoprostol Solution
62024962|NCT00695331|ACTIVE_COMPARATOR|2|Intravenous Oxytocin
62024963|NCT06635057|EXPERIMENTAL|Tirzepatide|Participants will receive tirzepatide subcutaneously (SC)
62024964|NCT04045457|OTHER|SIngle arm|Single arm, intervention All recipients were treated with dry needling technique into active myofascial trigger points They received 1 treatment weekly for three weeks.
62024965|NCT04576208|EXPERIMENTAL|Cohort 1|TAK-788 160 mg, capsules, orally, once daily (QD) with or without a low-fat meal until disease progression or as assessed by the investigator during every 3-week cycle.
62222012|NCT02258308|EXPERIMENTAL|CHW intervention|"The CHW intervention is in-home education and support by a community health worker (CHW). At the first home visit, the CHW assesses the participant's knowledge and skills related to asthma self-management, current status of the child's asthma, and resources and support for asthma self-management using a baseline questionnaire. The CHW will inspect the home environment using an Environmental Home Checklist to identify environmental triggers that can cause asthma symptoms and affect asthma control. The CHW makes up to three follow-up visits and two telephone visits during the year the participant is in the study. Participants receive resources to help them control asthma: vacuum cleaner, dust covers for a pillow and mattress and a green cleaning kit with cleaning supplies."
62222013|NCT02258308|NO_INTERVENTION|control|The control group receives standard asthma care, as provided by a primary health care provider. When the intervention period is over, the control group receives one visit with a CHW and the resources provided to the intervention group participants.
62222014|NCT02003573|EXPERIMENTAL|volasertib + decitabine|dose escalation and MTD (Maximum Tolerated Dose) Extension (Note: Decitabine is a Backbone Treatment and Volasertib is Investigational Medicinal Product (IMP))
62416394|NCT05659264|EXPERIMENTAL|SAD Stage: mRNA-0184|Participants will receive a single dose of mRNA-0184.
62416395|NCT05659264|EXPERIMENTAL|MAD Stage: mRNA-0184|Participants will receive up to 4 doses of mRNA-0184 administered over a treatment period of up to 16 weeks.
62416396|NCT05659264|PLACEBO_COMPARATOR|MAD Stage: Placebo|Participants will receive placebo matching to mRNA-0184 administered over a treatment period of up to 16 weeks.
62588226|NCT03452488|EXPERIMENTAL|350mg BIO101|BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
62797561|NCT05984706||Trauma-exposed children and adolescents|Focus group and Delphi survey
62797562|NCT05984706||Caregivers of trauma-exposed children and adolescents|Focus group and Delphi survey
62797563|NCT05984706||Clinical experts|Delphi survey
62797564|NCT04112303|EXPERIMENTAL|SOF/VEL|Participants received SOF/VEL (400/100 mg) orally once daily for up to 12 weeks.
62797565|NCT06725654||Institutionalized Orphan Children Residing in Children's Homes|Institutionalized orphan children reside in children's homes in Sivas, Turkey.
62797566|NCT03121365|ACTIVE_COMPARATOR|Standard/Board Book Arm|Parent-infant dyads randomized to the standard/board book arm will receive developmentally appropriate early reader board books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
62797567|NCT03121365|EXPERIMENTAL|Digital/E-Book Arm|Parent-infant dyads randomized to the digital/e-book arm will receive developmentally appropriate e-books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
62797568|NCT05114408|EXPERIMENTAL|Trimodal prehabilitation|Patients qualified for elective surgery that meet criteria for prehabilitation
62797569|NCT06530199|ACTIVE_COMPARATOR|control group|Simplified papilla preservation flap with enamel matrix derivative will be performed
62797570|NCT06530199|EXPERIMENTAL|Test group|Simplified papilla preservation flap with connective tissue graft and enamel matrix derivative will be performed
62024966|NCT04576208|EXPERIMENTAL|Cohort 2|TAK-788 160 mg, capsules, orally, QD with or without a low-fat meal and antidiarrheal prophylaxis administered during the first 8 weeks of treatment until disease progression or as assessed by the investigator during every 3-week cycle.
62024967|NCT06139575|EXPERIMENTAL|Lutetium Lu 177 JH020002 Injection|
62024968|NCT06559488|EXPERIMENTAL|Bevacizumab Intravitreal|Ten patients underwent pars plana vitrectomy under local anesthesia. Vitrectomy used 3 23-gauge sclerotomies, triamcinolone for hyaloid cleaning, and hemostasis by elevated pressure, endo-diathermy, or laser. Panretinal laser applied to unlasered retina. Retina examined for tears or bleeding. IOP set at 20mmHg, sclerotomies sutured if needed. Post-vitrectomy, 1.25 mg bevacizumab injected via 30-gauge needle in superotemporal or inferotemporal pars plana.
62024969|NCT06559488|EXPERIMENTAL|Control|Eight patients underwent pars plana vitrectomy under local anesthesia. Vitrectomy used 3 23-gauge sclerotomies, triamcinolone for hyaloid cleaning, and hemostasis by elevated pressure, endo-diathermy, or laser. Panretinal laser applied to unlasered retina. Retina examined for tears or bleeding. IOP set at 20mmHg, sclerotomies sutured if needed.
62024970|NCT04906200|EXPERIMENTAL|Group A (YES portal)|Patients receive access to YES portal for 9 months. Patients also complete surveys at baseline and 3, 6, and 9 months.
62024971|NCT04906200|ACTIVE_COMPARATOR|Group B (usual care)|Patients receive usual care for 9 months. Patients also complete surveys at baseline and 3, 6, and 9 months. After 9 months, patients may also receive access to YES portal for 3 months.
62024972|NCT00086346|ACTIVE_COMPARATOR|A|
62024973|NCT00086346|ACTIVE_COMPARATOR|B|
62024974|NCT02216331|EXPERIMENTAL|Group 1 TMC207 alone|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 1.
62024975|NCT02216331|EXPERIMENTAL|Group 1 TMC207 and rifapentine|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 29 and 600 mg of rifapentine administered as 4 tablets of 150 mg per tablet on each of Study Days 20-41.
62024976|NCT02216331|EXPERIMENTAL|Group 2 TMC207 alone|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 1.
62024977|NCT02216331|EXPERIMENTAL|Group 2 TMC207 and rifampicin|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 29 and 600 mg of rifampicin administered as 4 capsules of 150 mg per capsule on each of Study Days 20-41.
62024978|NCT01344460|EXPERIMENTAL|Arm 1|
62024979|NCT06114420||patients with local recurrence|
62024980|NCT06114420||patients without local recurrence|
62588227|NCT06375993|EXPERIMENTAL|ADI-001 Dose Escalation|ADI-001 is administered via infusion with ascending dose levels as a single dose to determine the maximum tolerated dose (MTD) or maximum assessed dose (MAD) of ADI-001.
62024981|NCT03339076|OTHER|For a single-arm trial|"Inclusion Criteria with intervention replacing either a foley catheter or self intermittent catheter with the M3 Mini Catheter~1. Males \> 50 years of age~2. Signed subject informed consent~3. Patients with actual urinary retention dependent on Foley Catheter or Intermittent Catheter~4. Inclusion will start once the M3 is placed and a functioning bladder is demonstrated.~Exclusion Criteria~1. Inability to undergo bladder catheterization with the M3 due to anatomical challenges (i.e. urethral stricture, bladder neck contracture, false passage or false passages or other history of urethral stricture)~2. Gross hematuria~3. Hypotonic Neurogenic Bladder (the placement of the M3 may isolate the cause of the retention with the bridging of the prostate as bladder dysfunction rather than prostate obstruction)."
62024982|NCT04218929|EXPERIMENTAL|Study Formula (SF)|New infant formula for term infants
62024983|NCT04218929|ACTIVE_COMPARATOR|Comparator Formula (CF)|Commercially available infant formula for term infants
62588228|NCT06375993|EXPERIMENTAL|ADI-001 Dose Extension|After dose level has been declared safe, additional patients can be enrolled at the declared safe dose to further investigate the safety profile of ADI-001.
62588229|NCT06375993|EXPERIMENTAL|ADI-001 Dose Expansion|Dose Expansion ADI-001 is administered via infusion at the MTD/MAD to confirm recommended phase 2 dose (Part 2).
62797571|NCT04359914||NCoV-A-COVID|"* adult patients of every age~* admission to hospital with suspected COVID-19 disease~* confirmed SARS-CoV-2 infection within 48 hours after admission"
62024984|NCT04218929|NO_INTERVENTION|Human Milk Reference Group|Human milk
62024985|NCT04529213|EXPERIMENTAL|Tooth tissue-borne (KBME) expander|In this tooth tissue-borne appliance, the occlusal surfaces of the molar and premolar teeth and half of the palatinal and buccal surfaces are covered with heat polymerized acrylic. Hyrax expansion screw is in the midline, as far as possible to the palate positioned close and parallel
62024986|NCT04529213|EXPERIMENTAL|Tooth-borne (Hyrax) expander|In this tooth-borne expansion appliance, orthodontic bands are placed on the right and left 1st premolar and 1st molar teeth of the patients and the bands are soldered to the Hyrax expansion screw. The expansion screw is in the midline, as far as possible to the palate positioned close and parallel
62024987|NCT04529213|EXPERIMENTAL|Bone-borne (MIDME) expander|This bone-borne expander includes 2 mini-screws with a diameter of 1.6 mm and a length of 10 mm on the right and left sides, coinciding between the roots of the 2nd premolar and 1st molar teeth in addition to the hyrax expansion screw.
62222015|NCT03339700|EXPERIMENTAL|Unique|Patients will receive reduced Busulfan and Cyclophosphamide (BUCY 2) conditioning regimen, consisting in the administration of two medications: Busulfan and Cyclophosphamide Plus: Gemcitabine. Then patients will undergo an Allogeneic Hematopoietic Stem Cell Transplantation.
62222016|NCT04802798|EXPERIMENTAL|Placebo, Fibre 1, Fibre 2|All three interventions will be provided in a randomized double-blind order. The interventions will consist of 8 grams per day of three different types of powdered food supplement that will be mixed with water and consumed for a 7-day period. The powdered food supplement will be either placebo (glucose), fibre 1 (derived from a plant-based food) or fibre 2 (derived from a different plant-based food).
62222017|NCT04802798|EXPERIMENTAL|Placebo, Fibre 2, Fibre 1|All three interventions will be provided in a randomized double-blind order. The interventions will consist of 8 grams per day of three different types of powdered food supplement that will be mixed with water and consumed for a 7-day period. The powdered food supplement will be either placebo (glucose), fibre 1 (derived from a plant-based food) or fibre 2 (derived from a different plant-based food).
62222018|NCT05829356|EXPERIMENTAL|Group 1: H3 mRNA /LNP dose 1|Participants will receive one intramuscular (IM) dose of H3 mRNA/LNP at Day 01
62222019|NCT05829356|EXPERIMENTAL|Group 2: H3 mRNA /LNP dose 2|Participants will receive one IM dose of H3 mRNA/LNP at Day 01
62222020|NCT05829356|EXPERIMENTAL|Group 3: H3 mRNA /LNP dose 3|Participants will receive one IM dose of H3 mRNA/LNP at Day 01
62222021|NCT05829356|EXPERIMENTAL|Group 4: H3 mRNA /LNP dose 4|Participants will receive one IM dose of H3 mRNA/LNP at Day 01
62222022|NCT05829356|EXPERIMENTAL|Group 5: H3 mRNA /LNP dose 5|Participants will receive one IM dose of H3 mRNA/LNP at Day 01
62222023|NCT05829356|ACTIVE_COMPARATOR|Group 6 (Control Group): RIV4 dose|Participants will receive one IM dose of RIV4 at Day 01
62416397|NCT02922439|EXPERIMENTAL|Tailored Intervention|Individuals will interact with a chronic disease self-management application that provides information tailored to age, race, language (English or Spanish) and level of health literacy.
62416398|NCT02922439|ACTIVE_COMPARATOR|Control|Individuals will interact with a chronic disease self-management application that provides the same information as the experimental intervention but is not personally tailored to level of health literacy.
62797572|NCT04359914||NCoV-A-CONTROL|"* adult patients of every age~* admission to hospital with suspected COVID-19 disease~* exclusion of SARS-CoV-2 infection within 48 hours after admission"
62797573|NCT04359914||NCoV-P-COVID|"* pediatric patients~* admission to hospital with suspected COVID-19 disease~* confirmed SARS-CoV-2 infection within 48 hours after admission"
62222024|NCT06183957|EXPERIMENTAL|hydrotherapy group|When women in this group are taken to their labor rooms (when the dilation is 4-5cm), they should be standing or standing, depending on their preferences, on their waist, abdomen or whole body, with the temperature of the water between 32-37 °C (the temperature preferred by the woman will be applied) for at least 20 minutes. Sitting shower application will be performed under the observation of the researcher midwife. The temperature of the flowing water will be measured with a bucket and a thermometer that helps evaluate the temperature. The application will be repeated when the dilation is 6-8 cm.
62222025|NCT06183957|NO_INTERVENTION|Control group|Women in this group will not undergo any treatment other than routine hospital protocol (midwifery care). Additionally, the vital signs (blood pressure, pulse) of the participants will be measured and recorded hourly by the midwife. These data will be recorded in each participant's file.
62222026|NCT03058835|EXPERIMENTAL|PrEP with Truvada|All study participants will be assigned to this arm and will receive Truvada tablets (tenofovir disoproxil and emtricitabine) for PrEP
62222027|NCT05900687|NO_INTERVENTION|Focus Group (Aim 1)|Participants give feedback about day-to-day challenges with GERD.
62222028|NCT05900687|NO_INTERVENTION|Focus Group (Aim 2)|Participants give feedback about mobile health app prototype
62797574|NCT04359914||NCoV-P-CONTROL|"* pediatric patient~* admission to hospital with suspected COVID-19 disease~* exclusion of SARS-CoV-2 infection within 48 hours after admission"
62222029|NCT05900687|EXPERIMENTAL|mHealth app (Aim 3)|Participants will be exposed to an app-based question prompt list with gamification features to promote medication adherence as part of their communication with their health provider.
62416399|NCT06521138|EXPERIMENTAL|Motivational interviewing group|Antenatal and postnatal motivational interviewing based on the transtheoretical model will be applied.
62416400|NCT06521138|OTHER|Control group|The control group receiving routine care.
62416401|NCT05166512|ACTIVE_COMPARATOR|Standard DPP|Standard DPP (over 12 months)
62797575|NCT05922189|EXPERIMENTAL|SBS Decompression Technique|The technique was preformed until the investigator felt a relaxation of the structures, with a maximum duration of 5 minutes.
62797576|NCT05922189|PLACEBO_COMPARATOR|Placebo Technique|The technique was preformed during 2 minutes.
62797577|NCT00783614|ACTIVE_COMPARATOR|1|Start antiretroviral therapy (ART) immediately and initiate aspirin 325mg po daily
62797578|NCT00783614|PLACEBO_COMPARATOR|2|Start antiretroviral therapy (ART) immediately and initiate placebo pill daily
62797579|NCT00783614|ACTIVE_COMPARATOR|3|Defer antiretroviral therapy (ART) for 1 month and immediately initiate aspirin 325mg po daily
62797580|NCT00783614|PLACEBO_COMPARATOR|4|Defer antiretroviral therapy (ART) for 1 month and immediately initiate placebo pill daily
62416402|NCT05166512|EXPERIMENTAL|DPP Cooks|Standard DPP plus DPP Cooks (over 12 months, with 6 active cooking sessions during the first 4 months)
62416403|NCT06563492|ACTIVE_COMPARATOR|EVA INSOLES|
62416404|NCT06563492|ACTIVE_COMPARATOR|3D INSOLES|
62797581|NCT00718510|ACTIVE_COMPARATOR|L-arginine first/placebo second|Patients with diagnosis of schizophrenia will be randomised to receive L-arginine first/placebo second 3 grams bid (cross-over design) in addition to treatment as usual. The active treatment period will be 3 weeks, with a wash-out period of 5 days and re-commencing on the alternative arm of the randomization
62588230|NCT05328206||Standard of care for intubated children with a cuffed endotracheal tube (c-ETT)|
62024988|NCT05115162|EXPERIMENTAL|elerehablitation home exercise group|"Telerehabilitation home exercise group received indoor walking and general exercise program for 6 weeks.~Indoor walking was performed 3 days a week, for 30 minutes. General exercise program was consisted of flexibility, strengthening the shoulder and trunk muscles, bridge exercises, lying on the back, cycling and squatting exercises. All of the general exercises were repeated 3 days a week, 2 sets and each set with 10 repetitions.~Two synchronized exercise education sessions were performed with the exercise group. In the first of these sessions, the content of the exercise program was explained. In the second, it was checked whether the exercises were done correctly. After synchronous education sessions, an asynchronous home exercise program, consisting walking and general exercise program continued for 6 weeks."
62024989|NCT05115162|NO_INTERVENTION|Control Group|This group did not participate in any exercise program for 6 weeks.
62797582|NCT00718510|PLACEBO_COMPARATOR|Placebo first/L-arginine second|Patients with diagnosis of schizophrenia will be randomised to receive placebo first/L-arginine second 3 grams bid (cross-over design) in addition to treatment as usual. The active treatment period will be 3 weeks, with a wash-out period of 5 days and re-commencing on the alternative arm of the randomization
62024990|NCT00587873|EXPERIMENTAL|1|MTX, 6-TG, and Leucovorin combination
62024991|NCT00244738|ACTIVE_COMPARATOR|Intervention|Patients who received castor oil for labor induction
62797583|NCT05149534|EXPERIMENTAL|Active TMS/WET|Active repetitive transcranial magnetic stimulation completed prior to written exposure therapy
62797584|NCT05149534|SHAM_COMPARATOR|Sham TMS/WET|Sham repetitive transcranial magnetic stimulation completed prior to written exposure therapy
62797585|NCT00488540|ACTIVE_COMPARATOR|Paracetamol (Acetaminophen)|Paracetamol (Acetaminophen) given at 2 and 8 hours post birth, measurement of EDIN-Score on day one of life, measurement of stress response after Guthrie-test on day 4 of life.
62416405|NCT04877535|EXPERIMENTAL|Intervention|ML will be used to create a report card for each patient that summarizes the preoperative assessment and intraoperative data. Report card data will be made available to providers through multiple methods: integration into electronic health records workflows, electronic health records notifications, mobile device notifications, and print outs in the paper chart
62797586|NCT00488540|PLACEBO_COMPARATOR|Placebo|Placebo given at 2 and 8 hours post birth, measurement of EDIN-Score on day one of life, measurement of stress response after Guthrie-test on day 4 of life.
62797587|NCT05940701|EXPERIMENTAL|intervention group|The intervention group will receive Curasept toothpaste with instructions and additionally at each visit a Curasept Biosmalto Mousse will be applied on the facial surface of the maxillary and mandibular anterior teeth using a tray.
62797588|NCT05940701|PLACEBO_COMPARATOR|control group|The control group will receive a fluoridated toothpaste (Colgate toothpaste) and instructed to brush at least three times/day.
62797589|NCT05309902|EXPERIMENTAL|Sequence 1: (Regimen A + Regimen B + Regimen C + Regimen D)|Regimen A (soticlestat 300 milligram \[mg\] tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen C (soticlestat placebo-matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 4.
62024992|NCT00244738|PLACEBO_COMPARATOR|Control|Patients who received sunflower oil as a placebo
62024993|NCT03674229|ACTIVE_COMPARATOR|Group I (information about weight management programs)|Participants receive information about commercially-available weight management programs and encouragement to participate in one of the programs for 6 months.
62024994|NCT03674229|EXPERIMENTAL|Group II (information, call from patient navigator)|Participants receive information about commercially-available weight management programs encouragement to participate in one of the programs for 6 months. Participants also receive 6 phone calls over 20-30 minutes each from an assigned patient navigator for 6 months.
62024995|NCT05059691||Observational (transbronchial cryobiopsy)|Patients undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy. Patients' medical records are also reviewed.
62588231|NCT04540341|EXPERIMENTAL|Mulligan mobilization group|Painless movement
62222030|NCT05900687|NO_INTERVENTION|Standard of care (Aim 3)|Participants will be exposed to standard of care communication with their health provider (no mHealth app).
62222031|NCT03710031||HSCT Survivors|PNS tracking will occur through blood and stool samples to track the interplay among psychoneurologic symptoms (PNS) as they relate to diminished QOL among survivors of HSCT.
62222032|NCT04399070|PLACEBO_COMPARATOR|Propofol group|patients were treated with propofol 1 mg/kg and saline bolus infusion before ECT
62222033|NCT04399070|ACTIVE_COMPARATOR|Ketamine group|patients were treated with propofol 1 mg/kg and ketamine 0.5 mg/kg bolus infusion before ECT
62222034|NCT04399070|EXPERIMENTAL|S-ketamine group|patients were treated with propofol 1 mg/kg and S-ketamine 0.25 mg/kg bolus infusion before ECT
62222035|NCT01178385|EXPERIMENTAL|Cognitive-behavioral therapy|Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
62222036|NCT01178385|ACTIVE_COMPARATOR|Treatment as Usual|Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
62797590|NCT05309902|EXPERIMENTAL|Sequence 2: (Regimen B + Regimen D + Regimen A + Regimen C)|Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen A (soticlestat 300 mg tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen C (soticlestat -matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition once on Day 1 of Treatment Period 4.
62222037|NCT01449136|EXPERIMENTAL|antibacterial cement|
62222038|NCT04580342|EXPERIMENTAL|Ivabradine group|
62222039|NCT04580342|EXPERIMENTAL|propranolol group|
62222040|NCT06610812|EXPERIMENTAL|KETOGENIC MEDITERRANEAN diet|It was consist of 20 adolescent females suffering from polycystic ovary disease. they received ketogenic Mediterranean diet program for 3 months with moderate aerobic exercises in the form of walking from 30 to 45 minutes a day, 3 times per week for 3 months.
62222041|NCT06610812|EXPERIMENTAL|HYPOCALORIC BALANCED DIET|It was consist of 20 adolescent females suffering from polycystic ovary disease. they received hypo-caloric balanced diet program for 3 months with moderate aerobic exercises in the form of walking from 30 to 45 minutes a day, 3 times per week for 3 months.
62222042|NCT03116737|EXPERIMENTAL|Benzocaine Otic Solution|
62416406|NCT04877535|NO_INTERVENTION|Pre-intervention|The standard of care. The report card will be electronically generated (to determine eligibility) but it will not be visible to clinicians.
62222043|NCT03116737|PLACEBO_COMPARATOR|Placebo|
62416407|NCT01947257|OTHER|ventilated patients|
62416408|NCT00983255|EXPERIMENTAL|SAD/ Part A|Single IV infusions of placebo or TR-701 FA given at 50, 100, 200, and 400 mg.
62416409|NCT00983255|EXPERIMENTAL|MAD / Part B|Multiple IV infusion of placebo or TR-701 FA given daily for 7 days at 200 and 400 mg.
62416410|NCT00983255|EXPERIMENTAL|Bioavailability / Part C|TR-701 FA tablet given once orally as a 200 mg tablet or TR-701 FA for injection given once as a 200 mg IV infusion.
62416411|NCT00983255|EXPERIMENTAL|Venous Tolerability/ Part D|IV infusions of placebo and 200 mg TR-701 FA given daily for 3 days,
62416412|NCT06565637|EXPERIMENTAL|Psychotherapy|Participants in this arm will experience the PRIDE intervention. PRIDE is a 14-session treatment that incorporates aspects of cognitive behavioral therapy for eating disorders (CBT-E) and SM-affirmative therapy. CBT-E aspects of treatment include in-session weighing, self-monitoring (food logs), regular eating, and techniques to address overvaluation of weight and shape. SM-affirmative therapy techniques include discussing the impact of minority stress on health, resilience, and strength within the SM community, specific manifestations of minority stress on eating and body image, current coping strategies, emotion regulation skills, and developing mindful, present-focused reactions to minority stress.
62222044|NCT00309296|EXPERIMENTAL|Longitudinal Care|One year of combined behavioral and pharamcological tobacco dependence treatment, with interim smoking reduciton for smokers who fail initial quit attempt.
62222045|NCT00309296|ACTIVE_COMPARATOR|Usual Care|Evidence based, state-of-the-science tobacco treatment; combined behavioral and pharmacological treatment for 8 weeks
62222046|NCT03896204|EXPERIMENTAL|telephone-supported group|
62222047|NCT03896204|EXPERIMENTAL|Other group|
62222048|NCT06610500||Population 1|Patients treated and stabilised by clozapine in the active queue of Medical-Psychological Center (CMP) of St-Etienne
62222049|NCT06610500||Population 2|Liberal psychiatrists practising in the Loire department, and hospital psychiatrists
62222050|NCT06610500||Population 3|Pharmacists practising in community pharmacies dispensing clozapine to patients, hospital Pharmacists in the Loire
62416413|NCT01480882|ACTIVE_COMPARATOR|Conventional Chest PhysioTherapy|Conventional Chest Physiotherapy (CCPT) is delivered by professional physiotherapist for 15 minutes.
62416414|NCT01480882|EXPERIMENTAL|Mechanical percussion|"Mechanical percussion will be delivered by a device called LEGA for 15 minutes"
62588232|NCT04540341|EXPERIMENTAL|Core stabilization group|Abdominal drawing-in maneuver
62222051|NCT04974242|EXPERIMENTAL|Physiotherapist-led exercise|Structured and progressive physiotherapist-led exercise programme. Reflective of current guidance for exercise programmes for people with rotator cuff disorders, an individualised programme developed in relation to the participant's specific goals will be prescribed by the physiotherapist and supported over approximately six contact sessions across a 12-week period.
62222052|NCT04974242|NO_INTERVENTION|Waiting-list control|Continue on the waiting list for rotator cuff repair surgery, as per usual care.
62222053|NCT04881552||Group 1|non-spontaneous reperfusion group at initial emergency coronary angiography (TIMI flow grade 0-II)
62024996|NCT04841057|EXPERIMENTAL|Standard BP limb length|50 cm BP limb length
62024997|NCT04841057|EXPERIMENTAL|Medium BP limb length|100 cm BP limb length
62222054|NCT04881552||Arm 2|spontaneous reperfusion group at initial emergency coronary angiography (TIMI flow grade III)
62222055|NCT00653445|EXPERIMENTAL|1|Rosuvastatin 40mg/Ezetimibe 10mg combination therapy
62222056|NCT00653445|EXPERIMENTAL|2|Rosuvastatin 40 mg
62222057|NCT05057845|EXPERIMENTAL|Cryoablation in combination with Tislelizumab plus lenvatinib|
62222058|NCT03725085|EXPERIMENTAL|Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)|"2 tablets of Mucinex™ (GGE, 600 mg ER bi-layer tablets, taken as 1200 mg BID dose) every 12 hours (twice daily, in the morning and the evening) orally with a full glass of water for 7 days.~GGE = Guaifenesin~BID = Twice in a day"
62222059|NCT00271518|EXPERIMENTAL|LB03002, sustained release human hGH|LB03002
62222060|NCT04894110|EXPERIMENTAL|EO2002 treatment - Group 1|
62222061|NCT04894110|ACTIVE_COMPARATOR|EO2002 treatment - Group 2 - low dose|
62222062|NCT04894110|ACTIVE_COMPARATOR|EO2002 treatment - Group 2 - mid dose|
62222063|NCT04894110|ACTIVE_COMPARATOR|EO2002 treatment - Group 2 - high dose|
62416415|NCT02417207|SHAM_COMPARATOR|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 \~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
62222064|NCT02892786|EXPERIMENTAL|experimental|
62222065|NCT01877473|ACTIVE_COMPARATOR|Reverse remodeling|Pretreatment with dofetilide or sotalol and restoration of sinus rhythm followed by PVI only ablation
62222066|NCT01877473|ACTIVE_COMPARATOR|Standard ablation|PVI ablation with additional CFAE and/or linear LA ablation
62222067|NCT02439073|EXPERIMENTAL|early initiated rehabilitation|A supervised 12-week rehabilitation program, initiated two weeks post surgery, containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.
62222068|NCT02439073|ACTIVE_COMPARATOR|late initiated rehabilitation|A supervised 12-week rehabilitation program, initiated 14 weeks post surgery, containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.
62222069|NCT05010837|EXPERIMENTAL|Kinesio taping with abdominal exercises|Kinesio taping will be applied along with abdominal exercises.
62024998|NCT04841057|EXPERIMENTAL|Long BP limb length|150 cm BP limb length
62024999|NCT02948179|EXPERIMENTAL|Preimplantation genetic diagnosis group|ADPKD patients will complete the whole process of preimplantation genetic diagnosis with healthy baby without pathogenic gene inheritance.
62025000|NCT02948179|NO_INTERVENTION|Natural pregnancy group|ADPKD patients, pathogenic mutations in PKD1, have natural pregnancy without preimplantation genetic diagnosis.The investigators will perform genetic tests on the blood or umbilical cord blood of infants born between January 2014 and June 2020.
62222070|NCT05010837|ACTIVE_COMPARATOR|Abdominal Exercises|Only abdominal exercises will be administered to the participants.
62222071|NCT04357197|EXPERIMENTAL|Closed-loop|Closed-loop administration of norepinephrine in critically ill patients
62222072|NCT00297596|EXPERIMENTAL|Intervention|Patients with HER2 positive breast cancer received treatment with oxaliplatin 130 mg/m2 IV day 1 and trastuzumab 6 mg/kg (following 8 mg/kg loading dose during cycle 1). Cycles were repeated every 21 days.
62222073|NCT02844725|EXPERIMENTAL|VVZ-149 injection|VVZ-149 injections will be mixed with saline, then intravenous infusion for 10hr. The drug product will be administrated with a loading dose of 1.8 mg/kg for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h for 9.5 hours.
62222074|NCT02844725|PLACEBO_COMPARATOR|Placebo|Placebo group will receive an water for injection the same volume and period of experimental group.
62222075|NCT02596438||Asian Americans|Foreign born or children of foreign born Asian American from Hepatitis B endemic areas residing in Sacramento, CA.
62222076|NCT01873066|EXPERIMENTAL|Closed-loop insulin delivery|Glucose level is controlled by the automated closed-loop glucose control system. After initial training with the closed-loop system devices, subjects will use the closed-loop system day and night at home for a total duration of 7 days (phase 1) and 21 days (phase 2).
62222077|NCT01873066|ACTIVE_COMPARATOR|real-time CGM alone|Glucose level will be controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM) during the day and night over 7 days (phase 1) and 21 days (phase 2).
62222078|NCT01455493|EXPERIMENTAL|A|
62222079|NCT06012253|EXPERIMENTAL|Home Based Walking Program|Effect of home-based walking program on peripheral neuropathy, fatigue and quality of life
62222080|NCT06012253|NO_INTERVENTION|Control group|"The control group will be given the Ministry of Health Physical Activity Guidelines.Routine care."
62222081|NCT05104281|EXPERIMENTAL|study drug|osimertinib 80 mg, oral daily and bevacizumab 15mg/KG body weight intravenously infusion every 21 days
62222082|NCT02359682||Age 20-39|Patients aged from 20 to 39 years old.
62222083|NCT02359682||Age 40-59|Patients aged from 40 to 59 years old.
62222084|NCT02359682||Age 60-79|Patients aged from 60 to 79 years old.
62025001|NCT03526900|EXPERIMENTAL|Atezolizumab|Induction phase: atezolizumab will be given intravenously (iv) at a dose of 1200 mg for 60 minutes on day 1 of each cycle. Subsequent atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity. Pemetrexed will be administered at a dose of 500 mg/m2 IV for 15 minutes on day 1 of each cycle. In addition, folic acid, vitamin B12, and dexamethasone 4 mg will be given the day before and the day after treatment with pemetrexed. Carboplatin will be given at a dose with an area under the 5 curve for 30 minutes on day 1 of each cycle, approximately 30 minutes after the pemetrexed infusion is complete. After completing 4 to 6 cycles of Carboplatino plus pemetrexed and atezolizumab, patients will continue with pemetrexed in combination with atezolizumab (maintenance phase) until they have an unacceptable toxicity, progression of the disease, decision of the patient/physician or have Completed 2 years of treatment.
62025002|NCT06094153|PLACEBO_COMPARATOR|Placebo|
62025003|NCT06094153|EXPERIMENTAL|HMO 1|
62025004|NCT06094153|EXPERIMENTAL|HMO 2|
62797591|NCT05309902|EXPERIMENTAL|Sequence 3: (Regimen C + Regimen A + Regimen D + Regimen B)|Regimen C (soticlestat placebo-matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen A (soticlestat 300 mg tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 4.
62025005|NCT06485232|EXPERIMENTAL|BCMA CAR-T Group|Universal BCMA CAR-T
62025006|NCT06485232|EXPERIMENTAL|CD19 CAR-T Group|Universal CD19 CAR-T
62025007|NCT06485232|EXPERIMENTAL|BCMA CAR-T + CD19 CAR-T Group|Universal BCMA CAR-T; Universal CD19 CAR-T
62025008|NCT00290823|EXPERIMENTAL|1|Participants will receive 6 mg dexamethasone daily for 10 days Participants will also receive albendazole and omeprazole.
62416416|NCT02417207|ACTIVE_COMPARATOR|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
62416417|NCT03542253||Age|
62416418|NCT03542253||Sex|
62416419|NCT03542253||triglyceride|
62416420|NCT03542253||Lipoprotein|
62416421|NCT03542253||CT|Target Reconstruction
62025009|NCT00290823|EXPERIMENTAL|2|Participants will receive 6 mg dexamethasone daily for 10 days, then 8 mg dexamethasone daily for 4 weeks with a 2-week taper. Participants will also receive albendazole and omeprazole.
62025010|NCT04538014|EXPERIMENTAL|Lu AF88434|
62416422|NCT03542253||micorRNA-A Plasma exocrine|
62416423|NCT03542253||micorRNA-A Paracancerous tiusse|
62416424|NCT03542253||pathologic diagnosis|
62416425|NCT03542253||hemolysis|
62416426|NCT03542253||ct-DNA|
62416427|NCT03542253||micorRNA-A in plasma|
62025011|NCT05903001||Patients with Asthma|
62025012|NCT05903001||Patients with COPD|
62025013|NCT05903001||Patients with Fibrosis|
62025014|NCT05903001||Patients with Pulmonary Hypertension|
62025015|NCT00129987|EXPERIMENTAL|Nurse group|An initial consultation of up to 45 min offered either by a practice based primary care nurse, followed by a second shorter face to face consultation and telephone follow-up for 1 year.
62025016|NCT00129987|EXPERIMENTAL|Lay educator group|An initial consultation of up to 45 min offered either by a lay educator, followed by a second shorter face to face consultation and telephone follow-up for 1 year.
62025017|NCT01118390|EXPERIMENTAL|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
62025018|NCT01118390|ACTIVE_COMPARATOR|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
62025019|NCT03452917|PLACEBO_COMPARATOR|Placebo|2 ml of normal saline (n=500)
62025020|NCT03452917|EXPERIMENTAL|sodium nitrite|45 mg IV of sodium nitrite (n=500) or 60 mg IV sodium nitrite (n=500) given during active resuscitation from out of hospital cardiac arrest.
62025021|NCT03013010|EXPERIMENTAL|Preoperative radiochemotherapy|"1 cycle preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.~5 weeks preoperative chemoradiotherapy.~1 cycle preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.~Gastric resection. 3 cycles adjuvant chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin."
62025022|NCT03013010|ACTIVE_COMPARATOR|Preoperative chemotherapy|"3 cycles preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.~Gastric resection. 3 cycles adjuvant chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin."
62025023|NCT00745927|NO_INTERVENTION|Room air insufflations|Room air will be used for insufflations during colonoscopy
62025024|NCT00745927|ACTIVE_COMPARATOR|CO2 insufflations|CO2 will be used for insufflations during colonoscopy
62025025|NCT03143218|ACTIVE_COMPARATOR|SMC with SP+AQ|Administration of RABIPUR® in Year 1 and Hepatitis A vaccine in Year 2 and 3, followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.
62025026|NCT03143218|ACTIVE_COMPARATOR|RTS,S/AS01|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1,2 and 3.
62416428|NCT03542253||Sample quality control|
62416429|NCT03542253||positive|
62416430|NCT03542253||negative|
62416431|NCT03542253||micorRNA-R in plasma|
62416432|NCT03542253||micorRNA-R in Plasma exocrine|
62416433|NCT03542253||Surgery|
62588233|NCT04540341|ACTIVE_COMPARATOR|conventional therapy group|Ultrasound TENS Hotpack
62797592|NCT05309902|EXPERIMENTAL|Sequence 4: (Regimen D + Regimen C + Regimen B + Regimen A)|Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen C (soticlestat placebo-matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen A (soticlestat 300 mg tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 4.
62797593|NCT05547126|ACTIVE_COMPARATOR|Anodal tDCS + dual-task training|"The anodic electrode (5x5 cm) will be applied to the primary motor area (C3/C4) ipsilateral to the lesion and the reference electrode (6x9 cm) to the deltoid muscle region.~Simultaneously with the tDCS sessions, participants will be submitted a protocol based on motor and cognitive dual-task training. The dual-task training will have a total duration of 20 minutes in each session."
62797594|NCT05547126|ACTIVE_COMPARATOR|tDCS dualsite + dual-task training|"Two active electrodes (5x5 cm) will be used, which will be positioned over the primary motor area (C3/C4) and over the dorsolateral prefrontal cortex (F3 or F4) in the ipsilateral hemisphere. For this stimulation modality, two active electrodes (anodic) and a reference electrode (6x9 cm) will be used on the deltoid muscle region.~Simultaneously with the tDCS sessions, participants will be submitted a protocol based on motor and cognitive dual-task training. The dual-task training will have a total duration of 20 minutes in each session."
62797595|NCT05547126|PLACEBO_COMPARATOR|tDCS sham + dual-task training|"Two electrodes will be used, which will be positioned over the primary motor area (C3/C4) and a reference electrode (6x9 cm) will be used on the deltoid muscle region, however the device will be configured in sham mode.~Simultaneously with the tDCS sessions, participants will be submitted a protocol based on motor and cognitive dual-task training. The dual-task training will have a total duration of 20 minutes in each session."
62797596|NCT04236674|NO_INTERVENTION|No intervention|
62797597|NCT04236674|EXPERIMENTAL|Buzzy|Thermomechanical device for periprocedural analgesia
62797598|NCT04236674|EXPERIMENTAL|Music Selection|Patient specified music selection for procedural room
62797599|NCT04236674|EXPERIMENTAL|Buzzy and Music Selection|A combination of use of the Buzzy device and patient specified music selection
62797600|NCT03348280||Vitamin D Deficient|Type 2 diabetics with high blood pressure and 25-hydroxyvitamin D levels of \<20 ng/ml
62797601|NCT03348280||Vitamin D Sufficient|Type 2 diabetics with high blood pressure and 25-hydroxyvitamin D levels of \>30 ng/ml
62797602|NCT06543888|EXPERIMENTAL|passive exoskeleton- assisted gait training programs|Behavioral: passive exoskeleton- assisted gait training programs Participants will receive 12 sessions of passive exoskeleton-assisted gait training programs (30 min/session, 3 sessions/week for 4 consecutive weeks).
62797603|NCT06543888|ACTIVE_COMPARATOR|conventional gait training programs|Participants will receive 12 sessions of conventional gait training programs (30 min/session, 3 sessions/week for 4 consecutive weeks).
62222085|NCT03624348|EXPERIMENTAL|Meditation Group|Participants in the intervention group will assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
62416434|NCT04160416|EXPERIMENTAL|mXELOXIRI|"Induction therapy is followed by the maintenance therapy. Induction treatment: XELOXIRI+CET/BEV Administered for 6 cycles (a maximum of 8 cycles).Bevacizumab (BEV): 5mg/kg (d.i.v.); Cetuximab 500mg/sq.m (d.i.v.)；Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) Irinotecan (IRI):135 mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-10) Administered every 2 weeks.~Maintenance treatment: CAP+CET/BEV. The following CAP+BEV/CET therapy will be repeated in 2-week cycles."
62416435|NCT04059484|EXPERIMENTAL|Amcenestrant|Daily amcenestrant dose administered orally under fed or fast condition
62416436|NCT04059484|ACTIVE_COMPARATOR|Fulvestrant/Aromatase inhibitors/Estrogen receptor modulator|"Control treatment of the choice of the physician depending on each participant's medical condition and in accordance with the approved label may include 1 of the following treatments used as monotherapy.~Fulvestrant~Aromatase inhibitors (anastrozole, letrozole, exemestane)~Selective estrogen receptor modulator (Tamoxifen)"
62797604|NCT04684069|ACTIVE_COMPARATOR|syringe free long axis in-plane|
62797605|NCT04684069|SHAM_COMPARATOR|Short axis out-of-plane|
62797606|NCT01757106|EXPERIMENTAL|Drug: Xenon|gaseous anesthetic, dosage: 50-60% (v/v) in oxygen, continuous application during surgery
62025027|NCT03143218|ACTIVE_COMPARATOR|RTS,S/AS01 PLUS SMC with SP+AQ|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.
62416437|NCT05992285|EXPERIMENTAL|cTBS group|the intensity of stimulus was 80% Resting motor threshold (RMT); the frequency of trains was 50 Hz and the number of pulses was three; and the frequency of intertrain intervals was 5 Hz and pulses number was 200. Two groups were repeatedly stimulated in the dentate nucleus of bilateral cerebellum, the interval of each group was 5min, and the number of stimulation pulses at each site was 1200.
62416438|NCT05992285|SHAM_COMPARATOR|sham group|The treatment of the sham group was the same as active group. The only difference was that the coil was flipped 180° in the sham group. The device also made the same sound but could not stimulate the brain.
62416439|NCT04526379|EXPERIMENTAL|children with PWS|Evaluation of cognitive abilities of children with PWS by several cognitive tasks and neuropsychological tests.
62416440|NCT04526379|OTHER|non affected children|Evaluation of cognitive abilities of children with PWS compared to a non-pathologic population of children by several cognitive tasks and neuropsychological tests
62433418|NCT02787226|ACTIVE_COMPARATOR|Reverse TSA - Continuous Perineural Ropivacaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine for postoperative analgesia after reverse TSA.
62025028|NCT01283269|EXPERIMENTAL|Memory Support System or Computer|
62222086|NCT03624348|NO_INTERVENTION|Wait list control group|Waitlist control group participants will continue their normal activities and not add any form of meditation during the study period.
62433419|NCT00091182|EXPERIMENTAL|Arm I|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
62797607|NCT01757106|ACTIVE_COMPARATOR|Drug: Sevoflurane|inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application during surgery
62797608|NCT00550017|EXPERIMENTAL|1|
62797609|NCT04448977||Multiple Sclerosis group 1|Individuals with Multiple Sclerosis who are going to be starting Ocrevus as determined by Neurologist as part of clinical care.
62797610|NCT04448977||Multiple Sclerosis group 2|Individuals with Multiple Sclerosis who are going to be starting Copaxone as determined by Neurologist as part of clinical care.
62797611|NCT04448977||Healthy Controls|Healthy individuals who are age, gender and education matched to the other groups.
62797612|NCT05924347||Cohort 1|60 adolescent girls (8-10 years old) at increased risk for idiopathic scoliosis development (an older sibling or parent diagnosed with idiopathic scoliosis)
62797613|NCT05924347||Cohort 2|60 adolescent girls or boys with the 22q11.2DS with increased risk for idiopathic-like scoliosis development.
62797614|NCT03232346|EXPERIMENTAL|Regimen 1|Rapid Monday to Friday oral naltrexone-induction procedure
62222087|NCT06519487|EXPERIMENTAL|Mid-Atlantic: Non-Hispanic Black Order 1|"Participants play Cyberball™ with virtual players who appear to be non-Hispanic White. The participant only receives the ball once during the entire game, while all the non-Hispanic White avatars will pass the ball back and forth with each other many times.~After completing surveys and providing saliva and blood samples, participants play Cyberball, in which they receive the ball from virtual players an equal number of times as the other avatars, regardless of their ethnicity. During this round, participants play cyberball with virtual players who do not have any obvious ethnic differences from them. The participant again only receives the ball once during the entire game, while the other avatars that look similar to them pass the ball back and forth with each other a number of times. After completing surveys and providing blood samples, participants receive the ball from virtual players an equal number of times as the other avatars, regardless of their ethnicity."
62222088|NCT06519487|ACTIVE_COMPARATOR|Mid-Atlantic: Non-Hispanic Black Order 2|Participants play Cyberball with virtual players who do not have any noticeable ethnic differences from them. The participants only receive the ball once during the entire game, but avatars that look similar to them pass the ball back and forth with each other several times. After completing surveys and providing saliva and blood samples, participants play Cyberball again but receive the ball from virtual players an equal number of times as the other avatars, regardless of the avatars' ethnicity. Participants play another session of Cyberball™ with virtual players who appear to be non-Hispanic White. The participant only receives the ball once during the entire game, while all the non-Hispanic White avatars will pass the ball back and forth with each other many times. After completing surveys and providing blood samples, participants again play Cyberball but receive the ball from virtual players an equal number of times as the other avatars, regardless of the avatars' ethnicity.
62222089|NCT06519487|EXPERIMENTAL|Mid-Atlantic: Non-Hispanic White Order 1|Participants play Cyberball™ with virtual players who appear non-Hispanic Black, or Hispanic. The participant receives the ball once during the game, while all the non-Hispanic Black or Hispanic avatars will pass the ball back and forth with each other many times. After completing surveys and providing saliva and blood samples, participants play Cyberball, in which they receive the ball from virtual players an equal number of times as the other avatars, regardless of their ethnicity. During this round, participants play cyberball with virtual players who do not have any noticeable ethnic differences from them. The participant again only receives the ball once during the entire game, while the other avatars that look similar to them pass the ball back and forth several times. After completing surveys and providing blood samples, participants receive the ball from virtual players an equal number of times as the other avatars, regardless of their ethnicity.
62416441|NCT03542500|NO_INTERVENTION|Control|Youth randomized into the control arm of this study will be quantitatively assessed at the same time points as youth randomized into the two treatment arms (baseline, 3-months, 12-months). Due to access to funding and feasibility, youth in the control arm and EPP-only arm will not have the opportunity to receive the YRI once the study period concludes. However, GIZ is conducting a phased roll out of their EPP programming, meaning they will offer their EPP throughout 2018 past their participation in Youth FORWARD. Youth will also be compensated for their participation in our quantitative assessments.
62797615|NCT03232346|EXPERIMENTAL|Regimen 2|5-week buprenorphine taper from maintenance dose of 8, 6, or 4mg
62797616|NCT06100679|NO_INTERVENTION|Control|Standard of care. Participants will have access to existing health centers and early childhood development centers.
62797617|NCT06100679|EXPERIMENTAL|Intervention|Participants will engage in the Responsible, Engaged and Loving (REAL) Fathers Intervention-an evidence-based community mentoring education program for young fathers and their spouses. Over 7 months, fathers receive monthly home visits from a community-identified male mentor. Mentors share information and skills-building tools on conflict resolution, non-violent discipline, family planning, and couple communication. At the end of each month, pairs or trios of mentors hold group reflection sessions with all mentored fathers. In months 5 and 6 of the intervention, spouses join the home visits and group sessions. Community-level intervention components include: 1) monthly educational poster campaigns that showcase nonviolent discipline and conflict resolution strategies; 2) community-hosted celebrations at the end of the intervention to acknowledge the accomplishments of the young fathers.
62797618|NCT05038865||Malocclusion group|500 12-19 year olds with malocclusion, defined as IOTN-DHC grade 3, 4 or 5. The adolescents are consecutively recruited new patients at three orthodontic centers; Center for Orthodontics and Pediatric Dentistry, Norrköping, Public Dental Service Östergötland; Department of Orthodontics, Folktandvården Stockholms län AB, Folktandvården Eastmaninstitutet, Stockholm, Sweden and Department of Orthodontics, Malmö University, Malmö, Sweden. Patients are examined at the first visit at the orthodontic department, before any orthodontic treatment is begun.
62797619|NCT05038865||No malocclusion group|175 12-19 year olds without malocclusion, defined as IOTN-DHC grade 1 or 2. Patients are consectively recruited adolescents examined at their general dentistry clinic.
62025029|NCT00658346||1|HIV-1 group O infected patients
62025030|NCT00658346||2|HIV-1 group M infected patients
62222090|NCT06519487|ACTIVE_COMPARATOR|Mid-Atlantic: Non-Hispanic White Order 2|Participants play Cyberball with virtual players who do not have any noticeable ethnic differences from them. The participants only receive the ball once during the game, but avatars that look similar to them pass the ball back and forth with each other several times. After completing surveys and providing saliva and blood samples, participants play Cyberball again but receive the ball from virtual players an equal number of times as the other avatars, regardless of the avatars' ethnicity. Participants play another session of Cyberball with virtual players who appear to be non-Hispanic Black or Hispanic. The participant receives the ball once during the game, while all the non-Hispanic Black or Hispanic avatars will pass the ball back and forth with each other many times. After completing surveys and providing blood samples, participants again play Cyberball but receive the ball from virtual players an equal number of times as the other avatars, regardless of the avatars' ethnicity.
62222091|NCT06519487|EXPERIMENTAL|Mid-Atlantic Hispanic Order 1|Participants play Cyberball™ with virtual players who appear to be non-Hispanic White. The participant receives the ball once during the game, while all the non-Hispanic White avatars will pass the ball back and forth with each other many times. After completing surveys and providing saliva and blood samples, participants play Cyberball, in which they receive the ball from virtual players an equal number of times as the other avatars, regardless of their ethnicity. During this round, participants play Cyberball with virtual players who do not have any noticeable ethnic differences from them. The participant again only receives the ball once during the entire game, while the other avatars that look similar to them pass the ball back and forth several times. After completing surveys and providing blood samples, participants receive the ball from virtual players an equal number of times as the other avatars, regardless of their ethnicity.
62222092|NCT06519487|ACTIVE_COMPARATOR|Mid-Atlantic Hispanic Order 2|Participants play Cyberball with virtual players who do not have any noticeable ethnic differences from them. The participants only receive the ball once during the entire game, but avatars that look similar to them pass the ball back and forth with each other several times. After completing surveys and providing saliva and blood samples, participants play Cyberball again but receive the ball from virtual players an equal number of times as the other avatars, regardless of the avatars' ethnicity. Participants play another session of Cyberball™ with virtual players who appear to be non-Hispanic White. The participant only receives the ball once during the entire game, while all the non-Hispanic White avatars will pass the ball back and forth with each other many times. After completing surveys and providing blood samples, participants again play Cyberball but receive the ball from virtual players an equal number of times as the other avatars, regardless of the avatars' ethnicity.
62416442|NCT03542500|EXPERIMENTAL|Entrepreneurship Training|Youth randomized into the Entrepreneurship Training-only arm will receive GIZ's employment programming approximately three months after the completion of the baseline assessments. The GIZ-supported Entrepreneurship Training program includes six training modules, delivered over three weeks, to include skills development, financial literacy, and other skills necessary to secure employment or engage in livelihood activities.
62416443|NCT03542500|EXPERIMENTAL|YRI+Entrepreneurship Training|Youth randomized into the YRI+Entrepreneurship Training arm will begin the YRI module within two weeks after the completion of baseline assessments. The YRI curriculum (12 modules), will be delivered in 12 weekly 90-minute sessions, with additional time taken as needed. These weekly sessions assume a peer-to-peer group learning format deemed culturally appropriate for a setting like Sierra Leone where limited resources for mental health services exist. Once youth complete the YRI they will complete a post-intervention (3-months) quantitative assessment. Following the completion of the quantitative assessments, youth will receive the Entrepreneurship Training.
62416444|NCT04682210|EXPERIMENTAL|Arm A|sintilimab 200mg + bevacizumab 7.5mg/kg IV Q3W
62416445|NCT04682210|NO_INTERVENTION|Arm B|Active surveillance
62797620|NCT04483726|EXPERIMENTAL|MIDP|minimally invasive distal pancreatectomy
62797621|NCT04483726|SHAM_COMPARATOR|ODP|open distal pancreatectomy
62797622|NCT03400826|EXPERIMENTAL|Treatment Group|The 30 participants randomized in this group will intake Simvastatin 40mg / day of orally at the same time in the evening, every day for the study duration of 12 weeks prior to undergoing hysterectomy/ myomectomy. The fibroid samples will be collected after the surgery to evaluate the effects of the study medication on the fibroid tissue.
62797623|NCT03400826|PLACEBO_COMPARATOR|Placebo Group|The 30 participants randomized in this group will intake Placebo 40mg / day orally at the same time in the evening every day for the study duration of 12 weeks prior to undergoing hysterectomy/ myomectomy. The fibroid samples will be collected after the surgery to evaluate the effects of the study medication on the fibroid tissue.
62797624|NCT03255317|EXPERIMENTAL|Within-participant micro-randomization|Intervention includes Reinforcers and Notifications through the app. At each available decision time, each participant is randomly assigned to either receive an engagement strategy or to not receive an engagement strategy.
62797625|NCT05065359|EXPERIMENTAL|Rodatristat Ethyl 300 mg BID - Japanese subjects|
62797626|NCT05065359|PLACEBO_COMPARATOR|Placebo match for Rodatristat Ethyl 300 mg BID - Japanese subjects|
62797627|NCT05065359|EXPERIMENTAL|Rodatristat Ethyl 300 mg BID - Caucasian subjects|
62797628|NCT05065359|PLACEBO_COMPARATOR|Placebo match for Rodatristat Ethyl 300 mg BID - Caucasian subjects|
62797629|NCT05065359|EXPERIMENTAL|Rodatristat Ethyl 600 mg BID - Japanese subjects|
62797630|NCT05065359|PLACEBO_COMPARATOR|Placebo match for Rodatristat Ethyl 600 mg BID - Japanese subjects|
62797631|NCT05065359|EXPERIMENTAL|Rodatristat Ethyl 600 mg BID - Caucasian subjects|
62797632|NCT05065359|PLACEBO_COMPARATOR|Placebo match for Rodatristat Ethyl 600 mg BID - Caucasian subjects|
62025031|NCT05152979|EXPERIMENTAL|Telepractice treatment (TP-T)|"Participants will receive 30 hours of training, 2-3 times a week in ten weeks using Verb Network Strengthening Treatment (VNeST).~Treatment will be done with a speech-language pathologist providing the therapy through an online platform."
62025032|NCT05152979|ACTIVE_COMPARATOR|In-clinic treatment (IC-T)|"Participants will receive 30 hours of training, 2-3 times a week in ten weeks using Verb Network Strengthening Treatment (VNeST).~Treatment will be done with a speech-language pathologist providing the therapy in person at a clinic."
62242983|NCT02198092||Control Group (FAP Genetically-Related)|"Genetically related family member of enrolled FAP patient.~Controls, i.e. relatives of patients: Willingness to give blood at each routine follow-up as advised for the diseased relative.~The patients of the control group participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating FAP patients.~If colectomy is performed in a FAP patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery.~Blood draws in FAP patients should always be accompanied by blood draws in their family member controls."
62416446|NCT04856917|EXPERIMENTAL|Imsidolimab 400/200 mg|Participants received imsidolimab 400 milligrams (mg) by subcutaneous (SC) injection on Day 1, followed by 200 mg on Days 29 and 57.
62416447|NCT04856917|EXPERIMENTAL|Imsidolimab 200/100 mg|Participants received imsidolimab 200 mg by SC injection on Day 1, followed by 100 mg on Days 29 and 57.
62416448|NCT04856917|PLACEBO_COMPARATOR|Placebo|Participants received imsidolimab matching placebo by SC injection on Days 1, 29, and 57.
62797633|NCT01504022|NO_INTERVENTION|Control group.|Control group.
62797634|NCT01504022|EXPERIMENTAL|Telecare, self monitoring, lifestyle counseling|Patients in the intervention group will measure their blood pressure with home blood pressure monitor which is linked to a secured website. Patients will measure as recommended in the European guidelines of hypertension. This includes 2 measurements in the morning and two times in the evening on 7 consecutive days every month. The measurements of the first day will be discarded. These measurements will be forwarded to the web-based system, which will be managed by the nurse practitioner and the research doctor. At least every month patients are contacted about the state of their condition. If needed, antihypertensive medication is added of adjusted by the nurse practitioner or research doctor under the supervision of one consultant physician. Tailored lifestyle advices are given every month.
62797635|NCT04427865|EXPERIMENTAL|Lactoferrin prophylaxis|200 mg oral lactoferrin daily
62025033|NCT00572572|EXPERIMENTAL|Arm A: Aprepitant, Then Placebo|Participants first received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 1, then received matched placebo PO daily on days 3 through 7 during study cycle 2
62025034|NCT00572572|EXPERIMENTAL|Arm B: Placebo, Then Aprepitant|Participants first received matched placebo PO daily on days 3 through 7 during study cycle 1, then received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 2
62025035|NCT00435370|EXPERIMENTAL|Tropisetron|Tropisetron (10mg/day) + risperidone(6mg/day)
62025036|NCT00435370|PLACEBO_COMPARATOR|Placebo|Placebo + risperidone (6mg/day)
62025037|NCT04993924|EXPERIMENTAL|Participants|Patients will start GnRH antagonist injections \[Cetrotide (cetrolix) or Orgalutran (ganirelix) - depending on their primary prescription\] for 3-6 days
62025038|NCT05360875|EXPERIMENTAL|Endometrial scratching group|
62025039|NCT05360875|NO_INTERVENTION|Non-scratching group|
62025040|NCT01175226|EXPERIMENTAL|BTA798|
62433420|NCT02739802|EXPERIMENTAL|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application
62797636|NCT04427865|NO_INTERVENTION|Control group|
62797637|NCT03776799|OTHER|Stent-avoiding approach|using clinically proven drug coated balloons
62797638|NCT03776799|OTHER|Stent-based approach|using drug eluting nitinol stents. Interwoven nitinol stents in heavily calcified lesions at the operator's discretion.
62025041|NCT01175226|PLACEBO_COMPARATOR|Placebo|
62222093|NCT06519487|EXPERIMENTAL|Southwest Non-Hispanic Black Order 1|Participants play Cyberball™ with virtual players who appear to be non-Hispanic White. The participant only receives the ball once during the entire game, while all the non-Hispanic White avatars will pass the ball back and forth with each other many times. After completing surveys and providing saliva and blood samples, participants play Cyberball, in which they receive the ball from virtual players an equal number of times as the other avatars, regardless of their ethnicity. During this round, participants play cyberball with virtual players who do not have any noticeable ethnic differences from them. The participant again only receives the ball once during the entire game, while the other avatars that look similar to them pass the ball back and forth several times. After completing surveys and providing blood samples, participants receive the ball from virtual players an equal number of times as the other avatars, regardless of their ethnicity.
62242984|NCT00194766|EXPERIMENTAL|1|Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
62242985|NCT02287311|EXPERIMENTAL|Group A: MABEL CTLs|"Patients with 1st or subsequent relapse.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
62433421|NCT02077192|EXPERIMENTAL|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
62588234|NCT06665334|EXPERIMENTAL|Huaier Granule|Oral administration of Huaier granule, 10g (1 bag) each time, 3 times a day, is recommended for at least 6 months until there is imaging progression of the disease, the end of the study, intolerable toxicity, withdrawal or death from the study for any reason, or the researcher determines that there is no longer benefit, whichever occurs first.
62433422|NCT01917578|EXPERIMENTAL|Half Cycles Group|Patients complete half of the whole cycles of neoadjuvant chemotherapy.
62588235|NCT06665334|NO_INTERVENTION|Routine clinical treatment|During routine clinical follow-up, patients who underwent R0 resection were found to have abnormally elevated levels of CEA, and therefore no intervention was generally given. If there is imaging progress, intolerable toxicity, or withdrawal from the study for any reason during the research period (whichever occurs first), routine clinical treatment will be administered.
62588236|NCT06665932|EXPERIMENTAL|Men with prostate cancer|
62588237|NCT03784209||lesions observed by pCLE|pCLE is used to distinguish the suspected lesions detected by white light endoscopy.
62797639|NCT04363879|ACTIVE_COMPARATOR|Endometrial scratch with Pipelle curette|For patients in the Pipelle curette group, physicians inserted the Pipelle curette into the uterus and removed an adequate endometrial sample using vigorous motion.
62025042|NCT00782730||Bladder Scan Group|Patients who agree to enroll in the trial and allow their known bladder volumes and residual bladder volumes to be measured by actual volumes retrograde instilled, and also by bladder scanner ultrasound.
62025043|NCT03969238||Patients/Providers|Of the1,000 participants: (1) 900 will enroll as participants who use the helpline resources via verbal consent and (2) 100 will enroll as providers via online consent prior to survey data collection.
62025044|NCT01466998|EXPERIMENTAL|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
62025045|NCT01466998|ACTIVE_COMPARATOR|Music Therapy|Participant will use an identical appearing device, programmed to play quiet, relaxing non-rhythmic music while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
62025046|NCT06169917|EXPERIMENTAL|Healthy participants|"Participants should be aged 18-40, in good health, capable of informed consent, without major medical/psychiatric conditions (e.g., heart disease, diabetes, autoimmune disorders, infectious diseases, major depressive disorder), chronic pain, respiratory issues, or ongoing acute pain, qualify. Exclusions: inability to follow instructions (e.g., language issues), recent alcohol/drug/analgesic use (\<24h), caffeine intake (\>100mg \<8h), or scar tissue/general reduced sensitivity in test areas.~Participants undergo three interventions. The heat stimulation intervention is performed twice. During one heat stimulation intervention, participants receive the 'resonance frequency breathing' intervention. During the other heat stimulation intervention, participants receive the 'natural frequency breathing' intervention. The order of the breathing interventions is counterbalanced across participants."
62025047|NCT04001829|EXPERIMENTAL|Arm A (paclitaxel)|Patients receive paclitaxel IV over 3 hours once weekly. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may also receive trastuzumab and/or pertuzumab per institution routine care per treating physician's discretion.
62222094|NCT06519487|ACTIVE_COMPARATOR|Southwest Non-Hispanic Black Order 2|Participants play Cyberball with virtual players who do not have any noticeable ethnic differences from them. The participants only receive the ball once during the entire game, but avatars that look similar to them pass the ball back and forth with each other several times. After completing surveys and providing saliva and blood samples, participants play Cyberball again but receive the ball from virtual players an equal number of times as the other avatars, regardless of the avatars' ethnicity. Participants play another session of Cyberball™ with virtual players who appear to be non-Hispanic White. The participant only receives the ball once during the entire game, while all the non-Hispanic White avatars will pass the ball back and forth with each other many times. After completing surveys and providing blood samples, participants again play Cyberball but receive the ball from virtual players an equal number of times as the other avatars, regardless of the avatars' ethnicity.
62416449|NCT03949283|ACTIVE_COMPARATOR|Physician Choice Treatment|"Participants will be treated with control chemotherapy treatment (standard-of-care chemotherapy chosen by the physician from the provided list).~Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~* Liposomal Doxorubicin;~* Docetaxel;~* Paclitaxel;~* Carboplatin;~* Cisplatin;~* Gemcitabine;~* Topotecan;~* Carboplatin, Gemcitabine;~* Cisplatin, Gemcitabine;~* Carboplatin, Liposomal Doxorubicin;~* Carboplatin, Paclitaxel;~* Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
62797640|NCT04363879|EXPERIMENTAL|Endometrial scratch with Shepard catheter|For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
62797641|NCT05897606|EXPERIMENTAL|effect multivitamin and minerals on NAFLD for 12 weeks|The intervention group received one capsule of multivitamin and minerals supplements every day, one hour after breakfast, for 12 weeks.
62416450|NCT03949283|EXPERIMENTAL|ChemoID-guided treatment|"Participants will be treated with ChemoID-guided standard-of-care chemotherapy drugs from the provided list.~ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:~* Liposomal Doxorubicin;~* Docetaxel;~* Paclitaxel;~* Carboplatin;~* Cisplatin;~* Gemcitabine;~* Topotecan;~* Carboplatin, Gemcitabine;~* Cisplatin, Gemcitabine;~* Carboplatin, Liposomal Doxorubicin;~* Carboplatin, Paclitaxel;~* Carboplatin, Docetaxel.~The treating physician will receive the ChemoID assay results from the ChemoID lab."
62416451|NCT00263393|OTHER|Algorithm-based care|An algorithm based approach to increase the identification of high-risk individuals in the community through encouraging opportunistic screening, and to increase the use of appropriate evidence based prevention strategies.
62797642|NCT05897606|PLACEBO_COMPARATOR|Placebo|the control group took a placebo prepared with the same shape and size of supplements.
62433423|NCT01917578|EXPERIMENTAL|Whole Cycles Group|Patients complete whole cycles of neoadjuvant chemotherapy.
62797643|NCT04947241|EXPERIMENTAL|Neoadjuvant therapy|Patients included are going to receive neoadjuvant therapy, surgery and adjuvamt therapy post surgery. Before surgery, patients will receive therapy as follows: PD-1 inhibitor: 240mg (day1) , intravenous, Q3W, 2cycles; cisplatin: 80 mg/m2(day1), intravenous , intravenous, Q3W, 2cycles Gemcitabine: 1000mg/m2(day1and day8), intravenous, Q3W, 2cycles
62797644|NCT02996526||Intact Vocal Cord Mobility|Patients with normal laryngeal function post thoracic surgery
62797645|NCT02996526||Vocal Cord Dysfunction|Patients with abnormal vocal cord movement of 1 or both vocal cords post thoracic surgery
62797646|NCT04132310||MINT Participants|Up to 60 MINT maternal participant are linked with 60 infant participants, and 60 partner participants.
62797647|NCT00191308|EXPERIMENTAL|Pemetrexed + Cisplatin|"Pemetrexed: 500 milligrams per square meter (mg/m\^2) intravenous (IV) every 21 days (q 21 days) for 3 cycles unless disease progression occurs~Cisplatin: 75 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs"
62222095|NCT06519487|EXPERIMENTAL|Southwest Non-Hispanic White Order 1|Participants play Cyberball™ with virtual players who appear non-Hispanic Black or Hispanic. The participant receives the ball once during the game, while all the non-Hispanic Black or Hispanic avatars will pass the ball back and forth with each other many times. After completing surveys and providing saliva and blood samples, participants play Cyberball, in which they receive the ball from virtual players an equal number of times as the other avatars, regardless of their ethnicity. During this round, participants play cyberball with virtual players who do not have any noticeable ethnic differences from them. The participant again only receives the ball once during the entire game, while the other avatars that look similar to them pass the ball back and forth with each other several times. After completing surveys and providing blood samples, participants receive the ball from virtual players an equal number of times as the different avatars, regardless of ethnicity.
62416452|NCT00263393|OTHER|Health-promotion|The health promotion arm has been designed to increase knowledge of the causes of cardiovascular disease and enhance use of preventive behaviours in the general population
62416453|NCT06689592|EXPERIMENTAL|Mobile Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation at home. Half of the SAINT protocol (Cole et al., 2020, 2022) is to be carried out. For this purpose, all 5 test subjects are treated with 5 sessions per day on 5 consecutive days (25 stimulations in total). An iTBS protocol (3 pulses at 50 Hz in 2 seconds, 8 seconds pause) with 1800 pulses (total duration: 10 minutes) should be used every hour with a break of 50 minutes (total of 9,000 pulses can be applied per day).
62797648|NCT06178614|EXPERIMENTAL|JNJ-87890387|In Part 1 (Dose escalation) participants will receive JNJ-87890387. The dose will be escalated sequentially until the recommended phase 2 dose (RP2D) regimen(s) have been identified. In Part 2 (Dose expansion), participants will receive JNJ-87890387 at the RP2D regimen(s) determined in Part 1.
62797649|NCT04616859|EXPERIMENTAL|Alcohol and Energy Drink (AmED)|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).~Women: Ethanol 172 ml (55 g) + ED 589 ml Men: Ethanol 219 ml (70 g) + ED 750 ml"
62222096|NCT06519487|ACTIVE_COMPARATOR|Southwest Non-Hispanic White Order 2|Participants play Cyberball with virtual players who do not have any noticeable ethnic differences from them. The participants only receive the ball once during the entire game, but avatars that look similar to them pass the ball back and forth with each other several times. After completing surveys and providing saliva and blood samples, participants play Cyberball again but receive the ball from virtual players an equal number of times as the other avatars, regardless of their ethnicity. Participants play another session of Cyberball with virtual players who appear to be non-Hispanic Black or Hispanic. The participant only receives the ball once during the entire game, while all the non-white avatars will pass the ball back and forth with each other many times. After completing surveys and providing blood samples, participants again play Cyberball but receive the ball from virtual players an equal number of times as the other avatars, regardless of the avatars' ethnicity.
62222097|NCT06519487|EXPERIMENTAL|Southwest Hispanic Order 1|Participants play Cyberball™ with virtual players who appear to be non-Hispanic White. The participant only receives the ball once during the entire game, while all the non-Hispanic White avatars will pass the ball back and forth with each other many times. After completing surveys and providing saliva and blood samples, participants play Cyberball, in which they receive the ball from virtual players an equal number of times as the other avatars, regardless of their ethnicity. During this round, participants play Cyberball with virtual players who do not have any noticeable ethnic differences from them. The participant again only receives the ball once during the entire game, while the other avatars that look similar to them pass the ball back and forth several times. After completing surveys and providing blood samples, participants receive the ball from virtual players an equal number of times as the other avatars, regardless of their ethnicity.
62222098|NCT06519487|EXPERIMENTAL|Southwest Hispanic White Order 2|Participants play Cyberball with virtual players who do not have any noticeable ethnic differences from them. The participants only receive the ball once during the entire game, but avatars that look similar to them pass the ball back and forth with each other several times. After completing surveys and providing saliva and blood samples, participants play Cyberball again but receive the ball from virtual players an equal number of times as the other avatars, regardless of the avatars' ethnicity. Participants play another session of Cyberball™ with virtual players who appear to be non-Hispanic White. The participant receives the ball once during the game, while all the non-Hispanic White avatars will pass the ball back and forth with each other many times. After completing surveys and providing blood samples, participants again play Cyberball but receive the ball from virtual players an equal number of times as the other avatars, regardless of the avatars' ethnicity.
62222099|NCT01837784||Elderly patients|
62222100|NCT01837784||Patients with diabetes mellitus|
62222101|NCT01837784||Patients with heart failure|
62222102|NCT01837784||Patients with resistant hypertension|
62797650|NCT04616859|ACTIVE_COMPARATOR|Alcohol and Energy drink Placebo|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).~Women: Ethanol 172 mL (55 g) + placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol 219 mL(70 g) + placebo ED 750 mL (a non-caffeinated soft drink)"
62797651|NCT04616859|ACTIVE_COMPARATOR|Alcohol placebo and Energy drink|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).~Women: Ethanol placebo (water) 172 mL + ED 589 mL Men: Ethanol placebo (water) 219 mL + ED 750 mL"
62797652|NCT04616859|PLACEBO_COMPARATOR|Alcohol placebo and Energy drink placebo|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).~Women: Ethanol placebo (water) 172 mL+ placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol placebo (water) 219 mL + placebo ED (a non-caffeinated soft drinks) 750 mL"
62797653|NCT00298974|EXPERIMENTAL|hydrocodone/acetaminophen extended release|
62797654|NCT00298974|PLACEBO_COMPARATOR|Placebo|
62025048|NCT04001829|EXPERIMENTAL|Arm B (docetaxel)|Patients receive docetaxel IV over 1 hour once every 3 weeks. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity. Patients may also receive cyclophosphamide, doxorubicin, trastuzumab, and/or pertuzumab per institution routine care per treating physician's discretion.
62025049|NCT01822652|EXPERIMENTAL|iC9-GD2 T Cells - fresh - CLOSED|The cells will be given IV over 5-10 minutes. There is a possibility for additional doses of iC9-GD2 T cells.
62025050|NCT01822652|EXPERIMENTAL|iC9-GD2 T Cells - frozen - CLOSED|The cells will be given IV over 5-10 minutes. There is a possibility for additional doses of iC9-GD2 T cells.
62025051|NCT01822652|EXPERIMENTAL|iC9-GD2 T cells,Cytoxan,Fludara,Keytruda|Fresh T cells will be given IV over 5-10 mins. There is a possibility for additional doses of iC9-GD2 T cells.
62416454|NCT06133907|EXPERIMENTAL|Samples Without DNA|Patients who came to the pneumoallergology department of the CHU de Nice since January 2014 for an allergological workup and with tryptasemia was ≥ 8ng/ml (at least once in patient history).
62222103|NCT05908045||Physical Therapists|"Physical Therapists currently working in a clinical setting.~Group Participants (Inclusion/Exclusion Criteria)~Inclusion Criteria:~1. Must be a licensed Physical Therapist~2. Must be actively be involved in clinical practice~3. Must have ≥ 5 years of experience practicing in a clinical setting as a Physical Therapist~Exclusion Criteria:~(1) Did not provide informed consent~The survey will be disseminated across the American Physical Therapy Association (APTA) email lists. Further potential candidates may be identified through existing professional networks, clinical settings, and social medial/internet-based searching."
62416455|NCT01590537||Group 1|
62416456|NCT01590537||Group 2|
62416457|NCT06650540|EXPERIMENTAL|Levofloxacin Plus Metronidazole Suppositories group|Clinical pregnancy outcomes of the first embryo transfer in patients with chronic endometritis treated with Levofloxacin Plus Metronidazole Suppositories.
62797655|NCT06500884|ACTIVE_COMPARATOR|Cohort A: Talquetamab|Participants with relapsed or refractory multiple myeloma (RRMM) (previously exposed to at least 1 proteasome inhibitor \[PI\], 1 immunomodulatory drug(s) \[IMiD\]), and an anti-CD38 monoclonal antibody \[mAb\]) will be treated with talquetamab subcutaneously until disease progression, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
62797656|NCT06500884|EXPERIMENTAL|Cohort B: Prophylaxis A and Talquetamab|Participants with RRMM (previously exposed to at least 1 PI, 1 IMiD, and an anti-CD38 mAb) will receive prophylaxis A along with talquetamab therapy. Participants will start the assigned prophylaxis 7 days before starting talquetamab treatment. After step-up dosing of talquetamab therapy, participants will be treated with talquetamab with prophylaxes for up to 12 months during prophylaxis treatment phase. The Talquetamab treatment phase will continue from Cycle 1 Day 1 (C1D1) until disease progression, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
62797657|NCT06500884|EXPERIMENTAL|Cohort C: Prophylaxis B and Talquetamab|Participants with RRMM (previously exposed to at least 1 PI, 1 IMiD, and an anti-CD38 mAb) will receive prophylaxis B along with talquetamab therapy. Participants will start the assigned prophylaxis 7 days before starting talquetamab treatment. After step-up dosing of talquetamab therapy, participants will be treated with talquetamab with prophylaxes for up to 12 months during prophylaxis treatment phase. The Talquetamab treatment phase will continue from C1D1 until disease progression, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
62025052|NCT01176253||25 newly diagnosed Type 1 diabetics|25 newly diagnosed Type 1 diabetics within onset of symptoms
62025053|NCT01176253||25 healthy volunteers|25 healthy volunteers (age \& sex matched)
62025054|NCT05633784|EXPERIMENTAL|Intervention group|At the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support.
62025055|NCT05633784|ACTIVE_COMPARATOR|Control group|At the beginning and at the end of the 6-month study period, patients of the Control group will perform outpatient cardiological visits. During the 6-month at home, patients will be followed in the usual care model by GP.
62025056|NCT03627403|EXPERIMENTAL|Selinexor, all patients|Single Arm Study, all patients will get selinexor
62025057|NCT03867331|EXPERIMENTAL|5 microgram VLPM01|5 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
62025058|NCT03867331|EXPERIMENTAL|15 microgram VLPM01|15 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
62222104|NCT06380855||Flexible colonoscope assisted taTME group|Flexible colonoscope assisted hybrid transanal total mesorectal resection (taTME) group
62416458|NCT06650540|ACTIVE_COMPARATOR|Levofloxacin co-administered with Metronidazole tablets group|Clinical pregnancy outcomes after the first embryo transfer in patients with chronic endometritis treated with Levofloxacin co-administered with Metronidazole tablets.
62416459|NCT04454957|EXPERIMENTAL|Mastering Diabetes|Adults (hospital employees, their spouses, and community members) who have been identified as having diabetes or prediabetes based on a health risk assessment, who have chosen to participate in Mastering Diabetes. They may or may not be receiving additional usual care.
62416460|NCT04454957|NO_INTERVENTION|Usual care|Employees and spouses of the hospital system who are participating in the employee wellness program, who have been identified as having diabetes or prediabetes based on a health risk assessment, who have chosen not to participate in Mastering Diabetes. They may or may not be receiving additional usual care.
62222105|NCT02757027|PLACEBO_COMPARATOR|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
62222106|NCT02757027|ACTIVE_COMPARATOR|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
62222107|NCT05727969|PLACEBO_COMPARATOR|Control group|The control group, lactated ringer solution will be infused.
62588238|NCT02729363|EXPERIMENTAL|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention delivered at the baseline visit to determine the immediate effects of guided relaxation intervention on stress and pain in outpatients with sickle cell disease.
62025059|NCT03867331|EXPERIMENTAL|30 microgram VLPM01|30 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
62025060|NCT03867331|EXPERIMENTAL|Controlled Human Malaria Infection (CHMI) Phase|Infectivity Control Participants, n=6
62025061|NCT05600608|EXPERIMENTAL|Oesophago- gastric adenocarcinoma patients|"Oesophagogastric adenocarcinoma (OG) cancer patients (who are neoadjuvant chemotherapy treatment naïve) will receive 120mls of a sterile oral stimulant drink (OSD) (manufactured by Ingenza ltd), which is an ISO accredited laboratory. The active component of the drink is iron sulphate (5g/l), pH 5-6.~Breath will be taken following an optimised methodology designed by the VOC laboratory at Imperial college London at baseline and then at 30, 60 and 90 minutes following consumption of the drink.~Participants will be nil by mouth for 6 hours prior to the breath test, they can have water up to 2 hours before the breath test."
62222108|NCT05727969|EXPERIMENTAL|Dexmedetomidine group|In the dexmedetomidine group, dexmedetomidine will be infused.
62222109|NCT02769559||Patients with macromasty|Female adult patients with symptomatic macromasty selected for elective reduction surgery
62222110|NCT05597462|EXPERIMENTAL|DFD-29|DFD-29 (minocycline hydrochloride) capsules, 40 mg will be administered orally once daily for 16 weeks.
62222111|NCT05597462|PLACEBO_COMPARATOR|Placebo|Placebo capsules will be administered orally once daily for 16 weeks.
62222112|NCT02775695|EXPERIMENTAL|Doxycycline Administered to Patients|Patients will receive oral doxycycline and trough serum concentrations for pharmacokinetic studies will be obtained.
62222113|NCT04647643||Paclitaxel Drug Coated Balloon|Patients treated with paclitaxel drug-coated balloon
62222114|NCT04647643||Paclitaxel Drug Coated Stent|Patients treated with paclitaxel drug-coated stent
62222115|NCT01851954|EXPERIMENTAL|clarithromycin|Population PK
62222116|NCT03071367|EXPERIMENTAL|Clinical Simulation|
62222117|NCT03071367|NO_INTERVENTION|Classical Learning|
62222118|NCT00149760|ACTIVE_COMPARATOR|Augmented Standard Medical Care|Participants will receive standard medical care augmented by a psychiatric consultation letter sent to the participants' primary care physician.
62222119|NCT00149760|EXPERIMENTAL|Cognitive-Affective Behavior Therapy|Participants will receive individually administered cognitive-affective behavior therapy as well as augmented standard medical care.
62222120|NCT01564628||All study participants|Population from 2 sites, sequential design with all patients undergoing CADScor1 intervention followed by the diagnostic testing the patients were referred to (procedure done according to standard of care and not part of study; computerized tomographic angiography (CTA) and, if relevant, coronary angiography (CAG) at Site 1 and CAG at site 2).
62222121|NCT05731453|EXPERIMENTAL|Polygenetic risk score|Assessment of polygenetic risk score for breast cancer
62222122|NCT00541398|EXPERIMENTAL|A|
62222123|NCT00541398|NO_INTERVENTION|B|
62416461|NCT03750916|EXPERIMENTAL|Anlotinib Hydrochloride plus Docetaxel|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Docetaxel (75mg/m2 IV d1) Drug: Anlotinib Hydrochloride plus Docetaxel
62416462|NCT00295529|EXPERIMENTAL|Multifaceted Educational Intervention|Intervention group received an interactive workshop, portfolio of primary care appropriate genomics tools, and Gene Messengers
62416463|NCT00295529|NO_INTERVENTION|No education|Educational materials at end of study
62416464|NCT01319747|ACTIVE_COMPARATOR|Percutaneous therapy|
62416465|NCT01319747|ACTIVE_COMPARATOR|VATS therapy|
62416466|NCT03354416||1/ Cohort 1|Subjects with an increased risk of prostate cancer or a diagnosis of prostatic cancer or suspicious for prostatic cancer lesions.
62797658|NCT06500884|EXPERIMENTAL|Cohort D: Prophylaxis C and Talquetamab|Participants with RRMM (previously exposed to at least 1 PI, 1 IMiD, and an anti-CD38 mAb) will receive prophylaxis C along with talquetamab therapy. Participants will start the assigned prophylaxis 7 days before starting talquetamab treatment. After step-up dosing of talquetamab therapy, participants will be treated with talquetamab with prophylaxes for up to 12 months during prophylaxis treatment phase. The Talquetamab treatment phase will continue from C1D1 until disease progression, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
62222124|NCT00585195|EXPERIMENTAL|1|
62222125|NCT01389427|EXPERIMENTAL|Torisel 15 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 15 mg
62222126|NCT01389427|EXPERIMENTAL|Torisel 25 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 25 mg
62222127|NCT01389427|EXPERIMENTAL|Torisel 50 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 50 mg
62222128|NCT01389427|EXPERIMENTAL|Torisel 75 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 75 mg
62222129|NCT03051243|ACTIVE_COMPARATOR|Linagliptin and Basal Insulin|linagliptin (trajenta) 5mg once daily combined with basal insulin (glargine Lantus; sanofi) 0.15-0.3 units/kg TDD before bed time.
62222130|NCT03051243|ACTIVE_COMPARATOR|Basal Insulin and Bolus Insulin|Basal Insulin (Glargine Lantus; Sanofi) based therapy once daily before bedtime and glulisine (Apidra; sanofi) before meals. insulin dose will be 0.5 units/kg divided half as insulin glargine once daily and half as insulin glulisine before meals.
62222131|NCT04182945|OTHER|Unobtrusive data collection|Unobtrusive data collection using noninvasive sensor systems.
62222132|NCT04987736||COVID-19 (RT-PCR +ve) patients|
62416467|NCT02628418|EXPERIMENTAL|Gloreha Group|"The patients in the Gloreha Group underwent to following interventions:~1. General Rehabilitation~2. Specific hand rehabilitation by Gloreha device"
62797659|NCT05585840|EXPERIMENTAL|Biofeedback-based virtual reality group/Intervention|When approaching the moment of the procedure (2 minutes before), children will be asked to put on the virtual reality glasses, saturation probe and respiratory sensor in addition to routine care. At this stage, the child will be assisted by the researcher. The launch of the mobile application on the researcher's phone will be provided just before the port needle placement (1 minute before). In this process, the child will provide biofeedback to the game with regular and deep breathing behavior. The game will end when the port pin placement is complete.
62222133|NCT00504621||sarcoidosis|Sarcoidosis known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009
62222134|NCT00504621||pulmonary fibrosis|Idiopathic pulmonary fibrosis (IPF) patients known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009
62222135|NCT02561065|EXPERIMENTAL|Lifestyle intervention high risk group.|Participants in the intervention group will receive the intervention on top of standard care.
62222136|NCT02561065|NO_INTERVENTION|Standard care high risk group.|Each participant in the standard care group will receive care as usual, provided by his own occupational physician (OP) and other possible care providers.
62222137|NCT02561065|EXPERIMENTAL|Lifestyle intervention low risk group.|Participants in the intervention group will receive the intervention on top of standard care.
62222138|NCT02561065|NO_INTERVENTION|Standard care low risk group.|Each participant in the standard care group will receive care as usual, provided by his own occupational physician (OP) and other possible care providers.
62416468|NCT02628418|OTHER|Control Group|"The patients in the Control Group underwent to following interventions:~1. General Rehabilitation~2. Specific hand rehabilitation performed by physiotherapist"
62416469|NCT00604734|OTHER|ReCap|ReCap Total Hip Resurfacing System
62222139|NCT01953653|OTHER|A: Begin with Interactive Voice Response (IVR) System|Group A participants are randomized the IVR system as Modality #1. After 33 days of diary completion using IVR, they switch to the interactive web response system (IWR)as Modality #2.
62797660|NCT05585840|NO_INTERVENTION|Control group|In the pediatric oncology unit where the study will conduct, there is no standard pharmacological and non-pharmacological application use to reduce pain, anxiety, and fear during intervention. Family presence and positive encouragement are used in routine care. For children in this group, port catheter needle insertion will be performed in accordance with their clinical routines.
62222140|NCT01953653|OTHER|B: Begin with Interactive Web Response (IWR) System|Group B participants are randomized to the IWR system as Modality #1. After 33 days of diary completion using IWR, they switch to the interactive voice response (IVR)system as Modality #2.
62222141|NCT01478139|EXPERIMENTAL|LIFT|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
62222142|NCT01478139|EXPERIMENTAL|LIFT-plug|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
62222143|NCT02013518|EXPERIMENTAL|Cognitive behavioural therapy|11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
62797661|NCT00990743|EXPERIMENTAL|SYL040012|
62797662|NCT01852838||Lung cancer patients, pre treatment|Patients who have diagnosed with lung cancer before treatment
62797663|NCT01852838||High risk patients for lung cancer|high risk patients who are age and co-morbidity matched controls without proof of lung cancer.
62797664|NCT00189839|ACTIVE_COMPARATOR|1|
62797665|NCT00189839|EXPERIMENTAL|2|
62222144|NCT02013518|OTHER|Control group|Treatment as usual at the participating memory clinics
62416470|NCT06698614||Acute Kidney Injury|20 patients with acute kidney injury (AKI). AKI diagnosis will be based on clinical and biochemical data reflecting KDIGO criteria.
62797666|NCT00203229|PLACEBO_COMPARATOR|Placebo|Dosing Schedule Morning Evening Daily Total Week 1-2 ---- 50mg 50mg Week 3-4 50mg 50mg 100mg Week 5 100mg 100mg 200mg Week 6 150mg 150mg 300mg Week 7 200mg 200mg 400mg Week 8 (if needed for pain) 200mg 300mg 500mg Week 9 (if needed for pain) 300mg 300mg 600mg Week 10 (if needed for pain) 300mg 400mg 700mg
62797667|NCT00203229|ACTIVE_COMPARATOR|Lamotrigine|Dosing Schedule Morning Evening Daily Total Week 1-2 ---- 50mg 50mg Week 3-4 50mg 50mg 100mg Week 5 100mg 100mg 200mg Week 6 150mg 150mg 300mg Week 7 200mg 200mg 400mg Week 8 (if needed for pain) 200mg 300mg 500mg Week 9 (if needed for pain) 300mg 300mg 600mg Week 10 (if needed for pain) 300mg 400mg 700mg
62797668|NCT01658007|EXPERIMENTAL|Sirolimus|Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leuk
62797669|NCT06703034|OTHER|Mild patients|Patients who experienced mild forms of COVID-19 during the first wave, without any prior vaccination, selected from the pre-existing COVID-Ser cohort (ClinicalTrial no. NCT04341142).
62797670|NCT06703034|OTHER|Severe patients|Patients who experienced severe forms of COVID-19 during the first wave, without any prior vaccination, selected from the pre-existing NOSO-COR IMMUNO cohort (ClinicalTrial no. NCT04637867).
62222145|NCT00816400|EXPERIMENTAL|MEDI-575, 3.0 mg/kg QWk Escalation Phase (Cohort 1)|Single lead-in dose of MEDI-575 at 0.5 mg/kg as a 60-minute intravenous (IV) infusion administered 7 days prior to first dose at 3.0 mg/kg; MEDI-575 administered at 3.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (once every 7 days \[QWk\]) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
62797671|NCT06263894|EXPERIMENTAL|Experimental group|The application of the Alexander Technique to the women included in the experimental group will be created by providing body awareness by directing their current posture and movements in line with three principles. In this way, self-management of the birth process in primiparous women will be established. In order to develop the body awareness of the primiparous woman, the Alexander Technique will be applied with the training program created by the researcher in line with the three principles.
62025062|NCT05600608|ACTIVE_COMPARATOR|Benign healthy control patients|Age, gender and demographic matched patients who have had a negative oesophagogastroscopy within 1 year which is negative for adenocarcinoma will be recuited into the comparison arm. Patients will be given the same OSD and breath will be sampled at the same time points as the experimental arm.
62222146|NCT00816400|EXPERIMENTAL|MEDI-575, 6.0 mg/kg QWk Escalation Phase (Cohort 2)|MEDI-575 administered at 6.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
62222147|NCT00816400|EXPERIMENTAL|MEDI-575, 9.0 mg/kg QWk Escalation Phase (Cohort 3)|MEDI-575 administered at 9.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
62222148|NCT00816400|EXPERIMENTAL|MEDI-575, 12 mg/kg QWk Escalation Phase (Cohort 4)|MEDI-575 administered at 12.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
62222149|NCT00816400|EXPERIMENTAL|MEDI-575, 15 mg/kg QWk Escalation Phase (Cohort 5)|MEDI-575 administered at 15.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
62222150|NCT00816400|EXPERIMENTAL|MEDI-575, 25 mg/kg Q3Wk Escalation Phase (Cohort 6)|MEDI-575 administered at 25.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (once every 21 days \[Q3Wk\]) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
62222151|NCT00816400|EXPERIMENTAL|MEDI-575, 35 mg/kg Q3Wk Escalation Phase (Cohort 7)|MEDI-575 administered at 35.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (Q3Wk) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
62222152|NCT00816400|EXPERIMENTAL|MEDI-575, 9.0 mg/kg QWk Expansion Phase|MEDI-575 administered at 9.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
62222153|NCT00816400|EXPERIMENTAL|MEDI-575, 25 mg/kg Q3Wk Expansion Phase|MEDI-575 administered at 25.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (Q3Wk) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
62222154|NCT02863471|EXPERIMENTAL|Gemcitabine|1000 milligram (mg)/ square meter (m²) body surface, intraperitoneal use, unique intraoperative application for 60 minutes
62222155|NCT01489891|ACTIVE_COMPARATOR|Lidocaine group|Blinded spraying 50 mg of pharyngeal topical lidocaine 180 seconds before sedated esophagogastroduodenoscopy (EGD)
62222156|NCT01489891|PLACEBO_COMPARATOR|Placebo|Excipients without lidocaine. The flavour taste is the same of active comparator ensuring the masking.
62222157|NCT04940000|EXPERIMENTAL|Patient with T3-T4 ORL cancer, relevant to surgery and/or radiotherapy and/or chemotherapy.|
62222158|NCT01022268||Infection, inflammation or allergy|"Children presenting via any means to St Mary's Hospital; this would include the A\&E department, the general and infectious disease wards and the paediatric intensive care unit.~Children needing blood tests for any clinical reason Children who, in the clinical judgement of the doctor assessing them, have presented because of a condition consistent with an infectious, inflammatory or allergic process"
62222159|NCT01022268||controls|children who do not have an infectious, inflammatory or allergic condition, who anyway require blood tests for clinical reasons
62416471|NCT06698614||Chronic Kidney Disease|20 age- and sex-matched patients with CKD will be recruited and the patients' eGFR will be matched to that of patients who had AKI and developed persistent renal impairment at the time of their interval scan (3-6 months from their baseline scan).
62416472|NCT06698614||Control Subjects|20 age-, sex- and cardiovascular risk factor- matched control subjects will be recruited and matched to the AKI cohort
62797672|NCT06263894|OTHER|Conventional group|The conventional (control group) will receive routine midwifery care during the birth process. Routine midwifery care includes follow-up of the pregnant woman and the baby and uninterrupted midwife support during the birth process.
62416473|NCT06698614||Vasculitis|20 patients with a new diagnosis of vasculitis (or an existing diagnosis with relapsing disease), and kidney involvement
62025063|NCT00208429|OTHER|Pinnacle Acetabular System|
62222160|NCT01668667|ACTIVE_COMPARATOR|GSK1838262 600 mg|Once-daily dose with food in the evening at approximately 5 PM
62222161|NCT01668667|ACTIVE_COMPARATOR|GSK1838262 450 mg|Once-daily dose with food in the evening at approximately 5 PM
62222162|NCT01668667|ACTIVE_COMPARATOR|GSK1838262 300 mg|Once-daily dose with food in the evening at approximately 5 PM
62222163|NCT01668667|PLACEBO_COMPARATOR|GSK1838262 placebo match|Once-daily dose with food in the evening at approximately 5 PM
62222164|NCT00883701||COPD patients|COPD patients who undergo exacerbation
62222165|NCT00883701||Non COPD patients (controls)|Subjects who undergo respiratory infection (acute bronchitis) without COPD or other respiratory illness
62222166|NCT06261164||Patients on hemodiafiltration with Cytosorb®|
62222167|NCT06261164||Patients on hemodiafiltration with Oxiris®|
62222168|NCT01492465|ACTIVE_COMPARATOR|AMG 876|
62222169|NCT01492465|PLACEBO_COMPARATOR|Placebo|
62222170|NCT01468467|EXPERIMENTAL|AC220|
62222171|NCT06227143||Opioid-free anesthesia|"Patients undergoing laparoscopic surgery under general anesthesia. Drugs used for the purpose of anesthesia:~Ketamine Dexmedetomidine Propofol Sevoflurane Lidocaine Betamethasone Paracetamol NSAID"
62222172|NCT06227143||Target Controlled Infusion|"Patients undergoing laparoscopic surgery under general anesthesia. Drugs used for the purpose of anesthesia:~Propofol Remifentanil Oxycodone Paracetamol NSAID Bethametasone"
62797673|NCT06206525|EXPERIMENTAL|Insulin dosing calculator|
62025064|NCT04695327|EXPERIMENTAL|Monotherapy|"Patients will receive multiple administrations of TILT-123.~Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level."
62222173|NCT06227143||Volatile anesthetics|"Patients undergoing laparoscopic surgery under general anesthesia. Drugs used for the purpose of anesthesia:~Sevoflurane Propofol Remifentanil Oxycodone Paracetmol NSAID Bethametasone"
62222174|NCT06025760|ACTIVE_COMPARATOR|Interventional group|Mechanically ventilated patients will receive a nutritional caloric intake of 25-30 kcal/kg/day with a high protein dose of 2 gm protein /kg/day within 24 hours of ICU admission.
62222175|NCT06025760|PLACEBO_COMPARATOR|Control group|patients will receive a nutritional caloric intake of 25-30 kcal/kg/day with a standard protein dose of 1.2 gm protein /kg/day within 24 hours of ICU admission.
62222176|NCT03751566|ACTIVE_COMPARATOR|Regimen A|Regimen A (control regimen): standard support treatment of adverse events of the radiotherapy.
62222177|NCT03751566|EXPERIMENTAL|Regimen B|Regimen B (acupuncture regimen): standard support treatment of adverse events of the radiotherapy and acupuncture.
62222178|NCT05551533|EXPERIMENTAL|Intervention|To use the mobile app developed by the study team for one month. The app has a few key features including a positive reflection journal, online peer support, knowledge sharing, self-assessment, and locally available resources. Participants in the intervention group will be required to complete at least two positive reflection journal entries per week, and will be encouraged to use other features of the app during the one month period.
62797674|NCT02196155|ACTIVE_COMPARATOR|BTX-A|Botulinum A toxin is injected each 100 U in both gastrocnemius muscle-bellies and 50 U in the soleus muscle, i.e. a total of 250 U.
62797675|NCT02196155|ACTIVE_COMPARATOR|Cortisone|Depot Medrol is injected at the plantar fascia insertion site at the calcaneus
62025065|NCT03418844|OTHER|Interest group (patients treated with chemotherapy)|Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment
62222179|NCT05551533|NO_INTERVENTION|Wait list|Participants in this group will be put on a wait-list for one month before they can use the app.
62222180|NCT05054153|EXPERIMENTAL|refined carbohydrate breakfast (Breakfast A)|white bread (50g) + milk powder (25g)
62222181|NCT05054153|EXPERIMENTAL|whole grain breakfast (Breakfast B)|plain oats (35g) + milk powder (25g)
62222182|NCT05054153|EXPERIMENTAL|intermittent fasting (IF)|
62222183|NCT06163911||No myocardial contractility abnormalities|
62222184|NCT06163911||Myocardial contractility abnormalities|
62025066|NCT03418844|OTHER|Patient control group (patients not treated with chemotherapy)|Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment
62025067|NCT03418844|OTHER|Healthy volunteers|Healthy volunteers will complete several self-questionnaires on living conditions and quality of life.
62222185|NCT01648686|ACTIVE_COMPARATOR|Women treated by bisphosphonate|Postmenopausal osteoporotic women treated by alendronate 70 mg weekly per os
62222186|NCT01648686|SHAM_COMPARATOR|Women didn't treat by bisphosphonate|Postmenopausal osteoporotic women untreated by bisphosphonates
62222187|NCT03010176|EXPERIMENTAL|Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions)|Participants with cutaneous (cut) or subcutaneous (subcut) lesions will receive escalating doses of ulevostinag monotherapy via IT injection on Days 1, 8, and 15 of each 21-day cycle for Cycles 1, 2, and 3 and then on Day 1 of each 21-day cycle for Cycles 4 and beyond for up to 35 cycles (up to approximately 2 years).
62222188|NCT03010176|EXPERIMENTAL|Part 1 Arm 2: Ulevostinag +Pembro (Cut/Subcut Lesions)|Participants with cut or subcut lesions will receive escalating doses of ulevostinag via IT injection on Days 1, 8, and 15 of each 21-day cycle for Cycles 1, 2, and 3 and then on Day 1 of each 21-day cycle for Cycles 4 and beyond PLUS pembrolizumab (pembro) via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
62242986|NCT02287311|EXPERIMENTAL|Group B: MABEL CTLs|"Patients with persistent active disease despite therapy.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
62797676|NCT02196155|PLACEBO_COMPARATOR|Saline|Placebo saline is injected in both gastrocnemius muscle-bellies and in the soleus muscle
62797677|NCT05177497|EXPERIMENTAL|treatment arm|
62797678|NCT05801666|EXPERIMENTAL|Acupuncture group|Acupuncture points: ST36 (Zusanli), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Neiguan), and LI4 (Hegu) Liv 3(Taichung).
62025068|NCT05522504||NC|healthy volunteer (Normal control)：(1) aged between 18 and 80 years; (2) The serum UA levels were lower than 420 μmol/L for a man and 360 μmol/L for a woman at least one time during the two clinical tests for the samples collected with 1-week interval; (3) without any clinically diagnostic severe diseases including but not limited to a tumor, diabetes, cardiovascular, renal, nervous, digestive and mental disorders
62025069|NCT05522504||AHU|Asymptomatic Hyperuricemia（AHU） were listed as follows: (1) aged between 18 and 80 years; (2) serum levels of UA were both greater than 420 μmol/L for a man and 360 μmol/L for a woman during the two clinical tests for the samples collected with about 1-week interval; (3) without self-reported history of the acute attack of gout; (4) without receiving medical treatment.
62025070|NCT05522504||AGA|Acute Gout Attack (AGA) were listed as follows: (1) age between 18 and 80 years; (2) diagnosis with AG at this hospital according to the criteria approved by the ACR Board of Directors and the EULAR Executive Committee in 2015; (3) and not receiving medical treatment 3 weeks prior to the blood collection.
62025071|NCT05522504||IG|The intercritical gout (IG) remission criteria for gout patients were listed as follows: (1) age between 18 and 80 years; (2) diagnosis with AG at this hospital according to the criteria approved by the ACR Board of Directors and the EULAR Executive Committee in 2015; (3) remission of clinical manifestations including redness, swelling, heat, and pain at local joint or bursa for at least three months since the last gout flare; (4) normal level (\<8.20 mg/L) of C-reactive protein (CRP) at the time of blood collection; (5) without tophi, imaging erosion, or chronic gouty arthritis
62025072|NCT05522504||AG|The Advanced gout (AG) criteria for gout patients were listed as follows:(1) age between 18 and 80 years; (2) diagnosis with AG at this hospital according to the criteria approved by the ACR Board of Directors and the EULAR Executive Committee in 2015; (3) remission of clinical manifestations including redness, swelling, heat, and pain at local joint or bursa for at least three months since the last gout flare; (4) normal level (\<8.20 mg/L) of C-reactive protein (CRP) at the time of blood collection; (5) with tophi, imaging erosion, or chronic gouty arthritis
62025073|NCT04989270||Patients undergoing Cesarean section|Group of patients undergoing Cesarean section between Jan'2015 to Dec'2019
62025074|NCT03269474||Experimental Group|Blood and tissue specimen will be collected from subjects with an EB diagnosis. Tissue specimen will be collected from blistered and nonblistered skin.
62025075|NCT03269474||Control Group|Blood and tissue specimen will be collected from healthy subjects with non-EB. Tissue specimen will be collected from an inconspicuous skin area.
62222189|NCT03010176|EXPERIMENTAL|Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions)|Participants with visceral lesions will receive escalating dose frequencies of ulevostinag via IT injection at escalating dose frequencies (Day 1 of each 21-day cycle for up to 35 cycles, then Days 1 and 8 of each 21-day cycle for two cycles, then Day 1 of each 21 day cycle up to 35 cycles, then Days 1, 8, and 15 of each 21-day cycle for two cycles followed by Day 1 of each 21-day cycle up to 35 cycles, PLUS pembrolizumab IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (approximately 2 years).
62222190|NCT03010176|EXPERIMENTAL|Part 2 Cohort A: HNSCC Anti-PD-1/PD-L1 Refractory|Participants with HNSCC who are anti-programmed cell death-1 or anti-programmed cell death-ligand 1 refractory will receive ulevostinag at the preliminary Recommended Phase 2 Dose (RP2D) determined by dose escalation in Part 1 Arm 1 and 2 via IT injection on Days 1, 8, and 15 of Cycles 1 and 2 and on Day 1 of each 21-day cycle from Cycle 3 onward (up to a total of 35 cycles) PLUS pembrolizumab via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
62222191|NCT03010176|EXPERIMENTAL|Part 2 Cohort B: Anti-PD-1/PD-L1 TrT-Naïve or Refractory TNBC|Participants with TNBC who are anti-PD-1/PD-L1 treatment-naïve or who have refractory unresectable locally advanced or metastatic TNBC will receive ulevostinag at the preliminary RP2D determined by dose escalation in Part 1 via IT injection on Days 1, 8, and 15 of Cycles 1 and 2 and on Day 1 of each 21-day cycle from Cycle 3 onward (up to a total of 35 cycles) PLUS pembrolizumab via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
62222192|NCT03010176|EXPERIMENTAL|Part 2 Cohort C: Anti-PD-1/PD-L1 TrT-Naïve Solid Tumors-Liver|Participants with solid tumors with liver metastases/lesions who are anti-PD-1/PD-L1 treatment-naïve will receive ulevostinag at the preliminary RP2D based on Part 1: ulevostinag + pembro (visceral lesions) treatment arm via IT injection in a to-be-determined dose and frequency, based on data from Arm 3, PLUS pembrolizumab via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
62222193|NCT02768311|EXPERIMENTAL|neolix rotary system (continuous rotation system)|Procedure: neolix rotary system post-treatment pain after using neolix rotary system
62222194|NCT02768311|EXPERIMENTAL|waveone rotary system (reciprocating system)|Procedure: waveone rotary system post-treatment pain after using waveone rotary system
62222195|NCT02768311|EXPERIMENTAL|hand files k-files|Procedure: hand files post-treatment pain after using hand files
62222196|NCT05156684|EXPERIMENTAL|placebo group|Control group: oral rehydration salts (ORS, Poursina, Tehran, Iran), two times daily
62025076|NCT00583557|EXPERIMENTAL|Belimumab|
62025077|NCT02846987|EXPERIMENTAL|Abemaciclib (LY2835219)|Patients will be treated with abemaciclib 200 mg bid.
62025078|NCT02353793|EXPERIMENTAL|ReadyHeat® blanket|Patient warming with ReadyHeat® blanket
62025079|NCT02353793|ACTIVE_COMPARATOR|Cotton wool blanket|Patient warming with cotton wool blanket
62025080|NCT01242527|PLACEBO_COMPARATOR|placebo|
62025081|NCT01242527|EXPERIMENTAL|Epanova 2 g|
62797679|NCT05801666|SHAM_COMPARATOR|Control group|Acupuncture on the sham points: ST36 (Zusanli), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Neiguan), and LI4 (Hegu) Liv 3(Taichung)(Sham 1\~5). Those points are not indicated to treat digestion in Chinese medicine and in a location of 1 cm lateral/medial and 1 cm distal/proximal to those points there is no acupuncture point.
62222197|NCT05156684|EXPERIMENTAL|pentoxifylline group|Intervention group 1: received pentoxifylline (TRENTAL 400 mg modified release tablets, OSPS; 400 mg ,two times daily)
62222198|NCT05156684|EXPERIMENTAL|Zinc group|Intervention group 2: received zinc ( Zinc Sulfate 220mg Capsules,One time daily)
62797680|NCT02532465|ACTIVE_COMPARATOR|Air-Q|The Air-Q is composed of an airway tube that connects to an elliptical mask with a cuff which is inserted through the patient's mouth, down the windpipe, and once deployed forms an airtight seal on top the glottis (unlike tracheal tubes which pass through the glottis) allowing a secure airway to be managed by a health care provider.
62797681|NCT02532465|EXPERIMENTAL|i-gel|The i-gel is designed to create a non-inflatable anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures whilst avoiding the compression trauma that can occur with inflatable supraglottic airway devices.
62416474|NCT06698614||Kidney failure undergoing transplantation|20 patients with kidney failure and will receive a kidney transplant in 1 month
62416475|NCT06698614||Kidney transplant rejection|20 patients with a biopsy proven diagnosis of transplant rejection
62416476|NCT05290805|EXPERIMENTAL|ECMO flow rate reduction|In the intervention cohort ECMO flow rate is reduced for the duration of CT image acquisition (max. 1-2 min.), if the hemodynamic and respiratory situation allows it. Feasibility is determined by the accompanying emergency physician right before the CT scan and adapted to the individually tolerable level (max. 50% of initial flow, no less than 1,5 litre/min). After image acquisition, ECMO flow rate is immediately returned to the initial or clinically optimal value at this moment.
62416477|NCT05290805|NO_INTERVENTION|no ECMO flow rate reduction|In this cohort ECMO flow rate is not reduced for CT image acquisition.
62416478|NCT06354439|EXPERIMENTAL|letrozole|Patients will receive 10mg of letrozole por 7 days.
62416479|NCT06354439|ACTIVE_COMPARATOR|Methotrexate|Patients will receive a single intramuscular dose of 100 mg of methotrexate.
62416480|NCT04180371|EXPERIMENTAL|Phase I - Dose escalation (BT5528)|Cohorts of participants will receive increasing doses of BT5528. It is expected that up to 72 participants will participate in this dose escalation arm.
62416481|NCT04180371|EXPERIMENTAL|Phase I - Dose escalation combination (BT5528 & nivolumab)|Cohorts of participants will receive increasing doses of BT5528 and a standard dose of nivolumab. It is expected that up to 24 participants will participate in this dose-escalation combination arm.
62797682|NCT04726683|EXPERIMENTAL|Dry needling|Trigger point dry needling on an active myofascial trigger point of the masseter muscle.
62416482|NCT04180371|EXPERIMENTAL|Phase II - Dose expansion 1 (BT5528)|A cohort of participants will receive the selected dose of BT5528 as a monotherapy. It is expected that up to 164 patients have solid tumors (Cohort 1: urothelial cancers, Cohort 2: ovarian cancer, Cohort 3: non-small cell lung cancer, Cohort 4: head and neck cancer, Cohort 5: triple-negative breast cancer, and Cohort 6: gastric/upper gastrointestinal cancer) historically known for high expression of EphA2 will participate in this dose-expansion arm, Cohort 7: urothelial MMAE exposed, Cohort 8: head and neck squamous cell carcinoma
62416483|NCT04541433|EXPERIMENTAL|AZD9833 monotherapy|Dose escalation of AZD9833 monotherapy for patients with ER+ HER2- advanced breast cancer
62416484|NCT03548454|EXPERIMENTAL|Duloxetine|Duloxetine starting at 20 mg per day and increasing to 60 mg per day as tolerated.
62416485|NCT03548454|EXPERIMENTAL|Desipramine|Desipramine starting at 25 mg per day and increasing to 75 mg per day as tolerated.
62416486|NCT01257100||Cases with NPC|Cases with NPC
62797683|NCT04726683|EXPERIMENTAL|Injection|Trigger point injection of lidocaine on an active myofascial trigger point of the masseter muscle.
62588239|NCT02729363|OTHER|Sickle cell experience discussion|Attention Control Group: This intervention is a 12-minute sickle cell disease experience discussion. In this computer-based discussion, patients talk about their sickle cell disease experience. The audio-taped questions and onscreen directions were programmed for self-administration. Subjects' responses will be captured via the microphone so that Data Collectors are not involved in this discussion process, and it is equivalent to the guided relaxation activity.
62797684|NCT04726683|PLACEBO_COMPARATOR|Placebo|Combines sham dry needling + sham injection.
62797685|NCT04726683|ACTIVE_COMPARATOR|Dry needling + Injection|Combines experimental dry needling and injection
62416487|NCT01257100||Hospital based controls|Hospital based controls
62416488|NCT06568614|EXPERIMENTAL|SYH2039|Monotherapy Dose Escalation (Solid Tumors)
62433424|NCT03980327|EXPERIMENTAL|probiotic|Lactobacillus rhamnosus (5 billion colony forming units per day) and Lactobacillus johnsonii (200 million colony forming units per day) given orally or through a gastrostomy tube daily for 3 months
62588240|NCT03734302|EXPERIMENTAL|Multiple dose oral administration|1mg Once Daily (QD) , oral administration,14 consecutive days
62588241|NCT06665958|EXPERIMENTAL|Experimental: Polyphenol extract low dose (hard capsule)|\<2% flavanol monomer hard capsule
62588242|NCT06665958|EXPERIMENTAL|Experimental: Polyphenol extract medium dose (hard capsule)|15% flavanol monomer hard capsule
62588243|NCT06665958|EXPERIMENTAL|Experimental: Polyphenol extract medium dose (gummy)|15% flavanol monomer x2 gummy
62797686|NCT05058222|ACTIVE_COMPARATOR|Deep breathing ex (10 reps) Group|The control program will consist of Deep Breathing Exercises (from Morning to night every three hours; each session consisting of 10 deep breaths with a few seconds pause between each set, for 3 days) in addition with progressive Exercises.
62797687|NCT05058222|EXPERIMENTAL|Deep breathing ex (30 reps) Group|The intervention group will perform additional Deep breathing Exercises (from Morning to night every three hours; each session consisting of 30 deep breaths with a few seconds pause between each set, for 3 days).
62222199|NCT05156684|EXPERIMENTAL|pentoxifylline+ zinc group|Intervention group 3: received pentoxifylline+ zinc (TRENTAL 400 mg modified release tablets, OSPS; 400 mg ,two times daily + Zinc Sulfate 220mg Capsules,One time daily )
62222200|NCT02322801||Cohort|
62222201|NCT06307899|EXPERIMENTAL|Group 1|Unilateral Corner Stretching
62222202|NCT06307899|EXPERIMENTAL|Group 2|Manual Stretching
62222203|NCT06307899|EXPERIMENTAL|Group 3|PNF Stretching
62222204|NCT01954966|ACTIVE_COMPARATOR|Progesterone 200 mg capsules|Subjects will be prescribed progesterone 200 mg capsules by the study Principal Investigator. Subjects will take 200 mg of progesterone daily for four days.
62222205|NCT01954966|PLACEBO_COMPARATOR|Progesterone 200 mg look-alike capsules|Subjects will be prescribed progesterone 200 mg look-alike placebo capsules by the study Principal Investigator. Subjects will take look-alike placebo capsules daily for four days.
62222206|NCT05323760|EXPERIMENTAL|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing (CPET) using a Quark CPET metabolic cart (Rome, Italy) according to American Thoracic Society (ATS) guidelines. A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute) adapted to the patient's functional capacities according to the examiner's free judgment, up to exhaustion.
62222207|NCT02335528|EXPERIMENTAL|SimCoach intervention|"Participants randomized to the SimCoach intervention arm interacted with Bill Ford, a simulated human (avatar) enacted in the SimCoach program. This white male avatar representing himself as an Army veteran who spoke to participants in a conversational manner. Participants interacted with him using a chat interface, where they could type responses to him. Bill Ford asked participants a series of questions that corresponded to validated PTSD or depression screening questionnaires. SimCoach then provided personalized recommendations for a symptom if the user reported experiencing the symptom at one of the two highest frequencies on the response scale. These recommendations consisted of a behavioral recommendation with an accompanying link to a website or online article on the topic."
62416489|NCT02791581|EXPERIMENTAL|Breast Cancer Patients|"Breast cancer patients receiving non-anthracycline or anthracycline chemotherapy Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.~Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, on 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.~Measurements will be repeated at 3±1, 12±2 and 24±2 months after initiation of chemotherapy treatment."
62416490|NCT02791581|EXPERIMENTAL|Non-Cancer Controls|"Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months. Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.~Measurements will be repeated at 3±1, 12±2 (after the completion of radiation) and 24±2 months after initiation of baseline activities."
62797688|NCT01988675||Partial Brain Irradiation|Patients will receive partial brain irradiation for malignant or benign brain tumors as standard of care. Patients will also have MRI (Magnetic Resonance Imaging) scans and neuropsychological/QOL (Quality of Life Questionnaire) tests prior during and after RT (Radiation Therapy).
62416491|NCT01823250|EXPERIMENTAL|CIFFTA|Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA)involves four months of intervention. Adolescents and families receive one family therapy session per week and an additional session which is either a psycho-educational session for the adolescent and/or parents, or an individual therapy session with the adolescent. There is a total of 2 sessions per week.
62416492|NCT01823250|ACTIVE_COMPARATOR|Traditional Family Therapy (TFT)|The Traditional Family Therapy condition consists of once per week family therapy based on Structural Family Theory and a didactic group intervention once per week in which HIV/STI risk is discussed.
62416493|NCT06700889||Overnight HEN group|This group will include participants who habitually feed overnight using home enteral nutrition (HEN).
62416494|NCT06700889||Daytime HEN Group|This group will include participants who habitually feed during the daytime (bolus or cycle) using home enteral nutrition (HEN).
62416495|NCT06474130||Chronic neck pain group|Pain was unilateral or bilateral between the superior nuchal line and 1st thoracic vertebra; Neck pain persisting for 3 months and above; Average pain intensity of last pain episode was between 2 and 8 based on the numerical rating scale (NRS).
62416496|NCT06474130||Healthy adults group|Do not have any complaints of current pain and impairments of neuromusculoskeletal systems within the last 6 months.
62416497|NCT06489028|EXPERIMENTAL|Verum|
62416498|NCT06489028|PLACEBO_COMPARATOR|Placebo|
62025082|NCT01242527|EXPERIMENTAL|Epanova 3 g|
62588244|NCT06665958|EXPERIMENTAL|Experimental: Polyphenol extract high dose (hard capsule)|26% flavanol monomer hard capsule
62416499|NCT00771654|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to the daily dosing of either oral Phentermine 37.5mg or placebo to commence at their 2 week follow-up appointment following their gastric band procedure
62416500|NCT00771654|EXPERIMENTAL|Phentermine|Subjects will be randomized to the daily dosing of either oral Phentermine 37.5mg or placebo to commence at their 2 week follow-up appointment following their gastric band procedure
62416501|NCT02558179||Nugent Score >/= 7|Signs and symptoms of vaginitis/vaginosis, including vaginal discharge, pruritis, irritation, and/or dyspareunia. Diagnosis of bacterial vaginosis (study group) according to Nugent score and/or diagnosis of vulvovaginal candidiasis; and/or diagnosis of Trichomonas vaginalis.
62416502|NCT02558179||Nugent Score< 7|Signs and symptoms of vaginitis/vaginosis, including vaginal discharge, pruritis, irritation, and/or dyspareunia. Bacterial vaginosis not diagnosed according to Nugent score (\<7).
62416503|NCT04681807|EXPERIMENTAL|Emotion Recognition Training|
62797689|NCT01988675||Whole Brain Irradiation|Patients will receive whole brain irradiation for brain metastases as standard of care. Patients will also have MRI (Magnetic Resonance Imaging) scans and neuropsychological/QOL (Quality of Life Questionnaire) tests prior during and after RT (Radiation Therapy).
62797690|NCT00941408||Diagnostic tumor core biopsy|
62222208|NCT02335528|NO_INTERVENTION|Content Matched Control|Participants assigned to the Content Matched Control condition arm completed text-based versions of the PCL PTSD screening inventory and PHQ-9 depression screening inventory. These instruments used standard, validated language and did not use the modified conversational versions used in the SimCoach intervention condition. The same personalized recommendations provided to the SimCoach group were provided as conventional text and links. After receiving personalized recommendations, participants completed text versions of primary help-seeking, perceived barriers to seeking help, and secondary outcome (user experience) measures.
62222209|NCT02335528|NO_INTERVENTION|No-Treatment Control|Participants randomized to the No-Treatment Control arm completed measures of the primary outcome (intentions to seek help) prior to being given a choice of SimCoach or the conventional screening administered in the other two arms of the study. After the help-seeking intention questionnaire was administered, participants were told that they would be asked some questions about any PTSD or depression symptoms that they might be having and were given the choice between chatting online with a virtual human or using an online form (options were presented in random order to prevent any influence of ordering on selection of the tool). After either interacting with SimCoach or filling out an online form, participants completed a questionnaire assessing user experience.
62222210|NCT00573092||1|Data and specimens from three large population-based studies of heart attack, sudden death, and stroke in people treated for high blood pressure with one of the four major classes of high blood pressure drugs
62222211|NCT01232179|ACTIVE_COMPARATOR|conventional prp|
62222212|NCT01232179|ACTIVE_COMPARATOR|targeted PRP|
62222213|NCT06301984|EXPERIMENTAL|Experimental|In the initial assessment, data regarding the general health status will be collected and imaging exams (panoramic X-ray of the anteroposterior, lateral and traction spine, and X-ray of the right and left hands) and laboratory tests (blood count, coagulogram, dosage of sodium and potassium, urea and creatinine levels, AST and ALT, PCR, ESR, type I urine and urine culture) will be requested. During the preoperative consultation, measurements of the study variables will be obtained from the imaging exams), in addition to obtaining photographs of the patients. To install the Insight GS system, the surgical approach will be carried out according to the manufacturer's instructions for use, briefly described below. A posterior midline skin incision is made from the upper to the lower instrumented level. Subfascial exposure of the spine is performed, ensuring that the facet joint capsules are spared. Pedicle screws are inserted bilaterally at the cranial and caudal ends of the instrumentati
62416504|NCT04681807|ACTIVE_COMPARATOR|Active Control Training|
62416505|NCT06701799|EXPERIMENTAL|CAF+ L-PRF 2 mm|Coronally Advanced Flap combined with in combination with a membrane 2 mm in thickness of L-PRF for the Treatment of RT1 Gingival Recession.
62797691|NCT04163575|EXPERIMENTAL|experimental:1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.
62797692|NCT04163575|EXPERIMENTAL|experimental:2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.
62797693|NCT04163575|EXPERIMENTAL|experimental:3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.
62797694|NCT03754517||Serofast status|The syphilitic patients who remain in a serologically positive state after therapy
62797695|NCT03754517||Untreated|untreated syphilis cases
62797696|NCT03754517||Serological cure|"In the early syphilis patients, at 6 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer.~In the late syphilis patients, at 12 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer."
62797697|NCT04757116|EXPERIMENTAL|iTind arm|The iTind is a minimally invasive temporary implant
62797698|NCT04757116|EXPERIMENTAL|UroLift|The UroLift is a minimally invasive permanent implant
62797699|NCT02504489|ACTIVE_COMPARATOR|Docetaxel (D)|A treatment cycle is 21 days. Treatment will be repeated until disease progression is detected by imaging studies or unacceptable toxicities are encountered. On Day 1, all patients will receive docetaxel 75 mg/m2 by intravenous (IV) infusion over 1 hour. Oral dexamethasone (16 mg, given as 8 mg twice daily) will be given on the day prior to, the day of (Day 1), and the day following docetaxel infusion (Day 2). Antiemetic prophylaxis will be administered according to institutional guideline for docetaxel. Institutional guideline/practice should be followed in the event of infusion/hypersensitivity reaction. Diphenhydramine and dexamethasone infusion may be administered in the event of infusion reaction.
62797700|NCT02504489|EXPERIMENTAL|Docetaxel + Plinabulin (DP)|The treatment regimen for Docetaxel (D) will be followed for this arm. In addition, on Days 1 and 8 of the 21 day cycle, patients will receive Plinabulin (P) administered via IV infusion over 60 minutes. On Day 1, the infusion begins 2 hours from the starting time of docetaxel infusion, i.e, approximately 60 minutes from the end of docetaxel infusion. On Day 8, patients must be given an anti-emetic prophylactically before the plinabulin infusion. If emesis persists after Day 8, with a grade \>1, plinabulin will be reduced to 20 mg/m2. Patients from the DP Arm who stop treatment with docetaxel due to toxicity or another medically acceptable reason, may continue treatment with plinabulin alone as previously described.
62797701|NCT03869554|EXPERIMENTAL|Renal disease|detection of Fabry disease
62416506|NCT06701799|EXPERIMENTAL|CAF+ L-PRF 1 mm|Coronally Advanced Flap combined with in combination with a membrane 1 mm in thickness of L-PRF for the Treatment of RT1 Gingival Recession.
62797702|NCT00704886|NO_INTERVENTION|1|verbal
62797703|NCT00704886|EXPERIMENTAL|2|video
62797704|NCT05276258|EXPERIMENTAL|Nerve Block Using Liposomal Bupivacaine and cryoSPHERE Ablation|The experimental group (75 participants) will undergo intercostal nerve block using liposomal bupivacaine and the cryoSPHERE ablation of intercostal nerves during robotic-assisted thoracoscopic operation at Houston Methodist Hospital.
62025083|NCT01242527|EXPERIMENTAL|Epanova 4 g|
62025084|NCT02801045|EXPERIMENTAL|art therapy|Individual 30-60 minutes art therapy sessions, twice a week, offering visual arts materials.
62416507|NCT02937285|ACTIVE_COMPARATOR|Standard care|Interferon alone
62797705|NCT05276258|OTHER|Historical Controls|A total of 75 propensity score-matched historical controls will be selected from the pool of patients who had standard intercostal nerve block using liposomal bupivacaine alone at Houston Methodist Hospital from January 1, 2017 through January 1, 2022, inclusively.
62416508|NCT02937285|EXPERIMENTAL|Experimental group|Mitoxantrone for 6 month followed by interferon
62416509|NCT01398449|EXPERIMENTAL|B|After esophagectomy, patients in Arm B will receive adjuvant chemotherapy, followed by elective nodal irradiation (ENI)
62416510|NCT01398449|ACTIVE_COMPARATOR|A|After esophagectomy, patients in Arm A will receive adjuvant chemotherapy only
62797706|NCT00128310|ACTIVE_COMPARATOR|Arm A: Vinorelbine|Arm A: Vinorelbine 30 mg/m2 will be administered as an intravenous infusion over 6-10 minutes on Study Days 1 and 8.
62797707|NCT00128310|EXPERIMENTAL|Arm B: Vinorelbine and Gemcitabine|Arm B: Vinorelbine 30 mg/m2 will be administered as an intravenous infusion over 6-10 minutes on Study Days 1 and 8. Gemcitabine will be administered following vinorelbine at a dose of 1200 mg/m2 as an intravenous infusion over 30 minutes.
62797708|NCT03676972|EXPERIMENTAL|LithoVue ureteroscope system|The LithoVue System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
62797709|NCT01926834|EXPERIMENTAL|Erigeron Injection|Erigeron Injection, 30ml,qd,i.v., for 7 days
62797710|NCT01926834|PLACEBO_COMPARATOR|placebo|normal saline, 500ml,i.v.,qd, for 7 days
62797711|NCT01926834|NO_INTERVENTION|health volunteers|health volunteers, no drug to be given.
62797712|NCT06276426|EXPERIMENTAL|Soy|The experimental group will be asked to consume 2 servings/day of soy foods for 3 months
62797713|NCT06276426|ACTIVE_COMPARATOR|Non-Soy Plant-Based Foods|The control group will be asked to consume 2 servings/day of non-soy plant-based foods for 3 months
62797714|NCT05248581||All Participants|Potential subjects for this registry must have Stage IV colorectal cancer with liver metastases and be candidates for liver transplantation based on multidisciplinary discussion by the Liver transplantation team. Patients must demonstrate favorable tumor biology and no evidence of extra hepatic disease.
62588245|NCT04713592|PLACEBO_COMPARATOR|Placebo|Participants received subcutaneous placebo injections during the 16-week Double-blind Period at Baseline (Day 1) and Week 4. Starting at Week 16, all participants received open-label risankizumab 150 mg subcutaneous injections once every 12 weeks (q12w) at Weeks 16, 28, and 40.
62222214|NCT00553072|ACTIVE_COMPARATOR|Magnesium sulphate, neurological outcome|Magnesium sulphate 250mg/kg after every 24 hours starting within 6 hours from birth
62222215|NCT00553072|PLACEBO_COMPARATOR|Placebo|Placebo every 24 hours for 3 doses starting from 6 hours after birth
62222216|NCT02880891|EXPERIMENTAL|splinted|splinted crown
62222217|NCT02880891|NO_INTERVENTION|non-splinted|single crown
62222218|NCT02988622|OTHER|Scar treated with Fraxel and CO2 laser|One half of scar is treated with Fraxel laser and the other half of scar is treated with CO2 laser.
62797715|NCT03470480|EXPERIMENTAL|Treatment rTMS + meth pictures|Participants in this group will receive real repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of methamphetamine-related pictures to evaluate response to methamphetamine visual cues while receiving real rTMS treatments. This group will be referred to as real METH (RM).
62797716|NCT03470480|ACTIVE_COMPARATOR|Treatment rTMS + neutral pictures|Participants in this group will receive real repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of neutral pictures to evaluate response to neutral visual cues while receiving real rTMS treatments. This group will be referred to as real neutral (RN).
62797717|NCT03470480|SHAM_COMPARATOR|Sham rTMS + meth pictures|Participants in this group will receive sham repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of methamphetamine-related pictures to evaluate response to methamphetamine visual cues while receiving sham rTMS treatments. This group will be referred to as sham METH (SM).
62797718|NCT03470480|SHAM_COMPARATOR|Sham rTMS + neutral pictures|Participants in this group will receive sham repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of neutral pictures to evaluate response to neutral visual cues while receiving sham rTMS treatments. This group will be referred to as sham neutral (SN).
62222219|NCT01762319|EXPERIMENTAL|Misoprostol|200 mcg Misoprostol SL 1 hour prior to fractional curettage
62222220|NCT01762319|PLACEBO_COMPARATOR|Vitamin B6|100 mg Vitamin B6 SL 1 hr prior to fractional curettage
62222221|NCT04985968|EXPERIMENTAL|Cobitolimod 250 mg|"Dose of 250 mg cobitolimod~2 treatments during induction study and subsequently every third week"
62222222|NCT04985968|EXPERIMENTAL|Cobitolimod 500 mg|"Dose of 500 mg cobitolimod~2 treatments during induction study and subsequently every third week"
62416511|NCT06123975||Adenomyosis Cohort|Infertile patients with adenomyosis who met the inclusion and exclusion criteria, after signing the informed consent form, the researchers recorded the clinical information of the patients and initiated the IVF-ET procedure. Peripheral blood was collected on the day of embryo transfer. And if the pregnancy test was positive at 14 days after embryo transfer, peripheral blood was collected at 21 days after the transfer and every 2 weeks thereafter until 12 weeks of gestation.
62797719|NCT03172312||Total thyroidectomy|Patients need to do total thyroidectomy According to guidelines
62797720|NCT03172312||Hemithyroidectomy|Patients need to do Hemithyroidectomy According to guidelines
62222223|NCT04985968|PLACEBO_COMPARATOR|Placebo|"Dose of Placebo~2 treatments during induction study and subsequently every third week"
62222224|NCT03260257|EXPERIMENTAL|Schizophrenia patients|Thirty SCZ patients will receive neurofeedback to enhance gamma band response in an open-label, proof of concept study.
62222225|NCT05644860|ACTIVE_COMPARATOR|Conventional Composite Group (Transbond XT)|Patients in which brackets will be bonded with conventional composite resin (Transbond XT)
62222226|NCT05644860|EXPERIMENTAL|Nanohybrid Compisite Group (Filtek Z250)|Patients in which brackets will be bonded with nanohybrid composite resin (Filtek Z250)
62416512|NCT01248130|ACTIVE_COMPARATOR|Omega-3 Fatty Acid Treatment|
62797721|NCT02460809|ACTIVE_COMPARATOR|In-lab tDCS|Three people with chronic stroke will participate in finger tracking training while receiving transcranial direct current stimulation (tDCS) in a controlled laboratory environment with an investigator.
62025085|NCT04750252|EXPERIMENTAL|Subjects with moderate to severe OA of the Knee|
62025086|NCT02574975|ACTIVE_COMPARATOR|Methacholine diagnosing group|Methacholine bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
62797722|NCT02460809|EXPERIMENTAL|In-home tDCS|Three people with chronic stroke will participate in finger tracking training while receiving transcranial direct current stimulation (tDCS) in their own home. Patients will be taught how to use a blue-tooth enabled telerehabilitation module that is being controlled by an investigator in the lab on the University campus. For safety, an investigator will be in the home with each patient during tDCS use and finger tracking training but will only be supervising procedures.
62025087|NCT02574975|EXPERIMENTAL|Adenosine monophosphate diagnosing group|Adenosine monophosphate bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
62025088|NCT02574975|EXPERIMENTAL|Leukotriene D4 diagnosing group|Leukotriene D4 bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
62025089|NCT02574975|EXPERIMENTAL|Astograh diagnosing group|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
62025090|NCT02574975|EXPERIMENTAL|budesonide /formoterol treatment group|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three month
62025091|NCT03236103|OTHER|Subjects with VAD in place|Adult patients with VAD in place who are admitted to the hospital for acute medical illness. The investigators will provide clinical recommendations to the subject's primary care provider.
62025092|NCT05960539||robotic procedures|surgical residents and experts; differentiation due to organ systems
62025093|NCT04679220|ACTIVE_COMPARATOR|Non-heated Resin Composite group|Patients received Non-heated nanofilled resin composite on one side of the mouth
62025094|NCT04679220|PLACEBO_COMPARATOR|Preheated Resin Composite group|Patients received preheated nanofilled resin composite on the other side of the mouth
62025095|NCT05127343|ACTIVE_COMPARATOR|Resin based sealant (Ultraseal XT Hydro)|
62588246|NCT04713592|EXPERIMENTAL|Risankizumab|Participants received risankizumab 150 mg subcutaneous injections during the 16-week Double-blind Period at Baseline (Day 1) and Week 4. Starting at Week 16, all participants received open-label risankizumab 150 mg subcutaneous injections once every 12 weeks (q12w) at Weeks 16, 28, and 40.
62588247|NCT03086928|EXPERIMENTAL|lava ultimate|lava ultimate is Resin nano-ceramic which is a mixture of a resin composite matrix and nano-ceramic fillers of approximately 80% by weight. The main advantages of this material over the glass ceramics are the stress absorbing action or stress distribution by having modulus of elasticity near to the tooth dentin and can be individualized intra-orally or extra-orally, either before or after definitive cementation.
62797723|NCT04030026|EXPERIMENTAL|NAL ER then placebo|Participants will receive NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID over a 3 week period, followed by a 2 week washout. They will then receive Placebo tablet (matching NAL ER BID) for 3 weeks.
62797724|NCT04030026|EXPERIMENTAL|Placebo then NAL ER|Participants will receive Placebo tablet (matching NAL ER BID) for 3 weeks, followed by a 2 week washout. They will then receive NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID over a 3 week period .
62588248|NCT03086928|ACTIVE_COMPARATOR|E.max cad|E.max is lithium disilicate glass ceramic, composed of quartz, lithium dioxide, phosphor oxide, alumina oxide, and potassium oxide with superior mechanical and optical properties if used for laminate veneers
62588249|NCT06480240|EXPERIMENTAL|Phase 1 Dose Escalation - Cohort 1|OBI-992 at dose level 1 mg/kg, Q3W
62588250|NCT06480240|EXPERIMENTAL|Phase 1 Dose Escalation - Cohort 2|OBI-992 at dose level 2 mg/kg, Q3W
62588251|NCT06480240|EXPERIMENTAL|Phase 1 Dose Escalation - Cohort 3|OBI-992 at dose level 4 mg/kg, Q3W
62025096|NCT05127343|ACTIVE_COMPARATOR|Glass ionomer based sealant (Fugi Triage)|
62025097|NCT04367168|ACTIVE_COMPARATOR|Colchicine|Colchicine PO
62025098|NCT04367168|PLACEBO_COMPARATOR|Placebo|Placebo PO
62025099|NCT06384651|ACTIVE_COMPARATOR|Intravenous Vancomycin|Patients will receive the orthopedic surgeon's standard of care pre-operative antibiotic regimen for TAA patients. This includes IV antibiotics (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg generally 1000-1750mg in 500mL normal saline (NS))
62025100|NCT06384651|EXPERIMENTAL|Intraosseous Vancomycin|"IV antibiotics per physician's standard of care: Typically ancef or cefepime is started in pre-op within 1 hour of incision. IV Vancomycin will not be given preoperatively in this group.~IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~IO Injection will take place into the medial malleolus."
62025101|NCT06512662|NO_INTERVENTION|Control|
62025102|NCT06512662|EXPERIMENTAL|Supportive care|
62025103|NCT02649686|EXPERIMENTAL|Durvalumab plus Trastuzumab|Durvalumab q3w until PD Trastuzumab q3w x 6
62025104|NCT02635477|EXPERIMENTAL|Intervention Group|frail elderly patients discharged from a cardiovascular hospitalization; provided with an actigraphy device that displays an adaptive personalized daily step count goal and audible alerts to increase physical activity
62025105|NCT02635477|EXPERIMENTAL|Control Group|frail elderly patients discharged from a cardiovascular hospitalization; provided with a matching actigraphy device that has a blacked-out screen and does not display step count goals or provide audible alerts (functions in silent monitoring mode only)
62025106|NCT06485778|EXPERIMENTAL|Radiation Therapy|These patients will then receive bilateral cervical nodal irradiation with the primary post operative site excluded (30 fractions). They will be monitored for both physician reported toxicities.
62588252|NCT06480240|EXPERIMENTAL|Phase 1 Dose Escalation - Cohort 4|OBI-992 at dose level 6 mg/kg, Q3W
62588253|NCT06480240|EXPERIMENTAL|Phase 1 Dose Escalation - Cohort 5|OBI-992 at dose level 8 mg/kg, Q3W
62588254|NCT06480240|EXPERIMENTAL|Phase 1 Dose Escalation - Cohort 6|OBI-992 at dose level 10 mg/kg, Q3W
62025107|NCT04812912||Participants with Colon Cancer|This patient population will have hormone biomarker analysis, questionnaire (QOL) administration, and, if the patient is male, semen analysis
62222227|NCT03452579|ACTIVE_COMPARATOR|Nivolumab + Standard Dose Bevacizumab|"nivolumab 240 mg IV and standard dose bevacizumab 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity.~Nivolumab is to be administered first. The second infusion will be bevacizumab, and will start no sooner than 10 minutes after completion of the nivolumab infusion"
62416513|NCT01248130|PLACEBO_COMPARATOR|Placebo (Sugar Pill)|
62588255|NCT06480240|EXPERIMENTAL|Phase 2 Cohort Expansion - Cohort 1a|Non-small cell lung cancer indication cohort - Randomized dose optimization cohort. Dose level to be determined by the Safety Review Committee based on data available.
62025108|NCT04812912||Participants with Rectal Cancer|This patient population will have hormone biomarker analysis, QOL administration, and, if the patient is male, semen analysis
62797725|NCT02481297|EXPERIMENTAL|Cohort 1: Refractory/Relapsed After Prior Therapy|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22), then with start of each course. Lirilumab 3 mg/kg by vein given on Day 1 of each cycle. Rituximab given for the first 12 cycles and Lirilumab continues for up to 24 cycles. Each cycle is 4 weeks.
62025109|NCT05372445|NO_INTERVENTION|Reference Group|"People between 30-60 years old, without obesity, prediabetes or type 2 diabetes.~The purpose of this group is to characterize gut microbiota and microbiome to set the reference values of the argentinian local population."
62025110|NCT05372445|ACTIVE_COMPARATOR|Obesity Group A|People between 30-60 years old, diagnosed with obesity assigned to the non-intensive intervention.
62222228|NCT03452579|EXPERIMENTAL|Nivolumab + Low Dose Bevacizumab|"nivolumab 240 mg IV and low dose bevacizumab 3mg/kg every 2 weeks until disease progression or unacceptable toxicity~Nivolumab is to be administered first. The second infusion will be bevacizumab, and will start no sooner than 10 minutes after completion of the nivolumab infusion"
62222229|NCT05596058|EXPERIMENTAL|Dual task (active exercise and cognitive task)|"The dual task protocol is going to be in 15 one-hour sessions once a week in the headache free days.~This protocol will be set up in the clinic of physiotherapy degree (University of Trieste in the Department of Medical, Surgical, and Health Sciences).~The physical training tasks will be associated with concomitant cognitive tasks specifically relying on executive function.~The goal is to engage the three core executive functions: inhibition (the ability to inhibit automated responses), working memory (the ability to hold, process, and manipulate information in mind) and shifting (the ability to change stimulus-response associations for performing an ongoing task).~Patients will be exposed to different cognitive tasks during physical activity such as walking or running on the treadmill, indoor cycling and balance exercises.~-"
62222230|NCT05596058|ACTIVE_COMPARATOR|active exercise only|The active exercise only intervention is going to consist of aerobic and flexibility training with a targeted duration of 1 hour, twice per week for 3 months.
62222231|NCT05596058|ACTIVE_COMPARATOR|Cognitive task trainig only|The Cognitive task training only engage the three core executive functions: inhibition (the ability to inhibit automated responses), working memory (the ability to hold, process, and manipulate information in mind) and shifting (the ability to change stimulus-response associations for performing an ongoing task).
62222232|NCT05589948|PLACEBO_COMPARATOR|Placebo Control 1|Calm Product Form 1 - control
62222233|NCT05589948|PLACEBO_COMPARATOR|Placebo Control 2|Calm Product Form 2 - control
62222234|NCT05589948|EXPERIMENTAL|Active Product 1.1|Calm Product Form 1 - active product 1
62222235|NCT05589948|EXPERIMENTAL|Active Product 2.1|Calm Product Form 2 - active product 1
62025111|NCT05372445|EXPERIMENTAL|Obesity Group B|People between 30-60 years old, diagnosed with obesity assigned to the intensive intervention.
62222236|NCT05589948|EXPERIMENTAL|Active Product 2.2|Calm Product Form 2 - active product 2
62416514|NCT06702189|ACTIVE_COMPARATOR|Experimental Condition|Active sessions will last 1 hour each. The following parameters will be used for electric stimulation: low frequency (20 Hz), low current intensity (2 mA), with a small pulse width of 25-170 microseconds. These parameters were previously found to be safe in human studies. Based on the clinical exam of each patient, the spastic muscles will be targeted.
62433425|NCT03980327|PLACEBO_COMPARATOR|control|1 mL of pure medium chain triglyceride oil given orally or through a gastrostomy tube daily for 3 months
62433426|NCT01575119|EXPERIMENTAL|In-patient surgery|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
62588256|NCT06480240|EXPERIMENTAL|Phase 2 Cohort Expansion - Cohort 1b|Non-small cell lung cancer indication cohort - Randomized dose optimization cohort. Dose level to be determined by the Safety Review Committee based on data available.
62588257|NCT06480240|EXPERIMENTAL|Phase 2 Cohort Expansion - Cohort 2|Small cell lung cancer indication cohort - OBI-992 dosed at putative recommended phase 2 dose.
62588258|NCT06480240|EXPERIMENTAL|Phase 2 Cohort Expansion - Cohort 3|Gastric cancer indication cohort - OBI-992 dosed at putative recommended phase 2 dose.
62025112|NCT05372445|ACTIVE_COMPARATOR|Prediabetes Group A|People between 30-60 years old, diagnosed with prediabetes assigned to the non-intensive intervention.
62025113|NCT05372445|EXPERIMENTAL|Prediabetes Group B|People between 30-60 years old, diagnosed with prediabetes assigned to the intensive intervention.
62025114|NCT05372445|ACTIVE_COMPARATOR|Type 2 Diabetes Group A|People between 30-60 years old, diagnosed with type 2 diabetes assigned to the non-intensive intervention.
62025115|NCT05372445|EXPERIMENTAL|Type 2 Diabetes Group B|People between 30-60 years old, diagnosed with type 2 diabetes assigned to the intensive intervention.
62025116|NCT02921802||Patients who received Revlimid|Among relapsed or refractory multiple myeloma and Myelodysplastic syndrome (MDS) with a deletion 5q cytogenetic abnormality patients, all patients who received Revlimid will be targeted in this surveillance.
62025117|NCT00941603|EXPERIMENTAL|SCH 900271 15 mg|Participants receive SCH 900271 15 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
62025118|NCT00941603|EXPERIMENTAL|SCH 900271 10 mg|Participants receive SCH 900271 10 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
62416515|NCT06702189|SHAM_COMPARATOR|Control Condition|The control arm will be a sham intervention. The patients will receive a sham stimulation, for which the same EXOPULSE Mollii suit will be used but the suit control unit will be programmed to start stimulating for 1 minute then it will shut off which could enable cutaneous sensations that mimic the active condition, aiming to achieve an effective blinding integrity. There is no risk related to the sham intervention since it consists of applying the same parameters used for the active session (low frequency: 20 Hz; current intensity: 2 mA; pulse width ranging from 25 to 175 µs) but for a shorter duration of time (1 minute).
62797726|NCT02481297|EXPERIMENTAL|Cohort 2: Untreated with High-rRisk mMolecular Features|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22), then with start of each course. Lirilumab 3 mg/kg by vein given on Day 1 of each cycle. Rituximab given for the first 12 cycles and Lirilumab continues for up to 24 cycles. Each cycle is 4 weeks.
62025119|NCT00941603|EXPERIMENTAL|SCH 900271 5 mg|Participants receive SCH 900271 5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
62025120|NCT00941603|EXPERIMENTAL|SCH 900271 2.5 mg|Participants receive SCH 900271 2.5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
62222237|NCT06384573|EXPERIMENTAL|lecanemab|Starting at Week 0, participants will receive open-label lecanemab administered intravenously approximately every 2 weeks for a minimum of 5 years utilizing a common close design.
62416516|NCT03568630||New Onset Diabetes/High-Risk Prediabetes|"Must meet one of the following criteria:~1. New onset type 2 diabetes diagnosed within the past 3 years, defined as Hemoglobin A1c ≥ 6.5%\*, fasting blood glucose \>126mg/dL confirmed on a subsequent day or as diagnosed by a physician~2. High-risk pre-diabetes: Hemoglobin A1c \>6.3% or A1c \>6.0% with fasting blood glucose \>110 or 2 hour oral glucose tolerance test between 140-200mg/dL; subjects who have been on metformin \<3 years are eligible"
62416517|NCT03568630||Pancreatic Cystic Neoplasm/Pancreatitis|"Must meet one of the following criteria:~1. Pancreatic cystic neoplasm for which resection, endoscopic ultrasound or serial imaging has been recommended~2. Chronic pancreatitis as defined by cross-sectional imaging, endoscopic ultrasound, functional testing abnormalities OR as diagnosed by a gastroenterologist"
62416518|NCT03568630||Inherited Risk|"Must meet one of the following criteria:~1. Two or more blood relatives with PDAC (includes 1st-3rd degree relatives as defined in Table 2)~2. One 1st degree relative with PDAC diagnosed before age 60~3. Germline mutation associated with a higher than average risk of PDAC including but not limited to the following: Hereditary breast and ovarian cancer syndromes BRCA1, BRCA2, PALB2 Hereditary nonpolyposis colon cancer (Lynch) syndrome MLH1, MSH2, MSH6, PMS2 Familial adenomatous polyposis (APC) Familial atypical multiple melanoma and mole syndrome CKDN2a, p16 Peutz-Jeghers syndrome STK11 Ataxia-telangiectasia ATM Juvenile polyposis syndromes SMAD4, BMPR1A Li Fraumeni TP53 Cystic fibrosis and unaffected carriers CFTR~4. Personal or family history which meets clinical criteria for a hereditary cancer syndrome and includes a relative with PDAC"
62416519|NCT04338646||Patients enrolled|Patient with multiple sclerosis and lower urinary tract symptoms, age \>18 Expanded Disability Status Scale score between 1 and 6.5
62797727|NCT04628780|EXPERIMENTAL|Dose Escalation (Part 1)|Participants will receive PF-07209960 at escalating dose levels
62797728|NCT04628780|EXPERIMENTAL|Dose Expansion (Part 2) - Cohort 1 (NSCLC)|Participants with non-small cell lung cancer (NSCLC) will receive PF-07209960 at the recommended dose from Part 1
62025121|NCT00941603|EXPERIMENTAL|SCH 900271 1 mg|Participants receive SCH 900271 1 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
62025122|NCT00941603|PLACEBO_COMPARATOR|Placebo|Participants receive two placebo tablets once daily in the morning with water in a fasted state for 8 weeks
62025123|NCT02386566||natalizumab|natalizumab 300 mg intravenous (IV) every 4 weeks; according to the approved product label of Tysabri in Switzerland
62025124|NCT00053833|EXPERIMENTAL|irinotecan|irinotecan
62025125|NCT01108081|EXPERIMENTAL|Arm 1|Physical activity
62025126|NCT01108081|EXPERIMENTAL|Arm 2|Diet
62025127|NCT01108081|ACTIVE_COMPARATOR|Arm 3|Health education
62025128|NCT01108081|EXPERIMENTAL|Arm 4|Combined physical activity and diet
62222238|NCT04714476|EXPERIMENTAL|Fit test of made-to-measure garments|Healthy subjects will test made-to-measure compression garments
62025129|NCT04915794|EXPERIMENTAL|Simulation based education|Simulation is a technique that creates a situation or environment that allows people to experience the representation of a real event, practice, learn, evaluate, test, or gain an understanding of systems or human actions
62025130|NCT04915794|NO_INTERVENTION|Traditional education|Necessary procedures explained theoretically
62025131|NCT06670092|EXPERIMENTAL|Experimental group|This group is treated according to Vojta therapy
62025132|NCT06670092|OTHER|Control group|This group does not receive treatment
62222239|NCT02379104||Healthy Volunteers|Healthy volunteers fulfilling inclusion/exclusion criteria for reference interval sample group are tested with ROTEM sigma
62222240|NCT02379104||Patients with expected coagulopathy|Patients with expected bleeding and coagulation problems during elective surgery or at the ICU, or trauma patients are tested with ROTEM sigma and ROTEM delta comparatively
62416520|NCT05854745|EXPERIMENTAL|Virtual HBB Teaching|HBB Virtual Training (Intervention): Participants will receive a blend of virtual training and telesimulation delivered by pediatricians from Ethiopia. The intervention consists of one day of virtual lectures and didactics from the HBB curriculum and skill assessments using neonatal mannequins.
62416521|NCT05854745|ACTIVE_COMPARATOR|In-person HBB Teaching|Participants will receive in-person HBB instruction by pediatricians from Ethiopia. The control consists of one day of HBB lectures and didactics and skill assessments using neonatal mannequins.
62416522|NCT04440631||Antibiotic therapy including rifampicin|
62416523|NCT04440631||Non-rifampicin antibiotic therapy|
62416524|NCT04440631||Control group (healthy volunteers)|
62416525|NCT06362252|EXPERIMENTAL|Cohort 1, Part A: Maintenance Only (I-DXd 12 mg/kg)|"Part A (Safety Run-in): Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only (I-DXd 12 mg/kg IV Q3W + atezolizumab 1200 mg IV Q3W).~A 5-day surveillance period between each of the first 3 participants (up to a maximum of 9 participants) dosed is included as a safety measure."
62416526|NCT06362252|EXPERIMENTAL|Cohort 2, Part A: Induction + Maintenance (I-DXd 8 mg/kg)|Part A (Safety Run-in): Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy (I-DXd 8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W).
62416527|NCT06362252|EXPERIMENTAL|Cohort 2, Part A: Induction + Maintenance (I-DXd 12 mg/kg)|Part A (Safety Run-in): Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of IL I-DXd induction therapy (12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy (I-DXd 12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W).
62416528|NCT06362252|EXPERIMENTAL|Cohort 1, Part B: Maintenance (I-DXd 8 mg/kg)|Part B: Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only (I-DXd 8 mg/kg IV Q3W + atezolizumab 1200 mg IV Q3W), starting at Cycle 1 Day 1.
62416529|NCT06362252|EXPERIMENTAL|Cohort 1, Part B: Maintenance (I-DXd 12 mg/kg)|Part B: Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only (I-DXd 12 mg/kg IV Q3W + atezolizumab 1200 mg IV Q3W), starting at Cycle 1 Day 1.
62588259|NCT04957641||Participants with HAE|Participants' data will be collected retrospectively from electronic medical records using chart review of de-identified data on participant demographics, HAE medical history and information on diagnostics, treatments and disease course assessments that are routinely performed in accordance with current guidelines and/or local standard of care which are entered into an Electronic data capture (EDC) system over multiple data collection waves up to 6 months.
62588260|NCT05423197|ACTIVE_COMPARATOR|panitumumab 30 mg|Subjects will be given a 30mg of panitumumab
62416530|NCT06362252|EXPERIMENTAL|Cohort 2, Part B: Induction + Maintenance (I-DXd 8 mg/kg)|Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy (I-DXd 8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W).
62588261|NCT05423197|EXPERIMENTAL|89Zr-panitumumab IV|Subjects will be given 89Zr-panitumumab IV
62588262|NCT05018403|EXPERIMENTAL|AON-D21|Single ascending doses by iv infusion.
62588263|NCT05018403|PLACEBO_COMPARATOR|Placebo|Placebo medication identical in appearance to active.
62588264|NCT02901119|EXPERIMENTAL|Whey protein|Patients are instructed to consume 20g of whey protein in the morning and 20g at night, during 15 days, as a supplement. Their regular usual diet is maintained.
62588265|NCT02901119|ACTIVE_COMPARATOR|Casein|Patients are instructed to consume 20g of casein in the morning and 20g at night, during 15 days, as a supplement. Their regular usual diet is maintained.
62588266|NCT04336319|EXPERIMENTAL|Patients with a confirmed diagnosis of UC who underwent IPAA|Patients who meet inclusion criteria will be enrolled and will sign an informed consent form. The study includes six visits to the IBD clinic and phone calls between visits.
62588267|NCT02464475|EXPERIMENTAL|OMT|
62025133|NCT04576884||Group 1|participants of less than 18 years old
62588268|NCT02464475|SHAM_COMPARATOR|Sham|
62588269|NCT02463344||MA09-hRPE|"Experimental: Subretinal injection of MA09-hRPE~* Cohort 1 50,000 cells~* Cohort 2 100,000 cells~* Cohort 2a Better Vision 100,000 cells~* Cohort 3 150,000 cells~* Cohort 4 200,000 cells"
62588270|NCT06665100|EXPERIMENTAL|PUL-042|PUL-042 Inhalation Solution
62588271|NCT06665100|PLACEBO_COMPARATOR|Sterile Saline for Inhalation|Placebo
62025134|NCT04576884||Group 2|participants aged from 18 years to 40 year
62025135|NCT04576884||Group 3|participants aged from 41 years to 60 years
62025136|NCT04576884||Group 4|participants over 60 years old
62416531|NCT06362252|EXPERIMENTAL|Cohort 2, Part B: Induction + Maintenance (I-DXd 12 mg/kg)|Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of IL I-DXd induction therapy (12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×minIV Q3W) followed by maintenance therapy (I-DXd 12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W).
62416532|NCT05828667|NO_INTERVENTION|Standard of Care Arm|Standard of care procedural steps per respective institution and attending physician's clinical practice.
62416533|NCT05828667|EXPERIMENTAL|Imaging-aided VT ablation|For subjects assigned to the imaging-aided VT ablation arm, CT and/or c-MRI derived myocardial scar will be merged with 3D electroanatomical mapping (EAM) prior to the ablation to allow for readily localization and characterization of VT substrates and potential re-entry circuits to be ablated. This integrated mapping of VT substrates sites to be ablated will be given to the electrophysiologist prior to the ablation.
62025137|NCT05955638|EXPERIMENTAL|MiSight dual focus contact lens|
62025138|NCT05955638|ACTIVE_COMPARATOR|Proclear single vision contact lens|
62025139|NCT06477445|EXPERIMENTAL|Combination group|Visual feedback balance training system combined with RFE
62025140|NCT06477445|ACTIVE_COMPARATOR|RFE group|Repetitive facilitative exercise (RFE)
62025141|NCT06477445|ACTIVE_COMPARATOR|CT group|Conventional therapy (CT)
62025142|NCT06635083|ACTIVE_COMPARATOR|Vacuum bell therapy|This group will use a vacuum bell for one hour in the morning and evening, as recommended by an experienced thoracic surgeon.
62025143|NCT06635083|EXPERIMENTAL|Vacuum bell therapy+telerehabilitation|Telerehabilitation based exercises and vacuum bell therapy will be applied to this group. Video conference software system will be installed on the subjects' laptops or tablets. After the evaluations, exercises will be taught to the individuals in the clinic. Then, the following exercises will be done with the physiotherapist via video conference 3 sessions per week.
62025144|NCT05004324|EXPERIMENTAL|Furestem-AD Inj.|"Investigational product name: FURESTEM-AD® inj. 5.0 X 10\^7 cells/1.5 mL~baseline (0week) Experimental group will receive Investigational product (FURESTEM-AD® inj. 5.0 X 10\^7 cells/1.5 mL).~After 12 weeks, Experimental group will receive placebo."
62025145|NCT05004324|PLACEBO_COMPARATOR|Placebo|"Placebo~baseline (0week) Placebo comparator group will receive placebo.~After 12 weeks, Placebo comparator group will receive Investigational product (FURESTEM-AD® inj. 5.0 X 10\^7 cells/1.5 mL)."
62025146|NCT02606838|EXPERIMENTAL|Persons with Diabetes|Untrained Persons with Diabetes used the Styx Lancing Device System to obtain fingerstick and Alternate Site palm capillary blood.
62222241|NCT02999126|EXPERIMENTAL|Group 1|Patients \< 65 years old Propofol 1% TCI induction using plasma concentration, Marsh model (Ke0=0.26 min-1) at 1 mcg/ml, increasing the target concentration by 0.5 mcg/ml every minute until LOC. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. CeLOC propofol concentration will be established and it will be observed for another 30 minutes. If BIS \<40 or \>65 propofol target concentration will be modified by 0,3 mcg/ml.
62222242|NCT02999126|EXPERIMENTAL|Group 2|Patients ≥ 65 years old Propofol 1% TCI induction using plasma concentration, Marsh model (Ke0=0.26 min-1) at 1 mcg/ml, increasing the target concentration by 0.5 mcg/ml every minute until LOC. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. CeLOC propofol concentration will be established and it will be observed for another 30 minutes. If BIS \<40 or \>65 propofol target concentration will be modified by 0,3 mcg/ml.
62222243|NCT06608173|NO_INTERVENTION|Control|Classrooms randomly assigned to this arm will receive instruction as usual, with no intervention
62025147|NCT03058770|EXPERIMENTAL|sensorimotor retraining program|Fifteen 40-minute sensorimotor retraining sessions will be provided over a 5-week period.
62025148|NCT03058770|ACTIVE_COMPARATOR|Relaxation technique|Subjects will perform fifteen 40-minute relaxation sessions over a 5-week period.
62025149|NCT00059683|EXPERIMENTAL|Cervical Cerclage Group|Women randomized to receive cerclage should receive cervical cerclage
62222244|NCT06608173|EXPERIMENTAL|radKIDS program|This is the intervention arm, with the radKIDS2.0 program delivered across 20 weeks.
62222245|NCT05923671||Thin Phenotype|Participants with transparent free gingiva of the maxillary central incisor
62222246|NCT05923671||Thick Phenotype|Participants with non-transparent free gingiva of the maxillary central incisor
62222247|NCT03307759|ACTIVE_COMPARATOR|SABR plus pembrolizumab|SABR followed by pembrolizumab
62222248|NCT03307759|ACTIVE_COMPARATOR|Pembrolizumab plus SABR|Pembrolizumab followed by SABR after cycle 1
62222249|NCT06609967|EXPERIMENTAL|PRF group|
62222250|NCT06609967|ACTIVE_COMPARATOR|Non-PRF group|
62222251|NCT02364843|EXPERIMENTAL|Dietary Threonine Intake|Physiological establishment of enteral intake of amino acid threonine required by infants ages 1 - 6 mos
62222252|NCT02776384||chronic heart failure|patients who are diagnosed with chronic heart failure with either preserved or reduced ejection fraction
62222253|NCT00939666|EXPERIMENTAL|Wait&see or TEM with intensive follow-up|All patients will be included in this arm
62416534|NCT06418074|ACTIVE_COMPARATOR|Ketone Monoester (KE4), then Placebo drink|For five days each subject will receive beta-hydroxybutyrate boned to R 1,3 Butandiol (KE4), then crossed over to receive placebo drink for 5 days.
62416535|NCT06418074|PLACEBO_COMPARATOR|Placebo drink, then Ketone Monoester (KE4)|For five days each subject will receive a placebo drink three times daily, then subjects are crossed over to receive beta-hydroxybutyrate boned to R 1,3 Butandiol (KE4).
62416536|NCT05718557|EXPERIMENTAL|PYX-106 Dose Escalation|Participants will receive escalating doses of PYX-106 to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of PYX-106, and to determine the recommended dose(s).
62416537|NCT01721200|OTHER|Decision Support Tool|This study will examine the efficacy of a web-based educational decision support tool.
62416538|NCT01721200|OTHER|Usual Care|Usual Care Group will receive their biologic drug teaching from their rheumatologist.
62416539|NCT02049580|EXPERIMENTAL|RIC regimen|Thiotepa, Fludarabine, Cyclophosphamide pre- and post- transplantation.
62416540|NCT06543095||Group 1|who underwent rib removal during the partial nephrectomy
62025150|NCT00059683|NO_INTERVENTION|Control Group|Women randomized to not receive cerclage represent the control arm
62025151|NCT03738410|ACTIVE_COMPARATOR|Control Arm|The control arm will receive standard of care.
62222254|NCT02849717|NO_INTERVENTION|Standard Care|Subjects are advised to maintain their normal level of activity
62416541|NCT06543095||Group 2|who didn't underwent rib removal during the partial nephrectomy
62025152|NCT03738410|EXPERIMENTAL|Mobile Health Messaging Arm|The Patient Navigation and Mobile Health Messaging Arm will receive standard of care, as well as patient navigation assistance and the mobile health intervention. The mHealth intervention includes psycho-educational messaging as well.
62025153|NCT03738410|NO_INTERVENTION|Focus Group Arm|The results of the focus groups will contribute to the wording and design of the intervention.
62025154|NCT01640756|EXPERIMENTAL|AqueSys Microfistula Implant|
62025155|NCT03259035|EXPERIMENTAL|chemotherapy (FOLFOX or CAPOX) followed by tumour excision|
62025156|NCT03874676||PEACE Rounds Clinicians|Nurses, physicians, care managers, chaplains, and other clinicians who attend PEACE rounds as part of their routine work in the hospital.
62025157|NCT02512718|EXPERIMENTAL|Fish Oil Lipid Emulsion|1 g/kg intravenous fish oil lipid emulsion (Omegaven) daily, provided starting day of transplant through day 30 or hospital discharge, whichever comes first.
62416542|NCT04668131|EXPERIMENTAL|Artificial tears|Artificial tears
62416543|NCT04668131|ACTIVE_COMPARATOR|Acupuncture|Acupuncture
62588272|NCT01323595|EXPERIMENTAL|Celecoxib|Celecoxib will be given for 6 days after surgery
62588273|NCT01323595|PLACEBO_COMPARATOR|Sugar pill|Sugar pill for 6 days after surgery.
62025158|NCT02512718|ACTIVE_COMPARATOR|Soybean Oil Lipid Emulsion|1 g/kg intravenous soybean oil lipid emulsion (SOLE) daily, provided starting day of transplant through day 30 or hospital discharge, whichever comes first.
62416544|NCT01405209||Atrial Fibrillation|Patients who develop atrial fibrillation
62416545|NCT01405209||Non Atrial FIbrillation|Patients without atrial fibrillation
62416546|NCT02660775|EXPERIMENTAL|schizophrenia|this project is to assess relevance of ClaCoS in schizophrenia compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
62416547|NCT02660775|EXPERIMENTAL|autism|this project is to assess relevance of ClaCoS in autism compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
62416548|NCT02660775|PLACEBO_COMPARATOR|healthy controls|this project is to assess relevance of ClaCoS in autism compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
62416549|NCT03603925||PET/MR + PET/CT|The interventions for participating in this research are centered around steps needed to safely and ethically collect a research PET/MR scan following a standard-of-care PET/CT scan. The patient will be imaged in at least one of several standard anatomic areas: head/neck, thorax, abdomen, pelvis or whole-body.
62588274|NCT03269617|PLACEBO_COMPARATOR|Placebo Comparator|Placebo control: 1 capsule containing rice maltodextrin consumed 1x daily for 28 days.
62025159|NCT02818205||Children with Autism Spectrum Disorder|Boys between the age of 4 to 11 years old with Autism Spectrum disorder will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation
62025160|NCT02818205||Typically Developing Children|Typically developing boys between the age of 4 to 11 years will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
62025161|NCT02192437|EXPERIMENTAL|Methionine restricted diet|Intervention will be a Sulfur amino acid restricted diet (methionine). Control diet for 4 weeks followed by a washout for 3-4 weeks, then a methionine restricted diet (70%) for 4 weeks, followed by 3-4 weeks washout period and then a methionine restricted diet (90%) for 4 weeks.
62025162|NCT02192437|EXPERIMENTAL|Methionine and cysteine restricted diet|Intervention will be a Sulfur amino acid restricted diet (methionine and cysteine). Control diet for 4 weeks followed by a washout for 3-4 weeks then a methionine and cysteine restricted diet (50%) followed by 3-4 weeks washout period and then a methionine and cysteine restricted diet (65%) for 4 weeks.
62025163|NCT01892748|ACTIVE_COMPARATOR|Cholecalciferol 50.000IU/week|patients will receive vitamin D3 (50.000 IU/week) for 24weeks
62025164|NCT01892748|PLACEBO_COMPARATOR|Placebo|patients receive placebo in similar capsules of cholecalciferol for 24weeks
62222255|NCT02849717|ACTIVE_COMPARATOR|Home-Based Exercise|Progressive walking and resistance exercise treatment
62222256|NCT01236365|EXPERIMENTAL|Atorvastatin|
62222257|NCT01236365|PLACEBO_COMPARATOR|Placebo|
62222258|NCT05925361|EXPERIMENTAL|intervention|All participants will undergo a laparoscopic single flap peritoneum vaginoplasty
62416550|NCT06568991|PLACEBO_COMPARATOR|Observational control group|Giving a meal plan and nutrition education. It need to define recruited subject intake low-protein formula's frequency ≦ 3 times/week
62416551|NCT06568991|ACTIVE_COMPARATOR|the True Low Protein Rice group|Use low protein rice to replace staple food in two meals during a day.
62416552|NCT00993629|ACTIVE_COMPARATOR|Arm 1|adjunctive pregnenolone
62416553|NCT00993629|PLACEBO_COMPARATOR|Arm 2|adjunctive placebo
62588275|NCT03269617|EXPERIMENTAL|Experimental|Bacteriophage mixture: 1 capsule containing rice maltodextrin and a mixture of 4 bacteriophages consumed 1x daily for 28 days.
62025165|NCT01337089|EXPERIMENTAL|Non-comparative, open-label Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray, in the morning and evening, up to a maximum of 10 sprays per day for 6 months. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligrams \[mg\]/milliliter \[mL\]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
62222259|NCT02115516|EXPERIMENTAL|Stage A: Grp A1 - 3,200 PfSPZ Challenge|Group A1 (PfSPZ Challenge) (n=9) receives three injections of 3,200 PfSPZ Challenge intravenous (IV) at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 19, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
62222260|NCT02115516|EXPERIMENTAL|Stage A: Grp A2 - 12,800 PfSPZ Challenge|Group A2 (PfSPZ Challenge) (n=9) starts when Group A1 receives the second immunization. Group A2 receives three injections of 12,800 PfSPZ Challenge IV at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 23, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
62025166|NCT04035941|EXPERIMENTAL|Feasibility|The cycle training intervention group
62025167|NCT04782323|EXPERIMENTAL|Group A aQII-1 Investigational|
62025168|NCT04782323|EXPERIMENTAL|Group B aQII-3 Investigational|
62025169|NCT04782323|EXPERIMENTAL|Group C aQII-6 Investigational|
62025170|NCT04782323|EXPERIMENTAL|Group D aQII-7 Investigational|
62025171|NCT04782323|EXPERIMENTAL|Group E aQII-9 Investigational|
62025172|NCT04782323|EXPERIMENTAL|Group F aQII-10 Investigational|
62025173|NCT04782323|EXPERIMENTAL|Group G aQII-11 Investigational|
62222261|NCT02115516|EXPERIMENTAL|Stage A: Grp A3 - 51,200 PfSPZ Challenge|Group A3 (PfSPZ Challenge) (n=9) starts when Group A2 receives the second immunization. Group A3 receives three injections of 51,200 PfSPZ Challenge IV at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. This group is scheduled to be unblinded with all other groups in Stage A Week on 27.
62222262|NCT02115516|PLACEBO_COMPARATOR|Stage A: Grp A1 - 0.9% Sodium Chloride|Group A1 (placebo) (n=5) receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 19, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
62222263|NCT02115516|PLACEBO_COMPARATOR|Stage A: Grp A2 - 0.9% Sodium Chloride|Group A2 (placebo) (n=5) starts when Group A1 receives the second immunization. Group A2 receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 23, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
62222264|NCT02115516|PLACEBO_COMPARATOR|Stage A: Grp A3 - 0.9% Sodium Chloride|Group A3 (placebo) (n=5) starts when Group A2 receives the second immunization. Group A3 receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. This group is scheduled to be unblinded with all other groups in Stage A on Week 27.
62222265|NCT02115516|EXPERIMENTAL|Stage B: Grp B1 - 51,200 PfSPZ Challenge|Group B1 (n=5) will receive the optimal PfSPZ Challenge immunizing dose from the dose-escalation phase (Stage A; 51,200 PfSPZ Challenge (NF54)), using the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), but for five instead of ten weeks. Group B1 will receive 3 injections of 51,200 PfSPZ Challenge (NF54) on days 0, 14 and 28. All volunteers in Group B1 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
62416554|NCT03649607|OTHER|Accelerated Resolution Therapy|Participants will complete a clinical intake assessment before meeting with the therapist and initiating the ART® protocol. Participants will receive the ART intervention over a 21-day period, where imaginal exposure and imagery re-scripting will be used replace previous traumatic experiences. The ART intervention will be assessed through pre- and post-test measures at 60-days post enrolment.
62025174|NCT04782323|ACTIVE_COMPARATOR|Group H Licensed QII Active Comparator|
62025175|NCT05157646|EXPERIMENTAL|Exercise trackers|Fitbit physical activity trackers
62222266|NCT02115516|PLACEBO_COMPARATOR|Stage B: Group B1 - 0.9% Sodium Chloride|Group B1 (placebo) (n=2) will receive three injections of 0.9% Sodium Chloride on days 0, 14 and 28. This group will follow the the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), but for five instead of ten weeks. All volunteers in Group B1 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
62025176|NCT06496828|EXPERIMENTAL|Biologically-oriented preparation technique (BOPT)|Patients in this group will undergo the biologically-oriented preparation technique.
62416555|NCT03923907|EXPERIMENTAL|EIM group|patients with Hypertension (HT) will be recruited by a trained nurse when the patient attends the yearly to bi-yearly complication screening program called the risk assessment and management program (RAMP) program. This program is provided to all patients with HT, who are seen in the Government-funded primary care clinics in Hong Kong. The nurse will encourage the patient by motivational interviewing techniques and prescribe exercise. Combined exercise skills will be taught in the 12-week weekly exercise classes by certified physical trainers. Peer support is encouraged during and after the 12-week program. Regular feedback, prompting and problem solving will be provided by the nurse at 3m, 6m, and 12m. Exercise level will be monitored by validated wrist trackers to feedback participants, nurse and physical trainer by mobile apps and website. Resources to exercise will be made known to patients by apps, website and healthcare professionals.
62222267|NCT02115516|EXPERIMENTAL|Stage B: Grp B2 - 51,200 PfSPZ Challenge|Group B2 (n=5) will receive 3 injections of 51,200 PfSPZ Challenge on days 0, 14 and 28, using same std chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), for 5 instead of 10 wks. But Group B2 will receive extended-release azithromycin (ER-AZ, 2g) on the day of 1st PfSPZ Challenge and monitored for parasitemia by quantitative real time polymerase reaction (qPCR). In case that all CQ+ER-AZ treated volunteers are parasite-free until Day 11 following first PfSPZ Challenge injection, it will indicate that ER-AZ effectively killed the parasites in the liver prior to development of parasitemia. With demonstration of the effectiveness of ER-AZ, the 2nd and 3rd immunizations will be done under ER-AZ alone, otherwise CQ prophylaxis will continue and ER-AZ will not be administered for the 2nd and 3rd injections. Group B2 will undergo homologous CHMI with PfSPZ Challenge, 10 weeks after the last immunization.
62222268|NCT02115516|PLACEBO_COMPARATOR|Stage B: Group B2 - 0.9% Sodium Chloride|Group B2 (placebo) (n=2) will receive three injections of 0.9% Sodium Chloride on days 0, 14 and 28, using the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), for 5 instead of 10 wks. But Group B2 will receive ER-AZ, 2g on the day of 1st placebo injection and monitored for parasitemia by qPCR. In case that all CQ+ER-AZ treated volunteers are parasite-free until Day 11 following 1st injection, it will indicate that ER-AZ effectively killed the parasites in the liver prior to the development of parasitemia. With demonstration of the effectiveness of ER-AZ, the 2nd and 3rd immunizations will be done under ER-AZ alone, otherwise CQ prophylaxis will be continued and ER-AZ will not be administered for 2nd and 3rd injections. Group B2 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after last immunization.
62222269|NCT02115516|EXPERIMENTAL|Stage B: Grp B3 - 51,200 PfSPZ Challenge|Group B3 (n=9) volunteers will receive CQ and PfSPZ Challenge simultaneously every five days with one additional dose of CQ five days after the third PfSPZ Challenge injection. A 10 mg/kg CQ base loading dose is given at the time of first PfSPZ Challenge inoculation, followed by 5 mg/kg CQ base on the day of second and third inoculation and five days after the last PfSPZ Challenge inoculation. Group B3 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
62222270|NCT02115516|PLACEBO_COMPARATOR|Stage B: Group B3 - 0.9% Sodium Chloride|Group B3 (placebo) (n=2) volunteers will receive CQ and 0.9% Sodium Chloride simultaneously every five days with one additional dose of CQ five days after the third placebo injection. A 10 mg/kg CQ base loading dose is given at the time of first placebo injection, followed by 5 mg/kg CQ base on the day of second and third injections and five days after the last placebo injection. Group B3 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
62222271|NCT00252577||Group 1|Veterans with bipolar disorder
62222272|NCT02634489|ACTIVE_COMPARATOR|Tamsulosin HCl and Solifenacin Succinate|Participants will receive daily doses of tamsulosin HCL and Solifenacin Succinate (3 dose strengths) as single tablets.
62222273|NCT02634489|ACTIVE_COMPARATOR|EC905 (tamsulosin HCI and solifenacin succinate)|Participants will receive a fixed combination tablet (3 dose strengths).
62433427|NCT01575119|ACTIVE_COMPARATOR|In-patient|Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
62588276|NCT01488422|ACTIVE_COMPARATOR|Group 1|Both groups will receive stress reduction materials. We expect both groups to achieve similar amounts of stress reduction, but to use different brain regions to do so.
62025177|NCT06496828|ACTIVE_COMPARATOR|Conventional preparation|Patients in this group will undergo the convention preparation technique.
62025178|NCT05907668|EXPERIMENTAL|Batoclimab|Participants will receive batoclimab 680 milligrams (mg) subcutaneously (SC) weekly (QW) injection for 12 weeks followed by 340 mg SC QW for 12 weeks.
62025179|NCT04074980|EXPERIMENTAL|Venous only|One venous whole blood draw will be performed into two anti-coagulated collection tubes
62025180|NCT04074980|EXPERIMENTAL|Fingerstick and Venous|One finger-stick sample of capillary blood (\~10µl/sample) from each subject, will be applied directly to a unique test strip for immediate measurement of INR on the LumiraDx Instrument. One further fingerstick sample is then obtained (\~10µl/sample) from a separate finger for immediate measurement of INR on the Coaguchek PRO. From each patient, one venous whole blood draw will also be performed into two anti-coagulated collection tubes.
62025181|NCT06019650|EXPERIMENTAL|E-CMAP Intervention|"CMAP is a culturally adapted brief problem-focused therapy, based on the principles of CBT which has been adapted with permission from a self-help guide called Life after self-harm(Schmidt \& Davidson, 2004). This intervention includes evaluation of the self-harm attempt, crisis skills, problem-solving and basic cognitive techniques to manage emotions, negative thinking and relapse prevention strategies."
62025182|NCT06019650|NO_INTERVENTION|Standard Routine Care|Local medical, psychiatric and primary care services provide standard routine care according to their clinical judgment and available resources
62025183|NCT01985594|ACTIVE_COMPARATOR|Utrogestan|oral tablet Utrogestan 400mg daily for 2 days
62222274|NCT03241225|EXPERIMENTAL|EM/PROTECT|This group of participants will receive the EM/PROTECT intervention, a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services.
62222275|NCT03241225|ACTIVE_COMPARATOR|EM/MH|This group of participants experiencing elder mistreatment will receive support services from staff trained in linking elder mistreatment victims to community mental health services.
62025184|NCT01985594|PLACEBO_COMPARATOR|Nifedipine|tablet Nifedipine 20 mg stat then 20 mg after 30 minutes then another 20 mg after 30 minutes followed by 10 mg three times daily for 2 days
62025185|NCT01056744|ACTIVE_COMPARATOR|DES|Implantation of a XIENCE® V everolimus eluting coronary stent (drug-eluting stent, DES)
62222276|NCT05336812|EXPERIMENTAL|Arm I (acalabrutinib, obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of cycle 13 and day 1 of cycles 14-18. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
62222277|NCT05336812|EXPERIMENTAL|Arm II (acalabrutinib, venetoclax)|Patients receive acalabrutinib PO BID on days 1-28. Patients also receive venetoclax PO QD on days 1-28 days of cycles 13-18. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
62222278|NCT02002650|EXPERIMENTAL|Pre-ERCP group|Pre-ERCP rectal Indomethacin in all patients.
62222279|NCT02002650|ACTIVE_COMPARATOR|Post-ERCP group|Post-ERCP rectal Indomethacin in high-risk patients.
62222280|NCT01956292||Intraparenchimal cerebral haemorrhage|
62222281|NCT05352568|EXPERIMENTAL|Cognitive Group|Computer Cognitive-Based Training
62416556|NCT03923907|NO_INTERVENTION|usual care|There is no extra intervention to patients allocated in this arm, except that they receive information and advice on lifestyle changes including benefits from exercise from the nurse at recruitment as stated above. Participants in both arms will have no changes in medication within the first 12-week to determine the BP difference between the two groups. In Hong Kong, patients have unlimited access to emergency department and general outpatient services. All patients with HT receive RAMP program counselling and screening every 1-2 years. These are not limited by the current trial.
62588277|NCT01488422|ACTIVE_COMPARATOR|Group 2|Both groups will receive stress reduction materials. We expect both groups to achieve similar amounts of stress reduction, but to use different brain regions to do so.
62025186|NCT01056744|ACTIVE_COMPARATOR|BMS/DEB|Implantation of a Coroflex Blue® coronary stent (bare metal stent, BMS) postdilated with a Sequent Please® paclitaxel-eluting balloon (drug-eluting balloon, DEB)
62222282|NCT05379504|EXPERIMENTAL|Self Management|"The 5A's Behavior Change Mode \[39\] is the framework for the self-management intervention. The five As will be addressed through the integration of the self-management intervention and the sensor system. There will be a minimum of four intervention sessions with each healthcare profession (OT, RN, and SW) for 12 visits per participant."
62222283|NCT05379504|ACTIVE_COMPARATOR|Health Education|Participant's randomized to the standard health education arm will receive the intervention at Month 1 and then months 3, 6, 9 and 12.
62588278|NCT06666959||patients undergoing endovascular coiling of cerebral aneurysm in Tongji hospital|The present clinical study was carried out with the aim of determine whether the inflammatory effect differs when using propofol or sevoflurane anesthesia.
62588279|NCT03103321|EXPERIMENTAL|"Arm A (Knowing your Options, Prostate Choice)"|"Patients receive decision aids Knowing your Options before and Prostate Choice during their consultation visit."
62222284|NCT01336803|EXPERIMENTAL|Feraheme|Intravenous injection of Feraheme, 5 mg Fe/kg
62025187|NCT04696068||Control|The patients included in this group will receive meals with the usual presentation (plastic trays) during six days. Their data will be collected at day 1 and day 6.
62025188|NCT04696068||Experimental|The patients included in this group will receive the main course in porcelain plates during six days. Their data will be collected at day 1 and day 6.
62025189|NCT02959489|ACTIVE_COMPARATOR|Amyloid Brain Imaging Non-Disclosure|Subjects will receive their Alzheimer's disease (AD) risk assessment based on age, gender, family history and ancestry.
62025190|NCT02959489|EXPERIMENTAL|Amyloid Brain Imaging Disclosure|"Subjects will receive both their elevated or not elevated amyloid neuroimaging results based on their brain scan interpretation and Alzheimer's disease (AD) risk disclosure. The AD risk assessment is based on age, gender, family history and ancestry."
62025191|NCT04901611|EXPERIMENTAL|Parental touch (pre-procedural)|Parents will stroke their baby on the posterior lower limb of the leg where the heel lance will be administered, at a speed of 3cm/s for 10 seconds using the whole hand and in one direction down the limb towards the foot. This will happen just before the control procedure and clinical heel lance.
62025192|NCT04901611|PLACEBO_COMPARATOR|Parental touch (post-procedural)|Parents will stroke their baby on the posterior lower limb of the leg where the heel lance was administered, at a speed of 3cm/s for 10 seconds using the whole hand and in one direction down the limb towards the foot. This will happen just after the control procedure and clinical heel lance.
62222285|NCT01014533|PLACEBO_COMPARATOR|Placebo|After 3 nights in the UM sleep lab and randomization, this arm receives placebo for one week. They then return to the sleep lab for the same procedures.
62433428|NCT01575119|EXPERIMENTAL|Out-patient surgery|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
62433429|NCT01575119|ACTIVE_COMPARATOR|Out-patient|Standard of care information, including distributing a patient education brochure, to provide information regarding perioperative smoking
62588280|NCT03103321|EXPERIMENTAL|"Arm B (Knowing your Options)"|"Patients receive Knowing your Options decision aid before their consultation visit."
62222286|NCT01014533|ACTIVE_COMPARATOR|Gabapentin|After spending 3 baseline nights in the UM sleep lab, alcohol dependent subjects are randomized. This arm receives gabapentin . On nights 1 and 2 of medication, the dose is 600 mg by mouth 30 min before bedtime. On nights 3-10, the dose is 1200 mg by mouth 30 min before bedtime. On nights 8-10 of medication, subjects return to the UM sleep lab and complete 3 sleep nights with the same procedures. On night 11, the dose is reduced to 600 mg by mouth 30 min before bedtime, and then stopped.
62222287|NCT06374173|EXPERIMENTAL|TGI-6 Injection|TGI-6 monotherapy dose escalation(Phase 1a) . TGI-6 monotherapy dose expansion(Phase 1b) .
62025193|NCT03433742|OTHER|Preoperative Group|This is a group of 30 patients who will be undergoing a total hip replacement with a Trident II shell. This group of patients will have their bloods drawn and tested for metal ion levels at a preoperative visit.
62025194|NCT03433742|OTHER|1 year Postoperative Group|This is the same group of 30 patients who are now one year post op after having a total hip replacement with a Trident II shell. This group of patients will have their bloods drawn and tested for metal ion levels at their one year visit.
62025195|NCT01703962||Patients with IDH1 R132H or wild type IDH1/IDH2 glioma|
62222288|NCT02952378|EXPERIMENTAL|Burn patients|Patients with burns exceeding 6-8 Total Burned Surface Area %
62222289|NCT02952378|EXPERIMENTAL|Healthy individuals|Healthy individuals without allergies.
62025196|NCT02228213|EXPERIMENTAL|Treatment|500 mcg MIS416 500 at 0.2 mg/mL administered i.v. once weekly for 52 weeks
62025197|NCT02228213|PLACEBO_COMPARATOR|Saline|Saline administered i.v. once weekly for 52 weeks
62025198|NCT06535191|EXPERIMENTAL|ASSET Intervention|Participants in the intervention group received Assistive Soft Skills and Employment Training (ASSET), a 10-week manualized soft skills intervention program to help students with ASD improve social and adaptive functioning, self-efficacy, work readiness, and anxiety.
62222290|NCT02708914|OTHER|UB-851|
62222291|NCT02708914|OTHER|Eprex then UB-851|
62222292|NCT04162613||Patients with ACL reconstruction in Lund and Umeå|Persons who have suffered a unilateral anterior cruciate ligament injury treated with reconstruction
62416557|NCT06703762|EXPERIMENTAL|He-Ne low level laser (LLL) + Conventional traditional treatment|It will include 34 patients with chronic neuropathic foot ulcer from both sex. They will receive He-Ne LLL for chronic neuropathic foot ulcer with pulsed wave form, visible ray, wave length of 632.8 nm, peak potency of 30 mW, (Laser -HTM). The application time will be 80 (4 J/cm2) seconds. The application will be 3 sessions /week for 4 weeks on the sole of the foot + Conventional traditional treatment.
62416558|NCT06703762|ACTIVE_COMPARATOR|Conventional traditional treatment|It will include 34 patients with chronic neuropathic foot ulcer from both sex. They will receive conventional traditional treatment (regular sharp debridement of calluses surrounding the ulcer, use of walking or total-contact casts for off-loading and regular moist dressing patients will be instructed to use only sodium chloride (saline solution 0.9%), regarding the daily asepsis of the ulcer).
62025199|NCT06535191|NO_INTERVENTION|Treatment As Usual|Participants in the treatment-as-usual is considered as control group and received typical education program.
62025200|NCT03277313|EXPERIMENTAL|Epoch 1|Pediatric participants with PIDD who were on IV or non-HYQVIA SC treatment with immunoglobulin were enrolled and treated with HYQVIA SC with a dose or interval ramp-up period of up to six weeks. HYQVIA dose was planned to be equivalent to 100% (± 5%) of pre-study treatment. Dose frequency was one treatment interval of one week, then one treatment interval of two weeks for participants who were planned to be treated every three weeks, and one more treatment interval of three weeks for participants who were planned to be treated every four weeks.
62025201|NCT03277313|EXPERIMENTAL|Epoch 2|Epoch 1 was followed by Epoch 2 with HYQVIA treatment infusions given once every 3 or 4 weeks, depending on the participant's previous IV dosing schedule (for IV pretreated participants) and at the discretion of the investigator and participant (for SC-pretreated participants) up to approximately 36 months.
62025202|NCT03708939|EXPERIMENTAL|glucose|
62025203|NCT03708939|EXPERIMENTAL|aspartame|
62025204|NCT03708939|EXPERIMENTAL|sucralose|
62025205|NCT03708939|EXPERIMENTAL|saccharin|
62025206|NCT03708939|EXPERIMENTAL|Stevia|
62025207|NCT03708939|EXPERIMENTAL|No supplement control|
62025208|NCT02206529|ACTIVE_COMPARATOR|Social Network Engagement+Std Treatment|"Social Network Engagement = content and activities to help the parent engage his/her social network in supporting healthy lifestyle behaviors.~Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)"
62025209|NCT02206529|OTHER|Standard Treatment|"This comparator arm consists of historical controls, participants in the FOCUS trial who received standard treatment.~Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)"
62025210|NCT05683340|EXPERIMENTAL|ETC-1002 180mg|
62025211|NCT05683340|PLACEBO_COMPARATOR|Placebo|
62025212|NCT00364858|OTHER|Q2 Cerezyme|Patients receiving Cerezyme one infusion every 2 weeks (Q2).
62025213|NCT00364858|OTHER|Q4 Cerezyme|Patients receiving Cerezyme one infusion every 4 weeks (Q4).
62025214|NCT03877718|EXPERIMENTAL|Arm 1: CL-H1T|Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine hydrochloride 18.75mg)
62222293|NCT01129466|ACTIVE_COMPARATOR|Supplement A followed by supplement B|
62222294|NCT01129466|ACTIVE_COMPARATOR|Supplement B followed by Supplement A|
62222295|NCT05885087|EXPERIMENTAL|Foley/Balloon catheter arm|Participants were assessed as having a favourable cervix using the modified Bishop score of equal to or more than 7. Three Foley balloon catheters attached side by side were inflated with 60mls each and a gentle traction of 250mls water applied.
62222296|NCT03107234||Patient with breast cancer requiring surgery to|
62222297|NCT02792673|ACTIVE_COMPARATOR|"Embryo Glue®"|Hyaluronan-enriched medium
62222298|NCT02792673|ACTIVE_COMPARATOR|"Global Total®"|30% Protein-supplemented Culture Medium
62222299|NCT02792673|EXPERIMENTAL|Autologous Follicular Fluid|a novel technique
62222300|NCT04580576||Female group|Pediatric female patients undergoing hematopoietic stem cell transplantation
62222301|NCT04580576||Male group|Pediatric male patients undergoing hematopoietic stem cell transplantation
62222302|NCT00901433||A|Usability study of the Personal Wheezometer
62025215|NCT03877718|EXPERIMENTAL|Arm 2: CL-H1T|Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5mg)
62588281|NCT03103321|EXPERIMENTAL|"Arm C (Prostate Choice)"|"Patients receive Prostate Choice decision aid during their consultation visit."
62588282|NCT03103321|ACTIVE_COMPARATOR|Arm D (usual care)|Patients undergo usual care.
62588283|NCT03032328|EXPERIMENTAL|vitamin D supplement|patient's will be given a vitamin D
62588284|NCT03268382|EXPERIMENTAL|APR-246 + PLD|
62416559|NCT06702514|EXPERIMENTAL|Balneotherapy Group|This group will receive 20 minutes of paraffin and 20 minutes of balneotherapy on both hands, five times a week for 4 weeks, for a total of 20 sessions, using one session per day. In addition, a daily exercise program (15 minutes of joint range of motion, 15 minutes of strengthening exercises) will be given once a day, accompanied by a physiotherapist.
62416560|NCT06702514|ACTIVE_COMPARATOR|Control Group|The control group was planned to receive 20 minutes of paraffin treatment on both hands, five times a week for 4 weeks, one session per day for a total of 20 sessions. In addition, a daily exercise program (15 minutes of joint range of motion, 15 minutes of strengthening exercises) will be given once a day, accompanied by a physiotherapist.
62416561|NCT05004181|EXPERIMENTAL|Part A - Cohort 1: 18 to 55 years of age|Participants received 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
62588285|NCT01895270|EXPERIMENTAL|Isradipine|Isradipine controlled-release formulation, 10 mg/day maintenance dose, will be administered according to the following dose procedures: Isradipine ingestion will occur under supervision 6 days per week, and a take-home dose will be given on Saturday for participants to take on Sunday. The initial dose of isradipine or placebo will be given on Day 3 of Week 1. The initial dose of isradipine will be 5 mg/day; the dose will increase to 10 mg/day on Day 3 of Week 3 and will continue through Day 2 of Week 7. On Day 3 of Week 7, isradipine will be decreased to 5 mg/day for 7 days. On Days 3-5 of Week 8, all participants will receive placebo. If ISR side effects are too severe at the 10-mg dose, isradipine will be decreased to 5 mg/day. If ISR side effects are too severe at 5 mg/day, isradipine will be discontinued and the participant will be discharged from the study and referred to local treatment agencies.
62588286|NCT01895270|PLACEBO_COMPARATOR|Placebo|Placebo will consist of microcrystalline cellulose. Two placebo capsules will be administered per day starting week 1 day 3 through the end of the isradipine taper.
62416562|NCT05004181|EXPERIMENTAL|Part A - Cohort 2: 18 to 55 years of age|Participants received 2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
62416563|NCT05004181|EXPERIMENTAL|Part A - Cohort 3: 18 to 55 years of age|Participants received1 dose of BNT162b2 (B.1.1.7) of 30 µg.
62416564|NCT05004181|EXPERIMENTAL|Part A - Cohort 4: 18 to 55 years of age|Participants received 1 dose of BNT162b2 (B.1.617.2) of 30 µg.
62588287|NCT03297918|ACTIVE_COMPARATOR|Intervention group|Patients will be asked to participate in a structured singing and respiratory training for 12 weeks.
62025216|NCT03877718|EXPERIMENTAL|Arm 3: Sumatriptan succinate 100 mg|Maximum dose within a 24 hour period: One capsule of sumatriptan succinate 100mg
62025217|NCT03877718|EXPERIMENTAL|Arm 4: Promethazine HCl 18.75 mg|Maximum dose within a 24 hour period: One capsule of promethazine HCl 18.75mg
62416565|NCT05004181|EXPERIMENTAL|Part A - Cohort 5: 18 to 55 years of age|Participants received 1 dose of BNT162b2 of 30 µg.
62588288|NCT03297918|NO_INTERVENTION|Control group|no intervention
62588289|NCT03778931|EXPERIMENTAL|Elacestrant|Subjects in Arm 1 will receive elacestrant
62588290|NCT03778931|ACTIVE_COMPARATOR|Standard of Care (SoC)|Subjects in Arm 2 will receive Investigator's choice of one of the Standard of Care drugs (fulvestrant, anastrozole, letrozole, or exemestane)
62588291|NCT05504798|ACTIVE_COMPARATOR|Group (A)|will receive a selected physical therapy program.
62025218|NCT03877718|EXPERIMENTAL|Arm 5: Promethazine HCl 37.5 mg|Maximum dose within a 24 hour period: One capsule of promethazine HCl 37.5mg
62025219|NCT03877718|EXPERIMENTAL|Arm 6: Placebo|Maximum dose within a 24 hour period: One capsule of placebo
62416566|NCT05004181|EXPERIMENTAL|Part A - Cohort 6: 18 to 55 years of age|Participants received 3 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
62222303|NCT02371213|EXPERIMENTAL|social networking on mobile phone|Audio-video media via social networking on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly plus usual antenatal care group-health education
62588292|NCT05504798|ACTIVE_COMPARATOR|Group (B)|will receive interrupted progressive serial casting in addition to a modified selected physical therapy program during casting.
62797729|NCT04628780|EXPERIMENTAL|Dose Expansion (Part 2) - Cohort 2 (RCC)|Participants with renal cell carcinoma (RCC) will receive PF-07209960 at the recommended dose from Part 1
62222304|NCT02371213|NO_INTERVENTION|no social networking on mobile phone|usual antenatal care group-health education
62416567|NCT05004181|EXPERIMENTAL|Part B - Cohort 1: 18 to 85 years of age|Participants received 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
62797730|NCT04628780|EXPERIMENTAL|Dose Expansion (Part 2) - Cohort 3 (UC)|Participants with urothelial carcinoma (UC) will receive PF-07209960 at the recommended dose from Part 1
62797731|NCT02233634|ACTIVE_COMPARATOR|CAD Patients|Administration of Oxygen via a mask, Hyperventilation, Combination of Oxygen administration and Hyperventilation, long breath-holds
62797732|NCT02233634|ACTIVE_COMPARATOR|Healthy Volunteers (Control Group)|Administration of Oxygen via a mask, Hyperventilation, Combination of Oxygen administration and Hyperventilation, long breath-holds
62797733|NCT02552030|EXPERIMENTAL|Blood pressure-measurement|Seven repetitive blood pressure measurements will be performed the left or right arm of all participants with an iPhone 4s and a conventional oscillometric device 'cuff device (Omron HBP-1300-E Pro)'
62222305|NCT03471260|EXPERIMENTAL|Treatment (venetoclax, ivosidenib, azacitidine)|Patients receive venetoclax PO daily on days 1-14. Patients also receive ivosidenib PO daily on days 15-28 of cycle 1 and days 1-28 of subsequent cycles. Patients may also receive azacitidine IV over 30-60 minutes or SC on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62222306|NCT01295762|OTHER|Type of neuroblastoma|Neonatal stages I Localized immediately resectable stages Localized immediately unresectable stages High-risk neuroblastoma Relapsed neuroblastoma
62222307|NCT02293304|EXPERIMENTAL|Self-etch approach|Application of universal adhesive as self-etch mode
62222308|NCT02293304|EXPERIMENTAL|Etch-and-rinse approach|Application of universal adhesive as etch-and-rinse mode
62222309|NCT02924064|EXPERIMENTAL|Teneligliptin 20mg|Teneligliptin (20mg once daily) for 24 weeks in combination with metformin
62222310|NCT02924064|PLACEBO_COMPARATOR|Placebo|Placebo for 24 weeks in combination with metformin
62222311|NCT02724059|EXPERIMENTAL|Patients with mediastinal lesions|Endo bronchial ultrasound (EBUS) with elastography followed by TBNA
62222312|NCT02851485|EXPERIMENTAL|GLPG1972 600 mg oral solution fasted|600 mg GLPG1972 administered as oral solution after overnight fasting
62222313|NCT02851485|EXPERIMENTAL|GLPG1972 600 mg oral tablet fasted|600 mg GLPG1972 administered as oral tablet after overnight fasting
62222314|NCT02851485|EXPERIMENTAL|GLPG1972 600 mg oral tablet fed|600 mg GLPG1972 administered as oral tablet after a high-fat high-calorie breakfast
62222315|NCT05015907|EXPERIMENTAL|Selective supraclavicular nerve block|After induction of anesthesia, the anesthesiologist sterilizes the skin of the area to be punctured. In the test group, an Ultrasound-guided selective supraclavicular nerve block is performed using 0.5% Ropivacaine 0.1mL/kg (Maximum dose: 5mL).
62416568|NCT05004181|EXPERIMENTAL|Part B - Cohort 4: 18 to 85 years of age|Participants received 1 dose of BNT162b2 (B.1.617.2) of 30 µg.
62416569|NCT05004181|EXPERIMENTAL|Part B - Cohort 6: 18 to 85 years of age|Participants received 3 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
62416570|NCT05004181|EXPERIMENTAL|Part C - Cohort 7: 18 to 85 years of age|Participants received 1 dose of BNT162b2 (B.1.1.529.1) of 30 µg.
62416571|NCT05004181|EXPERIMENTAL|Part C - Cohort 8: 18 to 85 years of age|Participants received 1 dose of BNT162b2 of 30 µg.
62222316|NCT05015907|ACTIVE_COMPARATOR|Control|The nerve block is not performed in the control group.
62222317|NCT03017300|EXPERIMENTAL|COPD（threshold IMT training）|COPD patient use Inspiratory muscle trainer (Threshold IMT®)
62222318|NCT03017300|EXPERIMENTAL|COPD（resisive training）|COPD patient use Inspiratory muscle trainer (PFLEX®)
62222319|NCT01719354|EXPERIMENTAL|Community Health center|Aftercare in a community Health center
62222320|NCT01719354|ACTIVE_COMPARATOR|Control|AFtercare as usual in hospital/Mental health centers of District Psychiatric Service (DPS.
62222321|NCT00702351|EXPERIMENTAL|Arm 1|150 µg Org 36286 (corifollitropin alfa)
62416572|NCT05004181|OTHER|Part C - Cohort 9: 18 to 85 years of age|Participants received no vaccination within 3 months after Visit 1.
62588293|NCT05504798|ACTIVE_COMPARATOR|Group (C)|will receive interrupted progressive serial casting and the modified selected physical therapy as group (B) in addition to neuromuscular electrical stimulation for ankle dorsiflexors and knee extensors muscles through cast windows
62222322|NCT00702351|EXPERIMENTAL|Arm 2|100 µg Org 36286 (corifollitropin alfa)
62222323|NCT01465347|EXPERIMENTAL|TSC 0.25 mg/kg for 9 or 18 doses|This was an open-label, sequential-cohort, dose-escalation study in two phases. Phase 1 was a safety run-in evaluating Trans Sodium Crocetinate (TSC) in 3 subjects who received 3 doses per week for 3 weeks (9 doses in total). Phase 2 engaged 56 subjects who received 3 doses per week for 6 weeks (18 doses in total). TSC was consistently dosed at 0.25mg/kg in both phases.
62222324|NCT05094505|ACTIVE_COMPARATOR|CONTROL GROUP|Exercise at sea level, normoxia. Control diet.
62797734|NCT02731495|EXPERIMENTAL|EGCG|Participants were randomly divided based on age, sex and severity of TBI in two groups. Randomization lists was computer-generated by a statistician and participants, project managers and employees at the clinic are completely unaware (blind) about intervention and control groups. At the first visit, baseline data were gathered and patients received EGCG supplement was in the form of 400 mg oral capsules with a purity of 80% catechin. EGCG powder of each capsule was dissolved in 10 ml deionized water and given to patients via gavage (1 capsule per day) for a week.
62222325|NCT05094505|EXPERIMENTAL|Ex. Hyp. GROUP|Exercise in hypoxia at 3000m altitude. Control diet.
62797735|NCT02731495|PLACEBO_COMPARATOR|Placebo|Placebo group only received 10 ml of deionized water via gavage for a week.
62797736|NCT06465329|ACTIVE_COMPARATOR|Chemotherapy+Cemiplimab|Control treatment
62797737|NCT06465329|EXPERIMENTAL|Arm 1: Chemotherapy+Cemiplimab+REGN7075|Investigational Treatment
62222326|NCT05094505|EXPERIMENTAL|Ex. Hyp. + LCD GROUP|Exercise in hypoxia at 3000m altitude. Low carbohydrate diet.
62222327|NCT03063801||Cardiac surgery|All adult patients having undergone surgery between January 2006 and December 2016 within the CHU Brugmann hospital.
62222328|NCT01103362|EXPERIMENTAL|flibanserin 100mg|flibanserin 100mg po qd
62222329|NCT05696301|EXPERIMENTAL|Interventionnal Group|These women will receive Tecar by Winback® technology \[CE medical 1984, Norma 60601-2, ISO9001, ISO13485, CET 400 VA and RET 100 Watts, weight 4 Kg\]. Each session will last for 20 minutes, and each individual will have 3 sessions over a period of 3 weeks
62222330|NCT05696301|SHAM_COMPARATOR|Control|The women will follow the same study design as the experimental group with activation of the portable placebo device identical to the active medical . Each session will last for 20 minutes, and each individual will have 3 sessions over a period of 3 weeks.
62222331|NCT06609772|NO_INTERVENTION|Control group|After obtaining the necessary legal and ethical permissions for data collection, the research will commence. During this stage of the study, participants who agree to take part in the research will be asked to fill out the informed consent form. To obtain the pre-test data for the research, all forms will be filled out. The patients will be called by the researcher on the 15th, 45th and 75th days to perform interim measurements (Interim measurement-1, Interim measurement-2, Interim measurement-3). On the 90th and 120th days, the patients will be called again by the researcher and the final tests will be applied.
62416573|NCT05996523|EXPERIMENTAL|Arm 1|PRGN 5x10\^11 Viral Particles (VP) SC plus pembrolizumab 200mg IV as induction/ neoadjuvant therapy
62416574|NCT04393831|ACTIVE_COMPARATOR|Retzius sparing|Using the Retzius technique, the surgeon will remove the prostate in a way that preserves a portion of the nerves and tissue structures that are typically removed during the conventional technique.
62416575|NCT04393831|NO_INTERVENTION|Conventional (non-Retzius) nerve sparing|A non-Retzius nerve sparing technique will be performed, according to surgeon's preference--nerve sparing during radical prostatectomy is performed with significant variation and there is an absence of universally agreed upon steps or techniques.
62588294|NCT05437874|PLACEBO_COMPARATOR|Natural Water|"355 ml of water should be drunk.~* Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
62222332|NCT06609772|EXPERIMENTAL|Individualized pain education group|During this stage of the study, participants who agree to take part in the research will be asked to fill out the informed consent form. The individualized pain education program is planned to be applied to all patients on the 6th postoperative day. To obtain the pre-test data for the research, all forms will be filled out. Individual education will be given to the patients in the experimental group in their own rooms and all questions asked by the patient will be answered after the education. The education booklet will be given to the patients after the individual education program. The patients in the experimental group will be informed that they will be called via video call for the 30th and 60th day reminder education. The patients will be called by the researcher on the 15th, 45th and 75th days to perform interim measurements. On the 90th and 120th days, the patients will be called again by the researcher and the final tests will be applied.
62222333|NCT02422862|EXPERIMENTAL|UC-TSM|Upper cervical translatoric spinal mobilization (UC-TSM). UC-TSM is a physical therapy technique used to improve range of movement, consisting on a manual stretching of the cervical spine of the patient during 30 minutes.
62222334|NCT02422862|NO_INTERVENTION|Control|The control group receive no treatment intervention during 30 minutes (a similar time as the UC-TSM group).
62222335|NCT01696838|EXPERIMENTAL|EA group|Electroacupuncture group
62222336|NCT01696838|EXPERIMENTAL|MOX group|Herbs-partitioned moxibustion group
62222337|NCT02709213||Patients with CT-diagnosed acute colitis|Patients with symptomatic colitis (fever and/or pain and/or diarrhea) proven by computed tomography
62416576|NCT04074356|ACTIVE_COMPARATOR|Healthy Controls|Healthy volunteers with no known gastrointestinal complications will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).
62416577|NCT04074356|ACTIVE_COMPARATOR|Achalasia subjects|Subjects who have undergone standard of care high resolution manometry that results in a diagnosis of achalasia will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).
62416578|NCT04074356|ACTIVE_COMPARATOR|Hypercontractile/spastic disorder subjects|Subjects who have undergone standard of care high resolution manometry that results in a diagnosis of hypercontractile/spastic disorder will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).
62416579|NCT06702462|EXPERIMENTAL|HFA-152A propellant followed by HFA-134A propellant|
62416580|NCT06702462|EXPERIMENTAL|HFA-134A propellant followed by HFA-152A propellant|
62416581|NCT00700037|EXPERIMENTAL|1|Atorvastatin 20mg
62416582|NCT00700037|ACTIVE_COMPARATOR|2|atorvastatin 5mg
62416583|NCT06216080||OCT-BIO-CVC cohort|Adult critically ill patients (\> 18 years of age) exposed to central venous catheter for at least two calendar days
62797738|NCT04479332|EXPERIMENTAL|Resuscitation Area|Critical patient is assigned to the resuscitation area for treatment under medical staff on personal protective equipment; Manpower distribution during tracheal intubation: 1-2 licensed physicians, 2-3 nurses (1 for preparing intubation materials and acts as the assist, 1-2 for administering medications and documentation); Manpower distribution during cardiopulmonary resuscitation: 2 licensed physicians (1 inside resuscitation area, 1 at nurses' station), 4 nurses (2 inside resuscitation area, 2 at the sterile area)
62797739|NCT04479332|EXPERIMENTAL|Negative Pressure Isolation Room|Critical patient is assigned to the negative pressure isolation room for treatment under medical staff on personal protective equipment; Manpower distribution during tracheal intubation: 1 licensed physician, 2 nurses (1 for preparing intubation materials, acts as the assist, and for administering medications; 1 for documentation at the anteroom); Manpower distribution during cardiopulmonary resuscitation: 2 licensed physicians (1 inside negative pressure isolation room, 1 at nurses' station), 5 nurses (2 inside negative pressure isolation room, 1 at the anteroom, 2 at the sterile area)
62797740|NCT02936388|EXPERIMENTAL|Arm A|SIRT: Transarterial radioembolisation with Yttrium-90-bearing resin microspheres (SIR-Spheres®)
62416584|NCT04130009|ACTIVE_COMPARATOR|TKA with tourniquet|This group was treated by TKA with the use of tourniquet
62797741|NCT02936388|ACTIVE_COMPARATOR|Arm B|DSM-TACE: Transarterial chemoembolisation with Cisplatin and EmboCept® S starch microspheres (PharmaCept GmbH)
62797742|NCT02466282|ACTIVE_COMPARATOR|Angiography-guidance|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
62797743|NCT02466282|EXPERIMENTAL|OCT-guidance|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
62797744|NCT05647590|EXPERIMENTAL|NSCLC patients|Patients with non-small cell lung cancer (NSCLC) will be enrolled in the study.
62416585|NCT04130009|ACTIVE_COMPARATOR|TKA without tourniquet|This group was treated by TKA without tourniquet
62416586|NCT03666299|EXPERIMENTAL|Lidocaine|Lidocaine treatment
62797745|NCT03930602|EXPERIMENTAL|BMS-986165+Fluvoxamine|
62797746|NCT03930602|EXPERIMENTAL|BMS-986165 only|
62222338|NCT04334954||Healthy Volunteers|Healthy Volunteers
62416587|NCT03666299|PLACEBO_COMPARATOR|Control|Placebo treatment
62416588|NCT04038255|ACTIVE_COMPARATOR|Usual Care|Participants in this group will receive a brief advice to quit smoking, 6-week supplies of nicotine replacement therapy (NRT), and self-help materials to quit smoking.
62797747|NCT03930602|EXPERIMENTAL|Fluvoxamine only|
62416589|NCT04038255|EXPERIMENTAL|Craving-to-Quit app|"Participants in this group will receive one in-person or online orientation session, 6-week supply of NRT, the Craving-to-Quit app, and two brief follow-up phone calls."
62416590|NCT04038255|EXPERIMENTAL|Group Mindfulness Training|Participants in this group will receive twice weekly group sessions (eight total during 4 weeks) that were manualized and delivered by instructors experienced in Mindfulness Training (MT) (a single therapist with \>4 years of training in MT).
62416591|NCT04798274|EXPERIMENTAL|Active cTBS|This intervention involves active repetitive magnetic stimulation. The coil emits a magnetic field
62797748|NCT06307626|EXPERIMENTAL|Efgartigimod arm|Participants with active, moderate-to-severe TED receiving Efgartigimod PH20 SC (subcutaneously) via pre-filled syringe (PFS)
62025220|NCT06636175|EXPERIMENTAL|Pilot/Cohort 1B: Dosimetry 64Cu-LLP2A|"- Will be asked to undergo 64Cu-LLP2A-PET/CT imaging at up to three separate time points for purposes of calculating human dosimetry. Imaging time points will be dependent upon day of the week injection occurs:~* Tuesday or Thursday injection: 0-60 minute multiple quick body scans + 120-180 min post injection body scan~* Wednesday or Friday injection: 0-60 minute multiple quick body scans + 180-240 min post injection body scan~* ALL PATIENTS: 15-28 hours post injection body scan on Wednesday (for Tuesday injection), Thursday (for Wednesday injection), Friday (for Thursday injection) or Saturday (for Friday injection)"
62025221|NCT06636175|EXPERIMENTAL|Cohort 2B: Quantitative 64Cu-LLP2A|- Will be asked to undergo dynamic PET/CT imaging centered over a known target lesion (as determined by other radiological imaging studies) beginning with 64Cu-LLP2A-PET/CT and continuing for a total of 60 minutes. An additional vertex to upper thigh body scan will be obtained between 60- and 180-minutes post injection or at the optimal imaging time point that was derived from cohort 1B.
62797749|NCT06307626|PLACEBO_COMPARATOR|Placebo arm|Participants with active, moderate-to-severe TED receiving Placebo PH20 SC (subcutaneously) via pre-filled syringe (PFS)
62025222|NCT04639414|EXPERIMENTAL|Combined treatment with Empagliflozin and Semaglutide|Combined treatment with Empagliflozin, film-coated tablet, 10mg once daily and Semaglutide, colourless solution in pre-filled pen, 1mg once weekly
62025223|NCT04639414|EXPERIMENTAL|Empagliflozin monotherapy|Empagliflozin, film-coated tablet, 10mg once daily and Placebo matching Semaglutide (colourless solution in pre-filled pen, once weekly)
62025224|NCT04639414|PLACEBO_COMPARATOR|Placebo|Placebo matching Empagliflozin (film-coated tablet, once daily) and Placebo matching Semaglutide (colourless solution in pre-filled pen, once weekly)
62025225|NCT06534788|EXPERIMENTAL|RI-MET group|"RI-MET group A will receive 3-5 repetitions of reciprocal inhibition to the shortened piriformis muscle in supine and prone positions i.e. 30-50% isometric contraction of the muscle opposite to the muscle to be stretched for 7-10 seconds, followed by inhalation, exhalation and rest period of 5 seconds and then a stretch (through the new barrier with patients' assistance) of 10-60 seconds hold.both groups will receive conventional physical therapy which they will be taught as a home plan. Following exercises are guided to the patient as home plan.~* Resisted abduction with Thera/resistance band~* Resisted bridging with Thera/resistance band~* Resisted clam exercise with Thera/resistance band"
62222339|NCT06336733|EXPERIMENTAL|ANAKINRA on Demand|On demand Anakinra 100 mg/j from the prodromal phase of the attack until 24 hours of remission (during 7 days maximum) + colchicine + on demand analgesics
62222340|NCT06336733|NO_INTERVENTION|Standard of Care|Usual analgesics + colchicine
62222341|NCT04377750|EXPERIMENTAL|Tocilizumab treatment group|Treatment: intravenous administration of monoclonal anti body anti- IL6R. The dose is 8 mg/kg up to total dose of 800 mg.
62222342|NCT04377750|PLACEBO_COMPARATOR|Placebo group|Placebo. intravenous administration of 100 ml of normal saline.
62222343|NCT02698085|EXPERIMENTAL|Intervention Goup|Actual Diacutaneous Fibrolysis
62222344|NCT02698085|SHAM_COMPARATOR|Placebo Group|Sham Diacutaneous Fibrolysis
62222345|NCT00096343|EXPERIMENTAL|Paclitaxel IV followed by Carboplatin IV|paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62797750|NCT06726226||Respiratory cohort|Preterm infants with a gestational age less than 29 weeks
62797751|NCT02771236||Participants with cataracts|Participants with cataracts
62222346|NCT02367820|EXPERIMENTAL|NKTR-181|NKTR-181 twice daily (BID) tablets
62222347|NCT05077085|EXPERIMENTAL|Strategy A: initial SoC + bezlotoxumab. SoC + FMT rescue therapy.|initial bezlotoxumab in addition to 14 days SoC oral antibiotic treatment with vancomycin 125 mg QID. 14 days of vancomycin 125mg QID plus fecal microbiota in case of treatment failure.
62222348|NCT05077085|ACTIVE_COMPARATOR|Strategy B: initial SoC + FMT. Fidaxomicin rescue therapy.|fecal microbiota transplantation in addition to 14 days SoC oral antibiotic treatment with vancomycin 125 mg QID. 10 days of fidaxomicin 200 mg BID in case of treatment failure.
62242987|NCT02287311|EXPERIMENTAL|Group C: MABEL CTLs|"Patients with active disease if immunosuppressive chemotherapy is contraindicated.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
62242988|NCT03588299|EXPERIMENTAL|BAY2599023 / (DTX201)|Adult patients with severe hemophilia A, who have been previously treated with FVIII products
62242989|NCT04084964|EXPERIMENTAL|Study group|These patients receive the home-hospitalisation platform
62797752|NCT02771236||Participants with corneal dystrophies|Participants with corneal dystrophies
62797753|NCT02771236||Participants with glaucoma|Participants with glaucoma or other anterior chamber anomalies
62797754|NCT02771236||Participants with lens refractive errors|Participants with lens refractive errors including myopia and hyperopia
62797755|NCT02771236||Participants with retinal degenerations|Participants with retinal degenerations
62025226|NCT06534788|EXPERIMENTAL|PFS-MET group|"PFS-MET group will receive 3-5 repetitions of post-facilitation stretch to the shortened piriformis muscle in supine and prone positions i.e. 20% maximal isometric contraction of the muscle to be stretched for 6-10 seconds, followed by a rapid stretch (through the new barrier) of 15 seconds hold.~After stretch, the muscle is allowed to relax in the midrange for up to 30 seconds.Both groups will receive conventional physical therapy which they will be taught as a home plan. Following exercises are guided to the patient as home plan.~* Resisted abduction with Thera/resistance band~* Resisted bridging with Thera/resistance band~* Resisted clam exercise with Thera/resistance band"
62025227|NCT04278053|EXPERIMENTAL|Nitrosigine supplementation|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (\~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, Nitrosigine (1.5 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
62025228|NCT04278053|EXPERIMENTAL|Citrulline-Malate supplementation|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (\~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, Citrulline-Malate (8 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
62222349|NCT04591431|EXPERIMENTAL|Tailored Therapy|"Experimental (TT) Patients will be treated with target therapy and/or immunotherapy according to their genomic profile evidenced by Foundation One test and independently from their type of cancer with one or more drugs of the following list (administered according to the SmPCs or IBs if under development):~TARGET THERAPY: ERLOTINIB (EGFR mutation) TRASTUZUMAB, PERTUZUMAB, TDM1, LAPATINIB (ERBB2 amplifications/mut) EVEROLIMUS (mTOR mutations, AKT mut) VEMURAFENIB, COBIMETINIB (BRAFV600E mutations) ALECTINIB, BRIGATINIB (ALK, RET) PALBOCICLIB (CDK4/6, CDKN2A/p16) PONATINIB (Bcr-abl) VISMODEGIB (SMO/PTCH1) ITACITINIB (JAK mutation) INCB054828 (FGFR1/2/3) IPATASERTIB (PI3K, AKT, PTEN) ENTRECTINIB (NTRK1/2/3 -TRK fusion proteins-, ROS1) ALPELISIB (PI3K, AKT) TEPOTINIB (MET amplification/exon14 skipping mutations) PRALSETINIB (RET) TALAZOPARIB (BRCA1/2, ATM, other HRD status) SELPERCATINIB (RET) IMMUNOTHERAPY: ATEZOLIZUMAB, NIVOLUMAB, IPILIMUMAB (MSI, HIGH TUMOR MUTATIONAL BURDEN, OTHER)"
62416592|NCT04798274|SHAM_COMPARATOR|Sham cTBS|This intervention involves sham (placebo) repetitive transcranial magnetic stimulation. The coil is blinded, but does not emit any magnetic field
62416593|NCT06653244|ACTIVE_COMPARATOR|group Midazolam|midazolam (administered intravenously at a dosage of 1 mg, up to a maximum dose of 3 mg) on demand
62416594|NCT06653244|ACTIVE_COMPARATOR|GROUP Morphine|morphine (administered intravenously at a dosage of 2-4 mg, up to a maximum dose of 8 mg every 12 hours
62222350|NCT04591431|ACTIVE_COMPARATOR|Standard of Care|Patients will be treated according the current version of the AIOM (Italian Association of Medical Oncology) guidelines for their type of cancer. As an example, patients could be treated with standard chemotherapy and/or targeted therapy according to the histological results.
62222351|NCT00837798||No history of AF|Patient should not have had a documented history of AF for a period of 3 months prior to enrollment.
62222352|NCT00391131|EXPERIMENTAL|Ig NextGen 16%|
62222353|NCT02110719|ACTIVE_COMPARATOR|Standard|"Patients will be given the following:~* no preoperative medications~* intraoperative medications per anesthesia~* postoperatively, patients will receive ibuprofen, tylenol and narcotics as needed"
62222354|NCT02110719|ACTIVE_COMPARATOR|Multimodal|"Patients in the multimodal arm will receive the following:~* preoperative celebrex and gabapentin~* intraoperative IV acetaminophen, dexamethasone, zofran~* postoperative scheduled IV acetaminophen, PO celebrex and gabapentin, and as needed PO narcotics~* patient will be discharged on scheduled ibuprofen and acetaminophen for 3 days followed by as needed use as well as as needed narcotics"
62242990|NCT04337255|ACTIVE_COMPARATOR|MIND DIET intervention|Allocation and blinding 3 year intervention of MIND Diet + counseling
62242991|NCT04337255|PLACEBO_COMPARATOR|Usual care diet intervention|3 year Intervention of usual care diet + counseling
62416595|NCT06653244|ACTIVE_COMPARATOR|Group Dexmedetomidine|dexmedetomidine ( administered intravenously, Load: 0.25 mcg/kg IV over 10 minutes , Maintenance 0.2-0.7 mcg/kg/hr continuous IV 7 infusion according to haemodynamics and sedation score of patient ; not to exceed 24 hr
62416596|NCT05531799|OTHER|Group 1 DARE/CYTOLOGY/HPV/HRA|Participant request physician assessment for Digital anal rectal exam, Anal cytology, Anal HPV test and High resolution anoscopy for every 6 months within 12 months period
62416597|NCT05531799|OTHER|Group 2 DARE/CYTOLOGY/HPV|Participant request physician assessment for Digital anal rectal exam, Anal cytology, Anal HPV test for every 6 months within 12 months period
62416598|NCT05531799|OTHER|Group 3 DARE/CYTOLOGY/HRA|Participant request physician assessment for Digital anal rectal exam, Anal cytology and High resolution anoscopy for every 6 months within 12 months period
62416599|NCT05531799|OTHER|Group 4 DARE/CYTOLOGY|Participant request physician assessment for Digital anal rectal exam, Anal cytology for every 6 months within 12 months period
62416600|NCT05531799|OTHER|Group 5 DARE/HPV/HRA|Participant request physician assessment for Digital anal rectal exam, Anal HPV test and High resolution anoscopy for every 6 months within 12 months period
62416601|NCT05531799|OTHER|Group 6 DARE/HPV|Participant request physician assessment for Digital anal rectal exam and Anal HPV test for every 6 months within 12 months period
62222355|NCT05490719|EXPERIMENTAL|QL1706 plus Chemotherapy and Radiotherapy|"Radiotherapy: Total 50.4Gy/28 fraction ,1.8Gy per time，5 fractions per week.~QL1706 will be administered at a dose of 5 mg/kg intravenously (IV), every 3 weeks, until progressive disease or intolerable or other reasons according to the criteria for termination of treatment). QL1706 will be administered up to 1 year.~Chemotherapy: Taxol 135 mg/m2, days 1, 22; Cisplatin 25 mg/m2, day 1-3, day 22-24."
62222356|NCT04369482|ACTIVE_COMPARATOR|Alcon Clareon|Implantation of an intraocular lens Alcon Clareon
62222357|NCT04369482|ACTIVE_COMPARATOR|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
62222358|NCT03154073|EXPERIMENTAL|Moderate Exercise Training|Exercise training program that will focus on engaging in \~150 minutes of moderate intensity exercise per week. Exercise will be supervised by trained staff.
62416602|NCT05531799|OTHER|Group 7 DARE/HRA|Participant request physician assessment for Digital anal rectal exam and High resolution anoscopy for every 6 months within 12 months period
62416603|NCT05531799|OTHER|Group 8 DARE|Participant request physician assessment for Digital anal rectal exam for every 6 months within 12 months period
62222359|NCT03154073|EXPERIMENTAL|Vigorous Exercise Training|Exercise training program that will focus on engaging in \~150 minutes of vigorous intensity exercise per week. Exercise will be supervised by trained staff.
62222360|NCT00713089||1|75 subjects randomised into the placebo arm of an ongoing randomised double-blind placebo controlled clinical trial at National University Hospital, Singapore
62416604|NCT05531799|OTHER|Self-collection CYTOLOGY/HPV|Participant request Self-sampling collection for Anal cytology and Anal HPV test for every 6 months within 12 months period
62416605|NCT05531799|OTHER|Self-collection CYTOLOGY|Participant request Self-sampling collection for Anal cytology for every 6 months within 12 months period
62416606|NCT05531799|OTHER|Self-collection HPV|Participant request Self-sampling collection for Anal HPV test for every 6 months within 12 months period
62222361|NCT00713089||2|The expecting mothers visiting at the well mother clinics at Gadjah Mada University Hospital were invited to participate in the study
62222362|NCT05189873|EXPERIMENTAL|HRT|HRT protocol : estradiol and progesterone
62416607|NCT05531799|OTHER|Self-collection control group CYTOLOGY/HPV|Participant request Self-sampling collection for Anal cytology and Anal HPV only at month 12
62416608|NCT01504789|EXPERIMENTAL|Cultural Related Material Group|Patients will be randomized to receive either culturally adapted AI materials or non-culturally adapted SI materials. Intervention materials will be mailed to patients every 2 weeks. Based on the results of the fitness tests, a specific exercise program will be presented. The research staff will call about every 2 weeks to check that materials were received and have been sent back whatever materials are due. The phone call should take no more than 15 minutes. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. The questionnaire packet will be mailed with a postage-paid return envelope. It should take about 10 minutes to complete the questionnaires.
62416609|NCT01504789|EXPERIMENTAL|Non-Cultural Related Material Group|Patients will be randomized to receive either culturally adapted AI materials or non-culturally adapted SI materials. Intervention materials will be mailed to patients every 2 weeks. Based on the results of the fitness tests, a specific exercise program will be presented. The research staff will call about every 2 weeks to check that materials were received and have been sent back whatever materials are due. The phone call should take no more than 15 minutes. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. The questionnaire packet will be mailed with a postage-paid return envelope. It should take about 10 minutes to complete the questionnaires.
62797756|NCT04764513|EXPERIMENTAL|Patients with hematological malignancies after allo-HSCT|"1. Patients with negative minimal residual disease or stable disease:~   After inclusion, patients will receive or not receive chemotherapy. Subsequently, patients will be dosed with γδ T cell.~2. Patients with positive minimal residual disease but not hematologic relapse:~   After inclusion, patients will receive chemotherapy. Subsequently, patients will be dosed with γδ T cell.~3. Patients with hematologic relapse:~After inclusion, patients will receive chemotherapy. Subsequently, patients will be dosed with γδ T cell."
62797757|NCT01407510|EXPERIMENTAL|Arm 1|
62797758|NCT05779020|EXPERIMENTAL|QIV-IB/dose 0.25ml|Butantan Quadrivalent Influenza Vaccine (split virion, inactivated)/dose 0.25ml
62222363|NCT05189873|EXPERIMENTAL|Long GnRH agonist + HRT|Long GnRH agonist + HRT protocol: Superfect and estradiol and progesterone
62222364|NCT03557580|ACTIVE_COMPARATOR|IS-5-MN R|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
62222365|NCT03557580|EXPERIMENTAL|IS-5-MN T1|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
62222366|NCT03557580|EXPERIMENTAL|IS-5-MN T2|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
62222367|NCT01642251|EXPERIMENTAL|Arm A (veliparib)|Patients receive veliparib PO BID on days 1-7, etoposide IV over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62222368|NCT01642251|ACTIVE_COMPARATOR|Arm B (placebo)|Patients receive placebo PO BID on days 1-7, etoposide IV over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62416610|NCT01504789|ACTIVE_COMPARATOR|Waitlist Group|Patients may choose to participate in the exercise program after 16-week assessment. After 4 months of exercise, all the follow-up tests repeated. Exercise recommendation then given, and all of the intervention materials.
62416611|NCT00717158|NO_INTERVENTION|I|Usual medical care. They received written healthy lifestyle information
62797759|NCT05779020|EXPERIMENTAL|QIV-IB/dose 0.50ml|Butantan Quadrivalent Influenza Vaccine (split virion, inactivated)/dose 0.50ml
62588295|NCT05437874|ACTIVE_COMPARATOR|Carbonated water|"355 ml of carbonated water should be drunk~* Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
62588296|NCT05437874|EXPERIMENTAL|Aspartame/acesulfame K|"355 ml of drink of diet coke should be drunk.~* Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
62588297|NCT05437874|EXPERIMENTAL|Saccharose|"355 ml of drink of regular coke should be drunk~* Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
62797760|NCT05779020|ACTIVE_COMPARATOR|TIVV-IB|Butantan Trivalent Influenza Vaccine (split virion, inactivated)/dose 0.25ml containing Influenza B virus - Victoria lineage
62797761|NCT05779020|ACTIVE_COMPARATOR|TIVY-IB|Butantan Trivalent Influenza Vaccine (split virion, inactivated)/dose 0.25ml containing Influenza B virus - Yamagata lineage
62797762|NCT05159999|EXPERIMENTAL|Home Systolic Blood Pressure <140 mmHg|Participants will take their home blood pressure two times per week (one in the morning and one in the evening) on non-dialysis days, ideally mid-week. Home blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a home systolic blood pressure target of \<140 mmHg.
62797763|NCT05159999|ACTIVE_COMPARATOR|Pre-Dialysis Systolic Blood Pressure <140 mmHg|Participants will have their blood pressure taken by an automated blood pressure device by dialysis unit staff using regular dialysis unit equipment according to usual clinical care. Pre-dialysis blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a pre-dialysis systolic blood pressure target of \<140 mmHg.
62797764|NCT05159999|OTHER|Home Systolic Blood Pressure <130 mmHg|This will be an optional, exploratory 2 month study at the end of the primary 10-month trial. Participants will take their home blood pressure two times per week (one in the morning and one in the evening) on non-dialysis days, ideally mid-week. Home blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a home systolic blood pressure target of \<130 mmHg.
62797765|NCT02935530|EXPERIMENTAL|s-LMWH|2125 I.U. subcutaneous injection for 5-10 days
62242992|NCT01729858||Metal-Ceramic|Metal Ceramic prosthesis with press on veneer with different thicknesses, different diameters of curvature of gingival embrasure and connector heights.
62416612|NCT00717158|ACTIVE_COMPARATOR|2|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
62588298|NCT00998075|ACTIVE_COMPARATOR|1|Esomeprazole 40 mg/ASA 325 mg Fixed Dose Combination Capsule
62797766|NCT02935530|ACTIVE_COMPARATOR|LMWH|4250 I.U. subcutaneous injection for 5-10 days
62797767|NCT02935530|EXPERIMENTAL|Argatroban|20mg, injection for 5-10 days
62797768|NCT05852691|EXPERIMENTAL|Arm A|Participants will receive tobemstomig every 3 weeks, plus nab-paclitaxel administered on a repeating schedule of 3 weeks on, 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.
62797769|NCT05852691|ACTIVE_COMPARATOR|Arm B|Participants will receive pembrolizumab every 3 weeks, plus nab-paclitaxel administered on a repeating schedule of 3 weeks on, 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.
62797770|NCT05172726|EXPERIMENTAL|Open Label|
62797771|NCT06166680||Healthy children|Healthy children between the ages of 4 to 17 will undergo tongue motor functions assessment and their parents will fulfill the Pediatric Sleep Questionnaire
62797772|NCT03217708||Children without OSA|Children for AT due to chronic tonsillitis without OSA.
62797773|NCT03217708||Children with OSA|Children with OSA for AT as determined by PSG
62797774|NCT05944679|PLACEBO_COMPARATOR|Group Xray|Xray at 1, 3, 6 and 12 months
62797775|NCT05944679|ACTIVE_COMPARATOR|Group No Xray|Xray at 12 months
62416613|NCT01825499||Very low birth weight infants|Infants \<=1500 g or \<=29 weeks gestational age admitted to Vermont Oxford Network member centers within 28 days of birth
62797776|NCT03178604|ACTIVE_COMPARATOR|Classic massage|Classic massage (CM) treatment based on petrissage. It applies: 1 minute of mild effleurage, 5 minutes of deep effleurage with the thumbs, 5 minutes of firm kneading and 1 minute of tapotement (20 minutes in total). This procedure was repeated for each muscle group.
62797777|NCT03178604|ACTIVE_COMPARATOR|Sham massage|Sham massage (SM). 20 minutes in total soft effleurage was performed. This procedure was repeated for each muscle group.
62588299|NCT00998075|ACTIVE_COMPARATOR|2|Esomeprazole Clinical Trial Capsule 40 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
62588300|NCT00998075|ACTIVE_COMPARATOR|3|Esomeprazole MUPS Tablet 40 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
62797778|NCT03642652|EXPERIMENTAL|SMS|"Each patient in the intervention group also received an automated text message up to a week after the positive FOBT result. The text read: Hello. There is a lab test result ready for you. Contact your physician for an explanation of the findings. Two additional automated text message reminders were sent to the patient at 2 weeks and 1 month reading, Hello, This is a reminder. It is essential that you contact your physician if you have not already done so."
62797779|NCT03642652|NO_INTERVENTION|Control|Routine care
62797780|NCT04033055|EXPERIMENTAL|CycloMesh™ soaked in ropivacaine hydrochloride 10mg/mL|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in ropivacaine hydrochloride 10mg/mL) is positioned once the surgery for the inguinal hernia repair has been performed."
62797781|NCT04033055|ACTIVE_COMPARATOR|CycloMesh™ soaked in saline solution 9°/°°|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in saline solution) is positioned once the surgery for the inguinal hernia repair has been performed."
62797782|NCT04372251|ACTIVE_COMPARATOR|Sinus tarsi approach (STA)|Patients randomized to this arm are operated with plate osteosynthesis via the sinus tarsi approach
62797783|NCT04372251|ACTIVE_COMPARATOR|Percutaneous Arthroscopically Assisted Osteosynthesis (PACO)|Patients randomized to this arm are operated with percutaneous reduction of the fracture and osteosynthesis with screws, assisted by subtalar arthroscopy
62797784|NCT03534102|NO_INTERVENTION|Standard of Care|Standard instructions from hospital. Subjects talk with hospital staff only when they call the hospital, when RA calls at various benchmarks, and at postoperative clinic visits. Subjects record opioid tapering in diary.
62797785|NCT03534102|EXPERIMENTAL|Improved Instructions|Improved opioid-tapering instructions given upon discharge from hospital. Subjects talk with hospital staff only when they call the hospital, when RA calls at various benchmarks, and at postoperative clinic visits. Subjects record opioid tapering in diary.
62797786|NCT03534102|EXPERIMENTAL|Improved Instructions and Educator|Improved opioid-tapering instructions given upon discharge from hospital. Subject receives regular phone calls from educator for counseling in opioid tapering. Subjects record opioid tapering in diary.
62797787|NCT01668849|EXPERIMENTAL|1 - Grape extract|Grape extract self-administered daily by mouth for 35 days during chemoradiation therapy.
62797788|NCT01668849|ACTIVE_COMPARATOR|2 - Lortab, Fentanyl patch, mouthwash|Standard oral mucositis therapy such as pain medication and anti-fungal mouth washes will be prescribed according to product labels.
62797789|NCT03360643|ACTIVE_COMPARATOR|Point-of-care ultrasound prior to radiology ultrasound|
62222369|NCT01947972|OTHER|protein intake of 4g/kg/d|Tailored protein fortification and nutritional status of preterm neonate. 4.5g protein per kg for preterms with body weight less than 1000g and 4g protein per kg for preterms with body weight more than 1000g, after human milk analysis. Intervention regards protein supplementation to fulfil the exact protein needs of preterms
62222370|NCT05692479||Group 1 and Group 2|Women With and Without Premenstrual Syndrome
62222371|NCT05308238|EXPERIMENTAL|Occupational therapy intervention group|Participants will receive 6 telehealth coaching sessions and 8 brief email or text check-ins over the course of 4 months. Participants will also receive a Fitbit and Engage PD Workbook.
62222372|NCT05308238|ACTIVE_COMPARATOR|Disease management education group|Participants will receive online educational videos that they can watch at their own convenience over the course of 4 months. There will be up to 6 hours of content, and the links to these online videos will be provided via email. Following completion of the study, individuals in this group will receive an Engage PD Workbook and one OT coaching session, if they choose to.
62797790|NCT03360643|ACTIVE_COMPARATOR|Radiology-performed ultrasound|
62797791|NCT04414163|EXPERIMENTAL|IMC-001|Single Dose level (IMC-001 20mg/kg, every 2 weeks)
62416614|NCT03787771||FMT recipents|Subject who has received or planning to receive FMT or other gut-related microbiota products in routine clinical practice or research
62416615|NCT03787771||FMT donors|Subject who has donated stool or planning to donate stool for FMT or production of other gut-related microbiota products in routine clinical practice or research.
62416616|NCT01261650|ACTIVE_COMPARATOR|transcranial direct current stimulation|transcranial direct current stimulation of the primary motor cortex
62416617|NCT01261650|SHAM_COMPARATOR|sham treatment|
62416618|NCT04188860|EXPERIMENTAL|Study group|The patients in the study group would accept the treatment of a combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel.
62416619|NCT01062100|EXPERIMENTAL|nuclear breast imaging|nuclear breast imaging using MBI Gamma camera
62797792|NCT04775563||Rheumatic diseases outpatients|All the rheumatic diseases outpatients from the National Institute of Medical Sciences and General Hospital.
62797793|NCT01300312|EXPERIMENTAL|1|
62797794|NCT01300312|ACTIVE_COMPARATOR|2|
62222373|NCT01076426|EXPERIMENTAL|Probiotics|probiotics treatment
62222374|NCT01076426|PLACEBO_COMPARATOR|Placebo|
62025229|NCT04278053|PLACEBO_COMPARATOR|Placebo|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (\~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, dextrose (8 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
62025230|NCT06397404||Patients with acute decompensated heart failure|The study involved patients over 18 years of age admitted to the hospital with acute heart failure and requiring intravenous administration of loop diuretics. Diagnosis was based on the European Society of Cardiology (ESC) heart failure guidelines, with patients presenting with dyspnoea at rest or with minimal exertion and signs and symptoms of congestion (rales on chest auscultation, peripheral oedema, swelling of the cervical veins, hepatomegaly, ascites, hepatojugular reflux) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) \>1000 pg/ml.
62025231|NCT01863680|EXPERIMENTAL|COL-1620|
62025232|NCT04852081||patients with HR+, HER2- advanced or metastatic breast cancer|patients with HR+, HER2- advanced or metastatic breast cancer
62025233|NCT01699880||conventional high FiO2 bag reservoir facemask|this group of patients is intubated according to our current practice that requires the use of a high FiO2 nonrebreathing with bag reservoir facemask to ensure preoxygenation in patients requiring tracheal intubation. a small nasal catheter is inserted just before laryngoscopy to ensure a low oxygen flow to allow oxygenation during laryngoscopy.
62797795|NCT05326711|EXPERIMENTAL|Telerehabilitation-based motor imagery training|"The first 2 weeks of the treatment period, will reserved for implicit motor imagery / lateralization training. It will be performed by the noi group application application that can be downloaded to the participants' mobile devices. Participants will be asked to use the app 3 times a day. In each application session, the right / left discrimination of the region in the photograph will be requested within 5 seconds and 30 photographs will be shown for each painful region. Each session will last 2-3 minutes on average. For 3rd to 8th weeks of the treatment period telehabilitation-based motor imagery training will be given to the participants individually, in synchronization, using the Google Meet videoconference platform, under the guidance of a physiotherapist. The duration of the sessions will last 20-30 minutes."
62797796|NCT05326711|NO_INTERVENTION|Control|No specific intervention
62222375|NCT01856777|OTHER|High sensitivity urine pregnancy test|Standard medical care and high sensitivity urine pregnancy test
62222376|NCT01856777|OTHER|Semi-quantitative panel test|Standard medical care and semi-quantitative panel test
62222377|NCT06453785|OTHER|Patients with suspected prostate cancer|Patients who undergo prostate biopsy for suspected prostate cancer. Each patient would undergo both a portable MRI-registered biopsy and a TRUS-image-fusion biopsy. To reduce the risk of bias between the two modalities, the order of the modality will be randomized 1:1. There will be no blinding of the surgeon.
62222378|NCT06130761|EXPERIMENTAL|PENG block (P group)|PENG BLOCK : 0.5 ml/kg of 0.25% bupivacaine is deposited between the psoas tendon anteriorly and pubic ramus posteriorly lifting it , and to perform the LFCN block 0.1 ml/kg of 0.25% bupivacaine is injected in lateral to femoral artery below anterior superior iliac spine .
62242993|NCT01729858||Ceramic-Ceramic|Zirconia computer aided design and computer milled cores with press on veneers with different thicknesses, gingival embrasure diameters and connector heights.
62416620|NCT03147040|EXPERIMENTAL|Carboplatin/Atezolizumab|Carboplatin AUC=1.5, weekly schedule, maximum 12 administrations Atezolizumab, 1200 mg flat dose, 3-weekly schedule, starting after two administrations of carboplatin
62588301|NCT06045299|EXPERIMENTAL|LNZ101 (Aceclidine/Brimonidine) ophthalmic solution|Enrolled subjects will be randomized to receive LNZ101, LNZ100, or placebo bilaterally once a day. Subjects will be instructed to dose 2 drops in both eyes (OU) (1 drop followed by 2 minutes later, another drop). Subjects will dose for 168 days.
62797797|NCT03779698|EXPERIMENTAL|BiodentineTM pulpotomy group|A Bioactive Dentine Substitute (BiodentineTM, Septodont Ltd., Saint Maur des Faussés, France) was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface.
62797798|NCT03779698|ACTIVE_COMPARATOR|Formocresol pulpotomy group|A sterile cotton pellet moistened with 1:5 concentration formocresol (Buckley's Formocresol, Sultan Healthcare, Englewood, NJ, USA) then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing.
62797799|NCT05133154|OTHER|Patients with low-grade glioma|Group 1
62797800|NCT05133154|OTHER|Patients with high-grade glioma|Group 2
62797801|NCT05133154|OTHER|Patients undergoing brain surgery for a non-tumor disease|Group 3
62797802|NCT01776840|PLACEBO_COMPARATOR|Treatment Arm A|
62797803|NCT01776840|EXPERIMENTAL|Treatment Arm B|
62797804|NCT06725082|EXPERIMENTAL|rhCOL3 Injection Group|RhCOL3 will be prepared as a 4mg/ml and injected around the tumor. After the surgical margin is confirmed to be safe by rapid frozen pathology during surgery, a second injection of 2ml will be administered around the surgical area skin (at points spaced along the skin incision).
62797805|NCT06725082|PLACEBO_COMPARATOR|Control Group|4ml of saline will be injected around the tumor before surgery. After the surgical margin is confirmed to be safe by rapid frozen pathology during surgery, 2ml of saline will be injected around the breast surgical area skin.
62797806|NCT04079595|EXPERIMENTAL|Open-faced head immonbilization masks|Masks used for immobilization of the head (CIVCO Radiotherapy, Orange City, Iowa) during radiation therapy with openings for the face
62797807|NCT04079595|ACTIVE_COMPARATOR|Closed-face head immobilization masks|Masks used for immobilization of the head (CIVCO Radiotherapy, Orange City, Iowa) during radiation therapy with the face closed
62797808|NCT00655629|EXPERIMENTAL|Vardenafil ODT (STAXYN, BAY38-9456)|Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
62797809|NCT00655629|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
62222379|NCT06130761|EXPERIMENTAL|TQL block (Q group)|QL is usually identified medial to the aponeurosis of transversus abdominis muscle vertically attached above the iliac crest. A 22-gauge 50 mm needle will be inserted in the plane from the posterior edge of the convex probe through the QL in an anteromedial direction. The needle tip will be placed between the PM muscle and the QL muscle and the local anesthetic will be injected into the fascial plane after aspiration test is negative. A volume 0.5 ml/kg of 0.25% bupivacaine is injected with maximum dose 2.5mg per kg of bupivacaine
62588302|NCT06045299|EXPERIMENTAL|LNZ100 (Aceclidine) ophthalmic solution|Enrolled subjects will be randomized to receive LNZ101, LNZ100, or placebo bilaterally once a day. Subjects will be instructed to dose 2 drops in both eyes (OU) (1 drop followed by 2 minutes later, another drop). Subjects will dose for 168 days.
62797810|NCT05747742|EXPERIMENTAL|RLRL of 50% intensity|"Participants will be treated with RLRL (50% intensity) twice per weekday with an interval of at least 4 hours, each treatment last 3 minutes.~Single-vision spectacles with power for correcting distance refraction will also be used if necessary. Cross over arms after one month of use and one month of washout period."
62797811|NCT05747742|ACTIVE_COMPARATOR|RLRL of 100% intensity|"Participants will be treated with RLRL (100% intensity) twice per weekday with an interval of at least 4 hours, each treatment last 3 minutes.~Single-vision spectacles with power for correcting distance refraction will also be used if necessary. Cross over arms after one month of use and one month of washout period."
62797812|NCT06579950|EXPERIMENTAL|Cool roof|Households will receive sunlight reflecting 'cool roof' coating on their roofs.
62797813|NCT06579950|NO_INTERVENTION|No cool roof|No cool roof application. Households will keep their original roofing for the duration of the trial.
62797814|NCT05168033|EXPERIMENTAL|Motor imagery training|"In addition to classic rehabilitation the experimental group will be assigned to motor imagery training.~This training will take place at 3 specific periods (4 weeks) during the rehabilitation process:~MI 1: immediately postoperative; MI 2: return to run; MI 3: change of directions and cutting;~To complete a motor imagery training session, participants of the experimental group will have to watch video clips in which rehabilitation exercises or sport specific situations will be shown. After watching, participants will have to mentally imagine they are performing these exercises themselves without actually moving. During each of the 3 motor imagery periods, subjects will be required to complete 20 sessions of 10-15 minutes each."
62797815|NCT05168033|ACTIVE_COMPARATOR|Classic rehabilitation|This group will follow the classic rehabilitation pathway after anterior cruciate ligament reconstruction.
62797816|NCT02618265|EXPERIMENTAL|Mobile terminal|Stroke received mobile terminal management for secondary prevention administration, as the same time platelet reactivity modified drug selection was performed. Mobile application management conducts the control and regulation for anti hypertension, statin and antiplatelet therapy to increasing drug compliance.
62797817|NCT02618265|ACTIVE_COMPARATOR|traditional management|Stroke received traditional management for secondary prevention administration
62797818|NCT02618265|ACTIVE_COMPARATOR|website platform management|Stroke received website platform management for secondary prevention administration. Website platform management conducts the control and regulation for anti hypertension, statin and antiplatelet therapy to increasing drug compliance.
62797819|NCT05341726|EXPERIMENTAL|BREATHE intervention|The patient's primary care provider (PCP) will deliver a brief intervention using motivational interviewing and shared decision making, in a one time 9-minute intervention integrated into an office visit for asthma. PCPs will follow a 4-step script tailored to erroneous asthma and inhaled corticosteroid (ICS) beliefs, as well as ACQ score, measured just prior to the office visit.
62797820|NCT05341726|ACTIVE_COMPARATOR|Control Intervention|The patient's primary care provider (PCP) will deliver a 9-minute scripted intervention on credible nutrition and lifestyle information. The control intervention is designed to not be specific enough to change strategies related to asthma control.
62797821|NCT02219334|EXPERIMENTAL|NoseFrida|If randomized to the NoseFrida group, the NoseFrida/filters will be given along with educational instruction of its use to the parents of patients admitted with bronchiolitis. The NoseFrida will be used by the parent to suction the nares of their infants/toddlers.
62222380|NCT05288153|EXPERIMENTAL|the metformin group|Patients in the metformin group shall receive oral metformin at 500 mg per day for 6 months.
62222381|NCT05288153|ACTIVE_COMPARATOR|the folate group|Patients in the folate group shall receive oral folate at 5 mg three times a day for 6 months.
62222382|NCT01457989||retigabine/ezogabine|retigabine/ezogabine; dose range up to 1200 mg/day
62588303|NCT06045299|PLACEBO_COMPARATOR|Placebo (Vehicle) ophthalmic solution|Enrolled subjects will be randomized to receive LNZ101, LNZ100, or placebo bilaterally once a day. Subjects will be instructed to dose 2 drops in both eyes (OU) (1 drop followed by 2 minutes later, another drop). Subjects will dose for 168 days.
62797822|NCT02219334|NO_INTERVENTION|NeoSucker|The NeoSucker (used for nasal suctioning) is part of the current standard of care for patients with bronchiolitis. The NeoSucker is used for removing nasal secretions by a nurse or respiratory therapist. The NeoSucker is a plastic tube which is used to suction the secretions. The bedside nurse will continue to use the NeoSucker as needed. NoseFrida will not be used for this sub group of patients.
62797823|NCT04085588||Group 1|"All patients were revived spinal anesthesia with 3 mL marcaine 0.5% and after surgery a 2 mg bolus morphine PCA pump was connected to them.~Before the skin incision, when sensorial block reached T10 dermatome level 2 μg / kg / min ketamine was started in Group 1. By the end of the operation ketamine infusion was reduced to 1 μg / kg / min."
62222383|NCT01485081|EXPERIMENTAL|Danubio|
62588304|NCT04767555|EXPERIMENTAL|ILM (inner limiting membrane) peeling|ILM peeling adding to standard vitreous surgery in patients suffering from retinal detachment
62222384|NCT01704638|EXPERIMENTAL|2677TT|Plasma kinetics of fluvoxamine and digoxin in this genotype
62222385|NCT01704638|OTHER|2677GG|plasma kinetics of fluvoxamine and digoxin in this genotype
62222386|NCT01181388|ACTIVE_COMPARATOR|intra-guide-catheter infusion of tirofiban|
62222387|NCT01181388|EXPERIMENTAL|intra-thrombus-aspiration-catheter infusion of tirofiban|
62242994|NCT02693782|PLACEBO_COMPARATOR|Placebo|15 g/day maltodextrin in 3 portions of 5 g.
62242995|NCT02693782|ACTIVE_COMPARATOR|Fibre supplement|15 g/day Wheat Bran Extract in 3 portions of 5 g.
62025234|NCT01699880||high flow nasal cannula oxygen|we wish to change our standard practice of preoxygenation and expand our use of high flow nasal cannula oxygen therapy to the tracheal intubation setting. Currently, used of high flow oxygen nasal cannula oxygen therapy to ensure oxygenation during intubation is limited to the patients already under high flow nasal cannula oxygen. the change of practice consists in the systematic use of high flow nasal cannula oxygen therapy in all patients requiring tracheal intubation in the ICU.
62025235|NCT03946839||ICU Survivors|sepsis/septic shock Patients with high risk of cognitive impairment who discharge from ICU
62025236|NCT03946839||Healthy Control|The control group have to be medically and cognitively healthy. These individuals are recruited from the community and all attempts will be made to match them on age,sex and education to individuals recruited for groups of ICU Survivors.
62025237|NCT05427331|EXPERIMENTAL|FMT capsule treatment group|drugs use generic name: FMT capsule dosage form: capsule dosage, frequency: 16 capsules once a week duration: 4 weeks
62797824|NCT04085588||Group 2|"All patients were revived spinal anesthesia with 3 mL marcaine 0.5% and after surgery a 2 mg bolus morphine PCA pump was connected to them.~Before the skin incision, when sensorial block reached T10 dermatome level 4 μg / kg / min ketamine was started . By the end of the operation ketamine infusion was reduced to 2 μg / kg /min and continued."
62797825|NCT04085588||Group 3|"All patients were revived spinal anesthesia with 3 mL marcaine 0.5% and after surgery a 2 mg bolus morphine PCA pump was connected to them.~Before the skin incision, when sensorial block reached T10 dermatome level 6 μg / kg / min ketamine was started . By the end of the operation ketamine infusion was reduced to 3 μg / kg /min and continued."
62025238|NCT05427331|PLACEBO_COMPARATOR|Placebo treatment group|drugs use generic name: Placebo dosage form:capsule dosage,frequency:16 capsules once a week duration:4 weeks
62222388|NCT02647216|ACTIVE_COMPARATOR|Mindfulness Based Cognitive Therapy (MBCT)|MBCT is a structured 8-week group intervention which integrates aspects of cognitive behavioral therapy (CBT) with components of the Mindfulness Based Stress Reduction (MBSR) program.
62222389|NCT02647216|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Subjects randomized to TAU will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study (for the TAU group) and outside of the study (for the MBCT group) will be assessed at the 3-month follow up (Visit 3).
62222390|NCT03078426|EXPERIMENTAL|Group 1 : UIP pattern|18 patients with UIP pattern at HRCT and IPF as a definite diagnosis.
62797826|NCT00704366|EXPERIMENTAL|1|AZD0530
62222391|NCT03078426|EXPERIMENTAL|Group 2 : possible UIP pattern|"7 patients with  possible  UIP pattern at HRCT with histopathology given by surgical lung biopsy making the diagnosis of IPF."
62222392|NCT03078426|EXPERIMENTAL|Group 3 : diagnosis of fibrosing sarcoidosis|15 patients with the diagnosis of fibrosing sarcoidosis after multidisciplinary discussion.
62242996|NCT00518388||Focus Group + Questionnaire|Participants that are self identified as Korean, Filipino, or Vietnamese.
62588305|NCT04767555|NO_INTERVENTION|No Peeling|standard vitreous surgery without ILM peeling in patients suffering from retinal detachment
62797827|NCT04917484|ACTIVE_COMPARATOR|Standard|Patients in this arm receive our standard treatment. Four treatment with standard dose of 7.4 GBq Lu-177-DOTATOC
62797828|NCT04917484|EXPERIMENTAL|Dosimetry|Patients in this treatment arm receive individualized calcuted treatment depending on kidney function and kidney dose. The treatment activity can differ from one treatment to the next.
62797829|NCT03712787|EXPERIMENTAL|300 mg/1000 mg Tilavonemab|Participants who received 300 mg tilavonemab in Study M15-566 receive 1000 mg tilavonemab in Study M15-570 via intravenous (IV) infusion every 4 weeks for up to 5.5 years.
62797830|NCT03712787|EXPERIMENTAL|1000 mg/1000 mg Tilavonemab|Participants who received 1000 mg tilavonemab in Study M15-566 continue on the same dose in Study M15-570 via IV infusion every 4 weeks for up to 5.5 years.
62797831|NCT03712787|EXPERIMENTAL|2000 mg/2000 mg Tilavonemab|Participants who received 2000 mg tilavonemab in Study M15-566 continue on the same dose in Study M15-570 via IV infusion every 4 weeks for up to 5.5 years.
62797832|NCT03712787|EXPERIMENTAL|PBO/2000 mg Tilavonemab|Participants who received placebo (PBO) in Study M15-566 receive 2000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks for up to 5.5 years.
62797833|NCT03635749|ACTIVE_COMPARATOR|DAPT + immediate high-intensity statin|This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); active atorvastatin calcium with high dosage in the early phase.
62797834|NCT03635749|OTHER|DAPT + delayed high-intensity statin|This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the ealy phase.
62797835|NCT03635749|OTHER|Aspirin+immediate high-intensity statin|This group will receive active aspirin and clopidogrel placebo; active atorvastatin calcium with high dosage in the early phase.
62797836|NCT03635749|PLACEBO_COMPARATOR|Aspirin+delayed high-intensity statin|This group will receive active aspirin and clopidogrel placebo; atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the early phase.
62797837|NCT04658004|EXPERIMENTAL|Administration of NKG2D CAR T-cells|
62797838|NCT04794270|EXPERIMENTAL|TEST/CONTROL|Eligible subjects that are habitual contact lens wearers will be randomized into the (TEST/CONTROL) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period.
62797839|NCT04794270|EXPERIMENTAL|CONTROL/TEST|Eligible subjects that are habitual contact lens wearers will be randomized into the (CONTROL/TEST) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period.
62797840|NCT04323059|EXPERIMENTAL|Standardized milk-based formulation|Formulation of maize with milk that is rich in methionine
62797841|NCT04323059|EXPERIMENTAL|Standardized non-milk based formulation|Formulation of maize with soybeans that is rich in methionine and lysine
62797842|NCT04323059|ACTIVE_COMPARATOR|Hospital-based formulation|Formulation of maize, milk and soybeans
62797843|NCT00412893|EXPERIMENTAL|Isavuconazole|Participants received a loading dose of isavuconazole, 200 mg three times a day by intravenous infusion (IV) for the first 2 days followed by a maintenance dose from Day 3 of 200 mg once daily either IV or orally until they reached a treatment endpoint or for a maximum of 84 days.
62588306|NCT05550909|ACTIVE_COMPARATOR|artesunate-amodiaquine (ASAQ)|Subjects will receive artesunate-amodiaquine (ASAQ) daily for 3 days.
62797844|NCT00412893|ACTIVE_COMPARATOR|Voriconazole|Participants received a loading dose of voriconazole, 6 mg/kg every 12 hours IV for the first 24 hours, followed by a maintenance dose of 4 mg/kg every 12 hours by IV on Day 2. Beginning on Day 3, participants received 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they reached a treatment endpoint or for a maximum of 84 days.
62797845|NCT00508326|EXPERIMENTAL|HAI Paclitaxel|Paclitaxel via Hepatic Artery Infusion (HAI)
62797846|NCT02559739||Sleep deficiency/fragmentation|Patients with sleep deficiency/fragmentation
62797847|NCT02559739||No sleep deficiency/fragmentation|Patients without sleep deficiency/fragmentation
62222393|NCT03078426|EXPERIMENTAL|Group 4 : lung diseases without reticulations|20 patients with lung diseases without reticulations (acute or sub-acute hypersensitivity pneumonitis, organizing pneumonia, isolated pleural plaques) .
62222394|NCT04556292|EXPERIMENTAL|SC10914 group|
62797848|NCT05990634|EXPERIMENTAL|LifeChamps Platform|Participants will be asked to use the LifeChamps platform and will be provided with the study equipment (sensors/home kit).
62797849|NCT02071134||Parkinson's disease|Subjects with Parkinson's disease who will receive Vercise DBS for deep brain stimulation.
62797850|NCT04438395||Enrolled AFL and AF Patients|All subjects that are enrolled are group one, as there is only one group of subjects in this study
62025239|NCT01775891|ACTIVE_COMPARATOR|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
62588307|NCT05550909|EXPERIMENTAL|ASAQ with 0.25mg/kg primaquine (PQ)|Subjects will receive artesunate-amodiaquine (ASAQ) daily for 3 days and a single dose of 0.25mg/kg primaquine (PQ) on the first day of ASAQ treatment.
62797851|NCT01862536|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62797852|NCT01862536|EXPERIMENTAL|Tadalafil|Daily use of tadalafil (study drug) at 40 mg orally.
62797853|NCT03211494|ACTIVE_COMPARATOR|Conventional lung protective ventilation|Use of conventional lung protective ventilation, according to the ARDSnet guidelines
62797854|NCT03211494|ACTIVE_COMPARATOR|INTELLiVENT-ASV|Use of INTELLiVENT-ASV
62797855|NCT06019078||Prospective Cohort|Patients admitted to participating ICUs who meet inclusion criteria monitored by 4 channel pEEG.
62797856|NCT06019078||Retrospective Cohort|Patients admitted to participating ICUs who meet inclusion criteria not monitored by 4 channel pEEG.
62797857|NCT03089580|EXPERIMENTAL|Intense Pulsed Light Treatment|Participants will have one eye randomized to receive the intense pulsed light (IPL) therapy treatment while their other eye will receive the sham treatment. Participants will receive approximately 15 light spots to areas around the eye, lower eyelid, cheek, side of the nose and temple. The energy level will be based on skin type. IPL will be administered 4 times throughout the study.
62797858|NCT03089580|PLACEBO_COMPARATOR|Sham Treatment|Participants will have the other eye randomized to receive a sham treatment. The sham treatment will be conducted by placing the intense pulsed light (IPL) device to approximately 15 areas around the eye, lower eyelid, cheek, side of nose and temple without delivery of the light. The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
62222395|NCT00408252|EXPERIMENTAL|Arm A|patients will receive SU011248 in monotherapy
62222396|NCT00879866|EXPERIMENTAL|1|
62222397|NCT05639660||Aflibercept group|Single arm, Aflibercept 2.0mg/0.05ml, intravitreal injection
62222398|NCT05069103|EXPERIMENTAL|Intervention|"Similar to the original TWIST trial, patients will receive access to the online tool hosted on the ISLA platform until postoperative day 30 which is composed of two parts:~1. A series of simple questions related to the detection of surgical wound infection (e.g. redness, swelling, fluid leakage, etc). These questions would be expected to be routinely asked during in-person assessment, and these questions have been previously developed and tested within the TWIST trial (the only change being the addition of questions specifically relating to the change in these symptoms).~2. At least one image of their surgical wound(s).~Patients will receive automated requests via notifications asking to complete the online tool over the 30-day period (every 3 days +/- 1 day), however they may also complete the online form whenever wished."
62222399|NCT04754204||Patients indicated for Mobile Cardiac Telemetry Monitoring|Patients indicated for Mobile Cardiac Telemetry Monitoring while meeting inclusion/exclusion criteria and enrolled in sequential manner.
62222400|NCT01582685|EXPERIMENTAL|Exercise Group|The intervention is a structured walking program which will be performed partly in the Pavilion Physical Therapy clinic and partly at home. The participant will be instructed in how hard to exercise, how long to exercise, and how many times in a week to exercise. You will also be instructed in how to exercise safely.
62222401|NCT01582685|NO_INTERVENTION|No Exercise|These participants will receive standard of care follow up.
62222402|NCT06608316|EXPERIMENTAL|Left DLPFC stimulation group|80% resting motor threshold (RMT) iTBS stimulated the left DLPFC 4 sessions per day at 15 min intervals (3min per session), 3 days per week for 3 weeks. Sham stimulation of the right DLPFC will be performed.
62222403|NCT06608316|EXPERIMENTAL|Bilateral DLPFC stimulation group|80% RMT iTBS stimulated the bilateral DLPFC 4 sessions per day at 15 min intervals (2 sessions on the left, 2 sessions on the right, 3 min per session), 3 days per week for 3 weeks.
62025240|NCT01775891|PLACEBO_COMPARATOR|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
62025241|NCT01579123|ACTIVE_COMPARATOR|Laser atherectomy|
62025242|NCT01579123|ACTIVE_COMPARATOR|Angioplasty|
62222404|NCT06608316|SHAM_COMPARATOR|Sham stimulation group|Sham coil stimulates the left and right DLPFC.
62416621|NCT06701786|EXPERIMENTAL|CAF+SCTG+ Compressive Suture|A tension-free trapezoidal flap will be elevated by the split-full-split technique. A 1-mm thick SCTG will be harvested from the palate as epithelialized graft. After epithelium removal, the graft was positioned and sutured 1mm apical to the cement-enamel junction with 5-0 resorbable sutures . The SCTG will then be covered by the tension-free coronally positioned flap by 5-0 silk sutures.After flap repositioning, two horizontal cross-mattress compressive sutures and one vertical cross-mattress compressive suture will be placed. All compressive sutures will be performed using 2.0 silk suture.
62416622|NCT06701786|ACTIVE_COMPARATOR|CAF+ SCTG alone|A tension-free trapezoidal flap will be elevated by the split-full-split technique. A 1-mm thick SCTG will be harvested from the palate as epithelialized graft. After epithelium removal, the graft was positioned and sutured 1mm apical to the cement-enamel junction with 5-0 resorbable sutures . The SCTG will then be covered by the tension-free coronally positioned flap by 5-0 silk sutures. No compressive suture will be performed.
62416623|NCT06702891||case group|The case group includes high-grade intraepithelial neoplasia of the stomach, early gastric cancer, and advanced gastric cancer.
62416624|NCT06702891||control group|Pathological findings in the control group showed no malignant changes in the stomach, including normal gastric mucosa, superficial gastritis, non atrophic gastritis, and gastric polyps, etc.
62588308|NCT05550909|ACTIVE_COMPARATOR|Artemether-Lumefantrine (AL)|Subjects will receive artemether-lumefantrine (AL) twice daily for 3 days.
62588309|NCT05550909|EXPERIMENTAL|Artemether-Lumefantrine-Amodiaquine (ALAQ)|Subjects will receive artemether-lumefantrine (AL) and amodiaquine (AQ) twice daily for 3 days.
62588310|NCT05550909|EXPERIMENTAL|Artemether-Lumefantrine-Amodiaquine (ALAQ) with 0.25 mg/kg primaquine (PQ)|Subjects will receive artemether-lumefantrine (AL) and amodiaquine (AQ) twice daily for 3 days and a single dose of 0.25mg/kg primaquine (PQ) on the first day of ALAQ treatment.
62588311|NCT01489254|EXPERIMENTAL|GTR|Drug
62588312|NCT01489254|ACTIVE_COMPARATOR|Copaxone®|Drug
62588313|NCT01489254|PLACEBO_COMPARATOR|Placebo|Drug
62588314|NCT02949843|EXPERIMENTAL|Arm I (nivolumab, pembrolizumab)|Patients receive nivolumab IV over 60 minutes every 2 weeks or pembrolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
62588315|NCT02949843|EXPERIMENTAL|Arm II (kinase inhibitor, chemotherapy, immunotherapy)|Patients receive tyrosine kinase inhibitor therapy PO targeting the initial oncogenic driver or other treatment for about 3 weeks.
62416625|NCT01365741|NO_INTERVENTION|Standard administration of Efient|The test person will ingest Efient in supine position, and remain supine during 2 hours, mimicing the way Efient is used for pre-PCI treatment today
62588316|NCT02949843|EXPERIMENTAL|Arm III (kinase inhibitor, targeted therapy, other treatment)|Patients receive tyrosine kinase inhibitor therapy PO targeting initial oncogenic driver, a drug targeting the secondary mutation, or other treatment for about 3 weeks.
62588317|NCT00239746|EXPERIMENTAL|1|
62588318|NCT00239746|PLACEBO_COMPARATOR|2|
62588319|NCT06584396||Observational|Patients undergo tissue collection during standard of care surgery, have their medical records reviewed, and complete questionnaires throughout the study.
62588320|NCT03957473||Single Arm|Single Arm - Use of Indigo Aspiration System with CAT RX Aspiration Catheter (mechanical thrombectomy) in high thrombus burden acute coronary vessel occlusions
62588321|NCT02244463|EXPERIMENTAL|Phase I: Dose Level 1 (PI DL1)|Phase I Dose Level 1 participants receive MLN0128 3 mg orally, daily for 28 days. Participants are treated until disease progression or withdrawal of consent.
62588322|NCT02244463|EXPERIMENTAL|Phase I: Dose Level 2 (PI DL2)|Phase I Dose Level 3 (dose escalation) participants received MLN0128 5 mg orally, daily for 28 days. Participants are treated until disease progression or withdrawal of consent.
62588323|NCT02244463|EXPERIMENTAL|Phase I: Dose Level 3 (PI DL3)|Phase I Dose Level 3 participants receive MLN0128 5 mg orally, daily for 28 days. Participants are treated until disease progression or withdrawal of consent.
62025243|NCT06535984|EXPERIMENTAL|white noise|In the research, white noise was provided to the experimental group
62588324|NCT02244463|EXPERIMENTAL|Phase I: Dose Level 3 (PI DL3) Expansion|Phase I Dose Level 3 participants receive MLN0128 5 mg orally, daily for 28 days. Participants are treated until disease progression or withdrawal of consent.
62588325|NCT02244463|EXPERIMENTAL|Phase II: ATC Cohort|Phase II participants receive MLN0128 at the recommended phase II dose of 5 mg orally, daily for 28 days. Participants are treated until disease progression or withdrawal of consent. All phase I participants treated at the maximum tolerated dose/ recommended phase II dose (DL3) are enrolled in the phase II part of the study according to the appropriate disease cohort.
62588326|NCT02244463|EXPERIMENTAL|Phase II: DTC Cohort|Phase II participants receive MLN0128 at the recommended phase II dose of 5 mg orally, daily for 28 days. Participants are treated until disease progression or withdrawal of consent. All phase I participants treated at the maximum tolerated dose/ recommended phase II dose (DL3) are enrolled in the phase II part of the study according to the appropriate disease cohort.
62588327|NCT01931956|EXPERIMENTAL|Non-High Risk|Includes patients who are candidate for mitral valve repair or replacement surgery, including cardiopulmonary bypass (i.e. non-high risk). The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant. This arm was evaluated as a separate study NCT00209274.
62588328|NCT01931956|EXPERIMENTAL|High Risk|Includes patients with a predicted procedural mortality risk calculated using the Society For Thoracic Surgeon (STS) surgical risk calculator of ≥12% or, in the judgment of a cardiac surgeon, the patient is considered a high risk surgical candidate due to the presence of pre-defined risk factors. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant. This arm was evaluated as a separate study NCT01940120.
62025244|NCT06535984|EXPERIMENTAL|swaddling|In the research, swaddling was provided to the experimental group
62025245|NCT06535984|EXPERIMENTAL|White Noise + Swaddling group|In the research, White Noise + Swaddling group were provided to the experimental group
62025246|NCT06535984|NO_INTERVENTION|Control group|The control group received routine care
62222405|NCT06112990|EXPERIMENTAL|Arm 1|Home-based, telehealth resistance training (RT) with creatine monohydrate supplementation (Cr)
62222406|NCT06112990|PLACEBO_COMPARATOR|Arm 2|Home-based, telehealth resistance training (RT) with placebo (PLA)
62222407|NCT06154109|EXPERIMENTAL|Xiaopi granules plus neoadjuvant chemotherapy|Xiaopi granules have a dosage of 18 g per bag, 18 g per administration, twice daily, for a total of 8 days per treatment course. The duration of the treatment course will align with that of the chemotherapy regimen. The neoadjuvant chemotherapy is developed based on the National Comprehensive Cancer Network (NCCN) guidelines. Different treatments and doses are according to the standard recommendations outlined in the guidelines. Treatment options may include AC-T, ECT, EC, TC, AC, TAC, TP, etc.
62222408|NCT06154109|EXPERIMENTAL|Xiaopi decoction plus neoadjuvant chemotherapy|Xiaopi decoction has a dosage of 18 g per bag, 18 g per administration, twice daily, for a total of 8 days per treatment course. The duration of the treatment course will align with that of the chemotherapy regimen. The neoadjuvant chemotherapy is developed based on the National Comprehensive Cancer Network (NCCN) guidelines. Different treatments and doses are according to the standard recommendations outlined in the guidelines. Treatment options may include AC-T, ECT, EC, TC, AC, TAC, TP, etc.
62025247|NCT03822923|EXPERIMENTAL|Experimental group|Neurodynamics (Dynamic Neural Mobilization) with conventional treatment (stretching, AROM) will be applied.
62025248|NCT03822923|ACTIVE_COMPARATOR|control group|Conventional treatment (stretching, AROM) will be applied
62025249|NCT00650546|EXPERIMENTAL|A pre treatment NAS score|liver biopsy score pre treatment with exenatide 5 micrograms SQ (sub-cutaneous) twice a day titrated to 10 mcg SQ twice a day as tolerated
62025250|NCT01914848|ACTIVE_COMPARATOR|Control Group|A routine care discharge planning with the social service
62222409|NCT06154109|PLACEBO_COMPARATOR|Placebo plus neoadjuvant chemotherapy|The placebo is a look-alike substance that contains no active drug and has a placebo inspection report. The dosage of 18g per bag, 18g per administration, twice daily, for a total of 8 days per treatment course. The duration of the treatment course will align with that of the chemotherapy regimen. The neoadjuvant chemotherapy is developed based on the National Comprehensive Cancer Network (NCCN) guidelines. Different treatments and doses are according to the standard recommendations outlined in the guidelines. Treatment options may include AC-T, ECT, EC, TC, AC, TAC, TP, etc.
62222410|NCT01823692|OTHER|Distal Radius Fracture|after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
62025251|NCT01914848|EXPERIMENTAL|Advance Care Planning ACP|"Patient get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.~--------------------------------------------------------------------------------"
62025252|NCT06470932|EXPERIMENTAL|Follow up|
62025253|NCT03956303|ACTIVE_COMPARATOR|Plain Levobupivacaine (Chirocaine (% 0.5)|Levobupivacaine 8 mg (Chirocaine (% 0.5)) + 20 mcg fentanyl Chirocaine Plain
62025254|NCT03956303|ACTIVE_COMPARATOR|Levobupivacaine (Chirocaine % 0,75) + dextrose 40|Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 40 Chirocaine Heavy 40
62025255|NCT03956303|ACTIVE_COMPARATOR|Levobupivacaine (Chirocaine % 0,75) + dextrose 60|Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 60 Chirocaine Heavy 60
62025256|NCT03956303|ACTIVE_COMPARATOR|Levobupivacaine (Chirocaine % 0,75) + dextrose 80|Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 80 Chirocaine Heavy 80
62025257|NCT03264989|EXPERIMENTAL|crizanlizumab|SEG101 (crizanlizumab) drug at a dose of 5.0 mg/kg (or 7.5 mg/kg for exploratory group) by IV infusion.
62025258|NCT01175668|EXPERIMENTAL|NMS/Clonidine|
62025259|NCT01175668|ACTIVE_COMPARATOR|NMS/Phenobarbital|
62222411|NCT01076192||Moderate-to-severe chronic plaque psoriasis|Participants with moderate-to-severe chronic plaque psoriasis treated with adalimumab in routine clinical practice
62222412|NCT02536807|EXPERIMENTAL|Hyaluronan|Hyaluronan gel injection
62222413|NCT02536807|PLACEBO_COMPARATOR|Control|Control placebo gel injection
62222414|NCT02335177|ACTIVE_COMPARATOR|Interventionnal arm|Interventional arm : patients at home with technologies for autonomy and tailored physical activity program.
62222415|NCT02335177|NO_INTERVENTION|Control arm|Control arm : patients with usual care home
62222416|NCT00978627|EXPERIMENTAL|IDegAsp OD|
62222417|NCT00978627|ACTIVE_COMPARATOR|IDet|
62222418|NCT02279225|PLACEBO_COMPARATOR|placebo (P)|Intervention without radiation
62222419|NCT02279225|EXPERIMENTAL|phototherapy (FT)|Intervention only with phototherapy radiation
62222420|NCT02279225|EXPERIMENTAL|phototherapy+Physical activity (FT+A)|Intervention associated
62222421|NCT02279225|EXPERIMENTAL|Physical activity (A)|Intervention with physical activity: the gold standard of treatment in fibromyalgia
62222422|NCT05416060|EXPERIMENTAL|Dulce Digital|Patients will participate in a text-based diabetes self-management educational and support (DSME/S) program and receive ongoing support via text messages designed to improve knowledge, health beliefs, self-management behaviors and clinical outcomes.
62222423|NCT05416060|EXPERIMENTAL|Project Dulce Telehealth DSME/S|Patients will participate in live a peer-led Telehealth diabetes self-management education and support program.
62222424|NCT05416060|EXPERIMENTAL|Project Dulce Live DSME/S|Patients will participate in live a peer-led Telehealth diabetes self-management education and support program.
62222425|NCT04541784|ACTIVE_COMPARATOR|3 counselling sessions with gynaecology-oncology nurses|Patients randomized to the control group will receive standardized care, 3 counselling sessions with a gynaecology-oncology nurse and written information at three points in time during 6 months after diagnosis/surgery.
62222426|NCT04541784|EXPERIMENTAL|Mobile app and 3 counselling sessions (WOMAN-PROIII)|"Standardized care and three counselling sessions with a gynaecology-oncology nurse and the use of the mobile app WOMAN-PRO III. Counselling sessions will take place at 3 points in time during 6 months after diagnosis/surgery. Additionally, the gynaecology-oncology nurse will instruct the patient to use the mobile app. It includes a diary for symptom assessment and gives graphical feedback. Further, the app includes disease and treatment related information. If a symptom occurs the app will give an evidence-based recommendation (Kobleder et al., 2016). The patients can use the app whenever they want for a period of six months."
62222427|NCT02220673|EXPERIMENTAL|BHT 0.1%|
62222428|NCT02220673|EXPERIMENTAL|BHT 0.5%|
62222429|NCT02220673|PLACEBO_COMPARATOR|Placebo for RMT-B|
62222430|NCT02220673|PLACEBO_COMPARATOR|Placebo for HFA-MDI|
62222431|NCT00742053|EXPERIMENTAL|1|Male or female inpatients, age ≥ 18 and ≤ 80 years, who are in normal sinus rhythm and do not have a pacemaker or other indwelling intracardiac device and require PICC insertion for their routine care will be studied. Intervention: ECG-guided Power PICC placement.
62222432|NCT00095732|EXPERIMENTAL|Low Liprotamase Dose|Liprotamase in a fixed combination of lipase (5,000 units), protease (5,000 units) and amylase (750 units) administered orally (one Size 5 capsule of liprotamase and five Size 2 capsules of placebo) with each of three meals and two snacks daily for 28 days
62222433|NCT00095732|EXPERIMENTAL|Mid Liprotamase Dose|Liprotamase in a fixed combination of lipase (25,000 units), protease (25,000 units) and amylase (3,750 units) administered orally (one Size 5 capsule of liprotamase, one Size 2 capsule of liprotamase, and four Size 2 capsules of placebo) with each of three meals and two snacks daily for 28 days
62222434|NCT00095732|EXPERIMENTAL|High Liprotamase Dose|Liprotamase in a fixed combination of lipase (100,000 units), protease (100,000 units) and amylase (15,000 units) administered orally (one Size 5 capsule of placebo and five Size 2 capsules of liprotamase) with each of three meals and two snacks daily for 28 days
62222435|NCT01003678|EXPERIMENTAL|Level 1|1 mg daily for 5 consecutive days followed by 23 days off drug
62222436|NCT05939531|ACTIVE_COMPARATOR|Standard Care|Standard post-stroke care
62222437|NCT05939531|EXPERIMENTAL|Intervention|BOUNCE Program
62222438|NCT01096485|EXPERIMENTAL|Arm 1|
62222439|NCT01096485|ACTIVE_COMPARATOR|Arm 2|
62222440|NCT02729285|EXPERIMENTAL|Ketorolac Tromethamine|On operation day, the patients were randomly assigned to receive intramuscular Ketorolac 60-mg 30 minutes before scleral buckle surgery.
62222441|NCT02729285|PLACEBO_COMPARATOR|placebo|On operation day, the patients were randomly assigned to receive placebo before scleral buckle surgery.
62222442|NCT00836420||liver|patients with acute liver failure
62222443|NCT02163564|NO_INTERVENTION|Focus groups|The first part of the study is to conduct focus groups of adolescents with insomnia and depression. The treatment arm is informed by responses provided by teens in the focus group portion.
62222444|NCT02163564|ACTIVE_COMPARATOR|Treatment|A modified cognitive behavioral therapy for insomnia is the treatment intervention in this treatment arm.
62222445|NCT01439152|EXPERIMENTAL|BAY94-9343 (Dose-Escalation)|BAY94-9343 was administered intravenously in this study. The starting dose for this first-in-man study was 0.15 mg/kg administered as a 1 hour infusion every 21 days. (ENROLLMENT CLOSED).
62222446|NCT01439152|EXPERIMENTAL|BAY94-9343 (Expansion)|"After Maximum tolerated dose (MTD) had been defined, expansion cohorts were conducted at the MTD dose. Overall up to 32 subjects were planned to be enrolled in the expansion cohort:~* Ovarian Carcinoma, 20 subjects~* Mesothelioma, 6-12 subjects (ENROLLMENT CLOSED)."
62416626|NCT01365741|ACTIVE_COMPARATOR|Upright administration of Efient|The test person will ingest Efient in an upright position, and remain supine during 2 hours.
62416627|NCT06544265|EXPERIMENTAL|SynKIR-310|Single dose IV administration of SynKIR-310
62222447|NCT01439152|EXPERIMENTAL|BAY94-9343 (1.8 mg/kg)|This part of study was randomized and open-label. BAY94-9343 in two parallel dose cohorts of twenty (20) patients with recurrent platinum-resistant or platinum partially-sensitive ovarian cancer and up to four (4) patients with advanced malignant epithelioid peritoneal mesothelioma and eight (8) patients with advanced pleural mesothelioma.
62222448|NCT01439152|EXPERIMENTAL|BAY94-9343 (2.2 mg/kg)|This part of study was randomized and open-label. BAY94-9343 in two parallel dose cohorts of twenty (20) patients with recurrent platinum-resistant or platinum partially-sensitive ovarian cancer and up to four (4) patients with advanced malignant epithelioid peritoneal mesothelioma and eight (8) patients with advanced pleural mesothelioma.
62222449|NCT05293951|EXPERIMENTAL|Mirror Therapy + Cross Education|"Cross Education: Experimental participants will perform resisted task-specific upper limb exercises. During the exercises, participants will pull a resistance cord with their non-affected arm, Mirror Therapy: Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~Training duration \& frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
62222450|NCT05293951|ACTIVE_COMPARATOR|Mirror Therapy Alone|"Mirror Therapy: Control participants will perform non-resisted task-specific upper limb exercises. Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~Training duration \& frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
62222451|NCT02879474||Patient with melanoma|
62222452|NCT05353946|ACTIVE_COMPARATOR|Elective Rotational Atherectomy|"Operators can decide elective use of rotational atherectomy (RA) or conventional angioplasty according to the calcification patterns of the coronary lesion evaluated by Intravascular ultrasound (IVUS) or by angiography if the IVUS cannot cross the lesion.~Procedure is performed with a Rotablator system, consisting of a rotating olive-shaped burr whose leading hemisphere is coated with microscopic diamond chips. The proximal end of the device has a housing unit containing the burr advancer, a fiberoptic tachometer cable, an irrigation port, and a nitrogen gas delivery hose, which permits the rapidly rotating of the burr. The RA catheter is introduced into the coronary artery over a stainless steel 0.09-inch wire to cross the lesion, then advanced with a slow pecking motion at a speed of 160,000 to 190,000 rpm with each ablation run \<15 seconds is performed. Burr size was with a burr/vessel ratio of 0.7. After RA, all patients received IVUS-guided percutaneous coronary intervention."
62222453|NCT05353946|ACTIVE_COMPARATOR|Bailout Rotational Atherectomy|The operators began with conventional angioplasty (non-compliant balloon dilatation) regardless of the calcification patterns in the coronary lesion, and rotational atherectomy (RA) can be used only as a bailout.
62222454|NCT00003849|EXPERIMENTAL|rituximab|Patients receive rituximab IV over 4-6 hours on day 1 weekly for 4 weeks. Patients are followed at 1, 3, 6, 9, and 12 months, then every 6 months for 3 years, then annually thereafter.
62222455|NCT04161625|EXPERIMENTAL|Safe Step - digital exercise program|"All included participants will receive full access to the Safe Step application and create their own individual program of strength and balance exercises. During 1 year the participants are recommended to exercise at least 30 minutes, 3 times a week and continuously progress their program. In addition they will every month receive an email with general falls prevention information in a short video.~Additional support to promote reach and exercise adherence will be provided in the format of technical support and try-out group exercises throughout the recruitment period."
62222456|NCT02973711|EXPERIMENTAL|Nilotinib + Ruxolitinib|"The first part of the trial will be Phase I and will enroll 25 participants. Participants will receive nilotinib BID and either 10, 15 or 20 mg of ruxolitinib BID. Maximum tolerated dose (MTD) of ruxolitinib will be determined.~The second part of the trial will be a Phase II and will enroll 25 subjects. Participants will receive nilotinib and the MTD of ruxolitinib."
62025260|NCT05870306|OTHER|PVI alone|High-density voltage mapping using a multipolar catheter (PentaRay or OctaRay, Biosense Webster, Diamond Bar, CA, USA) will be performed during AF. PVI will be performed with the standard protocol. If needed electrical cardioversion will be performed after PVI ablation. A 10-minute waiting period after isolation of each ipsilateral PV pair was applied to assess for acute reconnections. Additional RF applications were performed if needed at reconnection sites until PVI was achieved.
62222457|NCT06359691|EXPERIMENTAL|Usual Strategies - Year1|Usual strategies implemented in year 1, patient-focused and provider-focused strategies implemented in year 2, and sustainment in year 3.
62222458|NCT06359691|EXPERIMENTAL|Patient-Focused Strategies - Year1|Patient-focused strategies implemented in year 1, provider-focused strategies implemented in year 2, and sustainment in year 3.
62222459|NCT06359691|EXPERIMENTAL|Provider-Focused Strategies - Year1|Provider-focused strategies implemented in year 1, patient-focused strategies implemented in year 2, and sustainment in year 3.
62222460|NCT01426867|EXPERIMENTAL|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each affected eye 3 times a day for 7 days
62222461|NCT01426867|ACTIVE_COMPARATOR|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, 1 drop instilled in each affected eye 3 times a day for 7 days
62222462|NCT01426867|ACTIVE_COMPARATOR|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, 1 drop instilled in each affected eye 3 times a day for 7 days
62416628|NCT05810961|EXPERIMENTAL|efgartigimod IV|patients receiving infusions of efgartigimod
62416629|NCT05810961|EXPERIMENTAL|placebo|patients receiving infusions of placebo
62416630|NCT02202902|EXPERIMENTAL|Group 1 : 1H magnetic resonance spectroscopy and CMRI|Group 1 : Cushing's syndrome patients with diabetes mellitus or glucose intolerance
62416631|NCT02202902|EXPERIMENTAL|Group 2 : 1H magnetic resonance spectroscopy and CMRI|Group 2: Cushing's syndrome patients with normal glucose intolerance
62416632|NCT02202902|EXPERIMENTAL|Group 3 : 1H magnetic resonance spectroscopy and CMRI|age-, sex- and BMI-matched healthy volunteers
62025261|NCT05870306|EXPERIMENTAL|PVI PLUS HSC ABLATION|After standard PVI isolation point-by point ablation targeting HSC-EGMs will be performed. HSC-EGMs with a distance less than 5 mm between them will be addressed with a single application. The ablation index will be defined based on the LA wall thickness (LAWT) at the location of the HSC-EGM: LAWT \< 1mm: 300 f, LAWT 1-2 mm: 350 f, LAWT 2-3 mm: 400 f and LAWT \>3 mm: 450 f. This is the experimental intervention added to pulmonary veins isolation. This intervention, in terms of risks, is superimposable to the ablation of CFAEs or rotational activity, which are stablished techniques for PsAF catheter ablation
62025262|NCT04984044|ACTIVE_COMPARATOR|Experimental|This arm includes 36 Diabetic Peripheral Neuropathy patients receiving the antidiabetic medications
62025263|NCT04984044|PLACEBO_COMPARATOR|Control|This arm includes 36 Diabetic Peripheral Neuropathy patients receiving the antidiabetic medications
62025264|NCT04519229||Children in fostercare in CPP-treatment|Children in foster care taking part in Child-Parent Psychotherapy
62025265|NCT00275093|EXPERIMENTAL|Treatment (temsirolimus)|"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD."
62025266|NCT05046938|EXPERIMENTAL|intervention group|It was planned to apply 5 sessions of MI to the intervention group, and to follow-up 2 months after the interviews were completed.
62025267|NCT05046938|NO_INTERVENTION|control group|No application will be made to the students in the control group, and at the end of the study, a seminar on food addiction and quality of life will be given to the students.
62025268|NCT05588089|NO_INTERVENTION|Control group|"After the birth of the control group, the Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers as pre-tests in the clinic. After the training, the fathers will be called at the 2nd, 3rd, 4th, 8th and 12th weeks, and the Fathers' Participation in Baby Care Chart will be applied 5 times during 12 weeks. In addition, Father-Infant Attachment Scale and Infant Care Questionnaire were applied to fathers at 12 weeks as posttests.~Personal Information Form for Mothers will be filled by mothers in the postpartum clinic, mothers are called at 4th, 8th and 12th weeks and Edinburgh Postpartum Depression Scale and Postpartum Quality of Life Scale are applied."
62222463|NCT01630746|EXPERIMENTAL|TAK-438 20 mg/day|
62797859|NCT03120130|EXPERIMENTAL|Cohort 1|This cohort will include 3 patients with the first calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity (DLT) in this group the study continues including the next cohort. However, if If only one patient in a given cohort develops DLT, three more patients will be included at that dose level, up to a maximum total of six patients per dose level. If two or more of the three patients of a certain dose level develop DLT, this dose level is considered very toxic, and the study does not proceed. If this occurs at the first dose level, the study will be finalized. If only one in six patients at a dose level develops DLTs, escalation proceeds until Tolerated Maximum Dose.
62222464|NCT01630746|EXPERIMENTAL|TAK-438 40 mg/day|
62222465|NCT01703650||Resectable pancreas cancer|patients with resectable pancreas adenocarcinoma or neuroendocrine tumor underwent perfusion CT after intravenous iopromide administration
62797860|NCT03120130|EXPERIMENTAL|Cohort 2|This cohort will include 3 patients with the second calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
62222466|NCT01703650||Locally advanced Pancreas cancer|Patients with locally advanced pancreas cancer underwent perfusion CT after intravenous iopromide administration before and after chemotherapy.
62222467|NCT02902874|EXPERIMENTAL|Patients treated for anaplastic large cell lymphoma ( ALCL )|
62222468|NCT01170611|EXPERIMENTAL|AAISAFER alone - AAISAFER+PREVENTIVE ALGORITHM - DDD|
62222469|NCT06258226|ACTIVE_COMPARATOR|Conventional dosage reduction group|The drug reduction method of estazolam tablets (Shanghai Xinyi Pharmaceutical Co., Ltd., Shanghai, China, State Drugs Administration License No.: H31020644, 1 mg) will be given, with a starting dose of 1 mg, that is, the dosage of estazolam will be reduced by 25% (0.25mg) every week until the dosage will be stopped completely on the premise of no aggravation of insomnia symptoms.
62416633|NCT03425331|EXPERIMENTAL|Nivolumab+Ipilimumab|Nivolumab will be administered once every 2 weeks 1 mg/kg intravenously Ipilimumab will be administered once every 6 weeks 3 mg/kg intravenously
62416634|NCT04083274|ACTIVE_COMPARATOR|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
62797861|NCT03120130|EXPERIMENTAL|Cohort 3|This cohort will include 3 patients with the third calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
62797862|NCT03120130|EXPERIMENTAL|Cohort 4|This cohort will include 3 patients with the fourth calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
62222470|NCT06258226|EXPERIMENTAL|Auricular acupressure group|"Auricular acupressure therapy will be added based on the estazolam reduction method in the control group. The specific auricular points to be treated are Shenmen (TF4), Sympathetic (AH6), Endocrine (CO18), Heart (CO15), Liver (CO12) and Kidney (CO10). During the treatment, the acupuncturist will use a metal probe to identify the auricular points and ask the patients if they experience deqi sensations such as heat, numbness, distension, or pain. Once the auricular points have been confirmed, the ear will be disinfected using a 75% ethanol solution and dried using a sterile dry cotton ball. The acupuncturist will then hold the ear in place with their left hand while using their right hand to manipulate a tweezer and apply tape (0.5 x 0.5 cm) with vaccaria (Suzhou Konakang Medical Instrument Co., LTD., Suzhou, China) to the selected auricular point."
62222471|NCT06258226|SHAM_COMPARATOR|Sham auricular acupressure group|Based on the estazolam reduction method in the control group, the acupuncturist will place the same skin-colored adhesive tapes without vaccaria on the auricular points, but these tapes will not be pressed during treatment.
62222472|NCT05148143|EXPERIMENTAL|RALOX|Raltitrexed combined with oxaplatin
62222473|NCT04910789|EXPERIMENTAL|Thoracoabdominal approach|Radical surgery should be finished via Thoracoabdominal approach.
62222474|NCT04910789|ACTIVE_COMPARATOR|Transhiatal/transabdominal approach|Radical surgery should be finished via transhiatal/transabdominal approach.
62222475|NCT05367154||Eyes with SMILE surgeries|Eyes with SMILE surgeries which were performed by three surgeons with different experiences.
62222476|NCT04304573||Patients with hypocalcemia symptoms and low serum calcium|Patients with postoperative hypocalcemia defined as serum calcium levels \< 2.00 mmol/L. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
62222477|NCT04304573||Patients with hypocalcemia symptoms and normal serum calcium|Patients with hypocalcemia symptoms but without postoperative hypocalcemia defined as serum calcium levels \> 2.00 mmol/L. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
62222478|NCT04913454|EXPERIMENTAL|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks).
62797863|NCT03120130|EXPERIMENTAL|Cohort 5|This cohort will include 3 patients with the fifth calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
62222479|NCT04913454|ACTIVE_COMPARATOR|Cognitive training only|Cognitive training only (1 hour per day, per 5 days/week, for a total of 8 weeks).
62222480|NCT05361525|ACTIVE_COMPARATOR|Lipoabdominoplasty with anatomic definition|Lipoabdominoplasty with anatomic definition without over dissection on the lateral recti region
62416635|NCT04083274|SHAM_COMPARATOR|Group S = Sham block group|In group S, sham block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml normal saline will be administered for block.
62222481|NCT05361525|SHAM_COMPARATOR|traditional abdominoplasty|abdominoplasty with dissection in v- shaped pattern till coastal margin
62222482|NCT00666146||1|Case Families ( Family with a schizophrenia proband)
62222483|NCT00666146||2|Control Families
62416636|NCT01987843|EXPERIMENTAL|MT-1303-Low|MT-1303-Low Dose
62416637|NCT01987843|EXPERIMENTAL|MT-1303-Middle|MT-1303-Middle Dose
62416638|NCT01987843|EXPERIMENTAL|MT-1303-High|MT-1303-High Dose
62416639|NCT01987843|PLACEBO_COMPARATOR|Placebo|Placebo
62797864|NCT03120130|EXPERIMENTAL|Cohort 6|This cohort will include 3 patients with the sixth calculated dose of Amblyomin-X drug, the last dose calculated. The patient will receive the intravenous drug.
62222484|NCT00666146||3|Control subjects
62222485|NCT02861547||Traumatic brain injury|
62222486|NCT02255214||Surgical Patient|These are the results from the blood samples taken from the study participants.
62222487|NCT01096277|ACTIVE_COMPARATOR|Sitagliptin|100 mg sitagliptin per day for 2 weeks
62222488|NCT01096277|PLACEBO_COMPARATOR|Placebo|1 placebo tablet per day for 2 weeks
62416640|NCT06703294|OTHER|Varying degrees of crow's feet|Bovine collagen filling crow's feet
62416641|NCT04064931||recurrent abortion|women of childbearing age who have spontaneous abortion within 20 weeks of pregnancy for 2 or more consecutive times.
62797865|NCT06726447|EXPERIMENTAL|Artificial Intelligence Tool|The health centers assigned to this group will implement an artificial intelligence (AI) tool for clinical registration during outpatient consultations. Healthcare professionals will activate the tool at the beginning of the consultation and deactivate it at the end. The tool will be used to document interactions in real time, generating more detailed records and reducing the administrative burden.
62222489|NCT01096277|NO_INTERVENTION|Healthy Control|Healthy control subjects
62222490|NCT03573726|OTHER|Technically N/A, Crossover Design|Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
62222491|NCT05450094|ACTIVE_COMPARATOR|Comparator|The comparator arm enhances school-based mental health (SBMH) with universal screening and trains voluntary school teams to use the school-wide data to plan and make intervention referrals using an evidence-based in-service training and coaching model called Team-Initiated Problem Solving (TIPS).
62222492|NCT05450094|EXPERIMENTAL|Enhanced|The enhanced arm involves the enhancements to school-based mental health (SBMH) of the comparator arm with the addition of 3 additional empirically supported enhancements to mental health screening: 1) voluntary school teams will review screening and service receipt data disaggregated by racial/ethnic subgroups to identify and problem solve inequities; 2) Unintentional bias training for voluntary school teams, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias; and 3) Mental Health Literacy training for voluntary school teams in awareness and understanding of students' mental health well-being and need for intervention.
62222493|NCT00950222|EXPERIMENTAL|1:Imipenem/Amikacin|"patients will receive as empirical therapy for VAP imipenem associated with amikacin.After primary outcome measure, antibiotic therapy will be left at the discretion of the physician in charge of the patient.~Imipenem: recommended usual dosage for VAP treatment, IV (in the vein), every 8 hours~Amikacin: recommended usual dosage for VAP treatment (20mg/kg), IV (in the vein), single dose (at H0) for the 48 first hours of treatment"
62222494|NCT06021171|ACTIVE_COMPARATOR|Regular Girl (Sunfiber + Bifidobacterium lactis)|Regular Girl, a synbiotic supplement containing the Prebiotic Sunfiber + Bifidobacterium Lactis
62222495|NCT06021171|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin
62222496|NCT06021171|ACTIVE_COMPARATOR|Sunfiber|SunFiber, a prebiotic fiber supplement
62222497|NCT05480410|EXPERIMENTAL|Active intervention|Patients will receive 20 sessions of transcranial magnetic stimulation applied with the MagVenture Mag Pro R20 equipment, these sessions will be held daily from Monday to Friday, lasting 20 minutes at an intensity of 81% with a motor threshold of 90 A/ns.
62222498|NCT03787927|OTHER|5 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 5 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~The first 20 participants who complete the study will be randomized to this arm or '5 day RTP, then 5 day CSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
62222499|NCT03787927|OTHER|5 day RTP, then 5 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 5 day autologous CSP (cold-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~The first 20 participants who complete the study will be randomized to this arm or '5 day CSP, then 5 day RTP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
62222500|NCT03787927|OTHER|5 day RTP, then 10 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 10 day autologous CSP (cold-stored platelets).The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~After the first 20 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 10 day CSP' and '10 day CSP, then 5 day RSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
62222501|NCT03787927|OTHER|5 day RTP, then 15 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 15 day autologous CSP (cold-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~After the first 40 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 15 day CSP' and '15 day CSP, then 5 day RSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 15 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
62416642|NCT04064931||normal pregnancy history|Women of childbearing age who had a normal pregnancy history and are not in pregnancy status now.
62416643|NCT04064931||general population|Women of childbearing age in general examination.
62416644|NCT04926467|EXPERIMENTAL|Anakinra plus Chemotherapy|Patients will receive Anakinra during both pre-operative chemotherapy with Nab-paclitaxel, gemcitabine and cisplatin, followed by surgery and post-operative chemotherapy with 5-fluorouracil, oxaliplatin, and irinotecan.
62416645|NCT01935557|ACTIVE_COMPARATOR|Continuous heparin infusion group|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
62416646|NCT01935557|ACTIVE_COMPARATOR|Intermittent heparin infusion group|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
62416647|NCT01345058|EXPERIMENTAL|Lacosamide + Low-Dose Levetiracetam|Participants received lacosamide 50 mg twice a day for one week followed by 100 mg twice daily added to low dose levetiracetam ≤1500 mg/day (polytherapy) for 6 months in patients with breakthrough seizures on low-dose levetiracetam.
62416648|NCT01345058|OTHER|Control Group (High-Dose Levetiracetam)|Historical chart review of patients whose dose of levetiracetam was raised to high dose levetiracetam \>1500 mg/day (monotherapy) after a breakthrough seizure. No intervention was administered in the study.
62416649|NCT06566183|EXPERIMENTAL|GDMT|Participants with multivessel coronary artery disease (CAD) and heart failure with reduced ejection fraction (HFrEF) who are assigned to receive GDMT.
62416650|NCT06566183|EXPERIMENTAL|CABG|Participants with multivessel coronary artery disease (CAD) and heart failure with reduced ejection fraction (HFrEF) who are assigned to receive CABG.
62025269|NCT05588089|EXPERIMENTAL|Intervention group|"For the experimental group, Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers in the clinic after birth as a pre-test. In the clinic, baby care training was given to fathers practically in 30-35 minutes. After the applied training, the Baby Care Training Program Content prepared by the researchers was given to the fathers. After the training, the fathers were called at the 2nd, 3rd, 4th, 8th and 12th weeks, and the Paternals' Participation in Baby Care Chart was applied 5 times during 12 weeks. In addition, the fathers were called at the 12th week and the Infant Care Questionnaire Form was applied as a post-test and the Father-Infant Attachment Scale was applied.~Personal Information Form for Mothers was applied to the mothers after the birth in the clinic, and the mothers were called at the 4th, 8th and 12th weeks and the Edinburgh Postpartum Depression Scale and the Postpartum Quality of Life Scale were applied."
62222502|NCT03787927|OTHER|10 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 10 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets).The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~After the first 20 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 10 day CSP' and '10 day CSP, then 5 day RSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
62222503|NCT03787927|OTHER|15 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 15 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~After the first 40 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 15 day CSP' and '15 day CSP, then 5 day RSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 15 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
62416651|NCT06566183|EXPERIMENTAL|PCI|Participants with multivessel coronary artery disease (CAD) and heart failure with reduced ejection fraction (HFrEF) who are assigned to receive PCI.
62416652|NCT04227769|EXPERIMENTAL|healthy individuals|Two crossover visits with a washout period of at least 4 days in-between visits and at most two weeks: A) subcutaneous saline injection 3h before an oral standardized meal, B) subcutaneous injection of 100 mg of the IL-1 receptor antagonist anakinra 3h before an oral standardized meal. Treatments will be placebo controlled, crossover, double blinded. Standard dose of Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB), i. e. 100 mg/ 0.67 ml s. c. or 0.67 ml of saline s. c. (placebo)
62416653|NCT04227769|EXPERIMENTAL|obese patients with type 2 diabetes|Three crossover visits with a washout period of at least 4 days in-between: A) subcutaneous saline injection 3h before an oral standardized meal, B) subcutaneous injection of 100 mg of the IL-1 receptor antagonist anakinra 3h before an oral standardized meal, C) Additionally, after the second study day, participant in group 2 will be trained to self-inject the medication for 6 days. On the 7th day, an oral standardized meal test will be performed. Standard dose of Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB), i. e. 100 mg/ 0.67 ml s. c. or 0.67 ml of saline s. c. (placebo)
62416654|NCT05405478|EXPERIMENTAL|use of omalizumab in patients with refractory nasal polyp|15 patients group with arrival criteria
62416655|NCT05405478|EXPERIMENTAL|control group patients with refractory nasal polyp|15 patient that with arrival criteria cant arrive in the patients group
62416656|NCT01700335|EXPERIMENTAL|SyB L-1101|"In Cohort 1, SyB L-1101 1200 mg/day group, Participants were administered 1200 mg/day of SyB L-1101 intravenously for 3 consecutive days, followed by 11-day observation period.~In Cohort 2, SyB L-1101 1800 mg/day group, Participants were administered 1800 mg/day of SyB L-1101 intravenously for 3 consecutive days, followed by 11-day observation period.~For both Cohorts, the treatment period of 14 days constitutes 1 cycle, and the treatment was allowed for up to 8 cycles."
62416657|NCT05778227|ACTIVE_COMPARATOR|Ethylene Diamine Tetra Acetic acid|Final irrigation will be done with 5ml of EDTA for 1min which is the gold standard and compare it with experimental irrigants.
62222504|NCT06609694|EXPERIMENTAL|Inogen portable oxygen concentrator unit versus continuous flow (Pilot Study)|The aim of this pilot study is to examine whether clinically important indices during sleep are comparable between oxygen delivery by portable and by continuous flow.
62222505|NCT06609694|EXPERIMENTAL|Reducing the frequency of obstructive apnea (Main study)|The arm of the main study is still under development
62222506|NCT04200976|EXPERIMENTAL|Tele-CABA|Participants who engage in the Tele-CABA intervention.
62222507|NCT04200976|PLACEBO_COMPARATOR|Usual Care|Participants who do not engage in the Tele-CABA intervention during their time in the study. They will be eligible to receive Tele-CABA following completion of the 6-month questionnaires and cognitive assessment (as a courtesy).
62222508|NCT03212560||Newly diagnosed individuals|Newly diagnosed hematologic malignant patients included in the study. Inclusion and exclusion criteria were considered.
62416658|NCT05778227|EXPERIMENTAL|smearOFF|Final irrigation will be done with 5ml of EDTA for 1min which is the gold standard and compare it with experimental irrigants.
62416659|NCT05778227|EXPERIMENTAL|Etidronic acid/ Sodium Hypochlorite (HEBP/NaOCl)|During whole procedure of cleaning and shaping combination product of HEBP/NaOCl will be used
62416660|NCT05778227|EXPERIMENTAL|Maleic acid (MA)|Final irrigation of root canal treatment procedure will be done with 5ml of maleic acid for 1min.
62222509|NCT03212560||Healthy individuals|Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
62222510|NCT03106597|EXPERIMENTAL|Manidipine 20mg|50 patients will be administered orally manidipine 20mg/day after 1\~2 week run-in period
62222511|NCT03106597|ACTIVE_COMPARATOR|Amlodipine 10mg|50 patients will be administered orally amlodipine 10mg/day after 1\~2 week run-in period
62222512|NCT02054611|ACTIVE_COMPARATOR|Educational Module First|Respondents will complete the online educational module first, followed by the evaluation
62222513|NCT02054611|PLACEBO_COMPARATOR|Evaluation First|Respondents will complete the the evaluation first, followed by the online educational module
62222514|NCT04224571|EXPERIMENTAL|rituximab and bortezomib|to test whether adding rituximab in CD20 positive patients will have improvement in remission rate. (this arm terminated in October 2020) to add bortezomib in high risk patients at Induction to improve remission rate.
62416661|NCT05778227|NO_INTERVENTION|Control group|Final irrigation of root canal treatment will be done with 0.9% saline.
62416662|NCT05021120|EXPERIMENTAL|Intervention/treatment|Experimental
62416663|NCT03123120|EXPERIMENTAL|Spesolimab|1200 milligrams (mg) of Spesolimab (BI 655130) were administered every 4 weeks (q4w) via intravenous infusion over 12 weeks of treatment (3 injections of Spesolimab 1200 mg in total during the 12 weeks: at Week 0, 4, and 8 respectively).
62416664|NCT03123120|PLACEBO_COMPARATOR|Placebo|Matching placebo was administered via intravenous infusion over 12 weeks of treatment.
62416665|NCT03253601|EXPERIMENTAL|Strategy Training: iADAPT Application|Participants will use the iADAPT mobile health application to supplement to in-person and remote intervention sessions.
62416666|NCT03253601|ACTIVE_COMPARATOR|Strategy Training: Workbook|Participants will use a printed workbook to supplement to in-person and remote (by telephone) intervention sessions.
62416667|NCT02804191|EXPERIMENTAL|LO2A|Sodium Hyaluronate
62416668|NCT02804191|PLACEBO_COMPARATOR|Placebo-Controlled|Saline.
62416669|NCT04699721|EXPERIMENTAL|Arm 1|3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)
62222515|NCT00662935|EXPERIMENTAL|2|the sequence of stimulation begins by OFF
62222516|NCT00662935|EXPERIMENTAL|1|the sequence of stimulation begins by ON
62222517|NCT02531347|EXPERIMENTAL|Telemedical blood pressure monitoring|Telemedical home blood pressure measurements for three days every second week. The average of all measures excluding day one is electronically transmitted to the General Practitioners. Following communication primarily by email or telephone.
62222518|NCT02531347|ACTIVE_COMPARATOR|Conventional blood pressure monitoring|Conventional blood pressure monitoring
62416670|NCT05264818||Case group: primary open angle glaucoma|
62416671|NCT05264818||Control group: No Absence of optic nerve pathology|
62416672|NCT05851612|ACTIVE_COMPARATOR|group C(constant group)|Constant PEEP of 5 centimeter of water (cm H2O) will be applied
62416673|NCT05851612|ACTIVE_COMPARATOR|group D (driving group)|PEEP titration will be according to driving pressure
62222519|NCT01845909||young adults - Central region of Portugal|
62222520|NCT05083000|EXPERIMENTAL|Topotecan|"Subject will receive Topotecan as a single dose or 2 consecutive doses given via intravenous (IV). The starting dose level of Topotecan is 0.25mg. Subsequent dose levels will be 2 doses of 0.25mg, a single dose of 0.5mg and then 2 doses of 0.5mg.~Standard of care treatments for COVID-19 will be given together if available as per the following protocol:~1. IV Dexamethasone 6mg once daily for at least 5 days and not more than 10 days.~2. IV Remdesivir 200mg loading dose on day 1 followed by 100mg once daily for 4 days."
62222521|NCT01153958|EXPERIMENTAL|Colposeptine (A)|
62222522|NCT01153958|ACTIVE_COMPARATOR|Metronidazole (B)|
62222523|NCT00414037|EXPERIMENTAL|eszopiclone (Lunesta) 3mg|Subchronic (1-week) administration of 3mg Lunesta (eszopiclone)
62222524|NCT00414037|PLACEBO_COMPARATOR|Placebo|Placebo-treated group
62222525|NCT05448612|EXPERIMENTAL|Active Release Technique|In ART the particular muscle is taken from shortened to lengthened position or vice versa. Duration of treatment will be of 8-15min
62416674|NCT05851612|ACTIVE_COMPARATOR|group O (oxygenation group)|PEEP titration will be according to oxygenation method
62416675|NCT06700837||Hypoxic burden and Sleepiness in treated OSA patients|"In this retrospective study, we reviewed the files of all patients with OSA hospitalised to undergo both polysomnography (PSG) and the 40-min MWT in the Center for Sleep Medicine and Respiratory Disease, Lyon Academic Hospital from September 2017 to January 2020.~All these patients underwent a full night polysomnography."
62416676|NCT05552235|EXPERIMENTAL|Orthosis group|Use of Elbow Soft 300 device during sport practice
62416677|NCT05552235|OTHER|Control group|No medical device used during sport practice
62797866|NCT06726447|NO_INTERVENTION|Standard of care|In the centers assigned to this group, consultations will be carried out in the usual way, using traditional clinical recording methods, without additional technological intervention. This group will serve as a reference to compare differences in satisfaction, duration of consultations and quality of the clinical record.
62797867|NCT03329846|ACTIVE_COMPARATOR|Nivolumab + Placebo|"Specified dose on specified day~Participants will no longer receive BMS-986205 Placebo"
62797868|NCT03329846|EXPERIMENTAL|Nivolumab + BMS-986205|"Specified dose on specified day.~Participants have the option to discontinue BMS-986205, and continue nivolumab monotherapy, at investigator discretion"
62797869|NCT01809522|EXPERIMENTAL|Posterior reconstruction of the musculofascial plate|These patients will receive reconstruction of the muscolofascial plate after radical prostatectomy. The reconstruction will be performed using two 3-0 Poliglecaprone sutures (on RB-1 needles) tied together, with each individual length being 12-15 cm. seven - Ten knots will be placed when tying the sutures to provide a bolster. The free edge of the remaining Denonvillier's fascia will be identified after the prostatectomy and approximated to the posterior aspect of the rhabdosphincter and the posterior median raphe using one arm of the continuous suture. As a rule, four passes will be taken from the right to the left and the suture is locked. The second layer of the reconstruction will be then performed with the other arm of the suture approximating the posterior lip of the bladder neck (full thickness) and the vesicoprostatic muscle to the posterior urethral edge and to the already reconstructed median raphe .This suture will be then tied to the end of the first suture arm.
62797870|NCT01809522|NO_INTERVENTION|Standard radical prostectomy|
62797871|NCT00647504||1|Restenosis in Bare metal stent
62797872|NCT00647504||2|Restenosis in Drug eluting stent
62797873|NCT00647504||3|Stent thrombosis
62797874|NCT00647504||4|Control group
62797875|NCT02644317|EXPERIMENTAL|with modified shoe inserts|wear the modified shoe inserts and shoes for balance test.
62797876|NCT02644317|NO_INTERVENTION|without modified shoe inserts|only wear the shoes for balance test.
62797877|NCT04663503|EXPERIMENTAL|Intervention arm -Exercise Program|This structured exercise program will incorporate a specially designed, low intensity, resistance based exercise regime created by our physical therapist. It consists of strengthening, endurance, stretching and relaxation exercises tailored according to age and their ability to perform activities throughout their hospitalization (Appendix 3). This exercise program will be done three times a week for 30-45 mins supervised by the same physiotherapist throughout hospitalization and will be self-administered every weekend. A home exercise program printout with the appropriate resistance exercises will be provided to the family upon discharge, with instructions on how often to complete throughout the week. Discharged children will attend one supervised exercise session per week with the physiotherapist for six weeks. The family and patient will also be provided a weekly sheet to check off the days they completed strengthening and endurance exercises.
62222526|NCT05448612|EXPERIMENTAL|Muscles Energy Technique|In METs,the protocol will perform for 3 repetitions per day and thrice a week for 5 week.
62416678|NCT03911739|EXPERIMENTAL|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
62416679|NCT03911739|ACTIVE_COMPARATOR|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
62797878|NCT04663503|NO_INTERVENTION|Control arm- No intervention|The second arm of the study involves patients following standard of care during the HSCT period in the hospital with PT evaluation and management prescribed as needed by their transplant medical team including any additional PT interventions as a result of clinical indications. No additional intervention is incorporated in this group
62797879|NCT00234923|ACTIVE_COMPARATOR|1|Kaletra Monotherapy: lopinavir/ritonavir
62797880|NCT00234923|ACTIVE_COMPARATOR|2|Kaletra based triple therapy: lopinavir/ritonavir + lamivudine/zidovudine
62025270|NCT06532292|EXPERIMENTAL|HIFEM|During the initial appointment, participants will receive a comprehensive lifestyle advice leaflet covering pertinent information related to POP risk factors and guidance on diet, weight loss, the avoidance of heavy lifting, coughing, high-impact exercises. Following th educational component, participants will be asked to sit in an upright position at the center of an electromagnetic chair (such as the BTL EMSELLA, BTL Industries Inc., Boston MA) while remaining fully clothed for a duration of 28 minutes. To ensure optimal stimulation of the pelvic floor muscles, the physical therapist will carefully monitor the participant's chair posture throughout the treatment sessions and adjust the intensity of the electromagnetic stimulus according to the participant's tolerance threshold.
62025271|NCT06532292|ACTIVE_COMPARATOR|Biofeedback|The biofeedback group will undergo PFMT with biofeedback and/or electrostimulation, administered twice a week over 8 weeks by a skilled physical therapist. During the biofeedback and electrical stimulation, participants will assume a supine position with a 45° angle of hip and knee flexion, refraining from actively contracting the PFMs. The intravaginal probe will be inserted into the vagina. The frequency of electrostimulation will be set between 10-50 Hz based on participant tolerance and the pulse duration will be adjusted to 300-500 μs. The stimulation intensity will be set at the maximum tolerable level. During biofeedback, participants will receive visual instructions to guide them in relaxing and contracting their PFMs.
62222527|NCT03542461|EXPERIMENTAL|A_Nivolumab|Nivolumab 240 mg IV every 2 weeks until disease progression, unacceptable toxicity, patient refusal or Investigator's decision
62797881|NCT00790192|EXPERIMENTAL|Lurasidone 80mg|
62797882|NCT00790192|EXPERIMENTAL|Lurasidone 160mg|
62797883|NCT00790192|ACTIVE_COMPARATOR|Quetiapine XR|
62797884|NCT00790192|PLACEBO_COMPARATOR|Placebo|
62797885|NCT02089594|EXPERIMENTAL|Hyperbaric Oxygen Therapy (HBOT)|Hyperbaric Oxygen Therapy at 1.5 ATA (atmospheres absolute). The subjects will receive 40 low pressure HBOT's on a once/day, 5d/week eight week schedule.
62797886|NCT02089594|EXPERIMENTAL|No Hyperbaric Oxygen Treatment (HBOT)|Subjects will receive eight weeks of no hyperbaric treatment while they continue any pre-study maintenance medication and/or pre-study counseling. Subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
62416680|NCT06516549|EXPERIMENTAL|Skipping rope and informational pamphlet|The intervention group will be provided with a skipping rope and pamphlet with information on the importance of physical activity and ways to engage in physical activity. Both the skipping rope and pamphlet will be provided only once after completing the baseline interview.
62416681|NCT06516549|NO_INTERVENTION|Control|The control arm will not receive provision of intervention (no skipping rope or informational pamphlet).
62797887|NCT04416048|EXPERIMENTAL|Rivaroxaban|Subjects will receive treatment with rivaroxaban. (for more information see intervention description)
62797888|NCT04416048|OTHER|Standard of Care|Subjects will receive standard of care (SOC) treatment SOC with prophylactic LMWH or UFH
62797889|NCT03593057|EXPERIMENTAL|Manual therapy protocol|Manual therapy protocol and self-care advice and body awareness. Three sessions of manual therapy will be applied, (at the beginning, at 2 weeks and at 3 weeks).
62797890|NCT03593057|ACTIVE_COMPARATOR|Control group.|Advice on self-care and body awareness.
62797891|NCT03153475|OTHER|ATTUNE Revision Knee System|The ATTUNE Revision system is complementary to the ATTUNE primary knee portfolio and includes both rotating platform (RP) and fixed bearing (FB) configurations. The system includes a full compliment of implants designed to address the challenges faced in revision knee surgeries. These implants include Stemmable tibial and femoral components, augments, sleeves and offsets
62797892|NCT05350163|EXPERIMENTAL|HLA Matched Cohort I|5 x 10\^5/kg at 6-7 weeks post-transplant (Group A), 4-5 weeks post-transplant (Group B), or 2-3 weeks post-transplant (Group C)
62797893|NCT05350163|EXPERIMENTAL|HLA Matched Cohort II|5 x 10\^5/kg starting time point X (whichever was safest as determined by Matched Cohort I), 1 x 10\^6/kg 3-4 weeks after first dose, and 1 x 10\^6/kg 3-4 weeks after second dose
62222528|NCT03542461|OTHER|B_Best Supportive Care|Best Supportive Care until disease progression followed by Nivolumab at a dose of 240 mg IV until further disease progression, unacceptable toxicity, patient refusal or Investigator's decision.
62222529|NCT03735212|EXPERIMENTAL|Program Group|Participants in this group receive enhanced services as the intervention. These services include Motivational Enhancement, Incredible Years, and Contingency Management. Participants also receive case management services to support referrals to substance use.
62222530|NCT03735212|NO_INTERVENTION|Control Group|Participants in this group receive services as usual.
62222531|NCT02409069|EXPERIMENTAL|Transcutaneous vagus nerve stimulation (Nemos®, Cerbomed GmbH)|Stimulation of the ramus auricularis of the vagus nerve (ear)
62416682|NCT01426828|OTHER|Arm A|"Arm A will receive the CD3/CD28 activated autologous lymphocytes intravenously and subcutaneous injections of KLH only vaccine."
62416683|NCT01426828|OTHER|Arm B|Arm B will receive the CD3/CD28 activated autologous lymphocytes intravenously and subcutaneous injections of ID-KLH Vaccine Myeloma Immunoglobulin Idiotype Vaccine (id-KLH vaccine)
62416684|NCT04219956|EXPERIMENTAL|Polyamine deficient diet|Diet low in polyamines: the estimated calculated dose is 20 times lower that in an usual diet
62222532|NCT02409069|SHAM_COMPARATOR|Sham stimulation (Nemos®, Cerbomed GmbH)|Stimulation of the earlobe
62416685|NCT04219956|NO_INTERVENTION|Control|Usual Diet plus two snacks
62797894|NCT05350163|EXPERIMENTAL|HLA Matched Cohort III|5 x 10\^5/kg starting time point X (whichever was safest as determined by Matched Cohort I), 1 x 10\^6/kg 3-4 weeks after first dose, and 2 x 10\^6/kg 3-4 weeks after second dose
62797895|NCT05350163|EXPERIMENTAL|HLA Mismatched Cohort I|1 x 10\^5/kg at 6-7 weeks post-transplant (Group A), 4-5 weeks post-transplant (Group B), or 2-3 weeks post-transplant (Group C)
62222533|NCT02409069|NO_INTERVENTION|No stimulation|No stimulation
62222534|NCT05399420||functional kidney failure patients|Patients admitted to the nephrology department with suspicion of functional acute renal failures
62222535|NCT05399420||Organic kidney injury patients|Patients admitted to the nephrology department with suspicion of organic acute renal failure (kidney injury)
62222536|NCT01738425|EXPERIMENTAL|GIC-1001 oral tablets|GIC-1001; 125 mg oral tablets; Single ascending doses (SAD) from 125 mg to 1000 mg; multiple ascending dose (MAD) from 125 mg to 500 mg TID over 7 successive days
62222537|NCT01738425|PLACEBO_COMPARATOR|GIC-1001 matching placebo|Matching placebo, single or multiple dosing
62222538|NCT05178667|EXPERIMENTAL|High dose|4 capsules with 1.6g of active product per day: 2 at breakfast and 2 at dinner
62222539|NCT05178667|ACTIVE_COMPARATOR|Low dose|4 capsules with 0.8g of active product per day: 2 at breakfast and 2 at dinner
62416686|NCT00876109|EXPERIMENTAL|Group A: GDC-0941 QD Dose Escalation|Participants will receive GDC-0941 for up to 1 year, administered orally QD at a starting dose of 15 milligrams (mg).
62797896|NCT05350163|EXPERIMENTAL|HLA Mismatched Cohort II|1 x 10\^5/kg starting time point Y (whichever was safest as determined by Mismatched Cohort I), 5 x 10\^5/kg 3-4 weeks after first dose, and 5 x 10\^5/kg 3-4 weeks after second dose
62797897|NCT05350163|EXPERIMENTAL|HLA Mismatched Cohort III|1 x 10\^5/kg starting time point Y (whichever was safest as determined by Mismatched Cohort I), 5 x 10\^5/kg 3-4 weeks after first dose, and 1 x 10\^6/kg 3-4 weeks after second dose
62222540|NCT05178667|PLACEBO_COMPARATOR|Maltodextrin|4 placebo capsules (maltodextrin) per day: 2 at breakfast and 2 at dinner
62416687|NCT00876109|EXPERIMENTAL|Group B: GDC-0941 BID Dose Escalation|Participants will receive GDC-0941 for up to 1 year, administered orally BID at a starting dose determined from Group A assessments.
62222541|NCT00729872|EXPERIMENTAL|1|AG011: low dose
62797898|NCT00746616|EXPERIMENTAL|1|Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
62416688|NCT00876109|EXPERIMENTAL|Group C: GDC-0941 QD or BID Expansion|Participants will receive GDC-0941 for up to 1 year, administered orally QD or BID. The dose/regimen will be determined on the basis of data from Groups A and B.
62797899|NCT05911269|EXPERIMENTAL|TiMBRe|an eight-week, (45 min/week), theory driven, virtually-delivered, tailored music-based relaxation (TiMBRe) intervention to decrease anxiety in AYA cancer survivors with clinically-relevant anxiety.
62222542|NCT00729872|PLACEBO_COMPARATOR|2|Placebo: low dose
62222543|NCT00729872|EXPERIMENTAL|3|AG011: mid dose
62222544|NCT00729872|PLACEBO_COMPARATOR|4|Placebo: mid dose
62222545|NCT00729872|EXPERIMENTAL|5|AG011: high dose
62222546|NCT00729872|PLACEBO_COMPARATOR|6|Placebo: high dose
62222547|NCT01657851|EXPERIMENTAL|dutasteride/tamsulosin|The present study is planned to establish bioequivalence of Duodart® 0.5mg/0.4mg manufactured by GlaxoSmithKline to concomitant dosing with separate capsules of dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg formulations commercially available in Russia.
62222548|NCT01657851|ACTIVE_COMPARATOR|dutasteride|Dutasteride (Avodart®) is an approved potent dual type I and II, 5-alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery.
62222549|NCT01657851|ACTIVE_COMPARATOR|tamsulosin|Tamsulosin (Omnic®) is an alpha-1A-adrenocepter blocking agent approved for the treatment of signs and symptoms of benign prostatic hyperplasia
62222550|NCT00921596|OTHER|Totally endoscopic cardiac operation|Patients with cardiac diseases undergo cardiac operations with totally endoscopic and cardiopulmonary bypass
62222551|NCT05657717|EXPERIMENTAL|Intervention|Manukamed - 100% sterile manuka honey
62222552|NCT05657717|NO_INTERVENTION|Control|No intervention was given. Participants receive standard wound care of the tympanic membrane which includes 0.3% Ofloxacin otic ear drops which were used twice a day for 5 days.
62222553|NCT04129697|ACTIVE_COMPARATOR|Dexamethasone|
62222554|NCT04129697|ACTIVE_COMPARATOR|Methylprednisolone|
62416689|NCT03267316|EXPERIMENTAL|Dose escalation|Cohorts of 3 subjects will receive once weekly (Q1W) treatment with CAN04. The Dose Limiting Toxicity (DLT) observation period for each dose level will be the first 21 days of treatment with CAN04. \[Completed December 2018\]
62416690|NCT03267316|EXPERIMENTAL|Monotherapy (Q1W)|Subjects with either PDAC or NSCLC, will receive treatment with CAN04 monotherapy once weekly (Q1W).
62416691|NCT03267316|EXPERIMENTAL|Monotherapy (Q1W/Q2W)|Subjects with either PDAC or NSCLC, will receive treatment with CAN04 monotherapy once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W).
62416692|NCT03267316|EXPERIMENTAL|Combination - NSCLC (NCG)|Subjects with NSCLC will receive treatment with CAN04 once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W) in combination with standard-of-care therapy (cisplatin/gemcitabine).
62416693|NCT03267316|EXPERIMENTAL|Combination - PDAC|Subjects with PDAC will receive treatment with CAN04 once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W) in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine).
62416694|NCT03267316|EXPERIMENTAL|Combination - PDAC (1 mg/kg)|Subjects with PDAC will receive CAN04 on Day 1 and 15 in cycles of 28 days in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine). During first cycle CAN04 also to be administered on Day 8.
62797900|NCT05911269|ACTIVE_COMPARATOR|Attention-Control|Standard of care study staff calls and cancer survivorship resources
62797901|NCT03971565||Patients with chronic lymphocytic leukemia|Patient with a minimum period of 90 days without treatment
62797902|NCT04854551|EXPERIMENTAL|Placebo, Then Naltrexone|Participants first received placebo capsules each day in a blister pack for 5 days. After a washout period of at least 3 days, they then received naltrexone capsules (matching placebo capsules) at 25mg/day for days 1 and 2 and then 50mg/day for days 3-5 for 5 days.
62797903|NCT04854551|EXPERIMENTAL|Naltrexone, Then Placebo|Participants first received naltrexone capsules each day in a blister pack for 5 days. Days 1 and 2 were at 25mg/day, and days 3-5 were at 50mg/day. After a washout period of at least 3 days, they then received placebo capsules (matching naltrexone capsules) for 5 days.
62222555|NCT03170999||Subjects included in Focus groups|Approximately 45 subjects with COPD will participate in the focus group interviews for item identification. The group may contain subjects who are functionally illiterate and at least one third women will be recruited.
62222556|NCT03170999||Subjects included in cognitive interviews|Approximately 9 subjects with COPD will be involved in cognitive interviews and will be asked to respond to all of the items in the draft item set.
62222557|NCT03170999||Subjects included in candidate item set|Approximately 150 subjects with COPD will respond to the questions in candidate item set.
62222558|NCT00638781|ACTIVE_COMPARATOR|1|Desmoteplase 62.5 µg/kg BW i.v. bolus
62222559|NCT00638781|ACTIVE_COMPARATOR|2|Desmoteplase 90 µg/kg BW i.v. bolus
62222560|NCT00638781|ACTIVE_COMPARATOR|3|Desmoteplase 125 µg/kg BW i.v. bolus
62222561|NCT00638781|PLACEBO_COMPARATOR|4|Placebo i.v. bolus
62222562|NCT04580329|EXPERIMENTAL|NMES group|
62222563|NCT04580329|EXPERIMENTAL|control group|
62416695|NCT03267316|EXPERIMENTAL|Combination - PDAC (2,5 mg/kg)|Subjects with PDAC will receive CAN04 on Day 1 and 15 in cycles of 28 days in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine). During first cycle CAN04 also to be administered on Day 8.
62416696|NCT03267316|EXPERIMENTAL|Combination - non-squamous NSCLC (NCP)|Subjects with non-squamous NSCLC will receive CAN04 on Day 1 and 8 in cycles of 21 days in combination with standard-of-care therapy (carboplatin/pemetrexed).
62025272|NCT06532292|NO_INTERVENTION|Usual care group|Participants allocated to the usual care (i.e., no physical therapy) group will receive the usual care provided by their obstetricians or gynecologists based on clinical judgment, in addition to the lifestyle advice leaflet provided by the research team. The lifestyle advice leaflet will be given to the participants immediately after the baseline assessment, and the usual care group will have no planned contact with the project staff until 8 weeks after the baseline assessment.
62025273|NCT02030977|ACTIVE_COMPARATOR|Resveratrol|"Active Comparator: Resveratrol~1 Resveratrol capsules for 12 weeks"
62025274|NCT02030977|PLACEBO_COMPARATOR|Placebo|one capsule per day
62222564|NCT03929757|EXPERIMENTAL|Arm 1: Ad26.ZEBOV, MVA-BN-Filo|Participants will be administered 0.5 mL of Ad26.ZEBOV vaccine (5\*10\^10 viral particles \[vp\]) on Day 1 by intramuscular (IM) injection followed by 0.5 mL of MVA-BN-Filo (1\*10\^8 infectious units \[Inf U\]) vaccine by IM injection on Day 57. Participants will also receive a dose of MenACWY at the 6-months post-dose-2 visit. Upon completion of the main study, participants in the extension phase who were originally randomized to the control arm will receive the same vaccine regimen as the participants in the Ad26.ZEBOV, MVA-BN-Filo arm of the main study.
62222565|NCT03929757|ACTIVE_COMPARATOR|Arm 2: MenACWY|Participants will be administered 0.5 mL of MenACWY vaccine by IM injection on Day 1 and Day 57. Participants will also receive a dose of MenACWY at the 6-months post-dose-2 visit.
62222566|NCT02778854||cohort 1|Participants are recruited for diagnostic test
62222567|NCT02778854||cohort 2|participants are recruited for follow-up
62222568|NCT01066520|EXPERIMENTAL|Traumeel S ointment|Traumeel S ointment 2 g, 3 times daily topical during 14 days
62222569|NCT01066520|EXPERIMENTAL|Traumeel S gel|Traumeel S gel 2 g, 3 times daily topical during 14 days
62222570|NCT01066520|ACTIVE_COMPARATOR|Diclofenac gel|Diclofenac gel 2 g, 3 times daily topical during 14 days
62416697|NCT02095210|EXPERIMENTAL|[68Ga]ABY-025 PET imaging|Radiolabeled \[68Ga\]ABY-025
62025275|NCT01383538|EXPERIMENTAL|FOLFIRINOX Plus IPI-926|
62025276|NCT00709163|ACTIVE_COMPARATOR|1|
62222571|NCT00840151|NO_INTERVENTION|Treatment Group A|Individuals randomized to Treatment Group A will receive standard treatment for study weeks 1-6.
62222572|NCT00840151|EXPERIMENTAL|Treatment Group B|Individuals randomized to Treatment Group B will receive contingency management plus standard treatment for study weeks 1-6.
62416698|NCT05676164|ACTIVE_COMPARATOR|Control group|Oral Contrast Agent for Sonography from Huzhou East Asia Medical Supplies Co., LTD
62416699|NCT05676164|EXPERIMENTAL|Experimental group|Oral Contrast Agent for Sonography from Shandong branden Medical Device Co., LTD
62416700|NCT02395094|NO_INTERVENTION|Group 1 (Standard Procedure)|Group 1 (Standard Procedure) will receive BCCH standard care, which consists of topical anesthetic cream, waiting with parents in the playroom in the surgical daycare unit preoperatively, parental presence in the OR, the BCCH 'parent hug' and standard distraction techniques
62025277|NCT00709163|PLACEBO_COMPARATOR|2|
62416701|NCT02395094|EXPERIMENTAL|Group 2 (Child Life)|Group 2 (Child Life) will receive Child Life intervention applicable to the individual patient, on the day of surgery in addition to standard practices
62416702|NCT01906827||pregnant with ICP|pregnant with ICP
62416703|NCT06703086|ACTIVE_COMPARATOR|Nutritional plan only|Nutritional plan according to your caloric requirements for lifestyle
62416704|NCT06703086|ACTIVE_COMPARATOR|Nutritional plan and moderate aerobic exercise|nutritional plan and controlled moderate aerobic exercise that will consist of a goal of 10,000 steps or 150 minutes per week
62416705|NCT06703086|EXPERIMENTAL|Berberine, nutritional plan and moderate exercise|nutritional plan, moderate aerobic exercise and the phytopharmaceutical Berberine 500 mg every 8 hours for 3 months.
62588329|NCT01931956|EXPERIMENTAL|Compassionate Use|Patients that did not meet REALISM High Risk or Non-High Risk eligibility criteria were evaluated for consideration for either Emergency Use (EU) or Compassionate Use (CU). The objective of the Compassionate and Emergency Use Group of the EVEREST II REALISM study is to provide access to the MitraClip Device, in a non-commercial setting, for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant.
62025278|NCT05559918||Preloading with clopidogrel|
62025279|NCT05559918||In-hospital loading with clopidogrel|
62025280|NCT05212974||Nurses|Adult (≥ 20 and ≤80 years) male and female participants with verification of registered nurse license.
62025281|NCT05212974||General publics|Adult (≥ 20 and ≤80 years) male and female participants with reading abilities above the intermediate level.
62025282|NCT05976074|EXPERIMENTAL|Wearable device for tremor assessment|Subjects already implanted with a deep brain stimulation (DBS) system for therapy for essential tremor wear an Apple Watch and complete tremor assessment tasks detailed through the BrainRISE app four times a day for two weeks.
62222573|NCT00840151|NO_INTERVENTION|Aftercare Group A|All participants will be re-randomized after study week 6. Those participants assigned to Aftercare Group A will receive standard treatment for study weeks 7-12.
62222574|NCT00840151|EXPERIMENTAL|Aftercare Group B|All participants will be re-randomized after study week 6. Those participants assigned to Aftercare Group B will receive contingency management treatment plus standard treatment for weeks 7-12.
62222575|NCT06605664|EXPERIMENTAL|Hyperpolarized 13C pyruvate MRI|Hyperpolarized 13C pyruvate MRI before and 2-5 weeks after radiotherapy combined with atezolizumab and bevacizumab
62222576|NCT02791074||Control|"Healthy Volunteers will undergo the following studying procedures:~Echocardiography Arterial tonometry"
62416706|NCT06703086|NO_INTERVENTION|No intervention|patients who met the inclusion criteria but did not receive treatment or intervention, only somatometry and blood samples were taken.
62025283|NCT02946736|EXPERIMENTAL|Supervisor Intervention|Supervisors in the intervention group will go through the FSSB/sleep leadership training and receive actigraphy feedback.
62025284|NCT02946736|EXPERIMENTAL|Employee Intervention|Employees in the intervention group will receive actigraphy feedback.
62222577|NCT02791074||Heart Failure Patients|"Patients will undergo the following studying procedures:~NTproBNP Echocardiography Arterial tonometry"
62222578|NCT05514782|ACTIVE_COMPARATOR|Anti-Aging Daily Serum|Daily serum composed of a patent-pending botanical extract, bioavailable peptide, antioxidants, postbiotic(s), short term and long-term moisturizers. New product in development.
62222579|NCT05514782|PLACEBO_COMPARATOR|Placebo-Control|Vehicle control of the anti-aging daily serum.
62222580|NCT05657015|EXPERIMENTAL|Lepidium sativum|15 participants 15 participants with localized stage II or III, and grade A periodontitis received about 2ml of locally delivered Lepidium sativum in situ gel with scaling and root surface debridement once at the beginning of the study
62222581|NCT05657015|ACTIVE_COMPARATOR|simvastatin|15 participants with localized stage II or III, and grade A periodontitis received about 1.2% of locally delivered Simvastatin in situ gel with scaling and root surface debridement once at the beginning of the study
62222582|NCT06226740|EXPERIMENTAL|Cold Lateral Compaction (Control group)|After the root canal preparation was completed, the working length was checked with the master cone and periapical radiography. The master cone was then covered with root canal sealer and placed in the root canal. Then, a gap was created for the .02 angled lateral cones using #30, 25 and 20 finger spreader. The obturation process continued until the spreader went 2 mm beyond the level of the canal orifice. Next, a hot excavator removed the coronal gutta-percha 1 mm below the canal orifice.
62222583|NCT06226740|EXPERIMENTAL|Warm Vertical Compaction|After the root canal preparation was completed, the working length was checked with the master cone and periapical radiography. Root canal sealer was applied to the root canal walls using a master cone. HeatPlugger connected to the down-pack unit of the obturation system was adjusted to be 4 mm shorter than the working length. The master cone was cut 1 mm shorter than the working length with a heated plugger and applied to the root canal. Then, the heated plugger was advanced in the apical direction, and the apical region was obturated. Obturation was completed in 2 stages with gutta-percha in the gutta-percha cartridge connected to the remaining root canal cavity back-fill unit and heated to 200 °C. Heated gutta-percha was vertically condensed with HeatPlugger to 1 in the first stage and 2 in the second. The root canal obturation was completed by removing the gutta-percha 1 mm below the canal orifice.
62222584|NCT06226740|EXPERIMENTAL|Gutta Core|After the root canal preparation was completed, the working length was controlled with the master cone and periapical radiography. Root canal sealer was applied to the root canal walls using a master cone. Root canal obturation was completed with heated gutta-percha according to the manufacturer's instructions. The heated gutta-percha was slowly inserted into the canal up to the working length. After cutting the handle of the obturators at the level of the canal orifice with a hot excavator, it was condensed into the canal using a gutta-percha plugger. The coronal gutta-percha was removed 1 mm below the canal orifice using a hot excavator.
62222585|NCT03099499|EXPERIMENTAL|ONC201 treatment Arm|
62416707|NCT02444741|EXPERIMENTAL|Group I, Phase I (pembrolizumab + SBRT)|Patients who exhibit a lung lesion of size and location amenable to SBRT receive pembrolizumab IV over 30 minutes on day 1. Patients also receive SBRT in 4 fractions daily on days 2-5 or either IMRT, PBRT, or 3D-CRT in 15 fractions total concurrent with pembrolizumab administration on days 1-19. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
62588330|NCT01931956|EXPERIMENTAL|Emergency Use|Patients that did not meet REALISM High Risk or Non-High Risk eligibility criteria were evaluated for consideration for either Emergency Use (EU) or Compassionate Use (CU). The objective of the Compassionate and Emergency Use Group of the EVEREST II REALISM study is to provide access to the MitraClip Device, in a non-commercial setting, for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant.
62588331|NCT02288091|EXPERIMENTAL|Open-label|Subjects will receive oral inosine daily.
62588332|NCT02397954|EXPERIMENTAL|Zimura + Anti-VEGF|Subjects will receive monthly intravitreous injections of Zimura in combination with either Lucentis, Avastin or Eylea.
62588333|NCT02966678||Glaucoma|Patients with a diagnosis of glaucoma will undergo color vision test
62416708|NCT02444741|EXPERIMENTAL|Group I, Phase II (pembrolizumab + SBRT)|Patients who exhibit a lung lesion with size and location amenable to SBRT receive pembrolizumab IV on day 1 and SBRT on days 44-47 or IMRT, PBT, or 3D-CRT on days 43-61. Treatment with pembrolizumab repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
62416709|NCT02444741|EXPERIMENTAL|Group II, Phase I (pembrolizumab + IMRT, PBRT or 3D-CRT)|Patients who exhibit a lung lesion of size or location not amenable to SBRT, but amenable to WFRT receive pembrolizumab as in Group I and either IMRT, PBRT, or 3D-CRT in 15 fractions total on days 1-19 concurrent with pembrolizumab administration.
62797904|NCT06723444|EXPERIMENTAL|Intervention Group|The intervention group will receive paper and pencil learning and memory training exercises, administered twice a week for five weeks (10 training sessions).
62797905|NCT06723444|PLACEBO_COMPARATOR|Placebo Control Group|The placebo control group will receive paper and pencil placebo memory exercises administered twice a week for five weeks (10 placebo control sessions).
62797906|NCT01929382|ACTIVE_COMPARATOR|Actimmune (interferon gamma 1b)|Subjects \> 0.5m2 BSA will receive 50 mcg/m2 BSA and subjects ≤ 0.5m2 BSA will receive 1.5mcg/kg/dose, as SC injections three times weekly, from week 1 to week 3.
62797907|NCT01929382|EXPERIMENTAL|Actimmune(interferon gamma 1b) titration|30% of the recommended dose as SC injections three times weekly in week 1, 60% the recommended dose as SC injections three times weekly in week 2, and at the recommended dose as SC injections three times weekly in week 3
62797908|NCT00108771|EXPERIMENTAL|ZR-02-01 matrix fentanyl Patch|ZR-02-01 matrix fentanyl patch
62797909|NCT00108771|PLACEBO_COMPARATOR|Placebo Patch|
62797910|NCT03169335|EXPERIMENTAL|Experimental group|QL1101 + paclitaxel/carboplatin:subjects are given 15 mg/kg QL1101 on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles (at least 4 cycles).
62025285|NCT01420796|EXPERIMENTAL|Swallowing and breathing exercises|This group will perform both swallowing and breathing exercises for five weeks.
62797911|NCT03169335|ACTIVE_COMPARATOR|Control group|Avastin® + paclitaxel/carboplatin:subjects are given 15 mg/kg Avastin® on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles (at least 4 cycles).
62222586|NCT04004247|EXPERIMENTAL|Experimental group|"10-12 young healthy volunteers. Placed on semi-sitting position on the bed (40 deg.elevation). Calibration of electrical impedance tomography (EIT) on defined tidal volume 500ml, done with 500ml syringe connected to closed breathing circuit using full face mask as an interface.~Insertion an esophageal and nasopharyngeal catheter for pressures measurement. In the first phase - spontaneous breathing with full face mask at 0, 5 and 10 cm H20 levels of PEEP.~In the second phase - high flow oxygenation through nasal cannula, start with flow rate 10 L/min with gradual increase up to 60 L/min.~Spirometry to determine functional residual capacity (FRC) before and after procedure is planed."
62222587|NCT04991532||Dasatinib group|the CML patient treated with dasatinib
62222588|NCT04991532||Imatinib group|the CML patient treated with imatinib
62222589|NCT01588431|EXPERIMENTAL|(TPE-A) Followed by Concurrent RT(XPE-A), surgery|Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery
62222590|NCT03187574||Group A|group received Elevate Ant™ single-incision mesh
62222591|NCT03187574||Group B|group received Perigee™ transvaginal mesh
62222592|NCT01688687||Superficial gastric neoplasia|Patients with superficial gastric neoplasia on diagnostic endoscopy, recieved both conventional endoscopic forcpes biopsies and pCLE. All patients were subject to endoscopic resection of the lesion.
62222593|NCT06477822|EXPERIMENTAL|Sequence of manual therapy techniques|Participants receive a manual therapy secuence of techniques
62222594|NCT06477822|PLACEBO_COMPARATOR|Simulated manual therapy techniques|Participants receive a sequence of simulated manual therapy techniques
62222595|NCT02021097|EXPERIMENTAL|LNG100 mcg/EE20 mcg|
62416710|NCT02444741|EXPERIMENTAL|Group II, Phase II (pembrolizumab + XRT upon PD)|Patients who exhibit a lung lesion with size and location amenable to SBRT receive pembrolizumab IV as in Group I without XRT. At the first planned efficacy evaluation (5 weeks), patients exhibiting PD are treated with SBRT concurrent with the remaining cycles of pembrolizumab. In the event that lesion size has progressed to the point where the attending physician no longer considers SBRT safe, then the patient will be salvaged with IMRT, PBRT, or 3D-CRT and analyzed as part of the fourth treatment group.
62416711|NCT02444741|EXPERIMENTAL|Group III, Phase II (pembrolizumab + IMRT, PBRT, or 3D-CRT)|Patients who exhibit a lung lesion with size and location not amenable to SBRT, but amenable to WFRT receive pembrolizumab IV as in Group I and IMRT, PBRT, or 3D-CRT on days 43-61.
62416712|NCT02444741|EXPERIMENTAL|Group IV, Phase II (pembrolizumab + XRT upon PD)|Patients who exhibit a lung lesion with size and location not amenable to SBRT, but amenable to WFRT receive pembrolizumab IV as in Group I without XRT. The decision on when to start XRT will be assessed first at week 5 (after the second dose of pembrolizumab). If a patient has PD based on irRC then XRT will be delivered after the third dose of pembrolizumab, while patients with SD or PR will not start XRT and will continue to be followed. These patients will then have follow up CT scans 5 weeks after course 3 and then approximately every 3 months for the remainder of the trial; any patient at this point with PD will then have XRT delivered with the sixth dose of pembrolizumab.
62797912|NCT03863665|EXPERIMENTAL|Telemetric Bluetooth-enabled home BP monitors|Telemetric Bluetooth home BP monitors will be provided to participants during their inpatient stay or clinic visit, and will commence 3- times-daily readings immediately. The BP monitoring team will assess BP readings daily and advise medication adjustments to achieve a target BP of \<120/80 mm Hg
62797913|NCT03863665|NO_INTERVENTION|Standard clinical care|Standard clinical care including usual BP treatment, without home monitoring, undertaken in the clinical care setting (primary and/or secondary care)
62797914|NCT00561288|EXPERIMENTAL|1|2000 mg acetaminophen per day
62222596|NCT02021097|ACTIVE_COMPARATOR|LNG 150mcg/ EE 30mcg|
62222597|NCT03476213|EXPERIMENTAL|Group TCI|induction and anesthesia will be held by using target-controll infusion
62797915|NCT00561288|PLACEBO_COMPARATOR|2|2000 mg cornstarch per day
62797916|NCT00936806||Unilateral intracranial tumor|Subjects with unilateral intracranial tumor
62222598|NCT03476213|ACTIVE_COMPARATOR|Group TIVA|induction and anesthesia will be held by manual dosing of propofol and sufentanil
62416713|NCT02444741|EXPERIMENTAL|Group V, Phase II (low dose radiation therapy)|Patients with lesions amenable to SBRT or WFRT receive pembrolizumab IV as in Group I. Patients also receive either IMRT, PBRT, or 3D-CRT in 15 fractions to the primary lesions and low dose radiation therapy to other lesions on days 43-61 or SBRT in 4 fractions to primary lesions and low dose radiation therapy to other lesions on days 44-47.
62797917|NCT00936806||Control group|Subjects without intracranial pathology
62797918|NCT00991653||Breast cancer|Diagnosed with breast cancer 1/1/2003 - 31/12/2007.
62797919|NCT04496856|EXPERIMENTAL|Collagen|Participants of this arm are going to consume 30 g of collagen peptides daily for 30 days
62797920|NCT04496856|EXPERIMENTAL|Whey Protein|Participants of this arm are going to consume 30 g of whey protein daily for 30 days
62222599|NCT03235284|ACTIVE_COMPARATOR|Exercises|A program of therapeutic exercises (GC) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The GC treatment program consists of the following protocols: a) protocol 1: 20 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation),10 minutes diagonal exercise scapula (anterior and posterior elevation) and 10 minutes of exercise for trunk extension; b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training;
62222600|NCT03235284|ACTIVE_COMPARATOR|Nintendo Wii|"Nintendo Wii program (GW) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The GW treatment program consists of the following protocols: a) protocol 1 games (Boxing and Soccer); b) protocol 2 games (Golf and running). 20 minutes for each game"
62222601|NCT03235284|EXPERIMENTAL|Exercises and Nintendo Wii|In GCW program will be performed 20 minutes GC protocol (1 or 2, used alternately between sessions a week) and 20 minutes GW protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols
62797921|NCT05729932|EXPERIMENTAL|Intranasal Opioid Agonist|Participants will receive non-therapeutic, experimental doses of an opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered intransally (snorting).
62797922|NCT05729932|EXPERIMENTAL|Vaporized cannabis|Participants will receive non-therapeutic, experimental doses of active or placebo vaporized cannabis. Active cannabis/placebo will be administered once per session and will be administered via a vaporizer.
62797923|NCT05863884|OTHER|CHW Intervention|A six week CHW home-visit behavioral intervention examining changes in diabetes outcomes.
62797924|NCT03044366||Characteristics of Anesthesia management|Evaluate the average value of these data.
62797925|NCT03044366||Comorbidities|Evaluate the average value of these data.
62797926|NCT01633541|EXPERIMENTAL|platinum/docetaxel + AT-101|"platinum/docetaxel + AT-101 The platinum will either be cisplatin or carboplatin as deemed best by the medical oncologist.~(Both Arms) Day #1: Patients will undergo induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).~(AT-101 Arm) Days #1-3: Patients will receive AT-101 40 mg orally twice daily On Day 23 (+/- 3 days), there will be a direct laryngoscopy (DL) with tumor biopsy and blood draw, repeat CT scan of the neck with perfusion within a week biopsy."
62797927|NCT01633541|ACTIVE_COMPARATOR|Active Comparator arm|"(Both Arms) Day #1: Patients will undergo induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).~Day #23 (+/- 3 days): Patients will undergo a direct laryngoscopy (DL) with biopsy. Patients will also undergo a repeat CT scan of the neck with perfusion within a week (+/-) of their perspective biopsies."
62797928|NCT00575965|EXPERIMENTAL|Simvastatin|Simvastatin at 20 mg daily for the first week, then dose escalated weekly by 20 mg a day to a maximum of 80 mg daily by week 4. Patients were maintained on therapy until progression.
62797929|NCT04583995|EXPERIMENTAL|Cohort 1: SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
62797930|NCT04583995|PLACEBO_COMPARATOR|Cohort 1: Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
62797931|NCT04583995|EXPERIMENTAL|Cohort 2: SARS-CoV-2 rS/Matrix-M1 Adjuvant Plus Licensed Seasonal Flu Vaccine|2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.
62797932|NCT04583995|PLACEBO_COMPARATOR|Cohort 2: Placebo Plus Licensed Seasonal Flu Vaccine|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.
62797933|NCT06278766|EXPERIMENTAL|ABBV-552|Participants will receive ABBV-552 on Day 1.
62222602|NCT00306670|EXPERIMENTAL|Rituximab|Patients will receive rituximab.
62222603|NCT00306670|ACTIVE_COMPARATOR|Oral cyclophosphamide|Patients will receive oral cyclophosphamide.
62416714|NCT06540677|EXPERIMENTAL|Musical training (MT Group)|"Based on the literature review, we will establish 20 minute sessions three times per week over a period of 4 weeks for participants in the MT group. After this period, all the participants will be evaluated (session 1). An additional training period of 12 weeks, also with 20-min sessions three times per week, will then be conducted in the MT group, followed by another evaluation (session 2).~In sessions 0 (at enrollement), 1, and 2, they will complete the MuRQoL or MuQPP to evaluate their exposure to music and the AQoL-8D to evaluate their quality of life. Further, they will perform the Listen up test, the cognition tests, and the audiological tests in quiet and in noise."
62797934|NCT03728543|EXPERIMENTAL|Children 0-2yo|Children 0-2 years old with oncological diseases who need an MRI under general anesthesia, will receive sugammadex 2mg/kg IV
62797935|NCT03728543|ACTIVE_COMPARATOR|Children 2-18yo|Children 2-18 years old with oncological diseases who need an MRI under general anesthesia, will receive sugammadex 2mg/kg IV
62797936|NCT02743455|ACTIVE_COMPARATOR|Group 1|Subjects will receive 1.0x10\^8 TCID50 of MVA-BN as two doses subcutaneously on Day 1 and Day 29. N=15
62797937|NCT02743455|EXPERIMENTAL|Group 2|Subjects will receive 1.0x10\^8 TCID50 of MVA-BN-YF as two doses intramuscularly on Day 1 and Day 29. N=15
62797938|NCT02743455|EXPERIMENTAL|Group 3|Subjects will receive 1.0x10\^8 TCID50 of MVA-BN-YF + ISA 720 as two doses intramuscularly on Day 1 and Day 29. N=15
62797939|NCT02743455|EXPERIMENTAL|Group 4|Subjects will receive 1.0x10\^8 TCID50 of MVA-BN-YF + ISA 720 as a single dose intramuscularly on Day 1 and matching placebo on Day 29. N=15
62222604|NCT05420285|EXPERIMENTAL|Dapagliflozin|Dapagliflozin is taken orally, once daily at the dosage of 10 mg during 6 months.
62797940|NCT02743455|ACTIVE_COMPARATOR|Group 5|Subjects will receive = / \> 4.74 log10 PFU of YF-Vax as a single dose subcutaneously on Day 1 and matching placebo on Day 29. N=15
62797941|NCT02743455|EXPERIMENTAL|Group 6|Subjects with prior receipt of MVA-BN will receive 1.0x10\^8 TCID50 of MVA-BN-YF as two doses intramuscularly on Day 1 and Day 29. N=15
62416715|NCT06540677|NO_INTERVENTION|Non Musical training (NMT Group)|"Participants won't perform musical training. In sessions 0 (at enrolment), after 4 weeks , and again after 12 additional weeks, they will complete the MuRQoL or MuQPP to evaluate their exposure to music and the AQoL-8D to evaluate their quality of life. Further, they will perform the Listen up test, the cognition tests, and the audiological tests in quiet and in noise."
62416716|NCT00605839|EXPERIMENTAL|Glucopak Care|Glucopak cell phone and intensive monitoring. This group will be given the experimental device, and placed in close communication with the clinic.
62222605|NCT03801122|EXPERIMENTAL|Tranexamic acid 3g/day|Administration of tranexamic acid 3g/day, with 3 injections/8 hours.
62222606|NCT03801122|EXPERIMENTAL|Tranexamic acid 1.5g/day|Administration of tranexamic acid 1.5g/day, with 3 injections/8 hours.
62222607|NCT03801122|NO_INTERVENTION|No treatment|No treatment (no administration of tranexamic acid)
62222608|NCT02305836|EXPERIMENTAL|Electroacupuncture combined with donepezil|Every session will last for 30 minuets and will be given every other day. There are 36 sessions for each participant in all (3 session per week, 12 weeks).
62222609|NCT02305836|ACTIVE_COMPARATOR|donepezil|Donepezil will be given once daily before bed-time for the first 4-6 weeks. Based on the treatment effect, the dosage may be increased to 10 mg once daily before bed-time for the next 6-8 weeks. Donepezil will be taken for continuous 24 weeks. The full course of treatment is 36 weeks.
62222610|NCT00339222||1|Melanoma-prone families from dermatology clinics.
62222611|NCT05033873|EXPERIMENTAL|Group A: Universal Exercise Unit Therapy (UEU)|This experimental group will be given universal exercise unit therapy.
62222612|NCT05033873|EXPERIMENTAL|Group B: Sling Exercise Therapy (SET)|This experimental group will be given sling exercise therapy
62222613|NCT05033873|OTHER|Group C: Control Group|Control group will be given routine physical therapy
62222614|NCT03322072|EXPERIMENTAL|Real-Time Position Transponder Beacons|Patients in this arm will each be receiving 3 implanted real-time position transponder beacons (Calypso beacons)
62222615|NCT04822597|ACTIVE_COMPARATOR|Ice Pack|Ice will be placed on the breast prior to radioactive tracer injection (usual treatment)
62222616|NCT04822597|EXPERIMENTAL|Lidocaine Patch|A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection
62222617|NCT04822597|EXPERIMENTAL|Buzzy(R)|A vibrating distraction device (Buzzy(R)) and ice will be placed on the breast prior to radioactive tracer injection.
62222618|NCT04822597|EXPERIMENTAL|Lidocaine Patch and Buzzy(R)|A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection. This will be removed and a vibrating distraction device (Buzzy(R)) and ice will be placed on the breast just prior to radioactive tracer injection.
62416717|NCT00605839|ACTIVE_COMPARATOR|Cell Phone Care|Cell phone only, without the Glucopak. Participants will be given cell phones and encouraged to communicate more closely with the clinic, but will not use the Glucopak.
62416718|NCT00605839|PLACEBO_COMPARATOR|Usual Care|Usual care, without cell phone or glucopak
62416719|NCT05500235|EXPERIMENTAL|Smart phone based training|Smartphone-based training for Headmasters to implement the Tobacco Free Teachers-Tobacco Free Society program in their schools in Madhya Pradesh, India
62416720|NCT05500235|EXPERIMENTAL|In person training|In person training for Headmasters to implement the Tobacco Free Teachers-Tobacco Free Society program in their schools in Madhya Pradesh, India
62416721|NCT04278833|OTHER|Particulate Corticosteroid Injection|Intra-articular, peri-tendinous, or intra-bursal corticosteroid injection using 10-80mg of triamcinolone or 3-9mg of betamethasone depending on anatomical structure. Injections may be repeated up to 3 times in the 6 month study period based on physician discretion.
62416722|NCT04278833|OTHER|Non-particulate Corticosteroid Injection|Intra-articular, peri-tendinous, or intra-bursal corticosteroid injection using 4-10mg of dexamethasone depending on anatomical structure. Injections may be repeated up to 3 times in the 6 month study period based on physician discretion.
62797942|NCT02766634|EXPERIMENTAL|Filgrastim Hospira (US) followed by U.S.-approved Neupogen®|
62797943|NCT02766634|EXPERIMENTAL|U.S.-approved Neupogen® followed by Filgrastim Hospira (US)|
62797944|NCT05775016|PLACEBO_COMPARATOR|Placebo|Placebo (Resistant Dextrin) (n=40)
62222619|NCT01583153|ACTIVE_COMPARATOR|Hospital Inpatient Rehabilitation (HI)|
62222620|NCT01583153|ACTIVE_COMPARATOR|Hybrid Home Programme (HO)|
62222621|NCT04355247|EXPERIMENTAL|Single Arm|"* Patients will be admitted to a regular room in the hospital (not ICU)~* They will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.~* Methylprednisolone 80 mg IV bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital."
62222622|NCT00588185|EXPERIMENTAL|1|\[18F\]-Fluoro-2-Deoxy-D-Glucose and -\[18F\] Dihydro-Testosterone
62222623|NCT02644486|EXPERIMENTAL|A Group|
62222624|NCT02644486|EXPERIMENTAL|B Group|
62222625|NCT02644486|ACTIVE_COMPARATOR|C Group|
62222626|NCT03096704||slow transit time constipation|
62222627|NCT06238518|EXPERIMENTAL|Conventional lesion preparation plus Intravascular Lithotripsy strategy|IVL could be performed before, amidst, or after Conventional lesion preparation therapy; However, the use of IVL treatment is mandatory.
62222628|NCT06238518|ACTIVE_COMPARATOR|Conventional lesion preparation strategy|Conventional lesion preparation strategy includes the use of Compliant, noncompliant, cutting, or scoring balloons, Excimer laser coronary atherectomy, or Rotational atherectomy at the discretion of the operator.
62222629|NCT06159153|EXPERIMENTAL|Dynamic Ultrasonography assessment|Patients admitted for ACL injury and indication for arthroscopy will have dynamic ultrasound evaluation that will be compared with an MRI.
62416723|NCT04918927|EXPERIMENTAL|Arm 1: Favipiravir + Nitazoxanide|Oral Favipiravir 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Nitazoxanide at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7
62416724|NCT04918927|EXPERIMENTAL|Arm 2: Favipiravir + Nitazoxanide placebo|Oral favipiravir, 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Nitazoxanide matched placebo at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7.
62025286|NCT01420796|EXPERIMENTAL|Swallowing exercises|This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will perform sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
62222630|NCT02388685|EXPERIMENTAL|Home exercise|Patients will undergo home exercise therapy under the supervision of the exercise laboratory
62797945|NCT05775016|EXPERIMENTAL|750 mg/day Mitoburn (L-BAIBA)|750 mg/day Mitoburn (L-BAIBA)
62797946|NCT05775016|EXPERIMENTAL|1,500 mg/day Mitoburn (L-BAIBA)|1,500 mg/day Mitoburn (L-BAIBA)
62797947|NCT03510442||adult-onset Still's disease (AOSD)|Composed of patients with known or suspected AOSD as defined by Yamaguchi criteria.
62797948|NCT03510442||family members|Composed of family members of patients with systemic juvenile idiopathic arthritis, adult-onset Still's disease and related conditions.
62797949|NCT03510442||healthy volunteers|Composed of healthy adults and children (above the age of 6 years) who volunteer to participate in this protocol.
62797950|NCT03510442||related inflammatory conditions|Composed of patients with suspected inflammatory disease as indicated by the presence of episodic fever and/ or arthritis.
62797951|NCT03510442||systemic juvenile idiopathic arthritis (sJIA)|Composed of patients with known or suspected sJIA as defined by the international league of Associations for Rheumatology (ILAR) criteria
62797952|NCT01126723|EXPERIMENTAL|Tai Chi group|
62797953|NCT01126723|ACTIVE_COMPARATOR|Educational Control group|
62797954|NCT05094648||group A|Covidpatient Who pass on high flow nasal therapy
62797955|NCT05094648||group B|Covidpatient who failed on high flow nasal therapy and need NIV
62797956|NCT04339621||Treatment Naive|20 patients with AIH will be recruited that will be treatment naive at the time of recruitment.
62797957|NCT04339621||Treatment cessation review|77 AIH patients will be recruited who will have been on treatment for the past 18-24 months and will be coming in to meet their physician to review treatment cessation options
62797958|NCT01135615|OTHER|Sevelamer|
62025287|NCT01420796|EXPERIMENTAL|Breathing exercises|Expiratory Muscle Training will be performed with Threshold® (Respironics HealthScan, Inc, Cedar Grove, Nova Iorque, EUA).
62222631|NCT02388685|NO_INTERVENTION|No exercise|Patients will continue with usual care
62222632|NCT02909530|ACTIVE_COMPARATOR|First pass EZ Shot 3Plus then EZ Shot 2|Olympus EZ Shot 3Plus will be used to puncture the mass first (Intervention EUS-FNB with EZ Shot 3Plus first), then the 19G and EZ Shot 2 will be used to puncture the pancreatic mass.
62222633|NCT02909530|ACTIVE_COMPARATOR|First pass EZ Shot 2 then EZ Shot 3Plus|Olympus EZ Shot 2 will be used to puncture the mass first (Intervention EUS-FNB with EZ Shot 2 19G first), then the EZ Shot 3Plus will be used to puncture the pancreatic mass.
62222634|NCT02703090|PLACEBO_COMPARATOR|Placebo|Normal saline infusion
62797959|NCT01135615|OTHER|calcium acetate|
62797960|NCT03093337|EXPERIMENTAL|Psychomotor therapy|Early post hospital discharge psychomotor therapy.
62797961|NCT03093337|NO_INTERVENTION|Control|No specific support.
62797962|NCT06540963|EXPERIMENTAL|HRNB Bone/Bone Marrow|Cycles 1-6: Tipifarnib and Naxitamab Tipifarnib: on days 1-7 and 15-21 of each 28-day cycle. Naxitamab IV on Days 1, 3, and 5 of each cycle.
62797963|NCT06540963|EXPERIMENTAL|HRNB All others|Cycles 1-6: Tipifarnib and Naxitamab Tipifarnib: on days 1-7 and 15-21 of each 28-day cycle. Naxitamab IV on Days 1, 3, and 5 of each cycle.
62797964|NCT02011100|EXPERIMENTAL|CARNOSINE|3 months oral carnosine administration in a dose of 2 gram per day, twice a day 1 gram dose (1-0-1)
62797965|NCT02011100|PLACEBO_COMPARATOR|placebo|3 months placebo intake - taken twice a day (1-0-1)
62797966|NCT03115762|EXPERIMENTAL|ASKB1202|Subject to receive one intravenous (i.v.) infusion of ASKB1202
62797967|NCT03115762|ACTIVE_COMPARATOR|bevacizumab A|Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in China
62797968|NCT03115762|ACTIVE_COMPARATOR|bevacizumab B|Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in Europe
62797969|NCT06264999|ACTIVE_COMPARATOR|Journey II CR|Implantation of Journey II CR sacrificing the anterior cruciate ligament.
62797970|NCT06264999|ACTIVE_COMPARATOR|Journey II XR|Implantation of Journey II XR retaining the anterior cruciate ligament.
62222635|NCT02703090|ACTIVE_COMPARATOR|Drug lower dose|Remifentanil infusion
62222636|NCT02703090|ACTIVE_COMPARATOR|Drug higher dose|Remifentanil infusion
62222637|NCT03999996|EXPERIMENTAL|Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)|TDV 0.5 mL, injection, subcutaneously, once at Month 15 for participants from parent trials DEN-304 (US) or once at Month 42 for participants from parent trial DEN-315 (Mexico).
62416725|NCT06652269||Experimental|Group with equine-assisted psychotherapy
62416726|NCT06652269||Control|Group with psychotherapy
62797971|NCT03554928||Cocaine Dependent|Individuals with cocaine dependence
62797972|NCT03554928||Not Cocaine Dependent|Individuals without cocaine dependence
62797973|NCT05947617|EXPERIMENTAL|Arm 1: Low Dose (1 ml) VIX001|Participants in this arm will receive intravenous injections of VIX001 at a low dose of 1 ml. The intervention involves the administration of VIX001 diluted in clinical standard saline.
62797974|NCT05947617|EXPERIMENTAL|Arm 2: Intermediate Dose (3 ml) VIX001|Participants in this arm will receive intravenous injections of VIX001 at an intermediate dose of 3 ml. The intervention entails the administration of VIX001 diluted in clinical standard saline.
62797975|NCT05947617|EXPERIMENTAL|Arm 3: High Dose (10 ml) VIX001|Participants in this arm will receive intravenous injections of VIX001 at a high dose of 10 ml. The intervention involves the administration of VIX001 diluted in clinical standard saline.
62797976|NCT01559272|EXPERIMENTAL|Panel A|Panel A consists of 2 treatment groups
62025288|NCT06110312|EXPERIMENTAL|intervention group|In EU NAVIGATE, participants in the intervention group will receive a navigation intervention (also called NavCare-EU), alongside any usual care. Navcare-EU is a person- and family-centered navigation intervention, aimed at supporting older people with cancer throughout the care and illness continuum, via the involvement of a patient/family navigator. Navigators focus on connecting clients to social supports, both formal and informal, advocating for clients in meeting their quality-of-life goals, resourcing by identifying needs and negotiating access to meeting those needs, and engaging clients in what is most meaningful to them. Navigators are selected, trained, and mentored volunteers or professionals. NavCare-EU is based on the existing and successfully tested Nav-CARE(c) intervention from Canada.
62025289|NCT06110312|NO_INTERVENTION|control group|Participants in the control group will receive what is usual care in each of the participating countries for 24 weeks (primary trial outcome). After 24 weeks, they will also receive the navigation intervention (NavCare-EU) (fast-track RCT).
62025290|NCT00768274|EXPERIMENTAL|Arm A|Low-dose apabetalone (RVX000222) or placebo
62797977|NCT01559272|EXPERIMENTAL|Panel B|Panel B consists of 5 treatment groups
62797978|NCT01559272|EXPERIMENTAL|Panel C|Panel C consists of 1 treatment group
62797979|NCT01559272|EXPERIMENTAL|Panel D|Panel D consists of 4 treatment groups
62797980|NCT06709898|EXPERIMENTAL|Cognitive job accommodation|"* In intervention neuropsychological information will be individually processed and transferred systematically from the neurological unit to occupational health service (OHS) to help design the individually tailored work modifications.~* Information of the job accommodation will be given to employers.~* Cognitive job accommodation is carried out at the workplace in cooperation between the employer, employee and OHS.~* Feedback of the cognitively challenging work traits will be given to participants after returning to work."
62797981|NCT06709898|NO_INTERVENTION|Reference group|Employees return to work according to standard health care and workplace procedures.
62025291|NCT00768274|EXPERIMENTAL|Arm B|apabetalone (RVX000222) Dose-escalation or placebo
62222638|NCT03999996|PLACEBO_COMPARATOR|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once at Month 15 for participants from parent trial DEN-304 (US) or once at Month 42 for participants from parent trial DEN-315 (Mexico).
62222639|NCT03239613|OTHER|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
62797982|NCT02058446|EXPERIMENTAL|Study group|Amlodipine/Valsartan Single-Pill Combination
62797983|NCT06525779|ACTIVE_COMPARATOR|Macintosh Laryngoscope Group|Patient undergoing intubation with direct laryngoscope using macintosh laryngoscope
62222640|NCT04275089|EXPERIMENTAL|Reia Vaginal Pessary|
62222641|NCT04280341|EXPERIMENTAL|RC48-ADC in combinaton with Anti-PD1 Monoclonal Antibody|RC48-ADC(Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate) JS001(Recombinant Humanized Anti-PD1 Monoclonal Antibody)
62222642|NCT04307251|EXPERIMENTAL|Navio™ Robotics-assisted Surgical System|
62416727|NCT00745680||A|A: AMI patient
62416728|NCT06494059|EXPERIMENTAL|Upper-limb (arms) target group|Quadriplegic individuals with SCI who are primary non-ambulatory (walking) will be in this group for up to 2 months.
62222643|NCT04307251|EXPERIMENTAL|Conventional, non-robotics-assisted total knee surgical system|
62797984|NCT06525779|ACTIVE_COMPARATOR|McGrath Laryngoscope Group|Patient undergoing intubation with video laryngoscope using mcGrath laryngoscope
62797985|NCT03981679|EXPERIMENTAL|Biological collection|"For all the patients include in the study :~- Blood samples collected before the colonoscopy In parallel to this biological collection, standardized clinical data will be entered into a database"
62797986|NCT06725628||LNM group and NLNM group|The primary objective of this study is to evaluate the accuracy of the ThyMPR-CLNM model in predicting central lymph node metastasis (CLNM) in patients with stage T1 papillary thyroid carcinoma (PTC).
62797987|NCT06725732|EXPERIMENTAL|Intravenous|
62797988|NCT06725732|EXPERIMENTAL|Nebulized|
62797989|NCT02278926||Patients ultrasound lypo-hypertrophy identification|Type 1 diabetes patients with visible lypo-hypertrphy attended in outpatient clinic
62222644|NCT01351831|EXPERIMENTAL|Rehabilitation with strength training|
62222645|NCT01351831|ACTIVE_COMPARATOR|Rehabilitation without strength training|
62222646|NCT04806542|EXPERIMENTAL|TMR-group|8-week program for schoolchildren called TMR (Training for Resilience and Mindfulness).
62222647|NCT04806542|ACTIVE_COMPARATOR|Treatment as Usual|Individual counselling.
62222648|NCT01248546||Digital mammography|
62416729|NCT06494059|EXPERIMENTAL|Lower-limb (legs) target group|Quadriplegic or paraplegic individuals with SCI primary who can walk will be in this group for up to 2 months.
62416730|NCT06494059|EXPERIMENTAL|Trunk (torso) target group|Quadriplegic or paraplegic individuals with SCI who are primary wheelchair users will be in this group for up to 2 months.
62416731|NCT06494059|ACTIVE_COMPARATOR|Able-bodied target group|Individuals with no spinal cord injury will be in this group for up to 2 months.
62416732|NCT00865306|EXPERIMENTAL|Active CBT|"Seven parent-only and 8-13 child-only sessions focusing on CBT for anxiety disorders using the Being Brave protocol."
62416733|NCT00865306|NO_INTERVENTION|No intervention (wait-list controls)|Control children received no intervention.
62797990|NCT02278926||Control group|Type 1 diabetes patients with visible lypo-hypertrphy attended in outpatient clinic
62797991|NCT02938208|EXPERIMENTAL|Jupiter Full Face Mask|Participants to use full face mask in-home for a 14 ± 3 days in-home.
62797992|NCT03273335||Surgical patients|Surgical patients will undergo CSF biomarker assays, cognitive testing and fMRI scans.
62222649|NCT06379464||Patients with acute ischaemic stroke|Patients who met the diagnostic criteria of the 2018 Chinese guidelines for the diagnosis and treatment of acute ischemic stroke.
62222650|NCT06379464||Depressed patients|Patients who met the depression related criteria in the Chinese classification and diagnostic criteria for mental disorders.
62797993|NCT05263414|ACTIVE_COMPARATOR|Active tVNS|In the active tVNS session, tVNS will be delivered via a programmable stimulation unit connected to two titan ear electrodes mounted on a gel frame. Active tVNS will be delivered over the cymba conchae of the left ear for a 70 minutes session. Stimulation intensity will be set at an intensity corresponding to individual sensitivity threshold. The intensity of the stimulation will be gradually increased in order to reach the intensity of stimulation with a ramping-up phase of 30 secs. During the stimulation, participants will perform the tasks. At the end of the stimulation session participants will be asked to report possible side effects occurring during tVNS and to rate their feeling on several visual analogue scales.
62222651|NCT03367650|OTHER|ALS's patients in Guadeloupe and Martinique|"We shall determine:~* Impact of ALS in Guadeloupe and Martinique~* Prevalence of the ALS in Guadeloupe and Martinique on the duration of the study~* The distribution of ALS various phenotypes in our population of patients.~* We shall collect the date of the beginning of the symptoms of the SLA, the date of diagnosis of ALS, the date of death for the same individual and the origin of the death, the weight, the size, the albumin, CRP; in order to establish the forecast of the various clinical forms, the description of the evolution of the nutritional state.~* Search for transfers of genes TARDBP, VCP, SOD1 known and involved in the disease~* Search for possible environmental factors"
62222652|NCT06463561|ACTIVE_COMPARATOR|Control group|Conventional hygienic-dietary recommendations and promotion of daily physical activity
62797994|NCT05263414|SHAM_COMPARATOR|Sham tVNS|In the sham tVNS session tVNS will be delivered via a programmable stimulation unit connected to two titan ear electrodes mounted on a gel frame. Sham tVNS will be delivered over the left lobe auricle area, which is free from cutaneous vagal innervation. It will last 70 minutes. Stimulation intensity will be set at the intensity corresponding to the individual sensitivity threshold, as it will be defined on the left ear lobe. The intensity of the stimulation will be gradually increased to reach the intensity of the stimulation with a ramping up phase of 30 secs. During the sham stimulation, the tasks will be performed. At the end of the stimulation session participants will be asked to report possible side effects occurring during tVNS and to rate their feeling on several visual analogue scales.
62222653|NCT06463561|EXPERIMENTAL|CPAP group|Conventional hygienic-dietary recommendations and promotion of daily physical activity, plus treatment with positive airway pressure (CPAP)
62416734|NCT02467972|EXPERIMENTAL|UBF group|Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
62416735|NCT02467972|PLACEBO_COMPARATOR|Control|Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
62797995|NCT03571555||Young people with perinatally acquired HIV|Residential interventions (camps) and community based support (clubs)
62797996|NCT03571555||Caregivers of young people with perinatally acquired HIV|Community based support (clubs)
62797997|NCT02351765|EXPERIMENTAL|Acelarin & Cisplatin|"The maximum tolerated dose (MTD) of Acelarin in combination with 25mg/m2 Cisplatin will be determined.~The starting dose will be 625mg/m2 Acelarin which will be escalated to 725mg/m2 if the criteria for dose escalation is met (i.e. the proportion of dose limiting toxicities is acceptable as detailed in the protocol). Escalation will continue in accordance with the protocol up to a maximum of 925mg/m2. Only if the MTD is exceeded at the starting dose level (at least 2 of 3 participants or at least 2 of 6 participants have DLT at the first dose level) will there be a de-escalation to 500mg."
62222654|NCT05963373||Chronic diseased attendants above 18years old|
62222655|NCT05963373||Healthy attendants|
62222656|NCT00520169|ACTIVE_COMPARATOR|A|oral ketamine
62222657|NCT00520169|EXPERIMENTAL|B|intranasal ketamine
62797998|NCT02386982|EXPERIMENTAL|HMS5552 dose 1|HMS5552 75mg.Oral administration,twice per day.
62222658|NCT00520169|ACTIVE_COMPARATOR|C|intravenous ketamine
62222659|NCT02283073||Idiopathic Parkinson's disease|Patient with clinical diagnosis of Idiopathic Parkinson's Disease according to Queen Square Brain Bank Criteria up to one year prior to enrollment in study.
62222660|NCT02283073||Differential Diagnosis Group|MSA, PSP, CBD, Lewy body dementia, Essential Tremor, and Healthy Controls
62222661|NCT00095498|EXPERIMENTAL|Denosumab 180 mg|Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
62222662|NCT00095498|EXPERIMENTAL|Denosumab 60 mg|Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
62416736|NCT02467972|EXPERIMENTAL|Inulin group|Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
62416737|NCT02467972|EXPERIMENTAL|Nisin group|Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
62222663|NCT00095498|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injections on Day 1 and at Month 6.
62222664|NCT03983629||CDA patients|
62222665|NCT05421507||Patients with head and neck tumors with local recurrence or metastasis|"The patients in the group were treated with routine clinical treatment: 3D-PCT combined with CT-guided I-125 seeds implantation in the treatment of head and neck malignant tumors.~The prescription dose is given 110-150Gy according to tumor pathological type, tumor volume, history of previous radiotherapy and different surrounding normal tissues according to experience and routine diagnosis and treatment."
62222666|NCT04533568|EXPERIMENTAL|ibuprofen|400mg intravenous ibuprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
62222667|NCT04533568|EXPERIMENTAL|dexketoprofen|50 mg intravenous dexketoprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
62222668|NCT03639467|EXPERIMENTAL|Anlotinib plus gemcitabine/cisplatin|"In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first."
62222669|NCT06255327|NO_INTERVENTION|Control group|The control group participants underwent evaluations on the first day after 10 hours following surgery and, on the day, they were discharged from the clinic, by using pulse oximetry, sphygmometer, spirometry tests, VAS, MBDS and activity and mobility promotion (AMP). Participants in the control group were not given any information or training before or after the operation, and they were on routine hospital care.
62222670|NCT06255327|EXPERIMENTAL|Experimental group|The participants in the experimental group underwent the application of I COUGH (Incentive spirometry, Coughing/Deep breathing, Oral care, Understanding (Education of patient and family), Getting out of bed, and raising the Head of the bed). The participants underwent evaluations on the first day after 10 hours following surgery and, on the day, they were discharged from the clinic. Including Pulse Oximetry, Sphygmometer, Spirometry Tests, VAS, MBDS, AMP.
62222671|NCT05614154|ACTIVE_COMPARATOR|Povidone-iodine Group|The care of patients with central venous catheters will be done with Povidone iodine as long as they stay in the intensive care unit
62222672|NCT05614154|EXPERIMENTAL|hypochlorous active substance|The care of patients with central venous catheters will be done with antiseptic with hypochlorous active substance as long as they stay in the intensive care unit.
62222673|NCT05621577|OTHER|mandibular advancing device|using mandibular advancement device for treatment of obstructive sleep apnea
62222674|NCT05166187|EXPERIMENTAL|Intervention|Patients randomized to the intervention arm will have a Best Practice Advisory (BPA) displayed as part of the discharge order workflow. This BPA requires clinicians to choose an option before completing the discharge documentation. Options include ordering one of the appropriate statins or documenting that the medication is contraindicated, the patient declined, or the patient does not meet criteria for a high-intensity statin.
62797999|NCT02386982|EXPERIMENTAL|HMS5552 dose 2|HMS5552 75mg.Oral administration,once per day.
62222675|NCT05166187|NO_INTERVENTION|Usual Care|Patients randomized to the usual care arm will have the identical set of windows displayed in the discharge workflow minus the BPA window.
62798000|NCT00679835|EXPERIMENTAL|Group 1|8 mg/kg over a one hour infusion
62798001|NCT00679835|EXPERIMENTAL|Group 2|10mg/kg over a one or two hour infusion
62798002|NCT06368791|EXPERIMENTAL|Box Breathing|In the intervention phase of the N-of-1 trial participants are instructed to perform box breathing intervention. During the control phase of the N-of-1 trial, participants are instructed to proceed with their daily activities as usual without engaging in the anti-stress intervention.
62416738|NCT06371079||Traditional OVD group|In this group of patients, the ICL was implanted utilizing both cohesive and dispersive ophthalmic viscosurgical device.
62798003|NCT06368791|EXPERIMENTAL|Breathing and Mindfulness Exercise|In the intervention phase of the N-of-1 trial participants are instructed to perform the guided breathing and mindfulness exercise. During the control phase of the N-of-1 trial, participants are instructed to proceed with their daily activities as usual without engaging in the anti-stress intervention.
62798004|NCT00797849|ACTIVE_COMPARATOR|1|Wear prosthetics laminated with Farabloc surrounding the liner. If not wearing prosthetics, subject needs to wear Farabloc sock or glove over shrinker.
62798005|NCT00797849|SHAM_COMPARATOR|2|Wear prosthetics laminated with sham material surrounding the liner. If not wearing prosthetics, subject needs to wear sock or glove over shrinker.
62798006|NCT02517541|EXPERIMENTAL|Test period|The arm consists of a two-week baseline period where subjects apply their own product and a 12 weeks test period where the subjects apply the intervention (SenSura Mio Convex Soft)
62798007|NCT01398371|ACTIVE_COMPARATOR|Stable digoxin therapy|Participants need to have been receiving digoxin therapy for at least 3 months at a dose that results in digoxin plasma levels of 0.4-0.8 on 2 consecutive blood tests (at least 1 weeks apart) prior to randomisation. The dose of digoxin must remain stable for at least 2 weeks prior to randomisation.
62798008|NCT01398371|EXPERIMENTAL|Digoxin withdrawal|Participants will receive a placebo for 4 weeks.
62222676|NCT00781287|EXPERIMENTAL|Raltegravir + 3-drug anti-HIV therapy|
62416739|NCT06371079||Reduced OVD group|In this group of patients, the ICL was implanted with the use of cohesive OVD only.
62798009|NCT04487314||Patients without Chronic Venous Disease|Individuals who do not have signs of chronic venous diseases of lower legs according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)
62798010|NCT04487314||Patients with Chronic Veinous Disease|Individuals who have signs of chronic venous diseases of lower legs according to CEAP classification (telangiectases, varicose veins, venous edema, skin hyperpigmentation, lipodermatosclerosis, venous ulcer).
62025292|NCT00768274|EXPERIMENTAL|Arm C|high-dose apabetalone (RVX000222) or placebo
62025293|NCT03906370||MS patients/cases|Patients admitted for diagnostic investigations to the MS clinic were offered participation if aged \>18 years and no previous use of immunosuppressing or modifying drugs within 6 months. The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
62798011|NCT04799249|EXPERIMENTAL|Trilaciclib + gemcitabine + carboplatin|Trilaciclib (240mg/m2) + gemcitabine (1000 mg/m2) and carboplatin (AUC 2)
62798012|NCT04799249|PLACEBO_COMPARATOR|Placebo + gemcitabine + carboplatin|The subjects in the placebo arm will follow the same schedule as the trilaciclib arm, but will receive placebo instead of trilaciclib.
62222677|NCT00781287|ACTIVE_COMPARATOR|3-drug anti-HIV therapy|
62222678|NCT00521066||1|Prosima Pelvic Floor Repair System
62222679|NCT03856554|EXPERIMENTAL|Patients indicated for TLIF|Patients with lumbar degenerative spondylolisthesis, indicated for TLIF surgery
62798013|NCT00187252|EXPERIMENTAL|1|CRT + AF Suppression turned ON
62798014|NCT00187252|ACTIVE_COMPARATOR|2|CRT + AF Suppression turned OFF
62798015|NCT05943886|EXPERIMENTAL|Single dose of 0.5 mg HEC88473|Healthy subjects, receiving a single dose of 0.5 mg HEC88473 (N=8) or placebo(N=2) after meal.
62798016|NCT05943886|EXPERIMENTAL|Single dose of 1.7 mg HEC88473|Healthy subjects, receiving a single dose of 1.7 mg HEC88473 (N=8) or placebo(N=2) after meal.
62798017|NCT05943886|EXPERIMENTAL|Single dose of 5.1 mg HEC88473|"Healthy subjects, receiving a single dose of 5.1 mg HEC88473 (N=8) or placebo(N=2) after meal.~Obese subjects, receiving a single dose of 5.1 mg HEC88473 (N=8) or placebo(N=2) after meal."
62798018|NCT05943886|EXPERIMENTAL|Single dose of 10.2 mg HEC88473|Healthy subjects, receiving a single dose of 10.2 mg HEC88473 (N=8) or placebo(N=2) after meal.
62798019|NCT05943886|EXPERIMENTAL|Single dose of 17.0 mg HEC88473|Healthy subjects, receiving a single dose of 17.0 mg HEC88473 (N=8) or placebo(N=2) after meal.
62798020|NCT05943886|EXPERIMENTAL|Single dose of 25.5 mg HEC88473|Healthy subjects, receiving a single dose of 25.5 mg HEC88473 (N=8) or placebo(N=2) after meal.
62798021|NCT05943886|EXPERIMENTAL|Single dose of 35.7 mg HEC88473|Healthy subjects, receiving a single dose of 35.7 mg HEC88473 (N=8) or placebo(N=2) after meal.
62798022|NCT05943886|EXPERIMENTAL|Single dose of 47.6 mg HEC88473|Healthy subjects, receiving a single dose of 47.6 mg HEC88473 (N=8) or placebo(N=2) after meal.
62798023|NCT05943886|EXPERIMENTAL|Single dose of 62.9 mg HEC88473|Healthy subjects, receiving a single dose of 62.9 mg HEC88473 (N=8) or placebo(N=2) after meal.
62798024|NCT05943886|EXPERIMENTAL|Single dose of 81.6 mg HEC88473|Healthy subjects, receiving a single dose of 81.6 mg HEC88473 (N=8) or placebo(N=2) after meal.
62798025|NCT05943886|EXPERIMENTAL|Multiple doses of 5.1 mg HEC88473|T2DM subjects, receiving a weekly dose of 5.1 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
62798026|NCT05943886|EXPERIMENTAL|Multiple doses of 15.3 mg HEC88473|T2DM subjects, receiving a weekly dose of 15.3 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
62798027|NCT05943886|EXPERIMENTAL|Multiple doses of 30.6 mg HEC88473|"T2DM subjects, receiving a weekly dose of HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.~The 30.6 mg cohort was administered by titration."
62798028|NCT05943886|EXPERIMENTAL|Multiple doses of 45.9 mg HEC88473|"T2DM subjects, receiving a weekly dose of HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.~The 45.9 mg cohort was administered by titration."
62222680|NCT01885754||Lung cancer patient with cachexia|Muscle lumbar area \< 55cm2/m2 for men and \< 39 cm2/m2 for women
62222681|NCT01885754||Lung cancer patients without cachexia|Muscle lumbar area over 55cm2/m2 for men and 39 cm2/m2 for women
62222682|NCT03786523|EXPERIMENTAL|TRF|Time Restricted Feeding
62798029|NCT05943886|EXPERIMENTAL|Multiple doses of 68.0 mg HEC88473|"T2DM subjects, receiving a weekly dose of HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.~The 68.0 mg cohort was administered by titration."
62798030|NCT06514781||Use cyclopofol group|Initially use propofol as the sedative medication, with a continuous usage duration of more than 48 hours.
62798031|NCT06514781||Control group|Initially use non-propofol sedative medications, with a continuous usage duration of more than 48 hours.
62798032|NCT03007914||TCM cohort|Patients continue to receive the routine TCM treatments recommended by 2011 Chinese treatment guidelines of TCM for COPD.
62798033|NCT03007914||Conventional medicine cohort|Patients continue to receive the conventional medicine recommended by 2014 GOLD and Chinese treatment guidelines for COPD.
62798034|NCT01459445|OTHER|Metformin+Drospirenone / EE 30µg|
62798035|NCT02665182|EXPERIMENTAL|Up-positioning of the testes|Patients receive standard medical therapy and supportive therapy
62798036|NCT02665182|NO_INTERVENTION|Medical therapy only|Patients receive standard medical therapy only
62222683|NCT03786523|ACTIVE_COMPARATOR|CER|Continuous Energy Restriction
62222684|NCT04665570||Treatment|The decision to prescribe Acarbose/Metformin fixed dose combination (FDC) will be solely at the discretion of the Investigator and in accordance with his/her experience. Patients can only be enrolled in the study if the decision to treat with Acarbose/Metformin fixed dose combination has been made by the treating physician in advance and independent of study inclusion.
62222685|NCT03193359|EXPERIMENTAL|BOTOX®|BOTOX® (botulinum toxin Type A) 155U to 195U intramuscular (IM) injections to head/neck areas at Day 0 and Week 12.
62798037|NCT01361646|EXPERIMENTAL|LC350189|
62798038|NCT01361646|ACTIVE_COMPARATOR|Febuxostat|
62798039|NCT01361646|PLACEBO_COMPARATOR|Placebo|
62798040|NCT01748838|EXPERIMENTAL|Part 1: CTX-4430|
62798041|NCT01748838|PLACEBO_COMPARATOR|Part 1: Placebo + Mannitol|
62798042|NCT01748838|EXPERIMENTAL|Part 2: CTX-4430|
62798043|NCT01748838|PLACEBO_COMPARATOR|Part 2: Placebo + Mannitol|
62798044|NCT03166241|EXPERIMENTAL|study group|measure serum interleukin 21 level in patients with severe adverse drug reaction who show change in serum interleukin 21 before and after therapy the following investigation will be done at the begning of the study to patients: Complete Blood Picture Erythrocyte Sedimentation Rate Random blood sugar Liver function tests Kidney function tests
62222686|NCT04140019||NSTEMI|
62798045|NCT03166241|PLACEBO_COMPARATOR|control group|compare serum interleukin 21 level in patients with severe adverse drug reaction and healthy control subjects
62798046|NCT03221686|PLACEBO_COMPARATOR|Control|Total daily protein intake: 1.5 g protein/kg body weight
62798047|NCT03221686|ACTIVE_COMPARATOR|Intervention|55 mg zinc/day, 1251 mg vitamin C/day, and 15 g arginine/day. Total daily protein intake: 1.5 g protein/kg body weight
62798048|NCT04892082|EXPERIMENTAL|Mindful Moment|Mothers who present parenting stress equal or above 41 score on PSS will receive a web-based intervention to reduce parenting stress (the Mindful Moment program).
62798049|NCT04892082|ACTIVE_COMPARATOR|Control|All mothers who present parenting stress will have access to Mindful Moment intervention. The control group only receive the intervention at the end of the intervention group.
62798050|NCT06725641|EXPERIMENTAL|Test preparation：Methylcholine chloroacetate for inhalation|Inhale different concentrations of choline chloride solution
62798051|NCT06725641|ACTIVE_COMPARATOR|Reference preparation：Methylcholine chloroacetate for inhalation（Provocholine）|Inhale different concentrations of choline chloride solution
62798052|NCT01727596|EXPERIMENTAL|1|
62798053|NCT05066165|EXPERIMENTAL|Arm 1: NTLA-5001|Up to three escalation cohorts in phase 1 followed by one expansion cohort in phase 2. Subjects have AML and bone marrow blast count \<5%, administered by IV infusion following lymphodepleting chemotherapy.
62588334|NCT05903053|EXPERIMENTAL|Telehealth Intervention|"A multiple baseline design across subjects will be used with varying introduction of treatment elements. Baseline periods will be 3, 5, and 7 sessions with the baseline period of 3 and 5 sessions repeated twice for subsequent participants. An intense intervention phase will follow the baseline phase in which 45-60 minute treatment sessions will occur twice per week over the course of 4-6 weeks for a total of 8 sessions. Each week during the intense intervention phase, caregiver coaches will introduce a new treatment technique to the caregiver and allow for caregiver practice with immediate feedback. At the conclusion of the intense intervention phase, coaches will provide booster sessions with the caregivers once weekly for 1 month (4 sessions total)."
62588335|NCT04581109|EXPERIMENTAL|Patients with metastatic prostate cancer|
62588336|NCT04228146|EXPERIMENTAL|CBT-I condition|Participants in the CBT-I condition start the 6-week CBT-I immediately after randomization, complete the post-intervention assessment right after they finish the treatment, and complete the follow-up assessment six weeks after the post-intervention assessment.
62588337|NCT04228146|OTHER|Waitlist control condition|Participants in the waitlist control group complete the post-intervention assessment six weeks after the baseline assessment, start CBT-I (equivalent to that of the CBT-I group) immediately after completing the post-intervention assessment, and complete the follow-up assessment right after they finish the 6-week CBT-I.
62588338|NCT04743583||Endosonography group|Patients with known or suspected lung cancer or intrathoracic malignancy with indication to endosonography for diagnosis or staging of intrathoracic lymph nodes according to currently accepted international guidelines
62025294|NCT03906370||Healthy subjects/controls|Patients admitted for diagnostic investigations to the MS clinic were offered participation if aged \>18 years and no previous use of immunosuppressing or modifying drugs within 6 months. The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
62025295|NCT00990223|EXPERIMENTAL|Cohort 1|Healthy Volunteers - eplerenone versus placebo.
62025296|NCT03647501|ACTIVE_COMPARATOR|3D-printed titanium cage|Subjects enrolled in this arm will have the Nexxt Spine Nexxt MatrixxTM 3D-printed titanium cage (interbody cage) implanted at each level of 1 or 2-level lumbar arthrodesis procedures. All constructs will be supplemented with a pedicle screw system (Depuy Synthes Expedium) cleared for lumbar spinal fusion.
62025297|NCT03647501|ACTIVE_COMPARATOR|Poly-ether-ether-ketone (PEEK) cage|Subjects enrolled in this arm will have the HonourTM poly-ether-ether-ketone (PEEK) cage (interbody cage) implanted at each level of 1 or 2-level lumbar arthrodesis procedures. All constructs will be supplemented with a pedicle screw system (Depuy Synthes Expedium) cleared for lumbar spinal fusion.
62222687|NCT03447808|EXPERIMENTAL|Treatment (daratumumab, ibrutinib)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Beginning course 2, patients also receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62222688|NCT02337751|EXPERIMENTAL|TVP-1012 1mg Group|TVP-1012 (1 mg/day) once daily, either before or after breakfast.
62222689|NCT03857620|ACTIVE_COMPARATOR|Arm I (usual care)|Healthcare providers/institutions perform usual care.
62222690|NCT03857620|EXPERIMENTAL|Arm II (OPTI-Surg training and materials)|Healthcare providers/institutions receive OPTI-Surg training and informational materials.
62798054|NCT05066165|EXPERIMENTAL|Arm 2: NTLA-5001|Up to three escalation cohorts in phase 1 followed by one expansion cohort in phase 2. Subjects have AML and bone marrow blast count ≥5%, administered by IV infusion following lymphodepleting chemotherapy.
62025298|NCT04148443|EXPERIMENTAL|3 minutes period of preoxygenation|3 minutes of preoxygenation : participants in this group will receive 3 minutes of preoxygenation before intubation
62222691|NCT03857620|EXPERIMENTAL|Arm III (OPTI-Surg training and materials, coach)|Healthcare providers/institutions receive OPTI-Surg training and informational materials and meet with a coach.
62222692|NCT03451617|OTHER|Xpedition stent delivery system|
62798055|NCT02801565|EXPERIMENTAL|GH AQ|Controlled ovarian stimulation in the middle of the corpus (D21 days) of the previous menstrual cycle to use recombinant Human Growth Hormone Injection（rhGH） Injection 15IU/5mg/3mL/cartridge, 5IU per day, Subcutaneous injection after 20:00 until the HCG trigger day.
62222693|NCT03451617|OTHER|Alpine stent delivery system|
62222694|NCT05381610|EXPERIMENTAL|Neurogenic Bowel|This is a US-Only, early feasibility, Investigational Device Exemption - Non-Significant Risk (IDE-NSR), single-center, open label study evaluating the effects of Peristeen, compared to a LVE administered into the rectum. The subjects to be analysed will be subjects with : Neurogenic Bowel Dysfunction (NBD). The NBD cohort will be broken down into two phases: LVE and Peristeen. See Statistical section 10 for more infor-mation on cohort and sub-group analyses.
62222695|NCT05782023|EXPERIMENTAL|Digital empowerment|Usual-care + preventive intervention through digital empowerment
62798056|NCT06346574|EXPERIMENTAL|Experimental: Intervention Group|"Behavioral:~1. Access to health and wellness App from baseline to nine months.~2. Access to Guides from baseline to six months"
62798057|NCT06346574|ACTIVE_COMPARATOR|Delayed Intervention|"Behavioral:~1. No access to health and wellness App from baseline to six months~2. Access to App and Guide from six to nine months"
62798058|NCT04950465|EXPERIMENTAL|Test Dentifrice|Apply a full ribbon of toothpaste on the head of the toothbrush provided. Brush teeth for 1\*-timed minute, followed by brushing of the qualifying sensitive teeth. Following brushing rinse once with 10 milliliter (ml) of water from the rinsing cup provided.
62798059|NCT04950465|ACTIVE_COMPARATOR|Negative Control|Apply a full ribbon of toothpaste on the head of the toothbrush provided; brush teeth for 1\* timed minute. Following brushing rinse once with 10 ml of water from the rinsing cup provided.
62025299|NCT04148443|EXPERIMENTAL|5 minutes period of preoxygenation|5 minutes of preoxygenation: participants in this group will receive 5 minutes of preoxygenation before intubation
62222696|NCT05782023|NO_INTERVENTION|Usual care|Usual-care (cardiologist visit at 1, 3 and 12 months after AMI)
62222697|NCT04634929||bariatric surgery participants|participants with obesity planning to undergo bariatric surgery
62588339|NCT05413564|OTHER|optimized self-exclusion procedure A|optimized self-exclusion procedure by extending the suspension of commercial solicitations for a total of 9 months
62798060|NCT04950465|ACTIVE_COMPARATOR|Positive Control|Apply a full ribbon of toothpaste on the head of the toothbrush provided; brush teeth for 1\* timed minute. Following brushing rinse once with 10 ml of water from the rinsing cup provided.
62798061|NCT05184517|EXPERIMENTAL|Arm I|Oph1 0.5% CsA ophthalmic formulation followed by Restasis 0.05% CsA ophthalmic formulation
62798062|NCT05184517|EXPERIMENTAL|Arm II|Restasis 0.05% CsA ophthalmic formulation followed by Oph1 0.5% CsA ophthalmic formulation
62798063|NCT05864144|EXPERIMENTAL|Part A - SNS-101 Monotherapy Dose Escalation and Dose Expansion|SNS-101 IV alone every 21 days. Patients will initially enroll in dose escalation cohorts.
62798064|NCT05864144|EXPERIMENTAL|Part B - SNS-101 in combination with cemiplimab and Dose Expansion|SNS-101 IV and cemiplimab IV every 21 days. Patients will initially enroll in dose escalation cohorts.
62798065|NCT05864144|EXPERIMENTAL|Part C - Cohort Expansion - SNS-101 alone or in combination with cemiplimab|SNS-101 IV alone or in combination with cemplimab IV every 21 days at the RP2D.
62798066|NCT04775953|EXPERIMENTAL|Arm 1 (Dalbavancin)|Dalbavancin 1500 mg will be administrated intravenously (IV) over 30 (-/+10) minutes on Day 1 and 1500 mg IV over 30 (-/+10) minutes on Day 8, renally dose-adjusted to 1125 mg for subjects with Creatinine Clearance (CrCl) \<30 and not on dialysis. N=100
62798067|NCT04775953|ACTIVE_COMPARATOR|Arm 2 (Standard of Care)|For Methicillin-sensitive Staphylococcus aureus (MSSA): nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks) OR oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks OR cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks) For Methicillin-resistant Staphylococcus aureus (MRSA): vancomycin (dose per local standard of care × 4-6 weeks) OR daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks). N=100
62798068|NCT00587678|EXPERIMENTAL|Randomized|Patients are imaged at baseline and randomized to Simvistatin 40 mg each night or Simvistatin 40mg/Zetia 10mg each night for 2 years
62798069|NCT00587678|EXPERIMENTAL|Ezetemibe|Patients are imaged at baseline and treated with ezetimibe 10mg each night for 2 years.
62798070|NCT00061893|EXPERIMENTAL|Combination chemotherapy|Metastatic Ewing Sarcoma - 14-cycle study building on conventional tx (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, ifosfamide, etoposide) and adding two antiangiogenic agents: the vinca alkaloid vinblastine and the cyclooxygenase-2 inhibitor celecoxib. Refer to the Interventions section for dosages, method of delivery and frequency of administration.
62798071|NCT04653285|EXPERIMENTAL|motor skill practice + aerobic exercise|bout of aerobic exercise following motor skill practice
62798072|NCT04653285|ACTIVE_COMPARATOR|motor skill practice + rest|seated rest following motor skill practice
62798073|NCT06343727|EXPERIMENTAL|Egg white protein pudding|Participants will receive egg white pudding at the end of their dialysis treatments 3-days per week.
62025300|NCT01242475|EXPERIMENTAL|0.1µg/0.1 mL C-Tb|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
62798074|NCT06343727|ACTIVE_COMPARATOR|: Standard dietary supplement|Participants will receive Ensure Plus at the end of their dialysis treatments 3-days per week.
62798075|NCT01789684|EXPERIMENTAL|Active Provider Intervention|Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve 1) appropriate referral of breast cancer patients at risk for HBOC to genetic counseling in the community cancer center setting and 2) pre-surgical referral among newly diagnosed patients. They will also receive the National Comprehensive Cancer Network (NCCN) guidelines and Commission on Cancer definition of qualified genetics professional.
62222698|NCT04634929||conservative diet participants|participants with obesity planning to controlled conservative behavioral weight loss program
62222699|NCT04496531|EXPERIMENTAL|Active|Active group members use a device providing perceivable electrical stimulation
62222700|NCT04496531|SHAM_COMPARATOR|Sham|Group members use a device providing a non-perceivable stimulus
62222701|NCT01465529|EXPERIMENTAL|Active|
62222702|NCT01465529|PLACEBO_COMPARATOR|Placebo|
62222703|NCT03471156||Post EMR|Patients are observed post EMR procedure for pain. Standard of care data is collected
62222704|NCT03970070|EXPERIMENTAL|Health service research (Periop-OSMT)|Patients and/or support persons/family caregivers complete Periop-OSMT session in-person or via telephone over 20-40 minutes before surgery and before hospital discharge and group telehealth session over 1.5-2 hours at weeks 1-3, 4, 5, 6, and 7 post discharge
62798076|NCT01789684|NO_INTERVENTION|Passive Provider Intervention|Participating Sites assigned to the passive intervention cluster will only receive the National Comprehensive Cancer Network (NCCN) guidelines and Commission on Cancer definition of qualified genetics professional.
62222705|NCT01315353|EXPERIMENTAL|Arm A: Immediate cryotherapy (HPV test-and-treat)|Participants in Arm A (HPV test-and-treat) had cervical cryotherapy at entry. Post entry, participants in Arm A were seen at regular intervals for the collection of cervical specimens, cytology, and as needed, cervical colposcopy, directed biopsies, and LEEP.
62222706|NCT01315353|EXPERIMENTAL|Arm B: cytology-based strategy|Participants in Arm B followed a cytology-based management plan involving three steps- cytology, colposcopy with directed biopsies, and LEEP (as needed).
62416740|NCT04518475|EXPERIMENTAL|efficacy of eltrombopag combining rituximab|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L.~All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
62798077|NCT02466984|EXPERIMENTAL|metoclopramide subcutaneous|every two days, first from 10 to 20 and then from 20 to 30 mg/d
62798078|NCT02466984|ACTIVE_COMPARATOR|metoclopramide intravenous|first from 10 to 20 and then from 20 to 30 mg/d
62798079|NCT06170853|EXPERIMENTAL|Augmented reality glasses group|Three days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
62798080|NCT06170853|NO_INTERVENTION|Control group|No intervention/application will be made to the children who will be included in the control group.
62798081|NCT01054482|EXPERIMENTAL|Pre-operative chemotherapy|Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op \& Post-Op (total 4 cycles)
62798082|NCT01054482|ACTIVE_COMPARATOR|Pre-operative concurrent chemoradiation therapy|
62798083|NCT03650088|EXPERIMENTAL|Weight Loss Intervention|Behavioral weight loss program with digital tools including smartphone app for dietary self-monitoring using a 'traffic light' approach, physical activity tracker, smart scale, and blood glucose monitoring plus with weekly consultation (in person or phone) with an interventionist for behavioral lessons and supports.
62798084|NCT04555564|EXPERIMENTAL|Technicium 99 MAA|Participants will receive bronchial artery administration of Technicium 99 MAA
62798085|NCT00984308|EXPERIMENTAL|Intervention|The intervention group received unattended polysomnography and auto-titrating CPAP if sleep apnea was diagnosed
62798086|NCT00984308|OTHER|Control|The control group received usual clinical care which may include receipt of sleep diagnostic and therapeutic services
62798087|NCT00557999|OTHER|Experimental group|Application of a weaning mechanical ventilation protocol
62416741|NCT04518475|ACTIVE_COMPARATOR|efficacy of eltrombopag|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
62416742|NCT03943199|ACTIVE_COMPARATOR|Metamizole sodium|1 gram intravenous, will be diluted in 0.9% physiological solution of 100 ml, applied for 30 minutes
62798088|NCT00557999|NO_INTERVENTION|Control group|
62798089|NCT04120415|EXPERIMENTAL|Vaccine and Vedolizumab infusion|"Vaccine:~The vaccine is MVA HIV-B which is a solution of HIV MVA vectors in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml)."
62798090|NCT04120415|EXPERIMENTAL|Placebo vaccine and Vedolizumab infusion|"Placebo vaccine:~The placebo for MVA HIV-B to be used in this trial is a solution composed of S08 buffer (as for the MVA vaccine).~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml)"
62798091|NCT04120415|PLACEBO_COMPARATOR|Placebo vaccine and placebo infusion|"Placebo vaccine:~The placebo for MVA HIV-B to be used in this trial is a solution composed of S08 buffer (as for the MVA vaccine).~Placebo infusion:~Sodium Chloride (NaCl) 0.9% administered as an intravenous infusion (255ml)"
62798092|NCT05959460||1|This is an observation study to determine exclusive breastfeeding practice. Mother-child pairs were enrolled at 3 months ± 7d and were followed-up at 6 months ± 7d. Questionnaire was administered. Then, baseline saliva samples were collected and deuterium oxide dose was administered. Then, post-dose saliva samples were collected.
62798093|NCT02737579|OTHER|XFM guidance|X-ray fused cardiac MRI images used for guidance tool to perform cardiac catheterization procedure
62798094|NCT00836992||Control|Patient's QOL assessments data is not shared with the physician, nurse, and/or nurse practitioner and the patient
62798095|NCT00836992||Active|Patient's QOL assessments data is shared with the physician, nurse, and/or nurse practitioner and the patient immediately prior to the on-treatment visit.
62416743|NCT03943199|ACTIVE_COMPARATOR|Ketorolac|60 milligrams intravenously, it will be added to 20 ml with 0.9% physiological solution, it will be applied for 5 minutes
62798096|NCT02421796||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
62798097|NCT02421796||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group.
62798098|NCT02421796||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group.
62798099|NCT00286494|ACTIVE_COMPARATOR|Placebo|
62798100|NCT00286494|EXPERIMENTAL|Alogliptin 12.5 mg QD|
62798101|NCT00286494|EXPERIMENTAL|Alogliptin 25 mg QD|
62798102|NCT03679728||First trimester|Group of children from mother affected by Zika virus in the first trimester of pregnancy.
62798103|NCT03679728||Second trimester|Group of Children from mother affected by Zika virus in the second trimester of pregnancy.
62798104|NCT02650089|EXPERIMENTAL|Resistance Exercise Low intensity|The 40% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
62798105|NCT02650089|EXPERIMENTAL|Resistance Exercise High intensity|The 80% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 8 repetitions were performed for each exercise, with an interval of 90 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
62798106|NCT02650089|OTHER|Control|In the control session, the participants remained seated in a comfortable chair in the same environment of the resistance exercise sessions.
62798107|NCT04557540|EXPERIMENTAL|Arm I (Fasting WORD)|Participants receive the Fasting WORD intermittent fasting weight loss intervention consisting of 16 small-group lessons over 1.5 hours each QW for 2 months and then Q2W for 4 months.
62798108|NCT04557540|EXPERIMENTAL|Arm II (The WORD)|Participants receive The WORD CER weight loss intervention consisting of 16 small-group lessons over 1.5 hours each QW for 2 months and then Q2W for 4 months.
62798109|NCT04991675|ACTIVE_COMPARATOR|pelvic floor muscle exercises|Exercises were taught in the supine position, as described by Kegel (1948), and it was confirmed that the women learned to use the correct muscles with vaginal palpation. During the exercise, the participants were informed not to pull the abdomen inwards, not to tighten their legs and hip muscles, and not move their pelvis.
62798110|NCT04991675|ACTIVE_COMPARATOR|diaphragmatic breathing exercises|Diaphragmatic breathing exercise was taught in supine position. The movement of the symphysis pubis was examined to confirm that the pelvic floors' movement was also involved breathing. Abdominal palpation was used to elicit unawareness of the diaphragmatic breathing and to assess whether contractions were performed correctly.
62798111|NCT03288571|EXPERIMENTAL|Wharton Jelly Mesenchymal stem cells|"Intervention: Wharton Jelly Mesenchymal stem cells Site: Renal parenchyma Route of administration: ultrasound guided- intra-parenchymal total of 3 sites in each kidney.~Number of doses: 3 doses 2 weeks apart for each kidney. Time interval between each dose: 2 weeks Total volume of cell suspension infused: 3 ml/kidney; each site will receive a 1 ml cell suspension with a total volume of 3 ml in each kidney."
62798112|NCT06530212|EXPERIMENTAL|SGJIB|
62798113|NCT06530212|ACTIVE_COMPARATOR|SAS-JB|
62416744|NCT03943199|ACTIVE_COMPARATOR|Lysine Clonixinate|100 milligram intravenously, diluted in 5% glucose solution of 100 ml, applied for 30 minutes
62025301|NCT01242475|ACTIVE_COMPARATOR|2TU Tuberculin PPD RT 23 SSI|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
62416745|NCT03943199|PLACEBO_COMPARATOR|Placebo|20 milliliters of 0.9% physiological solution, will be applied for 5 minutes.
62416746|NCT02549885|EXPERIMENTAL|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
62416747|NCT02549885|EXPERIMENTAL|Static stretching|Static stretching of neck muscles.
62416748|NCT00122148|OTHER|1|
62416749|NCT06476171|EXPERIMENTAL|Control Group|A group of patients whose postoperative period proceeded without complications, in connection with which they were transferred to the specialized department within 1-2 days.
62416750|NCT06476171|EXPERIMENTAL|Group of patients with complications|Patients who had postoperative complications: pneumonia, wound infection, sepsis, multiple organ dysfunction.
62798114|NCT01233063|EXPERIMENTAL|Alive2|Lifestyle Intervention delivered via email and web
62798115|NCT01233063|EXPERIMENTAL|Alive2 plus automated phone/print|All of Arm 1 components, plus biweekly tailored automated phone coaching plus monthly tailored automated print materials.
62798116|NCT01233063|PLACEBO_COMPARATOR|Control|Monthly emailed newsletter on other aspects of wellness, excluding diet and physical activity
62798117|NCT04192955|ACTIVE_COMPARATOR|Active|Acetylsalicylic acid (ASA) will be given orally at a dose of 324 mg to be taken daily starting 3 days prior to the planned coiling procedure day, on the procedure day, and for one-day post-procedure.
62798118|NCT04192955|PLACEBO_COMPARATOR|Control|Lactose100-mg tablets to be taken daily starting 3 days prior to the planned coiling procedure day, on the procedure day, and for one-day post-procedure.
62798119|NCT04626375|PLACEBO_COMPARATOR|Placebo|Placebo (2 vials per os without active substance every 12 hours)
62798120|NCT04626375|ACTIVE_COMPARATOR|Bioarginine|Bioarginine (2 vials per os of 1.66 g every 12 hours)
62798121|NCT02756572|EXPERIMENTAL|Treatment (chemotherapy, HCT)|See Detailed Description
62798122|NCT01120106|ACTIVE_COMPARATOR|levosimendan|levosimendan continuous infusion at a rate of 0.1 mcg/kg\<min
62798123|NCT01120106|PLACEBO_COMPARATOR|placebo|saline infusion
62798124|NCT05154110|EXPERIMENTAL|strength training group|the group will receive strength training
62798125|NCT05154110|EXPERIMENTAL|whole body vibration stretching group|the group will receive stretching on whole-body vibration
62798126|NCT04459377|PLACEBO_COMPARATOR|Placebo|Sodium Chloride solution (9mg / ml) 0.2ml / kg slow intravenous injection (2ml / min).
62798127|NCT04459377|ACTIVE_COMPARATOR|K1|S-Ketamine (0.125 mg / kg body weight). (0.625mg / ml x 0.2ml / kg) slow intravenous injection (2ml / min).
62798128|NCT04459377|ACTIVE_COMPARATOR|K2|S-Ketamine (0.25 mg / kg body weight). (1.25mg / ml x 0.2ml / kg) slow intravenous injection (2ml / min).
62798129|NCT04037865|EXPERIMENTAL|PF-06651600 Severe Renal Impairment|This arm includes participants with severe renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
62798130|NCT04037865|EXPERIMENTAL|PF-06651600 Normal Renal Function|This arm includes participants with normal renal function who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
62798131|NCT04037865|EXPERIMENTAL|PF-06651600 Moderate Renal Impairment|This arm is in Part 2 which will be conducted if decision criterion to proceed to Part 2 is met. This arm includes participants with moderate renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
62798132|NCT04037865|EXPERIMENTAL|PF-06651600 Mild Renal Impairment|This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met. The arm includes participants with mild renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10.
62416751|NCT06065514||Patients Group|The study plans to include 120 consecutive patients above 18 years old presenting with STEMI, NSTEMI, or UA and referred for coronary angiography.
62798133|NCT00786318|EXPERIMENTAL|ziprasidone|
62798134|NCT00786318|ACTIVE_COMPARATOR|Standard therapy|
62798135|NCT04274868||Children and adolescents with liver tumor|Patients treated after 01/01/1990 for a primary liver tumor before the age of 18.
62025302|NCT03866993|EXPERIMENTAL|AK105 plus Carboplatin and Paclitaxel|Subjects receive AK105 200 mg intravenously (IV) plus Paclitaxel 175mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV Q3W until progression.
62588340|NCT05413564|OTHER|standard procedure|standard self-exclusion procedure B
62798136|NCT03741504|NO_INTERVENTION|No micro-osteoperforations (No MOPs)|Canine Distalization without micro-osteoperforations Distalization of the upper canine in working phase with coil spring of 100 gr of force
62798137|NCT03741504|EXPERIMENTAL|Micro-osteoperforations (MOPs)|Canine Distalization with micro-osteoperforations at the start of the distalization Distalization of the upper canine in working phase with coil spring of 100 gr of force
62798138|NCT03425825||LD-SCLC receiving 1st line treatment|patients with LD-SCLC receiving first-line treatment, including potential maintenance treatment
62798139|NCT03425825||ED-SCLC receiving 1st line treatment|patients with ED-SCLC receiving first-line treatment, including potential maintenance treatment
62798140|NCT03425825||relapsed/refractory receiving 2nd or later-line treatment|relapsed/refractory patients receiving second- or later-line treatment
62798141|NCT00592124|EXPERIMENTAL|1|Oral tenofovir disoproxil fumarate (TDF) for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
62798142|NCT00592124|EXPERIMENTAL|2|Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
62798143|NCT00592124|EXPERIMENTAL|3|Oral TDF and vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and vaginal tenofovir gel application for Weeks 15 through 20
62798144|NCT00592124|EXPERIMENTAL|4|Oral TDF and vaginal tenofovir gel application for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF for Weeks 15 through 20
62798145|NCT00592124|EXPERIMENTAL|5|Oral TDF for Weeks 1 through 6, oral TDF and vaginal tenofovir gel application for Weeks 8 through 13, and vaginal tenofovir gel application for Weeks 15 through 20
62798146|NCT00592124|EXPERIMENTAL|6|Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF and vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF for Weeks 15 through 20
62798147|NCT05607524|EXPERIMENTAL|Probiotics|Probiotic capsules, 500 mg each, two daily for a total of 1000 mg for 4 weeks
62798148|NCT05607524|PLACEBO_COMPARATOR|Placebo|The placebo capsules had the same composition as the experimental capsules, except that they did not contain probiotics, and should be used for 4 weeks.
62798149|NCT02588235|EXPERIMENTAL|Ezetimibe and Atorvastatin Therapy|Atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
62798150|NCT02588235|ACTIVE_COMPARATOR|Atorvastatin Therapy|Atorvastatin (20 mg/day）
62798151|NCT01640782|EXPERIMENTAL|Sequential regimen|Sequential treatment with CPT-11 plus Fluorouracil (FU), folinic acid (LV) and Docetaxel (TXT) plus Cisplatin (CDDP)
62798152|NCT01640782|ACTIVE_COMPARATOR|De Gramont regimen|Fluorouracil (5-FU), folinic acid (LV)
62798153|NCT02328248|EXPERIMENTAL|Biological patch|Use biological patch (Biodesign Surgisis Tissue Graft from Cook Biotech Incorporated) to repair hiatal hernia laparoscopically
62798154|NCT02328248|PLACEBO_COMPARATOR|Plastic patch|Use plastic patch (Parietex Composite from Sofradim Production) to repair hiatal hernia laparoscopically
62798155|NCT06312735|EXPERIMENTAL|Intervention group|Four-week, at-home VR intervention with a recommended daily use of 10-30 minutes
62798156|NCT06312735|NO_INTERVENTION|Control group|No intervention, patient is a waiting-list control
62222707|NCT01315353|EXPERIMENTAL|Arm C : Ineligible for randomization to Arm A or B|Participants were eligible for Arm C under the conditions noted in the inclusion criteria. Participants in Arm C had colposcopy and directed biopsies at entry. If CIN2+ was found by biopsy, then LEEP was performed and a follow-up visit 26 weeks after these procedures was scheduled for the collection of cervical specimens, cytology, and as needed, cervical colposcopy, directed biopsies, and LEEP. After the week 26 visit, Arm C participants went off study.
62222708|NCT05830045|EXPERIMENTAL|Ia： QLP2117 Dose escalation and PK expansion|
62222709|NCT05830045|EXPERIMENTAL|Ib：QLP2117 Dose expansion|
62222710|NCT03736473|OTHER|MEDI9447 monotherapy|Dose escalation of MEDI9447 monotherapy for patients with advanced solid malignancies
62222711|NCT01685671|ACTIVE_COMPARATOR|NESP 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
62222712|NCT01685671|EXPERIMENTAL|CKD-11101 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
62416752|NCT06065514||Control Group|60 patients will consist of the control group. The patient and control group will be matched at baseline by equating certain clinical characteristics of interest between the exposed and unexposed groups. The control group will consist of individuals to whom the obstructive coronary artery disease would be ruled out either by invasive or non-invasive coronary angiography or by myocardium perfusion SPECT or stress echocardiography.
62416753|NCT06113783|EXPERIMENTAL|Group 1- ACTIVE|Intra-articular injection at baseline of HYALUBRIX 60® plus PEP 3 times a week at home for the 12 months of observation;
62588341|NCT03583541|EXPERIMENTAL|Control arm: Bolstered treatment|Women in the control condition (and in the treatment arms) will receive treatment as usual (TAU) for FSW in the study area. Provided by RHSP, TAU includes: health education, HIV testing services, STI screening and treatment in a session that lasts about 2 hours, provided on a quarterly basis. This will be bolstered with 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention
62798157|NCT04538976|NO_INTERVENTION|Control|Patients in the control group will receive standard care.
62798158|NCT04538976|ACTIVE_COMPARATOR|Sildenafil|Patients in the Sildenafil group will receive standard care and targeted Sildenafil-treatment.
62798159|NCT03444493|EXPERIMENTAL|Exercise|The exercise group performed specific localized exercises aimed at restoring the stabilizing protective function of the transversus abdominis (TrA). The exercises were designed specifically to activate and train the isometric holding function of the TrA muscle at the affected vertebral segment. Additionally, the exercise group was informed about protecting for biomechanics of lumbar spine.
62798160|NCT03444493|NO_INTERVENTION|Control|Control group was informed about protecting for biomechanics of lumbar spine.
62798161|NCT01262859|EXPERIMENTAL|Study Intervention|Induction therapy consists of 3 cycles of bevacizumab 15mg/kg on day 1, cetuximab weekly days 1,8,15 (loading dose of cetuximab 400mg/m2 on cycle 1, day 1, then 250 mg/m2 on all subsequent administrations), cisplatin 75mg/m2 on day 1, docetaxel 75mg/m2 on day 1, repeated every 21 days. After 3 cycles of induction therapy, patients will receive standard radiation 70-74 Gy/ 200 cGy/ daily, 5 days/ week with concurrent weekly cisplatin 30mg/m2, cetuximab 250mg/m2 and bevacizumab 15mg/kg every 3 weeks x 3. There is optional surgery for non-responders in the primary (stable disease) after TPE-A.
62798162|NCT02558855|ACTIVE_COMPARATOR|Thrust Joint Manipulation|Patients will receive thrust joint manipulation to their lumbar spine in side lying.
62798163|NCT02558855|SHAM_COMPARATOR|Non-thrust Joint Manipulation|Patients will receive non-thrust joint manipulation, oscillations into slight rotation, without cavitation, to their lumbar spine in side lying.
62025303|NCT03866993|PLACEBO_COMPARATOR|placebo plus Carboplatin and Paclitaxel|Subjects receive placebo intravenously (IV) plus Paclitaxel 175mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV Q3W until progression.
62222713|NCT00284817|EXPERIMENTAL|1|MEDI-522
62222714|NCT00284817|EXPERIMENTAL|2|MEDI-522
62222715|NCT00284817|EXPERIMENTAL|3|MEDI-522
62222716|NCT00284817|EXPERIMENTAL|4|MEDI-522
62798164|NCT05315479|EXPERIMENTAL|N1539|N1539 (Meloxicam IV) 0.6 mg/kg (maximum 30 mg) Q24H
62222717|NCT00284817|EXPERIMENTAL|5|MEDI-522
62222718|NCT05025046||Ultrasound findings of thyroid nodules classified as type 3 and 4a of TIRADS|
62222719|NCT04524325|ACTIVE_COMPARATOR|Trans men|transgender men taking physiologic doses of testosterone for gender affirming hormone therapy
62222720|NCT04524325|NO_INTERVENTION|control|cisgender women not receiving testosterone and with normal sex hormone levels
62798165|NCT01103765|PLACEBO_COMPARATOR|classic strategy|after drug-eluting stent(DES) deployment perform of Intravascular ultrasound analysis without post-dilatation
62798166|NCT01103765|ACTIVE_COMPARATOR|post-dilatation strategy|After drug-eluting stent (DES) deployment IVUS analysis and systematic post-dilatation with noncompliant balloon 0.25mm larger than stent balloon. After post dilatation new IVUS analysis.
62222721|NCT04460885|EXPERIMENTAL|Insulin icodec|Insulin icodec + non-insulin anti-diabetic drugs. The pre-trial non-insulin anti-diabetic background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period
62416754|NCT06113783|NO_INTERVENTION|Group 2-CONTROL|Physical Exercise Program alone 3 times a week at home for the 12 months of observation.
62798167|NCT06408571||Experimental group|Patients with retinal vein obstruction and diabetic retinopathy
62798168|NCT06408571||Control group|Cataract surgery and vitrectomy patients
62798169|NCT03067246|ACTIVE_COMPARATOR|VBM Intubating Laryngeal Tube|Device: VBM Intubating Laryngeal Tube Intervention: VBM Intubating Laryngeal Tube insertion, seal pressure, endotracheal intubation
62798170|NCT03067246|ACTIVE_COMPARATOR|I-Gel|Device: I-Gel Intervention: I-Gel insertion, seal pressure, endotracheal intubation
62416755|NCT04417127|EXPERIMENTAL|Microfinance with Integrated Community-based Care|20 microfinance groups with n=450 participants will be randomized to receive the ICB intervention.
62416756|NCT04417127|ACTIVE_COMPARATOR|Microfinance with Standard of Care|20 microfinance groups with n=450 participants will be randomized to continue to receive standard of care from an AMPATH-supported rural health facility.
62798171|NCT01035671|EXPERIMENTAL|Low Dose|A0001 (0.5 g BID)
62798172|NCT01035671|EXPERIMENTAL|High Dose|A0001 (0.75 g BID)
62798173|NCT01035671|PLACEBO_COMPARATOR|Placebo|Placebo
62798174|NCT03692039|EXPERIMENTAL|M-pro files|Instrumentation using M-pro files in rotating motion
62798175|NCT03692039|ACTIVE_COMPARATOR|ProTaper Next files|Instrumentation using ProTaper Next files in rotating motion
62798176|NCT05308979|EXPERIMENTAL|1 Injection Site|100u Botox® injected at one intradetrusor site
62798177|NCT05308979|ACTIVE_COMPARATOR|10 Injection Sites|100u Botox® injected at 10 intradetrusor sites
62222722|NCT04460885|ACTIVE_COMPARATOR|Insulin glargine|Insulin glargine + non-insulin anti-diabetic drugs. The pre-trial non-insulin anti-diabetic background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period
62222723|NCT01496482||Patients without dry eye symptoms|Patients without dry eye symptoms as measured by standard questionnaire.
62222724|NCT01496482||Patients with dry eye symptoms|Patients with dry eye symptoms as measured by standard questionnaire.
62416757|NCT04417127|NO_INTERVENTION|Standard of Care without Microfinance|n=300 participants who receive care at an AMPATH health facility and who are not involved in microfinance will serve as matched contemporaneous controls. These participants will be actively followed over the 18-months of the trial.
62798178|NCT00980356|ACTIVE_COMPARATOR|Vildagliptin, 50 mg, peroral|
62798179|NCT00980356|PLACEBO_COMPARATOR|Placebo pill|
62798180|NCT02727907|EXPERIMENTAL|BCD-033|Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
62798181|NCT02727907|ACTIVE_COMPARATOR|Rebif|Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks, followed by 48 weeks of open-label BCD-033 usage
62798182|NCT02727907|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for 48 weeks, followed by 72 weeks of open-label BCD-033 usage
62798183|NCT04713488|EXPERIMENTAL|Sputnik Light Vaccine|solution for intramuscular injection Composition for 1 dose (0.5 ml): Active substance: recombinant serotype 26 adenoviral particles containing the SARS-CoV-2 S protein gene, in the amount of (1.0±0.5) x 10\*11 particles per dose.
62798184|NCT00997282|EXPERIMENTAL|OPC-262 2.5 mg|orally administered once daily for 24 weeks
62798185|NCT00997282|EXPERIMENTAL|OPC-262 5 mg|orally administered once daily for 24 weeks
62025304|NCT02043782|EXPERIMENTAL|First Coloplast Test|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.~First subjects are allocated to Coloplast Test; Secondly to either~1. Own product (baseline)~2. Competitor soft convex"
62025305|NCT02043782|EXPERIMENTAL|First Competitor soft convex|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.~First subjects are allocated to Competitor soft convex; Secondly to either~1. Own product (baseline)~2. Coloplast Test"
62025306|NCT02043782|EXPERIMENTAL|First Own product|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.~First subjects are allocated to Own product; Secondly to either~1. Coloplast Test~2. Competitor soft convex"
62025307|NCT01569516|EXPERIMENTAL|low dose|1mg, tid
62025308|NCT01569516|EXPERIMENTAL|Moderate dose|2mg,tid
62025309|NCT01569516|EXPERIMENTAL|High dose|4mg,tid
62416758|NCT06439511|ACTIVE_COMPARATOR|Pulse oxymetry|Pulse oxymetry is one of the gold standards for non invasive measurement of heart rate.
62798186|NCT00997282|PLACEBO_COMPARATOR|Placebo|orally administered once daily for 24 weeks
62798187|NCT04800848||Mask/No Mask|"The group will perform both situations in a randomized cross-over design:~* 1. Scholars will perform the fitness test with the use of a N95/FFP2 face mask~* 2. Scholars will perform the fitness test without the use of a N95/FFP2 face mask"
62798188|NCT05874284|EXPERIMENTAL|Experimental group|The nasopharyngeal suction with positive pressure method was employed in the sample group. In this method, the infant's head is turned to the side, 1-2 ml of PS is injected into the nostril with a syringe, and then positive pressure is exerted with the help of the end of the oxygen hose from the same nostril, with oxygen or air supply at 5-8 lt/min (if the baby requires oxygen, using an oxygen source) and the nasopharyngeal secretions are removed from the nostril into which PS has been not injected. The oxygen hose is held one centimetre away from the infant's nostril. The researchers prepared a guideline for nasopharyngeal suction with positive pressure based on the literature.
62798189|NCT05874284|NO_INTERVENTION|conroul group|The nasopharyngeal suction with negative pressure method was employed in the control group in this study. In this method, the nasal secretions were softened with 1-2 ml of physiological saline (PS), and then negative pressure suction was performed using a pine-tipped suction set. In the literature, neonatal aspiration pressure is defined as 60-100 mmHg. In this study, the suction pressure was kept between 60 and 80 mmHg, and no suction lasted for more than 15 seconds.
62798190|NCT01597635|EXPERIMENTAL|Part A|4 increasing doses of GSK2586881 given over 2 days
62025310|NCT01569516|PLACEBO_COMPARATOR|Placebo|0 mg, tid
62025311|NCT06218173||Early LA group|The group that received LA at the induction of the sedation
62798191|NCT01597635|EXPERIMENTAL|Part B|Repeat Medium-High dose of GSK2586881 (or placebo) over 3 days
62025312|NCT06218173||Late LA group|The group that received LA at the end of the sedation
62025313|NCT06100926|ACTIVE_COMPARATOR|Virtual reality group|subjects who undergo virtual reality immersion scene ab initio
62025314|NCT06100926|OTHER|control group|subjects who undergo virtual reality immersion scene in a second phase
62025315|NCT01260246|EXPERIMENTAL|sitagliptin|sitagliptin 100mg/daily for 6 months
62798192|NCT04341714||patients enrolled|Patients with telephone consultation on neurourology department, age \> 18
62416759|NCT06439511|EXPERIMENTAL|Smartphone app|This is a new smartphone application which can potentially measure heart rate in less than 30 seconds.
62416760|NCT01861730|EXPERIMENTAL|Cohort 1 Aeras404 (5ug H4/100nmol IC31) or Placebo|1 Dose; Subject ≥ 168 to ≤ 196 days of age
62798193|NCT02464618|NO_INTERVENTION|Usual care|The social contact of patients in this arm will not be contacted
62416761|NCT01861730|EXPERIMENTAL|Cohort 2 AERAS-404 (5ug H4/500nmol IC31) or Placebo|1 Dose; Subject ≥ 168 to ≤ 196 days of age
62798194|NCT02464618|ACTIVE_COMPARATOR|Social contact intervention|The social contact of patients in this arm will be contacted and asked to facilitate the endoscopy care plan of the patient
62798195|NCT02045095|EXPERIMENTAL|Schedule A: MLN7243 1 mg|MLN7243 1 milligram (mg), infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or disease progression (PD) or discontinuation of study for another reason, or until study is stopped.
62416762|NCT01861730|EXPERIMENTAL|Cohort 3A AERAS-404 (5ug H4/500nmol IC31) or Placebo|2 Doses; Subject ≥ 168 to ≤ 189 days of age
62025316|NCT01260246|PLACEBO_COMPARATOR|placebo|placebo match for 6 months
62025317|NCT04059926||Patients with lumen metal apossing stent|
62025318|NCT06388343|EXPERIMENTAL|Children with listening difficulties|Comorbid developmental disorders Longitudinal study design (3 years) ECLiPS-questionnaire + behavioral measures
62025319|NCT06388343|ACTIVE_COMPARATOR|Typically developing children|TD children perform the same behavioral tasks and ECLiPS-questionnaire to determine cut-off criteria for establishing a diagnosis.
62222725|NCT02375178|ACTIVE_COMPARATOR|Sterile saline solution|sterile Saline solution 0,9%
62222726|NCT02375178|EXPERIMENTAL|chlorhexidine|chlorhexidine 0,12% mouthwash
62222727|NCT02375178|EXPERIMENTAL|polyhexamethylene|polyhexamethylene biguanide 0,07% mouthwash
62222728|NCT05747053||AlloSure Assay prediction of Anti-body Mediated Rejection|Determine whether AlloSure predicts the incidence of active, chronic Anti-body Mediated Rejection and cellular rejection in high risk patients
62222729|NCT05778669||Cohort Group: Longitudinal follow-up intervention|Monitoring of medical, health and psychosocial conditions through questionnaires, on-site assessments and medical record checking.
62222730|NCT05184023|EXPERIMENTAL|Treatment group|
62416763|NCT01861730|EXPERIMENTAL|Cohort 3B AERAS-404 (15ug H4/500nmol IC31) or Placebo|2 Doses; Subject ≥ 168 to ≤ 189 days of age
62416764|NCT01861730|EXPERIMENTAL|Cohort 4 AERAS-404 (15ug H4/500nmol IC31) or Placebo|3 Doses; Subject ≥ 84 to ≤ 98 days of age
62416765|NCT01861730|EXPERIMENTAL|Cohort 5 AERAS-404 (50ug H4/500nmol IC31) or Placebo|3 Doses; Subject ≥ 84 to ≤ 98 days of age
62025320|NCT03186846|ACTIVE_COMPARATOR|multimodal monitoring|LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
62025321|NCT03186846|ACTIVE_COMPARATOR|placebo|No multimodal monitoring will be applied in control group.
62416766|NCT01861730|EXPERIMENTAL|Cohort 6 AERAS-404 (dose level pending) or Placebo|3 Doses; Subject ≥ 64 to ≤ 83 days of age
62416767|NCT02629627|EXPERIMENTAL|cojugated ALC/Leucine+Metformin|Intervention with conjugated linoleic acid/Leucine + 500mg in individuals with METS
62416768|NCT02629627|ACTIVE_COMPARATOR|Metformin+placebo conjugatedALC/leucine|active comparator with Metformin 500mg + Placebo of ACL/Leucine in individuals with METS
62416769|NCT02629627|PLACEBO_COMPARATOR|Placebo of Metformin|Active comparator with ACL/Leucine + Placebo of Metformin in individuals with METS
62416770|NCT02629627|PLACEBO_COMPARATOR|ACL/Leu placebo|Placebo comparator with ACL/Leu placebo + Metformin placebo in individuals with METS
62416771|NCT01870752|OTHER|Transplantation of previously cryopreserved ovarian tissue|Surgical transplantation of previously collected cryopreserved ovarian cortical tissue.
62416772|NCT05932407||Vortioxetine Tablet Treatment|Participants with depression who received Vortioxetine tablet treatment in accordance with package insert.
62416773|NCT05932407||SSRI Treatment|Participants with depression who received SSRI treatment in accordance with package insert.
62416774|NCT05027425|EXPERIMENTAL|Durvalumab + Tremelimumab + Liver Transplant|Patients will be treated with the immunotherapy combination for up to 4 months. After a minimum 28 day washout, they will undergo locoregional therapy per institutional standards. Eventually, after a minimum 72-day washout from the end of immunotherapy, they will undergo liver transplant.
62416775|NCT06291857|EXPERIMENTAL|CIC Vaccine|A single 0.5 mL IM injection on Day 0
62416776|NCT06291857|EXPERIMENTAL|Novavax COVID-19 Vaccine|A single 0.5 mL IM injection on Day 0
62416777|NCT06291857|EXPERIMENTAL|tNIV Vaccine|A single 0.5 mL IM injection on Day 0
62416778|NCT06291857|EXPERIMENTAL|Fluzone High-Dose|A single 0.5 mL IM injection on Day 0
62416779|NCT06702436||Invasive Treatment Group|The Invasive Treatment Group will include cancer patients aged 18 and older diagnosed with non-ST elevation myocardial infarction (NSTEMI) who received an invasive treatment approach. This group will consist of patients who underwent coronary angiography followed by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). These patients may have various cancer types, with no restriction on the diagnosis, but must have been treated with invasive procedures for NSTEMI during their hospitalization. The cohort will be assessed for mortality, re-hospitalization rates, and cardiovascular events. The study will also evaluate factors such as cancer stage, metastasis, and comorbidities to understand the outcomes of invasive treatment in this population.
62416780|NCT06702436||Conservative Treatment Group|The Conservative Treatment Group will include cancer patients aged 18 and older diagnosed with NSTEMI and managed with medical treatment alone. This group will consist of patients who received pharmacological management (antiplatelet therapy, anticoagulants, beta-blockers, statins) without coronary angiography or revascularization. These patients may have different cancer types, and the study will focus on those treated conservatively during their hospital stay. Mortality, re-hospitalization, and cardiovascular events will be assessed. The analysis will also consider cancer type, disease stage, comorbidities, and pharmacological therapy's impact on long-term outcomes.
62416781|NCT03350880|EXPERIMENTAL|PNF in Water - PNFW|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
62416782|NCT03350880|ACTIVE_COMPARATOR|PNF on Land - PNFL|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
62416783|NCT03347929|EXPERIMENTAL|Naproxen|Naproxen 500 mg twice daily
62416784|NCT03347929|PLACEBO_COMPARATOR|Placebo|Placebo 1 tablet twice daily
62025322|NCT01877109||Lymphoma|Lymphoma patients
62222731|NCT05184023|SHAM_COMPARATOR|Sham group|
62222732|NCT03299868|EXPERIMENTAL|Routine PICC group|PICC is initially routine insertion at the time of admission of hospice-palliative care unit
62222733|NCT03299868|ACTIVE_COMPARATOR|General IV group|PICC is inserted if 3 or more times of IV insertion trial per day is required for IV access
62222734|NCT03125720|EXPERIMENTAL|GUIDED group|Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response in the guided group.
62222735|NCT03125720|NO_INTERVENTION|Control group|No Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response.
62222736|NCT05682391|NO_INTERVENTION|Prospective experimental - no bed rest after intraoperative leak|Randomized after surgery if intraoperative CSF leakage occurs. The ratio for allocating into arm 1 vs. arm 2 is 2:1.
62222737|NCT05682391|ACTIVE_COMPARATOR|Prospective control - bed rest after intraoperative leak|Randomized after surgery if intraoperative CSF leakage occurs. The ratio for allocating into arm 1 vs. arm 2 is 2:1.
62222738|NCT05682391|NO_INTERVENTION|Prospective control - no bed rest after no intraoperative leak|Enters this arm if no intraoperative CSF leakage occurs.
62222739|NCT05682391|ACTIVE_COMPARATOR|Retrospective control - bed rest after intraoperative leak|Historical control, bed rest applied after intraoperative CSF leakage.
62416785|NCT03451227|EXPERIMENTAL|Dexmedetomidine Group|The study drug dexmedetomidine (PrecedexTM) is supplied as dexmedetomidine HCL 200mcg/vial (100mcg/ml). This will be added to 98 ml 0.9% NaCl to achieve a concentration of 2mcg/ml and infused at 0.2-1mcg/kg/hour from the start of the case. The infusion rate will be commenced at 1mcg/kg/hour in those less than or equal to 65 years of age, and at 0.7mcg/kg/hr in those greater than 65 years of age, and then titrated based on the intraoperative sedation scores (to achieve a Sedation and Agitation scale (SAS) score of less than or equal to 4) and cardiovascular parameters (within 30% of baseline).
62416786|NCT03451227|ACTIVE_COMPARATOR|Remifentanil Group|Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline)
62416787|NCT04954625|EXPERIMENTAL|Autologous Blood Patch|60-120ml of patient's blood will be drawn and inserted into patient's chest tube. A minimum of 60ml of blood is required, with the optimal amount of blood being 120ml.
62416788|NCT04954625|ACTIVE_COMPARATOR|Standard of Care (Per physician)|Chest tube remains intact without blood patch.
62798196|NCT02045095|EXPERIMENTAL|Schedule A: MLN7243 2 mg|MLN7243 2 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD, or discontinuation of study for another reason, or until study is stopped.
62025323|NCT04612179||All Comer Patients|All-comer patients (≥80 years) affected by acute coronary syn-drome (NSTE-ACS), stabile angina, or silent angina, who qualify for percutaneous coronary intervention (PCI) according to ESC-treatment guidelines and physicians' clinical routine estimation.
62222740|NCT05682391|NO_INTERVENTION|Retrospective control - no bed rest after no intraoperative leak|Historical control, bed rest not applied after no intraoperative CSF leakage.
62222741|NCT03639831|EXPERIMENTAL|Active group|Proprietary, standardized botanical extract
62222742|NCT03639831|PLACEBO_COMPARATOR|Placebo group|Placebo (maltodextrin)
62222743|NCT00700973|ACTIVE_COMPARATOR|Arm 1|Substance use disorder usual care
62222744|NCT00700973|EXPERIMENTAL|Arm 2|Interpersonal violence prevention intervention
62222745|NCT02611791|EXPERIMENTAL|Radiofrequency|Eight RF sessions were performed, with an interval of seven days between them. The application of Radiofrequency in the external genitalia.
62222746|NCT02611791|SHAM_COMPARATOR|Radiofrenquency Off|Eight RF sessions were performed, with an interval of seven days between them. The application of Radiofrequency in the external genital which was turned off, but a water-soluble gel was used
62222747|NCT04979650|ACTIVE_COMPARATOR|The intervention group|The intervention group will receive 1 gram of methylprednisolone succinate within 500 ccs of normal saline within 5 hours.
62222748|NCT04979650|PLACEBO_COMPARATOR|The control group|The control group will receive 500 g of normal saline without methylprednisolone succinate.
62222749|NCT04980443|EXPERIMENTAL|FIT positive individuals|FIT-positive individuals of whom we will collect blood samples and who will undergo a colonoscopy after blood sampling.
62222750|NCT03623854|EXPERIMENTAL|Treatment (nivolumab and relatlimab)|Participants receive nivolumab intravenously (IV) over 60 minutes and relatlimab via infusion over 60 minutes on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62222751|NCT06087926|EXPERIMENTAL|Medial Prefrontal Cortex - Control Site|Participants first undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3-week washout period, participants then undergo transcranial magnetic stimulation to the control site.
62222752|NCT06087926|EXPERIMENTAL|Control Site - Medial Prefrontal Cortex|Participants first undergo transcranial magnetic stimulation to the control site. After a 3-week washout period, participants then undergo transcranial magnetic stimulation to the medial prefrontal cortex.
62416789|NCT03070327|EXPERIMENTAL|BCMA Targeted CAR T Cells with or without Lenalidomide|
62416790|NCT04232696|EXPERIMENTAL|Neuspera Implantable Sacral Nerve Stimulation System|Implantation of the simulator.
62416791|NCT05619809|EXPERIMENTAL|Thermogenic Dietary Supplement|Arm in which the thermogenic dietary supplement is consumed.
62416792|NCT05619809|PLACEBO_COMPARATOR|Placebo Dietary Supplement|Arm in which the placebo supplement is consumed.
62416793|NCT05619809|NO_INTERVENTION|Control|Control arm with no intervention.
62588342|NCT03583541|EXPERIMENTAL|Treatment arm: HIVRR+S+FL|Women in this arm will receive TAU for FSW and the 4 HIVRR sessions (described above) and a single session following HIVRR specifically describing bank account opening, the matching process, and how to interact with banks. In this session our partnering banks will open up matched savings accounts for women in the two treatment arms. Women in both arms will save money in their matched savings accounts over a 10-month period post HIVRR. The study team will monitor the accounts using the statements received directly from the banks holding the accounts. Participants will receive monthly bank statements indicating their own savings and the associated match (1:1 match rate). They will also receive 6 financial literacy (FL) sessions provided twice a week for 3 weeks
62025324|NCT00518024|EXPERIMENTAL|1|Bilateral theta burst stimulation to the secondary auditory cortex
62222753|NCT03389906|EXPERIMENTAL|Gold|Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants).
62222754|NCT02667197||Opioid overdose and poisoning|
62025325|NCT00518024|EXPERIMENTAL|2|Bilateral theta burst stimulation to the tertiary auditory cortex
62416794|NCT02257411|ACTIVE_COMPARATOR|Ear-sized based and weight based formula|the sizes of the PLMA determined with the ear-based compared with the sizes according to the manufacturer's weight-based formula
62416795|NCT05804240||Surgical aortic valve replacement|Patients who have surgical aortic valve replacement
62416796|NCT05804240||Mini-sternotomy aortic valve replacement|Patients who have mini-sternotomy aortic valve replacement
62416797|NCT05804240||Transcatheter aortic valve replacement|Patients who have transcatheter aortic valve replacement
62416798|NCT06076538||Patient diagnosed with incidental solid renal mass|All patients at our institution who are diagnosed with indeterminate solid SRM and without prior treatment for the tumor, renal biopsy or contraindication to PET/MRI can be included in the study. This will be a prospective, non-randomized, non-blinded observational study. Patients will then be managed following the standard of care.
62416799|NCT06195072|EXPERIMENTAL|Amlitelimab|
62416800|NCT06195072|PLACEBO_COMPARATOR|Amlitelimab matching placebo|
62416801|NCT06195072|EXPERIMENTAL|BI 1015550|
62416802|NCT06195072|PLACEBO_COMPARATOR|BI 1015550 matching placebo|
62416803|NCT03907540|EXPERIMENTAL|Part 1, Treatment A--Belumosudil 200 mg Tablet|Belumosudil 200 mg tablet
62025326|NCT00518024|SHAM_COMPARATOR|3|Bilateral theta burst stimulation to a non-cortical region
62416804|NCT03907540|EXPERIMENTAL|Part 1, Treatment B--[14C]-KD025 IV Microdose|\[14C\]-KD025 at a dose of 100 μg in a 5 mL solution containing NMT 37 kBq (1000 nCi) \[14C\] over 15 min IV
62025327|NCT04658251||Patients with an intronic variant unknown in a gene implicated in cone disorders.|
62416805|NCT03907540|EXPERIMENTAL|Part 2, Treatment C--[14C]-KD025 Capsule|\[14C\]-KD025 200 mg capsule containing NMT 9.8 MBq (215 μCi)
62416806|NCT00736138|ACTIVE_COMPARATOR|1|training and pellots
62416807|NCT00736138|NO_INTERVENTION|2|control
62416808|NCT02092584|ACTIVE_COMPARATOR|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
62416809|NCT02092584|PLACEBO_COMPARATOR|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
62416810|NCT03256526|PLACEBO_COMPARATOR|Placebo|
62416811|NCT03256526|EXPERIMENTAL|PF-06835919 Low Dose|75 mg once daily
62588343|NCT03583541|EXPERIMENTAL|Treatment arm: HIVRR+S+FLM|"Women in this arm will receive TAU and the 4 HIVRR sessions (as above). Next, they will receive the savings session (described above) and 6 financial literacy (FL) sessions provided twice a week for 3 weeks, followed by 8 mentorship (M) sessions supporting transition to vocational, educational training, employment or business development, and receipt of a matched savings account to be used on short-term and/or long term consumption and skills development per participants own discretion/choice.~\*Revision note: Following COVID-19, with approval from NIMH (on record if requested), the HIVRR+S+FLM treatment of the study has been combined with the HIVRR+S+FL treatment arm. The total sample size has been revised to 532 participants, with approval from NIMH."
62588344|NCT06667492||Neuro-typical Children|Typically developing children aged 5 to 16 years with the ability of voluntary motor control are in included in the study.
62588345|NCT04369677||First-Episode Psychosis|Twenty individuals with FEP will complete a 24-hour continuous assessment of core body temperature using a CorTemp ingestible sensor (HQInc., Palmetto, FL).
62798197|NCT02045095|EXPERIMENTAL|Schedule A: MLN7243 4 mg|MLN7243 4 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
62798198|NCT02045095|EXPERIMENTAL|Schedule A: MLN7243 8 mg|MLN7243 8 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
62798199|NCT02045095|EXPERIMENTAL|Schedule A: MLN7243 12 mg|MLN7243 12 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
62798200|NCT02045095|EXPERIMENTAL|Schedule A: MLN7243 18 mg|MLN7243 18 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
62798201|NCT02045095|EXPERIMENTAL|Schedule A: MLN7243 Homozygous Mutant 4 mg|MLN7243 homozygous mutant 4 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
62798202|NCT04693559|OTHER|autogenous iliac bone graft (group A)|autogenous iliac bone graft will be used to fill the alveolar defect
62798203|NCT04693559|OTHER|Nano crystalline Hydroxyapatite (group B)|Nano crystalline Hydroxyapatite will be used to fill the alveolar defect
62025328|NCT01011010|OTHER|Single Arm|Single Arm Trial
62025329|NCT05166018|EXPERIMENTAL|SuMO Patient|"92 data will be collected during the patient care episode. Among the 92 criteria, 63 are pre-operative, 29 are post-operative in order to provide an evolutionary prediction during the management of the patient.~Post-operative follow-up criteria making it possible to establish the scalability or non-scalability of the quality of life after the surgical procedure.~The results will be compared to the prediction proposed by the machine learning algorithm."
62416812|NCT03256526|EXPERIMENTAL|PF-06835919 High Dose|300 mg once daily
62416813|NCT06315413|EXPERIMENTAL|Composite plug|Tooth extraction will be done a-traumatically followed by socket curettage and cleaning followed by xenograft filling for the socket and coverage with injected flowable composite plug which will then be stabilized using 5.0 polypropylene suture material with a figure of eight suture.
62416814|NCT06315413|ACTIVE_COMPARATOR|Exposed d-PTFE|Tooth extraction will be done a-traumatically followed by socket curettage and cleaning followed by xenograft filling for the socket and coverage with d-PTFE membrane which will be left exposed intentionally and secured using 5.0 polypropylene suture material with a figure of eight suture.
62416815|NCT04661124||Adult Normal Eyes|see Inclusion/Exclusion criteria; imaged with OCT and/or OCTA
62416816|NCT04661124||Adult Pathology Eyes|see Inclusion/Exclusion criteria; imaged with OCT and/or OCTA
62416817|NCT01129518|EXPERIMENTAL|Two Dose MenC Group|Two doses of MenC-CRM197 priming at 3 and 4 months of age.
62416818|NCT01129518|EXPERIMENTAL|Single Dose MenC-CRM197 Group|One dose of MenC-CRM197 priming at 3 months of age.
62416819|NCT01129518|EXPERIMENTAL|Single Dose MenC-TT Group|Single dose MenC-TT priming at 3 months of age
62416820|NCT01129518|EXPERIMENTAL|Control Group|Zero dose MenC priming
62416821|NCT01391910||post endoscopic sinus surgery for chronic rhinosinusitis|Patients who have undergone functional endoscopic sinus surgery for treatment of chronic rhinosinusitis and completed a pre-surgery SNOT-20
62416822|NCT06646536|EXPERIMENTAL|Anti-gravity Treadmill Group|Anti-gravity treadmill (Alter G) walking program in addition to physiotherapy and rehabilitation
62416823|NCT06646536|ACTIVE_COMPARATOR|Conventional Treadmill Group|Standard treadmill walking program in addition to physiotherapy and rehabilitation
62416824|NCT06646536|ACTIVE_COMPARATOR|Control Group|Physiotherapy and rehabilitation program
62416825|NCT05084937|ACTIVE_COMPARATOR|Structured transition|With the help of CeliCAT form
62416826|NCT05084937|NO_INTERVENTION|Routine practices|
62416827|NCT01610284|EXPERIMENTAL|BKM120 100mg + Fulvestrant|BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.
62416828|NCT01610284|PLACEBO_COMPARATOR|Placebo + Fulvestrant|BKM120 matching placebo daily and fulvestrant given until progression or as described in the protocol.
62416829|NCT01353794||Group 1|
62416830|NCT02118818||NO rheumatic heart disease by echo|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD. We will be using next generation sequencing to identify these differences.
62416831|NCT02118818||Rheumatic heart disease by echo|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD. We will be using next generation sequencing to identify these differences.
62798204|NCT02041325|EXPERIMENTAL|Lenalidomide|Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
62798205|NCT02041325|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
62798206|NCT03158324|EXPERIMENTAL|Advanced refractory solid tumors|Patients with advanced refractory solid tumors will be enrolled.
62222755|NCT06168552|EXPERIMENTAL|Arm A|The patient underwent Da Vinci robot or fluorescent laparoscopic-assisted radical resection of pancreatic cancer. The day before the operation, anti-EGFR antibody-IR800CW imaging agent was injected into the vein, and the fluorescence test was performed to evaluate the imaging of the primary lesions of the pancreas and the intra-abdominal lymph nodes. And to evaluate for the presence of imaging lesions in the liver, peritoneum, pelvic cavity, etc.
62222756|NCT00978796|ACTIVE_COMPARATOR|Sitagliptin|Patients will receive sitagliptin for 4 weeks and then cross over to sugar pill
62416832|NCT05851976|EXPERIMENTAL|Naproxen + duloxetine|
62416833|NCT05851976|PLACEBO_COMPARATOR|Naproxen + placebo|
62416834|NCT01462188|ACTIVE_COMPARATOR|Immediate stenting|Patients being randomized to the immediate stenting arm will be managed according to the guidelines. Irrespective of TIMI flow at presentation, investigators will be requested to thrombus aspirate immediately after successful wiring of the culprit vessel followed by direct stenting. In cases where insertion of thrombus removal catheter and/or direct stenting is not successful, balloon angioplasty will be allowed.
62416835|NCT01462188|EXPERIMENTAL|Delayed stenting|"Patients being randomized to the delayed/staged stenting arm will be managed with the aim to obtain stable TIMI 3 flow with no considerations given at the percentage of residual stenosis at the culprit lesion.~In patients presenting with TIMI 3 flow, investigators will be left free to wire the vessel and proceed to thrombus aspiration to decrease thrombus burden in the culprit lesion or to leave the vessel untreated at the time of index PCI. Patients presenting with suboptimal TIMI flow (i.e. less than 3), investigators are required to wire the vessel and thrombus aspirate. If stable (persisting for at least 5 minutes) TIMI 3 flow is obtained, investigators are requested to stop the procedure. The goal is to achieve s table TIMI 3 flow with no considerations given to the percentage of residual stenosis. Stenting in this arm will be allowed only on a bail-out strategy."
62416836|NCT02107807|EXPERIMENTAL|Arm 1: aH5N1 adult|aH5N1 healthy and non-healthy adults
62416837|NCT02107807|EXPERIMENTAL|Arm 2: aH5N1 elderly|aH5N1 healthy and non-healthy elderly
62416838|NCT02107807|ACTIVE_COMPARATOR|Arm 4: aTIV elderly|aTIV healthy and non-healthy elderly
62416839|NCT02107807|ACTIVE_COMPARATOR|Arm 3: aTIV adult|aTIV healthy and non-healthy adults
62588346|NCT04369677||Healthy|Twenty age-matched individuals with no psychotic disorder will complete a 24-hour continuous assessment of core body temperature using a CorTemp ingestible sensor (HQInc., Palmetto, FL).
62798207|NCT04502641|EXPERIMENTAL|Arm I|Patients receive induction chemotherapy with docetaxel-based, with or without cisplatin or fluorouracil. Treatment repeats every 21 days for 3 courses. Then, patients receive cisplatin on day 1 day 21, 3 weeks as one cycle and undergo concurrent radiotherapy once daily, 5 days a week, for 6 to 7 weeks.
62222757|NCT00978796|PLACEBO_COMPARATOR|Sugar pill|Subjects will receive sugar pill for 4 weeks and then cross over to active sitagliptin
62222758|NCT06422468|OTHER|FibriCheck recordings|
62222759|NCT05055505|NO_INTERVENTION|control phase|Schools will start in the control phase (SARS-CoV-2 diagnostic testing at an assessment center, primary care office or acute care center) and transition to the intervention phase at a randomly assigned time point over the course of the study.
62416840|NCT02181842||Pioglitazone|Pioglitazone 15-30 mg, tablet, orally, once daily for up to 48 weeks before or after breakfast (the dose can be adjusted; however, the maximum daily dose should not exceed 45 mg).
62416841|NCT02653469||Augmented ventilation with fluid loading|This is an observational study and as a diagnostic intervention, subjects in the study would receive mechanical ventilation with augmented tidal volume of 12ml/kg for 2min. Augmented ventilation is performed when the patient's PPV is within grey zone (9-13%). The investigators perform this procedure to every patients and do not assigh this intervention to the subjects of the study. Then, 6ml/kg of ballanced crystalloid loading will be infused to every patient.
62416842|NCT06700486|ACTIVE_COMPARATOR|comparator arm|Immediate implant and sticky bone
62416843|NCT06700486|OTHER|interventional arm|Socket shield
62416844|NCT05601193|EXPERIMENTAL|PRP group|Experimental: autologous PRP Bilateral ovaries autologous PRP injection under transvaginal ultrasound guidance. 3ml on each ovary.Once a month. two consecutive injections
62416845|NCT05601193|NO_INTERVENTION|Control group|No intervention
62798208|NCT04502641|ACTIVE_COMPARATOR|Arm II|Patients receive cisplatin on day 1 day 21, 3 weeks as one cycle and undergo concurrent radiotherapy once daily, 5 days a week, for 6 to 7 weeks.
62798209|NCT01505517||individuals with low back pain|
62798210|NCT01505517||healthy controls|
62798211|NCT01042925|EXPERIMENTAL|Arm 1|XL147 in combination with trastuzumab
62798212|NCT01042925|EXPERIMENTAL|Arm 2|XL147 in combination with trastuzumab and paclitaxel
62798213|NCT02111330|EXPERIMENTAL|Dose I - 80 mg PBF-509|one 80 mg PBF-509 capsule
62798214|NCT02111330|PLACEBO_COMPARATOR|Dose I - Placebo|one Placebo capsule
62798215|NCT02111330|EXPERIMENTAL|Dose II - 160 mg PBF-509|Two 80 mg PBF-509 capsule
62798216|NCT02111330|PLACEBO_COMPARATOR|Dose II - Placebo|Two Placebo capsule
62025330|NCT03662945|EXPERIMENTAL|Intervention group|Mobile Geriatric Team intervention including physicians and nurses with the aim of developing person-centered, safe, sustainable and coordinated care plans. These care plans are developed in collaboration with the patient, his/her relatives and staff from the municipality. Among the main ambitions of this concept are improved communication flows between patients, their relatives and healthcare providers in combination with the delivery of medical as well as care measures. Other ambitions are to avoid unnecessary traditional healthcare utilization in the form of inpatient care and EMR visits, for example.
62222760|NCT05055505|ACTIVE_COMPARATOR|Intervention phase|Schools will have take home saliva kits available at the school to support SARS-CoV-2 diagnostic testing. Schools will transition to the intervention phase at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study.
62222761|NCT01666379|EXPERIMENTAL|Fentanyl|
62222762|NCT01666379|PLACEBO_COMPARATOR|placebo|
62222763|NCT03824639|EXPERIMENTAL|Exercise group|Structured exercise
62222764|NCT03824639|ACTIVE_COMPARATOR|Control group|Health education
62416846|NCT02642991|EXPERIMENTAL|Phenacite Test lens then comfilcon A control lens|Participants were randomized to wear Phenacite test lens for one week then cross-over to wear comfilcon A control lens for one week.
62416847|NCT02642991|ACTIVE_COMPARATOR|Comfilcon A control lens then Phenacite test Lens|Participants were randomized to wear comfilcon A control lens for one week then cross over to Phenacite test lens for one week.
62416848|NCT03856879|NO_INTERVENTION|Usual care|Providers in this arm will provide usual care to their HIV+ patients with COPD.
62416849|NCT03856879|EXPERIMENTAL|Proactive E-consult|Providers in this arm will receive proactive E-consults with expert recommendations for COPD care prior to appointments with HIV+ patients with COPD.
62798217|NCT02111330|EXPERIMENTAL|Dose III - 240 mg PBF-509|three 80 mg PBF-509 capsule
62222765|NCT04908397|EXPERIMENTAL|Supplement|Form: 500 mg L-carnitine tablet Dosage: Subjects 50-90kg: 3g/day Subjects \<50kg or \>90kg: 50mg/kg/day Frequency: twice a day for 2 weeks
62416850|NCT05145660|EXPERIMENTAL|Involved site irradiation|"High-risk CTV1 : GTVnx plus a 10-mm margin to encompass the microscopic extension of the gross tumor, the whole nasopharynx, the high-risk structures recommended for CTVp2 by the contouring consensus\* (such as parapharyngeal space, skull base, pterygopalatine fossa and the inferior part of the nasal cavity and maxillary sinus), the VIIa, and the retrostyloid space above the bilateral transverse process of C1.~Low-risk CTV2:~N0/positive RPLN only: Bilateral cervical nodal region with the 3-cm caudal expansion below transverse process of C1, and at least covering the level II.~N1-2 (positive cervical LNs): Ipilateral cervical nodal region with the 3-cm expansion below the positive LN (GTVnd), and at least covering the level II; contralateral cervical nodal region with the 3-cm caudal expansion below the transverse process of C1, and at least covering the level II.~Suspicious LN: 1-cm expansion below the suspicious LN (GTVnd-suspicious)"
62798218|NCT02111330|PLACEBO_COMPARATOR|Dose III - Placebo|Three Placebo capsule
62588347|NCT06523556|EXPERIMENTAL|Phase I (Axatilimab)|Patients receive axatilimab IV over 30 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. At time of phase Ib completion, patients with clinical improvement may transition to phase II. Patients undergo bone marrow biopsy and aspiration and blood sample collection throughout the study.
62798219|NCT03197584|EXPERIMENTAL|NANT Ovarian Cancer Vaccine|avelumab, bevacizumab, capecitabine, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, paclitaxel, omega-3-acid ethyl esters, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6301, and hank®.
62798220|NCT00356681|PLACEBO_COMPARATOR|Arm A Placebo|Blinded AMG 706 placebo plus paclitaxel
62798221|NCT00356681|EXPERIMENTAL|Arm B Experimental|Blinded AMG 706 plus paclitaxel
62798222|NCT00356681|ACTIVE_COMPARATOR|Arm C Comparator|Open-label bevacizumab plus paclitaxel
62798223|NCT05375448|EXPERIMENTAL|Intervention|"Participants will perform an active femoral nerve mobilisation technique. The treatment will be performed at home.~Patients will receive a video model to perform the exercise during the 8 weeks of treatment. The treatment should be performed 10 repetitions twice a day, with one set recommended in the morning and one in the evening.~The treatment will be monitored by telephone and if there are any doubts, the session will be carried out together with the patient."
62798224|NCT04393168|EXPERIMENTAL|Patients with unilateral arm or leg lymphedema|
62798225|NCT06106048|EXPERIMENTAL|Group A|Group A was treated with closed kinetic chain exercises
62798226|NCT06106048|EXPERIMENTAL|Group B|Group B was treated with abdominal contraction exercises for periscapular activation
62798227|NCT01403155|EXPERIMENTAL|All subjects|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine) at Day o and Month 3.
62798228|NCT01362348|EXPERIMENTAL|pazopanib eye drops|pazopanib topical ocular administration
62798229|NCT06188026|EXPERIMENTAL|Sequence 1|All participants will be exposed to both interventions in a defined sequence. OC 8 days, NNC0194-0499 4 weeks, OC/NNC0194-0499 combined 1 week.
62798230|NCT03571204|ACTIVE_COMPARATOR|Group 1: ART prior to 3BNC117 + 10-1074 in HIV-1 subject|Subjects who began anti-retroviral therapy (ART) during primary HIV-1 infection within 12 weeks of diagnosis. ART was stopped after study day 3 and were given 3BNC117 and 10-1074 intravenously. Both 3BNC117 and 10-1074 were administered at 30 mg/kg dose level in separate bags of 250 mL normal saline in sequential administration. Subjects received 8 infusions of 3BNC117 and 10-1074 at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The total duration of therapy was 24 weeks.
62222766|NCT02844647|EXPERIMENTAL|MRI w/ Hyperpolarized Pyruvate (13C)|"Hyperpolarization of low natural abundance species such as 13C, when injected offers the potential of extracting metabolic information by real-time MR imaging of biochemical reactions within the body. The biochemical reactions, including lactate production, will be measured using MRI."
62222767|NCT05810454|EXPERIMENTAL|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES (interactive Physical and Cognitive Exercise System) involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
62222768|NCT05810454|ACTIVE_COMPARATOR|PACE (physical and cognitive exercise)|"PACE (Physical and Cognitive Exercise) involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
62222769|NCT01945060|EXPERIMENTAL|heart rate Control to Range System (hrCTR) THEN No heart rate Control to Range System (hrCTR)|The Diabetes Assistant (DiAs) Control-to-Range system is notified of heart rate during exercise. The study team member will activate and deactivate a heart rate button when the subject's heart rate exceeds and then returns below 140 beats per minute.
62222770|NCT01945060|PLACEBO_COMPARATOR|No heart rate Control to Range System (hrCTR) THEN heart rate Control to Range System (hrCTR)|Using the DiAs Platform, the Control-to-Range system is not notified of the heart rate during exercise. Heart rate not of interest in this arm.
62588348|NCT06523556|EXPERIMENTAL|Phase II (Axatilimab and azacitidine)|Patients receive axatilimab IV over 30 minutes on days 1 and 15 and azacitidine IV over 10-40 minutes or SC on days 1-7 of each cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve PR or better may continue for up to 24 total cycles. Patients who achieve less than PR receive 2 additional cycles and, if PR or better is achieved, may complete up to 24 total cycles. Patients undergo bone marrow biopsy and aspiration and blood sample collection throughout the study.
62798231|NCT03571204|PLACEBO_COMPARATOR|Group 1: ART prior to placebo treatment in HIV-1 subject|Subjects who began anti-retroviral therapy (ART) during primary HIV-1 infection within 12 weeks of diagnosis. ART was stopped after study day 3 and were given normal saline intravenously. Subjects received two separate bags of 250 mL normal saline in sequential administration. Subjects received 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The total duration of therapy was 24 weeks.
62798232|NCT03571204|EXPERIMENTAL|Group 2: 3BNC117 + 10-1074 in HIV-1 subject|Subjects who were not on anti-retroviral therapy (ART) during primary HIV-1 infection within the past 2 years. Subjects were given 3BNC117 and 10-1074 intravenously. Both 3BNC117 and 10-1074 were administered at 30 mg/kg dose level in separate bags of 250 mL normal saline in sequential administration. Subjects received 8 infusions of 3BNC117 and 10-1074 at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The total duration of therapy was 24 weeks.
62798233|NCT02238119|EXPERIMENTAL|tiotropium + formoterol|
62798234|NCT02238119|ACTIVE_COMPARATOR|tiotropium|
62798235|NCT02238119|ACTIVE_COMPARATOR|formoterol|
62222771|NCT06257524|EXPERIMENTAL|PDIM component 1, 2, and 3|"Intervention component 2 to be tested. Pediatric resources toolkits availability via Translating Emergency Knowledge for Kids network (TREKK). Investigators will provide resource toolkits to support clinical care in pediatric sepsis, seizure, diabetes ketoacidosis, dehydration, hypovolemic shock, and respiratory conditions.~Intervention component 3 to be tested: Ongoing interactions, and intensive training and education sessions. Investigators will hold training and education sessions at the sites. These will include (a) One on-site training (for 4-4.5 hours) with simulation sessions."
62588349|NCT06662864||patients|women aged 20 to 85 years old diagnosed with hormone receptor positive breast cancer
62588350|NCT06547125|EXPERIMENTAL|JUVÉDERM® VOLITE™|Participants in the treatment group will receive a single dose at the study initiation. Participants are eligible for touch up treatment.
62588351|NCT06547125|OTHER|Control - No Treatment|Participants in the control group will receive no treatment. At Month 2, these participants will have the option to receive the treatment.
62798236|NCT05188664|EXPERIMENTAL|LM-302 monotherapy dose escalation|LM-302 monotherapy dose escalation (part Ia). Accelerated titration combined with traditional 3+3 design will be used for monotherapy dose escalation (part Ia).
62025331|NCT03662945|NO_INTERVENTION|Control group|Standard care including primary care units, home care and home help.
62588352|NCT03098238|OTHER|Patients without humoral rejection or DSA|Renal transplant patients with systematic kidney biopsy at 3 months and 12 months Patients without humoral rejection or DSA (Donor Specific Antibodies)
62025332|NCT02607579|ACTIVE_COMPARATOR|Ropivacaine|This group is given an adductor canal block with Ropivacaine which is the previous gold standard medication.
62025333|NCT02607579|EXPERIMENTAL|Exparel|This group is given an adductor canal block with Exparel which is believed to last longer and provide a better pain relief post-operatively.
62025334|NCT01660763|EXPERIMENTAL|Sufentanil NanoTab PCA System/15 mcg|
62025335|NCT01660763|PLACEBO_COMPARATOR|Placebo Sufentanil NanoTab PCA System|
62025336|NCT04863352||Study group|Men who have been treated for localized or locally advanced prostate cancer with curative intent
62025337|NCT04863352||Matched population based controls|Existing population based data from men who participated in the Trøndelag Health Survey 2017-2019
62025338|NCT05227508|EXPERIMENTAL|Brizo SC012|A capsule containing 400 mg. SC012 (unique soy extract) TWICE A DAY : MORNING , EVENING.
62222772|NCT06257524|ACTIVE_COMPARATOR|PDIM component 1|Customized report to the general EDs and discussion with the general EDs on the gaps identified. Investigators will discuss customized baseline WPRS with each general ED, including implications of the gaps identified relative to their local context and the general ED priorities (1.5hrs/session x 2).
62222773|NCT04338087||Fertility treatments|Men participating in fertility treatments.
62222774|NCT04338087||Spontaneous pregnancy|Men whose wives conceived spontaneously.
62222775|NCT02621320|EXPERIMENTAL|Vitamin D|alcohol-based (Ethanol 65%) Vitamin D3 (Vi-De 3®. WILD) solution 6000IU per day.
62588353|NCT03098238|OTHER|Patient without humoral rejection with a DSA|Patient without humoral rejection with a DSA (Donor Specific Antibodies)Patients with a graft biopsy for a donor-specific anti-HLA antibody
62588354|NCT03098238|OTHER|Patients with humoral rejection|Patients with humoral rejection
62588355|NCT00435487|EXPERIMENTAL|A|
62588356|NCT00435487|ACTIVE_COMPARATOR|B|
62588357|NCT01068067|EXPERIMENTAL|pharmacogenetics plus SchE guided dosing|
62588358|NCT01068067|ACTIVE_COMPARATOR|standard dosing|
62588359|NCT02675621|PLACEBO_COMPARATOR|Control|Mix 1 flavored still beverage
62798237|NCT05188664|EXPERIMENTAL|LM-302 in combination therapy dose escalation|LM-302 in combination therapy dose escalation (part Ib).Accelerated titration combined with traditional 3+3 design will be used for LM-302 in combination with fixed dose Toripalimab dose escalation (part Ib).
62798238|NCT05188664|EXPERIMENTAL|LM-302 Dose Expansion|SMC will select appropriate dose(s) and/or tumor types for dose expansion study.
62798239|NCT04534686|EXPERIMENTAL|CogXergaming|CogXergaming based cognitive-motor balance training will be delivered to group A using the commercially available Wii-Fit Nintendo and a mouse in conjunction with cognitive training. All participants will undergo 18 sessions of training in a tapering manner for six weeks with 60-90 minutes of training per session, i.e., 3 sessions each week till the 6th week. Each session will be divided into 3 sub-sessions, where each sub-session will consist of playing 4 to 6 games in conjunction with cognitive task. All the games will be performed using a Wii-Fit balance board in front of a TV screen.
62798240|NCT04534686|EXPERIMENTAL|Matter of Balance Training|Participants in group B will undergo matter of balance training for 8 weeks (one session a week for 2 hours/day).
62798241|NCT05567250|EXPERIMENTAL|Experimental Intervention + Usual Care|Intervention group families will receive usual care and they will be connected via telephone to 211LA.
62798242|NCT05567250|NO_INTERVENTION|No Intervention: Usual Care|This group will receive usual care
62798243|NCT02038335||DMPA|Depot medroxyprogesterone acetate
62798244|NCT02038335||NET-EN|Norethisterone enantate
62025339|NCT05227508|PLACEBO_COMPARATOR|PLACEBO|A capsule containing 400 mg OF PLACEBO, TWICE A DAY: MORNING , EVENING.
62222776|NCT02621320|PLACEBO_COMPARATOR|Placebo|Same alcohol-based solution (Ethanol 65%) as intervention product but without cholecalciferol
62222777|NCT02020382|OTHER|Crohn adult colic|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
62222778|NCT02020382|OTHER|RCH adults|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
62588360|NCT02675621|ACTIVE_COMPARATOR|Phenolic beverage 1|Mix 2 flavored still beverage with a high dose phenolic extract
62588361|NCT02675621|ACTIVE_COMPARATOR|Phenolic beverage 2|Mix 3 flavored still beverage with a high dose phenolic extract1 and a fruit extract
62588362|NCT02675621|ACTIVE_COMPARATOR|Phenolic beverage 3|Mix 4 flavored still beverage with a low dose phenolic extract3 and a fruit extract
62588363|NCT06045403|EXPERIMENTAL|Combined intervention|Participants in the combined intervention group will receive real-time health risk warnings for heat waves and cold spells via a WeChat mini-program and will perform daily self-monitoring of BP and ECG using automated home devices.
62798245|NCT02038335||MPA/E2|Medroxyprogesterone acetate and estradiol cypionate
62798246|NCT02038335||LNG-I|Levonorgestrel subdermal implant
62798247|NCT02038335||ENG-I|Etonogestrel subdermal implant
62798248|NCT02038335||Cu-IUD|Copper IUD
62222779|NCT02020382|OTHER|Witnesses healthy adults|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
62222780|NCT02020382|OTHER|Witnesses adults with non-IBD inflammation|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
62222781|NCT02020382|OTHER|Children with colitis|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
62588364|NCT06045403|EXPERIMENTAL|Self-monitoring alone|
62798249|NCT05878535|ACTIVE_COMPARATOR|The Metformin Group (MG)|"The group (n=385) will receive metformin oral tablets in addition to the standard rate/rhythm control strategy and anticoagulation.~• Drug: metformin 850 mg oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. The dose can be up-titrated to 1500-2000 mg divided q8-12hr with meals in enrolled diabetic patients as a monotherapy or combined with sulfonylurea.~Other Name: Glucophage."
62025340|NCT00942929||Adolescents hospitalized for anorexia nervosa|Adolescent 12-18 years old, fulfilling the DSM IV criteria for anorexia nervosa, hospitalized for medical stabilization and/ or initiation of refeeding
62025341|NCT00942929||Controls|Adolescents 12-18 years old without anorexia nervosa hospitalized for reasons other than those involving the respiratory system and with no underlying lung disease
62222782|NCT02020382|OTHER|Witnesses healthy children|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
62222783|NCT04304521||Intensive care|Patients admitted in the intensive care unit of the University Hospital of Saint-Etienne, France between December 2018 and July 2019
62222784|NCT03045068|EXPERIMENTAL|Study Group|"Platelet Transfusion Management~1. Pre-Termination of CPB- Platelet Transfusion 10ml/kg to be administered to the patient via central venous access when the patient has been rewarmed to 35\*C, (the Sano or BT shunt clip is still on in children with SV physiology)~2. Post CPB- Platelet transfusion 10ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion."
62416851|NCT05145660|ACTIVE_COMPARATOR|Elective region irradiation|"High-risk CTV1 : GTVnx plus a 10-mm margin to encompass the microscopic extension of the gross tumor, the whole nasopharynx, the high-risk structures recommended for CTVp2 by the contouring consensus\* (such as parapharyngeal space, skull base, pterygopalatine fossa and the inferior part of the nasal cavity and maxillary sinus), the VIIa, and the retrostyloid space above the bilateral transverse process of C1.~Low-risk CTV2:~N0/positive RPLN only: Bilateral level III + Va N1-2 (positive cervical LNs): At least one subsequent level below CTV1"
62798250|NCT05878535|PLACEBO_COMPARATOR|The Placebo Control Group (PCG)|"The group (n=385) will receive placebo oral tablets in addition to the standard rate/rhythm control strategy and anticoagulation.~• Drug: Placebo oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. Other Name: Placebo"
62798251|NCT00741975|EXPERIMENTAL|1|Affect Management
62798252|NCT00741975|ACTIVE_COMPARATOR|2|General Health Promotion
62222785|NCT03045068|ACTIVE_COMPARATOR|Control Group|"Platelet Transfusion Management~1. Pre-Termination of CPB- No intervention~2. Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion."
62222786|NCT02117947|EXPERIMENTAL|Behavioral Counseling|Behavioral counseling used evidence-based smoking cessation intervention components as well as a theoretically-framed focus on behavioral shaping to promote the adoption of smoke-free homes and cars. Sessions included two, 1-hour in-home counseling and seven, 5-15 minute telephone follow-up sessions over 16 weeks. Content included health ed around the benefits of eliminating children's exposure to secondhand smoke; skills training around adoption and maintenance of smoke-free environments; goal setting, problem solving, and positive reinforcement for progress toward goals; coping skills training for smoking urge and mood management; and home support for maternal smoking behavior change achieve through family contracts and home detailing promoting pro-smoke-free home norms.
62222787|NCT02117947|ACTIVE_COMPARATOR|Self-help control|The self-help control group received a comprehensive self-help manual that outlined all of the goals and strategies covered in counseling, however, counseling was not provided to this group.
62222788|NCT01319630||Normal Saline|patients with severe sepsis/septic shock randomized to receive 1500 cc of Normal saline bolus as the resuscitation fluid.
62222789|NCT01319630||Albumin|patients with severe sepsis/septic shock randomized to receive 500 cc of Albumin 5% bolus as the resuscitation fluid.
62222790|NCT01319630||HES|patients with severe sepsis/septic shock randomized to receive 500 cc of Hydroxyethyl starch (HES 130kD) bolus as the resuscitation fluid.
62222791|NCT00652210|EXPERIMENTAL|MPM|Subject tissue was reviewed using multiphoton microscopy
62222792|NCT04555980|EXPERIMENTAL|Warm patch|the injection site was covered with warm patch.
62222793|NCT04555980|PLACEBO_COMPARATOR|Cotton patch|the injection site was covered with cotton patch.
62222794|NCT05986747|EXPERIMENTAL|Experimental Group|In the experimental group Video based CBT guided self help intervention will be provided
62416852|NCT06701409||Beach tennis player|After inclusion in the study, players will report their injuries monthly through an on-line questionnaire
62416853|NCT04166526||Group 1: Typically developing children|Participants of this group will not have a diagnosis of SCD. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
62416854|NCT04166526||Group 2: Children with SCD not receiving treatment|Participants of this group have a diagnosis of SCD, but do not receive chronic transfusions, gene therapy or bone marrow transplants. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
62588365|NCT06045403|NO_INTERVENTION|Control|
62588366|NCT00620360|EXPERIMENTAL|fructose|acute fructose administration
62588367|NCT03740347||Juvenile idiopathic arthritis and chronic pain|Patients followed for juvenile idiopathic arthritis and chronic pain in Necker Hospital
62025342|NCT01038908|ACTIVE_COMPARATOR|1|Each patient will receive an injection of technetium-99m sulfur colloid directed subareolar or around the tumor. The material will be prepared as per manufacturer's specifications. The dose will be 20mBq given the same day of 80mBq given the day before. The Nuclear Medicine Department at St Paul's Hospital will perform the injection as per normal sentinel lymph node mapping protocol.
62798253|NCT00567450|ACTIVE_COMPARATOR|B|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
62798254|NCT00567450|EXPERIMENTAL|A|30 ml of ropivacaine 0.75%
62798255|NCT04354662|EXPERIMENTAL|Toripalimab combined with FLOT|In the perioperative period, patients with resectable gastric cancer is treated with flot regimen combined with Toripalimab to observe whether the 3-year disease-free survival (DFS) rate, pathological remission rate, R0 resection rate, D2 radical resection rate, 5-year DFS rate and 5-year OS rate could be improved.
62798256|NCT03800121||Localized sarcoma with neoadjuvant chemotherapy|"In total, several blood tests specific to the EXOSARC study will be necessary:~* A first blood test of 7 mL during the initial assessment (inclusion)~* Then four blood samples of 32mL distributed over 6 months"
62798257|NCT03800121||Metastatic or locally advanced sarcoma|"In total, several blood tests specific to the EXOSARC study will be necessary :~* A first blood of 7 mL during the initial assessment (inclusion)~* Then three blood samples of 32 mL distribuated over 3 months"
62798258|NCT02946034|EXPERIMENTAL|Viekira Pak ± ribavirin or Mavyret|"12 week therapy with Viekira Pak ± ribavirin~8 or 12 week therapy with Mavyret"
62222795|NCT05986747|NO_INTERVENTION|Control Group|In the control group, the patients screened for depression or anxiety received treatment as usual (TAU). TAU consisted of standard care under the responsible family physician. TAU in Pakistan largely consists of pharmacological treatment with anti-depressant medication and follow-up in an outpatient clinic.
62025343|NCT01038908|ACTIVE_COMPARATOR|2|Each patient will receive an injection of technetium-99m sulfur colloid directed subareolar or around the tumor. The material will be prepared as per manufacturer's specifications. The dose will be 20mBq given the same day of 80mBq given the day before. The Nuclear Medicine Department at St Paul's Hospital will perform the injection as per normal sentinel lymph node mapping protocol.
62025344|NCT05284994|OTHER|TQ-B3525 Tablets + Osimertinib Mesylate Tablets.|TQ-B3525 tablets combined with osimertinib mesylate tablets, 30 days as a treatment cycle.
62025345|NCT03424681|EXPERIMENTAL|Modafinil|Modafinil 300 mg by mouth each day
62222796|NCT02293564|EXPERIMENTAL|gevokizumab|
62222797|NCT02744378|ACTIVE_COMPARATOR|Clobetasol Group|clobetasol propionate (0.05%) cream
62222798|NCT02744378|ACTIVE_COMPARATOR|Tacrolimus Group|tacrolimus (0.1%) cream
62222799|NCT01246739|NO_INTERVENTION|Follow-up|Patients who are diagnosed with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), who are followed only.
62222800|NCT01246739|EXPERIMENTAL|Surgery|Patients diagnosed with adrenal tumour and with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), operated with adrenalectomy
62222801|NCT05475652|SHAM_COMPARATOR|Sham (ligth touch)|Placebo intervention composed of light touch treatment on the cervical spine.
62222802|NCT05475652|EXPERIMENTAL|Manual therapy|Manual therapy applied to the cervical spine.
62222803|NCT03375528|EXPERIMENTAL|coronary artery disease patients|To define the Matrix metalloproteinases expression level in the neointimal hyperplasia induced by DES implantation
62222804|NCT00807287|EXPERIMENTAL|1|Placement of jejunal feeding tube using the unguided frictional method
62025346|NCT03424681|PLACEBO_COMPARATOR|Placebo|Identical looking capsule/number of capsules by mouth each day without active medication
62025347|NCT02813226|OTHER|Imaging|Molecular Imaging
62025348|NCT00856050|EXPERIMENTAL|letrozole|single arm trial - all patients received letrozole 2.5mg by mouth per day
62222805|NCT00807287|ACTIVE_COMPARATOR|2|Jejunal tube placement using the endoscopic method
62222806|NCT03701529|EXPERIMENTAL|Sevoflurane|1.5-2.5 vol% of sevoflurane is used for maintenance of anesthesia.
62222807|NCT03701529|ACTIVE_COMPARATOR|Propofol|2-5 mcg/ml of propofol is used continuously for maintenance of anesthesia using target-controlled infusion system.
62222808|NCT00292721|NO_INTERVENTION|Control|
62416855|NCT04166526||Group 3: Children with SCD who have undergone gene therapy|Participants of this group have a diagnosis of SCD and have had gene therapy at least one month prior to enrollment. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
62025349|NCT03903133|OTHER|vitamin E supplementation|vitamin E supplementation for three months (400-600 mg/day) (400 mg/day in those weighed less than 20 kg and 600 mg/day in those weighed at least 20 kg)
62025350|NCT02385448|EXPERIMENTAL|Dienogest|
62025351|NCT02385448|ACTIVE_COMPARATOR|Combined oral contraceptive pills|
62025352|NCT05776563|OTHER|Brain Glucose Levels in Participants with Type 2 Diabetes|Intensification of diabetes management
62025353|NCT00135954|OTHER|late intervention|cyclophosphamide and steroids started at time of renal insufficiency
62025354|NCT00135954|EXPERIMENTAL|early intervention|immediate start of cyclophosphamide and steroids
62025355|NCT04864015|PLACEBO_COMPARATOR|Conventional mouthpiece|Patients undergoing standard EGD using a conventional mouthpiece
62025356|NCT04864015|ACTIVE_COMPARATOR|Droplet reduction mouthpiece|Patients undergoing standard EGD using a new droplet reduction mouthpiece
62025357|NCT06021717|EXPERIMENTAL|Group A|PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1) as postoperative analgesia.
62025358|NCT06021717|ACTIVE_COMPARATOR|Group B|PCA morphine (Pfizer Inc., US) 1 mg ml-1 as postoperative analgesia.
62025359|NCT00941239|EXPERIMENTAL|metformin ER|Extended Release Metformin
62222809|NCT00292721|ACTIVE_COMPARATOR|Celecoxib|
62222810|NCT02006953|ACTIVE_COMPARATOR|Bolus|"Bolus: Total volume of feedings is determined by the amount of formula required to meet calorie and protein needs, which is determined by a Registered Dietitian. Volume of each bolus is determined by dividing the total volume of feeding by the desired number of feedings per day:~If child is less than 6 months: 8 feeds/day If child is 6-12 months 6 feeds/day If child is 12 months or greater: 5 feedings/day Rate of feeds is determine by the rate needed to infuse each bolus over 1 hour. Patient to remain NPO. Once at goal, if able to take PO, may offer orally first with remainder of goal volume over the remainder of the hour."
62222811|NCT02006953|ACTIVE_COMPARATOR|Continuous|Continuous: Total volume of feedings is determined by the amount of formula required to meet calorie and protein needs, which is determined by a Registered Dietitian. Rate of feeds is determined by dividing total volume of feedings by 24 hours. Patient is to remain NPO. Once at goal, if able to take PO, may offer hourly amount orally, but only 2x per day.
62222812|NCT02472197|EXPERIMENTAL|morcellation|
62222813|NCT02472197|ACTIVE_COMPARATOR|standard resection|
62222814|NCT03810131|NO_INTERVENTION|Waitlist control|This is a group who are waiting for treatment (the control group)
62222815|NCT03810131|EXPERIMENTAL|BOA online intervention|The is the group who are receiving the BOA online intervention.
62025360|NCT00941239|ACTIVE_COMPARATOR|metformin|Immediate release metformin
62222816|NCT06181331|EXPERIMENTAL|First stage intervention: eConquerFear|Participants in the eConquerFear intervention group will receive six online modules with each containing educational text, illustrative graphics, interactive exercises, and brief videos. Every module will teach a specific topic, such as self-examination and medical surveillance, values-based goal setting, attention training, detached mindfulness, worry management and treatment summary and relapse prevention.
62025361|NCT01234506|ACTIVE_COMPARATOR|secoisolariciresinol diglucoside|Secoisolariciresinol diglucoside (SDG) supplementation as 0.8g/day of BeneFlax containing 300 mg SDG. 1000 IU vitamin D as standard of care.
62222817|NCT06181331|ACTIVE_COMPARATOR|First stage intervention: eHealthMaintenance|Participants in the eHealthMaintenance group will receive six videos, which were designed to provide comprehensive lifestyle guidance (e.g., relaxation techniques, diet and physical activity advices) to help with survivors' maintenance of health in long-term.
62222818|NCT06181331|EXPERIMENTAL|Second stage intervention: ConquerFear-HK|ConquerFear-HK is a culturally adapted, manualized intervention consisting of 6 individual face-to-face sessions over 10 weeks.
62588368|NCT06666920|EXPERIMENTAL|Laser-assisted tooth bleaching technique|The left hemiarches of the patient's dentition received laser treatment during tooth bleaching procedure
62588369|NCT06666920|NO_INTERVENTION|Conventional tooth bleaching technique|The right hemiarches of the patient's dentition received laser treatment during tooth bleaching procedure
62588370|NCT02272842|EXPERIMENTAL|Vitamin B12|A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)
62588371|NCT02272842|PLACEBO_COMPARATOR|Placebo|A paste containing no vitamin administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)
62025362|NCT01234506|PLACEBO_COMPARATOR|Placebo|An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
62588372|NCT05892276|EXPERIMENTAL|CBD-WR|"300 mg CBD broad-spectrum oil will be administered within the reconsolidation window.~Preclinical studies demonstrate that the disruptive effects of CBD oil on memory reconsolidation depend on the timing of pharmacological administration (within 6 hours of memory reactivation).~Thus, participants will be asked to take a single 300mg oral dose of CBD broad-spectrum oil immediately after the trauma memory reactivation procedure."
62588373|NCT05892276|PLACEBO_COMPARATOR|PBO-WR|"Placebo oil will be administered within the reconsolidation window.~Participants will be asked to take a single dose of an MCT coconut oil placebo solution immediately after the trauma memory reactivation procedure."
62416856|NCT04166526||Group 4: Children with SCD who have chronic transfusions|Participants of this group have a diagnosis of SCD and receive chronic transfusions. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
62416857|NCT03985800|ACTIVE_COMPARATOR|TEAM-care as usual approach|Patients will be triaged based on their physical health (PH) and behavioral health (BH) complexity to determine the frequency of in-person visits and how much of these visits will be devoted to medical versus BH issues
62416858|NCT03985800|ACTIVE_COMPARATOR|TECH-telehealth approach|Each patient will have an initial face-to-face visit with the core treatment team described above and undergo the same triage process to determine their PH/BH care needs. Each TECH patient will participate in one face-to-face treatment team visit per year unless more frequent visits are deemed to be medically necessary; however, all other interactions will be conducted via technology-supported modalities
62588374|NCT05892276|ACTIVE_COMPARATOR|CBD-OR|"300mg CBD broad-spectrum oil will be administered outside of the reconsolidation window.~Participants will be asked to take a single 300mg oral dose of CBD broad-spectrum oil approximately 24 hrs after the trauma memory reactivation procedure.~Thus, CBD will be administered well beyond the critical period for memory reconsolidation. The inclusion of this third arm provides a more robust test of the specific reconsolidation theory-based study hypotheses and aids in controlling for any nonspecific possible anxiolytic effects of CBD."
62588375|NCT01509417|EXPERIMENTAL|Ad lib feeding|ad lib feedings following pyloromyotomy
62025363|NCT00951600|EXPERIMENTAL|1|Oxcarbazepine oral suspension 300 mg/5mL of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
62025364|NCT00951600|ACTIVE_COMPARATOR|2|Trileptal® (oxcarbazepine) oral suspension 300 mg/5mL of Novartis
62025365|NCT01699594|EXPERIMENTAL|Mannitol|This arm will assess the allergen induced change in airway responsiveness to mannitol bronchoprovocation.
62025366|NCT01699594|ACTIVE_COMPARATOR|Methacholine Chloride|This arm will assess the allergen induced change in airway responsiveness to methacholine bronchoprovocation.
62025367|NCT04915963|EXPERIMENTAL|vitamin D group|170 patients receiving a single dose of 400,000 IU of VD3 (2 vials of 200,000 IU VD3; B.O.N., BOUCHARA RECORDATI) orally or through a nasogastric tube
62416859|NCT05005000|EXPERIMENTAL|MFAT|
62416860|NCT05005000|ACTIVE_COMPARATOR|Steroid (Control)|
62416861|NCT00650637|EXPERIMENTAL|1|
62416862|NCT00650637|EXPERIMENTAL|2|
62416863|NCT02292732|EXPERIMENTAL|Trametinib/ ORTHO-NOVUM® tablet|Subjects in treatment period 1will take one active tablet from the ORTHO-NOVUM® tablet 1/35 dial-pack once daily at approximately the same time each day for 21 days (Days 1 through 21), followed by one placebo tablet once daily at approximately the same time each day for 7 days (Days 22 through 28). In addition, subjects will take trametinib 2 mg (1 tablet) once daily at approximately the same time each day for a total of 17 days (Days 12 through 28). Subjects in treatment period 2 will take one active tablet from the ORTHO-NOVUM® tablet 1/35 dial-pack once daily at approximately the same time each day for 11 days (Days 1 through 11). In addition, subjects will take trametinib 2 mg (1 tablet) once daily at approximately the same time each day for 11 days (Days 1 through 11).
62025368|NCT04915963|SHAM_COMPARATOR|Placebo group|170 patients receiving distilled water (2 vials of 1 ml distilled water) orally or through a nasogastric tube
62025369|NCT00569504||A, observatoin|inpatients and outpatients in Seoul National Hospital
62025370|NCT03153917|EXPERIMENTAL|melatonin and cortisol sampling|14 healthy volunteer nurses working on 12 hours night/day schedules in the Sleep Medicine Center of Lyon.
62416864|NCT04991116|EXPERIMENTAL|TILD q12 weeks|
62588376|NCT01509417|ACTIVE_COMPARATOR|FLAP diet after pyloromyotomy|FLAP diet after pyloromyotomy
62588377|NCT06641193|EXPERIMENTAL|verum group|verum group receive real 10 sessions of rTMS stimulation. once daily for 5 consecutive days a week.
62416865|NCT01889641||Patients with lupus|Patients with lupus (four levels of activity disease)
62416866|NCT01889641||healthy volunteers|Subjects controls
62416867|NCT00591526|NO_INTERVENTION|A|"Patients aged ≤ 60 years and with initial WBC ≤ 10000/mm3 Induction treatment~a) ATRA and chemotherapy ATRA 45 mg/m2/d until hematological CR first intensive chemotherapy course : DNR 60 mg/m2/d during 3 days AraC 200 mg/m2/d during 7 days~2) Consolidation treatment~1. First consolidation course (=2nd chemotherapy course) DNR 60 mg/m2/d d1-3 (intravenous bolus injection) AraC 200 mg/m2/d d1-7 (continuous infusion)~2. Second consolidation course AraC 1g/m2/12h d1-4 (1 hour infusion) Daunorubicin 45 mg/m2/d d1-3 (intravenous bolus injection) 3) Maintenance treatment~Consists of the combination of continuous low dose chemotherapy and intermittent ATRA, during 2 years~1. Continuous low dose chemotherapy~2. Intermittent ATRA"
62416868|NCT00591526|EXPERIMENTAL|B|Patients aged ≤ 60 years and with initial WBC ≤ 10000/mm3 (Group B) Same treatment as Group A but without AraC.
62588378|NCT06641193|SHAM_COMPARATOR|sham group|The sham group receives 10 sessions of rTMS stimulation, once daily for 5 consecutive days a week. However, a sham stimulation coil is used, which emits the same sound and vibration as the active coil but does not produce any induced electrical currents.
62588379|NCT04782453|EXPERIMENTAL|ToQuit|Participants from the ToQuit intervention arm will receive the messages on their mobile phones for 8 weeks. The messages will be sent for 3-4 days a week.
62588380|NCT04782453|OTHER|Control|Participants from the control group will be sent the details of other functional tobacco helplines in India.
62588381|NCT03554174|EXPERIMENTAL|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
62588382|NCT03554174|EXPERIMENTAL|Placebo/Medium Dose Psilocybin|Subjects in this arm receive placebo in the first session and medium dose psilocybin in the second session.
62588383|NCT03554174|EXPERIMENTAL|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
62025371|NCT01082666|EXPERIMENTAL|Continuous control|Continuous control of cuff pressure using a pneumatic device
62025372|NCT01082666|ACTIVE_COMPARATOR|Manual control|Manual control of cuff pressure is a routine practice in ICU patients
62025373|NCT05436782|ACTIVE_COMPARATOR|Group A|• Group A (control group) will receive routine physical therapy involving muscle strengthening exercises, range of motion exercises, and stretching exercises up to the patient's tolerance. Other exercises will be pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, and wobble board exercises. Each session will be of 60 minutes 5 times weekly for 6 weeks
62222819|NCT06181331|ACTIVE_COMPARATOR|Second stage intervention: eConquerFear+eHealthMaintenance|The augmented eConquerFear + eHealthMaintenance intervention is a combined unsupervised, self-guided web-based intervention that consists of 10 weekly online modules covering the content of eConquerFear and eHealthMaintenance interventions.
62416869|NCT00591526|NO_INTERVENTION|C|"1. First consolidation course (=2nd chemotherapy course) DNR 60 mg/m2/d d1-3 (intravenous bolus injection) AraC 200 mg/m2/d d1-7 (continuous infusion)~2. Second consolidation course AraC 1g/m2/12h d1-4 (1 hour infusion) Daunorubicin 45 mg/m2/d d1-3 (intravenous bolus injection)~CNS prophylaxis : consists of 5 intrathecal (IT) injections of MTX 15mg and AraC 50 mg (12 mg/m2 maximum 15 mg, and 30mg/m2, maximum 50 mg, respectively, in children) + depomedrol IT. I~3) Maintenance treatment"
62222820|NCT05403112|ACTIVE_COMPARATOR|Group I: autogenous bone rings|sinus lifting was augmented by bone rings were harvested from chin
62222821|NCT05403112|ACTIVE_COMPARATOR|GroupII : autogenous sticky bone|sinus lifting was augmented by autogenous sticky bone was harvested from chin and immediate implant placement
62222822|NCT03324191|PLACEBO_COMPARATOR|Placebo|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and placebo drink within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg \[1,1,1-13C3\] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
62222823|NCT03324191|EXPERIMENTAL|Tea beverage|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and tea within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg \[1,1,1-13C3\] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
62222824|NCT03324191|EXPERIMENTAL|Tea extract (medium concentration)|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and concentrated tea extract at a medium concentration within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg \[1,1,1-13C3\] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
62222825|NCT03324191|EXPERIMENTAL|Tea extract (high concentration)|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and concentrated tea extract at a high concentration within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg \[1,1,1-13C3\] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
62222826|NCT01435616|EXPERIMENTAL|LY2605541|LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC), once daily in combination with at least 2 pre-study oral antihyperglycemic medications (OAMs) prescribed by the personal physician, for 52 or 78 weeks
62588384|NCT03554174|EXPERIMENTAL|Medium Dose Psilocybin/Placebo|Subjects in this arm receive medium dose psilocybin in the first session and placebo in the second session.
62588385|NCT03301844|EXPERIMENTAL|Study treatment|Blephapad Combo twice daily for one month. Blephapad is a disposable wet wipe containing Hy-Ter® solution (sodium hyaluronate acid and 4-terpineol), aloe, natural anti-inflammatories and antiseptics.
62588386|NCT03301844|OTHER|Standard treatment|Wet, warm gauze twice daily for one month.
62588387|NCT06034938|EXPERIMENTAL|Single arm DOR/3TC/TDF|Doravirine 100 mg Lamivudine 300 mg Tenofovir disoproxil fumarate 245 mg Delstrigo (R): 1 pill/day for 48 weeks
62588388|NCT02176863|EXPERIMENTAL|Stage 1 Arm 1: 2 g/kg Flebogamma 5% DIF|Flebogamma 5% DIF 2 g/kg of body weight administered via intravenous infusion over 2 consecutive days (Flebogamma 5% DIF 1 g/kg infused on Day 1 and Flebogamma 5% DIF 1 g/kg infused on Day 2) every 4 weeks for 52 weeks.
62798259|NCT01358825|EXPERIMENTAL|Infanrix hexa Group|Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix hexa™ (DTPa-HBV-IPV/Hib) administered intramuscularly in study NCT00307034.
62798260|NCT01358825|EXPERIMENTAL|Infanrix-IPV/Hib Group|Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix-IPV/Hib™ (DTPa-IPV/Hib) administered intramuscularly in study NCT00307034.
62025374|NCT05436782|EXPERIMENTAL|Group B|Group B (experimental group) will receive routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals will be performed in lower extremity in D1 flexion pattern and D1 extension pattern up to patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks. The outcome measure will be measured at and 6th week interval
62025375|NCT00817089|PLACEBO_COMPARATOR|Group 1 Asn40 Placebo Placebo|Each alcohol session preceded by pretreatment with placebo oral tablet
62025376|NCT00817089|ACTIVE_COMPARATOR|Group 2 Asn40 Placebo Naltrexone|The first alcohol session preceded by pretreatment with placebo oral tablet. The second alcohol session preceded by pretreatment with naltrexone 50 mg as a single dose.
62025377|NCT00817089|PLACEBO_COMPARATOR|Group 3 Asp40 Placebo Placebo|Each alcohol session preceded by pretreatment with placebo oral tablet
62025378|NCT00817089|ACTIVE_COMPARATOR|Group 4 Asp40 Placebo Naltrexone|The first alcohol session preceded by pretreatment with placebo oral tablet. The second alcohol session preceded by pretreatment with naltrexone 50 mg as a single dose.
62222827|NCT01435616|ACTIVE_COMPARATOR|Glargine|Glargine titrated based on blood glucose readings, administered SC, once daily in combination with at least 2 pre-study OAMs prescribed by the personal physician, for 52 or 78 weeks
62222828|NCT02811731|EXPERIMENTAL|Candesartan and Amlodipine|Candesartan 16mg and Amlodipine 5mg, PO, 1days or 22days
62222829|NCT02811731|EXPERIMENTAL|CKD-330|CKD-330 16/5mg - B, PO, 1days or 22days
62222830|NCT01854723|EXPERIMENTAL|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
62222831|NCT01854723|ACTIVE_COMPARATOR|Continuation of insulin glargine|Patients in this arm will continue on insulin glargine and serve as a control group.
62798261|NCT04830579|OTHER|Sequence TR|17 subjects assigned to the sequence TR will receive a single 120 mg dose of the test product Etoricoxib (1 x 120 mg tablet), marked as T in the sequence, in Period 1 and a single 120 mg dose of the reference product Arcoxia® (1 x 120 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62798262|NCT04830579|OTHER|Sequence RT|17 subjects assigned to the sequence RT will receive a single 120 mg dose of the reference product Arcoxia® (1 x 120 mg tablet), marked as R in the sequence, in Period 1 and a single 120 mg dose of the test product Etoricoxib (1 x 120 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62798263|NCT00725049|ACTIVE_COMPARATOR|Dental implant (Nanotite)|Dental implants of short length placed without sinus lifts
62798264|NCT00725049|NO_INTERVENTION|Control group|Dental implants of standard length placed simultaneously with sinus augmentation
62798265|NCT02634333|SHAM_COMPARATOR|Observation (Prompt Sham)|Sham injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. Deferred aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
62798266|NCT02634333|EXPERIMENTAL|Prompt aflibercept|Aflibercept injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. More frequent aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
62798267|NCT05993663|EXPERIMENTAL|Intervention group|Intervention groups that will receive 12 Arts in Health session. There will be four groups of 15 individuals for reaching the needed sample size.
62798268|NCT05993663|NO_INTERVENTION|Control group|Control groups. Participants in these groups won't receive any group intervention, just regular health care.
62025379|NCT00237744|EXPERIMENTAL|Wrist/Hand FES + Whole Arm Motor Learning|Subjects \> 6 months following first stroke with diminished upper limb strength, coordination and function, who received whole arm motor learning training and FES of the wrist/hand.
62025380|NCT00237744|EXPERIMENTAL|Shoulder/Elbow Robotics + Whole Arm Motor Learning|Subjects\>6 months following first stroke with diminished upper limb strength, coordination and function, who received whole arm motor learning and shoulder/elbow robotics.
62798269|NCT03079063|EXPERIMENTAL|Eptacog alfa biosimilar for PK|Randomized, double-blind, single dose cross-over for PK, with 12 months follow up with eptacog alfa biosimilar provided for treatment of bleeding on demand - or - prophylaxis.
62798270|NCT03079063|ACTIVE_COMPARATOR|Novoseven|Randomized, double-blind, single dose cross-over for PK, with 12 months follow up with eptacog alfa biosimilar provided for treatment of bleeding on demand - or - prophylaxis.
62798271|NCT06270485|OTHER|ventilated children|Application of different PEEP-levels during invasive mechanical ventilation
62798272|NCT04526912|EXPERIMENTAL|VIB7734 Dose|Participants will receive a single subcutaneous dose of VIB7734.
62025381|NCT00237744|EXPERIMENTAL|Whole Arm Motor Learning|Subjects\>6 months following first stroke with diminished upper limb strength, coordination and function who received whole arm motor learning training without addition of FES or Robotics
62025382|NCT03246360|ACTIVE_COMPARATOR|Intermittent administration of cloxacillin|
62025383|NCT03246360|EXPERIMENTAL|continuous administration of cloxacillin|
62025384|NCT03998826|EXPERIMENTAL|Piroxicam drug|20 mg piroxicam
62025385|NCT03998826|PLACEBO_COMPARATOR|Placebo|placebo
62025386|NCT02861781||Type 2 diabetes|Type 2 diabetes according to ADA criteria
62025387|NCT02861781||Insulin resistance non diabetes|HOMA-IR criteria ≥ 3
62222832|NCT02814929||Demographic and Prenatal Characteristics|Gender, multiple pregnancy antenatal steroid therapy, invitro fertilisation, preeclampsia/eclampsia, infants of diabetic mother, chorioamnionitis will be compared among infants with and without ROP
62222833|NCT02814929||Neonatal Characteristics of infants|Neonatal characteristics: GA, BW, SGA, resuscitation in delivery room, RDS, duration of mechanical ventilation and oxygen therapy, intracranial hemorrhage, hemodynamically significant PDA, early/late sepsis, NEC, number of blood transfusions, BPD, breastfeeding and weight gain at postnatal 28th day will be compared among infants with and without ROP.
62025388|NCT02861781||Insulin sensitivity non diabetes|HOMA-IR criteria \< 3
62025389|NCT02219932|EXPERIMENTAL|Fampridine 10 mg BID|Prolonged-release fampridine 10 mg twice daily (BID) for up to 24 weeks
62025390|NCT02219932|PLACEBO_COMPARATOR|Placebo|Matched placebo 10 mg BID for up to 24 weeks
62416870|NCT00591526|NO_INTERVENTION|D|"Patients aged \>60 years and initial WBC ≤ 10000/mm3 Induction treatment~a) ATRA and chemotherapy ATRA 45 mg/m2/d until hematological CR first intensive chemotherapy course : DNR 60 mg/m2/d during 3 days (intravenous bolus injection) NO ARA C DURING THIS FIRST COURSE~2) Consolidation treatment~1. First consolidation course DNR 60 mg/m2/d d1-3 AraC 100 mg/m2/d d1-5 G-CSF~2. Second consolidation course DNR45 mg/m2/d d1-3 AraC 100 mg/m2/d d1-5 G-CSF~   3) maintenance treatment: similar to other groups"
62416871|NCT06567353|EXPERIMENTAL|Multi-mode ablation|Subjects in this arm will receive image-guided multi-mode ablation.
62416872|NCT06567353|ACTIVE_COMPARATOR|Conventional radiofrequency ablation|Subjects in this arm will receive image-guided radiofrequency ablation.
62416873|NCT04059900|EXPERIMENTAL|STW5 (Iberogast®, BAY98-7411)|The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.
62416874|NCT04059900|PLACEBO_COMPARATOR|Placebo|The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
62588389|NCT02176863|EXPERIMENTAL|Stage 1 Arm 2: 1 g/kg Flebogamma 5% DIF|Flebogamma 5% DIF 1 g/kg of body weight administered via intravenous infusion on Day 1 and 20 mL/kg of body weight of normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will also be administered on a separate day, for a total dosing period of 2 consecutive days. every 4 weeks for 52 weeks. The order of 1 g/kg of body weight of Flebogamma® 5% DIF or 20 mL/kg of body weight normal saline solution infused on 2 consecutive days will be randomly determined for each participant by the Interactive Web Response System (IWRS), which will remain the same for the participant for all infusion visits during the treatment period.
62798273|NCT04526912|PLACEBO_COMPARATOR|Placebo|Participants will receive a single subcutaneous dose of placebo (saline) matched to single dose of VIB7734.
62798274|NCT04344275|EXPERIMENTAL|Kinesio-taping (KT)|The skin will first be properly cleaned with rubbing alcohol. An I-shaped strip of Kinesio tape with a 5-cm width was applied over the middle trapezius from origin to insertion in the KT group. Kinesio-tape size was measured from the T3 spinal process to the acromion, while the subject is in sitting position relaxed with the arm at the trunk side. The subject was then instructed to move the arm into horizontal adduction and neck flexion. At this position, the tape was applied involving the middle trapezius, ending on the acromion, with 50% tension as recommended for this technique.
62798275|NCT04344275|PLACEBO_COMPARATOR|Placebo Kinesio-taping (KT)|Kinesio-tape was applied with no tension and technique on the middle trapezius.
62798276|NCT03315520|EXPERIMENTAL|Relapsed/refractory malignant lymphomas|Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation using BeEAC (Bendamustine, Cytarabine, Etoposide, Cyclophosphamide) conditioning regimen
62798277|NCT02442349|EXPERIMENTAL|AZD9291|Once daily tablet 80 mg
62798278|NCT05367570||Normal weight group|The first work package of this study is cross-sectional. The investigators will investigate the 24-hour movement behaviors, cardiometabolic parameters and some personal and environmental correlates.
62798279|NCT05367570||Overweight/obesity group|The first work package of this study is cross-sectional The investigators will investigate the 24-hour movement behaviors, cardiometabolic parameters and some personal and environmental correlates.
62798280|NCT05193162||Pancreatic ductal adenocarcinoma|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
62025391|NCT05130112|EXPERIMENTAL|HFNC then NC|High flow nasal cannula for 10 min (Period 1) and nasal cannula for 10 min (Period 2) after a 4-week washout period
62025392|NCT05130112|EXPERIMENTAL|NC then HFNC|Nasal cannula for 10 min (Period 1) and high flow nasal cannula for 10 min (Period 2) after a 4-week washout period
62025393|NCT03615157|EXPERIMENTAL|Home-based exercise rehabilitation|Patients will be submitted to a 12-weeks training program, with walking at 60-70% of heart rate reserve monitored by a heart rate monitor (30 minutes/session for 5 days/week) and peripheral muscle training including upper and lower limbs (50% of the 1-maximum repetition test)
62025394|NCT03615157|ACTIVE_COMPARATOR|Supervised exercise rehabilitation|Patients will be submitted to a 12-weeks training program, with sessions (3 days/week) supervised by a physiotherapist, including cycling at 60-70% of heart rate reserve and peripheral muscle training of upper and lower limbs (50% of the 1-maximum repetition test)
62025395|NCT04775446||Patients with malignant pleural mesothelioma treated with Nivolumab.|Patients with malignant pleural mesothelioma treated with Nivolumab.
62416875|NCT05392712|OTHER|healthy volunteers|
62416876|NCT05392712|EXPERIMENTAL|Chest pain patients who will undergo CAG or CTA|
62416877|NCT05392712|EXPERIMENTAL|AMI patients|
62416878|NCT04560920|EXPERIMENTAL|Experimental|This group will contribute PGHD and it will be available in the study visit.
62416879|NCT04560920|NO_INTERVENTION|Control|This group may contribute PGHD but if so, it will not be available during a study visit, it will be available to the provider in a subsequent visit.
62416880|NCT02572427|EXPERIMENTAL|Education for intubation skills|Interventions: Training for Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP); 7 minute excerpt from the NRP training video regarding intubation; cognitive instruction which consisted of equipment needed for intubation; hands on instruction using the Storz video laryngoscope with manikins in simulation lab.
62416881|NCT02572427|ACTIVE_COMPARATOR|No added education for intubation skills|Interventions: Training for Routine Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP) training; no additional training for intubating newborns.
62416882|NCT04556773|EXPERIMENTAL|Module 1: T-DXd + capecitabine|T-DXd: 5.4 mg/kg Q3W, intravenous use Capecitabine: 1000mg/m2 BID, days 1-14 Q3W, oral use
62416883|NCT04556773|EXPERIMENTAL|Module 2: T-DXd + durvalumab + paclitaxel|T-DXd: 5.4 mg/kg Q3W, intravenous use Durvalumab: 1120 mg Q3W, intravenous use Paclitaxel: 80 mg/m2 QW in 3-week cycles, intravenous use
62222834|NCT02814929||Incidence of any ROP and severe ROP|Incidence of any ROP, severe ROP and its treatment in relation to BW and GA will be evaluated. The same parameters will also be evaluated in preterm babies of refugees.
62588390|NCT02176863|PLACEBO_COMPARATOR|Stage 1 Arm 3: Placebo|Normal saline solution total dose of 40 mL/kg of body weight (equivalent volume of 2 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered over 2 consecutive days. On Day 1, a dose of 20 mL/kg of body weight Normal Saline Solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered and on Day 2, the second dose of 20 mL/kg of body weight. Normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered, every 4 weeks for 52 weeks.
62588391|NCT02176863|EXPERIMENTAL|Stage 2 Arm 1: Flebogamma 5% DIF|The dose of Flebogamma® 5% DIF selected from Stage 1 will be administered over 2 consecutive days every 4 weeks for 52 weeks.
62588392|NCT02176863|PLACEBO_COMPARATOR|Stage 2 Arm 1: Placebo|Normal saline solution total dose of 40 mL/kg of body weight (equivalent volume of 2 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered over 2 consecutive days. On Day 1, a dose of 20 mL/kg of body weight normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered and on Day 2, the second dose of 20 mL/kg of body weight normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered, every 4 weeks for 52 weeks.
62798281|NCT05193162||Chronic pancreatitis|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
62798282|NCT05193162||Pancreatic serous cystadenoma|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
62222835|NCT05551312|EXPERIMENTAL|Intervention|Virtual Essential Newborn Care (vENC) Training
62798283|NCT05193162||Pancreatic mucinous cystadenoma|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
62222836|NCT05551312|NO_INTERVENTION|Control|Standard of Care
62416884|NCT04556773|EXPERIMENTAL|Module 3: T-DXd + capivasertib|T-DXd: 5.4 mg/kg Q3W, intravenous use Capivasertib: 400 mg BID, oral use
62588393|NCT06664892|EXPERIMENTAL|Treatment Arm|
62222837|NCT04405349|EXPERIMENTAL|Combination Therapy|VB10.16 vaccinations. 11 intramuscular (i.m.) vaccinations for up to 48 weeks from first vaccination. 5 vaccinations of 3 mg VB10.16 during the first 12 weeks, followed by vaccination every 6 weeks for up to 48 weeks + Atezolizumab (1200 mg) intravenous (i.v.) infusion every 3 weeks.
62222838|NCT00719082||AARP Community|Members of AARP Geriatric Community
62588394|NCT05620732|EXPERIMENTAL|Treatment group|Patients treated with Claudin 18.2 CAR-T cells.
62588395|NCT06684951|ACTIVE_COMPARATOR|Group A|Intrauterine infusion of 700IU of human chorionic gonadotropin once immediately after ova pickup
62798284|NCT05193162||Intraductal papillary mucinous tumor|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
62798285|NCT05193162||Pancreatic neuroendocrine tumor|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
62798286|NCT05193162||Pancreatic acinar cell carcinoma|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
62025396|NCT02910622||Oncogramme breast|Taking a fragment of breast tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme
62222839|NCT05838144|ACTIVE_COMPARATOR|Acapella|Will use Acapella device 3 times per day for 15 minutes for 7 days beside medications and routine physical therapy program.
62222840|NCT05838144|PLACEBO_COMPARATOR|Only routine physical therapy program|Only they will receive medications and routine physical therapy program.
62222841|NCT03805347|EXPERIMENTAL|Medication|Extract of Helminthostachys zeylanica(L.)Hook in capsule, 1gm/time, 3 times daily
62222842|NCT03805347|PLACEBO_COMPARATOR|Starch|Starch in capsule，1gm/time, 3 times daily
62222843|NCT01992393|EXPERIMENTAL|TIME|This arm will receive the TIME intervention.
62222844|NCT01992393|NO_INTERVENTION|Treatment as Usual (TAU)|This arm will receive treatment as usual.
62222845|NCT02199743|ACTIVE_COMPARATOR|Lurasidone|Lurasidone 40mg po qhs with food x 1 week; Lurasidone 80mg po qhs with food x 3 weeks
62416885|NCT04556773|EXPERIMENTAL|Module 4: T-DXd + anastrozole|T-DXd: 5.4 mg/kg Q3W, intravenous use Anastrozole: 1 mg daily, oral
62416886|NCT04556773|EXPERIMENTAL|Module 5: T-DXd + fulvestrant|T-DXd: 5.4 mg/kg Q3W, intravenous use Fulvestrant: 500 mg Q4W, intramuscular use
62025397|NCT02910622||Oncogramme ovarian|Taking a fragment of ovarian tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme
62025398|NCT03882125|EXPERIMENTAL|Mindfulness|Assigned to a 6-week mindfulness-based relapse prevention course
62025399|NCT02300714|ACTIVE_COMPARATOR|AP group|oblique view approach during transforaminal epidural block
62025400|NCT02300714|ACTIVE_COMPARATOR|OB group|oblique view approach during transforaminal epidural block
62588396|NCT06684951|ACTIVE_COMPARATOR|Group B|Intrauterine infusion of 500IU of human chorionic gonadotropin once immediately after ova pickup
62025401|NCT01629329|ACTIVE_COMPARATOR|Aspirin, Acetaminophen, Caffeine pills|Patients receiving AAC(acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet)will receive 2 pills with active compound and placebo syringe with 2 ml of saline.
62025402|NCT01629329|ACTIVE_COMPARATOR|Prochlorperazine 10mg|Patients will receive active compound of Prochlorperazine 10mg via IV syringe and 2 unmarked placebo pills
62222846|NCT02199743|ACTIVE_COMPARATOR|Haloperidol|Haloperidol 4mg po qhs with food x 1 week; Haloperidol 8mg po qhs with food x 3 weeks.
62222847|NCT02199743|ACTIVE_COMPARATOR|Perphenazine|Perphenazine 16mg po qhs with food x 1 week; Perphenazine 32mg po qhs with food x 3 weeks.
62222848|NCT04235179|EXPERIMENTAL|SABR|Pelvic SABR for post-op endometrial cancer
62416887|NCT00973531|OTHER|Ambulatory APAP and SMT|Subjects placed on the APAP machine
62416888|NCT00973531|OTHER|Titration Polysomnogram with CPAP and SMT|Subjects placed on CPAP machine
62416889|NCT06698263|EXPERIMENTAL|Isotretinoin|Isotretinoin (40 mg) orally, once per week for 20 weeks
62416890|NCT06698263|PLACEBO_COMPARATOR|control group|Placebo identical in appearance and administration schedule.
62025403|NCT06077396|OTHER|To evaluate the effect of radial artery cannulation on hand perfusion|To evaluate the effect of radial artery cannulation on hand perfusion
62025404|NCT00221793|EXPERIMENTAL|1|Deep Brain Stimulation of the Subthalamic Nucleus
62025405|NCT00221793|ACTIVE_COMPARATOR|2|Later Deep Brain Stimulation of the Subthalamic Nucleus
62025406|NCT06336096|EXPERIMENTAL|Part A|Participants will be randomized to receive a single dose of SUZ in 1 of 6 treatment sequences with 3 dosing periods to assess the relative bioavailability of two tablet formulations and the effect of food on the PK of SUZ. There will be a 14-day washout period between each dosing period.
62025407|NCT06336096|EXPERIMENTAL|Part B|Participants will be randomized to receive a single dose of SUZ formulation in 1 of 2 treatment sequences with 2 dosing periods to assess the relative bioavailability of tablet formulation compared to a suspension of SUZ. There will be a 14-day washout period between each dosing period.
62025408|NCT06386484|EXPERIMENTAL|Boxers|
62025409|NCT06386484|NO_INTERVENTION|Controls|
62025410|NCT00852904||NCS Vanguard cohort|Women of child bearing potential, children born to women enrolled in the study, the children s biological and/or social fathers, and primary caregivers (if other than parent)
62025411|NCT03249623|EXPERIMENTAL|Beacon Caresystem|On randomisation to the Beacon group, a Beacon Caresystem will be connected to the patient. This involves connecting a pulse oximeter to the patient's finger (toe or ear) to measure pulse oximetry oxygen saturation and pulse, and placing a standard clinical respiratory gas analysis and flow sensor in the respiratory tubing connecting the ventilator to the patient. This sensor allows measurement of respiratory pressure, flow and volume; plus respiratory gas CO2 and O2.
62025412|NCT03249623|NO_INTERVENTION|Standard Care|For this group mechanical ventilation is managed according to standard care. A Beacon CareSystem will be connected to the patient, as for the Beacon Randomisation group, but the system will be used solely for data collection, and advice will be disabled. Physiological variables captured in this arm of the study will mirror the intervention arm. Decision relating to weaning, extubation, reintubation and sedation including level of seniority of personnel involved in the decision tree process will be documented accordingly.
62025413|NCT04332705||Patients with colon cancer|Patients with colon cancer of recent diagnosis will be recruited in consultation either in the surgical or gastroenterology departments
62025414|NCT04332705||Patients without colon cancer|Patients without colon cancer but with other gastrointestinal pathology needing a biopsy or a surgical procedure will be recruited either in the surgical or gastroenterology departments
62222849|NCT04199897|EXPERIMENTAL|Intervention group (sucrose + probiotics)|Sucrose rinsing 8 times a day for 14 days Probiotic lozenges 2 times a day for 25 days
62222850|NCT04199897|ACTIVE_COMPARATOR|Intervention group (sucrose + placebo|Sucrose rinsing 8 times a day for 14 days Placebo lozenges 2 times a day for 25 days
62222851|NCT04199897|PLACEBO_COMPARATOR|Control group (xylitol + probiotics)|Xylitol rinsing 8 times a day for 14 days Probiotic lozenges 2 times a day for 25 days
62222852|NCT04199897|PLACEBO_COMPARATOR|Control group (xylitol + placebo|Xylitol rinsing 8 times a day for 14 days Placebo lozenges 2 times a day for 25 days
62222853|NCT01404195|EXPERIMENTAL|Ensure Plus Advance, Supplement|Participating patients will be dispensed two bottles daily, one at breakfast and one in the evening, seven days a week.
62222854|NCT01404195|NO_INTERVENTION|Control|without supplementation
62416891|NCT01070407|EXPERIMENTAL|Arm A, group 1|4 volunteers
62416892|NCT01070407|EXPERIMENTAL|Arm A, group 2|4 volunteers
62416893|NCT01070407|EXPERIMENTAL|Arm A, group 3|5 volunteers
62416894|NCT01070407|EXPERIMENTAL|Arm B, group 5|4 volunteers
62416895|NCT01070407|EXPERIMENTAL|Arm B, group 6|4 volunteers
62416896|NCT01070407|EXPERIMENTAL|Arm B, group 7|5 volunteers
62416897|NCT01070407|EXPERIMENTAL|Arm C, group 9|5 volunteers
62416898|NCT01070407|EXPERIMENTAL|Arm C, group 10|5 volunteers
62416899|NCT01070407|EXPERIMENTAL|Arm C, group 11|4 volunteers
62416900|NCT04729634|OTHER|Mobilization and breathing training|Usual clinical care
62416901|NCT04718272|EXPERIMENTAL|Puncture tube group|After the operation, the traditional traditional silicone tube which placed through the surgical incision was removed in the operating room, and the small puncture tube was retained for thoracic drainage.
62416902|NCT04718272|NO_INTERVENTION|Traditional tubes group|Routine thoracic drainage management measures were adopted, that is, both of the small puncture tube and traditional silicone tube were retained after surgery.
62416903|NCT03022318|EXPERIMENTAL|once daily|carbidopa-levodopa 25-100 mg tablets once daily hs for up to 32 days
62798287|NCT05193162||Solid pseudopapillary tumor of pancreas|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
62025415|NCT05680168|ACTIVE_COMPARATOR|Group A: Extracorporeal Magnetic stimulation|Group (A): will receive rehabilitation program with exposure to ExMS, Patients will receive regular sessions of electromagnetic stimulation using Magneto STYM device, (Iskra medical d.o.o, Slovenia). Each session will last for 20 minutes. Patients will receive three weekly sessions for total of 20 sessions starting one month after catheter removal.
62025416|NCT05680168|ACTIVE_COMPARATOR|Group B: Extracorporeal Magnetic stimulation and pelvic floor exercises|Group (B): This group will receive a rehabilitation program depending ExMS with the protocol described above. In addition, this group will be advised for pelvic floor muscle training in serial training sessions with our therapist for PME.
62025417|NCT05680168|ACTIVE_COMPARATOR|Group C: Pelvic floor exercises|Group (C): This will be the control group. This group will be advised to do PME only. The pelvic floor exercises will consist of advice to the patients to contract the anal sphincter muscles in successive way as if holding flatus. The pelvic floor muscle training schedule and therapist in group B and group C will be the same.
62025418|NCT00596765|EXPERIMENTAL|1|Neuropsychological cognitive behavioral psychotherapy for patients with acquired brain injury consists of 25 weekly 1-hr sessions of individualized outpatient treatment. The therapeutical intervention is modularised, patients are assigned to specific interventional modules according to the results of cognitive testing and interviews. Modules concern on the one hand the treatment of deficits in attention, memory, and executive functions. On the other hand psychosocial adjustment to chronic illness is addressed through modules that concern the development of a positive self-concept, the adjustment of life-goals and coping with negative affect (e.g. depressive symptoms, irritability, guilt).
62025419|NCT00596765|OTHER|2|"Waiting list: Patients are randomly assigned to one of two existing groups after completion of the first session of various neuropsychological tests and interviews.~Patients assigned to the experimental group receive therapy immediately after completing the first session of various neuropsychological tests and interviews. Patients randomized to the waiting list receive the treatment as specified above after waiting for 5 month."
62025420|NCT04200066|EXPERIMENTAL|Experimental Arm|This arm will combine maprotiline with temozolomide and tamoxifen to determine the maximum tolerated dose.
62025421|NCT04100447|EXPERIMENTAL|Treatment Arm|All subjects will receive 1 dose of study drug (split into 2 administrations), over the 12 hours prior to surgery.
62025422|NCT05814523|EXPERIMENTAL|Ganaxolone IV solution + SOC IV AED|
62025423|NCT05814523|EXPERIMENTAL|Placebo IV solution + SOC IV AED|
62222855|NCT03505541||Control group|Healthy, term, non-obese (BMI \< 30) pregnant women with a singleton gestation scheduled for CS delivery at 37-41 weeks of gestation.
62222856|NCT03505541||Study group 1|Term pregnant, non-obese (BMI \<30), diagnosed with gestational diabetes, scheduled for CS delivery between 37-41 weeks of gestation.
62222857|NCT03505541||Study group 2|Term pregnant, obese (BMI \>30), non-diabetic and scheduled for CS delivery between 37-41 weeks of gestation
62222858|NCT02031692|ACTIVE_COMPARATOR|Vitamin D and calcium supplement|
62222859|NCT02031692|NO_INTERVENTION|Control|
62416904|NCT03022318|EXPERIMENTAL|3 times daily|carbidopa-levodopa 25-100 mg tablets 3 times daily,in the morning, with supper and hs for up to 32 days
62798288|NCT05193162||Blank paraffin section|
62798289|NCT02742220|EXPERIMENTAL|Isometric Handgrip Training Group|Experimental group will perform home-based unilateral handgrip exercise and will be recommended to increase daily physical activity levels.
62416905|NCT06702917||Cohort A|Undergoing a standard of care CCTA
62222860|NCT03481192|EXPERIMENTAL|A group using amnesic substances|"A group of patients admitted for IMV exclusively using amnesic substances. Benzodiazepines, benzodiazepines, tricyclic antidepressants, neuroleptics, antihistamines, other atropine substances, anti-epileptics and opiates.~Two visits for evaluation, the first one for the first evaluation of cognitive functions directly following the psychiatric interview, and the second one at 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place."
62416906|NCT06702917||Cohort B|Known history of heart attack (myocardial infarction) or undergoing a standard of care cardiac catheterization due to known disease
62416907|NCT01741259|EXPERIMENTAL|Meperidine PCEA|Epidural Meperidine (5mg/ml) bolus of 20 mg, lockout of 30 min, hourly limit of 50 mg.
62416908|NCT01741259|EXPERIMENTAL|Meperidine PCEA with basal|Epidural meperidine (5mg/ml) basal rate of 10 mg/hr, bolus 20 mg, lockout 30 min, hourly limit 40 mg
62588397|NCT06684951|NO_INTERVENTION|group C|patient not receive any treatement
62588398|NCT03939780|EXPERIMENTAL|Cohort 1|Subjects will be scanned twice (once with each of the tracers \[18F\]RO-948 and \[18F\]MK-6240)
62798290|NCT02742220|SHAM_COMPARATOR|Control Group|Control group will be recommended to increase daily physical activity levels.
62798291|NCT02485561|ACTIVE_COMPARATOR|Information only|INTERVENTION: Information about colon cancer and screening tests from sources such as the Centers for Disease Control and Prevention Screen for Life campaign.
62798292|NCT02485561|EXPERIMENTAL|Screener Narrative|INTERVENTION: Information + Personal Narrative from someone who was screened for colon cancer
62798293|NCT02485561|EXPERIMENTAL|Survivor Narrative|INTERVENTION: Information + Personal Narrative from someone who was screened for, and diagnosed with, colon cancer
62416909|NCT05260658|EXPERIMENTAL|Part A: CFTX-1554 Single Ascending Dose (SAD)|Up to 7 dose levels with CFTX-1554 administered as oral liquid formulation under fasted conditions (at 1 single dose level only, drug intake under fed conditions, and as capsule under fasted conditions and under fed conditions, will be assessed)
62798294|NCT04485949|EXPERIMENTAL|IGV-001|Participants will be implanted with biodiffusion chambers containing IGV-001 on Day 1 and explanted on Day 3 (at approximately 48 hours following implantation). After 6 weeks, participants will receive radiotherapy (RT) per institutional standards for 5 days per week along with temozolomide 75 mg/m\^2 orally, once daily (QD) for up to 12 weeks followed by temozolomide 150 to 200 mg/m\^2, orally, on Days 1 to 5 of each 28-day cycle for up to 6 cycles (Week 41).
62798295|NCT04485949|PLACEBO_COMPARATOR|Placebo|Participants will be implanted with biodiffusion chambers containing placebo on Day 1 and explanted on Day 3 (at approximately 48 hours following implantation). After 6 weeks, participants will receive RT per institutional standards for 5 days per week along with temozolomide 75 mg/m\^2 orally, QD for up to 12 weeks followed by temozolomide 150 to 200 mg/m\^2, orally, on Days 1 to 5 of each 28-day cycle for up to 6 cycles (Week 41).
62798296|NCT02896283|EXPERIMENTAL|low-level laser therapy|Low-level laser (Diode, 66o nanometer, power:200 milli Watt (mW), Continuous wave, time of irradiation:32 seconds)is irradiated in donor site
62025424|NCT04452461|OTHER|Single Arm Intervention|"1. Chemotherapy: 6 cycles (three months) of IV combination chemotherapy with mFOLFIRINOX on day 1 followed by one week of rest (14-day cycle). Alternatively, patients will receive three months of gemcitabine / nab-paclitaxel.~2. Re-staging CT scan with Carbohydrate Antigen (CA) 19-9 serum test.~3. Staging laparoscopy to rule out occult metastatic disease is optional based on surgeon's preference.~5. Pancreatectomy 4 weeks following the last day of Chemotherapy as per standard of care.~6. Adjuvant chemotherapy: as per standard of care. 7. Clinical assessment and CT scan with CA 19-9 serum test at 4-month intervals until identification of cancer recurrence.~8. Follow up of patients after 2 years every six months for up to 5 years following the initiation of treatment will be performed off-protocol as per standard of care."
62222861|NCT03481192|ACTIVE_COMPARATOR|A control group|"A control group that ingested exclusively non-amnesic substances among them most frequently ingested in this context, ie the following classes: level 1 analgesics, antibiotics, serotonergic and noradrenergic antidepressants, oral antidiabetic, thyroid hormones, anti oral coagulant.~Two visits for evaluation, the first one for the first evaluation of cognitive functions directly following the psychiatric interview, and the second one at 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place."
62222862|NCT03507660|EXPERIMENTAL|verbal instruction|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:~1. squeeze the pelvic floor muscles.~2. squeeze and lift the pelvic floor muscles as if stopping the flow of urine~3. Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.~4. squeeze the anus~5. shorten the penis~6. elevate the scrotum"
62222863|NCT03484845|ACTIVE_COMPARATOR|Oral lactoferrin|women who take oral lactoferrin sachets 100 mg twice daily for one month.
62222864|NCT03484845|ACTIVE_COMPARATOR|Oral ferrous fumarate|women who take oral ferrous fumarate tablet 30 mg elemental iron twice daily for one month.
62222865|NCT03484845|ACTIVE_COMPARATOR|Combined lactoferrin & ferrous fumarate|women who take lactoferrin sachets 100 mg and ferrous fumarate tablet 30 mg elemental iron once daily for one month.
62222866|NCT00976612||Nilotinib|Patients who receive nilotinib with failure to both imatinib and sunitinib
62416910|NCT05260658|PLACEBO_COMPARATOR|Part A placebo|Single placebo administration in study Part A
62798297|NCT02896283|PLACEBO_COMPARATOR|Turned-off laser|The same protocol is applied in te donor site, unless the laser is remained off.
62025425|NCT06410066||PATIENTS WITH HEMATOLOGIC MALIGNANCY aADMITTED TO THE ICU|all consecutive patients diagnosed with HM and admitted to both ICUs between January 2009 and December 2019.
62416911|NCT05260658|EXPERIMENTAL|Part B: CFTX-1554 Multiple Ascending Dose (MAD)|Up to 4 dose levels with CFTX-1554 in Part B. Doses and dosing frequency will be decided based on the results of study Part A.
62416912|NCT05260658|PLACEBO_COMPARATOR|Part B placebo|Multiple placebo administration in study Part B
62416913|NCT06703593|EXPERIMENTAL|Alpha Lipoic acid intervention arm|Alpha Lipoic acid 1200 mg daily for 6 months
62416914|NCT06703593|NO_INTERVENTION|No intervention arm|not taking Alpha Lipoic acid
62416915|NCT00956709|ACTIVE_COMPARATOR|Levobupivacaïne 0,5 %|
62025426|NCT04318340|ACTIVE_COMPARATOR|Standard Applicators|All patients will be fitted with the 2.6 cm applicator and sized up to the 3.0 cm applicator if tolerable.
62025427|NCT04318340|EXPERIMENTAL|Tapered Applicator|All patients will be fitted with the novel tapered 3.0 cm applicator. Patients have the option of having magnetic resonance imaging with the tapered applicator in place.
62416916|NCT00956709|ACTIVE_COMPARATOR|Ropivacaïne 0,5%|
62416917|NCT03290976|NO_INTERVENTION|Control Group|The control group will consist of patients who choose not to undergo CIM treatments for their CIPN-related symptoms. Participants in this arm of the study will receive standard conventional supportive care, as provided by their oncology health care professionals (HCPs), and closely monitored for any changes in the severity of their CIPN-related symptoms.
62416918|NCT03290976|ACTIVE_COMPARATOR|Intervention Group A: Single Modality (acupuncture)|Patients choosing to undergo CIM treatments, in addition to standard conventional care: Acupuncture x2/week, for 6 weeks.
62798298|NCT02747186|ACTIVE_COMPARATOR|Buffered 1% lidocaine|"In week One each subject would receive the anesthetic, 5cc, to block the Posterior alveolar, Anterior alveolar, Palatal nerves.Maxillary molar and canine tested for pulpal anesthesia.~At least a week later, injections for the maxillary field block would involve the alternate local anesthetic combination. Maxillary molar and canine tested for pulpal anesthesia."
62025428|NCT05675345|ACTIVE_COMPARATOR|HFNC only|
62025429|NCT05675345|EXPERIMENTAL|HFNC + CNEP10|
62025430|NCT05675345|EXPERIMENTAL|HFNC + CNEP20|
62025431|NCT05675345|EXPERIMENTAL|HFNC + CNEP30|
62025432|NCT03111927|NO_INTERVENTION|Reference Arm: Breastfed|Epidemiological reference group of breastfed infants.
62025433|NCT03111927|EXPERIMENTAL|Investigational|Infant Formula: enriched level of myelin-relevant nutrients
62025434|NCT03111927|ACTIVE_COMPARATOR|Control|Infant formula: standard level of myelin-relevant nutrients
62222867|NCT03588286|EXPERIMENTAL|Intervention Arm (Early EPS)|"The intervention group all undergo electrophysiologic study early after myocardial infarction (within 40 days of MI).~If the study is positive (inducible monomorphic ventricular tachycardia of cycle length greater than or equal to 200ms) participants have an ICD implanted. Participants with a negative study (no inducible arrhythmia or induced ventricular fibrillation/ ventricular flutter cycle length \<200ms) are discharged without an ICD.~A proportion of trial patients from both the intervention and control arms at \>48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury."
62588399|NCT03939780|NO_INTERVENTION|Cohort 2A|No PET scans will be done. Previous \[18F\]AV-1451 scans of selected aged matched older cognitively healthy controls (OC) subjects from the Baltimore Longitudinal Study of Aging (BLSA) study (IRB00047185) will be reanalyzed.
62588400|NCT03939780|EXPERIMENTAL|Cohort 2B1 - AD [18F]RO-948 and [18F]AV-1451|Alzheimer's Disease (AD) subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with AD will be scanned twice: once with \[18F\]RO-948 and a second scan with \[18F\]AV-1451 in randomized order and within one month of each other.
62588401|NCT03939780|EXPERIMENTAL|Cohort 2B2 - AD [18F]MK-6240 and [18F]AV-1451|AD subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with AD will be scanned twice: once with \[18F\]MK-6240 and a second scan with \[18F\]AV-1451 in randomized order and within one month of each other.
62798299|NCT02747186|ACTIVE_COMPARATOR|Non-Buffered lidocaine|"In week One each subject would receive the anesthetic, 5cc, to block the Posterior alveolar, Anterior alveolar, Palatal nerves. Maxillary molar and canine tested for pulpal anesthesia.~At least a week later, injections for the maxillary field block would involve the alternate local anesthetic combination. Maxillary molar and canine tested for pulpal anesthesia."
62798300|NCT04110912||Cardiac arrest|Ischaemic heart disease is the leading cause of death worldwide. However, this is a registry and no interventions are taking place
62025435|NCT02730819|EXPERIMENTAL|Illuminate Cream|Illuminate Cream is a skin-lightening formulation containing multiple drugs, including a retinoid, calcineurin inhibitor, anti-tyrosinase agent and sunscreen microfine zinc oxide. Approximately 0.5 grams to be applied topically to affected areas of skin once per day for 20 weeks.
62025436|NCT03939286|OTHER|movement group|intensified training (equipment, coordination, balance)
62222868|NCT03588286|ACTIVE_COMPARATOR|Control Arm (Standard Care)|"The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).~A proportion of trial patients from both the intervention and control arms at \>48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury."
62222869|NCT04314804|EXPERIMENTAL|Smoked cannabis (PPP001)|280 mg dried cannabis pellet -(9% THC / 2% CBD per pellet)
62222870|NCT04314804|PLACEBO_COMPARATOR|THC free placebo|280 mg dried extracted cannabis pellet (0% THC / 0.6% CBD per pellet)
62222871|NCT02831387|EXPERIMENTAL|0.017% P-321 Ophthalmic Solution|0.017% P-321 Ophthalmic Solution TID for 28 days.
62222872|NCT02831387|PLACEBO_COMPARATOR|Placebo|P-321 Ophthalmic Solution Placebo TID for 28 days.
62222873|NCT06472193|EXPERIMENTAL|cases|
62222874|NCT03081052|ACTIVE_COMPARATOR|Lung transplant with iNO|
62416919|NCT03290976|ACTIVE_COMPARATOR|"Intervention Group B: Multi-modality (acupuncture plus)"|Patients choosing to undergo CIM treatments, in addition to standard conventional care: Acupuncture with additional CIM treatment modalities, x2/week, for 6 weeks.
62416920|NCT06700434|ACTIVE_COMPARATOR|HP18|Bleaching agent containing Hydrogen Peroxide 18% and nano- hydroxyapatite
62416921|NCT06700434|ACTIVE_COMPARATOR|HP25|Bleaching agent containing Hydrogen Peroxide 20% and nano- hydroxyapatite
62416922|NCT06700434|ACTIVE_COMPARATOR|HP40|Bleaching agent containing Hydrogen Peroxide 40% and nano- hydroxyapatite
62416923|NCT05569421|EXPERIMENTAL|Treatment A: BGF MDI HFO 160/7.2/4.8 μg ex-actuator|Participants will receive Test formulation in 1 of 3 possible treatment sequences: ABB, BAB, or BBA. The reference formulation will be administered during 2 of the 3 treatment periods in order to estimate intra-subject variability.
62416924|NCT05569421|EXPERIMENTAL|Treatment B: BGF MDI HFA 160/7.2/4.8 μg ex-actuator|Participants will receive Reference formulation in 1 of 3 possible treatment sequences: ABB, BAB, or BBA. The reference formulation will be administered during 2 of the 3 treatment periods in order to estimate intra-subject variability.
62416925|NCT03660007||Fresh embryo transfer|This exposure is an IVF pregnancy with fresh embryo transfer performed directly after ovarian stimulation
62416926|NCT03660007||Frozen embryo transfer|This exposure is an IVF pregnancy with frozen embryo transfer, which was thawed and transferred in a later, non-stimulated cycle
62416927|NCT03660007||Natural pregnancy|Spontaneous pregnancy without IVF
62416928|NCT06660407|EXPERIMENTAL|Treatment (grid radiation therapy)|Patients undergo grid radiation therapy over a single fraction on day 1 and palliative radiation therapy over 5 fractions on days 2 and -1 post-grid in the absence of disease progression or unacceptable toxicity. Patients also receive SOC immunotherapy and undergo CT at the discretion of the physician and undergo blood sample collection throughout the study.
62222875|NCT03081052|ACTIVE_COMPARATOR|Lung transplant with iEPO|
62222876|NCT03081052|ACTIVE_COMPARATOR|Heart transplant & LVAD implantation with iNO|
62222877|NCT03081052|ACTIVE_COMPARATOR|Heart transplant & LVAD implantation with iEPO|
62222878|NCT02761876|EXPERIMENTAL|Intervention (Participatory education)|Participatory education
62222879|NCT02761876|NO_INTERVENTION|Control|Delayed participatory education
62222880|NCT02515877|EXPERIMENTAL|Radiotherapy + Vistide + Chemoterapy|
62416929|NCT05987527||Treatment group|"Subjects underwent a kidney transplant as per planned standard of care and were administered study drug TX200-TR101 in study TX200-KT02 post transplantation~Assigned interventions - subjects who received TX200-TR101 in clinical study TX200-KT02"
62798301|NCT04110912||Trauma|Worldwide, trauma is the number one cause of death and disability in people younger than 40 and confirmed for Canada as well for those under the age of 45. However, this is a registry and no interventions are taking place
62025437|NCT03939286|OTHER|control group|continuation of physical activity as usual
62222881|NCT01143779|EXPERIMENTAL|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
62025438|NCT03144557|EXPERIMENTAL|Intervention|Education protocol to correct inhalation technique
62025439|NCT05318729|EXPERIMENTAL|Vibration tool|"Use of the vibration tool 3 times per day for 10 minutes for each session Morning, mid-day, and evening.~Volarly for 5 minutes and dorsally for 5 minutes, for a total of 10 minutes during each session:"
62025440|NCT05318729|NO_INTERVENTION|Control|Standard of care, no vibration tool.
62222882|NCT06171347|EXPERIMENTAL|Experimental group|Patients in the experimental group will receive oral cold spray (tap water) in the postoperative period.
62416930|NCT05987527||Control group|Subjects underwent a kidney transplant as per planned standard of care in study TX200-KT02 with no study drug administered, up to 6 subjects
62416931|NCT02525146|EXPERIMENTAL|Intervention|Patients randomized to the intervention arm receive intensive social work case management based on the ARTAS (Antiretroviral Treatment and Access to Services) model. Patients may participate in 6-12 visits over a six-month period aimed at addressing barriers to re-engagement in HIV care. Participants complete a battery of research questions at Baseline, 6-months, and 12-months and HIV-1 viral load and CD4 count labwork at Baseline and at 12-months post enrollment.
62588402|NCT03939780|EXPERIMENTAL|Cohort 2B3 - OC [18F]RO-948 and [18F]AV-1451|OC subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with OC will be scanned twice: once with \[18F\]RO-948 and a second scan with \[18F\]AV-1451 in randomized order and within one month of each other.
62588403|NCT03939780|EXPERIMENTAL|Cohort 2B4 - OC [18F]MK-6240 and [18F]AV-1451|OC subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with OC will be scanned twice: once with \[18F\]MK-6240 and a second scan with \[18F\]AV-1451 in randomized order and within one month of each other.
62025441|NCT03769220||inpatient rehabilitation ward|"The first 20 participants will be recruited from the inpatient rehabilitation ward at Robert-Bosch-Hospital (RBK). The treating medical doctor will inform potentially eligible participants about the possibility of being involved in this study. Should participants confirm their interest a research assistant will complete a detailed information session and obtain written informed consent prior enrolment.~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
62025442|NCT03769220||outpatient rehabilitation clinic|"Further 20 participants will be recruited through the outpatient rehabilitation clinic at Robert-Bosch-Hospital (RBK). The treating doctor will again inform the potential participant about the study and invite them to participate. A research assistant will complete a detailed information session and written informed consent will be obtained prior enrolment.~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
62025443|NCT03769220||community dwelling older adults|"Lastly 20 community dwelling older adults will be invited to participate. Recruitment will occur through advertisement at a locally run seniors fitness group, conducted every Thursday at RBK. Older adults who are interested in being involved will be invited to receive additional information about the study and the involved procedures before providing written informed consent and being enrolled.~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
62025444|NCT05732168||Subjects with chronic ankle instability|Men and women with recurrent unilateral ankle instability problems
62025445|NCT05732168||Control group|Healthy men and women without ankle problems
62025446|NCT00709722|EXPERIMENTAL|1|NKT-01
62222883|NCT06171347|NO_INTERVENTION|Control group|Patients in the control group will not be intervened in the postoperative period except for standard care for thirst management.
62222884|NCT02438501|EXPERIMENTAL|LD-IFRT group|Chemotherapy / Low-dose involved-field radiotherapy
62416932|NCT02525146|NO_INTERVENTION|Usual Care|Patients randomized to the usual care arm are provide contact information for an HIV primary care clinic and for local AIDS service organizations. Patients are then encouraged to contact these organizations to re-establish care. Participants complete a battery of research questions at Baseline, 6-months, and 12-months and HIV-1 viral load and CD4 count labwork at Baseline and at 12-months post enrollment. Patients in the usual care arm are offered the intensive casework intervention after their 12-month followup is complete.
62416933|NCT05845671|EXPERIMENTAL|Dose Finding (Safety Lead-In) Cohort (<80 kg)|To estimate the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in adult participants with advanced NSCLC with ALK, ROS1, and RET gene fusions.
62416934|NCT05845671|EXPERIMENTAL|Dose Finding (Safety Lead-In) Cohort (≥80 kg)|To estimate the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in adult participants with advanced NSCLC with ALK, ROS1, and RET gene fusions.
62416935|NCT05845671|EXPERIMENTAL|Dose Expansion Cohort (<80 kg)|To estimate the objective response rate (ORR) of amivantamab in combination with common TKIs used in ALK, ROS1, and RET advanced NSCLC progressing on TKIs.
62416936|NCT05845671|EXPERIMENTAL|Dose Expansion Cohort (≥80 kg)|To estimate the objective response rate (ORR) of amivantamab in combination with common TKIs used in ALK, ROS1, and RET advanced NSCLC progressing on TKIs.
62416937|NCT01447628|ACTIVE_COMPARATOR|Ferinject or CosmoFer followed by Placebo|"IV iron formulation used in Europe - Ferinject - given over 15 minutes~IV iron formulation used in China - CosmoFer - over a period of 4 to 6 hours~IV Iron given at Week 0, Placebo (saline) given at Week 12."
62416938|NCT01447628|PLACEBO_COMPARATOR|Placebo followed by Ferinject or CosmoFer|"Placebo comparator~Placebo (saline) given at Week 0, IV Iron given at Week 12."
62416939|NCT06700941||Vaccinated female cohort (1996-2003)|This group consists of female participants born between 1996 and 2003 who were eligible for HPV vaccination starting in 2012 as part of the national immunization program in Colombia. These individuals received the vaccine and are being monitored for trends in healthcare service usage related to genital warts and preneoplastic cervical lesions.
62416940|NCT06700941||Unvaccinated Female Cohort (Before 1996)|This group includes female participants born before 1996 who were not part of the HPV vaccination program. They serve as a comparison group to assess trends in healthcare service usage for genital warts and preneoplastic cervical lesions before the implementation of the HPV vaccination program.
62588404|NCT02604498|EXPERIMENTAL|Liver function impaired|Subject with Moderate Impaired Hepatic Function. Nemonoxacin Malate Capsules 500mg single dose oral.
62025447|NCT03176693|ACTIVE_COMPARATOR|Phenoxybenzamine|3-4 weeks prior to date of surgery, patient will start phenoxybenzamine 10mg PO twice daily. Phenoxybenzamine will then be titrated to a blood pressure \<120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
62222885|NCT02438501|ACTIVE_COMPARATOR|IFRT group|Chemotherapy / Involved-field radiotherapy
62416941|NCT03213769|ACTIVE_COMPARATOR|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
62588405|NCT02604498|EXPERIMENTAL|Healthy Subjects|Healthy volunteers. Nemonoxacin Malate Capsules 500mg single dose oral.
62798302|NCT04110912||Sepsis|Sepsis is a clinical syndrome that results from dysregulation of the inflammatory response to severe infection. However, this is a registry and no interventions are taking place
62222886|NCT04172194||PT Group|patients with hepatocellular carcinoma treated by percutaneous thermoablation alone
62798303|NCT04110912||Stroke|Stroke is the second leading cause of death worldwide, and the leading cause of chronic disability. However, this is a registry and no interventions are taking place
62222887|NCT04172194||PT+TAC group|patients with hepatocellular carcinoma treated by pecutaneous thermoablation comined in a single session with trans-arterial chemoembolization
62222888|NCT04032054||A|mono-axial
62222889|NCT04032054||B|poly-axial
62222890|NCT02276183|EXPERIMENTAL|Arm1, Nutrition intervention, test formula and activity|
62222891|NCT04114630|EXPERIMENTAL|erenumab|Solution for s.c injection. Prefilled autoinjector
62222892|NCT03002753|EXPERIMENTAL|DM|Group of patients receiving detached mindfulness (for details, see detailed description of the study)
62025448|NCT03176693|EXPERIMENTAL|Doxazosin|3-4 weeks prior to date of surgery, patient will start doxazosin 1 mg PO daily. Phenoxybenzamine will then be titrated to a blood pressure \<120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
62025449|NCT05498259|EXPERIMENTAL|Orelabrutinib+R-CHOP-like|Orelabrutinib plus Rituximab for 21 days; Following Imaging examinations, patients with ≥25% tumor reduction, treat with orelabrutinib 150mg qd orally plus R-CHOP-like for 6 cycles; whereas, patients with \<25% tumor reduction, withdraw from the study，treat with R-CHOP-like alone for 6 cycle
62025450|NCT05548595|EXPERIMENTAL|Investigational|"Active ingredients (per tablet):~• NeumentixTM Phenolic~Complex K110-42:~* 450 mg Spearmint extract (Mentha spicata)~* 100 mg Alpha-Glyceryl Phosphoryl Choline~* 50 mg Phosphatidylserine (Sharp PS®)~* 10 mg Pyrroloquinoline quinone~Inactive ingredients (per tablet):~* Microcrystalline cellulose~* Maltodextrin~* Hardened rapeseed fat~* Magnesium salts from fatty acids (palm oil free)~* Silicon dioxide~* Glycerin~* Hydroxypropyl methylcellulose"
62025451|NCT05548595|PLACEBO_COMPARATOR|Placebo|"Active ingredients (per tablet):~N/A~Inactive ingredients (per tablet):~* Lactose monohydrate~* Magnesium stearate~* Microcrystalline cellulose"
62025452|NCT03825380|EXPERIMENTAL|T4032|
62025453|NCT03825380|ACTIVE_COMPARATOR|Lumigan®|
62025454|NCT01227850||Parenteral nutrition patients.|
62025455|NCT01384617|EXPERIMENTAL|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
62222893|NCT03002753|ACTIVE_COMPARATOR|CR|Group of patients receiving cognitive restructuring (for details, see detailed description of the study)
62798304|NCT03852017|EXPERIMENTAL|Mindfulness Audio Program|Mindfulness Audio Program is a daily audio-session, which teaches emotional self-regulation skills through the adoption of mindful awareness practices into one's life
62025456|NCT01384617|ACTIVE_COMPARATOR|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
62798305|NCT03852017|ACTIVE_COMPARATOR|Music Audio Program|Music Audio Program is a daily audio session of peaceful and relaxing music
62025457|NCT06635278|EXPERIMENTAL|Nurses receiving mindfulness meditation|"The experimental group received eight 60-minute weekly sessions of mindfulness meditation over eight weeks in a private and quiet room at the hospital, according to Smith's (2005) recommendation. The theory-based program (Smith, 2005) includes the ABC standardized versions of MBI (Smith, 2005), described as follows:~* Body sense meditation~* Rocking meditation~* Breathing meditation~* Mentra meditation~* Visual Image meditation~* External image meditation~* Meditation of a sound~* Open monitoring (Mindfulness) meditation"
62222894|NCT03002753|NO_INTERVENTION|WL|Waitlist control group, which, however, is again randomized after the waiting time in order to receive one of the two interventions (DM or CR).
62222895|NCT05309915|OTHER|Cohort 1|Dose 3mg of STP707 (8 subjects) + placebo (2 subjects) randomized
62222896|NCT05309915|OTHER|Cohort 2|Dose 6mg of STP707 (8 subjects) + placebo (2 subjects) randomized
62222897|NCT05309915|OTHER|Cohort 3|Dose 12mg of STP707 (8 subjects) + placebo (2 subjects) randomized
62222898|NCT05309915|OTHER|Cohort 4|Dose 24mg of STP707 (8 subjects) + placebo (2 subjects) randomized
62222899|NCT01280110|ACTIVE_COMPARATOR|Preserved (BAK 0.006%) lubricating drop|One group will receive preserved lubricating drops 4 times a day for 1 month.
62222900|NCT01280110|ACTIVE_COMPARATOR|Preservative-free lubricating drops|The second group will receive preservative-free lubricating drops 4 times a day for 1 month.
62222901|NCT00731120|PLACEBO_COMPARATOR|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
62222902|NCT00731120|EXPERIMENTAL|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg encapsulated tablets, orally, once daily for up to 8 weeks.
62222903|NCT00731120|EXPERIMENTAL|Vortioxetine 10 mg|Vortioxetine 10 mg encapsulated tablets, orally, once daily for up to 8 weeks.
62222904|NCT03206762|EXPERIMENTAL|Jetstream Atherectomy+Ranger DCB or Medtronic IN.PACT DCB|Jetstream Atherectomy used in conjunction with the Ranger DCB or Medtronic IN.PACT DCB
62222905|NCT03206762|ACTIVE_COMPARATOR|POBA+DCB (Ranger or IN.PACT)|POBA and then DCB treatment (Ranger or IN.PACT)
62222906|NCT03969381||1 lymphoma patients|pre therapy and post therapy of lymphoma patients
62222907|NCT05998473||Normal pressure hydrocephalus|Patients with a diagnosis of normal pressure hydrocephalus and who performed a gait analysis in laboratories
62222908|NCT05998473||Parkinson's disease|Patients with a diagnosis of Parkinson's disease and who performed a gait analysis in laboratories
62222909|NCT02729753|OTHER|CryoBalloon™ Full Ablation System|To evaluate CryoBalloon™ Full Ablation System for the ablation of 360 degrees of human esophageal epithelium in patients scheduled to undergo esophagectomy.
62222910|NCT02729753|OTHER|CryoBalloon™ Swipe Ablation System|To evaluate CryoBalloon™ Swipe Ablation System for the ablation of 90 degrees of human esophageal epithelium in patients scheduled to undergo esophagectomy.
62222911|NCT04110977|EXPERIMENTAL|Standard Care supported by a Reminder App (Arm A)|Treatment with Standard Care supported by a Reminder App, starting at the beginning of radiotherapy.
62222912|NCT04110977|ACTIVE_COMPARATOR|Standard Care alone (Arm B)|Treatment with Standard Care alone, starting at the beginning of radiotherapy.
62222913|NCT01091077|PLACEBO_COMPARATOR|Naringenin|Single dose of naringenin, compared to placebo in the same individual.
62222914|NCT05724589|EXPERIMENTAL|Epidermal Growth Factor Serum Application|Participants received Epidermal growth factor serum application on the face daily for two months compared to pre and post-results of skin quality.
62222915|NCT02729662|OTHER|Patients with ADPKD|This analysis set consists of patients whose at least 2 TKV data are available both before and after taking tolvaptan.
62222916|NCT05688982|OTHER|A--general information|Patients in Arm A will receive paper handouts with general oral health and aSDoH resources
62222917|NCT05688982|OTHER|B--geographic information|Patients in Arm B will receive paper handouts with geographically-proximate oral health and aSDoH resources.
62222918|NCT05688982|OTHER|C--geographic information and navigational assistance|Patients in Arm C will receive geographically-proximate oral health and aSDoH resources plus active navigational assistance.
62025458|NCT06635278|NO_INTERVENTION|Nurses will receive no intervention or materials from the experimenter|Control group will receive a traditional care provided usually for patients in the hospital
62222919|NCT00311727|EXPERIMENTAL|Influenza A/H5N1|232 subjects receiving Influenza A/H5N1 vaccine.
62222920|NCT02730598|EXPERIMENTAL|Hybrid Training System (HTS)|HTS stimulation while walking at a comfortable pace for 30 minutes.
62416942|NCT03213769|PLACEBO_COMPARATOR|carbapol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
62416943|NCT03544606|EXPERIMENTAL|isosorbide mononitrate group|In vaginal IMN group (group 1) 40 mg tablet of intra-vaginal IMN (Effox; MINAPHARMA, Cairo, Egypt) will be placed into the posterior fornix of the vagina, through a digital vaginal examination, every 4 h for a maximum of four doses.
62222921|NCT02730598|ACTIVE_COMPARATOR|Transcutaneous Electrical Nerve Stimulation (TENS)|Sensory TENS while walking at a comfortable pace for 30 minutes.
62025459|NCT02537912|ACTIVE_COMPARATOR|Sugarlock®|Subjects ingested 2 capsules Sugarlock® (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks.
62222922|NCT04998760|EXPERIMENTAL|ATG-008 + Chemotherapeutics|ATG-008: Oral, 30 mg QD+Paclitaxel: 175 mg/m2, intravenous infusion \>3 h, Day 1, Q3W; ATG-008: Oral, 30 mg QD+Carboplatin: AUC = 5, intravenous infusion \>1 h, Day 1, Q3W or Cisplatin: 75 mg/m2, intravenous infusion \>1h, Day 2, Q3W ; ATG-008: Oral, 30 mg QD+Doxorubicin hydrochloride liposome, 40 mg/m2, Day 1; Q4W;
62416944|NCT03544606|PLACEBO_COMPARATOR|placebos group|In the placebo group (group 2) 40 mg intra-vaginal pyridoxine placebos every 4 h for a maximum of four doses will be given
62416945|NCT02441959|ACTIVE_COMPARATOR|Endoscopic Discectomy|Randomized to Endoscopic Discectomy Lumbar discectomy Endoscopic Intervention type is lumbar endoscopic surgery- no device or drug
62416946|NCT02441959|ACTIVE_COMPARATOR|Open Discectomy|Randomized to Open Discectomy Lumbar discectomy Open Intervention type is lumbar open surgery- no device or drug
62416947|NCT02441959|OTHER|Open Discectomy-Cross Over Arm|Randomized to Endoscopic Discectomy Cross over to lumbar discectomy open based on surgeons assessment pre or post incision Intervention type is lumbar open surgery- no device or drug
62222923|NCT04998760|EXPERIMENTAL|ATG-010 + Chemotherapeutics|"perimental: ATG-010 + Chemotherapeutics ATG-010: Oral, 80 mg QW, Day 1/week of treatment cycles +Paclitaxel: 175 mg/m2, intravenous infusion \>3 h, Day 1, Q3W; ATG-010: Oral, 80 mg QW, Day~1/week of treatment cycles +Carboplatin: AUC = 5, intravenous infusion \>1 h, Day 1, Q3W or Cisplatin: 75 mg/m2, intravenous infusion \>1h, Day 2, Q3W ; ATG-010: Oral, 80 mg QW, Day 1/week of treatment cycles +Doxorubicin hydrochloride liposome, 40 mg/ m2, Day 1; Q4W;"
62222924|NCT01742611|EXPERIMENTAL|ASP1585 group|
62222925|NCT00757588|EXPERIMENTAL|Saxagliptin, 5 mg + insulin|Saxagliptin, 5 mg, plus insulin, administered to participants with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
62222926|NCT00757588|PLACEBO_COMPARATOR|Placebo + insulin|Placebo administered to participants with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
62222927|NCT02580643||APS Injection|Autologous Protein Solution
62222928|NCT03531944|EXPERIMENTAL|Community pharmacist-involved care|Community pharmacist-involved collaborative care in the management of type 2 diabetes mellitus
62222929|NCT03531944|PLACEBO_COMPARATOR|Usual care|Usual care with physician and as needed referral to nurses
62222930|NCT05601687|ACTIVE_COMPARATOR|Step-up Approach|Standard procedure where necrosectomy is only performed in the absence of clinical improvement 72 hours after placements of lumen-apposing metal stent.
62222931|NCT05601687|EXPERIMENTAL|Direct Endoscopic Necrosectomy|Necrosectomy will be performed in the same procedure as the placement of the lumen-apposing metal stent.
62416948|NCT05981365|EXPERIMENTAL|Part A|To evaluate the effect of multiple doses of voxelotor on the plasma pharmacokinetics (PK) of a single dose of bupropion, repaglinide, flurbiprofen, omeprazole, and midazolam
62416949|NCT05981365|EXPERIMENTAL|Part B|To evaluate the effect of multiple doses of voxelotor on the plasma PK of a single dose of metformin, furosemide, and rosuvastatin
62025460|NCT02537912|PLACEBO_COMPARATOR|Placebo|Subjects ingested 2 capsules placebo (Control group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks.
62222932|NCT01304433||1|hydroxyethyl starch (HES) 130/0.42
62222933|NCT01455857|EXPERIMENTAL|ITCA 650 40 mcg/day|
62222934|NCT01455857|EXPERIMENTAL|ITCA 650 60 mcg/day|
62416950|NCT00976859|NO_INTERVENTION|Waitlist control group|
62588406|NCT02733354||Control Group|Control Group:perform routine oral education.Both groups were asked to complete kidney disease knowledge questionnaire before education.
62025461|NCT03943095|EXPERIMENTAL|Test Dentifrice|Participants will be instructed to apply a strip of dentifrice (a full brush head) containing 5 % weight by weight (w/w) potassium nitrate and 0.454% w/w stannous fluoride (1100 parts per million \[ppm\] fluoride). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for at least one timed minute, twice daily (morning and evening), and will be permitted to rinse with water post-brushing.
62025462|NCT03943095|ACTIVE_COMPARATOR|Control Dentifrice|Participants will be instructed to apply a strip of dentifrice (a full brush head) containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for at least one timed minute, twice daily (morning and evening), and will be permitted to rinse with water post-brushing.
62025463|NCT03792113|EXPERIMENTAL|Autologous fibrin glue|The periodontal flap will be approximated on the test site using autologous fibrin glue on the under surface of the raised flap up to 2 mm from the coronal margin and repositioned back on to the root surface. Thereafter, the tissues will be kept in position with a gentle pressure using a wet gauze for 30 - 60 seconds.
62222935|NCT01455857|PLACEBO_COMPARATOR|ITCA placebo|
62222936|NCT00208780|EXPERIMENTAL|Dose-response of oral BH4|Eight subjects received 100 mg of oral BH4 twice a day and 8 received 200 mg twice daily.
62222937|NCT00208780|EXPERIMENTAL|Onset & duration of action of oral BH4|Eight hypertensive subjects were assigned to either 5 mg kg-1 day-1 (n=4) or 10 mg kg-1 day-1 (n=4) of BH4, given in two divided doses orally for 8 weeks.
62222938|NCT05806307|ACTIVE_COMPARATOR|misoprostol|15 patients will receive 800 microgram (tablet 200mcg X 4) misoprostol (Misotac 200 mcg, SIGMA pharmaceutical, Egypt) rectally one and half hour before operation.
62222939|NCT05806307|ACTIVE_COMPARATOR|Tourniquet|(15 patient): The operation will be performed with the use of Foleys catheter as an improvised tourniquet applied at the base of the uterus then infiltration myometrium overlying the leiomyoma with a solution composed of Bupivacaine Hcl 0.25% and 0.5 mg of epinephrine
62222940|NCT05806307|ACTIVE_COMPARATOR|Carbetocin|intramural; preparation of 100 μg of carbetocin ((Pabal, Ampoule 100 mcg in 1 ml, Carbetocin; FERRING, North York, Canada) diluted within 10 cm of saline (0.9%) in sterile syringe then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
62222941|NCT05806307|ACTIVE_COMPARATOR|Oxytocin|15 patients): who will receive oxytocin 40 I.U. intramyometrially (Syntocinon, Ampule 10 I.U. in 1 ml, Oxytocin; NOVARTIS, Basel, Switzerland) then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
62588407|NCT02733354||Intervention Group|Intervention Group ：On the basis of Control Group, watching video demonstration of each type of dialysis. The videos were based on real cases, showing patients with peritoneal and hemodialysis life modes, lasting for 20 minutes respectively for each type of dialysis. Both groups were asked to complete kidney disease knowledge questionnaire before education.
62588408|NCT05955001|EXPERIMENTAL|Tadalafil 5 mg daily|those patients will receive Tadalafil 5 mg daily after HoLEP
62588409|NCT05955001|EXPERIMENTAL|Placebo|Those patients will receive Placebo after HoLEP
62588410|NCT01183208|EXPERIMENTAL|Cohort 1 active treatment and placebo|Active treatment and placebo
62222942|NCT05806307|ACTIVE_COMPARATOR|combined TXA and ethamsylate|(Patient 15): will receive 1 g tranexamic acid (2 ampoules of kapron 500 mg, kapron®, Amoun, Egypt) and 500 mg ethamsylate (2 ampoule of ethamsylate 250 mg, Dicynone, OM pharma, Geneva, Switzerland) IV 10 minutes before skin incision by slowly intravenous injection Then infusion was applied continuously for 24 hours within 1 liter of saline as 1 mg/kg/hour.
62222943|NCT05806307|ACTIVE_COMPARATOR|vasopressin|15 women will receive terlipressin (Glypressin, Ferring, Egypt) intramyometrial injection of one ampoule of vasopressin containing 20 units in1 ml after dilution in 19 ml of normal saline during myomectomy.
62222944|NCT05806307|ACTIVE_COMPARATOR|bupivacaine and epinephrine|15 women in which the operation will be performed after infiltration of the serosa and / or myometrium overlying the leiomyoma before uterine incision with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries).
62416951|NCT00976859|EXPERIMENTAL|Imagery Modification|Via a internet research patients collect data on skin renewal which is discussed afterwards; in a guided imagery modification the patients imagines the process of skin renewal and the building of new skin cells
62416952|NCT06554665|EXPERIMENTAL|High-intensity interval training group|
62588411|NCT01183208|EXPERIMENTAL|Cohort 2 - Active treatment and placebo|Active treatment and placebo
62416953|NCT06554665|ACTIVE_COMPARATOR|Moderate-intensity continuous training group|
62588412|NCT01183208|EXPERIMENTAL|Cohort 3 Active Treatment and placebo|Active treatment and placebo
62588413|NCT03858725|EXPERIMENTAL|D569/CKD-374 5mg|"1. Period 1: D569 Tab. 1T~2. Period 2: CKD-374 5mg Tab. 1T"
62588414|NCT03858725|EXPERIMENTAL|CKD-374 5mg/D569|"1. Period 1: CKD-374 5mg Tab. 1T~2. Period 2: D569 Tab. 1T"
62222945|NCT02457559|EXPERIMENTAL|Tirabrutinib 40 mg once daily (CLL)|Participants with relapsed/refractory chronic lymphocytic leukemia (CLL) received tirabrutinib 40 mg once daily for up to 96 months from first dose in the parent study.
62222946|NCT02457559|EXPERIMENTAL|Tirabrutinib 80 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily for up to 96 months from first dose in the parent study.
62222947|NCT02457559|EXPERIMENTAL|Tirabrutinib 160 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily for up to 96 months from first dose in the parent study.
62222948|NCT02457559|EXPERIMENTAL|Tirabrutinib 320 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily for up to 96 months from first dose in the parent study.
62222949|NCT02457559|EXPERIMENTAL|Tirabrutinib 400 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily for up to 96 months from first dose in the parent study.
62222950|NCT02457559|EXPERIMENTAL|Tirabrutinib 500 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily for up to 96 months from first dose in the parent study.
62222951|NCT02457559|EXPERIMENTAL|Tirabrutinib 600 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily for up to 96 months from first dose in the parent study.
62416954|NCT06554665|ACTIVE_COMPARATOR|Stretching group|
62588415|NCT02136212|EXPERIMENTAL|Approach-positive AAT|Participants will receive 4 sessions over 2 weeks of a computerized AAT procedure designed to increase automatic approach responses for positive social cues.
62588416|NCT02136212|PLACEBO_COMPARATOR|Control AAT|Participants will receive 4 sessions over 2 weeks of a computerized AAT procedure in which there is no contingency between arm movement and positive social cues.
62588417|NCT04844034|ACTIVE_COMPARATOR|Active treatment|High-EPA multinutrient supplement.
62588418|NCT04844034|PLACEBO_COMPARATOR|Placebo|Inert oil mix.
62588419|NCT06580301|EXPERIMENTAL|YK012|"Participants will be assigned to a dose level of YK012 based on when the participants join this study.~Participants will receive YK012 by intravenous infusion (IV), once per week, four weeks per treatment cycle."
62588420|NCT03277469|EXPERIMENTAL|MRI Guided BRACHYTHERAPY with Tracker|"* Standard pelvic MRI sequences will be obtained~* MRI Tracker is used during catheter positioning with serial MR imaging during implant~* All patients will undergo 3D-based image acquisition for brachytherapy treatment planning per standard clinical practice~* The brachytherapy modality to be used is high-dose-rate brachytherapy using an iridum-192 stepping source"
62025464|NCT03792113|ACTIVE_COMPARATOR|4-0 silk suture|The periodontal flap will be approximated using 4-0 black silk suture.
62025465|NCT06309147|EXPERIMENTAL|50 mg Active|50mg BID
62222952|NCT02457559|EXPERIMENTAL|Tirabrutinib 300 mg twice daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily for up to 96 months from first dose in the parent study.
62222953|NCT02457559|EXPERIMENTAL|Tirabrutinib 160 mg once daily (NHL)|Participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) received tirabrutinib 160 mg once daily for up to 96 months from first dose in the parent study.
62798306|NCT03887013|NO_INTERVENTION|CHD routine therapy|Patients with CHD will be treated with evidence-based therapy including antiplatelet drugs,beta-blockers,statins,angiotensin-converting enzyme inhibitor (ACEI),nitrates,etc. Percutaneous coronary intervention (PCI) could be performed if needed.
62798307|NCT03887013|EXPERIMENTAL|CHD routine therapy+Trimetazidine|Apart from the drug and PCI therapy mentioned above,patients will be given treatment of trimetazidine.
62222954|NCT02457559|EXPERIMENTAL|Tirabrutinib 320 mg once daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily for up to 96 months from first dose in the parent study.
62222955|NCT02457559|EXPERIMENTAL|Tirabrutinib 480 mg once daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily for up to 96 months from first dose in the parent study.
62416955|NCT06638619|EXPERIMENTAL|Biofeedback Fixation Arm|Biofeedback training is a mind-body therapy that helps people learn to control their involuntary bodily functions, such as eye movements. The goal is to improve eye movement control to improve gaze stability.
62025466|NCT06309147|EXPERIMENTAL|100mg Active|100mg BID
62025467|NCT06309147|PLACEBO_COMPARATOR|Matching Placebo|50 and 100 mg matching placebo
62025468|NCT03850119|EXPERIMENTAL|Intradermal Nanofat|This side of the scar received intradermal injection of nanofat during the closure of the donor site.
62025469|NCT03850119|NO_INTERVENTION|Control|This side of the scar received no injection.
62025470|NCT00244075|ACTIVE_COMPARATOR|1|nutrition supplementation, recombinant human growth hormone, and exercise
62025471|NCT00244075|ACTIVE_COMPARATOR|2|nutrition supplementation only
62025472|NCT02014116|EXPERIMENTAL|Cohort 1 Dose Escalation|LY3009120 50 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
62025473|NCT02014116|EXPERIMENTAL|Cohort 2 Dose Escalation|LY3009120 100 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
62025474|NCT02014116|EXPERIMENTAL|Cohort 3 Dose Escalation|LY3009120 200 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
62025475|NCT02014116|EXPERIMENTAL|Cohort 4 Dose Escalation|LY3009120 400 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
62222956|NCT02457559|EXPERIMENTAL|Tirabrutinib 600 mg once daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily for up to 96 months from first dose in the parent study.
62798308|NCT00890747|EXPERIMENTAL|Treatment (sunitinib malate)|Patients receive sunitinib malate PO daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62798309|NCT03691597|ACTIVE_COMPARATOR|Adhesive resin cement|type of cement used for cementation of crowns have a good adhesion bond
62798310|NCT03691597|EXPERIMENTAL|Bioactive cement|recent cement improve the marginal integrity
62798311|NCT02882594||CIBA Study Cohort|Patients aged 1 to 13 years undergoing inhalation inductions for general anesthesia
62798312|NCT04080102|EXPERIMENTAL|High intensity interval training (HIIT)|
62798313|NCT04080102|EXPERIMENTAL|Essential Amino Acid Supplement|
62798314|NCT04080102|EXPERIMENTAL|High intensity interval training + Essential Amino Acid|
62798315|NCT04080102|NO_INTERVENTION|Control|
62798316|NCT03506997|EXPERIMENTAL|Pembrolizumab|Pembrolizumab will be given at a dose of 200mg IV every 3 weeks for a maximum of two years
62798317|NCT00006107|EXPERIMENTAL|Taxotere|"* Taxotere: (1 hour infusion once a week for four weeks)~* Radiation Therapy (5 days/week for 6-7 weeks)~* Surgery (if required) 14 -12 weeks after radiotherapy~* Follow-up"
62798318|NCT02591940||Aortic Coarctation|interventional treatment in heart catheter (stenting/angioplasty) surgical repair of coarctation
62798319|NCT02591940||Aortic Valve Disease|surgical repair in aortic valve disease (reconstruction/valve replacement)
62025476|NCT02014116|EXPERIMENTAL|Cohort 5 Dose Escalation|LY3009120 500 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
62416956|NCT06638619|ACTIVE_COMPARATOR|Saccadic Reading Arm|Saccadic reading training helps people to learn to control their involuntary eye movements. The goal is to improve eye movement control to improve saccadic and fixational behaviors during reading activities.
62798320|NCT03257124|EXPERIMENTAL|AZD9291 in BM or LM cohort in T790M positive|"1. Brain metastasis cohort (BM cohort)~2. Leptomeningeal metastasis cohort (LM cohort)"
62798321|NCT06440941|EXPERIMENTAL|one arm pre-post test|This study consists of two phases. In the first phase, a rule-based automated chatbot will be developed to facilitate mindfulness-based stress reduction (MBSR) interventions. The second phase will employ a single-group pretest-posttest design to evaluate the feasibility, acceptability, safety and preliminary efficacy of the chatbot-based MBSR intervention for university students with self-reported depressive symptoms. The study will be guided by the 'CONSORT 2010 checklist of information to include when reporting a pilot or feasibility trial'. This study specifically targets university students in Hong Kong and the intervention lasts eight weeks.
62025477|NCT02014116|EXPERIMENTAL|Cohort 6 Dose Escalation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
62025478|NCT02014116|EXPERIMENTAL|Cohort A Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
62416957|NCT02813785|EXPERIMENTAL|Atezolizumab|Participants will receive atezolizumab until loss of clinical benefit and will thereafter enter survival follow-up until death, loss to follow-up, withdrawal, or study end.
62025479|NCT02014116|EXPERIMENTAL|Cohort B Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
62025480|NCT02014116|EXPERIMENTAL|Cohort C Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
62025481|NCT02756624|EXPERIMENTAL|AC-170 0.24%|1 drop in each eye 3 times daily for up to 6 weeks
62588421|NCT03277469|EXPERIMENTAL|MRI Guided BRACHYTHERAPY without Tracker|"* Standard pelvic MRI sequences will be obtained~* Standard process is used with serial MR imaging to evaluate catheter position during implant~* All patients will undergo 3D-based image acquisition for brachytherapy treatment planning per standard clinical practice~* The brachytherapy modality to be used is high-dose-rate brachytherapy using an iridum-192 stepping source"
62588422|NCT01753661|EXPERIMENTAL|Project ASPIRE Treatment Condition|The Project ASPIRE Treatment condition will receive the Project ASPIRE intervention program which includes the linguistic feedback reports and the multimedia education sessions. This group will complete the same assessments as the control group.
62588423|NCT01753661|ACTIVE_COMPARATOR|EI-As-Usual Condition|As an ethical decision, eligible participants may roll over to the experimental group after satisfactory completion of this treatment.
62588424|NCT03015610|PLACEBO_COMPARATOR|Placebo|participants will receive oral blinded matched placebo once daily
62588425|NCT03015610|EXPERIMENTAL|Genotype-guided Lansoprazole|participants will receive oral blinded commercially available lansoprazole once daily with a dose appropriate for the participant's metabolizer phenotype
62588426|NCT02780141|EXPERIMENTAL|ASP1517 Low dose Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
62025482|NCT02756624|PLACEBO_COMPARATOR|AC-170 Vehicle|1 drop in each eye 3 times daily for up to 6 weeks
62025483|NCT03535649||Vedolizumab|Participants diagnosed with moderate to severe active UC and having failed tumor necrosis factor alpha (TNF alpha) antagonist therapy and who have initiated vedolizumab intravenous treatment between 17 August 2017 and the date when at least 100 cases are collected from approximately 15 participating sites will be observed from the date of UC diagnosis until the date when participant is enrolled into the study or until the end of treatment or death of participants or lost-to-follow up.
62025484|NCT03110289|EXPERIMENTAL|Superdonor FMT|Fecal microbiota transplantation from a healthy donor that was selected based on a fecal/blood screening, medical interview and on abundance of taxa of the investigators their interest
62222957|NCT00926497|EXPERIMENTAL|Procalcitonin group|Antibiotic therapy is discontinued when two consecutive Procalcitonin values are below predefined age-adjusted cut-off values. Antibiotic therapy could be prolonged despite fulfilled Procalcitonin criteria at the discretion of the attending physician.
62222958|NCT00926497|NO_INTERVENTION|Standard group|Standard treatment for suspected neonatal early-onset sepsis based on conventional laboratory parameters
62222959|NCT04750525|EXPERIMENTAL|BreEStim 120, then EStim 120|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation. EStim is transcutaneous electrical nerve stimulation.
62222960|NCT04750525|EXPERIMENTAL|EStim 120, then BreEStim 120|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation. EStim is transcutaneous electrical nerve stimulation.
62416958|NCT02813785|ACTIVE_COMPARATOR|Docetaxel|Participants will receive docetaxel until disease progression per standard RECIST v1.1 criteria or unacceptable toxicity and will thereafter enter survival follow-up until death, loss to follow-up, withdrawal, or study end.
62416959|NCT01722188||Optim Leads|
62416960|NCT04233788||Sequence optimization (Healthy Control Group 1 (10 Persons))|"The MEGA-based editing sequences as well as the SLOW-EPSI sequence will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used for optimization of the pulse sequences.~Aim: find those sequence parameters to obtain best spectral quality data (SNR, spatial resolution versus measurement time)."
62416961|NCT04233788||Healthy Control Group 2 (15 Persons)|"The best performing sequence which will be applied to this group using a 7T Terra scanner. Data will be used normative data for glutamate/glutamine and GABA levels in healthy controls.~Aim: normal reference data for future studies."
62416962|NCT04233788||Patient Group 1: Comparison of 5 different spectral editing sequences (30 Patients)|Two editing pulse sequence types will be applied to this group at a 3T Prisma and a 7T Terra scanner. The sequences being compared are MEGA-semiLASER-SVS, MEGA-semiLASER based MRSI (on both 3T and 7T) and SLOW-EPSI (on 7T only).
62416963|NCT04233788||Patient Group 1: Comparison of 4 different CEST sequences (30 Patients)|"Two different CEST sequence types will be applied to this group at a 3T Prisma and a 7T Terra scanner. The CEST performance will be compared between 3T and 7T, as well which of the two types in the best on each scanner.~Aim: which of the four sequence predicts the IDH-mutation status best."
62025485|NCT03110289|SHAM_COMPARATOR|Autologous FMT|Fecal microbiota transplantation derived from feces from the patient her/himself.
62025486|NCT06535360|EXPERIMENTAL|PRT PLTs stored in PAS|FDA approved and already used in this patient population tested for non-inferiority
62222961|NCT02868385|ACTIVE_COMPARATOR|Control group (A)|1x praziquantel: Children assigned to group A receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive no further treatment until the final visit (week 8).
62416964|NCT03367949|NO_INTERVENTION|Accuracy of surgical guide from Model optical scan|
62416965|NCT03367949|ACTIVE_COMPARATOR|Accuracy of surgical guide from Impression inversion Technique|
62416966|NCT06701890|EXPERIMENTAL|Adults planning to travel outside metropolitan France.|"Human biological samples :~* Blood sample~* fecal sample"
62416967|NCT06540222|EXPERIMENTAL|Intact cord|The neonate will be kept close to the mother with the cord intact. When in need of ventilatory support, the neonatal team will give ventilatory support with sustained cord circulation, following neonatal cardiopulmonary resuscitation guidelines. Cord clamping will be performed after respiration has been established and at the earliest after three minutes.
62416968|NCT06540222|ACTIVE_COMPARATOR|Standard care|Management according to standard care, including immediate cord clamping for neonates requiring ventilatory support. In cases where ventilatory support is not necessary, cord clamping will be performed within 60 seconds of birth, adhering to established clinical guidelines for neonatal management.
62222962|NCT02868385|EXPERIMENTAL|Intervention group (B)|4x praziquantel: Children assigned to group B receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive three consecutive praziquantel treatments (40 mg/kg) in the following six weeks with 2 weeks intervals.
62222963|NCT02633579|ACTIVE_COMPARATOR|Erythromycin lactobionate|40 mg erythromycin lactobionate was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %
62222964|NCT02633579|ACTIVE_COMPARATOR|Erythromycin lactobionate with atropine|40 mg erythromycin lactobionate was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %; Atropine sulfate was given as an i.v. bolus (15 µg/kg) followed by a continuous infusion of 15 µg/kg/h over 30 min
62222965|NCT02633579|PLACEBO_COMPARATOR|Atropine|"Atropine sulfate was given as an i.v. bolus (15 µg/kg) followed by a continuous infusion of 15 µg/kg/h over 30 min.~Infusion of saline as a placebo for erythromycin was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %"
62025487|NCT06535360|ACTIVE_COMPARATOR|Non-PRT PLTs stored in platelet additive solution (PAS)|FDA approved and already used in this patient population
62025488|NCT06240312|OTHER|All subjects|Each subject will be imaged at two different times and eye pressures
62025489|NCT06635980|EXPERIMENTAL|Arm I (Preoperative radiation therapy + surgery)|Patients undergo SOC chemotherapy followed by breast hypofractionated radiotherapy QD for a total of 5 fractions. Patients then undergo SOC breast surgery 10 weeks after radiation treatment. Patients also undergo CT, MRI, PET, CEDM, and/or breast US throughout the study. Additionally, patients undergo a breast biopsy and may undergo optional blood sample collection and tissue collection on study.
62222966|NCT02633579|PLACEBO_COMPARATOR|Placebo|Infusion of saline was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %; also placebo for atropine was given as an i.v. bolus of saline followed by a continuous infusion over 30 min
62222967|NCT05057299||Patients with extramedullary leukemia(eAML) with myeloid neoplasms|
62222968|NCT03394729|EXPERIMENTAL|Propolis tablet to limit dental biofilm|Individuals will be instructed to consume the tablet with propolis and xilytol to control dental biofilm, twice a day (at 10am and 5pm) for 7 days, giving a 30 day interval between the test and the control tablet.
62222969|NCT03394729|ACTIVE_COMPARATOR|Xilytol tablet to limit dental biofilm|Individuals will be instructed to consume the tablet with xilytol to control dental biofilm, twice a day (at 10am and 5pm) for 7 days, giving a 30 day interval between the test and the control tablet.
62416969|NCT03626207||Retinitis pigmentosa|Retinitis pigmentosa patients with severe visual impairment
62798322|NCT06085508|EXPERIMENTAL|Digital patient education to reduce kinesiophobia|Intervention: Patients with MI and/or AF and kinesiophobia meet 7 times in a group education via Zoom® video meetings with a tutor (nurse, physiotherapist) for 8 weeks and learn about PA, kinesiophobia, AF and/or CAD.
62025490|NCT06635980|EXPERIMENTAL|Arm II (Surgery + postoperative radiation therapy)|Patients undergo SOC chemotherapy and SOC breast surgery followed by breast hypofractionated radiotherapy QD for a total of 5 fractions. Patients also undergo CT, MRI, PET, CEDM, and/or breast US throughout the study. Additionally, patients undergo a breast biopsy and may undergo optional blood sample collection and tissue collection on study.
62222970|NCT01531010|ACTIVE_COMPARATOR|Pressure-limited ventilation|
62416970|NCT05789303|EXPERIMENTAL|Cohort 1: No Prior CAR T-Cell Therapy|This cohort will consist of 19 participants who have not had CAR T-Cell Therapy. Participants will receive belantamab mafodotin, carfilzomib, pomalidomide and dexamethasone.
62416971|NCT05789303|EXPERIMENTAL|Cohort 2: Prior CAR T-Cell Therapy|This cohort will consist of 64 participants who have had prior CAR T-Cell Therapy. Participants will receive belantamab mafodotin, carfilzomib, pomalidomide and dexamethasone.
62025491|NCT04837365|OTHER|patients with neuropsychological disorders|
62025492|NCT04837365|OTHER|patients without neuropsychological disorders|
62025493|NCT01552044|EXPERIMENTAL|spironolactone|Spironolactone 25mg/day
62416972|NCT05830123|EXPERIMENTAL|cohort 1 at HS-20093 8mg/kg (Phase 2a)|Participants in cohort 1 will be randomized to receive HS-20093 at 8 mg/kg.
62025494|NCT01552044|PLACEBO_COMPARATOR|Placebo|placebo tablets
62025495|NCT02169908|OTHER|Occurrence of painful neuropathy|Assessment of neuropathic pain with two devices (Thermotest and von Frey hairs) and with the Neuropathic Pain Symptom Inventory.
62025496|NCT00855517|EXPERIMENTAL|Punctal Plug|
62025497|NCT02459067|EXPERIMENTAL|ImmuniCell®|Subjects will receive 6 cycles of ImmuniCell®, one infusion over an hour, at two-week intervals. During Stage 1, intra-patient dose escalation to achieve a total dose of 30 x 109 γδ T cells.
62025498|NCT01545011|NO_INTERVENTION|standard|conventional respiratory rehabilitation
62025499|NCT01545011|EXPERIMENTAL|IMT|Inspiratory muscle training and conventional respiratory rehabilitation
62025500|NCT01492881|EXPERIMENTAL|Vorinostat, Bortezomib, Doxil|"Induction therapy will consist of up to 8 cycles of vorinostat, bortezomib, and doxil. One cycle is defined as 21 days.~Maintenance therapy will consist of Vorinostat and bortezomib. One maintenance cycle is 28 days and repeated for up to 1 year."
62025501|NCT06193421|EXPERIMENTAL|Ambroxol hydrochloride|Daily administration of Ambroxol in newly diagnosed GBA1 PD.
62025502|NCT04907240||Iliac|Subjects with de novo or restenotic lesions in the iliac arteries treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
62222971|NCT01531010|ACTIVE_COMPARATOR|Volume-targeted ventilation|
62222972|NCT03366623|OTHER|Hospital clown intervention|"The performance of the hospital clown included creating a relation with the child by using different techniques in the venipuncture procedure.~The hospital clown used distraction techniques with music, songs, toys, fake tattoos (a small sticker/label with a picture applied to the skin with water), dream journeys, storytelling and making agreements in collaboration with the child, parents and healthcare personnel."
62416973|NCT05830123|EXPERIMENTAL|cohort 1 at HS-20093 12mg/kg (Phase 2a)|Participants in cohort 1 will be randomized to receive HS-20093 at 12 mg/kg.
62416974|NCT05830123|EXPERIMENTAL|cohort 2 at HS-20093 12mg/kg (Phase 2a)|Participants in cohort 2 will receive HS-20093 at 12 mg/kg.
62416975|NCT05830123|EXPERIMENTAL|HS-20093(Phase 2b)|Participants will receive HS-20093 at the recommended dose from Phase 2a.
62416976|NCT05489068|EXPERIMENTAL|Motivational Interviewing at Intake (MII)|Clients allocated to the MII condition will receive a 90-minute pure Motivational Interviewing (MI) session.
62798323|NCT01922713|PLACEBO_COMPARATOR|white maize|white maize and a corn oil capsule
62798324|NCT01922713|EXPERIMENTAL|orange maize|orange maize and a corn oil capsule
62798325|NCT01922713|ACTIVE_COMPARATOR|vitamin A|white maize and a vitamin A capsule
62025503|NCT04907240||Superficial Femoral Artery (SFA)|Subjects with de novo or restenotic lesions in the SFA and proximal popliteal arteries treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
62025504|NCT04907240||Superficial Femoral Artery (SFA) In-Stent Restenosis (ISR)|Subjects with in-stent restenosis lesions in the SFA and proximal popliteal arteries treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
62025505|NCT04907240||AV access|Subjects with stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous (AV) access graft and in the venous outflow of dialysis access circuits, including the central veins treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
62222973|NCT03366623|OTHER|No hospital clown intervention|The clinical staff, defined as pediatric nurses and biomedical laboratory technologists, assisted the child in the venipuncture procedure with conventional communication, comfort and care techniques.
62222974|NCT00722527||Affected Population|Subjects with an elevated hemoglobin concentration or an elevated platelet count
62222975|NCT03922646|EXPERIMENTAL|NEAT Active Experimental Group|People in the active group will receive NEAT intervention
62416977|NCT05489068|ACTIVE_COMPARATOR|Intake as Usual (IAU)|Clients allocated to the IAU condition will receive the 90-minute standard assessment that is delivered to all clients entering intensive outpatient program (IOP)/outpatient program (OP).
62416978|NCT06458023|EXPERIMENTAL|TetraGraph (TM) NMT Monitor|TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
62416979|NCT04904978|EXPERIMENTAL|Trial Group|Use of Blanx Black Toothpaste
62416980|NCT04904978|ACTIVE_COMPARATOR|Control Group|Use of Colgate Sensation White toothpaste.
62416981|NCT03906565|EXPERIMENTAL|utidelone|Utidelone Injection: 40 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle, administered to enrolled patients with advanced or metastatic CRC
62416982|NCT03469141|NO_INTERVENTION|Control Group|The control group will continue to have the WC sensor system for measurement only and will not receive biofeedback after receiving instructions on the importance of pressure relief (PR) maneuvers for skin care, as well as training regarding the three pressure relief maneuvers. Materials (including fact sheets, etc.) will be incorporated in the educational content of the project.
62798326|NCT02286921|EXPERIMENTAL|Arm A: Testosterone cypionate or testosterone enanthate|Patients on BAT will receive testosterone cypionate or testosterone enanthate administered as an intramuscular injection. A dose of 400 mg of either agent will be injected intramuscularly (IM) every 28 days.
62798327|NCT02286921|EXPERIMENTAL|Arm B: Enzalutamide|Patients randomized to enzalutamide will be prescribed enzalutamide 40 mg tablets and instructed to take 4 tablets per day orally for 28 days/cycle.
62222976|NCT03922646|ACTIVE_COMPARATOR|Control Group|People in the control group will receive non-essential regularly-scheduled programming (active control) coinciding with the same timeframe
62222977|NCT03737474|EXPERIMENTAL|Brexpiprazole|2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
62416983|NCT03469141|EXPERIMENTAL|Intervention Group|The intervention group will receive biofeedback via the smartphone app.
62416984|NCT03841903||relapsing-remitting MS undergoing spinal cord MRI|
62416985|NCT03841903||secondary progressive MS undergoing spinal cord MRI|
62416986|NCT03841903||primary progressive MS undergoing spinal cord MRI|
62416987|NCT03841903||healthy control (HC) undergoing spinal cord MRI|
62222978|NCT04323631|EXPERIMENTAL|The intervention group|The intervention group will receive oral hydroxychloroquine. In the first day 400 mg twice daily, followed by 200mg twice daily on days 2-10 (continued after discharge if discharged before day 10).
62222979|NCT04323631|OTHER|The control group|The control group will not receive hydroxychloroquine.
62025506|NCT04907240||Popliteal Artery Aneurysms|Subjects with popliteal artery aneurysms treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
62222980|NCT05483634||Genital urinary symptoms of menopause|Menopause for one year, or age above 45 with symptoms of GSM
62222981|NCT00287495|EXPERIMENTAL|A|Patients with AIDS-KS receiving ritonavir will be given 200 mg BAY 43-9006 once daily with dose escalation up to 400 mg twice daily
62222982|NCT00287495|EXPERIMENTAL|B|Patients with AIDS-KS not receiving ritonavir will be given 200 mg BAY 43-9006 once daily with dose escalation up to 400 mg twice daily
62222983|NCT03643393|OTHER|incarceration rectal prolapse|
62222984|NCT04552977|EXPERIMENTAL|fluzoparil+temozolomide|Participants receive fluzoparil and temozolomide
62222985|NCT02469389|EXPERIMENTAL|Engaging in Community Roles and Experiences (ENCoRE)|Engaging in Community Roles and Experiences (ENCoRE) includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms. Behavioral strategies include motivational enhancement, psychoeducation, cognitive therapy, and social skills training.
62222986|NCT02469389|ACTIVE_COMPARATOR|Health & Wellness (H&W)|Health \& Wellness (H\&W) will focus on health and wellness issues and education on ways to better manage health-related concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application. Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions), 8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1session).
62222987|NCT00557934|EXPERIMENTAL|1|
62222988|NCT00730457|EXPERIMENTAL|A|Intramuscular (i.m.) vaccination of a single dose of 0.1 µg, 0.3 µg, 1 µg, 2 µg, 3 µg, 5 µg and 8 µg of STF2.HA1 (SI) (VAX125).
62222989|NCT02912676|EXPERIMENTAL|6TG/6MP/MTX|Single arm feasibility study aiming to demonstrate the applicability of combining incremental doses of oral 6-Thioguanine with oral daily 6-Mercaptopurine and oral weekly Methotrexate in order to achieve mean levels of DNA-TG above 500 fmol/mikrogram DNA.
62025507|NCT04907240||Trauma/Injury|Subjects with traumatic or iatrogenic vessel injuries in arteries that are located in the chest cavity, abdominal cavity, or pelvis (except for aorta, coronary, innominate, carotid, vertebral, and pulmonary arteries) treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
62025508|NCT04907240||Visceral Artery Aneurysms|Subjects with isolated visceral artery aneurysms treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
62222990|NCT02533570|EXPERIMENTAL|Brentuximab vedotin|4 dose groups
62222991|NCT02533570|PLACEBO_COMPARATOR|Placebo|Matching placebo
62222992|NCT00158860|EXPERIMENTAL|Valaciclovir|Participants received double blinded treatment of oral dose of Valacyclovir 1 g given as 2 x 500 mg caplets QD for 6 months (24 weeks).
62222993|NCT00158860|PLACEBO_COMPARATOR|Placebo|Participants received double blinded treatment of oral dose of matching placebo to Valacyclovir 1 gram (g) given as 2 x 500 milligram (mg) caplets once daily (QD) for 6 months (24 weeks).
62222994|NCT04000360|EXPERIMENTAL|High-Intensity Exercise Group|Mild to moderate Parkinson's disease patients: The exercise group will be asked to cycle 3x/week for 12 months on a Peloton bicycle which will be delivered to their home.
62222995|NCT04000360|NO_INTERVENTION|Usual and Customary Care Group|Mild to moderate Parkinson's disease patients, receiving no exercise intervention through the research. They will continue to receive usual and customary care for their Parkinson's disease during the 12 month period.
62222996|NCT01372423|ACTIVE_COMPARATOR|AMITIZA|Manufactured by Sucampo Pharmaceuticals (24 mcg administered for 7 days)
62222997|NCT01372423|PLACEBO_COMPARATOR|Placebo|Manufactured by Anchen Pharmaceuticals (24 mcg administered for 7 days)
62416988|NCT04461080|EXPERIMENTAL|Integrated care promoter|Patients who are randomized to the intervention group will be connected with a trained Community Health Worker (CHW). The CHW is a peer with lived-experience of system navigation that could have a background in social work, health promotion or community work. All CHWs will receive 2 weeks of training to assist participants with social needs.
62416989|NCT04461080|ACTIVE_COMPARATOR|Information on community resources|Patients randomized to the control group will receive a list of tailored written information.
62416990|NCT05080088||Colonoscopy Only Group|
62416991|NCT05080088||Artificial intelligence GI GENIUS ™ only Group|
62798328|NCT06725953|EXPERIMENTAL|Social Cognitive Theory-based, Technology-delivered Physical Activity Program|Participants will engage in a 12-week program of aerobic and muscle-strengthening physical activity. This program will be delivered remotely via two smartphone applications--one for providing health education, goal setting, and journaling features and the other for delivery of the physical activity program in a highly-personalized and HIPAA-compliant manner. Participants will receive a Fitbit to track their activity and resistance bands to use during their resistance training physical activity. All program components will be based in the Social Cognitive Theory and will target improving participants' physiological and psychological health outcomes.
62798329|NCT03874702||Ischemic stroke patients with <4.5 hours of onset .|analysis of the computed tomography without contrast and detection of early changes, scoring with ASPECTS score and integration to the machine learning data base.
62222998|NCT01372423|EXPERIMENTAL|Lubiprostone|Manufactured by Anchen Pharmaceuticals (24 mcg administered for 7 days)
62416992|NCT05080088||Endoscopic Cap and Artificial Intelligence GI GENIUS ™ Group|
62416993|NCT02801838|EXPERIMENTAL|Ventilator settings, morphine titration|First, ventilator settings optimization and when the clinician judges necessary (remains discomfortable), opioid titration with a maximum of 10mg of morphine
62416994|NCT06702566|EXPERIMENTAL|A: Serum ferritin in patients receiving immunotherapy|Patients will receive standardized anti-tumor therapy including immunotherapy according to clinical guidelines. Patients who treated with immuno-monotherapy, or immuno- plus targeted therapy, or immuno- plus chemotherapy will be recruit in to test the serum ferritin level
62025509|NCT04907240||Others|Subjects treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) but do not fit any of the cohorts listed above.
62416995|NCT06702566|ACTIVE_COMPARATOR|B: Serum ferritin in patients receiving targeted therapy|Patients will receive standardized anti-tumor therapy including targeted therapy according to clinical guidelines. Patients who treated with targeted monotherapy, or targeted plus chemotherapy will be recruit in to test the serum ferritin level
62416996|NCT06702566|ACTIVE_COMPARATOR|C: Serum ferritin in patients receiving chemotherapy|Patients will receive standardized anti-tumor therapy including chemotherapy according to clinical guidelines. Patients who treated with chemotherapy will be recruit in to test the serum ferritin level
62798330|NCT01313260||Epilepsy patients|Epilepsy patients selected before undergoing intracranial EEG recordings
62798331|NCT01313260||control group|Healthy volunteers
62025510|NCT02023385|EXPERIMENTAL|LLLT group|Subjects in the Low Level Laser Therapy (LLLT) group will be treated with the BTL-9000 LLLT
62588427|NCT02780141|EXPERIMENTAL|ASP1517 High dose Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
62588428|NCT04570527||Obesity|BMI\>=25
62222999|NCT01290315|EXPERIMENTAL|Ferric Carboxymaltose (FCM)|Intravenous iron
62223000|NCT01290315|ACTIVE_COMPARATOR|Iron Sucrose / Iron Dextran|Intravenous iron
62223001|NCT00408239|EXPERIMENTAL|1|Dose regimen 1
62223002|NCT00408239|ACTIVE_COMPARATOR|2|
62223003|NCT00408239|EXPERIMENTAL|3|Dose regimen 2
62798332|NCT01362608|EXPERIMENTAL|Canakinumab and placebo matching to triamcinolone acetonide|ACZ885H
62025511|NCT02023385|PLACEBO_COMPARATOR|Placebo group|Subjects in the Placebo group with be treated with the sham BTL-9000 LLLT
62025512|NCT05466318|EXPERIMENTAL|ChiCGB|Treated with chidamide, cladribine, gemcitabine and busulfan(ChiCGB) therapy followed by autologous hematopoietic stem cell transplantation.
62025513|NCT05466318|ACTIVE_COMPARATOR|BEAM|Treated with BCNU, etoposide, cytarabine and melphalan (BEAM) therapy followed by autologous hematopoietic stem cell transplantation.
62416997|NCT03533608|EXPERIMENTAL|Group PE|Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
62416998|NCT04324112|EXPERIMENTAL|Arm 1/Experimental therapy|Treatment with encorafenib and binimetinib
62416999|NCT04434235||Dynamic cervical stability|"The participant is asked to move the head in 6 directions in a sitting position and 30° leaning backward sitting position; lateral flexion (left / right), flexion, extension, and rotation (left / right). Results are to be taken for each direction and random at each axial load-level (0 kg, 1kg, 2 kg, and 3 kg). In total 24 measurements.~The duration of all measurement will be 60 minutes."
62417000|NCT04434235||Cervical Stiffness|The participant is asked to move the head in 4 directions; flexion, extension, and rotation (left / right). Joint-Position Error measurements will be executed in neutral sitting position. Additionally, stiffness will be measured in neutral sitting position and neutral sitting position with 45° cervical flexion. All measurements will be performed with 0 kg and 3 kg axal loading. In total 18 measurements.The duration of all measurement will be 60 minutes.
62417001|NCT06676241||ERCP, EST and simultaneous LC|Patients aged 18-55 years initially underwent ERCP with ES by an endoscopist with the consent of the patient or legal representative. Patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Laparoscopic cholecystectomy was performed immediately after ERCP with ES under general anesthesia
62588429|NCT04570527||Non-Obesity|BMI\<25
62588430|NCT06482268|OTHER|Single-center, open-label, uncontrolled|To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease
62588431|NCT06502600||The favourable outcomes group|
62588432|NCT06502600||The poor outcomes group|
62588433|NCT01431690|EXPERIMENTAL|Warfarin and Epanova|
62588434|NCT01431690|ACTIVE_COMPARATOR|Lovaza|
62025514|NCT02657278|OTHER|Symptomatic Peripheral arterial disease|Patients scheduled to undergo surgery or angioplasty of the iliofemoral segment for intermittent claudication.
62025515|NCT03068403|OTHER|Chemotherapy and Radiochemotherapy|
62025516|NCT03068403|OTHER|Radiochemotherapy|
62025517|NCT01776645|EXPERIMENTAL|Compassion cultivation training|
62588435|NCT05561907|ACTIVE_COMPARATOR|Surgical gastrojejunostomy (SGJ)|An anastomosis will be created between the stomach and the proximal loop of the jejunum during a laparoscopic surgical procedure.
62588436|NCT05561907|EXPERIMENTAL|Endoscopic gastrojejunostomy (EGJ)|A stent is placed between the stomach and adjacent small intestine under endoscopic ultrasound guidance during an upper endoscopic procedure.
62588437|NCT02667964|OTHER|Healthy controls|Spiroergometry
62588438|NCT02667964|OTHER|Patients with T2DM|Spiroergometry
62588439|NCT02667964|OTHER|Patients with T1DM|Spiroergometry
62025518|NCT05870098|OTHER|All participants|"All participants will receive:~1. Clinician or self-taken, pharyngeal and rectal swabs with FCU analysed individually~2. Self-taken pharyngeal, meatal, and rectal swabs analysed as a pooled specimen~3. Self-taken pharyngeal and rectal swabs with 1.5ml FCU analysed as a pooled specimen The FCU will be done after any meatal swabs. Patients will be instructed to only pass the first 5ml into the tube, and the tube will be pre-marked with a black line. Full pictoral instructions and verbal support will be given to enable them to complete the pooling process of the swabs and urine."
62025519|NCT02337647|OTHER|DCDC app|Subjects will evaluate the DCDC app
62223004|NCT01090427|EXPERIMENTAL|Ustekinumab Half-standard Dosage|Participants will receive ustekinumab at half the standard dosage at Weeks 0, 4, 16, 28, and 40. In addition, all participants will receive a single SC dose of placebo at Week 12.
62223005|NCT01090427|EXPERIMENTAL|Ustekinumab Standard Dosage|Participants will receive ustekinumab at the standard dosage at Weeks 0, 4, 16, 28, and 40. In addition, all participants will receive a single SC dose of placebo at Week 12.
62223006|NCT01090427|EXPERIMENTAL|Placebo|Participants will receive matching placebo at Week 0 and 4, followed by ustekinumab at half-standard or standard dosage at Weeks 12, 16, 28, and 40.
62798333|NCT01362608|ACTIVE_COMPARATOR|Triamcinolone acetonide 40 mg|ACZ885H
62798334|NCT01521026|EXPERIMENTAL|Cognitive Training|Cognitive training group
62417002|NCT06676241||ERCP, EST and LC in a delayed manner|Patients aged 0-17 years initially underwent ERCP with ES by an endoscopist with the consent of the patient or legal representative. Patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Laparoscopic cholecystectomy was performed in a delayed manner, not earlier than 7 days after ERCP
62417003|NCT00686231|EXPERIMENTAL|Dose Test 15mg NTG|Nitroglycerin 15mg (NTG) applied topically to one wrist and placebo to the other wrist at Visit 1
62798335|NCT01521026|NO_INTERVENTION|Standard Pharmacotherapy|
62798336|NCT04260789|OTHER|Treatment|Treatment with Seraph Filter
62223007|NCT03782220|EXPERIMENTAL|Kinesio taping group|"Kinesio taping group~* Application of kinesio taping to sternocleidomastoid, upper trapezium, levator scapulae muscles.~* Once a week , for 4 weeks"
62223008|NCT03782220|PLACEBO_COMPARATOR|Shame taping group|"Shame taping group~* Application of kinesio band to same muscles except for the defined method which is considered to be ineffective.~* Once a week , for 4 weeks"
62223009|NCT04217629|EXPERIMENTAL|SY-005 single-dose 0.75mg|4 subjects will be envolved in this group and be injected with 0.75mg of SY-005.
62223010|NCT04217629|PLACEBO_COMPARATOR|SY-005 single-dose 2.5mg|This group will be intiated in healthy subjects at a 2.5mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
62223011|NCT04217629|PLACEBO_COMPARATOR|SY-005 single-dose 5mg|This group will be intiated in healthy subjects at a 5mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
62223012|NCT04217629|PLACEBO_COMPARATOR|SY-005 single-dose 10mg|This group will be intiated in healthy subjects at a 10mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
62223013|NCT04217629|PLACEBO_COMPARATOR|SY-005 single-dose 15mg|This group will be intiated in healthy subjects at a 15mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
62223014|NCT04217629|PLACEBO_COMPARATOR|SY-005 single-dose 20mg|This group will be intiated in healthy subjects at a 20mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
62223015|NCT04217629|PLACEBO_COMPARATOR|SY-005 multiple-doses 5mg|This group will be intiated in healthy subjects at a 5mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.
62223016|NCT04217629|PLACEBO_COMPARATOR|SY-005 multiple-doses 10mg|This group will be intiated in healthy subjects at a 10mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.
62223017|NCT04217629|PLACEBO_COMPARATOR|SY-005 multiple-doses 20mg|This group will be intiated in healthy subjects at a 20mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.
62223018|NCT02977585|ACTIVE_COMPARATOR|group 1|high level support
62417004|NCT00686231|EXPERIMENTAL|Dose Test 30mg NTG|Nitroglycerin 30mg applied topically to one wrist and placebo to the other wrist at Visit 1
62798337|NCT04260789|NO_INTERVENTION|Control|
62223019|NCT02977585|NO_INTERVENTION|group 0|low level support
62223020|NCT01869582|EXPERIMENTAL|Doppler, Fetal heart rate|Eligible women in labour randomized to intermittent fetal heart rate assessments using a wind-up, hand-held Doppler
62223021|NCT01869582|EXPERIMENTAL|Fetoscope, Fetal heart rate|Eligible women in labour randomized to intermittent fetal heart rate assessments using a Pinard fetoscope, which is the current standard management
62223022|NCT01869582|EXPERIMENTAL|Upright Resuscitator, Resuscitation|Non-breathing newborn infants in need of positive pressure ventilation randomized to an Upright Resuscitator
62223023|NCT01869582|EXPERIMENTAL|Standard Resuscitator, Resuscitation|Non-breathing newborn infants in need of positive pressure ventilation randomized to a standard horizontal Resuscitator, which is the current standard management
62223024|NCT05665465|PLACEBO_COMPARATOR|Placebo|Participants will be administered 2 nasal sprays with a combined nicotine content of 0mg nicotine, 0.1mL
62223025|NCT05665465|EXPERIMENTAL|0.5mg nicotine|Participants will be administered 2 nasal sprays with a combined nicotine content of 0.5 mg nicotine, 0.1mL
62223026|NCT05665465|EXPERIMENTAL|1mg nicotine|Participants will be administered 2 nasal sprays with a combined nicotine content of 1.0 mg nicotine, 0.1mL
62223027|NCT02087709|EXPERIMENTAL|Low-calorie diet|The subjects were prescribed a daily energy intake 500 kcal lower than the estimated energy requirement.
62223028|NCT01241175|EXPERIMENTAL|magnesium sulfate|
62223029|NCT01241175|PLACEBO_COMPARATOR|normal saline|
62223030|NCT04161495|EXPERIMENTAL|Arm A: Prophylaxis|Participants who were on a prophylaxis treatment with a FVIII product prior to study EFC16293 including participants who rolled over from study OBS16221, received BIVV001 50 international units per kilogram (IU/kg) intravenous (IV) injection once-weekly (QW) for 52 weeks in the current study. Study OBS16221 participants with 6 months historical data on prophylaxis treatment with a marketed FVIII product prior to enrollment were analyzed as a subgroup (named as: Arm A: Historical Prophylaxis \[OBS16221\]) in the outcome measure analysis.
62417005|NCT00686231|EXPERIMENTAL|Combination Test 20mg Lidocaine|Lidocaine 20mg + Nitroglycerin 30mg applied topically to one wrist, Lidocaine 20mg + placebo applied to the other wrist, at Visit 2
62417006|NCT00686231|EXPERIMENTAL|Combination Test 40mg Lidocaine|Lidocaine 40mg + Nitroglycerin 30mg applied topically to one wrist, Lidocaine 40mg + placebo applied to the other wrist, at Visit 2
62417007|NCT06703840|PLACEBO_COMPARATOR|Placebo|LIB-01 Placebo, oral suspension
62798338|NCT06503809|EXPERIMENTAL|Ketogenic Diet|The Ketogenic Diet group will consume a very-low carbohydrate diet (\<50 g/day) diet. Participants will receive isocaloric packed-out meals for 26 weeks.
62798339|NCT06503809|ACTIVE_COMPARATOR|Standard Care|The Standard Care group will consume a diet consistent with the guidelines recommended by the American Diabetes Association that is high in non-starchy vegetables and lean protein sources and low in added sugar. Participants will receive isocaloric packed-out meals for 26 weeks.
62798340|NCT02610582|OTHER|Treatment arm|single subretinal injection of 1x10e11 vector genome particles of rAAV.hCNGA3 in each eye at different time-points
62798341|NCT02610582|OTHER|Waiting group Arm|Waiting group will serve as comparator group first and will receive the treatment at a later timepoint.
62223031|NCT04161495|EXPERIMENTAL|Arm B: On-Demand Then Prophylaxis|Participants who were on an on-demand treatment regimen with a FVIII product prior to study EFC16293, including participants who rolled over from study OBS16221, received BIVV001 50 IU/kg IV injection as an on-demand treatment (as needed for the treatment of bleeding episodes) from Week 1 to Week 26 in current study. At Week 26, participants in Arm B were switched to prophylaxis treatment, and received BIVV001 50 IU/kg, IV injection QW until Week 52.
62417008|NCT06703840|EXPERIMENTAL|LIB-01 10 mg|LIB-01 10 mg, oral suspension
62417009|NCT06703840|EXPERIMENTAL|LIB-01 25 mg|LIB-01 25 mg, oral suspension
62417010|NCT06703840|EXPERIMENTAL|LIB-01 50 mg|LIB-01 50 mg, oral suspension
62417011|NCT04806958|EXPERIMENTAL|Conventional Emergency Dispatch PLUS PulsePoint notification|Eligible 911 calls randomized to the experimental arm of the study will undergo usual dispatch of emergency services personnel as per pre-existing local protocols and activation of the PulsePoint system. When triggered, the system will push location data to all PulsePoint mobile application users within 400 meters of the emergency. Devices receiving the alerts from the PulsePoint system will alarm with auditory, tactile and visual stimuli. The application will present a map showing the exact location of the emergency and the closest public access defibrillator.
62417012|NCT04806958|NO_INTERVENTION|Conventional Emergency Dispatch|Patients randomized to the control arm will receive conventional emergency medical dispatching procedures as per pre-existing local protocols (e.g. dispatch of emergency vehicles, attempted dispatch-assisted CPR) without activation of the PulsePoint system. 911 calls randomized to the control arm will not be associated with any PulsePoint alerts.
62798342|NCT05757804||Non-disease controls|
62798343|NCT05757804||PD patients|
62025520|NCT00836823|EXPERIMENTAL|Alpha blocker|Alfuzosin 10mg
62223032|NCT00622258|EXPERIMENTAL|Everolimus|
62223033|NCT03525431|EXPERIMENTAL|Whole Exome Sequencing|Following consent and collection of standardized phenotypic data, probands and biological parents will undergo WES with variant analysis conducted utilizing primary gene lists based on referring clinical indication. After results provision and follow up 6-12 months later, clinical utility will be assessed in those with a positive result (pathogenic or likely pathogenic variant) and those with negative results (no variant returned or a VUS) using specific outcomes at each site to examine effectiveness for both the child and family.
62223034|NCT01559753|EXPERIMENTAL|8 days of antibiotic treatment|Patients will receive a combination antibiotic during 5 days and then 3 days of a single Beta Lactam antibiotic
62223035|NCT01559753|ACTIVE_COMPARATOR|15 days antibiotic treatment|All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for 10 days according to the group. The beta-lactam antibiotics will be administered in high doses during the first 3 days of treatment. Aminoglycosides will be administered in a single daily dose, with a loading dose the first day of treatment.
62223036|NCT05808881|EXPERIMENTAL|Nalmefene|Nalmefene hydrochloride (HCl) injection
62223037|NCT05808881|ACTIVE_COMPARATOR|Naloxone|Naloxone hydrochloride (HCl) injection
62798344|NCT05757804||DLB patients|
62798345|NCT05757804||MSA patients|
62798346|NCT05913830|EXPERIMENTAL|Experimental group:|Experimental Group A total of 36 methadone patients will receive auricular pressure
62025521|NCT03043664|EXPERIMENTAL|Arm 1|Keytruda (pembrolizumab) 200 mg intravenous (IV) infusion every 3 weeks and Somatuline Depot (lanreotide) 90 mg subcutaneous (SQ) injection every 3 weeks.
62025522|NCT01151670|EXPERIMENTAL|Arm I|Pioglitazone 22.5 mg once daily by mouth
62025523|NCT01151670|EXPERIMENTAL|Arm 2|Pioglitazone 45 mg once daily by mouth
62025524|NCT00001214||Group 1|Patients with pancytopenia
62223038|NCT02518321|EXPERIMENTAL|Standard Toileting First|This group will complete the standard toileting trial before the TAT toileting trial.
62417013|NCT06703125|EXPERIMENTAL|Children Undergoing Developmental Evaluation for Autism|Young children (ages 24-72 month) who are HIV exposed but uninfected (CHEU) and young children who are HIV unexposed but uninfected (CHUU) undergoing a standard of care developmental evaluation will be enrolled into the study. After the completion of the developmental evaluation, research participation includes a one-time eye-tracking activity in which the child will view a series of different pictures and movies while their eye movements and pupil diameter are tracked and recorded.
62417014|NCT05476276|EXPERIMENTAL|EN21-01 ISA|The EN21-01 Intervention Specific Analysis is detailed in the protocol (NCT#)
62798347|NCT05913830|NO_INTERVENTION|Control group:|Control group 36 bits No interventions implemented
62798348|NCT06528236||Training cohort|Training cohort is used to training artificial model based on multimodel ultrasound images or videos.
62798349|NCT06528236||Validation cohort|Validation cohort is used to validate artificial model.
62798350|NCT06528236||Internal test cohort|Internal test cohort is used to internally test artificial model.
62798351|NCT06528236||External test cohort|External test cohort is used to internally test artificial model.
62798352|NCT01380769|EXPERIMENTAL|CRLX101|
62798353|NCT01380769|OTHER|Best supportive care|
62798354|NCT03399630|ACTIVE_COMPARATOR|Injection of Autologous Adipose Tissue|Treatment knee receives injection of 1.5 cc's of adipose tissue mixed with 1.5 cc's of Lactated Ringers
62223039|NCT02518321|EXPERIMENTAL|TAT Toileting First|This group will complete the TAT toileting trial before the standard toileting trial.
62223040|NCT00946101|ACTIVE_COMPARATOR|MEDI3414 [Influenza A (H1N1) vaccine]|MEDI3414- Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10\^7 FFU (fluorescent focus units) of influenza virus type A/California/07/2009.
62223041|NCT00946101|PLACEBO_COMPARATOR|Placebo|Placebo - Placebo was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer
62223042|NCT01786473|EXPERIMENTAL|Testogel 1% 5g QD|
62223043|NCT01786473|PLACEBO_COMPARATOR|Placebo gel 5g QD|
62223044|NCT04331145|NO_INTERVENTION|Clopidogrel 75 mg|"Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hours before the index-TAVI procedure, patients with:~Normal basal platelet reactivity (PRU \< 160 assessed with VerifyNow P2Y12 assay): Patients will continue with clopidogrel 75 mg/day until TAVI and during the following three months. All patients will be assessed by clinical follow up and platelet reactivity according to the protocol. Prescription of aspirin 100mg/day will be encourage as per guidelines recommendations."
62223045|NCT04331145|ACTIVE_COMPARATOR|Ticagrelor 60 mg|"Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hrs before the index-TAVI procedure, patients with:~High on-treatment platelet reactivity (PRU ≥ 160 assessed with VerifyNow P2Y12 assay): Patients will be switched to receive ticagrelor 60mg twice daily initiating at least 24 hours before TAVI procedure, in order to arrive to the index TAVI procedure with at least two doses of 60 mg, and will continue with Ticagrelor 60mg twice per day during the following three months."
62223046|NCT01576250|EXPERIMENTAL|unilateral lower limb suspension|This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
62223047|NCT05557357|EXPERIMENTAL|EA Group|Subjects assigned to EA group will receive EA treatment twice weekly for 5 weeks.
62223048|NCT05557357|EXPERIMENTAL|EAWN Group|Subjects assigned to EAWN group will receive EAWN treatment twice weekly for 5 weeks.
62223049|NCT05557357|OTHER|Waitlist Control Group|Subjects assigned to waitlist control group will not receive treatment during the 10-week waiting period after baseline assessment.
62417015|NCT05476276|PLACEBO_COMPARATOR|Placebo Comparator|Each ISA will detail the use of the Placebo Comparator.
62223050|NCT05618834|EXPERIMENTAL|PPCI Arm|The ALF/PCH assigned as treatments will receive the four steps of PPCI including, stakeholder engagement and facility goal development, environment and policy assessment, staff education, and ongoing mentorship/motivation and support over a period of six-months by a research nurse facilitator (RNF), a registered nurse (RN) with prior experience in long-term care. The RNF will work with an identified internal/facility champion monthly to implement the four steps of PPCI.
62223051|NCT05618834|ACTIVE_COMPARATOR|PPCI-Staff Education Only Arm|The ALF/PCH assigned as controls will receive PPCI-staff education only (EO). The EO will include a 30-45 min in-service session and monthly f/u visits for booster education. The education content and process will be the same as outlined in Step 3 of the PPCI for treatment sites.
62223052|NCT04800432|EXPERIMENTAL|Feasibility and acceptability of ADAPT+|ADAPT+ is a family-based obesity intervention for high-risk Latino youth and their parents living in rural communities that incorporates culture-specific components and mindfulness-based approaches to promote adaptive health behaviors in a high-risk and underserved population.
62223053|NCT04800432|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) provides publicly available material in both English and Spanish on the role of diet and exercise in pediatric obesity in a one-time information session.
62417016|NCT05052879|EXPERIMENTAL|TORONTO 20 + 30/60|"The study is double-dummy. The patient must take 2 tablets before the sexual intercourse, as follows:~1 tablet of Toronto association, oral;~1 tablet of tadalafil placebo, oral."
62417017|NCT05052879|ACTIVE_COMPARATOR|TADALAFIL|"The study is double-dummy. The patient must take 2 tablets before the sexual intercourse, as follows:~1 tablet of tadalafil , oral;~1 tablet of Toronto association placebo, oral."
62417018|NCT06694974|EXPERIMENTAL|FIB-4 APP group|
62417019|NCT06694974|OTHER|standard group|
62417020|NCT06234930|EXPERIMENTAL|Active and Sham Audiovisual Stimulation (Mild AD and MCI due to AD):|Both active and sham stimulation conditions will be delivered to 25 cognitively impaired participants to demonstrate the mechanism of action of the intervention.
62417021|NCT06234930|EXPERIMENTAL|Active and Sham Audiovisual Stimulation (Cognitively Healthy):|Both active and sham stimulation conditions will be delivered to 25 healthy participants to demonstrate the mechanism of action of the intervention.
62417022|NCT02658500|EXPERIMENTAL|Infant Formula|200 newborns just consume the infant formula from 0-42 days to six months age.
62223054|NCT05537831|ACTIVE_COMPARATOR|Study Intervention Group (Ultrasound)|The ultrasound probe will be used for real-time needle and hematoma localization using the linear probe. The hematoma block will then be performed with aseptic technique. The skin will be prepped with chlorhexidine. A 20-gauge needle will be inserted in-plane into the hematoma site. A small amount of blood will be aspirated to confirm placement and 5-10 mL of 1% lidocaine will be infiltrated.
62588440|NCT06518174|ACTIVE_COMPARATOR|Cases undergone PRT|"Patients (or their legal guardians) who opt for participating in this pilot study will be consented and enrolled in the study. Patients will then be scheduled for a single study visit at the University of Colorado Hospital (UCH) that includes:~1. Pregnancy test~2. Pelvic MRI without and with contrast (if patient consents to contrast)~3. Transabdominal pelvic ultrasound using standard B-mode and Doppler US, SWE~4. Optional transvaginal ultrasound using standard B-mode and Doppler US, SWE"
62223055|NCT05537831|NO_INTERVENTION|Study Control Group (Landmark)|The ultrasound probe will be in place on the patient's arm to maintain single blinding of the study. The ultrasound machine will not be used for needle and hematoma localization. The hematoma block will then be performed with aseptic technique. The skin will be prepped with chlorhexidine. A 20-gauge needle will be inserted in-plane into the hematoma site. A small amount of blood will be aspirated to confirm placement and 5-10 mL of 1% lidocaine will be infiltrated.
62223056|NCT03082404|EXPERIMENTAL|Inspiratory muscle training group|Six times a week (three supervised at hemodialysis unit and other three times at home), 5 series, 10 repetitions, two-minutes interval or according to the patient tolerance.
62223057|NCT03082404|NO_INTERVENTION|Control group|The patients in this group will be evaluated at baseline and reassessed after five weeks of follow-up.
62223058|NCT01472094||Patients|All patients 65 years old with Stage I to III breast cancer who are beginning adjuvant or neo-adjuvant chemotherapy.
62223059|NCT00090129|EXPERIMENTAL|Onercept|
62223060|NCT00090129|PLACEBO_COMPARATOR|Placebo|
62223061|NCT06043583|ACTIVE_COMPARATOR|Intrauterine device|
62223062|NCT06043583|ACTIVE_COMPARATOR|Uterine artery embolization|
62223063|NCT03592550||Group A|Volunteers will be asked to receive ultrasound imaging in repeat voluntary breath hold and during free-breathing.
62223064|NCT03592550||Group B|Volunteers will be asked to receive ultrasound imaging in repeat voluntary breath hold and during free-breathing and in repeat spirometer assisted breath hold.
62223065|NCT04603638|ACTIVE_COMPARATOR|magnesium|participations will be given intravenous magnesium.
62417023|NCT02658500|OTHER|Breast Milk|100 newborns were just fed with breast milk from after birth to six months age.
62417024|NCT03280563|ACTIVE_COMPARATOR|Stage 1: Fulvestrant|Participants will receive fulvestrant until unacceptable toxicity or disease progression according to RECIST v1.1.
62223066|NCT04603638|PLACEBO_COMPARATOR|control|participations will be given intravenous isotonic.
62223067|NCT02716818|EXPERIMENTAL|Chronocort®|Chronocort® will be provided as 5mg, 10mg and 20mg capsules for oral administration. The starting dose for each subject will be based on the subjects previous glucocorticoid therapy dose and then dose titrated to effect.
62223068|NCT02716818|ACTIVE_COMPARATOR|standard glucocorticoid therapy|Subjects in this arm will continue previous oral glucocorticoid therapy titrated to effect.
62223069|NCT00599911|EXPERIMENTAL|Lu AA24530: 5 mg|
62223070|NCT00599911|EXPERIMENTAL|Lu AA24530: 10 mg|
62417025|NCT03280563|EXPERIMENTAL|Stage 1: Atezolizumab + Entinostat|Participants will receive doublet combination treatment with atezolizumab plus entinostat until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62417026|NCT03280563|EXPERIMENTAL|Stage 1: Atezolizumab + Fulvestrant|Participants will receive doublet combination treatment with atezolizumab plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62417027|NCT03280563|EXPERIMENTAL|Stage 1: Atezolizumab + Ipatasertib|Participants will receive doublet combination treatment with atezolizumab plus ipatasertib until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Prior to enrollment into this arm, the first 6 participants in the study will complete a safety run-in with atezolizumab plus ipatasertib.
62417028|NCT03280563|EXPERIMENTAL|Stage 1: Atezolizumab + Ipatasertib + Fulvestrant|Participants will receive triplet combination treatment with atezolizumab plus ipatasertib plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Prior to enrollment into this arm, the first 6 participants in the study will complete a safety run-in with atezolizumab plus ipatasertib.
62798355|NCT03399630|PLACEBO_COMPARATOR|Injection of Lactated Ringers|Placebo control group receives injection of 3 cc's of Lactated Ringers with no adipose tissue
62798356|NCT06461338|EXPERIMENTAL|Acupuncture|Acupuncture for 4 times every 3 weeks (one cycle of ICIs combined with chemotherapy) for 12 weeks (4 cycles of ICIs combined with chemotherapy)
62798357|NCT06461338|SHAM_COMPARATOR|Sham acupuncture|Sham acupuncture for 4 times every 3 weeks (one cycle of ICIs combined with chemotherapy) for 12 weeks (4 cycles of ICIs combined with chemotherapy)
62798358|NCT02106871|PLACEBO_COMPARATOR|Placebo|Placebo daily for 4 weeks
62798359|NCT02106871|ACTIVE_COMPARATOR|Sildenafil|50mg sildenafil daily for 4 weeks
62223071|NCT00599911|EXPERIMENTAL|Lu AA24530: 20 mg|
62223072|NCT00599911|ACTIVE_COMPARATOR|Duloxetine: 60 mg|
62223073|NCT00599911|PLACEBO_COMPARATOR|Placebo|
62223074|NCT02656823|EXPERIMENTAL|ANKYLOS C/X Implant A 6.6|ANKYLOS C/X Implant A 6.6 mm
62223075|NCT05963490|ACTIVE_COMPARATOR|monotherapy|a total of 54 patients will receive regorafenib monotherapy.
62223076|NCT05963490|EXPERIMENTAL|combination therapies|a total of 54 patients will first receive 1 cycle of regorafenib and toripalimab followed by hypofractionated/low-dose radiotherapy. Regorafenib and toripalimab will be continued after the completion of radiotherapy.
62417029|NCT03280563|EXPERIMENTAL|Stage 2: Atezolizumab + Bevacizumab + Endocrine Therapy|Those who progress or experience unacceptable toxicity during treatment in Stage 1 may be eligible to enter Stage 2. Participants will receive triplet combination therapy with atezolizumab plus bevacizumab plus one of three endocrine therapies (fulvestrant, exemestane, or tamoxifen) selected by the physician. Treatment in Stage 2 will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62417030|NCT03280563|EXPERIMENTAL|Stage 1: Mandatory On-Treatment Biopsy|For experimental combination arms that demonstrate clinical activity during the preliminary phase, the Sponsor may open enrollment into a separate mandatory on-treatment biopsy cohort for that combination.
62417031|NCT03280563|EXPERIMENTAL|Stage 1: Atezolizumab + Abemaciclib + Fulvestrant|Participants will receive triplet combination treatment with atezolizumab plus abemaciclib plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62588441|NCT06518174|SHAM_COMPARATOR|Controls|"Controls (or their legal guardians) who opt for participating in this pilot study will be consented and enrolled in the study. Patients will then be scheduled for a single study visit at the University of Colorado Hospital (UCH) that includes:~1. Pregnancy test~2. Pelvic MRI without and with contrast (if patient consents to contrast)~3. Transabdominal pelvic ultrasound using standard B-mode and Doppler US, SWE~4. Optional transvaginal ultrasound using standard B-mode and Doppler US, SWE"
62588442|NCT04736446|EXPERIMENTAL|I-gel® group|Continuous chest compressions from the start of the CPR with early i-gel® device insertion and asynchronous ventilations
62588443|NCT04736446|OTHER|Standard group|Basic (standard) management by using a ratio of 30 compressions and 2 face mask ventilations
62798360|NCT01257516|OTHER|Pregabalin immediate release, 300 mg|Reference Treatment
62025525|NCT02357212|OTHER|Early Invasive|Patients assigned to an early invasive strategy will undergo coronary angiography within 48 hours and have percutaneous coronary intervention or coronary artery bypass grafting performed as soon as possible during the initial hospitalization if deemed appropriate.
62798361|NCT01257516|EXPERIMENTAL|Pregabalin controlled release, 330 mg|
62798362|NCT02332174|EXPERIMENTAL|200-mg group|Ten healthy subjects were administered a single oral dose of 200 mg rufinamide tablets in fasted and fed state at day 1 and then received repeated oral doses of rufinamide (200 mg) once daily for 6 days.
62798363|NCT02332174|EXPERIMENTAL|400-mg group|Ten healthy subjects were administered a single oral dose of 400 mg rufinamide tablets in fasted state.
62798364|NCT02332174|EXPERIMENTAL|800-mg group|Ten healthy subjects were administered a single oral dose of 800 mg rufinamide tablets in fasted state.
62223077|NCT02119845|EXPERIMENTAL|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
62798365|NCT02332174|EXPERIMENTAL|1200-mg group|Ten healthy subjects were administered a single oral dose of 1200 mg rufinamide tablets in fasted state.
62223078|NCT00679393|OTHER|Fix|Open reduction internal fixation of severely comminuted calcaneal fracture (Sanders IV)
62223079|NCT00679393|OTHER|Fuse|Primary subtalar fusion of severely comminuted calcaneal fractures (Sanders IV).
62223080|NCT01462123||small polyps patients|Patients with one small polyps at colonoscopy
62025526|NCT02357212|OTHER|Conservative management|Patients assigned to conservative management will be treated with anti-anginal medications, aspirin, clopidogrel, atorvastatin, and other guideline recommended medicines. Patients will have an echocardiogram and adenosine stress testing
62223081|NCT00307502|EXPERIMENTAL|NVP|Nevirapine
62223082|NCT00307502|EXPERIMENTAL|EFV|Efavirenz
62223083|NCT00307502|EXPERIMENTAL|INV|Indinavir/ritonavir
62417032|NCT06080503|EXPERIMENTAL|Highly conformal hypofractionated radiotherapy|LT-SABR 42.5 Gy in 5 fractions Low-risk: twice/week Moderate-risk: weekly
62417033|NCT06080503|EXPERIMENTAL|Conventional radiotherapy|Conventional Radiotherapy 63 Gy in 28 fractions (T1) 65.25 Gy in 29 fractions (T2)
62417034|NCT06264271||Group with nutrition education|Patients who experienced at least one structured education session between 24 months before sensor initiation and 6 months after sensor initiation were allocated to the group with education.
62417035|NCT06264271||Group without nutrition education|Patients who received standard care, which may have included short education during routine visits or self-education through online resources or educational materials, were assigned into the group without education.
62417036|NCT00267579|EXPERIMENTAL|Treatment|50% randomized to receive Strongest Families (formerly Family Help Program): Behaviour treatment
62417037|NCT00267579|ACTIVE_COMPARATOR|Control|50% randomized to control group: standard/usual care for behaviour disorder
62417038|NCT06697756|EXPERIMENTAL|High-effort|The high-effort protocol will entail performing 3 sets per exercise, 8 repetitions per set, \~2.5 seconds per repetition, with 120 seconds between sets and exercises.
62417039|NCT06697756|EXPERIMENTAL|Low-effort|The low-effort protocol will entail performing 6 sets per exercise, 4 repetitions per set, \~2.5 seconds per repetition, with 60 seconds between sets and exercises.
62417040|NCT05482893|EXPERIMENTAL|Dose Escalation|An accelerated titration design will be employed for early dose levels, followed by the standard 3+3 design at higher dose levels.
62223084|NCT00307502|EXPERIMENTAL|NFV|Nelfinavir
62223085|NCT00307502|EXPERIMENTAL|SQV|Saquinavir/ritonavir
62223086|NCT00307502|EXPERIMENTAL|LPV|Lopinavir/ritonavir
62417041|NCT05482893|EXPERIMENTAL|Dose Expansion|Two dose levels will be explored; the recommended dose for expansion (RDE) from Part A, and another dose level.
62417042|NCT05482893|EXPERIMENTAL|Combination Expansion with Chemotherapy|"Part C, Cohort 1: 2L m/a GC/GEJ-C patients will receive PT886 in combination with Paclitaxel.~Part C, Cohort 2: 1L m/a PDAC patients will receive PT886 in combination with Gemcitabine plus nab-Paclitaxel (Abraxane).~Part C, Cohort 2b: 1L m/a PDAC patients will receive PT886 in combination with Gemcitabine plus FOLFIRINOX/mFFX."
62417043|NCT05482893|EXPERIMENTAL|Combination Expansion with KEYTRUDA® (pembrolizumab)|"Part D, Cohort 3: 2L or 3L m/a GC/GEJ-C patients will receive PT886 in combination with KEYTRUDA® (pembrolizumab).~Part D, Cohort 4: 1L HER2 negative m/a GC/GEJ-C patients will receive PT886 in combination with SOC chemotherapy and KEYTRUDA® (pembrolizumab).~Part D, Cohort 5: Patients with m/a GC/GEJ-C, that have progressed under 1L SOC chemotherapy, and zolbetuximab, will receive PT886 in combination with KEYTRUDA® (pembrolizumab)."
62417044|NCT04136626|EXPERIMENTAL|Perspectives OCD|12 week Smartphone-delivered cognitive behavioral therapy (CBT) for OCD.
62223087|NCT00307502|EXPERIMENTAL|ATV|Atazanavir
62223088|NCT00307502|EXPERIMENTAL|ATV/rtv|Atazanavir/ritonavir
62223089|NCT00307502|EXPERIMENTAL|Fos-APV|Fos-amprenavir/ritonavir
62223090|NCT00307502|EXPERIMENTAL|TPV|Tipranavir/ritonavir
62223091|NCT00307502|EXPERIMENTAL|DRV|Darunavir/ritonavir
62417045|NCT04136626|ACTIVE_COMPARATOR|The Health and Well-Being Program|12 week health and well-being education
62417046|NCT02817269|EXPERIMENTAL|Manual palpation group|For the manual palpation group, the reference position will be a lateral position, lying on the non affected shoulder while the affected side will be explored. The arm and elbow are flexed 90° resting on a pillow and legs placed with 90° hip and knee flexion to stabilize the body, with the head resting on a pillow to maintain body alignment. The physiotherapist will be in front of the participant and carried out the examination with flat palpation using the thumb to identify soreness taut band tried to elicit local twitch response and referred pain in the infraspinatus area. First, three attempts will be made to elicit an local twitch response (LTR) using snapping palpation if a response will be obtained. After LRT, referred pain could also be evoked by palpation.
62588444|NCT06668688||24-0395-KB|"Naturalistic User Experience ich bin alles @Schule"
62588445|NCT06330246|EXPERIMENTAL|colonization with Oxalobacter formigenes|Colonization with a live preparation of Oxalobacter formigenes, strain OxCC13.
62588446|NCT04146493||Vascular surgery group|Patients which are given unfractionated heparin during their vascular surgery.
62588447|NCT04146493||Thromboprophylaxis group|Patients which are given low molecular heparins as a thrombosprofylax after major surgery
62223092|NCT01690598|EXPERIMENTAL|Veliparib and Topotecan|
62223093|NCT03998982|ACTIVE_COMPARATOR|glycyrrhetinic acid Combining HD-DXM|Compound glycyrrhizin tablets 75mg three times per day, 1 month, and HD-DXM (orally at 40 mg daily for 4d )
62223094|NCT03998982|ACTIVE_COMPARATOR|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
62223095|NCT04725786|EXPERIMENTAL|Case group|The intervention of the research corresponds to the realization of a thoracic echography.
62223096|NCT04201964|EXPERIMENTAL|Intra-arterial administration of tenecteplase|Intra-arterial administration of tenecteplase (0.2-0.4 mg/min) immediately after thrombectomy device pass for 30-40 minutes.
62223097|NCT01237587|EXPERIMENTAL|Duloxetine|"Blinded treatment period: 30mg or 60mg once daily for 13 weeks~Open label extension: 30mg or 60mg Duloxetine once daily for 26 weeks~Taper period: 30mg Duloxetine or placebo once daily for 1 week."
62223098|NCT01237587|PLACEBO_COMPARATOR|Placebo|"Blinded treatment period:Placebo once daily for 13 weeks~Open label extension: 30mg or 60mg Duloxetine once daily for 26 weeks~Taper period: 30mg Duloxetine or placebo once daily for 1 week."
62223099|NCT04637178|EXPERIMENTAL|Resistance training added to endurance training|Participants (elite cyclists) will conduct heavy-load resistance training twice a week in addition to their habitual endurance training for ten weeks
62223100|NCT04637178|OTHER|Endurance training|Participants (elite cyclists) will conduct habitual endurance training-only for ten weeks
62417047|NCT02817269|EXPERIMENTAL|Deep dry needling group|For the deep dry needling group, the reference position will be a lateral position, lying on the non affected shoulder while the affected side will be explored. The arm and elbow are flexed 90° resting on a pillow and legs placed with 90° hip and knee flexion to stabilize the body, with the head resting on a pillow to maintain body alignment. The physiotherapist will be in front of the participant and carried out the examination with flat palpation using the thumb to identify soreness taut before making the needle insertion. Sterile stainless steel needles (length 40mm/caliber 0.32 with a cylindrical plastic guide) will be used.
62223101|NCT01251250|EXPERIMENTAL|Arm I|Patients receive oral Azadirachta indica once daily on days 1-28. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
62223102|NCT00320125|NO_INTERVENTION|1|Usual diet
62223103|NCT00320125|ACTIVE_COMPARATOR|2|Orange juice fortified with calcium
62223104|NCT00320125|ACTIVE_COMPARATOR|3|Dairy products
62223105|NCT06058754|EXPERIMENTAL|ADAPT Program|The ADAPT Program is a structured and individualized group-based program
62223106|NCT06058754|ACTIVE_COMPARATOR|Usual Occupational Therapy (UOT)|UOT is delivered by one occupational therapist in the clients homes or local environments. .
62223107|NCT06211881|EXPERIMENTAL|Chi-GVM|"Chi-GVM regimen (every 21 days is a treatment cycle):~Chidamide 20 mg orally;gemcitabine 1g/m2, twice a week, intravenous infusion on day 1, vinorelbine 20 mg/m2, infusion on day 1; Mitoxantrone Hydrochloride Liposome12 mg/m2, intravenous infusion on day 1; Chidamide maintenance therapy: 20 mg orally twice a week/28 days/cycle."
62223108|NCT06152809|EXPERIMENTAL|Cohort 1: Dose Level 0|"A maximum tolerated dose (MTD) will be established, and dosage will start at dose level 0. 5-10 participants at dose level 0 will complete:~* Baseline visit.~* Bone marrow biopsies: at screening visit #2, end of treatment, and at discretion of PI.~* Days -6 through -2: predetermined doses of standard-of-care lymphodepleting chemotherapy.~* Day 0: Predetermined dose of CIML NK cells 1x daily. Hospitalization for up to 3 to 4 weeks for CIML NK infusion.~* Days 0 through 12: Predetermined dose of IL-2 1x daily every other day for up to 7 doses.~* Day 7 through Day 21: Predetermined dose of Venetoclax 1 x daily.~* If ≤1 dose-limiting toxicities (DLTs) are observed, this dose will be the MTD, and 5 additional participants will be enrolled.~* Follow-up visits: Days 42, 60, 100 and months 6, 9, and 12."
62223109|NCT06152809|EXPERIMENTAL|Cohort 1: Dose Level -1|"De-escalation to dose level -1 will be conducted per protocol if DLTs occur in Cohort 1 dose Level 0. Participants will complete:~* Baseline visit.~* Bone marrow biopsies: at screening visit #2, end of treatment, and at discretion of PI.~* Days -6 through -2: predetermined doses of standard-of-care lymphodepleting chemotherapy.~* Day 0: Predetermined dose of CIML NK cells 1x daily. Hospitalization for up to 3 to 4 weeks for CIML NK infusion.~* Days 0 through 12: Predetermined dose of IL-2 1x daily every other day for up to 7 doses.~* Day 7 through Day 21: Predetermined dose of Venetoclax 1 x daily.~* Follow-up visits: Days 42, 60, 100 and months 6, 9, and 12."
62417048|NCT02122744|ACTIVE_COMPARATOR|Super Rapid Magstim Stimulator rTMS QP|rTMS QP is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients
62417049|NCT02122744|PLACEBO_COMPARATOR|Placebo|rTMS QP placebo (coil perpendicular to the scalp) is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients.
62417050|NCT06704074|EXPERIMENTAL|VR+TOT (task oriented training combined with occupational training)|The participants in this group are given VR-TOT training, which was created a virtual scene based on the participants' home and completed a series of occupational tasks. A Head-mounted-display VR device is used in this group.
62417051|NCT06704074|OTHER|TOT (task oriented training)|In this group, the occupational task is selected according to the level of the upper limb function assessment , and all the training programs are related to the activities of daily life (ADL).
62798366|NCT01525615|EXPERIMENTAL|tiotropium+olodaterol low dose|once daily 2 puffs, fixed dose combination (FDC) solution for inhalation Respimat
62798367|NCT01525615|EXPERIMENTAL|tiotropium+olodaterol high dose|once daily 2 puffs, FDC solution for inhalation Respimat
62223110|NCT02816242|EXPERIMENTAL|intervention|teaching anatomy by concept map
62223111|NCT02816242|SHAM_COMPARATOR|placebo|teaching anatomy by traditional method
62223112|NCT03272126|EXPERIMENTAL|vitamin D bolus|vitamin D 160 000 IU given as bolus
62223113|NCT03272126|EXPERIMENTAL|vitamin D daily|vitamin D 4000 IU daily for 28 days
62798368|NCT01525615|PLACEBO_COMPARATOR|placebo|once daily 2 puffs, solution for inhalation Respimat
62223114|NCT03272126|PLACEBO_COMPARATOR|placebo|identical looking as vitamin d
62223115|NCT00804089|EXPERIMENTAL|1|Traditional needle acupuncture
62223116|NCT00804089|ACTIVE_COMPARATOR|2|Myofascial trigger point dry needling
62223117|NCT00804089|ACTIVE_COMPARATOR|3|Myofascial trigger point acupressure
62223118|NCT01406964|EXPERIMENTAL|Arm A|Arm A performs a CAT test to study tubal factor causes
62223119|NCT01406964|EXPERIMENTAL|Arm B|In Arm B a histerosalpingography is performed.
62223120|NCT04185454|EXPERIMENTAL|First design level|Three Healthy Voluntary (HV) women were give the same starting daily dose of 100 g Jarlsberg
62798369|NCT00130169|EXPERIMENTAL|1|
62798370|NCT04526223|EXPERIMENTAL|treatment group|MF patients exposure to ruxolitinib during transplantation
62798371|NCT00644150|EXPERIMENTAL|1|Physicians of county level will receive Ai Shi Zi training provided by experts in the fields of HIV/STIs, behavioral counseling, and stigma reduction.
62798372|NCT00644150|EXPERIMENTAL|2|Physicians of township level will receive Ai Shi Zhi training provided by the county level physicians.
62223121|NCT04185454|EXPERIMENTAL|Second design level|Based on the results from the starting dose 5 + 5 HV get a new daily doses of Jarlsberg cheese
62417052|NCT06704074|NO_INTERVENTION|Traditional OT|Traditional OT , including but not limited : upper limb joints (shoulder, elbow, wrist, interphalangeal), muscle sensory stimulation (such as tapping, brushing, squeezing, etc.), active and passive range of motion training of upper limb joints, upper limb muscle strength training, wrist dorsal extension, grip and other training were carried out by using a roller and wooden nail board. ADL training (dressing, grooming, washing, eating, etc.).
62417053|NCT00000784||A|Consenting patients newly enrolled in either CPCRA 007 or CPCRA 006
62588448|NCT04146493||Cardiothoracic surgery|Patients which are given high dose unfractionated heparin during their open heart surgey
62798373|NCT00644150|EXPERIMENTAL|3|HIV/STI patients will receive standard of care and specialized care from physician participants trained in Ai Shi Zi.
62223122|NCT04185454|EXPERIMENTAL|Third design level|Based on the results from the second design level, the daily dose of Jarlsberg cheese for the next 7 HVs was given
62417054|NCT01149083|EXPERIMENTAL|Phase II (veliparib, carboplatin)|Patients receive veliparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, patients are taken off treatment for 1 week and may then continue to recieve veliparib along with carboplatin IV over 30 minutes on day 1 of each cycle. Cycles repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and may optionally undergo biopsies throughout the study. Patients undergo blood sample collection during screening and on study.
62417055|NCT01149083|EXPERIMENTAL|Safety Lead-In Phase (veliparib, carboplatin)|Patients receive veliparib PO BID twice daily on days 1-21 of each cycle and carboplatin IV over 30 minutes on day 1 of each cycle. Cycles repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and may optionally undergo biopsies throughout the study. Patients undergo blood sample collection during screening and on study.
62417056|NCT03311828|EXPERIMENTAL|Diagnostic (Copper 64Cu-DOTA-daratumumab, PET)|Patients receive daratumumab IV over 10-45 minutes, and within 6 hours, patients receive copper 64Cu-DOTA-daratumumab IV on day 0. Patients undergo PET on days 1 and 2.
62417057|NCT06137729|EXPERIMENTAL|PF-07899895|Participants will receive single or multiple ascending oral doses of PF-07899895.
62417058|NCT06137729|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo.
62417059|NCT06702748||Coronary microvascular dysfunction|angio-IMR\>=25
62417060|NCT06702748||Non-Coronary microvascular dysfunction|Angio-IMR\<25
62417061|NCT05995964|EXPERIMENTAL|Stage 1_PF-07275315|Stage 1 PF-07275315 Injections on Day 1, Week 1, Week 2, Week 4, Week 6, Week 8, Week 10 and Week 12.
62417062|NCT05995964|EXPERIMENTAL|Stage 1_PF-07264660|Stage 1 PF-07264660 Injections on Day 1, Week 1, Week 2, Week 4, Week 6, Week 8, Week 10 and Week 12.
62417063|NCT05995964|EXPERIMENTAL|Stage 1_Placebo|Stage 1 Placebo Injections on Day 1, Week 1, Week 2, Week 4, Week 6, Week 8, Week 10 and Week 12.
62417064|NCT05995964|EXPERIMENTAL|Stage 2_PF-07275315 or PF-07264660_Dose A|Stage 2 PF-07275315 or PF-07264660 Injections on Day 1, Week 4, Week 8 and Week 12.
62798374|NCT00644150|NO_INTERVENTION|4|Physicians of county level who will not participate in Ai Shi Zi training
62798375|NCT00644150|NO_INTERVENTION|5|Physicians of township level who will not participate in Ai Shi Zi training
62798376|NCT00644150|SHAM_COMPARATOR|6|HIV/STI patients who will receive standard care only
62798377|NCT00836186|OTHER|Radiation therapy|Women with non-metastatic breast cancer status post lumpectomy to negative margins and who are receiving whole breast irradiation as per standard treatment plan.
62798378|NCT01708863||Children with Hypoplastic Left Heart Syndrome (HLHS)|HLHS patients requiring Stage II Glenn surgery
62223123|NCT03636282|EXPERIMENTAL|Hockey FIT Program (Immediate Delivery)|Hockey FIT Program: A gender-sensitized, weight loss and healthy lifestyle program that engages men using the power of being a sports fan.
62223124|NCT03636282|NO_INTERVENTION|Wait-List Control (Delayed Delivery)|No intervention for 12 months. After 12 months, Hockey FIT program is offered.
62223125|NCT01013454|EXPERIMENTAL|Varenicline transdermal delivery system|
62417065|NCT05995964|EXPERIMENTAL|Stage 2_PF-07275315 or PF-07264660_Dose B|Stage 2 PF-07275315 or PF-07264660 Injections on Day 1, Week 4, Week 8 and Week 12.
62417066|NCT05995964|EXPERIMENTAL|Stage 2_PF-07275315 or PF-07264660_Dose C|Stage 2 PF-07275315 or PF-07264660 Injections on Day 1, Week 4, Week 8 and Week 12.
62417067|NCT05995964|EXPERIMENTAL|Stage 2_PF-07275315 or PF-07264660_Dose D|Stage 2 PF-07275315 or PF-07264660 Injections on Day 1, Week 4, Week 8 and Week 12.
62417068|NCT05995964|EXPERIMENTAL|Stage 2_Placebo|Stage 2 Placebo Injections on Day 1, Week 4, Week 8 and Week 12.
62417069|NCT03963739||Race: Non-Hispanic African American|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
62417070|NCT03963739||Race: Non-Hispanic White|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
62417071|NCT03963739||Income: Lower Income|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
62417072|NCT03963739||Income: Higher Income|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
62417073|NCT05489380|OTHER|Accumeasure last|Optical polyp size assessment, followed by biopsy forceps and then AccuMeasure measurement
62417074|NCT05489380|OTHER|AccuMeasure first|optical assessment, followed by AccuMeasure measurement and then biopsy forceps assisted assessment (2)
62417075|NCT05043324|EXPERIMENTAL|SARS-COV-2 (1)|Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (1) for various therapeutic purposes.
62417076|NCT05043324|EXPERIMENTAL|SARS-COV-2 (2)|Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (2) for various therapeutic purposes.
62417077|NCT06702709|EXPERIMENTAL|Group A|The treatment protocol of the IASTM group will consist on the preparation phase, application phase followed by strengthening. The session is given for 40 minutes for 4 weeks and 3 days per week.
62798379|NCT04618289|EXPERIMENTAL|Vitamin D Group|The vitamin D3-fortified fruit juice supplement that will be used is vitamin D3 cholecalciferol (4000 IU, 100 mcg, Fiatec Biosystem Sdn Bhd, Selangor, Malaysia).
62798380|NCT04618289|PLACEBO_COMPARATOR|Placebo Group|The matching placebo will be also custom-produced and will be produced in the same manner, without the active ingredients by the same company. The placebo produced will match with vitamin D3 in terms of appearance, size, colour and taste to achieve the double-blind design.
62025527|NCT04870801|NO_INTERVENTION|Low Oxygen Visits without Respirogen Micro-Oxygen|During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures.
62025528|NCT04870801|EXPERIMENTAL|Low Oxygen Visits with Respirogen Micro-Oxygen|During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures.
62798381|NCT03646708||SBCD patients starting a new biologic therapy|As part of your standard clinical care (soc), patient will be started on a biologic (anti-tumor necrosis factor (TNF)s, vedolizumab and ustekinumab) based on your interactions with your treating gastroenterologist after standard of care clinical assessment.
62798382|NCT01416402|OTHER|Arhalofenate with febuxostat and colchicine|
62223126|NCT02443974|EXPERIMENTAL|Knee brace group|Patients received knee brace with hinges (Fisiotensor®) and were instructed to use it in daily activities, every day, during six months
62223127|NCT02443974|EXPERIMENTAL|Knee sleeve group|Patients received knee sleeve without hinges (Fisiotensor®) and were instructed to use it in daily activities, every day, during six months
62223128|NCT02443974|NO_INTERVENTION|Control group|Keep medication usual
62223129|NCT00603226||1|Patients diagnosed with slow coronary artery flow during coronary angiography
62223130|NCT00603226||2|Patients with normal coronary artery flow observed during coronary angiography
62223131|NCT00883051|EXPERIMENTAL|50 mg Lasmiditan|50 mg lasmiditan administered orally (PO)
62223132|NCT00883051|EXPERIMENTAL|100 mg Lasmiditan|100 mg lasmiditan administered orally (PO)
62223133|NCT00883051|EXPERIMENTAL|200 mg Lasmiditan|200 mg lasmiditan administered orally (PO)
62223134|NCT00883051|EXPERIMENTAL|400 mg Lasmiditan|400 mg lasmiditan administered orally (PO)
62223135|NCT00883051|PLACEBO_COMPARATOR|Placebo|Placebo administered orally (PO)
62223136|NCT04557943|ACTIVE_COMPARATOR|Sodium Hyaluronate|Hyaluronate sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th
62223137|NCT04557943|EXPERIMENTAL|Prolotherapy|"Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:~in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th."
62223138|NCT06327308||Patient with cirrhosis requiring liver transplantation|
62223139|NCT02732977|OTHER|expert system|System for predicting patients heart failure, that can predict response to a personalized treatment from the analysis of a set of data (images, physiological data , treatment outcomes ) .
62223140|NCT02125747|OTHER|No Respiratory Therapy|Patients with acute exacerbation of chronic obstructive pulmonary disease. Patients received conventional treatment.
62223141|NCT02125747|EXPERIMENTAL|Respiratory therapy|Patients with acute exacerbation of chronic obstructive pulmonary disease. Patients received conventional treatment and Respiratory Therapy
62223142|NCT05296018|EXPERIMENTAL|Mandala|Mandala coloring page
62223143|NCT05296018|NO_INTERVENTION|Control group|Routine maintenance will be applied
62223144|NCT02825030|EXPERIMENTAL|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62223145|NCT04568694|EXPERIMENTAL|Delayed Lung Transplantation|Patients that received lung(s) delayed for transplantation
62223146|NCT04568694|ACTIVE_COMPARATOR|Conventional Lung Transplantation|Reference Therapy
62223147|NCT04226885|ACTIVE_COMPARATOR|fentanyl|patients will be given nebulized fentanyl 2μg/kg body weight 30 min before surgery
62223148|NCT04226885|ACTIVE_COMPARATOR|midazolam|The patients will be given nebulized midazolam 0.2 mg/kg body weight 30 min before surgery.
62223149|NCT04226885|ACTIVE_COMPARATOR|dexmedetomidine|The patients will be given nebulized dexmedetomidine 2 μg/kg body weight 30 min before surgery.
62223150|NCT00479492|EXPERIMENTAL|1|
62223151|NCT00479492|EXPERIMENTAL|2|
62223152|NCT00479492|EXPERIMENTAL|3|
62223153|NCT00479492|PLACEBO_COMPARATOR|4|
62223154|NCT01871701|EXPERIMENTAL|Quetiapine|Quetiapine 100 mg (Seroquel, Tablet)
62223155|NCT01871701|EXPERIMENTAL|Moxifloxacin|Moxifloxacin 400 mg (Avelox, Tablet)
62223156|NCT01871701|EXPERIMENTAL|Escitalopram|Escitalopram 20 mg (Lexapro, Tablet)
62223157|NCT01871701|PLACEBO_COMPARATOR|Placebo|Water intake
62223158|NCT03211754|EXPERIMENTAL|Obese patients|Treatment for 8 weeks
62223159|NCT04345757|NO_INTERVENTION|Standard instructions|Standard instructions: activity restrictions, including no strenuous exercise, sexual intercourse, or lifting objects greater than 25 pounds for 6 weeks or until evaluation at the 6 week postpartum visit
62223160|NCT04345757|EXPERIMENTAL|Study Group|Study group: Structured 10 week exercise protocol
62223161|NCT05443646|EXPERIMENTAL|HLX10 (Serplulimab) Consolidation After Chemotherapy Concurrent Hypofractionated Radiotherapy|Participants will receive at least 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) concurrently with Hypofractionated Radiotherapy, followed by HLX10 300 mg every 3 weeks (Q3W) with maximum 1 years or until disease progression, intolerable toxicity or other reasons specified in the protocol, whichever occurs first.
62417078|NCT06702709|ACTIVE_COMPARATOR|Group B|The neurodevelopment therapy for spastic diplegic cerebral palsy includes tone-inhibitory postures. This study will use five-tone inhibitory postures that will be appropriate for the reduction of muscle tone, elongation of lower extremities muscles, and improve gross motor function by enhancing balance and stability. The session is given for 40 minutes for 4 weeks and 3 days per week
62798383|NCT02724449|EXPERIMENTAL|Cavilon Advanced Barrier Film|Cavilon Advanced Barrier Film applied to areas of IAD
62798384|NCT03363516||Cases|Glucose normotolerant subjects with 1-h post-load plasma glucose \>155 mg/dL
62798385|NCT03363516||Controls|Glucose normotolerant subjects with 1-h post-load plasma glucose \<155 mg/dL
62417079|NCT03469882|EXPERIMENTAL|High protein and exercise (HPE) group|Begining within 48 hours of ICU admission participants will receive nutrition support with energy expenditure measured by indirect calorimetry, 2.0 to 2.2 g/kg/day of protein and in-bed cycle ergometry exercise.
62417080|NCT03469882|OTHER|Usual care group|Participants randomized to the usual care group will receive usual care protein and exercise
62588449|NCT06682702|EXPERIMENTAL|DNS Group|Patients diagnosed with adolescent idiopathic scoliosis participated in sessions twice a week for 8 weeks, with each session lasting 45 minutes. During the sessions, ISST Schroth exercises were combined with dynamic neuromuscular stabilization exercises.
62588450|NCT06682702|EXPERIMENTAL|Schroth Group|Patients diagnosed with adolescent idiopathic scoliosis participated in sessions twice a week for 8 weeks, with each session lasting 45 minutes. During the sessions, ISST Schroth exercises were performed.
62588451|NCT06529016|EXPERIMENTAL|Luminopia VR headset treatment|Using Dichoptic Therapy to Improve Intermittent Exotropia Control in children ages 4-7
62588452|NCT06666530||women living with HIV|women living with HIV during the perinatal period
62417081|NCT01474148|EXPERIMENTAL|Neuroprosthesis|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.
62417082|NCT05650658|ACTIVE_COMPARATOR|His/Left Bundle Branch Pacing (His/LBBP)|"Patients with LVEF≤35% at entry will receive a His/LBB defibrillator which includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular ICD lead, and an endocardial His-bundle or left bundle branch pacing lead directly pacing the intrinsic conduction system.~Patients with LVEF 36-50% at entry will receive His/LBB pacemaker which includes implantation of two leads, an endocardial right atrial lead, and an endocardial His-bundle or left bundle branch pacing lead directly pacing the intrinsic conduction system."
62417083|NCT05650658|ACTIVE_COMPARATOR|Biventricular Pacing (BiVP)|"Patients with LVEF≤35% at entry will receive a BiV defibrillator which includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular ICD lead, and and an epicardial left ventricular lead implanted in a branch of the coronary sinus.~Patients with LVEF 36-50% at entry will receive BiV pacemaker which includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular pacing lead, and and an epicardial left ventricular lead implanted in a branch of the coronary sinus."
62588453|NCT06668337|PLACEBO_COMPARATOR|Group A who received normal saline immediately after the administration of the|Participants in this group received normal saline immediately after the administration of the subarachnoid block (spinal anesthesia). This group serves as the control group to compare the effectiveness of ephedrine against no pharmacologic intervention
62588454|NCT06668337|EXPERIMENTAL|Group B who received ephedrine at a dosage of 1.25 mg/min immediately after the subarachnoid block|Participants in this group received ephedrine at a dosage of 1.25 mg/min immediately after the subarachnoid block. This dose is intended to prevent maternal hypotension by maintaining blood pressure during spinal anesthesia.
62588455|NCT06668337|EXPERIMENTAL|Group C who received ephedrine at a dosage of 1.5 mg/min immediately after the subarachnoid block|Participants in this group received ephedrine at a higher dosage of 1.5 mg/min immediately following the subarachnoid block. This intervention tests whether a slightly higher dose of ephedrine provides better prevention of maternal hypotension without increasing side effects.
62588456|NCT03766165|EXPERIMENTAL|Intervention|Job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
62588457|NCT03766165|OTHER|Control|Job announcements only
62588458|NCT06186479|EXPERIMENTAL|Verum|
62588459|NCT06186479|PLACEBO_COMPARATOR|Placebo|
62588460|NCT06585514|EXPERIMENTAL|CD19 CAR|Following the lymphodepleting treatment, patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
62588461|NCT05663645|EXPERIMENTAL|Health insurance educational guide|Eligible individuals will receive a health insurance educational guide to support choosing among 5 health plans for IVF coverage. They will also receive receive a one-page guide with a link to the Open Enrollment website that is available to all employees during the open enrollment period.
62588462|NCT05663645|NO_INTERVENTION|Usual care|Eligible individuals will receive a one-page guide with a link to the Open Enrollment website that is available to all employees during the open enrollment period.
62588463|NCT02657057|EXPERIMENTAL|Transcutaneous Tibial Nerve Stimulation|TENS SNS therapy is performed as follows; patient is asked to sit with legs slightly bent and an adhesive electrode is attached transcutaneously 5cm cephalic to either the right or left medial malleolus (subject choice). A surface electrode is placed on the medial surface of the ipsilateral calcaneum and both electrodes are connected to a low voltage electronic stimulator. The current is then set to the highest level tolerable to the subject (0-20 mA) and subject undergoes therapy for 30 minutes and 12 weeks (once-a-week session). Data are completed at baseline, after half therapy and after 12 weeks therapy.
62798386|NCT06304207|NO_INTERVENTION|Control|Control group participants will only be seen during the outcomes assessments at the MGH Institute of Health Professions at times 0, 1, and 2, but will receive no active supervised intervention. Control group participants will go home with discharge instructions to maintain a home exercise routine provided to them at discharge. Bi-weekly check in phone calls from the study team will continue to ensure participant engagement in the study. During the phone calls, participants will be encouraged to keep a log of their weekly activities in a journal.
62798387|NCT06304207|EXPERIMENTAL|Onsite Pulmonary Rehab|Supervised pulmonary rehabilitation including exercise training, activity counselling, and education provided onsite.
62798388|NCT06304207|EXPERIMENTAL|Telehealth Pulmonary Rehab|Supervised pulmonary rehabilitation including exercise training, activity counselling, and education provided remotely using Zoom videoconferencing technology.
62223162|NCT05703997|EXPERIMENTAL|Maintenance treatment with cyclic, 5-day calorie restriction plus atezolizumab|"The experimental maintenance treatment will consist of:~* triweekly cycles of 5-day calorie restriction (on days -2 through 2 of each cycle) in combination with~* atezolizumab (at a dose of 1200 mg, administered intravenously on day 0 of each cycle)~The experimental maintenance treatment will be administered until the occurrence of unacceptable toxic effects, disease progression, consent withdrawal or patient death.~Patients interrupting cyclic calorie restriction for any reason other than disease progression may continue the maintenance treatment with atezolizumab alone, if clinically indicated."
62417084|NCT05394831|EXPERIMENTAL|Phase 1 dose-escalation, Phase 1 dose-exploratory, Phase 2 dose-expansion|Single arm
62417085|NCT00501800||Caucasian|
62417086|NCT00501800||African American|
62588464|NCT02657057|ACTIVE_COMPARATOR|Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; patient is asked to sit with legs slightly bent. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial surface of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage electrical stimulator. The current is then set to the highest level tolerable to the subject (0-20 mA) and the subject undergoes therapy for 30 minutes and 12 weeks (once-a-week session). Data are completed at baseline, after half therapy and after 12 weeks therapy.
62798389|NCT05701020|EXPERIMENTAL|Adult women with an abnormal pap test|
62798390|NCT00152893|EXPERIMENTAL|Chromium|400 μg (200 μg pills, twice per day) of Cr-nicotinate
62798391|NCT00152893|PLACEBO_COMPARATOR|Placebo|Identical looking placebo (di-calcium phosphate)
62223163|NCT04824053|EXPERIMENTAL|UNICLA-A2 milk and its subproducts|Participants (n=17) ingest milk and dairy products made from cows homozygous for beta casein A2 during 3 months. These products are also enriched in insaturated fatty acids and selenium. The daily intake reflects the habitual consumption habits. Recommended amounts are 250 mL of milk, a yogurt and 50 g fresh cheese per day.
62417087|NCT00501800||Chinese|
62417088|NCT00501800||Latina (Mexican or Central American)|
62417089|NCT00501800||Filipina|
62417090|NCT06694168|EXPERIMENTAL|EPP with L-PRF as a filling material|This group will have the infrabony defect treated with the use of an EPP minimally invasive technique and the defect will be filled with L-PRF.
62417091|NCT06694168|ACTIVE_COMPARATOR|EPP with no defect filling material|This group will have the infrabony defect treated with the use of an EPP minimally invasive technique, but the defect will not be filled with L-PRF.
62417092|NCT04024280|EXPERIMENTAL|Intervention arm|Patients will perform a supervised physical exercise program specifically developed for breast cancer patients, based on the guidelines of the American College of Sports Medicine. The physical exercise program comprises 3 weekly sessions of 60 minutes each. Each session will involve an initial warm-up with light mobility exercises, followed by resistance and aerobic training and ending with a return to calm phase of light stretching exercises.
62417093|NCT04024280|NO_INTERVENTION|Control arm|Patients should maintain the usual physical activity
62798392|NCT01200303|ACTIVE_COMPARATOR|non-cathartic CTC and OC|This is a single arm, open label, prospective test comparison of non-cathartic, CAD-assisted CTC to segmentally unblinded optical colonoscopy (OC). All study subjects receive both tests, starting with CTC, followed by OC within 5 weeks. CTC results are recorded and revealed to endoscopist on a segment-by-segment basis after initial (blinded) OC evaluation; endoscopist can double check / confirm lesion presence after unblinding and this second read serves as reference standard.
62798393|NCT02289313|EXPERIMENTAL|Youth Healthy Living Program|Youth attending the Rochester Alternative Learning Center (ALC) will be enrolled in a youth healthy living program at the ALC.
62798394|NCT05527665||Patient group|"Women over 90 years of age Women who have received a suburethral sling at CHUGA in the gynecology or urology departments between January 2015 and June 2020.~Women who agreed to complete the PPSSQ"
62798395|NCT05527665||Healthy volunteers group|"-Adult women under 90 years of age, matched on age and menopausal status to the patient group Women who have never had surgery for stress urinary incontinence with a sub-urethral sling.~Women who agreed to complete the PPSSQ"
62798396|NCT06359613|EXPERIMENTAL|Gluten Free cupcake Group|Nutrient rich food product (cupcakes) from flour blends of Sorghum, chickpea, Flaxseed and Almond will be prepared and flour concentration will be so adjusted to provide \>20% daily value of nutrients for children of 3-8 years of age. 2 cupcakes/ day, 35g each will be provided to participants for 12 weeks.
62798397|NCT06359613|PLACEBO_COMPARATOR|Placebo group|Cupcakes from usually used gluten free rice flour will be prepared. 2 cupcakes/ day, 35g each will be provided to participants for 12 weeks.
62798398|NCT06309563|ACTIVE_COMPARATOR|Aminoacids|Patients with obesity treated with essential aminoacids (EAA-AC)
62798399|NCT06309563|PLACEBO_COMPARATOR|Control|Patients with obesity treated with placebo
62798400|NCT03501225|EXPERIMENTAL|ozone|tooth extraction under irrigation with ozonated water
62798401|NCT03501225|EXPERIMENTAL|water|tooth extraction under irrigation with ozonated water or doubly distilled water
62798402|NCT01217762|EXPERIMENTAL|11 Gy IRay|Day 0 Lucentis followed by 11 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 2)
62798403|NCT01217762|EXPERIMENTAL|16 Gy IRay|Day 0 Lucentis followed by 16 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 27)
62025529|NCT03999619|EXPERIMENTAL|Experimental|Children will enter into the Move 2 Learn program immediately following their first assessment (between week 0 to 10)
62025530|NCT03999619|OTHER|Wait-list Control|Children will not participate in the program until after their second assessment (between week 11 to 21). Their control period will take place between week 0 and 10.
62025531|NCT01957189|EXPERIMENTAL|Dutasteride with/ without Tamsulosin|All subjects will be assigned to the same treatment group
62025532|NCT06161909|EXPERIMENTAL|Group A|Postoperative adjuvant sintilimab 200mg fixed dose Q3W, immunotherapy will be administered for a total of 1 year.
62025533|NCT06161909|NO_INTERVENTION|Group B|Close observation.
62025534|NCT04258787||Group A: No Surgery Group|This group consists of adults ages 18 or older who have been diagnosed with Fuchs' dystrophy or pseudophakic bullous keratopathy but do not require surgery per standard-of-care guidelines.
62025535|NCT04258787||Group B: Surgery Group|This group consists of adults ages 18 or older who have been diagnosed with Fuchs' dystrophy or pseudophakic bullous keratopathy, who require Descemet's Stripping Endothelial Keratoplasty (DSAEK), Descemet's Membrane Endothelial Keratoplasty (DMEK), or Descemet's Stripping Only (DSO) surgery. All treatment decisions will be made by the attending physician based on standard-of-care guidelines. (The study does not designate a treatment modality or pay for the treatment.)
62223164|NCT04824053|PLACEBO_COMPARATOR|Placebo|"Participants (n=17) ingest conventional dairy products and milk daily during 3 months. As happens in the UNICLA-A2 arm, the daily intake reflects habitual dairy consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, recommended amounts are 250 mL of milk, a yogurt and 50 g fresh cheese per day."
62223165|NCT05441241|EXPERIMENTAL|Leap Motion Controller|
62025536|NCT03445468|EXPERIMENTAL|IL-YANG Quadrivalent Influenza Vaccine|The vaccine contains both B strain (Yamagata, Victoria)
62025537|NCT03445468|ACTIVE_COMPARATOR|IL-YANG Flu Vaccine Pre-filled Syringe|The vaccine contains the B/Yamagata strain and it was approved for commercial sale by Ministry of Food and Drug Safety.
62025538|NCT02779257|EXPERIMENTAL|Pasireotide|Off label use of pasireotide to treat refractory hypoglycemia due to an insulin-producing pancreatic neuroendocrine tumor
62025539|NCT03070522|ACTIVE_COMPARATOR|Placebo|Placebo
62223166|NCT05441241|ACTIVE_COMPARATOR|Standard care|
62223167|NCT04497922|ACTIVE_COMPARATOR|Treatment as usual in emergency department|Individuals triaged to a pod in the emergency department without rooms that are fitted with a virtual display screen
62223168|NCT04497922|EXPERIMENTAL|Virtual white board|Individuals triaged to a pod in the emergency department in a room that is fitted with a virtual display screen
62223169|NCT02457169|EXPERIMENTAL|Parent Engagement Intervention group|This group of parents will receive the brief, 2-4 hour intervention which will utilize motivational interviewing principles to enhance parents' preschool engagement as their children transition from Early Intervention to preschool.
62025540|NCT03070522|ACTIVE_COMPARATOR|Treatment|Prednisone
62025541|NCT01568047|PLACEBO_COMPARATOR|Placebo|"PLC, Placebo~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
62025542|NCT01568047|EXPERIMENTAL|BIA 9-1067 - 5 mg|"5 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
62025543|NCT01568047|EXPERIMENTAL|BIA 9-1067 - 15 mg|"15 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
62025544|NCT01568047|EXPERIMENTAL|BIA 9-1067 - 30 mg|"30 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
62025545|NCT03348254||1|Group one will consist of patients receiving a single shot antibiotic prophylaxis preoperatively before primary arthroplasty of hip or knee
62025546|NCT03348254||2|Group two will consist of patients receiving multiple shot antibiotic prophylaxis perioperatively before and after primary arthroplasty of hip or knee
62025547|NCT02082054|EXPERIMENTAL|PSE 120 mg, CM 8 mg, Atr 0.36 mg|Pseudoephedrine 120 mg,chlorpheniramine 8 mg, atropine 0.36 mg tablet dosed BID for 7.5 days
62223170|NCT02457169|OTHER|Attention Control|Waitlist Control Group: This group will receive the brief, 2-4 hour intervention which will utilize motivational interviewing principles to enhance parents' preschool engagement as their children transition from Early Intervention to preschool after a 3 month delay.
62223171|NCT02962960|EXPERIMENTAL|Anifrolumab - Lower dose|1ml, once every second week, one subcutaneous injection as added to stand of care, from week 0 to week 50
62223172|NCT02962960|PLACEBO_COMPARATOR|Placebo matching for lower dose of Anifrolumab|1ml, once every second week, one subcutaneous injection added to stand of care, from week 0 to week 50
62223173|NCT02962960|EXPERIMENTAL|Anifrolumab - Higher dose|2×1ml, once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
62417094|NCT06084481|EXPERIMENTAL|Cohort 1: Hepatocellular Carcinoma (HCC)|Participants with HCC will receive ABBV-400 for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.
62798404|NCT01217762|EXPERIMENTAL|16 Gy IRay - Radiation First|16 Gy IRay and Lucentis PRN (N = 13)
62223174|NCT02962960|PLACEBO_COMPARATOR|Placebo matching for higher dose of Anifrolumab|2×1ml , once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
62223175|NCT04098757||Migratens|2 sachets/day: 800 mg of α-Lipoic acid, 450 mg of magnesium bisglycinate, 300 mg of L-Tryptophan, 20 mcg of Vitamin D3, 2.4 mg of Vitamin B2, 25 mg of Niacin, 150 mg of Coenzyme Q10. Patients who receive Migratens food supplementation have to take 2 sachets / day for 12 weeks. The supplement will be prescribed as usual and the assumption of the same will be recorded by partecipants in the appropriate daily; if the subject does not continue the indication the data collected up to that moment will be considered.
62798405|NCT01217762|EXPERIMENTAL|24 Gy IRay|Day 0 Lucentis followed by 24 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 19)
62223176|NCT04098757||acupuncture|2 sessions a week, for a total of 10 (5 weeks), performed by the same operator, repeatable if necessary, after a therapeutic interval of at least one month. Each session lasts about 20-30 minutes per patient. Tewa J Type sterile disposable needles, coated, with a Chinese-style copper wire handle, with a guide tube, of 22x13 mm (CJ 2213) and 30x25 mm (CJ 3025) will be used. Acupuncture will be carried out by same trained operator.
62223177|NCT03117322|EXPERIMENTAL|Synbiotic|"Each participant will receive the next:~1. agave inulin (4 g) in powder~2. Lactobacillus reuteri DSM 17938 (1 x 10\^8 cfu) in 5 drops daily, once a day for four weeks."
62223178|NCT03117322|EXPERIMENTAL|Probiotic|Lactobacillus reuteri DSM 17938 (1 x 10\^8 cfu) in 5 drops and maltodextrin (4 g) in powder daily, once a day for four weeks.
62417095|NCT06084481|EXPERIMENTAL|Cohort 2: Pancreatic Ductal Adenocarcinoma (PDAC)|Participants with PDAC will receive ABBV-400 for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.
62417096|NCT06084481|EXPERIMENTAL|Cohort 3: Biliary Tract Cancers (BTC)|Participants with BTC will receive ABBV-400 for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.
62417097|NCT06084481|EXPERIMENTAL|Cohort 4: Esophageal Squamous Cell Carcinoma, (ESCC)|Participants with ESCC will receive ABBV-400 for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.
62417098|NCT06084481|EXPERIMENTAL|Cohort 5: Triple Negative Breast Cancer (TNBC)|Participants with TNBC will receive ABBV-400 for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.
62417099|NCT06084481|EXPERIMENTAL|Cohort 6: Hormone Receptor+/HER2-breast Cancer (HR+/HER2-BC)|Participants with HR+/HER2-BC will receive ABBV-400 for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.
62417100|NCT06084481|EXPERIMENTAL|Cohort 7: Head and Neck Squamous-cell-carcinoma (HNSCC)|Participants with HNSCC will receive ABBV-400 for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.
62417101|NCT06084481|EXPERIMENTAL|Cohort 8: PROC/Primary Peritoneal/Fallopian Tube Cancer|Participants with Platinum Resistant High Grade Epithelial Ovarian Cancer (PROC)/primary peritoneal/fallopian tube cancer will receive ABBV-400 for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.
62417102|NCT05480956|EXPERIMENTAL|SIRI Checklist|A standardized checklist of clinical items to review by the attending hospitalist with participants.
62588465|NCT06306404|EXPERIMENTAL|Hormones only|Participants will receive the standard care hormonal intervention.
62588466|NCT06306404|EXPERIMENTAL|Sleep intervention only|Participants will receive the sleep intervention, which includes cognitive behavioral therapy for insomnia, and circadian rhythm therapy.
62798406|NCT05782062|EXPERIMENTAL|Rotational Thrombectomy|Use of the Cleaner XT
62798407|NCT05782062|ACTIVE_COMPARATOR|Balloon Assisted maceration|Use of angioplasty balloons for balloon maceration
62798408|NCT04715529|EXPERIMENTAL|FZJ-003|
62025548|NCT02082054|EXPERIMENTAL|PSE 120 mg, CM 8 mg, Atr 0.24 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg tablets dosed BID for 7.5 days
62025549|NCT02082054|EXPERIMENTAL|PSE 120 mg, CM 8 mg, Atr 0.12 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 dosed BID for 7.5 days
62798409|NCT04715529|PLACEBO_COMPARATOR|Placebo|
62025550|NCT02082054|ACTIVE_COMPARATOR|PSE 120 mg, CM 8 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg white, scored, tablets with M27 on scored side and plain on the other side"
62025551|NCT02082054|EXPERIMENTAL|Atropine 0.24 mg|Atropine 0.24 mg tablets dosed BID for 7.5 days
62223179|NCT03117322|EXPERIMENTAL|Prebiotic|agave inulin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.
62223180|NCT03117322|PLACEBO_COMPARATOR|Placebo|maltodextrin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.
62798410|NCT06720857|EXPERIMENTAL|Hypertensive disorders in the puerperium|Identification of a risk stratification model and its predictive value for cardiovascular disorders in the puerperium
62798411|NCT01289093||laparoscopic ingunal herniotomy|
62798412|NCT01289093||laparoscopic incisional herniotomy|
62798413|NCT01289093||Lichtenstein inguinal herniotomy|
62798414|NCT01289093||laparoscopic umbilical hernia repair|
62798415|NCT02236468|EXPERIMENTAL|new EHFP|Group newly participating in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
62798416|NCT02236468|EXPERIMENTAL|old EHFP+WASH|Group participating in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010 + WASH/malaria behavior change communication since 2014
62798417|NCT02236468|OTHER|new EHFP+WASH|Group newly participating in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014 + WASH/malaria behavior change communication since 2014
62798418|NCT02236468|OTHER|old EHFP+WASH+LNS distribution|Group participating in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010 + WASH/malaria behavior change communication and distribution of LNS since 2014
62798419|NCT01157247|OTHER|Group SNI|Insertion of spinal needle with introducer
62798420|NCT01157247|OTHER|Group SNI+LA|Local infiltration of lidocaine was applied three minutes after insertion of spinal needle with introducer
62798421|NCT01157247|OTHER|Group SNI+F|Intravenous fentanyl was applied 3 min before insertion of spinal needle with introducer
62798422|NCT01157247|OTHER|Group SN|Spinal puncture was performed only with spinal needle without introducer, local anesthetic infiltration or intravenous fentanyl before spinal puncture.
62798423|NCT04005157|EXPERIMENTAL|Patients undergoing bronchoscopic MWA|Patients meeting the inclusion criteria will be enrolled in the study and undergo ENB guided MWA. Chest CT will be performed at 1 day after the procedure to confirm the complications and then at 1 month, every 3 months for 2 years, and every 6 months for 3 years thereafter after the procedure. PET/CT will be performed 3 months after MWA to assess the treatment response.
62798424|NCT01841723|EXPERIMENTAL|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Cycles repeat every 28 days for up to 8 cycles if lack of response to therapy, up to 12 cycles if failure to achieve an objective response (CR/PR), or continually at per physician discretion in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo bone marrow aspiration and biopsy, blood sample collection, and CT or ultrasound throughout the study.
62798425|NCT02018081|EXPERIMENTAL|Levofloxacin|Population having a community-acquired pneumonia of which the indication of the treatment is administration of Levofloxacin
62798426|NCT05031793|EXPERIMENTAL|Collaborative Care of TCM and Western Medicine|
62025552|NCT03362255|ACTIVE_COMPARATOR|Rapid speed of injection|Rapid speed of injection (3cc/sec) during thoracic epidurography thoracic epidural catheterization
62025553|NCT03362255|ACTIVE_COMPARATOR|Slow speed of injection|Slow speed of injection (1cc/sec) during thoracic epidurography thoracic epidural catheterization
62223181|NCT05363371|EXPERIMENTAL|Mindfulness based relapse prevention and peer mentoring|Treatment will utilize a group format. The twelve-week mindfulness based relapsed prevention group therapy intervention is co-led by a licensed counselor and a peer mentor for eight weeks, followed by group sessions led by peer mentors for an additional four weeks.
62223182|NCT05363371|ACTIVE_COMPARATOR|12 Step Treatment Program|Participants in the attentional control group will attend 12 weeks of a enhanced 12 step treatment program.
62798427|NCT05031793|ACTIVE_COMPARATOR|Western medicine|
62798428|NCT04965246|EXPERIMENTAL|Physical activity|the physical activity intervention will be structured to increase light-intensity aerobic physical activity, to achieve a total of 150 minutes per week. The intervention will also include weekly support calls from research staff to improve compliance to physical activity
62798429|NCT04965246|OTHER|Usual care|Participants randomized to the usual care control group will serve as the control group for 15 weeks, and receive no intervention during this time.
62798430|NCT00356707||1|This cohort comprises women from the Black Women's Health Study, a prospective study of African American women, who lived in the Los Angeles, New York, or Chicago metropolitan areas at the time of completion of the 1995, 1997, or 1999 questionnaires.
62798431|NCT03895333||study group|women with hearing loss and osteoporosis will develop the study group.
62798432|NCT03895333||control group|women who have hearing loss but have no osteoporosis will constitute the control group.
62223183|NCT02914977|EXPERIMENTAL|Low-dose daunorubicin (DNR)|Eligible patients will be treated with 5 days of low dose daunorubicin (DNR) for one cycle only.
62223184|NCT00545051|EXPERIMENTAL|Ibandronate|Participants received monthly oral ibandronate (150 milligrams \[mg\]) for 12 months.
62223185|NCT00545051|PLACEBO_COMPARATOR|Placebo|Participants received monthly oral placebo for 12 months.
62223186|NCT04901260||Quality Initiative|Each participant will be asked to complete the symptoms log daily for up to 6 months. Additional surveys will be completed throughout the study by participants and GAA clinical staff.
62223187|NCT00267085|EXPERIMENTAL|CML Vaccine|Imatinib mesylate subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months
62025554|NCT04866264|ACTIVE_COMPARATOR|Outpatient Group|"After signing the informed consent, outpatients will be invited for a clinical baseline visit at the Center on Aging and Mobility (CAM), where they will complete the dietary assessment with the eNutrition optimizer at the CAM guided by the study physicians, who will also interpret the immediate results and recommendations produced by the tool to the study participant.~For validating the eNutrition-Optimizer tool, participants will be asked to report their dietary intake in the past 24h during a 24-h diet recall phone call conducted by a trained interviewer on random days (weekday and weekend), so the participant cannot prepare or alter their habits. This 24h diet recall phone calls will be performed 4 times during the second half of the follow-up (month 4 to 6). In addition participants will complete the System Usability Scale at baseline and the subjective effectiveness questionnaire at month 6."
62025555|NCT04866264|ACTIVE_COMPARATOR|Inpatient Group|After signing the informed consent, inpatients (Senior trauma center/heart surgery) will do the dietary assessment with the eNutrition optimizer with supervision of a trained study physician to assess user feasibility in the inpatient setting. In addition they will have a follow-up phone call at month 3 to 6 to assess the subjective effectiveness of the eNO.
62025556|NCT00319098|EXPERIMENTAL|GSK1562902A Group|Male and female subjects aged 18 or over received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm. The group was further stratified by age for analyses.
62417103|NCT05480956|EXPERIMENTAL|Enhanced Peer Recovery Coach|Participants will receive the addiction medicine protocol plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
62588467|NCT06306404|EXPERIMENTAL|Hormones and Sleep intervention|Participants will receive both the sleep intervention, which includes cognitive behavioral therapy for insomnia, and circadian rhythm therapy, and the standard care hormonal intervention.
62025557|NCT00319098|ACTIVE_COMPARATOR|Fluarix+Placebo Group|Male and female subjects aged 18 or over received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm. The group was further stratified by age for analyses.
62025558|NCT01981135|SHAM_COMPARATOR|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
62025559|NCT01981135|EXPERIMENTAL|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
62025560|NCT03732287|EXPERIMENTAL|-5 degrees Celsius for 10 seconds|
62025561|NCT03732287|EXPERIMENTAL|-5 degrees Celsius for 20 seconds|
62025562|NCT03732287|EXPERIMENTAL|-10 degrees Celsius for 10 seconds|
62025563|NCT03732287|EXPERIMENTAL|-10 degrees Celsius for 20 seconds|
62025564|NCT00063947|EXPERIMENTAL|Treatment (radiotherapy, gemcitabine, erlotinib hydrochloride)|Chemoradiotherapy: Patients undergo radiotherapy 5 days a week for 5.5 weeks. Beginning on day 1 and continuing concurrently with radiotherapy, patients receive gemcitabine IV over 30 minutes twice weekly and oral erlotinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease proceed to maintenance therapy. Maintenance therapy: Beginning 4-7 weeks after the completion of chemoradiotherapy, patients receive maintenance chemotherapy comprising gemcitabine IV over 30 minutes on days 1 and 8 and oral erlotinib once daily. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
62025565|NCT00349089|ACTIVE_COMPARATOR|1|Cisplatin/Vinorelbine
62025566|NCT00349089|EXPERIMENTAL|2|Cisplatin/Pemetrexed
62588468|NCT06306404|NO_INTERVENTION|No intervention|The control group.
62588469|NCT05805800|EXPERIMENTAL|5HT3RA+Olanzapine|Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.On day 1-4, Olanzapine is delivered orally after dinner.
62025567|NCT04276545|EXPERIMENTAL|IV administration of dexmedetomidine|IV administration of a single loading dose DEX (0.5μg/kg)
62025568|NCT04276545|ACTIVE_COMPARATOR|IV administration of midazolam|IV administration of midazolam (0.05mg/kg)
62025569|NCT02843568|ACTIVE_COMPARATOR|Standard of Care|"Subjects undergo four-dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning. Subjects undergo laboratory biomarker analysis, including spirometry, diffusion capacity (DLCO), and lung volumes (FEV, FEV1). Subjects complete a self-assessment, RTOG defined acute evaluation toxicity evaluation, RTOG late toxicity evaluation, and constitutional assessment.~Radiation doses between 60-66 Gy using standard fractionation (1.8-2.0 Gy/fx) and 40-60 Gy stereotactic body radiation therapy (SBRT) hypofractionation schemes are utilized. Treatment volumes are at the discretion of the treating radiation oncologist and should follow standard of care."
62025570|NCT02843568|EXPERIMENTAL|Pulmonary Function Damage Reduction|All criteria and specifications in the standard of care arm are applicable for this arm, including the same 4DCT scans, and laboratory biomarker analysis. Subjects randomized to this arm of the trial will have the same prescribed radiation dose to the tumor volume and held to the same radiation dose criteria as the subjects in the standard of care arm (60-66 Gy using standard fractionation (1.8-2.0 Gy/fx) and 40-60 Gy stereotactic body radiation therapy (SBRT) hypofractionation). The fundamental difference will be radiation doses for these subjects will be redistributed away from regions predicted to cause the greatest reduction in pulmonary function if damaged.
62025571|NCT03358667||group A|single edentulism implant insertion tent screw 2mm augmentation peri-implant soft tissue
62223188|NCT04640077|OTHER|Part A Validation of Remote Scale Assessments|"Alternating at-home and on-site cognitive and functional scale assessments~Group 1: Cognitive/functional scale assessment at the study site (on-site), followed by an at-home assessment (VTC; video teleconference), or Group 2: Cognitive/functional scale assessment at home (VTC), followed by assessment on-site"
62417104|NCT05480956|EXPERIMENTAL|SIRI Checklist + Enhanced Peer Recovery Coach|"A standardized checklist of clinical items to review by the attending hospitalist with participants.~Participants will receive the addiction medicine protocol plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month."
62798433|NCT04148495|EXPERIMENTAL|Treatment group|Morphine IV and the placebo of acetaminophen IV.
62798434|NCT04148495|ACTIVE_COMPARATOR|Control group|Morphine IV and acetaminophen IV
62798435|NCT06726681||head trauma|Trauma patients admitted to Emergency department with a history of acute head injury and loss of consciousness
62798436|NCT02191371|EXPERIMENTAL|propofol|Propofol is used as a maintenance anesthetic to patients in the propofol group. Intervention: propofol infusion by target-controlled infusion for maintaining anesthesia propofol (Fresofol MCT 2%) target effect site concentration: 4\~5 mcg/ml, during general anesthesia
62798437|NCT02191371|EXPERIMENTAL|desflurane|"Desflurane is used as a maintenance anesthetic to patients in the desflurane group.~Intervention: Desflurane administration for maintaining anesthesia desflurane (Suprane) inhalation as 6\~8 vol% during general anesthesia"
62798438|NCT02952599||Patients treated with Edoxaban|Patients with established acute initial or recurrent VTE treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
62025572|NCT03358667||group B|single edentulism implant insertion cover screw and membrane augmentation peri-implant soft tissue
62025573|NCT02591654|EXPERIMENTAL|Pembrolizumab and FLT|Subjects will receive WB-DW MRI and FLT PET to assess disease burden after receiving pembrolizumab.
62223189|NCT04640077|OTHER|Part B Donanemab|Donanemab administered intravenously (IV)
62223190|NCT05405452|NO_INTERVENTION|No topical anesthesia|No topical anesthesia will be given during the trigger finger injection.
62223191|NCT05405452|EXPERIMENTAL|Topical coolant|The subject will have 5 seconds of sterile ethyl chloride sprayed at the site of the trigger finger injections just prior to the administration of the injection.
62588470|NCT05805800|ACTIVE_COMPARATOR|5HT3RA+Olanzapine+Dexamethasone|Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.On day 1-4, Olanzapine is delivered orally after dinner.On first day, dexamethasone is given orally within 30 minutes before cisplatin/adriamycin/cyclophosphamide administered.
62798439|NCT03015324|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine
62798440|NCT05301010|EXPERIMENTAL|Faceptor + Docetacel|Patients received a loading dose of Faceptor 8 mg/kg IV + docetaxel 75 mg/m\^2 IV on Cycle 1 followed by Faceptor 6 mg/kg IV + docetaxel 75 mg/m\^2 IV on the next 5 cycles (each cycle is 21 days)
62798441|NCT05301010|ACTIVE_COMPARATOR|Herceptin + Docetacel|Patients received a loading dose of Herceptin 8 mg/kg IV + docetaxel 75 mg/m\^2 IV on Cycle 1 followed by Herceptin 6 mg/kg IV + docetaxel 75 mg/m\^2 IV on the next 5 cycles (each cycle is 21 days)
62798442|NCT03863509||Exclusive Smokers|Smokes Daily; \>/= 5 cigarettes/day for last 6 months
62798443|NCT03863509||Exclusive E-Cig users|E-cig usage \>/= 5 days/week for last 3 months
62798444|NCT03863509||Never users|\< 100 cigarettes in lifetime, none for \> 5 years; \< 3 E-cig usage in lifetime
62798445|NCT03058926||Chronic Pancreatitis|
62798446|NCT03058926||Diabetes|
62798447|NCT03058926||Pancreatic Cancer|
62025574|NCT02909972|EXPERIMENTAL|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days
62025575|NCT02909972|EXPERIMENTAL|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
62025576|NCT05787418|EXPERIMENTAL|HH-120 group|HH-120 Nasal Spray
62798448|NCT02954614|EXPERIMENTAL|Intervention group|Active play in after school programs (ASP). Training program for ASP staff.
62025577|NCT05787418|PLACEBO_COMPARATOR|Control group|Placebo
62025578|NCT00877448|EXPERIMENTAL|Multimeric-001 250 Mcg|Multimeric-001 250 Mcg in PBS
62025579|NCT00877448|EXPERIMENTAL|Adjuvanted Multimeric-001 250 Mcg|250 Mcg in montanide
62025580|NCT00877448|PLACEBO_COMPARATOR|Phosphate Buffered saline|Non-adjuvanted placebo
62025581|NCT00877448|PLACEBO_COMPARATOR|Adjuvanted PBS|Adjuvant was montanide
62223192|NCT05405452|EXPERIMENTAL|Vibration|The subject will have a vibration device placed just proximal to the site of the trigger finger injection concurrent with the administration of the injection.
62223193|NCT05195502||Screening colonoscopy patients|Patients referred for out-patient colonoscopy in the Danish Colorectal Screening program
62223194|NCT05428930|EXPERIMENTAL|CKDB-501B|
62223195|NCT05428930|ACTIVE_COMPARATOR|Botox® 50U|
62223196|NCT04192903|EXPERIMENTAL|Chidamide combined with Cisplatin|"Chidamide: 30mg,PO,biw one week before cycle 1 treatment~Combined treatment period:~Cisplatin 75mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off Patients whose efficacy was evaluated as Complete Response (CR) / Partial Response (PR) / Stable Disease (SD) after the end of the combined treatment period received maintenance treatment with chidamide combined with cisplatin reduction.~Maintenance treatment period:~Cisplatin 25mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off"
62223197|NCT03467776||healthy|healthy control, 5 months to 3 years
62223198|NCT03467776||wheezing with atopy|suspected asthma with wheezing (\>3 episodes per year) and atopy
62588471|NCT04183582|EXPERIMENTAL|Intervention Group|Single arm group receiving Behavioural Activation, a facilitated self-help programme delivered by trained Health Visitors as six one hour sessions over four weeks.
62798449|NCT02954614|NO_INTERVENTION|Control group|ASP as usual.
62025582|NCT00877448|EXPERIMENTAL|Multimeric-001 500 Mcg|Multimeric-001 in PBS
62025583|NCT00877448|EXPERIMENTAL|Adjuvanted Multimeric-001 500 Mcg|Adjuvant was montanide
62025584|NCT00877448|EXPERIMENTAL|Multimeric-001 125 Mcg|Multimeric-001 in PBS
62025585|NCT01577706|ACTIVE_COMPARATOR|Alprazolam (A)|Alprazolam (Xanax), gel-capsule, 1mg, single-dose, 1-day
62798450|NCT01176058|ACTIVE_COMPARATOR|open label|
62798451|NCT00904735|EXPERIMENTAL|Arm I|Patients receive oral hydroxyurea twice daily and oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
62025586|NCT01577706|ACTIVE_COMPARATOR|Dextroamphetamine (D)|Dextroamphetamine (Dexedrine), gel-capsule, 20mg, single-dose, 1-day
62025587|NCT01577706|PLACEBO_COMPARATOR|Placebo (P)|Placebo gel-capsule, single-dose, 1-day
62025588|NCT02940990|PLACEBO_COMPARATOR|Group A|Participants in the Group A will receive 4-6 cycles of standard two-drug chemotherapy. After that, clinical observation or maintenance chemotherapy will be given.
62025589|NCT02940990|EXPERIMENTAL|Group B|Participants in the Group B will also receive 4-6 cycles of standard two-drug chemotherapy. However, they will receive an additional treatment of SBRT to primary lesions or metastatic lesions combined with GM-CSF.
62025590|NCT01230593|ACTIVE_COMPARATOR|Hot Compress|"Hot Compress"
62223199|NCT03467776||wheezing without atopy|wheezing without atopy
62223200|NCT03821753||Case|Patients with glycemic variability, defined by a coefficient of variation (CV)\> 43%, calculated from continuous glucose measurements data by Free Style Libre® (Abbott)
62223201|NCT03821753||Control|Patients without glycemic variability, defined by a coefficient of variation (CV) ≤ 43%, calculated from Free Style Libre® data and matched to patients in the Case group for HbA1c (+/- 0.5%)
62223202|NCT02922309|EXPERIMENTAL|experimental|Vocal Training via Telepractice
62223203|NCT02922309|ACTIVE_COMPARATOR|control|Vocal Training via face-to-face practice
62223204|NCT04552483|EXPERIMENTAL|Nitazoxanide|Patients received nitazoxanide 500mg 8/8hours, for 5 days.
62223205|NCT04552483|PLACEBO_COMPARATOR|Placebo|Patients received placebo 500mg 8/8hours, for 5 days.
62223206|NCT04459013||Patient of the orthodontic consultation|
62223207|NCT00901654|EXPERIMENTAL|ACE527|
62025591|NCT01230593|ACTIVE_COMPARATOR|Tobrex|"Hot Compress, Tobrex Drops, Tobrex Ointment"
62025592|NCT01230593|ACTIVE_COMPARATOR|Tobradex|"Hot Compress, Tobradex Drops, Tobradex Ointment"
62025593|NCT05496582||Asthma|Previously disgnosed asthma patients
62025594|NCT05496582||Control|Healthy participants
62025595|NCT01700608||plerixafor treated patients|lymphoma and myeloma patients
62025596|NCT04722965|ACTIVE_COMPARATOR|Fistulotomy with marsupialization|40 patients with a simple low transsphincteric anal fistula. A fistulotomy with marsupialization is performed.
62025597|NCT04722965|ACTIVE_COMPARATOR|Fistulotomy with open wound|40 patients with a simple low transsphincteric anal fistula. A fistulotomy leaving the wound open is performed.
62223208|NCT00901654|PLACEBO_COMPARATOR|Placebo comparator|
62223209|NCT02839759|EXPERIMENTAL|TELLYHealth Group|Subjects will receive the standard of care in hearing aid education and the TELLYHealth intervention for use over an 8 to12-week period and will be followed by their audiologist for 8 to 12 weeks.
62223210|NCT02839759|NO_INTERVENTION|Standard of Care Group|Subjects will receive the standard of care in hearing aid education and will be followed by their audiologist for 8 to 12 weeks.
62417105|NCT05480956|NO_INTERVENTION|Standard of Care|Participants will receive the stand hospital care while in-patient.
62588472|NCT00631410|EXPERIMENTAL|A|
62588473|NCT00631410|EXPERIMENTAL|B|
62588474|NCT06605950|EXPERIMENTAL|Group A|
62588475|NCT06605950|EXPERIMENTAL|Group B|
62588476|NCT06605950|EXPERIMENTAL|Group C|
62588477|NCT06605950|EXPERIMENTAL|Group D|
62798452|NCT00904735|EXPERIMENTAL|Arm II|Patients receive oral hydroxyurea twice daily in the absence of disease progression or unacceptable toxicity.
62798453|NCT04022863||ovarian tumor benign|all pathological proven benign ovarian tumors
62025598|NCT04829838|EXPERIMENTAL|Intravenous levetireacetam|Drug:Intravenous levetireacetam will be given at a loading dose of 20-30mg/kg then it will be added in maintainance dose of (5-30mg/kg/day)
62025599|NCT04829838|EXPERIMENTAL|intravenous phenytoin|Intravenous phenytoin will be given in loading dose of 20mg/kg then it will be added in maintainance dose i-e 5-8mg/kg/day
62025600|NCT01296828||MOUTH BREATHING CHILDREN|
62025601|NCT06670144||United Kingdom Women's Cohort|United Kingdom Women's Cohort Study. No interventions are to be administered in this observational prospective cohort study.
62025602|NCT04666493|EXPERIMENTAL|Facing Your Fears - Open label|All participants in the study will receive 12 weekly sessions of Facing Your Fears intervention, each lasting approximately 1 to 1.5 hour. Each session involves a component with all the parents and children (30-45 minutes) and a separate time with all the parents only (30-45 minutes). Additionally, there will be two check-in calls (30 minutes each) with the families after weeks 7 and 9 of the program.
62025603|NCT02429128|ACTIVE_COMPARATOR|Lean PCOS training|14 weeks exercise training
62025604|NCT02429128|OTHER|Lean healthy controls|14 weeks exercise training
62025605|NCT05016492|EXPERIMENTAL|Digital game group|The digital game group received the standard 4-week course of rehabilitation but with an additional 30-min interactive digital game training session per week.
62417106|NCT03296215||Observational|Patterno of admitted cases in Respiratory Intensive Care Unit at Assiut University Hospitals and Outcome
62417107|NCT06038916|PLACEBO_COMPARATOR|Placebo group|Patients in this group will receive basal treatment and placebo.
62798454|NCT04022863||ovarian tumor borderline|all pathological proven borderline ovarian tumors
62798455|NCT04022863||ovarian tumor malignant|all pathological proven malignant ovarian tumors
62417108|NCT06038916|EXPERIMENTAL|Low dose group|Patients in this group will receive basal treatment and placebo+ low-dose STSA-1002.
62417109|NCT06038916|EXPERIMENTAL|High dose group|Patients in this group will receive basal treatment and High-dose STSA-1002.
62433430|NCT05738564|ACTIVE_COMPARATOR|Group (EL) Epinepherine and Lidocaone group|Group (EL) (63 patients) received a session of nebulization in the pre-induction area, consisting of 1 ml epinephrine (1:1000 Martindale Pharma, an Ethypharm Group Company, ampoule 1 mg added to 9 ml of normal saline, then 1 ml of that put in nebulization cup + 2 ml lidocaine 2%), nebulized prior to the induction of anesthesia.(63 patients) received a session of nebulization in the pre-induction area, consisting of 1 ml epinephrine (1:1000 Martindale Pharma, an Ethypharm Group Company, ampoule 1 mg added to 9 ml of normal saline, then 1 ml of that put in nebulization cup + 2 ml lidocaine 2%), nebulized prior to the induction of anesthesia.
62798456|NCT00358007|EXPERIMENTAL|Cone Beam CT|
62798457|NCT00732875|EXPERIMENTAL|Open Label Infliximab + Methotrexate|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
62798458|NCT03477045|ACTIVE_COMPARATOR|Fish oil|Fish oil providing 450 mg of eicosapentaenoic acid plus docosahexaenoic acid per dose
62798459|NCT03477045|EXPERIMENTAL|Camelina seed oil|Camelina seed oil providing 450 mg of eicosapentaenoic acid plus docosahexaenoic acid per dose
62025606|NCT05016492|ACTIVE_COMPARATOR|Standard rehab group|The standard rehab group received the standard 4-week course of rehabilitation delivered in one 30-min session per week.
62025607|NCT04040985|OTHER|LEGION™ Primary|LEGION™ Primary Total Knee Arthroplasty (TKA)
62025608|NCT05684016|ACTIVE_COMPARATOR|Control|A control population (Non RRMS) will include a minimum of 20 age and gender matched healthy patients from the George Washington University (GWU) neurology outpatient clinic (being compared with those RRMS patients being treated with Gilenya® ) for whom Brain MRI's are being ordered as a result of their having headaches, dizziness, or other conditions where there is no physical evidence for neurologic impairment. All control patients will only be recruited by the full time Neurology Faculty at the GWU Medical Faculty Associates (MFA). Control patients will be asked to consent to have NeuroQuant added to their routine Brain MRI which will add 7 minutes to their time in the MRI scanner to obtain additional image data.
62223211|NCT00118651||Positive cases|"Positive radiographic findings were defined as the presence of a new air space opacities in the setting of acute respiratory symptoms. Patients with equivocal radiographic findings interpreted as possible pneumonia were considered positive cases"
62223212|NCT00118651||Control|Acute respiratory symptoms, negative chest radiographs, and a date of birth within five years of that of the positive case
62223213|NCT03842722||Critically ill septic patients|Cohort: patients admitted via the emergency department or hospital ward to the intensive care unit of Leiden University Medical Center with the diagnosis sepsis or septic shock, who receive fluid therapy (either colloid, crystalloid and/or red blood cell) in their first day of admission to the ICU.
62223214|NCT00424385|EXPERIMENTAL|Arm 1|Only 1 arm for the study - this arm gets both drugs, gleevec and sorafenib
62223215|NCT01825928|EXPERIMENTAL|paliperidone|paliperidone arm,3mg/pill,3mg/day.last84 days.
62223216|NCT01825928|PLACEBO_COMPARATOR|placebo|placebo group,3mg/pill,3mg/day non-forced titration method,last84 days.
62223217|NCT03390647|EXPERIMENTAL|Cohort A1|Japanese participants will receive a single oral dose of E6130 on Day 1 and Day 7 administered in the specified order (fasted/fed or fed/fasted) to evaluate the food effect.
62798460|NCT02741596|EXPERIMENTAL|Rollover Participants|Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.
62223218|NCT03390647|EXPERIMENTAL|Cohort B1|Caucasian participants will receive a single oral dose of either E6130 or placebo on Day 1.
62223219|NCT03390647|EXPERIMENTAL|Cohorts A2-A4|Japanese participants will receive multiple oral doses of E6130 or placebo on Days 1 to 5, administered in a randomized, dose-ascending manner.
62223220|NCT00827866|OTHER|1|Counselor-Initiated Tobacco Quit Line Group QL where the counselor contacts the client with a standardized intervention protocol)
62223221|NCT00827866|OTHER|2|Self-Paced Tobacco Quit Line Group which leaves the calling up to participants
62223222|NCT05467423|ACTIVE_COMPARATOR|Standard-dose|The standard-dose arm takes one 100mg of iron per day together with a meal, no matter breakfast, lunch or dinner - one tablet a day.
62798461|NCT02741596|EXPERIMENTAL|Non-rollover Participants|Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
62798462|NCT05069051|EXPERIMENTAL|Belimumab|Patients obtain belimumab in combination with rituximab/venetoclax
62798463|NCT05069051|ACTIVE_COMPARATOR|Standard of Care|Patients obtain the combination rituximab/venetoclax
62798464|NCT06726642||Test cohort|"All participants in the experimental cohort will provide blood samples tri-annually (every 4 months) for 4 years, either at the study hospital or at a local blood laboratory (e.g., LifeLabs). Whenever possible, patients will have research blood collected at the same time as routine blood collections for clinical purposes to avoid additional venipunctures. The samples will undergo cfDNA analysis and all results will be returned to participants by the study team. Participants who receive a positive cfDNA assay result will be offered follow-up diagnostic procedures to confirm or rule out the presence of a malignancy. Participants will also complete questionnaires and semi-structured interviews to explore their experience with cfDNA testing and understand perceptions of the clinical utility of cfDNA tests for HCS management."
62798465|NCT06726642||Control|Participants in the control cohort will not receive the cfDNA blood test and will continue to receive standard-of-care cancer surveillance according to current guidelines, as they were prior to study enrollment. Participants will complete questionnaires and semi-structured interviews to explore their experience with cfDNA testing and to understand their perception of the clinical utility of cfDNA tests for HCS management.
62798466|NCT00851617|EXPERIMENTAL|IMT Group|The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
62798467|NCT00851617|NO_INTERVENTION|Control Group|Patients were evaluated until weaning without interventions
62798468|NCT00378781|EXPERIMENTAL|Arm I|Minocycline hydrochloride + Edetate Calcium Disodium (M-EDTA) flush solution into CVC once daily.
62798469|NCT00378781|EXPERIMENTAL|Arm II|Heparin flush solution into CVC once daily.
62223223|NCT05467423|EXPERIMENTAL|Low-dose|The low-dose arm 12mg of iron a day. The first 6mg tablet in the morning on an empty stomach and the second 6mg tablet in the evening either one hour before or after eating - two tablets a day.
62223224|NCT01240226|EXPERIMENTAL|A|
62223225|NCT01240226|EXPERIMENTAL|B|
62223226|NCT01211288|ACTIVE_COMPARATOR|HIV negative group|This group contains participants consented to receive implants and identified as negative for HIV
62223227|NCT01211288|EXPERIMENTAL|HIV positive group|This group contains participants consented to receive implants and identified as positive for HIV
62223228|NCT03337451|EXPERIMENTAL|OPN-305|
62798470|NCT04803149|EXPERIMENTAL|Cooled Radiofrequency|Cooled radiofrequency energy will be delivered to target medial branch nerves in the lower back to reduce pain
62798471|NCT04803149|ACTIVE_COMPARATOR|Conventional Radiofrequency|Conventional radiofrequency energy will be delivered to target medial branch nerves in the lower back to reduce pain
62798472|NCT02151669|EXPERIMENTAL|Mediterranean Diet Group|Nutritional intervention to enhance the traditional Mediterranean diet pattern using new technology as an educational tool in primary care: DIET blog. Participants will be referred to a single annual visit and one group session per year for two years.
62223229|NCT04288999|EXPERIMENTAL|Arm A|"Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy~Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)~Adjuvant chemotherapy: CAPOX (capecitabine+oxaliplatin) or mFOLFOX6 (5-fluorouracil+l-leucovorin+oxaliplatin) or capecitabine or 5-fluorouracil (FU) +l-leucovorin (LV)~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
62588478|NCT03685357||Idiopathic Parkinson's|"Oral glucose tolerance test~The Unified Parkinson's Disease Rating Scale (UDPRS)."
62588479|NCT03685357||Diabetics receive sulphonylurea group|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score"
62588480|NCT03685357||Diabetics on sulphonylurea and metformin|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score"
62223230|NCT04288999|ACTIVE_COMPARATOR|Arm B|"Surgery plus Adjuvant chemotherapy~Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
62223231|NCT01522469|EXPERIMENTAL|Crenolanib Besylate|
62798473|NCT02151669|NO_INTERVENTION|Control group|Participants of control group will be referred to your doctor or nurse with reference to a report on specific according to your personal situation dietary recommendations.
62798474|NCT02464046|EXPERIMENTAL|JNJ-42847922 then Placebo|Participants receive 2\*20 milligram (mg) tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive matching placebo from Day 1 to Day 5 of period 2.
62798475|NCT02464046|EXPERIMENTAL|Placebo then JNJ-42847922|Participants will receive matching placebo from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 2.
62798476|NCT03591718|EXPERIMENTAL|BI 456906|
62798477|NCT03591718|EXPERIMENTAL|Placebo|
62798478|NCT04523857|EXPERIMENTAL|A (Abema)|Abemaciclib (150 mg BID)
62798479|NCT04523857|EXPERIMENTAL|B (Abema + HCQ)|"Abemaciclib (100 mg or 150 mg BID\*) + Hydroxychloroquine (600 mg BID)~\*Abemaciclib dose will be determined by safety cohort"
62798480|NCT04756804|EXPERIMENTAL|70% Isopropyl Alcohol novel preoperative skin antiseptic|70% v/v Isopropyl Alcohol novel preoperative skin antisepsis preparation
62798481|NCT04756804|ACTIVE_COMPARATOR|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol preoperative skin antiseptic|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol preoperative skin antisepsis preparation
62798482|NCT05590975|EXPERIMENTAL|Peer Supporter and Adult coach intervention|Intervention group will receive PACT module through peer supporters and adult coaches
62798483|NCT05590975|EXPERIMENTAL|Adult coach intervention|Intervention group will receive PACT module through adult coaches only
62798484|NCT05590975|NO_INTERVENTION|Control Group|Control group will receive PACT intervention after the completion of intervention and evaluation with 1st PACT intervention arm.
62798485|NCT02466763|ACTIVE_COMPARATOR|round window|Half of the participants will be randomized to the round window technique of cochlear implant device electrode insertion. Intervention for participants randomized to the round window arm include having the round window technique used for the electrode insertion during the participant's cochlear implant surgery. Participants in this arm of the study will also have a post operative CT scan at about three months after surgery.
62798486|NCT02466763|ACTIVE_COMPARATOR|cochleostomy|Half of the participants will be randomized to the cochleostomy technique of cochlear implant device electrode insertion. For the participants randomized to the cochleostomy arm, the surgeon will use a cochleostomy technique for the electrode insertion during the participant's cochlear implant surgery. Participants in this arm of the study will also have a post operative CT scan at about three months after surgery.
62798487|NCT02195570|EXPERIMENTAL|QSN with CM (QSN-CM).|Women will receive standard of care Quit Smoking Now tobacco education and support plus prize-based contingency management. Their smoking status will be monitored from quit date through 3 months postpartum via carbon monoxide and salivary cotinine levels. Women will earn chances to win prizes each time they test negative for smoking according to biochemical measures.
62798488|NCT02195570|ACTIVE_COMPARATOR|QSN Only|Women receive the standard of care Quit Smoking Now tobacco education and support only. Smoking status will be monitored from quit date through 3 months postpartum via carbon monoxide and salivary cotinine levels. Incentives are given for providing breath and salivary samples but are not contingent on smoking status.
62798489|NCT03547310|EXPERIMENTAL|MyoBeatz|The intervention consists of playing with the smartphone training program using the muscle signals picked up by surface electrodes. The study will run over a period of 5 weeks, with participants playing with the training program at home for 4 weeks.
62798490|NCT04043559||patients with an acute symptomatic infarction|
62798491|NCT04043559||controls with cryptogenic stroke|
62588481|NCT03685357||Healthy|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score~Oral glucose tolerance test"
62588482|NCT00153543|ACTIVE_COMPARATOR|PPV23|Receive one dose of PPV23
62588483|NCT00153543|EXPERIMENTAL|PCV7 + PPV23, 2 months|Receive one dose of PCV7 + 1 dose of PPV23 2 months later
62798492|NCT04800458|EXPERIMENTAL|thrombocytopenic patients|
62798493|NCT03573310|EXPERIMENTAL|Part 1: Dose escalation and RP2D Selection|Participants with solid tumors or non-Hodgkin lymphoma (NHL) will receive JNJ-64619178 orally as per the assigned sequential cohorts and doses will be escalated based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and clinical activity. One or more recommended Phase 2 dose(s) (RP2Ds) may be determined for further exploration.
62798494|NCT03573310|EXPERIMENTAL|Part 2:Dose Confirmation and Expansion|Participants with myelodysplastic syndromes (MDS) will receive JNJ-64619178 at a dose less than or equal to the RP2D selected in Part 1 for 24 weeks, or longer if there is evidence of clinical benefit. The dose level of JNJ-64619178 may be adjusted based on observed toxicities.
62798495|NCT01459588|EXPERIMENTAL|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
62025609|NCT05684016|ACTIVE_COMPARATOR|MS Subject on Gilenya|All the RRMS patients will have their Brain MRI with the addition of NeuroQuant. The 30 patients that are taking Gilenya® will have serial NeuroQuant/MRI and Neuropsychological testing (which is like an IQ test) using Automated Neuropsychological Assessment Matrices (ANAM) whether they are or are not experiencing cognitive issues. In addition, each study patient will undergo Extended Disability Status Score (EDSS) evaluation by a physician or a physician assistant at baseline and at 1 and 2 years. A group of 20 RRMS patients will undergo a second Brain MRI (not standard of care) with NeuroQuant evaluation 7 to 14 days after the initial study in order to confirm the reproducibility of this imaging technique. The cost for this repeat MRI will not be charged to you but will be borne by the sponsors of this study
62025610|NCT05684016|ACTIVE_COMPARATOR|MS Subject not on Gilenya|All the RRMS patients will have their Brain MRI with the addition of NeuroQuant.
62025611|NCT03558867|PLACEBO_COMPARATOR|Metformin + Healthy diet|Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
62223232|NCT03720873|EXPERIMENTAL|EGFR-TKIs and Anlotinib|Experimental:EGFR-TKIs and Anlotinib EGFR-TKIs:erlotinib 150mg QD or gefitinib250mgQD or icotinib 125 mg TID , Anlotinib 12mg po qd d1-14 q21d
62223233|NCT03028220|ACTIVE_COMPARATOR|Real time continuous glucose monitoring|Use of Dexcom G5 continuous glucose monitoring
62223234|NCT03028220|ACTIVE_COMPARATOR|Flash glucose monitoring|Use of Abbott FreeStyle Libre flash glucose monitoring
62223235|NCT01771107|EXPERIMENTAL|Treatment (brentuximab and combination chemotherapy)|Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62223236|NCT01184261|EXPERIMENTAL|Arm I|Patients attend behavioral sessions for smoking and binge drinking cessation over 30 minutes once weekly in weeks 1-6.
62223237|NCT01184261|EXPERIMENTAL|Arm II|Patients attend behavioral sessions for smoking cessation over 30 minutes once weekly in weeks 1-6.
62223238|NCT05896878|EXPERIMENTAL|Daily Supplement Treatment|Following study recruitment and obtaining consent, participants will complete a baseline urine test. The FPI is a simple urine test from Ethos Laboratories that screens for 11 biomarkers that are more likely to contribute to symptoms of pain.
62223239|NCT01122160|PLACEBO_COMPARATOR|placebo|Placebo with berries (blackberries + strawberries)
62223240|NCT01122160|EXPERIMENTAL|omeprazole|Prilosec (omeprazole) 20.6 mg tablet with berries (blackberries + strawberries)
62223241|NCT00561132|EXPERIMENTAL|1|
62223242|NCT00561132|PLACEBO_COMPARATOR|2|
62025612|NCT03558867|ACTIVE_COMPARATOR|Metformin + Personalized diet|Metformin (1500 mg/d, Extended Release) + Personalized diet based on an algorithm developed at the Weizmann Institute of Science (Zeevi et al, Cell 2015)
62025613|NCT02556021|EXPERIMENTAL|CJ-12420 50mg|CJ-12420 50 mg, tablet, once daily, oral administration for up to 4 weeks
62025614|NCT02556021|EXPERIMENTAL|CJ-12420 100mg|CJ-12420 100 mg, tablet, once daily, oral administration for up to 4 weeks
62025615|NCT02556021|PLACEBO_COMPARATOR|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
62223243|NCT03932669|EXPERIMENTAL|Nilotinib group|Patients with SCA and taking nilotinib treatment
62223244|NCT02822586|EXPERIMENTAL|Cohort A (Stage IB and Stage IIA to IIIB [if N0-1])|"(Eligible patients with Stage IB, IIA, IIB, and IIIA \[if N0-1\])~Brentuximab Vedotin 1.8 mg/kg IV every 3 weeks for 3 doses beginning 3 weeks prior to initiation of TSEB.~TSEB 12 Gy in 6 fractions at 2 Gy/fraction treated twice/week."
62223245|NCT02822586|EXPERIMENTAL|Cohort B(Stage IIA to IIIB; IVA;transformed CTCL)|"(Eligible patients with Stage IIA, IIB, IIIA \[if N2-3\]; IIIB; Stage IVA; and transformed CTCL)~Brentuximab Vedotin 1.8 mg/kg IV every 3 weeks for 3 doses beginning 3 weeks prior to initiation of TSEB.~TSEB 12 Gy in 6 fractions at 2 Gy/fraction treated twice/week.~Continuation of brentuximab every 3 weeks until disease progression or unacceptable toxicity or for up to 2 years as a study participant, (whichever occurs first)."
62223246|NCT06244420||Patients|patients with a histological diagnosis of soft tissue or bone malignant myoepithelioma treated from 1998 to 2021.
62798496|NCT01459588|EXPERIMENTAL|Carboxymethylcellulose Based Eye Drop Formulation B|Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
62223247|NCT04775771|EXPERIMENTAL|Animal Assisted Practice (Experimental) Group|
62223248|NCT04775771|NO_INTERVENTION|Control Group|
62223249|NCT05985421||Patients|
62798497|NCT01459588|ACTIVE_COMPARATOR|Carboxymethylcellulose Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
62025616|NCT06635044|EXPERIMENTAL|IDEP group|a pedal exerciser (RTL10273 Deluxe Folding Pedal Exerciser, Drive Medical Co. MPN) was utilized in performing leg cycling exercises while men were sitting. Before starting the session of intradialytic cycling, a 5-minute stretching of the lower limbs was performed as a warming up. Also, as cooling down, the same period of lower limbs' stretching was performed after ending intradialytic cycling
62223250|NCT05985421||Control|
62223251|NCT00709852|EXPERIMENTAL|Gadobutrol then Gadoteridol|Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) in Period 1 and a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v. in Period 2.
62223252|NCT00709852|EXPERIMENTAL|Gadoteridol then Gadobutrol|Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v. in Period 1 and a single dose of gadobutrol 0.1 mmol/kg bw via i.v. in Period 2.
62223253|NCT03107338|ACTIVE_COMPARATOR|DEXKETOPROFEN TROMETAMOL|Patients received a dose of 25 mg DKT in an oral suspension 15 minutes before surgery
62223254|NCT03107338|PLACEBO_COMPARATOR|Placebo|Patients received a dose of 500 mg Vitamin C in an oral suspension 15 minutes before surgery
62223255|NCT02937233|EXPERIMENTAL|4 Week Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 4
62798498|NCT01459588|ACTIVE_COMPARATOR|Carboxymethylcellulose Based Lubricant Eye Drops|Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
62798499|NCT02677194|EXPERIMENTAL|Exposition LED|The patient is his own witness. This is a randomization for the allocation of treatments (LED parameters) on 6 mini-zones of 1,5x1,5 cm at the level of forearm. Dermabrasion by fractional laser CO2 ablative, evaluation of the pain on every zone by VAS post-act : exposition to LED 590nm (4 or 12sec) or 630nm(4min30 or 15 min) or 830 nm (6 or 12 min).
62025617|NCT06635044|NO_INTERVENTION|control group|this group served as waitlist men.
62223256|NCT02937233|EXPERIMENTAL|2 Week Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 2
62223257|NCT02937233|EXPERIMENTAL|Single Vaccination Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 only
62223258|NCT01849159|ACTIVE_COMPARATOR|MSC group|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution. Infusions will be performed every 2 months for 1 year
62223259|NCT01849159|PLACEBO_COMPARATOR|Control Group|400 mL of 0.9% NaCl solution. Infusions will be performed every 2 months for 1 year
62588484|NCT00153543|EXPERIMENTAL|PCV7 + PPV23, 6 months|Receive one dose of PCV7 + 1 dose of PPV23 6 months later
62588485|NCT05670795|EXPERIMENTAL|recombinant follicle stimulating hormone|Gonal-f® (75 I.U., Merck Serono, Darmstadt, Germany)
62798500|NCT02677194|OTHER|Control|Device without any LED exposition : This is a randomization for the allocation of treatments (LED parameters) on 6 mini-zones of 1,5x1,5 cm at the level of forearm or control (1 mini-zone)
62588486|NCT05670795|ACTIVE_COMPARATOR|recombinant follicle stimulating hormone and clomiphene citrate|Gonal-f® (75 I.U., Merck Serono, Darmstadt, Germany) Klomen® (50 mg, Koçak Farma, Tekirdag, Turkey)
62223260|NCT05023421||Problematic media use of children with CP|The participants in the current study were parents of children with CP aged 4-18 years. They were recruited at the Hacettepe University Physical Therapy and Rehabilitation Faculty Cerebral Palsy and Pediatric Rehabilitation Unit and Special Education and Rehabilitation Centers. The inclusion criteria were having a child with CP aged 2-18 years without severe cognitive problems, being a primary caregiver.
62223261|NCT03795597|EXPERIMENTAL|Carfilzomib IV at dose: 20 mg/m2|The participants will receive Carfilzomib IV at dose: 20 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and Granulocyte-Colony stimulating factor (G-CSF) given daily until engraftment occurs.
62223262|NCT03795597|EXPERIMENTAL|Carfilzomib IV at dose: 27 mg/m2|The participants will receive Carfilzomib IV at dose: 27 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
62223263|NCT03795597|EXPERIMENTAL|Carfilzomib IV at dose: 36 mg/m2|The participants will receive Carfilzomib IV at dose: 36 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
62588487|NCT05431530||Ovarian cancer|Tumor involving rectosigmoid colon
62588488|NCT05972941|EXPERIMENTAL|Culturally targeted messages|Participants will view 8 nicotine and tobacco health messages with LGBT culturally targeted messages and imagery
62588489|NCT05972941|OTHER|Non-targeted messages|Participants will view 8 nicotine and tobacco health messages with universal messages and imagery
62588490|NCT04525014|EXPERIMENTAL|RRx-001, Temozolomide and Irinotecan|
62588491|NCT02050217|EXPERIMENTAL|Noninvasive ventilation|Neurally Adjusted Ventilatory Assist versus Pressure Support flow triggered delivered by helmet
62588492|NCT00119691|EXPERIMENTAL|Nesiritide + standard of care|Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
62798501|NCT02342223|EXPERIMENTAL|Voluma|"Subjects will be screened for severity on their HIV facial lipoatrophy according to the Carruthers Lipoatrophy Severity Scale (CLSS), and will receive subcutaneous injections of Voluma in the affected facial areas with the 'smile and fill' technique (Jagdeo 2014) based on Carruthers scoring scale.~Subjects with Carruthers Score level 2 will receive total of 2-6 syringes of Voluma.~Subjects with Carruthers Score level 3 will receive total of 4-8 syringes of Voluma.~Subjects with Carruthers Score level 4 will receive total of 6-12 syringes of Voluma.~All subjects will receive one Voluma treatment at initial time = 0 and may be eligible for touchup treatment, if necessary, at 2 weeks post-initial treatment."
62798502|NCT04617067|EXPERIMENTAL|All Patients|Open Label: Paricalcitol 12mcg once daily, orally every day of each 28 day cycle PLUS GEM (1000mg/m2) and Nab-paclitaxel (Abraxane®) (125mg/m2) on days 1, 8 and 15 of each cycle.
62798503|NCT05206721|EXPERIMENTAL|Intervention group|
62798504|NCT05206721|NO_INTERVENTION|Control group|
62798505|NCT04718623||Sepsis group (SG)|with source of infection and SOFA Score more than or equal 2
62798506|NCT04718623||Non-Sepsis Group (NSG)|with SOFA score less than 2
62798507|NCT04485559|EXPERIMENTAL|Treatment (trametinib, everolimus)|Patients receive dosing per their assigned dose level. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
62798508|NCT05206760||Trial participants|Patients with severe traumatic brain injury requiring craniotomy or ICP bolt insertion
62798509|NCT00361556|ACTIVE_COMPARATOR|1|The Back Book
62798510|NCT00361556|ACTIVE_COMPARATOR|2|The Back Guide
62798511|NCT00361556|ACTIVE_COMPARATOR|3|General health book
62798512|NCT06458543|EXPERIMENTAL|Experimental|"The experimental group includes 50 women of reproductive age (18 - 45 years old) with an established diagnosis of bacterial vaginosis.~Participants in the experimental group will be given the drug Bovgialuronidase azoximer and Metronidazole.~Bovhyaluronidase azoximer, vaginal suppositories 3000 IU, 1 suppository vaginally every other day, course of 10 days Metronidazole, tablets 500 mg, 1 tablet 2 times a day, orally, course 7 days"
62798513|NCT06458543|ACTIVE_COMPARATOR|Control|"The control group includes 50 women of reproductive age (18 - 45 years old) with an established diagnosis of bacterial vaginosis.~Metronidazole, tablets 500 mg, 1 tablet 2 times a day, orally, course 7 days"
62798514|NCT06165328||Cohort1|Patients with aged more than 50 years and had FIT test +
62798515|NCT02420704||Cleavage stage-thin endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness ≤7mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
62798516|NCT02420704||Cleavage stage-medium endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness 8-13mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
62798517|NCT02420704||Cleavage stage-thick endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness ≥14mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
62798518|NCT02420704||Blastocyst stage-thin endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness ≤7mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
62798519|NCT02420704||Blastocyst stage-medium endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness 8-13mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
62588493|NCT00119691|ACTIVE_COMPARATOR|Standard of care|Standard of care until adequate diuresis achieved
62223264|NCT03795597|EXPERIMENTAL|Carfilzomib IV at dose: 45 mg/m2|The participants will receive Carfilzomib IV at dose: 45 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
62588494|NCT01172223|EXPERIMENTAL|LAPADO|Non-pegylated liposomal doxorubicin (NPLD; Myocet, 60 mg/m2 i.v. day 1 q3 weeks), Paclitaxel (175 mg/m2 i.v. day 1 q3 weeks), and Lapatinib (GW572016, Tykerb, 750-1500 mg/d orally daily until the day of the definitive surgery)
62223265|NCT03795597|EXPERIMENTAL|Carfilzomib IV at dose: 56 mg/m2|The participants will receive Carfilzomib IV at dose: 56 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
62588495|NCT04500964||failed transcather aortic valve (Stenotic)|
62798520|NCT02420704||Blastocyst stage-thick endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness ≥14mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
62223266|NCT06006559|EXPERIMENTAL|EYU688|EYU688 administered by oral route
62223267|NCT06006559|PLACEBO_COMPARATOR|Placebo|Matching placebo
62223268|NCT06124781|EXPERIMENTAL|Patient with patch test reactions|Patient with at least one positive/doubtful patch test reaction for nickel, limonene hydroperoxide and/or linalool hydroperoxide
62223269|NCT03186131|ACTIVE_COMPARATOR|Oral Ibandronate alone|Monthly Oral Intake of Ibandronate
62223270|NCT03186131|ACTIVE_COMPARATOR|Oral Ibandronate and Vitamin D|Monthly oral intake of Ibandronate and daily oral intake of Vitamin D
62223271|NCT04487912|ACTIVE_COMPARATOR|Injection of 99m-Tc Tilmanocept|
62223272|NCT04487912|ACTIVE_COMPARATOR|Injection of 99m-Tc Nanocolloid|
62588496|NCT04500964||failed transcather aortic valve (Regurgitation)|
62223273|NCT05064683|EXPERIMENTAL|white noise|The newborns in the white noise group were listened to white noise for 24 hours using an Mp3 player and a decibel measuring device to measure the sound level.
62588497|NCT04500964||failed transcather aortic valve (Regurgitation and stenotic))|
62798521|NCT04039958|EXPERIMENTAL|T test|Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
62223274|NCT05064683|EXPERIMENTAL|facilitated tucking|The newborns in the facilitated tucking were given supine, prone, and lateral positions for 24 hours, depending on their clinical status.
62223275|NCT05064683|NO_INTERVENTION|control|Newborns in the control group did not receive any treatment other than routine applications while receiving Nasal CPAP support in the neonatal intensive care unit.
62223276|NCT00568035|ACTIVE_COMPARATOR|QR-333|
62223277|NCT00568035|PLACEBO_COMPARATOR|Placebo|
62588498|NCT04115475|ACTIVE_COMPARATOR|Healthy Volunteers (HV)|"* Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;~* physical assessment/milestones: Hammersmith Infant Neurological Examination (HINE)/ expanded Hammersmith functional motor scale (HFMSE)/ The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP Intend)/ Upper Limb Module (ULM)"
62588499|NCT04115475|EXPERIMENTAL|Spinal Muscular Atrophy (SMA) patients|"* Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;~* physical assessment/milestones: Hammersmith Infant Neurological Examination (HINE)/ expanded Hammersmith functional motor scale (HFMSE)/ The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP Intend)/ Upper Limb Module (ULM)"
62588500|NCT04411511||Lean children|Children between 4-18 years, living in the Netherlands.
62798522|NCT04039958|ACTIVE_COMPARATOR|B reference (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
62798523|NCT04039958|ACTIVE_COMPARATOR|B reference (second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
62798524|NCT01366599||Patients enrolled in IHCIS in 2006|Patients enrolled in IHCIS in 2006
62798525|NCT00462306||Pregnant population|The study group consisted of pregnant women, presenting to Prentice Women's Hospital of Northwestern Memorial Hospital for spontaneous labor, induction of labor, and scheduled cesarean delivery.
62798526|NCT00462306||Non-Pregnant Population|The study group consisted of non-pregnant females, presenting to Northwestern Memorial Hospital for ambulatory surgery
62798527|NCT06726772|EXPERIMENTAL|Intervention (Group Psychotherapy)|
62223278|NCT01670955|ACTIVE_COMPARATOR|Jobelyn + Ferrous Sulphate + Folic Acid|Caps Jobelyn 250mg, 12 hourly + Ferrous Sulphate 600mg thrice daily + Folic Acid 5mg daily
62223279|NCT01670955|ACTIVE_COMPARATOR|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
62223280|NCT03461276|EXPERIMENTAL|ABvac40|Six administrations of ABvac40; the first five administered once every 4 weeks and the sixth at week 42. Each administration consists of 1mL subcutaneous injection of ABvac40.
62223281|NCT03461276|PLACEBO_COMPARATOR|Placebo|Six administrations of Placebo; the first five administered once every 4 weeks and the sixth at week 42. Each administration consists of 1mL subcutaneous injection of the vaccine's vehicle buffer without the active component.
62223282|NCT02860611||Type 1 Diabetes|Patients with type 1 diabetes
62223283|NCT02860611||Type 2 Diabetes|Patients with type 2 diabetes
62223284|NCT02860611||Control|Healthy volunteers
62223285|NCT06014840|ACTIVE_COMPARATOR|Early diagnosis and treatment of COPD or Asthma|Treatment strategy using evidence-based guidelines for asthma or COPD provided to participant on the day of randomization
62223286|NCT06014840|OTHER|Delayed diagnosis and treatment of COPD or Asthma|Treatment strategy using evidence-based guidelines for asthma or COPD provided to participant at 12 weeks.
62223287|NCT06372678|EXPERIMENTAL|220 mg Group|CM326 220 mg, subcutaneous (SC)
62588501|NCT04411511||Children with overweight or obesity|Children between 4-18 years, living in the Netherlands. Besides inclusion from the general population, childhood expertise centres will contact their patients to pay attention to this study.
62223288|NCT06372678|EXPERIMENTAL|440 mg Group|CM326 440 mg, subcutaneous (SC)
62223289|NCT06372678|PLACEBO_COMPARATOR|placebo|matched placebo, subcutaneous (SC)
62223290|NCT04837898|ACTIVE_COMPARATOR|Haskap berry|A commercially available haskap berry freeze-dried) powder
62223291|NCT04837898|PLACEBO_COMPARATOR|Placebo|Black cherry KoolAid (Kraft Foods, USA) with added maltodextrin to match carbohydrate and calorie content
62223292|NCT03429829|EXPERIMENTAL|Flairesse varnish|Children were part of the LiveSmart tooth brushing program. They all received a new toothbrush at baseline and at every follow-up visit as well as fluoridated toothpaste. Their daily toothbrushing was supervised by the local trained non-professional assistant. In addition, fluoride varnish (22.600 ppm, DMG, Hamburg, Germany) was applied in 3-monthly intervals by the local non-professional assistants who had been trained beforehand and supervised at the first application.
62223293|NCT03429829|NO_INTERVENTION|Control|Children were part of the LiveSmart tooth brushing program. They all received a new toothbrush at baseline and at every follow-up visit as well as toothpaste. Their daily toothbrushing was supervised by the local trained non-professional assistant. Beyond that, the children in this arm were left untreated.
62223294|NCT00985153|EXPERIMENTAL|1|ProQuad Lot 1
62223295|NCT00985153|EXPERIMENTAL|2|ProQuad Lot 2
62223296|NCT00985153|EXPERIMENTAL|3|ProQuad Lot 3
62223297|NCT00985153|ACTIVE_COMPARATOR|4|M-M-R II + Varivax
62223298|NCT04280068|ACTIVE_COMPARATOR|Clinician Guide|Clinician Guide is an evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings.
62223299|NCT04280068|ACTIVE_COMPARATOR|Clinician Guide plus HealthCall|Clinician Guide plus the use of HealthCall, a smartphone application to monitor daily alcohol use, ART adherence and other health behaviors.
62223300|NCT00677326|EXPERIMENTAL|A|Peptide administered
62223301|NCT05569720|EXPERIMENTAL|ApTOLL treatment|Volunteers will receive a dose of ApTOLL of 0.1mg/kg administered intravenously as slow infusion one day and as a single bolus intravenous injection the second day. In a third and last admission day, volunteers will receive a dose of ApTOLL of 0.2mg/kg administered as a single bolus intravenous injection.
62223302|NCT04725474|EXPERIMENTAL|Phase 1 (Part A; dose escalation): CTL-002 Monotherapy + Checkpoint Inhibitor Combination|Up to 5 dose levels with visugromab (CTL-002) administered as IV monotherapy and in combination with a CPI
62223303|NCT04725474|EXPERIMENTAL|Phase 2 (Part B; expansion): visugromab (CTL-002) + Checkpoint Inhibitor Combination|At defined dose level(s) with visugromab (CTL-002)
62223304|NCT01398995|EXPERIMENTAL|90 minutes|Basal insulin infusion reduced to 50% of normal 90 minutes prior to exercise
62588502|NCT01226498|EXPERIMENTAL|Fresh blood auto-transfusion|
62588503|NCT01226498|EXPERIMENTAL|Old blood auto-transfusion|
62798528|NCT02330055|ACTIVE_COMPARATOR|Forty-five degrees elevated upper body position|"If the patient is randomized in this study arm after enrollment, the investigators will elevate the patients upper body to 45 degree prior to sleeping. The patient will wear a pulseoximeter (WristOx Model 3150) during the night. The investigators will collect the SpO2 and pulse rate with this device and then quantify desaturation events.~The investigators will ask the patient to fill out a questionnaire, which includes the P-SAP score, the STOP-BANG score, the Epworth Sleepiness Scale and the self-reported pain."
62798529|NCT02330055|PLACEBO_COMPARATOR|Non-elevated upper body position|"If the patient is randomized in this study arm after enrollment, the investigators will flatten the patients upper body to a supine position prior to sleeping. The patient will wear a pulseoximeter (WristOx Model 3150) during the night. The investigators will collect the SpO2 and pulse rate with this device and then quantify desaturation events.~The investigators will ask the patient to fill out a questionnaire, which includes the P-SAP score, the STOP-BANG score, the Epworth Sleepiness Scale and the self-reported pain."
62798530|NCT02425696||group 1|Normal individuals without migraine
62223305|NCT01398995|EXPERIMENTAL|60 minutes|Basal insulin infusion reduced to 50% of normal 60 minutes prior to exercise
62223306|NCT01398995|EXPERIMENTAL|30 minutes|Basal insulin infusion reduced to normal 30 minutes prior to exercise
62223307|NCT01398995|EXPERIMENTAL|Start|Basal insulin infusion reduced to 50% of normal at the start of exercise
62417110|NCT04794582|ACTIVE_COMPARATOR|ProGrip® Mesh reinforcement|Once the closure has been completed in 2 muscle-aponeurotic planes with continuous synthetic suture (Monomax® USP 0), the closure will be completed by placing the ProGrip® macroporous polypropylene monofilament mesh in supra-aponeurotic position using the surface with the polylactic acid microgrips, which act as Velcro, in direct contact with the superficial aponeurotic plane constituted by the aponeuroses of the greater oblique muscle and the crescentic line of the anterior rectus abdominis muscle. The polylactic acid microgrips provide immediate fixation, making additional fixation with stitches unnecessary, which makes the technique very easy to use and systematize among the different surgeons of the transplant team. The procedure is completed with the placement of a low caliber round Jackson-Pratt subcutaneous drain (10F) connected to a vacuum system that will be removed on post-transplant day 2 or 3
62588504|NCT01736774|EXPERIMENTAL|Usual care intervention|Primary care as required including medication
62588505|NCT01736774|EXPERIMENTAL|Physiotherapy treatment|Exercise and manipulative therapy
62588506|NCT03368885|EXPERIMENTAL|Experimental area PCI|"In this arm, in addition to the standard care for Polio eradication program activities of CGPP project, the following interventions are added:~Maternal dietary diversity; Diet diversity in complementary feeding; Exclusive breast feeding; Community mobilization; Capacity building; Convergence;Use of existing platforms VHSND; Strategic Use of Data"
62588507|NCT03368885|NO_INTERVENTION|Control area PCI|This arm will receive standard care with respect to Polio eradication program activities of CGPP such as awareness generation around Polio and routine immunization, hand washing and sanitation
62588508|NCT03596723|EXPERIMENTAL|KPI-121 1% BID (twice daily)|
62588509|NCT03596723|ACTIVE_COMPARATOR|Prednisolone acetate QID (four times daily)|
62588510|NCT06663423||Group 1|Depressive Disorder group - 9 participants.
62588511|NCT06663423||Group 2|Generalized Anxiety Disorder group - 9 participants.
62588512|NCT06663423||Group 3|Control group - 9 participants.
62588513|NCT06684509|NO_INTERVENTION|Non Atrovastatin group|control group of the same condition they will not tkae atrovastatin
62588514|NCT06684509|EXPERIMENTAL|Atrovastatin group|patients will receive atorvaststin 40mg/daily , started before anthracyclin treatment and continued 12 months
62588515|NCT01261572|EXPERIMENTAL|High dose group|ASP3350 high dose
62588516|NCT01261572|EXPERIMENTAL|Low dose group|ASP3350 low dose
62798531|NCT02425696||group 2|Migraineurs
62588517|NCT04167631|OTHER|Multiparametric MRI|Vesical Imaging-Reporting And Data System (VI-RADS) using multi-parametric MRI.
62588518|NCT05884099|EXPERIMENTAL|Intercostal cryoanalgesia AND single-injection paravertebral block|"* Videothoracoscopic-guided single-injection paravertebral block at T5 with 0.4 mL/kg of Bupivacaine 0.5% with adrenalin 5 mcg/mL (maximum 40 mL) at the beginning of surgery~* Cryoanalgesia 5 cm lateral to the neuraxial, on the inferior costal border, CO2 at (-)50C to (-)70C for 2 minutes, repeated on 7 costal levels (T3-T9), after the lung resection and before chest closure."
62588519|NCT05884099|ACTIVE_COMPARATOR|Single-injection paravertebral block|-Videothoracoscopic-guided single-injection paravertebral block at T5 with 0.4 mL/kg of Bupivacaine 0.5% with adrenalin 5 mcg/mL (maximum 40 mL) at the beginning of surgery
62588520|NCT05656352||Pakistan Cohort|
62588521|NCT05656352||Kenya Cohort|
62588522|NCT05656352||Zambia Cohort|
62798532|NCT05083533|EXPERIMENTAL|tele-rehabilitation|For the tele-rehabilitation online group, hamstring stretching exercises were performed with cameras and mutually via online applications.
62798533|NCT05083533|ACTIVE_COMPARATOR|home exercise|The home exercise group, the exercises were conveyed in the form of a brochure, in written form, on the necessary information. It was recorded how many days the home exercise group did the exercises on a weekly basis.
62798534|NCT04354376||Loop diuretics, thiazides, dihydropyridines|Reference group
62798535|NCT04354376||Telmisartan|Exposure group
62433431|NCT05738564|ACTIVE_COMPARATOR|Group( OL) Oxymetazoline and lidocaine group|Group OL (63 patients): These patients received five drops of lidocaine hydrochloride (Xylocaine 2%, 20 mg/ml; AstraZeneca, London, UK) using a prefilled dropper, followed by six drops of hydrochloride Oxymetazoline (Otrivin adult nasal drops 0.1%, 10 ml of 1 mg/ml; Novartis Consumer Health, UK Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK) in each nostril in the pre-induction room just before the induction of anesthesia
62433432|NCT02354976|PLACEBO_COMPARATOR|Placebo|
62798536|NCT05505344||Validation lab study|All participants will have a resting and exercising electrocardiogram (ECG) trace and a lung function test, called spirometry, will be performed. They will take part in a maximal CPET to determine V̇O2 peak. Participants will also have their V̇O2 peak estimated twice, twenty minutes apart, using the VentriJect Seismofit device. A short questionnaire will be administered to explore the acceptability of completing a maximal CPET and having V̇O2 peak estimated using VentriJect Seismofit.
62798537|NCT00771888|OTHER|1|lanreotide
62798538|NCT01822457|EXPERIMENTAL|Nike FuelBand (NFB)|Patients will receive a Nike Fuel Band to encourage exercise.
62798539|NCT01822457|NO_INTERVENTION|control|Standard follow-up
62798540|NCT05295875|EXPERIMENTAL|ALT-801 Dose Level 1|
62798541|NCT05295875|EXPERIMENTAL|ALT-801 Dose Level 2|
62798542|NCT05295875|EXPERIMENTAL|ALT-801 Dose Level 3|
62417111|NCT04794582|NO_INTERVENTION|Monomax® USP 0 2 planes closure|The control group will proceed according to standard clinical practice with closure using the technique in 2 muscle-aponeurotic planes with very long-term (3 months) absorbable synthetic continuous suture of poly(4-hydroxybutyrate), monofilament, elastic (Monomax® USP 0) according to the small-bites technique. In order to achieve masking of the participating subject, a small-bore (10F) Jackson-Pratt drain connected to a vacuum system will be placed in the subcutaneous space at the end of the procedure in a manner similar to the intervention group. In both treatment groups, the subcutaneous drain will be removed on post-transplant day 2 or 3.
62223308|NCT02188420|EXPERIMENTAL|Latency minus 3ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 3ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
62223309|NCT02188420|EXPERIMENTAL|Latency minus 5ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 5ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
62417112|NCT00667134||1|Subjects with diffuse scleroderma
62417113|NCT00667134||2|Subjects with limited scleroderma
62417114|NCT00667134||3|Subjects without a fibrosing or autoimmune disease.
62588523|NCT04807205|EXPERIMENTAL|Elite IQ Laser|The Elite IQ will be used on multiple areas of the body such as, but not limited to, the face, legs, and arms.
62588524|NCT06366347|EXPERIMENTAL|Arm 1: Abemaciclib + Letrozole|"Participants will be stratified by Primary Stage IVb (4b) vs. Primary Measurable Stage III (3)/IVa (4a) vs. Recurrent Endometrial Cancer and will complete study procedures as follows:~* Baseline visit with X-ray, CT, MRI, or PET scan.~* Cycles 1 through 3:~  --Days 1 through 21 of 21 day cycle: Predetermined dose of Abemaciclib 2x per day. Predetermined dose of Letrozole 1x per day.~* Cycle 4 and every 2 cycles thereafter:~  --Days 1 through 21 of 21 day cycle: Predetermined dose of Abemaciclib 2x per day. Predetermined dose of Letrozole 1x per day.~* X-ray, CT, MRI, or PET scan every 9 weeks for first 9 months, then every 12 months.~* End of Treatment visit with assessments and X-ray, CT, MRI, or PET scan.~* Follow up for up to 3 years."
62798543|NCT05295875|PLACEBO_COMPARATOR|Placebo|
62798544|NCT00893061|EXPERIMENTAL|Arm I|Patients receive oral tamoxifen citrate once daily for 1 year in the absence of disease progression or unacceptable toxicity.
62798545|NCT00893061|EXPERIMENTAL|Arm II|Patients receive an oral aromatase inhibitor (letrozole, anastrozole, or exemestane) once daily for 1 year in the absence of disease progression or unacceptable toxicity.
62798546|NCT00918099|ACTIVE_COMPARATOR|Avaulta mesh|Avaulta mesh
62798547|NCT00918099|ACTIVE_COMPARATOR|Anterior repair|Anterior repair
62798548|NCT00664885|EXPERIMENTAL|CSCT|
62223310|NCT02188420|EXPERIMENTAL|Latency minus 7ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 7ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
62223311|NCT02188420|ACTIVE_COMPARATOR|Latency plus 100ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency + 100ms), known to have no effect, where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
62223312|NCT02576301|EXPERIMENTAL|Phase 2 AML|OXi4503 at MTD plus cytarabine 1g/m2/day
62417115|NCT04637282|EXPERIMENTAL|PLX-200|This is randomized, placebo-controlled comparator study of PLX-200 in patients with CLN3 disease.
62417116|NCT04637282|PLACEBO_COMPARATOR|Placebo|This is randomized comparator study of PLX-200 vs. placebo in a 2:1 ratio in patients with CLN3 disease.
62588525|NCT06366347|EXPERIMENTAL|Arm 2: Pembrolizumab Every 3 Weeks|"Participants will be stratified by Primary Stage IVb (4b) vs. Primary Measurable Stage III (3) /IVa (4a) vs. Recurrent Endometrial Cancer and will complete study procedures as follows:~* Baseline visit with X-ray, CT, MRI, or PET scan.~* Predetermined dose of Pembrolizumab 1x every 3 weeks for up to 2 years.~* X-ray, CT, MRI, or PET scan every 9 weeks for first 9 months, then every 12 months.~* End of Treatment visit with assessments and X-ray, CT, MRI, or PET scan.~* Follow up for up to 3 years."
62798549|NCT00631904||Single Observation|Patients with permanent pacemakers undergoing medically indicated MRI scanning.
62798550|NCT02497183|EXPERIMENTAL|first|a repeat abdominal ultrasound exam to patients following the filling of bowel with contrast material per os.
62798551|NCT01534000|ACTIVE_COMPARATOR|CT guided group|For Patients with chest pain randomised to this arm, clinical decision will be based on the results of a Cardiac computed tomographic angiography (CCTA)
62223313|NCT02576301|EXPERIMENTAL|Phase 2 MDS|OXi4503 at MTD plus cytarabine 1g/m2/day
62433433|NCT02354976|EXPERIMENTAL|Omega-3 carboxylic acids 4g / day|
62798552|NCT01534000|NO_INTERVENTION|Control group|Patients with chest pain randomised to the control group will be evaluated using the standard functional-based strategy with either a treadmill stress-test or SPECT (single-photon emission computed tomography). A Cardiac CT will will be performed, but will be blinded for initial clinical evaluation.
62798553|NCT04108611|EXPERIMENTAL|systemic lupus in activity|Sixty systemic lupus patients in activity will receive conventional therapy (47 patient as cases 1) and immunadsortion (13 patients as cases 2) will be provided to the non responders
62798554|NCT04108611|OTHER|Control group 30 subjects|controls 1 (20 healthy volunteers, controls 2 (10 patients with glomerular diseases other than lupus) will do routine laboratory investigations
62798555|NCT02361333|EXPERIMENTAL|Teaching Intervention|Patients will be taught how to install and use a remote monitor.
62798556|NCT02361333|NO_INTERVENTION|No Intervention|Patients will not be taught how to install and use a remote monitor
62798557|NCT05273320|EXPERIMENTAL|Open Label|"Titration: Nabilone p.o., increased in 0.25 mg increments every 2 days to a maximum of 1 mg b.i.d.~Open label: Nabilone p.o. at maximum dose tolerated for 28 days Tapering: Nabilone p.o. decreased in 0.25 decrements per day"
62417117|NCT02362646|EXPERIMENTAL|MPC Intramyocardial Injection|Intramyocardial injections of 150 million MPCs
62417118|NCT02362646|SHAM_COMPARATOR|Control Solution|Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
62417119|NCT01072318|EXPERIMENTAL|Letrozole, DFS|Efficacy evaluation of extended letrozole after 5 year fareston use
62417120|NCT06700876||160 End-stage renal disease patients|End-stage renal disease on renal replacement therapy (hemodialysis or peritoneal dialysis) or status-post-living donor or deceased donor kidney transplantation aged more than or equal 18 years
62417121|NCT03533829|ACTIVE_COMPARATOR|Buzzy®|Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
62417122|NCT03533829|ACTIVE_COMPARATOR|Music|Music will be selected and listened to as a distraction before and during vaccination.
62417123|NCT03533829|ACTIVE_COMPARATOR|Buzzy® and Music|Buzzy® will be applied to the arm prior to and during vaccination and music will be selected and listened to before and during vaccination.
62417124|NCT01216319|EXPERIMENTAL|Nipple Reconstruction Cylinder|
62417125|NCT06700694|EXPERIMENTAL|Technology-assisted early mobilization group|Participants in the technology-assisted early mobilization group will receive protocol-oriented early mobilization program and technology-assisted, family-engaged in-bed activities within 72 hours of ventilator use.
62417126|NCT06700694|ACTIVE_COMPARATOR|Systematic early mobilization group|Participants allocated to the systematic early mobilization group will receive the same protocol-oriented early mobilization program within 72 hours of ventilator use.
62417127|NCT06700694|NO_INTERVENTION|Usual care group|Participants in the usual care group will receive routine rehabilitation treatment.
62417128|NCT04762316|EXPERIMENTAL|SB-UF Drug|Use SB-UF drugs to lose the size of Uterine Fibroids on Women the Pregnancy. Measuring the size of uterine fibroid. Monitor the disappearance of uterine fibroids from 4 - 40 weeks
62417129|NCT04762316|PLACEBO_COMPARATOR|SB-UF Placebo|Use SB-UF placebo to lose the size of Uterine Fibroids on Women the Pregnancy. Measuring the size of uterine fibroid. Monitor the disappearance of uterine fibroids from 4 - 40 weeks
62417130|NCT05887973||Wave 1|Youth participants who are enrolled in The T.R.I.G.G.E.R Project's summer youth employment program in 2022
62417131|NCT05887973||Wave 2|Youth participants who are enrolled in The T.R.I.G.G.E.R Project's summer youth employment program in 2023
62417132|NCT05887973||Wave 3|Youth participants who are enrolled in The T.R.I.G.G.E.R Project's summer youth employment program in 2024
62417133|NCT05887973||Wave 4|Youth participants who are enrolled in The T.R.I.G.G.E.R Project's summer youth employment program in 2025
62417134|NCT03368872|EXPERIMENTAL|Astaxanthin and exercise|Astaxanthin formulation intake for one month followed by a 3-month exercise training program with astaxanthin formulation intake.
62417135|NCT03368872|PLACEBO_COMPARATOR|Placebo and exercise|Placebo intake for one month followed by 3-month exercise training with placebo intake.
62417136|NCT01861600|EXPERIMENTAL|Experimental (EF) 1|For 8 weeks, infants will consume ad libitum per day S-26 Gold EF1
62417137|NCT01861600|ACTIVE_COMPARATOR|Standard Formula|For 8 weeks, infants will consume ad libitum per day. S-26 Gold
62417138|NCT01861600|EXPERIMENTAL|Experimental 2 (EF2) S-26 Gold|For 8 weeks, infants will consume ad libitum per day. S-26 Gold EF2
62417139|NCT01861600|OTHER|Human milk (HM)|For 8 weeks, infants will consume ad libitum per day. Human Milk
62223314|NCT02576301|EXPERIMENTAL|OXi4503 dose escalation|MTD for OXi4503 will be determined
62417140|NCT01861600|EXPERIMENTAL|Experimental formula (EF) 3|For 8 weeks, infants will consume ad libitum per day. S-26 Gold EF3
62417141|NCT03509688|EXPERIMENTAL|entecavir|drug:entecavir 0.5mg/day, one time/day,144weeks
62417142|NCT03509688|EXPERIMENTAL|entecavir+resveratrol|entecavir 0.5mg/day, 144weeks intervention:resveratrol 1000mg/day, 48weeks
62417143|NCT03509688|EXPERIMENTAL|entecavir+thymosin α1|entecavir 0.5mg/day, 144weeks thymosin α1 2 times/week, 24weeks
62417144|NCT01542879|EXPERIMENTAL|WB-DW-MR scan|simultaneous WB-DW-MR scan and 18-F FDG PET scan
62417145|NCT06702982|EXPERIMENTAL|Enrolled participants|The intervention administered in this study was a tele-nursing educational program aimed at improving cancer patients' management of chemotherapy-related symptoms and enhancing their quality of life. The program was delivered via a Telegram group, which provided a platform for regular interaction between the patients and nursing staff. The educational content was designed to address common chemotherapy-related symptoms, such as nausea, fatigue, pain, and loss of appetite, and to provide guidance on managing these symptoms effectively.
62417146|NCT00331604|EXPERIMENTAL|A|
62417147|NCT00331604|ACTIVE_COMPARATOR|B|
62417148|NCT00331604|ACTIVE_COMPARATOR|C|
62417149|NCT01802762|OTHER|NeMo Patch and NeMo Probe|TBI and SAH patients, one arm
62417150|NCT04165317|EXPERIMENTAL|PF-06801591 + BCG induction and maintenance|PF-06801591 in combination with Bacillus Calmette Guerin(induction+maintenance).
62417151|NCT04165317|EXPERIMENTAL|PF-06801591 + BCG induction only|PF-06801591 in combination with Bacillus Calmette Guerin (induction only).
62417152|NCT04165317|ACTIVE_COMPARATOR|BCG induction and maintenance|Bacillus Calmette Guerin (induction and maintenance).
62798558|NCT02707146|EXPERIMENTAL|Tablet in the waiting room|"Patients in the intervention arm will be met in the waiting room prior to their primary care visit and will use the Visit Planner tool application on the tablet"
62223315|NCT02576301|EXPERIMENTAL|OXi4503 + cytarabine dose escalation|MTD of the combination of OXi4503 + cytarbine will be determined
62223316|NCT04383808|EXPERIMENTAL|Arm-1|20 participants will be recruited, inject with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.
62223317|NCT04383808|EXPERIMENTAL|Arm-2|20 participants will be recruited from other imaging studies that have been already injected (pre-injected) with a radiopharmaceutical. These subjects wont receive an additional injection of radiopharmaceutical.
62417153|NCT04165317|EXPERIMENTAL|BCG Unresponsive CIS|PF-06801591
62798559|NCT02707146|ACTIVE_COMPARATOR|Health Education Handout|Patients in the control arm will be met in the waiting room prior to their primary care visit and will be given an educational pamphlet on health lifestyle to review
62223318|NCT04258501|EXPERIMENTAL|Mulberry fruit extract|1.5 g of mulberry fruit powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
62223319|NCT04258501|EXPERIMENTAL|Mulberry leaf extract|1.0 g of mulberry leaf powdered extract mixed into aa bowl containing 60 g of extruded rice + 300 ml of boiling water
62223320|NCT04258501|EXPERIMENTAL|White bean extract|3 g of white bean powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
62417154|NCT04165317|EXPERIMENTAL|BCG Unresponsive NMIBC|PF-06801591
62417155|NCT03473145|ACTIVE_COMPARATOR|Health Living Attention Control|Participants in the attention control condition will receive a healthy aging educational intervention. This group will receive one in-person health coaching sessions and 6 phone counseling sessions.
62417156|NCT03473145|EXPERIMENTAL|Reduce Sitting|Participants in the Reduce Sitting condition will receive an intervention aimed at reducing daily sitting time. This group will receive five in-person health coaching sessions and two phone counseling sessions.
62223321|NCT04258501|EXPERIMENTAL|Apple extract|2 g of apple powdered extract standardized in phloridzin mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
62417157|NCT03473145|EXPERIMENTAL|Sit-to-Stand Transition|Participants in the Sit-to-Stand Transition condition will receive an intervention aimed at increasing the daily number of brief sit-to-stand transitions. This group will receive five in-person health coaching sessions and two phone counseling sessions.
62798560|NCT01951651|EXPERIMENTAL|Exenatide|Exenatide 10 micrograms injected subcutaneously twice daily for 6 months
62798561|NCT01951651|EXPERIMENTAL|Glipizide|Glipizide 5 mg (tablet), one tablet twice daily orally for 6 months
62223322|NCT04258501|EXPERIMENTAL|Elderberry extract|2 g of elderberry powder extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
62223323|NCT04258501|EXPERIMENTAL|Turmeric extract|0.18 g of curcumin powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
62223324|NCT04258501|EXPERIMENTAL|Turmeric extract + Apple extract|0.18 g of curcumin powdered extract + 2 g of apple powdered extract standardized in phloridzin mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
62223325|NCT04258501|EXPERIMENTAL|Turmeric extract + Elderberry extract|0.18 g of curcumin powdered extract + 2 g of elderberry powder extract mixed into aa bowl containing 60 g of extruded rice + 300 ml of boiling water
62223326|NCT04258501|PLACEBO_COMPARATOR|Rice porridge control|Bowl containing 60 g of extruded rice + 300 ml of boiling water
62417158|NCT06420323||Treatment with NovoX® Cup|Patient gets treated with NovoX® Cup for 2 weeks.
62417159|NCT06420323||Treatment with Omnistrip®|Patient gets treated with Omnistrip® for 2 weeks.
62417160|NCT05430308|EXPERIMENTAL|Chlorhexidine-alcohol scrub|The surgical site selected for performing the thoracoscopy will be cleaned with 4%w/v chlorhexidine gluconate solution for 3 minutes. This will then be washed with normal saline and a sterile gauge. After drying chlorhexidine gluconate (2.5%v/v)-ethanol IP (70%v/v) will be applied and allowed to dry for 3 minutes before the incision.
62433434|NCT02354976|ACTIVE_COMPARATOR|Fenofibrate 200mg|
62798562|NCT01270178||Entecavir|
62798563|NCT06504810|PLACEBO_COMPARATOR|placebo group|
62417161|NCT05430308|ACTIVE_COMPARATOR|Povidone-iodine|The surgical site selected for performing the thoracoscopy will be just cleaned with normal saline followed by 10% w/v povidone-iodine solution and would be allowed to dry for 3 minutes before the incision
62588526|NCT06366347|EXPERIMENTAL|Arm 2B: Pembrolizumab Every 6 Weeks|"Participants will be stratified by Primary Stage IVb (4b) vs. Primary Measurable Stage III (3) /IVa (4a) vs. Recurrent Endometrial Cancer and will complete study procedures as follows:~* Baseline visit with X-ray, CT, MRI, or PET scan.~* Predetermined dose of Pembrolizumab 1x every 6 weeks for up to 2 years.~* X-ray, CT, MRI, or PET scan every 9 weeks for first 9 months, then every 12 months.~* End of Treatment visit with assessments and X-ray, CT, MRI, or PET scan.~* Follow up for up to 3 years."
62588527|NCT01662791|EXPERIMENTAL|Case Group|All individuals in the Case group (i.e., only the subjects who had lost weight) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO twice a day (BID) for 14 days. Subjects in the case group were in the study for 3 months.
62588528|NCT01662791|NO_INTERVENTION|Control Group|This arm consisted of subjects with Parkinson's Disease who had not experienced significant weight loss. These patients were in the study for one day.
62588529|NCT01472016|EXPERIMENTAL|Cohort A|ABT-700 will be administered by intravenous infusion at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-700.
62025618|NCT02312739|ACTIVE_COMPARATOR|Vicodin, Lorazepam and Oxygen|"Patients in this group will receive the Standard Oral Pain Medications consisting of Vicodin and Lorazepam, as well as intramuscular ketorolac at least 30 minutes prior to the procedure. Oxygen via scented mask will also given.~All participants randomized to this group will undergo in-office transcervical sterilization (Essure® procedure ) using standard technique."
62025619|NCT02312739|EXPERIMENTAL|Placebo pills and Nitrous Oxide|"Patients in this group will receive two placebo pills, as well as intramuscular ketorolac at least 30 minutes prior to the procedure. Nitrous oxide will be administered during the procedure via scented mask.~All participants randomized to this group will undergo in-office transcervical sterilization (Essure® procedure ) using standard technique."
62025620|NCT02571218|ACTIVE_COMPARATOR|mCPVA|"Subjects in the mCPVA arm will undergo intervention called modified circumferential pulmonary vein ablation, which is considered to be the standard ablation treatment for AF."
62223327|NCT00452426|EXPERIMENTAL|Sedation System|Computer-Assisted Personalized Sedation (CAPS) device used for delivery of sedation
62223328|NCT00452426|ACTIVE_COMPARATOR|Current Standard of Care|Site's current standard used for delivery of sedation
62417162|NCT04332835|EXPERIMENTAL|Intervention Group|Participants included in the experimental group will receive 500 milliliters of convalescent plasma, distributed in two 250 milliliters transfusions on the first and second day after starting the protocol. Simultaneously, they will receive the standard therapy defined by institutional protocol.
62417163|NCT04332835|ACTIVE_COMPARATOR|Control Group|Participants included in the control group will receive standard therapy defined by institutional protocol.
62417164|NCT06009159|EXPERIMENTAL|Transcutaneous Vagus Nerve Stimulation(tVNS)|receive tVNS 30 minutes per session, twice/day for 4 weeks and maintain regular medication treatment without change.
62588530|NCT01472016|EXPERIMENTAL|Cohort B|ABT-700 plus docetaxel.
62588531|NCT01472016|EXPERIMENTAL|Cohort C|ABT-700 plus FOLFIRI/cetuximab
62588532|NCT01472016|EXPERIMENTAL|Cohort D|ABT-700 plus erlotinib
62588533|NCT06111105||Colorectal cancer stage III|
62588534|NCT06111105||Colorectal cancer liver metastasis|
62223329|NCT05217498|EXPERIMENTAL|Istradefylline+low oxygen training|"Drug: Nourianz Other Names: KW6002, Istradefylline~Participants enrolled in this study arm will ingest a 20mg tablet/day containing istradefylline starting 14 days prior to the first low oxygen therapy and continuing for 14 additional days. Participants will consume a total of 28 istradefylline tablets.~Other: low oxygen training Other Names: therapeutic intermittent hypoxia, acute intermittent hypoxia~Participants will breathe 15 episodes/session of acute low oxygen via an automated air generator system (4 sessions/week x 2 weeks). During the 90-second episodes of low oxygen, air concentrations will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia) with 60-second room-air intervals (FIO2 0.21±0.02).~Throughout experimentation, blood pressure, respiratory rate, and heart rate will be monitored. We also will assess for changes in sleep quality and pain level."
62417165|NCT06009159|NO_INTERVENTION|Sham Control group|receive sham point stimulation 30 minutes per session, twice/day for 4 weeks and maintain regular medication treatment without change.
62417166|NCT01317069|EXPERIMENTAL|Fluorouracil implant|
62025621|NCT02571218|EXPERIMENTAL|Substrate+mCPVA|Subjects in the Substrate+mCPVA arm will undergo intervention of substrate mapping and substrate-targeted ablation guided by the investigational device, followed by completion of modified circumferential pulmonary vein ablation.
62025622|NCT05846516|EXPERIMENTAL|Cohort A|
62025623|NCT05846516|EXPERIMENTAL|Cohort B|
62417167|NCT03366155|EXPERIMENTAL|1/ Arm 1|HAIP chemotherapy + Systemic chemotherapy
62417168|NCT05269615|ACTIVE_COMPARATOR|Valsartan tablets|
62417169|NCT05269615|PLACEBO_COMPARATOR|Placebo tablets|
62417170|NCT05179486||Observational (biospecimen collection, questionnaire)|Participants complete a questionnaire over 20 minutes. Participants also undergo collection of blood and leftover tissue samples.
62433435|NCT01754181|EXPERIMENTAL|Proposed treatment by Diabeloop algorithm|the insulin dose is calculated by the algorithm based on the usual treatment of the patient, the ratio I / C, the intensity of physical activity and blood glucose sensor.
62433436|NCT01754181|NO_INTERVENTION|usual treatment|
62433437|NCT05549128|EXPERIMENTAL|photobiomodulation|laser therapy application for 10 minutes
62588535|NCT04560972|EXPERIMENTAL|Treatment (LB-100, carboplatin, etoposide, atezolizumab)|"INDUCTION: Patients receive LB-100 IV over 15 minutes on days 1 and 3, atezolizumab IV over 30-60 minutes on day 1, carboplatin IV over 30-60 minutes on day 1, and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: After completion of induction therapy, patients receive LB-100 IV over 15 minutes on days 1 and 3 and atezolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
62798564|NCT06504810|EXPERIMENTAL|experimental group|
62025624|NCT05846516|EXPERIMENTAL|Cohort C Treatment|
62798565|NCT02996630|OTHER|Healthy fetuses|Pregnant patients carrying a healthy fetus. Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging and bailey test.
62798566|NCT02996630|OTHER|Congenital Hearth Disease|Pregnant patients carrying a fetus with a moderate-severe congenital heart disease Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging, Surgical intervention, brain monitoring and bailey test.
62223330|NCT05217498|ACTIVE_COMPARATOR|Placebo+low oxygen training|"This is a placebo counterpart to the istradefylline drug.~Participants enrolled in this study arm will ingest a 20mg placebo tablet/day containing dextrose starting 14 days prior to the first low oxygen therapy (LOT) and continuing for 14 additional days. Participants will consume a total of 28 placebo tablets.~Other: low oxygen training Other Names: therapeutic intermittent hypoxia, acute intermittent hypoxia~Participants will breathe 15 episodes/session of acute low oxygen via an automated air generator system (4 sessions/week x 2 weeks). During the 90-second episodes of low oxygen, air concentrations will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia) with 60-second room-air intervals (FIO2 0.21±0.02).~Throughout experimentation, blood pressure, respiratory rate, and heart rate will be monitored. We also will assess for changes in sleep quality and pain level."
62433438|NCT05549128|SHAM_COMPARATOR|Sham photobiomodulation|sham laser therapy application for 10 minutes
62588536|NCT02076893|ACTIVE_COMPARATOR|Tramadol/gabapentin/ibuprofen|(A) Scheduled tramadol 1mg/kg Q6h \[max. 50mg\] for 5 days; plus tramadol 1mg/kg Q6h PRN \[max. 50mg\] for 5 days (B) Scheduled gabapentin 3 mg/kg \[max 150 mg\] Q6h for 5 days (C) PRN ibuprofen 10 mg/kg \[max. 500 mg\] Q6h PRN
62433439|NCT02972151|EXPERIMENTAL|Comprehensive treatment of TCM|The intervention is Comprehensive treatment of TCM,which including Oral medicine ,tradition chinese medicine enema, external treatment.
62588537|NCT02076893|PLACEBO_COMPARATOR|Tramadol/placebo/ibuprofen|(A) Scheduled tramadol 1mg/kg Q6h \[max. 50mg\] for 5 days; plus tramadol 1mg/kg Q6h PRN \[max. 50mg\] for 5 days (B) Scheduled placebo of same volume Q6h for 5 days (C) PRN ibuprofen 10 mg/kg \[max. 500 mg\] Q6h PRN
62025625|NCT05846516|NO_INTERVENTION|Cohort C Observational|
62433440|NCT02972151|ACTIVE_COMPARATOR|Expectant therapy|"Expectant treatment group patients were not treated during the observation period.~（3 months after the start of the trial and 1 months after the end of the trial.）"
62798567|NCT00269919|EXPERIMENTAL|Risperidone Long-Acting Injectable (RLAI)|The RLAI 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 2 years.
62798568|NCT02609061|ACTIVE_COMPARATOR|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
62798569|NCT02609061|ACTIVE_COMPARATOR|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
62798570|NCT02609061|ACTIVE_COMPARATOR|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate for treating furcation defect
62798571|NCT03754348|EXPERIMENTAL|NT1 group|hypothalamus neuroinflammation evaluation in Narcoleptic patients
62798572|NCT03754348|OTHER|Control group|hypothalamus neuroinflammation evaluation in control patients (patients without hypersomnia or inflammatory pathology)
62025626|NCT04992715|EXPERIMENTAL|Metastatic Non-Small Cell Lung Cancer|"Subjects with metastatic non-small cell lung cancer will be recruited as per protocol inclusion/exclusion criteria and will undergo \[99mTc\]-anti-PDL1 single-domain antibody (\[99mTc\]-NM-01) SPECT/CT imaging.~\[99mTc\]-NM-01 SPECT/CT images will be compared to immunohistochemistry PD-L1 expression results."
62025627|NCT01204190|EXPERIMENTAL|Arm 1|
62025628|NCT01204190|EXPERIMENTAL|Arm 2|
62025629|NCT01204190|EXPERIMENTAL|Arm 3|
62025630|NCT00202670||1|SPECT
62025631|NCT00202670||2|dobutamine echocardiography
62798573|NCT03754348|EXPERIMENTAL|KLS group|hypothalamus neuroinflammation evaluation in Kleine-Levin syndrome patients
62025632|NCT05954143|EXPERIMENTAL|BDC-1001 Single Agent|BDC-1001 administered intravenously (IV) every 2 weeks
62025633|NCT05954143|EXPERIMENTAL|BDC-1001 in Combination With Pertuzumab|BDC-1001 administered intravenously (IV) every 2 weeks, in combination with pertuzumab administered intravenously (IV) as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose every 3 weeks.
62025634|NCT01598480|ACTIVE_COMPARATOR|Control|Flamazine is applied on the wound in the control group instead and then covered with sterile gauze.
62025635|NCT01598480|EXPERIMENTAL|BCT Antimicrobial Dressing|The wound in the experimental group is first cleansed with normal saline and then applied with BCT Antimicrobial Dressing and covered by sterile gauze, and dressings will be changed every 3 days.
62025636|NCT04255160|EXPERIMENTAL|Estradiol|Transdermal estradiol (0.1mg/day patch)
62025637|NCT04255160|PLACEBO_COMPARATOR|Placebo|Placebo
62025638|NCT01126983|EXPERIMENTAL|Non-Suture|No suture will be used to secure the leads. Benzoin and Steri-Strips will be used like in the other two arms.
62025639|NCT06213883|EXPERIMENTAL|Response to Exercise and Rest|Study participants undergo Prescribed Exercise, Self-Paced Exercise, and Rest conditions over the course of 3 study days
62025640|NCT02685254|EXPERIMENTAL|Initial group therapy|'Structural skills training group' - Start up with weekly structured skills training group for 14 weeks supplemented by homework training
62025641|NCT02685254|OTHER|Initial control condition|Treatment as usual/clinical management the first 15 weeks pending deferred start of group therapy (partially cross-over)
62025642|NCT02205710|EXPERIMENTAL|Computerized cognitive training|Series of gamified tasks.
62025643|NCT02205710|PLACEBO_COMPARATOR|Computerized game training|Series of gamified tasks.
62025644|NCT05006170|EXPERIMENTAL|6 to below 10 kg weight band|Children with perinatal HIV infection whose weight from 6 kg to below 10 kg
62025645|NCT05006170|EXPERIMENTAL|10 to below 14 kg weight band|Children with perinatal HIV infection whose weight from 10 kg to below 14 kg
62025646|NCT05006170|EXPERIMENTAL|14 to below 20 kg weight band|Children with perinatal HIV infection whose weight from 14 kg to below 20 kg
62025647|NCT02692300|NO_INTERVENTION|Control Group|Patients will undergo standard anesthesia and will be blinded to EEG-based data, as per standard of care in this patient population.
62025648|NCT02692300|EXPERIMENTAL|EEG-Guided Group|Practitioners will follow the EEG-Guided protocol to limit the incidence of EEG burst suppression by decreasing administration of anesthesia. The EEG-guided protocol is suggestive rather than prescriptive, and practitioners will exercise judgment depending on the clinical situation.
62025649|NCT04239313|EXPERIMENTAL|Population I|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of low dose vaccine.
62798574|NCT01091779||Hypertensive and normotensive|
62798575|NCT00977626|EXPERIMENTAL|Part 1 AZD2423 or Placebo|AZD2423 or Placebo Oral Solution, multiple dosing during 10-14 days
62798576|NCT00977626|EXPERIMENTAL|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
62223331|NCT05217498|ACTIVE_COMPARATOR|Istradefylline+SHAM|"Drug: Nourianz Other Names: KW6002, Istradefylline~This is a SHAM counterpart to low oxygen therapy.~Participants enrolled in this study arm will ingest a 20mg tablet/day containing istradefylline starting 14 days prior to the first SHAM therapy and continuing for 14 additional days. Participants will consume a total of 28 istradefylline tablets.~Participants will breathe 15 episodes/session of SHAM via an automated air generator system (4 sessions/week x 2 weeks). The system will fill reservoir bags attached to a non-rebreathing face mask. During the 90-second episodes of SHAM, air concentrations will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.21±0.02 (normoxia) with 60-second room-air intervals (FIO2 0.21±0.02).~Throughout experimentation, blood pressure, respiratory rate, and heart rate will be monitored. We also will assess for changes in sleep quality and pain level."
62223332|NCT01877772|ACTIVE_COMPARATOR|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
62223333|NCT01877772|ACTIVE_COMPARATOR|Control|The control group will undergo standard rotator cuff repair.
62223334|NCT05934786|ACTIVE_COMPARATOR|Early intervention group|The intervention is planned to consist of six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months (8 weeks) per patient).
62223335|NCT05934786|ACTIVE_COMPARATOR|late intervention group|For 8 weeks this group will receive the usual treatment, then, after repeated cognitive evaluation, will receive the same intervention: six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months per patient).
62223336|NCT01449149|EXPERIMENTAL|Proton group|Proton radiation total dose 72.00 to 79.2 Gy(RBE) in 40-44 fractions
62223337|NCT06122480|EXPERIMENTAL|Treatment arm liver/lung oligometastasis|Eligible patients with hepatic or pulmonary oligometastatic adenocarcinoma of the pancreas must have received neoadjuvant FOLFIRINOX chemotherapy in cycles of 14 days, or other clinically indicated alternative. FOLFIRINOX is not a study treatment. Patients with pulmonary metastasis with tumor response or stable disease and a resectable primary tumor after the first 4 cycles can undergo resection of the primary tumor followed by resection of pulmonary metastases or vice versa, if feasible.Patients with hepatic metastasis with tumor response or stable disease and a resectable primary tumor can undergo explorative laparotomy and synchronous resection of the tumor and hepatic metastases, if feasible. In patients who undergo exploratory laparotomy and are deemed to have unresectable disease by the surgeon, the patient may receive 4 more cycles of neoadjuvant chemotherapy 2-4 week after surgery, before the patient will be re-evaluated for the eligibility for the Study Entry Screening.
62223338|NCT02785471|ACTIVE_COMPARATOR|Screening for Mental Health only|Participants in the Screening for Mental Health only (control) group will complete the online depression and suicide screening and receive immediate feedback and referrals.
62223339|NCT02785471|EXPERIMENTAL|Screening for Mental Health & Man Therapy|Participants assigned to Screening for Mental Health \& Man Therapy (intervention) group will be offered the Man Therapy program in conjunction with Screening for Mental Health.
62223340|NCT05356104|ACTIVE_COMPARATOR|Exenatide extended release|Prescribe study drug: Exenatide extended release. The dosage and frequency is 2mg once weekly via subcutaneous injection for 78 weeks
62223341|NCT05356104|NO_INTERVENTION|Standard of care|Standard medical therapy
62223342|NCT04621318|EXPERIMENTAL|SB16|SB16 (proposed denosumab biosimilar)
62223343|NCT04621318|ACTIVE_COMPARATOR|EU Prolia|EU sourced Prolia (denosumab)
62223344|NCT04621318|ACTIVE_COMPARATOR|US Prolia|US sourced Prolia (denosumab)
62223345|NCT02824419|EXPERIMENTAL|C11-methionine|To compare FDG and C11-methionine in the detection of sarcoidotic lesions.
62223346|NCT02824419|EXPERIMENTAL|68Ga-Dotanoc|To compare FDG and 68Ga-DOTANOC in the detection of sarcoidotic lesions.
62223347|NCT04318067|EXPERIMENTAL|Sleep problems i Attention Deficit Hyperactivity Disorder|Children age 6 to 12 years having ADHD and Sleeping problem will be treated with Melatonin 3 mg one a day (before bedtime)
62223348|NCT02784054|EXPERIMENTAL|Intracranial NGGCT|"1. Six cycles of chemotherapy with carboplatin, etoposide, bleomycin (CEB) and cyclophosphamide, etoposide, bleomycin (CyEB) regimen.~2. Peripheral blood stem cell collection during the first cycle of chemotherapy.~3. Surgery, if there is residual tumor after chemotherapy.~4. Tandem high dose chemotherapy (HDCT) and autologous stem cell transplantation (auto-SCT)~   * 1st HDCT: Carboplatin, thiotepa, etoposide~  * 2nd HDCT: Cyclophosphamide, melphalan~5. Reduced dose of radiotherapy"
62223349|NCT05606731|EXPERIMENTAL|Intervention Group|"The study's intervention is a parenting/caregiver training program that includes 1-month of weekly in-person sessions plus multi-media interactive text messaging. The weekly 1-hour-in-person sessions will be coupled with four interactive messages per week for a period of 4 weeks total, followed by booster text messages after completing the 4-week program."
62223350|NCT05606731|NO_INTERVENTION|Usual Care|"Usual care for caregivers of 2- to-5-year-olds will include the Women Infant and Children services : (1) monthly vouchers for nutritious food; (2) individual nutrition counseling at least twice per year; (3) nutrition education two times per year (1:1 counseling or online health education modules); and (4) referrals to family services."
62798577|NCT00977626|EXPERIMENTAL|Part 3 - AZD2423|AZD2423 Oral solution single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
62223351|NCT00577837|ACTIVE_COMPARATOR|1|5 mg risedronate, once daily for 6 months
62798578|NCT01974830||Adult Alpha-1 Patients|Adult Alpha-1 patients receiving augmentation therapy in the home through Coram
62223352|NCT00577837|EXPERIMENTAL|2|100 mg risedronate, once a month for 6 months
62223353|NCT00577837|EXPERIMENTAL|3|150 mg risedronate, once a month for 6 months
62798579|NCT01934491|EXPERIMENTAL|Cognitive Training A|emotional memory training exercise
62798580|NCT01934491|ACTIVE_COMPARATOR|Cognitive Training B|memory training exercise
62798581|NCT06185582|EXPERIMENTAL|Pain|A thermode stimulator of 3x3 cm will be placed on the areas and kept in place by means of Velcro tape. The temperature raises 1°C per second from a starting temperature of 32°C until itch reach or 46.5 °C. This temperature will be maintained for 2 minutes. Then the temperature will return to baseline temperature at a rate of 5°C /s.
62025650|NCT04239313|ACTIVE_COMPARATOR|Population II|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of low dose adjuvant.
62025651|NCT04239313|PLACEBO_COMPARATOR|Population III|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of placebo.
62025652|NCT01990235|EXPERIMENTAL|PREPARE intervention|The PREPARE arm will review the PREPARE website plus the easy-to-read advance directive (AD). Participants will review PREPARE on their own for ≥ 20 minutes with staff present to answer questions. During PREPARE, participants answer preference questions and make an action plan (i.e., commitment to engage in advance care planning). To ensure home access to PREPARE content, participants will be given a website login and PREPARE content in digital video disc (DVD), booklet, and pamphlet format as well as the action plan and AD. One to three days before a primary care visit, the PREPARE arm will receive a reminder to come to their appointment and to bring their action plan.
62025653|NCT01990235|NO_INTERVENTION|Control|The Control arm will review an easy-to-read AD. Controls will review the AD for ≥ 15 minutes with study staff present to answer questions and will take the AD home to complete if desired. One to three days before a primary care visit, controls will receive a reminder to come to their appointment.
62025654|NCT05397522|EXPERIMENTAL|Experimental group 1: Supervised Exercise by a physiotherapist via face to face|Participants in this group will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via face to face. The exercises will focus on breathing exercises, passive range of motion exercises within the pain limit for the joints associated with the surgery area, and strengthening exercises for the non-surgical areas.
62025655|NCT05397522|EXPERIMENTAL|Experimental group-2: Supervised Exercise by a physiotherapist via video conference|Participants in this group will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via video conference. The exercises will focus on breathing exercises, passive range of motion exercises within the pain limit for the joints associated with the surgery area, and strengthening exercises for the non-surgical areas.
62025656|NCT05397522|NO_INTERVENTION|Control group: Unsupervised exercise|Home based exercises will be explained to the patients and they will be asked to perform these exercises 2 days a week for 6 weeks.
62025657|NCT02504632|EXPERIMENTAL|test group|Patient with severe, symptomatic AS (Aortic valve area \< 0,6 cm2/m2 SC), deemed, after multidisciplinary heart team evaluation, contra-indicated or at high risk for surgery and suitable for TF TAVI with a MCV prosthesis.
62223354|NCT00577837|EXPERIMENTAL|4|200 mg risedronate, once a month for 6 months
62223355|NCT02717572|EXPERIMENTAL|FDG-PET/CT and FDG-PET/MR|"* 10 mCI fludeoxyglucose IV bolus approximately 60 minutes before first PET/CT~* Immediately following PET/CT scan, the participant will be moved to PET/MR scanner~* The scans will take place at baseline and also one more time point between Day 1 and Day 7. There needs to be at least 24 hours between the baseline and repeat imaging"
62223356|NCT04600492|ACTIVE_COMPARATOR|Active Comparator: Active drug group Riociguat|Riociguat 0.5mg、1.0mg、2.5mg
62223357|NCT04600492|PLACEBO_COMPARATOR|Placebo group|Placebo 0.5mg、1.0mg、2.5mg
62588538|NCT04144543|EXPERIMENTAL|White Noise|"The white noise used in our study is a fragment called Bebeğiniz ağlamasın-2 from Kolik album of Buzuki Orhan Osman, which was used in similar studies (Balci, 2006; Karakoc \& Turker, 2014; Kucukoglu et al., 2016).Since the white noise is a continuously monotonous sound, which is in the form of a hum, it resembles the sounds in mother's womb (Balci, 2006)."
62223358|NCT01209780|EXPERIMENTAL|TIV (3-8 years)|Non-Naive subjects received one dose and naive subjects received two doses, administered 4 weeks apart, of investigational trivalent influenza vaccine (TIV)
62223359|NCT01209780|ACTIVE_COMPARATOR|Control TIV (3-8 years)|Non-Naive subjects received one dose and Naive subjects received two doses, administered 4 weeks apart, of control vaccine. Subjects aged 3 to \<4 years and subjects aged 4 to 8 years received different control TIV.
62223360|NCT01209780|EXPERIMENTAL|TIV ( 9-17 years)|All subjects received one dose of investigational TIV. The subjects in this cohort were included only for safety analysis.
62223361|NCT01209780|ACTIVE_COMPARATOR|Control TIV ( (9-17 years)|All subjects received one dose of the control vaccine. The subjects from this cohort were included only for safety analysis.
62223362|NCT04602416||Control (Health)|The control had two sessions: the Introduction and another on Health. The health sessions were based on topics used by United States Peace Corps medical officers training volunteers about how to stay healthy in Tanzania: nutrition, worms, HIV/AIDS, and first aid.
62223363|NCT04602416||Entrepreneurship|The sessions for this arm were six: the two sessions of the Control arm, plus Sources of Capital, Marketing, Saving and Investing Profit, and Writing a Business Plan. Each session lasted one day.
62588539|NCT04144543|EXPERIMENTAL|Facilitated Tucking|Facilitated tucking is the procedure of holding the baby's arms and legs in a flexed position close to the midline of the torso, and the baby is able to move his/her extremities during this procedure (Caglayan, 2011).
62025658|NCT02504632|OTHER|control group|Patient with stable coronary artery disease, unscathed of AS Patient under aspirin treatment (75-160 mg/d for at least one week)
62223364|NCT04602416||Beekeeping|The Beekeeping arm had six sessions: the two sessions of the Control arm, plus Beginning Beekeeping, Environment-Forests-Bees, Building a Beehive, and Harvesting.
62223365|NCT04602416||All Interventions|This arm was 10 sessions, and included all sessions of the Control, Entrepreneurship, and Beekeeping
62588540|NCT04144543|EXPERIMENTAL|White Noise+Facilitated Tucking|Both applications performed together.
62025659|NCT05520580|NO_INTERVENTION|Conventional Group|Received a classic CS without intervention (Control group)
62025660|NCT05520580|EXPERIMENTAL|Assisted group|after uterotomy during CS, the mother was instructed and motivated to push for the delivery of the head and the shoulders of the baby. Simultaneously, the surgical assistant applied fundal pressure to support the mothers pushing if necessary.
62025661|NCT04932304|ACTIVE_COMPARATOR|Active stimulation|Participants recieving active trancranial direct current stimulation (tDCS) Parameters: 20 minutes anodal tDCS 1mA. Two times a week, for three weeks. Anode placed at F3, cathode placed at right cerebellum.
62025662|NCT04932304|PLACEBO_COMPARATOR|Sham stimulation|Participants recieving passive / sham trancranial direct current stimulation (tDCS) Two times a week, for three weeks. Anode placed at F3, cathode placed at right cerebellum.
62223366|NCT00666601|EXPERIMENTAL|Pilot study|3 subjects, open lable, microdialysis single dose.
62223367|NCT00666601|EXPERIMENTAL|Main Study|12 subjects, open label, single dose of 600 mg.
62223368|NCT03252847|EXPERIMENTAL|Phase 1 (Part 1, Dose Escalation)|Participants receive one of three doses of AAV2/5-RPGR
62223369|NCT03252847|EXPERIMENTAL|Phase 2 (Part 2; Expansion)|Participants receive one of two doses of AAV2/5-RPGR
62223370|NCT00055601|EXPERIMENTAL|Pelvic RT + paclitaxel + cisplatin|Induction: Twice-daily pelvic radiation therapy (RT) with paclitaxel and cisplatin; Consolidation: Twice-daily pelvic radiation therapy with paclitaxel and cisplatin if tumor response is T0/Ta/Tis or radical cystectomy if tumor response is ≥ T1; Adjuvant: gemcitabine, paclitaxel, and cisplatin.
62223371|NCT00055601|EXPERIMENTAL|Pelvic RT + fluorouracil + cisplatin|Induction: Twice-daily pelvic radiation therapy (RT) with fluoruracil and cisplatin; Consolidation: Twice-daily pelvic radiation therapy with fluoruracil and cisplatin if tumor response is T0/Ta/Tis or radical cystectomy if tumor response is ≥ T1; Adjuvant: gemcitabine, paclitaxel, and cisplatin.
62223372|NCT05598671|EXPERIMENTAL|without reverse insertion of a ureteral catheter|Percutaneous nephrolithotomy without reverse insertion of a ureteral catheter
62223373|NCT05598671|NO_INTERVENTION|Conventional|Percutaneous nephrolithotomy with reverse insertion of a ureteral catheter
62223374|NCT02112331|EXPERIMENTAL|Raw human milk / pasteurized human milk|"Raw human milk compared to pasteurized human milk. Two meals administration (20mL/kg) per day during 6 days in a randomized order, with an intragastric tube : one with raw milk and one with pasteurized milk.~In order to characterise gastric effluents at different postprandial times after ingestion and to measure gastric lipolysis and proteolysis, at each administration two gastric samples will be collected with the intragastric tube :~* one before the meal,~* and one either 35, 60 or 90 minutes (randomized time frame) after the meal."
62588541|NCT04525768||JAK2 mutation Group|Patients with portal caver cavernoma and gastroesophageal varices and JAK2 Mutation.
62588542|NCT04525768||Portal caver cavernoma Group|Patients with portal caver cavernoma and gastroesophageal varices without JAK2 Mutation.
62588543|NCT02807506|EXPERIMENTAL|Aim 1 (Survey): Elders|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept (elders, clinicians, caregivers), 2nd mobile base (elders only), and 3rd mobile base with arm in daily supportive tasks (elders only)
62798582|NCT06185582|EXPERIMENTAL|Capsaicin|Capsaicin patches (dosage form: transdermal patch 8% Qutenza, Astellas) will be applied on one squared area (4x4 cm2). The patch will be left in place for 20 minutes after which it will be removed.
62025663|NCT03052179|ACTIVE_COMPARATOR|VSL#3|VSL#3 poly-biotic 450 billion in sachet orally, two sachets in the morning and two sahcets in the evening for 30 days
62223375|NCT02112331|EXPERIMENTAL|Pasteurized human milk / pasteurized-homogenized human milk|"Pasteurized human milk compared to pasteurized-homogenized human milk. Two meals administration (20mL/kg) per day during 6 days in a randomized order, with an intragastric tube : one with pasteurized milk and one with pasteurized-homogenized milk.~In order to characterise gastric effluents at different postprandial times after ingestion and to measure gastric lipolysis and proteolysis, at each administration two gastric samples will be collected with the intragastric tube :~* one before the meal,~* and one either 35, 60 or 90 minutes (randomized time frame) after the meal."
62223376|NCT05576038|ACTIVE_COMPARATOR|L-Tryptophan|"L-tryptophan\* supplements (Tryptan, Valeant Canada LP): each treatment capsule contains 500 mg of L-Tryptophan; talc and magnesium stearate.~Study participants will be instructed to take 2 x 500 mg capsules (1000 mg) every 8 hrs, three times a day. (total daily dose: 3000 mg) for a total of 3 weeks.~Instructions will be printed on the label of the pill container."
62223377|NCT05576038|PLACEBO_COMPARATOR|Freedom SimpleCap Powder|"500 mg of SimpleCap Powder. Study participants will be instructed to take 2 x 500 mg capsules (1000 mg) every 8 hrs, three times a day. (total daily dose: 3000 mg) for a total of 3 weeks.~Instructions will be printed on the label of the pill container."
62223378|NCT00848926|EXPERIMENTAL|Brentuximab vedotin|
62588544|NCT02807506|EXPERIMENTAL|Aim 1 (Survey): Clinicians|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept (elders, clinicians, caregivers), 2nd mobile base (elders only), and 3rd mobile base with arm in daily supportive tasks (elders only)
62588545|NCT02807506|EXPERIMENTAL|Aim 1 (Survey): Caregivers|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept (elders, clinicians, caregivers), 2nd mobile base (elders only), and 3rd mobile base with arm in daily supportive tasks (elders only)
62588546|NCT02807506|EXPERIMENTAL|Aim 2: Deployment 1 (Elders)|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept (elders, clinicians, caregivers), 2nd mobile base (elders only), and 3rd mobile base with arm in daily supportive tasks (elders only)
62588547|NCT02807506|EXPERIMENTAL|Aim 2: Deployment 2 (Elders)|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept (elders, clinicians, caregivers), 2nd mobile base (elders only), and 3rd mobile base with arm in daily supportive tasks (elders only)
62588548|NCT04109820|EXPERIMENTAL|Sickle cell patients|Sickle Cell subjects administered oral MitoQ (20mg once a day for 14 days)
62588549|NCT04109820|ACTIVE_COMPARATOR|Non Sickle cell Control subjects|Normal control subjects administered oral MitoQ (20mg once a day for 14 days)
62025664|NCT03052179|PLACEBO_COMPARATOR|Placebo|Maltose in sachet orally, two sachets in the morning and two sahcets in the evening for 30 days
62025665|NCT00999479|EXPERIMENTAL|Monophasic OCP|Patients randomized to this study arm will receive combined oral contraceptive pills. Patients will follow up at 2, 6, 12, 18 and 24 months. On follow up visits pts will have clinical assessment with vaginal and rectal examinations and with transvaginal ultrasonography. As a measure of compliance, patients will return their empty pill packages
62223379|NCT03273556|EXPERIMENTAL|Aliaxin® EV Essential Volume|Comparison within subjects of Aliaxin® EV Essential Volume with and without Lidocaine 0.3%
62223380|NCT02224976|EXPERIMENTAL|Intensified training|Volunteers will increase exercise training by 30% from baseline
62588550|NCT04240704|EXPERIMENTAL|JBH492 single agent|Patients with R/R CLL or NHL
62588551|NCT05325645|EXPERIMENTAL|Brexpiprazole QW 48mg|Brexpiprazole QW 48mg, tablet, once weekly, for seven weeks(Initial dose Brexpiprazole QW 24mg)
62588552|NCT05325645|PLACEBO_COMPARATOR|Placebo|
62588553|NCT04704492|EXPERIMENTAL|Biological: SM03|Biological: SM03 600 mg or 900 mg intravenous (IV) on week 0 , 2.
62223381|NCT02596165|EXPERIMENTAL|Pulse wave analysis measurement|Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
62588554|NCT02872974||Exposed|Offspring of woman with GDM
62223382|NCT01775280|EXPERIMENTAL|Radioembolization|Radioembolization using Yttrium-90 microspheres using a transarterial approach
62588555|NCT02872974||Not exposed|Offspring of woman without GDM
62223383|NCT02463110|EXPERIMENTAL|1: Sertraline|ACS, depression
62223384|NCT02463110|PLACEBO_COMPARATOR|2: Placebo|ACS, depression
62223385|NCT02463110|OTHER|3: Control|ACS, no depression, no treatment
62223386|NCT05877313|ACTIVE_COMPARATOR|Nitric Oxide Releasing Solution 1X|"Foot bath with nitric oxide releasing solution (NORS) at 1X dosage delivered 3 times weekly (Mon, Wed, Fri).~500mL NORS in a footbath @ 4110 ppm\*min"
62223387|NCT05877313|ACTIVE_COMPARATOR|Nitric Oxide Releasing Solution 2X|"Foot bath with nitric oxide releasing solution (NORS) at 2X dosage delivered 3 times weekly (Mon, Wed, Fri).~500mL NORS in a footbath @ 12190 ppm\*min"
62223388|NCT05877313|PLACEBO_COMPARATOR|Vehicle Control|"Foot bath with sterile water delivered 3 times weekly (Mon, Wed, Fri)~500mL sterile water in a foot bath."
62223389|NCT05753371|EXPERIMENTAL|Glufor® 500 mg film-coated tablet|
62417171|NCT05540535||Bilateral Symmetrical Hearing Loss|"Adults aged 40 and older with a clinical diagnosis of bilateral symmetrical moderate, moderately-severe, severe, or profound sensorineural HL in the past three month and on.~Moderate hearing will be defined as a PTA between 41-55dB HL (0.5-4 kHz) in the better ear, moderately-severe hearing will be defined as a PTA between 56-70dB HL (0.5-4 kHz) in the better ear, severe HL will be defined as a PTA between 71-90dB HL (0.5-4 kHz) in the better ear and profound HL will be defined as a PTA above 90+dB HL (0.5-4 kHz) in the better ear. Asymmetry of HL will be defined as a difference in PTA that is greater than dB between ears or a difference greater than/equal to 20 dB at two contiguous frequencies or greater than/equal to 10 dB at three contiguous frequencies between ears."
62417172|NCT05540535||Control participants with normal hearing.|Normal hearing will be defined as a PTA below 25dB (0.5-4 kHz) bilaterally. Subjects above 65 years of age, with symmetric ARHL in the high frequencies (\>3K), with unaided PTA \< 40 dB (0.5-4KHz) will be included in the control group as well.
62417173|NCT05550675||Double incontinence|
62798583|NCT04600713|EXPERIMENTAL|PT-X and IMT|Physiotherapist-led exercise-based cardiac rehabilitation (PT-X) and inspiratory muscle training (IMT).
62223390|NCT05753371|ACTIVE_COMPARATOR|Glucophage® 500 mg film-coated tablet|
62223391|NCT06106529|EXPERIMENTAL|Venlafaxine|"In this open-label randomized controlled intrapatient cross-over study patients are randomly assigned to one of the two treatment groups.~After a one week baseline period, group 1 starts with venlafaxine 37.5 mg once daily for 7 days followed by 75 mg once daily for 5 weeks followed by a two-week wash-out period (no medication), hereafter the group starts with oxybutynin 5 mg twice per day for 6 weeks total."
62223392|NCT06106529|EXPERIMENTAL|Oxybutynin|After a one week baseline period, group 2 starts with oxybutynin 5 mg twice per day for 6 weeks total followed by a two-week wash-out period (no medication), hereafter the group starts with venlafaxine 37.5 mg once daily for 7 days followed by 75mg once daily for 5 weeks.
62223393|NCT03169101||HIV+ Smoking lab session first|HIV-infected smokers: diagnosed with HIV infection and exhibiting viral load of less than or equal to 1000 copies/mL and CD4+ counts of greater than or equal to 200 cells/mm3 within 6 months prior to enrollment Randomized to complete smoking-as-usual lab session first and 24-h abstinent lab session second
62223394|NCT03169101||HIV- Smoking lab session first|HIV-uninfected smokers: negative HIV status will be confirmed by an on-site rapid HIV blood test Randomized to complete smoking-as-usual lab session first and 24-h abstinent lab session second
62223395|NCT03169101||HIV+ Abstinent lab session first|HIV-infected smokers: diagnosed with HIV infection and exhibiting viral load of less than or equal to 1000 copies/mL and CD4+ counts of greater than or equal to 200 cells/mm3 within 6 months prior to enrollment Randomized to complete 24-h abstinent lab session first and smoking-as-usual lab session second
62223396|NCT03169101||HIV- Abstinent lab session first|HIV-uninfected smokers: negative HIV status will be confirmed by an on-site rapid HIV blood test Randomized to complete 24-h abstinent lab session first and smoking-as-usual lab session second
62223397|NCT01773291|EXPERIMENTAL|acupuncture|acupuncture on GV26 and 12 Well points
62223398|NCT01773291|EXPERIMENTAL|laser acupuncture|laser acupuncture on GV26 and 12 Well points
62223399|NCT01773291|SHAM_COMPARATOR|control group|laser acupuncture without laser output in control group.
62417174|NCT05550675||faecal incontinence|
62417175|NCT05550675||controls|
62417176|NCT05181709|PLACEBO_COMPARATOR|Cohort 1: Placebo / Sodium Chloride|Participants in Cohort 1 will receive placebo given IN+IM in combination. Placebo administration will be given in an ambulatory setting. IN administration will be immediately followed by IM administration. Participants will be monitored by the research staff for 1-hour after administration. Participants will be permitted to receive any additional federally authorized or approved vaccines 56 days after receiving placebo.
62798584|NCT04600713|NO_INTERVENTION|Control|The participants in the control group will be offered PT-X at the end of the control period.
62798585|NCT03202407|PLACEBO_COMPARATOR|calcium group|"will receive calcium-based phosphate binder (calcium carbonate ) 45-65 mg/kg orally divided 3 to 4 times/day for 3 months.~all the following investigation will be done before and after consecutive 3 months of administration :~* Complete blood count~* Kidney function tests (serum urea and creatinine)~* Serum total calcium level.~* Serum phosphorus level.~* Calcium × phosphorus product.~* Serum parathormone level.~* Serum alkaline phosphatase level.~* Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides).~* Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug"
62223400|NCT01530828||Premature infants|Weight less than 1000 grams, age 1 - 16 days.
62223401|NCT00460226||lamotrigine|there is only one group.
62223402|NCT04097392|EXPERIMENTAL|Diaphragm biofeedback reeducation plus inspiratory training|
62223403|NCT04097392|ACTIVE_COMPARATOR|Isolated high-intensity inspiratory muscle training|
62223404|NCT04688073|EXPERIMENTAL|Downhill running|Running at 60% VO2max on -15% slope for 30 min on a treadmill
62223405|NCT04688073|EXPERIMENTAL|Level running|Running at 60% VO2max on level surface for 30 min on a treadmill
62223406|NCT04688073|PLACEBO_COMPARATOR|Control|Rest 30 min
62433441|NCT03596918||Supportive care (vincristine sulfate, bleomycin sulfate)|Patients receive vincristine sulfate IV over 1-2 minutes and bleomycin sulfate IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62588556|NCT06428552|EXPERIMENTAL|Usual care at home for 12 weeks|Daily rehabilitation program of 40 minutes duration using a mobile application to be completed 6 days per week for 12 weeks
62025666|NCT00999479|PLACEBO_COMPARATOR|Placebo|Patients assigned to this arm will use non-hormonal, barrier contraceptives to prevent pregnancy.Patients will follow up at 2, 6, 12, 18 and 24 months. On follow up visits pts will have clinical assessment with vaginal and rectal examinations and with transvaginal ultrasonography. As a measure of compliance, patients will return their empty pill packages.
62025667|NCT00856401|EXPERIMENTAL|PTH1-84 in parent study|In the RELAY, RACE, and HEXT study participants utilize PTH1-84. In the REPLACE Study participants utilize PTH1-84 or placebo of PTH1-84.
62025668|NCT04357626||Completed discharged hospital rehabilitation electronic record|Completed discharged hospital rehabilitation electronic record of patients who underwent inpatient rehabilitation as part of routine clinical care.
62025669|NCT01574300||Biospecimens and biofluids|"This is a multi-cohort parallel study in which tumor, plasma and serum samples will be collected prior to the start of any therapeutic intervention for stage IV lung cancer. These biospecimens will be correlated with treatment and clinical data and distributed for peer reviewed research purposes to academic and community centers in the U.S. and Europe.~The biospecimens collected in CASTLE will be analyzed for a panel of biomarkers, currently including:~* tumor: epidermal growth factor receptor (EGFR), KRAS (Kirsten RAt Sarcoma) gene and EML4-ALK (echinoderm microtubule-associated protein-like 4 - anaplastic lymphoma kinase) translocations, and EGFR, TS (thymidylate synthase), ERCC1 (excision repair cross-complementing 1) and RRM1 (Ribonucleotide Reductase, M1 Subunit) gene expressions~* serum: proteomics predictive for EGFR-TKI (tyrosine kinase inhibotors)response"
62025670|NCT05934045||ALCL patient samples (serum)|serum collected at diagnosis, during treatment and/or at relapse
62025671|NCT02465593|EXPERIMENTAL|PEP503+5-FU/capecitabine+Radiotherapy|Patients will receive PEP503 given as intratumor injection on Day 1, followed by preoperative radiation therapy.
62025672|NCT04710797|EXPERIMENTAL|No Lymphadenectomy|Comprehensive staging surgery with no Lymphadenectomy
62025673|NCT04710797|ACTIVE_COMPARATOR|Lymphadenectomy|Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy
62025674|NCT04833023|ACTIVE_COMPARATOR|Haloperidol Arm|Haldol 2mg/ml oral solution
62025675|NCT04833023|ACTIVE_COMPARATOR|Olanzapine Arm|Olanzapine Actavis 5mg orodispersible tablet
62025676|NCT05119959|EXPERIMENTAL|Arm 1- CHEU + ECD intervention|Participants randomized to this arm will receive a bi-weekly community health worker-delivered ECD intervention for CHEUs
62025677|NCT05119959|ACTIVE_COMPARATOR|Arm 2- CHEU without ECD intervention|Participants randomized to this arm will receive the current Ministry of Health (MoH) standard of care with no formalized routine assessment of neurodevelopment.
62223407|NCT02292654|EXPERIMENTAL|Olipudase alfa|Participants received intravenous (IV) infusion of olipudase alfa once every 2 weeks (Q2W) for 64 weeks. Each participant underwent a dose escalation according to the following paradigm: 0.03, 0.1, 0.3, 0.3, 0.6, 0.6, 1.0, 2.0, 3.0 milligram per kilogram (mg/kg). Three (3) mg/kg was the target maintenance dose, which was maintained for the remaining duration of 64 treatment weeks.
62223408|NCT04937803|EXPERIMENTAL|Drug-coated balloon group|Patients assigned to drug-coated balloon group will receive angioplasty with drug-coated balloon for treatment of lesions.
62223409|NCT04937803|ACTIVE_COMPARATOR|Stent group|Patients assigned to drug-eluting stent group will receive a Zotarolimus -Eluting Coronary Stent treatment .
62223410|NCT03017534|EXPERIMENTAL|Gender Match, Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, wearing a labcoat and receive a detailed anatomic explanation of the technique.
62588557|NCT06093165|OTHER|A|Primary radiotherapy 54Gy/30 fractions
62588558|NCT06093165|OTHER|B|Any other dose and fractionation for primary radiotherapy than 54gy/30 fractions.
62588559|NCT02355184|EXPERIMENTAL|PRO 140|PRO 140 350mg weekly SQ injection.
62588560|NCT01826136|EXPERIMENTAL|Acapella|use of the Acapella device postoperatively
62588561|NCT01826136|NO_INTERVENTION|Control|
62025678|NCT05119959|ACTIVE_COMPARATOR|Arm 3- HIV Unexposed (HUU) without ECD intervention|Participants randomized to this arm will receive the current Ministry of Health (MoH) standard of care with no formalized routine assessment of neurodevelopment.
62588562|NCT01085630|EXPERIMENTAL|Arm I|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62025679|NCT05150730|EXPERIMENTAL|Quality-of-Life multidisciplinary care program|Six groups (between 10 -19 participants per group) received a meeting for two hours, the first hour being devoted to physical exercise, stimulating body awareness, improving mobility and muscle strengthening, relaxation and self-care.
62025680|NCT06635772|EXPERIMENTAL|HS-10390; high dose|HS-10390; high dose
62025681|NCT06635772|EXPERIMENTAL|HS-10390; low dose|HS-10390; low dose
62025682|NCT06635772|ACTIVE_COMPARATOR|irbesartan|Irbesartan will be administered daily as a 150-mg oral tablet. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg
62025683|NCT00399477|ACTIVE_COMPARATOR|Rasagiline mesylate|
62025684|NCT00399477|EXPERIMENTAL|Rasagiline mesylate plus adjunct therapy|Rasagiline mesylate with one of three adjunct therapies
62025685|NCT04054583||Residents|Residents living on a special care unit in a long-term care facility. All 60 residents residing in the unit pre- and post-renovation will be eligible, and all will have intermediate or advanced dementia.
62025686|NCT04054583||Family Members|Family members are defined as the key person who supports the resident on a regular basis. This could include a spouse, adult child, adult grandchild, niece or nephew, close friend, former neighbour, or other significant person to the resident.
62025687|NCT04054583||Staff|Staff are the people who work on the special care unit. They may work only briefly or work on the design of the renovations. Types include: managers, nurses, health care aides, recreation facilitators, social worker, occupational therapist, physiotherapist, rehabilitation assistant, speech language pathologist, physicians, designers, and cleaning staff.
62588563|NCT01085630|ACTIVE_COMPARATOR|Arm II|Patients undergo observation until disease progression.
62025688|NCT04076228||Pembrolizumab|Chinese lung cancer patients who will receive pembrolizumab will be enrolled in this study. Clinically, the treatment course of pembrolizumab is depended on the efficacy, but average cycle is about 3-4 weeks and patient will receive 6 treatment courses.
62025689|NCT05052970|EXPERIMENTAL|12 mg/m ^ 2 dose group (ArmA)|Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 12 mg/m\^2
62223411|NCT03017534|EXPERIMENTAL|Gender Match, Labcoat, No Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, wearing a labcoat, and receive a colloquial discussion of the technique.
62025690|NCT05052970|EXPERIMENTAL|16 mg/m ^ 2 dose group (ArmB)|Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 16 mg/m\^2
62025691|NCT05052970|EXPERIMENTAL|20 mg/m ^ 2 dose group (ArmC)|Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 20 mg/m\^2
62025692|NCT04418882||non septic open fracture|patients having had an open fracture without septic evolution
62025693|NCT04418882||septic open fracture|patients having had an open fracture with septic evolution
62025694|NCT04686903|EXPERIMENTAL|Epiduroscopy|Epiduroscopy in patients with FBSS
62025695|NCT04686903|EXPERIMENTAL|Racz catheter epidural procedure|Racz catheter epidural procedure in patients with FBSS
62223412|NCT03017534|EXPERIMENTAL|Gender Match, No Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a detailed anatomic explanation of the technique.
62223413|NCT03017534|EXPERIMENTAL|Gender Match, No Labcoat, No Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a colloquial discussion of the technique.
62223414|NCT03017534|EXPERIMENTAL|Gender Mis-match, Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, wearing a labcoat and receive a detailed anatomic explanation of the technique.
62223415|NCT03017534|EXPERIMENTAL|Gender Mis-match, Labcoat, No Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, wearing a labcoat, and receive a colloquial discussion of the technique.
62223416|NCT03017534|EXPERIMENTAL|Gender Mis-match, No Labcoat, Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, not wearing a labcoat, and receive a detailed anatomic explanation of the technique.
62223417|NCT03017534|EXPERIMENTAL|Gender Mis-match, No Labcoat, No Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a colloquial discussion of the technique.
62223418|NCT02844426|PLACEBO_COMPARATOR|Placebo|patients allowed to take maltodextrin by the experienced doctor.
62223419|NCT02844426|EXPERIMENTAL|synbiotic|patients are allowed to take synbiotic (BIFICOPEC) contained 0.63g bifid triple viable capsule (BIFICO) and 8g soluble dietary fiber (Pectin) .
62223420|NCT03573349|OTHER|Ketamine|Open-label, non-randomized
62223421|NCT03188406||Gastric cancer|Patients with clinical or histological diagnosis of stomach cancer
62223422|NCT03188406||Gastric intestinal metaplasia|Patients classified as OLGIM \>0
62223423|NCT03188406||Non-atrophic gastritis|Patients classified as OLGA 0
62223424|NCT00653601||1|Patients who receive bridge therapy with tirofiban who were previously on plavix for drug eluting or bare metal stent prior to scheduled invasive procedures
62223425|NCT00653601||2|"Patients who do NOT receive bridge therapy previously on plavix for drug eluting or bare metal stent prior to scheduled invasive procedures. This will entail of a matching case-control for the following characteristics.~* # of RF for stent thrombosis~* types of stents~* time frame when the stents were placed~* procedure type"
62798586|NCT03202407|EXPERIMENTAL|sevelamer group|"will receive the recommended daily dose of the Sevelamer hydrochloride phosphate binder 120-160 mg/kg orally 3 times per day for 3 months.~all the following investigation will be done before and after consecutive 3 months of administration :~* Complete blood count~* Kidney function tests (serum urea and creatinine)~* Serum total calcium level.~* Serum phosphorus level.~* Calcium × phosphorus product.~* Serum parathormone level.~* Serum alkaline phosphatase level.~* Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides).~* Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug"
62025696|NCT04686903|EXPERIMENTAL|Caudal epidural block|Caudal epidural block treatment of FBSS
62025697|NCT05978882|EXPERIMENTAL|Laparoscopic sentinel navigation surgery|compare the detection rate of sentinel lymph nodes to that of previous study (SENORITA1 trial)
62025698|NCT05108194|EXPERIMENTAL|Arm 1: Intervention|Participants (N=50) who endorse insomnia will be followed for 8 weeks. All participants will be asked to download a separate app to passively monitor sleep that will inform the personalized messages. Participants will also be asked to respond to daily prompts in order to validate the passive sleep data. The study includes two phases: (1) a training and validation phase and (2) an intervention phase. During phase 1, participants' sleep habits and other behaviors will be monitored for two weeks in order to validate and optimize the SMS personalized sleep intervention (PSI). In phase 2, participants will be transitioned to the intervention phase of the study.
62025699|NCT05631795|EXPERIMENTAL|Alpelisib + fulvestrant|Alpelisib 300 mg orally once daily starting on Cycle 1 Day 1 in combination with fulvestrant (intramuscular injection) 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28 day cycle.
62025700|NCT03815851|OTHER|Drain group|Place prophylactic drainage after surgery.
62025701|NCT03815851|OTHER|No-drain group|Not place prophylactic drainage after surgery.
62025702|NCT03704818|EXPERIMENTAL|Dapagliflozin 5mg|
62025703|NCT03704818|EXPERIMENTAL|Placebo|
62417177|NCT05181709|ACTIVE_COMPARATOR|Cohort 2: NDV-HXP-S low dose IN|Participants in Cohort 2 (low, IN) will receive a single administration of a low dose of NDV-HXP-S at 3.3x108 Egg-Infectious Dose50 (EID50). Participants will be given NDV-HXP-S in an ambulatory setting and be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.
62025704|NCT02127203||Chronic Periodontitis group (ChP)|20 patients aged \> 45 years and have presence of ≥2 non-adjacent sites per quadrant that were not first molars or incisors, with probing depth (PD) ≥5 mm, which bleed on gentle probing. The demonstrated radiographic bone loss ≥30% of the root length, patient with poor oral hygiene, the amount of accumulated plaque commensurate with the amount of clinical attachment level (CAL)
62223426|NCT00520325|OTHER|0.5 mg/kg|
62223427|NCT00520325|OTHER|1.0 mg/kg|
62223428|NCT05130853|EXPERIMENTAL|SoCIAL Group|Subjects will conduct SoCIAL programme once a week, for a total of 10 weeks. Every session consists of two different modules: 1) a training programme that helps patients recognize emotions and important social signals (such as facial expressions and prosody) and develop strategy focused on the Theory of Mind; 2) a training in narrative enhancement. Time of administration for both modules is 30 minutes; the operator, however, can choose to focus the session on one module rather than the other, based on the subject's specific needs.
62588564|NCT06666283|EXPERIMENTAL|AP303|
62588565|NCT06666283|PLACEBO_COMPARATOR|Placebo|
62588566|NCT03145961|NO_INTERVENTION|Observation|Patient will have blood samples collected for ctDNA analysis every 3 months for up to 2 years from starting ctDNA screening.
62798587|NCT02687464|EXPERIMENTAL|Non-operative treatment group|IV fluids, minimum 12 hrs IV antibiotics, minimum 12 hrs clear PO fluids only, regular clinical review. Discharge within 24 hrs after randomization, if study criteria met. If stable but not adequate improvement for discharge, non-operative management continues. If not improved by 48 hrs, appendectomy will be done. Discharge home once vital signs are within normal limits, light oral diet tolerated, adequate oral pain relief and mobile. Total 10 days of antibiotics (IV and oral) following randomization will be given. Antibiotics used vary between centers and will be current standard of care in that center; improving study feasibility and increased generalization of results.
62798588|NCT02687464|ACTIVE_COMPARATOR|Appendectomy group|Laproscopic appendectomy within 18 hrs of randomization. IV antibiotics given from time of randomization and continued post-operatively per the standardized treatment regimen: children with visibly normal appendix or non-perforated acute appendicitis will receive no further antibiotics; children with perforated appendicitis will continue IV antibiotics for a minimum of 3 days and then per local practice. The type of antibiotics used in each center will be identical to those used in the non-operative treatment group.
62798589|NCT04095182|EXPERIMENTAL|Zebinix 400mg|
62223429|NCT05130853|ACTIVE_COMPARATOR|Control Group - Treatment-as-usual (TAU)|Subjects that will be randomized in this group will receive their treatment as usual for the whole length of the study (10 weeks). TAU includes all the psychiatric therapies (pharmacological, psychological, occupational etc) that subjects may have begun before study's enrollment.
62223430|NCT04051736|EXPERIMENTAL|group 1|180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Sabin-IPV; 3rd: Sabin-IPV
62223431|NCT04051736|ACTIVE_COMPARATOR|group 2|180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Salk-IPV; 3rd: Salk-IPV
62223432|NCT03562247|ACTIVE_COMPARATOR|Usual Care of IPF|Newly diagnosed patients will continue to receive excellent healthcare as currently given in management of the lung disease
62223433|NCT03562247|EXPERIMENTAL|Telenursing|Patients will receive usual care with structured phone calls from the nurse practitioner and/or case manager occuring more frequently earlier in the diagnosis to help the patient and care giver understand all aspects of the disease and it time will evolve to managing symptoms outside of out-patient clinic visits.
62223434|NCT03562247|EXPERIMENTAL|Telenursing and Remote Monitoring|Patients will receive usual care with telenursing and will be given a hand held spirometer and puse oximeter and be asked to take daily measurements and report these via an electronic HIPAA approved secured platform for evaluation by the telenursing team.
62223435|NCT02139293|EXPERIMENTAL|auricular vagus nerve stimulation|"Study participants (healthy) are treated with auricular vagus nerve stimulation using five needle electrodes connected to an electrical stimulation device (PrimeStim). After acclimatization the stimulation is turned on for 20 minutes followed by 20 minutes of paused stimulation, 20 minutes of stimulation, and 10 minutes paused stimulation. This intervention is repeated on four consecutive days, whereas at each intervention only one of the four stimulation points (and one fixed reference point) is stimulated. Needle electrodes are applied at each study visit.~Stimulation points in the auricle are stimulated in random order. One stimulation pattern is tested. Stimulation amplitudes are adjusted with respect to a distinct but comfortable sensation at the auricle.~During the described protocol various biosignals are continuously recorded, including ECG, respiration, blood perfusion, oxygen saturation, transcutaneous oxygen tension, blood pressure and skin temperature."
62223436|NCT06329778||HBCC providers (no observation)|This group will include 100 purposively selected providers from diverse backgrounds who will each complete the provider questionnaire and will also be asked to recruit one or more families to complete the family survey.
62223437|NCT06329778||HBCC providers (observation)|This group will include 50 purposively selected providers from diverse backgrounds who will each complete the provider questionnaire, be asked to recruit one or more families to complete the family survey, and agree to have their child care setting observed by a field staff member.
62223438|NCT06329778||Families|This group will include up to 166 purposively selected families who will each receive the family survey.
62223439|NCT06115447||Polyglactin group|lung suturing with polyglactin
62223440|NCT06115447||Polypropylene Arm|lung suturing with Polypropylene
62223441|NCT00502086|EXPERIMENTAL|I|Viusid, three sachets daily during 96 weeks
62223442|NCT00502086|PLACEBO_COMPARATOR|2|Placebo three sachets daily during 96 weeks
62223443|NCT03587051|EXPERIMENTAL|Low glycemic index post-exercise diet|Lentil-based post-exercise meal
62223444|NCT03587051|ACTIVE_COMPARATOR|High glycemic index post-exercise diet|Instant potato, white bread, and egg white post-exercise meal
62223445|NCT02708654|EXPERIMENTAL|Intervention|Participants will be (1) given an electronic pill bottle for their diuretic and a Bluetooth scale; (2) asked to provide the coordinator with name and contact information of a family member or friend to serve as a support partner; (3) will be assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence and registering a weight measurement; and, (4) will determine their preferences for Way to Health platform communication methods during the study.(5) Research coordinators to remotely monitor weight gain thresholds and add alert into the participant's electronic health record for verified weight gain
62223446|NCT02708654|NO_INTERVENTION|Control|Participants will receive usual care.
62223447|NCT03019731|EXPERIMENTAL|Children with Tourette syndrome|Eligible children, between ages 7-13 years, with the diagnosis of Tourette syndrome or chronic motor/vocal tic disorder will be recruited from the Tourette Syndrome Clinics at Johns Hopkins (Dr. Singer). The Johns Hopkins Center has been acclaimed a Center of Excellence by the Tourette Association of America. This center currently follows more than 1,000 tic patients and averages 4-6 new referrals and 4 follow up patients weekly. Children will be randomly assigned to either the Therapist-directed Behavioral Therapy group or the Home-based DVD therapy group.
62223448|NCT03743467||Control group|Health subjects
62025705|NCT02127203||Resistant Control group (R)|20 age-sex matched patients who are \> 45 years exhibit no signs of periodontal disease as determined by the absence of the evidence of interproximal (CAL ≤ 1mm), PD \> 3 mm at any site, whole-mouth bleeding scores \<10% and have no clinical signs of gingival inflammation .
62025706|NCT02127203||Aggressive Periodontitis group (AgP)|20 patients who are aged \< 35 years and diagnosed with rapid attachment loss with periodontal pocket depth (PD) \> 4 mm around at least three teeth other than the first molars and incisors. Rapid bone destruction (\>50%bone loss at diseased sites). Weak relationship between dental plaque and the severity of gingival inflammation.
62025707|NCT02127203||Young Control group (YC)|20 age- and sex matched patients who are \< 35 years and exhibit no signs of periodontal disease.
62223449|NCT03743467||PD patients Hoehn Yahr 1|Patients with Hoehn Yahr stage 1
62223450|NCT03743467||PD patients Hoehn Yahr 2-3|Patients with Hoehn Yahr stage 2 and 3
62025708|NCT02320604|EXPERIMENTAL|Obese Subjects 1mg/kg|8 obese subjects will receive 1mg/kg Ambisome i.v. infused over 45 minutes
62223451|NCT03897764|EXPERIMENTAL|Superior Hypogastric Block group|The group which superior hypogastric block performed intraoperatively
62223452|NCT03897764|PLACEBO_COMPARATOR|placebo controlled group|The group which placebo used
62223453|NCT00636077|OTHER|HD-C4 Big|3 consecutive treatments with the HD-C4 Big dialyzer.
62223454|NCT00636077|OTHER|HD-C4 Small|3 consecutive treatments with the HD-C4 Small dialyzer.
62223455|NCT00636077|OTHER|F160NR|3 consecutive treatments with the F160NR dialyzer.
62223456|NCT00636077|OTHER|F200NR|3 consecutive treatments with the F200NR dialyzer.
62223457|NCT04801810|EXPERIMENTAL|Normobaric hypoxia (NH)|8 weeks of overnight exposure (8 hrs/night) to NH conditions (\~15% oxygen; achieved with nitrogen dilution, equivalent to \~8500 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
62223458|NCT04801810|SHAM_COMPARATOR|Normobaric normoxia (NN)|8 weeks of overnight exposure (8 hrs/night) to NN conditions (\~21% oxygen; sea level) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
62223459|NCT03865264|ACTIVE_COMPARATOR|Living Liver donor|"Recovery enhancement program:~1. At least 6 weeks of physical and relaxation skills training pre-transplant.~2. Taking nutritional drink for 5 days before and after the surgery.~3. Opioid sparing pain management."
62223460|NCT03865264|ACTIVE_COMPARATOR|Living Kidney donor|"Recovery Enhancement Program~1. At least 4 weeks of physical and relaxation skills training pre-transplant.~2. Taking nutritional drink for 5 days before and after the surgery.~3. Opioid sparing pain management."
62223461|NCT03865264|NO_INTERVENTION|Living Kidney donor (Control)|"1. Subjects maintain the same lifestyle without practicing physical training, relaxation skills or nutritional drink before and after the surgery.~2. To control post-op pain, subject will use medication per standard of care, including PCA pump."
62223462|NCT06203366|EXPERIMENTAL|Experimental group|"* got the Vojta treatment 30 minutes/session, 3 times/week for 8 weeks~* got the ADL and kinetic activities training 30 minutes, 3 times/week for 8 weeks"
62588567|NCT03145961|EXPERIMENTAL|Pembrolizumab Treatment|Patients will be given pembrolizumab every 3 weeks for up to a maximum of 12 months, with blood samples collected prior to each cycle for continued ctDNA analysis. Following treatment discontinuation, blood samples will be collected for ctDNA analysis every 3 months for a further 12 months.
62025709|NCT02320604|EXPERIMENTAL|Obese Subjects 2mg/kg|8 obese subjects will receive 2mg/kg Ambisome i.v. infused over 90 minutes
62025710|NCT05032703|EXPERIMENTAL|Arm ergometer|Children in group I will receive strength-endurance protocol of arm ergometer for 30 minutes in addition to the conventional physical therapy program for 30 minutes, per session, three times a week, for three consecutive months.
62223463|NCT06203366|NO_INTERVENTION|control group|- got the ADL and kinetic activities training 30 minutes, 3 times/week for 8 weeks
62223464|NCT05613374|ACTIVE_COMPARATOR|Control Group|"Participants in the control group will receive conventional functional training (conventional physical therapy program) for one hour as the following.~* Part (1) Postural reactions exercises. (for 30 minutes)~* Rest for 15 minutes between the first part and the second part.~* Part (2) Indoor open environment gait training exercises (over-ground gait training exercises.). (for 30 minutes)"
62242997|NCT01205997|ACTIVE_COMPARATOR|fentanyl|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
62025711|NCT05032703|EXPERIMENTAL|Trunk stabilization exercise|Children in group II will receive trunk stabilization exercises for 30 minutes in addition to the conventional physical therapy program for 30 minutes, per session, three times a week, for three consecutive months.
62025712|NCT01617421|EXPERIMENTAL|Yoga|This study used Hatha yoga (influenced by Integral, Iyengar, and Kripalu yoga) which includes postures (asanas), breathing techniques (pranayama) and meditation \[9\]. Biweekly, 60-minute, bilingual yoga classes were offered for 8 weeks at a yoga studio in Washington, DC. Classes were kept small (3-10 participants) to allow for pose modifications as needed for each participant. Participants were given instructions, bilingual manuals, and yoga equipment to encourage home practice. Participants were asked to keep journals to document the frequency and duration of home practice and their experience while on the study. After the last class, a yoga DVD and a list of local yoga studios were given to encourage continued practice.
62025713|NCT03973190|PLACEBO_COMPARATOR|RET Group|Closure of the alveolus by first intention through palatal flap sliding according to the technique of Khoury et al. (2000).
62223465|NCT05613374|EXPERIMENTAL|Experimental Group|"Participants in the experimental group will receive a treatment program that is comprised of two parts.~The first part included training, for (30 minutes), on The C-Mill virtual reality treadmill. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications. The C-Mill applies an augmented virtual reality environment, obstacle avoidance games, and a variety of balance challenges in a safe and controlled environment to increase walking adaptability and performance in everyday life.~There will be 15 minutes rest between parts one and two of the training program~The second part (conventional training program) (30 minutes) will include:~* Postural reactions exercises. ( 20 minutes)~* Indoor open environment gait training exercises (over-ground gait training exercises.). (10 minutes)"
62223466|NCT00140751|EXPERIMENTAL|Simplification|The patients included in this arm are on Monotherapy of Kaletra (Lopinavir/ritonavir)during 48 weeks
62223467|NCT00140751|NO_INTERVENTION|Continued|The patients included in this arm continue their treatment without any changes
62223468|NCT00964093|NO_INTERVENTION|No intervention|
62223469|NCT02217332|EXPERIMENTAL|dexpramipexole|dexpramipexole 150 mg BID
62223470|NCT05062187||Proprioseption in hemiparetics|Proprioception on balance and gait functions in hemiparetic individuals
62223471|NCT05062187||Healthy Individual|Proprioception on balance and gait functions in healthy individuals
62223472|NCT02377115|OTHER|Study cohort|Tablet computer application
62417178|NCT05181709|ACTIVE_COMPARATOR|Cohort 3: NDV-HXP-S low dose IM|Participants in Cohort 3 (low, IM) will receive a single administration of a low dose of NDV-HXP-S at 3.3x108 Egg-Infectious Dose50 (EID50). Participants will be given NDV-HXP-S in an ambulatory setting and be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.
62588568|NCT04015089|EXPERIMENTAL|Partially hydrolyzed formula (pHF)|Infants fed exclusively with a infant formula based on partially hydrolyzed serum cow's milk proteins.
62223473|NCT02105584|EXPERIMENTAL|LAA closure device|Implantation of LAA closure device
62588569|NCT04015089|ACTIVE_COMPARATOR|Standard formula (SF)|Infants fed exclusively with a standard formula based on intact cow's milk proteins
62223474|NCT01293305|EXPERIMENTAL|Chondroitin Sulfate + Glucosamine sulfate|Pharmaceutical form capsule.
62223475|NCT01293305|EXPERIMENTAL|Chondroitin Sulfate + Glucosamine Sulfate|Oral powder.
62223476|NCT01293305|ACTIVE_COMPARATOR|Condroflex®|Pharmaceutical form capsule.
62223477|NCT01293305|ACTIVE_COMPARATOR|CONDROFLEX®|Oral powder
62223478|NCT01170559|EXPERIMENTAL|Group 1: ILR Group|Group allocated to receiving an ILR in the A\&E department.
62223479|NCT01170559|NO_INTERVENTION|Group 2: Conventional|Group randomised to conventional lines of investigation
62223480|NCT01877837|EXPERIMENTAL|Related donor|"Matched sibling donors (9-10/10 marrow/PBSC or 5-6/6 UCB (single) with a total TNC dose of greater than 5 x 107/kg recipient weight), age 2-30 years after conditioning regimen Alemtuzumab , Fludarabine, and Melphalan.~1) Patients will receive a conditioning regimen composed of Alemtuzumab, Fludarabine, and Melphalan as detailed in the table below.~Day Treatment~* -22 Alemtuzumab 3mg IV (test dose)~* -21 Alemtuzumab 10mg IV~* -20 Alemtuzumab 15mg IV~* -19 Alemtuzumab 20mg IV~* -8 Fludarabine 30mg/m2 IV~* -7 Fludarabine 30mg/m2 IV~* -6 Fludarabine 30mg/m2 IV~* -5 Fludarabine 30mg/m2 IV~* -4 Fludarabine 30mg/m2 IV~* -3 Melphalan 140mg/m2 IV~* -2 Rest Day~* -1 Rest Day~* 0 Stem Cell Infusion"
62223481|NCT03470246|NO_INTERVENTION|CABG control group|The group of coronary artery disease patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after coronary artery bypass grafting. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
62433442|NCT03077828|EXPERIMENTAL|Treatment (pembrolizumab, etoposide, carboplatin, ifosfamide)|Patients receive pembrolizumab IV over 30 minutes on day 1, etoposide IV over 60 minutes on days 1-3 of courses 1-2, carboplatin IV over 60 minutes on day 2 of courses 1-2, and ifosfamide IV over 24 hours on day 2 of courses 1-2. Pembrolizumab in combination with ICE chemotherapy repeats every 21 days for 2 courses, patients will then receive pembrolizumab as monotherapy on course 3.
62798590|NCT04095182|PLACEBO_COMPARATOR|Placebo for Zebinix 400mg|
62798591|NCT04095182|EXPERIMENTAL|Zebinix 800mg|
62798592|NCT04095182|PLACEBO_COMPARATOR|Placebo for Zebinix 800mg|
62798593|NCT04095182|EXPERIMENTAL|Zebinix 1600mg|
62798594|NCT04095182|PLACEBO_COMPARATOR|Placebo for Zebinix 1600mg|
62798595|NCT03318380|EXPERIMENTAL|Diagnostic Contrast-Enhanced Ultrasound Imaging (CEUS)|Patients receive sulfur hexafluoride IV and undergo CEUS imaging over 10 minutes.
62798596|NCT01749878|EXPERIMENTAL|Group A: Cohorts 1 through 6|"Group A:~Cohorts 1 through 3 will receive REGN1500 subcutaneous (SC) or placebo Cohorts 4 through 6 will receive REGN1500 intravenous (IV) or placebo"
62798597|NCT01749878|EXPERIMENTAL|Group B|Group B will receive REGN1500 IV or placebo
62798598|NCT01749878|EXPERIMENTAL|Group C: Cohorts 1 and 2|"Group C:~Cohort 1 will receive REGN1500 SC or placebo Cohort 2 will receive REGN1500 IV or placebo"
62025714|NCT03973190|ACTIVE_COMPARATOR|SBC Group|Fill bone alveolus with Bone Ceramic® graft (Straumann AG, Basel, Switzerland) and cover it with palatal flap according to the technique of Khoury et al. (2000).
62025715|NCT03973190|ACTIVE_COMPARATOR|PRO Group|Alveolus sealing by a temporary ovoid pony of acrylic resin.
62025716|NCT03925636|EXPERIMENTAL|Dietary therapy for C. difficile colonization|Dietary therapy intervention for this arm is the Specific Carbohydrate Diet.
62223482|NCT03470246|EXPERIMENTAL|PACO intervention for CABG patients|The group of coronary artery disease patients receiving the PACO intervention for CABG patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after coronary artery bypass grafting. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
62223483|NCT03470246|NO_INTERVENTION|AVR control group|The group of aortic valve stenosis patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after aortic valve replacement. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
62417179|NCT05181709|ACTIVE_COMPARATOR|Cohort 4: NDV-HXP-S low dose IN+IM in combination|Participants in Cohort 4 (low, IN+IM) will receive low doses of NDV-HXP-S at 3.3x108 EID50. Participants will be given NDV-HXP-S in an ambulatory setting where IN and IM doses will be given in succession. Participants will be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.
62417180|NCT05181709|ACTIVE_COMPARATOR|Cohort 5: NDV-HXP-S high dose IN|Participants in Cohort 5 (high, IN) will receive high doses of NDV-HXP-S at 1x109 EID50. Participants will ONLY enroll into Cohort 5 if Cohort 2 (low dose IN) did not have any SAEs that required additional participants. Participants will be given NDV-HXP-S in an ambulatory setting and be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.
62798599|NCT03761186|ACTIVE_COMPARATOR|traditional diabetes diet|Participants in this arm will follow a diet with carbohydrate intake 50-60% of total energy intake
62798600|NCT03761186|EXPERIMENTAL|moderately low carbohydrate diet|Participants in this arm will follow a diet with carbohydrate intake 30-40% of total energy intake
62798601|NCT03761186|EXPERIMENTAL|strictly low carbohydrate diet|Participants in this arm will follow a diet with carbohydrate intake 15-20% of total energy intake
62798602|NCT05346575|ACTIVE_COMPARATOR|Usual Care|Participants randomized to this arm will receive the usual obesity care, but will complete assessments every 6 months.
62798603|NCT05346575|EXPERIMENTAL|TOTAL intervention|Participants randomized to this arm will watch the TOTAL intervention video and participate in 1:1 motivational sessions every 6 months. Participants will also complete assessments every 6 months.
62798604|NCT01575431||Stable angina|Patients who undergo an elective and successful single or multivessel percutaneous coronary intervention can be considered for the study.
62798605|NCT02307058|EXPERIMENTAL|LEAD RT Group|Participants in this group will receive the Lattice Extreme Ablative Dose (LEAD) radiotherapy. Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 39 fractions over approximately 8 weeks.
62798606|NCT02307058|EXPERIMENTAL|HEIGHT RT Group|Participants in this group will receive the Hypofractionated Extended Image-Guided Highly Targeted (HEIGHT) radiotherapy. Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 39 fractions over approximately 7 and a half weeks.
62798607|NCT04078555|EXPERIMENTAL|ENERGI-F703 GEL|topical application on target venous leg ulcer, twice daily
62798608|NCT04078555|PLACEBO_COMPARATOR|ENERGI-F703 GEL matched vehicle|topical application on target venous leg ulcer, twice daily
62798609|NCT02825615|ACTIVE_COMPARATOR|Conventional method (CM)|Radial artery cannulation has been done using the conventional method. Cannulation failure with this technique were tried with USG technique secondarily.
62798610|NCT02825615|EXPERIMENTAL|Ultrasound guided method (USG)|Radial artery cannulation is done with ultrasound guidance for this group of patients. Cannulation failure with this technique were tried with Conventional technique secondarily.
62798611|NCT03836768|EXPERIMENTAL|Experimental Treatment|DTRMWXHS-12, oral capsule, daily, 28 days as a cycle
62798612|NCT05711121|ACTIVE_COMPARATOR|S1 transforaminal|The group receiving S1 transforaminal epidural steroid injection
62798613|NCT05711121|ACTIVE_COMPARATOR|Caudal|The group receiving caudal epidural steroid injection
62798614|NCT05923814|EXPERIMENTAL|treatment arm|
62025717|NCT03663751|EXPERIMENTAL|Treatment|The peripheral and bone marrow T cell and mono nucleated cell chimerism will be closely followed-up. In case of decreasing donor chimerism, patients will receive low-dose decitabine with 5mg/m2 daily for 5 days every 6-8 weeks until the chimerism recovered to full donor type (\>98%).
62025718|NCT04656158|EXPERIMENTAL|Therapeutic horticulture|handling (gardening equipment) and gardening task (outdoor and greenhouse tasks)
62025719|NCT04656158|ACTIVE_COMPARATOR|Handiwork|Handling tasks (materials) and handiwork (manufacturing of piece of wooden furniture)
62798615|NCT02441023|EXPERIMENTAL|Nutritional therapy and education|"1. Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.~2. Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials."
62798616|NCT02441023|NO_INTERVENTION|Nutritional Therapy|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.
62223484|NCT03470246|EXPERIMENTAL|PACO intervention for AVR patients|The group of aortic valve stenosis patients receiving the PACO intervention for AVR patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after aortic valve replacement. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
62798617|NCT01951560|EXPERIMENTAL|valproic acid (Depacon)|Valproic acid by IV infusion over one hour
62798618|NCT01951560|PLACEBO_COMPARATOR|Isotonic saline solution|The placebo administered by IV infusion over 1 hour
62798619|NCT05864417|EXPERIMENTAL|Sunscreen|Participants will choose one facial sunscreen (SPF 70) out of the two (one with a light tone \[Color 2.0\] and another with a medium tone \[Color 3.0\]) based on the tone that best suits their skin color. At home, they will apply a generous amount of facial sunscreen to the face twice daily and will reapply when they feel the need up to 84 + (-) 2 days.
62798620|NCT02735668|ACTIVE_COMPARATOR|Shoulder Conventional Exercises|"The protocol consists in:~* Flexibility and Strengthening Exercises of the shoulder muscles conventionally performed in shoulder pathology treatment.~* Therapeutic Education about chronic shoulder pain.~The treatment duration is 1 day per week during 6 weeks."
62025720|NCT04691869|NO_INTERVENTION|Control|Patients will be randomized into a control group and study group. The control group will receive an informational discussion with the nurse-practitioner regarding steps to reduce the risk for osteoporosis, as well as an informational handout in their discharge papers.
62223485|NCT03470246|NO_INTERVENTION|MVR control group|The group of mitral valve insufficiency patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after mitral valve repair. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
62223486|NCT03470246|EXPERIMENTAL|PACO intervention for MVR patients|The group of mitral valve insufficiency patients receiving the PACO intervention for MVR patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after mitral valve repair. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
62223487|NCT06425874||Breast-conserving surgery|
62223488|NCT06425874||Mastectomy|
62223489|NCT06425874||Mastectomy with reconstruction|
62223490|NCT00470340|EXPERIMENTAL|1|Oxaliplatin, gemcitabine, cisplatin, lipiodol
62223491|NCT00470340|EXPERIMENTAL|2|Oxaliplatin, gemcitabine, cisplatin, lipiodol
62223492|NCT05451498|EXPERIMENTAL|Creatine Pre-Exercise|Consumes creatine within one hour before training and placebo within one hour after training
62223493|NCT05451498|EXPERIMENTAL|Creatine Post-Exercise|Consumes placebo within one hour before training and creatine within one hour after training
62223494|NCT05451498|PLACEBO_COMPARATOR|Placebo|Consumes placebo within one hour before training and placebo within one hour after training
62223495|NCT01813929|EXPERIMENTAL|Metformin|
62223496|NCT01813929|PLACEBO_COMPARATOR|Placebo|
62223497|NCT02865486|EXPERIMENTAL|Lipid emulsion: visit 2|One of four randomly assigned lipid emulsions
62223498|NCT02865486|EXPERIMENTAL|Lipid emulsion: visit 3|One of four randomly assigned lipid emulsions
62223499|NCT02865486|EXPERIMENTAL|Lipid emulsion: visit 4|One of four randomly assigned lipid emulsions
62433443|NCT06528028|EXPERIMENTAL|treatment group|Ceftazidime/avibactam（Taidingping®, Qilu Pharmaceutical Co., Ltd.） loading dose of 2.5g (2h infusion), then the standard dose and administration schedule, namely 2.5gQ8h, continuous infusion, the dose can be adjusted according to the instructions of renal function，The duration of medication is determined by the clinician
62223500|NCT04360317|EXPERIMENTAL|Experimental group|
62223501|NCT03046654|EXPERIMENTAL|Cervical cerclage|Women with a poor obstetric history that require cervical cerclage in order to avoid late abortion/early delivery.
62223502|NCT00705679|EXPERIMENTAL|1|TDF 300 mg tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
62223503|NCT00705679|EXPERIMENTAL|2|TDF placebo tablet taken orally once daily and one FTC 200 mg/TDF 300 mg tablet taken orally once daily for 12 to 36 months
62223504|NCT00705679|EXPERIMENTAL|3|TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
62223505|NCT00705679|EXPERIMENTAL|4|Application of tenofovir 1% vaginal gel once daily
62223506|NCT00705679|EXPERIMENTAL|5|Application of tenofovir placebo gel once daily
62223507|NCT05027997|EXPERIMENTAL|Dipraglurant 50 mg|
62223508|NCT05027997|EXPERIMENTAL|Dipraglurant 100 mg|
62223509|NCT05027997|PLACEBO_COMPARATOR|Placebo|
62223510|NCT05506579|EXPERIMENTAL|Intervention group|Exercises for knees, lower back and hip/groin in an expanded warm up program. In addition, the warm up program will include pelvic floor muscle training (PFMT). The warm up program will in total take approximately 12-15 minutes to conduct each training.
62223511|NCT05506579|NO_INTERVENTION|Control group|No intervention.
62223512|NCT04479631|EXPERIMENTAL|Cohort 1|BRII-196 dose level 1 or placebo
62223513|NCT04479631|EXPERIMENTAL|Cohort 2|BRII-196 dose level 2 or placebo
62223514|NCT04479631|EXPERIMENTAL|Cohort 3|BRII-196 dose level 3 or placebo
62223515|NCT00486629|EXPERIMENTAL|Intervention|Lifestyle intervention
62798621|NCT02735668|EXPERIMENTAL|Multimodal Physiotherapy|"The protocol consists in:~* Dry Needling in active myofascial trigger points.~* Neurodynamic techniques.~* Scapular exercises.~* Therapeutic Education about chronic shoulder pain.~The treatment duration is 1 day per week during 6 weeks."
62025721|NCT04691869|EXPERIMENTAL|Interventional|The study group will undergo the QUS (performed by a member of the study team) and receive the same informational discussion and handouts, with the addition of a QUS screening to take to their follow-up appointment. The QUS screening will come with a half-page description, describing the screening and what their results mean. A discussion lead by the nurse-practitioner, who is a member of the study staff, regarding the results will happen prior to discharge.
62798622|NCT02735668|EXPERIMENTAL|Scapular exercises|"The protocol consists in:~* Scapular exercises~* Therapeutic Education about chronic shoulder pain.~The treatment duration is 1 day per week during 6 weeks."
62798623|NCT02085018|EXPERIMENTAL|Omeprazole|Omeprazole 20 milligrams twice a day taken for 90 days
62798624|NCT02085018|PLACEBO_COMPARATOR|Matched placebo|Matched placebo twice a day taken for 90 days
62798625|NCT04755608|EXPERIMENTAL|Low Intensity Blood Flow Restriction Group|
62798626|NCT04755608|ACTIVE_COMPARATOR|High Intensity Resistant Training Group|
62798627|NCT01800383||Control|No Axis I psychiatric disorder and no trauma exposure
62798628|NCT01800383||Trauma-Exposed Normal Control|History of trauma exposure and subthreshold PTSD symptoms.
62798629|NCT01800383||PTSD|Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of PTSD as determined by the Structured Clinical Interview for DSM-IV-Text Revised
62798630|NCT00962637|EXPERIMENTAL|1|Androxal™ 12.5 mg
62798631|NCT00962637|EXPERIMENTAL|2|Androxal™ 25 mg
62798632|NCT00962637|ACTIVE_COMPARATOR|3|AndroGel®
62798633|NCT00962637|PLACEBO_COMPARATOR|4|Placebo
62798634|NCT02883803|EXPERIMENTAL|MSC|Patients hospitalized in recovery unit and having a very severe septic shock with community origin (≥ 2 organ failures other than hemodynamic) since less than 12 hours, will receive 10\^6/kg heterologous mesenchymal stem cells in 250 ml albumin 4%, infused for 30 minutes in central venous line.
62223516|NCT00486629|NO_INTERVENTION|Control|No intervention
62223517|NCT01354561|SHAM_COMPARATOR|control group|Physiotherapy in the control group were also done at hospital, in dorsal decubitus position at 30-degree elevation, all receiving the same treatment given for the paediatric inpatients, except nasotracheal suction, which was not performed due to ethical reasons.
62223518|NCT01354561|ACTIVE_COMPARATOR|respiratory disease group|Respiratory disease group consisting of hospitalized children with acute viral bronchiolitis
62223519|NCT06000137|EXPERIMENTAL|group S|sufentanil 2μg/kg + flurbiprofen 250mg+granisetron 6mg
62223520|NCT06000137|ACTIVE_COMPARATOR|group D1|dezocine 0.5mg/kg + flurbiprofen 250mg+granisetron 6mg
62223521|NCT06000137|ACTIVE_COMPARATOR|group D2|dezocine 0.6mg/kg + flurbiprofen 250mg+granisetron 6mg
62223522|NCT02880345|ACTIVE_COMPARATOR|Cohort 1 - 8 Gy x 3 fractions|8 Gy x 3 fractions
62223523|NCT02880345|ACTIVE_COMPARATOR|Cohort 2 - 17 Gy x 1 fractions|17 Gy x 1 fraction
62223524|NCT06226090|EXPERIMENTAL|TG103 7.5 mg|
62223525|NCT06226090|PLACEBO_COMPARATOR|Placebo 7.5 mg|
62223526|NCT06226090|EXPERIMENTAL|TG103 15 mg|
62223527|NCT06226090|PLACEBO_COMPARATOR|Placebo 15 mg|
62223528|NCT06226090|EXPERIMENTAL|TG103 22.5 mg|
62798635|NCT02883803|SHAM_COMPARATOR|Placebo|Patients hospitalized in recovery unit and having a very severe septic shock with community origin (≥ 2 organ failures other than hemodynamic) since less than 12 hours, will receive 250 ml albumin 4%, infused for 30 minutes in central venous line.
62798636|NCT05822882||Patients with epidural anesthesia|Patients following Abdominoplasty with postoperative epidural anesthesia via pain catheter
62798637|NCT05822882||Patients without epidural anesthesia|Patients following Abdominoplasty without postoperative epidural anesthesia
62798638|NCT05375591||Benign Nodules|CT scans of patients with a new lung nodule(s) subsequently confirmed to be benign and in the context of a previous history of radically treated cancer, will be identified at participating NHS sites and recruited.
62798639|NCT05375591||Metastatic Nodules|CT scans of patients with a new lung nodule(s) subsequently confirmed to be metastatic in nature and in the context of a previous history of radically treated cancer, will be identified at participating NHS sites and recruited.
62798640|NCT05375591||Second Primary Lung Cancers|CT scans of patients with a new lung nodule(s) subsequently confirmed to be a new second primary lung cancer and in the context of a previous history of radically treated cancer, will be identified at participating NHS sites and recruited.
62798641|NCT05413161|EXPERIMENTAL|ADL-018|150 mg/mL, Solution for injection in PFS
62798642|NCT05413161|ACTIVE_COMPARATOR|US-Licensed XOLAIR|150 mg/mL, Solution for injection in PFS
62223529|NCT06226090|PLACEBO_COMPARATOR|Placebo 22.5 mg|
62417181|NCT05181709|ACTIVE_COMPARATOR|Cohort 6: NDV-HXP-S high dose IM|Participants in Cohort 6 (high, IM) will receive high doses of NDV-HXP-S at 1x109 EID50. Participants will ONLY enroll into Cohort 6 if Cohort 3 (low dose IM) did not have any SAEs that required additional participants. Participants will be given NDV-HXP-S in an ambulatory setting and be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.
62417182|NCT05181709|ACTIVE_COMPARATOR|Cohort 7: NDV-HXP-S high dose IN+IM in combination|Participants in Cohort 7 (high, IN+IM) will receive high doses of NDV-HXP-S at 1x109 EID50. Participants will only enroll into Cohort 7 if Cohort 4 did not have an SAE that required additional participants. Participants will be given NDV-HXP-S in an ambulatory setting and be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collection and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.
62417183|NCT00345826|EXPERIMENTAL|Dasatinib|
62223530|NCT02407990|EXPERIMENTAL|BGB-A317 Phase 1A|
62588570|NCT05839197|EXPERIMENTAL|HAIC Combined With Apatinib and Camrelizumab|"All patients were treated with standard HAIC on the first day (D1). Immediately after the first HAIC, the liver function was reexamined. If the liver function was grade Child-Pugh A, Camrelizumab was given intravenously once every 3 weeks (D1) on the same day, 200mg/, once every 3 weeks (D1).~Apatinib capsule was given orally to 250mg within half an hour after breakfast on the second day (D2) after the first HAIC. The drug was given continuously once a day and stopped on the same day of each HAIC.~The combination of drugs for 3 weeks is a cycle.The treatment continued until the patient developed the disease or met the other criteria for terminating the study."
62798643|NCT05413161|ACTIVE_COMPARATOR|EU-Approved XOLAIR|150 mg/mL, Solution for injection in PFS
62798644|NCT00571974|EXPERIMENTAL|Phase 1 light dose escalation|"During Phase I, to determine the maximum tolerated energy density of the Pulse Dye Laser operated at 585 nm with a pulse time of 1.5 ms (PDL-585), when used in combination with 5-aminolevulinic acid (5-ALA) applied topically to the premalignant lesion.~The maximum tolerated energy density will be called the Maximum Tolerated Dose (MTD). Procedure: Fluorescence Diagnosis Imaging Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 6, 7 and 8 J/cm2."
62798645|NCT00571974|EXPERIMENTAL|Phase 2 - Treatment efficacy of PDT|"Procedure: Fluorescence Diagnosis Imaging~Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 8 J/cm2."
62223531|NCT02407990|EXPERIMENTAL|BGB-A317 Phase 1B|
62417184|NCT05361798|EXPERIMENTAL|1/Arm 1|De-escalating doses of M9241 if appropriate + SBRT
62417185|NCT05361798|EXPERIMENTAL|2/Arm 2a|Highest tolerated dose of M941+SBRT
62417186|NCT05361798|EXPERIMENTAL|3/Arm 2b|SBRT
62588571|NCT05866744|EXPERIMENTAL|Early Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet|Early 14:10 time-restricted feeding plus hypocaloric Mediterranean diet
62588572|NCT05866744|EXPERIMENTAL|Late Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet|Late 14:10 time-restricted feeding plus hypocaloric Mediterranean diet
62588573|NCT05866744|ACTIVE_COMPARATOR|Hypocaloric Mediterranean Diet Without Time Restriction In Feeding|Hypocaloric Mediterranean diet without time restriction in feeding
62588574|NCT06068881|EXPERIMENTAL|Tazverik (Tazemetostat)|800mg tablet orally twice daily in continuous 28-day cycles
62588575|NCT04366297|EXPERIMENTAL|Standard of Care (Intravenous Cannula)|obtaining intravascular access using a ready standard intravenous cannula
62798646|NCT00952029|EXPERIMENTAL|Maintenance with bevacizumab|FOLFIRI + Avastin and during the chemotherapy-free interval maintenance with bevacizumab
62798647|NCT00952029|ACTIVE_COMPARATOR|No maintenance with bevacizumab|FOLFIRI + Avastin and during the chemotherapy-free interval NO maintenance
62798648|NCT00673335|EXPERIMENTAL|Treatment arm|Letrozole, 1 tablet
62798649|NCT00673335|PLACEBO_COMPARATOR|Placebo|Comparator, 1 tablet
62223532|NCT00661479|EXPERIMENTAL|400 µg Brimonidine Tartrate Implant Group B|400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
62223533|NCT00661479|EXPERIMENTAL|200 µg Brimonidine Tartrate Implant Group B|200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
62223534|NCT00661479|EXPERIMENTAL|100 µg Brimonidine Tartrate Implant Group B|100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
62417187|NCT06701097|EXPERIMENTAL|Emotion regulation training group|Since the number of participants in the intervention group would prevent the training from being given as a group, the participants were divided into three different groups. Each group was given theoretical training on emotions, thoughts, physical symptoms resulting from emotions, and verbal and non-verbal ways of communicating emotions. The theoretical training was reinforced with activities such as relaxation exercises, role plays, imagination, brainstorming, etc. Each training lasted 60-90 minutes.
62588576|NCT04366297|EXPERIMENTAL|IO access using NIO® set|receive an IO line in the proximal tibia localization. IO lines are placed using an FDA-approved device called an NIO®.
62588577|NCT06666803|EXPERIMENTAL|FNB and blood sample analysis|
62223535|NCT00661479|EXPERIMENTAL|100 µg Brimonidine Tartrate Implant Group A|100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
62223536|NCT06124287||Crohn's Disease patients stopping biologic therapy|Crohn's Disease patients stopping biologic therapy and undergoing MR Enterography 3 months before or 1 month after this decision as part of standard clinical care.
62588578|NCT03545295|EXPERIMENTAL|QLB 2 10ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 10 ml coloring solution
62588579|NCT03545295|EXPERIMENTAL|QLB 2 20ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 20 ml coloring solution
62798650|NCT03730532|EXPERIMENTAL|Randomised CBT|Cognitive Behavioural Therapy Guided Self Help
62798651|NCT03730532|EXPERIMENTAL|Randomised CAT|Cognitive Analytic Therapy Guided Self Help
62798652|NCT03730532|EXPERIMENTAL|Preference CAT|Cognitive Analytic Therapy Guided Self Help
62798653|NCT03730532|EXPERIMENTAL|Preference CBT|Cognitive Behavioural Therapy Guided Self Help
62025722|NCT03980470|OTHER|Normal-dose versus Low-dose|"The standard intervention consists of the routinely performed cardiac CT datasets reconstructed with a standard iterative reconstruction algorithm (ASIR-V). Median radiation dose is about 0.5 mSv, range between about 0.2 and 1.2 mSv; median contrast agent administration about 45 mL, range between 35 and 55 mL.~The experimental intervention is an additional CT scan with a lower dose (about 20 to 50% decrease) and a similar contrast agent administration that is reconstructed with a deep-learning image reconstruction immediately after the clinical CT scan. The additional time required is about 5 minutes."
62025723|NCT03873649||Patients with subacute or chronic hypersensitivity pneumonitis|"Procedures that each subject will undergo include:~1. Chest CT scan to determine extent of disease.~2. Pulmonary function testing to determine severity of disease.~3. Bronchoscopy with lavage.~4. Venipuncture."
62025724|NCT03873649||Healthy Controls|"Inclusion:~1. Adult between the ages of 18 and 80 years old.~2. Non-smoker or previous smoker quit \>6months ago.~3. Able to understand the consent process and procedures involved in the study.~Exclusion:~1. Unable to understand the consent process or procedures involved in the study.~2. Pregnancy.~3. Suspicion of current infection or within the past 3 months.~4. Bleeding disorder or on anti-coagulants other than aspirin.~5. Any co-morbid condition that increases risk of bronchoscopy including but not limited to cardiac disease, uncontrolled hypertension, uncontrolled diabetes and/or morbid obesity."
62025725|NCT02667158||No shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
62588580|NCT03545295|EXPERIMENTAL|QLB 2 30ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 30 ml coloring solution
62223537|NCT05416801||Volleyball Group|Female Volleyball players who are currently playing in a university team and who are meeting the inclusion criteria.
62223538|NCT05416801||Control Group|Female university students who are meeting the inclusion criteria.
62588581|NCT03545295|EXPERIMENTAL|QLB 3 10ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 10 ml coloring solution
62798654|NCT00941759||Known or suspected Stage IV disease & an intact primary|Pt will be asked to undergo a research core needle biopsy of the primary tumor. If pts are not agreeable to a research biopsy then the original diagnostic biopsy material will be requested. They will also undergo a diagnostic biopsy of a metastatic site, if not already performed, and a blood draw as appropriate for correlative science studies. Additionally, patients will complete a general medical questions form at the time of enrollment.
62798655|NCT00941759||Unsuspected metastatic disease W/I 3 months of primary b|A blood sample will be collected and patients will complete a general medical questions form at the time of enrollment. Paraffin tissue from the prior surgical procedure will be obtained as Tissue sample. Paraffin tissue from the diagnostic biopsy of a metastatic site will also be obtained. In the event that fresh frozen tissue is available for either site this will also be requested.
62798656|NCT04597593||ADR Group|ISTH bleeding scale Major Bleeding
62798657|NCT04597593||Control Group|No ADR, No Treatment Failure
62798658|NCT04597593||Treatment Failure Group|Recurrent MI, Ischemic stroke, Other thromboembolic disorders
62798659|NCT01586949|EXPERIMENTAL|Treatment|Intervention: Daily Challenge
62798660|NCT01586949|NO_INTERVENTION|Control|Weekly Well-being, an email-based health information delivery service.
62798661|NCT03351647||Group Ustekinumab|Patients presenting an active crohn's disease (HBI score ≥ 4) with an indication of treatment by ustekinumab because of failure or unacceptable side effects of previous treatments, and who have already been treated by at least one anti TNF The patients must be 18 years old or older.
62025726|NCT02667158||Minimal shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
62025727|NCT02667158||Marked shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
62223539|NCT00990977|NO_INTERVENTION|controls|assessment only
62223540|NCT00990977|EXPERIMENTAL|cases|MBSR including brief information session and assessments
62223541|NCT04310384|ACTIVE_COMPARATOR|Endotracheal Intubation, gold standart|Standart of Care with Macintosh laryngoscope
62223542|NCT04310384|ACTIVE_COMPARATOR|Alternative|Endotracheal Intubation with novel device
62417188|NCT06701097|NO_INTERVENTION|Control group|Participants in the control group did not receive any training. Only pre-test, post-test, and follow-up tests were applied to the individuals in this group.
62417189|NCT03681275|EXPERIMENTAL|Tofacitinib|Patient will receive two days treatment with tofacitinib prior to the surgery.
62417190|NCT03681275|PLACEBO_COMPARATOR|Placebo|Patient will receive two days treatment with placebo prior to the surgery.
62588582|NCT03545295|EXPERIMENTAL|QLB 3 20ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 20 ml coloring solution
62588583|NCT03545295|EXPERIMENTAL|QLB 3 30ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 30 ml coloring solution
62588584|NCT05778435|EXPERIMENTAL|wireless fetal monitoring group|wireless fetal monitoring system was applied to the experimental group
62223543|NCT03218345|EXPERIMENTAL|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea)
62223544|NCT00569556|NO_INTERVENTION|Usual Care|Patients receive care through primary care provider
62223545|NCT00569556|EXPERIMENTAL|Case Management|Specially trained nurse case managers contact patients by telephone; monitor blood pressure, LDL, and HgbA1C;, and recommend lifestyle and medication changes as needed
62223546|NCT04962243||Patients undergoing repair of Achilles tendon rupture|Patients undergoing repair of Achilles tendon rupture
62417191|NCT04035694|EXPERIMENTAL|Intervention|Participants will receive access to Media Aware.
62417192|NCT04035694|NO_INTERVENTION|Delayed-Intervention Control|Participants will receive their regular health education programming not related to sexual health education or media literacy education.
62588585|NCT05778435|NO_INTERVENTION|Control group|Standard wired fetal monitoring system was applied to the control group.
62588586|NCT04913155|OTHER|Reporting group (coronary calcium score and emphysema score)|Coronary calcium score and emphysema score are reported to subjects
62025728|NCT02667158||Extensive shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
62025729|NCT02078284|EXPERIMENTAL|Cohort 1 with 0.5 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 0.5 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
62025730|NCT02078284|ACTIVE_COMPARATOR|Cohort 1 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
62025731|NCT02078284|EXPERIMENTAL|Cohort 2 with 1 unit of CPP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
62417193|NCT01299272|EXPERIMENTAL|LY2216684 + SSRI|"Acute Open-label (OL) Period: Participants received a starting dose of 12 milligrams (mg) LY2216684, administered orally, once daily for at least 2 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI). Then, based on efficacy and tolerability, the dose could be increased to 18 mg (and decreased back to 12 mg) over the next 6 weeks.~Stabilization OL Period: Participants meeting remission criteria continued on the same dose of LY2216684 for an additional 12 weeks. Participants who discontinued early during either OL Period were discontinued abruptly from LY2216684.~Double-blind (DB) Randomized Withdrawal Period: At 20 weeks, participants meeting criteria for randomization continued their current dose of LY2216684 for another 24 weeks. Participants who completed this period or discontinued early were randomized to abrupt (placebo for 2 weeks) or tapered (12 mg LY2216684 for 4 days, 6 mg LY2216684 for 4 days, then placebo for 6 days) discontinuation of LY2216684."
62025732|NCT02078284|ACTIVE_COMPARATOR|Cohort 2 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
62025733|NCT02078284|EXPERIMENTAL|Cohort 3 with 2 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 2 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
62025734|NCT02078284|ACTIVE_COMPARATOR|Cohort 3 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
62025735|NCT02078284|EXPERIMENTAL|Cohort 4 with 3 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 3 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
62223547|NCT04962243||Subjects who underwent physical examination during the same period|Subjects who underwent physical examination in the Physical Examination Center of Peking University Third Hospital during the same period
62417194|NCT01299272|PLACEBO_COMPARATOR|Placebo + SSRI|"Acute Open-label (OL) Period: Participants received a starting dose of 12 milligrams (mg) LY2216684, administered orally, once daily for at least 2 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI). Then, based on efficacy and tolerability, the dose could be increased to 18 mg (and decreased back to 12 mg) over the next 6 weeks.~Stabilization OL Period: Participants meeting remission criteria continued on the same dose of LY2216684 for an additional 12 weeks. Participants who discontinued early during either OL Period were discontinued abruptly from LY2216684.~Double-blind (DB) Randomized Withdrawal Period: At 20 weeks, participants meeting criteria for randomization were tapered from their LY2216684 dose to placebo following the regimen of 12 mg for 7 days, 6 mg for 7 days, and placebo for the remaining 22 weeks. Participants who completed this period or discontinued early continued to receive placebo for an additional 2 weeks"
62417195|NCT06567951|NO_INTERVENTION|Control group (without EVOO supplementation)|No intervention will be performed in this group of participants
62025736|NCT02078284|ACTIVE_COMPARATOR|Cohort 4 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP
62025737|NCT01140191|EXPERIMENTAL|WR 279,396|All subjects in this one-arm study will receive topical WR 279,396
62025738|NCT01055366|EXPERIMENTAL|Elazop (Azarga)|Elazop Treatment arm
62025739|NCT04986657|EXPERIMENTAL|Patients: ChromoSeq|ChromoSeq will be performed on bone marrow DNA from consented patients in parallel with the standard of care cytogenetics, FISH, and the MyeloSeq gene panel obtained from that sample, in a CLIA licensed environment using CLIA-compliant ChromoSeq procedures.
62025740|NCT04986657|NO_INTERVENTION|Stakeholders (Treating Physicians)|-Stakeholders (treating physicians) will complete surveys/questionnaires. As of protocol amendment 10/31/2023, the stakeholders (treating physicians) will no longer be completing surveys/questionnaires.
62025741|NCT00581529|EXPERIMENTAL|Radiotherapy|IMRT (Intensity-modulated Radiation Therapy), 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
62025742|NCT02106026|NO_INTERVENTION|Conventional|All expectant mothers received the usual information about the advantages of maternal milk during pre-natal period. Nurses provided the information in personalized dialogue with the women during obstetric consultations.
62025743|NCT02106026|EXPERIMENTAL|Preventive education|It was provided by the nurses during obstetric consultation in pre-natal period and averaged 30 minutes in duration. The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures. The nurses encouraged participation and gave the education in personalized dialogue with the woman. The information was reinforced with an illustrated explanatory leaflet.
62025744|NCT06496893|ACTIVE_COMPARATOR|Active 1200 mg per soft gel capsule|"Combination of Vitamin B1, B6, B12, D3, Chromium Picolinate, Proprietary Mulberry Leaf Extract, Cinnamon Bark Powder, Gymnema Sylvestre Extract, Insulina (Cissus Sicyoides) Leaf Extract, Alpha Lipoic Acid, Phellodendron Bark Extract (Berberine HCL), Cissus Quadrangularis Extract, Banaba Leaf Extract, \& Fish Oil.~Two soft gels to be taken with breakfast and two soft gels to be taken with dinner"
62025745|NCT06496893|PLACEBO_COMPARATOR|Placebo (Soyabean oil) 1200 mg per soft gel capsule|Two soft gels to be taken with breakfast and two soft gels to be taken with dinner
62025746|NCT02855099|ACTIVE_COMPARATOR|CR group|patients will be referred to our rehabilitation centre at the following week after the procedure, and assigned to a personalized rehabilitation program for duration of 3 month.
62025747|NCT02855099|NO_INTERVENTION|conservative group|No intervention
62417196|NCT06567951|EXPERIMENTAL|EVOO group (with EVOO supplementation)|The intervention will be daily EVOO suplementation (36mL) form gestational week 28 until delivery
62588587|NCT04913155|OTHER|Reporting group (coronary calcium score only)|Only coronary calcium score is reported to subjects
62223548|NCT02288247|EXPERIMENTAL|Enzalutamide|Participants received an OL treatment with enzalutamide 160 milligrams (mg) capsules, orally once daily from day 1 in period 1 until randomization to period 2, confirmation of ineligibility for period 2, intolerable toxicity, withdrawal, or death. Participants with confirmed disease progression on enzalutamide in period 1 and who continued to meet all eligibility criteria received enzalutamide 160 mg capsules, orally once daily in combination with docetaxel 75 milligrams per square meter (mg/m\^2) in a one-hour infusion every 3 weeks and prednisolone 5 mg orally twice daily, DB period 2. Docetaxel and prednisolone were administered up to 10 cycles (3 weeks/cycle) or more as assessed by the investigator. Enzalutamide was administered until disease progression, intolerable toxicity, withdrawal or death. Participants could continue the extension period, until investigator or participant decided to stop or disease progression, intolerable toxicity, withdrawal or death.
62223549|NCT02288247|PLACEBO_COMPARATOR|Placebo|Participants received an OL treatment with enzalutamide 160 mg capsules, orally once daily from day 1 in period 1 until randomization to period 2, confirmation of ineligibility for period 2, intolerable toxicity, withdrawal, or death. Participants with confirmed disease progression on enzalutamide in period 1 and who continued to meet all eligibility criteria received placebo matched to enzalutamide, orally once daily in combination with docetaxel 75 mg/m\^2 in a one-hour infusion every 3 weeks and prednisolone 5 mg orally twice daily, in period 2. Docetaxel and prednisolone were administered up to 10 cycles (3 weeks/cyle) or more as assessed by the investigator. Enzalutamide was administered until disease progression, intolerable toxicity, withdrawal or death. Participants could continue the extension period, until investigator or participant decided to stop or disease progression, intolerable toxicity, withdrawal or death.
62223550|NCT02627729|ACTIVE_COMPARATOR|Linear cutter-Circular stapler J pouch|J pouch anal anastomosis after laparoscopic low anterior resection
62223551|NCT02627729|ACTIVE_COMPARATOR|Circular stapler Side-to-end anastomosis|side to end coloanal anastomosis after laparoscopic low anterior resection
62417197|NCT06681896|EXPERIMENTAL|MICROFIT + Usual Care|MICROFIT intervention will be delivered in addition to Usual Care arm clinical review and advice. MICROFIT is a 24-week long personalized one-on-one exercise and dietary education intervention, along with home exercise guided by personal trainers. Exercise intervention includes High Intensity Interval Training (HIIT) and dietary advice focuses on incorporation of a Mediterranean-type diet.
62417198|NCT06681896|NO_INTERVENTION|Usual Care|All patients will be reviewed clinically by a cardiologist. They will address cardiovascular risk factors and prescribe any therapies as indicated by current medical guidelines, for example statin or ACE inhibitors. The Cardiologist will also provide routine, verbal one-off lifestyle advice in line with NICE guidance, recommending 150 minutes of moderate exercise per week, encouraging a healthy, balanced diet, weight loss, reducing alcohol consumption and smoking cessation where necessary.
62417199|NCT03926728|EXPERIMENTAL|Cohort A 85 mcg CTH522-CAF01|Cohort A received three IM vaccination of 85 mcg CTH522-CAF01 (Day 0, 28, and 112). This cohort was divided into two groups: Cohort A1 receives placebo at Day 28, 112, and 140, while cohort A2 received placebo at Day 28 and 112, but non-adjuvanted TO CTH522 boost at Day 140.
62417200|NCT03926728|EXPERIMENTAL|Cohort B 85 mcg CTH522-CAF01 + TO CTH522|Cohort B received three IM vaccination of 85 mcg CTH522-CAF01 (Day 0, 28, and 112). This cohort was divided into two groups: Cohort B1 received TO vaccination of the non-adjuvanted CTH522 at Day 28 and 112 and TO placebo at Day 140, while cohort B2 received the same for Day 28 and 112, but non-adjuvanted TO CTH522 boost at Day 140.
62025748|NCT06626191|ACTIVE_COMPARATOR|Interscalene brachial plexus block|After the patients are monitored and in the supine position, after appropriate field sterilization, interscalene brachial plexus block will be performed on the patients using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance. In the intraoperative period, intravenous analgesics (dexketoprofen 50 mg, tramadol 100 mg) will be given.
62025749|NCT06626191|ACTIVE_COMPARATOR|Serratus posterior superior intercostal plane block|After the patients are monitored and in the supine position, after appropriate field sterilization, a serratus posterior superior intercostal plane block will be performed on the patients using 30 ml of local anesthetic solution (0.25% bupivacain) under ultrasound guidance. In the intraoperative period, intravenous analgesics (dexketoprofen 50 mg, tramadol 100 mg) will be given.
62025750|NCT06626191|ACTIVE_COMPARATOR|Group without peripheral nerve block|After the patients are monitored, they will be operated under general anesthesia without peripheral nerve block and intraoperative intravenous analgesics (dexketoprofen 50 mg, tramadol 100 mg) will be given.
62025751|NCT04108546|EXPERIMENTAL|massage-electroacupuncture|Electroacupuncture will be applied throughout the back of the body, upper limbs and ears.Massage will follow the same paths of acupuncture points respectively
62223552|NCT05878301|OTHER|standard mixed meal (SMM)|standard mixed meal (SMM) consumed within 15 min to compared to the vegetable protein first followed 10 min later by carbohydrates it with the effect on postprandial glucose ,insulin and hunger rating
62223553|NCT02750982|EXPERIMENTAL|Laughter therapy|effects of Laughter therapy (LT) on mood, self-efficacy and other wellness measures in people with neurological conditions.
62223554|NCT00318071|EXPERIMENTAL|Treatment|Treatment arm patients had at least one Merci Retriever deployed
62417201|NCT03926728|EXPERIMENTAL|Cohort C 85 mcg CTH522-CAF01 + ID CTH522|Cohort C received three IM vaccination of 85 mcg CTH522-CAF01 (Day 0, 28, and 112). This cohort was divided into two groups: Cohort C1 received ID vaccination of the non-adjuvanted CTH522 at Day 28 and 112 and TO placebo at Day 140, while cohort C2 received the same for Day 28 and 112, but TO CTH522 boost at Day 140.
62417202|NCT03926728|EXPERIMENTAL|Cohort D 15 mcg CTH522-CAF01|Cohort D received three IM vaccination of 15 mcg CTH522-CAF01 (Day 0, 28, and 112). This cohort was divided into two groups: Cohort D1 received TO placebo given on Day 28, 112, and 140, while cohort D2 received ID placebo given on Day 28 and 112 and TO unadjuvanted CTH522 on Day 140.
62417203|NCT03926728|EXPERIMENTAL|Cohort E 85 mcg CTH522-CAF09b|Cohort E received three IM vaccination of 85 mcg CTH522-CAF09b (Day 0, 28, and 112). This cohort was divided into two groups: Cohort E1 received TO placebo given on Day 28, 112, and 140, while cohort E2 received ID placebo given on Day 28 and 112 and TO unadjuvanted CTH522 on Day 140.
62798662|NCT01699230|EXPERIMENTAL|Omega 3 supplemented patients|To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
62025752|NCT04108546|ACTIVE_COMPARATOR|Epidural analgesia|Epidural analgesia will be applied using ropivacaine 0.2%, 5-7% ml and Fentanyl 25 mcg
62025753|NCT00724347|EXPERIMENTAL|Arm 1|Hearing impaired listeners with hearing aids underwent two months of consonant identification training in their homes.
62223555|NCT05416073|EXPERIMENTAL|Esketamine-PCIA(patient controlled intravenous analgesia)|PCIA formula：100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline.
62223556|NCT05416073|ACTIVE_COMPARATOR|Sufentanil-PCIA(patient controlled intravenous analgesia)|PCIA formula：100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline.
62223557|NCT03635593|ACTIVE_COMPARATOR|CBD|10mg capsules Cannabidiol (CBD)
62588588|NCT04913155|OTHER|Reporting group (emphysema score only)|Only emphysema score is reported to subjects
62588589|NCT04913155|OTHER|Non-reporting group|Coronary calcium score and emphysema score are not reported to subjects
62588590|NCT04913155|NO_INTERVENTION|Low-risk group|No CT screening, collection of health data only
62588591|NCT04505540|EXPERIMENTAL|Bridge Clinic|Medication assisted treatment supervised by addiction bridge clinic until stabilized in treatment.
62223558|NCT03635593|ACTIVE_COMPARATOR|CBD+THC|10mg capsules Cannabidiol (CBD) +THC tetrahydrocannabinol (CBD 5mg + (THC)
62223559|NCT03635593|PLACEBO_COMPARATOR|Placebo|10mg capsules placebo
62798663|NCT01699230|NO_INTERVENTION|Control group|
62223560|NCT03730480|EXPERIMENTAL|Subjects with and without Diabetes test Contour Next and Contour TV3|All subjects test CONTOUR NEXT BGMS and CONTOUR TV3 BGMS
62798664|NCT04824469|EXPERIMENTAL|web based training|"* Patients on the first day; Patient Information Form (1st and 2nd part), Memorial Symptom Assessment Scale, Covid-19 Symptom Assessment Inventory, Morisky Compliance Scale, World Health Organization Quality of Life Scale Short Form Turkish Version, E-Health literacy scale on website or mobile devices Google via the form or by sending a phone link.~* Morisky Compliance Scale will be applied on the 7th day by sending a link to the website or mobile devices via google form.~* Patients in the intervention group will be asked to fill out the Covid-19 Symptom Assessment Inventory on the website when they experience changes in their symptoms.~* Patients in the intervention group will be provided with web-based training and telephone (SMS) reminder service for 4 weeks.~* All questionnaires and web site evaluation form will be filled in the pre-test after 4 weeks."
62223561|NCT03436251|EXPERIMENTAL|Local Hyperthermia at 44℃ for HPV+/CIN-1|Local hyperthermia at 44℃ for 30 mins on cervical region, at days of 1,2,3 and 17, 18. HPV+ and normal cytology or HPV+/CIN-1
62223562|NCT03436251|SHAM_COMPARATOR|local hyperthermia at 37℃ for 30 mins|HPV+/CIN-1
62223563|NCT03436251|ACTIVE_COMPARATOR|coniztion of the cervix treatment|coniztion of cervix for HPV+/CIN2, including LEEP or cold knife coniztion
62588592|NCT02320773||1. OAB patients taking Betmiga®|OAB patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment
62798665|NCT04824469|NO_INTERVENTION|standard care|The scales applied to the intervention group on the first day, by sending the E-Health literacy scale form or phone link via Google on mobile devices. The symptoms of the patients in the control group will be evaluated at the end of the 1st day, 7th day, 14th day and 4th day. No intervention was planned for the patients in the control group during the follow-up. In the standard practice protocol, after patients are informed for follow-up and treatment at home, they are called by the Ministry of Health and family physicians for symptom follow-up. The standard hospital protocol does not include a scheduled training program, telephone monitoring, or web-based training. After collecting the data in the intervention group, the website will be opened to the use of the control group.
62798666|NCT06006195||patients with dysphagia symptoms|
62798667|NCT06006195||patients without dysphagia symptoms|
62798668|NCT06375213||Cognitively healthy|This cohort includes participants with or without subjective complaints whose results of cognitive examination are normal. Participants will undergo clinical, epidemiological, and cognitive assessments, as well as biospecimen collection every two years, over an 8-year follow-up period.
62798669|NCT06375213||Mild cognitive impairment|This cohort includes participants whose results of cognitive examination are abnormal but have not met the criteria for dementia. Participants will undergo annual clinical, epidemiological, and cognitive assessments, as well as biospecimen collection, for a duration of six years.
62798670|NCT06375213||Late onset dementia|This cohort includes participants with dementia whose symptoms onset after the age of 65. Participants will undergo annual clinical, epidemiological, and cognitive assessments, as well as biospecimen collection, for a duration of two years.
62798671|NCT06375213||Early onset dementia|This cohort includes participants with dementia whose symptoms onset before the age of 65. Participants will undergo annual clinical, epidemiological, and cognitive assessments, as well as biospecimen collection, for a duration of six years.
62223564|NCT03436251|EXPERIMENTAL|Local Hyperthermia at 44℃ for CIN2/HPV+|Local hyperthermia at 44℃ for 30 mins at days of 1,2,3 and 17, 18. HPV+ and CIN2.
62223565|NCT06610786|EXPERIMENTAL|FCSB|Using foldable capsular scleral buckle surgery to treat primary rhegmatogenous retinal detachment (RRD) of medium complexity
62223566|NCT06610786|ACTIVE_COMPARATOR|PPV|Using pars plana vitrectomy to treat primary rhegmatogenous retinal detachment (RRD) of medium complexity
62223567|NCT01765166|EXPERIMENTAL|Control(ChO)|Children receive traditional SSGRIN child treatment with no parent involvement
62417204|NCT03926728|PLACEBO_COMPARATOR|Cohort F Placebo|Cohort F received three IM vaccinations of placebo in form of 0.9% NaCl saline (Day 0, 28, and 112).This cohort was divided into two groups: Cohort F1 received TO placebo given on Day 28, 112, and 140, while cohort F2 received ID placebo given on Day 28 and 112 and TO placebo on Day 140.
62223568|NCT01765166|EXPERIMENTAL|Parent attention control(PAC)|Children will participate in traditional SSGRIN treatment, and parents will participate in a weekly support group to meet with other parents regarding their child's peer relations and behavior. The support group will meet for a parallel amount of time (1 hour/week for 10 weeks) and be facilitated by two parents with no SSGRIN or Parent Guide experience. The PAC condition will reflect the social support functions of a parenting group, but no therapeutic skills training or other instructional materials will be provided.
62223569|NCT01765166|EXPERIMENTAL|Parent Guide-Home Study(PG-HS)|Children will receive traditional SSGRIN treatment, and parents will receive the Parent Guide to SSGRIN training by participating in the online Parent Guide Home Study (PG-HS) course. The PG-HS course will include all instructional content and materials for the in-person Parent Guide course, but parent will receive the training online.
62417205|NCT03751124|EXPERIMENTAL|Relugolix plus E2/NETA|Relugolix 40 mg co-administered with estradiol (1.0 mg) and norethindrone acetate (0.5 mg) for up to 52 weeks.
62588593|NCT02200536|EXPERIMENTAL|Test|Infant oral health promotion package
62588594|NCT02200536|ACTIVE_COMPARATOR|Control 1|Infant oral health pamphlet
62588595|NCT02200536|NO_INTERVENTION|Control 2|
62223570|NCT01765166|EXPERIMENTAL|Parent Guide(PG)|Children will receive traditional SSGRIN treatment and parents will receive parallel traditional in-person SSGRIN-Parent Guide treatment.
62588596|NCT00750516||Lacid|Hypotensive, non pregnant by history, non comfort care Emergency Department patients.
62223571|NCT05587439||Germline EGFR Mutations|Individuals known to carry or at risk for carrying germline EGFR mutations (e.g., T790M, R776G/H/X, V769M, V834L, V843I, P848L, and others that will be identified). Patients with lung cancer with a somatic EGFR mutation prior to the initiation of treatment or who are found to have a suspected germline EGFR mutation via ctDNA analysis are also eligible.
62223572|NCT05587439||Germline Non-EGFR Mutations|Individuals known to carry or at risk for carrying non-EGFR germline mutations (e.g., HER2, BRCA2, MET, YAP1, and others that will be identified). Patients with lung cancer with a somatic variant suggestive of a possible hereditary lung cancer risk are also eligible.
62223573|NCT05587439||Family History Or Multiple Primaries Or Multi-Focal Non-Small Cell Lung Cancer NSCLC|"Individuals and families with history of lung cancer where no pathogenic germline variant has been identified, but ascertained through history of one or more of the following:~* Multi-generational or first-degree relative with lung cancer~* Personal history of multiple primary lung cancers or other neoplasms~* Multi-focal lung cancer"
62417206|NCT03751124|PLACEBO_COMPARATOR|Placebo tablets and capsules|"* Placebo for relugolix co-administered with placebo for E2/NETA for up to 52 weeks or until heavy menstrual bleeding returns.~* Retreatment with open-label relugolix with E2/NETA will be offered if heavy menstrual bleeding returns."
62588597|NCT02345265|EXPERIMENTAL|Treatment (olaparib and cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo a biopsy of tumor, blood sample collection, MUGA or echocardiogram, and CT scan or MRI scan throughout the study.
62588598|NCT04671771|EXPERIMENTAL|Experimental: InnAVasc AVG treatment|"Patients will be surgically implanted with an InnAVasc Arteriovenous Graft (IG) in the forearm or upper arm using standard vascular surgical techniques. The graft will be placed in a straight (soft C) configuration in the upper arm, or looped configuration in the forearm (forearm loop) or upper arm (axillary loop)."
62588599|NCT06665321|EXPERIMENTAL|Internet-based psychodynamic therapy|The treatment consist of a 9 week long IPDT intervention based on Affect Phobia Therapy with weekly therapist support.
62025754|NCT06045962|ACTIVE_COMPARATOR|Uncomplicated Ureteroscopy and Stent Placement for 3-5 days|After standard of care ureteroscopic procedure stents will be left indwelling for 3-5 days
62025755|NCT06045962|EXPERIMENTAL|Uncomplicated Ureteroscopy and Stent Placement for 7-9 days|After standard of care ureteroscopic procedure stents will be left indwelling for 7-9 days
62588600|NCT06665321|NO_INTERVENTION|Wait-list control condition|Wait-list control condition, participants have the option to contact the treatment team in case of worsened symptoms.
62025756|NCT05123365|EXPERIMENTAL|Dose Level 1 (DL1)|"Patients take N-Acetylcysteince 600 mg orally twice daily.~This is the starting dose level for the study."
62025757|NCT05123365|EXPERIMENTAL|Dose Level 2 (DL2)|"Patients take N-Acetylcysteince 1200 mg orally twice daily.~If DL1 is well tolerated, the next cohort will progress to this dose level."
62025758|NCT05123365|EXPERIMENTAL|Dose Level 3 (DL3)|"Patients take N-Acetylcysteince 1800 mg orally twice daily.~If DL2 is well tolerated, the next cohort will progress to this dose level."
62025759|NCT00406575|PLACEBO_COMPARATOR|Placebo|Participants receive diluent via continuous IV infusion for 48 hours.
62025760|NCT00406575|EXPERIMENTAL|Low Dose rhRlx|Participants receive recombinant human relaxin (rhRlx) via continuous IV infusion for 48 hours at a rate of 100 µg/kg/day (corresponding to a dose of 4.2 µg/kg/hr).
62025761|NCT00406575|EXPERIMENTAL|High Dose rhRlx|Participants receive recombinant human relaxin (rhRlx) via continuous IV infusion for 48 hours at a rate of 500 µg/kg/day (corresponding to a dose of 21.0 µg/kg/hr).
62025762|NCT02094703|EXPERIMENTAL|levofloxacin and solifenacin succinate|Levofloxacin 500 mg tablet and solifenacin succinate 5 mg tablet by mouth once daily for 3 days
62025763|NCT02094703|ACTIVE_COMPARATOR|levofloxacin and placebo|Levofloxacin 500 mg tablet and placebo (for solifenacin succinate) by mouth once daily for 3 days
62025764|NCT02161744|EXPERIMENTAL|ADSCs administration|Patients with Chronic Obstructive Pulmonary Disease will be treated with a single dose of autologous adipose derived stem cells. Stem cells will be isolated using standard Lipoaspiration procedure under sterile conditions.
62223574|NCT05132192||PVT|Patients with pretransplant portal vein thrombosis
62223575|NCT05132192||non-PVT|Patients without pretransplant portal vein thrombosis
62223576|NCT01124773||Previous HT use and cognition|Women who were aged 50-54 at the time of randomization into the WHI hormone trials.
62223577|NCT01274832||Late-treated PD patients|Patients affected by Parkinson Disease, implanted with STN DBS and with an history of disease \> 10 years
62223578|NCT01274832||Early-treated PD patients|Patients affected by Parkinson Disease, implanted with STN DBS and with an history of disease \<7 years
62417207|NCT06498817|ACTIVE_COMPARATOR|Standard Recommendation|Standard recommendation given by government of Bangladesh on the use of oral rehydration solution (ORS) and a flyer on water treatment and handwashing with soap given at the health facility during the time of diarrhea patient treatment.
62588601|NCT06056960|EXPERIMENTAL|Physical Activity|The experimental group will perform a combination of endurance and balance training tailored to the subject.
62588602|NCT06056960|NO_INTERVENTION|Usual Activity|The control group will perform their usual daily activities.
62588603|NCT06513013|ACTIVE_COMPARATOR|"Group M bupivacaine + normal saline + MgSO4"|will receive 25 ml volume on each side ( 20 ml of 0.25% bupivacaine plus 5 ml of normal saline containing 250 mg of MgSO4 )
62025765|NCT06483750|NO_INTERVENTION|Control: No Systane iLux Treatment|No Systane iLux treatment at baseline visit two weeks prior to cataract surgery.
62025766|NCT06483750|EXPERIMENTAL|Systane iLux Treatment|Systane iLux administration at baseline visit two weeks prior to cataract surgery.
62223579|NCT02896049||Hyperthermia|treatment with the Celsius42 Hyperthermia System
62223580|NCT05919862|EXPERIMENTAL|Robot system|Prosthetically guided Implant placement utilising robotic surgery based on a digital plan.
62417208|NCT06498817|EXPERIMENTAL|CHoBI7 Scale-Up Program|Health promoter delivery of handwashing with soap, water treatment, and safe water storage module in the health facility to diarrhea patients and the patient's household members during the time of treatment. This module includes video testimonials from diarrhea patient households on how the patient benefits from adhering to the promoted behaviors, and a demonstration on how to construct homemade handwashing washing stations. This in-person module is reinforced by weekly voice, interactive voice response, and text messages for three months sent to the mobile phones of diarrhea patient household members from a doctor at diarrhea ward at local hospital.
62417209|NCT06528938|ACTIVE_COMPARATOR|Accelerated iTBS|Intermittent Theta Burst Stimulation (iTBS) will be applied to the left dorsolateral prefrontal cortex (DLPFC). Participants will receive daily sessions (Mon-Fri), three times a day for 10 days (2 weeks).
62417210|NCT06528938|ACTIVE_COMPARATOR|Standard iTBS|Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC. Participants will receive daily sessions (Mon-Fri), once a day for 30 days (6 weeks).
62417211|NCT06430385|EXPERIMENTAL|Cohort 1: ION440 Dose A|Participants will receive ION440 intrathecally at Dose A during Part 1/MAD, followed by ION440 Dose A during Part 2/LTE.
62417212|NCT06430385|EXPERIMENTAL|Cohort 2: ION440 Dose B|Participants will receive ION440 intrathecally at Dose B during Part 1/MAD, followed by ION440 Dose B during Part 2/LTE.
62417213|NCT06430385|EXPERIMENTAL|Cohort 3: ION440 Dose C|Participants will receive ION440 intrathecally at Dose C during Part 1/MAD, followed by ION440 Dose C during Part 2/LTE.
62417214|NCT06430385|SHAM_COMPARATOR|Sham Procedure|During the Part 1/MAD period, a lumbar procedure (LP) will be performed at the same frequency as ION440 administration. Participants will not receive ITB injections during this period. It will be followed by the open-label Part 2/LTE period, where participants will receive ION440 at the same dose as their enrolled cohort (e.g. Dose A, Dose B or Dose C).
62417215|NCT02548039||Asian Normogonadotrophic Anovulatory Women|Asian women with normal gonadotropin levels but do not ovulate.
62417216|NCT06702384||early stage curative disease|
62417217|NCT06702384||Locally advanced or metastatic disease|
62798672|NCT05957965|ACTIVE_COMPARATOR|Conventional exercise training group|30 patients will receive conventional physical therapy training only which consist of strengthening, proprioceptive exercises.
62798673|NCT05957965|EXPERIMENTAL|Wii Fit rehabilitation training group|30 patients Wii Fit group will receive Wii Fit rehabilitation training and the same conventional exercise training (strengthening, proprioceptive exercises)
62025767|NCT06668974||Allergic Rhinitis Cohort|This cohort consists of individuals with allergic rhinitis and a control group from the UK Biobank database, including 18,934 cases of allergic rhinitis and 64,595 controls. Genetic data were used to explore causal relationships with asthma.
62025768|NCT06668974||Asthma Cohort|This cohort includes individuals with asthma and a control group from the Finnish biobank database, consisting of 20,629 cases of asthma and 135,449 controls. Genetic data were analyzed to examine causal associations with allergic rhinitis.
62223581|NCT05919862|SHAM_COMPARATOR|Freehand surgery|Freehand implant placement by experienced surgeon.
62417218|NCT05709054|EXPERIMENTAL|Diaphragmatic excursion assessment with Ultrasonography|The time motion mode (M-mode) may be used to measure the diaphragm excursion in a curvilinear low-frequency transducer placed in the midclavicular line and angled in a cranial direction.
62417219|NCT05709054|EXPERIMENTAL|Chest wall expansion|The difference between the values obtained during deep inspiration and expiration will be determined by tape ruler (cm), high degrees represent better outcome, low degrees represent worse outcome.
62417220|NCT05709054|EXPERIMENTAL|Nijmegen Questionnaire|Screening tool used to detect patients with hyperventilation complaints and DB patterns. Scores\>20 are used as the cut-score to identify DB in patients with various conditions. NQ values in healthy individuals range from 10 to 12 ± 7 and values do tend to decrease towards these levels after breathing retraining.
62417221|NCT05709054|EXPERIMENTAL|Asthma Control Test|The ACT evaluates how well asthma affects daily functioning, and overall asthma control self-assessment. The score ranges from 5 (poor control of asthma) to 25 (well control of asthma). An ACT score \>19 indicates well-controlled asthma.
62433444|NCT06528028|EXPERIMENTAL|control group|Ceftazidime/avibactam（Taidingping®, Qilu Pharmaceutical Co., Ltd.）were given a load dose of 2.5g (2h infusion), followed by 2.5gQ8h, the dose can be adjusted according to renal function.The duration of medication is determined by the clinician.
62798674|NCT03214575|ACTIVE_COMPARATOR|Conventional method|For the Conventional method of ultrasound guided central venous catheter insertion,we use the ultrasound machine, eZono 4000 and linear array transducer L3-12NGS (3-12 MHz)
62223582|NCT06300385|EXPERIMENTAL|Experimental|These participants will receive electromyostimulation simultaneously with strengthening exercise.
62223583|NCT06300385|SHAM_COMPARATOR|Sham control|These participants will receive sham electromyostimulation (current turned off) simultaneously with strengthening exercise.
62223584|NCT04213950|EXPERIMENTAL|Post-implementation group|The post-implementation group will receive care that is enhanced by the rabies PEP quality improvement bundle.
62223585|NCT04213950|NO_INTERVENTION|Historical control group|The historical control group received care prior to implementation of the quality improvement bundle.
62798675|NCT03214575|EXPERIMENTAL|GPS method|For the GPS method, we use the ultrasound machine, eZono 4000 with built-in adaptive needle recognition software called eZGuide (eZono, Jena, Germany) and linear array transducer L3-12NGS (3-12 MHz).
62798676|NCT05622565||Training set|Multimodal ocular fundus images and corresponding reports collected from multiple screening sites in China.
62798677|NCT05622565||Internal Validation set|Records separated from the training set.
62223586|NCT03085030|EXPERIMENTAL|antioxidant group|This group will take antioxidant formula tablet once daily orally for one month before IVF/ICSI cycle
62223587|NCT03085030|PLACEBO_COMPARATOR|control group|This group will take placebo tablet once daily orally for one month before IVF/ICSI cycle
62223588|NCT01296347|NO_INTERVENTION|Saline|Patients will receive a placebo infusion of 0.9% sodium chloride, which will start 10 minutes prior to the start of the operation and continue for 96 hours.
62417222|NCT05709054|EXPERIMENTAL|Sf-12v2 questionnaire|With one or two questions per domain, it evaluates the exact eight health dimensions as the SF-36v2: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Higher ratings indicate better physical and mental well-functioning, ranging from 0 to 100. It has been suggested that a cut-off of 50 or less be used to identify a physical condition, while a score of 42 or less may signify clinical depression
62417223|NCT05709054|EXPERIMENTAL|Borg scale|The Borg dyspnea scale is a simple, scoring system extensively used to evaluate symptoms of shortness of breath and provides valuable data. It begins with 0, where you have no breathing problems, and rises to 10, where you have the most respiratory distress. As a result, healthcare professionals need to give patients enough time to learn and make sure they comprehend before using it
62417224|NCT05237934||Cohort 1|Participants with confirmed/suspected NENs including ACC
62417225|NCT06625047|EXPERIMENTAL|Health services research (temozolomide, telehealth, in-person)|Patients receive temozolomide PO QD on days 1-5 of each cycle. Cycles repeat every 28 days for up to 6 cycles per standard of care in the absence of disease progression or unacceptable toxicity. Patients complete alternating telehealth assessment visits and in-person assessment visits after each cycle of treatment.
62417226|NCT06567080|EXPERIMENTAL|JWCAR201 arm|Subjects in this arm will receive intervention with JWCAR201
62223589|NCT01296347|EXPERIMENTAL|ketamine|Patients will receive intravenous ketamine, starting 10 minutes prior to surgery and will continue for 96 hours
62223590|NCT03990831|OTHER|burn injury and normal patient|HbO2 PFC perfusion using fNIRS
62223591|NCT04367012||group 1 NAFLD and group 2 Non NAFLD|study from 20-60 years old.Subjects will be evaluated clinically by abdominal examination for evaluation of fatty liver and grades it into 3 grades .evaluation of fatty pancreas and grade it into 3 grades ,measuring blood pressure and physically by calculating body mass index (BMI) weight/height2
62223592|NCT04367012||Group1 NAFLD & Group 2 Non NAFLD|As the study is randomized cross sectional , all subjects whom have fatty liver by abdominal ultrasound included in group 1 NAFLD , and whom do not have fatty liver by abdominal ultrasound included in group 2.both groups was age and sex matched
62223593|NCT03002831|EXPERIMENTAL|CIK combined chemotherapy|Autologous Cytokine induced killer cells combined Tegafur, Gimeracil and Oteracil Potassium Capsules. After 2 to 4 days of chemotherapy, about 5×10９autologous cytokine induced killer cells are transfused into the vein of the patients in one hour.
62417227|NCT02703779|ACTIVE_COMPARATOR|Stem cell collection without in-vivo purging with Bortezomib|"Standard of Care Stem cell collection without in-vivo purging with Bortezomib. Standard of Care drugs Granulocyte colony-stimulating factor (G-CSF) +/- Mozobil (the latter if needed).~NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B"
62417228|NCT02703779|EXPERIMENTAL|Stem cell collection with in-vivo purging with Bortezomib|"Bortezomib will be given subcutaneously (SQ) at 1.3 mg/m2 on day -11 and day -8 followed by Granulocyte colony-stimulating factor (G-CSF) given SQ on day -4 thru day -1 and continued until the collection is completed. Mozobil will be given if needed.~There must be at least 72 hours between each dose of bortezomib. NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B"
62417229|NCT06448910|EXPERIMENTAL|Cadonilimab plus concurrent chemoradiotherapy|
62417230|NCT01818219|EXPERIMENTAL|Study|
62417231|NCT01186744|EXPERIMENTAL|Active Treatment (10 mg) BID / Placebo BID|Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
62588604|NCT06513013|ACTIVE_COMPARATOR|"Group D bupivacaine + normal saline + Neostigmine"|will receive 25 ml volume on each side ( 20 ml of 0.25% bupivacaine plus 5 ml of normal saline containing 500 mcg of Neostigmine
62588605|NCT04308278|EXPERIMENTAL|2LEBV® / 2LXFS®|6 months of treatment
62223594|NCT03002831|ACTIVE_COMPARATOR|Chemotherapy|Tegafur,Gimeracil and Oteracil Potassium Capsules 40-60mg, bid, po, D1-14, Q3w
62223595|NCT02816944|EXPERIMENTAL|EUS-guided laser ablation for refractory neoplasms|
62588606|NCT04308278|PLACEBO_COMPARATOR|Placebo|6 months of treatment
62588607|NCT04502225|EXPERIMENTAL|Elevation of the whole bed (tilt)|Tilt of the whole bed so that the participant's head is raised by 9 and/or 12 inches.
62223596|NCT02010528||Type 1 diabetes|Parents or caregivers of children and adolescents with type 1 diabetes
62223597|NCT02010528||Controls|Parents or caregivers of children and adolescents without diabetes
62588608|NCT04502225|EXPERIMENTAL|Elevation of the trunk|Elevation of the trunk by tilting just the head of the bed so that the participant's head is raised by 9 and/or 12 inches.
62588609|NCT04502225|EXPERIMENTAL|Elevation of the whole bed (tilt) - In home|Tilt of the whole bed so that the participant's head is raised by 8 inches.
62223598|NCT03866499|EXPERIMENTAL|BPI-7711|180 mg BPI-7711 capsule + 250mg gefitinib placebo tablet, QD
62223599|NCT03866499|ACTIVE_COMPARATOR|Gefitinib|180 mg BPI-7711 placebo capsule + 250mg gefitinib tablet, QD
62588610|NCT04502225|EXPERIMENTAL|Elevation of the trunk - In home|Elevation of the trunk by raising the head 8 inches on a wedge pillow.
62588611|NCT05650619||Enrolled participants prior to transplant|Participants will be consented.
62223600|NCT03897686|EXPERIMENTAL|NOLTREX™, II-III grade OA|72 patients with II-III grade of gonarthrosis will randomised to receive PAHG
62223601|NCT03897686|PLACEBO_COMPARATOR|Placebo, II-III grade ОА|72 patients with II-III grade of gonarthrosis will randomised to receive saline solution
62588612|NCT05650619||Enrolled participant after transplant|Participants will be consented.
62223602|NCT05577884||Multiple myeloma|Patients with suspicion of multiple myeloma and scheduled for CT
62223603|NCT00806572|EXPERIMENTAL|Treatment|
62223604|NCT00806572|NO_INTERVENTION|Control|
62223605|NCT03933527|NO_INTERVENTION|control group|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval).
62588613|NCT05650619||Retrospective participant data|Waiver of consent for secondary use of existing data.
62588614|NCT06667544|EXPERIMENTAL|RNK08954|Dose-escalation of RNK08954 oral dose therapy once daily.
62588615|NCT06407557|ACTIVE_COMPARATOR|Accelerometer|
62588616|NCT06407557|ACTIVE_COMPARATOR|No arm accelerometer|
62588617|NCT06260865|EXPERIMENTAL|MORA Cure|Participants randomly assigned to this arm will use the digital therapeutics, MORA Cure.
62025769|NCT05207696||Platelet-rich fibrin (PRF)|A total of 28 sites from 12 patients who underwent papilla reconstruction with PRF placed with semilunar incision in the maxillary anterior region were included in PRF group. ( Data of 12 patients were included in the study.)
62417232|NCT01186744|EXPERIMENTAL|Active Treatment (10 mg) BID|Continuous active treatment (CP-690,550) for 56 weeks
62417233|NCT01186744|EXPERIMENTAL|Active Treatment (5 mg) BID / Placebo BID|Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
62223606|NCT03933527|EXPERIMENTAL|coffee group|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval).During the tooth bleaching procedure and 3 weeks after the procedure,the participants will be instructed to make coffee rinses for 30 seconds, four times daily.
62223607|NCT03933527|EXPERIMENTAL|tea group|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval).During the tooth bleaching procedure and 3 weeks after the procedure,the participants will be instructed to make tea rinses for 30 seconds, four times daily.
62588618|NCT06260865|ACTIVE_COMPARATOR|Treatment as Usual|Participants randomly assigned to this arm will receive their treatment as usual only.
62588619|NCT06277323|NO_INTERVENTION|Arm 1: Quarterly performance email (current state, control condition)|Eligible, randomly assigned physicians will receive status quo quarterly emails with their performance report card.
62417234|NCT01186744|EXPERIMENTAL|Active Treatment (5 mg) BID|Continuous active treatment (CP-690,550) for 56 weeks
62417235|NCT04309760|ACTIVE_COMPARATOR|gender dysphoria subjects|Patients with MtF gender dysphoria (biological men who are transitioning to the female gender) attending the forensic psychiatric consultation for a request for hormone-surgical reassignment. Subjects will receive initial clinical assessment and MRI before and 6 months after initiation of hormone therapy
62417236|NCT04309760|OTHER|control subjects|Control group inclusions, of open-label patients without gender dysphoria.
62417237|NCT05717166|ACTIVE_COMPARATOR|Standard Arm (Arm 1)|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications.
62417238|NCT05717166|EXPERIMENTAL|Experimental Arm (Arm 2)|Consists of treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable (e.g. surgery, RFA, fractionated radiation, chemoradiation) if those are deemed to be preferable by the treating oncologists.
62588620|NCT06277323|EXPERIMENTAL|Arm 2: Monthly report card only|Eligible, randomly assigned physicians will receive behaviorally-informed monthly emails (monthly performance report card) intended to elevate their intentions to improve their performance (i.e., getting more of their patients to close care gaps).
62417239|NCT01126359|PLACEBO_COMPARATOR|Lidocaine then Placebo-Saline|
62417240|NCT01126359|ACTIVE_COMPARATOR|Placebo-Saline then Lidocaine|
62588621|NCT06277323|EXPERIMENTAL|Arm 3: Storyboard only|Eligible, randomly assigned physicians will receive status quo quarterly emails and get a more visible care gap banner in the electronic health record (EHR), intended to promptly remind them of each patient's care gaps at the start of a patient-physician encounter.
62417241|NCT06696261|EXPERIMENTAL|Lianxiaxiaopi Granules|
62417242|NCT06696261|PLACEBO_COMPARATOR|a simulated agent of Lianxiaxiaopi Granules|
62417243|NCT02174549|EXPERIMENTAL|Tirapazamine|Intra-arterial administration with tirapazamine before embolization to evaluate the response in metastatic liver lesions of NET
62417244|NCT04049448|EXPERIMENTAL|ABX464 50 mg|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks)
62433445|NCT02917616|EXPERIMENTAL|Alkaline water|Two liters (minimum) daily of alkaline drinking-water (pH=9) for 14 days
62433446|NCT02917616|ACTIVE_COMPARATOR|Neutral Water|Two liters (minimum) daily of neutral drinking-water (pH=7) for 14 days
62433447|NCT05060952||PJI|Patients with septic arthroplasty failure
62433448|NCT05060952||Aseptic|Patients with aseptic causes of arthroplasty failure
62433449|NCT03109522|EXPERIMENTAL|axillary reverse mapping|Axillary reverse mapping and sentinel lymph node biopsy (ARM/SLNB) or Axillary reverse mapping and axillary lymph node dissection (ARM/ALND)
62588622|NCT06277323|EXPERIMENTAL|Arm 4: Monthly report card AND Storyboard|Eligible, randomly assigned physicians will receive behaviorally-informed monthly emails and get a more visible care gap banner in the electronic health record (EHR) upon patient encounter.
62798678|NCT05622565||External Test set|Multimodal ocular fundus images and corresponding reports collected from multi-centers in China and around the world.
62223608|NCT04924933|EXPERIMENTAL|Patients (Epilepsy group)|Patients with drug-resistant focal epilepsy in whom an accelerated long-term forgetting is suspected (presence of a subjective memory complaint and absence of objective deficit in memory tests conducted in the frame of a routine comprehensive neuropsychological assessment)
62223609|NCT04924933|ACTIVE_COMPARATOR|Healthy volunteers (control group)|Age-matched healthy volunteers
62223610|NCT03625895||Anagrelide hydrochloride|Participants who received treatment with Anagrelide hydrochloride will be evaluated for this study. Participants will receive interventions as part of routine medical care.
62223611|NCT01830725||Gout/Hyperuricemia|Subjects with a diagnosis of hyperuricemia (defined as a uric acid of \> 7.2 mg/dl) and/or gout.
62223612|NCT01830725||Control|Approximate age and gender matched controls without hyperuricemia or gout
62223613|NCT02783664||Questionnaires to Evaluate Patient Stress Levels|
62223614|NCT01168323|EXPERIMENTAL|Spaced education clinicians - cohort 1|Spaced education clinicians receive four isomorphic cycles of 9 spaced education emails over 36-weeks (0-2 emails per week). Each email contained one question-explanation.
62223615|NCT01168323|NO_INTERVENTION|Control clinicians - cohort 2|Control clinicians received no intervention
62223616|NCT01094860|EXPERIMENTAL|Continuous Infusion Nelarabine|Starting dose 200 mg/m2 x 5 days
62223617|NCT04160520|EXPERIMENTAL|Pramipexole and half-standard dose of morphine|0.25 mg oral tablet of pramipexole in combination with 0.05mg/kg of IV morphine
62223618|NCT04160520|ACTIVE_COMPARATOR|Standard dose of morphine and placebo|0.1mg/kg of IV morphine in combination with a placebo pill
62223619|NCT02317315||Preterm labor group|Patients who are admitted for evaluation of preterm labor.
62588623|NCT06461078|ACTIVE_COMPARATOR|Active Comparator: Treatment Group|Radotinib 200mg, 2 Tablets, Fasting, Single dose
62588624|NCT06461078|ACTIVE_COMPARATOR|Active Comparator: Control Group|Radotinib 200mg, 2 Tablets, Standard diet, Single dose
62588625|NCT06061523|EXPERIMENTAL|Treatment Sequence ABC|"Participants will be administered sotorasib orally in the following order:~Treatment A - as 4 tablets under fasting conditions (test) Treatment B - as 8 tablets under fasting conditions (reference) Treatment C - as 4 tablets under fed conditions (test)"
62798679|NCT01912196|EXPERIMENTAL|MSI-195|"Patients randomized to the MSI-195 arm will receive treatment with 2 tablets (800 mg) of MSI-195 plus on-going antidepressant therapy (ADT).~MSI-195 800 mg (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug)"
62798680|NCT01912196|PLACEBO_COMPARATOR|Placebo|"Patients randomized to the placebo arm will receive 2 tablets placebo plus on-going antidepressant therapy (ADT).~Placebo (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug)."
62223620|NCT04209959|EXPERIMENTAL|low dose group|
62223621|NCT04209959|EXPERIMENTAL|middle dose group|
62223622|NCT04209959|EXPERIMENTAL|high dose group|
62223623|NCT02715791|OTHER|Usual Care|Patients randomized to the control group will receive usual care and upon the end of study will receive access to the Healthy Lifestyle App and the McMaster PHR
62223624|NCT02715791|OTHER|TAP-HC-DM|Patients randomized to the intervention group will get TAP-HC-DM intervention from time zero
62223625|NCT02754986|EXPERIMENTAL|measuring Holter electrocardiogram|Hotter ECG will be recorded continuously during hemodialysis
62223626|NCT02756273|EXPERIMENTAL|no bridge device|After the ileostomy creation, no bridge device was placed.
62223627|NCT02756273|ACTIVE_COMPARATOR|bridge device|A bridge device was placed after the stoma creation.
62223628|NCT00657202|EXPERIMENTAL|Ranibizumab|
62223629|NCT02270918|ACTIVE_COMPARATOR|Apixaban with Kcentra|Oral apixaban will be administered to steady state in healthy volunteers followed by a single infusion of prothrombin complex concentrate Kcentra at 25 units/Kg
62433450|NCT03109522|ACTIVE_COMPARATOR|standard axillary surgery|The control group will have standard sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) without identifying or sparing upper-limb lymphatics and nodes (blue dye is not injected).
62433451|NCT05386745|EXPERIMENTAL|Intervention|An online, asynchronous, self-paced, 10-week long, physical activity intervention.
62433452|NCT05386745|NO_INTERVENTION|Control|A waitlist control; continue with life/activity as usual. Control participants will receive access to the intervention at 10 weeks following all measurements.
62433453|NCT01026688|EXPERIMENTAL|Intervention|
62433454|NCT01026688|OTHER|Control|
62798681|NCT02373488|OTHER|control|lifestyle advice
62798682|NCT02373488|ACTIVE_COMPARATOR|intervention-1|connective tissue manipulation
62798683|NCT02373488|ACTIVE_COMPARATOR|intervention-2|abdominal massage
62798684|NCT06390683|EXPERIMENTAL|Rewilding|Yards of the housing units are rewilded with vegetation, deadwood and plant residuals.
62223630|NCT02270918|PLACEBO_COMPARATOR|Apixaban with placebo|Oral apixaban will be administered to steady state in healthy volunteers followed by a single infusion of saline
62223631|NCT03525951|OTHER|Typically Developing Children Study 2 (TD2)|No-intervention comparison group measured over time.
62223632|NCT03525951|EXPERIMENTAL|Children with Dev Language Disorder Study 2 (DLD2)|Enhanced Milieu Teaching
62223633|NCT03525951|EXPERIMENTAL|Children with Autism Spectrum Disorders Study 2 (ASD+DLD 2)|Enhanced Milieu Teaching
62223634|NCT03525951|OTHER|Typically Developing Children Study 1 (TD1)|No-intervention group for observational data comparison.
62223635|NCT03525951|OTHER|Children with Dev Language Disorder Study 1 (DLD1)|No-intervention group for observational data comparison.
62223636|NCT06253091|NO_INTERVENTION|robit-assist transperitoneal laparoscopic radical cystectomy|robit-assist radical cystectomy was performed transperitoneal
62417245|NCT06172127|EXPERIMENTAL|T-DXd induction treatment phase followed by PHESGO maintenance treatment phase|"All patients will receive a 6-cycle induction phase with T-DXd 5.4 mg/kg body weight administered as an intravenous (IV) infusion on day 1 (D1) of each 21-day cycle (Q3W).~Participants may continue with PHESGO if T-DXd is discontinued prematurely due to unacceptable toxicity prior to disease progression and following recovering to Grade ≤ 1 toxicity, to Grade 0 in case of ILD/pneumonitis, or to Grade 2 for alopecia/other toxicities not considered a safety risk. If any T-DXd unacceptable toxicity occurs during the first 6 cycles of induction phase with T-DXd, participants may receive taxane-based chemotherapy concomitantly with PHESGO treatment at the discretion of the investigator.~During the maintenance phase, all participants will receive PHESGO with a loading dose of 1200 mg pertuzumab/600 mg trastuzumab as a SC injection for 8 minutes on D1 of the first 21-day cycle, and with a maintenance dose of 600 mg pertuzumab/600 mg trastuzumab as a SC Q3W."
62588626|NCT06061523|EXPERIMENTAL|Treatment Sequence BAC|"Participants will be administered sotorasib orally in the following order:~Treatment B - as 8 tablets under fasting conditions (reference) Treatment A - as 4 tablets under fasting conditions (test) Treatment C - as 4 tablets under fed conditions (test)"
62223637|NCT06253091|EXPERIMENTAL|robit-assist extraperitoneal laparoscopic radical cystectomy|robit-assist radical cystectomy was performed extraperitoneal
62223638|NCT05678751||case group|patients with infertility
62223639|NCT05678751||control group|women that are capable of spontaneous intrauterine pregnanc
62223640|NCT04328883|ACTIVE_COMPARATOR|162 mg Non-Enteric-Coated Chewable aspirin|Non-enteric coated aspirin (162mg, single dose)
62223641|NCT04328883|EXPERIMENTAL|50 mg ASA inhalation powder|Dry powder inhaled aspirin (50mg,1 dry powder inhalation capsule using dry powder inhaler, single dose)
62223642|NCT04328883|EXPERIMENTAL|100 mg ASA inhalation powder|Dry powder inhaled aspirin (100mg,1 dry powder inhalation capsule using dry powder inhaler, single dose)
62223643|NCT06206252||Medical Cannabis Group|Participants will use designated medical cannabis products for the study duration.
62223644|NCT06206252||Control Group|Participants will not use any cannabis for the study duration.
62223645|NCT04379726||patients with CFRD|Patients with diagnosis of CFRD, after OGTT
62223646|NCT04379726||patients without CFRD|Patients without diagnosis of CFRD, after OGTT
62223647|NCT05444049|EXPERIMENTAL|Treatment|The NEURESCUE device will be used as an adjunct to ACLS.
62223648|NCT06347887||Colorectal cancer group|Patients who are 18 years of age and older and diagnosed with colorectal cancer.
62798685|NCT04051853|EXPERIMENTAL|Sorafenib with midazolam clearance test|"Before start of treatment patients receive a single oral dose of midazolam to phenotype CYP3A4 activity. Blood samples will be taken at several time points to measure sorafenib and midazolam concentrations.~Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be escalated with weekly intervals up to 400 mg BID (max dose)."
62223649|NCT06347887||Control group|Patients with other non-neoplastic diseases of the digestive system, and patients with non-colorectal cancer such as gastric cancer, esophageal cancer, breast cancer and lung cancer, etc. as well as Individuals without any diseases checked by colonoscopy.
62223650|NCT02794753|EXPERIMENTAL|True intervention|Working memory training on computer 5 weeks 25 sessions (5 sessions per week) 50 minutes per session
62223651|NCT02794753|ACTIVE_COMPARATOR|Active control|Similar time spent playing on computer 5 weeks 25 sessions (5 sessions per week) 50 minutes per session
62223652|NCT01526031|EXPERIMENTAL|BV1|1:10,000 bee venom (BV) acupuncture plus physiotherapy
62223653|NCT01526031|EXPERIMENTAL|BV2|1:30,000 bee venom (BV) acupuncture plus physiotherapy
62223654|NCT01526031|PLACEBO_COMPARATOR|NS|Normal saline injection plus physiotherapy
62417246|NCT06602037|EXPERIMENTAL|ImmunoPET imaging in patients with pancreatic cancers|Enrolled pancreatic cancer patients (locally advanced or metastatic cancer) will undergo a Trop2/CLDN18.2-targeted immunoPET/CT scanning.
62798686|NCT04051853|EXPERIMENTAL|Sorafenib with CYP cocktail test|"In this subgroup of 15 patients (in the Academic Medical Center Amsterdam), the midazolam test will be replaced by an oral cocktail of subclinical doses of caffeine, midazolam, omeprazole, warfarin and metoprolol and will be repeated after 4 weeks of treatment to assess the influence of sorafenib on cytochrome P450 (CYP) 1A2, 3A4, 2C19, 2C9 and 2D6 activity, respectively.~Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be escalated with weekly intervals up to 400 mg BID (max dose)."
62223655|NCT03390218|EXPERIMENTAL|TAO (Therapy Assisted Online)|TAO participants will attend a once weekly group in a computer lab. Each participant will complete an interactive educational module using an evidence based protocoled treatment for anxiety and/or depression, and have a brief session with the group leader to discuss application of the content. Participants will have access to a companion app they may use between sessions to practice skills and reinforce learning.
62223656|NCT03390218|ACTIVE_COMPARATOR|Treatment as usual|After the completion of a psychosocial assessment, and development of a treatment plan, clients are offered individual and group therapy sessions, case management services, and medication management services depending on the diagnoses. Individual and group therapy is often generic in nature as well, although some structured, evidence-based treatments are offered such as Psycho-Education Multi-Family Group and Illness Management Recovery.
62223657|NCT00591721|EXPERIMENTAL|Energy conservation education|Participants received 6-70 minute group teleconference sessions with an occupational therapist facilitator. The intervention provided education, guided discussion, and peer support for learning about and applying energy conservation principles
62223658|NCT00591721|OTHER|Wait list control|Participants received 6-70 minute group teleconference sessions with an occupational therapist facilitator. The intervention provided education, guided discussion, and peer support for learning about and applying energy conservation principles.
62223659|NCT06342271|EXPERIMENTAL|Nordic Walking group|The group will be training with a Nordic Walking protocol for 12- weeks, two times a week, completing 24 one-hour sessions.
62223660|NCT06342271|ACTIVE_COMPARATOR|Free Walking group|The group will be training with a Free Walking protocol for 12- weeks, two times a week, completing 24 one-hour sessions.
62223661|NCT00379743|ACTIVE_COMPARATOR|2|Individuals randomized to this arm receive the following interventions: 1) educational materials on recommended cancer-preventive services, plus 2) a health coordinator (patient navigator) who helps the participant schedule and keep appointments for cancer screening and/or treatment.
62223662|NCT00836095|OTHER|Supreme LMA|"Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant.~The choice of the airway device will be randomized by opening a sealed envelope immediately before induction. The airway device will be blindly inserted by an experienced attending anesthesiologist."
62223663|NCT00836095|ACTIVE_COMPARATOR|Proseal LMA|"Proseal is a multiple use, variant of the laryngeal mask airway.~The choice of the airway device will be randomized by opening a sealed envelope immediately before induction. The airway device will be blindly inserted by an experienced attending anesthesiologist."
62223664|NCT02610127||OBIZUR - Prospective Participants|Participants enrolled and treated with Obizur after the prospective study start date
62798687|NCT00239928|EXPERIMENTAL|EYE001|
62223665|NCT02610127||OBIZUR - Retrospective Participants|Retrospective chart review of participants treated with OBIZUR from product approval date until prior to the prospective study start date
62223666|NCT04555031|EXPERIMENTAL|kalifilcon A lenses|
62223667|NCT04555031|ACTIVE_COMPARATOR|Dailies Total 1|
62223668|NCT04555031|ACTIVE_COMPARATOR|Precision 1|
62223669|NCT04555031|ACTIVE_COMPARATOR|Biotrue ONEday|
62798688|NCT03810196|OTHER|TBI regimen|Standard of care myeloablative regimens will be used based on disease type and clinical status at time of transplant. Patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma will receive total body irradiation (TBI) regimen (thiotepa, cyclophosphamide, TBI).
62798689|NCT03810196|OTHER|TBI or busulfan regimen|Standard of care myeloablative regimens will be used based on disease type and clinical status at time of transplant. Patients not diagnosed with ALL or lymphoblastic lymphoma may receive either total body irradiation (TBI) regimen (thiotepa, cyclophosphamide, TBI) or busulfan containing regimen (thiotepa, cyclophosphamide, busulfan).
62798690|NCT01402817|EXPERIMENTAL|Sutent®/Sunitinib|Upon enrollment, subjects will receive Sutent® orally. Adults (Age \>18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.
62798691|NCT03568344||Community based tx seeking: baseline|Children \<5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including CHWs and primary health facilities during baseline period (no QA RAS administration).
62798692|NCT03568344||tx seeking @ referral facility: baseline|Children \<5 years of age seeking care for a severe febrile illness episode directly at the referral facility during baseline period (no QA RAS administration).
62798693|NCT03568344||Community based tx seeking: Post RAS|Children \<5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including CHWs and primary health facilities after QA RAS roll-out (after pre-referral QA RAS administration).
62223670|NCT04810143|EXPERIMENTAL|Aim 1|"All patients presenting for routine post-transplant care including, but not limited to: cardiac catheterization, cardiac biopsy, inpatient admission, or outpatient visits. A convenience sample of 25 inpatient samples will be collected for Aim 1. Although the assay developed by the MSCF will be validated for accuracy, the purpose of Aim 1 is to test real world application of the Mitra Microsampler tubes against the gold standard of blood collected by venipuncture in a controlled setting. To accomplish this, consecutive inpatient heart transplant patients will be enrolled. That sample will be collected at the same time (+/- 15 minutes) as a clinically-indicated, appropriately-timed venipuncture for measurement of a tacrolimus trough and prior to the subject taking tacrolimus so as to represent a trough."
62223671|NCT04810143|EXPERIMENTAL|Aim 2|Outpatient. A convenience sample of 25 outpatients collecting 1-2 samples will be collected for Aim 2. For those who agree to participate, the parent/patient will be taught by a member of the team on how to use the Microsampler to collect blood from a finger stick. They will be provided with a kit for collection of up to 2 samples and will also be provided with appropriate shipping materials to return samples to CCHMC. Participants will then be instructed to collect a sample in the Mitra Microsampler via fingerstick. In addition to the process of collecting the sample in Aim 2, appropriately-aged participants and/or families will be asked to fill out a brief survey regarding sample collection. This will include questions about the ease or difficulty of performing the steps and tolerability of the procedure relative to past experiences with values obtained by venipuncture.
62223672|NCT05396677|EXPERIMENTAL|Acetaminophen Condition|1000 mg acetaminophen
62223673|NCT05396677|PLACEBO_COMPARATOR|Placebo Condition|1000 mg microcrystalline cellulose
62223674|NCT06609720|EXPERIMENTAL|Group 1 subgroup A|Grade II furcation involvement treated with autogenous dentin graft
62223675|NCT06609720|EXPERIMENTAL|Group 1 Subgroup B|Grade II furcation involvement treated with demineralized freeze-dried bone allograft
62798694|NCT03568344||tx seeking @ referral facility: Post RAS|Children \<5 years of age seeking care for a severe febrile illness episode directly at the referral facility after QA RAS roll-out ( no QA RAS administration).
62223676|NCT06609720|EXPERIMENTAL|Group II subgroup A|Grade III furcation involvement treated with Autogenous dentin graft
62223677|NCT06609720|EXPERIMENTAL|Group II subgroup B|Grade III furcation involvement treated with demineralized freeze-dried bone allograft
62223678|NCT06442033|EXPERIMENTAL|Interventional Arm|All participants will exercise in a community setting 3x/week for 12 months
62223679|NCT05998538||TKA (Total Knee Arthroplasty) procedure|Total Knee Arthroplasty
62223680|NCT05998538||UKA (Uni Knee Arthroplasty) procedure|Uni Knee Arthroplasty
62417247|NCT03594175|EXPERIMENTAL|CUSA-081|Participants received 1 or 2 doses of CUSA-081, 0.7 milligrams (mg) (0.4 units) per 2 milliliter (mL) directly into the catheter lumen. Participants received the first dose at minute (min) 0, and the second dose (if needed) at min 90.
62588627|NCT01864109|EXPERIMENTAL|Patients with localized disease|"Patients with localized disease will receive six cycles of the combination as maintenance therapy following standard chemotherapy.~* Cycles 4-6 will include:~  * Ifosfamide 2,800 mg/m2/day on days 1-5~ * Etoposide 100 mg/m2/day on days 1-5~* Cycle 7 will include :~  * Cyclophosphamide will be given on days 1 and 2 at a dose of 2,100 mg/m2/day, or for patients \< 10 years of age at a dose of 70 mg/kg/day~ * Doxorubicin will be given on days 1 and 2 at a dose of 37.5 mg/m2/day~ * Vincristine will be given on day 1 at a dose of 2 mg/m2 or 0.067 mg/kg (whichever is lower, to a max dose of 2 mg)~* Cycles 8-13 will include:~  * Irinotecan will be given on 10 days over weeks 1 and 2 of a cycle at a dose of 20 mg/m2/day intravenously~ * Temozolomide will be given daily on the first 5 days of irinotecan administration at a dose of 100 mg/m2/day orally or intravenously"
62798695|NCT00748670|EXPERIMENTAL|A|
62798696|NCT03004911|EXPERIMENTAL|Mobile application|
62223681|NCT02299154|EXPERIMENTAL|Patient with memory disorders|psychological questionnaires
62223682|NCT02299154|EXPERIMENTAL|Accompanier|psychological questionnaires
62223683|NCT00626301|EXPERIMENTAL|1|Children who have completed HIV-NAT 017. Children treated with other double boosted PIs such as indinavir plus lopinavir/ ritonavir are also included.
62223684|NCT06266715|PLACEBO_COMPARATOR|Placebo Group|Cap escitalopram 10mg once daily (OD) for four weeks and injection 110ml NS twice daily (BD) for two weeks.
62223685|NCT06266715|EXPERIMENTAL|ATP Group|Cap escitalopram 10mg OD for four weeks and injection ATP 100mg in 100ml NS BD for two weeks.
62223686|NCT04901767||Receiving drug coated balloon (DCB)|
62798697|NCT03004911|ACTIVE_COMPARATOR|Paper booklet|
62223687|NCT04901767||Receiving drug eluting stent (DES)|
62223688|NCT04169230|EXPERIMENTAL|Citalopram|Single acute oral dose 20 mg Citalopram (tablet encapsulated in opaque capsule)
62223689|NCT04169230|PLACEBO_COMPARATOR|Placebo|Single acute oral dose Lactose Placebo (tablet encapsulated in opaque capsule)
62223690|NCT03864822|EXPERIMENTAL|Active tDCS|30s ramp to 2mA with 20 minute session of active High-Definition Transcranial Direct Current Stimulation at 2mA
62223691|NCT03864822|PLACEBO_COMPARATOR|Sham tDCS|30s ramp to 2mA with High-Definition Transcranial Direct Current Stimulation, then device stops stimulating for 20 minutes
62223692|NCT03902925|EXPERIMENTAL|Group 1- Sub-tenon plus lidocaine jelly|Patients are going to be submitted to lidocaine 2% jelly topical anesthesia for 5 minutes then to sub-tenon injection of 2-4 ml of ropivacaine 10% previous to 23 G pars plana vitrectomy.
62223693|NCT03902925|ACTIVE_COMPARATOR|Group 2- peribulbar|Patients are going to be submitted to peribulbar injection of 4-6 ml of ropivacaine 10% previous to 23 G pars plana vitrectomy.
62223694|NCT03567434|PLACEBO_COMPARATOR|Fluid Control|Participants first received a fluid control drink (i.e., juice) of the same volume of fluid as the alcohol condition. After at least a one-month washout period, they then received the alcohol condition.
62223695|NCT03567434|EXPERIMENTAL|Alcohol|Participants first received the alcohol condition with 95% ethanol and fruit juice (1:3 ratio). After at least a one-month washout period, they then received the fluid control condition with a volume fluid match.
62223696|NCT06064175|EXPERIMENTAL|Ibuprofen 400 mg-group 1|Patients will receive ibuprofen 400 mg/4 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
62417248|NCT03594175|PLACEBO_COMPARATOR|Placebo|Participants received 1 or 2 doses of placebo (normal saline) directly into the catheter lumen. Participants received the first dose at min 0, and the second dose (if needed) at min 90.
62417249|NCT03594175|ACTIVE_COMPARATOR|Alteplase|Participants received 1 or 2 doses of alteplase, 2 mg/mL, directly into the catheter lumen. Participants received the first dose at min 0, and the second dose (if needed) at min 90.
62223697|NCT06064175|EXPERIMENTAL|Ibuprofen 800 mg-group 2|Patients will receive ibuprofen 800 mg/8 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
62223698|NCT02192879|ACTIVE_COMPARATOR|Thoracic Epidural|
62223699|NCT02192879|ACTIVE_COMPARATOR|Continuous Paravertebral Catheter|
62798698|NCT03133247|EXPERIMENTAL|SHR-1316 dose-escalation|SHR-1316 doses will be escalated sequentially in 5 cohorts.
62798699|NCT02445872|EXPERIMENTAL|Arm A|Aprepitant: 125mg PO on day1, 80mg PO on day2 and day3. Palonosetron (a 5-HT3 receptor antagonist): 0.25 mg IV push on day 1 only. Dexamethasone: 5mg IV push once daily from day 1 to day 3,and 3.75mg PO on days 4-5.
62025770|NCT05207696||Connective tissue graft (CTG)|A total of 27 sites from 8 patients who underwent papilla reconstruction with CTG placed with semilunar incision in the maxillary anterior region were included in CTG group. (Data of 8 patients were included in the study.)
62223700|NCT02192879|ACTIVE_COMPARATOR|Patient-Controlled Analgesia|
62223701|NCT06066450||OSFITTM drug-eluting stents.|"Treatment Group: Group of patients who received treatment with OSFITTM drug-eluting stents.~Subgroup with OCT (OCT Subgroup): Subgroup of patients who underwent Optical Coherence Tomography (OCT) to verify stent placement accuracy."
62223702|NCT04589949|EXPERIMENTAL|ConvP|300 mL convalescent plasma with a minimum of neutralizing antibodies
62798700|NCT02445872|ACTIVE_COMPARATOR|Arm B|Palonosetron: 0.25 mg IV push on day 1 only. Dexamethasone: 5mg IV push once daily from day 1 to day 3,and 7.5mg PO on days 4-5.
62798701|NCT00419731|ACTIVE_COMPARATOR|1|Bupropion+Placebo
62798702|NCT00419731|EXPERIMENTAL|2|Bupropion+Naltrexone
62798703|NCT03401775|EXPERIMENTAL|Group1|Cognitive rehabilitation program will be administered for 4 weeks, three times a week, 30 minutes a day
62798704|NCT03401775|NO_INTERVENTION|Group2|No intervention will be administered
62223703|NCT04589949|ACTIVE_COMPARATOR|FFP|300 mL Fresh Frozen plasma
62223704|NCT06507202|EXPERIMENTAL|Remimazolam group|General anesthesia is induced by continuously injecting remimazolam (6 mg/kg/h) and remifentanil (2-6 ng/ml, target concentration controlled infusion) through an infusion pump. Afterwards, when the patient loses consciousness, rocuronium 0.6 mg/kg is injected for endotracheal intubation, and anesthesia is maintained with remimazolam (1-2 mg/kg/hr) and remifentanil after endotracheal intubation. When the surgery is completed, all anesthetic drugs being administered are stopped, and general anesthesia is terminated with flumazenil and sugammadex.
62223705|NCT06507202|ACTIVE_COMPARATOR|Propofol group|General anesthesia is induced by continuously injecting propofol (2-6 mg/ml, target concentration controlled injection) and remifentanil (2-6 ng/ml, target concentration controlled injection) using a TCI infusion pump. Afterwards, when the patient loses consciousness, rocuronium 0.6mg/kg is injected for endotracheal intubation, and anesthesia is maintained with propofol and remifentanil after endotracheal intubation. When the surgery is completed, all anesthetic drugs being administered are stopped, and general anesthesia is terminated through sugammadex.
62223706|NCT05464797|PLACEBO_COMPARATOR|Control group|
62223707|NCT05464797|EXPERIMENTAL|Direct Pulp Capping group|
62223708|NCT05464797|EXPERIMENTAL|Partial Pulpotomy group|
62223709|NCT05464797|EXPERIMENTAL|Complete Pulpotomy group|
62223710|NCT05464797|EXPERIMENTAL|Root canal treatment group|
62223711|NCT01022060|EXPERIMENTAL|A|Renalof
62223712|NCT01022060|PLACEBO_COMPARATOR|B|Placebo
62417250|NCT06210516|ACTIVE_COMPARATOR|Experimental Group|"Inspiratory muscle training, aerobic training, breathing exercises neurophysiologic rehabilitation will be applied to the experimental group. This treatment program will be applied 5 sessions a week and totally 30 sessions (6 weeks).~* Inspiratory muscle training~* Aerobic training~* Breathing Exercises~* Neurophysiological Exercise Program"
62417251|NCT06210516|ACTIVE_COMPARATOR|Control Group|"The control group will receive aerobic training, breathing exercises and neurophysiological rehabilitation, excluding inspiratory muscle training.~This treatment program will be applied 5 sessions a week and totally 30 sessions (6 weeks)."
62417252|NCT04359186|EXPERIMENTAL|Treatment Interruption Arm|
62223713|NCT00986674|EXPERIMENTAL|Arm I (carboplatin, paclitaxel, cetuximab)|Patients receive carboplatin IV over 15-30 minutes and paclitaxel IV over 3 hours on days 1 and 22 and cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cetuximab alone on days 1, 8, 15, 22, 29, and 36. Treatment with cetuximab repeats every 42 days in the absence of disease progression or unacceptable toxicity.
62417253|NCT03834961|EXPERIMENTAL|Treatment (larotrectinib)|Patients receive larotrectinib PO or by NG or G-tube BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity, or complete surgical resection of tumor.
62417254|NCT06702579||Patients receiving anticoagulation therapy|Adult patients on anticoagulation therapy who perform INR self-testing at home.
62417255|NCT06702579||Hemophilia A|Patients over 12 years old with congenital hemophilia A receiving prophylactic therapy.
62798705|NCT01806142|EXPERIMENTAL|Medium-chain triglycerides|During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.
62223714|NCT00986674|EXPERIMENTAL|Arm II (carboplatin, paclitaxel, cixutumumab)|Patients receive carboplatin and paclitaxel as in arm I. Patients also receive cixutumumab IV over 1 hour on days 1, 15, and 29. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cixutumumab alone on days 1, 15, and 29. Treatment with cixutumumab repeats every 42 days in the absence of disease progression or unacceptable toxicity.
62417256|NCT06702579||Healthcare professionals|Hematologists, hemophilia nurses, pharmacists or other healthcare providers currently involved in the care for patients with hemophilia.
62798706|NCT01806142|ACTIVE_COMPARATOR|Corn oil|During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
62025771|NCT05440864|EXPERIMENTAL|Tremelimumab in combination with Durvalumab preoperatively, followed by adjuvant Durvalumab|Patients will receive 1 dose Tremelimumab (300 mg) with Durvalumab (1500mg) at cycle 1 (4W) and 1 further cycle of Durvalumab (1500mg) pre surgical resection. Post-surgical resection patients will begin adjuvant Durvalumab (1500mg Q4W) to complete 13 cycles of treatment (or 11 post operatively) in total.
62417257|NCT06541925|EXPERIMENTAL|Injection with the needle-free (NF) system|The device used for needle free system was Comfort-in™ (Mika Medical Global Co, Busan, Korea) anesthesia device. The Comfort-in™ system, has a micro-hole injection needle (0.15 mm) that injects the anesthetic solution under the mucosa. The pressure can be controlled according to the dose of the drug to be used, thereby reduced the pain that may occur with the needle in the injection.
62417258|NCT06541925|ACTIVE_COMPARATOR|Injection with the traditional method (TM)|The TM was used with traditional syringe on the opposite side of the dental arch. The injection site was dried with a cotton-tip applicator, and topical anesthetic spray (Lidocaine 10%, Vemcain, Turkey) was applied to the injection area with cotton-tip for 1-2 min. The traditional injection was performed with a 26-gauge, 40-mm, disposable syringe with a needle (Genject, Turkey). The depth of penetration was only a few millimeters and 0.3ml of anesthetic solution was deposited.
62417259|NCT02787785|NO_INTERVENTION|Conventional Medical Therapy|This arm of the trial continues with their current conventional medical therapy.
62417260|NCT02787785|ACTIVE_COMPARATOR|Subcutaneous Implantable Cardioverter Defibrillator|This arm of the trial receives a subcutaneous implantable defibrillator.
62417261|NCT04074798|ACTIVE_COMPARATOR|Patients with low back pain|
62417262|NCT04074798|SHAM_COMPARATOR|Healthy controls|
62417263|NCT03671135|EXPERIMENTAL|TCA Intrastromal Inlay|A monocular intrastromal corneal inlay will be implanted.
62417264|NCT05620706|EXPERIMENTAL|Treatment group|GCP3 CAR-T cells
62417265|NCT06283745|ACTIVE_COMPARATOR|Platelet Rich Plasma (PRP)|Participants receive PRP intranasal injection into the olfactory cleft three times, separated by two weeks each. Blood is drawn from the patient. This is placed in a centrifuge and using a specialized PRP kit (Emcyte), the sequential spinning process isolates the platelet-rich plasma portion of the blood and we inject that back into the patient within the nasal cavity.
62417266|NCT06283745|ACTIVE_COMPARATOR|Saline|Participants receive saline injections into the olfactory cleft three times, separated by two weeks each. (Sham/placebo injections).
62417267|NCT06041269|EXPERIMENTAL|Rosnilimab SC Dose 1|This arm will receive treatment SC
62417268|NCT06041269|EXPERIMENTAL|Rosnilimab SC Dose 2|This arm will receive treatment SC
62798707|NCT01300806||myHERO SBIRT|
62025772|NCT03321981|EXPERIMENTAL|Cohort 1 doublet|zenocutuzumab + trastuzumab
62417269|NCT06041269|EXPERIMENTAL|Rosnilimab SC Dose 3|This arm will receive treatment SC
62417270|NCT06041269|PLACEBO_COMPARATOR|Placebo|This arm will receive Placebo
62417271|NCT06585202|EXPERIMENTAL|ATI-2138|ATI-2138 oral tablets BID
62417272|NCT06348823||thin biotype group|All subjects received oral hygiene instructions and, if needed, a dental cleaning of plaque and calculus. After calibration using digital photographs, intraoral scans, and CBCT, one dentist, who was not involved in the screening phase to avoid any bias, obtained all clinical parameters (gingival biotype, probing depth, gingival thickness, gingival width). Two test subjects were examined prior starting with enrollment and data collection.
62798708|NCT01300806||clinician administered SBIRT|
62798709|NCT05236608|EXPERIMENTAL|Nivolumab and ADG106|"Eligible patients will receive nivolumab and ADG106 by IV infusion according to the study phases below.~Phase 1b:~3 evaluable patients will be treated at the starting dose, and assessed for tolerability over the first cycle. Treatment related dose-limiting toxicities (DLT) will determine the next dose level to be studied. Dose escalation will follow the 3 + 3 study dose titration design.~Phase 2:~The dose of ADG106 given together with nivolumab will be the recommended dose in combination with nivolumab determined in phase 1b."
62417273|NCT06348823||thick biotype group|All subjects received oral hygiene instructions and, if needed, a dental cleaning of plaque and calculus. After calibration using digital photographs, intraoral scans, and CBCT, one dentist, who was not involved in the screening phase to avoid any bias, obtained all clinical parameters (gingival biotype, probing depth, gingival thickness, gingival width). Two test subjects were examined prior starting with enrollment and data collection.
62417274|NCT05631769|EXPERIMENTAL|HBR - 1M DAPT|Patients who receive percutaneous coronary intervention for coronary artery disease, and who have High bleeding risk (defined according to the ARC-HBR criteria) will be randomized to 1 month or 3 month DAPT duration.
62025773|NCT03321981|EXPERIMENTAL|Cohort 1 triplet|zenocutuzumab + trastuzumab + vinorelbine
62025774|NCT03321981|EXPERIMENTAL|Cohort 2|zenocutuzumab + endocrine therapy
62223715|NCT00986674|EXPERIMENTAL|Arm III (carboplatin, paclitaxel, cetuximab, cixutumumab)|Patients receive carboplatin, paclitaxel, and cetuximab as in arm I. Patients also receive cixutumumab as in arm II. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cetuximab as in arm I and cixutumumab as in arm II.
62223716|NCT04574050|EXPERIMENTAL|SELF-BREATHE|Access to a self -guided, internet -based intervention for patients with chronic breathlessness known as SELF-BREATHE
62223717|NCT04574050|NO_INTERVENTION|Control|standard / currently available NHS care
62223718|NCT05590884|EXPERIMENTAL|Age Group 1: patients aged 3 to 23 months|One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.
62223719|NCT05590884|EXPERIMENTAL|Age Group 2: patients aged 28 days to less than 3 months|One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.
62417275|NCT05631769|ACTIVE_COMPARATOR|HBR - 3M DAPT|Patients who receive percutaneous coronary intervention for coronary artery disease, and who have High bleeding risk (defined according to the ARC-HBR criteria) will be randomized to 1 month or 3 month DAPT duration.
62025775|NCT00839072|EXPERIMENTAL|Trazodone Contramid OAD|
62223720|NCT05590884|EXPERIMENTAL|Age Group 3: patients aged from birth to 27 days (term newborns)|One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.
62223721|NCT04308161|EXPERIMENTAL|vitamin D oral gel|"Topical oral vitamin D gel twice daily (Equivalent to 8000 I.U/day vitamin D) for six weeks.~Topical oral Vitamin D gel is prepared with the aid of pharmaceutics department, faculty of pharmacy, Alexandria University. It is prepared by using Cholecalciferol 2ml ampoule (200.000 I.U.) within topical oral gel formulation."
62223722|NCT04308161|ACTIVE_COMPARATOR|conventional therapy|"Conventional therapy (symptomatic treatment) which included:~* Miconaz oral gel~* BBC oral spray~* Oracure gel~* Alkamisr sachets~Dose: Three times a day for six weeks"
62223723|NCT04308161|EXPERIMENTAL|combination therapy|"Topical oral vitamin D gel twice daily (Equivalent to 8000 I.U/day vitamin D) for six weeks in combination with the symptomatic treatment~Symptomatic treatment which included:~* Miconaz oral gel~* BBC oral spray~* Oracure gel~* Alkamisr sachets~Symptomatic treatment dose: Three times a day for six weeks"
62223724|NCT01041131||Failed and/or Complicated VBG|
62223725|NCT03635073|EXPERIMENTAL|Soticlestat|Treatment: Soticlestat, tablets orally twice daily at optimized dose, titrated in up to 2 weeks of Dose Optimization Period, followed by Maintenance Period, which lasts until development is stopped by the sponsor, or the product is approved for marketing, or at any time at the discretion of the sponsor.
62223726|NCT03707197|EXPERIMENTAL|Meditation Group|The intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basic + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
62798710|NCT02893241||Cohort A|Patients ≥ 50 years old, with pre-existing comorbidities, who receive general anaesthesia
62798711|NCT02893241||Cohort B|Patients, who undergo caesarean section under spinal anaesthesia
62798712|NCT00597688|ACTIVE_COMPARATOR|1|Chlorhexidine gel
62798713|NCT00597688|PLACEBO_COMPARATOR|2|Placebo gel
62798714|NCT04477161|EXPERIMENTAL|Ketone Intervention|Subjects will take the Ketone Ester Elite Endurance Nutrition Drink. They will drink 1 bottle 4 times daily for 4 weeks
62798715|NCT00638495|EXPERIMENTAL|1|
62025776|NCT00839072|ACTIVE_COMPARATOR|Desyrel|
62025777|NCT04464187||Participants exposed to Elagolix-containing products|Pregnant participants exposed to Elagolix from 14 days after last menstrual period (LMP) or at any point during pregnancy.
62025778|NCT04464187||Participants not exposed to Elagolix-containing products|Pregnant participants with endometriosis, uterine fibroids, or other conditions based on approved indications and prescribing patterns of Elagolix-containing products not exposed to Elagolix from 14 days after LMP or at any point during pregnancy.
62025779|NCT04595708|EXPERIMENTAL|Intervention - Calls|Participants randomized to the intervention will receive a call of between 5 - 10 minutes in length each by a consistent caller, five times a week, Monday through Friday for 4 consecutive weeks to check in on them. After the first week of calls, subjects in the intervention arm will be asked if the frequency of calls is acceptable or if they would like to reduce the call frequency, potentially to a minimum of twice per week.
62025780|NCT04595708|NO_INTERVENTION|Control - No calls|Participants randomized to a control group will not receive the intervention calls. The control group will receive calls from a member of the research team at the beginning of the study to collect baseline survey data and at the post-4-week period to collect post-study survey data.
62025781|NCT05308862|EXPERIMENTAL|Intervention|Cluster randomization is going to take place via a computerized program prior to the workshops meaning that only those nurse aides, registered nurses and managers working in nursing homes allocated to the intervention group are going to develop an intervention together with the research group and then test it.
62223727|NCT03707197|NO_INTERVENTION|Wait-list Control Group|Wait-list control group participants will continue their normal activities and not engage in any form of meditation during the study period
62223728|NCT05208177|EXPERIMENTAL|SHR-1802 for injection combined with Camrelizumab for Injection and Famitinib Malate Capsules|
62025782|NCT05308862|NO_INTERVENTION|Control|Continue with usual care.
62025783|NCT01429259|EXPERIMENTAL|Meropenem 3 hour prolonged infusion|All 30 participants will receive meropenem as a 3 hour infusion.
62025784|NCT03844763|EXPERIMENTAL|Phase I - II trial of CTX, RT, Avelumab|CTX: 50 mg Daily untill PD or major toxicity; Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity; RT: 8 Gy single shot day 8.
62242998|NCT01205997|PLACEBO_COMPARATOR|placebo|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
62417276|NCT05631769|ACTIVE_COMPARATOR|LBR - 12M DAPT|Patients who receive percutaneous coronary intervention for coronary artery disease, and who do NOT have High bleeding risk (defined according to the ARC-HBR criteria) will be randomized to 3 month or 12 month DAPT duration.
62417277|NCT05631769|EXPERIMENTAL|LBR - 3M DAPT|Patients who receive percutaneous coronary intervention for coronary artery disease, and who do NOT have High bleeding risk (defined according to the ARC-HBR criteria) will be randomized to 3 month or 12 month DAPT duration.
62417278|NCT06703450||Participants with liver disease|Participants with liver disease for diagnosis of liver fibrosis to have DCE-MRI
62417279|NCT01339468|EXPERIMENTAL|Arm 1|Intravenous Prograf therapy followed by oral Advagraf therapy
62417280|NCT01339468|ACTIVE_COMPARATOR|Arm 2|Intravenous Prograf therapy followed by oral Prograf therapy
62417281|NCT06646991|OTHER|Nellcor oximeter|
62417282|NCT06646991|OTHER|Nonin Oximeter|
62588628|NCT01864109|EXPERIMENTAL|Patients with metastatic disease|"Patients will get 10 cycles of the combination intercalated between the final 4 cycles of standard chemotherapy.~* Cycles 4, 5, 7, 8, 10, 11, 13, 14, 16, and 17 will include:~  * Irinotecan will be given on 10 days over weeks 1 and 2 of a cycle at a dose of 20 mg/m2/day intravenously~ * Temozolomide will be given daily on the first 5 days of irinotecan administration at a dose of 100 mg/m2/day orally or intravenously~* Cycles 6, 9, and 12 will include:~  * Ifosfamide 2,800 mg/m2/day on days 1-5~ * Etoposide 100 mg/m2/day on days 1-5~* Cycle 15 will include:~  * Cyclophosphamide will be given on days 1 and 2 at a dose of 2,100 mg/m2/day, or for patients \< 10 years of age at a dose of 70 mg/kg/day~ * Doxorubicin will be given on days 1 and 2 at a dose of 37.5 mg/m2/day~ * Vincristine will be given on day 1 at a dose of 2 mg/m2 or 0.067 mg/kg (whichever is lower, to a max dose of 2 mg)"
62588629|NCT06137131|EXPERIMENTAL|straw phonation in air|Participants will be asked to phonate an /u/ vowel through a stirring straw in air with slightly pursed lips and a soft voice onset.
62588630|NCT06137131|EXPERIMENTAL|straw phonation in 2 cm water|Participants will be asked to phonate an /u/ vowel through a stirring straw, placed 2 cm below the water surface, with slightly pursed lips and a soft voice onset.
62025785|NCT01817049|EXPERIMENTAL|HAPA intervention|Coaches will receive a 3.5 hour HAPA-based coach education workshop prior to the start of the first study season.
62417283|NCT05297734|ACTIVE_COMPARATOR|Technology-based supportive cancer care|Patients receive educational materials to assist with advance care planning and symptom management through a technology-based supportive cancer care weekly during months 1-4 and every other week during months 5-12.
62417284|NCT05297734|EXPERIMENTAL|Redesigned team-based supportive cancer care|Patients are paired with a health educator who will discuss the same educational materials from ARM A either in person or by telephone discussions weekly during months 1-4 and every other week during months 5-12.
62417285|NCT04117958|EXPERIMENTAL|Dose-exploration phase|The dose-exploration phase of the study will estimate the MTD (Maximum Tolerated Dose) of AMG 199 using a Bayesian logistic regression model (BLRM). A RP2D (Recommended Phase 2 Dose) may be identified based on emerging safety, efficacy, and PD (Pharmacodynamics) data prior to reaching an MTD. Alternative dosing schedule(s) may be explored based on emerging PK (Pharmacokinetics) and safety data.
62417286|NCT04117958|EXPERIMENTAL|Dose-expansion phase|The dose-expansion phase will be conducted to confirm safety, PK, and PD at the MTD or RP2D and to obtain further safety and efficacy data and enable correlative biomarker analysis.
62798716|NCT00638495|PLACEBO_COMPARATOR|2|
62417287|NCT04959175|NO_INTERVENTION|Donors|Collection of research samples on bone marrow donors
62417288|NCT04959175|EXPERIMENTAL|Older, HLA-matched|Subjects age 60-85 with hematologic malignancies and an HLA-matched related or unrelated donor
62417289|NCT04959175|EXPERIMENTAL|Older, HLA-mismatched|Subjects age 60-85 with hematologic malignancies and an HLA-haploidentical or HLA-mismatched unrelated donor
62417290|NCT04959175|EXPERIMENTAL|Younger, HLA-matched|Subjects age 18-60 unfit for MAC with hematologic malignancies and an HLA-matched related or unrelated donor
62588631|NCT06137131|EXPERIMENTAL|straw phonation in 5 cm water|Participants will be asked to phonate an /u/ vowel through a stirring straw, placed 5 cm below the water surface, with slightly pursed lips and a soft voice onset.
62223729|NCT05173740|EXPERIMENTAL|Individually tailored rehabilitation intervention + usual care|A comprehensive neurocognitive assessment and a thorough individual assessment of rehabilitation needs will be conducted to inform the individually tailored intervention plan. Core intervention elements are: 1) comprehensive assessment of individual rehabilitation needs including neuropsychology tests in order to make a individually tailored intervention plan coordinated with the multidisciplinary rehabilitation team, 2) providing strategies to lessen impact for the individual cognitive impairment, 3) educating survivors and relatives about the impact of a cardiac arrest and consequences on daily life, 4) work preparation, including establishment of routines and opportunities to practice work skills and 5) collaboration with the local municipality's job centre and employers to plan, support and monitor graded RTW, 6) short term therapy by psychologist dealing with thoughts and behaviour in relation to cardiac arrest.
62223730|NCT05173740|ACTIVE_COMPARATOR|Usual care|All participants including those allocated to the usual care group will be seen by an occupational therapist if their MoCA screening score ≤26. Furthermore, if considered relevant by the discharging unit, survivors are referred for rehabilitation provided and delivered in the local municipality where the participant is resident. The content of the rehabilitation will typically be based on the content of the rehabilitation plan from the discharging hospital unit and an individual assessment of the survivors' expressed needs, within the local municipality where the participant is resident.
62223731|NCT01485055|EXPERIMENTAL|Infliximab and Basiliximab|"Other Names:~Simulect Remicade Monoclonal antibody~Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.~Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times."
62223732|NCT02684851|PLACEBO_COMPARATOR|Placebo|Inactive
62223733|NCT02684851|ACTIVE_COMPARATOR|Tranexamic|Tranexamic acid: anti-fibrinolytic agents
62223734|NCT00537693|ACTIVE_COMPARATOR|1|CRRT via Convection
62223735|NCT00537693|ACTIVE_COMPARATOR|2|CRRT via Diffusion
62223736|NCT05380037||Veterans with chronic stroke|Veterans with chronic stroke (n=50) must 1) have ischemic or hemorrhagic stroke, primary intracerebral hematoma, or subarachnoid hemorrhage with at least 6 month chronicity; 2) demonstrate ability to perform the interview and complete questionnaires and 3) endorse mild to severe psychosocial impairment
62223737|NCT05380037||Caregiver/Loved ones|Caregiver/Loved ones (n=25) must be familiar with the trajectory of function and recovery of the identified Veteran with chronic stroke
62588632|NCT06137131|ACTIVE_COMPARATOR|/u/ control condition|Participants will be asked to phonate an /u/ vowel with slightly pursed lips and a soft voice onset but without a straw.
62588633|NCT04128306|EXPERIMENTAL|Patient group|"A total of 120 patients with brain tumors will be divided into our two groups, divided as follows:~1. In the group Pre-Per, 20 patients will be included by localization of electrical stimulation (60 patients in total). A patient who would be stimulable in two different areas could be included in two different groups.~2. In the group Pre-End, the subjects will be distributed by localization of the brain tumor, by lobe. A total of 20 participants will be included per lobe, corresponding to the frontal, temporal or parietal lobes (as a reminder, a tumor in the occipital lobe is an exclusion criterion), for a total of 60 participants"
62025786|NCT01817049|PLACEBO_COMPARATOR|Attention control|Coaches will receive a 3.5 hour workshop prior to the start of the first study season, consisting of innocuous sport nutrition and sport psychology information as an attention control.
62223738|NCT05380037||Rehabilitation providers|Rehabilitation providers (n=25) of Veterans with chronic stroke must provide stroke-related care in the VA Healthcare system including (but not limited to) physical, speech, and occupational therapists, neurologists, and neuropsychologists
62223739|NCT04538443||hemodialysis group|One hundred children with ESRD who are treated with hemodialysis and their caregivers will participate in this study. They will be recruited from Nephrology Unit at Abo-Elreesh Hospital, Cairo University
62223740|NCT05196568|NO_INTERVENTION|patients not treated with the mimic fasting diet|Group treated with the mimic fasting diet
62223741|NCT05196568|EXPERIMENTAL|patients treated with the mimic fasting diet|Group treated with the mimic fasting diet
62223742|NCT04456569|EXPERIMENTAL|GAE + Standard of Care|Participants in this arm will receive geniculate artery embolization and standard of care.
62223743|NCT04456569|NO_INTERVENTION|Standard of Care|Participants in this arm will receive standard of care only.
62223744|NCT03520946|EXPERIMENTAL|Arm A (ramucirumab + TAS102)|Patients randomized to arm A will receive ramucirumab 8 mg/kg iv over 60 min on d1+15, q4w and TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression or intolerance or completion of 6 cycles.
62223745|NCT03520946|ACTIVE_COMPARATOR|Arm B (TAS102 only)|Patients randomized to arm B will receive TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression, intolerance or completion of 6 cycles.
62223746|NCT02486744|ACTIVE_COMPARATOR|80 Units of Acthar|Subjects assigned by random assignment to receive 80 Units of Acthar Gel 2x weekly for 6 months
62588634|NCT04128306|ACTIVE_COMPARATOR|Control group|A maximum of 120 healthy matched sex and age subjects with patients will also be included
62223747|NCT02486744|ACTIVE_COMPARATOR|40 Units of Acthar|Subjects assigned by random assignment to receive 40 Units of Acthar Gel 2x weekly for 6 months
62223748|NCT02687893|EXPERIMENTAL|Aerobic Exercise Week|Subjects will complete 45 minutes of aerobic exercise twice during a 7 day period. Exercise will be graded based on the participant's relative capacity determined at the screening visit. Each exercise session will be followed by 60 minutes of monitored resting recovery.
62223749|NCT02687893|EXPERIMENTAL|Resistance Exercise Week|Subjects will complete 45 minutes of anaerobic exercise twice during a 7 day period. Each exercise session will be followed by 60 minutes of monitored resting recovery.
62223750|NCT02687893|NO_INTERVENTION|No Exercise Week|Subjects will perform no exercise during this week.
62223751|NCT02479048|ACTIVE_COMPARATOR|Test meal 1 (TM1)|High fat meal (HF) with ½ avocado (\~68g)
62223752|NCT02479048|ACTIVE_COMPARATOR|Test meal 2 (TM2)|High fat meal (HF) with 1 avocado (\~136g)
62223753|NCT02479048|PLACEBO_COMPARATOR|Control meal (CM)|High carbohydrate, high saturated fat control meal (CM) without avocado.
62223754|NCT03069001|ACTIVE_COMPARATOR|Sofosbuvir-Simeprevir|"* Sofosbuvir 400 mg orally once-daily.~* Simeprevir 150 mg orally once-daily.~* Group A included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks."
62223755|NCT03069001|ACTIVE_COMPARATOR|Sofosbuvir-Ribavirin|"* Sofosbuvir 400 mg orally once-daily.~* Ribavirin orally twice-daily (according to body weight: 1000 mg daily in patients with a body weight of \<75 kg and 1200 mg daily in patients with a body weight of ≥75 kg).~* Group B included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks."
62223756|NCT02637570|EXPERIMENTAL|Hibiscus tea|420 mg Hibiscus 2 hour after dinner with 1 glass of cool water every day
62223757|NCT02637570|EXPERIMENTAL|green tea|450 mg green tea 2 hour after dinner with 1 glass of cool water every day
62223758|NCT02637570|PLACEBO_COMPARATOR|control group|450 mg placebo (dextrose) 2 hour after dinner with 1 glass of cool water every day
62223759|NCT05518682|EXPERIMENTAL|Single study arm|The Lenire device is CE marked in Europe and intended to reduce the symptoms of tinnitus. It comprises a handheld controller and an intra-oral device called a Tonguetip® Intra-Oral Device (IOD), which delivers gentle electrical stimulation to the tongue, and also comprises of a set of wireless consumer headphones that deliver audio stimulation. The sound and tongue stimulus parameters such as stimulus rate, stimulus intensity, and the timing relationship between the auditory and somatosensory stimulus events are grouped into stimulation Parameter Sets (PS). PS1 is used during the first 6-weeks of stimulation and PS4 is used during the second 6-weeks of stimulation, similar to what is routinely used for tinnitus individuals in Europe. For this study, the device software has been modified to allow users to adjust the headphone volume to a level that is comfortable and clearly audible instead of a preset volume with limited adjustments based on the patient's audiogram.
62223760|NCT01794637||the end-stage liver disease patients|the end-stage liver disease scheduled for liver transplantation
62223761|NCT04816331||Neonatal Encephalopathy (NE)|This study is a follow up of children at 2-3 years of age who were enrolled in the HRB-funded Neonatal Inflammation and Multiorgan dysfunction and Brain injUry reSearch group (NIMBUS) project. These babies had Neonatal Encephalopathy and required Therapeutic Hypothermia and are matched with controls. Detailed antenatal, birth, resuscitation, oxygen requirements throughout inpatient stay and detailed neonatal intensive care management were collected. In addition, details of Therapeutic Hypothermia treatment including initiation, duration and clinical examination, investigations including cranial USS, MRI, EEG and placental histology analysis performed as were recorded.
62223762|NCT04816331||Controls|The controls include age-matched normal children born at term with a normal delivery and postnatal course.
62223763|NCT04878354|PLACEBO_COMPARATOR|Placebo|Gelatine (fish source), mannitol and sodium hydroxide
62223764|NCT04878354|EXPERIMENTAL|Intervention/treatment|Sublingual allergy immunotherapy tablet, for daily administration SQ tree SLIT-tablet
62223765|NCT05182697|EXPERIMENTAL|SCI-210|Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily
62223766|NCT05182697|ACTIVE_COMPARATOR|CBD oil|CBD- active CBD oil with twice daily and CannAmide Placebo pills matched in appearance and taste to CannAmide active pill.
62223767|NCT06081504|EXPERIMENTAL|Wii fit exercises group|Fifteen patients will be engaged in the Wii Fit exercises program for 30 minutes in addition to the standard physical therapy program, 3 sessions a week for 12 weeks.
62223768|NCT06081504|EXPERIMENTAL|Pilates exercises group|Fifteen patients will be engaged in the Pilates exercises program for 30 minutes in addition to the standard physical therapy program, 3 sessions a week for 12 weeks.
62417291|NCT04959175|EXPERIMENTAL|Younger, HLA-mismatched|Subjects age 18-60 unfit for MAC with hematologic malignancies and an HLA-haploidentical or HLA-mismatched unrelated donor
62223769|NCT06081504|ACTIVE_COMPARATOR|Standard physical therapy group|Fifteen patients will be engaged in the Standard physical therapy program (lower limb stretching and strengthening exercises and deep friction massage) for 45 minutes, 3 sessions a week for 12 weeks.
62223770|NCT04229992|ACTIVE_COMPARATOR|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
62223771|NCT04229992|PLACEBO_COMPARATOR|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
62417292|NCT05886413||Intubated patient admitted in intensive care unit at the IUCPQ-UL after cardiac surgery|
62417293|NCT01514643||tibial plateau or plafond fracture|Tibial plateau or plafond fracture based on radiographs and/or CT scan will have synovial fluid aspirated from both the injured and uninjured joints in either the operating room if a procedure is planned for within 24 hours or in the emergency department. While the patient is under anesthesia in the operating room, the investigators will obtain blood samples.
62417294|NCT06537609|ACTIVE_COMPARATOR|De-escalation VS No De-escalation|
62417295|NCT06537609|ACTIVE_COMPARATOR|Oral beta-lactams VS Oral Non-beta-lactams|
62417296|NCT06537609|ACTIVE_COMPARATOR|Central vascular catheter retention VS Central vascular catheter replacement|
62417297|NCT06537609|ACTIVE_COMPARATOR|Cephalosporin VS Carbapenem for low risk AmpC organisms|
62417298|NCT06537609|ACTIVE_COMPARATOR|Routine follow-up blood culture VS No routine follow-up blood culture|
62798717|NCT04004910|EXPERIMENTAL|Immunopheresis® - Arm 1|All patients will receive up to 16 weeks of initial treatment as per study arm assignment, which will include up to 48 LW-02 column-based Immunopheresis® treatments over a 4-month period (up to 3 procedures per week) though treatment can be extended based on certain protocol-specfied conditions. Each patient assigned to the treatment with LW-02 column-based Immunopheresis® will require central vascular access for the procedure. This part is alrady completed.
62223772|NCT04229992|ACTIVE_COMPARATOR|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
62223773|NCT04229992|PLACEBO_COMPARATOR|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
62223774|NCT01457547|EXPERIMENTAL|DTPa 1 Group|
62223775|NCT01457547|ACTIVE_COMPARATOR|DTPa 2 Group|
62223776|NCT03083353|EXPERIMENTAL|isradipine|Participants will receive 15mg of immediate release isradipine.
62223777|NCT03083353|PLACEBO_COMPARATOR|placebo|Participants will receive a placebo pill identical in appearance to isradipine.
62223778|NCT05172427|ACTIVE_COMPARATOR|CLUE intervention (EMA + EMI)|"Participants will complete baseline questionnaires, followed by seven days of baseline EMA. After seven days of baseline EMA, they will have a meeting with a clinician and be given the CLUE intervention targeting intolerance of uncertainty. Following this intervention, participants will be given 14 days of EMA, which will include EMI prompts that they come up with at the end of the CLUE intervention (framed as key takeaways). After the two week period of EMA/EMI, participants will complete a post-intervention questionnaires. In addition to similar questionnaires to those administered at baseline, acceptability and feasibility of the intervention will be assessed at post-intervention. One month after post-intervention, participants will complete a one-month follow up questionnaire battery, that will again ask about acceptability and feasibility of the intervention, as well as parallel questions from baseline and post-intervention."
62223779|NCT05172427|ACTIVE_COMPARATOR|CLUE intervention (EMA only)|Participants will complete baseline questionnaires, followed by seven days of baseline EMA. After seven days of baseline EMA, they will have a meeting with a clinician and be given the CLUE intervention targeting intolerance of uncertainty. Following this intervention, participants will be given 14 days of EMA. After the two week period of EMA, participants will complete a post-intervention questionnaires. In addition to similar questionnaires to those administered at baseline, acceptability and feasibility of the intervention will be assessed at post-intervention. One month after post-intervention, participants will complete a one-month follow up questionnaire battery, that will again ask about acceptability and feasibility of the intervention, as well as parallel questions from baseline and post-intervention.
62223780|NCT05172427|NO_INTERVENTION|Waitlist control|Participants will complete baseline questionnaires, followed by seven days of baseline EMA. After seven days of baseline EMA, participants will be assigned 14 days of EMA. After the two week period of EMA, participants will complete a post-intervention questionnaires. In addition to similar questionnaires to those administered at baseline. One month after the post-intervention questionnaires, participants will complete a one-month follow up questionnaire battery, that will include parallel questions from baseline and post-intervention. As these participants did not receive the intervention following their baseline EMA, they will be given the opportunity to schedule an appointment for the intervention after they have completed their one-month follow up questionnaire.
62223781|NCT04394208|PLACEBO_COMPARATOR|Group 1|Patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment plus placebo
62223782|NCT04394208|EXPERIMENTAL|Group 2|patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + Silymarin Oral 420mg/day in 3 divided doses
62588635|NCT02497040|EXPERIMENTAL|bupivacaine,levobupivacaine|20 ml of 0.5% bupivacaine 20 ml of 0.5% levobupivacaine
62588636|NCT02497040|ACTIVE_COMPARATOR|levobupivacaine|20 ml of 0.5% levobupivacaine saline as a placebo
62798718|NCT04004910|EXPERIMENTAL|Immunopheresis® combined with low dose chemotherapy - Arm 2|All patients will receive up to 16 weeks of treatment as per study arm assignment, which will include up to 48 LW-02 column-based Immunopheresis® treatments over a 4-month period (up to 3 procedures per week) though treatment can be extended based on certain protocol-specfied conditions. Each patient will require central vascular access for the procedure. Patients also will receive a low dose chemotherapy regimen administered iv or oraly. Patients treated with combination will be administered their chemotherapy following the first LW-02 column-based Immunopheresis® procedure of each week starting from week 2, assuming first week of study treatment serves as a run-in period confirming good tolerance of Immunopheresis® alone.
62798719|NCT04004910|ACTIVE_COMPARATOR|Chemotherapy - Arm 3|Patients who are assigned chemotherapy arm of the study will be treated with low dose chemotherapy alone. The chemotherapy will be administered intravenously or oraly depending on the regimen used.
62798720|NCT05545072|EXPERIMENTAL|Dupilumab|Participants receiving dupilumab for 52 weeks following surgery for allergic fungal rhinosinusitis (AFRS).
62798721|NCT05545072|PLACEBO_COMPARATOR|Placebo|Participants receiving a placebo to match dupilumab for 52 weeks following surgery for allergic fungal rhinosinusitis (AFRS).
62588637|NCT02497040|ACTIVE_COMPARATOR|bupivacaine|20 ml of 0.5% bupivacaine saline as a placebo
62588638|NCT06666816||Group with neuromuscular disease|
62588639|NCT06666816||Control Group|
62588640|NCT05622305|EXPERIMENTAL|Online 1-Day CBT-Based Workshop|Participants assigned to the treatment arm will attend a day long CBT-based workshop delivered online by two trained public health nurses in addition to receiving usual care.
62588641|NCT05622305|NO_INTERVENTION|Treatment as Usual|Participants assigned to the control arm will continue to receive standard postnatal care from their healthcare providers.
62588642|NCT06666257|ACTIVE_COMPARATOR|SmartMomsAR|The active comparator arm will consist of women engaging in the SmartMoms intervention, however, the SmartMoms intervention will be culturally adapted to meet Arkansas women's needs as derived from formative work in Phase I
62025787|NCT06040489|EXPERIMENTAL|Oral Miltefosine and Pentoxifylline for Cutaneous Leishmaniasis|
62025788|NCT06040489|EXPERIMENTAL|Oral Miltefosine and Pentoxifylline for Mucous Leishmaniasis|
62025789|NCT06040489|ACTIVE_COMPARATOR|Intravenous Liposomal Amphotericin B for Cutaneous Leishmaniasis|
62025790|NCT06040489|ACTIVE_COMPARATOR|Intravenous Liposomal Amphotericin B for Mucous Leishmaniasis|
62025791|NCT03822299|NO_INTERVENTION|Placebo|Patients receive suspension of their own feces.
62025792|NCT03822299|ACTIVE_COMPARATOR|30 g donor dose|Patients receiving 30 g of a healthy donor feces.
62025793|NCT03822299|ACTIVE_COMPARATOR|60 g donor dose|Patients receiving 60 g of a healthy donor feces.
62223783|NCT02389608|EXPERIMENTAL|1- tDCS 2--FES|"1. Transcranial stimulation ( tDCS ) will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes and intensity 2mA associated active contraction of the TA muscle. Placebo tDCS will follow the same procedures as active tDCS with active, but the tDCS device will only be switched on for 20 seconds.~2. Functional electrical stimulation (FES) will be administered using QUARK® FES VIF 995 DUAL device. The duration of active FES will be 20 minutes, associated with active contraction of the TA muscle. The pulse width will be 250 µs, modulated at a frequency of 50 Hz, with one to two stimulation cycles (6 seconds on and 12 seconds off) and the intensity will be increased until reaching the motor threshold. Placebo FES will follow the same procedures as active FES , but the FES device will only be switched on for 20 seconds, following which the intensity will be gradually reduced to 0 mA."
62417299|NCT04601831|EXPERIMENTAL|Radiation Therapy to all residual FDG-avid sites*|"All patients enrolled in the trial will receive focal radiation therapy (RT) to all\* residual FDG-avid sites per Lugano criteria (Lugano 4-5) as noted on day 30 post-CAR-T PET/CT scan.~\*If \>5 distinct sites, physician discretion will be allowed as to how many sites are treated, with recommendation that at least all symptomatic and bulky (\>=7.5 cm in largest dimension) sites be treated."
62417300|NCT06700681|PLACEBO_COMPARATOR|TIVA with Propofol and intubation|Patient received cardiac electrophysiology studies and ablation under TIVA with Propofol induction and maintenance and airway is maintained with intubation and controlled ventilation.
62025794|NCT03535818|ACTIVE_COMPARATOR|Redo pulmonary vein isolation|
62025795|NCT03535818|ACTIVE_COMPARATOR|Ganglionated plexus ablation + redo pulmonary vein isolation|
62025796|NCT00620308|EXPERIMENTAL|CD-NP low-dose study drug|
62025797|NCT00620308|EXPERIMENTAL|CD-NP high-dose study drug|
62025798|NCT00620308|PLACEBO_COMPARATOR|Placebo|
62025799|NCT01735123|EXPERIMENTAL|extensively hydrolyzed casein formula|The investigators plan to randomize 60 out of 120 infants to be weaned to an extensively hydrolyzed casein formula. Recruited mothers are encouraged to breast-feed. The dietary intervention will be applied until 9 months of age. The minimum exposure time to the study formula should be 90 days. Signs of beta-cell autoimmunity, i.e. diabetes-associated autoantibodies, will be monitored in the study participants, although the study will not have sufficient power to detect statistically significant differences in the seroconversion rate between the groups due to the limited number of infants randomized.
62025800|NCT01735123|EXPERIMENTAL|cow's milk based infant formula|The investigators plan to randomize 60 out of 120 infants to be weaned to a cow's milk based infant formula. Recruited mothers are encouraged to breast-feed. The dietary intervention will be applied until 9 months of age. The minimum exposure time to the study formula should be 90 days. Signs of beta-cell autoimmunity, i.e. diabetes-associated autoantibodies, will be monitored in the study participants, although the study will not have sufficient power to detect statistically significant differences in the seroconversion rate between the groups due to the limited number of infants randomized.
62025801|NCT01686711|EXPERIMENTAL|SYR-322 25 mg , AD-4833 15 mg|
62223784|NCT04463173|EXPERIMENTAL|High fat food oral administration|Anaprazole 40mg, single dose, oral administration 30 minutes after breakfast with high fat food.
62417301|NCT06700681|EXPERIMENTAL|TIVA with Remimazolam and intubation|Patient received cardiac electrophysiology studies and ablation under TIVA with Remimazolam induction and maintenance and airway is maintained with intubation and controlled ventilation.
62798722|NCT00641004|EXPERIMENTAL|1|Rebamipide 100mg TID for 12 weeks
62025802|NCT01686711|EXPERIMENTAL|SYR-322 25 mg , AD-4833 30 mg|
62025803|NCT01686711|PLACEBO_COMPARATOR|SYR-322 25 mg , AD-4833 placebo|
62798723|NCT00641004|ACTIVE_COMPARATOR|2|Esomeprazole 40mg OD + Esomeprazole-matching placebo BID for 12 weeks
62798724|NCT01304602|EXPERIMENTAL|Irinotecan + BKM120|Irinotecan + BKM120 at the assigned cohort dose level.
62798725|NCT01669486||ICU patients|All patients admitted to ICU for a minimal hospitalization of 24 hours, invasive mechanically ventilated, will be evaluated with CPOT and BPS scores, during nurses work, in particular before and after nurses manoeuvers.
62798726|NCT03018613|ACTIVE_COMPARATOR|treatment for part 1|Fecal microbiota transplantation and traditional treatments will be used in patients with chronic functional constipation in part 1.
62798727|NCT03018613|PLACEBO_COMPARATOR|Placebo for part 2|The traditional treatments and normal saline will be used in patients with chronic functional constipation in part 2 according to associated guidelines.
62798728|NCT03905928|EXPERIMENTAL|18mg/ml Tobacco Flavor ECIG|Participants will be provided with an ECIG containing 15mg/ml nicotine concentration and a tobacco flavor.
62798729|NCT03905928|PLACEBO_COMPARATOR|0mg/ml Tobacco Flavor ECIG|Participants will be provided with an ECIG containing 0mg/ml nicotine concentration and a tobacco flavor.
62798730|NCT03905928|EXPERIMENTAL|18mg/ml Strawberry Vanilla Flavor ECIG|Participants will be provided with an ECIG containing 15mg/ml nicotine concentration and a strawberry vanilla flavor.
62798731|NCT03905928|PLACEBO_COMPARATOR|0mg/ml Strawberry Vanilla Flavor ECIG|Participants will be provided with an ECIG containing 0mg/ml nicotine concentration and a strawberry vanilla flavor.
62025804|NCT06276543||antibiotic-impregnated catheter group|Hydrocephalus patients implanted with antibiotic-impregnated catheter.
62798732|NCT05038150|EXPERIMENTAL|Cohort|"In part 1\&2, cohorts of 3 patients will be enrolled. The first patient of each cohort in Part 1 will be admitted to an infusion unit and treated with an IV infusion of SGN1 over 2 hours. Patients in Part 1 will enter Part 2 for extension treatment after completing the 28-day DLT observation period. Up to 5 cohorts will be evaluated.~Part 3 is an open-label, dose expansion phase.There will be at least 2 tumor types selected, expand between second to four dose level in each tumor type ."
62025805|NCT04651023|PLACEBO_COMPARATOR|control group|During the 12-week study period, the participants consumed two bottles (2 \*200 mL) of the experimental beverage (0g NnEx) per day with or after meals.
62223785|NCT04463173|EXPERIMENTAL|Fasting oral administration|Anaprazole 40mg, single dose, oral administration before breakfast.
62223786|NCT01481220|EXPERIMENTAL|Azacitidine + Eltrombopag|
62223787|NCT06132126|EXPERIMENTAL|LY3938577 (Part A)|LY3938577 administered Subcutaneously (SC).
62223788|NCT06132126|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered SC.
62223789|NCT06132126|ACTIVE_COMPARATOR|Insulin degludec (Part A)|Insulin degludec administered SC.
62223790|NCT06132126|EXPERIMENTAL|LY3938577 (Part B)|LY3938577 administered SC.
62223791|NCT06132126|ACTIVE_COMPARATOR|Insulin degludec (Part B)|Insulin degludec administered SC.
62798733|NCT03633110|EXPERIMENTAL|Part A|"Participants in Part A have no evidence of disease when they begin receiving GEN-009 Adjuvanted Vaccine, and have completed treatment with curative intent for their disease (eg, surgical resection, neoadjuvant and/or adjuvant chemotherapy, and/or radiation therapy).~Part A will consist of approximately 9 participants."
62798734|NCT03633110|EXPERIMENTAL|Part B|"Participants in Part B have advanced or metastatic solid tumors, and will receive GEN-009 Adjuvanted Vaccine in combination with PD-1 inhibitor therapy (nivolumab or pembrolizumab).~Part B will consist of up to 90 participants."
62798735|NCT04924517|EXPERIMENTAL|Extended Evening Fasting|Participants will eat between 8am-4pm
62798736|NCT04924517|ACTIVE_COMPARATOR|Control|Participants will eat between 8am-8pm
62223792|NCT04684251|EXPERIMENTAL|Treatment arm|The treatment arm will undergo the intervention with embolisation of their hemorrhoidal arteries. The embolisation will be performed using a standard right femoral puncture and after inserting a 5 Fr introducer sheath. The inferior mesenteric artery will be catheterised using a Simmons catheter (radiofocus-Terumo). The superior rectal arteries will be then catheterized with a rapid transit microcatheter Progreat microcatheter (Radiofocus-Terumo) and embolised with coils. The treatment will include the use of fluoroscopy for which the radiation protection department of Oxford University Hospitals NHS Foundation Trust has been consulted. The technical success of the procedure will be assessed fluoroscopically by achieving stasis of blood flow distally to the site of the embolization. CE marked coils will be used for the embolisation of the arteries feeding the haemorrhoids.
62223793|NCT02173431||BMI 20 to 24.99|30 patients
62223794|NCT02173431||BMI 25 to 29.99|30 patients
62223795|NCT02173431||BMI 30 to 34.99|30 patients
62223796|NCT02173431||BMI 35 to 39.99|30 patients
62025806|NCT04651023|EXPERIMENTAL|low concentration of NnEx group|During the 12-week study period, the participants consumed two bottles (2 \*200 mL) of the experimental beverage (1g NnEx) per day with or after meals.
62025807|NCT04651023|EXPERIMENTAL|high concentration of NnEx group|During the 12-week study period, the participants consumed two bottles (2 \*200 mL) of the experimental beverage (2g NnEx) per day with or after meals.
62025808|NCT04069975||No sedation|The group of patients who did endoscopies without sedation.
62025809|NCT04069975||Sedation|The group of patients who did endoscopies with sedation.
62025810|NCT03119766|EXPERIMENTAL|Kolofort|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
62223797|NCT02173431||BMI 40 to 44.99|30 patients
62223798|NCT02173431||BMI 45 to 49.99|30 patients
62223799|NCT02173431||BMI more than 50|30 patients
62223800|NCT04722939||Critical illness with acute kidney injury|See below for detailed inclusion/exclusion criteria
62223801|NCT00444899|EXPERIMENTAL|Intensive treatment|Submitted to an intensive follow-up by the dietician.
62223802|NCT00444899|ACTIVE_COMPARATOR|Usual treatment|Subjects will remain under the care of their endocrinologist and/or general practitioner.
62223803|NCT05714748|EXPERIMENTAL|Treatment Cohort|With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1 month interval.
62223804|NCT03486847|EXPERIMENTAL|Repetitive recruitment with PEEP|One alveolar recruitment at before surgery and repetitive alveolar recruitment (once an hour) during surgery
62223805|NCT03486847|ACTIVE_COMPARATOR|One recruitment with PEEP|One alveolar recruitment at before surgery
62223806|NCT01452659|EXPERIMENTAL|TAK-385 10 mg QD|
62798737|NCT06726382|ACTIVE_COMPARATOR|Esketamine Nasal Spray|250 ml water at 8.00 and 9.00 a.m. on the study day. Study drug dose (Esketamine Spravato, 28 mg) nasally at 9.00 a.m. on the study day.
62223807|NCT01452659|EXPERIMENTAL|TAK-385 20 mg QD|
62798738|NCT06726382|EXPERIMENTAL|Esketamine p.o. and water|250 ml water at 8.00 and 9.00 a.m. on the study day. Study drug dose (Esketamine Kalceks 5 mg/ml, 28 mg) p.o. at 9.00 a.m. on the study day.
62798739|NCT06726382|EXPERIMENTAL|Esketamine p.o. and grapefruit juice|250 ml grapefruit juice at 8.00 and 9.00 a.m. on the study day. Study drug dose (Esketamine Kalceks 5 mg/ml, 28 mg) p.o. at 9.00 a.m. on the study day.
62798740|NCT06726382|EXPERIMENTAL|Esketamine p.o. and Cobisistat|150 mg Cobisistat and 250 ml water at 8.00 a.m. on the study day. Study drug dose (Esketamine Kalceks 5 mg/ml, 28 mg) p.o. and 250 ml water at 9.00 a.m. on the study day.
62798741|NCT03976388|EXPERIMENTAL|Clinical virtual simulator|A clinical virtual simulator contains an interactive medical case depicting an acutely ill patient seeking care at the emergency department. The case will be delivered in small groups (up to 6 participants) in sessions lasting up to 20 minutes. After the simulation has been completed, a feedback session lasting up to 30 minutes will be delivered as well.
62798742|NCT03976388|ACTIVE_COMPARATOR|Standard educational session|A small-group discussion (up to 6 participants) using patients with the same condition as the one selected for the clinical simulator will be held for participants allocated to the control group. These sessions will be led by a physician and have a maximum duration of up to 60 minutes.
62798743|NCT04254224||Diverticulitis Hinchey I-IV|Patients with complicated diverticulitis (Hinchey I-IV) treated conservatively (iv antibiotics with or without percutaneous, transrectal or transvaginal drainage) or surgically.
62798744|NCT06725823|ACTIVE_COMPARATOR|suprascapular nerve block group|Patients will be placed in lateral position by using A high - frequency linear ultrasound probe will be placed approximately 2 cm medial to the medial border of the acromion and about 2 cm cranial to the superior margin of the scapular spine the needle will be inserted .The tip of the needle will be placed at the floor of the supraspinatus fossa where the nerve has passed
62798745|NCT06725823|ACTIVE_COMPARATOR|shoulder anterior capsular block group|Ultrasound guided injection For the SHAC block, with the patient in a beach-chair position and with the arm in extension, the subscapularis muscle is stretched posteriorly and becomes easily visible. With external rotation and abduction, the coracobrachialis and the biceps brachii muscles are displaced, allowing the visualization of the interfascial space between the deep lamina of the deltoid muscle fascia and the superficial lamina of the subscapularis fascia.Once the injection into the fascial space is achieved, the investigators can proceed towards the glenohumeral pericapsular space by crossing the subscapularis muscle with the needle. By injecting the pericapsular space, the investigators reach the terminal articular branches indistinctly from their origin. Furthermore, through the Weitbrecht foramen, a natural capsular foramen between the upper and middle glenohumeral ligaments, we also reach the intra-articular space .
62798746|NCT02266355|EXPERIMENTAL|OmalizumabTreatment Group|Omalizumab (Xolair) 300 mg SQ every 2 weeks
62798747|NCT03061435|OTHER|Screening anal Pap Smear - Negative (75%)|All patients will receive an anal Pap test. 75% of patients with a negative anal Pap will complete study with no further intervention.
62798748|NCT03061435|OTHER|Screening anal Pap Smear - Negative (25%)|All patients will receive an anal Pap test. Remaining 25% of patients will proceed to high-resolution anoscopy (HRA) clinic to assess the negative predictive rate of HRA.
62798749|NCT03061435|OTHER|Screening anal Pap Smear - Positive|All patients will receive an anal Pap test. Any patient with abnormal cytology on their Pap test will be referred to HRA clinic for management. This includes potential biopsy and treatment.
62798750|NCT00411671|EXPERIMENTAL|Sorafenib|Sorafenib 400 mg By Mouth Twice Daily for 28 Days.
62223808|NCT01452659|EXPERIMENTAL|TAK-385 40 mg QD|
62025811|NCT03119766|PLACEBO_COMPARATOR|Placebo|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
62223809|NCT01452659|PLACEBO_COMPARATOR|Placebo|
62417302|NCT06700681|EXPERIMENTAL|TIVA with Propofol and non-Intubated|Patient received cardiac electrophysiology studies and ablation under TIVA with Propofol induction and maintenance and airway is maintained with spontaneous ventilation without intubation(non-intubated).
62223810|NCT05187468|EXPERIMENTAL|ESWT 1|Extracorporeal Shockwave Therapy 1000 pulses, 60 mJ, 10 Hz
62223811|NCT05187468|EXPERIMENTAL|ESWT 2|Extracorporeal Shockwave Therapy 2000 pulses, 60 mJ, 10 Hz
62223812|NCT05187468|ACTIVE_COMPARATOR|Ultrasound therapy, Massage, Heat Pack|10 Min massage 5 min US therapy 10 min Heat pack
62223813|NCT05234229||covagrip women in immediate post partum|women in immediate post partum
62223814|NCT05234229||Caregivers|health care personnel
62223815|NCT05342909|EXPERIMENTAL|5x a week BFR training group|Subjects will perform 2 exercises (LAQ and squat) with BFR applied to dominant thigh daily (5x/wk). Exercises performed for 4 sets (30/15/15/15 reps) initially at 30% 1RM; with load increased by 5% every 2 weeks. Training program lasts for 8 weeks. They are also to continue with their regular independent exercise program.
62417303|NCT06700681|EXPERIMENTAL|TIVA with Remimazolam and non-Intubated|Patient received cardiac electrophysiology studies and ablation under TIVA with Remimazolam induction and maintenance and airway is maintained with spontaneous ventilation without intubation(non-intubated).
62588643|NCT06666257|EXPERIMENTAL|SmartMomsAR+CGM|Women will engage in the SmartMoms intervention culturally adapted to the needs of Arkansas women while also wearing unblinded CGM devices providing insights to glycemic trends in response to lifestyle factors.
62798751|NCT01855737||Warfarin Using Group|
62798752|NCT04974801|OTHER|Provox Life HMEs followed by Usual Care HMEs|Use of Provox Life devices during a period of six weeks followed by use of Usual Care devices during a period of six weeks.
62588644|NCT06627192||Group 1 Case|"Group Case (I):~This group will include 20 patients diagnosed with stage II periodontitis and controlled hypertension. They will receive NSPT and oral hygiene measures will be instructed following treatment."
62588645|NCT06627192||Group 2 Control|This group will include 20 patients diagnosed with stage II periodontitis and no hypertension. They will receive NSPT and oral hygiene measures will be instructed following treatment.
62798753|NCT04974801|OTHER|Usual Care HMEs followed by Provox Life HMEs|Use of Usual Care devices during a period of six weeks followed by use of Provox Life devices during a period of six weeks.
62025812|NCT02880046||Melanoma (LyteloMel)|
62223816|NCT05342909|EXPERIMENTAL|2x a week BFR training group|Subjects will perform 2 exercises (LAQ and squat) with BFR applied to dominant thigh twice a week (2x/wk). Exercises performed for 4 sets (30/15/15/15 reps) initially at 30% 1RM; with load increased by 5% every 2 weeks. Training program lasts for 8 weeks. They are also to continue with their regular independent exercise program.
62417304|NCT05505851|ACTIVE_COMPARATOR|A: Control|Corrective Exercises Hip Flexor Stretch 30 seconds hold 3 repetitions on each side Thoracolumbar extensors stretch 30 second holds 3 repetitions Abdominal Curl ups with hands at side 10 repetitions 2 sets Progression: • Abdominal curl up with arms crossed • Abdominal curl ups with hands behind head Pelvic bridging 10 seconds hold 10 repetitions 2 sets
62417305|NCT05505851|EXPERIMENTAL|B: Sequential Core Stability Corrective Exercise Approach|"1. Corrective Exercises~2. Diaphragm Training Program As per standardized pulmonary rehabilitation guidelines,. Participant will be advised to breathe in gently with an improved tidal volume for ten repetitions, then after a short interval of break 15 repetitions will be done again. 30 Repetitions in set of 15, 15 with the interval rest. 2 sets.~3. Pelvic floor Muscle training Participants will be asked to do pelvic floor training with high intensity (close to maximum) contractions with holding each muscle contraction for 6-8 seconds with relaxation of 6 seconds. Total 8 to 12 contractions.~4. Core Stability exercises~   1. Beginning~  2. Progressing~  3. Advanced"
62417306|NCT02854189|OTHER|patients with genu recurvatum|The medial osteoarthritis knees with genu recurvatum were included in this study. Patients had been treated with cemented minimally invasive surgery Oxford unicompartmental knee arthroplasty and had had a minimum of 24 months of follow-up.The incidence of postoperative genu recurvatum, postoperative hyperextension angle, and the knee society score were recorded.
62588646|NCT05747573|ACTIVE_COMPARATOR|A 100mg GB1211 tablet, fasted|Single dose of 100 mg GB1211 as a tablet (100 mg strength) under fasted conditions (n=4 per period)
62588647|NCT05747573|ACTIVE_COMPARATOR|B 100 mg GB1211 capsules, fasted|Single dose of 100 mg GB1211 as two capsules (50 mg strength) under fasted conditions (n=4 per period)
62798754|NCT05685342|EXPERIMENTAL|Preemptive administration group|Preemptive administration group will receive intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) for 15 minutes at the end of induction of anesthesia.
62798755|NCT05685342|ACTIVE_COMPARATOR|Preventive administration group|The preventive administration group will receive intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) for 15 minutes when surgical site closure starts.
62025813|NCT02880046||Lung cancer (TeloCap)|
62025814|NCT02880046||Renal carcinoma (EMIR)|
62223817|NCT05342909|NO_INTERVENTION|Control group|This group will not perform any BFR exercises. They are to continue with their regular independent exercise program.
62223818|NCT05505110|ACTIVE_COMPARATOR|Intervention Group|Vaginal Seeding
62223819|NCT05505110|SHAM_COMPARATOR|Control Group|Sterile Swab
62223820|NCT00289432|EXPERIMENTAL|1|Behavioral: Psychoeducative intervention
62223821|NCT00289432|ACTIVE_COMPARATOR|2|The Hospitals standard follow-up support group
62223822|NCT05077644|OTHER|Participants who use Stella App|Participant experience in using the mobile application and EPDS results
62223823|NCT02181387|ACTIVE_COMPARATOR|acetaminophen|1000 mg every 6 hours during labor up to maximum 3 doses
62223824|NCT02181387|PLACEBO_COMPARATOR|placebo|placebo capsule identical to the acetaminophen capsule will be administered every 6 hours to a maximum of 4 doses
62223825|NCT00383136|EXPERIMENTAL|1|Tirofiban
62223826|NCT00383136|ACTIVE_COMPARATOR|2|Abciximab
62223827|NCT03656237|EXPERIMENTAL|Usual training + Audits + LDHF training|"Usual training of health workers, in classroom, following standard curriculum~+ Mortality and Morbidity Audits in facility every two weeks followed by LDHF training focused on gaps in knowledge or practice identified during the audits"
62223828|NCT03656237|EXPERIMENTAL|Audits + LDHF training|Mortality and Morbidity Audits in facility every two weeks followed by LDHF training focused on gaps in knowledge or practice identified during the audits
62588648|NCT05747573|ACTIVE_COMPARATOR|C 100 mg GB1211 tablet, fed|Single dose of 100 mg GB1211 as a tablet (100 mg strength) under fed conditions (n=4 per period)
62588649|NCT06384521|EXPERIMENTAL|Intervention Arm|Lifestyle MIND
62588650|NCT06384521|OTHER|Wait-list control arm|Delayed Lifestyle MIND
62588651|NCT06665659||Monofocal IOL group|Participants who have had either the Tecnis Eyhance or OphthalmoPro Zoe monofocal lens implanted during routine cataract surgery
62798756|NCT00977171|EXPERIMENTAL|Droxidopa|
62798757|NCT03766659|OTHER|MOSE|EUS-FNB with MOSE
62798758|NCT03766659|OTHER|ROSE|EUS-FNA with ROSE
62798759|NCT02023957|EXPERIMENTAL|Interactive computer-assisted screening|Eligible patients completed the interactive computer-assisted screening (iCAS) tool in English or Spanish before seeing the consenting clinician. Participating patients then received the iCAS generated tailored recommendation sheet. Participating clinicians received the iCAS generated risk report.
62025815|NCT00519480|PLACEBO_COMPARATOR|Subjects receiving treatment P|Eligible subjects will receive placebo twice daily along with metformin twice daily for 13 days.
62025816|NCT00519480|EXPERIMENTAL|Subjects receiving treatment A|Eligible subjects will receive GSK189075 500 milligrams twice daily along with metformin twice daily for 13 days.
62025817|NCT00519480|EXPERIMENTAL|Subjects receiving treatment B|Eligible subjects will receive GSK189075 750 milligrams twice daily along with metformin twice daily for 13 days.
62223829|NCT03656237|ACTIVE_COMPARATOR|Usual Training|Control Arm exposed to usual training of health workers, in classroom, following standard curriculum
62223830|NCT02464150|EXPERIMENTAL|Participants|Participants are subjected to gluten intervention in an unblinded fashion.
62025818|NCT00254254|EXPERIMENTAL|Sequence 1|Exenatide 2.5 mcg - Exenatide 5 mcg - Placebo 0.02 mL
62025819|NCT00254254|EXPERIMENTAL|Sequence 2|Exenatide 2.5 mcg - Placebo 0.02 mL - Exenatide 5 mcg
62025820|NCT00254254|EXPERIMENTAL|Sequence 3|Placebo 0.02 mL - Exenatide 2.5 mcg - Exenatide 5 mcg
62025821|NCT05424419||double-brace group|AIS patients with daytime and nighttime braces
62025822|NCT05424419||single-brace group|AIS patients with a single brace for day and night
62025823|NCT00966940|OTHER|Travoprost-to-tafluprost|Travoprost first, with tafluprost second. Each product dosed for six weeks.
62798760|NCT02023957|NO_INTERVENTION|Usual Care|Eligible patients randomized to the control group completed their standard visit to the participating clinician. There was no pre-visit health risk screening. There were no tailored reports for the patients or clinicians.
62025824|NCT00966940|OTHER|Tafluprost-to-travoprost|Tafluprost first, with travoprost second. Each product dosed for six weeks.
62025825|NCT02323919|ACTIVE_COMPARATOR|SystemCHANGE|consists of self-efficacy enhancement and relapse prevention strategies, but is primarily anchored in a set of behavior change strategies based on System Improvement techniques.
62025826|NCT02323919|ACTIVE_COMPARATOR|CHANGE+|is based on several cognitive-behavioral theoretical frameworks: Social Problem-solving Model, Self-efficacy theory, Expectancy-value theory and Relapse Prevention theory.
62025827|NCT02323919|PLACEBO_COMPARATOR|Usual Care|Usual Care
62417307|NCT02854189|OTHER|patients without genu recurvatum|The medial osteoarthritis knees without genu recurvatum were included in this study. Patients had been treated with cemented minimally invasive surgery Oxford unicompartmental knee arthroplasty and had had a minimum of 24 months of follow-up.The incidence of postoperative genu recurvatum, postoperative hyperextension angle, and the knee society score were recorded.
62417308|NCT06584708|EXPERIMENTAL|Low-volume High intensity interval training|Group A: Low-volume High intensity interval training
62417309|NCT06584708|EXPERIMENTAL|Moderate intensity continous exercise|Group B: Moderate intensity continous exercise
62025828|NCT06264440|EXPERIMENTAL|Period 1|Participants will receive a single oral dose of BIIB122, while fasting, followed by a washout period.
62025829|NCT06264440|EXPERIMENTAL|Period 2|Participants will receive PPI pretreatment (rabeprazole) once daily (QD), followed by a single oral dose of BIIB122 while fasting, followed by a washout period.
62025830|NCT06264440|EXPERIMENTAL|Period 3|Participants will receive PPI pretreatment (rabeprazole) QD, followed by a single oral dose of BIIB122 while fed, followed by a washout period.
62417310|NCT03891732||MRI pathway|Plain biparametric MRI prostate applied to men with elevated PSA, on top of standard screening pathway using PSA and Prostate Health Index
62417311|NCT03891732||Standard screening pathway|Intervention: Using blood tests PSA and Prostate Health Index to screen men at risk of prostate cancer
62798761|NCT06467903|EXPERIMENTAL|one arm - 1000 patients, DR screening|SW as medical devices(investigational device) to evaluate the retinal image of the patient's eye (to identify if the patient has DR or if the patient is healthy) .
62025831|NCT02224729|EXPERIMENTAL|Bendamustine, Bortezomib, Dexamethasone (Standard)|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2; bortezomib SC on days 1, 8, 15, and 22; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 35 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than a VGPR or with more than 10% bone marrow plasmacytosis may receive 2 additional courses.
62025832|NCT02568527|EXPERIMENTAL|PLGA Scaffold|Poly Lactide-co-Glycolic Acid (PLGA) 50:50
62025833|NCT04171700|EXPERIMENTAL|Rucaparib|"Eligible participants will be enrolled in either Cohort A or Cohort B.~Cohort A: Up to 200 participants with deleterious mutations in BRCA1, BRCA2, PALB2, RAD51C or RAD51D.~Cohort B (Exploratory): Up to 20 participants with deleterious mutations in BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B."
62025834|NCT01357798|ACTIVE_COMPARATOR|Btx-A: Active Comparator|Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
62025835|NCT01357798|PLACEBO_COMPARATOR|Placebo Comparator|0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
62417312|NCT01080911|EXPERIMENTAL|spinal morphine 0.05 mg|spinal morphine 0.05 mg plus 0.5% heavy marcaine 3.5 ml
62417313|NCT01080911|ACTIVE_COMPARATOR|spinal morphine 0.1 mg|spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
62417314|NCT05722340|EXPERIMENTAL|NIVATS|Lung biopsy is performed using non-intubated video-assisted thoracic surgery (NIVATS).
62417315|NCT05722340|ACTIVE_COMPARATOR|IGAVATS|Lung biopsy is performed using Intubated general anaesthesia video-assisted thoracic surgery (IGAVATS).
62417316|NCT01493609|NO_INTERVENTION|Waitlist Control|
62417317|NCT01493609|EXPERIMENTAL|Click-East app|Participants will receive a copy of the game immediately following recruitment and assessment.
62417318|NCT06133348|EXPERIMENTAL|PRISM Intervention|This single-arm pilot study will (1) test feasibility, acceptability, and appropriateness of the PRISM intervention in individuals with breast cancer, (2) elicit patient perspectives on elements for future adaptation or expansion to meet the unique needs of women with breast cancer, (3) assess trajectory of patient-reported outcomes and biological measures of stress for patients with breast cancer receiving the PRISM intervention.
62417319|NCT04101721|EXPERIMENTAL|Aflibercept Group|Patients will receive a single intravitreal (IVT) injection per eligible eye at baseline.
62417320|NCT04101721|EXPERIMENTAL|Laser Group|Patients will undergo laser treatment in each eligible eye at baseline.
62417321|NCT05611710|PLACEBO_COMPARATOR|Placebo|The control group will be formed of 80 dengue patients with warning signs or severe dengue receiving placebo.
62417322|NCT05611710|EXPERIMENTAL|Anakinra|The intervention group will include 80 dengue patients with warning signs or severe dengue receiving anakinra.
62417323|NCT06560463||Cystic Fibrosis|
62025836|NCT06535750|EXPERIMENTAL|Rotator Cuff Patients with used to conventional rehabilitation|"Patients in the experimental group received strengthening exercises with theraband in addition to the standard treatment programme. This programme included the following:~Strengthening Exercises: Low-row, biceps strengthening, shoulder horizontal abduction and shoulder horizontal adduction, external rotation. After the pain decreased, strengthening exercises for subscapularis, infraspinatus, supraspinatus, teres minor, deltoid and scapulothoracic muscles were performed. The colour of the Theraband was chosen between yellow, red, green, blue and red to the extent tolerated by the patient."
62025837|NCT06535750|EXPERIMENTAL|Rotator Cuff Patients with used to conventional rehabilitation add to strenght exercise.|"Patients in the experimental group received strengthening exercises with theraband in addition to the standard treatment programme. This programme included the following:~Strengthening Exercises: Low-row, biceps strengthening, shoulder horizontal abduction and shoulder horizontal adduction, external rotation. After the pain decreased, strengthening exercises for subscapularis, infraspinatus, supraspinatus, teres minor, deltoid and scapulothoracic muscles were performed. The colour of the Theraband was chosen between yellow, red, green, blue and red to the extent tolerated by the patient."
62025838|NCT01108653|OTHER|Group 1: Usual care sick-leave management|
62025839|NCT01108653|OTHER|Group 2: Structuralised sick-leave program|
62025840|NCT00746837|EXPERIMENTAL|1|Single ascending IV dose, 3 treatment periods separated by a minimum 14 day washout between doses
62025841|NCT00746837|EXPERIMENTAL|2|2 cohorts single IV dose + multiple oral dose period separated by a minimum of 14 days washout between IV and oral dose
62025842|NCT06137391|EXPERIMENTAL|MIH and irreversible pulpitis|Group I (n=48) diagnosed with MIH and irreversible pulpitis. Group I will be randomly equally allocated into Group I A (n=24): partial pulpotomy (PP) and Group I B (n=24): full pulpotomy (FP). If pulpal bleeding cannot be controlled within 6 minutes using cotton pellets soaked in 3% sodium hypochlorite, the allocated procedure will be abandoned. The pulpotomy agent to be used will be mineral trioxide aggregate (MTA) and teeth will be restored using a resin modified glass ionomer restoration (RMGIC).
62025843|NCT06137391|ACTIVE_COMPARATOR|No MIH with irreversible pulpitis|Group II (n=48) diagnosed with irreversible pulpitis but not affected with MIH. Group II will be randomly equally allocated into Group II A (n=24): partial pulpotomy (PP) and Group II B (n=24): full pulpotomy (FP). If pulpal bleeding cannot be controlled within 6 minutes using cotton pellets soaked in 3% sodium hypochlorite, the allocated procedure will be abandoned. The pulpotomy agent to be used will be mineral trioxide aggregate (MTA) and teeth will be restored using a resin modified glass ionomer restoration (RMGIC).
62025844|NCT02008383|EXPERIMENTAL|Cabozantinib and Panitumumab|60 mg Cabozantinib PO daily and 6 mg/kg Panitumumab IV every 2 weeks.
62025845|NCT02008383|EXPERIMENTAL|Cabozantinib|60 mg Cabozantinib PO daily.
62223831|NCT00050037|EXPERIMENTAL|CD-ROM based CBT|Group is given a copy of the CD-ROM program to complete at home over 10 weeks. At the end of each week, these patients upload and transmit their encrypted tracking data to the research coordinator. At the end of the treatment, participants who have not improved are offered a course of traditional manual-based group therapy, follow-up in an ongoing maintenance group in an eating disorders program, or an alternative treatment.
62223832|NCT00050037|ACTIVE_COMPARATOR|Standard Group CBT|"Group undergoes standard group CBT. Therapy is administered over 10 weeks in five 90-minute sessions. The key topics are similar to those covered in the CD-ROM group: psychoeducation, developing a personal profile, standardizing meal times, recognizing emotional eating, increasing daily activity, learning the language of CBT, identifying automatic thoughts, restructuring thoughts, identifying cues and consequences, chaining, surfing the urge, and preventing relapses. Therapy sessions include a didactic section followed by group interaction and discussion. All group sessions are audiotaped and monitored."
62223833|NCT00050037|NO_INTERVENTION|Waiting List|Participants in the wait list control group undergo an initial assessment but receive no active intervention for 10 weeks. After 10 weeks, these patients undergo post-treatment assessment and are offered the opportunity to either enter group treatment in an eating disorders program or enter other appropriate treatment. Three-month follow-up data are not collected from these individuals.
62223834|NCT03944473|ACTIVE_COMPARATOR|neostigmine|Neostigmine is the acetylcholinesterase inhibitor most commonly used in pharmacologically reversing the effects of neuromuscular blockers \[8\]. Reversal of NMB is facilitated by increasing acetylcholine levels at nicotinic skeletal muscle-binding sites.
62223835|NCT03944473|EXPERIMENTAL|sugammadex|Sugammadex is a modified gamma-cyclodextrin, the first of a new class of drugs called selective relaxant binding agents, with an unusually high affinity for rocuronium. This medication offers an alternate mechanism of action to antagonize the effects of steroidal neuromuscular blockade agents.
62223836|NCT04684602|EXPERIMENTAL|Arm 1: Autoimmune Diseases|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for autoimmune conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
62223837|NCT04684602|EXPERIMENTAL|Arm 2: Cardiovascular Disorders|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for cardiovascular disorders and conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
62417324|NCT05828095|EXPERIMENTAL|Group #1: INO-6160/ 2.0 mg|The dose of INO-6160, 2 mg, will be administered as 2 separate intradermal (ID) injections, one in each arm
62588652|NCT01194128|EXPERIMENTAL|Psychoeducatioinal Support|The intervention is comprised of three modules (see Table 6), each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.
62025846|NCT03145116|EXPERIMENTAL|509|
62223838|NCT04684602|EXPERIMENTAL|Arm 3: Diabetes Complications|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for diabetes complications. Outcomes will be compared to results in peer-reviewed literature for several conditions.
62223839|NCT04684602|EXPERIMENTAL|Arm 4: Integumentary Disease|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for integumentary diseases and conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
62798762|NCT00004893|EXPERIMENTAL|IL12 Therapy|Patients begin therapy no sooner than 3 weeks and no later than 6 weeks since last chemotherapy dose. Patients receive interleukin-12 subcutaneously twice a week. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed at least every 3 months for 1 year. If no progression after 1 year, may be followed as needed for new signs or symptoms and survival for 5 years.
62223840|NCT04684602|EXPERIMENTAL|Arm 5: Musculoskeletal Disorders|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for orthopedic and musculoskeletal conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
62223841|NCT04684602|EXPERIMENTAL|Arm 6: Neurodegenerative Disorders|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for neurologic and neurodegenerative disorders. Outcomes will be compared to results in peer-reviewed literature for several conditions.
62223842|NCT04684602|EXPERIMENTAL|Arm 7: Pulmonary Disorders|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for pulmonary disorders. Outcomes will be compared to results in peer-reviewed literature for several conditions.
62798763|NCT00004893|NO_INTERVENTION|Observation|Patients are observed for 6 months. If disease progresses during first 6 months, patients may receive interleukin-12 as in arm I. Patients without disease progression within first 6 months may also then receive interleukin-12 as in arm I. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for toxicity only until interleukin-12 is discontinued.
62798764|NCT04415814|EXPERIMENTAL|Group 1 (Unilateral Pedicle Screw Fixation)|Patients will undergo stabilizing surgery on the lumbar spine for degenerative diseases of the spine. Pedicular screws will be installed unilaterally, which means on one side of the spinous processes. The system will be fixed with standard rod and blockers.
62417325|NCT05828095|EXPERIMENTAL|Group #2: INO-6160/ 2.0 mg with Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)|"The dose of INO-6160, 2 mg, will be administered as 2 separate intradermal (ID) injections, one in each arm.~The dose of Trimer 4571, 100 mcg, will be administered as 2 injections delivered intramuscularly (IM), one in each arm."
62417326|NCT06700850|OTHER|Prototype dressing (rectangle) vs Marketed dressing (rectangle) on knees|Each participant will receive a comparison pair Prototype dressing (rectangle) vs Marketed dressing (rectangle) applied to knees (one dressing per knee). Each dressing of the comparison pair will be randomised to either the right or left knee in a 1:1 ratio.
62417327|NCT06700850|OTHER|Prototype dressing (square) vs Marketed dressing (square) on thighs|Each participant will receive a comparison pair Prototype dressing (square) vs Marketed dressing (square) applied to thighs (one dressing per thigh). Each dressing of the comparison pair will be randomised to either the right or left thigh in a 1:1 ratio.
62417328|NCT02390973|ACTIVE_COMPARATOR|Sleeve gastrectomy|
62417329|NCT02390973|ACTIVE_COMPARATOR|Roux-en-Y Gastric Bypass|
62798765|NCT04415814|ACTIVE_COMPARATOR|Group 2 (Bilateral Pedicle Screw Fixation)|Patients will undergo stabilizing surgery on the lumbar spine for degenerative diseases of the spine. Pedicular screws will be installed bilaterally, which means on the both sides of the spinous processes. The system will be fixed with standard rods and blockers.
62798766|NCT02818972|EXPERIMENTAL|RelayPro|Endovascular treatment with the investigational device.
62798767|NCT06149455|EXPERIMENTAL|Short duration of preoperative antibiotics (2 days)|
62798768|NCT06149455|ACTIVE_COMPARATOR|Long duration of preoperative antibiotics (7 days)|
62798769|NCT02362724|EXPERIMENTAL|Sapphire|Subjects randomized to the experimental contact lens over the study duration
62798770|NCT02362724|ACTIVE_COMPARATOR|Pearl|Subjects randomized to the active comparator contact lens over the study duration
62798771|NCT03721341|ACTIVE_COMPARATOR|Standard arm|Standard of care treatment: palliative radiotherapy, chemotherapy, immunotherapy, hormones, or observation, is at the discretion of the treating oncologist.
62798772|NCT03721341|EXPERIMENTAL|Stereotactic Arm|Stereotactic ablative radiotherapy, plus standard of care treatment: chemotherapy, immunotherapy, hormones, or observation given at the discretion of the treating oncologist.
62798773|NCT01965704|EXPERIMENTAL|Ondansetron|Pregnant Women: ondansetron 8mg intravenously (IV) within 4 hours of delivery. Neonates: ondansetron 0.07 mg/kg given orally every 24 hours starting 4-8 hours after delivery, for up to 5 days (if IV line available in neonate, ondansetron 0.04 mg/kg IV every 24 hours for up to 5 days).
62223843|NCT04684602|EXPERIMENTAL|Arm 8: Sexual Dysfunction|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for sexual dysfunction conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
62223844|NCT04684602|EXPERIMENTAL|Arm 9: Urologic Disorders|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for urologic conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
62223845|NCT04684602|EXPERIMENTAL|Arm 10: Viral Illnesses|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for viral illnesses. Outcomes will be compared to results in peer-reviewed literature for several conditions.
62223846|NCT04643522||Before COVID-19|The semen parameters and sex-related hormone levels of the patients which were performed before the diagnosis of COVID-19.
62223847|NCT04643522||After COVID-19|The semen parameters and sex-related hormone levels of the patients which were performed after the diagnosis of COVID-19.
62417330|NCT02390973|ACTIVE_COMPARATOR|Biliopancreatic Diversion|
62417331|NCT02390973|ACTIVE_COMPARATOR|Control|the best medical management of their diabetes, non-surgical group
62588653|NCT01194128|ACTIVE_COMPARATOR|INformation only control group|"Participants in the control group will receive a portion of the standardized packet of written information that is also provided to the treatment group. This packet will contain several fact sheets from a nationally-recognized expert source in caregiving (the Family Caregiver Alliance's National Center on Caregiving) and a national information and advocacy group (the National Citizens' Coalition for Nursing Home Reform). The fact sheets are relevant to the placement of a family member into a nursing home and are linked to the content areas covered in the intervention. Documents in this packet include Caregiving and Depression, End of Life Decision Making, and Taking Care of You: Self-Care for Family Caregivers from the Family Caregiver Alliance; and Family Involvement in Nursing Home Care, Problem Solving, and Residents' Rights from the National Citizen's Coalition."
62223848|NCT00509808|SHAM_COMPARATOR|electrostimulation|Use of device for predetermined length
62798774|NCT01965704|PLACEBO_COMPARATOR|Placebo|"Pregnant Women: placebo given intravenously prior to delivery (volume to mimic the IV volume of the ondansetron group).~Neonates: placebo given orally every 24 hours, starting 4-8 hours after delivery, for up to 5 days with volume to mimic the oral volume of the ondansetron group (if IV line available, placebo may be given IV)."
62223849|NCT01457326||Immersion Therapy- Study|1. Patients who participate in the immersion therapy post-operative protocol and begin progressive weight bearing at 4 weeks (study)
62798775|NCT04005599|ACTIVE_COMPARATOR|Remifentanil group|Intravenous anesthesia with propofol and remifentanil
62798776|NCT04005599|EXPERIMENTAL|Magnesium group|Intravenous anesthesia with propofol and magnesium sulfate
62223850|NCT01457326||Control Group|2. Patients who undergo the traditional 10-week non-weight bearing post-operative care protocol (control)
62223851|NCT01201733|EXPERIMENTAL|Traditional Thai massage|The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region
62417332|NCT05524207||Vulnerable plaque group|Patients with preoperative contrast-enhanced intra-plaque contrast agent were classified as vulnerable plaque group
62417333|NCT05524207||Stable plaque group|The patients with no contrast agent enhancement in the plaque showed preoperative contrast-enhanced ultrasound were classified as stable plaque group
62417334|NCT05183230|EXPERIMENTAL|Proof-of-Concept WellPATH-PREVENT (R61)|
62798777|NCT05676307|EXPERIMENTAL|Bilateral Vestibular Hypofunction|Vestibular Rehabilitation in Bilateral Vestibular Hypofunction
62798778|NCT02686385|EXPERIMENTAL|Prednisolone + N-Acetylcysteine|Prednisolone for 20 days with NAC (N-Acetylcysteine) NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
62223852|NCT01201733|ACTIVE_COMPARATOR|Ultrasound therapy and hot pack|The participants will receive a thirty minutes session of Ultrasound therapy and hot pack
62223853|NCT05333679|EXPERIMENTAL|Intervention|POC adherence testing by a urine TFV assay with feedback
62223854|NCT05333679|NO_INTERVENTION|Standard of Care|Standard enhanced adherence counselling, SA Department of Health, March 2020
62223855|NCT02572882|OTHER|Single arm|This is a sequential study in which participants are observed (no intervention) for 8 weeks (pre-treatment), then participants self-administer p-inulin 8g orally twice daily for 12 weeks (treatment phase), and then observed for a final 8 weeks during which no treatment was administered (post-treatment).
62223856|NCT05182281|EXPERIMENTAL|Whole Body Vibration and Infrared Therapy Group|Patients in the whole body vibration and infrared group received vibration therapy with a frequency of 60 Hz and amplitude of 0.5-2 mm and infrared therapy at a wavelength of 550-950 nm 20 minutes daily session, 2 days per weeks for 3 months.1000 mg Ca and 880 IU vitamin D treatment were given.
62223857|NCT05182281|ACTIVE_COMPARATOR|Infrared Therapy Group|Patients in infrared therapy group received infrared therapy at a wavelength of 550-950 nm 20 minutes daily session, 2 days per weeks for 3 months.1000 mg Ca and 880 IU vitamin D treatment were given.
62223858|NCT05182281|OTHER|Classical Treatment Group|1000 mg Ca and 880 IU vitamin D treatment were given.
62417335|NCT05183230|EXPERIMENTAL|Optimized WellPATH-PREVENT (R33)|
62433455|NCT05485857|EXPERIMENTAL|Arrangement group|Experimental group: After the completion of laparoscopic-assisted colorectal cancer surgery, the chief surgeon performed laparoscopic small bowel arrangement before closing the abdomen, straightening the small bowel from the colon-small bowel anastomosis or the ileocecal valve to the ligament of Trevor, and restoring the original position of the small bowel. Afterwards, close the abdomen.
62223859|NCT02534454|EXPERIMENTAL|Active TDCS + Active Retraining|2.0 milliamperes (mA) of transcranial direct current stimulation (TDCS) applied during active nicotine avoidance retraining
62417336|NCT05183230|NO_INTERVENTION|Attention Control Usual Care (R33)|The AC-UC group will parallel the delivery of the WellPATH-PREVENT intervention and will also include: a) meetings during hospitalization: a non-clinical member of the team will present the control tablet and explain its use; b) scheduled or requested meetings through zoom: to parallel the delivery of WellPATH-PREVENT. The tablet will still have a link to schedule a meeting with a non-clinician member of the team. The meetings will focus on issues that the patient may have in using the tablet. There will not be any therapeutic or psychological interaction between participants in the control group and the team. The experimental and the control group will also be under usual outpatient care, which is arranged during the hospitalization by the inpatient treatment team.
62417337|NCT01684306|EXPERIMENTAL|Placebo|Study subjects received, in a double blind fashion, a placebo pill identical to the drug.
62417338|NCT01684306|EXPERIMENTAL|Modafinil|"Modafinil (Provigil), a drug on the market since 1997, is employed for the treatment of narcolepsy and other sleep disorders. In recent years, modafinil has also been used off-label to treat cognitive dysfunction in psychiatric disorders such as schizophrenia and Attention Deficit/Hyperactivity Disorder (ADHD).~Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil."
62417339|NCT03382457|EXPERIMENTAL|Treatment|Treatment with the Edwards Cardioband FIT Repair System
62417340|NCT05138900|EXPERIMENTAL|Stereotactic Body Radiation Therapy (SBRT)|A single fraction of targeted SBRT
62417341|NCT06562972|ACTIVE_COMPARATOR|Occlusal equilibration using articulating paper|The articulating paper method is a widely used technique for occlusal equilibration of complete dentures. The process begins by seating the dentures properly and using thin articulating paper to mark occlusal contacts as the patient lightly bites down. High spots are identified by darker or larger marks and are carefully reduced with a fine diamond or acrylic bur. The process is repeated until even contact is achieved across all teeth. The method also involves checking occlusion during different jaw movements and making necessary adjustments. Finally, the adjusted areas are polished, and the patient's comfort is assessed.
62417342|NCT06562972|EXPERIMENTAL|Occlusal equilibration using Occulosense|The Oculosense system, is an advanced tool in dentistry for analyzing occlusion, especially in denture equilibration. It includes an ultra-thin sensor and software that records and displays the force and timing of occlusal contacts in real-time. This system provides detailed data on force distribution, contact timing, and the center of force, offering 2D and 3D visualizations. It allows for precise, dynamic adjustments of dentures by identifying high-pressure areas and premature contacts. Despite its benefits, including high precision and quantifiable data, it is costlier and requires specialized training.
62417343|NCT06686602||NSCLC|Adult patients diagnosed with advanced or metastatic (stage IIIB/IIIC or IV) non-small cell lung cancer (NSCLC).
62417344|NCT06686602||HER2-negative Breast Cancer|Adult patients diagnosed with advanced or metastatic (stage IIIB/IIIC or IV) human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
62798779|NCT02686385|ACTIVE_COMPARATOR|N-Acetylcysteine|NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
62798780|NCT01380795|OTHER|Circulating Tumor Cell|blood sample CTC monitoring and CTC EGFR/K-ras status determination
62223860|NCT02534454|EXPERIMENTAL|Sham TDCS + Active Retraining|0.1 mA of transcranial direct current stimulation (TDCS) applied during active nicotine avoidance retraining
62223861|NCT02534454|EXPERIMENTAL|Active TDCS + Sham retraining|2.0 mA of transcranial direct current stimulation (TDCS) applied during sham nicotine avoidance retraining
62025847|NCT01248884|EXPERIMENTAL|GSK217744 Group 1|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of GSK217744 formulation A vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The GSK217744 and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
62025848|NCT01248884|EXPERIMENTAL|GSK217744 Group 2|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of GSK217744 formulation B vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The GSK217744 and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
62025849|NCT01248884|ACTIVE_COMPARATOR|Infanrix hexa Group|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of Infanrix hexa™ vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The Infanrix hexa™ and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
62025850|NCT01761747|EXPERIMENTAL|Ponatinib Treatment Arm|Ponatinib taken by mouth daily
62223862|NCT02534454|EXPERIMENTAL|Sham TDCS + Sham Retraining|0.1 mA of transcranial direct current stimulation (TDCS) applied during sham nicotine avoidance retraining
62223863|NCT05536752|EXPERIMENTAL|QA102 200mg group|Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months
62223864|NCT05536752|EXPERIMENTAL|QA102 400mg group|Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months
62223865|NCT05536752|PLACEBO_COMPARATOR|Placebo group|Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months
62223866|NCT04537559||pre-COVID-19 period|Patients hospitalized between 1.3.2019 and 28.02.2020
62223867|NCT04537559||per-COVID-19 period|Patients hospitalized between 1.3.2020 and 28.02.2022
62223868|NCT04537559||post-COVID-19 period|Patients hospitalized between 1.3.2022 and 28.02.2023
62223869|NCT03197779|EXPERIMENTAL|BMS-962212 Two Hour Administration|Intravenous administered over 2 hours of BMS-962212
62223870|NCT03197779|EXPERIMENTAL|BMS-962212 5 Day Administration|Intravenous administered over 5 days of BMS-962212
62223871|NCT03197779|EXPERIMENTAL|BMS-962212 and Aspirin|BMS-962212 intravenous administration, followed by aspirin oral administration, then combination administration of BMS-962212 and aspirin
62417345|NCT06626594||Patients enrolled|All patients admitted to the neonatology department and neonatal intensive care unit were assessed for behavioral status using the Chinese version of the Neonatal Sleep-Wake Assessment Tool. Sleep cycles were also monitored using an electroencephalogram.
62025851|NCT05978323|EXPERIMENTAL|Brief intervention|Intervention Group: Short face-to-face intervention interviews will be conducted with individuals in the intervention group. Interviews will be held in primary healthcare organizations' meeting rooms. Brief intervention interviews will be conducted with the intervention group. It was determined as the first evaluation and the follow-ups on the 1st day, 15th day, 1st month, 3rd month, and the last evaluation (6th month). Brief interventions, 5A for those who are ready to change their behavior (Ask, Advise, Assess, Assist, Arrange); Those who are not ready to change their behavior 5R (Relevance, Risks, Rewards, Roadblocks, Repetition) model will be used. Brief intervention interviews will take an average of 20-30 minutes. The talks will include awareness of overweight and obesity, a healthy diet, and exercise. By the researcher's prepared will be used for individuals with low health literacy educational materials.
62025852|NCT05978323|NO_INTERVENTION|Control|The control group will not be intervened except for the first and last face-to-face evaluation. At the end of the research, training materials for weight loss will be given.
62025853|NCT01097135|NO_INTERVENTION|Standard surgical skin preparation|
62025854|NCT01097135|ACTIVE_COMPARATOR|Standard Surgical Skin Preparation with Duraprep|standard surgical skin prep
62025855|NCT06669247|EXPERIMENTAL|REGN7945+Linvoseltamab|Phase 1 Phase 2
62025856|NCT06669247|EXPERIMENTAL|Linvoseltamab|Phase 2
62025857|NCT05921461||Control NON-PAD|Measurement using the VOTIS PedCheck system
62025858|NCT05921461||PAD patients|Measurement using the VOTIS PedCheck system
62025859|NCT03379025|EXPERIMENTAL|Early Intervention Group|JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks
62025860|NCT03379025|OTHER|Delayed Intervention Group|After a 12 week period of no electronic cigarette use, JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks
62223872|NCT03197779|PLACEBO_COMPARATOR|Placebo and Aspirin|Placebo intravenous administration, followed by aspirin, then combination administration of placebo and aspirin
62223873|NCT03197779|PLACEBO_COMPARATOR|Placebo|Placebo intravenous administration
62223874|NCT05026333|EXPERIMENTAL|High Stress Group|Group of high stress participants based on cutoff scores on the Perceived Stress Scale (PSS) and the STAI - State Anxiety Scale.
62223875|NCT05026333|EXPERIMENTAL|Low Stress Group|Group of low stress participants based on cutoff scores on the Perceived Stress Scale (PSS) and the STAI - State Anxiety Scale.
62223876|NCT02277002|PLACEBO_COMPARATOR|Placebo|Participants are exposed to unfiltered cabin air
62223877|NCT02277002|ACTIVE_COMPARATOR|Cabin Air Filter|Participants are exposed to filtered cabin air
62223878|NCT04267302|OTHER|Baby Bouncer Group|Participants in the group will be receiving a baby bouncer for use from infant's birth up to 8 months after birth.
62223879|NCT04267302|OTHER|Baby Bouncer Group with Infant T-Shirt with LENA|A subsample of the participants in the baby bouncer group will also receive infant t-shirts with wearable audio recorders.
62223880|NCT04267302|OTHER|Baby Carrier Group|Participants in the group will be receiving a baby carrier for use from infant's birth up to 8 months after birth.
62223881|NCT04267302|OTHER|Baby Carrier Group with Infant T-Shirt with LENA|A subsample of the participants in the baby carrier group will also receive infant t-shirts with wearable audio recorders.
62223882|NCT02761161|NO_INTERVENTION|Treatment as usual|TAU: medicine according to algorithm, manual-based cognitive therapy, psychoeducation
62223883|NCT02761161|ACTIVE_COMPARATOR|Mianserin|10-30 mg of mianserin af sleep enhancing
62223884|NCT02761161|ACTIVE_COMPARATOR|Imagery Rehearsal Therapy|Therapy focusing on nightmares
62223885|NCT02761161|ACTIVE_COMPARATOR|mianserin and Imagery Rehearsal Therapy|Both mianserin and IRT
62223886|NCT02315352|EXPERIMENTAL|Period 1 and 2|A-B or B-A where A: L-PZQ ODT (MSC 2499550A) put on tongue; B: Rac-PZQ ODT (MSC1028703A) put on the tongue
62798781|NCT06429449|EXPERIMENTAL|Cohort 1|Cohort 1 will be a conventional 3+3 dose-escalation study to determine maximum tolerated (MTD) or recommended dose of mitoxantrone when used with venetoclax+azacitidine.
62223887|NCT02315352|EXPERIMENTAL|Period 3, 4 and 5|C-D-E; C-E-D; D-E-C; D-C-E; E-C-D; E-D-C where C: L-PZQ ODT (MSC 2499550A) dispersed in water; D: Rac-PZQ ODT (MSC1028703A) dispersed in water; E: Cesol® 150 mg crushed in water
62223888|NCT03541174|EXPERIMENTAL|Aprocitentan 25 mg in Part 1 (double-blind)|Participants will receive aprocitentan 25 mg, orally, once daily in the morning for 4 weeks.
62025861|NCT02188017|ACTIVE_COMPARATOR|80 units|80 units ACTHAR gel will be given twice a week for 22 weeks after initial loading
62025862|NCT02188017|ACTIVE_COMPARATOR|40 units|40 units of ACTHAR gel will be given twice a week for 22 weeks after loading
62025863|NCT04133610|EXPERIMENTAL|Self-sampling device in media|Women will undergo clinician-obtained cervical swab and self-sampled cervicovaginal swab using self-sampling device in STM media. HPV will be detected by hybridization technique.
62025864|NCT04133610|EXPERIMENTAL|Dry self-sampling device|Women will undergo clinician-obtained cervical swab and self-sampled cervicovaginal swab using dry self-sampling device. HPV will be detected by hybridization and PCR techniques.
62025865|NCT01556113|ACTIVE_COMPARATOR|omega diet carrying CC/CG genotype|Subjects homozygous for the major allele of the rs73049 SNP or heterozygous (CC and CG)
62025866|NCT01556113|ACTIVE_COMPARATOR|omega diet carrying GG genotype|Subjects homozygous for the minor allele of the rs73049 SNP (GG)
62025867|NCT00652665|EXPERIMENTAL|A|Subjects received kali product under fasting conditions
62025868|NCT00652665|ACTIVE_COMPARATOR|B|Subjects received Aventis product under fasting conditions
62025869|NCT02081300|EXPERIMENTAL|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate: Initial dose: 225 mg TU BID. Dose titrated up to 300 mg TU BID or down to 150 mg TU BID based on serum T at Week 3 and 7.
62223889|NCT03541174|EXPERIMENTAL|Aprocitentan 12.5 mg in Part 1 (double-blind)|Participants will receive aprocitentan 12.5 mg, orally, once daily in the morning for 4 weeks.
62223890|NCT03541174|PLACEBO_COMPARATOR|Placebo in Part 1 (double-blind)|Participants will receive placebo (matching aprocitentan), orally, once daily in the morning for 4 weeks.
62223891|NCT03541174|EXPERIMENTAL|Aprocitentan 25 mg in Part 2 (single-blind, single arm)|After 4-weeks in the double-blind randomized part (Part 1), participants will received 25 mg aprocitentan, orally, once daily in the morning for 32 weeks.
62025870|NCT02081300|OTHER|Topical testosterone gel 1.62 %|Topical testosterone gel 1.62%: Initial dose: 40.5 mg T once daily. Dose titrated down to 20.25 mg or up to 81 mg based on serum T on Days 14 and 28
62025871|NCT01490346||ART treated individuals|
62025872|NCT05160922|OTHER|crizotinib|crizotinib oral treatment
62025873|NCT03448146|EXPERIMENTAL|Para-Toluenesulfonamide|"1. .The dose of PTS injected into multiple points in a single tumor was about 0.1-1.0 mL, and the appropriate specific doses were kept within the tumor without leakage. An appropriate low dose could be given firstly, and the following doses could be adjusted based on the response of patient and the tumor.~2. . In general, the daily dose of PTS injected into a single tumor was no more than 5mL, and the daily dose of PTS was no more than 10mL for each patient.~The injection was provided 2-3 times a week, with 2 weeks as a cycle of treatment. No less than 4 times of PTS treatment were recomended for the first cycle of treatment, and for other cycles of treatment, the number of PTS injections could be adjusted appropriately based on the condition of the patient."
62025874|NCT00646802|ACTIVE_COMPARATOR|A|Progesterone 200 mg
62025875|NCT00646802|PLACEBO_COMPARATOR|B|Placebo
62025876|NCT01127178|EXPERIMENTAL|E7016 + TMZ|
62025877|NCT04614389|OTHER|CEUS and SWE|CEUS \& SWE
62025878|NCT05599529||Pre-COVID|
62025879|NCT05599529||Peri-COVID|
62025880|NCT05658172|ACTIVE_COMPARATOR|Intensive Surveillance arm|Intensified surveillance. Prospective tumor marker (CA27.29, CA125, CEA), CTC and ctDNA testing of the blood samples. Abnormal findings of either marker (CA27.29 and/or CA125 and/or CEA and/or CTC and/or ctDNA) will be regarded as molecular relapse and trigger diagnostic imaging.
62025881|NCT05658172|PLACEBO_COMPARATOR|Standard Surveillance arm|Surveillance according to national guidelines. Blood samples will not be analyzed immediately and will therefore not trigger imaging. A biobank will be established for retrospective and translational studies. This procedure is necessary to ensure the partially double-blinded study design.
62025882|NCT01324492|EXPERIMENTAL|RAD001|
62223892|NCT03541174|EXPERIMENTAL|Aprocitentan 25 mg in Part 3 (double-blind withdrawal)|After 32-weeks in the single-blind, single-arm part (Part 2), participants will be re-randomized and receive aprocitentan 25 mg, orally, once daily in the morning for 12 weeks.
62223893|NCT03541174|PLACEBO_COMPARATOR|Placebo in Part 3 (double-blind withdrawal)|After 32-weeks in the single-blind, single-arm part (Part 2), participants will be re-randomized and receive placebo (matching aprocitentan), orally, once daily in the morning for 12 weeks.
62417346|NCT06087198||Healthy Donors|Ostensibly healthy subjects with a normal platelet count and without a history of hemostasis abnormalities, for establishing expected values for quality control
62417347|NCT06087198||Thrombocytopenia Patients|Subjects with thrombocytopenia who are planned to receive a platelet transfusion who have pre-transfusion and post-transfusion blood samples collected for testing
62417348|NCT04557982||Children aged 3 < 4 years|Children aged 3 \< 4 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
62223894|NCT00585416|EXPERIMENTAL|1|CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
62223895|NCT05801744|EXPERIMENTAL|Reciprocal inhibition up conditioning|Each participant completes 6 baseline sessions and 30 up conditioning sessions. In the 30 conditioning sessions, the magnitude of reciprocal inhibition in the paretic leg of participants post-stroke will be up conditioned.
62433456|NCT05485857|NO_INTERVENTION|No arrangement group|No arrangement group: After completing the routine operation of laparoscopic-assisted colorectal cancer surgery, the abdomen was closed directly.
62025883|NCT05035901|EXPERIMENTAL|visual-perception motor-coordination integration program|Visual-perception motor-coordination integration program (CCVPMCI) is a Chinese characteristic-based VMI-focused program involving the most Chinese-handwriting-related skills training. CCVPMCI mainly emphasizes the training role of visual-motor integration. The idea of CCVPMCI program will involve (1) visual motor integration training affiliated with visual perception and motor coordination as warm-up exercise, (2) more focus on visual spatial perception in connect with unique visual structure of Chinese characters, (3) the trace or component elements of Chinese characters as the interesting practice material and (4) appropriate challenge for learning.
62025884|NCT04701021|EXPERIMENTAL|TENDU|Three different doses of the TENDU vaccine are to be investigated: 40, 400 and 960μg.
62025885|NCT01897584|EXPERIMENTAL|Inverse IE|in only one group, inspiration to expiration ratio 1:2 to 1:1 will be applied during pneumoperitoneum
62025886|NCT02532218|ACTIVE_COMPARATOR|Active|ARI-3037MO (niacin analog) 3g bid for 24 wks
62025887|NCT02532218|PLACEBO_COMPARATOR|Placebo|Matching Placebo 3g bid for 24 wks
62025888|NCT01477034|EXPERIMENTAL|2,000 IU/day vitamin D3 x 6 months|Subjects will take a 2,000 IU daily vitamin D3 supplement for 6 months.
62223896|NCT04283331|EXPERIMENTAL|Bandage Contact Lens + Proparacaine|The eye that receives a bandage contact lens soaked in proparacaine.
62223897|NCT04283331|NO_INTERVENTION|Bandage Contact Lens WITHOUT Proparacaine|The eye that receives a bandage contact lens (standard of care).
62223898|NCT01530451|EXPERIMENTAL|A: Drug/ Placebo|Initial phase on Desmopressin and then cross over to placebo on the second phase
62588654|NCT04089566|EXPERIMENTAL|28/28 Milligram (mg) Safety Group|Part A: Participants with later-onset SMA will receive loading doses of 28 mg of nusinersen intrathecally on Days 1, 15 and 29 followed by maintenance doses of 28 mg on Days 149 and 269.
62025889|NCT01477034|EXPERIMENTAL|4,000 IU/day vitamin D3 x 6 months|Subjects will take a 4,000 IU daily vitamin D3 supplement for 6 months.
62025890|NCT01477034|EXPERIMENTAL|2,000 IU/day vitamin D3 x 3 months|Subjects will take a 2,000 IU daily vitamin D3 supplement for 3 months.
62025891|NCT01477034|EXPERIMENTAL|4,000 IU/day vitamin D3 x 3 months|Subjects will take a 4,000 IU daily vitamin D3 supplement for 3 months.
62025892|NCT03326999|EXPERIMENTAL|Investigational arm|Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine
62025893|NCT03326999|SHAM_COMPARATOR|Control arm|Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with saline
62025894|NCT03998527|EXPERIMENTAL|Non-Disabled (ND) and Spinal Cord Injured (SCI) controls|The ND Control group (n=6) and SCI Control group (n=6) will be used to assess related values as acute effects of transcutaneous electrical spinal cord stimulation (TcESCS) itself and will not receive any training intervention. The ND group will receive baseline assessments, then up to 12 (4-Respiratory function, 4-Arm function, and 4-Trunk function) TcESCS mapping experiments, followed by repeating the assessments in the presence of TcESCS. The investigators will decide which stimulation type should be used for the post-mapping assessments.
62223899|NCT01530451|EXPERIMENTAL|B: Placebo/ Drug|Initial phase on Placebo and then cross over to Desmopressin on the second phase
62223900|NCT00549783|ACTIVE_COMPARATOR|Botulinum toxin type A 900kD|First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
62223901|NCT00549783|PLACEBO_COMPARATOR|Placebo|First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
62223902|NCT02690922|EXPERIMENTAL|ph+ ALL with dasatinib|patients in the arm are newly diagnosed ph+ ALL,the patient first receive dexamethasone as pretreatment,then dasatinib and prednisone are used as inductive treatment,and methotrexate to consolidate the therapy.
62223903|NCT02721173|EXPERIMENTAL|Tazarotene group|This group will receive tazarotene 0.1% gel plus clindamycin 1% gel for 4 weeks.
62025895|NCT03998527|EXPERIMENTAL|Spinal Cord Injured (SCI) intervention groups|The respiratory training (RT) group (n=6) will receive the respiratory training intervention only); the transcutaneous electrical spinal cord stimulation (TcESCS) group (n=6) will receive transcutaneous spinal cord stimulation only; TcESCS + RT group (n=6) will receive TcESCS combined with RT; TcESCS + Arm Training (AT) group (n=6) will receive TcESCS combined with AT; and TcESCS + Trunk Training (TT) group (n=6) will receive TcESCS combined with TT.
62025896|NCT05017740|ACTIVE_COMPARATOR|ICSI|
62025897|NCT05017740|ACTIVE_COMPARATOR|PICSI|
62223904|NCT02721173|ACTIVE_COMPARATOR|Adapalene group|This group will receive adapalene 0.1% gel plus clindamycin 1% gel for 4 weeks.
62223905|NCT01321151|PLACEBO_COMPARATOR|Sugar Pill|Placebo control
62223906|NCT01321151|EXPERIMENTAL|Resveratrol|Intervention
62223907|NCT05839496|EXPERIMENTAL|Cervical Stabilization Training Group|The Cervical Stabilization Training Group applied cervical stabilization training three times a week for 8 weeks. Each session was completed in 45 minutes.
62025898|NCT06081660|ACTIVE_COMPARATOR|ACP education|"ACP education consisting of~* a brief social work screening,~* an educational pamphlet,~* advance directive forms (in English and Spanish), and~* community resource materials (i.e., handout)"
62025899|NCT06081660|EXPERIMENTAL|ACP education plus counseling|"ACP education plus counseling consisting of~* a brief social work screening,~* an educational pamphlet,~* advance directive forms (in English and Spanish), and~* community resource materials (i.e., handout);~* motivational interviewing~* decisional support, and~* patient navigation to address barriers"
62223908|NCT05839496|NO_INTERVENTION|Control Group|Control Group continued their medical treatment and they did not participate in any treatment for eight weeks.
62417349|NCT04557982||Children aged 4 < 5 years|Children aged 4 \< 5 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
62417350|NCT04557982||Children aged 5 < 6 years|Children aged 5 \< 6 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
62417351|NCT05967624|EXPERIMENTAL|Teleconsultation group|Eligible children managed by urban paramedic teams responding to 911 calls in the prehospital setting to support a future trial of clinical efficacy.
62798782|NCT06429449|EXPERIMENTAL|Cohort 2|After establishing the MTD of mitoxantrone, an expansion cohort will open. 10 subjects refractory to first-line therapy w/venetoclax+HMA, or respond then relapse after first-line therapy w/venetoclax+HMA, will enroll in the study \& receive a subsequent cycle of venetoclax+azacitidine at the dose \& schedule being administered per the standard of care, w/the determined MTD/recommended dose of IV mitoxantrone given days 1-4. Day 28 +/- 7 days of this cycle, a bone marrow biopsy will be repeated. In the absence of a ≥50% blast reduction from baseline, the subject will discontinue the study. If a CR, CRi, MLFS or blast reduction from baseline of ≥50% occurs, the subject can continue sequential cycles of venetoclax+azacitidine at the dose \& schedule being administered per the standard of care, with the MTD/recommended dose of mitoxantrone on days 1-4, up to 3 cycles. No subject will receive \>3 cycles of mitoxantrone.
62025900|NCT01169870|EXPERIMENTAL|Genexol-PM|Genexol-PM 300mg/m2, diluted with 500ml of 5% dextrose or normal saline, intravenous infusion over 1 hour on day 1, every 3 week cycle.
62223909|NCT03566654|EXPERIMENTAL|remote ischemic conditioning|Receiving remote ischemic conditioning (RIC) treatment with pressure set at 200 mmHg.
62223910|NCT03566654|SHAM_COMPARATOR|placebo remote ischemic conditioning|Receiving sham RIC treatment with pressure set at 50\~60 mmHg
62223911|NCT06109025|EXPERIMENTAL|EXPERIMENTAL GROUP|The sample will be composed mainly, but not exclusively, of adults of legal age, belonging to the group of university students.
62223912|NCT06109025|ACTIVE_COMPARATOR|CONTROL GROUP|The sample will be composed mainly, but not exclusively, of adults of legal age, belonging to the group of university students.
62223913|NCT05315882||Allogeneic stem cell transplantation|Observational, no interventional
62223914|NCT00126373|PLACEBO_COMPARATOR|Sugar pill|Placebo (sugar) pill with identical look to bupropion
62223915|NCT00126373|EXPERIMENTAL|buproprion|bupropion pill
62223916|NCT02679573|EXPERIMENTAL|Delafloxacin|IV delafloxacin with potential to switch to oral delafloxacin
62223917|NCT02679573|ACTIVE_COMPARATOR|Moxifloxacin/Linezolid|IV moxifloxacin with potential to switch to oral moxifloxacin, and potential to switch moxifloxacin to IV linezolid for confirmed MRSA
62223918|NCT03575988||Diabetes group|
62025901|NCT01169870|ACTIVE_COMPARATOR|Paclitaxel|Paclitaxel 175mg/m2, diluted with 500ml of 5% dextrose or normal saline, intravenous infusion over 3 hour on day 1, every 3 week cycle.
62223919|NCT03575988||Control group|
62223920|NCT01195051|EXPERIMENTAL|Electronic medication reconciliation|Providers have access to a new, computer-based application to facilitate documentation and prescribing of outpatient medications in the inpatient setting.
62223921|NCT01195051|NO_INTERVENTION|Control|
62223922|NCT00321373|EXPERIMENTAL|GSK1247446A-AS03 Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62223923|NCT00321373|EXPERIMENTAL|GSK1247446A Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62223924|NCT00321373|ACTIVE_COMPARATOR|Fluarix Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62223925|NCT05811923|PLACEBO_COMPARATOR|Placebo|Maltodextrin placebo capsules
62223926|NCT05811923|ACTIVE_COMPARATOR|200 mg caffeine|200 mg caffeine capsules
62223927|NCT05811923|EXPERIMENTAL|100 mg paraxanthine|100 mg paraxanthine capsules
62223928|NCT05811923|EXPERIMENTAL|200 mg paraxanthine|200 mg paraxanthine capsules
62223929|NCT05811923|EXPERIMENTAL|300 mg paraxanthine|300 mg paraxanthine capsules
62223930|NCT05811923|EXPERIMENTAL|200 mg caffeine + 200 mg paraxanthine|200 mg caffeine + 200 mg paraxanthine capsules
62223931|NCT05811923|EXPERIMENTAL|200 mg 1-methylxanthine|200 mg 1-methylxanthine capsules
62223932|NCT02323282|OTHER|ropivacine|
62223933|NCT04061447|EXPERIMENTAL|susceptibility-guided therapy|In the group of the empirical triple therapy, patients received rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.
62025902|NCT03221582|EXPERIMENTAL|EBR/GZR (Zepatier) - HCV/HIV co-infected|Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.
62223934|NCT04061447|ACTIVE_COMPARATOR|empirical clarithromycin-based triple therapy|In the group of gastric juice susceptibility-guided therapy, the eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
62417352|NCT01843439|EXPERIMENTAL|Intervention|"We designed a intervention study to correct additional risk factors in elderly asthma patients.~We offer following specific interventions simultaneously to intervention arm and will measure the effects of interventions after 1 years.~1. popularize and educate the asthma action plan~2. run a emergency call system for acute exacerbation~3. educate the proper techniques using inhalers~4. correct the deficiency of magnesium (magnesium 500mg per day)"
62417353|NCT06703541||Participants aged 25-44|"Subjects ages 25 to 44 at enrollment with normal cognition will undergo baseline visits including:~* Demographics~* Family history, medical history, current medications~* General physical and neurological exam, sensory and motor testing~* Vital signs~* Blood sample collected for PT/INR, blood count, genetic testing, and storage for future unspecified research on cognition and disorders associated with altered cognition~* Urine sample~* Neuropsychological testing~* Retinal imaging~* Testing of memory, thought processes, and recognition~* MRI~* Lumbar puncture"
62417354|NCT06703541||Participants aged 45-80|"Subjects ages 45 to 80 at enrollment with normal cognition, mild cognitive impairment, or dementia will undergo baseline visits including:~* Demographics and project partner demographics~* Family history, medical history, current medications~* General physical and neurological exam, sensory and motor testing~* Vital signs~* Blood sample collected for PT/INR, blood count, genetic testing, and storage for future unspecified research on cognition and disorders associated with altered cognition~* Urine sample~* Neuropsychological testing~* Retinal imaging~* Testing of memory, thought processes, and recognition~* MRI~* Lumbar puncture~Participants will be asked to participate in yearly evaluations until the time of death. Participants can withdraw at any time."
62417355|NCT06642610|OTHER|CF without diabetes|a person with cystic fibrosis and no diabetes
62417356|NCT06642610|OTHER|CF with Prediabetes|a person with cystic fibrosis and prediabetes
62798783|NCT06429449|EXPERIMENTAL|Cohort 3|Subjects in a morph remission w/ MRD+ after ≤3 cycles of soc ven+HMA will enroll \& receive mitox on days 1-4 at dose tbd that is below the MTD from cohort 1, concurrently w/ven+aza, at the dose \& schedule being soc admin, over a 28-day cycle. A BMBX w/ MRD assessment will be done day 28. If MRD- occurs, subseq treatment cycles will continue to admin ven+aza, at the dose \& schedule being soc admin, w/ the tbd dose of mitox on days 1-4, for max of 3 cycles. If MRD- does not occur, the next cycle may escalate the mitox dose to a level tbd \& not exceeding the MTD, w/ ven+aza at the dose \& schedule being soc admin. If MRD- occurs, subseq treatment cycles will continue to admin ven+aza, at the dose \& schedule being soc admin, with the tbd dose of IV mitox on days 1-4, for a max of 3 cycles. If MRD- does not occur, the next cycle may escalate the mitox to a level tbd \& not exceeding the MTD, w/ ven+aza at the dose \& schedule being admin per the soc. Subjects will not receive \>3 cycles.
62798784|NCT06429449|EXPERIMENTAL|Cohort 4|Subjects in a morphologic remission w/ MRD+ after \>3 cyc of soc ven/HMA will enroll 28-50 days after the previous ven/HMA cyc. Subjects will receive mitox IV days 1-4 at a dose tbd below the MTD from cohort 1; on day 14, the subject will start ven+aza at the dose \& schedule per the soc. On day 42, a BMBX, w/ MRD assessment, will be repeated. If MRD- occurs, subseq cyc will cont to admin ven+aza, at the dose \& schedule per the soc, with the tbd dose of IV mitox on days 1-4, for a max of 3 cyc of mitox. If MRD- does not occur, the next cyc will retain the same schedule \& may escalate the mitox to a dose level tbd \& not exceeding the MTD. If MRD- occurs, 1 add'l cyc of mitox at this dose, w/ ven+aza at the dose \& schedule per the soc, will be given. If MRD- does not occur, the next cyc will retain the same schedule \& may escalate the mitox to a level tbd \& not exceeding the MTD.
62798785|NCT05052190|ACTIVE_COMPARATOR|Text Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
62798786|NCT05052190|ACTIVE_COMPARATOR|Text Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text with no link to schedule an appointment.
62798787|NCT05052190|ACTIVE_COMPARATOR|Text Message R/R with Direct Appointment Schedule Link + text Pre-Appointment Reminder|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period.
62798788|NCT05052190|ACTIVE_COMPARATOR|Text Message R/R without Direct Appointment Schedule Link + Text Pre-Appointment Reminder|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period.
62798789|NCT05052190|ACTIVE_COMPARATOR|Portal Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
62798790|NCT05052190|ACTIVE_COMPARATOR|Portal Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
62417357|NCT06642610|OTHER|CF with diabetes|a person with cystic fibrosis and diabetes
62417358|NCT06700863||No xerostomia before radiotherapy|Resting saliva flow rate greater than 1ml/10min before radiotherapy
62025903|NCT03221582|EXPERIMENTAL|EBR/GZR (Zepatier) - HCV monoinfected|Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.
62025904|NCT01889537|EXPERIMENTAL|VR during burn care with Ketamine|Comparing Virtual Reality during burn care with Ketamine
62223935|NCT01762501|EXPERIMENTAL|Azilsartan|Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
62223936|NCT01762501|ACTIVE_COMPARATOR|Amlodipine|Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks
62223937|NCT05492461||Swiss Physicians|A group of approximately 10'000 physicians practicing in the cantons of Basel-Stadt, Basel-Landschaft, Aargau, Lucerne, Graubünden, Ticino and Vaud.
62798791|NCT05052190|ACTIVE_COMPARATOR|Portal Message R/R with Direct Appointment Schedule Link + Portal Pre-Appointment Reminder|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
62223938|NCT05492461||General population of Switzerland|A group of 10,000 people from the general population including the three language regions (German, Italian, and French)
62223939|NCT00038168|EXPERIMENTAL|Estramustine + Taxol|
62223940|NCT01795027|EXPERIMENTAL|S-1 plus Oxaliplatin|6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
62223941|NCT01795027|ACTIVE_COMPARATOR|S-1 single|S-1 40\~60mg twice daily for 14 days in 3 weeks for totally 16 courses after D2 resection
62223942|NCT02729831|EXPERIMENTAL|Interactive Decision Aid and Usual Care|Group receiving brief interactive decision aid and being seen by a provider assigned to usual care. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise.
62223943|NCT02729831|EXPERIMENTAL|Video decision aid and usual care|Group receiving long video decision aids and being seen by a provider assigned to usual care. The decision aids are the DVD and Booklets for hip and knee osteoarthritis from Health Dialog.
62223944|NCT02729831|EXPERIMENTAL|Interactive Decision Aid and Provider Report|Group receiving brief interactive decision aid and being seen by a provider assigned to intervention arm. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise. The provider intervention is a report that includes the patients' goals and treatment preferences.
62798792|NCT05052190|ACTIVE_COMPARATOR|Portal Message R/R without Direct Appointment Schedule Link + Portal Pre-Appointment Reminder|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
62798793|NCT05052190|NO_INTERVENTION|No R/R Message or Pre-Appointment Reminder|Participants do not receive any flu vaccine R/R message or Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment during the specified flu season.
62798794|NCT01582139|EXPERIMENTAL|Experimental Condition: (Heart-Rate Informed SSM+HMM)|An experimental condition involving an exercise session where the Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) is informed about heart rate
62798795|NCT01582139|NO_INTERVENTION|Control Condition (SSM+HMM)|A control condition involving an exercise session where the Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) is not informed about heart rate.
62025905|NCT01889537|EXPERIMENTAL|VR durin burn care without Ketamine|Comparing virtual reality during burn care without Ketamine.
62223945|NCT02729831|EXPERIMENTAL|Video decision aid and Provider report|Group receiving long video decision aids and being seen by a provider assigned to intervention arm. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog. The intervention is a report that includes the patients' goals and treatment preferences.
62223946|NCT01513577|EXPERIMENTAL|Minimal invasive pedicular screw|
62223947|NCT01513577|EXPERIMENTAL|Standard open insertion|
62223948|NCT04729998|OTHER|Sequence TR|17 subjects assigned to the sequence TR will receive a single 20 mg dose of the test product Rivaroxaban (1 x 20 mg tablet), marked as T in the sequence, in Period 1 and a single 20 mg dose of the reference product Xarelto® (1 x 20 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a standardized breakfast. The tablet must be swallowed whole and must not be chewed or broken.
62223949|NCT04729998|OTHER|Sequence RT|17 subjects assigned to the sequence RT will receive a single 20 mg dose of the reference product Xarelto® (1 x 20 mg tablet), marked as R in the sequence, in Period 1 and a single 20 mg dose of the test product Rivaroxaban (1 x 20 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a standardized breakfast. The tablet must be swallowed whole and must not be chewed or broken.
62223950|NCT04706767|EXPERIMENTAL|Effect of Co-administration Lidocaine and Dexmedetomidine on Quality of Recovery|
62223951|NCT04706767|EXPERIMENTAL|Effect of Dexmedetomidine infusion on Quality of Recovery|
62223952|NCT04706767|EXPERIMENTAL|Effect of Lidocaine infusion on Quality of Recovery|
62223953|NCT04706767|EXPERIMENTAL|Effect of saline infusion on Quality of Recovery|
62223954|NCT00640133|ACTIVE_COMPARATOR|Active DBS|Participants will receive deep brain stimulation.
62223955|NCT00640133|SHAM_COMPARATOR|Sham DBS|Participants will receive sham deep brain stimulation for several months and then active deep brain stimulation thereafter.
62223956|NCT00563888|EXPERIMENTAL|A|Narrative Exposure Therapy (NET)
62223957|NCT00563888|NO_INTERVENTION|B|Waitinglist Control Group
62417359|NCT06700863||Mild xerostomia during radiotherapy|During radiotherapy, a resting saliva flow rate between 0.5ml/10min-1ml/10min is considered mild dry mouth
62417360|NCT06700863||Moderate to severe xerostomia during radiotherapy|A resting saliva flow rate below 0.5ml/10min during radiotherapy is considered moderate to severe xerostomia
62417361|NCT06700863||Mild xerostomia after radiotherapy|After radiotherapy, a resting saliva flow rate between 0.5ml/10min-1ml/10min is considered mild dry mouth
62417362|NCT06700863||Moderate to severe xerostomia xerostomia after radiotherapy|A resting saliva flow rate below 0.5ml/10min after radiotherapy is considered moderate to severe xerostomia
62417363|NCT04720573|ACTIVE_COMPARATOR|Group N|Neostigmine was used for the reversal of neuromuscular blockade.
62417364|NCT04720573|ACTIVE_COMPARATOR|Group S|Sugammadex was used for the reversal of neuromuscular blockade.
62417365|NCT02795780|EXPERIMENTAL|Follow-up Flortaucipir PET Scan|
62417366|NCT06084572||GERD patients|
62223958|NCT02877238|ACTIVE_COMPARATOR|Group A|Sevoflurane plus remote ischemic preconditioning anesthesia will be induced and maintain with sevoflurane in addition to remote ischemic preconditioning which will be done after induction and before cardiopulmonary bypass by inflating the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3 cycles
62417367|NCT03889405|EXPERIMENTAL|Study group|Healthy 32 weeks or more pregnant women, at an early stage of labor.
62417368|NCT06080191|EXPERIMENTAL|Single arm|"A single IV infusion of CD19-CAR_Lenti_ALLO (allogeneic CD19-directed chimeric antigen receptor T-cells) on Day 0 after lymphodepletion. Patients will be divided in two cohorts based on donor HLA matching: cohort A (fully matched, familial or unrelated donor); cohort B (haploidentical donor).~Patients will receive the following lymphodepletion:~* Fludarabine (Flu) 30 mg/m2 per day on days -5, -4 and -3~* Cyclophosphamide (Cyclo) 1000 mg/m2 per day on days -5, -4 and -3.~CD19-CAR_Lenti_ALLO will be infused at the following dose levels:~Cohort A:~* DL1: 3.0 x10\^6 CAR+ cells/kg~* DL2: 5.0x10\^6 CAR+ cells/kg~Cohort B:~* DL1: 1x10\^6 CAR+ cells/kg~* DL2: 3x10\^6 CAR + cells/kg~If 2 DLT are observed in the dose level 1, an additional DL0 of 2.0x10\^6 CAR+ cells/kg (cohort A) or 0.5x10\^6 CAR+ cells/kg (cohort B) will be explored."
62417369|NCT06700785|EXPERIMENTAL|Lysine Butyrate|
62417370|NCT06700785|ACTIVE_COMPARATOR|Sodium buytrate|
62417371|NCT06700785|ACTIVE_COMPARATOR|Tributyrin|
62417372|NCT04137770|NO_INTERVENTION|control|Patients will receive routine post-operative analgesics
62417373|NCT04137770|EXPERIMENTAL|intervention|Patients will receive routine post-operative analgesics plus scheduled ketorolac and surgical site ice packs
62417374|NCT06243016|ACTIVE_COMPARATOR|High-Intensity Interval Training (HIIT) Breaks|Sitting interrupted every 30 min by 6-min HIIT bouts.
62417375|NCT06243016|SHAM_COMPARATOR|Light-Intensity Interval Training (HIIT) Breaks|Sitting interrupted every 30 min by 6-min LIIT bouts.
62223959|NCT02877238|ACTIVE_COMPARATOR|Group B|anesthesia will be induced and maintain with total intravenous anesthesia (propofol, midazolam plus fentanyl) during plus remote ischemic preconditioning in addition to remote ischemic preconditioning which will be done after induction and before cardiopulmonary bypass by inflating the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3 cycles
62223960|NCT00954486|EXPERIMENTAL|Epoetin alfa, 10,000 units/week|Epoetin alfa is a recombinant erythropoietin.
62417376|NCT05224141|EXPERIMENTAL|Pembrolizumab/Vibostolimab|Participants will receive 4 cycles (each cycle is 3 weeks) of a fixed-dose coformulation of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684A) every 3 weeks (Q3W), in combination with 100 mg/m\^2 etoposide, and platinum (Area Under the Curve (AUC) 5 mg/mL/min carboplatin or 75 mg/m\^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of MK-7684A Q3W until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1.
62417377|NCT05224141|ACTIVE_COMPARATOR|Atezolizumab|Participants will receive 4 cycles (each cycle is 3 weeks) of 1200 mg atezolizumab Q3W, in combination with 100 mg/m\^2 etoposide and platinum (AUC 5 mg/mL/min carboplatin or 75 mg/m\^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of atezolizumab Q3W until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1.
62417378|NCT00996918|EXPERIMENTAL|Bapineuzumab 0.5 mg/kg|bapineuzumab
62417379|NCT00996918|EXPERIMENTAL|Bapineuzumab 1.0 m/kg|bapineuzumab
62417380|NCT05043220|EXPERIMENTAL|Telemedicine|Telemonitoring via PPG (photoplethysmography) and PROM (patient reported outcome monitoring) via app
62417381|NCT06523309||Affective symptom group|A group of Alzheimer's patients showing emotional symptoms such as anxiety, depression, apathy, etc.
62417382|NCT06523309||Psychotic symptom group|A group of Alzheimer's patients showing psychotic symptoms such as delusions, hallucinations, etc.
62417383|NCT06523309||Hyperactivity symptom group|A group of Alzheimer's patients showing hyperactivity symptoms such as irritability, aggression, aberrant motor behaviour, etc.
62417384|NCT06523309||Euphoric symptom group|A group of Alzheimer's patients showing euphpric symptoms.
62417385|NCT00308100|EXPERIMENTAL|1|
62417386|NCT00308100|ACTIVE_COMPARATOR|2|
62417387|NCT06702215|EXPERIMENTAL|Experimental cm-PAS protocol followed by control cm-PAS protocol|Participants will undergo the experimental cm-PAS protocol in the first session of the experiment, followed by the control cm-PAS protocol in the second session. The experimental and the control PAS protocols will differ in the timing of TMS delivery, one effective and the other one uneffective in inducing plastic effects, as shown by previous studies on healthy participants.
62433457|NCT06180811|EXPERIMENTAL|Women's Health Delaware Food Farmacy|Participants will receive medically tailored groceries (10 meals per person in the household per week from enrollment to 4 weeks after delivery) high in micronutrients that are delivered to their homes weekly. They will also interact weekly with their assigned Community Health Worker to address social needs and patient-centered goals.
62223961|NCT02857166|EXPERIMENTAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
62223962|NCT06370533|EXPERIMENTAL|lifestyle intervention|"Health education: Individual face to face or telephone sessions and online health education material.~Diet behavior: The eight eating behavioral goals will be assigned to each participant with two for every 4-week cycle.~Physical activity: Women will be advised to gradually attaining the goal of 150 minutes of moderate- to vigorous-intensity physical activity per week and walk at least 6000 steps per day.~Weight monitoring: Self-monitoring of weight gain (regular self-weighing) and weight logging at least once a week was recommended."
62223963|NCT06370533|NO_INTERVENTION|usual-care control|Provision of usual prenatal care
62223964|NCT04001231|EXPERIMENTAL|Single arm of exenatide once-weekly suspension|Exenatide once-weekly suspension via subcutaneous (SC) injection
62223965|NCT04184739|ACTIVE_COMPARATOR|Group A|Standard treatment information (verbal and written) and access to a basic version of the App with a toothbrushing timer. The timer is necessary as the health behaviour outcome is toothbrushing duration.
62223966|NCT04184739|EXPERIMENTAL|Group B|As for group A, however, additionally the App will provide generic treatment information (a combination of videos and text)
62223967|NCT04184739|EXPERIMENTAL|Group C|As for group B, however, the patients will have access to the full functionality of the App and the App will allow patients to input their own personalised treatment information (including progress photographs), set goals, develop plans for achieving these and provide the patient and clinicians with appropriate dashboards to monitor progress.
62223968|NCT06415565|ACTIVE_COMPARATOR|control|Conventional physiotherapy practices will be performed.
62223969|NCT06415565|EXPERIMENTAL|mobilization|In addition to conventional physiotherapy applications, thoracic mobilization applications will be performed.
62223970|NCT01717092||Consecutive patients with acute PE|
62223971|NCT01000285|EXPERIMENTAL|Arm 1|"Bortezomib 1.0 mg/m2 intravenous (IV) Days 1-4~Etoposide 50 mg/m2/d 96 hour continuous intravenous infusion (CIVI) on Days 1-4~Vincristine 0.4 mg/m2/d 96 hour CIVI on Days 1-4~Doxorubicin 10 mg/m2/d 96 hour CIVI on Days 1-4~Prednisone 60 mg/m2/d PO on Days 1-5~Cyclophosphamide 375 mg/m2 IV on Day 5~Raltegravir 400 mg PO twice per day (BID) every day starting with cycle 2 therapy for the entire duration of the cycle.~Cycles will be repeated every 21-28 days for 2 cycles beyond best response, or a maximum of 6 cycles."
62223972|NCT02938260||Diltiazem|
62223973|NCT02938260||Metoprolol|
62223974|NCT06106932|ACTIVE_COMPARATOR|GnRH-a +|Group A \[GnRHa+\] consisted of 30 women with a mean age of 35.5 years and a mean BMI of 27 kg/m2. Seventeen of them were stage 2 and 13 were stage 3 endometriosis. They received GnRH-a \[leuprolide acetate\] for a period of 3 months prior to surgery, whereas they had not received any hormonal treatment within the 12 months before the surgical procedure.
62223975|NCT06106932|NO_INTERVENTION|GnRH-a -|Group B \[GnRHa-\] consisted of 30 patients with a mean age of 38 years and a mean BMI of 27 kg/m2. Sixteen of them had stage 2 and 14 had stage 3 endometriosis. They did not receive GnRH-a treatment before operation. In addition, no treatment with oral contraceptives or other therapy was administered within 12 months prior to surgery.
62223976|NCT04020627|EXPERIMENTAL|BiPAP Group|Bilevel Positive Airway Pressure
62223977|NCT04020627|EXPERIMENTAL|CPAP Group|Continuous Positive Airway Pressure
62417388|NCT06702215|EXPERIMENTAL|Control cm-PAS protocol followed by experimental cm-PAS protocol|Participants will undergo the control cm-PAS protocol in the first session of the experiment, followed by the experimental cm-PAS protocol in the second session. The experimental and the control PAS protocols will differ in the timing of TMS delivery, one effective and the other one uneffective in inducing plastic effects, as shown by previous studies on healthy participants.
62433458|NCT06180811|ACTIVE_COMPARATOR|Usual Standard of Care|Participants will receive the usual standard of care.
62223978|NCT05143983|ACTIVE_COMPARATOR|depressed subjects, positive valence music listening at first|patients with major depressive disorder will be recruited and will complete 3 cognitive tasks after listening to positive musical excepts (3 minutes)
62223979|NCT05143983|OTHER|depressed subjects, neutral valence music listening|patients with major depressive disorder will be recruited and will complete 3 cognitive tasks after listening to neutral valence musical excepts (3 minutes)
62223980|NCT05143983|OTHER|healthy controls, positive valence music listening|healthy individuals will be recruited and will complete 3 cognitive task after listening to positive valence musical excepts (3 minutes)
62223981|NCT05143983|OTHER|healthy controls, neutral valence music listening|healthy individuals will be recruited and will complete 3 cognitive task after listening to neutral valence musical excepts (3 minutes)
62223982|NCT05088018|EXPERIMENTAL|Active Cannabigerol|25 mg daily swallowable Cannabigerol tablets for 2 weeks, immediately followed by 50 mg daily swallowable Cannabigerol tablets for 2 weeks
62223983|NCT05088018|PLACEBO_COMPARATOR|Placebo|25 mg daily swallowable placebo tablets for 2 weeks, immediately followed by 50 mg daily swallowable placebo tablets for 2 weeks
62223984|NCT01798251|EXPERIMENTAL|XELOX-X|"XELOX: Oxaliplatin: 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine: 850mg/m\^2 bid, days 1-14, every 3 weeks and maximum 4 cycles, or progression/intolerance.~X Maintenance: Capecitabine 850mg/m\^2 bid, days 1-14, every 3 weeks after 4 cycles XELOX regimen, until progression/intolerance."
62223985|NCT01798251|ACTIVE_COMPARATOR|XELOX|XELOX: Oxaliplatin 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine 850mg/m\^2 bid, days 1-14, every 3 weeks, until progression/intolerance.
62223986|NCT03773315|EXPERIMENTAL|UMH group|This group takes UMH extract for 12 weeks
62223987|NCT03773315|PLACEBO_COMPARATOR|Placebo group|This group takes placebo for 12 weeks
62223988|NCT04727892||complications after epilepsy surgery|Group A with no complication; Group B with complications
62223989|NCT05235204|EXPERIMENTAL|Foley catheter removal day 2 or 3 post-operative procedure|According to review of internal clinical practices, the average duration of catheterization after Colovesical Fistula (CVF) repair is 10.8 days after CVF repair. The intervention in this study removes the Foley Catheter at 2 to 3 days post CVF repair.
62417389|NCT01873235||Main Cohort|This is an observational prospective cohort study of adults with autosomal dominant polycystic kidney disease (ADPKD) with estimated GFR at least 15cc/min/1.73m2. There are no therapeutic interventions in this observational cohort study.
62417390|NCT06567522|EXPERIMENTAL|ESP-L|After hip fracture surgery ultrasound-guided ESP-L shall be carried out at the L3-14 level with 30 mL of levobupivacaine 0.25%
62417391|NCT06567522|NO_INTERVENTION|No ESP-L|Conventional intravenous analgesia after hip fracture surgery
62417392|NCT04067856|ACTIVE_COMPARATOR|Bevacizumab|Intravitreal injection of 1.25mg/0.05cc bevacizumab
62417393|NCT04067856|ACTIVE_COMPARATOR|Dexamethasone implant|Intravitreal injection of 0.7mg dexamethasone implant
62417394|NCT06214793|EXPERIMENTAL|Taletrectinib|Taletrectinib 600mg will be given po daily every day within 2 hours of meals on days 1-21, on a 21-day cycle. Study drug will be given until intolerance, consent withdrawal, progression per RECIST 1.1, or death (i.e., no maximum number of cycles).
62417395|NCT04816877||Patient controlled analgesia (PCA) group|Patients in this group will be allocated to the PCA arm, i.e., they will be receiving a PCA pump for administration of opioids.
62588655|NCT04089566|ACTIVE_COMPARATOR|12/12 mg Active Control Group|Part B: Participants with infantile- or later-onset SMA will receive loading doses of 12 mg of nusinersen intrathecally on Days 1, 15, 29, and 64 followed by maintenance doses of 12 mg on Days 183 and 279. Sham procedure will be administered on Day 135.
62588656|NCT04089566|EXPERIMENTAL|50/28 mg Active Treatment Group|Part B: Participants with infantile- or later-onset SMA will receive loading doses of 50 mg of nusinersen intrathecally on Days 1 and 15 followed by maintenance doses of 28 mg on Days 135 and 279. Sham procedure will be administered on Days 29, 64 and 183.
62588657|NCT04089566|EXPERIMENTAL|12/50/28 mg Titration Group|Part C: Participants who have been receiving the approved dose of 12 mg for at least 1 year prior to entry, will receive a single bolus dose of 50 mg of nusinersen intrathecally on Day 1 (4 months after their most recent maintenance dose of 12 mg) followed by maintenance doses of 28 mg on Days 121 and 241.
62417396|NCT04816877||Physician directed analgesia (PDA) group|Patients in this group will be allocated to the PDA arm, i.e., they will be receiving opioids administered by the nurse, as and when directed by the physician.
62588658|NCT00184132|EXPERIMENTAL|Norwegian home style ward|The walls received wainscots, colourful wallpaper and paintings; the ceilings were lowered and had multiple lighting spots, the windows tasteful curtains; we put wardrobes, chairs, flowers and personal items in the patient rooms; and Italian ceramic tile covered the entire bathroom
62588659|NCT00184132|ACTIVE_COMPARATOR|sparsely furnished ward|traditional interior design and furnishings. The rooms had sparse furniture, walls in grey colours lacking pictures, no window curtains, single lamps in the ceiling 4 m high, bathroom with grey, laminated paint all over, and patient rooms with a single bed and a chair of metal tubes
62223990|NCT05690113||Clinical population|250 children aged from 7 to 17 will be recruited in 6 clinical departments (child and adolescent psychiatry, forensic medicine, psychotraumatism centers) They will complete the CATS scale as well as the SCARED (Screen for Child Anxiety and Related Disorders). Their parents will also complete the CATS and the SDQ (Strength and Difficulties Questionnaire) to assess convergent and divergent validity.
62223991|NCT05690113||Non-clinical population|250 children aged from 7 to 17 will be recruited in schools They will complete the CATS scale as well as the SCARED (Screen for Child Anxiety and Related Disorders). Their parents will also complete the CATS and the SDQ (Strength and Difficulties Questionnaire) to assess convergent and divergent validity.
62223992|NCT03607422|PLACEBO_COMPARATOR|Placebo / Upadacitinib|Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260.
62223993|NCT03607422|EXPERIMENTAL|Upadacitinib 15 mg QD|Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks.
62417397|NCT06701383|ACTIVE_COMPARATOR|Standard fluorscopy|Cryoablation using a balloon with standard fluoroscopy
62417398|NCT06701383|EXPERIMENTAL|3D CT overlay|Cryoablation using a balloon with 3D CT overlay
62417399|NCT03126682|ACTIVE_COMPARATOR|Wellbutrin during ECT 1|Drug - Wellbutrin SR 300Mg Extended-Release Tablet during ECT session 1
62417400|NCT03126682|ACTIVE_COMPARATOR|Wellbutrin during ECT 2|Drug - Wellbutrin SR 300Mg Extended-Release Tablet during ECT session 2.
62223994|NCT03607422|EXPERIMENTAL|Upadacitinib 30 mg QD|Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks.
62223995|NCT05319782|EXPERIMENTAL|Experimental arm|
62223996|NCT01159587||Group 1|
62223997|NCT01159587||Group 2|
62417401|NCT05581004|EXPERIMENTAL|Phase Ia: Dose Escalation|Participants in successive cohorts will receive escalating doses of RO7502175, as an intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
62417402|NCT05581004|EXPERIMENTAL|Phase Ia: Expansion|Participants with select solid tumors will receive a recommended dose of RO7502175, determined in Phase Ia Dose Escalation phase as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
62433459|NCT03724669|PLACEBO_COMPARATOR|waiting list|
62417403|NCT05581004|EXPERIMENTAL|Phase Ib: Dose Escalation|Participants in successive cohorts will receive escalating doses of RO7502175, as an IV infusion, in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
62417404|NCT05581004|EXPERIMENTAL|Phase Ib: Expansion|Participants with select solid tumors will receive a recommended dose of RO7502175, determined in Phase Ib Dose Escalation phase, as an IV infusion, in combination with a fixed dose of atezolizumab or pembrolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
62223998|NCT03765099|EXPERIMENTAL|Animal-Assisted Interactions|Children and their caregivers randomly assigned to the intervention group will spend approximately 15 min with a registered canine and its owner during potentially anxiety-producing visits to the hospital.
62223999|NCT03765099|ACTIVE_COMPARATOR|Usual Care|Children and their caregivers randomly assigned to the usual care group will receive usual care which may include play therapy, music therapy or visits with a social worker during their visits to the hospital.
62224000|NCT04705129|EXPERIMENTAL|zanubrutinib+Tislelizumab|Zanubrutinib 160mg Bid, D1-21, po；Tislelizumab 200mg, D1, ivgtt
62224001|NCT01365832|EXPERIMENTAL|Sleep apnea|"Participants with Obstructive Sleep Apnea (OSA).This arm will undergo a pre-treatment blood draw, six months of Continuous Positive Airway Pressure (CPAP) to treat OSA, and a post-treatment blood draw 3 and 6 months later.~Intervention: Procedure: Continuous Positive Airway Pressure (CPAP)"
62224002|NCT04049799||Medically-supervised withdrawal (MSW)|
62224003|NCT04049799||Opioid agonist treatment (OAT)|
62224004|NCT02903173||Women who undergo cesarean delivery|
62224005|NCT04147078|EXPERIMENTAL|cell_therapy|tumor neoantigen primed DC vaccines are administrated, 2-3 week interval, totally 3-5 times
62224006|NCT01598311|EXPERIMENTAL|CB-183,315|Participants took CB-183,315 250 mg twice daily (b.i.d.) and placebo capsules b.i.d. by mouth for 10 days.
62224007|NCT01598311|ACTIVE_COMPARATOR|Vancomycin|Participants took vancomycin 125 mg four times daily (q.i.d.) by mouth for 10 days.
62224008|NCT01874431|EXPERIMENTAL|Finerenone (BAY94-8862) (1.25 mg)|1.25 mg dose oral once daily for 90 days
62224009|NCT01874431|EXPERIMENTAL|Finerenone (BAY94-8862)(2.5 mg)|2.5 mg dose oral once daily for 90 days
62224010|NCT01874431|EXPERIMENTAL|Finerenone (BAY94-8862)(5 mg)|5 mg dose oral once daily for 90 days
62224011|NCT01874431|EXPERIMENTAL|Finerenone (BAY94-8862)(7.5 mg)|7.5 mg dose oral once daily for 90 days
62224012|NCT01874431|EXPERIMENTAL|Finerenone (BAY94-8862) (10 mg)|10 mg dose oral once daily for 90 days
62224013|NCT01874431|EXPERIMENTAL|Finerenone (BAY94-8862) (15 mg)|15 mg dose oral once daily for 90 days
62224014|NCT01874431|EXPERIMENTAL|Finerenone (BAY94-8862)(20 mg)|20 mg dose oral once daily for 90 days
62224015|NCT01874431|PLACEBO_COMPARATOR|Placebo|Placebo oral dose once daily for 90 days
62224016|NCT00672893||Observation|Patients who present to the clinic with airway obstruction and who are designated to undergo intervention
62224017|NCT02330146|EXPERIMENTAL|RCT-01|Cultured, autologous hair follicle cells suspended in cryomedium
62224018|NCT02330146|PLACEBO_COMPARATOR|Placebo|cryomedium
62224019|NCT05129553|EXPERIMENTAL|Single Use|The participants will then be given the Béa Applicator and Béa Cervical Cap with accompanying instructions for single-use in a home use environment.
62224020|NCT03293641|EXPERIMENTAL|Zinc Sulfate Tablet|Zinc Sulfate Tablet 10 mg, 3 times a week plus Standard of Care for 6 months
62224021|NCT03293641|PLACEBO_COMPARATOR|Control Arm|Standard of Care for 6 months
62224022|NCT01998087|EXPERIMENTAL|Breastfeeding support|A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three standardized phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following birth of the baby.
62417405|NCT02953418|EXPERIMENTAL|Radiofrequency ablation|Step-wise endoscopic RFA with the Barrx™ Flex Radiofrequency Ablation System using will be performed in 3 month intervals up to 12 months.
62224023|NCT01998087|ACTIVE_COMPARATOR|General Support|The active control group of mothers will receive a brochure in pregnancy covering general pregnancy and parenting issues and follow-up phone calls but breastfeeding issues will not be specifically addressed. If a mother raises any breastfeeding issue she will be referred to appropriate support.
62224024|NCT01998087|NO_INTERVENTION|Standard Care|This group will receive standard antenatal care provided by their chosen gynaecologist and obstetrician, consisting of regular antenatal visits. No written materials or telephone calls are routinely provided to pregnant women in Croatia.
62224025|NCT04886895|EXPERIMENTAL|Let's Move Intervention|Let's Move intervention will be administered and videotaped for 20 infant/caregiver dyads. Therapy will occur weekly (30-60 minutes per session) for 16 weeks, alternating between clinic and home (video telehealth) sessions. Each month, there will be two clinic-based sessions followed by 2 telehealth-based sessions
62224026|NCT02797574|ACTIVE_COMPARATOR|Vitiligo Diagnosed Group|Clinically diagnosed with non-segmental vitiligo
62224027|NCT02797574|ACTIVE_COMPARATOR|Healthy Control Group|20 normally pigmented control subjects who are between the ages of 18 and 50
62224028|NCT01970345|EXPERIMENTAL|IGF-1|"Randomized, placebo-controlled, crossover format with 12 weeks in each treatment arm (IGF-1 and placebo), separated by a four-week wash-out phase.~Dose titration will be initiated at 0.04 mg/kg twice daily by subcutaneous injection, and increased, as tolerated, every week by 0.04 mg/kg per dose to a maximum of 0.12 mg/kg twice daily. Doses may be decreased according to tolerability by 0.04 mg/kg per dose. Medication will be administered twice daily with meals, and preprandial glucose monitoring will be performed by parents at treatment initiation, prior to each injection, and until a well tolerated dose is established."
62224029|NCT01970345|PLACEBO_COMPARATOR|Placebo|Placebo
62417406|NCT05425277|EXPERIMENTAL|RIT Training Group|Providers in the RIT group (n=30) will receive an 8-hour virtual workshop (2 half-days) on RIT implementation and caregiver coaching. Each provider will invite 2 families in their caseload to participate in the study. Providers will coach families in the use of RIT. One intervention session for each enrolled family will be videotaped and scored for RIT fidelity.
62588660|NCT03409432|EXPERIMENTAL|Treatment (brentuximab vedotin, lenalidomide)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on day 1-21. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
62224030|NCT06153927||Patients with CCTA and FFR assessment|Patients with CAD who underwent CCTA, invasive coronary angiography, and FFR measurement will be included in this study.
62224031|NCT01561404|EXPERIMENTAL|Everolimus|Conversion from calcineurin inhibitor (CNI) to MTOR inhibitor (everolimus)
62224032|NCT01345773||Patients receiving gastric cancer surgery|
62224033|NCT03868605|EXPERIMENTAL|EMR/ESD|Standard EMR or ESD technique
62224034|NCT03868605|EXPERIMENTAL|Over- the- scope full- thickness resection device|Endoscopic full thickness resection
62224035|NCT06502912||elderly patients (aged ≥ 65 years)|elderly patients undergoing non-neurosurgical and non-cardiac procedures
62224036|NCT02504515|ACTIVE_COMPARATOR|Homeopathy|
62224037|NCT02504515|ACTIVE_COMPARATOR|Allopathy homeopathy control|
62224038|NCT02504515|ACTIVE_COMPARATOR|Acupuncture|
62224039|NCT02504515|ACTIVE_COMPARATOR|Allopathy acupuncture control|
62224040|NCT02504515|ACTIVE_COMPARATOR|Anthroposophic medicine|
62224041|NCT02504515|ACTIVE_COMPARATOR|Allopathy anthroposophy control|
62224042|NCT03224923|EXPERIMENTAL|Personalized Treatment Algorithm|"A DAPT score using various patient demographics will be calculated:~If score under 2, patients will receive only aspirin 81 mg once daily~If DAPT score is ≥ 2~* A point-of-care bedside genetic test using a buccal swab will be conducted in order to determine medication regimen~* Those with a positive genetic test (presence of CYP2C19\*2 or CYP2C19\*3), will receive 60mg Ticagrelor twice daily~* Those with a negative genetic test (absence of CYP2C19\*2/\*3) will receive 75mg clopidogrel once daily"
62224043|NCT03224923|ACTIVE_COMPARATOR|Long-Term Ticagrelor|Patients will be given 60mg Ticagrelor twice daily with no aspirin
62224044|NCT05071196|EXPERIMENTAL|Facilitated Vegan Diet|The facilitated vegan participants will self-prepare and consume 2 vegan meal kits per day for 4 weeks
62417407|NCT05425277|ACTIVE_COMPARATOR|Daily Routines|Providers in the Routines Control group (n=30) will receive a 3-hour virtual workshop focused on helping providers coach caregivers on how to increase children's participation and social engagement during everyday home routines (i.e., snack time, bedtime, bath time, and family playtime). Each provider will invite 2 families in their caseload to participate in the study. One intervention session for each enrolled family will be videotaped and scored for RIT fidelity to ensure contamination has not occurred and the control condition providers are not utilizing RIT strategies.
62588661|NCT06525025||Traditional Chinese Medicine Tongue Image Group|Internally, using random allocation, divided into training group and validation group
62588662|NCT06525025||Traditional Chinese Medicine Constitution Data Group|Internally, using random allocation, divided into training group and validation group
62224045|NCT05071196|ACTIVE_COMPARATOR|Standard Omnivorous Diet|The standard omnivorous arm will self-prepare and consume 2 non-vegan meal kits per day for 4 weeks
62224046|NCT05191992|EXPERIMENTAL|experimental|The group will receive CPR training with the e-learning method and will learn skills with a handmade mannequin.
62224047|NCT01934361|EXPERIMENTAL|Lomustine+ buparlisib (Phase Ib)|
62224048|NCT01934361|EXPERIMENTAL|carboplatin+ buparlisib (Phase Ib)|
62224049|NCT01934361|EXPERIMENTAL|lomustine+ buparlisib (Phase II)|
62224050|NCT01934361|PLACEBO_COMPARATOR|lumustine + placebo (Phase II)|
62224051|NCT01934361|EXPERIMENTAL|carboplatin+ buparlisib (Phase II)|
62224052|NCT00626678|EXPERIMENTAL|1|Oral administration of prednisone and azathioprine throughout study
62224053|NCT00626678|PLACEBO_COMPARATOR|2|Oral administration of prednisone and placebo throughout study
62224054|NCT00372229|EXPERIMENTAL|Valganciclovir Cytomegalovirus (CMV) Prophylaxis|
62224055|NCT00372229|ACTIVE_COMPARATOR|Pre-emptive CMV Therapy|
62224056|NCT06056232|EXPERIMENTAL|MIED group|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge, and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression, and other emotional problems.
62224057|NCT06056232|EXPERIMENTAL|MIED+DT group|The increase in distress tolerance dosage involves incorporating additional psychoeducational content related to distress tolerance and corresponding exercises to enhance distress tolerance within the MIED (Mindfulness Intervention for Emotional Distress) program.
62224058|NCT06056232|EXPERIMENTAL|MIED-DT group|The decrease in distress tolerance dosage entails reducing exercises related to distress tolerance within the MIED, such as interoceptive exposure exercises and challenging tasks.
62224059|NCT04694430||Severe exacerbation of COPD|N = 250
62224060|NCT04694430||Mild and moderate exacerbations of COPD|N = 250
62224061|NCT04600154|EXPERIMENTAL|MS-20|4ml, twice, daily
62224062|NCT04600154|PLACEBO_COMPARATOR|Placebo|4ml, twice, daily
62224063|NCT06376123||Video assisted thoracoscopic surgery patients|Patients, assigned for elective lung surgery, older than 18 years and requiring one-lung ventilation.
62417408|NCT00764244|ACTIVE_COMPARATOR|1|Vitrectomy
62417409|NCT00764244|ACTIVE_COMPARATOR|2|Intravitreal triamcinolone injections
62417410|NCT00764244|ACTIVE_COMPARATOR|3|Laser photocoagulation
62417411|NCT05838508|EXPERIMENTAL|Exercise A-B Intervention|The Exercise A first, then the Exercise B intervention.
62417412|NCT05838508|EXPERIMENTAL|Exercise B-A Intervention|The Exercise B first, then the Exercise A intervention.
62417413|NCT05042687|EXPERIMENTAL|Tc99m sestamibi|MBI uses an injection of a small amount of radioactive material called technetium99m (Tc99m) sestamibi
62417414|NCT03506646|EXPERIMENTAL|Beetroot juice-Placebo|Subjects will be tested on two different days, first day will be baseline and Beetroot juice and second day will be Placebo. Testing will take place forty-minutes after Beetroot juice/placebo intake. There will be a 2-week washout between testing days.
62417415|NCT03506646|EXPERIMENTAL|Placebo-Beetroot juice|Subjects will be tested on two different days, first day will be baseline and Placebo and second day will be Beetroot juice. Testing will take place forty-minutes after placebo/beetroot juice intake. There will be a 2-week washout between testing days.
62224064|NCT04558749||Study group|The study population comprised women that will attend their routine visit to the antenatal clinic. The study population will be recruited by using simple random sampling method after verbal consent will be obtained. Resident in the Department of Obstetrics and Gynaecology who will be trained to administer the questionnaire will interview women. Face masks will be provided to the study population during the process of data collection.
62224065|NCT02390050|ACTIVE_COMPARATOR|Bexagliflozin tablets, 5 mg|Bexagliflozin tablets, 5 mg, once daily by mouth before breakfast
62224066|NCT02390050|ACTIVE_COMPARATOR|Bexagliflozin tablets, 10 mg|Bexagliflozin tablets, 10 mg, once daily by mouth before breakfast
62224067|NCT02390050|ACTIVE_COMPARATOR|Bexagliflozin tablets, 20 mg|Bexagliflozin tablets, 20 mg, once daily by mouth before breakfast
62224068|NCT02390050|PLACEBO_COMPARATOR|Bexagliflozin tablets, placebo|Bexagliflozin tablets, placebo, once daily by mouth before breakfast
62224069|NCT05025202|EXPERIMENTAL|IET|Participants allocated to this arm performed 4 weeks of isometric wall squat exercise training, 3 times per week.
62417416|NCT03983850|NO_INTERVENTION|Donor Arm|Collection of bone marrow and/or PBSC (Up to 40 donors)
62417417|NCT03983850|EXPERIMENTAL|Phase I Dose De-escalation|PTCy at de-escalating doses (25 mg/kg/day on days +3 and +4, and PTCy 25 mg/kg on day +4) to assess for safety and determine Phase II dose (up to 12 evaluable patients)
62417418|NCT03983850|EXPERIMENTAL|Phase I duration de-escalation of MMF|MMF at de-escalating duration (days +5 to +18 only, no MMF))
62417419|NCT03983850|EXPERIMENTAL|Phase I Pilot for Comparative Data|Standard PTCy 50 mg/kg/day on days +3 and +4, in a small pilot (up to 5 evaluable patients) for comparative data
62417420|NCT03983850|EXPERIMENTAL|Phase II Efficacy|PTCy at shortest duration, safe dose (from Phase I) to assess efficacy at providing adequate protection from grade 3-4 acute GVHD (up to 14 additional patients)
62417421|NCT03983850|EXPERIMENTAL|Phase II efficacy of reduced duration MMF|MMF at duration identified from de-escalation evaluation.
62417422|NCT06701266||Patient have apical periodontitis|Patient have single rooted tooth with apical periodontitis that undergo RCT in MUCM.
62224070|NCT05025202|SHAM_COMPARATOR|Sham|Participants allocated to this arm performed 4 weeks of isometric wall squat training, but the training prescription was intentionally provided at an insufficient intensity to achieve any physiology stimulus.
62224071|NCT05025202|NO_INTERVENTION|No intervention control|Participants allocated to this arm did not perform any exercise and were required to maintain usual daily habits.
62417423|NCT05259696|EXPERIMENTAL|Dose Escalation - Monotherapy|"Subjects will receive E-602 as monotherapy.~Planned monotherapy dose levels: 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg."
62417424|NCT05259696|EXPERIMENTAL|Dose Escalation - Combination|"Subjects will receive E-602 in combination with cemiplimab.~E-602 dose(s): Will be initiated at dose level(s) that have previously completed dosing and DLT assessments as monotherapy.~Cemiplimab dose: 350 mg."
62417425|NCT05259696|EXPERIMENTAL|Expansion - Monotherapy|Subjects will receive E-602 as monotherapy at the recommended Phase 2 dose determined in Phase 1.
62417426|NCT05259696|EXPERIMENTAL|Expansion - Combination|"Subjects will receive E-602 in combination with cemiplimab.~E-602 dose: Subjects will receive E-602 at the recommended Phase 2 dose determined in Phase 1 in combination with cemiplimab.~Cemiplimab dose: 350 mg."
62417427|NCT03443180|OTHER|Dietary intervention|Participants will be asked to remove food containing gluten and ATI from their diets for 4 weeks.
62588663|NCT06525025||Traditional Chinese Medicine Doctor Patient Dialogue Data Group|Data used for fine-tuning traditional Chinese medicine models
62588664|NCT04256317|EXPERIMENTAL|Phase 1, Stage A (Dose Escalation)|In Cycle 1 (28 days per cycle), single dose oral azacitidine will be administered, followed by subcutaneous (SC) azacitidine, ASTX030 and oral cedazuridine on a specific dosing schedule; in Cycle 2, oral ASTX030 (cedazuridine + azacitidine) will be administered
62224072|NCT01207037|OTHER|Intervention|
62224073|NCT03533985|EXPERIMENTAL|Song of Kin|Voice (with or without guitar)- lullaby/ Holding meter
62224074|NCT03533985|EXPERIMENTAL|Gato box|Simple rhythms using Remo Gato box will be played by the MT-BC using a 3rd to comfort, engage or sedate
62224075|NCT03533985|EXPERIMENTAL|Ocean disc|Creating a consistent womb-like sound soundscape to comfort, engage or sedate
62224076|NCT03533985|EXPERIMENTAL|Contingent singing|"Provision of communicative vocalization-parantese to engage with infants, prosodic responses to infant cues (eye contact, body position)"
62417428|NCT01087333||1|Patients with hematologic malignancies or solid tumors.
62588665|NCT04256317|EXPERIMENTAL|Phase 1, Stage B (Dose Expansion)|Oral cedazuridine + azacitidine will be administered separately at the recommended dose for expansion (RDE)
62224077|NCT03533985|EXPERIMENTAL|Tonal Vocal holding|Providing a 'blanket of tone' to comfort, engage or sedate
62224078|NCT03533985|EXPERIMENTAL|Muted shaker|If infant is awake, the muted shaker will be used to entrain to the infant's vital signs-to comfort, soothe or sedate
62417429|NCT01087333||2|Normal Donors who are defined as individuals without a diagnosis of or history of any cancer.
62417430|NCT05910320|EXPERIMENTAL|Wearable Vital Signs Monitoring Device|
62417431|NCT06036173||developed lymphedema after breast cancer surgery|
62417432|NCT06036173||did not develop lymphedema after breast cancer surgery|
62417433|NCT06036173||without a history of any cancer surgery|
62417434|NCT04758611|EXPERIMENTAL|Treatment Arm|The Treatment Arm receives the eShunt implant
62417435|NCT06590987|NO_INTERVENTION|Usual care|After a baseline assessment of standard clinical tests, participants will start with a 6-week usual care control period. After 6 weeks, participants undergo the midterm assessments.
62417436|NCT06590987|EXPERIMENTAL|Strolll AR|After 6 weeks, participants undergo the midterm assessments. Then, participants will start with the 8-week Strolll AR intervention (i.e., 2 weeks of practice supervised in the clinic and 6 weeks of training independently at home) and will receive a final assessment hereafter.
62417437|NCT06539702||2/Group B (Benign), Group M (Malign)|"Mean Platelet Volume (MPV), Neutrophil/lymphocyte Ratio (NLR), Platelet/Lymphocyte Ratio (PLR) and Lymphocyte/Monocyte Ratio (LMR) will be recorded in preoperative hemograms. Among the patients included in the study, BRAF molecular testing will be performed on the preoperative cytology of 25 patients whose thyroidectomy materials were reported to be malignant. with thyroid nodule identified by Bethesda 3 cytology were examined retrospectively. According to the pathology results, they were divided into 2 groups: benign and malignant.~Group B (Benign);Preoperative hemogram parameters, Bethesda 3 cytology, Thyroidectomy, benign pathology.~Group M (Malign);Preoperative hemogram parameters, Betheda 3 cytology, Thyroidectomy, malign pathology, BRAF molecular test"
62224079|NCT04578782|EXPERIMENTAL|BOTOX|155 UI of Botox were injected according to the approved PREEMPT protocol (the only FDA-approved injection pattern for chronic migraine), in 31 sites. From visit 5, the PREEMPT 'follow-the-pain' paradigm was applied in patients falling in the 'non-responder' or 'partial responder' classes after the first BoNT-A injection, with the possibility to increase the doses up to 195 UI in maximum 39 sites. The injections were every 3 months for 4 cycles
62224080|NCT05180188|NO_INTERVENTION|Placebo periode|In the first study period, participants will not be exposed to any intervention and will be advised to not start any new medications, diets or participate in any activities which could influence their health.
62224081|NCT05180188|EXPERIMENTAL|Exercise periode|In the second period, participants will perform regular moderate-intensity exercise 3 times/week.
62224082|NCT05589168|EXPERIMENTAL|Triage Nurse|Triage nurse
62224083|NCT05589168|ACTIVE_COMPARATOR|No Triage Nurse|No triage nurse
62224084|NCT04695743|EXPERIMENTAL|Intervention|Attendance at online CST groups
62224085|NCT04695743|NO_INTERVENTION|Control|Treatment as usual
62224086|NCT02482077|EXPERIMENTAL|SOF+RBV 8 wk|Participants will receive SOF+RBV for 8 weeks.
62224087|NCT02482077|EXPERIMENTAL|SOF+RBV 12 wk|Participants will receive SOF+RBV for 12 weeks.
62224088|NCT02482077|EXPERIMENTAL|SOF+DCV 8 wk|Participants will receive SOF+DCV for 8 weeks.
62224089|NCT02482077|EXPERIMENTAL|SOF+DCV 12 wk|Participants will receive SOF+DCV for 12 weeks.
62224090|NCT02482077|EXPERIMENTAL|LDV/SOF 8 wk|Participants will receive LDV/SOF for 8 weeks.
62224091|NCT02482077|EXPERIMENTAL|LDV/SOF 12 wk|Participants will receive LDV/SOF for 12 weeks.
62224092|NCT01148914||Baseline level of biomarkers|
62224093|NCT03939091|OTHER|Ultrasonography|Renal Ultrasonography
62224094|NCT02269332||Screening Colonoscopy|Referred for a screening colonoscopy or polyp surveillance or had one in the last 2 weeks
62224095|NCT06118996|EXPERIMENTAL|Patients at Risk of Breast Cancer|These patients will be imagined with an experimental device designed to acquire ultrasound in three dimensional volumes
62417438|NCT01582828|ACTIVE_COMPARATOR|Epicardial (surgical) ablation|Epicardial Pulmonary vein isolation
62588666|NCT04256317|EXPERIMENTAL|Phase 2, Sequence A|Oral ASTX030 (cedazuridine + azacitidine) will be administered in Cycle 1, followed by SC azacitidine in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
62798796|NCT03385226|EXPERIMENTAL|Pembrolizumab with radiotherapy|"All patients will receive~* single 200mg pembrolizumab IV infusions given 3-weekly until 2 years post study entry, termination of treatment, disease progression or unacceptable toxicity~* radiotherapy, 12Gy in 3 fractions"
62798797|NCT01844453|EXPERIMENTAL|Luteal Phase Arm|Local Endometrial Injury in mid-luteal phase (cycle day 21-26) prior to the treatment cycle.
62798798|NCT01844453|EXPERIMENTAL|Proliferative Phase Arm|Local Endometrial Injury in early proliferative phase of current treatment cycle (cycle day 2-3).
62798799|NCT01844453|NO_INTERVENTION|Control Arm|No Local Endometrial Injury will be performed. Patients will undergo a routine fresh IVF treatment cycle.
62798800|NCT03229109|EXPERIMENTAL|Group 1|Age 18-25, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
62224096|NCT04196101|EXPERIMENTAL|EDP-938|Subjects will take EDP-938 tablets (800 mg) once a day orally for 5 days
62224097|NCT04196101|PLACEBO_COMPARATOR|Placebo|Subjects will take EDP-938 matching placebo tablets once a day orally for 5 days
62224098|NCT05346133|OTHER|SPI-A Adolescents|Adolescents with moderate risk will receive the SPI-A intervention from the provider. Adolescents with high risk will be immediately taken to the mental health specialist at the primary care clinic. Following creation of the safety plan, patients are followed-up with at least twice to assess risk and review their plan. Following completion of the pilot, the investigators will interview all included providers as well as 18 adolescents who participated in SPI-A and their caregivers.
62224099|NCT00504660|ACTIVE_COMPARATOR|1: Anaplastic Tumors|Anaplastic Tumors - 6-TG 80 mg/m\^2 orally (PO) every 6 hours Day 1-3; Temozolomide 150 mg/m\^2 PO daily Days 4-8, after 6 day rest Capecitabine 825 mg/m\^2 and Celebrex 400 mg PO every 12 hours Day 14-27 for 28 day course.
62798801|NCT03229109|EXPERIMENTAL|Group 2|Age 26-35, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
62798802|NCT03229109|EXPERIMENTAL|Group 3|Age 36-45, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
62798803|NCT03229109|EXPERIMENTAL|Group 4|Age 46-50, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
62798804|NCT04861935|PLACEBO_COMPARATOR|ultrasound evaluation of sacral region in normal pediatric patients|"Ultrasound evaluation of sacral region will be performed to detect spinal abnormality.~Dural sac level and its distance to estmated injection site, optimal entry angle for caudal block will be measured."
62798805|NCT04861935|ACTIVE_COMPARATOR|ultrasound evaluation of sacral region in patients with sacral dimple|"Ultrasound evaluation of sacral region will be performed to detect spinal abnormality.~Dural sac level and its distance to estmated injection site, optimal entry angle for caudal block will be measured."
62224100|NCT00504660|ACTIVE_COMPARATOR|2: Anaplastic Tumors|"Anaplastic Tumors - 6-TG 80 mg/m\^2 PO every 6 hours Day 1-3, Lomustine 100 mg/m\^2 PO on Day 4; Capecitabine 825 mg/m\^2 PO every 12 hours Days 11-24, and Celebrex 400 mg PO every 12 hours Days 11-24.~Participants if previously received Temozolomide but not Lomustine (CCNU) will receive Lomustine; or if had Gliadel wafers and Temozolomide with radiotherapy (XRT) will receive Temozolomide."
62798806|NCT03652935|EXPERIMENTAL|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction (MBSR) program consists of an 8-week (2.5 hr/wk) program with a 6-hour silent mindful practice retreat after the fifth week. A licensed clinical psychologist, certified as an MBSR instructor, will provide instruction to all groups. Mindfulness will be taught using breath awareness, sitting and walking meditation, and mindful yoga. Participants will be given a standardized session-by-session program workbook containing weekly objectives and assignments, as well as two practice recordings and the book, Full Catastrophe Living (Kabat-Zinn, J, 1990).
62798807|NCT03652935|ACTIVE_COMPARATOR|Health Education Series|The active comparator condition consists of an 8-week educational series, administered in group-format, and matched in duration and frequency to the MBSR program. Session topics include: 1) Understanding Breast Cancer and Risks for Breast Cancer, 2) Breast Cancer Treatment, 3) Communicating Effectively with your Health Care Providers; Keeping your Medical Records, 4) Genetic Testing and Cancer, 5) Nutrition and Cancer, (6) Cooking Demonstration, 7) Bone Health, and 8) Image and Cancer (American Cancer Society - Look Good, Feel Better). The program content and objectives were reviewed by four content experts (oncology clinicians) and two breast cancer survivors.
62417439|NCT01582828|EXPERIMENTAL|Hybrid|Epicardial (surgical) ablation \& Endocardial assessment
62417440|NCT04977830|OTHER|Thoracic Insufficiency Group|Thoracic insufficiency syndrome patients undergoing surgery
62798808|NCT02463279|EXPERIMENTAL|SinuSys Dilation System|Opening of previously constrained frontal recess and/or sphenoid sinus ostia via dilation procedure (sinuplasty)
62798809|NCT02340065|ACTIVE_COMPARATOR|standard colonoscopy|total polyp/adenoma detection with standard colonoscopy, polyp/adenoma detection in the right colon with standard colonoscopy
62417441|NCT05043168||Patients with COVID-19|Polymerase Chain Reaction-positive SARS-CoV-2 infection
62417442|NCT05043168||Patients post-SARS-CoV-2 vaccination|Onset of kidney disease potentially relatable to SARS-CoV-2 vaccination based on clinical grounds
62417443|NCT04793815|EXPERIMENTAL|Cryo-activation and anti-PD-1 monotherapy combination|
62417444|NCT05218083|EXPERIMENTAL|REmotely Monitored, Mobile health supported Multidomain Rehabilitation Program with HIIT|Patients will receive our REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training Program (REMM-HIIT) with iWatch/iPhone.
62433460|NCT03724669|EXPERIMENTAL|Benzodiazepines and Z-drugs knowledge|
62224101|NCT00504660|ACTIVE_COMPARATOR|3: Glioblastoma Multiforme|"Glioblastoma Multiforme - 6-TG 80 mg/m\^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m\^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m\^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle.~Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide."
62224102|NCT02034370||Included patients|All ten patients included in this cohort. Shoulder surgery patients that are getting a nerve block and are at high risk for OSA. They will receive a Lung-function spirometry test and an overnight sleep test.
62417445|NCT05218083|NO_INTERVENTION|Exercise education without personalized sessions or feedback|Patients will receive an exercise handout and iWatch/iPhone. Patients return home to exercise without personalized instruction and coaching.
62433461|NCT06205199|EXPERIMENTAL|Hydromorphone group|Hydromorphone 50 micrograms combined with ropivacaine 15 mg was injected into the subarachnoid space
62798810|NCT02340065|ACTIVE_COMPARATOR|Endocuff-assisted colonoscopy|total polyp/adenoma detection with Endocuff-assisted colonoscopy, polyp/adenoma detection in the right colon with Endocuff-assisted colonoscopy
62798811|NCT01435213|EXPERIMENTAL|Atipamezole|
62798812|NCT01435213|EXPERIMENTAL|Atomoxetine|
62798813|NCT01435213|EXPERIMENTAL|Ketamine|
62798814|NCT01435213|EXPERIMENTAL|Insulin-induced hypoglycemia|
62798815|NCT01435213|EXPERIMENTAL|Cold pressor test|
62798816|NCT01435213|EXPERIMENTAL|Placebo|
62798817|NCT02397304|EXPERIMENTAL|Pre-exercise food|Pre-exercise food provision
62798818|NCT02397304|EXPERIMENTAL|Post-exercise food|Post-exercise food provision
62798819|NCT04712370|ACTIVE_COMPARATOR|Conventional caudal block|Patients of this group will receive the conventional method (blind technique without ultrasound) of caudal block
62798820|NCT04712370|EXPERIMENTAL|Ultrasound-guided caudal block|Patients of this group will receive caudal block using ultrasound.
62798821|NCT04712370|EXPERIMENTAL|Ultrasound guided erector spinae plane Block|Patients of this group will receive ultrasound guided erector spinae plane Block at the level of the transverse process of the second lumbar vertebrae(L2) .
62798822|NCT05362929|EXPERIMENTAL|Hybrid Fractional laser - SOC|23 participants with fitzpatrick skin type IV-V will be in this arm. At the first visit, participants will undergo informed consent, education about the procedure, education about proper sun-care, and will be provided sunscreen. Participants will be prescribed a prescription of hydroquinone or a retinol to prevent hyperpigmentation, per standard of care. If participants choose to take this they will wait one month of taking the prescription and then begin treatment sessions. If not, participants can begin treatment sessions right away. Treatment consists of 3 laser sessions with the Sciton Halo hybrid fractional laser. Session amount depends on the degree of improvement. At each session before and after images will be collected. At each session participants will fill out the dermatology quality of life survey as well as a patient satisfaction survey.
62025906|NCT05430529|EXPERIMENTAL|Brief Alcohol Intervention for Intervention Group|"During the face-to-face smoking cessation counseling session, HCPs will first play a 2 - 3 minutes short video with electronic devices to participants who are allocated to intervention group.~After the short video, HCPs will ask participants to share their thoughts and willingness of alcohol control. Participants are expected to show 4 responses: (1) refuse to attempt alcohol control; agree to attempt alcohol control that (2) quit drinking totally, (3) quit drinking for 2 weeks, or (4) reduce the alcohol consumption. HCPs will deliver personalized advice according to participants' choices and encourage them to receive the WhatsApp message reminders.~In all participants, HCPs will invite them to receive WhatsApp messages reminders for incoming 4 weeks (3 messages per week).~Nevertheless, HCPs can also choose to provide AUDIT-based brief intervention to the participants."
62025907|NCT05430529|ACTIVE_COMPARATOR|Short Advice for Control Group|If the control group participant encountering difficulties in smoke cessation caused by alcohol usage, HCP will provide short advice to them. Participant will be urged not to drink during smoke quitting. If drinking is unavoidable, participant should not drink exceed the low-risk drinking portion recommended by Department of Health, which is 2 standard alcohol units for men and 1 stand alcohol unit for women per day. HCPs will remind participants to aware their drinking portion, in order to quit smoke successfully.
62224103|NCT05778344|EXPERIMENTAL|Home-based pulmonary rehabilitation group|The home-based pulmonary rehabilitation group will receive breathing exercise instructions using online learning materials soon after randomization. The participants will receive a home-based exercise plan, which comprises aerobic exercise and resistance exercise with instruction sheets. The participants will also be given a smart watch (to record heart rate, step count and distance in daily life) and a portable pulse oximeter (to monitor heart pulse and oxygen saturation during exercise) for 12 weeks. Teletechnology will be incorporated into home-based pulmonary rehabilitation via videotelephony (or telephone calls if indicated). Time points for these teletechnology-assisted consultations will be at day 7, day 14 after randomization and every 2 weeks after that until the completion of the study (week 12).
62224104|NCT05778344|ACTIVE_COMPARATOR|Usual care group|The usual care group will receive breathing exercise instructions using online learning materials soon after randomization. The participants will also receive general exercise education and exercise safety principles but not any consultation about their physical activity/exercise during the study period.
62224105|NCT05367232|EXPERIMENTAL|ICP-033 Dose Escalation|Drug: ICP-033 tablet Administered orally，once a day，every 28 days is a cycle.
62224106|NCT01783847|EXPERIMENTAL|Recombinant human erythropoietin (EPO)|Intravenous EPO 10,000 IU for 5-13 years of age and 20,000 IU for \>13 years/ day for 3 days
62417446|NCT05558605|EXPERIMENTAL|Screening/Management Plan|AI-guided echo acquisition performed using a desktop echo machine (uSmart 3300, Terason, Burlington, MA) with AI software (Caption Health, Brisbane, CA) obtained by a non-expert (eg. clinic nurse, registrar general practitioner or physician) at the remote clinic, usually on the day of clinic review. Images will then be uploaded onto a secure cloud and downloaded at the core lab for measurement, interpretation and reporting.
62417447|NCT05558605|ACTIVE_COMPARATOR|Usual care|Standard echo acquisition by a sonographer either at a referral hospital, or by a visiting team - usually necessitating a delay. Measurement, interpretation and reporting will happen as usual.
62417448|NCT04338581|EXPERIMENTAL|AMG 714|Participants will be administered 300 mg AMG 714 subcutaneously on Day 0 and every 2 weeks thereafter through week 10 (for a total of 6 doses).
62798823|NCT05362929|EXPERIMENTAL|Hybrid Fractional laser- Non- SOC|23 participants with Fitzpatrick skin type I-III will be in this arm. At the first visit, participants will undergo informed consent, education about the procedure, education about proper sun-care, and will be provided sunscreen. Participants will be prescribed a prescription of hydroquinone or a retinol to prevent hyperpigmentation, per standard of care. If participants choose to take this they will wait one month of taking the prescription and then begin treatment sessions. If not, participants can begin treatment sessions right away. Treatment consists of 3 laser sessions with the Sciton Halo hybrid fractional laser. Session amount depends on the degree of improvement. At each session before and after images will be collected. At each session participants will fill out the dermatology quality of life survey as well as a patient satisfaction survey.
62798824|NCT03997669||experimental group|patients with malignant pleural effusion
62798825|NCT03997669||control group|patients with benign pleural effusion
62798826|NCT01370265|ACTIVE_COMPARATOR|Regadenoson, then Adenosine|Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the first intervention period. Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the second intervention period (after washout period). Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered.
62798827|NCT01370265|ACTIVE_COMPARATOR|Adenosine, then Regadenoson|Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the first intervention period. Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered. After a washout period, Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the second intervention period.
62025908|NCT06288984|EXPERIMENTAL|active rTMS|
62025909|NCT06288984|SHAM_COMPARATOR|sham rTMS|
62025910|NCT06631586|EXPERIMENTAL|CD patients randomized to MTP-101C|
62433462|NCT06205199|NO_INTERVENTION|Control group|Ropivacaine 15 mg was injected into the subarachnoid space
62417449|NCT04338581|PLACEBO_COMPARATOR|Placebo|Participants will be administered 300 mg AMG 714 subcutaneously on Day 0 and every 2 weeks thereafter through week 10 (for a total of 6 doses).
62798828|NCT02392806|ACTIVE_COMPARATOR|BabiPlus, Respiralogics|Infants randomized to the BabiPlus device will be extubated to BabiPlus Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the B\&B Bubbler device for 24 hours
62798829|NCT02392806|ACTIVE_COMPARATOR|B&B Bubbler, B&B medical Technologies|Infants randomized to the B\&B Bubbler device will be extubated to B\&B Bubbler Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the BabiPlus device for 24 hours
62798830|NCT06302946|EXPERIMENTAL|experimental group|will receive neuromuscular stimulation , mindfulness breathing and traditional physiotherapy program
62798831|NCT06302946|ACTIVE_COMPARATOR|control group|the control group will stick to the traditional physiotherapy program only.
62025911|NCT06631586|EXPERIMENTAL|CD patients randomized to MTP-101S|
62025912|NCT03982394||Participants treated with Risankizumab|Treatment decision independently made of study enrollment
62025913|NCT03982394||Participants treated with other approved biological therapies|Treatment decision independently made of study enrollment
62025914|NCT01218152||cancer patients|patients who are seen by oncologists and who are willing to donate an extra blood sample when blood is taken routinely
62224107|NCT01783847|ACTIVE_COMPARATOR|Methylprednisolone|Just Intravenous Methyl prednisolone 250 mg every 6 hours for 3 days.
62224108|NCT01783847|OTHER|Observation|Observation
62224109|NCT00584649|OTHER|Single Group Assignment|electrophysiology study and radiofrequency ablation
62224110|NCT03141385|EXPERIMENTAL|RIPC intervention|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
62224111|NCT03141385|SHAM_COMPARATOR|Control|Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
62224112|NCT01775267|EXPERIMENTAL|ALPPS|Patients undergo Liver partition and portal vein ligation to induce hypertrophy of the future liver remnant
62224113|NCT01775267|ACTIVE_COMPARATOR|PVO|Patient undergo portal vein embolization or ligation
62224114|NCT02630693|ACTIVE_COMPARATOR|Palbociclib (100mg)|Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
62224115|NCT02630693|ACTIVE_COMPARATOR|Palbociclib (125mg)|Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
62417450|NCT05533112|NO_INTERVENTION|Control|Control Group, no Intervention received
62798832|NCT03612336|EXPERIMENTAL|Intervention group|
62025915|NCT01218152||NF1 patients|patients, who have neurofibromatosis type 1 and who have developped an MPNST,donating a blood sample
62025916|NCT02984540|EXPERIMENTAL|LOW-CARBOHYDRATE DIET|The low-carbohydrate diet will consist of a meal plan of less than 20 grams of carbohydrates per day to be consumed over 6 weeks. Foods that provide high levels of healthy fats (preferably low in saturated fats) will be generously included in the diet plan. Various lean meats, fish, and nutrient rich foods that meet the requirement of less than 20 grams total carbohydrates per day will be included in the meal plans. Carbohydrates will be expected to make up less than 10% of total caloric intake. Participants in the low-carbohydrate diet group will receive a supply of extra virgin olive oil at study visits to incorporate into their individualized meal plans.
62224116|NCT01871753|EXPERIMENTAL|Antibiotics|10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up).
62224117|NCT01871753|NO_INTERVENTION|No treatment|no antibiotics delivered in case of asymptomatic bacteriuria, independently of the number of asymptomatic episodes.
62224118|NCT04619901||Parents only|
62224119|NCT04619901||Children and Parents|
62224120|NCT06290674|ACTIVE_COMPARATOR|Study Group (A) (ESWT)|30 participants will receive Extracorporeal Shockwave (one session per week for 6 weeks), in addition to a balanced low-calorie diet (1500 k/cal for 6 weeks).
62224121|NCT06290674|PLACEBO_COMPARATOR|Control Group (B)|30 participant will receive Balanced low-calorie diet (1500 k/cal for 6 weeks), only.
62417451|NCT05533112|EXPERIMENTAL|Preop Stimulation|Binaural Beat Stimulation preoperatively
62417452|NCT05533112|EXPERIMENTAL|Postop Stimulation|Binaural Beat Stimulation postoperatively
62417453|NCT05533112|EXPERIMENTAL|Pre- & Postop Stimulation|Binaural Beat Stimulation pre- and postoperatively
62417454|NCT06623526|EXPERIMENTAL|Sequence Group 1|13 subjects, Cross-over, Single dose of YHR2402 on day 1, Co-Administration of YHR2402 and YHR2403 on day 15
62417455|NCT06623526|EXPERIMENTAL|Sequence Group 2|13 subjects, Cross-over, Co-Administration of YHR2402 and YHR2403 on day 1, Single dose of YHR2402 on day 15
62798833|NCT03612336|ACTIVE_COMPARATOR|Control group|
62798834|NCT04924595|NO_INTERVENTION|Regular treatment|
62798835|NCT04924595|EXPERIMENTAL|Exercise Intervention|
62798836|NCT04708093|EXPERIMENTAL|whole body vibration training (WBVT)|whole body vibration group
62798837|NCT04708093|NO_INTERVENTION|Controlled|advised about healthy dieting
62798838|NCT05397769|EXPERIMENTAL|Envafolimab group|Envafolimab is a PD-L1 antibody by hypodermic injection. Envafolimab will be administrated with 300mg each time, every three weeks for a total of 22 cycles since the first day of induction chemotherapy.
62417456|NCT03491020||Respiratory syncytial virus (RSV)|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify RSV.
62798839|NCT06726486|EXPERIMENTAL|Intervention Group (Atémpero)|Participants received an arginine-enriched ONS called Atémpero®.
62417457|NCT03491020||Enteroviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify enterovirus.
62417458|NCT03491020||Adenoviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify adenovirus.
62798840|NCT06726486|ACTIVE_COMPARATOR|Control Group|Participants received a complete high-protein, high-calorie diet with mixed fiber.
62798841|NCT05514054|EXPERIMENTAL|Imlunestrant|Imlunestrant administered orally.
62798842|NCT05514054|ACTIVE_COMPARATOR|Investigator's Choice of Endocrine Therapy|Investigator's choice of tamoxifen, anastrozole, letrozole, or exemestane administered per local approved label.
62025917|NCT02984540|EXPERIMENTAL|LOW-FAT DIET|The low-fat diet will consist of a low-fat, higher-carbohydrate meal plan to be consumed over 6 weeks. Participants will be encouraged to limit their amount of fat intake to less than 40 grams per day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber. Various lean meats and other sources of protein will be included in the diet plan. Carbohydrates will be expected to make up 50-60% of total caloric intake.
62025918|NCT02759159|EXPERIMENTAL|AD-true acupuncture|"True acupuncture at the four-gateacupoints will be administered on AD patients"
62025919|NCT02759159|SHAM_COMPARATOR|AD-sham acupuncture|"Sham acupuncture at the four-gateacupoints will be administered on AD patients"
62025920|NCT02759159|EXPERIMENTAL|Mild Cognitive Impairment(MCI)-true acupuncture|"True acupuncture at the four-gateacupoints will be administered on MCI patients"
62025921|NCT02759159|SHAM_COMPARATOR|MCI-sham acupuncture|"Sham acupuncture at the four-gateacupoints will be administered on MCI patients"
62417459|NCT03491020||Coronaviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify coronavirus.
62417460|NCT03491020||Metapneumoviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify metapneumovirus.
62417461|NCT03491020||Chlamydia pneumoniae|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify chlamydia pneumoniae.
62417462|NCT03491020||Mycoplasma|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify mycoplasma.
62417463|NCT03491020||Parainfluenza|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify parainfluenza.
62433463|NCT01149616|ACTIVE_COMPARATOR|Intervention|Dexamethasone 8mg iv x 1
62433464|NCT01149616|PLACEBO_COMPARATOR|Placebo|placebo
62798843|NCT01426958|ACTIVE_COMPARATOR|treatment A|1 tablet afatinib single dose
62798844|NCT01426958|EXPERIMENTAL|treatment B|2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day
62798845|NCT01426958|EXPERIMENTAL|treatment C|2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day
62798846|NCT03596203|EXPERIMENTAL|Treatment group|
62798847|NCT03546556|EXPERIMENTAL|Allogeneic|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo Fluorothymidine FLT-PET-MRI imaging on two separate occasions.
62798848|NCT03546556|EXPERIMENTAL|Autologous|3 patients undergoing autologous stem cell transplant will also undergo Fluorothymidine FLT-PET-MRI imaging the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
62798849|NCT03136016|NO_INTERVENTION|control|without any activity
62798850|NCT03136016|EXPERIMENTAL|educational activities|The students will receive educational activities in the classroom.
62798851|NCT03136016|EXPERIMENTAL|nudging|The students will receive changes in the school environment (nudge strategies);
62025922|NCT03609827||Pediatric patients undergoing Hematopoietic Stem Cell Transplant|Children undergoing allogeneic hematopoietic stem cell transplant (alloHCT) at University of California, San Francisco Benioff Children's Hospital.
62224122|NCT03265938||Indirect laryngoscopy|Head and neck pathology patients undergoing indirect laryngoscopy. Patients with a past medical history of active or previously treated head and neck pathology.
62224123|NCT00538915|EXPERIMENTAL|Nabi-IGIV Infused Every 3- or 4-Weeks|
62224124|NCT06357013||Grup-1: Suprainguinal fascia iliaca compartment block|
62417464|NCT03491020||Neisseria meningitides|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify neisseria meningitides.
62798852|NCT03136016|EXPERIMENTAL|nudging + educational activities|The students will receive educational activities and changes in the school environment.
62798853|NCT01559675|ACTIVE_COMPARATOR|Hydrocortisone High Dose|Intervention: Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
62798854|NCT01559675|EXPERIMENTAL|Hydrocortisone Low Dose|Intervention: 1/3 Intravenous equivalent dose (IVED) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD) 1, followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
62798855|NCT00402467|EXPERIMENTAL|Arm 6|
62025923|NCT03335553|EXPERIMENTAL|Single ascending dose (SAD): BMS-986235 or Placebo|BMS-986235 or Placebo oral dose
62025924|NCT03335553|EXPERIMENTAL|Multiple ascending dose (MAD): BMS-986235 or Placebo|BMS-986235 or Placebo oral dose
62025925|NCT04931511|EXPERIMENTAL|Gluteal muscle injection plus physical therapy group|Gluteal muscle injection (corticosteroid 1ml+normal saline 4ml) + Subacromial Ultrasound Guided injection (sodium chloride 5ml) + Physical therapy
62798856|NCT00402467|EXPERIMENTAL|Arm 1|
62798857|NCT00402467|EXPERIMENTAL|Arm 2|
62798858|NCT00402467|EXPERIMENTAL|Arm 3|
62224125|NCT06357013||Grup-2: Local infiltration analgesia|
62224126|NCT02990312|EXPERIMENTAL|Sirolimus + Maraviroc|Participants will be placed on the combination of Sirolimus and Maraviroc, unless they are already on one of these medications.
62224127|NCT00506987|EXPERIMENTAL|SCH 486757|
62224128|NCT00506987|PLACEBO_COMPARATOR|Placebo|
62224129|NCT04018599|EXPERIMENTAL|40 mg MSB11022 via Auto-injector|Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via an auto-injector on Day 1.
62224130|NCT04018599|EXPERIMENTAL|40 mg MSB11022 via Pre-filled Syringe|Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via a pre-filled syringe on Day 1.
62417465|NCT03491020||Bordetella pertussis|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify bordetella pertussis.
62417466|NCT03491020||Rhinovirus|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify rhinovirus.
62417467|NCT01508923|EXPERIMENTAL|Treatment period 1|
62798859|NCT00402467|EXPERIMENTAL|Arm 4|
62798860|NCT00402467|EXPERIMENTAL|Arm 5|
62025926|NCT04931511|EXPERIMENTAL|Subacromial Ultrasound Guided injection plus physical therapy group|Gluteal muscle injection(sodium chloride 5ml)) + Subacromial Ultrasound Guided injection(corticosteroid 1ml+normal saline 4ml) + Physical therapy
62224131|NCT06227078|ACTIVE_COMPARATOR|Active Kinesiotaping + Physiotherapy|"The application of kinesiotaping for grade 2 osteoarthritis involves the application of an anchor strip at one end of the affected joint, typically with no stretch. Apply the kinesiotape with the desired amount of stretch, usually around 50-80% of its maximum stretch capacity. Direct the tape along the muscle or joint in a specific pattern, such as I, Y, or X depending on the therapeutic goal. Finish with an anchor strip at the opposite end, with no stretch to secure the tape in place.~Physiotherapy:~Apply TENS: Low-frequency TENS (2-10 Hz) that produces a tingling or buzzing sensation without causing discomfort or pain. TENS sessions may last between 20 to 30 minutes per session.~Strengthening exercises:~1. Quadriceps Sets:~2. Straight Leg Raises:~3. Seated Leg Press:~4. Hamstring Curls:~5. Calf Raises:~   * Repeat the exercises for 10 times, 3 sets in a session for 8 weeks."
62417468|NCT01508923|PLACEBO_COMPARATOR|Treatment period 2|
62417469|NCT04445194|EXPERIMENTAL|Population I|Population I has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population I is intramuscular injection of deltoid muscle of upper arm with low dose of vaccine.
62417470|NCT04445194|EXPERIMENTAL|Population II|Population II has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population II is a high-dose vaccine intramuscular injection of deltoid muscle of the upper arm.
62417471|NCT04445194|PLACEBO_COMPARATOR|Population Ⅲ|Population Ⅲ has 10 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅲ is a placebo intramuscular injection of deltoid muscle of the upper arm.
62417472|NCT03813394|EXPERIMENTAL|Treatment Arm A|Intravenous pembrolizumab alone,D8 of 21-day cycle.
62025927|NCT00648076|EXPERIMENTAL|1|Divalproex Sodium Extended-Release Tablets 500 mg
62025928|NCT00648076|ACTIVE_COMPARATOR|2|Depakote ER® Tablets 500 mg
62025929|NCT03613857||Clopidogrel group|Anterior myocardial infarction patients undergoing percutaneous coronary intervention take loading dose 600 mg oral clopidogrel (plavix) tablets before the procedure.
62025930|NCT03613857||Ticagrelor group|Anterior myocardial infarction patients undergoing percutaneous coronary intervention take loading dose180 mg oral ticagrelor (brilique) tablets before the procedure.
62025931|NCT03066531|EXPERIMENTAL|ACT-based intervention|The ACT-based intervention integrates educational topics on heart healthy behaviours with mindfulness and acceptance training regarding difficult thoughts and feelings, clarification of health-related values and commitment to behave in the valued direction while contacting difficult experiences.
62025932|NCT03066531|ACTIVE_COMPARATOR|CBT-based intervention included in Usual Care|"These programs are based on current guidelines for the long- term multi-disciplinary rehabilitation and prevention of obese patients, including Cognitive Behavioral Therapy (CBT), in a group setting, as Gold Standard.~Assigned Interventions: Behavioral: usual care (CBT)"
62025933|NCT00198068||Group 1: aPL+/SLE-|Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM \>= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM \>= 40 units; no SLE
62025934|NCT00198068||Group 2: aPL+/SLE+|Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM \>= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM \>= 40 units AND SLE defined as four or more American College of Rheumatology criteria for SLE.
62025935|NCT00198068||Group 3: aPL-/SLE+|No antiphospholipid antibodies; SLE defined as four or more American College of Rheumatology criteria for SLE.
62025936|NCT00198068||Group 4: aPL-/SLE-|Healthy controls: no antiphospholipid antibodies; no SLE
62417473|NCT03813394|EXPERIMENTAL|Treatment Arm B|Intravenous pembrolizumab preceded by an infusion of bevacizumab (Day 1 of 21-day cycle).
62417474|NCT03330847|ACTIVE_COMPARATOR|Olaparib monotherapy|All randomized patients will receive Olaparib monotherapy 300 mg twice daily (BD).
62417475|NCT03330847|ACTIVE_COMPARATOR|Olaparib+Ceralasertib|All randomized patients will receive Olaparib 300 mg twice daily+Ceralasertib 160 mg once daily (OD).
62588667|NCT04256317|EXPERIMENTAL|Phase 2, Sequence B|SC azacitidine will be administered in Cycle 1, followed by oral cedazuridine + azacitidine tablets/capsules in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
62798861|NCT02068326|EXPERIMENTAL|Mentalization Based Treatment|"the experimental intervention is a year-long manualized program that comprises four components:~* Five individual case-formulation sessions,~* MBT-I, an introductory pedagogical program for patients (three weekly sessions)~* MBT-G, MBT-program in groups (37 weekly sessions)~* MBT-P, a psychoeducation program for the patients' parents or parents substitutes (six sessions)."
62798862|NCT02068326|ACTIVE_COMPARATOR|Treatment As Usual|Participants randomized to the control group will receive Treatment As Usual (TAU). TAU is defined as comprising at least 12 monthly individual supportive sessions provided by non-MBT trained mental health professionals in the Department of Child and Adolescent Psychiatry in Region Zealand. Additional supportive sessions or other types of intervention may be offered to the patients according to the needs of the patients as evaluated by mental health professionals responsible for his/hers treatment. Hence, TAU may vary considerably in number and type of intervention across clinics and patients. All mental health services delivered during the treatment period to patients in the TAU group will be monitored and registered.
62798863|NCT02915042|EXPERIMENTAL|Experimental group|Intervention group 1: pre-operative administration of IV dexmedetomidine 1mcg/kg
62798864|NCT02915042|PLACEBO_COMPARATOR|Placebo group|Intervention group 2: placebo
62798865|NCT04440826|ACTIVE_COMPARATOR|Whole Food Meal|Whole foods meal - grilled cheese and drink meal
62798866|NCT04440826|EXPERIMENTAL|Processed Food Meal|Highly processed foods - grilled cheese and drink meal
62798867|NCT04440826|EXPERIMENTAL|Gluten-Free and Lactose-Free Meal|Gluten-free and lactose-free foods - grilled cheese and drink meal
62798868|NCT06495021|NO_INTERVENTION|Control|Patients in the control group will receive normal standard care, including any prescriptions, follow-up instructions, etc., as given by the provider to help treat their condition.
62798869|NCT06495021|EXPERIMENTAL|Treatment|Patients will receive lymphatic pump OMT therapy in addition to other standard care (similar to the control patients, this would be a medication, follow-up instructions, etc.)
62798870|NCT01943812|EXPERIMENTAL|Substituted FET cycle and GnRHa|Substituted FET GnRH-a 2 bolus two days before Estradiol 6 mg Progesterone (Crinone) 180 mg
62798871|NCT01943812|ACTIVE_COMPARATOR|Substituted FET cycle|substituted FET cycle Estradiol Progesterone
62798872|NCT01968330|EXPERIMENTAL|Go!®to sleep|Patients in the sleep intervention arm will undergo a sleep wellness program entitled Go!®to sleep as part of their group prenatal visits. This intervention is a six-week online program developed by the Cleveland clinic for non-pregnant patients suffering from insomnia. In collaboration with the Cleveland clinic sleep disorders center researchers will modify the program to fit the specific needs of a pregnant population. Subjects will receive access to the program and instructed on its use at their initial group prenatal visit. In subsequent visits subjects will be able to discuss their experience with the program.
62025937|NCT00724282|OTHER|Eszopiclone or Placebo|Subjects receive either eszopiclone or placebo for 9 days, followed by 3 week washout, then crossover to opposite treatment. Treatment is double-blinded.
62224132|NCT06227078|PLACEBO_COMPARATOR|Placebo Kinesiotaping + Physiotherapy|"The application of kinesiotaping for grade 2 osteoarthritis involves the application of an anchor strip at one end of the affected joint, typically with no stretch. Apply the kinesiotape without stretch, Direct the tape along the muscle or joint in a specific pattern, such as I, Y, or X depending on the therapeutic goal. Finish with an anchor strip at the opposite end, with no stretch to secure the tape in place.~Physiotherapy:~Apply TENS: Low-frequency TENS (2-10 Hz) that produces a tingling or buzzing sensation without causing discomfort or pain. TENS sessions may last between 20 to 30 minutes per session.~Strengthening exercises:~1. Quadriceps Sets:~2. Straight Leg Raises:~3. Seated Leg Press:~4. Hamstring Curls:~5. Calf Raises:~   * Repeat the exercises for 10 times, 3 sets in a session for 8 weeks."
62224133|NCT01018147|EXPERIMENTAL|CT Imaging|Patients undergo 4-D, 4-dimensional computed tomography, CT imaging prior to radiotherapy sessions and once a week at the end of treatment.
62224134|NCT04123574|EXPERIMENTAL|Single Arm|BXCL701 will be administered for one week at a dose of 0.2 mg, twice daily (BID). If BXCL701 is well-tolerated after the first week of treatment, the dose will be increased to 0.3mg BID for a total daily dose of 0.6mg to all patients for the second week of treatment.
62224135|NCT03207100|EXPERIMENTAL|Analgesia-first minimal sedation group|Using analgesia-first minimal sedation strategy to implement antihypertensive therapy.
62224136|NCT03207100|ACTIVE_COMPARATOR|Antihypertensive drug treatment group|Using routine antihypertensive drugs to implement antihypertensive therapy.
62224137|NCT00851448|EXPERIMENTAL|1|Oral nutritional supplement containing n-3 fatty acids, amino acids, antioxidants
62224138|NCT00851448|PLACEBO_COMPARATOR|2|isocaloric, isonitrogenous
62224139|NCT00547820|EXPERIMENTAL|A|with application of urinary sensor
62224140|NCT00547820|PLACEBO_COMPARATOR|B|without use of urinary sensor
62224141|NCT01739491||Bendamustine hydrochloride|Adult Filipino patients with chronic lymphocytic leukemia will be taking bendamustine hydrochloride as per the dosing regimen given on product insert approved in Philippines.
62224142|NCT03966807||Digital-based support|Digital support will consist of referral for the participant to visit https://smokefree.gov, a website which offers a menu of internet- and text-based support options.
62798873|NCT01968330|NO_INTERVENTION|Routine prenatal care|Patients in the routine prenatal care arm will complete prenatal care in a group setting and will not complete the sleep intervention.
62417476|NCT03330847|ACTIVE_COMPARATOR|Olaparib+adavosertib|All randomized patients will receive Olaparib 200 mg BD +adavosertib 150 mg BD. Following the discontinuation of adavosertib+olaparib treatment arm on 18 April 2019, patients receiving treatment with adavosertib+olaparib treatment were offered the opportunity to continue treatment on olaparib monotherapy at the approved dose (300 mg bd).
62417477|NCT02412696|ACTIVE_COMPARATOR|Positive Airway Pressure|Positive airway pressure and nasal dilator strips during sleep.
62224143|NCT03966807||traditional-based support +nicotine replacement therapy(NRT)|Traditional support will consist of participant referral to the Indiana Tobacco Quitline (1-800-QUIT-NOW) which is a telephone hotline that connects participants to Indiana smoking cessation resources.
62417478|NCT02412696|PLACEBO_COMPARATOR|Nasal Dilator Strips|Nasal dilator strips during sleep.
62417479|NCT03688503|ACTIVE_COMPARATOR|magnesium|magnesium glycinate supplement, 480 mg/day
62417480|NCT03688503|PLACEBO_COMPARATOR|placebo|placebo supplement
62798874|NCT04248127|EXPERIMENTAL|Honey sweetened yogurt|1 tbsp. of honey in 0.6 cup (150g) of plain yogurt. The participants will be asked to consume 2 morning servings of the yogurt for a total of 2 tbsp. of the assigned honey per day.
62798875|NCT04248127|PLACEBO_COMPARATOR|Sugar sweetened yogurt|Sugar will be added to 0.6 cup (150g) of plain yogurt in an isocaloric amount compared to the honey. The participants will be asked to consume 2 morning servings of the yogurt per day.
62025938|NCT04243876||paraoxanase|Enzyme level
62025939|NCT04243876||Myocardial infarction|RESULTS OF ANGIOGRAPHY
62417481|NCT03724292|PLACEBO_COMPARATOR|Placebo|Dose-matched placebo administered as oral capsule(s) once daily
62417482|NCT03724292|EXPERIMENTAL|VTP-43742 Dose 1|VTP-43742 administered as oral capsule(s) once daily
62417483|NCT03724292|EXPERIMENTAL|VTP-43742 Dose 2|VTP-43742 administered as oral capsule(s) once daily
62417484|NCT03724292|EXPERIMENTAL|VTP-43742 Dose 3|VTP-43742 administered as oral capsule(s) once daily
62417485|NCT03724292|EXPERIMENTAL|VTP-43742 Dose 4|VTP-43742 administered as oral capsule(s) once daily
62417486|NCT03724292|EXPERIMENTAL|VTP-43742 Dose 5|VTP-43742 administered as oral capsule(s) once daily
62025940|NCT02597959||risk factors of musculoskeletal injuries|trainees for surgical assistants - determining the level of risk
62224144|NCT04728412|EXPERIMENTAL|patients undergoing bronchoscopy under sedation with or at risk of respiratory failure|
62224145|NCT03190447|ACTIVE_COMPARATOR|Conventional dressing|The conventional dressing (sterile gauzes) will be applied
62224146|NCT03190447|EXPERIMENTAL|Aquacel Surgical®|Postoperative sterile dressing composed by non-woven inner pad (in contact with wound) Technology Hydrofiber® formed from sodium carboxymethylcellulose
62224147|NCT03190447|EXPERIMENTAL|Mepilex Border post-op®|Flexible absorbent all-in-one post-op dressing, super-absorbent fibres for high and fast absorption with optimised retention.
62224148|NCT03190447|EXPERIMENTAL|Opsite post-op visible®|Adhesive dressing with absorbent foam in the form of a grid to visualize the wound without lifting the dressing
62224149|NCT03190447|EXPERIMENTAL|Urgotul ABSORB border silicona®|A soft-adherent TLC (Technology Lipido-Colloid) layer (polymers and hydrocolloid particles) combined with an absorbent polyurethane foam pad and a highly absorbent layer. A vapour permeable waterproof outer film with silicone adhesive on the edges.
62025941|NCT02597959||design wearable devices|Creating feedback mechanism to reduce surgical assistant musculoskeletal risk
62025942|NCT05305144|EXPERIMENTAL|ophthalmological and vascular assessments|This single-center national interventional study aims to collect ophthalmological (retinal image acquisition) and blood pressure (vascular assessment) data from 400 young adults from the Bordeaux bio-Share cohort, during two visits taking place one year apart.
62224150|NCT05096585|PLACEBO_COMPARATOR|normal sleep|Subjects will go to sleep at their normal bedtime and normal sleep duration (7-9 hr)
62224151|NCT05096585|EXPERIMENTAL|delayed bedtime sleep restriction|Subjects will go to sleep at 2 hr later than their normal bedtime
62224152|NCT05096585|EXPERIMENTAL|early waking sleep restriction|Subjects will wake up 2 hr earlier than their normal wake time
62025943|NCT00423124|EXPERIMENTAL|A|
62025944|NCT04952545|EXPERIMENTAL|Cohort 1: ALXN2050 (Dose 1)|Participants will receive ALXN2050 (Dose 1) as follows under fasting conditions: 120-milligrams (mg) single dose, 3-day washout, then 120-mg twice daily (BID) dosing.
62025945|NCT04952545|EXPERIMENTAL|Cohort 1: Placebo (Dose 1)|Participants will receive placebo (Dose 1) as follows under fasting conditions: 120-mg placebo single dose, 3-day washout, then 120-mg placebo BID dosing.
62224153|NCT06046963|EXPERIMENTAL|Immunotherapy combined with intravenous and intraperitoneal chemotherapy|advanced gastric/gastroesophageal junction (GC/GEJ) adenocarcinoma patients with malignant ascites who have agreed to receive Immunotherapy combined with intravenous and intraperitoneal chemotherapy
62224154|NCT01011387|OTHER|NPWT system|Negative pressure wound therapy
62224155|NCT03310905|EXPERIMENTAL|Isolated Abdominal Wall Transplant|
62224156|NCT03310905|EXPERIMENTAL|Abdominal Wall with Solid Organ Transplant|
62224157|NCT05584787|EXPERIMENTAL|TPLA in patients with prostate cancer|Patients diagnosed with low- and intermediate risk unifocal prostate cancer undergo to focal laser ablation therapy.
62224158|NCT04539782|EXPERIMENTAL|Physiotherapy intervention|Pelvic floor muscle training given by a physiotherapist in four sessions and follow up phone calls twice in 14 weeks
62224159|NCT04539782|NO_INTERVENTION|No intervention|Standard care
62224160|NCT02202382|PLACEBO_COMPARATOR|non-V + P group|no surgery and placebo (12 weeks)
62224161|NCT02202382|ACTIVE_COMPARATOR|V + P group|Surgery with placebo (12 weeks)
62224162|NCT02202382|ACTIVE_COMPARATOR|non-V + KRG group|no surgery with KRG (korean red ginseng, 1.5 gm daily 12weeks)
62224163|NCT02202382|EXPERIMENTAL|V + KRG group|Surgery with KRG (1.5 gm daily 12weeks)
62224164|NCT01377753|EXPERIMENTAL|Arm 1/Magnetic Resonance (MR) Thermal Image Guided Laser Ablation|Eligible subjects will undergo MR thermal image guided laser ablation of all biopsy proven areas of prostate cancer using one or multiple laser probes during a single procedure lasting approximately two hours in duration.
62224165|NCT03705377||Head Start children and families|children (2,400), parents (2,400), classrooms/teachers (720), program directors (180), center directors (360), family service staff (168)
62224166|NCT00834145|EXPERIMENTAL|1|Patients will receive a NormaTec pump and perform active pumping twice daily during hospitalization and thereafter once daily in addition to routine medical therapy.
62224167|NCT00834145|NO_INTERVENTION|2|Routine medical treatment
62224168|NCT01088828||Group A|"Foetuses with clubfoot identified in utero (n=15). Of these:~* around 10 will be born with clubfoot and will form most of Group B,~* around 5 will be born without clubfoot and will form part of group C."
62224169|NCT01088828||Group B|Neonates affected by clubfoot (n=10)
62224170|NCT01088828||Group C|Control group of unaffected neonates (n=10)
62224171|NCT01088828||Group D|Young adults having completed treatment (n=5)
62025946|NCT04952545|EXPERIMENTAL|Cohort 2: ALXN2050 (Dose 2)|Participants will receive ALXN2050 (Dose 2) as follows under fasting conditions: 180-mg single dose, 3-day washout, then 180-mg BID dosing.
62025947|NCT04952545|EXPERIMENTAL|Cohort 2: Placebo (Dose 2)|Participants will receive placebo (Dose 2) as follows under fasting conditions: 180-mg placebo single dose, 3-day washout, then 180-mg placebo BID dosing.
62224172|NCT01088828||Group E|Control group of young unaffected adults (n=5)
62417487|NCT06366204|EXPERIMENTAL|Test Lysine Intake|Randomly assigned one of 7 test lysine intakes that range from deficient to excess (12mg/kg/d to 84mg/kg/d). Participants may complete up to 4 study days, at different randomly assigned intakes.
62798876|NCT00056979|EXPERIMENTAL|Fludarabine, CAMPATH-1H , Anti-CD45, FK506|Fludarabine will be given as a daily IV (intravenous, by vein) infusion for a total of 5 days. CAMPATH-1H will be given as a daily 4-hour IV (intravenous, by vein) infusion for three days. Anti-CD45 will be given as a daily 6-hour IV infusion over the next 4 days. To help prevent body from rejecting the transplant, the drug FK506 will be given, starting two days before the transplant and continuing for three months.
62798877|NCT00776971|EXPERIMENTAL|Sugar-sweetened soft drink|54g sugar/L, 180kJ/100mL
62798878|NCT00776971|EXPERIMENTAL|Aspartame-sweetened soft drink|1.5kJ/100mL
62798879|NCT00776971|ACTIVE_COMPARATOR|Semi-skimmed milk|202kJ/100mL
62025948|NCT04625803|EXPERIMENTAL|chemotherapy, PD-1 inhibitor and Apatinib|Participants received 5 preoperative cycles of PD-1 inhibitor and chemotherapy (mFOLFOX6), 2 months of apatinib, followed by surgery. Apatinib,PD-1 inhibitor and chemotherapy needed to be stopped for 4-6 months before operation. 1 month after surgery, 7 cycles of mFOLFOX6 combined with PD-1 monoclonal antibody were performed as adjuvant therapy.
62025949|NCT06486259||ventral|"Ventral half of the lung~.."
62025950|NCT06486259||Dorsal|Dorsal half of the lung
62025951|NCT03380442|EXPERIMENTAL|Psilocybin group|This group will receive a single oral 25mg dose of psilocybin under surveilled and safe conditions.
62417488|NCT02763007|EXPERIMENTAL|alogliptin+pioglitazone|A group who treat with alogliptin+pioglitazone: The Combination of Alogliptin 25 mg and pioglitazone 30 mg daily add on metformin for 28 week as extension and followed by 2 years of observation
62417489|NCT02763007|ACTIVE_COMPARATOR|alogliptin|A group who treat with alogliptin: Alogliptin 25 mg daily add on metformin for for 28 week as extension and followed by 2 years of observation
62417490|NCT02763007|ACTIVE_COMPARATOR|pioglitazone|A group who treat with pioglitazone: Pioglitazone 30 mg daily add on metformin for for 28 week as extension and followed by 2 years of observation
62798880|NCT00776971|PLACEBO_COMPARATOR|Water|0kJ/100mL
62798881|NCT00014079||Group 1|"DNA is examined for unstable elements (microsatellite instability and loss of heterozygosity) by analyzing at least 10 separate (CA)n-repeats localized to 5 separate chromosomes (5q, 8p, 15, 17p, and 18q). Loss of heterozygosity is analyzed for at least four chromosomal arms (5q, 8p, 17p, and 18q) and later other chromosomes (e.g., 1, 14, and 22). Immunohistochemistry is used to test for the presence or absence of the genes involved in DNA mismatch repair (hMLH1 and hMSH2).~Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment."
62798882|NCT04720521|EXPERIMENTAL|OE+white light|Using white light firstly to observe from esophagus to duodenum and then switch OE mode to observe from antrum to esophagus.
62798883|NCT04720521|NO_INTERVENTION|White light|Using White light to observe from esophagus to duodenum.
62798884|NCT02432586|OTHER|Intensive Education|Attendance of 2 intensive education sessions
62798885|NCT01515631||Study|Patients with alagille syndrome
62025952|NCT03380442|ACTIVE_COMPARATOR|Ketamine group|This group will receive a single intranasal 125mg dose of ketamine under surveilled and safe conditions.
62224173|NCT04870684||sucess of revascularization|group of patients for whom after thrombolysis neurological improvement will be observed and recanalization on imaging will be seen.
62224174|NCT01653067|EXPERIMENTAL|Rituximab, Temsirolimus, DHAP, intravenous|"This is a multicenter, open label, single arm, phase II study. There will be no placebo usage within this trial. In the part I, dose escalation part, of this trial 6 patients will be included in each dose level. There will be 4 cohorts, administering up to a maximum of 4 cycles 25 mg, 50 mg, 75mg or 100mg Temsirolimus in combination with Rituximab and DHAP.~Treatment regimen part I:~Part I - Cohort A, B, C, D, X Temsirolimus 25 (A), 50 (B), 75 (C),100 (D) or 15 (X) mg, Day 1, 8, Rituximab (375 mg/m² day 2) Dexamethasone 40mg day 3-6 Cisplatine 100 mg/m² day 3 Cytarabine 2x2 g/m² day 4~...repeat day 22, up to a maximum of 4 cycles~In the part II of the trial 40 patients will be included to receive the full target dose, established within the part I of the study."
62224175|NCT00398645|EXPERIMENTAL|Arm 1|
62224176|NCT03924908|EXPERIMENTAL|VRH|Virtual reality hypnosis
62224177|NCT03924908|ACTIVE_COMPARATOR|VR|Virtual reality
62224178|NCT02667587|EXPERIMENTAL|Nivolumab + Temozolomide + Radiotherapy|Nivolumab: specified dose on specified days; IV (intravenous) infusion Temozolomide: 75 mg (milligram)/meter squared daily during Radiotherapy, 4 week treatment break, 150 mg/meter squared Day 1-5 for Cycle 1 and increased to 200 mg/meter squared Day 1-5 for Cycle2-Cycle 6 as tolerated; orally (additional cycles may be permitted with approval of sponsor) Radiotherapy: 2 gray units (joule of radiation energy per kilogram) 5 times per week for 6 weeks
62417491|NCT04328311|EXPERIMENTAL|Active|Watermelon juice
62798886|NCT06409910|EXPERIMENTAL|Arm 1: Moderately Hypofractionated Radiotherapy|External beam radiotherapy 54 Gy in 20 fractions to prostate bed +/- 44 Gy in 20 fractions to pelvic lymph nodes delivered daily.
62025953|NCT03380442|NO_INTERVENTION|No-treatment group|This group will be included in the study as a no-treatment group, so that natural time-dependent changes in depressive symptoms can be controlled for and thus the antidepressive effects of ketamine and psilocybin treatment can be verified
62025954|NCT01479660|PLACEBO_COMPARATOR|Control|
62025955|NCT01479660|EXPERIMENTAL|Probiotic|
62025956|NCT02742727|EXPERIMENTAL|CAR-pNK Cell immunotherapy|Enrolled patients will receive CAR-pNK cell immunotherapy with a novel specific chimeric antigen receptor targeting CD7 antigen by infusion.
62025957|NCT06283979|EXPERIMENTAL|Interventional STIMULAN VG|"Ulcer bursectomy and debridement and STIMULAN VG insertion into the ulcer cavity.~Flap closure. Peri-operative antibiotics."
62025958|NCT06283979|ACTIVE_COMPARATOR|Standard of Care (SoC)|Ulcer bursectomy, debridement and flap closure. Peri-operative antibiotics.
62025959|NCT02328326|EXPERIMENTAL|CO-IMPACT|patient and supporter (dyad) receive one coaching session on action planning, communicating with providers, navigation skills and support skills; preparation by phone before patients' primary care visits; after-visit summaries by mail; and biweekly automated phone calls to prompt action on new patient health concerns
62025960|NCT02328326|ACTIVE_COMPARATOR|PACT|patient and their health supporter (dyad) will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
62025961|NCT02574546||Surgery|Women undergoing mastectomy are eligible for enrollment.
62025962|NCT02048384|EXPERIMENTAL|A - metformin alone|metformin alone Arm A patients will receive metformin 850mg orally twice a day on a 28 day cycle.
62025963|NCT02048384|ACTIVE_COMPARATOR|B - metformin + rapamycin|metformin + rapamycin Arm B patients will receive 850mg orally twice a day and rapamycin 4mg orally once a day on a 28 day cycle.
62025964|NCT03575923||Intervention site 1|2 planted trees; bulb planting
62025965|NCT03575923||Comparison site 1A|
62025966|NCT03575923||Comparison site 1B|
62025967|NCT03575923||Intervention site 2|12 planted trees; bulb planting; artificial tree decorations (string lights)
62025968|NCT03575923||Comparison site 2A|
62025969|NCT03575923||Comparison site 2B|
62025970|NCT03575923||Intervention site 3|3 planted trees; artificial tree decorations (string lights, tree socks)
62025971|NCT03575923||Comparison site 3A|
62025972|NCT03575923||Comparison site 3B|
62025973|NCT03575923||Intervention site 4|8 planted trees; bulb planting; artificial tree decorations (string lights, tree socks)
62025974|NCT03575923||Comparison site 4A|
62588668|NCT04256317|EXPERIMENTAL|Phase 3, Sequence A|Participants will receive ASTX030 in Cycle 1, followed by SC azacitidine in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
62025975|NCT03575923||Comparison site 4B|
62025976|NCT05028998||Veterans with Opioid Use Disorder receiving care through the Veterans Health Administration|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~Additionally, we will be recruiting 30 of these individuals to participate in our Aim 3 qualitative interviews."
62025977|NCT05028998||Veterans with Alcohol Use Disorder receiving care through the Veterans Health Administration|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
62025978|NCT05028998||Patients with Opioid Use Disorder for whom Market Scan Medicaid Claims data is available|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
62025979|NCT05028998||Patients with Alcohol Use Disorder for whom Market Scan Medicaid Claims data is available|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
62025980|NCT05028998||Patients with Opioid Use Disorder for whom Market Scan Commercial Insurance Claims data is available|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
62025981|NCT05028998||Patients with Alcohol Use Disorder for whom Market Scan Commercial Claims data is available|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
62025982|NCT05028998||Patients with Opioid Use Disorder receiving care outside of Veterans Health Administration|We will be recruiting 30 of these individuals to participate in our Aim 3 qualitative interviews.
62025983|NCT05028998||Opioid Use Disorder Treatment Providers who provide treatment in the Veterans Health Administration|We will be recruiting 15 of these individuals to participate in our Aim 3 qualitative interviews.
62025984|NCT05028998||Opioid Use Disorder Providers who treat outside the Veterans Health Administration|We will be recruiting 15 of these individuals to participate in our Aim 3 qualitative interviews.
62025985|NCT05028998||Opioid Use Disorder Treatment and Policy Decision Makers|We will be recruiting 20 of these individuals to participate in our Aim 3 qualitative interviews.
62025986|NCT02932618|EXPERIMENTAL|On-demand Treatment|Participants will receive recombinant von Willebrand factor (rVWF) treatment for non-surgical bleeding episodes over a 12 to 18-month period.
62025987|NCT02932618|EXPERIMENTAL|Elective Surgery|12-24 hours prior to surgery and within 3 hours of surgery. Minor surgery: infuse every 12-24 hours for at least 48 hours based on post-operative dosing. Oral Surgery: infuse at least once within first 8-12 hours post-surgery based on post-operative dosing. Major Surgery: infuse every 12-24 hours for at least first 96 hours post-surgery based on post-operative dosing.
62417492|NCT04328311|OTHER|Control|Low nitrate water.
62417493|NCT05282810||cartilage tympanoplasty|use cartilage in tympanoplasty for recuurent perforation
62588669|NCT04256317|EXPERIMENTAL|Phase 3, Sequence B|Participants will receive SC azacitidine in Cycle 1 followed by ASTX030 in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
62798887|NCT06409910|EXPERIMENTAL|Arm 2: Ultrahypofractionated Radiotherapy|External beam radiotherapy 30 Gy in 5 fractions to prostate bed +/- 25 Gy in 5 fractions to pelvic lymph nodes delivered on alternate days.
62025988|NCT02932618|EXPERIMENTAL|Emergency Surgery|Within 3 hours prior to surgery. Minor surgery: infuse every 12-24 hours for at least 48 hours based on post-operative dosing. Oral Surgery: infuse at least once within first 8-12 hours post-surgery based on post-operative dosing. Major Surgery: infuse every 12-24 hours for at least first 96 hours post-surgery based on post-operative dosing.
62025989|NCT00700687|EXPERIMENTAL|1|PA32540
62025990|NCT00700687|EXPERIMENTAL|2|PA32540 and celecoxib
62025991|NCT00700687|ACTIVE_COMPARATOR|3|aspirin and celecoxib
62025992|NCT06296719|EXPERIMENTAL|Chit-Chat|The Chit-Chat intervention, covering five areas, including (1) Serious illness in older adults, (2) Realities of caring and dying from a carer's perspective, (3) Introduction to the importance of advance care planning for individuals and communities, (4) Effective communication between older adults, family members, and healthcare professionals in ACP conversations (i.e. listening to the wishes and preferences of older adults regarding their needs), and (5) audience participation and clarification including questions, answers and concerns.
62025993|NCT06296719|NO_INTERVENTION|Waitlist Control|No intervention
62025994|NCT00679003|EXPERIMENTAL|1|Social learning and cognitive behavioral therapy (SLCBT)
62025995|NCT00679003|ACTIVE_COMPARATOR|2|Education and support (ES)
62025996|NCT00875680|EXPERIMENTAL|autoPPC|
62025997|NCT03431077|EXPERIMENTAL|LJPC-501|Angiotensin II administered via continuous infusion (1.25 - 40 ng/kg/min) for 24 hours up to 168 hours.
62025998|NCT03563495|ACTIVE_COMPARATOR|tissue engineered group|autogenous bone marrow derived and cultured stem cells loaded on collagen matrix was implanted in the alveolar cleft in the study group (1st arm)
62025999|NCT03563495|ACTIVE_COMPARATOR|autogenous bone graft group|autogenous cortico-cancellous bone graft harvested from the anterior iliac crest was implanted in the alveolar cleft of the control group (2nd arm)
62026000|NCT04834323|ACTIVE_COMPARATOR|group (1)|included 42 patients who were subjected to distal mesogastric fixation after laparoscopic sleeve gastrectomy
62026001|NCT04834323|NO_INTERVENTION|group (2)|included 42 patients who were subjected to laparoscopic sleeve gastrectomy alone without distal mesogastric fixation
62026002|NCT05818735|EXPERIMENTAL|the electroacupuncture group|the electroacupuncture and the placebo drug
62026003|NCT05818735|PLACEBO_COMPARATOR|the drug group|the sham acupuncture and the drug Escitalopram
62026004|NCT05450874||Training cohort|
62588670|NCT06597448|EXPERIMENTAL|Online CBT Group|Participants randomized to the Intervention group will attend a 9-week online CBT group co-led by a Public Health Nurse and a Peer (individual who has recovered from PPD and received training to deliver the intervention) in addition to receiving usual care.
62026005|NCT05450874||Validation cohort|
62026006|NCT02794493|EXPERIMENTAL|Arm I|Patients receive Traditional Chinese Medicine Formula LC09 by soaking their affected hand and feet 20 min twice daily.
62026007|NCT02794493|PLACEBO_COMPARATOR|Arm II|Patients receive placebo by soaking their affected hand and feet 20 min twice daily.
62026008|NCT02246998|EXPERIMENTAL|STB+iohexol|Participants will receive STB+iohexol for 24 weeks.
62026009|NCT02246998|EXPERIMENTAL|RTV+ATV+TVD+iohexol|Participants will receive RTV+ATV+TVD+iohexol for 24 weeks.
62026010|NCT02246998|EXPERIMENTAL|ATR+iohexol|Participants will receive ATR+iohexol for 24 weeks.
62026011|NCT02246998|EXPERIMENTAL|RTV+ATV+ABC/3TC+iohexol|Participants will receive RTV+ATV+ABC/3TC+iohexol for 24 weeks.
62026012|NCT04613414|EXPERIMENTAL|Early Management|Scheduled for sleep physician appointment within 1 month of home sleep apnea test/triage
62026013|NCT04613414|NO_INTERVENTION|Usual Care|Scheduled for sleep physician appointment approximately 6 months after home sleep apnea test/triage
62026014|NCT03321019||Healthy controls|Men and women between the ages of 45 and 85 years without Parkinson's disease, or any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
62026015|NCT03321019||Parkinson's disease|Men and women between the ages of 45 and 85 years with Parkinson's disease, and without any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
62026016|NCT01159938|EXPERIMENTAL|T2DM, albuminuria but normal kidney function|
62026017|NCT01159938|NO_INTERVENTION|Healthy participants|
62026018|NCT01159938|EXPERIMENTAL|T2DM, normal urinary albumin excretion rate (UAER)|
62026019|NCT00355082|EXPERIMENTAL|lamotrigine 300|300 mg/day treatment
62026020|NCT00355082|EXPERIMENTAL|lamotrigine 250|250 mg/day treatment
62026021|NCT03436979||Subjects|Subjects who are undergoing surgical treatment for uterine prolapse will be included in the study and will be treated using the NeuGuide™ System.
62026022|NCT00280332||A|colonic adenoma
62026023|NCT00280332||B|colonic without adenoma
62026024|NCT06413667||Control participants|Healthy control participants without intervention
62026025|NCT06413667||Chronic Whiplash Associated Disorder|Chronic Whiplash Associated Disorder without intervention
62026026|NCT06413667||Tension headache|Tension headache without intervention
62026027|NCT05509829|EXPERIMENTAL|NPWT group|Patients who receive NPWT after surgery.
62026028|NCT05509829|NO_INTERVENTION|Control group|Retrospective cohort who did not receive NPWT.
62026029|NCT02308436|EXPERIMENTAL|Candida Mouthwash with Curolox™ Peptide|Repeated applications 2.5 ml or 5 ml twice daily
62026030|NCT00822510|EXPERIMENTAL|Telephone Interpersonal Counseling|Telephone delivered interpersonal counseling support intervention. Intervention was for 8 weeks. Participants were called on the telephone each week for about 30 minutes.
62026031|NCT00822510|ACTIVE_COMPARATOR|Telephone delivered education only|Telephone delivered education only. Educational topics included prostate cancer health, side effects, physical activity, diet. Participants were called on the telephone each week for about 30 minutes.
62026032|NCT01782131|EXPERIMENTAL|Posaconazole (POS)|Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.
62798888|NCT02494986|EXPERIMENTAL|Rilpivirine|Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other antiretrovirals (ARVs).
62798889|NCT05939999|EXPERIMENTAL|Elastic tape (ET)|The group that will participate in the 8 weeks pulmonary rehabilitation protocol using the elastic tape.
62026033|NCT01782131|ACTIVE_COMPARATOR|Voriconazole|Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.
62026034|NCT03617640||Hirschsprung's disease patients|Children diagnosed with Hirschsprung's disease or Hirschsprung's disease associated enterocolitis
62026035|NCT03617640||control patients|Children diagnosed and treated for miscellaneous bowel diseases
62798890|NCT05939999|SHAM_COMPARATOR|Sham (SH)|The group that will participate in the pulmonary rehabilitation protocol using micropore tape.
62798891|NCT04633382|EXPERIMENTAL|Conducting research of enhanced recovery after surgery|"1. Informing the patient about the course of the operation and the postoperative period. Psychological preparation.~2. Refusal from complete starvation. Carbohydrate drink 2 hours before surgery.~3. Refusal of cleansing enemas.~4. Refusal of premedication. NSAIDs 30 minutes before surgery~5. Prevention of thromboembolic complications~6. Multimodal analgesia: epidural catheter, paracetamol.~7. Minimally invasive access.~8. Prevention of hypothermia~9. Targeted infusion therapy.~10. Failure or limited time use of drainages: gastric, intra-abdominal, bile duct drainage.~11. Early activation of the patient.~12. Early enteral nutrition.~13. Prevention of nausea and vomiting."
62026036|NCT06152120|EXPERIMENTAL|ACP Intervention arm|The group which will participate in nurse-facilitated advance care planning intervention.
62026037|NCT06152120|NO_INTERVENTION|Usual care arm|The group which will not participate in nurse-facilitated advance care planning intervention.
62224179|NCT02667587|PLACEBO_COMPARATOR|Nivolumab placebo + Temozolomide + Radiotherapy|Nivolumab Placebo: specified dose on specified days; IV infusion Temozolomide: 75 mg/meter squared daily during Radiotherapy, 4 week treatment break, 150 mg/meter squared Day 1-5 for Cycle 1 and increased to 200 mg/meter squared Day 1-5 for Cycle2-Cycle 6 as tolerated; orally (additional cycles may be permitted with approval of sponsor) Radiotherapy: 2 gray units 5x/week x 6 weeks
62026038|NCT04937374|ACTIVE_COMPARATOR|Rehmannia glutinosa leaf extract|One capsule to be taken after breakfast for 56 days
62026039|NCT04937374|PLACEBO_COMPARATOR|Microcrystalline Cellulose (MCC)|One capsule to be taken after breakfast for 56 days
62026040|NCT00390052|EXPERIMENTAL|Arm I|Patients will receive a 2-hour infusion of 3-AP once in week 1. Beginning in week 2, they will receive 3-AP by mouth twice a day 3 days a week for 3 weeks. Treatment with 3-AP by mouth may repeat every 4 weeks for as long as benefit is shown.
62026041|NCT04586140||Patients with COVID-19 infection|This study will be carried out on patient data usually collected as part of their care. The patients were infected with COVID-19 and hospitalized between 03/25/2020 and 05/07/2020, and who benefited from GAREC's intervention.
62026042|NCT04586140||Nursing staff AND GAREC Members|This study also concerns data collected in the context of semi-structured interviews with health professionals, in a prospective manner. These are caregivers who are members of GARED or who called on GAREC between 25/03/2020 and 07/05/2020.
62224180|NCT04592042|EXPERIMENTAL|Feel-Good-Group|Pre-post assessment of feasibility and putative efficacy of an emotion-oriented cognitive-behavioral group intervention over 8 sessions and four weeks.
62417494|NCT05282810||temporalis fascia graft in tympanoplasty|use temporalis fascia as a graft in tympanoplasty for recuurent perforation
62433465|NCT05198115|ACTIVE_COMPARATOR|Aerobic group|The intervention consisted of aerobic exercise training, which was taught to participants face-to-face at a meeting. At the end of the session, we provided the intervention group with CDs and educational posters containing all the exercises
62433466|NCT05198115|PLACEBO_COMPARATOR|Eight Weeks of Aerobic Exercise|The control group was subjected to all the pre-and post-assessments but were not asked to perform the exercise intervention. Instead, we phone-called them to give a reminder for filling out the questionnaires.
62026043|NCT02239887||WaveCrest LAA occlusion device|Left Atrial Occlusion
62026044|NCT03913273|EXPERIMENTAL|Intervention group|Intervention: AMI transtibial amputation
62026045|NCT03913273|ACTIVE_COMPARATOR|Control group|Intervention: Standard transtibial amputation
62026046|NCT02106468|ACTIVE_COMPARATOR|prednisone 50 mg tablet|This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
62026047|NCT02106468|ACTIVE_COMPARATOR|Omega-3 capsules 1000 mg|This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
62026048|NCT00566228|EXPERIMENTAL|Immunologic autograft engineering|Patients' stem cells are collected according to modified Amicus settings (i.e., MNC OFFSET = 0.0 and RBC = 7.0). Patients undergo ASCT IV on the day of apheresis (lymphocyte enriched autograft).
62026049|NCT00566228|ACTIVE_COMPARATOR|Standard autograft collection|Patients' stem cells are collected according to standard Amicus settings (i.e., MNC OFFSET = 1.5 and RBC OFFSET = 5.0). Patients undergo ASCT IV on the day of apheresis.
62026050|NCT01211626|ACTIVE_COMPARATOR|Part A, Group 1 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 200 mg of ANA773 (n=6) or placebo (n=2)
62026051|NCT01211626|ACTIVE_COMPARATOR|Part A, Group 2 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 400 mg of ANA773 (n=6) or placebo (n=2)
62026052|NCT01211626|ACTIVE_COMPARATOR|Part A, Group 3 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 800 mg of ANA773 (n=6) or placebo (n=2)
62026053|NCT01211626|ACTIVE_COMPARATOR|Part A, Group 4 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 1200 mg of ANA773 (n=6) or placebo (n=2)
62224181|NCT00153062|PLACEBO_COMPARATOR|Aggrenox, Clopidogrel placebo, Micardis|Aggrenox (25mg/200mg) bid, clopidogrel placebo qd, Micardis (80mg) qd
62224182|NCT00153062|PLACEBO_COMPARATOR|Aggrenox placebo, clopidogrel,, Micardis|Clopidogrel (75mg) qd; Aggrenox placebo bid, Micardis (80mg) qd
62224183|NCT00153062|PLACEBO_COMPARATOR|Aggrenox, clop placebo, micardis placebo|Aggrenox (25mg/200mg) bid, clopidogrel placebo qd, Micardis placebo qd
62224184|NCT00153062|PLACEBO_COMPARATOR|Aggrenox plcebo, clop, micardis placebo|Clopidogrel (75mg) qd, Aggrenox placebo bid, Micardis placebo qd.
62417495|NCT06628323|EXPERIMENTAL|Virtual Reality based therapy added real-time EEG-based neurofeedback (VR-NF)|Participants in the experimental group undergo 8 sessions of a manualized virtual reality-based intervention added real-time EEG neurofeedback aiming to enhance the control and sense of power in relation to the dominant hallucinated voice. Together with the therapist, the participants create a digital representation (avatar) in virtual reality corresponding to the visual perception and sound of the voice. During therapy, the participants will be encouraged to engage in a dialogue with the avatar. While immersed in virtual reality, EEG recordings will be conducted by electrodes connected to a cap on the participants' head. Processed EEG-data will provide real-time information on the participants' brain activity associated with the emotional distress when confronted with the avatar and will be visible both to the participant and therapist. The feedback will be used to continuously adjust the intervention to the brain activity and aims to help the participant practice emotion regulation.
62588671|NCT06597448|NO_INTERVENTION|Treatment as Usual|Participants randomized to the No Intervention group will continue to receive treatment as usual (standard postnatal care). A list of resources will be emailed.
62588672|NCT06457412|EXPERIMENTAL|Intervention Group|Intervention group for the treatment of childhood obesity
62588673|NCT06233916|OTHER|[14C] D-1553 group|Single arm study
62588674|NCT00454220|PLACEBO_COMPARATOR|Placebo|
62588675|NCT00454220|EXPERIMENTAL|0.01 mg MRrhTSH + 131-I arm|
62588676|NCT00454220|EXPERIMENTAL|0.03 mg MRrhTSH + 131-I arm|
62588677|NCT03218826|EXPERIMENTAL|Treatment (docetaxel, PI3Kbeta inhibitor AZD8186)|Patients receive docetaxel IV over 1 hour on day 1 and PI3Kbeta inhibitor AZD8186 PO BID for 5 days each week. Cycles repeat every 21 days until April 30, 2022 in the absence of disease progression or unacceptable toxicity.
62224185|NCT02810548|PLACEBO_COMPARATOR|OFD alone|Control group: including 15 defects that will receive open flap debridement (OFD).
62224186|NCT02810548|ACTIVE_COMPARATOR|PRF + OFD|Test group (1): including 15 defects that will receive platelet rich fibrin (PRF) with open flap debridement (OFD).
62224187|NCT02810548|ACTIVE_COMPARATOR|Bone + OFD|Test group (2): including 15 defects that will receive nanohydroxyapatite bone graft with open flap debridement OFD).
62224188|NCT02810548|ACTIVE_COMPARATOR|PRF + Bone + OFD|Test group (3): including 15 defects that will receive nanohydroxyapatite bone graft with platelet rich fibrin (PRF) after open flap debridement (OFD).
62588678|NCT06662487|EXPERIMENTAL|Free Weight Resistance Training (FWRT)|Participants in the experimental group will engage in a 10-week free weight resistance training program. This program will consist of 3 weekly sessions, including exercises such as squats, deadlifts, and bench presses, among others. The training will focus on progressively increasing the intensity, working within a range of 60% to 80% of the one-repetition maximum (1RM).
62026054|NCT01211626|ACTIVE_COMPARATOR|Part A, Group 5 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 1600 mg of ANA773 (n=6) or placebo (n=2)
62026055|NCT01211626|ACTIVE_COMPARATOR|Part B, Group 6 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 2000 mg of ANA773 (n=6) or placebo (n=2)
62026056|NCT01211626|ACTIVE_COMPARATOR|Part B, Group 7 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 1200 mg of ANA773 (n=6) or placebo (n=2)
62026057|NCT01211626|ACTIVE_COMPARATOR|Part B, Group 8 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 1600 mg of ANA773 (n=6) or placebo (n=2)
62026058|NCT01211626|ACTIVE_COMPARATOR|Part B, Group 9 HCV Infected Patient|multiple oral doses(5 administrations) every other day of 2000 mg of ANA773 (n=8) or placebo (n=2)
62026059|NCT02758431|PLACEBO_COMPARATOR|Group 1: Acyline plus placebo (No Testosterone Add-Back)|Acyline plus placebo gel and placebo tablet.
62026060|NCT02758431|ACTIVE_COMPARATOR|Group 2: Acyline plusTestosterone|Acyline plus transdermal testosterone gel plus placebo tablet.
62026061|NCT02758431|ACTIVE_COMPARATOR|Group 3: Acyline plus Testosterone plus Arimidex)|Acyline plus transdermal testosterone gel plus Aromatase inhibitor (Arimidex) oral.
62026062|NCT00741234|EXPERIMENTAL|A|Advanced solid tumors
62026063|NCT00741234|EXPERIMENTAL|B|Advanced hematologic malignancies
62026064|NCT00741234|EXPERIMENTAL|C|Myelodysplastic Syndrome
62026065|NCT03744156|EXPERIMENTAL|Cognitive Behavioral Treatment-Insomnia|Cognitive Behavioral Treatment-Insomnia. 8 Session treatment focusing on behavior and cognitions related to sleep and pain.
62026066|NCT03744156|EXPERIMENTAL|Sleep Hygiene Education|Sleep Hygiene Education. 8 Session treatment focusing on sleep hygiene education.
62588679|NCT06662487|NO_INTERVENTION|Control Group|Participants in the control group will not receive any intervention and will be instructed to continue with their usual daily routine. These participants will be evaluated pre- and post-intervention in the same manner as the experimental group but will not participate in the training program.
62588680|NCT01436877|EXPERIMENTAL|device|Insertion of Temporary Implantable Nitinol Device (TIND)
62026067|NCT05106257|EXPERIMENTAL|Condition #1|Education = short Walking training = on Inhaler training = on Caregiver support = on
62026068|NCT05106257|EXPERIMENTAL|Condition #2|Education = short Walking training = on Inhaler training = on Caregiver support = off
62026069|NCT05106257|EXPERIMENTAL|Condition #3|Education = short Walking training = on Inhaler training = off Caregiver support = on
62026070|NCT05106257|EXPERIMENTAL|Condition #4|Education = short Walking training = on Inhaler training = off Caregiver support = off
62026071|NCT05106257|EXPERIMENTAL|Condition #5|Education = short Walking training = off Inhaler training = on Caregiver support = on
62026072|NCT05106257|EXPERIMENTAL|Condition #6|Education = short Walking training = off Inhaler training = on Caregiver support = off
62433467|NCT02803723|EXPERIMENTAL|Holding-cuddling + Sucrose|The Holding-cuddling is started 5 minutes before and the sucrose administration is started 2 minutes before blood sampling.
62433468|NCT02803723|ACTIVE_COMPARATOR|Sucrose alone|The sucrose administration is started 2 minutes before blood sampling.
62433469|NCT04181996|PLACEBO_COMPARATOR|Placebo|Placebo: Sugar pill manufactured to mimic colchicine 0.6 mg capsule. Placebo to be taken once a day.
62433470|NCT04181996|EXPERIMENTAL|Colchicine|Colchicine: 0.6 mg colchicine capsule to be taken once a day.
62026073|NCT05106257|EXPERIMENTAL|Condition #7|Education = short Walking training = off Inhaler training = off Caregiver support = on
62026074|NCT05106257|EXPERIMENTAL|Condition #8|Education = short Walking training = off Inhaler training = off Caregiver support = off
62026075|NCT05106257|EXPERIMENTAL|Condition #9|Education = long Walking training = on Inhaler training = on Caregiver support = on
62026076|NCT05106257|EXPERIMENTAL|Condition #10|Education = long Walking training = on Inhaler training = on Caregiver support = off
62026077|NCT05106257|EXPERIMENTAL|Condition #11|Education = long Walking training = on Inhaler training = off Caregiver support = on
62026078|NCT05106257|EXPERIMENTAL|Condition #12|Education = long Walking training = on Inhaler training = off Caregiver support = off
62026079|NCT05106257|EXPERIMENTAL|Condition #13|Education = long Walking training = off Inhaler training = on Caregiver support = on
62026080|NCT05106257|EXPERIMENTAL|Condition #14|Education = long Walking training = off Inhaler training = on Caregiver support = off
62026081|NCT05106257|EXPERIMENTAL|Condition #15|Education = long Walking training = off Inhaler training = off Caregiver support = on
62026082|NCT05106257|EXPERIMENTAL|Condition #16|Education = long Walking training = off Inhaler training = off Caregiver support = off
62433471|NCT01311297||Perioperative ovarian cancer patients|
62224189|NCT00505284|PLACEBO_COMPARATOR|Placebo|
62026083|NCT01332877|EXPERIMENTAL|enriched breakfast|high carbohydrate, high protein breakfast providing 600 kcal, 50% carbohydrate, 20% protein, 30% fat
62026084|NCT03749551||Participants|diagnostic test - patients serving as their own controls
62026085|NCT03787368|EXPERIMENTAL|Dose 1 of BAY1213790|Single intravenous infusion BAY1213790 (Dose 1)
62026086|NCT03787368|EXPERIMENTAL|Dose 2 of BAY1213790|Single intravenous infusion BAY1213790 (Dose 2)
62026087|NCT03787368|PLACEBO_COMPARATOR|Placebo|Single intravenous infusion placebo
62026088|NCT04313634|EXPERIMENTAL|Dasatinib plus Quercetin Treatment Goup|Subjects will receive Dasatinib (D; 100 mg for two days) plus Quercetin (Q; 1000 mg total daily for three consecutive days taken orally on an intermittent schedule (starting every 28 days) with no-therapy periods in between dosing regimens, repeated every 28 days over 20 weeks, resulting in five total dosing periods throughout the entire intervention
62026089|NCT04313634|EXPERIMENTAL|Fisetin Treatment Group|Subjects will receive Fisetin (F; \~20 mg/kg/day for three consecutive days) taken orally on an intermittent schedule (starting every 28 days) with no-therapy periods in between dosing regimens, repeated every 28 days over 20 weeks, resulting in five total dosing periods throughout the entire intervention
62026090|NCT04313634|NO_INTERVENTION|Untreated Control Group|Subjects will not receive any intervention
62224190|NCT00505284|ACTIVE_COMPARATOR|Perampanel 2mg|
62224191|NCT00505284|ACTIVE_COMPARATOR|Perampanel 4mg|
62433472|NCT01311297||Pregnant patients|
62433473|NCT01311297||Female healthy volunteers|
62588681|NCT06665126|EXPERIMENTAL|Test Product Group|Participants in this group will receive the test product, a prebiotic and probiotic supplement.
62026091|NCT02360709||CRE8 group|CRE8 sirolimus-eluting stent
62026092|NCT02588391|EXPERIMENTAL|Active Brain Training|"The children in this arm receive one type of Brain Training with online computer games that actively matches their skill level."
62026093|NCT02588391|EXPERIMENTAL|Passive Brain Training|"The children in this arm receive one type of Brain Training with online computer games that are at a consistent skill level."
62026094|NCT02588391|OTHER|Cross-over|"Following completion of the 6-month follow-up sessions after completion of Brain Training, each group is allowed to cross-over to the other arm of Brain Training (open-label extension)."
62026095|NCT00804947|EXPERIMENTAL|Intravenous busulfan and melphalan|
62026096|NCT03974880||patency group|Freedom from restenosis or clinically driven re-intervention in the treated lesion at 1,3,6,12 months after procedures
62026097|NCT03974880||restenosis group|Restenosis was defined as a reduction in the luminal diameter of more than 50 percent according to any imaging examinations such as duplex ultrasound, CTA, MRI or DSA Re-intervention in the treated segment for the clinical progression at 1,3,6,12 months after procedures
62026098|NCT03974880||the second adverse events group|a composite of all-cause death, myocardial infarction, and stroke and any amputation at 1,3,6,12 months after procedures
62026099|NCT05147818||Cases|"200 Diabetic patients of 18 year and older (either type 1or 2) presented by AKI based on KIDIGO Definition \& Staging. KDIGO definition of AKI: Increase in serum creatinine by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 h, or Increase in serum creatinine to ≥1.5 times baseline that is known or presumed to have occurred within the prior 7 days, or Urine volume \<0.5 mL/kg/h for 6 h.~KDIGO staging of AKI: (1) stage 1: Serum creatinine 1.5-1.9 × baseline or ≥0.3 mg/dL (≥26.5 µmol/L) increase / Urine output \<0.5 mL/kg/h for 6-12 h (2) stage 2; Serum creatinine 2.0-2.9 × baseline / Urine output \<0.5 mL/kg/h for ≥12 h (3) stage 3: Serum creatinine 3.0 × baseline, increase in serum creatinine to ≥4.0 mg/dL (≥353.6 µmol/L), initiation of renal replacement therapy, or, in patients \<18 years, decrease in eGFR to \<35 mL/min per 1.73 m2 / Urine output \<0.3 mL/kg/h for ≥24 h or anuria for ≥12 h ."
62224192|NCT00505284|ACTIVE_COMPARATOR|Perampanel 6mg|
62433474|NCT04575038|EXPERIMENTAL|Brequinar 100 mg|Brequinar oral capsules 100 mg x 5 days
62433475|NCT04575038|PLACEBO_COMPARATOR|Placebo|Placebo for Brequinar capsules x 5 days
62224193|NCT00505284|ACTIVE_COMPARATOR|Perampanel 8mg|
62224194|NCT01731509|ACTIVE_COMPARATOR|Standard FETO|Group of fetus that undergo fetal endoscopic tracheal occlusion between 26 0/7 weeks and 28 6/7 weeks.
62224195|NCT01731509|EXPERIMENTAL|Early FETO|Group of fetus that undergo fetal endoscopic tracheal occlusion between 22 0/7 weeks and 24 6/7 weeks.
62224196|NCT02335710||Smith & Nephew Journey II BCS TKA|Subjects must be implanted with a Smith \& Nephew Journey II bi-cruciate stabilizing (BCS) total knee arthroplasty (TKA) implanted by Dr. Harold Cates
62224197|NCT02335710||Normal knee|Subjects must have a healthy, functioning knee with no osteoarthritis or knee pathologies
62224198|NCT06006689|PLACEBO_COMPARATOR|Placebo group|Qishen Yiqi Dripping Pills placebo, 3 bags, take orally after meals, 3 times a day
62433476|NCT01999387||Completed OIT|Patients who completed OIT \>6 months prior to enrollment
62433477|NCT00333333||SGA infants|Infants who are thought to be small for gestational age (SGA)
62588682|NCT06665126|PLACEBO_COMPARATOR|Active Placebo Group|Participants in this group will receive an active placebo.
62588683|NCT06665126|PLACEBO_COMPARATOR|Excipient Placebo Group|Participants in this group will receive an excipient placebo.
62224199|NCT06006689|EXPERIMENTAL|Low dose group|Low dose Qishen Yiqi Dripping Pills, 3 bags, take orally after meals, 3 times a day
62224200|NCT06006689|EXPERIMENTAL|High dose group|High dose Qishen Yiqi Dripping Pills, 3 bags, take orally after meals, 3 times a day
62224201|NCT02501798|EXPERIMENTAL|Drug: Methylphenidate|Drug: Methylphenidate 7 days dosage as (prior to study) clinically titrated long acting Equasym (brand)
62224202|NCT02501798|ACTIVE_COMPARATOR|Drug: Placebo|Drug: Placebo 7 days Empty green-yellow capsule
62026100|NCT05147818||Controls|200 Diabetic patients of 18 year and older with no AKI (either type 1or 2) Matched to controls in age ,sex
62026101|NCT02563912|EXPERIMENTAL|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
62026102|NCT02563912|ACTIVE_COMPARATOR|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
62026103|NCT01230697||Sofanenib and Hypophosphatemia|Patients with advanced renal cells carcinoma and hepatocarcinoma in treatment with Sorafenib
62026104|NCT06244784|EXPERIMENTAL|Intervention Group|Participants in the intervention group will receive the training course on healthy work environment
62224203|NCT01248780|EXPERIMENTAL|Golimumab + methotrexate (MTX)|Participants will receive golimumab 50 mg as subcutaneous (SC) (under the skin) injections administered every 4 weeks for up to 48 weeks. In addition, participants will receive a stable dose of MTX.
62224204|NCT01248780|EXPERIMENTAL|Placebo + methotrexate (MTX)|Participants will be administered Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48. In addition, participants will receive a stable dose of MTX.
62224205|NCT06171581|EXPERIMENTAL|experimental-stress ball|"The study is planned to consist of two groups as experimental and control.~No intervention will be given to the control group."
62224206|NCT06171581|EXPERIMENTAL|no intervention- none|"The study is planned to consist of two groups as experimental and control.~No intervention will be given to the control group."
62224207|NCT02112838|ACTIVE_COMPARATOR|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
62224208|NCT02112838|ACTIVE_COMPARATOR|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
62224209|NCT02112838|PLACEBO_COMPARATOR|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
62224210|NCT04690868|EXPERIMENTAL|ARM 1|Period 1 : Reference Drug(AD-2131) Period 2 : Test Drug(AD-213-A)
62224211|NCT04690868|EXPERIMENTAL|ARM 2|Period 1 : Test Drug(AD-213-A) Period 2 : Reference Drug(AD-2131)
62224212|NCT00933855||communication training workshop|"The patient intervention is a 1 hour communication workshop entitled: Getting the Most out of your Doctor's Visit. The workshops will be offered to both patients and family members, but data will be collected only for patients. The workshops will be held on location at Queens Cancer Center."
62026105|NCT06244784|NO_INTERVENTION|Control Group|
62026106|NCT06218017|EXPERIMENTAL|HFNO first|This study follows a crossover design employing a randomized controlled methodology. Patients undergoing gastrointestinal endoscopy and receiving deep sedation were monitored using electronic tracheal sound auscultation. Within this group, patients first underwent a 10-minute session of high-flow nasal oxygen (50 L/min) followed by the utilization of the standard low-flow nasal oxygen (4 L/min). Electronic tracheal sound recordings were obtained during both the high-flow and low-flow nasal oxygen administrations. The aim is to develop an algorithm capable of mitigating the noise generated specifically by the high-flow nasal oxygen.
62026107|NCT06218017|ACTIVE_COMPARATOR|HFNO later|This study follows a crossover design employing a randomized controlled methodology. Patients undergoing gastrointestinal endoscopy and receiving deep sedation were monitored using electronic tracheal sound auscultation. Within this group, patients first underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min). Electronic tracheal sound recordings were obtained during both the high-flow and low-flow nasal oxygen administrations. The aim is to develop an algorithm capable of mitigating the noise generated specifically by the high-flow nasal oxygen
62224213|NCT00901186|EXPERIMENTAL|RFB002|RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.
62026108|NCT01503905|ACTIVE_COMPARATOR|Docetaxel plus epirubicin|
62026109|NCT01503905|ACTIVE_COMPARATOR|docetaxel plus epirubicin plus cyclophosphamide|
62224214|NCT00901186|ACTIVE_COMPARATOR|Laser photocoagulation|At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.
62224215|NCT01506609|EXPERIMENTAL|Veliparib with Temozolomide|Veliparib 40 mg twice daily (BID) Days 1 through 7 plus TMZ 150 to 200 mg/m\^2 QD Days 1 through 5 in each 28-day cycle.
62433478|NCT00333333||Pre-eclampsia exposed|Infants who are born to mothers who had pre-eclampsia
62026110|NCT05462366||Mother|healthy mothers
62026111|NCT05462366||Infant|healthy infants
62026112|NCT01793792|OTHER|Device: LVIS|"The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.~Device: LVIS™ and LVIS™ Jr. MicroVention Low-profile Visualized Intraluminal Support Device"
62798892|NCT04633382|PLACEBO_COMPARATOR|Conducting research of traditional recovery after surgery|"1. Informing the patient about the course of the operation and the postoperative period. Psychological preparation.~2. Fasting for 2 days~3. Use of cleansing enemas. Bowel preparation~4. Premedication~5. Prevention of thromboembolic complications~6. Without multimodal analgesia~7. Traditional access.~8. Prevention of hypothermia~9. Targeted infusion therapy.~10. Use of drains: gastric, intra-abdominal, bile duct drainage.~11. Activation of patients within 2 days.~12. Enteral nutrition after 2 days after surgery.~13. Without the use of metoclopramide"
62224216|NCT01506609|PLACEBO_COMPARATOR|Placebo with Carboplatin and Paclitaxel|Placebo BID Days 1 through 7 plus carboplatin target area under the curve (mg•min/mL) (AUC) 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m\^2 administered on Day 3 of each 21-day cycle.
62224217|NCT01506609|EXPERIMENTAL|Veliparib with Carboplatin and Paclitaxel|Veliparib 80 mg BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m\^2 administered on Day 3 of each 21-day cycle.
62224218|NCT04961658|EXPERIMENTAL|Treatment Arm - Dose Cohort 1|Participants will receive a single dose of GEM00220 at 15 million cells
62224219|NCT04961658|EXPERIMENTAL|Treatment arm - Dose Cohort 2|Participants will receive a single dose of GEM00220 at 60 million cells
62798893|NCT04053166|EXPERIMENTAL|Individualized home-based physical activity|The subjects of this arm will have a daily goal in number of steps based on the initial 2 first week evaluation of daily number of steps. They will wear connected wrists, and will be contacted twice a month by phone call by the adapted physical activity trainer to revaluate these goals.
62798894|NCT04053166|ACTIVE_COMPARATOR|Control group|The subjects of this arm will not have evaluation of daily steps and recommendations regarding physical activity and sedentary behaviour. They will be asked to live as usual.
62798895|NCT01854970|EXPERIMENTAL|Patient|
62798896|NCT00930085|EXPERIMENTAL|SELDI-TOF MS|The proteic profiling is performed by SELDI-TOF mass spectroscopy.
62798897|NCT06073652|ACTIVE_COMPARATOR|Control formula group|The Control Formula group will receive 1st age infant formula exclusively for the first six months.
62798898|NCT06073652|EXPERIMENTAL|Experimental formula group|The Experimental Formula group will receive 1st age infant formula identical to Control formula, but supplemented with a HMO blend and a probiotic exclusively for the first six months.
62798899|NCT06415461|EXPERIMENTAL|Arm 1: Low dose|The first three subjects will receive the 30 x 106 TNC dose.
62798900|NCT06415461|EXPERIMENTAL|Arm 2: Medium Dose|The next three subjects will receive the 60 x 106 TNC dose.
62224220|NCT04961658|EXPERIMENTAL|Treatment arm - Dose Cohort 3|Participants will receive a single dose of GEM00220 at 150 million cells
62224221|NCT04961658|EXPERIMENTAL|Treatment arm - Dose Cohort 4|Participants will receive two doses of GEM00220 at 150 million cells each, seperated by 24 hours
62224222|NCT01828788|EXPERIMENTAL|Ropivacaïne|Prospective, controlled, randomised, parallel, single-centre, single-blinded trial, comparing to a control (conventional care with no locoregional anaesthesia) an infusion of ropivacaine through two multihole catheters placed lateral to the sternum. In both groups, postoperative analgesia will be achieved by paracetamol plus titrated then self-administered intravenous morphine.
62224223|NCT01828788|PLACEBO_COMPARATOR|Placebo|Prospective, controlled, randomised, parallel, single-centre, single-blinded trial, comparing to a control (conventional care with no locoregional anaesthesia) an infusion of ropivacaine through two multihole catheters placed lateral to the sternum. In both groups, postoperative analgesia will be achieved by paracetamol plus titrated then self-administered intravenous morphine.
62224224|NCT04932668|EXPERIMENTAL|Home-based Electrical Stimulation Program for lower limb spasticity|Single arm prospective intervention study to assess the feasibility and impact of a home-based program. Patient will apply home-based NMES on their leg for 20 minutes, 5 days a week for 4 weeks. At the end of the study, an outcome measures will be assessed and patient will be required to answer a questionnaires on their experience.
62433479|NCT00285415|OTHER|Doc and Car|Receiving Doc and Car
62433480|NCT00553033||A|
62798901|NCT06415461|EXPERIMENTAL|Arm 3: High Dose|The next three subjects will receive the 90 x 106 TNC dose.
62798902|NCT06363734|EXPERIMENTAL|osimertinib in combination with dalpiciclib|
62798903|NCT00992355|ACTIVE_COMPARATOR|Tobramycin 0.3% - Dexamethasone 0.1%|
62798904|NCT00992355|ACTIVE_COMPARATOR|Tobramycin-Dexamethasone plus Ketorolac tromethamine|
62798905|NCT05161923||Per oral endoscopy myotomy|The per-oral endoscopic myotomy, or POEM, is a minimally invasive surgical procedure for the treatment of achalasia wherein the inner circular muscle layer of the lower esophageal sphincter is divided through a submucosal tunnel.\[1\] This enables food and liquids to pass into the stomach, a process that is impaired in achalasia. The tunnel is created, and the myotomy performed, using a flexible endoscope, meaning the entire procedure can be done without external incisions.
62798906|NCT03842033|OTHER|PEAKmAAP|"The Pulmonary Education and Asthma Knowledge mobile asthma action plan (PEAKmAAP) group will use a mobile app that will help manage asthma. Participants will be asked to enter asthma symptoms or peak flow every day. The PEAKmAAP guides participants when to take asthma medicines and sends reminders to take their medicines every day. mAAP also provides reminders when to get asthma medicines refilled. Asthma education messages and video links are also pushed via notification."
62798907|NCT03842033|OTHER|PEAKmAAP-Data Sharing (DS)|PEAKmAAP with Data Sharing (PEAKmAAP-DS) group will be asked to enter asthma symptoms or peak flow every day. The PEAKmAAP guides participants when to take asthma medicines and sends reminders to take their medicines every day. PEAKmAAP also provides reminders when to get asthma medicines refilled. Asthma education messages and video links are also pushed via notification. The primary care provided (PCP) will receive monthly reports to help them know how the participant's asthma symptoms are over time.
62798908|NCT03842033|OTHER|Nutrition Map (NutriMap) Usual Care|Participants in this arm will use a smartphone application that sends daily non-asthma-related reminder for attention control. Participants will be asked to log their daily fruits and vegetables eaten. Participants will answer survey questions about their asthma and symptoms management.
62026113|NCT02624804|EXPERIMENTAL|Stem Cell Educator Therapy|"Patients will have apheresis performed and then have their own blood returned to them with the educated lymphocytes"
62433481|NCT03418077|EXPERIMENTAL|energy drink|Participants will serve as their own controls and have repeated measures obtained to determine if there is a difference between the placebo-control and energy drink arms
62026114|NCT06495008||Patients|Patients with cancer having finished immunotherapy \>2 yrs ago
62026115|NCT06495008||caregivers|Caregivers of patients with cancer
62026116|NCT04242927|EXPERIMENTAL|Nicotinic acid + Routine care|Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care.
62026117|NCT04242927|ACTIVE_COMPARATOR|Routine care|Routinely apply urea ointment and provide best supportive care.
62026118|NCT01018901|EXPERIMENTAL|Arm I|Patients and their partners complete surveys. Sexual function of men is assessed by the International Index of Erectile Function; sexual function of women is assessed by the Female Sexual Function Index.
62026119|NCT04680221|ACTIVE_COMPARATOR|Treatment|The transversus abdominis plane block is a procedure involving injection of a local anesthetic solution into the abdominal plane between the internal oblique muscle and the transversus abdominis muscle. In our institution, this is done under ultrasound guidance which is the current standard to improve efficacy and limit complications. Liposomal bupivacaine uses an innovative technology consisting of lipid-based particles containing active pharmaceutical agent (bupivacaine) which extends the duration of the medication through a process of gradual release for metabolism.This drug delivery technology extends the duration of action to up to 96 hours when given at a dose of 266 mg liposomal bupivacaine admixed with 30 ml of bupivacaine 0.25% and 30 ml of saline. Forty ml of solution is deposited on the left side of the abdomen and 40 ml on the right.
62224225|NCT02550470||Randomized to Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.7,8
62224226|NCT02550470||Randomized to Drager 800 Absorbent|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
62417496|NCT06628323|ACTIVE_COMPARATOR|Virtual Reality - based therapy|Participants in the control group will be offered 8 sessions of a manualized virtual reality - based therapy that follows the same principles as described in the experimental arm. Together with the therapist, the participants create a digital representation (avatar) in virtual reality that corresponds to their visual perception of and sounds like their hallucinated voice. Thoughout the therapy sessions, the participants will be encouraged to engage in a dialogue with the 'avatar', voiced by the therapist who will alternate between talking as the 'avatar' and as a supportive therapist. The therapy aims at enhancing the participants' control and feeling of power in relation to the dominant hallucinated voice. Furthermore, the therapy focuses on regulating the emotional distress associated with the hallucinated voice.
62798909|NCT05072938|ACTIVE_COMPARATOR|Nizatidine Monotherapy|Nizatidine Monotherapy
62798910|NCT05072938|EXPERIMENTAL|Rebamipide/Nizatidine Combination Therapy|Rebamipide/Nizatidine Combination Therapy
62798911|NCT02875379|EXPERIMENTAL|HME|Passive humidification with heat and moisture exchanger, Y-piece circuit.
62798912|NCT02875379|EXPERIMENTAL|HH33|Heated humification (MR 730, Fisher \& Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
62798913|NCT02875379|EXPERIMENTAL|HH37|Heated humification (MR 730, Fisher \& Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
62798914|NCT02875379|EXPERIMENTAL|NoH|Passive humidification, double tube circuit
62026120|NCT04680221|PLACEBO_COMPARATOR|Control|The transversus abdominis plane block will be performed under ultrasound guidance with deposition of 80 ml of saline (40 ml on either side).
62026121|NCT06226376|ACTIVE_COMPARATOR|EXOPULSE Mollii Suit Stimulation Active.|This will be the EXOPULSE Mollii Suit Active Stimulation. Stimulation will go on for 60 minutes while control unit is on for 60 minutes.
62026122|NCT06226376|SHAM_COMPARATOR|EXOPULSE Mollii Suit Stimulation Sham.|This will be the EXOPULSE Mollii Suit Sham Stimulation. Stimulation will go on for 1 minute then it turns off while the control unit will remain on for total of 60 minutes
62026123|NCT04269928||Adrenal Artery Ablation|Patients in the intervention group will be treated with ablation of adrenal gland by endovascular injection of dehydrated alcohol
62026124|NCT04269928||Adrenalectomy|Patients in this group will be treated with unilateral laparoscopic adrenalectomy
62026125|NCT06634914|EXPERIMENTAL|Moonbrew 30 Days|30 Days of the Moonbrew Sleep cocktail consumed before bed.
62798915|NCT03342417|EXPERIMENTAL|Neoadjuvant Breast Cancer|"Newly diagnosed patients who have Stage II-III breast cancer, with the primary cancer in place. These patients have not received prior therapy for their breast cancer and intend to undergo surgery after completion of investigational neoadjuvant therapy.~Each patient will be treated with two 6-week treatment cycles of Nivolumab 240 mg administered by intravenous (IV) infusion over 30 minutes and Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes. Nivolumab is given every two weeks (q2w) whereas Ipilimumab is given every 6 weeks (q6w), both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1 and 43. On these days, Ipilimumab is to be given immediately after Nivolumab."
62798916|NCT03342417|EXPERIMENTAL|Platinum-resistant ovarian cancer|Platinum-resistant/refractory ovarian cancer (PRROC) patients. Each patient will be treated with four 6-week treatment cycles of Nivolumab 240 mg administered by IV infusion over 30 minutes and Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes. Nivolumab is given q2w whereas Ipilimumab is given q6w, both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1, 43, 85 and 127. On these days, Ipilimumab is to be given immediately after Nivolumab.
62026126|NCT06670326|EXPERIMENTAL|Baseline-Preparation-Imagery Rescripting-Post Treatment|Each participant follows this sequence: (1) 5-9 weeks waitlist during which no treatment is offered; (2) 4 weekly preparatory sessions. During these sessions the rationale of ImRs will be explained in more detail and a list of painful (childhood) memories to be addressed with ImRs is to be compiled, based on any further input from the patient; and a case conceptualization is made; (3) 12 sessions (45-60 minutes) of ImRs will be offered to participating patients. The ImRs treatment will be based upon the protocol described by Arntz \& Weertman (1999). This protocol can be modified to tailor the needs of this study more specifically. (4) After end of active treatment (ImRs) 4 weeks follow during which only weekly assessments are done.
62798917|NCT03342417|EXPERIMENTAL|Advanced gastric cancer patients|"Advanced gastric cancer patients who are recurrent/refractory to a prior therapy not involving herceptin.~Each patient will be treated with four 6-week treatment cycles of Nivolumab and Ipilimumab . Nivolumab is given q2w whereas Ipilimumab is given q6w, both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1, 43, 85 and 127. On these days, Ipilimumab is to be given immediately after Nivolumab."
62798918|NCT00852865|EXPERIMENTAL|1|24 healthy volunteers consuming L.farciminis during three weeks
62026127|NCT01815177|EXPERIMENTAL|Arthroscopic transosseous fixation|Patients with torn rotator cuff randomized to experimental treatment receive a complete arthroscopic transosseous cuff repair
62026128|NCT01815177|OTHER|Repair using suture anchors|Patients randomized to this arm receive an arthroscopic rotator cuff repair using suture anchors.
62026129|NCT03398538|EXPERIMENTAL|Mirragen Wound Matrix Dressing|MIRRAGEN™ Advanced Wound Matrix is intended for the use in the management of wounds including diabetic ulcers. Wound matrix dressing to be used per manufacturer instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing
62026130|NCT03398538|ACTIVE_COMPARATOR|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
62224227|NCT02550470||Randomized to Drager Free|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
62224228|NCT00528645|EXPERIMENTAL|Treatment (saracatinib)|Patients receive oral AZD0530 once daily for up to 2 years in the absence of disease progression or unacceptable toxicity. Blood samples are obtained at baseline and periodically during study to determine levels of circulating tumor cells for defined translational studies.
62224229|NCT00435591|EXPERIMENTAL|Dose Regimen 1|Placebo loading dose + 20mg/day continuous infusion conivaptan per ampoule
62224230|NCT00435591|EXPERIMENTAL|Dose Regimen 2|Conivaptan loading dose (20mg)+ 20mg/day continuous infusion conivaptan per ampoule
62224231|NCT00435591|EXPERIMENTAL|Dose Regimen 3|Placebo loading dose + 20mg/day continuous infusion conivaptan per premix bag
62224232|NCT00435591|EXPERIMENTAL|Dose Regimen 4|Conivaptan loading dose (20mg) + 20mg/day continuous infusion conivaptan per premix bag
62026131|NCT00774735|EXPERIMENTAL|Sequence 1|
62026132|NCT00774735|EXPERIMENTAL|Sequence 2|
62026133|NCT05582434|EXPERIMENTAL|One gel treatment|Every participant will be instructed to apply a topical retinoid every day.
62026134|NCT05582434|EXPERIMENTAL|Two gel treatment|One-third of the participants will be instructed to apply adapalene and the clindamycin phosphate/benzoyl peroxide gel every day.
62224233|NCT02561754|ACTIVE_COMPARATOR|Face-To-Face/CD|Delivery: Face-to-face Diet: Conventional diet
62224234|NCT02561754|EXPERIMENTAL|Technology delivery/CD|Delivery: Technology Diet: Conventional diet
62224235|NCT02561754|EXPERIMENTAL|Technology delivery/eSLD|Delivery: Technology Diet: enhanced Stop Light Diet
62224236|NCT02951767|EXPERIMENTAL|Cohort 1: Treatment-naive Cisplatin Ineligible Participants|Participants with advanced disease who are treatment-naive for advanced urothelial carcinoma and cisplatin ineligible will receive atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
62417497|NCT04112667||Normal Macular Health|\>=60 years old with no macular disease
62224237|NCT06328751|EXPERIMENTAL|Case Group|The case group will watch a 7-minute immersive virtual reality video of mindfulness meditation with image and sound in the office of the Oncology Control Center Foundation (FCECON), using Samsung® gear VR virtual reality glasses and Samsung® smart watch.
62417498|NCT04112667||Early Macular Degeneration|\>=60 years old with early age-related macular degeneration
62417499|NCT04112667||Young Normals|20-30 years old with normal macular health
62026135|NCT05582434|EXPERIMENTAL|Three gel treatment|One-third of the participants will be instructed to apply adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day.
62026136|NCT06348394|ACTIVE_COMPARATOR|Intracardiac echocardiography Left atrial appendage closure.|Intra cardiac echocardiography will be performed prior to left atrial appendage closure.
62026137|NCT06348394|PLACEBO_COMPARATOR|Traditional transesophageal echocardiography guided Left atrial appendage closure|Transesophageal Echocardiography will be performed under general anesthesia.
62026138|NCT02278601|EXPERIMENTAL|MPIB modified programmed intermittent bolus|Modified programmed intermittent bolus (MPIB) up-down frequency of 5mls ropivacaine/fentanyl solution in bolus with epidural delivery system
62026139|NCT02278601|EXPERIMENTAL|CIPCEA|computer integrated patient controlled epidural analgesia (CIPCEA) up-down variable basal infusion of ropivacaine/fentanyl solution with epidural delivery system
62026140|NCT02278601|ACTIVE_COMPARATOR|patient controlled epidural analgesia with basal infusion|patient controlled epidural analgesia (PCEA) with fixed basal infusion of ropivacaine/fentanyl solution with epidural delivery system
62798919|NCT00852865|PLACEBO_COMPARATOR|2|24 healthy volunteers consuming placebo during three weeks
62798920|NCT03292068|EXPERIMENTAL|Acupuncture, acupressure|"Intervention with Pyonex-needles \& Usual care; applied to the acupoints LI4 , LI11, PC6 and ST36 bilaterally before surgery. Pyonex needles are embedded in a 2 mm round plastic piece sitting on a round, skin friendly patch of about 8 mm in diameter. The patch can remain for seven days. The needle can be stimulated by gently touches the plastic bubble by the patch.~Intervention Acupressure \& Usual care; a 'kulplåster (1.5 mm a ball on a small piece of adhesive tape) both ears before postoperative drug administration. Kulplåster can remain for ten days or until they fall off. Children and their parents will be asked to fill in a diary of when the needle is stimulated, for what reason and when the symptoms are alleviated. In the diary is also filled in on the kulplåster remains."
62798921|NCT03292068|EXPERIMENTAL|Timbal diet|"Timbal diet including ice cream \& Usual care.The specially designed diet, originally made for patients suffering of dysphagia, named timbalkost will be used. The specially designed food/diet, timbalkost will be given as lunch and dinner. The consistency of timbalkost is smooth. It does not require more thorough processing of the mouth. As a snack, a protein-enriched ice cream, made with egg yolks and cream, will be made available. The food will be given to the child for 3-7 days depending on how quickly the child can return to normal food. A powder that jellify liquids to facilitate swallowing will also be used if and when needed. The children or their parents will be asked to fill in a food diary during one week after surgery."
62026141|NCT05469321||Patients|patients presenting to the CHU of Nîmes for an acute or subacute neurological picture after having consumed N2O.
62224238|NCT06328751|ACTIVE_COMPARATOR|Active Control Group|The active control group will watch a 7-minute mindfulness meditation video presented via cell phone with image and sound in the office of the Oncology Control Center Foundation (FCECON), using a Samsung® smart watch.
62224239|NCT06328751|ACTIVE_COMPARATOR|Passive Control Group|The passive control group will perform meditation breathing exercises based on instructions and through an audio played from the health professional for 4 minutes in the office of the Oncology Control Center Foundation (FCECON), using a Samsung® smart watch.
62026142|NCT03223298|EXPERIMENTAL|Botulinum Toxin Type A|The intramuscular injections will be performed with the patient awake in the oral and maxillofacial surgery clinic. Three injection sites into bilateral masseter muscles and two injection sites into bilateral temporalis muscles will be identified by having the patient clench. The sites will be marked with a surgical pen prior to injections. The skin at the injection sites will be cleaned with an alcohol swab. Via a 1cc TB syringe and a 30-gauge needle, the subject will then receive 100 units of reconstituted botulinum toxin A. 37.5 units will be injected into each masseter muscle and 12.5 units into each temporalis muscle. A written post-operative instruction sheet will be provided to all patients.
62224240|NCT00559702|EXPERIMENTAL|1|Natalizumab IV (Participants with secondary progressive multiple sclerosis)
62224241|NCT00559702|EXPERIMENTAL|2|Natalizumab IM (Participants with secondary progressive multiple sclerosis)
62224242|NCT00559702|EXPERIMENTAL|3|Natalizumab SC (Participants with secondary progressive multiple sclerosis)
62224243|NCT00559702|OTHER|4|Standard of care as determined by the Investigator and Treating Neurologist (Participants with secondary progressive multiple sclerosis)
62224244|NCT00559702|EXPERIMENTAL|5|Natalizumab SC (Participants with relapsing forms of multiple sclerosis)
62224245|NCT00559702|EXPERIMENTAL|6|Natalizumab IV (Participants with relapsing forms of multiple sclerosis)
62224246|NCT05316415|EXPERIMENTAL|Acemaşiran Music Group|Listening to Acemaşiran music for 40 minutes in successive three days and two times a day (noon and evening) Routine clinical care
62224247|NCT05316415|NO_INTERVENTION|Control Group|Routine clinical care
62224248|NCT02075541|EXPERIMENTAL|10-AS01E group|Subjects in this group will receive the investigational NTHi vaccine.
62417500|NCT02548117|ACTIVE_COMPARATOR|Finasteride|ARM 1 subjects will receive finasteride 5 mg orally daily.
62417501|NCT02548117|NO_INTERVENTION|No Treatment|The ARM 2 (control group) will not receive any study treatment.
62417502|NCT06102824|EXPERIMENTAL|Organoid-guided treatment|Subjects randomized to the organoid-guided treatment (OGT) group will be treated with the drugs predicted to be the most sensitive through PDO drug sensitivity screening. Drugs that the subjects have progressed on before randomization will not be screened. The drugs selected for organoid screening are from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).
62798922|NCT03292068|OTHER|Extended telephone counseling|Extended telephone counseling \& Usual care : A nurse will contact the child, or the child´s parents, by telephone on day 1, 3, 5 and 10 for extended telephone counseling postoperatively (POD), to provide support and information. The child's well-being will be assessed, response given to queries and concerns, advice and explanations related to the problems expressed or identified, proper interventions will be promoted and reassurance provided. The nurse will fill in a protocol on what topics the counseling was about at each call and the child and/or parent a diary.
62026143|NCT03223298|PLACEBO_COMPARATOR|0.9% Sodium Chloride Injection|The intramuscular injections will be performed with the patient awake in the oral and maxillofacial surgery clinic. Three injection sites into bilateral masseter muscles and two injection sites into bilateral temporalis muscles will be identified by having the patient clench. The sites will be marked with a surgical pen prior to injections. The skin at the injection sites will be cleaned with an alcohol swab. Via a 1cc TB syringe and a 30-gauge needle, the subject will then receive unpreserved 0.9% sodium chloride. A written post-operative instruction sheet will be provided to all patients.
62026144|NCT05911854|EXPERIMENTAL|Study group (A) Multi-waved Locked System Laser group|
62026145|NCT05911854|EXPERIMENTAL|Study group (B) Cold Compression Therapy group|
62026146|NCT05911854|ACTIVE_COMPARATOR|Group (C) Control group|
62026147|NCT05930093|PLACEBO_COMPARATOR|Placebo|Placebo without active ingredient
62026148|NCT05930093|ACTIVE_COMPARATOR|2 cap.LivPhcD/per day|515mg/LivPhcD cap. 2 cap./per day
62026149|NCT05930093|ACTIVE_COMPARATOR|4 cap.LivPhcD/per day|515mg/LivPhcD cap. 4 cap./per day, BID
62026150|NCT05930093|ACTIVE_COMPARATOR|6 cap.LivPhcD/per day|515mg/LivPhcD cap. 6 cap./per day, TID
62026151|NCT01101737|NO_INTERVENTION|Usual care|Patients not invited to the nurse-led clinic will continue with usual GP care
62026152|NCT01101737|EXPERIMENTAL|Nurse-led blood pressure clinic|Patients randomly allocated to the intervention will be invited to a specialist nurse-led blood pressure clinic.
62026153|NCT04745676|EXPERIMENTAL|Experimental|The SICG program consists of the Serious Illness Conversation Guide as well as training and system-level support for physicians to conduct ACP conversations.
62026154|NCT05916508|ACTIVE_COMPARATOR|Positive Control|2 brushings per day (AM and PM)
62224249|NCT02075541|PLACEBO_COMPARATOR|Control group|Subjects in this group will receive placebo.
62224250|NCT01948726|EXPERIMENTAL|Hypofractionation with SIB|
62433482|NCT03418077|PLACEBO_COMPARATOR|Placebo-control|Participants will serve as their own controls and have repeated measures obtained to determine if there is a difference between the placebo-control and energy drink arms
62798923|NCT05099796|ACTIVE_COMPARATOR|Transforaminal epidural steroid injection (TESI) group|"This procedure was applied only once.~1 to 2 cc of the contrast agent (300 mg/50 mL iohexol) was given and the distribution pattern was visualized. Once the epidural distribution of the contrast agent was confirmed without vascular flow, a mixture of 40 mg (1mL) of triamcinolone acetonide, 2 cc of physiological saline, and 2 cc (0.5%) of bupivacaine was injected."
62224251|NCT05502549|EXPERIMENTAL|CB03-154 SAD 10mg|Participants will receive CB03-154 10mg orally once daily in a fasted state.
62224252|NCT05502549|PLACEBO_COMPARATOR|Placebo SAD 10mg|Participants will receive placebo 10mg orally once daily in a fasted state.
62224253|NCT05502549|EXPERIMENTAL|CB03-154 SAD 20mg|Participants will receive CB03-154 20mg orally once daily in a fasted state.
62588684|NCT06665035|EXPERIMENTAL|Cohort 1: Tetravalent Dengue Vaccine (TDV) 0.5 mL (Age group: >=12 to <21 months)|Participants with the age group \>= 12 to \< 21 months receive TDV 0.5 mL subcutaneous (SC) injection, on Day 1 and Day 90.
62224254|NCT05502549|PLACEBO_COMPARATOR|Placebo SAD 20mg|Participants will receive placebo 20mg orally once daily in a fasted state.
62224255|NCT05502549|EXPERIMENTAL|CB03-154 SAD 30mg|Participants will receive CB03-154 30mg orally once daily in a fasted state.
62224256|NCT05502549|PLACEBO_COMPARATOR|Placebo SAD 30mg|Participants will receive placebo 30mg orally once daily in a fasted state.
62798924|NCT05099796|ACTIVE_COMPARATOR|Caudal epidural steroid injection (CESI) group|"This procedure was applied only once~1 to 2 cc of the contrast agent (300 mg/50 mL iohexol) was given and the distribution pattern was visualized which showed bilateral L5-S3 distribution without vascular flow. A mixture of 40 mg (1mL) of triamcinolone acetonide, 7 cc of physiological saline, and 2 cc (0.5%) of bupivacaine was injected. A total of 10 cc mixture was used for CESI."
62026155|NCT05916508|SHAM_COMPARATOR|Negative Control|2 brushings per day (AM and PM)
62798925|NCT04174690|EXPERIMENTAL|Balance|Volunteers aged from 18 years to over 60 years were selected without compromise. The tests were performed in a single session lasting 1 hour where the volunteers will do the tests on the force platform.
62798926|NCT02839850|EXPERIMENTAL|ATTUNE Cementless RP TKA|Subjects will receive a cementless, rotating platform total knee arthroplasty
62798927|NCT06727461|EXPERIMENTAL|Home-based Feeding EnhancEment in Dementia (Feed@home)|"1. Within 3 days after discharge, a nurse will conduct a teleconsultation (30-45 minutes) with the caregiver to assess feeding issues, and offer recommendations and caregiver education materials on feeding strategies.~2. In Weeks 1-3 after discharge, there will be 2 home visits by speech therapists (each time 45 - 60 minutes) to assess feeding issues at home and provide instructions on feeding techniques and training.~3. In week 4, there will be a teleconsultation with the nurse (30 - 45 minutes) to discuss any problems arising.~4. In Weeks 5-8 after discharge, there will be a home visit by nurse (45 - 60 minutes), followed by a teleconsultation with the nurse in the final week (30 - 45 minutes). An additional visit by the speech therapist may be arranged if needed.~5. The intervention will be resumed after any pauses resulting from patient readmissions to the hospital."
62798928|NCT06727461|NO_INTERVENTION|Control|The patient will receive usual care from the hospital and follow-up care as instructed by the hospital.
62798929|NCT01764711|EXPERIMENTAL|Low Salt Diet POTS|Each participant will be asked to sit in a chair for 30 minutes prior to a blood draw. Then a small dose of cosyntropin is administered intravenous. Blood samples will be drawn again at 30 minutes and 60 minutes after the drug has been given.
62798930|NCT01764711|EXPERIMENTAL|Low Sodium Diet Controls|Each participant will be asked to sit in a chair for 30 minutes prior to a blood draw. Then a small dose of cosyntropin is administered intravenous. Blood samples will be drawn again at 30 minutes and 60 minutes after the drug has been given.
62798931|NCT03871062|ACTIVE_COMPARATOR|topical anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times
62026156|NCT05916508|EXPERIMENTAL|Experimental Control|Brush with Positive control in the morning and negative control in the evening
62026157|NCT05639738|OTHER|All subject|Clinical and instrumental measurements
62588685|NCT06665035|EXPERIMENTAL|Cohort 1: Placebo (Age group: >=12 to <21 months)|Participants with the age group \>= 12 to \< 21 months receive placebo (normal saline), SC injection, on Day 1 and Day 90.
62026158|NCT04307186|EXPERIMENTAL|Gadobutrol + Gadoquatrane|Participants will receive one intravenous (IV) injection of gadobutrol 0.1 millimole(s) gadolinium/kilogram body weight (mmol Gd/kg bw) and one IV injection of Gadoquatrane (BAY1747846).
62026159|NCT01367262|EXPERIMENTAL|Radiolabeled LY2886721|Single 25 milligram (mg) oral dose containing 80 microCuries of radiolabeled LY2886721
62026160|NCT02919579|EXPERIMENTAL|Part A: Sequence ABC (Placebo+Alcohol+Esketamine)|Participants will receive intranasal placebo on Day 1 and oral placebo on Day 2 \[Treatment A\] in Period 1, then intranasal placebo on Day 1 and Oral alcohol on Day 2 \[Treatment B\] in Period 2, followed by intranasal esketamine on Day 1 and oral placebo on Day 2 \[Treatment C\] in Period 3.
62026161|NCT02919579|EXPERIMENTAL|Part A: Sequence BCA (Placebo+Alcohol+Esketamine)|Participants will receive Treatment B in Period 1, then Treatment C in Period 2, followed by Treatment A in Period 3.
62224257|NCT05502549|EXPERIMENTAL|CB03-154 SAD 45mg|Participants will receive CB03-154 45mg orally once daily in a fasted state.
62224258|NCT05502549|PLACEBO_COMPARATOR|Placebo SAD 45mg|Participants will receive placebo 45mg orally once daily in a fasted state.
62224259|NCT05502549|EXPERIMENTAL|CB03-154 FE 20mg|Participants will receive CB03-154 20mg orally once daily in a fed state.
62224260|NCT05502549|EXPERIMENTAL|CB03-154 MAD 10mg|Participants will receive CB03-154 10mg orally once daily in a fasted state, for 14 consecutive days.
62588686|NCT06665035|EXPERIMENTAL|Cohort 2: TDV 0.5 mL(Age group: >=6 to <12 months)|Participants with the age group \>=6 to \<12 months receive TDV, 0.5 mL SC injection, on Day 1 and Day 90.
62798932|NCT03871062|EXPERIMENTAL|two step anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.2 ml subconjunctival injection
62798933|NCT03811444|EXPERIMENTAL|simulation of skin pricking type 420|The evaluator simulated the capillary blood sampling with the safety lancet type 420
62224261|NCT05502549|PLACEBO_COMPARATOR|Placebo MAD 10mg|Participants will receive placebo 10mg orally once daily in a fasted state, for 14 consecutive days.
62224262|NCT05502549|EXPERIMENTAL|CB03-154 MAD 20mg|Participants will receive CB03-154 20mg orally once daily in a fasted state, for 14 consecutive days.
62417503|NCT06102824|ACTIVE_COMPARATOR|Treatment of physician's choice|Subjects randomized to the treatment of physician's choice (TPC) group will receive physician-chosen therapy from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).
62798934|NCT03811444|EXPERIMENTAL|simulation of skin pricking type 430|The evaluator simulated the capillary blood sampling with the safety lancet type 430
62798935|NCT03811444|EXPERIMENTAL|simulation of skin pricking type 520|The evaluator simulated the capillary blood sampling with the safety lancet type 520
62224263|NCT05502549|PLACEBO_COMPARATOR|Placebo MAD 20mg|Participants will receive placebo 20mg orally once daily in a fasted state, for 14 consecutive days.
62224264|NCT05502549|EXPERIMENTAL|CB03-154 SAD 5mg|Participants will receive CB03-154 5mg orally once daily in a fasted state.
62224265|NCT05502549|PLACEBO_COMPARATOR|Placebo SAD 5mg|Participants will receive placebo 5mg orally once daily in a fasted state.
62224266|NCT06258460|EXPERIMENTAL|the two-day psychotherapy training program with 8-week follow-ups intervention group|All participants from the intervention group will receive the two-day psychotherapy training program. They will receive a hard copy booklet of the psychotherapy training program at recruitment. In addition, supervision-based group meeting will be hold at week 1, 2, 4, and 8 during follow-ups, and each meeting will be lasted for approximately two hours. At each follow-up meeting, the teachers, including psychotherapists and psychiatrists, will be prepared to answer any psychotherapy related questions, encourage them to practice psychological interventions, and provide more information for participants' clinical application of psychotherapy.
62224267|NCT06258460|PLACEBO_COMPARATOR|the wail-list control group|After consent is given, participants who are allocated to the wail-list control group will receive a message encouraging them to complete all questionnaires from baseline to the last follow-up at 8 weeks. They will receive messages via WeChat to thank them for being in the study and reminding them of the time until the completion of the study at 8 weeks follow-up. They will receive a digital booklet of the psychotherapy training program via the WeChat individual messaging platform at recruitment, or a hard copy on request. After the trial ends, participants in the control arm will be able to receive the psychotherapy training program for free.
62224268|NCT01650246|EXPERIMENTAL|lesinurad 400 mg|
62224269|NCT01586637|EXPERIMENTAL|Art Therapy|This group performed dance classes and regarding the art therapy they have art classes where they learn how to use the drawing to express feelings. The classes were twice a week.
62224270|NCT01586637|EXPERIMENTAL|Walking|The group walked twice a week during one hour.
62224271|NCT04842097|EXPERIMENTAL|Mindfulness-based stress reduction intervention|Online 8-week group program, once per week
62026162|NCT02919579|EXPERIMENTAL|Part A: Sequence CAB (Placebo+Alcohol+Esketamine)|Participants will receive Treatment C in Period 1, then Treatment A in Period 2, followed by Treatment B in Period 3.
62026163|NCT02919579|EXPERIMENTAL|Part A: Sequence CBA (Placebo+Alcohol+Esketamine)|Participants will receive Treatment C in Period 1, then Treatment B in Period 2, followed by Treatment A in Period 3.
62026164|NCT02919579|EXPERIMENTAL|Part A: Sequence ACB (Placebo+Alcohol+Esketamine)|Participants will receive Treatment A in Period 1, then Treatment C in Period 2, followed by Treatment B in Period 3.
62026165|NCT02919579|EXPERIMENTAL|Part A: Sequence BAC (Placebo+Alcohol+Esketamine)|Participants will receive Treatment B in Period 1, then Treatment A in Period 2, followed by Treatment C in Period 3.
62026166|NCT02919579|EXPERIMENTAL|Part B: Placebo+Esketamine|Participants will receive intranasal placebo on Day 1, followed by intranasal esketamine on Days 4, 8, 11, 15, 18, 22 and 25.
62224272|NCT04842097|NO_INTERVENTION|Waiting list|Controls will not receive any intervention during this time. They are on chronic pain clinics waiting list
62224273|NCT02936128|EXPERIMENTAL|TruSkin®|Cryopreserved skin allograft
62224274|NCT02936128|ACTIVE_COMPARATOR|Wound Cover|Active Comparator for Venous Leg Ulcers
62417504|NCT06617858|EXPERIMENTAL|AMB-05X|
62798936|NCT05503186|EXPERIMENTAL|Text Message Intervention Study Condition|The intervention is a text message intervention. Text messages will provide guidance on secure storage and disposal of prescription opioids to participants who have been dispensed a prescription opioid. Participants in the intervention study condition will receive a series of text messages that aim to facilitate secure storage and disposal of unused opioid prescriptions.
62798937|NCT05503186|ACTIVE_COMPARATOR|Control Study Condition|Participants assigned to the control study condition will not receive the text message intervention. Participants assigned to the control study condition will receive a standard of care of treatment which is whatever guidance that is provided to them by their physician and/or pharmacist.
62026167|NCT03678948|ACTIVE_COMPARATOR|Radiofrequency-Based Debridement|The Smith and Nephew WEREWOLF COBLATION System is indicated for all soft tissue types in the knee. The WEREWOLF COBLATION System is a FDA cleared bipolar, radiofrequency electrosurgical system designed for use in orthopaedic/arthroscopic surgical procedures.
62224275|NCT00371228|EXPERIMENTAL|1|Umbilical cord not cut until pulsation stops, in order to provide additional blood to newborn.
62224276|NCT00371228|NO_INTERVENTION|2|Umbilical cord cut soon after birth without waiting for pulsing to stop.
62224277|NCT06096987|EXPERIMENTAL|Electronic medical record portal video group|Assigned to receive videos regarding electronic medical record portals and information shared in electronic medical record portals
62026168|NCT03678948|ACTIVE_COMPARATOR|Mechanical Debridement|
62026169|NCT04712526||AEON Endostapler|Stapling performed with AEON Endostapler
62026170|NCT03277222|ACTIVE_COMPARATOR|IN insulin 40 IU|Drug: IN insulin Dosage form: intranasal Dose: 40 IU Frequency: bid Duration: 16 weeks
62026171|NCT03277222|PLACEBO_COMPARATOR|IN Sterile Saline|Drug: Sterile Saline Dosage form: intranasal Frequency: bid Duration: 16 weeks
62026172|NCT00538161|EXPERIMENTAL|Low tidal volume arm|
62026173|NCT00538161|ACTIVE_COMPARATOR|Conventional tidal volume arm|
62224278|NCT06096987|ACTIVE_COMPARATOR|General adolescent health video group|Assigned to receive videos regarding general adolescent health issues
62026174|NCT03931434|ACTIVE_COMPARATOR|Aged Garlic Extract (AGE)|2400mg of Aged Garlic Extract (AGE)
62026175|NCT03931434|PLACEBO_COMPARATOR|Placebo|The Placebo does not contain any Aged Garlic Extract (AGE)
62026176|NCT00497380|EXPERIMENTAL|Arginine enriched nutrition|
62026177|NCT00497380|PLACEBO_COMPARATOR|Nutrition|
62026178|NCT05227287||ADH 1/2 DMS|Participants with ADH1 or ADH2. No investigational product will be administered to participants in this study. Participants will only receive standard of care (SoC) treatment as directed by the participants' treating physicians.
62026179|NCT06422741|EXPERIMENTAL|grape seed proanthocyanidin extract|Participants will receive the grape seed proanthocyanidin extract (GSPE) for 6 weeks.
62026180|NCT06422741|PLACEBO_COMPARATOR|Placebo|Participants will receive the placebo for 6 weeks.
62026181|NCT03631186||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
62026182|NCT03434119|EXPERIMENTAL|Soliqua 100/33|Soliqua 100/33 (Insulin glargine/lixisenatide) once daily in the morning within 1 hour before breakfast, on top of oral anti-diabetic drug (OAD) therapy for 26 weeks.
62026183|NCT03434119|ACTIVE_COMPARATOR|Lantus|Lantus (Insulin glargine) once daily at any time of the day but at about the same time every day on top of OAD therapy for 26 weeks.
62026184|NCT05200923|EXPERIMENTAL|Pelvic health Electrically Evoked Recording (PEER) 2 Study|Collect physiological signals
62026185|NCT03376321|EXPERIMENTAL|Treatment Arm 1 (pimodivir + Standard-of-Care [SOC] treatment)|Participants will receive pimodivir 600 milligram (mg) orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in the protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment is determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of SOC cannot be changed (example, switching one influenza antiviral for another) during either treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in case of suspected adverse event (AE).
62026186|NCT03376321|PLACEBO_COMPARATOR|Treatment Arm 2 (placebo + SOC treatment)|Participants will receive placebo matching to pimodivir orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than day of first study drug intake. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either treatment period/extension phase, with the exception that an influenza antiviral may be discontinued in case of a suspected AE.
62026187|NCT05610553|EXPERIMENTAL|3D printing guide plate group|3D-printed customized guide plate will be used to guide the puncture in percutaneous disc decompression surgeries.
62798938|NCT02147756|ACTIVE_COMPARATOR|CO2RE|Fractional CO2 laser system that utilizes a sealed off, all metal carbon dioxide gas tube that is Radio Frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The system has a programmable 2 axis scanning laser beam device that allows the physician to select the skin area coverage from a selection of predetermined patterns in different sizes based on the skin area to be treated. The versatility of the fractional CO2RE system enables precise, effective and simultaneous treatment of the skin's surface in the middle, and deep dermal levels.
62798939|NCT02147756|ACTIVE_COMPARATOR|RePair|Fractional CO2 system that comprises an infrared laser controlled by an embedded processor and a handpiece that directs the laser treatment. The device laser has a wavelength of 10.6μm and its tissue chromophore is water. It delivers multiple low energy pulses in microscopic spots as the handpiece glides over the skin surface. The selected energy determines the depth and width for each microscopic treatment zone (MTZs).
62798940|NCT02534415|ACTIVE_COMPARATOR|Periodontal dressing material|Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
62433483|NCT05983237|EXPERIMENTAL|Camre+Fluzo+TMZ|This arm will enroll patients who has advanced melanoma with a genetic HR mutation/ alteration .
62798941|NCT02534415|EXPERIMENTAL|0.2% Hyaluronic acid gel|0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
62026188|NCT05610553|ACTIVE_COMPARATOR|Conventional guidance group|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
62026189|NCT03002181|EXPERIMENTAL|PNE group|Pain neurophysiology education group.
62026190|NCT03002181|EXPERIMENTAL|Red Flag group|Red Flags education group.
62026191|NCT06635252||Patients with Alzheimer's disease|Prospective cohort study based on data from the Stockholm Creatinine Measurements (SCREAM) project. Patients diagnosed with AD and mixed dementia and registered in the Swedish Registry for Cognitive/Dementia Diseases are included.
62798942|NCT02534415|EXPERIMENTAL|0.8% Hyaluronic acid gel|0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
62026192|NCT02015897|ACTIVE_COMPARATOR|Physical TherapyB|Group B
62026193|NCT02015897|PLACEBO_COMPARATOR|Physical TherapyA|Group A
62026194|NCT02116634|EXPERIMENTAL|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
62026195|NCT05267041|EXPERIMENTAL|Cohort of Adults with lung cancer|Patients newly diagnosed with lung cancer.
62026196|NCT03958903|EXPERIMENTAL|Neurophysiological recording and stimulation of amygdala|Recording and stimulation of amygdala using Neuropace RNS devices at certain points through out the behavioral tasks.
62417505|NCT03927989|EXPERIMENTAL|Treatment Arm|Advice to quit and brief discussion of tobacco use plus dual nicotine replacement therapy plus 8 weeks of gain-framed text messages tailored to lung cancer screening patients
62798943|NCT01900795|EXPERIMENTAL|V117957|
62798944|NCT01900795|ACTIVE_COMPARATOR|Ibuprofen|
62798945|NCT01900795|PLACEBO_COMPARATOR|Placebo|
62798946|NCT04168229|EXPERIMENTAL|ITE Hearing Aid|The subjects will wear the ITE devices in a field test for 10 +/-7 days. At the second and third visits they will perform speech testing in the lab in three randomized conditions (unaided, aided with ITE, and aided with BTE).
62798947|NCT04168229|ACTIVE_COMPARATOR|BTE Hearing Aid|The subjects will wear the BTE devices in a field test for 10 +/-7 days. At the second and third visits they will perform speech testing in the lab in three randomized conditions (unaided, aided with ITE, and aided with BTE).
62417506|NCT03927989|ACTIVE_COMPARATOR|Standard Care|Advice to quit and brief discussion of tobacco use
62417507|NCT00774722|EXPERIMENTAL|Metronidazole|
62798948|NCT03294590|EXPERIMENTAL|Oral health text messages (OHT)|Participants in this arm will receive the OHT parent targeted text messages to reduce caries and improve oral health behaviors among low income families visiting community-based, urban pediatric clinics.
62798949|NCT03294590|ACTIVE_COMPARATOR|Child wellness text messages (CWT)|Participants in this arm will receive the CWT parent targeted text messages to improve child wellness (e.g., reading time, safety) among low income families visiting community-based, urban pediatric clinics.
62026197|NCT02358577|EXPERIMENTAL|Cycle ergometry|Participants will receive In-bed cycling for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first).
62026198|NCT02358577|ACTIVE_COMPARATOR|Usual care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization
62026199|NCT01415791|EXPERIMENTAL|Active 1|8 subjects will receive ICI176,334-1
62026200|NCT03607305|ACTIVE_COMPARATOR|BP limb 70cm|Patients underwent a RYGB with a biliopancreatic limb of 70cm
62026201|NCT03607305|EXPERIMENTAL|BP limb 120cm|Patients underwent a RYGB with a biliopancreatic limb of 120cm
62026202|NCT04298567||Treatment|Female and male patients with a diagnosis of CAD or symptomatic PAD will be enrolled within 4 weeks after the decision for treatment with rivaroxaban 2.5mg \[BID\] plus ASA 75mg \[OD\] has been made by the investigator.
62026203|NCT06092996|NO_INTERVENTION|Sling|Participants in the sling group will wear a sling according to current standard of care: 3 weeks postoperatively (2 weeks all the time, 3rd week at night and while in the community)
62026204|NCT06092996|EXPERIMENTAL|No Sling|Participants in the no sling group will only wear a sling for three days postoperatively
62026205|NCT00607451|EXPERIMENTAL|1|
62026206|NCT00607451|EXPERIMENTAL|2|
62026207|NCT00607451|EXPERIMENTAL|3|
62026208|NCT00607451|EXPERIMENTAL|4|
62417508|NCT00774722|PLACEBO_COMPARATOR|Placebo|
62417509|NCT03603405|EXPERIMENTAL|Experimental: ADV/HSV-tk (gene therapy)|"Experimental: ADV/HSV-tk (gene therapy)~The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 30 sessions (over 6 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent with the radiotherapy dependent on patient status based on best clinical judgment following the Stupp protocol.~Patient can receive second treatment of HSV-tk after 6 months."
62224279|NCT01800084|EXPERIMENTAL|Patients undergoing SPECT-CT|"The patients in this study are scheduled for a SPECT-CT at the Nîmes University Hospital as part of their normal care regimen.~Intervention: Device: Asir Image Acquisition"
62417510|NCT04382560|EXPERIMENTAL|Intervention group|The intervention group will receive a Deep Breathing Training and a Compassion Intervention. Deep Breathing Training and Compassion Intervention will be administered once, on two consecutive days, and will last for 30 minutes.
62417511|NCT04382560|NO_INTERVENTION|Wait-list control group|The waiting list group will receive the intervention at the end of the study.
62417512|NCT03457727|EXPERIMENTAL|Subjects receiving danirixin: Part A|Subjects will receive a single oral dose of 50 mg danirixin reference and test formulations with food and 240 mL of water in a cross-over manner.
62417513|NCT03457727|EXPERIMENTAL|Subjects receiving danirixin without omeprazole: Part B|Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) in fasted or fed state in a cross-over manner.
62417514|NCT03457727|EXPERIMENTAL|Subjects receiving danirixin with omeprazole: Part B|Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) along with once daily 40 mg OMP capsule in fasted or fed state in a cross-over manner.
62417515|NCT03526679|EXPERIMENTAL|Experimental arm|The combination of lenvatinib and eribulin
62417516|NCT05317000|ACTIVE_COMPARATOR|Arm A: 5-azacytidine|"Patients will receive 5-azacytidine 75mg/m2 IV daily x 5. Treatment must begin on a Monday.~Patients will receive anti-emetic premedication with prochlorperazine 10 mg IV, a 5HT3 antagonist per institutional guidelines, aprepitant or fos-aprepitant, and prn lorazepam on day 1. Day 2-5 patients will receive prochlorperazine 10 mg IV. Subsequent day 5HT3 antagonist therapy will be determined per institutional guidelines, as recommendations vary based on the half-life of the agent chosen. PRN lorazepam can be used days 2-5.~Dexamethasone will be reserved for patients who are not controlled by the initial regimen.~A single cycle of 5-azacytidine will be administered and the patient scheduled for surgery in the period of day 16 through day 18."
62224280|NCT03120247|ACTIVE_COMPARATOR|DEX I|OTM Dexmetetomidine 1µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
62224281|NCT03120247|ACTIVE_COMPARATOR|DEX II|OTM Dexmetetomidine0.75µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
62417517|NCT05317000|ACTIVE_COMPARATOR|Arm B: Nivolumab|"Nivolumab will be administered at a dose of 240 mg IV day 1 and day 15. Treatment must be given on a Monday or Tuesday.~No premedication will be given. Patients will be observed following the initial dose of nivolumab per institutional Surgery will be scheduled in the period of day 16 through day 18."
62417518|NCT05317000|EXPERIMENTAL|Arm C: Combination 5-azacytidine and Nivolumab|"Patients will receive 5-azacytidine 75mg/m2 IV daily x 5. Treatment must begin on a Monday. 5-azacytidine will be given prior to nivolumab on day 2.~Patients will receive anti-emetic premedication with prochlorperazine 10 mg IV, a 5HT3 antagonist per institutional guidelines, aprepitant or fos-aprepitant, and prn lorazepam on day 1. Day 2-5 patients will receive prochlorperazine 10 mg IV. Subsequent day 5HT3 antagonist therapy will be determined per institutional guidelines, as recommendations vary based on the half-life of the agent chosen. PRN lorazepam can be used days 2-5.~Nivolumab will be administered at a dose of 240 mg IV day 2 and day 16. No additional premedication will be given on day 16. Dexamethasone will be reserved for patients whose nausea and/or emesis is not controlled by the initial regimen. Surgery will be scheduled in the period of day 17 through day 18."
62417519|NCT06537440|EXPERIMENTAL|Acupuncture group|Patients take the supine position, acupuncture site local use of 75% alcohol cotton balls to disinfect the acupuncture point acupuncture point, tianshu acupuncture point diastolic the needle, the rest of the acupuncture point finger cut method into the needle, fast into the needle, the acupuncture point area has numbness, distension, sinking and radiating sensation, that is, to obtain the feeling of the needle. Foot Sanli line twisting tonic method, Tianshu, Zhigou line twisting diarrhea three times. Stimulation for 30 min, continuous wave 10 Hz, current intensity 0.5 \~ 4 m A to the extent tolerated by the patient. The connection mode was one group of Tianshu points, one group of ipsilateral Zhigou and Hegu points, and one group of ipsilateral Fengsanli and Shangjiuxu points. 1 time/d, 5 times a week.
62417520|NCT06537440|SHAM_COMPARATOR|Sham Acupuncture group|The method of comforting sham acupuncture was used. Non-meridian and non-acupuncture points are selected, and in principle the corresponding medial yin meridian is used as the reference point. The manipulation and depth of needling, the selection of needles and electroacupuncture were consistent with those of the experimental group.
62417521|NCT00016835|ACTIVE_COMPARATOR|Supra-gingival scaling and placebo|"This group receives a placebo (instead of systemic antibiotic), supra-gingival oral prophylaxis, and ultrasonic removal of supra-gingival calculus with water irrigation at the initial treatment visit. At the 9-month follow-up visit, this group will receive sub-gingival ultrasonic scaling with povidone-iodine irrigation.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
62026209|NCT00464542|OTHER|Metronidazole|Observational before and after treatment Drug: Metronidazole 500 mg, taken by mouth, two times a day, 7 days
62224282|NCT03120247|ACTIVE_COMPARATOR|DEX III|OTM Dexmetetomidine 0.5µg/kg. Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
62224283|NCT00612469|PLACEBO_COMPARATOR|NaF|Sodium fluoride application
62798950|NCT01492790|EXPERIMENTAL|Cholecystectomy first|Patients enrolled in this arm will undergo emergency cholecystectomy first without any common bile duct imaging
62798951|NCT01492790|ACTIVE_COMPARATOR|Sequential common bile duct imaging/cholecystectomy|Patients enrolled in this arm will undergo common bile duct imaging and, if needed, ERCP first followed by emergency cholecystectomy
62798952|NCT02219854|EXPERIMENTAL|Laparoscopic gastrectomy|Laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
62798953|NCT02219854|ACTIVE_COMPARATOR|Open gastrectomy|Open distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
62798954|NCT03116711|ACTIVE_COMPARATOR|Positive CIQ plus High Carbohydrate Diet|Positive Carbohydrate Intolerance Questionnaire (CIQ) plus 30% carbohydrate, 45% protein, 25% fat diet
62798955|NCT03116711|ACTIVE_COMPARATOR|Positive CIQ plus High Protein Diet|Positive Carbohydrate Intolerance Questionnaire (CIQ) plus 20% carbohydrate, 45% protein, 35% fat diet
62798956|NCT03116711|ACTIVE_COMPARATOR|Negative CIQ plus High Carbohydrate Diet|Negative Carbohydrate Intolerance Questionnaire (CIQ) plus 30% carbohydrate, 45% protein, 25% fat diet
62798957|NCT03116711|ACTIVE_COMPARATOR|Negative CIQ plus High Protein Diet|Negative Carbohydrate Intolerance Questionnaire (CIQ) plus 20% carbohydrate, 45% protein, 35% fat diet
62224284|NCT00612469|EXPERIMENTAL|V3|Topical application of 3% vancomycin
62224285|NCT00612469|EXPERIMENTAL|V10|Topical application of 10% vancomycin
62417522|NCT00016835|EXPERIMENTAL|Subgingival scaling and metronidazole|"This group receives ultrasonic scaling with local anesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation, and metronidazole as an oral systemic antibiotic at the initial treatment visit.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
62417523|NCT00016835|EXPERIMENTAL|Subgingival scaling and doxycycline|"This group receives ultrasonic scaling with local anesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation, and doxycycline as an oral systemic antibiotic at the initial treatment visit.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
62417524|NCT05979688|EXPERIMENTAL|Yogic breathing exercise|Participation in a 6 weekly virtual yogic breathing exercise training with 1-3 sessions per week.
62417525|NCT05979688|NO_INTERVENTION|Waitlist control|Participation in usual daily activities
62798958|NCT02083835||post-surgical patients|post-surgical patients \> 18 years
62798959|NCT02083835||pediatric patients post-op day 1|pediatric patients \<18 years on post-op day 1 (sub-project QUIPSI - PAIN OUTinfant)
62798960|NCT02949726|OTHER|Cancer-treated patients receiving NIRFLI|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
62798961|NCT01398007|NO_INTERVENTION|Conventional syringe|Conventional syringe
62798962|NCT01398007|EXPERIMENTAL|Camouflage syringe|The camouflage syringe is divided into three parts: head, body and tail. Head consists of bristles to apply topical anesthesia. The body holds the normally used conventional syringe and presents with a slot to check the aspiration results. The tail hides the conventional syringe loaded with the local anesthetic solution. This syringe is made up of cold-cure acrylic with a colorful toy-like look.
62798963|NCT04507607|EXPERIMENTAL|Pregnant women with CHB|Start taking TAF at 24 weeks of gestation until delivery. The liver function, viral load and antigen status were reviewed monthly and 10 ml peripheral blood was collected.
62224286|NCT00612469|ACTIVE_COMPARATOR|CHX|Topical application of 1% chlorhexidine
62224287|NCT05191277|EXPERIMENTAL|Open discontinuation (OD)|Participants will discontinue their antidepressant medication and will be fully informed about treatment (i.e., high expectation).
62224288|NCT05191277|EXPERIMENTAL|Hidden discontinuation (HD)|Participants will discontinue their antidepressant medication, but will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
62224289|NCT05191277|EXPERIMENTAL|Open continuation (OC)|Participants will remain on their initial antidepressant medication and will be fully informed about treatment (i.e., high expectation).
62224290|NCT05191277|EXPERIMENTAL|Hidden continuation (HC)|Participants will remain on their initial antidepressant medication, but will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
62224291|NCT02157922|ACTIVE_COMPARATOR|Alginate oligosaccharide|Inhalation of a dry powder OligoG in the first treatment period, and of placebo the second period
62224292|NCT02157922|PLACEBO_COMPARATOR|Placebo|Inhalation of placebo dry powder in the first treatment period, and OligoG in the second period
62224293|NCT01617304|EXPERIMENTAL|low AGE, glucose|Food prepared by boiling/steaming and 20 g of glucose 3 times a day in a water solution
62224294|NCT01617304|EXPERIMENTAL|low AGE, fructose|Food prepared by boiling/steaming and 20 g of fructose 3 times a day in a water solution
62417526|NCT02265640|EXPERIMENTAL|BIIL 284 BS boli - fasted|
62417527|NCT02265640|EXPERIMENTAL|BIIL 284 BS boli - fed|
62417528|NCT02265640|ACTIVE_COMPARATOR|BIIL 284 BS tablet C - fasted|
62798964|NCT04507607|ACTIVE_COMPARATOR|women with CHB|Nonpregnant women taking TAF for antiviral therapy were regularly rechecked for liver function, viral load, and antigens.
62798965|NCT02741635|EXPERIMENTAL|New Nasal Pillows Mask|Participants to use nasal pillows mask one night in lab overnight polysomnography.
62798966|NCT02028533|ACTIVE_COMPARATOR|Patients 1|Participants will receive intranasal oxytocin 40 International Units (IU).
62798967|NCT02028533|PLACEBO_COMPARATOR|Patients 2|Participants will receive 40 International Units of intranasal placebo.
62798968|NCT04334304|ACTIVE_COMPARATOR|Posterior Stabilized TKA without robot-assistance|A TKA procedure will carried out: Posterior Stabilized TKA without robot-assistance
62798969|NCT04334304|EXPERIMENTAL|Posterior Stabilized with robot-assistance|A TKA procedure will carried out: Posterior Stabilized TKA with robot-assistance
62417529|NCT02265640|ACTIVE_COMPARATOR|BIIL 284 BS tablet C - fed|
62588687|NCT06665035|EXPERIMENTAL|Cohort 2: Placebo (Age group: >=6 to <12 months)|Participants with the age group \>=6 to \<12 months receive placebo (normal saline), SC injection, on Day 1 and Day 90.
62798970|NCT04334304|EXPERIMENTAL|Bicruciate retaining TKA without robot-assistance|A TKA procedure will carried out: Bicruciate retaining TKA without robot-assistance
62798971|NCT04334304|EXPERIMENTAL|Bicruciate retaining TKA with robot-assistance|A TKA procedure will carried out: Bicruciate retaining TKA with robot-assistance
62798972|NCT03769259|EXPERIMENTAL|Brief Cognitive Behavioral Therapy|
62798973|NCT03769259|ACTIVE_COMPARATOR|Present-Centered Therapy|
62798974|NCT04593524|ACTIVE_COMPARATOR|Treatment Group|24 participants, which are treatment group (I) which receives nutritional counseling, vitamin D 1000 IU, vitamin A 6000 IU
62417530|NCT03501407||Erythema migrans|Patients for whom a diagnosis of acute phase of Lyme disease is done on the basis of the existence of an erythema migrans and a tick bite history in the days preceding the occurrence of erythema (before and after antibiotics treatment) will be recruited
62798975|NCT04593524|ACTIVE_COMPARATOR|Counseling Group|24 participants which only receives nutritional counseling for 28 days
62798976|NCT02742831|EXPERIMENTAL|Intervention|"The intervention group will receive a one-on-one in-person intervention of 6 sessions, each lasting approximately 60 minutes. The intervention is intended to be delivered over a period of 12 weeks, with sessions occurring every 1-2 weeks. The overview of the 6 sessions is as follows:~1. Behavioral chain analysis of episodes where parent felt stressed and episode where things went well. Identification of sources of interpersonal support.~2. Stress relief. Development of a detailed crisis plan.~3. Problem solving techniques.~4. Emotional regulation exercises.~5. Positive parenting, review of parenting challenges.~6. Reflection, repeat behavioral chain analysis. Update crisis plan."
62798977|NCT02742831|ACTIVE_COMPARATOR|Control|The families in the control group will be contacted by a member of the study team 6 times in 12 weeks to approximate the frequency of contact that the intervention group receives. The study team member will check in with families on the telephone or in person and will help them connect with clinic and community resources as needed.
62798978|NCT02028442|EXPERIMENTAL|Enadenotucirev|
62798979|NCT05201794|EXPERIMENTAL|High-dose JNJ-64281802 regimen (HDR)|Participants will receive JNJ-64281802 400 milligrams (mg) loading dose (LD) twice daily for 48 hours (2 days), followed by JNJ-64281802 150 mg maintenance dose (MD) once daily for 26 days in fed conditions.
62798980|NCT05201794|EXPERIMENTAL|Low-dose JNJ-64281802 regimen (LDR)|Participants will receive JNJ-64281802 150 mg LD twice daily for 48 hours (2 days), followed by JNJ-64281802 50 mg MD once daily for 26 days in fed conditions.
62798981|NCT05201794|PLACEBO_COMPARATOR|Placebo|Participants will receive JNJ-64281802 matching placebo LD and MD from Day 1 to Day 28.
62798982|NCT05810363|EXPERIMENTAL|EP group|Patients in this group will receive etomidate- propofol mixture during induction and maintenance.
62798983|NCT05810363|EXPERIMENTAL|P group|Patients in this group will receive propofol during induction and maintenance.
62798984|NCT00226057|EXPERIMENTAL|Raptiva Open Label|Raptiva administered by weekly subcutaneous injections. First dose of 0.7mg/kg. Subsequent doses will be of 1mg/kg SQ weekly.
62798985|NCT00494585|EXPERIMENTAL|CEP-701|80 mg orally twice a day for 30 days
62798986|NCT01073449||Cardiac device|All patients implanted with a cardiac device, pacemaker(PM)or Implantable Cardioverter Defibrillator (ICD)
62798987|NCT05497089|EXPERIMENTAL|Temelimab 54mg/kg|Monthly IV repeated dose in addition to standard of care
62798988|NCT05497089|PLACEBO_COMPARATOR|Placebo|Monthly IV repeated dose in addition to standard of care
62798989|NCT04872192|ACTIVE_COMPARATOR|transversus|patients received transversus thoracic muscle plane block and injection of 15 ml bupivacaine 0.25% on each side.
62798990|NCT04872192|SHAM_COMPARATOR|general anaesthesia group|the same bilateral technique was done on both sides and 15 ml saline was injected during each side of TTPB technique.
62798991|NCT00867165|EXPERIMENTAL|Ezetimibe|Ezetimibe 10-mg tablet once daily for 12 weeks
62224295|NCT01617304|EXPERIMENTAL|high AGE, fructose|Food prepared by frying/baking and 20 g of fructose 3 times a day in a water solution
62417531|NCT03501407||No-erythema migrans|"Patients with unspecific symptoms (the most common symptoms being:~headache, arthralgia, myalgia, febrile episode) appearing within 3 months after a tick bite will be recruited"
62588688|NCT01906307|EXPERIMENTAL|LJPC-501|LJPC-501, continuous infusion
62588689|NCT04218331|EXPERIMENTAL|JASPER only|This group will consist of the child and therapist having one-on-one, JASPER sessions, twice a week.
62588690|NCT04218331|ACTIVE_COMPARATOR|JASPER + PROMPT|This group will consist of the child and therapist having one-on-one, JASPER sessions plus Prompts for Restructuring Oral Muscular Phonetic Targets (PROMPT), twice a week.
62588691|NCT01514838|EXPERIMENTAL|1941 group|Once daily over a 24-week treatment period
62588692|NCT01514838|ACTIVE_COMPARATOR|acarbose group|Once daily over a 24-week treatment period
62417532|NCT01842516|EXPERIMENTAL|LCB01-0371 800mg|LCB01-0371 800mg
62417533|NCT01842516|EXPERIMENTAL|LCB01-0371 1200mg|LCB01-0371 1200mg
62417534|NCT01842516|PLACEBO_COMPARATOR|Placebo|Placebo
62588693|NCT05352672|EXPERIMENTAL|A: fianlimab+cemiplimab dose 1|As defined in Protocol Amendment 5
62798992|NCT00867165|PLACEBO_COMPARATOR|Placebo|Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks
62798993|NCT03987477|EXPERIMENTAL|Experimental group|The experimental group will be exposed to a brief online program aimed at the modification of negative emotional cognitive biases. The program consists of an introduction and four 1-hour sessions, in video format. In each session, participants are required to complete some open questions and scales about the type of cognitive bias addressed in each session. All sessions are structured in four parts: 1) description and examples of some specific cognitive biases; 2) information about negative consequences of each bias; 3) explanation of adaptive strategies to modify cognitive biases (i.e., the four-questions approach used in standard Cognitive behavioral therapy); and 4) use of some practices to familiarize participants with the use of those strategies.
62798994|NCT03987477|OTHER|Waiting list group|The control group will be composed of individuals waiting for the treatment. Participants will not be exposed to the experimental program or any other between the pre-evaluation and the post-evaluation sessions. Participants in this group will have access to the potential benefits of the intervention after the post-evaluation of both groups.
62798995|NCT06725459|EXPERIMENTAL|Prophylactic ciNPWT|Participants in this arm will receive the prophylactic closed incision negative pressure wound therapy (ciNPWT) on one breast following reduction mammaplasty. The ciNPWT will be applied for up to 7 days postoperatively to promote wound healing and prevent complications.
62026210|NCT00884429|ACTIVE_COMPARATOR|1- Conventional Chest Physiotherapy|Percussion , thorax compression and Postural Drainage/suction if necessary
62224296|NCT01617304|EXPERIMENTAL|high AGE, glucose|Food prepared by frying/baking and 20 g of glucose 3 times a day in a water solution
62224297|NCT05780320||Pharmaco-Surgical Arm|
62224298|NCT05780320||Standard of Care Arm|
62224299|NCT01656382|ACTIVE_COMPARATOR|5 mg/kg/d ABLC x 14 days|5 mg/kg/d of Amphotericin B Lipid Complex for 14 days
62224300|NCT01656382|EXPERIMENTAL|10/kg/kg/d x 7 days|10 mg/kg/d of Amphotericin B Lipid Complex for 7 days
62798996|NCT06725459|ACTIVE_COMPARATOR|Standard Adhesive Dressing|Participants in this arm will receive the standard adhesive strip dressing (Prineo Ethicon NJ) on the other breast following reduction mammaplasty. The standard dressing will be used as a control to compare postoperative outcomes against the ciNPWT.
62224301|NCT04048954||APPLITABAC arm|Use of a smartphone application on screening for complications related to tabagism
62224302|NCT05902312|ACTIVE_COMPARATOR|repetitive Transcranial Magnetic Stimulation|rTMS on a MagPro X100 research grade stimulator (MagVenture) equipped with a B70 fluid-cooled coil. Participant will receive the MDD FDA-approved iTBS protocol (triplet 50 Hz bursts repeated at 5 Hz, 2 s ON and 8 s OFF; 600 pulses per session; total duration of 3 min 9 s, 120% hand motor threshold)
62798997|NCT02046707|EXPERIMENTAL|Patients with chronic heart failure|
62798998|NCT02046707|OTHER|Controls|
62798999|NCT05396053|ACTIVE_COMPARATOR|Control|A traditional physical therapy program
62224303|NCT05902312|EXPERIMENTAL|deep Transcranial Magnetic Stimulation|dTMS on a research Brainsway system equipped with an H7-Coil. Participants will receive the MDD FDA-cleared 18 Hz stimulation protocol (2 sec ON, 20 sec OFF, 55 trains; 1980 pulses per session; 20 min 10 s duration; 120% hand motor threshold)
62224304|NCT02843477||Fluid loading group|Spontaneously breathing patients before induction of general anesthesia who receive fluid loading
62224305|NCT03871842|ACTIVE_COMPARATOR|active tDCS|20-minute of daily anodal stimulation (2mA) above the left dorsolateral prefrontal cortex during 5 days per week for 4 weeks.
62224306|NCT03871842|SHAM_COMPARATOR|sham tDCS|20-minute of daily sham stimulation above the left dorsolateral prefrontal cortex during 5 days per week for 4 weeks.
62417535|NCT03955718|EXPERIMENTAL|Motherly App|A smartphone app with an automated intervention that provides strategies to prevent maternal depression and to promote child development: (1) behavioral activation, (2) sleep hygiene, (3) physical activity, (4) social support, (5) nutrition, (6) prenatal care schedule, and (7) educational content.
62417536|NCT03955718|ACTIVE_COMPARATOR|Educational App (Active Control)|An app with educational content about gestation, maternal health and mental health, child development, etc.
62417537|NCT03494816|EXPERIMENTAL|Axitinib|Axitinib - oral tablet twice daily for 8 weeks prior to surgery. Starting dose 5mg.
62417538|NCT06354764||Adults who attended the emergency department|
62799000|NCT05396053|EXPERIMENTAL|Study 1|Mirror therapy plus traditional physical therapy program
62224307|NCT02780154|EXPERIMENTAL|1600 7G8 PfSPZ|N= 7-9 participants will receive 1600 7G8 PfSPZ DVI in a volume of 500mcL
62224308|NCT02780154|EXPERIMENTAL|3200 7G8 PfSPZ|N= 9 participants will receive 3200 7G8 PfSPZ DVI in a volume of 500mcL
62026211|NCT00884429|ACTIVE_COMPARATOR|2- Chest physiotherapy- Actual techniques|slow prolonged expiration and clearance rhinopharynx and suction if necessary
62026212|NCT00884429|ACTIVE_COMPARATOR|3- Airway Suction|Suction superior airways. Only in admission.
62026213|NCT03668145|EXPERIMENTAL|MSC group|mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8 plus UDCA.
62224309|NCT02780154|EXPERIMENTAL|3200 NF54 PfSPZ|N= 5-6 participants will receive 3200 NF54 PfSPZ DVI in a volume of 500mcL
62417539|NCT05640908||Prospective|Participants who have scheduled spinal fusion with pelvic fixation/fusion using iFuse Bedrock Granite. These participants will be followed for 2 years.
62417540|NCT05256563||Right brain stroke survivors|People with right brain stroke who are recruited to the study.
62417541|NCT05278949|OTHER|The scleral pocket for the primary implanted IOL|single arm
62799001|NCT05396053|EXPERIMENTAL|Study 2|Constraint-induced movement therapy plus traditional
62799002|NCT06726707|EXPERIMENTAL|Copper-based product|Individuals enrolled in the treatment with diapers embedded with a copper-based product.
62799003|NCT06726707|ACTIVE_COMPARATOR|Control|Individuals enrolled in the treatment with diapers associated with a barrier product.
62799004|NCT00950846|EXPERIMENTAL|Umbilical Cord Blood Transplant Treatment Plan|Busulfan, Cytoxan, Fludarabine, Cord Blood Stem Cell Infusion
62799005|NCT04203836|EXPERIMENTAL|Fed|Single oral dose given after a full breakfast
62417542|NCT06588660|EXPERIMENTAL|Treatment (ST-067, teclistamab)|Patients receive ST-067 SC on days 1, 8, 15 and 22 of cycle 1, on days 8, 15 and 22 of cycle 2, then on days 1 and 15 of subsequent cycles. Patients also receive teclistamab SC on days 1, 3, 5, 15 and 22 of cycle 2 then on days 1 and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection throughout the trial and bone marrow aspiration and biopsy on study.
62417543|NCT02404272||Preterm neonates|All preterm neonates of less than 34 weeks' of gestation admitted to the Neonatology and Neonatal Intensive Care unit of an university hospital located in Lyon, France
62799006|NCT04203836|EXPERIMENTAL|Fasting|Single oral dose given in fasting state
62224310|NCT02780154|EXPERIMENTAL|4800 7G8 PfSPZ|N= 2-3 participants will receive 4800 7G8 PfSPZ DVI in a volume of 500mcL
62224311|NCT02780154|EXPERIMENTAL|800 7G8 PfSPZ|N= 7-9 participants will receive 800 7G8 PfSPZ DVI in a volume of 500mcL
62224312|NCT00857272|ACTIVE_COMPARATOR|HalfLytely with 10mg bisacodyl|Active control
62224313|NCT00857272|EXPERIMENTAL|HalfLytely with 5mg bisacodyl|Investigational dose
62224314|NCT00666393|EXPERIMENTAL|001|
62224315|NCT04433546|EXPERIMENTAL|High Dose (100 mg) Group|High: Pemziviptadil (PB1046) 100 mg subcutaneous (SC) weekly for 4 weeks or until hospital discharge
62224316|NCT04433546|EXPERIMENTAL|Middle Dose (40 mg) Group|Middle: Pemziviptadil (PB1046) 40 mg SC weekly for 4 weeks or until hospital discharge
62224317|NCT04433546|PLACEBO_COMPARATOR|Low Dose (10 mg) Control Group|Low Control: Pemziviptadil (PB1046) 10 mg SC weekly for 4 weeks or until hospital discharge
62224318|NCT03549533||artificial insemination|Patient who perform his first artificial insemination will be included. Samples of sperm will be analyzed.
62224319|NCT05496946|EXPERIMENTAL|Model with low proximity to reality group|The students included in the experimental group 1 practiced the head bathing skill on a model with low proximity to reality. The model used here is a human model belonging to the Gaumard Scientific company with low proximity to reality.
62224320|NCT05496946|EXPERIMENTAL|Standardized patient Group|The students in the experimental group 2 practiced the head bath skill on the standardized patient. A standardized patient is a healthy individual pretending to be a patient.
62224321|NCT00475930|EXPERIMENTAL|1|2% chlorhexidine gluconate impregnated cloths, self applied three times weekly
62224322|NCT00475930|PLACEBO_COMPARATOR|2|Comfort Bath cloths, self applied three times weekly
62224323|NCT05951296|EXPERIMENTAL|Leramistat|Leramistat once daily
62224324|NCT05951296|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62224325|NCT01013597|EXPERIMENTAL|LBH589|
62224326|NCT04540393|EXPERIMENTAL|Arm A|Single arm
62224327|NCT03819738|EXPERIMENTAL|fMRI intervention|
62224328|NCT04281550|EXPERIMENTAL|Think drink intervention|The Think Drink multicomponent hydration intervention was introduced into the intervention group care homes through a staff workshop.
62417544|NCT05923541|EXPERIMENTAL|RD13-02 cell infusion|drugs use generic name : RD13-02 CAR-T cell injection; dosage form : Cell injection; dosage : 2×10\^8 CAR+ T cells; frequency : Once.
62417545|NCT00757198|EXPERIMENTAL|1|remifentanil o.1 mcg/kg/min
62799007|NCT06151444|ACTIVE_COMPARATOR|Standard group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62799008|NCT06151444|EXPERIMENTAL|Intensive group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62799009|NCT03335735|EXPERIMENTAL|Loss-Framed Text Messages|Loss-framed text message
62799010|NCT03335735|NO_INTERVENTION|Control|Participants in this arm will not receive any intervention.
62224329|NCT01844947|EXPERIMENTAL|vinflunine + sorafenib|Single arm study.
62224330|NCT02582567|EXPERIMENTAL|Exercise intervention|3 times per week from the 17th week of gestation until delivery
62224331|NCT02582567|NO_INTERVENTION|Control group|Usual care (control) group
62224332|NCT01822301|EXPERIMENTAL|Repeat Facial fat grafting|
62224333|NCT01012713|EXPERIMENTAL|Open-Label Treatment|All patients will receive treatment with Clobex Spray, Vectical Ointment, and Excimer Laser
62224334|NCT02364791|ACTIVE_COMPARATOR|standard treatment|standard techniques to achieve air leak control after complex thoracic surgical procedures
62224335|NCT02364791|EXPERIMENTAL|standard treatment plus hemopatch|the addition of hemopatch to standard techniques to achieve air leak control after complex thoracic surgical procedures
62224336|NCT01958307|EXPERIMENTAL|Intervention|Lifestyle intervention
62224337|NCT01958307|NO_INTERVENTION|No intervention|Standard prenatal care, short information leaflet about healthy lifestyle in pregnancy
62224338|NCT01006473|EXPERIMENTAL|Exercise training group|Exercise training is performed in subgroups of 6 patients supervised by two physiotherapists. Exercise prescription consisted of a 15-min warm-up, walking up to 30 min, followed by a 15-min cooling-down. The exercise intensity during the first 2 weeks corresponds to 55% at 65% of the HR peak reached at the baseline exercise test. In posterior sessions, individual adjustments are performed with gradual increases in order to reach the adequate target HR training intensity, as determined by the Karvonen formula {(maximal HR - HR at rest) x 50 to 70% + HR at rest}. Exercise training is performed in the morning, three times a week (on alternate days) for a total of 12 weeks (36 sessions).
62224339|NCT01006473|NO_INTERVENTION|Inactive control group|No intervention
62224340|NCT06299085|OTHER|50 adult patients suffering from severe or morbid obesity|"50 adult patients suffering from severe or morbid obesity (BMI ≥ 35 kg/m2 in the presence of comorbidities and BMI ≥ 40 kg/m2, respectively), male and female, candidates for bariatric surgery (Sleeve Gastrectomy and Roux-en-Y Gastric Bypass).~Two timepoints: T0 (pre-hospitalization) and T1 (follow-up 12 months +/- 1 month).~Expected assessments at T0 and T1:~* Blood chemistry tests to monitor metabolic markers involved in dietary and metabolic changes.~* Bone densitometry for body composition analysis (DEXA).~* Analysis of pre-intervention walking and the ability to recover motor activity after bariatric surgery using gait analysis."
62224341|NCT04388397|EXPERIMENTAL|Immediate-access Arteriovenous Grafts|Immediate-access Arteriovenous Grafts as a vascular access for hemodialysis patients
62224342|NCT04388397|ACTIVE_COMPARATOR|Standard Arteriovenous Grafts|Standard Arteriovenous Grafts as a vascular access for hemodialysis patients
62417546|NCT00757198|ACTIVE_COMPARATOR|2|remifentanil 0.3 mcg/kg/min
62224343|NCT03536299|ACTIVE_COMPARATOR|Single-Task Gait|The Single-Task Gait group will be provided with gait training without the Dual-Task cognitive tasks.
62224344|NCT03536299|EXPERIMENTAL|Dual-Task Gait|The Dual-Task Gait group will be provided with gait training AND secondary cognitive tasks during gait training.
62224345|NCT04537182|EXPERIMENTAL|LVRS treatment group|A bilateral lung volume reduction surgery (LVRS) by video-assisted thoracoscopic surgery (VATS) is performed under general anesthesia with double lumen endobronchial intubation. Unilateral treatment is accepted in cases with severe adhesions or intraoperative instability making a bilateral procedure unsafe.
62224346|NCT04537182|ACTIVE_COMPARATOR|BLVR study group|Unilateral bronchoscopic lung volume reduction with endobronchial valves (EBV) is performed using a flexible bronchoscope under general anesthesia and under full attendance of an anesthesiologist. Valves are placed unilaterally in segmental or subsegmental bronchi in the target lobe with the goal of complete atelectasis.
62224347|NCT03810352||Patients with ITP|Patients with primary or secondary immune thrombocytopenia
62224348|NCT01613560|EXPERIMENTAL|PEPI：2-4 group-A|
62224349|NCT01613560|ACTIVE_COMPARATOR|PEPI：2-4 group-B|
62417547|NCT06550362|EXPERIMENTAL|Iron every other day|Oral iron daily at 6 mg (elemental)/kg/day (max 200 mg elemental) taken every other day.
62417548|NCT06550362|ACTIVE_COMPARATOR|Iron every day|Oral iron daily at 6 mg (elemental)/kg/day (max 200 mg elemental) taken every day.
62417549|NCT00442338|EXPERIMENTAL|Montelukast 7 mg|Montelukast 7 mg IV administration
62588694|NCT05352672|EXPERIMENTAL|A1: fianlimab+cemiplimab dose 2|As defined in Protocol Amendment 5
62799011|NCT03335735|EXPERIMENTAL|Gain-Framed Messaging Group|Gain-framed text message
62799012|NCT02297386|EXPERIMENTAL|[18F] DIHYDRO-TESTOSTERONE PET|"The diagnostic intervention of this study is the use of FDHT PET in localized prostate cancer. Patients will undergo a 30 minute dynamic scan of the pelvis followed by a whole body scan of approximately 30-minutes duration. The dynamic scan will be optional, but strongly encouraged. PET scanning will preferably be done on the GE Discovery STE PET/CT scanner or the equivalent generation of scanner. The PET scans are routinely quantitative, that is corrected for attenuation and scatter and adjusted for system sensitivity and providing parametric images in terms of standardized uptake values (SUV) (= μCi found/gm tissue / μCi injected/gm body mass)."
62799013|NCT05630950|EXPERIMENTAL|Smoking cessation application|
62799014|NCT05630950|ACTIVE_COMPARATOR|Written smoking cessation information|
62799015|NCT01218581|ACTIVE_COMPARATOR|group A|Group A received oral letrozole (2.5 mg/day, Femara, Novartis PharmaServices, Basel, Switzerland)
62799016|NCT01218581|ACTIVE_COMPARATOR|group B|group B received goserelin subcutaneosly (3.6 mg/month, Zoladex@, Zeneka Pharma International, UK)
62224350|NCT01613560|ACTIVE_COMPARATOR|PEPI：0-1group|
62224351|NCT02768870|EXPERIMENTAL|Harpoon Medical Device|This is a prospective, single arm, nonrandomised, multi-center EU study to demonstrate the performance and safety of the Harpoon Medical device in patients with degenerative MR.
62224352|NCT05788211||REFRACTORY CARDIOGENIC SHOCK|All patients with medical or postcardiotomy refractory cardiogenic shock requiring renal replacement therapy concomitant with venoarterial extracorporeal membrane oxygenation.
62224353|NCT00705354|ACTIVE_COMPARATOR|1|Control group undergoing standard ESS will have a saline soaked Nasopore sponge placed during surgery and will receive routine oral antibiotics post-operatively
62224354|NCT00705354|EXPERIMENTAL|2|Treatment group undergoing ESS will have Nasopore sponge soaked with Bacitracin, but will not receive oral antibiotics post-operatively
62026214|NCT03668145|PLACEBO_COMPARATOR|control|placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 4, 8 plus UDCA.
62417550|NCT00442338|EXPERIMENTAL|Montelukast 14 mg|Montelukast 14 mg IV administration
62417551|NCT00442338|ACTIVE_COMPARATOR|Aminophylline 250 mg|Aminophylline 250 mg IV drip administration
62417552|NCT06229262|ACTIVE_COMPARATOR|Mango Group|Participants in the Mango group will consume 1.5 cups of mangos for 12 weeks
62417553|NCT06229262|NO_INTERVENTION|control group|The control group will receive no dietary intervention. they will follow usual diet and abstain from eating mangos
62417554|NCT06345183||Participants treated with Nivolumab + Ipilimumab combination therapy|
62417555|NCT06345183||Participants treated with Pembrolizumab + Lenvatinib combination therapy|
62417556|NCT00568100|EXPERIMENTAL|1|COPD patients
62588695|NCT05352672|EXPERIMENTAL|B: pembrolizumab+placebo|As defined in Protocol Amendment 5
62588696|NCT05352672|EXPERIMENTAL|C: cemiplimab+placebo|As defined in Protocol Amendment 5
62588697|NCT04953689|EXPERIMENTAL|Intervention|
62799017|NCT01433796||Antiretroviral therapy, tuberculosis|Patients eligible for starting ART in health centres in Ethiopia
62799018|NCT01706523|EXPERIMENTAL|STX209|Active treatment with STX209
62224355|NCT04694404|EXPERIMENTAL|S-1 Plus Oxaliplatin|Oxaliplatin 85 mg/m2 (D1, q2w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-10, q2w)
62224356|NCT06199674|EXPERIMENTAL|PBM group|wear PBM device daily during the fixed-appliance orthodontic treatment
62224357|NCT06199674|SHAM_COMPARATOR|Control group|wear sham device daily during the fixed-appliance orthodontic treatment
62224358|NCT05162989|EXPERIMENTAL|iCare HOME2 vs iCare IC200|Measurement of intraocular pressure (IOP) with iCare IC200 reference tonometer compared to iCare HOME2 test tonometer. Measurement will be performed to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (\>16 to \<23 mmHg), or High IOP (≥23 mmHg).
62224359|NCT00903630|EXPERIMENTAL|Phase 1 - Dose Level 1|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: 10 mg daily on Days 1-28 every 28 days
62224360|NCT00903630|EXPERIMENTAL|Phase I - Dose Level 2|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: 15 mg daily on Days 1-28 every 28 days
62224361|NCT00903630|EXPERIMENTAL|Phase 2|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: maximum tolerated dose from Phase I portion of the study (10mg) daily on Days 1-28 every 28 days
62224362|NCT06244485|EXPERIMENTAL|Part 1: Dose Escalation Phase (Sub-protocol B)|Participants with previously treated, advanced, or metastatic HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma will receive valemetostat in combination with T-DXd.
62224363|NCT06244485|EXPERIMENTAL|Part 1: Dose Escalation Phase (Sub-protocol C)|Participants with previously treated, locally advanced, unresectable, or metastatic non-squamous non-small cell lung cancer (NSCLC) with or without actionable genomic alteration(s) will receive valemetostat in combination with datopotamab deruxtecan (Dato-DXd).
62224364|NCT06244485|EXPERIMENTAL|Part 1: Dose Escalation (Sub-protocol A)|Participants with unresectable or metastatic HER2-low IHC\]1+ or IHC 2+/ISH-negative breast cancer will receive valemetostat in combination with T-DXd.
62224365|NCT06244485|EXPERIMENTAL|Part 2: Dose Expansion (Sub-protocol B)|Participants with previously treated, advanced, or metastatic HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma will receive valemetostat at the RDE in combination with T-DXd at RDE.
62224366|NCT06244485|EXPERIMENTAL|Part 2: Dose Expansion (Sub-protocol C)|Participants with previously treated, locally advanced, unresectable, or metastatic non-squamous non-small cell lung cancer (NSCLC) with or without actionable genomic alteration(s) will receive valemetostat at the RDE in combination with datopotamab deruxtecan (Dato-DXd).
62224367|NCT06244485|EXPERIMENTAL|Part 2: Dose Expansion (Sub-protocol A)|Participants with unresectable or metastatic HER2-low IHC\]1+ or IHC 2+/ISH-negative breast cancer will receive valemetostat at the RDE in combination with T-DXd at RDE.
62417557|NCT06060314|OTHER|Patients|Patients presented with symptoms of numbness at night, pain, or tingling sensation in the fingers particularly at night diagnosed by a consultant orthopedic surgeon on physical examination.
62588698|NCT04953689|NO_INTERVENTION|Waitlist Control|
62799019|NCT00806910|ACTIVE_COMPARATOR|Treatment|Subjects will be treated with Intravenous Vaprisol along with Nesiritide infusion and intravenous Furosemide (either continuous infusion or bolus injections - total dose of Furosemide received will be calculated at the end of the study).
62799020|NCT00806910|PLACEBO_COMPARATOR|Placebo|Subjects will be given Placebo (at the same rate of Vaprisol given in the treatment arm) along with Nesiritide infusion and intravenous Furosemide (either continuous infusion or bolus injections - total dose of Furosemide received will be calculated at the end of the study).
62224368|NCT03213860|ACTIVE_COMPARATOR|eye mask|
62224369|NCT03213860|NO_INTERVENTION|Control|
62417558|NCT06060314|OTHER|Principle Investigator|The principal investigator will carry out the whole study.
62588699|NCT03202940|EXPERIMENTAL|Cobimetinib + Alectinib|Alectinib administered twice daily at pre-determined dosage orally Cobimetinib administered daily at pre-determined dosage orally
62026215|NCT03043183|EXPERIMENTAL|Preoperational nutrition support group|Scored patient-generated subjective global assessment(PG-SGA) ≥2，\<9 Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
62026216|NCT03043183|NO_INTERVENTION|Conventional group|PG-SGA ≥2，\<9
62224370|NCT01670760|EXPERIMENTAL|Zero-Heat-Flux|This is a single arm study. All patients will have deep tissue temperature monitored from the nasopharyngeal and lateral forehead sites simultaneously.
62224371|NCT02036879|NO_INTERVENTION|Main study|"The main study is an observational study.~All women will be followed for one menstrual cycle (or approximately one month) observationally off of any hormone supplementation. They will have 3 study visits corresponding to their menstrual cycle phases (menses, ovulation, and luteal).~Women participating in the main study may participate in the optional interventional sub-study.~Men participating in this study will be followed for 1 month observationally. They will have 3 study visits that correlate with the female arm of this study."
62224372|NCT02036879|EXPERIMENTAL|Loestrin Optional Substudy|Women participating in the main study may participate in the optional sub-study. Following a negative urine pregnancy test, women will be started on once daily oral Loestrin (1.5 mg norethindrone + 0.03 mg ethyl estradiol). They will be followed for two months on this agent and have 2 additional study visits.
62417559|NCT06060314|OTHER|Consultant Orthopedic Surgeon|Consultant Orthopedic Surgeon will be outcome assessor.
62417560|NCT05447559|PLACEBO_COMPARATOR|Intraoperative only Surgical Antimicrobial Prophylaxis Arm|Placebo administered every 8-hours following the preoperative dose (time=0) for a total of five postoperative doses
62417561|NCT05447559|OTHER|Intraoperative and 24-hours Postoperative Surgical Antimicrobial Prophylaxis Arm|Cefazolin (2g) administered 8-hourly following the preoperative dose (time=0) for two doses then placebo 8-hourly for three doses (total of 5 postoperative doses of cefazolin/placebo)
62417562|NCT05447559|ACTIVE_COMPARATOR|Intraoperative and 48-hours Postoperative Surgical Antimicrobial Prophylaxis Arm|Cefazolin (2g) administered every 8-hours following the preoperative dose (time=0) for a total of five postoperative doses
62417563|NCT04638829|OTHER|Avatrombopag|Avatrombopag 20 mg oral tablet formulation for 90 days
62224373|NCT04690530||patients admitted in medical intensive care unit who require mechanical ventilation and sedation|The main goals of the study are to characterize cerebral hemodynamics and oxygenation as well as to study the effects of therapeutics on it in critically-ill patients. For this purpose, we plan to include all consecutive patients admitted in our medical intensive care unit who require mechanical ventilation and sedation and in whom the attending physician decides to perform one of the studied therapeutics (fluids, vasopressors or inotropes administration, blood transfusion, prone positioning, passive leg raising test, end-expiratory occlusion test) within the first 72h of ventilation onset. Cerebral hemodynamics (cerebral blood flow and cerebral autoregulation) as well as cerebral oxygenation will be non-invasively studied before and after therapeutics.
62224374|NCT02628782|EXPERIMENTAL|InSeal VCD|InSeal's Vascular Closure Device Use of the experimental VCD to close the access site of the artery
62417564|NCT06215313|EXPERIMENTAL|Patients with PTSD|Patients with PTSD will be randomly assigned to either EMDR or IR. They will receive two 75-minute sessions of either EMDR or IR each week, with one additional coaching session in both conditions (EMDR and IR).
62799021|NCT03789240|EXPERIMENTAL|1|Window of treatment with Copanlisib 60mg via IV for a single 28 day cycle, once weekly for the first 3 weeks and then a 1 week break followed by induction therapy with copanlisib and rituximab. Induction therapy will be 6 cycles (28 days) of: copanlisib dose and administration same as window, rituximab 375mg/m2 via IV, once weekly for the first 4 weeks during cycle 1, subsequent cycles (cycles 2-6), rituximab will be dosed only once on day 1 of the cycle.
62799022|NCT02016651|EXPERIMENTAL|Right side position|Premature infants on mechanical ventilation are kept on their right side
62799023|NCT02016651|NO_INTERVENTION|Supine position|Premature infants on mechanical ventilation are kept on their back
62799024|NCT04184284||Primary Study Cohort - Anti-IL5/IL5R naïve patients|Severe eosinophilic asthma patients who have never received anti-Interleukin-5 / anti-Interleukin-5-receptor (anti-IL-5/anti-IL-5R) biologic treatment for severe eosinophilic asthma, for whom the investigator had decided to initiate benralizumab biologic treatment.
62799025|NCT04184284||Secondary Study Cohort - Biologic experienced patients|Patients that previously received a biologic treatment for severe asthma (at least one dose).
62799026|NCT04929678|EXPERIMENTAL|Braive™ Growth Modulation System (Braive™ GMS)|
62799027|NCT01412528|OTHER|Eight different allergens will be standardized in this study|
62799028|NCT05669859|EXPERIMENTAL|Telerehabilitation Group|It consists of postoperative patients included in the rehabilitation program consisting of approximately one hour of exercise training to be conducted via remote online video-conference (WhatApp Messenger app) for eight weeks, with 2 sessions per week.
62799029|NCT05669859|NO_INTERVENTION|Control Group|It consists of patients who are called for control by the physician periodically for radiological evaluation and physical examination in the post-surgical period, and who are not included in any rehabilitation program as in routine post-surgical practice.
62799030|NCT06609083|EXPERIMENTAL|Smoked THC|Each participant in this arm will receive 0, 5, and 30mg of THC over the course of six visits. Each participant will also receive combustible cigarettes containing 0.03mg and 0.80mg of nicotine.
62799031|NCT06609083|EXPERIMENTAL|Vaporized THC|Each participant in this arm will receive 0, 5, and 30mg of THC over the course of six visits. Each participant will also receive combustible cigarettes containing 0.03mg and 0.80mg of nicotine.
62799032|NCT02733445||dasatinib cohort|Patients with CML receiving dasatinib
62799033|NCT02733445||nilotinib cohort|Patients with CML receiving nilotinib
62799034|NCT01946217||Observational (questionnaire administration)|Participants complete the IMPACTS survey comprising questions about socio-demographic information and clinical trial participation.
62799035|NCT05928403||medial pivot|Return to sport rate for patients with a Medial Pivot knee prosthesis
62799036|NCT05928403||medial bearing|Return to sport rate for patients with a Medial Bearing knee prosthesis
62799037|NCT05928403||cruciate retaining|Return to sport rate for patients with a Cruciate Retaining prosthesis
62799038|NCT00854230|EXPERIMENTAL|1|Naltrexone
62799039|NCT00854230|PLACEBO_COMPARATOR|2|
62799040|NCT06630806|EXPERIMENTAL|Part A (Dose escalation)|Participants will receive SAR446523
62799041|NCT06630806|EXPERIMENTAL|Part B Dose-1 (Dose optimization)|Participants will receive SAR446523 Dose-1
62799042|NCT06630806|EXPERIMENTAL|Part B Dose-2 (Dose optimization)|Participants will receive SAR446523 Dose-2
62799043|NCT00509470|ACTIVE_COMPARATOR|telmisartan plus low-dose hydrochlorothiazide|12 week combination therapy with telmisartan plus low-dose hydrochlorothiazide
62799044|NCT00509470|ACTIVE_COMPARATOR|Amlodipine|Amlodipine is continuously administered.
62799045|NCT01016600|EXPERIMENTAL|Cohort 1|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 25 mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
62799046|NCT01016600|EXPERIMENTAL|Cohort 2|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 50 mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
62799047|NCT01016600|EXPERIMENTAL|Cohort 3|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
62799048|NCT01016600|EXPERIMENTAL|Phase II|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 75 mg/m2 (dose determined in Phase I) mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
62417565|NCT06215313|EXPERIMENTAL|Patients with depression|Patients with depression will be randomly assigned to either EMDR or IR. They will receive two 75-minute sessions of either EMDR or IR each week, with one additional coaching session in both conditions (EMDR and IR).
62799049|NCT04851626|EXPERIMENTAL|Intervention group - hypnotic intervention for persistent pelvic pain|Participants underwent education about persistent pain and a 7 week 7 recording online hypnotic intervention. Women with persistent pelvic pain.
62799050|NCT04851626|OTHER|Control group - waitlist control|Control group of women with persistent pelvic pain no intervention completed assessment and concluding measures but did not undergo hypnotic intervention.
62224375|NCT04789772|EXPERIMENTAL|Laser acupuncture group|Laser acupuncture group receive laser acupuncture treatment with cognitive behavioral therapy.
62224376|NCT01206543|EXPERIMENTAL|Intraoperative imaging|
62588700|NCT06611540|EXPERIMENTAL|Prevention (self-collected and clinician-collected samples)|Patients undergo self-collection of a vaginal sample and then undergo clinician-collection of a cervical test sample. Patients then undergo SOC colposcopy with cervical biopsy/endocervical curettage and/or cervical excisional procedures as clinically indicated.
62588701|NCT03919695|EXPERIMENTAL|Kisoboka: structural and behavioral intervention|The KISOBOKA intervention adapts and combines a behavioral intervention with a structural component. The behavioral intervention component includes, alcohol screening, financial literacy training, and counseling and goal setting related to savings, alcohol use, and HIV care engagement. The structural intervention component changes the mode of work payment from cash to mobile money.
62224377|NCT01362257|EXPERIMENTAL|14C-GSK573719 Oral Solution|single dose of 1000µg
62799051|NCT05624307||Patient with chronic back pain|Patients admitted to the chronic pain service at the Calot Institute with chronic low back pain for at least three months, not responding to well-conducted conservative treatment
62224378|NCT01362257|EXPERIMENTAL|14C-GSK573719 IV Solution|single dose of 65µg
62224379|NCT00724438||1|Obese women: women with a body mass index (BMI) \>30
62224380|NCT00724438||2|Normal weight women: women with a BMI \<25
62224381|NCT02926144|EXPERIMENTAL|Laryngoscope with video|Use of the video-laryngoscope McGrath Mac with use of the video feature
62224382|NCT02926144|ACTIVE_COMPARATOR|Laryngoscope without video|Use of the video-laryngoscope McGrath Mac without use of the video feature
62224383|NCT03868072|EXPERIMENTAL|Reference/Test|"1. Period 1: XELJANZ 5Mg Tablet 1T~2. Period 2: Chong Kun Dang Tofacitinib Tablet 1T"
62224384|NCT03868072|EXPERIMENTAL|Test/Reference|"1. Period 1: Chong Kun Dang Tofacitinib Tablet 1T~2. Period 2: XELJANZ 5Mg Tablet 1T"
62417566|NCT06215313|EXPERIMENTAL|Patients with PTSD and depression|Patients with PTSD and depression will be randomly assigned to either EMDR or IR. They will receive two 75-minute sessions of either EMDR or IR each week, with one additional coaching session in both conditions (EMDR and IR).
62588702|NCT03919695|ACTIVE_COMPARATOR|Screening and Referral|Brief feedback on AUDIT-C score, referral for alcohol counseling, and briefly discussion of the importance of HIV care engagement and adherence.
62799052|NCT06690905|EXPERIMENTAL|Piperacillin-tazobactam administered in a prolonged infusion|Piperacillin-tazobactam dose will be administered over 3 hours for piperacillin-tazobactam dosages every 6 hours or over 4 hours for piperacillin-tazobactam dosages every 8 hours.
62224385|NCT00784693|EXPERIMENTAL|Tanezumab|
62224386|NCT00784693|PLACEBO_COMPARATOR|Placebo|
62224387|NCT05846347|EXPERIMENTAL|GC012F injection (CD19-BCMA CAR-T cells)|Dose level： DL1：1±20%×10\^5/kg, DL2：2±20%×10\^5/kg DL3：3±20%×10\^5/kg
62224388|NCT01821287||CHD Infants|Infants with a single ventricle (Congenital Heart Disease) CHD admitted to Cincinnati Children's Hospital Medical Center (CCHMC) for neonatal medical management or surgical palliation
62224389|NCT01821287||Normal Controls|Healthy newborns (full-term infants with no known medical problems) recruited from Cincinnati Children's Hospital Medical Center (CCHMC) and private practices
62224390|NCT02896920||Participants receiving adalimumab/ Humira®|Participants with HS for whom a change in treatment to Humira® is made by the treating physician
62224391|NCT02502799|ACTIVE_COMPARATOR|Continued Monitoring and Assessment|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. Participants randomized to the continued monitoring and assessment arm will receive no additional intervention. Primary and secondary outcomes will be monitored.
62799053|NCT06690905|ACTIVE_COMPARATOR|Piperacillin-tazobactam administered in a standard infusion|Piperacillin-tazobactam dose will be administered over 30 minutes for every piperacilline-tazobactam administered in the study (as instructed by the drug's monograph)
62224392|NCT02502799|ACTIVE_COMPARATOR|PT with ACBT|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. For participants randomized to the PT with ACBT arm, parents will participate in behavioral parent training (PT) and adolescents will participate in cognitive behavioral therapy to reduce substance use (CBT).
62224393|NCT02502799|ACTIVE_COMPARATOR|PT with ACBT and Methylphenidate|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. For participants randomized to the PT with ACBT and Methylphenidate arm, parents will participate in behavioral parent training (PT) and adolescents will participate in cognitive behavioral therapy to reduce substance use (ACBT). Adolescents will also receive methylphenidate.
62224394|NCT01997307||Stratification by gender and age, including 4 age categories|\>=55-64 years
62224395|NCT01997307||Age >=65 to 74|
62224396|NCT01997307||Age >=75 to 84|
62224397|NCT01997307||Age >=85|
62224398|NCT05259020|EXPERIMENTAL|ID140009|
62224399|NCT05259020|ACTIVE_COMPARATOR|ID1803+ID1805|
62224400|NCT02725801|ACTIVE_COMPARATOR|one-port|intervention is placement of one-port tissue expander at time of reconstruction
62224401|NCT02725801|ACTIVE_COMPARATOR|two-port|intervention is placement of two-port tissue expander at time of reconstruction
62224402|NCT06284720|EXPERIMENTAL|Experimental: real tACS|5 sessions of gamma tACS (40 Hz) at 2 mA over the Precuneus
62224403|NCT06284720|SHAM_COMPARATOR|Placebo Comparator: sham tACS|5 sessions of sham over the Precuneus
62224404|NCT01523925|EXPERIMENTAL|Combined dCIT with FET|Combined distributed constraint induced therapy with functional electrical therapy
62224405|NCT01523925|EXPERIMENTAL|Combined BAT with FET|Combined bilateral arm treatment with functional electrical therapy
62224406|NCT01523925|ACTIVE_COMPARATOR|Control intervention group|Control intervention
62224407|NCT01523925|EXPERIMENTAL|dCIT|distributed constraint induced therapy
62224408|NCT01523925|EXPERIMENTAL|BAT|bilateral arm treatment
62417567|NCT06702501|EXPERIMENTAL|Single Arm - Procedure & Follow up|Subjects will undergo minimally invasive pericardiotomy under fluoroscopic guidance and general anesthesia using the PeriCut Catheter System
62417568|NCT06542445|ACTIVE_COMPARATOR|CBD oil enriched with terpenes|24% CBD, terpenes, MCT oil.
62417569|NCT06542445|PLACEBO_COMPARATOR|Placebo oil|fragrances and flavors, MCT oil.
62799054|NCT03686904|PLACEBO_COMPARATOR|SOC GROUP [Cohort A]|Debridement, SOC irrigation \& SOC topical gel
62224409|NCT05660486|EXPERIMENTAL|Aromatherapy group|Participants in this group will receive, lavender essential oil applied to their surgical mask for 5 minutes prior to scheduled standard of care ultrasound guided musculoskeletal procedure.
62224410|NCT05660486|PLACEBO_COMPARATOR|Placebo group|Participants in this group will receive water applied to their surgical mask for 5 minutes prior to scheduled standard of care ultrasound guided musculoskeletal procedure.
62224411|NCT04908462|EXPERIMENTAL|Part A Healthy volunteers: Single ascending doses|
62224412|NCT04908462|EXPERIMENTAL|Part B Healthy Volunteers Multiple ascending doses|
62224413|NCT02650882|PLACEBO_COMPARATOR|placebo|Placebo group (PG) Nine athletes who maintained their regular sporting activities and were submitted to the IMT program for 12 weeks with a fixed load at 15% MIP, placebo protocol.
62224414|NCT02650882|EXPERIMENTAL|Experimental|Experimental group (EG) Ten athletes who maintained their regular sporting activities and were submitted to the IMT program for 12 weeks with a progressive load at 60%, 70% and 80 % of MIP.
62224415|NCT03139110||Control|Patients treated in emergency departments without the presence of a mediator.
62224416|NCT03139110||Mediation|Patients treated in emergency departments with the presence of a mediator.
62224417|NCT02111187|ACTIVE_COMPARATOR|LDE225 (Arm1)|Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
62224418|NCT02111187|NO_INTERVENTION|Observation Arm (Arm2)|Observation Arm (Arm2) will receive no treatment prior to prostatectomy.
62224419|NCT03561012|EXPERIMENTAL|Intervention arm|
62224420|NCT03561012|ACTIVE_COMPARATOR|Control Arm|
62224421|NCT06063811||LVAD patients|Patients with end-stage heart failure with an LVAD implanted undergoing VT ablation.
62224422|NCT03759951|EXPERIMENTAL|Control|No intervention. Participated only in measurements at baseline, at 6 months and at 12 months.
62224423|NCT03759951|EXPERIMENTAL|DoIT-1|Participated in a supervised 1-year workout exercise training program once per week and in measurements at baseline, at 6 months and at 12 months.
62224424|NCT03759951|EXPERIMENTAL|DoIT-2|Participated in a supervised 1-year workout exercise training program twice per week and in measurements at baseline, at 6 months and at 12 months.
62224425|NCT03759951|EXPERIMENTAL|DoIT-3|Participated in a supervised 1-year workout exercise training program thrice per week and in measurements at baseline, at 6 months and at 12 months.
62224426|NCT01639781|ACTIVE_COMPARATOR|flavanol rich intervention|flavanol rich drink
62224427|NCT01639781|PLACEBO_COMPARATOR|flavanol free intervention|flavanol free drink
62224428|NCT06610136|EXPERIMENTAL|Caffeine - Males|
62224429|NCT06610136|PLACEBO_COMPARATOR|Placebo - Males|
62417570|NCT03993288|EXPERIMENTAL|Ferrum Lek|Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks
62799055|NCT03686904|ACTIVE_COMPARATOR|SOC TOPICAL GEL & TORRENT X GROUP [Cohort B]|Debridement, benzalkonium irrigation \& SOC topical gel
62799056|NCT03686904|ACTIVE_COMPARATOR|BLASTX and SALINE (SOC) GROUP [Cohort C]|Debridement, SOC saline irrigation \& benzalkonium gel
62417571|NCT03993288|ACTIVE_COMPARATOR|MALTOFER|Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks
62799057|NCT03686904|ACTIVE_COMPARATOR|BLASTX and TORRENTX GROUP [Cohort D]|Debridement, benzalkonium irrigation \& benzalkonium gel
62799058|NCT05682339|ACTIVE_COMPARATOR|Quinine only|In this arm, participants will receive a 10 ml intragastric bolus of 300 mg quinine followed 30 min later by 100 ml intragastric bolus of control for L-isoleucine.
62799059|NCT05682339|ACTIVE_COMPARATOR|L-isoleucine only|In this arm, participants will receive a 10 ml intragastric bolus of control for quinine followed 30 min later by 100 ml intragastric bolus of 5 g L-isoleucine.
62799060|NCT05682339|ACTIVE_COMPARATOR|Quinine + L-isoleucine|In this arm participants will receive a 10 ml intragastric bolus of 300 mg quinine followed 30 min later by 100 ml intragastric bolus of 5 g L-isoleucine.
62224430|NCT06610136|EXPERIMENTAL|Caffeine - Females|
62417572|NCT04668300|EXPERIMENTAL|Treatment (oleclumab, durvalumab)|Patients receive oleclumab IV over 1 hour every 2 weeks for 5 doses, then every 4 weeks thereafter. Patients also receive durvalumab IV over 1 hour every 4 weeks. Cycle repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62417573|NCT05690464|ACTIVE_COMPARATOR|magnesium|magnesium glycinate supplement, 480 mg/day
62799061|NCT05682339|PLACEBO_COMPARATOR|Control|In this arm, participants will receive a 10 ml intragastric bolus of control solution followed 30 min later by 100 ml intragastric bolus of control solution.
62799062|NCT05432284|PLACEBO_COMPARATOR|Placebo|Placebo (ambient air)
62799063|NCT05432284|EXPERIMENTAL|Vaporized high THC alone|30mg of vaporized pure THC
62799064|NCT05432284|EXPERIMENTAL|Vaporized low THC alone|15mg of vaporized pure THC
62799065|NCT05432284|EXPERIMENTAL|Vaporized low beta-myrcene|2mg of vaporized beta-myrcene
62799066|NCT05432284|EXPERIMENTAL|Vaporized high beta-myrcene|9mg of vaporized beta-myrcene
62799067|NCT05432284|EXPERIMENTAL|Vaporized low THC and low beta-myrcene|15mg vaporized THC with 2mg vaporized beta-myrcene
62799068|NCT05432284|EXPERIMENTAL|Vaporized low THC and high beta-myrcene|15mg vaporized THC with 9mg vaporized beta-myrcene
62417574|NCT05690464|PLACEBO_COMPARATOR|placebo|placebo supplement
62417575|NCT04443673|EXPERIMENTAL|Glycine|Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
62417576|NCT04443673|NO_INTERVENTION|Control|Participants will receive the habitual treatment for their severe condition.
62417577|NCT03992456|EXPERIMENTAL|Arm A (panitumumab)|Patients receive panitumumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for a maximum of 24 cycles in the absence of disease progression or unacceptable toxicity.
62588703|NCT02100995|EXPERIMENTAL|STOP Intervention|The STOP treatment includes content designed to simultaneously and explicitly target both chronic pain and obesity. Treatment components are drawn from evidence-based interventions for chronic pain and obesity, separately.
62799069|NCT05432284|EXPERIMENTAL|Vaporized high THC and low beta-myrcene|30mg vaporized THC with 2mg vaporized beta-myrcene
62799070|NCT05432284|EXPERIMENTAL|Vaporized high THC and high beta-myrcene|30mg vaporized THC with 9mg vaporized beta-myrcene
62224431|NCT06610136|PLACEBO_COMPARATOR|Placebo - Females|
62224432|NCT05994404||Anterior Cervical Discectomy and Fusion|Ventral decompression and fusion was performed using multi-level discectomy (including partial or single level corpectomy) with fusion and plating. Allograft was used at each disc space and all compressive osteophytes were removed using the operating microscope. Plate fixation was done with rigid, semi-constrained, or dynamic titanium plates to optimize fusion and minimize complications.
62799071|NCT01187485|EXPERIMENTAL|Androderm® 2.5mg|Study subjects will be randomized to one of the study arms: 2.5 mg of Androderm®.
62799072|NCT01187485|EXPERIMENTAL|Androderm® 5.0 mg|Study subjects will be randomized to one of the study arms: 5.0 mg of Androderm®.
62799073|NCT01187485|EXPERIMENTAL|Androderm® 7.5mg|Study subjects will be randomized to one of the study arms: 7.5 mg of Androderm®.
62224433|NCT05994404||Posterior Instrumented Cervical Fusion|Dorsal decompression and instrumented fusion was performed using midline cervical laminoectom with the application of lateral mass screws and rods for rigid fixation. Local bone was used along with allograft to promote a lateral mass fusion.
62799074|NCT06727019|EXPERIMENTAL|red-light|In the low-level red-light (LLRL) group, the children used LLRL irradiation twice a day for 3-minute sessions, ensuring a gap of over 4 h between each use
62799075|NCT06727019|EXPERIMENTAL|atropine|participants in the atropine group used 0.01% low-dose atropine eye drops once each night
62417578|NCT03992456|ACTIVE_COMPARATOR|Arm B (regorafenib, trifluridine and tipiracil hydrochloride)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12, or regorafenib PO QD on days 1-21, at the discretion of the treating physician. Treatment repeats every 28 days for a maximum of 24 cycles in the absence of disease progression or unacceptable toxicity.
62417579|NCT04104490||Severe pulmonary arterial hypertension.|"This cohort will consist of patients with severe pulmonary arterial hypertension.~This is defined as mean pulmonary arterial pressure 25 mm Hg or greater and pulmonary artery occlusion pressure 15 mmHg or less measured by right cardiac catheterization and a clinical diagnosis of severe disease.~Participants will be without signs of left heart disease, lung disease and or hypoxia, chronic thromboembolic pulmonary hypertension or pulmonary hypertension of unclear multifactorial mechanisms.~This is an observational study with no interventions."
62417580|NCT04104490||Mild-moderate pulmonary arterial hypertension|"This cohort will consist of patients with mild-moderate pulmonary arterial hypertension.~This is defined as mean pulmonary arterial pressure 25 mm Hg or greater and pulmonary artery occlusion pressure 15 mmHg or less measured by right cardiac catheterization and a clinical diagnosis of mild-moderate disease.~Participants will be without signs of left heart disease, lung disease and or hypoxia, chronic thromboembolic pulmonary hypertension or pulmonary hypertension of unclear multifactorial mechanisms.~This is an observational study with no interventions."
62417581|NCT04104490||Reference subjects without pulmonary hypertension|Reference subjects will be healthy people, age- and sex-matched to the other two cohorts, who have no pulmonary artery hypertension.
62417582|NCT06087991||Quantitative Interviews|Any Castleview patient who participates in this model will be emailed both the Patient Satisfaction Questionnaire Short Form (PSQ 18) and the Government Performance and Results Act surveys after hospital discharge, six months, and at discharge for buprenorphine.
62417583|NCT06087991||Qualitative Interviews|Qualitative interviews among providers, stakeholders and community members associated with Castleview Hospital will be conducted after the model has been deployed. The qualitative interviews will come from The Consolidated Framework for Implementation Research (CFIR) which is a validated tool that was developed that was developed to evaluate implementation studies.
62417584|NCT03684473|EXPERIMENTAL|Yoga Intervention|Participants in the intervention condition will be assigned to an 8-week online delivered trauma-informed yoga protocol focused on home-based daily practice of yoga and mindfulness meditation.
62417585|NCT01305486||XenMatrix|
62417586|NCT06704152|EXPERIMENTAL|Dose Escalation Cohorts|AML, ALL and MDS HLA-A\*02:01 and HA-1-positive (H/H or H/R) patients with an identified HLA-matched, HA-1-negative (R/R) donor will be dosed in dose escalation cohorts
62417587|NCT06704152|EXPERIMENTAL|BSB-1001 Expansion Dose|Once the maximum tolerated dose (MTD) or promising dose is reached additional AML HLA-A\*02:01 and HA-1-positive (H/H or H/R) patients with an identified HLA-matched, HA-1-negative (R/R) donor will be enrolled in the expansion cohort.
62224434|NCT05994404||Laminoplasty|Laminoplasty was performed using an open-door approach with the application of plates and screws at each treated level. Ceramic or allograft laminar spacers (surgeon's choice) were used with titanium plates and screws to expand the spinal canal diameter.
62224435|NCT04074863|ACTIVE_COMPARATOR|Darrach|Surgical procedure: resection of distal ulna
62224436|NCT04074863|ACTIVE_COMPARATOR|Prosthesis|Surgical procedure: ulnar head replacement
62224437|NCT01502020|ACTIVE_COMPARATOR|Zyclara™|
62224438|NCT01502020|EXPERIMENTAL|Generic Imiquimod Cream, 3.75%|
62417588|NCT00929201|ACTIVE_COMPARATOR|Sita + Met then Sita/Met FDC|Participants receive sitagliptin (Sita) 50 mg and metformin (Met) 500 mg individual tablets administered concomitantly as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin/metformin (Sita/Met) 50/500 mg FDC tablet administered as a single dose during Period 2.
62799076|NCT04491968|EXPERIMENTAL|Mindfulness Oriented Recovery Enhancement|The Mindfulness Oriented Recovery Enhancement arm will participate in eight, weekly, two-hour group sessions.MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
62799077|NCT04491968|OTHER|Methadone Treatment as Usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
62224439|NCT01502020|PLACEBO_COMPARATOR|Vehicle Cream|
62224440|NCT02301260|EXPERIMENTAL|Speed of Processing Training (SPT)|SPT will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
62224441|NCT02301260|PLACEBO_COMPARATOR|Placebo control group|Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 sessions)
62224442|NCT04949360|ACTIVE_COMPARATOR|Standard CBTi (CBTi-S):|This is a positive control group/active comparator, in which standard CBTi (the golden standard behavioral treatment for insomnia) will be made available. This treatment consists of an eight-week treatment composed by weekly and structured appointments with a board-certified sleep psychologist. The professionals performing the CBTi sessions will not be part of the research team. Due to the restriction imposed by the COVID-19 pandemic, the appointments will be made remotely (video calls with psychologists), which have already been proven to be equivalent to the in-person CBTi.
62224443|NCT04949360|PLACEBO_COMPARATOR|Minimal intervention - Sleep hygiene (MI-SH):|This group corresponds to a negative control group/placebo comparator, subjected to minimal intervention. It is based on the delivery of informative material regarding normal sleep pattern and sleep hygiene (through regular mail and e-mail). This procedure is more adequate as a control than the commonly used no-treatment or waiting list controls, due to the behavioral nature of insomnia.
62224444|NCT04949360|EXPERIMENTAL|Online CBTI (CBTI-O)|This group will receive access to an eight-month CBTi-based treatment through the SleepUp app. The platform will be updated into a non-commercial version, and all features other than the CBTi track, the sleep log and the clinical tests will be removed. This way, the participants of this group will receive interventions equivalent to the standard in-person CBTi, but provided through a digital platform. The treatment last eight weeks.
62224445|NCT04949360|EXPERIMENTAL|Online CBTi + additional features (CBTi-O+)|This group will have access to the complete premium version of SleepUp platform. It includes those presented in the CBTi-O group and other therapeutic and complementary features (including meditation audios and videos, mindfulness therapy, relaxation soundtracks, sleep hygiene tips, virtual assistant, and telehealth.
62224446|NCT05221671|NO_INTERVENTION|not received information leaflet|"During the preoperative anesthesia clinic examination, demographic data will be recorded and routine information about anesthesia will be provided. However, the information leaflet will not be handed to the patient and parents.~The m-YPAS scale for pediatric patients will be evaluated and filled by the investigators before the anesthesia induction. Parents will be asked to fill out questionnaires for anxiety assessment and anesthesia knowledge level in the waiting room before the procedure."
62224447|NCT05221671|ACTIVE_COMPARATOR|received information leaflet|"During the preoperative anesthesia evaluation, the children and their parents, who are included in the group who will receive information leaflets according to randomization, will be given information leaflets and both the child and their parents will be asked to read them before the procedure day. Age-appropriate brochures will be provided for children, and parent information leaflets will be provided for parents.~The m-YPAS scale for pediatric patients will be evaluated and filled by the investigators before the anesthesia induction. Parents will be asked to fill out questionnaires for anxiety assessment and anesthesia knowledge level in the waiting room before the procedure."
62224448|NCT01300962|EXPERIMENTAL|BYL719 ARM B|Treatment with BYL719 and Capecitabine
62224449|NCT01300962|EXPERIMENTAL|BKM120 ARM A|Treatment with BKM120 and capecitabine
62224450|NCT01300962|EXPERIMENTAL|ARM C|BKM 120 plus capecitabine plus trastuzumab
62224451|NCT01300962|EXPERIMENTAL|ARM D|BKM120 plus capecitabine plus lapatinib
62417589|NCT00929201|ACTIVE_COMPARATOR|Sita/Met FDC then Sita + Met|Participants receive sitagliptin/Metformin 50 mg/500 mg FDC tablet administered as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 2.
62417590|NCT04400253|EXPERIMENTAL|Intervention group|The intervention group will receive a 18-week in-person program. The program includes the following components: multi family group counseling, group exercise classes, mother group discussion, daughter group discussion and Fitbit.
62417591|NCT04400253|NO_INTERVENTION|Control group|The group group will receive print materials about physical activity.
62417592|NCT06156631|EXPERIMENTAL|Participants receive DASH-ExMAMI intervention.|Jordanian participants who are adults (age between ≥ 18 and 65 years), have had diagnosed with hypertension and has started his or her treatment plan, and have uncontrolled hypertension (The average systolic blood pressure reading that is equal to or higher than 130 mmHg and/or diastolic blood pressure that is equal to or higher than 90 mmHg for the last two patients' records available at the health centre.
62224452|NCT04918667|EXPERIMENTAL|Berberine MetX™ Ultra Absorption|16 healthy subjects will receive orally 500 mg of berberine in two capsules of Berberine MetX™ Ultra Absorption.
62224453|NCT04918667|ACTIVE_COMPARATOR|Berberine MetX™|16 healthy subjects will receive orally 500 mg of berberine in one capsule of Berberine MetX™ (reference product).
62224454|NCT01248065|PLACEBO_COMPARATOR|Ciclesonide + placebo|
62224455|NCT01248065|EXPERIMENTAL|Ciclesonide + Vitamin D|
62224456|NCT00511901|PLACEBO_COMPARATOR|Placebo & Niferex|Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks
62224457|NCT00511901|ACTIVE_COMPARATOR|epoetin alpha & Niferex|40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks
62224458|NCT06407596|EXPERIMENTAL|group 1: high intensive laser|HILT was applied 3 times per week, totaling 9 sessions for three weeks.
62224459|NCT06407596|EXPERIMENTAL|group 2: TENS+Ultrasound|tens+us used combined. 5 times per week. total 15 sessions for three weeks
62224460|NCT05813977|EXPERIMENTAL|Group 1: Tritube (FCV) used during tracheostomy|The patient is intubated with Tritube® after the removal of the conventional endotracheal tube (ETT) and Tritube® was advanced until proximal to the carina. Before starting the PDT, measurements with ATP bioluminescence-based method (3M Clean-trace®) were made by taking sample from a sterile PVC (poly vinyl chloride) surface (10 cm2) which is held 50 cm over the operation site. After PDT with Griggs method (Portex), the measurements were repeated by taking sample from surface.
62224461|NCT05813977|NO_INTERVENTION|Group 2: Conventional endotracheal tube used during tracheostomy|In the patient who was intubated with a conventional endotracheal tube (ETT), the tube was withdrawal to the vocal cords. Before starting the PDT, measurements with ATP bioluminescence-based method (3M Clean-trace®) were made by taking sample from a sterile PVC surface (10 cm2) which is held 50 cm over the operation site. After PDT with Griggs method (Portex), the measurements were repeated by taking sample from surface.
62224462|NCT03903016|EXPERIMENTAL|Test (T)|Insulin Lispro (SAR342434), 200 Units/ml, single dose on day 1 of each period
62417593|NCT06156631|NO_INTERVENTION|Participants who do not receive DASH-Ex MAMI|Jordanian participants who are adults (age between ≥ 18 and 65 years), have had diagnosed with hypertension and has started his or her treatment plan, and have uncontrolled hypertension (The average systolic blood pressure reading that is equal to or higher than 130 mmHg and/or diastolic blood pressure that is equal to or higher than 90 mmHg for the last two patients' records available at the health centre.
62433484|NCT04487145|EXPERIMENTAL|HIV-infected children on EFV-based ART (E3)|30 HIV-infected children age 3 - 10 years on EFV-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
62026217|NCT04540107|EXPERIMENTAL|Cohort 1 (MRI, MRSI) (CLOSED TO ENROLLMENT)|Patients undergo MRI and MRSI scans over 1 hour at baseline. Patients then continue to undergo MRSI scans that follow the clinical MRI schedule set by doctors to monitor patients' care. Participants enrolled in cohort 1 may later enroll in cohort 2 of study once eligibility has been reviewed and approved by neuro-oncologist
62224463|NCT03903016|ACTIVE_COMPARATOR|Reference (R)|Insulin Lispro Sanofi® ,100 Units/ml, single dose on day 1 of each period
62224464|NCT01553331|ACTIVE_COMPARATOR|conventional diathermy hook|Laparoscopic cholecystectomy made with diathermy hook starting from Calot´s triangle
62224465|NCT01553331|ACTIVE_COMPARATOR|ultrasonic dissection|Laparoscopic cholecystectomy made with ultrasonic dissection starting from gallbladder fundus
62224466|NCT02331251|EXPERIMENTAL|Arm 1|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 on day 1 and day 8 every 21 days
62224467|NCT02331251|EXPERIMENTAL|Arm 2|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 900 mg/m2 on day 1 and 8 and docetaxel 75 mg/m2 on day 8 every 21 days
62224468|NCT02331251|EXPERIMENTAL|Arm 3|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2 on day 1 and day 8 every 21 days
62224469|NCT02331251|EXPERIMENTAL|Arm 4|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 and vinorelbine 25 mg/m2 on day 1 and day 8 every 21 days
62224470|NCT02331251|EXPERIMENTAL|Arm 5|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Irinotecan 300 mg/m2 on day 1 every 21 days
62224471|NCT02331251|EXPERIMENTAL|Arm 6|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Liposomal doxorubicin 30 mg/m2 on day 1 every 21 days
62224472|NCT06598722|EXPERIMENTAL|BCL-2 inhibitors combined with the HyperCVAD regimen for newly diagnosed T-ALL/LBL|
62224473|NCT06598722|OTHER|propensity score matching with historical data|
62417594|NCT03665246|EXPERIMENTAL|Intervention (iMBC/ECD + C-PrES)|The intervention group of women/children dyads who consent will receive 14 sessions of the Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) curriculum in addition to the C-PrES curriculum. Upon completion of 14 sessions, women will continue to receive MNCHN and ECD messages and group-based iMBC booster sessions every 3 months.
62417595|NCT03665246|NO_INTERVENTION|Control (C-PrES)|The control group of women/children dyads who consent will have exposure to 14 sessions of the C-PrES curriculum which promotes the adoption of key MNCHN behaviors (e.g. newborn care, exclusive breastfeeding, etc.). Upon completion of 14 sessions, women will continue to receive MNCHN and ECD messages.
62417596|NCT06704022|EXPERIMENTAL|Interventional Arm|Ingestion of the ONS
62224474|NCT02389920|EXPERIMENTAL|Nilotinib|nilotinib 400mg BID for 12 months
62224475|NCT01991054|EXPERIMENTAL|vitamin D3 supplementation|The study group participants will receive vitamin D3 supplementation (120,000 I.U per month)for 6 months
62224476|NCT01991054|PLACEBO_COMPARATOR|placebo group|placebo group, 15 ml per month for 6 months
62224477|NCT02022267||study group|Patients with a minimum age of three years from our prospective, consecutive database of patients with clubfoot treated with the Ponseti method beginning in 2002 are considered for this study. Patients with unilateral or bilateral idiopathic clubfoot are included. Patients with clubfoot associated with syndromes or neurological diseases, with mild clubfoot that required fewer than three casts for initial correction, who first presented at an age older than three months, who were living outside of the country, and who were initially treated elsewhere with more than three casts are excluded.
62224478|NCT02022267||control group|healthy children of employees of our hospital
62224479|NCT01323634|EXPERIMENTAL|Fluticasone Furoate / GW642444 (vilanterol)|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
62026218|NCT04540107|EXPERIMENTAL|Cohort 2 (MRI, hyperpolarized carbon C 13 pyruvate, MRSI)|Patients undergo MRI scan at baseline. Patients then receive hyperpolarized carbon C 13 pyruvate IV over less than 1 minute and undergo MRSI scan at baseline. Patients then continue to undergo MRSI scans that follow the clinical MRI schedule set by doctors to monitor patients' care.
62224480|NCT01323634|ACTIVE_COMPARATOR|Fluticasone Propionate / salmeterol|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
62224481|NCT02882139||Electrical storm|Documentation of 3 or more episodes of sustained ventricular arrhythmia within 24h or documentation of sustained ventricular tachycardia lasted at least 12h
62224482|NCT04788511|EXPERIMENTAL|Semaglutide|All participants will receive either semaglutide 2.4 mg once weekly or placebo once weekly as add-on to standard of care. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose.
62224483|NCT04788511|PLACEBO_COMPARATOR|Placebo (semaglutide)|All participants will receive either semaglutide 2.4 mg once weekly or placebo once weekly as add-on to standard of care. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose.
62417597|NCT00398632|EXPERIMENTAL|Duloxetine|Duloxetine 60 mg, by mouth, once daily or twice daily (as needed to control symptoms of major depression)
62417598|NCT00424515|EXPERIMENTAL|Treatment Arm|Imatinib
62433485|NCT04487145|EXPERIMENTAL|HIV-infected children on DTG-based ART (D3)|30 HIV-infected children age 11 - 17 years on DTG-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
62433486|NCT04487145|EXPERIMENTAL|HIV-infected children on LPV/r-based ART (L1)|20 HIV-infected children age 3 - 10 years on LPV/r-based ART for at least 10 days will take one oral dose DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
62026219|NCT04122417||Control Group|"The mothers and infants in the experimental and control groups were assigned to the groups by randomization method. Therapeutic touch didn't apllied to control group.~Babies in the control group who took care practices in accordance with normal hospital procedures."
62026220|NCT04122417||Yakson Group|"The touch method was taught to the mothers in the Yakson group by the researcher in the first three days after the birth with the training brochure, video and applications on the model that are prepared in accordance with expert opinion.~In yakson method, mother's fingers are closed, and she should touch in a way that does not apply excessive pressure. The method is applied for a total of 15 minutes in three cycles. First 5 minutes is resting the hand, 5 minutes is gentle caressing, and another 5 minutes of resting the hand."
62026221|NCT04122417||Gentle Human Touch Group|"The touch method was taught to the mothers in the Gentle Human Touch group by the researcher in the first three days after the birth with the training brochure, video and applications on the model that are prepared in accordance with expert opinion.~Mother slowly places one hand on the baby's hand and the other over pelvic cavity, covering the waist and hips of the baby.~The touch is preserved for 15 minutes. In order to ensure equal touch for the duration of gentle human touch, the mother sits on a stool and her elbows have to be at the same level with baby's bed"
62026222|NCT04198129|EXPERIMENTAL|Treatment|Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies), then the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days (Amoxicillin and Clavulanic acid which is clinically interchangeable with Unasyn), or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies). If the patient is discharged home prior to completing 7 days of oral antibiotic therapy, patient will receive prescription to finish the remaining doses of antibiotics for a total period of 7 days.
62026223|NCT04198129|ACTIVE_COMPARATOR|Control|Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care.
62026224|NCT00388414|PLACEBO_COMPARATOR|Placebo - sugar pill|
62026225|NCT00388414|EXPERIMENTAL|Duloxetine|
62224484|NCT06183749||group 1general body trauma (Group 1)|Diagnosed as traumatic brain injury due to general body trauma neurosurgery in the emergency department and hospitalized for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit and those who have been in intensive care within the past two years.
62224485|NCT06183749||isolated head trauma (Group 2).|diagnosed as traumatic brain injury due isolated head trauma neurosurgery in the emergency department and hospitalized for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit and those who have been in intensive care within the past two years.
62224486|NCT01618604||Healthy|26 healthy voluntary probands
62224487|NCT04543487|EXPERIMENTAL|Control Group|Group name
62224488|NCT04681599|NO_INTERVENTION|Nebulization without filter or scavenger|Subject will use a standard nebulizer
62224489|NCT04681599|EXPERIMENTAL|Nebulization with a filter or scavenger|Subject will use a nebulizer with a filter placed at the other end of nebulizer mouthpice or a scavenger outside the nebulizer mask
62224490|NCT04681599|NO_INTERVENTION|High-flow nasal cannula|Subject will use high-flow nasal cannula at 40 L/min
62417599|NCT06701695|ACTIVE_COMPARATOR|Periarticular injection group|Patients in the periarticular injection group were administered a 100 mL periarticular solution comprising 200 mg of bupivacaine (40 mL), 60 mg of ketorolac (2 mL), 8 mg of dexamethasone (2 mL), 2 mg of 1:1000 epinephrine (2 mL), and standard saline solution (54 mL). This solution was prepared in two 50 mL syringes. The first syringe containing 50 mL of the cocktail was injected into the capsule and gluteal muscles before femoral stem insertion. Following joint capsule closure, the second syringe containing 50 mL of the periarticular injection cocktail was infiltrated into the fascia lata muscle, subcutaneous tissue, and wound layers.
62224491|NCT04681599|EXPERIMENTAL|High-flow nasal cannula with a scavenger face tent|Subject will use high-flow nasal cannula at 40 L/min, with a scavenger face tent
62224492|NCT04681599|ACTIVE_COMPARATOR|High-flow nasal cannula with a surgical mask|Subject will use high-flow nasal cannula at 40 L/min, with a surgical mask over nasal cannula
62417600|NCT06701695|SHAM_COMPARATOR|Control group|Participants in the control group underwent standard hemiarthroplasty treatment, with no administration of periarticular injections.
62417601|NCT06700811|EXPERIMENTAL|Ketogenic diet|KetoVie® 4:1 Formula will be administered by oral feeding or gastrostomy tube as indicated. The duration of the diet will be from the time of enrollment up to 12 months of age or until 3 months after a diagnosis of Epileptic Spasms (range 3-15 months).
62417602|NCT04729504|OTHER|Adapted Project BRAVE Group|Participants in this group will receive a single session intervention of a culturally and linguistically adapted Project BRAVE.
62417603|NCT03970278||All Participants|All participants enrolled in study 401GSDIA02 will have received a single IV dose of DTX401 during their participation in study 401GSDIA01 (NCT03517085).
62417604|NCT06567457|EXPERIMENTAL|SCB-2023B|Participants will receive one booster dose with SCB-2023B vaccine on Day 1
62417605|NCT06567457|ACTIVE_COMPARATOR|SCB-2019|Participants will receive one booster dose with SCB-2019 vaccine on Day 1
62417606|NCT02287142|ACTIVE_COMPARATOR|Interscalene|Single-shot Interscalene Nerve Block with ropivacaine 0.5%
62417607|NCT02287142|ACTIVE_COMPARATOR|Supraclavicular|Single-shot Supraclavicular Nerve Block with ropivacaine 0.5%
62224493|NCT05601947|EXPERIMENTAL|Structured Proprioception and Closed Kinetic Chain Exercises Group|In addition to electrotherapy and conventional exercise program applications, structured proprioception and closed kinetic chain exercises will be applied for 3 weeks under the supervision of a physiotherapist. A rest period of 10 seconds will be given between exercises.
62224494|NCT05601947|EXPERIMENTAL|Wii Based Balance Training Program Group|In addition to electrotherapy and conventional exercise program, wii-based balance training program will be applied 5 days a week for 3 weeks.
62224495|NCT04803331|EXPERIMENTAL|cT1-2N0M0 oral cancer patients|Patients undergo routine sentinel lymph node procedure (99mTc injection, planar imaging, SPECT-CT and surgery) for clinical purposes. After 99mTc injections and imaging has been executed peritumoral SPIO injections are performed by a medical doctor. A T2\*-weighted iron sensitive MRI scan is made 1 hour later.
62224496|NCT04150601|ACTIVE_COMPARATOR|Spontaneous slow vital capacity|Participants will have to perform a slow vital capacity according to the guidelines, from total lung capacity to residual volume
62417608|NCT02287142|ACTIVE_COMPARATOR|Suprascapular|Single-shot Suprascapular Nerve Block with ropivacaine 0.5%
62224497|NCT04150601|ACTIVE_COMPARATOR|SIMEOX|Participants will have to perform a passive exhalation using the SIMEOX, starting from total lung capacity and going until achieving residual volume
62417609|NCT01193829||NSCLC patients|
62417610|NCT06542068|EXPERIMENTAL|Line Bot Assistance Group|During the internship, students will use the Line Bot as a support tool.The Line Bot aims to provide psychological health support and stress management resources, helping students cope with stress and challenges encountered during their clinical internships.
62799078|NCT04050618|EXPERIMENTAL|ocufilcon D control lens, then fanfilcon A test lens|Participants will wear the ocufilcon D control lens for 4 weeks, then crossover to fanfilcon A test lens for 4 weeks of daily wear.
62224498|NCT04150601|ACTIVE_COMPARATOR|PEP|Participants will have to perform an active exhalation using a PEP device, starting from total lung capacity and going until achieving residual volume
62224499|NCT00346632|EXPERIMENTAL|KW-2449|Treatment with ascending doses of KW-2449
62224500|NCT00956748|ACTIVE_COMPARATOR|Ciprodex otic solution|ciprofloxacin 0.3% / dexamethasone 0.1% otic solution
62224501|NCT00956748|EXPERIMENTAL|Ciprodex with 2% NAC|Ciprodex otic solution (ciprofloxacin 0.3% / dexamethasone 0.1%) augmented with 2% N-acetylcysteine
62224502|NCT05748691||Pre-implementation group|Clinical use of hs-cTnI in patients with suspected acute coronary syndrome
62417611|NCT06542068|NO_INTERVENTION|Control Group|This group will not receive assistance from the Line Bot chatbot. These students will receive only the regular internship support and resources without the use of any technological assistance tools.
62417612|NCT05630235|EXPERIMENTAL|CBD/CBD-A followed by placebo group|Participants in this group will receive a one time dose of CBD/CBD-A on visit 2, followed by a placebo on visit 3 after a two-week period.
62417613|NCT05630235|EXPERIMENTAL|Placebo followed by CBD/CBD-A group|Participants in this group will receive a placebo on visit 2, followed by a one time of CBD/CBD-A on visit 3 after a two-week period.
62417614|NCT02050373|EXPERIMENTAL|Low-Level laser|In the laser group, an indium phosphide, galium and aluminum (InGaAIP) diode laser (660nm, 40mW, 0.16 J, 4 J/cm2) was used to irradiate oral mucosa. Subjects received the LLLT from the first day of the conditioning regimen and continued until D+7. Laser therapy was applied by a single dentist expertise in laser irradiation. The tip touched the mucosa of the lips, right and left buccal mucosa, right and left lateral tongue, ventral tongue and buccal floor, giving a total of 10 points per region.
62799079|NCT04050618|EXPERIMENTAL|etafilcon A controls, then fanfilcon A test lens|Participants will wear the etafilcon D control lens for 2 weeks, then crossover to fanfilcon A test lens for 2 weeks of daily wear.
62799080|NCT02660853|OTHER|Severe Asthma|Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines
62799081|NCT05781074|EXPERIMENTAL|Cryoablation combined with Sintilimab and lenvatinib|Cryoablation treatment starts at day 0. Sintilimab will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62799082|NCT05539001||systemic lupus erythematosus group|Based on hospitalization and follow-up data, the enrolled patients were divided into severe group and mild group by BILAG score independently by specialized researchers.
62799083|NCT04050449||Group 1: Switch to TLD from NNRTI first-line regimen|Participants switching to TLD from a first-line regimen containing a NNRTI. These participants will be divided into two subgroups based upon their HIV-1 RNA level in a sample obtained at entry, before starting TLD. Group 1a will include participants with viremia (HIV-1 RNA \>1000 copies/mL at start of TLD) and Group 1b will include participants with suppressed viral load (HIV-1 RNA ≤1000 copies/mL at start of TLD).
62417615|NCT02050373|NO_INTERVENTION|Control|In the control group, patients receive only the preventive protocol bone marrow transplant industry, consisting of mouthwashes and sodium fluoride. For ethical reasons, individuals who present oral mucositis grade 2 (WHO) will receive LLLT.
62417616|NCT05358392|EXPERIMENTAL|emotional freedom technique|5 sessions of EFT\* will be applied to this group on the first day of the treatment, 1st Control, 2nd Control, before the OPU procedure and before the embryo transfer. Subjective discomfort level will be measured with SUD\*\* before and after each application.
62417617|NCT05358392|NO_INTERVENTION|control|No application will be made to this group. Infertility stress scale will be filled in the case and control group at the beginning of the treatment and after the embryo transfer.
62417618|NCT05919069|EXPERIMENTAL|Group 1|Participants with mild hepatic impairment (CP Class A, score of 5 or 6)
62417619|NCT05919069|EXPERIMENTAL|Group 2|Participants with moderate hepatic impairment (CP Class B, score of 7 to 9)
62417620|NCT05919069|EXPERIMENTAL|Group 3|Participants with severe hepatic impairment (CP Class C, score of 10 to 15)
62417621|NCT05919069|EXPERIMENTAL|Group 4|Participants with normal hepatic function matched on a group level regarding age, body weight, and sex to the impaired groups
62417622|NCT05461248|EXPERIMENTAL|Experimental group|The stoma drainage fluid was reinfused once a week for 2 months after radical rectal surgery. For each reinfusion, eat liquid food the day before, collect 400-600mL of stoma discharge on the same day (if the stoma fluid is too small, it can be mixed with warm water), and use an enema bag to reinfuse from the patient's anus. Generally, the flow rate is controlled at about 100mL/min.
62417623|NCT05461248|SHAM_COMPARATOR|Conventional group|The conventional group received no additional intervention.
62588704|NCT02100995|ACTIVE_COMPARATOR|Standard Care Weight (SCW)|The weight loss intervention includes content focused around nutrition and eating habits, stimulus control and behavioral change, and physical activity. This content has been chosen because of its demonstrated effectiveness and importance in behavioral interventions to reduce weight.
62224503|NCT05748691||Post-implementation group|Clinical use of hs-cTnT in patients with suspected acute coronary syndrome
62224504|NCT04555382||AKI group|this group are included patients who have not occured acute kidney injury at first, however acute kidney injury are occured soon afterwards during the observation period.
62224505|NCT04555382||non-AKI group|this group are included patients who have not occured acute kidney injury during the observation period.
62224506|NCT04026880|ACTIVE_COMPARATOR|Treatment Arm|weekly IM administration of 25 mg Testosterone Enanthate for 12 weeks
62224507|NCT04026880|PLACEBO_COMPARATOR|Control Arm|Weekly IM administration of placebo for 12 weeks
62224508|NCT00862147|EXPERIMENTAL|ICDP|International Child Development Program
62224509|NCT00862147|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual
62224510|NCT00005597|EXPERIMENTAL|Temozolomide|200 mg/m\^2/day, PO, on Days 1-5 of each 28 day cycle.
62224511|NCT02165254|OTHER|high dose tai chi intervention|
62417624|NCT02709759|ACTIVE_COMPARATOR|MI|Motivational interviewing focused on reducing alcohol use, delivered by videoconferencing.
62417625|NCT02709759|ACTIVE_COMPARATOR|BA|Brief Advice to reduce drinking delivered by videoconferencing
62417626|NCT02709759|ACTIVE_COMPARATOR|MI + ITM|Motivational intervention to reduce drinking, delivered by videoconferencing, plus Interactive text messaging around alcohol use
62417627|NCT02709759|ACTIVE_COMPARATOR|BA + ITM|Brief Advice to reduce drinking, delivered by videoconferencing, plus Interactive text messaging around alcohol use
62588705|NCT02100995|ACTIVE_COMPARATOR|Standard Care Pain (SCP)|The chronic pain intervention is focused around reconceptualization of pain, decreasing catastrophizing, and increasing self-efficacy for pain. This content has been chosen because of its demonstrated effectiveness and importance in non-pharmacological interventions to improve pain management.
62224512|NCT02165254|OTHER|standard dose tai chi intervention|
62224513|NCT01054170|EXPERIMENTAL|AZD9668|
62417628|NCT02709759|ACTIVE_COMPARATOR|MI + ITM + EI|Participants in this arm receive MI delivered by videoconferencing and ITM over 9 months rather than 1
62417629|NCT02709759|ACTIVE_COMPARATOR|BA + ITM + EI|Participants in this arm receive BA delivered by videoconferencing and ITM over 9 months rather than 1
62417630|NCT02709759|ACTIVE_COMPARATOR|BA + EI|Participants in this arm receive BA delivered by videoconferencing over 9 months rather than 1
62417631|NCT02709759|ACTIVE_COMPARATOR|MI + EI|Participants in this arm receive MI delivered by videoconferencing over 9 months rather than 1
62588706|NCT05600309|EXPERIMENTAL|Favezelimab/Pembrolizumab|Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.
62224514|NCT01054170|PLACEBO_COMPARATOR|Placebo|
62224515|NCT03173677|ACTIVE_COMPARATOR|Lipid intake|12 subjects had 300 Calories of lipids or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
62224516|NCT03173677|ACTIVE_COMPARATOR|Glucose intake|12 subjects had 300 Calories of glucose or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
62224517|NCT03173677|ACTIVE_COMPARATOR|Protein intake|12 subjects had 300 Calories Whey protein intake or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
62224518|NCT02183051|EXPERIMENTAL|Meloxicam 15 mg|
62224519|NCT02183051|EXPERIMENTAL|Meloxicam 7.5 mg|
62224520|NCT02183051|EXPERIMENTAL|Meloxicam 3.75 mg|
62224521|NCT02183051|EXPERIMENTAL|Meloxicam 1.875 mg|
62224522|NCT02183051|ACTIVE_COMPARATOR|Ibuprofen 400 mg|
62224523|NCT02183051|ACTIVE_COMPARATOR|Ibuprofen 200 mg|
62224524|NCT02183051|PLACEBO_COMPARATOR|Placebo|
62224525|NCT03845569|OTHER|Habitual Protein phase|A trial investigating protein oxidation/metabolism that was used to model resistance trained individual's habitual dietary protein intake (2.2g/kg/d).
62224526|NCT03845569|EXPERIMENTAL|Moderate Protein Phase|A series of three trials over a one week period investigating protein oxidation/metabolism that was used to investigate the metabolic response of decreased protein intake (1.2g/kg/d) over a period of five days (trials on days 1, 3, 5 following reduction in protein intake from 2.2g/kg/d to 1.2g/kg/d) relative to the Habitual protein phase trial.
62026226|NCT02964845|EXPERIMENTAL|WISH with CHW and referral to HFM|Subjects will be assigned a CHW for intervention sessions along with receiving primary care from Highland Family Medicine. CHWs will use the SDT-based, trauma-specific motivational approach in the intervention to engage women during 6 sessions. The duration of the intervention is 3 months. Each session will last 1 hour and will take place in a community location. CHW's will also help facilitate primary care by linking subjects to primary care and will use electronic records to update and receive input from medical providers, and support treatment recommendations from Trillium Health. CHWs will empower women to convey their needs to providers for HIV risk reduction, SUD, co-morbidity (MH, IPV) treatment and will support autonomy and competence for treatment in the intervention sessions.
62026227|NCT02964845|OTHER|Enhanced Treatment as Usual control|eTAU participants will be given an HIV risk reduction information sheet made in cooperation with Trillium Health, HIV health providers. The sheet will include sex and drug behavioral risk reduction strategies and information on obtaining PrEP. The eTAU group is also facilitated to receive healthcare by having a cell phone, a primary care clinic which accepts patients, and bus passes.
62026228|NCT06669000||Gout patients treated according to a Treat-to-Dissolve strategy|Patients initiated with ULT (urate target less than 40 mg/L), and followed every 6 months with Ultrasound until complete urate dissolution
62224527|NCT04987086|EXPERIMENTAL|PSMA PET Arm|The PSMA PET arm received PSMA PET and enhanced CT at the same time in the diagnosis of the patients with suspected renal cancer.
62224528|NCT03655821|ACTIVE_COMPARATOR|Arm A (BSA-based dosing)|Dosing of pemetrexed is based on BSA according drug label
62224529|NCT03655821|EXPERIMENTAL|Arm B (renal function based dosing)|Dosing of pemetrexed is based on renal function, calculated to reach the target AUC.
62224530|NCT00757783|EXPERIMENTAL|darunavir|darunavir 800 mg tablet once daily for 48 weeks,emtricitabine \[FTC\]/tenofovir \[TDF\] 200/300 mg tablet once daily for 48 weeks,ritonavir 100 mg capsule or tablet once daily for 48 weeks
62224531|NCT00757783|EXPERIMENTAL|atazanavir|atazanavir 300 mg capsule once daily for 48 weeks,emtricitabine \[FTC\]/tenofovir \[TDF\] 200/300 mg once daily for 48 weeks,ritonavir 100 mg capsule or tablet once daily for 48 weeks
62224532|NCT02736305|EXPERIMENTAL|Regorafenib|Patients will receive Regorafenib 120mg once daily, with consideration for dose escalation to 160mg if there are no toxicities
62224533|NCT01177579|NO_INTERVENTION|Aim 1; Biomarkers|Blood concentrations of copper coenzymes will be monitored for 1 year
62417632|NCT06662435|EXPERIMENTAL|GYNCOG Intervention|Participants in the GYNCOG arm will be asked to participate in a home-based cognitive training program utilizing BrainHQ on study-provided tablets.
62417633|NCT06662435|NO_INTERVENTION|Control Group|Patients in the Control Group arm will receive usual care with no cognitive intervention.
62417634|NCT06702735|EXPERIMENTAL|Intervention group (with feedback)|Collection of VAS scores and lung function. Explanation about the Rainbow tool to visualize symptom perception, and use of this tool during intervention phase. Feedback sessions with health care professional to evaluate symptom perception using the Rainbow tool.
62026229|NCT02854540|EXPERIMENTAL|Hand A (iontophoresis) vs. Hand B (no treatment)|During the treatment period, participants will be asked to treat one hand with the hydrogel electrode-based iontophoresis device. Participants will also be asked to leave the other hand untreated.
62026230|NCT03646513||SMF Short Modular Femoral Stem Implanted Subjects|Subjects who have been implanted with the SMF Short Modular Femoral Stem for primary total hip arthroplasty.
62026231|NCT05354700|EXPERIMENTAL|HLX07+HLX10+Chemotherapy|HLX07+HLX 10+Chemotherapy (Carboplatin-Etoposide)
62026232|NCT06273852|EXPERIMENTAL|PBA-0405|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected at 1-2 days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of PBA-0405, as single agents. Each microdose is simultaneously injected in a columnar fashion through each of 8, or 5, (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node.
62026233|NCT05255640||patients with ischemia of the lower limbs|
62026234|NCT04498650|PLACEBO_COMPARATOR|Placebo|
62224534|NCT01177579|EXPERIMENTAL|Copper supplement Arm|4 mg or 8 mg copper will be compared in a randomized controlled study
62224535|NCT01177579|NO_INTERVENTION|Normal Controls|Normal subjects will be used to generate reference measures.
62224536|NCT04532203|EXPERIMENTAL|Administration of CAR T-cells|Dose escalation follows the standard 3+3 doseescalation design. A total of 3 dose levels are set for subjects.
62224537|NCT02953860|EXPERIMENTAL|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given, in conjunction with Fulvestrant, PO daily.
62224538|NCT01633983|EXPERIMENTAL|Methotrexate|Chronic CSC will be given an immediate MTX treatment
62224539|NCT01633983|EXPERIMENTAL|Delayed treatment|Acute CSC will be followed for 3 months for a spontaneous resolution before the treatment is offered
62224540|NCT04703231||Natural menopause(Control group)|Female patients between 45-60 years of age diagnosed with menopause without any intervention
62224541|NCT04703231||Surgical Menopause (Case group)|Female patients aged 45-60 years included in the study 3 months after bilateral oophorectomy and hysterectomy
62224542|NCT01688830|EXPERIMENTAL|BI 655075|
62224543|NCT01688830|PLACEBO_COMPARATOR|Placebo|
62224544|NCT01688830|EXPERIMENTAL|BI 655075 with dabigatran|
62224545|NCT01762891|EXPERIMENTAL|Celecoxib|Celecoxib 200mg/day oral rout Intervention: celecoxib 200mg oral rout administered durng 15 days and followed by administration of rofecoxib 25mg/day during 15 days, placebo 15 days and acetaminophen 3g/day during 15 days.
62224546|NCT01414140||Group 1|
62242999|NCT01205997|ACTIVE_COMPARATOR|magnesium sulphate|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
62224547|NCT02558504|ACTIVE_COMPARATOR|Oesophagectomy|While surgical reference technique for invasive cancer of the lower esophagus is the technique according to Lewis Santy, there is no consensus on the technique and surgical approaches lack of specific work in the particular case of superficial lesions . The centers will have the choice of using the technique according to Lewis Santy with gastric plasty or technique of esophagectomy without thoracotomy with lower mediastinal dissection. In the absence of consensus to date available, abdominal surgery time will be by laparotomy or laparoscopy (laparoscopic assisted technique called). In both cases, an exploratory laparoscopy for diagnostic purposes is realized to remove an extension of the disease that would indicate against-resection with curative intent. For surgery, patients will be put under antisecretory therapy proton-pump inhibitor; this at least throughout the duration of the study.
62224548|NCT02558504|EXPERIMENTAL|Radiofrequency ablation|"The equipment processing is:~* The radiofrequency generator,~* The radiofrequency balloon 360,~* the radiofrequency probe 90.~The radiofrequency treatment should be carried out according to the following protocol:~* The radiofrequency treatment is done within 2 months following the last endoscopic assessment.~* The maximum number of sessions is 4, including 2 maximum with 360 Halo probe.~* Endoscopy is performed under general anesthesia.~* The removal must begin at the top 1cm above the upper pole of the lesion and must end 1cm below the lower pole of the lesion.~* The patient is left fasting until morning. In case of chest pain, the patient may receive analgesics.~* During the time of treatment, the patient must follow an antisecretory therapy pump inhibitor with dual proton dose orally. The patient should avoid taking aspirin or nonsteroidal anti-inflammatory drugs during the 10 days following each session."
62224549|NCT03418831|ACTIVE_COMPARATOR|Raloxifene|Raloxifene Hydrochloride
62224550|NCT03418831|PLACEBO_COMPARATOR|Placebo|placebo tablet
62224551|NCT00693797||I, observation|patients with aortic stenosis
62224552|NCT00693797||II, observation|patients with aortic stenosis
62224553|NCT00818649|EXPERIMENTAL|Velcade + Vorinostat|This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.
62224554|NCT01895283|EXPERIMENTAL|Moderate-intensity training|Regular supervised moderate-intensity training on a bike ergometer, three times per week, for 30 minutes a total of 10 weeks.
62224555|NCT01408615||All Enrolled Participants|Women undergoing COS in combination with a GnRH antagonist for the development of multiple follicles in an ART program.
62417635|NCT06702735|EXPERIMENTAL|Intervention group (without feedback)|Collection of VAS scores and lung function. Explanation about the Rainbow tool to visualize symptom perception, and use of this tool during intervention phase.
62224556|NCT01948908|EXPERIMENTAL|200 mcL VOA|Intranasal midazolam administered in 200 mcL VOA
62224557|NCT01948908|EXPERIMENTAL|500 mcL VOA|Intranasal midazolam administered in 500 mcL VOA.
62224558|NCT01948908|EXPERIMENTAL|1000 mcL VOA|Intranasal midazolam administered in 1000 mcL VOA.
62224559|NCT02830945|OTHER|Control Brochure Arm|Control Arm households receive a culturally tailored Stroke and CVD brochure for prevention.
62417636|NCT06702735|NO_INTERVENTION|Control group|Collection of VAS scores and lung function. No additional intervention.
62224560|NCT02830945|EXPERIMENTAL|Motivational Interviewing Intervention Arm|The MI intervention households receive three aspects of the intervention: digital stories, motivational interviewing talking circle and the option to receive text messages to adhere to the action plan.
62224561|NCT00655291|PLACEBO_COMPARATOR|A|
62224562|NCT00655291|EXPERIMENTAL|B|
62224563|NCT04572113||No collar|Cervical range of motion and tissue interface pressure measurements are recorded while subject are not wearing a cervical collar
62224564|NCT04572113||DJO collar|Cervical range of motion and tissue interface pressure measurements are recorded while subject are wearing a DJO cervical collar
62224565|NCT04572113||Miami J collar|Cervical range of motion and tissue interface pressure measurements are recorded while subject are wearing a Miami J cervical collar
62224566|NCT02032277|ACTIVE_COMPARATOR|Arm A|Veliparib + carboplatin + paclitaxel followed by doxorubicin/cyclophosphamide (AC)
62224567|NCT02032277|PLACEBO_COMPARATOR|Arm C|Placebo + placebo + paclitaxel followed by AC.
62224568|NCT02032277|PLACEBO_COMPARATOR|Arm B|Placebo + carboplatin + paclitaxel followed by AC
62224569|NCT00784355|EXPERIMENTAL|1:Laparoscopic cholecystectomy|Surgery
62224570|NCT00784355|NO_INTERVENTION|2:controls|non-surgical control group
62224571|NCT03715439||Leucocyte- and Platelet-rich Fibrin|Dental implant placed into post-extraction sites preserved with leucocyte- and platelet-rich fibrin
62224572|NCT03715439||Control|Dental implant placed into non-preserved post-extraction sites
62224573|NCT04680754|EXPERIMENTAL|Experimental Arm|"Routine nursing care (use of analgesics, IV fluid therapy and wound care) was applied to patients in experimental group after thyroidectomy. A brochure was developed in line with the literature on head-neck stretching exercises. Since the patients came to the clinic on surgery day, the exercises were examined by the patient on the first postoperative day. The patient was asked to perform the exercises 3 times a day, in the morning, noon and evening for a month, provided that each movement was 5 times. Then, the Patient and Observer Scar Rating Scale (POSAS)  was applied.~The pain level of the patient on postoperative day 1 was evaluated using VAS. For further evaluations, the patient was called by phone at the 1st week and 1st month. Neck pain and discomfort status was evaluated with the Neck Pain and Disability Scale (NPAD), and then the scar appearances with the Patient and Observer Scar Assessment Scale by requesting neck photographs at the 1st week and 1st month."
62417637|NCT06581848||Elranatamab|Patients who have been prescribed Elranatamab by their physician as monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
62417638|NCT00514709|EXPERIMENTAL|Group 1|DTaP-Hep B-PRP-T + OPV vaccine group
62417639|NCT00514709|EXPERIMENTAL|Group 2|Tritanrix-HepB/Hib™ + OPV vaccine group
62417640|NCT05357261|ACTIVE_COMPARATOR|Daily home delivered meals|A lunch-time meal delivered to participants' homes five days per week with wellness check and socialization.
62799084|NCT04050449||Group 2: Switch to TLD from boosted PI second-line regimen|Participants switching to TLD from a second-line regimen containing a boosted PI. These participants will be divided into two subgroups based upon their HIV-1 RNA level in a sample obtained at entry, before starting TLD. Group 2a will include participants with viremia (HIV-1 RNA \>1000 copies/mL at start of TLD) and Group 2b will include participants with suppressed viral load (HIV-1 RNA ≤1000 copies/mL at start of TLD).
62224574|NCT04680754|NO_INTERVENTION|Control Arm|"Routine nursing care (use of analgesics, IV fluid therapy and wound care) was applied to the control group after thyroidectomy. Follow-up of the patients with the scales applied in the experimental group were also performed to the control group at the same intervals. After thyroidectomy, patients were called by phone in the 1st week and 1st month. Neck pain and discomfort scale and Patient and Observer Scar Rating Scale were applied again in both phone calls. Photographs of the scar appearance at the 1st week and the 1st month were requested from the patients."
62224575|NCT00841880|EXPERIMENTAL|1|2 weeks run-in of Ramipril 5 mg followed by 8 weeks of Ramipril + Felodipine
62224576|NCT00841880|ACTIVE_COMPARATOR|2|2 weeks run-in of Ramipril 5 mg followed by 8 weeks of Ramipril 10 mg
62224577|NCT00482573|EXPERIMENTAL|Group LE|Seventeen (54.8%) patients, composed group LE, were randomly assigned for the infusion of 1.8 mL (one cartridge) by the modified anesthesia into the periodontal ligament (PDLm injection) of 2% lidocaine solution with epinephrine 1:100,000. Their ages were ranging from 18 to 44 years (mean:29.6), they were diagnosed as having rheumatic valve disease, in a functional class I or II according to classification of the NYHA. Gestation age ranged from 28 to 36 weeks (mean:31.8), and the BMI from 18.7 to 32.9 (mean:23.8) kg/m2. All the patients had the restauration done in their inferior premolar and/or molar teeth.
62224578|NCT00482573|ACTIVE_COMPARATOR|Group LNE|Fourteen (45.2%) patients, composed group LNE, were randomly assigned for the infusion of 1.8 mL (one cartridge) by the modified anesthesia into the periodontal ligament (PDLm injection) of 2% lidocaine solution without epinephrine. Their ages were ranging from 22 to 33 years (mean:26.6), they were diagnosed as having rheumatic valve disease, in a functional class I or II according to classification of the NYHA. Gestation age ranged from 29 to 37 weeks (mean:32.1), and the BMI from 18.5 to 38.1 (mean:22.8) kg/m2. All the patients had the restauration done in their inferior premolar and/or molar teeth.
62224579|NCT03700073|EXPERIMENTAL|Walk training plus virtual reality|Experimental group (GTVR): The intervention consisted of treatment with the robotic CL1Walker gait training system in combination with virtual reality
62224580|NCT03700073|ACTIVE_COMPARATOR|Walk training|Control group (GT): The intervention consisted of treatment with the robotic CL1Walker gait training system
62224581|NCT03794687||Distal Radial Artery|Left heart catheterization via the distal radial artery (dorsal aspect of the hand at the base of the thumb).
62224582|NCT05137015|EXPERIMENTAL|Intervention|The intervention group will use the new injury prevention program at least twice per week in their training sessions.
62224583|NCT05137015|NO_INTERVENTION|Control|The control group will continue their usual training routine.
62224584|NCT05141812||ACLR group|ACLR participants would be 7 months post surgery
62224585|NCT05141812||healthy control group|Healthy uninjured participants who are actively engaged in gaelic football or hurling.
62417641|NCT05357261|EXPERIMENTAL|Frozen, Drop-shipped Meals|Ten frozen meals that are mailed to participants every two weeks.
62417642|NCT03650179||Patients enrolled in the cohort|Patients over 18 years old, consulting for functional digestive disease, without neurologic or urologic disease, and performing an urodynamic examination in neuro-urology and functional explorations department.
62224586|NCT05379660|EXPERIMENTAL|T1 treatment group|TEAS initiates at 30 minutes before induction and lasts for 30 minutes
62417643|NCT05705544|ACTIVE_COMPARATOR|ILLUMISITE™ Platform (EMN bronchoscopy)|Participants in the ILLUMISITE™ Platform arm will undergo a diagnostic bronchoscopy with the ILLUMISITE™ Platform (EMN) machine.
62417644|NCT05705544|ACTIVE_COMPARATOR|Ion™ Endoluminal System (SSCB bronchoscopy)|Participants in the Ion™ Endoluminal System arm will undergo a diagnostic bronchoscopy with the Ion™ Endoluminal System (SSCB) machine.
62417645|NCT04491942|EXPERIMENTAL|Arm I (cisplatin, elimusertib)|Patients receive cisplatin IV over 1-2 hours on day 1 and 8, and elimusertib PO QD on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62417646|NCT04491942|EXPERIMENTAL|Arm II (cisplatin, gemcitabine, elimusertib)|Patients receive cisplatin IV over 1-2 hours on day 1 and 8, gemcitabine IV over 30 minutes on days 1 and 8, and elimusertib PO QD on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62417647|NCT03493945|EXPERIMENTAL|Arm 1.1|M7824 + N-803
62417648|NCT03493945|EXPERIMENTAL|Arm 2.1A|M7824 + BN-Brachyury during phase IIA
62417649|NCT03493945|EXPERIMENTAL|Arm 2.1B|M7824 + BN-Brachyury during phase IIB
62417650|NCT03493945|EXPERIMENTAL|Arm 2.2A|M7824 + BN-Brachyury + N-803 during phase IIA
62224587|NCT05379660|EXPERIMENTAL|T2 treatment group|TEAS initiates immediately after skin incision and lasts for 30 minutes
62224588|NCT05379660|EXPERIMENTAL|T3 treatment group|TEAS initiates immediately after extubating and lasts for 30 minutes
62224589|NCT05379660|NO_INTERVENTION|control group|Electrodes are placed on the same acupoints, but no current is given
62417651|NCT03493945|EXPERIMENTAL|Arm 2.2B|M7824 + BN-Brachyury + N-803 during phase IIB
62417652|NCT03493945|EXPERIMENTAL|Arm 2.3A|M7824 + BN-Brachyury + N-803 + Epacadostat during phase IIA
62417653|NCT03493945|EXPERIMENTAL|Arm 2.3B|M7824 + BN-Brachyury + N-803 + Epacadostat during phase IIB
62417654|NCT04519203|ACTIVE_COMPARATOR|SPI group|Group of patients where opioid consumption will be guided using SPI target
62588707|NCT05600309|ACTIVE_COMPARATOR|Standard of Care (Regorafenib or TAS-102)|At the Investigator's choice, participants will receive 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle or 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
62588708|NCT01598233|EXPERIMENTAL|Intragastric balloon|Patients submitted to six-month intragastric balloon
62224590|NCT06476145||EMR-MM|"Mucosal markings are placed clearly outside the visible margin of the lesion (polyp) by placing superficial cautery marks with the tip of the endoscopic snare approximately 3 mm away from the polyp margin. Successful marking with diathermy is established by visual identification of white circular dots around the entire outer border of the lesion. EMR is then performed as per standard technique as described above."
62224591|NCT06476145||EMR-STSC|Endoscopic mucosal resection with thermal margin ablation (STSC) will be performed of the entire margin of the mucosal defect, by using a light touch with 1 to 2 mm of the exposed snare tip aiming to create a 2 to 3 mm rim of completely ablated tissue around the entire circumference of the resection defect. Successful STSC is confirmed by the presence of a rim of whitening mucosa around the defect
62224592|NCT01657513|EXPERIMENTAL|tnf-alfa treatment (infliximab, adalimumab, or etanercept)|This arm includes all the patients of the study. They are patients who are start treatment with a tnf-alfa blocking drug
62588709|NCT06666010|EXPERIMENTAL|Adult participants with confirmed StUD - Active|PEX010 containing 25 mg psilocybin
62588710|NCT06666010|PLACEBO_COMPARATOR|Adult participants with confirmed StUD - Placebo|PEX010 containing 1 mg psilocybin
62588711|NCT04333407|EXPERIMENTAL|Active Arm|
62588712|NCT04333407|NO_INTERVENTION|Control Arm|
62588713|NCT01328145|ACTIVE_COMPARATOR|ASA|
62224593|NCT05351684|EXPERIMENTAL|Intensified|Group of patients whose treatment will be intensified with an additional 50mg of dolutegravir on top of regular treatment (Triumeq: ABC/3TC/DTG).
62224594|NCT05351684|NO_INTERVENTION|Control|Group of patients without modification of baseline treatment (Triumeq: ABC/3TC/DTG).
62417655|NCT04519203|ACTIVE_COMPARATOR|Control Group|Group of patients where only standard monitoring and patient reaction will be used to guide opioid administration during intraoperative period
62417656|NCT05862714|ACTIVE_COMPARATOR|Group A Fluconazole|Oral fluconazole (400 mg stat) given to patients.
62417657|NCT05862714|ACTIVE_COMPARATOR|Group B Itraconazole|Oral Itraconazole (1000 mg stat) given to patients.
62417658|NCT06374147|EXPERIMENTAL|SVS mattress arm|The intervention group will receive standard therapy ( Caffeine Citrate) plus continuous SVS stimulation using the Prapela SVS incubator pad. Treatment with the pad will continue until an infant is apnea-free for 3 days and \<2 weeks from anticipated discharge or at the clinician's discretion to discontinue treatment. After ending treatment, clinicians will observe patients 24 hours later and if apnea returns, should re-initiate treatment as needed.
62417659|NCT06374147|NO_INTERVENTION|Standard|The control group will receive only standard therapy, using an inert pad (identical to the SVS pad, its controller, and green light, but without the transducer and therefore incapable of vibration), in order to mask caregivers
62433487|NCT04487145|EXPERIMENTAL|HIV-infected children on LPV/r-based ART (L3)|30 HIV-infected children age 3 - 10 years on LPV/r-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
62417660|NCT06337968|ACTIVE_COMPARATOR|Ultrasound guided circum-psoas block|Injection of 20ml 0.2% ropivacaine around the antero-lateral margin of psoas major muscle at the level of iliac crest with an in-plane approach under ultrasound guidance. Then the transducer was placed at the level of Lumbar vertebra 5 to obtain the paramedian transverse plane of the intertransverse ligament and lumbosacral ligament. An additional 20ml 0.2% ropivacaine was injected when the needle punctured the lumbosacral ligament.
62417661|NCT06337968|PLACEBO_COMPARATOR|Sham block|Perform ultrasound scanning without puncture.
62417662|NCT03178474|ACTIVE_COMPARATOR|Breast-Fed Group|The infants will be fed with human breast milk by their mother
62417663|NCT03178474|EXPERIMENTAL|TOFER Formula Group|TOFER Infant formula,TOFER®: Infants will be fed by using TOFER® infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age.
62417664|NCT03178474|EXPERIMENTAL|JINLINGGUAN Formula Group|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: Infants will be fed by using JINLINGGUAN (PRO-KIDO™ I-PROTECH®) infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age.
62417665|NCT03848000|EXPERIMENTAL|Exercise Programme and NHS Standard Care|Exercise and NHS standard care.
62417666|NCT03848000|ACTIVE_COMPARATOR|NHS Standard Care only|Alcohol addiction counselling.
62417667|NCT05991778||Group of Patients who Survived (S)|The group is defined by the number of patients who survived.
62417668|NCT05991778||Group of Patients who Died (D)|The group is defined by the number of patients who died.
62417669|NCT06290609|EXPERIMENTAL|Vibrotactile Coordinated Reset stimulation|Participants will receive vCR stimulation, involving vibratory stimulation of the fingertips, with the Stanford CR Glove on a daily or weekly basis.
62417670|NCT05556031||REDUCE|Standard care
62417671|NCT01251874|EXPERIMENTAL|Treatment (veliparib, F 18 fluorothymidine, carboplatin)|Patients receive carboplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-7 or 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo fluorothymidine PET scan and peripheral blood cell and tumor tissue collection periodically for correlative studies.
62588714|NCT01328145|PLACEBO_COMPARATOR|Placebo|
62588715|NCT03798509|EXPERIMENTAL|Human CD19 targeted T Cells Injection|
62588716|NCT02913014|ACTIVE_COMPARATOR|Arm 1- No AAD post Ablation|Subjects will not resume their Anti Arrhythmic Drugs after cryoballoon-ablation for paroxysmal atrial fibrillation.
62588717|NCT02913014|NO_INTERVENTION|Arm 2-Resume AAD post Ablation|Subjects will resume their pre-ablation Anti Arrhythmic Drugs after cryoballoon-ablation for paroxysmal atrial fibrillation, during the 90 day blanking period following the ablation.
62588718|NCT01945853|EXPERIMENTAL|7 Tesla MRI|7T MRI will be done on ALS patients at baseline and at 6 month intervals.
62588719|NCT05701956|EXPERIMENTAL|Intravenous tenecteplase+endovascular thrombectomy|Patients will receive intravenous tenecteplase (0.25mg/kg, max 25mg) plus endovascular thrombectomy.
62224595|NCT05074485|EXPERIMENTAL|Placebo plus nociceptive pain challenge, then anakinra plus nociceptive pain challenge|Pharmacological challenge (with placebo) plus nociceptive pain challenge, then pharmacological challenge (with anakinra) plus nociceptive pain challenge
62224596|NCT05074485|EXPERIMENTAL|Anakinra plus nociceptive pain challenge, then placebo plus nociceptive pain challenge|Pharmacological challenge (with anakinra) plus nociceptive pain challenge, then pharmacological challenge (with placebo) plus nociceptive pain challenge
62224597|NCT05134441|EXPERIMENTAL|IMU-838|"IMU-838 (vidofludimus calcium), a small molecule inhibitor of DHODH.~Formulation:~Tablets with 15 or 30 mg IMU-838 for once daily oral intake in the morning."
62224598|NCT05134441|PLACEBO_COMPARATOR|Placebo|Matching placebo, as described for the test product, identical number of tablets as given for IMU-838.
62224599|NCT05358028|EXPERIMENTAL|Hand arm Bimanual intensive Technique including Lower extremity (HABIT-IL)|Hand arm Bimanual activities involving Lower extremity
62224600|NCT05358028|ACTIVE_COMPARATOR|Hand Arm bimanual intensive Technique (HABIT)|Hand arm Bimanual activities without involvement of lower extremity
62224601|NCT04854668|EXPERIMENTAL|Anlotinib + CapeOx|Anlotinib combined with CapeOx(Oxaliplatin+Capecitabine) were used for 4-8 cycles, each cycle is 3 weeks. After 8 cycles, the regimen is changed to Anlotinib combined with Capecitabine.
62224602|NCT04854668|ACTIVE_COMPARATOR|Bevacizumab + CapeOx|Bevacizumab combined with CapeOx(Oxaliplatin+Capecitabine) were used for 4-8 cycles, each cycle is 3 weeks. After 8 cycles, the regimen is changed to Bevacizumab combined with Capecitabine.
62224603|NCT01789645|EXPERIMENTAL|Conservative group|The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
62224604|NCT01789645|ACTIVE_COMPARATOR|Surgical group|The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
62224605|NCT04617561|ACTIVE_COMPARATOR|Ursodeoxycholic Acid group|Ursodeoxycholic Acid 13-15mg/kg/d
62224606|NCT04617561|EXPERIMENTAL|Ursodeoxycholic Acid+Low Dose Glucocorticoid group|Ursodeoxycholic Acid 13-15mg/kg/d+Methylprednisolone 12mg/d in induction period and 2-4mg/d in maintenance period
62224607|NCT04219397|NO_INTERVENTION|Control|Patients in this group will receive usual care from the acute pain medicine service, and will go home with standardized multimodal analgesic protocol. There will be no interventions provided. They will receive a follow up phone call survey and be asked to return a completed medication education calendar that is provided as a part of usual APS care.
62224608|NCT04219397|EXPERIMENTAL|Medication take back education intervention|Patients in this group will receive usual care from the acute pain medicine service, and will go home with standardized multimodal analgesic protocol as described in the control group. They will receive a standardized education intervention. This intervention will educate patients and their families about medication take back programs, and will provide tailored directions to the closest medication take back center from their home, and also an option for medication take back that is located in close proximity to Riley Hospital clinics.
62224609|NCT04219397|EXPERIMENTAL|Home disposal kit intervention|Patients in this group will receive usual care from the acute pain medicine service, and will go home with standardized multimodal analgesic protocol as described in the control group. They will receive standardized education about how to use the medication home disposal kit : Dispose Rx(r), and they will be instructed to use this kit to dispose of any left over opioid medications that they may have after they have competed therapy for pain management at home.
62224610|NCT05234112|EXPERIMENTAL|Uganda, India, Bangladesh|hrHPV self-test, followed by VIA inspection for hrHPV-positive women.
62417672|NCT05302700|EXPERIMENTAL|Early Parental Sensitivity Intervention Program|The protocol will last five to seven days for preterm infant mothers.
62588720|NCT05701956|ACTIVE_COMPARATOR|Endovascular thrombectomy alone|Patients will receive endovascular thrombectomy alone.
62026235|NCT04498650|EXPERIMENTAL|300 mg|Dose in weeks 1 and 2: 50 mg once daily (evening) Dose in weeks 3 and 4: 50 mg BID Dose in weeks 5-8: 150 mg BID Dose in weeks 9-24: 300 mg BID
62224611|NCT05234112|EXPERIMENTAL|Slovakia|hrHPV self-test, followed by Pap-smear for cytology
62224612|NCT00619203|ACTIVE_COMPARATOR|A|Two active ingredients
62224613|NCT00619203|ACTIVE_COMPARATOR|B|One active ingredient
62224614|NCT00619203|ACTIVE_COMPARATOR|C|One (other) active ingredient
62224615|NCT00619203|PLACEBO_COMPARATOR|D|
62224616|NCT04067375||Pregnant women, HPA-1a positive|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a positive.
62224617|NCT04067375||Pregnant women, HPA-1a negative with HPA-1a alloantibodies|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a negative and have formed anti-HPA-1a alloantibodies.
62224618|NCT04067375||Pregnant women, HPA-1a negative without HPA-1a alloantibodies|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a negative and did not have formed anti-HPA-1a alloantibodies.
62224619|NCT00850603|ACTIVE_COMPARATOR|Group 1|0.5 mL Subcutaneous arm (Menomune® )
62224620|NCT00850603|EXPERIMENTAL|Group 2|0.1 mL Subcutaneous arm (Menomune®)
62026236|NCT04498650|EXPERIMENTAL|600 mg|Dose in weeks 1 and 2: 50 mg once daily (evening) Dose in weeks 3 and 4: 50 mg BID Dose in weeks 5-8: 150 mg BID Dose in weeks 9-12: 300 mg BID Dose in weeks 12-24: 600 mg BID
62026237|NCT01303289|EXPERIMENTAL|Group 1|The group 1 will receive the experimental product T-Diet plus Standard for 3 months.
62224621|NCT00850603|EXPERIMENTAL|Group 3|0.05 mL Intradermal arm (Menomune®)
62224622|NCT00850603|EXPERIMENTAL|Group 4|0.1 mL Intradermal arm (Menomune®)
62224623|NCT00850603|EXPERIMENTAL|Group 5|0.15 mL Intradermal arm (Menomune®)
62224624|NCT02796625|EXPERIMENTAL|Painful Stimuli|Participants will be exposed to painful heat
62224625|NCT03881618|EXPERIMENTAL|electroacupuncture+auricular pressure|a group :electroacupuncture+auricular pressure for 20 minutes twice a week for 4 weeks
62224626|NCT03881618|ACTIVE_COMPARATOR|auricular pressure|b group :auricular pressure for 20 minutes twice a week for 4 weeks.
62224627|NCT04650308|ACTIVE_COMPARATOR|Healthy group|healthy men and women aged 20-60 years old.
62224628|NCT04650308|ACTIVE_COMPARATOR|Non-healthy group|pregnant women, nursing mothers, impaired kidney and liver function, chronic disease, or other metabolic disorders.
62224629|NCT04419883||Anesthesia Providers|Anesthesia providers from 15 different health care facilities in the United States.
62224630|NCT01721460|EXPERIMENTAL|Dexmedetomidine during MER|The study is performed in patients undergoing DBS electrode implantation to their STN for the treatment of parkinson's disease. Microelectrode recording (MER) is performed as part of STN electrode implantation surgery, to increase the precision of the stimulating electrode placement. The study includes administration of dexmedetomidine while recording electrical activity at a single location to evaluate the effects of this drug on the MER.
62224631|NCT04015999|EXPERIMENTAL|Intervention arm|MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)
62224632|NCT04015999|ACTIVE_COMPARATOR|Control arm|Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)
62224633|NCT06138054|EXPERIMENTAL|MI-CBTech|An 8-week experimental intervention that combines two treatments, Motivational Interviewing (MI) and Cognitive Behavioral Therapy (CBT). The format of the intervention will be a combination of in-person sessions and remote elements (together called MI-CBTech) delivered via mobile phone or other smart device.
62588721|NCT06226805|EXPERIMENTAL|BB-031|A single dose of BB-031 will be administered via IV bolus injection
62224634|NCT06138054|ACTIVE_COMPARATOR|Mindfulness control|An 8-week active control intervention that combines supportive therapy and mindfulness training. The format of the intervention will be a combination of in-person sessions and remote elements delivered via mobile phone or other smart device.
62224635|NCT04451174|EXPERIMENTAL|Treatment|Prednisone 40 mg days 1 to 4. Then Prednisone 20 mg days 5 to 8.
62224636|NCT04451174|NO_INTERVENTION|Control|
62224637|NCT02218294|EXPERIMENTAL|[14C] BCX4161|Includes a radiolabelled dose of \[14C\] BCX4161 and unlabelled BCX4161
62224638|NCT02377141|ACTIVE_COMPARATOR|Endoscopic Variceal Band Ligation (EVBL)|Participants in this group will receive standard medical care consisting of vasoactive drugs (Terlipressin 2mg QDS (where there are no contraindications e.g. severe ischaemic heart disease), antibiotics, and entry into a variceal banding programme (in-patient or out-patient).
62224639|NCT02377141|ACTIVE_COMPARATOR|Early TIPSS|For those randomized to early TIPSS the Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure will be performed within 72 hours (and preferably within the first 24 hours) after initial endoscopy. Vasoactive drugs will be continued until the TIPSS is performed and antibiotics continued for 5-7 days.
62417673|NCT05302700|NO_INTERVENTION|Control group|The control group received general routine nursing guidance.
62417674|NCT06702488|ACTIVE_COMPARATOR|The dexmedetomidine|29 patients will receive a bolus dose of dexmedetomidine (0.5 μg kg-1) over 10 minutes before induction followed by an infusion (0.3 μg kg-1 h-1), which will be discontinued at the skin closure.
62588722|NCT06226805|PLACEBO_COMPARATOR|Placebo|A single dose of matching placebo will be administered via IV bolus injection
62417675|NCT06702488|ACTIVE_COMPARATOR|The magnesium sulfate|29 patients will receive 20 mg/kg as loading dose over 10 minutes before induction then maintenance dose 5 mg/kg/hour, which will also be discontinued at the skin closure
62224640|NCT01651442|ACTIVE_COMPARATOR|Non-drug Sleep Therapy 1|
62224641|NCT01651442|ACTIVE_COMPARATOR|Sleep Medication 1|
62417676|NCT04241185|EXPERIMENTAL|Pembrolizumab + Chemotherapy + Radiotherapy|Participants receive pembrolizumab plus one of three chemotherapy regimens chosen by investigator, plus one of three radiotherapy regimens chosen by investigator.
62417677|NCT04241185|PLACEBO_COMPARATOR|Placebo + Chemotherapy + Radiotherapy|Participants receive placebo to pembrolizumab plus one of three chemotherapy regimens chosen by investigator, plus one of three radiotherapy regimens chosen by investigator.
62224642|NCT01651442|ACTIVE_COMPARATOR|Non-drug Sleep Therapy 2 Following Non-drug Sleep Therapy 1|
62588723|NCT06666868|EXPERIMENTAL|Sustained CARD|CARD is being used for the 2nd year in a row as the vaccination delivery framework in participating pharmacies (It was used in the 2023-2024 fall/winter vaccination season and is now being sustained in the 2024-2025 fall/winter season). CARD comprises of education, environment, engagement and evaluation components.
62224643|NCT01651442|ACTIVE_COMPARATOR|Sleep Medication 2 Following Sleep Medication 1|
62224644|NCT01651442|ACTIVE_COMPARATOR|Non-drug Sleep Therapy 1 Following Sleep Medication 1|
62224645|NCT01651442|ACTIVE_COMPARATOR|Sleep Medication 1 Following Non-drug Sleep Therapy 1|
62224646|NCT05463692|EXPERIMENTAL|Single Arm - CAMELLIA Cohort|To better understand contextual factors among people who identify as women in Alabama that predict STI/HIV infection and PrEP use, we will refine an existing evidence-based mobile health app (HealthMpowerment or HMP) to optimally engage and retain a digital cohort of women at-risk for HIV infection (i.e. prior infection in the past 3 months with gonorrhea or syphilis). Using a sampling strategy based on geospatial analysis of HIV-risk, we will enroll and follow our factors associated with incident STI/HIV infection as well as utilization of PrEP through self-collected STI/HIV testing and survey assessments.
62224647|NCT02197767|EXPERIMENTAL|rituximab|rituximab 1000 mg infusion two weeks apart for a total of two infusions. Retreated with identical rituximab 1000 mg infusion two weeks apart at six months after the first infusion for a grand total of four infusions.
62417678|NCT03735238||Lupus Patients|All lupus patients, regardless of if they are having an active flare
62433488|NCT04487145|ACTIVE_COMPARATOR|HIV-uninfected children (C1)|20 HIV-uninfected children age 3-10 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. PK samples are collected after the 1st dose. Control group for L1.
62588724|NCT06666868|ACTIVE_COMPARATOR|First-time CARD|CARD is being used for the 1st time as the vaccination delivery framework in participating pharmacies (2024-2025 fall/winter vaccinations only). CARD comprises of education, environment, engagement and evaluation components.
62588725|NCT04164173|EXPERIMENTAL|EzPAP|The patient will have EzPAP postoperative respiratory therapy as 3 x 10 breaths at a 1:4 ratio four times daily
62224648|NCT02571049|EXPERIMENTAL|Sumatriptan 3 mg then 6 mg|DFN-11 (sumatriptan, 3 mg) and placebo first then two DFN-11 injections
62224649|NCT02571049|EXPERIMENTAL|Sumatriptan 6 mg then 3 mg|Two DFN-11 (sumatriptan, 3 mg) injections first then DFN-11 injection and placebo
62224650|NCT01304238||lepirudin|lepirudin treated subjects
62224651|NCT01304238||danaparoid|danaparoid treated subjects
62224652|NCT01304238||argatroban|argatroban treated subjects
62224653|NCT01304238||fondaparinux|fondaparinux treated subjects
62224654|NCT00552877|ACTIVE_COMPARATOR|1|Cypher Select plus stent
62224655|NCT00552877|ACTIVE_COMPARATOR|2|Xience V stent
62224656|NCT04125732|EXPERIMENTAL|AdVEGFXC1 at 1x10^9 vp|
62224657|NCT04125732|EXPERIMENTAL|AdVEGFXC1 at 1x10^10 vp|
62224658|NCT04125732|EXPERIMENTAL|AdVEGFXC1 at 4x10^10 vp|
62224659|NCT04125732|EXPERIMENTAL|AdVEGFXC1 at 1x10^11 vp|
62224660|NCT02424903||with prosthetic joint infection|Patients admitted for a septic revision surgery
62224661|NCT02424903||without prosthetic joint infection|Patients admitted for an aseptic revision surgery
62224662|NCT01176279|ACTIVE_COMPARATOR|Manual and automated washing of the line|Place in the radial artery the system of invasive monitoring of the blood pressure (BD DTXPlus ™). Insert in line a second 3-way stopcock above the one that has the BD DTXPlus ™; this second 3-way stopcock will be called proximal key. On the distal 3-way stopcock key (the one of TM BD DTXPlus ™), put the needless connector included in the kit to make the extractions of blood. Connect an arterial blood sampling syringe on the proximal 3-way stopcock key. With the assembled system, it is necessary to print a curve of invasive determination of the blood pressure.
62224663|NCT01176279|EXPERIMENTAL|Automated washing of the line|Place in the radial artery the system of invasive monitoring of the blood pressure (BD DTXPlus ™). Insert in line a second 3-way stopcock above the one that has the BD DTXPlus ™; this second 3-way stopcock will be called proximal key. On the distal 3-way stopcock key (the one of BD DTXPlus™), put the needless connector included in the kit to make the extractions of blood. On the proximal 3-way stopcock key put a second identical needless connector: in the intervention group the two 3-way stopcock keys have, each one, a needless connector. With the assembled system, it is necessary to print a curve of invasive determination of the blood pressure.
62224664|NCT03664089|EXPERIMENTAL|Intervention|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds \[1.1 kg\]/ankle), instructions on ankle weight usage (wear during normal activity for 2 hours/day, 7 days/week). The weight type and weight amount were chosen based on previously published literature and used in our preliminary work.
62799085|NCT04050449||Group 3: Concomitant TLD and RIF-containing TB treatment|Participants initiating concomitant TLD and RIF-containing TB treatment, with an additional daily dose of dolutegravir (DTG) 50mg. For participants already on RIF-containing TB treatment when TLD treatment is started, TLD treatment must be started within 8 weeks (56 days) of the start of RIF-containing TB treatment. Group 1, 2, or 4 participants who start RIF-containing TB treatment after enrollment will have additional evaluations at the start and end of concomitant HIV and TB treatment but will not be co-enrolled in Group 3 (their additional evaluations will, however, be considered when analyzing data from Group 3).
62224665|NCT03664089|PLACEBO_COMPARATOR|Control|All women in the control group will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
62224666|NCT01662726|EXPERIMENTAL|Irosustat|Irosustat 40mg OD for a minimum of 2 weeks until follow up FLT-PET/CT. For those patients consented to a repeat tumour biopsy, treatment will be extended to that day before the procedure.
62224667|NCT04100668|EXPERIMENTAL|Data collection|Comparing radial arterial line, Sensifree's Alpha sensor and PPG sensor pressure waveforms
62224668|NCT01879215|ACTIVE_COMPARATOR|Suprapatellar Approach|Suprapatellar Approach to Intramedullary Nailing. Surgeons will be allowed to use any size intramedullary tibial nail through an suprapatellar incision and splitting the quadriceps tendon.
62224669|NCT01879215|ACTIVE_COMPARATOR|Infrapatellar Approach|Infrapatellar Approach Intramedullary Nailing. Surgeons will be allowed to use any size intramedullary tibial nail through an infrapatellar incision using either a medial parapatellar approach or a transpatellar approach. The knee will then be scanned using T1Rho MRI at 2 weeks postoperatively and 6 months postoperatively.
62224670|NCT03824782|NO_INTERVENTION|Standard of Care|Infants in the control arm received standard examinations to screen for retinopathy of prematurity.
62224671|NCT03824782|EXPERIMENTAL|Standard of Care + Phototherapy Mask|Infants in the treatment arm will have a standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided. Infants will then receive standard examinations to screen for retinopathy of prematurity. The mask will be removed for the examination but reapplied promptly afterward.
62224672|NCT02171416|PLACEBO_COMPARATOR|Placebo|Placebo s.c every 7 days
62224673|NCT02171416|EXPERIMENTAL|Rilonacept 160mg|Rilonacept s.c every 7 days
62224674|NCT05453123|ACTIVE_COMPARATOR|paper-handout arm|the paper-handout arm is the control group taking the home exercise printed in the paper handout.
62224675|NCT05453123|EXPERIMENTAL|intervention arm|the intervention arm is the experimental group where they take home exercise and motivational text messages by WhatsUp
62224676|NCT01244321||CoSeal Group|Subjects with indication for LVAD implantation, meeting the requirements for LVAD implantation. Patients for whom LVAD removal is anticipated not earlier than 6 weeks after LVAD implantation.
62224677|NCT01244321||CoSeal Control Group|Subjects who had a LVAD for more than 6 weeks.
62224678|NCT01795482|EXPERIMENTAL|Group 2, Prewarming only before general anaesthesia|Active forced-air warming for 15 min after completion of epidural anaesthesia / before start of general anaesthesia. Continued active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
62224679|NCT01795482|EXPERIMENTAL|Group 3, Prewarming before epidural and general anaesthesia|Active forced-air warming for 15 min before start of epidural anaesthesia and for 15 min after completion of epidural anaesthesia / before start of general anaesthesia. Continued active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
62588726|NCT04164173|EXPERIMENTAL|Metaneb|The patient will have Metaneb postoperative respiratory therapy as 10 minutes Continuous Positive End Expiratory Pressure (CPEP) four times daily
62417679|NCT06702293|EXPERIMENTAL|Intervention Arm|This fully automated and self-administered intervention will be delivered via a Health Insurance Portability and Accountability Act (HIPAA) compliant mobile app developed in collaboration with Intellect Inc., a Singapore-based mobile health company with broad reach and prior research collaborations in the Asia Pacific region. A detailed discussion focusing on the engineering of the application including the user interface, data acquisition and curation technology, security and privacy assurance is available from the authors.
62417680|NCT06702293|ACTIVE_COMPARATOR|Control|Participants in the active control group will download use the Healthy365 app, a mobile health application managed by the Singapore government's Health Promotion Board. The Healthy365 app offers a variety of useful general health-related content which are not specific to skin disease. These include personalized health tracking, participation in fitness challenges, access to nutritional guidance, and personalized lifestyle recommendations.
62417681|NCT06700512|OTHER|Comparison of Study Device with Own devices|within subject design: compare Pure C\&G 7IX to subjects' own hearing aids
62417682|NCT05524714|EXPERIMENTAL|solubilized Xanthohumol low dose|single dose of 86 mg micellar solubilized Xanthohumol
62588727|NCT04164173|EXPERIMENTAL|Intermittent Positive Pressure Breathing (IPPB)|The patient will have Intermittent positive pressure breathing (IPPB) postoperatively for 10 minutes four times daily
62799086|NCT04050449||Group 4: ART-naive initiating TLD therapy|Antiretroviral therapy (ART)-naïve participants initiating therapy with TLD
62799087|NCT02320929|EXPERIMENTAL|Intraoperative irrigation only|The infected tendon sheath is irrigated intraoperatively, the catheter is removed, and small rubber srains are left in small incisions.
62224680|NCT01795482|NO_INTERVENTION|Group 1, control group|No active warming before start of epidural or general anaesthesia, active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
62224681|NCT03377309|EXPERIMENTAL|Fycompa|Dose will be increased by 2mg/day increments every one week to reach a maximum dose of 8 mg/day. Treatment phase will be stable dose for 12 weeks then followed by washout period over 2 weeks.
62224682|NCT01748877|EXPERIMENTAL|NXN-462|capsule, 200 mg, bi.d. 28-days
62224683|NCT01748877|PLACEBO_COMPARATOR|Placebo|capsule, b.i.d. 28-days
62224684|NCT04466046||PONV group|Patients with PONV after administration of midazolam 0.05mg/kg with ramosetron 0.3mg or palonosetron 0.075mg
62224685|NCT04466046||no PONV group|Patients with no PONV after administration of midazolam 0.05mg/kg with ramosetron 0.3mg or palonosetron 0.075mg
62224686|NCT00370331|EXPERIMENTAL|Treatment arm plus standard of care|Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
62224687|NCT00370331|PLACEBO_COMPARATOR|placebo plus standard of care|Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
62224688|NCT02035644|EXPERIMENTAL|Jinlida granules|Jinlida granules, a traditional Chinese medicine, was a herbal formula which was developed under cognition of the theory in the onset of diabetes
62224689|NCT02035644|PLACEBO_COMPARATOR|placebo granules|placebo prepared in indistinguishable granules
62417683|NCT05524714|EXPERIMENTAL|solubilized Xanthohumol high dose|single dose of 172 mg micellar solubilized Xanthohumol
62417684|NCT05524714|ACTIVE_COMPARATOR|native Xanthohumol low dose|single dose of 86 mg native Xanthohumol
62417685|NCT05524714|ACTIVE_COMPARATOR|native Xanthohumol high dose|single dose of 172 mg native Xanthohumol
62417686|NCT04631406|EXPERIMENTAL|Neural Stem cells injected intracerebrally|Subject cohorts will be treated with increasing doses of Neural Stem Cells injected intracerebrally using a traditional 3+3 trial design
62417687|NCT06656390|EXPERIMENTAL|Part A: Dose-escalation Phase, Part B: Dose-expansion Phase|"A dose-escalation study to determine the MTD and the subsequent doses for dose expansion study (Part B).~A dose-expansion study which will enroll the select indications."
62417688|NCT00719758|EXPERIMENTAL|1|Cross-over study
62417689|NCT01342367|EXPERIMENTAL|Oral Androgen Therapy|Subjects will receive two oral hormonal drugs (bicalutamide with dutasteride or bicalutamide with finasteride)
62417690|NCT06567626||DST Co-Design (Work Package 1)|"* 40 people with lived experience of coronary revascularisation~* 38 healthcare professionals"
62417691|NCT06567626||DST Feasibility (Work Package 2)|"* 40 people awaiting coronary revascularisation~* 8 healthcare professionals"
62417692|NCT02076139|EXPERIMENTAL|Nyaditum resae® 10e4|The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e4 Colony-forming units (CFUs) of Nyaditum resae®.
62588728|NCT04064970||PASS Cohort|
62588729|NCT06664970|EXPERIMENTAL|Azacitidine or Ruxolitinib combined with Selinexor|Azacitidine or Ruxolitinib combined with Selinexor
62026238|NCT01303289|ACTIVE_COMPARATOR|Group 2|The group 2 will receive the control product Jevity (Abbott Laboratories) for 3 months.
62026239|NCT06007092|EXPERIMENTAL|level dose 1 HPVDC injection|10 patients with experimental injection at 1.0 mg
62026240|NCT06007092|PLACEBO_COMPARATOR|level dose 1 placebo injection|2 patients with experimental injection at 1.0 mg
62799088|NCT02320929|ACTIVE_COMPARATOR|Intra- and postoperative irrigation|The infected tendon sheath is irrigated intraoperatively, the catheter is kept in place, the irrigation is continued postoperatively 3 times a day for 3 days.
62026241|NCT06007092|EXPERIMENTAL|level dose 2 HPVDC injection|10 patients with experimental injection at 3.0 mg
62026242|NCT06007092|PLACEBO_COMPARATOR|level dose 2 placebo injection|2 patients with experimental injection at 3.0 mg
62417693|NCT02076139|EXPERIMENTAL|Nyaditum resae® 10e5|The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e5 CFUs of Nyaditum resae®.
62417694|NCT02076139|PLACEBO_COMPARATOR|Placebo|The subjects will receive 1 drinkable vial (4mL) of distilled water per day during 14 days.
62588730|NCT06683105|ACTIVE_COMPARATOR|Standard of Care|This group will not use the app for the first 30 days, then begin using it for the following 30 days.
62588731|NCT06683105|EXPERIMENTAL|MyIBDDiet users|This group will use the MyIBDDiet app for 60 days and compared with the standard of care group.
62588732|NCT03078010|ACTIVE_COMPARATOR|Piperacillin-tazobactam|
62799089|NCT06726148|EXPERIMENTAL|ECI830 Single Agent (Arm A)|Phase I
62799090|NCT06726148|EXPERIMENTAL|Dose Escalation Combination ECI830 + ribociclib + fulvestrant (Arm B)|Phase I
62799091|NCT06726148|EXPERIMENTAL|Ribociclib in combination with fulvestrant (Arm C)|Phase II
62799092|NCT06726148|EXPERIMENTAL|ECI830 in combination with fulvestrant (Arm D)|Phase II
62799093|NCT06726148|EXPERIMENTAL|ECI830 in combination with ribociclib and fulvestrant (Arm E)|Phase II
62588733|NCT03078010|EXPERIMENTAL|cefepime|
62799094|NCT06726148|EXPERIMENTAL|ECI830 in combination with ribociclib and fulvestrant (Arm F)|Phase II
62799095|NCT06727253|EXPERIMENTAL|Single arm|"The single arm - post-operative CD patients - will be used as a representative model to mimic the immunopathogenic pathway of health-to-disease transition.~This arm will receive an orally administered glycan."
62799096|NCT06726694|ACTIVE_COMPARATOR|class II malocclusion patients|class II molar relation correction by advanced maxillary molar distalization appliance
62799097|NCT04871425|EXPERIMENTAL|Ketamine|Participant will receive 2mg IV midazolam and 0.2-0.5mg/kg IV ketamine over 2 minutes, which can be repeated q5 minutes until appropriate analgesia is achieved.
62799098|NCT04871425|ACTIVE_COMPARATOR|Fentanyl|Participant will receive 2mg IV midazolam and 0.5-1mcg/kg IV fentanyl over 2 minutes, which can be repeated q5m until appropriate analgesia is achieved.
62799099|NCT03741972||Treatment|Patients with diabetes and heart failure that are treated with iSGLT2
62799100|NCT02636205|EXPERIMENTAL|Armeo|Group receiving Armeo therapy
62224690|NCT00361660|EXPERIMENTAL|1|Therapy is provided every other day 3 days per week (Monday, Wednesday, Friday).
62799101|NCT04110782||Radium223|
62799102|NCT04472234|OTHER|BPA level|BPA (Bisfenol A) in urine, blood and follicle fluid samples
62799103|NCT05440812|EXPERIMENTAL|Care As Usual plus STAIRS|Care as usual added with a eight week STAIRS-training
62799104|NCT05440812|NO_INTERVENTION|Care As Usual|Care as usual added with three information letters
62799105|NCT02316561|EXPERIMENTAL|Single dose ablative radiotherapy|Eligible patients for single dose ablative radiotherapy according to inclusion and exclusion criteria
62799106|NCT06468098|EXPERIMENTAL|Cohort 1|IBI363 combined with chemotherapy in patients with advanced NSCLC who have failed at least one prior line of standard therapy (which needs to include immunotherapy)
62799107|NCT06468098|EXPERIMENTAL|Cohort 2A|IBI363 combined with chemotherapy as first-line in patients with advanced colorectal cancer, including a safety run-in phase and a randomized controlled phase
62799108|NCT06468098|EXPERIMENTAL|Cohort 2B|IBI363 combined with chemotherapy as first-line in patients with advanced colorectal cancer, including a safety run-in phase and a randomized controlled phase
62799109|NCT06468098|EXPERIMENTAL|Cohort 3|IBI363 combined with chemotherapy in patients with advanced biliary tract tumors that have failed or are intolerant to first-line standard therapy
62799110|NCT06468098|EXPERIMENTAL|Cohort 4|IBI363 combined with chemotherapy in second-line in patients with Advanced Esophageal Squamous Cell Carcinoma
62799111|NCT06468098|EXPERIMENTAL|Cohort 5|IBI363 combined with chemotherapy in second-line in patients with Advanced Gastric Cancer
62799112|NCT06468098|EXPERIMENTAL|Cohort 6|IBI363 combined with chemotherapy in patients with Advanced Triple-Negative Breast Cancer
62799113|NCT06468098|EXPERIMENTAL|Cohort 7|IBI363 combined with chemotherapy in patients with platinum-resistant ovarian cancer that has failed or is intolerant to standard therapy
62799114|NCT06468098|EXPERIMENTAL|Cohort 8|IBI363 Combined with Investigator's Choice Standard of Care(SOC) in Patients with Advanced Solid Tumors
62799115|NCT06345625||Fallers|Community dwelling older adults with an age above 65 years. A participant is categorized as faller in case of a history of ≥2 falls in the previous 12 months and with identified high fall risk on the TUG (i.e., completion time ≥13.5 seconds). A fall is defined as an event that results in a person coming to rest inadvertently on the ground/floor/other lower level (WHO, 2021). Asyncopal fall, identified through the report of a loss of consciousness during the fall, has a different etiology and therefore will not be counted as a fall (Ang et al., 2020).
62799116|NCT06345625||Non-Fallers|Community dwelling older adults with an age above 65 years. A participant is included as non-faller in case of a history of 0 falls in the previous 12 months and without an identified fall risk on the TUG test (i.e., completion time ≤13.5 seconds).
62799117|NCT04803851|EXPERIMENTAL|Treatment group|Anlotinib plus AK105
62799118|NCT05682742|EXPERIMENTAL|Robotic-assisted surgery|Subjects scheduled to undergo robotic-assisted surgery
62224691|NCT00361660|ACTIVE_COMPARATOR|2|The same therapy is provided daily Monday through Friday
62417695|NCT05470140|EXPERIMENTAL|Experimental: WU-NK-101|"A non-engineered Natural Killer (NK) cell derived from peripheral blood mononuclear cells (PBMC) that is cytokine-reprogrammed, expanded, and cryopreserved to create an allogeneic enhanced Memory-like anti-tumor NK cell therapy product.~Each 28-day cycle of treatment consists of 3 doses of WU-NK-101 administered on Day 1, Day 8, and Day 15."
62588734|NCT05789888||Study group|The study group consisted of 75 people (46 women and 29 men) with gender (BMI=30.0-39.9 kg/m2).
62588735|NCT05789888||Control group|The control group included 41 people (31 women and 10 men) with normal weight (BMI=18.5-24.9 kg/m2).
62588736|NCT06667024|ACTIVE_COMPARATOR|Control group|Patients received the standard spinal anesthesia with 0.5% 3 ml according to the patient hyperbaric bupivacaine only.
62588737|NCT06667024|EXPERIMENTAL|Dexmedetomidine (study) group|Patients received dexmedetomidine 4 μg and 0.5% (3-4 ml according to the patient's height) hyperbaric bupivacaine.
62799119|NCT02847559|EXPERIMENTAL|Treatment (bevacizumab, electric field therapy)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 of courses 1-4. Beginning on day 1 of course 5, patients may choose to receive bevacizumab IV every 3 weeks or remain on the every 2-week schedule. Patients also undergo electric field therapy using Optune (formerly NovoTTF-200A System) daily over 18 hours. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62799120|NCT02729441|ACTIVE_COMPARATOR|Ramipril|"Maximal recommended dose of ramipril Altace® (10 mg/d) given as an active comparator for 12 week."
62799121|NCT02729441|EXPERIMENTAL|Perindopril|"Perindopril Coversyl® at maximal recommended dose (8 mg/d) as experimental therapy for 12 weeks."
62799122|NCT04265807|ACTIVE_COMPARATOR|Intervention Group|A standard non-invasive blood pressure cuff (e.g., American Diagnostics Corporation, Hauppauge, NY but any one can be used off the shelf) and disposable plastic clamp (e.g.,Medline Industries Incorporated, Mundelein, IL) can be used to apply RIC in patients resuscitated from OHCA via three cycles of 5-mins. inflation to 200 mmHg followed by 5-mins. deflation of a blood pressure cuff on an upper extremity. The cuff occludes the artery; the clamp maintains pressure in the air bladder of the cuff during the inflation periods.
62224692|NCT03715582|EXPERIMENTAL|trimetazidine|The randomization will be done with a list generated by the central pharmacy of the Hospital das Clínicas, Medical School, USP. When the patient is randomized to the trimetazidine pill group, he / she will initiate the medication at 70 mg oral dose (2 tablets of Vastarel ® MR 35 mg single dose) 2 hours before the procedure.
62224693|NCT03715582|EXPERIMENTAL|placebo|The randomization will be done with a list generated by the central pharmacy of the Hospital das Clínicas, Medical School, USP. When randomized to the placebo oral tablets group, the patient will receive placebo (orally, 2 single dose tablets) also 2 hours prior to PCI.
62224694|NCT01025401|NO_INTERVENTION|Motor manifestations during seizures|
62799123|NCT04265807|SHAM_COMPARATOR|Control Group|The control group will have a sham package opened at the bedside as soon as feasible after ED arrival. This will be identical in size, weight and appearance as that in the intervention group, but will contain a sham device. Upon identification that the patient has been randomized to the control group, the care team will proceed with all other resuscitative measures as in the the intervention group.
62224695|NCT05946057||Otoferlin participant group|Individuals with hearing impairment who have a molecular genetic diagnosis involving otoferlin
62224696|NCT02041520|EXPERIMENTAL|Omega 3 fatty acids|omega 3 fatty acids, 2.4 g per day, requiring intake 2 capsules (600mg each one) in the morning and two at night (Zonelabs, Marblehead MA) for 6 months.
62417696|NCT06427954|ACTIVE_COMPARATOR|THRIVE Digital Health App|Patients assigned to the intervention will be provided a study-issued tablet computer from which they will access the THRIVE digital health app. Study staff will give intervention patients a comprehensive tutorial and detailed instructions regarding how to use the app. Tutorial sessions may be conducted in person during a clinic appointment, via telephone, and/or via Zoom videoconferencing. Participants will complete the intervention modules at their desired pace over approximately 10 weeks.
62588738|NCT01663285|EXPERIMENTAL|Neoadjuvant Gemcitabine and Cisplatin|Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
62588739|NCT00574470|EXPERIMENTAL|1|Treatment with daclizumab/infliximab
62224697|NCT02041520|PLACEBO_COMPARATOR|Placebo|Placebo (olive oil gelcaps) in similar presentation as omega 3 fatty acids, requiring intake 2 capsules in the morning and two at night (Perfect Source, Fullerton CA, product code number PER 1016, lot number 8A0019/1600-1)
62224698|NCT03775889|EXPERIMENTAL|Behavioral|Behavioral Gardening Exposure
62799124|NCT00844376|OTHER|Test|Extemporaneous preparation suspension Atorvastatin prototype formulation
62224699|NCT04881981|EXPERIMENTAL|SCART Arm|Single Arm patients will be treated with SCART to different dose levels.
62224700|NCT04951154||Participants with Suspected Lung Cancer|Eligible participants with suspected lung cancer will be enrolled and undergo diagnostic and research bronchoscopic biopsies and research blood sample collection for biomarker analysis. Those participants who proceed to surgical resection will have additional research samples taken from the resected tumor and additional research blood samples drawn for biomarker analyses at the resection visit and at the post-operative follow up visit. Participants will then be followed clinically for two years for evidence of recurrence or until participants with confirmed lung cancer recurrence, whichever occurs earlier.
62224701|NCT04828200||sarcopenic patints with knee ostheoarthritis|12 patients between the ages of 50-70, who have been followed up with the diagnosis of knee Ostheoarthritis (OA) patients with sarcopenia.All subjects were evaluated by the European Working Group on Sarcopenia in Older People (EWGSOP) diagnostic criteria for the diagnosis of sarcopenia.
62224702|NCT04828200||non sarcopenic patients with knee ostheoarthritis|90 patients between the ages of 50-70, who have been followed up with the diagnosis of knee Ostheoarthritis (OA) patients.
62588740|NCT03562611|ACTIVE_COMPARATOR|flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg
62799125|NCT00844376|OTHER|Reference|Commercial atorvastatin tablet (Lipitor®)
62799126|NCT04485546|EXPERIMENTAL|OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj|
62799127|NCT03762031|EXPERIMENTAL|GC4711 30mg|
62799128|NCT03762031|EXPERIMENTAL|GC4711 60mg|
62799129|NCT03762031|EXPERIMENTAL|GC4711 90mg|
62799130|NCT03762031|EXPERIMENTAL|GC4711 120mg|
62799131|NCT03762031|PLACEBO_COMPARATOR|Placebo|
62799132|NCT03762031|EXPERIMENTAL|GC4711 75mg|
62799133|NCT03762031|EXPERIMENTAL|GC4711 105mg|
62799134|NCT01108913|ACTIVE_COMPARATOR|Bimosiamose|
62799135|NCT01108913|PLACEBO_COMPARATOR|Placebo|
62799136|NCT06692140|EXPERIMENTAL|Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent|Percutaneous coronary interventin with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent
62799137|NCT06692140|ACTIVE_COMPARATOR|Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent)|Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent)
62799138|NCT01603589|ACTIVE_COMPARATOR|MiECC group|Patients operated for elective coronary artery bypass grafting with the use of minimal invasive extracorporeal circulation (MiECC).
62799139|NCT01603589|ACTIVE_COMPARATOR|CECC group|Patients operated for elective coronary artery bypass grafting under conventional extracorporeal circulation (CECC).
62799140|NCT04034784|EXPERIMENTAL|Discrete(TM)|Intraperitoneal injection
62799141|NCT04034784|SHAM_COMPARATOR|Control Lactated Ringer's Solution (Control LRS)|Intraperitoneal injection
62799142|NCT02392130|ACTIVE_COMPARATOR|Active Drug|Clobetasol propionate 0.05% ointment
62799143|NCT02392130|EXPERIMENTAL|Experimental Drug|LEO 130852A gel 1%
62799144|NCT02392130|PLACEBO_COMPARATOR|Placebo Drug|LEO 130852A placebo gel
62799145|NCT00491491|EXPERIMENTAL|Z-BEAM|ibritumomab tiuxetan (zevalin) BEAM
62799146|NCT00491491|ACTIVE_COMPARATOR|standard BEAM|standard BEAM chemotherapy
62224703|NCT04828200||control group|33 patients between the ages of 50-70, who have been followed up not being exposed to be sarcopenia or knee OA
62799147|NCT04846322||ED delirium & dementia screening & outpatient referral|Routine ED screening for delirium and memory problems with referral for outpatient assessment of cognitive impairment.
62224704|NCT05276297|EXPERIMENTAL|ASO24-TI Group|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 24 weeks of Treatment 1 period, followed by GSK3528869A (Treatment 2) study intervention administered at Days 1, 57, 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week, with the possibility to extend up to 12 weeks.
62799148|NCT00106327|EXPERIMENTAL|1|6-month supervised treadmill exercise program
62224705|NCT05276297|ACTIVE_COMPARATOR|ASO24 Group|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 24 weeks of Treatment 1 period, followed by non-active control (Treatment 2) study intervention administered at Days 1, 57, 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week, with the possibility to extend up to 12 weeks.
62224706|NCT05276297|EXPERIMENTAL|ASO12-TI Group|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 12 weeks of Treatment 1 period, followed by GSK3528869A (Treatment 2) study intervention administered at Days 1, 57, 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week, with the possibility to extend up to 12 weeks.
62224707|NCT05276297|ACTIVE_COMPARATOR|ASO12 Group|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 12 weeks of Treatment 1 period, followed by non-active control (Treatment 2) study intervention administered at Days 1, 57, 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week, with the possibility to extend up to 12 weeks.
62417697|NCT06427954|NO_INTERVENTION|Usual Care|Patients assigned to the usual care group will not receive the digital app but rather standard oncology care.
62417698|NCT01150409|EXPERIMENTAL|hydrocortisone|Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
62224708|NCT00250939|EXPERIMENTAL|1|
62224709|NCT02423928|EXPERIMENTAL|Cryoimmunotherapy|"Patients with castration resistant prostate cancer and imaging proven metastases will be treated by autologous dendritic cell based cryoimmunotherapy of the prostatic tumor tissue assisted by immunomodulation consisting of low-dose metronomic cyclophosphamide for all patients plus ipilimumab for the latter half of all patients.~Update January 2019: The protocol was changed as approved by the Norwegian Medicines Agency and the Regional Ethical Committee in Western Norway for the 3 last patients of altogether 18 patients. Consequently, the 3 last patients received 200 mg i.v. of pembrolizumab (and no ipilimumab) post-CryoIT."
62224710|NCT01639495|EXPERIMENTAL|THERMOCOOL® SMARTTOUCH™ Catheter|
62417699|NCT01150409|PLACEBO_COMPARATOR|Normal Saline (placebo)|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
62417700|NCT05103410|ACTIVE_COMPARATOR|Aripiprazole|Patients will receive Aripiprazole 30 mg tablet orally 3 h before surgery
62417701|NCT05103410|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo tablet which is identical in appearance, size, shape, and color to aripiprazole 3 h before surgery.
62417702|NCT01731431|ACTIVE_COMPARATOR|Insulin|standard protocol of insulin treatment for gestational diabetes
62417703|NCT01731431|EXPERIMENTAL|Glyburide|initial dose 2.5 mg per day increased if necessary until 10mg twice a day if glycemia is not controlled
62417704|NCT06442384|EXPERIMENTAL|VLNC cigarettes plus access to tobacco and non-tobacco flavored e-cigarettes|Smokers who meet eligibility criteria will enter 2 weeks of monitoring of usual brand smoking. Participants will then be randomly assigned to a 4-week intervention
62417705|NCT06442384|EXPERIMENTAL|VLNC cigarettes plus access to only tobacco flavored e-cigarettes|Smokers who meet eligibility criteria will enter 2 weeks of monitoring of usual brand smoking. Participants will then be randomly assigned to a 4-week intervention
62417706|NCT06703723||Male subjects, aged 18-50 requiring a semen fluid evaluation. • Positive IgG serological test result|
62799149|NCT00106327|EXPERIMENTAL|2|6-month supervised lower extremity progressive resistance training program
62799150|NCT00106327|ACTIVE_COMPARATOR|3|Diet/nutrition control group
62799151|NCT04566601|EXPERIMENTAL|BI 1358894 5mg|
62417707|NCT06703723||Healthy|Healthy
62417708|NCT01470352|PLACEBO_COMPARATOR|Placebo|
62799152|NCT04566601|EXPERIMENTAL|BI 1358894 25mg|
62224711|NCT01664598|EXPERIMENTAL|Tocilizumab|
62224712|NCT05630482|EXPERIMENTAL|Healthy Family Foundations Intervention|Participants randomized to the HFF intervention condition will participate in 10 weekly 2 hour classes (5 prenatal and 5 postnatal) in groups of 5-10 couples. Due to COVID, all classes will take place via Zoom. The classes will be led by male/female facilitator teams. The facilitators will be hired, trained and supervised by Penn State. Postnatal classes will occur 2-8 months after birth and will also be weekly and last 2 hours each.
62224713|NCT05630482|ACTIVE_COMPARATOR|Control Condition|Participants randomized to the control condition will receive standard of care and opportunities for education at their site, including information about infant growth and development, infant care (including brief, standard information regarding breastfeeding/introduction to solid food), and quality childcare selection.
62224714|NCT04248660||Uterine artery doppler measurements|"Uterine artery doppler measurements will be made in the same patients at 11-14 weeks and 20-22 weeks of pregnancy.~Doppler results will be classified according to pregnancy results and primary results will be doppler findings."
62224715|NCT04421183||1|preeclampsia
62588741|NCT03562611|EXPERIMENTAL|nalbuphine|nalbuphine intraoperative administration 0.1mg/kg
62799153|NCT04566601|EXPERIMENTAL|BI 1358894 75mg|
62799154|NCT04566601|EXPERIMENTAL|BI 1358894 125mg|
62799155|NCT04566601|PLACEBO_COMPARATOR|Placebo|
62799156|NCT00241722|EXPERIMENTAL|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally twice daily (BID) for 12 months.
62026243|NCT03788486|EXPERIMENTAL|2-3 Joule light device for MGD/Dry eye|patients who qualify for the study will receive interventional in office treatments with the light treatment device in the upper and lower lids for defined periods of time twice weekly for a total of one month. Non-invasive tear break up, subjective questionnaires and corneal fluorescein staining will be measured through the course of the study.
62026244|NCT04273633|EXPERIMENTAL|INTERVENTION|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant shoulder
62026245|NCT04273633|PLACEBO_COMPARATOR|Placebo Monopolar Radiofrequency stimulus|To simulate the application of Monopolar Radiofrequency stimulus on the dominant shoulder
62026246|NCT00443248|EXPERIMENTAL|Vaginal Heat Wash-Out Device|
62026247|NCT04898153|EXPERIMENTAL|aXess|Patients will be implanted with the Xeltis hemodialysis access graft (aXess)
62026248|NCT00373789|EXPERIMENTAL|Botox A|up to two injections of 200 Units of intra-detrusor Botulinum Toxin A , which must be separated by at least eight weeks and no more than 52 weeks
62224716|NCT04421183||4|normal pregnancy without complication
62224717|NCT04421183||2|hellp
62588742|NCT03562611|EXPERIMENTAL|nalbuphine and flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg and nalbuphine intraoperative administration 0.1mg/kg
62588743|NCT04292262||AKI|
62588744|NCT04292262||Non AKI|
62417709|NCT01470352|ACTIVE_COMPARATOR|treatment|Duloxetine will be given in a daily dose of 30 mg for 5 weeks
62417710|NCT04365842|EXPERIMENTAL|Digital exercise group|"After the 6-week digital intervention, 1) qualitative interviews have done with 6-15 patients from intervention group to assess the feasibility of digital intervention.~2) The primary outcomes are hand pain and function and exercise adherence will be evaluated for all participants"
62417711|NCT04365842|ACTIVE_COMPARATOR|Waiting list conrol|A hand rehabilitation home program will be given to the patients in the group through the telephone messages with brochures.
62588745|NCT05842447|EXPERIMENTAL|367 mg Pomanox group|One capsule daily with 367 mg of Pomanox®P30 for 12 weeks
62799157|NCT00241722|PLACEBO_COMPARATOR|Placebo|Placebo was administered orally BID for 12 months.
62026249|NCT00373789|PLACEBO_COMPARATOR|Placebo|up to two injections of inactive injection (carrier saline), which must be separated by at least eight weeks and no more than 52 weeks
62026250|NCT00299234|PLACEBO_COMPARATOR|2|placebo
62026251|NCT00299234|EXPERIMENTAL|1|atomoxetine
62026252|NCT02493127|EXPERIMENTAL|Standard PCS|Grip strength measurements and completes standard PCS
62026253|NCT02493127|EXPERIMENTAL|Positive PCS|Grip strength measurements and completes positively adjusted PCS
62026254|NCT00655187||Group A|Cases
62026255|NCT00655187||Group B|Controls
62224718|NCT04421183||3|eclampsia
62417712|NCT01205542|EXPERIMENTAL|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
62417713|NCT01205542|ACTIVE_COMPARATOR|Reference|Health check and advice to continue ordinary physical activity
62417714|NCT01612780|EXPERIMENTAL|XprESS Multi-Sinus Dilation Tool|Balloon sinus dilation
62417715|NCT05005130|EXPERIMENTAL|Cluster 1 (George)|3 months without TASKPEN (Standard of Care) and 6 months with TASKPEN.
62417716|NCT05005130|EXPERIMENTAL|Cluster 2 (Chilengi)|6 months without TASKPEN (Standard of Care) and 3 months with TASKPEN
62417717|NCT05863078||Group following the Menus of Change diet|
62588746|NCT05842447|EXPERIMENTAL|700 mg Pomanox group|One capsule daily with 700 mg of Pomanox®P30 for 12 weeks
62588747|NCT05842447|PLACEBO_COMPARATOR|Control group|One capsule daily with maltodextrin for 12 weeks
62588748|NCT04210908|EXPERIMENTAL|Biofeedback|The patient will be instructed to bear down during 4 consecutive contractions while monitoring head descent using transperineal ultrasound. In the study group, patients will observe the descent of the head during contraction on the ultrasound display screen.
62588749|NCT04210908|NO_INTERVENTION|Control|The patient will be instructed to bear down during 4 consecutive contractions while monitoring head descent using transperineal ultrasound. In the control group, patients will not observe the ultrasound display screen.
62799158|NCT03921034|ACTIVE_COMPARATOR|continuous ACB with IPACK block|ACB bolused with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine followed by an 8 ml/hr continuous infusion of ropivacaine 0.2% and IPACK block with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine
62799159|NCT03921034|SHAM_COMPARATOR|continuous ACB with sham subcutaneous saline injection|ACB bolused with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine followed by an 8 ml/hr continuous infusion of ropivacaine 0.2% and a sham IPACK block with subcutaneous saline injection along the medial thigh
62026256|NCT06497439|EXPERIMENTAL|Treatment 1|2 tablets of Silfamin 150 mg twice daily
62026257|NCT06497439|PLACEBO_COMPARATOR|Treatment 2|2 tablets of Placebo twice daily
62026258|NCT03538535|EXPERIMENTAL|Go/No-Go Active Learning (GOAL)|Adaptation of Behavioral Activation, focused on reinforcement learning strategies.
62026259|NCT02446132|EXPERIMENTAL|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 52-week period
62026260|NCT02446132|EXPERIMENTAL|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 52-week period
62026261|NCT02446132|EXPERIMENTAL|AVP-786 (dose 3)|AVP-786 dose 3; capsules administered twice a day over a 52-week period
62224719|NCT05361876||Young Male|Healthy men with some sport experience
62224720|NCT05361876||Young Female|Healthy female with some sport experience
62224721|NCT05114239|EXPERIMENTAL|Timolol|Timolol 0.25% applied to distal or posterior half of wound edge twice daily prior and adjunct to prior wound care.
62224722|NCT05114239|PLACEBO_COMPARATOR|Standard Wound Care|Petrolatum ointment
62224723|NCT03843931|ACTIVE_COMPARATOR|GLA:D|8 weeks of education (1 session/week for 2 weeks) and exercise therapy (2 sessions/week for 6 week)
62224724|NCT03843931|PLACEBO_COMPARATOR|Intra-articular saline injection|Intra-articular saline injection (5 ml of 0.9% sodium chloride) every 2 weeks over an 8-week period
62417718|NCT05863078||Group not following the menus of Change diet|
62417719|NCT02856620||Moderate AS with HF|
62417720|NCT02856620||Severe AS with HF|
62417721|NCT02856620||Moderate AS without HF|
62799160|NCT01839058||Non Cardiac Chest Pain Patients|Patients with Chest Pain where Coronary Artery Disease has been formally ruled out are to undergo esophageal manometry testing.
62799161|NCT01839058||Healthy Controls|Healthy volunteers without esophageal symptoms are to undergo esophageal manometry testing.
62799162|NCT06344728|EXPERIMENTAL|Brensocatib Treatment Sequence AB|Participants will receive a single dose of the pediatric oral brensocatib solution (Treatment A) on Day 1 followed by a washout period of 9 days. On Day 10, participants will receive a single dose of the oral brensocatib tablet (Treatment B).
62799163|NCT06344728|EXPERIMENTAL|Brensocatib Treatment Sequence BA|Participants will receive a single dose of the oral brensocatib tablet (Treatment B) on Day 1 followed by a washout period of 9 days. On Day 10, participants will receive a single dose of the pediatric oral brensocatib solution (Treatment A).
62799164|NCT01086774|EXPERIMENTAL|Systane Ultra|Systane Ultra Lubricant Eye Drops
62417722|NCT02856620||Severe AS without HF|
62417723|NCT02856620||HFpEF without AS|
62417724|NCT02856620||Normal age-matched controls|
62417725|NCT05723042|EXPERIMENTAL|EMS with CIMT group|
62799165|NCT05356832||continent|able to hold urine during sports
62799166|NCT05356832||incontinent|leaking urine during sports
62243000|NCT06428500|EXPERIMENTAL|Part 1a: QTX3046 monotherapy dose escalation|QTX3046 will be administered orally at escalating doses as defined in the protocol based on dose level assignment
62417726|NCT05723042|ACTIVE_COMPARATOR|EMS Group|
62417727|NCT03737760||Older Adults|Community-dwelling men and women age 70+ years
62799167|NCT02735148|NO_INTERVENTION|Conventional Training|Conventional training sessions generally consisted of exercises which aimed to improve range of motion, strength, and movement quality in upper and lower extremity as an in-patient rehabilitation protocol. Also developing static and dynamic postural control and increasing walking distance were the other aims of training. Duration of the Conventional Training is 45 minute per session, 3 days a week for 6 weeks.
62588750|NCT01098500||Cancer patients|Adults (age ≥18 years) with at least two ICD-9 codes for a particular cancer within a 6 month timeframe and at least one code for a TKI drug that occurs on or after the first cancer diagnosis code
62799168|NCT02735148|EXPERIMENTAL|Body Weight Supported Treadmill Training|"Body weight supported treadmill training (BWSTT) was composed of outpatients who were undertaken only BWST training with 45-minute sessions, 2 days a week during 6 weeks.~BWST Training~Locomat (Hocoma) was used in BWSTT group with 20 % body weight reduced. The participants walked on device at 1.8 km/h (0.5 m/sec) velocity. For each participant body weight portion was ensured by a security belt while walking. Each session took 45 minutes including setup, commands and rest time. Verbal instructions were used for encouragement but no manual assistance was given to improve gait pattern."
62417728|NCT03737760||Younger Adults|Healthy young adults, age 20-40 years for baseline assessments only
62417729|NCT06229379|EXPERIMENTAL|"Digital twin patient"|"The students in the Digital twin patient group were trained in history taking using a digital twin patient on the first day of a training program, and then took a 15-minute clinical questioning exam using the digital twin patient on the second day."
62417730|NCT06229379|OTHER|Real patient|"The students in the Real patient group were trained in history taking using a real patient on the first day of a training program, and then took a 15-minute clinical questioning exam using the digital twin patient on the second day."
62417731|NCT06195358|ACTIVE_COMPARATOR|Control Arm|The control arm will receive printed caregiving materials.
62417732|NCT06195358|EXPERIMENTAL|Intervention Arm|The intervention arm will receive the smartphone application.
62417733|NCT06280794|EXPERIMENTAL|Laser acupuncture Group|"Steroids. Patients in the laser acupuncture group (LA group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy).~In LA group, we choose 5 acupoints on the affected side. It includes ST2(Si Bai), ST4(Di Cang), ST6(Jia Che), GB14(Yang Bai), GB20(Feng chi). We choose 6 acupoints, including LI4 (He Gu), LI11(Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), LR3 (Tai Chong).~Laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm), 500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, administered for 3 times per week in the first 2 weeks, and 1500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, in the last 2 weeks, 12 times total treatment."
62433489|NCT04487145|ACTIVE_COMPARATOR|HIV-uninfected children (C3a)|30 HIV-uninfected children age 3-10 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. PK samples are collected after the 3rd dose. Control group for E3 and L3.
62799169|NCT02735148|NO_INTERVENTION|Combined Training|Combined Training consisted of inpatient participants who were treated with 45 minute-conventional training, 5 days a week during 6 weeks. Additionally this group had 45 minute-BWST training, 2 days a week during 6 weeks.
62799170|NCT02583919|EXPERIMENTAL|ISIS-GCGRRx - Dose Level 1|ISIS-GCGRRx - Dose Level 1
62799171|NCT02583919|EXPERIMENTAL|ISIS-GCGRRx - Dose Level 2|ISIS-GCGRRx - Dose Level 2
62799172|NCT02583919|PLACEBO_COMPARATOR|Placebo|Placebo
62224725|NCT04398407|EXPERIMENTAL|Coaching and Achievement of Peer Providers (CAPP)|"CAPP will consist of 16 individualized, one-on-one sessions using Zoom or other videoconferencing software and occurring over a 4-month period. Coaching meetings will take approximately one hour per week. The coach will tailor and individualize the modules and time spent on modules to meet the goals of each peer provider.~Modules:~Module 1: Establishing and solidifying the working alliance, understanding the work setting and role Module 2: Understand Generic drivers of burnout and role stress Module 3: Discuss specific sources of role stressors and burnout Module 4: Set SMART Goals Module 5: Overcome challenges for workplace success Module 6: Develop Skills for Workplace Success Module 7: Managing co-worker and supervisory relations in the workplace Module 8: Wrap-up sessions~During the first stage of research, the CAPP intervention will be further developed and refined, prior to the Randomized clinical trial."
62224726|NCT04398407|ACTIVE_COMPARATOR|Enhanced control|"The enhanced control condition will include 1 generic informational session conducted by a CAPP coach.During that session, the coach will introduce the key concepts under study and provide information about the drivers of burnout and role stress. The CAPP coach will discuss the need to set goals to overcome these challenges and will provide one article via email describing burnout and role stressors that is suitable for a lay person."
62224727|NCT05323396|ACTIVE_COMPARATOR|Parasite-positive arm|Participants will be evaluated for intestinal parasitic infection by stool microscopy, stool PCR and Strongyloides IgG from plasma. If positive by either of these, the participant will be treated for the detected parasitic infection. The biomarker levels of this parasite-positive group will be compared to the parasite-negative group. Additionally the parasite-positive pre-treatment biomarker levels will be compared to the parasite-positive post-treatment levels.
62224728|NCT05323396|NO_INTERVENTION|Parasite-negative arm|"Participants will be evaluated for intestinal parasitic infection by stool microscopy, stool PCR and Strongyloides IgG from plasma. If negative by all of these tests on the initial sample collection, the participants will not receive treatment and will be in the parasite-negative/no intervention arm."
62224729|NCT00557180||BASALT|Participants in the ACRN BASALT study
62224730|NCT00557180||TALC|Participants in the ACRN TALC study
62224731|NCT05337358|ACTIVE_COMPARATOR|Lithium disilicate|The intervention will be: Prosthetic endocrown
62799173|NCT03953833|EXPERIMENTAL|recombinant anti-HER2 humanized monoclonal antibody conjugate|Drug Name : Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection R \& D code: B003 Drug Type : Biological Products
62799174|NCT04257890|EXPERIMENTAL|CBT intervention group|In addition to the information about IGD of the control group, the intervention group will receive eight weekly group-based 90-minute CBT sessions.
62799175|NCT04257890|ACTIVE_COMPARATOR|Wait-list control group|Members will receive printed education material about IGD but not CBT during the treatment period.
62799176|NCT00750724|PLACEBO_COMPARATOR|B|2 ml of Normal saline intraarticular injection to the knee joint weekly for 5 weeks
62799177|NCT00750724|EXPERIMENTAL|A|2 ml of 25 mg sodium hyaluronate intraarticular injection to the knee joint weekly for 5 weeks
62799178|NCT05456880|EXPERIMENTAL|BEAM-101|BEAM-101 manufactured with autologous CD34+ hematopoietic stem cells collected by plerixafor mobilization and edited ex vivo. No maximum dose has been set for BEAM-101; all of the gene edited cells that pass release specifications will be administered to the patient. BEAM 101 will be administered as a single dose by IV infusion.
62799179|NCT02322437|EXPERIMENTAL|Home treatment|Patients in need of acute psychiatric inpatient care are treated at their houses by mobile treatment teams instead of treatment at mental hospitals whenever home treatment is possible and appropriate.
62026262|NCT02443181|EXPERIMENTAL|Activa PC+S|Patients will be implanted with standard DBS electrodes for treatment of essential tremor, at the Vim nucleus of the thalamus, and an additional subdural electrode array overlying hand motor cortex.. The patient will receive standard of care programming for thalamic stimulation for essential tremor. During research study visits, implementation and evaluation of closed-loop DBS using the PC+S system will be performed.
62224732|NCT05337358|ACTIVE_COMPARATOR|Fiber reinforced composite|The intervention will be: Prosthetic endocrown
62588751|NCT04635995|EXPERIMENTAL|Monotherapy dose escalation|The monotherapy dose escalation phase includes 8 dose levels of LVGN7409. Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
62799180|NCT02322437|ACTIVE_COMPARATOR|Treatment as usual|Patients in need of acute psychiatric inpatient care are treated at a mental hospital.
62026263|NCT03666039|EXPERIMENTAL|Sensorimotor training|The participants will receive a tablet-based app for at home training that contains sensorimotor components.
62026264|NCT03666039|ACTIVE_COMPARATOR|Control training|The participants will receive a tablet-based app for at home training that contains relaxing components.
62224733|NCT01941719|EXPERIMENTAL|enhanced foot care education|In addition to the standard diabetic foot self-care instruction, the importance of daily foot self-care was reinforced at baseline by viewing personal barefoot plantar pressure in gait
62224734|NCT01941719|ACTIVE_COMPARATOR|Standard Foot Care Education|Reviewed the standard diabetic foot self-care instructions, including daily foot inspection and proper footwear at all times.
62224735|NCT00477334|EXPERIMENTAL|1|Famciclovir 1000 mg; twice a day for one day.
62224736|NCT00477334|PLACEBO_COMPARATOR|2|Placebo; twice a day for one day.
62799181|NCT05946941|EXPERIMENTAL|Deucravacitinib, Dose 1|
62799182|NCT05946941|EXPERIMENTAL|Deucravacitinib, Dose 2|
62799183|NCT05946941|PLACEBO_COMPARATOR|Placebo, followed by Deucravacitinib Dose 1 or Dose 2|
62799184|NCT05768412||All patients|All patients undergoing Radial Artery Access requiring interventional radiology.
62799185|NCT01201720|OTHER|Albumin|Albumin solution for infusion 5%. dosage: 43,5 millimole intravenouse use , 6 plasma exchange with albumin in 11 days and administration of polyclonal gamma globulin.6 sessions
62799186|NCT06176742|EXPERIMENTAL|Bubble Positive Expiratory Pressure Device|Diaphragmatic breathing technique will be the baseline treatment. B group will be treated with bubble positive expiratory pressure device. Patients will be encouraged to blow down the tubing into the water, and make bubbles. This creates positive pressure back up the tubing and into patient's airways and lungs. As the pressure holds open your patient's airways, it helps more air to move in and out of their lungs. All study participant will receive a total of 18 treatment sessions over a six-week period, which consisted of 03 treatment sessions per week.
62588752|NCT06482294|EXPERIMENTAL|Non ant-inflammatory rescue medication|Salbutamol 200 mcg pMDI x2
62799187|NCT06176742|ACTIVE_COMPARATOR|Active Cycle Breathing Technique|"Diaphragmatic breathing technique will be the baseline treatment.A group will be treated with active cycle breathing technique. The technique consists of inspiratory hold technique, deep breathing and forced expiration. These are repeated in a cycle until your chest feels clear. You can carry out ACBT when either sitting or lying down.~Physiotherapist will discuss this with you during your physiotherapy assessment. All study participant will receive a total of 18 treatment sessions over a six-week period, which consisted of 03 treatment sessions per week."
62799188|NCT00026702||All|Subjects at least three years old
62799189|NCT04692675|EXPERIMENTAL|AS + mpMRI|Active surveillance (AS) with the following: a) Initial PSA and DRE screen; then, PSA screening every 12 months, with DRE every year mpMRI or prostate biopsy is performed; b) Initial mpMRI and then prior to all biopsies; c) Initial systemic prostate biopsy and MRI/US fusion-guided prostate biopsy of all suspicious lesions; then, every 2 years for 5 years and then every 3 years
62588753|NCT06482294|EXPERIMENTAL|Anti-inflammatory rescue medication|(Salbutamol 200 mcg + either Fluticason 250 mcg DPI or Beclometasone 400 mcg DPI or Budesonide 400 mcg pMDI ) x2
62799190|NCT00882232|EXPERIMENTAL|1|Cross-linked hyaluronan gel and radiotherapy. Cross-linked hyaluronan gel is injected under anesthesia between the prostate and rectum prior to the start of radiotherapy. The gel pushes the prostate away from the rectum over several months, thereby reducing the dose of radiation delivered to the rectum. Hyaluronic acid is a naturally-occurring substance that is gradually absorbed by the body.
62588754|NCT00901017|ACTIVE_COMPARATOR|Straumann BoneCeramic|Straumann BoneCeramic
62026265|NCT04289857|EXPERIMENTAL|Experimental group|Each session will last a maximum of 5 minutes, taking place for 3 days a week, over a period of 4 weeks. The intervention will be performed at the start of training (before warm-up).
62588755|NCT00901017|ACTIVE_COMPARATOR|Bio-Oss|Geistlich Bio-Oss
62588756|NCT05426486|EXPERIMENTAL|ARX788 + pyrotinib maleate|ARX788 1.5 mg/kg intravenously (IV) every three weeks plus pyrotinib maleate 320 mg orally once daily for 6 cycles
62799191|NCT04579341|ACTIVE_COMPARATOR|probiotics arm|probiotics administered in addition to insulin regimen
62026266|NCT04289857|NO_INTERVENTION|Control group|Athletes included in the control group will not perform any intervention, continuing with their usual routine.
62026267|NCT05653505||Endovascular therapy|According to current guideline recommendations, patients enrolled in this cohort will receive standardized perioperative management, endovascular therapy, and postoperative medical therapy.
62224737|NCT01873222|EXPERIMENTAL|OFDI-guided PCI & IVUS|"* Assessment by IVUS at post-PCI~* Assessment by OFDI at a 8-month follow-up"
62224738|NCT01873222|ACTIVE_COMPARATOR|IVUS-guided PCI & OFDI|"* Assessment by OFDI at post-PCI~* Assessment by OFDI at a 8-month follow-up"
62417734|NCT06280794|SHAM_COMPARATOR|Sham laser acupuncture Group|"Steroids. Patients in the laser acupuncture group (LA group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy).~In LA group, we choose 5 acupoints on the affected side. It includes ST2(Si Bai), ST4(Di Cang), ST6(Jia Che), GB14(Yang Bai), GB20(Feng chi). We choose 6 acupoints, including LI4 (He Gu), LI11(Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), LR3 (Tai Chong).~The Sham LA group received the same laser device and the same acupoints. The device showed the same red light but did not emit a laser, administered for 3 times per week in the 4 weeks."
62224739|NCT01242137||Extensive metabolizers|
62417735|NCT06280794|OTHER|Control group|Steroids.
62417736|NCT05150340|EXPERIMENTAL|Epoch 1: TAK-771 Ramp up Period|TAK-771 included IGI 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants received subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution. The dose of 10% IGI was increased from 1/3 of full dose to full dose in 3 weeks for participants who received TAK-771 once every 3 weeks, or from 1/4 of full dose to full dose in 6 weeks for participants who received TAK-771 once every 4 weeks.
62417737|NCT05150340|EXPERIMENTAL|Epoch 2: TAK-771 Full Dose Treatment Period|TAK-771 included Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants received subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 3, or 4 weeks for up to Week 27 for participants with 4-Week dosing interval or Week 25 for participants with 3-Week dosing interval.
62417738|NCT03745326|EXPERIMENTAL|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-KRAS G12D mTCR PBL + highdose aldesleukin
62417739|NCT03745326|EXPERIMENTAL|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-KRAS G12D mTCR PBL + high-dose aldesleukin
62417740|NCT04730544|EXPERIMENTAL|Experimental Arm A|"Treatment for 108 weeks (one cycle = 12 weeks; 9 cycles):~Nivolumab 480 mg every 4 weeks (27 infusions) and ipilimumab 1 mg/kg every 6 weeks (18 infusions) for a total of 24 months of treatment (or less in case of RECIST progression (PD) or limiting toxicity, whichever occurs first)."
62417741|NCT04730544|ACTIVE_COMPARATOR|Control Arm B|"Induction of 12 weeks (one cycle = 3 weeks; 4 cycles):~Nivolumab 240 mg and ipilimumab 1 mg/kg every 3 weeks for 4 dosing cycles (4 infusions of nivolumab and ipilimumab), Maintenance of 96 weeks (one cycle = 4 weeks; 24 cycles): Nivolumab 480 mg every 4 weeks for 24 dosing cycles (24 infusions) for a total of 24 months of treatment (or less in case of RECIST progression (PD) or limiting toxicity, whichever occurs first)."
62417742|NCT01556165|EXPERIMENTAL|rasagiline|
62417743|NCT01556165|PLACEBO_COMPARATOR|placebo|
62417744|NCT06666426|ACTIVE_COMPARATOR|Hollister|
62417745|NCT06666426|EXPERIMENTAL|PureWick|
62588757|NCT05426486|ACTIVE_COMPARATOR|trastuzumab + pertuzumab + docetaxel + carboplatin|Trastuzumab (8 mg/kg first dose, followed 6 mg/kg) puls pertuzumab (840 mg first dose, followed 420 mg) plus docetaxel (75 mg/m3) plus carboplatin (AUC6) IV every 3 weeks for 6 cycles
62588758|NCT05487404|EXPERIMENTAL|ADX-629 Oral Tablets|
62588759|NCT05487404|PLACEBO_COMPARATOR|Placebo|
62799192|NCT04579341|NO_INTERVENTION|control|regular insulin regimen
62799193|NCT02910466|EXPERIMENTAL|rhPTH(1-84)|Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 36 months. The dose will be individualized based on albumin-corrected serum calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.
62224740|NCT01242137||Intermediate mtabolizers|
62417746|NCT03768388|OTHER|Fasting State|A single 600 mg dose of levoketoconazole administered in a fasting state.
62417747|NCT03768388|OTHER|Fed State|A single 600 mg dose of levoketoconazole administered in a fed state.
62417748|NCT06154772|EXPERIMENTAL|Color Therapy|Balancing body chakras with colors. Colors are applied to the body's chakras for 10-15 minutes.
62417749|NCT06154772|NO_INTERVENTION|Control Group|Routine maintenance will be applied
62417750|NCT05418387|EXPERIMENTAL|Group A|Patients randomized to receive the Social Support Network intervention
62417751|NCT05418387|ACTIVE_COMPARATOR|Patient Navigation|Patients randomized to receive Usual Care (patient navigation)
62417752|NCT06700525|EXPERIMENTAL|StandUPTV only|The StandUPTV application is used to monitor and reduce sedentary screen time (SST). The StandUPTV app has three components: LOCKOUT: Electronic lockout turns off screens when a predetermined limit is reached (50% of baseline value of weekly sedentary screen time). The app also includes planning tools and personalized strategies to limit SST. TEXT: Push notification prompts provide reminders, coaching, and personalized feedback (up to 2 per day). EARN: Opportunities to earn SST by engaging in MVPA, measured in 10-minute bouts.
62588760|NCT06665737|ACTIVE_COMPARATOR|Early receiving G-CSF group|Early receiving G-CSF group Patients in early receiving G-CSF group accept within 72 hours post chemotherapy
62588761|NCT06665737|PLACEBO_COMPARATOR|Late receiving G-CSF group|Last receiving G-CSF group Patients in early receiving G-CSF group accept after 72 hours post chemotherapy
62588762|NCT05821517|ACTIVE_COMPARATOR|Standard of care|An anticipated analgesia protocol composed of PARACETAMOL 1g +/- OXYNORM 5 mg or 10 mg according to patients weight and pain intensity as evaluated by a simple numeric rating scale is administred prior to the reduction procedure. Inhaled equimolar mixture of oxygen and notrous oxyde (MEOPA) at a 15L/min flux is administered concomitantly to the reduction procedure.
62588763|NCT05821517|EXPERIMENTAL|Medical device : VR headset|"Use of a  virtual reality  (VR) headset of  Pico G2  type with  HypnoVR  software and audio headset  Taotronics BH22  during all the reduction care"
62799194|NCT04197349|EXPERIMENTAL|Part A Cohort 1-8|ALD1910/Placebo; Single Dose IV infusion on Day 1
62799195|NCT04197349|EXPERIMENTAL|Part B Cohort 9|ALD1910/Placebo+Sumatriptan; Single Dose IV infusion on Day 1
62224741|NCT01242137||Poor metabolizers|
62224742|NCT05444569|EXPERIMENTAL|LY3537021 + Liraglutide (Part A)|Liraglutide administered subcutaneously (SC) followed by liraglutide in combination with LY3537021 given SC.
62224743|NCT05444569|EXPERIMENTAL|Liraglutide + Placebo (Part A)|Liraglutide administered SC followed by liraglutide in combination with placebo given SC.
62417753|NCT06700525|EXPERIMENTAL|StandUPTV + Action Plans|Combining the StandUPTV application with personalized action plans to enhance the maintenance of reduced eSST. At baseline, participants will receive Action Planning Education, action planning worksheet, and weekly personalized text messages reinforcing the action plan. Participant will then receive a daily StandUPTV alert after performing 30 minutes of eSST, and they have 60 minutes after the alert to engage in their active chosen non-sedentary behavior. Financial Incentives: Participants can earn up to $30 per month during the 4-month intervention by starting 10 minutes of their non-sedentary replacement behavior within 60 minutes of the alert. Participants start with $30 in their account and lose $2 for each day they do not perform the behavior. Notifications will be sent via SMS and the StandUPTV app.
62417754|NCT04540315|EXPERIMENTAL|Intervention - MobiMD app|Intervention group will receive notifications to their smart device through MobiMD app. Participants will be asked to fill out reports and upload all clinically relevant data using the app. Engaging with the app will be in addition to the standard of care follow-up.
62799196|NCT04197349|EXPERIMENTAL|Part B Cohort 10|ALD1910/Placebo; Single dose subcutaneous injection on Day 1
62026268|NCT05653505||Endovascular therapy+Remote ischemic conditioning|"Patients enrolled in this cohort will receive the same treatment as those in the endovascular therapy alone cohort as well as additional remote ischemic conditioning treatment.~Remote ischemic conditioning treatment protocol: RIC will be applied immediately after admission to the integrated neurovascular ward and the treatment continues until the patient is discharged, Once the patient is discharged, the choice of whether to continue RIC treatment depends on the patient's preference. RIC was induced through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 5 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure), and 5 minutes of deflation twice a day."
62224744|NCT05444569|EXPERIMENTAL|LY3537021 + Liraglutide & Placebo + Liraglutide (Part B)|"LY3537021 administered SC followed by liraglutide administered SC in treatment period 1.~Placebo administered SC followed by liraglutide administered SC in treatment period 2."
62224745|NCT05444569|EXPERIMENTAL|Placebo + Liraglutide & LY3537021 + Liraglutide Part B)|"Placebo administered SC followed by liraglutide administered SC in treatment period 1.~LY3537021 administered SC followed by liraglutide administered SC in treatment period 2."
62417755|NCT04540315|NO_INTERVENTION|Standard of Care|The standard of care control group will receive conventional postoperative care. Participants will receive reported outcome survey by email.
62799197|NCT02423057|EXPERIMENTAL|1|TdCyd will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles
62799198|NCT03140397|PLACEBO_COMPARATOR|Placebo|Capsules filled with mannitol and silicon dioxide
62799199|NCT03140397|EXPERIMENTAL|6-prenylnaringenin|500 mg 6-PN plus mannitol and silicon dioxide
62026269|NCT05811338|NO_INTERVENTION|Project 1 - Phase 1: Development/Refinement of VR program; Usability Testing/Development of Training|The study includes one session that will last approximately 2 - 3 hours. The study involves completing some questionnaires that gather background demographic information and a structured needs assessment interview to gather information on user preferences, usability problems, implementation and training protocols.
62224746|NCT04183309||Pediatric anesthetized patients|Pediatric anesthetized patients undergoing abdominal laparoscopy surgery (simple-arm study).
62224747|NCT01598623|EXPERIMENTAL|Oxytocin+ Non Specific Counselling|
62224748|NCT01598623|EXPERIMENTAL|Oxytocin + Social Skills training|
62224749|NCT01598623|PLACEBO_COMPARATOR|Placebo + Non Specific Counselling|
62224750|NCT01598623|EXPERIMENTAL|Placebo + Social Skills Training|
62417756|NCT03911466|EXPERIMENTAL|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
62799200|NCT03140397|EXPERIMENTAL|8-prenylnaringenin|500 mg 8-PN plus mannitol and silicon dioxide
62799201|NCT05946603|SHAM_COMPARATOR|RARP + IS-002|Subjects will receive IS-002, but during surgery NO fluorescence imaging will be performed.
62799202|NCT05946603|EXPERIMENTAL|RARP + IS-002 + intraoperative near-infrared imaging|Subjects will receive IS-002, and during surgery fluorescence imaging will be performed.
62799203|NCT03623763||Healthy individuals|Individuals without any complaints and chronic diseases
62799204|NCT03623763||Swimmers|Elite athletes - swimmers to distance of national team of Uzbekistan
62224751|NCT05915650|EXPERIMENTAL|Pain Neuroscience Education Group|
62224752|NCT05915650|EXPERIMENTAL|Routine Education Group|
62224753|NCT04080921|EXPERIMENTAL|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
62588764|NCT05821517|EXPERIMENTAL|Medication : Methoxyflurane analgesia|Self administered inhalated methoxyflurane (maximal inhaled dose : 3 mL)
62588765|NCT02041117|OTHER|Rosuvastatin|
62799205|NCT03623763||Synchronized swimmers|Elite athletes - swimmers of national team of Uzbekistan
62026270|NCT05811338|EXPERIMENTAL|Project 1 - Phase 2: VR Program|"Training will occur over 3 days and be conducted by research investigators in the participants' homes. Training will include training on the proper placement of the headset, the viewing lens, system headphones, and safety guidelines. The research investigator will aid in the set-up of the VR system in the home, which will be pre-loaded with applications, and will recommend an area to use the system to ensure a safe play area free of obstacles. Participants will be provided with practice tasks between training sessions. Participants will be provided with a hands-on performance assessment at the beginning of the second session and concepts/procedures that are problematic will be reviewed. Participants will be contacted one-week post training to determine if they are having any problems by study investigators. Following training, participants will use the CAST VR program and tablet at will, though encouraged to use it at least three times per week for 20 minutes."
62026271|NCT05811338|ACTIVE_COMPARATOR|Project 1 - Phase 2: Tablet Control Condition|"Training will occur over 3 days and be conducted by research investigators in the participants' homes. Participants in the control condition will receive a tablet, internet support for 2 months and training (including training on cybersecurity). This will include instructions for accessing content similar to, but in 2-D, so less immersive than that included in the VR program (e.g., virtual museum tours, One click, etc.). Participants will complete all assessments and will be provided with an Android tablet that has a 10.1 display, built in modem, and a front facing camera. Research investigators are providing people with tablets for standardization. Research Assessor (RA) Training, Certification and Treatment Fidelity. At follow-up assessments, assessors and data analysts will be blinded to treatment condition."
62224754|NCT03133052|ACTIVE_COMPARATOR|training group|Intervention: Internet-based adaptive cognitive control training program. 5 x 30 minutes per week, for 12 weeks.
62224755|NCT03133052|PLACEBO_COMPARATOR|control group|Intervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 12 weeks.
62224756|NCT01528176|OTHER|(CKD) stages III-V and non -CKD patients|We recruited patients with wide range of eGFR
62224757|NCT01173406|SHAM_COMPARATOR|Standard care (SC)|Standard care
62224758|NCT01173406|ACTIVE_COMPARATOR|Extended education (ME+SC)|Motivational enhancement education + Standard care
62224759|NCT00226031|ACTIVE_COMPARATOR|1|Usual care.
62224760|NCT00226031|EXPERIMENTAL|2|Mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the family physician and a letter and educational package for the women.
62224761|NCT02519400|EXPERIMENTAL|Amitriptyline|Single oral dose of amitriptyline, 25 mg
62417757|NCT03911466|ACTIVE_COMPARATOR|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
62417758|NCT06271941|EXPERIMENTAL|Endoscopic Mucosal Resection (EMR)+Hybrid Argon Plasma Coagulation (h-APC)|Standard endoscopic mucosal resection (EMR) technique will be used for the primary removal of all polyps, utilizing submucosal injection. Electrocautery snare technique will be facilitated using standard microprocessor-controlled electrocautery (e.g., ERBE VIO Endocut 3-1-6). Ablation of the margin and base of the polypectomy site will be performed using Hybrid Argon Plasma Coagulation (h-APC, Erbe Hybrid APC).
62417759|NCT06271941|ACTIVE_COMPARATOR|Endoscopic Mucosal Resection (EMR) + Snare tip soft coagulation (STSC)|Standard endoscopic mucosal resection (EMR) technique will be used for the primary removal of all polyps, utilizing submucosal injection. Electrocautery snare technique will be facilitated using standard microprocessor-controlled electrocautery (e.g., ERBE VIO Endocut 3-1-6). Ablation of the margin of the polypectomy site will be performed using Snare tip soft coagulation (STSC).
62799206|NCT02412228|EXPERIMENTAL|Ixazomib Regimen|"Cycle 1: Ixazomib: 4mg/day 1, 8, 15, Cyclophosphamide: 50 mg/day continuous daily, Dexamethasone: 20 mg/day 1, 8, 15 Cycles 2-6: Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18, Cyclophosphamide: 50 mg/day continuous, daily, Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18~Maintenance:~Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years"
62224762|NCT02485782||Hemodialysis patients|"* midweek dialysis session~* patients on maintenance hemodialysis at least 3 months~* stable dry weight~* single-pool Kt/V \>1.4~* no clinical cardiovascular disease during the 6 months preceding entry"
62224763|NCT02853838|EXPERIMENTAL|Prolonged slow expiration+provoked coughing+ST|Prolonged slow expiration+provoked coughing+Standard Therapy
62224764|NCT02853838|ACTIVE_COMPARATOR|Manual chest wall vibration+ST|Manual chest wall vibration+Standard Therapy
62224765|NCT01413776|EXPERIMENTAL|Dietary supplement|Pregnant women in 37 villages.
62224766|NCT01413776|NO_INTERVENTION|Control group|Pregnant women in 38 villages
62224767|NCT04646538|EXPERIMENTAL|X3 group|
62224768|NCT03259360|EXPERIMENTAL|The Put It Out Project (POP):|a culturally tailored intervention developed for SGM young adults on Facebook
62224769|NCT03259360|EXPERIMENTAL|Tobacco Status Project (TSP):|the original TSP intervention (non-tailored) delivered to groups of only SGM participants on Facebook
62224770|NCT02873143||The APA2011 cohort|In September 2011, students at 4 upper secondary schools in Aalborg were invited to answer an online questionnaire and to be part of the APA2011 cohort. From 2846 potential responders, 2200 adolescents responded to the questionnaire, corresponding to a response rate of 77%. A total of 504 adolescents indicating knee pain at least monthly were successfully contacted (a response rate of 83% of those who reported their telephone numbers) and were asked standardized questions on the telephone. This forms the cohort of 504 adolescents with knee pain. In addition a random selected group of adolescents without knee pain in 2011 will be contacted and asked the same questions as those with knee pain.
62224771|NCT03019796|EXPERIMENTAL|PLACEBO FIRST THEN MEDICATED|Subjects first receive the PLACEBO tablet during 72 hours (full withdrawal). After a week of taking again their medication (MEDICATION TRIAL), they will be tested again. This procedure will be repeated before and after 4 months of aerobic training.
62224772|NCT03019796|EXPERIMENTAL|MEDICATED FIRST THEN PLACEBO|Subjects first receive their antihypertensive MEDICATION tablet (habitual dose prescribed by their primary care doctors). After a week they will take a PLACEBO tablet for 72 hours and will be tested again. This procedure will be repeated before and after 4 months of aerobic training.
62417760|NCT01005407|EXPERIMENTAL|HEPLISAV and/or Placebo|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
62224773|NCT01942265|EXPERIMENTAL|Group 4|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21
62799207|NCT01231919|EXPERIMENTAL|Treatment (Akt inhibitor)|Patients receive oral Akt inhibitor MK2206 every other day (schedule 1) OR once weekly (schedule 2) on days 1-28. Treatment repeats every 28 days for up 12 courses (1 year) in the absence of disease progression or unacceptable toxicity.
62799208|NCT03764644|EXPERIMENTAL|Combined ABMT and CBT|9 sessions of Attention Bias Modification Treatment (dot-probe based of 160 trials) followed by individual Cognitive Behavioral Therapy via FRIENDS program
62799209|NCT03764644|SHAM_COMPARATOR|Combined Sham ABMT and CBT|9 sessions of Sham Attention Bias Modification Treatment (dot-probe based of 160 trials) followed by individual Cognitive Behavioral Therapy via FRIENDS program
62799210|NCT05252949|ACTIVE_COMPARATOR|Study Supplement: OEA|26 subjects will take the supplement (oleoylethanolamide) during the first phase of the study. 200mg will be taken twice a day for the 10-week period in phase one.
62799211|NCT05252949|PLACEBO_COMPARATOR|Control|26 subjects will take the placebo during the first phase of the study (10 weeks).
62224774|NCT01942265|EXPERIMENTAL|Group 3|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
62417761|NCT01005407|ACTIVE_COMPARATOR|Engerix-B(1)|1.0 mL Engerix-B
62799212|NCT01493401|EXPERIMENTAL|Midurethral sling|Currently available midurethral procedures for stress urinary incontinence can be used.
62799213|NCT01395901|EXPERIMENTAL|Palonosetron and placebo to Ondansetron|Intervention: Drug: Palonosetron
62799214|NCT01395901|ACTIVE_COMPARATOR|Ondansetron and placebo to Palonosetron|Intervention: Drug: Comparator: Ondansetron
62799215|NCT03413124|ACTIVE_COMPARATOR|Capsule then Tablet|MGL-3196 Capsule on Day 1 followed by MGL-3196 Tablet on Day 5
62799216|NCT03413124|ACTIVE_COMPARATOR|Tablet then Capsule|MGL-3196 Tablet on Day 1 followed by MGL-3196 Capsule on Day 5
62224775|NCT01942265|EXPERIMENTAL|Group 1|100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
62417762|NCT02102529||bowel endometriosis|laparoscopic colonic resection
62799217|NCT03776747|EXPERIMENTAL|Group One: Prone MRI Scans|Subjects will have vitals, pulmonary function tests, initial proton MRI scan, prone hyperpolarized 3 helium gas scan
62799218|NCT03776747|ACTIVE_COMPARATOR|Group Two: Supine MRI scans|Subjects will have vitals, pulmonary function tests, initial protocol MRI scan, supine hyperpolarized 3 helium gas scan
62799219|NCT03087513|ACTIVE_COMPARATOR|Initial Arm|The study participants will receive either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline).
62224776|NCT01942265|EXPERIMENTAL|Group 2|100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
62799220|NCT03087513|ACTIVE_COMPARATOR|Crossover Arm|The study participants will receive the study medication that was not given in the initial arm (either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline) .
62799221|NCT00001186||Cohort 1|Children 7-17 years of age who are currently being treated for cancer or are up to 5 years post therapy.
62224777|NCT01942265|EXPERIMENTAL|Group 5|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 21
62224778|NCT01942265|EXPERIMENTAL|Group 9|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21
62224779|NCT01942265|EXPERIMENTAL|Group 8|100 subjects receive 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 0 and 21
62224780|NCT01942265|EXPERIMENTAL|Group 7|100 subjects receive 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 21
62224781|NCT01942265|EXPERIMENTAL|Group 6|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 21
62224782|NCT01942265|EXPERIMENTAL|Group 10|100 subjects receive 45 mcg sanofi A/H7N9 antigen on Day 0 and 21
62224783|NCT06056193|ACTIVE_COMPARATOR|Plain Balloon Angioplasty|Plain Balloon Angioplasty will be used to treat lesions
62224784|NCT06056193|ACTIVE_COMPARATOR|Sirolimus-coated Balloon Angioplasty|Sirolimus-coated Balloon Angioplasty will be used to treat lesions after preparing vessel with plain balloon angioplasty
62224785|NCT00777946|EXPERIMENTAL|Aliskiren 300 mg/Amlodipine 5 mg|Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.
62224786|NCT00777946|EXPERIMENTAL|Aliskiren 300 mg/Amlodipine 10 mg|Participants received 1 Aliskiren/Amlodipine 300/10 mg tablet + 1 Placebo to Aliskiren tablet orally once daily in the morning for 8 weeks.
62417763|NCT03347474|EXPERIMENTAL|Bilateral surgical implantation of DBS system to NAc|
62417764|NCT06704126|EXPERIMENTAL|Passive movement only|Participants undergo passive movement training only
62799222|NCT00001186||Cohort 2|Young adults with cancer (YACers) 18-25 years of age acting as counselors at Camp Fantastic and are enrolled in another NIH protocol.
62799223|NCT01826656|OTHER|post-menopausal osteoporotic women|Subjects of test group will follow a tooth extraction and they will perform a CBCT scan within 10 days from the extraction and after 3 months (+/-15 days)
62224787|NCT00777946|ACTIVE_COMPARATOR|Aliskiren 300 mg|Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.
62417765|NCT06704126|EXPERIMENTAL|Passive movement + intermittent blood flow restriction|Participants undergo passive movement training with blood flow restriction applied intermittently during the passive movement protocol
62417766|NCT06704126|NO_INTERVENTION|Control|Sitting still in Biodex only - no movement
62799224|NCT01826656|ACTIVE_COMPARATOR|non-osteoporotic post-menopausal women|Subjects of the control group will follow a tooth extraction and will perform a CBCT scan within 2 days from the extraction and after 3 months (+/- 2 days)
62799225|NCT06396819|EXPERIMENTAL|Therapeutic intervention using povidone collagen|
62799226|NCT06396819|PLACEBO_COMPARATOR|Therapeutic intervention using placebo|
62799227|NCT01889225||Multiple Risk Factor Intervention Trial - Usual Group|
62799228|NCT01889225||Multiple Risk Factor Intervention Trial - Referred Group|
62799229|NCT01889225||Framingham Heart study|
62799230|NCT01889225||Framingham Offspring cohort|
62799231|NCT01889225||Atherosclerosis Risk In Communities|
62799232|NCT01889225||Charleston Heart study|
62224788|NCT02935933|ACTIVE_COMPARATOR|Paravertebral block with bupivacaine|patients received 20 ml of bupivacaine 0.25% paravertebrally in 3 levels, divided into 6-7 ml in each level
62224789|NCT02935933|ACTIVE_COMPARATOR|Paravertebral block with bupivacaine + morphine|patients received 20 ml of bupivacaine 0.25% +5 mg morphine paravertebrally in 3 levels, divided into 6-7 ml in each level.
62224790|NCT02935933|ACTIVE_COMPARATOR|Paravertebral block with bupivacaine + dexmedetomidine|patients received 20 ml of bupivacaine 0.25% + 1 μg/kg dexmedetomidine paravertebrally in 3 levels divided into 6-7 ml in each level.
62799233|NCT01889225||Cardiovascular Health study|
62799234|NCT01889225||Rancho Bernardo study|
62799235|NCT01889225||Nurses' Health I study|
62799236|NCT01889225||Panel Study Income Dynamics|
62799237|NCT01889225||MRFIT Referred Care|
62799238|NCT01889225||HDFP Referral Care|
62799239|NCT01889225||Alameda County Health and Ways of Living Study|
62799240|NCT01889225||Nurses' Health II study|
62799241|NCT01889225||Tecumseh County Health study|
62799242|NCT01889225||EPESE-East Boston|Established Populations for Epidemiologic Studies of the Elderly-East Boston
62799243|NCT01889225||EPESE-Duke|Established Populations for Epidemiologic Studies of the Elderly-Duke
62799244|NCT01889225||EPESE-Iowa|Established Populations for Epidemiologic Studies of the Elderly-Iowa
62799245|NCT01889225||EPESE-New Haven|Established Populations for Epidemiologic Studies of the Elderly-New Haven
62799246|NCT03610841||preterm labor|Workgroup consists of patients which diagnosed with preterm labor between the age of 21 and 34
62799247|NCT03610841||healthy|24-36 6/7 weeks of pregnant between the age of 21 and 34
62799248|NCT06437262|ACTIVE_COMPARATOR|0.20% CHX gel|Participants underwent a single application of the 0.20% CHX gel. Samples were collected in basal conditions (i.e., before application) and at 5 minutes, 1 hour, 3 hours, 5 hours and 7 hours after application.
62799249|NCT06437262|EXPERIMENTAL|0.20% CHX and Cymenol gel|Participants underwent a single application of the 0.20% CHX + Cymenol gel. Samples were collected in basal conditions (i.e., before application) and at 5 minutes, 1 hour, 3 hours, 5 hours and 7 hours after application.
62799250|NCT03800238|EXPERIMENTAL|Telehealth Delivery Format|This group will participate in the Powerful Tools for Caregivers program using a telehealth delivery method.
62799251|NCT03800238|ACTIVE_COMPARATOR|Standard Delivery Format|This group will participate in the Powerful Tools for Caregivers program in person.
62799252|NCT03066063|ACTIVE_COMPARATOR|Amblyopia standard of care group|A standard of care group will be prescribed patching for two or six hours per day, seven days per week. Standard of care group participants with best-corrected vision worse than 20/200 in their amblyopic eye will be prescribed six hours of patching daily, while participants whose best-corrected visual acuity is 20/200 or better will be prescribed two hours of patching daily.
62799253|NCT03066063|EXPERIMENTAL|Amblyopia iCare group|Participants assigned to an experimental group will play iCare vision therapy games for approximately 20 minutes per day, five days per week.
62799254|NCT03066063|ACTIVE_COMPARATOR|Convergence insufficiency standard of care group|A standard of care group for convergence insufficiency will perform pencil pushups for 20 minutes per day, five days per week.
62799255|NCT03066063|EXPERIMENTAL|Convergence insufficiency iCare group|The iCare experimental group for convergence insufficiency will be prescribed vision therapy gameplay for approximately 20 minutes per day, five days per week.
62799256|NCT06235567|EXPERIMENTAL|Dextenza insert|"This is a prospective, open-label, single-center, randomized, investigator-sponsored clinical study to compare dexamethasone intracanalicular insert and corticosteroid drops for post-treatment in patients undergoing epithelium-off corneal collagen cross linking surgery. The participant's worse eye will be randomized to one of the two treatments, and the fellow eye will receive the alternate treatment when undergoing the procedure at a subsequent date at least three weeks later. There will be a baseline/screening visit, a surgical/ insertion visit for each eye, and follow up visits over 6 months, for a total of 10 visits per patient.~The study drug, DEXTNZA, is administered during the surgical procedure and the patient does not need to do any additional steps."
62243001|NCT06428500|EXPERIMENTAL|Part 1b: QTX3046 dose escalation in combination with cetuximab|QTX3046 will be administered orally at escalating doses as defined in the protocol in combination with intravenous cetuximab based on dose level assignment
62224791|NCT03221192||Subjects participating in CE and CD interviews|Twenty adult subjects from the US and 10 adult subjects from Germany with severe recurrent nasal polyps who have received nasal polyp surgery in the past 10 years prior to screening will be asked to participate in CE and CD interviews
62224792|NCT03221192||Subjects participating in interview and real-time data capture|Ten subjects from the US with severe recurrent nasal polyps who are participating in CE and CD interviews will be asked to complete the real-time data capture app task.
62224793|NCT03087019|EXPERIMENTAL|Pembrolizumab + Radiation|"* Up to 5 metastatic lesions targeted with radiation~* Over 5 fractions starting within 7 calendar days following the first dose of pembrolizumab~* Pembrolizumab will be administered on day 1 of each 21day cycle~* Pembrolizumab is delivered intravenously"
62417767|NCT01102972|EXPERIMENTAL|ATV + ABC/3TC|Subjects will change to ATV 400mg administered as two 200mg capsules orally, once daily and to the fixed-dose combination tablet of ABC 600mg/3TC 300mg (EPZICOM) administered as one tablet orally, once daily for 48 weeks. The subject's pre-study RTV will be discontinued.
62799257|NCT06235567|ACTIVE_COMPARATOR|topical prednisolone acetate 1% (PredForte) eye drops|"This is a prospective, open-label, single-center, randomized, investigator-sponsored clinical study to compare dexamethasone intracanalicular insert and corticosteroid drops for post-treatment in patients undergoing epithelium-off corneal collagen cross linking surgery. The participant's worse eye will be randomized to one of the two treatments, and the fellow eye will receive the alternate treatment when undergoing the procedure at a subsequent date at least three weeks later. There will be a baseline/screening visit, a surgical/ insertion visit for each eye, and follow up visits over 6 months, for a total of 10 visits per patient.~The patient will administer the anti-inflammatory steroid drops on the same 4 week post-operative schedule that is commonly used in standard of care. They will do one drop of Pred Forte in the affected eye 4 times a day for a week, 3 times a day for the second week, 2 times a day for the third week, and once a day for the fourth week."
62799258|NCT01125800|EXPERIMENTAL|LDE225 233mg/m2 daily dose|Pediatric dose.
62799259|NCT01125800|EXPERIMENTAL|LDE225 372mg/m2 daily dose|Pediatric dose.
62799260|NCT01125800|EXPERIMENTAL|LDE225 425 mg/m2 daily dose|Pediatric dose.
62799261|NCT01125800|EXPERIMENTAL|LDE225 680 mg/m2 daily dose|Pediatric dose.
62799262|NCT01125800|EXPERIMENTAL|LDE225 800 mg/m2 daily dose|Adult dose
62799263|NCT00786799|ACTIVE_COMPARATOR|Omega-3 Fatty Acids|
62417768|NCT01102972|ACTIVE_COMPARATOR|ATV + RTV + TDF/FTC|Subjects will continue their pre-study therapy, un-modified, of ATV 300mg administered as one capsule orally, once daily plus RTV 100mg administered orally, once daily plus fixed dose combination tablet tenofovir 300mg/emtricitabine 200mg administered as one tablet orally, once daily for 48 weeks.
62417769|NCT05548543|EXPERIMENTAL|Sequence 1|Period 1: RLD2202 +RLD2203 Period 2: HCP2202 Period 3: RLD2202 +RLD2203 Period 4: HCP2202
62799264|NCT00786799|PLACEBO_COMPARATOR|Placebo|
62799265|NCT04222296|OTHER|Cochlear Implant and Hearing Aid|Comparing performance of conventional hearing aid fitting to Phonak's Bimodal Fitting formula using the Phonak Naida Link hearing aid. All patients are tested in a bimodal (hearing aid plus cochlear implant) setup. Initial tests are completed with the Advanced Bionics Naida Q70 or Q90 sound processor and the patient's own hearing aid. In this arm, a patient's own hearing aid is replaced with the Phonak Naida Link hearing aid to test if there is a benefit.
62799266|NCT04222296|OTHER|Cochlear Implant alone|To determine if the addition of a contralateral routing of signal (CROS) microphone on the un-implanted ear improves performance. Baseline tests are completed with Advanced Bionics Naida Q70 or Q90 sound processors. Patients are then given the Phonak Naida Link CROS aid to test if there is a benefit.
62224794|NCT03087019|EXPERIMENTAL|Pembrolizumab|"* Pembrolizumab will be administered on day 1 of each 21day cycle~* Pembrolizumab is delivered intravenously"
62224795|NCT04407585||Covid-19 Symptom Study app-user|UK-based Covid-19 Symptom Study primary app-user completing self-reports in the app
62224796|NCT04315051|PLACEBO_COMPARATOR|Placebo Gel|Placebo gel daily application for 4 weeks
62224797|NCT04315051|ACTIVE_COMPARATOR|Cohort 1|DBI-001 Gel daily application for 4 weeks
62224798|NCT06524206|EXPERIMENTAL|Awareness, Courage, and Love intervention|"The Awareness, Courage and Love intervention will consist of a single 120-minute online session delivered in a group format via a videoconferencing application (e.g., Zoom). The theme of the session will evolve around making friends and being seen to reinforce the appetitive functions of social connection."
62224799|NCT06524206|NO_INTERVENTION|Waitlist control group|Waitlist control group will not receive the intervention
62224800|NCT05939973|OTHER|Crossover|Continuation of POSE2.0 expansion study evaluating the safety and preliminary effectiveness of the Pose 2 procedure using the g-Cath EZ Suture Anchor Delivery Catheter as a primary weight loss intervention in the control arm, defined as crossover subjects from POSE2.0 Expansion Study.
62224801|NCT04412291|ACTIVE_COMPARATOR|Standard-of-care Treatment (SOC)|"SOC according to local recommendations at the Karolinska University Hospital:~Oxygen supplementation so to achieve SpO2\>93%. Thrombosis prophylaxis (Fragmin or Innohep or Klexane or new oral anticoagulants incl. dabigatran, apixaban or rivaroxaban).~Steroids (Betapred)"
62224802|NCT04412291|ACTIVE_COMPARATOR|Anakinra + SOC|"Anakinra: A total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.~SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2\>93%. Thrombosis prophylaxis (Fragmin or Innohep) Steroids (Betapred) Prophylactic broad spectrum antibiotics for seven days.."
62224803|NCT04412291|ACTIVE_COMPARATOR|Tocilizumab + SOC.|Tocilizumab: 8mg/kg for a single infusion iv up to max 800 mg. If no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2\>93%. Thrombosis prophylaxis (Fragmin or Innohep) Steroids (Betapred) Prophylactic broad spectrum antibiotics for seven days.
62224804|NCT05469750|EXPERIMENTAL|Dalpiciclib+ letrozole +capecitabine|"Dalpiciclib 150 mg was given orally once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~letrozole 2.5mg po qd capecitabine 1000mg/m2 po bid"
62224805|NCT05795244|EXPERIMENTAL|Experimental|
62224806|NCT06156618|ACTIVE_COMPARATOR|Active nitrate|"Arm Description: Nitrate Intervention Arm~Intervention: Beetroot Juice (BJ) with Nitrate Supplements~Dosage Form: Liquid Dosage: 70 ml Frequency: Twice daily Duration: Seven days Participants assigned to this arm will receive Beetroot Juice (BJ) containing nitrate supplements. The intervention involves the ingestion of 70 ml of BJ twice daily for a duration of seven days. The BJ are designed to be indistinguishable in taste and appearance, ensuring blinding during the study. This arm is a crucial component of the double-blind, randomized crossover trial investigating the effects of nitrate supplements on oral microbiome recovery, blood pressure, and arterial stiffness in both healthy individuals and those with Dental Erosion. Detailed protocol and participant information available in attached documentation."
62243002|NCT06428500|EXPERIMENTAL|Part 2: QTX3046 monotherapy dose expansion|QTX3046 will be administered orally at the recommended phase 2 dose (RP2D) based on cohort assignment
62243003|NCT06428500|EXPERIMENTAL|Part 3: QTX3046 dose expansion in combination with cetuximab|QTX3046 will be administered orally at the recommended phase 2 dose (RP2D) in combination with intravenous cetuximab based on cohort assignment
62243004|NCT06735599|EXPERIMENTAL|Wild Blueberry|22 g of freeze-dried wild blueberry freeze-dried powder per day
62417770|NCT05548543|EXPERIMENTAL|Sequence 2|Period 1: HCP2202 Period 2: RLD2202 +RLD2203 Period 3: HCP2202 Period 4: RLD2202 +RLD2203
62417771|NCT02617446|PLACEBO_COMPARATOR|Placebo|IV infusion of placebo for 24 hours
62417772|NCT02617446|EXPERIMENTAL|Istaroxime 0.5 µg/kg/min|The istaroxime treatment dosed at 0.5 µg/kg/min via IV infusion for 24 hours
62588766|NCT05244278|EXPERIMENTAL|Operating room equipped with the CADe (Medtronic-GI genius for real-time detection)|The Medtronic-GI genius (CADe) system can be used to detect polyps of all sizes. Use of CADe is left to the discretion of the treating physician performing the colonoscopy. If used CADe will provide real-time feedback throughout each colonoscopy procedure and will alert the endoscopists of the presence of a polyp in the endoscopy field by displaying a bounding box on the same screen.
62588767|NCT05244278|NO_INTERVENTION|Colonoscopy performed in room without CADe system|In the control group (standard colonoscopy), the participating endoscopists will detect and classify colorectal lesions without using any AI modules.
62588768|NCT01399411||AHS Cohort|licensed pesticide applicators and their spouses from Iowa and North Carolina already enrolled in the Agricultural Health Study (AHS)
62588769|NCT00177853|EXPERIMENTAL|1|Celecoxib, Irinotecan and Concurrent Radiotherapy
62588770|NCT06666322|ACTIVE_COMPARATOR|Control group|randomized to standard of care
62588771|NCT06666322|EXPERIMENTAL|Experimental group 1|randomized to experimental antifungal therapy #1
62417773|NCT02617446|EXPERIMENTAL|Istaroxime 1.0 µg/kg/min|The istaroxime treatment dosed at 1.0 µg/kg/min via IV infusion for 24 hours
62417774|NCT01812577||Thoracic paravertebral block (TPVB)|Twenty patients receiving thoracic paravertebral block at level of T7, before the interventistic procedure.
62588772|NCT06666322|EXPERIMENTAL|Experimental group 2|randomized to experimental antifungal therapy #2
62799267|NCT04222296|OTHER|Hearing Aid and Hearing Aid|Comparing performance of conventional hearing aid fitting to a modified signal processing strategy more aligned with how a cochlear implant manages sound. All patients are tested initially with their own hearing aids to obtain a baseline measurement. Patients are then fitted with a modified Phonak hearing aid to determine if performance improves.
62224807|NCT06156618|PLACEBO_COMPARATOR|Placebo nitrate|"Arm Description: Placebo Intervention Arm~Intervention: Placebo ( Beetroot Juice depleted from nitrate), Identical to the active nitrate in texture, taste, colour and smell.~Dosage Form: Liquid Dosage: 70 ml Frequency: Twice daily Duration: Seven days Participants in the placebo intervention arm will receive a liquid placebo consisting of flavored water with discolouring dyes. The placebo is administered in the same manner as the active intervention, with participants ingesting 70 ml twice daily for a duration of seven days. This arm serves as a control group in the double-blind, randomized crossover trial, allowing for a comparison with the effects observed in the Beetroot Juice (BJ) with nitrate supplements arm. The order of treatment (BJ or placebo) is randomly assigned and reversed during the second phase of the study to ensure unbiased results. Detailed protocol and participant information available in attached documentation."
62799268|NCT02342964|OTHER|MUCO-FIBRO|Measures of hepatic elasticity
62799269|NCT04601012||Patients with COVID19|The patients with previous diagnosis of COVID19
62224808|NCT03012607|EXPERIMENTAL|Perfect Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET \[TRUVADA\] once daily for 6 weeks
62224809|NCT03012607|EXPERIMENTAL|Moderate Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET \[TRUVADA\] 4 times per week (Monday, Wednesday, Friday, and Saturday) for 6 weeks
62224810|NCT03012607|EXPERIMENTAL|Poor Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET \[TRUVADA\] 2 times per week (Monday, Thursday) for 6 weeks
62224811|NCT03945682|EXPERIMENTAL|Therapist|Intervention therapist at 2 centres providing 8 week intervention programme 50% embedded qualitative study
62417775|NCT01812577||Deep Sedation (DS)|Twenty patients receiving local and intravenous anesthesia during the procedure.
62417776|NCT01262274|ACTIVE_COMPARATOR|ANA|
62799270|NCT04601012||Control subjects|Healthy subjects without actual and previous ocular diseases
62799271|NCT05078372|ACTIVE_COMPARATOR|Ropivacaine and midazolam epidural administration|"An elastomeric pump was prepared for epidural infusion. This was prepared with 150 mg (20 ml) of 0.75% ropivacaine plus midazolam at 50 mcg / kg / 12 hrs. The solution was made up to 125 ml with physiological solution.~And 20 ml of physiological solution, was intraarticular administered as placebo."
62799272|NCT05078372|ACTIVE_COMPARATOR|Ropivacaine and midazolam intraarticular administration|"Ropivacaine 0.75% at 1.5 mg / kg was used with midazolam at 50 mcg / kg, to complete 20 ml of solution and was administrated on the knee articulation after tourniquet release.~And an elastomeric pump was prepared for epidural infusion, with 150 ml of physiological solution as placebo."
62224812|NCT03945682|NO_INTERVENTION|Usual Standard of Care|Participants continue with usual care and existing therapy recorded in study diary
62224813|NCT01822509|EXPERIMENTAL|Treatment (ipilimumab, nivolumab)|See Detailed Description.
62224814|NCT04218149|ACTIVE_COMPARATOR|Group S|Serratus plane block with 25 ml %0.25 bupivacaine
62417777|NCT01262274|EXPERIMENTAL|ANA+UFT|
62417778|NCT04793828|EXPERIMENTAL|Intervention (velibra)|Arm consisting of participants who receive velibra, an internet-based cognitive behavioral therapy program.
62799273|NCT04780165|EXPERIMENTAL|Single-arm|
62799274|NCT02401165|OTHER|patient|patient
62417779|NCT06396091|EXPERIMENTAL|zolbetuximab and mFOLFIRINOX|Participants will receive 1 of 2 dose levels of zolbetuximab in combination with mFOLFIRINOX.
62417780|NCT06019286||COPD cases|COPD patients for whom biological marker and dermatological score will be measured
62417781|NCT06019286||Control group|non COPD subjects for whom biological marker and dermatological score will be measured
62417782|NCT06234124|EXPERIMENTAL|Arm AB: Variable Friction Shoe Training, AFO Training|Baseline (T0), 12 weeks Variable Friction Shoe Training, Follow-up (T1), 2-week washout, Follow-up (T2), 12 weeks AFO Training, Follow-up (T3)
62417783|NCT06234124|EXPERIMENTAL|Arm BA: Ankle Foot Orthosis (AFO) Training, Variable Friction Shoe Training|Baseline (T0), 12 weeks AFO Training, Follow-up (T1), 2-week washout, Follow-up (T2), 12 weeks Variable Friction Shoe Training, Follow-up (T3)
62417784|NCT06700746|EXPERIMENTAL|Prolotherapy|Solution 3.6 mL of 25% dextrose and 0.4 mL xylocaine total 4.0 mL And Solution 3.5 mL of 15% dextrose and 0.8 mL xylocaine total 4.3 mL each site Injection interval week 0, 3 and 6 Ultrasound guided injection Injection into enthesis points
62417785|NCT06700746|ACTIVE_COMPARATOR|Extracorporeal shock wave therapy (ESWT)|ESWT Treatment interval week 0, 1 and 2 Energy intensity 0.20-0.25 mJ/mm2 per impulse Frequency 4-5 Hz for 2,000 shocks
62417786|NCT06275893|EXPERIMENTAL|IC14 (atibuclimab)|IC14 (atibuclimab) 20 mg/kg intravenously every 3 weeks for 12 weeks (4 doses)
62799275|NCT05443724|EXPERIMENTAL|CVL-231 30 mg|Participants will receive CVL-231 30 milligrams (mg) tablet, once daily for 52 weeks.
62224815|NCT04218149|ACTIVE_COMPARATOR|Grup E|Erector spinae plane block with 25 ml %0.25 bupivacaine
62417787|NCT00923013|EXPERIMENTAL|1|Cladribine with immediate Rituximab
62417788|NCT00923013|ACTIVE_COMPARATOR|2|Cladribine with Rituximab delayed by at least 6 months after Cladribine if and when minimal residual disease is detected
62799276|NCT06361758|EXPERIMENTAL|Cadonilimab+Lenvatinib|
62799277|NCT04359199||Radiotherapy with chemotherapy|Patients treated with definitive RT and chemotherapy (cisplatin) or targeted therapy (cetuximab)
62799278|NCT04359199||Radiotherapy with immunotherapy|Patients treated with definitive RT and immunotherapy (pembrolizumab, nivolumab, or durvalumab)
62799279|NCT05561582|EXPERIMENTAL|High Intensity Exercise|Participants will complete a knee extension exercise with weight equivalent to 75% of their 1-repetition maximum for 3 sets of 10 repetitions.
62224816|NCT00983931|ACTIVE_COMPARATOR|Colchicine alone|-baseline colchicine pharmacokinetics
62224817|NCT00983931|EXPERIMENTAL|Colchicine with Cyclosporine|-colchicine pharmacokinetics in presence of cyclosporine
62224818|NCT01520220|EXPERIMENTAL|Part A: LY2784544 Dosing Regimen A|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days.
62224819|NCT01520220|EXPERIMENTAL|Part A: LY2784544 Dosing Regimen B|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days.
62224820|NCT01520220|EXPERIMENTAL|Part B: LY2784544 Dosing Regimen A|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days.
62224821|NCT01520220|EXPERIMENTAL|Part B: LY2784544 Dosing Regimen B|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days.
62224822|NCT02518490|EXPERIMENTAL|Sapphire lens|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
62224823|NCT02518490|ACTIVE_COMPARATOR|enfilcon A|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
62243005|NCT06735599|PLACEBO_COMPARATOR|Placebo|22 g of freeze-dried macronutrient-matched placebo powder per day
62243006|NCT06734650||Peripheral waveform collection group|"1. Peripheral Venous Pressure Variation~2. Stroke Volume Variation~3. Pulse Pressure Variation~4. Pleth Variability Index"
62243007|NCT03149614|ACTIVE_COMPARATOR|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000.
62243008|NCT03149614|EXPERIMENTAL|Vertebral Resonant Oscillation (POLD method)|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
62243009|NCT05388851|EXPERIMENTAL|Prevention (Educational training)|Participants complete an educational training module and complete questionnaire at baseline (before educational training module) and 3 months after completing educational training.
62243010|NCT05706012||Gastro-enterologists and anticoagulation specialists|An online survey will be sent to question current clinical practice in long-term antithrombotic management of AMI in SBS patients.
62243011|NCT05322850|EXPERIMENTAL|Orca-Q|
62243012|NCT00628303|EXPERIMENTAL|1|Motavizumab
62243013|NCT00628303|PLACEBO_COMPARATOR|2|Placebo
62243014|NCT06735222|EXPERIMENTAL|HT-Ac → HT-EPA → Oleacore®|Group 1 will consume HT-Ac in the first week, HT-EPA in the second week and Oleacore® in the third week.
62243015|NCT06735222|EXPERIMENTAL|HT-EPA → Oleacore® → HT-Ac|Group 2 will consume HT-EPA in the first week, Oleacore® in the second week and HT-Ac in the third week.
62243016|NCT06735222|EXPERIMENTAL|Oleacore® → HT-Ac → HT-EPA|Group 3 will consume Oleacore® in the first week, HT-Ac in the second week and HT-EPA in the third week.
62243017|NCT02978079|EXPERIMENTAL|Pupillometry in stroke patients|All eligible patients will undergo pupillometry test for the finding of Horner's syndrome
62243018|NCT03944135|EXPERIMENTAL|Experimental group|The sample consisted of 40 people: 20 in an experimental group. There were 5 men and 15 women.
62243019|NCT03944135|ACTIVE_COMPARATOR|Control group|The sample consisted of 40 people: 20 in a control group. There were 5 men and 15 women.
62243020|NCT02877472|EXPERIMENTAL|Experimental group|Patients with avascular necrosis of the femoral head after femoral neck fracture surgery will undergo core decompression and porous tantalum rod implantation (experimental group).
62243021|NCT02877472|EXPERIMENTAL|Control group|Patients with avascular necrosis of the femoral head after femoral neck fracture surgery will undergo core decompression (control group).
62243022|NCT01770613|EXPERIMENTAL|Stem Cells|ALLOGENEIC MESENCHYMAL BONE MARROW CELLS
62243023|NCT01770613|PLACEBO_COMPARATOR|Control|Lactated Ringer's Solution
62243024|NCT04575025||Tabrecta tablets|Patients administered Tabrecta by prescription
62243025|NCT02682472|EXPERIMENTAL|SettleIN|SettleIN - Adjustment to care programme intervention
62243026|NCT00387764|EXPERIMENTAL|pazopanib arm|This was a single arm study, therefore no control arm.
62243027|NCT06630286|EXPERIMENTAL|Blinded Phase: ISL/LEN + Placebo-to-Match (PTM) B/F/TAF|Participants will receive an initial dose of ISL/LEN (Dose A), followed by once weekly ISL/LEN (Dose B) from Day 8 onwards up to Week 96. Participants will also receive PTM B/F/TAF once daily from Day 1 up to Week 96.
62243028|NCT06630286|EXPERIMENTAL|Blinded Phase: PTM ISL/LEN + B/F/TAF|Participants will receive an initial dose of PTM ISL/LEN (Dose A), followed by once weekly PTM ISL/LEN (Dose B) from Day 8 onwards up to Week 96. Participants will also receive B/F/TAF (50/200/25 mg) once daily up from Day 1 up to Week 96.
62799280|NCT05561582|EXPERIMENTAL|Low Intensity Exercise|Participants will complete a knee extension exercise with weight equivalent to 30% of their 1-repetition maximum for 3 sets of 10 repetitions.
62799281|NCT05561582|NO_INTERVENTION|Quiet Rest|Participants will sit quietly for two minutes, three times.
62224824|NCT00394082|EXPERIMENTAL|ABI-007 plus Bevacizumab|ABI-007 is administered on days 1, 8 and 15 at 125 mg/m\^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If a patient develops intolerable toxicity to only one of the drugs, the other drug may be continued as single agent therapy in the absence of progression, as long as the treating physician feels this is in the best interests of the patient.
62224825|NCT02881905|ACTIVE_COMPARATOR|ball attachment|completely edentulous patients having single median mandibular implant to retain mandibular overdenture.the attachment used is the conventional ball attachment
62224826|NCT02881905|EXPERIMENTAL|CM LOC attachment|completely edentulous patients having single median mandibular implant to retain mandibular overdenture.the attachment used is the cm loc attachment
62224827|NCT03060460|EXPERIMENTAL|Ultrasound arm - Randomized group|Ultrasound guided sheath insertion
62224828|NCT03060460|NO_INTERVENTION|Conventional arm - Randomized group|Conventional arm during randomized phase
62224829|NCT03060460|NO_INTERVENTION|Historical control group|Conventional arm, non-randomization phase
62224830|NCT04395027|NO_INTERVENTION|Usual care|These patients will not have their iatrogenic septal defect closed.
62224831|NCT04395027|EXPERIMENTAL|Device|These patients will have their iatrogenic septal defect closed after the mitral intervention is completed.
62799282|NCT01860833|ACTIVE_COMPARATOR|diclofenac 75 mg/day|diclofenac 75 mg once day slow release
62224832|NCT03187691|EXPERIMENTAL|CAMB 200 mg|200 mg CAMB (MAT2203) Oral Amphotericin B
62417789|NCT00923013|EXPERIMENTAL|3|Non-randomized group receving Cladribine with immediate Rituximab (before rather than after the 1st of the 5 daily doses of cladribine on day 1)
62417790|NCT04950413|ACTIVE_COMPARATOR|Traditional Treatment Arm|conventional physical therapy program (infrared, stretching exercise, isometric strengthening exercise)
62799283|NCT01860833|ACTIVE_COMPARATOR|diclofenac 150 mg/day|diclofenac 75 mg bid
62799284|NCT01860833|ACTIVE_COMPARATOR|ibuprofen 1200 mg/day|ibuprofen 600 mg bid
62799285|NCT01860833|ACTIVE_COMPARATOR|ibuprofen 1800 mg/day|ibuprofen 600 mg tid
62799286|NCT01860833|ACTIVE_COMPARATOR|celecoxib 200 mg/day|celecoxib 200 mg once day
62026272|NCT05811338|EXPERIMENTAL|Project 2 - Phase 2: Active Intervention Group|"Participants will receive a tablet with the adaptive program and be provided with internet service following the baseline assessment.~Participants will receive a 3-day training in their home that will include basic tablet/internet training and training on the features of the system. The training will also encompass a module on internet etiquette and security against potential spam and fraud. Participants will be provided with practice tasks in between sessions. Participants will be provided with a hands-on performance assessment at the end of the second session and concepts/procedures that are problematic will be reviewed."
62799287|NCT01860833|ACTIVE_COMPARATOR|celecoxib 400 mg/day|celecoxib 200 mg bid
62224833|NCT03187691|EXPERIMENTAL|CAMB 400 mg|400 mg CAMB (MAT2203) Oral Amphotericin B
62224834|NCT03187691|EXPERIMENTAL|CAMB 800mg|800 mg CAMB (MAT2203) Oral Amphotericin B
62224835|NCT01411839|EXPERIMENTAL|Cognitive-Behavioral Therapy (CBT-AD)|This arm type is a cognitive-behavioral therapy program intervention for issues of medication adherence and depression. The intervention is a therapy program intervention involves 10-weekly or biweekly sessions, with 2 booster session, and focused on psychoeducation, behavioral activation, cognitive restructuring, and problem-solving. A letter was sent to their medical provider indicating that mild symptoms of depression were detected and that they were enrolled in this intervention, but no details were provided regarding their assignment to one of two conditions/arms.
62224836|NCT01411839|NO_INTERVENTION|Control-Standard Care|Those randomized to the control condition are not involved in the CBT-AD therapy intervention. They receive standard care as usual. A letter was sent to their medical provider indicating that mild symptoms of depression were detected and that they were enrolled in this intervention, but no details were provided regarding their assignment to one of two conditions/arms. The participants in the control arm are followed and matched to a participant in the intervention arm.
62417791|NCT04950413|EXPERIMENTAL|IASTM treatment arm|Instrument-assisted soft tissue mobilization (IASTM) is a therapeutic technique that is based on the soft tissue mobilization rationale introduced by James Cyriax.
62417792|NCT04950413|EXPERIMENTAL|Phonophoresis treatment arm|It will be consisted of 1 MHz pulsed mode with an intensity set at 1.5 W/cm2.
62417793|NCT04950413|EXPERIMENTAL|Combined IASTM and phonophoresis treatment arm|Combined phonophoresis and M2t Blade
62417794|NCT04049695|EXPERIMENTAL|Exercise Intervention|This arm will receive a 12-month individually tailored phone and email-based exercise program.
62417795|NCT04049695|ACTIVE_COMPARATOR|Health & Wellness Intervention|This arm will receive a 12-month health and wellness program.
62799288|NCT03373929|OTHER|PFO Closure Rate|Evaluate closure rate of clinically relevant septal defects including PFO, ASD (less than 1 cm with redundant septal tissue), trans septal puncture sites, repair of ASA (when an appropriate PFO or small ASD defect is present) and rate of recurrent neurologic embolic event in patients with cryptogenic stroke and PFO
62799289|NCT03373929|OTHER|Published PFO Device Closure|Compare PFO closure rate and safety of closure of septal occluders in published PFO clinical trials.
62799290|NCT01381393||Ibandronate|The subjects with osteoporosis in postmenopausal women
62799291|NCT06538922|EXPERIMENTAL|Single Session Family Intervention|Participants will complete a single session consultation intervention delivered remotely to provide family with feedback on using evidence-based family practices in daily life.
62799292|NCT03148366|EXPERIMENTAL|Levofloxacin based sequential therapy|"Levofloxacin based sequential therapy~: sequential therapy containing levofloxacin for 14 days D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days"
62224837|NCT03080428|ACTIVE_COMPARATOR|Endopredict®|genomic test Endopredict® realized on surgery tumour samples
62224838|NCT03080428|ACTIVE_COMPARATOR|Prosigna®|genomic test Prosigna® realized on surgery tumour samples
62224839|NCT03080428|ACTIVE_COMPARATOR|OncotypeDX®|genomic test OncotypeDX® realized on surgery tumour samples
62224840|NCT03080428|ACTIVE_COMPARATOR|Mammaprint® assay|genomic test Mammaprint® assay realized on surgery tumour samples
62224841|NCT01676181|ACTIVE_COMPARATOR|Adenotonsillectomy|Total removal of tonsils and adenoids with cold steel
62224842|NCT01676181|ACTIVE_COMPARATOR|Adenotonsillotomy|Partial removal of tonsils with coblation and total removal of adenoids with cold steel
62224843|NCT05521945|EXPERIMENTAL|Intermittent Fasting Group|eight hours eating window and 16 hours for fasting among healthy population
62224844|NCT05521945|ACTIVE_COMPARATOR|Customized Dietary group|Customized diet plan according to participants' calorie intake and according to their respective Body Mass Index
62224845|NCT05521945|PLACEBO_COMPARATOR|Control group|Normal routine diet
62224846|NCT00617253|EXPERIMENTAL|A|
62224847|NCT00617253|EXPERIMENTAL|B|
62224848|NCT00617253|EXPERIMENTAL|C|
62224849|NCT00617253|EXPERIMENTAL|D|
62224850|NCT05714098|EXPERIMENTAL|Exercise|Each cohort of 5-8 participants will exercise 3 days a week for up to 12 weeks. Exercise sessions will be virtual
62224851|NCT03407664||Men Screened for AAA in England|Men invited into the NHS AAA Screening programme in England in the years 2013-2017.
62417796|NCT05960773|EXPERIMENTAL|1/ Arm 1|Decitabine/cedazuridine (35 mg decitabine and 100 mg cedazuridine; PO QD)
62224852|NCT02783768|EXPERIMENTAL|E-cigarette first|Participants will undergo the e-cigarette exposure prior to the first two MRI measures, and then they will undergo the sham exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.
62799293|NCT03148366|ACTIVE_COMPARATOR|bismuth quadruple therapy (BQ)|bismuth quadruple therapy for 10 days (BQ) D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
62799294|NCT00811603|ACTIVE_COMPARATOR|1|Patients who receive antibiotic prophylaxis after clamping of the umbilical cord
62224853|NCT02783768|EXPERIMENTAL|Sham first|Participants will undergo the sham exposure prior to the first two MRI measures, and then they will undergo the e-cigarette exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.
62224854|NCT03840915|EXPERIMENTAL|Cohort A: Cisplatin or Carboplatin + Pemetrexed + Bintrafusp alfa|Participants received 2400 miligrams (mg) Bintrafusp alfa along with Cisplatin or Carboplatin, and Pemetrexed every 3 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
62224855|NCT03840915|EXPERIMENTAL|Cohort B: Carboplatin + Paclitaxel or Nab-paclitaxel + Bintrafusp alfa|Participants received 2400 mg Bintrafusp alfa along with Carboplatin, and Paclitaxel or Nab-paclitaxel every 3 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
62224856|NCT03840915|EXPERIMENTAL|Cohort C: Cisplatin or Carboplatin + Gemcitabine + Bintrafusp alfa|Participants received 2400 mg Bintrafusp alfa along with Cisplatin or Carboplatin, and Gemcitabine every 3 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
62417797|NCT02454413|SHAM_COMPARATOR|brush + water|denture brushing with water and soap + overnight storage in water
62417798|NCT02454413|ACTIVE_COMPARATOR|brush + cleansing tablet|denture brushing with water and soap + overnight storage in water with a cleansing tablet
62417799|NCT02454413|SHAM_COMPARATOR|ultrasonic cleaning + water|ultrasonic denture cleaning + overnight storage in water
62417800|NCT02454413|ACTIVE_COMPARATOR|ultrasonic cleaning + cleansing tablet|ultrasonic denture cleaning + overnight storage in water with a cleansing tablet
62799295|NCT00811603|EXPERIMENTAL|2|Patients who receive antibiotic prophylaxis prior to skin incision
62799296|NCT02166619|EXPERIMENTAL|tDCS + physical therapy|Firstly, patients will undergo electrophysiological evaluation: motor evoked potential, motor threshold and silent period in both hemispheres. After those procedures, bihemispheric tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the non-affected hemisphere. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions.
62026273|NCT05811338|ACTIVE_COMPARATOR|Project 2 - Phase 2: Waitlist Control|Participants will receive a 3-day training in their home. Participants will also receive a tablet, internet support for 12 months and training. This will include instructions for accessing content pertaining to the research study.
62417801|NCT06495268|ACTIVE_COMPARATOR|Individualised data-driven hearing rehabilitation|Participants in the intervention group will receive data-driven, regularly controlled hearing aid rehabilitation that is not part of the standard care protocol.
62417802|NCT06495268|ACTIVE_COMPARATOR|Standard care hearing rehabilitation|The participants in the control group will receive the standard care HA rehabilitation currently conducted at the KUH Hearing Center.
62417803|NCT02099331|EXPERIMENTAL|Melatonin|The investigators will administer melatonin at 40mg by mouth (two 20 mg tablets), nightly prior to sleep. The administration will start 2 days prior to the scheduled surgery date and will continue until post-operative day 3.
62417804|NCT02099331|PLACEBO_COMPARATOR|Placebo|The investigators will administer matching Placebo by mouth (two tablets to match Melatonin), nightly prior to sleep. The administration will start 2 days prior to the scheduled surgery date and will continue until post-operative day 3.
62417805|NCT06462469|EXPERIMENTAL|Ruxolitinib|Participants will receive ruxolitinib orally of 10 mg BID daily (given as two 5-mg tablets, approximately 12 hours apart).
62417806|NCT06702592|EXPERIMENTAL|Virtual support|Participants will have access to the virtual support platform.
62417807|NCT06702592|OTHER|Patient educational material|Participants will have access to patient educational material only.
62417808|NCT06228469||Women diagnosed with cytolytic vaginosis|Women presenting to an outpatient clinic with vaginitis symptoms and diagnosed with cytolytic vaginosis.
62417809|NCT03818867|EXPERIMENTAL|Cerclage arm|Pregnancies which had cervical cerclage inserted.
62417810|NCT03818867|NO_INTERVENTION|No-cerclage arm|Pregnancies which did not have cervical cerclage inserted.
62417811|NCT00639158|ACTIVE_COMPARATOR|ABT-335 + atorvastatin + ezetimibe|
62417812|NCT00639158|PLACEBO_COMPARATOR|Placebo + atorvastatin + ezetimibe|
62417813|NCT06538844|EXPERIMENTAL|Human albumin treatment group|
62417814|NCT06538844|PLACEBO_COMPARATOR|Placebo group|
62417815|NCT06568367|EXPERIMENTAL|Solriamfetol 150mg|Up to 12 weeks
62417816|NCT06568367|EXPERIMENTAL|Solriamfetol 300mg|Up to 12 weeks
62417817|NCT06568367|PLACEBO_COMPARATOR|Placebo|Up to 12 weeks
62588773|NCT06666322|EXPERIMENTAL|Experimental group 3|randomized to experimental antifungal therapy #3
62799297|NCT02166619|SHAM_COMPARATOR|Sham tDCS + physical therapy|Firstly, patients will undergo electrophysiological evaluation: motor evoked potential, motor threshold and silent period in both hemispheres. After those procedures, bihemispheric sham tDCS will be applied. Anodal electrode will be on the affected hemisphere and the cathodal electrode, on the non-affected hemisphere. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off after 30 seconds. After bihemispheric sham tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions.
62799298|NCT06109064|EXPERIMENTAL|chemotherapy+Unrelated Umbilical Cord Blood microtransplantation|"Intermittent infusion of HLA mismatched or incompletely matched granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (G-PBSC) during routine chemotherapy without the use of immunosuppressants, abbreviated as microtransplantation"
62799299|NCT05268510|EXPERIMENTAL|Chemotherapy plus Pembrolizumab followed by Pembrolizumab and Olaparib|"Chemotherapy plus Pembrolizumab 2 cycles à 6 weeks:~Pembrolizumab+mod FOLFOX-6:~* Pembrolizumab 400 mg 30 min. day 1~* Oxaliplatin 85 mg/m² 2h day 1, 15, 29~* Leucovorin 400 mg/m² 2h day 1, 15, 29~* 5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29~or~Pembrolizumab+CapOx:~* Pembrolizumab 400 mg 30 min. day 1~* Oxaliplatin 130 mg/m² 2h day 1,22~* Capecitabine 1.000 mg/m² bid. day 1-14, 22-35~Consolidation phase Pembrolizumab and Olaparib max 16 cycles à 6 weeks:~* Pembrolizumab 400 mg 30 min. day 1~* Olaparib 300 mg bid. cont. day 1 to 42"
62799300|NCT04668768|EXPERIMENTAL|Glucarpidase|Prophylactic glucarpidase treatment
62799301|NCT00670904|ACTIVE_COMPARATOR|1|Pharmacist-delivered group program for smoking cession.
62799302|NCT00670904|PLACEBO_COMPARATOR|2|Brief standard care session for tobacco smoking cessation delivered over the telephone.
62799303|NCT01722019|ACTIVE_COMPARATOR|radiofrequency ablation with VNUS closure fast|Radiofrequency ablation will be performed with VNUS closure fast.
62799304|NCT01722019|EXPERIMENTAL|laser ablation and Tulip fiber|Laser ablation with a 1470 nm wave length in combination with a new fiber, the Tulip fiber.
62224857|NCT03840915|EXPERIMENTAL|Cohort D: Docetaxel + Bintrafusp alfa|Participants received 2400 mg Bintrafusp alfa along with Docetaxel every 3 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
62224858|NCT02114710|EXPERIMENTAL|Hydrocortisone|little doses of hydrocortisone
62799305|NCT04355403|EXPERIMENTAL|Hyalo Gyn gel|Vaginal application of Hyalo Gyn gel in prefilled applicators
62799306|NCT04355403|NO_INTERVENTION|No treatment|No treatment application
62799307|NCT05900037|EXPERIMENTAL|GATT-Patch|Hemostatic Patch
62799308|NCT05900037|ACTIVE_COMPARATOR|SURGICEL® Original|Hemostatic Patch
62799309|NCT01469273|NO_INTERVENTION|Control group|Only observation; observation period: 1 year.
62224859|NCT02114710|NO_INTERVENTION|Placebo|Placebo
62224860|NCT00114413|ACTIVE_COMPARATOR|Reference Strategy|Participants in the reference strategy group will undergo the eNO procedure but will follow NAEPP guidelines alone for asthma treatment without eNO measurements for the rest of the study.
62224861|NCT00114413|EXPERIMENTAL|Biomarker Strategy|Participants in the biomarker strategy group will follow NAEPP treatment guidelines, as well as eNO measurements, to determine asthma treatment at each study visit.
62224862|NCT06119672|ACTIVE_COMPARATOR|systemic probiotic (A)|Systemic probiotic capsules will be given twice daily in addition to topical application of topical clobetasol in orabase twice daily
62224863|NCT06119672|ACTIVE_COMPARATOR|topical corticosteroid (B)|topical clobetasol in orabse application will be given 4 times daily ( 3 times after meals and once before bed time) prophylactic topical antifungal will be given in the fourth week to prevent candidal infection
62417818|NCT06703554|EXPERIMENTAL|Sage oil mouthwash|Sage oil obtained from a local market of herbal products in Egypt. In order to identify chemical composition of sage essential oils and overall purity, Gas Chromatography/ Mass Spectrometry analysis (GC/MS) performed
62417819|NCT06703554|ACTIVE_COMPARATOR|Chlorohexidine Mouthwash|0.12% chlorhexidine gluconate in a base containing water, 11.6% alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, and sodium saccharin
62026274|NCT05811338|NO_INTERVENTION|Project 3 - Phase 1: Problem Space Specification and Task Selection|Both the subject matter experts and older adult participants will participate in individual structured interviews for each activity category, 1.5 - 2 hours in length. This qualitative data will provide rich contextualized information regarding the specific needs of older adults for access to services, financial health management, and Medicare.gov services utilization. This data will be used to identify current barriers and facilitators to successful healthcare management that could be targeted by technology solutions and/obtain details of the challenges that are common in each activity category.
62799310|NCT01469273|EXPERIMENTAL|Early Treatment group (E)|1 x 1 ml of EcN suspension/day on 10 consecutive days, application in the morning before feeding/nursing, first application 48h after birth, latest. Observation period: 1 year.
62799311|NCT01469273|EXPERIMENTAL|Late Treatment Group (L)|1 x 1 ml of EcN suspension/day on 10 consecutive days, application in the morning after feeding/nursing, starting on the first day of the 7th month of life. Observation period: 1 year.
62026275|NCT05811338|NO_INTERVENTION|Project 3 - Phase 2: Development of Digital Assistant Tools|The study includes one session that will last approximately 2 - 3 hours. The study involves interactions with digital assistants developed by the research team, the participants will answer structured interview questions regarding their experiences using the system. The researchers will assess the participants' comments along dimensions such as type of information requested, preference for format of information, points of confusion, and likes and dislikes of features, which will form the basis for a prioritized list of features/functions to be modified for the next prototype iteration.
62224864|NCT01970722|EXPERIMENTAL|Treatment (surgery, HIPEC cisplatin)|"Patients undergo surgery and receive hyperthermic cisplatin IP over 60 minutes.~Beginning at least 3 weeks after surgery, patients may receive carboplatin, paclitaxel, pegylated liposomal doxorubicin hydrochloride, or gemcitabine hydrochloride IP or IV at the discretion of the medical and gynecologic oncologists."
62799312|NCT03853135||Behçet group|Forty two patients diagnosed to have Behçet disease fulfilling the International Study Group Criteria for Behçet disease in whom measurement of serum endocan levels will be performed.
62799313|NCT03853135||control group|including 42 age and sex matching healthy volunteers as control group in whom measurement of serum endocan levels will be performed.
62799314|NCT06627335||Infants of women with AD exposed to ruxolitinib cream during pregnancy|
62799315|NCT06627335||Infants of women with AD exposed to a TCS prior to or during pregnancy|
62224865|NCT01999270|EXPERIMENTAL|Irinotecan, Bevacizumab and FDOPA-PET/MRI imaging|Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider.
62224866|NCT01886612|EXPERIMENTAL|DVT Prophylaxis|"Neuromuscular electrical stimulation is to be applied using a custom-built, two-channel stimulator (Duo-STIM (stimulator), Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 5 minutes.~Intermittent pneumatic compression is to be applied using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 1 second duration over a period of 5 minutes."
62224867|NCT02979392|EXPERIMENTAL|Phase I|Part A, Dose escalation TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) IV once every 3 weeks (Phase I starting dose 75 mg/m2) Part B, Expansion TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) IV once every 3 weeks (RP2D dose determined in part A)
62224868|NCT01288521|EXPERIMENTAL|Tacrolimus + Ketoconazole, Then Tacrolimus alone|Participants first received tacrolimus in combination with with ketoconazole. After a 1-2 week washout they received tacrolimus alone.
62224869|NCT01288521|EXPERIMENTAL|Tacrolimus alone, Then Tacrolimus + Ketoconazole|The participants first received tacrolimus alone. After a 1-2 week washout period they received tacrolimus in combination with ketoconazole.
62417820|NCT03398161|EXPERIMENTAL|Treatment (ultra low dose radiation therapy)|Patients undergo ultra low dose radiation therapy at the discretion of the treating physician.
62799316|NCT03122210|OTHER|Control group|In this group, the nursing staff administed oxygen supply if necessary with the usual pratice in care unit for 24 hours after myocard infarction. In this group the SpO2 was recorded any time with FreeO2 device - recording mode.
62417821|NCT06703996|EXPERIMENTAL|Supportive care (InBody Band 3 fitness tracker)|Patients wear the InBody Band 3 fitness tracker continuously and participate in check-in/goal-setting discussions over 20-30 minutes weekly for 6 weeks.
62417822|NCT06667076|EXPERIMENTAL|Cohort 1: Amivantamab and Lazertinib|Participants will receive Amivantamab subcutaneous (SC) injection in combination with Lazertinib orally in 28-day cycles until disease progression, withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first.
62588774|NCT06666322|EXPERIMENTAL|Experimental group 4|randomized to experimental antifungal therapy #4
62224870|NCT00050115||Hepatitis A + AA cohort|Subjects seen either at Clinical center or by outside physician
62417823|NCT06667076|EXPERIMENTAL|Cohort 2: Amivantamab and Chemotherapy|Participants will receive Amivantamab SC injection in combination with chemotherapy (carboplatin and pemetrexed) intravenous (IV) infusion in 21-day cycles until disease progression, withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first.
62417824|NCT02339428|EXPERIMENTAL|Diclophenac sodium 100mg p.o.|Patients will be given 100mg of diclophenac sodium two hours prior to colonoscopy.
62799317|NCT03122210|OTHER|FreeO2 with SpO2 target = 92%|In this group oxygen flow was automatically adjusted with the FreeO2 device (automatic titration of oxygen flow) to achived SpO2 target set by clinicial for 24 hours after myocard infarction. In this group, the SpO2 target was set at 92%.
62799318|NCT03122210|OTHER|FreeO2 with SpO2 target =97%|In this group oxygen flow was automatically adjusted with the FreeO2 device (automatic titration of oxygen flow) to achived SpO2 target set by clinicial for 24 hours after myocard infarction. In this group, the SpO2 target was set at 97%.
62799319|NCT04121702|ACTIVE_COMPARATOR|PEP-H|Physical exercise program at a hospital
62799320|NCT04121702|EXPERIMENTAL|PEP-PSC|Physical exercise program with tele-monitoring in a public sport centre
62224871|NCT00593294|EXPERIMENTAL|A,1,I|
62224872|NCT00593294|ACTIVE_COMPARATOR|B, 2, II|
62224873|NCT00593294|PLACEBO_COMPARATOR|C,3,III|
62224874|NCT03465098|EXPERIMENTAL|enrolled patients|All enrolled patients will be received a strict low carbohydrate (\< 3gr/day of carbohydrate) and 12h fasting before 18F-FDG PET/CT exam and 24h after a 18F-FDG PET/CT preceded by a low carbohydrate diet with 12h fasting
62417825|NCT02339428|PLACEBO_COMPARATOR|Placebo|Patients will be given placebo tablets of same appearance as the intervention.
62224875|NCT05566977|EXPERIMENTAL|patients with autoimmune disease :lupus nephritis and type1 diabetes melitus|single arm of patients with autoimmune diseases : patients of the first group selected as refractory lupus nephritis. patients of the second group of autoimmune diseases are selected to have type1 diabetes Meletus.
62224876|NCT02688907|EXPERIMENTAL|AZD1775|AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.
62417826|NCT05529992|EXPERIMENTAL|Velaglucerase Alfa (VPRIV)|Participants will receive VPRIV intravenous infusion once every other week (EOW) for 60 (+10) minutes as per physician treatment plan for up to 51 weeks.
62417827|NCT06701175|NO_INTERVENTION|No Intervention|Patients will receive no intervention
62799321|NCT04157803|OTHER|Patient cohort|Patients with polyps\> 5mm with suspicion of tubular, tubulovillious or serrated adenomas, found during a videcolonoscopy.
62799322|NCT00778115|EXPERIMENTAL|1|Loperamide HCl 2 mg and simethicone 125 mg tablets of ranbaxy
62799323|NCT00778115|ACTIVE_COMPARATOR|2|Imodium® Advanced caplets
62799324|NCT02447614||Surgery|Adenotonsillectomy
62799325|NCT02447614||Conservative treatment|Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists
62224877|NCT03128008|EXPERIMENTAL|Carboplatin/Paclitaxel with radiation therapy|Single arm, non randomized, open label study. Eligible subjects will receive standard of care Carboplatin IV once a week, Paclitaxel IV once a week given concurrently with daily hyperfractionated radiation therapy (RT). RT will be delivered as 6 fractions weekly.
62224878|NCT02534298|EXPERIMENTAL|single sided deafness|single sided deafness and asymmetrical hearing loss patients functional magnetic resonance imaging
62799326|NCT02447614||no treatment|just regular follow-up
62799327|NCT00970918|EXPERIMENTAL|1|
62224879|NCT02534298|OTHER|control group|Normal hearing subject functional magnetic resonance imaging
62417828|NCT06701175|ACTIVE_COMPARATOR|Nerve Block|Patients in the anterolateral geniculate nerve block group will receive 20 cc of 0.25% bupivacaine with epinephrine distributed evenly between two injection sites by an 18G or 21G long needle. After completion of knee arthroscopy, the first injection is targeted at 2 fingerbreadths superior to the superolateral aspect of the patella. The needle is inserted down to the femur, pulled back slightly, and the surrounding area is infiltrated with 10 cc of anesthetic. The second injection is targeted approximately 2 to 3 fingerbreadths laterally to the first injection and 2 to 3 fingerbreadths proximal to the lateral epicondyle in line with the lateral femur. Once again, the needle is inserted down until bone is encountered and then slightly retracted 1 to 2 mm before infiltration with the remaining 10 cc of anesthetic.
62799328|NCT03737136|NO_INTERVENTION|Plasmapheresis|5 Sessions Plasmapheresis and 100 mg/kg Intra venous immunoglobulin at the end of each session and one dose 375mg/m2 rituximab at the end of last session
62799329|NCT03737136|ACTIVE_COMPARATOR|Plasmapheresis plus Bortezomib|Drug 5 Sessions Plasmapheresis and 100 mg/kg Intra venous immunoglobulin at the end of each session and one dose 375ml/m2 rituximab at the end of last session plus bortezomib Injections 1.3mg/m2 intravenously on days 1, 4, 8, and 11
62799330|NCT03667157|ACTIVE_COMPARATOR|moderate-to-severe Graves Orbitopathy|active, moderate-to-severe Graves Orbitopathy according to EUGOGO.
62799331|NCT03667157|ACTIVE_COMPARATOR|Dysthyroid Orbit Neuropathy|Dysthyroid Orbit Neuropathy according to EUGOGO
62799332|NCT04410718||The intensive care unit cohort|Patients (with or without diabetes) with COVID-19 admitted to the intensive care unit
62799333|NCT04410718||The hospitalisation cohort|Patients with diabetes and COVID-19 admitted to the medical ward
62224880|NCT04059419|EXPERIMENTAL|Experimental|30 Patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
62224881|NCT04059419|ACTIVE_COMPARATOR|Control|Should remain under geriatric care after randomization.
62224882|NCT02817022|OTHER|developmentally supportive care|enrolled neonates will be provided routine supportive care as per existing NICU protocols. This will be carried out in the initial 6 months (0-180 days) of study commencement. This group will serve as control group (group A). During subsequent 6 months (181-360 days) of the study period, enrolled neonates fulfilling the inclusion criteria will be provided routine supportive care and the components of developmentally supportive care(DSC). DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment. This group will be designated as group B
62799334|NCT05915299||OCS Heart Transplant Recipients|All heart transplant recipients who are transplanted with an OCS perfused donor heart are eligible for this registry.
62799335|NCT06727214||MIBC patients who received NAT|muscle invasive bladder cancer patients who received neoadjuvant chemotherapy
62799336|NCT00268918|EXPERIMENTAL|Docetaxel / PTK787|"Docetaxel: Lead In: Given intravenously on Day 1 and Day 14 Afer Lead in: Given intravenously on day 1, 8, 15, 22 of each 28-day cycle.~PTK787: Lead In: Given orally on day 4 and day 14 After Lead In: Given orally once a day."
62799337|NCT04033744|EXPERIMENTAL|PRF (platelet-rich fibrin)|PRF will be used after the extraction of the third molar to prevent periodontal defects to second molar
62799338|NCT04033744|ACTIVE_COMPARATOR|spontaneous healing|after the extraction of the third molar the socket will be left to heal spontaneously
62799339|NCT02173106|EXPERIMENTAL|Group A: steroid & Cyclosporin|oral methylprednisolone 0.4mg/kg/d and 3.5\~5mg/kg/d cyclosporin for 6 months.
62799340|NCT02173106|NO_INTERVENTION|Group B: no steroid & Cyclosporin|no steroid and cyclosporin and waiting for spontaneous remission for 6 months
62799341|NCT06489145|EXPERIMENTAL|Technology-enhanced Rehabilitation|Patients will participate in technology-enhanced rehabilitation programs in addition to multidisciplinary traditional treatment.
62799342|NCT06489145|ACTIVE_COMPARATOR|Standard Rehabilitation|Patients will participate in multidisciplinary traditional treatment only
62799343|NCT04707495|EXPERIMENTAL|Smartphone Application (SPSRS)|"The experimental group receives video-viewing intervention using the SPSRS application, which is a smartphone application. SPSRS is programmed to present 150 ms of positive words after presenting 17 ms of self-confidence-boosting words in videos.~These words are repeated every 5 s. The words to increase self-confidence are can, let us try, good luck, able, and do not worry. These self-confidence-boosting words randomly appear in the four corners of the screen. The positive words are nice, great, fantastic, satisfactory, and enjoyable. These words are displayed at the center of the screen. Interveners use the SPSRS application according to the operating manual. The participants will use an iPhone managed by interveners to watch a pre-determined 10-minute video."
62799344|NCT04707495|ACTIVE_COMPARATOR|Smartphone Application (YouTube)|The control group uses the same iPhone as the experimental group. The control group uses the YouTube application to receive video-viewing intervention. The control group videos do not show confidence-boosting and positive words. The control group watches the same video as the experimental group for 10 min.
62224883|NCT03587077|EXPERIMENTAL|study group|Women will receive vaginally one tablet misoprostol 200 mcg(Misotac; Sigma Pharma, SAE, EGYPT) plus one tablet isosorbide mononitrate 40 mg(Effox 40 mg; Minapharm). A trained clinical nurse will introduce the tablets, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position.
62799345|NCT06344429|EXPERIMENTAL|Stellest lenses spectacle|34 children wear Stellest lenses for all day.
62799346|NCT06344429|EXPERIMENTAL|Stellest lenses+0.05% atropine|33 children wear Stellest lenses for all day, and 0.05% atropine eye drops is dropped once nightly in both eyes.
62799347|NCT06344429|PLACEBO_COMPARATOR|Single vision lenses+0.05% atropine|33 children wear Single lenses for all day, and 0.05% atropine eye drops is dropped once nightly in both eyes.
62026276|NCT05811338|EXPERIMENTAL|Project 3 - Phase 3: DATA Condition|Participants in the DATA condition, instead of access to a generic digital assistant, will have DATA at their disposal to solve the queries and will be encouraged to use it as the primary resource. Qualitative data on how they use this tool, in isolation and in conjunction with other sources of information, will be collected. Following completion of the problems, as in Phase 2, measures of DATA usability will be collected including usefulness and comprehension associated with each tool, perceived mental workload, and usability with an efficient, two-item test based on the widely used System Usability Scale: UMUX-LITE). The investigators will then conduct an audio-recorded semi-structured exit interview about various perceptions participants had regarding the challenges associated with successfully solving the health-management problems.
62224884|NCT03587077|PLACEBO_COMPARATOR|control group|Women will receive vaginally one tablet misoprostol 200 mcg Plus one tablet placebo.A trained clinical nurse will introduce the tablets, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position.
62224885|NCT05833633||Group of DMD patients with different type of small mutations (Group 1)|Group of DMD patients with different type of small mutations (15 ambulant or not-ambulant patients)
62224886|NCT05833633||Group of DMD patients with non sense mutations in treatment with Traslarna (Group 2)|Group of 10 ambulant DMD patients with non sense mutations in treatment with Traslarna (3-\[5-(2-fluoro-phenyl)-\[1,2,4\]oxadiazole-3-yl\]-benzoic acid).
62799348|NCT02072265||Port-A implantation and chemotherapy|Patients scheduled for Port-A implantation and subsequent chemotherapy
62224887|NCT02009761|EXPERIMENTAL|BI 655064 120 mg / 180 mg|"The patients were administered 120 mg BI 655064 solution for subcutaneous injection q1w (once a week) subcutaneously for 4 weeks.~Patients who showed an increase in platelet count above or equal to 100 x 10\^9/L continued treatment with 120 mg BI 655064 solution for subcutaneous injection q1w for additional 8 weeks, followed by 12 weeks of follow-up.~Patients whose platelet count stayed below 100 x 10\^9/L continued treatment for 2 weeks with 180 mg BI 655064 solution for subcutaneous injection q1w followed by 120 mg BI 655064 solution for subcutaneous injection q1w for additional 6 weeks, followed by 12 weeks of follow-up."
62224888|NCT02907164|ACTIVE_COMPARATOR|Group 1: Control|People receive emails encouraging them to sign up for the challenge. The email does not mention the number of people who have signed up.
62224889|NCT02907164|EXPERIMENTAL|Group 2: Norm|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up.
62799349|NCT02072265||Port-A infection|Patients receiving Port-A removal due to infection
62799350|NCT01522326|EXPERIMENTAL|Metoclopramide|150 subjects with acute mountain sickness will be randomly assigned to take metoclopramide.
62224890|NCT02907164|EXPERIMENTAL|Group 3: Norm and health motive|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up AND highlights that the challenge helps people to stay fit in a fun way.
62799351|NCT01522326|ACTIVE_COMPARATOR|Ibuprofen|150 subjects with acute mountain sickness will be randomly assigned to take ibuprofen.
62224891|NCT02907164|EXPERIMENTAL|Group 4: Norm and reward motive|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up AND highlights that the challenge helps people to stay active and earn rewards.
62224892|NCT01878214|EXPERIMENTAL|Intervention group|Targeted messaging
62224893|NCT01878214|ACTIVE_COMPARATOR|Control group|Standard messaging
62224894|NCT03742284|OTHER|SoftOx Wound Irrigation Solution|SoftOx Wound Irrigation Solution is Medical Device that will be applied to rinse acute wounds.
62224895|NCT05085236|EXPERIMENTAL|Fu's subcutaneous needling (FSN) in combination with rehabilitation|In this arm, the subjects will receive the intervention of FSN combined with regular rehabilitation program on Day1, Day2, and Day4, in total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finishing, the subjects will receive assessments on Day8 and Day15.
62224896|NCT05085236|ACTIVE_COMPARATOR|Rehabilitation|In this arm, the subjects will receive the intervention of regular rehabilitation program prescribed by physician of rehabilitation. On Day1, Day2, and Day4, the subjects will receive assessments before and after each interventions. After total treatments finishing, the subjects will receive assessments on Day8 and Day15.
62224897|NCT00580645|EXPERIMENTAL|varenicline|varenicline 1mg/day or 2mg/day
62224898|NCT00580645|PLACEBO_COMPARATOR|Placebo|Placebo Controlled
62224899|NCT05344040|EXPERIMENTAL|Remotely Delivered and Supported Aerobic Walking Exercise Training|
62224900|NCT05344040|ACTIVE_COMPARATOR|Remotely Delivered and Supported Stretching and Toning|
62224901|NCT01340651|EXPERIMENTAL|Ruxolitinib 25 mg SR/10, 15, or 20 mg IR|Participants began administration with 25 mg ruxolitinib sustained release (SR) once daily (QD). After 8 weeks, if there was inadequate efficacy, the dose level could be titrated to 50 mg SR QD or 25 mg SR every other day (QOD) alternating with 50 mg SR QOD. At Week 16, participants transitioned to ruxolitinib 10, 15, or 20 mg immediate release (IR) orally twice daily. Participants who continued to demonstrate benefit in the opinion of the investigator could remain on ruxolitinib IR until the last participant completed Week 36 or the commercial availability of ruxolitinib IR, whichever was earlier; the dose received was based on platelet counts at the time of transition.
62417829|NCT06701175|ACTIVE_COMPARATOR|Portal Anesthesia|Patients in the portal anesthesia group will also receive 20 cc of 0.25% bupivacaine with epinephrine distributed evenly between portal sites. After completion of knee arthroscopy, portal tracts are closed and the knee is ensured to be evacuated of residual fluid. An 18G or 21G long needle is then used to infiltrate each portal tract where the anesthetic will be delivered.
62799352|NCT02249936|EXPERIMENTAL|AZD1722 HCl Capsule|15 mg bid AZD1722 HCl and 20 mg bid Omeprazole
62799353|NCT02249936|EXPERIMENTAL|AZD1722 HCl Tablet|15 mg bid AZD1722 HCl and 20 mg bid Omeprazole
62224902|NCT00819962|OTHER|TAP|ksu
62224903|NCT02487732|ACTIVE_COMPARATOR|Ticagrelor|180mg loading dose, 90mg twice daily for 5 weeks, then crossover to prasugrel
62224904|NCT02487732|ACTIVE_COMPARATOR|Prasugrel|60mg loading dose, 10mg once daily for 5 weeks, then crossover to ticagrelor
62224905|NCT02850367|ACTIVE_COMPARATOR|Acute intake|Evaluation after acute intake of the food supplement.
62224906|NCT02850367|ACTIVE_COMPARATOR|Chronic intake|Evaluation before and after chronic intake of the food supplement.
62417830|NCT04930536|EXPERIMENTAL|Acalabrutinib Capsule|Single-arm study
62417831|NCT06312761|EXPERIMENTAL|Arm 1 Oral testosterone undecanoate without Curcumin|Oral testosterone undecanoate 237 mg Day 2
62417832|NCT06312761|EXPERIMENTAL|Arm 2 Oral testosterone undecanoate with Curcumin|Oral testosterone undecanoate 237 mg \& Curcumin 630 mg Day 3
62799354|NCT02249936|EXPERIMENTAL|AZD1722 Free-base Tablet|15 mg bid AZD1722 and 20 mg bid Omeprazole
62799355|NCT01692977|EXPERIMENTAL|Alzheimer disease patients|Alzheimer disease patients
62799356|NCT01692977|ACTIVE_COMPARATOR|control|healthy control subjects.
62799357|NCT04608604|ACTIVE_COMPARATOR|Physiotherapy 1|
62224907|NCT01401582|NO_INTERVENTION|care as usual|care as usual, no intervention, just observation of natural change/ trajectories over time
62417833|NCT06312761|OTHER|Relugolix 120 mg single dose|All subjects will received Relugoliz on Day 1
62417834|NCT06701240|EXPERIMENTAL|ParentChild+|The ParentChild+ intervention consists of two 30-minute home visits per week for 46 weeks (92 visits), in which both parent and child are present. These visits may sometimes take place remotely, if best for the family. Each week, the family receives a new book or toy, and tips for promoting child learning.
62799358|NCT04608604|ACTIVE_COMPARATOR|Physiotherapy 2|
62799359|NCT04268108||group 1|"arm 1: secondary resistance to anti-PD-1 therapy: this patients group received liquid tumor infiltrating lymphocytes combined anti-PD-1 therapy.~arm 2: primary resistance to anti-PD-1 therapy: this patients group received FC preconditioning before received liquid tumor infiltrating lymphocytes"
62417835|NCT06701240|ACTIVE_COMPARATOR|FamilyNutrition+|The FamilyNutrition+ active control consists of a 92-contact, 46-week program, mirroring the intervention. However, instead of meeting with an early learning specialist, families in FamilyNutrition+ receive texts, emails, and zoom calls related to healthy nutrition and recipe ideas. In addition, families receive $25/month for groceries-a similar magnitude to the cost of the books and toys they would receive in ParentChild+.
62417836|NCT03939728||Chest radiography and lung ultrasound|All patients will be enrolled, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
62224908|NCT01401582|EXPERIMENTAL|Implementation of Dementia Care Manager|"Subjects in this arm will be provided with a specialised Dementia Care Manager to be included in a subsidiary support system"
62224909|NCT04782401|ACTIVE_COMPARATOR|Genicular Nerve Block|
62224910|NCT04782401|ACTIVE_COMPARATOR|Physical Therapy|
62417837|NCT04986605|EXPERIMENTAL|Administration of Extracorporeal Photopheresis Treatment|"Duration of treatment: 48 weeks. Treatments occur on 2 consecutive days every 4 weeks.~Dose of UVADEX: Treatment Volume x 0.017 = mL of UVADEX for each treatment Treatment Volume (TV) is defined as: The total volume of Buffy Coat plus prime solution that will undergo photoactivation.~Route of administration: Extracorporeal"
62799360|NCT05935020|ACTIVE_COMPARATOR|Usual Care|Referral to municipal rehabilitation after TKA
62417838|NCT05147350|EXPERIMENTAL|Phase 1: RP-6306 in combination with FOLFIRI Dose Escalation|RP-6306 will be administered as oral capsules Multiple dose levels of RP-6306 (oral) and FOLFIRI (IV)
62433490|NCT04487145|ACTIVE_COMPARATOR|HIV-uninfected children (C3b)|30 HIV-uninfected children age 11-17 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. Control group for D3.
62799361|NCT05935020|OTHER|Return to Everyday Life|No referral to municipal rehabilitation after TKA
62799362|NCT05096065|EXPERIMENTAL|Treatment A: Leuprolide Oral Tablet, 120 mg QD|Leuprolide Oral Tablet (Ovarest), 120 mg (2 x 60 mg tablets), administered once daily (QD), for up to 35 consecutive days with food-intake restrictions.
62799363|NCT05096065|EXPERIMENTAL|Treatment B: Leuprolide Oral Tablet, 80 mg QD|Leuprolide Oral Tablet (Ovarest), 80 mg (2 x 40 mg tablets), administered once daily (QD) for up to 35 consecutive days with food-intake restrictions.
62799364|NCT05096065|EXPERIMENTAL|Treatment C: Leuprolide Oral Tablet, 60 mg QD|Leuprolide Oral Tablet (Ovarest), 60 mg, administered once daily (QD) for up to 29 consecutive days with food-intake restrictions.
62799365|NCT05096065|EXPERIMENTAL|Treatment D: Leuprolide Oral Tablet, 60 mg BID|Leuprolide Oral Tablet (Ovarest), 60 mg, administered twice daily (BID), 12 hours apart for up to 35 consecutive days with food-intake restrictions.
62224911|NCT06336720|OTHER|Single Arm|open label administration of translingual neurostimulation.
62224912|NCT05444153|EXPERIMENTAL|Oral semaglutide|Participants will receive once daily oral semaglutide tablet for 104 weeks in a dose escalation fashion of 3milligrams (mg), 7mg, 14 mg and 25 mg once every four weeks during the first 16 weeks and a maintenance dose of 55 mg for the rest 88 weeks.
62224913|NCT05444153|ACTIVE_COMPARATOR|Empagliflozin|Participants will receive once daily empagliflozin tablet for up to 104 weeks, starting with a dose of 10 mg for the first 8 weeks and the maintenance dose of 25 mg for the rest 96 weeks.
62224914|NCT02743156|ACTIVE_COMPARATOR|angiography-guided PCI|angiography-guided percutaneous coronary intervention
62224915|NCT02743156|EXPERIMENTAL|IVUS-guided PCI|intravascular ultrasound guided percutaneous coronary intervention
62224916|NCT01285609|EXPERIMENTAL|Ipilimumab + Paclitaxel and Carboplatin|"Ipilimumab + Active Chemo Backbone~Ipilimumab: IV solution, intravenous (IV), 10 mg/kg, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)~Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses~Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses"
62417839|NCT03495700|EXPERIMENTAL|L-PRF block|"For the test group the sub-sinus cavity will be filled with L-PRF block and the window will be closed with L-PRF membranes.~Eight tubes (9 ml) of venous blood will be collected from the patients. For 6 tubes (red cap) a 12 min centrifugation at 2700 rpm/408g RCF will be followed. Two tubes (white cap) will be centrifuged (IntraSpin, Intra-Lock, Florida, USA) for 3 minutes only to form the Liquid Fibrinogen.~The L-PRF clots will be removed from the tubes using surgical tweezers. The clots will be thereafter gently compressed into membranes using a sterile metal box (Xpression, Intra-Lock, Florida, USA).~To prepare the L-PRF Block, L-PRF membranes will be cut into small pieces and mixed with DBBM (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland). The Liquid Fibrinogen will be added to the homogeneous mix, and stirred gently for ± 10 seconds while shaping it to the L-PRF block"
62224917|NCT01285609|PLACEBO_COMPARATOR|Placebo + Paclitaxel and Carboplatin|"Placebo + Active Chemo Backbone~Placebo: IV solution, IV, 0.9% sodium chloride or 5% dextrose, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)~Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses~Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses"
62588775|NCT02984761|EXPERIMENTAL|Stereotactic radiotherapy|Stereotactic radiotherapy is an FDA approved treatment for lung cancer. However, for purposes of this study, it is being delivered to an operable population that is typically treated with surgical resection. Participants randomized to stereotactic radiotherapy will be treated according to the location of the tumor. Peripheral tumors will receive either 18 Gy x 3, 14 Gy x 4, or 11.5 Gy x 5 fractions, while central tumors will be treated with 10 Gy x 5. There will not be any elective coverage of local microscopic spread or regional lymph nodes.
62224918|NCT05142384|EXPERIMENTAL|Mom-Net|"Mom-Net is a guided Internet intervention. Mom-Net is distinct from other CBT interventions for depression in addressing the link between maternal depression and parenting. Mom-Net's content includes core CBT skills taught in ways that are relevant to one's parenting interactions. Mothers will participate in Mom-Net with either high- or low-intensity coaching as determined by which version their HS was randomized to offer. Coaching is provided by HS staff.~In the high-intensity version, coaches provide support both for engaging with the intervention and for learning content. Coaching phone calls occur weekly (20-30 min call per session). In the low-intensity version, coaches provides supportive accountability for engaging with the intervention. Mothers participate in 4 (10-15) min calls occurring post-randomization, and 3- and 6-weeks later."
62588776|NCT02984761|ACTIVE_COMPARATOR|Surgery|Participants randomized to surgery will undergo a standard lobectomy or limited anatomic pulmonary resection (segmentectomy) under general anesthesia. Non-anatomic (wedge) resections are not permitted. Pathological specimens must contain a separately divided pulmonary artery and bronchus, as well as sampled lymph nodes from mediastinal lymph node stations. Participants found to have incidental nodal involvement after surgery will be referred for adjuvant chemotherapy, with our without postoperative radiotherapy.
62417840|NCT03495700|ACTIVE_COMPARATOR|DBBM|For the control group the sub-sinus cavity will be filled with deproteinized bovine bone mineral (DBBM). The product used will be a xenograft (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland). The window will be closed with a collagen membrane (Bio-Gide, Geistlich AG, Wolhusen, Switzerland).
62417841|NCT06473961|EXPERIMENTAL|Treatment Arm|Participants with advanced NSCLC using cryopreserved GC101 TIL
62417842|NCT00068003||1/Cancer Patients|Patients with a current diagnosis of cancer
62417843|NCT00068003||2/Healthy Volunteers|Healthy volunteers
62588777|NCT01575652|ACTIVE_COMPARATOR|ACE-I|Group using ACEIs
62417844|NCT06330545|EXPERIMENTAL|Patients with Dupuytren's Contacture|Patients with Dupuytren's Contacture will undergo Collagenase Clostridium Histolyticum injection and release followed by two 5-day courses of radiation therapy separated by 6-8 weeks. They will then be followed for 3 years for recurrence.
62417845|NCT06635577|EXPERIMENTAL|Proportion Judgements|This is the sole arm of the study. All participants will be observed under normal conditions and then those same participants will undergo a behavioral intervention.
62433491|NCT06424925||COVID-19 1° wave|Hospitalized patients for COVID19 pneumonia during first wave (FEB-MAY 2020)
62433492|NCT06424925||COVID-19 2° wave|Hospitalized patients for COVID19 pneumonia during the second wave (OCT-DEC 2020)
62588778|NCT01575652|NO_INTERVENTION|ACE-I, 2|group not using ace-i
62588779|NCT05774665|EXPERIMENTAL|Omega-3|Omega-3 fatty acid (ProEPA Xtra) capsules containing a total of 4 g/day of eicosapentaenoic acid (EPA), administered for 12 weeks.
62588780|NCT05774665|PLACEBO_COMPARATOR|Placebo|Placebo capsules containing soybean oil (about 54% omega-6 and 6% omega-3, but no EPA or docosahexaenoic acid (DHA)), and matched to the ProEPA Xtra capsules in terms of appearance, odor, and taste.
62799366|NCT05096065|EXPERIMENTAL|Treatment E:Leuprolide Oral Tablet (Ovarest), 40 mg BID|Leuprolide Oral Tablet (Ovarest), 40 mg, administered twice daily (BID), 12 hours apart for up to 29 consecutive days with food-intake restrictions.
62799367|NCT06568042|EXPERIMENTAL|LY3848575 Dose 1|LY3848575 low dose administered subcutaneously (SC).
62799368|NCT06568042|EXPERIMENTAL|LY3848575 Dose 2|LY3848575 mid dose administered SC.
62799369|NCT06568042|EXPERIMENTAL|LY3848575 Dose 3|LY3848575 high dose administered SC.
62799370|NCT06568042|PLACEBO_COMPARATOR|Placebo|Placebo administered SC.
62799371|NCT01080807|EXPERIMENTAL|150 mg/day armodafinil|
62417846|NCT05940467|EXPERIMENTAL|Sleep Loss|Participants will undergo a night shift work like schedule and be monitored with non-invasive devices while at-home (at set intervals) and during an in-lab phase (hourly) during a 97 continuous-hour protocol. During the in-lab phase, which is approximately 48 continuous hours, participants will undergo a 24-hour period of sleep loss, followed by a brief opportunity for an in-lab sleep opportunity of 5 hours, followed by another period of 19 hours of sleep loss before returning home for at-home monitoring. Measures of interest include arterial stiffness as measured by pulse wave velocity (PWV) and changes in subjective ratings (e.g., fatigue and sleepiness). Other measures include cognitive performance, total sleep during the protocol, and sleep depth during an in-lab sleep opportunity.
62417847|NCT01107834||Healthy Control|HIV-negative children born to healthy, HIV-negative women
62417848|NCT01107834||Exposed to HIV/HAART|HIV-negative children exposed to HIV and HAART in utero
62799372|NCT01080807|PLACEBO_COMPARATOR|Matching placebo|
62799373|NCT06703567|ACTIVE_COMPARATOR|Standard|GEP test information (as per standard hospital policy)
62417849|NCT03220893|EXPERIMENTAL|Observational (MBI, DBT)|Participants undergo DBT and MBI at year 0 and year 1 screening.
62799374|NCT06703567|EXPERIMENTAL|GEP film|Standard policy + the relevant GEP information film
62799375|NCT06456827|OTHER|vertical grower|Patients belonging to group 1 will be patient with vertical growth pattern who have undergone fixed orthodontic cases and are ready for debonding with FMA of 26 0 or more. Begg's Retainer will be formed by conventional method and delivered within 24 hours of debonding. Changes in levels of bone turnover markers CTX-bone resorption and BALP-bone formation using ELISA and compare the bite force
62799376|NCT06456827|OTHER|Horizontal grower|Patients belonging to group 2 will be patient with horizontal growth pattern who have undergone Fixed orthodontic cases and are ready for debonding with with FMA Of 24 o or less.Changes in levels of bone turnover markers CTX-bone resorption and BALP-bone formation using ELISA and compare the bite force
62799377|NCT06200753||Endovascular therapy|
62799378|NCT06200753||Best medical treatment|
62799379|NCT03400852|EXPERIMENTAL|Period 1: MNK-1411|Participants receive MNK-1411 at a dosing volume appropriate to body weight during Period 1
62224919|NCT05142384|ACTIVE_COMPARATOR|Treatment as Usual/Waitlist|HS sites provide ongoing social and instrumental support to parents, including helping to connect families to needed services including community mental health providers. Additionally, research staff will provide lists of local mental health providers and information to support treatment seeking. Research staff will also provide National Crisis Lines for Mental Health Emergencies. Staff will inform participants to call research staff if they have trouble accessing services so that staff may provide additional help. Finally, staff will share a case note documenting referrals with the women's family service worker, so that worker may provide locally based assistance to the woman in accessing services. Subsequent to T2 assessment, participants in the TAU/Waitlist condition, will be offered the Mom-Net intervention variant (high- v low-intensity coaching) being provided by their respective HS agencies.
62224920|NCT06191653|EXPERIMENTAL|Treatment group|The adapted form of the MSC, composed for 12 sessions, will be delivered on a weekly basis in group. This intervention program intends to cultivate a compassionate-self as well as increase the awareness of personal patterns of functioning and learning to respond to them in a kind, courageous, and fierce way. All the sessions will be delivered in a space on each YDC.
62224921|NCT06191653|NO_INTERVENTION|Control Group|This group, wich will be a waiting list control goup, will not receive any mind training or group intervention during the study. Participants of this group will be assessed at 4 different time points (pre- and post-treatment and at a 3- and 6-month follow-up). After all assessment moments are completed, the intervention program will be delivered with the caregivers of this group. These caregivers will receive the intervention after the end of all assessment moments and at a time to be agreed with the Portuguese Juvenile Ministry of Justice. Adolescents cared both by wokers in the TG and CG will not receive any intervention during the study.
62224922|NCT05309343||Exposed group|Western medicine treatment with Chinese medicine treatmen
62224923|NCT05309343||Non-exposed group|Western medicine treatment
62417850|NCT05778591|EXPERIMENTAL|Placebo, buprenorphine|One group will receive placebo first, then buprenorphine (0.15mg).
62417851|NCT05778591|EXPERIMENTAL|Buprenorphine, placebo|One group will receive buprenorphine (0.15mg) first, then placebo.
62433493|NCT06424925||COVID-19 3° wave|Hospitalized patients for COVID19 pneumonia during the third wave (GEN-MAY 2021)
62433494|NCT06424925||COVID-19 4° wave|Hospitalized patients for COVID19 pneumonia during the fourth wave (NOV 2021-MAR 2022)
62433495|NCT01915381|ACTIVE_COMPARATOR|Control group|follow up detraining effect of multimodal intervention
62799380|NCT03400852|EXPERIMENTAL|Period 1: Placebo|Participants receive placebo at a volume appropriate to body weight during Period 1
62799381|NCT03400852|EXPERIMENTAL|Period 2: MNK-1411|All participants receive MNK-1411 at a dosing volume appropriate to body weight during Period 2
62799382|NCT04809571|EXPERIMENTAL|Photoacoustic imaging and Confocal Raman spectroscopy measurement|
62799383|NCT06707337|EXPERIMENTAL|Participant Group|Brief Self-compassion Program will be held in a face-to-face hospital environment for the patients with colorectal cancer in the experimental group. This training program has been developed based on the concepts of Mindfulness-Based Compassionate Living and Mindfulness-Based Stress Reduction Programs. The content and topics of the sessions in the program are arranged according to the conceptual structure and flow of the mindfulness-based model. The training program was created in a certain flow, based on the introduction to a short self-compassion program (1 sessions), the importance of self-compassion and self-care in the cancer experience (1 sessions), a self-compassionate approach to challenging emotions and situations (1 sessions). There are 3 sessions in the program and the frequency of sessions is 3 times a week, and each session lasts approximately 45 minutes. The training program will be applied to 33 patients with colorectal cancer in the experimental group.
62799384|NCT06707337|NO_INTERVENTION|Control Group|There will be no training or intervention.
62799385|NCT00970112|PLACEBO_COMPARATOR|Placebo|Placebo 1 hour before surgery
62799386|NCT00970112|EXPERIMENTAL|Etoricoxib|Etoricoxib 1 hour before surgery
62799387|NCT00970112|EXPERIMENTAL|Dexamethaone|Dexamethasone 1 hour before surgery
62799388|NCT02487095|EXPERIMENTAL|1/Phase I VX-970 (M6620) + topotecan|VX-970 (M6620) + topotecan at escalating doses
62799389|NCT02487095|EXPERIMENTAL|2/Phase II VX-970 (M6620) + topotecan|VX-970 (M6620) + topotecan at maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D)
62799390|NCT04522453|ACTIVE_COMPARATOR|paper mental health Gap Action Program-Intervention Guide|This arm will be training and supervision as usual employing the standard paper version of the mental health Gap Action Program-Intervention Guide. Primary care workers will be trained to use the paper version of this tool and will use the paper version when evaluating patients.
62224924|NCT01295177|PLACEBO_COMPARATOR|vehicle cream|Intervention: Placebo cream vehicle. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream (cream with the same constitution but without insulin). The placebo cream vehicle was used for 8 weeks.
62224925|NCT01295177|PLACEBO_COMPARATOR|cream insulin|Intervention: insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with insulin cream (cream with the same constitution but with insulin). The insulin cream was used for 8 weeks.
62224926|NCT04020705|EXPERIMENTAL|Citicoline eye drops (OMK1)|45 patients will be treated with active treatment (OMK1)
62224927|NCT04020705|PLACEBO_COMPARATOR|hypromellose based ocular lubricant|45 patients will be treated with placebo (lubricant eye drops)
62224928|NCT01724853|OTHER|Surgery|Preferred surgery
62224929|NCT01724853|OTHER|Conservative|Conservative treatment
62417852|NCT04925453|EXPERIMENTAL|Active tDCS|"Based on previous studies targeting working memory, focality of current delivery, and comfort and tolerance levels, (Paulo S. Boggio et al., 2006; Hill et al., 2016; Hoy et al., 2013; Teo, Hoy, Daskalakis, \& Fitzgerald, 2011), we will use a 2 mA current administered via two circular carbon rubber core electrodes in saline-soaked surface sponges (25 cm2), placed in a neoprene headcap with marked locations based on the 10-10 EEG system. The anodal stimulating electrode will be at location F3, over left dorsolateral prefrontal cortex (DLPFC) and the cathodal electrode at location F4, over right DLPFC. Two reference electrodes, CMS and DRL, will be attached to the EarClip and applied to the earlobe with conductive gel.~Before each training session, the impedance of the electrodes will be checked and verified to be ≤15 KOhm. Additionally, the stimulation will be terminated if the impedance of the electrodes is \> 20 KOhm. The current and impedance will be recorded for every session."
62417853|NCT04925453|SHAM_COMPARATOR|Sham tDCS|"For sham stimulation, the electrodes will be placed at the same positions as for active stimulation (F3 and F4). After an initial ramp-up period of 30 seconds, stimulation fades out over a period of 30 seconds. Additionally, at the end of the sham stimulation period, stimulation will fade in over a period of 30 seconds and then end with a final 30 second ramp-down period. Participants will feel the initial itching sensation associated with tDCS and experience the ramp-down period at the end of the sham stimulation period but will receive no active current during the rest of the sham stimulation period. This method of sham stimulation has been shown to be reliable (Gandiga et al., 2006).~Before each training session, the impedance of the electrodes will be checked and verified to be ≤15 KOhm. Additionally, the stimulation will be terminated if the impedance of the electrodes is \> 20 KOhm. The current and impedance will be recorded for every session."
62417854|NCT05981573||Visit 2|"AIM 2 : Determine if an RMM can assess the status of taking a prescribed dose of methadone. To complete this aim, the peak and trough concentrations of a witnessed methadone dose will be assessed in ISF collected through the surface of the skin using existing ISF extraction methods and assessed outside the body via differential pulse voltammetry (DPV) for up to 6 hours. Methadone metabolites and protein binding factors may be assessed in the collected ISF samples using (LC-MS). We hypothesize that the methadone peak and trough levels as well as the metabolites in the blood samples will correlate with the levels of methadone in ISF.~The Investigators hypothesize that the methadone peak and trough levels as well as the metabolites in the blood samples will correlate with the levels of methadone in ISF."
62224930|NCT00690560|EXPERIMENTAL|R-CHOP14 chemotherapy|
62224931|NCT02869100|EXPERIMENTAL|Spondyloarthritis Patients|
62224932|NCT01182701|ACTIVE_COMPARATOR|Behavioral intervention|
62224933|NCT01182701|NO_INTERVENTION|Education support|
62224934|NCT02940405|EXPERIMENTAL|ketorolac tromethamine|One tablet of Ketorolac tromethamine 10-mg one hour before endodontic treatment
62224935|NCT02940405|PLACEBO_COMPARATOR|placebo tablet|One tablet of a placebo one hour before endodontic treatment
62224936|NCT02927600|EXPERIMENTAL|Low GI Rice Breakfast|Intake of low GI breakfast
62224937|NCT02927600|EXPERIMENTAL|High GI rice Breakfast|Intake of High GI breakfast
62224938|NCT02927600|EXPERIMENTAL|Low GI Rice Dinner|Intake of low GI dinner
62224939|NCT02927600|EXPERIMENTAL|High GI Rice Dinner|Intake of High GI dinner
62417855|NCT05981573||Visit 3|AIM 3: Determine if an RMM can continuously assess the status of taking a prescribed dose of methadone over time. To complete this aim, the pharmacokinetic profile of a witnessed methadone dose will be assessed in ISF continuously from the surface of the skin using the RMM for up to 12 hours (Aim 3a) and over 3 days (Aim 3b). Methadone metabolites will also be assessed over these three time points in the continuously collected ISF samples using LC-MS. The Investigators hypothesize that a clinician can recognize a dose taken and the methadone metabolites from the RMM generated measurements in the ISF.
62588781|NCT04007562||Lipin-1 deficiency|Patients suffering from Lipin-1 deficiency havebenefited from an off-label use treatment by Hydroxychloroquine Sulfate as part of their care for at least 6 months.
62588782|NCT02674308||Vedolizumab|
62588783|NCT02674308||Other Biologic Agents|
62588784|NCT03521115|EXPERIMENTAL|Smart Choices 4 Teens|A web-based intervention consisting of 3 main components (Communication, Alcohol, Relationships) provided to both parents and teens was completed by parents and teens individually. At the end of each component, discussion guidelines were given to promote communications and to offer skill building practices between parent and teen regarding the component topic. Both the parent and teen were required to complete the component and discussion before moving to the next component. Numbers are provided for the number of families
62588785|NCT03521115|NO_INTERVENTION|Control condition|This group was provided with websites where information was available regarding the same topics.
62588786|NCT04253639||Chronic pain patients|
62588787|NCT03045432|EXPERIMENTAL|video-teaching materials|"* regular passive ROM exercise~* regular rehabilitation programe~* alternative video-teaching materials"
62588788|NCT03045432|OTHER|control group|"* regular passive ROM exercise~* regular rehabilitation programe~* regular oral-teaching materials"
62588789|NCT04910685|EXPERIMENTAL|(Part 1) Elenestinib Dose 1 + BSC|Patients will receive best supportive care (BSC) and Dose 1 of elenestinib. BSC will be determined on a per patient basis. Elenestinib will be administered orally, once daily until completion of Part 1.
62799391|NCT04522453|EXPERIMENTAL|digital mental health Gap Action Program-Intervention Guide|This arm will be training and supervision in an experimental approach using a digital version of version of the mental health Gap Action Program-Intervention Guide. The digital version allows for interactive decision making on diagnoses and care, and it allows for entering of patient data. Primary care workers in this arm will be trained to use the digital version of this tool and will use the digital version when evaluating patients.
62224940|NCT02238574|EXPERIMENTAL|follow up & surgery|CIN positive with surgery and intensified follow up
62417856|NCT05981573||Visit 1|Aim 1: Characterize dermal interstitial fluid (ISF) in healthy adults with Liquid Chromatography-Mass Spectroscopy (LC-MS) based proteomics and Differential Pulse Voltammetry. To complete this aim, the dermal interstitial fluid will be extracted from the surface of the skin of healthy adults over a period up to 3 hours. The participants may also have continuous monitoring of their intradermal differential pulse voltammogram using the RMM. We hypothesize that the protein content of ISF will be 50% the level of normal human serum levels and contain potential protein biomarkers of disease status. We also hypothesize that the baseline DPV will be stable over this time period.
62224941|NCT02238574|ACTIVE_COMPARATOR|follow up|CIN positive, only intensified outpatient follow up
62588790|NCT04910685|EXPERIMENTAL|(Part 1) Elenestinib Dose 2 + BSC|Patients will receive BSC and Dose 2 of elenestinib. BSC will be determined on a per patient basis. Elenestinib will be administered orally, once daily until completion of Part 1.
62588791|NCT04910685|EXPERIMENTAL|(Part 1) Elenestinib Dose 3 + BSC|Patients will receive BSC and Dose 3 of elenestinib. BSC will be determined on a per patient basis. Elenestinib will be administered orally, once daily until completion of Part 1.
62588792|NCT04910685|PLACEBO_COMPARATOR|(Part 1) Placebo + BSC|Patients will receive BSC and matching placebo. BSC will be determined on a per patient basis. Placebo will be administered orally, once daily until completion of Part 1
62588793|NCT04910685|EXPERIMENTAL|(Part 2) Elenestinib RD + BSC|Patients will receive BSC and the recommended dose (RD) of elenestinib. BSC will be determined on a per patient basis. Elenestinib will be administered orally, once daily for approximately 24 weeks
62588794|NCT04910685|PLACEBO_COMPARATOR|(Part 2) Placebo + BSC|Patients will receive BSC and matching placebo. BSC will be determined on a per patient basis. Placebo will be administered orally, once daily once daily for approximately 24 weeks
62588795|NCT04910685|EXPERIMENTAL|(Part 3) Elenestinib RD + BSC|Patients will receive open-label BSC and the RD of elenestinib for up to approximately 4 years.
62588796|NCT04910685|EXPERIMENTAL|(Part M) Elenestinib RD + BSC|Patients will receive BSC and the RD of elenestinib. BSC will be determined on a per patient basis. Elenestinib will be administered orally, once daily for the duration of participation in the study.
62799392|NCT04235348||BELIEVE|Consists of subjects referred to a colonoscopy between June 1, 2017, and December 1, 2019, in the hospital of Southern Denmark
62799393|NCT03539965||Single-arm cohort|Initially, patients will be analyzed in a single group. After determining the status of the biomarkers, the patient sample will be divided into specific groups for comparative purposes.
62799394|NCT06726057|ACTIVE_COMPARATOR|Multicomponent hypertension intervention|The multicomponent hypertension intervention arm (control arm) will receive the proven multicomponent hypertension intervention (MCHI) comprising four components.
62026277|NCT05811338|ACTIVE_COMPARATOR|Project 3 - Phase 3: Usual-Tool Control Condition|Participants will have access to a generic, non-adapted voice assistant available on a provided tablet. The experimenter will use a standard script that allows for guidance to participants in searching for information relevant to the problems. Participants will indicate when they are ready to move on to the next problem, which will be followed by their assessment of the confidence they have in having solved the problem, their comprehension of the information associated with the problem, their assessment of the usefulness of the available information, and the perceived mental workload they experienced in solving the problem. Investigators will track, code, and analyze participants' online interactions with any websites they use. For each of the three task activity domains, overall performance scores will be computed, as will performance scores for the simpler and more complex problems.
62799395|NCT06726057|EXPERIMENTAL|Implementation strategies in conjunction with multicomponent hypertension intervention|Implementation strategies in conjunction with multicomponent hypertension intervention arm (Intervention arm) will receive implementation strategies in conjunction with multi-component hypertension intervention (MCHI)
62799396|NCT02924493|EXPERIMENTAL|Low FODMAP diet|This group will follow a exclusion diet called low FODMAP diet, which is a diet with restriction of fermentable carbohydrates. The patients will be guided on how to avoid some foods and how to include others. The patients will follow the diet for four weeks.
62799397|NCT02924493|PLACEBO_COMPARATOR|Control diet|This group will follow a placebo diet, which is designed to imitate the low FODMAP diet by restricting specific foods. However, it is randomly selected foods that will be excluded in this diet, so that it works only as a control diet. The patients in this group will also be guided how to follow the diet for four weeks.
62799398|NCT02261363||Ecig group 1|
62026278|NCT05641688|EXPERIMENTAL|PI-2620 PET Scan|
62026279|NCT00505739|EXPERIMENTAL|Mifepristone|
62026280|NCT01265329|NO_INTERVENTION|Control|No sperm selection
62026281|NCT01265329|EXPERIMENTAL|Annexine V negative|Sperm selection with Annexine V protein
62417857|NCT05785299|ACTIVE_COMPARATOR|Double blind placebo controlled challenge test|Introduction of cow's milk by means of an adjusted double blind placebo controlled challenge test
62417858|NCT05785299|ACTIVE_COMPARATOR|Home introduction test|Introduction of cow's milk by means of a standardized schedule
62588797|NCT04910685|EXPERIMENTAL|PK Groups (Dose 2 or Dose 3)|Patients will receive BSC and Dose 2 or Dose 3 of elenestinib. BSC will be determined on a per patient basis. Elenestinib will be administered orally for the duration of participation in the study.
62588798|NCT04910685|EXPERIMENTAL|(Part S) Elenestinib + BSC|Participants with Smoldering Systemic Mastocytosis (SSM) will receive open-label BSC and elenestinib for up to approximately 4 years.
62026282|NCT03701750|EXPERIMENTAL|Experimental Arm|Low Molecular Weight Heparin (enoxaparin sodium) + routine luteal phase support
62026283|NCT03701750|NO_INTERVENTION|Control Arm|routine luteal phase support
62588799|NCT04688320|EXPERIMENTAL|Recombinant nonimmunogenic staphylokinase|lyophilisate for preparation of a solution for intravenous administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, intravenously as a quick single bolus injection for 10-15 seconds, regardless of body weight.
62224942|NCT01893437|EXPERIMENTAL|Single oral dose group|
62417859|NCT06272448|EXPERIMENTAL|Intervention|Telerehabilitation for 3 months
62417860|NCT02364414|OTHER|Cohort|Orthodontic patients, aged 11-18 who fulfill the inclusion/exclusion criteria and provide written informed consent to participate will undergo intra-oral scan. This will be repeated 2 weeks later.
62799399|NCT02261363||Ecig group 2|
62799400|NCT02598284|EXPERIMENTAL|Point of Care (POC) Only|Clinics will receive facilitation to implement point-of-care (POC) quality improvement strategies to accelerate performance on ABCS clinical measures. All strategies will focus on aspects of the clinical encounter.
62417861|NCT02285452|ACTIVE_COMPARATOR|Thorax wrap with ginger flour (Zingiberis Rhizoma plv.)|Thorax wrap with ginger flour, duration max. 20 minutes
62417862|NCT02285452|ACTIVE_COMPARATOR|Thorax wrap with mustard flour (Sinapis nigrea semen)|Thorax wrap with mustard flour, duration max 20 minutes
62588800|NCT04688320|EXPERIMENTAL|Alteplase|Alteplase® is administered in accordance with the instructions for use for pulmonary embolism( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.
62588801|NCT01852201|NO_INTERVENTION|Best medical therapy|"Patients randomized to the control group will receive best conventional MT for acute ischemic stroke as determined by the attending stroke physician. Standardization of medical management in both arms will occur according to the following:~* General medical management according to AHA/ASA guidelines~* Admission to monitored or intensive care unit for at least 24 hours~* Aggressive hypertensive-hypervolemic therapy should be used only in the case of symptomatic blood pressure fluctuations or if blood pressure drops below the normal range for the patient~* Antithrombotics: ASA 325 mg PO qd for 7 days (clopidogrel may be used as adjunctive therapy if indicated for cardiac disease) then per discretion of treating physician~* Close monitoring of BP and glucose with treatment according to AHA/ASA guidelines~* Follow-up imaging study required in any patient with neurologic deterioration"
62588802|NCT01852201|EXPERIMENTAL|Endovascular treatment|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
62799401|NCT02598284|EXPERIMENTAL|POC + Population Managment (PM)|Clinics will receive facilitation to implement point-of-care (POC) quality improvement strategies as well as population management (PM) strategies to accelerate performance on ABCS clinical measures. Strategies in this arm will occur both at the clinical encounter and strategies aimed at the time between clinical encounters.
62799402|NCT05617144|EXPERIMENTAL|Treatment|
62799403|NCT03148613|OTHER|18-49 year old smokers using COBSS|"Younger smokers - Assessment of intended user performance in use scenarios, user documentation assessment, subjective feedback and rating scales.~NOTE: 18-49 year Age Arm intended to evaluate human factors and usability of COBSS in younger smokers"
62799404|NCT03148613|OTHER|≥50 year old smokers using COBSS|"Older smokers- Assessment of intended user performance in use scenarios, user documentation assessment, subjective feedback and rating scales.~NOTE:≥50 year Age Arm intended to evaluate human factors and usability of COBSS in younger smokers"
62799405|NCT02050009|EXPERIMENTAL|Treatment (metformin hydrochloride, carboplatin, paclitaxel)|Patients receive metformin hydrochloride BID on days 1-21, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62417863|NCT02285452|PLACEBO_COMPARATOR|Thorax wrap with warm water (placebo)|Thorax wrap with warm water (placebo), duration: 20 minutes
62417864|NCT06607692|EXPERIMENTAL|Lu-DOTATATE (Lutathera® ) and olaparib|"Lu-DOTATATE (Lutathera®) and olaparib for a maximum of 4 cycles unless unacceptable toxic effects occur, there is centrally confirmed disease progression (according to RECIST v1.122) on imaging, the patient is unable or unwilling to adhere to trial procedures, the patient withdraws consent, or the patient dies.~177Lu-DOTATATE will be administered intravenously, on day 1, every 8 weeks, at a fixed dose of 200 mCi (7.4 GBq) for children \>= 12 years old infused intravenously over a period of 30 minutes. For children younger than 12 years old, the dose that will be administered is 200 MBq per kilogram of body weight (maximum 7.4 GBq) infused intravenously over a period of 30 minutes. Concomitant to 177Lu-DOTATATE, patients will receive IV fluids and an IV infusion of amino acid solution for renal protection23. Patients will receive four infusions every 8 weeks (maximum cumulative radioactivity, 29.6 GBq \[800 mCi\]).~Olaparib will be administered PO, BID, days 2-29, every 8 weeks"
62417865|NCT00458016|EXPERIMENTAL|1|
62417866|NCT00458016|EXPERIMENTAL|2|
62417867|NCT00458016|EXPERIMENTAL|3|
62417868|NCT00458016|EXPERIMENTAL|4|
62417869|NCT00458016|PLACEBO_COMPARATOR|5|
62417870|NCT02765542|EXPERIMENTAL|Automated phone calls|Automated disease assessment \& self-care support phone calls for up to 12 weeks.
62417871|NCT06009432|EXPERIMENTAL|Intervention Group|In addition to the program given to the control group, the study group will be given proprioceptive neuromuscular facilitation exercise as previously described (Smedes et. al., 2021). These applications will be applied to the patients for 8 weeks, 2 days a week in the clinical environment after the initial evaluation. In addition, both groups will be told that they can contact the researcher when requested.
62417872|NCT06009432|ACTIVE_COMPARATOR|Control Group|The control group will receive the usual post-operative care of stretching lower extremity strengthening balance exercises activities of daily living recommendations.
62417873|NCT06182852||glucagon-like peptide-1receptor agonists|Once a week, hypodermic injection.
62417874|NCT02118896|EXPERIMENTAL|1: FK506E (MR4)|Single open arm of FK506E (MR4). Since this was an extension study for many studies, generally the dose given at enrollment was to be continued. The investigator was permitted to adjust the subject's dose and modify the MR4 dose regimen as deemed necessary to minimize Adverse Events (AEs) and maintain effective immunosuppression. MR4 capsules were taken orally, once daily in the morning. MR4 capsules were to be swallowed with fluid (preferably water) on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal. MR4 was supplied as 0.5 mg, 1 mg and 5 mg capsules in amber glass bottles or in blister packs.
62417875|NCT06236711|EXPERIMENTAL|tDCS interventional arm|Participants will receive a 30-minute tDCS treatments at 2 mA twice daily over the course of 5 days.
62417876|NCT05604521|ACTIVE_COMPARATOR|Group 1a: PfSPZ Vaccine|"45 participants will receive 3 doses of 9.0x10\^5 PfSPZ Vaccine on Days 1, 8, and 29 with a total dose of 2.7x10\^6 PfSPZ Vaccine.~Group 1a: Approximately half (22/23) of the volunteers will undergo CHMI 3 weeks after last immunization by exposure to 3.2x10\^3 PfSPZ Challenge (7G8)."
62417877|NCT05604521|ACTIVE_COMPARATOR|Group 1b: PfSPZ Vaccine|"45 participants will receive 3 doses of 9.0x10\^5 PfSPZ Vaccine on Days 1, 8, and 29 with a total dose of 2.7x10\^6 PfSPZ Vaccine.~Group 1b: Approximately half (22/23) of the volunteers will undergo CHMI 12 weeks after last immunization by exposure to 3.2x10\^3 PfSPZ Challenge (7G8)."
62417878|NCT05604521|PLACEBO_COMPARATOR|Group 2a: Normal Saline Controls|"15 participants will receive 3 doses of normal saline on Days 1, 8, and 29.~Group 2a: Approximately half (7/8) of the volunteers will undergo CHMI 3 weeks after last immunization by exposure to 3.2x10\^3 PfSPZ Challenge (7G8)."
62799406|NCT02171507|ACTIVE_COMPARATOR|Dabigatran etexilate|
62026284|NCT04642638|EXPERIMENTAL|Phase 2: INO-4800 Dose Group 1|Participants received one ID injection of 1.0 milligram (mg) of INO-4800 followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
62026285|NCT04642638|EXPERIMENTAL|Phase 2: INO-4800 Dose Group 2|Participants received two ID injections of 1.0 mg (total 2.0 mg per dosing visit) of INO-4800 followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
62026286|NCT04642638|PLACEBO_COMPARATOR|Phase 2: Placebo Dose Group 1|Participants received one ID injection of placebo followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
62026287|NCT04642638|PLACEBO_COMPARATOR|Phase 2: Placebo Dose Group 2|Participants received 2 ID injections of placebo followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
62026288|NCT04642638|EXPERIMENTAL|Phase 3: INO-4800 Dose Group (2.0mg per dosing visit)|Participants received two 1.0 mg ID injections of INO-4800, each followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
62026289|NCT04642638|PLACEBO_COMPARATOR|Phase 3: Placebo Dose Group|Participants received 2 ID injections of placebo per dosing visit, each followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
62026290|NCT00986999|EXPERIMENTAL|rosuvastatin|rosuvastatin 10 mg qd increased to 20 mg qd as tolerated
62026291|NCT06280430||Patients with behcet disease|
62224943|NCT04771949||All patients coming to the University Clinic of Dentistry|All patients coming to the dental University Clinic will be screened for the inclusion in the study.
62224944|NCT03814187|EXPERIMENTAL|Inclisiran|"Inclisiran sodium 300 milligrams (mg) was administered as a single SC injection on Day 1\*, 90, then every 180 days to Day 990.~\*Subjects who received blinded placebo in the feeder study received blinded inclisiran and subjects who received blinded inclisiran in the feeder study received blinded placebo on Day 1 in ORION-8. Subjects from the open label ORION-3 study did not receive any injection of study drug on Day 1. Their first dose of study medication was at day 90"
62026292|NCT06280430||Healthy control group|
62026293|NCT01934218|ACTIVE_COMPARATOR|Gel-One|3 mL, a single intra-articular injection of Gel-One
62417879|NCT05604521|PLACEBO_COMPARATOR|Group 2b: Normal Saline Controls|"15 participants will receive 3 doses of normal saline on Days 1, 8, and 29.~Group 2b: Approximately half (7/8) of the volunteers will undergo CHMI 12 weeks after last immunization by exposure to 3.2x10\^3 PfSPZ Challenge (7G8)."
62224945|NCT04463212||Patient|Diagnosis of probable SVCR evoked, faced with a single or repeated episode of unusual thunderclap or rapidly progressive headache, and demonstration of diffuse vasospasms via sectional imaging (angiography, angio-MRI or cerebral arteriography) or an increase in transcranial doppler speeds
62224946|NCT04463212||Subject control|Subject without SVCR (current and history)
62417880|NCT03080272||Spinal Surgery|No intervention will take place. Recruiting Autumn 2017 until spring 2018
62417881|NCT03080272||Gastric sleeve|No intervention will take place. Recruiting Autumn 2017 until spring 2018
62417882|NCT03080272||Total knee arthroplasty|No intervention will take place. Recruiting Spring 2018 until Summer 2018
62417883|NCT03080272||Shoulder arthroplasty|No intervention will take place. Recruiting Winter 2017 until Summer 2018
62417884|NCT03080272||Maxillofacial surgery|No intervention will take place. Recruiting 6 march 2017 until Autumn 2017
62026294|NCT01934218|PLACEBO_COMPARATOR|Phosphate Buffered Saline (PBS)|3 mL, a single intra-articular injection of PBS
62026295|NCT05846724|EXPERIMENTAL|Single Arm|
62026296|NCT02544906|NO_INTERVENTION|Control|No drugs will be given. the emergence agitation will be monitored and recorded
62026297|NCT02544906|EXPERIMENTAL|Propofol group|Propofol at dose of 1 mg/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded
62026298|NCT02544906|EXPERIMENTAL|dexmedetomedine group|dexmedetomedine at dose of .5 mic/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded
62026299|NCT03874364|ACTIVE_COMPARATOR|Lidocaine gel, counselling, monitor|
62026300|NCT03874364|ACTIVE_COMPARATOR|Lidocaine gel, counselling, no monitor|
62224947|NCT04310891||Markerless|Markerless Tumour Tracking will be used to observe the radiation beam is accurately targeting the tumour.
62417885|NCT05981118|ACTIVE_COMPARATOR|Betamethasone dipropionate 0.05%|The betamethasone dipropionate 0.05% cream group will be treated with betamethasone dipropionate 0.05% cream once daily on both legs until clear or up to 12 weeks.
62417886|NCT05981118|ACTIVE_COMPARATOR|Tapinarof|The tapinarof group will be treated with 1% tapinarof cream applied once daily to both legs until clear or up to 12 weeks.
62799407|NCT02171507|ACTIVE_COMPARATOR|Diclofenac|
62799408|NCT02171507|EXPERIMENTAL|Dabigatran etexilate + diclofenac|
62799409|NCT02314325|ACTIVE_COMPARATOR|Standard prophylaxis|Advate \[Antihemophilic Factor(Recombinant)\] 20-40 IU/kg 5-7 infusions per 14days
62799410|NCT02314325|EXPERIMENTAL|Pharmacokinetic tailored prophylaxis|Advate \[Antihemophilic Factor(Recombinant)\] dose determined by individual patient pharmacokinetics and infusions administerd on alternate days
62026301|NCT03874364|ACTIVE_COMPARATOR|Lidocaine gel, no counselling, monitor|
62026302|NCT03874364|ACTIVE_COMPARATOR|Lidocaine gel, no counselling, no monitor|
62026303|NCT03874364|PLACEBO_COMPARATOR|Lubricating gel, counselling, monitor|
62026304|NCT03874364|PLACEBO_COMPARATOR|Lubricating gel, counselling, no monitor|
62026305|NCT03874364|PLACEBO_COMPARATOR|Lubricating gel, no counselling, monitor|
62026306|NCT03874364|PLACEBO_COMPARATOR|Lubricating gel, no counselling, no monitor|
62799411|NCT02274792|EXPERIMENTAL|Etanercept|Participants received etanercept 50 mg subcutaneously twice a week (BIW) for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
62799412|NCT04232033|ACTIVE_COMPARATOR|Fibroblast growth factor 21 infusion|Fibroblast growth factor 21 infusion
62799413|NCT04232033|PLACEBO_COMPARATOR|Placebo infusion (saline)|Saline infusion
62799414|NCT02036125|EXPERIMENTAL|Ultrasound guided injection|Ultrasound guided injection of 40 mg of methylprednisolone
62799415|NCT02036125|ACTIVE_COMPARATOR|Blind injection|Blind injection of 40 mg of methylprednisolone
62799416|NCT04064749|NO_INTERVENTION|Control|Participants will receive screening (i.e. services as usual) provided by a national credit counseling program.
62799417|NCT04064749|EXPERIMENTAL|Intervention|Participants will receive screening services provided by the credit counseling program plus added brief intervention services by University of Maryland School of Social Work (UMSSW). Added intervention services include: 1) feedback about the individual's gambling, and 2) text messages to support the individual.
62026307|NCT05637138|OTHER|Healthy volunteer|"The totality of the measurements will be carried out on a single visit following the obtaining of the consent (obtained the same day or during a preceding visit).~The total duration of this single visit, including the time of information, the collection of consent and all the measurements is estimated at 2 hours per subject.~Before the installation of the different measuring devices, a preliminary interview and a clinical examination will be carried out in order to verify in particular the absence of skin lesions.~The measurement of subcutaneous microcirculation (no unit) and tcpO2 (kPa) will be carried out simultaneously with the measurement of CO2 diffusion (main criterion), during a single session of measurements at 5 different temperatures (non-thermostated, then thermostated at 35, 38, 41 and 44°C)"
62026308|NCT00513669|EXPERIMENTAL|1 PEV301&302|The vaccine includes two antigens (CSP and AMA1- derived)in combination and formulated with virosomes
62026309|NCT00513669|ACTIVE_COMPARATOR|2 Influenza vaccine|Inflexal V is the comparator that includes 3 antigens from flu formulated in virosomes
62026310|NCT06635447|EXPERIMENTAL|Cohort 1|Capivasertib+Fulvestrant
62026311|NCT06635447|EXPERIMENTAL|Cohort 2|Capivasertib+Fulvestrant
62026312|NCT04163302|EXPERIMENTAL|CD19+ Lymphoma|This study is to evaluate the efficacy and safety of CD19-PD1-CART cells therapy for patients with Relapsed/Refractory B Cell Lymphoma.
62026313|NCT01525290|EXPERIMENTAL|intravenous tissue plasminogen activator|Intervention drug: intravenous tissue plasminogen activator (tPA), alteplase
62224948|NCT03327337|EXPERIMENTAL|experimental group|operate with Arthroscopic Assisted Balloon Tibioplasty on this group patients
62224949|NCT03327337|OTHER|control group|operate with open reduction and internal fixation on this group patients
62224950|NCT03830749|EXPERIMENTAL|Single Arm|Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone
62417887|NCT06446973|NO_INTERVENTION|Control group|35 healthy individuals
62799418|NCT04494074|EXPERIMENTAL|Fever Control by external cooling|External cooling during 48 hours to obtain normothermia
62799419|NCT04494074|NO_INTERVENTION|Fever respected, no cooling|Fever respect without any antipyretic therapy
62799420|NCT01450059||Spontaneous delivery|Approximately 15 HiV exposed Newborns with low HiV transmission risk, born via spontaneous delivery.
62799421|NCT01450059||Cesarean section|Approximately 15 HiV exposed Newborns with low HiV transmission risk, born via cesarean section.
62799422|NCT06084936|EXPERIMENTAL|Glofitamab monotherapy|Participants will receive two intravenous (IV) obinutuzumab pretreatments prior to receiving IV glofitamab for 12 cycles (cycle length = 21 days).
62799423|NCT06084936|ACTIVE_COMPARATOR|BR or R-Len|Participants will receive bendamustine + rituximab for up to 6 cycles (cycle length = 28 days), or rituximab + lenalidomide (cycle length = 28 days) until disease progression.
62026314|NCT01525290|PLACEBO_COMPARATOR|Placebo|Intervention drug: placebo
62224951|NCT02058654|EXPERIMENTAL|Creatine Group|Whey protein (30 g) and creatine supplement (5 g) shaken with 250-300 ml water in a blender bottle, and the full shake to be taken twice a day for 14 days.
62224952|NCT02058654|PLACEBO_COMPARATOR|Placebo Group|Whey protein (30 g) and bulking agent powder (5 g) shaken with 250-300 ml water in a blender bottle, and the full shake to be taken twice a day for 14 days.
62417888|NCT06446973|ACTIVE_COMPARATOR|Meniscus tear group|35 patients diagnosed with meniscus tear
62417889|NCT03436407||PrEP Group|Subject offered to start PrEP treatment in routine clinical practice
62799424|NCT03659799|ACTIVE_COMPARATOR|Aspart - 60-minutes postprandial exercise|
62799425|NCT03659799|ACTIVE_COMPARATOR|Aspart - 120-minutes postprandial exercise|
62799426|NCT03659799|ACTIVE_COMPARATOR|FiAsp - 60-minutes postprandial exercise|
62799427|NCT03659799|ACTIVE_COMPARATOR|FiAsp - 120-minutes postprandial exercise|
62799428|NCT03699917||Patients with SVV < 12|Patients undergoing pancreaticoduodenectomy with an intraoperative stroke volume variation of less than 12.
62799429|NCT03699917||Patients with SVV > or = 12|Patients undergoing pancreaticoduodenectomy with an intraoperative stroke volume variation of greater than or equal to 12.
62799430|NCT01293825|EXPERIMENTAL|Medication Adherence Bipolar Disorder|There was only one group in this study. All participants received the study drug Ziprasidone.
62799431|NCT06727305|ACTIVE_COMPARATOR|sirolimus 0.5 mg Arm|Participant would receive 0.5 mg of sirolimus.
62799432|NCT06727305|ACTIVE_COMPARATOR|sirolimus 1 mg Arm|Participant would receive 1 mg of sirolimus.
62799433|NCT06727305|ACTIVE_COMPARATOR|sirolimus 2 mg Arm|Participant would receive 2 mg of sirolimus.
62799434|NCT06727305|ACTIVE_COMPARATOR|everolimus 0.5 mg Arm|Participant would receive 0.5 mg of Everolimus.
62799435|NCT06727305|ACTIVE_COMPARATOR|everolimus 1 mg Arm|Participant would receive 1 mg of Everolimus.
62799436|NCT06727305|ACTIVE_COMPARATOR|everolimus 2 mg Arm|Participant would receive 2 mg of Everolimus.
62799437|NCT06725472||Paramedian flap skin incision group|Patients undergoing open heart surgery with median sternotomy undergo a skin incision 2-3 cm lateral to the sternum's medium.
62224953|NCT04633798|EXPERIMENTAL|IPL/Lipiflow|the group in which patients treated with IPL combined with lipiflow
62224954|NCT04633798|ACTIVE_COMPARATOR|IPL/MGX|the group in which patients treated with IPL combined with meibomian gland massage
62417890|NCT03436407||Control Group|"1. Enrolled patients will be regarded as their own control when it comes to their sexual health and quality of life reported for period prior to inclusion in the study.~2. Subjects diagnosed with HIV within last 12 months in general clinical practice and referred to the outpatient clinic at the Dept. of Infectious Diseases, OUS. (details in protocol 3.3.2)~3. Frequency of STI reported to the National Institute of Public Health (MSIS) will be compared with the frequency of STIs in the study cohort."
62417891|NCT03626857|EXPERIMENTAL|NMES+ECC|Neuromuscular electrical stimulation (NMES) and Eccentric Exercise (ECC). Patients randomized to the NMES+ECC group will first receive NMES for 2x/week for 8 weeks, beginning at the first post-operative visit. Beginning at 9 weeks after anterior cruciate ligament reconstruction (ACLR) patients will begin to receive eccentric exercise 2x/week for an additional 8 weeks. For NMES, patients will have electrical stimulation delivered to their quadriceps. Fifteen isometric actions lasting 10 seconds each will be elicited during each session. For eccentric exercise, patients will train for 4 sets of 10 repetitions. This group will also receive standard of care ACL rehabilitation alongside the study interventions.
62224955|NCT04178044|EXPERIMENTAL|GB223-group 1|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:7mg/kg,single dose administration; 2 subjects receive placebo.
62417892|NCT03626857|PLACEBO_COMPARATOR|NMES placebo + ECC placebo|"Neuromuscular electrical stimulation (NMES) placebo + Eccentric Exercise (ECC)placebo arm. Patients randomized to the NMES placebo + ECC placebo group will first receive NMES placebo for 2x/week for 8 weeks, beginning at the first post-operative physical therapy visit. Beginning at 9 weeks after anterior cruciate ligament reconstruction (ACLR) patients will begin to receive an eccentric exercise placebo 2x/week for 8 weeks.~For the NMES placebo, patients will have NMES placebo delivered to their quadriceps 2x/week for 8 weeks beginning at the first post-operative visit. Fifteen isometric actions lasting 10 seconds each will be elicited during each session.~For the eccentric exercise placebo, patients will begin to receive eccentric exercise two times per week for 8 weeks. Patients will train for 4 sets of 10 repetitions."
62417893|NCT04590417|OTHER|20 HIV-negative TGW|A single-arm prospective PK study of HIV-negative TGW taking FHT and daily PrEP.
62417894|NCT05410457||thrombolysis group|Inclusion criteria: a) age ≥18 years; B) hospital admission for acute ischemic stroke; C) the time from onset to admission ≤ 4.5 hours; D) received intravenous thrombolysis; E) signed informed consent.
62224956|NCT04178044|EXPERIMENTAL|GB223-group 2|21mg/kg
62224957|NCT04178044|EXPERIMENTAL|GB223-group 3|63mg/kg
62417895|NCT05410457||thrombectomy group|Inclusion criteria: a) age ≥18 years; B) hospital admission for acute ischemic stroke; C) the time from onset to admission ≤ 24 hours; D) vascular assessment by CTA or multimodal MRI; E) received thrombectomy; F) signed informed consent.
62417896|NCT05410457||stent group|Inclusion criteria: a) age ≥18 years; B) hospital admission due to ischemic stroke; C) vascular assessment by CTA or multimodal MRI; D) received stent implantation ; E) Signed informed consent.
62417897|NCT05410457||regular treatment group|Inclusion criteria: a) age ≥18 years; B) hospital admission due to ischemic stroke; C) received regular medical treatment; D) signed informed consent.
62417898|NCT05410457||young stroke group|Inclusion criteria: a) age between 18 and 50 years of age (45/55Y); B) hospital admission due to ischemic stroke; C) received CT or MRI imaging assessment; D) signed informed consent.
62799438|NCT06725472||Control group|Patients undergoing open heart surgery with median sternotomy undergo a classical skin incision on the medium of the sternum.
62224958|NCT04178044|EXPERIMENTAL|GB223-group 4|119mg/kg
62224959|NCT04178044|EXPERIMENTAL|GB223-group 5|140mg/kg
62224960|NCT04585776|EXPERIMENTAL|LY900014 + Insulin Degludec|LY900014 (100 units/milliliter (U/mL)) is a prandial insulin administered subcutaneously (SC) 0-2 minutes before meals. Insulin degludec (100 U/mL) is a basal insulin administered once daily SC. Participants received individually adjusted insulin doses during the 35-day titration period. The target glucose values were: fasting glucose 80-110 milligrams per deciliter (mg/dL), overnight glucose excursion (the difference between bedtime and prebreakfast glucose levels) \< or = +/- 30 mg/dL, postprandial glucose peak \<140 mg/dL or \<20% increase from premeal level. Following the titration period, there was an 11-day maintenance period during which the doses were kept unchanged unless for safety reasons.
62224961|NCT03717129|ACTIVE_COMPARATOR|Genvoya Oral dose|Single observed oral dose of Genvoya whole tablet
62224962|NCT03717129|EXPERIMENTAL|Genvoya Crushed Dose|Single observed oral dose of Genvoya crushed tablet
62224963|NCT04708925||group A- conservative therpay|hypertriglyceridemia-induced acute pancreatitis patients who recieved conservative therapy
62224964|NCT04708925||group B- plasmapharesis therapy|hypertriglyceridemia-induced acute pancreatitis patients who recieved plasmapharesis therapy
62224965|NCT01116882|ACTIVE_COMPARATOR|SOS|Patients randomized to the SOS arm are transferred to tertiary hospitals for their PCI procedure.
62224966|NCT01116882|EXPERIMENTAL|Non-SOS|Patients in the non-SOS arm are randomized to stay at the community hospitals for their PCI procedure.
62224967|NCT03270397|EXPERIMENTAL|Active participants|"The first 20 students who signed up for the course: The group- theory and practice were included. No exclusion criteria were used. Full attendance in the course which includes 13 sessions was mandatory. In each session, students were assigned to different body image tasks that were discussed in the coming session. All students completed a self-report questionnaire at baseline and conclusion of the course."
62224968|NCT03270397|NO_INTERVENTION|Controls|All the other students, that requested to sign up for the course but did not have a place, served as control group. All students completed a self-report questionnaire at baseline and conclusion of the course.
62224969|NCT00416234|ACTIVE_COMPARATOR|1|Laparoendoscopic Rendez vous (one stage management of cholelithiasis/choledocholithiasis)
62224970|NCT00416234|ACTIVE_COMPARATOR|2|preoperative ERCP and CBD clearance followed by lap cholecystectomy (two stage management of cholelithiasis/choledocholithiasis)
62224971|NCT02749240|OTHER|Youth Empowerment Seminar, YES!|An 8-week innovative bio-psycho-social program (Youth Empowerment Seminar, YES!) will be offered to at risk youth participating in programs or resources offered by Youth Opportunities Unlimited. The YES! program will be taught in two phases: (1) an active learning phase which consists of four consecutive days (3 hrs/day) of SEL skills taught in a multi-modality interactive format as well as SKY training, and (2) a reinforcement phase which involves weekly follow up sessions (75-90 mins each) for the 7 weeks following the active phase. Two certified instructors from the Art of Living Foundation (Spencer Delisle and Mark Frye) will deliver this training under supervision of Ronnie Newman (RN). After the initial 4 day training, participants will be asked to practice SKY daily for 20-25 minutes in addition to attending the weekly follow up sessions.
62224972|NCT04149730||Patients with primary PEA.|Patients at St. Olavs hospital who suffer cardiac arrest and pulseless electrical activity (PEA) as primary rhythm during 2018-2021. 120 episodes from St. Olavs hospital were collected previously (2010-2013). In addition 200 cases will be available from the hospital of The University of Pennsylvania, Philadelphia, USA.
62224973|NCT02020759||Patient on ECMO|Neurological monitoring with transcranial Doppler ultrasound
62224974|NCT02020759||Healthy subjects|Neurological monitoring with transcranial Doppler ultrasound
62799439|NCT04533321|OTHER|Patients genotyped positive for MET-N375S polymorphism|will be treated with orally administered daily dose of afatinib (Gilotrif®) in a fasting state (1 hour before or 2 hours after meals).
62799440|NCT01333293|EXPERIMENTAL|Omalizumab|
62026315|NCT06636435|EXPERIMENTAL|CBA-1205: Part 1|"CBA-1205 injection is administered at 2-week intervals in seven cohorts (0.1, 0.3, 1, 3, 10, 20, 30 mg/kg) for solid tumor.~In the study treatment period, CBA-1205 is intravenously administered at 2-week intervals in a 28-day cycle."
62224975|NCT02020759||ICU patients|Neurological monitoring with transcranial Doppler ultrasound
62224976|NCT02041234|ACTIVE_COMPARATOR|Roux-en-Y Gastric Bypass (RYGB)|Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
62799441|NCT01333293|PLACEBO_COMPARATOR|Placebo|
62799442|NCT06726525|EXPERIMENTAL|HPMC+GlicoPro Group|
62799443|NCT06726525|ACTIVE_COMPARATOR|HPMC alone Group|
62799444|NCT02795117|EXPERIMENTAL|Test product|
62799445|NCT02795117|ACTIVE_COMPARATOR|Reference product|
62799446|NCT02795117|PLACEBO_COMPARATOR|Placebo product|
62799447|NCT00181766|EXPERIMENTAL|Strattera (atomoxetine)|
62799448|NCT00673582|EXPERIMENTAL|1|10 mg/day rosuvastatin for 96 weeks
62799449|NCT00673582|PLACEBO_COMPARATOR|2|Placebo
62224977|NCT02041234|ACTIVE_COMPARATOR|Best Medical Treatment|"Anti-diabetic medications provided (Mono- or Combination- therapy):~Incretin analogues: Liraglutide up to 3 mg daily Or DPP-4 Inhibitors: Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily Xenical: Up to 120 mg tds SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily Participants will also take lipids \& BP medications according to standard of care."
62224978|NCT01904123|EXPERIMENTAL|Treatment (STAT3 inhibitor WP1066)|Patients receive STAT3 inhibitor WP1066 PO BID on Monday, Wednesday, and Friday of weeks 1 and 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62799450|NCT03796065|EXPERIMENTAL|FSI-R Treatment|Families randomized into the FSI-R Treatment arm will receive the 10-module Family Strengthening Intervention in addition to any outside services or programs they are participating in.
62224979|NCT04985760|EXPERIMENTAL|Randomized Blinded Trimer 4571 Vaccine 100mcg|Six (6) participants will receive Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant as a 1ml intramuscular injection at Day 0, Week 8 and Week 20.
62224980|NCT04985760|PLACEBO_COMPARATOR|Randomized Blinded Placebo for Trimer 4571 Vaccine 100mcg|Two (2) participants will receive the placebo control for Trimer 4571 vaccine 100mcg as a 1ml intramuscular injection at Day 0, Week 8 and Week 20.
62224981|NCT04985760|EXPERIMENTAL|Randomized Blinded Trimer 4571 Vaccine 500mcg|Eighteen (18) participants will receive Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant as a 1.1ml intramuscular injection at Day 0, Week 8 and Week 20.
62224982|NCT04985760|PLACEBO_COMPARATOR|Randomized Blinded Placebo for Trimer 4571 Vaccine 500mcg|Six (6) participants will receive the placebo control for Trimer 4571 vaccine 500mcg as a 1.1ml intramuscular injection at Day 0, Week 8 and Week 20.
62224983|NCT00715962|ACTIVE_COMPARATOR|Mobility Group|The Walking Intervention includes assistance to walk twice daily with or without a rolling walker. In addition, a behavioral intervention that included goal setting and discussion of how to overcome mobility barriers was used to encourage the mobility group to be more active throughout hospital stay. Participants will keep a diary of out of bed activity and will be encouraged to set goals for additional out of bed activity daily.
62224984|NCT00715962|PLACEBO_COMPARATOR|Control Group|The control group will receive twice daily friendly visits to counter the attention being paid to the intervention group. They will complete a diary but of visitors to their room.
62224985|NCT03585413|ACTIVE_COMPARATOR|Specific Micronutrient-probiotic-combination|"Intake of one micronutrient capsule three times daily and probiotic powder twice daily starting on the first day after hospital discharge until 12 weeks postoperatively.~The micronutrient capsules consist of vitamins, minerals, phytochemicals and bioactive substances. The probiotic supplement is a powder of 10 different species of probiotic bacteria."
62224986|NCT03585413|PLACEBO_COMPARATOR|Micronutrient-placebo-combination|"Intake of one micronutrient capsule three times daily and placebo powder twice daily starting on the first day after hospital discharge until 12 weeks postoperatively.~The micronutrient-control-combination consists of a micronutrient capsule (vitamins and minerals) but without phytochemicals and bioactive substances, and a placebo powder manufactured to mimic the probiotic powder."
62224987|NCT03531970|EXPERIMENTAL|Dexamethasone|lidocaine \& Dexamethasone
62224988|NCT03531970|PLACEBO_COMPARATOR|Non-dexamethasone|lidocaine \& Placebo
62224989|NCT05128994|EXPERIMENTAL|Non-invasive FES|Wearable FES sleeve with non-invasive user controls
62224990|NCT03508037|EXPERIMENTAL|Experimental group|The subject receives the Functional Electrical Stimulation (FES) when he or she has the intention to move. It is obtained through electroencephalography.
62224991|NCT03508037|ACTIVE_COMPARATOR|Control group|The subject receives the Functional Electrical Stimulation (FES) after o before (0.5 seconds) when he or she has the intention to move. It is obtained through electroencephalography.
62224992|NCT04719884|NO_INTERVENTION|Control group|Standard perioperative anesthesia management
62224993|NCT04719884|ACTIVE_COMPARATOR|Study group|Perioperative extended haemodynamic monitoring of fluid loading, cardiac output and changes of peripheral vascular resistance by analysing the arterial curve was provided by non-invasive haemodynamic monitoring (LIDCO Rapid, Lidco Ltd., United Kingdom).In SG fluid optimisation was performed before pneumoperitoneum and after abdominal desuflation with actions to achieved CI, MAP and SI within 80% of baseline values.
62799451|NCT03796065|NO_INTERVENTION|FSI-R Control|Families randomized into the FSI-R Control arm will not receive the FSI-R treatment. Instead, they will continue with their usual care, referred to as Treatment as Usual (TAU).
62799452|NCT04909489||PDR group|Phlegm-Dampness Retention syndrome group
62224994|NCT05909995|EXPERIMENTAL|Dose Escalation|"* Participants with RCC and MSI-H/dMMR CRC will receive 1 of two doses of INCB099280 BID with up to 4 doses of ipilimumab 1 mg/kg Q3 weeks~* Participants with Melanoma and HCC will receive 1 of 2 doses of INCB099280 BID with up to 4 doses of 3 ipilimumab 3 mg/kg Q3 weeks"
62224995|NCT05909995|EXPERIMENTAL|Dose Expansion|"* Participants with RCC will receive 1 of two doses of INCB099280 BID with up to 4 doses of ipilimumab 1 mg/kg Q3 weeks of ipilimumab~* Participants with HCC will receive 1 of two doses of INCB099280 BID with up to 4 doses of ipilimumab 3 mg/kg Q3 weeks of ipilimumab"
62799453|NCT04909489||SKYD group|Spleen and Kidney Yang Deficiency syndrome group
62799454|NCT04909489||NC group|Normal Control group
62799455|NCT04585204|ACTIVE_COMPARATOR|50 gr-100 gr OGTT|patients are tested firstly by 50 gr OGTT after that if necessary by 100 gr OGTT
62799456|NCT04585204|ACTIVE_COMPARATOR|75 gr OGTT|patients are tested by 75 gr OGTT
62799457|NCT04792021|ACTIVE_COMPARATOR|N-acetylcysteine (NAC)|Patients receiving N-acetylcysteine (NAC)
62799458|NCT04792021|NO_INTERVENTION|Control|Patients not receiving N-acetylcysteine (NAC)
62799459|NCT01242592|EXPERIMENTAL|Homeopathy|
62799460|NCT01242592|PLACEBO_COMPARATOR|Placebo|
62224996|NCT06318715|EXPERIMENTAL|modified deep extubation|This modified deep extubation (mDE) occurs while the patient is still anaesthetized but at a lower dose of anaesthetic gas than previously described, and balanced with long acting opioids to attenuate the airway reaction.
62224997|NCT06318715|EXPERIMENTAL|standard awake extubation|awake extubation (AE) is still considered the standard practice.
62224998|NCT04176146|EXPERIMENTAL|Nudge Letter|Participants receive a letter that highlights their performance vs. peer organizations on up to seven care delivery practices featured in the National Survey of Healthcare Organizations and Systems (NSHOS). The letter includes a link to access technical assistance resources and is sent alongside the participant's NSHOS respondent report.
62224999|NCT04176146|NO_INTERVENTION|Control Letter|Participants receive a letter with a link to technical assistance resources; the letter is sent alongside the participant's NSHOS survey respondent report.
62225000|NCT04708210|EXPERIMENTAL|Phase Ia Dose-Escalation Stage: IBI319|
62225001|NCT02905071|EXPERIMENTAL|Study 1 Group 1 G1 (n =50)|filling of Serenat at baseline (T1)
62026316|NCT06636435|EXPERIMENTAL|CBA-1205: Part 2|"CBA-1205 (20, 30 mg/kg) injection is administered at 2-week intervals in 28-day cycles for HCC patients.~In the study treatment period, the study drug is administered at 2-week intervals."
62225002|NCT02905071|EXPERIMENTAL|Study 1 Group 2 G2 (n=50)|Serenat at baseline T1 and 3 others questionnaires
62225003|NCT02905071|EXPERIMENTAL|Study 1 Group 3 G3 (n =50)|filling of Serenat at baseline T1 and T2 (one week after baseline).
62225004|NCT02905071|EXPERIMENTAL|Study 2 Ancillary study (n=50)|filling of Serenat, HADS, STAY-Y and BDI at baseline T1
62026317|NCT06636435|EXPERIMENTAL|CBA-1205: Part 3|"CBA-1205 (30 mg/kg) injection is administered at 2-week intervals in 28-day cycles for HCC patients.~In the study treatment period, the study drug is administered at 2-week intervals."
62225005|NCT03018951||Tool Development Stage|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
62417899|NCT05410457||unexplained stroke group|Inclusion criteria: a) age ≥18 years; B) hospital admission due to ischemic stroke; C) Received CT or MRI imaging assessment; D)TOAST was classified as unknown cause type (including two or more causes and no cause was found by auxiliary examination); E) signed informed consent.
62588803|NCT05587504|EXPERIMENTAL|Cigarette and/or e-Cigarette users|Each participant will participate in 4 sessions. During each session, participants will first complete a 10-puff product use period with the ECIG assigned for that session, then a 30-minute ad lib product use period, and then a cigarette/e-cigarette challenge paradigm.
62026318|NCT06282627||Non-hospitalised individuals|No intervention. Observational study
62026319|NCT05226208||Women with not severe labour pain|Group 1 included 282 patients (pain level ≥7 mm according to the VAS).
62026320|NCT05226208||Women with severe labour pain|Group 2 included 84 patients (pain level ≤ 6 mm using the VAS).
62026321|NCT06361082|NO_INTERVENTION|Non-ACLR Control Group|Control group arm. Subjects In this arm will receive MRI and ultrasound examination, without receiving any treatment.
62026322|NCT06361082|EXPERIMENTAL|ACLR Intervention Arm|Intervention group arm. Subjects In this arm will receive MRI and ultrasound examination, before and after receiving ACL reconstruction.
62026323|NCT00725166||Young|Young men 19-25 years old
62026324|NCT00725166||Old|old men 70-76 years old, who participate in the PROOF study (NCT 00759304)
62225006|NCT03018951||Pilot Test 1|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
62417900|NCT05268341|EXPERIMENTAL|Treatment|computer assisted intervention targeting expressive grammar for preschoolers with DLD
62417901|NCT05268341|NO_INTERVENTION|No treatment|business as usual classroom (educational) services
62026325|NCT01294839|EXPERIMENTAL|RVOTs|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in RVOTs arm, the RV lead of this group patients will be implanted in right ventricular outflow tract septum,the accumulated ventricular pacing percentage should be over 80% by adjusting AV delays.
62026326|NCT01294839|EXPERIMENTAL|AAI|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in AAI arm, the RV lead of this group patients will be implanted in right ventricular apex.
62225007|NCT03018951||Pilot Test 2|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
62225008|NCT06108882|EXPERIMENTAL|Manual Ischemic Compression with Strain Counter Strain technique|Participants in this group will receive Manual Ischemic Compression with Strain Counter Strain technique.
62225009|NCT06108882|ACTIVE_COMPARATOR|Manual Ischemic Compression|Participants in this group will receive only Manual Ischemic Compression
62026327|NCT01294839|ACTIVE_COMPARATOR|RVA|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in RVA arm, the RV lead of this group patients will be implanted in right ventricular apex, the accumulated ventricular pacing percentage should be over 80% by adjusting AV delays.
62225010|NCT05827432|EXPERIMENTAL|NAFLD|Participants with different degree of steatohepatitis and NAFLD will undergo one FCI scan.
62225011|NCT02143557|EXPERIMENTAL|Fat-Modified Breast Milk|Infants in this arm of the study were fed their own mother's breast milk where the fat layer was removed by centrifugation. Prior to feeding, extra energy and nutrients were added to the defatted breast milk.
62225012|NCT02143557|ACTIVE_COMPARATOR|MCT-formula group|Infants in this arm of the study were fed a MCT-containing medical food which is the current standard of care.
62225013|NCT02798965|OTHER|Control|patients with goiter or nodule
62225014|NCT02798965|EXPERIMENTAL|Graves' disease|patients with Graves' disease
62225015|NCT01335087|ACTIVE_COMPARATOR|Lifestyle|Standard care for OSA: lifestyle, and sleep hygiene counselling
62225016|NCT01335087|EXPERIMENTAL|Continuous positive airway pressure CPAP|CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling
62225017|NCT01335087|NO_INTERVENTION|Reference|This group will be followed according to cardiovascular protocols and will be evaluated as a reference group.
62225018|NCT04070443|EXPERIMENTAL|Induction phase with Ponatinib followed by Imatinib|"Ponatinib (Iclusig®) : Tyrosine Kinase Inhibitor (BCR-ABL); oral (tablets) : 30mg/day during 6 months (induction phase); Takeda \& Incyte Biosciences.~Imatinib (either Glivec® or any generic form) : Tyrosine Kinase Inhibitor (BCR-ABL, ABL, KIT and PDGFRA receptor tyrosine kinases); oral : 400 mg/day during at least 30 months (then, depending of MR4.5)"
62433496|NCT01915381|EXPERIMENTAL|application smartphone-based group|Smartphone-based application group (SG) sample will have a reminder to do Phisical activity everyday where patients will have to select if they have done or they haven´t done physical activity.
62433497|NCT01462695|EXPERIMENTAL|Treatment (sunitinib)|Patients receive sunitinib malate orally (PO) once daily (QD) on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
62799461|NCT06722872|EXPERIMENTAL|Laughter therapy group|Pre-tests were collected 10 days before the therapy began. The elderly participants were introduced individually and informed face-to-face about laughter therapy. Therapy sessions were conducted face-to-face twice a week, with a total of 12 sessions. Each laughter therapy session lasted 50 minutes. Post-tests were collected immediately after the final therapy session. Four weeks later, follow-up tests were also conducted face-to-face.
62225019|NCT03312283|EXPERIMENTAL|QL1205|QL1205 injection (0.5mg) by vitreous injection once a month for three months（D1、D29、D57）
62225020|NCT03312283|ACTIVE_COMPARATOR|Lucentis|Lucentis® injection(0.5mg) by vitreous injection once a month for three months（D1、D29、D57）
62225021|NCT00737971|ACTIVE_COMPARATOR|A|Avastin intravitreal injection D0, Week 4, Week 8
62225022|NCT00737971|ACTIVE_COMPARATOR|B|Triamcinolone intravitreal injection
62225023|NCT00737971|ACTIVE_COMPARATOR|C|Avastin + Triamcinolone intravitreal injection simultaneously
62225024|NCT01550445|NO_INTERVENTION|steroid withdrawal|The clinical outcome after kidney transplantation, under the immunosuppression of steroid withdrawal starting at 3 months post-transplantation using tacrolimus, mycophenolate mofetil, and basilixumab should be analyzed.
62225025|NCT00989131|EXPERIMENTAL|Paclitaxel, micellar (Paclical®)|
62225026|NCT00989131|ACTIVE_COMPARATOR|Paclitaxel, CrEL (Taxol®)|
62225027|NCT02850120||Unconfounded|"All hospital admissions including Tension-free Vaginal Tape (TVT), Trans-obturator tape (TOT) or suprapubic sling (SS) procedures with:~1. no concomitant procedures,~2. any concomitant procedures which were considered unlikely to have an effect on outcomes from their mesh insertion, or~3. only other concomitant procedures which were considered likely to be rescue procedures treating complications caused by the mesh insertion procedure itself."
62225028|NCT02850120||Confounded|All hospital admissions for insertion of Tension-free Vaginal Tape (TVT), Trans-obturator tape (TOT) or suprapubic sling (SS) procedures with concomitant procedures likely to affect outcomes.
62225029|NCT03741452|EXPERIMENTAL|Transversalis fascia plane block|The transversalis fascia plane block will be administrated to this group at end of the surgery under general anesthesia. An intravenous patient-controlled analgesia device within tramadol will be given to the patients postoperatively.
62433498|NCT06542328||Pulmonology|
62433499|NCT06542328||Orthopaedic|
62799462|NCT06722872|NO_INTERVENTION|No intervention group|The control group did not receive laughter therapy; they continued with routine nursing home care. Pre-tests, post-tests, and follow-up tests were collected on the same days as the experimental group. After the follow-up tests were completed, a 30-minute laughter therapy session was provided to control group participants who wished to participate.
62799463|NCT01591941|ACTIVE_COMPARATOR|CON group|Control Group underwent a standard soccer warm-up
62799464|NCT01591941|EXPERIMENTAL|Core-PAC|Experimental took part in the Core position and control movement strategy (Core-PAC) warm-up
62225030|NCT03741452|NO_INTERVENTION|Control group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with tramadol. No block will be performed.
62225031|NCT02050711|OTHER|Usual care|Patients will receive usual care from their general practitioners/pulmonologists.
62417902|NCT06652113|EXPERIMENTAL|hydroxychloroquine and levothyroxine group|Corresponding oral treatment will be initiated after randomization and preconceptually, and continue to the end of pregnancy or until 60 weeks post-randomisation if pregnancy does not occur. Patients in the experimental group will be given a combined oral treatment of hydroxychloroquine (HCQ) and levothyroxine. Hydroxychloroquine sulfate tablets (Fenle, 0.1g) will be given at a total daily dose of 0.2g to 0.4g based on individual weight: patients weighing ≤46kg take HCQ tablets 0.2g/d, patients weighing \>46kg and \<62kg take HCQ tablets 0.3g/d, patients weighing ≥62kg take HCQ tablets 0.4g/d. Levothyroxine sodium tablets (Euthyrox, 50 μg) will be given 12.5μg \~50 μg daily based on patients' TSH levels and weights: TSH ≥ 2.5 mIU/L, the dosage is 50 μg/d; TSH \< 2.5 mIU/L, the dosage is 25 μg/d; when the patient's weight is less than 50kg, the dosage is reduced by 50%.
62417903|NCT06652113|OTHER|levothyroxine group|Corresponding oral treatment will be initiated after randomization and preconceptually, and continued to the end of any pregnancy or until 60 weeks post-randomisation if pregnancy does not occur. Patients assigned in the control group will be given levothyroxine daily. Levothyroxine sodium tablets (Euthyrox, 50 μg) will be given 12.5μg \~50 μg daily based on patients' TSH levels and weights: TSH ≥ 2.5 mIU/L, the dosage is 50 μg/d; TSH \< 2.5 mIU/L, the dosage is 25 μg/d; when the patient's weight is less than 50kg, the dosage is reduced by 50%.
62417904|NCT05013827||Company representatives|
62588804|NCT04707703|EXPERIMENTAL|SOC plus Isavuconazonium sulfate|SOC plus intravenous isavuconazonium sulfate 372 mg every 8 hours for 6 doses followed by 372mg once daily for up to 28 days
62588805|NCT04707703|PLACEBO_COMPARATOR|SOC plus Placebo|SOC plus intravenous placebo every 8 hours for 6 doses followed by once daily for up to 28 days
62588806|NCT04131647|ACTIVE_COMPARATOR|Weight Maintenance|Heart Healthy nutrition, walking, resistance band exercise
62417905|NCT06222879|EXPERIMENTAL|Part A|
62588807|NCT04131647|EXPERIMENTAL|Weight Maintenance + Intermittent Fasting|Heart Healthy nutrition, walking, resistance band exercise and intermittent fasting (2 small meals per day) one day per week for 24 weeks.
62417906|NCT06222879|EXPERIMENTAL|Part B|
62417907|NCT06222879|EXPERIMENTAL|Part C|
62026328|NCT00886158||Solid Organ Transplant Recipients|Solid organ transplant recipients receiving their care at Seattle Children's Hospital
62225032|NCT02050711|EXPERIMENTAL|Pulmonary rehabilitation|Patients will enrol in a 12-week PR program consisting on exercise training (3 times a week) and psychoeducation (once a week).
62225033|NCT00687973|EXPERIMENTAL|Valsartan/amlodipine 160/10 mg|Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.
62588808|NCT06234631|EXPERIMENTAL|Pre - and post-operative CBD|Participants will take 300 milligrams (mg)/day on days 1-36 (150mg twice a day \[b.i.d.\])
62417908|NCT05136664|EXPERIMENTAL|Part A: Patiromer|Part A: 4-week, single-arm patiromer treatment phase (4 weeks)
62417909|NCT05136664|PLACEBO_COMPARATOR|Part B: Placebo|Part B: 8-week randomized, parallel group, placebo-controlled withdrawal phase
62417910|NCT05136664|EXPERIMENTAL|Part B: Patiromer|Part B: 8-week randomized, parallel group, placebo-controlled withdrawal phase
62417911|NCT06274853|EXPERIMENTAL|SAD Cohort 1|A single oral dose of 100 mg GS-441524 under fasted conditions
62417912|NCT06274853|PLACEBO_COMPARATOR|SAD Placebo|Matching Placebo under fasted conditions
62417913|NCT06274853|EXPERIMENTAL|SAD Cohort 2|A single oral dose of 300 mg GS-441524
62417914|NCT06274853|EXPERIMENTAL|SAD Cohort 3|A single oral dose of 600 mg GS-441524
62417915|NCT06274853|EXPERIMENTAL|SAD Cohort 4|A single oral dose of 1000 mg GS-441524
62588809|NCT06234631|EXPERIMENTAL|Pre-operative placebo plus post-operative CBD|Participants will take placebo prior to surgery days 1-7, then days 8-36 participants will take CBD 300 milligrams (150mg twice a day \[b.i.d.\])
62588810|NCT06234631|EXPERIMENTAL|Pre-operative CBD plus post-operative placebo|Participants will take CBD 300 milligrams (mg) /day prior to surgery on days 1-7 (150mg twice a day \[b.i.d.\]), then days 8-36 will take placebo twice a day \[b.i.d.\]
62588811|NCT06234631|PLACEBO_COMPARATOR|Pre- and post-operative placebo|Participants will take placebo on days 1-36 twice a day \[b.i.d.\]
62588812|NCT01858116|EXPERIMENTAL|[68Ga]ABY-025|
62588813|NCT00526357|OTHER|A|Of the 24 asthmatic subjects, 12 will be enrolled who are taking beta2 agonists alone to treat their asthma
62588814|NCT00526357|OTHER|B|Of the 24 asthmatic subjects, 12 will be enrolled who are taking beta2 agonists and inhaled steroids to treat their asthma
62026329|NCT02256462|EXPERIMENTAL|Interventional|Adalimumab levels and antibodies will be obtained with every laboratory examination (every 2 months, except for the first 2 visits). Dose or interval adjustment will be performed as followed:when trough levels results taken prior to ADA injection are above 5 µg/ml no change in dosing is required. Detectable levels below 5 µg/ml will result in interval decrease to every week. If levels are still below 5 µg/ml dose will be increased to 40 mg (in patients receiving less than 40 mg). Undetectable levels below 0.3µg/ml will be followed by antibodies (ATAs) measurement. If ATAs are persistently above 8 µg/ml the patient will discontinue the study. If ATAs are below 8 µg/ml ADA intervals will be decreased to every week.
62026330|NCT02256462|NO_INTERVENTION|Clinical|"Adalimumab levels and antibodies will be requested based on physician judgment when there are signs of loss of response (LOR). Dose and interval adjustment will be performed according to clinical measures: Following physician decision trough levels and ATAs will be collected and further adjustment may be considered according to results. Interval adjustment will be performed as described for the interventional arm.~LOR is defined as PCDAI equal or higher than 10 or CRP higher than 0.5 mg/dl (5mg/l) and/or Fecal calprotectin higher than 150 mcg/gr (If lower than 150 at randomization)."
62026331|NCT04820764|EXPERIMENTAL|CardioMech Mitral Valve Repair System (MVRS)|
62026332|NCT01408160|EXPERIMENTAL|Treatment (Combotox, cytarabine)|Patients receive high-dose cytarabine IV over 2-3 hours every 12 hours on days 1-3 and deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins IV over 4 hours on days 8, 10, and 12. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62026333|NCT05644548||Hypertension|No intervention
62026334|NCT05644548||Diabetes mellitus|No intervention
62026335|NCT05644548||Dyslipidemia|No intervention
62026336|NCT00524134|EXPERIMENTAL|1|Carvedilol-CR up to 80mg daily, used as a P-glycoprotein inhibitor to increase drug concentrations in specific regions of the brain.
62026337|NCT06634758|EXPERIMENTAL|"intervention"|When the studies in the literature are examined, it has been presented that nursing care based on Watson's Human Caring Model increases the quality of life in various diagnosed patient groups, reduces depression and pain, increases sleep quality and provides glycemic control . However, to our knowledge, no research has been conducted on individuals with MS based on Watson's Human Caring Model. Based on the idea that the model to be used will cause a positive change in the quality of life of MS patients, it is anticipated that this model-based research, which is preferred, can guide the treatment, support and counseling services that nurses provide to MS patients and strengthen nursing care.
62026338|NCT05300724||Intermediate AMD|Participants with iAMD will be evaluated for the progression of iAMD to more advanced atrophic AMD stages, such as nascent geographic atrophy (nGA) or incomplete retinal pigment epithelium and outer retinal atrophy (iRORA), and subsequently from nGA or iRORA to complete retinal pigment epithelium (cRORA) and outer retinal atrophy or geographic atrophy (GA), on Day 1 and thereafter every 12 weeks up to the end of the Observation Period, approximately 3 years.
62026339|NCT01156753|EXPERIMENTAL|CDX-011|
62225034|NCT00687973|ACTIVE_COMPARATOR|Atenolol/amlodipine 100/10 mg|Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.
62026340|NCT01156753|ACTIVE_COMPARATOR|"Investigator's Choice chemotherapy"|
62026341|NCT04780204|EXPERIMENTAL|Antiviral Treatment|Tenofovir Alafenamide 25mg once daily , Oral
62026342|NCT04780204|NO_INTERVENTION|Matched Historical Controls|Patients who did not receive antiviral treatment during their follow-up period, and matched with the treatment group in a 1:2 ratio according to their baseline characteristics
62225035|NCT00913315|EXPERIMENTAL|tolterodine + tamsulosin|
62225036|NCT00913315|ACTIVE_COMPARATOR|tamsulosin + placebo|
62225037|NCT01094379|ACTIVE_COMPARATOR|Standard lap chole|Laparoscopic cholecystectomy using four entry sites to the abdominal cavity
62417916|NCT06274853|EXPERIMENTAL|SAD Cohort 5|Optional Cohort - dose TBD
62417917|NCT06274853|EXPERIMENTAL|Food Effect|Randomized, balanced, single-dose, two-treatment (fed vs fasting), two-period, two sequence crossover study part in healthy human subjects Treatment A: a single oral dose of TBD mg GS-441524 under fasted conditions Treatment B: a single oral dose of TBD mg GS-441524 under fed conditions
62225038|NCT01094379|ACTIVE_COMPARATOR|Single incision lap chole|Laparoscopic cholecystectomy using one entry site to the abdominal cavity
62225039|NCT06398977|ACTIVE_COMPARATOR|Dagliflozin group|Patients in this group were treated with dagliflozin 10 mg, oral once daily, for 24 weeks, in addition to receiving basic treatments such as peritoneal dialysis and antihypertensive and hypoglycemic therapy.
62225040|NCT06398977|NO_INTERVENTION|Control group|This group of patients received peritoneal dialysis and basic treatments such as antihypertensive and hypoglycemic therapy.
62225041|NCT05007808|EXPERIMENTAL|G001 Topical Gel|G001 Topical Gel, 4 grams applied to the index knee four times a day over 4 weeks.
62225042|NCT05007808|PLACEBO_COMPARATOR|Vehicle Topical Gel|Vehicle Topical Gel, 4 grams applied to the index knee four times a day over 4 weeks.
62417918|NCT06274853|EXPERIMENTAL|MAD Cohort 1|Multiple oral doses of TBD mg GS-441524under fasted or fed conditions twice daily for 5 days (Days 1 to 5) and only a morning dose on Day 6
62417919|NCT06274853|EXPERIMENTAL|MAD Cohort 2|Multiple oral doses of TBD mg GS-441524under fasted or fed conditions twice daily for 5 days (Days 1 to 5) and only a morning dose on Day 6
62417920|NCT06274853|EXPERIMENTAL|MAD Cohort 3|Multiple oral doses of TBD mg GS-441524under fasted or fed conditions twice daily for 5 days (Days 1 to 5) and only a morning dose on Day 6
62417921|NCT06274853|PLACEBO_COMPARATOR|MAD Placebo|Matching Placebo under fasted or fed conditions
62417922|NCT06702670|EXPERIMENTAL|Treatment with Diphenhydramine|
62417923|NCT06702670|ACTIVE_COMPARATOR|Usual Care|
62417924|NCT05811260|ACTIVE_COMPARATOR|Myofascial Release|Group A (Myofascial release technique) on low back 3 repetitions (30 second rest between reps), lasting for 30 s for each myofascial track for 1 set to targeted muscles (plantar fascia, gastrocnemius, hamstrings, and erector spinae). The position will be held for 10-15 seconds when a pain point is found lacrosse ball excellent for this type of massage because their surface area is much less than that of foam rollers.
62417925|NCT05811260|ACTIVE_COMPARATOR|Post facilitation stretch|Group B (Post facilitation stretch) static stretching exercises for the low back (plantar fascia, gastrocnemius, hamstrings, and erector spinae). Static stretching involved 3 sets of 3 repetitions for each muscle with a 30-second hold and 30-second rest interval for each repetition.
62417926|NCT04824560|OTHER|BP Education|All participants enrolled receive blood pressure education.
62417927|NCT06703632|OTHER|PreveCol test after a FOBT positive result|Average-risk participants from the colorectal cancer screening programme with FOBT positive result who are eligible to undergo colonoscopy
62417928|NCT06061302|EXPERIMENTAL|Immediate yoga group|20 participants randomized to immediate yoga intervention group will participate together in a weekly 40-minute guided mindful yoga intervention for a total of 12 consecutive weeks. After each session, participants will be asked to complete the Edmonton Symptom Assessment System (ESAS-r) through MyDataHelps app. At the end of each session, participants will be asked additional questions via MyDataHelps such as completion of yoga session on-site or remotely, the length of time they participated in the session, any additional yoga sessions during the past week, and comments regarding the session/intervention. These participants will also complete health-related quality of life (HRQOL) assessment (EORTC QLQ-C30) at baseline, 6 weeks, and 12 weeks during active yoga intervention.
62417929|NCT06061302|ACTIVE_COMPARATOR|Waitlist yoga group (delayed yoga intervention group)|20 participants randomized to this group will start the yoga intervention at week 13 and participate in 12 consecutive weeks of weekly 40 minute guided mindful yoga. Participants in this group will complete ESAS-r every 3 weeks and EORTC QLQ-C30 every 6 weeks for the first 12 weeks. These participants will also complete HRQOL assessment (EORTC QLQ-C30) at baseline, 6 weeks, and 12 weeks during active yoga intervention, weeks 13-24.
62417930|NCT06700772|EXPERIMENTAL|open sinus lifting using bone marrow aspirate from maxillary tuberosity mixed with bovine bone|Under local anesthesia a 20 gauge needle that will be inserted inside tuberosity until aspiration is positive and then the aspirate will be collected in heparin treated tube (1ml anticoagulant citrate dextrose) for each 15 ml of aspirate The aspirate will be centrifuged at 3000 rpm for 10 minutes to separate the BMAC The upper layer containing the plasma and platelet will be separated using sterile peptide tube leaving the BMAC Mixing BMAC with bovine bone (2cc of bio-oss) and it will be applied in grafted sinus
62417931|NCT06700772|ACTIVE_COMPARATOR|Open sinus lifting using autogenous bone mixed with bovine bone|After injection of local anesthesia a crystal incision will be done from a point corresponding to occlusal surface along external oblique ridge and extending anteriorly and inferiorly through the buccal mucosa Subperiosteal dissection will be done to expose the retromolar area ACM bur will be used to collect autogenous bone and mixing it with bovine bone 50 : 50 Then this mixture will be packed into the grafted area
62417932|NCT06703021|EXPERIMENTAL|Sentinel|Participants will receive GSBR-1290 or Placebo administered orally.
62417933|NCT06703021|EXPERIMENTAL|Cohort 1a|Participants will receive GSBR-1290 or Placebo administered orally.
62417934|NCT06703021|EXPERIMENTAL|Cohort 1b|Participants will receive GSBR-1290 or Placebo administered orally.
62417935|NCT06703021|EXPERIMENTAL|Cohort 1c|Participants will receive GSBR-1290 or Placebo administered orally.
62417936|NCT06562439|NO_INTERVENTION|Developmental Screening|Participants in this group will complete developmental screening at 9, 18, and 30 months of age.
62417937|NCT06562439|EXPERIMENTAL|Developmental Screening + Home-Based Intervention|Participants in this group will complete developmental screening at 9, 18 and 30 months of age and monthly home visits with the family using the Parents as Teachers curriculum.
62417938|NCT04057898|EXPERIMENTAL|MN-166|Subjects will take MN-166 10 mg capsules, up to 50 mg twice a day for 12 months.
62417939|NCT04057898|PLACEBO_COMPARATOR|placebo|Subjects will take up to 5 matching placebo capsules twice a day for 12 months.
62417940|NCT05726318|OTHER|Culture-directed antibiotic|Participants will be directed to refrain from taking antibiotics until results of urine culture are reported, which is expected within 48-72h.
62225043|NCT00508703||CT Scan + IMRT Radiation Therapy|
62225044|NCT01820013|EXPERIMENTAL|Customised Orthoses|Customised Dynamic Elastomeric Fabric Orthoses (DEFO)
62225045|NCT01820013|ACTIVE_COMPARATOR|Rigid 'off the shelf' pelvic support|Serola Sacroiliac Belt.
62225046|NCT05222724|EXPERIMENTAL|Tachifene|paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
62225047|NCT05222724|ACTIVE_COMPARATOR|Brufen|ibuprofen 600 mg, film coated tablets. One tablet 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
62225048|NCT05275725|EXPERIMENTAL|Sildenafil|
62588815|NCT06478433|EXPERIMENTAL|Munatoril|"Experimental: Munatoril From day 1 to day 7 postoperatively: SID administration of Munatoril® Aerosol Combo by aerosol therapy, in the morning + TID administration of an over-the-counter sterile isotonic solution by Lavonase® syringe.~From day 8 to day 14 postoperatively:~SID administration of Munatoril® Aerosol Combo via Lavonase® syringe, in the morning + TID administration of an over-the-counter sterile isotonic solution, via Lavonase® syringe.~- From postoperative day 15 to day 29: TID administration via Lavonase® syringe of an isotonic solution obtained by diluting Munatoril® Aerosol Combo hypertonic solution"
62225049|NCT04058366|EXPERIMENTAL|ELX/TEZ/IVA|"Part A: Participants received ELX (elexacaftor) 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period for 96 weeks.~Part B: Participants from certain countries participated in Part B and continued to receive ELX 200 mg qd /TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 48 weeks."
62225050|NCT01007643|EXPERIMENTAL|Wii Fit (TM) Interactive Video Game|Wii Fit (TM) Interactive Video Game
62225051|NCT01007643|ACTIVE_COMPARATOR|Traditional Home Exercise Program|Traditional Home Exercise Program
62225052|NCT01210664|EXPERIMENTAL|Polyclonal Regulatory T Cells|Patients with Type 1 Diabetes Mellitus will have their regulatory T cells (Tregs) isolated by researchers and receive Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells by infusion
62225053|NCT02440009|ACTIVE_COMPARATOR|Glucocorticoid group|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
62225054|NCT02440009|EXPERIMENTAL|Itraconazole plus glucocorticoid group|Oral itraconazole 200 mg BD for 6 months AND oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma.
62225055|NCT02311868|EXPERIMENTAL|SYNBIOTIC|Patients of this group assumed Probinul-Neutro® po 5g three times a day for 30 day
62225056|NCT02311868|PLACEBO_COMPARATOR|Placebo|patients of this group received 5g of placebo 3 times a day for 30 days
62417941|NCT05726318|ACTIVE_COMPARATOR|Empiric antibiotic|Antibiotic Protocol. For participants in the empiric Rx arm, we will choose an antibiotic with consideration of patient reported allergies, current medications and current IDSA guidelines. If there is a contraindication to the first antibiotic on the list they will progress to the next option until a suitable selection is achieved.
62417942|NCT02316743|EXPERIMENTAL|Levothyroxine|Levothyroxine supplementation
62417943|NCT04923906|EXPERIMENTAL|Aumolertinib and platinum-based chemotherapy|
62417944|NCT04923906|ACTIVE_COMPARATOR|Aumolertinib|
62026343|NCT03007823|EXPERIMENTAL|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62026344|NCT03007823|NO_INTERVENTION|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62026345|NCT03049046|ACTIVE_COMPARATOR|CC100 250 mg|CC100 250 mg once daily by mouth for 7 days
62799465|NCT05653661|EXPERIMENTAL|Treatment (AP160-complex)|Patients receive AP160-complex IV on study. Patients in the dose-escalation cohort undergo computed tomography/magnetic resonance imaging (MRI) scans, tissue biopsies, and collection of blood samples throughout the trial. Patients in the dose-expansion cohort undergo MRI scan during screening, collection of blood samples during screening and on study, and tissue biopsies throughout the trial.
62225057|NCT02304796|EXPERIMENTAL|Unified CBT|Group psychotherapy according to the principles of the Cognitive-Behavioral Unified Protocol for Trans-diagnostic Treatment of Emotional Disorders (Barlow et al., 2011).
62225058|NCT02304796|EXPERIMENTAL|Combined CBT-DMT|Group psychotherapy combining cognitive-behavioral principles and techniques with dance/movement therapy techniques.
62225059|NCT04622774|EXPERIMENTAL|IMGC936|Single-arm. IMGC936 administered every 3 weeks.
62225060|NCT01227577|EXPERIMENTAL|Nilotinib|Participants received 300 mg twice daily (b.i.d.). Dose increases to 400 b.i.d. were permitted, per Investigator's discretion.
62225061|NCT03271021|EXPERIMENTAL|FMX101, 4% minocycline foam|FMX101, 4% minocycline foam applied topically once daily for 12 weeks
62225062|NCT03271021|PLACEBO_COMPARATOR|Vehicle foam|Vehicle foam applied topically once daily for 12 weeks
62225063|NCT04782466|EXPERIMENTAL|Intervention|The participant receives the intervention immediately following baseline measurements.
62225064|NCT04782466|OTHER|Waitlist attention-control|The participant receives the control condition for 6 months following baseline measurements. After 6 months, the baseline measurements are repeated and then the participant receives the intervention.
62225065|NCT00763737|EXPERIMENTAL|FETO|prenatal FETO at 30-31+6 weeks and removal at 34-34+6 wks, followed by standardized postnatal care
62225066|NCT00763737|NO_INTERVENTION|Expectant management|expectant management during pregnancy followed by standardized neonatal care
62225067|NCT02662101|EXPERIMENTAL|Single arm, exsalt application|
62225068|NCT01601886||Before SUPPORT|01/03-06/05
62225069|NCT01601886||During SUPPORT recruitment|07/05-02/09
62225070|NCT01601886||After SUPPORT|03/09-06/10
62225071|NCT01882933|EXPERIMENTAL|Curative Gastrectomy + HIPEC|Curative gastrectomy with D1-D2 lymph node dissection + HIPEC with oxaliplatin
62225072|NCT01882933|OTHER|Curative Gastrectomy|Curative gastrectomy with D1-D2 lymph node dissection
62225073|NCT02445001|EXPERIMENTAL|ICG loaded erythrocytes|Ability to directly visualize erythrocyte dynamics within the retinal and choroidal microcirculations would facilitate focused investigations into the relationships between vasomotion (i.e., pulsatile erythrocyte movement through capillaries) and oxygen distribution to localized tissue regions.
62225074|NCT05373160||Healthy young group|Individuals who are 18-35 years, did not diagnosed with musculoskeletal disorder, and volunteers
62225075|NCT01105754|NO_INTERVENTION|Standard Care|Parents of children in the standard care group will complete the baseline assessment, but no asthma prompt will be created for either the caregiver or provider, and no information regarding the interview will be shared with the provider. After the baseline assessment, the office visit will proceed according to usual care.
62225076|NCT01105754|EXPERIMENTAL|Multifaceted Prompting Intervention|Multifaceted Prompting Intervention
62225077|NCT01508715|ACTIVE_COMPARATOR|Concentric exercise group|The participants in this group will perform the intervention exercises by actively completing the lifting portion of the resistive shoulder exercises. The physical therapist will then perform the lowering portion of the exercise for the participant.
62225078|NCT01508715|EXPERIMENTAL|Eccentric exercise group|The participants in this group will actively perform the lowering portion of the resistive shoulder exercises in the intervention. The physical therapist will perform the lifting portion of the exercise for the participant.
62026346|NCT03049046|ACTIVE_COMPARATOR|CC100 500 mg|CC100 500 mg once daily by mouth for 7 days
62225079|NCT01952054|EXPERIMENTAL|Denosumab|Participants receive a single subcutaneous (SC) administration of Denosumab 120 mg every 4 weeks (+/- 5days). Starting week 5, in addition to receiving Denosumab every 4 weeks, participants receive a hormonal agent chosen by each physician, excluding the agent that participants received at adjuvant therapy setting.
62225080|NCT01677897|EXPERIMENTAL|Metformin|Metformin 2x1000mg orally per day
62225081|NCT00760006|ACTIVE_COMPARATOR|Unasyn Antibiotic Arm|Unasyn® is a parenteral antibiotic that combines ampicillin with sulbactam, a beta-lactamase inhibitor. All subjects enrolled in the study will receive a single dose of antibiotic or saline solution (placebo control) intravenously, as the IV will already be in place as standard of care for surgery. The study aims to assess the efficacy of the prophylactic antibiotic in cleft surgery to: decrease the incidence of surgical site infections, speed the progression of postoperative healing, improve the final quality of wound healing achieved, and decrease the rate of palatal fistula formation.
62225082|NCT00760006|PLACEBO_COMPARATOR|Saline Placebo Arm|Saline Placebo. All subjects enrolled in the study will receive a single dose of antibiotic or saline solution (placebo control) intravenously, as the IV will already be in place as standard of care for surgery. This will act as the placebo control.
62026347|NCT03049046|ACTIVE_COMPARATOR|CC100 1000 mg|CC100 1000 mg once daily by mouth for 7 days
62588816|NCT06478433|ACTIVE_COMPARATOR|Control|"Active Comparator: Control Day 1 to day 7 postoperative: SID administration of Hypertonic Solution by aerosol therapy, in the morning + TID administration of an over-the-counter sterile isotonic solution by Lavonase® syringe.~Postoperative day 8 to day 14:~SID administration of hypertonic solution via Lavonase® syringe, in the morning + TID administration of an over-the-counter sterile isotonic solution, via Lavonase® syringe.~- Postoperative day 15 to day 29: TID administration via Lavonase® syringe of an isotonic solution."
62588817|NCT01911481|EXPERIMENTAL|hydration|after recruitment the women in hydration group will be invited to drink 2 litres of water,in 2 hours
62588818|NCT01911481|NO_INTERVENTION|control|
62417945|NCT06180577||Adolescent Nerivio Users|Adolescent with migraine who used Nerivio at least once
62588819|NCT05744310|ACTIVE_COMPARATOR|ALS patients that choose life prolonging treatment with LTMV and their families|
62588820|NCT05744310|ACTIVE_COMPARATOR|ALS patients that decline life prolonging treatment with LTMV and their families|
62588821|NCT06662474|ACTIVE_COMPARATOR|cognitive stimulation arm|will engage in exercises like sudoku, word games, and painting by numbers for 30 minutes per day, three days per week, for a duration of 12 weeks
62799466|NCT02485132||T2DM at SU initiation|T2DM newly prescribed a SU
62799467|NCT04320017||COVID-19 patients|Patients diagnosed with COVID-19 by PCR done on nasal sample.
62799468|NCT02637765|NO_INTERVENTION|Control Group|Usual Physical Activity
62799469|NCT02637765|EXPERIMENTAL|Intervention Group|8-week increased physical activity program
62799470|NCT00896298|ACTIVE_COMPARATOR|1 Leptin|Active Comparator for 4 months, then for 8 months.
62799471|NCT00896298|PLACEBO_COMPARATOR|2 Sugar pill|Placebo for 4 months, then active comparator for 8 months.
62799472|NCT01649934|NO_INTERVENTION|Scheduling as Usual|Participants will be subject to the current appointment scheduling procedures.
62799473|NCT01649934|EXPERIMENTAL|Contact Clinic|This group will be required to contact the clinic themselves to make appointments.
62799474|NCT01649934|EXPERIMENTAL|Implementation Intentions|This group will create Implementation Intentions to contact the clinic to make their appointments and to attend those appointments.
62026348|NCT03049046|PLACEBO_COMPARATOR|Placebo|Placebo once daily by mouth for 7 days
62588822|NCT06662474|ACTIVE_COMPARATOR|psychoeducation and cognitive stimulation arm|will engage in exercises like sudoku, word games, and painting by numbers for 30 minutes per day, three days per week, for a duration of 12 weeks and also hold open group meetings for psychoeducation (1 meeting every 2 weeks, 6 meetings in total).
62799475|NCT04254666|OTHER|Physical Literacy & Food Literacy Intervention|This is a pilot project to assess the feasibility of a physical literacy and food literacy intervention for adolescents with ID ages 12-16 years.
62799476|NCT04557800|EXPERIMENTAL|DNL151|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (10 days); Part C: Single-dose cohort; Part D: Additional multiple-dose cohort (28 days); Part E Multiple-ascending dose cohorts (14 days)
62799477|NCT04557800|PLACEBO_COMPARATOR|Placebo|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (10 days); Part C: Single-dose cohort; Part D: Additional multiple-dose cohort (28 days); Part E Multiple-ascending dose cohorts (14 days)
62799478|NCT06421038|EXPERIMENTAL|Thyme honey|10 patients will be treated by thyme honey application (100% pure natural honey, applied by themselves) on their ulcers three times a day for 7 days.
62799479|NCT06421038|ACTIVE_COMPARATOR|kenalog in orabase|10 patients will be treated by kenalog in orabase (Triamcinolone acetonide 0.1% in oral paste 5g), three times a day for 7 days only.
62799480|NCT01340586|EXPERIMENTAL|Group A: Apixaban|
62799481|NCT01340586|EXPERIMENTAL|Group B: Apixaban|
62799482|NCT06351150|EXPERIMENTAL|Angiotensin Ⅱ Injection|Angiotensin II injection is administered via central vein, and the drug dosage is adjusted according to Mean Arterial Pressure (MAP), with an allowable dose of 1.25\~160 ng/kg/min. Maximum 168 h.
62799483|NCT06351150|PLACEBO_COMPARATOR|Placebo|The placebo is administered via central vein, and the drug dosage is adjusted according to MAP, with an allowable dose of 1.25\~160 ng/kg/min. Maximum 168 h.
62026349|NCT01757769|EXPERIMENTAL|Silodosin|Silodosin capsule 8 mg daily for 24 weeks
62799484|NCT04544358|EXPERIMENTAL|BAILAMOS©|BAILAMOS© includes a 4-month, twice-weekly dance program. The PI and a professional dance instructor co-developed an extensive BAILAMOS© Dance Manual and class-by-class schedule.
62799485|NCT04544358|NO_INTERVENTION|Control|Randomized to wait list, received BAILAMOS© program after data collection.
62799486|NCT00711672||1|Medical Oncologists treating patients with metastatic colorectal cancer
62799487|NCT00711672||2|Patients with metastatic colorectal cancer receiving re-staging CT scans
62799488|NCT02539901||12-30 months-old deaf children|Children with deafness of bilateral deep perception had : Evaluation of the detection of non-linguistic sounds, Early Social Communication Scale (ECSP) and psychomotor infancy development scale or Lézine Brunet-Revised scale
62799489|NCT02539901||6-9 years-old deaf children|"Free hearing test categorization and NEPSY (two domains: memory and learning and attention and executive functions) in 6-9 years-old deaf child cohort with deafness of bilateral deep perception and carrying a cochlear implant"
62026350|NCT00467870|EXPERIMENTAL|1|750 mg dose of testosterone undecanoate
62026351|NCT00467870|EXPERIMENTAL|2|1000 mg dose testosterone undecanoate
62026352|NCT04458948|EXPERIMENTAL|Hydroxychloroquine and Azithromycin|All subjects receive Hydroxychloroquine and Azithromycin.
62026353|NCT03362554|EXPERIMENTAL|Intervention|
62026354|NCT03362554|NO_INTERVENTION|Control|
62026355|NCT03375619||Participants who received CAR-T cells.|Participants who received CAR-T cells at Froedtert Hospital \& the Medical College of Wisconsin in clinical trials (e.g., NCT05976555, NCT05094206, NCT05990465, NCT03019055 or NCT04186520).
62026356|NCT02896855|ACTIVE_COMPARATOR|Arm A: Placebo + Trastuzumab + Docetaxel|Placebo matched to pertuzumab, trastuzumab (8-milligrams per kilogram \[mg/kg\] loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-milligrams per square meter \[mg/m\^2\]) were administered by intravenous (IV) infusion every 3 weeks until disease progression or unacceptable toxicity.
62026357|NCT02896855|EXPERIMENTAL|Arm B: Pertuzumab + Trastuzumab + Docetaxel|Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles), trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-mg/m\^2) were administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
62225083|NCT03277573|EXPERIMENTAL|Salsalate|Drug: Salsalate 2 tablets twice daily (3,000 mg total daily) by mouth for 12 months
62225084|NCT03277573|PLACEBO_COMPARATOR|Placebo|Drug: Placebo 2 tablets twice daily by mouth for 12 months
62225085|NCT03787082|EXPERIMENTAL|Chlorhexidine Gluconate Mouthwash|rinse with chlorhexidine gluconate 0.12% (15mL) mouthwash before administration of 14N Sodium Nitrate 1,000 mg/11.18 mmol, oral
62026358|NCT03848533|EXPERIMENTAL|melatonin plus metformin|"It will be indicate metformin 850 mg tablets, once a day in the morning (before breakfast) per 90 days.~Will administrate melatonin 5 mg lengthed release capsules, once a day in the night (before bedtime) per 90 days."
62026359|NCT03848533|ACTIVE_COMPARATOR|metformin plus placebo|"It will be indicate metformin 850 mg tablets, once a day in the morning (before breakfast) per 90 days.~Will administrate homologated placebo once a day in the night (before bedtime) per 90 days."
62225086|NCT03787082|PLACEBO_COMPARATOR|Placebo Mouthwash|rinse with placebo mouthwash (15mL) before administration of 14N Sodium Nitrate 1,000 mg/11.18 mmol, oral
62026360|NCT03848533|EXPERIMENTAL|melatonin plus placebo|"It will be indicate homologated placebo once a day in the morning (before breakfast) per 90 days.~Will administrate melatonin 5 mg lengthed release capsules, once a day in the night (before sleep) per 90 days."
62026361|NCT03334123|EXPERIMENTAL|Functional training and cycling|Participants in this group will perform 20 minutes of functional training before dialysis (in the first 8 weeks) and intradialysis cycling exercise during dialysis. Participants will also receive exercise counselling; investigators will teach them how to practice at home by practice and examples given during the 20 minutes of functional training pre-dialysis. In the second phase of additional eight weeks participants will perform the functional training at home on non-dialysis days in addition to intradialysis cycling. Kinesiologist will monitor, advice and motivate them.
62026362|NCT03334123|ACTIVE_COMPARATOR|Cycling|This active control comparator group will perform intradialytic cycling on an adapted ergometer 3 times per week for 4 months without functional training prior to dialysis procedure and without exercise counselling.
62225087|NCT01115751|EXPERIMENTAL|LY2780301|"Part A: daily dosing~Part B (if determined as needed by pharmacokinetic, pharmacodynamic, and safety data): twice daily dosing~Part C: Dose and frequency as determined by Parts A and B of the study."
62225088|NCT04260880||Test group 1|individuals with mild depression
62225089|NCT04260880||Test group 2|individuals with moderate depression
62225090|NCT04260880||control group|systemically healthy individuals
62225091|NCT01944371|EXPERIMENTAL|disulfiram 500mg|500mg disulfiram by mouth per day for 3 days
62417946|NCT06481995|EXPERIMENTAL|Fibrogammin (FXIII)|Women in the intervention group receive FXIII intravenously in addition to the standard of care treatment for PPH. FXIII is administered when blood loss is \> 700 ml. Women weighing \<80 kg receive 1250 IU Fibrogammin®; women weighing 80-99.9 kg receive 1500 IU Fibrogammin®; thus ensuring a dose of 15-20 IU FXIII per kg body weight according to the manufacturer's recommendation.
62026363|NCT03102398|EXPERIMENTAL|Single-arm and Open-label Study|
62026364|NCT02860728|EXPERIMENTAL|Resistance training|Patients with COPD will participate in 4 weeks (12 sessions) of individualized, non-linear, lower body resistance training.
62026365|NCT00811863||1|Subjects with moderate renal insufficiency defined as an eGFR 30-60 mL/min/1.73 m2
62225092|NCT01944371|EXPERIMENTAL|disulfiram 1000mg|1000mg disulfiram by mouth per day for 3 days
62225093|NCT01944371|EXPERIMENTAL|disulfiram 2000mg|2000mg disulfiram per mouth per day for 3 days
62225094|NCT03534323|EXPERIMENTAL|Duvelisib +Venetoclax,|"Duvelisib will be given alone for the first seven days. On day 8 Venetoclax will be added.~* Duvelisib will be administered orally twice daily~* Venetoclax will be administered orally daily~* All patients will be admitted for administration of the initial dose of venetoclax at each dose escalation"
62799490|NCT02539901||12-30 months-old normal hearing children|Evaluation of the detection of non-linguistic sounds in 12-30 months-old normal hearing child cohort
62799491|NCT02539901||6-9 years-old normal hearing children|'Free hearing test categorization' in 6-9 years-old normal hearing child cohort
62417947|NCT06481995|NO_INTERVENTION|Control|Women in the control group will be treat according to the standard of care procedure for PPH.
62417948|NCT01772394|ACTIVE_COMPARATOR|Cognitive Remediation Therapy (CRT)|Active : CRT
62026366|NCT00811863||2|Subjects with severe renal insufficiency defined as an eGFR \<30 mL/min/1.73 m2 and ESRD defined as requiring dialysis
62026367|NCT02715128|ACTIVE_COMPARATOR|real tDCS|anode over electrode position F3, cathode over F4, 20 min, 2mA intensity
62417949|NCT01772394|SHAM_COMPARATOR|Sham Therapy (ST)|Sham : ST
62417950|NCT03528967|EXPERIMENTAL|Arm 1|"Patients going on ASPIRIN 100 mg/day combined with ENOXAPARIN 4000 IU per dat prevention treatment according to randomization:~* Administer Aspirin 100 mg Oral Tablet, Enteric Coated once daily~* Administer the Enoxaparin preventive dose of 4000 IU as a subcutaneous Enoxaparin 40 mg / 0.4 mL Prefilled Syringe once daily~* Start treatment from inclusion visit~* Maintain treatment until the day of delivery, or the appearance of a complication (Retroplacental hematoma (RPH), preeclampsia (PE) , In utero fetal death (IUFD), or Intrauterine growth restriction (IUGR) and its complications)"
62026368|NCT02715128|SHAM_COMPARATOR|sham tDCS|frequency and duration correspondent active tDCS, ramp in and ramp out periods only without intermittent stimulation
62417951|NCT03528967|OTHER|Arm 2|"Patients going on ASPIRIN 100 mg/day prevention treatment alone according to randomization:~* Administer only Aspirin 100 mg Oral Tablet, Enteric Coated once daily~* Administer orally~* Start treatment from inclusion visit~* Maintain treatment until 35 Weeks of Amenorrhea (WA)"
62417952|NCT03576547|EXPERIMENTAL|Treatment (ponatinib, venetoclax, dexamethasone, rituximab)|See Detailed Description
62799492|NCT05089643|EXPERIMENTAL|CA|Anlotinib 10mg Qd D1-14 Capecitabine 1G /m2 Bid D1-14 / Q21D
62026369|NCT00006154|EXPERIMENTAL|A|Patients will receive combination antiretroviral therapy with a protease inhibitor
62026370|NCT00006154|ACTIVE_COMPARATOR|B|Patients will receive combination antiretroviral therapy without a protease inhibitor
62026371|NCT06534476|EXPERIMENTAL|Patient Education|The intervention group was given 40-50 minutes of training.
62026372|NCT06534476|NO_INTERVENTION|Control Group|Routine nursing care was given to hemodialysis patients in this group without any training.
62799493|NCT05364463|EXPERIMENTAL|Ultrasound and hyperemia|Use of ultrasound and hyperemia to puncture radial artery.
62799494|NCT05364463|EXPERIMENTAL|Ultrasound only|Use of ultrasound only to puncture radial artery.
62799495|NCT05364463|EXPERIMENTAL|Hyperemia only|Use of hyperemia and palpation to puncture radial artery.
62799496|NCT05364463|NO_INTERVENTION|Palpation|Use of palpation to puncture radial artery (control group).
62799497|NCT01007357|OTHER|Body MRI healthy volunteers|Body MRI to optimize sequences in healthy individuals and in disorder subjects
62799498|NCT00530738|EXPERIMENTAL|1|treatment with Lipoplus \& Nutriflex plus (commercially available and marketed 2 Chamber Bag)
62799499|NCT00530738|ACTIVE_COMPARATOR|2|treatment with Lipofundin MCT \& Nutriflex plus (commercially available and marketed 2 Chamber Bag)
62799500|NCT02382445|EXPERIMENTAL|Anesthesia depth monitor|Anesthesia depth is aimed to be between BIS 50-60
62026373|NCT02287103|EXPERIMENTAL|Skipping Breakfast (NoB)|The patients in No B will omit the breakfast and will continue the overnight fast until lunch. Will eat only lunch and dinner. In YesB will eat all three meals
62026374|NCT02287103|ACTIVE_COMPARATOR|Eating Breakfast (YesB):|The patients in YesB will eat all three mealswill consume three meals: breakfast, lunch and dinner
62026375|NCT04804358|OTHER|Anorexic women|Anorexic women with or without history of psychological trauma will perform study procedure : sociodemographic and clinical assessments, measurement of cardiac variability and salivary cortisol changes, before, during and after the exposition test.
62026376|NCT05282524|EXPERIMENTAL|Simulated patient|Women recruited from a general population subject to inclusion/exclusion criteria, who will participate at a minimum four times in the study
62026377|NCT05282524|EXPERIMENTAL|Naive patient|Women recruited from a general population subject to inclusion/exclusion criteria, who will participate only once in the study
62026378|NCT05069441||Patients with extubation after a weaning trial|Patients who sucessfully complete a spontaneous breathing trial are enrolled in this group.
62026379|NCT05194397|EXPERIMENTAL|Nicotinamide Riboside (NR)|"Investigators will use Good Manufacturing Process (GMP)-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA). Investigators dose based on body weight, and monitor for adverse effects (AEs).~For individuals with weight \> 72 kg: 900 mg po qd x 16 wks.~For individuals with weight \> 48 kg and ≤ 72 kg: 600 mg po qd x 16 wks.~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 16 wks."
62799501|NCT02382445|SHAM_COMPARATOR|Control group|Anesthesia depth is monitored but blinded to the anesthesiologist
62026380|NCT05194397|PLACEBO_COMPARATOR|Placebo|"Matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule). Doses of placebo will match the body weight schema for dosing of NR. Investigators dose based on body weight, and monitor for adverse effects (AEs).~For individuals with weight \> 72 kg: 900 mg po qd x 16 wks.~For individuals with weight \> 48 kg and ≤ 72 kg: 600 mg po qd x 16 wks.~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 16 wks."
62225095|NCT02649946|EXPERIMENTAL|Covera Vascular Covered Stent following PTA|Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)
62225096|NCT02649946|ACTIVE_COMPARATOR|PTA only using uncoated PTA Balloon|Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.
62225097|NCT03946150||P/FP Ratio|P/FP Ratio is calculated in ARDS Patients retrospectively and analyse whether this new formula with PEEP can appropriately diagnose the Severity of Oxygenation with different levels of PEEP.
62225098|NCT03946150||P/F ratio|P/F ratio is the current Berlin definition of ARDS in Calculating the severity of Oxygenation.
62225099|NCT03059069|EXPERIMENTAL|Glitamin|800mg/day
62417953|NCT03612713|ACTIVE_COMPARATOR|Oxycodone Medication First|one hour before fMRI scan participants will be given a single dose 15mg immediate release oxycodone
62417954|NCT03612713|PLACEBO_COMPARATOR|Placebo First|one hour before fMRI scan participants will be given a single dose placebo.
62417955|NCT04331392|EXPERIMENTAL|Spatial navigation intervention|
62417956|NCT04331392|ACTIVE_COMPARATOR|Educational Videos|
62417957|NCT05670496||Patients|Patients at risk, suspected of having, have a history of, or currently have a diagnosed hearing, balance or communication disorder.
62588823|NCT06662474|PLACEBO_COMPARATOR|placebo|is considered a control group, consisting of people who maintained their lifestyle up until their inclusion in the study without following additional measures
62588824|NCT05320835|EXPERIMENTAL|Experimental|behavioral training with 6 sessions
62588825|NCT05320835|ACTIVE_COMPARATOR|comparison|Attention control
62225100|NCT03059069|PLACEBO_COMPARATOR|Placebo|same shape, color, size tablet as Glitamin
62225101|NCT01452321|PLACEBO_COMPARATOR|Sham rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of sham (placebo) rTMS delivered to the left dorsolateral prefrontal cortex.
62417958|NCT00266461|EXPERIMENTAL|TU-100 7.5g/day|Subjects will be randomized to TU-100 7.5g, 15g, or no active treatment group. Subjects will take a daily dose divided into 3 times a day.
62417959|NCT00266461|EXPERIMENTAL|TU-100 15g/day|Subjects will be randomized to TU-100 7.5g, 15g, or no active treatment group. Subjects will take a daily dose divided into 3 times a day.
62417960|NCT00266461|NO_INTERVENTION|Water|Subjects will be randomized to TU-100 7.5g, 15g, or no active treatment group. Subjects will take a daily dose divided into 3 times a day.
62588826|NCT03482297|EXPERIMENTAL|Automated Abdominal Binder|Participants will be studied on three separate study days, two days apart: one day for baseline measurements (placebo pill t.i.d), one day for treatment with 10 mg midodrine t.i.d (standard of care), and one day for treatment with the automated abdominal binder combined with placebo pill t.i.d The automated abdominal binder will be placed during the morning orthostatic trial on the active/sham binder study day. The binder will inflate automatically (\~40 mmHg) every time the participant stands up throughout the study day.
62417961|NCT04372563||healthy|Healthy patients with normal aortic dimensions
62417962|NCT04372563||ascending aortic dilation 45-55, operated on|patients with ascending aortic dilation 45-55, tricuspid aortic valves operated on
62417963|NCT04372563||ascending aortic dilation 45-55, non operated on|patients with ascending aortic dilation 45-55, tricuspid aortic valves non operated
62417964|NCT06704061|EXPERIMENTAL|Online Yoga|Postures, meditation, breathing exercises
62417965|NCT06704061|ACTIVE_COMPARATOR|Acceptance and Commitment Therapy|Behavioral medicine
62799502|NCT04014283|ACTIVE_COMPARATOR|BRCA(+) Selenium deficiency|Placebo: 100 Supplement: 100
62799503|NCT04014283|ACTIVE_COMPARATOR|BRCA(+) Selenium excess|Diet modification: 500 Observation: 500
62799504|NCT04014283|ACTIVE_COMPARATOR|BRCA(-) Selenium deficiency|Placebo: 900 Supplement: 900 Diet modification: 900 Observation: 900
62799505|NCT04014283|ACTIVE_COMPARATOR|BRCA(-) Selenium excess|Diet modification: 1100 Observation: 1100
62799506|NCT04014283|ACTIVE_COMPARATOR|BRCA(+) Selenium excess, age > 50|Diet modification: 200 Observation: 200
62799507|NCT04093713|OTHER|participants|participants are subjected to a novel technique to block the inferior alveolar nerve depending on extraoral landmarks
62225102|NCT01452321|ACTIVE_COMPARATOR|Active rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of active rTMS delivered to the left dorsolateral prefrontal cortex.
62225103|NCT04928430|EXPERIMENTAL|XAV-19|XAV-19
62417966|NCT01950572||1/Eligible cancer diagnosis|Subjects with mesothelioma, thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers
62799508|NCT00876161|EXPERIMENTAL|DAS181|
62799509|NCT00876161|PLACEBO_COMPARATOR|Lactose|
62799510|NCT00005961|EXPERIMENTAL|Arm I|Patients receive O6-benzylguanine IV over 1 hour, followed 1 hour later by carmustine IV over 1 hour on day 1. Treatment continues every 6 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
62225104|NCT04928430|PLACEBO_COMPARATOR|Placebo|
62225105|NCT02970474|OTHER|All Participants|All participants will undergo the same schedule. Each participant will be fitted with a conventional and a 3D printed bolus prior to receiving radiation therapy. Each bolus will be assessed for optimal dose distribution of the radiation to the tumor through computer stimulation. The bolus, either conventional or 3D printed, that is found to be superior will be used for the actual radiation therapy treatment.
62225106|NCT02091648|EXPERIMENTAL|I Can Cope Intervention|"Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques."
62225107|NCT02091648|ACTIVE_COMPARATOR|Standard Education Intervention|"this group will receive the standard American Lung Association Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute recommendations for asthma education."
62417967|NCT00001238||Disease Category I|Patients, biologic family members with a suspected or an established diagnosis of an inherited urologic malignancy in which the disease gene is known, including VHL and HPRC
62799511|NCT05306587||Multiple Myeloma|40 patients with Multiple Myeloma in Department of Hematology at Odense University Hospital, Denmark
62799512|NCT02532608|EXPERIMENTAL|Acute sleep deprivation|Registration of habitual sleep and sleep after sleep deprivation
62225108|NCT02091648|NO_INTERVENTION|No treatment control|"This group will receive no treatment during the course of the study and will have the option to receive the Open Airways program after their participation in the study is complete."
62417968|NCT00001238||Disease Category II|Patients and biologic family members with a suspected or an established diagnosis of an inherited urologic malignancy in which the disease gene is not yet known
62799513|NCT01076959||Humira|The sponsor was required to include all patients diagnosed with rheumatoid arthritis and who were treated Humira in routine medical practice during the review period by the PMDA. The safety analysis set included all patients who met all eligibility criteria and received at least one dose of Humira. The full analysis set included all patients who were treated with Humira for at least 2 weeks and had complete DAS 28 assessments at baseline and at least one other time point.
62799514|NCT01409447|EXPERIMENTAL|Biphasic osteochondral composite|feasibility study for the new medical device \& technique
62225109|NCT02872831|ACTIVE_COMPARATOR|22G SharkCore™ needle|Covidien has recently released a novel SharkCore™ Fine Needle Biopsy (FNB) system for EUS-guided tissue acquisition of solid gastrointestinal lesions. With its unique bevel design, this needle has shown promising results to acquire histologic tissue as per oral communication with physicians around the country
62417969|NCT00001238||Disease Category III|Patients and biologic family members with a urologic malignant disease of suspected, but not proven genetic etiology
62417970|NCT05092802|EXPERIMENTAL|HLX208|
62417971|NCT04218344||Acute Coronary Syndrome - Iscaemia|Patients who present with chest pain, undergo emergency angiogram and receive a cardiac stent.
62417972|NCT04218344||Acute Coronary Syndrome - Non-Ischaemic|Patients who present with chest pain but angiography reveals normal coronary arteries.
62417973|NCT05900531|EXPERIMENTAL|K-757 (Panel A)|
62799515|NCT01523418||Group 1|
62417974|NCT05900531|EXPERIMENTAL|K-757 (Panel B)|
62417975|NCT05900531|EXPERIMENTAL|K-757 + sitaglipitin (Panel C)|
62225110|NCT02872831|ACTIVE_COMPARATOR|22G BNX EUS-FNA needle|The standard 22G BNX Endoscopic Ultrasound Fine needle aspiration (Beacon Endoscopic, Newton, MA) needle is routinely used for the evaluation of solid mass lesions in the pancreas and gastrointestinal tract.
62026381|NCT05194397|EXPERIMENTAL|Exercise Intervention and NR|"The exercise program consists of at-home training sessions including: aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strength training exercises.~Participants in this arm will receive both the Exercise Intervention and the NR."
62799516|NCT06279455|NO_INTERVENTION|Control Group|"Pregnant women in the control group were not trained and routine follow-up was performed in the outpatient clinic.~Female Sexual Function Index (FSFI) and International Consultation on Incontinence Questionnaire-Female Lower Urinary Tract Symptoms Long Form (ICIQ-FLUTS LF) at 18-20 weeks of gestation, Mid-term Evaluation Form at 26 weeks of gestation and FSFI and ICIQ-FLUTS LF at 32 weeks of gestation were applied to pregnant women in the control group participating in the study. Data on the birth process were collected between 3-7th days after birth with the Birth Process Follow-up Form."
62026382|NCT05194397|EXPERIMENTAL|Exercise Intervention and Placebo|"The exercise program consists of at-home training sessions including: aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strength training exercises.~Participants in this arm will receive both the Exercise Intervention and the Placebo"
62026383|NCT00936364|EXPERIMENTAL|Group I (Stage I of study)|Patients fast for 24 hours on day -1
62799517|NCT06279455|EXPERIMENTAL|Experimental Group|"Two sessions of training were given using the Pelvic Floor Health \& Sexual Life in Pregnancy Training Booklet and the pelvic floor muscle exercise training video developed by the researcher between 18-20 weeks of pregnancy. Before the training, the FSFI and the ICIQ-FLUTS LF were administered to the pregnant women. Pregnant women were asked to perform pelvic floor muscle exercises, 3 sets a day, 3 days a week, for 12 weeks, starting from the 20th week of pregnancy, and record them in the Pelvic Floor Muscle Exercise Follow-up Form created by the researcher. By scanning the literature, 1 set of exercise was determined as 8-12 slow contractions (6-8 seconds) followed by 3-4 fast contractions (1 second)."
62417976|NCT05900531|EXPERIMENTAL|K-757 and K-833 (Panel D)|
62799518|NCT03626961||discharge|patients discharged from icu
62799519|NCT03626961||readmission|patients readmitted icu in 48 hours after icu discharge
62799520|NCT01463241|OTHER|BASIC treatment|As an open trial, all participants in this study will receive the BASIC treatment.
62799521|NCT00268840|EXPERIMENTAL|unique|Taxotère - Gemzar
62799522|NCT03368365|OTHER|Ventilotel ®|Using of the spirometer of Aqsitania company, Ventilotel ®.
62417977|NCT05900531|EXPERIMENTAL|K-757 and K-833 (Panel E)|
62417978|NCT05900531|PLACEBO_COMPARATOR|Panel A|
62417979|NCT05900531|PLACEBO_COMPARATOR|Panel B|
62799523|NCT06359717||164 new diagnoses, 108 BCR, and 171 follow-up|1. 164 new diagnoses. 2.108 BCR. 3. 171 follow-up
62799524|NCT03956550|EXPERIMENTAL|REGN5069 Low Dose|Randomized in a 1:1:1 ratio
62799525|NCT03956550|EXPERIMENTAL|REGN5069 High Dose|Randomized in a 1:1:1 ratio
62799526|NCT03956550|EXPERIMENTAL|Matching Placebo|Randomized in a 1:1:1 ratio
62026384|NCT00936364|EXPERIMENTAL|Group II (Stage I of study)|Patients fast for 48 hours on days -2 and -1
62417980|NCT05900531|PLACEBO_COMPARATOR|Panel C (+ sitagliptin)|
62417981|NCT05900531|PLACEBO_COMPARATOR|Panel D|
62417982|NCT05900531|PLACEBO_COMPARATOR|Panel E|
62417983|NCT06201598||Patients treated with p64MW HPC and p48MW HPC|Patients with intracranial aneurysms or dissections undergoing endovascular treatment with p64MW HPC and p48MW HPC flow-diverting devices.
62799527|NCT06531486|EXPERIMENTAL|Phase I dose escalation/Phase II dose expansion|"Experimental: XS-02 Dosage form:capsule Specification: 5mg，25mg Dose: Phase I dose escalation, orally, once daily, the administration schedule (including dose,administration frequency/interval, administration cycle, etc.) can be adjusted according to the experimental data. Phase II Dose Expansion/Optimal Dose selection, will be determined based on the Phase I dose escalation results.~Method of administration: Oral"
62799528|NCT05104307||Cardiac Performance System (NSR)|Subjects will wear Cardiac Performance System (CPS) non-invasive device during their standard echocardiogram
62417984|NCT01171131||Chronic TBI Patients - Non-penetrating|"Chronic TBI patients should have a history of head trauma manifesting in one or more of the following:~1. Loss of consciousness~2. Post-traumatic amnesia~3. Focal neurologic deficits, seizure~4. Persistent symptoms of increased arousal (e.g. difficulty falling or staying asleep, anger and hypervigilance)~5. Impairment in social, occupational, or other important areas of functioning (e.g. problems with work and relationships.) Patients will be excluded from the study if we are unable to obtain informed consent and if they are non-communicative (i.e. in a vegetative state)."
62433500|NCT04087382|ACTIVE_COMPARATOR|Intervention group|it included 32 patients with acute ischemic stroke beyond the time of window (more than 6 hours) assigned to mechanical thrombectomy) plus the conventional treatment (Aspirin 150 mg and atorvastatin 40 mg).
62433501|NCT04087382|OTHER|non-intervention group|it included 25 patients with acute ischemic stroke beyond the time of window (more than 6 hours) who received medical treatment (Aspirin 150 mg and atorvastatin 40 mg).
62225111|NCT01312012|EXPERIMENTAL|The effectiveness and feasibility, using antiviral therapy|Experimental: Subjects receive tenofovir disoproxil fumarate (TDF) oral use prior to delivery in pregnant women with positive serum HBeAg and HBsAg and high HBV DNA levels \> 10\^8copies / mL, to reduce the rate of mother to infant transmission of HBV infection, and also to monitor the safety of the therapy.
62026385|NCT00936364|EXPERIMENTAL|Group III (Stage I of study)|Patients fast for 72 hours on days -3, -2, and -1
62026386|NCT00936364|EXPERIMENTAL|Group IV (Stage I of study)|Patients undergo a modified 48-hour fast with minimal caloric intake on day -2 and -1
62026387|NCT04573920|EXPERIMENTAL|Atrasentan 0.75 mg|Once daily oral administration of 0.75 mg atrasentan
62026388|NCT04573920|EXPERIMENTAL|Atrasentan 1.5 mg|Once daily oral administration 1.5 mg atrasentan (FSGS cohorts only)
62026389|NCT05724797|EXPERIMENTAL|NRS-033: Cohorts 1-3|Cohorts 1-3: 6 participants in each cohort will receive active drug (NRS-033)
62026390|NCT05724797|PLACEBO_COMPARATOR|Placebo: Cohorts 1-3|Cohorts 1-3: 2 participants in each cohort will receive the matching placebo dose
62026391|NCT03809182|EXPERIMENTAL|Dexmedetomidine|After anesthesia induction, patients who were randomized to the Dexmedetomidine group received a bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery. In the case of intraoperative increment of the blood pressure and/or heart rate more than 25% from its baseline, fentanyl 1ug/kg was administered.
62026392|NCT03809182|PLACEBO_COMPARATOR|0.9% Sodium-chloride|After anesthesia induction, patients who were randomized to the Placebo group received a bolus and infusion of 0.9% normal saline at the same rate as the Dexmedetomidine group until the end of surgery. In the case of intraoperative increment of the blood pressure and/or heart rate more than 25% from its baseline, fentanyl 1ug/kg was administered.
62026393|NCT00814372|EXPERIMENTAL|MBX-102 400|
62026394|NCT00814372|EXPERIMENTAL|MBX-102 600|
62026395|NCT00814372|PLACEBO_COMPARATOR|Placebo|
62026396|NCT00814372|ACTIVE_COMPARATOR|Actos|30-45 mg
62026397|NCT00563784|EXPERIMENTAL|Erlotinib + Paclitaxel + Carboplatin|Oral Erlotinib 150 mg daily + Paclitaxel 45 mg/m\^2 by vein weekly + Carboplatin 2 AUC by vein weekly and Radiation Therapy 63 GY/35 fractions for 7 weeks cycles
62799529|NCT05357716||Arm A|Up to 40 patients will be enrolled in Arm A. Subjects will wear the HeartWatch and an Event Recorder for up to 72 hours. Subjects will be asked to document their activities (standing, sitting, walking, exercise, or laying down). Event recorder subjects will collect user-triggered and auto-triggered data.
62799530|NCT05357716||Arm B|Up to 10 patients will be enrolled in Arm B.Subjects will wear the HeartWatch and Holter monitor for up to 48 hours. Subjects will be asked to document their activities (standing, sitting, walking, exercise, or laying down). Holter subjects will record diary information on their activities and any relevant symptoms.
62799531|NCT05771766|EXPERIMENTAL|Postural Drainage with Aerobic Training|The intervention group will undergo Postural Drainage and additional Aerobic Training thrice a week for two weeks as well along with postural drainage. Aerobic training will include a 5-step stair-climbing and 10-step walk during each session.
62799532|NCT05771766|ACTIVE_COMPARATOR|Postural Drainage|the group will receive postural drainage as baseline treatment thrice a week for two weeks.
62799533|NCT02631980|EXPERIMENTAL|IV iron|Postoperative iv iron administration (Ferinject) upon arrival in after surgery recovery room
62026398|NCT03729219|EXPERIMENTAL|ETVAX|Contains inactivated Tetravalent ETEC vaccine, 10 ug Double-mutant heat-labile toxin (dmLT) and effervescent power for oral solution administered twice 14 (plus minus 7) days intervals.
62026399|NCT03729219|PLACEBO_COMPARATOR|Placebo|Effervescent power for oral solution administered wice 14 (plus-minus 7) days intervals
62026400|NCT05794191||Persons living with HIV (PLWH)|Adults with HIV
62026401|NCT00818948|PLACEBO_COMPARATOR|Placebo|2 subjects of each cohort (cohort 1 to 6) will receive placebo
62026402|NCT00818948|OTHER|AMG811|Six subjects in each cohort (cohort 1 to 6) will receive AMG 811
62026403|NCT01773226|EXPERIMENTAL|"Autologous Protein Solution APS(TM)"|Patients who have been treated with a single, intra-articular injection.
62026404|NCT03085563|ACTIVE_COMPARATOR|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method.
62026405|NCT03085563|ACTIVE_COMPARATOR|Intranasal Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'.
62225112|NCT01312012|NO_INTERVENTION|Control|Subjects receive no intervention, but with blood tests for mothers and infants before and after delivery, as a comparative group to experimental arm.
62026406|NCT01800877|OTHER|Liberal Approach|In the liberal approach group, we will titrate vasopressors to maintain mean arterial pressures between 75 and 80 mmHg.
62026407|NCT01800877|OTHER|Restrictive Approach|We will titrate vasopressors to maintain mean arterial pressures between 60 and 65 mmHg.
62026408|NCT03401970|ACTIVE_COMPARATOR|Acellular carbohydrate diet|Prescribed dietary pattern. Carbohydrates from acellular sources, e.g., refined flour/bakery products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population.
62026409|NCT03401970|EXPERIMENTAL|Cellular carbohydrate diet|Prescribed dietary pattern. Carbohydrates from cellular sources, e.g., root vegetables, fruits, whole-grain rice, non-flour grain products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population similar to the acellular carbohydrate diet.
62026410|NCT03401970|EXPERIMENTAL|Low-carbohydrate high-fat diet|Prescribed dietary pattern. Energy largely from fat, cellular carbohydrate sources, and otherwise similar food types as in the acellular/cellular carbohydrate diets including at least 500 grams of fruits/vegetables per day.
62026411|NCT05197959|NO_INTERVENTION|Group A-Control|Participants in this arm will not experience any intervention during a 4 week period of time. Participants will experience their standard medical care.
62799534|NCT02631980|PLACEBO_COMPARATOR|IV placebo|Postoperative iv placebo administration upon arrival in after surgery recovery room
62799535|NCT05217940|EXPERIMENTAL|Women With Prior HPV for Anal Neoplasia|Standard of care anal cancer screening with anal cytology, HPV testing and high resolution anoscopy.
62799536|NCT00663013|ACTIVE_COMPARATOR|1|The first treatment session will involve 5-7 minutes of burn wound care while distracted by VR, and 5-7 minutes of burn wound care without the distraction of VR. The second session of burn wound care (performed within the next 3 days) will involve 5-7 minutes of burn wound care without the distraction of VR, and 5-7 minutes of burn wound care with the distraction of VR. The treatment order will be randomized.
62799537|NCT00663013|ACTIVE_COMPARATOR|2|The first treatment session will involve 5-7 minutes of burn wound care while distracted by VR, and 5-7 minutes of burn wound care without the distraction of VR. The second session of burn wound care (performed within the next 3 days) will involve 5-7 minutes of burn wound care without the distraction of VR, and 5-7 minutes of burn wound care with the distraction of VR. The treatment order will be randomized.
62026412|NCT05197959|EXPERIMENTAL|Group B-rTMS and sensorimotor training|Repetitive transcranial magnetic stimulation (rTMS) will be delivered at 10 Hz, 2000 pulses targeting the hand representation of the left primary motor cortex. Immediately following rTMS, participants will perform sensorimotor training. Nerve stimulation will be applied to the second through fifth digits and the wrist of the affected limb to cue movement. This intervention will be performed approximately 4 days per week for 4 weeks. In addition, participants will experience their standard medical care.
62417985|NCT01171131||Chronic TBI Patients - Blast|"Chronic TBI Blast injury patients should have a history of head trauma manifesting in one or more of the following:~1. Loss of consciousness~2. Post-traumatic amnesia~3. Focal neurologic deficits, seizure~4. Persistent symptoms of increased arousal (e.g. difficulty falling or staying asleep, anger and hypervigilance)~5. Impairment in social, occupational, or other important areas of functioning (e.g. problems with work and relationships.) Patients will be excluded from the study if we are unable to obtain informed consent and if they are non-communicative (i.e. in a vegetative state)."
62799538|NCT01867736|EXPERIMENTAL|Passeo-18 Lux DRB|Passeo-18 Lux Drug Releasing Balloon catheter
62799539|NCT01867736|ACTIVE_COMPARATOR|Standard PTA (POBA)|Uncoated Passeo-18 PTA balloon catheter
62799540|NCT03359174|EXPERIMENTAL|All-trans retinoic acid (ATRA) therapy|Fixed low dose of ATRA 10 mg twice daily for 24 weeks.
62799541|NCT04100382|EXPERIMENTAL|Laser and SLA implants|Surgical placement of short implants in maxillary posterior teeth with Laser surface treated and SLA surface treated dental implants
62026413|NCT05197959|EXPERIMENTAL|Group C-Sensorimotor training|Participants will perform sensorimotor training intervention. Nerve stimulation will be applied to the second through fifth digits and the wrist of the affected limb to cue movement. This intervention will be performed approximately 4 days per week for 4 weeks. In addition, participants will experience their standard medical care.
62026414|NCT03449602|EXPERIMENTAL|Mini-thoraoscopy|The mini-thoracoscope manufactured by Richard Wolf GmbH, Knettligen, Germany will be used for performing thoracoscopic pleural biopsies. It has an outer diameter of 5.5 mm and a working channel diameter of 3.5 mm.
62225113|NCT03466801|EXPERIMENTAL|Group prednisone|Prednisone was taken 1mg/kg/d(maximum 60mg/d)for 8 weeks to start.Then decreased 5mg every 2 weeks; When reduced to 40mg,reduced 5mg every 4 weeks. When reduced to 20mg, reduced 2.5mg every 8 weeks until the end.
62225114|NCT03466801|ACTIVE_COMPARATOR|Group MP and CTX|The first month,Methylprednisolone(MP) was injected for 3 days(weight \>60kg,500mg/d;\<60 kg,300mg/d),and 0.4mg/kg/d for 27 day.The second month,Cyclophosphamide(CTX) orally was 100mg/d for 1 month.And this regimen is repeated for six months.
62225115|NCT01827618|EXPERIMENTAL|Rapamycin|Rapamycin 3mg orally daily x 4weeks prior to radical cystectomy
62417986|NCT01171131||Healthy Volunteers|"Healthy volunteers include gender, age and race matched volunteers able to provide informed consent who have,~1. No significant medical history~2. Take no medications (other than birth control pills)~3. Fever free~4. No history of head trauma or recent injury/infection~5. No history of neurological or psychiatric disorders or alcohol or drug dependency."
62417987|NCT03130855|EXPERIMENTAL|inferior alveolar nerve block with 4% articaine|inferior alveolar nerve block using 4% articaine anesthetic solution
62417988|NCT03130855|ACTIVE_COMPARATOR|buccal infiltration with 4% articaine|buccal infiltration using 4% articaine anesthetic solution
62417989|NCT06466187|EXPERIMENTAL|PF-08052666|PF-08052666 monotherapy
62417990|NCT00414011|EXPERIMENTAL|Moxifloxacin|Moxifloxacin eye drops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
62417991|NCT00414011|EXPERIMENTAL|Gatifloxacin|Gatifloxacin eyedrops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
62417992|NCT00874042|EXPERIMENTAL|ARQ 197 in combination with gemcitabine|
62417993|NCT06452316|EXPERIMENTAL|CSB-001 BID|One drop CSB-001 twice daily for two 8-week dosing periods in the study eye(s)
62417994|NCT06452316|EXPERIMENTAL|CSB-001 QID|One drop CSB-001 four times daily for two 8-week dosing periods in the study eye(s)
62433502|NCT00415961|EXPERIMENTAL|1|CoStar Paclitaxel drug eluting stent
62799542|NCT01001117|EXPERIMENTAL|Laser treated|Eye treated with LensAR Laser System
62799543|NCT01001117|ACTIVE_COMPARATOR|Control Eye|Contralateral eye treated with conventional phaco-emulsification
62799544|NCT04311489|EXPERIMENTAL|Ularitide|Test product. Continuous intravenous infusion with 30 ng/kg/min for 48 hours.
62799545|NCT04311489|PLACEBO_COMPARATOR|Placebo|Matching placebo. Continuous IV infusion for 48 hours.
62799546|NCT03824002|EXPERIMENTAL|patients treated with dulaglutide|Diabetes therapy with dulaglutide and various combinations of aspart insulin, glargine, metformin, repaglinide
62225116|NCT01827618|NO_INTERVENTION|Control|
62026415|NCT03449602|ACTIVE_COMPARATOR|Conventional rigid thoracoscopy|The rigid thoracoscope manufactured by Richard Wolf GmbH, Knettligen, Germany will be used for performing thoracoscopic pleural biopsies. It has an outer diameter of 10 mm and channel internal diameter of 5 mm.
62026416|NCT02964936|EXPERIMENTAL|ASP1517 Low dose group|Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.
62433503|NCT00003070|EXPERIMENTAL|Stratum 1 < 350/mg/m2 anthracycline dose|\< 4 years of age at diagnosis \< 4 years since cessation of anthracycline treatment
62588827|NCT03482297|SHAM_COMPARATOR|Sham binder|Participants will be studied on three separate study days, two days apart: one day for baseline measurements (placebo pill t.i.d), one day for treatment with 10 mg midodrine t.i.d (standard of care), and one day for treatment with the sham binder combined with placebo pill t.i.d. The sham binder will be placed during the morning orthostatic trial on the active/sham binder study day. The sham binder will inflate automatically (\~5 mmHg) every time the participant stands up throughout the study day.
62799547|NCT03824002|ACTIVE_COMPARATOR|patients not treated with dulaglutide|Diabetes therapy with various combinations of aspart insulin, glargine, metformin, repaglinide but without dulaglutide
62799548|NCT04608565|OTHER|Remote biomonitoring sensor device|250 readings for a power of 80% and to detect a 5% difference in measurements with 95% confidence interval from mothers and newborns was ascertained. Once 3 probes were strapped (radiant warmer, RBM device and multichannel), a waiting period of 10 minutes for temperature stabilization was given. First RBM device \& multichannel probe provided readings continuously (every few seconds); Then radiant warmer probe and manual thermometer readings were taken every 15 minutes for 5 timings: 0, 15, 30, 45 and 60 minutes. Participant safety for newborns was ensured following routine appropriate care protocols.
62799549|NCT05897034|ACTIVE_COMPARATOR|control group|This group will take doxycycline 100 mg twice daily
62799550|NCT05897034|ACTIVE_COMPARATOR|Comparative group|This group will take doxycycline 100 mg twice daily, pentoxifylline 400 mg twice daily, and nitazoxanide 500 mg twice daily.
62026417|NCT02964936|EXPERIMENTAL|ASP1517 High dose group|Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.
62026418|NCT04651452|ACTIVE_COMPARATOR|Value Affirmation|Participants in the value affirmation condition will complete six writing prompts regarding their personal values over the course of six months. For example, participants will be given a list of values and will be asked to rate them in order of importance within their own lives and write about a time when their top value was particularly important. Participants will write for about ten minutes each session. The intervention tasks will be completed on a secure, online website that each individual participant will be emailed a link to. Participants can also receive paper copies via postal mail if they prefer.
62799551|NCT04593758|EXPERIMENTAL|CPI-613 + Hydroxychloroquine|dosing regimen was 600mg hydroxychloroquine PO followed 2 hours later by 2,000 mg/m2 of CPI-613 by central IV infusion over 2 hours followed by 600 mg hydroxychloroquine PO 12 hours following the initial dose daily on days 1 through 5 of every 28 days.
62799552|NCT02484755|EXPERIMENTAL|gefitinib|gifitinib 250 mg oral administration once daily for a total of 4 weeks.
62799553|NCT00604565|EXPERIMENTAL|SFP dialysate|dialysate with added soluble ferric pyrophosphate (SFP)
62026419|NCT04651452|ACTIVE_COMPARATOR|Reflective Journaling|Participants in the reflective journaling condition will complete six writing prompts over the course of six months. However, the reflective journaling condition will be writing about values that are not important to them and discuss why they could be important to others. In other tasks, they will write about aspects of daily life (e.g. morning routine). Participants will write for about ten minutes each session. The intervention tasks will be completed on a secure, online website that each individual participant will be emailed a link to. Participants can also receive paper copies via postal mail if they prefer.
62799554|NCT00604565|PLACEBO_COMPARATOR|standard dialysate|standard dialysate without soluble ferric pyrophosphate (SFP)
62026420|NCT06029907|OTHER|Study population|All patients will receive a smoking cessation and pain management intervention combined with clinician-prescribed varenicline.
62026421|NCT02484794|ACTIVE_COMPARATOR|Treatment as Usual|Patients will receive standard outpatient treatment that consists of group psychotherapy, skills training, self-monitoring, nutritional counselling, and meal support.
62799555|NCT00806988|ACTIVE_COMPARATOR|Mitral Valve Repair|Participants will undergo CABG and a mitral valve repair procedure.
62026422|NCT02484794|EXPERIMENTAL|Treatment with Smartphone App|Patients will receive the same standard outpatient treatment but will use the smartphone application instead of the paper food record. Patients in this group will receive daily feedback through the app, as opposed to weekly, but will still attend the weekly nutritional counselling group.
62026423|NCT03391479|EXPERIMENTAL|Avelumab and Best Supportive Care|"Avelumab will be given intravenously (by vein) at a dose of 10 mg/kg, once every 2 weeks~Best supportive care will be provided as required."
62026424|NCT02165150|EXPERIMENTAL|Wheelchair-bound Senior Elastic Band|WSEB interventions three times per week, 40 minutes per practice
62026425|NCT02165150|NO_INTERVENTION|Control|routine care
62026426|NCT02361853||Active labor at term|Women in active labor normal pregnancy at term
62026427|NCT02361853||Non-active labor at term|"Women, normal pregnancy at term who come for usual follow up without signs for labor ( contraction / show discharge/ rupture of membranes)."
62026428|NCT02361853||Active labor, pre-term|Women in active pre term labor (34- 37w) normal pregnancy.
62026429|NCT04198662|ACTIVE_COMPARATOR|Cryoneurolysis and placebo intercostal nerve block|Active cryoneurolysis: 3 mL of normal SALINE will be injected into the muscle superficial to the nerve followed by an ACTIVE cryoneurolysis procedure using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods.
62026430|NCT04198662|SHAM_COMPARATOR|Sham cryoneurolysis and active intercostal nerve block|Sham cryoneurolysis: 3 mL of ropivacaine 0.5% (with epinephrine) will be injected perineurally to provide the intercostal nerve block followed by a SHAM cryoneurolysis procedure with a probe that vents the nitrous oxide prior to reaching the probe tip using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods.
62026431|NCT00246636|ACTIVE_COMPARATOR|OM5/LOV111859 (double-blind study) - Antara|Antara (fenofibrate) + placebo
62026432|NCT00246636|EXPERIMENTAL|OM5X/LOV111860 (extension study) - Open-Label Antara + Lovaza|Open-label Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
62417995|NCT05636501|ACTIVE_COMPARATOR|Treat-to-target Prednisolone Taper|"Patients randomized to the Treat-to-target group is prescribed with a systematic prednisolone taper according to a specific scheme. The starting dose can be increased if remission is not reached initially or in case of relapse, folloved by taper according to the specific scheme. A nurse will make a minimum of 5 phone consultations the first year, and hereafter minimum every 3 months."
62026433|NCT00246636|EXPERIMENTAL|OM5/LOV111859 (double-blind study) - Antara + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
62417996|NCT05636501|PLACEBO_COMPARATOR|Usual Care|"Patients randomized to usual care are dismissed from the hospital after the diagnosis and the prednisolone taper are subsequently performed by discretion of the patient's general practitioner."
62026434|NCT05619614||Patients|Participating patients who undergo colonoscopy
62026435|NCT05619614||Endoscopists CADe|Physicians performing CADe colonoscopy
62026436|NCT05619614||Endoscopists CC|Physicians performing conventional colonoscopy
62026437|NCT01306162|EXPERIMENTAL|A: Dabigatran alone (Reference)|Capsule, oral administration with 240 mL water
62026438|NCT01306162|EXPERIMENTAL|B: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
62417997|NCT06458712|EXPERIMENTAL|DSB2455 Dose Escalation & Expansion|DSB2455 Dose Escalation \& Expansion
62799556|NCT00806988|ACTIVE_COMPARATOR|CABG|Participants will undergo CABG.
62799557|NCT06261593|EXPERIMENTAL|Experimental group|"The intervention will consist of carrying out a physiotherapy protocol, consisting of strength training through blood flow restriction, with an occlusion pressure of 40-50% of the LOP (Limb Occlusion Pressure) and a load of 20-30%. of 1RM performed ad hoc for patients with hemophilic arthropathy.~The intervention protocol will be carried out in person under the supervision of the main researcher. The intervention will last 4 weeks, with a frequency of 3 weekly sessions. In total there will be 12 sessions lasting approximately 30-45 minutes."
62799558|NCT06261593|NO_INTERVENTION|Control group|The patients included in the control group will not receive any Physiotherapy intervention and will continue with their usual routine, being evaluated in the same periods as the rest of the patients
62799559|NCT02279667|EXPERIMENTAL|Group A|"1. st period - 16 mL oral suspension 50 mg/mL~2. nd period - Four 200 mg tablets~3. rd period - One 800 mg tablet"
62026439|NCT01306162|EXPERIMENTAL|C: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
62026440|NCT01306162|EXPERIMENTAL|D: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
62026441|NCT01306162|EXPERIMENTAL|E: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
62026442|NCT01116817|EXPERIMENTAL|LPV/r monotherapy 400/100 mg twice daily, orally administered|LPV/r monotherapy 400/100 mg twice daily, orally administered
62026443|NCT01116817|ACTIVE_COMPARATOR|Lumbar puncture|LPV/r 400/100 mg twice daily + 2 NRTI, orally administered.
62799560|NCT02279667|EXPERIMENTAL|Group B|"1. st period - One 800 mg tablet~2. nd period - 16 mL oral suspension 50 mg/mL~3. rd period - Four 200 mg tablets"
62026444|NCT03130582||Disease status at mobilization PR|
62026445|NCT03130582||Disease status at mobilization PD|
62026446|NCT04271930|EXPERIMENTAL|Mindfulness Awareness Practices for Insomnia|Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with 5 minutes and increasing to 20 minutes over the course of the 6-week intervention - as is standard with the Mindfulness Awareness Practices (MAPs) course - with practice prior to bedtime. An intervention training manual is the cornerstone of standardized delivery of MAP-I. Participants are also provided with a book on mindfulness (Fully Present: The Science, Art, and Practice of Mindfulness, authored by the Mindfulness Awareness Research Center (MARC) leader and MAP-I instructor Diana Winston) as well as access to the University of California Los Angeles (UCLA) Mindful App courtesy of the MARC at UCLA (via personal iPhone or study-administered tablets per patient preference), which contains pre-recorded guided meditations for use in daily practice.
62026447|NCT04271930|ACTIVE_COMPARATOR|Sleep Health Education|Six individual 1-hour videos will be shown to participants at the same time points as, and with equal duration to, the MAP-I intervention. These videos will be recorded presentations that have been modified for HCT recipients based upon similar SHE interventions delivered in prior studies. Similar to the intervention group, patients in the SHE group will also participate in group Zoom chat sessions with equal frequency and duration lead by a study research coordinator. These sessions will allow for general patient interaction to discuss sleep and any questions or comments they may have, as lead by the group facilitator.
62225117|NCT01667211|EXPERIMENTAL|albumin-bound paclitaxel plus nedaplatin|albumin-bound paclitaxel plus nedaplatin: Intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
62225118|NCT00987246|EXPERIMENTAL|LAS41005|
62225119|NCT00987246|ACTIVE_COMPARATOR|LAS106521|
62417998|NCT06702878|EXPERIMENTAL|Nasal antimicrobial photodisinfection therapy (aPDT)|Nasal antimicrobial photodisinfection therapy
62417999|NCT06702878|NO_INTERVENTION|Standard of Care Surgical Preventions - Control|Standard of Care surgical site prevention measures
62418000|NCT03030482|EXPERIMENTAL|Touch massage|Patients will have a touch massage session during 30 minutes the intervention will take place remotely (1 h) of all events that can generate anxiety
62026448|NCT05679492|EXPERIMENTAL|Meplazumab|First dose: 0.2 mg/kg - Day 1; second dose: 0.2 mg/kg - Day 8
62418001|NCT03030482|NO_INTERVENTION|control|standard care ICU
62418002|NCT06297616|EXPERIMENTAL|Part A: LY3841136|LY3841136 administered subcutaneously (SC)
62799561|NCT02279667|EXPERIMENTAL|Group C|"1. st period - Four 200 mg tablets~2. nd period - One 800 mg tablet~3. rd period - 16 mL oral suspension 50 mg/mL"
62799562|NCT03930693|EXPERIMENTAL|Normotensive pregnant women|Normotensive pregnant women
62799563|NCT03930693|EXPERIMENTAL|Hypertensive pregnant women|Hypertensive pregnant women
62799564|NCT03930693|EXPERIMENTAL|Normotensive non-pregnant women|Normotensive non-pregnant women
62799565|NCT03930693|EXPERIMENTAL|Hypertensive non-pregnant women|Hypertensive non-pregnant women
62026449|NCT05679492|PLACEBO_COMPARATOR|Placebo|First dose: control - Day 1; second dose: control - Day 8
62225120|NCT00987246|PLACEBO_COMPARATOR|Placebo|
62225121|NCT02639598|EXPERIMENTAL|flunarizine|"This study consisted of two periods: a prospective baseline screening period lasting up to 2 weeks (week -2 to week 0, T0), and a treatment period lasting 8 weeks after enrollment (weeks 0-8, T1-T4).~The treatment phase consisted of a 2-week titration period (T1) and a 6-week maintenance period (T2-T4). During the titration period, subjects were given 5 mg/day flunarizine once daily in the first week, followed by 10 mg/day flunarizine in divided doses (twice daily) in the second week. When subjects could not tolerate this target dose, the initial dose was continued through T4."
62225122|NCT02639598|ACTIVE_COMPARATOR|topiramate|"This study consisted of two periods: a prospective baseline screening period lasting up to 2 weeks (week -2 to week 0, T0), and a treatment period lasting 8 weeks after enrollment (weeks 0-8, T1-T4).~The treatment phase consisted of a 2-week titration period (T1) and a 6-week maintenance period (T2-T4). During the titration period, subjects were given 25 mg/day topiramate once daily in the first week, followed by 50 mg/day topiramate in divided doses (twice daily) in the second week. When subjects could not tolerate this target dose, the initial dose was continued through T4."
62225123|NCT02594761|EXPERIMENTAL|Treatment A|Hercules: 8 mg/kg i.v. infusion over 90 minutes
62225124|NCT02594761|ACTIVE_COMPARATOR|Treatment B|Herceptin EU: 8 mg/kg i.v. infusion over 90 minutes
62225125|NCT02594761|ACTIVE_COMPARATOR|Treatment C|Herceptin US: 8 mg/kg i.v. infusion over 90 minutes
62799566|NCT01593631|ACTIVE_COMPARATOR|2 billion lyoph. yoghurt bacteria|
62799567|NCT01593631|ACTIVE_COMPARATOR|3300 FCC acid lactase|
62799568|NCT01593631|ACTIVE_COMPARATOR|9000 FCC acid lactase|
62225126|NCT00326404|EXPERIMENTAL|1|
62225127|NCT00326404|ACTIVE_COMPARATOR|2|
62225128|NCT03536754|PLACEBO_COMPARATOR|Group A|Placebo (N=10)
62418003|NCT06297616|PLACEBO_COMPARATOR|Part A: Placebo|Placebo administered SC
62418004|NCT06297616|EXPERIMENTAL|Part B: Tirzepatide + LY3841136-Placebo|Tirzepatide administered SC along with volume-matched LY3841136-Placebo administered SC
62418005|NCT06297616|EXPERIMENTAL|Part B: LY3841136 + Tirzepatide-Placebo|LY3841136 administered SC along with volume-matched Tirzepatide-Placebo administered SC
62799569|NCT01593631|ACTIVE_COMPARATOR|Combination of Substances of arm 1 and 2|
62799570|NCT01593631|PLACEBO_COMPARATOR|Placebo|
62799571|NCT00478842|EXPERIMENTAL|1|Deep brain stimulation
62225129|NCT03536754|EXPERIMENTAL|Group B|CCX140-B 5 mg once daily (N=10)
62225130|NCT03536754|EXPERIMENTAL|Group C|CCX140-B 10 mg twice daily (N=10)
62588828|NCT06041542||Case group|Collect video of hand grasping from patients with cervical spondylotic myelopathy through intelligent video analysis system.
62225131|NCT03536754|EXPERIMENTAL|Group D|CCX140-B 15 mg twice daily (N=10)
62225132|NCT06164392|EXPERIMENTAL|Neuroma ICG|Subjects will receive Intravenous ICG to generate a Fluorescence Angiogram of the Neuroma
62799572|NCT01479868|EXPERIMENTAL|TMC435 + pegylated interferon alpha-2a + ribavirin|Patients will be administered TMC435 150 mg along with pegylated interferon alpha-2a 180 microgram and ribavirin 1000 or 1200 mg for 12 weeks. Pegylated interferon alpha-2a and ribavirin will only be continued until 24 to 48 weeks.
62799573|NCT02693041|ACTIVE_COMPARATOR|PROBIOTIC in low-risk women|In low-risk women, probiotic group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (\> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
62799574|NCT02693041|PLACEBO_COMPARATOR|PLACEBO in low-risk women|In low-risk women, placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
62588829|NCT06041542||Control group|Collect video of hand grasping from normal people through intelligent video analysis system.
62799575|NCT02693041|ACTIVE_COMPARATOR|PROBIOTIC in women with a prior PTB|In women with a prior preterm birth (PTB), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (\> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
62225133|NCT02245906|PLACEBO_COMPARATOR|Control drink|300 ml control drink containing equal amount of total fiber and pectine as Brazilian fruit drink, acute study / one time administration
62225134|NCT02245906|EXPERIMENTAL|Brazilian fruit peel|300 ml test drink containing Brazilian fruit peel flour, acute study / one time administration
62225135|NCT02245906|PLACEBO_COMPARATOR|Negative control drink|300 ml control drink without containing amount of total fiber and pectine as Brazilian fruit drink, acute study / one time administration
62225136|NCT05345808|OTHER|Formulated Posterior Sub Tenon Triamcinolone|All the eyes received single dose 40 mg of Triamcinolone Acetonide (TA) and VISCOAT which is 20 mg sodium chondroitin sulphate and 15 mg sodium hyaluronate (0.5 ml) through posterior subtenon route using NAGATA subtenon canula.
62225137|NCT01955889|EXPERIMENTAL|Mobile Health Technology|Stretching and strengthening exercises provided via video using mobile health technology; walk daily using a pedometer; interact with a physical therapist remotely through an exercise application on a tablet device over 12 month period
62225138|NCT01955889|ACTIVE_COMPARATOR|Control|Stretching and strengthening exercises provided using printed photographs; walk daily using a pedometer; interact with a physical therapist at the beginning of the 12 month study; no use of mobile technology
62418006|NCT06297616|EXPERIMENTAL|Part B: LY3841136 + Tirzepatide|LY3841136 administered SC along with Tirzepatide administered SC
62418007|NCT06297616|PLACEBO_COMPARATOR|Part B: LY3841136-Placebo + Tirzepatide-Placebo|Volume-matched LY3841136-Placebo administered SC along with volume-matched Tirzepatide-Placebo administered SC
62418008|NCT00996008|PLACEBO_COMPARATOR|Placebo only|Subjects will apply placebo cream to all 4 target lesions
62588830|NCT06041542||Differentiate group|Collect video of hand grasping from Stroke and Parkinson's disease through intelligent video analysis system.
62799576|NCT02693041|PLACEBO_COMPARATOR|PLACEBO in women with a prior PTB|In women with a prior preterm birth (PTB), placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
62588831|NCT02524886|ACTIVE_COMPARATOR|Immediate stimulation|Patients will be implanted with a Medtronic electorde and Active PC pulse generator for deep brain stimulation at baseline and GPi electric stimulation will start immediately after surgery
62588832|NCT02524886|SHAM_COMPARATOR|Delayed stimulation|Patients will be implanted with a Medtronic electorde and Active PC pulse generator for deep brain stimulation at baseline and GPi electric stimulation will start 3 months after surgery
62588833|NCT05314322|EXPERIMENTAL|High frequency group|Deep brain stimulation's parameter: Frequency adjusted to 130Hz, with other parameters fixed
62026450|NCT06180564|EXPERIMENTAL|Intra-operative Infra-red thermography|. In the test group after devascularisation of the bowel segment surgeon marked the resection line using their conventional method, then IRT was used to determine the resection line using infra- red camera in rainbow display mode. Resection line was determined by abrupt colour change (corresponds to decrease in temperature \>3 degree Celsius) over the visualised bowel wall. Margins were revised if difference between surgeon and IRT determined resection lines were more than 1cm apart.
62026451|NCT06180564|NO_INTERVENTION|Conventional without Infra-red thermography|Resection margin determined by conventional visual and palpatory method
62026452|NCT04326491||HCC|Participants are diagnosed with HCC on top of cirrhosis
62026453|NCT04326491||Cirrhosis with no HCC|Participants are diagnosed with cirrhosis but have no HCC
62026454|NCT06322914||Technical successful group|Technical success of CTO PCI was defined as successful CTO revascularization with achievement of \<30% residual diameter stenosis within the treated segment and restoration of antegrade TIMI flow grade 3.
62026455|NCT06322914||Technical unsuccessful group|Technical unsuccess of CTO PCI was defined as unsuccessful CTO revascularization（guide wire or stent cannot cross through the lesion）
62026456|NCT01443962|EXPERIMENTAL|Zero positive end expiratory pressure|Number: 30, apply no PEEP during the pneumoperitoneum during the laparoscopic cholecystectomy PEEP was not applied whole investigation period
62026457|NCT01443962|ACTIVE_COMPARATOR|positive end expiratory pressure|applying PEEP 10 cmH2O during pneumoperitoneum continuously
62026458|NCT05273710|OTHER|Zinc absorption study|Zinc absorption is determined from each of 3 test meals in all subjects.
62026459|NCT01944046|PLACEBO_COMPARATOR|DB Placebo Nasal Spray|Placebo treatment during weeks 0-24 double blind phase
62026460|NCT01944046|ACTIVE_COMPARATOR|DB Oxytocin Nasal Spray|DB Oxytocin- quadruply masked treatment with intranasal oxytocin during weeks 0-24 of study during double blind phase of study
62026461|NCT01944046|ACTIVE_COMPARATOR|open label intranasal oxytocin|non masked treatment with intranasal oxytocin from weeks 24-48 in those participants who completed first 24 weeks of double blind treatment
62026462|NCT01870271|EXPERIMENTAL|DCPT|Treatment with developmentally adapted D-CPT. 30 to 36 individual treatment sessions. Treatment sections comprise a commitment phase (5 sessions), emotion regulation phase (6 sessions), CPT (15 sessions) and a final phase targeting developmentally-related challenges (4 sessions).
62026463|NCT02068989||Stress Hyperglycemic Group|Repeat HbA1C in 1 year
62418009|NCT00996008|ACTIVE_COMPARATOR|Active plus placebo|Subjects will receive CT 327 on 2 of 4 target lesions located on one side of their body. On the remaining 2 target lesions on the other side of their body, placebo will be applied.
62418010|NCT04242784||Spoke Hospital|Patients that undergo the Code Stroke process at Spoke Hospitals
62026464|NCT02068989||Euglycemic Group|Repeat HbA1C in 1 year
62026465|NCT06365580|EXPERIMENTAL|Kylo-0603|In part 1, subjects will receive single dose Kylo-0603 orally at dose levels of 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, 4.6 mg, 8.6 mg, 12 mg, 16 mg and 20 mg on Day 1. In part 2, subjects will receive Kylo-0603 4.6 mg on Day 1 in fasted state and on Day 4 after a standard high-fat meal. In part 3, subject will receive Kylo-0603 orally once daily for 14 days at dose levels of 1.2 mg, 2 mg, 4 mg, 8 mg, 12 mg, and 16 mg.
62026466|NCT06365580|PLACEBO_COMPARATOR|Placebo|Subjects will receive matching placebo in part 1, part 2 and part 3.
62026467|NCT04731649|EXPERIMENTAL|Sex Education + Standard Care|The experimental arm will receive the FTT + intervention
62026468|NCT04731649|NO_INTERVENTION|No Education + Standard Care|The control arm will not receive the FTT + intervention
62026469|NCT00324623|EXPERIMENTAL|Lymphodepletion, vaccine, IMP321 adjuvant|
62026470|NCT03813329|PLACEBO_COMPARATOR|Placebo|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of Calcium carbonate
62026471|NCT03813329|ACTIVE_COMPARATOR|Acute Sodium Bicarbonate|3 doses of calcium carbonate (110 mg·kg-1, 130 mg·kg-1, 160 mg·kg-1), followed by one acute does (300 mg·kg-1) of sodium bicarbonate.
62026472|NCT03813329|EXPERIMENTAL|Modified Sodium Bicarbonate|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
62026473|NCT02169674|ACTIVE_COMPARATOR|10-11 Year-olds|Recombinant hepatitis B virus vaccine (EngerixB, GlaxoSmithKline Vaccines)
62026474|NCT02169674|ACTIVE_COMPARATOR|15-16 Year-olds|Recombinant hepatitis B virus vaccine (EngerixB, GlaxoSmithKline Vaccines)
62026475|NCT00977262|EXPERIMENTAL|Healthy control subjects, High saturated fat shake|
62225139|NCT01149356|EXPERIMENTAL|Arm I|Patients receive oral exemestane once daily on days 1-21 and oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62225140|NCT01149356|ACTIVE_COMPARATOR|Arm II|Patients receive exemestane as in arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62225141|NCT05374161|EXPERIMENTAL|Brief ACT-based intervention|A 6- week ACT intervention for depression and physical pain will be delivered.
62026476|NCT00977262|EXPERIMENTAL|Healthy control subjects, High Monounsaturated fat shake|
62026477|NCT00977262|EXPERIMENTAL|Healthy control subjects, High Polyunsaturated fat shake|
62026478|NCT00977262|EXPERIMENTAL|Healthy obese subjecs, High saturated fat shake|
62026479|NCT00977262|EXPERIMENTAL|Healthy obese subjects, High monounsaturated fat shake|
62588834|NCT05314322|EXPERIMENTAL|Low frequency group|Deep brain stimulation's parameter: Frequency adjusted to 60Hz, with other parameters fixed
62026480|NCT00977262|EXPERIMENTAL|Healthy obese subjects, High polyunsaturated fat shake|
62026481|NCT00977262|EXPERIMENTAL|Obese diabetes type 2 subjects, High Saturated fat shake|
62026482|NCT00977262|EXPERIMENTAL|Obese diabetes type 2 subjects, High Monounsaturated fat shake|
62026483|NCT00977262|EXPERIMENTAL|Obese diabetes type 2 subjects, High polyunsaturated fat shake|
62225142|NCT05374161|OTHER|Waitlist control group (WL)|The WL control group will receive treatment as usual, just like women in the experimental condition.
62026484|NCT06670690|ACTIVE_COMPARATOR|Atenolol Group|patients will be premedicated with atenolol (50mg)
62026485|NCT06670690|ACTIVE_COMPARATOR|propranolol Group|patients will be premedicated with propranolol (10mg)
62026486|NCT06670690|ACTIVE_COMPARATOR|Ivabradine Group|patients will be premedicated with Ivabradine (5mg)
62026487|NCT02907333|ACTIVE_COMPARATOR|Intervention group|Women who are advised to use condom during the time period between diagnosis and follow-up
62026488|NCT02907333|NO_INTERVENTION|Control group|Women who are not contacted with advise to use condoms
62026489|NCT02359526|EXPERIMENTAL|ILUVIEN 190 ug intravitreal implant|All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
62225143|NCT00414687|EXPERIMENTAL|Arm 1|
62799577|NCT02693041|ACTIVE_COMPARATOR|PROBIOTIC in women with a prior PE|In women with a prior preeclampsia (PE), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (\> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
62026490|NCT02520635||TEMODAL® standard therapy regimen|4 weeks after surgery, patients are administered with radiotherapy that consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily 5 dyas a week over a period of 6 weeks. Concomitant TEMODAL® are administered orally at a daily dose of 75mg/m2 from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days. After a 4-week break, patients were then to receive up to 6 cycles of adjuvant TEMODAL® chemotherapy according to the standard 5-day schedule every 28 days.The dose is 150mg/m2 once daily for cycle 1 and is increase to 200mg/m2 at the beginning of cycle 2, so long as there were no hematologic toxic effects.
62026491|NCT02520635||post-surgery supra-early TEMODAL® chemotherapy|Within 24 hours after surgery, Supra-early TEMODAL® Chemotherapy is administered orally at 75mg/m2/day for 28 days for patients pathologically confirmed as GBM. 4 weeks after surgery, patients are administered with radiotherapy that consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily 5 dyas a week over a period of 6 weeks. Concomitant TEMODAL® are administered orally at a daily dose of 75mg/m2 from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days. After a 4-week break, patients were then to receive up to 6 cycles of adjuvant TEMODAL® chemotherapy according to the standard 5-day schedule every 28 days.The dose is 150mg/m2 once daily for cycle 1 and is increase to 200mg/m2 at the beginning of cycle 2, so long as there were no hematologic toxic effects.
62026492|NCT02976766|EXPERIMENTAL|Gypenosides|
62026493|NCT02976766|PLACEBO_COMPARATOR|Placebo|
62026494|NCT04741568|EXPERIMENTAL|Parental Psychoeducational Intervention|A brief (one-day or two half days) psychoeducation workshop will be provided alongside a website with downloadable content will be made available to review and refresh any skills and techniques. The psychoeducational intervention will be delivered by a research fellow and research assistant with a background in psychology and delivered in line with a protocol.
62026495|NCT04741568|NO_INTERVENTION|Wait List Control|Parents randomised to the control arm will be put on the waiting list (wait-list controls) to receive the group intervention after the active treatment group have completed their final follow-up at 3 months.
62026496|NCT00748436|PLACEBO_COMPARATOR|A|Matching placebo twice a day
62799578|NCT02693041|PLACEBO_COMPARATOR|PLACEBO in women with a prior PE|In women with a prior preeclampsia (PE), placebo Group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
62799579|NCT05336578|EXPERIMENTAL|1- PRF|After wisdom tooth extraction PRF located to the extraction socket
62026497|NCT00748436|EXPERIMENTAL|B|Betahistine 24 mg twice a day (48 mg/day total)
62026498|NCT00748436|EXPERIMENTAL|C|Betahistine 48 mg twice a day (96 mg/day total)
62026499|NCT02648698|EXPERIMENTAL|Antibiotic group|This group received antibiotic therapy
62026500|NCT02648698|NO_INTERVENTION|Control group|This group did not receive antibiotic therapy
62026501|NCT05540236|EXPERIMENTAL|The experimental group were given therapeutic intervention|The experimental group were given therapeutic intervention of single ear auricular pellet acupressure at the stomach(CO4), cardia(CO3), liver(CO12), occiput(AT3), shenmen(TF4) and subcortex(AT4) acupuncture points
62026502|NCT05540236|PLACEBO_COMPARATOR|The control group were given sham intervention|The control group were given sham intervention of single ear auricular pellet acupressure at the knee(AH4) and thoracic vertebrae(AH11) acupuncture points
62026503|NCT03850392|ACTIVE_COMPARATOR|ice|"16 knee arthritis patients treated by local ice (Thermogel®, Artsana, Grandate, Italy - 30 minutes application - twice within one single day).~Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®,Ethypharm, Saint-Cloud, France) was performed before removing the needle."
62225144|NCT04257591|EXPERIMENTAL|hamstring strengthening|8-week protocol (3 days per week) based on isometric, concentric and excentric exercisesof hamstrings
62225145|NCT04257591|NO_INTERVENTION|Control|No intervention added to regular training.
62418011|NCT04242784||Hub Hospital|Patients that undergo the Code Stroke process at Hub Hospitals
62588835|NCT00941863|EXPERIMENTAL|Sorafenib 100 mg (50-mg tablet)|Dose-escalation cohort 1: Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
62799580|NCT05336578|NO_INTERVENTION|PRF free|Only surgical procedure of the wisdom tooth extraction is performed
62418012|NCT04242784||Transfer|Patients that undergo the Code Stroke process at a Spoke Hospital and transfer to the Hub Hospital
62418013|NCT06701279||group 1|Patients with brain traumatic injury
62418014|NCT04950803|ACTIVE_COMPARATOR|Active arm|Subjects will take microbiome immunity formula (SIM01) daily for 6 months
62026504|NCT03850392|ACTIVE_COMPARATOR|CO2|16 knee arthritis patients treated by local hyperbaric cold CO2 at -78°C (Cryo+®, Cryonic, Salins-les-Bains, France - 2 minutes-applied twice within one single day). Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®, Ethypharm, Saint-Cloud, France) was performed before removing the needle.
62026505|NCT03850392|NO_INTERVENTION|contralateral non-treated knees|16 contralateral arthritic knees : the synovial fluid was collected and analysed according to the same procedure but no cold treatment was applied (while the corresponding contralateral arthritic knees were treated by ice) : At 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®,Ethypharm, Saint-Cloud, France) was performed before removing the needle.
62026506|NCT03421925|OTHER|Divided mesh group|In this group, surgeon will use a mesh divided in to two legs in laparoscopic totally extraperitoneal repair
62026507|NCT03421925|OTHER|Non divided mesh group|In this group, surgeon will use a non divided mesh in laparoscopic totally extraperitoneal repair
62418015|NCT04950803|PLACEBO_COMPARATOR|Placebo arm|Subjects will take active vitamin daily for 6 months
62588836|NCT00941863|EXPERIMENTAL|Sorafenib 200 mg (50-mg tablet)|Dose-escalation cohort 2: Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
62588837|NCT00941863|EXPERIMENTAL|Sorafenib 400 mg (50-mg tablet)|Dose-escalation cohort 3: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
62588838|NCT00941863|EXPERIMENTAL|Sorafenib 400 mg (200-mg tablet)|Dose-escalation cohort 4: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet). Treatment were planned until primary completion date (PCD).
62026508|NCT03296995|EXPERIMENTAL|flash glucose monitoring system|Subjects in the arm measure blood glucose by flash glucose monitoring system.
62418016|NCT06695832||Adjunctive fosfomycin|All patients receiving adjunctive fosfomycin (the combination therapy group).
62418017|NCT06695832||Standard antibiotic monotherapy group|All patients not receiving fosfomycin, i.e., those receiving daptomycin alone for MRSA bacteraemia or cloxacillin alone for MSSA bacteraemia.
62418018|NCT06079801|EXPERIMENTAL|Real tDCS|Patients will undergo real tDCS applied to both DLPC. Two daily sessions of 20 minutes each were administered (40 minutes a day in total), with a 5-minutes break in between, 5 days a week (Monday to Friday) and with 20 tDCS sessions in total for participant
62418019|NCT06079801|PLACEBO_COMPARATOR|Sham tDCS|Patients will undergo sham tDCS applied to both DLPC. Two daily sessions of 20 minutes each were administered (40 minutes a day in total), with a 5-minutes break in between, 5 days a week (Monday to Friday) and with 20 tDCS sessions in total for participant
62418020|NCT06079801|ACTIVE_COMPARATOR|anti-CGRP|Patients will undergo anti-CGRP treatment
62418021|NCT02530320|EXPERIMENTAL|Palbociclib (PD0332991)|Palbociclib will be administrated orally at a dose of 125 mg/day during 21 days followed by a break of 7 days. All patients included will be treated in the same arm. Treatment will be administrated until disease progression, unacceptable adverse side effects or study end.
62588839|NCT00941863|EXPERIMENTAL|Sorafenib 400 mg (Expansion)|Dose-expansion cohort: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion. Treatment were planned until primary completion date (PCD). 25 of 119 participants from the Expansion Phase, were still on the treatment as of 31 May 2005. Of these, 6 subjects were continuing to receive sorafenib in combination with carboplatin and/or paclitaxel and 19 subjects were receiving single-agent sorafenib until 18 Sep 2008.
62588840|NCT06121011||Cipaglucosidase alfa/Miglustat-treated patients|
62588841|NCT06121011||Other Enyzme Replacement Therapy (ERT)-treated patients|
62588842|NCT06121011||Untreated patients (those who are not currently receiving any medical therapy for Pompe disease)|
62588843|NCT04210284|EXPERIMENTAL|Nutritional supplementation|Given Ensure Max Protein Nutrition shake 2 weeks before surgery and continued 2 weeks after surgery.
62418022|NCT03287102|OTHER|Temporal inverted ILM peeling group|The internal limiting membrane is peeled from the temporal side of the fovea only
62418023|NCT03287102|OTHER|Complete ILM peeling group|The internal limiting membrane is completely removed around the fovea
62418024|NCT05350969|EXPERIMENTAL|CDR132L 5 mg|CDR132L 5 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57
62026509|NCT02576574|EXPERIMENTAL|Avelumab Biweekly|
62026510|NCT02576574|EXPERIMENTAL|Avelumab Weekly|
62026511|NCT02576574|ACTIVE_COMPARATOR|Chemotherapy|
62026512|NCT06010589|EXPERIMENTAL|Intervention: DWJ1558|
62418025|NCT05350969|EXPERIMENTAL|CDR132L 10 mg|CDR132L 10 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57
62418026|NCT05350969|PLACEBO_COMPARATOR|Placebo|Placebo intravenous in single dose on Day 1, Day 29 and Day 57
62433504|NCT00003070|EXPERIMENTAL|Stratum 2 < 350mg/m2 anthracycline dose|\< 4 years of age at diagnosis \>= 4 years since cessation of anthracycline treatment
62588844|NCT04210284|NO_INTERVENTION|No Nutritional supplementation|Treatment as usual
62588845|NCT04435977|EXPERIMENTAL|Cabozantinib|Drug: Cabozantinib Subjects who meet all study eligibility criteria will take tablets containing 60 mg of cabozantinib once daily orally. Required dose reductions will be in decrements of 20 mg cabozantinib (maximum two dose reductions).
62799581|NCT04205526|EXPERIMENTAL|Active rTMS|Sub-acute stroke patients will be randomized to receive actual rTMS treatment. 1Hz rTMS will be applied over contralesional M1 at an intensity of 120% resting motor threshold once daily for 30 minutes (approximately 1800 pulses) for a total of 15 sessions.
62799582|NCT04205526|SHAM_COMPARATOR|Sham control|Sub-acute stroke patients randomized to receive sham rTMS. For sham-stimulation, the TMS coil will be placed over the inter-hemispheric fissure at the vertex and stimulation will be performed with low intensity (10% resting motor threshold). This will cause similar skin sensations as real stimulation but will not induce currents in motor relevant areas.
62418027|NCT05702827|EXPERIMENTAL|bupivacaine-meloxicam|All patients will receive a total of 20 cc lidocaine with epinephrine injection intra-operatively along the trocar path via the suprapubic incisions, as is standard practice to help with hydrodissection for the procedure. 3-4 cc of bupivacaine-meloxicam will be infiltrated into each suprapubic abdominal incision in the study group
62418028|NCT05702827|NO_INTERVENTION|Standard of Care|All patients will receive a total of 20 cc lidocaine with epinephrine injection intra-operatively along the trocar path via the suprapubic incisions, as is standard practice to help with hydrodissection for the procedure.
62418029|NCT04920162|OTHER|Skin deseases biospecimens collection|Collect of blood samples without DNA into patients who had a vitiligo or a melanoma at day 0 until 1 year after their treatment
62418030|NCT01417208||SNaP® Wound Care System|
62799583|NCT00500188|EXPERIMENTAL|7 Days|Imatinib Mesylate 300 mg orally twice daily starting 7 days before surgery.
62799584|NCT00500188|EXPERIMENTAL|5 Days|Imatinib Mesylate 300 mg orally twice daily starting 5 days before surgery.
62799585|NCT00500188|EXPERIMENTAL|3 Days|Imatinib Mesylate 300 mg orally twice daily starting 3 days before surgery.
62418031|NCT05728918|PLACEBO_COMPARATOR|Placebo|Placeo group
62026513|NCT06010589|EXPERIMENTAL|Intervention: DWC202310 and DWC202311|
62418032|NCT05728918|EXPERIMENTAL|Treatment|Experimental group
62418033|NCT05664841|EXPERIMENTAL|magic trick training|Participation in a 6 weekly virtual magic trick training camp with three lessons per week.
62418034|NCT05664841|NO_INTERVENTION|waitlist control|Participation in usual daily activities.
62433505|NCT00003070|EXPERIMENTAL|Stratum 3 < 350mg/m2 anthracycline dose|\>= 4 years of age at diagnosis \< 4 years since cessation of anthracycline treatment
62588846|NCT03388775||Patients with deep venous thrombosis|"Five-year prospective records of deep venous thrombosis have been collected by the RHEUNI group of five public schools in the State of São Paulo.~Demographic data of patients will be evaluated along with the main risk factors, clinical picture, diagnostic methods, use of different drugs to treat the disease and its complications."
62588847|NCT04261413|EXPERIMENTAL|RS-0139|There will be only RS-0139 arm in the study.
62799586|NCT06202963|ACTIVE_COMPARATOR|Group 1|In group 1, hydrodilatation will be performed with intra-articular 40 mg triamcinolone, lidocaine, and physiological saline through a posterior approach to the shoulder, guided by ultrasonographic imaging. Fluid injection will continue until distension is observed in the shoulder joint capsule by ultrasonography. The amount of fluid given will be recorded.
62799587|NCT06202963|ACTIVE_COMPARATOR|Group 2|The second group will undergo hydrodilatation with intra-articular 40 mg triamcinolone, lidocaine, and physiological saline through a posterior approach to the shoulder, guided by ultrasonographic imaging. The amount of fluid given will be recorded. Additionally, with ultrasonographic evaluation, 2 cc of physiological saline will be injected into the corocohumeral ligament.
62799588|NCT02638324|ACTIVE_COMPARATOR|Renal nervous denervation.|Renal nervous denervation is performed to the patients who do not response properly to conventional therapy. The patients are randomised according to the waiting list principle.
62799589|NCT02638324|ACTIVE_COMPARATOR|Renal nervous denervation (delayed)|Renal nervous denervation is performed after six months on the waiting list
62225146|NCT05187182|EXPERIMENTAL|Dose Escalation (CA4948 + FOLFOX + Nivolumab)|"* CA4948 (dose will depend on dose level assigned) twice daily by mouth. Standard of care mFOLFOX7 every 14 days. Nivolumab every 14 days.~* Each cycle is 14 days."
62225147|NCT05187182|EXPERIMENTAL|Dose Expansion Cohort A (CA4948 + FOLFOX + Nivolumab)|"* CA4948 (dose will be the recommended phase II dose found in the dose escalation portion of study) twice daily by mouth. Standard of care mFOLFOX7 every 14 days. Nivolumab every 14 days.~* Each cycle is 14 days."
62225148|NCT05187182|EXPERIMENTAL|Dose Expansion Cohort B (CA4948 + FOLFOX + Pembrolizumab + Trastuzumab)|"* CA4948 (dose will be the recommended dose found in the dose escalation portion of study) twice daily by mouth Standard of care mFOLFOX7 every 14 days. Pembrolizumab on day 1 of every 3 cycles. Trastuzumab every 14 days.~* Each cycle is 14 days."
62225149|NCT00413972|EXPERIMENTAL|Vytorin 10/10|Ezetimibe 10 mg with Simvastatin 10 mg
62225150|NCT00413972|EXPERIMENTAL|Vytorin 10/20|Ezetimibe 10 mg with Simvastatin 20 mg
62418035|NCT03262519||Patients at UCSD Sleep Medicine Clinic|Patients referred for sleep testing (either home sleep testing or in-lab full polysomnography) will be approached for participation.
62418036|NCT06701071|EXPERIMENTAL|Long Clomid|Clomid with gonadotropins throughout the entire duration of ovarian stimulation without addition of GnRH antagonist
62799590|NCT02042521|EXPERIMENTAL|Healthy Smokers (Active then Placebo)|"Healthy individuals who smokes at least 20 cigarettes per day~Interventions: Dietary Supplement, Lactose Placebo"
62799591|NCT02042521|EXPERIMENTAL|Healthy Smokers (Placebo then Active)|"Healthy individuals who smokes at least 20 cigarettes per day~Interventions: Dietary Supplement, Lactose Placebo"
62799592|NCT00879385|EXPERIMENTAL|All patients|All participants enrolled.
62225151|NCT00413972|EXPERIMENTAL|Vytorin 10/40|Ezetimibe 10 mg with Simvastatin 40 mg
62225152|NCT00413972|PLACEBO_COMPARATOR|Placebo|
62225153|NCT02789254|EXPERIMENTAL|Experimental: FLYSYN|IV infusion over a 3-hr duration
62225154|NCT05040984||solifenacin|
62225155|NCT05040984||mirabegron|
62225156|NCT05609201||Cases|36 participants with a multidisciplinary team diagnosis of IPF or non-IPF fibrotic-ILD
62225157|NCT05609201||Healthy Control|5 Age, sex and ethnicity matched controls
62225158|NCT02118558|EXPERIMENTAL|Negative Pressure Wound Therapy (NPWT)|
62225159|NCT02118558|ACTIVE_COMPARATOR|standard prophylactic therapy|
62225160|NCT03430531|EXPERIMENTAL|Sphenopalatine ganglion block|Sphenopalatine ganglion block: this block will be performed by inserting swabs, with lidocaine squirted on them, into each nostril and reaching the nasopharyngeal wall.
62225161|NCT04033185|ACTIVE_COMPARATOR|study group|virtual reality, robot-assisted gait training, conventional treatment
62225162|NCT04033185|OTHER|control group|conventional treatment
62225163|NCT04822831|EXPERIMENTAL|Long-term Ventilator-dependent Patients with intervention|45 Degree Semi-recumbent Position With Upper Limb Exercise Training on Long-term Ventilator-dependent Patients
62225164|NCT04822831|EXPERIMENTAL|Long-term Ventilator-dependent Patients without intervention|There is no intervention on Long-term Ventilator-dependent Patients ,and just keep routine treatment.
62225165|NCT02723526||Single arm|
62225166|NCT02684253|EXPERIMENTAL|Nivolumab 3mg/kg IV every 2 weeks|Nivolumab 3mg/kg IV every 2 weeks
62225167|NCT02684253|EXPERIMENTAL|Stereotactic Body Radiotherapy & Nivolumab|"Image Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Nivolumab).~Nivolumab 3mg/kg IV starting day 1 and then every 2 weeks thereafter. Treatment with Nivolumab will continue until progression or unacceptable toxicity."
62418037|NCT06701071|ACTIVE_COMPARATOR|5-day Clomid|Clomid only for 5 days starting on day 2 or 3 of menses with gonadotropins, with GnRH antagonist added when the lead follicle reaches \~14mm.
62418038|NCT06213389|EXPERIMENTAL|Patients to entubate with EzVision® videolaryngoscopy|Patients will intubate with EzVision® videolaryngoscopy
62418039|NCT06213389|OTHER|Patients to intubate with Macintosh blade|Patients will intubate with Macintosh blade
62418040|NCT06703918||Case Group|This group includes infants and young children diagnosed with Clostridium difficile infection (CDI). Participants in this group have been identified based on medical records andpatient questionnaires showing confirmed CDI diagnosis. This group will be analyzed for epidemiological characteristics and biomarkers associated with CDI.
62418041|NCT06703918||Control Group|This group includes infants and young children without Clostridium difficile infection (CDI). These participants have no record of CDI diagnosis and serve as the control group to identify risk factors and biomarkers by comparing with the case group.
62799593|NCT04390243|EXPERIMENTAL|Treatment (encorafenib, binimetinib)|Patients receive encorafenib PO QD and binimetinib PO BID on days 1-25. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
62799594|NCT02656355|NO_INTERVENTION|Stage 1:Healthy people|To establish baseline and reliability.
62799595|NCT02656355|NO_INTERVENTION|Stage 2:Healthy people|To establish stage 3 training protocol.
62418042|NCT05924672|EXPERIMENTAL|Treatment (NaF PET/CT/MDP, Ra-223, PSMA PET)|Patients undergo NaF PET/CT or MDP scan within 45 days prior to cycle 1 day 1. Patients then receive standard of care Ra-223 IV on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo PSMA PET/CT over 45-60 minutes between 30-60 days after the last dose of Ra-223. Patients also undergo collection of blood samples during screening, on day 1 of every Ra-223 cycle, and at 30 days after the last dose of Ra-223. Patients may also undergo NaF PET/CT or MDP scans during Ra-223 treatment as clinically indicated, and/or CT scans during screening and Ra-223 treatment as clinically indicated.
62588848|NCT06498024|ACTIVE_COMPARATOR|Consumption of 1 of 2 control rice cereal products|This arm will provide one of the 2 white rice control products and there will be a minimum of three days separating each visit.
62799596|NCT02656355|NO_INTERVENTION|Stage 2:PD people|To establish stage 3 training protocol.
62026514|NCT06499870|EXPERIMENTAL|Treatment (relugolix, enzalutamide, IGRT)|Patients receive relugolix PO QD and enzalutamide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 18 months in the absence of disease progression or unacceptable toxicity. After 4 months of treatment with relugolix and enzalutamide, patients begin IGRT per standard of care. Patients also undergo fluorine F 18 piflufolastat PET/MRI and CT on the trial, undergo collection of blood samples throughout the trial, and undergo biopsy during follow up.
62026515|NCT01197079||MSM|Young men (under 26 years of age) who have sex with men
62026516|NCT01197079||Parents|Parents of Boys aged 9 to 18 years
62026517|NCT05909865|EXPERIMENTAL|Therapeutic exercise plus education|The treatment will consist of a progressive resistance exercise program along with education.
62026518|NCT03694548|OTHER|Part A Survey: Group 1 Adolescent Patients with SCD|Adolescent patients with SCD and chronic pain completed a survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
62225168|NCT04900987|EXPERIMENTAL|Treatment group|After putting adequate manual pressure proximal to radial puncture site, dry and sterile application of steri-strip followed by pneumatic TR band for 1 to 2 hour.
62418043|NCT01467674||Healthy|
62418044|NCT01467674||Chronic Periodontitis|
62418045|NCT01467674||Better Controlled T2DM|
62418046|NCT01467674||Poor Controlled T2DM|
62418047|NCT05209139|EXPERIMENTAL|Beetroot supplementation|Acute beetroot juice supplementation
62418048|NCT05209139|PLACEBO_COMPARATOR|Placebo supplementation|Acute placebo supplementation
62418049|NCT06568107|EXPERIMENTAL|EASE Intervention|Thirty-two persons with dementia will be exposed by an interventionist to an Environmental And Sensory Experience (EASE) intervention which involves a tailored, person-centered nature scene projected with associated nature sounds. A within-person design will be used where the participants will serve as their own controls and be observed 30 minutes prior to, 30 minutes during, and for 30 minutes directly after EASE.
62418050|NCT06264362|EXPERIMENTAL|Tailored Physical Activity Program for Pain|Specific characteristics of the intervention delivered in Phase 2 will be based on the information gathered from stakeholders in Phase 1.
62418051|NCT01258231||Cardiac surgery|Adult patients undergoing cardiac surgery
62799597|NCT02656355|EXPERIMENTAL|Stage 3:PD APA training group|Weight shift training and APA feedback.
62799598|NCT02656355|EXPERIMENTAL|Stage 3:PD Balance training group|Weight shift training without APA feedback.
62026519|NCT03694548|OTHER|Part A Survey: Group 2 Parents of Adolescent Patients with SCD in Part A|Parents of adolescent patients with SCD and chronic pain from Group 1 completed a survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
62026520|NCT03694548|EXPERIMENTAL|Part B Yoga Program|Participants from Part A Group 1 had the opportunity to enroll in Part B to receive eight in-person instructor-led group yoga sessions.
62026521|NCT02796339|ACTIVE_COMPARATOR|Mastiha|This arm of patients will receive natural Mastiha supplements at the dosage of 2.8g daily. Patients with active disease will be administered with supplements for 3 months, whereas patients in remission will be administered with supplements for 6 months.
62026522|NCT02796339|PLACEBO_COMPARATOR|Placebo|This arm of patients will receive placebo . Patients with active disease will be administered with placebo for 3 months, whereas patients in remission will be administered with placebo for 6 months.
62418052|NCT02264509||Arterial insufficiency and HIV|Of a cohort of 206 HIV patients will be randomly selected 206 for Ankle-brachial index to identify wich suffer symptomatic or asymptomatic arterial insufficiency
62588849|NCT06498024|ACTIVE_COMPARATOR|Final consumption of 1 of 2 control rice cereal products|This arm will provide one of the 2 white rice control products and there will be a minimum of three days separating each visit.
62799599|NCT02656355|NO_INTERVENTION|Stage 3:PD Control group|Control group
62799600|NCT05842759|OTHER|Hypotension Avoidance Strategy|"After the patients' arrival in the induction area, routine anesthetic monitoring (electrocardiography and pulse oximetry) will be established. In all patients, the arterial catheter for continuous intraarterial blood pressure monitoring will be inserted before anesthetic induction (after the insertion site has been infiltrated with a local anesthetic). An uncalibrated pulse wave analysis monitor (MostCareUP, Vygon, Aachen, Germany) will be connected to the patient monitor for advanced hemodynamic monitoring of including cardiac output, systemic vascular resistance, stroke volume variation, and pulse pressure variation.~Besides continuous intraarterial blood pressure monitoring, the hypotension avoidance strategy will be applied."
62799601|NCT04863391||early/none vs.|For identification of early/none (i.e., non-referral level) Age Related Macular Degeneration (ARMD)
62026523|NCT03407638|ACTIVE_COMPARATOR|PROUD Intervention|Primary care clinics randomized to the PROUD Intervention will implement the Massachusetts (MA) Model of collaborative care for opioids use disorders (OUDs). The PROUD trial provides financial support to cover the nurse case manager (NCM) salary and technical assistance for the duration of the study, but the health systems-not investigators-implement the MA Model as part of quality improvement, and the health system and its clinicians provide all clinical care.
62225169|NCT04900987|NO_INTERVENTION|Control group|Application of pneumatic TR band alone for 4 hours as per usual practice
62588850|NCT06498024|EXPERIMENTAL|Consumption of 1 of 4 rice products|This arm will provide 1 of the 4 randomly assigned rice products to the participant and there will be a minimum of three days separating each visit.
62418053|NCT04943913|EXPERIMENTAL|Tumor Infiltrating Lymphocytes|1x10\^9-5x10\^10 in vitro expanded autologous TILs will be infused i.v. to patients with brain glioma after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
62418054|NCT01213004|EXPERIMENTAL|thoracic (study group 1) malignancies|On the same day as the CBCT scans and treatment session, patients will receive a research-only respiration correlated CT (RCCT scan), for calculating motion-corrected CBCT. The localization accuracy of motion-corrected CBCT using same-day RCCT will be compared to that using the standard RCCT from simulation.
62588851|NCT06498024|EXPERIMENTAL|Second consumption of 1 of 4 rice products|This arm will provide 1 of the 4 randomly assigned rice products to the participant and there will be a minimum of three days separating each visit.
62588852|NCT06498024|EXPERIMENTAL|Third consumption of 1 of 4 rice products|This arm will provide 1 of the 4 randomly assigned rice products to the participant and there will be a minimum of three days separating each visit.
62588853|NCT06498024|EXPERIMENTAL|Final consumption of 1 of 4 rice products|This arm will provide 1 of the 4 randomly assigned rice products to the participant.
62588854|NCT00177840|EXPERIMENTAL|1|True acupuncture using true needles
62588855|NCT00177840|SHAM_COMPARATOR|2|sham acupuncture using sham needles
62588856|NCT06683287|EXPERIMENTAL|red-light|Children in this group received a red-light apparatus (LS-03B; Yishiliang Inc), which has been deemed safe by the State Administration for Market Regulation of China. They were directed to utilize this apparatus twice a day for 3-minute sessions, ensuring a gap of over 4 hours between each use.
62799602|NCT04863391||intermediate/late AMD|intermediate/late (i.e., referral level) Age Related Macular Degeneration (ARMD)
62799603|NCT03098862||1|Direct EBOV exposure risk controls
62799604|NCT03098862||2|EVD fatal cases
62799605|NCT03098862||3|EVD survivor cases
62799606|NCT03098862||4|No known EBOV exposure population controls
62799607|NCT01964417|ACTIVE_COMPARATOR|4L-split Dose of PEG Solution|4L-split Dose of PEG Solution for bowel preparation
62799608|NCT01964417|ACTIVE_COMPARATOR|Low-volume PEG Plus Ascorbic Acid|Low-volume PEG Plus Ascorbic Acid for bowel preparation
62799609|NCT05687721|EXPERIMENTAL|Therapeutic arm|Copanlisib will be administered through intravenous infusion (IV) at 60 mg on Day 1, 8 and 15, and avelumab will be administered 800 mg IV on Day 1 and 15 of each 4-week treatment cycle for up to 26 cycles
62799610|NCT01153126|NO_INTERVENTION|No Intervention: Usual Care|A group receiving usual care plus 5 reliable websites
62799611|NCT01153126|EXPERIMENTAL|Intervention|A group using the Comprehensive Health Enhancement Support System (CHESS.)
62799612|NCT00972335|EXPERIMENTAL|Combination Therapy|"Everolimus; this drug will be dosed at 10 mg orally DAILY for the duration of the study.~Bevacizumab; this drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study"
62799613|NCT06504316|EXPERIMENTAL|oXiris|The subjects will be accepted oXiris filter at the first treatment session for 72 hours.
62588857|NCT06683287|EXPERIMENTAL|distant-image screen group|participants were given a distant-image screen ( RIO-Max2.0; Ruishi Inc), and were asked to use this device for ≥1 hour/day
62799614|NCT06504316|ACTIVE_COMPARATOR|ST 150|The subjects will be accepted ST 150 filter at the first treatment session for 72 hours.
62799615|NCT02378688|EXPERIMENTAL|MT-1303|
62799616|NCT02378688|PLACEBO_COMPARATOR|Placebo|
62799617|NCT01209351|PLACEBO_COMPARATOR|Placebo|Placebo
62799618|NCT01209351|EXPERIMENTAL|teduglutide|
62799619|NCT00605124|EXPERIMENTAL|exercise|progressive exercise, home-based exercise program, tree exercise sessions weekly, chec-up visits every third month
62588858|NCT06683287|EXPERIMENTAL|red-light plus distant image screen|For this group, participants were given a red-light device (LS-03B; Yishiliang Inc) and a distance image screen device ( RIO-Max2.0; Ruishi Inc), and were asked to use red-light twice a day for 3-minute sessions, ensuring a gap of over 4 hours between each use, and use distant image screen for ≥1 hour/day
62588859|NCT06683287|NO_INTERVENTION|control|No intervention
62588860|NCT06666452|EXPERIMENTAL|Intervention|The COMFI intervention
62588861|NCT02126267|EXPERIMENTAL|Full mouth disinfection - FMD|n = 10: Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days
62588862|NCT02126267|EXPERIMENTAL|FMD + chlorhexidine (FMD-CX)|n = 15: Same as FMD with the inclusion of chlorhexidine in office (application of chlorhexidine (CX) (1%) gel in pockets after scaling, brushing tongue for 1 min. with CX (1%) gel and mouthwash at the beginning and end of each session with CX 0.2% for 30 seconds (with the form of a gargle in the last 10 seconds)). In addition, use was made of homemade CX 0.2% for 60 days after the scaling in a single phase.
62588863|NCT02126267|EXPERIMENTAL|FMD + azithromycin (FMD-AZ)|n = 15: Same as with the FMD include the use of azithromycin (500 mg) once daily for 3 consecutive days. Medication was started the same day as the end of the scaling.
62588864|NCT02126267|EXPERIMENTAL|Scaling and root planing (SRP)|(n = 13): scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;
62588865|NCT02126267|EXPERIMENTAL|SRP + azithromycin (SRP-AZ)|n = 11: Same as scaling and root planing group (SRP) with inclusion of the use of azithromycin (500 mg) once daily for 3 consecutive days. Medication was started the same day as the end of the last scaling hemi-arch;
62588866|NCT02126267|EXPERIMENTAL|SRP + chlorhexidine (SRP-CX)|n = 13 : Same as group scaling and root planing (SRP) with the inclusion of home use of CX 0.2% for 60 consecutive days after the end of the first session of scaling
62588867|NCT05831176|EXPERIMENTAL|Part A: Phase 2|Randomized 1:1
62799620|NCT00605124|ACTIVE_COMPARATOR|Conventional treatment|Normal treatment, single guidance to home exercise
62799621|NCT02218645|EXPERIMENTAL|WE 941 OD|
62799622|NCT02218645|ACTIVE_COMPARATOR|Brotizolam|
62799623|NCT02364141|EXPERIMENTAL|Trunk restraint therapy|Reaching training with trunk restraint by a harness that limited the trunk movements.
62799624|NCT02364141|ACTIVE_COMPARATOR|Trunk unrestraint therapy|Unrestraint reaching training, only with verbal feedback to maintain the trunk right position.
62799625|NCT01729299|PLACEBO_COMPARATOR|saline|Saline: 0.9% saline solution
62799626|NCT01729299|EXPERIMENTAL|ghrelin and exendin (9-39)|Ghrelin+Ex-9: Combination of ghrelin and Ex-9,
62588868|NCT05831176|EXPERIMENTAL|Part B: Phase 3|Randomized 1:1:1
62799627|NCT01729299|EXPERIMENTAL|Exendin (9-39)|Exendin (9-39) (25 µg/kg) bolus over 1 min followed by a continuous infusion of 2.5 µg/kg/min
62225170|NCT01478529|EXPERIMENTAL|Treatment Arm A|low dose of mirabegron
62225171|NCT01478529|EXPERIMENTAL|Treatment Arm B|high dose of mirabegron
62225172|NCT02450799|EXPERIMENTAL|AcrySof IOL|Acrylic IOL, prior implantation (1994-2000) in one or both eyes
62225173|NCT02450799|ACTIVE_COMPARATOR|Silicone IOL|Silicone IOL, prior implantation (1994-2000) in one or both eyes
62225174|NCT02450799|ACTIVE_COMPARATOR|PMMA IOL|PMMA IOL, prior implantation (1994-2000) in one or both eyes
62799628|NCT01729299|EXPERIMENTAL|ghrelin|synthetic human Acyl Ghrelin (0.28 μg/kg) bolus over 1 min followed by 2 μg/kg/h continuous infusion,
62799629|NCT03242629|ACTIVE_COMPARATOR|oral group|
62799630|NCT03242629|EXPERIMENTAL|enema group|
62799631|NCT05716061|EXPERIMENTAL|median approach|Sacral ESPB performed from the median sacral crest of 2.level of sacrum.
62799632|NCT05716061|ACTIVE_COMPARATOR|intermediate approach|Sacral ESPB performed bilateral and between the median and intermediate sacral crest of 2.level of sacrum.
62799633|NCT03035799|EXPERIMENTAL|Paleolithic Diet|Paleolithic Diet
62799634|NCT03035799|ACTIVE_COMPARATOR|General Healthful Diet|General Healthful Diet
62799635|NCT00483405|OTHER|Single Arm Trial|Single Arm Trial
62799636|NCT05565937|EXPERIMENTAL|BL-3100-NBR03|BL-3100-NBR03 multi-purpose solution
62799637|NCT05565937|ACTIVE_COMPARATOR|renu® Advanced Formula|renu® Advanced Formula multi-purpose solution
62799638|NCT02222558|EXPERIMENTAL|Period 1: Single Dose|Period 1: Each study subject will receive an escalating single dose of TSX-002 (60, 90, 120, 180, 240 mg), with a minimum 3 day wash-out between each of the 5 escalating doses. After completing the 240 mg dose, a 7 day wash-out period will occur prior to Period 2.
62799639|NCT02222558|EXPERIMENTAL|Period 2: Two Times Daily Dosing 90 mg|Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days.
62799640|NCT02222558|EXPERIMENTAL|Period 3: Two Times Daily Dosing 120 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted two times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
62799641|NCT02222558|EXPERIMENTAL|Period 3: Three Times Daily Dosing 90 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted three times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
62799642|NCT02222558|EXPERIMENTAL|Period 3: Two Times Daily Dosing 180 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted two times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
62026524|NCT03407638|NO_INTERVENTION|Usual Primary Care|Clinics randomized to usual primary care do not receive any resources or support from the study but are free to improve opioid use disorder (OUD) care in any way they choose.
62026525|NCT01154166|EXPERIMENTAL|ReQuip PR|Ropinirole PR tablets of 2.0 mg, 4.0mg and 8.0 mg
62799643|NCT02222558|EXPERIMENTAL|Period 3: Three Times Daily Dosing 120 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted three times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
62799644|NCT01556451|EXPERIMENTAL|Zoster Vaccine Live|Single subcutaneous injection of 0.65 mL in the deltoid region of arm on Day 1
62026526|NCT01154166|PLACEBO_COMPARATOR|Placebo|Placebo
62225175|NCT00427895|EXPERIMENTAL|13vPnC Cohort 1, Vaccination 1|Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.
62225176|NCT00427895|ACTIVE_COMPARATOR|23vPS Cohort 1, Vaccination 1|Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.
62225177|NCT00427895|EXPERIMENTAL|13vPnC Cohort 2, Vaccination 1|Participants aged 50-59 years given a 0.5 mL dose administered on day 1.
62225178|NCT00427895|EXPERIMENTAL|13vPnC Cohort 3, Vaccination 1|Participants aged 18-49 years given a 0.5 mL dose administered on day 1.
62225179|NCT00427895|EXPERIMENTAL|13vPnC Cohort 1, Vaccination 2|Participants aged 60-64 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.
62225180|NCT00427895|ACTIVE_COMPARATOR|23vPS Cohort 1, Vaccination 2|Participants aged 60-64 years who received 23vPS at vaccination 1 receive a 0.5 mL dose of 23vPS administered 3-4 years after dose 1.
62225181|NCT00427895|EXPERIMENTAL|13vPnC Cohort 2, Vaccination 2|Participants aged 50-59 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.
62225182|NCT04097301|EXPERIMENTAL|MLM-CAR44.1 T-cells infusion|"PHASE I: i.v. single dose of MLM-CAR44.1 T-cells: 0.5 x 10E6/Kg or 1 x 10E6/Kg or 2 x10E6/Kg according to the BOIN design.~PHASE IIa: i.v. single dose of MLM-CAR44.1 T-cells corresponding to the maximum tolerated dose (MTD).~Phase I and IIa Pre-treatment: lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3"
62433506|NCT00003070|EXPERIMENTAL|Stratum 4 < 350mg/m2 anthracycline dose|\>= 4 years of age at diagnosis \>= 4 years since cessation of anthracycline treatment
62433507|NCT00003070|EXPERIMENTAL|Stratum 5 >= 350mg/m2 anthracycline dose|\< 4 years of age at diagnosis \< 4 years since cessation of anthracycline treatment
62433508|NCT00003070|EXPERIMENTAL|Stratum 6 >=350mg/m2 anthracycline dose|\< 4 years of age at diagnosis \< 4 years since cessation of anthracycline treatment
62225183|NCT02996565|ACTIVE_COMPARATOR|Best Practice Clinic-Based Care|Patients with uncontrolled hypertension who receive primary care in clinics assigned to the Best Practice Clinic-Based Care intervention.
62799645|NCT05960981|EXPERIMENTAL|Intervention grup|The work is one-armed. It consists of only those in the intervention group. After the study was announced, informed consent was obtained from those who agreed to participate in the study. Afterwards, the participants filled out the Demographic Data Form, Repetitive Behavior Scale-Revised (RBS-R), Social Communication Checklist-Revised (SCC-R), Child Behavior Checklist-Dysregulation Profile (CBCL-DP) forms before the intervention program started. When the 8-week online group-based parent mediated intervention program was over, they filled out formsRepetitive Behavior Scale-Revised (RBS-R), Social Communication Checklist-Revised (SCC-R), Child Behavior Checklist-Dysregulation Profile (CBCL-DP) again in the first week.
62799646|NCT04977284|EXPERIMENTAL|TCSCS|
62799647|NCT05265208|EXPERIMENTAL|Capecitabine combined with SIRT|Patients in the experimental arm will be treated with capecitabine combined with Selective Internal Radiotherapy (SIRT) before surgery.
62799648|NCT05265208|OTHER|Surgery only|Patients in the control group will receive surgery only.
62026527|NCT00455195|EXPERIMENTAL|Alglucosidase Alfa/Alglucosidase Alfa|Participants who received alglucosidase alfa during the double-blind study and, if they completed the double-blind study, continued that treatment during the extension study. Participants received an intravenous (IV) infusion of 20 mg/kg of alglucosidase alfa every other week (qow) until their participation in both the AGLU02704 (NCT00158600) and AGLU03206 studies combined equaled a minimum of 104 weeks.
62225184|NCT02996565|ACTIVE_COMPARATOR|Telehealth Care|Patients with uncontrolled hypertension who receive primary care in clinics assigned to the Telehealth Care intervention.
62225185|NCT01043393|EXPERIMENTAL|Psoriasis involving 10-15% BSA|Patients 18 years of age or older with a confirmed diagnosis of moderate to severe plaque psoriasis having involvement of 10-15% of their body surface area.
62225186|NCT01043393|EXPERIMENTAL|Psoriasis involving >15% of BSA|Patients 18 years of age or older with a confirmed diagnosis of moderate to severe plaque psoriasis having involvement of \>15% of their body surface area.
62225187|NCT05314790||control group (CG)|Without intervening Educational Program
62799649|NCT05892601|EXPERIMENTAL|Intervention|Mother kisses were applied to the experimental group. Kisses were delivered by the mother, free of oral ulcers, with a standard 5-second pressing of both lips on the affected body part followed by an exaggerated puckering sound.
62799650|NCT05892601|NO_INTERVENTION|Control|The invasive intervention was performed with the standard method in the control group.
62799651|NCT04729725|EXPERIMENTAL|Treatment (SAR439459, cemiplimab)|Patients receive SAR439459 IV over 30 minutes on day 1 and cemiplimab IV over 30 minutes on day 1 starting cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62799652|NCT00586859|EXPERIMENTAL|A|NDO Full-thickness Plicator Procedure
62799653|NCT05282069|PLACEBO_COMPARATOR|Placebo|DA-8010 placebo + Solifenacin succinate placebo
62799654|NCT05282069|EXPERIMENTAL|DA-8010 2.5mg|DA-8010 2.5mg + Solifenacin succinate placebo
62799655|NCT05282069|EXPERIMENTAL|DA-8010 5mg|DA-8010 5mg + Solifenacin succinate placebo
62026528|NCT00455195|EXPERIMENTAL|Placebo/Alglucosidase Alfa|Participants given placebo during the double-blind study, completed the double-blind study (study AGLU02704, NCT00158600), and qualified to continue into the extension study on alglucosidase alfa. Participants received an intravenous (IV) infusion of 20 mg/kg of alglucosidase alfa every other week (qow) for up to 52 weeks. Only the alglucosidase alfa treatment experience is included in this extension study.
62225188|NCT05314790||training group (TG)|Group who has received an Educational Program (EP). The implementation of an EP based on meetings within the Department, coordinated by an outside tutor (outreach visit model). The EP content was defined beforehand by a Scientific Board, on the basis of evidence-based guidelines (EBGs) and an up-to-date literature review, but also with a specific focus on any departures from standard clinical practice recommendations (CPRs) identified at each IM department in phase 1.
62799656|NCT05282069|ACTIVE_COMPARATOR|Solifenacin 5mg|DA-8010 placebo + Solifenacin succinate 5mg
62799657|NCT00936702|EXPERIMENTAL|Treatment (carboplatin, paclitaxel, and everolimus)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Patients also receive everolimus PO QD on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62799658|NCT02296567|ACTIVE_COMPARATOR|Group 1 Lucentis 4 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
62026529|NCT01359800||Treatment-naive HIV+ subjects|
62026530|NCT01359800||HAART-treated HIV+ subjects|
62225189|NCT05003440|EXPERIMENTAL|NNC0385-0434 15 mg|15 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days
62225190|NCT05003440|PLACEBO_COMPARATOR|Placebo (NNC0385-0434 15 mg)|Oral placebo will be administered once-daily over 10 consecutive days
62225191|NCT05003440|EXPERIMENTAL|NNC0385-0434 40 mg|40 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days
62225192|NCT05003440|PLACEBO_COMPARATOR|Placebo (NNC0385-0434 40 mg)|Oral placebo will be administered once-daily over 10 consecutive days
62225193|NCT05003440|EXPERIMENTAL|NNC0385-0434 100 mg|100 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days
62225194|NCT05003440|PLACEBO_COMPARATOR|Placebo (NNC0385-0434 100 mg)|Oral placebo will be administered once-daily over 10 consecutive days
62588869|NCT05831176|EXPERIMENTAL|Part C: Extended Active Treatment Period|Eligible participants from Part A and Part B will enter Part C. Part A participants will get Dose 1. Part B participants who received Dose 1 or Dose 2 will remain on Dose 1 or Dose 2. Part B placebo participants will be randomized 1:1 to receive Dose 1 or Dose 2.
62588870|NCT05147922|EXPERIMENTAL|Booster Training Group|Participants randomized to intervention will undergo booster training sessions with the RQI cart (including audiovisual feedback) at 3, 6 and 9 months post instructor-led training session. Following each of these booster sessions, the participants will undergo 1 minute assessments, without feedback.
62225195|NCT05117164|NO_INTERVENTION|control group|Patients will receive enteral feeding based on the practice of the leading physician.
62225196|NCT05117164|EXPERIMENTAL|intervention|"Infants will receive enteral feeding based on the following protocol.~Enteral nutrition Minimal enteral nutrition (MEN) will begin within 72 hours life at 10 to 20. mL/kg/day, via bolus gravity breast milk/donor human milk. MEN will not be included in the caloric goals.~Advancements in feeding will be set at 20-30 mL/kg/day, but not more than 10ml per feeding portion to reach a goal of 150ml/kg/day, but not than 120ml/kg/day cases of fluid restriction).~The goal will be to reach an overall daily caloric intake of minimum 100kcal/kg/d."
62588871|NCT05147922|NO_INTERVENTION|No Booster Training Group|Participants randomized to the control group will undergo 1 minute assessments, without feedback, at 6 and 9 months. Participants will not be able to access the RQI cart outside of their assessment.
62799659|NCT02296567|ACTIVE_COMPARATOR|Group 2 Avastin 4 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
62799660|NCT02296567|ACTIVE_COMPARATOR|Group 3 Eylea 4 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
62225197|NCT03305731|EXPERIMENTAL|Activating Behavior for Lasting Engagement|Participants will engage in the ABLE intervention.
62225198|NCT00390585|EXPERIMENTAL|A|Iodixanol 320
62588872|NCT06580509|EXPERIMENTAL|Nebulized Tranexamic Acid|Subjects will be adminstered nebulized TXA post-tonsillectomy if they return to the emergency room with hemorrhage after surgery
62799661|NCT02296567|ACTIVE_COMPARATOR|Group 4 Lucentis 6 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
62799662|NCT02296567|ACTIVE_COMPARATOR|Group 5 Avastin 6 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
62799663|NCT02296567|ACTIVE_COMPARATOR|Group 6 Eylea 6 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
62799664|NCT02296567|ACTIVE_COMPARATOR|Group 7 Lucentis 8 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
62799665|NCT02296567|ACTIVE_COMPARATOR|Group 8 Avastin 8 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
62799666|NCT02296567|ACTIVE_COMPARATOR|Group 9 Eylea 8 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
62799667|NCT02296567|ACTIVE_COMPARATOR|Group 10 Control Group no treatment|Blood samples will be collected from patients who are not receiving anti-VEGF treatment.
62026531|NCT03467659|EXPERIMENTAL|Cracked whole wheat porridge|Large particle whole wheat porridge
62026532|NCT03467659|EXPERIMENTAL|Semolina wheat porridge|Large particle refined wheat porridge
62588873|NCT06580509|PLACEBO_COMPARATOR|Nebulized Saline|Subjects will be adminstered nebulized saline post-tonsillectomy if they return to the emergency room with hemorrhage after surgery
62588874|NCT03903094||Subjects With Overactive Bladder Treatment|Subjects who have dispensing records for treatment of overactive bladder will be included
62799668|NCT03027622||long term quality of life|to evaluate conservatively managed third molars with mild pericoronitis at first, third and sixth months by using OHIP-14 TR
62799669|NCT05152459|EXPERIMENTAL|Treatment (tazemetostat, umbralisib, ublituximab)|Patients receive ublituximab IV on days 1, 8, and 15 of cycle 1, day 1 of cycle 2-6, and day 1 of every 3 cycles thereafter. Patients also receive tazemetostat PO BID umbralisib by PO QD on days 1-28. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
62026533|NCT03467659|EXPERIMENTAL|Whole wheat flour porridge|Small particle whole wheat porridge
62026534|NCT03467659|EXPERIMENTAL|Refined wheat flour porridge|Small particle refined wheat porridge
62026535|NCT03467659|EXPERIMENTAL|Refined wheat flour porridge,fine bran|Small particle refined wheat porridge with small particle bran
62026536|NCT03467659|EXPERIMENTAL|Refined wheat flour porridge,coarse bran|Small particle refined wheat porridge with large particle bran
62225199|NCT00390585|ACTIVE_COMPARATOR|B|Iomeprol 350
62225200|NCT01873820|EXPERIMENTAL|Calcium ascorbate -> ascorbic acid|
62588875|NCT03903094||Subjects Without Overactive Bladder Treatment|Subjects who do not have dispensing records for treatment of overactive bladder will be included
62799670|NCT05620082||Malnourished older adults in hospital|Participants will be given oral nutritional supplementation twice per day for 4 days, in addition to normal meals, in a crossover design. The products will be offered in-between breakfast and lunch, and after dinner. Products will include traditional sip-feeds (an anonymous ready-made drink supplement, 125g, 306kcal, 18.3g protein) and a new fortified porridge (Adams Vital Nutrition Ltd. High Protein Oats, 157g, 230kcal, 15g protein).
62799671|NCT01784731||Patients|
62799672|NCT01265381||Cohort of Chernobyl Cleanup Workers in Ukraine|Thyroid cancer cases and matched controls in the cohort
62225201|NCT01873820|EXPERIMENTAL|Ascorbic acid -> calcium ascorbate|
62418055|NCT01213004|EXPERIMENTAL|abdominal (study group 2) malignancies|On the same day as the CBCT scans and treatment session, patients will receive a research-only respiration correlated CT (RCCT scan), for calculating motion-corrected CBCT. The localization accuracy of motion-corrected CBCT using same-day RCCT will be compared to that using the standard RCCT from simulation.
62799673|NCT02640547||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
62026537|NCT06669897||Questionnaire|Chronic cough
62026538|NCT02854098||with functional constipation|n = 200 patients with functional constipation examined for BHJS age 3 -18 years meet inclusion criteria, do not fulfill exclusion criteria
62225202|NCT02475239|EXPERIMENTAL|Postural restriction|The patients were instructed to avoid head movements, wear a soft collar during the daytime, wear a supporting pillow and sleep in the semi-upright position at a 45 degree head elevation from the horizontal plane during the nighttime for 48 hours.
62225203|NCT02475239|ACTIVE_COMPARATOR|Normal daily activity|The patients did not follow any postural restrictions and were asked to live as normally as possible.
62225204|NCT02084056|EXPERIMENTAL|FDC first, fasted|Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fasted
62225205|NCT02084056|EXPERIMENTAL|Single tablets first, fasted|single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fasted
62225206|NCT02084056|EXPERIMENTAL|FDC first, fed|Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fed
62225207|NCT02084056|EXPERIMENTAL|Single tablets first, fed|single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fed
62418056|NCT05754749|EXPERIMENTAL|Contrast-enhanced digital breast tomosynthesis (CE-DBT)|Participants with known breast lesions will be imaged using contrast-enhanced digital breast tomosynthesis (CE-DBT) with Iohexol 350 mg I/mL.
62418057|NCT00713713|EXPERIMENTAL|1|Two different tidal volumes (6 and 12 ml.kg-1 of ideal weight) are alternatively delivered to patients 30 minutes each one. The order of the two tidal volumes is randomized. Between the two study tidal volumes, patient returns for 30 minutes to the tidal volume used before the study recruitment.
62418058|NCT01823237|ACTIVE_COMPARATOR|rTMS|rTMS condition, rTMS will be applied at 0.1-0.5 Hz frequency at a subthreshold intensity
62026539|NCT02854098||without functional constipation|n = 200 patient with functional constipation examined for BHJS age 3 -18 years meet inclusion criteria, do not fulfill exclusion criteria
62418059|NCT01823237|PLACEBO_COMPARATOR|rTMS sham|Placebo condition will use a sham coil and apply a very small magnetic stimulus
62418060|NCT03356431|EXPERIMENTAL|Supervised group exercise|The supervised exercise group will receive a lower extremity exercise treatment, under physiotherapist supervision for 60 min, two times a week (12 sessions).
62026540|NCT04946201||With Extractions|Patients in this group will undergo dental extractions.
62418061|NCT03356431|EXPERIMENTAL|Home-based exercise|"For the home-based exercise group, exercises will be demonstrated to the patient with the supervision and guidance of a physiotherapist in an exercise session. These patients will perform the same exercise protocol at home at least twice a week.~In addition to the initial session, subjects will perform further two supervised sessions (at one week and four weeks after the initial session).~The exercise program are the same as the supervised group exercise."
62418062|NCT03891979|EXPERIMENTAL|Pembrolizumab + Antibiotics|Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.
62418063|NCT05019638|ACTIVE_COMPARATOR|Regional anesthesia group|Standard single-shot anesthesia consists of bupivacaine 0.25% with epinephrine 1:400,000.
62418064|NCT05019638|EXPERIMENTAL|Local multimodal analgesia group|Local multimodal analgesia composition will include 5mg of morphine, 500 mg of epinephrine, 15mg of ketorolac, and 20mg of bupivacaine.
62026541|NCT04946201||Without Extractions|Patients in this group will not undergo dental extractions.
62026542|NCT00547560|OTHER|GSI+Placebo|
62225208|NCT01554774||GOLD II|Will be included in this group the patients with COPD stage II
62225209|NCT01554774||GOLD III|Will be included in this group the patients with COPD stage III
62225210|NCT01554774||GOLD IV|Will be included in this group the patients with COPD stage VI.
62418065|NCT04682639|EXPERIMENTAL|Etrasimod Dose 1|
62799674|NCT00909506|PLACEBO_COMPARATOR|Placebo|Placebo
62799675|NCT00909506|ACTIVE_COMPARATOR|Metformin 500 mg/d|Metformin 500 mg/d
62799676|NCT00909506|ACTIVE_COMPARATOR|Metformin 1000 mg/d|Metformin 1000 mg/d
62799677|NCT00466440|EXPERIMENTAL|docetaxel + prednisone + enzastaurin|Regimen A: docetaxel 75 milligrams per square meter (mg/m\^2), intravenous (IV) is administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 milligrams (mg) oral (po), twice daily (BID) every day. In Cycle 1, enzastaurin is given as a loading dose of 1125 mg on the day prior to docetaxel and prednisone therapy, followed by enzastaurin 500 mg po, daily (QD) for the remaining Period 2 (chemotherapy) and Period 3 (maintenance).
62799678|NCT00466440|PLACEBO_COMPARATOR|docetaxel + prednisone + placebo|Regimen B: docetaxel 75 mg/m\^2, IV is administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 mg po, BID every day. In Cycle 1, placebo is given as a loading dose on the day prior to docetaxel and prednisone therapy, followed by po, QD placebo for the remaining Period 2 (chemotherapy) and Period 3 (maintenance), until unblinding.
62225211|NCT04584775|EXPERIMENTAL|Traditional Chinese Medicine plus Standard Care|Participants in this group will receive standard Palliative Care and will additionally see a practitioner of Traditional Chinese Medicine. No strict protocol for the actual intervention exists (pragmatic approach). The participants will at least receive acupuncture and/or chinese herbal medicine. The standard care will include any established medical intervention according to currently available guidelines in palliative care.
62225212|NCT04584775|OTHER|Standard Care|The standard care will include any established medical intervention according to currently available guidelines in palliative care.
62225213|NCT02483585|PLACEBO_COMPARATOR|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. At week 12 participants began treatment with erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
62418066|NCT04682639|EXPERIMENTAL|Etrasimod Dose 2|
62418067|NCT04682639|PLACEBO_COMPARATOR|Placebo and Etrasimod|Participants will receive etrasimod matching placebo tablet during the Double-Blind Treatment Period and etrasimod tablet during the Extension Treatment Period.
62588876|NCT05260463|EXPERIMENTAL|Silver-coated Implant|The summary description and intended purpose of the investigational device (LOQTEQ® antibacterial silver-coated system) is the same as that of the comparator device (LOQTEQ® 3.5 System (uncoated) system). The investigational device differs from the comparator device in that its surface which has been modified by the addition of an antibacterial coating.
62418068|NCT05874479|EXPERIMENTAL|Active Portable Air Cleaner (PAC)|Using a double-blind randomized process, active PACs (with HEPA filters inside) will be assembled and placed in the bedroom of study participants. Initiation of the PAC devices will occur at baseline on Day 0. After completion of enrollment, consent and the placement of PACs, electricity monitors, and PurpleAir monitoring, the PAC will be turned on. Participants will be instructed to keep the PACs on in bedrooms during the study duration, closing bedroom doors at night and during the day, when possible. The PAC will run for 24 hours on Day 0 of the study protocol before the 30-day treatment period begins. A kilowatt meter will be installed with the PAC to monitor electricity usage as a measure of adherence.
62433509|NCT00003070|EXPERIMENTAL|Stratum 7 >= 350mg/m2 anthracycline dose|\>= 4 years of age at diagnosis \< 4 years since cessation of anthracycline treatment
62433510|NCT00003070|EXPERIMENTAL|Stratum 8 >= 350mg/m2 anthracycline dose|\>= 4 years of age at diagnosis \>= 4 years since cessation of anthracycline treatment
62799679|NCT00466440|EXPERIMENTAL|docetaxel + prednisone + enzastaurin (modified Regimen A)|Modified Regimen A, including pharmacokinetic (PK) characterization: Participants were treated with a modified investigational regimen with no dose escalation: docetaxel 75 mg/m2, IV was administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 mg po, BID every day. In Cycle 1, enzastaurin was given as a loading dose of 1125 mg starting on Day 4, followed by enzastaurin 500 mg po, QD for the remaining Period 2 (chemotherapy) and Period 3 (maintenance).
62799680|NCT01308086|ACTIVE_COMPARATOR|FOLFOX 4 - 6months or XELOX -6months|
62799681|NCT01308086|EXPERIMENTAL|FOLFOX4 -3months or XELOX -3months|
62225214|NCT02483585|EXPERIMENTAL|Erenumab|Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. Participants continued to receive erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
62225215|NCT03938545|EXPERIMENTAL|Regimen A-RVT-1401|Regimen A= RVT-1401 680 mg weekly for 12 weeks
62225216|NCT03938545|EXPERIMENTAL|Regimen B-RVT-1401|Regimen B= RVT-1401 340 mg weekly for 12 weeks
62225217|NCT03938545|EXPERIMENTAL|Regimen C-RVT-1401|Regimen C= RVT-1401 255 mg weekly for 12 weeks
62225218|NCT03938545|PLACEBO_COMPARATOR|Placebo|for 12 weeks
62225219|NCT02924428|EXPERIMENTAL|Diamondpolar applicator, AC Dual applicator|"Radio frequency (RF) and pulsed magnetic field (PEMF) treatment followed by intense pulsed light (IPL) treatment delivered to the skin using the Venus Versa system.~The RF and PEMF applicator has 4 electrodes which emit RF and PEMF simultaneously.~The IPL applicator operates a blue light (415 nm) and also red light (630 nm) simultaneously. The IPL applicator also includes a sapphire cooled light guide of 10x30mm."
62225220|NCT02924428|ACTIVE_COMPARATOR|AC Dual applicator treatment|"Intense pulsed light (IPL) treatment delivered to the skin using the Venus Versa system.~The IPL applicator operates a blue light (415 nm) and also red light (630 nm) simultaneously. The IPL applicator also includes a sapphire cooled light guide of 10x30mm."
62225221|NCT05973435||General Anesthesia|
62225222|NCT05973435||Spinal anesthesia|
62225223|NCT03634020|EXPERIMENTAL|DynamX Sirolimus-eluting Coronary Bioadaptor System|2.5 - 3.5mm 14mm, 18mm and 28mm
62225224|NCT02216474|SHAM_COMPARATOR|Sham transcranial direct current stimulation (frontal cortex)|Transcranial direct current stimulation will be ramped up over 60 seconds and then ramped down gradually to encourage blinding to condition.
62225225|NCT02216474|EXPERIMENTAL|Anodal transcranial DC stimulation (frontal cortex)|Anodal transcranial direct current stimulation to prefrontal cortex for approximately 15 minutes plus ramp up and down time
62225226|NCT01347762|EXPERIMENTAL|Nabilone|nabilone titrated to 2 mg daily
62225227|NCT01347762|PLACEBO_COMPARATOR|Placebo|Placebo
62225228|NCT02482337|EXPERIMENTAL|POEM procedure|Patients who underwent POEM
62225229|NCT02090959|EXPERIMENTAL|Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for up to 144 weeks.
62225230|NCT01130233|EXPERIMENTAL|robotic|robotic assisted rectal resection
62225231|NCT01130233|ACTIVE_COMPARATOR|laparoscopic|laparoscopic rectal resection
62225232|NCT03620916|EXPERIMENTAL|Intrathecal morphine|Intrathecal morphine (0,4 mg) immediately before operation
62418069|NCT05874479|SHAM_COMPARATOR|Sham PAC|Using a double-blind randomized process, sham PACs (with no filters inside) will be assembled and placed in the bedroom of study participants. Initiation of the PAC devices will occur at baseline on Day 0. After completion of enrollment, consent and the placement of PACs, electricity monitors, and PurpleAir monitoring, the PAC will be turned on. Participants will be instructed to keep PACs on in bedrooms during the study duration, closing bedroom doors at night and during the day, when possible. The PAC will run for 24 hours on Day 0 of the study protocol before the 30-day treatment period begins. A kilowatt meter will be installed with the PAC to monitor electricity usage as a measure of adherence.
62225233|NCT03620916|ACTIVE_COMPARATOR|Intravenous morphine|Intravenous morphine (0,15 mg/kg body mass) immediately after the operation
62225234|NCT00950950|PLACEBO_COMPARATOR|Placebo|Participants were randomized to receive matching placebo administered by subcutaneous injection once every 4 weeks (Q4W) for 3 months.
62225235|NCT00950950|EXPERIMENTAL|Romosozumab|Participants were randomized to receive 3 mg/kg romosozumab administered by subcutaneous injection once every 4 weeks (Q4W) for 3 months.
62225236|NCT00006373|EXPERIMENTAL|TIME|Topotecan, Ifosfamide, Mesna and Etoposide
62225237|NCT00783900|ACTIVE_COMPARATOR|metoprolol|
62418070|NCT03837340|EXPERIMENTAL|FACT|Patients with SMI, receiving evidence-based interventions by the community mental health teams (CMHTs), inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
62225238|NCT00783900|ACTIVE_COMPARATOR|biatrial pacing|
62225239|NCT05706753|EXPERIMENTAL|Milvexian + Midazolam + Ethinylestradiol/Drospirenone|Participants will receive midazolam on Day 1 and Day 19; ethinylestradiol and drospirenone on Day 2 and Day 20; and milvexian from Day 7 to Day 24.
62225240|NCT02819466||volunteers|Healthy volunteers over the age of 18 years employed by Amiens University Hospital 3D echography
62418071|NCT03837340|ACTIVE_COMPARATOR|CAU (Care as usual)|Patients with SMI receiving usual care, meaning mostly medical treatment
62225241|NCT03279445||African American|Patient of African American race
62225242|NCT03279445||Caucasian|Patient of Caucasian race
62225243|NCT01620112|ACTIVE_COMPARATOR|low clonidine concentration|clonidine concentration 1 ml on 40 ml of lidocaine 1.5% for upper brachial plexus
62225244|NCT01620112|ACTIVE_COMPARATOR|lidocaine 20 ml 1,5%|lidocaine 20 ml 1,5% without clonidine for axillary brachial plexus block for upper limb surgery
62225245|NCT01620112|ACTIVE_COMPARATOR|high clonidine concentration|clonidine concentration 150 mcg on 20 ml of lidocaine 1,5% for upper brachial plexus
62225246|NCT01620112|ACTIVE_COMPARATOR|40 ml lidocaine 1,5%|40 ml of lidocaine 1,5% without clonidine for upper brachial plexus
62225247|NCT03211312||older people with cardiac diseases|undergoing teeth extraction surgery
62225248|NCT03020654|EXPERIMENTAL|Treatment group|Virtual environment with fast moving objects these are graded in intensity from 1-7. Participants complete head and eye exercises within the environment using focus points such as benches and lanterns for a six week treatment program.
62225249|NCT03020654|ACTIVE_COMPARATOR|Control group|Virtual environment with no movement graded at grade 0. Participants complete head and eye exercises within the environment using focus points such as benches and lanterns for a six week treatment program.
62418072|NCT05681026|EXPERIMENTAL|Yoga Sessions|Participants will take part in Yoga of gentle movements, breathing exercises, relaxation techniques, and meditation all tailored to the participant's needs.
62418073|NCT04427956|ACTIVE_COMPARATOR|Isotonic riboflavin|CXL (UVA 9mW/cm2) treatment using isotonic riboflavin
62799682|NCT01867749|EXPERIMENTAL|Group Interpersonal Psychotherapy (IPT-G)|Participants in the IPT-G condition will receive 12 group therapy sessions over 2 weeks as well as 2 individual (pre-group and 1-month booster sessions). In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. This study adapted IPT for treatment of depression after perinatal loss.
62799683|NCT01867749|ACTIVE_COMPARATOR|Coping with Depression (CWD)|The Coping with Depression (CWD) course is a highly structured, manualized psycho-educational group treatment for MDD. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. CWD will consist of an individual pre-group interview, 12 group therapy sessions over 12 weeks and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
62418074|NCT04427956|ACTIVE_COMPARATOR|Hypotonic riboflavin|CXL (UVA 9mW/cm2) using hypotonic riboflavin
62418075|NCT04427956|ACTIVE_COMPARATOR|Iontophoresis|Iontophoresis with Ricrolin with following CXL (UVA 9mW/cm2).
62418076|NCT06626568|EXPERIMENTAL|gluteal injection|"gluteal injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4, ultrasound-guided subacromial injection of 5 ml of normal saline at week 0,2,4.~The participants were instructed to perform home rehabilitation exercise for 12 weeks. 30 minutes of home-based self-rehabilitation exercises in the morning, afternoon, and evening, with a total of 90 minutes per day. Standard instructional videos and demonstrations by outpatient rehabilitation therapists are provided to participants. Each exercise, including wall-climbing, table-climbing, and back-climbing, should be performed for 10 minutes, with a total of 30 minutes per session."
62418077|NCT06626568|ACTIVE_COMPARATOR|subacromial injection|"gluteal injection of 5 ml normal saline at week 0,2,4, ultrasound-guided subacromial injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4.~The participants were instructed to perform home rehabilitation exercise for 12 weeks. 30 minutes of home-based self-rehabilitation exercises in the morning, afternoon, and evening, with a total of 90 minutes per day. Standard instructional videos and demonstrations by outpatient rehabilitation therapists are provided to participants. Each exercise, including wall-climbing, table-climbing, and back-climbing, should be performed for 10 minutes, with a total of 30 minutes per session."
62418078|NCT06579469||B cell acute lymphoblastic leukemia (B cell acute lymphoblastic leukemia (B-ALL) ) cohort|B-ALL participants who have received CAR T cell therapy from 3 months through 2 years post-infusion from the most proximal CAR T cell infusion received prior to enrollment.
62225250|NCT05247554|EXPERIMENTAL|Hydroxychloroquine+low-dose prednisone|Hydroxychloroquine, tablets, 400mg/day for 6 months combined with Prednisone, 20mg/day for 1 month, then 10mg/day for 20 weeks (ie up to M6). The cumulative doses of prednisone during the 6 months of the study will be 1820mg
62418079|NCT06579469||Other hematologic malignancy|Other hematologic malignancy participants who have received CAR T cell therapy from 3 months through 2 years post-infusion from the most proximal CAR T cell infusion received prior to enrollment.
62418080|NCT06579469||Solid tumor (ST)|ST participants who have received CAR T cell therapy from 3 months through 2 years post-infusion from the most proximal CAR T cell infusion received prior to enrollment.
62418081|NCT06502730|NO_INTERVENTION|Control group|Mothers of preterm neonates who will not receive COPE program.
62418082|NCT06502730|EXPERIMENTAL|Study group|Mothers of preterm neonates who will receive COPE program.
62418083|NCT05531591|EXPERIMENTAL|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets), titrated from 2-15 mg daily based on symptom severity and side effects.
62418084|NCT05531591|EXPERIMENTAL|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, titrated from 150-300 mg daily based on symptom severity and side effects.
62799684|NCT00900666|PLACEBO_COMPARATOR|Saline injection|
62225251|NCT05247554|ACTIVE_COMPARATOR|Medium-dose prednisone|"prednisone, tablets, 40mg/day for 4 weeks, then 30mg/day for 2 weeks, then 20mg/day for 2 weeks, then 15mg/day for 2 weeks, then 10mg/day for 14 weeks (i.e. up to M6).~The cumulative doses of prednisone during the 6 months of the study will be 2870mg "
62799685|NCT00900666|EXPERIMENTAL|Botulinum toxin injection|
62799686|NCT03958058||Anti-borrelial antibiotic therapy|
62799687|NCT03958058||No antibiotics|Patients who received symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
62799688|NCT02936817|OTHER|Aerobika® device|For a period of 15 +/- 3 days all subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily). HRCT scans wil be taken at visit 1 and visit 3.
62799689|NCT03108794||Immune tolerance phase|Immune tolerance phase is diagnosed based on the presence of high serum levels of HBV-DNA, hepatitis B e antigen (HBeAg), but normal or minimally elevated serum alanine aminotransferase (ALT), and normal liver or only minimal histological activity and scant fibrosis.
62026543|NCT05942508|EXPERIMENTAL|TQB2450 Injection + Anlotinib Hydrochloride Capsules|TQB2450 injection: 1200 mg/time, intravenous drip, day 1, Q3W; Anlotinib Hydrochloride Capsules: 8 mg/dose, once daily (QD), continuously used for 2 weeks, stopped for 1 week, and taken orally before breakfast (the starting dose of Anlotinib Hydrochloride is 8 mg, and it is allowed to be increased to 10 mg after two cycles of use)
62026544|NCT06635733|EXPERIMENTAL|Intervention Group (Rhapsode Capable™ Platform)|Participants (healthcare providers) in this group will receive the PACE adaptive learning modules and participate in In-Person Skills Practice (ISP) sessions facilitated by clinical champions. The ISP sessions will be managed using the Rhapsode Capable™ platform, which allows for scheduling, real-time performance feedback, and tracking of progress. The intervention is designed to enhance pediatric care competencies by blending adaptive e-learning with structured, feedback-driven skills practice.
62225252|NCT00038974|EXPERIMENTAL|Interferon and rivavirin|All patients received peginterferon alfa-2a in a dose of 180 μg weekly and ribavirin in a dose of 1000 (for patients with a body weight of ⩽75 kg) or 1200 mg (for those with a body weight of \>75 kg) daily.
62225253|NCT02344563|EXPERIMENTAL|Meropem|0.5g/vial,one vial
62225254|NCT02344563|ACTIVE_COMPARATOR|Mepem|0.25g/vial ,two vials
62225255|NCT03687047|EXPERIMENTAL|New complete dentures|"Steps: 1) Preliminary impressions will be done using stock trays and impression compound; 2) primary casts will be fabricated to make custom trays for definitive impressions; 3) definitive impressions will be made using zinc oxide eugenol impression paste;4) definitive impressions will be poured with type III dental stone to obtain mastercasts; 5)jaw relations will be recorded, and the casts will be mounted on the articulator; 6) the artificial acrylic resin teeth will be arranged, esthetics will be verified, and the trial dentures will be flasked and polymerized (72°C per 12 hours). The dentures will be finished and polished for insertion and follow-up. After denture insertion, post-denture insertion instructions such as oral hygiene will be explained to the patients.~The Oral Health Related to Quality of Life assessment will be conducted before treatment (Baseline) and at 3, 6, 9, 12 months after treatment."
62418085|NCT05531591|EXPERIMENTAL|Switch to Bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended, titrated from 150-300 mg daily based on symptom severity and side effects.
62418086|NCT05531591|EXPERIMENTAL|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 mEq/L (milliequivalents/liter).
62418087|NCT05531591|EXPERIMENTAL|Switch to Nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml.
62418088|NCT04967989|EXPERIMENTAL|First Randomization: Low Energy SLT|"Low energy SLT will consist of 100 treatment spots delivered at 0.4mJ per spot throughout the full 360° treatment, with the exception that energy can be reduced to 0.3mJ if bubbles are seen with 5 consecutive spots and can be increased back to a maximum of 0.4mJ is no bubbles are seen with 5 consecutive spots.~Regardless of energy level randomization, energy may be adjusted downward in 0.1mJ increments throughout the procedure in response to factors such as heavy focal pigmentation or patient discomfort."
62225256|NCT04664439|EXPERIMENTAL|CT-FFR|The CCTA images of the patients in this group will be analyzed and the FFR values of the lesions will be measured using the indicated software. ICA will be determined according to the value of CTFFR.
62225257|NCT04664439|NO_INTERVENTION|direct ICA|The patients will be submitted to undergoing ICA procedure according to the decision of the investigators.
62225258|NCT04322838||Patients|30 patients with self-reported seasonal allergic airway symptoms in the period from 1st of August to 15.th of october
62225259|NCT04322838||Controls|15 non-allergic individuals
62433511|NCT02691806|EXPERIMENTAL|research arm|Each of the 14 participants will undergo the same 2 days experimental protocol, separated by at least 2 days rest.
62433512|NCT04863456|EXPERIMENTAL|HIPA group of Puget grade 1|the tumor abuting or displacing the hypothalamus in the preoperative MR images
62799690|NCT03108794||HBeAg positive CHB|HBeAg positive CHB is defined as those with HBsAg positive for more 6 months, HBeAg positive, high HBV DNA, elevated serum levels of ALT and histological activity.
62799691|NCT03108794||HBeAg negative CHB|HBeAg negative CHB is defined as those with HBeAg negative, anti-HBe positive, lower serum HBV DNA levels and histological necroinflammation and fibrosis.
62225260|NCT01990560|EXPERIMENTAL|Mifepristone|Mifepristone 300mg tablets taken once daily with dose increase of no more than 300mg once monthly and to a maximum dose of 1200mg daily as indicated by symptom response
62225261|NCT05907278|EXPERIMENTAL|Intervention|The ACE Program is a culturally inclusive, 4-H after school club where youth meet once a week for 12 weeks virtually. They also receive groceries to make a meal 1 day a week.
62225262|NCT03597074||1|Patients without AKI progression Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
62418089|NCT04967989|ACTIVE_COMPARATOR|First Randomization: Standard Energy SLT|"Standard SLT will be performed as follows: beginning at 0.8 mJ, energy will be titrated up or down within the first 5-10 spots until champagne bubbles are visualized with every 2nd or 3rd spot. Energy can be titrated throughout the procedure, in response to variations in pigmentation, to ensure the appearance of champagne bubbles with every 2nd or 3rd spot throughout the full 360° treatment. Energy should be increased if no bubbles are seen with 5 consecutive spots and decreased if bubbles are seen with 5 consecutive spots.~Regardless of energy level randomization, energy may be adjusted downward in 0.1mJ increments throughout the procedure in response to factors such as heavy focal pigmentation or patient discomfort."
62418090|NCT04967989|EXPERIMENTAL|Second Randomization: Annual Low Energy Repeat SLT|At month 12, eligible subjects will be re-randomized to undergo repeat SLT either annually at low energy or as needed at initially assigned energy (from first randomization). The method of SLT delivery is as described in the sections above.
62418091|NCT04967989|ACTIVE_COMPARATOR|Second Randomization: As-Needed Repeat SLT at Initial Energy|At month 12, eligible subjects will be re-randomized to undergo repeat SLT either annually at low energy or as needed at initially assigned energy (from first randomization). The method of SLT delivery is as described in the sections above.
62418092|NCT06334354||Breast Cancer Survivor (BCS)|Enrolled participants will be asked to complete a one-time, remote neurocognitive assessment. The neurocognitive assessment will consist of the CogSuite Neurocognitive Battery, an online, remotely deliverable battery of cognitive experimental measures, and a standard battery of remote neuropsychological measures. DNA will be collected via mailed saliva kits to assess Apolipoprotein E (APOE) status.
62433513|NCT04863456|EXPERIMENTAL|HIPA group of Puget grade 2|hypothalamic involvement (the hypothalamus is no longer identifiable) in the preoperative MR images
62225263|NCT03597074||2|Patients with Transient AKI Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
62588877|NCT05260463|ACTIVE_COMPARATOR|Uncoated Implant|The summary description and intended purpose of the investigational device (LOQTEQ® antibacterial silver-coated system) is the same as that of the comparator device (LOQTEQ® 3.5 System (uncoated) system) and differes only in the lack of the antibacterial coating.
62588878|NCT06683690||Group A: Leprosy Patients|About 30 patients affected with Leorosy
62588879|NCT06683690||Group B: Healthy People|About 30 Healthy participants
62588880|NCT02771691|EXPERIMENTAL|MBT therapy plus treatment as usual|Mentalization based group treatment for adolescents plus standard care
62588881|NCT02771691|NO_INTERVENTION|Treatment as usual alone|Standard care provided by local Child and Adolescent Mental Health Services
62799692|NCT03108794||Inactive HBsAg carriers|Inactive HBsAg carriers was defined as those with HBsAg positive than 6 months, with low HBV DNA and persistently normal ALT, without evidence of cirrhosis.
62799693|NCT03108794||Compensated cirrhosis|"Diagnosis of compensated cirrhosis can be made if one of the following criteria was met:~1. by liver histology: Ishak fibrosis stage 5-6 or METAVIR F4.~2. endoscopy-proven gastroesophageal varices, afrter excluding non-cirrhotic portal hypertension.~3. at least 2 features of cirrhosis:~   1. irregular liver surface, granular or nodular liver parenchyma, with or without splenomegaly (spleen thickness \> 4.0cm or \> 5 rib units) on ultrasound ,CT or MRI;~  2. PLT\<100×109/L without other causes;~  3. Serum album in\<35 g/L or INR\>1.3 or PT prolongs\>3s;~  4. LSM\>13 kpa (ALT\<5×ULN)."
62799694|NCT03108794||Decompensated cirrhosis|Decompensated cirrhosis was diagnosed based on the presence of ascites, bleeding esophageal varices and/or hepatic encephalopathy in cirrhotic patients.
62225264|NCT03597074||3|Patients with Persistent AKI Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
62225265|NCT06037629||Preterm neonates in intensive care|Preterm neonates born \<36 completed weeks of gestation with postmenstrual age \<36 weeks
62225266|NCT01350310|EXPERIMENTAL|Intramyocardial Injections|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Electromechanical mapping will be used to identify viable myocardium and intramyocardial injections in the target areas will be performed with NOGA catheter. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure.
62588882|NCT01455272|EXPERIMENTAL|high-risk leukemia|
62588883|NCT04533412|EXPERIMENTAL|Targeted self-management barrier support|Intervention group - Targeted self-management barrier support, home-based pulmonary rehabilitation, and emergency medication with community health workers
62588884|NCT04533412|ACTIVE_COMPARATOR|Guided COPD education|Control group - Guided COPD education with a COPD educator
62588885|NCT00827723||Alcoholic|Alcoholic cirrhotic patient with resectable hepatocellular carcinoma
62588886|NCT00827723||Viral|Viral cirrhotic patient with resectable hepatocellular carcinoma
62588887|NCT01283295||Immune complications|Transplant recipients who develop a clinically recognized complication with potential immune etiology or ramifications. Examples include opportunistic infection, rejection, malignancy, alloantibody formation or immunosuppressive drug toxicity.
62799695|NCT03108794||Hepatocellular carcinoma|Diagnosis of hepatocellular carcinoma（HCC）can be established when one of the following one of the following 2 criteria:（1）in cirrhotic patients with nodules of 1cm or larger with typical features of HCC ( arterial enhancement with washout in venous or delay phase) on 2 radiological studies or with 1 radiological study and elevation of serum AFP; or（2）histological evidence of HCC.
62799696|NCT04201665|EXPERIMENTAL|carbetocin|Patients will receive a single dose of carbetocin 100 mcg (Pabal ®) at admission to high dependency obstetric unit after cesarean section.
62799697|NCT04201665|ACTIVE_COMPARATOR|oxytocin|Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.
62799698|NCT02947646|EXPERIMENTAL|BabyGentleStick™ ON, then BabyGentleStick™ OFF|Experimental intervention, then Active Comparator.
62799699|NCT02947646|EXPERIMENTAL|BabyGentleStick™ OFF, then BabyGentleStick™ ON|Active Comparator, then Experimental intervention.
62799700|NCT04233203||Faster Aspart|All T1DM adult patients attended in Ciudad Real General University Hospital and treated with CSII and insulin Faster Aspart.
62799701|NCT05041283|NO_INTERVENTION|Standard Preparation|Control arm; patients receive a standard support for bowel preparation consisting of a explanatory dialogue with a gastroenterologist and a brochure with a structurated description of bowel preparation and colonoscopy conduct
62799702|NCT05041283|ACTIVE_COMPARATOR|Phone-call Supported Preparation|In addition to standard preparation, patients receive a phone call every day starting at 3 days before colonoscopy in which a investigator explains key points of bowel preparation and patients can ask questions concerning bowel preparation and colonoscopy conduct.
62799703|NCT05041283|EXPERIMENTAL|Chatbot Supported Preparation|In addition to standard preparation, patients receive an access to a chatbot which can be contacted via Whats App starting at 3 days before colonoscopy. The chatbot is programed to answer questions concerning bowel preparation and colonoscopy conduct.
62799704|NCT00644020||Group 1|the Tyroserleutide for injection at the dosage of 3mg/d
62799705|NCT00644020||Group 2|the Tyroserleutide for injection at the dosage of 6mg/d
62799706|NCT00644020||Group 3|the Tyroserleutide for injection at the dosage of 12mg/d
62799707|NCT00644020||Group 4|the placebo group
62799708|NCT02305771|OTHER|Healthy volunteers|"20 healthy volunteers will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~* Electroencephalography~* MRI"
62026545|NCT06635733|ACTIVE_COMPARATOR|Control Group (Paper-based ISP)|Participants (healthcare providers) in this group will also receive the same PACE adaptive learning modules and participate in In-Person Skills Practice (ISP) sessions facilitated by clinical champions. However, ISP sessions will be conducted using paper-based assessments. Clinical champions will manually track performance, provide feedback, and schedule sessions using paper forms. The control group will not have access to real-time digital feedback or automated progress tracking.
62026546|NCT03227770|ACTIVE_COMPARATOR|regular hemodialysis|Blood purification (including low-flux hemodialysis, high-flux hemodialysis, or hemodiafiltration) treatment ≥10 hours per week
62418093|NCT06334354||Non-cancer Control (NCC)|Enrolled participants will be asked to complete a one-time, remote neurocognitive assessment. The neurocognitive assessment will consist of the CogSuite Neurocognitive Battery, an online, remotely deliverable battery of cognitive experimental measures, and a standard battery of remote neuropsychological measures. DNA will be collected via mailed saliva kits to assess Apolipoprotein E (APOE) status.
62588888|NCT01283295||Stable Transplant Recipient|Patients who demonstrate immune stability characterized by stable graft function without evident complication. These patients serve as comparators for Group 1
62799709|NCT06095219||Asymptomatic volunteers|Healthy individuals without history of hip pain or problems willing to undergo MRI of the hip.
62799710|NCT06095219||Hip Dysplasia|This group is defined according to the following radiographic parameter: lateral center edge angle (LCE) \< 23°. The data was obtained from a retrospective study.
62799711|NCT06095219||cam Deformity|This group is defined according to the following radiographic parameter: alpha angle \> 60°. The data was obtained from a retrospective study.
62418094|NCT00852072|ACTIVE_COMPARATOR|Single-operator cholangioscopy guided laser lithotripsy|Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy
62418095|NCT00852072|ACTIVE_COMPARATOR|Balloon sphincteroplasty|Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
62418096|NCT06701201||SynKIR-110|Participants who previously received SynKIR-110 in an interventional trial
62418097|NCT06701201||SynKIR-310|Participants who previously received SynKIR-310 in an interventional trial
62418098|NCT06702904|EXPERIMENTAL|Peripheral nerve stimulation for upper-limb prosthesis|
62418099|NCT06702904|EXPERIMENTAL|Peripheral nerve stimulation for lower-limb prosthesis|
62418100|NCT06702904|EXPERIMENTAL|Spinal cord stimulation for upper-limb prosthesis|
62588889|NCT01283295||Pre-Transplant Longitudinal|Patients who are candidates for kidney, pancreas, liver or lung transplant will be enrolled and followed longitudinally.
62799712|NCT06095219||Acetabular retroversion|This group is defined according to the following radiographic parameters:positive posterior- wall- sign, positive ischial spine sign, and positive cross- over- sign. The data was obtained from a retrospective study.
62799713|NCT06095219||Acetabular protrusion|This group is defined according to the following radiographic parameter: positive protrusion sign. The data was obtained from a retrospective study.
62588890|NCT01283295||Organ Donors|Donors for individuals meeting the criteria for Cohorts 1-3
62799714|NCT06095219||Deep hip|This group is defined according to the following radiographic parameter: LCE angle \> 39°. The data was obtained from a retrospective study.
62799715|NCT01941329|EXPERIMENTAL|Ranimizumab + Panretinal photocoagulation (PRP)|3 Intravitreous injections of ranibizumab combined with standard PRP (2 ± 1 weeks after injection), at month-0, month-1 and month-2 that can be repeated after month-3, with always at least 1 month of interval between injections.
62799716|NCT01941329|ACTIVE_COMPARATOR|Panretinal photocoagulation (PRP)|"Panretinal photocoagulation treatment (PRP) between month-0 and month-2, with 1 mandatory laser session in month-0 and more laser sessions as needed until Month-2 to complete the PRP treatment.~After completing the PRP treatment, PRP sessions can be repeated from Month-3 to Month-11."
62026547|NCT03227770|EXPERIMENTAL|hemoperfusion combined with hemodialysis|Combination of hemodialysis and hemoperfusion treatment at least once every two week
62026548|NCT02540200|ACTIVE_COMPARATOR|Standard treatment|The patients undergo standard bone marrow stimulation technique (i.e. microfracture) for the treatment of their chondral lesions of the hip. This is currently the standard treatment for this condition.
62026549|NCT02540200|EXPERIMENTAL|BST-CarGel|In addition to undergoing the standard intervention with microfracture, BST-CarGel (the device of interest for the study) is applied during the intervention.
62026550|NCT01174342||Pregnant women|Healthy pregnant women
62026551|NCT00561223|EXPERIMENTAL|1|"This study will examine the hypothesis that iloprost maintains and improves ventilation perfusion matching in patients with COPD as reflected by 1) a constant or reduced alveolar to arterial O2 difference as calculated from the measured arterial blood gases obtained before and after iloprost administration, 2) an improvement in the lung diffusing capacity for carbon monoxide that occurs in the absence of a change in spirometry, 3) an improvement in the ventilatory equivalent for oxygen and CO2 measured by expired gas analysis.~It is anticipated that a positive result in this pilot study would lead to a larger long-term study examining the effect of iloprost on gas exchange, exercise tolerance and quality of life in patients with COPD."
62026552|NCT03920917|EXPERIMENTAL|Cryoballoon Pulmonary Vein isolation|"1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm second or third cryoballoon catheter will be used.~4. Esophageal temperature will be monitored to prevent esophageal injury.~5. Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~6. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~7. The procedure and cryoablation times will be evaluated.~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
62026553|NCT03920917|ACTIVE_COMPARATOR|Radiofrequency Pulmonary Vein isolation|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter.~2. Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~3. Additional superior vena cava-right atrial septal linear ablation will be performed with a radiofrequency catheter.~4. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~5. Evaluated the procedure and radiofrequency ablation time.~6. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
62418101|NCT06702904|EXPERIMENTAL|Spinal cord stimulation for lower-limb prosthesis|
62418102|NCT06702904|EXPERIMENTAL|Dorsal root ganglion stimulation for upper-limb prosthesis|
62418103|NCT06702904|EXPERIMENTAL|Experimental: Dorsal root ganglion stimulation for lower-limb prosthesis|
62418104|NCT06702904|EXPERIMENTAL|Motor Cortex Stimulation for upper-limb prosthesis|
62588891|NCT01283295||Disease state|Individuals with liver, renal or pulmonary diseases that may lead to the development or organ failure.
62799717|NCT05460611|EXPERIMENTAL|Androgenetic Alopecia|The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by Sciton. Each laser treatment will take approximately 10 to 15 minutes per subject to target androgenetic alopecia.
62799718|NCT05460611|EXPERIMENTAL|Scarring Alopecia|The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by Sciton. Each laser treatment will take approximately 10 to 15 minutes per subject to target scarring alopecia.
62799719|NCT03709004|EXPERIMENTAL|Pacifier|Mother given a pacifier during birth hospitalization, along with other baby items
62799720|NCT03709004|NO_INTERVENTION|Control|Mother not given a pacifier, just the other baby items
62418105|NCT06702904|EXPERIMENTAL|Motor Cortex Stimulation for lower-limb prosthesis|
62418106|NCT01827072|EXPERIMENTAL|NPB-01|Intravenous immunoglobulin
62588892|NCT01283295||Normal Volunteers|
62799721|NCT03647657|EXPERIMENTAL|Entresto second|First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N without and second injection with additional medication of Sacuitril (100 mg Entresto)(crossover)
62799722|NCT03647657|EXPERIMENTAL|Entresto first|First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and second injection without additional medication of Sacuitril (100 mg Entresto)(crossover)
62799723|NCT02838758|EXPERIMENTAL|Cryoablation|Ultrasound guided perineural cryoablation. The mechanism of therapeutic cryoablation involves using short and repeated cycles of freezing and thawing to cause axonal degeneration and disrupt neuronal activity without damage to epineurium and perineurium.
62799724|NCT02838758|ACTIVE_COMPARATOR|Lidocaine|Ultrasound guided perineural lidocaine injection. Under ultrasound guidance, roughly 3cc of 2% lidocaine will be injected near the neuroma.
62799725|NCT02838758|PLACEBO_COMPARATOR|Saline|Ultrasound guided perineural normal saline injection. Under ultrasound guidance, roughly 3cc of normal saline will be injected near the neuroma.
62799726|NCT02184923|EXPERIMENTAL|verticality measurements|
62799727|NCT05979337|EXPERIMENTAL|Empowered Relief (ER) class|Daily Diaries
62418107|NCT05572658||mRNA-1345: Exposed|Eligible US participants from the mRNA-1345-P301 (P301) study who received the mRNA-1345 vaccine.
62799728|NCT05979337|EXPERIMENTAL|Health Education (HE) class|
62799729|NCT05979337|EXPERIMENTAL|Empowered Relief (ER) class and Health Education (HE) class|If randomized to both classes, the HE class will occur first with a week break in between to the ER class.
62799730|NCT05979337|OTHER|Treatment as Usual (TAU)|
62799731|NCT06270953||Obervational group|Patients admitted in the SNF facility during the study period
62799732|NCT06270953||Control group|Historical control with patients admitted in the SNF before the study period
62799733|NCT02620592|ACTIVE_COMPARATOR|ZYDPLA1 tablet|ZYDPLA1 tablets: Route of administration: Oral Dosage (Single Ascending Study): 1 mg, 5mg, 20mg, 50mg, 100mg, 200mg Multiple Ascending Study: 100mg, 200mg Food effect and Gender effect study: 200mg
62418108|NCT05572658||Placebo/Control: Referent|Eligible US participants from the P301 study who received placebo and eligible US-based, matched, unvaccinated RWD participants.
62418109|NCT00256217|EXPERIMENTAL|Anastrozole|
62418110|NCT05596227|PLACEBO_COMPARATOR|control group|Patients will not recieve either erector spinae plane block nor thoracolumbar interfascial plane block
62418111|NCT05596227|ACTIVE_COMPARATOR|Erector spinae plane block|Patients will recieve ultrasound guided erector spinae plane block.
62418112|NCT05596227|ACTIVE_COMPARATOR|Thoracolumbar interfascial plane block|Patients will recieve ultrasound guided thoracolumbar interfascial plane block.
62418113|NCT05408533|ACTIVE_COMPARATOR|Silver-Coated Catheter|
62418114|NCT05408533|PLACEBO_COMPARATOR|Standard Catheter|
62799734|NCT02620592|PLACEBO_COMPARATOR|Placebo|Placebo tablets: Route of administration: Oral Dosage (Single Ascending Study): 1 mg, 5mg, 20mg, 50mg, 100mg, 200mg Multiple Ascending Study: 100mg, 200mg Food effect and Gender effect study: 200mg
62799735|NCT05200715||Patients affected by autoinflammatory diseases|
62799736|NCT01186302|OTHER|Midlevel provider|Patients were assigned to a midlevel provider (arm 1) or to a physician (arm 2) for their abortion.
62418115|NCT06526390|EXPERIMENTAL|f-URS with S-UAS group|f-URS with S-UAS will be performed for patients.
62418116|NCT06526390|OTHER|mini-PCNL group|mini-PCNL will be performed for patients.
62418117|NCT01713478|EXPERIMENTAL|cirrhotic patients|"Study will include 50 cirrhotic patients, divided in 2 subgroups: 25 with alcoholic cirrhosis, and 25 with viral cirrhosis~1. Routine blood samples~2. Electrocardiogram (12 leads)~3. Specific biomarkers: proBNP, troponin, myocardial fibrosis (β cross laps and procollagen type-1 amino terminal), and markers of inflammation (PCR-hs, IL1, IL6, IL 10, TNFα); oxidative stress: carbonyl in plasmatic proteins, and the antioxidant capacity of plasma.~4. Comprehensive Echocardiography"
62418118|NCT01713478|ACTIVE_COMPARATOR|normal controls|50 normals subjects with the same procedures as cirrhotic patients: echocardiography, ECG, biomarkers
62418119|NCT06587100||Observational Group I: Fitbit only|Participants receive Fitbit device while undergoing non-interventional, standard of care, radiation therapy.
62799737|NCT01186302|OTHER|Physician arm|Patients were assigned to a midlevel provider (arm 1) or to a physician (arm 2) for their abortion.
62799738|NCT02114463|EXPERIMENTAL|Local analgesic|This group uses local analgesia infusion pump of 0.2% ropivacaine 360ml through periarticular infiltration for postoperative analgesia.
62799739|NCT02114463|ACTIVE_COMPARATOR|Intravenous analgesic|This group is treated with intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg.
62799740|NCT02536027|EXPERIMENTAL|septic AKI patients|septic AKI patients requiring CVVH
62799741|NCT03686735||Satisfaction measure 1|25% of the cohort
62799742|NCT03686735||Satisfaction measure 2|25% of the cohort
62799743|NCT03686735||Satisfaction measure 3|25% of the cohort
62799744|NCT03686735||Satisfaction measure 4|25% of the cohort
62799745|NCT03030001|EXPERIMENTAL|PD-1 antibody expressing CAR-T cells|PD-1 antibody expressing mesothelin specific CAR-T cells
62799746|NCT03072264|EXPERIMENTAL|Body in Mind Training (BMT)|This is a group intervention (10-15 participants) that consists of 5 weekly sessions lasting 2 hours. In our protocol, we added 3 more final sessions of 2 hours in order to emphasize the practices, specially in self-compassion, resulting in 8 weeks of intervention.
62588893|NCT02496091||ATLANTIS Abutment|The investigational product (ATLANTIS abutment) is already included in a restoration in the subject at enrollment, thus this study does not involve the installation of any investigational products.
62799747|NCT03072264|ACTIVE_COMPARATOR|Medication|In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
62799748|NCT03072264|ACTIVE_COMPARATOR|Quality of Life Group|This is a group intervention (10-15 participants) that consists of 8 weekly sessions lasting 2 hour in which individuals will receive psychoeducation on various aspects of quality of life that have na impact in reducing anxiety.
62799749|NCT01574508|EXPERIMENTAL|Continuous Subcutaneous Insulin Infusion|CSII
62799750|NCT01574508|ACTIVE_COMPARATOR|Multiple Daily Insulin Injections|MDI
62799751|NCT02750670|EXPERIMENTAL|GD2P|Obinutuzumab 1000mg by IV for 1.5-6.5 hours with Gemcitabine 1000mg/m\^2 by IV for 30 minutes with dexamethasone 40mg by mouth daily and Cisplatin 75mg/m\^2 by IV for 1 hour all for a duration of 3 cycles
62799752|NCT00775996|EXPERIMENTAL|1|15 mg clorazepate dipotassium tablets of ranbaxy
62799753|NCT00775996|ACTIVE_COMPARATOR|2|(TranxeneeT-Tab®) 15 mg clorazepate dipotassium tablets
62026554|NCT03346629|EXPERIMENTAL|Mifepristone + Misoprostol|Intervention: 200mg mifepristone followed 24-48 h later with 400mcg misoprostol (repeat Q3)
62799754|NCT00496080|EXPERIMENTAL|DUAO Device|Doppler-guided uterine artery occlusion device (Single-arm study)
62026555|NCT05504460|EXPERIMENTAL|test group|The test group will use the investigational device Hydrogen-Oxygen Generator with Nebulizer (manufactured by Shanghai Asclepius Meditec Co., Ltd.) + basic treatment (supportive treatment determined by the investigator based on the condition of the patients)
62026556|NCT05504460|ACTIVE_COMPARATOR|Control Group|the control group will use basic treatment only
62026557|NCT06634927|EXPERIMENTAL|Experimental group|Experimental group: Semaglutide injection, specifications: 1.34 mg/mL, 1.5 mL (pre-filled injection pen), 0.25 mg , subcutaneous abdominal injection.
62026558|NCT06634927|ACTIVE_COMPARATOR|Active Comparator|Control group: Ozempic ® injection, 1.34 mg/mL, 1.5 mL (pre-filled injection pen), 0.25 mg , subcutaneous injection into the abdomen.
62026559|NCT03272438|ACTIVE_COMPARATOR|No schedule control|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will also monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions.
62418120|NCT06587100||Observational Group II: Fitbit + Apple HealthKit|Participants receive Fitbit device and will utilize personal Apple HealthKit-based devices (iPhone, Apple Watch, etc.) to concurrently contribute Apple HealthKit-based data while undergoing non-interventional, standard of care, radiation therapy.
62799755|NCT05072106|ACTIVE_COMPARATOR|Single agent lurbinectedin cycle|3.2 mg/m² as a 1-hour i.v. infusion on Day 1.
62026560|NCT03272438|EXPERIMENTAL|Consistent schedule condition|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions. In addition they will plan when, where, and how they will take steps in consistent contexts, i.e., that are very similar from day to day.
62026561|NCT03272438|ACTIVE_COMPARATOR|Inconsistent schedule condition|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions. In addition they will plan when, where, and how they will take steps in inconsistent contexts, i.e., that vary from day to day.
62225267|NCT01350310|ACTIVE_COMPARATOR|Intracoronary Injections|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Patients will undergo myocardial perfusion scintigraphy and CD34+ cells will be injected intracoronary in the artery supplying segments of reduced viability. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure.
62225268|NCT01350310|ACTIVE_COMPARATOR|Ischemic heart disease|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Electromechanical mapping will be used to identify viable myocardium and intramyocardial injections in the target areas will be performed with NOGA catheter. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure
62225269|NCT01154010|ACTIVE_COMPARATOR|Active Device|"ActiPatch, a device that emits a low frequency energy called pulsed electromagnetic field (PEMF), will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids."
62225270|NCT01154010|PLACEBO_COMPARATOR|Placebo Device|Patients wear the PEMF placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.
62225271|NCT01932567|EXPERIMENTAL|Positive expiratory pressure|Use of positive expiratory pressure during 3 minutes
62225272|NCT01932567|EXPERIMENTAL|Incentive spirometry|Use of incentive spirometry during 3 minutes
62225273|NCT01932567|EXPERIMENTAL|manual airway clearance technique|Use of manual airway clearance technique during 3 minutes
62225274|NCT00758277|ACTIVE_COMPARATOR|Levetiracetam|
62225275|NCT00758277|PLACEBO_COMPARATOR|Placebo|
62225276|NCT00994084|ACTIVE_COMPARATOR|Lifestyle modification|This arm receives the intervention program that includes structured physical activities and nutrition and behavior lessons
62225277|NCT00994084|PLACEBO_COMPARATOR|Control|This arm receives no intervention
62418121|NCT04011904|EXPERIMENTAL|Traditional Inuit Diet|This will be a traditional Inuit diet (TID) rich in marine mammals (such as walrus, seal, and whale), fish, caribou and musk ox, with low intake of grains, fast food and other imported foods. The TID diet will be high in fat (\>40 of the energy (E%)) and low in carbohydrate (\<30 E%).
62418122|NCT04011904|PLACEBO_COMPARATOR|Westernized Diet|This will be a Westernized diet will be consisting of high amounts of grains, potatoes, rice and imported meats from livestock animals (beef, pork and chicken). The Westernized diet will be high in carbohydrate (55-65 E%) and lower in fat (30-35 E%).
62418123|NCT01898117|ACTIVE_COMPARATOR|Carbo/cyclo|Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 Q 4 weeks
62418124|NCT01898117|ACTIVE_COMPARATOR|Carbo/cyclo + Atezolizumab|Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 atezolizumab 840 mg d1,15 Q 4 weeks
62225278|NCT04443101||Group（SN6CWS）|Group（SN6CWS）：Implant SN6CWS intraocular lens
62225279|NCT04443101||Group（MI60）|Group（MI60）：Implant MI60 intraocular lens
62225280|NCT04443101||Group（Aspira-aA）|Group（Aspira-aA）：Implant Aspira-aA intraocular lens
62225281|NCT01362777|EXPERIMENTAL|In-Patient Rehabilitation|"Sessions of rehabilitation contains :~* Individualized exercise training~* Educational activities~* Dietary advices"
62225282|NCT01362777|ACTIVE_COMPARATOR|Educational activities alone|"Out-patient control arm contains only :~-Educational activities"
62225283|NCT02720367|EXPERIMENTAL|7-Day Regimen|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the TURBT.
62225284|NCT02720367|EXPERIMENTAL|21-Day Regimen|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 21. TAR-200 releases gemcitabine gradually during the 21 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 42.
62418125|NCT01898117|ACTIVE_COMPARATOR|Paclitaxel|Paclitaxel 90 mg/m2 d1, 8, 15 Q 4 weeks
62418126|NCT01898117|ACTIVE_COMPARATOR|Paclitaxel + atezolizumab|Paclitaxel 90 mg/m2 d1, 8, 15 atezolizumab 840 mg d1,15 Q 4 weeks
62799756|NCT05072106|ACTIVE_COMPARATOR|Bosentan co-administration cycle|"* Bosentan: 125 mg (one film-coated tablet of 125 mg) orally (p.o.) twice daily in the morning and in the evening during the prior five consecutive days before the day of lurbinectedin infusion (Day 1), and once daily on Day 1 (before lurbinectedin infusion).~* Lurbinectedin: 3.2 mg/m² as a 1-hour i.v. infusion on Day 1 in first three patients. Dose for remaining five patients will depend on PK and safety outcomes in first three patients."
62026562|NCT04867577||vertebral osteoporotic compression fracture|Patients with osteoporotic vertebral compression receiving vertebroplasty or cemented screws reconstruction
62418127|NCT05354206|EXPERIMENTAL|Evaluation of motor evoked potentials during non-invasive spinal cord stimulation and leg movements|This arm will receive the transcranial magnetic stimulation to evaluate the excitability of the corticospinal tract first then the arm will receive the loud auditory stimuli to evaluate the excitability of the reticulospinal track second.
62588894|NCT06392113||Adults with an intellectual disability|Completion of ACTION FALLS programme
62588895|NCT06392113||Carers of adults with an intellectual disability|Completion of ACTION FALLS programme
62026563|NCT01404312|EXPERIMENTAL|RPT plus INH Regimen (Arm A)|Participants received RPT (dosage based on their weight), 300 mg of INH, and 25 mg or 50 mg of pyridoxine (vitamin B6) each day during Weeks 1 to 4. During Weeks 5 to 36, participants did not receive any study medications.
62799757|NCT04189705|EXPERIMENTAL|MCT-SR|Drug: MCT-SR 2 times/day for 2 weeks
62799758|NCT04189705|ACTIVE_COMPARATOR|Mucosta Tab.|Drug: Mucosta Tab. 3 times/day for 2 weeks
62799759|NCT02868411|EXPERIMENTAL|Patients admitted for traveller's fever|
62225285|NCT05158998|OTHER|propofol group|For patients in the propofol group, anaesthesia will be maintained with propofol infusion(target controlled infusion), of which the target concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)). Propofol infusion will be stopped at the end of surgery.
62225286|NCT05158998|OTHER|sevoflurane group|For patients in the sevoflurane group, anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)). Sevoflurane inhalation will be stopped at the end of surgery.
62225287|NCT04960189|EXPERIMENTAL|Acupuncture|GB34 acupuncture will be applied every day. Patients will receive standard medical treatment
62225288|NCT04960189|NO_INTERVENTION|Controls|Patients will only receive standard medical treatment
62225289|NCT02292927|NO_INTERVENTION|Pre-intervention|Patients treated as standard before intervention
62225290|NCT02292927|ACTIVE_COMPARATOR|Post-intervention arm = Prehabilitation|Introduction of rehabilitation program
62225291|NCT01572753|EXPERIMENTAL|Post-dose fasting 120 mins/50 ml water|
62225292|NCT01572753|EXPERIMENTAL|Post-dose fasting 60 mins/50 ml water|
62418128|NCT05354206|EXPERIMENTAL|Reaction time evaluation during non-invasive spinal cord stimulation and leg movements|This arm will receive the loud auditory stimuli to evaluate the excitability of the reticulospinal tract first then the arm will receive the transcranial magnetic stimulation to excite the corticospinal tract second
62418129|NCT02426294|EXPERIMENTAL|Pioglitazone|Pioglitazone is a Pioglitazone hydrochloride, and white circle-shaped tablet. It is administered once-daily with 15mg, with or without meals. The once-daily administration begins with 15mg, and if need increase, researchers can increase up to 30mg at week 12.
62799760|NCT00614679|EXPERIMENTAL|1|single arm trial of experimental catheter lock solution
62418130|NCT02426294|ACTIVE_COMPARATOR|Glimepiride|The generic name of Glimepiride is Glimepiride, and it is a green snowman-shaped tablet. The once-daily administration begins with 2mg, and if need increase, researchers can increase up to 4mg at week 12.
62799761|NCT02927392|EXPERIMENTAL|Pre-menopausal women|To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women. We will also explore whether suppression of ovarian hormones in pre-menopausal women (using leuprolide acetate) impairs BAT activity.
62799762|NCT02927392|NO_INTERVENTION|Post-menopausal women|To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women.
62799763|NCT05932797|ACTIVE_COMPARATOR|Intervention group|Multimodal rehabilitation: physical, psychological and cognitive training and treatment program at the Teaching and Research Assistance Center of the University of Magellanus.
62799764|NCT05932797|NO_INTERVENTION|Control group|Individuals who must maintain their daily habits and/or usual care at their health center.
62026564|NCT01404312|ACTIVE_COMPARATOR|INH Regimen (Arm B)|Participants received 300 mg of INH and 25 mg or 50 mg of pyridoxine (vitamin B6) each day during Weeks 1 to 36.
62225293|NCT01572753|EXPERIMENTAL|Post-dose fasting 30 mins/50 ml water|
62588896|NCT06392113||Clinicians working with adults with an intellectual disability|Completion of ACTION FALLS programme
62799765|NCT05548517|EXPERIMENTAL|Time restricted eating and calorie restriction|Subjects will be asked to adhere to a calorie-restricted diet and will be counseled by a dietitian for diet and lifestyle behavior education. In addition, they will be asked to only consume calories during a 9-hour window (15:9).
62799766|NCT05548517|ACTIVE_COMPARATOR|Calorie restriction alone|Subjects will be asked to adhere to a calorie-restricted diet and will be counseled by a dietitian for diet and lifestyle behavior education. They will be advised to continue to consume foods throughout the day and into the evening.
62799767|NCT01366989||Total Ankle Arthroplasty with calcaneal stem|Patients received the TAA with calcaneal stem between 12/6/05 \& 11/13/07 at approximately 28 sites.
62799768|NCT01541046|EXPERIMENTAL|Biogaia L. reuteri DSM 17938|Biogaia L. reuteri DSM 17938, probiotic infant drops (5 drops=10\^8 cfu),5 drops, once per day for 21 days.
62799769|NCT01541046|PLACEBO_COMPARATOR|Probiotic Placebo|Placebo drops (sunflower oil, medium chain triglyceride oil, silicon chloride), 5 drops, once a day for 21 days.
62225294|NCT01572753|EXPERIMENTAL|Post-dose fasting 15 mins/50 ml water|
62225295|NCT01572753|EXPERIMENTAL|Post-dose fasting 120 mins/120 ml water|
62225296|NCT01572753|EXPERIMENTAL|Post-dose fasting 60 mins/120 ml water|
62225297|NCT01572753|EXPERIMENTAL|Post-dose fasting 30 mins/120 ml water|
62225298|NCT01572753|EXPERIMENTAL|Post-dose fasting 15 mins/120 ml water|
62225299|NCT02608593||Implant reconstruction with Strattice|Women having immediate breast reconstruction with partial or total Strattice cover
62225300|NCT02608593||Implant reconstruction without Strattice|Women having immediate implant based breast reconstruction where no Strattice has been used
62225301|NCT02870335|EXPERIMENTAL|Manual Therapy|The objective of treatment is to restore esta possible limitation of global mobility to major lower limb joints and remove any tensions from the musculature involved in a relevant way in this sport.
62588897|NCT05780151|ACTIVE_COMPARATOR|Conventional|"In RADIAL, the main study intervention is a methodological intervention with patients being recruited into three arms with different level of decentralization. Additionally, participants in all arms are switching from their previously used basal insulin to Toujeo®, which is the clinical intervention, in the protocol defined as the study drug.~The conventional arm is modelled after a previous clinical trial with a similar indication and intervention and aims to represent current state-of-the art clinical trial conduct."
62588898|NCT05780151|ACTIVE_COMPARATOR|Hybrid|"In RADIAL, the main study intervention is a methodological intervention with patients being recruited into three arms with different level of decentralization. Additionally, participants in all arms are switching from their previously used basal insulin to Toujeo®, which is the clinical intervention, in the protocol defined as the study drug.~The hybrid trial design is defined as a trial containing conventional trial elements, such as site-based recruitment and screening visits, as well as decentralised trials elements, such as a remote follow-up period and data collection"
62588899|NCT05780151|ACTIVE_COMPARATOR|Remote|"In RADIAL, the main study intervention is a methodological intervention with patients being recruited into three arms with different level of decentralization. Additionally, participants in all arms are switching from their previously used basal insulin to Toujeo®, which is the clinical intervention, in the protocol defined as the study drug.~The remote arm is fully decentralised and aims to represent future decentralised clinical trial practice using a decentralised recruitment model, intervention period and data collection."
62799770|NCT04253613||periodontal therapy|Systemically healthy subjects with periodontitis that have the sides treated with non-surgical periodontal treatment (NSPT) split-mouth designed study
62418131|NCT06694571|EXPERIMENTAL|Skin cancer prevention education|Program components of a rural-adapted skin cancer prevention intervention (i.e., education, action planning exercise, risk assessment activity) will be co-implemented by the research team and participating school staff during a single- or double-session, in-class visit lasting up to 90 minutes. Students will be asked to complete surveys at baseline and one month post-intervention.
62418132|NCT05880485|EXPERIMENTAL|Online Adaptive Radiotherapy|Patients receive online adaptive radiotherapy with 5-10mm PTV margin. The CTV contours of the following areas: gross tumor volume (GTV), cervix (if not already encompassed by the GTV), uterus, parametria, ovaries, vaginal tissue, obturator nodal chain, internal iliac nodal chain, external iliac nodal chain, presacral nodal chain and common iliac nodal chain. The upper border of CTV is at the level of aortic bifurcation. A dose of 50.4Gy is delivered to CTV with online adaptive radiotherapy.
62418133|NCT01211613|EXPERIMENTAL|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
62588900|NCT02906228|EXPERIMENTAL|GSM 900 MHz|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
62588901|NCT02906228|EXPERIMENTAL|TETRA 385 MHz|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
62588902|NCT02906228|EXPERIMENTAL|Sham Exposure|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
62799771|NCT04253613||periodontal+laser therapy|Systemically healthy subjects with periodontitis that have the contra-lateral sides treated with laser biostimulation therapy(LBT) adjunct to non-surgical periodontal treatment(NSPT) split-mouth designed study
62418134|NCT01211613|EXPERIMENTAL|Mechanical Manipulation|Doctor of chiropractic will apply a mechanically-assisted thrust to the lumbar spine of research participants using the Activator IV Instrument.
62418135|NCT01211613|ACTIVE_COMPARATOR|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
62418136|NCT06509815|EXPERIMENTAL|MIRA in the NSICU|The Intervention arm will experience the device, MIRA, during their stay in the NSICU.
62418137|NCT06509815|NO_INTERVENTION|Control|The Control arm will not experience the device.
62418138|NCT06314074|EXPERIMENTAL|Oscillometric blood pressure monitoring at 2.5-minute intervals|"In patients assigned to oscillometric blood pressure monitoring at 2.5-minute intervals, oscillometric upper-arm cuff blood pressure will be measured and displayed on the patient monitor every 2.5 minutes during surgery.~Blood pressure will additionally measured with BLINDED continuous non-invasive finger-cuff blood pressure monitoring."
62418139|NCT06314074|ACTIVE_COMPARATOR|Oscillometric blood pressure monitoring at 5-minute intervals|"In patients assigned to oscillometric blood pressure monitoring at 5-minute intervals, oscillometric upper-arm cuff blood pressure will be measured and displayed on the patient monitor every 5 minutes during surgery.~Blood pressure will additionally measured with BLINDED continuous non-invasive finger-cuff blood pressure monitoring."
62433514|NCT04341818|EXPERIMENTAL|Strength Training and Vitamin D monthly|Four weeks of Vitamin D (50.000 IU once per month) followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
62799772|NCT04253613||diabetic periodontal therapy|Type 2 diabetic(DM2) subjects with periodontitis that have the sides treated with non-surgical periodontal treatment (NSPT) split-mouth designed study
62418140|NCT02291172|EXPERIMENTAL|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry. The comprehensive communication intervention: (a) teaches foundational social communicative behaviors, (b) related skills that predict long term language outcomes, (c) a range of communicative functions, (d) spoken language skills, (e) provides children with an immediate mode of communication, (f) incorporates instructional methods, contexts, and partners that increase both the critical skills for spoken language and social use of language. Because parents are essential partners for young children with ASD who are learning to communicate, we (g) include parents
62799773|NCT04253613||diabetic periodontal+laser therapy|Type 2 diabetic(DM2) subjects with periodontitis that have the contra-lateral sides treated with laser biostimulation therapy(LBT) adjunct to non-surgical periodontal treatment (NSPT) split-mouth designed study
62799774|NCT04226508|NO_INTERVENTION|Control|
62799775|NCT04226508|EXPERIMENTAL|Physical exercise|
62225302|NCT02870335|ACTIVE_COMPARATOR|Proprioceptive neuromuscular facilitation|It is a stretching technique with the aim of increasing the ROM. It includes passive static stretching and contract-relax.
62225303|NCT03622619|EXPERIMENTAL|Manuka eye drops|
62225304|NCT03622619|ACTIVE_COMPARATOR|Systane Ultra|
62225305|NCT00003657|EXPERIMENTAL|High Dose ICF with Amifostine|"* Patients undergo peripheral blood stem cell transplantation (PBSC) harvest on day -8,~* ifosfamide IV, carboplatin IV etoposide IV (ICE) by 96 hour continuous infusion on days -7 to -4.~* Patients receive amifostine IV twice a day on days -7 to -3.~* PBSCs are reinfused on day 0.~* Filgrastim (G-CSF) is administered subcutaneously beginning on day 0 at least 2 hours after infusion of the stem cells and continuing until blood cell counts recover.~* Patients are followed monthly for the first 2 months and then for survival."
62225306|NCT04249154|OTHER|Post-op IMRT & hormonal therapy|The protocol is designed to recruit patients who have undergone prostatectomy and high risk features of the disease were found post-operatively or for patients that, after prostatectomy, a PSA rise has been documented will be enrolled in the Phase II trial. Patients will receive Eligard injection 8-12 weeks before starting radiation. The second injection is given 12 weeks after the first one concomitant with radiation therapy.
62225307|NCT05365048|EXPERIMENTAL|Local Tailoring|The intervention arm will include 20 clinics randomly assigned to the intervention arm. All physicians, nurses, department administrator and other staff members from the pediatric departments randomized to this arm will be included in the study, as well as parents of HPV vaccine eligible children (9-12 years old) who had one or more visits with their pediatric provider during the data collection period.
62225308|NCT05365048|EXPERIMENTAL|Prescribed Strategy|The intervention arm will include 20 clinics randomly assigned to the intervention arm.. All physicians, nurses, department administrator,s and other staff members from the pediatric departments randomized to this arm will be included in the study, as well as parents of HPV vaccine eligible children (9-12 years old) who had one or more visits with their pediatric provider during the data collection period.
62225309|NCT05365048|NO_INTERVENTION|Usual Care|The intervention arm will include 20 clinics randomly assigned to the usual care arm. All physicians, nurses, department administrators,s and other staff members from the pediatric departments randomized to this arm will be included in the study, as well as parents of HPV vaccine eligible children (9-12 years old) who had one or more visits with their pediatric provider during the data collection period.
62225310|NCT04661956|EXPERIMENTAL|Transbronchial cryobiopsy|Transbronchial cryobiopsy was performed in the patiens of pulmonary peripheral nodule
62225311|NCT04661956|OTHER|Transbronchial lung biopsy|Transbronchial lung biopsy was performed in the patiens of pulmonary peripheral nodule
62225312|NCT04401852|ACTIVE_COMPARATOR|MgSO4 group|will receive a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose
62225313|NCT04401852|PLACEBO_COMPARATOR|placebo group|will receive an equal volume of isotonic 0.9% saline over 15-20 minutes
62225314|NCT04061538|EXPERIMENTAL|Zinc sulfate|Zinc sulfate 20 mg by mouth, once a day for 10 days
62225315|NCT04061538|PLACEBO_COMPARATOR|Placebo|Placebo tablet, once a day for 10 days
62225316|NCT05163171||patient consulting or hospitalized in addiction structure|patient consulting or hospitalized in addiction structure
62418141|NCT02291172|NO_INTERVENTION|Business as Usual Control Group|All children, regardless of group assignment will participate in all assessments. Children randomized to the control group will not receive intervention, but will complete all other research procedures. Other treatments that all children receive in the community will be recorded with bi-monthly surveys.
62799776|NCT04210674|EXPERIMENTAL|The traditional medicinal product of Argan spinosa oil|The researcher talked to children's caregivers, explained the study process and provided general consistent tips to the all of them, including firstly washing the affected area only with warm water, disposing the area to the fresh air and keep the area dry; secondly spreading the traditional medicinal product of Argan spinosa oil on the affected area sparingly over the lesions borders forth times per day, then diaper the baby; finally not to apply any on the affected area such as wet wipes, essence contained soaps, barrier cream or other medications during the seventh day of the trial. The home follow-up visits took place and the researcher re-evaluated diaper area using the 5- point grading scale in the first, third and seventh day of trial.
62225317|NCT00642772|EXPERIMENTAL|Group Physical Therapy|12-week group-based program of physical therapy. Participants will meet approximately every other week for a total of 6 visits. The group sessions will include education about appropriate self-care for knee osteoarthritis and instructions and participation in group exercises. Participants will also be instructed in a home exercise program.
62225318|NCT01092741|EXPERIMENTAL|Gleevec|Gleevec 400 mg by mouth (P.O.) twice daily = 800 mg total daily dose
62225319|NCT02492022|EXPERIMENTAL|Probiotic L008-1|Encapsuled combinaison of 2 probiotics
62225320|NCT02492022|EXPERIMENTAL|Probiotic L008-2|Encapsuled combinaison of 2 probiotics
62225321|NCT02492022|PLACEBO_COMPARATOR|Placebo|Encapsuled non active ingredients
62225322|NCT06265064||Difficult mask ventilation|Difficult Mask Ventilation Grading (by Han et al.) Grade 1 mask ventilation can be easily performed by a single person Grade 2 requires the use of equipment such as an oropharyngeal airway Grade 3 necessitates the involvement of two or more personnel for mask ventilation or increasing oxygen flow Grade 4 indicates an inability to perform mask ventilation If the grade is ≥ 3, it signifies difficult mask ventilation
62418142|NCT05887674|EXPERIMENTAL|Multi-domain intervention group|Patients in this arm will receive multi-domain life-style intervention including low inflammatory-index diet, exercise, and cognitive training.
62225323|NCT06265064||non-difficult mask ventilation|Difficult Mask Ventilation Grading (by Han et al.) Grade 1 mask ventilation can be easily performed by a single person Grade 2 requires the use of equipment such as an oropharyngeal airway Grade 3 necessitates the involvement of two or more personnel for mask ventilation or increasing oxygen flow Grade 4 indicates an inability to perform mask ventilation If the grade is \< 3, it signifies non-difficult mask ventilation
62418143|NCT05887674|EXPERIMENTAL|Exercise and cognitive training|Patients in this arm will receive the intervention of exercise and cognitive training.
62418144|NCT05887674|NO_INTERVENTION|Standard health counseling at baseline|Patients in this arm will have their habitual diet and life style. No particular intervention or consultation would be provided.
62418145|NCT03463824|EXPERIMENTAL|Experimental Group 1|Participants will produce progressively larger lumbar flexion excursions at each game level and across treatment sessions.
62418146|NCT03463824|EXPERIMENTAL|Experimental Group 2|Participants will produce progressively larger lumbar flexion excursions at each game level and across treatment sessions.
62418147|NCT02407405|EXPERIMENTAL|1|Selumetinib 50 mg BID daily
62418148|NCT05270512|EXPERIMENTAL|Treatment with Dermal Cooling System|Dermal Cooling System will be used in all eligible subjects.
62418149|NCT01556646|EXPERIMENTAL|Tolvaptan|Open label study of tolvaptan. First 3 days as an inpatient then outpatient for the remainder of the study
62418150|NCT01970696||Ovarian Stromal Tumors|
62418151|NCT01970696||Testicular Stromal Tumors|
62418152|NCT01970696||Ovarian Small Cell Carcinoma|
62418153|NCT04629300|EXPERIMENTAL|Supportive Care Mobile Application|"Complete study questionnaires at two time points:~* upon enrollment at baseline prior to randomization~* approximately 12 weeks after the baseline assessment time point.~Participants will be provided with a study-issued tablet computer to access mobile app and receive a comprehensive tutorial and detailed instructions on how to use the app.~Participants will have approximately 10 weeks to complete the intervention modules at self initiated pace. The app will provide prompts as reminders to complete the modules.~Participants will receive standard oncology care. Study staff will monitor participant use of supportive care services, such as social work, psychology, psychiatry, and palliative care."
62418154|NCT04629300|ACTIVE_COMPARATOR|Usual Care|"Complete study questionnaires at two time points:~* upon enrollment at baseline prior to randomization~* approximately 12 weeks after the baseline assessment time point.~Participants will receive standard oncology care. Study staff will monitor participant use of supportive care services, such as social work, psychology, psychiatry, and palliative care."
62418155|NCT06703736||Multiple osteochondromas patients|The cohort is composed of patients suffering from hereditary multiple osteochondromas (HMO) and it contains 30 subjects: 15 minors (6-17 years) and 15 adults (18-40 years). The inclusion criteria of HMO cohort are: clinical and/or molecular diagnosis of Multiple Osteochondromas; male and female subjects; collection of appropriate informed consent; ability to walk a linear path without aids; presence of OM localized at lower limbs; ability to undergo all procedures required by the protocol. Are excluded from the cohort subjects with body mass index (BMI) equal to or greater than 30.
62418156|NCT06703736||Healthy subjects|Healthy subjects are control population, equivalent in gender and age to the investigated population. The cohort is composed of 30 subjects: 15 minors (6-17 years) and 15 adults (18-40 years).The inclusion criteria of healthy cohort are: absence of neuro-muskuloskeletal or other limb-limiting conditions in the lower limbs; male and female subjects; collection of appropriate informed consent; ability to undergo all procedures required by the protocol. Are excluded from the cohort subjects with body mass index (BMI) equal to or greater than 30.
62588903|NCT04988906|NO_INTERVENTION|Before Arm|The before arm of the study prehospital providers will provide resuscitation as per standard practice. The providers will utilize the Zoll Accuvent device without activation of the real-time dashboard. This will allow us to collect baseline ventilation data.
62799777|NCT04210674|ACTIVE_COMPARATOR|The conventional topical steroid ointment|The researcher talked to children's caregivers, explained the study process and provided general consistent tips to the all of them, including firstly washing the affected area only with warm water, disposing the area to the fresh air and keep the area dry; secondly spreading the conventional topical steroid ointment on the affected area sparingly over the lesions borders forth times per day, then diaper the baby; finally not to apply any on the affected area such as wet wipes, essence contained soaps, barrier cream or other medications during the seventh day of the trial. The home follow-up visits took place and the researcher re-evaluated diaper area using the 5- point grading scale in the first, third and seventh day of trial.
62225324|NCT00728585|EXPERIMENTAL|Arm I (palifermin)|Patients receive palifermin IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity. Patients then receive palifermin IV on days 0, 1, and 2 after autologous or allogeneic hematopoietic stem cell transplantation.
62225325|NCT00728585|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity. Patients then receive placebo IV on days 0, 1, and 2 after autologous or allogeneic hematopoietic stem cell transplantation.
62799778|NCT01820286|EXPERIMENTAL|Positive psychology intervention|4-week positive psychology intervention of 1 positive psychology exercise per week. Exercises will include 1) recalling 3 good events, 2) writing a letter of thankfulness, 3) using a personal strength, 4) envisioning a best possible future.
62799779|NCT01820286|ACTIVE_COMPARATOR|Recollection intervention|4-week recollection intervention of 1 recollection exercise per week. Exercises will include recalling events related to 1) daily activities, 2) health, 3) social life, 4) morning and evening.
62225326|NCT02725346|EXPERIMENTAL|Computer-assisted planning|Acromioplasty with planification
62225327|NCT02725346|ACTIVE_COMPARATOR|No planning|Acromioplasty without planification
62225328|NCT06492122|EXPERIMENTAL|[225Ac]Ac-FL-020|Treatment with \[225Ac\]Ac-FL-020 administered intravenously. 10 patients will also receive \[111In\]In-FL-020 for dosimetry purposes.
62225329|NCT02542111|EXPERIMENTAL|V-GDP|Bortezomib 1.6 mg/m2/d iv d1 and d8 Gemcitabine 1000mg/m2/d iv d1 and d8 Dexamethasone 40mg/d iv d1-4 cisplatin 25 mg/m2 iv d2-4 Frequency every 28 days Total cycles 4
62225330|NCT04103060|EXPERIMENTAL|Cerdulatinib 0.37% gel|Cerdulatinib 0.37% gel applied topically twice daily
62799780|NCT01179581|EXPERIMENTAL|1|single ascending doses
62799781|NCT01179581|PLACEBO_COMPARATOR|2|single dose placebo
62225331|NCT04103060|PLACEBO_COMPARATOR|Vehicle gel|Vehicle gel applied topically twice daily
62799782|NCT01179581|EXPERIMENTAL|3|multiple dose, 10 days, capsules (dosing depends on outcome of single-dose part; can be once or twice daily).
62799783|NCT01179581|PLACEBO_COMPARATOR|4|multiple dose, capsules, 10 days; scheme to match that of Study Arm 3.
62799784|NCT02794766|EXPERIMENTAL|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion colony forming units (CFU) per oral each 12 hours for 10 days
62799785|NCT02794766|ACTIVE_COMPARATOR|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
62799786|NCT02794766|PLACEBO_COMPARATOR|Placebo|Placebo 1 gum per oral each 12 hours, for 10 days
62799787|NCT02135055|EXPERIMENTAL|Normal immune function|The value of monocyte human leukocyte antigen-DR (mHLA-DR) is equal to or more than 15000 monoclonal antibody.
62799788|NCT02135055|EXPERIMENTAL|Moderate immunosuppression|The value of mHLA-DR is equal to or more than 10000 and less than 15000 monoclonal antibody.
62225332|NCT01471496|EXPERIMENTAL|prophylactic injection therapy group|In addition to medical therapy which included 2x 30 mg Pantoprazole and intravenous fluids this group of the patients recieved injection therapy.
62799789|NCT02135055|EXPERIMENTAL|Sever immunosuppression|The value of mHLA-DR is equal to or more than 5000 and less than 10000 monoclonal antibody.
62799790|NCT02135055|EXPERIMENTAL|Immune paralysis|The value of mHLA-DR is less than 5000 monoclonal antibody.
62799791|NCT02354274|ACTIVE_COMPARATOR|Standard: Homogeneous dose plan|Treatment will be given over 33 treatments. The dose is 66 Gy.
62799792|NCT02354274|EXPERIMENTAL|Escalation: Inhomogeneous dose plan|"Radiation dose is increased to tumor and lymph nodes based on an inhomogeneous dose distribution determined by the most active ( FDG-PET criteria ) area of the node compared to a standard uniform dose distribution.~Treatment will be given over 33 treatments. The dose is as high as possible taking the tolerance of the normal tissue into consideration"
62799793|NCT04379063||Canadian physicians during COVID-19 pandemic|Any physician who is practicing in Canada during the COVID-19 pandemic, whether they hold a full, provisional, or post-graduate in-training license.
62799794|NCT04115384|EXPERIMENTAL|Insulin (Novolin-R)|Regular insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril) BID
62225333|NCT01471496|NO_INTERVENTION|control group|This group of the patients recieved medical therapy only.
62799795|NCT02987751|EXPERIMENTAL|Glargine + Glulisine|Insulin Glargine + Glulisine (12U/day + 4U/day) at pre-breakfast/dinner for 24 weeks
62225334|NCT05945797|EXPERIMENTAL|Dexa Arm|Experimental arm patients will be receiving 2 ml (4mg) of dexamenthasone prior to undergoing ERCP.
62225335|NCT05945797|PLACEBO_COMPARATOR|NS Arm|Placebo arm patients will be receiving 2 ml of normal saline prior to undergoing ERCP.
62225336|NCT01795573|OTHER|Cultured Treg cells|Co-culturing of recipient dendritic cells and donor Treg cells given prior to allogeneic stem cell transplant
62225337|NCT03329560|EXPERIMENTAL|Oral fecal microbiota transplantation|All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.
62225338|NCT03834051|EXPERIMENTAL|Open Label|Fecal Microbiota Transplantation
62225339|NCT03855423|EXPERIMENTAL|Tocotrienol-rich Fraction (TRF)|Pre-operative patients will be receiving TRF at different doses assigned to them in a cohort of 3 patients at each level.
62225340|NCT03060668|EXPERIMENTAL|Study Group|"Caloric needs will be determined by indirect calorimetry. Patients in this group will receive 2.0 to 2.2 grams/kg/day of protein.~Nutritional therapy will be initiated in the first 24 hours after admission.~Nutritional formula will be Peptamen Intense (1.0 kcal/ml, 93 g/L protein (Nestle Health Care)."
62799796|NCT02987751|ACTIVE_COMPARATOR|Premixed Analogue Insulin (70/30)|Premixed analogue Insulin (70/30) 16U/day at pre-breakfast/dinner for 24 weeks
62799797|NCT04639544|PLACEBO_COMPARATOR|Control group|Volunteers will take 1 capsule per day with maltodextrin for 6 months
62799798|NCT04639544|EXPERIMENTAL|Probiotic group|Volunteers will take 1 capsule per day with the Lactobacillus strain for 6 months
62799799|NCT02498288|EXPERIMENTAL|Isotretinoin Arm|All subjects in this study will be randomized to receive all the 3 distinct medications of isotretinoin in a sequential manner. Subjects will receive a single dosage of two capsules x 20 mg (40 mg) orally, for three periods, six sequences, with a wash-out period of two weeks to eliminate the first dosage.
62799800|NCT01242878||healthy volunteers|ethnically matched people who do not have sickle cell disease
62799801|NCT01242878||patients|sickle cell disease patients
62799802|NCT02544503|EXPERIMENTAL|Stroke Patients|Subjects will undergo single pulse transcranial magnetic stimulation (TMS), paired pulse transcranial stimulation (ppTMS), and low frequency repetitive transcranial magnetic stimulation (rTMS) at one month and six months post stroke.
62799803|NCT02544503|ACTIVE_COMPARATOR|Healthy Controls|Subjects will undergo single pulse transcranial magnetic stimulation (TMS), paired pulse transcranial stimulation (ppTMS), and low frequency repetitive transcranial magnetic stimulation (rTMS) at one month and six months.
62799804|NCT00068341|EXPERIMENTAL|Arm I (neoadjuvant therapy)|see intervention description
62799805|NCT00068341|EXPERIMENTAL|Arm II (neoadjuvant therapy)|please see intervention description
62799806|NCT00068341|EXPERIMENTAL|HER2/neu negative patients|please see intervention description
62799807|NCT01634776|PLACEBO_COMPARATOR|Corn oil|1288 mg/day corn oil
62799808|NCT01634776|EXPERIMENTAL|Flaxseed oil|1200 mg/day flaxseed oil
62799809|NCT00376129|EXPERIMENTAL|I|
62799810|NCT05287386|EXPERIMENTAL|Pemigatinib|Selective FGFR1-3 inhibitor
62026565|NCT01412944|EXPERIMENTAL|AIN457 subcutaneous (s.c.)|During the intravenous (I.V.) period, participants received two 150 mg s.c. injections of AIN457 at randomization and week 4, and AIN457 placebo I.V. at randomization, week 2 and week 4. During the maintenance period, participants received 300 mg s.c. of open-label AIN457.
62225341|NCT03060668|ACTIVE_COMPARATOR|Control Group|"Patients in this group will receive 25 Kcal/kg/day and 1.4 to 1.5 grams/kg/day of protein.~Nutritional formula in this group will be Novasource senior (Nestle Health Care).~Nutritional therapy will be initiated in the first 24 hours after admission."
62225342|NCT01401907|EXPERIMENTAL|Early Palliative Care|Subjects receive standard of care with early palliative care.
62225343|NCT01401907|NO_INTERVENTION|Standard of Care|Subjects receives standard of care
62588904|NCT04988906|ACTIVE_COMPARATOR|After Arm|The after arm of the study the prehospital providers will provide resuscitation as per standard practice. The real-time ventilation dashboard will be activated and the providers will use real-time feedback to monitor ventilation quality during the resuscitation.
62588905|NCT04114201|EXPERIMENTAL|PSI|Patients received TKA using patient-specific Instrumentation.
62588906|NCT04114201|ACTIVE_COMPARATOR|Conventional|Patients received TKA conventional Instrumentation.
62588907|NCT01730027|EXPERIMENTAL|ADC3680|ADC3680 oral once daily
62225344|NCT00928447|EXPERIMENTAL|rHuPH20|Participant's upper back will be divided into 2 equal spaces and will receive Regimen 1 and 2 in 4 spaces respectively. In Regimen 1, a single row of 4 patches, each with the nickel sulfate concentration (NSC) (1, 2.5, or 5%) determined at screening, will be applied to the upper space at Day 1. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. An ID injection containing rHuPH20 (3,000 Units \[U\]) will be administered once daily (QD) for 5 days at the center of each area of reaction. In Regimen 2, a single row of 4 sites in the lower space will be injected intradermally with drug rHuPH20 (3,000 U) at Day 1. Ten minutes after the injections, patches with the NSC (1, 2.5, or 5%) determined at screening will be applied to the injection sites. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. As during pretreatment, an ID injection containing rHuPH20 will be then administered QD for 5 days.
62588908|NCT01730027|PLACEBO_COMPARATOR|Placebo|Placebo oral once daily
62588909|NCT01730027|ACTIVE_COMPARATOR|montelukast|montelukast oral once daily
62225345|NCT00928447|PLACEBO_COMPARATOR|Placebo|Participant's upper back will be divided into 2 equal spaces and will receive Regimen 1 and 2 in 4 spaces respectively. In Regimen 1, a single row of 4 patches, each with the NSC (1, 2.5, or 5%) determined at screening, will be applied to the upper space at Day 1. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. An ID injection containing placebo will be administered QD for 5 days at the center of each area of reaction. In Regimen 2, a single row of 4 sites in the lower space will be injected intradermally with placebo at Day 1. Ten minutes after the injections, patches with the NSC (1, 2.5, or 5%) determined at screening will be applied to the injection sites. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. As during pretreatment, an ID injection containing placebo will be then administered QD for 5 days.
62225346|NCT02042222|ACTIVE_COMPARATOR|Standard Arm|Half of the subjects initiating hydroxyurea will be randomly assigned to the standard treatment arm, consisting of escalation to the maximum tolerated dose (MTD) of hydroxyurea utilizing a previously published algorithm. Hydroxyurea dosing will commence at 20+/-2.5 mg/kg/day, given as a single daily oral dose. All patients will be offered the choice of a liquid formulation of hydroxyurea or hydroxyurea tablets, with the exact dose rounded up or down to the closest practical dose based on the chosen formulation but not differing from the intended dose by more than 2.5 mg/kg. It should take approximately 6 to 12 months for subjects to reach the MTD on this arm.
62225347|NCT02042222|ACTIVE_COMPARATOR|Alternative Treatment Arm|"Half of the subjects initiating hydroxyurea therapy will be assigned to the alternative treatment arm of the study. In this arm, the predicted hydroxyurea MTD will be calculated for each subject.~As in the dose-escalation arm, the exact dose will be rounded up or down to the closest practical dose based on the chosen formulation of hydroxyurea. Since the most common toxicity associated with hydroxyurea use is excessive myelosuppression, the maximum dose at which a subject in the dose-prediction arm will be started will be 30 mg/kg/day or 2000 mg/day. Patients with a higher predicted MTD will subsequently be escalated to this higher dose after four weeks on therapy if there is no evidence of toxicity."
62225348|NCT03432715|EXPERIMENTAL|Wellness Champions for Change + Students|Schools randomized to the WCC+S arm will receive both the Teacher Intervention and the Student Wellness Champion Intervention.
62225349|NCT03432715|EXPERIMENTAL|Wellness Champions for Change|Schools randomized to the WCC+S arm will receive only the Teacher Intervention.
62225350|NCT03432715|NO_INTERVENTION|Control|The control group will not receive either intervention. Schools will be given a modified SWC curriculum as well as the teacher training at the end of the data collection period.
62418157|NCT06704035|EXPERIMENTAL|Early OGTT Results Revealed|The results of the early OGTT conducted before 16 weeks' gestation will be revealed to the participants. If the results indicate gestational diabetes mellitus (GDM) by the WHO 2013 criteria, immediate follow-up actions, including appropriate treatments, will be taken. Those with a normal result will undertake the universally offered routine OGTT at 24-28 weeks' gestation.
62588910|NCT03173742|EXPERIMENTAL|T1, T2, T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
62588911|NCT03173742|EXPERIMENTAL|T1, T3, T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
62588912|NCT03173742|EXPERIMENTAL|T2,T1,T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
62418158|NCT06704035|NO_INTERVENTION|Early OGTT Results Concealed|Participants in this arm will undergo an early oral glucose tolerance test (OGTT) before 16 weeks' gestation, however, the results will be concealed from the participants and study investigators, and results will not be acted upon (unless they are suggestive of pre-existing type 2 diabetes mellitus as reviewed by an independent clinician, in which case appropriate follow-up will be arranged). All participants (except those with results suggestive of type 2 diabetes) will undertake the routine OGTT at 24-28 weeks' gestation, as per standard care.
62225351|NCT02731573|EXPERIMENTAL|Treatment arm|Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care with treatment by D-PLEX.
62225352|NCT02731573|OTHER|Control arm|Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care.
62418159|NCT04377516|EXPERIMENTAL|Transabdominal Sonography-guided Biofeedback group|pelvic floor muscle training with transabdominal sonography-guided Biofeedback
62225353|NCT02860494|EXPERIMENTAL|Topical everolimus 0.1%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
62026566|NCT01412944|EXPERIMENTAL|AIN457 I.V.|During the I.V. period, participants received AIN457 10mg/kg I.V. at randomization, week 2 and week 4, and AIN457 placebo s.c. at randomization and week 4. During the maintenance period, participants received 300 mg s.c. of open-label AIN457.
62225354|NCT02860494|EXPERIMENTAL|Topical everolimus 0.5%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
62225355|NCT02860494|EXPERIMENTAL|Topical everolimus 1%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
62418160|NCT04377516|ACTIVE_COMPARATOR|Exercise group|pelvic floor muscle training
62418161|NCT04377516|PLACEBO_COMPARATOR|Control group|pelvic girdle education
62418162|NCT04377516|PLACEBO_COMPARATOR|Health group|pelvic girdle education
62418163|NCT04974593|EXPERIMENTAL|H2BT-positive|
62588913|NCT03173742|EXPERIMENTAL|T2,T3,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
62225356|NCT02860494|PLACEBO_COMPARATOR|Topical placebo|Topical placebo will be identical to the everolimus topical formulation. Topical placebo will be applied to the affected areas, once daily, in the evening, for 6 months by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
62418164|NCT04974593|EXPERIMENTAL|H2BT-negative|
62418165|NCT06501989|EXPERIMENTAL|Chemotherapy with 5-FU/Leucovorin (LV) alone, with oxaliplatin or irinotecan or both|Plasma specimens will be collected for the measurement of plasma 5-FU level from patients receiving 5-FU/LV alone, with oxaliplatin (mFOLFOX6) or irinotecan (FOLFIRI), or both (mFOLFOXIRI) chemotherapy. 5-FU doses will be modified based on the assay results.
62418166|NCT02552394|EXPERIMENTAL|HuJ591 Administration|6 subjects will be treated at 300 mg dose. The decision about treating subjects at the lower dose will depend upon their response. If ≥4 of 6 subjects respond at the 300 mg level, then 6 more subjects will be recruited at the 200 mg level. If ≥4 of 6 subjects respond at the 200 mg level than 6 more subjects will be recruited at the next dose level of 100 mg. If ≥ 4/6 subjects respond at this level, then 6 subjects will be recruited at the last dose level of 50 mg. At any level, if the first four consecutive subjects respond, the next two subjects will be enrolled in the same dose-level cohort and further subjects will be recruited at the next dose level. Response at every dose level is defined by conversion from an unfavorable CTC count at baseline to a favorable CTC count.
62418167|NCT02981667||Active men and women|Healthy, active men and women ages 18-45 yr completed 1 bout of high intensity interval training and moderate intensity continuous training in a randomized, crossover design.
62418168|NCT01176578|EXPERIMENTAL|T2DM|Type 2 Diabetes Mellitus
62418169|NCT01176578|EXPERIMENTAL|IGT|Impaired Glucose Tolerance
62418170|NCT01176578|ACTIVE_COMPARATOR|NGT|Normal Glucose Tolerance
62418171|NCT06192264|EXPERIMENTAL|ASC40 dose 1|ASC40 dose 1 84 days of treatment
62418172|NCT06192264|PLACEBO_COMPARATOR|ASC40 Placebo|ASC40 Placebo 84 days of treatment
62418173|NCT04652635|ACTIVE_COMPARATOR|Nail plate removal, nail bed repair|Participants will undergo nail plate removal and nail bed repair, and follow up at clinic visits at 1 week, 3 months, and 6 months
62026567|NCT04799015|EXPERIMENTAL|Dexamethasone|Dexamethasone 10mg IV + metoclopramide 10mg IV
62026568|NCT04799015|PLACEBO_COMPARATOR|Placebo|Placebo IV + metoclopramide 10mg IV
62588914|NCT03173742|EXPERIMENTAL|T3,T1,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
62225357|NCT05636722|EXPERIMENTAL|Intervention group|Participants in this group (all participants) were asked to complete a questionnaire before and after (6 weeks after baseline) using the online self-help intervention (unguided web-based intervention).
62225358|NCT01711723|EXPERIMENTAL|Renal Impaired Group|Subjects with renal impairment received darapladip 160 mg daily for 10 consecutive days.
62225359|NCT01711723|EXPERIMENTAL|Healthy Control Group|Healthy volunteers matching with renal impairment subjects for gender, age and BMI; received darapladip 160 mg daily for 10 consecutive days.
62225360|NCT00861523|ACTIVE_COMPARATOR|1. thiamine|Pregnant women until 12 week of gestation who refer to the ER because of nausea and vomiting and didn't improve after hydration, will receive thiamine IV
62225361|NCT00861523|ACTIVE_COMPARATOR|2. promethazine|Pregnant women until 12 week of gestation who refer to the ER because of nausea and vomiting and didn't improve after hydration, will receive promethazine IV
62418174|NCT04652635|NO_INTERVENTION|Observation|Participants will follow up at clinic visits at 1 week, 3 months, and 6 months
62588915|NCT03173742|EXPERIMENTAL|T3,T2,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
62418175|NCT05188807|EXPERIMENTAL|The patient with cervical pathology|we will perform airway ultrasonography before the patients intubations and we will intubate the patients before cervical surgery
62799811|NCT02574273|ACTIVE_COMPARATOR|Secret Agent Society (SAS) Program|The Secret Agent Society (SAS) Program is an intervention which involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home. Parents will attend weekly parent support training sessions. 3 and 6 month booster sessions are conducted with both parents and children to help families with maintaining the skills that they have learned and to problem-solve new challenges that arise. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits, for both parent and child participants.
62799812|NCT02574273|OTHER|Waitlist Group / Treatment As Usual|Participants may be randomly allocated to the wait list control condition, where participants will receive treatment as usual during the 3 month period when the intervention group will participate in the SAS Program. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic. The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits.
62799813|NCT05462249||Vaccinated|Patients who have been vaccinated against HPV virus.
62588916|NCT03400709|EXPERIMENTAL|N-acetylcisteine group|
62588917|NCT03400709|PLACEBO_COMPARATOR|Control group|
62588918|NCT02602132|EXPERIMENTAL|Clamping group|Indwelling urinary catheter is clamped before removal and unclamped when the patient expresses his desire to urinate.
62026569|NCT02167828|EXPERIMENTAL|Social Support|Participants will be trained to give one another ongoing, theory-based but personally-tailored advice, recommendations, and support to encourage entry to HIV medical care, remaining in care, and adhering to medication regimens when they are prescribed. The intervention's intent is to increase mutual support, positive attitudes, intentions, plans, and collective self-efficacy for care engagement.
62225362|NCT03743285|EXPERIMENTAL|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
62225363|NCT06004011|EXPERIMENTAL|ARROW strategies|The ARROW strategies which use peer-peer support at the patient level (through peer counselors), at the provider level (through peer lead education sessions) and at the health system level (through a health collaborative forum) to deliver high quality screenings and ensure cancer treatment completion.
62225364|NCT06004011|ACTIVE_COMPARATOR|One-time education|The comparator arm participants will receive one-time education and usual care services.
62225365|NCT02039453|EXPERIMENTAL|Fentanyl arm|The subjects of this arm will consist of the patients who undergo colonoscopy with sedative agents, propofol and fentanyl.
62225366|NCT02039453|ACTIVE_COMPARATOR|Pethidine arm|The subjects of this arm will consist of the patients who undergo colonoscopy with sedative agents, propofol and pethidine.
62418176|NCT06680089|EXPERIMENTAL|CD70-targeted immunoPET imaging|Enrolled patients will undergo a CD70-targeted immunoPET/CT scanning.
62418177|NCT02856282||Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Two sprays into each nostril once a day, preferably in the morning. Once symptoms are under control ,a maintenance dose of one spray may be used accordingly
62588919|NCT02602132|NO_INTERVENTION|Free drainage group|The urinary catheter will be removed without prior clamping.
62588920|NCT05971238|EXPERIMENTAL|Eye-tracking, pupillometry and scene rating indoors & outdoors|
62588921|NCT04677556|OTHER|Severe acute bronchiolitis|Infants under 6 months admitted in Pediatric Intensive Care Unit for a severe acute bronchiolitis needing NIV (modified Woof clinical asthma score (WCAS) \>4 and/or hypercapnic acidosis (pH\<7,3 and/or pCO2\>50mmHg)
62588922|NCT01919684|ACTIVE_COMPARATOR|Active|LGD-6972
62588923|NCT01919684|PLACEBO_COMPARATOR|Placebo (Captisol®)|Vehicle Control (Captisol®)
62588924|NCT04321356||Stryker Triathlon PCR TKA|Subjects implanted with a Stryker Triathlon PCR TKA
62799814|NCT05462249||Not vaccinated|Patients who have not been vaccinated against HPV virus.
62799815|NCT02587520|EXPERIMENTAL|Adolescents: SP0173 Formulation 1|Healthy participants aged 10-18 years received a single dose of the SP0173 Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap) vaccine.
62799816|NCT02587520|EXPERIMENTAL|Adolescents: SP0173 Formulation 2|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
62799817|NCT02587520|EXPERIMENTAL|Adolescents: SP0173 Formulation 3|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
62799818|NCT02587520|EXPERIMENTAL|Adolescents: SP0173 Formulation 4|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
62799819|NCT02587520|ACTIVE_COMPARATOR|Adolescents: Adacel®|Healthy participants aged 10-18 years received Adacel®.
62799820|NCT02587520|ACTIVE_COMPARATOR|Adolescents: Boostrix®|Healthy participants aged 10-18 years received Boostrix®.
62799821|NCT02587520|EXPERIMENTAL|Adults: SP0173 Formulation 1|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
62799822|NCT02587520|EXPERIMENTAL|Adults: SP0173 Formulation 2|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
62799823|NCT02587520|EXPERIMENTAL|Adults: SP0173 Formulation 3|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
62026570|NCT02167828|NO_INTERVENTION|No Intervention|Participants in this arm will not receive an intervention.
62418178|NCT04921189|ACTIVE_COMPARATOR|The combined supplement of Ascorbic acid, Thiamine, and Cortisol|The combined administration of 3 drugs will be administered through intravenous infusion over 60 min every 12 h for 3 days for the out-of-hospital cardiac arrest survivors treated with targeted temperature management.
62418179|NCT04921189|PLACEBO_COMPARATOR|Placebo|An identical volume of 0.9% saline (150mL) administered through intravenous infusion over 60 min every 12 h for 3 days.
62418180|NCT05697835|EXPERIMENTAL|Behavioral activation and medication optimization|"Behavioral activation (BA) will begin perioperatively and will span across 3 months postoperatively, with sessions approximately weekly or biweekly, depending on patient preference \& health condition.~Medications will be reviewed by a team of interventionists to minimize brain-toxic medications and optimize doses of antidepressants and other mental health medications. In-hospital and after discharge, the interventionists' role will include coordinating with the care teams to ensure that medication changes that were introduced preoperatively are maintained."
62418181|NCT05697835|OTHER|Control (treatment as usual)|Participants in control arm will continue care as usual. They will receive printed resources for supporting sleep hygiene, stress reduction, cognitive and mental health exercises, as well as community resources for older adults.
62588925|NCT04321356||Stryker Triathlon PS TKA|Subjects implanted with a Stryker Triathlon PS TKA
62588926|NCT04321356||Zimmer Persona PCR TKA|Subjects implanted with a Zimmer Persona PCR TKA
62588927|NCT04321356||Zimmer Persona PS TKA|Subjects implanted with a Zimmer Persona PS TKA
62588928|NCT02240927|ACTIVE_COMPARATOR|Enoxaparine|During first trimester, warfarin is stopped and enoxaparine is started in 1mg/kg dose twice a day. Dose is adjusted according to Anti Factor Xa levels (between 0.7-1.2). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
62588929|NCT02240927|ACTIVE_COMPARATOR|Enoxaparine and 2.5 mg warfarin|If the patient's therapeutic warfarin dose is more than 5 mg before pregnancy, warfarin dose is decreased to 2.5 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1.0). Full dose warfarin is continued after first trimester and dose is regulated according to INR (between 2.5-4)
62418182|NCT06703658|EXPERIMENTAL|Part A-AZD5004|Participants will receive AZD5004 orally.
62799824|NCT02587520|EXPERIMENTAL|Adults: SP0173 Formulation 4|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
62799825|NCT02587520|ACTIVE_COMPARATOR|Adults: Adacel®|Healthy participants aged 19-64 years received Adacel®.
62418183|NCT06703658|PLACEBO_COMPARATOR|Part A-Placebo|Participants will receive matching Placebo orally.
62799826|NCT02587520|ACTIVE_COMPARATOR|Adults: Boostrix®|Healthy participants aged 19-64 years received Boostrix®.
62799827|NCT02587520|EXPERIMENTAL|Older Adults: SP0173 Formulation 1|Healthy participants aged greater than equal to (\>=65) years received a single dose of the SP0173 Tdap vaccine.
62799828|NCT02587520|EXPERIMENTAL|Older Adults: SP0173 Formulation 2|Healthy participants aged \>=65 years received a single dose of the SP0173 Tdap vaccine.
62799829|NCT02587520|EXPERIMENTAL|Older Adults: SP0173 Formulation 3|Healthy participants aged \>=65 years received a single dose of the SP0173 Tdap vaccine.
62799830|NCT02587520|EXPERIMENTAL|Older Adults: SP0173 Formulation 4|Healthy participants aged \>= 65 years received a single dose of the SP0173 Tdap vaccine.
62799831|NCT02587520|ACTIVE_COMPARATOR|Older Adults: Adacel®|Healthy participants aged \>=65 years received Adacel®.
62799832|NCT02587520|ACTIVE_COMPARATOR|Older Adults: Boostrix®|Healthy participants aged \>=65 years received Boostrix®.
62799833|NCT03038126|ACTIVE_COMPARATOR|CCHT|Veterans Administration (VA) CCHT with an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).
62799834|NCT03038126|PLACEBO_COMPARATOR|Usual care|
62799835|NCT05414890||Cell Based Assay (CBA)|The sera samples from patients and control subjects, upon clinic visits, as well as during follow up, will be randomly numbered. All samples will be blindly tested with CBA by different operators.
62225367|NCT03241303|EXPERIMENTAL|Acarbose|50 mg and 100 mg glucobay tablets. 2 weeks. Other name: Precose
62225368|NCT03241303|PLACEBO_COMPARATOR|Placebo Oral tablets|180 mg. 2 weeks.
62418184|NCT06703658|EXPERIMENTAL|Part B-AZD5004|Participants will receive AZD5004 orally.
62418185|NCT06703658|PLACEBO_COMPARATOR|Part B-Placebo|Participants will receive matching Placebo orally.
62418186|NCT04650984|ACTIVE_COMPARATOR|Arm 1|Patients will receive 75 mg/m2 doxorubicin once every 3 weeks (reference treatment).
62418187|NCT04650984|EXPERIMENTAL|Arm 2|Patients will receive 13 µg/kg L19TNF on days 1, 3 and 5 every 3 weeks in combination with 60 mg/m2 doxorubicin (once every 3 weeks).
62418188|NCT06220513|ACTIVE_COMPARATOR|Group A (ESP) block group|the first group (ESP) will be placed in the lateral decubitus position. The ultrasound probe will be placed in longitudinal orientation at the level of the T7 spinous process and then moved the probe 3 cm laterally from the midline. The ultrasound landmarks, which included the T7 transverse process and the overlying erector spinae muscle, will be identified. Under complete aseptic conditions, an 80-mm 21-gauge block needle will be inserted in plane at an angle of 30-40° in cranial-to-caudal direction until the tip contacted the T7 transverse process. After hydro-dissection with 3 mL of isotonic saline solution confirmed the correct needle tip position, 30 mL of 0.25% bupivacaine and dexamethasone 4mg will be injected deep to the erector spinae muscle. The same procedure will be repeated with 30 mL of 0.25% bupivacaine solution and dexamethasone 4mg on the contralateral side.
62418189|NCT06220513|ACTIVE_COMPARATOR|Group B TAP block group|patients who will receive TAP block. A high-frequency ultrasound probe placed transversely, approximately midway between the iliac crest and costal margin shows the three muscle layers of the abdominal wall. A regional block needle can then be inserted anteriorly and slightly away from the probe and carefully advanced until it reaches the transversus plane. In this 'in-plane' technique. The needle and its tip are visualised throughout the procedure, as it enters the transversus plane after piercing the fascial layer below the internal oblique muscle. The needle will be directed toward the transversus abdominis fascia and injected 30 mL of 0.25% bupivacaine and dexamethasone 4mg between the rectus abdominis and transversus abdominis muscles. The same procedure will be repeated with 30 mL of 0.25% bupivacaine solution and dexamethasone 4mg on the contralateral side.
62418190|NCT04537052|EXPERIMENTAL|Onl Femoral vein|Ultrasound-guided controlled injection begins, and the venous diameter and gap between valves are reduced
62418191|NCT00987571||Carpal Tunnel patients|These patients have documented carpal tunnel syndrome
62418192|NCT00987571||Normal Subjects|These individuals have no carpal tunnel syndrome
62418193|NCT05395702|EXPERIMENTAL|Drug: Interferon Gamma|Antibacterial therapy + IFN-G administered intramuscularly 100,000 IU once a day daily for 5 days
62418194|NCT05395702|NO_INTERVENTION|Control: No intervention|Only antibacterial therapy
62418195|NCT02143401|EXPERIMENTAL|Treatment (navitoclax, sorafenib tosylate)|Patients receive navitoclax PO QD on days 1-21 (days 1-28 cycle of 1 only) and sorafenib tosylate PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62418196|NCT06701136|EXPERIMENTAL|Sudapyridine (WX-081) Alone|Participants will receive Sudapyridine (WX-081) tablets orally at a specified dose once daily for 10 days (in Study A and Study B) or once under fasting and fed conditions (in Study C). Pharmacokinetic sampling and safety assessments will be conducted.
62418197|NCT06701136|EXPERIMENTAL|Sudapyridine (WX-081) Combined with Itraconazole or Rifampin|Participants will receive Sudapyridine (WX-081) tablets orally at a specified dose once daily for 7 days while co-administered with itraconazole (Study A) or rifampin (Study B). Pharmacokinetic sampling and safety assessments will be conducted.
62418198|NCT06103864|EXPERIMENTAL|Dato-DXd + durvalumab|Arm 1: Dato-DXd + durvalumab
62418199|NCT06103864|ACTIVE_COMPARATOR|Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab|Arm 2: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin)
62418200|NCT06103864|EXPERIMENTAL|Dato-DXd|Arm 3: Dato-DXd
62418201|NCT06043518||Patients with congenital amputation|
62418202|NCT06043518||Healthy subjects|
62418203|NCT03694483||Patient population|Male individuals with elevated PSA and a positive MRI-driven biopsy AND male individuals with diagnosed prostate cancer (but prior to any treatment)
62418204|NCT03694483||Control Population|Male individuals with elevated PSA and a negative MRI-driven biopsy
62418205|NCT03425786|EXPERIMENTAL|Early BPPV Management|Diagnostic and treatment training for BPPV.
62225369|NCT03241303|EXPERIMENTAL|Exendin (9-39)|Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.
62225370|NCT03241303|PLACEBO_COMPARATOR|Placbo Saline|9 mg/ml placebo saline infusion on experimental day.
62418206|NCT03425786|ACTIVE_COMPARATOR|Late BPPV Management|Diagnostic training for BPPV. Sports Medicine providers will refer patients positive for BPPV to an Otolaryngologist at our institution for treatment.
62418207|NCT06650800|EXPERIMENTAL|Patient with major depressive episode|
62418208|NCT05388136|ACTIVE_COMPARATOR|Control Arm|"Conventional (standard) FU entails frequent clinical exams and routine imaging (17 visits including a visit at randomization, plus 4 or 7 imaging depending on smoking habits of the participant) during 5 years of FU.~PRO with rating scale is to be completed monthly by the participant, but no alert will be generated and the participating center will not arrange urgent appointment, except in case of self-referral for any reasons."
62418209|NCT05388136|EXPERIMENTAL|Individualized Deintensified Arm|"Individualized de-intensified FU entailing less frequent clinical exams and no routine imaging (11 visits including visit at randomization) without any routinely planned imaging during 5 years of FU.~PRO with rating scale is to be completed monthly by the participant. The PRO result will trigger an alert to the participant and to the site in conditions indicating possible REC/SPM. In case of possible (recurrence or secondary primary malignancy) REC/SPM, an 'open urgent appointment' will be arranged for the participant by the participating centers' team within 2 weeks."
62418210|NCT01766141|NO_INTERVENTION|Acute versus chronic low back pain|No manipulative intervention. Phlebotomy for inflammatory biomarker determinations to compare acute versus chronic at baseline.
62588930|NCT02240927|ACTIVE_COMPARATOR|Enoxaparine and 4 mg warfarin|If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
62588931|NCT02240927|ACTIVE_COMPARATOR|Warfarin|If the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy and the dose is adjusted according to INR level (between 2.5-4).
62588932|NCT03261726|EXPERIMENTAL|MedEl Test Electrode Placer|MedEl Test Electrode Placed at VIIIth nerve tumor resection
62588933|NCT06350435|EXPERIMENTAL|Experimental Group|
62588934|NCT06350435|OTHER|Control group|
62799836|NCT05414890||CBA-TSA Assay|The sera samples from patients and control subjects, upon clinic visits, as well as during follow up, will be randomly numbered. All samples will be blindly tested with CBA-TSA by different operators.
62026571|NCT04744480|EXPERIMENTAL|The combined topical anesthesia induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia，3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.
62225371|NCT05972031|EXPERIMENTAL|Person-centred integrated care intervention|The core of the person-centered approach is a cyclical process and for EMBOSS developed for patients with low SES. The practice nurse in the GP will act as case manager and can consult other health providers. The first step in the intervention is assessing the integral health status of the patient (health across multiple domains), using a visual conversation tool. The second step is discussing the results with the patient. Personal goals are formulated in the third step. In the fourth step, the healthcare professional and patient will choose through shared-decision making the most appropriate interventions and support to achieve these goals, which are documented in a personal plan. Next, referrals are made if necessary and the treatment is started. An evaluation is planned and carried out. All practices in the EMBOSS intervention group will be trained by Pharos on how to recognize and provide GDM to low SES patients using appropriate communication skills and the specific tools.
62418211|NCT01766141|EXPERIMENTAL|Spinal manipulation (SMT)|Inflammatory biomarker determinations after a course of 6 SMT interventions over the period of 2 weeks; a single SMT per treatment.
62418212|NCT01766141|NO_INTERVENTION|No treatment controls|Asymptomatic subjects. Biomarker determinations at time zero and again two weeks later.
62418213|NCT04532489|OTHER|Group 1|These subjects, 6 planned (3 male, 3 female), will be to obtain normal tissue distribution of \[18F\]NP-59 and confirm calculated radiation dosimetry and optimal uptake time.
62588935|NCT04864340|EXPERIMENTAL|threshold stimulation (tetanic)|
62588936|NCT04864340|EXPERIMENTAL|upper threshold stimulation (tetanic)|
62588937|NCT04864340|EXPERIMENTAL|threshold stimulation (pressure)|
62799837|NCT06473220|OTHER|Reference group|The reference group carried out routine nursing, that is, the most appropriate intervention measures were properly formulated according to the actual condition degree and various levels of physical fitness of the patients, and the patients were urged to take drugs according to the doctor's advice every day. Nurses should conduct oral health promotion for patients; Administering medication and a daily healthy diet regimen; Patients with orientation and language communication disorders were given nursing care step by step. Continuous care for 2 months.
62799838|NCT06473220|EXPERIMENTAL|Study group|The research group cooperated with the implementation of narrative nursing. The detailed measures are as follows: ① Establish a narrative nursing special group. ② Narrative data collection. ③ Pay attention to the scientific evaluation of narrative content. ④ Edit the narrative reasonably. ⑤ Strengthen interview intervention. Continuous care for 2 months.
62799839|NCT03410524|ACTIVE_COMPARATOR|Simethicone with PEG-3350 bisacodyl preparation|"Treatment arm:~200 mg Simethicone in 3 mL of liquid formulation mixed with low volume PEG-3350 bisacodyl combination preparation. Bowel preparation taken as per directions including the evening before and the day of the procedure."
62799840|NCT03410524|PLACEBO_COMPARATOR|Placebo with PEG-3350 bisacodyl preparation|"Placebo arm:~3 mL of water mixed with low volume PEG-3350 bisacodyl combination preparation. Bowel preparation taken as per directions including the evening before and the day of the procedure."
62799841|NCT00598936||Cardiac Surgery or Hospitalization|"Patients scheduled for a Cardiac Surgery procedure, two types of cerebral oximetry devices were compared at the same time during the surgical procedure.~The second group were patients hospitalized (in the Intensive Care Unit or ICU, with any diagnosis, excluding head trauma patients. Those patients were monitored using two types of cerebral oximetry devices at the same time for up to 72 hours."
62799842|NCT04494906|EXPERIMENTAL|Interactive stepping exercise group|Participants will execute interactive stepping exercise 2 times per week for 8 weeks (16 sessions).
62026572|NCT04744480|NO_INTERVENTION|The routine induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia.In the routine induction group，all procedures will be the same as those of the topical anesthesia group, The drug will be replaced with constant volume saline.
62588938|NCT04864340|EXPERIMENTAL|upper threshold stimulation (pressure)|
62588939|NCT04864340|PLACEBO_COMPARATOR|non nociceptive procedure (fine touch)|
62588940|NCT06582719|EXPERIMENTAL|Nutritional Counseling plus AI Intervention|
62588941|NCT06582719|ACTIVE_COMPARATOR|Nutritional Counseling|
62588942|NCT05225298|ACTIVE_COMPARATOR|Static frequency|Test based screening for SARS-CoV-2 every two weeks
62588943|NCT05225298|ACTIVE_COMPARATOR|Dynamic frequency|Test based screening for SARS-CoV-2 ranging from once a week to once every four weeks anchored to county COVID-19 case rates
62588944|NCT05902091|EXPERIMENTAL|Exercising participants|Participants will receive 4 weeks of neurophysiology-based intervention, forty-five minutes of individual session, twice a week.
62588945|NCT01344993|EXPERIMENTAL|MA09-hRPE|"Experimental: Subretinal injection of MA09-hRPE~* Cohort 1 50,000 cells~* Cohort 2 100,000 cells~* Cohort 2a Better Vision 100,000 cells~* Cohort 3 150,000 cells~* Cohort 4 200,000 cells"
62799843|NCT04494906|ACTIVE_COMPARATOR|Square stepping exercise group|Participants will execute square stepping exercise 2 times per week for 8 weeks (16 sessions).
62799844|NCT02929030||NANO Plus SES|All patients will be treated with NANO plus sirolimus-eluting stent. Patients will be prescribed with clopidogrel and aspirin before the index procedure. The lesions will be predilted if necessary before stent implantation. There are no specific limitations on coronary lesions according the study criteria.
62799845|NCT03029468|EXPERIMENTAL|Computerized CBT|Computerized cognitive behavioral therapy (cCBT) for pain via an integrated smartphone and web-based skills training program: The training plan will help users learn how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation. The cCBT arm emphasizes skills acquisition and learning through practice; thus, the program involves regular homework assignments, and follow-up with the care coach and social network about issues faced and what skills were or could be used. This intervention is consistent with the tailored behavioral services patients would receive individually or as a group when working with a psychologist or behavioral pain specialist.
62799846|NCT03029468|ACTIVE_COMPARATOR|e-Education|Participants will receive pain education through online modules that they will be asked to complete using their personal or study-provided smartphone. Each module includes learning tasks, a reading assignment, and a short quiz based on material. The education group will receive care coach contact on the same schedule as the cCBT group. The care coach will provide supportive therapy and encouragement to complete modules and apply the lessons to their daily life.
62799847|NCT03029468|NO_INTERVENTION|Usual Care|Participants who are not eligible or who are not randomized into one of the intervention arms of this study will serve as a comparison group to ensure we are treating a representative sample of patients. Further, patients who were eligible but were not randomized into one of the intervention arms will serve as a usual care control group.
62799848|NCT03384940|EXPERIMENTAL|DS-8201a Cohort A|Cohort A is comprised of participants with HER2-positive (IHC 3+ or IHC 2+/ISH +) who will receive DS-8201a once every 3 weeks
62799849|NCT03384940|EXPERIMENTAL|DS-8201a Cohort B|Cohort B is comprised of participants with HER2 IHC 2+/ISH - who will receive DS-8201a once every 3 weeks
62799850|NCT03384940|EXPERIMENTAL|DS-8201a Cohort C|Cohort C is comprised of participants with HER2 IHC 1+ who will receive DS-8201a once every 3 weeks
62799851|NCT02186574|ACTIVE_COMPARATOR|Pre-emptive tenofovir|Tenofovir disoproxil
62026573|NCT01998373|EXPERIMENTAL|patient training and patient without training|Experimental group 1: patient education intervention group (PIGE) Experimental group 2: patient without intervention group (PWIG)
62225372|NCT05972031|NO_INTERVENTION|Usual care|"Practices in the control group provide care as usual, which consists of the SDM programmes according to the national care standards and General Practice guidelines (NHG) for DM2, COPD and CVD. According to these protocolised programmes, patients with COPD, CVD or DM2 visit their general practice at a standard frequency per year (1 - 4 times) and standard monitoring measurements and topics are discussed.~The practices that are randomised to the control group will not receive any additional training related to this study."
62225373|NCT02875977|EXPERIMENTAL|Experimental Counseling|Patients randomized to this arm receive experimental counseling on the importance of attending PFPT appointments. This includes the standard 2-page educational handout and a 4-minute educational video.
62418214|NCT05982158|ACTIVE_COMPARATOR|Cognitive Behavioural Therapy (CBT)|The standard therapy arm will be based on a focused cognitive behavioural therapy (CBT) protocol for AVHs. Sessions will involve discussing the characteristics of participant's AVHs, before applying core CBT approaches, adapted to the AVH experience, to conduct a thorough cognitive behavioural assessment with a focus on coping strategy enhancement and cognitive restructuring.
62418215|NCT05982158|EXPERIMENTAL|Avatar Therapy|The experimental arm will use avatar therapy. Sessions will involve generating an audio-visual avatar as a virtual representation of the primary 'voice' that the participant hears. This will be used to recreate AVHs experientially and allow participants to practice alternative ways of responding to the 'voice'. This innovative approach will be combined with the use of broader CBT methods.
62418216|NCT06320080|EXPERIMENTAL|TQB2223 injection+ AK105 Injection|TQB2223 injection combined with AK105 (Penpulimab) injection, once every three weeks. 21 days as a treatment cycle.
62418217|NCT03080402|EXPERIMENTAL|High KAM|Mechanically-driven neuromuscular training. 2 times per week for 6 weeks for a total of 12 sessions. Perturbation training
62418218|NCT03080402|NO_INTERVENTION|Normal KAM|No intervention
62799852|NCT02186574|PLACEBO_COMPARATOR|Placebo|Placebo
62799853|NCT00165178|EXPERIMENTAL|Individualized ASP dose|
62799854|NCT00165178|ACTIVE_COMPARATOR|Fixed dose ASP|
62799855|NCT00165178|EXPERIMENTAL|Dexamethasone|
62799856|NCT00165178|ACTIVE_COMPARATOR|Prednisone|
62799857|NCT00462007|EXPERIMENTAL|1|Stalevo
62799858|NCT02564393||T|Control
62799859|NCT02564393||A|Adult with cystic fibrosis
62418219|NCT03430037|EXPERIMENTAL|Treatment|Fisetin 20/mg/kg/day, orally for 2 consecutive days, for 2 consecutive months.
62799860|NCT01982123|EXPERIMENTAL|SPECT/CT Mid-& Post-RT|Investigational 99mTc-MAA and 99mTc-DTPA SPECT/CT mid-radiation therapy (up to 1 week post-treatment), and at 3-6 months post-treatment.
62799861|NCT02564133|EXPERIMENTAL|detection of a patent foramen ovale|
62799862|NCT02959359|OTHER|DAA treatment arm|Active DAA treatment ('Ledipasvir 90mg/Sofosbuvir 400 mg plus Ribavirin' ) for HCV-HCC patients after curative resection or ablation.
62799863|NCT02341352|NO_INTERVENTION|Control|Only behavioral education for Caregiver
62799864|NCT02341352|EXPERIMENTAL|fluoride varnish|fluoride varnish every 6 months
62799865|NCT02341352|EXPERIMENTAL|ImmunoglobulinY|anti-S.mutans Immunoglobulin yolk for everyday use
62799866|NCT02341352|EXPERIMENTAL|Probiotics|Probiotics use for 1 months
62799867|NCT00671034|EXPERIMENTAL|Arm I (combination chemotherapy)|Patients receive calaspargase pegol together with combination chemotherapy. Patients receive chemotherapy PO, IV, SC, and IT. Some patients also undergo radiation therapy to the head. Treatment may continue for up to 4 years.
62799868|NCT00671034|ACTIVE_COMPARATOR|Arm II (combination chemotherapy)|Patients receive pegaspargase together with combination chemotherapy. Patients receive chemotherapy PO, IV, SC, and IT. Some patients also undergo RT to the head. Treatment may continue for up to 4 years.
62799869|NCT06527586|EXPERIMENTAL|Si-Hy (Otufilcon A)|
62799870|NCT06527586|ACTIVE_COMPARATOR|Si-Hy soft contact lens|
62026574|NCT01998373|NO_INTERVENTION|control without education|this group did not receive an education
62588946|NCT06301607|EXPERIMENTAL|Intermittent Oro-esophageal Tube Feeding+comprehensive rehabilitation therapy|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
62026575|NCT02635815||Group I|twenty six patients with history of bleeding or had an attack of bleeding during one year follow-up. All underwent upper gastrointestinal endoscopy.
62026576|NCT02635815||Group II|thirty four patients without bleeding. All underwent upper gastrointestinal endoscopy.
62026577|NCT00417937|ACTIVE_COMPARATOR|1|Azelaic acid 15 % gel once daily
62418220|NCT03430037|PLACEBO_COMPARATOR|Placebo|Placebo capsules orally for 2 consecutive days, for 2 consecutive months.
62418221|NCT02416167|ACTIVE_COMPARATOR|FYU-981 High dose|Drug: FYU-981 High dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
62225374|NCT02875977|ACTIVE_COMPARATOR|Standard Counseling|Patients randomized to this arm receive standard counseling on the importance of attending PFPT appointments. This includes the standard 2-page educational handout.
62418222|NCT02416167|ACTIVE_COMPARATOR|FYU-981 High middle dose|Drug: FYU-981 High middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High middle dose arm receive active drug, FYU-981 High middle dose.
62799871|NCT00655538|EXPERIMENTAL|Dalcetrapib|
62799872|NCT00655538|PLACEBO_COMPARATOR|Placebo|
62225375|NCT01439360|EXPERIMENTAL|D-QIV|Subjects received 1 or 2 doses of candidate influenza Influsplit™ Tetra vaccine (GSK2321138A).
62225376|NCT01439360|ACTIVE_COMPARATOR|Control|In function of their age and D-QIV-vaccine status, subjects received Prevenar 13® or Havrix® Junior and possibly a varicella vaccine (Varilrix® or Varivax/ProVarivax ®).
62799873|NCT03708718|ACTIVE_COMPARATOR|Prednisolone|"Prednisolone 5mg enteric-coated tablets, over-encapsulated in a hard gelatine capsule and filled with lactose BP. The prednisolone will be self-administered, orally with water before or after a meal once a day. Dosing will be continuous for a total of 6 months.~The total dose prescribed will be equivalent to approximately 0.3mg/kg/day. The minimum dose prescribed will be 10mg per day (2 capsules) and a maximum of 30mg per day (6 capsules).~From August 2020: The prednisolone is no longer over-encapsulated. Prednisolone 5mg enteric-coated tablets will be prescribed and taken as above."
62026578|NCT00417937|ACTIVE_COMPARATOR|2|Azelaic acid 15 gel twice daily
62026579|NCT02699177||Suspected PCD but negative|"CBF measurements:~1. Patients with suspected PCD will have their nasal cavity photographed using a Sony-video camera that will record the reflected light of a green LED bulb.Ciliary beat frequency (CBF) will be calculated by interferometry using a program developed by the PI.~2. Patients will undergo a nasal brush biopsies. The fresh biopsies will be analyzed by high-speed video microscopy to calculate CBF.~3. The two methods will be compared."
62225377|NCT01466621||Previously RV Paced|Patients who were RV paced prior to receiving a cardiac resynchronization therapy device.
62225378|NCT01466621||Non-Previously RV Paced|Patients who received a CRT device without being previously RV paced.
62418223|NCT02416167|ACTIVE_COMPARATOR|FYU-981 Middle dose|FYU-981 Middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
62799874|NCT03708718|PLACEBO_COMPARATOR|Placebo oral capsule; From August 2020 - 'no additional treatment'|"The placebo will be a hard gelatine capsule filled with lactose BP and identically matched to the prednisolone capsules. The placebo will be self-administered once a day, orally with water before or after a meal. Dosing will be continuous for a total of 6 months.~From August 2020 - no placebo capsule will be administered."
62799875|NCT02922335|EXPERIMENTAL|Multisystemic Therapy - Emerging Adults|Multisystemic Therapy for Emerging Adults (MST-EA) is designed to help emerging adults (ages 18-21) with mental illness who have been in trouble with the law. MST-EA is a treatment program specifically for emerging adults, to increase skills and capacities that can help them reduce their antisocial behavior and help reduce problems caused by mental health illness, and alcohol or drug use when present.
62026580|NCT02699177||Suspected PCD but positive|"CBF measurements:~1. Patients with suspected PCD will have their nasal cavity photographed using a Sony-video camera that will record the reflected light of a green LED bulb.Ciliary beat frequency (CBF) will be calculated by interferometry using a program developed by the PI.~2. Patients will undergo a nasal brush biopsies. The fresh biopsies will be analyzed by high-speed video microscopy to calculate CBF.~3. The two methods will be compared."
62026581|NCT03793881|EXPERIMENTAL|Nutritional Strategy|Nutritional counseling based on the quality of the diet, the Food Guide for the Brazilian Population and concepts of mindfulness and mindful eating; dietary guidance based on feasible goals built together (patient and nutritionist).
62588947|NCT06301607|ACTIVE_COMPARATOR|Nasogastric Tube Feeding+comprehensive rehabilitation therapy|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the group was given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements."
62588948|NCT02878564|EXPERIMENTAL|Praziquantel treatment|Participants will be HIV-uninfected women with asymptomatic Schistosoma mansoni infection; the study will examine the impact of standard praziquantel therapy (40 mg/kg po single dose) on genital immunology and HIV susceptibility.
62588949|NCT01680159|EXPERIMENTAL|TA-650|
62588950|NCT06611553|EXPERIMENTAL|Prevention (self-collected and clinician-collected samples)|Patients undergo self-collection of a vaginal sample and then undergo clinician-collection of a cervical test sample. Patients then undergo standard of care colposcopy with or without biopsy/endocervical curettage and/or cervical excisional procedures as clinically indicated.
62588951|NCT05565378|ACTIVE_COMPARATOR|Pembrolizumab Monotherapy|Participants will be administered with pembrolizumab as monotherapy in a fixed dose.
62588952|NCT05565378|EXPERIMENTAL|Dostarlimab Monotherapy|Participants will be administered with dostarlimab as monotherapy in a fixed dose.
62588953|NCT05565378|EXPERIMENTAL|Substudy 1A|Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose A).
62588954|NCT05565378|EXPERIMENTAL|Substudy 1B|Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose B).
62799876|NCT02922335|ACTIVE_COMPARATOR|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU) emerging adults will get the treatments that they usually receive when they have a mental illness and have been in trouble with the law. They will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
62799877|NCT02857673|EXPERIMENTAL|Intervention Group|The intervention group will receive Child Abuse Prevention Problem Solving (CAPPS), a one-on-one, workbook-based intervention of six sessions, each lasting approximately 30-60 minutes. CAPPS is intended to be delivered over a period of 12 weeks, with sessions occurring every 1-2 weeks. Sessions will be delivered at the medical home by bachelor level providers, whose availability and level of training mimic those of existing medical home care coordinators.
62799878|NCT02857673|ACTIVE_COMPARATOR|Active Control Group|Parents in both study groups will receive the standard medical and social work services offered in the patient-centered medical homes where their children receive care. In addition, to account for potential surveillance bias, families in the control group will be contacted by a member of the study team six times over 12 weeks, approximating the frequency of contact that the intervention group receives from the CAPPS providers. The study team member will not be trained in CAPPS and will adhere to a case management model consistent with resources available in the medical home, checking in with control families and offering to help identify existing clinic and community resources as needed.
62026582|NCT03793881|ACTIVE_COMPARATOR|Dietary Prescription|Individualized dietary prescription according to the guidelines of the Brazilian Society of Cardiology.
62026583|NCT01273727|NO_INTERVENTION|No Ozurdex|Arm 1(control) - Patients who have had epi-retinal membrane peeling and have macular edema at least 3 months (90 days) after surgery. These patients will followed without Ozurdex. The patients will be treated with current standard of care, including topical and intravitreal or subtenon's medication.
62225379|NCT01827293|ACTIVE_COMPARATOR|Promethazine|IV promethazine (25 mg)
62418224|NCT02416167|ACTIVE_COMPARATOR|FYU-981 Low dose|Drug: FYU-981 Low dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
62588955|NCT05565378|EXPERIMENTAL|Substudy 1C|Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose C).
62588956|NCT05565378|EXPERIMENTAL|Substudy 2A|Participants will be administered with dostarlimab, fixed dose belrestotug, and fixed dose nelistotug
62588957|NCT06565026|EXPERIMENTAL|CS-206|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
62026584|NCT01273727|EXPERIMENTAL|Ozurdex 3 months after surgery|Patients who have had epi-retinal membrane peeling and have residual macular edema 3 months after surgery. These patients will receive an Ozurdex implant
62225380|NCT01827293|ACTIVE_COMPARATOR|lorazepam|IV lorazepam (2 mg)
62418225|NCT02416167|PLACEBO_COMPARATOR|Placebo|Drug: Placebo, (Oral daily dosing for 12 weeks) Subjects randomized to the placebo arm receive placebo.
62418226|NCT06696066|EXPERIMENTAL|Peer Recovery Support Pilot Program Implementation and Assessment|Participants will be offered services from a certified recovery specialist (i.e., the Peer Recovery Support program). This will entail a CRS meeting one-on-one with the patient at regular intervals (e.g., weekly) to provide support to the participant for a 6-month period. CRS services are patient-centered and driven by a patient's own recovery goals, thus the frequency, timing, duration, modality (in-person, phone), and location of meetings (in the clinic or in a community setting such as a coffeeshop) are flexible and determined collaboratively by the CRS and patient.
62418227|NCT03325062|EXPERIMENTAL|Experimental: MOVE|Movement pattern training in addition to contemporary progressive rehabilitation
62026585|NCT01273727|EXPERIMENTAL|Ozurdex 6 months or longer after surgery|Patients who have had epiretinal membrane peeling and have residual macular edema at least 6 months after surgery
62026586|NCT06635798|EXPERIMENTAL|GR2001|If randomized to GR2001, participant will receive a single IM gluteal injection of GR2001
62026587|NCT06635798|ACTIVE_COMPARATOR|HTIG|If randomized to HTIG, participant will receive a single IM gluteal injection of HTIG
62026588|NCT04586855||Healthy persons|Noninvasive ventilation and Cough Assist
62026589|NCT02345057|EXPERIMENTAL|CS-3150 0.625 mg|One CS-3150 0.625 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
62026590|NCT02345057|EXPERIMENTAL|CS-3150 1.25 mg|Two CS-3150 0.625 mg tablets administered orally, once daily after breakfast.
62225381|NCT02277041|ACTIVE_COMPARATOR|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
62799879|NCT05846360||ORCHARDS Study Specimens|Archived ORCHARDS study specimens
62799880|NCT05138029|EXPERIMENTAL|Anti-VEGF treatment group|Visual acuity and center thickness of the macula
62799881|NCT05138029|EXPERIMENTAL|Inner limiting membrane stripping group|Visual acuity and center thickness of the macula
62799882|NCT05138029|EXPERIMENTAL|Glucocorticoid treatment group|Visual acuity and center thickness of the macula
62799883|NCT05616468|EXPERIMENTAL|BGT007 Cell Injection|"In this study, 23 patients diagnosed with recurrent/metastatic nasopharyngeal carcinoma will receive a single intravenous infusion of BGT007 cells after enrollment, with a dose of 5.0 × 10\^5cells/kg，1.0 × 10\^6cells/kg，3.0 × 10\^6cells/kg，6.0 × 10\^6cells/kg，1.0 × 10\^7cells/kg。 One subject was enrolled in each of the first two dose groups, and the other three dose groups were enrolled in accordance with the conventional 3+3 dose increase."
62799884|NCT04005261||patients with type 2 diabetes treated with insulin|"Patients with type 2 diabetes who have been using insulin for at least six months.~They should be older than 18 years The patients should be presented to the Diabetes Outpatient Clinics of Istanbul Medeniyet University Goztepe Training and Research Hospital"
62799885|NCT04157777|EXPERIMENTAL|massage|Among women who applied to Maternity Hospital 350 pregnant women were assigned to massage group. Participants in massage group filled out an information form including socio-demographic characteristics. Perineum massage with olive oil in the second period of delivery was performed to massage group.In massage group when they progressed to full dilatation of the cervix, the midwife inserted two fingers inside vagina and using a sweeping motion gently stretched the perineum with lubricant 5 up to 10 minutes, in and between mother's pushing in the second stage of labour.
62799886|NCT04157777|EXPERIMENTAL|control|Among women who applied to Maternity Hospital 350 pregnant women were assigned to control group. Participants in control group filled out an information form including socio-demographic characteristics.And, no other interventions except for applications performed routinely in the delivery room were done.In control group just Ritgen Maneuver was applied. At last, we com-pared the rate of intact perineum, episiotomy and laceration, mean duration of the second stage of labor and Apgar score in 1 and 5 minutes be-tween two groups.
62799887|NCT03688815||Patients with ischemic heart disease|Patients with ischemic heart disease scheduled for myocardial perfusion scintigraphy were enrolled. Biomarkers were analysed form periferal blood. Patients outcome data were followed up to 5 years.
62026591|NCT02345057|EXPERIMENTAL|CS-3150 2.5 mg|One CS-3150 2.5 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
62026592|NCT02345057|EXPERIMENTAL|CS-3150 5.0 mg|Two CS-3150 2.5 mg tablets administered orally, once daily after breakfast
62026593|NCT02345057|PLACEBO_COMPARATOR|Placebo|Two placebo tablets to match CS-3150 tablet, administered orally, once daily after breakfast.
62026594|NCT03956017|EXPERIMENTAL|Ubiquinone|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
62026595|NCT03956017|PLACEBO_COMPARATOR|Placebo|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
62026596|NCT02545673|EXPERIMENTAL|Enhanced Linkage|Participants will receive the enhanced linkage to care Intervention. Behavioral: Enhanced linkage to care Intervention Multiple sessions will focus on providing orientation to the HIV care system, counseling to help clients identify and reduce barriers to engagement in care, assistance disclosing and identifying a treatment supporter, and stigma reduction through increasing social support. The approach is guided by the HIV Stigma Framework.
62026597|NCT02545673|ACTIVE_COMPARATOR|Standard-of-care plus|Behavioral: Participants will receive the standard-of-care (paper-based referrals) plus return of CD4 test results to their home.
62418228|NCT03325062|ACTIVE_COMPARATOR|CONTROL|Contemporary progressive rehabilitation
62418229|NCT04983823|EXPERIMENTAL|Heart failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)|"1. Optimization of pharmacotherapy:~   This will be performed by a supervising clinician and will comprise treatment with angiotensin-converting enzyme inhibitor (ACEi, Ramipril) and beta blocker (Metoprolol) for cardioprotection.~2. Exercise intervention: Individualized training program will be provided by an exercise physiologist"
62026598|NCT05245864|EXPERIMENTAL|physical therapy with blood flow restriction|
62026599|NCT05245864|OTHER|physical therapy without blood flow restriction|Standard of care.
62026600|NCT01257295|PLACEBO_COMPARATOR|control|No additions of fiber to a breakfast meal
62026601|NCT01257295|ACTIVE_COMPARATOR|low viscous, low gelling|low viscous, low gelling fibre added to breakfast meal
62026602|NCT01257295|ACTIVE_COMPARATOR|high viscous, low gelling|high viscous, low gelling fibre added to breakfast meal
62026603|NCT01257295|ACTIVE_COMPARATOR|low viscous, high gelling|low viscous, high gelling fibre added to breakfast meal
62026604|NCT01257295|ACTIVE_COMPARATOR|high viscous, high gelling|high viscous, high gelling fibre added to breakfast meal
62026605|NCT01257295|ACTIVE_COMPARATOR|fibre supplement|high viscous, high gelling fibre is added, not to the breakfast meal, but as supplement
62026606|NCT01580917||Diabetic Test|Diabetic individuals with a history of previous plantar ulcer and a high risk of developing a foot ulceration
62026607|NCT01580917||Healthy Controls|Non-diabetic, healthy individuals with low risk of developing a neurogenic foot ulcer
62026608|NCT01293708||Hospital Cohort|All 80+ year old that had had an ICU stay of \>=24 hrs. Followed until hospital d/c
62026609|NCT01293708||Longitudinal Cohort|All 80+ year old that had had an ICU stay of \>=24 hrs. Followed for 12 months
62225382|NCT02277041|ACTIVE_COMPARATOR|Misoprostol|Misoprostol ( Misotac, Sigma, Egypt) is a stable, synthetic form of prostaglandin E1 analogue. Patients wil be given 600 microgram of misotac immediately postoperative.
62418230|NCT04983823|ACTIVE_COMPARATOR|Usual care|All medical management for participants allocated to this group will be at the discretion of their usual care healthcare professional(s).
62026610|NCT05843942||Non-pregnant women of reproductive age|In the first stage, a three-day food consumption record will be taken from 50 non-pregnant (menstruating) women of reproductive age in order to determine the foods to be included in the food consumption frequency section, and the questionnaire sections and questions (nutrition habits and food consumption frequency questionnaire) will be designed. In the second stage of the study, the questionnaire developed in the first stage will be applied to 350 non-pregnant (menstruating) volunteer women of reproductive age through face-to-face interviews. A 24-hour recall food consumption record will be taken. In this stage, the blood parameters of at least 100 individuals whose blood counts have already been taken for routine tests and treatments and who meet the inclusion criteria. In the third stage, the questionnaire will be applied again to 75 individuals who have completed the second stage at least 2 weeks later in order to evaluate the reliability of the questionnaire results.
62026611|NCT04122079||Clinical (outpatients)|Patients receiving mental health treatment at the three psychotherapeutic centers; two university clinics and a family mental health clinic
62026612|NCT04122079||Clinical (self-reported)|Students and community nonstudent participants who were receiving psychological or psychiatric treatment
62026613|NCT04122079||Non-clinical (Community)|Members of the community
62026614|NCT04122079||Non-clinical (Students)|University undergraduate students
62225383|NCT04340323|EXPERIMENTAL|Group A-intensive exercise group|"Dosage of intensive exercise group - 12 weeks, five times a week for 30 minutes per day; five times with education by a physiotherapist, followed by continuation at home.~PFMT with lumbopelvic stabilization. Exercise up to five times a week for up to 30 minutes per day, after initial training with a physiotherapist.~1. Educating probands about anatomy, physiology and pelvic floor muscle function.~2. Training of pelvic floor muscles in different positions.~3. Training of pelvic floor muscles with six stabilization exercises - activation of deep trunk muscles."
62799888|NCT02426463|ACTIVE_COMPARATOR|Propofol|Plasma samples and patient data are collected prospectively from 40 neonates who receive propofol as part of their care in the neonatal intensive care unit at the Turku University Hospital, Turku, Finland.
62026615|NCT04544462||Infertile patients|Patients attending an IVF center for infertility treatment
62026616|NCT03719456|EXPERIMENTAL|Flexible ureteroscope|
62418231|NCT06700603|OTHER|Patients with progression within 3 months of completion of irinotecan treament|Cohort 1 was for patients who progressed within 6 months of the end of adjuvant therapy for early pancreatic cancer with a prior irinotecan regimen or for patients with advanced disease who had imaging-confirmed progression within 3 months of the end of first-line therapy.
62418232|NCT06700603|OTHER|Cohort 2: Patients with disease progression after 3 months of the end of irinotecan treatment|Cohort 2 is for patients who have progressed more than 6 months after the end of adjuvant therapy for early pancreatic cancer on prior irinotecan regimens or more than 3 months after the end of first-line therapy for patients with advanced disease
62418233|NCT04651582|EXPERIMENTAL|Cognitive Training|20 hours of computerized brain exercises
62026617|NCT01365494|ACTIVE_COMPARATOR|Group A-Zagreb|Purified Chick Embryo Cell Inactivated Rabies Vaccine, administered intramuscularly (IM) according to the 2-1-1 (Zagreb) schedule (i.e., 2 doses of vaccine administered on day 0 and 1 dose of vaccine each administered on day 7 and day 21)
62026618|NCT01365494|ACTIVE_COMPARATOR|Group B-Essen|Purified Chick Embryo Cell Inactivated Rabies Vaccine, administered IM according to the 1-1-1-1-1 (Essen) schedule (i.e., 1 dose of vaccine administered on day 0, 3, 7, 14, and 28)
62026619|NCT03131648|EXPERIMENTAL|Initial treatment period - Tralokinumab Q2W|"Week 0 to Week 16:~Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks."
62026620|NCT03131648|PLACEBO_COMPARATOR|Initial treatment period - Placebo Q2W|"Week 0 to Week 16:~Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks."
62026621|NCT03131648|EXPERIMENTAL|Maintenance treatment period - Tralokinumab Q2W|"Week 16 to Week 52:~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks."
62026622|NCT03131648|EXPERIMENTAL|Maintenance treatment period - Tralokinumab Q4W|"Week 16 to Week 52:~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.~Subjects in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks."
62026623|NCT03131648|PLACEBO_COMPARATOR|Maintenance treatment period - Placebo Q2W|"Week 16 to Week 52:~Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks."
62026624|NCT03131648|PLACEBO_COMPARATOR|Maintenance treatment period - Placebo|"Week 16 to Week 52:~Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks."
62418234|NCT04651582|ACTIVE_COMPARATOR|Cognitively Stimulating Activities|20 hours of computerized brain exercises
62225384|NCT04340323|ACTIVE_COMPARATOR|Group B-low-intensity exercise group|"Dosage of low-intensity exercise group - 12 weeks, twice a week for 15 minutes per day; five times with physiotherapist education, followed by continuation at home.~PFMT with lumbopelvic stabilization. Exercise up to five times a week for up to 30 minutes per day, after initial training with a physiotherapist.~1. Educating probands about anatomy, physiology and pelvic floor muscle function.~2. Training of pelvic floor muscles in different positions.~3. Training of pelvic floor muscles with six stabilization exercises - activation of deep trunk muscles."
62418235|NCT01588678|EXPERIMENTAL|DS-3078a|"Part 1 - Dose escalation of DS-3078a to determine the maximum tolerated dose (MTD) will be guided by the modified continuous reassessment method (mCRM) using a Bayesian logistic regression model (BLRM) following escalation with overdose control (EWOC) principle.~Before starting mCRM, initial dose escalation will proceed following an accelerated titration in which single subjects will be enrolled into sequential dose levels with a dose increment of up to 100% from the previous dose.~Upon completion of Part 1 with established MTD and tentative recommended phase 2 dose (RP2D), the Dose Expansion (Part 2) will begin with the intention of further assessing the safety and tolerability of DS-3078a, confirming the RP2D, determining the Pharmacodynamic response in tumor samples, and evaluating preliminary efficacy of DS-3078a in subjects."
62418236|NCT03784612|EXPERIMENTAL|App-technology group|"Participants in the App-technology group arm will use a newly developed smartphone application (app), containing a 12-week healthy eating program.~Intervention: App-technology for healthy eating habits."
62588958|NCT02932527|EXPERIMENTAL|infertile men exposed to cannabis|Male with isolated teratozoospermia or associated with asthenozoospermia and / or oligozoospermia and / or necrozoospermia defined according to WHO recommendations (WHO guidelines, 2010) and the David amended classification (Auger et al., 2001) with normal constitutional karyotype (46, XY) exposed to cannabis; The exposure to cannabis is not an intervention in the study but is a pre-condition for inclusion. Blood intake and semen samples collection are done. Questionnaire about cannabis consumption are assessed to patient.
62588959|NCT02932527|OTHER|infertile men not exposed to cannabis|Male with isolated teratozoospermia or associated with asthenozoospermia and / or oligozoospermia and / or necrozoospermia defined according to WHO recommendations (WHO guidelines, 2010) and the David amended classification (Auger et al., 2001) with normal constitutional karyotype (46, XY) not exposed to cannabis; The exposure to cannabis is not an intervention in the study but is a pre-condition for inclusion. Blood intake and semen samples collection are done. Questionnaire about cannabis consumption are assessed to patient.
62225385|NCT02814201||Parkinson best-On|two hours after taking two tablets of 125 mg dispersible Modopar®
62225386|NCT02814201||Parkinson worst-off|after a drug withdrawal period ( morning fasting all dopaminergic treatment since the day before midnight)
62225387|NCT02814201||Huntington|
62225388|NCT02814201||Control|Data collected from the existing database
62418237|NCT03784612|NO_INTERVENTION|Control group|The control group will receive standard care.
62418238|NCT03797339||Discovery cohort|1000 cases of coronary heart disease follow-up cohort was used for multi-omics target discovery.During the follow-up period, the information about the occurrence and risk factors of adverse cardiovascular events will be collected.
62799889|NCT02426463|ACTIVE_COMPARATOR|Oxycodone|Plasma samples and patient data are collected prospectively from 40 neonates who receive oxycodone as part of their care in the neonatal intensive care unit at the Turku University Hospital, Turku, Finland.
62588960|NCT05277636|EXPERIMENTAL|125 mg MDMA|MDMA (125 mg)
62588961|NCT05277636|EXPERIMENTAL|125 mg S-MDMA|S-MDMA (125 mg)
62588962|NCT05277636|EXPERIMENTAL|125 mg R-MDMA|R-MDMA (125 mg)
62588963|NCT05277636|EXPERIMENTAL|250 mg R-MDMA|R-MDMA (250 mg)
62588964|NCT05277636|PLACEBO_COMPARATOR|Placebo|Placebo
62799890|NCT05317065|EXPERIMENTAL|Mindfullness Based Stress Reduction|Mindfullness Based Stress Reduction (MBSR) therapy
62799891|NCT05317065|NO_INTERVENTION|Control|Control
62799892|NCT00300755|ACTIVE_COMPARATOR|1|Arm 1- Low Dose pantoprazole
62799893|NCT00300755|ACTIVE_COMPARATOR|2|Arm 2- Medium Dose pantoprazole
62799894|NCT00300755|ACTIVE_COMPARATOR|3|Arm 3- High Dose pantoprazole
62799895|NCT00993408|EXPERIMENTAL|ACT-293987 (NS-304) and matching placebo|"Subjects will be randomized to the study following screening.~Each subject will then undergo an acute hemodynamic study with right heart catheterization after a single oral administration of ACT-293987 (NS-304)on Day 0. The objectives are to collect data about the drug effect on the right heart hemodynamic parameters (PVR, calculated SVR and PVR/SVR) measured by right heart catheterization after single oral dose administration of NS-304 and to assess the safety and tolerability of a single oral dose of NS-304."
62799896|NCT02562716|EXPERIMENTAL|Arm I (mFOLFIRINOX, surgery)|Patients receive oxaliplatin IV over 2 hours and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive 5-fluorouracil IV over 46 hours on days 1-3 and 15-17. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or better undergo pancreatectomy 4-8 weeks after completion of first 3 courses of treatment. Within 4-8 weeks following pancreatectomy, patients receive an additional 3 courses of oxaliplatin, irinotecan hydrochloride, and fluorouracil treatment in the absence of disease progression or unacceptable toxicity.
62799897|NCT02562716|EXPERIMENTAL|Arm II (gemcitabine, nab-paclitaxel, and surgery)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or better undergo pancreatectomy 4-8 weeks after completion of first 3 courses of treatment. Within 4-8 weeks following pancreatectomy, patients receive an additional 3 courses of paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride treatment in the absence of disease progression or unacceptable toxicity.
62799898|NCT05661279|ACTIVE_COMPARATOR|Group C:|control group who will be given general anesthesia only
62799899|NCT05661279|ACTIVE_COMPARATOR|Group R:|Rhomboid intercostal block then general anesthesia
62799900|NCT05661279|ACTIVE_COMPARATOR|group S|Serratus anterior plane block then general anesthesia
62799901|NCT01056939|ACTIVE_COMPARATOR|NAVA|Children randomised in this arm will be treated with neurally adjusted ventilatory assist
62799902|NCT01056939|ACTIVE_COMPARATOR|Control|Patients randomized to control group will be treated with pressure controlled ventilation (PC) when they are newborns and older children in this group will be treated with pressure regulated volume controlled (PRVC) ventilation.
62799903|NCT00657982|EXPERIMENTAL|1|RAD001 10 BID 6 weeks before definite treatment for localized prostate cancer
62799904|NCT03246789|EXPERIMENTAL|Engage-M|Participants will meet individually with a therapist once before beginning weekly group sessions for eight weeks. Each weekly session will last approximately 50 minutes. Study investigators have trained Engage-M therapists to provide participants with a group therapy approach called Engage-M. During the weekly therapy sessions, therapists will encourage participants to engage in physical and social activities that you find pleasurable or rewarding.
62799905|NCT03246789|ACTIVE_COMPARATOR|Wellness in Mind and Body (W-MH)|Participants will meet with a therapist for group therapy once a week for eight weeks. Each weekly session will last approximately 50 minutes. During these weekly sessions, the therapist will educate participants about health and mental health.
62799906|NCT03088527|EXPERIMENTAL|RAD140 Part A and Part B|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of RAD140.~Part B, Safety Expansion: Once the maximum tolerated dose (MTD) has been identified and/or a recommended dose escalation (RDE) has been determined, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary clinical activity of the recommended dose."
62799907|NCT01366326|EXPERIMENTAL|Arm 1|Methylnaltrexone bromide
62799908|NCT03094117|ACTIVE_COMPARATOR|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
62799909|NCT03094117|EXPERIMENTAL|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
62799910|NCT01865227|ACTIVE_COMPARATOR|Group Counseling|The major aim of the post-operative counseling groups is to engage patients in discussing and exchanging their thoughts on issues of concern related to their surgery and overall well-being. The selected patients will be informed about the purpose of these support groups and will be made aware that their attendance is entirely voluntary.
62225389|NCT03068533|ACTIVE_COMPARATOR|Strontium acetate toothpaste|All eligible patients will receive mechanical debridement in 1 or 2 sessions within 1 week before final evaluation.
62799911|NCT01865227|NO_INTERVENTION|Standard treatment|
62799912|NCT00207311|PLACEBO_COMPARATOR|Xenical placebo|Xenical placebo PO three times daily with meals plus enrollment into the Xenicare program for 36 weeks followed by 48 weeks of therapy with Pegasys (180mcg/ml) plus weight based ribavirin for HCV genotype 1 or 4 and 24 weeks of therapy with Pegasys (180mcg/ml) plus 800mg ribavirin for HCV genotypes 2 and 3.
62799913|NCT00207311|ACTIVE_COMPARATOR|Xenical (orlistat)|Xenical (orlistat) 120mg PO three times daily with meals plus enrollment into the Xenicare program for 36 weeks followed by 48 weeks of therapy with Pegasys (180mcg/ml) plus weight based ribavirin for HCV genotype 1 or 4 and 24 weeks of therapy with Pegasys (180mcg/ml) plus 800mg ribavirin for HCV genotypes 2 and 3.
62799914|NCT02174991|EXPERIMENTAL|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, \& Kopczynski, 2011). It is currently in phase II testing.
62799915|NCT02174991|EXPERIMENTAL|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, \& Kopczynski, 2011). It is currently in phase II testing.
62799916|NCT05371925|ACTIVE_COMPARATOR|Sulodexide group|the participant will receive one Sulodexide capsule of 250LRU twice a day for 8 weeks
62799917|NCT05371925|PLACEBO_COMPARATOR|control group|the participant will receive on placebo capsule twice a day for 8 weeks of same appearance as IMP
62799918|NCT01561235|ACTIVE_COMPARATOR|Normal Protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).~Macronutrient content: Protein: 14 E%, Fat: 30 E% and carbohydrate: 56E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
62225390|NCT03068533|EXPERIMENTAL|Arginine/calcium carbonate toothpaste|All eligible patients will receive mechanical debridement in 1 or 2 sessions within 1 week before final evaluation.
62225391|NCT00728611|EXPERIMENTAL|1|
62799919|NCT01561235|EXPERIMENTAL|Medium-high protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).~Macronutrient content: Protein: 25E%, Fat: 30 E% and carbohydrate: 45E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
62799920|NCT01561235|EXPERIMENTAL|High Protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).~Macronutrient content: Protein: 50 E%, Fat: 30 E% and carbohydrate: 20E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
62799921|NCT00348985|EXPERIMENTAL|PXD101 in Combination with Bortezomib (PS-341)|Patients receive PXD101 IV over 30 minutes on days 1-5 and bortezomib IV on days 1, 4, 8, and 11 (2, 5, 8, and 11 during course 1).
62799922|NCT05617781||Control|
62799923|NCT05617781||Patient|
62799924|NCT06138769|EXPERIMENTAL|Lenvatinib|Lenvatinib 12 mg (body weight 60 kg or greater) or 8 mg (body weight \< 60 kg) once orally every day
62799925|NCT05210491|EXPERIMENTAL|The observation of eyelid positioning and EEG pulses from the eyelid on increasing brightness|In a dimly lit room the participant will place their chin on the slit lamp We will use t he optimal background illumination used for Humphrey and Goldman visual fields which is 31.5 apostilbs (10Lux 9 They will look into the video camera placed 50cm away, which will have a dimmable remote control ring light fitted around it. The part icipant will have a reference measure taped to the headrest and three electrodes placed around the right eye. One active electrode place on the lower lid and one reference electrode towards the temporal margin and one earth electrode placed on the forehead The brightness of the ring light will be increased via the dimmer switch whilst simultaneously recording the lux with the LED light meter. The participant will be advised t o close their eyes if the brightness becomes uncomfortable and this will be repea ted three times.
62799926|NCT05910216|EXPERIMENTAL|Group Dance & Music (Online)|Social Telerehabilitation with Dance \& Music (Online): The dance intervention will be instructed by a physiotherapist and dance professional, who will follow a structure based on the materials of the Dance for Parkinson's (USA) ® method
62799927|NCT05910216|ACTIVE_COMPARATOR|Group Multimodal Therapeutic Exercise & Music (Online)|Social Telerehabilitation with Multimodal Therapeutic Exercise \& Music (Online): The intervention with multimodal therapeutic exercise will be instructed by a physiotherapist, who will follow a structure based on a previous study and Physical Therapy Guidelines for People with PD
62799928|NCT01588444|EXPERIMENTAL|cancellous FDBA (LifeNet)|grafting with cancellous mineralized freeze-dried bone allograft (LifeNet Health)
62225392|NCT00728611|ACTIVE_COMPARATOR|2|
62225393|NCT00728611|PLACEBO_COMPARATOR|3|
62225394|NCT05999097|EXPERIMENTAL|Short Chain Fructooligosaccharides Group|This group will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours for 10 days, diluted in 250 ml
62225395|NCT05999097|PLACEBO_COMPARATOR|Placebo Group|This group will receive Corn Starch as a Placebo control 12 gr. every 24 hours for 10 days, diluted in 250 ml
62225396|NCT04601701|EXPERIMENTAL|CRVO: Bevacizumab and intravitreal Dexamethasone.|Participants with CRVO will receive a combination of Bevacizumab and intravitreal Dexamethasone.
62225397|NCT04601701|ACTIVE_COMPARATOR|CRVO: Bevacizumab|Participants with CRVO will receive a combination of Bevacizumab only.
62225398|NCT03336567||Subjects with hematological malignancies|It will include subjects with Refractory Diffuse Large B-cell Lymphoma and Multiple Myeloma, Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) and/or who participated in a CAR-T clinical trial or autologous treatment. Subjects will undergo a telephonic interview for up to 90 minutes.
62225399|NCT03336567||Subjects with NSCLC or soft-tissue sarcoma|It will Include subjects with NSCLC on second or later-line therapy or soft-tissue sarcoma on second or later line therapy. Subjects will undergo a telephonic interview for up to 90 minutes.
62026625|NCT03131648|EXPERIMENTAL|Open-label treatment - Tralokinumab + optional TCS|"Week 16 to Week 52:~Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered Tralokinumab subcutaneous (SC) injection + optional TCS\* regimen Q2W.~OR~Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS\* regimen Q2W.~\*TCS = topical corticosteroids."
62418239|NCT03797339||Validation corhort|3000 coronary heart disease follow-up cohorts was used for validating the results from the discovery corhort. During the follow-up period, the occurrence and risk factors of adverse cardiovascular events.Predictive mathematical models based on multi-omics combination will be constructed finally.
62418240|NCT05965401|EXPERIMENTAL|Pharmacogenetic (PGx)-Guided|Participants and their physician will receive a one-time prescribing report after completing baseline for selective serotonin reuptake inhibitors with dosing information based on CYP2B6, CYP2C19, and CYP2D6 genotype data, and GLAD-PC dosing guidelines for fluoxetine as there are no pharmacogenetic guidelines for this medication.
62225400|NCT03336567||Oncologists from academic centers with CGT experience|It will include oncologists using TCR therapies, CAR-T or participating in CAR-T or TCR therapy clinical trials. Oncologists will undergo a telephonic interview for up to 60 minutes.
62799929|NCT01588444|EXPERIMENTAL|cortical FDBA (LifeNet)|CORTICAL FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)
62799930|NCT01197599||Spinal Cord Injury|
62799931|NCT01197599||Able-Bodied Control|
62799932|NCT04567641||Enteral Nutrition|
62799933|NCT04567641||Parenteral nutrition|
62799934|NCT05817838|OTHER|Attention control: Academic Engagement|This intervention will be delivered using a similar format and schedule as the financial incentive+nutrition education, motivational interviewing and dietary norms intervention group (i.e., 11 community health worker led in-person group based sessions at the Center for Southeast Asians, 3 MI phone calls, and text messages). The content will focus on family-specific family engagement methods to improve children's academic outcomes.
62799935|NCT05817838|EXPERIMENTAL|Financial incentive only|Participants will receive weekly financial incentive coupons to purchase eligible foods at the partnering Southeast Asian grocery store. Research Assistants will explain the coupon procedures during the randomization phone call. Research Assistants will mail the adult a schedule of coupon disbursement dates. RAs will mail one month's worth of coupons (4, $15 coupons) to each adult's home. Coupons will be used at point-of-sale. Participants' will receive an automated weekly text message via Qualtrics directing them to upload their photos to the system if they used coupons during that week.
62799936|NCT05817838|EXPERIMENTAL|Financial incentive + nutrition education, motivational interviewing, dietary norms messages|The intervention consists of a) four $15 financial incentive coupons each month; b) twice-monthly group-based nutrition education at the Center for SEA; c) motivational interviewing (months 1, 3, 5); and d) weekly dietary norms text messages sent to adults and twice-monthly dietary norms infographics presented at nutrition education sessions for children. The research assistants will disburse one months' worth of the financial incentive coupon at the nutrition education sessions (or home mailings for absent participants). Families will attend 11 fortnightly, group-based nutrition education sessions lasting one hour. Southeast Asian community health workers will lead the sessions. Research assistants trained in motivational interviewing will call the adults. The calls will last 15-20 minutes. Adults will receive a series of weekly, interactive descriptive dietary norms text messages. Children will see descriptive dietary norms infographics at children's nutrition education sessions.
62799937|NCT03779659|EXPERIMENTAL|Synapse TENS device|SYnapse TENS device will be used for alleviating pain through electrical stimulation. This is a battery powered device where an electrical current is applied intra-orally on the buccal and lingual sides using an intra-oral pad applicator. This device has been cleared for marketing by the Food and Drug Administration (FDA) and the prescribed electrical field falls almost a 10 factor level lower than routine pulp testing devices used in dentistry. The TENS device was previously tested in a pilot study with promising results. Chair side application and at-home use of the device by the patient was shown to drastically reduce pain and discomfort associated with orthodontic tooth movement.
62799938|NCT03779659|ACTIVE_COMPARATOR|Topical anesthetic gel|Topical anesthetic Gel is the active comparator in this study. The topical anesthesia (anesthetic gel) Centrix LolliCaine with 20% benzocaine in single package of 0.3 ml will be used. The amount of local anesthetic used will not exceed the maximum allowable dose, which will be calculated for each patient based on his/her age and weight prior to the dental procedure. This will be done based American Association of Pediatric Dentistry guidelines for the use of local anesthesia.
62799939|NCT03631342|EXPERIMENTAL|VCV20|Volume-controlled ventilation mode under constant flow of 20 Lpm. The inspired volume was progressively increased until the maximum pressure reached 40cmH2O.
62225401|NCT03336567||Oncologists from community clinics|It will include oncologists from community clinics who evaluate, prescribe, treat, and actively interact with subjects with NSCLC or soft tissue sarcoma, who have used immuno-oncology (IO) therapies. Oncologists will undergo a telephonic interview for up to 60 minutes.
62225402|NCT02319577|EXPERIMENTAL|Gefitinib plus oral vinorelbine|"Arm A (21-days cycles until progressive disease or unacceptable toxicity):~Oral vinorelbine 60 mg/mq on days 1,8 Gefitinib 250 mg daily from day 9 to day 21"
62799940|NCT03631342|EXPERIMENTAL|VCV40|Volume controlled ventilation mode under constant flow of 40 Lpm. The inspired volume was progressively increased until the maximum pressure reached 40cmH2O.
62799941|NCT03631342|EXPERIMENTAL|PCV|Pressure controlled ventilation mode, inspiratory time of 1 second. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
62225403|NCT02319577|ACTIVE_COMPARATOR|Gefitinib alone|"Arm B (21-days cycles until progressive disease or unacceptable toxicity):~Gefitinib 250 mg daily from day 1 to day 21"
62588965|NCT05802407|EXPERIMENTAL|MRD-guided|Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will receive a later-line therapy.
62026626|NCT03131648|EXPERIMENTAL|Open-label short-term- Tralokinumab + optional TCS|"Week 52 to Week 68 \[Short term extension (Japan only)\] :~Japanese subjects who were transferred to the open-label tralokinumab Q2W arm at Week 16 continued an additional 16 weeks (Week 52 to Week 66) of open-label treatment to receive 52 weeks of active therapy."
62418241|NCT05965401|ACTIVE_COMPARATOR|Guidelines for Adolescent Depression in Primary Care (GLAD-PC)-Guided|Participants and their physician will receive a one-time prescribing report after completing baseline for selective serotonin reuptake inhibitors based on GLAD-PC dosing guidelines.
62799942|NCT03631342|EXPERIMENTAL|PCV+Tins|Pressure controlled ventilation mode and inspiratory pressure was increased every 5cmH2O, until the maximum pressure of 40 cmH2O was reached. The inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP.
62799943|NCT03631342|EXPERIMENTAL|PSV|Pressure support ventilation mode, with progressive increases of 5 cmH2O at inspiratory pressure, until reaching Pmax of 40 cmH2O. The expiratory sensitivity was adjusted by 25% for all patients.
62799944|NCT04502537||Roxadustat|treatment with roxadustat
62799945|NCT04502537||erythropoietin|treatment with erythropoietin
62799946|NCT06051669||iLivTouch then FibroScan|"Subjects in the Group iLivTouch then FibroScan will be measured using iLivTouch first and then FibroScan based on the randomization result."
62799947|NCT06051669||FibroScan then iLivTouch|"Subjects in the Group FibroScan then iLivTouch will be measured using FibroScan first and then iLivTouch based on the randomization result."
62799948|NCT05055024|EXPERIMENTAL|NLS-2 (mazindol extended release)|NLS-2 (mazindol extended release) administered once a day.
62799949|NCT02420379|EXPERIMENTAL|Open-Label|Approximately 20 patients will receive weekly infusions of eteplirsen 30 mg/kg .
62799950|NCT02420379|NO_INTERVENTION|Control Group|Approximately 20 patients with DMD not amenable to exon 51 skipping will be observed for 96 weeks.
62799951|NCT04280055|EXPERIMENTAL|Psilocybin|
62799952|NCT01235013|EXPERIMENTAL|Maraviroc|
62026627|NCT00856583|EXPERIMENTAL|Sertindole|Normally in the range of 4 to 20 mg/day
62026628|NCT00856583|ACTIVE_COMPARATOR|Risperidone|Normally in the range of 2 to 8 mg/day
62225404|NCT05341596||Reintubation after planned extubation|Reintubation after planned extubation(RAP) was defined as repeat endotracheal intubation in the PACU after planned extubation of the initial endotracheal intubation for general anesthesia or combined general anesthesia other than that performed in the operating room.
62418242|NCT06702085|EXPERIMENTAL|first group|thirty older adults (with obesity, metabolic syndrome, and chronic subjective tinnitus) administered supervised changes in their lifestyle (walking exercise for 40 minutes applied on treadmill for three time per week and low caloric diet) for twelve weeks
62799953|NCT01235013|NO_INTERVENTION|Control|Patients continue with their usual treatment
62799954|NCT03109184|NO_INTERVENTION|Waitlist Control|Parents and teens enrolled in the study and randomized to the control condition wait until they complete their 3-month and 9-month follow-up surveys before completing the web-based program.
62225405|NCT05341596||matched group|Patients without RAP during the PACU stay were designated as the matched group
62418243|NCT06702085|NO_INTERVENTION|second group|thirty older adults (with obesity, metabolic syndrome, and chronic subjective tinnitus) served as control patients who did not receive any changes in their lifestyle
62588966|NCT05802407|NO_INTERVENTION|Routine treatment|Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will continued their current therapy.
62799955|NCT03109184|EXPERIMENTAL|Project STRONG|The web-based program consists of a number of games, activities, and didactic information that teens move through with their parent. Didactic information introduces teens and parents to specific emotion management, communication, and problem solving strategies as well as sexual health and healthy relationship information. Games and activities allow parents and teens to practice and apply strategies to developmentally appropriate situations.
62799956|NCT05568628||lacating femals|screening of breast lesions in lactating female
62799957|NCT05568628||pregnant|screening of breast lesions in pregnant female
62799958|NCT00855621|ACTIVE_COMPARATOR|Single microelectrode|Surgical procedure performed using single microelectrode recording guidance intraoperatively
62799959|NCT00855621|ACTIVE_COMPARATOR|Multiple microelectrode|Surgical procedure performed using multiple microelectrode recording guidance intraoperatively
62799960|NCT00724672||ETA|RA patients who were scheduled to receive etanercept 50 mg subcutaneously once weekly
62799961|NCT00724672||IFX|RA patients who were scheduled to receive infliximab 3 mg/kg IV at Weeks 0, 2, and 6
62026629|NCT01362621||Children 6 to less than 12 years of age|
62026630|NCT04634604|ACTIVE_COMPARATOR|Laser|For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by Occupational Safety and Health Administration (OSHA) and facility standards, will be followed.
62026631|NCT04634604|EXPERIMENTAL|Bevacizumab|For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.
62026632|NCT06626828|EXPERIMENTAL|Electroacupuncture group|After sterilization, disposable sterilized needles (0.25 × 40 mm, Taichi disposable acupuncture needles, Suzhou Shenlong Medical Apparatus Company, Suzhou, China) are inserted by the Registered Chinese Medicine Practitioner (RCMP) into the acupoints of Shenting (GV24), left Benshen (GB13), right Benshen (GB13), Baihui (GV20), and Sishencong (EX-HN 1). Acupoints are then stimulated by the Huatuo SDZ-II electroacupuncture device.
62026633|NCT06626828|NO_INTERVENTION|Control group|Blank control group with no further intervention.
62026634|NCT06636240|ACTIVE_COMPARATOR|control arm|standard atopic dermatitis treatment
62026635|NCT06636240|EXPERIMENTAL|experimental arm|add-on 200 ml/day mulberry juice with standard therapy
62799962|NCT00724672||ADA|RA patients who were scheduled to receive adalimumab 40 mg subcutaneously biweekly
62225406|NCT02394951|EXPERIMENTAL|Pregabalin|Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
62225407|NCT02394951|PLACEBO_COMPARATOR|Placebo|Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
62225408|NCT04869631||Aortic valve stenosis undergoing aortic valve replacement|Aortic valve stenosis undergoing aortic valve replacement.
62225409|NCT00583934||A|Those six months post treatment for head and neck cancer.
62418244|NCT03259867|EXPERIMENTAL|Advanced Hepatocellular carcinoma|"PD-1 inhibitor (Nivolumab 360 mg Q3W IV ) starts at day 1, and continues until progression.~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
62799963|NCT00724672||non-diseased controls|Healthy individuals who contributed their RNA/cDNA samples prior to the study and for whom ethical approval has already been obtained.
62799964|NCT03168828|EXPERIMENTAL|TAR-302-5018|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
62799965|NCT05599737|EXPERIMENTAL|Radiotherapy|"Stereotactic radiotherapy in 5 fractions (on alternate day)~* Whole prostate: 36.25 Gy - 7.25Gy/fraction~* GTV-RT (boost): target 50 Gy - 10 Gy/fraction"
62799966|NCT04484870|EXPERIMENTAL|Danshu capsule group|The patients in Danshu group were treated with Danshu capsule, 2 tablets per time, 3 times a day (0.45g/ tablets)，The course of treatment was 6 months
62799967|NCT04484870|ACTIVE_COMPARATOR|ursodeoxycholic acid group|UDCA group, 250mg/ was taken orally twice a day (0.25g/, Losan Pharma GmbH company). The course of treatment was 6 months
62225410|NCT02179450||Blepharospasm|Patients suffering from Blepharospasm
62225411|NCT02179450||Cervical Dystonia|Patients suffering from cervical dystonia
62418245|NCT03259867|EXPERIMENTAL|Metastatic Gastro-esophageal cancer|"PD-1 inhibitor (Nivolumab 360 mg Q3W IV) starts at day 1, and continues until progression.~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
62026636|NCT06111950|OTHER|RNU4ATAC patient|Patient with bi-allelic mutation of the RNU4ATAC gene
62026637|NCT06111950|OTHER|RNU4ATAC fetus|Fetus with bi-allelic mutation of the RNU4ATAC gene
62225412|NCT02179450||Bilateral facial palsy|Patients suffering from bilateral facial palsy of inflammatory origin
62225413|NCT02179450||Healthy Control|Control subjects
62225414|NCT02968082|PLACEBO_COMPARATOR|Placebo group (P group)|"The group that not existed scopolamine ingredient.~dosage form: apply~dosage: 1.5 mg~frequency: 1 times (at 9 p.m. of the day before the operation day)~duration: Until the 24hr after operation.~Patients will be applied patch that not existed scopolamine ingredient."
62418246|NCT05808894|EXPERIMENTAL|extended transection group|the patients in extended transection group obtain extended pancreatic neck transection during laparoscopic pancreaticoduodenectomy.
62799968|NCT01664182|EXPERIMENTAL|Arm I (trebananib monotherapy)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
62799969|NCT01664182|EXPERIMENTAL|Arm II (trebananib and anti-VEGF therapy)|Patients receive trebananib as in Arm I and either bevacizumab IV over 30-90 minutes on days 1, 15, and 29, pazopanib hydrochloride PO QD on days 1-42, sorafenib tosylate PO BID on days 1-42, or sunitinib malate PO QD on days 1-28. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
62799970|NCT03806621||Rotational Atherectomy|
62799971|NCT02486016|EXPERIMENTAL|Duragesic Reference Fentanyl TDS|Each volunteer participates in two procedure days using the Duragesic reference (RLD) fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
62799972|NCT02486016|ACTIVE_COMPARATOR|Apotex Generic Fentanyl TDS|Each volunteer participates in two procedure days using the Apotex generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
62799973|NCT02486016|ACTIVE_COMPARATOR|Mylan Generic Fentanyl TDS|Each volunteer participates in two procedure days using the Mylan generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
62799974|NCT03337971|PLACEBO_COMPARATOR|PLACEBO|"Intervention: Dietary Supplement: PLACEBO A group of subjects ingesting a liquid beverage (0.3g per kg body mass ; 1.2kcal/kg body mass) at 10:00pm, 3h post-absorptive of a standardised evening meal.~Samples for the measurement of biomarkers of change in the rate of bone turnover appearing in the blood to be collected for the immediate 4h, and excreted in urine, 24h post-ingestion"
62799975|NCT03337971|ACTIVE_COMPARATOR|Milk-based protein matrix|"Intervention: Dietary Supplement: MBPM A group of subjects ingesting a liquid beverage (0.3g per kg body mass ; 1.2kcal/kg body mass) at 10:00pm, 3h post-absorptive of a standardised evening meal.~Samples for the measurement of biomarkers of change in the rate of bone turnover appearing in the blood to be collected for the immediate 4h, and excreted in urine, 24h post-ingestion"
62799976|NCT03512301|EXPERIMENTAL|CAMCI Baseline Only|Computerized and paper-pencil neuropsychological tests, baseline
62026638|NCT06111950|OTHER|RNU4ATAC parent|Parent of patient or fetus with bi-allelic mutation of the RNU4ATAC gene and who present themselve mono-allelic mutation of the RNU4ATAC gene
62026639|NCT06111950|OTHER|RTTN patient|Patient with bi-allelic mutation of the RTTN gene
62026640|NCT06111950|OTHER|RTTN fetus|Fetus with bi-allelic mutation of the RTTN gene
62026641|NCT04848038|ACTIVE_COMPARATOR|Core and Fusion Training|150 minutes/week of Core and Fusion exercise, a mix of low impact toning, strengthening, flexibility and balance exercises.
62026642|NCT04848038|ACTIVE_COMPARATOR|Endurance Training|Moderate-intensity endurance training such as brisk walking, 150 minutes/week over 3-5 days. Progression based on a set schedule. In addition 0-2 days of Core and Fusion control exercise will also be recommended.
62026643|NCT04848038|ACTIVE_COMPARATOR|Weight Training|Progressive resistance training 2 days/week, non-consecutive, of 2 sets (10 - 15 repetitions) of 10 exercises (\~75 minutes/week). Progression based on repetition completion and 1-repetition maximum. In addition 3 days of Core and Fusion control exercise will also be recommended.
62026644|NCT04848038|ACTIVE_COMPARATOR|Combined Endurance and Weight Training|Moderate-intensity endurance training such as brisk walking, 150 minutes/week over 3-5 days. Progression based on a set schedule. Progressive resistance training 2 days/week, non-consecutive, of 2 sets (10 - 15 repetitions) of 10 exercises (\~75 minutes/week). Progression based on repetition completion and 1-repetition maximum.
62026645|NCT06573398|EXPERIMENTAL|CRT+PD-1 inhibitor+Thymalfasin|All eligible 20 subjects will receive a neoadjuvant therapy regimen of chemoradiotherapy combined with anti-PD-1 monoclonal antibody and Thymalfasin.
62026646|NCT05307549||Post-COVID patients|Adults survivors from severe COVID-19
62026647|NCT05307549||Controls|Healthy adult controls
62225415|NCT02968082|EXPERIMENTAL|Scopolamine group (S group)|"'Scopolamine (1.5mg) 1 patch'~The group that existed scopolamine ingredient~dosage form: apply~dosage: 1.5 mg~frequency: 1 times (at 9 p.m. of the day before the operation day)~duration: Until the 24hr after operation.~Patients will be applied patch that existed scopolamine ingredient."
62418247|NCT05808894|NO_INTERVENTION|conventional transection group|the patients in conventional transection group obtain conventional pancreatic neck transection during laparoscopic pancreaticoduodenectomy.
62799977|NCT03512301|EXPERIMENTAL|CAMCI Baseline + Follow-Up|Computerized and paper-pencil neuropsychological tests, Baseline + Follow-Up
62799978|NCT06456255|EXPERIMENTAL|Injection|- Injection 0.25% bupivacaine with 1:200,000 epinephrine
62799979|NCT06456255|PLACEBO_COMPARATOR|Sham injection|- Sham injection (only puncture, no injecting anything)
62799980|NCT00419939||1|ab 10 patientsr with acquired severe brain injury (GCS 3 - 9), \>18 år, PTA phase at the end (GOAT scoring), RLAS score at minimum 4 and informed consent in writing
62799981|NCT05935332|EXPERIMENTAL|RPT193 400 mg|
62799982|NCT05935332|PLACEBO_COMPARATOR|Placebo|
62418248|NCT05758246|EXPERIMENTAL|Fisetin- dose 1|Elderly (\>=65 years) patients admitted to the hospital with an acute infection and sequential organ failure assessment score sufficient for a diagnosis of sepsis, will be given the first dose of fisetin.
62418249|NCT05758246|EXPERIMENTAL|Fisetin- dose 2|Elderly (\>=65 years) patients admitted to the hospital with an acute infection and sequential organ failure assessment score sufficient for a diagnosis of sepsis, will be given the 2nd does of fisetin.
62588967|NCT01297439|OTHER|group M|"Normal delivery without pushing maneuver suctioning of fetal nose and mouth during delivery"
62588968|NCT01297439|EXPERIMENTAL|group C|"Pushing maneuver on the fetal head"
62225416|NCT03343301|EXPERIMENTAL|Bemarituzumab 6 mg/kg + mFOLFOX6|Participants received 6 mg/kg bemarituzumab administered every 2 weeks (Q2W) and mFOLFOX6 chemotherapy administered Q2W until unacceptable toxicity, disease progression, or death.
62588969|NCT02482467|OTHER|Cases|Prenatal diagnosis of ovarian cyst
62588970|NCT02482467|OTHER|controls|No prenatal diagnosis of cyst
62588971|NCT00991094||Observational (questionnaire)|Patients undergoing standard of care proton therapy are assessed for toxicities weekly during proton treatment, then from 1 to 3 times up to 90 days from the start of treatment and annually thereafter. Patients also complete questionnaires over 15-20 minutes at baseline, weekly during treatment, and every 2 weeks during follow up for up to 3 months.
62799983|NCT04643626|EXPERIMENTAL|IG|artificial intelligence dietary application, iDSA, will be introduced and installed. Explanation on the function and application of iDSA will be given. Daily energy and macro-nutrients requirement target will bed set. The daily energy and macronutrients requirement target is secured by password. Subjects will record their daily dietary intake (food with cooking method and portion size) and nutrition impact symptoms via smartphone application at least 3 times a week. Subjects able to keep track their intake at home. During follow up session, subjects show the iDSA diet intake summary records to Researcher for further assessment.
62799984|NCT04643626|NO_INTERVENTION|CG|CG will receive conventional dietitian care includes nutrition care process using conventional 24 hours diet recall method for dietary assessment
62799985|NCT05684458|EXPERIMENTAL|Reiki Group|Patient Descriptive Information Form, Edmonton Symptom Diagnosis Scale (ESTO), and European Association for Cancer Research and Treatment BR23 Quality of Life Scale (EORTC-QLQ-BR232) will be administered to the Reiki group. Then, under the guidance of a researcher holding a Usui Reiki Master \& Teacher degree, a total of 26 patients in the intervention group will be given a short 30-minute application to energy centers by researchers with a second-degree Reiki practitioner. On the second and on third days, 30 minutes of short Reiki will be done remotely. After 3 days and 10 days after the patients were included in the study, the post-tests will be performed by calling the patients.
62799986|NCT05684458|NO_INTERVENTION|Control Group|Patient Descriptive Information Form, Edmonton Symptom Diagnosis Scale (ESTO), and European Association for Cancer Research and Treatment BR23 Quality of Life Scale (EORTC-QLQ-BR232) will be administered to the control group. No treatment will be applied to the patients. Post-tests will be applied to all patients 3 days and 10 days after they were included in the study.
62799987|NCT01877512|ACTIVE_COMPARATOR|Low dose Growth Hormone|Halve of the group of men and group of women will receive a decrease of their regular dose of Growth Hormone treatment, with the IGF-I target level of -2 - -1 SD score (low dose=LD).
62799988|NCT01877512|ACTIVE_COMPARATOR|High dose Growth Hormone|Halve of the group of men and group of women will receive an increase of their regular dose of Growth Hormone treatment, with the IGF-I target level of 1 - 2 SD score (high dose=HD).
62225417|NCT03343301|EXPERIMENTAL|Bemarituzumab 15 mg/kg + mFOLFOX6|Participants received 15 mg/kg bemarituzumab administered Q2W with a single additional bemarituzumab 7.5 mg/kg dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.
62588972|NCT06335693|EXPERIMENTAL|adjuvant hypofractionated radiotherapy|Patients after radical prostatectomy with high-risk pathological factors will receive hypofractionated post-prostatectomy radiotherapy in 15 fractions.
62799989|NCT01214005|EXPERIMENTAL|schizophrenia|Smokers with schizophrenia or schizoaffective disorder
62418250|NCT05758246|PLACEBO_COMPARATOR|Placebo|Elderly (\>=65 years) patients admitted to the hospital with an acute infection and sequential organ failure assessment score sufficient for a diagnosis of sepsis will receive placebo treatment.
62418251|NCT03060252||The overall individuals taking ZGGJ Pill|The overall individuals taking ZGGJ Pill with recommended dosage and achieving the inclusion criteria.
62418252|NCT02690532||High risk group|Children who are at high risk for developing celiac disease (siblings diagnosed with celiac disease).
62588973|NCT00331331||Patients|Participants with appropriate ocular disorders who were previously enrolled as part of the MUST study and patients who participate in other intramural NIH studies
62588974|NCT00184717|EXPERIMENTAL|0.033 mg / NN-220|In the 156-week main period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
62799990|NCT01214005|OTHER|non-psychiatric|smokers without psychiatric illness
62799991|NCT01512095|EXPERIMENTAL|Norditropin®|
62799992|NCT01512095|ACTIVE_COMPARATOR|Nutropin AQ®|
62225418|NCT05974215|ACTIVE_COMPARATOR|group 1|patients received mandibular implant supported removable overdenture
62418253|NCT02690532||Non-celiac group|Children who are self-diagnosed with non-celiac gluten sensitivity.
62418254|NCT02690532||Control Group|Healthy control group (matched for age and gender).
62418255|NCT03287141|SHAM_COMPARATOR|First intervention|The subjects did a shuttle walk test without any previous intervention.
62418256|NCT03287141|EXPERIMENTAL|Second intervention|Subjects underwent 30 minutes of noninvasive ventilation (CPAP) and then re-performed the shuttle walk test.
62418257|NCT03287141|EXPERIMENTAL|Third intervention|Subjects underwent 30 minutes of noninvasive ventilation (Bi-pap) and then re-performed the shuttle walk test.
62418258|NCT06274385|EXPERIMENTAL|Betalain-rich Concentrate|A single dose of a BRC supplementation
62418259|NCT06274385|PLACEBO_COMPARATOR|Placebo|A single dose of a placebo
62588975|NCT00184717|EXPERIMENTAL|0.067 mg / NN-220|In the 156-week main period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
62418260|NCT04843332|NO_INTERVENTION|Usual Oncology Care|This arm is the control group. They will receive usual oncology care from their regular oncologist and care team with no change in their care plan or treatment as a result of the intervention. Outcomes will be assessed at each of the following times: baseline, 3-months, 6-months, and 12-months.
62433515|NCT04341818|EXPERIMENTAL|Strength Training and Vitamin D daily|Four weeks of Vitamin D (800 IU once per day) followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
62799993|NCT01910402|EXPERIMENTAL|DTG/ABC/3TC FDC|As per the randomization schedule subjects will be administered with DTG/ABC/3TC (50mg/600mg/300mg) FDC tablet OD up to Week 48 and if continued if applicable in the Continuation Phase. DTG/ABC/3TC FDC may be administered with or without food
62799994|NCT01910402|ACTIVE_COMPARATOR|ATV +RTV +TDF/FTC FDC|As per the randomization schedule subjects will be administered with ATV (300mg capsule) +RTV (100mg tablet) + TDF/FTC (300mg/200mg tablet) FDC OD up to Week 48. ATV+RTV+ TDF/FTC FDC must be taken with food
62799995|NCT03564613||HIV positive pregnant women|Data from approximately 250 HIV positive pregnant women with exposure to DTG from potential investigational sites across Europe will be included.
62799996|NCT01729286|ACTIVE_COMPARATOR|PriMatrix Moist Wound Therapy|sharp debridement, Primatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
62799997|NCT01729286|OTHER|Standard of Care Moist Wound Therapy|sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
62799998|NCT03062020|EXPERIMENTAL|Intervention group: QUIPP tool arm|In this group, QUIPP tool will be used to select and manage patients attending our PBPC: high-risk patients will be followed-up in our PBPC and low-risk patients will be discharged from PBPC and managed in a low-risk unit.
62799999|NCT03062020|NO_INTERVENTION|Control group: no QUIPP tool arm|Women will be managed according to current clinical practice.
62800000|NCT03106064|PLACEBO_COMPARATOR|Usual Care Group|Intervention: Usual care
62800001|NCT03106064|EXPERIMENTAL|Intervention Group|Intervention:Promoting independence in self-care
62800002|NCT05745311|EXPERIMENTAL|low-dose group （The KPCXM18 injection）|Intravenous infusion of 20 mg twice daily at intervals of 12±2 hours for 10 days.
62800003|NCT05745311|EXPERIMENTAL|middle-dose group （The KPCXM18 injection）|Intravenous infusion of 60 mg twice daily at intervals of 12±2 hours for 10 days.
62588976|NCT00184717|NO_INTERVENTION|No treatment|No somatropin (NN-220) treatment was given in the 52-week main period. Subjects was re-randomised to recive two dosing regimens (0.033 mg/kg/day or 0.067 mg/kg/day) in the 208-week extension period
62800004|NCT05745311|EXPERIMENTAL|high-dose group （The KPCXM18 injection）|Intravenous infusion of 100 mg twice daily at intervals of 12±2 hours for 10 days.
62800005|NCT05745311|PLACEBO_COMPARATOR|Placebo|Intravenous infusion twice a day with an interval of 12±2 hours for 10 days.
62800006|NCT01053494|ACTIVE_COMPARATOR|Arm I (WAITLIST CONTROL GROUP)|Patients and caregivers receive standard of care and are offered the massage intervention after 8 weeks.
62800007|NCT01053494|EXPERIMENTAL|Arm II (TOUCH)|"Caregivers undergo a 60-minute training session on simple massage techniques, including the Massage Toolkit, comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist. Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks."
62800008|NCT01053494|EXPERIMENTAL|Arm III (TOUCH+)|"Caregivers undergo a 60-minute training session on simple massage techniques, including the Massage Toolkit, comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist. Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks. Caregivers also receive a 45-minute massage by the massage therapist."
62800009|NCT02151188|OTHER|Bread and water|co-ingestion control session
62588977|NCT00184717|EXPERIMENTAL|No treatment --> 0.033 mg|In the 208-week extension period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period
62588978|NCT00184717|EXPERIMENTAL|No treatment --> 0.067 mg|In the 208-week extension period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period
62588979|NCT03277729|EXPERIMENTAL|Treatment (CD20-specific CAR T cell, chemotherapy)|Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.
62588980|NCT04334343|ACTIVE_COMPARATOR|Athletic group|
62800010|NCT02151188|EXPERIMENTAL|bread with cow milk co-ingestion|co-ingestion bread with cow milk
62800011|NCT02151188|EXPERIMENTAL|bread with soy milk co-ingestion|co-ingestion bread with soy milk
62800012|NCT02151188|EXPERIMENTAL|preload cow milk|preload cow milk 30 min, then bread
62588981|NCT04334343|ACTIVE_COMPARATOR|Sedentary exercise group|
62588982|NCT04334343|ACTIVE_COMPARATOR|Sedentary no-exercise group|
62588983|NCT04550676|EXPERIMENTAL|High intensity interval training|
62588984|NCT04550676|ACTIVE_COMPARATOR|Continuous moderate intensity exercise|
62588985|NCT02067884|EXPERIMENTAL|Diagnostic (CEUS, SWE)|Patients undergo dynamic contrast-enhanced ultrasound imaging and shear wave elastography at baseline, 2-3 weeks after initiation of chemotherapy, and before surgery.
62588986|NCT03875482|EXPERIMENTAL|Risankizumab|Subcutaneous (SC), self-administered 150 mg doses of risankizumab at Weeks 0, 4, and 16
62588987|NCT03875482|PLACEBO_COMPARATOR|Placebo|Subcutaneous (SC), self-administered doses of placebo solution at Weeks 0, 4, and 16
62588988|NCT00801203|EXPERIMENTAL|1|Induced Reflex Cough Test (IRCT) followed by Voluntary Cough Test (VCT)
62800013|NCT02151188|EXPERIMENTAL|preload soy milk|preload soy milk 30 min, then bread
62800014|NCT03525691|EXPERIMENTAL|Minimal distension|Tidal volume 4 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)
62026648|NCT06086223|EXPERIMENTAL|those patients who will go for ORIF plus arthroscopy|"we will start with a standard ankle arthroscopy. A leg holder and ankle joint distractor will be used. We will start with the anteromedial portal and introduce the 4-mm scope into the ankle joint. Next, under direct visualization, and taking care to preserve any branches of the superficial peroneal nerve, we will perform the anterolateral portal.~We will carry out a standard diagnostic ankle arthroscopy to evaluate the ankle cartilage, wash intra-articular haematoma, identify, and remove any intra-articular fracture fragments and loose bodies, perform dynamic ligamentous stress examinations while directly visualizing the syndesmosis, the deltoid ligament, and the lateral collateral ligament.~Following fracture fixation, arthroscopy will be also used as a second look to evaluate the quality of both articular and syndesmotic reduction, perform any needed arthroscopic intervention for deltoid ligament injury or management of chondral lesions (OCLs)"
62225419|NCT05974215|ACTIVE_COMPARATOR|group 2|patients received mandibular implant supported fixed overdenture
62225420|NCT02162589||POEM for Achalasia|Any patient who has undergone clinically indicated and/or standard of care POEM for the treatment of Achalasia.
62433516|NCT04341818|EXPERIMENTAL|Strength Training and no Vitamin D|Four weeks of no vitamin D administration followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
62588989|NCT00801203|EXPERIMENTAL|2|Voluntary Cough Test (VCT) followed by Induced Reflex Cough Test (IRCT)
62588990|NCT06683833|EXPERIMENTAL|Egyptian MTA|"* Complete caries removal from the cavity.~* The liquid of Egyptian MTA (Toothmate) will be mixed with powder according to the manufacturers' instructions.~* The capping materials will be placed with the passive application on the deepest part of the cavity. Only light pressure will be applied on the MTA mixture using a wet cotton pellet to ensure adaptation of the material onto the dentin.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities."
62800015|NCT03525691|EXPERIMENTAL|Maximal recruitment|Tidal volume 4 ml/kg PBW and PEEP adjusted to maintain a plateau pressure between 23 - 25 cmH2O + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)
62800016|NCT03525691|ACTIVE_COMPARATOR|Standard|Tidal volume 6 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) without ECCO2R (no sweep gas flow, blood flow = 400 mL/min)
62588991|NCT06683833|EXPERIMENTAL|Biodentine|"* Complete caries removal from the cavity.~* Gently tapping a capsule of Biodentine (Septodont) on a hard surface to loosen the powder, then opening the capsule, Detaching a single-dose container of liquid and gently tapping on the sealed cap to force all the liquid down the container, Twisting cap to open, Then Pouring 5 drops from the single-dose container into the capsule, Then Closing the capsule and Placing it on a mixing device for 30 seconds, Then Collecting Biodentine with the instrument supplied in the box.~* The capping materials will be placed with the passive application on the deepest part of the cavity.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities."
62026649|NCT06086223|EXPERIMENTAL|patients who will go for ORIF without arthroscopy|"* Posterior malleolus fractures will be addressed when it is present whatever its size.~* The fibula fractures will be fixated using either a posterolateral or direct lateral incision. Lag screws will be used when the fracture pattern allows, and all fractures will be also treated with a neutralization or antiglide plate depending on the pattern and approach.~* If a medial malleolus fracture is present, this will be addressed through a direct medial incision. These fractures will be either fixed with cannulated screws or tension band cerclage wiring or a plate and screw construct depending on the fracture pattern.~* Once all bony injuries will be stabilized, a Cotton test will be performed under live fluoroscopy to determine syndesmosis stability. If positive, the syndesmosis will be stabilized using fully threaded screws."
62026650|NCT06291805||wtATTR-CM patients (n = 100)|"Clinical history, physical examination, ECG, advanced echocardiography, blood and urine samples, cardiac magnetic resonance imaging (CMRI), and QoL questionaires (KCCQ, EQ-5Q-5L and ATTR-QoL)).~Subgroup with these patient (n = 10): A endomyocardial biopsy."
62026651|NCT06291805||Control (n = 20)|Blood and urine samples. To rule out cardiac disease: clinical history, physical examination, ECG and advanced echocardiography.
62225421|NCT00898898||Arm I|Tissue samples from protocol NCCTG-N9831 are obtained for immunohistochemistry and fluorescence in situ hybridization analysis of MYC, IGF- 1R, PTEN, and TOP2A genes. Exons 9 and 20 of PIK3CA gene are amplified via polymerase chain reaction; mutations in exons 9 and 20 of PIK3CA gene are identified.
62418261|NCT04843332|EXPERIMENTAL|Community Health Worker Intervention|This arm is the treatment group. Patients randomized into the intervention will be assigned a community health worker who will contact the patient to begin the intervention. They will receive usual oncology care from their regular oncologist and care team but will also receive supplemental support and health education from a community health worker. The lay health worker will assist patients in ensuring that patients discuss the following with their cancer care teams: 1) precision medicine 2) cancer diagnosis and treatment plan 3) adherence to treatments and 3) goals of care and 4) symptom burden. Outcomes will be assessed at each of the following times: baseline, 3-months, 6-months, and 12-months.
62418262|NCT06057233||Patients|mqMRI and GABA-MRS data will be collected in patients suffering from mesial temporal lobe epilepsy
62418263|NCT06057233||Volunteers|mqMRI and GABA-MRS data will be collected in healthy volunteers
62418264|NCT06298318|EXPERIMENTAL|vodka(1g/kg body weight)|After an 8-hour overnight fast, the participants drink vodka(1g/kg body weight)
62225422|NCT00995969|PLACEBO_COMPARATOR|Placebo only|Subjects will apply placebo cream to both target lesions
62225423|NCT00995969|ACTIVE_COMPARATOR|Active plus placebo|Subjects will apply CT 327 to one target lesion and placebo to the other target lesion
62225424|NCT04500431|EXPERIMENTAL|spCART-269|spCART-269 administered by intravenous (IV) infusion
62225425|NCT00812331|EXPERIMENTAL|Genotype 2|Participants with chronic genotype 2 hepatitis C virus (HCV) infection
62225426|NCT00812331|EXPERIMENTAL|Genotype 3|Participants with chronic genotype 3 HCV infection
62225427|NCT00812331|EXPERIMENTAL|Genotype 4|Participants with chronic genotype 4 HCV infection
62026652|NCT06442371|EXPERIMENTAL|High Intensity interval training + Quranic Listening|
62418265|NCT06298318|PLACEBO_COMPARATOR|equal amount of water|After an 8-hour overnight fast, the participants drink equal amount of non-alcoholic beverages with the same taste and colour but without alcohol
62225428|NCT00812331|EXPERIMENTAL|Genotype 5|Participants with chronic genotype 5 HCV infection
62026653|NCT06442371|ACTIVE_COMPARATOR|High Intensity interval training|
62026654|NCT00497653|EXPERIMENTAL|DCI|
62026655|NCT00497653|PLACEBO_COMPARATOR|Placebo|
62026656|NCT00344682|EXPERIMENTAL|memantine|memantine (5-20mg a day)
62026657|NCT00344682|PLACEBO_COMPARATOR|Placebo|placebo (5-20mg a day)
62225429|NCT00812331|EXPERIMENTAL|Genotype 6|Participants with chronic genotype 6 HCV infection
62225430|NCT03430206|NO_INTERVENTION|Control|Control subjects will undergo their scheduled procedure and recovery with the usual care. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
62418266|NCT02864953|EXPERIMENTAL|BIIB093|BIIB093 administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.
62418267|NCT02864953|PLACEBO_COMPARATOR|Placebo|Placebo administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.
62418268|NCT05148455||pregnant women|
62418269|NCT05148455||non-pregnant women (control group)|
62433517|NCT02309632|ACTIVE_COMPARATOR|Pathway 1|Individuals at high risk of pancreatic cancer who will participate in Pancreatic Cancer Screening Pathway 1
62026658|NCT01230476|EXPERIMENTAL|Cetuximab and chemotherapy|2 cycles of neoadjuvant cisplatin and 5FU (3 weekly), given with weekly cetuximab, followed by 7 doses of weekly cisplatin and cetuximab concurrent with radiotherapy
62433518|NCT02309632|ACTIVE_COMPARATOR|Pathway2|Individuals at high risk of pancreatic cancer who will participate in Pancreatic Cancer Screening Pathway 2
62433519|NCT01418261|EXPERIMENTAL|Renal Denervation|Subjects are treated with the renal denervation procedure after randomization and maintained baseline anti-hypertensive medications
62418270|NCT06700564||research group|This study adopts a prospective research design, with 60 patients suspected of having liver mass undergoing 18F-FDG PET/enhanced MR examination over one year. The inclusion criteria are as follows: age ≥ 18 years old; Patients suspected of having liver metastasis or liver lesions, based on clinical symptoms and laboratory tests (such as alpha-fetoprotein level); Preliminary findings from other routine imaging examinations; Able to perform 18F-FDG PET/MR examination and agree to follow the research procedure. The exclusion criteria are as follows: patients with a history of allergy to MR contrast agents; Pregnant or lactating women; Patients with severe heart disease, renal failure, liver failure, etc; Patients who are unable to cooperate in completing PET/MR examinations. This study passed the ethical review of Shanghai Oriental Hospital, and patients signed informed consent forms after enrollment.
62225431|NCT03430206|EXPERIMENTAL|Intervention|Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-2L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
62225432|NCT01162317|ACTIVE_COMPARATOR|Arm 1: sham acupuncture|sham acupuncture
62418271|NCT06543511|EXPERIMENTAL|Germline Genetic Testing|"Participants will be enrolled and will complete study procedures as follows:~* Baseline visit with educational video and questionnaires.~* Skin punch biopsy.~* Genetic testing results.~* Surveys and questionnaires.~* Follow up via medical records for up to 2 years from time of study consent."
62418272|NCT02517346|ACTIVE_COMPARATOR|Standard follow up-Sleep Unit|Patients diagnosed as OSA, treated with CPAP and followed up in sleep unit
62418273|NCT02517346|EXPERIMENTAL|Telemonitoring|Patients diagnosed as OSA and treated with CPAP in sleep unit, followed up by telemonitoring system
62418274|NCT06262347|EXPERIMENTAL|Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME)|"Drug: Naloxone kit~Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to participants, which may be useful in the event of a future opioid overdose.~Behavioral: Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME)~TOME entails a trained RA: 1) administering a REDCap survey to assess an individual's opioid-overdose/MOUD knowledge; and 2) reviewing the personal feedback reports with the recipient."
62225433|NCT01162317|EXPERIMENTAL|Arm 2: acupuncture|acupuncture
62026659|NCT04111081|EXPERIMENTAL|Auricular pressure|Use wangbuliuxing seed to stimulate auricular acupuncture point.
62800017|NCT05806320|EXPERIMENTAL|Intrauterine Sound Listening Group 1|This group consisted of 15 infants with 26-32,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. The babies were listened to the sound obtained in 3 time periods. If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. Before the procedure, the baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00. During the baby procedure, uterine sound was listened to the baby in the prone position monitored with a monitor device and recorded on video between 11:00-11.30/13.45-14.15/17.00-17.30 hours. After the procedure, the baby was watched with a monitor device and recorded on video between 11.30-11.45/14.15 and 14.30/17.30-17.45.
62800018|NCT05806320|EXPERIMENTAL|Intrauterine Sound Listening Group 2|This group consisted of 15 infants with 33-36,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. The babies were listened to the sound obtained in 3 time periods. If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. Before the procedure, the baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00. During the baby procedure, uterine sound was listened to the baby in the prone position monitored with a monitor device and recorded on video between 11:00-11.30/13.45-14.15/17.00-17.30 hours. After the procedure, the baby was watched with a monitor device and recorded on video between 11.30-11.45/14.15 and 14.30/17.30-17.45.
62800019|NCT05806320|NO_INTERVENTION|Control Group 1|"This group consisted of 15 infants with 26-32,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. Babies in this group were followed up at specified time intervals without any intervention.~If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. The baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00 hours; 11:00-11.30/13.45-14.15/17.00-17.30 hours; 11.30-11.45/14.15- 14.30/17.30-17.45."
62225434|NCT02915302|ACTIVE_COMPARATOR|Fluzone Quadrivalent Vaccine, 0.25-mL|Participants received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per ACIP guidance, a second 0.25-mL dose of Fluzone Quadrivalent vaccine was administered at Day 28.
62588992|NCT06683833|ACTIVE_COMPARATOR|Calcium Hydroxide|"* Complete caries removal from the cavity.~* According to the manufacturers' instructions, Dispensing equal volumes of base and catalyst pastes on the parchment paper pad provided. Using a Dycal (Dentsply) Liner applicator, stirring immediately to mix thoroughly until a uniform color is achieved, complete mixing occurs within 10 seconds, using the ball-pointed Dycal Liner applicator or similar instrument, the mix will be placed directly on the cavity.~* The capping materials will be placed with the passive application on the deepest part of the cavity.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities."
62588993|NCT01855243|ACTIVE_COMPARATOR|glargine plus supplemental glulisine|Patients who will be recruited to be treated with glargine/glulisine, will received 50% of TDD as detailed demonstrated in Umpierrez et al., studies . as This includes administration of glargine (Lantus®) once every night plus glulisine (Apidra®) before each meal for BG ≥ 150 mg/dL. Glargine dose will be calculated as 0.2 U/kg/day for admission BG less than 200 mg/dL or 0.3 U/kg/day for BG exceeding 200 mg/dL. Glargine was given using Solostar Flex-Pen® once daily in the evening around 8:00 pm. Glulisine was given using the Solostar Flex-Pen® three times just before the meals for BG \> 150 mg/dL according to hospital sliding scale. To avoid hypoglycemia, if for any reason, a subject missed a meal, the dose of glulisine will be held.
62588994|NCT01855243|ACTIVE_COMPARATOR|70/30 insulin plus supplemental lunch insulin|Modified split-mixed insulin protocol adopted by Umpierrez et al., will be applied to patients treated with 70/30 insulin. Insulin dose will be started at 0.4 U/kg/day for admission BG less than 200 mg/dL or 0.5 U/kg/day for BG above 200 mg/dL. Two thirds of total daily dose (TDD)will be given before breakfast and 1/3 of TDD before dinner. Supplemental lunchtime regular insulin dose will given for BG \> 150 mg/dL . Patients previously treated with 70/30 insulin before admission initially will receivethe same regimen as at in home.
62588995|NCT01855243|ACTIVE_COMPARATOR|Sliding Scale insulin (SSI)|For SSI group, regular insulin will be administered three times daily subcutaneously approximately 30 min before meal for BG \> 150 mg/dL (or every 8 hours if a patient was not eating) according to hospital sliding scale table
62588996|NCT03193112||Study group|The investigators analyze the intraocular pressure changes on patients who have been using Agomelatine for their primary depressive disorder. For the treatment of depression, patients will have been started routinely Agomelatine tablet of 25 mg orally. The investigators measure the eye pressure for one months in those patients receiving standard depression treatment.
62588997|NCT06365710|EXPERIMENTAL|Telerehabilitation|The telerehabilitation group will start the physiotherapy guided by the digital care pathway postoperatively. The pathway includes videos, photos, animations and written material for rehabilitation of the operated hand. The same weightbearing instructions and mobilization exercises are shown in the videos and photos as are instructed in the physiotherapist appointment in the traditional physiotherapy group.
62588998|NCT06365710|ACTIVE_COMPARATOR|Traditional Physiotherapy|The traditional physiotherapy group will attend appointment with the physiotherapist at two-week and five week timepoints. After this, this group can attend additional physiotherapist appointments if seen necessary by the physiotherapist or the surgeon.
62588999|NCT05193344|EXPERIMENTAL|Digital solution group|Participants will be instructed to download a remote symptom monitoring and lifestyle-changing mobile application to which they will have access for 12 months. The program aims to provide remote symptom monitoring by having participants enter data (on diet, exercise, weight, etc) and answer questionnaires via the SidekickHealth platform, and to empower positive lifestyle changes. Beyond this, all patients in the interventional arm will also receive standard of care as defined below for the control arm.
62589000|NCT05193344|ACTIVE_COMPARATOR|Standard of care - control group|All participants in the control arm will receive best medical therapy including start or optimization of secondary preventive pharmacotherapy, and advise on modifiable risk factors. The participants in the control arm will also receive an information leaflet about relevant lifestyle modifications for HF. After the baseline measurements and data collection, there will be scheduled visits to a health care provider at 3, 6, and 12 months.
62225435|NCT02915302|EXPERIMENTAL|Fluzone Quadrivalent Vaccine, 0.5-mL|Participants received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per ACIP guidance, a second 0.5-mL dose of Fluzone Quadrivalent vaccine was administered at Day 28.
62225436|NCT04510831|EXPERIMENTAL|Refined maize|Two portions of porridge prepared with refined maize flour with extrinsic addition of labelled FeSO4 (isotopic iron 54)
62433520|NCT01418261|SHAM_COMPARATOR|Control group|Subjects go through renal angiogram and Subjects maintained baseline anti-hypertensive medications
62433521|NCT04421885|EXPERIMENTAL|A: TBPM-PI-HBr (Reference - fasted)|600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fasted conditions.
62433522|NCT04421885|EXPERIMENTAL|B: TBPM-PI-HBr (Test - fasted)|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fasted conditions.
62225437|NCT04510831|EXPERIMENTAL|T.molitor native chitin|Two portions of porridge prepared with refined maize flour mixed with dried intrinsically labelled Tenebrio molitor (isotopic iron 57) native chitin and extrinsic addition FeSO4 (isotopic iron 58)
62225438|NCT04510831|EXPERIMENTAL|T.molitor reduced chitin|Two portions of porridge prepared with refined maize flour mixed with dried intrinsically labelled Tenebrio molitor (isotopic iron 57) reduced chitin and extrinsic addition FeSO4 (isotopic iron 58)
62225439|NCT02670031||Newly Diagnosed Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
62418275|NCT06262347|ACTIVE_COMPARATOR|Control|"Drug: Naloxone kit~Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to participants, which may be useful in the event of a future opioid overdose.~Behavioral: SAMHSA handouts~SAMHSA handouts: 1) Opioid Overdose Prevention Toolkit: Safety Advice for Patients and Family Members; 2) Opioid Overdose Prevention Toolkit: Recovering from Opioid Overdose; and 3) Medication-Assisted Treatment for Opioid Addiction: Facts for Families and Friends. These handouts can be offered as physical copies or electronically."
62418276|NCT05902767|EXPERIMENTAL|Nut Group|Participants will receive a supply of mixed nuts containing: 1 Brazil nut (\~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days. They will also receive dietary counselling on how to follow the Australian Dietary Guidelines.
62418277|NCT05902767|OTHER|Control Group|Participants will follow the same protocol as the Nut group regarding appointments and collection of information. At the visits, they will receive dietary counselling on how to follow the Australian Dietary Guidelines
62418278|NCT02368119|EXPERIMENTAL|Group 1|VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp (n=10) or VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp (n=10). Randomization to booster of MVA-EbolaZ or PBS placebo will be completed 4 to 16 weeks after priming dose.
62418279|NCT02368119|EXPERIMENTAL|Group 2|VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp (n=20) or VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp (n=20). Randomization to booster of MVA-EbolaZ or PBS placebo will be completed 4 to 16 weeks after priming dose.
62418280|NCT05840497|EXPERIMENTAL|Resistance exercise|
62418281|NCT05840497|NO_INTERVENTION|Control Group|Standard control and usual recommendations.
62418282|NCT00455923|EXPERIMENTAL|Seretide|Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.
62418283|NCT00455923|EXPERIMENTAL|Flixotide|Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.
62418284|NCT04318041|EXPERIMENTAL|diacerein (Artrodar)|
62418285|NCT04318041|PLACEBO_COMPARATOR|placebo|
62418286|NCT05779046|EXPERIMENTAL|HIT 1:1|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:1 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternating with low intensity 50-55% of maximum heart rate for 1 minute ).
62418287|NCT05779046|EXPERIMENTAL|HIT 1:2|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:2 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternate with low intensity 50-55% of maximum heart rate for 2 minutes).
62418288|NCT05519267|EXPERIMENTAL|MBSWSC programme|The Experimental group will take part in the Mindfulness Based Social Work and Self Care (MBSWSC) programme (6 sessions). MBSWSC will be facilitated by two accredited mindfulness practitioners, who are also qualified social workers. Sessions will be supplemented by brief homework activities.
62418289|NCT05519267|ACTIVE_COMPARATOR|MBSC Programme|The Active comparator group will take part in the Mindfulness and Self-compassion (MBSC) programme (3 sessions). MBSC will be facilitated by two accredited mindfulness practitioners, who are also qualified social workers. Sessions will be supplemented by brief homework activities.
62418290|NCT05798923|EXPERIMENTAL|LAM-001|
62418291|NCT00561093|EXPERIMENTAL|A|Group A (n=25) Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
62418292|NCT00561093|EXPERIMENTAL|B|Group B (n=25) Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND Placebo to imitate pentoxiphylline while undergoing hemodialysis and the following non-dialysis day (6 days per week)
62418293|NCT00561093|EXPERIMENTAL|C|Group C (n=25) Placebo dietary supplement to imitate Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
62418294|NCT00561093|PLACEBO_COMPARATOR|D|Group D (n=25) Placebo to imitate Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND Placebo to imitate pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
62418295|NCT01778452|ACTIVE_COMPARATOR|Natural cycle|Natural cycle endometrial biopsy, lh+7
62418296|NCT01778452|EXPERIMENTAL|Antagonist cycle + endometrial priming.|Antagonist cycle + endometrial priming for egg donation program. endometrial biopsy, p4+5
62418297|NCT01778452|EXPERIMENTAL|Agonist cycle + endometrial priming.|Agonist cycle + endometrial priming for egg donation program endometrial biopsy, p4+5
62589001|NCT06666166|EXPERIMENTAL|Gastric or gastroesophageal junction adenocarcinoma|
62589002|NCT06666166|EXPERIMENTAL|Advanced colorectal cancer|
62589003|NCT06624007|EXPERIMENTAL|Intervention A|They will apply pediatric Nursing Excellence (PNE) model for children having orthopedic surgery
62589004|NCT06624007|NO_INTERVENTION|Control group|They will provide routine care for children having orthopedic surgery
62589005|NCT02388815|EXPERIMENTAL|Intervention|FreeStyle Libre Flash Glucose Monitoring System
62589006|NCT05706220||Control group|"* Ophthalmologic examination (best-corrected visual acuity, cover and uncover tests, slit-lamp biomicroscopy, funduscopy)~* Eye movement recording with the Tobii™ Pro Nano hardware package eye-tracking system and Tobii™ Pro Lab - full edition software~* Visual processing speed~* Microperimetry~* Optical coherence tomography"
62225440|NCT02670031||Well-Controlled Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
62225441|NCT02670031||Resistant Essential Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
62225442|NCT05897450||Patients with TAP block|After induction of anesthesia, TAP block was applied to the patients under ultrasound guidance.
62225443|NCT05897450||Patients without TAP block|
62225444|NCT02481947|EXPERIMENTAL|BLI400 Laxative|21 gm BLI400 powder
62225445|NCT02481947|ACTIVE_COMPARATOR|Lubiprostone|24 mcg capsule bid
62418298|NCT05349890|EXPERIMENTAL|CDX-1140 + TCR-T + Pembro|Patients will receive CDX-1440, TCR-T, and pembrolizumab.
62418299|NCT03976076|EXPERIMENTAL|JBPOS0101 (investigational product)|During Treatment Period 1, the IP was administered at 6 mg/kg, per oral (PO), twice a day (BID), once in the morning and 12 hours following the morning dose during the first 7 days of Treatment Period 1. Starting from the PM dose on Visit 3, the dose was escalated and patients received the Investigational Product (JBPOS0101) (IP) at a dose of 9 mg/kg orally BID. Starting on Day 15, the dose was escalated again and patients received the IP at a dose of 15 mg/kg orally BID until the end of Treatment Period 1 (Day 28). Each dose of the IP was administered after at least a 2-hour fast. Food was given 2 hours after dosing.
62418300|NCT03981614|EXPERIMENTAL|Arm A (binimetinib, palbociclib)|Patients receive binimetinib PO BID on days 1-28 and palbociclib PO QD on days 1-21. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62418301|NCT03981614|EXPERIMENTAL|Arm B (trifluridine and tipiracil hydrochloride)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with disease progression may optionally crossover to Arm A.
62418302|NCT06702345|EXPERIMENTAL|Cohort A (TCD spores only)|Volunteers in cohort A will be exposed to a once a day capsule with 10\^4 CFU TCD spores for 12 days. First, a pilot group of 5 volunteers will be exposed to flag safety signals. If in this pilot group TCD exposure is well tolerated and less than 70% of the volunteers (\< 4 out of 5 volunteers) reaches a microbiological AND clinical endpoint, the trial will escalate to the second cohort, cohort B. If, however, in the pilot group TCD exposure is well tolerated and at least 70% of the volunteers (≥4 out of 5 volunteers) reaches a microbiological AND clinical endpoint, a confirmatory group of another 15 volunteers will be included in cohort A (total 20 volunteers). If in this total of 20 volunteers sat least 70% (≥ 14 out of 20 volunteers) reaches a clinical AND microbiological endpoint, no further escalation to cohort B or C will be done. If, however, less than 70% of the 20 volunteers in cohort A reaches a clinical AND microbiological endpoint, escalation will continue to cohort B.
62433523|NCT04421885|EXPERIMENTAL|C: TBPM-PI-HBr (Test - fed)|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fed conditions.
62433524|NCT04051632||Type 1 Diabetes patients treated with the Medtronic 670G|Type 1 Diabetes patients treated with the Medtronic 670G at Boston Childrens Hospital
62433525|NCT03292783|EXPERIMENTAL|NOV150101 (ABL001)|
62433526|NCT06458686|PLACEBO_COMPARATOR|Control group|This group does not take any drug. It will take placebo.
62589007|NCT05706220||Clinically Isolated Syndrome Patients|"* Ophthalmologic examination~* Eye movement recording with the Tobii™ Pro Nano hardware package eye-tracking system and Tobii™ Pro Lab - full edition software~* Visual processing speed~* Microperimetry~* Optical coherence tomography~* Patients with a history of optic neuritis will undergo additional tests at the discretion of the researcher (e.g. visual field, FarnsworthTest)"
62589008|NCT05706220||Relapsing-remitting Multiple Sclerosis Patients|"* Ophthalmologic examination (best-corrected visual acuity, cover and uncover tests, slit-lamp biomicroscopy, funduscopy)~* Eye movement recording with the Tobii™ Pro Nano hardware package eye-tracking system and Tobii™ Pro Lab - full edition software~* Visual processing speed~* Microperimetry~* Optical coherence tomography~* Patients with a history of optic neuritis will undergo additional tests at the discretion of the researcher (e.g. visual field, FarnsworthTest)"
62589009|NCT05706220||Primary Progressive Multiple Sclerosis Patients|"* Ophthalmologic examination (best-corrected visual acuity, cover and uncover tests, slit-lamp biomicroscopy, funduscopy)~* Eye movement recording with the Tobii™ Pro Nano hardware package eye-tracking system and Tobii™ Pro Lab - full edition software~* Visual processing speed~* Microperimetry~* Patients with a history of optic neuritis will undergo additional tests at the discretion of the researcher (e.g. visual field, FarnsworthTest)~* Optical coherence tomography"
62589010|NCT02475265|EXPERIMENTAL|estradiol 0.045mg/levonorgestrel 0.015mg|6 months of estradiol 0.045mg/levonorgestrel 0.015mg (once weekly patch).
62589011|NCT02737085|EXPERIMENTAL|Diffuse Large B Cell Lymphoma(DLBCL)|The trial will be conducted in a manner of simon two-stage design with Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with Diffuse Large B Cell Lymphoma(DLBCL). Only when the expected reaction rate is achieved the 30 patients left can be recruited.
62026660|NCT04111081|SHAM_COMPARATOR|Sham auricular pressure|Use wangbuliuxing seed to stimulate auricular acupuncture point.
62225446|NCT04999098|ACTIVE_COMPARATOR|treatment group 1: Echinaforce Forte (EFF) Tablets (chewed)|"1st arm (EFF group): Slowly sucking 1 Echinaforce Forte tablet (1 tablet: 1'200mg EF) until dissolution Dose 1. Another 2 X 1 EF Forte tablets (total of 2 tablets: 2'400 mg EF) is taken one-by-one Dose 2 after swab sampling, which is repeated after complete dissolution of the second dose of EF Forte tablets."
62589012|NCT06652438|PLACEBO_COMPARATOR|Revumenib-placebo|"day 1-28 Placebo~Treatment will be on a continuous 28-day cycle schedule and continued until disease progression, development of unacceptable toxicity, death, withdrawal by subject or other protocol defined criteria for discontinuation (whichever comes first)."
62589013|NCT06652438|EXPERIMENTAL|Revumenib|"day 1-28 Revumenib~Treatment will be on a continuous 28-day cycle schedule and continued until disease progression, development of unacceptable toxicity, death, withdrawal by subject or other protocol defined criteria for discontinuation (whichever comes first)."
62589014|NCT05573477|EXPERIMENTAL|ATB-1011 + ATB-1012|Participants will receive 1 tablet/day of each drug for 12 weeks
62589015|NCT05573477|EXPERIMENTAL|ATB-1012 + ATB-1013|Participants will receive 1 tablet/day of each drug for 12 weeks
62589016|NCT05573477|ACTIVE_COMPARATOR|ATB-1011|Participants will receive 1 tablet/day of each drug for 12 weeks
62589017|NCT05573477|ACTIVE_COMPARATOR|ATB-1012|Participants will receive 1 tablet/day of each drug for 12 weeks
62589018|NCT05011786||Open repair group|children with inguinal hernia who were repaired with open high ligation of the hernia sac through an inguinal incision.
62225447|NCT04999098|ACTIVE_COMPARATOR|treatment gorup 2: Echinaforce Chewable (EFC) Tablets (chewed)|"2nd arm (EFC group): Slowly sucking 1 x 3 Echinaforce Chewable tablets (total 3 tablets: 1'200mg EF) until dissolution Dose 1. Another dose of 2 x 2 \& 1 x 3 EF Chewable tablets (total 7 tablets: 2'800mg EF) are slowly sucked Dose 2 after swab sampling, which is repeated after complete dissolution of the second dose of EF Chewable tablets."
62589019|NCT05011786||Laparoscopic repair group|children with inguinal hernia who were repaired laparoscopically by closing the the PPV at the level of internal ring with a purse string suture
62589020|NCT05730582|ACTIVE_COMPARATOR|Generic Screening Invitation|Patients randomized to this study arm will receive the generic letter to inform them that they are at risk for T2D and that they are not up to date on screening. The letter also informs them that a screening test has been ordered, and requests that they complete testing at their clinic lab. The letter is signed by the patient's primary care provider and sent in both English and Spanish. This letter was previously developed and has been in use by the Parkland Diabetes Detection Program.
62026661|NCT06636617|EXPERIMENTAL|3.70 GBq (100 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single dose 3.70 GBq (100 mCi) of 177Lu-JH04.
62026662|NCT06636617|EXPERIMENTAL|5.55 GBq (150 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single dose 5.55 GBq (150 mCi) of 177Lu-JH04.
62026663|NCT06636617|EXPERIMENTAL|7.40 GBq (200 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single dose 7.40 GBq (200 mCi) of 177Lu-JH04.
62225448|NCT04999098|ACTIVE_COMPARATOR|treatment group 3: Echinaforce Tincture (EFT, gargling)|"3rd arm (EFT group): Gargling of 2 x 19 drops of Echinaforce tincture (1'200 mg EF) is diluted in 2 x35 mL water Dose 1. Another dose of 3 x 30 drops of Echinaforce tincture (2'800 mg EF) diluted in 3 x35 mL water for 15 sec each Dose 2, gargled for 15 sec and swallowed after swab sampling, which is repeated after gargling of the second dose of EF Tincture."
62026664|NCT01201434|EXPERIMENTAL|Probiotics, Treatment, Food Additive|
62589021|NCT05730582|EXPERIMENTAL|Targeted-Tailored Screening Invitation|Patients randomized to this study arm will receive the tailored letter, which uses messaging developed collaboratively by patients and clinical stakeholders under a prior NIH-funded research study (STU 2021-0743), in addition to available EHR data, to inform patients that they are at risk for Type 2 Diabetes based on specific clinical characteristics and that they are not up to date on screening. The letter also informs them that a screening test has been ordered, and requests that they fast and complete testing at their clinic lab within 60 days. Fasting instructions will specify nothing to eat or drink except water for at least 8 hours. The letter will be signed electronically by the patient's primary care provider and sent in both English and Spanish.
62589022|NCT05730582|NO_INTERVENTION|Standard of Care|Patients randomized to this study arm will receive opportunistic screening based on routine clinical activities. Patients will be assigned a study number for tracking purposes, but no intervention activities via the Parkland Dysglycemia Detection Program will occur for this study arm.
62589023|NCT06174298|EXPERIMENTAL|GCSF-Supplemented Embryo Transfer Media|"Intervention Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician."
62589024|NCT06174298|PLACEBO_COMPARATOR|Standard Embryo Transfer Media|"Control Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of standard embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Control Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of standard embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician."
62589025|NCT03687398||control|does not have endometriosis or related diseases and not under any drug therapy does not have any benign or malign disease
62589026|NCT03687398||patient|has laparoscopically proven endometriosis
62589027|NCT04717050|EXPERIMENTAL|Progressive combine training (PCT)|"Participants will be randomly assigned to Progressive combine training (PCT) group.~Participants will have two (2) baseline tests, then begin a two phase PCT program.~* Phase 1: Supervised 16-week resistance and cardiovascular exercise at a local YMCA (months 1-4) or remotely at home via Zoom~* Participants will receive midpoint testing, approximately week 8.~* Phase 2: Unsupervised 16-week resistance and cardiovascular exercise at a local YMCA (months 5-8) or remotely at home~* Participants will receive midpoint testing, approximately two months into phase 2.~After the two (2) 16-week phases, participants will be followed for 4 months."
62589028|NCT04717050|ACTIVE_COMPARATOR|Attention Control (AC)|"Participants will be randomly assigned to Attention Control (AC) group.~Two (2) baseline tests will be performed prior to starting the program. Participants will perform 12 months of home-based stretching and have a 1x test performed during months 2, 4, 6, 8 and 10. Two (2) tests will be performed in month 12."
62225449|NCT01834677||Healthy Human|
62225450|NCT01834677||Depressed Human|
62225451|NCT01834677||Depressed Human, Undergoing Electroconvulsive Therapy|Electroconvulsive Therapy is being received as standard of care, not as a study intervention.
62225452|NCT01834677||Human Diagnosed with Parkinson's Disease|
62225453|NCT01028937|EXPERIMENTAL|Hyperopia|The NTK Optimal Keratoplasty System/Procedure is indicated for the temporary improvement of distance uncorrected visual acuity (in patient eyes that have manifest refraction, spherical equivalent equal to +1.0 to +2.5 Diopters, with less than or equal to 0.75 Diopters of refractive astigmatism (minus cylinder format) and with uncorrected distance visual acuity less than 20/40 but greater than or equal to 20/80. Patients must be at least 40 years of age with a documented stability of refraction for the prior 12 months, as demonstrated by a change of less than or equal to 0.5 Diopters in MRSE. The magnitude of D-UCVA improvement by Opti-K treatment may diminish over time, caused by some regression of effect in addition to natural progressive loss of accommodation and, for most patients, progressive hyperopic shift with increasing age.
62225454|NCT03948555||Acute aortic dissection|stable patients with confirmed diagnosis of acute AD.
62225455|NCT03948555||Chronic aortic dissection|patients with diagnosis of chronic AD, being followed up in outpatient aortic clinic.
62026665|NCT02830594|EXPERIMENTAL|Treatment (pembrolizumab, RT)|"INITIAL TREATMENT: Patients undergo palliative external beam RT daily. On day 1, patients undergo the first RT fraction and then receive pembrolizumab intravenously (IV) over 30 minutes. Cycles repeat every 3 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity.~SECOND PHASE: Patients who achieve a complete response, stop study treatment, and then experience radiographic disease progression may be eligible for the second phase at the discretion of the investigator if no cancer treatment was administered since the last dose of pembrolizumab and trial eligibility safety parameters are met. Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 17 cycles in the absence of disease progression or unacceptable toxicity."
62026666|NCT00120393|ACTIVE_COMPARATOR|G1|
62026667|NCT00120393|ACTIVE_COMPARATOR|G2|
62026668|NCT01610323|EXPERIMENTAL|Exercise group|Exercise intervention
62026669|NCT01610323|OTHER|Control group|Standard care
62026670|NCT06175494|EXPERIMENTAL|Experimental group|Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
62026671|NCT06175494|ACTIVE_COMPARATOR|Control group|Recombinant COVID-19 Variant Vaccine（ Sf9 Cell）
62026672|NCT06175494|PLACEBO_COMPARATOR|Placebo control group|Placebo control
62026673|NCT03905226||Heart Failure|Patients whom initiated a hospital pathway for heart failure management within the Paris Saint Joseph Hospital Group (GHPSJ) between January 1, 2015 and December 31, 2018.
62225456|NCT02666846|EXPERIMENTAL|Cohort 1: TIB200 gel 10%|All Cohort 1 participants: TIB200 gel (10%, w/w ibuprofen)
62225457|NCT02666846|ACTIVE_COMPARATOR|Cohort 1: Nurofen gel 10%|All Cohort 1 participants: Nurofen Max Strength gel (10%, w/w ibuprofen)
62225458|NCT02666846|ACTIVE_COMPARATOR|Cohort 1: Nurofen tablets|All Cohort 1 participants: Nurofen oral tablets (2 x 400 mg ibuprofen)
62225459|NCT02666846|PLACEBO_COMPARATOR|Cohort 1: TIB200 Placebo gel|All Cohort 1 Participants: TIB200 matching placebo gel
62026674|NCT02393079|EXPERIMENTAL|Active helmet LED|Description of the intervention: 18 patients will undergo 18 sessions of transcranial LED therapy (ACTIVE HELMET) with 30 minutes duration each. The sessions take place over 6 weeks. The therapy will be performed with a helmet that covers the frontal and parietal region.
62026675|NCT02393079|SHAM_COMPARATOR|Sham group|Description of the intervention: 18 patients will undergo 18 sessions of transcranial LED therapy (INACTIVE HELMET) with 30 minutes duration each. The sessions take place over 6 weeks. The therapy will be performed with a helmet that covers the frontal and parietal region.
62026676|NCT03931577|EXPERIMENTAL|C-reactive protein rapid testing|Continuous (workshop and monthly web-based training) disease-focused intervention with the use of C-reactive protein rapid testing.
62026677|NCT03931577|EXPERIMENTAL|Enhancement of communication skills|Continuous (on-site and monthly online training) illness-focused intervention with enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets.
62026678|NCT03931577|EXPERIMENTAL|C-reactive protein + communication skills|Continuous (workshop and monthly web-based training) disease-focused intervention with C-reactive protein rapid testing and on-site and continuous (monthly online training illness-focused intervention) with enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets.
62225460|NCT02666846|ACTIVE_COMPARATOR|Cohort 2: DCF100 gel 2%|All Cohort 2 Participants: DCF100 gel (2% w/w diclofenac)
62225461|NCT02666846|EXPERIMENTAL|Cohort 2: DCF100 gel 4%|All Cohort 2 Participants: DCF100 gel (4% w/w diclofenac)
62225462|NCT02666846|ACTIVE_COMPARATOR|Cohort 2: Voltaren gel 2%|All Cohort 2 Participants: Voltaren Emulgel (2% diclofenac)
62225463|NCT02666846|ACTIVE_COMPARATOR|Cohort 2: Voltarol oral tablet|All Cohort 2 Participants: Voltarol oral tablet (50 mg - diclofenac)
62026679|NCT03931577|NO_INTERVENTION|Usual care|Usual care.
62026680|NCT06060171||Natural history|Natural history of the three common valvular lesions; aortic stenosis, aortic regurgitation and mitral regurgitation. Patients with mild, moderate and severe valvular heart disease (VHD) will be followed up at 1-year to measure progression in remodelling (hypertrophy, ischaemic, scar).
62225464|NCT02666846|PLACEBO_COMPARATOR|Cohort 2: DCF100 Placebo gel|All Cohort 2 Participants: DCF100 matching placebo gel
62225465|NCT02666846|ACTIVE_COMPARATOR|Cohort 3: SPR300 gel (15%:7%)|All Cohort 3 Participants: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)
62225466|NCT02666846|PLACEBO_COMPARATOR|Cohort 3: SPR300 Placebo gel|All Cohort 3 Participants: SPR300 matching placebo gel
62433527|NCT06458686|ACTIVE_COMPARATOR|Intervention group|This group will take Vitamin D
62418303|NCT06702345|EXPERIMENTAL|Cohort B (vancomycin pretreatment + TCD spores)|Volunteers in cohort B will be exposed first to 5 days of oral vancomycin pretreatment, 4 times a day 250mg, followed immediately by once a day capsule with 10\^4 CFU TCD spores for 12 days. First, a pilot group of 5 volunteers will be exposed to flag safety signals. If in this pilot group TCD exposure is well tolerated and less than 70% of the volunteers (\< 4 out of 5 volunteers) reaches a microbiological AND clinical endpoint, the trial will escalate to the third cohort, cohort C. If, however, in the pilot group TCD exposure is well tolerated and at least 70% of the volunteers (≥4 out of 5 volunteers) reaches a microbiological AND clinical endpoint, a confirmatory group of another 15 volunteers will be included in cohort B (total 20 volunteers). If in this total of 20 volunteers at least 70% (≥ 14 out of 20 volunteers) reaches a clinical AND microbiological endpoint, no further escalation to cohort C will be done. If, however, this is less then 70%, escalation continues to cohort C.
62800020|NCT05806320|NO_INTERVENTION|Control Group 2|"This group consisted of 15 infants with 33-36,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. Babies in this group were followed up at specified time intervals without any intervention.~If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. The baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00 hours; 11:00-11.30/13.45-14.15/17.00-17.30 hours; 11.30-11.45/14.15- 14.30/17.30-17.45."
62800021|NCT00035490|PLACEBO_COMPARATOR|1|Placebo tablets
62026681|NCT06060171||Multisystem impact of VHD|Patients with severe symptomatic VHD will undergo non-invasive brain and cardiac magnetic resonance imaging (MRI) plus other non-invasive imaging tests to quantify small blood vessels across the cardiovascular system at baseline and at 6 months after surgical aortic valve replacement at which point a myocardial biopsy is taken.
62026682|NCT06060171||Response to intervention.|Patients with severe symptomatic VHD undergoing intervention will be followed up at 6 months to assess reverse remodelling after valve intervention. In those undergoing open-heart surgery, a myocardial biopsy will be taken to validate and complement non-invasive imaging.
62026683|NCT04898608|EXPERIMENTAL|Exercise group|The patients will participate in intradialytic exercise 3 times a week for 24 weeks.
62800022|NCT00035490|EXPERIMENTAL|2|75 mg azimilide
62026684|NCT04898608|NO_INTERVENTION|Control group|The patients will receive regular care and treatment in every dialysis sessions without any intradialytic exercise.
62433528|NCT01399021|OTHER|Flat Davol drain|both arms will have flat davol drains placed at the end of the parotidectomy surgery
62433529|NCT05979051|EXPERIMENTAL|Treatment group A|SHR-1703
62589029|NCT00003762|EXPERIMENTAL|Arm I: docetaxel + gemcitabine|"Patients receive docetaxel IV over 1 hour on day 1 followed by gemcitabine IV over 30 minutes on days 1, 8, and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
62800023|NCT00035490|EXPERIMENTAL|3|125 mg azimilide
62800024|NCT05076201|EXPERIMENTAL|Patients with completed rehab|The aim of this research is to follow-up a cohort of patients at the end of their detoxification cure (cocaïne).
62800025|NCT01333228|EXPERIMENTAL|Endothelial Progenitors Cells|Autologous bone marrow-derived endothelial progenitor cells
62800026|NCT02285335|EXPERIMENTAL|Low group|GINST15 3g/day
62800027|NCT02285335|EXPERIMENTAL|High group|GINST15 6g/day
62225467|NCT02442492|ACTIVE_COMPARATOR|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
62225468|NCT02442492|PLACEBO_COMPARATOR|Placebo|Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
62225469|NCT00628264|EXPERIMENTAL|AP214|
62225470|NCT00628264|PLACEBO_COMPARATOR|Placebo|
62225471|NCT05035784|ACTIVE_COMPARATOR|Fecal supernatant|Fecal supernatant is used for treatment of childhood Constipation
62225472|NCT05035784|PLACEBO_COMPARATOR|non-Fecal supernatant|Placebo is used for treatment of childhood Constipation
62800028|NCT01952236|EXPERIMENTAL|Web+Mobile|A best-practices Web-based smoking cessation program integrated with a tailored treatment program delivered using a smartphone application.
62800029|NCT01952236|ACTIVE_COMPARATOR|Web Only|A best-practices Web-based smoking cessation program.
62800030|NCT02025179|EXPERIMENTAL|Teriparatide and vibration|"Experimental: Teriparatide and vibration~Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months~Device: Vibration 10 min/day for 12 months"
62589030|NCT00003762|EXPERIMENTAL|Arm II: docetaxel + gemcitabine|"Patients receive docetaxel IV over 1 hour and gemcitabine IV over 30 minutes on days 1 and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
62800031|NCT03154385|EXPERIMENTAL|arm 1|"Two intravenous perfusions of 1 g of Rituximab (Mabthera ®) at W0 and W2 coupled with 100 mg intravenous methylprednisone to avoid potential allergic reactions.~Five belimumab (Benlysta ®) injections will be administered (W0 + 2days, W2 + 2 days, W4, W8, W12) at 10mg/kg doses. The first two injections are administered 2 days after Rituximab perfusions. The adopted experimental scheme was once used to show use of belimumab in systemic lupus erythematosus in accordance with AMM regulation"
62800032|NCT05274386|OTHER|Averaging time 4to6 s|The SpO2 averaging time will be set to 4to6 s for the next 12 hours. All elements of care will be as routinely used, except the changing of the averaging time setting.
62225473|NCT06139016|EXPERIMENTAL|Treatment group|This single arm will include all participants of the study, who will all receive the intervention
62225474|NCT02628496|EXPERIMENTAL|Arm 1: CLM|"* On the day of surgery, participants will have placement of laser-safe endotracheal tube and a rigid laryngoscope will be introduced into the oral cavity to gain access to the laryngeal introitus and then placed into suspension (standard of care)~* Fluorescein dye will be administered intravenously~* Confocal laser probe will be introduced through the rigid laryngoscope and touched first on the lesion of concern and put into scanning mode in order to obtain photos and video footage of the lesions. The probe will then be placed on normal appearing vocal fold tissue to obtain a control sample.~* The remainder of the procedure is standard excisional biopsy and KTP laser photoablation"
62418304|NCT06702345|EXPERIMENTAL|Cohort C (clindamycin pretreatment + TCD spores)|Volunteers in cohort C will be exposed first to five days of oral clindamycin pretreatment, three times a day 600mg, followed immediately by once-a-day dosing of 104 CFU TCD spores (capsules) for 12 consecutive days. First, a small pilot group of five volunteers will be exposed to flag safety signals. If in this pilot group TCD exposure is well tolerated and less than 70% of the volunteers (\< 4 out of 5 volunteers) reaches a microbiological AND clinical endpoint, the trial will stop. If, however, in the pilot group TCD exposure is well tolerated and at least 70% of the volunteers (≥4 out of 5 volunteers) reaches a microbiological AND clinical endpoint, a confirmatory group of another 15 volunteers will be included in cohort C (total 20 volunteers), after which the trial will stop.
62418305|NCT03146507|OTHER|Normal pregnant women at 32-34 weeks group|
62418306|NCT03146507|OTHER|Intrauterine growth restriction at 32-34 weeks group|
62418307|NCT03394274||Transfusion|Patients (n:892) were enrolled who underwent elective major surgery between the 01/01/2016-31/12/2016, and over the age of 18 years. They separated subgroups as restrictive and liberal blood transfusion groups
62418308|NCT04676607|EXPERIMENTAL|treatment group|SHR7390
62589031|NCT00003762|EXPERIMENTAL|Arm III: docetaxel + gemcitabine|"Patients receive docetaxel IV on day 1 and gemcitabine IV on days 1, 8, and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
62589032|NCT00922506|EXPERIMENTAL|doxazosin plus tolterodine SR 2 mg|doxazosin plus tolterodine SR(2 mg, qd) for 12 weeks
62589033|NCT00922506|EXPERIMENTAL|doxazosin plus tolterodine SR 4 mg|doxazosin plus tolterodine SR(4 mg,qd) for 12 weeks
62800033|NCT05274386|OTHER|Averaging time 10 s|The SpO2 averaging time will be set to 10 s for the next 12 hours. All elements of care will be as routinely used, except the changing of the averaging time setting.
62800034|NCT05274386|OTHER|Averaging time 16 s|The SpO2 averaging time will be set to 16 s for the next 12 hours. All elements of care will be as routinely used, except the changing of the averaging time setting.
62225475|NCT02293148|EXPERIMENTAL|GSK1278863 (Part A)|All subjects will receive a single, oral 500 mg dose of GSK1278863 on Day 1 administered as 5 x 100 mg tablets of GSK1278863. Additional doses/cohorts may be added depending upon the emerging safety, tolerability, pharmacokinetic and/or pharmacodynamics findings at the 500 mg dose level in Part A
62418309|NCT03047031||All nintedanib treated patients (group B + group C)|
62418310|NCT03047031||Group II- pirfenidone patients|
62418311|NCT03047031||Group III - pirfenidone patients|
62418312|NCT05968703|EXPERIMENTAL|Vertical Nuclear Trajectory|Participants will receive combined STN + NBM DBS. The lead placed within the NBM will use a vertical trajectory targeting the nucleus itself.
62418313|NCT05968703|EXPERIMENTAL|Lateral NBM Bundle Trajectory|Participants will receive combined STN + NBM DBS. The lead placed within the NBM will use a lateral trajectory targeting the lateral efferent bundle from the NBM
62418314|NCT03466788|OTHER|Patients treated with chemotherapy|
62418315|NCT03466788|OTHER|Patients not treated with chemotherapy|
62418316|NCT06703905|ACTIVE_COMPARATOR|PD group|Traditional minimally invasive pancreaticoduodenectomy
62418317|NCT06703905|EXPERIMENTAL|expanded PD group|Traditional minimally invasive pancreaticoduodenectomy combined with the TRIANGLE procedure
62418318|NCT05268523|EXPERIMENTAL|Education and Strategies Intervention Group|Participants will use a videoconferencing system to participate in the Education and Strategies Intervention composed of 1 session per week (1.5 hrs/session) over the course of 8 weeks.
62418319|NCT05268523|ACTIVE_COMPARATOR|Mindfulness Skills Intervention Group|Participants will use a videoconferencing system to participate in the Mindfulness Skills Intervention composed of 1 session per week (1.5 hrs/session) over the course of 8 weeks.
62418320|NCT05268523|NO_INTERVENTION|No-Treatment Control Group|Participants adhere to the standard of care (no study treatment) for 8 weeks.
62433530|NCT05979051|PLACEBO_COMPARATOR|Treatment group B|SHR-1703 Placebo
62026685|NCT04450615|EXPERIMENTAL|Training group|"The first part of the program aims in pelvic and hip mobility and includes the following exercises, glute bridge, single-leg glute bridge, side-lying clam, side plank and side plank with hip abduction, on stable surface.~The second part consists of exercises for deep and superficial trunk muscles. In the first exercise the participants learn to activate the transversus abdominis muscle from the crook-lying position, by performing abdominal hollow. Other exercises include the front plank, trunk curl-up, trunk curl-up on stable surface and curl-up on unstable surface (Swiss ball).~The third part of the program consists of exercises for strengthening the lumbar multifidus muscle. The participants will perform prone trunk extension, superman exercise, quadruped diagonal arm and leg lift, single leg supine bridge and supine bridge on unstable surface (Swiss ball)."
62026686|NCT04450615|NO_INTERVENTION|Control group|The participants of this group will follow their typical daily routine
62026687|NCT05959850|EXPERIMENTAL|Experimental: Active|Ambroxol taken 3x daily. Variation in doses as follow-up progresses. For detailed information, see Intervention Description.
62026688|NCT05959850|PLACEBO_COMPARATOR|Placebo Comparator: Control|Glucose Placebo, taken 3x daily. Variation in doses as follow-up progresses. For detailed information, see Intervention Description.
62026689|NCT03016871|EXPERIMENTAL|Cohort A (nivolumab, etoposide, ifosfamide, carboplatin)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 14 days for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with CR or PR receive nivolumab for an additional 6 weeks. Patients with only SD after 6-week nivolumab treatment receive nivolumab for an additional 6 weeks or receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2 every 21 days for 6 weeks per physician/investigator's discretion. Patients with PD after 6-week nivolumab treatment or patients with PR, SD, or PD after 12-week nivolumab treatment receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
62225476|NCT02293148|EXPERIMENTAL|GSK1278863 (75 mg/500 mg)/Moxifloxacin 400 mg/Placebo (Part B)|Subjects will be assigned to one of four treatment sequences (A-1 x Moxifloxacin placebo tablet, 3 x 25 mg tablets of GSK1278863, 2 x GSK1278863 matched placebo; B-1 x Moxifloxacin placebo tablet, 5 x 100 mg tablets of GSK1278863; C-1 x Moxifloxacin placebo tablet, 5 x GSK1278863 matched placebo tablets; D-1 x 400 mg Moxifloxacin tablet, 5 x GSK1278863 matched placebo tablets) (ABDC, BCAD, CDBA, DACB) in accordance with the randomization schedule
62225477|NCT02303015||Danish germ cell cancer patients|Danish patients with germ cell cancer diagnosed from 1984 to 2007.
62225478|NCT01003574|OTHER|Control Arm|Control arm will receive standard care for risk of cardiac sequelae - a mailed, tailored (neither generic nor targeted) print summary of individualized information about the survivor's treatment, late effects risks, and recommended follow-up and lifestyle modifications.
62225479|NCT01003574|OTHER|Test Arm|Test arm will receive standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
62225480|NCT01548378|EXPERIMENTAL|High Dose|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
62225481|NCT01548378|EXPERIMENTAL|Middle Dose|Patients in this treatment group will receive 6mg NL003 respective in D0、14、28
62225482|NCT01548378|EXPERIMENTAL|Low Dose|Patients in this treatment group will receive 4mg NL003 in D0、14、28
62225483|NCT01548378|PLACEBO_COMPARATOR|Placebo|Patients in this group will receive normal saline respective in D0、14、18
62225484|NCT02075268|OTHER|10 mg, 30 mg|To compare PKPD of prasugrel 10 or 30 mg, 4 subjects will be given 10 mg of prasugrel (one tablet of 10 mg of Effient) on day 1 as a single oral dose and another 4 subjects will be given 30 mg of prasugrel (3 tablets of 10 mg of Effient) on day 1 as a single oral dose.
62225485|NCT00648154|EXPERIMENTAL|1|Letrozole Tablets 2.5 mg
62225486|NCT00648154|ACTIVE_COMPARATOR|2|Femara® Tablets 2.5 mg
62225487|NCT01124032|EXPERIMENTAL|ADHD adults|
62225488|NCT01124032|EXPERIMENTAL|healthy adults|
62225489|NCT01638494|EXPERIMENTAL|Colecalcium testing|administration of Colecalcium
62225490|NCT01774487|EXPERIMENTAL|Pentoxifylline|"All newly-diagnosed biliary atresia patients fulfilling the study's inclusion criteria will receive oral pentoxifylline, 20 mg/kg/day divided in three doses for a total of 90 days.~The hospital pharmacy will create a 20 mg/ml oral pentoxifylline solution using 400 mg pentoxifylline tablets and established compounding recipes."
62433531|NCT02086526|EXPERIMENTAL|Metformin|Metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.
62589034|NCT05150808|ACTIVE_COMPARATOR|Intervention IRS|Intervention IRS insecticide will be sprayed on the walls and ceilings of 8 clusters
62225491|NCT04262817|EXPERIMENTAL|E-cigarette flavor|In this arm, participants will receive two experimental e-cigarette flavors
62589035|NCT05150808|ACTIVE_COMPARATOR|Control IRS|WHO approved IRS insecticide will be sprayed on the walls and ceilings of 8 clusters
62026690|NCT03016871|EXPERIMENTAL|Cohort B (nivolumab, etoposide, ifosfamide, carboplatin)|Patients receive nivolumab IV over 30 minutes on cycle 1 (cycle 1 is 14 days), day 1 in the absence of disease progression or unacceptable toxicity. Beginning in cycle 2, patients receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
62026691|NCT06316843|EXPERIMENTAL|1500 Valacyclovir 200 Celecoxib|Treatment will consist of four blue 375mg valacyclovir capsules and one white 200 mg celecoxib capsule
62026692|NCT06316843|EXPERIMENTAL|750 Valacyclovir 200 Celecoxib|Treatment will consist of two blue 375mg valacyclovir capsules, two blue placebo capsules, and one white 200 mg celecoxib capsule
62026693|NCT06316843|PLACEBO_COMPARATOR|Matched Color Placebo Capsules|Treatment will consist of four blue placebo capsules and one white placebo capsule
62026694|NCT01194141|EXPERIMENTAL|Exercise training|Aerobic exercise training 45-60 min/3x/week/12 weeks
62026695|NCT06387563|EXPERIMENTAL|Group A: Abdominal activation using pressure biofeedback|"Group A PBF assisted abdominal muscle activation training (30 min, 3x /week /4 weeks) Progressive Muscle Relaxation for 5 min Pressure biofeedback assisted abdominal muscle activation training. Frequency: 25 min; 10 sec hold, 15 sec relax, 10 reps Progression criteria in training: Maintaining 3 - 5 mmHg pressure on PBF dial while performing abdominal muscle activation.~Exercises for Group For biofeedback assisted abdominal muscle activation training these exercises will be performed:~1. Supine abdominal muscle activation (45° Hip knee flexion)~2. Both hip and knee 90° flexion~3. One side hip and knee 90° flexion with other fully extended~4. One side hip and knee 90° flexion with other fully extended + heel 12 cm raised~5. Both legs fully extended with heel 12 cm raised~6. Partial curl ups~7. Prone lying abdominal muscle activation~8. Prone leg raises~9. Prone upper back extension simple~10. Prone reciprocal UE/LE exercises"
62026696|NCT06387563|EXPERIMENTAL|Group B: Abdominal activation using SEMG biofeedback|"GROUP B:~SEMG-BF assisted abdominal muscle activation training (30 min, 3x/ week/ 4 weeks) Progressive Muscle Relaxation for 5 min Surface EMG-BF assisted abdominal muscle activation training. Frequency: 25 min; 10 sec hold, 15 sec relax, 10 reps Maintaining minimal volumetric contraction of abdominal muscle activation (as per person) on SEMG device with abdominal muscle activation for set frequency~Exercises for Group B For biofeedback assisted abdominal muscle activation training these exercises will be performed:~1. Supine abdominal muscle activation (45° Hip knee flexion)~2. Both hip and knee 90° flexion~3. One side hip and knee 90° flexion with other fully extended~4. One side hip and knee 90° flexion with other fully extended + heel 12 cm raised~5. Both legs fully extended with heel 12 cm raised~6. Partial curl ups~7. Prone lying abdominal muscle activation~8. Prone leg raises~9. Prone upper back extension simple~10. Prone reciprocal UE/LE exercises"
62026697|NCT04873375|EXPERIMENTAL|Cemiplimab|After inclusion, all patients will be treated with Cemiplimab 350mg intravenously every three weeks
62026698|NCT01159496|EXPERIMENTAL|Active|
62026699|NCT01159496|PLACEBO_COMPARATOR|Placebo|
62026700|NCT00645398|EXPERIMENTAL|A|
62026701|NCT00645398|EXPERIMENTAL|B|
62225492|NCT04262817|EXPERIMENTAL|E-cigarette nicotine form|In this arm, participants will receive two forms of nicotine in an e-cigarette
62225493|NCT03660800|EXPERIMENTAL|CTAP101 Capsules 450mcg/weekly fasted|
62225494|NCT03660800|EXPERIMENTAL|CTAP101 Capsules 900mcg/weekly fasted|
62225495|NCT03660800|EXPERIMENTAL|CTAP101 Capsules 1800mcg/weekly fasted|
62225496|NCT03660800|EXPERIMENTAL|CTAP101 Capsules 900mcg/weekly fed|
62225497|NCT02344004|NO_INTERVENTION|Multi-drug Regimen|Participants received their already prescribed anti-mycobacterial regimen (based on the 2007 American Thoracic Society/Infectious Diseases Society of America \[ATS/IDSA\] Guidelines)
62418321|NCT05839119|EXPERIMENTAL|Treatment|"In patients with androgen receptor positive (AR+), pT2 - pT4, N0 - N1, M0 urothelial cell carcinoma (UCC) of the bladder. The study medication, Degarelix, will be administered concurrently with neoadjuvant gemcitabine/cisplatin.~* SOC Neoadjuvant Chemotherapy: Gemcitabine/Cisplatin 21-day cycles (4 cycles total)~* Gemcitabine: 1000 mg/m2 (IV) Days 1 and 8 of each cycle~* Cisplatin: 70 mg/m2 (if borderline renal function: 35 mg/m2) (IV) Day 1 of each cycle (if borderline renal function, days 1 and 8 of each cycle).~* Study Medication: Degarelix (SC) Every 28-days (3 cycles total) Day -7 to -2 of cycle 1, then as defined in the study calendar (approximately q28 days). initial dose is 240 mg administered as two 120 mg (3 mL) injections (SC), followed by subsequent doses at 80 mg (4 mL) administered as one injection (SC)"
62589036|NCT04977336|EXPERIMENTAL|VX-548|Participants will be randomized to receive different dose levels of VX-548.
62589037|NCT04977336|ACTIVE_COMPARATOR|Hydrocodone bitartrate/acetaminophen (HB/APAP)|Participants will receive HB/APAP.
62026702|NCT00645398|EXPERIMENTAL|C|
62026703|NCT00645398|PLACEBO_COMPARATOR|D|
62026704|NCT00941187||patients after a first episode of pulmonary embolism|
62026705|NCT02978365|EXPERIMENTAL|Patients|Male patients who undergone shoulder surgery to repair chronic instability (at least 1 shoulder dislocation prior to surgery). Time since surgery will be between 26 and 28 weeks. Patients will go through filling questionnaires and isokinetic strength measurements.
62225498|NCT02344004|EXPERIMENTAL|LAI + Multi-drug Regimen|"Participants received LAI 590 mg QD in addition to their already prescribed anti-mycobacterial regimen (based on the 2007 ATS/IDSA Guidelines)~LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes"
62225499|NCT02274818|NO_INTERVENTION|Standard Duty Hour Schedule|IM programs randomized to the currently mandated duty 16 hour standards (maximum work duration of 16 hours for interns and 28 hours for PGY2-3); this schedule may involve night float.
62225500|NCT02274818|EXPERIMENTAL|Flexible Duty Hour Schedule|"IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:~* No more than 80 hours of work per week (when averaged over 4 weeks)~* 1 day off in 7 (when averaged over 4 weeks)~* In-house call no more frequently than every 3rd night (when averaged over 4 weeks)"
62225501|NCT00669994|EXPERIMENTAL|Arm 1|
62225502|NCT03898401|EXPERIMENTAL|1 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62418322|NCT04489888|EXPERIMENTAL|Pembrolizumab + Carboplatin + Paclitaxel|Participants will receive pembrolizumab plus carboplatin plus paclitaxel. Pembrolizumab will be administered via intravenous (IV) infusion at a dose of 200 mg on Day 1 of each 21-day cycle for up to 35 cycles (up to \~2 years). Carboplatin will be administered via IV infusion at area under curve (AUC) 5 mg/mL/minute on Day 1 of each 21-day cycle for up to 6 cycles (up to \~4 months). At investigator's choice, paclitaxel will be administered via IV infusion at a dose of 100 mg/m\^2 on Day 1 and Day 8 of each 21-day cycle for up to 6 cycles (up to \~4 months) or at a dose of 175 mg/m\^2 on Day 1 of each 21-day cycle for up to 6 cycles (up to \~4 months).
62418323|NCT02341976|OTHER|Vibratory platform exercises|Vibratory platform exercises: different positions on a vibratory platform in different frequencies
62418324|NCT02507115|EXPERIMENTAL|TMAP|Alcohol-related Text messages 4 days/week for 6 weeks
62418325|NCT02507115|SHAM_COMPARATOR|Control|Motivational Text messages 4 days/week for 6 weeks
62418326|NCT02936479|EXPERIMENTAL|Berinert treatment|
62418327|NCT04534088|ACTIVE_COMPARATOR|Standard Behavioral Weight Loss plus Non-Weight-Related VR app|The VR tool was an attention control and was not weight related.
62418328|NCT04534088|EXPERIMENTAL|Standard Behavioral Weight Loss plus Weight-Related VR app|The Intervention's VR tool was designed to enable practice of behavioral skills taught in weekly group meetings, including managing social and home environmental cues for eating and activity.
62418329|NCT03574194|EXPERIMENTAL|Methionine-restricted diet|6-10 weeks methionine-restricted diet (MRD) curative intent radiation therapy course of 6 weeks or less.
62418330|NCT05340023||Patient with suspicion of Chronic ThromboEmbolic Pulmonary Hypertension (CTEPH)|"* right cardiac catheterization (usual practice)~* a blood sample (inclusion for all patients with suspicion)~* if diagnosis of Chronic thromboembolic pulmonary hypertension confirmed a another bood sample at 6 months"
62418331|NCT02515981|EXPERIMENTAL|Incentives|Participants randomly assigned to the incentive arm, will receive cash incentives for engaging in healthy lifestyle behaviors.
62418332|NCT02515981|EXPERIMENTAL|No Incentives|Participants randomly assigned to the no incentives arm, will not receive cash incentives for engaging in healthy lifestyle behaviors.
62026706|NCT04862143|EXPERIMENTAL|Alpelisib + fulvestrant|Participants were administered alpelisib at a daily dose of 300 mg for 12 cycles of 28 days and fulvestrant at a dose of 500 mg via intramuscular injection on Cycle 1 Day 1 and Cycle 1 Day 15, and Day 1 of each subsequent cycle up to Cycle 12. Pre-menopausal women also received goserelin at a dose of 3.6 mg on Day 1 of each cycle.
62026707|NCT01244152|EXPERIMENTAL|Intervention|
62026708|NCT01244152|ACTIVE_COMPARATOR|Control Group|
62026709|NCT01640691|EXPERIMENTAL|Study vaccine (AdimFlu-W)|0.5 mL/dose, a total of 2 doses, 21 days apart
62418333|NCT05445778|EXPERIMENTAL|Arm 1|Mirvetuximab Soravtansine (MIRV) plus Bevacizumab
62418334|NCT05445778|ACTIVE_COMPARATOR|Arm 2|Bevacizumab monotherapy
62418335|NCT00953927|EXPERIMENTAL|Investigational Vaccine|MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.
62418336|NCT00953927|PLACEBO_COMPARATOR|Control Group|Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.
62418337|NCT03273712|EXPERIMENTAL|90Y-DOTA-tyr3-Octreotide|Patients will receive 3 doses of 90YDOTATOC followed by 90Y-DOTATOC PET scans, with 6 -8 weeks between doses. They will be followed for 6-9 months after the last treatment dose. CT or MRI scans will be given at the 3 month and 6-9 month followups plus a 68Ga-DOTATOC or DOTATATE PET scan at the 6-9 month followup. The exact dose of 90YDOTATOC therapy for each patient will be determined by dosimetry.
62418338|NCT06567990|OTHER|Patients with T2D and MASLD without advanced fibrosis (AF) (COHORT A)|Patients with T2D and MASLD without advanced fibrosis (AF) at baseline in the NAFLD-Care study
62026710|NCT04247854|ACTIVE_COMPARATOR|Probiotic|
62026711|NCT04247854|PLACEBO_COMPARATOR|No intervention|
62026712|NCT03089424|PLACEBO_COMPARATOR|Placebo PBMT|Application of PBMT (Photobiomodulation Therapy) without any dose (0 Joule) and The Back Book (educational information booklet).
62800035|NCT06147999|EXPERIMENTAL|Treatment Group|The 14 active Biophoton Generators packed with the same 32-Oz metal can will be labeled with a code and placed under a hotel bed. Each participant will rest on the bed during the entire study period for 4 weeks. Participants will receive biophotons inside of the biophoton field generated by 14 active Biophoton Generators
62800036|NCT06147999|PLACEBO_COMPARATOR|Control Group|The 14 inactive Biophoton Generators packed with the same 32-Oz metal can will be labeled with a code and placed under a hotel bed. Each participant will rest on the bed during the entire study period for the first 2 weeks. Then will be switched to the active treatment group for being treated for 4 weeks. Participants will receive placebo effect from the 14 inactive comparators.
62800037|NCT06423456|ACTIVE_COMPARATOR|Research group|During the procedure, intravenous lidocaine of 0.15 ml/kg 1% will be administered intraoperatively before general anesthesia and infusion of lidocaine of 1%(at a dose of 0.2 ml/kg/hour) will be performed during the procedure.
62800038|NCT06423456|PLACEBO_COMPARATOR|Control group|In the control group, 0.9% saline solution will be used instead of lidocaine.
62800039|NCT02551341|NO_INTERVENTION|control|normal ventilation
62800040|NCT02551341|EXPERIMENTAL|intervention|higher PEEP ventilation
62800041|NCT05701293||LEAD patients undergoing endovascular treatment with implantation of Renzan stent|
62800042|NCT00549315|EXPERIMENTAL|1|
62800043|NCT02348593|ACTIVE_COMPARATOR|75 mg of JZP-110|Once Daily Dosing
62800044|NCT02348593|ACTIVE_COMPARATOR|150 mg JZP-110|Once Daily Dosing
62800045|NCT02348593|ACTIVE_COMPARATOR|300 mg of JZP-110|Once Daily Dosing
62800046|NCT02348593|PLACEBO_COMPARATOR|Placebo|Once Daily Dosing
62800047|NCT06175481||control group|
62026713|NCT03089424|ACTIVE_COMPARATOR|PBMT active|Application of PBMT (Photobiomodulation Therapy) active and The Back Book (educational information booklet).
62225503|NCT03898401|EXPERIMENTAL|2 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62418339|NCT06567990|OTHER|Patients with T2D and MASLD, without diagnosis of cirrhosis (COHORT B)|Patients with T2D and MASLD with presence of advanced fibrosis (AF) and without cirrhosis at baseline in the NAFLD-Care study
62418340|NCT03891875|EXPERIMENTAL|Elamipretide|Once daily 40 mg subcutaneous injection of elamipretide using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.
62800048|NCT06175481||experimental group|
62800049|NCT04317040|EXPERIMENTAL|Efprezimod alfa|Participants receive single dose of 480 mg efprezimod alfa, diluted to 100 ml with normal saline, intravenous (IV) infusion in 60 minutes on Day 1.
62800050|NCT04317040|PLACEBO_COMPARATOR|Placebo|Participants receive single dose of placebo as normal saline solution 100 ml, IV infusion in 60 minutes, on Day 1.
62800051|NCT04188938||Occult pneumothorax in trauma patients|Age\>16, multi-trauma, consulted thoracic surgeon, underwent CXR- CT.
62800052|NCT05201508|ACTIVE_COMPARATOR|Sutures only|Traditional suture closure of hiatal defect
62026714|NCT02878993||Intubated infants|Recording of diaphragm EMG
62225504|NCT03898401|EXPERIMENTAL|3 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62589038|NCT04977336|PLACEBO_COMPARATOR|Placebo|Participants will receive placebos matched to VX-548 and HB/APAP.
62800053|NCT05201508|EXPERIMENTAL|Polyglactin mesh|In addition to traditional sutures, key hole polyglactin mesh for hiatal defect closure.
62800054|NCT02336230|EXPERIMENTAL|Remestemcel-L 2×10^6 MSCs/kg|Participants were treated with intravenous (IV) remestemcel-L at a dose of 2×10\^6 mesenchymal stromal cells (MSCs)/kilogram (kg) actual body weight at Screening, twice per week, for each of 4 consecutive weeks (initial therapy) given at least 3 days apart and no more than 5 days apart for any infusion. Eligible participants received an additional once per week infusion, for each of 4 consecutive weeks (continued therapy) of remestemcel-L and twice per week infusions, for each of 4 consecutive weeks (aGVHD flare therapy) of remestemcel-L at the same initial therapy dose of 2×10\^6 MSCs/kg actual body weight at Screening.
62800055|NCT01574274|ACTIVE_COMPARATOR|SC-PEG (Arm A)|Patients in this arm were randomized to receive IV Calaspargase Pegol (SC-PEG) 2500 IU/m2, administered as a single dose during induction and for 30 weeks post-induction. In the post-induction phases, IV SC-PEG was administered every 3 weeks (for a total of 10 post-induction doses). Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, and Continuation, and varied based off risk classification.
62800056|NCT01574274|ACTIVE_COMPARATOR|Oncaspar (Arm B)|Patients in this arm were randomized to receive IV Oncaspar 2500 IU/m2, administered as a single dose during induction and for 30 weeks post-induction. In the post-induction phases, IV Oncaspar was administered every 2 weeks (for a total of 15 post-induction doses). Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, and Continuation, and varied based off risk classification.
62800057|NCT01186185|EXPERIMENTAL|Fludrocortisone|
62800058|NCT04947696||1|Patients undergoing a Whipples procedure for pancreatic cancer
62800059|NCT00490269|ACTIVE_COMPARATOR|Dronabinol|
62800060|NCT00490269|PLACEBO_COMPARATOR|Placebo|
62800061|NCT00502671|EXPERIMENTAL|1|
62800062|NCT01459484|EXPERIMENTAL|Mifamurtide arm|Chemotherapy for patients who over express ABCB1/P-glycoprotein (methotrexate, cisplatinum, doxorubicine, ifosfamide + mifamurtide)
62800063|NCT01459484|OTHER|3 drugs arm|High grade osteosarcoma treatment for patients who do not over express ABCB1/P-glycoprotein
62800064|NCT03371693|EXPERIMENTAL|HIPEC|"Patients will undergo a CRS plus HIPEC and IVCT. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the abdominal cavity is bathed in a warm solution of anti-cancer medications for 60 minutes.~A single drug lobaplatin(30mg/m2)will be administered in normal saline via HIPEC and it will be continued for 60 minutes in the hyperthermic phase (41°C-43°C). HIPEC will be performed at the 1st, 3rd and 5th day after CRS. The intravenous chemotherapy(IVCT) will start from 7th-14th day after CRS."
62026715|NCT01511952|ACTIVE_COMPARATOR|Music intervention- SGA|Infants will be randomly assigned to receive one of three music interventions randomized for the AM or PM
62026716|NCT01511952|ACTIVE_COMPARATOR|Music Intervention- RDS|Infants will be randomly assigned to receive music-one of 3 randomized interventions in the AM or PM
62026717|NCT01511952|ACTIVE_COMPARATOR|Music Intervention- Sepsis|Infants randomly assigned to receive one of three interventions-randomized for the AM or PM
62026718|NCT05827367|EXPERIMENTAL|high power pain thershold ultrasound|"Patients will reseiv high power pain ultrasound~,intrinsic muscle strength and plantar fascia streatching"
62026719|NCT05827367|EXPERIMENTAL|myofascial release|Plantar fascia myofascial release,gastrocnmias Myofascial release ,soluse myofascial release,foot interstice muscle strength and plantar fascia streatching
62026720|NCT05827367|PLACEBO_COMPARATOR|control arm|Plantar fascia stretching and foot interstice muscle strength
62026721|NCT06043921||Unresectable Pancreatic Cancer|
62026722|NCT06043921||Resectable Pancreatic Cancer|
62026723|NCT02255175|EXPERIMENTAL|Perimenopausal women, depressed|Participants will receive transdermal estradiol (100μg/day) for 3 weeks. Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
62026724|NCT02255175|ACTIVE_COMPARATOR|Perimenopausal women, non-depressed|Participants will receive transdermal estradiol (100μg/day) for 3 weeks. Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
62026725|NCT01518205|EXPERIMENTAL|LDL-apheresis and TT|"The patient of the experimental Arm, in addition to Traditional Therapy (TT), will undergo a cycle of 10 LDL-apheresis session.~Apheretic treatment scheme: 10 apheretic session carried out as follow: first and second apheresis with a 3 days interval (i.e. 2 treatment in one week), then one session per week (every 7 days).~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used."
62026726|NCT01518205|NO_INTERVENTION|Traditional Treatment|"All patients will receive the traditional treatment for the ulcer healing Standardized medication.~All lesions taken into consideration will be treated in a standardized way, with a different approach according to the presence of a possible infection.~The evolution of lesions might be documented by means of mapping the same by drawing their profiles on an Opsite film.~antibiotics therapy (according to antibiogram). Anti-platelet therapy. Statin therapy."
62026727|NCT02601313|EXPERIMENTAL|Axicabtagene ciloleucel/brexucabtagene autoleucel (KTE-X19)|Participants with relapsed/refractory mantle cell lymphoma (MCL) will receive conditioning chemotherapy (CTE) consisting of fludarabine 30 mg/m\^2/day and cyclophosphamide 500 mg/m\^2/day intravenous (IV) infusion for 3 days followed by a single infusion of axicabtagene ciloleucel at a targeted dose of 2 x 10\^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg on Day 0 or brexucabtagene autoleucel (KTE-X19) at a targeted dose of 2 x 10\^6 CAR T cells/kg, with a maximum dose of 2 x 10\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 1 or brexucabtagene autoleucel at a targeted dose of 0.5 x 10\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 2.
62026728|NCT06205511||Main Group|Single group, observational cross-sectional cohort.
62026729|NCT03571061|ACTIVE_COMPARATOR|whole colon water immersion group|whole colon water immersion group: the air supply was turn off until the cecum was reached. For adequate lumen distention to advance the colonoscope tip, warm water which stored in 1L bottles and maintained 37°C with a water bath, was instilled intermittently into the colon through the auxiliary working channel of colonoscope using a footswitch-controlled flushing pump
62026730|NCT03571061|EXPERIMENTAL|sigmoid water immersion group|sigmoid water immersion group: air pump would be turned off and the procedure would be switched from water immersion method to air insufflation method after successful passage through the descending sigmoid junction.
62026731|NCT03571061|PLACEBO_COMPARATOR|carbon dioxide (CO2) insufflation|carbon dioxide (CO2) insufflation group: carbon dioxide (CO2) was insufflated through out the whole procedure for advancement and inspection when needed.
62589039|NCT06684171|EXPERIMENTAL|Echocardiography-guided group|Patients randomized to the echocardiography-guided group will undergo TEER procedure under fully echo guidance.
62589040|NCT06684171|ACTIVE_COMPARATOR|Fluoroscopy-guided group|Patients randomized to the fluoroscopy-guided group will undergo TEER procedure under combined guidance of X ray and echo.
62589041|NCT01281670|NO_INTERVENTION|No vibration|
62026732|NCT04093622||Genetically engineered NK Cell - treated|Long term follow-up of subjects who have received lentivirus-mediated genetically engineered NK Cells.
62589042|NCT01281670|ACTIVE_COMPARATOR|vibration|
62589043|NCT01421225|ACTIVE_COMPARATOR|Standard Insulin Pump Therapy first, then Closed Loop|Standard therapy day 1, Closed-Loop therapy day 2.
62589044|NCT01421225|ACTIVE_COMPARATOR|Closed Loop first, then Standard Insulin Pump Therapy|Closed-loop therapy day 1, standard therapy day 2.
62589045|NCT06435143|OTHER|Patient with pressure injury stage 1 and stage 2|Patient admitted to hospital with a confirmed stage 1 and 2 pressure injuries. Prelivia device will be applied to skin around pressure injury. Intermittent electrical stimulation will be administered for 10 seconds every 10 minutes to improve blood flow and muscle contraction to the area, simulating movement
62589046|NCT02230696|EXPERIMENTAL|Test Product|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray - Perrigo
62026733|NCT03701724|EXPERIMENTAL|Systematic maintenance rTMS (arm A)|Active rTMS treatment followed, for responders, by systematic maintenance rTMS Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT...)
62026734|NCT03701724|EXPERIMENTAL|rTMS course in case of relapse (arm B)|Active rTMS treatment followed, for responders, by additional rTMS courses, in case of relapse Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT...)
62026735|NCT03701724|SHAM_COMPARATOR|Sham rTMS (arm C)|sham rTMS followed, for responders, by either systematic sham mTMS (50%) or additional sham rTMS course in case of relapse(50%) Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT...)
62026736|NCT01788683|ACTIVE_COMPARATOR|Regenexx SD|Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged tendon.
62589047|NCT02230696|ACTIVE_COMPARATOR|Reference Product|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray - Meda
62589048|NCT02230696|PLACEBO_COMPARATOR|Placebo Product|Placebo nasal spray
62589049|NCT03603730|EXPERIMENTAL|taVNS|Active or inactive taVNS
62800065|NCT03371693|OTHER|Non HIPEC|Patients will undergo only CRS and IVCT. Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS.
62026737|NCT01788683|ACTIVE_COMPARATOR|Exercise Therapy|Subjects will be instructed in a set of appropriate rotator cuff strengthening exercises and given an instructional hand-out to take home.
62225505|NCT03898401|EXPERIMENTAL|4 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62589050|NCT06667479|EXPERIMENTAL|Cold Tub Immersion Group (CI)|Participants will utilize the research cold tub (10 ºC, 4-minutes, 3 times a week), following a standardized protocol (see intervention description).
62589051|NCT06667479|EXPERIMENTAL|Cold Shower Group (CS)|Participants will utilize the research shower area (10 ºC, 4-minutes, 3 times a week), following a standardized protocol (see intervention description).
62589052|NCT06667479|OTHER|Control Group (CO)|Participants will not undergo any cold tub or cold shower intervention.
62589053|NCT04068376|ACTIVE_COMPARATOR|Control group (C-GR)|Control group of an aerobic-balance-stretching exercise program led by a coach for 24 weeks (C-GR).
62589054|NCT04068376|EXPERIMENTAL|T1-GR training sessions by health professional|The T1-GR will consist of 60-minute training sessions delivered three days a week during a 24-week period. Each session will be guided by a health professional with a nursing background previously certified to coach SSE trainings by the Institute of Square-Stepping Exercise in Mie, Japan (Chief Tomohiro Okura and Overseas Director Professor Ryosuke Shigematsu).
62589055|NCT04068376|EXPERIMENTAL|T2-GR older adults and their caregivers|"In the case of T2-GR, older adults and their caregivers will participate in the same SSE program led by a coach for 12 weeks; older adults will then be asked to continue SSE at home under the supervision and with the active participation of their caregivers for another 12 weeks. They will be asked to practice SSE for 60 minutes, three times a week, and to reach a ≥65% heart rate increase. In the field of sports, the people who perform the above-mentioned activities are called pacers, and they supervise physical activity through active accompaniment of older adults."
62589056|NCT02161237|EXPERIMENTAL|standard dose group|Oral
62026738|NCT05512494|EXPERIMENTAL|Quadrivalent Influenza Vaccine (Split Virion), inactivated Lot 1|420 participants including 120 subjects aged 9-17 years and 300 subjects aged 18-59 years will receive one dose of quadrivalent influenza vaccine of commercial scale production lot 1.
62026739|NCT05512494|EXPERIMENTAL|Quadrivalent Influenza Vaccine (Split Virion), inactivated Lot 2|420 participants including 120 subjects aged 9-17 years and 300 subjects aged 18-59 years will receive one dose of quadrivalent influenza vaccine of commercial scale production lot 2.
62026740|NCT05512494|EXPERIMENTAL|Quadrivalent Influenza Vaccine (Split Virion), inactivated Lot 3|420 participants including 120 subjects aged 9-17 years and 300 subjects aged 18-59 years will receive one dose of quadrivalent influenza vaccine of commercial scale production lot 3.
62026741|NCT03057548|ACTIVE_COMPARATOR|Pulmonary Vein Isolation (PVI)|"Cryoablation only of Pulmonary Veins~or~Radiofrequency ablation only of Pulmonary Veins~Pulmonary Vein Isolation (PVI) alone."
62589057|NCT02161237|EXPERIMENTAL|optimized dose group|Oral
62026742|NCT03057548|EXPERIMENTAL|PVI & Posterior Left Atrial Ablation|"Cryoablation of Pulmonary Veins plus RF ablation of Posterior Left Atrial Wall~or~Radiofrequency ablation of Pulmonary Veins plus RF ablation of Posterior Left Atrial Wall~PVI ablation plus ablation of the Posterior Left Atrial Wall (PLAW)"
62026743|NCT01276587|EXPERIMENTAL|Single arm|
62026744|NCT06035133|EXPERIMENTAL|radiotherapy removal TNT plus group|Six induction chemotherapy rounds of the CapeOX regimen were administered. RAS, BRAF, and MSI were found when the first patients were examined. Patients were given CapeOX + cetuximab for RAS wild-type patients, CapeOX + bevacizumab for RAS mutant patients, and CapeOX + cetuximab for MSI-H patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks. A surgical procedure was carried out two weeks after consolidation chemotherapy ended.
62026745|NCT04148248||Patients|Patients with a diagnosis of chronic constipation
62026746|NCT00254982|EXPERIMENTAL|Group 1 (high-need)|Adult participants with moderate to severe plaque psoriasis who were either not controlled by, or were intolerant to or had contraindications to at least two currently available systemic therapies (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).
62225506|NCT03898401|EXPERIMENTAL|5 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62225507|NCT03898401|EXPERIMENTAL|6 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62418341|NCT03891875|PLACEBO_COMPARATOR|Placebo|Once daily subcutaneous injection of placebo using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.
62589058|NCT03100968|ACTIVE_COMPARATOR|Palpation Group|The palpation group will have an epidural placed after manual palpation of the spine.
62589059|NCT03100968|ACTIVE_COMPARATOR|Ultrasound Group|The ultrasound group will have an epidural placed after identifying midline with the ultrasound.
62589060|NCT00981669|EXPERIMENTAL|rotavirus vaccine|3 doses with 6 weeks interval
62589061|NCT00981669|PLACEBO_COMPARATOR|placebo|3 doses with 6 weeks interval
62800066|NCT03071887|EXPERIMENTAL|Intervention|Treatment arm - Relaxation Response Resiliency Program (3RP) (this is an open pilot; the treatment arm is the only arm)
62800067|NCT01055561|EXPERIMENTAL|Patients|
62026747|NCT00254982|EXPERIMENTAL|Group II (low-need)|Adult participants with moderate to severe plaque psoriasis who had undergone pretreatment with no more than one currently available systemic therapy (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).
62589062|NCT04739072||Ancillary-correlative (biospecimen collection)|Patients undergo collection of blood samples at baseline, during each neoadjuvant therapy treatment, prior to surgical resection, and up to 4 times per year for up to 5 years. Patients also undergo collection of tissue sample at time of surgical resection. Patients medical records may also be reviewed.
62589063|NCT01257763|EXPERIMENTAL|Study device|The study device is a transdermal microneedle array designed to introduce microscopic channels into the skin. The study device arm will receive application of this device.
62800068|NCT01055561|EXPERIMENTAL|Healthy volunteers|
62800069|NCT02807207|EXPERIMENTAL|Sequence I|treatment sequence: A/B/C
62800070|NCT02807207|EXPERIMENTAL|Sequence II|treatment sequence: A/C/B
62800071|NCT02807207|EXPERIMENTAL|Sequence III|treatment sequence: B/A/C
62589064|NCT01257763|SHAM_COMPARATOR|Sham device|The sham device will be very similar in appearance to the study device. The sham device arm will receive application of this device.
62589065|NCT03991650||Control|"n=30 healthy participants will be recruited using social networks and leaflets of information distributed by the research team at the Hospital Cliníc de Barcelona.~The participants will be monitored over the course of one month using the humanITcare app U-Shine, which will track participant's sociability, device usage, and location frequency using mobile sensors. Participants' data will also be monitored with a FitBit device to track sleep schedules, heart rate, and step count. During the weekly follow-up, they will have to complete the three clinical questionnaires taken at the initial visit."
62589066|NCT03991650||Experimental|"The recruitment process will be carried out in patients of external consultations and the day hospital of the Addictions Unit at the Hospital Clinic of Barcelona.~n=30 patients with Anxiety and Alcohol Use Disorder.~The participants will be monitored over the course of one month using the humanITcare app U-Shine, which will track participant's sociability, device usage, and location frequency using mobile sensors. Participants will also be monitored using a FitBit device to track sleep schedules, heart rate, and step count. During the weekly follow-up, they will have to complete the three clinical questionnaires taken at the initial visit."
62800072|NCT02807207|EXPERIMENTAL|Sequence IV|treatment sequence: B/C/A
62800073|NCT02807207|EXPERIMENTAL|Sequence V|treatment sequence: C/A/B
62800074|NCT02807207|EXPERIMENTAL|Sequence VI|treatment sequence: C/B/A
62800075|NCT04832932||80 years of age or older|Individuals 80-89, 90-99, 100 years of age and older who received COVID-19 vaccine
62589067|NCT06321861|EXPERIMENTAL|Caffeine|Participants will take a caffeine pill (3mg/kg of body mass) 60 minutes before the physical exercise test.
62589068|NCT06321861|PLACEBO_COMPARATOR|Placebo|Participants will take a placebo pill 60 minutes before the physical exercise test.
62225508|NCT03898401|EXPERIMENTAL|7 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62589069|NCT06321861|OTHER|No substance|Participants receive no pills in this condition before the physical exercise test.
62589070|NCT04308499|EXPERIMENTAL|Digital cognitive-behavioral therapy for insomnia (dCBTI)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) structured into 6 weekly sessions
62589071|NCT04308499|ACTIVE_COMPARATOR|Sleep hygiene education (SHE)|Recognized and commonly prescribed set of sleep hygiene instructions
62589072|NCT04163133|EXPERIMENTAL|two days delay of trigger group|Two days later of trigger than regular trigger timing day (three follicles reach 17mm) .
62800076|NCT04832932||60-79 years of age|Individuals 60-69 and 70-79 years of age who received COVID-19 vaccine
62800077|NCT04832932||40-59 years of age|Individuals in 40-49, 50-59 age range who received COVID-19 vaccine
62800078|NCT04832932||18-39 years of age|Individuals in 18-29, 30-39 age range who received COVID-19 vaccine
62800079|NCT04832932||MEBO/PATM|Individuals with present or past MEBO/PATM symptoms who received COVID-19 vaccine
62800080|NCT04832932||Chronic Disease|Individuals with self-reported chronic health conditions who received COVID-19 vaccine
62800081|NCT04291573|ACTIVE_COMPARATOR|HD-tDCS and Virtual Reality Therapy|Patients will receive their usual rehabilitation program each day, which includes a conventional session (30min) and virtual reality therapy session (Armeo Spring) combined with real stimulation (30min) over 13 consecutive training days (3 weeks)
62800082|NCT04291573|SHAM_COMPARATOR|Sham stimulation and Virtual Reality Therapy|Patients will receive their usual rehabilitation program each day, which includes a conventional session (30min) and virtual reality therapy session (Armeo Spring) combined with Sham stimulation (30min) over 13 consecutive training days (3 weeks)
62800083|NCT02172638|EXPERIMENTAL|FAST-TRACK Group|Patients in this group will be managed according to an specifically designed FAST-TRACK protocol which will include: Preoperatory nutritional management and coaching by surgeon, anesthetist, nutritionist and specifically trained nurse personnel, reduced preoperatory fasting, avoiding use of intraabdominal drainages, specific anesthetic management to reduce intraoperative stress, avoiding use of Nasogastric tube, avoiding the need for major opioid in postoperatory analgesia and use of an standardized postoperatory management protocol directed to obtain an early oral intake and mobilization with a the goal of normal diet and deambulation in the 3rd day after surgery.
62800084|NCT02172638|ACTIVE_COMPARATOR|Classical management group|Patients assigned to this group will receive the standard management preformed in our center until now. This management includes a preoperatory control exclusively by the surgeon and anesthetist, minimum of 8h fasting previous to surgery, loose use of intraabdominal drainage , systematic use of nasogastric tube whenever rectum resection or omentectomy is performed, Postoperative analgesia following standing Vall d'Hebron protocols for Moderate-severe postoperative pain, which include use of combined analgesia with non opioids drugs and major Opioids, and usual flexible, non standardized postoperatory management with mobilization and oral intake progression depending on perceived evolution by attending surgeon.
62800085|NCT00354679|EXPERIMENTAL|Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, & Surger|"Induction therapy: Patients receive cisplatin IV over 30 minutes and irinotecan hydrochloride IV over 30 minutes on days 1, 8, 22, and 29. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 22.~Combination therapy and radiotherapy: Patients receive cisplatin and irinotecan hydrochloride as in induction chemotherapy on days 43, 50, 64, and 71. Patients also receive bevacizumab IV over 30-90 minutes on days 43 and 64. Patients undergo external beam radiotherapy 5 days a week for 6 weeks beginning on day 43. Surgery: Patients undergo surgery 6-8 weeks after finishing combination therapy and radiotherapy.~Maintenance therapy: Approximately 6 weeks after surgery, patients receive bevacizumab IV over 30-90 minutes every 3 weeks for 6 months"
62800086|NCT02093793|EXPERIMENTAL|High Rate Spinal Cord Stimulation|PRECISION SCS Adapted for High-Rate SCS
62800087|NCT02093793|ACTIVE_COMPARATOR|Commercial Rate Spinal Cord Stimulation|PRECISION SCS Adapted for High-Rate SCS
62026748|NCT05234944|EXPERIMENTAL|Intervention|A CDCES trained by the research team will deliver the intervention via HIPAA compliant telehealth/videoconferencing platform. There will be 2 sessions within approximately 6 months. Prior to each session, participants will complete an assessment of T1D-specific health-related quality of life, which will generate a summary report for each person that lists aspects of quality of life that are going well and aspects that are potential areas for improvement. The CDCES will review the reports with the participants, focusing on building on areas of strength and teaching brief behavioral strategies or resources to address aspects of quality of life that could be improved. Strategies may include stress management, problem-solving techniques, goal-setting, strategies to seek social support, or other brief behavioral skills. The CDCES will also offer information about relevant resources and will provide referrals for mental health support as needed.
62026749|NCT05740462|EXPERIMENTAL|Dietary app 1|Dietary app recommends high iron or iron-focused recipes
62225509|NCT03898401|EXPERIMENTAL|8 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62225510|NCT03898401|EXPERIMENTAL|9 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62225511|NCT03898401|EXPERIMENTAL|10 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62225512|NCT03898401|EXPERIMENTAL|11 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62225513|NCT03898401|EXPERIMENTAL|12 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62225514|NCT03898401|EXPERIMENTAL|13 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62418342|NCT03953768|EXPERIMENTAL|Patients undergoing device implantation|Patients undergoing device implantation with vagal nerve stimulator (VNS) for epilepsy
62589073|NCT04163133|NO_INTERVENTION|regular trigger group|regular trigger timing when three follicles reach 17mm bilateral.
62418343|NCT05197881|EXPERIMENTAL|Daily Adaptive External Beam Radiation Therapy|Daily adaptive radiation therapy delivered with Varian Ethos treatment system.
62418344|NCT06224673|EXPERIMENTAL|Cohort 1: HR+/HER2-low|Participants with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)-low will receive ARX788 intravenously over 90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants also undergo CT, PET/CT, and collection of blood samples throughout the study.
62589074|NCT03657342|EXPERIMENTAL|L-CsA treatment plus SoC|Liposomal Cyclosporine A 5 mg twice daily for 48 weeks + Standard of Care Therapy
62589075|NCT03657342|ACTIVE_COMPARATOR|Control treatment|In this arm only the standard of care is administered. Standard of care is a maintenance regimen of immunosuppressive agents.
62589076|NCT02122705||VPIA remifentanil|VPIA remifentanil labour analgesia
62800088|NCT01817023|EXPERIMENTAL|RT alone|SIB-IMRT was given to the patients with a regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
62026750|NCT05740462|SHAM_COMPARATOR|Dietary app 2|Dietary app recommends standard iron recipes
62026751|NCT05740462|EXPERIMENTAL|Hydroponic unit 1|Growing vitamin B12 biofortified plants in a hydroponic unit and will be randomised to dietary app 1 or 2
62026752|NCT05740462|NO_INTERVENTION|Hydroponic unit 2|No hydroponic unit be given to participants and will be randomised to dietary app 1 or 2
62026753|NCT01926106|EXPERIMENTAL|nIPPV|the infants in the arm were supported by Nasal Intermittent Positive-Pressure Ventilation(nIPPV)
62026754|NCT01926106|ACTIVE_COMPARATOR|nCPAP|the infants in the arm were supported by Nasal Continuous Positive Airway Pressure(nCPAP)
62026755|NCT06246877|EXPERIMENTAL|virtual reality applied group|"Before the K-wire is removed and dressed, the three-dimensional video that the child likes and wants to watch will be placed on virtual reality glasses and attached to the child.~During the procedure, the child will be allowed to watch videos through virtual reality glasses."
62026756|NCT06246877|NO_INTERVENTION|control group|During the removal and dressing of the wire, the child's attention will be diverted by asking some questions (where she lives, the name of the school she attends, what grade she attends, etc.).
62026757|NCT02528214|PLACEBO_COMPARATOR|Placebo q2w|2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection every 2 weeks (q2w) for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable inhaled corticosteroid (ICS). OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
62225515|NCT03898401|EXPERIMENTAL|14 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62418345|NCT06224673|EXPERIMENTAL|Cohort 2: TNBC|Participants with confirmed triple negative breast cancer (TNBC), human epidermal growth factor receptor 2 (HER2)-low will receive ARX788 intravenously over 90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants also undergo CT, PET/CT, and collection of blood samples throughout the study.
62418346|NCT02842086|EXPERIMENTAL|F/TAF|F/TAF+ F/TDF placebo for at least 96 weeks
62418347|NCT02842086|EXPERIMENTAL|F/TDF|F/TDF+ F/TAF placebo for at least 96 weeks
62418348|NCT02842086|EXPERIMENTAL|Open-label|Once all participants have been on blinded treatment for at least 96 weeks, the study will be unblinded and participants will be offered the option to continue on open-label F/TAF treatment for 96 weeks.
62418349|NCT02842086|EXPERIMENTAL|Open-Label Extension|Participants who remain on study at Open-label Week 96 will have the option to continue on open-label F/TAF treatment in the Open-label extension phase for 408 weeks.
62418350|NCT06483711|EXPERIMENTAL|Healthy Lifestyle Kit Group|Participants will receive a healthy lifestyle kit and be asked interview questions about its efficacy.
62418351|NCT02574507|EXPERIMENTAL|Couples-Based Behavioral Weight and Symptom Management|Participants will receive 12 session (6 weekly and 6 biweekly) of a behavioral weight and symptom management intervention.
62418352|NCT06703372|EXPERIMENTAL|Diode laser|
62418353|NCT06703372|PLACEBO_COMPARATOR|placebo diode laser|
62418354|NCT05654623|EXPERIMENTAL|ARV-471|
62418355|NCT05654623|ACTIVE_COMPARATOR|Fulvestrant|
62418356|NCT04008121|EXPERIMENTAL|Adult participants with normal or diseased eyes|500 mg dose of intravenous fluorescein sodium followed by ocular angiography; after a minimum of 3 days, participants will receive a single intravenous dose of MB-102 at 4 μmol/kg followed by ocular angiography
62418357|NCT04840901|EXPERIMENTAL|Lebrikizumab (Reference) - Pre-Filled Syringe with Needle Safety Device|2-milliliter (mL) (125 milligrams per milliliter \[mg/mL\]) Lebrikizumab administered subcutaneously (SC) via pre-filled syringe with needle safety device (PFS-NSD).
62418358|NCT04840901|EXPERIMENTAL|Lebrikizumab (Test) - Autoinjector|2-mL (125 mg/mL) Lebrikizumab administered SC via autoinjector (AI).
62418359|NCT02830646|OTHER|DFG mesure|Measure the effect of gastric bypass on the report DFG / VEC
62418360|NCT05229562|EXPERIMENTAL|Cohort 1: Low-Dose|Participants will receive Dose 1 of BIIB122, orally, once on Day 1.
62418361|NCT05229562|EXPERIMENTAL|Cohort 2: Mid-Dose|Participants will receive Dose 2 of BIIB122, orally, once on Day 1.
62418362|NCT05229562|EXPERIMENTAL|Cohort 3: High-Dose|Participants will receive Dose 3 of BIIB122, orally, once on Day 1.
62418363|NCT05229562|EXPERIMENTAL|Cohort 4: High-Multi-Dose|Participants will receive Dose 3 of BIIB122, orally, once daily (QD), for 10 days.
62026758|NCT02528214|EXPERIMENTAL|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
62026759|NCT04090307|EXPERIMENTAL|TLC Group Prenatal Care|TLC will start in the late first trimester or early second trimester and run for \~6-10 sessions. Groups of 2-10 consented women, with two or more GDM risk factors, will meet under the supervision of an obstetric provider (nurse practitioner or MD) and co-facilitator (health educator, nutritionist, or nurse) for two-hour sessions. A major focus of TLC will be education, and much of each visit will be spent on pregnancy, exercise/nutrition education, and behavioral health.
62418364|NCT05152004|EXPERIMENTAL|High dose dual therapy|Rabeprazole (Pariet) 20 mg and amoxicillin (Amolin) 750 mg q.i.d for 14 days
62589077|NCT01046058|EXPERIMENTAL|Panel A: TMC435 150 mg|Participants enrolled in Panel A had moderate hepatic failure and received TMC435 150 mg once daily for 7 days.
62026760|NCT04090307|NO_INTERVENTION|Traditional Prenatal Care|Subjects randomized to routine care will receive their prenatal care with their primary obstetric provider. Patients are seen for 10-15 minutes every four weeks until 28 weeks' gestation, every two weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits focus on routine screening tests and prenatal care. Traditional care participants will receive a phone call once a month, until 28 weeks gestation, from a nurse practitioner to check-in on pregnancy goals, healthy eating, and exercise. Each subject's medical chart will be reviewed for demographics, antenatal management, maternal and neonatal outcomes.
62026761|NCT00970502|EXPERIMENTAL|erlotinib + celecoxib|
62026762|NCT01576601||Hopkins|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
62026763|NCT01576601||Childrens Hospital of Philadelphia|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
62418365|NCT05152004|ACTIVE_COMPARATOR|Hybrid therapy|Rabeprazole (Pariet) 20 mg and amoxicillin (Amolin) 1 g b.i.d. for 7 days, followed by rabeprazole (Pariet) 20 mg, amoxicillin(Amolin)1 g, clarithromycin (Klaricid) 500 mg, and metronidazole (Flagyl) 500 mg b.i.d. for 7 days
62418366|NCT05020730|EXPERIMENTAL|PTM-001 400 mg daily for 12 weeks|
62418367|NCT05020730|PLACEBO_COMPARATOR|Placebo daily for 12 weeks|
62589078|NCT01046058|EXPERIMENTAL|Panel B: TMC435 150 mg|Participants enrolled in Panel B had severe hepatic impairment and received TMC435 150 mg once daily for 7 days after the safety of TMC435 150 mg once daily for 7 days was evaluated in participants enrolled in Panel A.
62418368|NCT06472050|ACTIVE_COMPARATOR|Romosozumab/denosumab|Romosozumab for 12 months, then denosumab for 36 months
62418369|NCT06472050|ACTIVE_COMPARATOR|Denosumab/denosumab|Densoumab for 48 months
62589079|NCT01740908||Hyperbaric Oxygen Treatment|Six healthy adult individuals (18-65 yrs), with no current, ongoing infection or chronic disease will be recruited for this study. Treatment study subjects will undergo a daily exposure to 2.0 ATA, 100% Oxygen for 90 minutes over 5 days.
62589080|NCT01740908||Baseline|Two healthy study subjects with no current, ongoing infection or chronic disease will be rectuited to serve as a baseline group. Study subjects will not be exposed to HBO, but will have blood drawn at the same time as the treatment group.
62589081|NCT06666504||All participants|All eligible participants will be consented and enrolled into the study.
62589082|NCT05038501||Comorbidities in Oncosurgery patients|Prevalence of comorbidities as Coronary artery disease, Hypertension , Diabetes Mellitus,Hypothyroidism and Corona Virus Infection will be studied in patients undergoing Oncosurgeries.
62800089|NCT01817023|ACTIVE_COMPARATOR|CCRT group|SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume and cisplatin 100mg/m2 was given at d1, d22,d43 during radiotherapy.
62800090|NCT03168412|EXPERIMENTAL|the Accelerated Vaccination Schedule Group|Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,7,21 day.
62418370|NCT06700499|EXPERIMENTAL|AK120 300mg Q2W(Double the initial dose)|AK120 600mg (first day) then 300mg Q2W SC until week 14.
62418371|NCT05255354||Diffuse Large B Cell Lymphoma|For DLBCL patients, prospective blood samples will be collected, in provided collection kits, at: pre-lymphodepletion chemotherapy, Day+14, Day+28, Day+90, Day+180, and potentially at relapse following CAR infusion. For DLBCL, PET/CT scan images done prior to CAR19 therapy, Day 28 post-infusion, 3 months post-infusion, and 6 months post-infusion of CAR19 cells
62589083|NCT04136379||Clinic monitoring|Patients who attend a warfarin clinic for management of their INR
62800091|NCT03168412|ACTIVE_COMPARATOR|the Standard Vaccination Schedule Group|Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
62418372|NCT05255354||Follicular Lymphoma|For FL patients, prospective blood samples will be collected, in provided collection kits, at: pre-lymphodepletion chemotherapy, Day+14, Day+28, Day+90, Day+180, Day+365, and potentially D+547 and at relapse following CAR infusion. For FL patients, PET/CT scan images done prior to CAR19 therapy, Day 28 post-infusion, 3 months post-infusion, and 6 months post-infusion of CAR19 cells
62418373|NCT05255354||Mantle Cell Lymphoma|For MCL patients, prospective blood samples will be collected, in provided collection kits, at: pre-lymphodepletion chemotherapy, Day+14, Day+28, Day+90, Day+180, Day+365, and potentially D+547 and at relapse following CAR infusion. For MCL patients, PET/CT scan images done prior to CAR19 therapy, Day 28 post-infusion, 3 months post-infusion, and 6 months post-infusion of CAR19 cells
62418374|NCT00732784|OTHER|1|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 15; and Gleevec® once daily on days 1 and 15 (i.e., Gleevec® alone on day 1, and combination of Gleevec® and calcium supplement on day 15).
62589084|NCT04136379||Home monitoring|Patients who undertake home monitoring of their INR using a CoaguChek POC device
62589085|NCT05511532|EXPERIMENTAL|Foot orthoses|Hallux limitus
62589086|NCT02810717|EXPERIMENTAL|active TBS|40 patients with TRD will receive active theta-burst stimulation using a MagPro X1000 between the two PET measurements
62589087|NCT02810717|SHAM_COMPARATOR|sham TBS|40 patients with TRD will receive sham stimulation using a MagPro X1000 between the two PET measurements. After the second PET scan they will receive active TBS
62589088|NCT04232917|EXPERIMENTAL|2LPAPI® arm|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
62800092|NCT01579227||1-TOP group 1|TOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
62589089|NCT04232917|PLACEBO_COMPARATOR|Placebo arm|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
62589090|NCT02979912|EXPERIMENTAL|Platelet Lysate|Autologous platelet lysate dispensed into eye droppers to be applied four times a day for a total of four weeks.
62589091|NCT04303520|EXPERIMENTAL|anti-CD19/CD22 CAR-T cells|Administration with anti-CD19/CD22 CAR-T cells in the CD19-positive ALL patients
62589092|NCT03582982|EXPERIMENTAL|Eccentric overload exercise|
62800093|NCT01579227||TOP group 2|TOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
62800094|NCT01579227||OTOP group-1|OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
62418375|NCT00732784|OTHER|2|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 1; and Gleevec® once daily on days 1 and 15 (i.e., combination of Gleevec® and calcium supplement on day 1, Gleevec® alone on day 15).
62418376|NCT05088525|ACTIVE_COMPARATOR|Two-tunnel meniscal root repair without a peripheral stabilization suture|Standard root repair surgery.
62418377|NCT05088525|EXPERIMENTAL|Meniscal root repair with an additional transtibial peripheral stabilization suture|Meniscus root repair with an added stabilization suture
62418378|NCT03455114|EXPERIMENTAL|capsular fixation surgery|patients required capsule centration safely undergo capsular fixation surgery with AssiAnchor under local anesthesia .
62418379|NCT02752451|OTHER|CO|8 subjects who did not undergo arthroscopy simulation training prior to assessment on cadaveric specimens. These served as controls.
62589093|NCT02033967|ACTIVE_COMPARATOR|CVP|Central venous pressure-guided vasodilator-induced hypovolemia
62589094|NCT02033967|EXPERIMENTAL|SVV|stroke volume variation-guided vasodilator-induced hypovolemia
62589095|NCT03565042||MoA ustekinumab|Patients with a diagnosis of psoriatic arthritis according to the CASPAR criteria with at least one swollen knee or ankle joint who are planning to receive treatment with ustekinumab at the outpatient clinic. An arthroscopy will be done in the swollen knee/ankle at week 0, 12 and 24.
62589096|NCT04777786|EXPERIMENTAL|Physical Therapy Intervention|Individualized physical therapy treatments will be provided based on impairments identified during assessments. Treatment may include but is not limited to the following: passive, assisted and active ROM, manual therapy, soft tissue massage, myofascial release, therapeutic activities and exercise and patient education. Treatment duration and frequency will be specific to each patient, providing personalized care. This type of intervention is considered a pragmatic approach, which will allow for generalization of the results due to the similarity with clinical practice.71 Pilot data indicates women will receive physical therapy intervention 1-2x/week for 3-6 weeks beginning \~4 weeks after surgery (x̄=10 visits).
62589097|NCT04777786|NO_INTERVENTION|Usual Care|The usual care group will be instructed to continue with their typical daily activities.
62589098|NCT03494231|EXPERIMENTAL|HLX06, in patients with solid cancers|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX06 once per week. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 500, 750, 900, 1200, 1500 mg, starting from 500 mg/kg.
62589099|NCT06049186|EXPERIMENTAL|CRD group|Patients in the calorie-restricted diet (CRD) group will have strict calorie-restriction diets for 8 weeks and then weight stability for 4 weeks.
62800095|NCT01579227||OTOP group-2|OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
62800096|NCT01579227||TAM Group 1|TAM group 1 will have #2 biopsy collected 21 days after 1st biopsy collected. Tamoxifen cream and placebo cream will be applied where biopsies are collected from 1 week prior to having the biopsy procedure until the second biopsy is collected (21 days later).
62800097|NCT01579227||Normal Skin|Placebo group will apply placebo and TCT cream that will be applied daily to a specified area on the subjects legs (normal skin) for 5 weeks. One leg will be applied with placebo and the other will be applied with TCT cream. Subjects will return weekly for 5 weeks, where non-invasive measurements using Laser Speckle imaging, will be completed at each study visit
62800098|NCT05976802|EXPERIMENTAL|High dose budesonide rectal foam|
62800099|NCT05976802|EXPERIMENTAL|Low dose budesonide rectal foam|
62800100|NCT05976802|PLACEBO_COMPARATOR|Matching placebo rectal foam|
62418380|NCT02752451|EXPERIMENTAL|CBAT|8 Subjects who received 4 hours of simulation training on the Cigar Box Arthroscopy Trainer. They then underwent assessment on cadaveric specimens.
62418381|NCT02752451|EXPERIMENTAL|AKAT|8 Subjects who received 4 hours of simulation training on the Anatomic Knee Arthroscopy Trainer. They then underwent assessment on cadaveric specimens.
62418382|NCT04950322|EXPERIMENTAL|Treatment group A|
62418383|NCT04950322|PLACEBO_COMPARATOR|Treatment group B|
62418384|NCT06568666|EXPERIMENTAL|Lumbar manipulation group|Lumbar spinal manipulation was also performed in the lateral recumbent position and HVLA thrust was applied to the segment where dysfunction was detected. The spinal process was determined as the contact point and the direction of HVLA thrust was from posterior to anterior.
62418385|NCT06568666|EXPERIMENTAL|Sacroiliac Joint Manipulation Group|The participant lies on his/her side on the healthy side; the lower knee is in extension while the upper knee is flexed and placed in the popliteal fossa of the lower knee. The participant's hands are left free on the ribs at the lower level. The practitioner crosses the movement barrier with the stabilizing hand, allowing the tissues to relax. The practitioner performs HVLA thrust of the iliac bone into posterior or anterior rotation (in the opposite direction of dysfunction) with the stabilizing hand.
62589100|NCT06049186|ACTIVE_COMPARATOR|Control group|Patients in the control group will receive regular diets and metformin 1500 mg daily for 12 weeks. Participants allocated to the control group are followed by the conventional approach (usual care) based on regular visits respecting the usual schedule dictated by the rules of general practice.
62589101|NCT04922255|ACTIVE_COMPARATOR|disposable urethral support device|disposable urethral support device
62026764|NCT01576601||Childrens Hospital Boston|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
62026765|NCT03655158|EXPERIMENTAL|ozone group|After gingivectomy and gingivoplasty, right quadrants of the surgical areas were assigned to receive ozone therapy in all patients
62800101|NCT01619839|EXPERIMENTAL|100 mg NKTR-181|100 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days.
62589102|NCT04922255|ACTIVE_COMPARATOR|Reusable Underwear|Reusable Underwear
62026766|NCT03655158|NO_INTERVENTION|non-ozone group|placebo application, left quadrants received regular air from the ozone generator.
62418386|NCT06568666|NO_INTERVENTION|Control Group|No treatment has been carried out.
62589103|NCT04922255|ACTIVE_COMPARATOR|pelvic floor muscle therapy (PFMT)|Pelvic floor muscle therapy
62026767|NCT06634472||Patients requiring computer-assisted jaw reconstruction with microvascular free flaps|"Inclusion criteria~1. Age ≥18 years, both genders;~2. Provided signed and dated informed consent form;~3. Indicated for immediate or secondary reconstructive surgery with osteocutaneous FFF.~Exclusion criteria~1. Patients who are pregnant;~2. Patients who have medically compromised conditions and cannot tolerate surgery;~3. Patients who are unable to receive pre-operative CT/CTA scans, such as those with iodine allergy;~4. Patients who have anatomical variation preventing the safe harvest of FFF;"
62026768|NCT04867564||NSCLC patients treated with curative radiotherapy|Consecutive NSCLC patients treated with standard RT with curative intent with or without platinum-based CHT
62026769|NCT05655793||With Neurodegeneration|Includes patients with mild cognitive impairment and dementia
62418387|NCT05629117|EXPERIMENTAL|Personalized Diabetes Text Messaging (DB-TEXT) combined with Peer Support Education Group|Patients who are assigned to the DB-TEXT+PSE group will receive personalized short text message services twice weekly at approximately noon on Monday and Thursday for three months (12 weeks). Additionally they will receive peer support education weekly during three month.
62418388|NCT05629117|ACTIVE_COMPARATOR|Personalized Diabetes Text Messaging (DB-TEXT) Group|The participants in the Personalized DB-TEXT group will receive the personalized short text message twice weekly at approximately noon on Monday and Thursday for three months (12 weeks).
62418389|NCT05629117|NO_INTERVENTION|Control Group|Health education related to diabetes management will be provided to the control group once a month during three months
62589104|NCT04042389|EXPERIMENTAL|WhatsApp|WhatsApp reminders
62800102|NCT01619839|EXPERIMENTAL|200 mg NKTR-181|200 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days.
62800103|NCT01619839|EXPERIMENTAL|300 mg NKTR-181|300 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days
62026770|NCT05655793||Without Neurodegeneration|Includes healthy controls and patients with subjective cognitive decline
62026771|NCT01868581|EXPERIMENTAL|insulin degludec|
62589105|NCT04042389|EXPERIMENTAL|Email|Email reminders
62589106|NCT04042389|OTHER|Control|No reminder
62589107|NCT01404754|PLACEBO_COMPARATOR|Lactose (Inactive Placebo)|Participant receives inactive placebo during day-long experimental session.
62589108|NCT01404754|ACTIVE_COMPARATOR|3,4-methylenedioxymethamphetamine|Participant receives 120 mg midomafetamine HCl possibly followed by 40 mg midomafetamine HCl during a day-long experimental session.
62026772|NCT01868581|EXPERIMENTAL|IDegAsp|
62026773|NCT05493280|OTHER|Healthy Participants- Pre-Ttreatment Only|"Subjects who are interested in treatment for hyperpigmentation will be enrolled for this study.~Subjects will be pre-treated with tretinoin/hydroquinone prior to treatments. No post-treatment care."
62418390|NCT06160674||COPD|30 COPD participants, 16 Female and 14 Male.
62418391|NCT06160674||HC|38 HC participants, 20 Female and 18 Male.
62418392|NCT03172390|EXPERIMENTAL|Cohort of patients : ascending aorta dilatation|measure of ascending aorta quality and quantity parameters by 4D Cardiac magnetic resonance
62418393|NCT02740660|EXPERIMENTAL|Caffeine 100mg / Albuterol 4mg|One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.
62589109|NCT01095978||Acute upper respiratory tract diseases, bronchitis, pneumonia|
62589110|NCT02141412|ACTIVE_COMPARATOR|Group I|Patients in Group I will receive dexmedetomidine 0.25 µg/kg IV (over 10 min) at closure of sevoflurane
62589111|NCT02141412|ACTIVE_COMPARATOR|Group II|Patients in Group II will receive dexmedetomidine 0.5 µg/kg IV (over 10 min) at closure of sevoflurane
62589112|NCT02141412|ACTIVE_COMPARATOR|Group III|Patients in Group III will receive dexmedetomidine 1 µg/kg IV (over 10 min) at closure of sevoflurane
62589113|NCT02141412|PLACEBO_COMPARATOR|Group IV|Patients in Group IV will receive same volume of normal saline at closure of sevoflurane
62589114|NCT01946958|EXPERIMENTAL|Trained in Primary Care (PC) Triple P|This group received standardized training in Primary Care (PC) Triple P.
62589115|NCT01946958|EXPERIMENTAL|Care as Usal|This group provided care as usual. This group was not trained in PC Triple P interventions.
62589116|NCT06279650|EXPERIMENTAL|Self-hypnosis|
62800104|NCT01619839|EXPERIMENTAL|400 mg NKTR-181|400 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days
62800105|NCT01619839|PLACEBO_COMPARATOR|Placebo|Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181.
62800106|NCT04734717|EXPERIMENTAL|COVID19|
62800107|NCT04734717|EXPERIMENTAL|Controll|
62418394|NCT02740660|PLACEBO_COMPARATOR|Placebo|One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.
62800108|NCT03941496|EXPERIMENTAL|AZA Treatment|"In Phase Ib dose escalation stage, participants will receive subcutaneous (SQ) AZA once daily x 5 days. Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). All participants receive standard of care antibiotics against tuberculosis.~Dose Escalation Strategy to identify the lowest dose of AZA that decreases DNA methylation and restores immune function is listed below. Proceeding to Phase IIa will proceed if stopping criteria are met at any of the steps below and FDA/IRB approval is obtained:~1. 5 mg/m\^2 subcutaneous (SQ) once daily x 5 days for 8 individuals~2. 15 mg/m\^2 subcutaneous (SQ) once daily x 5 days for 8 individuals~3. 30 mg/m\^2 subcutaneous (SQ) once daily x 5 days for 8 individuals~4. 50 mg/m\^2 SQ once daily x 5 days for 8 individuals~5. 75 mg/m\^2 once daily x 5 days for 8 individuals"
62800109|NCT01168726|EXPERIMENTAL|Protective Behavioral Strategies|Personalized feedback on use of protective behavioral strategies.
62800110|NCT01168726|EXPERIMENTAL|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
62225516|NCT03898401|EXPERIMENTAL|15 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62225517|NCT03898401|EXPERIMENTAL|16 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62225518|NCT03898401|EXPERIMENTAL|17 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62225519|NCT03898401|EXPERIMENTAL|18 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62418395|NCT05365594|ACTIVE_COMPARATOR|Self Selected Pace|Tennis shoes, CAM Boot, CAM Boot plus EvenUp Lift
62418396|NCT05365594|ACTIVE_COMPARATOR|Speed Walking Pace|Tennis shoes, CAM Boot, CAM Boot plus EvenUp Lift
62418397|NCT04608656|EXPERIMENTAL|Intervention arm 1: Livestock feed only|Households in villages assigned to intervention arm 1 will receive a pre-defined amount of feed to maintain two tropical livestock units for a total of 60 days during the dry season (when animals would be moved away in search of pastures).
62418398|NCT04608656|EXPERIMENTAL|Intervention arm 2: 1. Provision of Livestock feeds, 2. Nutrition counselling|Households recruited into intervention arm two will receive livestock feeds similar to intervention arm 1 and will be enrolled in a nutritional education and counselling program through Infant and Young Child Nutrition (IYCF) feeding program and household food utilization. The IYCF program through the Baby Friendly Community Initiative (BFCI) will include the promotion of exclusive breastfeeding in the first six months, continued breastfeeding up to the age of two years, adequate complementary feeding, hygiene promotion and the uptake of child health services including immunization, treatment of illness, moderate and severe acute malnutrition and micro-nutrient supplementation.
62418399|NCT04608656|NO_INTERVENTION|Control arm|The households recruited under this arm will receive none of the two study interventions. These households will receive identical assessment and data collection like other study households in the study. Their access to support through other interventions will be monitored. Households within the control arm will receive nutritional counselling and education given outside of the project. This is mainly at health facilities when mothers present for antenatal care or visit health facilities seeking healthcare. On some occasions in places where community health volunteers are present, nutritional counselling and education may be provided at the community level. The study instruments have been designed to collect information at the household level if such nutritional counselling and education has been provided.
62418400|NCT06074159|OTHER|In-clinic report-back|200 participants receive their personal exposure results from a clinician
62418401|NCT06074159|OTHER|Online|200 participants receive their personal exposure results from a website online
62418402|NCT01179256|EXPERIMENTAL|CURCUMIN|oral supplementation of curcumin 2000mg
62418403|NCT01179256|PLACEBO_COMPARATOR|PLACEBO|oral PLACEBO TABLET
62418404|NCT06417723|EXPERIMENTAL|Block group|Bilateral maxillary nerve block was planned to be performed using 10 cc 0.25% bupivacaine via suprazigomatic approach after providing airway safety in the block group with general anaesthesia applications. The haemodynamic values (blood pressure arterial, peak heart rate, peripheral oxygen saturation), postoperative numeric pain scores and postoperative quality of recovery index (QoR-15) values at the 24th hour will be recorded .
62800111|NCT01168726|ACTIVE_COMPARATOR|Alcohol Education|Educational information about harms associated with heavy drinking.
62418405|NCT06417723|NO_INTERVENTION|Control group|No intevention was planned for this group. Only genaeral anesthesia applications will use for surgery. The haemodynamic values (blood pressure arterial, peak heart rate, peripheral oxygen saturation), postoperative numeric pain scores and postoperative quality of recovery index (QoR-15) values at the 24th hour will be recorded .
62418406|NCT06704009|EXPERIMENTAL|NT-101 0.05 mM|
62418407|NCT06704009|EXPERIMENTAL|NT-101 0.2 mM|
62418408|NCT03016988|OTHER|Bortezomib,Fludarabine and Cytarabine|Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11; Fludarabine(F) 25mg/m2, intravenously day 1-3; Cytarabine(A) 500mg/m2 for 3 days(day1-3).
62418409|NCT04318002|EXPERIMENTAL|Group 1A|Volunteers (aged 18-45 years) of low malaria exposure status will receive 3 doses of 10µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 2
62589117|NCT06279650|ACTIVE_COMPARATOR|Psyco-education and cognitive behavioral therapy|
62418410|NCT04318002|EXPERIMENTAL|Group 1B|Volunteers (aged 18-45 years) of low malaria exposure status will receive 2 doses of 50µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 1 dose of 10µg RH5.1 /50µg Matrix-M at month 6.
62418411|NCT04318002|EXPERIMENTAL|Group 2A|Volunteers (aged 5-17 months) of low malaria exposure status will receive 3 doses of 10µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 2.
62418412|NCT04318002|EXPERIMENTAL|Group 2B|Volunteers (aged 5-17 months) of low malaria exposure status will receive 3 doses of 10µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 6.
62800112|NCT00774293|EXPERIMENTAL|1|Arnica 5CH and Bryonia 9CH (homeopathic drugs)
62800113|NCT00774293|PLACEBO_COMPARATOR|2|placebo Arnica 5CH and Bryonia 9CH
62800114|NCT01475435|ACTIVE_COMPARATOR|chronic periodontitis|Saliva and GCF samples will be evaluated before and after treatment from patients treated of chronic periodontitis.
62800115|NCT01475435|PLACEBO_COMPARATOR|periodontally healthy individuals|Saliva and GCF samples will be evaluated from periodontally healthy individuals at baseline.
62800116|NCT01475435|ACTIVE_COMPARATOR|chronic periodontitis with diabetes type 2|Saliva and GCF samples will be evaluated before and after treatment from patients with diabetes type 2 treated of chronic periodontitis
62418413|NCT04318002|EXPERIMENTAL|Group 2C|Volunteers (aged 5-17 months) of low malaria exposure status will receive 2 doses of 50µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 1 dose of 10µg RH5.1 /50µg Matrix-M at month 6.
62418414|NCT04318002|EXPERIMENTAL|Group 2D|Volunteers (aged 5-17 months) of high malaria exposure status will receive 2 doses of 50µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 1 dose of 10µg RH5.1 /50µg Matrix-M at month 6.
62418415|NCT06583538|EXPERIMENTAL|Online Exercise|Online personalised rehabilitation consisting of strengthening, aerobic and stretching. 40mins per session, twice per week, for 12 weeks
62418416|NCT04564287||Fully Recovered Individuals|Individuals with history of Covid-19 infection who have fully recovered without residual neurological symptoms
62589118|NCT02045862|ACTIVE_COMPARATOR|Mirabegron 50 mg|Participants received mirabegron 50 mg once a day for 52 weeks.
62800117|NCT01475435|PLACEBO_COMPARATOR|periodontally healthy individuals with diabetes type 2|Saliva and GCF samples will be evaluated from periodontally healthy individuals with diabetes type 2 at baseline
62418417|NCT04564287||Patients with neuro-PASC|Patients with history of Covid-19 infection and persistent neurological symptoms (Post-Acute Sequelae of SARS CoV-2 Infection, neuro-PASC)
62418418|NCT00729703|EXPERIMENTAL|1|Dual-chamber detection and activated treatment (at least ATP) in the slow VT-zone plus activated AAIsafeR pacing (basic rate 60 bpm).
62800118|NCT01521507|EXPERIMENTAL|LipiFlow System|Treatment with LipiFlow System at randomization in Stage 1 of study
62418419|NCT00729703|EXPERIMENTAL|2|Single-chamber ICD following clinical practice but with a monitoring zone active to allow the documentation of all occurring ventricular arrhythmias
62589119|NCT02045862|ACTIVE_COMPARATOR|Solifenacin 5 mg|Participants received solifenacin 5 mg once a day for 52 weeks.
62589120|NCT02045862|EXPERIMENTAL|Solifenacin 5 mg + Mirabegron 50 mg|Participants received solifenacin 5 mg and mirabegron 50 mg once a day for 52 weeks.
62589121|NCT06666179|EXPERIMENTAL|Group 1 (SCB-1019T 90 µg)|24 children (2-\<6 years of age) will receive low-dose unadjuvanted SCB-1019T (90 µg) at Day 1
62589122|NCT06666179|EXPERIMENTAL|Group 2 (SCB-1019T 90 µg + Alum)|24 children (2-\<6 years of age) will receive low-dose alum-adjuvanted SCB-1019T (90 µg) at Day 1
62026774|NCT05493280|OTHER|Healthy Participants- Post-Treatment Only|"Subjects who are interested in treatment for hyperpigmentation will be enrolled for this study.~Subjects will wash out of any topical medications and will receive treatment. Post-treatment care will include use of temovate for 4 days."
62026775|NCT02995603|EXPERIMENTAL|Patient rotation|Patients will be rotated horizontally, using the Nano-X patient rotation system, and asked to complete validated questionnaires to quantify their experience.
62026776|NCT05154864||SBUF-SMUF|All patients underwent standard of care cardiac surgery, cardiopulmonary bypass and SBUF-SMUF with effluent removal of 30 ml/kg/hr and physiologic solution replacement of 25ml/kg/hr.
62026777|NCT06299501|EXPERIMENTAL|Routine group|Nurses within the routine group receive training and are assigned to inform about family violence at the home visit that takes place when the child is newborn and to by routine ask questions about family violence to mothers at the 6-8 weeks visit to CHC.
62026778|NCT06299501|EXPERIMENTAL|Indication group|Nurses within the indication group receive training and are assigned to inform about family violence at the home visit when the child is newborn and to pose questions about family violence on evidence based indication.
62225520|NCT03898401|EXPERIMENTAL|19 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62225521|NCT03898401|EXPERIMENTAL|20 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62225522|NCT03898401|EXPERIMENTAL|21 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62225523|NCT03898401|EXPERIMENTAL|22 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62418420|NCT04022759|ACTIVE_COMPARATOR|Treatment as Usual|Participants randomised to the 'treatment as usual' group will receive behavioural activation guided-self help intervention as routinely delivered in the service.
62418421|NCT04022759|EXPERIMENTAL|Treatment with Security Prime|Participants randomised to the experimental group will receive behavioural activation guided self-help intervention as is routinely delivered in the service with additional attachment security priming intervention.
62418422|NCT05623449|EXPERIMENTAL|combination of face-to-face and teleconsultation hypnosis consultation|The first and the last hypnosis sessions in face-to-face, and the other 3 intermediate sessions being conducted by teleconsultation.
62418423|NCT05623449|ACTIVE_COMPARATOR|face-to-face hypnosis consultation|5 face-to-face hypnosis sessions
62418424|NCT06224192|EXPERIMENTAL|Rocatinlimab Dose 1 Prefilled Syringe (PFS)|Rocatinlimab will be self-administered subcutaneously using a PFS. Participants will receive rocatinlimab for 52 weeks.
62418425|NCT06224192|EXPERIMENTAL|Rocatinlimab Dose 2 PFS|Rocatinlimab will be self-administered subcutaneously using a PFS. Participants will receive rocatinlimab for 52 weeks.
62418426|NCT06224192|EXPERIMENTAL|Rocatinlimab Dose 2 Autoinjector (AI)|Rocatinlimab will be self-administered subcutaneously using an AI. Participants will received rocatinlimab for 52 weeks.
62418427|NCT06254963|EXPERIMENTAL|Sand jump training|Participants will conduct 6 weeks (twice weekly) supplemental jump training on a sand surface (within their warm ups) in addition to their regular training.
62418428|NCT06254963|ACTIVE_COMPARATOR|Land jump training|Participants will conduct 6 weeks (twice weekly) supplemental jump training on a land surface (within their warm ups) in addition to their regular training.
62418429|NCT05996549|EXPERIMENTAL|Influenza vaccination arm|In the Influenza vaccination hospital, the investigators have run an influenza vaccination campaign before the influenza season, where the vaccines are free to high-risk patients. Posters and leaflets containing information on influenza vaccination have been displayed at the vaccination booths and key hospital locations with information on the vaccination. Eligible patients from inpatients and outpatients of all departments have been offered to take the vaccine during the vaccination campaign. Nurses/ Health Assistants (HA) have provided vaccines after receiving written consent. Vaccination cards have been issued to the participants. All enrolled vaccine recipients are informed about notifying of possible adverse events after immunization (AEFI). To report any AEFI, the investigators are following the existing surveillance channel established by the WHO and the Ministry of Health and Family Welfare(MoHFW), the government of Bangladesh.
62589123|NCT06666179|PLACEBO_COMPARATOR|Group 3 (Placebo)|8 children (2-\<6 years of age) will receive 0.9% NaCl saline placebo at Day 1
62589124|NCT06666179|EXPERIMENTAL|Group 4 (SCB-1019T 180 µg)|24 children (2-\<6 years of age) will receive high-dose unadjuvanted SCB-1019T (180 µg) at Day 1
62589125|NCT06666179|EXPERIMENTAL|Group 5 (SCB-1019T 180 µg + Alum)|24 children (2-\<6 years of age) will receive high-dose alum-adjuvanted SCB-1019T (180 µg) at Day 1
62589126|NCT06666179|PLACEBO_COMPARATOR|Group 6 (Placebo)|8 children (2-\<6 years of age) will receive 0.9% NaCl saline placebo at Day 1
62589127|NCT05983991|EXPERIMENTAL|Subject with a germline GATA2 mutation (Interventional prospective cohort)|
62026779|NCT06299501|ACTIVE_COMPARATOR|Treatment as usual|Nurses within the treatment as usual group do not receive training but ask questions when they suspect ongoing violence in the family.
62026780|NCT01651429|EXPERIMENTAL|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation, 17 of which will be spent in the laboratory.
62026781|NCT06245785||liver resection|
62418430|NCT05996549|NO_INTERVENTION|Control arm ( unvaccination arm)|In the control hospital, the investigators are also enrolling participants meeting the high-risk group individual criteria. However, no vaccination campaigns are conducted.
62418431|NCT03390452|EXPERIMENTAL|Intervention|"The parents will receive Mobile phone messages about oral hygiene and healthy dieting of their children through teachers.~The message format will be text and images, depending upon the education/ literacy level of the parents. Parents will be reminded and information reinforced, at frequent intervals for a period of six months.~Oral hygiene of School children will be assessed before intervention, after 6 months interval"
62418432|NCT03390452|NO_INTERVENTION|Control|The primary school children in the control group will not receive any intervention via their parents or teachers (in-active controls) but will be observed on selected outcome measures for baseline data, then at six month interval to compare for differences (if any) with intervention group.
62418433|NCT06702176|ACTIVE_COMPARATOR|Experimental Condition|Active sessions will last 1 hour each. The following parameters will be used for electric stimulation: low frequency (20 Hz), low current intensity (2 mA), with a small pulse width of 25-170 microseconds. These parameters were previously found to be safe in human studies.
62418434|NCT06702176|SHAM_COMPARATOR|Control Condition|The control arm will be a sham intervention. The patients will receive a sham stimulation, for which the same Exopulse Mollii suit will be used but the control unit will be programmed to start stimulating for 1 minute then it will shut off which could enable cutaneous sensations that mimic the active condition, aiming to achieve an effective blinding integrity. There is no risk related to the sham intervention since it consists of applying the same parameters used for the active session (low frequency: 20 Hz; current intensity: 2 mA; pulse width ranging from 25 to 170 µs) but for a shorter duration of time (1 minute).
62800119|NCT01521507|ACTIVE_COMPARATOR|Warm Compress and Lid Hygiene|Control group receiving warm compress therapy and lid hygiene at randomization in Stage 1 of study and crossover LipiFlow System treatment in Stage 2 of study
62800120|NCT04441411|OTHER|NEMOST-AIS|This study is designed as a cohort study.
62418435|NCT04415177|EXPERIMENTAL|VR Program A|Software with active intervention
62418436|NCT04415177|ACTIVE_COMPARATOR|VR Program B|Software without active intervention
62589128|NCT01302444|ACTIVE_COMPARATOR|Tadalafil|first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort
62589129|NCT01302444|PLACEBO_COMPARATOR|Placebo|first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks
62800121|NCT01626924|EXPERIMENTAL|2-Iminobiotin|
62800122|NCT00626275|EXPERIMENTAL|ADL5859 -- 200 mg (Part A)|ADL5859: 200 milligrams (mg), capsules, administered orally as a single dose during 1 of 3 Treatment Periods in Part A of the study
62800123|NCT00626275|ACTIVE_COMPARATOR|Naproxen -- 500 mg (Part A)|Naproxen: 500 mg, capsules, administered orally as a single dose during 1 of 3 Treatment Periods in Part A of the study
62800124|NCT00626275|PLACEBO_COMPARATOR|Placebo (Part A)|Matching placebo, capsules, administered orally, as a single dose during 1 of 3 Treatment Periods in Part A of the study
62800125|NCT00626275|EXPERIMENTAL|ADL5859 - 100 mg (Part B)|ADL5859: 100 mg, capsules, administered orally, twice daily (BID) for 2 weeks during Part B of the study
62800126|NCT00626275|PLACEBO_COMPARATOR|Placebo (Part B)|Matching placebo, capsules, administered orally, BID for 2 weeks during Part B of the study
62800127|NCT02079038|ACTIVE_COMPARATOR|Totalis™ Direct Decompression Procedure|Totalis
62800128|NCT02079038|ACTIVE_COMPARATOR|Comparator Procedure|Comparator Surgical Procedure
62026782|NCT06245785||transarterial chemoembolisation|
62026783|NCT05870280|EXPERIMENTAL|RESPONSE GROUP|After signing the voluntary consent form, the participants will be filled in the socio-demographic data collection form, the hypoglycemic attudes and behavior scale, the risk perception scale. A total of 4 group nurse coaching meetings will be held with individuals with type 1 diabetes, one to one over 7 days, under the framework of Theory of Integrative Nurse Coaching. Each of these interviews will last an average of 40-60 minutes. Interviews will be held online through the Zoom® webconferencing program at times scheduled jointly with the client. After the coaching meetings are over, the scales will be filled again and the HbA1c level will be requested from the blood results ordered at the doctor's request. In the coaching interviews, the materials specific to the coaching training received by the researchers (techniques such as the wheel of life, imagination, sabotage work, strong questions, Cartesian questions, SWOT analysis) will be used.
62026784|NCT06167681|EXPERIMENTAL|NouvNeu001|
62800129|NCT05668910||malignant group|patients diagnosed with high grade Intraepithelial neoplasia or GC (\> 50% of patients in stage I and II)
62800130|NCT05668910||non-malignant group|healthy individuals and patients with non-atrophic gastritis, gastric ulcer, gastric polyp or other benign gastric diseases
62800131|NCT04504981|OTHER|Y2Prevent Intervention|Y2Prevent will include several intervention components (i.e., My Legacy, Sources of Influence, Healthy Relationships, Goal Setting, Health and Self-Efficacy, and Mentorship). These intervention components are intended to assist participants: a) explore future adult identity and envision a positive future, b) develop behavioral skills related to problem-solving and goal-setting, c) develop behavioral skills related to communication, negotiation and conflict resolution with romantic and sexual partners, d) identify ways to safeguard their future by taking responsibility for their health, e) obtain information about HIV transmission and HIV prevention, including HIV testing, treatment as prevention (TaSP) and the availability of PrEP and PEP for prevention, and f) a participant-identified mentor to provide support and encouragement related to behavior change and implementing their future goals and plans.
62800132|NCT01451489|ACTIVE_COMPARATOR|Cyclophosphamide|CTX
62026785|NCT01826591|EXPERIMENTAL|Experimental: Low-Carbohydrate Diet|Healthy, Low-Carbohydrate Diet
62026786|NCT01826591|EXPERIMENTAL|Experimental: Low-Fat Diet|Healthy, Low-Fat Diet
62589130|NCT05272384|EXPERIMENTAL|Treatment (nivolumab, decitabine and cedazuridine)|Patients receive decitabine and cedazuridine PO QD on days 1-3 or 1-5 of each cycle and nivolumab IV over 30 minutes on day 15 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT and collection of blood samples throughout the trial.
62026787|NCT04025073|EXPERIMENTAL|Intervention Group|The intervention group will be assigned to the DASH diet with moderately reduced caloric intake and will participate in a nutrition education program.
62026788|NCT04025073|EXPERIMENTAL|Control Group|The control group will continue to follow the standard hospital diet and will participate in the same nutrition education program as the intervention group.
62589131|NCT05502133||Acute Intermittent Porphyria (AIP)|"Symptomatic patients with Acute Intermittent Porphyria (AIP)~A member of an AIP family who possesses an AIP pathogenic mutation and is/has been symptomatic (experienced acute attacks). Parents with no known HMBS mutations or heterozygote with familial mutation or a first, second or third degree relative of the above."
62026789|NCT03451838||Diabetes mellitus|Pregnant women with diabetes mellitus will be examined by us to measures placental volume and thickness ,IV thickness and HbA1c
62026790|NCT03451838||control group|Pregnant women with no medical disorders will be examined by us to measures placental volume and thickness ,IV thickness and HbA1c
62589132|NCT01312168|NO_INTERVENTION|Healthy non-OSA control|
62418437|NCT03125915|ACTIVE_COMPARATOR|CHTC as usual|Participants receive couples HIV testing and counseling following the CDC approved protocol.
62418438|NCT03125915|EXPERIMENTAL|CHTC + communication skills videos|The couple views communication skills training videos together prior to participating in a CHTC session following the CDC approved protocol.
62418439|NCT03125915|EXPERIMENTAL|CHTC + substance use module|The couple completes a CHTC session which includes the substance use calendar and structured debriefing activity. This is administered following Step 5 in the standard CDC protocol, just prior to delivery of HIV test results.
62418440|NCT03125915|EXPERIMENTAL|CHTC + video + substance use module|The couple views communication skills training videos together prior to participating in a CHTC session which includes administration of the substance use calendar and structured debriefing activity.
62589133|NCT01312168|EXPERIMENTAL|OSA receiving therapeutic CPAP|
62589134|NCT01312168|SHAM_COMPARATOR|OSA receiving subtherapeutic CPAP|
62800133|NCT01451489|EXPERIMENTAL|FK506|0.05-0.1mg/kg/d;adjust the dose according the serum concentration(aim 5-10ng/ml),maximum dose 6mg/day;divided in twice, interval 12 hours.
62026791|NCT03028168|EXPERIMENTAL|Intervention Yôga|Active protocol with yôga body movements performed along with respiratory vigorous, without contentions. Two sessions per week, with 45 minutes duration.
62026792|NCT03028168|EXPERIMENTAL|Intervention breathing technique|Passive protocol, seated patient, no significant body movements. Breathing technique, with alternate nostril breathing combined to inspiratory and expiratory retentions.Two sessions per week, with 45 minutes duration
62225524|NCT03898401|EXPERIMENTAL|23 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62225525|NCT03898401|EXPERIMENTAL|24 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62418441|NCT02445222|OTHER|Previously treated CAR-T patients|Patients who previously were exposed to lentiviral-based CART cell therapy
62418442|NCT04593589|EXPERIMENTAL|Transplantation|Submandibular Gland Stem Cell Transplantation
62418443|NCT04464200|EXPERIMENTAL|19(T2)28z1xx CAR T cells|Cohorts of 3-6 patients will be infused with escalating doses of 19(T2)28z1XX CAR T cells to establish the RP2D. There are 4 planned flat-dose levels: 25x10\^6, 50 x 10\^6, 100 x 10\^6 and 200 x 10\^6 CAR T cells and one de-escalation dose: 12.5 x 10\^6 CAR T cells. A standard 3+3 dose escalation design will be implemented starting from dose 1.
62418444|NCT01220037|EXPERIMENTAL|Young regular diet|During the time of the study this group will adhere to a standardized regular diet.
62418445|NCT01220037|EXPERIMENTAL|Young low protein diet|During the time of the study this group will adhere to a standardized low protein diet.
62418446|NCT01220037|EXPERIMENTAL|Young high protein|During the time of the study this group will adhere to a standardized high protein diet.
62589135|NCT03733080||1|ages 18 and older
62589136|NCT06668857|EXPERIMENTAL|Oculomotor and pupillomotor quantitative measurements|The investigators will assess oculomotor and pupillomotor function at the bedside and quantitatively both in the acute stage (i.e., within the first 5 days after symptom onset on the ward) and again after 3 months at follow-up (in the outpatient center). They will measure visually-triggered saccadic eye movements and pursuit eye movements in the horizontal and vertical plane and assess pupillary responses to light. For comparison with established paradigms, they will also assess spontaneous nystagmus at primary gaze (with/without fixation), vertical ocular alignment on alternating cover test (looking for vertical deviations, termed skew deviation), gaze-evoked nystagmus on lateral gaze (GEN), and the horizontal head-impulse test (hHIT). The investigators will also test hearing. Bedside and quantitative testing will be performed at the same time.
62589137|NCT04681911|EXPERIMENTAL|Inetetamab Combined With Pyrotinib and Chemotherapy|"Inetetamab: 8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.~Pyrotinib: 400mg, oral, every day.~Chemotherapy: the choice of physicians，as the following regimens:~Capecitabine, 1000 mg/m2, d1-d14, 3-week cycle Gemcitabine, 1000 mg/m2, D1, D8, 3-week cycle Vinorelbine, 25-30 mg/m2, D1, D8, 3-week cycle Carboplatin, AUC = 6, 3-week cycle Albumin paclitaxel, 100 mg/m2, weekly Eribulin, 1.4 mg/m2, D1, D8, 3-week cycle"
62589138|NCT02029989|EXPERIMENTAL|Extended Treatment Group|Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference and Comprehensive Medication Management
62225526|NCT03898401|EXPERIMENTAL|25 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62418447|NCT01220037|EXPERIMENTAL|Elderly|During the time of the study this group will adhere to a standardized high protein diet
62800134|NCT02707068|EXPERIMENTAL|QOLITI|"Intervention group receives the QOLITI (Quality Of LIfe Tool for IBD) manual immediately to work with over the course of several weeks along with 3 x 30 minutes of telephone support by a trained healthcare professional. Telephone calls will occur at two, four and six weeks post-randomisation.~Participants will be invited to discuss their experiences after the end of the actual study. These interviews are no obligatory part of the QOLITI study."
62589139|NCT02029989|ACTIVE_COMPARATOR|Usual Treatment Group|Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference
62026793|NCT03028168|EXPERIMENTAL|Control group|Control group (standard pharmacological treatment). Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization.
62418448|NCT04632563||Member of BioResource|Any BioResource member who consents to take part in the study and completes the study questionnaire.
62026794|NCT06532682|EXPERIMENTAL|Drug: Dapagliflozin 10 MG + ACE inhibitor|Using ACE inhibitors/ARBs as standard treatment, dapagliflozin is administered at a dose of 10 mg once daily, without food restrictions, for a total treatment duration of 24 weeks.
62225527|NCT03898401|EXPERIMENTAL|26 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62589140|NCT01375621||AHS cohort|population of S. aureus asymptomatic rural Iowans
62589141|NCT01375621||Non-AHS group|symptomatic S. aureus infections in rural Iowans.
62418449|NCT04297254|EXPERIMENTAL|Lenvatinib 12 mg or 8 mg|Participants with body weight (BW) greater than or equal to (\>=) 60 kilogram (kg), will receive lenvatinib 12 milligram (mg) (03 capsules), and participants with BW less than (\<) 60 kg, will receive lenvatinib 8 mg, (02 capsules), orally, once daily with or without food in 28-day cycles for a maximum 6 cycles of 4 weeks each for a total of 24 weeks or until disease progression, death, intolerable or unacceptable toxicity, or withdrawal of consent, whichever occurs earlier.
62589142|NCT05318248|EXPERIMENTAL|Clonidin|pill 0,15 mg clonidin
62800135|NCT02707068|NO_INTERVENTION|Waitlist Control group (WLC)|Waitlist control group waits until after the study finishes to receive the same manual, but without telephone support sessions.
62800136|NCT02300259|EXPERIMENTAL|LY2623091 (Group 1)|LY2623091 administered orally once on Day 1 of Period 1.
62800137|NCT02300259|EXPERIMENTAL|Itraconazole + LY2623091 (Group 1)|200 mg itraconazole administered orally twice daily on Day 1 of Period 2 and once daily on Days 2 - 20 of Period 2. Single oral dose of LY2623091 coadministered on Day 6 of Period 2.
62800138|NCT02300259|EXPERIMENTAL|Simvastatin (Group 2)|20 mg simvastatin administered orally once daily on Day 1.
62800139|NCT02300259|EXPERIMENTAL|LY2623091 + Simvastatin (Group 2)|LY2623091 administered orally once daily on Days 3 - 13. Single oral dose of 20 mg simvastatin coadministered on Day 12.
62800140|NCT02300259|EXPERIMENTAL|Tadalafil (Group 3)|5 mg tadalafil administered on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
62800141|NCT02300259|EXPERIMENTAL|Tadalafil + LY2623091 (Group 3)|LY2623091 administered orally once daily on Day 1 up to Day 15 of Period 2. 5 mg tadalafil co-administered once daily on Day 10 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
62800142|NCT02300259|EXPERIMENTAL|LY2623091 (Group 4)|LY2623091 administered orally once on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
62026795|NCT06532682|EXPERIMENTAL|Drug: Dapagliflozin 5 MG + ACE inhibitor|Using ACE inhibitors/ARBs as standard treatment, dapagliflozin is administered at a dose of 5 mg once daily, without food restrictions, for a total treatment duration of 24 weeks.
62026796|NCT06532682|ACTIVE_COMPARATOR|Drug: ACE inhibitor|Using ACE inhibitors/ARBs as standard treatment for a total treatment duration of 24 weeks.
62026797|NCT05034003|EXPERIMENTAL|zirconia crowns|Zirconia crowns placed on primary incisor teeth
62026798|NCT05034003|EXPERIMENTAL|composite strip crowns|composite strip crowns placed on primary incisor teeth
62418450|NCT06303622|EXPERIMENTAL|MRUS arm|Targeted biopsies will be performed by software-assisted MRI-ultrasound fusion registration . Software-based fusion targeted biopsy of 4 cores per target followed by 12-core systematic biopsy will be performed. The fusion or overlay of 3D MRI and USG images create a detailed 3D prostate image with both targeted and systematic biopsy core locations recorded.
62589143|NCT05318248|PLACEBO_COMPARATOR|Placebo|placebo pill
62589144|NCT03190668|ACTIVE_COMPARATOR|First Regimen Group|The first regimen will consist of a bolus dose of Cefazolin 30mg/kg up to a maximum of 2000mg IV administered prior to surgical incision. The same pre-operative dose of Cefazolin will be repeated every 3 hours until the completion of surgery. Two will paraspinal muscle microdialysis catheters and two subcutaneous microdialysis catheters will be inserted.
62800143|NCT02300259|EXPERIMENTAL|Diltiazem + LY2623091 (Group 4)|240 mg diltiazem administered once daily on Days 1 to 13 of Period 2. Single oral dose of LY2623091 coadministered on Day 4 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
62800144|NCT05032482|OTHER|Investigational Treatment 1|Investigational treatment mode (stimulation pattern) 1
62800145|NCT05032482|OTHER|Investigational Treatment 2|Investigational treatment mode (stimulation pattern) 2
62800146|NCT05032482|OTHER|Investigational Treatment Mode - Open Label|Investigational treatment mode (stimulation pattern)
62800147|NCT00920855|EXPERIMENTAL|Bendamustine and Bortezomib|Bendamustine in escalating doses of 50, 70 or 90 mg/m\^2 as combination therapy with bortezomib at 1.0 mg/m\^2/dose administered for up to eight 28 day cycles.
62800148|NCT03004729|OTHER|CoMiSS|Measure of CoMiSS followed by two weeks eviction Cow's milk protein diet and second CoMiSS measurement.
62800149|NCT06063863|EXPERIMENTAL|Nurse led screening for ROP with OPTOS camera|Screening completed by nurse trained in the use of an OPTOS camera to obtain images, at the same time as screening via standard procedure by a trained ophthalmologist using binocular indirect ophthalmoscopy (BIO).
62800150|NCT04249856||Women examined by colposcopy|Women referred to colposcopy at our facilities who met inclusion criteria
62800151|NCT04892264|EXPERIMENTAL|Arm A (belantamab mafodotin, lenalidomide, daratumumab)|"INDUCTION: Patients receive belantamab mafodotin IV over 30 minutes on day 1 of odd number cycles, lenalidomide PO QD on days 1-21, and daratumumab IV over 90 minutes on days 1, 8, 15, and 22 of cycles 1 and 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning cycle 13, patients receive belantamab mafodotin IV over 30 minutes on day 1 of odd number cycles (starting cycle 13), lenalidomide PO QD on days 1-21, and daratumumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
62800152|NCT04892264|EXPERIMENTAL|Arm B (belantamab mafodotin, lenalidomide, daratumumab, Dxevo)|"INDUCTION: Patients receive belantamab mafodotin IV over 30 minutes on day 1 of cycles 2, 4, 6, 8, 10, and 12, lenalidomide PO QD on days 1-21, daratumumab IV over 90 minutes on days 1, 8, 15, and 22 of cycles 1 and 3, and days 1 and 15 on cycles 5, 7, 9, and 11. Patients also receive dexamethasone PO on days 1, 8, 15 and 22. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning cycle 13, patients receive belantamab mafodotin IV over 30 minutes on day 1 of even numbered cycles, lenalidomide PO QD on days 1-21, and daratumumab IV over 90 minutes on day 1 of odd numbered cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
62800153|NCT00915863|ACTIVE_COMPARATOR|Billroth-II-type|Billroth-II-type reconstruction after pancreaticoduodenectomy
62800154|NCT00915863|EXPERIMENTAL|Isolated Roux-en-Y|Isolated Roux-en-Y type reconstruction after pancreaticoduodenectomy
62800155|NCT06419075|PLACEBO_COMPARATOR|Normal Saline (NaCl 0.9%)|Local infiltration of 50 cc NaCl 0.9% into the vaginal submucosa during colpocleisis dissection
62800156|NCT06419075|EXPERIMENTAL|Tranexamic Acid (2 mg/dL)|Local infiltration of 50 cc Tranexamic Acid (2 mg/dL) into the vaginal submucosa during colpocleisis dissection
62800157|NCT06419075|EXPERIMENTAL|Vasopressin (0.1 U/dL)|Local infiltration of 50 cc Vasopressin (0.1 U/dL) into the vaginal submucosa during colpocleisis dissection
62800158|NCT02227004||MRI in patients with Pacemaker or ICD|Perform MRI in patients with pacemaker or ICD and evaluate patient and device safety
62026799|NCT05034003|NO_INTERVENTION|Control tooth|Caries-free primary incisor tooth
62026800|NCT01197950|ACTIVE_COMPARATOR|Manual Acupuncture|Manual stimulation
62026801|NCT01197950|EXPERIMENTAL|Electro Acupuncture|Electrical and manual stimulation
62026802|NCT01197950|NO_INTERVENTION|Standard care|No acupunture
62026803|NCT01311492|PLACEBO_COMPARATOR|Healthy Lifestyle Program|The purpose of the healthy lifestyle group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest.
62026804|NCT01311492|ACTIVE_COMPARATOR|Physical Activity Intervention|The physical activity program includes aerobic, strenth, flexibility and balance training.
62026805|NCT06635395||patients with Rotator cuff injury|Scale validity and reliability The aim of this study is to adapt the Baltimore Orthopedic Subscapularis Score (BOSS) to Turkish society in patients with rotator cuff injury and to make its validity and reliability in Turkish. It has 5 questions. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
62418451|NCT06303622|ACTIVE_COMPARATOR|COG arm|The biopsy operator reviews the MR images and creates a mental three-dimensional representation of the prostate and the lesion within it to guide biopsy. Cognitive registration is a visual guidance technique in which the surgeon samples a visually estimated location on transrectal ultrasound (TRUS) corresponding to the MRI suspicious regions. Cognitive-guided biopsy is performed by taking 4 cores from each target followed by 12-core systematic biopsies.
62418452|NCT02587325|EXPERIMENTAL|Nab-Sirolimus Dose Cohort 1|nab-Sirolimus Dose Cohort 1 at 10 mg/m2, given once weekly intravenously for 16 weeks. The initial 16-Week treatment was followed optionally by up to 32 weeks of therapy (Extension Part)
62589145|NCT03190668|ACTIVE_COMPARATOR|Second Regimen Group|The second regimen will consist of an initial bolus dose of 30 mg/kg up to maximum of 2000 mg. Following the initial bolus dose a continuous Cefazolin drip will start until the end of surgery. Cefazolin drip dose will be 10 mg/(kg\*h) up to maximum of 667 mg/h.Two microdialysis catheters will be inserted into a paraspinal muscle and two microdialysis catheters will be inserted subcutaneously.
62589146|NCT03702075|EXPERIMENTAL|Experimental group|Patients allocated to the experimental group were included in a self-administered program combining self-myofascial release using foam rollers and roller balls and active upper limb neurodynamic exercises. It consisted of three sessions of 50-60 minutes per week for 4 consecutive weeks.
62800159|NCT05590052|ACTIVE_COMPARATOR|Bipolar Electrosurgery group (n=60)|Group A
62800160|NCT05590052|ACTIVE_COMPARATOR|Thermocautery group (n=60)|Group B
62800161|NCT03483896|NO_INTERVENTION|Control|At the 4 facilities in the control arm, participants received the usual care. During the period from 8:00 - 10:00 AM each day, the control group was taken to a similar sized area indoors (without daylight) for socialization under typical electrical lighting conditions.
62026806|NCT01329601|EXPERIMENTAL|Cognitive Intervention|StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
62026807|NCT01329601|ACTIVE_COMPARATOR|Booklet-based training|Home based training of episodic memory using paper-pencil exercizes
62026808|NCT05319691|ACTIVE_COMPARATOR|Yoga Now (Treatment Group)|An initial 12-week Treatment Phase of weekly virtual yoga classes (Yoga Now) followed by a 12-week Follow-up Phase.
62026809|NCT05319691|NO_INTERVENTION|Yoga Later (Wait List Control Group)|A wait-list control group (Yoga Later) will receive usual care. After the 24 week study period, participants in Yoga Later will be offered the yoga intervention in a non-study format.
62418453|NCT02587325|EXPERIMENTAL|Nab-Sirolimus Dose Cohort 2|nab-Sirolimus Dose Cohort 2 at 1.0 mg/m2, given once weekly intravenously for 16 weeks. The initial 16-Week treatment was followed optionally by up to 32 weeks of therapy (Extension Part)
62418454|NCT02587325|EXPERIMENTAL|Nab-Sirolimus Dose Cohort 3|nab-Sirolimus Dose Cohort 3 at 2.5 mg/m2, given once weekly intravenously for 16 weeks. The initial 16-Week treatment was followed optionally by up to 32 weeks of therapy (Extension Part)
62589147|NCT03702075|NO_INTERVENTION|Control group|Those patients allocated to the control group received a booklet with information regarding neck pain and explaining basic exercises for active mobilization and stretching with pictures and a short text.
62589148|NCT06664697||Retrospective|Retrospective Review of patient records
62589149|NCT06664697||Prospective|Prospective data collection of subjects receiving a cochlear implant with robotic-assisted cochlear implant
62589150|NCT06668038|EXPERIMENTAL|Multidisciplinary and multicenter validation of re-irradiation with curative intent|"Validation by a multicenter group of multi-professional experts (radiotherapists and physicists) of:~* re-irradiation indication~* EQD2 cumulated doses using MiM"
62589151|NCT03033316|EXPERIMENTAL|IV Liposomal Dexamethasone|IV Liposomal Dexamethasone given 1 to 4 times in total over period of maximally 4 weeks
62589152|NCT04774419|EXPERIMENTAL|Radiation and Dostarlimab (THIS ARM IS COMPLETED)|Patients will undergo standard intensity modulated radiation therapy (IMRT) to the pelvic nodes and vaginal cuff (total dose of 45-50.4Gy at 1.8 Gy per fraction) for 5-6 weeks and receive IV Dostarlimab every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of Dostarlimab.
62800162|NCT03483896|ACTIVE_COMPARATOR|Daylight Intervention|At the 4 facilities in the active light intervention arm, staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
62800163|NCT01115868|EXPERIMENTAL|Group 2 - 2 doses of Prevascar and placebo|
62800164|NCT01115868|EXPERIMENTAL|Group 1 - 2 doses of Prevascar and placebo|
62800165|NCT01115868|EXPERIMENTAL|Group 3 - 2 doses of Prevascar and placebo|
62800166|NCT01115868|EXPERIMENTAL|Group 4 - 2 doses of Prevascar and placebo|
62800167|NCT03601260|OTHER|Gout Patients|Allopurinol 100 mg-300mg/day as secondary treatment in gout patients
62800168|NCT00346125|ACTIVE_COMPARATOR|Preferred Standard Regimen|Subjects with soft tissue sarcoma who are receiving pegylated liposomal doxorubicin hydrochloride, Ifosfamide with mesna and pegfilgrastim - Repeat every 28 days for 4 cycles total
62800169|NCT00346125|ACTIVE_COMPARATOR|Alternative Treatment Regimen|Subjects with soft tissue sarcoma who are receiving Doxorubicin hydrochloride, Ifosfamide with mesna and pegfilgrastim - Repeat every 28 days for 4 cycles total
62800170|NCT01102036|PLACEBO_COMPARATOR|Yoghurt without probiotics|Yoghurt without probiotic bacteria
62418455|NCT02587325|EXPERIMENTAL|Nab-Sirolimus Dose Cohort 4|nab-Sirolimus Dose Cohort 4 at 5.0 mg/m2, given once weekly intravenously for 16 weeks. The initial 16-Week treatment was followed optionally by up to 32 weeks of therapy (Extension Part)
62418456|NCT02587325|EXPERIMENTAL|Nab-Sirolimus Dose Cohort 5|nab-Sirolimus Dose Cohort 5 at 7.5 mg/m2, given once weekly intravenously for 16 weeks. The initial 16-Week treatment was followed optionally by up to 32 weeks of therapy (Extension Part)
62800171|NCT01102036|ACTIVE_COMPARATOR|Cultura yoghurt|Cultura yoghurt with L casei F19, acidophilus La5 adn B lactis Bb 12
62800172|NCT02346175|EXPERIMENTAL|Cohort1|5-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
62800173|NCT02346175|EXPERIMENTAL|Cohort2|10-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
62800174|NCT02346175|EXPERIMENTAL|Cohort3|20-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
62800175|NCT05478642||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
62800176|NCT05478642||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
62800177|NCT06278792|ACTIVE_COMPARATOR|Standard of Care|48 hour diuretic management at the treating physician's discretion
62800178|NCT06278792|EXPERIMENTAL|Intervention|48-hour nurse-led natriuresis-guided protocol
62800179|NCT04486651|EXPERIMENTAL|HX008 plus Irinotecan|Participants recieve HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus irinotecan 160 mg/m², IV, Q2W.
62800180|NCT04486651|PLACEBO_COMPARATOR|Placebo plus Irinotecan|Participants recieve placebo intravenous (IV) every 3 weeks (Q3W) plus irinotecan 160 mg/m², IV, Q2W.
62800181|NCT01677325|EXPERIMENTAL|Chinese herb|Chinese herb
62800182|NCT03138421|EXPERIMENTAL|ABX-1431 HCl|
62800183|NCT03138421|PLACEBO_COMPARATOR|Placebo|
62800184|NCT02679755|EXPERIMENTAL|Experimental arm|Palbociclib plus Letrozole
62800185|NCT04230915|ACTIVE_COMPARATOR|Low Dose Rocuronium|This group patients will determine as those who were administered 0.3 mg/kg rocuronium
62800186|NCT04230915|NO_INTERVENTION|Strandart Dose Rocuronium|This group patients will determine as those who were administered 0.6 mg/kg rocuronium
62800187|NCT01864343|EXPERIMENTAL|Pre- and perinterventional hypothermia|Cooling will be initiated by the application of cooling pads in the out-of-hospital setting followed by an infusion of 1000-2000ml of cold saline. In the cath lab a endovascular cooling catheter will be placed into the inferior vena cava via a femoral vein to achieve a core temperature of \<35°C prior to revascularization.
62800188|NCT00947271|EXPERIMENTAL|DVD 1 plus assessment 1|Participants will view educational DVD 1 and complete the first version of the study assessment.
62800189|NCT00947271|EXPERIMENTAL|DVD 1 plus assessment 2|Participants will view educational DVD 1 and complete the second version of the study assessment.
62800190|NCT00947271|EXPERIMENTAL|DVD 2 plus assessment 1|Participants will view educational DVD 2 and complete the first version of the study assessment.
62026810|NCT06023056||Delayed vaccination group after gastrointestinal surgery|Newborns undergoing gastrointestinal surgery are delayed from receiving hepatitis B vaccination in the vaccination institutions due to the impact of surgery.
62026811|NCT06023056||The group of vaccination on time after gastrointestinal surgery|Newborns undergoing gastrointestinal surgery shall be vaccinated with hepatitis B vaccine on time by vaccination institutions.
62225528|NCT03898401|EXPERIMENTAL|27PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62225529|NCT03898401|EXPERIMENTAL|28 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62225530|NCT03898401|EXPERIMENTAL|29 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62589153|NCT04774419|EXPERIMENTAL|Hypofractionated IMRT and Dostarlimab|Treatment will consist of short-course, hypofractionated IMRT to deliver 25 Gy to the vaginal cuff and pelvic lymph nodes in 5 daily fractions over one week. Participants will receive TSR-042 500mg every 3 weeks over 30 minutes for 4 cycles, followed by 1 dose of 1000mg for cycle 5.
62589154|NCT06610630|EXPERIMENTAL|AI-assisted group|
62589155|NCT06610630|NO_INTERVENTION|Conventional control group|
62589156|NCT05500248|EXPERIMENTAL|Leave-In-Situ Arm|standard, high-definition colonoscopy with the use of Medtronic GI Genius module including both CADe and CADx. Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.
62589157|NCT05500248|ACTIVE_COMPARATOR|Standard arm|standard, high-definition colonoscopy with the use of Medtronic GI Genius module including both CADe and CADx. All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
62589158|NCT06665425|EXPERIMENTAL|Arm 1|Epaminurad 9mg, C2406 0.6mg
62589159|NCT03834766|ACTIVE_COMPARATOR|AMPH ER Tab|Amphetamine Extended Release Tablets 5, 10, 15 and 20 mg
62589160|NCT03834766|PLACEBO_COMPARATOR|Matching Placebo|Matching Placebo Tablets 5, 10, 15 and 20 mg
62225531|NCT03898401|EXPERIMENTAL|30 PRp|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index \<15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
62225532|NCT04330131|EXPERIMENTAL|Treated families|The treated families will complete up to 3 interventions: 3Ts - Newborn, 3Ts - Well Baby, and 3Ts - Let's Talk! The ideal progression is that treated families will complete all three interventions. Before completing their first intervention, participants will complete set of baseline surveys measuring their knowledge and beliefs about child development. They will repeat these measures when their child is 6 months, 9 months, 1-, 2-, and 3-years old.
62225533|NCT04330131|NO_INTERVENTION|Comparison Families|Comparison families will not receive any of the 3Ts interventions but will complete the same surveys as the treatment group at study enrollment and again when their child is 6 months, 9 months, 1-, 2-, and 3-years old.
62225534|NCT04697771|EXPERIMENTAL|Intervention Group|First Evaluation - Fine Motor Skills Training - 8 week - 3 session per week - 40 minute per session - Second Evaluation
62589161|NCT01993953|ACTIVE_COMPARATOR|BodyPump|Resistance training in group, with one instructor. This pre-choreographed class contains 10 to 12 exercises with a barbell, weights and a step. Number of repetitions throughout the class varies between muscle groups, but is generally high (20-100).
62589162|NCT01993953|ACTIVE_COMPARATOR|Personal training|The PT will instruct proper technique to their clients, correct the training and technique, control the intensity and serve as a motivator at each training session.
62589163|NCT01993953|ACTIVE_COMPARATOR|Resistance training with instructor|Participants in this group are aimed to perform resistance training individually, based on two sessions with an instructor and a standarized training program given prior to the intervention. After six weeks, all participants in this group received a second instruction, as well as evaluation of the training protocol.
62589164|NCT01993953|NO_INTERVENTION|Controlgroup|Control group - This group will be instructed to continue their activity and diet patterns. After the intervention period, they will be offered free exercise with BP at a fitness centre (12 weeks) and resistance training with a instructor at the Norwegian School of Sport Science.
62589165|NCT02419612|EXPERIMENTAL|Saxagliptin 5 mg/ dapagliflozin 10mg or Placebo|Saxagliptin 5 mg /dapagliflozin 10 mg Placebo once a day orally
62589166|NCT02419612|EXPERIMENTAL|Glimepiride or Placebo|Glimepiride or placebo 1mg or 2mg or 3mg or 4mg or 6mg once a day orally
62589167|NCT03270319||ICU patient|"Critically ill patients in our adult intensive care unit with the following characteristics:~* advanced hemodynamic monitoring in place including pulmonary artery catheter and arterial catheter~* intubated or tracheostomy in place~* echocardiography requested by the treating physician~* intervention of interest: hemodynamic assessment done by echocardiography and thermodilution (pulmonary artery catheter)"
62589168|NCT03726294|EXPERIMENTAL|NBM-BMX|
62026812|NCT06023056||Control group|Children who are free of disease and have vaccination and physical examination on time.
62026813|NCT01299246|EXPERIMENTAL|improving self-care|
62026814|NCT06534346|EXPERIMENTAL|DA-302168S (fed+fasting)|
62026815|NCT06534346|EXPERIMENTAL|DA-302168S (fasting+fed)|
62026816|NCT04495673|EXPERIMENTAL|tDCS with Cognitive Training|DLPFC stimulation with tDCS with simultaneous cognitive training
62026817|NCT04495673|ACTIVE_COMPARATOR|Sham tDCS with Cognitive Training|Sham tDCS with simultaneous cognitive training
62225535|NCT04697771|NO_INTERVENTION|Control Group|First Evaluation - 8 week waiting period - Second Evaluation
62225536|NCT06610110|EXPERIMENTAL|Genotype AA - Male - Caffeine|
62225537|NCT06610110|EXPERIMENTAL|Genotype AC or CC - Male - Caffeine|
62225538|NCT06610110|PLACEBO_COMPARATOR|Genotype AA - Male - Placebo|
62225539|NCT06610110|PLACEBO_COMPARATOR|Genotype AC or CC - Male - Placebo|
62225540|NCT06610110|EXPERIMENTAL|Genotype AA - Female - Caffeine|
62225541|NCT06610110|EXPERIMENTAL|Genotype AC or CC - Female - Caffeine|
62418457|NCT04454619|ACTIVE_COMPARATOR|Hand antisepsis with propanolol-1 60%|Effectiveness of pre-surgical hand washing in reducing bacterial load using propanolol-1 60% as control
62418458|NCT04454619|EXPERIMENTAL|Hand antisepsis with Clorhexidina and solution|chlorhexidine gluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate.
62418459|NCT06696001|ACTIVE_COMPARATOR|Psychoeducation|Psychoeducation will be used in this study as a control condition. The 60 minute session will be structured to provide general educational information on depression and evidence-based strategies to reduce symptoms. The information will be presented in generic format and will not be tailored to be client-specific.
62589169|NCT04435756||Observational (blood collection)|Patients undergo collection of blood every 3-6 months for up to 3 years.
62225542|NCT06610110|PLACEBO_COMPARATOR|Genotype AA - Female - Placebo|
62418460|NCT06696001|EXPERIMENTAL|Behavioral Activation|Behavioral Activation (BA) is a psychotherapy modality that can be used to treat depression. The 60 minute session of BA is designed to actively engage with the client in creating personalized goals and ways in which maladaptive coping mechanisms maintaining depression can be addressed and replaced with increased exposure to positive reinforcement.
62418461|NCT01275521|EXPERIMENTAL|BONT-A intra-prostatic injection|
62418462|NCT01275521|ACTIVE_COMPARATOR|optimized medical BPH treatment|
62800191|NCT00947271|EXPERIMENTAL|DVD 2 plus assessment 2|Participants will view educational DVD 2 and complete the second version of the study assessment.
62800192|NCT01787630|EXPERIMENTAL|Hyaluronic acid|Hyaluronic acid will be injected in the space between the prostate and rectum prior to radiotherapy to perform a dorsal movement of rectum.
62800193|NCT00670371||1|Patients having the following diagnoses are eligible for inclusion into the study: schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, delusional disorder, affective psychosis with mood incongruent delusions, psychotic disorder not otherwise specified or patients being actively psychotic.
62800194|NCT00670371||2|Closest relative(s) /informal caregiver(s)
62800195|NCT05246371|EXPERIMENTAL|propofol and dexmedetomidine|Patients will receive maintenance of general anesthesia by TIVA using combination of propofol and dexmedetomidine
62225543|NCT06610110|PLACEBO_COMPARATOR|Genotype AC or CC - Female - Placebo|
62225544|NCT04137965||Testicular torsion group|Men having undergone surgery for testicular torsion between 01.01.2003 and 12.31.2012
62225545|NCT04137965||Control group|Men without knowledge of their fertility status and who have never had their semen analyzed
62225546|NCT02757391|EXPERIMENTAL|Treatment (CD8 +T cell therapy, pembrolizumab)|Beginning 2 days prior to CD8+ T cell infusion, patients receive cyclophosphamide IV over 30 minutes. Patients undergo CD8+ T cell infusion IV over 2 hours on day 0 and receive aldesleukin SC BID on days 1-14. Beginning on day 1 about 24 hours after CD8+ T cell infusion, patients receive pembrolizumab IV over 30-60 minutes on weeks 3, 6, 12, and 15.
62225547|NCT03038230|EXPERIMENTAL|MCLA-117 bispecific antibody|"Dose escalation cohorts, with escalating doses of MCLA-117 until MTD or RP2D is reached. The dose is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment.~Part 2-Expansion Cohort: The RP2D of MCLA-117 is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment."
62225548|NCT02876198||Patients treated with anti-VEGF|
62418463|NCT06340087|EXPERIMENTAL|10% Sucrose|10% (w/v) sucrose in water
62418464|NCT06340087|EXPERIMENTAL|Sucrose + Hesperetin|7% (w/v) sucrose in water + 50 mg/L Hesperetin
62418465|NCT06340087|EXPERIMENTAL|7% sucrose|7% (w/v) sucrose in water
62418466|NCT05003739|EXPERIMENTAL|Logica Mirror|Since the trial is not comparative, the only arm implies the use of the investigational device (Logica Mirror femoral stem)
62418467|NCT06523465|EXPERIMENTAL|Simvastatin combined with Amlodipine besylate|after 1:1 randomization, 60 patients with primary aldosteronism were treated with Simvastatin combined with Amlodipine besylate for 6 months
62418468|NCT06523465|EXPERIMENTAL|Simvastatin combined with Spironolactone and Amlodipine besylate.|after 1:1 randomization, 60 patients with primary aldosteronism were treated with Simvastatin combined with Spironolactone and Amlodipine besylate for 6 months
62589170|NCT05828680||Elective cardiac surgery|
62589171|NCT06015503|EXPERIMENTAL|PLB1004|PLB1004 given alone as monotherapy
62800196|NCT05246371|EXPERIMENTAL|desflurane|Patients will receive maintenance of general anesthesia by desflurane.
62800197|NCT04052308|ACTIVE_COMPARATOR|Control group|"Two days of lectures about knee OA, but will also come to the hospital after the first class to consult about nutritional habits to be improved; therapy session with the psychologists, sessions with the physical therapy team; sessions with the physical educators team.~They will be submitted to 24-hour ambulatory blood pressure monitoring (ABPM) at baseline and at the end fo the study; The arterial stiffness and endothelial reactivity will be assessed by measurement of the carotid-femoral pulse wave velocity by means of a non-invasive automatic device at baseline and at the end fo the study; Answer EQ-5D-5L at baseline and at the end fo the study."
62800198|NCT04052308|EXPERIMENTAL|Continuous group|Two days of lectures about knee OA, but will also come to the hospital after the first class to consult about nutritional habits to be improved; therapy session with the psychologists, sessions with the physical therapy team; sessions with the physical educators team. The supervised exercise sessions will consist of 10 min of warm-up stretching exercises, 40 min of treadmill (40 min on treadmill at 60% of reserve heart rate), 20 min of sub-maximal strength training and 10 min of cooling exercises. They will be submitted to 24-hour ambulatory blood pressure monitoring (ABPM) at baseline and at the end of the study. The arterial stiffness and endothelial reactivity will be assessed by measurement of the carotid-femoral pulse wave velocity by means of a non-invasive automatic device at baseline and at the end of the study.
62225549|NCT00558194|EXPERIMENTAL|1|Standard behavioral weight loss treatment with cognitive and affective skills training
62225550|NCT00558194|ACTIVE_COMPARATOR|2|Standard behavioral weight loss treatment
62418469|NCT06523465|EXPERIMENTAL|Amlodipine besylate combined with Spironolactone|after 1:1 randomization, 60 patients with primary aldosteronism were treated with Amlodipine besylate combined with Spironolactone for 6 months
62418470|NCT01284231|EXPERIMENTAL|MEDI-565 - Dose Escalation|Up to 15 dose-escalation cohorts will be enrolled
62418471|NCT01284231|EXPERIMENTAL|MEDI-565 Dose Expansion Arm 1|20 subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biologic dose
62418472|NCT01284231|EXPERIMENTAL|MEDI-565 Dose Expansion Arm 2|20 subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biologic dose
62418473|NCT01284231|EXPERIMENTAL|MEDI-565 Dose Expansion Arm 3|Subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biological dose
62418474|NCT06543134||Group A|Patients who developed postoperative hypothermia were included in this group.
62589172|NCT04259658|EXPERIMENTAL|Calcium electroporation treatment|Experimental treatment with calcium electroporation for cutaneous metastases.
62589173|NCT04391322||Group 1|Healthy participants without lung disease
62589174|NCT04391322||Group 2|Participants with stable cystic fibrosis
62589175|NCT04391322||Group 3|Participants with cystic fibrosis, anticipated to receive treatment with CFTR-modulator therapy. Please note: treatment is determined by your physician as part of your normal therapy plan.
62589176|NCT04391322||Group 4|Participants with CF who are between 4-8 years old and are starting triple combination modulator therapy using the rapid lung and abdominal imaging methods.
62589177|NCT06053892|ACTIVE_COMPARATOR|AR US|Augmented reality sonography guidance for shoulder punctures
62589178|NCT06053892|ACTIVE_COMPARATOR|standard US|standard sonography guidance for shoulder punctures
62589179|NCT06053892|ACTIVE_COMPARATOR|Fluoroscopic|Fluroscopic guidance for shoulder punctures
62225551|NCT04471623|EXPERIMENTAL|DeTAP Study App and Home Devices|Monitoring of OAC administration, OAC adherence, and clinical status through combined decentralized technologies
62418475|NCT06543134||Group B|Patients who did not develop postoperative hypothermia were included in this group.
62418476|NCT00826176|EXPERIMENTAL|Sugammadex in Caucasian Subjects|At 1-2 post-tetanic counts (PTC) after the last dose of rocuronium, 4.0 mg.kg-1 sugammadex was to be administered. Caucasian subjects living in Europe.
62418477|NCT00826176|EXPERIMENTAL|Sugammadex in Chinese Subjects|At 1-2 post-tetanic counts (PTC) after the last dose of rocuronium, 4.0 mg.kg-1 sugammadex was to be administered. Chinese subjects living in China.
62418478|NCT06580782|ACTIVE_COMPARATOR|Pitocin|Control group will receive only the standard-dose synthetic oxytocin (Pitocin) alone for labor induction or augmentation.
62418479|NCT06580782|EXPERIMENTAL|Calcium Carbonate with Pitocin|Participants will start an oral calcium carbonate regimen at the same time as initiating synthetic oxytocin (Pitocin) infusion.
62418480|NCT04450979|ACTIVE_COMPARATOR|Bioactive hydrolysate|20 g of hydrolysed rice protein
62589180|NCT01951612|EXPERIMENTAL|Executive Function Training Program|Participants in this group will receive the novel intervention training.
62589181|NCT01951612|ACTIVE_COMPARATOR|Psychoeducational Training Program|Participants in this group will receive the control intervention training.
62589182|NCT02730377|EXPERIMENTAL|Liraglutide 1.8 mg|Add-on to metformin
62589183|NCT02730377|ACTIVE_COMPARATOR|OAD|Add-on to metformin. Treatment with one OAD selected at the discretion of the investigator. Subjects randomised to the OAD arm must remain on the same OAD throughout the trial.
62589184|NCT03285568||Palbociclib|women at least 18 years old, with ER+, HER2- advanced breast cancer, and were receiving palbociclib
62589185|NCT03953053|EXPERIMENTAL|FLACS Group|Femto Laser treated (anterior Capsulotomy and Fragmentation of lens body before phaco emulification)
62589186|NCT03953053|ACTIVE_COMPARATOR|Manual Group|Gold Standard Method with manual rhexis with pinzette and phaco emulsification
62589187|NCT03305861|EXPERIMENTAL|ThuLEP|Thulium laser enucleation of prostate
62589188|NCT03305861|EXPERIMENTAL|Green LEP|Greenlight laser enucleation of prostate
62225552|NCT04046718|EXPERIMENTAL|electroacupuncture|the study group received electroacupuncture stimulation at different points
62225553|NCT04046718|NO_INTERVENTION|control group|a control group with no intervention
62418481|NCT04450979|PLACEBO_COMPARATOR|Placebo|20 g micro crystalline cellulose
62418482|NCT06564467|EXPERIMENTAL|JMT202 SAD experimental group|Participants in SAD experimental groups will receive a single subcutaneous injection of JMT202 on Day 1.
62418483|NCT06564467|PLACEBO_COMPARATOR|Placebo SAD group|Participants in SAD experimental groups will receive a single subcutaneous injection of placebo on Day 1.
62418484|NCT06537947|EXPERIMENTAL|Endovascular interventions|
62418485|NCT04911127|PLACEBO_COMPARATOR|Placebo|Participants will take capsules containing medium chain triglyceride (MCT) oil
62589189|NCT06668389|EXPERIMENTAL|SGLT2 inhibitor Group|Dapagliflozin 10mg once daily orally from Visit 1 (Week 1) to Visit 3 (Week 12 ± 1)
62589190|NCT06668389|NO_INTERVENTION|Control Group|Routine care
62589191|NCT05295732|EXPERIMENTAL|TMB-001 0.05%|TMB-001 0.05% ointment: Induction phase QD for 3 weeks, followed by BID for 9 weeks. Maintenance therapy for additional 12 weeks randomized QD vs BID
62026818|NCT02493361|EXPERIMENTAL|Treatment|Pembrolizumab: 200 mg IV, Day 1 of each cycle pIL-12: 1/4 tumor volume at concentration of 0.5 mg/mL intratumoral, Days 1, 5, and 8 of each odd cycle
62800199|NCT04052308|EXPERIMENTAL|Interval group|Two days of lectures about knee OA, but will also come to the hospital after the first class to consult about nutritional habits to be improved; therapy session with the psychologists, sessions with the physical therapy team; sessions with the physical educators team. The supervised exercise sessions will consist of 10 min of warm-up stretching exercises, 40 min of treadmill (40 min on treadmill with alternating intensity between 50% and 80%) of HR, resulting in an average load of 60% ((50% 2) + 80% 3)), 20 min of sub-maximal strength training and 10 min of cooling exercises. They will be submitted to 24-hour ambulatory blood pressure monitoring (ABPM) at baseline and at the end of the study. The arterial stiffness and endothelial reactivity will be assessed by measurement of the carotid-femoral pulse wave velocity by means of a non-invasive automatic device at baseline and at the end of the study.
62800200|NCT03604029||Qualifying Subjects|Qualifying subjects who are high risk for ACS.
62800201|NCT03604029||Qualifying Subjects with ACS|Qualifying subjects who are diagnosed with ACS
62800202|NCT05173909|EXPERIMENTAL|group H|BIS closed-loop target controlled infusion group with BIS value of 55
62800203|NCT05173909|EXPERIMENTAL|group L|BIS closed-loop target controlled infusion group with BIS value of 45
62418486|NCT04911127|EXPERIMENTAL|200mg CBD twice daily|Participants will take capsules containing cannabidiol amounting to 200mg CBD twice daily
62589192|NCT05295732|PLACEBO_COMPARATOR|Vehicle|Matching vehicle ointment with no action isotretinoin: Induction phase QD for 3 weeks, followed by BID for 9 weeks. Cross over to 12 weeks TMB-001 0.05% BID.
62589193|NCT05295732|EXPERIMENTAL|Maximal use|Optional Parallel Arm to evaluate the systemic exposure and safety of TMB-001 0.05% under conditions of maximal use.
62589194|NCT05274841|OTHER|Identified support needs|Identified need of either support from a psychologist, nurse, doctor, socialworker or a combination of theese.
62800204|NCT00556894|EXPERIMENTAL|CF101 0.1 mg|CF101 0.1 mg was given orally q12h
62800205|NCT00556894|EXPERIMENTAL|CF101 1 mg|CF101 1 mg was given orally q12h
62026819|NCT04266028|EXPERIMENTAL|DM-101 Single Dose|Participants received a single subcutaneous (SC) dose of DM-101 30 ng on Day 1
62026820|NCT04266028|PLACEBO_COMPARATOR|Placebo Single Dose|Participants received a single SC injection of placebo on Day 1
62225554|NCT04762823|EXPERIMENTAL|PD-ctDCS|People with Parkinson's disease will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
62225555|NCT04762823|SHAM_COMPARATOR|PD-sham|People with Parkinson's disease will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is turned on (4 mA) for 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.
62589195|NCT06684964||Asciminib|Patients who have been receiving asciminib for up to 6 months prior to study start
62026821|NCT04266028|EXPERIMENTAL|DM-101 Low Multiple Ascending Doses (MAD)|Participants received 5 biweekly administered SC doses of DM-101 as follows: 30 ng on Day 1,50 ng on Day 14, 100 ng on Day 28, 42, and 56.
62418487|NCT04911127|EXPERIMENTAL|400 mg CBD twice daily|Participants will take capsules containing cannabidiol amounting to 400mg CBD twice daily
62800206|NCT00556894|PLACEBO_COMPARATOR|Placebo|Matched placebo was given orally q12h
62800207|NCT02380287|EXPERIMENTAL|Cohort no.1|This cohort includes just one subject who will receive the maximum safe starting dose of BCD-085 (0.05 mg/kg) subcutaneously. If the dose limitating toxicity occurs within the first seven days after injection the study will be stopped. If there is no DLT within mentioned above period then Cohort no.2 is included.
62418488|NCT03923816|EXPERIMENTAL|Group (R)|Restrictive fluid strategy:6 mL/kg/h of Lactated Ringer (LR).
62418489|NCT03923816|EXPERIMENTAL|Group (C)|Conservative fluid strategy: 12 mL/kg/h of Lactated Ringer (LR).
62225556|NCT04762823|ACTIVE_COMPARATOR|NH-ctDCS|Neurologically healthy older adults will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the non-dominant side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
62418490|NCT03978897|EXPERIMENTAL|Blood flow restriction with physical/occupational therapy|physical/occupational therapy including use of blood flow restriction tourniquet over 6 visits (within a twelve week period).
62589196|NCT06665997|EXPERIMENTAL|Depot Medroxyprogesterone Acetate (Depo-Provera)|All participants will receive a 150mg dose intramuscular administration of depot medroxyprogesterone acetate (DMPA) injectable suspension after a 3-month baseline with no hormonal contraception.
62225557|NCT04762823|SHAM_COMPARATOR|NH-sham|Neurologically healthy older adults will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the non-dominant side. Stimulation is turned on (4 mA) for 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.
62225558|NCT01636960|EXPERIMENTAL|Participants receiving PegIFN alfa-2b|Participants receive PegIFN alfa-2b 6 µg/kg subcutaneously (SC) on Day 1 of each week for 8 weeks (Induction) and then 3 µg/kg SC once weekly for up to 252 weeks (Maintenance).
62225559|NCT02037633|ACTIVE_COMPARATOR|Fascia iliaca compartment block|
62225560|NCT02037633|ACTIVE_COMPARATOR|Fentanyl|
62225561|NCT02866084|EXPERIMENTAL|Device|Neuromodulation
62225562|NCT02618915|EXPERIMENTAL|DTX101, Cohort 1|a single peripheral intravenous (IV) infusion of 1.6 x 10\^12 genome copies (GC)/kg DTX101
62225563|NCT02618915|EXPERIMENTAL|DTX101, Cohort 2|a single peripheral IV infusion of 5.0 x 10\^12 GC/kg DTX101
62225564|NCT05513924|ACTIVE_COMPARATOR|Group A (topical latanoprost)|20 vitiligo patients will receive topical latanoprost solution (the concentration of the solution is 0.005%, pharmaceutically available eye-drop formulation)
62225565|NCT05513924|ACTIVE_COMPARATOR|Group B (topical 5-fluorouracil)|20 vitiligo patients will receive topical 5-fluorouracil 5% solution available as ampoules (Utoral®, EIMC United Pharmaceuticals, Egypt)
62225566|NCT01398722|ACTIVE_COMPARATOR|Intensive insulin therapy|Intensive insulin therapy(Blood glucose target: 110-150 mg/dL)
62225567|NCT01398722|ACTIVE_COMPARATOR|Conventional insulin therapy|Conventional insulin therapy(Blood glucose target: 150-180 mg/dl)
62225568|NCT00570050|EXPERIMENTAL|Intranasal Insulin nasal spray|
62225569|NCT00570050|EXPERIMENTAL|Placebo nasal spray (i.e., no active treatment)|
62225570|NCT06391060||Patient characteristics group|Retrospective evaluation and comparison of demographic characteristics, pre-operative TNM stage, distance from anal verge, tumor size, tumor grade, American Society of Anesthesiologists (ASA) score, and body mass index (BMI) were conducted among both patient groups. Peri-operative and post-operative data, including morbidity and mortality, were assessed, alongside parameters such as distal resection margin (DRM), proximal resection margin (PRM), harvested lymph nodes (HLN), and Clavien-Dindo Classification (CDC) scores. Diagnosis of anastomotic leakage was confirmed by clinical suspicion (e.g., changes in drainage, fever, abdominal pain) and further validated through contrast enema observed during follow-up computed tomography (CT). Hospital stay and readmission rates were monitored for up to 90 days post-surgery.
62225571|NCT06391060||Post-operative group|Post-operative outcomes encompassed operative duration, estimated blood loss, time to first flatus passage, duration of liquid diet, and length of hospital stay following surgery. Operative duration comprised the time from initial skin incision to closure, including the time needed for robotic surgery docking and undocking. Upon experiencing initial flatulence, patients transitioned to a liquid diet. Hospital stay duration was measured from the time of surgery to discharge. The overall cost of surgery, including surgical procedures, anesthesia, medications, and post-operative care, was considered in the total expenditure analysis
62225572|NCT02601664|ACTIVE_COMPARATOR|Combined Intervention|Combined intervention: pre-PCI intracoronary vasodilator and glycoprotein IIb/IIIa inhibitor administration, use of an EPD if technically feasible, and complete coverage of the lipid core plaque, if technically feasible
62225573|NCT02601664|ACTIVE_COMPARATOR|Conventional PCI|Conventional PCI
62225574|NCT04171453||Open-label|This study was open-label with only one treatment group. Lyrica CR was prescribed in accordance with usual clinical practice.
62225575|NCT01196273||Regional Ruhrgebiets Cohort|
62225576|NCT02769377|NO_INTERVENTION|Control|patients who decline or unable to do self-monitoring of blood glucose
62225577|NCT02769377|ACTIVE_COMPARATOR|Breeze2 glucometer|patients who do self-monitoring of blood glucose, but do not transfer data via mobile-phone
62225578|NCT02769377|EXPERIMENTAL|Breeze2 glucometer and H2|patients who do self-monitoring of blood glucose and transfer data via mobile-phone
62225579|NCT02679352|EXPERIMENTAL|SMR stemless|Patients requiring a primary anatomic or reverse shoulder arthroplasty, due to symptomatic painful degenerative joint diseases with good bone stock
62225580|NCT05208671|EXPERIMENTAL|NOURISH Food Box|12-week food assistance with low Dietary Inflammatory Index (DII) foods
62225581|NCT05208671|NO_INTERVENTION|Wait-list Control|Wait-list control group eligible to receive NOURISH box after study period
62026822|NCT04266028|PLACEBO_COMPARATOR|Placebo Low MAD|Participants received 5 biweekly administered SC injections of placebo on Day 1,14, 28, 42, and 56.
62225582|NCT03291587|EXPERIMENTAL|Intervention|"Training of Lung Cancer Screening Personnel on implementation of the United States Public Health Service (US PHS) Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study~Data collection from Patients: demographics, health status, smoking history, quitting behavior, perceptions of lung cancer risk and worry, impact of screening on tobacco use behavior, and exposure to the intervention. (baseline, \<14 days, 3 months, and 6 months)"
62418491|NCT03978897|ACTIVE_COMPARATOR|Evidence based physical/occupational therapy|evidence based physical/occupational therapy program over 6 visits (within a twelve week period) without use of blood flow restriction tourniquet
62418492|NCT05077774|OTHER|Harmony TPV System|Intervention Device: Harmony Transcatheter Pulmonary Valves and Delivery System
62418493|NCT00718978|OTHER|B|the investigators grafted sheets based on the HYAFF11p80® scaffold (the one with the lowest degree of esterification)
62418494|NCT00718978|OTHER|A|the investigators grafted sheets based on the HYAFF11® scaffold (the one with the highest degree of esterification).
62418495|NCT00718978|OTHER|A-B|the investigators grafted sheets based on the HYAFF11® scaffold and sheets based on the HYAFF11p80 ® scaffold
62433532|NCT02086526|OTHER|Delayed Start Metformin|After baseline study visit, this arm will return after three months without metformin for a repeat of the baseline study visit prior to initiating metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.
62589197|NCT05332275|EXPERIMENTAL|Intervention Arm - T.E.C.H. Parenting|"Intervention Arm participants will enroll in a web-based psychoeducational group (15 parents per group across 4 groups). Participants will receive psychoeducational information on media parenting, and they will be invited to participate in an online group discussion board to share their experiences with other parents in the intervention. In weeks 2-5, participants will learn about 4 domains of media parenting: 1) Talk to your child about media; 2) Educate your child about media-related risks; 3) Co-View/Co-Use media and technology actively with your child; and 4) establish House rules for media usage. Week 6 will review information and provide an expert clinician to support parent problem solving. Participants will receive 2-3 weekly push messages via text messaging prompting practice of skills learned in the group setting. Participants will be assessed at baseline, immediately following the 6 week intervention, and 3 months after the intervention is completed."
62589198|NCT05332275|ACTIVE_COMPARATOR|Control Arm - General Positive Parenting|The Control Arm of the RCT is the attention control group. These participants will enroll in a web-based psychoeducational group (four groups of 15 parents each). They will receive 6 weeks of online psychoeducational material, including 2-3 push messages prompting skill practice. Parents will have access to an online discussion board to share experiences with other parents. This group will match the intervention arm of the study in number of study staff contacts, time of start/duration of the group, peer support, and availability of a professional in week six for consultation on parenting issues. Control participants will not receive information on media parenting. Participants in this group will be assessed at baseline, immediately following the six-week intervention period, and 3 months after intervention completion. Participants will be asked about exposure to TECH Parenting content at baseline and follow up to address potential contamination effects across study arms.
62589199|NCT01744379|EXPERIMENTAL|200 mg lesinurad|200 mg lesinurad or placebo fasted and fed
62589200|NCT01744379|EXPERIMENTAL|400 mg lesinurad|400 mg lesinurad or placebo fasted and fed
62589201|NCT01744379|EXPERIMENTAL|100 mg lesinurad|100 mg lesinurad or placebo fasted and fed
62589202|NCT01744379|EXPERIMENTAL|50 mg lesinurad|50 mg lesinurad or placebo fasted and fed
62800208|NCT02380287|EXPERIMENTAL|Cohort no.2|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.05 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 3 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 3."
62589203|NCT01744379|EXPERIMENTAL|600 mg lesinurad|600 mg lesinurad or placebo fasted and fed
62026823|NCT04266028|EXPERIMENTAL|DM-101 High MAD|Participants received 5 biweekly administered SC doses of DM-101 as follows: 30 ng on Day 1,50 ng on Day 14, 100 ng on Day 28, 200 ng (dose divided into two SC injections) on Day 42, and 300 ng (dose divided into three SC injections) on Day 56.
62418496|NCT03225820||Overall Pharmacogenomics|"All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the usual care arm (no study-specific PGx information available to providers for these patients). Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance.~NOTE: The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits."
62418497|NCT03225820||Warfarin Sub-Study|"All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the warfarin sub-study, in which patients will be randomized in 1:1 fashion to the pharmacogenomics arm of the study. Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance.~NOTE: Warfarin is prescribed as a standard of care drug. The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits."
62418498|NCT05446376|EXPERIMENTAL|68Ga-citrate PET/CT|
62418499|NCT05947799|OTHER|Video medication module then text self-monitoring module|Patients are provided education via an online animated video on heart failure medications followed by a online text document on heart failure self-monitoring.
62418500|NCT05947799|OTHER|Text medication module then video self-monitoring module|Patients are provided education via an online text document on heart failure medications followed by a online animated video on heart failure self-monitoring.
62418501|NCT05947799|OTHER|Video self-monitoring module then text medication module|Patients are provided education via an online animated video on heart failure self-monitoring followed by a online text document on heart failure medications.
62418502|NCT05947799|OTHER|Text self-monitoring module then video medication module|Patients are provided education via an online text document on heart failure self-monitoring followed by a online animated video on heart failure medication management.
62418503|NCT01346501||Adalimumab|"Participants with Rheumatoid Arthritis (RA) who continued adalimumab treatment after completion of study M06-859, participated in the observational period of studies P12-069 and P12-707.~Other name for adalimumab is Humira."
62026824|NCT04266028|PLACEBO_COMPARATOR|Placebo High MAD|Participants received 5 biweekly administered SC injections of placebo as follows: single injection on Day 1, 14 and 28; two injections on Day 42; three injections on Day 56.
62418504|NCT01346501||Non-adalimumab|Patients who discontinued adalimumab treatment after completion of the study M06-859.
62418505|NCT04528992|EXPERIMENTAL|Physical Therapy with BFR|Participants will begin BFR therapy as early as 2 weeks after surgery. The initial 2 weeks after surgery, or prior to initiation of BFR will consist of the physical therapy following the surgeon's postoperative protocol.
62418506|NCT04528992|ACTIVE_COMPARATOR|Physical Therapy without BFR|Participants will undergo standard physical therapy following the surgeon's postoperative protocol.
62418507|NCT01902524|EXPERIMENTAL|Fentanyl-TTS|Study drug administered in a form of one patch, either 21.0 cm2 or 10.5 cm2.
62418508|NCT03974217|EXPERIMENTAL|Talazoparib Part I|"* Talazoparib is administered orally on a daily basis~* Hydroxyurea is allowed for up to two cycles per institutional guidelines"
62418509|NCT03974217|EXPERIMENTAL|Talazoparib + Decitabine Part II|"* Talazoparib is administered orally on a daily basis~* Hydroxyurea is allowed for up to two cycles per institutional guidelines~* Decitabine on days 1-5"
62418510|NCT06384365||Control|Healthy test subjects, BMI 18.5 - 24.99 kg/m², sporting activity per week ≤ 150 minutes
62418511|NCT06384365||Athlectic|BMI 18.5 - 29.99 kg/m², intensive physical activity per week \> 6 h (spread over min. 3 days)
62418512|NCT06658275|EXPERIMENTAL|GROUP A (Constraint-Induced Movement Therapy)|Participants will undergo Constraint-Induced Movement Therapy(one hour), which will be administered by their parents under the guidance of a therapist through tele- rehabilitation for 3 days in a week for 8 weeks
62418513|NCT06658275|EXPERIMENTAL|GROUP B (Bi-manual intensive therapy)|Participants will undergo Bimanual therapy(one hour), which will be administered by their parents under the guidance of a therapist through tele-rehabilitation for 3 days in a week for 8 weeks.
62418514|NCT03930056|EXPERIMENTAL|C-Brace II Group|Subjects will be assigned a C-Brace II orthotic for use.
62418515|NCT03930056|ACTIVE_COMPARATOR|Traditional Group|Subjects will continue with their own KAFO (non C-Brace II) use.
62433533|NCT05715606|EXPERIMENTAL|Administration of Metabolically Armed CD19 CAR-T cells|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. A dose of metabolically armed CD19 CAR-T cells will be infused on day 0.
62433534|NCT00700284|PLACEBO_COMPARATOR|A|
62433535|NCT00700284|EXPERIMENTAL|B|
62589204|NCT06666088|NO_INTERVENTION|Control Group|The control group will not participate in the physical or cognitive exercise intervention but will receive general recommendations for comprehensive health care. This includes discussions about the benefits of engaging in physical and cognitive exercise, as well as advice on managing physical and mental health. All proposed physical and mental assessments will be conducted with the control group at the beginning of the study and after 12 weeks. Additionally, during the study period, they will be monitored for any changes in physical activity levels that may occur throughout the intervention. Follow-up will also include tracking nutritional changes, sleep habits, and stress levels.
62800209|NCT02380287|EXPERIMENTAL|Cohort no.3|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 4 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 4."
62800210|NCT02380287|EXPERIMENTAL|Cohort no.4|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.825 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 5 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 5."
62800211|NCT02380287|EXPERIMENTAL|Cohort no.5|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 1.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 6 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 6."
62800212|NCT02380287|EXPERIMENTAL|Cohort no.6|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 1.75 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 7 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 7."
62800213|NCT02380287|EXPERIMENTAL|Cohort no.7|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 2.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 8 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 8."
62225583|NCT03291587|NO_INTERVENTION|Usual Care|"No training or performance coaching calls on personnel, just usual clinic practice.~Data collection from Patients: demographics, health status, smoking history, quitting behavior, perceptions of lung cancer risk and worry, impact of screening on tobacco use behavior, and exposure to the intervention. (baseline, \<14 days, 3 months, and 6 months)"
62225584|NCT00716508|ACTIVE_COMPARATOR|A|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
62418516|NCT04504097|EXPERIMENTAL|HIV self-testing + m-Health|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, condoms and lubricant, in addition to contact information for confirmatory testing and linkage to care at MARPI clinics. We will provide a 24-hour contact number to text, managed through WelTel system that will flag these messages in real-time. Participants will also receive a weekly bidirectional SMS hosted by WelTel to check how they are.
62418517|NCT04504097|ACTIVE_COMPARATOR|HIV self-testing|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, condoms and lubricant, in addition to contact information for confirmatory testing and linkage to care at MARPI clinics
62418518|NCT04504097|NO_INTERVENTION|Standard of Care|Participants will receive information about HIV testing, care and support services at MARPI clinics and provide a pamphlet of information about HIV \& HIV prevention strategies.
62418519|NCT04493099|EXPERIMENTAL|Treatment (decitabine, alvocidib hydrochloride, venetoclax)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10, alvocidib hydrochloride IV over 1 hour on days 1-3, 1-5, 1-7, 1-10, or 1-14, and venetoclax PO QD on days 1-14 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive decitabine IV over 1 hour on days 1-5, alvocidib hydrochloride IV over 1 hour on days 1-3, 1-5, 1-7, 1-10 or 1-14, and venetoclax PO QD on days 1-10. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
62418520|NCT06672458|EXPERIMENTAL|Acute SCI Group|Individuals with traumatic spinal cord injury (SCI) with a neurological level at or above T1 spinal cord level; Abbreviated Injury Scale (AIS) A, B, C or D impairment grade; less than 6 months post injury. Participants in this group will be in the study for up to 12 weeks
62800214|NCT02380287|EXPERIMENTAL|Cohort no.8|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 3.0 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level."
62800215|NCT04041934|EXPERIMENTAL|cohorte 1|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.11
62800216|NCT04041934|EXPERIMENTAL|cohorte 2|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.07
62800217|NCT04041934|EXPERIMENTAL|cohort 3|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.04
62418521|NCT06672458|EXPERIMENTAL|Chronic SCI Group|Individuals with traumatic spinal cord injury (SCI) with a neurological level at or above T1 spinal cord level; Abbreviated Injury Scale (AIS) A, B, C or D impairment grade; more than 6 months post injury. Participants in this group will be in the study for up to 12 weeks
62589205|NCT06666088|EXPERIMENTAL|Experimental Group|"The experimental group will participate in a 12-week program combining cognitive stimulation and strength training, with two sessions per week. Each cognitive session, lasting 45 minutes to 1 hour, will aim to improve memory, attention, processing speed, and executive functions through activities like memory games and problem-solving tasks. A professional in neuropsychology or occupational therapy will lead these sessions, adapting activities to participants' abilities.~Strength training will also be conducted twice a week for 45 minutes to 1 hour, focusing on exercises that strengthen major muscle groups and improve balance and coordination. Participants will use light weights, resistance bands, and bodyweight exercises, tailored to their physical levels. A specialized trainer will oversee the program, adjusting exercise intensity to ensure safety and optimize benefits."
62800218|NCT04676295|EXPERIMENTAL|PE intervention|A 12-month lifestyle intervention program to improve mothers and their children blood pressure and CVD risk profile.
62800219|NCT04676295|NO_INTERVENTION|PE control|The control group continue habitual lifestyle but will perform the same baseline and follow-up measurements as the intervention group. They will be given general written information on healthy eating.
62800220|NCT04676295|NO_INTERVENTION|Non-PE control|The control group continue habitual lifestyle but will perform the same baseline and follow-up measurements as the intervention group. They will be given general written information on healthy eating.
62800221|NCT04321044|OTHER|Renal Denervation|We attempt to identify predictors of blood pressure response to renal denervation by using a GWAS (Genome wide association study) approch
62800222|NCT02849119|EXPERIMENTAL|Transperitoneal approach|Laparoscopic or Robotic Partial Nephrectomy through transperitoneal approach
62800223|NCT02849119|EXPERIMENTAL|Retroperitoneal approach|Laparoscopic or Robotic Partial Nephrectomy through retroperitoneal approach
62800224|NCT00497757|EXPERIMENTAL|Cardiac Failure Patients|Recipients treated with an enriched hematopoetic stem cell infusion from the heart donor's bone marrow
62800225|NCT01687608|EXPERIMENTAL|AskBio009 Dose Escalation|Single Dose of a Self-Complementing Optimized Adeno-associated Virus (AAV) Serotype 8 Factor IX Gene Therapy
62800226|NCT00545090|EXPERIMENTAL|1|
62800227|NCT02939534||PD and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Parkinson's disease
62800228|NCT02134860|ACTIVE_COMPARATOR|Isocaloric diet|3 daily meals
62800229|NCT02134860|ACTIVE_COMPARATOR|Alternate daily fasting|One meal (25% of caloric need) every second day and four meals (175% of caloric need) every second day
62589206|NCT06668012|ACTIVE_COMPARATOR|A - Symptomatic patients|Treatment with Palomacare® vaginal gel for 6 days
62589207|NCT06668012|ACTIVE_COMPARATOR|B - Asymptomatic patients|Treatment with Palomacare® vaginal gel for 6 days
62225585|NCT00716508|ACTIVE_COMPARATOR|B|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
62418522|NCT06672458|EXPERIMENTAL|Acute PNI Group|Individuals with PNI that are within 6 months pre- or post-UE nerve transfer surgery. Participants in this group will be in the study for up to 12 weeks
62589208|NCT06668012|NO_INTERVENTION|C - Asymptomatic patients|Monitored follow-up
62589209|NCT02671084|EXPERIMENTAL|Sevoflurane Group|Sevoflurane Group called group A patients will receive sevoflurane. The patients of group A will receive facial mask properly attached to your face, inspiratory fraction of sevoflurane 3%, with therapeutic target of 1.2% expired fraction into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. This procedure is sufficient to induce the pre anesthetic conditioning in the group exposed to sevoflurane. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.
62589210|NCT02671084|PLACEBO_COMPARATOR|Control Group|Control Group called group B patients who will not receive sevoflurane. The patient of group B will receive facial mask properly attached to your face into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.
62026825|NCT04266028|EXPERIMENTAL|DM-101 2-Day Ultra-Rush Dose Escalation|Participants received 9 SC doses of DM-101 as follows: 100, 250, 500, 1000, 2500, 5000, 10000 and 25000 ng during Day 1 and Day 2.
62225586|NCT00753051|ACTIVE_COMPARATOR|1.|clozapine as the main agent and it will be adjuncted by haloperidol
62418523|NCT06672458|EXPERIMENTAL|Chronic PNI Group|Individuals with PNI that are 6 months or more post-UE nerve transfer surgery. Participants in this group will be in the study for up to 12 weeks
62418524|NCT02087826|ACTIVE_COMPARATOR|Carriers of the SLC16A11 risk allele|"Day 1: Mixed Meal Tolerance Test~Day 3-7: 500mg metformin, twice daily~Day 8: Mixed Meal Tolerance Test in presence of Metformin"
62418525|NCT02087826|PLACEBO_COMPARATOR|Non-carriers of the SLC16A11 risk allele|"Day 1: Mixed Meal Tolerance Test~Day 3-7: 500mg metformin, twice daily~Day 8: Mixed Meal Tolerance Test in presence of Metformin"
62418526|NCT06700421|OTHER|Group A|Patients with grade 0-1 radiation pneumonitis were enrolled and treated with adebrelimab combined with apatinib within 42 days after definitive chemoradiotherapy
62418527|NCT06700421|OTHER|Group B|Patients with grade 2 radiation pneumonitis were enrolled and treated with adebrelimab combined with apatinib within 56 days after definitive chemoradiotherapy
62418528|NCT00797316|EXPERIMENTAL|Aliskiren plus Hydrochlorothiazide|Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.
62418529|NCT00797316|ACTIVE_COMPARATOR|Aliskiren|Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.
62418530|NCT05512286|EXPERIMENTAL|Preoperative radiotherapy|Radiotherapy followed by mastectomy and DIEP flap reconstruction
62418531|NCT05512286|ACTIVE_COMPARATOR|Postmastectomy radiotherapy|Radiotherapy after mastectomy and DIEP flap reconstruction
62418532|NCT06542692|EXPERIMENTAL|study group|Whole body vibration therapy added group
62418533|NCT06542692|EXPERIMENTAL|control group|
62418534|NCT06055959|EXPERIMENTAL|Zilucoplan Arm|Study participants will receive zilucoplan in pre-defined dose based on their weight.
62418535|NCT04434209|EXPERIMENTAL|NephroCheck-guided interventions|
62418536|NCT04434209|ACTIVE_COMPARATOR|Standard of Care|Standard of Care assessment and treatment
62418537|NCT04500054|EXPERIMENTAL|Music Intervention Group|The music intervention group listened to the music by the researchers for the duration of 15 minutes one hour before the surgery as well as the standard care.
62418538|NCT04500054|NO_INTERVENTION|No Intervention Group|The control group patients received standard care only.
62418539|NCT06354972||Minimally invasive periodontal regeneration|Minimally-invasive surgical technique (MIST) procedure using both biological inductors and bone xenograft.
62418540|NCT04978194|EXPERIMENTAL|Online group|"Online group: online university-based 9-weeks intervention to promote better management of emotions and learning. This intervention included:~1. 9- video capsules (one per week)~2. An exchange room on each video on a private discord group"
62418541|NCT04978194|EXPERIMENTAL|Hybrid group|"Hybrid group: hybrid university-based 9-weeks intervention to promote better management of emotions and learning. This intervention included: 10 lessons of 2 hours including~1. The viewing of the videos~2. A time of exchange between students, and with the teacher"
62418542|NCT04978194|NO_INTERVENTION|Control group|Control group: No intervention, only two measurement times of 9 weeks apart. Nothing has changed.
62418543|NCT04301089|EXPERIMENTAL|Experimental intervention|Experimental VR Intervention, Survey or Questionnaire Completion and Sample Submission
62418544|NCT06515080||Children/Anesthesia|
62418545|NCT06153979||Group 1 - Actue MeV Infection|Participants have acute MeV infection.
62418546|NCT06153979||Group 2 - No Actue MeV Infection|Participants do not have acute MeV infection.
62418547|NCT05454579||- 150 HIV-positive participants, both who were diagnosed with HIV infection and new cases.|Newly diagnosed HIV-infected participants will be linked to care to start ART. Known HIV-positive participants will be linked to care if they are not in care already. All HIV-positive participants will undergo viral load and CD4 testing at screening/baseline, and be invited back every 6 months for assessment of adherence, viral load testing, STI testing, FBS and lipid profile. A CD4 count will be repeated at Month 12 and Month 24.
62026826|NCT04266028|PLACEBO_COMPARATOR|Placebo 2-Day Ultra-Rush Dose Escalation|Participants received 9 SC injections of placebo during Day 1 and Day 2.
62026827|NCT03793985|EXPERIMENTAL|A (R+T+R+T)|Period 1 : R Period 2 : T Period 3 : R Period 4 : T
62026828|NCT03793985|ACTIVE_COMPARATOR|B (T+R+T+R)|Period 1 : T Period 2 : R Period 3 : T Period 4 : R
62026829|NCT06635421||Patient participants receiving in clinic nurse administered long-acting injectable ART|People with HIV on long acting cabotegravir + rilpivirine who elect to continue to receive their injections in clinic by a nurse
62026830|NCT06635421||Patient participants receiving pharmacist administered long-acting injectable ART in pharmacy|People with HIV on long acting cabotegravir + rilpivirine who elect to continue to receive their injections in a satellite pharmacy by a pharmacist
62026831|NCT06635421||Staff participants|Staff involved in the long-acting injectable ART workflow
62026832|NCT03286023||Stereotactic radiation|Stereotactic radiation for brain metastases
62026833|NCT05847218|EXPERIMENTAL|Cohort A1 (750mg RHN-001 or Placebo) in fasting state|Eligible 16 subjects will be randomized in Cohort A1 (n=16; 12 active: 4 Placebo) and fast for at least 10 hours on check-in day after dinner till 4 hours after they receive the investigational product (RHN-001 750mg caplet) or placebo at the study site on the morning of Day 2 of the study.
62026834|NCT05847218|EXPERIMENTAL|Cohort A2 (750mg RHN-001 or Placebo) in fed state|Eligible 16 subjects will be randomized in Cohort A2 (n=16; 12 active: 4 Placebo) and will receive the investigational product (RHN-001) or placebo on Day 2 (dosing day) within 30 minutes after a standard breakfast. All subjects will undergo a 24-hour PK study during their stay at the clinical trial site.
62026835|NCT05847218|EXPERIMENTAL|Cohort B1 (1500mg RHN-001 or Placebo) in fasting state|Eligible 16 subjects will be randomized in Cohort B1 (n=16; 12 active: 4 Placebo) and fast for at least 10 hours on check-in day after dinner till 4 hours after they receive the investigational product (RHN-001 1500mg caplet) or placebo at the study site on the morning of Day 2 of the study.
62026836|NCT05847218|EXPERIMENTAL|Cohort B2 (1500mg RHN-001 or Placebo) in fed state|Eligible 16 subjects will be randomized in Cohort B2 (n=16; 12 active: 4 Placebo) and will receive the investigational product (RHN-001) or placebo on Day 2 (dosing day) within 30 minutes after a standard breakfast. All subjects will undergo a 24-hour PK study during their stay at the clinical trial site.
62589211|NCT02196688|ACTIVE_COMPARATOR|treatment arm|treatment arm- subjects will receive Fruquintinib 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
62026837|NCT02418325|EXPERIMENTAL|AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
62589212|NCT02196688|PLACEBO_COMPARATOR|control arm|control arm- subjects will receive Fruquintinib placebo 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
62589213|NCT03660189|NO_INTERVENTION|Usual care|Usual care with a one bag system of IV fluids, as recommended in the American Diabetes Association consensus statement guidelines from 2009.
62589214|NCT03660189|EXPERIMENTAL|Two bag system|A two bag system of IV fluids will be used during insulin infusion administration.
62026838|NCT03633383||Transfemoral Approach|
62026839|NCT03633383||Transapical Approach|
62026840|NCT04223011|EXPERIMENTAL|In-Hospital Recovery Coach Intervention|As this is a single-arm, open-label study, all subjects will receive the interventional arm, specifically in-hospital manualized sessions with the recovery coach.
62026841|NCT05614297||Patients with ACL injuries|Patients who have sustained an ACL injury, surgically or non-surgically treated.
62026842|NCT06284811|EXPERIMENTAL|Percussion therapy group|After exercises completed, individuals receive percussion therapy on quadriceps for 10 minutes for both sides. Afterwards individuals will be evaluated again.
62225587|NCT00753051|ACTIVE_COMPARATOR|2.|clozapine as the main agent and it will be adjuncted by electroconvulsive therapy
62589215|NCT02437396||Treatment naive GD1|Type 1 Gaucher disease subjects who are naive to any treatment
62800230|NCT00397384|EXPERIMENTAL|Treatment (cetuximab and erlotinib hydrochloride)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and erlotinib hydrochloride PO QD on days 8-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62800231|NCT02469350|EXPERIMENTAL|Rehabilitation with serious game|18 rehabilitation sessions with serious game during a 6-8 weeks period
62026843|NCT06284811|ACTIVE_COMPARATOR|Massage therapy group|After exercises completed, individuals receive massage therapy on quadriceps for 10 minutes for both sides. Afterwards individuals will be evaluated again.
62026844|NCT05699434||Obstetrics and Gynecology residenst and experts|Obstetrics and Gynecology residents and expert knowledge of, attitudes toward, practice behaviors, and self-confidence levels of caring for lesbian, bisexual, and transgender (LBT+) patients in Turkey ( Istanbul)
62225588|NCT02545023||Observational (Supportive care, health-related QOL)|Participants complete the demographic questionnaire, SCNS-34, SF-36, and the Lifestyle Needs Survey. Within 1 year of completing questionnaires, some participants may complete a one-hour in-person one-on-one interview comprising questions about the challenges and experiences of cancer survivorship, their health and well-being, and supportive care needs.
62026845|NCT06636513|EXPERIMENTAL|SMT04 Arm|Each subject will take 1 sachet of SMT04 daily for 3 months.
62225589|NCT02954068|ACTIVE_COMPARATOR|IV Infusion|Oxytocin 10 IU, 500 ml IV infusion within 40 minutes + intra muscular injection of placebo, 10 IU
62800232|NCT05701007||Patients diagnosed with metastatic castration sensitive prostate cancer (mCSPC)|
62026846|NCT06057350|ACTIVE_COMPARATOR|Surgery|Patients randomized to surgery are treated according to current guidelines with either open, laparoscopic or robotic surgical segmental bowel resection corresponding to lymphovascular drainage of the cancer.
62026847|NCT06057350|EXPERIMENTAL|EFTR (Endoscopic Full-Thickness Resection)|Patients randomised to EFTR are treated using devices approved for eFTR in the European Union and affiliated countries for the indication as applied in the trial. Before EFTR, the scar is identified and documented. The colonoscope is then removed, the EFTR device mounted, the colonoscope re-introduced, and eFTR performed.
62026848|NCT06427785||Remimazolam group|Thirty patients underwent elective lower extremity surgery receive spinal anesthesia, and then, remimazolam besylate was given intravenously with an induction dose of 3mg/min. When the MOAA/S (Modified Observer's Assessment of Alertness/Sedation) score was ≤1, remimazolam besylate was maintained at 1mg/min for 24min, and finally stopped. Wavelet index, MOAA/S score, blood pressure, heart rate, respiratory rate, and pulse oxygen saturation were continuously monitored during the period.
62026849|NCT01610700|EXPERIMENTAL|GW-1000-02|Active treatment
62225590|NCT02954068|ACTIVE_COMPARATOR|IM administration|Oxytocin 10 IU via intra muscular injection + Intravenously administered placebo, 10 IU, 500ml
62026850|NCT01610700|PLACEBO_COMPARATOR|Placebo|Control
62026851|NCT04847635|EXPERIMENTAL|Subthreshold laser group|To evaluate the efficacy of Subthreshold laser in the treatment of reticular pseudodrusen.
62225591|NCT02729428||Exercise trained young adults|Exercise trained young adults between the age of 18-35 years.
62225592|NCT02729428||Sedentary young adults|Sedentary young adults between the age of 18-35 years.
62225593|NCT02729428||Exercise trained older adults|Exercise trained older adults between the age of 55-75 years.
62225594|NCT02729428||Sedentary older adults|Sedentary older adults between the age of 55-75 years.
62225595|NCT03523429|EXPERIMENTAL|blinatumomab|blinatumomab administered during the early consolidation phase in patients ≤ 55 years with high-risk Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukaemia (ALL) with MRD \< 0.1% (\< 1×10-3) after induction therapy.
62225596|NCT03038438|EXPERIMENTAL|Abre|Abre Venous Self-expanding Stent System
62225597|NCT05365217|EXPERIMENTAL|Arm A - Nonacog beta pegol (On-demand/Prophylaxis)|Participants on on-demand treatment for 28 weeks, thereafter prophylactic treatment
62225598|NCT05365217|EXPERIMENTAL|Arm B - Nonacog beta pegol (Prophylaxis)|Participants on prophylactic treatment only
62225599|NCT02624310|EXPERIMENTAL|Droxidopa First, Placebo Second|Participants in this arm will receive droxidopa first, then cross over and receive placebo
62800233|NCT05701007||Patients diagnosed with metastatic castration resistant prostate cancer (mCRPC)|
62026852|NCT04847635|SHAM_COMPARATOR|Sham group|The light from the retinal illumination system on the laser device will be used instead of the laser beam in all follow-up evaluations.
62026853|NCT05234294||Omicron cases|All confirmed COVID-19 cases during January 2022 in the Faroe Islands
62800234|NCT05759689|EXPERIMENTAL|Diagnose Dumping after supplement consumption|Carbohydrate ingestion to provoke dumping syndrome related symptoms
62800235|NCT05759689|ACTIVE_COMPARATOR|Fat supplementation|A high fat supplement was added to the carbohydrate liquid meal that was previously used for diagnosis.
62800236|NCT01757314||CA 1 and 2 anethesia residents|palpation technique
62800237|NCT01757314||Ca1 and 2 residents|ultrasound guided technique
62225600|NCT02624310|EXPERIMENTAL|Placebo First, Droxidopa Second|Participants in this arm will receive placebo first, then cross over and receive droxidopa
62026854|NCT05234294||Controls|Participants in previous serological surveys during 2020 in the Faroe Islands.
62225601|NCT04984525|EXPERIMENTAL|Part 1 Cohort 1 MAD HV: SYNB1934 (3 x 10^11 live cells)|HV subjects receive SYNB1934 (3 x 10\^11 live cells) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
62225602|NCT04984525|EXPERIMENTAL|Part 1 Cohort 2 Crossover HV: SYNB1934 (6 x 10^11 live cells)|HV subjects receive SYNB1934 (6 x 10\^11 live cells) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2 Following a ≥ 7-day washout period HV subjects receive SYNB1618 (6 x 10\^11 live cells), at least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
62225603|NCT04984525|EXPERIMENTAL|Part 1 Cohort 3 MAD HV: SYNB1934 (1 x 10^12 live cells)|HV subjects receive SYNB1934 (1 x 10\^12 live cells) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
62225604|NCT04984525|EXPERIMENTAL|Part 1 Cohort 4 MAD HV: SYNB1934 (optional)|HV subjects receive SYNB1934 (at a dose to be determined based on the data from the first 3 cohorts) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
62225605|NCT04984525|EXPERIMENTAL|Part 1 Cohort 5 MAD HV: SYNB1934 (optional)|HV subjects receive SYNB1934 (at a dose to be determined based on the data from the first 3 cohorts) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
62225606|NCT04984525|EXPERIMENTAL|Part 2 Crossover with PPI vs No PII|HV subjects receive SYNB1934 (at or below the MTD from Part 1) with PPI At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2 Following a ≥ 14-day washout period HV subjects receive SYNB1934 (at or below the MTD from Part 1) without PPI At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
62225607|NCT00454454||No treatment|
62225608|NCT02314845|EXPERIMENTAL|Optimal PEEP|"Patients submitted to general anesthesia and abdominal laparoscopic surgery (number=10) or open surgery (number=10) will be submitted to a recruitment maneuver followed by a PEEP titration procedure using Electrical Impedance Tomography (EIT). Patients will be mechanically ventilated during intraoperative period using Optimal PEEP determined by Electrical Impedance and FIO2 of 0.5."
62589216|NCT02437396||Treated GD1|Type 1 Gaucher disease who are stable on therapy (on the specific ERT and/or SRT and specific dose for at least 2 years)
62589217|NCT02437396||Healthy Volunteers (No longer recruiting)|Age matched healthy controls. No new participants will be enrolled to this arm.
62800238|NCT00918177|EXPERIMENTAL|Early patients|
62026855|NCT05487508|ACTIVE_COMPARATOR|Dexamethasone CCABG|Dexamethasone administered 1 mg per kg body weight (maximum dose 100 mg), given single dose after induction of anesthesia. Surgeon then carried out the conventional coronary artery bypass graft procedure with the use of cardiopulmonary bypass machine.
62026856|NCT05487508|PLACEBO_COMPARATOR|Placebo CCABG|Normal saline (NaCl 0.9%) administered 1 mg per kg body weight (maximum dose 100 mg), given single dose after induction of anesthesia. Surgeon then carried out the conventional coronary artery bypass graft procedure with the use of cardiopulmonary bypass machine.
62026857|NCT05487508|ACTIVE_COMPARATOR|Dexamethasone OPCAB|Dexamethasone administered 1 mg per kg body weight (maximum dose 100 mg), given single dose after induction of anesthesia. Surgeon then carried out the off-pump coronary artery bypass procedure without the use of cardiopulmonary bypass machine.
62225609|NCT02314845|OTHER|Low PEEP|"Patients submitted to general anesthesia and abdominal laparoscopic surgery (number=10) or open surgery (number=10) will be submitted to a recruitment maneuver followed by a PEEP titration procedure EIT. In this arm, the ventilator will be set with a PEEP=4 cmH2O (Low PEEP) and FIO2 of 0.5 during intraoperative period."
62589218|NCT04836026||HF20™ for Pediatric CRRT|Pediatric patients in an intensive care unit requiring CRRT for acute kidney injury (AKI)
62800239|NCT00918177|EXPERIMENTAL|Moderate Patients|
62800240|NCT05098730|EXPERIMENTAL|Stroke survivors with pets|Stroke survivors with pets will receive strategy training for 10-15 sessions, 45 minutes each session, delivered by a trained occupational therapist in the home.
62800241|NCT05098730|ACTIVE_COMPARATOR|Stroke survivors without pets|Stroke survivors without pets will receive strategy training for 10-15 sessions, 45 minutes each session, delivered by a trained occupational therapist in the home.
62800242|NCT05577923|EXPERIMENTAL|T-sunflower group|Patients will be treated with Trastuzumab, Pyrotinib, Dalpiciclib plus Fulvestrant.
62589219|NCT06059391|EXPERIMENTAL|Arm I (Triplex vaccination)|"DONORS: Donors receive Triplex vaccine IM on day 0 and then undergo stem cell mobilization with G-CSF on days 5 to 9 and apheresis for peripheral blood stem cell collection on days 10 to 14 per standard of care. Donors may optionally undergo blood sample collection on study.~RECIPIENTS: Recipients undergo pre-transplant conditioning on days -60 to 0 and undergo HCT with the donor peripheral blood stem cells within 9 weeks of donor vaccination on day 0. Recipients undergo blood sample collection on study."
62026858|NCT05487508|PLACEBO_COMPARATOR|Placebo OPCAB|Normal saline (NaCl 0.9%) administered 1 mg per kg body weight (maximum dose 100 mg), given single dose after induction of anesthesia. Surgeon then carried out the off-pump coronary artery bypass procedure without the use of cardiopulmonary bypass machine.
62026859|NCT05056649||Heart Failure Patients with impaired ejection fraction|
62026860|NCT05396586|ACTIVE_COMPARATOR|Condition 1|Training type 1 will be administered in the first part of the crossover trial and Training type 2 will be administered in the second part of the trial. Each training part consists of 20 twenty-minute long sessions with the recommended frequency of 2 sessions per work day. Thus each training part can be completed in 10 work days (2 weeks).
62589220|NCT06059391|PLACEBO_COMPARATOR|Arm II (Placebo)|"DONORS: Donors receive placebo IM on day 0 and undergo stem cell mobilization with G-CSF on days 5 to 9 and apheresis for peripheral blood stem cell collection on days 10 to 14 per standard of care. Donors may optionally undergo blood sample collection on study.~RECIPIENTS: Recipients undergo pre-transplant conditioning on days -60 to 0 and undergo HCT with the donor peripheral blood stem cells within 9 weeks of donor vaccination on day 0. Recipients undergo blood sample collection on study."
62589221|NCT00968981|EXPERIMENTAL|A|
62589222|NCT00968981|EXPERIMENTAL|B|
62589223|NCT00968981|EXPERIMENTAL|C|
62589224|NCT03639207||1|Patients treated with ledipasvir/sofosbuvir in the Kaiser Permanente Northern California
62589225|NCT06491589||Group A|EVAR with arterial line monitoring
62589226|NCT06491589||Group B|EVAR with no arterial line monitoring
62589227|NCT03973931|NO_INTERVENTION|Usual Care|This group will not receive an intervention. We have included a usual care group to demonstrate the impact of the text messaging interventions above and beyond usual care given that many prior medication adherence interventions have demonstrated small to negligible effects.
62589228|NCT03973931|EXPERIMENTAL|Generic Nudge|A generic reminder text will be delivered to patients to refill their medication at days 1, 3, 5, 7 and 10 after they been labeled as non-adherent.
62800243|NCT01613677|EXPERIMENTAL|BKM120|
62800244|NCT03391934|EXPERIMENTAL|Cetuximab+ FOLFIRI|Cetuximab (Produced by CinnaGen Co.): 400 mg/m2 weekly in the first dose and 250 mg/m2 in the next doses Irinitecan: 180 mg/m2 biweekly Leucovorin: 400 mg/m2 biweekly Fluorouracil: 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly
62800245|NCT03391934|ACTIVE_COMPARATOR|Cetuximab + FOLFIRI|Erbitux® (Produced by Merk Co.): 400 mg/m2 weekly Irinitecan: 180 mg/m2 biweekly Leucovorin: 400 mg/m2 biweekly Fluorouracil: 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly
62800246|NCT00652795|EXPERIMENTAL|A|Subjects received the Par product (Doxycycline Monohydrate) under fasting conditions.
62800247|NCT00652795|ACTIVE_COMPARATOR|B|Subjects received the Oclassen's product (Monodox) Capsules under fasting conditions.
62800248|NCT00642590||1|Healthy couples who are planning their first pregnancy.
62026861|NCT05396586|ACTIVE_COMPARATOR|Condition 2|Training type 2 will be administered in the first part of the crossover trial and Training type 1 will be administered in the second part of the trial. Each training part consists of 20 twenty-minute long sessions with the recommended frequency of 2 sessions per work day. Thus each training part can be completed in 10 work days (2 weeks).
62026862|NCT06415682|EXPERIMENTAL|double-site high frequency rTMS over the bilateral M1 of the lower leg and SMA|Patients in the Experimental group underwent ten sessions of double-site high frequency rTMS over the bilateral M1 of the lower leg and SMA.
62433536|NCT00068237|EXPERIMENTAL|Surgery + Transfer + Radiation|Submandibular salivary gland transfer at the time of surgery for the primary tumor and neck nodes followed by post-operative radiation therapy.
62433537|NCT01438333|EXPERIMENTAL|Lactobacillus brevis|
62800249|NCT06223685|EXPERIMENTAL|Probiotic|"Dosage 2x1 capsule per day. 12 weeks~Probiotic, which will contain a combination of four freeze-dried strains of probiotic bacteria in DRcaps enteral capsulesTM . These are capsules that protect the probiotics from the effects of hydrochloric acid in the stomach, as they only dissolve in the intestines. The tested composition of probiotics is on sale in Poland, Italy, Taiwan, among other countries. It has a positive recommendation of the Institute Pomnik-Center for Children's Health No. 16/DJW/2022.~(Lactococcus lactis Rosell® - 1058, Lactobacillus casei Rosell® - 215, Lactobacillus helvetius Rosell® - 52, Bifidobacterium bifidum Rosell® - 71)"
62800250|NCT06223685|PLACEBO_COMPARATOR|Placebo|"Capsules that look identical to the probiotic and contain potato starch and a shell: hydroxypropylmethylcellulose, gellan gum.~Dosage 2x1 capsule per day. 12 weeks"
62800251|NCT06223685|NO_INTERVENTION|Control group|The control group will consist of healthy subjects (25 subjects) without SIBO (with a negative hydrogen-methane test) and without NAFLD (CAP\<248dB/m, TE\<6.5kPa).
62800252|NCT02057861||non-diabetic|non-diabetic group; 2 mg/kg sugammadex iv, postoperatively Extubation times were recorded.
62800253|NCT02057861||diabetic|Diabetic group; 2 mg/kg sugammadex iv, postoperatively Extubation times were recorded
62800254|NCT00675909|ACTIVE_COMPARATOR|Oral Midazolam|Oral midazolam 0.5mg/kg
62418548|NCT05454579||- 150 HIV-negative participants who are already receiving PrEP or who will accept PrEP.|HIV-negative participants will be offered PrEP. Those who accept PrEP will enroll in the PrEP program in each country, undergo creatinine testing at screening/baseline and be invited back at Month 1, Month 3, and every three months thereafter for HIV testing and assessment of adherence. STI testing, FBS, creatinine and lipid profile will be repeated every 6 months.
62418549|NCT05454579||- 150 HIV-negative participants who will refuse PrEP.|HIV-negative participants who do not wish to start PrEP will be invited back at every three months for HIV-testing. STI-testing, FBS and lipid profile will be repeated every 6 months.
62800255|NCT00675909|EXPERIMENTAL|Aerosolized intranasal midazolam|Intranasal midazolam 0.3mg/kg
62418550|NCT00712907|ACTIVE_COMPARATOR|1|vitamin C (Mayrhofer)
62418551|NCT00712907|PLACEBO_COMPARATOR|2|Placebo
62418552|NCT04149288|ACTIVE_COMPARATOR|High-polyphenol olive oil|Participants will consume 40 mL of high-polyphenol olive oil each day at home for 2 weeks.
62418553|NCT04149288|ACTIVE_COMPARATOR|Low-polyphenol olive oil|Participants will consume 40 mL of low-polyphenol olive oil each day at home for 2 weeks.
62418554|NCT06222398||Exoskeleton Users|This study includes patients who are current exoskeleton users. Exoskeleton users will engage in normal activities of daily living (ADLs) that they currently perform at wheelchair level while using the exoskeleton. Researchers will observe the ADLs the exoskeleton users are and are not able to complete while using their exoskeleton.
62418555|NCT01059942||Hospitalist physicians/house-staff|Consented Academic Hospitalist and Internal Medicine Residency staff
62418556|NCT06390111|EXPERIMENTAL|Nadofaragene Firadenovec|Eligible subjects will receive nadofaragene firadenovec. This will be instilled quarterly in the bladder followed by quarterly disease assessments.
62800256|NCT00675909|EXPERIMENTAL|Aerosolized buccal midazolam|Buccal midazolam 0.3mg/kg
62800257|NCT04932239|EXPERIMENTAL|Road traffic crashes first aid education module|It is an education module aiming to address the topics related to first aid: Recognizing emergency, Call for help, Scene safety, Airway and breathing, Haemorrhage control, First aid kit, Immobilization of fractures and transport of injured people.
62800258|NCT04932239|PLACEBO_COMPARATOR|Tuberculosis prevention education module|This education module covers the definition of the disease, types ways of prevention in working place, and its management
62800259|NCT01749306|OTHER|ABH001|ABH001 application plus wound care dressings.
62800260|NCT01749306|OTHER|Control|Control wound treatment
62800261|NCT02607618|EXPERIMENTAL|iclaprim|iclaprim 80 mg intravenous every 12 hours
62800262|NCT02607618|ACTIVE_COMPARATOR|vancomycin|vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
62800263|NCT05727735|ACTIVE_COMPARATOR|Medtronic Signia Stapler|Patients randomized to this arm will undergo RTS segmentectomy with the Medtronic Signia Stapler.
62800264|NCT05727735|EXPERIMENTAL|Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling|Patients randomized to this arm will undergo RTS segmentectomy with the Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling.
62800265|NCT04521322|PLACEBO_COMPARATOR|Control|Participants in this arm will receive a nasal spray with placebo
62800266|NCT04521322|EXPERIMENTAL|Experimental|Participants in this arm will receive a nasal spray with Iota-Carrageenan
62800267|NCT04995536|EXPERIMENTAL|Treatment (radiation therapy, CAS3/SS3)|Patients undergo radiation therapy on days 1 and 2 tumor-bearing lymph node, and receive CAS3/SS3 intratumorally on days 2, 4, 16, and 18. Patients assigned to dose level 3 also receive CAS3/SS3 intratumorally on days 9, 11, 23, and 25.
62800268|NCT02851303|ACTIVE_COMPARATOR|Morphine|"Dose given q 3 - 4 hrs with feeds; do not exceed 4 hrs between doses Morphine (0.04mg/0.1ml)~Score Dose For Initiation 0-8 0 None 9-12 0.04 mg/dose 13-16 0.08 mg/dose 17-20 0.12 mg/dose 21-24 0.16 mg/dose 25 or above 0.20mg/dose~Morphine Maintenance/Escalation~* Maintain dose if score 0-8~* Increase dose by 0.02 if score is 9-12 (rescore before dosing) • Increase dose by 0.04 if score 13-16~* Increase score by 0.06 if score 17-20~Weaning Instructions:~* Maintain on dose 48 hrs before starting weaning~* Wean 0.02 mg morphine every day for a score is 0-8 • Defer wean for score 9-12~Re-escalation~* If neonate scores 9-12 re-score as described for initiation,~* If second score is in 9-12 increase morphine 0.01 mg q3-4 hrs • If 2 consecutive scores 13-16, increase 0.02 mg q3-4 hrs~* If 2 consecutive scores in 17-20, increase 0.04 mg q3-4 hrs etc"
62800269|NCT02851303|ACTIVE_COMPARATOR|Methadone|Step 1: 0.7 mgs/Kg/24 hrs. divided by into six doses (q 4 hrs) is starting dose Step 2: Decrease dose by half, which is 50% of starting dose, EVERY 4 hours. Step 3: Same dose which is 50% of starting dose EVERY 6 hours. Step 4: Same dose which is 50% of starting dose EVERY 8 hours. Step 5: Same dose which is 50% of starting dose EVERY 12 hours. Step 6: Decrease dose by half, which is 25% of starting dose EVERY 12 hours. Step 7: Same dose which is 25% of starting dose q 24 hours
62800270|NCT04816214|EXPERIMENTAL|Run-in part: Capmatinib + Osimertinib|In the run-in part, up to two dose levels of capmatinib in combination with osimertinib were planned to be investigated. The initial dose level for the combination therapy was capmatinib 400 mg orally twice daily (b.i.d) and osimertinib 80 mg orally once per day (q.d). If a dose de-escalation was necessary, a lower dose level was defined as capmatinib 400 mg orally b.i.d and osimertinib 40 mg orally q.d.
62800271|NCT04816214|EXPERIMENTAL|Randomized part: Capmatinib + Osimertinib|"In the randomized part, capmatinib in combination with osimertinib was to be administered at the recommended Phase III regimen (defined in the safety run-in part).~The study was terminated early based on Sponsor's decision unrelated to safety concerns and the randomized part of the study was not initiated."
62800272|NCT04816214|ACTIVE_COMPARATOR|Randomized Part: Platinum + Pemetrexed Based Doublet Chemotherapy|In the randomized part, platinum-pemetrexed based doublet chemotherapy was to follow local guidelines as per standard of care and products labels. Participants randomized to platinum-pemetrexed based doublet chemotherapy arm were to be allowed to crossover to receive capmatinib in combination with osimertinib. The study was terminated early based on Sponsor's decision unrelated to safety concerns and the randomized part of the study was not initiated.
62418557|NCT06700954|EXPERIMENTAL|legume-rich Planetary Health Diet|legume-rich diet based on the Planetary Health Diet, with a focus on vegetable protein
62433538|NCT01438333|PLACEBO_COMPARATOR|Placebo|5 tablets a day for 6 weeks
62800273|NCT02820675|OTHER|intervention|all hospitals participating in the icosmos trial will be supported in implenatation of the two main interventions.
62800274|NCT00825188|ACTIVE_COMPARATOR|eplerenone|
62418558|NCT06700954|EXPERIMENTAL|control diet based on Western Diet low in legumes|diet based on the Western dietary pattern including animal protein sources (= control diet)
62800275|NCT00825188|ACTIVE_COMPARATOR|amlodipine|Amlodipine 5-10mg daily times 8 weeks
62800276|NCT02754531|EXPERIMENTAL|Subjects|USG was used to measure the internal transversal subglottic diameter on the crichoid cartilago level while the head was in sniffing position. After USG measurement was recorded, Cole formula was used to measure internal diameter of uncuffed endotracheal tube.
62800277|NCT02976935||Healthy Volunteers|Subjects will receive 1L non-hyperpolarised 129Xenon to inhale. Then:Subjects will inhale the first hyperpolarised 129Xenon calibration dose (up to 1L, which may be a mix of hyperpolarised 129Xenon and N2) and hold their breath while the MRI scan is performed. Then:A further series of inhalations will be performed up to a maximum of 3 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L). Optional Study Visit #2:Identical to Study Visit 1 but with the further series of inhalations being up to a maximum of 4 (maximum total exposure to hyperpolarised 129Xenon will be 5L).Optional Study Visit #3: Identical to Study Visit 2 (maximum total exposure to hyperpolarised 129Xenon will be 5L)
62225610|NCT05056987|OTHER|TOTAL30, then AOHP|Lehfilcon A contact lenses worn first, with senofilcon A contact lenses worn second, as randomized. The lehfilcon A contact lenses will be worn for approximately 28 days. The senofilcon A contact lenses will be worn for approximately 14 days. Lenses will be worn bilaterally (in both eyes) in a daily wear modality, with AOSEPT PLUS with HydraGlyde used for nightly cleaning and disinfection.
62433539|NCT00845026|EXPERIMENTAL|LY2140023|LY2140023 (80 mg/day), given orally twice daily as two 40-mg tablets for 24 weeks
62433540|NCT00845026|ACTIVE_COMPARATOR|aripiprazole|aripiprazole (20 mg/day), given orally once daily for 24 weeks
62589229|NCT03973931|EXPERIMENTAL|Optimized nudge|An optimized nudge text will be delivered to patients to remind them to refill their medications at days 1, 3, 5, 7 and 10 after they have been labeled as non-adherent.
62800278|NCT02976935||Chronic Obstructive Pulmonary Disease|Subjects will receive 1L bag of non-hyperpolarised 129Xenon to inhale. Then:Subjects will inhale the first hyperpolarised 129Xenon calibration dose (up to 1L, which may be a mix of hyperpolarised 129Xenon and N2) and hold their breath for required time while the MRI scan is performed.Then:A further series of inhalations will be performed up to a maximum of 3 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L). Optional Study Visit #2: Identical to Study Visit 1 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L)
62800279|NCT06192849|EXPERIMENTAL|Furmonertinib|This arm plans to enroll 20 subjects, treating with furmonertinib 160mg/d, until disease recurrence, death or intolerability. The maximum duration of treatment is three years.
62225611|NCT05056987|OTHER|AOHP, then TOTAL30|Senofilcon A contact lenses worn first, with lehfilcon A contact lenses worn second, as randomized. The senofilcon A contact lenses will be worn for approximately 14 days. The lehfilcon A contact lenses will be worn for approximately 28 days. Lenses will be worn bilaterally (in both eyes) in a daily wear modality, with AOSEPT PLUS with HydraGlyde used for nightly cleaning and disinfection.
62225612|NCT01822288|EXPERIMENTAL|Tibolone group|Tibolone (2.5 mg per day)for 12 consecutive weeks. Tibolone should be paid by patient herself, and does not cover by Taiwan Government health insurance.
62225613|NCT01822288|ACTIVE_COMPARATOR|Conventional hormone therapy group|Estradiol valerate (E2V) 1mg \& medroxyprogesterone acetate (MPA) 2.5 mg per day for 12 consecutive weeks, and this drug is paid by Taiwan Government health care insurance.
62225614|NCT02918578|EXPERIMENTAL|"Phone group"|see intervention description
62225615|NCT02918578|EXPERIMENTAL|"Phone and SMS group"|see intervention description
62225616|NCT02918578|ACTIVE_COMPARATOR|"single writing group"|see intervention description
62433541|NCT00845026|ACTIVE_COMPARATOR|olanzapine|olanzapine (15 mg/day), given orally once daily for 24 weeks
62800280|NCT03594773|EXPERIMENTAL|Interpersonal Psychotherapy|Participants randomized to this arm will be treated with 8 sessions over the course of 8 to 12 weeks by a therapist trained in IPT. Participants will complete brief questionnaires before and after treatment sessions. Before each session, they will report on their psychological distress. Following each session, participants and therapists will both complete assessments of the working alliance and rate their own and the other person's affective and interpersonal behavior.
62225617|NCT02819206|OTHER|Uveitis|Patient with a prescription of a microbiologic diagnostic of uveitis
62225618|NCT03297723||Experimental arm|The experimental group will be constituted after the medical staff was trained to TPE. Cancer patients will benefit from a PEP aiming at learning how to better manage their pain.
62225619|NCT03297723||Controle arm|The control group will be constituted before the training of the medical staff to TPE. Patients' pain will be managed conventionally.
62225620|NCT06191497|ACTIVE_COMPARATOR|Non-smokers|15 non-smoking subjects with diagnosed periodontitis. All of them underwent NSPT
62225621|NCT06191497|EXPERIMENTAL|Non-smokers+ CHX|15 non-smoking subjects with diagnosed periodontitis. All of them underwent NSPT and used 0.12% chlorhexidine mouthwash for 15 days after therapy
62589230|NCT03973931|EXPERIMENTAL|Optimized nudge plus AI Chat Bot|An optimized nudge text will be delivered to patients to remind them to refill their medications at days 1 and 3 after they have been labeled as non-adherent. If the patient has not filled their medication on days 5 and 7, in addition to receiving an optimized nudge text, an AI will conduct interactive chat via a chat bot to assess barriers filling the medication as described in Aim 1 above. If they still have not filled the medication, they will receive another message on day 10.
62225622|NCT06191497|ACTIVE_COMPARATOR|Smokers|15 cigarette smoking subjects with diagnosed periodontitis. All of them underwent NSPT
62225623|NCT06191497|EXPERIMENTAL|Smokers + CHX|15 cigarette smoking subjects with diagnosed periodontitis. All of them underwent NSPT and used 0.12% chlorhexidine mouthwash for 15 days after therapy
62418559|NCT06703671|EXPERIMENTAL|electroacupuncture group|"In the electroacupuncture group, the acupuncture point prescription is based on the Evidence-based Practice Guidelines for Non-surgical Treatment of lumbar disc Herniation. The best clinical acupuncture treatment strategy was determined by the expert committee.Electroacupuncture was applied to the standard acupoints (BL-23,BL-25,EX-B2,BL-40,GB-34) for 30 min per treatment, and the treatment was performed 3 times per week (with an interval of 1-2 days between treatments), with a total of 12 treatments received over 4 weeks. Point selection and location refer to the current national standard GB/T 12346-2021 Meridian point Name and Location."
62418560|NCT06703671|SHAM_COMPARATOR|sham-acupuncture group|In the sham-acupuncture group,the prescription of this sham acupuncture scheme was made with reference to SHARE: Report Guidelines and Clinical Trial List of sham acupuncture and Research on acupuncture point Localization in the treatment of chronic low back Pain.Sham-acupuncture treatments were performed on noacupoints (Sham-BL-23,Sham-BL-25,Sham-EX-B2,Sham-BL-40,Sham-GB-34) for a duration of 30 min for each treatment session, and 3 treatments were performed per week (with an interval of 1-2 days between each treatment session), for a total of 12 treatments over 4 weeks.
62418561|NCT03303807|OTHER|Extracorporeal CO2 removal|Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)
62418562|NCT05689034|ACTIVE_COMPARATOR|Azvudine|Azvudine in Patients at Potential Risk of Progressing to Severe COVID-19 Infection
62418563|NCT05689034|PLACEBO_COMPARATOR|Placebo|Placebo in Patients at Potential Risk of Progressing to Severe COVID-19 Infection
62418564|NCT06700798|EXPERIMENTAL|OR-R|Orelabrutinib 150mg, oral, once daily, Days 1-28, with a cycle of 4 weeks; Cycles 1-24； Rituximab: 375mg/m\^2, intravenous, Day 1, with a cycle of 4 weeks; Cycles 1-6
62418565|NCT06700798|ACTIVE_COMPARATOR|R-CVP|"Rituximab: 375mg/m\^2, intravenous, Day 1, with a cycle of 3 weeks; Cycles 1-8； Cyclophosphamide: 750mg/m\^2, intravenous, Day 1, with a cycle of 3 weeks;Cycles 1-8； Vincristine: 1.4mg/m\^2 (maximum 2mg), intravenous, Day 1, with a cycle of 3 weeks;Cycles 1-8； Prednisone: 60mg/m\^2, oral, Days 1-5, with a cycle of 3 weeks，Cycles 1-8~Subsequently, maintenance with rituximab monotherapy until two years from the start of treatment or until toxicity intolerable."
62418566|NCT03113175|EXPERIMENTAL|Collabri Flex|Collaborative care
62418567|NCT03113175|EXPERIMENTAL|Consultation-Liaison|Consultations with general practitioner
62418568|NCT05133843|OTHER|Coronary physiology|Assession of complete coronary physiology in TAVI candidates with intermediate coronary artery stenosis before and 6 months after TAVI.
62225624|NCT00125502|EXPERIMENTAL|I|n=200; 20 micrograms gB with MF59
62225625|NCT00125502|PLACEBO_COMPARATOR|II|n=200; placebo (normal saline)
62225626|NCT04831294|EXPERIMENTAL|Cannabidiol (CBD)|A tincture containing 125mg broad spectrum CBD oil (6.7%), 24mg sunflower lecithin (1.3%), 56mg peppermint oil (3.0%), and 1661mg hempseed oil (89.0%) will be administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
62225627|NCT04831294|PLACEBO_COMPARATOR|Placebo|A tincture containing 149mg sunflower lecithin (8.0%), 56mg peppermint oil (3.0%), 1661mg hempseed oil (89.0%) will be administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
62225628|NCT02701140|ACTIVE_COMPARATOR|Ticagrelor|Ticagrelor will be given in a loading dose of 180 mg followed by a dose of 90 mg twice daily.
62800281|NCT03594773|EXPERIMENTAL|Cognitive Behavioral Therapy|Participants randomized to this arm will be treated with 8 sessions over the course of 8 to 12 weeks by a therapist trained in CBT. Participants will complete brief questionnaires before and after treatment sessions. Before each session, they will report on their psychological distress. Following each session, participants and therapists will both complete assessments of the working alliance and rate their own and the other person's affective and interpersonal behavior.
62800282|NCT02660164||Cohort A: High-Risk of Concussion|Middle school, high school and college athletes of either gender participating in sports where high-risk of concussion is anticipated: football, soccer, lacrosse, hockey, basketball, ice hockey, field hockey, rugby, cheerleading, boxing, and gymnastics.
62800283|NCT02660164||Cohort B: Low-Risk of Concussion|Middle school, high school and college athletes of either gender participating in sports where low-risk of concussion is anticipated: swimming, track, volleyball, baseball, softball and golf.
62589231|NCT06665178|EXPERIMENTAL|Sacituzumab Govitecan|Patients will receive SG at an initial dose of 10 mg per kilogram intravenously on day 1 and 8 of 21 day cycles.
62589232|NCT05526846|EXPERIMENTAL|Invervention group|Participants will receive an educational intervention about how to incorporate more plant foods into their diet.
62225629|NCT02701140|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel will be given in a loading dose of 600 mg followed by a dose of 75 mg once a day.
62225630|NCT06215027|EXPERIMENTAL|Dance|Dance
62418569|NCT02280915|EXPERIMENTAL|Fortified savoury food product 1|Savoury food product fortified with iron
62418570|NCT02280915|EXPERIMENTAL|Fortified savoury food product 2|Savoury food product fortified with iron
62418571|NCT02280915|EXPERIMENTAL|Fortified savoury food product 3|Savoury food product fortified with iron
62589233|NCT04201158||Obese Group (Girl)|Diagnosed with the obesity according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria.Diagnosed with a neurological disease or another clinical diagnosis that may affect the cognitive state, musculoskeletal and neurological disease, symptomatic heart disease, lung disease, diabetes, hypertension and malignant disease, which may affect the performance of exercise and using the drug that affects appetite and weight are the exclusion criteria.
62589234|NCT04201158||Obese Group (Boy)|Diagnosed with the obesity according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Diagnosed with a neurological disease or another clinical diagnosis that may affect the cognitive state, musculoskeletal and neurological disease, symptomatic heart disease, lung disease, diabetes, hypertension and malignant disease, which may affect the performance of exercise and using the drug that affects appetite and weight are the exclusion criteria.
62589235|NCT04201158||Control Group (Girl)|Being normal weight according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Having comorbidities which may affect exercise performance and other physical tests, diagnosed with the cardiovascular problems, musculoskeletal and neurological diseases, cognitive or motor limitation or other chronic diseases are exclusion criteria.
62589236|NCT04201158||Control Group (Boy)|Being normal weight according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Having comorbidities which may affect exercise performance and other physical tests, diagnosed with the cardiovascular problems, musculoskeletal and neurological diseases, cognitive or motor limitation or other chronic diseases are exclusion criteria.
62589237|NCT04550806||GDM|
62225631|NCT05138367|EXPERIMENTAL|UCA-PSC|Subsequent to isolation and culture of UCA-PSCs, UCA-PSCs (GMP grade, from Clinical Center for Stem Cell Research of the Affiliated Drum Tower Hospital of Nanjing University Medical School, licensed by the National Institute for China Food and Drug Control) were injected into the ovaries of patients with hormone replacement treatment, which consisted of Premarin (0.625 mg/days on days 1 through 25) combined with Provera (10 mg/day for 10 days a month with monthly withdrawal bleeding).
62418572|NCT02280915|EXPERIMENTAL|Fortified savoury food product 4|Savoury food product fortified with iron
62433542|NCT00845026|ACTIVE_COMPARATOR|risperidone|risperidone (4 mg/day), given orally, once or BID for 24 weeks
62589238|NCT04550806||non-GDM|
62589239|NCT05948761|PLACEBO_COMPARATOR|Placebo|Hypoxic generator without active elements, pulsewise ventilation assured to ascertain blinding
62589240|NCT05948761|EXPERIMENTAL|Active intervention|FiO2 0.16 for 5 minutes interspersed with 5 minutes normoxia (intermittent hypoxia)
62589241|NCT04762485|EXPERIMENTAL|CD38 positive relapsed or refractory acute leukemia|Biological/Vaccine: Humanized CD7 CAR-T cells Split intravenous infusion of CD7 CAR-T cells \[dose escalating infusion of (0.5- 10)x10\^6 CD7 CAR-T cells/kg
62800284|NCT03355846|EXPERIMENTAL|AAF treated with Centella® Complex|Centella® Complex 1 cps 60 mg per os
62800285|NCT03355846|EXPERIMENTAL|AAF treated with Proctocella® cream|Proctocella® Complex cream to be applied in anal area and anal canal
62800286|NCT03355846|EXPERIMENTAL|AAF treated with Flavonil® cps|Flavonil® 1 cps 300 mg per os
62800287|NCT03355846|EXPERIMENTAL|AAF treated with Flavonil® Cream|Flavonil® Cream Cream to be applied in anal region and anal canal
62800288|NCT03355846|EXPERIMENTAL|AAF treated with Rectalgan Mousse|Rectalgan Mousse cleansing cleanser for anal and perineal region
62800289|NCT03015636|EXPERIMENTAL|Behavioral: Adjusted CBT-i for ADHD|Cognitive Behavioral group intervention for sleep problems in ADHD, based on Cognitive Behavioral Therapy for insomnia and behavioral treatment for Sleep Phase Disorders.
62800290|NCT03015636|OTHER|Treatment as Usual|Treatment as Usual. (After about ten weeks, participants in this condition are offered the experimental group treatment.)
62589242|NCT01534598|EXPERIMENTAL|Single Arm|FdCyd + THU administered on an intermittent schedule in 21-day cycles per dose escalation table. THU will be administered orally at a fixed dose of 3000 mg 30 minutes prior to FdCyd.
62026863|NCT06415682|ACTIVE_COMPARATOR|single-site high frequency rTMS over the bilateral M1 of the lower leg|Patients in the Active Comparator group underwent ten sessions of single-site active magnetic stimulation with high frequency rTMS over the bilateral M1 of the lower leg.
62026864|NCT06415682|SHAM_COMPARATOR|sham magnetic stimulation on the bilateral M1 of the lower leg|Patients in the Sham Comparator group underwent ten sessions of double sham rTMS on the bilateral M1 of the lower leg.
62026865|NCT00628329||1|
62026866|NCT00628329||2|
62026867|NCT03447418|OTHER|no treatment, open label|
62026868|NCT03506971|EXPERIMENTAL|Participants|"As part of this research, families will benefit from~* pediatric nurse's interventions : home visits by a pediatric nurse who will center around three times: a time of observation of the development and progress of the baby, a time for play with the baby and a time to listening the parents.~* psychologist's evaluation and joint home visits : home visits by the coordinating psychologist to evaluate three areas: child development, parenthood and parent-child interaction."
62225632|NCT05138367|EXPERIMENTAL|WJ-MSC|Subsequent to isolation and culture of WJ-MSCs, WJ-MSCs (GMP grade, from Clinical Center for Stem Cell Research of the Affiliated Drum Tower Hospital of Nanjing University Medical School, licensed by the National Institute for China Food and Drug Control) were injected into the ovaries of patients with hormone replacement treatment, which consisted of Premarin (0.625 mg/days on days 1 through 25) combined with Provera (10 mg/day for 10 days a month with monthly withdrawal bleeding).
62225633|NCT03293693|EXPERIMENTAL|Test meal 1|Test meal with 0.5 g beta-glucan
62225634|NCT03293693|EXPERIMENTAL|Test meal 2|Test meal with 3.5 g beta-glucan
62225635|NCT03293693|EXPERIMENTAL|Test meal 3|Test meal with 8 g beta-glucan
62225636|NCT01853137|EXPERIMENTAL|FLMGM Treatment Group|
62225637|NCT01853137|NO_INTERVENTION|Untreated Class II Control Group|
62225638|NCT03217643|EXPERIMENTAL|Brentuximab Vedotin|The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.
62225639|NCT03676231|EXPERIMENTAL|High-dose SGM-1019|
62589243|NCT01960270|EXPERIMENTAL|Alone controlateral stimulation|"Device: INTERSTIM II~* Stimulator II activated~* Stimulator I not activated~* Measure of efficacy on bladder hyperactivity"
62589244|NCT01960270|EXPERIMENTAL|2 sides-stimulation|"Device: INTERSTIM II~* Stimulator I and II activated~* Measure of efficacy on bladder hyperactivity"
62589245|NCT04563533|EXPERIMENTAL|adults of phase I|Healthy people aged 18-59
62589246|NCT04563533|EXPERIMENTAL|teenagers of phase I|Healthy people aged 6-17
62026869|NCT03506971|OTHER|Control|"psychologist's evaluation : home visits by the coordinating psychologist to evaluate three areas: child development, parenthood and parent-child interaction."
62026870|NCT00760864|EXPERIMENTAL|TAK-715 25 mg BID|
62026871|NCT00760864|EXPERIMENTAL|TAK-715 50 mg BID|
62026872|NCT00760864|EXPERIMENTAL|TAK-715 100 mg BID|
62026873|NCT00760864|ACTIVE_COMPARATOR|Methotrexate|
62026874|NCT05531396|ACTIVE_COMPARATOR|Health Education|
62225640|NCT03676231|EXPERIMENTAL|Low-dose SGM-1019|
62589247|NCT04563533|PLACEBO_COMPARATOR|elderly of phase I|Healthy people 60 years old and above
62800291|NCT00203164|EXPERIMENTAL|rasagiline mesylate|rasagiline mesylate 1 mg oral once daily
62800292|NCT03385148|EXPERIMENTAL|colorectal patients|the colorectal patients undergo 68Ga-Sgc8 PET/CT
62026875|NCT05531396|EXPERIMENTAL|Agility Training Group|
62026876|NCT06028269|EXPERIMENTAL|Sound 1|A sound will be played while moving the head
62026877|NCT06028269|EXPERIMENTAL|Sound 2|A sound (different from Sound 1) will be played while moving the head
62026878|NCT06028269|NO_INTERVENTION|No Sound|No sound will be played while moving the head
62026879|NCT04848025|EXPERIMENTAL|3D customized airway stents|
62418573|NCT05647733|EXPERIMENTAL|Restrictive group: Low splanchnic blood volume Restrictive fluid management strategy|The intervention group is targeted at lowering splanchnic blood volume using a phlebotomy and restricting fluid infusion, individualized to the physiological needs of this population and the distinct LT surgical phases. The strategy will first consist of performing a phlebotomy without fluid replacement at the start of surgery.We will combine it with fluid restriction to prevent excessive fluid administration and its effect on splanchnic blood volume and blood loss, combined with the effect of the phlebotomy, as well as to limit fluid overload, as previously reported. Fluid will be administered to compensate blood loss and treat severe hemodynamic instability.The phlebotomy will be transfused back at the beginning of the reperfusion phase where fluid management will be based on a goal-directed therapy (GDT) using either PPV or SV, as in the control group.
62589248|NCT04563533|EXPERIMENTAL|Toddler of phase I|Healthy people aged 2-5
62589249|NCT04563533|PLACEBO_COMPARATOR|Infants of phase I|6 weeks old-2 years old healthy person
62589250|NCT04563533|EXPERIMENTAL|elderly of phase II|Healthy people 60 years old and above
62589251|NCT04563533|PLACEBO_COMPARATOR|Toddler of phase II|Healthy people aged 2-5
62589252|NCT04563533|EXPERIMENTAL|Infants of phase II|6 weeks old-2 years old healthy person
62589253|NCT04494061||HSCT - Hematopoetic Stem Cell Proliferation|Patients who received hematopoietic stem cell transplant
62589254|NCT04494061||IHSCP - Impaired HSC proliferation|Patients with impaired hematopoietic stem cell proliferation
62589255|NCT02119689||Diabetic Patients|Mild, Moderate and Severe Retinopathy
62589256|NCT02119689||Healthy Controls|Age and sex matched Healthy Controls
62589257|NCT03830684|EXPERIMENTAL|low-dose group|Baicalein Tablets group
62589258|NCT03830684|EXPERIMENTAL|high-dose group|Baicalein Tablets group
62589259|NCT03830684|PLACEBO_COMPARATOR|placebo group|control group
62589260|NCT04026828||Periodontitis Group|Chronic periodontitis and aggressive periodontitis patients
62589261|NCT04026828||Control Group|Both periodontal and medically healthy volunteers.
62026880|NCT01141192|ACTIVE_COMPARATOR|Vitamin D3 supplement|60,000 IU vitamin D3 oral supplement provided every four weeks at weeks 0, 4, 8, and 12 in the form of one 50,000 and two 5,000 IU vitamin D3 supplements in gelcap form.
62026881|NCT01141192|PLACEBO_COMPARATOR|Sugar Pill|Inactive placebo tablets identical in appearance to the active comparator provided every four weeks at weeks 0,4,8,and 12.
62026882|NCT06635408||Aki group|Cystatin c biomarker will be assessed to predict occurrence of early acute kidney injury
62026883|NCT06635408||Non-Aki group|participants in this group will not develop acute kidney injury throughout the study duration
62225641|NCT03676231|PLACEBO_COMPARATOR|Placebo|
62225642|NCT02202954|ACTIVE_COMPARATOR|Guided Self-rehabilitation Contract|"In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.~The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary."
62225643|NCT02202954|NO_INTERVENTION|Conventional rehabilitation|conventional therapy in the community
62225644|NCT01424904|EXPERIMENTAL|DGB-01|All subjects will receive DGB-01 during the study. Approximately one-half of the subjects during the first period and the other half during the second period.
62225645|NCT05130242||Cement-augmented Pedicle Screws (CPS) Group|
62225646|NCT05130242||Hybrid Construct (HC) group|
62225647|NCT01771120||Asthma Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
62225648|NCT01771120||Rhinitis Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
62225649|NCT01771120||Asthma and Rhinitis Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
62225650|NCT01771120||Healthy Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
62225651|NCT01251731|EXPERIMENTAL|Treatment Group 1|
62225652|NCT01251731|EXPERIMENTAL|Treatment Group 2|
62225653|NCT01251731|EXPERIMENTAL|Treatment Group 3|
62225654|NCT01251731|EXPERIMENTAL|Treatment Group 4|
62225655|NCT05203354|ACTIVE_COMPARATOR|NB-UVB group|Patients who receive Narrowband ultraviolet B phototherapy
62225656|NCT05203354|ACTIVE_COMPARATOR|Acitretin group|Patients who receive acitretin
62800293|NCT00760656||Research Participants|Participants with a diagnosis of childhood malignancy treated or followed at SJCRH
62800294|NCT00760656||Control Participants|Siblings, parents, relatives or friends of St. Jude patients or former patients or SJCRH employees who are not SJLIFE study team members or supervised by a SJLIFE study team members
62800295|NCT01344902|EXPERIMENTAL|Hexaminolevulinate|
62589262|NCT03879525|EXPERIMENTAL|EMR Group|Participants assigned to this arm will complete the questionnaires in the EMR using the EMR-based-interventional method.
62589263|NCT03879525|ACTIVE_COMPARATOR|Phone Group|Participants assigned to this arm will complete the questionnaires via the Phone using the Telephone-based-standard method.
62589264|NCT02062164||bariatric surgery group|subjects who participate in the overall project and undergo bariatric surgery
62589265|NCT02062164||conservative care group|subjects who participate in the overall project and do not undergo bariatric surgery
62589266|NCT05180721|EXPERIMENTAL|Use of patient portal for diabetes management|A multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).
62589267|NCT04193956||POINTING|
62589268|NCT04799054|EXPERIMENTAL|Part 1 Monotherapy Dose Escalation and Optimization: TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist in escalating doses to evaluate safety/tolerability and to determine the MTD and RP2D.
62589269|NCT04799054|EXPERIMENTAL|Part 2 Combination Dose Escalation and Optimization: TransCon TLR7/8 Agonist with Pembrolizumab|TransCon TLR7/8 Agonist with Pembrolizumab in escalating doses to evaluate safety/tolerability and determine the MTD and RP2D.
62589270|NCT04799054|EXPERIMENTAL|Part 3 Phase 2 Combination Dose Expansion: TransCon TLR7/8 Agonist with Pembrolizumab|TransCon TLR7/8 Agonist with Pembrolizumab using RP2D from Part 2 to evaluate safety/tolerability and anti-tumor activity of the combination in indication-specific dose expansion cohorts.
62589271|NCT06219824|ACTIVE_COMPARATOR|control Group|pulpotomy treatment for the young permanent teeth will be done using conventional powder and liquid Mineral Trioxide Aggregate followed by Glassionomer restoration and stainless steel crown
62589272|NCT06219824|EXPERIMENTAL|Experimental|pulpotomy treatment for the young permanent teeth will be done using premixed ready for use bioceramic MTA followed by Glassionomer restoration and stainless steel crown
62589273|NCT03060174|OTHER|monitoring and non-medical prophylaxis of delirium|The treatment group will receive monitoring and prophylaxis of delirium. The study arm designed to prevent delirium incorporates reorientation (watches, calendar, family photos, use of hearing aids, glasses and dentures, cognitive stimulation (newspaper, magazines, radio, television), early mobilisation, early enteral nutrition, early removal of drains or catheters, normalizing sleep-awake-rhythm.
62589274|NCT03060174|NO_INTERVENTION|Standard|The standard group will receive standard monitoring and standard treatment. The indication, choice and dosage of the medication used to treat delirium will be at the discretion of the ward doctor and will not be influenced by this study. The chosen medication as well as its dosage will be documented.
62026884|NCT01490632|PLACEBO_COMPARATOR|Placebo|Part A: Placebo administered orally (PO) once daily (QD) for 12 weeks. Part B: Placebo participants stayed on placebo or re-randomized to baricitinib 8 milligram (mg) or 10 mg PO QD for 12 weeks. Part C: Baricitinib participants re-randomized to 4 mg or placebo PO QD for 16 weeks. Part D: Retreated with Part B efficacious dose.
62589275|NCT06077773|EXPERIMENTAL|EP262 50 mg|
62589276|NCT06077773|EXPERIMENTAL|EP262 150 mg|
62589277|NCT06077773|PLACEBO_COMPARATOR|Placebo|
62589278|NCT06077773|EXPERIMENTAL|EP262 25 mg|
62589279|NCT03659916|EXPERIMENTAL|A4250|"Capsules for oral administration (40 or 120 µg/kg) once daily for 72 weeks, or 40 µg/kg/day for the first 12 weeks followed by 120 µg/kg/day for the remaining 60 weeks"
62589280|NCT04057547|EXPERIMENTAL|Experimental group|Mesalazine sustained-release granules, orally, 0.5g/time, 4-6 times/d Modified Gegen Qinlian Decoction, Oral, 7.2g per bag, 2 times / day, 30 minutes before breakfast and dinner
62589281|NCT04057547|ACTIVE_COMPARATOR|Control group|Mesalazine sustained-release granules, orally, 0.5g/time, 4-6 times/d Bifico(Bifidobacterium triple viable capsule), orally，2 capsules/time, 2 days/time.
62589282|NCT05465538|OTHER|Cannabis using older adults|Subjects undergo a single PET scan using \[11C\]UCB-J
62589283|NCT05465538|OTHER|Healthy controls|Subjects undergo a single PET scan using \[11C\]UCB-J
62589284|NCT06667947|ACTIVE_COMPARATOR|Group 1|Caudal Block
62589285|NCT06667947|ACTIVE_COMPARATOR|Group 2|Penile Block
62589286|NCT00883467|OTHER|1|baseline MR signal prior to, during and 30 minutes after an ischemic period of 20 minutes
62589287|NCT00883467|OTHER|2|baseline MR signal prior to, during and 30 minutes after an ischemic period of 20 minutes with additional 5 minutes of cuff stenosis directly after cuff release
62589288|NCT00883467|OTHER|3|short time preconditioning, other details according arm 2
62589289|NCT00883467|OTHER|4|long time preconditioning, other details according arm 2
62589290|NCT02021188||Carotid artery disease|Participants with symptomatic or asymptomatic carotid artery plaques
62589291|NCT02021188||Coronary artery disease|Participants with stable coronary artery disease or recent acute coronary syndrome
62589292|NCT06262945||Group 1|platelet rich fibrin placed into the socket of the extraciton tooth + Augmentin 1gr tablet prescribed 2 times a day
62589293|NCT06262945||Group 2|platelet rich fibrin placed in to the socket of the extractraciton tooth combined with low laser treatment extraorally to the extraction area for three days within surgery day + Augmentin 1gr tablet prescribed 2 times a day
62589294|NCT06262945||Group 3|Low Laser Treatment was applied to the extraorally to the extraction area for three days within surgery day + Augmentin 1gr tablet prescribed 2 times a day
62589295|NCT06262945||Control group.|Tradional osteomy was made. + Augmentin 1gr tablet prescribed 2 times a day
62589296|NCT02938988|EXPERIMENTAL|Test group|Scaling and root planning and antimicrobial photodynamic therapy with red laser (658nm; 0.1W; 2229J/cm², 10s per point) and methylene blue dye (100μg/ml). Repetition after 3, 7 and 14 days.
62589297|NCT02938988|ACTIVE_COMPARATOR|Control Group|Scaling and root planning Repetition after 3, 7 and 14 days.
62589298|NCT03826264||Korea Centers|Seoul, Korea All Patients undergoing TAVR
62800296|NCT06367439|EXPERIMENTAL|Virtual Reality Exercise Condition|Participants will complete a virtual reality (VR) exercise tutorial (Supernatural gameplay) and a Supernatural affect measurement workout (Flow or Boxing) in the Behavioural Medicine Lab (UVic). The tutorial will include watching Supernatural YouTube instructional videos, then completing a Supernatural training (\~5-6 min), a 'getting started' low intensity Supernatural workout (\~3 min), a low intensity Supernatural workout (\~3 min), and a medium intensity Supernatural workout (\~3 min). Participants will then complete the affect measurement medium intensity Supernatural workout (18-20 min). Participants will be provided a Virtual Reality headset (i.e., Meta Quest 3 headset) equipped with a Supernatural account for 10 weeks and will be instructed to participate in 75 minutes of medium intensity Supernatural physical activity per week which is equivalent to 75 minutes of vigorous physical activity (in line with the Canadian physical activity guidelines).
62800297|NCT06367439|NO_INTERVENTION|Waitlist Control Condition|Participants will complete a control treadmill walk/run exercise session in the Behavioural Medicine Lab (30 min) that emulates the lab-based Supernatural exercise session (intervention condition). The treadmill run/walk will be the comparison condition for examining the effects of Supernatural exercise on mood and affect. First, participants will complete a 10 min treadmill orientation where they will walk for 3 min at 3 mph, walk for 3 min at 3.5 mph, walk/jog for 3 min at 4 mph, and walk for 1 min at 3 mph. Participants will then complete a 19.5-20 min treadmill walk/jog where they will complete a 1 min warmup at 3 mph, walk/jog for 17.5 min at 4 mph. Participants will then be asked to continue as they are for 10 weeks and will have the opportunity to bring home the Meta Quest 3 headset equipped with Supernatural for 10 weeks post-study.
62800298|NCT03165370||Insomnia|those with unsatisfactory sleep quantity and/or quality (difficulty with sleep induction, awakenings during the night, early morning awakening, total sleep time, and overall quality of sleep), complaint of a minimum frequency (at least three times a week) and duration (1 month), marked distress caused by the sleep problem and/or interference with ordinary activities of daily living
62800299|NCT02804126|EXPERIMENTAL|TAP (transversus abdominis plane)|Ultrasound-guided transversus abdominis plane block at the end of cesarean section
62800300|NCT02804126|EXPERIMENTAL|QL (quadratus lumborum)|Ultrasound-guided quadratus lumborum block at the end of cesarean section
62026885|NCT01490632|EXPERIMENTAL|Baricitinib 2 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
62026886|NCT01490632|EXPERIMENTAL|Baricitinib 4 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
62800301|NCT02987465||Chronic Kidney Disease patients|Up to 12 patients with anaemia associated with CKD.
62589299|NCT03826264||Stanford University|California, USA All Patients undergoing TAVR
62589300|NCT03826264||Northwestern University|Evanston, Illinois, USA All Patients undergoing TAVR
62589301|NCT03826264||Cheng-Hsin Hospital|Taipei, Taiwan All Patients undergoing TAVR
62589302|NCT00330343|EXPERIMENTAL|Naloxone|continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour
62589303|NCT02232828|EXPERIMENTAL|Selective removal|
62589304|NCT02232828|ACTIVE_COMPARATOR|Stepwise removal|
62589305|NCT05475990|EXPERIMENTAL|Hydroxyethyl starch coload group|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia
62589306|NCT05475990|EXPERIMENTAL|Crystalloid coload group|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia.
62589307|NCT06437717|ACTIVE_COMPARATOR|only normal saline as nasal irrigation|
62589308|NCT06437717|ACTIVE_COMPARATOR|normal saline as nasal irrigation followed by sesame oil nasal drops|
62589309|NCT06437717|ACTIVE_COMPARATOR|only Ringer's lactate solution as nasal irrigation|
62589310|NCT06437717|ACTIVE_COMPARATOR|Ringer's lactate solution as nasal irrigation followed by sesame oil nasal drops|
62589311|NCT06666634|OTHER|Dynamic sentinel node biopsy with 99mTc-nanoscan and ICG-99mTc-nanoscan|The patient first receives a one-time injection with 99mTc-nanoscan, then a one-time injection with ICG-99mTc-nanoscan, both dosage are according to routine care.
62589312|NCT05483686|EXPERIMENTAL|Shine Intervention|Experimental group participants will have access to the mobile Shine intervention.
62800302|NCT02987465||Healthy Volunteers|Up to 12 healthy subjects will be recruited such that age and gender are similar to the CKD patients. These subjects will be recruited as negative controls for a baseline assessment of healthy physiology. These subjects will not be treated with Darbepoetin.
62800303|NCT02987946|ACTIVE_COMPARATOR|Fraxiparine|Intervention: All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice. After randomization the patients in this arm will be subjected to fraxipareine 2850 IE daily. According to current guidelines in the LUMC the Fraxiparine dose is doubled to 5600 IE in patients with a weight above 100 kg.
62418574|NCT05647733|ACTIVE_COMPARATOR|Liberal group: Optimized cardiac output liberal fluid management strategy|The control group will receive a liberal intraoperative fluid management strategy optimizing cardiac output throughout the surgery. It will consist of administering 250 mL fluid boluses until SV stops to increase by more than 10% or until PPV is below 12%, a dynamic indicator of fluid responsiveness validated in many surgical populations, including ESLD patients undergoing a LT.This strategy is informed by data from recent clinical trials on benefits of GDT in major surgery, data on strategies used in major surgery, liver resection or LT and our survey on current practice.
62418575|NCT03739996|EXPERIMENTAL|CAB LA + VRC07-523LS|"Step 1: CAB administered orally as one 30 mg tablet once daily, plus two NRTIs, for 5 weeks.~Step 2: CAB LA loading dose (600 mg) administered as one IM injection at Step 2 entry study visit, and maintenance dose (400 mg), starting at 4 weeks after CAB LA loading dose, and then every 4 weeks through Week R2+44.~VRC07-523LS (40 mg/kg) administered as an IV infusion starting at Step 2 entry and then every 8 weeks through Week R2+40.~Step 3: SOC oral ART regimen for approximately 48 weeks."
62418576|NCT06155149|EXPERIMENTAL|EXPERIMENTAL GROUP|All of the families constituting the sample of the study (30 mobile application-study group) will be told about burn prevention and first aid practices with a training (powerpoint presentation) prepared by the executive researcher in line with the literature and their questions will be answered. Then, the training to be given with the mobile application will be downloaded to the phones of the families in the experimental group and the training will continue through the application.
62418577|NCT06155149|SHAM_COMPARATOR|CONTROL GROUP|All of the families constituting the sample of the study (30 control group) will be told about burn prevention and first aid practices with a training (powerpoint presentation) prepared by the executive researcher in line with the literature and their questions will be answered.
62418578|NCT06073041|EXPERIMENTAL|Adopter|Clinics that decide to adopt the EIMG Program
62418579|NCT06073041|NO_INTERVENTION|Non Adopter|Clinics that decide not to adopt the EIMG Program
62418580|NCT05037812|PLACEBO_COMPARATOR|Saline injection|Saline
62418581|NCT05037812|EXPERIMENTAL|Multimodal injections|"Superficial multimodal analgesia composition includes 5mg morphine, 500 micrograms epinephrine, and 4ml normal saline.~Deep medial multimodal analgesia composition includes 2.5mg morphine, 40 micrograms clonidine, 15mg ketorolac, and 4ml normal saline."
62418582|NCT02737072|EXPERIMENTAL|20 mg LY2510924 + 1500 mg Durvalumab|20 milligrams (mg) LY2510924 given subcutaneously (SQ) once daily in combination with 1500 mg durvalumab given intravenously (IV) on Day 1 of each cycle (28 days).
62418583|NCT02737072|EXPERIMENTAL|30 mg LY2510924 + 1500 mg Durvalumab|30 mg LY2510924 given SQ once daily in combination with 1500 mg durvalumab given IV on Day 1 of each cycle (28 days).
62418584|NCT02737072|EXPERIMENTAL|40 mg LY2510924 + 1500 mg Durvalumab|40 mg LY2510924 given SQ once daily in combination with 1500 mg durvalumab given IV on Day 1 of each cycle (28 days).
62418585|NCT03500887|OTHER|1. Bag inflated so that intrabagpressure increases with 2 mmHg|
62418586|NCT03500887|OTHER|2. Bag inflated to ¾ volume of 1|
62418587|NCT06144931|NO_INTERVENTION|Control Group|Patients in this group will be operated under spinal anesthesia
62418588|NCT06144931|ACTIVE_COMPARATOR|PENG Group|Patients in this group will undergo PENG block guided by ultrasound then spinal anesthesia will performed
62418589|NCT05110625|EXPERIMENTAL|Intervention A|Participants will receive Messaging Intervention
62418590|NCT05110625|EXPERIMENTAL|Intervention B|Participants will receive messaging intervention plus online education to their primary healthcare workers
62418591|NCT05110625|NO_INTERVENTION|Control|Participants will receive usual care only, and their healthcare workers will not receive online education
62433543|NCT02176174||White|Self-reported ethnic group of Black, using the United Kingdom Census categories, as recorded in electronic health records.
62433544|NCT02176174||Black|Self-reported ethnic group of Black, using the United Kingdom Census categories, as recorded in electronic health records.
62433545|NCT02176174||South Asian|Self-reported ethnic group of South Asian, using the United Kingdom Census categories, as recorded in electronic health records.
62433546|NCT02176174||Mixed/Other|Self-reported ethnic group of Mixed or other, using the United Kingdom Census categories, as recorded in electronic health records.
62800304|NCT02987946|EXPERIMENTAL|IPD|Intervention: IPD Device: After randomization the patients in this arm will be subjected to fraxiparine 2850 IE daily and intermittent pressure devices for at least 48 hours or until mobilization. The intermittent pressure device is a leg pump delivered by Converis(R).
62800305|NCT02418039|PLACEBO_COMPARATOR|MHE and normal protein diet|Normal protein content (0.8 g/kg/day)
62800306|NCT02418039|EXPERIMENTAL|MHE and high protein diet|Patients with minimal hepatic encephalopathy will received a high protein diet (1.5 g/kg/day)
62589313|NCT05483686|ACTIVE_COMPARATOR|Control Videos|Control condition participants will be texted an embedded link to a series of videos developed by the Centers for Disease Control. These videos describe healthy HIV-related behaviors for trans women of any status (e.g., recommended testing frequencies, PrEP, ART, condoms), includes videos of trans women describing their experiences with HIV. All control participants will have access to Shine at the end of the research study (i.e., approximately six months after recruitment).
62589314|NCT00798343|ACTIVE_COMPARATOR|Seasonal vaccine|Seasonal influenza vaccination
62589315|NCT00798343|EXPERIMENTAL|Pandemic vaccine|MF59-adjuvanted H5N1 monovalent vaccine
62800307|NCT02935647|EXPERIMENTAL|Propofol|Participants will receive intravenous propofol titrated rapidly at 100-200 mcg/kg/min to reach 80% burst-suppression and then maintained there for 15 minutes, after which propofol administration will be discontinued and the participant will be allowed to awaken.
62800308|NCT01636635|ACTIVE_COMPARATOR|Young (18-45 years)|Obese young women (18-45y) undergoing calorie restriction.
62800309|NCT01636635|EXPERIMENTAL|Older (>60 years)|Obese older women (\>60y) undergoing calorie restriction.
62225657|NCT05203354|NO_INTERVENTION|Control group|It includes apparently healthy people who will be compared to patients in the measurement of Omentin-1 level
62418592|NCT05353491|EXPERIMENTAL|Technology assisted Thinking Healthy Program delivered by peers|"A technology adapted version of the Thinking Healthy Program (THP) delivered by peers using multimedia android based app. The bespoke android app leverages human-centered design and makes use of 2-d videos demonstrating narrative scripts delivered by culturally appropriate animated avatars representing depressed mothers, families, peers and mental health experts.~It is designed as a low intensity psychosocial multicomponent intervention based on cognitive behavioral approaches. The THP improves depression through psychoeducation, behavior activation, thought challenging, improving problem solving skills and by activating social support networks.~The intervention program comprises of 8 sessions delivered by trained peers."
62433547|NCT05955170|EXPERIMENTAL|Combination of tucatinib-Oral VP16-trastuzumab|"The safety run in part will be a safety evaluation including 6 patients at dose D of Oral VP16 per day, trastuzumab 600mg SC flat dose or 6mg/kg IV every 3 weeks and tucatinib 300mg PO BID.~The evaluable population for DLT in this Part 1 is defined as patients who have completed the first 2 cycles of treatment (i.e.6 weeks) and received 100% of the planned dose of tucatinib-Oral VP16-trastuzumab.Patients treated at Dose Recommended during the safety run-in part will be considered as evaluable for the part II."
62433548|NCT04927819||short-length implant (<6.5 mm)|
62433549|NCT04927819||non-short length implant (≥6.5 mm)|
62800310|NCT03094741|EXPERIMENTAL|CancerLife Feasibility Group|Participants will be recruited through advertisements targeted to a specific audience using the keywords cancer and cancer survivors
62589316|NCT03572725|ACTIVE_COMPARATOR|Gas tamponade|Gas as intraocular tamponade.
62589317|NCT03572725|EXPERIMENTAL|Air tamponade|Air as intraocular tamponade.
62589318|NCT05343039|EXPERIMENTAL|Treatment Group|Participants will receive a tVNS device.
62800311|NCT05920317||Principal group|Analysis of the CT scans
62800312|NCT04303481|OTHER|normal diet|
62800313|NCT04303481|EXPERIMENTAL|weight loss program kit|
62800314|NCT04303481|EXPERIMENTAL|weight loss program kit with A. muciniphila prebiotics|
62800315|NCT03607942|EXPERIMENTAL|Experimental Formula|The experimental group will receive a liquid supplement containing 2 specific HMOs
62800316|NCT03607942|PLACEBO_COMPARATOR|Control Formula|The control group will receive a liquid placebo
62800317|NCT05047861|EXPERIMENTAL|Study group|patients will receive the implant in the previously preserved socket using Socket shield technique with Alloplastic graft material
62800318|NCT05047861|ACTIVE_COMPARATOR|Control group|patients will receive the implant in the previously preserved socket shield with Autogenous dentin graft
62800319|NCT03026881|EXPERIMENTAL|Fluzoparib + Apatinib + Paclitaxel|
62800320|NCT02698826|EXPERIMENTAL|Adult patients resuscitated from cardiac arrest|Rapid FiO2 optimization protocol
62800321|NCT04578951||Patients receiving a prosthesis from the FHK® range|
62800322|NCT02944214|EXPERIMENTAL|Febuxostat|take orally,10-80mg per day, for 1 year,start with a low dose, and adjust the dose according to the level of uric acid
62225658|NCT01178554|ACTIVE_COMPARATOR|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
62225659|NCT01178554|EXPERIMENTAL|Standard Manual Treatment (SMT)|Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
62589319|NCT05343039|EXPERIMENTAL|Non-Treatment Group|Participants will not receive a tVNS device.
62589320|NCT01279122|NO_INTERVENTION|Nanoflex IOL|
62589321|NCT01520779||Patients with recurrence|Hepatocellular carcinoma patients with intra-hepatic or distant recurrence of hepatocellular carcinoma within 1 year after radiofrequency ablation
62589322|NCT01520779||Patients with no recurrence|Hepatocellular carcinoma with no intra-hepatic or distant recurrence of hepatocellular carcinoma within 1 year after radiofrequency ablation
62589323|NCT00682370|EXPERIMENTAL|A1|0.3 mg/kg heme arginate
62589324|NCT00682370|EXPERIMENTAL|A2|1 mg/kg heme arginate
62800323|NCT02944214|EXPERIMENTAL|Benzbromarone|take orally,12.5-100mg per day, for 1 year,start with a low dose, and adjust the dose according to the level of uric acid
62800324|NCT04485897|EXPERIMENTAL|icare HOME|
62800325|NCT04769570|ACTIVE_COMPARATOR|Group IPSB|In the first group of patients (Group IPSB), ultrasound-guided interscalene brachial plexus block will be applied 30 minutes before surgery.
62800326|NCT04769570|ACTIVE_COMPARATOR|Group SSNB|In the second group of patients, ultrasound-guided interscalene brachial plexus block and suprascapular nerve block will be applied 30 minutes before surgery.
62800327|NCT04769570|ACTIVE_COMPARATOR|Group Control|Patients in the third group (Group C), will be considered the control group and no block will be performed.
62800328|NCT01721863|EXPERIMENTAL|Exercise training|Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
62800329|NCT01721863|NO_INTERVENTION|control group|Control group conducted the usual care
62589325|NCT00682370|EXPERIMENTAL|A3|3 mg/kg heme arginate
62589326|NCT00682370|PLACEBO_COMPARATOR|P|Placebo
62418593|NCT05353491|ACTIVE_COMPARATOR|Standard Thinking Healthy Program delivered by community health workers|"The Thinking Healthy Programme (THP) is a CBT-based manualised paper version of the intervention targeting women with perinatal depression in low socioeconomic settings.~The CBT techniques include guided discovery using illustrated brief vignettes, behavioural activation, and problem solving. Non-specific techniques include empathic listening and promoting social support from key family members for the mother in negotiating challenges during the perinatal period. This intervention programme is paper based utilizing reference manual, health calendar and job aid as tools for delivering content.~The intervention employs these techniques to improve outcomes in three areas: maternal well-being, mother-infant interaction and relationship with significant others. The intervention consists of 8 core sessions starting in the second or third trimester of pregnancy and continuing to 3 months postnatal."
62418594|NCT05368714|EXPERIMENTAL|Economic Empowerment (EE)|EE consists of a child development account (CDA) held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda).
62418595|NCT05368714|EXPERIMENTAL|Multiple Family Group (MFG) - based Family Strengthening (FS) Intervention:|MFG-based consists of 16 sessions focused on building support for parents and families by providing opportunities for parents and children to communicate in a safe setting with other families who have shared experiences. Core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
62418596|NCT05368714|EXPERIMENTAL|Combined EE plus MFG-based FS|EE+ MFG-based FS combines both the child development account and 16 sessions of MFG.
62418597|NCT03716804|EXPERIMENTAL|Intervention group|"Intervention:~To the prescribers- Educational intervention about guideline and present sensitivity trend.~To the Patients- Tablet Nitrofurantoin(100 mg), two times daily at 12 hours interval for 7 days."
62418598|NCT03716804|ACTIVE_COMPARATOR|Control Group|"Intervention:~To the Patients- Tablet Ciprofloxacin, 500 mg or,Tablet Cefixime 200 mg or,Tablet Cefuroxime 250 mg (According to physician's personal choice)."
62418599|NCT06536946||Participants|50 formalin fixed parrafin embedded tissue blocks of cutaneous squamous cell carcinoma and its mimickers , from each block 2 tissue section; one tissue section stained by Hematoxilin and Eoisin and other tissue section will be stained immunohistochemically by anti human B-catenin
62589327|NCT05137067|OTHER|Chemotherapeutic agent A (Docetaxel)|The patients with breast cancer will receive chemotherapeutic agent A
62589328|NCT05137067|PLACEBO_COMPARATOR|Chemotherapeutic agent A (Docetaxel) plus placebo|The patients with breast cancer will receive chemotherapeutic agent A plus a placebo.
62589329|NCT05137067|ACTIVE_COMPARATOR|Chemotherapeutic agent A (Docetaxel) plus RaproCell|The patients with breast cancer will receive chemotherapeutic agent A plus RaproCell.
62589330|NCT05137067|OTHER|Chemotherapeutic agent B (Cisplatin)|The patients with lung cancer will receive Chemotherapeutic agent B
62589331|NCT05137067|PLACEBO_COMPARATOR|Chemotherapeutic agent B (Cisplatin) plus placebo|The patients with lung cancer will receive Chemotherapeutic agent B plus placebo.
62589332|NCT05137067|ACTIVE_COMPARATOR|Chemotherapeutic agent B (Cisplatin) plus RaproCell|The patients with lung cancer will receive Chemotherapeutic agent B plus RaproCell.
62589333|NCT05137067|OTHER|Chemotherapeutic agent C (Docetaxel)|The patients with prostate cancer will receive Chemotherapeutic agent C
62589334|NCT05137067|PLACEBO_COMPARATOR|Chemotherapeutic agent C (Docetaxel) plus placebo|The patients with prostate cancer will receive Chemotherapeutic agent C plus placebo.
62589335|NCT05137067|ACTIVE_COMPARATOR|Chemotherapeutic agent C plus (Docetaxel) RaproCell|The patients with prostate cancer will receive Chemotherapeutic agent C plus RaproCell.
62589336|NCT01843140||Young female cancer survivors|
62589337|NCT06685523|NO_INTERVENTION|Group healty|
62589338|NCT06685523|EXPERIMENTAL|Mechanical debridement group|
62589339|NCT06685523|EXPERIMENTAL|Er:YAG laser applied group|
62589340|NCT06685523|EXPERIMENTAL|Diyot laser applied group|
62589341|NCT04259424|EXPERIMENTAL|Aerobic Exercise + Upper Extremity Rehabilitation|Subjects will receive a total of 18 intervention sessions. In each intervention session, subjects will perform 15 minutes of aerobic exercise on a stationary cycle followed by 200 repetitions of an upper extremity rehabilitation program.
62589342|NCT02994225|EXPERIMENTAL|Study arm|"Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.~Near Infra-red images acquisition is performed during surgery"
62589343|NCT04949646|EXPERIMENTAL|pIONM|"In the experimental group pIONM will be performed intraoperatively. For the implementation of pIONM, a special device, that allows simultaneous monitoring of sphincter signals and bladder manometry, will be introduced. This device will employ the placement of a bipolar electrode in the internal and external anal sphincter. Moreover, another electrode will be placed on the surrounding tissues. For bladder manometry, the catheter will be connected to the pressure sensor, and subsequently to the pIONM monitor. Intraoperatively, depending on the approach (open or laparoscopic), the respective bipolar stimulator will be used.~Prior to the initiation of pIONM, urinary bladder will be drained and filled with 200 ml R/L. The pIONM parameters will be the following: 1-25 milliampere current, 30 Hz frequency and 200 μs monophasic pulses."
62589344|NCT04949646|NO_INTERVENTION|Control|In the control group pIONM will not be performed intraoperatively
62589345|NCT05996341|EXPERIMENTAL|LBPADIM_BFR group|"Recipient No. 12 lower ribs and upper rechargeable nylon ribs , charge to 160mmHg and do ADIM at the same time and retract the abdominal muscles and let the belly fold inward and upward toward the spine and hold for 10 seconds, once.~The total number of intervention was 20 minutes, once a time, a total of 4 minutes."
62800330|NCT05947318|EXPERIMENTAL|tACS - 70 Hz group|The group will receive the training program plus 20 minutes of tACS at 70 Hz in the C3 or C4 electrode position (depending of the hemiparetic arm) during a specific kinetic and kinematic tasks in every training session.
62589346|NCT05996341|PLACEBO_COMPARATOR|LBPADIM_shan BFR group|"The recipient has a rechargeable nylon rib under the 12th rib , but it is not filled and does not cause abdominal muscle BFR, which is used as the BFR of abdominal muscle.~At the same time, we also do ADIM authentication,and retract the abdominal muscles and let the belly fold inward and upward toward the spine and hold for 10 seconds, once.~The total number of intervention was 20 minutes, once a time, a total of 4 minutes."
62225660|NCT01178554|EXPERIMENTAL|Modular Maual Treatment (MMT)|Therapists used a modular manual (Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems; Chorpita \& Weisz, 2004) to help children with primary problems of anxiety, depression, and conduct.
62800331|NCT05947318|ACTIVE_COMPARATOR|tACS - 7 Hz group|The group will receive the training program plus 20 minutes of tACS at 7 Hz in the C3 or C4 electrode position (depending of the hemiparetic arm) during a specific kinetic and kinematic tasks in every training session.
62418600|NCT06703112|ACTIVE_COMPARATOR|ovarian tumors|
62225661|NCT06025162||LMWH dosing strategies|"MDMC's trauma VTE prophylaxis guideline will be used to classify patients into two treatment arms (weight-based or standard dose) based on their dose of enoxaparin at 48 hours post-VTE prophylaxis initiation"
62418601|NCT05204628|EXPERIMENTAL|XZP-3621|Participants will receive XZP-3621 tablets orally at a dose of 500 mg QD with food until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
62418602|NCT05204628|ACTIVE_COMPARATOR|Crizotinib|Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
62418603|NCT06445738|EXPERIMENTAL|Radiotherapy Omission|"Participants with nil, minimal or mild parenchymal enhancement on pre-operative MRI whose pathology meets inclusion/exclusion requirements for omission of post-operative radiotherapy will be allocated to Arm A, unless the participant prefers to receive Standard Treatment (Arm B) or following clinical team recommendation.~Arm A participants will be divided into 2 groups:~* Arm A1: Grade 1 or 2/HER2 negative (low risk)~* Arm A2: Grade 3 and/or HER2 positive (high risk)"
62418604|NCT06445738|ACTIVE_COMPARATOR|Standard Treatment|"Participants who are found to be ineligible for RT omission on study; includes management of MRI-detected lesions.~Participants with any of:~* Moderate or marked parenchymal enhancement on pre-operative MRI~* A malignant occult lesion identified on MRI; or~* Pathology that does not meet inclusion/exclusion criteria will receive standard multidisciplinary team recommendations to guide treatment. Participants may also be included in Arm B due to their own preference or following clinical team recommendation."
62418605|NCT03022019|NO_INTERVENTION|No ReNovaCell treatment|Lesion on the same patient that receives only standard therapy, no ReNovaCell treatment.
62589347|NCT05996341|EXPERIMENTAL|HealthyADIM_BFR group|"Tested The top rechargeable nylon under the 12th rib , charge to 160mmHg and do ADIM password at the same time, and tand retract the abdominal muscles and let the belly fold inward and upward toward the spine and hold for 10 seconds, once.~The total number of intervention was 20 minutes, once a time, a total of 4 minutes."
62589348|NCT06277869|EXPERIMENTAL|Thermal Jacket|As a intervention, the enrolled preterm or low birthweight neonates gets the thermal jacket as well as Kangaroo Mother Care for thermal care.
62800332|NCT05947318|SHAM_COMPARATOR|tACS - sham group|The group will receive the training program plus 30 seconds of tACS at 70 Hz in the C3 or C4 electrode position (depending of the hemiparetic arm) in every training session.
62225662|NCT04308343|ACTIVE_COMPARATOR|Methotrexate group|
62418606|NCT03022019|EXPERIMENTAL|ReNovaCell treatment|Lesion on the same patient that receives the ReNovaCell treatment
62418607|NCT05534191|EXPERIMENTAL|Intervention|This group will use a functional training system developed specifically for football players to improve their physical strength and movement abilities on the field.
62418608|NCT05534191|ACTIVE_COMPARATOR|Positive control|This group will use general strength exercises with the purpose of improving physical strength.
62418609|NCT05534191|NO_INTERVENTION|Negative control|Control group A group that is not treated
62418610|NCT05900739|EXPERIMENTAL|Intervention 1: Virtual Campus|This group received 7 sessions (one every 7 days) of one hour through moodle virtual campus (webinar) to work TPB constructs: attitude; subjective norms; perceived behavioural control and intention.
62225663|NCT04308343|ACTIVE_COMPARATOR|Letrozole group|
62225664|NCT04308343|ACTIVE_COMPARATOR|Gonadotropins releasing hormone antagonist group|
62225665|NCT05000073|EXPERIMENTAL|Experimental Arm|
62225666|NCT05000073|ACTIVE_COMPARATOR|Control arm|
62225667|NCT03054402|EXPERIMENTAL|Dose escalation/BAY1834845|Subjects will receive a single dose of BAY1834845 in the morning of the PK profile day
62225668|NCT03054402|PLACEBO_COMPARATOR|Placebo|Subjects will receive a single dose of placebo in the morning of the PK profile day
62225669|NCT03990493|EXPERIMENTAL|PV-001-DV in Combination with PV-001-DC|Intratumoral injection of PV-001-DV (1 injection) and IV Infusion of PV-001-DC (every 3 weeks for total of 4 infusions)
62026887|NCT01490632|EXPERIMENTAL|Baricitinib 8 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
62418611|NCT05900739|EXPERIMENTAL|Intervention 2: Facebook|This group received 25 educational impacts (2-5 per week - during 7 weeks) through a private group of facebook. Activities were: posts, stories and Facebook Lives as workshops (recorded)
62418612|NCT05900739|EXPERIMENTAL|Intervention 3: Instagram|This group received 35 educational impacts (4-6 per week - during 7 weeks) through a private account of instagram. Activities were: posts, stories and Instagram Lives as workshops (recorded)
62418613|NCT05900739|NO_INTERVENTION|Control|Information about Mediterranean Diet was provided but no activities nor interventions took place.
62418614|NCT03430557|EXPERIMENTAL|Periapical surgery with PRP|MTA Retrograde filling will be performed after apicectomy for involved teeth and PRP will be filled in the lesion before closure of flap
62418615|NCT03430557|ACTIVE_COMPARATOR|Periapical surgery without PRP|MTA Retrograde filling will be performed after apicectomy for involved teeth and flap will be closed without placement of PRP
62418616|NCT06701188|NO_INTERVENTION|Mobile App Alone|"Mobile app control group. Exposure time will be similar between participants in both the intervention and control groups as both will have: (1) continuous access to the app for self-monitoring of exercise, blood pressure, and weight; (2) weekly push text messages with access to a library of educational content for learning that is self-paced on the app over 6 months; and (3) assigned 1 video per month on a variety of health topics related to older adults via the app that match exposure time (approximately 20-30 minutes) with the intervention group. The videos will be created or resourced from reputable organizations. Our team will send weekly short one-way messages on goals, barriers, self-management, etc. that the intervention group will also receive. The 1-way messages will be derived from a bank of 210 secondary prevention messages for CVD (PA, nutrition, stress management, heart disease facts, etc.)."
62418617|NCT06701188|EXPERIMENTAL|Mobile app + Social|"The intervention group will also receive Virtual coaching. The coach will evaluate goals, progress, facilitators (use of the buddy system) and barriers with an emphasis on forming healthy PA habits that will be sustained long-term over the life course. Social support: For the social support component, we will provide ground rules for communication (e.g., positive posts, use of likes, comments, etc.). Groups will be comprised of 4-6 participants with consecutive recruitment."
62418618|NCT05867173|EXPERIMENTAL|Performance Assessed with Experimental Sound Processing Strategy|Patients listening to experimental cochlear implant processing strategy.
62026888|NCT01490632|EXPERIMENTAL|Baricitinib 10 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or discontinued from the study for 12 weeks. Part C: Participants re-randomized to 4mg dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
62418619|NCT05867173|NO_INTERVENTION|Control|"Patients listening to their clinical cochlear implant using their own processor (their everyday listening situation)."
62418620|NCT05867173|SHAM_COMPARATOR|Experimental Control|"Patients listening to experimental cochlear implant using a processing strategy like thier clinical program, a clinical like program."
62418621|NCT05713916|EXPERIMENTAL|Intervention: Population Health Coordinator|For subject randomized to the intervention arm, population health coordinators will notify the established longitudinal specialty clinician (cardiologist or nephrologist) or the primary care provider (PCP) that their patient has a recent echocardiogram demonstrating left ventricular hypertrophy (LVH). The outpatient clinician will be notified via the electronic health record (EHR) messaging system that the finding of LVH -- in the absence of significant valvular heart disease or a previously diagnosed cardiomyopathy -- may reflect undiagnosed or untreated hypertension.
62418622|NCT05713916|NO_INTERVENTION|Observation: Usual Care|Those subjects randomized to the observation arm will receive usual care and their clinicians will not be notified about the finding of LVH on a prior echocardiogram until after study completion.
62418623|NCT01576731|ACTIVE_COMPARATOR|Tenofovir + emtricitabine + lopinavir/r|Standard postexposure prophylaxis combination
62418624|NCT01576731|EXPERIMENTAL|Tenofovir + Emtricitabine + Raltegravir|new postexposure prophylaxis combination
62418625|NCT01845090|ACTIVE_COMPARATOR|Lanthanum carbonate|Lanthanum carbonate 375mg\~750 mg tid for 6 months
62418626|NCT01845090|ACTIVE_COMPARATOR|Calcium carbonate|Calcium carbonate 500mg\~1000 mg tid for 6 months
62800333|NCT04870502|ACTIVE_COMPARATOR|Clomiphene citrate and Ubiquinol|Controlled ovarian stimulation (COS) was done by Clomiphene Citrate (Fertab® 50 mg tablets, Zynova. SITCO Pharma.) as 150 mg (3 tablets) daily for 5 days (from 2nd day till 6th day of the cycle) together with Ubiquinol (active form of Coenzyme Q10) starting from 2nd day till the day of human Chorionic Gonadotropin (hCG) triggering in a dose of 100 mg capsules orally once daily, immediately after meal (Nutraquinol®; Jamjoom Pharma Nutraceuticals).
62800334|NCT04870502|ACTIVE_COMPARATOR|Human Menopausal Gonadotropins (hMG)|Controlled ovarian stimulation (COS) was done by Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given from 2nd day of the cycle in a dose ranging from 75 to 225 IU according to the patient's response.
62800335|NCT03678311|OTHER|Sleep Apnea ahi > 5|If Sleep Apnea index is \> 5 and diagnosed with Long QT Syndrome
62026889|NCT04973137|EXPERIMENTAL|Birtamimab plus Standard of Care Chemotherapy- For Double-blind Phase and OLE Phase of study|"Intravenous administration of 24 mg/kg birtamimab every 28 days.~Drug: Standard of Care Chemotherapy. Bortezomib-containing chemotherapy regimen (e.g. cyclophosphamide, bortezomib, and dexamethasone (CyBorD)) according to the institutional standard of care.~The initiation of daratumumab treatment at randomization is allowed at the discretion of the Investigator; initiation at any other time during the Double-blind Phase is prohibited. For subjects who did not initiate daratumumab at randomization during the Double-blind Phase, daratumumab may be initiated at any time during the OLE Phase at the Investigator's discretion."
62800336|NCT03488966|EXPERIMENTAL|MB-EAT|Behavioral: group psychotherapy. Eight weekly sessions, each session is 2 hours in duration.
62800337|NCT03488966|NO_INTERVENTION|Waitlist Control|Wait list control.
62225670|NCT02825784|EXPERIMENTAL|Renastart|"Compared to cows' milk and/or standard pediatric enteral feeds, Renastart has the following additional nutritional features that are beneficial in children with CKD: lower phosphorus, calcium and vitamin A. The powder presentation allows flexibility with dilutions to facilitate the provision of adequate energy and protein to support growth in children with CKD.~For each subject, the recommended daily intake of Renastart is determined by the dietitian in collaboration with the local PI and primary nephrologist based on individual nutritional requirements, specifically dietary intake of potassium and serum potassium levels.~Renastart is to be given by the clinician and based on clinical and nutritional needs. Standard preparation guidelines can be found on the Renastart label."
62418627|NCT06598540|EXPERIMENTAL|Kindness-focused intervention arm|Mindset intervention framing food choices as an opportunity to practice self-kindness. Individuals randomized to this arm will participate in a 15-20-minute live virtual educational session delivered via the Stanford Zoom platform. The recording of the session will be available on a private and secure educational platform for those who cannot attend the live session and for future review. After participating in the initial educational session, participants can engage in brief (less than 10 minutes) web-based activities on their own time during weeks 2 and 4.
62418628|NCT06598540|ACTIVE_COMPARATOR|Health-focused intervention arm|Brief education intervention framing food choices as a component of a healthy lifestyle. Individuals randomized to this arm will participate in a 15-20-minute live virtual educational session. After participating in the initial educational session, participants will have the option to engage in brief (less than 10-minute) web-based activities on their own time during weeks 2 and 4.
62418629|NCT03102138||observation|subjects treated in B4711001 with PF-05206388 will be assessed
62418630|NCT02656875|EXPERIMENTAL|TRV130|"For clinician-administered bolus dosing, TRV130 initial dose is administered and supplemental dosing is available, if clinically indicated. Subsequent doses may be administered every 1 to 3 hours as needed.~For PCA dosing, the TRV130 regimen consists of a loading dose, a demand dose, and a lockout interval."
62418631|NCT03660514|NO_INTERVENTION|Standard Family Planning|Counseling Clients receive standard FP counseling services.
62418632|NCT03660514|EXPERIMENTAL|Jovenes Sanos Intervention in FP Counseling|Clients receive the Jovenes Sanos intervention in addition to standard FP counseling services.
62418633|NCT01467401|EXPERIMENTAL|A|
62418634|NCT01467401|ACTIVE_COMPARATOR|B|
62418635|NCT04427930|EXPERIMENTAL|JOINTSTEM|Long Term Follow-up after Jointstem Transplantation
62418636|NCT06526923|EXPERIMENTAL|Cohort 1|Single inhalational administration of SP-101 and doxorubicin Dose 1
62418637|NCT06526923|EXPERIMENTAL|Cohort 2|Single inhalational administration of SP-101 and doxorubicin Dose 2
62418638|NCT06526923|EXPERIMENTAL|Dose Expansion|Single inhalational administration of SP-101 and doxorubicin Selected Dose
62418639|NCT06499896|EXPERIMENTAL|MTP-101-C (Cohort 1: Steroid R/R biologic-naive dermatitis)|"Patients given MTP-101-C (encapsulated fecal microbiota, containing \~5 x 1011 bacteria derived from healthy donors).~Dosing:~5 capsules/day (Day 1); 2 capsules/day (D2-D28)"
62418640|NCT06499896|EXPERIMENTAL|MTP-101-C (Cohort 2: Steroid R/R biologic-naive colitis)|"Patients given MTP-101-C (encapsulated fecal microbiota, containing \~5 x 1011 bacteria derived from healthy donors).~Dosing:~5 capsules/day (Day 1); 2 capsules/day (D2-D28)"
62418641|NCT05907902|EXPERIMENTAL|Aspirin|low-dose aspirin, 100 mg once daily, one 100mg tablet
62589349|NCT06277869|ACTIVE_COMPARATOR|Kangaroo Mother Care|As a control, the enrolled preterm or low birthweight neonates gets the conventional Kangaroo Mother Care only.
62589350|NCT01676740|PLACEBO_COMPARATOR|Mild anemia, normal hematinics|Mild anemia, normal iron studies, serum folate and vitamin B12 levels - will receive placebo
62589351|NCT01676740|EXPERIMENTAL|Anemia, normal hematinics|Mild anemia, deficient iron, folate or vitamin B12 levels Iron supplement will be given
62800338|NCT02753426|OTHER|Doxycycline-Placebo|Doxycycline 20mg capsule for 30 days, 30-day washout, and then placebo capsule for 30 days.
62418642|NCT05907902|NO_INTERVENTION|standard protocol|standard of care, UIA management according to guidelines.
62418643|NCT05558189|EXPERIMENTAL|Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
62418644|NCT05755724|EXPERIMENTAL|Remote immersive virtual reality group (3D) teaching|Telesimulation using immersive VR technology. Briefly, students will have a 360° camera mounted to their head, which will broadcast their first-person perspective to their teachers. Teachers will be able to immerse themselves in the perspective of the trainee using a virtual reality HMD (Oculus Quest 2), which allows them to look around freely and view equipment, hand movements, etc. and offer instruction accordingly.
62418645|NCT05755724|PLACEBO_COMPARATOR|Remote 2 D teaching|Telesimulation using standard teleconferencing software and equipment including 2D computer monitors, webcams, and an ultrasound machine linked to a computer (enabling ultrasound images to be transmitted).
62418646|NCT06567288|EXPERIMENTAL|spencer muscle energy technique|Spencer muscle energy technique (SMET) attempts to re-establish functional relationship between soft and articular tissues of the shoulder region, minimizes inflammatory and later developing fibrotic process, and restores arterial, venous, and lymphatic flow. Like other OMT procedures, it not only restores joint functions, but enhances positive well-being and full expression of a patient's life. In this technique, passive, smooth, rhythmic motion of the shoulder joint is done by the therapist to stretch contracted muscles, ligaments, and capsule (Babu And Putcha.,2022).
62589352|NCT01676740|OTHER|Deficeicnt hematinics|Iron supplement will be provided
62589353|NCT05548205|EXPERIMENTAL|Continuous Glucose Monitoring (CGM)|Patients in the CGM group will be instructed to wear a CGM uninterruptedly for 2 weeks duration.
62589354|NCT05548205|ACTIVE_COMPARATOR|Blood Glucose Monitoring (BGM)|Patients in the BGM group will be instructed to check their blood glucose utilizing fingerstick glucose monitoring multiple times daily depending on their insulin regimen for 2 weeks duration.
62589355|NCT06666023||Infection Group|Patients affected by PJI and Spondylodiscitis
62589356|NCT06666023||Control Group|Patients with post-contusive or inflammatory or arthritic suffusion
62800339|NCT02753426|OTHER|Placebo-Doxycycline|Placebo capsule for 30 days, 30-day washout, and then Doxycycline 20mg capsule for 30 days.
62800340|NCT02021942|EXPERIMENTAL|SOM230 LAR|SOM230 LAR in a dosage of 60 mg i.m. once every 4 weeks
62225671|NCT03457363|EXPERIMENTAL|Double Trunk Mask|DTM will be add above nasal cannula
62418647|NCT06103838|EXPERIMENTAL|18F-fluciclovine PET/CT in Multiple Myeloma|Evaluate 18F-fluciclovine PET/CT in participants with multiple myeloma at Timepoint #1, Timepoint #2 ( after induction treatment (NDMM) or six months (RRMM)) and at Timepoint #3 (the time of progression or 5 years).
62800341|NCT03104179|EXPERIMENTAL|Treatment|CPB with Cytosorb
62800342|NCT03104179|NO_INTERVENTION|Control|CPB without Cytosorb (Control)
62418648|NCT06235125|EXPERIMENTAL|Cytalux with Near Infrared Imaging|All participants will receive Cytalux and undergo near infrared imaging.
62418649|NCT00567996|EXPERIMENTAL|Indacaterol 150 μg|"Indacaterol 150 μg once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
62418650|NCT00567996|PLACEBO_COMPARATOR|Placebo|"Placebo to Indacaterol once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
62418651|NCT00567996|ACTIVE_COMPARATOR|Salmeterol 50 μg|"Salmeterol 50 μg twice daily delivered via a proprietary dry powder inhaler in the morning and in the evening. Placebo to Indacaterol daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI).~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
62418652|NCT03934437|EXPERIMENTAL|mLTCR|The mLTCR intervention consists of two smartphone applications (app), one for patients and one for patient supporters, to help facilitate communication.
62418653|NCT03934437|ACTIVE_COMPARATOR|LTC|Existing linkage to care and retention (LTCR) services which are standard-of-care
62418654|NCT03654807|EXPERIMENTAL|High Intensity Walking|HIW (70-80% HRmax)
62418655|NCT03654807|EXPERIMENTAL|Casual Speed Walking|Self selected pace
62418656|NCT00403923||Patients with known lactose intolerance|
62418657|NCT06675695||New use of osimertinib|Exposure group
62589357|NCT04233567|EXPERIMENTAL|Treatment (infigratinib)|Patients receive infigratinib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62800343|NCT06009367|EXPERIMENTAL|Investigated group with fascial manipulation|Participants in this group received one treatment of fascial manipulation by Stecco method
62225672|NCT03457363|ACTIVE_COMPARATOR|Nasal Cannula Alone|Patients receive oxygen only thought nasal Cannula
62225673|NCT01682382||choroidal neovascular (CNV) AMD subjects|Subjects diagnosed with CNV (AREDS Grade 4b)
62800344|NCT06009367|NO_INTERVENTION|Control group with no intervention|Participants in this group received no treatment
62800345|NCT04965324||Anaesthesia Depth BIS 35|BIS 35
62225674|NCT01682382||dry AMD subjects|Subjects diagnosed with dry AMD (AREDS Grade 3)
62225675|NCT01682382||age-matched controls|Subjects without AMD (AREDS Grade 1)
62225676|NCT00744523|EXPERIMENTAL|Mo.ma cerebral protection device|Mo.Ma cerebral protection device
62225677|NCT02110615|EXPERIMENTAL|Primary Care Practice Changes|The clinical intervention components included (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. Healthy Weight Clinics (HWC); (4) integrating community health workers into the primary care and HWC teams; and (5) health center environmental changes to support behavior change modification.
62225678|NCT06184074||Breast Cancer Patients Using Aromatase Inhibitors Group|Breast cancer patients using aromatase inhibitors at least 1 year
62418658|NCT06675695||New use of erlotinib or gefitinib|Reference group
62418659|NCT03441958|EXPERIMENTAL|ECT-001 (UM171) expanded cord blood|"1. Patients will receive a reduced intensity conditioning regimen containing Cyclophosphamide 50 mg/kg, Fludarabine 40 mg/m2 x 5 days and total body irradiation 200 cGy.~2. The cord to be expanded is thawed 7 days prior to transplant and undergoes CD34+ selection. The CD34+ product will be placed in the fed-batch culture with UM171 for a 7-day expansion and is infused fresh on Day 0. The CD34- product is cryopreserved and will be thawed and infused on Day +1.~3. Patients will receive standard supportive care and GVHD prophylaxis with Mycophenolate mofetil and Tacrolimus."
62418660|NCT00418756|EXPERIMENTAL|Rifampin + nilotinib|
62589358|NCT03865615|EXPERIMENTAL|Oxytocin First|Subjects will receive oxytocin prior to their first scanning session, and placebo prior to their second scanning session.
62800346|NCT04965324||Anaesthesia Depth BIS 50|BIS 50
62800347|NCT02185066|EXPERIMENTAL|Group 1|"Single-dose crossover~1. Reference: Atorvastatin 20mg and Metformin XR 500mg~2. Test: CJ-30056 20/500mg~Once daily Oral administration with 7days of washout period"
62800348|NCT02185066|EXPERIMENTAL|Group 2|"Single-dose crossover~1. Test: CJ-30056 20/500mg~2. Reference: Atorvastatin 20mg and Metformin XR 500mg~Once daily Oral administration with 7days of washout period"
62800349|NCT03407417|EXPERIMENTAL|Fit Testing|Patients who self selected to receive FIT screening after interaction with the Application
62589359|NCT03865615|EXPERIMENTAL|Placebo First|Subjects will receive placebo prior to their first scanning session, and oxytocin prior to their second scanning session.
62589360|NCT03966924|EXPERIMENTAL|Rotational fractional resection (1.5mm Diameter Device)|Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)
62589361|NCT05120518||Pediatric patients with cancer and non-cancer tumor types|Pediatric patients with cancer and non-cancer tumor types (solid, liquid, neuro-oncology and stem cell)
62589362|NCT00987870|EXPERIMENTAL|BFH772 cream 1%|
62225679|NCT06184074||Breast Cancer Patients Group|Breast cancer patients who have not used aromatase inhibitors before
62589363|NCT00987870|PLACEBO_COMPARATOR|Placebo to BFH772 cream 1%|
62589364|NCT00987870|EXPERIMENTAL|BFH772 ointment 1%|
62589365|NCT00987870|PLACEBO_COMPARATOR|Placebo to BFH772 ointment|
62589366|NCT00987870|ACTIVE_COMPARATOR|calcipotriol/betamethasone ointment|
62589367|NCT03250390|EXPERIMENTAL|patients|Patients with bronchopulmonary cancer who have not yet received therapeutic treatment.
62589368|NCT03250390|ACTIVE_COMPARATOR|controls|The controls consisted of 2 groups: smokers and non-smokers.
62589369|NCT00839527|ACTIVE_COMPARATOR|metformin + glimepiride + pioglitazone + albiglutide placebo|Metformin + glimepiride + pioglitazone + matching albiglutide placebo
62589370|NCT00839527|EXPERIMENTAL|metformin + glimepiride + pioglitazone placebo + albiglutide|Metformin + open-label glimepiride + pioglitazone matching placebo + albiglutide
62589371|NCT00839527|ACTIVE_COMPARATOR|met + glimepiride + pioglitazone placebo + albiglutide placebo|metformin + open-label glimepiride + pioglitazone placebo + albiglutide placebo
62589372|NCT05399862|ACTIVE_COMPARATOR|Group A|Patients will be given Lactobacillus reuteri probiotic in addition to standard triple therapy. The probiotic is prepared in a capsule form (200mg each capsule), given as 1 capsule per day after meal for 4 weeks.
62800350|NCT03407417|ACTIVE_COMPARATOR|Non-FIT testing|Patients who elected not to have FIT testing after interaction with the application
62225680|NCT04667078|EXPERIMENTAL|Cangrelor group|treated by P2Y12 inhibitor (cangrelor) in addition to MT and BMM. The dose of cangrelor will be started with a 30 micrograms/kg IV bolus over 1 minute right after randomization and before MT. The bolus will be immediately followed with 4 micrograms/kg/min IV infusion for the duration of MT up to 4 hours. Cangrelor infusion will be stopped at the end of the MT procedure and will not go further 4 hours. Transition to oral antiplatelet therapy will be possible 1 hour after cangrelor infusion discontinuation. No other anti-thrombotic drug is authorized during cangrelor infusion. MT technique choice is left to the investigator decision.
62225681|NCT04667078|ACTIVE_COMPARATOR|Best medical management group|treated by BMM associated to MT. Anti-thrombotic including alteplase are authorized if they follow the recommendations of the international guidelines. If alteplase infusion is given, no other anti-thrombotic drug is allowed for the following 24 hours. MT technique choice is left to the choice of the investigator.
62225682|NCT02879422|OTHER|Diabetic patients with proliferative diabetic retinopathy|
62225683|NCT02879422|OTHER|Diabetic patients with non proliferative diabetic retinopathy|
62225684|NCT01783041|PLACEBO_COMPARATOR|5% dextrose|Infants randomized to the placebo group will receive 5% dextrose intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of placebo (5% Dextrose) will be given to the study patients.
62225685|NCT01783041|EXPERIMENTAL|L-carnitine|Infants randomized to the study group will receive L-carnitine intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
62225686|NCT04882995|EXPERIMENTAL|Intervention - Received fiber|Participants received 14 doses of psyllium fiber packet (Metamucil, 3.4g). They were instructed to take 1 packet twice a day beginning 7 days before surgery.
62225687|NCT04882995|NO_INTERVENTION|Control - Did not receive fiber|Participants did not take any preoperative fiber.
62225688|NCT03509454||Type 1 DM, Normo albuminuric|Type 1 diabetics with no history of albumnuria (UACR \< 30 mg/g in 2 out of 3 consecutive samples)
62225689|NCT03509454||Type 1 DM, Micro albuminuric|Type 1 diabetics with history of micro albumnuria (UACR 30-299 mg/g in 2 out of 3 consecutive samples)
62225690|NCT03509454||Type 1 DM, Macro albuminuric|Type 1 diabetics with history of macro albumnuria (UACR 30-299 mg/g in 2 out of 3 consecutive samples)
62225691|NCT03509454||Healthy subjects|Subjects with no history of diabetes, other diseases or intake of medicine which in the judgement of the investigator could affect the results, specifically renal, cardiovascular or inflammatory/infectious diseases should be considered for exclusion.
62225692|NCT00759915|OTHER|1|Treatment A (test product) followed by Treatment B (reference product)
62225693|NCT00759915|OTHER|2|Treatment B (reference product) followed by Treatment A (test product)
62225694|NCT05485467||Heart transplant recipients|All patients will undergo coronary CT angiography and the presence of CAV will be defined in accordance with the ISHLT criteria. At the time of CT angiography, the patient will undergo a detailed clinical evaluation, and cardiac echo and we will also collect blood samples, perform extensive biochemical analysis and measure CD34+ cell count in peripheral venous blood
62225695|NCT03994289|NO_INTERVENTION|Control|Participants remain seated for 2 hours after the intake of a standardized breakfast.
62225696|NCT03994289|EXPERIMENTAL|Motor-assisted cycling|Participants will perform 3 bouts of motor-assisted cycling, each bout lasting 10 minutes, after the intake of a standardized breakfast.
62225697|NCT03994289|EXPERIMENTAL|FES cycling|Participants will perform 3 bouts of FES cycling, each bout lasting 10 minutes, after the intake of a standardized breakfast.
62225698|NCT01927926|EXPERIMENTAL|Whey-protein & polydextrose snack|Whey-protein \& polydextrose snack bar.
62418661|NCT04834297|EXPERIMENTAL|SVS mattress|Infants randomized to the experimental arm will have the SVS mattress placed in their crib within 48 hours of birth and will continue till discharge home after the completion of monitoring phase of NOWS or till determination is made to initiate pharmacotherapy for NOWS.
62418662|NCT04834297|NO_INTERVENTION|Standard mattress|Infants randomized to the no intervention arm will continue to be cared for using the standard hospital crib mattress throughout their birth hospitalization.
62418663|NCT00637793|PLACEBO_COMPARATOR|1|Placebo capsules
62418664|NCT00637793|EXPERIMENTAL|2|2 capsules in the am of each treatment period
62418665|NCT00637793|EXPERIMENTAL|3|2 capsules in the am of each treatment period
62418666|NCT00637793|EXPERIMENTAL|4|2 capsules in am of each treatment period
62418667|NCT06701305|EXPERIMENTAL|Part 1: Efinopegdutide|Part 1: Participants receive a single subcutaneous (SC) dose of efinopegdutide.
62418668|NCT06701305|PLACEBO_COMPARATOR|Part 1: Placebo|Part 1: Participants receive a single SC dose of placebo.
62418669|NCT06701305|EXPERIMENTAL|Part 2: Efinopegdutide|Part 2: Participants receive multiple SC doses of efinopegdutide titrated from Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, or Dosage 6. Participants receive a SC dose of efinopegdutide, Dosage 1 on Days 1 and 8; Dosage 2 on Days 15 and 22; Dosage 3 on Days 29, 36, 43 and 50; Dosage 4 on Days 57, 64, 71 and 78; Dosage 5 on Days 85, 92, 99, 106; and Dosage 6 on Days 113, 120, 127, and 134. Participants also receive oral acetaminophen on Day -2, Day 6, 62, and 83.
62418670|NCT06701305|PLACEBO_COMPARATOR|Part 2: Placebo|"Part 2: Participants receive multiple SC doses of Placebo titrated from Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, or Dosage 6.~Participants receive a SC dose of Placebo, Dosage 1 on Days 1 and 8; Dosage 2 on Days 15 and 22; Dosage 3 on Days 29, 36, 43 and 50; Dosage 4 on Days 57, 64, 71 and 78; Dosage 5 on Days 85, 92, 99, 106; and Dosage 6 on Days 113, 120, 127, and 134. Participants also receive oral acetaminophen on Day -2, Day 6, 62, and 83."
62418671|NCT06651931||Survivors|Cohort of patients who survived from the hospital until they were discharged.
62589373|NCT05399862|PLACEBO_COMPARATOR|Group B|Placebo used in the study contains corn starch with 0.12% of iron oxide yellow, prepared in indistinguishable capsule form as probiotic,; given as 1 capsule per day after meal for 4 weeks.
62589374|NCT03204929|EXPERIMENTAL|Cu(II)ATSM|Cu(II)ATSM dosed once daily
62225699|NCT01927926|PLACEBO_COMPARATOR|Control snack|Control snack bar containing minimal protein and not polydextrose.
62225700|NCT03173573|EXPERIMENTAL|Part 1 SAD FDL176 level 1 to 6|Part 1: Single dose of FDL176 test formulation Level 1 to 6 on healthy males.
62225701|NCT03173573|PLACEBO_COMPARATOR|Part 1 SAD Placebo|Part 1: Single dose of Placebo for FDL176.
62225702|NCT03173573|EXPERIMENTAL|Part 2 SAD FDL176 at fasted state|Part 2: single dose of FDL176 test formulation, fasted state.
62418672|NCT06651931||Non-survivors|Cohort consisting of patients who died during hospitalization.
62418673|NCT06263543|EXPERIMENTAL|Sacituzumab Govitecan (SG) Infusion|SG will be administered on Days 1 and 8 of continuous 21-day cycles at 10 mg/kg via intravenous (IV) infusion until disease progression or unacceptable toxicity.
62225703|NCT03173573|EXPERIMENTAL|Part 2 SAD FDL176 at fed state|Part 2: single dose of FDL176 test formulation, fed state
62225704|NCT03173573|EXPERIMENTAL|Part 3 SAD FDL176 test formulation|Part 3: Single dose of FDL176 test formulation on healthy females.
62225705|NCT03173573|PLACEBO_COMPARATOR|Part 3 SAD placebo|Part 3: Single dose of Placebo for FDL176.
62418674|NCT02362243|PLACEBO_COMPARATOR|Control Group|Participants in the control arm will complete the placebo comparator intervention.
62418675|NCT02362243|EXPERIMENTAL|Supervised Exercise Group|Participants in the supervised exercise intervention arm will perform the experimental intervention under direct 1-on-1 supervision of an exercise specialist.
62418676|NCT02362243|EXPERIMENTAL|Web-based Exercise Group|Participants in the web-based exercise intervention arm will perform the experimental intervention with use of a web-based exercise system for exercise instruction and guidance, and without direct 1-on-1 on-site supervision.
62418677|NCT03962218|EXPERIMENTAL|Early Aquatic Therapy (EAT)|Aquatic physiotherapy treatment at time 1 (week 1)
62418678|NCT03962218|OTHER|Late Aquatic Therapy (LAT)|Control for Group 1 for the 5 first weeks of Group 1 treatment. Aquatic physiotherapy treatment at time 2 (week 6).
62589375|NCT03798301|EXPERIMENTAL|Treatment Arm|Suspension of CMV-specific T-cells in 10 mL of 0.9% NaCl with 2% HSA. Single dose max. 25,000 T cells/kg body weight (BW) of the recipient delivered via IV bolus injection.
62589376|NCT06682715|EXPERIMENTAL|whey group|They will be given 24g of whey protein 5 days per week post workout.
62589377|NCT06682715|PLACEBO_COMPARATOR|maltodextrin|35g of maltodextrin will be given 5 days per week post workout.
62589378|NCT05711186|OTHER|Structured SDM|Structured shared decision making for the choice between SAVR and TAVR
62589379|NCT05711186|OTHER|Usual Care|Usual care for the choice between SAVR and TAVR
62589380|NCT05113771|EXPERIMENTAL|Liafensine 1mg|
62418679|NCT03111407|OTHER|iAssist group|patients will have primary total knee arthroplasty with the iAssist. The iAssist Knee System is a computer assisted stereotaxic surgical instrument system to assist the surgeon in the positioning of orthopedic implant system components intra-operatively. It involves surgical instruments and position sensors to determine alignment axes in relation to anatomical landmarks and to precisely position alignment instruments and implant components relative to these axes.
62418680|NCT03111407|OTHER|conventional instrumentation|patients will have primary total knee arthroplasty with the conventional instrumentation.
62800351|NCT06130241|OTHER|female with breast cancer and positive axillary lymphnodes|female patients with breast cancer with initially positive axillary lymphnodes who underwent neoadjuvant chemotherapy
62800352|NCT00330759|ACTIVE_COMPARATOR|zoledronic acid|denosumab placebo with active zoledronic acid
62225706|NCT03173573|EXPERIMENTAL|Part 4 MAD FDL176 Level 1 to 3|Part 4: Dose escalation of FDL176 test formulation Level 1 to 3.
62418681|NCT00928785|EXPERIMENTAL|REPEVAX|
62418682|NCT00928785|ACTIVE_COMPARATOR|Monovalent tetanus vaccine|
62418683|NCT06702956|ACTIVE_COMPARATOR|control conventional method|conventional method of canine retraction using brackets
62418684|NCT06702956|ACTIVE_COMPARATOR|study laser corticotomy|an accelerated orthodontic movement using Waterlase MDTM Turbo all-tissue laser for corticotomy
62418685|NCT05150821||experimental|patients during lockdown
62418686|NCT05150821||control group|patients before lockdown
62418687|NCT01955473|EXPERIMENTAL|Sym004|
62418688|NCT02704299|EXPERIMENTAL|Autologous T cells-Based Immunotherapy|Surgery Chemotherapy Autologous T cells-Based Immunotherapy
62418689|NCT02246231|EXPERIMENTAL|NF2 who has an auditory implant|
62225707|NCT03173573|PLACEBO_COMPARATOR|Part 4 MAD Placebo|Part 4: Dose escalation of Placebo for FDL176 Level 1 to 3.
62225708|NCT03173573|EXPERIMENTAL|Part 5 SAD FDL176 test formulation|Part 5: Single dose of FDL176 test formulation.
62418690|NCT03935451|PLACEBO_COMPARATOR|Placebo|The placebo group will receive a similarly appearing full supply of a twice daily placebo oral tablet.
62418691|NCT03935451|EXPERIMENTAL|Experimental|The treatment arm will receive a full supply of twice daily 2.5 milligram (mg) dosing of apixaban beginning on the first day of hospital discharge.
62418692|NCT01413685|NO_INTERVENTION|Tacrolimus|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
62418693|NCT01995773||Healthy Controls|Healthy control women
62418694|NCT06630936||Catheter ablation cohort|Patients who receive pulsed field ablation procedure
62418695|NCT06630936||Drug treatment cohort|Patients who receive regular drug therapy
62589381|NCT05113771|EXPERIMENTAL|Liafensine 2mg|
62800353|NCT00330759|EXPERIMENTAL|denosumab|active denosumab with zoledronic acid placebo
62225709|NCT03261245||Cas|Onset of a hypertension disorder during pregnancy
62225710|NCT03261245||Controls|No hypertension disorder during pregnancy
62225711|NCT05717231|EXPERIMENTAL|laughter yoga|Laughter yoga was performed face-to-face with the intervention group for 35-40 minutes twice a week and in 6 sessions in total.
62418696|NCT06604299|EXPERIMENTAL|Digital CBT-MM|Digital CBT-MM is a digital intervention including mindfulness and cognitive behavioral elements for individuals with binge eating disorder. Mindful Courage will consist of 18-weeks of self-guided modules. Elements included in the intervention include psychoeducation, self-monitoring, regular eating, goal-setting, weekly weighing, eating a sufficient amount of food at each meal, eating a range of foods (including foods that patients may fear), reduction of overvaluation of weight and shape, addressing shape/body checking or avoidance, behavior chain analysis, problem solving, awareness and acceptance of binge eating urges, thoughts and emotions, values awareness, values clarification, values-based decision making, self-compassion, exploring needs underlying binge eating urges, mindful eating, hunger and fullness awareness, self-compassion, and self-care. Weekly mindfulness practice (at least 3x per week) is heavily emphasized.
62800354|NCT05456789|EXPERIMENTAL|Combined interventional treatment|Combined catheter-based fibrinolysis and thrombectomy plus conventional treatment
62800355|NCT05456789|ACTIVE_COMPARATOR|conventional treatment|Conventional treatment
62225712|NCT05717231|NO_INTERVENTION|Control group|No intervention was performed for the control group
62418697|NCT06538207|EXPERIMENTAL|ONO-4578+ONO-4538+mFFX|
62800356|NCT04085276|EXPERIMENTAL|JS001 Plus Nab-Paclitaxel|Patients will receive both JS001 and Nab-Paclitaxel.
62800357|NCT04085276|PLACEBO_COMPARATOR|Placebo Plus Nab-Paclitaxel|Patients will receive both placebo and Nab-Paclitaxel.
62225713|NCT04200521||Healthy weight individuals|Cross-sectional observation on healthy participants who will be recruited from the general population from both genders (Lebanese and Emirati Subjects).
62225714|NCT04200521||Obese individuals|Prospective study of 3 months duration (pre and post design) on obese Emirati and Lebanese participants undergoing bariatric procedure irrelevant of the study, from Qassimi Hospital In sharja and Middle East Institute of Health University Hospital, Lebanon
62225715|NCT01257425|OTHER|Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.|
62418698|NCT06538207|EXPERIMENTAL|ONO-4578+ONO-4538+GnP|
62418699|NCT05292079||Coronary Artery Disease (CAD)|
62589382|NCT05113771|PLACEBO_COMPARATOR|Placebo|
62800358|NCT02134535||laboratory specimens|cervical biopsies vaginal biopsies blood
62800359|NCT03945461|EXPERIMENTAL|Gum chewing|Chew xylitol based, peppermint flavored gum for 30 minutes every two hours during the hours of 7 am to 9 pm, for the first 24 hours after your surgery
62800360|NCT03945461|NO_INTERVENTION|Standard Care|Standard hospital management with no deviations from usual care
62800361|NCT06144879|EXPERIMENTAL|the double-rod group|posterior spinal corrective surgery with osteotomy (two rods without dual-headed screw)
62800362|NCT06144879|EXPERIMENTAL|the three-rod group|posterior spinal corrective surgery with osteotomy (three rods with one dual-headed screw)
62800363|NCT06144879|EXPERIMENTAL|the four-rod group|posterior spinal corrective surgery with osteotomy (four rods with two dual-headed screws)
62800364|NCT05115968||OSA case|Chinese children aged 6-11 years old with habitual snoring (≥3 nights per week) and polysomnography (PSG) confirmed OSA (obstructive apnoea hypopnoea index (OAHI) of ≥1/hour), with adenotonsillar hypertrophy and clinical indications for adenotonsillectomy will be recruited as cases.
62225716|NCT01257425|OTHER|Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.|
62225717|NCT01574209||Celiac Disease|Patients suffering from coeliac diseases confirmed by small intestinal biopsy
62225718|NCT01574209||IBS patients|Patients suffering from irritable bowel syndrome (IBS) according to Rome III criteria
62225719|NCT01574209||Healthy subjects|Healthy subjects as control group
62225720|NCT05314920|EXPERIMENTAL|transdiagnostic cognitive-behavioural therapy (TD-CBT)|Transdiagnostic cognitive-behavioral group therapy: The psychological interventions will be manualized. Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12-week period.
62800365|NCT05115968||Control|Non-OSA subjects (with PSG OAHI \<1/hour) who undergo adenotonsillectomy for other reasons such as recurrent tonsillitis.
62800366|NCT05854355|EXPERIMENTAL|Intervention|This group received the multi-component school and home-based intervention (physical activity programme (aimed to increase children's physical activity and decrease sedentary behaviour)
62225721|NCT05314920|ACTIVE_COMPARATOR|relaxation therapy|The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. Patients will receive 7 sessions (1.5 hr/session) in groups of 8-10 individuals over a 12-week period.
62225722|NCT04881604|EXPERIMENTAL|Adjustable Compression Wrap|Daily use of the adjustable compression wrap on the upper limb with breast cancer-related lymphedema during phase 2 of compressive therapy.
62418700|NCT04127994|EXPERIMENTAL|3 meals|"Patients with type 2 diabetes will be submitted to a 3 meal regimen for 3 months.~We will compare their basal complete blood chemistry, somatometric measurements versus the same variables after 3 months."
62418701|NCT04127994|EXPERIMENTAL|6 meals|"Patients with type 2 diabetes will be submitted to a 6 meal regimen for 3 months.~We will compare their basal complete blood chemistry, somatometric measurements versus the same variables after 3 months."
62800367|NCT05854355|NO_INTERVENTION|Control|"The primary school children in the control group did not receive the intervention.~The control arm continued with their usual practice and lesson delivery, no environmental changes were made to their classrooms."
62800368|NCT05189912|EXPERIMENTAL|Specimen retrieving bag group|Resected polyps were retrieved by specimen retrieving bag. This group was set as a experimental group.
62225723|NCT04881604|ACTIVE_COMPARATOR|Compression Sleeve|Daily use of the compressive sleeve on the upper limb with breast cancer-related lymphedema during phase 2 of compressive therapy
62225724|NCT05008861|EXPERIMENTAL|FMT with anti-PD-1/PD-L1 treatment|
62225725|NCT04375020||group1 on GABA|The first group was on insulin therapy in the form of toujeo once daily and Novorapid 3 times daily and they received GABA nutritional supplement 750mg per day.
62225726|NCT04375020||group 2 on just insulin|The second group was only on insulin injection in the form of toujeo once daily and Novorapid 3 times daily.
62225727|NCT00776126||1|All enrolled subjects will undergo digital breast tomosynthesis.
62225728|NCT00648817|PLACEBO_COMPARATOR|Group 1|"* Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil) for the first 14 days of the study.~* Tenofovir DF placebo tablet QD for the last 14 days of the study."
62225729|NCT00648817|ACTIVE_COMPARATOR|Group 2|"* Tenofovir DF placebo tablet QD for the first 14 days of the study.~* Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil) for the last 14 days of the study."
62225730|NCT01108107|OTHER|Chemotherapy only|Chemotherapy only, if mutations in KRAS, BRAF or PIK3CA gene
62225731|NCT01108107|OTHER|Chemotherapy + biological treatment|Addition of biological treatment, if no mutations in KRAS, BRAF, and PIK3CA genes.
62225732|NCT06178393||OA monotherapy|
62418702|NCT01038531|ACTIVE_COMPARATOR|low-tidal-volume ventilation|Goal tidal volume is 6 cc/kg ideal body weight.
62418703|NCT01038531|EXPERIMENTAL|APRV|APRV allows spontaneous breathing.
62433550|NCT04261933||Semaglutide s.c. once-weekly|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
62433551|NCT04454970|EXPERIMENTAL|Urethral catheterisation device (UCD)|First attempt of urethral catheterisation using the Urethrotech(R) Urethral catheterisation device (UCD)
62800369|NCT05189912|ACTIVE_COMPARATOR|Suction group|"Resected polyps were retrieved by removing the colonoscope suction valve and connecting a polyp trap to suction onto the instrument channel port.~This group was set as a control group."
62225733|NCT06178393||Nusinersen monotherapy|
62589383|NCT05036057||COPD patients and their proxies|"Patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD), the COPD Assesment Test (CAT), the Saint George Respiratory Disease Questionnaire (SGRQ), the Charlson Comorbidity Index, and will rate the disease and general knowledge level on a numerical scale.~Proxies of patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD) and will rate the disease and general knowledge level on a numerical scale."
62800370|NCT03707301||Cancer patients performing sophrology sessions|Cancer patients performing sophrology sessions will be recruited in this study, and will complete questionnaires of satisfaction and the Hospital Anxiety and Depression scale.
62800371|NCT06271044|NO_INTERVENTION|RAILESS|Railess group including patients to bw followed up wihtout postoperative radioiodine treatment
62800372|NCT06271044|ACTIVE_COMPARATOR|rairinn|THose patients receiving radioiodine treatment according to the normal treatment practice at that time
62800373|NCT04787107|EXPERIMENTAL|10 Minute Chair Massage|Chair massage for 10 minutes once a week for 5 weeks
62800374|NCT04787107|EXPERIMENTAL|10 Minute Scheduled Break|Scheduled 10-minute break once a week for 5 weeks
62800375|NCT05831592|OTHER|Diagnostic accuracy of muscle ultrasound in undernutrition|All included patients will undergo an muscle ultrasound assessment in undernutrition
62800376|NCT02172144|EXPERIMENTAL|BI 1744 CL|
62800377|NCT02172144|PLACEBO_COMPARATOR|Placebo|
62225734|NCT06178393||Other DMTs switched to OA|
62225735|NCT06178393||OA add-on other DMTs|
62225736|NCT06178393||Combination, other DMTs with OA|
62800378|NCT02172144|ACTIVE_COMPARATOR|Moxifloxacin (Avalox®)|
62800379|NCT00056693|EXPERIMENTAL|A|
62800380|NCT04424667|ACTIVE_COMPARATOR|Holder pasteurization|Donor milk pasteurized by Holder method (62.5ºC, 30 minutes)
62800381|NCT04424667|EXPERIMENTAL|HTST pasteurization|Donor milk pasteurized by High Temperature Short Time (HTST) method (72ºC, 15 seconds)
62800382|NCT01606969|EXPERIMENTAL|Dex group|dexmedetomidine-lidocaine solution,
62225737|NCT06178393||Other treatment sequence|
62225738|NCT03263286|EXPERIMENTAL|HandSOME|The intervention is given to this group.
62225739|NCT03339570||Orthopedic treatment|This is the prospective cohort which includes 20 patients presenting three-four proximal humeral fracture who were treated non-surgically and followed prospectively during 12 months.
62800383|NCT01606969|ACTIVE_COMPARATOR|Control group|epinephrine-lidocaine solution
62800384|NCT04358302|EXPERIMENTAL|Device use|"All participants will be provided with the electronic pill bottle cap called Pillsy to use with their regular HCQ prescription bottles at the start of the study."
62800385|NCT04380389|OTHER|profound hypoxia|
62800386|NCT02228317|EXPERIMENTAL|Telemedicine consultation|EMTs will systematically establish teleconsultation by either telephone or video with the EMDC-physician in all cases of non-critical illness
62800387|NCT01127243|ACTIVE_COMPARATOR|inpatient LSH|LSH means laparoscopic supracervical hysterectomy
62800388|NCT01127243|EXPERIMENTAL|Day-case LSH|LSH means laparoscopic supracervical hysterectomy
62800389|NCT05797402||young-aged patients|Patients aged 18 to 45 years old.
62800390|NCT05797402||middle-aged patients|Patients aged 46 to 64 years old.
62800391|NCT05797402||elderly patients|Patients aged 65 and older.
62800392|NCT02089919|PLACEBO_COMPARATOR|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62800393|NCT02089919|EXPERIMENTAL|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62418704|NCT05167227|NO_INTERVENTION|Control|"The Control arm participates in monthly interactive webinars and quarterly short courses.~Monthly interactive webinars will offer brief didactic presentations by SMEs, examples of models of care, and a facilitated Q\&A. These webinars will be convened to rapidly disseminate findings and emerging best practices to a large-scale, national audience.~Quarterly short courses will be developed to summarize key findings from past weekly teleECHO sessions. These quarterly short courses will be formatted as a learning module with the use of presentation slides and videos online that are accessible asynchronously."
62418705|NCT05167227|EXPERIMENTAL|Intervention|The Intervention arm participates in weekly teleECHO sessions with monthly interactive webinars and quarterly short courses.
62418706|NCT02630004|EXPERIMENTAL|Melatonin|Melatonin oral gel 3%
62418707|NCT02630004|PLACEBO_COMPARATOR|Placebo|Placebo oral gel
62225740|NCT04943367|ACTIVE_COMPARATOR|GROUP TEAS|Patients will receive TEAS bilaterally at two acupoints: Hegu (L14) and Neiguan (PC6).
62225741|NCT04943367|PLACEBO_COMPARATOR|Control Sham Group|Patients in the sham group will be undergoing electrode attachment on the target acupoints without electronic stimulation.
62418708|NCT00695604|PLACEBO_COMPARATOR|1|"Placebo Comparator~All patients assigned to this group will receive:~1. Placebo via Metered Dose Inhaler (MDI).~2. Albuterol via MDI."
62418709|NCT00695604|ACTIVE_COMPARATOR|2|"Active Comparator~All patients assigned to this group will receive:~1. Fluticasone via MDI.~2. Albuterol via MDI."
62418710|NCT05652686|EXPERIMENTAL|Part A: Dose Escalation|A standard 3+3 dose escalation design will be employed.
62418711|NCT05652686|EXPERIMENTAL|Part B: Dose Expansion|Part B cohorts will open after the dose level considered for RDE has been cleared in Parts A, C and D.
62800394|NCT02089919|EXPERIMENTAL|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62418712|NCT05652686|EXPERIMENTAL|Part C: Chemotherapy Combination Therapy|Part C of the study will include Cohorts C1 and C2, combining PT217 with chemotherapy.
62225742|NCT03198182|EXPERIMENTAL|Module A|BMS-986036 Arm
62225743|NCT03198182|PLACEBO_COMPARATOR|Module B|Placebo Arm
62418713|NCT05652686|EXPERIMENTAL|Part D: ICI Combination Therapy|In part D, PT217 will be given in combination with atezolizumab, either alone or in combination with chemotherapy.
62418714|NCT04070469|EXPERIMENTAL|Patient reveiving amoxycillin|all patient included in this study
62418715|NCT05607719|EXPERIMENTAL|Bretzri followed by Bevespi Group|Participants in this group will receive Bretzri for 4-weeks followed by 8-weeks of Bevespi.
62418716|NCT05607719|EXPERIMENTAL|Bevespi followed by Bretzri Group|Participants in this group will receive Bevespi for 8-weeks followed by 4-weeks of Bretzri.
62418717|NCT02758951|EXPERIMENTAL|Perioperative systemic therapy and CRS-HIPEC|"At the discretion of the treating physician, perioperative systemic therapy consists of either four 3-weekly neoadjuvant and adjuvant cycles of capecitabine with oxaliplatin (CAPOX), six 2-weekly neoadjuvant and adjuvant cycles of 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX), or six 2-weekly neoadjuvant cycles of 5-fluorouracil/leucovorin with irinotecan (FOLFIRI) followed by either four 3-weekly (capecitabine) or six 2-weekly (5-fluorouracil/leucovorin) adjuvant cycles of fluoropyrimidine monotherapy. Bevacizumab is added to the first three (CAPOX) or four (FOLFOX/FOLFIRI) neoadjuvant cycles.~CRS-HIPEC is performed according to the Dutch protocol in all study centres."
62418718|NCT02758951|ACTIVE_COMPARATOR|Upfront CRS-HIPEC alone|CRS-HIPEC is performed according to the Dutch protocol in all study centres.
62800395|NCT02089919|EXPERIMENTAL|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62800396|NCT06550219|EXPERIMENTAL|nasal intermittent positive pressure ventilation group|
62800397|NCT06550219|EXPERIMENTAL|nasal continuous positive pressure ventilation group|
62800398|NCT06550219|EXPERIMENTAL|nasal high flow cannula group|
62800399|NCT01343030||Patients with implants|Patients with silicone implants and fat grafting.
62225744|NCT03069612|EXPERIMENTAL|rTMS Active Group|Repetitive transcranial magnetic stimulation (rTMS) will be administered bilaterally to the dorsolateral prefrontal cortex (DLPFC) at 20 Hz, 90% RMT in 25 trains.
62225745|NCT03069612|SHAM_COMPARATOR|rTMS Sham Group|Repetitive transcranial magnetic stimulation (rTMS) will be administered bilaterally to the dorsolateral prefrontal cortex (DLPFC) at 20 Hz, 90% RMT in 25 trains with a sham coil.
62225746|NCT05488015|EXPERIMENTAL|Intervention|1 week of familiarisation through videos, audios and information documents, followed by 8 weeks of self-treatment with two GPR postures.
62800400|NCT00410761|NO_INTERVENTION|1|Placebo vandetanib
62225747|NCT05488015|ACTIVE_COMPARATOR|Control|No change in lifestyle habits during the 8-week trial.
62225748|NCT02175251|ACTIVE_COMPARATOR|low frequency (1Hz)|low frequency
62225749|NCT02175251|SHAM_COMPARATOR|Sham Comparator|Sham Comparator
62225750|NCT02175251|EXPERIMENTAL|high frequency (20Hz)|high frequency
62225751|NCT01516242||NovoPen® 4|
62225752|NCT02669511|OTHER|PQR309|A single arm study with PQR309, a phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), 60mg/80mg given once a day, orally.
62225753|NCT05493215|EXPERIMENTAL|Imatinib TDM|Patients with diagnosed gastrointestinal stromal tumor (GIST) who are currently being treated with imatinib.
62225754|NCT06355193|EXPERIMENTAL|LGLQ group|
62225755|NCT06355193|EXPERIMENTAL|LHQW group|
62418719|NCT05226013|EXPERIMENTAL|PEGylated Urate Oxidase for Injection|PEGylated Urate Oxidase for Injection，specification:5mg，Single dose ascending.Healthy subjects were divided into three dose groups (0.5mg, 1mg, 2mg), and hyperuricemia patients were divided into four dose groups (2mg, 4mg, 8mg, 12 mg), with increasing dose design.Each group will receive the experimental drug in 6 subjects.
62418720|NCT05226013|PLACEBO_COMPARATOR|Placebo|Placebo , specification: 5mg,Single dose. Groups received the placebo in 2 patients per group.
62418721|NCT06701708||Normal|
62418722|NCT00928135|ACTIVE_COMPARATOR|7% Hypertonic saline|5 ml of 7% saline twice daily
62800401|NCT00410761|EXPERIMENTAL|2|Vandetanib
62800402|NCT02412098|EXPERIMENTAL|Moderate Hepatic Impairment (Cohort 1)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
62800403|NCT02412098|EXPERIMENTAL|Severe Hepatic Impairment (Cohort 2)|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
62800404|NCT02412098|EXPERIMENTAL|Mild Hepatic Impairment (Cohort 3)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
62225756|NCT06355193|PLACEBO_COMPARATOR|placebo control group|
62225757|NCT04847726|EXPERIMENTAL|CEUS with perfluorobutane and sulfur hexafluoride|Contrast-enhanced ultrasound with perfluorobutane and sulfur hexafluoride for the hepatic lesion.
62225758|NCT02878681|EXPERIMENTAL|Group 1|Monthly intravitreal injections of 0.5 mg ranibizumab for six months
62225759|NCT02878681|EXPERIMENTAL|Group 2|Monthly intravitreal injections of 2 mg aflibercept for the initial three months followed by monthly intravitreal injections of 0.5 mg ranibizumab for the next three months.
62225760|NCT02878681|EXPERIMENTAL|Group 3|Monthly injections of 2 mg aflibercept for six months
62225761|NCT04843553|ACTIVE_COMPARATOR|active|Participants receiving oral vitamin B-3
62225762|NCT04843553|PLACEBO_COMPARATOR|placebo|Participants receiving oral inactive pill
62225763|NCT01315496|EXPERIMENTAL|Imunoglobulin G|The enrolled patients will be randomized to receive supplementation of IVIG in ICU within 48 hours after hospital arrival admission for 3 consecutive days.
62418723|NCT00928135|EXPERIMENTAL|Hypertonic xylitol|5 ml of 15% xylitol twice daily
62418724|NCT00045396|EXPERIMENTAL|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-14. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
62026890|NCT04973137|PLACEBO_COMPARATOR|Placebo plus Standard of Care Chemotherapy- For Double-blind Phase of study|"Intravenous 0.9% Saline administration as a placebo every 28 days.~Drug: Standard of Care Chemotherapy. Bortezomib-containing chemotherapy regimen (e.g. cyclophosphamide, bortezomib, and dexamethasone (CyBorD)) according to the institutional standard of care. Initiation of daratumumab at randomization allowed at the discretion of the investigator."
62026891|NCT05053087|EXPERIMENTAL|Ropivacaine intermittent bolus|Subjects will have a catheter placed in the Post Anesthesia Care Unit following clinically indicated surgery with 0.2% ropivacaine dispersed in pulsed intermittent bolus.
62418725|NCT04760847|EXPERIMENTAL|Intermittent Fasting|Patients in Group A will then receive information regarding intermittent fasting, which would include fasting for a 16-hour period each day, followed by ingestion of an appropriate number of calories for the remaining part of the day.
62418726|NCT04760847|ACTIVE_COMPARATOR|Control|These subjects will undergo standard caloric dietary guidance. Patients in group B will also be given the above information, though not be asked to intermittently fast.
62418727|NCT06576375|ACTIVE_COMPARATOR|Dapagliflozin|Patients will receive Dapagliflozin 10 mg once daily orally for 12 weeks (Forxiga® AstraZeneca company)
62026892|NCT05053087|EXPERIMENTAL|Ropivacaine continuous|Subjects will have a catheter placed in the Post Anesthesia Care Unit following clinically indicated surgery with 0.2% ropivacaine dispersed in a continuous infusion.
62225764|NCT01315496|PLACEBO_COMPARATOR|Placebo control|The enrolled patients will be randomized to receive supplementation of placebo (0.9% NaCl) in ICU within 48 hours after hospital arrival admission for 3 consecutive days.
62225765|NCT00557648|EXPERIMENTAL|1|CBT for children only
62225766|NCT00557648|EXPERIMENTAL|2|CBT for children with parental involvement
62225767|NCT00557648|NO_INTERVENTION|3|No intervention control group: families free to seek treatment on their own
62225768|NCT06483529|EXPERIMENTAL|ROELEC PROTOCOL|ROELEC measurements consist of the application of a sine or multisine excitation pressure signal superimposed on the ventilation signal. The novelties are in the smart design of the excitation signal, not the way it is applied to the patient.
62225769|NCT06483529|ACTIVE_COMPARATOR|dynamic P/V curves|dynamic ventilatory pressure volume curves generated during the standard ventilation settings
62225770|NCT06483529|OTHER|low flow P/V curves|static ventilatory pressure volume curves will be generated during the procedure to assure that the patients ventilation is between the lower inflection point and the higher inflection point. this P/V curves will also be analysed but will not be included in the primary endpoint analysis
62225771|NCT06483529|OTHER|SOTA|Standard of care oscillometry protocol will also generate low flow P/V curves but will not be included in the primary endpoint analysis
62225772|NCT04925973|EXPERIMENTAL|Treatment arm|Tofacitinib 10mg PO BID
62225773|NCT06084156|EXPERIMENTAL|HSK7653 and Metformin|
62225774|NCT02518126||control|Women with IUGR embryos so that their fetal weight estimate puts them in a percentile bellow 10th percentile
62225775|NCT02518126||IUGR|Women with AGA embryos so that their fetal weight estimate puts them in a percentile between 20th and 80th percentiles
62418728|NCT06576375|ACTIVE_COMPARATOR|Metformin|Patients will receive Metformin 1000 mg once daily orally for 12 weeks (control group) (Glucophage® Merck company)
62800405|NCT05809609|EXPERIMENTAL|Ketamine|Participants in this arm will receive a single intravenous injection, antidepressant dose of Ketamine hydrochloride (0.5mg/kg)
62800406|NCT05809609|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive a single intravenous injection of an inactive placebo (0.9% sodium chloride)
62800407|NCT05053659|EXPERIMENTAL|Loncastuximab tesirine & venetoclax|"Participants will receive a baseline disease assessment via PET/CT in FDG avid lymphomas; CT scan (chest, abdomen, pelvis; inclusion of neck in selected cases). Bome marrow biopsy in selected cases.~Premedication includes:~* Allopurinol (to reduce uric acid) 300mg orally daily starting day -1 and continuing at least until day 7 of each cycle.~* Dexamethasone (steroid pre-medication) 4mg orally twice daily on day -1, day 1 and day 2 of each cycle.~* Adequate oral hydration starting on day -1 or -2, defined as 1 - 2 liters of oral intake of liquids in 24 hours~Study treatment to be given every 21 days.~* Loncastuximab tesirine (50 - 150 μg/kg) intravenously (IV) on day 1 of each 21-day cycle~* Venetoclax (400 - 800 mg) orally, every day on days 1 - 5 of each 21-day cycle. Dose ramp-up on cycle 1 (over days 1 - 5 for target dose 400mg, 1 - 6 for target dose 600mg and 1 - 7 for target dose 800mg"
62225776|NCT02942238|EXPERIMENTAL|Complete Mesocolic Excision|the group underwent laparoscopic right hemicolectomy with CME. In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
62800408|NCT04699656|EXPERIMENTAL|Plazomicin Injection|plazomicin (30-minute IV infusion at 2.5 mg/kg) single dose given before IHD and single dose given after IHD
62800409|NCT04868617|EXPERIMENTAL|Test Product|The non-CE marked test product is a stoma product based on the flat SenSura® Mio 1-piece (1-pc) and the flat 2-piece with mechanical coupling (2-pc MC) product that includes a novel skin protective layer in the baseplate.
62800410|NCT04868617|ACTIVE_COMPARATOR|Sensura Mio Comparator - Standard of Care|"The following comparator products will be used in this investigation:~* SenSura® Mio 1-piece (1-pc) flat, Midi bag with normal outlet and~* SenSura® Mio 2-piece with mechanical coupling (2-pc MC) flat, Maxi or Midi bag with normal outlet"
62225777|NCT02942238|ACTIVE_COMPARATOR|D3 lymph node dissection|the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 lymph node dissection group(D3), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue. No.6 lymph node should be dissected in this group.
62225778|NCT04710160|ACTIVE_COMPARATOR|Novel fast setting calcium silicate ( Protooth)|In the form of powder and liquid to be mixed together to form paste.
62225779|NCT04710160|EXPERIMENTAL|MTA|In form of powder to be mixed with saline to form paste.
62225780|NCT03993821|EXPERIMENTAL|Burosumab|Burosumab, which is FDA-approved for X-linked hypophosphatemic rickets, will be given monthly, for a total of 12 months and titrated to achieve a target fasting serum phosphorus level within normal range for age. The chosen starting dose of burosumab will be 0.3 mg/kg given SQ Q4W. The maximum dose allowed in this protocol is 2.0 mg/kg. Burosumab will be administered via subcutaneous (SC) route.
62225781|NCT01814202|EXPERIMENTAL|PTM202|PTM202 is a medical nutrition product
62225782|NCT01814202|PLACEBO_COMPARATOR|Placebo|The placebo is a placebo for PTM202, a food product that can not be distinguished from PTM202 by appearance, taste or odor
62225783|NCT04564651|EXPERIMENTAL|platelet transfusion treatment|
62225784|NCT04564651|NO_INTERVENTION|standard medical treatment|
62225785|NCT01590017|EXPERIMENTAL|Cistplatin and Radiation Therapy|Cisplatin 40 mg/m2 (max = 70 mg) IV over 30-60 minutes given weekly on days 1, 8, 15, 22, 29 and 36 for a total of 6 weekly cycles. Radiation therapy over 8 weeks: External pelvic radiation therapy (41.4-45.0 Gy/1.8 Gy per fraction/23-25 fractions/five weeks), intracavitary brachytherapy (low dose: 35-43.6 Gy/1-2 implants; high dose: 18-28 Gy/2-4 implants), with parametrial boost to involved parametria (5.40 - 9.00 Gy/1.8 Gy/3-5 fractions/3-5 days).
62225786|NCT00732225|ACTIVE_COMPARATOR|DisCoVisc|Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)
62225787|NCT00732225|ACTIVE_COMPARATOR|DuoVisc|Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)
62225788|NCT00732225|ACTIVE_COMPARATOR|BioVisc|Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)
62225789|NCT00732225|ACTIVE_COMPARATOR|Healon5|AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)
62225790|NCT00732225|ACTIVE_COMPARATOR|Amvisc Plus|Bausch \& Lomb Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)
62225791|NCT00541060|ACTIVE_COMPARATOR|A|250 young patients presenting several carious lesions
62225792|NCT00541060|PLACEBO_COMPARATOR|B|160 young adults totally caries free
62225793|NCT00831337|EXPERIMENTAL|Liver cirrhosis compensated|VSL3 supplemented twice daily for 28 days
62589384|NCT02032862|EXPERIMENTAL|Sage tablets|Sage extract, 3400 mg , DER 1:17, in once daily application over 12 weeks treatment phase
62026893|NCT05053087|PLACEBO_COMPARATOR|Single shot adductor canal|Subjects will have a catheter placed in the Post Anesthesia Care Unit following clinically indicated surgery with saline.
62225794|NCT00831337|EXPERIMENTAL|Liver cirrhosis decompensated|VSL3 supplemented twice daily for 28 days
62589385|NCT02032862|PLACEBO_COMPARATOR|Placebo|Placebo, matching the verum in size and appearance, in once daily application over 12 weeks treatment phase
62589386|NCT03103373|ACTIVE_COMPARATOR|Conventional monitor group|Patients will be monitoring with invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnography and electrocardiography Echocardiography group: Patients will be monitoring with echocardiography, invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnogrphy and electrocardiography
62589387|NCT03103373|ACTIVE_COMPARATOR|Echocardiography group|Patients will be monitoring with echocardiography, invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnography and electrocardiography
62589388|NCT05284591||DRd with daratumumab iv de novo|Patients either continue DRd with daratumumab iv, switch to daratumumab sc or switch multiple times iv/sc
62589389|NCT05284591||DRd with daratumumab sc de novo|Patients either continue DRd with daratumumab sc, switch to daratumumab iv or switch multiple times sc/iv
62589390|NCT02713269|EXPERIMENTAL|Treatment (thermal ablation, SSRS)|Patients undergo thermal ablation and CT-guided SSRS via intensity-modulated radiation therapy on different dates within a 1-14 day window. The order of treatment is at the doctor's discretion.
62589391|NCT05517109|NO_INTERVENTION|Control group. Standart care|Standart hemodynamic goals: systolic blood pressure 160-185 mmHg in first 24 hours after intravenous thrombolysis
62589392|NCT05517109|EXPERIMENTAL|Systolic blood pressure ≤ 160 mmHg|Lower hemodynamic goals: systolic blood pressure ≤ 160 mmHg in first 24 hours after intravenous thrombolysis
62589393|NCT02458768|EXPERIMENTAL|IVF-M HP Inj.|"administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.~Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results)."
62589394|NCT02458768|ACTIVE_COMPARATOR|Menopur® Inj.|"administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.~Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results)."
62589395|NCT00642096|EXPERIMENTAL|1|Metoprolol Succinate + Hydrochlorothiazide
62589396|NCT00642096|ACTIVE_COMPARATOR|2|Metoprolol Succinate
62589397|NCT00642096|ACTIVE_COMPARATOR|3|Hydrochlorothiazide
62589398|NCT04173975|EXPERIMENTAL|With knee exoskeleton|"The rehabilitation training will be focused on lower limb with specific activities for knee instability, and will concern both physical training (e.g., locomotion task, balance exercise, muscle reinforcement, proprioceptive task) and occupational treatment tasks (e.g., transferring/mobility, meal preparation, house-working).~Each session will be 45 minutes long. Three time per week, for three weeks.~The patients allocated in this arm will perform the training wearing the BELK device."
62589399|NCT04173975|NO_INTERVENTION|Without exoskeleton|"The rehabilitation training will be focused on lower limb with specific activities for knee instability, and will concern both physical training (e.g., locomotion task, balance exercise, muscle reinforcement, proprioceptive task) and occupational treatment tasks (e.g., transferring/mobility, meal preparation, house-working).~Each session will be 45 minutes long. Three time per week, for three weeks.~The patients allocated in this arm will perform the training without any exoskeleton."
62589400|NCT06497972|ACTIVE_COMPARATOR|Consumption of the control white bread product|This arm will provide the white bread control product and there will be a minimum of three days separating each visit.
62026894|NCT04246034|EXPERIMENTAL|Cases|As described by Saaristo et al. in 2012, the surgical technique starts with wide axillary scar removal, followed by elevation of contralateral dual flap which includes DIEP/MS-TRAM with attached groin lymph nodes and fat, then the anastomosis is preferably done to internal mammary vessels.
62026895|NCT06459687|EXPERIMENTAL|Socazolimab+Chemotherapy±Bevacizumab|"6\~8 cycles of Socazolimab (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w.~Followed with Socazolimab (5 mg/kg), Q3w."
62225795|NCT00831337|EXPERIMENTAL|Control group|VSL3 supplemented twice daily for 28 days
62225796|NCT04384315||EVRF|Patients that have undergone Endovenous Radio Frequency® (EVRF®) from F Care Systems (Belgian) for the treatment of primary great and short saphenous vein reflux.
62225797|NCT03536260|ACTIVE_COMPARATOR|Immediate implant with Xenograft|
62225798|NCT03536260|ACTIVE_COMPARATOR|Immediate implant with Nanobone|
62225799|NCT00680784|EXPERIMENTAL|HKT-500 Ketoprofen Topical Patch|Randomized, double-blind, placebo-controlled, multicenter study in men and women 18 years of age or older who have a painful, acute, benign, ankle sprain of the lateral ligament(s) within the previous 48 hours.
62225800|NCT00680784|PLACEBO_COMPARATOR|Placebo Patch|Treatment with placebo patch
62225801|NCT02334501|EXPERIMENTAL|Treatment A (Period 1) and Treatment B (Period 2)|Treatment A (240mg Neratinib x1) Treatment B (30mg Lansoprazole X 7 days + 240mg Neratinib x1)
62225802|NCT01515397|EXPERIMENTAL|balanced gelatine solution|isotonic colloidal volume substitute
62225803|NCT01515397|ACTIVE_COMPARATOR|non-balanced gelatine solution|colloidal volume substitute
62800411|NCT06048159|EXPERIMENTAL|High Definition tACS with Short-term Memory Focused Speech Therapy|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages.The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS stimulation for 20-minutes with 2 milliampere (mA) peak-to-peak intensity. Stimulation will be maintained no longer than 20 minutes. This will be paired with short-term memory focused speech therapy.
62800412|NCT06048159|SHAM_COMPARATOR|Sham-High Definition tACS with Short-term Memory Focused Speech Therapy|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. The current is turned on and increased in a ramplike fashion for 10 to 30 seconds and then ramped down. In this way, the participants experience the same initial sensations (mild tingling) as the active tACS groups. This will be paired with short-term memory focused speech therapy.
62800413|NCT05072730|EXPERIMENTAL|Super high-pressure balloon (OPN NC)|Patients will be treated with a Super High Pressure percutaneous transluminal coronary angioplasty (PTCA) Balloon (OPN NC).
62800414|NCT05072730|EXPERIMENTAL|Intravascular lithotripsy (IVL)|Patients will be treated with intravascular lithotripsy (IVL).
62800415|NCT01635595||Patients with BIM|Patients affected by adenocarcinoma of the distal esophagus and cardia with preoperative diagnosis of BIM underwent subtotal esophagectomy and gastric pull up.
62800416|NCT01635595||Patients without BIM|Patients affected by adenocarcinoma of the distal esophagus and cardia without preoperative diagnosis of BIM underwent subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy.
62800417|NCT03847935||Surgery|Patients who underwent surgical release of A1 pulley
62026896|NCT06459687|PLACEBO_COMPARATOR|Placebo+Chemotherapy±Bevacizumab|"6\~8 cycles of placebo (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w.~Followed with placebo (5 mg/kg), Q3w."
62026897|NCT06633640|EXPERIMENTAL|Intervention|Conventional flap with algae-based substitute (AlgOss) combined with collagen membrane
62225804|NCT01558011|EXPERIMENTAL|chemotherapy|"Chemotherapy:~Drug: Capecitabine, Oxaliplatin, Docetaxel Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy."
62225805|NCT03275129|EXPERIMENTAL|Ultrasound assessment of heart and lungs|Patients (over the age of 18) who will be undergoing surgery for hip fracture repair. These patients will receive an ultrasound of the heart and lungs to determine whether or not information gained from this ultrasound assessment is significant enough to influence their anesthetic care plan.
62225806|NCT01744223|EXPERIMENTAL|SCT, BPX-501 dose 1, Rimiducid if needed|"2x10E5 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
62225807|NCT01744223|EXPERIMENTAL|SCT, BPX-501 dose 2, Rimiducid if needed|"5x10E5 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
62418729|NCT03199898||34-32 GA|premature infants born \<34,6-32,1 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
62433552|NCT04454970|ACTIVE_COMPARATOR|Bardia Aquafil Foley catheter|First attempt of urethral catheterisation using the Bardia Aquafil Foley catheter
62589401|NCT06497972|EXPERIMENTAL|Consumption of 1 of 2 rice cake products|This arm will provide 1 of the 2 randomly assigned rice products to the participant and there will be a minimum of three days separating each visit.
62800418|NCT03847935||corticosteroid injections only|Patients who underwent local corticosteroid injections only, and no other treatment
62800419|NCT03847935||hand therapy only occupational/physical|1 visit: orthosis fabrication, range of motion, nodule and ice massage.
62800420|NCT03847935||Injection and Hand therapy|This group of participants received a combination of corticosteroid injection in the affected finger and one visit of hand therapy.
62800421|NCT03847935||Modality Hand Therapy|Ongoing hand therapy treatment, which included the above plus modalities such as ultrasound or iontophoresis.
62800422|NCT03847935||Injection and Modality Hand Therapy|Ccombination of local cortiscosteroid injection to the affected digit and ongoing hand therapy with modalities.
62800423|NCT05366634|EXPERIMENTAL|Cohort 1|Single injection of MDK-703 (dose level 1) or matching placebo
62800424|NCT05366634|EXPERIMENTAL|Cohort 2|Single injection of MDK-703 (dose level 2) or matching placebo
62800425|NCT05366634|EXPERIMENTAL|Cohort 3|Single injection of MDK-703 (dose level 3) or matching placebo
62800426|NCT01387126|EXPERIMENTAL|Novel fibre supplement|The full dose of the study intervention is 15 grams per day.
62800427|NCT01387126|NO_INTERVENTION|Weight management program|
62800428|NCT04973072|NO_INTERVENTION|Control|Participants in this arm will not receive any intervention.
62800429|NCT04973072|EXPERIMENTAL|One large reward|Participants in this arm will receive S$300 if they reach the PBF goal at the end of 12 weeks.
62026898|NCT06633640|NO_INTERVENTION|Control group|Conventional flap with collagen membrane
62026899|NCT02959060|EXPERIMENTAL|BMS-986177 and Rifampin|
62026900|NCT04088097|EXPERIMENTAL|Cognitive-Behavioral Therapy|Adapted Cognitive-Behavioral Therapy (CBT) for adolescents with binge eating or loss-of-control eating.
62026901|NCT04088097|OTHER|Control Condition|Educational materials related to adolescent health and nutrition.
62026902|NCT02633878|EXPERIMENTAL|NSTW + OP|NSTW one dose by oral in the morning and in the evening respectively until 12 weeks of gestations (max 84 days); OP 100mg tablet by oral, every 8 hours until 12 weeks of gestations (max 84 days).
62026903|NCT02633878|EXPERIMENTAL|NSTW + OP placebo|NSTW one dose by oral in the morning and in the evening respectively until 12 weeks of gestations (max 84 days); OP Placebo 100mg tablet by oral, every 8 hours until 12 weeks of gestations (max 84 days).
62026904|NCT02633878|EXPERIMENTAL|NSTW Placebo + OP|NSTW Placebo one dose by oral in the morning and in the evening respectively until 12 weeks of gestations (max 84 days); OP 100mg tablet by oral, every 8 hours until 12 weeks of gestations (max 84 days).
62800430|NCT04973072|EXPERIMENTAL|Small wins|Participants in this arm will receive cash rewards capped by S$300, depending on which intermediate goals they reach and the PBF at the end of the 12 weeks.
62800431|NCT02366312|EXPERIMENTAL|vismodegib|The 150-mg vismodegib drug product is a hard gelatin capsule formulation for oral administration. This study involves one year of treatment with Erivedge (150 mg/day) plus two years of follow-up.
62800432|NCT02178761|ACTIVE_COMPARATOR|Angioplasty alone|plain old balloon angioplasty alone
62800433|NCT02178761|ACTIVE_COMPARATOR|Stenting|Balloon angioplasty plus stenting
62800434|NCT02178761|ACTIVE_COMPARATOR|drug-eluting balloon|Balloon angioplasty with drug-eluting balloon
62800435|NCT02178761|ACTIVE_COMPARATOR|biodegradable vascular scaffold stent|Stenting with biodegradable vascular scaffold stent
62800436|NCT04640233|EXPERIMENTAL|Primary Group|Gam-COVID-Vac combined vector vaccine, 0.5 ml/dose + 0.5 ml/dose prime-boost immunization on day 1 (component I rAd26-S) and on day 21 (component II rAd5-S)
62800437|NCT04640233|PLACEBO_COMPARATOR|Control Group|Placebo, 0.5 ml/dose + 0.5 ml/dose immunization on days 1 and 21
62800438|NCT05021770|EXPERIMENTAL|Phase Ib|"Orelabrutinib dose escalation will occur using a standard 3+3 dose-escalation approach to determined the maximum tolerated dose(MTD) of orelabrutinib dose in combined with thiotepa, beginning at dose level I (150 mg daily) and potentially escalating to dose level 2 (200mg) with rules for escalation and de-escalation. If the dose-limiting toxicity is not found, the dose of 200mg will be used for phase II trial (RP2D).~Orelabrutinib: 150mg or 200mg orally daily. Thiotepa: The dose of thiotepa is fixed as 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)."
62800439|NCT05021770|EXPERIMENTAL|Phase II|"Participants will receive orelabrutinib and thiotepa at the pre-determined dosage level established in Phase 1b, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion. The response will be evaluated every 2 cycles.~Orelabrutinib: RP2D (150 mg or 200 mg qd) Thiotepa:Sintilimab: The dose of thiotepa is fixed as 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)."
62800440|NCT04081779|ACTIVE_COMPARATOR|Arm I (patient-generated SCP)|Patients receive a self-generated SCP (i.e., generated from baseline questionnaire responses).
62026905|NCT02633878|PLACEBO_COMPARATOR|NSTW Placebo + OP Placebo|NSTW Placebo one dose by oral in the morning and in the evening respectively until 12 weeks of gestations (max 84 days); OP Placebo 100mg tablet by oral, every 8 hours until 12 weeks of gestations (max 84 days).
62026906|NCT06538090|EXPERIMENTAL|Early Movers Intervention|Participants will receive an educational resource (i.e., hard copy hand-out), access to a digital app with an online toolkit and weekly text messages that includes tips and supportive messaging.
62026907|NCT06538090|NO_INTERVENTION|Control|Participant will receive standard care.
62026908|NCT02276300|EXPERIMENTAL|HER2-Peptid-Vakzine, Cyclophosphamide|Her2-peptide vaccination, Sargramostim, Imiquimod, Cyclophosphamide
62026909|NCT01857544|EXPERIMENTAL|Aflibercept 2.0mg|Single arm - Intravitreal Aflibercept 2.0mg, 0.05 milliliters, monthly for 6 months.
62026910|NCT04383912|EXPERIMENTAL|onabotulinum toxin A group (brow)|"Product name: Onabotulinum toxin A (Botox A, Allergan), 50 unit vials Product code: 93094EC~Description: The side randomized to treatment will receive an injection of 20 units of onabotulinum toxin A as the final step of a direct brow lift surgery. The surgeon will visually divide the surgical incision in half, and divide the volume of the injection evenly between the two sides. This will be a one time administration."
62026911|NCT04383912|PLACEBO_COMPARATOR|placebo group (brow)|"Product name: normal saline~Description: The side randomized to placebo will receive an injection of normal saline as the final step of a direct brow lift surgery. The surgeon will visually divide the surgical incision in half, and divide the volume of the injection evenly between the two sides. This will be a one time administration."
62800441|NCT04081779|EXPERIMENTAL|Arm II (patient-generated SCP, educational counseling)|Patients receive a self-generated SCP as in Arm I. Patients also receive a 30-minute telephone-based educational counseling session on survivorship care administered by trained lay health counselors.
62800442|NCT01390922||Subjects prescribed botulinum injection|Subjects prescribed botulinum injection
62800443|NCT03827655|PLACEBO_COMPARATOR|Placebo|TAK-954 placebo-matching, 60-minute infusion, intravenously (IV), once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
62589402|NCT06497972|EXPERIMENTAL|Final consumption of 1 of 2 rice cake products|This arm will provide 1 of the 2 randomly assigned rice products to the participant.
62026912|NCT06568692|EXPERIMENTAL|PCS6422 40 mg + Capecitabine 300 mg|Fixed single dose of PCS6422 administered with Capecitabine 150 mg BID over 7 days
62418730|NCT03199898||32-28 GA|premature infants born \<32-28,1 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
62589403|NCT02056457|EXPERIMENTAL|Responsible fatherhood or healthy marriage|
62589404|NCT02056457|EXPERIMENTAL|Control|
62589405|NCT05631691|EXPERIMENTAL|Experimental Group|school students
62589406|NCT05631691|NO_INTERVENTION|Comparison Group|school students
62589407|NCT02266472|EXPERIMENTAL|Fixed dose combination|Single dose empagliflozin/metformin
62589408|NCT02266472|ACTIVE_COMPARATOR|Single tablets combination|single doses empagliflozin and metformin
62589409|NCT04775706|EXPERIMENTAL|HM15912 0.5 mg/kg, 1.0mg/kg, 1.5mg/kg Active|
62800444|NCT03827655|EXPERIMENTAL|TAK-954 0.1 mg/100 mL|TAK-954 0.1 milligrams per 100 milliliters (mg/100 mL), 60-minute infusion, IV, once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
62589410|NCT04775706|PLACEBO_COMPARATOR|Matching Placebo|
62589411|NCT06040970|EXPERIMENTAL|Ovarian cancer Cohort|DEC 3+3 dose expansion of Sacituzumab Govitecan in Combination with Cisplatin
62800445|NCT03827655|EXPERIMENTAL|TAK-954 0.5 mg/100 mL|TAK-954 0.5 mg/100 mL, 60-minute infusion, IV, once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
62589412|NCT06040970|EXPERIMENTAL|Endometrial cancer Cohort|DEC 3+3 dose expansion of Sacituzumab Govitecan in Combination with Cisplatin
62800446|NCT03827655|EXPERIMENTAL|TAK-954 0.1 mg/100 mL + Placebo|TAK-954 0.1 mg/100 mL, 60-minute infusion, IV, once presurgery on Day 1 and once daily placebo infusions postsurgery up to Day 10 or until resolution of upper and lower GI function.
62418731|NCT03199898||28-23 GA|premature infants born \<28-23,0 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
62800447|NCT03827655|EXPERIMENTAL|TAK-954 0.5 mg/100 mL + Placebo|TAK-954 0.5 mg/100 mL, 60-minute infusion, IV, once presurgery on Day 1 and once daily placebo infusions postsurgery up to Day 10 or until resolution of upper and lower GI function.
62589413|NCT05575401|ACTIVE_COMPARATOR|Tonsillectomy +/- adenoidectomy|Participants will undergo extracapsular tonsillectomy +/- adenoidectomy.
62589414|NCT05575401|EXPERIMENTAL|Tonsillectomy +/- adenoidectomy with lateral pharyngoplasty|Participants will undergo extracapsular tonsillectomy +/- adenoidectomy and lateral pharyngoplasty.
62800448|NCT03573323|EXPERIMENTAL|Ixekizumab|"A starting dose of 160 milligram (mg) of ixekizumab was given as 2 subcutaneous (SC) injections at Week 0. During the Induction Period, ixekizumab 80 mg was given every 2 weeks (Q2W) at Weeks 2, 4, 6, 8, 10, and 12. During the Extension Period, ixekizumab 80 mg was given as 1 SC injection (Q4W) every 4 weeks at Weeks 16 and 20.~The Post Treatment Follow Up Period was for safety monitoring following the last treatment period."
62589415|NCT04679012|EXPERIMENTAL|Polatuzumab vedotin plus R-EPCH|Polatuzumab vedotin will be given in conjunction with 6 cycles of R-EPCH (rituximab, etoposide, prednisone, cyclophosphamide, hydroxydaunorubicin). The dosing schedule and regimen for R-EPCH will follow established protocols. Polatuzumab vedotin will be administered on Day 1 of each 21-day cycle.
62026913|NCT06568692|EXPERIMENTAL|PCS6422 40 mg + Capecitabine 450 mg or 150 mg|Fixed single dose of PCS6422 administered with Capecitabine 225 mg or 75 mg BID over 7 days
62418732|NCT06026124|EXPERIMENTAL|Children with Developmental Language Disorder|These children have a significant delay in language development in the absence of hearing impairment, cognitive delay, autism, or neurological injury/disease.
62589416|NCT06664983|ACTIVE_COMPARATOR|TPC chemotherapy|NAB-paclitaxel; cisplatin or lobaplatin and capecitabine
62589417|NCT06664983|EXPERIMENTAL|Cadonilimab with TPC chemotherapy|cadonilimab plus TPC chemotherapy (NAB-paclitaxel, cisplatin or lobaplatin ; and capecitabine
62589418|NCT06663280|ACTIVE_COMPARATOR|Intervention group|Participants in the intervention group were patients with hypertension who had been provided ADELE for the duration of the study. The observation period per participant was 3 months on average. Data on the primary, secondary and exploratory endpoints were gathered using questionnaires at study inclusion (t0) and an average of 3 months after randomization (t1).
62589419|NCT06663280|NO_INTERVENTION|Control group|"Participants in the control group were patients with hypertension who were not provided with ADELE for the duration of the study. The observation period per participant was 3 months on average. Data on the primary, secondary and exploratory endpoints were collected using questionnaires at study inclusion (t0) and an average of 3 months after randomization (t1).~In addition, after the end of the observation period (from t0 to t1), the participants in the control group were offered an extension of a further 3 months on average using ADELE (from t1 to t2)."
62800449|NCT03573323|EXPERIMENTAL|Guselkumab|"During the Induction Period, guselkumab 100 mg was given as 1 SC injection at Weeks 0, 4 and 12. 1 placebo injection (to maintain the blind) was given at Weeks 0, 2, 6, 8, and 10. During the Extension Period, guselkumab 100 mg was given at Week 20. 1 placebo injection (to maintain the blind) was given at Week 16.~The Post Treatment Follow Up Period was for safety monitoring following the last treatment period."
62800450|NCT05471544|EXPERIMENTAL|Sulfadoxine-Pyrimethamine + Amodiaquine (SPAQ)|Children aged 3-59 months will receive SPAQ in the intervention arm
62225808|NCT01744223|EXPERIMENTAL|SCT, BPX-501 dose 3, Rimiducid if needed|"1x10E6 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
62225809|NCT01744223|EXPERIMENTAL|SCT, BPX-501 dose 4, Rimiducid if needed|"3x10E6 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant .~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
62225810|NCT03634696|EXPERIMENTAL|Field test participants|Late-stage adult cancer patients seeking care at Ocean Road Cancer Center, consenting to participate in mPCL application field test
62418733|NCT06026124|EXPERIMENTAL|Children with typical language development|Children whose language development is as expected for their age.
62418734|NCT04196439|ACTIVE_COMPARATOR|continuous epidural analgesia|continuous lumbar epidural catheter inserted preoperatively before induction of general anaesthesia
62800451|NCT05471544|NO_INTERVENTION|Control|Children aged 3-59 months will not receive SPAQ in the control arm
62418735|NCT04196439|ACTIVE_COMPARATOR|continuous supra-inguinal fascia iliaca compartment block|ultrasound guided supra-inguinal FICB with insertion of catheter for continuous infusion before induction of general anaesthesia.
62418736|NCT05430009|EXPERIMENTAL|Arm 1|This is an open-label, single-arm, single center clinical trial to evaluate the feasibility of liver SBRT (up to 4 metastases) during the first cycle of physician's choice ICI for NSCLC.
62418737|NCT03100786|ACTIVE_COMPARATOR|Dexamethasone|standard anti-tuberculosis drugs plus dexamethasone for 6-8 weeks
62800452|NCT00584415|ACTIVE_COMPARATOR|GP + PVI ablation|This study contains only one arm, which is GP ablation + PV antrum isolation. The intervention (GP ablation + PV isolation) was performed using ThermoCool Navistar catheters in all patients
62800453|NCT06164665|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone administered as a 15 mg oral dose per day for 5 days
62800454|NCT06164665|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose pill administered as an oral dose per day for 5 days
62800455|NCT01167374|EXPERIMENTAL|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
62800456|NCT04450940|EXPERIMENTAL|PACV|The PACV arm received the PACV survey at baseline in order to assess the impact of administration on vaccine hesitancy. All participants received the PACV at 6-month follow up.
62026914|NCT06568692|ACTIVE_COMPARATOR|Capecitabine 2000 mg/m2|Standard capecitabine dose at 1000 mg/m2 BID
62026915|NCT01840423|EXPERIMENTAL|ODM-104|Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days
62026916|NCT01840423|PLACEBO_COMPARATOR|Placebo|Oral capsules given once daily for one day or three times daily for 7 days
62418738|NCT03100786|PLACEBO_COMPARATOR|Identical placebo|standard anti-tuberculosis drugs plus placebo for 6-8 weeks
62418739|NCT05748483|EXPERIMENTAL|Atogepant|Participants will receive atogepant in double-blind period. From Week 25, eligible participants will receive atogepant in open-label period.
62418740|NCT05748483|ACTIVE_COMPARATOR|Topiramate|Participants will receive topiramate in double-blind period. From Week 25, eligible participants will receive atogepant in open-label period.
62800457|NCT04450940|SHAM_COMPARATOR|Placebo|The placebo arm received a placebo survey on general childhood health topics at baseline. All participants received the PACV at 6-month follow up.
62800458|NCT03393494|EXPERIMENTAL|Perrigo active|Test product
62026917|NCT01840423|ACTIVE_COMPARATOR|entacapone + levodopa/carbidopa|entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day
62800459|NCT03393494|ACTIVE_COMPARATOR|Reference active|RLD product
62225811|NCT03634696|ACTIVE_COMPARATOR|Control participants|Late-stage adult cancer patients seeking care at Ocean Road Cancer Center, consenting to serve as controls for mPCL field test
62225812|NCT04483505|EXPERIMENTAL|Rogaratinib + palbociclib + fulvestrant|
62589420|NCT05243680|EXPERIMENTAL|Participants diagnosed with asthma receiving GSK3511294 (Depemokimab)|
62589421|NCT04818645|EXPERIMENTAL|ASSERT insertable cardiac monitor|The ASSERT implantable cardiac monitor (ICM) is an FDA-approved device that can be injected into the subcutaneous tissue and can provide automatic as well as patient triggered electrocardiographic recordings of symptomatic episodes during long term follow-up. This Implantable cardiac monitor is paired with a remote monitoring smartphone application called My Merlin that capable of rapid remote review of electrograms to be utilized in this study for arrhythmia detection. The ASSERT ICM is indicated for the monitoring and diagnostic evaluation of patients who experience unexplained symptoms such as: dizziness, palpitations, chest pain, syncope, and shortness of breath, as well as patients who are at risk for cardiac arrhythmias. It is also indicated for patients who have been previously diagnosed with atrial fibrillation or who are susceptible to developing atrial fibrillation.
62225813|NCT03446729|EXPERIMENTAL|Memory Self Monitoring (MSM)|"Intervention: Guided self-help Behavioral Weight Loss. The MSM group is assigned to self-monitor in habit books what they consume in their previous meal immediately prior to each meal, similar to other studies exploring the effect of episodic meal memory on food intake."
62800460|NCT03393494|PLACEBO_COMPARATOR|Perrigo placebo|placebo product
62225814|NCT03446729|ACTIVE_COMPARATOR|Caloric Self Monitoring (CSM)|"Intervention: Guided self-help Behavioral Weight Loss. The CSM group is assigned to self-monitor what food they consume, and the associated caloric content after each meal in their habit books in line with traditional BWL self-monitoring."
62589422|NCT04818645|ACTIVE_COMPARATOR|Conventional Management|The conventional management arm will use arrhythmia signs and symptoms to determine occurrence of arrhythmias.
62800461|NCT04014062|EXPERIMENTAL|INTP5 Period I Crossover|"Period I: Subjects received a single dose of INTP5 subcutaneously at a dose of 6 mg/0.6 mL.~Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of US Neulasta."
62800462|NCT04014062|ACTIVE_COMPARATOR|US Neulasta Period I Crossover|"Period I: Subjects received a single dose US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.~Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of INTP5."
62026918|NCT00251810||general anaesthesia|
62589423|NCT05272228|ACTIVE_COMPARATOR|Coenzyme Q10 (ubiquinone)|Synonyms: Co-Q10; Ubiquinone; Ubidecarenone; 2,5-Cyclohexadiene-1,4-dione, 2- \[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-,6,10,14,18,22,26,30,34,38- tetracontadecaenyl\]-5,6-dimethoxy-3-methyl CAS number: 303-98-0 Molecular formula: C59H90O4 USP standard Content: Co-Q10 (ubiquinone), bulking agent (maltodextrin), capsule (HPCM- hydroxypropyl methyl cellulose), anti-adherents (magnesium stearate and anhydrous silica) Dosage: 2 capsules, total 100 mg Co-Q10
62800463|NCT02611817|EXPERIMENTAL|Vedolizumab SC 108 mg Maintenance Arm|"Open-label Induction: vedolizumab IV 300 milligram (mg), infusion at Week 0 (Day 1) and Week 2 (Day 15)~Double-blind Maintenance: vedolizumab SC 108 mg injection once every 2 weeks (Q2W) starting at Week 6 up to Week 50"
62800464|NCT02611817|PLACEBO_COMPARATOR|Placebo SC Maintenance Arm|"Open-label Induction: vedolizumab IV 300 mg, infusion at Week 0 (Day 1) and Week 2 (Day 15)~Double-blind Maintenance: matching placebo to vedolizumab SC injection Q2W starting at Week 6 up to Week 50"
62800465|NCT00754377||PBLI Curriculum group|To evaluate preliminary data on a PBLI curriculum grounded on QI system projects.
62800466|NCT00754377||Comparison group|Received a different curriculum.
62800467|NCT02257229||Surgical|Corrective Surgery only
62026919|NCT04959045|EXPERIMENTAL|intervention group (Flipped Teaching Method Group)|Intervention group students will be given skill training with the Flipped Teaching method.
62026920|NCT04959045|NO_INTERVENTION|Control group (Traditional Method Group)|Control group students will receive skill training with the traditional method. No intervention will be made.
62026921|NCT02096653|EXPERIMENTAL|X-ray guided intra-articular injection|Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine into the SI (sacroiliac joint) cavity under fluoroscopic guidance
62026922|NCT02096653|ACTIVE_COMPARATOR|Landmark-guided SI joint injection|Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine at the point of maximal tenderness (3 ml)
62225815|NCT05566496||Tourette|Age less than 18 years old Diagnosed as Tourette syndrome or chronic tic disorders No other neuropsychiatric disorders
62225816|NCT05566496||Healthy|Age less than 18 years old No other neuropsychiatric disorders
62225817|NCT02574156|EXPERIMENTAL|Conventional Group|Patients randomized for Conventional Group will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 140 mg/dl and 180 mg/dl.
62225818|NCT02574156|EXPERIMENTAL|Moderate Group|Patients randomized for ModerateGroup will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 100 mg/dl and 130 mg/dl.
62225819|NCT03422588|EXPERIMENTAL|Intracorporeal|Totally laparoscopic right colectomy with intracorporeal anastomosis
62225820|NCT03422588|ACTIVE_COMPARATOR|Extracorporeal|Laparoscopic assisted right colectomy with extracorporeal anastomosis
62026923|NCT02508480|EXPERIMENTAL|Photovoice|Participants in this arm will attend a 10-week peer-led Photovoice program conducted in group format.
62225821|NCT05213897||30 subjects testing positive for Covid-19|30 subjects testing positive for Covid-19 using the proprietary SARS-CoV-2 Antigen Assay
62800468|NCT02257229||Non-Surgical|Correction with casting, braces, Physical therapy, other non-surgical methods
62225822|NCT05213897||30 subjects testing negative for Covid-19|30 subjects testing negative for Covid-19 using the proprietary SARS-CoV-2 Antigen Assay
62225823|NCT04252768|EXPERIMENTAL|Eftilagimod alpha + Paclitaxel|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 80 mg/m2 paclitaxel intravenously on Day 1, 8 and 15 and 30 mg efti subcutaneously on Day 1 and 15 in a 28-day (4-week) cycle. Efti will always be given after paclitaxel. The maintenance phase comprises 6 visits with 4 weekly intervals; during each such visit 30 mg efti is given subcutaneosuly as monotherapy.
62800469|NCT02257229||Non-surgical + surgical|Correction with casting, braces, Physical therapy, other non-surgical methods subsequently followed by Corrective Surgery
62800470|NCT01220167|EXPERIMENTAL|Sequence ABC|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
62800471|NCT01220167|EXPERIMENTAL|Sequence BCA|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
62800472|NCT01220167|EXPERIMENTAL|Sequence CAB|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
62800473|NCT04915443|EXPERIMENTAL|Periotome Group|An Atraumatic simple extraction procedure is done to teeth or roots with sound form indicated for simple extraction using H.ZEPF 26.182.13 \& 26.182.11 periotome instrument.
62800474|NCT04915443|EXPERIMENTAL|Piezotome Group|An Atraumatic simple extraction procedure is done to teeth or roots with sound form indicated for simple extraction using SOLO LED PIEZOTOME Kit with ESSENTIAL tips from SATELEC ACTEON.
62800475|NCT05458206|EXPERIMENTAL|diaphragmatic release, and conventional|"Diaphragmatic release:~The patients will be positioned in the supine position. The therapist stood at the head of the patient. The therapist makes manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th ) with hypothenar regions of the hands and the last three fingers. During the patient's inspiration, the therapist will gently pull the points of hand contacts toward the head and slightly laterally, while elevating the ribs simultaneously. During exhalation, the therapist will deepen hand contact toward the inner coastal margins for 5 to 7 minute conventional therapy: the patient will receive chin-in, interscapular exercises, and pectoralis stretch"
62800476|NCT05458206|EXPERIMENTAL|mulligan SNAG mobilization, and conventional|"mulligan snag: Apply a passive intervertebral movement in a superior anterior direction along the facet plane. While maintaining this glide as the patient actively moves in any range of physiological movement and then sustains it at the end range position for a few seconds. (3 sets,10 repetitions) conventional therapy: the patient will receive chin-in, interscapular exercises, and pectoralis stretch"
62800477|NCT05458206|EXPERIMENTAL|mulligan SNAG mobilization, diaphragmatic release, and conventional|"Diaphragmatic release:~The patients will be positioned in the supine position. The therapist stood at the head of the patient. The therapist makes manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th ) with hypothenar regions of the hands and the last three fingers. During the patient's inspiration, the therapist will gently pull the points of hand contacts toward the head and slightly laterally, while elevating the ribs simultaneously. During exhalation, the therapist will deepen hand contact toward the inner coastal margins. (5 to 7 minutes) mulligan snag: Apply a passive intervertebral movement in a superior anterior direction along the facet plane. While maintaining this glide as the patient actively moves in any range of physiological movement and then sustains it at the end range position for a few seconds(3 sets,10 repetitions) conventional therapy: the patient will receive chin-in, interscapular exercises, and pectoralis stretch"
62800478|NCT05458206|ACTIVE_COMPARATOR|the conventional therapy|the patient will receive chin-in, inter-scapular exercises, and pectoralis stretch (3 sets,10 repetitions)
62433553|NCT02899052|EXPERIMENTAL|Venetoclax + Carfilzomib + Dexamethasone|"Part 1: Evaluate the safety and pharmacokinetic profiles while providing information to determine the appropriate doses of venetoclax and carfilzomib (VenKd) to be used in the VenKd combination in approximately 18 participants. The dose levels are Venetoclax 400 mg or 800 mg; Carfilzomib 20/27 mg/m2, 20/70 mg/m2, and/or 20/56 mg/m2; Dexamethasone 40 mg~Part 2: Further evaluate the safety and efficacy profile of the VenKd combination selected after completion of Part 1 in approximately 22 additional participants. Participants may discontinue Kd but may continue receiving venetoclax once daily (QD) as monotherapy.~Part 3: Further evaluation of the efficacy of the VenKd combination after completion of Part 1 and Part 2 in 7 additional participants.~Part 4, An additional 65 participants t(11;14) positive will receive varying doses of the VenKd combination or carfilzomib and dexamethasone"
62225824|NCT02314182|EXPERIMENTAL|A Primary tumor resection + chemotherapy|PT resection + systemic chemotherapy +/- target therapy
62225825|NCT02314182|OTHER|B Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab|Chemotherapy (+/- target therapy)
62026924|NCT02508480|ACTIVE_COMPARATOR|Enhanced Control|Participants in this arm will attend a 60-minute peer-led group discussion on stigma and discrimination, and be eligible to participate in the 10-week Photovoice program after completing all study assessments.
62589424|NCT05272228|EXPERIMENTAL|Q10 MICROENCAPSULATED|IP1:Q10 MICROENCAPSULATED. ENG: Ingredient BMT® Coenzyme Q10 Content Co-Q10 (ubiquinone), stabiliser (gum arabic), bulking agent (maltodextrin), capsule (HPCM- hydroxypropyl methyl cellulose), olive oil, corn starch, anti-adherents (magnesium stearate and anhydrous silica), acidity regulator (citric acid, acetic acid) HPMC capsules, size '0', 50 mg/capsule Dosage: 2 capsule, total 100 mg Co-Q10
62589425|NCT05272228|EXPERIMENTAL|Final formulated product BQSM®|IP2: Final formulated product BQSM® Ingredients: Rosehip (Rosa canina) fruit extract standardised to min. 70 % of vitamin C (L-ascorbic acid), capsule (HPCM- hydroxypropyl methyl cellulose), BMT® Coenzyme Q10 (ubiquinone), vitamin E (D-alfa tocopheryl acetate), vitamin A (retinyl acetate), L-selenomethionine, bulking agent (maltodextrin), stabiliser (gum arabic), olive oil, corn starch, anti-adherents (magnesium stearate and anhydrous silica), acidity regulator (citric acid, acetic acid) HPMC capsule, size '0', 50 mg/capsule Dosage: 2 capsule, total 100 mg Co-Q10
62418741|NCT06201962|EXPERIMENTAL|Massage|Before the procedure, written and verbal consent will be obtained from the newborn's guardian and brief information will be given about the massage to be performed on the newborn. Before applying massage to premature babies, their 24-hour sleep duration will be evaluated with an actigraphy device. Starting from the face with gentle touches, massage will be applied to the baby's forehead, around the eyes and cheeks with 2 fingers, without pressing too much. Then, the chest area will be massaged with circular movements from right to left, and then the upper and lower extremities will be massaged. Finally, the massage will be completed by turning the baby face down and applying gentle pressure to the back area. Massage applications will be performed for 15 minutes every morning and evening for two days. On the morning of the second day, an actigraphy device will be attached to the premature babies' ankles and their 24-hour sleep will be re-evaluated.
62589426|NCT03229928||Stakeholder Advisory Panel|The investigators will recruit 2 parents of children with IDD, 2 special education teachers, and 2 behavior health professionals to assist with the development and initial testing of the upgraded MOCHA application features to test usability.
62026925|NCT04179032|EXPERIMENTAL|Belimumab 200 mg|Participants with Systemic Lupus Erythematosus were administered with Belimumab 200 milligram per milliliter (mg/mL) subcutaneous (SC) injection. The dosing frequency was based on body weight. Participants who weigh more than or equal to 50 kilograms were administered every week, who weigh between 30 to less than 50 kg were administered every 10 days and who weigh less than 30 kg were administered every 2 weeks.
62026926|NCT05403489||Group B (bronchoalveolar lavage)|"Patients who underwent BAL\* were named Group B~\* BAL: bronchoalveolar lavage"
62026927|NCT05403489||Group E (endotracheal aspirate)|"Patients who received ETA\*\* were named Group E.~\*\* ETA: Endotracheal aspirate"
62589427|NCT03229928||Primary Participants|The study primarily involves recruitment of clinically referred minor patients with IDD and their parents and teachers. Parents and teachers of 10 patients with IDD and co-morbid behavior problems will be asked to collect data via the MOCHA application on the frequency, antecedents,consequences, and other correlates of specific behavioral concerns.
62589428|NCT03229928||Sensor Wearing Participants|These will be the same participants from aim 2. All participants will be offered the opportunity to wear the sensors and provide and chose which ones they would prefer to wear. Two participants will be asked to wear the sensor for 48 hours in order to pilot test the feasibility of syncing sensor and MOCHA application data collection.
62589429|NCT04795193|EXPERIMENTAL|MICS-CABG|Patients undergoing MICS-CABG.
62589430|NCT04795193|ACTIVE_COMPARATOR|OPCABG|Patients undergoing thoracotomy OPCABG.
62589431|NCT03373994||18F-FDG PET/CT initial-time imaging|PET/CT imaging was underwent 5min after 18F-FDG injection.
62589432|NCT03373994||18F-FDG PET/CT balanced-time imaging|PET/CT imaging was underwent 60min after 18F-FDG injection.
62589433|NCT06619808|EXPERIMENTAL|Hyperbaric Oxygen Therapy|Participants receive 20 session of hyperbaric oxygen therapy (HBOT) in 1 month (inhalation of 100% oxygen in a pressure chamber under 2.0 ATA for 60 minutes).
62800479|NCT04399395|ACTIVE_COMPARATOR|Lifestyle and naltrexone/bupropion|
62800480|NCT04399395|OTHER|Lifestyle|
62800481|NCT03501732|EXPERIMENTAL|Values Affirmation plus Risk Feedback|Values Affirmation with Risk Feedback in substance use and HIV domains of risk
62800482|NCT03501732|ACTIVE_COMPARATOR|Risk Feedback|Sham Values Affirmation with Risk Feedback in substance use and HIV domains of risk
62026928|NCT06042829|EXPERIMENTAL|Intubation with aerosol box|Aerosol box group where patient will be intubated using aerosol box
62026929|NCT06042829|ACTIVE_COMPARATOR|Intubation without Aerosol box|Without aerosol box group whereby patients will be intubated without aerosol box.
62026930|NCT04627766|EXPERIMENTAL|Monitored children|PICU Children that will be monitored with the device
62225826|NCT04200885|ACTIVE_COMPARATOR|Postoperative NSAID Prescription|Patients in this arm received common postoperative prescriptions following removal of their impacted third molars for seven days; twice a day 500 mg amoxicillin+125 mg clavulanic acid, twice a day 25 mg dexketoprofen trometamol and three times a day 1.5 mg/ml clorhexidine gluconate+1.2 mg/ml benzydamine hydrochloride containing 200 ml mouthwash.
62589434|NCT06619808|NO_INTERVENTION|Symptomatic Treatment|Participants receive basic symptomatic treatments like antidiabetic drug, antihypertensive drug, and hepatic protector.
62800483|NCT03501732|NO_INTERVENTION|Sleep Control|Description of sleep habits in lieu of values affirmation/sham values affirmation. No risk feedback
62800484|NCT04134481||low intervention group|from 0-7 clustered nursing intervention
62800485|NCT04134481||high intervention group|from 8-15 clustered nursing intervention
62800486|NCT00075621|OTHER|tandem transplant|"Drug: filgrastim 16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection~Drug: melphalan 200 mg/kg over 2 days~Procedure/Surgery: autologous peripheral blood stem cell transplantation~autologous peripheral blood stem cell transplantation"
62800487|NCT03515824|EXPERIMENTAL|Part A: MK-1696 20 mg|Participants received 20 mg of MK-1697 by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
62800488|NCT03515824|EXPERIMENTAL|Part A: MK-1697 65 mg|Participants received 65 mg of MK-1697 by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
62418742|NCT06201962|EXPERIMENTAL|Foot Reflexology|Before the procedure, written and verbal consent will be obtained from the newborn's guardian and brief information will be given about the foot reflexology to be performed on the newborn. In addition to daily routine nursing care and monitoring for premature babies, before applying foot reflexology, the actigraphy device will be attached to the babies' ankles and their 24-hour sleep duration will be evaluated. In the reflexology group, the researcher will hold the baby's foot with his left hand and gently massage each foot with the thumb of his right hand for 15 minutes. Foot reflexology will be performed for 15 minutes every morning and evening for two days. On the morning of the second day, an actigraphy device will be attached to the premature babies' ankles and their 24-hour sleep will be re-evaluated.
62800489|NCT03515824|EXPERIMENTAL|Part A: MK-1697 200 mg|Participants received 200 mg of MK-1697 by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
62800490|NCT03515824|EXPERIMENTAL|Part B: Expansion Cohort|Participants with select tumor types were to receive MK-1697 at the RP2D by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
62800491|NCT06024486||JIA cases|juvenile idiopathic arthritis cases
62800492|NCT06024486||CONTROL|age and sex matched healthy controls
62800493|NCT02718729|OTHER|Rectal cancer patients|All patients who will fulfill the inclusions criteria. Patients will undergo formal curative radical Laparoscopic resection for rectal cancer
62800494|NCT05705466|EXPERIMENTAL|Navtemadlin in combination with pembrolizumab|"Navtemadlin will be administered orally, once daily (QD), on days 1-7 in a 21-day cycle.~Pembrolizumab will be administered intravenously on Day 1 of a 21-day cycle."
62800495|NCT05705466|PLACEBO_COMPARATOR|Navtemadlin placebo in combination with pembrolizumab|"Navtemadlin placebo will be administered orally, once daily (QD), on days 1-7 in a 21-day cycle.~Pembrolizumab will be administered intravenously on Day 1 of a 21-day cycle."
62418743|NCT06201962|EXPERIMENTAL|Control|Newborns will receive routine medical treatment and nursing care and will not undergo any procedures. Before the procedure, written and verbal consent will be obtained from the newborn's guardian and brief information about the study will be given. Premature babies will have their 24-hour sleep recorded with actigraphy 1 day in advance. Then, the nursing care that premature babies receive in their daily routine will be given for two days. On the morning of the second day, an actigraphy device will be attached to the left foot of the premature babies and their 24-hour sleep on the second day will be recorded.
62418744|NCT06394830|EXPERIMENTAL|Open Label Arm|VNX001 intravesical administration PRN up to 6 doses over 14 days. The VNX001 effective dose is 15 mL of buffered lidocaine HCl (200 mg) and sodium heparin (50,000 USPU).
62418745|NCT01961635|EXPERIMENTAL|Zirconia Abutments|Place zirconia one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
62418746|NCT01961635|EXPERIMENTAL|Titanium Abutments|Place titanium one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
62800496|NCT03178383|EXPERIMENTAL|Integrated Approach|In this approach, rather than developing a separate health ministry, cancer activities could be integrated throughout existing church ministries (e.g. men's, women's, seniors).
62800497|NCT03178383|ACTIVE_COMPARATOR|Standard Comparison|Standard group churches will not be asked to, or provided special encouragement to technical assistance with, institutionalizing health promotion activities in their churches.
62800498|NCT05425329|EXPERIMENTAL|Probiotic treatment|P. acidilatici, CECT 7483, L. plantarum CECT 7484, L. plantarum CECT7485 in a ration of 1:1:1 at a dose of 3b cfu/day.
62800499|NCT05425329|PLACEBO_COMPARATOR|Placebo treatment|Capsules indistinguishable from intervention containing maltodextrin.
62800500|NCT04098809|ACTIVE_COMPARATOR|Catheter 16 French|16 French urinary catheter
62800501|NCT04098809|ACTIVE_COMPARATOR|Catheter 20 French|20 French urinary catheter
62800502|NCT05279859|EXPERIMENTAL|Dose Escalation (Part 1): ERAS-007 plus gilteritinib|ERAS-007 will be administered in combination with gilteritinib to study participants with R/R FLT3 mutated AML in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
62800503|NCT05279859|EXPERIMENTAL|Dose Escalation (Part 2): ERAS-601 plus gilteritinib|ERAS-601 will be administered in combination with gilteritinib to study participants with R/R FLT3 mutated AML in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
62800504|NCT05279859|EXPERIMENTAL|Dose Expansion (Part 3): ERAS-007 plus gilteritinib|ERAS-007 will be administered at the recommended dose (as determined from Part 1) in combination with gilteritinib to study participants with R/R FLT3 mutated AML.
62800505|NCT05279859|EXPERIMENTAL|Dose Expansion (Part 4): ERAS-601 plus gilteritinib|ERAS-601 will be administered at the recommended dose (as determined from Part 2) in combination with gilteritinib to study participants with R/R FLT3 mutated AML.
62800506|NCT00452790|EXPERIMENTAL|A|
62800507|NCT00452790|ACTIVE_COMPARATOR|B|
62800508|NCT04375917|ACTIVE_COMPARATOR|Active|Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation
62800509|NCT04375917|NO_INTERVENTION|control|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously
62800510|NCT02741245|ACTIVE_COMPARATOR|Ezetimibe 10 mg|1 Ezetimibe 10 mg tablet and 2 Rosuvastatin placebo capsules once daily for 12 weeks
62800511|NCT02741245|ACTIVE_COMPARATOR|Rosuvastatin 2.5 mg|1 Rosuvastatin 2.5 mg capsule, 1 Rosuvastatin placebo capsule and 1 Ezetimibe placebo tablet once daily for 12 weeks.
62800512|NCT02741245|ACTIVE_COMPARATOR|Rosuvastatin 5.0 mg|2 Rosuvastatin 2.5 mg capsules and Ezetimibe placebo tablet once daily for 12 weeks.
62589435|NCT04570865|EXPERIMENTAL|Dapagliglozin|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
62800513|NCT02741245|EXPERIMENTAL|Ezetimibe 10 mg+ Rosuvastatin 2.5 mg|1 Ezetimbie 10 mg tablet, 1 Rosuvastatin 2.5 mg capsule and 1 Rosuvastatin placebo capsule once daily for 12 weeks.
62026931|NCT04897295|ACTIVE_COMPARATOR|Active tDCS|The intervention will be the stimulation with transcranial Direct Current Stimulation (tDCS). Each patient will undergo a 20 minutes session with anode placed on the right Dorso-Lateral Prefrontal Cortex (RDLPFC) and the cathode on the left DLPFC (LDLPFC); the tDCS will administrate a 1 mA stimulation. During the intensive treatment phase participant will undergo one stimulation/day for 5 consecutive days. After this, participants will receive one stimulation per week for 3 months with the same parameters. Device: tDCS device (E.M.S. Electromedical Systems, Bologna, Italy) with a maximum output of 5 mA and administered by two 25-cm2 sponge electrodes of rectangular shape.
62026932|NCT04897295|SHAM_COMPARATOR|Sham tDCS|The intervention will be the stimulation with sham transcranial Direct Current Stimulation (sham tDCS). The device will be set by staff member not involved with data collection analysis to ensure the blinding of assessors. The device will be set to give a weak amperage for the first and the last 20 second of stimulation to ensure the blinding of participant giving them a similar sensation experienced by the active tDCS participants without stimulate brain tissues. Device: tDCS device (E.M.S. Electromedical Systems, Bologna, Italy) with a maximum output of 5 mA and administered by two 25-cm2 sponge electrodes of rectangular shape.
62026933|NCT04543929|ACTIVE_COMPARATOR|exercise|exercise prescription + standard of care
62026934|NCT04543929|NO_INTERVENTION|no exercise|no exercise prescription + standard of care
62026935|NCT00649012|EXPERIMENTAL|1|Pioglitazone HCl Tablets 45 mg
62026936|NCT00649012|ACTIVE_COMPARATOR|2|Actos® Tablets 45 mg
62026937|NCT05491473||Control|Patients who did not receive the application of iNPWT at the donor site.
62418747|NCT01961635|EXPERIMENTAL|Cad-Cam Acrylic abutments|Place cad-cam acrylic one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
62418748|NCT06700720|EXPERIMENTAL|Dose 1 treatment arm|Dose 1 YN001 will be administrated intravenously twice in a week.
62418749|NCT06700720|EXPERIMENTAL|Dose 2 treatment arm|Dose 2 YN001 will be administrated intravenously weekly.
62800514|NCT02741245|EXPERIMENTAL|Ezetimibe 10 mg+ Rosuvastatin 5.0 mg|1 Ezetimbie 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules once daily for 12 weeks.
62800515|NCT01022658|ACTIVE_COMPARATOR|detemir|Insulin detemir at dinner or bedtime
62026938|NCT05491473||Negative pressure|Patients who received the application of iNPWT at the donor site.
62026939|NCT01707602|EXPERIMENTAL|Arm A|Type Vaccine Name: INTANZA® 15 T Description : transcutaneous vaccination
62026940|NCT01707602|ACTIVE_COMPARATOR|Arm B|Type: Vaccine Name: INTANZA® 15ug Description : intradermal vaccination
62418750|NCT04539236|EXPERIMENTAL|Luspatercept + Lenalidomide Group|"Phase 1B: Luspatercept will be administered at starting dose 1.0 mg/kg and can be titrated to 1.33 and 1.75 mg/kg dependent on participant response. Lenalidomide will be administered in a dose escalation design between 3 cohorts to determine MTD (2.5 mg, 5 mg and 10 mg daily dose on a 21-day cycle). MTD will be defined as the dose level with 0 or 1 DLT out of 6 participants. MTD will be declared as the RP2D for the Phase II portion of the study.~Phase II: Luspatercept will be administered at 1.0 mg/kg and can be titrated to 1.33 and 1.75 mg/kg dependent on participant response. Lenalidomide will be administered with the RP2D daily for 21 days on a 21 day cycle.~Treatment with combination of Lenalidomide and Luspatercept will continue as long as a participant is deriving clinical benefit, in the opinion of the treating physician, for up to 5 years or until disease progression or treatment intolerance."
62418751|NCT03845855|EXPERIMENTAL|Virtual reality with robotic gait|virtual reality treatment with robotic gait therapy 2 times for week by 6 weeks.
62589436|NCT00593034||1|"Participants in this study will be 12-21 year old patients who have been referred to the Adolescent Substance Abuse Program for evaluation of drug or alcohol use and are participating in the parent study, Medical Office Intervention for Adolescent Drug Abuse."
62800516|NCT01022658|ACTIVE_COMPARATOR|aspart|Insulin aspart before each meal
62589437|NCT05509465|EXPERIMENTAL|Ergonomic chinrest used with low shoulder rest (EC+)|Participants will play the violin using the ergonomic chinrest with a low Kun Super shoulder rest (EC+) for a two-week period to test its usability and acceptability. Each day participants have to use half of their playing time with EC+.
62418752|NCT03845855|ACTIVE_COMPARATOR|Robotic gait therapy only|only robotic gait therapy 2 times for week by 6 weeks
62800517|NCT01022658|ACTIVE_COMPARATOR|detemir and aspart|
62800518|NCT04935073|EXPERIMENTAL|Traditional Chinese Medicine herbs treatment group|the treatment group will receive treatment with the Chinese herbal formula on the 5th day of the menstrual cycle and lasts to 14 days after IVF-ET.
62800519|NCT04935073|ACTIVE_COMPARATOR|Western medicine group|The control group will be treated with conventional Western medicine
62800520|NCT02158871|EXPERIMENTAL|Contact-based mental health education|"The Beyond Silence' program is 12 hours in length: six 1.5-2 hour in-person group sessions every other week, plus five online sessions between each of the in-person sessions."
62800521|NCT02158871|ACTIVE_COMPARATOR|Mental health literacy training|"Mental Health First Aid training consists of twelve hours of standardized, module-based mental health literacy training offered in a group format. It will be offered as 2 full-day training sessions (or four half-day sessions)."
62800522|NCT06316349|ACTIVE_COMPARATOR|Isolated Resistance Training Program Group|Four sets of 10 knee extension repetitions will be performed with a 90-second rest interval between sets.
62026941|NCT01707602|ACTIVE_COMPARATOR|Arm C|Type : Vaccine Name: Vaxigrip® Description :Intramuscular vaccination
62026942|NCT02535065|EXPERIMENTAL|Endovascular Graft|The Zenith Low Profile AAA Endovascular Graft and ancillary components
62800523|NCT06316349|EXPERIMENTAL|Neuromuscular Electrical Stimulation Group|Neuromuscular electrical stimulation will be performed in muscles of the femoral quadriceps, simultaneously with the same resistance exercise program as the Isolated Resistance Training Program Group.
62800524|NCT02625805|EXPERIMENTAL|Participants diagnosed with ADD/ADHD|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv) and Methylphenidate administration
62800525|NCT02625805|EXPERIMENTAL|Healthy participants|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv) and Methylphenidate administration
62026943|NCT05044572|EXPERIMENTAL|Open chain kinetic exercises|
62589438|NCT05509465|EXPERIMENTAL|Ergonomic chinrest used without shoulder rest (EC-)|Participants will play the violin using the ergonomic chinrest without a shoulder rest for a two-week period to test its usability and acceptability. Each day participants have to use half of their playing time with EC-.
62800526|NCT02721602|EXPERIMENTAL|Intervention Group|Families in the Families Preventing Diabetes Together intervention group will be asked to participate in four in-person sessions at a local Fairview North metropolitan area clinic over the course of two months. Sessions will focus on age-appropriate nutrition and diabetes education, meal planning and cooking skills, healthful eating, and eating meals as a family. All family members will be asked to attend and will be involved in all four, two-hour sessions. The parent with diabetes will also complete one goal setting telephone call based on motivational interviewing techniques during the intervention period.
62800527|NCT02721602|NO_INTERVENTION|Measurement Only|No intervention only measurements
62026944|NCT05044572|EXPERIMENTAL|Forward head posture correction exercises|
62026945|NCT03507166|EXPERIMENTAL|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
62026946|NCT06024928|EXPERIMENTAL|Automated Insulin Delivery in the Basal Insulin Titration Phase|Participants will use Automated Insulin Delivery (AID) for 10 days in the Basal Insulin Titration (BIT) Phase. This group will then return to their original home therapy (basal insulin using pen) using the new setting in the Maintenance Phase (MP) with a blinded CGM. The total daily insulin (TDI) requirement during the BIT Phase will be translated to a basal insulin dose.
62026947|NCT06024928|NO_INTERVENTION|Standard Care with Study Continuous Glucose Monitor|Participants will use a study Continuous Glucose Monitor (CGM) along with their original home therapy and will be contacted by a study physician as per standard care to adjust their insulin doses if needed. This group will then transition into a 10-day Maintenance Phase (MP) using a blinded CGM, where the basal dose will be maintained.
62589439|NCT03400150|EXPERIMENTAL|balloon group|Marking + balloon implantation + IMRT
62800528|NCT03641040|EXPERIMENTAL|VOG group|Measurement: Video-oculography(VOG) measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
62800529|NCT03641040|ACTIVE_COMPARATOR|APCT group|Measurement: Alternative prism cover test(APCT) measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
62800530|NCT02137824|EXPERIMENTAL|sinus floor elevation|
62800531|NCT03544021|EXPERIMENTAL|CART-19|The relapsed/refractory ALL patients will receive allogenic or autologous CD19-Targeted CAR-T cells infusion after FC chemotherapy.
62026948|NCT04431323|EXPERIMENTAL|biopsychosocial intervention|"Young adults with MS will receive an intervention (group setting) composed of physical activities (duration: 10-12 weeks; either dancing or walking) and psychosocial interventions (6-8 encounters).~\[The intervention will start as soon as 8-10 patients will have been enrolled. A waiting list will be then created and patients contacted when the subsequent group starts. This waiting list does not serve as control group.~One or more groups, respectively for the psychological intervention and the physical activities, may start at the same time but on different days, considering also the results of the co-creation phase.\]"
62026949|NCT00783536|EXPERIMENTAL|1|"* Clinical and demographic information~* Clinical and Laboratory information"
62800532|NCT02444949|EXPERIMENTAL|endostar+DF+IMRT|patient first receive one periodicity chemotherapy(DDP (25mg/m2/d; ivgtt; d1～3)+5-FU (600mg/m2/d; ivgtt; d1～5)+endostar (150mg/5d; civ; d1～5)), then given IMRT (5 times per week, 6 weeks). After rest 4 weeks, continue to give the chemotherapy (21 days for a periodicity, 3 periodicities).
62026950|NCT00783536|ACTIVE_COMPARATOR|2|"* Clinical and demographic information~* Clinical and Laboratory information"
62800533|NCT02444949|OTHER|DF+IMRT|patient first receive one periodicity chemotherapy(DDP (25mg/m2/d; ivgtt; d1～3)+5-FU (600mg/m2/d; ivgtt; d1～5)), then given IMRT (5 times per week, 6 weeks). After rest 4 weeks, continue to give the chemotherapy (21 days for a periodicity, 3 periodicities).
62800534|NCT04068246|PLACEBO_COMPARATOR|Control group|patients will receive the standard therapy (methotrexate) plus placebo tablets
62800535|NCT04068246|EXPERIMENTAL|Metformin group|patients will receive the standard therapy plus 1 g metformin daily.
62026951|NCT04393545|ACTIVE_COMPARATOR|HV night splint (SP) group|
62026952|NCT04393545|ACTIVE_COMPARATOR|exercise (EX) group|
62026953|NCT04393545|ACTIVE_COMPARATOR|high-voltage galvanic stimulation (EL) group|
62026954|NCT04450589|ACTIVE_COMPARATOR|ALRV5XR|The ALRV5XR (active) group will receive ALRV5XR active treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the placebo products.
62589440|NCT03400150|SHAM_COMPARATOR|Control group|Marking + IMRT
62026955|NCT04450589|PLACEBO_COMPARATOR|Placebo|The Placebo group will receive a placebo (vehicle) treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the active products. The placebo shampoo, conditioner and serum will have the same base materials (vehicle) as their counterparts but will not contain active ingredients, and will therefore be similar in viscosity and color.
62800536|NCT03573141||Knee OA patients receiving Physical Therapy|Only 1 group was included in this study. Subject's physical activity and sleep quality were assessed at baseline, prior to treatment. Follow up data was collected immediately after a course of physical therapy then again 8 weeks later.
62800537|NCT01817426|ACTIVE_COMPARATOR|infliximab|Patients in this arm are randomized to continue IFX therapy at an unchanged dosage and frequency.
62800538|NCT01817426|PLACEBO_COMPARATOR|Placebo|Patients in this arm are randomized to receive matching placebo.
62800539|NCT03637660|ACTIVE_COMPARATOR|1|2.4 million units (MU) of Benzathine penicillin G (BPG) intramuscularly on Day 1, n=280
62800540|NCT03637660|EXPERIMENTAL|2|2.4 million units (MU) of Benzathine penicillin G (BPG) intramuscularly weekly for three successive weeks, n=280
62800541|NCT00428948|EXPERIMENTAL|Tolvaptan|Participants received the highest tolerated split-dose regimen (upon awakening and 9 hours later) of tolvaptan 45/15 mg, 60/30 mg, or 90/30 mg orally for 36 months.
62800542|NCT00428948|PLACEBO_COMPARATOR|Placebo|Participants received placebo (upon awakening and 9 hours later) orally for 36 months.
62800543|NCT02083692|EXPERIMENTAL|Metformin|
62589441|NCT06666153|EXPERIMENTAL|Treatment Cohort|EBV immunological agent administration on day 0,7,14,21 and 42 for Intradermal or Subcutaneous Injection
62589442|NCT02636231|ACTIVE_COMPARATOR|IMRT and concurrent Endostar|"IMRT and concurrent Endostar (Endostatins) to treat locally recurrent NPC patients; Endostar is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.~IMRT is to give GTV 60Gy in 27 fractions."
62589443|NCT02636231|EXPERIMENTAL|IMRT alone|IMRT alone to treat locally recurrent NPC patients. IMRT is to give GTV 60Gy in 27 fractions.
62800544|NCT05753488||ınflammation|
62800545|NCT05753488||non inflammation|
62026956|NCT01224262|EXPERIMENTAL|Fluzone + 0.45 mg LIQ001|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (0.45mg)
62418753|NCT02428959|EXPERIMENTAL|Amyl Nitrite|Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle.The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
62800546|NCT05531981||initial surgical treatment group|"After the patients were enrolled in the study according to the criteria, they were given standard treatment. The patients were followed up every 3\~6 months within 2 years after treatment and every 6\~12 months from 3 to 5 years after treatment, including general and gynecological physical examination, cervical or vaginal cytology test, HPV typing test, SCC, CA125, and imaging examination such as CT or MRI if necessary.~Peripheral blood samples were collected to detect HPV E7 ctDNA before treatment, 2 weeks after surgery, (1 month after adjuvent radiotherapy if available) and at 6, 12, 18, 24, 30, and 36 months of follow-up."
62800547|NCT05531981||initial concurrent chemoradiotherapy group|"After the patients were enrolled in the study according to the criteria, they were given standard treatment. The patients were followed up every 3\~6 months within 2 years after treatment and every 6\~12 months from 3 to 5 years after treatment, including general and gynecological physical examination, cervical or vaginal cytology test, HPV typing test, SCC, CA125, and imaging examination such as CT or MRI if necessary.~Peripheral blood samples were collected to detect HPV E7 ctDNA before treatment, 1 month after radiotherapy and at 6, 12, 18, 24, 30, and 36 months of follow-up."
62418754|NCT02606864|EXPERIMENTAL|BAYa2502 without food|Oral intake of a single 120 mg nifurtimox dose under fasted conditions
62418755|NCT02606864|EXPERIMENTAL|BAYa2502 with food|Oral intake of a single 120 mg nifurtimox dose under fed conditions after ingestion of a high calorie and high fat breakfast
62418756|NCT05025241|EXPERIMENTAL|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
62418757|NCT00902278|ACTIVE_COMPARATOR|Flulaval|
62418758|NCT00902278|ACTIVE_COMPARATOR|Fluvirin|
62589444|NCT02618837|ACTIVE_COMPARATOR|Downstream strategy arm|downstream administration strategy of P2Y12 receptor blockers (prasugrel or ticagrelor)
62589445|NCT02618837|ACTIVE_COMPARATOR|Upstream strategy arm|upstream administration strategy (ticagrelor only)
62589446|NCT04870424|EXPERIMENTAL|Colchicine|
62589447|NCT04870424|PLACEBO_COMPARATOR|Placebo|
62589448|NCT06168734|EXPERIMENTAL|Cefepime-taniborbactam|cefepime-taniborbactam (2g/0.5g) IV every 8 hours.
62800548|NCT02754921|EXPERIMENTAL|Ultra-perc|
62026957|NCT01224262|EXPERIMENTAL|Fluzone + 1.8 mg LIQ001|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (1.8mg)
62418759|NCT00902278|ACTIVE_COMPARATOR|Fluzone|
62418760|NCT00902278|ACTIVE_COMPARATOR|Fluarix|
62418761|NCT00902278|ACTIVE_COMPARATOR|Affluria|
62418762|NCT05350748||Cohort 1|Participants with myelodysplastic syndromes and associated malignancies
62418763|NCT05350748||Cohort 2|Participants (controls) without MDS or associated malignancies, contributing bone marrow
62589449|NCT06168734|ACTIVE_COMPARATOR|Meropenem|Comparator: meropenem (2g) IV every 8 hours.
62589450|NCT02814786|EXPERIMENTAL|Equinus cohort|"15 childrens who have a fixed equinus defined as a fixed limitation of dorsiflexion inferior to 0°.~Interventions: MRI scanner and gait analysis"
62589451|NCT02814786|EXPERIMENTAL|Control cohort|"In this cohort, there will be 15 childrens with age and gender matched to equinus cohort and with no history of lower limb musculo-skeletal injury in past 6 months.~Interventions: MRI scanner and gait analysis"
62589452|NCT05253586||Laparoscopic Arm|This cohort of participants will have their procedure completed by a human surgeon.
62589453|NCT05253586||Robotic Arm|This cohort of participants will have their procedure completed by the Versius Surgical Robotic System.
62589454|NCT00993343|ACTIVE_COMPARATOR|Cyclosporine + Methotreaxte|
62589455|NCT00993343|ACTIVE_COMPARATOR|sirolimus + tacrolimus|
62589456|NCT02000622|EXPERIMENTAL|Olaparib|Olaparib tablet 300mg bd po
62800549|NCT02754921|EXPERIMENTAL|Ciaglia Blue Dolphin|
62800550|NCT04698603|EXPERIMENTAL|Phase 1 (Part A): GH001 dose A|
62026958|NCT01224262|ACTIVE_COMPARATOR|Fluzone|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)
62026959|NCT04336254|EXPERIMENTAL|hDPSCs group|Routine treatment + Intravenous injection of human dental pulp stem cells
62026960|NCT04336254|PLACEBO_COMPARATOR|Control group|Routine treatment + Intravenous saline injection (Placebo)
62026961|NCT03634774|EXPERIMENTAL|Step 1 CHOICE+|Receives the intervention first
62026962|NCT03634774|OTHER|Step 2 CHOICE+|Received intervention four months after baseline
62800551|NCT04698603|EXPERIMENTAL|Phase 1 (Part A): GH001 dose B|
62800552|NCT04698603|EXPERIMENTAL|Phase 2 (Part B): GH001 Individualized Dosing Regimen|
62800553|NCT02300363|EXPERIMENTAL|Treatment A|10 mg oral rosuvastatin administration
62800554|NCT02300363|EXPERIMENTAL|Treatment B|400 mg oral LX4211 qd administration
62800555|NCT02300363|EXPERIMENTAL|Treatment C|10 mg oral rosuvastatin administration + 400 mg oral LX4211 qd administration
62225827|NCT04200885|ACTIVE_COMPARATOR|Preoperative Submucosal Corticosteroid Injection|Patients in this arm were administered 8mg/2ml dexamethasone 21-phosphate preoperatively after local anesthesia were obtained. Injection site was the depth of buccal sulcus near operation site. For the patients in this arm 25 mg dexketoprofen trometamol was excluded from postoperative prescription in order not to affect the anti-inflammatory effects of corticosteroid. Instead of NSAID, three times a day 500 mg paracetamol was prescribed. The patients were advised not to exceed maximal dosage of 3000 mg (6 tablets) in a day.
62800556|NCT02505659|EXPERIMENTAL|EXPERIMENTAL GROUP|Sessions are aiming to neuromuscular and functional training. Each session starts with trunk muscle activation. Patients will then have to realize a neuromuscular training on Huber Motion Lab® followed by multiple exercises targeting functional stability and neuromuscular control. From the 4th session, a jump sequence will be added to the previous exercices. Exercises used in this protocol are based upon successful exercises of protocols already performed on patients with anterior cruciate ligament rupture.
62225828|NCT04200885|ACTIVE_COMPARATOR|Postoperative Therapeutic Elastic Bandage Application|In this arm the therapeutic elastic bandage applications were immediately performed after removal of mandibular third molars. The distance between tragus-lateral commissura line and supraclavicular lymph nodes was measured and the tapes were then cut into 5 tails. The base of the tape was placed on supraclavicular lymph nodes and tails were placed on the site to cover parotid, submandibular, submental and superficial cervical lymph nodes. The tapes were removed on postoperative second day.
62225829|NCT01528501|EXPERIMENTAL|I|
62225830|NCT03404141|EXPERIMENTAL|Experimental group|"The intervention administered to the experimental group will be a cognitive-behavior therapy applied by two specifically trained psychologists.~Due to COVID-19 pandemic, this group will be implemented online using a videocall online platform (from April 2019 to the end of mobility restrictions)."
62225831|NCT03404141|ACTIVE_COMPARATOR|Control group|The intervention administered to the control group will consist on a regular parent craft classes offered by the community midwife Due to COVID-19 pandemic, this group will be implemented online using a videocall online platform (from April 2019 to the end of mobility restrictions).
62800557|NCT02505659|NO_INTERVENTION|CONTRL GROUP|a control group (without preoperative reeducation)
62800558|NCT00479336|PLACEBO_COMPARATOR|1|
62225832|NCT04732494|EXPERIMENTAL|Arm A: Tislelizumab plus Ociperlimab|Participants will receive tislelizumab (200 milligrams \[mg\]) plus ociperlimab (900 mg) intravenously once every 3 weeks.
62225833|NCT04732494|PLACEBO_COMPARATOR|Arm B: Tislelizumab plus Placebo|Participants will receive tislelizumab (200 mg) plus placebo intravenously once every 3 weeks.
62225834|NCT00932113|ACTIVE_COMPARATOR|Adalimumab|Dosing will be on day 1 and then weekly. For the injections, dosing will occur according to product recommendations. Patients will receive 80mg adalimumab (2 pre-filled syringes, each with 40mg) on day 1, and then 40mg on week 1 and then every 2 weeks (from week 1 through week 15).
62418764|NCT02875431||ACDF or cervical vertebral body replacement|
62418765|NCT06538909|EXPERIMENTAL|PD with VR int.|Parkinson's disease patients using Virtual reality intervention that include physical activity and cognitive
62418766|NCT06604949|EXPERIMENTAL|LP-003|Single dose administration, with a dosage of 200 mg LP-003
62800559|NCT00479336|EXPERIMENTAL|2|
62800560|NCT00479336|EXPERIMENTAL|3|
62800561|NCT00479336|EXPERIMENTAL|4|
62800562|NCT05523544|OTHER|schematherapy|all (8) participant wil recieve the same treatment, schematherpay which is treatment as usual for personality disorders in forensic psychiatric care. They will be asked however to fill in extra questionnaires to study the effect of the treatment.
62800563|NCT05322434|EXPERIMENTAL|experimental group|Postpartum breastfeeding training, which is routinely done immediately after birth, and breastfeeding counseling will be provided in the 1st, 2nd, 4th and 6th months after birth.
62800564|NCT05322434|NO_INTERVENTION|control group|Postpartum breastfeeding education will be given routinely immediately after birth.
62026963|NCT03634774|OTHER|Step 3 CHOICE+|Receives intervention eight months after baseline
62589457|NCT02000622|ACTIVE_COMPARATOR|Physician's choice chemotherapy|Capecitabine 2500 mg/m2 d1-14 q 21, or Vinorelbine 30 mg/m2 d1,8 q 21, or Eribulin 1.4 mg/m2 d1,8 q 21
62589458|NCT03242876|PLACEBO_COMPARATOR|Control meal|Control will be 109 g white bread and 200 mL water. The glycaemic response to the test meal will be compared to the response of the control meal.
62589459|NCT03242876|EXPERIMENTAL|Test meal|Test will be 109 g white bread and 200 mL water containing 3.819 g citric acid and 119 mg malic acid adjusted to pH 3.2. The glycaemic response to this meal will be compared to that of the control meal.
62589460|NCT05138276|EXPERIMENTAL|Autologous cord blood mononuclear cells|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 24 hours after birth ,dose is 50 million cells/kg
62589461|NCT05138276|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride infusion 24 hours after birth
62026964|NCT04766619||Staff and stakeholders|For the longitudinal process evaluation - staff and stakeholders who have had direct contact or involvement with and have an understanding of OptmiseRx and/or PINCER will be invited to take part in an interview or focus group, an observation and/or complete a questionnaire. For the consolidated learning exercise - those who are in a position to influence the wider adoption of these interventions will be invited to take part in an interview or development workshop.
62589462|NCT03264924||Phase A, Study One|Semi-structured interviews to investigate staff and patients' experiences of participating and facilitating cardiac and pulmonary rehabilitation.
62589463|NCT03264924||Phase A, Study Two|Focus group with rehabilitation stakeholders to discuss perceived feasibility and acceptability of the intervention design.
62589464|NCT03264924||Phase A, Study Three|Pilot of the intervention, using a group of exercise physiologists external to the community rehabilitation services.
62589465|NCT03264924||Phase B|Community rehabilitation service staff will participate in the intervention. Patients will then participate in the rehabilitaiton programme. Physical activity levels of patients will be recorded throughout the rehabilitation programme and for six months post-discharge. Qualitative and quantitative follow-up sessions will patients will take place at discharge (8 weeks after start of rehabilitation), and three and six months post-discharge.
62026965|NCT04766619||Patients|Patients registered with a practice who have attended a consultation (or other related activity) for the PINCER intervention OR selected by their clinical care team OR attached to a patient group within a Clinical Commissioning Group (CCG) or practice OR patients identified through social media who have a long-term health condition and/or are taking any medication that requires them to have regular blood tests and have had a medication review in the past six month will be invited to take part in an interview or focus group.
62589466|NCT02682823|EXPERIMENTAL|Caregivers|CGs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
62026966|NCT04766619||Public and patient representatives|For the consolidated learning exercise - patient and public representatives who have an understanding of the related medicines management issues in primary care will be invited to take part in an interview or workshop.
62589467|NCT02682823|EXPERIMENTAL|Healthcare Professionals|HCPs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
62589468|NCT02682823|EXPERIMENTAL|RA Group 1 (Self-Administration)|Participants with RA will perform self-injection of SC tocilizumab with the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
62026967|NCT05477134|EXPERIMENTAL|The study cohort consisting of youth with type 2 diabetes and healthy controls|"In Study Day 1, participants will be given a primed dose of stable isotopes followed by continuous intravenous infusions for 5 hours. The investigators will use the following isotopes: U-13C6-Arg, 5,5-2H2-Cit, 15N2-Orn, 2H5-Phe, and Na13CO3.~On Study Day 2, participants will drink a 75-gram glucose solution prior to an oral glucose tolerance test.~On Study Day 3, participants will drink a 75-gram glucose solution and will be injected 5-gram arginine into their veins."
62589469|NCT02682823|OTHER|RA Group 2 (Administration by CG)|CGs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
62026968|NCT04387084|EXPERIMENTAL|Treatment (STF, PD-1/PD-L1 inhibitor)|Patients undergo STF for 47-48 hours prior to immunotherapy and for 24 hours after immunotherapy with standard of care pembrolizumab given IV over 30 minutes, nivolumab IV over 30 minutes, cemiplimab IV over 30 minutes, avelumab IV over 60 minutes, atezolizumab IV over 60 minutes, or durvalumab IV over 60 minutes on day 3. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
62418767|NCT06604949|PLACEBO_COMPARATOR|Placebo|Single dose administration of LP-003 placebo
62418768|NCT06408454||Psoriasis patients|IL-17, Bcl-3, IκBζ gene expression levels were examined
62589470|NCT02682823|OTHER|RA Group 3 (Administration by HCP)|HCPs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visit 1 (Day 0) will be performed by the study nurse. Visits 2 and 3 (Days 14 and 28) will be conducted by the HCP for use/performance evaluation.
62589471|NCT02000336|EXPERIMENTAL|Prednisolone 10|Prednihexal (Prednisolon), daily oral tablet, 10 mg during week one to four, 7,5 mg during week five to eight. Finally 5 mg for four weeks.
62800565|NCT02056795|EXPERIMENTAL|Electroacupuncture|Subjects will do balance assessment in lab. In treatment room, practitioner will clean insertion area with alcohol swab, allow adequate time to dry, and insert 2 Asia-Med Special No 16 (0.30x30mm) needles: one at proximal insertion of fibularis longus anterior to fibular neck, in proximity to common fibular nerve (GB-34); one over sinus tarsi and lateral ligaments of ankle mortise (GB-40). Needles will be inserted approximately 1-2cm, connected for 10 min at 2Hz to electrical stimulation (ITO ES-130, 500 ohm test load, 1 to 500Hz). Needles will disposed of in sharps container. Area will be wiped with long handled cotton swab, pressure will be applied for 2 seconds. Subjects will be asked to slowly get up from table and return to lab for second balance assessment.
62800566|NCT02056795|SHAM_COMPARATOR|Control|As with experimental group, controls will do balance assessment pre- and post-intervention. Streitberger placebo needles (Asia-Med, 0.03 x 30 mm), blunted with a telescoping mechanism, will be used. Subjects will feel slight prick, and shaft will telescope into handle, creating illusion of skin penetration. Needles will be held in place by plastic ring covered by a bandage. They are validated for blinding. They will be placed over non-traditional acupuncture points on medial aspect of leg, in direct opposition to treatment group needles. Needle placement is not intended to produce therapeutic outcome. The needles will be connected to a wire, which will be turned on for 10 minutes but no stimulation will be felt.
62800567|NCT01505959|EXPERIMENTAL|Conventional|
62800568|NCT01505959|ACTIVE_COMPARATOR|Telemedicine|
62800569|NCT01284517|EXPERIMENTAL|Lurasidone 20-120 mg flexible dose|
62800570|NCT01284517|PLACEBO_COMPARATOR|Placebo|
62026969|NCT05419648||PV and ET patients|For the main objective, the cohort will be composed of PV and ET patients, some with a history of thrombosis and some without any history of thrombosis. A comparison will also be performed between patients with different MPN (PV or ET) and different driver mutation (JAK2V617F, JAK2 exon 12, CALR, MPL or absence of such mutations)
62225835|NCT00932113|ACTIVE_COMPARATOR|Methotrexate (MTX)|Patients will be dosed according to the CHAMPION study in single weekly doses of methotrexate: 7.5mg at week 0, 10mg at week two, and 15mg at week 4 for all patients. For each subject if the PASI did not decrease by at least 50% from baseline (PASI-50) at week 8, dosing will be increased to 20mg per week; the dose will be maintained at 15mg per week if PASI-50 was achieved at week 8. If PASI-50 was not achieved at week 12, dosing will be increased to 25mg per week; the dose will be maintained at 20mg per week if the PASI-50 was achieved at week 12. All patients on methotrexate will also receive a dietary supplement of oral folate (5mg per week). Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study.
62800571|NCT02114138||Surgical Group|Adults undergoing major in hospital surgery; pathogenesis of perioperative acute kidney injury; urine collection
62800572|NCT02114138||Healthy Control|Healthy Adult volunteers who are willing to provide a 200 ml urine sample.
62800573|NCT02510001|EXPERIMENTAL|Dose Escalation Phase Cohort 1 Dose level 1|Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
62225836|NCT05273697|ACTIVE_COMPARATOR|Underwater cold snare polypectomy group|Cold snare polypectomy after complete immersion of the polyp in the water
62418769|NCT06408454||Control group|IL-17, Bcl-3, IκBζ gene expression levels were examined
62418770|NCT01262729|EXPERIMENTAL|Xenon-Arm|Patients in Xenon-Arm will be inhalated with xenon within 2 hours additionally to therapeutical hypothermia after successful cardiopulmonary resuscitation.
62589472|NCT02000336|EXPERIMENTAL|Prednisolone 60|Prednihexal (Prednisolon), daily oral tablet, 60 mg during the first week, weekly tapering: 40 mg, 20mg, 15mg, 10mg, 7,5mg. 7,5mg continued for one more week. Finally 5 mg for four weeks
62589473|NCT02000336|PLACEBO_COMPARATOR|Placebo|daily oral tablet
62589474|NCT03453034|EXPERIMENTAL|TQ-B3233 capsule|QD or BID; patients are given the doses according to the protocal, and a cycle is 28 days.
62800574|NCT02510001|EXPERIMENTAL|Dose Escalation Phase Cohort 2 Dose level 2|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
62800575|NCT02510001|EXPERIMENTAL|Dose Escalation Phase Cohort 3 Dose level 3|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle
62800576|NCT02510001|EXPERIMENTAL|Dose Escalation Phase Cohort 4 Dose level 4|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
62800577|NCT02510001|EXPERIMENTAL|Dose Escalation Phase Cohort 7 Dose level 5|Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
62800578|NCT02510001|EXPERIMENTAL|Dose Escalation Phase Cohort 13 Dose level 5a|Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration
62026970|NCT05169359|OTHER|Intervention|The study is a type 2 hybrid Effectiveness Implementation trial. The study uses a stepped wedge design. Patients are in a usual care phase until their clinic begins active implementation. Once active implementation begins, patients will view the Speak Up! Video intervention prior to their visit. The 10-minute video program will be provided to patients for viewing on an iPad (or other modality such as a portable DVD player, computer, or TV as appropriate to the site based on PDSA activities during implementation planning). Nurses may also send a video link to the patient via secured messaging as a method of watching the video before the primary care visit.
62418771|NCT01262729|ACTIVE_COMPARATOR|MTH|Patients after successful cardiopulmonary resuscitation will be treated only with therapeutical hypothermia
62418772|NCT06172933|EXPERIMENTAL|Move with Meaning|In Move with Meaning, participants will engage in twice weekly, interactive text message sessions, which are accompanied by audio content to promote engagement in the program. In the first session of each week, participants will review their physical activity goal and positive psychology topic from last week, then learn about a new positive psychology and physical activity topic and ultimately set a new physical activity goal for the week. In the second session, participants will either be reminded of the content of the audio file and the goal they set earlier that week. The program will run for eight weeks.
62418773|NCT06172933|NO_INTERVENTION|Wait-list control|Participants in the wait-list control condition will engage in usual medical care for eight weeks, then will complete the Move with Meaning program.
62800579|NCT02510001|EXPERIMENTAL|Dose Expansion Phase|Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.
62800580|NCT02510001|EXPERIMENTAL|Dose Escalation Phase Cohort 12 Dose level 5 (Interval dosing)|Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
62800581|NCT02148523|EXPERIMENTAL|Weekly Adherence Report|Adherence report to subject every 7 days.
62800582|NCT02148523|EXPERIMENTAL|Weekly Adherence Peer-Comparison Report|Adherence report to subject every 7 days with tailored comparison messages based on subject's adherence.
62800583|NCT02148523|OTHER|Usual Care|Usual care with GlowCap.
62225837|NCT05273697|ACTIVE_COMPARATOR|Conventional cold snare polypectomy group|Cold snare polypectomy in colon lumen dilated with air
62800584|NCT04184219||Group|People potentially interested in health issues
62800585|NCT00659074|EXPERIMENTAL|A|Ondansetron ODT
62800586|NCT00659074|ACTIVE_COMPARATOR|B|Zofran ODT
62800587|NCT05533996|OTHER|Pregnant women prior to 14 weeks|"The sonographic examination will be conducted as an additional part after completing anatomical survey. . For the most accurate measurements, we will reduce the image depth to decrease the margin of error. We will conduct an initial abdominal sweep in all participants from the xiphoid to the umbilicus to detect the area of maximum pre-peritoneal fat thickness. Then, we will measure the maximum pre-peritoneal fat thickness and minimum subcutaneous fat thickness.~Furthermore, all measurements will be conducted after inspiration to avoid its generated tension with the transducer just touching the skin avoiding compression of the subcutaneous fat. Two measurements will be taken to investigate the inter-observer effect. Then, BFI will be calculated using the following formula: BFI = pre-peritoneal fat (mm) x subcutaneous fat (mm) / Height (cm). Results will be communicated to the site primary investigator. The treating obstetrician will be blinded to these results."
62026971|NCT04418804|EXPERIMENTAL|Healthy|Participants without an active diagnosis of pleural disease.
62225838|NCT03080831|ACTIVE_COMPARATOR|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|
62225839|NCT03080831|ACTIVE_COMPARATOR|Glucion 5%|
62418774|NCT06702124|EXPERIMENTAL|Rotigotine 4 mg|Rotigotine 4 mg/24 hours transdermal patch administration
62800588|NCT03173404|EXPERIMENTAL|Group I|Patients underwent hysteroscopy examination before IVF cycle.
62800589|NCT03173404|NO_INTERVENTION|Group II|Patients underwent direct IVF cycle without previous hysteroscopy.
62800590|NCT04569292||Cancer patients|"* confirmation of COVID-19 in the laboratory (RT-PCR techniques);~* suspected cases of COVID-19; clinically diagnosed based on symptoms (fever\> 37.5 °, decrease in oximeter saturation by at least 5%, cough, diarrhea, otitis, dysgeusia, myalgia, arthralgia, conjunctivitis and rhinorrhea) + close contact a COVID-19 subject positive;~* asymptomatic cases; diagnosed based on positive swab results but without symptoms"
62800591|NCT00539994|EXPERIMENTAL|Treatment B|200mg BID retapamulin 5 days
62800592|NCT00539994|PLACEBO_COMPARATOR|Treatment C|200mg BID placebo 5 days
62800593|NCT00539994|EXPERIMENTAL|Treatment A|200mg BID retapamulin 3 days and placebo BID 2 days for a total of 5 days
62800594|NCT04533724|EXPERIMENTAL|Study group|Recruit 30 outpatient/inpatient schizophrenia patients (dominant negative symptoms) in Shanghai Mental Health Center .
62800595|NCT04533724|NO_INTERVENTION|Healthy control group|15 cases of normal healthy people (control group) with similar eating habits and ages in the same region were matched with study group.
62800596|NCT03710122|EXPERIMENTAL|Vancomycin|
62800597|NCT03710122|PLACEBO_COMPARATOR|Placebo|
62800598|NCT05492240|EXPERIMENTAL|i-STRONGER|The high-intensity rehabilitation intervention, termed i-STRONGER, relies on principles of physiologic overload using an 8-repetition max (8RM) to promote muscle strengthening and emphasizes functional carryover for independence.
62418775|NCT06702124|PLACEBO_COMPARATOR|Placebo|Placebo transdermal patch administration
62418776|NCT05674864|PLACEBO_COMPARATOR|Group 1 (Control Group)|consists of 46 patients who will receive Amoxicillin 1 gm three times daily plus Lansoprazole 30 mg three times daily plus Placebo 1 capsule three times daily for 14 days.
62418777|NCT05674864|ACTIVE_COMPARATOR|Group 2 (Linex ® group)|consists of 46 patients who will receive Amoxicillin 1 gm three times daily plus Lansoprazole 30 mg three times daily plus Linex ® capsule (which contains Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus) 1 capsule three times daily for 14 days.
62418778|NCT01366365|EXPERIMENTAL|Arm 1|IV methylnaltrexone (MNTX)
62418779|NCT01366365|PLACEBO_COMPARATOR|Arm 2|placebo
62418780|NCT05145647|EXPERIMENTAL|Add-on Brachytherapy|The evaluation for feasibility of surgery takes place 5-6 weeks after CCRT. Any subject whose tumor status is resectable at evaluation but declines surgical proposal will be eligible to be enrolled in the following study phase.
62418781|NCT05899218|EXPERIMENTAL|Photo-Novella|Participants in the photo-novella intervention will be asked to take 12 photographs and write a caption for each photo based on two prompts.
62418782|NCT05899218|EXPERIMENTAL|Digital Storytelling|Participants in the digital storytelling intervention will be asked to create two videos (1-3 minutes each) based on two prompts.
62418783|NCT06213974||All Participants|Participants who have received maribavir treatment for the approved indication after marketing authorization (de novo participants) and before marketing authorization (legacy participants) under expanded access type of program or compassionate use in the real-world setting. Data will be collected prospectively and/or retrospectively from the medical records during this observational period of 16 weeks.
62418784|NCT00014859||Population-based cohort|Descriptive cohort of population-based DNA samples from the newborn screening program in Missouri with vital statistics based, linked phenotype data
62418785|NCT00014859||Trio sequencing cohort|Affected infant/child (term or near term infant with progressive respiratory distress or other rare pulmonary phenotype or older child with interstitial lung disease or other rare pulmonary phenotype) and parents
62418786|NCT06090500|EXPERIMENTAL|Submucosal Cryotherapy|preoperative submucosal infiltration injection of (2.5C-5C) cold saline
62418787|NCT06090500|ACTIVE_COMPARATOR|Submucosal NSAIDs|preoperative submucosal infiltration injection of Diclofenac sodium
62589475|NCT05969483||sedated and ventilated pediatric critical care patients|All sedated and ventilated critically ill patients will be exposed to the Masimo Sedline® sensor. Its pEEG scores, including the PSI, will be registered by the patient primary nurse every 4 hours for the first 5 days of ventilation. At the same time, CBS will be evaluated by a specialized PICU nurse and by a critical-care expert physician, blinded to each other. In case of chemically paralyzed patients, a paralysis holiday will be performed when clinically possible . A CBS will be assessed when the paralytic agents will be considered washed out. The patient's analgosedation strategy and analgosedation protocol will not be standardized but will be decided by the treating physician based on the international recommendations.
62800599|NCT05492240|ACTIVE_COMPARATOR|Usual Care|The Usual Care SNFs will continue clinical practice as normal, and sites will not have any overlap of personnel or training with i-STRONGER SNFs.
62418788|NCT06090500|ACTIVE_COMPARATOR|Submucosal corticosteroids|preoperative submucosal infiltration injection of dexamethasone
62418789|NCT06090500|NO_INTERVENTION|Control|no preoperative injection apart from the normal anaesthetic routine
62418790|NCT06520371|EXPERIMENTAL|Percutaneous radiofrequency group|Patients will receive percutaneous radiofrequency.
62418791|NCT06520371|ACTIVE_COMPARATOR|Conventional radiofrequency group|Patients will receive conventional radiofrequency.
62418792|NCT03004417|EXPERIMENTAL|CHF 6001 Dose1|CHF6001 via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
62418793|NCT03004417|EXPERIMENTAL|CHF 6001 Dose 2|CHF6001 via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
62418794|NCT03004417|PLACEBO_COMPARATOR|Placebo|Matching placebo via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
62418795|NCT05388032|EXPERIMENTAL|sodium reduction intervention|The sodium reduction intervention is a dietician-led behavioral intervention consisting of two phases, first a 3-month intensive intervention phase, followed by a 9-month maintenance phase. The overall goal of the intervention is to reduce sodium intake to \<2,300 mg per day based on the most recent guideline from the National Academies of Medicine. Both phases will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake.
62418796|NCT05388032|NO_INTERVENTION|Usual Diet|Participants randomized to the usual diet group will receive standard care from their providers with no study intervention.
62800600|NCT01227980|ACTIVE_COMPARATOR|Pexacerfont|Pexacerfont was given orally as a loading dose of 300 mg/day for 1 week, followed by 100mg/day for 16-20 days
62800601|NCT01227980|PLACEBO_COMPARATOR|Placebo|Oral placebo was given during the 1-week loading dose phase, and during the next 16-20 days
62800602|NCT05737251|EXPERIMENTAL|PoET Group|Participants received two sessions of PoET and filled out the questionnaires.
62800603|NCT05737251|NO_INTERVENTION|Control Group|Participants only filled out the questionnaires.
62800604|NCT04579640|NO_INTERVENTION|Control|Standard of care (national recommendation of 400 IU/day vitamin D)
62800605|NCT04579640|EXPERIMENTAL|Intervention: Lower-dose vitamin D|Offer of a daily dose of 800 IU (20 micrograms) cholecalciferol to individuals with 25-hydroxyvitamin D level \<75 nmol/L
62800606|NCT04579640|EXPERIMENTAL|Intervention: Higher-dose vitamin D|Offer of a daily dose of 3200 IU (80 micrograms) cholecalciferol to individuals with 25-hydroxyvitamin D level \<75 nmol/L
62800607|NCT04840082|EXPERIMENTAL|Collecting of Clinical Specimens for COVID-19 Testing|Nasopharyngeal swab is performed on all participants to collect specimens for Rapid antigen COVID-19 Testing
62418797|NCT05105035|ACTIVE_COMPARATOR|Placebo|Patients are administered either IV ceftazidime or IV meropenem per standard of care and placebo. Placebo will be administered every 12 hours for Days 1-14.
62225840|NCT04778241|EXPERIMENTAL|Micro-Osteoperforation group|All the participants bonded by the care provider with 0.022 inch MBT prescription appliance (Ortho TechanologyTM,USA). Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental group before placing the initial leveling arch wire. MOPs were placed at three sites i.e., interproximally between mandibular canine and lateral incisor on both sides and between central incisors in the midline on labial aspect of mandible.
62418798|NCT05105035|EXPERIMENTAL|ARV-1801 (ACG-701)|Patients are administered either IV ceftazidime or IV meropenem per standard of care and active ARV-1801. Day 1 dosing will be two doses of 1500mg of ARV-1801 administered 12 hours apart. Days 2-14 dosing will be 600mg of ARV-1801 administered every 12 hours.
62225841|NCT04778241|NO_INTERVENTION|Control group|All the participants in this group bonded by the principal investigator with 0.022-inch slot MBT prescription appliance (Ortho TechanologyTM,USA). No micro-osteoperforation was used in this group.
62225842|NCT05248074|OTHER|Fasting group|"Period 1 : Single oral administration of ABN401 800 mg (3 x 250 mg + 2 x 25 mg) after an overnight fast~Peroid 2: Single oral administration of ABN401 800 mg (3 x 250 mg + 2 x 25 mg) in fed condition. High-fat meal (over 900 kcal)"
62418799|NCT06470841|EXPERIMENTAL|CHG Combined With Venetoclax and Azacytidine|Patients were treated by CHG Combined With Venetoclax and Azacytidine
62225843|NCT05248074|OTHER|Fed group|"Peroid 1: Single oral administration of ABN401 800 mg (3 x 250 mg + 2 x 25 mg) in fed condition. High-fat meal (over 900 kcal)~Period 2: Single oral administration of ABN401 800 mg (3 x 250 mg + 2 x 25 mg) after an overnight fast"
62589476|NCT05961306||antenatal period|Pregnant women between 20 and 24 weeks of pregnancy will be invited to participate
62589477|NCT05961306||postnatal period|Moms, 6 to 10 weeks after delivery will be invited to participate
62589478|NCT06348433|EXPERIMENTAL|Ketogenic diet group|The subjects were treated with ketogenic diet. Ketogenic diet is a formula diet with high fat, low carbohydrate, proper amount of protein and other nutrients.ASD behavioral intervention measures are designed to help ASD patients improve their social communication skills, communication skills, behavior and other difficulties. Common intervention methods of ASD behavior include cognitive behavioral therapy, social skills training and so on.
62589479|NCT06348433|NO_INTERVENTION|Ordinary diet group|ASD behavioral intervention measures are designed to help ASD patients improve their social communication skills, communication skills, behavior and other difficulties. Common intervention methods of ASD behavior include cognitive behavioral therapy, social skills training and so on.
62589480|NCT04028869||Glycyrrhizin preparation treatment group|Clinical effect of glycyrrhizic acid preparation for 144 weeks of autoimmune liver disease and safety during treatment
62589481|NCT00574353|EXPERIMENTAL|1|FMISO PET study.
62589482|NCT02350686|EXPERIMENTAL|capecitabine+oxaliplatin|XELOX every 3 weeks
62225844|NCT02869360||Multiple Sclerosis (MS) patients|4 Secondary Progressive MS patients on no disease modifying therapy 4 Primary Progressive MS patients on no disease modifying therapy 4 Relapsing-Remitting MS patients on no disease modifying therapy 4 Relapsing-Remitting MS patients on Glatiramer Acetate 40 mg three times a week
62225845|NCT02869360||Healthy Controls|4 Healthy volunteers aged between 18-60 years of age
62225846|NCT01011426|ACTIVE_COMPARATOR|Bisacodyl|
62225847|NCT01011426|PLACEBO_COMPARATOR|empty opague capsule|
62225848|NCT02088437|ACTIVE_COMPARATOR|Usual care|usual care physiotherapy - once daily treatment whilst inpatient in acute hospital
62418800|NCT02437929||Patients receiving standard procedures|
62418801|NCT06543238|EXPERIMENTAL|Breastfeeding card game|Breastfeeding card game group: Breastfeeding education will be given to 30 primiparous pregnant women in the intervention group using the card game method twice, two weeks apart.
62418802|NCT06543238|NO_INTERVENTION|Control Group|No application will be made to this group by the researcher.
62225849|NCT02088437|EXPERIMENTAL|Intensive physiotherapy|additional once daily physiotherapy and once daily allied health assistant intervention
62225850|NCT00437723|EXPERIMENTAL|1|
62225851|NCT00437723|NO_INTERVENTION|2|
62225852|NCT01095107|OTHER|Control Arm = Decreased Energy Density|Decreased energy density = 35-50 grams of fat per day between meals and snacks
62225853|NCT01095107|OTHER|Treatment Arm = Increased Energy Density|increased increased energy density : Intake \> 50 grams of fat per day between meals and snacks
62418803|NCT00969267|EXPERIMENTAL|Stimulation A|with needle A stimulation
62418804|NCT00969267|ACTIVE_COMPARATOR|Stimulation B|with stimulation
62418805|NCT00969267|SHAM_COMPARATOR|Stimulation C|without needle
62418806|NCT05044832|EXPERIMENTAL|Personalized Music|Those assigned to the music group will receive music in the preoperative holding area as well as in the post-operative care unit in addition to standard care.
62589483|NCT05173168|EXPERIMENTAL|Probiotic Dietary Supplement|resB® Lung Support - 1 capsule 2x daily for 4 weeks
62589484|NCT04429555|EXPERIMENTAL|Active Treatment Group|
62589485|NCT04429555|PLACEBO_COMPARATOR|Placebo Treatment Group|
62225854|NCT02368496|EXPERIMENTAL|Children and young adults on long-term parenteral nutrition|long-term parenteral nutrition : 2 years
62225855|NCT00414713|ACTIVE_COMPARATOR|1|Regular transfusion
62225856|NCT00414713|ACTIVE_COMPARATOR|2|Restricted transfusion
62225857|NCT04302441|EXPERIMENTAL|NXH group|Patients should receive four cycles of NXH regimen (vinorelbine at 25 mg/m2 iv infusion on day 1 and day 8 plus capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle, trastuzumab at 6mg/kg iv infusion on day1 every 3 weeks to 1 year).
62225858|NCT04302441|NO_INTERVENTION|H group|Patients should receive trastuzumab at 6mg/kg iv infusion on day1 every 3 weeks to 1 year.
62225859|NCT01971710|OTHER|Community Leader Engagement|Trained formal and informal community leaders conducting community dialogues and advocacy, and developing community action plans
62418807|NCT05044832|NO_INTERVENTION|Standard of Care|Those assigned to the Standard of Care arm will only receive standard of care in the preoperative holding area as well as in the post-operative care unit
62800608|NCT06206993|EXPERIMENTAL|Resistance training on the Kieser A5 pelvic floor trainer|"Participants will receive a supervised full body resistance exercise program with 10-12 machines twice weekly.~The resistance training for the experimental group includes an intervention program on the Kieser A5 pelvic floor trainer. The training is a predetermined program of the Kieser Training AG. A standardized instruction protocol and custom settings of the seat minimize training or measurement variations. The exercise on the Kieser A5 pelvic floor muscle trainer is standardized and will take 120 s in total which is based on current training theories."
62225860|NCT01971710|OTHER|Community Days|Community gatherings involving participatory dialogue, guided discussion, and the provision of education and selected health services.
62225861|NCT01971710|OTHER|Community Peer Groups|Pregnant women attend 4 weekly peer-led classes in community peer groups. Men attending 4 peer-led education sessions in community peer groups
62225862|NCT01203280|EXPERIMENTAL|balance, neck isometric strength and range of motion|
62225863|NCT02212210|ACTIVE_COMPARATOR|Methylprednisolone|1cc of 80mg methylprednisolone to be diluted with 1cc preservative free normal saline
62225864|NCT02212210|PLACEBO_COMPARATOR|Normal saline|2cc preservative free normal saline
62225865|NCT01835938|EXPERIMENTAL|1- Erlotinib|"Erlotinib is a first class HCV entry inhibitor. In this study, Erlotinib will be administered in escalating doses in sequential patient cohorts for 14 days as follows:~* Dose level (DL) 1 = 50 mg / day,~* Dose level (DL) 2 = 100 mg / day, and~* Dose level (DL) 3 = 150 mg / day .~Each Dose Level (DL) includes 4 patients (3 patients treated with Erlotinib and one patient treated with the Placebo). Dose escalation will proceed to the subsequent DL in the absence of DLT (dose-limiting toxicity) in 2 patients receiving Erlotinib."
62418808|NCT06096181|ACTIVE_COMPARATOR|Propofol + Remifentanil|Participants are randomly selected to receive Propofol + Remifentanil TIVA as their anesthesia. Dose of IV Propofol is 100-200 mcg/kg/min and dose of Remifentanil is 0.2-0.5 mcg/kg/min. TIVA is titrated to keep bispectral index (BIS) \< 55-60 to ensure patient is asleep.
62225866|NCT01835938|PLACEBO_COMPARATOR|placebo|
62225867|NCT00390910|EXPERIMENTAL|Synflorix™ + Infanrix™ hexa Group I|Very preterm infants born after a gestation period of 27-30 weeks (189-216 days)
62225868|NCT00390910|EXPERIMENTAL|Synflorix™ + Infanrix™ hexa Group II|Mild pretem infants born after a gestation period of 31-36 weeks (217-258 days)
62225869|NCT00390910|EXPERIMENTAL|Synflorix™ + Infanrix™ hexa Group III|Infants born after a gestation period of more than 36 weeks (more than 258 days)
62225870|NCT02463565||hospitalized patients|
62225871|NCT00691405|EXPERIMENTAL|A1|Arformoterol 5 mcg BID for 14 days
62225872|NCT00691405|EXPERIMENTAL|A2|Arformoterol 15 mcg BID for 14 days
62225873|NCT00691405|EXPERIMENTAL|A3|Arformoterol 25 mcg BID for 14 days
62225874|NCT00691405|PLACEBO_COMPARATOR|A4|Placebo inhalation solution BID for 14 days
62225875|NCT00691405|EXPERIMENTAL|B1|Arformoterol 15 mcg QD for 14 days
62225876|NCT00691405|EXPERIMENTAL|B2|Arformoterol 25 mcg QD for 14 days
62225877|NCT00691405|EXPERIMENTAL|B3|Arformoterol 50 mcg QD for 14 days
62800609|NCT06206993|ACTIVE_COMPARATOR|Resistance training without pelvic floor biofeedback Kieser A5 pelvic floor trainer|"Participants will receive a supervised full body resistance exercise program with 10-12 machines twice weekly.~Participants in the active comparator group perform the resistance training unit without the pelvic floor biofeedback device A5 and undergo conventional pelvic floor muscle training with a physiotherapist once a week before the resistance training unit starts. Participants are individually informed about the anatomy and function of the pelvic floor muscles and how to correctly contract them. The methodical structure for the movement therapy after prostatectomy suggests that the participants first lay down, then go in the seat, then above the all fours position stand in the upright position tt be treated. Each exercise lasts 3 to 5 min and the session lasts around 20 - 30 min."
62800610|NCT04806074|PLACEBO_COMPARATOR|Single-moment, unspecified delivery of food literacy information|Non-specific food-related national and international guidelines were made digitally available in a website exclusively accessible to all the participants from the comparison group.
62225878|NCT00691405|PLACEBO_COMPARATOR|B4|Placebo inhalation solution QD for 14 days
62225879|NCT02567500|EXPERIMENTAL|Patients with auditory hallucination|"Patients with auditory hallucination:~Evaluation at time 0 and 6 month after of:~* The social cognitive marker (NeuroPsychologic assessment (NEPSY) II) : theory of mind and affect recognition~* The emotional marker:~  * Differential Emotion Scale IV (DES IV): emotional individual stability~ * Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~* Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~* Evaluation of diagnosis with Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV criteria:~  * Mini International Neuropsychiatric Interview (MINI) -Kids~ * Psychosis section of Kiddie-SADS"
62225880|NCT02567500|PLACEBO_COMPARATOR|Patients without auditory hallucination|"Patients without auditory hallucination:~Evaluation at time 0 and 6 month after of:~* The social cognitive marker (NEPSY II) : theory of mind and affect recognition~* The emotional marker:~  * Differential emotion scale IV (DES IV): emotional individual stability~ * Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~* Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~* Evaluation of diagnosis with Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV criteria:~  * Mini International Neuropsychiatric Interview (MINI) -Kids~ * Psychosis section of Kiddie-SADS (Schedule for Affective Disorders and Schizophrenia )"
62225881|NCT03253965|EXPERIMENTAL|Walking: Treadmill then Overground|Walking while receiving auditory cueing intervals from a metronome and music. Testing performed using metronome normal, metronome slow, and metronome fast speed settings as well as music normal, music slow, and music fast tempos. Subjects will also walk with no auditory cueing.
62225882|NCT03253965|EXPERIMENTAL|Walking: Overground, then Treadmill|Walking while receiving auditory cueing intervals from a metronome and music. Testing performed using metronome normal, metronome slow, and metronome fast speed settings as well as music normal, music slow, and music fast tempos. Subjects will also walk with no auditory cueing.
62225883|NCT02288533|EXPERIMENTAL|real-tDCS|Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).
62026972|NCT04418804|EXPERIMENTAL|Pneumothorax|Participants diagnosed with pneumothorax during the past 24 hours.
62026973|NCT04418804|EXPERIMENTAL|Pleural effusion|Participants diagnosed with current pleural effusion during the past 48 hours.
62225884|NCT01223586||Regression|Patients with regression of plaque volume by statin
62225885|NCT01223586||Non regression|Patients without regression of plaque volume by statin
62225886|NCT02742636|EXPERIMENTAL|Group A (treatment group)|The patients in this group will have their catheter directly removed in the OR after LH.
62225887|NCT02742636|ACTIVE_COMPARATOR|Group B (control group)|The patients in the control group will have their catheter removed according to the regular protocol of the hospital (at least 6 hours in place).
62225888|NCT00690118|ACTIVE_COMPARATOR|1|
62225889|NCT00690118|PLACEBO_COMPARATOR|2|
62225890|NCT01270971|EXPERIMENTAL|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%
62225891|NCT01270971|PLACEBO_COMPARATOR|Solution Vehicle|Solution Vehicle
62225892|NCT00515632|EXPERIMENTAL|Balaglitazone 10 mg per day|
62225893|NCT00515632|EXPERIMENTAL|Balaglitazone 20 mg per day|
62225894|NCT00515632|ACTIVE_COMPARATOR|Pioglitazone 45 mg per day|
62225895|NCT00515632|PLACEBO_COMPARATOR|Placebo|
62225896|NCT02925013|EXPERIMENTAL|Study group|Pregnant women at delivery
62225897|NCT02925013|OTHER|Control group|Women in fertility age not pregnant
62026974|NCT05477355|EXPERIMENTAL|Intervention Arm|Participants will be provided the 5 session intervention.
62026975|NCT05477355|ACTIVE_COMPARATOR|Wait list control arm|Participants will not be provided Group PM+ in Phase 1 but will be provided the intervention after all participants in the initial intervention arm receive Group PM+.
62225898|NCT05526066|EXPERIMENTAL|ARCT-810|Participants receive an initial intravenous (IV) infusion ARCT-810. If considered safe and well tolerated, participants will receive up to 5 additional IV infusions of ARCT-810 administered at 14-day intervals.
62800611|NCT04806074|EXPERIMENTAL|Personalised, weekly delivery of food literacy information matched with behaviour strategies|Food-related tips - including theoretical knowledge, practical competencies, and behaviours - from national and international guidelines were specifically matched with Behaviour Change Techniques from the BCT Taxonomy v1. These personalised material were made digitally available in a website exclusively accessible to all the participants from the experimental group. Presenting each week's topic, a small video featuring the lead psychologist was also made available each week.
62800612|NCT01954641|EXPERIMENTAL|ACCURE Navigator|For those patients assigned to the ACCURE Navigator, the ACCURE Real-Time Registry is programmed to automatically alert the Navigator when a patient misses a scheduled treatment appointment and to require the Navigator to include details as to how she addressed and resolved that missed appointment, ensuring the ACCURE Navigator's proactive approach to addressing such issues. In addition, a warning message will be produced if no follow-up appointments or procedures are scheduled within 21 days of the index visit.
62026976|NCT05082090||Implanted with Orthofix Spinal products|Study will include 2000+ subjects implanted with Orthofix Spine devices including spine fixation systems and motion preservation systems (i.e. M6-C artificial cervical disc and M6-L artificial lumbar disc)
62418809|NCT06096181|ACTIVE_COMPARATOR|Propofol + Dexmedetomidine|Participants are randomly selected to receive Propofol + Dexmedetomidine as their anesthesia. Dose of Propofol is 100-200 mcg/kg/min and dose Dexmedetomidine is ) 0.2-0.7 mcg/kg/hr. TIVA is titrated to beep bispectral index (BIS) \< 55-60 to ensure patient is asleep.
62418810|NCT01257737|EXPERIMENTAL|HPN-100|Participants continued HPN-100 treatment after completion of HPN-100-005SE, HPN-100-007, or HPN-100-012SE.
62418811|NCT06099327||Postoperative after cardiac surgery|Patients after cardiac surgery will participate in the trial during their postoperative stay on the cardiothoracic ward.
62418812|NCT05074602|EXPERIMENTAL|SHR8008|
62418813|NCT05074602|ACTIVE_COMPARATOR|Fluconazole|
62589486|NCT05263856|EXPERIMENTAL|Laser acupuncture intervention|In this arm, subjects will receive laser acupuncture (LA) intervention during hospitalization after total knee replacement (TKR) surgery until discharge once a day. LA will stimulate on the 1) bilateral reflection areas of ear associated knee and pain mechanism, including Knee, Sympathetic Autonomic, Zero, Thalamus, Master Cerebral, Master Sensorial points, with 6 points unilaterl and 12 points in total, and 2) myofascial trigger point around knee joint, which may affect function performance and prognosis after TKR, including quadriceps, tensor fascia lata,adductor major,sartorius, hamstrings, gastrocnemius muscles, with 10 points in total.
62589487|NCT04796623|EXPERIMENTAL|TQB3616 capsules combined with fulvestrant injection|TQB3616 capsules 180 mg given orally, once daily in 28-day cycle. Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.
62026977|NCT00692172|EXPERIMENTAL|1|
62589488|NCT01675570|EXPERIMENTAL|RX-10045 active arm|RX-10045 Opththalmic Solution, 0.09%
62589489|NCT01675570|PLACEBO_COMPARATOR|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution
62225899|NCT05526066|PLACEBO_COMPARATOR|Placebo, Normal Saline|Participants receive an initial IV infusion of placebo. If considered safe and well tolerated, participants receive up to 5 additional IV infusions of placebo administered at 14-day intervals.
62026978|NCT06530407|EXPERIMENTAL|Group 1|10 sedentary women
62026979|NCT06530407|EXPERIMENTAL|Group 2|10 sedentary men
62026980|NCT03094572|NO_INTERVENTION|visual motor tasks with dominant arm (1)|experimental arm for the first sub-study healthy volunteer
62026981|NCT03094572|NO_INTERVENTION|control tasks with dominant arm|control arm for the first sub-study healthy volunteer
62418814|NCT03392415|ACTIVE_COMPARATOR|Initial conservative treatment|Optimal medical therapy and option for crossover after 6 months or fulfillment of certain conditions
62418815|NCT03392415|EXPERIMENTAL|initial interventional treatment|CTO PCI attempt as initial strategy with medical optimization simultaneously
62418816|NCT02214004|EXPERIMENTAL|Trastuzumab and Letrozole|- Concurrently initiate two drugs on Day 1 of Cycle 1
62418817|NCT06533891|EXPERIMENTAL|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (\~980 mg DPA, 380 mg EPA, 1720 mg DHA)
62418818|NCT06533891|ACTIVE_COMPARATOR|n-3 control|4 g/d n-3 control (\~980 oleic acid, 380 mg EPA, 1720 mg DHA)
62418819|NCT06533891|PLACEBO_COMPARATOR|Placebo|"4 g/d placebo control (light olive oil)"
62418820|NCT01080209|EXPERIMENTAL|Brimo PS DDS® 400 μg (2 implants)|Patients who received Brimo PS DDS® 400 μg (2 implants) in a previous study.
62418821|NCT01080209|EXPERIMENTAL|Brimo PS DDS® 400 μg (1 implant)|Patients who received Brimo PS DDS® 400 μg (1 implant) in a previous study.
62026982|NCT03094572|NO_INTERVENTION|visual motor tasks with non-dominant arm|control arm for the second sub-study healthy volunteer
62418822|NCT01080209|EXPERIMENTAL|Brimo PS DDS® 200 μg (2 implants)|Patients who received Brimo PS DDS® 200 μg (2 implants) in a previous study.
62418823|NCT01080209|EXPERIMENTAL|Brimo PS DDS® 200 μg (1 implant)|Patients who received Brimo PS DDS® 200 μg (1 implant) in a previous study.
62589490|NCT05463744|EXPERIMENTAL|Insulin Efsitora Alfa|Participants will receive insulin efsitora alfa by subcutaneously (SC)
62225900|NCT01802567|EXPERIMENTAL|Guided Therapy- Pediatric Gene Analysis Platform|A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
62800613|NCT01954641|ACTIVE_COMPARATOR|Usual Care by Cancer Center Care Team|A list of registry warnings about all patients enrolled in the study will be delivered securely to a designated representative at the clinic.
62800614|NCT02780466||Patients with septic shock|
62800615|NCT05159518|EXPERIMENTAL|PRT2527|PRT2527 will be administered by intravenous infusion
62225901|NCT02134977||Leuprorelin Acetate|Subcutaneous administration of leuprorelin acetate 11.25 mg once every 12 weeks
62800616|NCT03392220|EXPERIMENTAL|undergo unilateral (affected side) neck dissection (II-IV)|patient undergo affected side neck dissection, along with the excision of the laryngeal primary tumor
62800617|NCT03392220|EXPERIMENTAL|undergo bilateral neck dissection (II-IV)|patient undergo bilateral neck dissection, along with the excision of the laryngeal primary tumor
62800618|NCT01123616|ACTIVE_COMPARATOR|non-triclosan-coated|Two arms are separeted by computer randomization at abdomial wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
62800619|NCT01123616|ACTIVE_COMPARATOR|triclosan coated suture|Two arms are separeted by computer randomization at abdomial wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
62418824|NCT01080209|EXPERIMENTAL|Brimo PS DDS® 100 μg (1 implant)|Patients who received Brimo PS DDS® 100 μg (1 implant) in a previous study.
62418825|NCT01080209|EXPERIMENTAL|Brimo PS DDS® 50 μg (1 implant)|Patients who received Brimo PS DDS® 50 μg (1 implant) in a previous study.
62418826|NCT01080209|SHAM_COMPARATOR|Sham|Patients who received sham in a previous study.
62418827|NCT05073276|ACTIVE_COMPARATOR|Non-weightbearing for the first six weeks after surgery|Not weightbearing after surgery
62418828|NCT05073276|EXPERIMENTAL|Partial weight -bearing for the first six weeks after surgery|Partial weightbearing will be defined as 40% of the patient's body weight.
62418829|NCT04688814|ACTIVE_COMPARATOR|Morphine Group|Patients will receive GA and analgesia will be based on opioids mainly intravenous morphine. Intravenous morphine in a dose of 0.05 mg/kg will be given as a rescue analgesic when the VAS ≥4 postoperatively for 24 hours
62589491|NCT05463744|ACTIVE_COMPARATOR|Insulin Degludec|Participants will receive insulin degludec SC
62800620|NCT01999296||Patients undergoing laparoscopic surgery|
62026983|NCT03094572|NO_INTERVENTION|visual motor tasks on dominant arm, flexion movement|experimental arm for the third sub-study healthy volunteer
62026984|NCT03094572|NO_INTERVENTION|visual motor tasks on dominant arm, extension movement|experimental arm for the third sub-study healthy volunteer
62418830|NCT04688814|EXPERIMENTAL|SEQ group|Patients will receive ultrasound guided SEQ block preoperatively before the induction of general anaesthesia. Twenty five ml of 0.25 % bupivacaine will be given in the QL plane and 25 ml of the same concentration will be given in the erector spine plane
62800621|NCT02939586|ACTIVE_COMPARATOR|Haemodialysis|regular convectional haemodialysis 3times/weekly
62800622|NCT02939586|ACTIVE_COMPARATOR|Haemodiafiltration|post-dilution haemodiafiltration
62800623|NCT04252131|EXPERIMENTAL|Cassia seed|oral administration of Cassia seed (3.0g), once/day for 12 weeks
62026985|NCT03094572|EXPERIMENTAL|visual motor tasks|fourth sub-study with hemiplegic patient
62418831|NCT04007744|EXPERIMENTAL|Treatment (sonidegib, pembrolizumab)|Patients receive sonidegib PO QD on days 1-8, and pembrolizumab IV over 30 minutes on day 8. Treatment repeats every 21 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62418832|NCT06017856||obese and overweight|Overweight and obese subjects, defined as body mass index (BMI) percentile ≥85%, participating the in life-style intervention program in the child sport center at Meir medical center
62418833|NCT06017856||normal weight|normal weight subjects defined as body mass index (BMI) percentile \<85%, with no other chronic conditions
62418834|NCT03554473|EXPERIMENTAL|Arm A/M7824 Monotherapy|M7824 (IV) monotherapy once every 21 days on a 21-day cycle. If patients have progressive disease on arm A, they may receive combination therapy of M7824 and Temozolomide.
62225902|NCT02050152|PLACEBO_COMPARATOR|0% nitrous oxide|Explicit and implicit memory will be tested in 0% nitrous oxide
62225903|NCT02050152|ACTIVE_COMPARATOR|30% nitrous oxide|Explicit and Implicit memory in 30% nitrous oxide
62800624|NCT04252131|PLACEBO_COMPARATOR|Cassia seed placebo|oral administration of Cassia seed placebo (3.0g), once/day (90% of starch and 10% of cassia obtusifolia) for 12 weeks
62800625|NCT06193642|EXPERIMENTAL|experimental|"Through gait analysis acquisition sessions in the most comprehensive configuration possible on a test group of patients, the aim is to identify measures to be collected at regime for simplified evaluation including patient acceptability.~Patients will be asked to complete quality of life questionnaires."
62800626|NCT02436018|NO_INTERVENTION|Control group|Oxygen(2L/min) supplied with nasal catheter
62800627|NCT02436018|EXPERIMENTAL|Nasopharyngeal airway group|Oxygen(2L/min) supplied directly through WEI NASAL JET without jet ventilator
62225904|NCT02050152|ACTIVE_COMPARATOR|60% nitrous oxide|Explicit and Implicit memory with 60% nitrous oxide
62225905|NCT01242358|EXPERIMENTAL|Capnography|Arm with capnographic monitoring
62418835|NCT03554473|EXPERIMENTAL|Arm B/M7824 plus topotecan|M7824 (IV) on day 1 plus topotecan (IV) on days 1-5 of a 21-day cycle. At least 6 subjects to receive M7824 plus topotecan to determine safety. 4 more patients enrolled at initial or lower dose for efficacy. If efficacious, an additional 12 subjects enrolled.
62225906|NCT01242358|PLACEBO_COMPARATOR|Standard monitoring|Standard monitoring
62418836|NCT03554473|EXPERIMENTAL|Arm C/M7824 plus temozolomide|M7824 (IV) days 1 and 15 plus temozolomide (oral) on days 1-5 of a 28-day cycle. At least 6 subjects with SCLC to receive M7824 plus temozolomide to determine safety. 4 more SCLC patients enrolled at initial or lower dose for efficacy. If efficacious, an additional 12 SCLC subjects enrolled. After the 6 safety SCLC cohort, subjects with extrapulmonary small cell cancers will be enrolled.
62418837|NCT06068842||Participants Undergoing Chart Review|Participants treated for non small cell lung cancer undergoing chart review and retrospective mesenchymal epithelial transition (MET) overexpression (OE) testing of tissue biopsies.
62418838|NCT04296071||Group 1|patients who tend to have longer CPB
62800628|NCT02436018|EXPERIMENTAL|WEI NASAL JET group|Oxygen supplied through WEI NASAL JET with a manual jet ventilator
62225907|NCT00153504|EXPERIMENTAL|Housing and Health Study housing rental assistance|
62225908|NCT00153504|ACTIVE_COMPARATOR|Standard local practice housing assistance|
62800629|NCT03009851|EXPERIMENTAL|OBCHI|This small group process intervention focuses upon the cultural heritage of the residents in LTC settings measuring quality of life, activity engagement and social participation.
62800630|NCT03009851|NO_INTERVENTION|Control|The control group only received the typical activities conducted in LTC facilities.
62800631|NCT02537717|EXPERIMENTAL|Sapphire lens|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye. Both test and control lenses will be used in a daily wear modality for one month.
62800632|NCT02537717|ACTIVE_COMPARATOR|enfilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye. Both test and control lenses will be used in a daily wear modality for one month.
62800633|NCT00669214|EXPERIMENTAL|Efalizumab|
62800634|NCT00669214|PLACEBO_COMPARATOR|Placebo|
62026986|NCT03094572|NO_INTERVENTION|visual motor tasks with dominant arm (2)|experimental arm for the second sub-study healthy volunteer
62026987|NCT03574168|EXPERIMENTAL|CD19-CAR-T Cells|Subjects will receive CD19-CAR-T Cells on Day 0 : 100% of total dose.
62026988|NCT02568787|EXPERIMENTAL|Rice bran arabinoxylan compound (RBAC)|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
62026989|NCT02568787|PLACEBO_COMPARATOR|Placebo|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
62225909|NCT00122460|EXPERIMENTAL|Cetuximab Plus Chemotherapy|
62225910|NCT00122460|ACTIVE_COMPARATOR|Chemotherapy alone|
62225911|NCT01546350|NO_INTERVENTION|Control - regular ART treatment|patients will have up to two embryos replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patients in the control group do not have a pregnancy to term from that fresh cycle, they will be offered free PGD either for the frozen embryos of that cycle or for the next cycle (up to the center and patient). Data from that PGD is not part of the study.
62225912|NCT01546350|EXPERIMENTAL|Test - PGD|patients will have grade A,B or C blastocysts hatched on day 5, biopsied on day 5, analyzed by array CGH, and a single euploid embryo transferred on day 6. Any morulas developing to grade A,B or C blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle.
62225913|NCT00156819|ACTIVE_COMPARATOR|Fluticasone|Participants continued fluticasone (100 microgram twice daily) treatment.
62225914|NCT00156819|EXPERIMENTAL|Montelukast|Participants were changed to Montelukast (5 or 10 mg each night).
62225915|NCT00156819|EXPERIMENTAL|Fluticasone plus salmeterol|Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.
62418839|NCT04296071||Group 2|Patients who have shorter CPB
62418840|NCT03203746|EXPERIMENTAL|Group I: Lycopene + SRP|Lycopene, 0.1 ml injected once in the periodontal pocket after scaling and root planing
62418841|NCT03203746|ACTIVE_COMPARATOR|Group II: SRP only|Scaling and root planing only without lycopene
62418842|NCT03203746|NO_INTERVENTION|Group III: healthy subjects|No intervention
62589492|NCT04599348|EXPERIMENTAL|Active Ginseng treatment|People with CFS or Fibromyalgia will receive HRG 80 Red GInseng
62589493|NCT03609931||Mitral Valve repair|Patients undergoing mitral valve repair
62800635|NCT02195375|EXPERIMENTAL|Flutiform 500/20 µg BID|Flutiform 250/10 (2 puffs BID)
62800636|NCT02195375|EXPERIMENTAL|Flutiform 250/10 µg BID|Flutiform 125/5 (2 puffs BID)
62800637|NCT02195375|ACTIVE_COMPARATOR|Seretide Accuhaler 50/500 µg BID|Seretide Accuhaler 50/500 (BID)
62800638|NCT04603261||eGFR <30 mL/min/1.73m2|Patients with eGFR \<30 mL/min/1.73m2 in absence of dialysis referred for an elective procedure with intravascular administration of iodinated contrast material at Maastricht UMC+.
62800639|NCT04603261||eGFR 30-59 mL/min/1.73m2|For each included patient with eGFR \<30 mL/min/1.73m2, two patients matched for age, sex and contrast procedure type will be included: one with eGFR 30-59 mL/min/1.73m2 and one with eGFR \>=60 mL/min/1.73m2.
62800640|NCT04603261||eGFR >=60 mL/min/1.73m2|For each included patient with eGFR \<30 mL/min/1.73m2, two patients matched for age, sex and contrast procedure type will be included: one with eGFR 30-59 mL/min/1.73m2 and one with eGFR \>=60 mL/min/1.73m2.
62800641|NCT01865760|EXPERIMENTAL|Gastric bypass surgery, hypoglycemia|Subjects with previous gastric bypass surgery (more then 1 year ago) and symptomatic hypoglycemia according to Whipples triade. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal. They will furthermore undergo two additional liquid mixed meal; one with concomitant treatment with synthetic Exendin 9-39 and another with treatment with Octreotide. All tests will be separated by at least one week.
62800642|NCT01865760|ACTIVE_COMPARATOR|Gastric bypass surgery, asymptomatic|Subjects with previous gastric bypass surgery (more then 1 year ago) without any signs of hypoglycemia. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.
62589494|NCT02117921|EXPERIMENTAL|MBS therapy education|
62589495|NCT05853549|EXPERIMENTAL|optical surface monitoring system group|Every radiotherapy fraction from each patients with OSMS technology. Marks were placed on each patient's skin to align the room lasers for presetup, and the setup was completed with information from the OSMS. The deviation values of setup were obtained. The absolute values of setup error and error distribution of the standard laser-based setup and OSMS in the multi-directions were compared.
62589496|NCT01072435|ACTIVE_COMPARATOR|patient-controlled sedation|PCS
62589497|NCT01072435|ACTIVE_COMPARATOR|target-controlled infusion|TCI
62589498|NCT06668272|EXPERIMENTAL|Small Changes program|
62800643|NCT01865760|OTHER|Controls|Healthy non-operated control subjects, matched on BMI, age and sex. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.
62800644|NCT01100320|EXPERIMENTAL|Reformulated OXY 40 mg|Reformulated OXY 40 mg x 1 dose
62589499|NCT06668272|ACTIVE_COMPARATOR|Standard behavioral therapy for weight loss|
62589500|NCT00533702|EXPERIMENTAL|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab)
62589501|NCT00533702|ACTIVE_COMPARATOR|IMC-1121B (ramucirumab) + dacarbazine|IMC-1121B (ramucirumab) + dacarbazine
62800645|NCT01100320|ACTIVE_COMPARATOR|Original OxyContin® (OXY) 40 mg|Original OxyContin® (OXY) 40 mg x 1 dose
62800646|NCT03938896|OTHER|platelet rich plasma|It started with puncture of the vein and taking specific amount of autologous blood from the participantnearly a sample of 20 ml of venous blood (Co AY, 2012).The blood sample was put in a sterile tube containing an anticoagulant as sodium citrate.Then the blood sample wascentrifuged for 15 minutes at 1800 rpmwhich leads to separation of the plasma at the top layer from the packed RBCs at the bottom layer. The RBCs layer is removedthenanother centrifugationwas done at 3500 rpm for 10 minuteswhich leads to formation of a more concentratedplatelet layer after removal of PPP(Anitua et al., 2012).Patients were put in supine position. Betadine was used to disinfect the skin of the heel. 1 ml of local anesthesitic (lidocaine) was injected;then, by the same syringe, 2.5 ml of PRP was injected in the tenderestarea.After extraction of the needle, a bandage was puton the injected area.
62800647|NCT03938896|OTHER|corticosteroid|Patients were put in the supine position. Injection was done usingthe medial technique. Identification of the tenderest point of the heel was done by palpation. Antiseptic solution was used to disinfect the skin overlying theheel. Then1ml of 40 mg methylprednisolone acetate and 1 ml of local anaesthetic as lidocaine 2% were injected into the plantar fascia by a 22gauge needle.
62800648|NCT04362995||SARS-CoV-2 Infection|St. Jude Children's Research Hospital employees with SARS-CoV-2 infection
62800649|NCT04362995||Controls|St. Jude Children's Research Hospital employees uninfected with SARS-CoV-2 infection
62800650|NCT04362995||Long Term Follow Up (LTFU)|Subset of participants who participated in the original SJTRC study and agree to continue in LTFU
62800651|NCT03579706|EXPERIMENTAL|Intervention|The intervention condition will involve participants completing baseline measures, the Cognitive Anxiety Sensitivity Treatment, post measures, and a 4 month follow up assessment.
62800652|NCT03579706|PLACEBO_COMPARATOR|Control|The control condition will involve participants completing baseline measures, the Physical Health Education Training, post measures, and a 4 month follow up assessment.
62800653|NCT02817126|EXPERIMENTAL|Robot-assisted surgery|Patients undergo robot-assisted resections.
62800654|NCT02817126|ACTIVE_COMPARATOR|Laparoscopic surgery|Patients undergo laparoscopic resections.
62800655|NCT01216683|EXPERIMENTAL|Arm A then Arm D (Induction with Bendamustine + Rituximab; Continuation with Rituximab)|"Arm A (induction): Patients receive rituximab intravenously (IV) on day 1 and bendamustine hydrochloride IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Arm D (continuation): Beginning 4 weeks after the completion of induction therapy, patients who have stable disease or better at time of post-induction restaging receive rituximab IV on day 1. Treatment repeats every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
62800656|NCT01216683|EXPERIMENTAL|Arm B then Arm E (Induction with Bendamustine + Rituximab + Bortezomib; Continuation with Rituximab)|"Arm B (induction): Patients receive rituximab IV on day 1; bortezomib IV on days 1, 4, 8, and 11; and bendamustine hydrochloride IV over 1 hour on days 1 and 4. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Arm E (continuation): Beginning 4 weeks after the completion of induction therapy, patients who have stable disease or better at time of post-induction restaging receive rituximab as in arm D."
62026990|NCT06357728|EXPERIMENTAL|Continuous glucose monitoring arm|Continuous glucose monitoring sensor: All study participants wear the sensor on the back of either right or left upper arm for up to 10 days. Glucose levels will be recorded from the interstitial fluid every 5 minutes using intermittent/ flash glucose scanning. Data will be captured using a receiver.
62026991|NCT01434758||Children|Children age 0-15 years presenting to NHP thought to have TB infection
62225916|NCT02426346|ACTIVE_COMPARATOR|JOIN FOR ME|The JOIN for ME curriculum includes 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Weekly meetings are scheduled for 60 minutes and are facilitated by a YMCA coach. Interventions include behavioral weight control and parent-based incentives. Parents attend group at weeks 1, 2 and 16 with their teen.
62225917|NCT02426346|EXPERIMENTAL|TEEN JOIN|Similar to the JOIN FOR ME condition, adolescents in the TEEN JOIN condition attend 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Interventions include behavioral weight control, group-based physical activity, and group-based incentives. Parents attend separate meetings at weeks 1, 2, and 16.
62225918|NCT05134077|EXPERIMENTAL|kidneys with simple cysts|Patients involve from Citi Clinical Hospital with simple renal accidentally discovered cyst.
62225919|NCT05134077|ACTIVE_COMPARATOR|contralateral kidneys without cyst|Рatients involve from Citi Clinical Hospital with simple renal accidentally discovered cyst.
62225920|NCT04330703||Cases|Children and adolescents referred for their first visit to the outpatient clinic at the Child and Adolescent Psychiatry Department (BUGL) (n=15) will be invited to participate.
62589502|NCT03470155||functional mitral insufficiency op|Patients with functional mitral insufficiency with restricted leaflet movement during systole (type IIIb Carpentier) undergoing operative reconstruction (mitral valve repair)
62225921|NCT04330703||Contol|Age and sex-matched child from the same postal area (n=15).
62225922|NCT04330703||Syblings|Same parent siblings close in age to the study subjects (cases only) (+3y) (n=x)
62225923|NCT04600193|EXPERIMENTAL|Phosphate modified diet with organic phosphate|
62225924|NCT04600193|EXPERIMENTAL|Phosphate modified diet with inorganic phosphate|
62589503|NCT02209142|EXPERIMENTAL|pan-genomic screen|A pan-genomic screen by blood prelevement and psychometric data collection will be set-up on a subset of MDE and control samples to identify mRNA candidates for a transcriptional signature of MDE,
62589504|NCT02209142|SHAM_COMPARATOR|control|a pan genomic screening by blood prelevement and psychometric data collection wil be performed on healthy subject
62026992|NCT02997358|ACTIVE_COMPARATOR|Doxorubicin|6 cycles - 1 cycle every 3 weeks (day 1 to day 21) On day 1: Doxorubicin 75 mg/m² IV
62225925|NCT06241768|EXPERIMENTAL|Text message 1|Version 1 of the text message invitation to use the cloud-based colorectal cancer screening program
62225926|NCT06241768|EXPERIMENTAL|Text message 2|Version 2 of the text message invitation to use the cloud-based colorectal cancer screening program
62225927|NCT06241768|EXPERIMENTAL|Text message 3|Version 3 of the text message invitation to use the cloud-based colorectal cancer screening program
62225928|NCT06241768|EXPERIMENTAL|Text message 4|Version 4 of the text message invitation to use the cloud-based colorectal cancer screening program
62225929|NCT05384444|EXPERIMENTAL|Fasting mimicking diet|The cyclic FMD diet consists of a 5 day regimen: day 1 diet of the diet supplies \~1000 kcal (10% protein, 56% fat, 34% carbohydrate), day 2-5 are identical in formulation and provide 800 kcal (9% protein, 44% fat, 47% carbohydrate). At least 4 cyclic FMDs will be performed after operation.
62589505|NCT01760486|ACTIVE_COMPARATOR|Shape Up Rhode Island|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive periodic newsletters throughout the 12 month trial.
62026993|NCT02997358|EXPERIMENTAL|doxorubicin + trabectedin followed by maintenance trabectedin|"1. Doxorubicin + trabectedin 6 cycles - 1 cycle every 3 weeks (day 1 to day 21) Doxorubicin 60 mg/m² IV D1, then Trabectedin 1.1 mg/m² per CIV 3 hours D1. Surgery for residual disease is possible after 6 cycles (in case of non evolutive disease)~2. In case of response or stable disease after 6 cycles 3-weeks cycle until disease progression or for a maximum of 12 months of treatment (maximum 17 cycles in maintenance therapy), whichever occurs first Trabectedin 1.1 mg/m² per CIV 3 hours"
62026994|NCT03177304|EXPERIMENTAL|Web based IPT Training|All subjects (trainees) received the web based training, consisting of an on-line tutorial, remote live training via videoconferencing, and access to a post-training web portal
62026995|NCT06152536|EXPERIMENTAL|Meal 2|Meal with a vegetarian protein
62589506|NCT01760486|EXPERIMENTAL|Shape Up Rhode Island + Professional Coach + Incentives|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive a professional weight loss coach and will be incentivized for submitting information to their coach and meeting weight goals.
62026996|NCT06152536|ACTIVE_COMPARATOR|Meal 1|Meal with animal protein
62589507|NCT01760486|EXPERIMENTAL|Shape Up Rhode Island + Peer Coach + Incentives|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive a peer coach and will be incentivized for reporting to their coach and meeting weight goals.
62225930|NCT05384444|NO_INTERVENTION|regular diet|regular diet
62225931|NCT00723021|EXPERIMENTAL|PF-04191834 30mg|
62589508|NCT02833844|EXPERIMENTAL|Double-Blind Placebo SC QM/Open-Label Evolocumab 420 mg SC QM|Double-blind placebo subcutaneous (SC) injection every 4 weeks (QM) for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.
62589509|NCT02833844|PLACEBO_COMPARATOR|Double-Blind Evolocumab 420 mg SC QM/Open-Label Evolocumab 420 mg SC QM|Double-blind evolocumab SC injection QM for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.
62589510|NCT04441320|EXPERIMENTAL|CMUS group|Coated metal ureteral stent is indwelled.
62589511|NCT04441320|OTHER|DJS group|Double-J stent is indwelled
62589512|NCT01219764|ACTIVE_COMPARATOR|Full Dose|Full dose of Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.
62589513|NCT01219764|EXPERIMENTAL|Half dose|Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days.
62589514|NCT01290978|ACTIVE_COMPARATOR|ChloraPrep|Applied ChloraPrep on the application site per manufacturer's instruction
62589515|NCT01290978|ACTIVE_COMPARATOR|DuraPrep|Apply DuraPrep to the application site per manufacturer's instruction
62800657|NCT01216683|EXPERIMENTAL|Arm C then Arm F (Induction with Bendamustine+Rituximab; Continuation with Lenalidomide + Rituximab)|"Arm C (induction): Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Arm F (continuation): Immediately after completing induction therapy, patients who have stable disease or better at time of post-induction restaging receive oral lenalidomide on days 1-21. Treatment repeats every 4 weeks for 13 courses in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of induction therapy, these patients receive rituximab IV on day 1. Treatment repeats every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
62800658|NCT02493036|EXPERIMENTAL|High Dose SYN-010|42-mg SYN-010
62800659|NCT01560286|EXPERIMENTAL|Group 1|4-8 week induction of rAvPAL-PEG at 2.5 mg, followed by titration to maintenance dose
62800660|NCT02739399|OTHER|Patient receiving phenylephrine 2ug/kg|phenylephrine 2ug/kg in case of hypotension
62800661|NCT03032263|ACTIVE_COMPARATOR|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
62800662|NCT03032263|EXPERIMENTAL|Video Laryngoscopy|These patients will undergo Video Laryngoscopy for nasal intubation. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
62800663|NCT03149172|EXPERIMENTAL|Equimatrix®|Equimatrix® + Mucograft or alternatives
62800664|NCT03149172|EXPERIMENTAL|Bio-Oss®|Bio-Oss® + Mucograft or alternatives
62800665|NCT03149172|EXPERIMENTAL|Endobon®|Endobon® + Mucograft or alternatives
62800666|NCT02867735|EXPERIMENTAL|LKA651|
62800667|NCT02867735|SHAM_COMPARATOR|Sham Comparator|
62800668|NCT05332847|ACTIVE_COMPARATOR|intervention group|The intervention group underwent clinical evaluation and a bedside-focused sonographic assessment
62800669|NCT05332847|NO_INTERVENTION|control group.|The control group underwent clinical evaluation without POC-US
62800670|NCT05242393||Retrospective cohort|Patients with acute ischemic stroke admitted to the Stroke Unit of one participating center in 2018-2022. The data collected within clinical routine will be analyzed including stroke characteristics at baseline and at discharge (10-14 days after admission), neuroimaging data, sleep characteristics (routine polygraphy study), heart rate variability, routine blood tests.
62800671|NCT05242393||Prospective cohort|Approximately 200-250 patients with acute ischemic stroke admitted to the Stroke Unit of one participating center in 2022-2024 will undergo the assessment of medical records, stroke characteristics, the assessment of sleep characteristics and blood sampling for the evaluation of genetic biomarkers of circadian rhythms at baseline (within 2-3 days of admission) and at 10-14 days (at discharge).
62800672|NCT01799226|ACTIVE_COMPARATOR|Toothpaste without Triclosan|This arm will use a toothpaste that does not contain triclosan
62225932|NCT00723021|EXPERIMENTAL|PF-04191834 100mg|
62225933|NCT00723021|EXPERIMENTAL|PF-04191834 2000mg|
62225934|NCT00723021|ACTIVE_COMPARATOR|zileuton|
62026997|NCT03985423|EXPERIMENTAL|Emapalumab|Patients were administered Emapalumab-Lzsg by intravenous (i.v.) infusion over a period of 1 to 2 hours, at an initial dose of 6 mg/kg and continued at 3 mg/kg, every 3 days for the first 2 weeks (Study Day \[SD\] 15), and then twice-a-week. If the treating physician deemed appropriate, the dose of emapalumab could be increased (up to 10 mg/kg), guided by clinical and laboratory response.
62225935|NCT00723021|PLACEBO_COMPARATOR|placebo|
62225936|NCT01730781||Schizophrenia|Patients diagnosed with schizophrenia both on medication and off medication
62225937|NCT01730781||Cannabis dependence|Frequent users of cannabis
62225938|NCT01730781||Family history of alcoholism|Healthy volunteers with a first degree relative with alcoholism
62225939|NCT01730781||Prodrome for psychotic illness|Not meeting full criteria for psychotic illness but exhibiting prodromal symptoms
62800673|NCT01799226|EXPERIMENTAL|Triclosan|This arm will use colgate total which contains triclosan
62800674|NCT02472574|EXPERIMENTAL|0.3 mg|Subjects randomized to the 0.3 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle, followed by up to 4 doses of 0.3 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
62225940|NCT01730781||Healthy Volunteers|Healthy volunteers with no current or past major medical or psychiatric history
62800675|NCT02472574|EXPERIMENTAL|0.5 mg|Subjects randomized to the 0.5 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle,followed by up to 4 doses of 0.5 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
62800676|NCT02472574|EXPERIMENTAL|1.0 mg|Subjects randomized to the 1.0 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle,followed by up to 4 doses of 1.0 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
62800677|NCT02311114||Telehomecare patients|Observational fieldwork, in depth interviews and surveys up to 4 times will be conducted.
62800678|NCT02311114||Health care providers|In-Depth interviews, observational fieldwork and one time survey will be conducted.
62418843|NCT04968743|EXPERIMENTAL|Participants With Unilateral Stroke|"Participants with self-reported unilateral stroke will take part in two experimental sessions:~First, for assessment of stroke characteristics and MRI scan, and second, the main transcranial magnetic stimulation experiment. During the first experimental session, the unilateral stroke will be confirmed. In participants with stroke, TMS will be applied over the motor cortex on the affected and non-affected hemisphere at the intensity of up to 120% resting motor threshold."
62418844|NCT04968743|EXPERIMENTAL|Participants Without Unilateral Stroke|"Participants without self-reported unilateral stroke will take part in two experimental sessions:~First, for assessment of stroke characteristics, and second, the main transcranial magnetic stimulation experiment. During the first experimental session, the lack of unilateral stroke will be confirmed. In participants without stroke, TMS will be applied targeting at the intensity of up to 120% resting motor threshold both left and right hemisphere."
62418845|NCT05128487|EXPERIMENTAL|NDI-101150 (Monotherapy)|Patients in escalation and expansion, will receive NDI-101150 capsules orally once daily continuously in 4-week cycles (28 days).
62418846|NCT05128487|EXPERIMENTAL|NDI-101150-Pembrolizumab (Combination therapy)|Patients in escalation and expansion phase, will receive NDI-101150 capsules orally once daily continuously in 3-week cycles (21 days), along with pembrolizumab via intravenous (IV) infusion at a dose of 200 mg every 3 weeks.
62418847|NCT02748616|EXPERIMENTAL|Ursodiol|Subjects will begin to take 300 mg Ursodiol following Visit #1 and continue for a total of 8 (eight) weeks.
62418848|NCT06343142|PLACEBO_COMPARATOR|Lunch nut-free meal|Participants will receive an isocaloric meal without nuts at lunchtime.
62418849|NCT06343142|EXPERIMENTAL|Lunch nut meal|Participants will receive an isocaloric meal with nuts at lunchtime.
62418850|NCT06343142|PLACEBO_COMPARATOR|Dinner nut-free meal|Participants will receive an isocaloric meal without nuts at dinner.
62418851|NCT06343142|EXPERIMENTAL|Dinner nut meal|Participants will receive an isocaloric meal with nuts at dinner.
62800679|NCT02311114||Telehomecare administrators|In depth interviews will be conducted
62800680|NCT02311114||Telehomecare technicians|In-depth interviews, observational fieldwork will be conducted.
62800681|NCT04055779||Induced hypotension and arterial occlusion pressure|The patients will receive induced hypotensive anesthesia and the tourniquet pressure will be based on the the tourniquet pressure will be determined based on the AOP which will be determined by the estimation formula (AOP=\[SBP+10\]/KTP) . The calculation is based on using initial SBP and tissue padding coefficient values , according to limb circumferences of the patient.After calculation of AOP, tourniquet pressures will be determined by adding a safety margin of 20 mmHg to AOP values(tourniquet pressure=AOP+20 mmHg).
62800682|NCT04055779||induced hypotension and limb occlusion pressure|the patients will receive induced hypotensive anesthesia and the tourniquet pressure will be based on the LOP.using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP .the tourniquet cuff will be inflated to the pressure according to theguidelines of the Association of Perioperative Registered Nurses(AORN) which recommends that a safety margin of 40 mmHg should be added for AOP below 130 mmHg, 60 mmHg for AOP between 131 mmHg and 190 mmHg, and 80 mmHg for AOP above 190 mmHg for adult patients
62225941|NCT01730781||PTSD-Post Traumatic Stress Disorder|Patients diagnosed with Post Traumatic Stress Disorder
62225942|NCT01730781||Opioid Use Disorder|Patients diagnosed with Opioid Use Disorder
62418852|NCT06516510|OTHER|Sequence A|Patients in Sequence A will receive lutetium (177Lu) rhPSMA 10.1 followed by lutetium (177Lu) vipivotide tetraxetan
62418853|NCT06516510|OTHER|Sequence B|Patients in Sequence B will receive lutetium (177Lu) vipivotide tetraxetan followed by lutetium (177Lu) rhPSMA 10.1
62418854|NCT02076113|ACTIVE_COMPARATOR|Ventral|Ventral Decompression with Fusion
62418855|NCT02076113|ACTIVE_COMPARATOR|Dorsal|Dorsal Decompression with Fusion or Dorsal Laminoplasty
62800683|NCT00703924|EXPERIMENTAL|WR 279,396|WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin
62800684|NCT00703924|PLACEBO_COMPARATOR|Placebo|Topical cream vehicle containing all of the components in WR 279,396 except the active ingredients.
62418856|NCT06553131||Surgical Patients Receiving Non-Depolarizing Neuromuscular Blockade|Surgical patients having surgery that requires muscle relaxation with non-depolarizing neuromuscular blockers and monitoring of the depth of muscle blockade.The muscle response to nerve stimulation will be compared between the ulnar and median nerve.
62418857|NCT03821142|EXPERIMENTAL|Calistar S|Single arm cohort trial
62589516|NCT06648200|ACTIVE_COMPARATOR|Therapy With Toripalimab Combined With Platinum-based Doublet Chemotherapy|In this arm, 50 patients with extensive-stage small cell lung cancer or relapsed within more than 6 months after SCLC radical treatment will receive 4 circles of toripalimab combined with platinum-based doublet chemotherapy. Then patients received maintenance treatment with toripalimab until the disease progressed.
62589517|NCT06648200|EXPERIMENTAL|Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy|In this arm, 50 patients with extensive-stage small cell lung cancer or relapsed within more than 6 months after SCLC radical treatment will receive 4 circles of toripalimab and JS004 combined with platinum-based doublet chemotherapy. Then patients received maintenance treatment with toripalimab and JS004 until the disease progressed.
62589518|NCT05467904|ACTIVE_COMPARATOR|Xltranplus|Xltanplus is a full hemp flower formulation with cannabinoids and terpenes
62589519|NCT05467904|ACTIVE_COMPARATOR|Xltran|Xltran contains terpenes extracted from the hemp flower
62589520|NCT05467904|PLACEBO_COMPARATOR|Placebo|Placebo will be an inactive formulation of water, sunflower lecithin and polysorbate
62026998|NCT05360979|EXPERIMENTAL|Neoadjuvant and adjuvant therapy|After signing the informed consent, eligible subjects who meet the inclusion criteria will receive neoadjuvant therapy comprising envafolimab combined with platinum-containing chemotherapy and recombinant human endostatin, as well as postoperative envafolimab single-agent adjuvant therapy.
62026999|NCT03859323|EXPERIMENTAL|Single Ascending Dose (SAD): 0.2 mg/kg|Participants will receive single subcutaneous (SC) injection of 0.2 mg/kg SHP681 in the abdomen.
62225943|NCT03995667|EXPERIMENTAL|Prevention (TTFields therapy, questionnaire)|Patients undergo TTFields therapy over 18-24 hours daily. Cycles repeat every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
62225944|NCT06486038|EXPERIMENTAL|Multidisciplinary and innovative approach|"MRI examination using experimental sequences on 3 Tesla scanner. Neuromotor assessment by an ad-hoc evaluation of the neuromotor skills that includes upper and lower limb assessment.~Neurophysiological Assessment: Motor evoked potential (MEP) and Somatosensory evoked potential (SEP) evaluations.~Neurological and clinical data (including mJOA and Barthel Index) Surgery (if applicable) using a cage in Polyetheretherketone (PEEK) or modern carbon fiber material."
62225945|NCT03272581|NO_INTERVENTION|Control Group|Control group followed routine basketball training and traditional strength training.
62225946|NCT03272581|EXPERIMENTAL|Training Group|Functional exercises were applied to training group for 20 weeks (2 days/week) with routine basketball training.
62225947|NCT00550875|EXPERIMENTAL|1|
62418858|NCT06096870|EXPERIMENTAL|Arm 1|Enzalutamide
62225948|NCT00550875|EXPERIMENTAL|2|10\* concentration of arm 1
62225949|NCT00550875|PLACEBO_COMPARATOR|3|
62225950|NCT02963610|EXPERIMENTAL|Pembrolizumab, Lenalidomide|"Phase I The treatment will be given on a 21-day cycle, with a dose of pembrolizumab given on day1(IV) and doses of lenalidomide given on day 1-14 (orally). The dose of pembrolizumab will be fixed at 200 mg. The dose of lenalidomide will depend upon the patient cohort. Cohort 1 will receive 10mg, Cohort II will receive 15mg and cohort 3 will receive 20mg of lenalidomide.~Phase II The treatment will be given on a 21-day cycle, with a dose of pembrolizumab given on day1(IV) and doses of lenalidomide given on day 1-14 (orally). The dose of pembrolizumab will be fixed at 200 mg. Maximum Tolerated Dose (MTD) of lenalidomide as determined by the Phase I study will be given in Phase II study."
62418859|NCT06096870|EXPERIMENTAL|Arm 2|Enzalutamide+M9241
62418860|NCT03599843|EXPERIMENTAL|ACCESS|Individuals that consent to the study will be assigned to a 12-week exercise program (ACCESS)
62418861|NCT02670980|EXPERIMENTAL|Retina Implant|Intelligent Retinal Implant System
62418862|NCT04542902|EXPERIMENTAL|Allergic asthma patients|Allergic asthma patients and sensitization to house dust mites (D. pteronyssinus) allergen.
62418863|NCT04542902|EXPERIMENTAL|Severe eosinophilic asthma patients|
62589521|NCT00270153|PLACEBO_COMPARATOR|enalapril|
62418864|NCT04542902|ACTIVE_COMPARATOR|Healthy subjects as a control group|Healthy subjects without allergic and other chronic respiratory diseases (control group).
62418865|NCT05736432|EXPERIMENTAL|Blueberries-Phase I|feeding will consist of 1 C frozen wild blueberries along with ¾ C low-fat Mountain High yogurt (total energy intake=170 kcal)
62418866|NCT05736432|PLACEBO_COMPARATOR|Syrup-Phase I|feeding will consist of an isocaloric feeding of ¾ C yogurt mixed with artificially flavored and colored blueberry syrup (Torani)
62418867|NCT05736432|EXPERIMENTAL|Blueberries-Phase II|1 C frozen wild blueberries along with ¾ C low-fat Mountain High yogurt (total energy intake=170 kcal) along with a) dietary intervention, b) daily text messaging, and c) daily at-home weighing with a WiFi-enabled scale
62589522|NCT00270153|PLACEBO_COMPARATOR|Placebo|
62589523|NCT01334671|EXPERIMENTAL|group 1, Atorvastatin|STEMI patients will be randomly divided into three groups Group 1 which has been give 80mg atorvastatin before PCI will be administered with atorvastatin 40mg per day for one month,then 20mg per day until the end of the trial
62589524|NCT01334671|EXPERIMENTAL|group 2 , Atorvastatin|Group 2 will be administered with atorvastatin 40mg per day for one month,then 20mg per day until the end of the trial
62589525|NCT01334671|EXPERIMENTAL|group 3 , Atorvastatin|Group 3 will be administered with atorvastatin 20mg per day until the end of the trial
62589526|NCT03099213|EXPERIMENTAL|Ramipril|Receiving ramipril with the recommended initial dose of 2.5 mg once daily; depending on the tolerability, the dose should be gradually increased. The increase should be implemented by doubling the dose after one to two weeks. Three or four weeks later, the dose should be doubled again up to the usual maintenance dose of 10 mg once daily.
62589527|NCT02906631||patients admitted to the ICU for AE|Adult patients with all-cause encephalitis admitted to an intensive care unit.
62589528|NCT02738879|EXPERIMENTAL|Sitagliptin|Sitagliptin 100 mg, oral, once daily for 30 weeks
62589529|NCT02738879|PLACEBO_COMPARATOR|Placebo|Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
62589530|NCT03814720|EXPERIMENTAL|Group 1: H1ssF_3928 (20 mcg), ages 18-40 years|H1ssF_3928 (20 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0)
62418868|NCT05736432|PLACEBO_COMPARATOR|Syrup-Phase II|isocaloric feeding of ¾ C yogurt mixed with artificially flavored and colored blueberry syrup (Torani) along with a) dietary intervention, b) daily text messaging, and c) daily at-home weighing with a WiFi-enabled scale
62418869|NCT03644459|EXPERIMENTAL|LYN00101|Intravenous Infusion at the rate of 8 mg/kg of the patient's weight every 14 days.
62589531|NCT03814720|EXPERIMENTAL|Group 2A: H1ssF_3928 (60 mcg), ages 18-40 years|H1ssF_3928 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
62589532|NCT03814720|EXPERIMENTAL|Group 2B: H1ssF_3928 (60 mcg), ages 41-49 years|H1ssF_3928 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
62589533|NCT03814720|EXPERIMENTAL|Group 2C: H1ssF_3928 (60 mcg), ages 50-59 years|H1ssF_3928 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
62589534|NCT03814720|EXPERIMENTAL|Group 2D: H1ssF_3928 (60 mcg), ages 60-70 years|H1ssF_3928 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
62589535|NCT06022276|EXPERIMENTAL|Monotherapy or combination therapy based on Nimotuzumab|Nitozumab injection 400mg/cycle, every 21 days/cycle, until disease progression, intolerable toxicity or death, or subject decision to withdraw from the study.The molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Nitozumab+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
62589536|NCT01607060|EXPERIMENTAL|Lactulone|Patients receiving lactulone
62589537|NCT01607060|ACTIVE_COMPARATOR|Control|Observational group. Compare to lactulone group.
62589538|NCT02035033||low calcium supplement|low calcium supplement
62589539|NCT02035033||Calcium intake 500-1000 mg per day|Calcium intake 500-1000 mg per day
62800685|NCT02722226|EXPERIMENTAL|Simulation based sedation learning (Intervention Group)|The program includes online learning. It is followed by development of interactive presentations, based on simulated cases or simulated patients (actors), low fidelity simulation for specific technical skills as well as high fidelity scenarios of complications related to sedation.
62800686|NCT02722226|NO_INTERVENTION|Control Group|
62418870|NCT03910010|EXPERIMENTAL|Experimental: placebos|Fibromyalgia participants will enter in an optional placebo trial. This phase of the study will test the clinical usefulness of the biomarkers. We will measure how expectation of starting a new treatment reduces 'clinical back pain' in each participant. Positive treatment expectations will be induced by giving them capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules four times a day and report their pain on paper forms organized as a calendar or on REDCap.
62589540|NCT02035033||Calcium intake above 1000 mg per day|Calcium intake above 1000 mg per day
62589541|NCT03088163|EXPERIMENTAL|DWI-MRI|
62589542|NCT04951570||Hematoma Expansion (HE) group|
62589543|NCT04951570||non-HE group|
62800687|NCT00681889|EXPERIMENTAL|Treatment Arm|10 Patients will receive treatment (Ranibizumab)
62800688|NCT03771651|EXPERIMENTAL|Aspirin|Subjects will take 81mg tablets of aspirin daily for 14 days prior to surgery for removal of fallopian tubes.
62800689|NCT03647826|EXPERIMENTAL|Mind Power Intervention Group 1|"Entire school classes will be randomly divided into two interventions (Mind Power Intervention Group 1 or Mind Power Intervention Group 2). The content in the two interventions are exactly the same, except the time when they are conducted.~The first arm is the Mind Power Intervention Group 1. This intervention is the first and starts in September 2018 and last for 10 weeks."
62027000|NCT03859323|EXPERIMENTAL|Single Ascending Dose (SAD): 0.5 mg/kg|Participants will receive single SC injection of 0.5 mg/kg SHP681 in the abdomen.
62418871|NCT03910010|NO_INTERVENTION|Waitlist|Fibromyalgia participants will not be given any placebo and will be requested to report their pain on paper forms organized as a calendar or on REDCap.
62589544|NCT03812770|EXPERIMENTAL|Sorafenib plus HAIC of OXA|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin
62589545|NCT03812770|ACTIVE_COMPARATOR|Sorafenib plus HAIC of FOLFOX|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin, Fluorouracil and Leucovorin
62589546|NCT06619496|ACTIVE_COMPARATOR|Human-led fall prevention programs|Participants will complete any human-led fall prevention program of their choice, in a group setting either in-person or via Zoom.
62589547|NCT06619496|EXPERIMENTAL|Avatar-led fall prevention program|Participants will complete an avatar-led fall prevention program at their local community center or community room of their housing complex
62589548|NCT02666196|EXPERIMENTAL|DAA-I 6mg|Subjects given solid compound in vials containing 6mg per vial
62589549|NCT02666196|EXPERIMENTAL|DAA-I 50mg|Subjects given solid compound in vials containing 50mg per vial
62589550|NCT02666196|EXPERIMENTAL|DAA-I 110mg|Subjects given solid compound in vials containing 110mg per vial
62800690|NCT03647826|EXPERIMENTAL|Mind Power Intervention Group 2|"The second arm is the Mind Power Intervention Group 2. This arm starts the intervention in January 2019 (six months later than Group 1). Group 2 function as a Control Group.~The Experiment containes arm 1 and arm 2; With an delayed intervention design."
62800691|NCT00746278|EXPERIMENTAL|1|Laparoscopic ovarian cystectomy using bipolar
62800692|NCT00746278|EXPERIMENTAL|2|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
62800693|NCT00746278|ACTIVE_COMPARATOR|3|Laparoscopic ovarian cystectomy using suture
62589551|NCT02666196|PLACEBO_COMPARATOR|Placebo|Subjects given 25ml placebo dissolved in 200ml water
62589552|NCT06661681|EXPERIMENTAL|Cognitive Functional Therapy|Cognitive Functional Therapy (CFT) will be conducted weekly in sessions lasting approximately 60 minutes over 8 weeks.
62589553|NCT06661681|ACTIVE_COMPARATOR|Therapeutic exercises group|Individuals assigned to this group will be treated twice a week for eight weeks, wich each session will last approximately 40 to 60 minutes.
62800694|NCT03292380||Caffeine intake recall|All subjects completed 24-hour urine collection, and subsequently completed the 24-hour Caffeine Intake Recall (CIR-24) developed by the research group and the Caffeinated Beverage Frequency Questionnaire (CBQ) developed by the Fred Hutchison Cancer Centre. The order of completing the CIR-24 and the CBQ was alternated each day of data collection.
62800695|NCT01236521|EXPERIMENTAL|Arm 1: Pharmacological (MED)|Subjects in the Pharmacological (MED) arm will receive at least 8 contacts with the nurse care managers (NCM) over the trial period. Participants will have an initial visit at baseline to assess their current and past treatments for chronic lower back pain, pain intensity, and pain-related limitations. Patients' opioids will be adjusted and/or co-analgesics (or adjuvants) will be initiated. During follow-up calls, patients' pain severity, response to treatment, adherence, adverse effects, and desire to change current treatment will be assessed. Follow-up NCM telephone contacts will occur at 2 and 4 weeks after baseline, and months 2, 3, 4, 6, and 9 months. On average, these calls last between 10 to 20 minutes. Detailed logs will be kept of the timing and content of patient contacts.
62800696|NCT01236521|EXPERIMENTAL|Arm 2: Behavioral treatment (CBT)|Veterans randomized to behavioral treatment arm (CBT) will receive a series of 8 pain self-management/coping skills training sessions delivered by one of three primary-care based clinical psychologists. Since optimal application of non-pharmacological interventions for pain involves tailoring to patient needs, participants will be introduced to a menu of self-management and coping skills rather than receive a prescribed program. Delivery of the behavioral intervention will employ a flexible approach that is easily adapted to individual preferences and perceived need for learning specific pain coping skills. Tailoring will include the selection of relevant content and skills and assessment of readiness to change behaviors.
62800697|NCT02471014||Obese Individuals|Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.
62800698|NCT02471014||Normal Individuals|Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.
62800699|NCT02194595|EXPERIMENTAL|Basal insulin and exenatide|Participants in this arm will undergo an 8-week course of treatment with exenatide and insulin glargine. Exenatide will be initiated at 5ug subcutaneous (sc) bid (before breakfast and before dinner) for the first 4 weeks, followed by 10ug bid for the next 4 weeks. Glargine sc injection at bedtime will be titrated to fasting glucose.
62418872|NCT03910010|NO_INTERVENTION|Healthy Controls|Healthy control participants will complete the main part of the study, but will not be asked to take a placebo or be placed on a waitlist.
62418873|NCT05975216||Diagnosed-but-untreated|Diagnosed but untreated (DBU) HCV patients through positive serology with positive or unknown HCV RNA in UZ Brussel between 2012 - 2022.
62800700|NCT02194595|ACTIVE_COMPARATOR|Basal insulin only|Participants in this arm will undergo an 8-week course of treatment with glargine sc injection at bedtime, titrated to target fasting glucose.
62800701|NCT02194595|ACTIVE_COMPARATOR|Basal Insulin and bolus insulin|Participants in this arm will undergo an 8-week course of multiple daily insulin injection therapy, consisting of titrated basal insulin glargine at bedtime and insulin lispro before each meal.
62800702|NCT04373226|EXPERIMENTAL|22q11.2DS|Children aged from 4 to 11 years old with 22q11.2 deletion syndrome
62418874|NCT02414867||1|Normal weight mothers
62418875|NCT02414867||2|Overweight/Obese mothers
62418876|NCT06565559||Study Cohort|All surgical patients that fit the study eligibility criteria.
62027001|NCT03859323|EXPERIMENTAL|Single Ascending Dose (SAD): 1 mg/kg|Participants will receive single SC injection of 1 mg/kg SHP681 in the abdomen.
62418877|NCT05630703|EXPERIMENTAL|Mindfulness Training|Behavioral: Mindfulness-based Eating Awareness Training in IBS - The MB-IBS-EAT is an 8-week intervention with weekly 1-hour sessions in a web-based group format.
62418878|NCT05630703|ACTIVE_COMPARATOR|fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet|Dietary: Low FODMAP Diet - Subjects in the FODMAP group will be provided dietary instructions by a registered dietician during weekly 1-hour sessions in a web-based group format.
62418879|NCT02460861|ACTIVE_COMPARATOR|PCA Magdeburg|Prostate cancer conducted for RPVE with curative Intention, biopsies of the prostatic fossa in Magdeburg
62800703|NCT04373226|ACTIVE_COMPARATOR|NON22q11.2DS|Children aged from 4 to 11 years old without developmental disease
62418880|NCT02460861|ACTIVE_COMPARATOR|Non-prostate cancer Magdeburg/Gronau|Conducted for CE in Male with bladder cancer or other indication for cystectomy but without prostate cancer in Magdeburg or Gronau, biopsies of the prostatic fossa in Gronau
62418881|NCT02460861|ACTIVE_COMPARATOR|PCA Gronau|Prostate cancer conducted for ETRARP with curative Intention, biopsies of the prostatic fossa
62418882|NCT05001763|PLACEBO_COMPARATOR|Placebo|Glucose, 2mg, tablet.
62800704|NCT06097065||Non pregnant people with prediabetes or diabetes|Non pregnancy meeting the diagnosis of prediabetes or diabetes.
62800705|NCT06097065||Non pregnant people with normal glucose tolerance|Non pregnant population with normal Oral Glucose Tolerance Test results.
62800706|NCT06097065||pregnant people with gestational diabetes mellitus|Pregnant people who meet the diagnosis of gestational diabetes.
62800707|NCT06097065||pregnant people with normal glucose tolerance|Pregnant people with normal Oral Glucose Tolerance Test results.
62800708|NCT05307354|EXPERIMENTAL|Nerve Mobilization Group|Tibial nerve mobilization in addition to foot-ankle joint range of motion exercises
62418883|NCT05001763|EXPERIMENTAL|Prucalopride|Prucalopride, 2mg, tablet. First given 2 days before surgery beginning on POD 1, until defecation or for a maximum of 7 days of postoperative treatment.
62800709|NCT05307354|ACTIVE_COMPARATOR|Control group|Only joint range of motion exercises
62800710|NCT03862183||dyslipidemia in hypertension|
62800711|NCT03862183||hypertension|
62800712|NCT04402424||Two-Week Rule Colorectal Patients|Patients that the GP has referred to two-week rule colorectal clinics at Royal Surrey County Hospital with bowel symptoms or found to be anaemic
62800713|NCT03062514|EXPERIMENTAL|Experimental|Subjects'Vagus Nerve stimulator is on always
62800714|NCT03062514|SHAM_COMPARATOR|Control|Subjects'Vagus Nerve stimulator is off from enrollment to 3 month
62418884|NCT02996461|EXPERIMENTAL|Group 1|ZIKV DNA vaccine administered IM via needle and syringe at a single dosage of 4 mg on Day 0, week 4 and week 8.
62800715|NCT02472717|EXPERIMENTAL|Interventional arm|liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
62418885|NCT02996461|EXPERIMENTAL|Group 2|ZIKV DNA vaccine administered IM via needle and syringe as a split dose of two .5 ml injections on Day 0, week 4 and week 8.
62418886|NCT02996461|EXPERIMENTAL|Group 3|ZIKV DNA vaccine administered IM via needle-free injection device, PharmaJet, as a split dose of two .5 ml injections on Day 0, week 4 and week 8.
62418887|NCT06117566|EXPERIMENTAL|WX390 0.5 mg + Toripalimab 240mg|Participants will receive WX390 continuous oral dosing (0.5 mg once a day) and Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks).
62418888|NCT06117566|EXPERIMENTAL|WX390 0.7 mg + Toripalimab 240mg|Participants will receive WX390 continuous oral dosing (0.7 mg once a day) and Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks).
62418889|NCT06117566|EXPERIMENTAL|WX390 0.9 mg + Toripalimab 240mg|Participants will receive WX390 continuous oral dosing (0.9 mg once a day) and Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks).
62800716|NCT02472717|PLACEBO_COMPARATOR|Placebo arm|Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
62800717|NCT05880966|EXPERIMENTAL|COBRE Single Group|All participants will complete the 6-mos functional fitness interventions
62800718|NCT00837200|EXPERIMENTAL|Oncaspar, Doxil, Decadron Regimen|Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
62800719|NCT01178268|ACTIVE_COMPARATOR|XIENCE V EECSS|Patients who will receive this stent.
62800720|NCT01178268|ACTIVE_COMPARATOR|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
62800721|NCT00842556|ACTIVE_COMPARATOR|Dapagliflozin|
62800722|NCT00842556|ACTIVE_COMPARATOR|Glimepiride|
62800723|NCT00842556|ACTIVE_COMPARATOR|Dapagliflozin + Glimepiride|
62800724|NCT00842556|ACTIVE_COMPARATOR|Sitagliptin|
62800725|NCT00842556|ACTIVE_COMPARATOR|Dapagliflozin + Sitagliptin|
62800726|NCT06166381|ACTIVE_COMPARATOR|control|This group will receive parenteral antibiotics to prevent infection in the surgery.
62800727|NCT06166381|EXPERIMENTAL|clinical trial|This group will include patients who will receive parenteral antibiotics combined with vancomycin presoaked solution for the graft.
62800728|NCT01635231|ACTIVE_COMPARATOR|thiazide, diuretic|1.25 mg thiazide twice daily for 5 days
62800729|NCT01635231|ACTIVE_COMPARATOR|amiloride, diuretic|5 mg of amiloride twice daily
62800730|NCT01635231|PLACEBO_COMPARATOR|calcium|placebo twice daily for 5 days
62800731|NCT02686918|EXPERIMENTAL|consultation by Advanced Practice Nurse.|During consultations, patients will be seen successively by Advanced Practice Nurse and referent oncologist.
62800732|NCT02168907|EXPERIMENTAL|Treatment (CPI-613, bendamustine hydrochloride, rituximab)|Patients receive 6,8-bis(benzylthio)octanoic acid intravenously IV over 2 hours on days 1-4 (week 1) and days 1 and 4 (weeks 2 and 3). Patients also receive bendamustine hydrochloride IV over 30 minutes on days 4 and 5 and rituximab on day 5 of week 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62800733|NCT01773486|ACTIVE_COMPARATOR|Hesperidin|Subjects will receive oral hesperidin 500 mg/day
62800734|NCT01773486|PLACEBO_COMPARATOR|Placebo|subjects will receive matching placebo to hesperidin daily for 1 month
62800735|NCT02747810|EXPERIMENTAL|New TENS design|To determine the function and safety of the strap design by evaluating the electrical connection to electrode, 2) the security in the insole and the electronic unit, and 3) facilitating observation and hand access to the top panel for adjusting the stimulation strength. 4) to elicit toe twitching with stimulation of tribal nerve
62418890|NCT06473558|EXPERIMENTAL|Participants seen at University Hospitals Cleveland Medical Center Emergency Department|Eligible patients must present with non-emergent concerns of Emergency Severity Index (ESI) level 3, 4, or 5. Patients will complete assessments and questionnaires and end with being recorded reading a story to capture facial expressions and audio cues.
62800736|NCT02478463|EXPERIMENTAL|Cabotegravir|Subject will receive CAB 30 mg tablet once daily oral dose for 28 days (4 weeks) followed by a washout period of 14 to 42 days. After the washout, subject will receive a single dose of CAB LA 600 mg IM to gluteal region.
62800737|NCT05974930||Patients with STEMI undergoing IVUS-guided primary PCI|The ULTRA-STEMI trial will include consecutive patients with STEMI undergoing IVUS-guided primary PCI. All participants will undergo: IVUS intra-coronary imaging at baseline-, post-intervention and post-optimization. If manual thrombus aspiration is needed, the aspirated thrombotic material will be collected to be micro-CT scanned. Post-PCI iFR will be also performed in each participant. Clinical, angiographic and peri-procedural data will be collected. Each participant will be subject to telephone follow-up at 1, 6 and 12 months.
62027002|NCT03859323|EXPERIMENTAL|Single Ascending Dose (SAD): 2 mg/kg|Participants will receive single SC injection of 2 mg/kg SHP681 in the abdomen.
62027003|NCT03859323|EXPERIMENTAL|Single Ascending Dose (SAD): 4 mg/kg|Participants will receive single SC injection of 4 mg/kg SHP681 in the abdomen.
62418891|NCT06362616|EXPERIMENTAL|Preoperative accelerated partial breast re-irradiation|Patients receive preoperative accelerated partial breast irradiation of the in situ tumor in the breast followed by repeat breast conserving surgery
62800738|NCT02248805|EXPERIMENTAL|Does Escalation Arm A|MGD007 treatment once weekly
62800739|NCT02248805|EXPERIMENTAL|Dose Escalation Arm B|MGD007 treatment once every 3 weeks
62800740|NCT02248805|EXPERIMENTAL|Dose Expansion Arm C|MGD007 once every 3 weeks for K-ras wild-type and mutant metastatic CRC
62800741|NCT02248805|EXPERIMENTAL|Dose Expansion Arms|MGD007 2, 3, 6, or 12 doses/cycle
62027004|NCT03859323|PLACEBO_COMPARATOR|Single Ascending Dose (SAD): Placebo|Participants will receive single SC injection of placebo matched to SHP681 in the abdomen.
62027005|NCT03859323|EXPERIMENTAL|Multiple Ascending Dose (MAD): 0.2 mg/kg|Participants will receive SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
62027006|NCT03859323|EXPERIMENTAL|Multiple Ascending Dose (MAD): 0.5 mg/kg|Participants will receive SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
62027007|NCT03859323|EXPERIMENTAL|Multiple Ascending Dose (MAD): 1 mg/kg|Participants will receive SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
62418892|NCT06228053|EXPERIMENTAL|SX-682 + enzalutamide|
62800742|NCT02908126|EXPERIMENTAL|Oxytocin intravenous|single dose of intravenous (IV) oxytocin
62800743|NCT02908126|EXPERIMENTAL|Oxytocin tablet|single dose of oxytocin tablet
62800744|NCT04609631|EXPERIMENTAL|Tai Chi (5 times/week)|5 sessions of Tai Chi per week for 12 weeks
62800745|NCT04609631|EXPERIMENTAL|Tai Chi (3 times/week)|3 sessions of Tai Chi per week for 12 weeks
62800746|NCT04609631|EXPERIMENTAL|Tai Chi (1 time/week)|1 session of Tai Chi per week for 12 weeks
62225951|NCT06288646||Confirmed Lung Cancer|"To be eligible for the lung cancer group:~* Aged 50 and over;~* Current or former smoker with smoking history ≥ 20 pack-years;~* Capacity to give informed consent;~* Non-metastatic non-small cell lung cancer, that has not been treated~* No history of active cancer in the past 5 years (exceptions include: Ductal carcinoma in situ (DCIS), cervical intraepithelial neoplasia (CIN), non-invasive bladder cancer, non-melanoma skin cancers, Gleason prostate cancer ≤ 6);~* Able to provide a breath sample.~To be eligible for a second breath sample:~* Same as above, in addition to, and with the exception of criterion 4:~* Non-metastatic non-small cell lung cancer, which has undergone surgical resection;~* 6 months since completion of surgery, radiation, and chemotherapy on primary NSCLC;~* CT scan at least 6 months after surgical resection, confirming the absence of lung cancer."
62225952|NCT06288646||Control|"For a participant to be eligible in the study control group:~* Aged 50 and over;~* Current or former smoker with smoking history ≥ 20 pack-years;~* Capacity to give informed consent;~* No history of active lung cancer;~* No pulmonary nodule(s);~* No active cancer in the last 5 years; (Note: DCIS, CIN, non-invasive bladder cancer, non-melanoma skin cancers, Gleason ≤ 6 prostate cancer will be exceptions);~* Ability to provide a breath sample."
62418893|NCT00016406|ACTIVE_COMPARATOR|AC followed by P|doxorubicin and cyclophosphamide followed by paclitaxel followed by surgery
62418894|NCT00016406|EXPERIMENTAL|AC+G followed by P|weekly doxorubicin and daily cyclophosphamide with filgrastim followed by paclitaxel followed by surgery
62418895|NCT04024722|EXPERIMENTAL|Single ovary treatment|
62418896|NCT04024722|EXPERIMENTAL|Dual ovary treatment|
62418897|NCT06355583|PLACEBO_COMPARATOR|Placebo|Patients randomised on to the placebo arm will swallow 10 placebo capsules once at the second study visit approximately 2 weeks before the stem cell transplantation. The capsules contain inactive ingredients (microcrystalline cellulose and magnesium stearate) and will have the same appearance, weight, and packaging weight to the IMT capsules in the treatment arm to maintain treatment blinding.
62589554|NCT05037357||nasopharyngeal carcinoma patients|Plasma EBV DNA quantification by quantitative polymerase chain reaction (qPCR) assays in different medical centers.
62589555|NCT04466098|EXPERIMENTAL|Mesenchymal Stromal Cells|Three fixed doses of MSC approximately 48 hours apart.
62589556|NCT04466098|PLACEBO_COMPARATOR|Placebo|Three fixed doses of placebo control approximately 48 hours apart.
62589557|NCT01863316|EXPERIMENTAL|1) I gel group|using supraglottic airway I gel
62418898|NCT06355583|ACTIVE_COMPARATOR|EBX-102-02|Patients randomised on to the Treatment arm will swallow 10 capsules once at the second study visit approximately 2 weeks before the stem cell transplantation. Each capsule will contain 1x10\^6 - 1x10\^9 colony forming units (CFU)/g of viable microorganisms and will have the same appearance, weight and packaging weight to the placebo capsules in the treatment arm to maintain treatment blinding.
62418899|NCT05789420|ACTIVE_COMPARATOR|Product Sequence 1|"After at least 23 hours of abstinence from any Tobacco or Nicotine Product (TNP) on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or performed a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence.~The list of possible sequences are:~P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R"
62418900|NCT05789420|ACTIVE_COMPARATOR|Product Sequence 2|"After at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or performed a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence.~The list of possible sequences are:~P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R"
62589558|NCT01863316|ACTIVE_COMPARATOR|2) LMA Supreme group|using supraglottic airway LMA Supreme
62589559|NCT06278363|EXPERIMENTAL|Sexual Nursing Care|"Group 1 patients receive Sexual Nursing Care, involving personalized counseling by a nurse to address sexual dysfunctions post-stroke. The intervention includes partner involvement to foster new intimacy, sexual education, and exercises. Four 45-minute outpatient sessions with the nurse and partner are provided. Any emerging issues requiring diagnostic investigation will be communicated to the referring specialist."
62800747|NCT04609631|ACTIVE_COMPARATOR|cognitive behavior therapy (CBT)|1 session of CBT per week for 12 weeks
62800748|NCT04609631|NO_INTERVENTION|Waiting-list|Participants will maintain their routine treatment and life style for 12 weeks.
62800749|NCT02139072||CoaguChek XS|INR measured by CoaguChek XS in patients with APL at visit 1 and visit 2, in addition to routine measure by standard lab draw
62800750|NCT02139072||Standard Lab Draw|INR measured by standard lab draw at visit 1 and visit 2 for non-APL patients, in addition to routine measurement by CoaguChek XS
62800751|NCT02802566|EXPERIMENTAL|Investigative|This arm receives a standard prenatal (provided by the study) and a micronutrient supplement.
62800752|NCT02802566|ACTIVE_COMPARATOR|Control|Standard prenatal vitamin provided by the study
62800753|NCT01412164|EXPERIMENTAL|Firehawk|Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
62800754|NCT01587144|PLACEBO_COMPARATOR|Placebo|Participants will receive a matching placebo as an adjunct in initial six weeks of concomitant therapy with TMZ and radiation, followed by a maintenance phase of six cycles of TMZ given on Days 1 to 5 of a 28-day cycle (+/- 3 days).
62800755|NCT01587144|ACTIVE_COMPARATOR|Lucanthone|Participants will receive Lucanthone as an adjunct in initial six weeks of concomitant therapy with TMZ and radiation, followed by a maintenance phase of six cycles of TMZ given on Days 1 to 5 of a 28-day cycle (+/- 3 days).
62800756|NCT03703544|EXPERIMENTAL|High glycemic index|Subjects will consume locally consumed meals which are high glycemic index for breakfast, lunch snack and dinner will be provided.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
62800757|NCT03703544|EXPERIMENTAL|Low glycemic index|Subjects will consume locally consumed meals which are low glycemic index for breakfast, lunch snack and dinner will be provided. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
62800758|NCT05441631|ACTIVE_COMPARATOR|Intensive insulin therapy|
62800759|NCT05441631|ACTIVE_COMPARATOR|Conventional insulin therapy|
62800760|NCT03870295|EXPERIMENTAL|Patients suffering from polyneuropathies|Type C fibre conduction velocity determination in patients suffering from polyneuropathy
62418901|NCT05789420|ACTIVE_COMPARATOR|Product Sequence 3|"After at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or performed a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence.~The list of possible sequences are:~P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R"
62589560|NCT06278363|ACTIVE_COMPARATOR|Standard Nursing Care:|"Patients in Group 2 receive a standard nursing care approach. In this group, no specific structured interventions for sexual dysfunctions are provided. Management of sexual dysfunctions occurs based on the clinical case and standard care approach.~Care sessions follow a routine program, without specific interventions for the sexual sphere.~As in Group 1, any emerging issues during treatment that require further diagnostic investigation will be communicated to the referring specialist.~Both groups will be evaluated for the impact of treatment not only quantitatively, through the analysis of the effect of counseling on sexual and relational aspects but also qualitatively, to investigate psychorelational changes and mood impact on the quality of life of the involved couples."
62800761|NCT03870295|ACTIVE_COMPARATOR|Control patients|Type C fibre conduction velocity determination in control patients
62800762|NCT06219096|EXPERIMENTAL|The new ICG & HSA injection Group (experimental group)|After ligation of the targeted hepatic segmental portal vein, a novel ICG protocol is used (0.5mg ICG powder is added to 20mL normal saline containing 500mg human albumin, shaken and allowed to stand for more than 5 minutes to form a stable complex, with final concentrations of ICG 0.025mg/mL and human albumin 25mg/mL). This ICG-albumin conjugate solution is then administered intravenously at a rate of 1mL/min. The infusion is stopped when sufficient fluorescence enhancement is observed in the negative-staining liver regions.
62800763|NCT06219096|ACTIVE_COMPARATOR|The guideline-recommended ICG injection Group (active comparator group)|After ligation of the targeted hepatic segmental portal vein, 2.5mg of ICG (concentration 2.5mg/mL) is administered intravenously as a bolus injection.
62225953|NCT06288646||Stable pulmonary nodule|"For a participant to be eligible for admission to the stable lung nodules group:~* Aged 50 and over;~* Current or former smoker with smoking history ≥ 20 pack-years;~* Capacity to give informed consent;~* No history of active lung cancer or other active cancer in the past 5 years; (Note: DCIS, CIN, non-invasive bladder cancer, non-melanoma skin cancers, Gleason prostate cancer ≤ 6 or lower will be exceptions);~* Presence of one or more stable lung nodules (as determined by the principal investigator);~* Ability to provide a breath sample."
62418902|NCT05789420|ACTIVE_COMPARATOR|Product Sequence 4|"After at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or performed a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence.~The list of possible sequences are:~P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R"
62418903|NCT05789420|ACTIVE_COMPARATOR|Product Sequence 5|"After at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or perform a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence.~The list of possible sequences are:~P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R"
62027008|NCT03859323|EXPERIMENTAL|Multiple Ascending Dose (MAD): 2 mg/kg|Participants will receive SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
62027009|NCT03859323|EXPERIMENTAL|Multiple Ascending Dose (MAD): 4 mg/kg|Participants will receive SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
62027010|NCT03859323|PLACEBO_COMPARATOR|Multiple Ascending Dose (MAD): Placebo|Participants will receive SC injection of placebo matched to SHP681 once weekly for 5 weeks in the abdomen.
62027011|NCT00125216|OTHER|Arm 1|Single subject design - participant receives three administrations of the same treatment
62225954|NCT05030545|EXPERIMENTAL|Eplerenone Treatment|Eplerenone (50-100mg daily, as tolerated by blood pressure and potassium) for 6 months
62225955|NCT01994668|EXPERIMENTAL|Lorazepam|
62027012|NCT01873794|ACTIVE_COMPARATOR|Bright white light|using systematic light exposure (SLE), consisting of a daily 30-minute exposure to as much as 10,000 lux of light from a commercially available light box
62225956|NCT01994668|PLACEBO_COMPARATOR|Placebo|
62800764|NCT03004365|ACTIVE_COMPARATOR|Arm 1A: 27.2 mg C16G2|Subjects in Study Arm 1 will receive up to 1 mL of 27.2 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
62800765|NCT03004365|PLACEBO_COMPARATOR|Arm 1B: 27.2 mg Placebo|Subjects in Study Arm 1 will receive up to 1 mL of 27.2 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
62800766|NCT03004365|ACTIVE_COMPARATOR|Arm 2A: 13.6 mg C16G2|Subjects in Study Arm 2 will receive up to 1 mL of 13.6 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
62800767|NCT03004365|PLACEBO_COMPARATOR|Arm 2B: 13.6 mg Placebo|Subjects in Study Arm 2 will receive up to 1 mL of 13.6 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
62800768|NCT03004365|ACTIVE_COMPARATOR|Arm 3A: 54.4 mg C16G2|Subjects in Study Arm 3 will receive up to 1 mL of 54.4 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
62225957|NCT01776541|EXPERIMENTAL|aH5N1c-High Dose|Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.
62225958|NCT01776541|EXPERIMENTAL|aH5N1c-Low dose|Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.
62418904|NCT05789420|ACTIVE_COMPARATOR|Product Sequence 6|"After at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or perform a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence.~The list of possible sequences are:~P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R"
62800769|NCT03004365|PLACEBO_COMPARATOR|Arm 3B: 54.4 mg Placebo|Subjects in Study Arm 3 will receive up to 1 mL of 54.4 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
62027013|NCT01873794|ACTIVE_COMPARATOR|Dim red light|using systematic light exposure (SLE), consisting of a daily 30-minute exposure to as much as 10,000 lux of light from a commercially available light box
62225959|NCT01964885|ACTIVE_COMPARATOR|IQP-AS-105|One tablet daily
62418905|NCT04446117|EXPERIMENTAL|Experimental Arm|Subjects with mCRPC will receive cabozantinib 40mg oral, qd + atezolizumab 1200mg infusion, q3w
62418906|NCT04446117|ACTIVE_COMPARATOR|Control Arm|Subjects with mCRPC will receive active comparator of EITHER abiraterone 1000mg oral, qd + prednisone 5 mg oral, bid; OR enzalutamide 160mg oral, qd as designated by the Investigator prior to randomization
62418907|NCT05588128||Cohort 1|Participants with biochemically recurrent prostate cancer
62418908|NCT05945147|EXPERIMENTAL|Ketamine and Midazolam|Participants will receive intravenous infusions of ketamine and midazolam for 4 hours each day, over 5 consecutive days, in an outpatient setting.
62418909|NCT05945147|PLACEBO_COMPARATOR|Midazolam and Saline|Participants will receive intravenous infusions of midazolam and normal saline for 4 hours each day, over 5 consecutive days, in an outpatient setting.
62418910|NCT04282733|EXPERIMENTAL|Mindfulness Rounds|Participants will be exposed to thrice weekly Mindfulness Rounds education on the Unit; participation in the actual sessions is voluntary.
62418911|NCT04282733|NO_INTERVENTION|Control|No intervention will take place on this Unit
62418912|NCT01604148||HoLEP group|Holmium Laser Enucleation of Prostate Group
62418913|NCT04440163|EXPERIMENTAL|1-Immuno Subset (ACWY Naive,MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
62418914|NCT04440163|EXPERIMENTAL|2-Immuno Subset (ACWY Naive, Trumenba/MenACWY-CRM)|ACWY Naive subjects, Trumenba/MenACWY-CRM
62418915|NCT04440163|EXPERIMENTAL|3-Immuno Subset (ACWY Experienced,MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
62418916|NCT04440163|EXPERIMENTAL|4-Immuno Subset (ACWY Experienced,Trumenba/MenACWY-CRM)|ACWY Experienced subjects, Trumenba/MenACWY-CRM
62800770|NCT06101706|OTHER|Psoriatic arthritis patients|
62800771|NCT06101706|OTHER|Cutaneous psoriasis patients|
62800772|NCT03697642|EXPERIMENTAL|NG tube placement with nasopharyngeal tube|
62800773|NCT03697642|ACTIVE_COMPARATOR|NG tube placement without nasopharyngeal tube|
62800774|NCT04308941|ACTIVE_COMPARATOR|Scleral Tonopen|The first 10 subjects will be randomly chosen for the first cohort (scleral TonoPen)
62800775|NCT04308941|ACTIVE_COMPARATOR|Scleral Pneumatonometer|The second 10 subjects will be randomly chosen for the second cohort (scleral pneumatonometry)
62027014|NCT05620758|EXPERIMENTAL|Nd YAG laser|
62027015|NCT05620758|EXPERIMENTAL|Diode laser 980 nm|
62225960|NCT01964885|PLACEBO_COMPARATOR|Placebo|One tablet daily
62225961|NCT02782689|EXPERIMENTAL|Kit Biflex|The Kit Biflex® will be applied according to manufacturer recommendations for 16 weeks or until full healing.
62225962|NCT02782689|ACTIVE_COMPARATOR|Profore|The compression system Profore will be applied according to manufacturer recommendations for 16 weeks or until full healing.
62418917|NCT04440163|EXPERIMENTAL|5-Safety Subset (ACWY Naive,MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
62418918|NCT04440163|EXPERIMENTAL|6-Safety Subset (ACWY Naive,Trumenba/MenACWY-CRM)|ACWY Naive subjects, Trumenba/MenACWY-CRM
62418919|NCT04440163|EXPERIMENTAL|7-Safety Subset (ACWY Experienced,MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
62418920|NCT04440163|EXPERIMENTAL|8-Safety Subset (ACWY Experienced,Trumenba/MenACWY-CRM)|ACWY Experienced subjects, Trumenba/MenACWY-CRM
62800776|NCT04308941|ACTIVE_COMPARATOR|Diaton|The third 10 subjects will be randomly chosen for the third cohort (Diaton).
62800777|NCT00202761|EXPERIMENTAL|PIH|Intensified training of children with CP. Functional training (motor, speech, executive function). Coaching of parents by psychologist, individually and in groups.
62225963|NCT06276907|EXPERIMENTAL|Plasma Exchange|On day 1 Response assessment will be done to assess the need for a second session from day 3-7 and subsequently every week till day 28. A minimum of 3 sessions would be considered in the first seven days. The duration of each session would be 3-4 hours. Patients with partial response (not meeting criteria for a complete response after 3 sessions) would be considered for additional sessions as decided by the treating physician until desired complete response, adverse effects, liver transplant, death, or clinical futility. The complete response will be defined as a sustained reduction in bilirubin and international normalized ratio without any clinical worsening requiring discontinuation of therapy. Failure of therapy would be defined as the development of adverse effects, new onset sepsis, or organ failure. In such patients, further sessions would be deferred. Blood access was established with a double-lumen catheter inserted into the patient's femoral or jugular vein.
62418921|NCT05165277|EXPERIMENTAL|Acidic phosphate buffer solution|The pH5.2 PBS will be given into the midpoint of the left tibialis muscle with flow rate of 0-40ml/hr for 2-26 minutes, that is, totally 5.5 ml of PBS.
62418922|NCT05165277|PLACEBO_COMPARATOR|Neutral phosphate buffer solution|The pH 7.4 PBS will be given into the midpoint of the left tibialis muscle with flow rate of 0-40ml/hr for 2-26 minutes, that is, totally 5.5 ml of PBS.
62418923|NCT05220904|PLACEBO_COMPARATOR|Placebo Comparator:placebo practice+spectacles|Patients will take placebo practices with spectacles every two days.
62418924|NCT05220904|EXPERIMENTAL|Experimental： perceptual learning practice+spectacles|Patients will take perceptual learning practices with spectacles every two days.
62418925|NCT05088980|EXPERIMENTAL|VOLBELLA with Lidocaine|Participants will receive VOLBELLA with Lidocaine on Day 1 and followed for 12 months.
62418926|NCT05088980|PLACEBO_COMPARATOR|Control Group|Participants will be followed for 3 months. Participants can opt to receive VOLBELLA with Lidocaine after 3 months and followed for 9 months.
62418927|NCT05420818|EXPERIMENTAL|Active Group|Patients who underwent transversalis fascia inversion during TEP
62418928|NCT05420818|NO_INTERVENTION|Control Group|Patients who did not undergo transversalis fascia inversion during TEP
62418929|NCT04215952|EXPERIMENTAL|SFA Experimental Intervention|A modified version of Semantic Feature Analysis will be administered.
62418930|NCT04215952|ACTIVE_COMPARATOR|SFA Active Comparator Intervention|A standard version of Semantic Feature Analysis will be administered.
62225964|NCT06276907|ACTIVE_COMPARATOR|Standard Medical Treatment|Patients randomized to SMT Group will be given standard medical therapy (SMT) only included as per requirement.
62225965|NCT02349646||Treated subjects|All subjects recruited and treated with the Axium neurostimulator
62418931|NCT06702358|OTHER|Infrared laser diode|"Laser pointer instruments Product Details Infrared laser diode made in Italy, it must be perpendicular with direct contact to each point.~Each point will stimulate bilaterally by a laser beam of the following parameters wave length 904 nm; strength, 24 mW; energy, 0.1 J; stimulation time, 30 s/point"
62418932|NCT04289584|EXPERIMENTAL|Experimental group|Each session will last 15 minutes, taking place for 2 days a week, over a period of 4 weeks. The intervention will take place at the beginning of the training session. Prior to training, strength and proprioception exercises will be performed.
62418933|NCT04289584|NO_INTERVENTION|Control group|The players included in the control group will follow their usual routine prior to their Taekwondo training.
62418934|NCT01933932|EXPERIMENTAL|Selumetinib + Docetaxel|Three 25mg Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle
62418935|NCT01933932|EXPERIMENTAL|Placebo + Docetaxel|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
62800778|NCT05206175|EXPERIMENTAL|Primary Arm|Components of the Affect Therapeutic Program for MUD Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine-based addiction counseling with clinical personnel, twice-weekly group therapy, and monthly psychiatrist appointments for evaluation and management and medication support, as needed.
62800779|NCT05577338|EXPERIMENTAL|training group|Theory of Mind psychotherapy psychotherapy
62800780|NCT05577338|ACTIVE_COMPARATOR|active control group|receive disease-related health knowledge
62800781|NCT05010096|EXPERIMENTAL|Arm I (elimusertib, copanlisib)|Patients receive Patients receive elimusertib PO BID on days 1-3 and 15-17, and copanlisib IV over 1 hour on days 4 and 18. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may continue to receive elimusertib PO BID and copanlisib IV at the discretion of the treating physician.
62027016|NCT05620758|EXPERIMENTAL|Diode laser 940 nm|
62225966|NCT05012891||Study Population|Fifty (n=50) consecutive patients with lower-extremity disability or chronic pain (unilateral or bilateral), undergoing a rehabilitation course in a Day-Care Center setting.
62418936|NCT06132100|PLACEBO_COMPARATOR|traditional incentive spirometry|patients with traditional incentive spirometry
62418937|NCT06132100|EXPERIMENTAL|digitalized incentive spirometry|patients with digitalized incentive spirometry
62418938|NCT01363518||Operative|Operative group would have had surgery to treat their broken humerus.
62418939|NCT01363518||Nonoperative|Nonoperative group would have been treated with a brace, no surgery.
62800782|NCT05010096|EXPERIMENTAL|Arm II (elimusertib, copanlisib)|Patients receive elimusertib PO BID on days 1-3 and 15-17, and copanlisib IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may continue to receive elimusertib PO BID and copanlisib IV at the discretion of the treating physician.
62800783|NCT03187119|EXPERIMENTAL|Pictorial Asthma Action Plan|Young people in the Pictorial Asthma Action Plan (PAAP) arm will receive a PAAP generated by their asthma provider using a software program developed for the study. The PAAP will be personalized according to the young person's gender, race, favorite sport/activity, provider's gender, provider's clinic contact details, and hospital in emergency situations. The PAAP contains minimal text, instead illustrating each participant's asthma regimen using pictures, such as color-coded daily controller and rescue inhalers. Each participant will receive multiple copies of their PAAP, after receiving a brief education session with their provider, outlining the treatment summarized in the PAAP.
62800784|NCT03187119|ACTIVE_COMPARATOR|Written Asthma Action Plan|Young people in the Written Asthma Action Plan (WAAP) arm will receive a WAAP generated by their asthma provider using using the National Heart, Lung, and Blood Institute (NHLBI) template. The WAAP will be personalized according to the young person's treatment plan. Each participant will receive multiple copies of their WAAP, after receiving a brief education session with their provider, outlining the treatment summarized in the WAAP.
62800785|NCT06385119|EXPERIMENTAL|Treatment 1|Treatment 1: 900 mg plixorafenib (6 × 150 mg tablets) administered after overnight fast (fasted state).
62800786|NCT06385119|EXPERIMENTAL|Treatment 2|Treatment 2: 900 mg plixorafenib (6 × 150 mg tablets) + cobicistat (1 × 150 mg tablet) administered after overnight fast (fasted state).
62800787|NCT06385119|EXPERIMENTAL|Treatment 3|Treatment 3: 900 mg plixorafenib (6 × 150 mg tablets) + cobicistat (1 × 150 mg tablet) administered following a high fat, high caloric meal (fed state).
62800788|NCT06385119|EXPERIMENTAL|Treatment A|Treatment A: 900 mg plixorafenib administered after overnight fast (fasted state).
62800789|NCT06385119|EXPERIMENTAL|Treatment B|Treatment B: 900 mg plixorafenib administered following a high-fat high caloric meal (fed state-high fat meal).
62800790|NCT06385119|EXPERIMENTAL|Treatment C|Treatment C: 900 mg plixorafenib administered following a low-fat meal (fed state-low-fat meal).
62800791|NCT06385119|EXPERIMENTAL|Treatment D|Treatment D: 900 mg plixorafenib administered with 150 mg cobicistat following a low-fat meal (fed state-low-fat meal).
62800792|NCT06139341|EXPERIMENTAL|BI 765845 treatment group|
62800793|NCT06139341|PLACEBO_COMPARATOR|Placebo group|
62027017|NCT05620758|EXPERIMENTAL|Diode laser 660 nm|
62225967|NCT01600820|EXPERIMENTAL|1 = Tested product 1|
62800794|NCT03700801|EXPERIMENTAL|Triple combination therapy group|triple combination therapy group: Triple oral hypoglycemic therapy based on metformin 0.5mg twice a day, dapagliflozin 10mg per day plus saxagliptin 5mg per day.
62225968|NCT01600820|EXPERIMENTAL|2 = tested product 2|
62800795|NCT03700801|ACTIVE_COMPARATOR|Premixed insulin therapy group|premixed insulin therapy group: The initial total dose is 0.3U-0.5U/Kg, twice a day, subcutaneous injection before breakfast and dinner, adjusted according to the blood glucose level detected by the blood glucose meter
62800796|NCT03361293|ACTIVE_COMPARATOR|Cognitive Training and Active tDCS|5 sessions of computerized cognitive training on tasks of attention, concentration, set-shifting, and memory - plus active tDCS (also 5 sessions).
62800797|NCT03361293|SHAM_COMPARATOR|Cognitive Training and Sham tDCS|"5 sessions of computerized cognitive training on tasks of attention, concentration, set-shifting, and memory - plus sham tDCS (also 5 sessions) which consists of placebo stimulation with tDCS (ramp-up, but no actual stimulation)."
62800798|NCT02241148|ACTIVE_COMPARATOR|Acetaminophen 500mg|The control group will receive treatment with acetaminophen 500mg and physical therapy rehabilitation
62800799|NCT02241148|EXPERIMENTAL|Kinesio taping|The experimental treatment group will receive acetaminophen 500mg and physical therapy rehabilitation, plus the application of the technique NUCAP Medical Upper Knee Spider ® Kinesio taping
62800800|NCT03170700|NO_INTERVENTION|Control|Participants will receive a nutrition program without parental feeding content. They will attend the nutrition program (Eating Smart • Being Active).
62800801|NCT03170700|EXPERIMENTAL|In-person|Nutrition program with in-person parental feeding content.
62225969|NCT01600820|PLACEBO_COMPARATOR|3 = Control product|
62225970|NCT02608320|EXPERIMENTAL|Treatment Sequence (ACB) Position (RLR)|Participants will receive treatment A (Duragesic 12.5 microgram per hour \[mcg/h\]) applied to right paraspinal side in period 1, then treatment C (aged JNJ- 35685-AAA-G016 12.5 mcg/h) applied to left paraspinal side in period 2 and then treatment B (New JNJ-35685- AAA-G016 12.5 mcg/h) applied to right paraspinal side in period 3.
62225971|NCT02608320|EXPERIMENTAL|Treatment Sequence (BAC) Position (RLR)|Participants will receive treatment B applied to right paraspinal side in period 1, then treatment A applied to left paraspinal side in period 2 and then treatment C applied to right paraspinal side in period 3.
62027018|NCT05620758|EXPERIMENTAL|Diode laser 635 nm|
62225972|NCT02608320|EXPERIMENTAL|Treatment Sequence (CBA) Position (RLR)|Participants will receive treatment C applied to right paraspinal side in period 1, then treatment B applied to left paraspinal side in period 2 and then treatment A applied to right paraspinal side in period 3.
62225973|NCT02608320|EXPERIMENTAL|Treatment Sequence (BCA) Position (RLR)|Participants will receive treatment B applied to right paraspinal side in period 1, then treatment C applied to left paraspinal side in period 2 and then treatment A applied to right paraspinal side in period 3.
62225974|NCT02608320|EXPERIMENTAL|Treatment Sequence (CAB) Position (RLR)|Participants will receive treatment C applied to right paraspinal side in period 1, then treatment A applied to left paraspinal side in period 2 and then treatment B applied to right paraspinal side in period 3.
62225975|NCT02608320|EXPERIMENTAL|Treatment Sequence (ABC) Position (RLR)|Participants will receive treatment A applied to right paraspinal side in period 1, then treatment B applied to left paraspinal side in period 2 and then treatment C applied to right paraspinal side in period 3.
62027019|NCT03669029|EXPERIMENTAL|Week 6 Responders|In patients with clinical response at week 6, serum golimumab levels and anti-golimumab antibody levels will be correlated with clinical response.
62589561|NCT04895735|EXPERIMENTAL|Treatment (pembrolizumab, pemetrexed)|Patients receive pembrolizumab IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Cycles of pemetrexed disodium repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who had stable disease, partial response, or complete response after completion of 35 cycles of pembrolizumab, may continue pembrolizumab for an additional 17 cycles (1 year) in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection, CT, PET/CT or MRI and may also undergo PSMA PET on study.
62589562|NCT01513265|ACTIVE_COMPARATOR|RASP|
62418940|NCT04583384|OTHER|Assigned Intervention|"Addition to the cervical angio-MRI, of a sequence of 1H-SRM 3T (SUCCESS) centered on the lesion studied, performed according to the following parameters: PRESS asymmetric monovoxel PROBE, TE 144 ms, TR 2500 ms, 768 or 1024 medium."
62418941|NCT05370781|EXPERIMENTAL|Peer led diabetes self-management support (PLDSMS)|Participants in the PLDSMS arm will receive 10 hours of diabetes self-management education (DSME) with a certified diabetes care and education specialist. This group will then transition into monthly 90-minute diabetes self-management support (DSMS) with trained peer leaders for 6 months. After the DSMS sessions, the group will transition into 6 months of ongoing support and will be encouraged to continue DSMS through initiatives that are important to them.
62418942|NCT05370781|ACTIVE_COMPARATOR|Control Group|Participants in the control group will receive 10 hours of diabetes self-management education (DSME) with a certified diabetes care and education specialist.
62418943|NCT06700629|OTHER|DPH repair outcome|Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, ...): A. Preoperative preparation: All patients will be subjected to evaluation including: 1. Measurement of penile length and width (in cm). 2. The shape of glans. (clefted , incomplete ceft, flat) 3. Glans size is measured by cubic centimetres. 4. Presence or absence of chordee and its degree. 5. Urethral plate condition and it's length, width and surface area. 6. Condition of skin over the urethra. 7. Presence of penile torsion. All patients should undergo preoperative surgical fitness including; complete blood picture, prothrombin time, concentration and INR, ECG and renal function test. Prophylactic systemic antibiotics are given intraoperatively.
62589563|NCT01513265|NO_INTERVENTION|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care with registration of drug use at admission and discharge without interference of RASP or clinical pharmacist.
62800802|NCT03170700|EXPERIMENTAL|Online|Nutrition program with online parental feeding content.
62800803|NCT03550612||Neonates with hypoxic ischemic encephalopathy|Cranial ultrasound,Magnetic resonant imaging and amplitude integrated encephalogram performed to All neonates with hypoxic ischemic encephalopathy in period between January 2010 to December 2015.
62225976|NCT02608320|EXPERIMENTAL|Treatment Sequence (ACB) Position (LRL)|Participants will receive treatment A applied to left paraspinal side in period 1, then treatment C applied to right paraspinal side in period 2 and then treatment B applied to left paraspinal side in period 3.
62225977|NCT02608320|EXPERIMENTAL|Treatment Sequence (BAC) Position (LRL)|Participants will receive treatment B applied to left paraspinal side in period 1, then treatment A applied to right paraspinal side in period 2 and then treatment C applied to left paraspinal side in period 3.
62225978|NCT02608320|EXPERIMENTAL|Treatment Sequence (CBA) Position (LRL)|Participants will receive treatment C applied to left paraspinal side in period 1, then treatment B applied to right paraspinal side in period 2 and then treatment A applied to left paraspinal side in period 3.
62800804|NCT00506870|NO_INTERVENTION|1|Conventional follow-up of anticoagulation
62800805|NCT00506870|EXPERIMENTAL|2|Self-monitoring of anticoagulation
62800806|NCT02783196|EXPERIMENTAL|Liraglutide (LIR)|Type 2 diabetic randomized to start with two 40 days treatment periods starting with Liraglutide ( IR) treatment, and then after 2 weeks of wash-out, will crossover to second treatment period of 40 days with placebo (PLA)
62800807|NCT02783196|PLACEBO_COMPARATOR|Placebo (PLA)|Type 2 diabetic randomized to start with two 40 days treatment periods starting with placebo ( PLA) treatment, and then after 2 weeks of wash-out, will crossover to second treatment period of 40 days with Liraglutide ( LIR)
62800808|NCT01224119|EXPERIMENTAL|Amplex (synthetic bone graft)|
62800809|NCT01224119|ACTIVE_COMPARATOR|Autograft bone|
62800810|NCT02256566|EXPERIMENTAL|emotional memory training exercise|study training exercise - Emotional Faces Memory Task (EFMT)
62800811|NCT02256566|ACTIVE_COMPARATOR|memory training exercise|an active control exercise (CT)
62800812|NCT03652181||CASH (Cavernous Angiomas with Symptomatic Hemorrhage)|The adjudicated definition of CASH (Cavernous Angiomas with Symptomatic Hemorrhage) requires diagnostic evidence of new lesional bleeding or hemorrhagic growth, in association with directly attributable symptoms.
62800813|NCT02055287|EXPERIMENTAL|LY03004- 12.5|LY03004 dosage strength at 12.5mg
62800814|NCT02055287|EXPERIMENTAL|LY03004 - 25|LY03004 Dose Strength 25mg
62800815|NCT02055287|EXPERIMENTAL|LY03004- 37.5|LY03004 Dose Strength 37.5mg
62800816|NCT02055287|EXPERIMENTAL|LY03004 - 50|LY03004 Dose Strength 50mg
62800817|NCT00706446|EXPERIMENTAL|1 - Tio/ICS in the Arg/Arg genotype|Tiotropium bromide 18 mcg qd plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Arg genotype
62800818|NCT00706446|EXPERIMENTAL|2 - Tio/ICS in the Arg/Gly genotype|Tiotropium bromide 18 mcg QD plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Gly genotype
62027020|NCT03669029|EXPERIMENTAL|Week 6 Non Responders|In patients without clinical response at week 6, golimumab treatment will be optimized.
62225979|NCT02608320|EXPERIMENTAL|Treatment Sequence (BCA) Position (LRL)|Participants will receive treatment B applied to left paraspinal side in period 1, then treatment C applied to right paraspinal side in period 2 and then treatment A applied to left paraspinal side in period 3.
62225980|NCT02608320|EXPERIMENTAL|Treatment Sequence (CAB) Position (LRL)|Participants will receive treatment C applied to left paraspinal side in period 1, then treatment A applied to right paraspinal side in period 2 and then treatment B applied to left paraspinal side in period 3.
62225981|NCT02608320|EXPERIMENTAL|Treatment Sequence (ABC) Position (LRL)|Participants will receive treatment A applied to left paraspinal side in period 1, then treatment B applied to right paraspinal side in period 2 and then treatment C applied to left paraspinal side in period 3.
62225982|NCT02608320|EXPERIMENTAL|Treatment Sequence (DFE) Position (RLR)|Participants will receive treatment D (Duragesic 100 mcg/h) applied to right paraspinal side in period 1, then treatment F (aged JNJ-35685-AAA-G021 100 mcg/h) applied to left paraspinal side in period 2 and then treatment E (new JNJ-35685-AAA-G021 100 mcg/h) applied to right paraspinal side in period 3.
62800819|NCT00706446|EXPERIMENTAL|3 - Tio/ICS in the Gly/Gly genotype|Tiotropium bromide 18 mcg QD plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Gly/Gly genotype
62027021|NCT00601926|EXPERIMENTAL|Bevacizumab|15 mg/kg over 90 minutes
62027022|NCT04613973||Patients included in the PRADO program|Patients hospitalized for global heart failure or left ventricular insufficiency in the Cardiology department of the GHPSJ between January 2016 and September 2018, included in the support program for Return To Home for Heart Failure (PRADO)
62027023|NCT04613973||Patients not included in the PRADO program|Patients hospitalized for global heart failure or left ventricular insufficiency in the Cardiology department of the GHPSJ between January 2016 and September 2018, not included in the Return A DOmicile support program for Heart Failure (PRADO)
62027024|NCT05851404||South East Asian Region (SEAR)|Patients that underwent thyroidectomy for indeterminate thyroid nodules in the SEAR
62027025|NCT05851404||Americas Region (AMR)|Patients that underwent thyroidectomy for indeterminate thyroid nodules in the AMR
62225983|NCT02608320|EXPERIMENTAL|Treatment Sequence (EDF) Position (RLR)|Participants will receive treatment E applied to right paraspinal side in period 1, then treatment D applied to left paraspinal side in period 2 and then treatment F applied to right paraspinal side in period 3.
62225984|NCT02608320|EXPERIMENTAL|Treatment Sequence (FED) Position (RLR)|Participants will receive treatment F applied to right paraspinal side in period 1, then treatment E applied to left paraspinal side in period 2 and then treatment D applied to right paraspinal side in period 3.
62225985|NCT02608320|EXPERIMENTAL|Treatment Sequence (EFD) Position (RLR)|Participants will receive treatment E applied to right paraspinal side in period 1, then treatment F applied to left paraspinal side in period 2 and then treatment D applied to right paraspinal side in period 3.
62589564|NCT03315286|EXPERIMENTAL|Device: SHADE Ultraviolet Sensor|Patients will receive an Ultraviolet (UV) sensor that will quantify their UV exposure through a linked smartphone application. Patients will also receive clinical counseling by their dermatologist regarding sun protection and avoidance
62225986|NCT02608320|EXPERIMENTAL|Treatment Sequence (FDE) Position (RLR)|Participants will receive treatment F applied to right paraspinal side in period 1, then treatment D applied to left paraspinal side in period 2 and then treatment E applied to right paraspinal side in period 3.
62225987|NCT02608320|EXPERIMENTAL|Treatment Sequence (DEF) Position (RLR)|Participants will receive treatment D applied to right paraspinal side in period 1, then treatment E applied to left paraspinal side in period 2 and then treatment F applied to right paraspinal side in period 3.
62225988|NCT02608320|EXPERIMENTAL|Treatment Sequence (DFE) Position (LRL)|Participants will receive treatment D applied to left paraspinal side in period 1, then treatment F applied to right paraspinal side in period 2 and then treatment E applied to left paraspinal side in period 3.
62800820|NCT00706446|ACTIVE_COMPARATOR|4 - LABA/ICS in the Arg/Arg genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Arg genotype
62589565|NCT03315286|ACTIVE_COMPARATOR|Standard of Care Counseling|Patients will receive clinical counseling by their dermatologist regarding sun protection and avoidance
62800821|NCT00706446|ACTIVE_COMPARATOR|5 - LABA/ICS in the Arg/Gly genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Gly genotype
62800822|NCT00706446|ACTIVE_COMPARATOR|6 - LABA/ICS in the Gly/Gly genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Gly-Gly genotype
62800823|NCT04404231|SHAM_COMPARATOR|No infrared light therapy|This arm does not receive any phototherapy
62800824|NCT04404231|ACTIVE_COMPARATOR|810 nm|Many clinical studies have used 810nm twice a week for 4 weeks. This is the standard.
62800825|NCT04404231|EXPERIMENTAL|945nm|This wavelength has been chosen as a comparison to 810, to see if it works better.
62800826|NCT04404231|EXPERIMENTAL|random frequency|A wavelength between 650-1100nm which is picked at random
62800827|NCT00191334|EXPERIMENTAL|A|
62800828|NCT04612166|EXPERIMENTAL|Intervention|Patients will receive a medication action plan approved by themselves and their primary care providers to reduce their medications. They will also receive check in calls and follow ups from study health coaches to monitor their progress. During health coaching sessions motivational interviewing techniques and patient empowerment strategies will be used by trained health coaches. Participants will also participate in assessments for the study (baseline and quarterly follow ups) and will complete up to 12 months of falls calendars.
62800829|NCT04612166|NO_INTERVENTION|Control|Will participate in assessments for the study (baseline and quarterly follow ups) and will complete up to 12 months of falls calendars. No intervention will be given to this group, but standard practices of care delivered by the MercyOneSM Health Network.
62800830|NCT04549545|ACTIVE_COMPARATOR|Vivaer Procedure|"The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal valves in a single study session. Each side of the nose will be treated with up to four (4) non-overlapping applications of RF energy at the junction of the upper and lower lateral cartilage on the lateral nasal wall. Treatment settings to be used are: temperature 60° C, power 4 watts, treatment time 18 seconds, and cooling time 12 seconds. No repeat (touch up) procedures will be permitted after the initial procedure through the end of the study (24 months)."
62800831|NCT04549545|SHAM_COMPARATOR|Sham Control Procedure|The sham control procedure will be performed in the study clinic using the Vivaer ARC Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
62800832|NCT03654794||Patients with hemochromatosis|"The study is conducted with mononuclear cells obtained from patients undergoing phlebotomy as part of a hemochromatosis treatment.~The blood samples will be recovered immediately after their completion. 40 mL of blood will be collected and the mononuclear cells separated using a ficoll gradient.~Cell pharmacokinetics of tacrolimus"
62800833|NCT04671433|EXPERIMENTAL|Experimental - Immediate Treatment|Intermediate dose.
62800834|NCT04671433|OTHER|Deferred Treatment|Deferred Treatment
62800835|NCT04671433|EXPERIMENTAL|Experimental Immediate Treatment|Low dose.
62800836|NCT00685165|EXPERIMENTAL|Primidone 50 mg Tablets|A single dose of primidone 50 mg administered after an overnight fast of at least 10 hours.
62800837|NCT00685165|EXPERIMENTAL|Primidone (Mysoline®) 50 mg Tablets|A single dose of Mysoline® 50 mg administered after an overnight fast of at least 10 hours.
62225989|NCT02608320|EXPERIMENTAL|Treatment Sequence (EDF) Position (LRL)|Participants will receive treatment E applied to left paraspinal side in period 1, then treatment D applied to right paraspinal side in period 2 and then treatment F applied to left paraspinal side in period 3.
62589566|NCT02669901|OTHER|Patients with opioid use disorder|All participants received Naloxone autoinjector as a preventative tool for accidental opioid overdose
62589567|NCT06403163||Transfused patients|patients who received an hemostatic product
62589568|NCT02481999||Study group: Patients|"470 children for elective surgery 0,5 to 8 years~Analysis of EEG data will divided in four age-related groups because of the different baseline EEG activity:~* 0.5 - 12 month: 5-7 Hz activity / blocked by eye opening~* 12 - 36 month: 7-8 Hz activity / Variability 5 - 10 Hz~* 3 - 6 years: 8 Hz activity / amplitude 100µV~* 6 - 8 years 10Hz activity / amplitude 100 µV"
62589569|NCT02481999||Control group: Healthy children for POCD assessment|80 healthy children (siblings of study group children and children from Kindergarten) 0,5 to 8 years with no operation
62800838|NCT03083366|EXPERIMENTAL|Sacral neuromodulation|Bilateral sacral neuromodulation will start within 3 months of spinal cord injury, as well as standard neurogenic bladder care.
62800839|NCT03083366|NO_INTERVENTION|Standard care|Patients will receive standard neurogenic bladder care.
62800840|NCT06483724|EXPERIMENTAL|Group 1 (n = 41) cervical tourniquet|"in group 1 the investigators using a sterile Foley catheter (Ch 16/18 French) down to the lowest point and secures it en bloc around the cervix at the level of the uterosacral ligaments, approximately 3-4 cm below the incision. Then, tighten and fix ."
62800841|NCT06483724|EXPERIMENTAL|Group 2 (n=41) uterine artery ligation|in group 2the investigators ligated the uterine vessels in a continuous manner at the level of the utero-vesical fold on each side.
62800842|NCT00808093|OTHER|fixed sequence|fixed sequence (14 days fasted followed by 14 days either high fat or standard meal
62800843|NCT02869633|EXPERIMENTAL|Treatment (ibrutinib)|Beginning between 60-90 days post donor stem cell transplant, patients receive ibrutinib PO QD until 1 year post donor stem cell transplant in the absence of disease progression or unacceptable toxicity.
62800844|NCT02356172||Healthy Controls|Healthy males or females who are greater than or equal to 18 years old.
62589570|NCT03014297|EXPERIMENTAL|everolimus + fosbretabulin|everolimus + fosbretabulin
62800845|NCT02356172||Patients|Males or females with a diagnosis of IGD (Isolated GnRH Deficiency) who are greater than or equal to 18 years old.
62800846|NCT03074708|OTHER|3D visualization and 3D printing|From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.
62800847|NCT06062979||Enhanced (MORE) implementation (i.e., MORE group)|Study participants in this condition will be those engaged in clinical care as part of the MORE program, receiving supportive, wrap-around, and home-based HIV care services; all participants will be offered injectable Cabenuva and studied with regard to uptake and outcomes. Participants in this group will receive quantitative health survey assessments as per standard of care at Whitman-Walker Health. Participants will be offered quantitative and qualitative assessments regarding their experiences related to Cabenuva.
62800848|NCT06062979||Standard-of-care implementation (i.e., comparison group)|Study participants in this comparison condition will be those engaged in clinical care receiving Cabenuva per standard of care at Whitman-Walker Health. Participants in this group will contribute ongoing electronic health record data under the auspices of an IRB-granted waiver of informed consent and waiver of HIPAA authorization.
62800849|NCT03360903|EXPERIMENTAL|Placebo then Caffeine|Anesthetized volunteers will be allowed to wake after injection of saline (placebo control) followed by a washout period and then anesthetized again and allowed to wake after injection of caffeine (15 mg/ kg).
62800850|NCT03360903|EXPERIMENTAL|Caffeine then Placebo|Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg) followed by a washout period and then anesthetized again and allowed to wake after injection of saline (placebo control).
62800851|NCT04149249|EXPERIMENTAL|Experimental: Intervention Group (CONNECT)|Patients complete CONNECT, the Video Doctor over 30-45 minutes on an iPad in the waiting room before their lung cancer screening test appointment.
62800852|NCT04149249|ACTIVE_COMPARATOR|Control Group|"Patients complete CONNECT assessment only over 30-45 minutes on an iPad in the waiting room before their lung cancer screening test appointment.~Individuals who are randomized to the control group will undergo the same assessment questions and all follow up assessments like the intervention group. Instead of viewing and participating in the interactive Video Doctor about Smoking Cessation, they receive a handout containing smoking cessation resources."
62800853|NCT01202266|EXPERIMENTAL|5 mg PF-05161704 or Placebo|
62800854|NCT01202266|EXPERIMENTAL|15 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
62800855|NCT01202266|EXPERIMENTAL|50 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
62800856|NCT01202266|EXPERIMENTAL|150 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
62800857|NCT01202266|EXPERIMENTAL|xx mg PF-05161704 or Placebo|Planned dose and dosing regimen will be determined based on emerging PK and safety data.
62800858|NCT01202266|EXPERIMENTAL|xxx mg PF-05161704 or Placebo|Dose will be determined based on data from previous 5 arms.
62800859|NCT01202266|EXPERIMENTAL|yy mg PF-05161704 or Placebo|Dose will be determined based on data from previous 6 arms
62800860|NCT01202266|EXPERIMENTAL|yyy mg PF-05161704 or Placebo|Dose will be determined based on data from previous 7 arms.
62800861|NCT04543773|EXPERIMENTAL|rTMS|Subjects will receive rTMS to the area of the DLPFC most anticorrelated with the ACC.
62800862|NCT00566423|EXPERIMENTAL|1|Patients with Pulmonary Arterial Hypertension
62800863|NCT05532358|EXPERIMENTAL|anle138b (TEV-56286) as perpetrator (part I)|"Drug: TEV-56286 300 mg QD (single dose and multiple dose for 14 days)~Victim drugs:~Caffeine 200 mg Midazolam 2 mg"
62800864|NCT05532358|EXPERIMENTAL|anle138b (TEV-56286) as victim (part II)|"Drug: fluvoxamine 100 mg QD for 5 days~Victim drug:~TEV-56286 150 mg QD for 14 days + 5 days of co-administation with fluvoxamine"
62735285|NCT04490525|EXPERIMENTAL|Intervention|The intervention group will participate in the telerehabilitation program (please see detailed description of telerehabilitation program and technologies). The two steps in the telerehabilitation program last up to six months depending on how fast the titration of medicine in step one will be conducted. The intervention group will spend 5-10 minutes every day on monitoring themselves. Every month, an online questionnaire has to be filled in which will take up to 5 minutes. At enrolment, after titration of medicine, and the end of rehabilitation, the patient will fill in an online questionnaire. This will take 5 minutes each time. Selected patients and relatives will be asked if they wish to participate in interviews after participation in the trial. Each interview will last less than one hour. Number of interviews will be decided when data saturation has been achieved.
62800865|NCT04714164|EXPERIMENTAL|Teletherapy Group CBT participants|Patients over the age of 65 with either a Major Depressive Disorder or Generalized Anxiety Disorder who will be participating in a Group CBT delivered by Teletherapy
62225990|NCT02608320|EXPERIMENTAL|Treatment Sequence (FED) Position (LRL)|Participants will receive treatment F applied to left paraspinal side in period 1, then treatment E applied to right paraspinal side in period 2 and then treatment D applied to left paraspinal side in period 3.
62225991|NCT02608320|EXPERIMENTAL|Treatment Sequence (EFD) Position (LRL)|Participants will receive treatment E applied to left paraspinal side in period 1, then treatment F applied to right paraspinal side in period 2 and then treatment D applied to left paraspinal side in period 3.
62225992|NCT02608320|EXPERIMENTAL|Treatment Sequence (FDE) Position (LRL)|Participants will receive treatment F applied to left paraspinal side in period 1, then treatment D applied to right paraspinal side in period 2 and then treatment E applied to left paraspinal side in period 3.
62225993|NCT02608320|EXPERIMENTAL|Treatment Sequence (DEF) Position (LRL)|Participants will receive treatment D applied to left paraspinal side in period 1, then treatment E applied to right paraspinal side in period 2 and then treatment F applied to left paraspinal side in period 3.
62225994|NCT02966951|EXPERIMENTAL|adipose tissue mesenchymal stem cell|Intra-articular adipose tissue derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of ATMSC in each dose
62589571|NCT06164847|EXPERIMENTAL|AERO Program|"Before their first physiotherapy appointment, patients will be asked to respond to four specific questions to guide the treatment (see link below).~After this, they will receive usual physiotherapy care and a HEP for managing osteoporosis. The number of exercises given for the HEP should minimally be three to maximum six, performed at least three days per week for 12 weeks (time of the final assessment).~After providing the HEP, patients in the intervention group are asked questions which explore their subjective abilities of the COM-B Model (capability, opportunity, or motivation) of undertaking the exercise program. Based on these answers and with the help of further discussions with the patient, the physiotherapist makes an assessment and decides which domains of the COM-B model might be useful to target. In the following 30 minutes PT-sessions, the therapist suggests one or more specific actions to enhance adherence. The participants must attend at least 4 out of 6 sessions."
62800866|NCT02938195|EXPERIMENTAL|experimental arm|PF regimen (cis-platinum of 25 mg/m2/d, d1-3; 5-fluorouracil of 500mg/m2/d, d1-4) every 4 weeks for 2 cycles concurrently with three-dimensional radiation therapy or intensity-modulated radiotherapy followed by surgery 4-8weeks after neoadjuvant therapy in a standard manner.
62800867|NCT05065905|EXPERIMENTAL|Interferon|"All participants receive subcutaneous interferon-gamma (Ingaron®) 500,000 IU alternated with Interal® (interferon alpha) 3,000,000 IU every other day~Interventions:~Drug: Ingaron® Drug: Interal® Drug: Antituberculosis complex therapy"
62800868|NCT05065905|EXPERIMENTAL|Interferon daily|"All participants receive subcutaneous interferon-gamma (Ingaron®) 500,000 IU given with Interal® (interferon alpha) 3,000,000 IU every day~Interventions:~Drug: Ingaron® Drug: Interal® Drug: Antituberculosis complex therapy"
62225995|NCT05185583|EXPERIMENTAL|Sequence A: Methylphenidate, Placebo|Participants will first receive methylphenidate capsules twice daily for four weeks. Doses will be administered four hours apart. The maximum dose is determined based on the participant's weight. After a 2-day washout, participants then receive Placebo (matching methylphenidate capsules) twice daily for four weeks.
62800869|NCT05065905|NO_INTERVENTION|Control|"All participants receive only basic antimicrobial treatment~Interventions:~Drug: Antituberculosis complex therapy"
62225996|NCT05185583|EXPERIMENTAL|Sequence B: Placebo, Methylphenidate|Participants will first receive Placebo capsules twice daily for four weeks. Doses will be administered four hours apart. After a 2-day washout, participants then receive methylphenidate capsules (matching Placebo capsules) twice daily for four weeks. The maximum dose is determined based on the participant's weight.
62800870|NCT00662207|EXPERIMENTAL|Arm 1|Use a vibrator on the patient's bottom to determine if it will induce a bladder contraction; Use an anal dilator to determine if urethral relaxation will occur
62225997|NCT06109675|EXPERIMENTAL|Education group|
62800871|NCT04067934|EXPERIMENTAL|Jumping exercise|High-impact exercise intervention: 3 sessions per week for four weeks Each session will consist of three jumping-based exercises, performed for three sets of various repetitions, following a progressive protocol with increasing volume/intensity.
62800872|NCT00871871|EXPERIMENTAL|Part I, Placebo-HCTZ|Placebo in Period 1 followed by HCTZ in Period 2
62800873|NCT00871871|EXPERIMENTAL|Part I, HCTZ-Placebo|HCTZ in Period 1, followed by placebo in Period 2
62225998|NCT06109675|NO_INTERVENTION|Control group|
62225999|NCT03905161||Myasthenia patients|Danish patients with myasthenia gravis seen at the Department of Neurology, Rigshospitalet
62226000|NCT01080495|OTHER|TEE (transesophageal echcardiography)|all patients get TEE and all parameters (radial strain, fractional shortening and fractional area change) are evaluated
62800874|NCT00871871|EXPERIMENTAL|Part II, Placebo-ISMN|Placebo in Period 1, followed by ISMN in Period 2
62800875|NCT00871871|EXPERIMENTAL|Part II, ISMN-Placebo|ISMN in Period 1, followed by placebo in Period 2
62800876|NCT01544426|EXPERIMENTAL|Office hysteroscopy and endometrial snip|Office hysteroscopy and endometrial snip
62800877|NCT01544426|ACTIVE_COMPARATOR|Office hyteroscopy|Office hysteroscopy
62800878|NCT05651100|EXPERIMENTAL|arm 1|sequential CD19 and CD22 targeted CAR-T cells treat
62800879|NCT04494035|EXPERIMENTAL|AVATR-Toronto|Thrombectomy of arteriovenous graft using CAPERE Thrombectomy System
62800880|NCT04452019|ACTIVE_COMPARATOR|Standing frame|Use of standard standing frame
62800881|NCT04452019|EXPERIMENTAL|"Innowalk Pro"|"Use of a new device; Innowalk Pro"
62800882|NCT06306209||MDD|80 patients with a depressive episode in course of major depression (MDD) and treated with SSRI's will be studied. The study does not include the evaluation of pharmacological treatments. The treatments will be administered in the judgment of the attending physician, independently of the experimental protocol.
62800883|NCT06270914|EXPERIMENTAL|Intervention|The intervention group will receive the intervention Norwegian manualized program of SW-PBIS, N-PALS (Positiv Atferd, Støttende Læringsmiljø, og Sammhandling).
62226001|NCT02684357|PLACEBO_COMPARATOR|Placebo (Part A)|Participants were randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
62589572|NCT06164847|ACTIVE_COMPARATOR|Standard care|"The control group will receive six PT sessions as standard care. The first session is 60 minutes and the following sessions are 30 minutes. In regular clinical practice, standard care for people with osteoporosis includes measures such as home exercise programs, mobilizations, soft tissue techniques, or training with gym equipment. The HEP in the control group is based on the physical assessment of the physical therapist. The therapists in the control group do not have any restrictions for the exercises chosen. The participants must attend at least 4 out of 6 sessions of the control program."
62589573|NCT05784324||Employees within the municipal health, care and welfare services|All employees within the municipal health, care and welfare services. No internvention. We investigate the relationship between caracteristics of their shift systems and potential outcomes.
62800884|NCT06270914|ACTIVE_COMPARATOR|Active control|Control group in the first wave of data collection is selected in accordance quasi-experimental design with nonequivalent control group. The teachers in the control group will, instead of a wait-list intervention, a shortened version of SW-PBIS containing only classroom leadership lectures. The schools that are part of the classroom management group also send staff for instructor training (ten training sessions, 25 hours in total, just as much as the SW-PBIS schools). Similar to the SW-PBIS group, the instructors in this group educate and supervise school staff, supported by a team at the school. Both groups have access to a manual and supporting materials. This design does not pose threats to the internal validity of the study, as classroom leadership is one of principles of PBIS framework. In this way it will be possible to explore the specific contribution of schoolwide PBS in contrast to classroom leadership only.
62800885|NCT06270914|NO_INTERVENTION|Control|Control group in the second wave of data collection constitutes a wait-list control group and will not be engaged in any kind of intervention during the intervention period.
62418944|NCT02837263|EXPERIMENTAL|SBRT + Pembrolizumab|Subjects will receive stereotactic body radiotherapy (SBRT) within 4 weeks of enrollment. Following SBRT, subjects will receive one cycle of pre-operative pembrolizumab given as an IV over approximately 30 minutes. Surgical management to remove all known sites of metastatic disease should occur 2 weeks post pembrolizumab treatment. Approximately 4-8 weeks after surgery subjects will being the second phase of pembrolizumab treatment. They will receive this treatment every 3 weeks (cycle) for 8 more cycles after surgery. Prior to the 5th cycle of pembrolizumab subjects will also have tumor imaging (CT or MRI).
62418945|NCT03760926|EXPERIMENTAL|May Health Procedure|May Health Procedure performed with use of the May Health Kit intended for transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to polycystic ovary syndrome.
62418946|NCT00792818|EXPERIMENTAL|curcuma domestica|1,500 mg/day (oral) divided into 3 times for 28 days
62418947|NCT00792818|ACTIVE_COMPARATOR|Ibuprofen|1,200 mg/day (oral) divided into 3 times for 28 days
62418948|NCT01066039|EXPERIMENTAL|Bisoprolol|
62418949|NCT03830229||1/Germline positive mesothelioma|Individuals with mesothelioma who have a BAP1 or other DNA repair/cancer predisposition mutation regardless of CLIA confirmation
62800886|NCT05229484|EXPERIMENTAL|Intervention Group: an integrated multimodal lifestyle intervention (MLifeI)|The MLifeI program focused on the roles of health responsibility, review of lipid profile, complications of imbalanced lipid profile, lipid management and nutritional education.
62800887|NCT05229484|NO_INTERVENTION|Control group|The control group is the Treatment as Usual (TAU).
62800888|NCT05862909|EXPERIMENTAL|Intervention group (IG 1)|CHD-specific web-based emotion regulation intervention
62800889|NCT05862909|ACTIVE_COMPARATOR|Intervention group (IG 2)|General web-based emotion regulation intervention
62800890|NCT05862909|NO_INTERVENTION|Waitlist control group (CG)|8-week waiting period
62800891|NCT03464409|ACTIVE_COMPARATOR|SCI Patient - Nerve Transfer Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury seeking nerve transfer surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline (pre-operatively), Early Followup (1 month post-operatively) and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
62226002|NCT02684357|ACTIVE_COMPARATOR|Ustekinumab (Part A)|Participants randomized to receive double-blind (DB) ustekinumab 45 or 90 mg (based on screening weight) by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
62418950|NCT03830229||2/CLIA confirmed germline mutation without mesothelioma|Individuals with a CLIA confirmed BAP1 or other DNA repair/cancer predisposition mutation who do not have a diagnosis of mesothelioma
62418951|NCT03148327|EXPERIMENTAL|Regimen A: Phase I|The intervention will be looking at radiotherapy + drug Durvalumab (MEDI 4736)
62418952|NCT03148327|EXPERIMENTAL|Regimen A: Phase II|The intervention will be looking at radiotherapy + drug Durvalumab (MEDI 4736)
62418953|NCT03148327|ACTIVE_COMPARATOR|Regimen B: Phase II|Radiotherapy alone
62418954|NCT03541668|EXPERIMENTAL|Group A|Recombinant human urokinase (rhPro-UK)
62418955|NCT03541668|ACTIVE_COMPARATOR|Group B|Alteplase(rt-PA)
62418956|NCT00358670|ACTIVE_COMPARATOR|Maintenance Infliximab|Infliximab 5 mg/kg by body weight every 8 weeks
62800892|NCT03464409|ACTIVE_COMPARATOR|SCI Patient - Tendon Transfer Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury seeking tendon transfer surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline (pre-operatively), Early Followup (1 month post-operatively) and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
62800893|NCT03464409|ACTIVE_COMPARATOR|SCI Patient - No Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury who did not chose to have surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline, Early Followup (1 month later), and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
62800894|NCT02657889|EXPERIMENTAL|niraparib plus pembrolizumab|"Phase 1: Dose-escalation: ascending doses of niraparib up to 300mg/day orally (PO) on Days 1-21 and pembrolizumab 200mg intravenously (IV) on Day 1 of each 21-day cycle~Phase 2: niraparib (recommended Phase 2 dose) in combination with pembrolizumab 200mg IV on Day 1 of each 21-day cycle"
62800895|NCT00574717|EXPERIMENTAL|A|Infants will receive spectacle under-correction of their hyperopia.
62800896|NCT04008875||Successful weaning/extubation|"Successful weaning will be defined as a patient who completes a planned 30-minute spontaneous breathing trial.~Successful extubation will be defined as a patient who completes a planned 30-minute spontaneous breathing trial and is not reintubated in the first 48 hours after extubation."
62800897|NCT04008875||Failed weaning/extubation|"Failed weaning will be defined as a patient who did not complete a planned 30-minute spontaneous breathing trial.~Failed extubation will be defined as a patient who did not complete a planned 30-minute spontaneous breathing trial, in the first 48 hours after extubation are reintubated, have unplanned non-invasive ventilation (NIV) or who have a tracheostomy."
62800898|NCT02719613|EXPERIMENTAL|Elotuzumab|This is a continuation roll-over study for patients receiving benefit from prior elotuzumab protocols. All participants will receive elotuzumab and/or other study drugs as per previous protocol.
62800899|NCT02610686|OTHER|Chloroquine|Single treatment arm
62800900|NCT02917135||Angel® Catheter|All consecutive, hospitalized patients in whom the Angel® Catheter is placed, or there has been an attempt to place, at selected Registry sites.
62800901|NCT06173583||Adult In-patient Cardiac surgery|Adult patients undergoing elective open-heart surgery
62800902|NCT03461107||patients with heart failure|
62800903|NCT02037139|ACTIVE_COMPARATOR|Control (screening)|screening only (standard care control)
62800904|NCT02037139|ACTIVE_COMPARATOR|Educational brochure|Screening + illustrated educational brochure
62800905|NCT02037139|EXPERIMENTAL|Education|Screening + illustrated educational brochure + an in-person educational intervention
62800906|NCT02792478||RAS wild-type subjects|The blood samples will be collected according to the site's routine clinical practice usually prior to each treatment cycle and at the follow-up visits. Analysis of the RAS mutation status will be carried out on blood samples taken at baseline, on those carried out at 20 +/-2 weeks after the start of treatment (in any case, prior to the second tumour assessment) and on the sample obtained upon progression, coinciding with routine clinical practices for collecting blood. Blood Samples will be collected to all subjects participating (119 subjects.)Objective to evaluate the RAS mutation status at baseline in liquid biopsies in subjects with RAS wild type metastatic colorectal cancer.
62027026|NCT05851404||Eastern Mediterranean Region (EMR)|Patients that underwent thyroidectomy for indeterminate thyroid nodules in the EMR
62226003|NCT02684357|EXPERIMENTAL|Risankizumab (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
62800907|NCT02792478||Patient RAS WT|As in cohort 1 blood samples will be collected for all subjects participating (119) 10 ml will be used for analysis of the RAS mutation status. The mutation status of BRAF and EGFR will be also analysed with the IdyllaTM (Biocartis) tests in this Cohort 2. In 20 patients included in Cohort 2, 10 ml additional taken at baseline will be used in order to determine the RAS mutation status by the BEAMing technique and 10 ml additional taken at disease progression will be used to determine the mutational profile in genes other than RAS by a NGS technique.
62800908|NCT04838535|OTHER|PCOS follicular fluid|
62800909|NCT05788055||Acute Coronary Syndrome Patients|Stool Analysis will be done for all cases to detect H.pylori Antigen and results will be analysed into infected patients and non infected patients.
62800910|NCT05788055||Chronic Stable Angina Patients|Stool Analysis will be done for all cases to detect H.pylori Antigen and results will be analysed into infected patients and non infected patients.
62800911|NCT06198387|EXPERIMENTAL|hormone and RT|Patients with de novo oligo-metastatic prostate cancer will receive a two-year course of androgen deprivation therapy (ADT) in combination with abiraterone, along with synchronous metastasis-directed radiation and prostate radiotherapy.
62800912|NCT02316418|EXPERIMENTAL|Hairstetics™ anchoring system|Prosthetic hair implantation using the Hairstetics™ anchoring system, followed by attachment of hair extensions.
62800913|NCT06457061||Right Hemiplegia|
62800914|NCT06457061||Left Hemiplegia|
62800915|NCT06423469||TBI patients|TBI patients to be monitored daily with the brain4care system for fifteen days
62418957|NCT00358670|EXPERIMENTAL|Intermittent Infliximab|Infliximab 5 mg/kg by body weight at Weeks 0, 2, 6 and 14 following a 50% reduction in Psoriasis Area and Severity Index (PASI) from the Study P04271 Baseline
62418958|NCT01260168||Colorectal cancer patients|Subjects will be men and women, 40-90 years of age, inclusive, each with a colonoscopic biopsy-based diagnosis of colorectal cancer (CRC) and/or an intact pre-malignant colorectal lesion large enough to require surgical excision or complex colonoscopic polypectomy.
62418959|NCT03443973|EXPERIMENTAL|Gantenerumab|Gantenerumab will be administered as SC injections with gradual uptitration.
62418960|NCT03443973|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as SC injections with gradual uptitration.
62418961|NCT00317967|EXPERIMENTAL|1|Atorvastatin
62418962|NCT00317967|PLACEBO_COMPARATOR|2|Placebo
62418963|NCT03852407|EXPERIMENTAL|Fludarabine-Melphalan-Cyclophosphamide|FM-PTCy conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and cyclophosphamide 50 mg/kg on days +3 and +4.
62589574|NCT05784324||Employees within the municipal health, care and welfare services 2|Employees within the municipal health, care and welfare services, replying to a survey. Sample is drawn by representative unions. No internvention. We investigate the relationship between caracteristics of their shift systems and potential outcomes.
62800916|NCT06000748|ACTIVE_COMPARATOR|Low MAP-Target|This group will be randomized to a treatment algorithm that utilizes a low MAP-target (\<80 mmHg) to determine if titration of vasoconstrictors is needed.
62800917|NCT06000748|ACTIVE_COMPARATOR|High MAP-Target|This group will be randomized to a treatment algorithm that utilizes a high MAP-target (≥80 mmHg) to determine if titration of vasoconstrictors is needed.
62800918|NCT06444035|EXPERIMENTAL|Treatment of myofascial pain syndrome by local injection of pain points|Subjects received subcutaneous injection of HA35 injection 100mg / 5mL / day near the back pain point for 15 days.
62800919|NCT00600951||1|Patients with moderate chronic kidney disease (stage 3, according to the classification of chronic kidney disease by the National Kidney Foundation, i.e., with eGFR comprised between 30 and 59 mL/min/1.73m2)
62418964|NCT03852407|EXPERIMENTAL|Fludarabine-Melphalan-thymoglobulin|FM-ATG conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and ATG (Thymoglobulin®, Genzyme), at a dose of 2.5 mg/kg/d on days -2 and -1.
62418965|NCT06430307|EXPERIMENTAL|Saussurea Involucrata Liquid Tonic|Saussurea Involucrata Liquid Tonic 20ml/time, 2 times a day, orally on an empty stomach. Total treatments 8 weeks, followed up to 12 weeks.
62418966|NCT06430307|PLACEBO_COMPARATOR|placebo of Saussurea Involucrata Liquid Tonic|placebo of Saussurea Involucrata Liquid Tonic 20ml/time, 2 times a day, orally on an empty stomach. Total treatments 8 weeks, followed up to 12 weeks.
62589575|NCT05784324||Users of the municipal health, care and welfare services.|Users of the municipal health, care and welfare services.No internvention. We investigate the relationship between caracteristics of the shift systems worked and potential outcomes for users.
62589576|NCT04335981|EXPERIMENTAL|FT-CC and Swallow Exercises|
62589577|NCT04335981|ACTIVE_COMPARATOR|Swallow Exercises|
62800920|NCT00600951||2|Patients with severe chronic kidney disease or kidney failure (stages 4 and 5, according to the classification of chronic kidney disease by the National Kidney Foundation, i.e., with eGFR stably below 30 mL/min/1.73m2)
62800921|NCT03309748|ACTIVE_COMPARATOR|Dental Prophylaxis|Standard dental prophylaxis
62800922|NCT03309748|ACTIVE_COMPARATOR|Dental prophylaxis + antimicrobial photodynamic therapy|Dental prophylaxis + aPDT
62800923|NCT01695135|EXPERIMENTAL|Abiraterone acetate plus prednisone|
62800924|NCT01695135|EXPERIMENTAL|Placebo plus prednisone|
62800925|NCT02720341|EXPERIMENTAL|ARMin|Therapy on ARMin robotic device
62800926|NCT04835779||SFN Patients|Patients with diagnosed Small Fibre Neuropathy
62800927|NCT04835779||Patients undergoing chemotherapy|Patients undergoing chemotherapy and are expected to develop SFN as a result
62800928|NCT04835779||Healthy Volunteer|Healthy test person
62800929|NCT04835779||Healthy Volunteer PREPs|For the pain-evoked potentials (PREPs), 20 additional healthy control subjects are to be included. Four subjects (2 male, 2 female) from each of the age decades 20-29, 30-39, 40-49, 50-59, 60-69.
62800930|NCT00725595||E, 2, III|To treat CSR with ASV and Bilevel ventilators
62800931|NCT03835299|NO_INTERVENTION|Fear Control|Participants who report blood donation-related fear who are assigned to this study arm will answer several questions then proceed through the normal blood donation process.
62027027|NCT05851404||the Europe Region (EUR)|Patients that underwent thyroidectomy for indeterminate thyroid nodules in the EUR
62027028|NCT05851404||Western Pacific Region (WPR)|Patients that underwent thyroidectomy for indeterminate thyroid nodules in the WPR
62800932|NCT03835299|EXPERIMENTAL|Fear Intervention|Participants who report blood donation-related fear who are assigned to this study arm will answer several questions and view a brief presentation of coping strategies presented via a computer tablet. They will then proceed through the normal blood donation process.
62800933|NCT03835299|NO_INTERVENTION|No Fear Control|Participants who report no blood donation-related fear will proceed through the normal blood donation process.
62800934|NCT01473732|EXPERIMENTAL|Everolimus (Zortress)|
62027029|NCT03033303|EXPERIMENTAL|Hu3F8/GM-CSF Plus Isotretinoin|In this phase II single arm trial, patients with HR-NB in first CR or VGPR undergo consolidation by using hu3F8/GM-CSF x5 cycles and isotretinoin x6 cycles. Isotretinoin starts after cycle 2 of hu3F8/GM-CSF.
62800935|NCT01473732|ACTIVE_COMPARATOR|Reduced dose Tacrolimus (Prograf)|
62800936|NCT04012580|EXPERIMENTAL|Therapist-assisted ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. In addition to the program, participants will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact provided on a weekly basis.
62800937|NCT04012580|NO_INTERVENTION|Treatment as usual control|Participants will not receive access to the transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) program for 12-weeks. Participants will be permitted to access community resources (e.g., support groups). After 12-weeks, participants will be offered the program although their treatment data will not be included in the current study.
62800938|NCT01744249|EXPERIMENTAL|Axitinib + Sandostatin LAR|Axitinib 5 mg BID + Sandostatin LAR 30mg/28 days
62800939|NCT01744249|PLACEBO_COMPARATOR|Placebo + Sandostatin LAR|Placebo BID + Sandostatin LAR 30mg/28 days
62800940|NCT02664662|EXPERIMENTAL|tailored education|Tailored rehabilitated education is which fit for each breast cancer patients after surgery in clinic. We design three of tailored books for experimental group. Each patients will be tailored by three principles. First, the educated times and hours are depended on patients physical function and learning ability. Second, the material is depended on each patient's life experience. Finally, the educated content is depended on patient's operation method.
62800941|NCT02664662|NO_INTERVENTION|standard education|Only provide one paper of post operation and give education of rehabilitated exercise
62027030|NCT03912857|EXPERIMENTAL|test group|"Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.~Apatinib :250 mg or 375 mg, qd"
62027031|NCT03721380|EXPERIMENTAL|BDRC|At the time of assignment to the counseling intervention arm of the study, there will be an initial meeting between the subject and the assigned counselor. As described in the counseling manual, this initial session is designed to introduce the counselor, review the purpose and expectations of counseling, review the rules of confidentiality, agree on attendance times and rescheduling rules, and to begin to collect information from the participant on their drug use and risk behaviors. Behavioral contracting is a key component to this counseling approach.
62226004|NCT03975595|ACTIVE_COMPARATOR|Meditation Group A|"A brief meditation intervention involving guided breathing and/or attention exercises (further information withheld to preserve blinding).~Meditation Group A is the Savoring Meditation Condition. Participants in this condition were trained to generate positive emotions through savoring a pleasant autobiographical memory in a multi-sensory manner."
62589578|NCT04231929|EXPERIMENTAL|BioPearl™ loaded with doxorubicin|Chemoembolization with doxorubicin-loaded BioPearl™ microspheres
62800942|NCT06436534|EXPERIMENTAL|Ganciclovir|"Screening phase(Day -14±2\~0):Mometasone furoate nasal spray(50μg/spray), take 1 spray once a day.~Treatment phase(Day 1\~14±2): Ganciclovir capsules(250mg), take 2 capsules twice a day + Mometasone furoate nasal spray(50μg/spray), take 1 spray once a day.~Follw-up phase(Day 14\~28±2):Mometasone furoate nasal spray(50μg/spray), take 1 spray once a day."
62800943|NCT06436534|PLACEBO_COMPARATOR|Placebo|"Screening phase(Day -14±2\~0):Mometasone furoate nasal spray(50μg/spray), take 1 spray once a day.~Treatment phase(Day 1\~14±2): Ganciclovir simulant capsules(0mg), take 2 capsules twice a day + Mometasone furoate nasal spray(50μg/spray), take 1 spray once a day.~Follw-up phase(Day 14\~28±2):Mometasone furoate nasal spray(50μg/spray), take 1 spray once a day."
62800944|NCT06117436|NO_INTERVENTION|Control Group|patients will receive standard wound care and diabetes management (that includes bed rest with elevation, antibiotics, analgesics, and dressings).
62800945|NCT06117436|ACTIVE_COMPARATOR|Cilostazol Group|patients will receive Cilostazol 100 mg tablets per oral once daily in addition to standard wound care and diabetes management.
62027032|NCT03721380|OTHER|TAU|Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs.
62027033|NCT02609243|ACTIVE_COMPARATOR|intensive consulting, conventional diet|subjects receive 16 units of nutritional consulting, first 3 weeks of intervention phase are designed as a conventional hypocaloric low-fat diet referring to DGE guidelines (below 30 % fat), followed by 11 months of isocaloric-to-moderate-hypocaloric low-fat diet (below 30 kcal% fat ) - dietary intervention without supplement
62226005|NCT03975595|ACTIVE_COMPARATOR|Meditation Group B|"A brief meditation intervention involving guided breathing and/or attention exercises (further information withheld to preserve blinding).~Meditation Group B is the Breathing Meditation Condition. Participants in this condition were trained to relax and body and take deep breaths in a self-directed manner."
62226006|NCT02868866|EXPERIMENTAL|Immediate intervention|Training of church committee followed by 12 months of technical assistance phone calls.
62418967|NCT06568120|NO_INTERVENTION|Standard care|Children aged 3-6 who require nebulizer treatment in the emergency department, along with their families, will first be informed by one of the researchers. Then, children who are randomly assigned to the control group will be treated according to the institution's standard care procedures. The child and their family will be informed immediately before the treatment procedure. During the treatment, the child will be treated using a standard nebulizer mask appropriate for their age, in accordance with the institution's routine care procedures, and the parent will remain with the child throughout the treatment. The child's level of fear will be assessed by both the child and the nurse before and during the treatment. Additionally, the nurse will record the total duration of inhaler treatment and the child's adherence to the treatment.
62800946|NCT06117436|ACTIVE_COMPARATOR|Cilostazol & Selenium Group|Cilostazol 100 mg tablets plus Selenium 200 mcg tablets per oral once daily, in addition to standard wound care and diabetes management.
62800947|NCT05177614|EXPERIMENTAL|Upper-level multiple micronutrient-fortified bouillon cube|10 gram shrimp-flavoured bouillon cube, consumed ad-lib, fortified with six micronutrients
62800948|NCT05177614|EXPERIMENTAL|Lower-level multiple micronutrient-fortified bouillon cube|10 gram shrimp-flavoured bouillon cube, consumed ad-lib, fortified with six micronutrients
62589579|NCT04724343|ACTIVE_COMPARATOR|Agonist Group (Long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
62589580|NCT04724343|EXPERIMENTAL|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
62589581|NCT03774524|ACTIVE_COMPARATOR|Misoprostol with TA|400 μg of sublingual misoprostol (two tablets) plus 1 gm tranexamic acid in 100 ml saline by iv rout
62800949|NCT05177614|PLACEBO_COMPARATOR|Control (iodine-fortified bouillon cube)|10 gram shrimp-flavoured bouillon cube, consumed ad-lib, fortified with one micronutrient
62589582|NCT03774524|ACTIVE_COMPARATOR|Misoprostol with placebo to TA|400 μg of sublingual misoprostol (two tablets) plus 110 ml saline by iv rout
62589583|NCT03774524|PLACEBO_COMPARATOR|placebo to Misoprostol with placebo to TA|placebo to misoprostol plus placebo to tranexamic acid
62589584|NCT04434469|EXPERIMENTAL|Arm A Flat Dose Escalation: RO7297089|Participants in Arm A will receive the target dose of RO7297089 as a flat dose at each scheduled study drug administration visit
62589585|NCT04434469|EXPERIMENTAL|Arm B Split Dose Escalation: RO7297089|Participants in Arm B will receive the first target dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose will be administered at subsequent study drug administration visits.
62800950|NCT04258930|ACTIVE_COMPARATOR|Group A: Aluminum sulphate and calcium acetate drying soaks|Group A will receive 10 minute soaks every 8 hours with a solution prepared with aluminum sulphate and calcium acetate powder (Domeboro® (Advaita Pharmaceuticals, México)) diluted in 500 ml of clean cold water.
62800951|NCT04258930|EXPERIMENTAL|Group B: Topical sterile silicone gel for wounds|Group B will receive topical silicone sterile gel for wounds (Stratamed gel®, (Stratapharma, Switzerland)) applied every 8 hours.
62226007|NCT02868866|NO_INTERVENTION|Delayed intervention|20 churches are followed but receive no intervention.
62800952|NCT04258930|EXPERIMENTAL|Group C: Hydrocolloid dressing|Group C will apply an extra thin hydrocolloid dressing to all the open areas (Duoderm Extra Thin® (Convatec, USA)) with dressing changes every 48 to 72 hours depending on the amount of wound exudate.
62800953|NCT06333379||IPA group|Investigators enrolled patients who meet diagnostic criteria for IPA according to EORTC/MSG: new exudative lung lesions unresponsive to antimicrobial therapy; positive Aspergillus on LRT and/or BALF microscopy cultures, positive BALF GM and positive BALF NGS results for Aspergillus. Investigators will test and compare the EBC-GM and BALF-GM levels in these patients.
62226008|NCT02354508|EXPERIMENTAL|Pasireotide LAR|Patients who qualify for the core phase of the study will be treated with pasireotide LAR 40 mg initially. Patients not achieving biochemical control can be up-titrated to pasireotide LAR 60 mg.
62589586|NCT04434469|EXPERIMENTAL|Arm C Step Dose Escalation: RO7297089|No participants enrolled. Enrollment for the GO41582 study was stopped in July 2021 due to limited activity as a single agent which did not meet the Sponsor's internal criteria for further clinical development.
62589587|NCT04434469|EXPERIMENTAL|Phase I Expansion Stage: RO7297089|No participants enrolled. Enrollment for the GO41582 study was stopped in July 2021 due to limited activity as a single agent which did not meet the Sponsor's internal criteria for further clinical development.
62589588|NCT00076752|EXPERIMENTAL|Autologous HSCT in SLE|"Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).~SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion."
62800954|NCT06333379||control group|Investigators enrolled patients who were mechanically ventilated patients without Aspergillus infection or colonization. BALF and EBC samples from the same patients were collected less than 4 hours apart, and BALF samples were used for NGS and microbiological cultures. Investigators will test and compare the EBC-GM and BALF-GM levels in these patients.
62800955|NCT06144463|NO_INTERVENTION|Control group|No intervention will be given
62800956|NCT06144463|SHAM_COMPARATOR|traditional group|Non-invasive cardiac output monitoring ( NICOM ) assisted fluid resuscitation.
62800957|NCT06144463|EXPERIMENTAL|LUGFR group|lung ultrasound-guided fluid resuscitation
62800958|NCT04806971||Periodontitis|Patients with grade B / C, stage III periodontitis were classified based on the new classification criteria.Clinical attachment loss ≥5 mm, probing depth (PD) ≥6 mm, ≥20 teeth and radiographic bone loss extending to the root middle third. Grade was assessed considering the radiographic bone loss in the most affected tooth in the dentition as a function of age (Grade B=0.25-1.0, Grade C= \>1.0).
62027034|NCT02609243|ACTIVE_COMPARATOR|conventional consulting, low-carb diet|subjects receive 8 units of nutritional consulting, first 3 weeks of intervention phase are designed as a very-low calory ketogenic (low-carb) diet (\< 40 g CH / day), following 11 months are restricted to not more than 40 % energy intake by carbohydrates under isocaloric-to-moderate-hypocaloric conditions - dietary intervention without supplement
62027035|NCT02609243|ACTIVE_COMPARATOR|conventional consulting, conventional diet|subjects receive 8 units of nutritional consulting, first 3 weeks of intervention phase are designed as a conventional hypocaloric low-fat diet referring to DGE guidelines (below 30 % fat), followed by 11 months of isocaloric-to-moderate-hypocaloric low-fat diet (below 30 kcal% fat) - dietary intervention without supplement
62027036|NCT02609243|ACTIVE_COMPARATOR|intensive consulting, low-carb diet|subjects receive 16 units of nutritional consulting, first 3 weeks of intervention phase are designed as a very-low calory ketogenic (low-carb) diet (\< 40 g CH / day), following 11 months are restricted to not more than 40 % energy intake by carbohydrates under isocaloric-to-moderate-hypocaloric conditions - dietary intervention without supplement
62027037|NCT03674177|EXPERIMENTAL|RSV MAT formulation 1 Group|Subjects received a single dose (30 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
62027038|NCT03674177|EXPERIMENTAL|RSV MAT formulation 2 Group|Subjects received a single dose (60 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
62027039|NCT03674177|EXPERIMENTAL|RSV MAT formulation 3 Group|Subjects received a single dose (120 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
62418968|NCT06568120|EXPERIMENTAL|Dragon Mask Group|Children who present to the emergency department and require nebulizer treatment will be randomly assigned to either the experimental or control groups. First, one of the researchers will meet with the child and their parent to provide information about the study. If the child and family agree to participate and are assigned to the experimental group, the child will be asked which mask design they prefer to use during the inhaler treatment: a dragon or a turtle. Additionally, before the treatment, the fear level of each child will be assessed by both the child and the nurse. During the treatment process, the children will receive nebulizer treatment appropriate for their age, and the duration and adherence to the treatment will be recorded by the nurse. Similarly, fear levels will be measured immediately before and during the treatment.
62418969|NCT04717869||ICU Patients|Adult Surgical, Cardiothoracic, and Neuro- ICU patients will be enrolled within 48 hrs of admission
62418970|NCT04141761|EXPERIMENTAL|Treatment Group|
62418971|NCT04141761|PLACEBO_COMPARATOR|Placebo Group|
62589589|NCT04185012|EXPERIMENTAL|Benralizumab|Benralizumab 30 mg administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks, for a treatment-period of 16 weeks
62589590|NCT04185012|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks, for a treatment-period of 16 weeks
62800959|NCT04806971||Healthy|The periodontally healthy subjects without any clinical sign of inflammation,not showing a history of periodontitis; PD ≤3 mm; \<10% of sites with BOP; an absence of detectable bone loss and/or attachment ; without extensive caries or restorations and presence of at least 28 permanent teeth. In addition, all the control subjects showed the absence of any local or systemic pathology.
62800960|NCT05064371|EXPERIMENTAL|Eptinezumab|Participants will receive eptinezumab 100 milligrams (mg) at the Baseline visit (Week 0) and eptinezumab 100 mg or 300 mg (depending upon the treatment response) at Weeks 12, 24, 36, and 48 by intravenous (IV) infusions.
62800961|NCT01861626|OTHER|sequence 1 : Test drug - Reference|
62800962|NCT01861626|OTHER|Sequence 2 : Reference - Test drug|
62800963|NCT01909999|EXPERIMENTAL|Immediate loading implants|The clinical and immunological comparisons compared implants that received Immediate loading prosthesis, i.e., full arch Branemark protocol prosthesis installed within 3 days after surgery, with unloaded implants.
62226009|NCT00004145|EXPERIMENTAL|Arm A|Fludarabine (30mg/m2/day x 5 days on days -9 to -5), cyclophosphamide (2gm/m2/day on day -5), antithymocyte globulin (10mg/kg/day x 4 days on days -5 to -2), tacrolimus (.03 mg/kg/day IVPB continuous infusion), mycophenolate mofetil (1mg PO BID, days +1 to +60), allogenic peripheral blood stem cells
62226010|NCT01730794|OTHER|Conventional Lung Protective Ventilation|In this group, patients will be ventilated in either volume A/C, pressure A/C, pressure support, pressure regulated volume control or volume support based on the discretion of the medical team with TV 4-8 ml/kg PBW range and PP or pressure (control or support) level \<30 cmH2O.
62418972|NCT03811366|OTHER|Corticosteroid monotherapy|"All patients in the acute phase will be treated with corticosteroid monotherapy, unless presents a contraindication or persistence/ recurrence of inflammation with regressive corticosteroid monotherapy.This is the unique arm of the present study.~Treatment protocol includes a three-day course of intravenous methylprednisolone (1000 mg per day) followed by a high dose of oral prednisone (1.0 mg/kg/day) with a slow tapering with dose equal or less than 0.1mg/kg/day after 10 months. The prednisone dose is scheduled to be reduced in a 0.1 mg/kg-step ladder until it reaches 0.3 mg/kg (i.e. for an individual with 60 kg, dose would be 20 mg): from 1 to 0.8 mg/kg every two to three weeks; at 0.7 mg/kg for 4 weeks; at 0.6 mg/kg for two to three weeks; from 0.5 mg/kg every 4 weeks; from 0.3 to 0.15 mg/kg every 6 weeks; and 0.1 mg/kg, 0.075 mg/kg and 0.05 mg/kg for 8 weeks each."
62418973|NCT02587000|ACTIVE_COMPARATOR|Ulipristal acetate|ESMYA® : 2 tablets of 5mg per day during 3 months, per os
62418974|NCT02587000|PLACEBO_COMPARATOR|Placebo|2 tablets of 5mg per day during 3 months, per os
62418975|NCT02757261|EXPERIMENTAL|Application of Low-level laser therapy.|The intervention will be twelve sessions (two per week). Laser parameters: wavelength - 786.94 nm; conventional tip; energy density - 25 J/cm²; intensity - 1.675 mW/cm²; output power - 70 mW (0.070 W); and exposure time - 20 seconds per point. The point application method will be used with direct contact with the skin (spot beam of 0.04 cm²), following the protocol suggested by Carvalho et al.50 and Venezian et al.44 A potentiometer will be used to determine the mean power of the laser equipment to ensure the safety of the operator.
62418976|NCT02757261|EXPERIMENTAL|Treatment with Occlusal splint.|The intervention will be a maxillary occlusal splint will be used on the maxilla with palatal and occlusal coverage. Following the protocol established by Hachmann et al., the children will only use the splint at night for two months, with weekly adjustments of a quarter turn.46
62418977|NCT02757261|ACTIVE_COMPARATOR|Placebo laser|Placebo laser will be performed using the same equipment.
62418978|NCT02757261|NO_INTERVENTION|Children without bruxism|Control group
62418979|NCT00002879|EXPERIMENTAL|cladribine|Patients receive cladribine (2-chlorodeoxyadenosine; 2-CdA) daily for 5 days every 4 weeks for a maximum of 6 courses; response is assessed after every 2 courses. Patients in complete remission or with stable disease discontinue treatment and are followed; those with disease progression at any time are removed from study. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and annually for 2 years.
62418980|NCT04057352|OTHER|Citadel Embolization Device|The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.
62418981|NCT01585064||DAS28-IOMS|Physicians randomized to the DAS28-IOMS will treat patients according to a protocol aimed at achieving a DAS28 score under 2.4.
62418982|NCT01585064||0SJ-IOMS|Physicians randomized to the 0SJ-IOMS will treat patients according to a protocol aimed at attaining a count of zero swollen joint (28 joints evaluated).
62418983|NCT01585064||Routine Care (RC)|Physicians randomized to the RC group will treat study patients as per routine care and according to their own judgment.
62418984|NCT03821688|EXPERIMENTAL|SAS-JB|laparoscopic single anastomosis sleeve jejunal bypass
62418985|NCT03821688|ACTIVE_COMPARATOR|MGB|laparoscopic mini gastric bypass
62418986|NCT03821688|ACTIVE_COMPARATOR|LSG|laparoscopic sleeve gastrectomy
62418987|NCT01097850|OTHER|Right|Application of henna paste to right hand/foot plus CeraVe moisturizer
62418988|NCT01097850|OTHER|Left|Application of henna paste to the left hand/foot plus CeraVe moisturizer
62418989|NCT05660837|EXPERIMENTAL|T1: Mixed mode social support group|This group will receive programs in both online and off-line setting. There will be one face-to-face group session to get to know participant's peer group members. After the in-person group meeting, participants will meet in WhatsApp group. In WhatsApp group, facilitator will provide the following program
62418990|NCT05660837|EXPERIMENTAL|Online social support group|This group will receive the same program as mixed mode social support group. The key differences would be delivery of all program components online.
62418991|NCT05660837|NO_INTERVENTION|Control|"This is the control group.~Control group will only participate in baseline and follow-up survey"
62418992|NCT05724576|EXPERIMENTAL|Low dose allogeneic mesenchymal stromal cells|Intracoronary administration 1.5 x 10\^7 OmniMSC-AMI in first AMI patients who just underwent primary PCI
62418993|NCT05724576|EXPERIMENTAL|High dose allogeneic mesenchymal stromal cells|Intracoronary administration 3.0 x 10\^7 OmniMSC-AMI in first AMI who just underwent primary PCI
62418994|NCT06551948|EXPERIMENTAL|Psyllium|15 g psyllium
62589591|NCT06328816|EXPERIMENTAL|routine rehabilitation treatment+Computer-assisted Cognitive Function Training|In this study, each patient received a continuous 15-day treatment. During the treatment, both groups of patients received routine rehabilitation treatment. The experimental group additionally underwent computer-assisted cognitive training, which generated training content of corresponding difficulty based on the patient's cognitive impairment assessment results. The training was conducted seven days a week, once a day, for a duration of 30-45 minutes per session.
62589592|NCT06328816|ACTIVE_COMPARATOR|routine rehabilitation treatment|In this study, each patient received a continuous 15-day treatment. During the treatment, both groups of patients received routine rehabilitation treatment.The control group was given conventional cognitive training.
62589593|NCT05877690|EXPERIMENTAL|Group M|
62418995|NCT06551948|EXPERIMENTAL|methylcellulose|15 g methylcellulose
62418996|NCT06551948|PLACEBO_COMPARATOR|Maltodextrin|15 g maltodextrin
62418997|NCT04442763|EXPERIMENTAL|Densah burs|Osseodensification using Densah burs
62418998|NCT04442763|ACTIVE_COMPARATOR|Standard drills|conventional drilling using standard drills
62418999|NCT04700215|ACTIVE_COMPARATOR|Group 01 Effectiveness of BiPAP in reducing post CABG pulmonary complications|Bilevel positive airway pressure device after every 6 hours
62027040|NCT03674177|PLACEBO_COMPARATOR|Control Group|Subjects received a single placebo saline injection at Day 1, intramuscularly into the deltoid region of the non-dominant arm
62027041|NCT01437592|EXPERIMENTAL|IDeg|
62226011|NCT01730794|OTHER|NAVA Ventilation Group|In the NAVA group, NAVA level will be set initially at zero, then the maximum Edi will be determined as the average level over the next 3 to 5 breaths without ventilatory support or PEEP. The actual NAVA level will then be titrated by the clinician to achieve the following: 1) an Edi equal to approximately 50% of the maximum Edi, 2) an average tidal volume of between 4 to 8 ml/kg predicted body weight (PBW), and 3) an average respiratory rate between about 15 and 40 per minute. In addition, the trigger sensitivity should be set as sensitive as possible without causing auto-triggering and the maximum pressure limit in NAVA should be set at 40 cm H2O.
62027042|NCT02460991|EXPERIMENTAL|DEB-TACE|ONCO-DOX (Doxorubicin loaded Microspheres) up to 150 mg per treatment; treatments can be repeated every 4-8 weeks until complete tumor response is achieved.
62027043|NCT02460991|ACTIVE_COMPARATOR|Sorafenib|200 mg Sorafenib twice daily; continue until unacceptable toxicity or unequivocal tumor progression
62027044|NCT04040803|EXPERIMENTAL|10 Hz tACS|"Stimulation will be applied at 10 Hz tACS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.~10 Hz tACS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
62027045|NCT04040803|EXPERIMENTAL|20 Hz tACS|"Stimulation will be applied at 20 Hz tACS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.~20 Hz tACS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
62027046|NCT04040803|EXPERIMENTAL|70Hz tACS|"Stimulation will be applied at 70 Hz tACS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.~70 Hz tACS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
62027047|NCT04040803|EXPERIMENTAL|0.1-640Hz tRNS|"Stimulation will be applied at 0.1-640Hz tRNS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.~0.1-640Hz tRNS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
62027048|NCT04040803|SHAM_COMPARATOR|Sham|"Stimulation will be performed only for 10 s before the fade out, with 20 Hz tACS and an intensity of 1.5 mA (peak to peak).~Sham condition will be applied over pseudo-stimulation of pharyngeal cortex region and contralateral supraorbital region."
62027049|NCT02917980||surgical treatment|patients with structural heart disease received surgical treatment
62027050|NCT02917980||interventional treatment|patients with structural heart disease received interventional treatment
62226012|NCT04912271|EXPERIMENTAL|Granisetron transdermal patch (other name: sancuso), aprepitant or fosaprepitant, dexamethasone|Patients received granisetron transdermal patch plus dexamethasone followed by oral aprepitant or fosaprepitant infusion Granisetron transdermal patch Aprepitant 125 mg PO D1, 80 mg PO D2-D3; Fosaprepitant 150 mg IV D1 Dexamethasone 7.5-10 mg IV/PO D1
62419000|NCT04700215|ACTIVE_COMPARATOR|Group 02 Effectiveness of IS in reducing post CABG pulmonary complications|Incentive spirometry for 15 minutes after every 4 hours
62419001|NCT06702033|EXPERIMENTAL|Arm 1: Radiation therapy + Cisplatin|"* Standard of care surgery will occur before adjuvant therapy.~* It is recommended that radiation therapy begin within 28 to 49 days (and no later than 56 days).~* The total dose to the postoperative tumor bed will be 4200 cGy in 21 fractions of 200 cGy each over 4 weeks.~* Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 3780 cGy in 21 fractions of 180 cGy each.~* Cisplatin will be given on the same day as one of the initial 5 doses of radiation therapy."
62589594|NCT05877690|EXPERIMENTAL|Group p|
62589595|NCT01538134||Cases|Patients with ultrasonographic diagnosis of fetal growth restriction.
62589596|NCT01538134||Control|Patients with normal pregnancies at term.
62800964|NCT01909999|ACTIVE_COMPARATOR|Unloaded Implants|The variables, immunological and clinical, obtained in immediate loading groups were compared to unloaded implants, i.e., no prosthetic rehabilitation during osseointegration.
62027051|NCT02917980||surgical combined with interventional treatment|patients with structural heart disease received surgical combined with interventional treatment
62027052|NCT02747342|EXPERIMENTAL|SHR3680; SHR3680+SHR3162|In dose esclation and expansion phase, SHR3680 will be administered orally In combination phase, SHR3680 will be administered together with SHR3162
62027053|NCT06635967|EXPERIMENTAL|frequency-specific patterned rTMS|Patients will receive a 5-day, once-daily frequency-specific patterned rTMS treatment via a circular coil applied to the auditory cortex. Each session will last 40 minutes and will be stimulated at an intensity of 80% resting motor threshold (RMT).
62027054|NCT06635967|ACTIVE_COMPARATOR|1 Hz rTMS|Patients will receive a 5-day, once-daily 1Hz rTMS treatment via a circular coil applied to the auditory cortex. Each session will last 40 minutes and will be stimulated at an intensity of 80% resting motor threshold (RMT).
62027055|NCT04727866|EXPERIMENTAL|Rostral tsDCS|DCS cathode over \~C3-C5 posteriorly, anode over \~C5-T1 anteriorly
62027056|NCT04727866|EXPERIMENTAL|Caudal tsDCS|DCS cathode over \~T1-T4 posteriorly, anode over \~C5-T1 anteriorly
62027057|NCT04727866|EXPERIMENTAL|Coronal tsDCS|DCS cathode over C5-C7 transverse process on target side, anode over C5-C7 transverse process on non-target side.
62027058|NCT00827034|OTHER|A|A: Warfarin alone
62027059|NCT00827034|OTHER|B|B: Dimebon and Warfarin co-administration
62027060|NCT04936412|EXPERIMENTAL|Personalized brace group|Personalized brace for patients
62027061|NCT04936412|ACTIVE_COMPARATOR|Conventional brace group|Conventional brace for patients
62226013|NCT04912271|ACTIVE_COMPARATOR|Palonosetron, aprepitant or fosaprepitant, dexamethasone|Patients received intravenous palonosetron plus dexamethasone followed by oral aprepitant or fosaprepitant infusion Palonosetron 0.25 mg IV D1 Aprepitant 125 mg PO D1, 80 mg PO D2-D3; Fosaprepitant 150 mg IV D1 Dexamethasone 7.5-10 mg IV/PO D1
62419002|NCT06702033|EXPERIMENTAL|Arm 2A: Radiation therapy|"* Standard of care surgery will occur before adjuvant therapy.~* It is recommended that radiation therapy begin within 28 to 49 days (and no later than 56 days).~* The total dose to the postoperative tumor bed will be 4200 cGy in 21 fractions of 200 cGy each over 4 weeks.~* Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 3780 cGy in 21 fractions of 180 cGy each."
62589597|NCT03641625|EXPERIMENTAL|Intervention|In addition to usual care during surgery, the intraoperative management will be additionally managed based on the guidance of muscular tissue oxygen saturation and non-invasive hemodynamic monitoring.
62589598|NCT03641625|NO_INTERVENTION|Control|Patients will receive the usual care. Muscular tissue oxygen saturation and non-invasive hemodynamic monitoring will be used but blinded to care givers.
62589599|NCT03544099|EXPERIMENTAL|Pembrolizumab for NPC patients|Pembrolizumab 200 mg Q3W IV infusion, Day 1 of each 3 week cycle, for 35 cycles
62589600|NCT04448522|EXPERIMENTAL|Reduced dosage IMRT group|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent cheomtherapy with IMRT dosage of 63.6 Gy
62589601|NCT04448522|ACTIVE_COMPARATOR|Conventional dosage IMRT group|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent cheomtherapy with IMRT dosage of 69.96 Gy
62589602|NCT06470893|EXPERIMENTAL|OCD-NET Group|Participants will receive the OCD-NET intervention for up to 12 months.
62589603|NCT05571124|EXPERIMENTAL|Therapeutic exercise|It consists of implementing active breaks at the workstation through the use of the open source Learning Management System Sakai \[33\], It will be easy to use by the participants due to the platform is used by them in their daily work. Also, an administrative worker from the university will be involved in creating the modules where the content will be allocated to ensure that the navigation in the platform is user-friendly for them.musculoskeletal pathologies with sedentary lifestyles and maintained postures. The type of online application will depend on the results obtained in the qualitative phase, as we will adapt to the workers' preferences to facilitate accessibility to the content and make the experience as satisfactory as possible for them.
62800965|NCT03645733|NO_INTERVENTION|Control Group|The control group will be at the standard dialysate temperature of 36.5 °C (which is the standard of care in the sites), 3 times a week for 12 months
62800966|NCT03645733|EXPERIMENTAL|Lower Temperature Group|These patients will receive haemodialysis with a dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached. Patients who would fail to tolerate the temperature of 35 °C, the lowest tolerated temperature will be carried over to the end of the study.
62226014|NCT00241852|EXPERIMENTAL|Behavioral Intervention: Asthma: It's a Family Affair|Separate student and parent intervention groups.
62419003|NCT06702033|EXPERIMENTAL|Arm 2B: Radiation therapy|"* Standard of care surgery will occur before adjuvant therapy.~* It is recommended that radiation therapy begin within 28 to 49 days (and no later than 56 days).~* The total dose to the postoperative tumor bed will be 3780 cGY in 21 fractions of 180 cGy each over 4 weeks.~* Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 3360 cGy in 21 fractions of 160 cGy each."
62589604|NCT05571124|NO_INTERVENTION|No intervention|Participants of the control group will be on a waiting list, encouraging them to maintain the same as usual in their daily activities and working hours. Once the intervention is finished, they will have access to the platform with the same content as the intervention group.
62589605|NCT04000542|EXPERIMENTAL|Eligible Participants|Eligible Participants that consent will receive the pharmacist intervention.
62589606|NCT01782417|OTHER|Patient and provider intervention|participants will receive a patient and provider intervention
62226015|NCT00241852|ACTIVE_COMPARATOR|Behavioral Control Group|Students and parents participate in an education only control group
62226016|NCT02350777|EXPERIMENTAL|active infection and/or organ compromise or GVHD.|This protocol includes two single-arm phase II trials to assess the efficacy and confirm the safety of administration of TCD stem cell boost or bone marrow (BM) HPC (M) boost from the original donor for patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
62226017|NCT02350777|EXPERIMENTAL|active infection, active or controlled GVHD &/or organ compro|This protocol includes two single-arm phase II trials to assess the efficacy and confirm the safety of administration of TCD stem cell boost or bone marrow (BM) HPC (M) boost from the original donor for patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
62589607|NCT01986127|EXPERIMENTAL|Adalimumab|single administration of Adalimumab 80mg diluted in 5ml saline
62589608|NCT01986127|PLACEBO_COMPARATOR|saline|5 ml of saline
62589609|NCT04960241|ACTIVE_COMPARATOR|Homebased telerehabilitation|Patients randomized to this group will receive interactive virtual rehabilitation using a mobile app. The telerehabilitation is based on sensor technology, developed by ICURA. This technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patient with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. This technology has already been successfully implemented in several different rehabilitation facilities across Denmark, and, hence, reflects current clinical practice.
62800967|NCT03645733|NO_INTERVENTION|Caregivers|Patients, who consent for the study, will be asked to identify the most suitable carer to participate in the study who could be approach in person, over the phone or by post as deemed suitable by the research team and convenient by the carer. Patient's permission to contact their identified carer will be recorded. Carers of consenting patients will be approached in the same manner as above after obtaining patients consent to contact their carers. Patients will still be able to take part in the study even if their carer declines consent.
62800968|NCT00585117|EXPERIMENTAL|1 CNS|imaging with CuATSM
62800969|NCT00585117|EXPERIMENTAL|2. Head and Neck|Imaging with CuATSM
62800970|NCT00585117|EXPERIMENTAL|3. Lung|imaging with CuATSM
62800971|NCT00585117|EXPERIMENTAL|4. Prostate|PET imaging with CuATSM
62800972|NCT00585117|EXPERIMENTAL|5. Esophagus|PET imaging with CuATSM
62589610|NCT04960241|ACTIVE_COMPARATOR|Homebased rehabilitation|This group will be instructed in similar exercises as patients allocated to telerehabilitation. However, this group will receive a written exercise-program with instructions to perform these exercises at home. The home-based exercise program will be created using exercise templates from Exorlive. Using a link provided in the exercise-program, the patients will be able to see short instruction-videos of the individual exercises.
62226018|NCT02739295|EXPERIMENTAL|G-CSF|An intravenous dose of 5 microg/kg of G-CSF (Neupogen) will be administered daily, from admission (day 0) to day 4.
62226019|NCT02739295|PLACEBO_COMPARATOR|Placebo|An intravenous dose of 5 ml of NaCl 0.9% will be administered daily, from admission (day 0) to day 4.
62226020|NCT05386797|EXPERIMENTAL|Geniculate Artery Embolization arm|
62800973|NCT03155724|EXPERIMENTAL|MultiPole Pacing|Traditional biventricular pacing CRT non-responders at the 3 or 6 month QP ExCELs study follow-up.
62800974|NCT03528226|EXPERIMENTAL|Exercise Training|
62800975|NCT03528226|OTHER|Control|
62800976|NCT06500637|EXPERIMENTAL|TB006|TB006 is a humanized immunoglobulin G4 (IgG4) (S228P) type monoclonal antibody that is highly specific and has a high affinity to human Galectin-3 (hGal-3). Galectins are a ubiquitous group of proteins found in a variety of cells, tissues, and extravascular spaces, and are involved in numerous metabolic processes and functions. The galectins preferentially bind to β-galactoside derivatives and can cross-link surface glycoproteins by binding galactose residues. The Gal-3 protein plays an important role in different pathogenic conditions, including neurodegenerative and neuroinflammatory disorders. Serum levels of Gal-3 have been found to be elevated in ASD.
62800977|NCT06500637|PLACEBO_COMPARATOR|Placebo|Identical IV solution without TB006 product
62800978|NCT05113446||MCI(Mild Cognitive Impairment) group|"* Inclusion criteria : Patients 65 years of age or older who are admitted to a LTC(long-term care) facilities, Patients diagnosed with mild cognitive impairment by doctors, Patients with a score of 18 or more and 23 or less on the Mini-Mental State Examination~* Exclusion criteria : Patients unable to measure the delirium assessment tool, The Short Confusion Assessment Methods (S-CAM) (Inouye, 2014) due to severe vision and hearing problems, Patients with serious psychiatric or neurological diagnosis,Patients who died or were transferred on the day of admission, Patients receiving emergency treatment at the time of the delirium assessment or unable to measure or intervene with S-CAM due to hospital circumstances"
62226021|NCT02418221|EXPERIMENTAL|DAOSiN®/ Placebo & ProvokAmin® Ingestion|A sample of blood is drawn from Patient, blood pressure \& pulse are recorded. Patient will ingest 2 capsules of either DAOSiN® or Placebo, followed by 2 tablets of ProvokAmin 20 minutes later. After an additional 40 minutes blood pressure and pulse are recorded and another sample of blood is drawn. Patient is handed a questionaire for self-evaluation to record any symptoms for the following After between 7 and 15 days the whole cycle is repeated switching between active treatment and Placebo.
62226022|NCT06328907|EXPERIMENTAL|comprehensive rehabilitation therapy+Intermittent Oro-esophageal Tube Feeding|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy.~The group is given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
62226023|NCT06328907|ACTIVE_COMPARATOR|comprehensive rehabilitation therapy+Nasogastric Tube Feeding|Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy.Besides, this group is given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements.
62226024|NCT00969527|EXPERIMENTAL|A|Oncoxin + Viusid
62226025|NCT00969527|PLACEBO_COMPARATOR|B|
62419004|NCT06702033|EXPERIMENTAL|Arm 2C: Radiation therapy + Cisplatin|"* Standard of care surgery will occur before adjuvant therapy.~* It is recommended that radiation therapy begin within 28 to 49 days (and no later than 56 days).~* The total dose to the postoperative tumor bed will be 3000 cGy in 15 fractions of 200 cGy over 3 weeks.~* Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 2700 cGy in 15 fractions of 180 cGy each.~* Cisplatin will be given on the same day as one of the initial 5 doses of radiation therapy."
62419005|NCT03461029||BIS|Group of 196 patients in whom sedation monitoring is performed using the Bispectral Index Monitoring (BIS) system.
62419006|NCT01754480|EXPERIMENTAL|Fibrin Sealant Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
62419007|NCT01754480|ACTIVE_COMPARATOR|Surgicel®|Surgicel® is a sterile, absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
62419008|NCT06565572|EXPERIMENTAL|nL-FLVC-001 Arm|nL-FLVC-001 is an antisense oligonucleotide that will be injected into the vitreous
62419009|NCT03003728|EXPERIMENTAL|Study Treatment|Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26; Melphalan 200 mg/m2 Ivia intravenous infusion on day -3; ASCT on day -2; ENK infusion on day 0; ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22.
62419010|NCT03640442|EXPERIMENTAL|Modified ramped position group|In this group, induction of anesthesia will be performed in the modified ramped position.
62419011|NCT03640442|ACTIVE_COMPARATOR|Ramped position group|In this group, induction of anesthesia will be performed in the ordinary ramped position.
62419012|NCT04085263|SHAM_COMPARATOR|Control group|The patients in this group will receive sham rhomboid intercostal and subserratus plane.
62419013|NCT04085263|EXPERIMENTAL|Rhomboid intercostal and subserratus plane block group|The patients in this group will be receive real ultrasound-guided rhomboid intercostal and subserratus plane.
62419014|NCT03850262||patients with posterolateral corner trauma of the knee|
62589611|NCT04960241|ACTIVE_COMPARATOR|No physical rehabilitation|This group of randomised patients will not be given any physical rehabilitation intervention. This means no physical activity or exercise designed and prescribed for restoring normal function or reducing pain cause by disease, injury or surgery. The no intervention group will be encouraged to stay active and continue life as usual, gradually returning to their activities of daily living when they feel ready for it.
62589612|NCT03164564|EXPERIMENTAL|Arm A: CAB + Placebo TDF/FTC + CAB LA|During Step 1, participants will receive daily oral CAB and oral TDF/FTC placebo for 5 weeks. In Step 2, participants will receive injections of CAB LA at two time points 4 weeks apart and every 8 weeks thereafter and daily oral TDF/FTC placebo beginning at Week 5. In Step 3, participants will receive daily TDF/FTC for up to 48 weeks, starting no later than 8 weeks after the last injection.
62589613|NCT03164564|ACTIVE_COMPARATOR|Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA|During Step 1, participants will receive daily TDF/FTC and oral CAB placebo for 5 weeks. In Step 2, participants will receive daily TDF/FTC and placebo for CAB LA injections at two times points 4 weeks apart and every 8 weeks thereafter beginning at Week 5. In Step 3, participants will receive daily TDF/FTC for up to 48 weeks, starting no later than 8 weeks after the last injection.
62226026|NCT05729607|ACTIVE_COMPARATOR|Connective tissue graft|Autogenous connective tissue graft harvested from the palate as a free gingival graft and then de-epithelialized
62226027|NCT05729607|EXPERIMENTAL|Dermal matrix + EMD|Acellular dermal matrix and enamel matrix derivative
62226028|NCT01848561||Immunomodulatory Therapy|Patients who are being prescribed and treated with Immunomodulatory Therapy
62226029|NCT01848561||Adalimumab (Humira) Treatment|Patients who are prescribed and treated with Adalimumab
62226030|NCT02706912|EXPERIMENTAL|VOTA Group|All enrolled subjects are in this arm. After pre-assessment subjects have an 8-week waiting period, after which a mid-assessment takes place. Subject then participate in VOTA therapy for 8 weeks, followed by a post-assessment . The pre-/mid-assessment difference is used to control for spontaneous recovery. The mid-/post-assessment difference is used to ascertain efficacy.
62419015|NCT06323343|EXPERIMENTAL|Video Intervention|Participants assigned to the video intervention group receive a text message prior to their prenatal fetal anomaly appointment. Embedded in that text message is a link to an animated video which provides education on best practices of communicating with providers.
62419016|NCT06323343|ACTIVE_COMPARATOR|Webpage links|Participants assigned to the webpage links group receive links to the clinic's publicly available webpages prior to their prenatal fetal anomaly appointment. The webpages provide background about the providers and services available as well as a tour of the clinic.
62589614|NCT02113098|EXPERIMENTAL|Treadmill, ankle load|The experimental group will perform gait training on a treadmill with added load to the non-paretic lower limb
62226031|NCT03433053|PLACEBO_COMPARATOR|Control|Participants will be exposed to a generic HIV testing message.
62226032|NCT03433053|EXPERIMENTAL|Experiment|Participants will be exposed to a targeted HIV testing message, developed specifically for African American women.
62226033|NCT01060540|EXPERIMENTAL|CR+G|conventional risk counseling (lifetime risk, fasting plasma glucose, and family history) plus genetic testing for type 2 diabetes
62226034|NCT01060540|ACTIVE_COMPARATOR|CR+EYE|conventional risk counseling (lifetime risk, fasting plasma glucose, and family history) plus eye disease counseling
62226035|NCT01218893|ACTIVE_COMPARATOR|15-15-15|This group will receive three times 15 infected mosquito bites under chloroquine prophylaxis, as we know that this dose is protective.
62226036|NCT01218893|EXPERIMENTAL|10-10-10|This group will receive three times 10 infected and 5 uninfected mosquito bites under chloroquine prophylaxis.
62589615|NCT02113098|ACTIVE_COMPARATOR|Treadmill|The control group (active comparator) will perform gait training on a treadmill
62226037|NCT01218893|EXPERIMENTAL|5-5-5|This group will receive three times 5 infected and 10 uninfected mosquitobites under chloroquine prophylaxis.
62226038|NCT01218893|PLACEBO_COMPARATOR|0-0-0|This group will receive three times 15 uninfected mosquitobites under prophylaxis.
62226039|NCT06231342|ACTIVE_COMPARATOR|Direct Laryngoscopy (DL)|Standard laryngoscope use to insert the endotracheal tube and removing the stylet without any rotation.
62419017|NCT02167100||Retained in Care|Each patient who had at least 2 practice visits separated by ≥90 days in a year involving HIV laboratory monitoring until 31st of March 2014.
62419018|NCT02167100||Lost to follow-up (LTFU)|Each patient who had at 2 practice visits separated by ≥90 days in a year involving HIV laboratory monitoring but did not maintain regular attendance at HHMP until 31st March, 2014.
62419019|NCT03638102|EXPERIMENTAL|Sleep intervention|Sleep extension
62589616|NCT03603145|EXPERIMENTAL|Immediate insertion|Randomized to insertion within 48 hours of medical abortion
62589617|NCT03603145|NO_INTERVENTION|Standard Insertion|Insertion at 2-4 weeks post medical abortion
62226040|NCT06231342|ACTIVE_COMPARATOR|Direct laryngoscopy (DLE) plus Endotracheal Tube (ETT) 180 maneuver|Standard laryngoscope use to insert the endotracheal tube and removing the stylet using a 180-degree rotation.
62419020|NCT03638102|ACTIVE_COMPARATOR|Healthy living|Health education
62419021|NCT03328468|EXPERIMENTAL|Breathing Exercise|
62226041|NCT06231342|ACTIVE_COMPARATOR|Video laryngoscopy plus Endotracheal Tube (ETT) 180 maneuver (VLE)|Video laryngoscope use to insert the endotracheal tube and removing the stylet using a 180-degree rotation.
62419022|NCT06247254|EXPERIMENTAL|Intensive Tailored Telehealth Management (ITTM)|The ITTM intervention involves a comprehensive, multi-dimensional approach to using real-time BP data to manage BP after stroke. ITTM includes an in-person visit during which participants will complete a series of questionnaires within the COMPASS-CP® web application and will receive a COMPASS-BP Action Plan home safety checklist, Blood Pressure (BP) Matters documents, and referrals to local resources, as needed.
62419023|NCT06247254|OTHER|Intensive Clinic Management (ICM)|The ICM arm includes BP management at in-person follow-up visits occurring every 2 months when BPs are at target and if not in target, monthly visits. Medications will be adjusted to lower BP to the target using evidence-based guidelines and in the context of whether the participant can effectively manage their medications and BP. ICM participants will receive a COMPASS Care plan, which will evaluate social and functional factors for managing stroke recovery.
62419024|NCT04976335|ACTIVE_COMPARATOR|Versawrap|
62419025|NCT04976335|NO_INTERVENTION|No Versawrap|
62419026|NCT06498557||Group S|SFIP block will be applied for postoperative analgesic purposes
62419027|NCT06498557||Group IP|SFIP block will be applied for postoperative analgesic purposes
62419028|NCT04804293|EXPERIMENTAL|Operative treatment (surgical decompression) for carpal tunnel syndrome|Shear wave elastography (SWE) will be used to assess the stiffness of tissue. Patients will be revaluated at 3 and 6 months post-operatively. Patient will sit done in a chair. The investigators will scan the wrist area of both arms to acquire SWE map. This imaging will be done before the treatment. We will repeat the imaging study at 3 and 6 months after the treatment. Each ultrasound imaging session will take about less than 10 min. The investigators do not expect any discomfort during the imaging.
62419029|NCT04804293|EXPERIMENTAL|Corticosteroid injection treatment for carpal tunnel syndrome|Shear wave elastography (SWE) will be used to assess the stiffness of tissue. Patients will be revaluated after 6 weeks following corticosteroid injection. Patient will sit done in a chair. The investigators will scan the wrist area of both arms to acquire SWE map. The investigators do not expect any discomfort during the imaging.
62419030|NCT06138626|EXPERIMENTAL|Alert active|Anesthesia provider will see alert when fresh gas flow is excessive
62419031|NCT06138626|NO_INTERVENTION|Alert inactive|Anesthesia provider will not see alert when fresh gas flow is excessive
62419032|NCT06154122|EXPERIMENTAL|Virtual Reality Plus Treatment As Usual|"3 sessions of virtual reality upper limb treatment for up to 30 minutes each will be administered each week for 12 weeks.~Participants randomised to the VR treatment arm will also receive treatment as usual for their upper limbs (see Treatment As Usual)."
62419033|NCT06154122|ACTIVE_COMPARATOR|Treatment As Usual|Usual upper limb rehabilitation is delivered by occupational therapists and physiotherapists and aims to build strength of the upper limbs and optimise function. Patients receive hand therapy once per day and physiotherapy twice per day. Rehabilitation is highly individualised.
62419034|NCT03899506||Olanzapine|Patients receiving 10 mg IM Olanzapine per the ED protocol
62419035|NCT03899506||Midazolam|Patients receiving 5 mg IM Midazolam per the ED protocol
62419036|NCT00033137||Family Members|A relative of a patient with a confirmed or suspected diagnosis of BHD (related by blood)
62419037|NCT00033137||Non-Biologic Family Members|Spouses enrolled primarily for linkage analysis(Spouses have been removed from the inclusion criteria for this study. This closed cohort has been created for spouses previously enrolled on study.)
62419038|NCT00033137||Patients|Patients with phenotype or genotype suggestive of Birt Hogg Dub(SqrRoot)(Copyright) and/or Renal tumor histology consistent with BHD
62419039|NCT05208944|EXPERIMENTAL|Part A|"Safety lead-in, modified 3+3 design. Part A:~Cohort 1: THIO total 360 mg per cycle (120 mg on Days 1-3 Q3W) plus 350 mg cemiplimab on Day 5; Cohort 2 (pending emerging data from Cohort 1): THIO total 180 mg per cycle (60 mg on Days 1-3 Q3W) plus 350 mg cemiplimab on Day 5"
62419040|NCT05208944|EXPERIMENTAL|Part B|Cohort 1: THIO total 60 mg per cycle (20 mg on D1-3 Q3W) plus 350 mg cemiplimab on Day 5; Cohort 2: THIO total 180 mg per cycle (60 mg on D1-3 Q3W) plus 350 mg cemiplimab on Day 5; Cohort 3 (pending emerging data from Part A): THIO total 360 mg per cycle (120 mg on Days 1-3 Q3W) plus 350 mg cemiplimab on Day 5
62419041|NCT05208944|EXPERIMENTAL|Optional Part C|THIO total 540 mg per cycle (180 mg on D1-3 Q3W) plus 350 mg cemiplimab on Day 5
62419042|NCT04114578||Neonatal profile|ECHO in first 24 hours of life - ideally ECHO at Day 3-5 of life ECHO at 2-3 weeks of life or before discharge (whichever comes first) Data collected at each echocardiography: blood pressure at beginning of ECHO, pre and post-ductal saturation, respiratory support, use of inotropes and dosages, use of iNO and dosage and last blood gas
62419043|NCT04114578||Infant profile ( 4 month and/or 9 month)|Echocardiography Age and stage questionnaires CAT/CLAMS assessment
62419044|NCT04114578||Pediatric profile 3, 5 and/or 8years|Echocardiography Age and stage questionnaires CAT/CLAMS assessment Results from 18 months PMA Bailey will be retrieved
62419045|NCT04114578||Pre-adolescent/adolescent profile 11,14 and/or 17 years|Echocardiography Pediatric Quality of Life inventory survey
62419046|NCT02627885|ACTIVE_COMPARATOR|ICBT|Internet-based CBT for Parkinsons Disease with therapist contact added to standard medical treatment
62419047|NCT02627885|OTHER|SMT|Standard Medical Treatment for Parkinsons Disease only
62589618|NCT03865810||Gastric Surgery|Adult patients undergoing elective gastric surgery for cancer
62589619|NCT06450873|EXPERIMENTAL|Treatment (TTM)|Patients receive TTM PO QD or BID starting at the time of study registration and continuing up to the day prior to SOC surgery (up to 3-6 weeks) in the absence of disease progression or unacceptable toxicity.
62589620|NCT02539290|EXPERIMENTAL|Uterine flushing|Detection of ovulation, injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge, and sexual intercourse within 12 hours after intervention
62800979|NCT06129279|EXPERIMENTAL|İntervention (EFT) group|"In order to determine the students who meet our study criteria, PİF, DDF, VAS, MSS and Short Form 36 will be applied for the pre-test to female students studying in the relevant departments of KBÜ SBF.~To EFT Group; After the first tests are done, the 1st EFT session will be held, the 2nd EFT session will be held 30 days later, and the final tests will be done 30 days later. During this period, affirmations will be given depending on the need. Each session is planned to last an average of 45 minutes - 1 hour, and duration and affirmations will be arranged according to the woman's individual difficulties, perspective, support systems, past traumas and emotional blockages.~4th Procedure: Preliminary tests will be carried out and then the 1st EFT session will be held.~5. Procedure: After 30 days, the first final tests will be performed and then the second EFT session will be held.~Procedure 6: After 30 days, only the 2nd final tests will be performed."
62800980|NCT06129279|NO_INTERVENTION|Control group|"In order to determine the students who meet our study criteria, PİF, DDF, VAS, MSS and Short Form 36 will be applied for the pre-test to female students studying in the relevant departments of KBÜ SBF. Students in the control group will receive routine counseling regarding primary dysmenorrhea, and no extra intervention or practice will be performed.~Procedure 1: Preliminary tests will be conducted and then general training for dysmenorrhea will be conducted.~2nd Process: 30 days later, the questions of the students who will take the 1st post-test will be answered.~3rd Procedure: After 30 days, the second final tests will be performed."
62800981|NCT04796363|EXPERIMENTAL|ESPB Bubivacaine 0.25%|20 patients will receive US-guided deep ESPB block before induction of general anaesthesia using 20 ml bupivacaine 0.25 % and 5 ml of radiocontrast dye (Omnipaque) at the level of T4.
62800982|NCT04796363|ACTIVE_COMPARATOR|ESPB Bubivacaine 0.125%|20 patients will receive US-guided deep ESPB block before induction of general anaesthesia using 40 ml bupivacaine 0.125 % and 5 ml of radiocontrast dye (Omnipaque) at the level of T4.
62226042|NCT01506453|ACTIVE_COMPARATOR|Gabapentin|Active treatment arm.
62226043|NCT01506453|PLACEBO_COMPARATOR|Placebo|Placebo arm.
62226044|NCT05658237|EXPERIMENTAL|therapeutic group|
62226045|NCT02479321|NO_INTERVENTION|Control group|Hemodynamic optimization according to the standards of perioperative monitoring of our center. In the intraoperative period hemodynamic monitoring will be done by management of blood pressure, heart rate and oxygen saturation
62226046|NCT02479321|EXPERIMENTAL|GDT noninvasive monitoring group|GDT based on noninvasive monitoring System ClearSight® and Platform EV Clinic 1000®
62419048|NCT05069168||LVEFrecovery|patient who shows improvement of left ventricular systolic function
62419049|NCT05069168||Non LVEF recovery|patient who don't show improvement of left ventricular systolic function
62419050|NCT03464045||type 2 diabetes patients|
62419051|NCT05204888|ACTIVE_COMPARATOR|Usual COPD care|The intervention : A pulse oximeter to record heart rate and pulse oximetry on a daily basis will be provided. A smart phone and charger will also be provided to answer a short questionnaire that queries daily respiratory symptoms plus enter heart rate and pulse oximetry data
62589621|NCT02539290|SHAM_COMPARATOR|Vaginal flushing|Detection of ovulation, injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge, and sexual intercourse within 12 hours after intervention
62419052|NCT05204888|ACTIVE_COMPARATOR|Usual COPD care with use of the myAirvo 3 integrated humidifier and flow generator.|The intervention is the myAirvo 3 humidifier with integrated flow generator delivered through the Optiflow™ + Duet nasal cannula.
62589622|NCT05529875|ACTIVE_COMPARATOR|Group PRO|"Anesthesia was induced by sufentanil citrate 0.2ug/kg and propofol in TCI effect compartment concentration 4-6ug/kg.~Anesthesia was maintained with propofol in TCI effect compartment concentration 3-4ug/kg."
62589623|NCT05529875|ACTIVE_COMPARATOR|Group SEVO|"Anesthesia was induced by sufentanil citrate 0.2ug/kg and sevoflurane in the method of vital capacity with inspired-limb drug concentration measured upon 6%.~Anesthesia was then maintained with sevoflurane in vaporizer concentration 1.5-2%."
62589624|NCT01658124|EXPERIMENTAL|Tranexamic acid|(total dose 8 grams)
62589625|NCT01658124|PLACEBO_COMPARATOR|Placebo|(Sodium Chloride 0.9%)
62589626|NCT03645746|EXPERIMENTAL|Cohort 1|Cohort 1 will receive a single IV dose of REGN5069 or matching placebo
62589627|NCT03645746|EXPERIMENTAL|Cohort 2|Cohort 2 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
62226047|NCT04723420|ACTIVE_COMPARATOR|Steamroller Technique|Following intravitreal gas injection, patient positioned face down for 4-6 hours and subsequently patient changes the position of the head so that the bubble is then placed directly over the retina break.
62226048|NCT04723420|ACTIVE_COMPARATOR|Direct Technique|Following intravitreal gas injection, patient is immediately positioned so that the bubble is placed directly over the retina break.
62226049|NCT06367673|EXPERIMENTAL|CAR-NK cell therapy in Adult subjects with r/r AML|
62226050|NCT02511912|EXPERIMENTAL|V-Wave|"This is a single arm study, all eligible patients will receive the V-Wave implantable shunt.~The V-Wave device is implanted via standard femoral venous access and inter-atrial septal puncture intervention and is placed through the Fossa Ovalis."
62226051|NCT05874154|EXPERIMENTAL|Tibial nerve selective neurotomy|
62226052|NCT05874154|ACTIVE_COMPARATOR|Botulinum toxin injection|
62226053|NCT00250926|EXPERIMENTAL|Bortezomib, Dexamethasone, Rituximab|A cycle of therapy consisted of bortezomib 1.3 mg/m(2) intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m(2) on day 11. Patients received four consecutive cycles for induction therapy and then four more cycles, each given 3 months apart, for maintenance therapy.
62419053|NCT00998582|ACTIVE_COMPARATOR|Abacavir|Participants randomized to this arm will continue abacavir and their other HIV medications with no changes
62419054|NCT00998582|EXPERIMENTAL|Tenofovir|Participants randomized to this arm will switch from taking abacavir (co-formulated with lamivudine as Epzicom) and start taking tenofovir (co-formulated with emtricitabine as Truvada), and continue their other HIV medications
62800983|NCT04796363|PLACEBO_COMPARATOR|No ESPB|20 patients will undergo standard general anaesthesia as a control group and postoperative analgesia with intravenous morphine patient controlled analgesia (PCA) and rescue analgesia if required.
62800984|NCT05201404|EXPERIMENTAL|Namodenoson (CF102)|Namodenoson 25 mg orally BID, until disease progression or unacceptable adverse events
62800985|NCT05201404|PLACEBO_COMPARATOR|Placebo|Matching placebo orally BID, until disease progression or unacceptable adverse events
62800986|NCT04480840|PLACEBO_COMPARATOR|Placebo|
62800987|NCT04480840|EXPERIMENTAL|PLN-74809 Dose Level 1|Dose: 40 mg;
62800988|NCT04480840|EXPERIMENTAL|PLN-74809 Dose Level 2|Dose: 80 mg; PLN-74809 Dose Level 2 following PLN-74809 Dose Level 1
62800989|NCT04480840|EXPERIMENTAL|PLN-74809 Dose Level 3|Dose: 160 mg; PLN-74809 Dose Level 3 following PLN-74809 Dose Level 2
62800990|NCT04480840|EXPERIMENTAL|PLN-74809 Dose Level 4|Dose: 320 mg; PLN-74809 Dose Level 4 following PLN-74809 Dose Level 3
62800991|NCT02003534|EXPERIMENTAL|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
62226054|NCT01704768|EXPERIMENTAL|COPE/Healthy Lifestyles TEEN Program|COPE is a manualized 15-session educational and cognitive-behavioral skills building program guided by Cognitive Behavioral Theory with physical activity as a component of each session.
62419055|NCT01990079|EXPERIMENTAL|QUIT4Ever|QUIT4EVER is an intervention that combines 4 guideline-based smoking cessation counseling sessions, bupropion and nicotine replacement therapy, mobile contingency management, and the smart-phone application Stay Quit Coach.
62800992|NCT02335307||Control|Patients will continue to receive their current pain management therapy. In addition, a pain assessment questionnaire will be administered at baseline and 3 months.
62800993|NCT02335307||Implementation|Patients will undergo CYP2D6 genotyping, with results entered into the medical record to assist the physician with prescribing pain medication. In addition, a pain assessment questionnaire will be administered at baseline and 3 months.
62800994|NCT02335307||Physician assessment|At the end of the study, a 20-item survey will be administered to physicians who treated patients enrolled in the study. The survey will assess whether having CYP2D6 genotype results is useful to inform prescribing decisions for pain medication from the physician's perspective.
62800995|NCT00507013|OTHER|2|
62800996|NCT05156788|EXPERIMENTAL|PD-1 antibody +Lenvatinib+Gemox|Tilelizumab 200mg, d1 Q3W Lenvatinib 8mg, po, qd, Gemox chemotherapy Gemcitabine 1000mg/m2, d1, 8, Q3W, + oxaliplatin 85mg/m2 d1, Q3W
62800997|NCT05071170||Degree of food processing and food texture|"Processed vs unprocessed foods based on NOVA classification~Soft and hard foods manipulated by cooking method"
62800998|NCT04893434|EXPERIMENTAL|DCE-MR images with Gadobutrol (GBCA)|10 volunteers will undergo a single DCE-MRI of the normal cervix to fine-tune parameters and test the performance of reconstruction and quantification algorithms. Goldenangled radial LAVA data will be continuously acquired for 5 minutes and the contrast agent will be injected intravenously after 1 minute (same contrast agent and injection rate. 60 gynecologic cancer patients will be enrolled (inclusion criterion: newly diagnosed gynecologic cancer scheduled for standard of care pelvic MRI for staging). Data from 30 of the patients will be used to assess repeatability; DCE-MRI will be acquired at baseline and repeated 48 hours (+/- 24 h) later (no therapy between the 2 scans). Data from the other 30 patients will be used to document treatment induced changes in DCE-MRI; patients in this group will undergo DCE-MRI at baseline and repeated after 2 weeks (+/- 3 days) of completion of chemoradiation treatment.
62800999|NCT04038541|OTHER|Prebiotic/ Probiotic|These subjects will be assigned to first receive prebiotics (Prebiotin Prebiotic Fiber Stick Pac) for 6 weeks. Then after a 6 week wash-out period, subjects will take probiotics (Visbiome®) for 6 weeks (followed again by a 6 week washout period).
62801000|NCT04038541|OTHER|Probiotic/ Prebiotic|These subjects will be assigned to first receive probiotics (Visbiome®) for 6 weeks. Then after a 6 week wash-out period, subjects will take (Prebiotin Prebiotic Fiber Stick) for 6 weeks (followed again by a 6 week washout period).
62801001|NCT02611726|ACTIVE_COMPARATOR|Acupuncture treatment|Individualized acupuncture needle insertion according to traditional Chinese and Japanese medicine on top of standard medical care during In-Vitro-Fertilization. Acupuncture needles will be inserted to body surface points following traditional diagnosis (anamnesis, tongue, pulse and abdomen inspection) according to practitioner discretion.
62419056|NCT01990079|ACTIVE_COMPARATOR|Control Contact Condition|This intervention combines 4 guideline-based smoking cessation counseling sessions, bupropion and nicotine replacement therapy, and mobile contingency management.
62419057|NCT00463814|EXPERIMENTAL|Part A: Dose Escalation AZD6244 25 mg|Participants will receive a single oral dose of AZD6244 25 mg capsule on Day 1 followed by continuous twice daily (bd) dosing from Day 2 onwards, until disease progression or another protocol-defined discontinuation criterion will be met, whichever will occur first.
62589628|NCT03645746|EXPERIMENTAL|Cohort 3|Cohort 3 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
62226055|NCT01704768|PLACEBO_COMPARATOR|Healthy Teens Attention Control Program|Healthy Teens is an attention control program that controls for the time spent with the adolescents in the COPE group is essential to determining the efficacy of the experimental program.
62419058|NCT00463814|EXPERIMENTAL|Part A: Dose Escalation AZD6244 50 mg|Participants will receive a single oral dose of AZD6244 50 mg capsule on Day 1 followed by continuous dosing from Day 2 onwards, until disease progression or another protocol-defined discontinuation criterion will be met, whichever will occur first.
62419059|NCT00463814|EXPERIMENTAL|Part A: Dose Escalation AZD6244 75 mg|Participants will receive a single oral dose of AZD6244 75 mg capsule on Day 1 followed by continuous dosing from Day 2 onwards, until disease progression or another protocol-defined discontinuation criterion will be met, whichever will occur first.
62589629|NCT03645746|EXPERIMENTAL|Cohort 4|Cohort 4 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
62589630|NCT03645746|EXPERIMENTAL|Cohort 5|Cohort 5 will receive a single SC dose of REGN5069 or matching placebo
62589631|NCT03645746|EXPERIMENTAL|Cohort 6|Cohort 6 will receive a single sequential ascending SC dose of REGN5069 or matching placebo
62419060|NCT00463814|EXPERIMENTAL|Part A: Dose Escalation AZD6244 100 mg|Participants will receive a single oral dose of AZD6244 100 mg capsule on Day 1 followed by continuous dosing from Day 2 onwards, until disease progression or another protocol-defined discontinuation criterion will be met, whichever will occur first.
62419061|NCT00463814|EXPERIMENTAL|Part B: Relative Bioavailability (Sequence 1) and Safety Assessment Phase|Participants in relative bioavailability phase will receive a single oral dose of AZD6244 100 mg free-base suspension (mix and drink) on Day 1. Following a washout period of 7 days, participants will receive a single oral dose of AZD6244 75 mg capsule on Day 8 (Sequence 1). In the safety assessment phase, participants who will participate in the relative bioavailability phase will receive oral AZD6244 75 mg capsule bd dosing from Day 9 onwards until disease progression or another protocol-defined discontinuation criterion will be met, whichever will occur first.
62419062|NCT00463814|EXPERIMENTAL|Part B: Relative Bioavailability (Sequence 2) and Safety Assessment Phase|Participants in relative bioavailability phase will receive a single oral dose of AZD6244 75 mg capsule on Day 1. Following a washout period of 7 days, participants will receive a single oral dose of AZD6244 100 mg free-base suspension (mix and drink) on Day 8 (Sequence 2). In the safety assessment phase, participants who will participate in the relative bioavailability phase will receive oral AZD6244 75 mg capsule bd dosing from Day 9 onwards until disease progression or another protocol-defined discontinuation criterion will be met, whichever will occur first.
62589632|NCT03645746|EXPERIMENTAL|Cohort 7|Cohort 7 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
62589633|NCT04068012|EXPERIMENTAL|Intervention|Ventilator management using the proposed protocol in both acute and weaning phases
62589634|NCT05256654|EXPERIMENTAL|LY3561774 Dose 1|Participants will receive LY3561774 subcutaneously (SC)
62589635|NCT05256654|EXPERIMENTAL|LY3561774 Dose 2|Participants will receive LY3561774 SC
62589636|NCT05256654|EXPERIMENTAL|LY3561774 Dose 3|Participants will receive LY3561774 SC
62801002|NCT02611726|NO_INTERVENTION|Control|Standard medical care during In-Vitro-Fertilization.
62801003|NCT04260646|ACTIVE_COMPARATOR|Standard Urotherapy without enuresis alarm|Standard urotherapy inclunding normalized fluid intake and times voidings. The timed voiding regime of every 2 hours will be assisted by a timer Watch.
62226056|NCT02435758|EXPERIMENTAL|Preservation of Denonvilliers Fascia|Preservation of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for male mid-low rectal cancer patients
62589637|NCT05256654|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo
62589638|NCT06234202|EXPERIMENTAL|Bioactive Sleeve then Control Sleeve|Each pitcher will be instructed to sleep with the assigned sleeve on the throwing arm after each game that he pitches
62589639|NCT06234202|EXPERIMENTAL|Control Sleeve then Bioactive Sleeve|Each pitcher will be instructed to sleep with the assigned sleeve on the throwing arm after each game that he pitches
62589640|NCT05033262|NO_INTERVENTION|Control|Participants who are allocated to the control arm will complete baseline measures and then receive usual advanced care planning care and discussions with the nursing facility staff. Control arm participants will not review the Our Memory Care Wishes website. Participants will complete follow up measures one week after the baseline interview.
62801004|NCT04260646|EXPERIMENTAL|Standard Urotherapy with enuresis alarm|Standard urotherapy inclunding normalized fluid intake and times voidings. The timed voiding regime of every 2 hours will be assisted by a timer Watch. In addition an enuresis alarm will be provided and worn by the participants during the night.
62801005|NCT03487991|EXPERIMENTAL|personalized behavioral recommendations|Will receive recommendations for altering sleep related behavior based on data from in-home monitoring.
62801006|NCT03487991|NO_INTERVENTION|educational control|Will receive the data without recommendations. Will receive personalized recommendations after the follow up assessment.
62801007|NCT01158911||non-diabetic Chronic Kidney disease|
62226057|NCT02435758|NO_INTERVENTION|Excision of Denonvilliers Fascia|Standard TME surgery (U-shaped excision of Denonvilliers fascia) in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for male mid-low rectal cancer patients
62589641|NCT05033262|EXPERIMENTAL|Intervention|Participants allocated to the intervention group will complete baseline measures. Then, the participant will review the Our Memory Care Wishes website and enter advanced care planning decisions and preferences into the website. Participants will complete follow up measures one week after the baseline interview. Participants receiving the intervention will complete additional follow up measures which include surveys measuring the ease of use of the website.
62589642|NCT04130542|EXPERIMENTAL|LVGN6051|The dose escalation phase includes 10 dose levels of LVGN6051, and the highest dose is up to 10mg/kg. Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
62226058|NCT06168097|EXPERIMENTAL|100 women undergoing surgery (laparoscopy / laparotomy) with presumed diagnosis of endometriosis|"1. We Will take Both blood and tissue samples used to study them.~2. We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~3. Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~4. It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis."
62589643|NCT05949047|EXPERIMENTAL|Distancing|Participants will receive structured cognitive emotion regulation training from an experimenter during an approximately 10-minute interaction via videoconference in which detailed instructions for implementation of the distancing strategy is explained (i.e. appraising an emotional stimulus as an objective, impartial observer).
62589644|NCT05949047|ACTIVE_COMPARATOR|Reinterpretation|Participants will receive structured cognitive emotion regulation training from an experimenter during an approximately 10-minute interaction via videoconference in which detailed instructions for implementation of the reinterpretation strategy is explained (i.e. imagining a better outcome than what initially seemed apparent).
62801008|NCT05831358|EXPERIMENTAL|Multiple Myeloma Screening Experience|Participants will partake in a multiple myeloma screening program. The screening involves a blood sample and the completion of a questionnaire to gauge participants' multiple myeloma knowledge.
62226059|NCT06168097|NO_INTERVENTION|100 women undergoing surgery for gynaecological disorders other than endometriosis or adenomyosis|". We Will take Both blood and tissue samples used to study them. 2. We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~3.Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~4. It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis."
62419063|NCT06239792|EXPERIMENTAL|Sleep Promotion Program|Participants will receive the Sleep Promotion Program (SPP), consisting of 2 individual sessions with a clinician via telehealth (or in-person if desired), about 2 weeks apart, and web-based intervention components.
62419064|NCT06702371|EXPERIMENTAL|Mindset Intervention|Participants who are randomised to the intervention arm will complete all three modules of the EMBody intervention across six weeks. They will also complete online surveys at baseline (T0), weeks two (T1), four (T2), six (T3), 10 (T4), and 18 (T5). Data will be analysed after the T5 data collection point. There will be an additional 12-month long-term follow up (T6), with a go/no-go decision depending on trial findings; these data will be published separately.
62419065|NCT06702371|NO_INTERVENTION|Waitlist Attention Control|Participants randomised to the waitlist attention control arm will complete the online surveys at the same timepoints as participants randomised to the intervention arm. After the 12-month long-term follow-up survey (T6), participants in the waitlist control arm will be sent the EMBody intervention materials.
62419066|NCT05968664|ACTIVE_COMPARATOR|Time Invariant Pulse(TIP) Stimulation|The control arm for this study will be the Time Invariant Pulse stimulation which is used in standard of care Spinal Cord Stimulation therapy. TIP tonic stimulation is delivered with fixed amplitude, pulse width, and frequency parameters.
62419067|NCT05968664|EXPERIMENTAL|Time Variant Pulse (TVP) Stimulation|The time variant pulse (TVP) stimulation will serve as the experimental arm for this study. There are two ways of delivering TVP stimulation to the spinal cord. TVP stimulation can either vary in intensity or it can vary rate, referred to as intensity-modulated TVP or rate-modulated TVP, respectively.
62419068|NCT06315569|EXPERIMENTAL|Group A (two 3000m runs 24 hours apart)|Run a second 3000m run 24 hours after completing the first 3000m run
62419069|NCT06315569|EXPERIMENTAL|Group B (two 3000m runs 48 hours apart)|Run a second 3000m run 48 hours after completing the first 3000m run
62419070|NCT01039402||1|Adults ≥ 50 years old
62589645|NCT05949047|NO_INTERVENTION|"No regulation Look Only"|"The No Regulation Look Only Control group will serve as a habituation and natural history control; they will see the same emotional images, but they will only be cued to look and respond naturally for all trials."
62589646|NCT01173731|EXPERIMENTAL|AFQ056|
62589647|NCT06654830|EXPERIMENTAL|RATT|robotic-assisted thoracoscopic thymectomy
62589648|NCT06654830|ACTIVE_COMPARATOR|VATT|video-assisted thoracoscopic thymectomy
62801009|NCT01000623|EXPERIMENTAL|Arm I|Patients receive oral venlafaxine once or twice daily in weeks 2-8. Patients see a therapist once a week to learn hypnosis in weeks 2-5. Patients continue hypnosis at home in weeks 6-8.
62589649|NCT06078358|EXPERIMENTAL|Resistance exercise training|Participants undergo 8 weeks (3 days/week) of resistance exercise training.
62589650|NCT06078358|NO_INTERVENTION|Control|Participants do not perform 8 weeks of resistance exercise training.
62589651|NCT02135107|EXPERIMENTAL|Arm A|
62589652|NCT02135107|EXPERIMENTAL|Arm B|
62589653|NCT02135107|EXPERIMENTAL|Arm C|
62589654|NCT02135107|EXPERIMENTAL|Arm D|
62801010|NCT01000623|ACTIVE_COMPARATOR|Arm II|Patients receive oral venlafaxine once or twice daily in weeks 2-8. Patients see a therapist once a week to learn focused attention in weeks 2-5. Patients continue focused attention at home in weeks 6-8.
62801011|NCT01000623|ACTIVE_COMPARATOR|Arm III|Patients receive oral placebo once or twice daily in weeks 2-8. Patient see a therapist once a week to learn hypnosis in weeks 2-5. Patients continue hypnosis at home in weeks 6-8.
62589655|NCT01033032|EXPERIMENTAL|Amrubicin Phase I/II|Systemic therapy with amrubicin
62589656|NCT06089408|EXPERIMENTAL|Arm I (weighted blanket)|Patients use a weighted blanket for 30 minutes during the infusion appointment.
62801012|NCT01000623|ACTIVE_COMPARATOR|Arm IV|Patients receive oral placebo once or twice daily in weeks 2-8. Patient see a therapist once a week to learn focused attention in weeks 2-5. Patients continue focused attention at home in weeks 6-8.
62801013|NCT04378270|EXPERIMENTAL|PopSole™ offloading device|This is an external insole device that fits into a shoe and is reusable for a given subject, not for one-time use. It is comparable to other off-the-shelf insoles readily available and presents minimal risk to the participant during the four weeks of study participation.
62419071|NCT02380248|EXPERIMENTAL|Systane|Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops, 1 drop QID in each eye for 90 days
62419072|NCT06702007|NO_INTERVENTION|Housing First As Usual|Housing First as usual includes housing provision and management, fulfillment of basic needs (e.g., food, clothing), nursing/medical services and case management.
62419073|NCT06702007|EXPERIMENTAL|Housing First + eHaRT-A|HaRT-A comprises three concrete treatment components: 1) measurement and participant-led tracking of indicators of alcohol-related harm (e.g., number of drinks, blackouts), 2) elicitation of harm-reduction and health related quality of life (HRQoL) goals (e.g., drink slower, eat healthier, reconnect with family), and 3) discussion of safer-drinking strategies (e.g., taking B-complex vitamins, eating prior to or during alcohol use, avoiding mixing alcohol and other drugs). HaRT-A honors community representation within harm-reduction intervention development and acknowledges the larger forces (familial, community, geopolitical) at play in substance use, thus emphasizing the wisdom of the participant in defining their own pathway to recovery.
62589657|NCT06089408|ACTIVE_COMPARATOR|Arm II (regular blanket)|Patients use a regular blanket for 30 minutes per standard of care during the infusion appointment.
62801014|NCT00732823|PLACEBO_COMPARATOR|Profile A|No device worn
62801015|NCT00732823|ACTIVE_COMPARATOR|Profile B|Foot 40 mmHg, ankle 40 mmHg, mid-calf 35 mmHg, upper calf 30 mmHg
62801016|NCT00732823|ACTIVE_COMPARATOR|Profile C|Foot 50 mmHg, ankle 50 mmHg, mid-calf 45 mmHg, upper calf 40 mmHg
62801017|NCT00732823|ACTIVE_COMPARATOR|Profile D|Foot 60 mmHg, ankle 60 mmHg, mid-calf 55 mmHg, upper calf 50 mmHg
62801018|NCT00956371|PLACEBO_COMPARATOR|P|
62801019|NCT00956371|EXPERIMENTAL|E|
62801020|NCT03018899|EXPERIMENTAL|paravertebral block|patients received ultrasound guided two-segment paravertebral block for percutaneous nephrolithotomy
62801021|NCT03018899|ACTIVE_COMPARATOR|Epidural|patients received thoracic epidural anesthesia for percutaneous nephrolithotomy
62801022|NCT05622604|NO_INTERVENTION|no intervention condition|no intervention
62801023|NCT05622604|EXPERIMENTAL|autonomous use condition|Participants will be given a free subscription to the Pray.com app and will be directed to use the app five days per week.
62801024|NCT05622604|EXPERIMENTAL|meditative prayer condition|Participants will be given a free subscription to the Pray.com app and will be directed to listen to a meditation prayer five days per week.
62801025|NCT06461663|EXPERIMENTAL|Treatment with BCL|Subjects will undergo breast conserving surgery with the Breast Cancer Locator (BCL)
62801026|NCT06268652|EXPERIMENTAL|Organoid-guided personalized treatment|Subjects randomly assigned to OGPT need to provide sufficient tissue for organoid culture. After successful organoid culture, drug screening will be performed, and they will be treated with drugs predicted to be sensitive by PDO drug susceptibility screening.
62419074|NCT03843034||Study group|Infertile women with autoimmune disease
62419075|NCT03843034||Control group|Women from couples with severe male infertility
62419076|NCT06393673|EXPERIMENTAL|HS-10384 Dose 1|Dose level 1 of HS-10384
62419077|NCT06393673|EXPERIMENTAL|HS-10384 Dose 2|Dose level 2 of HS-10384
62419078|NCT06393673|PLACEBO_COMPARATOR|Placebo|
62419079|NCT04066192|PLACEBO_COMPARATOR|Placebo|Participants in this Arm will take a medically inert placebo. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the capsule orally each morning.
62801027|NCT06268652|ACTIVE_COMPARATOR|Treatment of physician's choice|Subjects in the TPC arm will receive treatment with one of the following regimens selected by the physician following NCCN guidelines: capecitabine, gemcitabine, vinorelbine, and eribulin. If it is HER2-positive, anti-HER2 therapy can be combined with it, except for ADC drugs.
62589658|NCT06138509||Patients|"Patients with albinism aged 2 to 17 years old and followed in the MAGEC-Necker reference center (reference center for rare diseases of the skin and mucous membranes of genetic origin), during the inclusion period.~During an initial or a follow-up consultation for patients with albinism, an additional volume of blood will be drawn during a blood sample drawn as part of routine care."
62226060|NCT04566926|EXPERIMENTAL|Part 1: Cohort 1 (Placebo or JNJ-64140284)|Participants will receive matching placebo in Treatment A or JNJ-64140284 (as formulation 1) in Treatment B or JNJ-64140284 (as formulation 2) in Treatment C on Day 1 under fasted condition. Participants will receive treatment in either of the 6 treatment sequences (ABC, BCA, CAB, CBA, ACB or BAC) in Period 1, 2, or 3 under fasted condition. Each period is separated by washout period of 5 days.
62226061|NCT04566926|EXPERIMENTAL|Part 1: Cohort 2 (Placebo or JNJ-64140284)|Participants will receive matching placebo (Treatment D) or JNJ- 64140284 (as formulation 1) in Treatment E or JNJ-64140284 (as formulation 2) in Treatment F. Participants will receive treatment in either of 6 treatment sequence (DEF, EFD, FDE, FED, DFE or EDF) in Period 1, 2, or 3 under fed condition. Each period is separated by washout period of 5 days.
62226062|NCT04566926|EXPERIMENTAL|Part 2: Cohorts 1-7 (JNJ-64140284 or Placebo)|Participants will receive JNJ 64140284 formulation 1 or 2 or matching placebo under fasting condition in Cohorts 1 to 7 on Day 1.
62226063|NCT04566926|EXPERIMENTAL|Part 3: Cohorts 1-2 (JNJ-64140284 or placebo)|Participants will receive JNJ-64140284 formulation 1 or 2 or matching placebo under fed condition in Cohorts 1 to 2 on Day 1.
62226064|NCT05786430|EXPERIMENTAL|experimental arm|
62226065|NCT01453803|EXPERIMENTAL|Intravenous Injection and Intanasal infusion of AD-SVF|AD-SVF
62226066|NCT05276609|EXPERIMENTAL|HS-20093 (Phase Ia: Dose escalation)|There are seven escalating dose cohorts.
62226067|NCT05276609|EXPERIMENTAL|HS-20093 (Phase Ib: Dose expansion)|The recommended dose from the dose-escalation stage and other potential doses will be further explored.
62226068|NCT01477320|ACTIVE_COMPARATOR|Pantoprazole 40mg IV daily and tube feed|
62226069|NCT01477320|PLACEBO_COMPARATOR|Placebo and tube feed.|
62226070|NCT04103385|EXPERIMENTAL|Reconnecting to Internal Sensations and Experiences|"Aims to improve interoception or connection to the body's emotions \& internal sensation and reduce suicidal ideation."
62419080|NCT04066192|ACTIVE_COMPARATOR|BREX 2mg|The BREX 2mg group will start at the same dose at the BREX 4mg group and titrate up at the same rate, so the BREX 2mg Arm will take .5 mg of brexpiprazole on day 1-2, 1 mg on day 3-4, and 2mg on day 5, to reach its final 2mg dose for day 5-14. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the medication orally each morning.
62419081|NCT04066192|ACTIVE_COMPARATOR|BREX 4mg|The BREX 4mg group will start at the same dose as the BREX 2mg group and titrate up at the same rate, so the BREX 4mg Arm will take .5 mg of brexpiprazole on day 1-2, 1 mg on day 3-4, 2mg on day 5-6, and 4mg on day 7 to reach its final 4mg dose for days 7-14. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the medication orally each morning.
62801028|NCT04864249|EXPERIMENTAL|SNOO Responsive Bassinet|Will receive and be instructed on the use of the SNOO responsive bassinet for their newborn + the current standard of care of safe sleep education in the postpartum period
62226071|NCT04103385|ACTIVE_COMPARATOR|Restoring Individual Strength and Energy|Aims to reduce life stressors and improve physical health
62226072|NCT02564874|EXPERIMENTAL|Savory snack|1-2 assigned snacks to be taken in determined portions equivalent to 15% of dietary energy intake, chosen from 9-point hedonic preferences questionnaire completed by participant (chips, pretzels, etc.)
62226073|NCT02564874|EXPERIMENTAL|Sugary beverage|1-2 soda-based drinks/juice to be taken in determined portions equivalent to 15% of dietary energy intake, chosen from 9-point hedonic preferences questionnaire completed by participant (coke, sprite, etc.)
62226074|NCT05638997|EXPERIMENTAL|Instrument Assisted Manipulation Group|Instrument Assisted Manipulation + Core exercises
62226075|NCT05638997|EXPERIMENTAL|Mulligan Mobilization with Movement Group|Mulligan Mobilization with Movement + Core exercises
62226076|NCT05638997|ACTIVE_COMPARATOR|Control group|Core exercises
62226077|NCT06347406|EXPERIMENTAL|Blood flow restriction combined with physiotherapy and education|Blood flow restriction, combined with physiotherapy exercises and patient education
62226078|NCT06347406|PLACEBO_COMPARATOR|Control Group|physiotherapy exercises
62226079|NCT05344482||Overall cohort: Secukinumab|Included all the patients treated with secukinumab
62226080|NCT05232994|EXPERIMENTAL|combination metformin and esomeprazole|Combination 2 g of oral extended release metformin, in divided doses and Esomeprazole 20mg daily until delivery.
62226081|NCT05232994|NO_INTERVENTION|expectant management|
62226082|NCT01432717|EXPERIMENTAL|ACE-536|Subjects assigned to 1 of 5 possible dosing groups.
62226083|NCT01432717|PLACEBO_COMPARATOR|Placebo|
62226084|NCT06164080|NO_INTERVENTION|Antenatal corticosteroid non-administration|Pregnant women who did not use antenatal corticosteroid before 34 weeks
62226085|NCT06164080|ACTIVE_COMPARATOR|Antenatal corticosteroid administration|Pregnant women using antenatal corticosteroids for any reason before 34 weeks
62589659|NCT06138509||Control patients|"Control patients are patients who were seen at Necker-Enfants Malades Hospital during the inclusion period, in the emergency and surgical departments, and whose care required a blood test analyzed in the Necker-Enfants Malades Hospital hematology laboratory.~These patients will be selected on their age (2 to 17 years old), and must have a normal complete blood count and CRP. Leftover blood not used by the hospital hematology laboratory will be used for study analyses."
62589660|NCT05524896||Low FFR|Invasive FFR value \<= 0.8
62419082|NCT06238128|EXPERIMENTAL|ORRS training group|Online Naloxone training
62226086|NCT03244085|EXPERIMENTAL|100 mg BID|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (100 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
62419083|NCT06238128|SHAM_COMPARATOR|Waitlist group|"Participants will receive non-active opioid overdose response training. Investigators will provide online training about opioid prevalence in US, opioid mechanism, side effect, and addiction. However, Investigators do not provide any knowledge about opioid overdose management and naloxone in this training.~Once the project is completed, participants will receive online Naloxone training."
62589661|NCT05524896||High FFR|Invasive FFR value \> 0.8
62226087|NCT03244085|EXPERIMENTAL|200 mg BID|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (200 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
62226088|NCT03244085|EXPERIMENTAL|600 mg QD|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (600 mg once a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
62226089|NCT06098456|EXPERIMENTAL|Treatment|The patients in this group undergo treatment with Epigallocatechin gallate 200mg, Hyaluronic acid 50mg, Vitamin B12 1mg and Folic acid 400mcg by oral route once per day.
62226090|NCT06098456|NO_INTERVENTION|Control|The patients in this group follow the routine clinical practice, namely the clinical monitoring.
62419084|NCT06236074|OTHER|Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours|
62419085|NCT03469362|EXPERIMENTAL|Extracorporeal Urinary Diversion (ECD)|Participants will be randomized to receiving ECD after scheduled Robotic Assisted Radical Cystectomy (RARC).
62589662|NCT02655510|EXPERIMENTAL|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients with MELD 11-20 will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg. After demonstrating absence of side effects in this group, patients in MELD 21-28 will follow the same dose escalation regiment as the MELD 11-20 group.
62589663|NCT00476268|EXPERIMENTAL|beclometasone /formoterol|beclomethasone dipropionate 100 µg plus formoterol 6 µg pMDI
62226091|NCT02198079||Cystic Fibrosis|Children with Cystic Fibrosis
62226092|NCT02731794|EXPERIMENTAL|LVA group|LVA group: left ventricular assist group.
62226093|NCT02731794|ACTIVE_COMPARATOR|BiVA group|BiVA group: Biventricular assist group.
62226094|NCT01864057|ACTIVE_COMPARATOR|Cambodian mothers|thiamine hydrochloride 100 mg orally daily for 5 days
62589664|NCT00476268|ACTIVE_COMPARATOR|Beclomethasone|Beclomethasone dipropionate (BecotideTM) 250 µg/unit dose pMDI aerosol via CFC propellant.
62589665|NCT00476268|ACTIVE_COMPARATOR|Formoterol powder 12 µg/unit dose|Formoterol powder 12 µg/unit dose (Foradil™)
62589666|NCT06666101|PLACEBO_COMPARATOR|Placebo|Olive oil
62801029|NCT04864249|ACTIVE_COMPARATOR|Usual Care|Will receive the current standard of care of safe sleep education in the postpartum period
62801030|NCT00394199|EXPERIMENTAL|1|FlutiForm 100/10ug
62226095|NCT01864057|NO_INTERVENTION|American mothers|Baseline blood and breast milk sample collection
62226096|NCT02070003|EXPERIMENTAL|Motivational Interviewing and Physician Guided Opioid Weaning|Patients will go through motivational interviewing with the study physician via phone once a week for 7 weeks, and once a month up to a year as applicable, until patient completes the protocol.
62226097|NCT02070003|NO_INTERVENTION|Usual Care|
62226098|NCT01115660|EXPERIMENTAL|stroke education|Patients in this arm receive a telephone call by a medication coach who reviews their condition and importance of adherence to medication regimen.
62226099|NCT01115660|NO_INTERVENTION|control arm|Subjects in this arm received instruction at hospital discharge and a 3-month follow-up call to collect study data.
62226100|NCT01621113|EXPERIMENTAL|Locomotor Training + Dalfampridine|Subjects randomized to this group will undergo 10 weeks of double-blind treatment with extended release dalfampridine tablets (10 mg twice daily) while simultaneously receiving locomotor training therapy (5 sessions per week x 10 weeks = 50 sessions total).
62419086|NCT03469362|EXPERIMENTAL|Intracorporal Urinary Diversion (ICD)|Participants will be randomized to receiving ICD after scheduled Robotic Assisted Radical Cystectomy (RARC).
62419087|NCT03424382||Phase I|Participants will complete an intake form and assessment tool survey on an electronic device provided by research staff in their hospital room. If an individual is unable to complete the instrument, he or she may have another individual enter his or her answers on the electronic device.
62419088|NCT03424382||Phase II|Participants will complete an intake form and assessment tool survey on an electronic device provided by research staff in their hospital room. If an individual is unable to complete the instrument, he or she may have another individual enter his or her answers on the electronic device.
62226101|NCT01621113|PLACEBO_COMPARATOR|Locomotor Training + Placebo|Subjects randomized to this group will undergo identical treatment, but will take placebo tablets while simultaneously receiving locomotor training therapy (5 sessions per week x 10 weeks = 50 sessions total).
62801031|NCT00394199|EXPERIMENTAL|2|Fluticasone 100
62226102|NCT01498367|NO_INTERVENTION|Usual care|Participants in the control group receive usual care. Usual care consists of regular visits to the specialist when required. In the occasion of the visit, HbA1c and glucose measurements are performed and the current oral or insulin therapy is modified if necessary. Patients also receive basic education in the management of diabetes.
62226103|NCT01498367|EXPERIMENTAL|Telemonitoring of diabetes 2 patients|Patients will have one educational visit to set up the system and explain how it works. Patients will download their measurements from their tele-glucose meter to their mobile phone and the data will be transferred to the regional database. The care team (a nurse specially trained and the allocated physician) will regularly access the patient's home diary, and will provide the appropriate counselling and medication changes as frequently as necessary. In addition to blood glucose measurements, routine questions about symptoms and eventual difficulties related to diabetes as well as diabetic management will be routinely captured and reported.
62226104|NCT02625727|EXPERIMENTAL|hyaluronic acid group|hyaluronic acid injection
62226105|NCT02625727|ACTIVE_COMPARATOR|hyaluronic acid and corticosteroid group|hyaluronic acid combined corticosteroid injection
62226106|NCT03154060|EXPERIMENTAL|Intervention|Using 3 Abbott FreeStyle Libre Flash Glucose Monitoring sensors in parallel and measure 7 times a day BG by capillary finger stick testing.
62226107|NCT03566446|EXPERIMENTAL|36 aminoacid CALR exon 9 mutated peptide|15 vaccines, over the course of 1 year
62226108|NCT05491304|EXPERIMENTAL|Non-severe DXM group|Dexamethasone (DXM): week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering.
62419089|NCT03772548||Patients with spinal cord injury|
62419090|NCT03772548||Healthy subjects|
62419091|NCT05769192|EXPERIMENTAL|Group 1|Group 1 will be applied classical physiotherapy and classical massage
62419092|NCT05769192|PLACEBO_COMPARATOR|Group 2|Group 2 will be applied classical physiotherapy and placebo massage
62419093|NCT03260491|EXPERIMENTAL|Dose Escalation: Cohort 1, 3.2 mg/kg|Participants in the Dose Escalation Cohort 1 will receive HER3-DXd intravenously (IV) once every three weeks at 3.2 mg/kg.
62419094|NCT03260491|EXPERIMENTAL|Dose Escalation: Cohort 2, 4.8 mg/kg|Participants in Dose Escalation Cohort 2 will receive HER3-DXd intravenously (IV) once every three weeks at 4.8 mg/kg.
62419095|NCT03260491|EXPERIMENTAL|Dose Escalation: Cohort 3, 5.6 mg/kg|Participants in Dose Escalation Cohort 3 will receive HER3-DXd intravenously (IV) once every three weeks at 5.6 mg/kg.
62419096|NCT03260491|EXPERIMENTAL|Dose Escalation: Cohort 4, 6.4 mg/kg|Participants in Dose Escalation Cohort 3 will receive HER3-DXd intravenously (IV) once every three weeks at 6.4 mg/kg.
62419097|NCT03260491|EXPERIMENTAL|Dose Expansion: Cohort 1, EGFR mutant|Participants with adenocarcinoma NSCLC with EGFR mutations in the Dose Expansion Cohort 1 will receive HER3-DXd IV once every three weeks at the established recommended dose for expansion (RDE).
62419098|NCT03260491|EXPERIMENTAL|Dose Expansion: Cohort 2, EGFR wild-type|Participants with squamous or non-squamous NSCLC without EGFR-activating mutations in the Dose Expansion Cohort 2 will receive HER3-DXd IV once every three weeks at the established recommended dose for expansion (RDE).
62419099|NCT03260491|EXPERIMENTAL|Dose Expansion: Cohort 3a, EGFR mutant|Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3a will receive HER3-DXd IV once every three weeks at the established recommended dose for expansion (RDE) or, if applicable, adjusted RDE (aRDE).
62419100|NCT03260491|EXPERIMENTAL|Dose Expansion: Cohort 3b, EGFR mutant|Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3b will receive HER3-DXd IV once every three weeks following an up-titration regimen (Cycle 1, Day 1: 57% of RDE or aRDE; Cycle 2, Day 1: 86% of RDE or, if applicable aRDE; Cycle 3 and subsequent cycles, Day 1: 114% of RDE or aRDE).
62589667|NCT06666101|ACTIVE_COMPARATOR|Predominant EPA|4 capsules MorEPA plus (Minami Neslé) daily; 590 mg EPA (20:5 n-3) and 130 mg DHA (22:6 n-3)/gels Total: 2360 mg EPA + 520 mg DHA daily; Total in n-3: 2880 mg daily
62801032|NCT00394199|ACTIVE_COMPARATOR|3|Formoterol 10
62226109|NCT05491304|EXPERIMENTAL|Non-severe Ruxo group|Ruxolitinib(Ruxo): body weight (BW)\<10kg: 2.5mg Bid; 10-20kg: 5mg Bid; \>20kg: 10mg Bid; Orally for 4 weeks.
62419101|NCT03260491|EXPERIMENTAL|Dose Expansion: Cohort 4, EGFR mutant|Participants with NSCLC (including any histology other than small-cell or combined small-cell and non-small cell) with an EGFR-activating mutation will receive HER3-DXd IV at 5.6 mg/kg every 3 weeks.
62419102|NCT03260491|EXPERIMENTAL|Dose Expansion: Cohort 5, KRAS-G12C mutant NSCLC|Participants with locally advanced or metastatic NSCLC whose tumors harbor a KRAS-G12C mutation and that have progressed on the most recent line of therapy will receive HER3-DXd IV at 5.6 mg/kg every 3 weeks.
62801033|NCT05294315|ACTIVE_COMPARATOR|Single level block arm - Control|Single level erector spinae block at 4th transverse process
62801034|NCT05294315|EXPERIMENTAL|Bi-level block arm - Intervention|Bi-level erector spinae block at 4th and 6th transverse process
62801035|NCT04348266|EXPERIMENTAL|RFA|The assigned location will be treated with RFA at all lesion.
62801036|NCT04348266|NO_INTERVENTION|Control|No treatment will not be performed at this location. However, if endoscopist detects any suspicious lesion during the scheduled endoscopy, the biopsy will be done and standard treatment will be performed accordingly.
62226110|NCT05491304|EXPERIMENTAL|Severe HLH-94 group|"DXM: week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering.~Etoposide (VP16): 100-150mg/m2 twice in the first two weeks, and once every week to week 8."
62226111|NCT05491304|EXPERIMENTAL|Severe HLH-94 plus ruxolitinib group|"DXM: week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering.~Etoposide (VP16): 100-150mg/m2 twice in the first two weeks, and once every week to week 8.~Ruxolitinib(Ruxo): body weight (BW)\<10kg: 2.5mg Bid; 10-20kg: 5mg Bid; \>20kg: 10mg Bid; Orally for 4 weeks."
62226112|NCT02470910|EXPERIMENTAL|Magnetic resonance imaging|MRI examination after intraprostatic fiducial markers have been placed and prior to beginning radiotherapy
62226113|NCT00815620||1|patients undergoing local ablative therapy such as transcatheter-arterial chemoembolization or selective interal radiotherapy
62226114|NCT00815620||2|patients undergoing surgery or radiofrequency ablation
62226115|NCT00815620||3|patients undergoing peptide receptor radiotherapy
62226116|NCT01668511|EXPERIMENTAL|Group 1|Randomized 7 drug/2 placebo by group
62226117|NCT01668511|EXPERIMENTAL|Group 2|Randomized 7 drug/2 placebo by group
62226118|NCT01668511|EXPERIMENTAL|Group 3|Randomized 7 drug/2 placebo by group
62226119|NCT01668511|EXPERIMENTAL|Group 4|Randomized 7 drug/2 placebo by group
62226120|NCT01048671||Antiretroviral combination therapy including raltegravir|Participants received ARV combination treatment including raltegravir. Treatment of participants was at the discretion of the investigator who provided standard care in a real life setting.
62226121|NCT03972254|EXPERIMENTAL|Intervention|Caregivers and their child will interact for 10 minutes while being observed and videotaped. Psychoeducation will be provided and goal setting will occur to ensure dyad specific relationship gains are made.
62226122|NCT04219579|EXPERIMENTAL|Continuous infusion|Immediately after operation, 2000 international unit (IU) of Antithrombin-III (AT-III) concentrate is loaded for 1 hour. AT-III concentrate 3000 IU is continuously infused through following 71 hours.
62226123|NCT04219579|ACTIVE_COMPARATOR|Intermittent infusion|Every 6 hours, 500 IU of AT-III concentrate is infused through 1 hour during the first 72 hours after liver transplantation.
62226124|NCT06159322||First-line treatment group|This group will consist of 20 patients with schizophrenia or schizoaffective disorder who are primarily prescribed olanzapine. Treatment will be carried out by the physicians within their circle of care, however, we will record their symptoms as they continue treatment.
62226125|NCT06159322||Treatment-resistant group|This group will consist of 20 patients with schizophrenia or schizoaffective disorder who are primarily prescribed clozapine due to poor treatment response to first-line antipsychotic agents. Treatment will be carried out by the physicians within their circle of care, however, we will record their symptoms as they continue treatment.
62226126|NCT03672656|EXPERIMENTAL|pattern scanning laser system Pascal|
62226127|NCT03672656|ACTIVE_COMPARATOR|conventional laser|
62226128|NCT02766166||Predictive Monitoring|
62226129|NCT02766166||No Predictive Monitoring|
62226130|NCT02541123||Cohort A|CT negative for acute intracranial lesion with initial blood draw within 4 hours of head injury
62226131|NCT02541123||Cohort B|CT negative for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
62226132|NCT02541123||Cohort C|CT positive for acute intracranial lesion with initial blood draw within 4 hours of head injury
62226133|NCT02541123||Cohort D|CT positive for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
62226134|NCT02541123||Cohort E|Uninjured control group
62589668|NCT06666101|ACTIVE_COMPARATOR|Predominant DHA|4 capsules MorDHA (Minami Neslé) daily; 480 mg DHA (22:6 n-3) and 104 mg EPA (20:5 n-3)/gels Total: 1920 mg DHA + 416 mg EPA daily; Total in n-3: 2336 mg daily
62226135|NCT05229731||Case group|Patients with visual snow syndrome according to international criteria
62226136|NCT05229731||Control group|Patients without visual snow syndrome according to international criteria
62226137|NCT06336954|EXPERIMENTAL|experimental group|Adibelimab (1200mg, IV, every 3 weeks) combined with Famitinib (20mg, daily, orally) and Albumin-bound Paclitaxel (260mg/m2, Day 1, every 3 weeks).
62226138|NCT04511182|EXPERIMENTAL|exercise intervention group|Patients will receive standard medications plus EBCR 。Education covering topics related to AMI and exercise for AMI will be implemented and any consultations on exercise prescription and disease management will be explained by a cardiac rehabilitation team consisting of cardiologists, cardiology nurses and physiotherapists.
62226139|NCT04511182|NO_INTERVENTION|Usual care group（control）|Patients will receive standard medications according to national guidelines, as well as education and consultations as intervention group. However，no exercise prescription is given,
62419103|NCT02912884||PV|Patients with a diagnosis of polycythaemia vera.
62801037|NCT02424617|ACTIVE_COMPARATOR|Arm A|designed to determine the maximum dose of bemcentinib that can be safely administered in combination with erlotinib administered at the approved oral dose level of 150 mg daily. It is anticipated that a maximum of three bemcentinib dose levels will be evaluated, with up to approximately 18 participants enrolled. In the absence of unacceptable toxicity, participants will be allowed to continue receiving bemcentinib in combination with erlotinib until disease progression.- (Arm completed)
62027062|NCT02513017|EXPERIMENTAL|Stimulus Control Instructions (SCI)|"SCI is a behavioral treatment that aims to assist persons with insomnia to re-associate the bed and the bedroom with falling asleep or back to sleep, and to acquire a consistent sleep pattern. SCI entails specific instructions that focus on developing new sleep habits, such as avoiding activities other than sleep (e.g., reading, watching TV) in bed, and getting out of bed if unable to fall asleep and engaging in quiet activities until sleepy.~A trained therapist will deliver the session in which the following topics will be covered: education about sleep, factors that influence sleep, behaviors that promote or interfere with sleep, and SCI. The session will be offered in a small group (4-6) format, based on availability of participants and to avoid any delay in treatment receipt."
62027063|NCT02513017|EXPERIMENTAL|Sleep Restriction Therapy (SRT)|SRT aims at consolidating sleep by limiting sleep to a specified time and restricting the amount of time spent in bed. Sleep time is individualized based on the persons' sleep needs, and the sleep-wake schedule is planned to fit the persons' lifestyle. The sleep-wake schedule is changed to accommodate improvements in the persons' sleep, over time.. A trained therapist will deliver the session in which the following topics will be covered: education about sleep, factors that influence sleep, behaviors that promote or interfere with sleep, and SRT. The session will be offered in a small group (4-6) format, based on availability of participants and to avoid any delay in treatment receipt.
62027064|NCT02513017|NO_INTERVENTION|No therapy|No behavioral therapy for the management of insomnia is provided. However, a list of general recommendations and suggestions are provided to participants.
62027065|NCT04768010|EXPERIMENTAL|Misoprostol|Participants will receive 100-200 micrograms of oral misoprostol twice daily.
62226140|NCT00546130|EXPERIMENTAL|1|Irinotecan hydrochloride + Cisplatin + Krestin Therapy
62226141|NCT01088373|EXPERIMENTAL|Azacitidine, Lenalidomide|
62226142|NCT00617474|EXPERIMENTAL|1|Group of patient with anemia, that treated by erythropoietin
62226143|NCT00617474|PLACEBO_COMPARATOR|2|Patients group with anemia that treated by placebo
62027066|NCT04578262|EXPERIMENTAL|Epley Manoeuvre|Epley manoeuvre in participants with Multiple Sclerosis who suffer from benign paroxysmal positional vertigo. Only one administration.
62226144|NCT03226210|EXPERIMENTAL|NovoRapid group (group Asp)|
62226145|NCT03226210|EXPERIMENTAL|Prandilin group (group Lis)|
62419104|NCT02912884||ET|Patients with a diagnosis of essential thrombocythaemia.
62589669|NCT06666101|ACTIVE_COMPARATOR|EPA and DHA combined|2 capsules Mor DHA (total 1220 mg DHA) + 2 soft gels Mor EPA (total 1388 mg EPA): 2608 mg daily
62226146|NCT03733639|ACTIVE_COMPARATOR|Tisseel®|"Once the esophagojejunal anastomosis is done the patient is randomized (Tisseel® vs no product). In the arm Tisseel® surgeon dispenses the product all over the anastomosis. The rest of the surgical procedure is as usual."
62226147|NCT03733639|OTHER|no Tisseel®|"Once the esophagojejunal anastomosis is done the patient is randomized (Tisseel® vs no product). In the arm  noTisseel® surgeon performs the surgical procedure as usual."
62226148|NCT02442154|EXPERIMENTAL|Early tracheostomy|To do an early tracheostomy within 24hours of admission of the severely head injured patients
62226149|NCT02442154|NO_INTERVENTION|standard of care|To use the standard of care of mulago hospital for the management of the severely head injured patients
62226150|NCT02926274||Whole Blood|Adult male trauma patients presenting with systolic blood pressure \<100 will receive up to 6 units of whole blood when available.
62226151|NCT02926274||Component therapy|Adult female patients presenting with systolic blood pressure \<100, as well as adult male patients with systolic blood pressure \<100 during periods when whole blood is not available, will receive component therapy (1:1:1 packed red blood cells: plasma:platelets) for transfusion.
62589670|NCT04410120||Asthma with recent (<4/52) asthma attack|
62589671|NCT05037136||Ablation|Participants recruited from the LoTO_CASA_AF trial (ClinicalTrials.gov Identifier: NCT04280042) who underwent either conventional catheter ablation or thoracoscopic surgical ablation to treat their long standing persistent AF with be asked to continue downloading data from their implanted loop recorder and monitor their heart rate and physical activity level (step count) using a wrist worn activity tracker.
62226152|NCT03802084|EXPERIMENTAL|vactosertib/imatinib combination|
62226153|NCT00682890|PLACEBO_COMPARATOR|1|Placebo tablet and birth control pill daily
62027067|NCT04578262|SHAM_COMPARATOR|Sham Manoeuvre|The second group will received a sham manoeuvre. However after the experimental intervention ends, this groups will also receive Epley manoeuvre.
62226154|NCT00682890|ACTIVE_COMPARATOR|2|metformin 2000 mg and birth control pill daily
62801038|NCT02424617|ACTIVE_COMPARATOR|Arm B|will incorporate a Simon-like two-stage design with relaxed stopping for futility to evaluate the safety, pharmacokinetics and clinical activity of bemcentinib in combination with erlotinib in participants with an activating EGFR mutation who have progressed after receiving prior EGFR TKI inhibitors or who have progressed after osimertinib.
62801039|NCT02424617|ACTIVE_COMPARATOR|Arm C|will evaluate the safety, pharmacodynamics and clinical activity of bemcentinib when administered in combination with erlotinib in participants with an activating EGFR mutation who have received at least twelve weeks of erlotinib without disease progression (Open to enrolment).
62801040|NCT02424617|OTHER|Run in Arm|The primary goal of the Run-in Cohort is to establish the safety and tolerability of bemcentinib administered as a single agent. Eligible participants will have either exhausted existing licensed therapies or be unsuitable for treatment with existing licensed therapies for NSCLC. bemcentinib will be administered at a loading dose of 600 mg on Day 1 and Day 2 of Cycle 1, followed by 200 mg daily thereafter (Arm completed)
62027068|NCT01343082|EXPERIMENTAL|1|DE-111 ophthalmic solution
62027069|NCT02909777|EXPERIMENTAL|CUDC-907|"* CUDC-907 orally administered~* CUDC-907 once daily for 5 consecutive days per week followed by two days without dosing~* Dose level assigned at registration~* Pre-dose pharmacokinetic blood sample will be collected~* Dose escalation will follow a standard 3+3 design"
62027070|NCT05601479|EXPERIMENTAL|Acetyl-L-carnitine group(ALC group)|At the beginning of the first chemotherapy of the oxaliplatin regimen, acetyl-L-carnitine 500mg will be given orally three times daily for 24 weeks.
62027071|NCT05601479|NO_INTERVENTION|Blank Control group|No drugs for the prevention and treatment of peripheral neuropathy will be given.
62027072|NCT05935345|EXPERIMENTAL|Addressing NSSI in schools|During the four months of active experimental condition, adolescents receive five sessions of the youth aware of mental health program in the class room, and one additional session on NSSI. Parents and school staff receive an online psychoeducation on NSSI. School health care personnel receive a 2-day workshop on NSSI and suicidality.
62226155|NCT04417296||nonlaboring term singleton pregnancies|"All patients had an uncomplicated pregnancy and to define a pregnancy uncomplicated we adopted Chappell's definition: a normotensive pregnancy, delivered at \>37 weeks, ending in a live-born baby who was not small for gestational age and did not have any other notable pregnancy complications"
62226156|NCT03456284|EXPERIMENTAL|Normothermic Liver perfusion|This group has the liver grafts preserved using the Normothermic Liver perfusion Device
62226157|NCT06153225|EXPERIMENTAL|Sub study 1|All subjects will receive 4 study products (300ml each) on 4 different visits in a randomized order. In total in both arms combined, 7 products will be tested.
62226158|NCT06153225|EXPERIMENTAL|Sub study 2|All subjects will receive 4 study products (300ml each) on 4 different visits a randomized order. In total in both arms combined, 7 products will be tested.
62226159|NCT00703768||A|Patients who have been identified as having a doubling in PSA from nadir of greater than one year
62801041|NCT02532517|EXPERIMENTAL|Enterprise|
62027073|NCT05935345|OTHER|Control condition|Participating adolescents, parents, teachers and school health care personnel receive no intervention during four months
62027074|NCT01732393|ACTIVE_COMPARATOR|oral quercetin capsules|Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks
62027075|NCT01732393|PLACEBO_COMPARATOR|oral placebo capsules|Patients in the placebo group received two placebo capsules containing lactose .
62226160|NCT00703768||B|Patients who have been identified as having a doubling in PSA from nadir of less than one year.
62226161|NCT04734093||Sohag university recruited patients|
62226162|NCT04734093||Minia university recruited patients|
62226163|NCT04734093||Assuit university recruited patients|
62226164|NCT04734093||Kasr Elini recruited patients|
62027076|NCT00769366|EXPERIMENTAL|Psychotherapy|Psychotherapy and medical therapy
62027077|NCT00769366|ACTIVE_COMPARATOR|Control|Optimal medical therapy
62027078|NCT06635187||Stroke patients|Adult stroke patients will be recruited to undergo a series of examinations on oral-motor and speech functions.
62027079|NCT06635187||Control group|Neurologically healthy adults residing in Hong Kong will undergo the same set of assessments and procedures as the stroke patient group.
62226165|NCT04734093||Tanta university recruited patients|
62226166|NCT04734093||Monofia university recruited patients|
62226167|NCT04734093||Aswan university recruited patients|
62589672|NCT03646214|EXPERIMENTAL|Midline traction oral appliance|Subjects will wear the oral appliance nightly for 4 weeks. Must snore or have other evidence of sleep disordered breathing.
62226168|NCT04734093||Ain shams university recruited patients|
62801042|NCT02912715|EXPERIMENTAL|Paclitaxel releasing angioplasty balloon|Intervention treatment of balloon angioplasty with Paclitaxel releasing angioplasty balloon(Passeo-18 Lux) in new and non-stented re-stenotic lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA)
62801043|NCT02917785|EXPERIMENTAL|Karman curettage|after a retained product of interception is observed in ultrasound examination, the women in this arm will undergo Karman curretage.
62801044|NCT02917785|NO_INTERVENTION|Control|
62589673|NCT03646214|NO_INTERVENTION|Control|Subjects who do do not wish to wear the oral appliance will have their sleep monitored in parallel to the experimental subjects for 4 weeks.
62027080|NCT04994626|EXPERIMENTAL|Ibrutinib Combined With Rituximab|"Induction therapy: Ibrutinib 560mg administered oral once a day of each 21-day cycle for 6 cycles. Rituximab 375mg/m² administered intravenously (IV) on Day 1 of each 21-day cycle for 6 cycles.~Maintenance therapy: Ibrutinib 560mg administered oral once a day of each 56-day cycle for 6 cycles. Rituximab 375mg/m² administered intravenously (IV) on Day 1 of each 56-day cycle for 6 cycles."
62027081|NCT00548769|EXPERIMENTAL|Sequence ADBC|Subjects will be administered formulation A, formulation D, formulation B and formulation C across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
62027082|NCT00548769|EXPERIMENTAL|Sequence BACD|Subjects will be administered formulation B, formulation A, formulation C and formulation D across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
62027083|NCT00548769|EXPERIMENTAL|Sequence CBDA|Subjects will be administered formulation C, formulation B, formulation D and formulation A across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
62801045|NCT01284998||B-BOP lock|Subjects who needs a fixation of osteotomy of the basis of the first metatarsal and for whose surgeon has recommended that a B-BOP® Lock plate from INTEGRA be implanted can be enrolled in this study
62801046|NCT01980095|EXPERIMENTAL|RHB-105|RHB-105 is an 'all-in-one' combination oral capsule consisting of 2 different antibiotics and a proton pump inhibitor combined in a single capsule.
62226169|NCT01645293|EXPERIMENTAL|Genetically modified T cells #1138|
62226170|NCT06467149||To select a suitable frailty screening scale for future frailty screening of breast cancer patients|Only basic inquiries and measurements are performed on the patient, without any intervention.
62226171|NCT04754308|OTHER|Patients referred to social nurse|"After obtaining informed consent, the social nurse reviews the online-questionnaire with the patient and performs a lung function examination requiring the patient to blow into a plastic tube. If a patient is identified as having obstructive reduction of lung function, they are offered a referral to a local pulmonary medicine department or GP for further investigation - regardless of whether or not they have a diagnosed or undiagnosed lung disease.~In addition, participants are questioned about their motivation for smoking cessation and are informed of the options for this (in hospital and/or referral to the municipality)."
62226172|NCT03037931|ACTIVE_COMPARATOR|Ferric Carboxymaltose|Ferric Carboxymaltose 2 doses intravenously of 15mg/kg to a maximum individual dose of 750mg 7 days apart and a maximum combined dose of 1500mg - repeated every 6 months as indicated by the results of iron indices.
62226173|NCT03037931|PLACEBO_COMPARATOR|Placebo|Normal saline 15ml - 2 doses 7 days apart repeated every 6 months.
62226174|NCT00648830|EXPERIMENTAL|1|Clarithromycin 250 mg immediate-release oral tablet
62027084|NCT00548769|EXPERIMENTAL|Sequence DCAB|Subjects will be administered formulation D, formulation C, formulation A and formulation B across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
62226175|NCT00648830|ACTIVE_COMPARATOR|2|Biaxin® (Clarithromycin) 250 mg tablet
62589674|NCT06667518||Children with Cerebral Palsy|Children with cerebral palsy, aged 5 to 16 years, classified at GMFCS levels I to III.
62027085|NCT02478294||the surgical intervention group|Thoracoscopic LAA Excision plus AF Ablation. Patients receiving thoracoscopic left atrial appendage excision plus atrial fibrillation alation
62226176|NCT02088164||Healthy men|Healthy men who received PSA screening
62801047|NCT01980095|PLACEBO_COMPARATOR|Placebo|Capsules that look like the RHB-105 product but contain no active ingredient.
62226177|NCT05321147|EXPERIMENTAL|PTCL that express KIR3DL2|lacutamab will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
62226178|NCT04210869|EXPERIMENTAL|Experimental|Mixed nuts
62589675|NCT00688701|PLACEBO_COMPARATOR|Placebo (Two-Step Titration)|2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 12.
62589676|NCT00688701|PLACEBO_COMPARATOR|Placebo (One-Step Titration)|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, then 20 mcg QD up to Week 12.
62589677|NCT00688701|EXPERIMENTAL|Lixisenatide (Two-Step Titration)|2-step initiation regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 12.
62801048|NCT01975363|EXPERIMENTAL|Arm I (lower dose curcumin)|Participants receive 50 mg dose curcumin PO BID for 3 months. Biomarker analyses of breast adipose tissue and plasma samples will be obtained at baseline and 3 months. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin and also stored at -80°C for biomarker analysis. Assessment of dietary intake by food frequency questionnaires and 24 hour dietary recalls will be used to assess usual dietary habits. All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
62226179|NCT04210869|NO_INTERVENTION|Control|No mixed nuts
62226180|NCT03781999|EXPERIMENTAL|Actiful|a supplement containing 500 mg orange extract and 200 mg pomegranate actives
62226181|NCT03781999|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62226182|NCT06385431||Patients with cardiovascular and metabolic disease|
62801049|NCT01975363|EXPERIMENTAL|Arm II (higher dose curcumin)|Participants receive 100 mg dose curcumin PO BID for 3 months. Biomarker analyses of breast adipose tissue and plasma samples will be obtained at baseline and 3 months. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin and also stored at -80°C for biomarker analysis. Asssessment of dietary intake by food frequency questionnaires and 24 hour dietary recalls will be used to assess usual dietary habits. All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
62801050|NCT02229188|ACTIVE_COMPARATOR|Problem Solving Therapy|Problem Solving Therapy is an evidence-based behavioral treatment for late life depression proven effective with different geriatric groups including ambulatory; medically ill; older adults with executive dysfunctions; and more recently, low-income, disabled older adults.
62801051|NCT02229188|EXPERIMENTAL|Evolution|Evolution is a plasticity intervention in the form of a video driving game that targets the cognitive conflict network.
62226183|NCT02116101|ACTIVE_COMPARATOR|Bright Momchilovtsi yogurt|Bright Momchilovtsi yogurt Contains 1×106cfu/g prebiotics including Lactobacillus bulgaricus and Streptococcus thermophilus
62226184|NCT02116101|PLACEBO_COMPARATOR|Bright Dairy Beverage|Dairy beverage product without prebiotics
62226185|NCT01328717|EXPERIMENTAL|Intended Users of the System|Subjects with diabetes used Contour Link Investigational Blood Glucose Monitoring System
62226186|NCT04112121|EXPERIMENTAL|Patients Meeting the Chaplain at the Bedside|First meeting with the chaplain, coupled with biblical readings at the bedside.
62226187|NCT04112121|EXPERIMENTAL|Patients Meeting the Chaplain at the Chapel|First meeting with the chaplain, coupled with biblical readings at the hospital's chapel
62226188|NCT04112121|NO_INTERVENTION|Patients Not Meeting the Chaplain|In the control group we enrolled patients whose diagnoses and number of days in the hospital was similar to the intervention groups (covariate-adaptive, blocked, stratified randomization method).
62226189|NCT02738736|EXPERIMENTAL|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all post-randomisation visits, targeting sodium intake of \<100mmol/day (\<2.3g/day).
62226190|NCT02738736|NO_INTERVENTION|Usual Care|Participants randomized to usual care will also attend a dietitian-developed healthy eating guidance session but will not receive specific recommendations targeting sodium intake.
62226191|NCT01509287||Donnai-Barrow Syndrome (DBS)|Individuals affected with Donnai-Barrow Syndrome (DBS)
62226192|NCT01509287||Unaffected|Healthy family members of individuals affected with Donnai-Barrow Syndrome (DBS)
62226193|NCT04389736|EXPERIMENTAL|SIT|Sitting
62419105|NCT04711824|EXPERIMENTAL|Study Treatment Arm|Cycle 1 of study treatment will consist of Olaparib twice daily concurrently with stereotactic radiosurgery (SRS). Olaparib will start one week prior to SRS and continue during and following SRS (1-5 fractions) for up to 28 days total. Once the subject has recovered from SRS, Cycle 2 will be initiated with physician's choice systemic therapy and durvalumab. Cycle 2+ will equal 21 days. During Cycles 2 and 3, physician's choice systemic monotherapy will be given along with durvalumab. Each cycle will last 21 days. Imaging to evaluate intracranial and extracranial disease will be performed after Cycle 3, and subjects with response will continue with the systemic therapy and durvalumab until progression (intracranial or extracranial), unacceptable toxicity or death.
62419106|NCT03608072|EXPERIMENTAL|Dose group 1|
62226194|NCT04389736|EXPERIMENTAL|STAND|Standing
62226195|NCT04389736|EXPERIMENTAL|NMES|Self-selected maximal intensity of neuromuscular electrical stimulation
62226196|NCT06254768|EXPERIMENTAL|Unblinded|They will wear the device and have access to their data- UNBLINDED ARM
62226197|NCT06254768|EXPERIMENTAL|Blinded|They will wear the device but will not have access to their data- BLINDED ARM
62226198|NCT04956172|ACTIVE_COMPARATOR|Tone A|Tone A uses an 80dB standard tone
62226199|NCT04956172|EXPERIMENTAL|Tone B|Tone B uses a 93dB standard tone
62226200|NCT05629403||exclusive breastfeeding|breastfeeding exclusively
62226201|NCT05629403||formula feeding|formula feeding
62226202|NCT05918250|EXPERIMENTAL|mRNA-2736|Participants will receive mRNA-2736.
62226203|NCT03987178|EXPERIMENTAL|Head Dunk|Subjects who are assigned to be in this arm are asked to sit in a hot tub for 15 minutes and instructed to submerge his or her head in the hot tub at least once and at least up to the eyebrows during his or her time in the hot tub.
62226204|NCT03987178|PLACEBO_COMPARATOR|No Head Dunk|Subjects assigned to this arm are asked to sit in a hot tub for 15 minutes but to keep his or her chin above water during the entire time.
62589678|NCT00688701|EXPERIMENTAL|Lixisenatide (One-Step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to Week 12.
62801052|NCT02229188|PLACEBO_COMPARATOR|Words|Words is a challenging crosswords type of game that will serve as the placebo comparator to Evo.
62801053|NCT05523336||Paediatric patients receiving HCTS with infectious complications post HCTS|Paediatric patients receiving allogeneic hematopoietic stem cell transplantation (HCTS) and who present with infectious complications post HSCT or with transplant related complications (acute graft-versus-host disease- GvHD-, sinusoidal obstruction syndrome -SOS-, engraftment-ES- and pre-engraftment syndrome- pre-ES-, graft failure, thrombotic microangiopathy associated with HSCT- TA-TMA or those without complications post HSCT).
62801054|NCT05523336||Paediatric patients receiving HCTS without infectious complications post HCTS|Paediatric patients receiving HCTS without infectious complications post HCTS
62801055|NCT05759897|EXPERIMENTAL|Group A|Subjects will receive HRS-7535 administered orally
62801056|NCT05759897|EXPERIMENTAL|Group B|Subjects will receive HRS-7535 administered orally
62801057|NCT05759897|EXPERIMENTAL|Group C|Subjects will receive escalated dose of HRS-7535 administered orally
62801058|NCT05759897|EXPERIMENTAL|Group D|Subjects will receive escalated HRS-7535 administered orally
62801059|NCT05759897|PLACEBO_COMPARATOR|Group E|Subjects will receive Placebo administered orally
62027086|NCT02478294||oral anticoagulant treatment group|Warfarin or Novel Oral Anticoagulants. Patients receiving warfarin treatment (INR 2.0-3.0) or novel oral anticoagulants
62027087|NCT01262508||Risk Population|Patients being suspected to be at risk of hemodynamic instability due to medical history
62589679|NCT05685264|EXPERIMENTAL|Ponsegromab low dose|
62589680|NCT05685264|EXPERIMENTAL|Ponsegromab high dose|
62589681|NCT06109649|EXPERIMENTAL|Afamelanotide and NB-UVB Light|
62027088|NCT04196400|ACTIVE_COMPARATOR|Steroid injection|Steroid (betamethasone) 2 ml is injected subcutaneously after finishing the operation at the repair site.
62027089|NCT04196400|NO_INTERVENTION|Control Group|
62027090|NCT02860598||Group 1|Patient with AML de novo or secondary myelodysplasia, in Complete Remission (CR) after induction and / or salvage therapy and candidate to receive a consolidation therapy
62027091|NCT02860598||Group 2|Patient with hematologic malignancies (ALL, AML, chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, myeloma, myeloproliferative syndrome (MDS)) and candidate for blood marrow or stem cell or placental blood transplantation.
62027092|NCT00407537|EXPERIMENTAL|Caduet|Open label caduet added to usual care regimen followed by investigators.
62801060|NCT05570266||Cases|"Cases are taken by recruiting women who:~* have no first degree family history of breast or ovarian cancer~* are or had been diagnosed with primary breast cancer or tested positive for high penetrance genes (e.g. BRCA 1/2)~* menarche age \>12 years old~* premenopausal"
62027093|NCT03836287|EXPERIMENTAL|Active|Sofpironium bromide, 15% gel, once per day
62027094|NCT03836287|PLACEBO_COMPARATOR|Vehicle|Vehicle gel, once per day
62589682|NCT06109649|OTHER|NB-UVB Light|
62589683|NCT03467867|EXPERIMENTAL|Venetoclax + Rituximab|Participants will be initially placed in a venetoclax 5 weeks ramp-up period, and will be administered an initial 20 mg oral tablet dose once daily (QD), incrementing weekly up to a maximum dose of 400 mg. Participants will then continue taking venetoclax 400 mg QD from Week 5 onwards, as directed by the investigator in combination with rituximab 375 mg/m\^2 IV on Day 1 of Cycle 1 followed by 13.4 mL of rituximab SC 1,600 mg/26,800 Units vial (1,600 mg rituximab and 26,800 Units hyaluronidase human) on Day 1 of Cycle 2-6.
62589684|NCT05461521||Family members of patients admitted to the ICU|
62589685|NCT05461521||Health care professionals|
62589686|NCT05461521||Patients|
62589687|NCT04880798|EXPERIMENTAL|124I PET/CT|All eligible patients will be allocated to this arm (single-arm study).
62589688|NCT05236374|EXPERIMENTAL|Beef Protein|A beef stew, providing 8.8 mg zinc, 37.9 mg protein (approximately 500 kcal/d energy);
62027095|NCT00958035|EXPERIMENTAL|LATISSE®|bimatoprost ophthalmic 0.03% solution
62027096|NCT00958035|PLACEBO_COMPARATOR|Placebo|vehicle sterile solution
62027097|NCT04797247|EXPERIMENTAL|LIB003 (lerodalcibep)|300 mg subcutaneously monthly (Q4W)
62419107|NCT03608072|EXPERIMENTAL|Dose group 2|
62419108|NCT03608072|EXPERIMENTAL|Dose group 3|
62419109|NCT06566755|EXPERIMENTAL|Cadonilimab (AK104) combined with chemotherapy and bevacizumab|"Participants receive Cadonilimab PLUS chemotherapy and bevacizumab of each 21-day cycle.~Treatment period (4-8 cycles)：~* Cadonilimab: 10mg/kg, intravenous infusion, D1, Q3W;~* CapeOx chemotherapy regimen Q3W+ bevacizumab, Q3W:~oxaliplatin: 130 mg/m2 intravenous infusion, D1, Q3W capecitabine: 850 mg/m2 orally, D1-14, Q3W, twice daily; bevacizumab injection: 7.5mg/kg, IV, D1, Q3W. Maintenance treatment period：~* Cadonilimab: 10mg/kg, administered D1, Q3W;~* capecitabine: 1000 mg/m2 orally, D1-14, Q3W, twice daily;~* bevacizumab injection: 7.5mg/kg, IV, D1, Q3W."
62589689|NCT05236374|ACTIVE_COMPARATOR|Animal Protein|A control plant protein stew, providing 8.8 mg zinc, 37.9 mg protein (approximately 500 kcal/d energy);
62589690|NCT02175082|ACTIVE_COMPARATOR|Forced exercise cycling|Cycling exercise at approximately 90 rpm
62589691|NCT02175082|ACTIVE_COMPARATOR|Self-selected pace cycling|Cycling at self selected rate, with same aerobic level as forced cycling group
62589692|NCT03337945|EXPERIMENTAL|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
62589693|NCT03369834|NO_INTERVENTION|Control Group|the volunteers of this group will not be submitted to the intervention.
62589694|NCT03369834|EXPERIMENTAL|Red LED group|in the volunteers of this group will be applied Red Light-emitting diode device with the length 620nm wave along the entire tibialis anterior muscle and bilateral sural triceps.
62027098|NCT04797247|PLACEBO_COMPARATOR|Placebo|matching placebo subcutaneously monthly (Q4W)
62027099|NCT02958436|EXPERIMENTAL|Cohort 1|Dose regimen 1 of REGN3500 (IV) versus placebo
62027100|NCT02958436|EXPERIMENTAL|Cohort 2|Dose regimen 2 of REGN3500 (IV) versus placebo
62589695|NCT03369834|ACTIVE_COMPARATOR|LED group infrared|in the volunteers of this group will be applied Infrared Light-emitting diode device with the wavelength of 940nm throughout the tibialis anterior muscle and bilateral sural triceps.
62027101|NCT02958436|EXPERIMENTAL|Cohort 3|Dose regimen 3 of REGN3500 (IV) versus placebo
62027102|NCT02958436|EXPERIMENTAL|Cohort 4|Dose regimen 4 of REGN3500 (SC) versus placebo
62027103|NCT02958436|EXPERIMENTAL|Cohort 5|Dose regimen 5 of REGN3500 (IV) versus placebo
62027104|NCT01060215|ACTIVE_COMPARATOR|Infusion|20cc saline infusion into the knee joint
62027105|NCT01060215|NO_INTERVENTION|No infusion|
62027106|NCT05864794|EXPERIMENTAL|Screening population|Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease.
62419110|NCT04335565|NO_INTERVENTION|Water|250 ml of water mixed with 1g of citric acid.
62419111|NCT04335565|ACTIVE_COMPARATOR|Sugar|65g of sugar dissolved in 250ml of water
62419112|NCT04335565|EXPERIMENTAL|Stevia|5g of stevia dissolved in 250ml of water
62419113|NCT00850837|EXPERIMENTAL|1|Participants will apply Acidform lubricant twice daily for 14 consecutive days between menses
62589696|NCT03369834|ACTIVE_COMPARATOR|LED group mixed|in the volunteers of this group will be applied Infrared and Red Light-emitting diode device with the wavelength of 940nm and 620nm throughout the tibialis anterior muscle and bilateral sural triceps.
62589697|NCT03369834|PLACEBO_COMPARATOR|Sham Group|LED device off.
62027107|NCT06669975|EXPERIMENTAL|Part 1 (Dose escalation)|
62027108|NCT06669975|EXPERIMENTAL|Part 2 (Dose Expansion)|
62419114|NCT00850837|PLACEBO_COMPARATOR|2|Participants will apply HEC gel twice daily for 14 consecutive days between menses
62419115|NCT06567132|NO_INTERVENTION|PCOS and Healthy Periodontium|Women who are diagnosed with PCOS and have healthy periodontium. Clinical periodontal indices, saliva and gingival crevicular fluid samples were obtained.
62027109|NCT03607448||Diabetes Mellitus Type 1 and Type 2|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and expected to perform at least 8 capillary BG test per day. Site Staff will determine when subject will undergo either a hypoglycemia induction or a hyperglycemia induction. Study staff will perform IV blood draw to obtain blood plasma for YSI sampling every 15 min when glucose as measured by YSI is above 70mg/dL and below 240 mg/dL.
62027110|NCT01218438|EXPERIMENTAL|Study Epochs 1-4|"Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.~Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.~Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.~Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion."
62027111|NCT06634953||Adolescent female volleyball athletes|willingness to participate in the research, female gender, experience of menstruation cycles for at least 1 year, age between 10 and 19 years, volleyball sport license for at least 3 years, and practice of volleyball at least 4 days a week for at least 3 years
62027112|NCT06634953||Healthy adolescent females|willingness to participate in the research, female gender, experience of menstruation cycles for at least 1 year, age between 10 and 19 years,
62226205|NCT00906945|EXPERIMENTAL|Dose Level 1|"* G-CSF 10 mcg/kg SQ on Days 1-8~* Plerixafor 240 mcg/kg/d IV qd~* Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~* Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~* Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
62226206|NCT00906945|EXPERIMENTAL|Dose Level 2|"* G-CSF 10 mcg/kg SQ on Days 1-8~* Plerixafor 320 mcg/kg/d IV qd~* Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~* Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~* Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
62589698|NCT04370704|EXPERIMENTAL|Phase 1 Part 1|Part 1 will confirm the safety of INCAGN02385 and INCAGN02390 when used in combination. INCAGN02385 will be administered first intravenously followed by INCAGN02390.
62801061|NCT05570266||Cohort|"Controls are taken from clients who visited Breast Cancer Care Alliance (BCCA) and:~* have no family history of breast or ovarian cancer~* premenopausal~* menarche age \>12 years old~* asymptomatic~* do not have any first-degree relationship with the cases~* consented for the study and follow up"
62226207|NCT00906945|EXPERIMENTAL|Dose Level 3|"* G-CSF 10 mcg/kg SQ on Days 1-8~* Plerixafor 420 mcg/kg/d IV qd~* Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~* Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~* Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
62226208|NCT00906945|EXPERIMENTAL|Dose Level 4|"* G-CSF 10 mcg/kg SQ on Days 1-8~* Plerixafor 560 mcg/kg/d IV qd~* Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~* Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~* Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
62226209|NCT00906945|EXPERIMENTAL|Dose Level 5|"* G-CSF 10 mcg/kg SQ on Days 1-8~* Plerixafor 750 mcg/kg/d IV qd~* Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~* Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~* Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
62226210|NCT00906945|EXPERIMENTAL|MTD - Phase II|"* G-CSF MTD determined in Phase 1 SQ on Days 1-8~* Plerixafor MTD determined in Phase 1 mcg/kg/d IV qd~* Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~* Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~* Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
62419116|NCT06567132|ACTIVE_COMPARATOR|PCOS and Gingivitis|Women who are diagnosed with PCOS and have gingivitis.Clinical periodontal indices, saliva and gingival crevicular fluid samples were obtained. Non-surgical periodontal treatment was performed.
62589699|NCT04370704|EXPERIMENTAL|Phase 1 Part 2|Part 2 will confirm the safety of the triple combination of INCAGN02385 + INCAGN02390 + INCMGA00012, following confirmation of the safety of the doublet in Part 1. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012.
62226211|NCT04017676|NO_INTERVENTION|Control group|The first group will be under the usual treatment conditions (TAU)
62226212|NCT04017676|EXPERIMENTAL|Experimental group|The second group will be exposed to a multidisciplinary therapeutic program that has a monitoring component and after two months an intervening component will be.
62419117|NCT06567132|ACTIVE_COMPARATOR|Systemically healthy and Gingivitis|Women who are systemically healthy and have gingivitis. Clinical periodontal indices, saliva and gingival crevicular fluid samples were obtained. Non-surgical periodontal treatment was performed.
62801062|NCT01620229|EXPERIMENTAL|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV on day 1. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
62801063|NCT00302341|EXPERIMENTAL|1|pafuramidine maleate, oral tablet, 100 mg bid X 14 days
62801064|NCT00302341|ACTIVE_COMPARATOR|2|TMP/SMX oral tablet, 15 mg/kg, split tid X 21 days
62226213|NCT01786187|ACTIVE_COMPARATOR|Symptom Experience Group|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive planned, structured, weekly telephone visits to report the experience of symptoms and health-related quality of life information.
62226214|NCT01786187|EXPERIMENTAL|Light Physical Activity Group|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light physical activity program to help manage a specific symptom related to cancer and cancer treatment.
62419118|NCT06567132|NO_INTERVENTION|Systemically and Periodontally Healthy|Women who are systemically healthy and have healthy periodontium. Clinical periodontal indices, saliva and gingival crevicular fluid samples were obtained.
62419119|NCT01138852|EXPERIMENTAL|ampicillin-sulbactam|This is the drug used to prevent post-cesarean infection
62419120|NCT01138852|ACTIVE_COMPARATOR|cefuroxime|This drug was compared to ampicillin sulbactam for prevention of infection
62419121|NCT00003166|EXPERIMENTAL|Treatment (bryostatin 1, vincristine sulfate)|"Patients receive bryostatin 1 IV over 24 hours followed immediately by vincristine IV. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy may receive subsequent courses every 3 weeks and then every 4 weeks after 24 months of treatment. Patients may return to a 2- or 3-week treatment course at the discretion of the principal investigator.~Cohorts of 3 patients receive escalating doses of bryostatin 1 until the MTD is determined. The MTD is defined as the dose preceding that at which at least 1 of 3 patients experience dose-limiting toxicity."
62589700|NCT04370704|EXPERIMENTAL|Phase 2 Cohort A|Phase 2 will determine preliminary efficacy and proof of concept for the combination of INCAGN02385 + INCAGN02390 + INCMGA00012. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012
62589701|NCT04370704|EXPERIMENTAL|Phase 2 Cohort B|Phase 2 will determine preliminary efficacy and proof of concept for the combination of INCAGN02385 + INCAGN02390 + INCMGA00012. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012
62226215|NCT01108679||Buprenorphine|Opioid-dependent drug users who are initiating buprenorphine treatment at the Albert Einstein College of Medicine Division of Substance Abuse (DoSA) or at Montefiore's Comprehensive Health Care Center (CHCC).
62226216|NCT02216305|ACTIVE_COMPARATOR|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorrhoidal base with absorbable suture
62226217|NCT02216305|ACTIVE_COMPARATOR|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorrhoid. Other procedures will not be associated.
62226218|NCT00596427|PLACEBO_COMPARATOR|Placebo tablet 3 tablets 2x/day|Type-2 diabetes mellitus patients
62226219|NCT00596427|EXPERIMENTAL|Colesevelam HCL 625 mg: 3 tablets 2x/day|Type-2 diabetes mellitus patients
62226220|NCT04714931|OTHER|Sentinel Lymph Node|Sentinel lymph nodes which can be identified with the tracer involvement will be removed. Then, systematic lymphadenectomy will be performed according to the routine practice.
62419122|NCT01361698|EXPERIMENTAL|IMR program|The program is organised into 11 curriculum topic areas: recovery strategies, practical facts about mental illness, the stress-vulnerability model, building social support, using medication effectively, drug and alcohol use, reducing relapses, healthy lifestyle, coping with stress, coping with problems and symptoms, and getting your needs met in the mental health system. In this Danish trial IMR will be implemented in group format with 10 patients assigned to each group and two IMR facilitators, and the IMR program will require nine months of weekly sessions to complete.
62589702|NCT04370704|EXPERIMENTAL|Phase 1 Part 3|Part 1 will confirm the safety of INCAGN02385 + INCAGN02390 + INCMGA00012 when used in combination.
62589703|NCT04370704|EXPERIMENTAL|Phase 1 Part 4|Part 1 will confirm the safety of INCAGN02385 + INCAGN02390 + INCMGA00012 in combination.
62589704|NCT00679289|EXPERIMENTAL|Cohort 1|"KW2871: 5 mg/m\^2 IV every 2 weeks until disease progression~HDI: 20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression"
62589705|NCT00679289|EXPERIMENTAL|Cohort 2|"KW2871: 10 mg/m\^2 IV every 2 weeks until disease progression~HDI: 20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression"
62801065|NCT06262386|EXPERIMENTAL|Patient at risk for disease relapse after surgery|"1. we utilized a relapse prediction model that combined perioperative variation trends of circulating tumor cells and pathologic characteristics that were collated with relapse~   1. circulating tumor cell variation trend: difference between the CTC count on post-operation day 3 and day 1; difference between the CTC count on post-operation day 3 and post-operation~  2. pathologic staging 0-1a/ 1b-4~2. patient with high relapse for relapse~   * Adjuvant was recommended as NCCN guidelines recommended"
62801066|NCT03353844|EXPERIMENTAL|Intradialytic exercise group|These patients will get intradialytic exercise every sessions of hemodiafiltration
62801067|NCT03353844|NO_INTERVENTION|Standard dialysis group|regular and standard of care in every hemodiafiltration sessions (as usual) without intradialytic exercise.
62801068|NCT02621307|EXPERIMENTAL|Salba|50g glucose 25g ground Salba (Salba Corporation Ltd, Buenos Aires, Argentina) 200ml water
62226221|NCT05359497|OTHER|Additional sequences and extra MRI|"PSC patients, suspected for having a dominant stenosis, that undergo additional LMS sequences next to standard care MRI prior to ERCP and an additional MRI/MRCP with additional LMS sequences 8 weeks after ERCP.~MRI images will be analysed by the post-processing tool called MRCP+ and Liver Multiscan, which are performed after the MRI is performed."
62226222|NCT01440712|EXPERIMENTAL|Gastrografin|Patients located in this group will be treated with the administration of 100 ml of gastrografin by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
62226223|NCT01440712|PLACEBO_COMPARATOR|physiological serum|Patients included in this group will be treated with 100 ml of physiological serum 0,9% by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
62801069|NCT02621307|EXPERIMENTAL|Flax|50g glucose 31g ground Flax (Bob's Red Mill Natural Raw Whole Flaxseed) 200ml water
62226224|NCT00592254||A|
62226225|NCT01696942|EXPERIMENTAL|Cimzia treatment arm|Beginning at 4 weeks after surgery, patients would be randomly assigned using a pulled card method to receive certolizumab at a dose of 400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks thereafter up to 12 months after enrollment.
62226226|NCT01696942|ACTIVE_COMPARATOR|Mesalamine treatment arm|Beginning at 4 weeks after surgery, patients would be randomly assigned to receive mesalamine 800 mg orally three times daily for twelve months following enrollment.
62226227|NCT04253067|ACTIVE_COMPARATOR|Active fCO2 laser treatment|Laser probe will be inserted into the vagina. The laser treatment is delivered at 6 points to the vaginal wall. Delivery begins at the most proximal and the wand is retracted by 1 cm and another row of laser treatment is delivered. The number of levels is determined by vaginal length.
62419123|NCT01361698|NO_INTERVENTION|Treatment as usual|Patients randomised to the control group will get 'treatment as usual' only. This means individual adapted interdisciplinary treatment including medication, individual support, occupational therapy, psycho-education and group therapy.
62027113|NCT02654080|EXPERIMENTAL|Group 1: Vaccine|Participants will receive the HIV-1 nef/tat/vif, env pDNA vaccine at Day 0 and Months 1 and 3. They will receive the rVSV HIV envC vaccine boost at Months 6 and 9.
62027114|NCT02654080|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will receive placebo vaccine at Day 0 and Months 1, 3, 6, and 9.
62419124|NCT06254859||Normal Signal Group.|During the surgical procedure, there was no occurrence of a decrease in recurrent laryngeal nerve signals or a decrease of less than 10%.
62419125|NCT06254859||Signal Decrease 10-50%.|During the surgical procedure, the signal of the recurrent laryngeal nerve decreased by 10-50%.
62589706|NCT00679289|EXPERIMENTAL|Cohort 3|"KW2871: 20 mg/m\^2 IV every 2 weeks until disease progression~HDI: 20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression"
62801070|NCT02621307|PLACEBO_COMPARATOR|Control|50g glucose 200ml water
62801071|NCT05128201|EXPERIMENTAL|System treatment plus consolidative radiotherapy and Maintenance treatment|4-6 Cycles System chemotherapy (Camrelizumab , Gemcitabine and cisplatin or nedaplatin) ; And local consolidative radiotherapy for all metastatic lesion (30-45Gy/3-8F) and Maintenance of Camrelizumab (total 2 years; from first cycles of System chemotherapy to last cycles of miantenance of camrelizumab)
62801072|NCT06284850||treatment with empagliflozin 10mg od|empagliflozin 10mg OD
62801073|NCT03212118|OTHER|Treatment as usual|"Treatment as usual untouched. This is the standard The Norwegian Labour and Welfare Administration (NAV) procedure."
62801074|NCT03212118|ACTIVE_COMPARATOR|Two talks|Two standard talks (not including elements from motivational interviewing)
62027115|NCT01485510|EXPERIMENTAL|Glasgow Infant and Family Team (GIFT)|A service developed by Charles Zeanah and colleagues in New Orleans, that aims to improve the mental health of maltreated infants.
62027116|NCT01485510|ACTIVE_COMPARATOR|Family Assessment & Contact Service|A social-work based service that aims to assess maltreated children and make recommendations about their future care.
62027117|NCT05164822||Necrotizing Vasculitis|"Patient with an initial diagnosis or a relapse of :~- Systemic Vasculitic Neuropathy (SVN): Primary Necrotizing Vasculitis answering the Chapel Hill Consensus Conference criteria associated with a symptomatic Vasculitic Peripheral Neuropathy~Or~- Non Systemic Vasculitic Neuropathy (NSVN): pure symptomatic peripheral neurological impairment without systemic visceral impairment"
62027118|NCT06635096|EXPERIMENTAL|Multimodal Thermal Therapy alone|Multimodal Thermal Therapy
62027119|NCT03387852|EXPERIMENTAL|SAR440340|Participants received 2 injections of SAR440340 300 milligram (mg) along with 1 injection of dupilumab placebo, subcutaneous (SC) once every 2 weeks (Q2W) for 12 weeks.
62027120|NCT03387852|ACTIVE_COMPARATOR|Dupilumab|Participants received 1 injection of dupilumab 300 mg along with 2 injections of SAR440340 placebo, SC Q2W for 12 weeks.
62027121|NCT03387852|EXPERIMENTAL|SAR440340 + Dupilumab|Participants received 2 injections of SAR440340 300 mg along with 1 injection of dupilumab 300 mg, SC Q2W for 12 weeks.
62027122|NCT03387852|PLACEBO_COMPARATOR|Placebo|Participants received 2 SC injections of SAR440340 placebo along with 1 SC injection of dupilumab placebo Q2W for 12 weeks.
62226228|NCT04253067|SHAM_COMPARATOR|Sham fCO2 laser treatment|Laser probe will be inserted into the vagina. To prevent the delivery of laser energy, the laser will remain in standby mode during the visit. Keeping the laser in standby mode prevents laser exposure. The treatment will appear to be the same as the active treatment. The machine maintains a low humming noise while in standby mode.
62226229|NCT03174912|ACTIVE_COMPARATOR|Group 1|Whole patient group (patients not treated with BCG and patients treated with BCG)
62419126|NCT06254859||Signal Decrease 50-90%.|During the surgical procedure, the signal of the recurrent laryngeal nerve decreased by 50-90%.
62589707|NCT06572579||Ultrasound-guided pharmacopuncture group|Patients diagnosed with spinal disorders who have undergone ultrasound-guided pharmacopuncture treatment
62589708|NCT03401840|EXPERIMENTAL|postoperative SBRT|SBRT consists of a total dose of 36 Gy in 6 fractions over 11-13 days
62589709|NCT02986282|OTHER|Single arm|Interventions - repeated ankle - brachial index measurement before and after electrical cardioversion in patients with atrial fibrillation
62735286|NCT04490525|NO_INTERVENTION|Control|The control group will follow a conventional rehabilitation program (Egstrup et al 2015). The control subjects will participate in medicine titration for 1- 3 months and conventional rehabilitation for 3 months. The participation in the control group will last up to six months. The exact period depends on how fast the titration of medicine is conducted. At enrolment, after titration of medicine, and end of rehabilitation, the patient will fill in a questionnaire. This will take 5 minutes each time.
62027123|NCT00413153|ACTIVE_COMPARATOR|1|Boosted Reyataz (300mg atazanavir + 100mg ritonavir)
62027124|NCT00413153|ACTIVE_COMPARATOR|2|Kaletra (pre-study dose)
62027125|NCT00283504|EXPERIMENTAL|all patients received Xolair/active drug|One arm:active drug
62027126|NCT03675386|ACTIVE_COMPARATOR|Control Group|Patients in the control group will receive standard care, which involves standard postoperative follow-up with their surgeon/primary care provider. Patients will also be sent with a link for an online multimedia tool during each follow-up time point that will provide information and education regarding non-pharmacologic techniques for managing pain. At the end, all patients in the control arm will be invited to join the TPSP after one year of follow-up if they are still taking opioids.
62027127|NCT03675386|EXPERIMENTAL|Interventional Group|Patients in the interventional group will be given a Transitional Pain Service follow-up appointment at the following postoperative time points (2 to 6 visits for the first two months, and then 1 to 2 visits on a monthly basis until one year). At each visit, patients will meet with the clinical psychologist and chronic pain specialist. Patients in the intervention group will have access to the Manage My Pain (MMP) App. which allows people living with pain to quickly and easily track their pain and function on a daily basis on their smartphones or a browser on their desktop or mobile device. One-page clinical reports will capture the changes in patients' outcome data between clinical visits over the course in time.Clinic visits can be offered in person at the hospital or over telehealth (video conference) based on the patient's preference and clinician's judgment for telehealth suitability.
62226230|NCT03174912|NO_INTERVENTION|Group 2|Patients not treated with BCG
62226231|NCT03174912|ACTIVE_COMPARATOR|Group 3|Patients treated with BCG
62226232|NCT04413773|ACTIVE_COMPARATOR|Treatment as usual|Treatment as Usual, Explanation of standard procedures before, during and after surgery by nurse
62419127|NCT06254859||Signal Absence Group.|During the surgical procedure, the signal of the recurrent laryngeal nerve decreased by more than 90% or completely disappeared.
62589710|NCT04870099|EXPERIMENTAL|Guided self-help|"Participants are given access to the World Health Organization's (WHO) Doing what matters in times of stress: An illustrated guide (https://www.who.int/publications/i/item/9789240003927) virtually (i.e., as a pdf) and/or in print. Each participant is assigned an eCoach -- an undergraduate, post-baccalaureate, or graduate research assistant -- who will meet with the participant for a 60-minute welcome call describing the intervention and 3-6 sessions of guidance focused on promoting adherence to the manual and using skills in everyday life."
62589711|NCT02223936|OTHER|children with Prenatal enlarged nuchal transluce|
62589712|NCT02223936|OTHER|Control|
62589713|NCT06667102|EXPERIMENTAL|Improving Teacher Fidelity to SISI|A noncurrent multiple baseline design across teacher participants will be utilized to assess the extent of support required by teachers to become proficient in SISI implementation. In this study, the independent variable is the SISI training, and the dependent variable is teacher fidelity to the SISI program as measured by the SISI fidelity checklist.
62027128|NCT06067087||Patients with advanced cancer|Patients with advanced cancer that are referred to the Enhanced Supportive Care Team at University College London Hospital
62226233|NCT04413773|EXPERIMENTAL|Treatment as usual + Video|Treatment as usual and additionally Video
62226234|NCT05677152|ACTIVE_COMPARATOR|Zoledronic Acid|zoledronic acid 5 mg (Aclasta®) administered as single intravenous infusion (100 ml): Verum
62226235|NCT05677152|PLACEBO_COMPARATOR|physiological saline solution 0.9%|Sodium chloride (physiological saline solution 0.9%) administered as single intravenous infusion (100 ml): Placebo
62419128|NCT05179655|EXPERIMENTAL|ERITA + TAU (Treatment as usual)|The Emotion Regulation Individual Therapy for Adolescents (ERITA) intervention as add-on to TAU consists of 11 weeks, manualized online therapy based on the methods of Cognitive Behavioral Therapy (CBT), Dialectical Behavior Therapy (DBT), and Acceptance and Commitment Therapy (ACT) adapted for youth
62419129|NCT05179655|OTHER|TAU (Treatment as usual)|Within mental health services in Denmark child and adolescent psychiatrists provide specialized treatment for young psychiatric patients as outpatient services. In this study the control intervention (TAU) consists of clinical assessment and treatment for patient's current primary psychiatric condition (referral condition and A-diagnosis).
62419130|NCT02599610|ACTIVE_COMPARATOR|Digital vaginal examination|Patients assigned to this group will be followed-up with digital vaginal examinations as described in intervention protocol.
62419131|NCT02599610|EXPERIMENTAL|Transperineal ultrasound examination|Patients assigned to this group will be followed-up with transperineal ultrasound examinations as described in intervention protocol.
62589714|NCT06667102|EXPERIMENTAL|Control and Experimental Groups: SISI Efficacy|"This pre- and post- study provides baseline data on deaf children's sign language development prior to receiving SISI. Additionally, each participating teacher will submit a recorded instructional unit showcasing their best methods for supporting sign language development. This provides a further layer of baseline analysis, allowing the PI to assess the instructional methods already in use prior to SISI professional development and implementation. Demographic data for both teachers and students will also be collected in preparation for the quasi-experiment study.~Then, teachers will be assigned to either an experimental group, which will receive SISI professional development, or a control group that will continue with their usual teaching practices. In this quasi-experiment study, SISI's efficacy will be evaluated by comparing outcomes between the two groups."
62589715|NCT06667102|EXPERIMENTAL|Pre- and Post- Descriptive Study Data of Language Outcomes Children|Up to 40 children from 4 classes will provide pre- and post-data in which they respond to a prompt in sign language on video.
62735287|NCT05151159||FIGO group 1A1|20 subjects with tumor invasion depth up to 1 mm
62735288|NCT05151159||FIGO group 1A2|20 subjects with an invasion depth of 1 - 3 mm
62226236|NCT05034302||Recordings|Selection criteria include individuals between the ages of 18-85 years, no major chronic illness that impair mobility and able to complete activities of daily living without assistance. We will recruit approximately equal number of men and women and 30% of the sample will be racial or ethnic minorities.
62226237|NCT04262947|ACTIVE_COMPARATOR|Conventional Method|Placement of peripheral venous catheter using conventional methods
62226238|NCT04262947|EXPERIMENTAL|VeinViewer Visualization Only|Use of a VeinViewer to visualize the most suitable target. Once the target has been identified and marked, the device will be placed aside and the peripheral venous catheter will be placed using conventional methods
62226239|NCT04262947|EXPERIMENTAL|Constant Imaging with VeinViewer|Identification of the most suitable target and placement of a peripheral venous catheter under constant imaging with a VeinViewer
62419132|NCT06414265|EXPERIMENTAL|Treatment Arm|SATURN Trans-septal Transcatheter mitral valve replacement (TMVR) System
62419133|NCT05242146|EXPERIMENTAL|GB5121|GB5121 orally twice per day (BID)
62419134|NCT06404931|SHAM_COMPARATOR|Vaginal hysterectomy plus anterior colporrhaphy|Vaginal hysterectomy plus anterior colporrhaphy
62419135|NCT06404931|SHAM_COMPARATOR|Vaginal hysterectomy plus sacrospinous fixation with Anchorsure® device|Vaginal hysterectomy plus sacrospinous fixation with Anchorsure® device
62419136|NCT06404931|EXPERIMENTAL|Vaginal hysterectomy plus matrix reinforcement and sacrospinous fixation with Anchorsure® device|Vaginal hysterectomy plus matrix reinforcement and sacrospinous fixation with Anchorsure® device
62419137|NCT04456764|EXPERIMENTAL|SaFTiE|The SaFTiE intervention includes: \[a\] real-time text-message assessments of fatigue and sleep during and between scheduled shift work; \[b\] tailored text-message alerts that promote adopting evidence based strategies for mitigating fatigue when high levels of fatigue or sleepiness are reported; \[c\] a mobile app that delivers goal setting, summary data of sleep/fatigue indicators from all study participants, and video interviews of EMS clinicians focused on sleep and fatigue.
62735289|NCT05151159||FIGO group 1B1|20 subjects with invasion depth up to 2 cm
62226240|NCT01279512|EXPERIMENTAL|Metformin reciepiants|Infertile overweight women with PCO who received Metformin
62226241|NCT01279512|EXPERIMENTAL|Acarbose reciepiants|Infertile overweight women with PCO who received Acarbose
62027129|NCT04956393|EXPERIMENTAL|Immediate SOAR Program|Participants with a past sport-related knee injury randomized to the 'immediate intervention' group will complete an 8-week (weeks 1-8) SOAR program (Knee Camp, home-based exercise-therapy and physical activity with tracking, weekly 1:1 physiotherapist counseling sessions, and optional weekly group-based exercise classes) followed by an additional 8 weeks (weeks 10-17) of home-based exercise-therapy and physical activity with tracking, weekly 1:1 PT counseling sessions, and optional weekly group-based exercise classes. Consented trained physiotherapists will deliver the SOAR program throughout the study period to one or more immediate SOAR group knee injury participants.
62027130|NCT04956393|OTHER|Delayed SOAR Program|Participants with a past sport-related knee injury randomized to the 'delayed intervention' group will have a 9-week unstandardized delay before completing an 8-week SOAR program (weeks 10-17). During the delay (weeks 1-9) the delay comparison intervention will be unstandardized to reflect usual care in Canada. After the 9-week delay, these participants will complete an 8-week (weeks 10-17) SOAR program (Knee Camp, home-based exercise-therapy and physical activity with tracking, weekly 1:1 PT counseling sessions, and an optional weekly group-based exercise classes). Consented trained physiotherapists will deliver the SOAR program from week 10 to week 17 to one or more delayed SOAR group knee injury participants.
62419138|NCT04456764|PLACEBO_COMPARATOR|Attention Placebo Control|The attention placebo control includes: \[a\] real-time text-message assessments of teamwork during and between scheduled shift work; \[b\] text-message alerts that promote techniques for mitigating poor teamwork when episodes of poor teamwork are reported; \[c\] a mobile app that delivers goal setting, summary data of teamwork indicators from all study participants, and video interviews of EMS clinicians focused on teamwork.
62419139|NCT06433765||BRIUMVI® Exposed Cohort|Pregnant participants with MS who are exposed to any dose of BRIUMVI® at any time during pregnancy (from conception to pregnancy outcome) or before pregnancy (within 6 months of the date of conception \[DOC\]).
62027131|NCT05133557|PLACEBO_COMPARATOR|Placebo|Half the participants receiving placebo gum (2 gram; 1 gram xylitol) first,
62027132|NCT05133557|EXPERIMENTAL|BBE gum|Half receiving first the BBE gum (2 gram; 1 gram xylitol and 100 mg BBE) that were identical in size, shape, color and flavor. After 1 week the groups cross-over and chewed the other gum.
62027133|NCT03797534|NO_INTERVENTION|Standard anticoagulant group|
62027134|NCT03797534|EXPERIMENTAL|Bayesian model group|
62027135|NCT04698980|OTHER|participants selected according to their G6PD activity|"* 50 subjects with severe deficit G6PD activity (\<30% of the median in the general population, ie 3.6U / g Hb), adults or children two years and over.~* 50 subjects with intermediate G6PD activity (30-80%), adults.~* 50 subjects with normal G6PD activity (\> 80% ie\> 9.6U / g Hb), adults."
62027136|NCT04850534||EGD+NSBB|Patients receiving both endoscopic therapy and non-selective beta-blockers for treating high-risk esophagogastric varices
62027137|NCT04850534||EGD|Patients receiving mono endoscopic therapy for treating high-risk esophagogastric varices
62027138|NCT03447769|EXPERIMENTAL|canakinumab|Participants received 200mg of canakinumab subcutaneously every 3 weeks for up to 18 cycles (approximately 54 weeks)
62027139|NCT03447769|PLACEBO_COMPARATOR|Placebo|Participants received canakinumab placebo subcutaneously every 3 weeks for up to 18 cycles (approximately 54 weeks)
62027140|NCT02341716|ACTIVE_COMPARATOR|Walk advice|All WA patients receive best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and are recommended outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The WA patients are unsupervised during the study period and are followed by a blinded observer at baseline, three, six and 12 months.
62027141|NCT02341716|ACTIVE_COMPARATOR|Hospital-based supervised exercise|All SET patients receive the same basic treatment as WA patients: best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and recommendation of outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The SET group in addition receives three times weekly during six months in-hospital muscle exercise therapy in a group supervised by a physiotherapist. After the six months of supervised exercise therapy, the SET patients are recommended to continue the same muscle exercise therapy at home, but without feedback, between seven and 12 months.
62226242|NCT00640081|ACTIVE_COMPARATOR|D|Intermittent chemotherapy plus intermittent cetuximab treatment comprising 12 weeks of chemotherapy plus cetuximab followed by a period off all therapy, with reintroduction of the same chemotherapy and cetuximab regimen for a further 12 weeks after initial progression off treatment
62589716|NCT06667102|EXPERIMENTAL|Single Case Research Design: Deaf Children's Language Growth|Single case research design will provide robust day-to-day data of causal relations between SISI and sign language skills. Given teachers' high fidelity in SISI implementation, a noncurrent multiple baseline design across child participants will be applied to assess the extent of SISI improving deaf children's target sign language skills in a year. The independent variable of this study is the SISI implementation, which is used to improve the dependent variables which will be target sign language skills.
62226243|NCT00640081|EXPERIMENTAL|E|Intermittent chemotherapy plus continuous cetuximab treatment comprising 12 weeks of chemotherapy plus cetuximab followed by a period of withdrawal of the chemotherapy, but continued weekly cetuximab monotherapy (maintenance cetuximab), with reintroduction of the same chemotherapy regimen to the cetuximab for a further 12 weeks after initial progression off chemotherapy treatment
62226244|NCT03172676|NO_INTERVENTION|Helicobacter pylori negative patients|chronic immune thrombocytopenic purpura patients who will be diagnosed negative for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients.
62226245|NCT03172676|ACTIVE_COMPARATOR|Helicobacter pylori positive patients with intervention|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients will receive treatment of Helicobacter pylori: Amoxicillin for 14 days, Clarithromycin for 14 days and Proton pump inhibitor for one month).
62419140|NCT06433765||BRIUMVI® Unexposed Cohort|Pregnant participants with MS who are not exposed to any dose of BRIUMVI® or other anti-CD20 monoclonal antibodies at any time during pregnancy but may be exposed to other products for the treatment of MS.
62419141|NCT04711850||Imlifidase treatment in feeder Study 16-HMedIdeS-12|No treatment is given in this long-term follow-up study. In the feeder study (16-HMedIdeS-12) the patients in this group were treated with imlifidase.
62419142|NCT04711850||Plasma exchange (PE) treatment in feeder Study 16-HMedIdeS-12|No treatment is given in this long-term follow-up study. In the feeder study (16-HMedIdeS-12) the patients in this group were treated with PE.
62589717|NCT05040607||Primary Ciliary Dyskinesia (PCD)|"The first stage of the study:~Data of 20 PCD patients from the database recorded between 10 July 2015 and 10 January 2017.~The second stage of the study:~-Data of 14 PCD patients who had lower inspiratory muscle strength from the same database underwent supervised inspiratory muscle training (IMT) with tapered flow resistive loading using Powerbreathe K5 device at our research unit and airway clearance techniques (ACT) as a home-based therapy for 6 weeks from the database recorded between 10 July 2015 and 10 January 2017."
62589718|NCT05040607||Healthy Group|Data of 20 healthy subjects from the database recorded between 10 July 2015 and 10 January 2017.
62589719|NCT04863781|EXPERIMENTAL|Intervention|All 11 modules will include the following elements: introduction to the topic; two types of assessments (1) adherence to at-home relaxation training practice (following week 2) and (2) 3-5 topic-specific questions to tailor video-based content; a cognitive component; a relaxation component; and a wrap up that includes a brief assessment of module comprehension. Each user will view 5-7 videos per module. Videos will be tailored to user and will last between 2 and 4 minutes. Total time per module will be 20 to 30 minutes. Between modules, users will receive (based on their timing preferences) supportive texts intended to motivate continued engagement or to affirm the life experiences of African American women
62589720|NCT04863781|ACTIVE_COMPARATOR|Control|Two mobile courses: Introduction to Stress Management and Techniques for Coping with Stress. Users will be informed that the courses will be completed on their phone, that they are video-based, and that they should spend between 20 and 30 minutes each week, for the next 11 weeks, learning the material. The introductory course defines stress, describes the different sources of stress, and the influence of personality on stress. The coping module includes training in cognitive coping skills, guided imagery, progressive relaxation, autogenic training, and the importance of physical activity to manage stress. All lessons include course assessments. During the intervention period, controls will receive weekly text messages encouraging completion of material.
62589721|NCT02056366|ACTIVE_COMPARATOR|α-lipoic acid|α-lipoic acid PO medication, 600mg per day, for 6weeks α-lipoic acid PO medication, 1200mg per day, for 6weeks
62589722|NCT02056366|NO_INTERVENTION|No treatment group|No Intervention
62419143|NCT06702943||Pediatrics patients having EVD and suffering from meningitis caused by MDR bacteria|
62419144|NCT06703268|EXPERIMENTAL|HSK7653|HSK7653 10mg Q2W
62419145|NCT06703268|ACTIVE_COMPARATOR|Daily DPP-4 inhibitor|Daily DPP-4 inhibitor
62589723|NCT02358109|EXPERIMENTAL|Intervention arm|Intervention group receive directed classes of physical conditioning, 3 hours/week during a period of 16 weeks
62589724|NCT02358109|NO_INTERVENTION|Control arm|Control group do not receive physical conditioning intervention but usual care advice and are measured at the beginning and at the end of the study
62589725|NCT05529615|OTHER|stage II with high risk and stage III with low risk（T1-3N1）|ctDNA will be detected at 7 days after surgical treatment. If，ctDNA(-)-\> observation； ctDNA(+)-\> 1:1 randomized as Capeox chemotherapy 3 months and observation. CtDNA will be detected at 4 months after surgical treatment.
62589726|NCT05529615|OTHER|stage III with high risk（T4 or N2 or both）|"ctDNA will be detected at 7 days after surgical treatment. All the stage III with high risk will receive Capeox chemotherapy 3 months. ctDNA will be detected after the completion of Capeox chemotherapy 3 months. If，ctDNA(-) -\> observation； ctDNA(+) -\> 1:2 randomized as Capeox chemotherapy 3 monthsand second line treatment（decided by physician）.~CtDNA will be detected at 7 months after surgical treatment."
62589727|NCT03992573|EXPERIMENTAL|Study group|
62801075|NCT03212118|EXPERIMENTAL|Motivational interviewing|Two standard talks with a motivational interviewing content.
62226246|NCT03172676|NO_INTERVENTION|Helicobacter pylori positive patients without intervention|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients will not receive treatment of Helicobacter pylori during the study,these patient group will receive treatment of Helicobacter pylori after the end of the study
62419146|NCT05116761|PLACEBO_COMPARATOR|Treatment Arm 1|Normal Saline 100 mL
62226247|NCT00368160|EXPERIMENTAL|1|eszopiclone 3 mg
62419147|NCT05116761|EXPERIMENTAL|Treatment Arm 2|Normal saline 85 mL and ExoFlo 15 mL, which is 10.5 x 10\^8 EV
62419148|NCT01278446|EXPERIMENTAL|Test Formula|New hydrolyzed whey formula
62419149|NCT01278446|ACTIVE_COMPARATOR|Control Formula|Commercially available hydrolyzed infant formula
62419150|NCT01534429||chronic post-herniorraphy pain|patients with severe chronic post-herniorraphy pain
62419151|NCT02091388|EXPERIMENTAL|LY03004 25 mg|5 intramuscular injections 25 mg over 113 days
62419152|NCT02091388|ACTIVE_COMPARATOR|Risperdal® Consta® 25 mg|5 intramuscular injections 25 mg over 113 days
62419153|NCT06702657|EXPERIMENTAL|Group A: stenting group|
62226248|NCT00368160|PLACEBO_COMPARATOR|2|Placebo tablet
62027142|NCT02341716|ACTIVE_COMPARATOR|Home-based supervised exercise|All HET patients receive the same basic treatment as WA patients: best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and recommendation of outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The HET group patients in addition perform the same muscle exercise therapy three times weekly during six months as the SET patients, but in their homes, and are supervised and given feedback by phone calls every 14th day by a physiotherapist. After six months of supervised exercise therapy, the HET patients are recommended to continue the same muscle exercise therapy, but without feedback, between seven and 12 months.
62027143|NCT04000906|EXPERIMENTAL|Experimental Arm|Pressurized intraperitoneal aerosol chemotherapy (PIPAC) administration of Nab paclitaxel and cisplatin
62801076|NCT00431626|EXPERIMENTAL|Laser TURP with dutasteride|Prior to and after standard treatment with laser TURP, dutasteride is applied to each patient
62801077|NCT00431626|PLACEBO_COMPARATOR|Laser TURP with placebo|Prior to and after standard treatment with laser TURP, placebo is applied to each patient
62027144|NCT00402753|EXPERIMENTAL|Group 1|Physical exercise group: Combined supervised physical activity: Endurance and Resistive strength
62027145|NCT00402753|NO_INTERVENTION|Group 2|Usual care control group
62226249|NCT02703493|EXPERIMENTAL|Cohort 1|Patients will receive 6 weeks of Intensity-Modulated Radiation Therapy (IMRT) (standard of care) followed by the dose escalated stereotactic radiosurgery (SRS Boost). Cohort 1 will receive 8 Gy in a single fraction, cohort 2 will receive 10 Gy in a single fraction and cohort 3 will receive 10 Gy split into two fractions.
62419154|NCT06702657|ACTIVE_COMPARATOR|Group A: medical therapy group|
62419155|NCT06702657|OTHER|Group B : stenting group|
62419156|NCT03237481|EXPERIMENTAL|Treatment Group 1: HTX-011|HTX 011 (bupivacaine/meloxicam)
62419157|NCT03237481|ACTIVE_COMPARATOR|Treatment Group 2: Bupivacaine HCI|Bupivacaine HCl
62419158|NCT03237481|PLACEBO_COMPARATOR|Treatment Group 3: Saline Placebo|Saline placebo
62419159|NCT06666517|SHAM_COMPARATOR|1- Subtyping of Breast Cancer Patients.|Biopsy collection from patients who were diagnosed with breast cancer, subtyping of biopsy materials, and identification of patients with Luminal A, Luminal B, HER2 positive group, and triple-negative types.
62589728|NCT03992573|NO_INTERVENTION|Control group|
62801078|NCT03225235|EXPERIMENTAL|Hypofractionated Stereotactic SBRT|"By assuming a hypofractionated irradiation scheme, it is assumed that between the fractions sublethal radiation damage is being treated and the time factor does not significantly affect RT result. The SBRT fractional dose was determined on the basis of a Biologically Effective Dose (BED) calculation using a linear-square model, which assumes that α / β takes the following values for:~* tumor (RS) = 1.5~* Late rectal and bladder complications = 3.0~* early rectal and bladder complications = 10.0."
62801079|NCT02241564||Malignancy post transplantation|
62419160|NCT06666517|SHAM_COMPARATOR|5- Surgery Phase|Surgery after neoadjuvant chemotherapy
62419161|NCT06666517|NO_INTERVENTION|2- Identification of patients to be included in the study.|Identification of patients diagnosed with breast cancer who meet the study's eligibility criteria.
62419162|NCT06666517|EXPERIMENTAL|3- Second Biopsy|Taking biopsies from the center of the tumor and the peritumoral stroma of the same mass during marking of the mass before neoadjuvant chemotherapy
62226250|NCT03006731|EXPERIMENTAL|High Intensity Training|High Intensity Interval Training patients will attend the centre 3 times/week for 24 weeks. All subjects will participate in MICE aerobic training 5 days/week in the first four weeks of the study to provide a foundation of fitness and endurance for the safe prescription of HIIT. Subsequently, the HIIT group will replace 3 MICE training days with 3 HIIT. HIIT sessions will include two 20 minute protocols; 30:60 second work:active rest ratio, and 120:180 second work:active rest ratio on a treadmill with a harness for fall protection. In addition to supervised exercise training (3 times/week), MICE will be conducted 2 times/week in the home/community, which has been shown to be both safe and effective
62419163|NCT06666517|NO_INTERVENTION|4- Detection of cancer-associated fibroblasts|Analysis of cancer-associated fibroblasts using immunohistochemical methods on materials taken from the periphery and center of patients' tumors during the second biopsy.
62801080|NCT05206149|EXPERIMENTAL|Intranasal Administration of Glucagon|Intranasal administration of glucagon in healthy subjects
62419164|NCT06666517|NO_INTERVENTION|6- Statistically Analyze|The investigators compare cancer-associated fibroblast densities by analyzing monitored patients' clinical and pathological data and statistically analyze and interpret the results.
62589729|NCT06667791|EXPERIMENTAL|Study Group|
62589730|NCT06667791|ACTIVE_COMPARATOR|Control|
62589731|NCT00971087|OTHER|Biopsy|subjects presenting for a breast biopsy procedure, subject will be imaged before her biopsy procedure with the investigational 2D plus 3D mammography system
62589732|NCT00971087|OTHER|screening|subjects presenting for routine asymptomatic mammograms and will then have an investigational 2D plus 3D mammogram
62589733|NCT05908123|EXPERIMENTAL|Blank Center CARE Model (Communication, Advocacy, Resilience, Education)|
62589734|NCT04596709|ACTIVE_COMPARATOR|Vitalose|dissolved in water
62589735|NCT04596709|ACTIVE_COMPARATOR|isomaltulose|dissolved in water
62589736|NCT04596709|PLACEBO_COMPARATOR|sucrose|dissolved in water
62801081|NCT05206149|PLACEBO_COMPARATOR|Intranasal Administration of Placebo|Intranasal administration of placebo (isotonic saline solution) in healthy subjects
62226251|NCT03006731|ACTIVE_COMPARATOR|Moderate Intensity Exercise|Moderate Intensity Continuous Exercise patients will attend the centre 3 times/week for 24 weeks. Participants will be progressed to 30 to 60 minutes of continuous exercise at the heart rate that occurred at the anaerobic threshold on the exercise test. Participants will exercise on a treadmill with a harness ofr fall protection. In addition to supervised exercise training (3 times/week), MICE will be conducted 2 times/week in the home/community by both cohorts.
62226252|NCT03825653||one group|"This study will be carried out on three hundred postmenopausal.They will be selected from gynecological outpatient clinic of (Oum El Masryn Hospital).~their age will range from 60-70 years.Their BMI will not exceed 30 kg/m2. They are complaining from stress urinary incontinence."
62419165|NCT05961319||Utilizing Smart Home Monitoring System in a Simulated Home Environment (in Hospital)|The project involves recruiting participants who will reside in a simulated condo environment within the Glenrose Rehabilitation Hospital. These participants will be remotely monitored using various sensors, including ones that track their interactions with appliances and furniture, smart biomechanics devices that assess their physical balance and strength, and a positioning system. By collecting and analyzing data from these sensors, the project aims to gain insights into the participants' daily activities, functional abilities, physical condition, and spatial behaviour.
62419166|NCT06701370|EXPERIMENTAL|Task oriented Training Group|"Conventional rehabilitation + Upper arm Ergometer~+ Task oriented Training"
62419167|NCT06701370|ACTIVE_COMPARATOR|Conventional Rehabilitation Group|Conventional rehabilitation + Upper arm Ergometer
62419168|NCT00739206|EXPERIMENTAL|Cohort 1|Adult patients with uncomplicated malaria
62419169|NCT00739206|EXPERIMENTAL|Cohort 2|Pediatric patients with uncomplicated malaria
62419170|NCT00739206|EXPERIMENTAL|Cohort 3|Pediatric patients with severe malaria
62419171|NCT05330611|EXPERIMENTAL|Ultrasound-guided Cryoneurolysis: Group A|"Patients who are admitted to the Emergency Department after a traumatic injury. Patients will have rib fractures in any of ribs 3-9. Patients will be 18-64 years of age and will be randomized (1:1) to the ultrasound-guided cryoneurolysis group within 72 hours of admission to the ED.~Intervention is ultrasound-guided cryoneurolysis of intercostal nerves creating lost lasting pain relief. Device used for cryoneurolysis is Iovera Smart tip 190"
62419172|NCT05330611|ACTIVE_COMPARATOR|Standard-of-Care : Group B|Patients who are admitted to the Emergency Department after a traumatic injury. Patients will have rib fractures in any of ribs 3-9. Patients will be 18-64 years of age and will be randomized (1:1) to Standard of Care which typically includes multi-modal pain therapy and pulmonary toilet.
62419173|NCT01516684|EXPERIMENTAL|Arm I (EMLA)|Patients receive topical EMLA cream 60 minutes to 4 hours prior to the LP followed by standard sedation with fentanyl citrate and propofol.
62419174|NCT01516684|ACTIVE_COMPARATOR|Arm II (placebo)|Patients receive topical placebo cream 60 minutes to 4 hours prior to the LP followed by standard sedation with fentanyl citrate and propofol.
62589737|NCT04596709|PLACEBO_COMPARATOR|glucose|dissolved in water
62735290|NCT05151159||FIGO group 1B2|20 subjects with tumor invasion depth\> 2 cm 20 subjects with tumor invasion depth\> 2 cm
62801082|NCT00949507||anaesthesia using propofol|the children are anaesthetized using intravenous anaesthesia with propofol and remifentanil; a binasal catheter is used for administration of oxygen during the anaesthesia
62735291|NCT04762992|EXPERIMENTAL|Intervention group, enoxaparin|Enoxaparin subcutaneous injections
62801083|NCT00949507||anaesthesia using sevoflurane|the patients are anaesthetized using sevoflurane 1 MAC; a laryngeal mask is used
62801084|NCT05639231|EXPERIMENTAL|INTOMOB intervention|"The intervention will be multilevel, targeting the patients, healthcare professionals (HCPs) and environment, as described under Intervention description."
62801085|NCT05639231|NO_INTERVENTION|Control|"Control procedure in the randomized trial:~* Patients will receive standard of care, including physiotherapy if prescribed by the hospital physician and usual mobility recommendations and support by the HCPs.~* HCPs will neither complete the e-learning, nor receive the checklist and the oral presentation.~* The environment will not be modified in regards to mobility. Already existing information on this topic (e.g., small posters hanging in patient rooms) will not be removed, since it corresponds to current standard of care in some hospitals.~In the pilot study, there will be no control procedure, since the objective is to assess experience and feasibility of the intervention, not its effects."
62801086|NCT01900158|EXPERIMENTAL|Phase I|Experimental PCI treatment in dose escalation cohorts consist of Amphinex injection (at different doses) plus a single standard dose of Gemcitabine (1000 mg/m2) plus intraluminal light at the tumour area (at different doses). In addition up to 8 cycles of standard chemotherapy doses of Gemcitabine (1000 mg/m2) and Cisplatin (25 mg/m2) was provided. In the Extended part of the study (last cohort) an additional PCI treatment was introduced at Cycle 5 in the treatment Schedule.
62801087|NCT01128049|ACTIVE_COMPARATOR|Normal Patient Population|Non-Dry Eye patient population (intervention remains the same across all arms)
62226253|NCT03296033|ACTIVE_COMPARATOR|24 Hours group|Group one will be instructed to administer their last dose of enoxaparin at 07:00 in the morning on the day prior to their scheduled surgery date. This will mean that patients who have their surgery scheduled for 07:00 the following day will be 24-hours removed from their last dose. Patients presenting for surgery later in the day would be slightly farther removed from their last dose, however this is currently considered normal clinical practice.
62226254|NCT03296033|EXPERIMENTAL|36 Hours Group|Group 2 will be instructed to administer their last dose of enoxaparin at 19:00 in the evening two days prior to their scheduled surgery date. Patients presenting for surgery at 07:00 two days later will be 36-hours removed from their last dose. Patients presenting for surgery later in the day would be slightly farther removed from their last dose, but again this mimics normal clinical practice in which the timing of the last dose of self-administered enoxaparin is not routinely adjusted based on the scheduled surgical start time.
62419175|NCT06336538|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy|MBCT-Brief includes 8 weekly 1-hour group sessions delivered either via telephone or video teleconferencing. The decision to deliver the intervention either via phone or teleconferencing will be made based on participant preference obtained during the formative focus groups. Telephone delivery of MBCT-Brief only requires a landline, while teleconferencing requires either a smartphone, tablet, or computer with audio and video functionality. During the MBCT-Brief intervention the instructor will lead in-session practice of medication and cognitive therapy exercises, guided inquiry, and assign and review at-home practice exercises. All sessions will be audio-recorded. Participants will be encouraged to practice daily meditation in between group sessions for 20 minutes, 6 days per week. Participants will complete practice logs to document daily meditation practice.
62419176|NCT01874015|ACTIVE_COMPARATOR|mesenchymal cell and fibroblast transplantaion|The patients with crohn's disease who underwent mesenchymal cell and fibroblast injection.
62419177|NCT01874015|ACTIVE_COMPARATOR|mesenchymal cell transplantaion|The patients with Crohn's disease who underwent mesenchymal cell transplantation.
62419178|NCT04498806|EXPERIMENTAL|Intervention|Pre-op appointment, patient will receive Fitbit device to track physical activity.
62419179|NCT02235415||Motens|
62419180|NCT01556464|EXPERIMENTAL|ACPAP|Patients in the intervention group will be introduced to the auto-adjusting CPAP (ACPAP) (ResMed S9) during the day and placed on it at night with a nocturnal oximetry and ACPAP download to assess its effectiveness and pressure requirements. The intervention is the application of the ACPAP. The patients will be discharged on ACPAP pressure determined by the ACPAP download (95th percentile pressure in absence of significant air leak) and will be scheduled for an outpatient repeat diagnostic PSG and, if indicated, a full night titration study.
62801088|NCT01128049|ACTIVE_COMPARATOR|MGD Patient Population|Meibomium Gland Dysfunction population(intervention remains the same across all arms)
62801089|NCT01128049|ACTIVE_COMPARATOR|ADDE Population|Aqueous Deficient Dry Eye population(intervention remains the same across all arms)
62801090|NCT03008161|EXPERIMENTAL|Cohort 1|Participants will receive monthly IV infusions of either low dose NPT088 (6 participants) or placebo (3 participants) for a total of 6 months
62801091|NCT03008161|EXPERIMENTAL|Cohort 2|Participants will receive monthly IV infusions of either mid-low dose NPT088 (6 participants) or placebo (3 participants) for a total of 6 months
62801092|NCT03008161|EXPERIMENTAL|Cohort 3|Participants will receive monthly IV infusions of either mid-high dose NPT088 (16 participants) or placebo (8 participants) for a total of 6 months
62801093|NCT03008161|EXPERIMENTAL|Cohort 4|Participants will receive monthly IV infusions of either high dose NPT088 (16 participants) or placebo (8 participants) for a total of 6 months
62801094|NCT05083429||Salmeterol inhaler|Reference group
62801095|NCT05083429||Tiotropium|Exposure group
62801096|NCT01751009|EXPERIMENTAL|Vitamin A supplements|Sprinkles with Vitamin A
62801097|NCT01751009|ACTIVE_COMPARATOR|Sprinkles without Vitamin A|Made of other micronutrients without Vitamin A
62801098|NCT01648634|EXPERIMENTAL|Nebivolol|
62801099|NCT01648634|PLACEBO_COMPARATOR|Placebo|
62801100|NCT05845086|EXPERIMENTAL|Intervention group (Preoperative patient education)|In addition to the usual care provided by the nurses, the intervention group will be provided with multimedia-supported written and verbal pre-operative patient training, reinforced by the teach-back method, created according to the literature.
62801101|NCT05845086|NO_INTERVENTION|Control group (Usual care)|The control group continued to receive the usual care
62801102|NCT04097366|NO_INTERVENTION|Standard of Care|Control arm, no supplementary imaging is given. Participants have mammographic screening 3-yearly as per current standard of are.
62801103|NCT04097366|ACTIVE_COMPARATOR|Abbreviated MRI (ABB-MRI)|Supplementary imaging with abbreviated MRI at study entry and 18 months after baseline mammogram.
62226255|NCT02072161|EXPERIMENTAL|ETC-1002 120 mg/day|Orally, once daily in morning as capsules
62801104|NCT04097366|ACTIVE_COMPARATOR|Automated Breast Ultrasound (ABUS)|Supplementary imaging with automated breast ultrasound at study entry and 18 months after baseline mammogram.
62801105|NCT04097366|ACTIVE_COMPARATOR|Contrast Enhanced Mammography (CESM)|Supplementary imaging with contrast enhanced spectral mammography at study entry and 18 months after baseline mammogram.
62226256|NCT02072161|EXPERIMENTAL|ETC-1002 180 mg/day|Orally, once daily in morning as capsules
62226257|NCT02072161|PLACEBO_COMPARATOR|Placebo|Orally, once daily in morning
62226258|NCT05347420||Diabetic peripheral neuropathy|Patients with diabetic peripheral neuropathy
62801106|NCT02374151||Women with IUPC|Women at term in second or third phase of labor who are indicated to have an IUPC during active labor
62801107|NCT06005181|EXPERIMENTAL|Music listening then piano training|Participants will listen to music for 10 minutes per day for 12 weeks. After one week of assessments, participants will practice piano for 10 minutes per day for 12 weeks.
62801108|NCT06005181|EXPERIMENTAL|Piano training then music listening|Participants will practice piano for 10 minutes per day for 12 weeks. After one week of assessments, participants will listen to music for 10 minutes per day for 12 weeks.
62801109|NCT02304523|EXPERIMENTAL|Test 1|"CDFR0612 Solution 150mL will be mixed with water of 350ml to prepare a bowel cleansing preparation solution 500mL. Take it within 30min. After then, take additional water 500ml within 30min.~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
62226259|NCT05347420||non diabetic peripheral neuropathy|Patient without diabetic peripheral neuropathy
62226260|NCT03182452||Pre Phase (no Alarm Advisor)|No Software installed
62226261|NCT03182452||Post Phase (Alarm Advisor installed)|Software implemented and staff trained (Interventional Phase)
62226262|NCT03862846|EXPERIMENTAL|Group|REN001 Low Dose
62226263|NCT05140941|EXPERIMENTAL|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet, one tablet taken once daily for 84 days
62226264|NCT03234985||acute myeloid leukemia patients|Patients over 18 years with acute myeloid leukemia
62226265|NCT06218147|NO_INTERVENTION|Standard care group|Participants in this group will meet with their CHW for 8 sessions (almost weekly from weeks 14 to 27 gestation) and then 4 sessions (almost biweekly from weeks 28-35 gestation) to match the contact provided in dietary-lifestyle behavioral intervention group. Sessions will be held in person, with videoconferencing and phone call options available when in person is not possible. In these brief check-in sessions, the CHW will be focused on maintaining regular contact, connecting participants to community resources, checking in about any new or ongoing medical issues described by participant during each session visit, and providing overall general information about diabetes management when indicated. CGM will be blinded for both groups.
62226266|NCT06218147|EXPERIMENTAL|Nutrition-behavior lifestyle program group|"Participants in this group meet with their CHWs for 8 sessions (almost weekly from weeks 14 to 27 gestation) and then 4 sessions (almost biweekly from weeks 28-35 gestation). Sessions are held in person, with videoconferencing and phone call options available when in person is not possible. CGM wear is blinded in both groups. The topics for each session are:~1. Welcome and Understanding Diabetes in Pregnancy~2. Understanding Food Groups \& Setting Goals~3. Understanding Carbohydrate Types \& Portions~4. Reading Nutrition Labels \& Understanding Added Sugar~5. Exercise in Pregnancy \& Carbohydrate Counting~6. Grocery Shopping \& Using SNAP or WIC Benefits~7. Managing Stress - Communal Coping as a Family~8. Getting Ready for Baby \& My Family Plan~9. How to Receive Social Support~10. Making Choices at Restaurants \& Social Eating Settings~11. Learning Empowered Communication with Providers~12. Maintaining Changes \& Staying Motivated"
62226267|NCT00889018|ACTIVE_COMPARATOR|group 1|chemotherapy using carboplatin 560mg/m2
62419181|NCT01556464|NO_INTERVENTION|Control|The control group will receive nocturnal oxygen or no therapy while in the hospital and after discharge at the discretion of the attending physician. They will be scheduled for outpatient repeat diagnostic PSG and then, if indicated, a full night titration study.
62801110|NCT02304523|EXPERIMENTAL|Test 2|"CDFR0613 Solution 150mL will be mixed with water of 350ml to prepare a bowel cleansing preparation solution 500mL. Take it within 30min. After then, take additional water 500ml within 30min.~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
62226268|NCT00889018|EXPERIMENTAL|group 2|chemotherapy using 750mg/m2 carboplatin
62226269|NCT00665158|ACTIVE_COMPARATOR|UC|Usual Care Group
62226270|NCT00665158|ACTIVE_COMPARATOR|BI|Behavioural Intervention Group
62735292|NCT04762992|PLACEBO_COMPARATOR|Placebo, normal saline|Normal saline subcutaneous injections
62801111|NCT02304523|ACTIVE_COMPARATOR|Comparator|"Coolprep Powder A and B will be mixed with water to prepare a mixture of a bowel cleansing preparation solution 500mL. Repeat it twice. Take these of IL (2 \* 500mL) within 1 hour. After then, take additional 500ml water.~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
62735293|NCT01530854||Septic|
62735294|NCT01530854||Healthy|
62419182|NCT03173807|ACTIVE_COMPARATOR|dietary and exercise counseling|The duration of study in Arm A will be 24 months, with study assessments and interventions (review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer) done at baseline, 3 months, 6 months, 12 months and 24 months.
62801112|NCT01992588|EXPERIMENTAL|FIAsp followed by NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
62801113|NCT01992588|EXPERIMENTAL|NovoRapid® followed by FIAsp|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
62027146|NCT03293823|EXPERIMENTAL|vision-based speed of processing (VSOP) cognitive training|use the INSIGHT online program (Posit Science), which includes five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All exercises share visual components and focus on accuracy and fast reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
62419183|NCT03173807|ACTIVE_COMPARATOR|standard of care|The duration of study in Arm B will be 24 months, with study assessments and interventions (review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer) done at baseline, 12 months, 15 months, 18 months and 24 months. At 12 months, participants in Arm B will be offered the same intervention that Arm A received during months 1-12.
62419184|NCT01679418|ACTIVE_COMPARATOR|Drain placement (Group A)|Patients in group A received a wound drain after surgery.
62419185|NCT01679418|SHAM_COMPARATOR|No-drain placement (group B)|Patients assigned to group B, did not receive a wound drain after surgery.
62419186|NCT06568263||Celiac disease|Children diagnosed with celiac disease on a gluten-free diet
62419187|NCT06568263||Healthy|Healthy children on a regular diet
62419188|NCT00788008|ACTIVE_COMPARATOR|1|Inhalational anesthesia with isoflurane
62419189|NCT00788008|ACTIVE_COMPARATOR|2|total intravenous anesthesia with propofol
62419190|NCT05443503|OTHER|Intervention|"Patients can choose among or choose to be assigned to 2 tracks for management for their low back pain. The tracks include one focused on relaxation and symptom management, and another track on increasing activity. Each include educational material adapted from various sources from North America Spine Society (NASS), Center for Disease Control (CDC), National Institue of Health (NIH).~Patients will stay in track for 28 days. After this, they may choose to remain in track and continue to perform maintenance activities or to engage in a different track."
62419191|NCT04327609|EXPERIMENTAL|SELUTION SLR™ DEB|Med Alliance SELUTION SLR™ 018 DEB Sirolimus Eluting Balloon Catheter.
62419192|NCT04327609|ACTIVE_COMPARATOR|Control Treatment|POBA
62419193|NCT00830271|EXPERIMENTAL|Vicryl plus/Monocryl plus|"Vicryl plus and Monocryl plus is the active comparator arm. These are the active sutures, coated with triclosan antiseptic, being used in the closure of skin and subcutaneous tissues after breast cancer surgery."
62419194|NCT00830271|PLACEBO_COMPARATOR|vicryl/monocryl|"Plain Vicryl or Monocryl suture currently the standard which are not coated with triclosan, serve as the control."
62419195|NCT04897334|ACTIVE_COMPARATOR|Transcranial Direct Current Stimulation (tDCS) + cognitive therapy|Participants will undergo 5 daily sessions of tDCS for 20 minutes using a montage in which an anode (2 mA) is placed over left dorsolateral prefrontal cortex and the cathode will be place on the right supraorbital area. Subjects will participate in cognitive therapy during stimulation.
62419196|NCT04897334|SHAM_COMPARATOR|Sham Transcranial Direct Current Stimulation (tDCS) + cognitive therapy|Participants will undergo 5 daily sessions of sham tDCS for 20 minutes using a montage in which an anode (2 mA) is placed over left dorsolateral prefrontal cortex and the cathode will be place on the right supraorbital area. Subjects will participate in cognitive therapy during stimulation.
62419197|NCT06145880||Mild pre-capillary PH|Right heart catheterisation (performed as part of usual care) diagnoses pulmonary hypertension and categorises it as mild and pre-capillary.
62419198|NCT06145880||Moderate pre-capillary PH|Right heart catheterisation (performed as part of usual care) diagnoses pulmonary hypertension and categorises it as moderate and pre-capillary.
62419199|NCT06145880||Severe pre-capillary PH|Right heart catheterisation (performed as part of usual care) diagnoses pulmonary hypertension and categorises it as severe and pre-capillary.
62419200|NCT06145880||Post capillary PH|Right heart catheterisation (performed as part of usual care) diagnoses pulmonary hypertension and categorises it as post-capillary.
62419201|NCT06145880||No PH|Right heart catheterisation (performed as part of usual care) demonstrates normal pulmonary pressures (i.e. no evidence of pulmonary hypertension).
62419202|NCT01217567|EXPERIMENTAL|1st c-section, no previous lower abdominal surgery - s.l.|
62419203|NCT01217567|EXPERIMENTAL|Woman with previous ceasarean section - staples left|
62419204|NCT01217567|EXPERIMENTAL|1st c-section, no previous lower abdominal surgery|
62226271|NCT00966277|EXPERIMENTAL|Group 1: Dalteparin|Dalteparin 5000 units subcutaneous, by injection under the skin, daily for 16 weeks.
62419205|NCT01217567|EXPERIMENTAL|Woman with previous ceasarean section|
62419206|NCT03259763|ACTIVE_COMPARATOR|EUS-guided gastroenterostomy (EUS-GE)|In this technique, the gastric wall and its adjacent small intestine are punctured by a needle to make a connection between the stomach and small intestine. Then a lumen-apposing metal stent is deployed at the puncture site to keep the stomach-small intestine connection open.
62419207|NCT03259763|ACTIVE_COMPARATOR|Enteral Stenting (ES)|In this technique, under endoscopic visualization, a guidewire will be advanced through the obstructed part of the stomach. Then an enteral self-expandable metal stent will be deployed under direct endoscopic visualization and fluoroscopic guidance.
62419208|NCT01783860|EXPERIMENTAL|Oral Azithromycin|Two 250 mg capsules (500 mg) of Azithromycin for the first day and 250mg/day for the next 4 days.
62419209|NCT01783860|ACTIVE_COMPARATOR|Doxycycline|Oral doxycycline 100mg capsule every 12 hours for one month
62419210|NCT03428217|PLACEBO_COMPARATOR|Pbo-Cabo|Placebo twice daily (BID) + cabozantinib (60 mg once daily \[QD\]) administered orally on Days 1 through 28 of each 28-day cycle until disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) or unacceptable toxicity, whichever occurred first.
62419211|NCT03428217|EXPERIMENTAL|CB-Cabo|CB-839 800 mg BID + cabozantinib (60 mg QD) administered orally on Days 1 through 28 of each 28-day cycle until disease progression per RECIST v1.1 or unacceptable toxicity, whichever occurred first.
62419212|NCT01721824|EXPERIMENTAL|IPS-MA|"The IPS-MA method consists of five basic services for the participants. 1)Individual mentor support, based on psychiatric knowledge. 2)Coordination by the mentor of activities, internal as well as from external providers. 3)Career counseling aimed at people with mental illnesses. 4)Impartial help to clarify private economy. 5) Contact to employers to help participants obtain jobs, and keep them.~Participants will receive the IPS-MA method in addition to treatment as usual."
62419213|NCT01721824|NO_INTERVENTION|Control group|"Participants randomised to the control group will receive treatment as usual only. This means the standard support offered by the social- and health services in Denmark."
62419214|NCT06696729|EXPERIMENTAL|Mirabilite Application Group|Participants will receive a 500-gram external application of Mirabilite on the abdominal incision site, replaced regularly to maintain efficacy.
62419215|NCT06696729|SHAM_COMPARATOR|Standard Care Group|Participants will receive standard postoperative care with regular sterile dressing changes, without additional topical treatments.
62419216|NCT04322383|EXPERIMENTAL|Arm 1/Experimental therapy|Treatment with binimetinib
62419217|NCT02184169|EXPERIMENTAL|HLHS|Patients undergoing palliative repair.
62419218|NCT02184169|ACTIVE_COMPARATOR|TGA|Surgical repair of TGA.
62419219|NCT01518985|PLACEBO_COMPARATOR|Placebo|Intravenous infusion of saline (0.9%) for 4 hours with smoking of one unfiltered cigarette at 30 minutes post-study-drug administration start
62419220|NCT01518985|EXPERIMENTAL|Bendavia|Intravenous infusion of Bendavia (0.25mg/kg/hr) for 4 hours with smoking of one unfiltered cigarette at 30 minutes post-study-drug administration start
62226272|NCT00966277|NO_INTERVENTION|Group 2: Control|No study drug.
62226273|NCT00604266||1|10-15 patients with potentially resectable hiilar cholangiocarcinoma
62226274|NCT02126696||Patients on anti-retroviral therapy|The cohort consists of patients on first-line anti-retroviral therapy since at least 6 months, followed at one of the facilities involved in the study.
62419221|NCT01810393|EXPERIMENTAL|Trastuzumab IV Then Trastuzumab SC|Participants will receive treatment with Trastuzumab IV for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab SC for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.
62419222|NCT01810393|EXPERIMENTAL|Trastuzumab SC Then Trastuzumab IV|Participants will receive treatment with Trastuzumab SC for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab IV for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.
62419223|NCT03860987|EXPERIMENTAL|1|Treatment
62419224|NCT05685199||Case Group|Participants with heavy menstrual bleeding (HMB)
62419225|NCT05685199||Control Group|Participants without heavy menstrual bleeding (HMB)
62419226|NCT02449967|EXPERIMENTAL|HepaSphere|pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
62419227|NCT02449967|NO_INTERVENTION|control|pancreatic cancer patients did not receive any interventional therapy
62027147|NCT03293823|ACTIVE_COMPARATOR|active control|The standardized computerized leisure activities program - MLA, including crossword puzzle, Sudoku, etc. will be used
62027148|NCT03711981|ACTIVE_COMPARATOR|TAP block of 10cc Liposomal bupivacaine|Patients in this arm of the study would receive a bilateral Laparoscopic Assisted TAP block with 10cc Liposomal bupivacaine, 10cc 0.25% bupivacaine and 10cc normal saline each bilaterally at the beginning of their surgery.
62027149|NCT03711981|NO_INTERVENTION|Routine pre-incisional injections at trocar incision sites|The patients in the control arm of the study would receive routine pre-incisional injections at the trocar incision sites using a total of 20cc 0.25% bupivacaine.
62027150|NCT05393232|EXPERIMENTAL|Dietitian-Assisted DASH groceries|Participants will order groceries sufficient to meet their caloric needs each week for 12 weeks with the assistance of a dietitian/nutrition interventionist. Groceries will be delivered to participants' homes or picked up at a convenient location. The dietitian/nutrition interventionist will provide brief educational content at the time of food delivery. Orders will be placed via phone or through virtual counseling sessions. During the remainder of the study (months 4-12), participants will be asked to apply what they learned without the provision of groceries.
62801114|NCT03846050|EXPERIMENTAL|BAC Feedback, immediate onset|"Participants will receive aBAC Feedback/Warning intervention based on their assessed BAC. Participants in this arm will have a warning presented on their smartphone when they provide a breath sample that indicated their BAC has reached a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.~In this condition, participants will start their 6 week AA portion of their participation immediately after their laboratory session, and will be followed for 6 weeks afterwards.~Comparisons between the two experimental conditions will allow for inferences about the onset and offset of any effects of the BAC Feedback/Warning intervention."
62801115|NCT03846050|EXPERIMENTAL|BAC Feedback, delayed onset|"Participants will receive the BAC Feedback/Warning intervention based on their assessed BAC during drinking events.The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.~In this condition, participants will be followed for 6 weeks after their laboratory session prior to starting their 6 week AA portion of their participation.~Comparisons between the two experimental conditions will allow for inferences about the onset and offset of any effects of the BAC Feedback/Warning intervention."
62027151|NCT05393232|ACTIVE_COMPARATOR|Self-directed shopping (referent assignment)|Participants will receive a monthly stipend over a 3 month period and some basic information about healthy eating. The stipend is not restricted to foods. During the remainder of the study (months 4-12), participants will be asked to continue their typical shopping without the provision of the monthly stipend.
62419228|NCT03549845|EXPERIMENTAL|CHAP Intervention|The Cardiovascular Health Awareness Program (CHAP) intervention is an on-site drop-in, monthly, cardiovascular risk assessment program run by trained volunteers with community-led group health sessions that deliver education and information about access to community health resources. The education sessions will be delivered by national and provincial and local community organizations utilizing already developed material as much as possible, but maintaining consistency across both provinces. Health education sessions will include topics such as: Physical Activity, Healthy Eating, Stress, Tobacco Use, High Blood Pressure, Role of Pharmacist: How they can assist people, and Appropriate use of 9-1-1. This intervention will be held in a common room in selected subsidized housing buildings.
62419229|NCT03549845|NO_INTERVENTION|Control|The control buildings will receive usual care which will be wellness programs already present in the building prior to the RCT if these are present. Not all control buildings will have wellness programs.
62419230|NCT01093365|EXPERIMENTAL|Schizophrenia|To measure the effects of varenicline on cognition of smokers with schizophrenia.
62419231|NCT05443009|ACTIVE_COMPARATOR|Lidocaine|"Thirty-eight (38) children will receive conventional infiltration anesthesia (buccal infiltration injection followed by complementary injections on the palatal region) with 2% lidocaine and 1:100,000 epinephrine at a dose previously calculated by weight. Two-thirds of the anesthetic will be injected into the buccal area and 1/3 into the palatal area.~Other Names: Control Group"
62419232|NCT05443009|EXPERIMENTAL|Articaine|"Thirty-eightt (38) children will receive a single buccal infiltration injection with 4% articaine and 1:100,000 epinephrine at a dose previously calculated by weight.~Other Names: Test Group"
62419233|NCT06233058|EXPERIMENTAL|Sequence 1-Drospirenone+ Ethinyl Estradiol test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Drospirenone 3 mg + Ethinyl Estradiol 0.03 mg Tablets test product, treatment 2= Drospirenone 3 mg + Ethinyl Estradiol 0.03 mg Tablets reference product.
62027152|NCT02342067|EXPERIMENTAL|Group 1 (Cenicriviroc, PGZ, CVC+PGZ)|Treatment A: CVC 150 mg QD for 10 days followed by 10-day washout Treatment B: PGZ 45 mg QD for 10 days Treatment C: co-administration of PGZ 45 mg QD + CVC 150 mg QD for 10 days
62027153|NCT02342067|EXPERIMENTAL|Group 2 (Pioglitazone, CVC, CVC+PGZ)|Treatment B: PGZ 45 mg QD for 10 days followed by 10-day washout Treatment A: CVC 150 mg QD for 10 days Treatment C: co-administration of CVC 150 mg QD + PGZ 45 mg QD for 10 days
62419234|NCT06233058|EXPERIMENTAL|Sequence 1-Drospirenone+ Ethinyl Estradiol reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Drospirenone 3 mg + Ethinyl Estradiol 0.03 mg Tablets test product, treatment 2= Drospirenone 3 mg + Ethinyl Estradiol 0.03 mg Tablets reference product.
62419235|NCT05346237||Adult laryngectomised patients|Patients who have undergone total laryngectomy and completed minimal their 12-month period without disease after surgery and post-operative treatments such as radiotherapy or chemotherapy
62419236|NCT04595565|EXPERIMENTAL|Sacituzumab govitecan|Sacituzumab govitecan is administered intravenously 10 mg/kg body weight on days 1, 8 q3w for eight cycles.
62419237|NCT04595565|OTHER|Treatment of physician´s choice|TPC, defined as capecitabine or platinum-based chemotherapy for eight cycles or Observation.
62419238|NCT05469815|EXPERIMENTAL|Lost Children Society Game|Online therapeutic role-playing session
62419239|NCT04977388|ACTIVE_COMPARATOR|Northera™ (Droxidopa) (Treatment A)|Northera (Droxidopa) (Treatment A) will be provided to adult subjects as a capsule with 100mg, 200mg, or 300mg of Northera (Droxidopa) contained within gelatin color capsules (sky blue and white, size 0) based on findings from the dose titration visit. These capsules are physically indistinguishable from the Treatment B (placebo) capsules. Frequency of administration (by mouth) will be twice daily for six weeks.
62419240|NCT04977388|PLACEBO_COMPARATOR|Placebo (Treatment B)|Empty gelatin color capsules (sky blue and white, size 0) filled with cellulose microcrystalline and physically indistinguishable from Treatment A capsules. Frequency of administration (by mouth) will be twice daily for six weeks
62419241|NCT03022929|NO_INTERVENTION|Adapted Intervention|The investigators will use GetSmart materials published by the CDC appropriate to the emergency department and urgent care settings and select and adapt brochures and other campaign messages for acute care providers.
62419242|NCT03022929|EXPERIMENTAL|Enhanced Intervention|"The investigators will use all of the methods of the Adapted Intervention. In addition to these methods, the investigators will add posters within exam rooms which will include modified GetSmart content and other nudges such as physician pictures with their signed public commitment to antibiotic stewardship or flair denoting commitment to stewardship. The investigators will also provide physicians with personalized monthly performance ranking with each physician receiving the designation of top performer or not a top performer based on their appropriate antibiotic prescribing practices for acute respiratory infections. This will be the Enhanced Antimicrobial Stewardship Commitment and Feedback intervention."
62419243|NCT00068653|EXPERIMENTAL|Celecoxib & ZD1839|"Celecoxib: 400mg orally two times a day, taken with meals.~ZD1839: 250 mg po every day, taken with or without food."
62419244|NCT04129515|EXPERIMENTAL|PHASE 1: NovoTTF-200A + PEMBROLIZUMAB|"The Phase I portion of the study will have a 3 + 3 design and consist of one cohort treated~* NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle.~* Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle"
62419245|NCT04129515|EXPERIMENTAL|PHASE 2: NovoTTF-200A + PEMBROLIZUMAB|"* NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle.~* Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle"
62419246|NCT04406129|EXPERIMENTAL|FMT capsules|Intervention: FMT capsules containing extensively screened donor stool. FMT capsules will be orally taken on Day 1, Day 7 (Week 1) and Day 14 (Week 2).
62419247|NCT04406129|PLACEBO_COMPARATOR|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug. Placebo capsules will be orally taken on Day 1, Day 7 (Week 1) and Day 14 (Week 2).
62419248|NCT05225428|EXPERIMENTAL|QUALITATIVE ASSESSMENT|"This part of the research study involves watching a brief educational video about genetic testing for inherited cancer risk (about 8 minutes) before completing a short interview by video or telephone with trained researchers. This interview will be digitally recorded for later review.~It is expected that about 20 people will take part in this part of the research study.~In the larger part of the study that will happen after this part of the study, it is expected 1000 people will participate."
62027154|NCT03061994||Cardiomyopathy|"Children(older than 18 years old) are diagnosed as cardiomyopathy by three cardiologists and recruited in pediatric heart center,Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.~Adults are diagnosed as cardiomyopathy by three cardiologists and recruited in the department of cardiology ,Beijing Anzhen Hospital."
62027155|NCT03061994||Control|Healthy children and adults are recruited in Beijing Anzhen Hospital, with negative results of echocardiography and clinical lab examination.
62226275|NCT04323774|NO_INTERVENTION|Aim 1-Part 1 Stakeholder Interview|"This arm will focus on finding the best format for the study intervention (called AYA-RISE) whether AYA-RISE is easy to use; and whether patients, family caregivers, and providers find AYA-RISE acceptable.~The research study procedures include:~* Using and reviewing AYA-RISE~* Participating in audio-recorded, 30-minute interviews"
62801116|NCT03846050|PLACEBO_COMPARATOR|Minimal Assessment Control|"Participants will receive the No BAC Feedback/Warning intervention. Participants in this condition will complete the laboratory and interview portions of the project. However the AA portion of the project will not contain warning about their BAC (No BAC Feedback/Warning) and will ask fewer questions regarding their AID decisions.~The role of this condition is to provide a baseline comparison of AID behavior for the two active assessment conditions."
62801117|NCT01754974|EXPERIMENTAL|Peginterferon Lambda-1a + Ribavirin|Peginterferon Lambda-1a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks
62801118|NCT01754974|ACTIVE_COMPARATOR|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks
62226276|NCT04323774|EXPERIMENTAL|Aim 1-Part 2|"This arm is a pilot study of the study intervention (called AYA-RISE).~The activities involved in this part of the study are:~* Baseline Questionnaire~* Using and reviewing AYA-RISE~* Follow-up Questionnaire~* Brief interviews to get feedback on AYA-RISE"
62801119|NCT02959593|EXPERIMENTAL|Glaucoma patients|To view commercially available content through the VISIOR video goggles for thirty minutes
62801120|NCT02959593|EXPERIMENTAL|Healthy subjects|To view commercially available content through the VISIOR video goggles for thirty minutes.
62801121|NCT01219309|ACTIVE_COMPARATOR|Omega 3/6 treatment|
62801122|NCT01219309|PLACEBO_COMPARATOR|Placebo|
62801123|NCT03599791|EXPERIMENTAL|Azelastine Hydrochl. + Fluticasone Prop.|Drug: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT Nasal Spray, consists of a fixed-dose combination of azelastine hydrochloride and fluticasone propionate; 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
62801124|NCT03599791|ACTIVE_COMPARATOR|Azelastine hydrochloride|Drug: Azelastine Hydrochloride 0.137 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
62801125|NCT03599791|ACTIVE_COMPARATOR|Fluticasone propionate|Drug: Fluticasone Propionate 0.05 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
62226277|NCT04323774|ACTIVE_COMPARATOR|Aim 2-Genetic Counseling|"The names of the study activities involved in this study are:~* Baseline Questionnaire~* Follow-up Questionnaire~* Medical record review~The study procedures will all take place on the day of the patient's regularly scheduled clinic visit. Participants will be in this research study for up to 1 year."
62226278|NCT04323774|EXPERIMENTAL|Aim 2- Genetic Counseling with AYA-RISE|"The names of the study activities involved in this study are:~* Baseline Questionnaire~* Follow-up Questionnaire~* Medical record review~* Using the study intervention, AYA-RISE~The study procedures will all take place on the day of the patient's regularly scheduled clinic visit. Participants will be in this research study for up to 1 year."
62226279|NCT04323774|NO_INTERVENTION|Aim 3 Semi-structured interviews|Each site will conduct 30-minute interviews with patients, caregivers, and providers, and site principal investigators.
62419249|NCT05225428|EXPERIMENTAL|RCT-VERDI|A randomized controlled trial (RCT) will evaluate the VERDI model vs. standard genetic counseling
62801126|NCT02734693|EXPERIMENTAL|Dasotraline 4mg|Dasotraline capsule 4mg/day
62801127|NCT02734693|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62801128|NCT00820469|EXPERIMENTAL|1|Patients treated by rituximab
62801129|NCT00820469|EXPERIMENTAL|2|Patients treated by rituximab and plasma exchange
62801130|NCT01507688|EXPERIMENTAL|Arm 1 SSM Intervention|Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
62801131|NCT01507688|NO_INTERVENTION|Arm 2 Usual Care|Usual care
62801132|NCT04499937|EXPERIMENTAL|Streak incentive|Subjects start with no money in an account, but they earn a fixed amount with each response. In this arm, each adult report is worth $3.17 so an adult subject can earn up to $200 if he/she responds to all surveys. If an adult completes at least 75% of the reports, he/she will receive an $100 bonus for a total maximum of $300. In this arm, each child report is worth 0.52 cents so a child subject can earn up to $33 if he/she responds to all surveys. If a child completes at least 75% of the reports, he/she will receive a $17 bonus for a total maximum of $50.
62801133|NCT04499937|EXPERIMENTAL|Loss-based incentive|Subjects start with the maximum possible compensation, but money is deducted for each missed response. Adult subjects will lose $4.76 for each missed survey. Child subjects will lose $0.79 for each missed survey.
62801134|NCT04499937|ACTIVE_COMPARATOR|Flat-fee control status quo condition|Subjects will receive the maximum possible compensation at the end of the study regardless of response rate.
62801135|NCT04499937|ACTIVE_COMPARATOR|Flat-Fitbit control status quo condition|Subjects will be compensated by keeping the Fitbit at the end of the study regardless of response rate.
62801136|NCT03287999||Haemophilia patients|Persons with haemophilia A or B - 240 to be recruited
62801137|NCT03287999||Healthy volunteers|Healthy volunteers - 10 to be recruited
62801138|NCT06502496|EXPERIMENTAL|art-therapy|Art therapy workshops : groups of 6 to 12 patients supervised over a session of 1.5 to 2 hours, in the presence of an artist and the nursing staff (psychologist, nurse, doctor). There are 6 sessions per group, with an average of one week between sessions.
62027156|NCT05321524|EXPERIMENTAL|SD (1.5mg adult-equivalent dose of OCA) + MD Low dose (1.5mg adult-equivalent dose of OCA)|"At Single Dose (SD) phase, eligible subjects will receive a 1.5 mg adult-equivalent, body weight-based single dose of OCA on Day 1. Enrollment in the Multiple Dose (MD) Phase will occur in a sequential fashion. At Day 28, the first 8 (±1) eligible subjects will be assigned to the Low Dose Cohort and will receive a 1.5 mg adult-equivalent dose of OCA daily for 4 weeks.~The adult-equivalent dose is based on a 70-kg adult. 2 OCA tablet dose strength (0.1mg and 1.5mg) are available in the study and dose will be determined using weight based dosing chart."
62027157|NCT05321524|EXPERIMENTAL|SD (1.5mg adult-equivalent dose of OCA) + MD Medium dose (5mg adult-equivalent dose of OCA)|"At Single Dose (SD) phase, eligible subjects will receive a 1.5 mg adult-equivalent, body weight-based single dose of OCA on Day 1. Upon safety and tolerability assessment in the Low Dose Cohort, 8 (±1) eligible subjects will be assigned to the Medium Dose Cohort and will receive a 5 mg adult-equivalent dose of OCA daily for 4 weeks.~The adult-equivalent dose is based on a 70-kg adult. 3 OCA tablet dose strength (0.1mg, 1.5mg and 5mg tablets) are available in the study and dose will be determined using weight based dosing chart."
62027158|NCT05321524|EXPERIMENTAL|SD (1.5mg adult-equivalent dose of OCA) + MD High dose (10mg adult-equivalent dose of OCA)|"At Single Dose (SD) phase, eligible subjects will receive a 1.5 mg adult-equivalent, body weight-based single dose of OCA on Day 1. Upon safety and tolerability assessment in the Medium Dose Cohort, 8 (±1) eligible subjects will be assigned to the High Dose Cohort and will receive a 10 mg adult-equivalent dose of OCA daily for 4 weeks.~The adult-equivalent dose is based on a 70-kg adult. 3 OCA tablet dose strength (0.1mg, 1.5mg and 5mg tablets) are available in the study and dose will be determined using weight based dosing chart."
62419250|NCT05225428|EXPERIMENTAL|RCT-Genetic Counseling|A randomized controlled trial (RCT) will evaluate the VERDI model vs. standard genetic counseling
62419251|NCT02969473|ACTIVE_COMPARATOR|PF group|This is the active comparator group. All patients in this group will receive concurrent chemoradiotherapy with PF regimen (5-fluorouracil plus cisplatin).
62419252|NCT02969473|EXPERIMENTAL|DP group|This is the experimental group. All patients in this group will receive concurrent chemoradiotherapy with DP regimen (docetaxel plus cisplatin).
62801139|NCT06502496|ACTIVE_COMPARATOR|relaxation|Relaxation workshops (control group): groups of 6 to 12 patients supervised over a session of 1.5 to 2 hours, in the presence of the psychologist. 5 sessions per group, with an average of one week between sessions.
62801140|NCT02768493|EXPERIMENTAL|low dose group|Patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block.
62801141|NCT02768493|ACTIVE_COMPARATOR|high dose group|Patients in the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block.
62801142|NCT03157375|OTHER|0°|Implantation of the intraocular lens Vivinex p261 on axis 0°
62801143|NCT03157375|OTHER|45°|Implantation of the intraocular lens Vivinex p261 on axis 45°
62801144|NCT03157375|OTHER|90°|Implantation of the intraocular lens Vivinex p261 on axis 90°
62801145|NCT03157375|OTHER|135°|Implantation of the intraocular lens Vivinex p261 on axis 135°
62801146|NCT01230463|ACTIVE_COMPARATOR|15 mg ketorolac IV|
62801147|NCT01230463|ACTIVE_COMPARATOR|30 mg ketorolac IV|
62801148|NCT02435004|OTHER|Spinal Modulation Axium™|Spinal Modulation Axium™: an external trial neurostimulator (TNS) is used for the trial period, followed by an implanted neurostimulator (INS) if the TNS is successful. The TNS and INS are a pacemaker-sized devices that send out mild electrical pulses. The stimulator contains a battery and electrical components. Both TNS and INS are constant voltage devices. The TNS is used first and is worn on the outside of the clothing. The INS is implanted under the skin and support:
62027159|NCT03524222|EXPERIMENTAL|Home Hospitalization|Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
62027160|NCT04933682|EXPERIMENTAL|Part 1: ALXN2050 plus Fluconazole|"Period 1: Participants will receive a single dose of ALXN2050 alone and in the presence of multiple doses of fluconazole.~Period 2: Participants will receive multiple doses of ALXN2050 alone and in the presence of multiple doses of fluconazole.~Scheduled pharmacokinetics (PK) blood samples for both ALXN2050 and fluconazole will be collected, with a washout period of at least 14 days between the last dose of fluconazole in Period 1 and the first dose of ALXN2050 in Period 2."
62027161|NCT04933682|EXPERIMENTAL|Part 2: ALXN2050 plus Rifampin|"Participants will receive a single dose of ALXN2050 alone and in the presence of both single and multiple doses of rifampin.~Scheduled PK blood samples for both ALXN2050 and rifampin will be collected."
62027162|NCT02271386|EXPERIMENTAL|Intervention|Clinicians in the intervention arm will receive the three-part intervention (Supporting Practice for ADHD, or SPA) which includes: education about ADHD management and communication training, collaborative consultation, and performance feedback, for the first 8 months of the study.
62027163|NCT02271386|OTHER|Control|Clinicians in the control arm will receive no intervention for the first 8 months of the study, then will receive the full SPA intervention for the last 8 months of the study.
62419253|NCT04512391||Erector Spinae|patients who are administered ultrasound guided ESPB at T4 vertebrae level with long acting local anesthetic (%0,25 bupivacaine) and followed up with patient controlled analgesia device and all records about aforementioned data is completely available.
62419254|NCT04512391||Control|patients who are not administered any regional analgesic technique and followed up with patient controlled analgesia device and all records about aforementioned data is completely available.
62027164|NCT02263300||Supine- Supine|Group A (supine-supine) will first practice fiberoptic intubation with the iLarynx oriented in the supine position. Learning curves, global rating scale and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the SUPINE then UPRIGHT position. At the end of one week,the same medical student will then perform the intubation with the mannequin in both positions.
62027165|NCT02263300||Upright-upright|Group B (upright-upright) will first practice fiberoptic intubation with the iLarynx oriented in the upright position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the UPRIGHT then SUPINE position.At the end of one week, the same medical student will then perform the intubation with the mannequin in both positions.
62027166|NCT02263300||Supine -upright|Group C( supine -upright) will first practice fiberoptic intubation with the iLarynx oriented in the supine position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the UPRIGHT then SUPINE position. At the end of one week, The same medical student will then perform the intubation with the mannequin in both positions.
62027167|NCT02263300||Upright - supine|Group D( upright - supine) will first practice fiberoptic intubation with the iLarynx oriented in the upright position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the SUPINE then UPRIGHT position. At the end of one week, the same medical student will then perform the intubation with the mannequin in both positions.
62226280|NCT06446960|EXPERIMENTAL|lidocaine 20 mg/ml|Name (INN and/or speciality) : Lidocaine 20 mg/ml Pharmaceutical form: Injectable Route of administration: Peri-Nervous Dosage for administration: 20ml Duration of treatment: 2 bolus administrations at 14 day intervals
62801149|NCT04186767|EXPERIMENTAL|Weight loss|
62419255|NCT00872573|OTHER|C-Stem™ AMT Femoral Component|
62419256|NCT05674721|EXPERIMENTAL|Advil PM Liqui-Gels Minis|Participants will be randomly assigned as per cross-over design to receive a single dose of 2 Advil PM Liqui-Gels Minis capsules orally on day 1 of period 1 and will receive single dose of 2 Advil PM Liqui-Gels capsules orally on day 1 of period 2 with at least 7 days washout period. Participants will be instructed to consume the entire amount of ambient temperature water (approximately 240 milliliters \[mL\]) along their investigational product.
62801150|NCT05802589|ACTIVE_COMPARATOR|Control Group (no peripheral block applied)|No peripheral block was applied to this group and it was accepted as the control group. Standard multimodal analgesia and rescue analgesia according to NRS score were applied to each group.
62801151|NCT05802589|ACTIVE_COMPARATOR|Lumbar Erector Spinae Plane Block (L-ESPB) Group|Lumbar erector spinae plane block was applied to this group under ultrasound guidance. Standard multimodal analgesia and rescue analgesia according to NRS score were applied to each group.
62226281|NCT06446960|EXPERIMENTAL|levobupivacaine 1.25 mg/ml|Name (INN and/or speciality) : Levobupivacaine (Chirocaine), 1.25 mg/ml Pharmaceutical form: Injectable Route of administration: Peri-Nervous Dosage for administration: 20ml Duration of treatment: 2 bolus administrations at 14 day intervals
62419257|NCT05674721|ACTIVE_COMPARATOR|Advil PM Liqui-Gels|Participants will be randomly assigned as per cross-over design to receive a single dose of 2 Advil PM Liqui-Gels capsules orally on day 1 of period 1 and will receive single dose of 2 Advil PM Liqui-Gels Minis capsules orally on day 1 of period 2 with at least 7 days washout period. Participants will be instructed to consume the entire amount of ambient temperature water (approximately 240 mL) along their investigational product.
62589738|NCT04080843|EXPERIMENTAL|Group A|"Patients in the study group will receive the following treatment:~21 days as a treatment cycle, Anlotinib 12 mg/day, Orally(D1-D14); Capecitabine 850 mg/m2,Orally(D1-D14), Bid; Oxaliplatin 130 mg/m2, iv(D1).~If anlotinib is not tolerated(except Hand-foot skin reaction), the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again. After 6 cycles of combined therapy, patients will receive capecitabine and anlotinib as maintenance therapy until tumor progression."
62226282|NCT06446960|PLACEBO_COMPARATOR|Sodium chloride (NaCl) 0.9|Name (INN and/or speciality) : Sodium chloride (NaCl) 0.9 Pharmaceutical form: Injectable Route of administration: Peri-Nervous Dosage for administration: 20ml Duration of treatment: 2 bolus administrations at 14 day intervals
62226283|NCT03650517||Robotic Right Colectomy with ICA|"Robot-assisted surgery (RAS), allows many types of complex MIS procedures using robotic systems to aid in surgical procedures providing more precision, flexibility and control than is possible with other MIS techniques.~Intracorporeal anastomosis: when the anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique. A Pfannenstiel incision will be done exclusively for specimen extraction."
62419258|NCT03187288|EXPERIMENTAL|CFI-400945|CFI-400945 will be given by mouth at 64,96,128,160,192 or 224 mg/day, everyday until intolerable side effects or disease progression.
62419259|NCT04656782||Expert panelists|Expert panelists will be recruited from EORTC Imaging Group, EORTC GI Group, ESOI and ESGAR and will actively participate in the imaging survey rounds.
62589739|NCT00264069||001|
62589740|NCT00264069||002|
62589741|NCT04379596|EXPERIMENTAL|Arm 1A|T-DXd and 5-fluorouracil (5-FU)
62589742|NCT04379596|EXPERIMENTAL|Arm 1B|T-DXd and capecitabine
62589743|NCT04379596|EXPERIMENTAL|Arm 1C|T-DXd and durvalumab
62589744|NCT04379596|EXPERIMENTAL|Arm 1D(b)|T-DXd, capecitabine, and oxaliplatin
62589745|NCT04379596|EXPERIMENTAL|Arm 1E(a)|T-DXd, 5-FU, and durvalumab
62589746|NCT04379596|EXPERIMENTAL|Arm 1E(b)|T-DXd, capecitabine, and durvalumab
62419260|NCT04656782||Facilitators|The two central facilitators will moderate and guide the survey rounds. Blinded results will be forwarded to the expert panelists by the facilitators. Further Survey rounds will be adapted by the facilitators according to the previous answers given by the panelists.
62419261|NCT04177745|EXPERIMENTAL|Hot Application|Before PVC was inserted, the researcher applied a hot application to the catheter insertion site (inner surface of the forearm) using a hot pack for one minute. Then, the researcher made the second vein assessment and inserted a 20-G peripheral catheter into the inner surface of the forearm.
62419262|NCT04177745|EXPERIMENTAL|Cold Application|Before PVC was inserted, the researcher applied a cold application to the catheter insertion site (inner surface of the forearm) using a cold pack for one minute. Then, the researcher made the second vein assessment and inserted a 20-G peripheral catheter into the inner surface of the forearm.
62419263|NCT04177745|NO_INTERVENTION|Standard Practice|The standard practice of the clinic was made. Accordingly, the researcher performed the vein assessment after the participants filled out the questionnaire, and then inserted the 20-G catheter into the inner surface of their forearm without any application. Afterwards, she assessed the pain and anxiety levels of the patients twice before and after the catheter insertion procedure.
62419264|NCT01247207|EXPERIMENTAL|Ataluren|Participants will receive 3 doses of ataluren oral suspension per day (10 mg/kg in the morning, 10 mg/kg at mid-day and 20 mg/kg in the evening).
62419265|NCT05504408||Systemic Mastocytosis with associated t(8;21) AML|SM and AML were diagnosed according to the 5th edition WHO classification criteria.
62419266|NCT05504408||The t(8;21) AML without Systemic Mastocytosis|The t(8;21) AML patients do not have associated Systemic Mastocytosis according to the 5th edition WHO classification criteria and no AML1-ETO clone was detected in mast cells.
62419267|NCT05504408||OSM (Oligo-mastocytic SM) with associated t(8;21) AML|The t(8;21) AML patients do not have associated Systemic Mastocytosis according to the 5th edition WHO classification criteria, but AML1-ETO clones were detected in mast cells.
62419268|NCT02379338|EXPERIMENTAL|Dynamic Brain Cohort|The Dynamic Brain cohort will include up to 10 patients who will undergo a dynamic brain \[18F\]Fluortriopride PET/CT scan over a period of approximately 2 hours. Subjects in this cohort will also undergo a research brain MRI, generally on a separate day from the PET/CT.
62589747|NCT04379596|ACTIVE_COMPARATOR|Arm 2A|Trastuzumab, 5-FU or capecitabine, and cisplatin or oxaliplatin
62589748|NCT04379596|EXPERIMENTAL|Arm 2B|T-DXd monotherapy
62589749|NCT04379596|EXPERIMENTAL|Arm 2C|T-DXd, 5-FU or capecitabine
62589750|NCT04379596|EXPERIMENTAL|Arm 2D|T-DXd, pembrolizumab and 5-FU or capecitabine
62589751|NCT04379596|EXPERIMENTAL|Arm 2E|T-DXd and pembrolizumab
62589752|NCT04379596|EXPERIMENTAL|Arm 2F|T-DXd, pembrolizumab and 5-FU or capecitabine
62589753|NCT04379596|EXPERIMENTAL|Arm 3A|T-DXd, Volrustomig and 5-FU or capecitabine
62589754|NCT04379596|EXPERIMENTAL|Arm 3B|T-DXd, Volrustomig and 5-FU or capecitabine
62589755|NCT04379596|EXPERIMENTAL|Arm 4A|T-DXd, Rilvegostomig and 5-FU or capecitabine
62589756|NCT04379596|EXPERIMENTAL|Arm 4B|T-DXd, Rilvegostomig and 5-FU or capecitabine
62801152|NCT05802589|ACTIVE_COMPARATOR|Pericapsular Nerve Group Block (PENGB) Group|Pericapsular nerve group block was applied to this group under ultrasound guidance. Standard multimodal analgesia and rescue analgesia according to NRS score were applied to each group.
62801153|NCT06371105|EXPERIMENTAL|Training group|Performing a 10-week water-based aerobic training (thrice/week)
62027168|NCT04581941||Patients with essential tremor|Patients with essential tremor who have clinically been deemed candidates for DBS (Deep Brain Stimulation) surgery. Deep brain stimulation is an FDA approved therapy that involves surgical implantation of electrodes in deep brain targets and an implantable pulse generator delivers electrical pulses. This intervention is not part of the study. The investigators are going to recruit patients who receive the Medtronic Percept device, which allows for brain signal recordings (this feature is FDA approved). The investigators will be conducting an observational study using this device to collect data that the subjects receive as standard of care.
62589757|NCT06666075|NO_INTERVENTION|Control Group|The control group will not participate in the physical or cognitive exercise intervention but will receive general recommendations for comprehensive health care. This includes discussions about the benefits of engaging in physical and cognitive exercise, as well as advice on managing physical and mental health. All proposed physical and mental assessments will be conducted with the control group at the beginning of the study and after 12 weeks. Additionally, during the study period, they will be monitored for any changes in physical activity levels that may occur throughout the intervention. Follow-up will also include tracking nutritional changes, sleep habits, and stress levels.
62801154|NCT06371105|NO_INTERVENTION|Control group|Maintaining their usual activities during the interventional period
62801155|NCT01855412||Claudication (Rutherford 2-3)|Patients who have been diagnosed with PAD and are classified as on the Rutherford Scale as Rutherford 2-3. Patients may be treated with any FDA-cleared endovascular PAD treatment.
62027169|NCT01876173|EXPERIMENTAL|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
62027170|NCT01876173|NO_INTERVENTION|Usual care|The control group will not receive the patient decision aid prior to consultation with the physician.
62027171|NCT04112147|EXPERIMENTAL|Antroquinonol capsule 100mg|Patients will receive 12-week of 50mg BID Antroquinonol
62027172|NCT04112147|EXPERIMENTAL|Antroquinonol capsule 200mg|Patients will receive 12-week of 100mg BID Antroquinonol
62801156|NCT01855412||CLI Rutherford 4-5|Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 4-5. Patients may be treated with any FDA-cleared endovascular PAD treatment.
62801157|NCT01855412||CLI Rutherford 6|Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 6. Patients may be treated with any FDA-cleared endovascular PAD treatment.
62801158|NCT01835821|EXPERIMENTAL|prosthesis|"NobelProcera™ Crown shaded zirconia:~The device is an individual, ceramic core (figure a) made of shaded zirconium with an anatomic contour providing homogenous veneering material thickness and a minimum core thickness of 0.4 or 0.7mm. The core is veneered with dental porcelain (IPS e.max Ceram) at the dental laboratory"
62801159|NCT03471312||treated with magnesium therapy|will receive magnesium sulphate 10 mg \\kg \\day as a single oral dose for one month duration
62801160|NCT03471312||treated with placebo drug|will receive placebo drug
62027173|NCT04112147|PLACEBO_COMPARATOR|Placebo oral capsule|Patients will receive 12-week of 50mg BID Antroquinonol placebo
62027174|NCT03869775||control group|no additional disease
62419269|NCT02379338|EXPERIMENTAL|Biodistribution Cohort|The Biodistribution cohort will include up to10 patients who will undergo a series of whole body biodistribution \[18F\]Fluortriopride PET/CT scans over a period of approximately 4 hours.
62419270|NCT06083883|EXPERIMENTAL|Dose escalation - Inpatient and Outpatient|Participants will be assigned to receive a dose level of NK cells based on when the participants joins the study. Up to 6 participants will be enrolled at each dose level. If no intolerable side effects are seen after the first 3-6, the next group of participants will get at higher dose. Up to 4 dose levels of NK cells will be tested. If the first dosing group shows intolerable side effects, a lower dose will be tested.
62801161|NCT01662323|ACTIVE_COMPARATOR|Training of the GP's, intervention|General practitioners are trained to diagnose and treat heart failure according the recommendations of the NHG-standard.
62801162|NCT01662323|ACTIVE_COMPARATOR|Controle|General practitioners giving care as usual to their heart failure patients.
62801163|NCT01657175|EXPERIMENTAL|Supportive care|The patients randomized to the supportive care arm get an extended supportive care during the first year after surgery.
62027175|NCT03869775||working group-1|additional disease only DM and no cardıovascular autonomous neuropathıa
62027176|NCT03869775||working group-2|additional disease only DM and pozitif cardıovascular autonomous neuropathıa
62027177|NCT03124641|EXPERIMENTAL|Hypothermic oxygenated perfusion (HOPE)|Application of Hypothermic machine perfusion (HOPE) for 1-2 hours
62027178|NCT03124641|ACTIVE_COMPARATOR|Conventional cold storage (CCS)|Conventional cold storage
62027179|NCT00822029|EXPERIMENTAL|1|FOSAMAX (oral bisphosphonate)
62027180|NCT00822029|PLACEBO_COMPARATOR|2|PLACEBO
62419271|NCT05338437|EXPERIMENTAL|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation of the quadriceps. 45 minutes, 5 days per week
62419272|NCT05338437|NO_INTERVENTION|Control|No treatment control
62419273|NCT03851107|EXPERIMENTAL|Community-based activity program|Engagement in 6-week community-based activity program
62801164|NCT01657175|NO_INTERVENTION|Control|"The patients randomized to the control group get care as usual"
62801165|NCT01253291|EXPERIMENTAL|30mg/120 mg LY2127399|Participants in the 30 milligrams (mg) every 4 weeks arm of the lead-in study will receive 30 mg every 4 weeks until the safety of the 120 mg every 4 weeks dose is confirmed in the lead-in study.
62801166|NCT01253291|EXPERIMENTAL|120 mg LY2127399|Participants in the 60 mg every 4 weeks, 120 mg every 4 weeks and 120 mg every 2 weeks arms of the lead-in study will receive 120 mg every 4 weeks as these participants will enroll in this study after the safety of the 120 mg every 4 weeks dose in the lead-in study is confirmed.
62801167|NCT02869399|EXPERIMENTAL|Experimental arm|The experimental arm is based on a dietary intervention in addition to standard recommendations.The diet will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences. The intervention strategy will focus on reducing inflammation and reducing glycaemia and insulinaemia while promoting nutrient-rich diet. Patients will be taught how to prepare traditional Mediterranean meals (healthy, satiating, palatable and easy to prepare).
62027181|NCT02159482|EXPERIMENTAL|interferon-alfa-2a|Starting within 6 months after completion of the dendritic cell vaccine, a dose of interferon alfa-2a will be administered subcutaneously in the skin of the arm, thigh or abdomen every other day for a total of 6 injections.
62027182|NCT04890002|EXPERIMENTAL|Far-infrared emitting pyjamas (FIR pyjamas) group|Subjects in this group will be provided the Far-infrared emitting pyjamas. The FIR pyjamas was fabricated by using two textile materials, pure cotton fibres and the proposed man-made FIR fibres with the far-infrared emitting function.
62801168|NCT02869399|NO_INTERVENTION|Control arm|Patients in the control arm will not receive specific suggestions concerning diet, but standard healthy lifestyle recommendations will be given. The recommendations, including nutritional consultation if needed by standard practice of care, will be reinforced at each clinical visit and through a leaflet according to primary cancer prevention nutritional guidelines. Patients in the control group will not receive any of the recipes or educational materials given to the intervention group and they will not have kitchen classes.
62801169|NCT05598281|EXPERIMENTAL|AMG 510 + Digoxin|Participants will receive digoxin on Day 1 and both AMG 510 + digoxin on Day 7.
62801170|NCT06110013||A|Patients on invasive mechanical ventilation
62027183|NCT04890002|SHAM_COMPARATOR|Sham-pyjamas Group|To control the placebo effect in the FIR pyjamas group, participants in this group will receive pyjamas with identical physical appearance which are produced using the same fabrication process as the pyjamas received in FIR pyjamas group. The sham-pyjamas are made of pure cotton fibres and man-made fibres without the far-infrared emitting function. The participants will be asked to wear the sham-pyjamas daily at night for 6 consecutive weeks.
62027184|NCT05643885||apixaban|patients treated with apixaban
62027185|NCT05643885||Low molecular weight heparin (LMWH)|patients treated with low molecular weight heparin
62027186|NCT04378244|EXPERIMENTAL|DeltaRex-G|"Escalating doses of DeltaRex-G i.v daily for 7 days as follows:~Dose Level I: 3-6 patients will receive 1 x 10e11 cfu/dose Dose Level II: 3-6 patients will receive 2 x 10e11 cfu/ dose Dose Level III: 3-6 patients will receive 3 x 10e11 cfu/dose"
62027187|NCT03879798|EXPERIMENTAL|DS-3201b and Irinotecan|The first part of this study is a phase I trial to assess the safety and tolerability of DS-3201b in combination with fixed-dose irinotecan. The second part of this study will be an open label, single-arm phase II study of DS-3201b at the established recommended phase II dose (RP2D) in combination with fixed-dose irinotecan.
62027188|NCT03786601||Group A,|High-risk HPV infection in postmenopausal women
62027189|NCT03786601||Group B|High-risk HPV negative in postmenopausal women
62419274|NCT06107127|ACTIVE_COMPARATOR|Researcher 1|Using their symptomatic arm participants will be asked to push against a fixed force dynamometer (hand held force gauge), starting with a low level of effort and gradually increasing their effort stopping either at the point that they start to feel pain or when they feel they have pushed as forcefully as they can.
62419275|NCT06107127|ACTIVE_COMPARATOR|Researcher 2|Using their symptomatic arm participants will be asked to push against a fixed force dynamometer (hand held force gauge), starting with a low level of effort and gradually increasing their effort stopping either at the point that they start to feel pain or when they feel they have pushed as forcefully as they can.
62419276|NCT01531062|EXPERIMENTAL|Nigella sativa|Nigella sativa extracts, 300 mg twice daily
62419277|NCT01531062|PLACEBO_COMPARATOR|Placebo|
62419278|NCT05408910|EXPERIMENTAL|Treatment|Participants in this arm will receive Rifaximin 550 mg three times daily for 14 days.
62419279|NCT05408910|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive placebo three times daily for 14 days.
62419280|NCT05600868|ACTIVE_COMPARATOR|EMDR+dual attention|.Processing the trauma with exposition and dual attention.
62419281|NCT05600868|ACTIVE_COMPARATOR|EMDR + fixed point|Processing the trauma with exposition and fixed point.
62419282|NCT05600868|ACTIVE_COMPARATOR|EMDR + exposition|Processing the trauma with exposition.
62419283|NCT01226615|EXPERIMENTAL|1|Chondroitin sulphate
62419284|NCT01226615|PLACEBO_COMPARATOR|2|Placebo
62419285|NCT06574217|EXPERIMENTAL|Stepping Stones|
62419286|NCT06574217|SHAM_COMPARATOR|Like|
62419287|NCT04303117|EXPERIMENTAL|Arm 1/Monotherapy|Treatment with NHS-IL12 at de-escalating doses if necessary
62801171|NCT06110013||B|Patients on Non invasive mechanical ventilation
62419288|NCT04303117|EXPERIMENTAL|Arm 1a/Monotherapy Expansion|Treatment with NHS-IL12 at MTD
62801172|NCT06110013||C|Patients Not on mechanical ventilation
62801173|NCT00752193|EXPERIMENTAL|1|Probiotic lactobacilli
62801174|NCT00752193|PLACEBO_COMPARATOR|2|Placebo
62801175|NCT04325893|ACTIVE_COMPARATOR|Hydroxychloroquine|
62027190|NCT03786601||Group C|High-risk HPV infection in gestational women
62027191|NCT03786601||Group D|High-risk HPV negative in gestational women
62027192|NCT00511004|ACTIVE_COMPARATOR|Diethylcarbamazine/Albendazole -STD|Standard therapy of DEC (300mg) and albendazole (400mg) yearly
62027193|NCT00511004|ACTIVE_COMPARATOR|Diethylcarbamazine/Albendazole- HD1|High dose of DEC (300mg) and albendazole (800mg) yearly
62027194|NCT00511004|ACTIVE_COMPARATOR|Diethylcarbamazine/Albendazole-HD2|High dose of DEC (300mg) and albendazole (800mg) twice yearly (every 6 months)
62027195|NCT05742373|EXPERIMENTAL|Fasted exercise|Exercise training in the fasted state
62419289|NCT04303117|EXPERIMENTAL|Arm 2/Combination therapy|Treatment with NHS-IL12 at MTD and M7824 at a fixed dose
62801176|NCT04325893|PLACEBO_COMPARATOR|Placebo|
62226284|NCT03650517||Robotic Right Colectomy with ECA|"Robot-assisted surgery (RAS), allows many types of complex MIS procedures using robotic systems to aid in surgical procedures providing more precision, flexibility and control than is possible with other MIS techniques.~Extracorporeal anastomosis: when the anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed."
62226285|NCT03650517||Laparoscopic Right Colectomy with ICA|"Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a surgical technique in which operations are performed far from their location through small incisions (usually 0.5-1.5 cm) elsewhere in the body.~Intracorporeal anastomosis: when the anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique. A Pfannenstiel incision will be done exclusively for specimen extraction."
62419290|NCT03667586|EXPERIMENTAL|Group Cognitive Behavioral Therapy|Cognitive behavioral psychotherapy sessions will be conducted at an appropriately accommodated office of the Psychiatry Department in groups of 6-10 patients and will be coordinated by a qualified psychologist of the research team. Each session will be of 90 minutes duration. The initial two sessions will be psycho-educational and the remaining sessions will be based on the principles of Cognitive Behavioral Therapy (CBT). In total, the psychotherapeutic intervention will last for 6 months with participants attending weekly sessions for the first 3 months and monthly follow-up sessions for the next 3 months.
62027196|NCT05742373|ACTIVE_COMPARATOR|Fed exercise|Exercise training in the fed state
62801177|NCT05293067||carotid endarterectomy|High-sensitive troponin would be measured in patients undergoing carotid endarterectomy (CEA). Patients would be followed during the immediate postoperative period (until discharge from hospital), one month after, one and two years following the surgery, when researchers will gather information regarding the study outcomes during a regular postoperative control, or through telephone interviews.
62801178|NCT05293067||carotid artery stenting|High-sensitive troponin would be measured in patients undergoing carotid artery stenting (CAS). Patients would be followed in the immediate postoperative period (until discharge from hospital), one month after, one and two years following the surgery, when researchers will gather information regarding the study outcomes during a regular postoperative control, or through telephone interviews.
62801179|NCT02081157||Breast Mastopexy with or without reduction using GalaFlex Mesh|Breast mastopexy with or without reduction, using GalaFLEX mesh
62801180|NCT02864589|EXPERIMENTAL|I-HRT|Internet-delivered habit reversal training
62801181|NCT02864589|EXPERIMENTAL|I-ERP|Internet-delivered exposure and response prevention
62801182|NCT06152510||Children with autism spectrum condition|Thirty children with autism spectrum condition and with medium-high functioning, aged 4 to 13 years, IQ \> 75, in the absence of motor deficits due to another clinical condition.
62801183|NCT06152510||Children with typical development|Thirty children with typical development aged 4 to 13 years, IQ \> 75, in the absence of motor deficits due to clinical condition.
62801184|NCT03553758|EXPERIMENTAL|Ketamine|15 subjects undergoing ketamine general anesthesia.
62801185|NCT03202342|EXPERIMENTAL|Water/gluc/gluc+EB/EB/gluc+EB_cold|First Water 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 22 C, then Ethyl butyrate 22 C and then Glucose + Ethyl butyrate 0 C
62801186|NCT03202342|EXPERIMENTAL|Water/gluc+EB/gluc/gluc+EB_cold/EB|First Water 22 C, then Glucose + Ethyl butyrate 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 0 C and then Ethyl butyrate 22 C
62801187|NCT03202342|EXPERIMENTAL|Gluc/water/EB/gluc+EB/glucose+EB_cold|First Glucose 22 C, then Water 22 C, then Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 22 C and then Glucose + Ethyl butyrate 0 C
62801188|NCT03202342|EXPERIMENTAL|Gluc/EB/water/gluc+EB_cold/gluc+EB|First Glucose 22 C, then Ethyl butyrate 22 C, then Water 22 C, then Glucose + Ethyl butyrate 0 C and then Glucose + Ethyl butyrate 22 C
62027197|NCT05742373|NO_INTERVENTION|Control|No exercise training
62801189|NCT03202342|EXPERIMENTAL|EB/Gluc/gluc+EB_cold/water/glucose+EB|First Ethyl butyrate 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 0 C, then Water 22 C and then Glucose + Ethyl butyrate 22 C
62801190|NCT03202342|EXPERIMENTAL|EB/gluc+EB_cold/gluc/glucose+EB/water|First Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 0 C, then Glucose 22 C, then Glucose + Ethyl butyrate 22 C and then Water 22 C
62801191|NCT03202342|EXPERIMENTAL|Gluc+EB_cold/water/glucose+EB/glucose/EB|First Glucose + Ethyl butyrate 22 C, then Water 22 C, then Glucose + Ethyl butyrate 0 C, then Glucose 22 C and then Ethyl butyrate 22 C
62801192|NCT03202342|EXPERIMENTAL|Gluc+EB_cold/glucose+EB/water/EB/glucose|First Glucose + Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 0 C, then Water 22 C, then Ethyl butyrate 22 C and then Glucose 22 C
62801193|NCT03202342|EXPERIMENTAL|Gluc+EB_cold/gluc+EB/EB/water/glucose|First Glucose + Ethyl butyrate 0 C, then Glucose + Ethyl butyrate 22 C, then Ethyl butyrate 22 C, then Water 22 C and then Glucose 22 C
62801194|NCT03202342|EXPERIMENTAL|Gluc+EB_cold/EB/gluc+EB/glucose/water|First Glucose + Ethyl butyrate 0 C, then Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 22 C, then Glucose 22 C and then Water 22 C
62801195|NCT01365286|ACTIVE_COMPARATOR|Ivabradine-Placebo|
62027198|NCT01891123|PLACEBO_COMPARATOR|body surface area|patients receive fixed dose of PTX or DOC based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2. Patients should finish up to 6 cycles chemotherapy
62801196|NCT01365286|ACTIVE_COMPARATOR|Placebo-Ivabradine|
62801197|NCT00759161|ACTIVE_COMPARATOR|1|AN2728 Ointment, 5%
62801198|NCT00759161|PLACEBO_COMPARATOR|2|AN2728 Ointment Vehicle
62027199|NCT01891123|ACTIVE_COMPARATOR|Detection Kit|PTX 175mg/m2, DOC 75mg/m2 at first cycle. the dose of PTX or DOC will adjust based on the pharmacokinetic results of previous cycle. A optimal target of PTX(TC\>0.05) and DOC(AUC) have been set from published PK model with an established limited sampling strategy
62226286|NCT03650517||Laparoscopic Right Colectomy with ECA|"Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a surgical technique in which operations are performed far from their location through small incisions (usually 0.5-1.5 cm) elsewhere in the body.~Extracorporeal anastomosis: when the anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed."
62027200|NCT06055296|EXPERIMENTAL|COMPRENDO Intervention|"Parent participants randomized to the intervention group will receive the COMPRENDO intervention that includes 2-4 visits led by a peer navigator across a 4-week period. Navigator visits will last about 16 - 60 minutes depending upon the needs and desires of the parent. Navigator sessions will be conducted in the parents' preferred language (either English or Spanish). Peer navigators will:~* Discuss general concepts related to informed consent and treatment options, including standard of care and clinical trials. The navigator will not discuss specific medications with parents.~* Attend the informed consent discussion parents have with their child's oncologist.~* Help parents come up with questions when the oncologist talks about cancer treatment options.~* Go over the consent forms. Answer questions parents may have to the best of their ability.~* Meet with parents over 4 weeks. During these meetings, the navigator will facilitate decision-making."
62027201|NCT06055296|NO_INTERVENTION|Usual Care|Parents will participate in an informed consent conference with the oncologist to discuss treatment options for the child as per each institution's procedure.
62027202|NCT06582615|EXPERIMENTAL|Arm I (MIND-TNBC counseling)|Patients receive MIND counseling sessions over 30-60 minutes weekly for 4 weeks then over 15 minutes biweekly for 4 sessions over 8 weeks and follow a personalized diet for 12 weeks. Patients also wear a Fitbit and undergo dried blood spot collection on study and during follow up.
62027203|NCT06582615|ACTIVE_COMPARATOR|Arm II (general health recommendations counseling)|Patients receive general health recommendations counseling sessions over 30-60 minutes weekly for 4 weeks then over 15 minutes biweekly for 4 sessions over 8 weeks. Patients also wear a Fitbit and undergo dried blood spot collection on study and during follow up. After 6 month follow-up, patients may receive the MIND counseling sessions as in Arm I.
62027204|NCT04001465|ACTIVE_COMPARATOR|Volumetric methacholine challenge|Methacholine challenge performed per the volumetric method using an Aerogen Solo vibrating mesh nebulizer
62027205|NCT04001465|ACTIVE_COMPARATOR|Methacholine challenge with spirometer|Methacholine challenge performed per the volumetric method using an Aerogen Solo vibrating mesh nebulizer fitted with an ultrasonic spirometer
62027206|NCT04144673|EXPERIMENTAL|Investigational Product|
62027207|NCT04144673|PLACEBO_COMPARATOR|Placebo|
62027208|NCT04178551|OTHER|Implementation Facilitation|The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.
62027209|NCT04178551|NO_INTERVENTION|Comparison Cohort|All other sites in VA not receiving CONDUIT implementation support or participating in other dedicated MOUD implementation activities during the same time period
62027210|NCT02765932|ACTIVE_COMPARATOR|Placebo Therapy|Dummy Movements
62027211|NCT02765932|EXPERIMENTAL|Psychosensory Therapy|Will involve touch technique, havening.
62027212|NCT04195503|OTHER|liver transplantation|Surgical Intervention - Liver transplantation
62027213|NCT04846504|ACTIVE_COMPARATOR|MMBFM program with clinician coach support|Telephonic coaching provided by licensed mental health professionals to support and encourage participants' engagement in and completion of the 8-session online MMBFM program.
62419291|NCT03667586|PLACEBO_COMPARATOR|Standard care|Regular brief follow-ups by the gastroenterologists and the nurse of the research team
62419292|NCT06414954|EXPERIMENTAL|NMD670 high dose|
62419293|NCT06414954|EXPERIMENTAL|NMD670 mid dose|
62419294|NCT06414954|EXPERIMENTAL|NMD670 low dose|
62419295|NCT06414954|PLACEBO_COMPARATOR|Placebo|
62589758|NCT06666075|EXPERIMENTAL|Experimental Group|The intervention for the experimental group implements a digital and interactive reminiscence program, starting with a preparation phase to select participants based on predefined criteria. Personalized content is developed for each individual, creating digital profiles that include photographs, music, videos, and significant life anecdotes tailored to evoke emotional memories. Care staff receive training on using the software and reminiscence techniques to facilitate the intervention. The implementation phase includes group and individual digital reminiscence sessions held twice a week for eight weeks, lasting about 60 minutes each. These sessions present selected digital content to promote discussion and memory sharing. Interactive activities, such as games and exercises, foster active participation, while the facilitator encourages participants to share stories and emotions, creating a supportive environment.
62226287|NCT06112561|ACTIVE_COMPARATOR|Cardiac output/index/SVR|Record of CO/CI/SVR before and after weaning form ECC from radial and femoral artery cannula.
62226288|NCT06112561|ACTIVE_COMPARATOR|Hypotension event|Prevent of hypotension event calculated from radial/femoral artery cannula
62226289|NCT00603720|ACTIVE_COMPARATOR|L-Name in Young|20 individuals age 18-35 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME.
62226290|NCT00603720|ACTIVE_COMPARATOR|Phenylephrine|25 individuals age 18-35 will be getting an infusion of phenylephrine (primarily an alpha agonist) during 3 separate PET study days
62419296|NCT04824040||Study group|Patients with a genetically confirmed dysferlinopathy.
62419297|NCT04824040||Control group|Healthy Volunteers
62419298|NCT05523310||Training group|The training group will be used to develop the prediction model, based on their reported daily questionnaire. Participants in the training group will not be included in the Validation group
62419299|NCT05523310||Validation group|"The validation group will be used only for validation (test) of the prediction model (Naïve group). Participants in the validation group could not be recruited from the training group"
62419300|NCT02094573|EXPERIMENTAL|Brigatinib 90 mg|Brigatinib 90 mg, tablets, orally, once daily in each Cycle of 28 days until disease progression or intolerable toxicity (median duration of exposure was 402 days).
62801199|NCT04437485|EXPERIMENTAL|eIMPACT-DM intervention|eIMPACT-DM is a 6-month, modernized, collaborative, stepped care intervention consisting of (1) computerized and telephonic cognitive-behavioral therapy for depression and (2) select antidepressant medications included in an algorithm optimized for diabetes risk reduction. It is a collaborative care intervention in which a multidisciplinary team delivers established depression treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that modernizes the IMPACT intervention by harnessing technology to minimize staff and space requirements. Interventions are Good Days Ahead, Problem Solving Treatment in Primary Care, and select FDA-approved antidepressants. The treatment team consists of a depression clinical specialist, a supervising MD with expertise in primary care and IMPACT, and the patients' primary care providers (PCPs).
62226291|NCT00603720|ACTIVE_COMPARATOR|L-arginine in Young|20 individuals age 18-35 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
62226292|NCT00603720|ACTIVE_COMPARATOR|L-arginine in Old|20 individuals age 60-75 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
62226293|NCT00603720|EXPERIMENTAL|L-NAME in Old|20 individuals age 60-75 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME
62801200|NCT04437485|ACTIVE_COMPARATOR|Active Control|Active Control (AC) consists of depression education (study staff), symptom monitoring (study staff), and primary care for depression (clinical staff).
62226294|NCT03214094||Vonoprazan 10 mg|The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily. Participants will receive interventions as part of routine medical care.
62226295|NCT04647812|EXPERIMENTAL|Technology-assisted rehabilitation|Augmented exercise therapy with novel technology
62226296|NCT04647812|EXPERIMENTAL|Conventional rehabilitation|Traditional multidisciplinary rehabilitation
62226297|NCT04076748|EXPERIMENTAL|Experimental|"\* Intra Nasal Sufentanil (50 µg.ml-1): Load dose : 0.3 µg. kg-1, Followed by bolus : 5 µg / 10 minutes with 2 bolus maximum.~As soon as the venous route and ten minutes after the last administration of sufentanil:~* Morphine IV: 3 mg / 5 minutes.~* Objective: numeric rating scale (NRS) ≤ 3/10."
62419301|NCT02094573|EXPERIMENTAL|Brigatinib 90 mg - 180 mg|Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in Cycle 2 and onward Cycles of 28 days until disease progression or intolerable toxicity (median duration of exposure was 522 days).
62419302|NCT03514121|EXPERIMENTAL|Phase 1a dose escalation/1b dose expansion|The study consists of Phase 1a dose escalation, Phase 1a dose exploration, Phase 1a combination safety-lead-in and Phase 1b dose expansion
62419303|NCT03983369|EXPERIMENTAL|"preventive treatment with LLLT (Laser group)"|
62419304|NCT03983369|PLACEBO_COMPARATOR|control group with a placebo intervention|
62419305|NCT00486213|ACTIVE_COMPARATOR|Pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
62419306|NCT00486213|PLACEBO_COMPARATOR|Placebo|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
62419307|NCT06111313|EXPERIMENTAL|Focal Therapy lattice extreme ablative dose (FTLEAD), RT Only, Arm A|Participants in this group will receive the FTLEAD treatment only and will be followed for up to 5.5 years.
62027214|NCT04846504|ACTIVE_COMPARATOR|MMBFM program with peer coach support|Telephonic coaching provided by trained peers with lived experience of perinatal depression to support and encourage participants' engagement in and completion of the 8-session online MMBFM program.
62589759|NCT01433445|EXPERIMENTAL|Cohort 1|Subjects will be treated with ruxolitinib 5 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
62801201|NCT00143910||Renal transplant recipient|Recipients of successful renal transplant
62801202|NCT03218384|EXPERIMENTAL|Ferric Carboxymaltose|HF patients with functional iron deficiency assigned to receive one-time dose of Ferric Carboxymaltose 750 mg. Participants will undergo serial assessment before and 4 weeks after study drug administration
62226298|NCT04076748|ACTIVE_COMPARATOR|Control|"\* EMONO : Given by respiratory administration via a face mask at a rate suitable for patient ventilation (generally at least 9l.min-1), Until a venous route is obtained and without exceeding 30 minutes.~\* Morphine IV: Load dose: 0.1mg. kg-1 as soon as possible; Then bolus: 3mg / 5 minutes.~\* Objective: NRS ≤ 3/10"
62226299|NCT06020742|EXPERIMENTAL|MT transfer|
62027215|NCT04846504|ACTIVE_COMPARATOR|Patient facing strategy intervention arm|Centralized outreach and recruitment of women receiving prenatal care by study team using email, letter, or text, without direct involvement of OB providers.
62027216|NCT04846504|ACTIVE_COMPARATOR|Patient facing plus clinic facing strategy intervention arm|OB clinic providers' use of printed recruitment materials and/or electronic medical records prompts to recommend/refer women receiving prenatal care to access the MMBFM program. These clinic facing implementation strategies will be added to the patient facing strategies of centralized outreach and recruitment of women receiving prenatal care by study team using email, letter, or text
62027217|NCT04469179|EXPERIMENTAL|Cohort 1|10mg/kg SAB-185 in normal (0.9%) saline; concentration 4mg/mL (0.4%)
62226300|NCT01978522|EXPERIMENTAL|NICOLA Participants|All participants enrolled in the NICOLA cohort
62226301|NCT04983641|NO_INTERVENTION|Control - No Pre-Visit Message|o Patients were assigned PROMIS forms in the domains of Depression (PROMIS-D) and Pain Interference (PROMIS-PI) in addition to Upper Extremity Function (PROMIS-UE) and/or Physical Function (PROMIS-PF). These forms were available for remote completion in each respective patient's MyChart portal at 1 week prior to their clinic appointment. Patients in this arm were not sent any reminder e-mails or MyChart messages concerning PROMIS form completion at any timepoint prior to their scheduled clinic visit.
62419308|NCT06111313|EXPERIMENTAL|Focal Therapy lattice extreme ablative dose (FTLEAD), uSTADT, Arm B|Participants in this group will receive the FTLEAD treatment and ultra short-term androgen deprivation therapy (ADT) and will be followed for up to 5.5 years.
62419309|NCT06111313|EXPERIMENTAL|Lattice extreme ablative dose followed by hypofractionated RT (HypoLEAD), Arm C|Participants in this group will receive LEAD RT followed by moderately hypofractionated RT (HypoLEAD) and standard of care androgen deprivation therapy and will be followed for 5.5-8 years.
62419310|NCT06111313|EXPERIMENTAL|Lattice extreme ablative dose followed by hypofractionated RT (HypoLEAD), uSTADT, Arm D|Participants in this group will receive LEAD RT with ultra short-term ADT followed by moderately hypofractionated RT (HypoLEAD) and standard of care ADT and will be followed for 5.5-8 years.
62419311|NCT02088294|NO_INTERVENTION|Non-intervention control|No intervention will be delivered.
62419312|NCT02088294|EXPERIMENTAL|Lifestyle Education (LS)|"The lifestyle curriculum will be taught in twice weekly after-school sessions of \~1.25 hours, one physical activity and one nutrition-related, delivered over 12-weeks during the course of a single academic semester. The lifestyle program will utilize the Shape Up curriculum of SOSMentor, a community non-profit collaborator, modified to seamlessly integrate key concepts of the non-diet philosophy of Intuitive Eating. The curriculum fully encompasses health-promoting nutrition and physical activity practices consistent with consensus recommendations ."
62419313|NCT02088294|EXPERIMENTAL|LS + Stress Reduction Guided Imagery|"In addition to the after school lifestyle classes, participants will receive group Interactive Guided Imagery (IGI) consisting of standard stress reduction imagery practices, delivered once weekly for 12 weeks as an after school class of \~1.25 hours. The group IGI will be delivered by certified facilitators in the context of the facilitated group process known as Council, a group communication process used by many indigenous and other cultures."
62419314|NCT02088294|EXPERIMENTAL|LS + Activity/Eating Guided Imagery|"In addition to the after school lifestyle classes, participants will receive group Interactive Guided ImagerySM (IGI) delivered once weekly for 12 weeks as an after school class of \~1.25 hours. The group IGI will be delivered by certified facilitators in the context of the facilitated group process known as Council, a group communication process used by many indigenous and other cultures. Participants in this arm will receive stress reduction IGI for 4 wks, plus 8 weekly sessions with IGI content designed to promote physical activity and healthy eating."
62419315|NCT03933826||Patients who have selected radical cystectomy|Patients with a diagnosis of recurrent high-grade NMIBC that failed first-line BCG and who have selected radical cystectomy as their second-line treatment
62419316|NCT03933826||Patients who have selected medical management|Patients with a diagnosis of recurrent high-grade NMIBC that failed first-line BCG and who have selected medical management as their second-line treatment
62589760|NCT01433445|EXPERIMENTAL|Cohort 2|Subjects will be treated with ruxolitinib 10 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
62589761|NCT01433445|EXPERIMENTAL|Cohort 3|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
62801203|NCT03218384|ACTIVE_COMPARATOR|Placebo|HF patients with functional iron deficiency assigned to receive one-time dose of Placebo (saline injection). Participants will undergo serial assessment before and 4 weeks after study drug administration.
62801204|NCT04918706|EXPERIMENTAL|MSC week 4 and 3 before LVRS2|Allogeneic mesenchymal Stromal cells: 2 x 10\^6/kg body weight MSC in a range of 1.5 x 10\^6 MSC/ kg to 2.5 x 10\^6 MSC/kg (at a maximum of 200 x10\^6 MSC per study participant) with 5% DMSO iv
62801205|NCT04918706|PLACEBO_COMPARATOR|Placebo week 4 and 3 before LVRS2|Placebo: consisting of a 5% DMSO-solution in isotonic solution
62801206|NCT04918706|EXPERIMENTAL|MSC week 12 and 11 before LVRS2|Allogeneic mesenchymal Stromal cells: 2 x 10\^6/kg body weight MSC in a range of 1.5 x 10\^6 MSC/ kg to 2.5 x 10\^6 MSC/kg (at a maximum of 200 x10\^6 MSC per study participant) with 5% DMSO iv
62027218|NCT04469179|EXPERIMENTAL|Cohort 2|25mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%)
62027219|NCT04469179|EXPERIMENTAL|Cohort 3|50mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%)
62027220|NCT04469179|PLACEBO_COMPARATOR|Placebo|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
62027221|NCT05807711|ACTIVE_COMPARATOR|Experimental: Intervention group|"Adult end stage renal disease patients maintained on hemodialysis three times a week for at least 3 months with resistant hypertension as determined by pre-dialysis BP \> 140/90 mm Hg, post-dialysis BP \> 130/80 mm Hg despite the use of three or more drugs.~Patients will be assigned to take one tablet daily containing L-methylfolate and methylcobalamine.~Patients will be followed over a period of 3 months after which blood pressure measurement and blood sampling would be repeated and compared to baseline values."
62027222|NCT05807711|NO_INTERVENTION|No Intervention: Control group|"Adult end stage renal disease patients maintained on hemodialysis three times a week for at least 3 months with resistant hypertension as determined by pre-dialysis BP \> 140/90 mm Hg, post-dialysis BP \> 130/80 mm Hg despite the use of three or more drugs.~Patients will be followed over a period of 3 months after which blood pressure measurement and blood sampling would be repeated and compared to baseline values."
62027223|NCT00744653|OTHER|1|Patients with local-regional recurrence of breast cancer, lesion over 3 cm.
62027224|NCT00360308|PLACEBO_COMPARATOR|Placebo|matching E2007 and matching entacapone
62027225|NCT00360308|ACTIVE_COMPARATOR|E2007|2 mg once daily in the evening, Weeks 0→2 (2 weeks) and 4 mg once daily in the evening, Weeks 2→18.
62027226|NCT00360308|ACTIVE_COMPARATOR|Entacapone|200 mg with each dose of Levodopa.
62027227|NCT00918359||HI|Subjects who experienced heat exhaustion or heat stroke in their past and will be identified by heat tolerance test (HTT) as Heat Intolerance .
62027228|NCT00918359||HT|Subjects who experienced heat exhaustion or heat stroke in their past and will be identified by heat tolerance test (HTT) as Heat Tolerance .
62226302|NCT04983641|EXPERIMENTAL|E-mail Arm|o Patients were assigned PROMIS forms in the domains of Depression (PROMIS-D) and Pain Interference (PROMIS-PI) in addition to Upper Extremity Function (PROMIS-UE) and/or Physical Function (PROMIS-PF). These forms were available for remote completion in each respective patient's MyChart portal at 1 week prior to their clinic appointment. Patients in this arm were sent an initial reminder e-mail message at 1 week prior to their scheduled clinic visit regarding PROMIS form completion. If patient's did not fill out PROMIS forms by 3 days prior to their visit, they were sent a second reminder e-mail message.
62419317|NCT02618707||Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
62419318|NCT05123586|EXPERIMENTAL|LY3361237|Participants are administered LY3361237 subcutaneously (SC) and standard of care (SOC)
62027229|NCT03845348|EXPERIMENTAL|TD3|TD3, bi-daily x 4 weeks
62027230|NCT03845348|EXPERIMENTAL|TD7|TD7, bi-daily x 4 weeks
62027231|NCT03845348|ACTIVE_COMPARATOR|Ketoconazole 2%|Ketoconazole 2% shampoo bi-daily x 4 weeks
62027232|NCT04619641|ACTIVE_COMPARATOR|High flow nasal cannula (HFNC)|HFNC will be applied by means of a dedicated device (AIRVO2, Fisher \& Paykel Healthcare, Auckland, New Zealand). Gas flow will be set at 50 L/min, and humidification chamber will be set at 31°C.
62801207|NCT04918706|PLACEBO_COMPARATOR|Placebo week 12 and 11 before LVRS2|Placebo: consisting of a 5% DMSO-solution in isotonic solution
62027233|NCT04619641|ACTIVE_COMPARATOR|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet."
62027234|NCT04619641|ACTIVE_COMPARATOR|HFNC+CPAP|"HFNC+CPAP consists in the contemporaneous application of HFNC and CPAP through helmet. HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity, while CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
62027235|NCT04880759|EXPERIMENTAL|Bike desks in classroom|All participants receive the same intervention: the use of bike desks during school.
62226303|NCT04983641|EXPERIMENTAL|"Digital Patient Portal MyChart Arm"|o Patients were assigned PROMIS forms in the domains of Depression (PROMIS-D) and Pain Interference (PROMIS-PI) in addition to Upper Extremity Function (PROMIS-UE) and/or Physical Function (PROMIS-PF). These forms were available for remote completion in each respective patient's MyChart portal at 1 week prior to their clinic appointment. Patient's in this arm were sent an initial reminder MyChart message at 1 week prior to their scheduled clinic visit regarding PROMIS form completion. If patients did not fill out PROMIS forms by 3 days prior to their visit, they were sent a second reminder MyChart message.
62226304|NCT05419453||Parkinson's|Those with Parkinson's Disease
62027236|NCT01056224|EXPERIMENTAL|1.25 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
62027237|NCT01056224|EXPERIMENTAL|1.5 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
62027238|NCT01056224|EXPERIMENTAL|1.75 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.75 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
62027239|NCT01056224|EXPERIMENTAL|1 ug/kg normo-tensive 65-75 year olds|A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
62801208|NCT04050059|ACTIVE_COMPARATOR|2% Lidocaine group|In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited) skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal anesthesia induction.
62027240|NCT01056224|EXPERIMENTAL|1.25 ug/kg normo-tensive 65-75 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
62027241|NCT01056224|EXPERIMENTAL|1.5 ug/kg normo-tensive 65-75 year olds|"1.5 ug/kg normo-tensive 65-75 year olds~A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old."
62027242|NCT01056224|EXPERIMENTAL|1 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
62027243|NCT01056224|EXPERIMENTAL|1.25 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
62027244|NCT01056224|EXPERIMENTAL|1.5 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
62027245|NCT05802459||Patients undergoing complex esophageal reconstruction|All the patients who are candidates for complex esophageal reconstruction performed by the Complex Esophageal Reconstruction Functional Unit of the Bellvitge University Hospital (UREC-HUB), during the study period.
62027246|NCT04071938|ACTIVE_COMPARATOR|Intervention group|"Physicians: 10 GPs from 10 practices who treat patient with Spinal cord injury (SCI) and 10 SCI specialists.~Patients: 270 people with SCI within 25 minutes vehicle driving distance to the GP practices will be in the intervention group"
62027247|NCT04071938|NO_INTERVENTION|Control group|"Physicians: 20 GPs who treat patient with SCI will not receive any intervention. They will be completing the questionnaire (DOC) and assessed for satisfaction with collaboration with the SCI specialist.~Patients: 210 people with spinal cord injury outside the catchment area of the intervention group will be receiving usual care (no intervention)"
62027248|NCT03887377|EXPERIMENTAL|Breast receiving botulinum toxin|"Following reconstruction one horizontal incisional wound will be selected to receive a series of botulinum toxin injections along the wound.~Injection abobotulinum toxin at time of surgery, single injection time with 30 gauge needle superficially, dosage determined by length of scar 5-15U per cm"
62027249|NCT03887377|PLACEBO_COMPARATOR|Breast receiving placebo|The other breast will be injected with bacteriostatic normal saline in a similar fashion to the other breast. The injector will be blinded to the contents of the syringe.
62027250|NCT03894449|PLACEBO_COMPARATOR|Placebo only|
62027251|NCT03894449|EXPERIMENTAL|Prebiotic Inulin & Iron Salt FeSO4|
62226305|NCT05320549|EXPERIMENTAL|Exercise|Participants have the opportunity to engage in face-to-face and/or online exercise classes
62419319|NCT05123586|PLACEBO_COMPARATOR|Placebo|Placebo administered SC and SOC given at matching intervals
62801209|NCT04050059|ACTIVE_COMPARATOR|EMLA cream group|In EMLA (Eutectic Mixture of Local Anesthesia- lidocaine 2.5% and prilocaine 2.5%) cream group, EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion
62801210|NCT03523494||Normal limb|Normal
62801211|NCT03523494||Abnormal limb|Lymph Edema
62801212|NCT02750852||Analysis group|Create an algorithm to predict blood loss using patients data
62801213|NCT02750852||Control group|The algorithm was applied to analyze sensitivity and specificity
62801214|NCT05757648|EXPERIMENTAL|Buffered Anesthetic Side/Non-buffered Anesthetic Side|"Patients will be randomized to one side of the mouth getting the buffered anesthetic and the other side of the mouth to the non-buffered anesthetic.~Patients will be randomized to one side of the mouth getting the buffered anesthetic and the other side of the mouth to the non-buffered anesthetic."
62027252|NCT03894449|EXPERIMENTAL|Prebiotic GOS & Iron Salt FeSO4|
62027253|NCT03894449|EXPERIMENTAL|Prebiotic Inulin & Iron Salt NaFeEDTA|
62226306|NCT05320549|NO_INTERVENTION|Usual care control|Participants continue to engage with usual care provided on discharge from the hospital.
62226307|NCT04310033||Cases|"* \> 18 years old~* Non-opposition of the patient or relatives~* Lung, head and neck or colorectal cancer~* Non scheduled ICU admission~* At least 24 hours of ICU stay~* Alive at ICU discharge~* Able to answer by phone to quality of life questionary"
62419320|NCT04113564|EXPERIMENTAL|IV remimazolam|IV remimazolam administration of 0.025 mg/kg body weight
62419321|NCT04113564|EXPERIMENTAL|Oral remimazolam|Oral remimazolam Administration of 0.14 mg/kg Body weight
62419322|NCT03944798|ACTIVE_COMPARATOR|Surveillance Arm I|Clinical assessment and chest radiograph (CXR) every six months for two years
62419323|NCT03944798|EXPERIMENTAL|Surveillance Arm II|Clinical assessment and CXR every three months for two years
62419324|NCT03944798|EXPERIMENTAL|Surveillance Arm III|Clinical assessment and chest computed tomography (CT) every six months for two years
62419325|NCT03944798|EXPERIMENTAL|Surveillance Arm IV|Clinical assessment and chest CT every three months for two years
62226308|NCT04310033||Controls|"Cancer patients not admitted in ICU, matched with the cases according to~* the type of primary cancer~* the presence or absence of oncogenic addiction~* the setting of anticancer treatment (curative/palliative)~* the line of anticancer treatment (none/L1/L2-L3/\>L3)."
62226309|NCT04869943|EXPERIMENTAL|Enobosarm Treatment Group|Subjects in the Enobosarm Treatment Group will receive enobosarm 9mg each day by mouth until disease progression or an unacceptable adverse event is observed. The total duration of the study for a subject in the study from screening to follow-up visit is not standardized and will be different for each subject.
62226310|NCT04869943|ACTIVE_COMPARATOR|Control Treatment Group|Subjects in the Control Treatment Group will receive an ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site. The decision of which comparator treatment will be used will be made prior to randomization. After radiographic progression, subjects randomized to the Control Treatment Group may be crossed over to receive enobosarm 9mg.
62027254|NCT03894449|EXPERIMENTAL|Prebiotic GOS & Iron Salt NaFeEDTA|
62027255|NCT04172792|ACTIVE_COMPARATOR|high-caloric fatty diet|intake of 405 kcal (45g fat) per day in addition to normal food intake
62027256|NCT04172792|EXPERIMENTAL|ultra-high-caloric fatty diet|intake of 810 kcal (90g fat) per day in addition to normal food intake
62027257|NCT04172792|EXPERIMENTAL|ultra-high-caloric carbohydrate-rich diet|intake of 900 kcal (111.4g carbohydrate, 34.9g fat, 36.0g protein) in addition to normal food intake
62027258|NCT04172792|NO_INTERVENTION|control|normal food intake (no intervention)
62027259|NCT01968213|EXPERIMENTAL|Rucaparib|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
62226311|NCT03487354|ACTIVE_COMPARATOR|Single daily dose|
62226312|NCT03487354|ACTIVE_COMPARATOR|Multiple daily doses|
62226313|NCT02529631|ACTIVE_COMPARATOR|Drug: orlistat 60mg capsules|"A tailored blister-strip for one day contains~* three capsules with orlistat 60mg Administration: 3 times daily 1 capsule with each meal containing fat concomitant with~* six placebo tablets Administration: 3 times daily 2 tablets with each main meal"
62226314|NCT02529631|ACTIVE_COMPARATOR|Medical device: polyglucosamine|"A tailored blister-strip for one day contains~* three placebo capsules Administration: 3 times daily 1 capsule with each meal containing fat concomitant with~* six tablets Administration: 3 times daily 2 tablets (whereas the 2 tablets in the mold breakfast are placebo tablets and the remaining 4 tablets for lunch and dinner contains poliglucosamine"
62226315|NCT04439682|EXPERIMENTAL|Study group|Aerobic exercise will be performed for a single session
62226316|NCT04439682|ACTIVE_COMPARATOR|Control group|Aerobic exercise will be performed to healthy population for a single session
62801215|NCT06451627|EXPERIMENTAL|esketamine|Esketamine ( 50mg, dissolved in 50ml normal saline ) will be infused at a speed of 0.3mg / kg / h during surgery .Total intravenous anesthesia with propofol ,remifentanil will be implemented for anesthesia maintenance based on the bispectral index(BIS) and keep BIS between 40-60 .
62027260|NCT01968213|PLACEBO_COMPARATOR|Placebo|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
62027261|NCT00003011|ACTIVE_COMPARATOR|Marmistat|10 mg PO BID
62027262|NCT00003011|PLACEBO_COMPARATOR|Placebo|10 mg PO BID
62027263|NCT04733560|EXPERIMENTAL|Pudendal nerve block|25 women will receive pudendal nerve blocks of 0.25% Bupivicaine 10ml administered vaginally prior to making any surgical incisions.
62027264|NCT04733560|SHAM_COMPARATOR|Placebo|25 women will receive sham pudendal nerve blocks using normal saline. These will also be administed vaginally prior to making any surgical incisions.
62027265|NCT01437449|EXPERIMENTAL|Cisplatin + Docetaxel + Cetuximab|Patients will be treated weekly with cisplatin, docetaxel, and cetuximab.
62027266|NCT02103439|EXPERIMENTAL|Algeron|Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight \<65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight \> 105 kg)
62027267|NCT02103439|ACTIVE_COMPARATOR|PegIntron|PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight \<65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight \> 105 kg).
62027268|NCT05542355|EXPERIMENTAL|Part A (Open-Label EXL01 Maintenance Therapy)|Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
62027269|NCT05542355|EXPERIMENTAL|Part B (EXL01 Maintenance Therapy)|Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
62027270|NCT05542355|PLACEBO_COMPARATOR|Part B (Placebo Maintenance Therapy)|Oral EXL01 matched placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
62027271|NCT05108337|EXPERIMENTAL|Scpb group|Superficial cervical plexus block group
62801216|NCT06451627|PLACEBO_COMPARATOR|saline|Saline will be infused at a speed of 0.3mg / kg / h during surgery .Total intravenous anesthesia with propofol ,remifentanil will be implemented for anesthesia maintenance based on the bispectral index(BIS) and keep BIS between 40-60 .
62801217|NCT01453140|EXPERIMENTAL|Cyclophosphamide and Sirolimus|cyclophosphamide and sirolimus combo
62027272|NCT05108337|SHAM_COMPARATOR|Control group|Saline group
62027273|NCT00935025|EXPERIMENTAL|1, AZD1305|
62027274|NCT00935025|PLACEBO_COMPARATOR|2, Placebo|
62027275|NCT04977167|EXPERIMENTAL|Part 1:HG146 Monotherapy, Dose-escalation Cohort|Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, 21 days/ cycle. Escalating doses of HG146 will be evaluated using 3+3 approach.
62027276|NCT04977167|EXPERIMENTAL|Part 2A:HG146 + PD-(L)1 antibody, Dose escalation Cohort|"Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, along with PD-(L)1 antibody IV once every 3 weeks (Q3W),21 days/ cycle.~Escalating doses of HG146 in combination with PD-(L)1 antibody will be evaluated."
62226317|NCT03475615|EXPERIMENTAL|SOXP|
62226318|NCT03475615|ACTIVE_COMPARATOR|SOX|
62226319|NCT01084629||Surveillance Barrett's esophagus|Patients scheduled for endoscopic surveillance of Barrett's esophagus
62226320|NCT01084629||Barrett's esophagus post ablation|Patients scheduled for surveillance endoscopy who have undergone ablative therapies (PDT, RF ablation) for their Barrett's esophagus
62226321|NCT00975767|EXPERIMENTAL|MGCD265+erlotinib|
62226322|NCT00975767|EXPERIMENTAL|MGCD265+docetaxel|
62226323|NCT02579499|ACTIVE_COMPARATOR|Fixed high-potent statin group|According to 2013 ACC/AHA guideline, patients will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels.
62419326|NCT03079869|OTHER|Ferric Citrate|Auryxia, 210 mg ferric iron tablets equivalent to 1 g of ferric citrate are supplied as 200 tablets in 400-cc high-density polyethylene bottles.
62226324|NCT02579499|EXPERIMENTAL|Targeted LDL-C goal statin group|Patients will be tiltrated statin intensity guided by follow-up LDL-C level
62226325|NCT05175638||Control|A total of 20 term newborn infants with a median gestational age of 40 weeks (range: 37-42 weeks) will be selected from the Gynecology and Obstetrics Hospital (Assiut University). All control infants should have an Apgar score of \> 9 at 1, 5, and 10 minutes.
62226326|NCT05175638||Study group|"Thirty newborn infants born for Covid-19 positive mothers will be prospectively included in this study. The diagnosis of hypoxia will made based on Apgar score, clinical signs present during the first hours of life and acid-base status.~The following inclusion criteria will be used (all necessary): Covid-19 positive mothers, term newborn (\>37 completed gestational weeks), free from severe malformations. All infants will be examined generally, systemically and neurologically at birth for clinical assessment of HIE if present and for detection of outcome of these neonates."
62226327|NCT02032914||Colonoscopic examination group|The patients diagnosed with cryptogenic pyogenic liver abscess
62419327|NCT01238172|EXPERIMENTAL|Arm A - MEAL Program Intervention|Patients will receive dietary education and telephone counseling sessions over 24 months.
62419328|NCT01238172|EXPERIMENTAL|Arm B - Prostate Cancer Foundation Booklet|Patients receive information about diet, nutrition, exercise and cancer. Patients also receive regularly scheduled newsletters.
62419329|NCT06568913|EXPERIMENTAL|Persistent or chronic ITP not responsive to steroids|The Outcome of the Thrombopoietin Receptor Agonists in Pediatric Patient With Persistent or Chronic ITP Unresonsive to Steroids
62419330|NCT00179218|ACTIVE_COMPARATOR|1|only protein supplementation
62419331|NCT00179218|ACTIVE_COMPARATOR|2|protein supplementation plus exercise
62419332|NCT02093468|PLACEBO_COMPARATOR|Saline|Saline administered IV for 12 hours
62419333|NCT02093468|EXPERIMENTAL|Lower Dose|MST-188 loading dose 100 mg/kg IV for 1 hour followed by 25 mg/kg/hr for 11 hours
62419334|NCT02093468|EXPERIMENTAL|Higher Dose|MST-188 loading dose 200 mg/kg IV for 1 hour followed by 75 mg/kg/hr for 11 hours
62419335|NCT04262024|ACTIVE_COMPARATOR|Group A|Women with hyperprolactinemia are scheduled for cabergoline therapy cabergoline 1.5-2 mg/week. for one month plus health education.
62419336|NCT04262024|ACTIVE_COMPARATOR|Group B|Women with hyperprolactinemia are scheduled for cabergoline therapy 1.5-2 mg/week. for one month without health education.
62226328|NCT01959022|EXPERIMENTAL|Doxazosin XL|Subjects will participate in a 2 week flexible-dose titration of doxazosin XL based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
62419337|NCT06606106|EXPERIMENTAL|LY3537031 Part A (Cohorts 1-7)|Multiple-ascending doses of LY3537031 administered subcutaneously (SC)
62419338|NCT06606106|PLACEBO_COMPARATOR|Placebo Part A|Placebo administered SC
62419339|NCT06606106|EXPERIMENTAL|LY3537031 Part B (Cohorts 8-11)|Multiple-ascending doses of LY3537031 administered SC
62419340|NCT06606106|PLACEBO_COMPARATOR|Placebo Part B|Placebo administered SC
62419341|NCT06606106|EXPERIMENTAL|LY3537031 Part C (Cohorts 12-15)|Multiple-ascending doses of LY3537031 administered SC
62419342|NCT06606106|PLACEBO_COMPARATOR|Placebo Part C|Placebo administered SC
62419343|NCT04329013|ACTIVE_COMPARATOR|Left lateral position|The patient will be in left lateral position during EGD
62419344|NCT04329013|EXPERIMENTAL|Prone position|The patient will be in prone position during EGD
62419345|NCT03307902|EXPERIMENTAL|Imiquimod + ID HBVv|topical imiquimod + intradermal hepatitis B vaccination
62419346|NCT03307902|ACTIVE_COMPARATOR|Aqueous + ID HBVv|topical aqueous + intradermal hepatitis B vaccination
62419347|NCT03307902|ACTIVE_COMPARATOR|Imiquimod + IM HBVv|topical imiquimod + intramuscular hepatitis B vaccination
62419348|NCT03910101|ACTIVE_COMPARATOR|Hand surgery and intensive rehabilitation|"The surgical treatment for reducing spasticity comprises lengthening of tendons, muscle release and occasionally correction of deformities. Lengthening of a tendon or releasing a muscle from its insertion, results in relaxation of the whole muscle-tendon unit. Hence, the spasticity is not gone, but reduced in strength.~The tendon lengthening procedures is performed by a stair-step incision technique followed by reattachment in the lengthened position using a side-to-side, cross-stich technique. The load to failure of the sutured tendon is approximately 200Newton, which gives a sufficient safety margin for early active mobilization of the tendons involved. This suture technique thus enables active training directly after surgery.~Postoperative rehabilitation includes wrapping and a custom-made splint, for day and night use, muscle activation and passive stretching 2-4 times per day without the splint."
62419349|NCT03910101|ACTIVE_COMPARATOR|Botulinum toxin injections|Botulinum toxin injections are given in spastic muscles of the upper extremity. Dosage and number of injections per muscle vary depending on the degree and extent of spasticity. For optimal effect on hand function, botulinum toxin is accompanied by the treatment of individualized exercise and splinting when needed.
62419350|NCT04681495|OTHER|Usability of Bullying Prevention Online Application|This intervention has a single arm. It consists of conducting focus groups and usability testing of a bullying prevention online application for middle-school-aged students.
62419351|NCT04760574||Case group|HIV infected men who have sex with men
62801218|NCT01453140|EXPERIMENTAL|Lowdose IL-2, Cytoxan + Sirolimus|Low dose IL-2 with Cytoxan + Sirolimus Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.
62226329|NCT04953325|EXPERIMENTAL|Experimental Group|180 subjects (including 90 adults aged 18-59 years and 90 elderly aged 60 year and older）will receive two doses of inactivated COVID-19 vaccine on day 0 and day 28
62589762|NCT01433445|EXPERIMENTAL|Cohort 4|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 15 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
62226330|NCT04953325|PLACEBO_COMPARATOR|Control Group|90 subjects (including 45 adults aged 18-59 years and 45 elderly aged 60 year and older）will receive one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of Inactivated Hepatitis A Vaccine on day 28
62589763|NCT01433445|EXPERIMENTAL|Cohort 5|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 20 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
62801219|NCT01453140|EXPERIMENTAL|Lowdose IL-2, Vidaza, cyclophosphamide & Sirolimus|Lowdose IL-2, Vidaza, cyclophosphamide (Cytoxan) \& Sirolimus Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza).
62801220|NCT01082250|OTHER|Reference Formulation|Dosed 12.5% drugload 3X40mg
62801221|NCT01082250|OTHER|Test Formulation|25% Drugload 1X120mg
62419352|NCT04760574||Control group|HIV non-infected men
62419353|NCT06459401|EXPERIMENTAL|Neuroprosthesis-Assisted Walking Evaluation|Participants with chronic stroke will perform a series of short overground walking evaluations at a self-selected fast walking speed with the neuroprosthesis powered and unpowered. When the neuroprosthesis is powered, it provides active neurostimulation assistance for foot clearance and propulsion. When the neuroprosthesis is unpowered, it is worn by the participant but does not provide active assistance.
62419354|NCT02993016|EXPERIMENTAL|patient-specific instruments group|procedure: PSI (patient-specific instruments) will be used as the cutting guide in total knee arthroplasty.
62419355|NCT02993016|ACTIVE_COMPARATOR|conventional instruments group|procedure: Conventional instruments will be used as the cutting guide in total knee arthroplasty.
62419356|NCT06568887|EXPERIMENTAL|Dextrose Water|
62419357|NCT06568887|ACTIVE_COMPARATOR|Corticosteroid Injection|
62419358|NCT00402779|EXPERIMENTAL|Erlotinib|Balanced randomization: Erlotinib 150 mg continuous administration for 1 year.
62589764|NCT01433445|EXPERIMENTAL|Cohort 6/6+|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 25 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
62226331|NCT05067465|EXPERIMENTAL|Milk and dairy products|"Standardized diet over five days (n = 40) - composed of cow milk, cheese, cream cheese, cream, valess milk schnitzel~Test meal on day 6 (n = 12) - composed of milk, cheese, cream cheese, cream"
62226332|NCT05067465|EXPERIMENTAL|Whole-grain products (rich in soluble fibers)|"Standardized diet over five days (n = 40) - composed of oatmeal, oat bran, oat milk, whole wheat pasta, whole wheat bread, hummus~Test meal on day 6 (n = 12) - composed of oatmeal, oat bran, oat milk"
62226333|NCT05067465|EXPERIMENTAL|Sausage and processed meat (pork)|"Standardized diet over five days (n = 40) - composed of Lyoner (pig), Viennese (pig), minced meat (pig)~Test meal on day 6 (n = 12) - composed of Lyoner (pig), Viennese (pig)"
62226334|NCT05067465|EXPERIMENTAL|Meat-free sausage and meat alternatives (based on egg, pea, soy)|"Standardized diet over five days (n = 40) - composed of Mortadella (egg-based), Viennese (egg-based), vegan mince (soy-based)~Test meal on day 6 (n = 12) - composed of Mortadella (egg-based), Viennese (egg-based)"
62226335|NCT05199194|EXPERIMENTAL|Mechanical Thrombectomy preceded by TNK|Subjects assigned to this arm will receive an intravenous bolus of tenecteplase (0.25mg/kg) before the mechanical thrombectomy.
62226336|NCT05199194|PLACEBO_COMPARATOR|Mechanical Thrombectomy preceded by Placebo|Subjects assigned to this arm will receive an intravenous bolus of matching placebo (with the same volume of infusion as of 0.25mg/kg of tenecteplase) before the mechanical thrombectomy.
62419359|NCT00402779|PLACEBO_COMPARATOR|Placebo|Balanced randomization: Placebo continuous administration for 1 year.
62226337|NCT05764928|EXPERIMENTAL|Phase I: 1.5 mg/kg BLEX404|Oral administration BID
62226338|NCT05764928|EXPERIMENTAL|Phase I: 3.0 mg/kg BLEX404|Oral administration BID
62226339|NCT05764928|EXPERIMENTAL|Phase I: 6.0 mg/kg BLEX404|Oral administration BID
62226340|NCT05764928|EXPERIMENTAL|Phase II: RDL of BLEX 404|Oral administration BID
62226341|NCT03796260|EXPERIMENTAL|F1 to F06 Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib F1 (test formulation) on Day 1 of Period 1 after a standardized meal. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib F06 (reference formulation) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
62226342|NCT03796260|EXPERIMENTAL|F06 to F1 Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib F06 (reference formulation) on Day 1 of Period 1 after a standardized meal. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib F1 (test formulation) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
62226343|NCT02749435||Standard of Care + digital disease management cohort|Participants will have access to the smart phone- and web portal-based digital disease management tool in addition to standard care.
62226344|NCT02749435||Standard of Care cohort|Participants will have standard care with no access to the digital disease management tool.
62226345|NCT00118755|EXPERIMENTAL|1|
62419360|NCT05924555||LcFAOD-patients|Patients with long-chain Fatty Acid Oxidation including CPT2-, CACT-, VLCAD-, LCHAD-, or MTP-deficiency
62419361|NCT05924555||Healthy controls|Controls are matched based on Age, Sex, BMI and comparable activity score assessed using the SQUASH questionnaire
62419362|NCT05759182|EXPERIMENTAL|Bambini Teens Training|Ten participants will complete 30-minute sessions twice a week over six weeks, totalling 12 interventions.
62589765|NCT05290064|EXPERIMENTAL|1/UPF HH, UPF HL, UNF LL, UPF LL|Four diets in the order specified
62589766|NCT05290064|EXPERIMENTAL|2/ UPF HL, UPF LL, UPF HH, UNF LL|Four diets in the order specified
62589767|NCT05290064|EXPERIMENTAL|3/ UPF LL, UNF LL, UPF HL, UPF HH|Four diets in the order specified
62589768|NCT05290064|EXPERIMENTAL|4/ UNF LL, UPF HH, UPF LL, UPF HL|Four diets in the order specified
62589769|NCT01951534|EXPERIMENTAL|Breast Reconstruction Decisional Aid (BRDA)|In the BRDA arm, participants will be provided with a website address for using the Breast Reconstruction Decisional Aid, a secure password, and instructions for using the website for the decisional aid.
62226346|NCT00118755|ACTIVE_COMPARATOR|2|
62226347|NCT04384185|EXPERIMENTAL|Group A: Exercise therapy|Group A: will perform an exercise protocol to improve the stability of the spine muscle of low-back
62027277|NCT04977167|EXPERIMENTAL|Part 2B-1：HG146 combination Expansion Cohort 1|Subjects who have not been treated with PD-(L)1 antibody，will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.
62226348|NCT04384185|EXPERIMENTAL|Group B. Manual therapy and exercises|Group B: Will be treated with manual therapy in the diaphragm muscle and the same protocol of therapeutic exercise applied in group A
62226349|NCT01210261|ACTIVE_COMPARATOR|Autoset S8|Single night auto-titrating CPAP treatment using the reference device (Resmed Autoset S8) with polysomnographic monitoring
62226350|NCT01210261|EXPERIMENTAL|Somnilink SPAP|Single night auto-titrating CPAP treatment using the test device with polysomnographic monitoring
62226351|NCT01685164||LNG-IUS|Nulliparous women
62226352|NCT01685164||Cu-IUD|Nulliparous women
62226353|NCT01853982|EXPERIMENTAL|Ceftolozane/Tazobactam|3000 milligrams (mg) ceftolozane/tazobactam (comprised of 2000 mg ceftolozane and 1000 mg tazobactam), administered intravenously (IV), every 8 hours for 8 days
62226354|NCT01853982|ACTIVE_COMPARATOR|Piperacillin/Tazobactam|4500 mg piperacillin/tazobactam (comprised of 4000 mg piperacillin and 500 mg tazobactam), administered IV, every 6 hours for 8 days
62226355|NCT00343252|EXPERIMENTAL|Teriparatide|Teriparatide 20 micrograms (ug)/day, subcutaneous, 18 months plus once weekly oral placebo
62226356|NCT00343252|ACTIVE_COMPARATOR|Risedronate|Risedronate 35 milligrams (mg)/once weekly, oral, 18 months plus daily subcutaneous injection placebo
62226357|NCT00519038|EXPERIMENTAL|1|Patients treated according to clinical pathways
62226358|NCT00519038|OTHER|2|Patients treated according to usual care
62027278|NCT04977167|EXPERIMENTAL|Part 2B-2：HG146 combination Expansion Cohort 2|Subjects who have progressed on PD-(L)1 antibody, will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.
62027279|NCT04034433|EXPERIMENTAL|Exercise|
62027280|NCT04034433|NO_INTERVENTION|Control|
62226359|NCT04157231|NO_INTERVENTION|Usual Care|Usual care to be provided to patients as per hospital guidelines for 3 months
62226360|NCT04157231|OTHER|Intervention arm|"The intervention consists of training and education of the site staff about the treatment protocol for the different components of the management plan will be provided on two occasions. This intervention will run for 3 months.~Refresher training will be given monthly during the intervention."
62226361|NCT01468831|PLACEBO_COMPARATOR|Placebo|Participants injected with bevacizumab for three months followed by PRN dosing and placebo twice daily for 24 months
62419363|NCT03467919|EXPERIMENTAL|MFAT(Micro Fragmented Adipose Tissue)|Intra-articular knee injection of autologous Micro Fragmented Adipose Tissue harvested from the thigh using tumescent lipoaspiration and processing with minimal manipulation. This harvested tissue will then be injected into the patient's knee.
62419364|NCT03467919|ACTIVE_COMPARATOR|Conventional therapy|Intra-articular injection of corticosteroid (Triamcinolone 40mg).
62419365|NCT00583128|EXPERIMENTAL|1|AST-120, 2 gram sachets
62419366|NCT00583128|PLACEBO_COMPARATOR|2|Celphere® CP-305, stained to match appearance of AST-120, in 2g sachets
62419367|NCT02622607|EXPERIMENTAL|ZOL|Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 months for 12 months.
62419368|NCT02622607|NO_INTERVENTION|Control|No investigational treatment
62801222|NCT06166940||Conventional Management|
62419369|NCT03286400||CTAG Device with ACTIVE CONTROL|All consecutive patients meeting protocol selection criteria, consented, with an intention to be treated with CTAG Device with ACTIVE CONTROL.
62419370|NCT01811121|EXPERIMENTAL|5-aminolévulinique acid (5-ALA)|5-aminolévulinique acid :microsurgical resection guided by fluorescence (CGF) in addition to the usual techniques of neuronavigation, after oral administration of 20mg/kg of 5-ALA 3-5 hours prior to surgical incision
62419371|NCT01811121|PLACEBO_COMPARATOR|Placebo|Laroscorbine :microsurgical excision guided solely by neuronavigation, after oral administration of a placebo 3 to 5 hours before the surgical incision
62419372|NCT06697977|EXPERIMENTAL|treatment group|
62419373|NCT06697977|PLACEBO_COMPARATOR|control group|
62801223|NCT05923840|ACTIVE_COMPARATOR|Female Postural Tachycardia Syndrome (POTS) patients without orthostatic hyperpneic hypocapnia|Female POTS patients without orthostatic hyperpneic hypocapnia identified by tilt table testing and respiratory monitoring.
62801224|NCT05923840|ACTIVE_COMPARATOR|Female POTS patients with orthostatic hyperpneic hypocapnia|Female POTS patients without orthostatic hyperpneic hypocapnia identified by tilt table testing and respiratory monitoring.
62801225|NCT05923840|ACTIVE_COMPARATOR|Healthy Female vounteers|Healthy Female vounteers
62801226|NCT00684996|ACTIVE_COMPARATOR|Phase II Arm I|Patients receive bevacizumab (10mg/kg) IV over 30-90 minutes on days 1 and 15.
62801227|NCT00684996|ACTIVE_COMPARATOR|Phase II Arm II|Patients receive bevacizumab IV as in arm I at the RPTD determined in phase I, and humanized monoclonal antibody MEDI-522 (8mg/kg) IV over 30 minutes on days 1, 8, 15, and 22.
62801228|NCT03746327|EXPERIMENTAL|Sivextro arm|200 mg milligram per day during 4 weeks
62801229|NCT02956343||AF|Five minutes pulse wave recording in patients with atrial fibrillation at the time of recruitment
62801230|NCT02956343||SR|Five minutes pulse wave recording in patients with sinus rhythm at the time of recruitment
62801231|NCT00590187|EXPERIMENTAL|A sapacitabine|200 mg b.i.d. x 7 days every 3-4 weeks
62801232|NCT00590187|EXPERIMENTAL|B sapacitabine|300 mg b.i.d. x 7 days every 3 - 4 weeks
62801233|NCT00590187|EXPERIMENTAL|C sapacitabine|400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
62801234|NCT00590187|EXPERIMENTAL|D sapacitabine|200 mg b.i.d. x 7 consecutive days every 4 weeks
62801235|NCT00590187|EXPERIMENTAL|E sapacitabine|300 mg q.d. x 7 consecutive days every 4 weeks
62801236|NCT00590187|EXPERIMENTAL|F sapacitabine|300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
62801237|NCT00590187|EXPERIMENTAL|G sapacitabine|200 mg b.i.d. x 7 consecutive days every 4 weeks
62801238|NCT00590187|EXPERIMENTAL|H sapacitabine|300 mg q.d. x 7 consecutive days every 4 weeks
62027281|NCT03478891|EXPERIMENTAL|Group 1: 5 mg/kg IV|Group 1 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5 mg/kg.
62419374|NCT05255783|OTHER|Critically ill adults requiring insulin|Patients admitted to the intensive care unit requiring insulin infusion to maintain blood glucose within target range
62419375|NCT04247646|ACTIVE_COMPARATOR|Melatonin|Melatonin 5 mg sublingual nightly x 29 nights, starting on post-operative day 0.
62419376|NCT04247646|PLACEBO_COMPARATOR|Placebo|Placebo troche, sublingual nightly x 29 nights, starting on post-operative day 0.
62419377|NCT03192566|EXPERIMENTAL|Tylenol Dosing|"Dosing of Tylenol for postoperative pain relief will include:~children \< 16 years; 650 mg every 6 hours, max 2.6 gram per 24 hours and children \> or equal to 16 years every 6 hours 1 g of acetaminophen, max 4 gram per 24 hours)."
62419378|NCT05633901|PLACEBO_COMPARATOR|Standard of Care|Standard verbal counseling provided to patients by clinic nurse about post-operative expectations
62419379|NCT05633901|ACTIVE_COMPARATOR|Educational Video|An educational video to aid standard counseling packet on post-operative expectations
62801239|NCT00590187|EXPERIMENTAL|I sapacitabine|100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
62801240|NCT03101566|EXPERIMENTAL|Gemcitabine + Cisplatin + Nivolumab|"Drug: Gemcitabine 1000 mg/m2 IV on days 1,8 every 3 weeks~Drug: Cisplatin 25 mg/m2 IV on days 1,8 every 3 weeks~Drug: Nivolumab 360 mg IV on day 1 every 3 weeks~If there is continued benefit after 6 months, then:~Drug: Nivolumab 240 mg IV on day 1 every 2 weeks"
62801241|NCT03101566|EXPERIMENTAL|Nivolumab + Ipilimumab|"Drug: Ipilimumab~1 mg/kg IV on day 1 every 6 weeks~Drug: Nivolumab 240 mg IV on day 1 every 2 weeks"
62801242|NCT05258136|EXPERIMENTAL|EBV-DNA positive patients|EBV-DNA positive patients
62801243|NCT01028417|EXPERIMENTAL|Group 1|Group 1 receives the intervention - insertion of platinum microcoil followed by nodule excision
62801244|NCT01028417|NO_INTERVENTION|Group 2|Group 2 receives the standard of care - nodule excision, but without the microcoil insertion
62027282|NCT03478891|EXPERIMENTAL|Group 2: 25 mg/kg IV|Group 2 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25 mg/kg.
62801245|NCT05882812|EXPERIMENTAL|SAM Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM Device emits continuous ultrasound at 3 megahertz(MHz) frequency and 0.132 watts/cm\^2 intensity.
62027283|NCT03478891|EXPERIMENTAL|Group 3: 50 mg/kg IV|Group 3 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50 mg/kg.
62027284|NCT04445818|EXPERIMENTAL|More Appreciation|"A 6-minute engaging video will be shown, illustrating examples where a mother initially withholds her appreciation for her son's effort in school and later express it. The video will also capture the effect on the child and the family. Attributional discussion questions will follow to elicit positive outcomes of expressing appreciation and the negative outcomes of withholding appreciation (e.g., What may be the long-term effects of showing appreciation on your child, family, or on yourself?). Key points will be summarised and reinforced to enhance behavioural intention (Schwarzer \& Luszczynska, 2008). Then the participants will be asked to plan by indicating when (e.g., Saturday afternoon), what (e.g., child helping a younger sibling prepare for a dictation test), and how (e.g., I can see that you gave up your leisure time to help your sister with the spelling. Thank you!) they would express appreciation to their children."
62027285|NCT04445818|EXPERIMENTAL|Less Criticism|"Participants will watch a 6-minute video showing examples of a father criticising his son, which will be replaced by positive communication later, and the different reactions evoked in the child and the family. Then, participants will have an attributional discussion on the negative effects of criticism (e.g., negative effect on self-worth and motivation) and positive outcomes of using constructive feedback (e.g., promptly identifying undesirable behaviours without relating to personal traits or abilities). In small groups, they will work out alternatives (i.e., constructive feedback; termed positive reminder in the intervention) to criticism, and each plan and write down when (e.g., after school), what (e.g., low test marks), and how (e.g., How do you prepare for the tests?)"
62226362|NCT01468831|EXPERIMENTAL|Minocycline|Participants injected with bevacizumab for three months followed by PRN dosing and 100mg minocycline twice daily for 24 months
62226363|NCT04236115|ACTIVE_COMPARATOR|Articaine 4% with 1:00.000 Adrenaline|if the patient was in articaine group, buccal infiltration technique was applied by inserting a short needle at the height of buccal sulcus along the long axis of the subject tooth for extraction.
62226364|NCT04236115|ACTIVE_COMPARATOR|Prilocaine with 3% Felypressin (0.03 I.U. per ml)|if the patient was in prelocaine group, buccal infiltration technique was applied by inserting a short needle at the height of buccal sulcus along the long axis of the subject tooth for extraction.
62226365|NCT03887390|NO_INTERVENTION|Usual Care|Participants in this arm will receive care as usual.
62226366|NCT03887390|EXPERIMENTAL|Depression Medication Choice|Participants in this arm will have the Depression Medication Choice decision aid be made available to their clinician to be used during their clinical encounter.
62226367|NCT00636753||1|schizophrenic patients
62801246|NCT05882812|ACTIVE_COMPARATOR|SAM Ultrasound Device and SAM Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with SAM patch(0% diclofenac).
62801247|NCT05882812|ACTIVE_COMPARATOR|Diclofenac Patch|Patients wear 2.5% diclofenac patch for 4 hours at least 5 days a week for 8 weeks combined.
62801248|NCT03433963|EXPERIMENTAL|L-Arg supplement group|Study participants in the group will take L-Arg supplement during the trial.
62801249|NCT03433963|PLACEBO_COMPARATOR|Control group|Study participants in the group will take placebo during the trial.
62226368|NCT00636753||2|controls
62801250|NCT01867762|EXPERIMENTAL|JNJ 49095397|
62226369|NCT02871856|OTHER|Single|Single arm only, CT screening of lung
62226370|NCT00601419||Somatropin|Patients administered Somatropin.
62226371|NCT01386073|ACTIVE_COMPARATOR|FreshKote|
62226372|NCT01386073|PLACEBO_COMPARATOR|Systane|
62801251|NCT01867762|PLACEBO_COMPARATOR|Placebo|
62801252|NCT03159559|EXPERIMENTAL|Treatment group|In the treatment group ,patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days ;
62801253|NCT03159559|NO_INTERVENTION|Control group|In the control group, patients received conventional therapy only.
62226373|NCT02084745|ACTIVE_COMPARATOR|Simultaneous implantation|Simultaneous implantation of a glaucoma drainage device at the time of Boston keratoprosthesis type 1 surgery
62226374|NCT02084745|ACTIVE_COMPARATOR|Implantation at post-Kpro at 6 months|Implantation of a glaucoma drainage device 6 months after Boston keratoprosthesis type 1 surgery
62419380|NCT06538246|EXPERIMENTAL|Blueprint adaptive coping skills intervention|This is a unique adaptive coping skills intervention developed over years of research that targets patients hospitalized for cardiorespiratory conditions. Participants will receive 4 weeks of different Blueprint content through a mobile app. Each week's session includes a within-app HADS survey for safety monitoring. A printed or PDF workbook with complementary content and QR links to app videos is provided.
62801254|NCT06301451|EXPERIMENTAL|General dietary guidance and hydrogen water group|Trial group is treated with general dietary guidance and hydrogen water prepared by portable hydrogen rich water machine.
62801255|NCT06301451|NO_INTERVENTION|General dietary guidance group|Control group is treated with general dietary guidance.
62801256|NCT04807686|ACTIVE_COMPARATOR|traditional algorithm|
62226375|NCT05103293|EXPERIMENTAL|PTC group|Patients randomized into this group receiving PTC test and choose regimens according to this test results
62226376|NCT05103293|NO_INTERVENTION|Control group|Patients randomized into this group receiving routine regimens according to subtypes
62226377|NCT02429674|OTHER|TranS-C and IPT-A|12 sessions of weekly outpatient psychotherapy for adolescent depression.
62419381|NCT06538246|ACTIVE_COMPARATOR|Education program control|This is cardiorespiratory condition-specific content through an iterative process, informed by research on informational needs and past successful education programs. Participants will receive 4 weeks of different 10-minute informational videos unrelated to Blueprint content through a mobile app. Each week's session includes a within-app HADS survey for safety monitoring. A printed or PDF workbook with complementary content and QR links to app videos is provided.
62419382|NCT04985357||Carcinoma-Associated Malignant Fluid|Diagnosis of any kind of carcinoma with a malignant fluid (pleural effusion or ascites) where drainage is clinically indicated as part of SOC, and a new course of treatment is upcoming.
62419383|NCT04985357||Carcinoma Solid Tissue Specimen|Diagnosis of any kind of carcinoma where a needle biopsy or tissue resection is clinically indicated as part of SOC, and a new course of treatment is upcoming.
62419384|NCT04985357||Multiple Myeloma|Diagnosis of relapsed multiple myeloma where bone marrow biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.
62419385|NCT04985357||Acute myelogenous leukemia (AML)|Diagnosis of acute myelogenous leukemia where a blood draw or bone marrow biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.
62419386|NCT04985357||Triple Negative Breast Cancer (TNBC)|Diagnosis of Stage IV Triple Negative Breast Cancer where a needle biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.
62419387|NCT04985357||Peripheral Blood Cell Immune Competency|Diagnosis of any cancer where a blood draw is clinically indicated as part of SOC, a new course of treatment is upcoming, and checkpoint inhibitor therapy being considered for next line of treatment.
62419388|NCT05012098|EXPERIMENTAL|1/Arm 1|Treatment with Bintrafusp alfa
62419389|NCT02083770|EXPERIMENTAL|Cancer Clinical Trials Education Program|Cancer Clinical Trials Education Program is offered to English- and Spanish-speaking Hispanics in the experimental arm. This program was designed to promote increased clinical trials literacy among Hispanic Americans. Increased clinical trials knowledge and a better understanding of clinical trials is anticipated to create more positive attitudes, and perceptions about clinical trials among Hispanic Americans.
62801257|NCT04807686|EXPERIMENTAL|notched-type algorithm|
62801258|NCT05200065|EXPERIMENTAL|Thulium Laser Enucleation|Patients in this arm will undergo thulium laser enucleation of the prostate.
62801259|NCT05200065|EXPERIMENTAL|Bipolar Enucleation|Patients in this arm will undergo bipolar enucleation of the prostate.
62801260|NCT03160339|EXPERIMENTAL|PXVX0047 treatment group|Subjects will receive PXVX0047 vaccine and Teva Placebo-to-Match
62801261|NCT03160339|ACTIVE_COMPARATOR|Teva Ad4/Ad7 treatment group|Subjects will receive Teva Ad4/Ad7 vaccine and PXVX0047 Placebo-to-Match
62226378|NCT04312893|EXPERIMENTAL|Acupuncture group (ACU)|Patients in acupuncture group will receive traditional Chinese acupuncture combined with Tung's style acupuncture using Press Tack Needle (PYONEX Φ0.20×0.6 mm made by Seirin Corporation). The needles appear identical to the press tack placebo with the only different is the needle itself which was removed in the placebo needles. The following acupoints will be used: HT 7 (Shen Men), PC 6 (Nei Guan), Yin Tang (EX-HN 3), San Shang (55-02) (three point from Dong's acupuncture system) and the auricular Shen Men point. The treatment will use bilateral acupuncture (if patient's condition does not allow it, unilateral acupuncture will be done). The patient will lie in a supine position during the treatment. Acupuncturist will disinfect the acupoint location with an alcohol pad (70% alcohol), then the acupuncturist will press the needles sticker to the mentioned above acupoints. Interventions will be given on day 1, 3, and 5 after patient's enrolment.
62801262|NCT02383875|EXPERIMENTAL|Opticourses education intervention|People living in the northern districts of Marseille with in very deprived social situation: very low incomes, heavy financial dependence on social benefits, over-representation of people covered by arrangements for controlling poverty and people covered by free social security
62801263|NCT04528641|EXPERIMENTAL|Arm 1 - Low dose|Arm-1 Healthy adult volunteers aged 18-55y will receive IM single dose of 5e10vp. N=15
62801264|NCT04528641|EXPERIMENTAL|Arm 2 - Intermediate dose|Arm-2 Healthy adult volunteers aged 18-55y will receive IM single dose of 1e11vp. N=15
62027286|NCT04445818|EXPERIMENTAL|Fruit and Vegetable|This workshop will emphasise the importance of consuming at least 5 portions of fruit and vegetable daily for a healthy diet, and aim to boost participants' self-efficacy in achieving this. Participants will be presented with examples of one portion of fruit or vegetable, and then create their own recipes. They will also consider how to overcome obstacles of consuming more portions. Each participant will set goals and write down plans on when, where, what, and how they would increase their fruit and vegetable intake of their children and family as a whole.
62027287|NCT04950699||Control|Patients without typical symptoms of coronary heart disease, and coronary angiography or coronary CT showed no significant stenosis (coronary stenosis less than 30%), they were non coronary heart disease group, namely control group.
62226379|NCT04312893|PLACEBO_COMPARATOR|Control group (CON)|Patients randomized to the control group will receive press tack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element. The point selection will be identical to acupuncture group: HT 7 (Shen Men), PC 6 (Nei Guan), Yin Tang (EX-HN 3), San Shang (55-02) (three point from Dong's acupuncture system) and the auricular Shen Men point. The treatment methods and patients position will be identical to acupuncture group. Interventions will be given on day 1, 3, and 5 after patient's enrolment.
62226380|NCT05657886|NO_INTERVENTION|Control group|The mothers in the control group were given routine care.
62226381|NCT05657886|EXPERIMENTAL|Half swaddle|HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
62419390|NCT02083770|PLACEBO_COMPARATOR|Neighborhood Watch Education Program|The Neighborhood Watch Program created by the Bureau of Justice Assistance and the National Crime Prevention Council was selected for inclusion in the control arm of this study. It provided participants with a program of equivalent length and format, as well as an equivalent focus on improving the well-being of Hispanic Americans. It also provided an opportunity to evaluate the impact of the Neighborhood Watch Program.
62801265|NCT04528641|EXPERIMENTAL|Arm 3 - High dose|Arm-3 Healthy adult volunteers aged 18-55y will receive IM single dose of 2e11vp. N=15
62419391|NCT04335994|ACTIVE_COMPARATOR|Standard of Care|Patients receive standard of care for diagnosing obstructive sleep apnea, which is in-laboratory polysomnography.
62419392|NCT04335994|EXPERIMENTAL|Home Sleep Apnea Test|Patients will undergo assessment for obstructive sleep apnea using a home sleep apnea test.
62419393|NCT05038410|ACTIVE_COMPARATOR|Wobenzym®|Medicinal product Wobenzym® containing Bromelain (67.5-76.5 mg) adjusted to 450 FIP units, Trypsin (32-48mg) adjusted to 24 µkat and Rutoside trihydrate (100mg).
62419394|NCT05038410|PLACEBO_COMPARATOR|PLACEBO|No active ingredients. The active ingredients will be substituted by microcrystalline cellulose.
62419395|NCT01364246|EXPERIMENTAL|Human umbilical cord mesenchymal stem cells transplantation|Intervention group
62419396|NCT03416153|ACTIVE_COMPARATOR|Standard Treatment|Patients will receive a single prescription of 70 Gy in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy)
62419397|NCT03416153|EXPERIMENTAL|De-escalation Treatment|Patients will initially receive a single prescription of 70 Gy in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). If certain parameters are met radiation therapy will be reduced to 54Gy to high risk Planned Target Volume (PTV) and 43.2Gy to low risk PTV all in 27 fractions.
62419398|NCT06700759||Group 1|Patients who received 18 hours of infusion feeding, 6 hours of waiting and one hour of drainage
62419399|NCT06700759||Group 2|Patients who received 5 hours of infusion feeding, 1 hour of waiting and one hour of drainage
62801266|NCT04528641|EXPERIMENTAL|Arm 4 - Low dose|Arm-4 Healthy elderly volunteers aged 65-85y will receive IM single dose of 5e10vp. N=16
62801267|NCT04528641|EXPERIMENTAL|Arm 5 - Intermediate dose|Arm-5 Healthy elderly volunteers aged 65-85y will receive IM single dose of 1e11vp. N=15
62589770|NCT01951534|OTHER|Usual Care (UC)|In the UC Condition, the participant will not be given the web-based decisional aid but will be given the Cancer Support Community pamphlet. This 56-page pamphlet contains information about the types of Breast Reconstruction, lists reasons why women choose reconstruction, key factors to considering when deciding, how to plan for surgery, possible risks, and a glossary of terms. The pamphlet is primarily informational. It is not customized, not interactive.
62801268|NCT04528641|EXPERIMENTAL|Arm 6 - High dose|Arm-6 Healthy elderly volunteers aged 65-85y will receive IM single dose of 2e11vp. N=15
62226382|NCT05657886|EXPERIMENTAL|Kangaroo care|The application was applied at twice a day and for 60 min, every day for 6 months in a row. While the mothers were taken to the NICU and practiced at home prior to kangaroo care, hand hygiene and breast care were provided within the scope of infection prevention rules. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm and suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together.
62801269|NCT00883961|EXPERIMENTAL|Supervised exercise|
62801270|NCT00883961|NO_INTERVENTION|Control group|The patients will not carry out a structured exercise program.
62226383|NCT05657886|EXPERIMENTAL|Half swaddle+Kangaroo care|HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.The application was applied at twice a day and for 60 min, every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm and suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. In the continuation of the KB application, the mother was asked to breastfeed her baby.
62226384|NCT01580969|EXPERIMENTAL|Dose Level 0: 100 mg bid|Patients receiving minocycline 100 mg bid, bevacizumab, and radiation therapy.
62226385|NCT01580969|EXPERIMENTAL|Dose Level 1: 200 mg bid|Patients receiving minocycline 200 mg bid, bevacizumab, and radiation therapy.
62226386|NCT01580969|EXPERIMENTAL|Dose Level 2: 400 mg bid|Patients receiving minocycline 400 mg bid, bevacizumab, and radiation therapy.
62419400|NCT06700759||Group 3|Patients who were fed with continuous infusion for 24 hours and drained for one hour
62419401|NCT01966107|EXPERIMENTAL|Aclidinium Bromide|Two-week washout/run-in period \[for patients on a long-acting muscarinic antagonist (LAMA)\] followed by a maximum of 36-month double-blind treatment period.
62419402|NCT01966107|PLACEBO_COMPARATOR|Placebo|Two-week washout/run-in period \[for patients on a long-acting muscarinic antagonist (LAMA)\] followed by a maximum of 36-month double-blind treatment period.
62589771|NCT04619329|EXPERIMENTAL|GSMs-TACE+ Surgical Resection Group|After TACE using Lobaplatin and GSMs (150-350μm, 350-560μm, 560-710μm or 710-1000μm), patients will receive surgical resection 15-30 days later, as specified per protocol.
62801271|NCT01594320|EXPERIMENTAL|Group A|
62589772|NCT04619329|ACTIVE_COMPARATOR|Surgical Resection Group|Patients will receive surgical resection, as specified per protocol.
62801272|NCT01594320|EXPERIMENTAL|Group B|
62801273|NCT01594320|EXPERIMENTAL|Group C|
62801274|NCT01594320|EXPERIMENTAL|Group D|
62801275|NCT01594320|EXPERIMENTAL|Group E|
62801276|NCT01594320|EXPERIMENTAL|Group F|
62801277|NCT02620982|EXPERIMENTAL|ARIES Application|Low intensity Extracorporeal Shockwave Application utilizing the Dornier Aries
62801278|NCT05499377|ACTIVE_COMPARATOR|Tobacco-Flavored IQOS|Tobacco - where menthol smokers will only have access to tobacco-flavored HeatSticks to use in the IQOS 2.4 Tobacco Heating System
62801279|NCT05499377|EXPERIMENTAL|Menthol-Flavored IQOS|Menthol - where menthol smokers will only have access to menthol-flavored HeatSticks to use in the IQOS 2.4 Tobacco Heating System
62801280|NCT00580723|EXPERIMENTAL|PRK 124|Topical PRK 124 (Pyratine-6)(0.125%) moisturizing lotion applied twice daily to the face for 48 weeks. Subjects will wash their faces prior to application. The applications will occur in the mornings and one hour before bedtime.
62801281|NCT04145882|ACTIVE_COMPARATOR|No additional osteotomy|
62801282|NCT04145882|EXPERIMENTAL|varisation osteotomy addition|
62589773|NCT06093737|EXPERIMENTAL|COPE Intervention|Is a three session brief group psychoeducational intervention. Session 1 is 4 hours, Session 2 and 3 are 1.5 hours. It is delivered in groups of 8-15 people with sessions spaced 1 month apart.
62801283|NCT04145882|EXPERIMENTAL|supination osteotomy addition|
62801284|NCT04145882|EXPERIMENTAL|both (varisation + supination) osteotomies addition.|
62589774|NCT06093737|ACTIVE_COMPARATOR|House Meeting Control|Is a 1.5 hour group meeting delivered in groups of 8-15 people spaced 1 month apart.
62589775|NCT01702480|EXPERIMENTAL|Part 1: GSK2981710 10 gram (g)|Eight subjects will receive single dose of GSK2981710 in the form of 10 g medium-chain triglycerides (MCT) powder daily for 14 days.
62027288|NCT04950699||myocardial infarction|This group includes acute myocardial infarction (ST segment elevation and non ST segment elevation) and old myocardial infarction. The diagnostic basis of acute myocardial infarction: cardiac biomarkers (cardiac troponin and / or myocardial enzymes) increased or decreased, at least once the value exceeded the upper limit of normal, and there was the following evidence of myocardial ischemia: (1) clinical symptoms of myocardial ischemia（ 2) New changes of myocardial ischemia appeared in ECG, i.e. new ST segment changes or left bundle branch block（ 3) Pathological Q wave appeared in ECG（ 4) Imaging evidence showed new loss of myocardial viability or regional wall motion abnormalities. Diagnosis of old myocardial infarction: the patient provided a history of previous myocardial infarction and confirmed as old myocardial infarction by the third or First Hospital of Peking University.
62027289|NCT03851653|EXPERIMENTAL|Lifestyle Intervention Group (LIG)|Participants from this group will receive a cognitive-behavioral intervention addressing weight loss and lifestyle habits such as hypocaloric diet, moderate exercise, smoking and alcohol avoidance, and sleep hygiene. This behavioral intervention will be combined with the usual treatment for OSA, i.e. CPAP.
62589776|NCT01702480|EXPERIMENTAL|Part 1: GSK2981710 20 g|Eight subjects will receive single dose of GSK2981710 in the form of 20 g MCT powder daily for 14 days.
62027290|NCT03851653|NO_INTERVENTION|Control group|Participants from the control group will not receive any type of intervention apart from the usual care (CPAP).
62589777|NCT01702480|EXPERIMENTAL|Part 1: GSK2981710 30 g|Eight subjects will receive single dose of GSK2981710 in the form of 30 g MCT powder daily for 14 days.
62589778|NCT01702480|EXPERIMENTAL|Part 1: GSK2981710 40 g|Eight subjects will receive single dose of GSK2981710 in the form of 40 g MCT powder daily for 14 days.
62226387|NCT05068245|NO_INTERVENTION|Routine pain control|The routine pain control group will receive instructions to take ibuprofen 600 mg 30 minutes prior to the procedure. These instructions will be given to all participants.
62226388|NCT05068245|EXPERIMENTAL|Routine pain control plus music|Patients randomized to receive music in addition to routine pain control measures, will be instructed to take ibuprofen 600 mg 30 minutes prior to the procedure. These instructions will be given to all participants. Preselected classical music will be played for this group throughout the procedure.
62589779|NCT01702480|PLACEBO_COMPARATOR|Part 1: Placebo|Eight subjects will receive single dose of matching placebo daily for 14 days.
62801285|NCT04688359|EXPERIMENTAL|Intervention group|Those receiving nurse-lead Guided Self Determination (GSD) for one to three times over six months starting four to six months after recruitment and first measurement.
62027291|NCT04145752|EXPERIMENTAL|Nurse-led femoral nerve block|"Trained nurses in ED provide ultrasound guided single-shot femoral nerve block shortly after (at arrival emergency department) the patient is diagnosed with a hip fracture.~Drug: Ropivacaine 3 mg/kg, single-shot"
62027292|NCT04145752|ACTIVE_COMPARATOR|Standard of care|Nurses do not provide ultrasound guided single-shot FNB and the patient follows the standard of care course.
62027293|NCT04321720|EXPERIMENTAL|3-g footbath|Footbath with 3g mustard flour per liter of water
62226389|NCT06147284|EXPERIMENTAL|Traditional exercise|This is an intervention with six 90-minute sessions. Progressive traditional exercise including warm-up exercises, resistance training, stretching routines, and cool-down exercises will be introduced. Both face-to-face and home-based online modes of delivery are available.
62419403|NCT03297801||Fish oil group|Women who chose to supplement with fish oil, rich in omega-3 polyunsaturated fatty acids, during gestation or lactation.
62589780|NCT01702480|EXPERIMENTAL|Part 2: GSK2981710 (dose to be decided from Part 1)|The subjects will receive single dose of GSK2981710 in the form of MCT powder (dose to be decided from Part 1) daily for 14 days.
62589781|NCT01702480|PLACEBO_COMPARATOR|Part 2: Placebo|The subjects will receive single dose of matching placebo daily for 14 days..
62589782|NCT05421702|ACTIVE_COMPARATOR|Group A Operable colon cancer cases|All patients with operable colon cancer who will undergo laparoscopic conventional colectomy
62589783|NCT05421702|ACTIVE_COMPARATOR|Group B Operable colon cancer cases|All patients with operable colon cancer who will undergo laparoscopic complete mesocolic excision
62589784|NCT03861299|EXPERIMENTAL|Awake craniotomy|Cortical stimulation is performed with a bipolar electrical stimulator. The Boston naming test and repetition of words is done in cooperation with a neuropsychologist/linguist, who will inform the neurosurgeon of any kind of speech arrest or dysarthria. When localizing the motor and sensory cortex, the patient is asked to report any unintended movement or sensation in extremities or face. Functional cortical areas are marked with a number. When the tumour margins or white matter is encountered or when on regular neuronavigation the eloquent white matter tracts are thought to be in close proximity, subcortical stimulation (biphasic currents of 8-16 mA, pulse frequency 60 Hz, single pulse phase duration of 100 microsec., 2-second train) is performed to localize functional tracts.
62801286|NCT04688359|NO_INTERVENTION|Control group|Those not receiving nurse-lead Guided Self Determination (GSD) for one to three times over six months starting four to six months after recruitment and first measurement.
62801287|NCT05712070|EXPERIMENTAL|smart group|Smartphone App-based healthcare
62027294|NCT04321720|EXPERIMENTAL|6-g footbath|Footbath with 6g mustard flour per liter of water
62027295|NCT04321720|EXPERIMENTAL|12-g footbath|Footbath with 12g mustard flour per liter of water
62801288|NCT05712070|ACTIVE_COMPARATOR|control group|a book-based self-education
62801289|NCT01156714|OTHER|Arm 1: Treadmill Training|Treadmill training with aerobic exercise
62801290|NCT01156714|OTHER|Arm 2: Memory Training|Memory training with computerized memory program
62801291|NCT01156714|OTHER|Arm 3: Treadmill and Memory Training|Combination of treadmill training and computerized memory program
62027296|NCT04321720|PLACEBO_COMPARATOR|Warm water footbath|Footbath with warm water only
62027297|NCT02423473|ACTIVE_COMPARATOR|Connective tissue graft (CTG)|After local anesthesia, the surgical procedure performed was the trapezoidal-type of CAF (de Sanctis \& Zucchelli, 2007). After the flap was raised, the exposed root surface was gently scaled and planed until it became smooth. Afterward, a thin and small connective tissue graft that was sutured over the root surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
62226390|NCT06147284|EXPERIMENTAL|Yoga intervention|The intervention, comprising six 90-minute sessions, will be delivered by a trained mindful yoga instructor in group format. The intervention is based on our previously tested mindfulness yoga programme for people with PD (31). Following a universal Hatha Yoga practice, the session comprises mindfulness practice of yoga sequence, breathing exercise, and guided meditation. Both face-to-face and home-based online modes of delivery are available.
62226391|NCT06147284|EXPERIMENTAL|Arts-based intervention|Participants in the six 90-minute sessions in this intervention will be engaged in art-making processes through multiple art modalities such as visual arts, dance/ movement, music, drama, and creative writing. Each section is usually structured with Filling-in - greetings and check-in, Bridging - warm-up, Decentering - arts making and appreciation, Harvesting - sharing and response, and Closure. Both face- to-face and home-based online modes of delivery are available.
62226392|NCT06147284|EXPERIMENTAL|Somatic intervention|The intervention involves six 90-minute sessions led by a trained somatic practitioner in group format. Participants will be guided to bring awareness to their body and to connect with their internal sensations through exploring imageries related to their somatic experiences. They will also learn some somatic techniques that enable them to use their bodies more effectively. Both face-to-face and home- based online modes of delivery are available.
62226393|NCT01635920|EXPERIMENTAL|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn bilaterally for a minimum of 5 days per week, 8 hours per day, in daily wear modality for 4 weeks.
62226394|NCT01635920|ACTIVE_COMPARATOR|AIR OPTIX® AQUA|Lotrafilcon B contact lens worn bilaterally for a minimum of 5 days per week, 8 hours per day, in daily wear modality for 4 weeks.
62226395|NCT05150951|EXPERIMENTAL|Experimental group|Novel exploration is used before extinction in an attempt to strengthen the extinction consolidation.
62226396|NCT05150951|EXPERIMENTAL|Control group|Participants perform a control task (visual attention) instead of the novel exploration.
62589785|NCT03861299|ACTIVE_COMPARATOR|Craniotomy under general anesthesia|Trephination and tumour resection are performed without any additional neuro-psychological monitoring or brain mapping, guided by STEALTH-neuronavigation.
62589786|NCT02764957|ACTIVE_COMPARATOR|intervention|400 mg green coffee extract capsules twice per day for 8 weeks The Green coffee extract is standardised with 45% total chlorogenic acid by HPLC
62801292|NCT00966511||Lung resection candidates|Study participants will be patients who are candidates for lung resection (lobectomy or greater)
62801293|NCT01787461|EXPERIMENTAL|Imedeen|Imedeen is the study product
62801294|NCT01787461|PLACEBO_COMPARATOR|Placebo|
62801295|NCT02354235|EXPERIMENTAL|Canagliflozin + Teneligliptin|Patients receive Canagliflozin for 24 weeks in combination with Teneligliptin.
62801296|NCT02354235|PLACEBO_COMPARATOR|Placebo + Teneligliptin|Patients receive placebo for 24 weeks in combination with Teneligliptin.
62801297|NCT04709042|EXPERIMENTAL|Chordal tension measurement and cardiac Magnetic Resonance Imaging|All patient candidates for NeoChord implantation according to the standard of care will be considered for inclusion in this clinical study. Chordal tension measurement will be performed during Neochord implantation. Moreover, all patients will undergo cardiac Magnetic Resonance Imaging (MRI) exam before the surgery, as well as at 3 months follow-up.
62801298|NCT03345329||Periodontal patient|
62801299|NCT03345329||Healthy person|
62801300|NCT03345329||Peri-implantitis patient|
62226397|NCT05660239|OTHER|Wakiso district-Urban Parish|"Study participants together with the relevant community stakeholders will co-design feasible communication and activity-based change projects that are based on both cultural and scientific norms, to reduce epilepsy stigma in the community.~Researchers will then compare the Quality of Life, Attitudes and Beliefs about Living with Epilepsy scores and the Kilifi Stigma Scale scores following the implementation of the community change projects in an urban parish to see if there is improvement in these assessments scores."
62801301|NCT01011673|ACTIVE_COMPARATOR|Ketorolac|Ketorolac 30mg IVSS
62801302|NCT01011673|ACTIVE_COMPARATOR|Metoclopramide|metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
62419404|NCT03297801||No fish oil group|Women who chose not to supplement with fish oil during gestation or lactation.
62419405|NCT05836571|ACTIVE_COMPARATOR|Arm A (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity for 4 cycles. Patients then receive nivolumab IV on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans, tumor biopsies, and collection of blood throughout the trial.
62419406|NCT05836571|EXPERIMENTAL|Arm B (cabozantinib, nivolumab, ipilimumab)|Patients receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity. Patients receive nivolumab IV and ipilimumab IV on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity for 4 cycles. Patients then receive nivolumab IV on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans, tumor biopsies, and collection of blood throughout the trial.
62419407|NCT05182008|EXPERIMENTAL|Decision Aid|Patients will be guided to an online interactive decision aid tool.
62419408|NCT05182008|ACTIVE_COMPARATOR|Usual Care|Patients will be guided to visit the clinic website of the Nova Scotia Women's Choice Clinic.
62419409|NCT06188689|EXPERIMENTAL|Pacing|Separate ventricular and atrial pacing trains will be administered at different cycle lengths and the ventricular repolarization response on the first sinus beat following the subsequent pause will be evaluated.
62419410|NCT05078632||Healthy volunteers|healthy volunteers
62226398|NCT05660239|OTHER|Wakiso district-Rural Parish|"Study participants together with the relevant community stakeholders will co-design feasible communication and activity-based change projects that are based on both cultural and scientific norms, to reduce epilepsy stigma in the community.~Researchers will then compare the Quality of Life, Attitudes and Beliefs about Living with Epilepsy scores and the Kilifi Stigma Scale scores following the implementation of the community change projects in a rural parish to see if there is improvement in these assessments scores."
62801303|NCT05435664|EXPERIMENTAL|Intervention Group|During the first interview, the nurses in the intervention group were informed about PGE in a convenient and quiet room within the hospital, face-to-face and face-to-face. Afterwards, the researcher 15 minutes of application was made with the accompaniment. In order for the participants to practice at home, a voice recording containing the PGE steps voiced by the researcher in his own voice was sent to the nurses' phones. Nurses were asked to perform the PGE exercise by listening to the audio recording file for 15 minutes once a day for 4 weeks. In addition, daily reminders were made by creating a group over the WhatsApp application in order to prevent it from being forgotten. They were asked to provide feedback on their compliance with the program. At the beginning of the study, at the beginning of the study, at the 1st, 2nd, 3rd and 4th weeks (at the end of the application), the 'Fatigue Severity Scale' was administered again through face-to-face interviews.
62226399|NCT03720860||Sepsis|Patients admitted to the intensive care unit with sepsis
62226400|NCT03720860||Surgery|Patinets subjected to major surgery and then admitted to the intensive care unit
62419411|NCT05078632||intensive care patient|patient hospitalized in intensive care unit
62419412|NCT04175691||AIS group|This group includes patients with acute ischemic stroke (AIS).
62801304|NCT05435664|NO_INTERVENTION|Control group|"No intervention was made to the nurses in the control group. In the second and fourth weeks of the study, the Fatigue Severity Scale will be applied again through face-to-face interviews. At the end of the study, nurses will be informed about PGE and a voice recording will be sent to their phones from the WhatsApp application, containing the PGE steps, which the researcher voiced with her voice."
62801305|NCT02282280||Study Group|All patients included in the study
62801306|NCT02582645|EXPERIMENTAL|OWT - open window technique|In this arm, a palatally impacted canine will be exposed surgically and left for max 9 months. No traction will be applied during this time.
62801307|NCT02582645|ACTIVE_COMPARATOR|CWT - closed window technique|In this arm, a palatally impacted canine will be exposed surgically, an attachment will be bonded to the tooth and traction will be applied after healing period is complete (1-2 weeks).
62226401|NCT03720860||Non-inflamed|Otherwise healthy patients admitted to the intensive care unit because of intoxication.
62226402|NCT01104116|EXPERIMENTAL|PET/CT imaging|Surgical patients will undergo \[18F\]-FDG PET/CT imaging
62226403|NCT05066737|EXPERIMENTAL|patients who has pelvic organ prolapse and underwent lateral suspension via V-notes surgery|
62226404|NCT01683903||Non coronary patients (NC)|Patient with myocardial infarction with non-coronary (NC) etiology
62226405|NCT01683903||Coronary patients (C)|Patients with myocardial infarction due to coronary disease
62226406|NCT05532982||Parkinson's disease patients|Parkinson's disease patients of Asian descent
62226407|NCT05532982||Parkinson's disease patients' care-givers|Care partners of Parkinson's Disease patients of Asian descent
62226408|NCT05532982||Clinicians|Clinical providers of patients with Parkinson's disease, including physicians, nurses, nurse practitioners, physician assistants, physical therapists, etc.
62226409|NCT05532982||Community stakeholders|Advocates for the Asian American community
62226410|NCT04646915||Patients with CuRC undergoing day surgery|Patients with CuRC undergoing laparoscopic colectomy or anterior resection in day surgery center.
62419413|NCT04175691||HC group|This group includes healthy controls (HC).
62801308|NCT03380897|ACTIVE_COMPARATOR|Outpatient group|"After insertion of induction catheter for labor, women of the outpatient group can go home and assess their pain with visual analogy scale at home. The intervention is to go home.~Intervention for outpatient group was to go home."
62801309|NCT03380897|PLACEBO_COMPARATOR|Inpatient group|"After insertion of induction catheter for labor, women of the inpatient group assess their pain with visual analogy scale in the ward. The intervention is to stay at ward.~Intervention for inpatient group was to stay at ward."
62226411|NCT05636956|EXPERIMENTAL|Patients who receive education and counseling program|Patients with CIEDs and low health literacy received education and counseling program by researchers.
62419414|NCT04376918|ACTIVE_COMPARATOR|Begin with BVGA|"After initial anesthesia induction, anesthetized volunteers will be ventilated through through the BVGA for 2 minutes and then through the face-mask for 2 minutes. The normal anesthesia procedures will then be resumed.~The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation The Mask is a classic face mask"
62801310|NCT04140396|PLACEBO_COMPARATOR|Placebo Comparator|Participants will receive placebo infusion consisting of normal saline
62226412|NCT05636956|NO_INTERVENTION|Patients who receive clinical routine care|Patients with CIEDs and low health literacy received only clinical routine care.
62419415|NCT04376918|ACTIVE_COMPARATOR|Begin with Face-mask|"After initial anesthesia induction, anesthetized volunteers will be ventilated through the face mask for 2 minutes and then through the BVGA for 2 minutes. The normal anesthesia procedures will then be resumed~The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation The Mask is a classic face mask"
62419416|NCT04885816|EXPERIMENTAL|Drug Eluting Balloon (DEB)|High Bleeding Risk patients treated with 2.5 - 4.0 mm drug-eluting balloons (DEB). Bailout stenting is permitted in case of a flow-limiting dissection or significant recoil (\>30% in main branch and \>50% side-branch), includes both stable coronary artery disease (SCAD) and acute coronary syndromes (ACS) patients undergoing elective Percutaneous Coronary Intervention (PCI).
62419417|NCT04885816|ACTIVE_COMPARATOR|Drug Eluting Stents (DES)|High Bleeding Risk patients treated with 2.5 - 4.0 mm drug-eluting stents (DES). Includes both stable CAD and ACS patients undergoing elective PCI.
62589787|NCT02764957|PLACEBO_COMPARATOR|control|placebo capsules twice per day for 8 weeks have identical appearance to Green coffee extract capsules and contain starch
62226413|NCT05316701|EXPERIMENTAL|Orca-T|For patients randomized to the Orca-T arm, Orca-T will be administered after myeloablative conditioning regimen. Single-agent GVHD prophylaxis with tacrolimus will be administered following Tcon infusion (generally Day +3).
62419418|NCT00399919|EXPERIMENTAL|PLC|Investigational drug
62419419|NCT00399919|PLACEBO_COMPARATOR|Placebo|
62589788|NCT01432912|NO_INTERVENTION|Patients|
62589789|NCT00338520||Healthy Controls (HC)|Healthy control children will be enrolled from out-patient well-baby visits.
62589790|NCT00338520||Uncomplicated Malaria (UM)|Febrile children admitted to the hospital with Plasmodium falciparum parasitemia, no other cause of fever identified, no evidence of severe malaria (as listed in Study Protocol, Section 5.2 under exclusion criteria for UM), and no co-infection with other malaria species will be enrolled in the UM group.
62589791|NCT00338520||Cerebral Malaria (CM)|Comatose children admitted to the hospitals will be evaluated by the house physician and/or member of the study team. If lumbar puncture is obtained, the parent or guardian will be approached for permission to enroll the child into the study. Parasitemic children with no other cause of coma identified will included in the CM group.
62589792|NCT00338520||Non-malaria CNS disease (NMC)|Children without parasitemia and diagnosed with a non-malaria cause of coma or CNS disease will be enrolled in the non-malaria CNS disease group.
62419420|NCT06696313|OTHER|Insignia|Total hip replacement CT-RSA vs gold standard RSA
62589793|NCT06667388|EXPERIMENTAL|Group A|
62589794|NCT06667388|ACTIVE_COMPARATOR|Group B|
62226414|NCT05316701|ACTIVE_COMPARATOR|Standard of Care alloHCT Control|For patients randomized to the standard-of-care control arm, an unmanipulated allograft derived from the peripheral blood of a matched donor will be administered after a myeloablative conditioning regimen. Dual-agent prophylaxis consisting of tacrolimus plus methotrexate will be administered starting on Day -3.
62419421|NCT04883411|EXPERIMENTAL|Treatment|Two-Level ACDF with CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System.
62419422|NCT06627244|EXPERIMENTAL|Tebentafusp in combination with Radioembolization Group|"Participants in this group will first be administered Yttrium 90 Trans-Arterial Radioembolization (Y90 TARE) therapy, followed by a 14 to 28 day recovery period. Participants will then be administered Tebentafusp once weekly during every 28-day cycle. Participants may receive up to 24 months or 24 cycles of Tebentafusp therapy.~Total participation is about 3 years."
62419423|NCT03888131|EXPERIMENTAL|CHF 1535 100/6 µg pMDI|2 inhalations BID Total Daily Dose = 400/24µg
62419424|NCT03888131|ACTIVE_COMPARATOR|Symbicort® Turbohaler®|2 inhalations BID Total Daily Dose = 640/18µg
62419425|NCT02944682|EXPERIMENTAL|Liquefied petroleum gas cookstove|Participants randomized to the experimental arm will receive a liquefied petroleum gas (LPG) cookstove and 18-month supply of LPG.
62226415|NCT01195285|ACTIVE_COMPARATOR|Single-Incision Laparoscopic Cholecsytectomy (SILS)|
62226416|NCT01195285|ACTIVE_COMPARATOR|Traditional Laparoscopic Cholecystectomy (TLC)|
62589795|NCT06116682|EXPERIMENTAL|Treatment (amivantamab)|Patients receive amivantamab IV on days 1 and 2 in week and once a week in weeks 2-4 of cycle 1 and then on days 1 and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and collection of blood samples throughout the trial.
62589796|NCT02165189|EXPERIMENTAL|Simeprevir plus Sofosbuvir plus Ribavirin (Arm 1)|Participants will be administered simeprevir capsule 150 milligram (mg), sofosbuvir 400 mg tablet, and ribavirin 2 x 200 mg tablets (for participants weighing less than 75 kilogram \[kg\]) or 3 x 200 mg tablets (for participants weighing more than 75 kg weight), orally once daily up to 12 weeks.
62589797|NCT02165189|EXPERIMENTAL|Simeprevir plus Sofosbuvir (Arm 2)|Participants will be administered simeprevir capsule 150 mg and sofosbuvir 400 mg tablet orally once daily up to 12 weeks.
62589798|NCT02165189|EXPERIMENTAL|Simeprevir plus Sofosbuvir (Arm 3)|Participants will be administered simeprevir 150 mg capsule and sofosbuvir 400 mg tablet orally once daily 24 weeks.
62589799|NCT02394496|EXPERIMENTAL|ARM 1|Fulvestrant + Placebo Lapatinib
62589800|NCT02394496|EXPERIMENTAL|ARM 2|Fulvestrant + Aromatase Inhibitors + Placebo Lapatinib
62589801|NCT02394496|EXPERIMENTAL|ARM 3|Fulvestrant + Lapatinib
62027298|NCT02423473|EXPERIMENTAL|Connective tissue graft plus composite resin restoration.|After local anesthesia, the surgical procedure performed was the trapezoidal-type of CAF (de Sanctis \& Zucchelli, 2007). After the flap was raised, a sterile rubber dam was placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M ESPE - St. Paul, MN, USA), following the manufacturer's instructions. Afterward, a thin and small connective tissue graft that was sutured over the restoration surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
62027299|NCT06171113|EXPERIMENTAL|6 mg single ascending dose (SAD) Group|Participants receive a 6 mg single dose of GSK4024484 or matching placebo, in a fasted state.
62027300|NCT06171113|EXPERIMENTAL|12 mg SAD Group|Participants receive a 12 mg single dose of GSK4024484 or matching placebo, in a fasted state.
62027301|NCT06171113|EXPERIMENTAL|24 mg SAD Group|Participants receive a 24 mg single dose of GSK4024484 or matching placebo, in a fasted state.
62027302|NCT06171113|EXPERIMENTAL|40 mg SAD Group|Participants receive a 40 mg single dose of GSK4024484 or matching placebo, in a fasted state.
62027303|NCT06171113|EXPERIMENTAL|60 mg SAD Group|Participants receive a 60 mg single dose of GSK4024484 or matching placebo, in a fasted state.
62027304|NCT06171113|EXPERIMENTAL|80 mg SAD Group|Participants receive a 80 mg single dose of GSK4024484 or matching placebo, in a fasted state.
62027305|NCT06171113|EXPERIMENTAL|Food Effect Group|Participants receive a single study dose of either GSK4024484 or matching placebo in a fed state.
62589802|NCT02394496|EXPERIMENTAL|ARM 4|Fulvestrant + Lapatinib + Aromatase Inhibitors
62589803|NCT06431893|EXPERIMENTAL|pegtibatinase|
62419426|NCT02944682|NO_INTERVENTION|Control|Participants in the control group will not receive a liquefied petroleum gas (LPG) stove and will continue using traditional cooking methods (open fire or traditional stoves), or the cooking method of their choice. Control households will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research.
62589804|NCT04151160||Case Subjects|Infants with hemodynamically significant congenital heart disease.
62589805|NCT04151160||Control Subjects|Healthy infants with no heart disease or non-hemodynamically significant congenital heart disease.
62589806|NCT06269380|EXPERIMENTAL|Normal esophagogastroduodenoscopy|Patients with normal esophagogastroduodenoscopic findings and biopsy samples were obtained.
62589807|NCT02228239|EXPERIMENTAL|Sequence 1 (ABC)|Participants will receive Treatment A (esketamine 84 milligram (mg) intranasally and 1 placebo capsule) in Period 1, Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 2 and Treatment C (placebo intranasally and placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
62589808|NCT02228239|EXPERIMENTAL|Sequence 2 (BCA)|Participants will receive Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 1, Treatment C (placebo intranasally and placebo capsule) in Period 2 and Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
62027306|NCT06171113|EXPERIMENTAL|100 mg SAD Group|Participants receive a 100 mg single dose of GSK4024484 or matching placebo.
62801311|NCT04140396|ACTIVE_COMPARATOR|Active Comparator|Participants will receive a lidocaine infusion
62027307|NCT06171113|EXPERIMENTAL|Optional Group|Participants may be included in this group, to allow flexibility if the dose escalation needs modification or a dose level needs to be added or repeated.
62027308|NCT06171113|EXPERIMENTAL|10 mg multiple ascending doses (MAD) Group|Participants receive a single dose of 10 mg per day of GSK4024484 or matching placebo during 3 subsequent days (30 mg total).
62027309|NCT06171113|EXPERIMENTAL|20 mg MAD Group|Participants receive a single dose of 20 mg per day of GSK4024484 or matching placebo during 3 subsequent days (60 mg total).
62027310|NCT06171113|EXPERIMENTAL|30 mg MAD Group|Participants receive a single dose of 30 mg per day of GSK4024484 or matching placebo during 3 subsequent days (90 mg total).
62027311|NCT04478279|EXPERIMENTAL|Dose Escalation|This cohort only patients diagnosed with locally advanced or metastatic melanoma, carcinoma or sarcoma of any tumor type who are refractory or intolerant to all available therapies. ST101 will be administered intravenously (IV), initially once per week.
62226417|NCT05969743|EXPERIMENTAL|Letermovir|Patients meeting the inclusion criteria will receive letermovir 480 mg per day. Patients receiving concomitant cyclosporine will receive 240 mg of letermovir. Letermovir will be given during 14 weeks or until prednisone dose is reduced below 0.2 mg / kg / day, whichever comes earlier.
62226418|NCT02067117|EXPERIMENTAL|influenza split vaccine|
62226419|NCT03829293|EXPERIMENTAL|High-flow nasal cannula oxygenation group|Participants in the experimental group will receive high-flow nasal oxygen therapy (HFNO) during gastrointestinal endoscopy under sedation (with a flow at 70L/min and oxygen inspired fraction (FiO2) 50%) through a dedicated system, the THRIVETM (Fisher\&Paykel, New-Zealand)
62027312|NCT04478279|EXPERIMENTAL|Dose Expansion HR+ Breast|This cohort must have progressed after 1-2 hormone based therapies. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
62226420|NCT03829293|NO_INTERVENTION|Standard Oxygenation|Participants in the current standard of care will receive standard oxygenation by nasal prongs (with a flow at 6L/min) or naropharyngeal catheter (with a flow at 5L/min) or standard face mask (with a flow at 6L/min)
62226421|NCT00458887||Ancillary/Correlative (ototoxicity assessment)|"Patients undergo hearing tests (conventional, otoscopy, ultrahigh frequency, and otoacoustic emission testing) for management of therapy complications before the first course of planned cisplatin, before each subsequent course of cisplatin, and 4 weeks after the last dose of cisplatin.~Patients who are scheduled to receive hematopoietic progenitor stem cell transplantation undergo hearing tests for management of therapy complications before the transplantation and 4 weeks after transplantation."
62419427|NCT02600910||Manual Wheelchair User Cohort|"Physical Exam. Screening exam performed by a licensed physical therapist to confirm inclusion/exclusion criteria.~Assessment of Shoulder Function in Everyday Life. Shoulder motion \& hand loading data will be collected over a few days, twice per yr for 3-5 yrs in home \& community environment.~Magnetic Resonance Imaging (MRI) of Shoulders. Imaging will use standard clinical protocol once per yr for 3-5 yrs.~Shoulder Strength Testing. Once per yr for 3-5 yrs. Additional Variables. Updated demographic info will be collected yearly including but not limited to weight, chair type, health status, and job type."
62589809|NCT02228239|EXPERIMENTAL|Sequence 3 (CAB)|Participants will receive Treatment C (placebo intranasally and placebo capsule) in Period 1, Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 2 and Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
62801312|NCT03166696||acute cerebral infarction|the registry and follow up of consecutive patients who were admitted and diagnosed with acute cerebral infarction
62801313|NCT03166696||acute myocardial infarction|the registry and follow up of consecutive patients who were admitted and diagnosed with acute myocardial infarction
62801314|NCT01425034|ACTIVE_COMPARATOR|Cast group|The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
62226422|NCT03297931|ACTIVE_COMPARATOR|Commercial corn chips + Onion dip|Corn chips + onion dip
62226423|NCT03297931|EXPERIMENTAL|Commercial pulse chip + pulse spread|Pinto bean chip + hummus
62226424|NCT03297931|EXPERIMENTAL|Novel pulse chip + pulse spread|Yellow pea chip + hummus
62226425|NCT03297931|EXPERIMENTAL|Commercial pulse chip + non-pulse spread|Pinto bean chip + onion dip
62226426|NCT03297931|EXPERIMENTAL|Novel pulse chip + non-pulse spread|Yellow pea chip + onion dip
62226427|NCT03297931|EXPERIMENTAL|Non-pulse chip + pulse spread|Corn chips + hummus
62589810|NCT02228239|EXPERIMENTAL|Sequence 4 (CBA)|Participants will receive Treatment C (placebo intranasally and placebo capsule) in Period 1, Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 2 and Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
62589811|NCT02228239|EXPERIMENTAL|Sequence 5 (ACB)|Participants will receive Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 1, Treatment C (placebo intranasally and placebo capsule) in Period 2 and Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
62801315|NCT01425034|ACTIVE_COMPARATOR|Motion group|The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
62801316|NCT05189470|OTHER|Control group|These participants will receive the usual care of the respective outpatient clinics.
62027313|NCT04478279|EXPERIMENTAL|Dose Expansion Melanoma|This cohort must have Melanoma that has progressed after/or on treatment with an immune checkpoint inhibitor (CPI) and have received 1-2 prior lines of therapy for their advanced/metastatic disease. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
62226428|NCT00601094|EXPERIMENTAL|experimental arm|
62226429|NCT02391454|OTHER|Group A|usual care
62226430|NCT02391454|EXPERIMENTAL|Group B|usual care + RunKeeper app
62589812|NCT02228239|EXPERIMENTAL|Sequence 6 (BAC)|Participants will receive Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 1, Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 2 and Treatment C (placebo intranasally and placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
62226431|NCT01377597|EXPERIMENTAL|ranibizumab intravitreal injection|
62226432|NCT03435523|EXPERIMENTAL|Open lung approach|Recruitment maneuver during OLV in thoracic surgery
62226433|NCT05540288|EXPERIMENTAL|Nalmefene|
62226434|NCT05540288|PLACEBO_COMPARATOR|Placebo|
62226435|NCT03815786|EXPERIMENTAL|CKD patients|CKD patients stage 3b-4 will follow a 2-months supplementation of either symbiotic or placebo
62419428|NCT02600910||Matched Able-bodied Cohort|"Physical Exam. Screening exam performed by a licensed physical therapist to confirm inclusion/exclusion criteria.~Assessment of Shoulder Function in Everyday Life. Shoulder motion \& hand loading data will be collected over a few days, twice per yr for 3-5 yrs in home \& community environment.~Magnetic Resonance Imaging (MRI) of Shoulders. Imaging will use standard clinical protocol once per yr for 3-5 yrs.~Shoulder Strength Testing. Once per yr for 3-5 yrs. Additional Variables. Updated demographic info will be collected yearly including but not limited to weight, health status, and job type."
62419429|NCT06555133|EXPERIMENTAL|yttriuM-90 in combination with capEcitabine and aTezolizumab|Atezolizumab 1,200 mg IV every 3 weeks for 5 doses Capecitabine 825 mg/m2 PO BID for 2 weeks beginning on the date of each Y-90 therapy administration Y-90 radioembolization one or both hemilivers based on distribution of disease
62419430|NCT05565872|EXPERIMENTAL|Urban training Intervention + therapeutic education program with face-to-face supervision|Patients will be advised to walk in the defined urban trails with face-to-face supervision
62589813|NCT05795816|ACTIVE_COMPARATOR|Testofen|Testofen in capsule form - taken as 2 x 300 mg daily with food (1 in the morning and 1 in the evening)
62226436|NCT03815786|OTHER|Controls|Healthy volunteers will follow a 2-months supplementation of either symbiotic or placebo
62589814|NCT05795816|PLACEBO_COMPARATOR|Microcrystalline cellulose|Microcrystalline cellulose in capsule form - taken as per Active comparator
62589815|NCT05146427|EXPERIMENTAL|Active Slow-wave enhancement|Participants will wear the Philips SmartSleep Deep Sleep Headband which will play auditory tones to selectively enhance slow-wave activity.
62589816|NCT05146427|SHAM_COMPARATOR|Sham Slow-wave enhancement|Participants will wear the Philips SmartSleep Deep Sleep Headband which will not be programmed to enhance slow-wave activity
62589817|NCT06379971|PLACEBO_COMPARATOR|Placebo|Participants will take 8 placebo capsules each containing 1100mg Rice Bran Oil and 150mg Pumpkin Seed Oil every day in place of phosphatidylcholine supplement.
62226437|NCT02860780|EXPERIMENTAL|Part A: prexasertib + ralimetinib|"Cohort 1: 60 milligrams (mg) prexasertib (LY2606368) given intravenously (IV) and 100 mg ralimetinib given orally.~Cohort 2: 60 mg prexasertib (LY2606368) given intravenously (IV) and 200 mg ralimetinib given orally."
62226438|NCT02860780|EXPERIMENTAL|Part B1: prexasertib + ralimetinib (colorectal cancer)|60 mg prexasertib (LY2696368) given IV and 200 mg ralimetinib given orally. Participants receive prexasertib IV on Days 1 and 15 and ralimetinib every 12 hours (Q12H) Days 1 and 14 of a 28 day cycle.
62226439|NCT04497454|ACTIVE_COMPARATOR|ARDSNet|ARDSNet protocol (low PEEP-FiO2 table). Ventilatory mode: volume-controlled ventilation Tidal volume (VT) will be adjusted to 4-6 mL/Kg of PBW and Plateau pressure \< 30 cmH2O for the at least the first 12 hours after inclusion in the protocol pH should be maintained between 7.35-7.45 Oxygenation (SpO2) target ranges 90-95% Maximum respiratory rate = 35 breaths/min PEEP and FIO2 adjusted according to the low PEEP-FiO2 Table.
62226440|NCT04497454|EXPERIMENTAL|EIT-Group|The goal is to maintain driving pressure (DP) \< 16 cmH2O. Ventilatory mode: pressure-controlled ventilation After a recruitment a maneuver, PEEP will be chosen according to a PEEP titration maneuver monitored with electrical impedance tomography Plateau pressure may exceed 30 cmH2O and VT may exceed 6 mL/Kg if DP \< 16 cmH2O pH should be maintained between 7.15-7.40 Oxygenation (SpO2) target ranges 90 -95% Maximum respiratory rate = 50 bpm
62226441|NCT01580423|EXPERIMENTAL|aprepitant|
62226442|NCT01580423|PLACEBO_COMPARATOR|inert powder|
62226443|NCT06195254||SBRT+PD-1 blockers|pembrolizumab (200 mg every 3 weeks), carelizumab (200 mg every 3 weeks), tislelizumab (200 mg every 3 weeks), sintilimab (200 mg every 3 weeks), zimberelimab (240 mg every 3 weeks) until the tumor progressed or the side effects became intolerable.
62589818|NCT06379971|ACTIVE_COMPARATOR|Phosphatidylcholine|Participants will take 8 900mg capsules of phosphatidylcholine every day, the equivalent of approximately 1028 mg of choline per day until delivery
62419431|NCT05565872|ACTIVE_COMPARATOR|Urban training Intervention + therapeutic education program with telematic supervision|Patients will be advised to walk in the defined urban trails with telematic supervision
62589819|NCT05890352|EXPERIMENTAL|Part I, Arm I (tafasitamab, lenalidomide, tazemetostat)|Patients receive tafasitamab IV, lenalidomide PO, and tazemetostat PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.
62801317|NCT05189470|EXPERIMENTAL|Intervention group|Participants that are randomized to the intervention group will receive both inforatio technique and usual care. Inforatio technique will be applied at baseline, 3, 6, 9 and 12 week- follow-up as long as the ulcers have a diameter of minimum four mms and have not developed infection, necrosis, positive probe-to-bone test, exposure of joint or tendon; or underlying osteomyelitis. In addition, inforatio technique will not be applied on ulcers that are covered by scab if the wound care staff assess that the scab should not be removed from the ulcer.
62801318|NCT01328704||Triathletes|Group of individuals who are participating in a triathlon training program at the Avera Sports Institute
62226444|NCT05318677||1|"Fifteen patients with spina bifida aged 8-12 years living in Denizli province were included in the study. The participants were informed about the research and read the voluntary consent form, and written consent was obtained from their families since the participants were children.~Children with literate, well cooperated, aged 8-12 years, and attending any primary school were included in the study. Children who had a second illness and could not be contacted were not included in the study. Non-dominant and dominant extremities of all cases were evaluated by the tests. It was recorded socio-demographic data were questioned. Sensory evaluation forms for upper extremities, Bruininks-Oseretsky motor proficiency, and ability tests were administered by a physiotherapist."
62801319|NCT04073186|EXPERIMENTAL|ACUVUE® OASYS with Transitions™|Eligible subjects between the ages of 40 to 70 years of age and habitual wearers of soft contact lenses will be fitted with the study lens for two wearing cycles.
62419432|NCT06702306|NO_INTERVENTION|Control Group|"At 1, 6 \& 12 months post-procedure, patient will have specialist clinic appointment, with the following:~* Wound inspection, pedal pulse palpation~* Questionnaires to assess quality of life \& pain (EQ5D-L, VASCUQOL-6, Barthel index, NRS-11)"
62589820|NCT05890352|EXPERIMENTAL|Part I, Arm III (tafasitamab, lenalidomide, zanubrutinib)|Patients receive tafasitamab IV, lenalidomide PO, and zanubrutinib PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.
62801320|NCT03636217|EXPERIMENTAL|LGI-Milk Breakfast|Low glycemic index and milk content (LGI-Milk) breakfast as a test meal
62801321|NCT03636217|EXPERIMENTAL|LGI-Kefir Breakfast|Low glycemic index and kefir content (LGI-Kefir) breakfast as a test meal
62801322|NCT03636217|EXPERIMENTAL|HGI-Kefir Breakfast|High glycemic index and kefir content (HGI-Kefir) breakfast as a test meal
62027314|NCT04478279|EXPERIMENTAL|Dose Expansion GBM|Primary (de novo) GBM that has recurred or progressed (per modified RANO criteria) after 1 standard treatment regimen. Standard therapy is defined as maximal surgical resection, radiotherapy, and concomitant temozolomide with radiotherapy or adjuvant chemotherapy with temozolomide. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
62801323|NCT04564170||ED|Patients with Eating Disorders
62027315|NCT04478279|EXPERIMENTAL|Dose Expansion CRPC|CRPC that has progressed after previous treatment with taxanes, abiraterone and enzalutamide/apalutamide. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
62027316|NCT04478279|EXPERIMENTAL|Dose Expansion Recurrent Glioblastoma|Recurrent GBM patients must have completed radiation at least 3 months prior to minimize the inclusion of patients with pseudoprogression. Recurrent GBM patients must have unequivocal radiographic evidence of tumor progression by contrast-enhanced magnetic resonance imaging (MRI) scan within 21 days prior to registration. Patients must be able to delay surgery for 2 - 4 weeks per investigator decision
62027317|NCT04478279|EXPERIMENTAL|Newly Diagnosed Glioblastoma|Newly diagnosed patients with a suboptimal resection or biopsy must be candidates for another surgical resection as determined by neurosurgical evaluation or multidisciplinary team based on the current standard of care that suggests that maximal safe resection is beneficial. Recurrent GBM patients must be candidates for tumor resection
62027318|NCT05202561|EXPERIMENTAL|Arm A|Drug: RNA tumor vaccine Administration: intramuscular injection Dose: 600 ng/ time Dosing cycle: Day 1, day 4, day 7, and day 14.
62027319|NCT05202561|EXPERIMENTAL|Arm B|"Drug: RNA tumor vaccine+Navuliumab Administration: intravenous injection Dose: 3 mg/kg Timing of administration: Administration was initiated 14 days after the first intramuscular injection of the RNA tumor vaccine.~Duration of administration: once every 2 weeks."
62027320|NCT04399629|ACTIVE_COMPARATOR|PCIT-ED|Parent-Child Interaction Therapy - Emotional Development (PCIT-ED) is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
62027321|NCT04399629|EXPERIMENTAL|Parenting Wisely|Online parenting training
62419433|NCT06702306|EXPERIMENTAL|Ultrasound Surveillance Group|"Will receive the same care as control group, plus, lower limb arterial ultrasound, ankle and toe blood pressure checks before every in-person clinic appointment at 1, 6 \& 12 months.~Intervention arm participants are invited to take part in 1:1 interview with the research team after 6 months held as per participants' preference on MS Teams, via telephone, or in person."
62589821|NCT05890352|EXPERIMENTAL|Part II, Arm I (tafasitamab, lenalidomide, tazemetostat)|Patients receive tafasitamab IV, lenalidomide PO, and tazemetostat PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.
62801324|NCT04564170||HC|Healthy Controls without eating disorders
62801325|NCT02289677|EXPERIMENTAL|Intubation during chest compression|Intubation during mannequin chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control, Redmond, WA, USA).
62027322|NCT04898335||Tendyne|all patients treated with a Tendyne Mitral Valve System
62801326|NCT05266417|EXPERIMENTAL|Active|Insulin (Novolin R) and Glutathione (INS-GSH)
62801327|NCT05266417|PLACEBO_COMPARATOR|Control|Placebo
62801328|NCT03064646|EXPERIMENTAL|Organ Preservation|The experimental strategy is the omission of radical surgery if complete or almost complete response after neoadjuvant treatment for locally advanced rectal cancer
62801329|NCT04528160|EXPERIMENTAL|Pain neuroscience education and exercise|"This group will receive an 8-week intervention (1 session per week) of pain neuroscience education and exercise.~PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. Exercise will include mobility, balance and strength exercises."
62801330|NCT04528160|ACTIVE_COMPARATOR|Usual care|This group will receive usual care administered by general practitioners at primary care.
62801331|NCT01276262|PLACEBO_COMPARATOR|Treatment A|Monophasic oral contraceptive (Microgynon® 30) with placebo tablets
62801332|NCT01276262|EXPERIMENTAL|Treatment B|Monophasic oral contraceptive (Microgynon® 30) and fostamatinib
62801333|NCT01395732|EXPERIMENTAL|1|
62801334|NCT02181114|EXPERIMENTAL|Expert System Coaching|Patients in the intervention group will receive coaching based off the answers provided in the computer-based Expert System that is designed to track their readiness level to pursue a living donor kidney transplant.
62801335|NCT02181114|NO_INTERVENTION|Control|Patients in the control group will only receive the standard of care education that is offered at the UCLA Kidney and Pancreas Transplant Center which consists of a powerpoint presentation on their Evaluation Day appointment.
62801336|NCT02545608|EXPERIMENTAL|Restylane Vital in both hands|Open group used to develop a proper use of injection technique for Restylane Vital
62801337|NCT02545608|OTHER|Restylane Vital and No treatment|Split-hand design: Restylane Vital in one hand and initially no treatment in the other hand
62801338|NCT06097026|NO_INTERVENTION|Standard treatment (CONT)|The patient will be managed according to the routine clinical protocol, homogenizing the interventions in both participating centers.
62027323|NCT03348891|OTHER|Subgroup 1|Patients treated with anti-PD-1 alone (nivolumab or pembrolizumab)
62027324|NCT03348891|OTHER|Subgroup 2|Patients treated with the combined treatment anti-PD-1+anti-CTLA-4 (nivolumab + ipilimumab)
62027325|NCT01343368|EXPERIMENTAL|Interventional - Received Leuprolide|Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
62027326|NCT01343368|ACTIVE_COMPARATOR|Observational Arm|Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
62027327|NCT06183801|EXPERIMENTAL|Probiotic 1|Subjects take probiotics capsule three times a day before meal.
62027328|NCT06183801|EXPERIMENTAL|Probiotic 2|Subjects take probiotics capsule three times a day before meal.
62801339|NCT06097026|EXPERIMENTAL|iNO 20-40 ppm|In this arm, inhaled nitric oxide therapy will be initiated at 20 ppm immediately after randomization and after initial data collection. The dose will be reassessed after the first 30 min and may be increased to a maximum of 40 ppm depending on the response observed in ventricular function.
62027329|NCT06183801|EXPERIMENTAL|Probiotic 3|Subjects take probiotics capsule three times a day before meal.
62027330|NCT06183801|EXPERIMENTAL|Probiotic 4|Subjects take probiotics capsule three times a day before meal.
62027331|NCT06183801|EXPERIMENTAL|Probiotic 5|Subjects take probiotics capsule three times a day before meal.
62027332|NCT06183801|PLACEBO_COMPARATOR|Placebo 1|Subjects take probiotics capsule three times a day before meal.
62226445|NCT05318677||2|"20 healthy subjects as a control group aged 8-12 years living in Denizli province were included in the study. The participants were informed about the research and read the voluntary consent form, and written consent was obtained from their families since the participants were children.~Children with literate, well cooperated, aged 8-12 years, and attending any primary school were included in the study. Children who had a second illness and could not be contacted were not included in the study. Non-dominant and dominant extremities of all cases were evaluated by the tests. It was recorded socio-demographic data were questioned. Sensory evaluation forms for upper extremities, Bruininks-Oseretsky motor proficiency, and ability tests were administered by a physiotherapist."
62419434|NCT05327790|EXPERIMENTAL|LFMT capsules + vedolizumab|The initial loading dose is 15 capsules, administered on day 0, in the clinic under direct observation, followed by 5 capsules daily starting on day 1 for 8 weeks at home. All subsequent doses will be dispensed to participants.
62226446|NCT05780554|ACTIVE_COMPARATOR|Cyclophosphamide 50 mg/kg|
62226447|NCT05780554|EXPERIMENTAL|Cyclophosphamide 25 mg/kg|
62027333|NCT06183801|EXPERIMENTAL|Probiotic 6|After 1 month wash out,subjects take probiotics capsule three times a day before meal.
62419435|NCT05327790|PLACEBO_COMPARATOR|Placebo capsules + vedolizumab|The placebo capsules will appear identical to the LFMT capsules; however, the capsules will contain 2 ingredients: trehalose and neusilin, which are components in LFMT capsules.
62419436|NCT05327790|EXPERIMENTAL|LFMT capsules + ustekinumab|The initial loading dose is 15 capsules, administered on day 0, in the clinic under direct observation, followed by 5 capsules daily starting on day 1 for 8 weeks at home. All subsequent doses will be dispensed to participants.
62419437|NCT05327790|PLACEBO_COMPARATOR|Placebo capsules + ustekinumab|The placebo capsules will appear identical to the LFMT capsules; however, the capsules will contain 2 ingredients: trehalose and neusilin, which are components in LFMT capsules.
62027334|NCT06183801|EXPERIMENTAL|Probiotic 7|After 1 month wash out,subjects take probiotics capsule three times a day before meal.
62027335|NCT06183801|PLACEBO_COMPARATOR|Placebo 2|After 1 month wash out,subjects take probiotics capsule three times a day before meal.
62027336|NCT00793416|EXPERIMENTAL|ShuntCheck measure|All patients will have ShuntCheck measurements along with radionuclide shunt patency testing.
62027337|NCT06106477|EXPERIMENTAL|Intermittent Fasting|Enrolled subjects are expected to start the study intervention after completion of definitive therapy and within three months of starting AET.
62027338|NCT01465893|ACTIVE_COMPARATOR|vitamin D|vitamin d 50000/w
62027339|NCT01465893|SHAM_COMPARATOR|control|follow up
62027340|NCT01829269||Patients with a defibrillator|The study population is that of patients with a defibrillator to have a change of probe.
62027341|NCT06669988|EXPERIMENTAL|VR Group|In the VR group, participants will wear virtual reality headsets, experiencing immersive learning in a 3D space with interactive scenarios. Interactive buttons will assist them, making it feel as if they are physically entering a large-scale food service environment. The immersive learning focuses on operating large kitchen equipment, and the first-person perspective will make participants feel as if they are truly in the environment, preparing food in real-time. The VR experience will cover everything from clothing regulations, hygiene and safety precautions, and the use of large kitchen equipment to food service procedures and emergency response. All these aspects are integrated into the learning process.
62226448|NCT02889003|EXPERIMENTAL|CML patients following molecular response loss|
62226449|NCT04420715|EXPERIMENTAL|Less-experienced group|The participant who has completed the number of PCI less than 200 before recruiting
62226450|NCT04420715|EXPERIMENTAL|Experienced group|The participant who has completed the number of PCI more than 200 before recruiting
62027342|NCT06669988|EXPERIMENTAL|Video Group|In the video group, participants will watch a video that features scenarios similar to those in the VR experience. However, instead of interacting with a 3D space, the content will be presented in a 2D format without the immersive spatial element.
62027343|NCT06669988|SHAM_COMPARATOR|Written Materials Group|In the written materials group, the content will be presented through photos and text, without offering dynamic visuals or the immersive 3D spatial experience.
62027344|NCT02171468|EXPERIMENTAL|Dabigatran high dose|
62027345|NCT02171468|EXPERIMENTAL|Dabigatran low dose|
62027346|NCT04589923||Group 1 - participants expected to have abnormal oxygen saturation|Within each study session, participants will have their oxygen saturation, heart rate and respiratory rate measured three times using standard of care equipment and methods. At the same time, video of the participant's face will be captured using the Lifelight® Data Collect app running on a tablet positioned opposite them. The app will upload the RGB data extracted from this video to the cloud for subsequent analysis and processing aligned to the study's primary and secondary objectives only. The app does not return any measurements to the user or participant.
62419438|NCT06702813|EXPERIMENTAL|CHFO group|"After checking the availability of the CHFO machine (MetaNeb® system), the inclusion and non-inclusion criteria, the patient is included. The following procedures are performed:~1. installation of an EIT belt in the 4th or 5th intercostal space (Pulmovista® 500, Dräger);~2. continuous recording of digital and analogic data after collecting initial data from the patient within 10 minutes before CHFO treatment, successive 10-minutes CHFO were performed. At the end of the treatment, all the data is collected."
62027347|NCT04589923||Group 2 - participants expected to have abnormal blood pressure|Within each study session, participants will have their blood pressure and respiratory rate measured three times using standard of care equipment. At the same time, video of the participant's face will be captured using the Lifelight® Data Collect app running on a tablet positioned opposite them. The app will upload the RGB data extracted from this video to the cloud for subsequent analysis and processing aligned to the study's secondary objectives only. The app does not return any measurements to the user or participant.
62226451|NCT00451880|EXPERIMENTAL|Arm 1|XL281 administered once a day
62226452|NCT00451880|EXPERIMENTAL|Arm 2|XL281 administered twice a day
62419439|NCT03393312|EXPERIMENTAL|Bifrontal tDCS|"20 minutes of 2 mA transcranial direct current stimulation (tDCS), with the anode placed over the left dorsolateral prefrontal cortex and the cathode placed over the right dorsolateral prefrontal cortex (F3 and F4 according to the 10/20 international EEG system, respectively).~The stimulation will be applied before or during task performance, depending on the condition assignment."
62226453|NCT00451880|EXPERIMENTAL|Arm 3|XL281 administered once a day. Subjects in this arm will be dosed under fed conditions, fasted conditions, and with a concomitant single dose of 40 mg famotidine, during the second, third, and fourth week of the first cycle.
62226454|NCT05586074|EXPERIMENTAL|Clifutinib|Subjects received 40 mg dose orally once a day in continuous 28-day cycles, at least 2 hours before and after food. Clifutinib treatment continued until sujects met one of the treatment discontinuation criteria.
62243029|NCT06630286|EXPERIMENTAL|Open- Label Extension (OLE) Phase|"After the end of Blinded Phase at Week 96, if safety and efficacy of ISL/LEN are demonstrated following review of unblinded data, all participants will be given an option to enter the open-label extension phase to receive ISL/LEN in an extension phase until ISL/LEN becomes available or until the sponsor elects to discontinue the study, whichever occurs first.~Participants receiving ISL/LEN and PTM B/F/TAF during the blinded phase will continue to take ISL/LEN weekly.~Participants receiving B/F/TAF and PTM ISL/LEN during the blinded phase will take an initial dose of ISL/LEN (Dose A), followed by once weekly ISL/LEN (Dose B) from Day 8 onwards."
62419440|NCT03393312|SHAM_COMPARATOR|Sham tDCS|"Participants receive 20 minutes of sham tDCS, with the anode placed over the left dorsolateral prefrontal cortex and the cathode placed over the right dorsolateral prefrontal cortex (F3 and F4 according to the 10/20 international EEG system, respectively). In sham tDCS, stimulation starts with 8s fade in followed by 30s direct current followed by 5s fade out followed by 870s without any stimulation.~The stimulation will be applied before or during task performance, depending on the condition assignment."
62419441|NCT02168205|EXPERIMENTAL|4 mg Pomalidomide - Fed|On Day 1, participants will receive a single oral dose of 4 mg pomalidomide under fed conditions.
62027348|NCT00142480|EXPERIMENTAL|Capecitabine, Oxaliplatin, Bevacizumab|There are two phases of study treatment. Phase I includes all patients and will last 6 weeks. During this phase, oxaliplatin will be given intravenously (IV) on days 1, 8, 22, and 29; bevacizumab will be given IV on days 1, 15, and 29; capecitabine will be administered orally on days 1-14 and 22-35. Radiation therapy will be given once daily for 5 days (Monday-Friday) per week for a total of 28 treatments. Phase II has two groups: 1) patients who had tumors removed prior to entering study and 2) patients who entered the study with advanced disease. Patients who had their tumors removed prior to entering the study will be treated with the above 6-week regimen twice for a total of 12 weeks of treatment. Patients who were unresectable prior to entering the study but then were deemed resectable after treatment on trial will undergo resection. Following surgical recovery (8-10 weeks) they will be treated again with the above 6-week regimen twice for a total of 12 weeks of treatment.
62027349|NCT04279249|ACTIVE_COMPARATOR|HEPA Filtration|
62027350|NCT04279249|SHAM_COMPARATOR|Sham HEPA Filtration|
62419442|NCT02168205|EXPERIMENTAL|4 mg Pomalidomide - Fasted|On Day 1, participants will receive a single oral dose of 4 mg pomalidomide under fasted conditions
62419443|NCT02168205|EXPERIMENTAL|4 mg Pomalidomide + caffeine - Non-smoking|Participants will remain in the clinical site for a total of 10 days. They will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, participants will receive a single oral dose of 4 mg pomalidomide.
62027351|NCT00206648|EXPERIMENTAL|Arm 1|
62027352|NCT00206648|ACTIVE_COMPARATOR|Arm 2|
62027353|NCT00982462|PLACEBO_COMPARATOR|Corn oil placebo|Micro-encapsulated powder containing corn oil placebo.
62027354|NCT00982462|EXPERIMENTAL|Long-chain polyunsaturated fatty acids|Micro-encapsulated powder containing 1:1 ratio of the omega-3 long-chain polyunsaturated fatty acids, docosahexaenoic acid (DHA) and the omega-6 fatty acid, arachidonic acid (ARA) from algal and fungal sources, respectively.
62419444|NCT02168205|EXPERIMENTAL|4 mg Pomalidomide + caffeine - Smoking|Participants will be required to smoke approximately 20 cigarettes a day for 10 days. They will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, participants will receive a single oral dose of 4 mg pomalidomide.
62419445|NCT00954694|EXPERIMENTAL|introductory exercise regimen|sedentary adults will be introduced to an introductory fitness regimen using the NuStep
62027355|NCT04608474|EXPERIMENTAL|Evolocumab only|This arm includes subjects who are treated using Evolocumab.
62027356|NCT04608474|EXPERIMENTAL|Evolocumab plus statin|This arm includes subjects who are treated using a combination of Evolocumab and a statin-based drug.
62027357|NCT02945085|EXPERIMENTAL|Home Based Care Team|Primarily in-home treatment provided by team led by nurse practitioner with geriatrics and geriatric psychiatry expertise.
62419446|NCT02125734|EXPERIMENTAL|Treatment sequence 1|QVA149 from day 1 to day 28 and tiotropium from day 29 to day 56
62419447|NCT02125734|EXPERIMENTAL|Treatment sequence 2|Tiotropium from day 1 to day 28 and QVA149 from day 29 to day 56
62419448|NCT05359640||quality of pain|We will recorded the pain by using a short pain questionnaire and a McGill pain questionnaire.
62419449|NCT05359640||consumption of analgesics|The consumption of analgetics, VAS score and improvement of quality of life will be monitored.
62589822|NCT05890352|ACTIVE_COMPARATOR|Part II, Arm II (tafasitamab, lenalidomide)|Patients receive tafasitamab IV and lenalidomide PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.
62589823|NCT05890352|EXPERIMENTAL|Part II, Arm III (tafasitamab, lenalidomide, zanubrutinib)|Patients receive tafasitamab IV, lenalidomide PO, and zanubrutinib PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.
62801340|NCT06097026|EXPERIMENTAL|iNO 20 - 40 ppm + Lung recruitment (iNO-RM)|After 30 min after initiation of nitric oxide therapy following randomization, once patient stability has been confirmed, a brief recruitment maneuver will be performed and the subsequent PEEP level will be individualized according to the best lung compliance. Ventilation will then continue with the standard baseline ventilator settings, but with the PEEP level individually optimized.
62801341|NCT05315492|EXPERIMENTAL|Intervention communes|CCC intervention
62801342|NCT05315492|NO_INTERVENTION|Control communes|Standard care
62801343|NCT02688244|ACTIVE_COMPARATOR|Irrigation|Irrigation of the area with at least 300ml normal saline using the power suction/irrigator
62801344|NCT02688244|ACTIVE_COMPARATOR|No irrigation|Only suction with the power suction/irrigator without saline attached
62801345|NCT05247086|NO_INTERVENTION|Convention closure|Conventional closure of the surgical wound after mesh removal surgery.
62589824|NCT05001087||Patients registry|"Non-interventional, multicentre, retrospective and prospective registry. In order to increase the sample size and the validity of the Registry, patients who were diagnosed with myeloma since 1st January 2019 will also be included retrospectively, once their informed consent has been obtained by the enrolling centre. Being a registry, patients will be enrolled consecutively according to their appointments at the centre, at the discretion of their doctor and only once the patient has signed the informed consent form.~Also patients participating in interventional or other observational studies can be enrolled. In case of patients enrolled in interventional trials, only baseline and survival data can be collected for the period in with the patient is in interventional trial.~The data will be collected using an electronic data capture (EDC) platform. Hospital visits are planned every 6 months."
62589825|NCT03069599||10 IRE locally advanced|patients undergoing in situ IRE for locally advanced pancreatic
62801346|NCT05247086|EXPERIMENTAL|Negative pressure therapy|Negative pressure therapy of the surgical wound after mesh removal surgery.
62801347|NCT03725631|EXPERIMENTAL|Biopsy proven NAFLD patients|150 subjects who are diagnosed with NAFLD with biopsy from September 2016 to October 2018.
62801348|NCT02627872||COPD patients (GOLD I-II)|Participants with mild-to-moderate COPD (GOLD I-II)
62801349|NCT02627872||Smoker Control Group|Actively smoking participants with normal lung function (do not have COPD)
62801350|NCT02627872||Healthy Never-smoker Control Group|Healthy participants that never have smoked
62419450|NCT06702696|EXPERIMENTAL|Aronia group|The Aronia group will consume 30 g of freeze-dried aronia powder (n=25).
62589826|NCT03069599||10 IRE borderline resection|patients undergoing margin accentuation IRE for borderline resectable disease
62589827|NCT03069599||10 resection only|patients undergoing surgical resection only
62589828|NCT02683382|EXPERIMENTAL|Moisturizing Eye Product (product in development)|Moisturizing eye product in liquid form (medical device product in development). Part 1 of the study: Administered to both eyes 4 times/day for 1 day. Part 2: to one eye 4 times/day for 9 days. Part 3: to one eye 4 times/day for 45 days. Parts 2 \& 3: treatment eyes randomized.
62589829|NCT02683382|ACTIVE_COMPARATOR|Moisturizing Eye Product, Comparison|Moisturizing eye product in liquid form (medical device CE-marked). Part 2 of the study: Administered to one eye 4 times/day for 9 days. Treatment eyes randomized.
62589830|NCT02683382|NO_INTERVENTION|No treatment|Part 3 of the study: other eye is a control eye with no treatment for 45 days.
62419451|NCT06702696|PLACEBO_COMPARATOR|Placebo group|The placebo group will consume placebo powder (n=25).
62801351|NCT04538638|ACTIVE_COMPARATOR|Mesenteric Sparing ileocolic resection|Standard procedure for CD, ileocolic resection without removal of the mesentery.
62801352|NCT04538638|ACTIVE_COMPARATOR|Central mesenterectomy ileocolic resection|Experimental procedure for CD: ileocolic resection in which the mesentery is taken up to the level of the ileocolic trunc.
62801353|NCT04618003||Athletes with Spinal Cord Injury|Group of athletes with spinal cord injury that was assessed at rest and during a physical activity in virtual reality.
62801354|NCT04618003||Non-athletes with spinal cord injury|Group of non-athletes with spinal cord injury that was assessed at rest and during a physical activity in virtual reality.
62801355|NCT04618003||Able-bodied control group|Group of non-athletes able-bodied control subjects that was assessed at rest and during a physical activity in virtual reality.
62801356|NCT01901406||ERM|idiopathic epiretinal membrane patients
62801357|NCT03485066|EXPERIMENTAL|Training|20 healthy participants, 4 week training of a challenging cognitive task (Tetris) between PET/MR measurements
62027358|NCT02945085|ACTIVE_COMPARATOR|Telephone Based Care Team|Primarily telephone-based treatment provided by existing care management program offered by collaborating Medicare Advantage insurer.
62027359|NCT06588491|EXPERIMENTAL|KYV-101 CAR-T cells with lymphodepletion conditioning|Dosing with KYV-101 CAR T cells
62801358|NCT03485066|NO_INTERVENTION|Control|20 healthy participants, no training between PET/MR measurements
62801359|NCT02870283|ACTIVE_COMPARATOR|Lithium|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (A) Started Lithium (900mg-1500mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~1. First step: Monotherapy with Lithium (900-1500mg) Non responsive patients: 2nd step.~2. Second step: Randomization for lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) OR lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).~   Non responsive patients: 3rd step.~3. Third step: Crossover lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) X lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).~   Non responsive patients: 4th step.~4. Fourth step: Association with risperidone (1-6mg)"
62419452|NCT06279481|EXPERIMENTAL|Virtual Reality|The virtual reality hardware includes a headset (OLED display mode), a headset cable, a High-Definition Multimedia (HDM) cable, a processor unit, an Alternating Current (AC) power converter, a six-axis dynamic sensing system (three-axis gyroscope, three-axis accelerator sensor), a cinema AC screen, and a camera. The software that patients would be engaged in is highly interactive and requires total attention for about 15 minutes. The device would be tried out by the patients prior to the operation.
62801360|NCT02870283|ACTIVE_COMPARATOR|Acid Valproic|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (B) Started Valproic Acid (1000mg-1500mg).~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~1. First step: Monotherapy with Valproic Acid (1000mg-1500mg) Non responsive patients: 2nd step.~2. Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.~3. Third step: Crossover: lithium (900mg-1500mg) + carbamazepine (600mg-1200mg). Non responsive patients: 4th step.~4. Fourth step: Association with risperidone (1-6mg)"
62801361|NCT02870283|ACTIVE_COMPARATOR|Carbamazepine|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (C) Started Carbamazepine (600mg-1200mg).~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~1. First step: Monotherapy with Carbamazepine (600mg-1200mg). Non responsive patients: 2nd step.~2. Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.~3. Third step: Crossover: lithium (900mg-1500mg) + valproic acid (1000mg-1500mg). Non responsive patients: 4th step.~4. Fourth step: Association with risperidone (1-6mg)"
62027360|NCT03360461|EXPERIMENTAL|EMI-137|Ten participants to receive the IMP - EMI-137 1 to 3 hours before laparoscopic colonic resection surgery. Dose range 0.02mg/kg to 0.13mg/kg will be administered.
62027361|NCT02633384|EXPERIMENTAL|SMOFlipid|infants subjected to corrective surgery for congenital abnormalities and needing prolonged PN using a new generation intravenous lipid emulsion
62027362|NCT02633384|OTHER|Lipofundin|infants subjected to corrective surgery for congenital abnormalities and needing prolonged PN using a current intravenous lipid emulsion
62589831|NCT00880230|EXPERIMENTAL|Scuba Iliac Stent System|Device: Scuba™ iliac stent
62027363|NCT04939480|EXPERIMENTAL|Atezolizumab|Pre-operative administration of atezolizumab 1200 mg followed by definitive resection of the tumor, followed by standard of care radiotherapy or radio-chemotherapy.
62027364|NCT03738540|EXPERIMENTAL|Experimental|This is the experimental arm of the study. This includes 25 weekly then biweekly sessions of experimental therapy via telephone. Therapy description withheld to protect the integrity of the study.
62243030|NCT04191187|EXPERIMENTAL|Conditioning Regimen + Transplant|All participants will receive a conditioning regimen of Fludarabine, Melphalan and Total Body Irradiation prior to transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT)
62419453|NCT06279481|NO_INTERVENTION|Control|Patients undergo traditional colonoscopy procedures.
62419454|NCT03476837|EXPERIMENTAL|Behavioral Treatment|Following baseline, the CHWs will deliver three doses of the intervention to the treatment (intervention) group over a 6-month period with follow-up at 12 months for all WCGs. At 1, 3, and 6 months, WCGs will receive motivational interviewing, educational materials and biofeedback based on the child's saliva sample and WCG's carbon monoxide.
62419455|NCT03476837|ACTIVE_COMPARATOR|Control|WCGs will receive educational materials in the mail at 1, 3, and 6 months.
62027365|NCT03738540|ACTIVE_COMPARATOR|Control|This is the control arm of the study. This includes This includes 25 weekly then biweekly sessions of control therapy via telephone.Therapy description withheld to protect the integrity of the study.
62419456|NCT02494583|EXPERIMENTAL|Pembrolizumab Monotherapy (Pembro Mono)|Participants will receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W). Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
62801362|NCT01101035|EXPERIMENTAL|Febuxostat|Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.
62419457|NCT02494583|EXPERIMENTAL|Pembrolizumab + SOC Chemotherapy (Pembro Combo)|Participants will receive pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m\^2 Q3W plus 5-FU 800 mg/m\^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m\^2 twice a day (BID) on Days 1-14 Q3W may be substituted for 5-FU per local guidelines. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
62419458|NCT02494583|PLACEBO_COMPARATOR|Placebo + SOC Chemotherapy (SOC)|Participants receive placebo IV Q3W plus cisplatin 80 mg/m\^2 Q3W plus 5-FU 800 mg/m\^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m\^2 BID on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.
62801363|NCT01101035|ACTIVE_COMPARATOR|Allopurinol|Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was \<6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance \[eCLcr\] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was \<6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but \<60 mL/min).
62801364|NCT04113317|EXPERIMENTAL|Treatment Group|Subcutaneous injection of G-CSF with dose of 5μg/kg/day for 5 days consecutively, in addition to a single dose every 3 days up to 12 times, as well as liver cirrhosis standard regimen
62801365|NCT04113317|NO_INTERVENTION|Control Group|Liver cirrhosis standard treatment only
62801366|NCT01485159||All|All subjects enrolled in the study
62801367|NCT03324243|EXPERIMENTAL|Crenolanib|
62027366|NCT04377646|ACTIVE_COMPARATOR|Hydroxychloroquine & Zinc|"Will receive:~* Hydroxychloroquine 400 mg at day 1 and day 2, then a weekly dose of 400 mg up to 2 months.~* Zinc 15 mg at daily dose up to 2 months"
62027367|NCT04377646|ACTIVE_COMPARATOR|Hydroxychloroquine|"Will receive:~* Hydroxychloroquine 400 mg at day 1 and day 2, then a weekly dose of 400 mg up to 2 months.~* Placebo of Zinc"
62243031|NCT03298672|EXPERIMENTAL|NDX-1017|NDX-1017 will be administered via subcutaneous injection
62027368|NCT04377646|PLACEBO_COMPARATOR|Placebo|Will receive a double placebo (Hydroxychloroquine and Zinc) up to 2 months
62419459|NCT03591107|EXPERIMENTAL|PTSD Care Management (PCM)|In addition to the education and feedback components for both conditions the PCM intervention provides access to a trained Care Manager (CM) who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist.
62801368|NCT00988884|EXPERIMENTAL|Concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1
62419460|NCT03591107|ACTIVE_COMPARATOR|Minimally Enhanced Usual Care (MEU)|The MEU condition will consist of only clinician education, patient education (Information Sheet) and feedback about having a probably diagnosis of PTSD to both the clinician and patient.
62419461|NCT03315910|EXPERIMENTAL|Motivational Interviewing( MI) (Yes vs. No)|Participants will receive two motivational informed cessation sessions; the first delivered face to faceor via telephone by the SC during the patient's initial lung cancer screening visit or during the shared decision making discussion or within about 1 week following their screening visit, and the second session delivered by telephone by the SC approximately 4 to 8 weeks after the first MI session.
62801369|NCT00988884|EXPERIMENTAL|Non-concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1
62589832|NCT03229447|ACTIVE_COMPARATOR|E-learning intervention|The E-learning intervention consists of two 20-minute e-learning modules that combine a didactic component with testimonials from respected professionals in the fields of addiction treatment and criminal justice. Module 1 describes the nature of opioid addiction and treatment modalities. Module 2 addresses specific criminal justice concerns of cost, acceptance, usefulness, and diversion, perceived obstacles to providing MAT access as described to us by Ohio criminal justice professionals in formative phase. All courts recruited for the study are exposed to E-Learning.
62027369|NCT06163755|EXPERIMENTAL|Group- 1, Morphine Group|Morphine 3mg group+0.5% Bupivacaine (total volume 5ml) for Intra-articular knee injection.
62027370|NCT06163755|ACTIVE_COMPARATOR|Group- 2 , DepoMedrol ( Methylprednisone) Group|(control Group - Standard of care ) - DepoMedrol 40mg + 0.25% Bupivacaine (total Volume 5 ml) for Intra-articular knee injection.
62027371|NCT01343511|EXPERIMENTAL|Rehabilitation plus hCB-MNCs treatment|Participants will be given rehabilitation therapy plus human cord blood mononuclear cells transplantation with a 6 months follow-up.
62243032|NCT03298672|PLACEBO_COMPARATOR|Placebo|Placebo will be administered via subcutaneous injection
62243033|NCT04061551|EXPERIMENTAL|EC Clinic Support|Whole of practice interventions delivery through nurse-led model
62027372|NCT01343511|EXPERIMENTAL|Rehabilitation plus hCB-MNCs and hUC-MSCs therapy|Participants will be given rehabilitation therapy plus combination of hCB-MNCs together with hUC-MSCs transplantation with a 6 months follow-up.
62226455|NCT05586074|ACTIVE_COMPARATOR|Salvage Chemotherapy|Subjects received chemotherapy in 28-day cycles. Subjects on Low-Dose Cytarabine (LoDAC) received 10 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10\~14 days. Subjects on azacitidine received 75 mg/m\^2 daily by SC for 7 days. Subjects on decitabine received 20 mg/m\^2 daily by IV injection for 5 days. Subjects on LoDAC or azacitidine or decitabine treatment continued until they met discontinuation criteria. Subjects on Ara-C±IDA chemotherapy received cytarabine 1\~3 g/m\^2 daily by IV for 3 days and idarubicin 10 mg/m\^2 daily by IV for 3 days. Participants on FLAG-IDA chemotherapy received G-CSF 300 μg/m\^2 daily by SC for 6 days (days 1-6), fludarabine 30 mg/m\^2 daily by IV for 5 days (days 2-6), cytarabine 1\~2 g/m\^2 daily by IV for 5 days (days 2-6) and idarubicin 10 mg/m\^2 daily by IV for 3 days (days 2-4). Subjects receiving Ara-C±IDA or FLAG-IDA received 1 cycle of therapy and were assessed for response on day 28+/-2 days.
62419462|NCT03315910|EXPERIMENTAL|Nicotine Replacement Therapy (NRT) Patch (Yes vs. No)|Participants will receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day and written instructions to use the patch daily starting on date they mutually agreed upon with their site coordinator. Participants who smoke fewer than 10 cigarettes per day will receive 4-weeks of the 14mg patch (2 boxes), and 2-weeks of the 7mg patch (1 box). Those who smoke 10 or more cigarettes per day will receive 4-weeks of the 21mg patch (2 boxes) and 2-weeks of the 14mg patch (1 box). Participants will receive their study medications from their site coordinator on the day of their screening appointment or via mail from Arrowhead Promotion \& Fulfillment.
62419463|NCT03315910|EXPERIMENTAL|NRT Lozenge (Yes vs. No)|Participants will receive will receive 6 packs of NRT 2mg lozenge and written instructions to use the lozenge PRN to help manage acute nicotine withdrawal. Participants will be instructed to use the NRT lozenges no more than every 1-2 hours as needed. Participants will receive their study medications from their site coordinator on the day of their screening appointment or via mail from Arrowhead Promotion \& Fulfillment.
62589833|NCT03229447|EXPERIMENTAL|Change Team Intervention|Half of the courts exposed to e-learning will be randomly assigned to a change team intervention. The change team will reinforce the information in the modules and provide instrumental assistance in linking courts to MAT providers and financial resources.
62589834|NCT04721119|EXPERIMENTAL|Local Infiltration Anesthetic|This group of patients will receive the local infiltration anesthetic only.
62027373|NCT01435577|EXPERIMENTAL|Tapentadol intravenous|Tapentadol will be given by intravenous infusion. Tapentadol will be administered every 4 hours. Ibuprofen 600 mg orally may be given as rescue medication for pain not controlled by Tapentadol alone.
62027374|NCT01435577|PLACEBO_COMPARATOR|Matching placebo intravenous|Placebo (0.9% sodium chloride and water for injection). Ibuprofen 600 mg orally may be given as rescue medication for pain.
62027375|NCT04265755|EXPERIMENTAL|Single arm|Erenumab packed in a SureClick® Autoinjector Pen (AI)
62589835|NCT04721119|EXPERIMENTAL|Local Infiltration Anesthetic + Adductor Canal Block|This group of patients will receive the local infiltration anesthetic and adductor canal block combination.
62801370|NCT01528930|EXPERIMENTAL|Amikacin for inhalation|"Drug: Amikacin~* Amikacin is provided for inhalation via nebulization.~* 500 mg of amikacin is administered once daily using the Pari-Boy N/Long Life Nebulizer.~* Administration time is approximately 20 minutes.~* Amikacin will be administered for 2 years."
62801371|NCT03868033|EXPERIMENTAL|Continuous Denosumab|Continuous anti-resorptive therapy by Denosumab for 2 years
62801372|NCT03868033|EXPERIMENTAL|Zoledronic acid to Denosumab|treat with Zoledronic acid for one year and then shift to Denosumab for another one year
62226456|NCT02107053|EXPERIMENTAL|IV iron + PJ|Each patient will serve as a self control
62226457|NCT02107053|EXPERIMENTAL|No IV iron + PJ|Each patient will serve as a self control
62801373|NCT03868033|EXPERIMENTAL|Continuous Zoledronic acid|Continuous anti-resorptive therapy by Zoledronic acid for 2 years
62801374|NCT03868033|EXPERIMENTAL|Zoledronic acid to observation|"treat with Zoledronic acid for one year and then close follow up by bone turn over marker.~resume another dose of Zoledronic acid if elevated CTX level above normal range"
62801375|NCT06393075|EXPERIMENTAL|combined care guidance|Pain care guidance animation Rehabilitation exercise guidance animation Demonstrate how to perform rehabilitation exercises Demonstrate how to use a walker
62801376|NCT06393075|ACTIVE_COMPARATOR|general care guidance|Verbal explanation of pain and rehabilitation exercise instructions after surgery
62801377|NCT02023307|EXPERIMENTAL|Rhytidectomy with Covidien|25 patients receiving a mid-face lift in short-flap rhytidectomy
62589836|NCT06665204|EXPERIMENTAL|Clinical Practice Guideline-adherent Care|Participants randomized to receive CPG-adherent care will first receive a comprehensive clinical examination following the PFP CPG Decision Tree guidelines. Their treatment plan of care will correspond to any and all impairment subcategories, as defined by the PFP CPG.
62226458|NCT02107053|EXPERIMENTAL|IV iron no PJ|Each patient will serve as a self control
62226459|NCT01236339|EXPERIMENTAL|TIPS|TIPS with GORE® VIATORR® TIPS Endoprosthesis
62226460|NCT01236339|ACTIVE_COMPARATOR|LVP|"Large Volume Paracentesis~\*A subject may be crossed-over from large volume paracentesis to TIPS with GORE® VIATORR® TIPS Endoprosthesis if the subject has completed their six month study visit and has met the criteria for cross-over (LVP failure)."
62226461|NCT02304601||Comorbid symptoms|
62226462|NCT02304601||No comorbid symptoms|
62589837|NCT06665204|ACTIVE_COMPARATOR|Standard-of-Care|All participants randomized to the SoC group will receive routine physical therapy evaluations and treatments in the outpatient physical therapy clinics at each participating military treatment facility, at the discretion of the staff physical therapist.
62589838|NCT01180699|EXPERIMENTAL|influenza vaccine - intradermal|intradermal versus intramuscular
62226463|NCT00336895|EXPERIMENTAL|Liver Transplant Subjects|All subjects in this study will receive Myfortic 360mg or 720 mg BID for 90 days.
62226464|NCT03368469|EXPERIMENTAL|transcranial direct current stimulation|Transcranial direct current stimulation (35 sq cm anode over left dorsolateral prefrontal cortex, 35 sq cm cathode over right supraorbital area, 1 mA current, 20 min per treatment session, 1 session per day, 10 treatment sessions over two weeks)
62226465|NCT05933408||Patients with serious infectious complications|Complications were graded according to the five grade Clavien-Dindo classification (CD 1-5). Complications have been divided into mild (CD 1-2) and severe (CD 3-5).
62419464|NCT03315910|EXPERIMENTAL|Message Framing (Gain vs. Loss)|Overall, a robust body of health communication literature demonstrates that gain-framed messages may be more effective than loss-framed or non-framed (neutral) messages for encouraging smoking cessation. In other words, quitting messages that promote smoking cessation are more persuasive if they emphasize the benefits of quitting (gain-framed) rather than the risks (loss-framed) of persistent smoking (25, 26). Included with the written communication of their LDCT-LCS results, participants will receive a printed individualized quitting message that emphasizes either the benefits of quitting (gain-framed) or the risks of continuing to smoke (loss-framed).
62589839|NCT01180699|ACTIVE_COMPARATOR|influenza vaccine - intramuscular|
62801378|NCT06206460||Open Label Placebo with Treatment Rationale|
62226466|NCT05933408||Patients without complications|Patients with infectious complications who formed group 1, were matched 1:1 with patients without complications (group 2). Case-matched analysis was performed by selecting patients for the control group from the group of patients paired by age, ASA scale, stage of cancer and type of surgery.
62226467|NCT05958641||Investigation Team|Questionnaires assessed adolescents aged 14-35 years old (including 14,25 years old) who agreed to participate in the study
62226468|NCT00873314|EXPERIMENTAL|Bed rest|
62226469|NCT00873314|PLACEBO_COMPARATOR|Activity restriction|
62027376|NCT04974216|EXPERIMENTAL|R-Lena-Tafa|"12 cycles of 28 days. From C1 to C6 : rituximab + tafasitamab + lenalidomide and from C7 to C12: tafasitamab and lenalidomide~Patients with Progressive Disease or Stable Disease after 3 cycles should start a conventional chemotherapy (rituximab + cyclophosphamide + adriamycine + vincristine + prednisone R-miniCHOP) at Investigator's discretion according to local practices"
62027377|NCT02244944|EXPERIMENTAL|EZ-URSO Combination Therapy|Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.
62226470|NCT05353933|EXPERIMENTAL|TEA + PPI|Thread embedding acupuncture (TEA) every 2 weeks in 4 weeks (twice). Combined with oral pantoprazole 40 mg capsules (Pantostad 40 CAP) once daily for 4 weeks.
62226471|NCT05353933|ACTIVE_COMPARATOR|PPI|Oral pantoprazole 40 mg capsules (Pantostad 40 CAP) once daily for 4 weeks.
62027378|NCT02594891|EXPERIMENTAL|endoscopic retrograde biliary drainage|Patients will undergo endoscopic retrograde biliary drainage (ERBD) with 8.5 F plastic stent with proximal flap when bile duct stones were removed clearly with ERCP. The stent will be taken out with endoscopy three months later if not discharge self-driven.
62226472|NCT04825483|EXPERIMENTAL|Weight loss and exercise|In addition to the physiotherapist-prescribed exercise program, participants in the weight loss and exercise group will also undergo six consultations with a dietitian. They will undergo a ketogenic very low-calorie diet (VLCD) including meal replacements, with an intensive weight loss phase and weight maintenance phase. The exercise component will be the same as that provided for the exercise only comparator. All dietitian and physiotherapy consultations will be delivered online by video-conference platform.
62027379|NCT02594891|PLACEBO_COMPARATOR|endoscopic nasobiliary drainage|Patients will undergo endoscopic nasobiliary drainage (ENBD) when bile duct stones were removed clearly with ERCP. The nose bile duct will be pulled out 3-5 days later if no cholangitis occurrence.
62226473|NCT04825483|ACTIVE_COMPARATOR|Exercise only|Participants will undergo five consultations (30-45 minutes) with a physiotherapist over 6 months for prescription of a home-based strengthening exercise program and physical activity plan (to be conducted independently at home), as well as OA education. All consultations will be conducted remotely via video-conference.
62419465|NCT06582888|EXPERIMENTAL|Varenicline|Following the baseline assessment, participants randomized to receive varenicline will complete an 8-day titration period to achieve the target dose. Titration of varenicline will be as follows: 0.5 mg once daily for Days 1-3, 0.5 mg twice daily for Days 4-7, and 1 mg twice daily on Day 8. Participants then return to the lab on Day 9 (or Days 10, 11 if necessary) for testing at the target dosage (1 mg twice daily) and continue at that dose for eight additional days (Days 10-17) for mobile monitoring.
62419466|NCT06582888|PLACEBO_COMPARATOR|Placebo|Following the baseline assessment, participants randomized to receive placebo pill will follow the same dosing schedule as the active arm. They will return to the lab on Day 9 (or Days 10, 11 if necessary) for testing and continue at that dosing schedule for eight additional days (Days 10-17) for mobile monitoring.
62419467|NCT04534127|EXPERIMENTAL|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62419468|NCT03145558|EXPERIMENTAL|Trans-Arterial Tirapazamine Embolization (TATE)|Patients will receive a fixed dose of Tirapazamine combined with embolization using Lipiodol and Gelfoam.
62589840|NCT01944917||Chronic musculoskeletal pain|Chronic musculoskeletal pain - treated with electromagnetic field Chronic musculoskeletal pain - placebo
62027380|NCT00631423||1|Patients with vena cava inferior thrombosis
62027381|NCT00631423||2|Patients with isolated lower-extremity DVT matched for gender and age
62027382|NCT05006625||Adolescents and Young Adults|Adolescents and Young Adults Seeking HIV Treatment and Prevention
62027383|NCT05006625||Service Providers|Service Providers for Adolescents and Young Adults Seeking HIV Treatment and Prevention
62027384|NCT05353335|EXPERIMENTAL|nighttime dosing of one anti-hypertensive medication|13 participants will be randomized to nighttime dosing of one anti-hypertensive medication. After 1 week, a repeat ABPM will be obtained. At 1 month from randomization, another ABPM will be obtained. Following this, there will be a 2-week washout period, during which all subjects will be on their usual anti-hypertensive regimen. A repeat ABPM will be obtained after the washout period. Next, the subjects will crossover to the opposite arm and an ABPM will be obtained after 1 week. A final ABPM will be obtained at 1 month after crossover.
62226474|NCT01248091|PLACEBO_COMPARATOR|Placebo gel|
62226475|NCT01248091|EXPERIMENTAL|Nitroprusside Gel|
62226476|NCT03392545|EXPERIMENTAL|Combined immune adjuvants and radiation|Patients with malignant gliomas will receive combined immune adjuvants (GM-CSF, TLR ligands) and radiation. The safety and efficacy will be analyzed.
62226477|NCT00833131|EXPERIMENTAL|1|25 Gy in 5 fractions of 5 Gy over 5 days. One week interval. Consolidating chemotherapy of 3 courses of FOLFOX4. Surgery 10-11 weeks from beginning of radiation and at least 4 weeks from the last dose of fluorouracil.
62226478|NCT00833131|ACTIVE_COMPARATOR|2|Conventionally fractionated chemoradiation with 50.4 Gy total dose in 28 fractions of 1.8 Gy over 5.5 weeks. Surgery 10-11 weeks from beginning of radiation and at least 4 weeks from the last dose of radiation.
62226479|NCT03344653|ACTIVE_COMPARATOR|Resolute Onyx stent|Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be randomly allocated in a 1:1 fashion to treatment with a Resolute Onyx stent or the BioFreedom stent followed by 1-month DAPT. Subjects implanted with the Resolute Onyx stent will be assessed for non-inferiority compared to those implanted with the BioFreedom stent using a composite safety endpoint of cardiac death, myocardial infarction, and definite/probable stent thrombosis, at 1 year post-procedure.
62589841|NCT03764878||Normal weight|BMI 18.5-24.9 kg/m\^2 low risk pregnancy
62801379|NCT06206460||Open Label Placebo without Treatment Rationale|
62801380|NCT04801758|EXPERIMENTAL|Analytical Treatment Interruption|Participants who received VRC01 or placebo and got HIV while enrolled in HVTN 704/HPTN 085 (NCT02716675).
62801381|NCT02483780|EXPERIMENTAL|Storytelling intervention|"Two communes will be assigned to intervention group. Within each commune, 25 adults with HTN will be enrolled.~Patients will receive 2 DVDs with stories of patients who have successfully controlled their hypertension and Learn More section, which will be coordinated with specific patient stories and will fill in gaps not covered by the storytellers."
62226480|NCT03344653|ACTIVE_COMPARATOR|BioFreedom stent|Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be randomly allocated in a 1:1 fashion to treatment with a Resolute Onyx stent or the BioFreedom stent followed by 1-month DAPT. Subjects implanted with the Resolute Onyx stent will be assessed for non-inferiority compared to those implanted with the BioFreedom stent using a composite safety endpoint of cardiac death, myocardial infarction, and definite/probable stent thrombosis, at 1 year post-procedure.
62226481|NCT03876782||IOLMaster group|IOL power for all cataract participants will be measured with IOLMaster and Verion
62226482|NCT04662541|EXPERIMENTAL|Mobile Integrated Health (MIH)|Patients with urgent medical needs are seen and treated in the home by trained community paramedics. The community paramedics perform a standardized assessment, including a physical examination, vital signs, home safety evaluation, and medication reconciliation. During the MIH encounter, the emergency medicine physician at each site is contacted via telemedicine. Physicians can access clinical notes, discharge summaries, and medication lists via the institutional EHR. Adjustments to outpatient medications can be e-prescribed and follow-up appointments can be scheduled with primary care clinicians.
62419469|NCT03145558|ACTIVE_COMPARATOR|Trans-Arterial ChemoEmbolization (TACE)|Patients will receive a mixture of doxorubicin and Lipiodol into the tumor feeding artery followed by injection of Gelfoam to induce embolization per standard procedure.
62589842|NCT03764878||Pregestational diabetes mellitus|Type 1 or Type 2 diabetes mellitus diagnosed prior to the pregnancy or in the first trimester
62589843|NCT03764878||Obese|Pre-pregnancy BMI ≥ 30.0 kg/m\^2
62801382|NCT02483780|NO_INTERVENTION|Usual care|"Two communes will be assigned to usual care group. Within each commune, 25 adults with HTN will be enrolled.~Patients will receive 2 DVDs with only didactic material about common non-communicable diseases but without hypertension related stories."
62801383|NCT00503269|ACTIVE_COMPARATOR|1|30 ml of 1% Lignocaine with 1:10,000 Adrenaline
62801384|NCT00503269|ACTIVE_COMPARATOR|2|Standard General anaesthesia with Enflurane and Propofol.
62801385|NCT04220346|EXPERIMENTAL|Tablet group|The Tablet group played the game with Tablet during the whole circumcision.
62801386|NCT04220346|NO_INTERVENTION|Control group|The control group did not play game with Tablet during the procedure.
62801387|NCT04400058|EXPERIMENTAL|Octagam 10%|Octagam 10%
62801388|NCT04400058|PLACEBO_COMPARATOR|Saline Solution|Placebo
62801389|NCT02124213|EXPERIMENTAL|Cohor 1 - 30 mg|Cohort will include approximately 4 HVs/completers who will receive a single 30 mg dose of PF-06412562.
62801390|NCT02124213|EXPERIMENTAL|Cohort 2 ( adaptive dose, optional)|Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1.
62226483|NCT04662541|ACTIVE_COMPARATOR|Transitions of care coordinator (TOCC)|Patients receive a follow-up phone calls for a nurse coordinator within 48-72 hours of hospital discharge. Phone calls include clinical/social needs assessment with escalation to primary care team, emergency care, or social work as needed; patient education; and reminder about follow-up appointments.
62226484|NCT01813331||Chronic Heart Failure Patients|Chronic Heart Failure patients older than 65 years, which accept to participate to the study and give their informed written consent and consecutively refer to the A.R.C.A Campania Cardiologists in the pertaining healthcare districts.
62226485|NCT00568802|EXPERIMENTAL|Hydroxyurea|
62226486|NCT00568802|PLACEBO_COMPARATOR|Placebo|
62226487|NCT00342875||Population Controls|Control subjects were selected randomly from state Department of Motor Vehicle and Centers for Medicare and Medicaid Services (CMS) beneficiary records.
62226488|NCT00342875||Urinary Bladder Cases|patients with histologically confirmed carcinoma of the urinary bladder
62226489|NCT03378505|EXPERIMENTAL|Mobile App|Half of the students randomly assigned
62226490|NCT03378505|EXPERIMENTAL|Reflection|Half of the students randomly assigned
62801391|NCT02124213|EXPERIMENTAL|Cohort 3 ( adaptive dose, optional)|Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.
62801392|NCT05417737||Ozone group|Patients treated with ozone as adjuvant palliative therapy. The procedure of ozone administration, dosage, frequency, and duration of ozone treatment will depend on the treated symptom and clinical evolution. Usually planned 40 sessions.
62801393|NCT06156280|EXPERIMENTAL|TQH2929 Injection (1 mg/kg)|TQH2929 Injection 1 mg/kg is administered as a single dose.
62801394|NCT06156280|EXPERIMENTAL|TQH2929 Injection (3 mg/kg)|TQH2929 Injection 3 mg/kg is administered as a single dose.
62801395|NCT06156280|EXPERIMENTAL|TQH2929 Injection (10 mg/kg)|TQH2929 Injection 10 mg/kg is administered as a single dose.
62801396|NCT06156280|EXPERIMENTAL|TQH2929 Injection (20 mg/kg)|TQH2929 Injection 20 mg/kg is administered as a single dose.
62801397|NCT06156280|EXPERIMENTAL|TQH2929 Injection (30 mg/kg)|TQH2929 Injection 30 mg/kg is administered as a single dose.
62027385|NCT05353335|ACTIVE_COMPARATOR|remain on their current regimen|13 participants will be randomized to remain on their current regimen. After 1 week, a repeat ABPM will be obtained. At 1 month from randomization, another ABPM will be obtained. Following this, there will be a 2-week washout period, during which all subjects will be on their usual anti-hypertensive regimen. A repeat ABPM will be obtained after the washout period. Next, the subjects will crossover to the opposite arm and an ABPM will be obtained after 1 week. A final ABPM will be obtained at 1 month after crossover.
62027386|NCT05688904|ACTIVE_COMPARATOR|Imipramine|Topical 4% Imipramine
62801398|NCT06156280|EXPERIMENTAL|TQH2929 Injection (40 mg/kg)|TQH2929 Injection 40 mg/kg is administered as a single dose.
62027387|NCT05688904|PLACEBO_COMPARATOR|Vehicle|Vehicle
62419470|NCT06274697|EXPERIMENTAL|Magnetic sensor|The CapMagic device is a small magnetic sensor, whose technology is derived from magnetocardiography, with a very weak field identical to that of a refrigerator magnet, which is placed on the foot or toe to record curves reflecting the state of the arterial network. It does not require direct skin contact.
62419471|NCT06565689|EXPERIMENTAL|YK012|Drug: YK012 Patients will be administered with YK012 by intravenous infusion every two weeks (Q2W, 4 weeks in a treatment cycle). Treatment will be continued until disease progression, intolerable toxicity, withdrawal of consent, patient being lost to follow-up, death or up to 6 cycles, whichever occurs first.
62801399|NCT06156280|PLACEBO_COMPARATOR|Placebo Injection|Placebo injection is administered as a single dose or multiple doses (once every two weeks).
62801400|NCT06156280|EXPERIMENTAL|TQH2929 Injection (900 mg)|TQH2929 Injection 900 mg is administered once every two weeks.
62801401|NCT06156280|EXPERIMENTAL|TQH2929 Injection (1500 mg)|TQH2929 Injection 1500 mg is administered once every two weeks.
62801402|NCT06156280|EXPERIMENTAL|TQH2929 Injection (1800 mg)|TQH2929 Injection 1800 mg is administered once every two weeks.
62801403|NCT00295542|ACTIVE_COMPARATOR|1|Treatment on awakening
62801404|NCT00295542|ACTIVE_COMPARATOR|2|Treatment at bedtime
62801405|NCT05627635|EXPERIMENTAL|Phase I (3B-FOLFOX)|Patients receive FOLFOX, bevacizumab, balstilimab, and botensilimab IV on study. Patients undergo an x-ray, CT scan, PET scan, and/or MRI throughout the trial. Patients also undergo blood sample collection during screening and on study.
62027388|NCT02590718|EXPERIMENTAL|Group 1|optimized postoperative management(lying without the pillow for half an hour after lumbar puncture)
62027389|NCT02590718|NO_INTERVENTION|Group 2|traditional postoperative management(lying without the pillow and fasting water and food for four hours after lumbar puncture)
62027390|NCT04895267|EXPERIMENTAL|Real Low-field thoracic magnetic stimulation (LF-ThMS)|Crossover, single-blind session of low field thoracic magnetic stimulation (real LF-ThMS)
62419472|NCT02296047|EXPERIMENTAL|Group A|The medication order: subjects inhaled placebo,ipratropium bromide 80μg, salbutamol 400μg in sequence.
62419473|NCT02296047|EXPERIMENTAL|Group B|The medication order: subjects inhaled placebo, salbutamol 400μg, ipratropium 80μg in sequence.
62419474|NCT03810742|EXPERIMENTAL|Nanoliposomal Irinotecan + TAS-102|different dosage combination by Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
62801406|NCT05627635|EXPERIMENTAL|Phase II, Arm I (3B-FOLFOX)|Patients receive FOLFOX, bevacizumab and balstilimab IV with botensilimab IV at a lower dose on study. Patients undergo an x-ray, CT scan, PET scan, and/or MRI throughout the trial. Patients also undergo blood sample collection during screening and on study.
62027391|NCT04895267|SHAM_COMPARATOR|Sham Low-field thoracic magnetic stimulation (LF-ThMS)|In the same patients the coils are positioned in the same coordinates for sham exposure, but the pulse generator is not turned on. Subjects are blinded for the real LF-ThMS or sham stimulation conditions.
62801407|NCT05627635|EXPERIMENTAL|Phase II, Arm II (3B-FOLFOX)|Patients receive FOLFOX, bevacizumab and balstilimab IV with botensilimab IV at a higher dose on study. Patients undergo an x-ray, CT scan, PET scan, and/or MRI throughout the trial. Patients also undergo blood sample collection during screening and on study.
62801408|NCT04862065|OTHER|Screening|Alinity s Anti-HCV and Alinity s Anti-HCV II. A follow-up visit may be needed if investigational Alinity s Anti-HCV II result is discordant after supplemental testing.
62801409|NCT02518971|EXPERIMENTAL|tamsulosin|0.4 mg daily for five days pre-op through post-op day one (seven total)
62801410|NCT02518971|PLACEBO_COMPARATOR|placebo|One capsule daily for five days pre-op through post-op day one (seven total)
62801411|NCT03997526||3C Patch treatment|Medicare beneficiaries with diabetes and hard-to-heal non-healing ulcers of the foot will receive usual care (i.e., care consistent with the IWGDF guidance on use of interventions to enhance the healing of chronic ulcers of the foot in diabetes) supplemented by the application of the 3C Patch (A platelet-rich plasma gel patch comprised of distinct fibrin, platelet, and leukocyte substantially parallel layers, prepared without the use of any added reagents through a two-step centrifugation process)
62027392|NCT00096135|EXPERIMENTAL|CNS Patients-Treatment (combination chemotherapy)|All patients receive common induction (vincristine sulfate, dexamethasone, daunorubicin hydrochloride \& intrathecal triple therapy (ITT: MTX, therapeutic hydrocortisone and cytarabine)), consolidation (cytarabine, pegaspargase, filgrastim, re-induction (vincristine, dexamethasone, daunorubicin), and intensification chemotherapy (MTX, leucovorin calcium, mercaptopurine, etoposide, cyclophosphamide \& ITT.
62027393|NCT00096135|EXPERIMENTAL|Testicular Relapse Patients (Combination chemotherapy)|All patients receive common induction (vincristine sulfate, dexamethasone, daunorubicin hydrochloride \& intrathecal triple therapy (ITT: MTX, therapeutic hydrocortisone and cytarabine)), consolidation (cytarabine, pegaspargase, filgrastim, testicular radiation therapy, re-induction (vincristine, dexamethasone, daunorubicin), and intensification chemotherapy (MTX, leucovorin calcium, mercaptopurine, etoposide, cyclophosphamide \& ITT.
62027394|NCT04464564|EXPERIMENTAL|AVP-786|Participants will be assigned to treatment with AVP-786 capsules administered twice a day over a 12-week period.
62027395|NCT04464564|PLACEBO_COMPARATOR|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
62027396|NCT01660906|EXPERIMENTAL|Dasatinib (100 mg)|
62226491|NCT05169138|PLACEBO_COMPARATOR|massage group with lavender essential oil|Pregnant women (n:37) who participated in this group were given an intense massage for at least 10 minutes in each phase during the first phase of labor. Visual Analog Pain Scale and McGill Melzack Pain Questionnaire were applied before and after the application, and the process was completed with a total of 6 measurements.
62027397|NCT02345512|OTHER|Falls|Wearing of Lycra splinting garment
62027398|NCT03919994||ABILIFY MAINTENA®|Subjects newly initiated
62226492|NCT05169138|PLACEBO_COMPARATOR|group of inhalations with lavender essential oil|Pregnant women (n:44) who participated in this group were administered inhalation with lavender oil at an intensity of at least 10 minutes in each phase during the first phase of labor. Visual Analog Pain Scale and McGill Melzack Pain Questionnaire were applied before and after the application, and the process was completed with a total of 6 measurements.
62243034|NCT02088814|EXPERIMENTAL|'EPICAP'|Secondary preventive psychological intervention with parents of children ages 1-4 with acute burn injuries, consisting of psychoeducation, trauma narrative, storybook, provision of coping skills
62243035|NCT02088814|NO_INTERVENTION|Medical treatment as usual|Medical treatment of burn injuries as usual
62801412|NCT06023940|EXPERIMENTAL|High Fiber|Subjects are provided a high-fiber diet for 2 weeks. Tests include: blood biochemistries, body composition measured via DEXA, fecal sample collection, and anthropometrics measured
62027399|NCT03919994||ARISTADA®|Subjects newly initiated
62027400|NCT03919994||INVEGA SUSTENNA®|Subjects newly initiated
62027401|NCT03919994||RISPERDAL CONSTA®|Subjects newly initiated
62027402|NCT02508311|ACTIVE_COMPARATOR|Active Oral Beta-2|Subjects will receive 16 weeks of active medication.
62027403|NCT02508311|PLACEBO_COMPARATOR|Placebo|Subjects will receive 16 weeks of placebo medication.
62027404|NCT06613347|EXPERIMENTAL|Whitening Regimen|
62027405|NCT06613347|ACTIVE_COMPARATOR|Whitening MW|
62027406|NCT06613347|PLACEBO_COMPARATOR|Negative Control|
62027407|NCT06536114|EXPERIMENTAL|Criteria-based Rehabilitation for Injured Shoulders Paradigm (CRISP).|The CRISP group will undergo physical therapy treatment, directed by a research physical therapist, including both supervised physical therapy and a guided home exercise program.
62226493|NCT05169138|NO_INTERVENTION|control group|No application was made to the pregnant women (n:40) who participated in this group in each phase of the first phase of labor. Despite this, the Visual Analog Pain Scale and McGill Melzack Pain Questionnaire, which were applied at the beginning of each phase in order to increase the reliability of the results, were re-evaluated 30 minutes after the measurements, even though there was no application, and the process was completed with a total of 6 measurements.
62226494|NCT00715260||UP Patients on HD|Uremic Pruritus (UP) patients maintained on hemodialysis (HD)
62226495|NCT02947269|EXPERIMENTAL|Intervention group|Patients will receive an oral capsule containing 2mg Prucalopride 2-3 hours preoperatively. Study medication (2mg oral Prucalopride daily) will continue for 6 days postoperatively or until the patient has achieved the study's primary outcome.
62226496|NCT02947269|PLACEBO_COMPARATOR|Placebo group|Patients will receive an oral capsule containing a placebo 2-3 hours preoperatively. Study medication (placebo) will continue for 6 days preoperatively or until the patient has achieved the study's primary outcome.
62226497|NCT01436851|EXPERIMENTAL|Storage mite and placebo nasal challenge|Provocation in the nose with an allergen extract of a storage mite (A. Siro or L. Destructor) and with placebo allergen extract (physiologic salt water)
62226498|NCT01927029|EXPERIMENTAL|Progesterone|Daily administration of vaginal progesterone, 180mg, in gel, from 18 weeks to 34 weeks.
62226499|NCT01927029|PLACEBO_COMPARATOR|Placebo|Placebo Gel, for daily use from 18 weeks to 34 weeks.
62226500|NCT01055379|EXPERIMENTAL|Rasagiline|
62226501|NCT01055379|PLACEBO_COMPARATOR|Placebo|
62226502|NCT03990181|EXPERIMENTAL|Meal & natural polyphenol supplement (NPPS)|A meal, labelled with stable iron isotope as ferrous sulphate, consumed with the natural polyphenol supplement
62226503|NCT03990181|EXPERIMENTAL|Drink & natural polyphenol supplement|A drink, labelled with stable iron isotope as ferrous sulphate, consumed with the natural polyphenol supplement
62226504|NCT03990181|PLACEBO_COMPARATOR|Meal & control supplement (CS)|A meal, labelled with stable iron isotope as ferrous sulphate, consumed with a control supplement
62419475|NCT06400329|EXPERIMENTAL|Pain neuroscience education|The educational content will be presented to the participants at a computer station in the format of a website to navigate to simulate the experience and information that they may come across while browsing the internet for information about knee OA. The content will include 4 components, regardless of the education type. These components include knee osteoarthritis (OA)-related images, facts and myths, disease related concepts, and patient-doctor statements. The distinction between the two educational approaches lies in how information is presented. PNE focuses more on the neurophysiology of pain and approaches it from the perspective that knee OA pain is manageable, using neutral to positive language and emphasizes the importance of physical function and staying active. After the educational content is delivered, the participants will be shown the content again and will be asked to talk aloud about each page that they were shown.
62801413|NCT06023940|NO_INTERVENTION|Control|Subjects are not provided any diet, instead they eat what they choose for two weeks while they participate in a series of tests including: fecal sampling, food records, questionnaires/surveys, and anthropometrics
62801414|NCT00624273|OTHER|1, active ulcers|sildenafil treatment
62226505|NCT03990181|PLACEBO_COMPARATOR|Drink & control supplement|A drink, labelled with stable iron isotope as ferrous sulphate, consumed with a control supplement
62801415|NCT00998465||Obese, hypertension|Obese patients with hypertension and a body mass index 40-50 kg/m2
62226506|NCT04844801|ACTIVE_COMPARATOR|Risk control strategy|Magnesium sulfate + control of the modifiable NOSVA risk factors
62226507|NCT04844801|ACTIVE_COMPARATOR|Rate control strategy|"Risk-control + low-dose amiodarone"
62226508|NCT04844801|ACTIVE_COMPARATOR|Rhythm control strategy|"Risk-control + high-dose amiodarone +/- electrical cardioversion"
62226509|NCT00753272|EXPERIMENTAL|FluNG Group|subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
62801416|NCT00998465||Control|Control subjects without hypertension and body mass index \< 30 kg/m2
62801417|NCT00998465||Obese, normotension|Obese patients without hypertension and a BMI between 40-50 kg/m2
62801418|NCT01740713|EXPERIMENTAL|Deferiprone, dose level 1|single dose level of 8.3 mg/kg every 8 hours for a corresponding total daily dose of 25 mg/kg/day.
62801419|NCT01740713|EXPERIMENTAL|Deferiprone, dose level 2|single dose level of 16.7 mg/kg every 8 hours for a corresponding total daily dose of 50 mg/kg/day.
62801420|NCT01740713|EXPERIMENTAL|Deferiprone, dose level 3|single dose level of 33.3 mg/kg every 8 hours for a corresponding total daily dose of 100 mg/kg/day.
62801421|NCT01802008|ACTIVE_COMPARATOR|3-minute withdrawal time|"For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist."
62801422|NCT01802008|ACTIVE_COMPARATOR|6-minute withdrawal time|"For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist."
62801423|NCT01963195|EXPERIMENTAL|Icotinib|Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicity occurred. The overall study period takes about 24 months
62419476|NCT06400329|ACTIVE_COMPARATOR|Biomedical education|"In Standard Pain Education, the emphasis is on the structural pathology of knee OA and the outdated but common understanding of the disease process as a degenerative one, potentially conveying negative and threatening language.~After the educational content is delivered, the participants will be shown the content again and will be asked to talk aloud about each page that they were shown."
62419477|NCT02437539|EXPERIMENTAL|68Ga-NOTA-AE105 PET|One injection of 68Ga-NOTA-AE105 (app. 200 MBq) followed by 3 PET/CT scans 10 minutes, 1 hour and 2 hours post injection
62226510|NCT00753272|ACTIVE_COMPARATOR|Fluarix Group|subjects received 2 doses (1 dose per season) of Fluarix™ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
62589844|NCT05248256|EXPERIMENTAL|Radiation Dose Limitations to VMAT|Patients confirmed to have T1-T3 N1-N3 (Stage IIIA-IIIC) or select Stage IV primary adeno- or squamous cell-carcinoma of the lung will be treated per standard of care; concurrent chemoradiotherapy for 6 to 6.5 weeks, followed by consolidative immunotherapy. A CT simulation scan is obtained with the patient in the treatment position allowing the radiation oncologist to delineate intended tumor targets and organs at risk (OAR). Using specialized treatment planning software, a radiation plan is generated with the goal of maximizing tumor coverage with intended prescription dose and minimizing unintended radiation dose to OARs below established thresholds. The primary intervention of this trial will be sparing the thoracic bone marrow. This will be done by delineating the thoracic bone marrow on the CT simulation scan and applying vertebral marrow-specific OAR constraints during treatment planning to optimally spare radiation dose to this structure during treatment
62589845|NCT06559865|EXPERIMENTAL|Breathing exercises|In addition to the standard rehabilitation care in the concussion clinic, the intervention group will have a daily 10-minutes paced breathing home-exercise program. The paced breathing exercise including inhale for 4-second and exhale for 6-seconds, for a total of 6 breaths per minute.
62419478|NCT05622799|EXPERIMENTAL|Mind-Body MedicineTraining|A two part (4 days for each part) mind-body medicine training program
62419479|NCT06094543|EXPERIMENTAL|Patient Engagement Tool (PET)|Participants will use the PET weekly for 12 weeks
62419480|NCT06094543|NO_INTERVENTION|Usual Care|Usual Clinic Follow up every 6 weeks for 12 weeks
62419481|NCT06654960|EXPERIMENTAL|Single arm|
62419482|NCT00728988|EXPERIMENTAL|Atorvastatin Group|
62801424|NCT02348125|EXPERIMENTAL|Mitochondrial Cocktail|"The precise content of the Mitochondrial Cocktail will be:~* ubiquinol (liquid form, 150 mg/kg subject weight/day~* carnitine, 50 mg/kg subject weight/day~* alpha-lipoic acid, 100 mg/ day"
62419483|NCT00728988|OTHER|Usual Care Group|
62419484|NCT01950195|EXPERIMENTAL|Brain|"A cohort of six (6) patients will be treated at Dosing Schedule 1. If the observed dose limiting toxicity (DLT) rate is less ≤33%, the dose cohort will be expended to a total of 15 patients. Brain and spine metastases will be evaluated as two separate cohorts.~If the first schedule produces DLTs in \>33% of patients, the Second Dosing schedule will be implemented. If the second dosing schedule produces DLTs in \>33% of patients, the Third Dosing schedule will be implemented.~After 6 patients were enrolled in a cohort, their safety and toxicity will be continuously monitored till 12 weeks (3 months) after the initial dose of Ipilimumab is given for evaluating dose-limiting toxicities."
62419485|NCT01950195|EXPERIMENTAL|Spine|"A cohort of six (6) patients will be treated at Dosing Schedule 1. If the observed dose limiting toxicity (DLT) rate is less ≤33%, the dose cohort will be expended to a total of 15 patients. Brain and spine metastases will be evaluated as two separate cohorts.~If the first schedule produces DLTs in \>33% of patients, the Second Dosing schedule will be implemented. If the second dosing schedule produces DLTs in \>33% of patients, the Third Dosing schedule will be implemented.~After 6 patients were enrolled in a cohort, their safety and toxicity will be continuously monitored till 12 weeks (3 months) after the initial dose of Ipilimumab is given for evaluating dose-limiting toxicities."
62801425|NCT01955993||Fentanyl use for surgical pain|Adolescent patient having surgery
62801426|NCT00894140|OTHER|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
62801427|NCT03530943|ACTIVE_COMPARATOR|Academic Stress Management|Students assigned to the Academic Stress Management (ASM) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks during which time they will receive 100% exposure to various evidence-based academic stress management tools.
62801428|NCT03530943|EXPERIMENTAL|Human Animal Interaction Enhanced|Students assigned to the Human Animal Interaction - Enhanced (HAI-E) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks. This group receives 50% exposure to structured and unstructured animal assisted activities and 50% exposure to various evidence-based academic stress management tools.
62226511|NCT01635400|OTHER|UGT1A1 wild type (6/6)|
62226512|NCT01635400|OTHER|UGT1A1 heterozygous genotype (6/7)|
62226513|NCT01635400|OTHER|UGT1A1 homozygous genotype(7/7)|
62226514|NCT04270201||Case group|OSCC patients (n = 60)
62226515|NCT04270201||Control group|Healthy volunteers (n = 240)
62226516|NCT01183078|OTHER|Free-hand technique|Free-hand technique utilized to find screw holes.
62419486|NCT03474640|EXPERIMENTAL|Part A|Sequential dose escalation (3+3)
62801429|NCT03530943|EXPERIMENTAL|Human Animal Interaction only|Students assigned to the Human Animal Interaction - only (HAI-O) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks. This group will be receive 100% exposure to structured and semi-structured animal assisted activities.
62589846|NCT06559865|NO_INTERVENTION|Usual care|Treatment for a concussion involves relative physical and cognitive rest for 24-48 hs, then a focus on gradually returning to normal activities and school as symptoms improve. Follow-up with healthcare professionals in the concussion clinic to ensure a safe and effective recovery and full return to school and sport. The concussion clinic follow-up includes meeting with a coordinator and physical therapist, and with a psychologist or MD if necessary
62801430|NCT00583336|EXPERIMENTAL|Diagnostic|
62419487|NCT03474640|EXPERIMENTAL|Part B|Indication specific dose cohorts: Esophageal Cancer, Gastric Cancer/GEJ, Biliary Tract Cancer, Soft Tissue Sarcoma (excluding Leiomyosarcoma) or Chondrosarcoma, Neuroendocrine Cancer, and other tumors (including Nasopharyngeal Cancer (NPC), Hepatocellular Carcinoma (HCC), MSI-H/dMMR tumors).
62801431|NCT02662972|EXPERIMENTAL|Botulinum Toxin|The patients will be injected with 25 IU of Botulinum Toxin Type A towards the sphenopalatine ganglion in the affected side (ipsilateral to the pain)
62801432|NCT02690350|EXPERIMENTAL|Cohort 1 U3-1784 2.5 mg/kg|U3-1784 (2.5 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
62801433|NCT02690350|EXPERIMENTAL|Cohort 2 U3-1784 3.75 mg/kg|U3-1784 (3.75 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
62801434|NCT02690350|EXPERIMENTAL|Cohort 3 U3-1784 5.6 mg/kg|U3-1784 (5.6 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
62801435|NCT04619615|EXPERIMENTAL|Asynchronous self-directed digital training|A digital training program platform that delivers an interactive case-based modular curriculum covering evidence-based psychotherapy principles and IPT-specific principles and strategies with homework will take roughly 13 hours to complete, with 4.5 hours of online learning, and an additional 7.5 hours of reading and homework assignments. The reading and homework includes viewing captioned videotaped role plays and completing self-directed lesson plans. The digital curriculum leverages audio, video, and visual content, and is self-directed - for completion within a 2-week period. Residents can access this content through a smartphone, tablet or computer at their own pace, revisit modules and digital content as needed, and access a curated list of additional resources to supplement their learning.
62801436|NCT04619615|ACTIVE_COMPARATOR|Synchronous large group online workshop|This condition will reflect training as usual. Training will involve the same content contained in the asynchronous self-directed digital training platform, except delivered over a one day (4.5 hours of online instruction) workshop; and residents will be required to do the same reading and homework of lesson plans and viewing of the on-line videotaped role plays (an additional \~7.5 hours in total).
62801437|NCT06073613||control group|healthy individuals, aged 18 years or older and free of chronic skin diseases, willing to participate in the study
62801438|NCT06073613||Patients with CSDs|Patients with CSDs (psoriasis, atopic dermatitis, autoimmune bullous diseases, or systemic lupus erythematosus,...) were diagnosed by the dermatologists with over 5 years of experience and supportive laboratory tests, aged 18 years or older, and willing to participate in the study
62801439|NCT04208308|NO_INTERVENTION|Control negative group|Without supplementation
62226517|NCT01183078|OTHER|Wand technique|Wand technique is utilized to find screw holes.
62226518|NCT03133754|EXPERIMENTAL|DP-PEEP|recruitment maneuver + individualized PEEP
62226519|NCT03133754|ACTIVE_COMPARATOR|RM-5|recruitment maneuver + fixed standard PEEP
62226520|NCT00437736|EXPERIMENTAL|Single arm dose escalation|
62589847|NCT06665048|EXPERIMENTAL|Oxycodone group|Administer oxycodone hydrochloride (0.1 mg/kg) intravenously half an hour before surgery.
62801440|NCT04208308|EXPERIMENTAL|Experimental negative group I|"Chia seeds supplementation (25 g)~On dose (25g) of chia seeds contains:~energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg"
62801441|NCT04208308|EXPERIMENTAL|Experimental negative group II|"Chia seeds supplementation (15 g)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
62027408|NCT06536114|ACTIVE_COMPARATOR|Standard of Care|The standard of care group will serve as the control arm and complete a period of physical rehabilitation under the supervision of a Military Health System physical therapist without study-specific guidance or interventions.
62801442|NCT04208308|EXPERIMENTAL|Experimental negative group III|"Combine supplementation: chia seeds and fish oil~Daily dose:~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
62801443|NCT04208308|EXPERIMENTAL|Experimental negative group IV|"Fish oil supplementation~Daily dose:~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
62027409|NCT06515912|EXPERIMENTAL|Low BMI|BMI 18.5 - 22 kg/m\^2 Intervention: Ketogenic diet 28 days
62226521|NCT00160043|EXPERIMENTAL|Arm 1|
62226522|NCT00160043|EXPERIMENTAL|Arm 2|
62027410|NCT06515912|ACTIVE_COMPARATOR|High BMI|BMI 30-35 kg/m\^2 Intervention: Ketogenic diet 28 days
62419488|NCT00500656|EXPERIMENTAL|Randomized controlled -Icatibant|"Subjects received S.C icatibant+ oral placebo~Icatibant Form: solution for injection, 3 mL, 10 mg/mL Single dose: 30 mg (3 mL)~Placebo Form: hard capsule Single dose: 2 capsules Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart"
62419489|NCT00500656|ACTIVE_COMPARATOR|Randomized controlled-Tranexamic acid|"Subjects received oral Tranexamic acid+ S.C. placebo~Tranexamic acid Form: over encapsulated film tablet Single dose: 1000 mg (2 capsules) Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart~Placebo Form: solution for injection, matched to icatibant for injection Single dose: 3 mL Frequency: one subcutaneous injection in the abdominal region"
62419490|NCT00500656|EXPERIMENTAL|Controlled Open-label / laryngeal attack|Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.
62027411|NCT00659633|EXPERIMENTAL|Lidocaine|Intravenous lidocaine for neuropathic pain
62027412|NCT06636552|OTHER|Single-arm|"* A consolidation phase which includes two 21-day consolidation cycles of D-CVD~* A maintenance phase which includes twenty-four 28-day cycles of daratumumab monotherapy (applicable for subjects who have achieved ≥PR at the end of consolidation phase \[Cycle 8\])"
62226523|NCT04916080|EXPERIMENTAL|after treatment|chronic kidney disease patients after receiving NAC for 3 months
62226524|NCT01411215||RA, AS|Rheumatoid arthritis patients Ankylosing spondylitis patients
62419491|NCT00500656|EXPERIMENTAL|Untreated patients at the baseline|Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing were treated in the open label phase with icatibant
62419492|NCT04350073||COVID-19 ICU Patients|COVID-10 patients with respiratory failure admitted to the ICU
62419493|NCT04350073||ICU Patients (Control)|Non-COVID-19 respiratory failure patients requiring mechanical ventilation \> 48 h receiving similar ICU standards of care at Duke
62801444|NCT04208308|NO_INTERVENTION|Control positive group|Without supplementation
62027413|NCT02393495|EXPERIMENTAL|Ultrasound guided group|the female will be asked to be full bladder. the trans-abdominal probe will be placed by an assistant on the suprapubic region. under speculum examination, the intrauterine device IUD (TCu 380A) will be placed till it reaches the fundus of the uterus and then released.
62027414|NCT02393495|EXPERIMENTAL|Non ultrasound guided group|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound.
62027415|NCT00518947|ACTIVE_COMPARATOR|1|Continued-Lithium
62027416|NCT00518947|EXPERIMENTAL|2.|Verapamil
62027417|NCT00518947|EXPERIMENTAL|3.|Verapamil plus Lithium
62027418|NCT01941862|EXPERIMENTAL|Anxiety Risk Reduction|The anxiety risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
62226525|NCT05787028|EXPERIMENTAL|AD16|The experimental group received AD16, which was a tablet with a dosage form of 10mg/tablet. Take warm water orally on an empty stomach in the morning, once a day.7 dosing cohorts will receive a single oral dose of AD16.
62226526|NCT05787028|PLACEBO_COMPARATOR|placebo|"The placebo group received AD16 placebo, which was a tablet with a dosage form of 10mg/tablet. Take warm water orally on an empty stomach in the morning, once a day.~7 dosing cohorts will receive a single oral dose of AD16 placebo."
62419494|NCT04870307|OTHER|Primary Care Practices|A practice-based implementation study will be conducted with 50 practices, with baseline data collection, and overlapping with interim measurements of care quality and process outcomes, followed by a final data collection at the end of the intervention (including baseline measures plus semi-structured interviews. The practice based approach to increasing testing will be compared to a community-based approach using mobile-setting to increase testing. Additional, non-clinical trial components of this study include patient surveys to understand facilitators and barriers to SARS-CoV-2 testing and identification of legal/ethical, socioeconomic, and behavioral implications of increased testing. Patients are not direct subjects in this part of the study. Intervention will target practices and practice members.
62419495|NCT06703346|EXPERIMENTAL|Letetresgene autoleucel|
62801445|NCT04208308|EXPERIMENTAL|Experimental positive group I|"Chia seeds supplementation (25 g)~On dose (25g) of chia seeds contains:~energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg"
62419496|NCT06586255|EXPERIMENTAL|Concurrent Immunotherapy and Radiation Therapy|Subjects will receive the standard of care procedures and follow-up for immunotherapy and radiation therapy. The part of this study that is research is receiving both of these treatments at the same time.
62419497|NCT04615286|EXPERIMENTAL|Short course|Antibiotic course of 2-3 weeks overall duration for treating pleural infection
62419498|NCT04615286|ACTIVE_COMPARATOR|Long course|Antibiotic course of 4-6 weeks overall duration for treating pleural infection
62419499|NCT01658982||cirrhotic patients|cardiopulmonary exercise testing
62419500|NCT05941299|EXPERIMENTAL|REGENERA breast implant implantation|Single monolateral breast implant
62419501|NCT02269501|EXPERIMENTAL|Exercise treatment|Exercise treatment
62419502|NCT02269501|NO_INTERVENTION|No treatment|No treatment
62226527|NCT02708719|OTHER|Pulmonary rehabilitation|multimodal pulmonary Rehabilitation program (3 weeks Duration)
62419503|NCT06699940||Adolescent Cohort|Patients in TrakStar database between the age of 12-21 who received at least one TMS treatment.
62419504|NCT03166709|ACTIVE_COMPARATOR|Treatment As Usual|Intensive Outpatient Program (IOP) addiction treatment
62419505|NCT03166709|EXPERIMENTAL|Experimental|Secondary Prevention Intervention (PARS) plus Treatment as Usual
62419506|NCT01747239|EXPERIMENTAL|Cabazitaxel|25 mg/m2 IV every three weeks
62419507|NCT03613194|OTHER|Patients with metastatic colorectal cancer|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~* Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~* Peritoneal liquid~* none tumoral peritoneum~* Portal blood~* Peripheral blood~* Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
62226528|NCT01538927|EXPERIMENTAL|Fibrin Sealant|One quadrant surgically elevated will be closed with fibrin sealant
62226529|NCT01538927|PLACEBO_COMPARATOR|Suture|The surgically elevated flap is closed with non resorbable sutures.
62226530|NCT00971243|EXPERIMENTAL|MP-513 Lowest Dose and Metformin|
62419508|NCT03425773|EXPERIMENTAL|BVAC-B|BVAC-B IV injection at 0, 4, 8, 12nd weeks.
62419509|NCT05664451|ACTIVE_COMPARATOR|Streamlined Practice Facilitation (SPF) implementation of UI-Assist|Streamlined practice facilitation encompasses multiple well-established strategies from the Expert Recommendations for Implementing Change (ERIC) as field-tested in and updated after EvidenceNOW. To ensure the interventions and tools offered are consistent across practices, practice facilitators will receive training and support on UI-Assist, milestones, tracking tools for documenting changes made by sites, etc. according to a Practice Facilitation Training Manual and toolkit that will be built based on ones used for prior EvidenceNOW initiatives.
62419510|NCT05664451|EXPERIMENTAL|Streamlined Practice Facilitation (SPF) + Partnership Building (PB) implementation of UI-Assist|In addition to streamlined practice facilitation, those practices allocated to Streamlined Practice Facilitation plus Partnership Building (SPF+PB) will have facilitation and configurable solutions that engage community resources and enable coalition building. In addition to a MetaStar practice facilitator, a partnership facilitator from the Wisconsin Institute for Healthy Aging (WIHA) will identify existing local community resources with which the practice may choose to partner.
62226531|NCT00971243|EXPERIMENTAL|MP-513 Low Dose and Metformin|
62226532|NCT00971243|EXPERIMENTAL|MP-513 Medium Dose and Metformin|
62226533|NCT00971243|EXPERIMENTAL|MP-513 High Dose and Metformin|
62226534|NCT00971243|PLACEBO_COMPARATOR|Placebo and Metformin|
62419511|NCT04192799|EXPERIMENTAL|Direct Admission|Referring providers contact the hospital to arrange for a child to be admitted directly into the pediatric hospital medicine unit.
62419512|NCT04192799|ACTIVE_COMPARATOR|ED Admission|Children initially present at the Emergency Department and are then admitted to the pediatric hospital medicine unit.
62419513|NCT05617898|EXPERIMENTAL|Motivational Interview Intervention|This arm involves three 45-minute sessions on motivational interviewing targeting sensitivity to social reward.
62419514|NCT05617898|ACTIVE_COMPARATOR|Active Control Intervention|This arm involves three 45-minute sessions on didactic training on nutrition.
62419515|NCT05648968|EXPERIMENTAL|Ianalumab low dose|Participants will receive low dose ianalumab intravenously
62419516|NCT05648968|EXPERIMENTAL|Ianalumab high dose|Participants will receive high dose ianalumab intravenously
62419517|NCT05648968|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo intravenously
62419518|NCT06347003|EXPERIMENTAL|Plozasiran Injection|4 doses of plozasiran (ARO-APOC3) by subcutaneous (sc) injection
62419519|NCT06347003|PLACEBO_COMPARATOR|Placebo|calculated volume to match active treatment by sc injection
62419520|NCT06404281|EXPERIMENTAL|γδ T-PD-1 Ab cells|Patients will receive 6 cycles of ex-vivo expanded γδ T-PD-1 Ab cells treatments,at two-weeks' intervals.γδ T-PD-1 Ab cells are transfused to patients in atypical 3+3 dose-escalation design(Dose escalation,3x10\^7/kg,1x10\^8/kg,3x10\^8/kg).
62419521|NCT05788237|EXPERIMENTAL|SSA Group 1: Combination|Combination (RSVpreF + qIRV) (Visit 1) followed by placebo (Visit 2). RSVpreF and qIRV are administered as concomitantly but as individual injections.
62419522|NCT05788237|EXPERIMENTAL|SSA Group 2: Sequential|Sequential administration of qIRV (Visit 1) followed by RSVpreF (Visit 2)
62419523|NCT05788237|EXPERIMENTAL|SSB Group 1: Combination (RSVpreF + qIRV) 1.0-mL formulation|RSVpreF lyophilized cake reconstituted with water for injection and mixed with qIRV, yielding an injection volume of 1.0 mL
62589848|NCT06665048|NO_INTERVENTION|Control group|The same routine anesthesia induction was given, and the same dose of normal saline was intravenously administered half an hour before the end of the operation to ensure that the operation conditions were the same as those of the control group except for the study drugs.
62589849|NCT05712213||pIPOM Group|Laparoscopic Incisional Hernia repair was performed with closure of fascia with non-absorbable suture (pIPOM)
62589850|NCT05712213||sIPOM Group|Laparoscopic Incisional Hernia was performed without fascia closure (sIPOM)
62735295|NCT01802580|EXPERIMENTAL|Intervention - internet reminder survey|Treatment phase is 12 months. During the intervention, each subject will receive fluocinonide 0.05% ointment, a standard treatment for psoriasis. If their psoriasis could be suitably treated with fluocinonide, then they will be asked to participate in the study. At the initial study visit, fluocinonide will be dispensed in a small jar with a MEMS® electronic monitoring cap attached. Subjects will be asked to apply the medication twice daily. They will be asked to the entire affected area, excluding face and genitals. Subjects will be instructed to apply the smallest amount of study medication sufficient to cover the affected areas. At the end of the treatment phase, subjects will have a feedback session with specific results of adherence behavior revealed. They will receive weekly surveys via internet to complete.
62226535|NCT02949466|EXPERIMENTAL|triamcinolone and hyaluronic acid group|combined triamcinolone (Triamcinolone 10 mg 1cc) and hyaluronic acid (2 cc) injections: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined triamcinolone and hyaluronic acid injections to hyaluronic acid injections
62226536|NCT02949466|ACTIVE_COMPARATOR|hyaluronic acid group|hyaluronic acid (2cc) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined triamcinolone and hyaluronic acid injections to hyaluronic acid injections
62226537|NCT02752074|EXPERIMENTAL|Pembrolizumab + Epacadostat|Pembrolizumab + Epacadostat
62226538|NCT02752074|ACTIVE_COMPARATOR|Pembrolizumab + Placebo|Pembrolizumab + Placebo
62226539|NCT00183365|EXPERIMENTAL|1|Participants will receive the Protecting Families Program with individual parent training
62226540|NCT00183365|ACTIVE_COMPARATOR|2|Participants will receive parent training alone
62226541|NCT06225011|EXPERIMENTAL|Treatment (fluoxetine)|Patients receive fluoxetine PO once QD for 10 days prior to surgery.
62226542|NCT01277367|ACTIVE_COMPARATOR|A|These members will be offered no additional incentives
62226543|NCT01277367|EXPERIMENTAL|B|These members will receive regular communications by Discovery Vitality.
62419524|NCT05788237|EXPERIMENTAL|SSB Group 2: Combination (RSVpreF +qIRV) 0.5-mL formulation|RSVpreF lyophilized cake reconstituted with qIRV to yield an injection volume of 0.5 mL
62419525|NCT06350266|NO_INTERVENTION|Control|This arm will receive no intervention outside of usual care.
62419526|NCT06350266|EXPERIMENTAL|Other Healthcare Resources|This arm will receive text messages suggesting alternatives to seeking care at a Geisinger emergency department such as seeing their Geisinger CMSL primary care provider in person or virtually (telehealth). Text suggesting these alternatives may also be included in a modified discharge paperwork packet.
62419527|NCT05125302|EXPERIMENTAL|PK Cohort: Ubrogepant Dose A|Participants aged 6 to 11 will receive oral tablets of ubrogepant for PK analysis to determine appropriate dose for main study.
62419528|NCT05125302|EXPERIMENTAL|PK Cohort: Ubrogepant Dose B|Participants aged 6 to 11 will receive oral tablets of ubrogepant for PK analysis to determine appropriate dose for main study.
62419529|NCT05125302|EXPERIMENTAL|Main Study: Children Ubrogepant Low Dose|Participants aged 6 to 11 (after dose selection) will receive oral tablets of low dose ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.
62027419|NCT01941862|EXPERIMENTAL|Mood Risk Reduction|The mood risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for perceived burdensomeness and thwarted belongingness. The psychoeducational component will focus on dispelling myths related to burdensomeness and belongingness and describe their role in the development of mood symptoms.
62027420|NCT01941862|EXPERIMENTAL|Combined Risk Reduction|The combined intervention will involve all of the interventions in the anxiety and mood risk reduction conditions and thus will not be matched for length.
62027421|NCT01941862|NO_INTERVENTION|Repeated Contact Control|"Participants assigned to the repeated contact group will be assigned a personal study coordinator. The coordinator will contact them at specific intervals during the study. The rationale for these contacts will be provided (e.g., checking in on their status and helping to administer some brief measures). During the three weeks (corresponding to treatment session intervals for those in one of the active treatment conditions), the study coordinator will contact the participant once per week for a brief phone check in where suicide risk will be evaluated. Participants in the control group will also meet with their study coordinator during each of the scheduled follow-up visits."
62027422|NCT04039113|ACTIVE_COMPARATOR|Tezepelumab|Tezepelumab, SC, Q4W
62027423|NCT04039113|PLACEBO_COMPARATOR|Matching Placebo|Matching placebo, SC, Q4W
62027424|NCT00990652|EXPERIMENTAL|Bortezomib + Temozolomide|Patients receive an injection of bortezomib 1.7mg/m\^2 on days 1, 4 and 8. Patients then undergo their standard of care surgery on day 8 or 9 to remove the tumor. Once recovered from surgery, patients receive combination treatment with temozolomide and bortezomib in periods called cycles (1 cycle = 28 days). Temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle, and bortezomib injections are given on days 7 and 21 of each cycle.
62027425|NCT04480294|EXPERIMENTAL|Part 1a Treatment group 1|Intervention: Drug1: HRS5091, dose 1; Drug2: Placebo Healthy subjects
62226544|NCT01277367|EXPERIMENTAL|C|These members will nominate a charity which will benefit financially based on participants' level of physical activity.
62226545|NCT01277367|EXPERIMENTAL|D|These members are entered into a prize draw for a monthly cash prize if they achieve physical activity targets.
62226546|NCT01277367|EXPERIMENTAL|E|These members will receive a direct payment.
62226547|NCT01277367|EXPERIMENTAL|F|These members will be offered the opportunity to choose one of three incentive options at the time of enrollment in the study.
62226548|NCT05780892|EXPERIMENTAL|Emotional Wellbeing|This arm consists of 6 30-minute group sessions taking place every 2 weeks for a total of 12 weeks. The sessions will be led by licensed therapists based on cognitive behavioral therapy and acceptance and commitment therapy. Session topics are sequential in nature such that each session builds on the previous session. Between sessions, participants will complete worksheets based on the material covered in the previous session. If a participant misses a session, they will be provided with a pre-recording with the content they missed.
62226549|NCT05780892|EXPERIMENTAL|EHR Skills Optimization|This arm consists of 6 individual educational sessions taking place every 2 weeks for a total of 12 weeks which will be scheduled to accommodate clinicians schedule and preferences. These sessions will be led by a member of the clinical informatics team and target optimization of the EHR. The sessions will be conducted on site, virtually, or a combination of both onsite and virtual. Between sessions participants are to note any challenges, questions, or recommendations related to the EHR. If participant misses 2 sessions, they will be asked to reschedule, but if they miss 3 sessions they may be asked to withdraw from the intervention.
62226550|NCT05780892|EXPERIMENTAL|Performance Improvement|This arm consists of 6 virtual group sessions taking place over every 2 weeks for a total of 12 weeks. The sessions target improving perceptions of the work environment through foundational performance improvement knowledge and skills, and they will be led by a member of the systems-reengineering team. Between sessions, participants will be asked to follow through on tasks outlined in the learning sessions and share in the next session. If a session is missed, they will be provided with a prerecording of the didactic material presented in the learning sessions.
62027426|NCT04480294|EXPERIMENTAL|Part 1a Treatment group 2|Intervention: Drug1: HRS5091, dose 2; Drug2: Placebo Healthy subjects
62027427|NCT04480294|EXPERIMENTAL|Part 1a Treatment group 3|Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo Healthy subjects
62027428|NCT04480294|EXPERIMENTAL|Part 1a Treatment group 4|Intervention: Drug1: HRS5091, dose 4; Drug2: Placebo Healthy subjects
62027429|NCT04480294|EXPERIMENTAL|Part 1a Treatment group 5|Intervention: Drug1: HRS5091, dose 5; Drug2: Placebo Healthy subjects
62027430|NCT04480294|EXPERIMENTAL|Part 1b Treatment group 3|Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo Healthy subjects Food effect
62027431|NCT04480294|EXPERIMENTAL|Part 1c Treatment group 6|Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo Healthy subjects
62226551|NCT05780892|ACTIVE_COMPARATOR|Control|Participants randomly assigned to the control condition will continue as usual care and will not complete any intervention during the duration of the study.
62226552|NCT00971932|EXPERIMENTAL|Cetuximab + Cisplatin/Carboplatin + Fluorouracil (5-FU)|
62226553|NCT01459419|EXPERIMENTAL|anti-CD3 monoclonal antibody|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up to 9 subjects will be treated at each dosage level
62226554|NCT01459419|PLACEBO_COMPARATOR|Sodium chloride|Up to 9 subjects will receive placebo. Subjects will receive the drug in a similar manner as as the treatment group
62226555|NCT05620368|EXPERIMENTAL|Mindfulness-based teleintervention|8-week Mindfulness and Compassionate Living Course (MCLC). The course will be held online (using the Zoom platform) with weekly sessions lasting 2.5 hours each, as well as a day of silent practice (mini-retreat of 4 hours).
62801446|NCT04208308|EXPERIMENTAL|Experimental positive group II|"Chia seeds supplementation (15 g)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
62226556|NCT05620368|ACTIVE_COMPARATOR|Usual care intervention|The facility provides psychological support for parents as needed and at the request of the parent. Support includes individual support of a psychologist (1h / week), consultation with a teacher (special pedagogue and early school education teacher, 1h / week), individual consultation with observation of a child with a Venetian mirror (1h / week).
62226557|NCT05788393|EXPERIMENTAL|Dexmedetomidine group|This group will receive continuous intraoperative dexmedetomidine IV infusion \[1ug/kg dexmedetomidine over 15 min as a loading dose and 0.5ug/kg/h for maintenance\].
62419530|NCT05125302|EXPERIMENTAL|Main Study: Children Ubrogepant High Dose|Participants aged 6 to 11 (after dose selection) will receive oral tablets of high dose ubrogepant Dose B for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.
62419531|NCT05125302|PLACEBO_COMPARATOR|Main Study: Children Ubrogepant Placebo|Participants aged 6 to 11 (after dose selection) will receive oral tablets of placebo-matching ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of placebo-matching ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.
62419532|NCT05125302|EXPERIMENTAL|Main Study: Adolescents Ubrogepant Low Dose|Participants aged 12 to 17 will receive oral tablets of ubrogepant low dose for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.
62419533|NCT05125302|EXPERIMENTAL|Main Study: Adolescents Ubrogepant High Dose|Participants aged 12 to 17 will receive oral tablets of ubrogepant high dose or qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.
62419534|NCT05125302|PLACEBO_COMPARATOR|Main Study: Adolescents Ubrogepant Placebo|Participants aged 12 to 17 will receive oral tablets of placebo-matching ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of placebo-matching ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.
62419535|NCT05199545|EXPERIMENTAL|Dietary supplement group|2 tablets / day for 6 weeks of the dietary supplement (Rhodiola rosea L. and Crocus sativus L.), to be taken every day in the morning with a large glass of water, from D1 to D42.
62419536|NCT05199545|PLACEBO_COMPARATOR|Placebo group|2 tablets / day for 6 weeks of the placebo, to be taken every day in the morning with a large glass of water, from D1 to D42.
62419537|NCT05747261|EXPERIMENTAL|Cohort 1|Subjects in Cohort 1 will receive ANB-004 at a dose 1. Depending on the DLT, the cohort may include 1 to 6 subjects in the first stage and 9 to 12 in the second stage.
62801447|NCT04208308|EXPERIMENTAL|Experimental positive group III|"Combine supplementation: chia seeds and fish oil~Daily dose:~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
62226558|NCT05788393|EXPERIMENTAL|Lidocaine group|This group will receive continuous intraoperative lidocaine IV infusion \[1.5 mg/kg lidocaine over 15 min as a loading dose and 1.5 mg/kg/h for maintenance\].
62226559|NCT05821439||Premenstrual period|For the premenstrual period evaluation, the participants' 10 days before menstruation will be taken as a reference.
62226560|NCT05821439||Menstrual period|For the evaluation of the menstrual period, the first 3 days when symptoms are seen more will be taken as a reference.
62243036|NCT06093815|EXPERIMENTAL|Arm 1|Subjects in Arm 1 will receive injections of biostimulatory products (Radiesse, Sculptra, Ellanse, HArmonyCa) at 3 timepoints (six months, three months and two weeks) prior to removal of redundant abdominal tissue.
62419538|NCT05747261|EXPERIMENTAL|Cohort 2|Subjects in Cohort 2 will receive ANB-004 at a dose 2. The dose for Cohort 2 will be determined at the IDMC meeting. Depending on the DLT, the cohort may include 1 to 6 subjects in the first stage and 9 to 12 in the second stage.
62419539|NCT05747261|EXPERIMENTAL|Cohort 3|Subjects of Cohort 3, if included, will receive the drug at a dose 3. The dose for Cohort 3 will be determined at the IDMC meeting. Depending on the DLT, the cohort may include 1 to 6 subjects in the first stage and 9 to 12 in the second stage.
62226561|NCT06161168|EXPERIMENTAL|Baseline Phase (10 or 21 days)|In this study, participants will be randomly allocated to a baseline (A) phase that is further divided into two sub-phases, with different durations of either 10 or 21 days. The allocation to different durations of the baseline phase is randomized in order to mitigate threats to internal validity. During the baseline (A) phase, a representative baseline will be established through repeated measurements of the PQRS. Following the baseline phase (A), the 8-week intervention phase (B) is implemented, followed by a second 3-week (A) phase. There is no separate control group in this study, and all participants receive the same intervention during the intervention phase (B).
62419540|NCT06540924||Study group|Being diagnosed with Adolescent Idiopathic Scoliosis (AIS) between the ages of 10 and 18 group. Having a Cobb angle of 10 degrees or greater on a plain radiograph. Not having any known genetic disorders. Not having any diseases known to play a role in the etiology of scoliosis (degenerative, neuromuscular, congenital scoliosis, etc., are excluded).
62419541|NCT06540924||Control group|Healthy individuals between the ages of 10-18 who do not have scoliosis by physical examination and/or imaging.
62801448|NCT04208308|EXPERIMENTAL|Experimental positive group IV|"Fish oil supplementation~Daily dose:~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
62226562|NCT01213160|EXPERIMENTAL|AZD4547|
62226563|NCT02866539|ACTIVE_COMPARATOR|Polyherbal capsule|Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.
62226564|NCT02866539|PLACEBO_COMPARATOR|Placebo|Placebo will contain an inert substance
62226565|NCT01856556|EXPERIMENTAL|NRX-1074, 1 mg|1 mg IV
62801449|NCT03291483|EXPERIMENTAL|whole body vibration group|basketball players had done exercises on whole body vibration platform.
62801450|NCT03291483|SHAM_COMPARATOR|plyometric training|Basketball players had done same plyometric exercises
62226566|NCT01856556|PLACEBO_COMPARATOR|Placebo|Saline
62226567|NCT01856556|EXPERIMENTAL|NRX-1074, 5 mg|5 mg IV
62226568|NCT01856556|EXPERIMENTAL|NRX-1074, 10 mg IV|10 mg
62226569|NCT01856556|EXPERIMENTAL|NRX-1074, 50 mg IV|50 mg
62226570|NCT01856556|EXPERIMENTAL|NRX-1074, 25 mg PO|25 mg
62226571|NCT01856556|EXPERIMENTAL|NRX-1074, 125 mg PO|125 mg
62226572|NCT03738345|EXPERIMENTAL|Oxygenation on hypoxemia patients|Adult patients with hypoxemia will be recruited, their own breathing profiles (inspiratory flow, respiratory rates and tidal volume) will be measured. Then patients will be placed on high flow nasal cannula (HFNC), HFNC flow will be titrated based on the hospital's policy or protocol and patient's comfort, patient's clinical effects on oxygenation will be monitored and recorded during the titration process.
62226573|NCT03738345|EXPERIMENTAL|Lung expansion on healthy volunteer|Adult healthy volunteers will be recruited, their own breathing profiles (inspiratory flow, respiratory rates and tidal volume) will be measured. Then they will be placed on HFNC, HFNC flow will be increased sequentially by research protocol and their comfort, subjects' lung expansion effects in different flow will be quantified by Electrical impedance tomography (EIT), a noninvasive assessment tool. Their comfort will also be assessed using a visual scale.
62419542|NCT06701292|EXPERIMENTAL|PVS-PVI|
62419543|NCT06701292|ACTIVE_COMPARATOR|WACA|
62419544|NCT06061601|EXPERIMENTAL|Exoskeleton Stroke group|This group will receive gait rehabilitation with the exoskeleton for 20 sessions in clinic.
62419545|NCT06061601|NO_INTERVENTION|Healthy control group|The quantitative data, including EMG and 3D kinematics, from 10 healthy controls walking with the exoskeleton will serve as comparative data for the experimental group.
62801451|NCT02738749|OTHER|ICD group|Adult patients with newly implanted ICD devices for primary prevention will be enrolled. At baseline, 3-, 6-, 9-, and 12-month followup visit, the medial information and blood samples will be collected.
62801452|NCT05561023|OTHER|Phase Ⅰ a clinical study|"3 + 3 dose escalation scheme"
62801453|NCT02781675|EXPERIMENTAL|Western Diet|Dietary Intervention: 3 wks of a typical Western Diet
62801454|NCT02781675|EXPERIMENTAL|Mediterranean Diet|Dietary Intervention: 3 wks of a Mediterranean-style diet
62243037|NCT06093815|EXPERIMENTAL|Arm 2|Subjects in Arm 2 will receive injections of 1 of 2 selected biostimulatory products (Radiesse or Sculptra) at 1 timepoint (6 months) prior to removal of redundant abdominal tissue.
62801455|NCT02781675|EXPERIMENTAL|Modified Mediterranean Diet|Dietary Intervention: 3 wks of a Mediterranean-style diet including full fat dairy products
62589851|NCT06562634|EXPERIMENTAL|Ultrasound-Guided Erector Spinae Plane Block|The patient will be placed in a prone position. A convex-array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process .The tip of the transverse process is centered on the ultrasound screen and the probe is then rotated into a longitudinal orientation 2-3 cm lateral to vertebral column, in which the following layers will be visible superficial to the acoustic shadows of the transverse processes: skin, subcutaneous tissue, erector spinae muscle and psoas muscle. The lumbar skin region will be sterilized, local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the L4 transverse process. A total of 20ml bupivicaine 0.25%, and 20 ml xylocaine 1% will be injected into the ESP on the affected side.
62589852|NCT06562634|EXPERIMENTAL|Morphine|intravenous morphine will be given in a dose of 0.1-0.2mg/kg to maintain intraoperative analgesia.
62589853|NCT05130710||case|26 patients with gastric cancer wo were referred to our center between February 25th to December 25th of 2020.
62589854|NCT05130710||control|54 patients with gastric cancer wo were referred to our center between February 25th to December 25th of 2019.
62589855|NCT03981900||Rheumatoid arthritis|All participants with a diagnosis of moderate to severe active rheumatoid arthritis and treated with Tofacitinib
62589856|NCT00519428|EXPERIMENTAL|escitalopram + bupropion|escitalopram plus bupropion extra long (XL) as dual treatment (i.e., this is not a SINGLE treatment arm; all patients assigned this arm received both medications)
62589857|NCT00519428|ACTIVE_COMPARATOR|escitalopram|escitalopram monotherapy
62589858|NCT00519428|ACTIVE_COMPARATOR|bupropion|bupropion extra long (XL) monotherapy
62589859|NCT05484856|EXPERIMENTAL|Experimental|Patients with Osteoarthritis A total of 140 patients ( May 2016 to june 2020) were treated with intra articular adipose derived stromal cells (ADSC)) also known as Stromal vascualr fraction administration
62589860|NCT02796066|PLACEBO_COMPARATOR|Vehicle|Vehicle gel
62589861|NCT02796066|EXPERIMENTAL|Low Dose Active|Low Dose of TSN2898
62589862|NCT02796066|EXPERIMENTAL|Mid Dose Active|Mid Dose of TSN2898
62801456|NCT03276429||Lung Cancer patients|All patients with lung cancer that referred to a tertiary Oncology Unit.
62226574|NCT04043689|ACTIVE_COMPARATOR|tACS stimulation of the right frontal region|Active tACS stimulation of the right frontal region (around the right FEF, EEG electrode FC2) at a high-beta frequency (30 Hz) with the goal of visibly training EEG recordings, frontal oscillatory activity and right fronto-parietal synchrony (FEF-IPS, or between FC2 and P4 electrodes) in the high-beta band (\~ 30 Hz) which facilitates attentional orientation and visual perception in the two visual hemi-fields, but more particularly the targets present on the blind field of vision.
62226575|NCT04043689|ACTIVE_COMPARATOR|tACS stimulation of the occipito-parietal region|Active tACS stimulation of the occipito-parietal posterior contralesional region(around the right IPS, EEG electrode P4), at an alpha frequency (10 Hz) which will induce on the EEG recordings an oscillatory drive in the alpha band ( \~ 10Hz) and an increase in synchrony at this frequency band on the stimulated posterior occipital and parietal lobe (EEG electrodes P4 and 02), but also, by transcallosal push-and-pull phenomena, a desynchronization effect of the contralateral posterior occipital and parietal area (EEG electrodes P3 and 01), which will facilitate attention orientation and target detection in the blind visual field of view.
62226576|NCT04043689|SHAM_COMPARATOR|TACS stimulation of the right frontal (FEF)|. Condition TACS stimulation of the right frontal (FEF) at a high-beta frequency (30 Hz) for half of the patients and unilateral occipital cortex (right / left) at an alfa frequency (10 Hz) for the other half . This condition will control the possible placebo effects of tACS stimulation and the potential effects of visual field enhancement with repetition of perimetry tests. This condition will also verify the lack of changes in cerebral rhythm activity in the case of an application without effective electrical current.
62226577|NCT01589237|EXPERIMENTAL|LCQ908|Patients initiated at 10 mg/day. After at least 8 weeks of treatment with a dose, optional up-titration to the next possible dose will be allowed. One down titration allowed from the highest dose attained.
62226578|NCT02838771|EXPERIMENTAL|Research group participants|"Research group consisted of 171 elderly nursing home residents and 82 outpatients of the Hospital of Lithuanian University of Health Sciences.~The participants were given the dysphagia screening questionnaire, consisted of 16 questions and the several sips of water to drink (clinical water drinking test for dysphagia screening)."
62589863|NCT02796066|EXPERIMENTAL|High Dose Active|High Dose of TSN2898
62589864|NCT04946084|OTHER|Healthy Children|Samples taken from nasal swabs, nasal wash, blood draws and in the case of acute otitis media, tympanocentesis
62589865|NCT04857814|EXPERIMENTAL|Device|All participants will wear the device to assist in determining the feasibility of wearing the device.
62589866|NCT01482143|EXPERIMENTAL|All Study subjects|
62801457|NCT05077930|EXPERIMENTAL|Convalescent Plasma|The investigational product is anti-SARS-CoV-2 convalescent plasma obtained from former patients identified as having recovered from COVID-19 and obtained by Centro de Hematologia e Hemoterapia do Paraná - Hemepar following national blood donation guidelines and Brazilian Health Regulatory Agency (ANVISA) criteria. Potential donors will be screened using an anti-SARS-CoV-2 serologic assay and antibody levels will be determined. Participants will receive the standard of care treatment and a single unit of convalescent plasma (volume=200 mL or 400 mL).
62589867|NCT06308029|EXPERIMENTAL|eHealth self-management support program|This web-based eHealth program consists of two parts. First participants will complete a pain science education program. After being primed in the educational program, barriers for a physically active lifestyle should be removed and participants should be able to apply the learned information in the second part. The second part of the self-management support program consists of daily activity planning and strategies to promote an active lifestyle.
62801458|NCT05077930|ACTIVE_COMPARATOR|Standard of care|Standard of care treatment according to the institutional protocol.
62801459|NCT05983471|EXPERIMENTAL|Treatment Arm 1|2 weeks of blinded active treatment, followed by 2 weeks of blinded placebo treatment (wash-out), followed by 2 weeks of blinded placebo treatment, followed by 1 week of follow-up with neither active nor placebo treatment
62801460|NCT05983471|EXPERIMENTAL|Treatment Arm 2|2 weeks of blinded placebo treatment, followed by 2 weeks of blinded placebo treatment (wash-out), followed by 2 weeks of blinded active treatment, followed by 1 week of follow-up with neither active nor placebo treatment
62226579|NCT02838771|OTHER|Control group participants|Community-dwelling elderly healthy individuals. The participants were given the dysphagia screening questionnaire, consisted of 16 questions and the several sips of water to drink (clinical water drinking test for dysphagia screening).
62226580|NCT01513980|NO_INTERVENTION|Control group|Treatment as usual
62226581|NCT01513980|EXPERIMENTAL|Self monitoring for patients with COPD|Procedure: self-monitoring for patients with severe COPD
62226582|NCT01513980|EXPERIMENTAL|Nurse monitoring for patients with COPD|Procedure: nurse-monitoring for patients with severe COPD
62226583|NCT00770341|EXPERIMENTAL|MK-3009 (daptomycin) 4 mg/kg|
62226584|NCT00770341|ACTIVE_COMPARATOR|Vancomycin|
62226585|NCT00770341|EXPERIMENTAL|MK-3009 (daptomycin) 6 mg/kg|
62243038|NCT00516620|ACTIVE_COMPARATOR|1|Participants receive Health Canada's Food Guide and Physical Activity guide.
62027432|NCT04480294|EXPERIMENTAL|Part 2 Treatment group 7|Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo CHB subjects
62419546|NCT06558630||Patient in need of airway management.|All patients who undergo airway management in de ED. In this study, airway management is defined as the process of planning, preparation and execution of endotracheal intubation. While the term airway management can also be used for techniques such as placing an oropharyngeal tube, patients are only included if endotracheal intubation is attempted.
62801461|NCT03955614|EXPERIMENTAL|St Marys Hospital|25 cases will be observed before the intervention and then 25 cases will be observed with the intervention
62027433|NCT04480294|EXPERIMENTAL|Part 2 Treatment group 8|Intervention: Drug1: HRS5091, dose 4; Drug2: Placebo CHB subjects
62027434|NCT04480294|EXPERIMENTAL|Part 2 Treatment group 9|Intervention: Drug1: HRS5091, dose 5; Drug2: Placebo CHB subjects
62027435|NCT06438861|ACTIVE_COMPARATOR|100U intradetrusor onabotulinumtoxinA plus vibegron|Each patient will undergo intradetrusor onabotulinumtoxinA injections of 100U either in the office or in the operating room depending on patient and provider preference. Patients randomized to this arm will begin taking vibegron 75mg daily, which is the standard dose, starting the day of their procedure and continue for 3 months.
62027436|NCT06438861|PLACEBO_COMPARATOR|100U intradetrusor onabotulinumtoxinA plus placebo|Each patient will undergo intradetrusor onabotulinumtoxinA injections of 100U either in the office or in the operating room depending on patient and provider preference. Patients randomized to this arm will begin taking a placebo pill daily starting the day of their procedure and continue for 3 months.
62027437|NCT02777593|OTHER|Zone 2 Aneurysm|Includes primary (hypothesis-driven) aneurysm cohort and continued access. Subjects enrolled for treatment with the TBE device with proximal implantation in aortic Zone 2.
62027438|NCT02777593|OTHER|Zone 2 Non-aneurysm|Includes dissection, traumatic transection and other isolated aortic lesion cohorts. Subjects enrolled for treatment with the TBE device with proximal implantation in aortic Zone 2.
62027439|NCT06065072||Normal|
62027440|NCT06065072||Cataract|
62027441|NCT06065072||Special eye|
62027442|NCT02221206|ACTIVE_COMPARATOR|Treatment|mini-screw implant anchorage-assisted retraction of maxillary incisors
62801462|NCT03955614|EXPERIMENTAL|University College Hospital|25 cases will be observed before the intervention and then 25 cases will be observed with the intervention
62801463|NCT03955614|EXPERIMENTAL|Chelsea and Westminster Hospital|25 cases will be observed before the intervention and then 25 cases will be observed with the intervention
62801464|NCT00086047|EXPERIMENTAL|Coping Skills|Patients will receive 8 weeks of behavioral training in pain coping strategies
62801465|NCT00086047|ACTIVE_COMPARATOR|Education|Patient will receive 8 weekly sessions of education about fibromyalgia syndrome.
62801466|NCT06725771|EXPERIMENTAL|Bupleurum Plus Dragon Bone and Oyster Shell Decoction with sertraline|observation group
62801467|NCT06725771|ACTIVE_COMPARATOR|Sertraline|Control group
62027443|NCT02221206|NO_INTERVENTION|Control|regular maximum anchorage
62027444|NCT05481762||Asymptomatic adult patients|
62027445|NCT01930773|EXPERIMENTAL|Genotyping Arm|Rapid genotyping to select optimal P2Y12-inhibitor for PCI.
62027446|NCT01930773|EXPERIMENTAL|Phenotying Arm|The use of platelet function testing to select the optimal P2Y12-inhibitor for PCI.
62027447|NCT01930773|NO_INTERVENTION|Conventional Arm|Regular approach for performing elective PCI.
62027448|NCT02182193|EXPERIMENTAL|BIBF 1120 capsules charge 1|
62027449|NCT02182193|EXPERIMENTAL|BIBF 1120 capsules charge 2|
62027450|NCT02182193|ACTIVE_COMPARATOR|BIBF 1120 drinking solution|
62027451|NCT02980367|EXPERIMENTAL|ACL Rehabilitation Group|Non-surgical management \[Rehabilitation\] with option for later Anterior Cruciate Ligament (ACL) reconstruction, only if required.
62801468|NCT05628142|OTHER|CATAMARAN SI Joint Fusion System|Subjects previously treated with the CATAMARAN Fixation Device
62027452|NCT02980367|ACTIVE_COMPARATOR|ACL Reconstruction Group|Surgical Management - Anterior Cruciate Ligament (ACL) reconstruction surgery
62226586|NCT05077657||Single-Arm|This is a multi-center, single arm, open-label study to evaluate the safety of complex high-risk PCI using Impella and surveillance with the Saranas Early Bird Bleed Monitoring System (EBBMS).
62419547|NCT06702046|EXPERIMENTAL|TCPRF acupuncture group|we choose ST34 (Liangqiu), SP10 (Xuehai), GB34 (Yanglingquan), SP9 (Yinlingquan) around the affected knee. The TCPRF device is a wearable modality with innovative pulse radiofrequency technology aimed at alleviating symptomatic chronic pain, which revealed that UHF (500-kHz sine wave, 2-Hz frequency with a 25-ms pulse). It was attached to the electrode pad through magnetic attraction. A 500-KHz stimulus was delivered. The symmetric two-phase sine wave has a 2-Hz frequency witha 25-ms pulse width. The treatment has 15 min per time. treatment is administered for 30 minutes each session, divided into two 15-minute phases. After the first 15 minutes, the treatment is paused and then restarted for an additional 15 minutes. The output peak current was 13.2 mA and the output peak voltage was 6.6 V at 500 Ω.
62419548|NCT06702046|SHAM_COMPARATOR|Sham group|same protocol will be done on the same acupoints, but the machine will be turn off interiorly. Therefore, although the machine still has lights and a vibrating sensation, it will not release PRF waves.
62419549|NCT01146886|EXPERIMENTAL|BI 135585|1 single dose per subject as oral solution in Part 1, or 3 single doses per subject as oral solution and 2 different tablet formulations in Part 2
62419550|NCT01146886|PLACEBO_COMPARATOR|Placebo to BI 135585|1 single dose per subject as oral solution in Part 1
62801469|NCT03240887|EXPERIMENTAL|Peer Group Connection (PGC)|Ninth-grade participants are assigned to small groups of 10-14 students that attend weekly peer group outreach sessions led by older peer leaders.
62801470|NCT03240887|NO_INTERVENTION|Business as usual|Ninth grade students remain in their regularly scheduled school classes or activities during PGC outreach times.
62801471|NCT03067428|ACTIVE_COMPARATOR|Glucose|Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as glucose powder.
62419551|NCT05192954|EXPERIMENTAL|Vessel sealing device|Vessel sealing device to be utilized for vaginal hysterectomy
62027453|NCT02415400|ACTIVE_COMPARATOR|Apixaban|5 mg or 2.5 mg Apixaban tablets orally twice per day
62027454|NCT02415400|ACTIVE_COMPARATOR|Vitamin K Antagonist|VKA tablets orally once daily
62419552|NCT05192954|NO_INTERVENTION|Conventional clamping and suturing method|Vaginal hysterectomy will be performed utilizing conventional Heaney clamps, scissors, and suturing material.
62801472|NCT03067428|PLACEBO_COMPARATOR|Fructose|Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as fructose powder.
62027455|NCT02415400|PLACEBO_COMPARATOR|Acetylsalicylic acid film coated tablet|81 mg Acetylsalicylic acid film coated tablet orally once daily
62027456|NCT02415400|PLACEBO_COMPARATOR|Placebo matching Acetylsalicylic acid film coated tablet|Placebo matching Acetylsalicylic acid film coated tablet once daily
62226587|NCT04719325|EXPERIMENTAL|Herbert screw|
62226588|NCT04719325|ACTIVE_COMPARATOR|Lag screw|
62226589|NCT06067568|EXPERIMENTAL|Part 1, Dose A|Participants will receive a single dose of Lutikizumab Dose A.
62801473|NCT06375070||small-shunt Group|small (3-9 bubbles)
62801474|NCT06375070||moderate-shunt Group|(10-30 bubbles)
62801475|NCT06375070||large-shunt Group|\>30 bubbles
62801476|NCT01051687|NO_INTERVENTION|control skin patches|no intervention will be given to the patches
62801477|NCT01051687|ACTIVE_COMPARATOR|botulinum toxin A|Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.
62027457|NCT02951325|NO_INTERVENTION|Standard|"Surgery +/- chemotherapy only~* Surgery (Standard/routine care) Cysto-prostatectomy and pelvic nodal dissection as part of their standard care.~* Chemotherapy All patients following cysto-prostatectomy (inclusive of those received neo-adjuvant chemotherapy) will receive upto 4 cycles of adjuvant chemotherapy if medically fit for the same. The chemotherapy regimen, doses and schedule will be as per standard institutional practice. No concomitant chemotherapy with radiotherapy is recommended.~No radiation therapy will be given."
62226590|NCT06067568|EXPERIMENTAL|Part 1, Dose B|Participants will receive a single dose of Lutikizumab Dose B.
62226591|NCT06067568|EXPERIMENTAL|Part 2|Han Chinese participants will receive a single dose of Lutikizumab.
62226592|NCT01548560|EXPERIMENTAL|Dapivirine Vaginal Gel|Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
62801478|NCT01174771||PSP patients|People that have been clinically diagnosed with atypical parkinsonism, i.e., PSP
62801479|NCT01174771||CBD patients|People that have been clinically diagnosed with atypical parkinsonism, i.e., CBD
62419553|NCT00759759|OTHER|1|Treatment A (test product) followed by Treatment B (reference product)
62027458|NCT02951325|EXPERIMENTAL|Test|"Surgery +/- chemotherapy as per standard arm and Radiation therapy as experimental intervention~Radiation Therapy:~All patients will be treated with conformal radiotherapy technique with intensity modulated radiotherapy with or without image guidance. The radiotherapy will start within 8 weeks from the date of surgery if adjuvant chemotherapy has not been planned. The radiotherapy will start within 4 weeks from the date of last chemo cycle, in patients who will be given adjuvant chemotherapy.~Dose Prescription:~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) will be prescribed for the nodal PTV. In case of R1 and/or R2 resection dose to the pelvic nodes and tumour bed may be increased to 54-56 Gy in 28 fractions depending on the constraints achieved during planning.~Patient assessments: Clinical assessment for toxicity evaluation and disease status. QOL evaluation of the patients."
62027459|NCT01458574|PLACEBO_COMPARATOR|Placebo Comparator|
62419554|NCT00759759|OTHER|2|Treatment B (reference product) followed by Treatment A (test product)
62027460|NCT01458574|EXPERIMENTAL|CP-690,550 5 mg Arm|
62027461|NCT01458574|EXPERIMENTAL|CP-690,550 10 mg Arm|
62226593|NCT01548560|PLACEBO_COMPARATOR|Placebo Gel|Dosage form: vaginal gel Dosage: N/A Frequency: 7 daily doses
62226594|NCT01548560|EXPERIMENTAL|Dapvirine Vaginal Film|Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
62419555|NCT05421715|EXPERIMENTAL|ALL ADOLESCENTS|For all adolescents, the proposed treatment consists, in addition to conventional care,an individual digital care and education(TELEDUC-DIAB)for 6 months using digital devices (myDiabby + Kidia).
62589868|NCT06308029|ACTIVE_COMPARATOR|Face-to-face rehabilitation program|The face-to-face rehabilitation program combines pain science education with an active behavioral approach. First, 2-3 individual face-to-face sessions are organized with a physical therapist (recruited and trained by the research team) to provide pain science education. The content of this pain science education program is the same as for the eHealth program. Similar as in the eHealth program, this education intervention includes advice for activity management, while experiencing pain and other symptoms, in order to remove barriers for an active lifestyle. The educational information will be presented verbally (explanation by the therapist) and written (information leaflet, summaries, pictures, metaphors and diagrams on computer and paper). After the education, the physical therapist will discuss proper goal setting with the patient to reach an active lifestyle and will coach the participant to reach these goals with maximum 6 face-to-face sessions.
62589869|NCT06308029|NO_INTERVENTION|Usual care group|Usual care for breast cancer survivors with persistent pain consists of primarily a pharmacological approach and general advice to stay or become active. This information is given to the participant by means of a brochure.
62589870|NCT06180369|OTHER|GC Fuji Triage ® GC America Inc., Alsip, Illinois )|Fissure sealant application with GC Fuji Triage (GC America Inc., Alsip, Illinois )
62801480|NCT01174771||Age-matched healthy controls|People that have not been diagnosed with any kind of neurologic movement disorder.
62801481|NCT00531258|ACTIVE_COMPARATOR|1|
62801482|NCT00531258|PLACEBO_COMPARATOR|2|
62801483|NCT02225093|EXPERIMENTAL|1:Caffeine, Dextromethorphan and Enzalutamide|1-sequence crossover here
62801484|NCT02601404||Bioresorbable Scaffold|Patients receiving percutaneous coronary intervention (PCI) for coronary artery disease using Absorb™(Abbott Vascular)
62801485|NCT03633851|EXPERIMENTAL|Toric intraocular MX60T lens|one eye will receive toric MX60T lens
62801486|NCT03633851|OTHER|Standard MX60 plus corneal incisions|the other eye will receive standard MX60 lens with corneal incisions
62801487|NCT00836589||Data Collection Group|
62801488|NCT05336786|EXPERIMENTAL|Diagnostic (perflutren lipid microspheres, ultrasound)|Patients receive perflutren lipid microspheres IV over 5-6 minutes and undergo ultrasound over 30 minutes. Patients may receive up to 2 additional doses of perflutren lipid microspheres
62027462|NCT01093352|NO_INTERVENTION|Standard|Standard expose and bond.
62226595|NCT01548560|PLACEBO_COMPARATOR|Vaginal Film|Dosage form: vaginal film Dosage: N/A Frequency: 7 daily doses
62226596|NCT00888004|EXPERIMENTAL|Active|
62419556|NCT04886232|EXPERIMENTAL|VP1 Lido US - NC|Injection to the left cheek via needle and to the right cheek via canula
62801489|NCT05402670||Dermatomyositis group|patient with dermatomyositis
62419557|NCT04886232|EXPERIMENTAL|VP1 Lido US - CN|Injection to the left cheek via canula and to the right cheek via needle
62419558|NCT04886232|ACTIVE_COMPARATOR|Restylane Lyft Lidocaine - NC|Injection to the left cheek via needle and to the right cheek via canula
62419559|NCT04886232|ACTIVE_COMPARATOR|Restylane Lyft Lidocaine - CN|Injection to the left cheek via canula and to the right cheek via needle
62419560|NCT06702995|EXPERIMENTAL|Phase Ib|Participants with mCRPC will receive XNW5004 at escalating dose levels in combination with enzalutamide.
62801490|NCT05402670||control group|health check-up population
62801491|NCT06089278|EXPERIMENTAL|300mg of TQH2722 injection|TQH2722 injection, 14 days as a treatment cycle.
62801492|NCT06089278|EXPERIMENTAL|600mg of TQH2722 injection|TQH2722 injection, 14 days as a treatment cycle.
62801493|NCT06089278|PLACEBO_COMPARATOR|TQH2722 injection matching placebo|TQH2722 injection matching placebo, 14 days as a treatment cycle.
62801494|NCT04540965|EXPERIMENTAL|Telaglenastat and Famotidine|Famotidine
62801495|NCT04540965|PLACEBO_COMPARATOR|Telaglenastat and Placebo for Famotidine|Placebo for famotidine
62226597|NCT00888004|PLACEBO_COMPARATOR|Placebo|
62226598|NCT05202548||Lymphadenitis TB|The group study was blocked paraffin from lymphadenitis tuberculosis patient that already confirmed diagnosis histopathological anatomy (PA histopathology)
62419561|NCT06702995|EXPERIMENTAL|Phase IIa|Participants with mCRPC will receive XNW5004 in combination with enzalutamide.
62801496|NCT01683708||Symbiotic group|Jaundiced patients who have symbiotic therapy
62419562|NCT06702995|EXPERIMENTAL|Phase IIb|Participants with mCRPC will receive XNW5004 in combination with enzalutamide or enzalutamide alone
62589871|NCT06180369|OTHER|BeutiSealant (Shofu, Kyoto, Japonya)|Fissure sealant application with BeutiSealant (Shofu, Kyoto, Japonya)
62027463|NCT01093352|EXPERIMENTAL|Alveolar-decortication|Following surgical exposure of the impacted canine, additional perforations will be made in the surrounding cortical bone prior to wound closure.
62226599|NCT02285465|EXPERIMENTAL|ASP3700 multiple ascending dose cohort|
62226600|NCT02285465|PLACEBO_COMPARATOR|Placebo cohort|
62226601|NCT04499820|EXPERIMENTAL|NUTROF Group|vitamin and DHA supplementation
62419563|NCT03112096|EXPERIMENTAL|Cognitively Healthy Subjects|Cognitively healthy subjects will receive an IV injection, \[18F\]THK-5351 injection
62419564|NCT03112096|EXPERIMENTAL|Alzheimer's Disease Subjects|Cognitively healthy subjects will receive an IV injection, \[18F\]THK-5351 injection
62419565|NCT05526924|EXPERIMENTAL|Dose-Finding Group 1: Dose Level 1 (Part 1 of Study)|"The purpose of part 1 is to determine the best tolerated dose of study drugs with the least side effects. Dose escalation means that some participants will receive a different (higher) dose than other participants depending on when they join the study. This is to determine side effects at different doses and find a dose that will be safe to give to all participants. Participants in this group will receive:~1. One dose of tislelizumab (200 mg) 15 days before chemoradiotherapy (CRT) given intravenously (by IV), which means through a vein.~2. Chemoradiotherapy over a period of 5 weeks. During each cycle of CRT, participants will receive:~   * Pamiparib (20 mg daily on days 0-5 of each cycle) along with 5FU and hydroxyurea for 5 days.~  * Radiation will also be given two times a day for 5 days~3. After CRT, participants will rest for roughly 8 days without study drugs or radiation then they will receive tislelizumab (200 mg) for 12 months by IV over 30 minutes every 6 weeks."
62589872|NCT00960986|EXPERIMENTAL|Duloxetine 60 mg with food|Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks
62589873|NCT00960986|EXPERIMENTAL|Duloxetine 60 mg without food|Duloxetine 60 mg capsule po QD without food for 8 weeks
62589874|NCT00960986|EXPERIMENTAL|Duloxetine 30 mg with food|Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks
62589875|NCT00960986|EXPERIMENTAL|Duloxetine 30 mg without food|Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks
62589876|NCT03573531||Donor Human Milk|Donor Human Milk (processed by a human milk bank) Sampled at two different neonatal units in the United Kingdom Collection of 5 ml of otherwise routinely discarded donor human milk
62589877|NCT03573531||Preterm Milk|Preterm transitional or mature breast milk Sampled from healthy mothers of preterm babies (born , 37 weeks gestational age) at a neonatal unit in the United Kingdom Collection of 5 ml at a time point of routine expression
62589878|NCT03573531||Term Milk|Term mature breast milk Sampled from healthy mothers of term babies in the community (e.g. Baby Cafes). Collection of 5 ml expressed for this study
62226602|NCT04499820|PLACEBO_COMPARATOR|MERALUT Group|vitamin A, natural flavonoids, lutein and zeaxanthin and no DHA
62243039|NCT00516620|ACTIVE_COMPARATOR|2|Participants receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
62243040|NCT00516620|ACTIVE_COMPARATOR|3|Participants receive intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products.
62243041|NCT00516620|ACTIVE_COMPARATOR|4|Participants receive intensive dietary counseling for 6 months to decrease intake of sweetened soft drink.
62589879|NCT05741853|EXPERIMENTAL|Lexical Retrieval Training|Naming intervention for individuals with logopenic or semantic variant PPA.
62589880|NCT05741853|EXPERIMENTAL|Video Implemented Script Training for Aphasia|Script training intervention for individuals with nonfluent/agrammatic PPA.
62801497|NCT01683708||No Symbiotic therapy|Jaundiced patients who not have symbiotic therapy
62801498|NCT05549011||PENG block|This cohort will include participants to whom a PENG block is performed before positioning for spinal anesthesia
62801499|NCT05549011||SIFI block|This cohort will include participants to whom a SIFI compartment block is performed before positioning for spinal anesthesia
62801500|NCT02590731||Control group|Pfeiffer test 6 or above. No or mild cognitive impairment
62419566|NCT05526924|EXPERIMENTAL|Dose-Finding Group 2: Dose Level 2 (Part 1 of Study)|"The purpose of part 1 is to determine the best tolerated dose of study drugs with the least side effects. Dose escalation means that some participants will receive a different (higher) dose than other participants depending on when they join the study. This is to determine side effects at different doses and find a dose that will be safe to give to all participants. Participants in this group will receive:~1. One dose of tislelizumab (200 mg) 15 days before chemoradiotherapy (CRT) given intravenously (by IV), which means through a vein.~2. Chemoradiotherapy over a period of 5 weeks. During each cycle of CRT, participants will receive:~   * Pamiparib (20 mg twice daily on days 0-5 of each 14 -day cycle) along with 5FU and hydroxyurea for 5 days.~  * Radiation will also be given two times a day for 5 days~3. After CRT, participants will rest for roughly 8 days without study drugs or radiation then they will receive tislelizumab (200 mg) for 12 months by IV over 30 minutes every 6 weeks."
62589881|NCT05847738||Group A: (left side of the patient|prepared 2 sizes larger than the IBF, to size 35#/.04 mesial canals and 40#/.04 distal canals.
62589882|NCT05847738||Group B (right side of the patient|prepared 3 sizes larger than the IBF, to size 40#/.04 mesial canals and 45#/.04 distal canals.
62589883|NCT00201461|ACTIVE_COMPARATOR|1|Best medical therapy
62801501|NCT02590731||Cognitivt impaired|Pfeiffer test less than 6. Moderate to severe cognitive impairment.
62801502|NCT00756366|ACTIVE_COMPARATOR|1|Heart Failure-OSA Group, randomized to early CPAP
62801503|NCT00756366|ACTIVE_COMPARATOR|2|Heart Failure-OSA Group, randomized to late CPAP
62801504|NCT00756366|OTHER|3|Heart Failure- no OSA, no CPAP therapy, observational group
62419567|NCT05526924|EXPERIMENTAL|Dose-Finding Group 3: Dose Level 3 (Part 1 of Study)|"The purpose of part 1 is to determine the best tolerated dose of study drugs with the least side effects. Dose escalation means that some participants will receive a different (higher) dose than other participants depending on when they join the study. This is to determine side effects at different doses and find a dose that will be safe to give to all participants. Participants in this group will receive:~1. One dose of tislelizumab (200 mg) 15 days before chemoradiotherapy (CRT) given intravenously (by IV), which means through a vein.~2. Chemoradiotherapy over a period of 5 weeks. During each cycle of CRT, participants will receive:~   * Pamiparib (40 mg twice daily on days 0-5 of each 14 -day cycle) along with 5FU and hydroxyurea for 5 days.~  * Radiation will also be given two times a day for 5 days~3. After CRT, participants will rest for roughly 8 days without study drugs or radiation then they will receive tislelizumab (200 mg) for 12 months by IV over 30 minutes every 6 weeks."
62243042|NCT06105788|EXPERIMENTAL|Exercise|Arm 1: All participants, knee OA and pain-free individuals, will undergo a single exercise of arm exercise using an arm ergometer and;
62589884|NCT00201461|EXPERIMENTAL|2|STARFlex arm
62589885|NCT02849860|EXPERIMENTAL|IDP-121 Lotion|Lotion
62589886|NCT05286736||Early (untreated) Parkinson's Disease|Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria.
62589887|NCT05286736||Healthy Controls|Age- and sex-matched healthy controls.
62589888|NCT06631521|EXPERIMENTAL|Combination Therapy Arm|This arm is designed to evaluate the safety and feasibility of the combination therapy using darolutamide and relugolix as neoadjuvant treatment before radical prostatectomy (RP) in patients with high-risk prostate cancer (PCa).
62589889|NCT02836379||Breakthrough Cancer Pain|No intervention (Non-interventional study)
62589890|NCT03998644||healthy|Subjects without colorectal disorders.
62589891|NCT03998644||precancerous|Subjects with risk factors that may contribute to the carcinogenesis.
62589892|NCT03998644||colorectal cancer|Patients who were identified by standard procedures to suffer with colorectal cancer.
62801505|NCT02826343|OTHER|COPD Advair|"Subjects will undergo hyperpolarized xenon MRI with perfusion imaging, before and after a 90 day course of Adair.~All subjects belong to one arm and will receive same treatment. Then they are compared at baseline and 3 month post intervention (described below) for within same-subject changes.~Subjects will be administered with~1. Hyperpolarized Xenon129 inhalation during MRI twice (at baseline and post 3 month Advair)~2. Gadolinium intravenous contrast during MRI twice (at baseline and post 3 month Advair)~3. Advair diskus: strength 250mcg/50mcg, one puff twice a day for 3 months."
62801506|NCT00700440|EXPERIMENTAL|Cetuximab|400mg/m\^2 intravenous infusion one week before radiotherapy, then 250mg/m\^2 intravenous infusion weekly during radiotherapy
62801507|NCT03591926|EXPERIMENTAL|"BAL Arm"|Subjects in this arm will undergo a bronchoalveolar lavage (BAL) procedure at baseline and after two weeks of treatment.
62801508|NCT03591926|EXPERIMENTAL|"Non-BAL Arm"|Subjects in this arm will not undergo any BAL procedures.
62243043|NCT06105788|ACTIVE_COMPARATOR|Lower Body Exercise|Arm 2: All participants, knee OA and pain-free individuals, will undergo a single exercise of leg exercise using a cycling ergometer.
62801509|NCT02784795|EXPERIMENTAL|LY3039478 + Taladegib|LY3039478 given orally 3 times per week (TIW) in combination with taladegib given orally daily on a 28 day cycle. A single dose of taladegib will also be given on day 1 during a 3-day lead-in period.
62801510|NCT02784795|EXPERIMENTAL|LY3039478 + LY3023414|LY3039478 given orally TIW in combination with LY3023414 given orally every 12 hours on a 28-day cycle. A single dose of LY3023414 will also be given on day 1 during a 3-day lead-in period.
62243044|NCT04351763|EXPERIMENTAL|Amiodarone|"Amiodarone - administered intravenously~Bolus of 150 mg is given over a minimum of 10 min, with subsequent continuous infusion of 1 mg/min for 6 h, next continuous infusion of 0.5 mg/min for 18 h, then switch to oral administration.~Oral administration~200 to 400 mg/day (adjust dosage based on cardiac response and age) up to discharge."
62801511|NCT02784795|EXPERIMENTAL|LY3039478 + Abemaciclib|LY3039478 given orally TIW in combination with abemaciclib given orally every 12 hours on a 28-day cycle. A single dose of abemaciclib will also be given on day 1 during a 3-day lead-in period.
62801512|NCT02784795|EXPERIMENTAL|LY3039478 + Cisplatin/Gemcitabine|LY3039478 given orally TIW in combination with cisplatin and gemcitabine given as intravenous (IV) infusions on days 1 and 8 of a 21 day cycle.
62801513|NCT02784795|EXPERIMENTAL|LY3039478 + Gemcitabine/Carboplatin|LY3039478 given orally TIW in combination with gemcitabine and carboplatin given as IV infusions on days 1 and 8 of a 21 day cycle.
62801514|NCT03984539|ACTIVE_COMPARATOR|CBT-E|Participants will be randomly assigned to one of two conditions (CBT-E or CBT-T). CBT-E will occur over the course of 25 weeks and be delivered as it typically is in the clinic setting of the investigators.
62801515|NCT03984539|EXPERIMENTAL|CBT-T|Participants will be randomly assigned to one of two conditions (CBT-E or CBT-T). Participants who agree to participate will receive 10 weeks of CBT-T.
62801516|NCT02030522|EXPERIMENTAL|Prospective Treatment Cohort of ART|The target population (n=200) of persons treated with the intervention, Accelerated Resolution Therapy, will consist of U.S. service members and veterans who have symptoms indicative of a current diagnosis of PTSD. No age limit or duration of symptoms of PTSD will be imposed for study eligibility, and it is anticipated that most, if not all, of eligible and enrolled participants will have had prior deployments to conflicts dating back to the 1970s, including the Vietnam War, Persian Gulf conflict, and wars in Iraq and Afghanistan. No person will be excluded on the basis of race, ethnicity, gender, or disability.
62419568|NCT05526924|EXPERIMENTAL|Dose Expansion Group ( Part II of Study)|Part 2 (dose expansion phase): The purpose of this part is to continue to evaluate the dose of study drugs that is the best tolerated and has the least side effects. This part will start once the dose is selected from part 1. Enrollment in this part of the study is dependent on when participants join the study. Approximately 18 subjects will be enrolled in Part 2.
62419569|NCT01968837|NO_INTERVENTION|Cervical cancer screening|
62419570|NCT06568211|EXPERIMENTAL|Group A: VR first|Those assigned to Group A will be placed in the Virtual Reality (VR) intervention phase first. All participants will begin with a baseline picture book condition (week 0), and then those in Group A, will complete the VR intervention condition in the first two weeks (weeks 1 \& 2). After completing the two weeks of VR intervention, participating families will be asked to complete a set of standardized questionnaires. The following next two weeks (weeks 3 \& 4), participants will complete the Tablet-only intervention phase. At the end of this phase, participating families will again complete the same standardized questionnaires and will participate in a semi-structured interview about their experiences. Each session is expected to include 20 minutes of VR exposure. Each session will also be video-recorded for later analyses.
62419571|NCT06568211|EXPERIMENTAL|Group B: Tablet-only first|Those assigned to Group B will be placed in the Tablet-only intervention phase first. All participants will begin with a baseline picture book condition (week 0), and then those in Group B, will complete the Tablet-only condition in the first two weeks (weeks 1 \& 2). After completing the two weeks of Tablet-only intervention, participating families will be asked to complete a set of standardized questionnaires. The following next two weeks (weeks 3 \& 4), participants will complete the VR intervention phase. At the end of this phase, participating families will again complete the same standardized questionnaires and will participate in a semi-structured interview about their experiences. Each session is expected to include 20 minutes of VR exposure. Each session will also be video-recorded for later analyses.
62419572|NCT06613412|EXPERIMENTAL|5G group|Biopsies of patients with pulmonary peripheral lesions (PPL) were performed using a remotely operated robotic bronchoscopy system supported by a 5G network.
62801517|NCT00567853|OTHER|MEMO 3D ring|All patients in the study will be implanted with the MEMO 3D ring
62801518|NCT04796597|EXPERIMENTAL|Single-arm|Implantation of subcutaneous leads and connection to an external EEG amplifier
62801519|NCT05864222|EXPERIMENTAL|Nurses Working in an Academic Health System (AHS)|Nurse participants will receive aromatherapy (AT) after baseline measurements. Each day, the participants will pick up AT stickers to wear throughout the day on their staff badges. Participants will receive monthly emails, reminding them to wear the AT every day that they are working.
62419573|NCT06613412|NO_INTERVENTION|local group|In the absence of 5G network support, a local robotic bronchoscopy system is utilized to perform biopsies on patients with pulmonary peripheral lesions (PPL).
62419574|NCT00092235||Cohort 1|Patients who have undergone an allogeneic stem cell transplant and are diagnosed with cGVHD
62419575|NCT00092235||Cohort 2|Pediatric patients who have undergone an allogeneic stem cell transplant and are diagnosed with cGVHD
62419576|NCT00092235||Cohort 3|Patients who have undergone an allogeneic stem cell transplant and choose to submit biopsy, blood and urine samples only
62419577|NCT00092235||Cohort 4|Patients who have undergone an allogeneic stem cell transplant and are not diagnosed with cGVHD
62226603|NCT05448781|EXPERIMENTAL|endostatin combined with PD-1 antibody and platinum-containing two-drug chemotherapy|"Recombinant human vascular endostatin (Endu): 210 mg (14 PCS), administered by continuous intravenous pumping for 72h every three weeks on the first day of each cycle.Pemetrexed: 500mg/m2, administered intravenously every three weeks on the first day of each cycle.Paclitaxel:175mg/ m2, administered intravenously every three weeks on the first day of each cycle.Albumin paclitaxel:260mg/ m2, administered intravenously every three weeks on the first day of each cycle.~Carboplatin:5/AUC, maximum dose limited to 600mg, or 75 mg/m2 cisplatin, is administered intravenously every three weeks on the first day of each cycle Tirelizumab: a recommended dose of 200mg/ time, administered every three weeks on the first day of each cycle until disease progression or unacceptable toxicity is developed."
62801520|NCT01966523|EXPERIMENTAL|Intervention|Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
62801521|NCT01966523|OTHER|Usual Care|Residents will receive usual care for infections
62226604|NCT05350631|NO_INTERVENTION|Control|only follow-ups consultations, phone contact and TVE workshop with the AJA mobile team centralized by the IDEC
62226605|NCT05350631|EXPERIMENTAL|Experimental|using a digital tool in addition to follow-ups by consultations, phone contact and PTE workshop with the AJA mobile team centralized by the IDEC
62419578|NCT02418559|EXPERIMENTAL|JNJ-63623872 (300 mg) or Placebo|Participants will receive JNJ-63623872 300 milligram (mg) or placebo tablet orally once on Day 1 under fasted conditions.
62419579|NCT02418559|EXPERIMENTAL|JNJ-63623872 (600 mg) or Placebo|Participants will receive JNJ-63623872 600 mg (2\*300 mg) or placebo tablet orally once on Day 1 under fasted conditions.
62801522|NCT02982564|EXPERIMENTAL|Low Intensity Exercise|Participants engage in low intensity endurance exercise.
62801523|NCT02982564|EXPERIMENTAL|Moderate Intensity Exercise|Participants engage in moderate intensity endurance exercise.
62801524|NCT02577692|EXPERIMENTAL|Oxygen|Day 1: breathing of 100% oxygen; Day 2: ambient air breathing
62801525|NCT02577692|EXPERIMENTAL|Ambient|Day 1: breathing of 100% oxygen; Day 2: ambient air breathing
62801526|NCT05068258|EXPERIMENTAL|Venous leg ulcers patients undergoing lymphovenous bypass|
62801527|NCT03833869|EXPERIMENTAL|Assisted hatching|Five-day frozen embryos will undergo assisted hatching prior to embryo transfer
62801528|NCT03833869|NO_INTERVENTION|Control|Five-day frozen embryos will not undergo any additional procedures prior to embryo transfer
62801529|NCT05839171|EXPERIMENTAL|Person's Chosen Music + Mandala coloring|Every day for at least 20 minutes/7-10 days
62801530|NCT05839171|EXPERIMENTAL|Meditation Music + Mandala coloring|Every day for at least 20 minutes/7-10 days
62801531|NCT05839171|NO_INTERVENTION|Standard care|Every day
62801532|NCT02798939||cirrhotic patients|
62801533|NCT06499493|EXPERIMENTAL|Experimental: Myofascial induction in gastrocnemius|A 3-pass shallow leg gliding technique was applied first, followed by 5 minutes of the deep myofascial calf induction technique described by Pilat.
62801534|NCT04985721|EXPERIMENTAL|Pamiparib and Tiselizumab|
62801535|NCT00867516|EXPERIMENTAL|1|ALD518 80 mg
62801536|NCT00867516|EXPERIMENTAL|2|ALD518 160 mg
62801537|NCT00867516|EXPERIMENTAL|3|ALD518 320 mg
62801538|NCT00867516|PLACEBO_COMPARATOR|4|No ALD518
62801539|NCT06527118|ACTIVE_COMPARATOR|The Group to which the Self-Care Skills Learning Activity Program will be implemented|"The Activity Program for Learning Self-Care Skills, which was prepared by the educator after receiving expert opinions, was applied individually to each child in the intervention group for 12 weeks. The training was 1 day a week for 40 minutes."
62801540|NCT06527118|NO_INTERVENTION|Self-Care Skills Learning Activity Program Not Implemented Group|No intervention was applied to the control group.
62419580|NCT02418559|EXPERIMENTAL|JNJ-63623872 (1200 mg) or Placebo|Participants will receive JNJ-63623872 1200 mg (4\*300 mg) or placebo tablet orally once on Day 1 under fasted conditions.
62419581|NCT05619484|NO_INTERVENTION|Participant's prescribed ankle-foot orthosis|
62419582|NCT05619484|EXPERIMENTAL|Smart AFO|
62801541|NCT01681160|EXPERIMENTAL|MAGGOT THERAPY & conventional therapy T|Maggot therapy,ADMINISTERED TWO TIMES AS A NEW METHODS OF DRESSING in experimental group.conventional therapy ,administered two times in control group
62801542|NCT04681105|EXPERIMENTAL|Treatment (flotetuzumab)|"INDUCTION THERAPY: Patients receive flotetuzumab via continuous IV infusion on days 1-28. Patients who achieve SD/PR (Cohort A) or PR/CI (Cohort B), receive an additional induction cycle. Patients who achieve PR (Cohort A) or PR/CI/MMR (Cohort B) after cycle 2 re-induction, may continue induction therapy for up to 4 more cycles.~CONSOLIDATION THERAPY: Patients who achieve CR/CRi/CRh/MLFS (Cohort A) or CR/MR (Cohort B) after cycle 1 or cycle 2 of induction therapy, receive flotetuzumab via continuous IV infusion on days 1-28 for up to 5 and 6 cycles, respectively, in the absence of disease progression or unacceptable toxicity. Patients with PR (Cohort A) or PR/CI/MMR (Cohort B) who have received up to 6 cycles of induction therapy may receive up to 2 cycles of consolidation therapy in the absence of disease progression or unacceptable toxicity."
62801543|NCT03920254|EXPERIMENTAL|Active Treatment TD-1473 with Dose A|Oral daily dose of TD-1473 for up to 156 weeks
62801544|NCT03920254|EXPERIMENTAL|Active Treatment TD-1473 with Dose B|Oral daily dose of TD-1473 for up to 156 weeks
62801545|NCT03920254|EXPERIMENTAL|Active Treatment TD-1473 with Dose C|Oral daily dose of TD-1473 for up to 156 weeks
62801546|NCT00741052|EXPERIMENTAL|1|Ciprofloxacin
62801547|NCT00741052|ACTIVE_COMPARATOR|2|Azithromycin
62801548|NCT03391661|EXPERIMENTAL|Chronic Pain and the Brain|This condition is a 15 to 20-minute exercise that patients complete in which they examine variables in themselves that suggest that their pain is driven by central nervous system processes / their brains.
62027464|NCT03353818|ACTIVE_COMPARATOR|Golf|In three different golf clubs patients will be introduced how to play golf. They will be taught techniques and recieve basic golf equipment. A total of 1 year membership free membership in the golf clubs will be given.
62027465|NCT03353818|PLACEBO_COMPARATOR|Placebo|No intervention given. No restrictions on physical activity.
62801549|NCT03391661|PLACEBO_COMPARATOR|Health Behavior Control|This 15 to 20-minute exercise is designed as a control condition that has face validity as helpful and that relates to health. Thus, patients are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections).
62226606|NCT06414187|EXPERIMENTAL|IABP-arm|"Patients assigned IABP therapy will undergo IABP insertion as promptly as possible, with a target interval from randomization to insertion of less than 30 minutes. Implantation of the IABP balloon can be established either in the cardiac catheterization laboratory or at bedside in the ICU or cardiac care unit. The steering committee of this trial recommends the use of an appropriate-sized IABP balloon according to the instructions for use.~Low-dose vasopressors (noradrenaline/norepinephrine up to 0.2 ug/kg/min) are allowed next to IABP support. The necessity of increasing the noradrenaline/norepinephrine dose with at least 0.2 ug/kg/min or the necessity to initiate de-novo inotropic agents to reach a mean arterial blood pressure of at least 65 mmHg is considered treatment escalation."
62226607|NCT06414187|NO_INTERVENTION|Standard of care-arm|"When a patient is randomized to the standard of care-arm, the definitive treatment strategy is up to the discretion of the treating physician (providing no IABP is inserted). The treatment strategy may include fluid management as well as administration of inotropes and vasopressors. The only imposed difference in treatment is the omission of IABP, as the dose of inotropes and vasopressors is not expected to be high in early cardiogenic shock.~The final decision to escalate in the strategy of mechanical circulatory support (including to initiate IABP in the standard of care-arm) is up to the discretion of the treating physician. However, the steering committee feels escalation in MCS strategy is appropriate in case of persistent mean arterial pressure \<65 mmHg with incessant lactate levels \>5.0 mmol/L when pharmacologic support was already intensified (e.g. the noradrenaline/norepinephrine dose exceeds 0.2 ug/kg/min or inotropic support was already administered)."
62027466|NCT06152224|EXPERIMENTAL|8 week use of Leva|
62226608|NCT04950504|EXPERIMENTAL|CNP-201 250 mg|200 mL intravenous infusion on Day 1 and Day 8: 250 mg CNP-201
62226609|NCT04950504|EXPERIMENTAL|CNP-201 450 mg|200 mL intravenous infusion on Day 1 and Day 8: 450 mg CNP-201
62226610|NCT04950504|EXPERIMENTAL|CNP-201 650 mg|200 mL intravenous infusion on Day 1 and Day 8: 650 mg CNP-201
62226611|NCT04950504|PLACEBO_COMPARATOR|Placebo|200 ml intravenous infusion on Day 1 and Day 8: CNP-201 Placebo
62226612|NCT04390022|ACTIVE_COMPARATOR|Ivermectin|Participants on this arm will receive a single, oral dose of ivermectin 400 mcg/kg at the enrolment visit.
62801550|NCT04392817|EXPERIMENTAL|the participating group in the intervention|patient complaining of seppch rerrors due t ovelopharyngeal insufficiency and underwent the intervention
62801551|NCT02420093|EXPERIMENTAL|Experimental Group|"The experimental group will use the Pelvis Support Assembly per US Patent number US 8,857,906 B2, in the seat of their work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting."
62801552|NCT02420093|NO_INTERVENTION|Control Group|"The control group will not use the Pelvis Support Assembly per US Patent number US 8,857,906 B2 but will continue in their current sitting arrangement during the same 3 week interval"
62801553|NCT05184530||Statin Group|AMI patients with Statin therapy.
62027467|NCT06152224|ACTIVE_COMPARATOR|16 week use of Leva|
62027468|NCT05008679|NO_INTERVENTION|Control|patients with heart failure to receive standard HF therapy
62027469|NCT05008679|EXPERIMENTAL|Oseltamivir|patients with heart failure to receive oseltamivir (at a dose of 75 mg twice daily) for 1 month in addition to standard HF therapy
62027470|NCT06634628|EXPERIMENTAL|Cohort 1|Radioligand \[11C\]CHDI-00491009 3 HCs - MRI and PET Radioligand is administered 1x each person
62027471|NCT06634628|EXPERIMENTAL|Cohort 2|Radioligand \[11C\]CHDI-00491009 6 HCs - MRI and PET 6 PwHD HD-ISS Stage 2 - MRI and PET Radioligand administered 2x (TRT) for 3 HCs and 3 PwHD Radioligand administered 1x for 3 HCs and 3 PwHD In addition, optional CSF collection for all PwHD
62027472|NCT06634628|EXPERIMENTAL|Cohort 3|Radioligand \[11C\]CHDI-00491009 6 HCs - MRI and PET 6 PwHD HD-ISS Stage 3 - MRI and PET Radioligand administered 1x for 6 HCs and 6 PwHD In addition, optional CSF collection for all PwHD Depending on previous results and as decided by executive committee, TRT may be included in Cohort 3. A TRT decision would include one extra imaging session per participant (i.e., radioligand administered 2x per participant.)
62027473|NCT05499975|EXPERIMENTAL|Older adults completing the CHAMP tool before treatment decision is made|Eligible participants who consent to the study will be asked to complete questionnaires about socio-demographic characteristics, literacy, and technology comfort. Subsequently, participants will be asked to complete the CHAMP tool at home or in the clinic before their medical appointment with the oncologist. Next, participants will see their oncologist for their consultation. Approximately one week after the consultation, participants will be asked to complete 3 questionnaires about their experience and satisfaction with the CHAMP tool
62801554|NCT05184530||Ezetimibe Group|AMI patients with Statin plus Ezetimibe therapy.
62801555|NCT05184530||PCSK9i Group|AMI patients with Statin plus PCSK9i therapy.
62801556|NCT05184530||Triple Group|AMI patients with Statin plus Ezetimibe plus PCSK9i therapy
62801557|NCT00407186|EXPERIMENTAL|1chemoradiotherapy|5 weeksadjuvant treatment; radiotherapy and concomitant chemotherapy with cisplatin and capecitabine.
62801558|NCT00407186|ACTIVE_COMPARATOR|2chemotherapy|3 adjuvant courses epirubicin, cisplatin, capecitabine.
62801559|NCT02239159|NO_INTERVENTION|Control|Electrodes will be attached, but stimulation will not be given
62801560|NCT02239159|SHAM_COMPARATOR|Non-acupoint TES|TES is for transcutaneous electric stimulation.Stimulation will be given through electrodes attached to non-acupoints
62801561|NCT02239159|EXPERIMENTAL|Acupoint TES|Transcutaneous stimulation will be given through acupoints
62027474|NCT06247306|EXPERIMENTAL|real-time fMRI neurofeedback (of the ACC)|Participants are instructed to reduce their stress-response by attempts to upregulate the ACC activity contigent on real-time feedback.
62027475|NCT06247306|SHAM_COMPARATOR|Yoke-control group|Participants receive previously recorded feedback signal from other participants\&#39; ACC activity instead of their own live ACC activity.
62027476|NCT05938634|EXPERIMENTAL|Precontemplation|The intervention that would involve the Processes of Change that people use when they would be in the Precontemplation Stage of Change.
62027477|NCT05938634|EXPERIMENTAL|Contemplation-based intervention|The intervention that would involve the Processes of Change that people use when they would be in the Contemplation Stage of Change.
62027478|NCT05938634|EXPERIMENTAL|Preparation-based intervention|The intervention that would involve the Processes of Change that people use when they would be in the Preparation Stage of Change.
62027479|NCT05938634|EXPERIMENTAL|Action-based intervention|The intervention that would involve the Processes of Change that people use when they would be in the Action Stage of Change.
62027480|NCT05938634|EXPERIMENTAL|Maintenance-based intervention|The intervention that would involve the Processes of Change that people use when they would be in the Maintenance Stage of Change.
62226613|NCT04390022|PLACEBO_COMPARATOR|Placebo|Participants on the arm will receive a single, oral dose of placebo tablets at the enrollment visit.
62226614|NCT02637973|EXPERIMENTAL|Empagliflozin|Empagliflozin, film-tablet, 25mg once daily
62419583|NCT05165368|EXPERIMENTAL|Intraneural Facilitation® Therapy (INF® Therapy) + Dietary Education|The INF® Therapy+ group will receive dietary education with weekly follow-up by a physical therapist either in person, or via email or text message. The INF® Therapy+ group will additionally receive meal preparation ideas and sample menus promoting a gluten-free diet.
62801562|NCT00498459|EXPERIMENTAL|ICAPS|Promotion Physical Activity
62801563|NCT00498459|NO_INTERVENTION|Control|No specific physical activity promotion Ususal school program
62801564|NCT01721161|EXPERIMENTAL|BIIB033|Participants will receive BIIB033 once every 4 weeks for 20 weeks (a total of 6 doses).
62801565|NCT01721161|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
62801566|NCT03333707|EXPERIMENTAL|Active|Participants will be provided will full access to the Pacifica app.
62801567|NCT03333707|NO_INTERVENTION|Wait List|Participants will be placed on a wait list and will receive access to the app after 1 month.
62801568|NCT02848222|EXPERIMENTAL|Twice Daily Application of Bruder compress|Ten minute application of the Bruder Moist Heat Compress in the morning prior to contact lens insertion and ten minute application in the evening after lens removal
62801569|NCT02848222|EXPERIMENTAL|Once Daily Application of Bruder compress|Ten minute application of the Bruder Moist Heat Compress in the evening after lens removal
62801570|NCT02848222|SHAM_COMPARATOR|Twice Daily Application of warm washcloth|Ten minute application of a hot-water warmed washcloth in the morning prior to contact lens insertion and ten minute application in the evening after lens removal
62801571|NCT02447016|EXPERIMENTAL|eviplera (complera)|Tab eviplera QD
62801572|NCT02447016|ACTIVE_COMPARATOR|atripla|Tab Atripla QD
62801573|NCT04958499|EXPERIMENTAL|Bio-Healthy Park|This group is the experimental group. The intervention program consisted in the realization of the program on bio-healthy machinery.
62801574|NCT04958499|NO_INTERVENTION|Control|Adults and older assigned to the control group will not received any structured exercise programme. They will maintain their usual physical activities.
62801575|NCT00880698|EXPERIMENTAL|HIV-uninfected RotaTeq|HIV-1 uninfected participants receiving 3 doses of RotaTeq vaccine at intervals of 4-10 weeks with the third dose administered by 32 weeks of age.
62801576|NCT00880698|PLACEBO_COMPARATOR|HIV-uninfected Placebo|HIV-1 uninfected participants receiving 3 doses of placebo at intervals of 4-10 weeks with the third dose administered by 32 weeks of age
62801577|NCT00880698|EXPERIMENTAL|HIV-infected RotaTeq|HIV-1 infected participants receiving 3 doses of RotaTeq vaccine at intervals of 4-10 weeks with the third dose administered by 32 weeks of age.
62801578|NCT00880698|PLACEBO_COMPARATOR|HIV-1 infected Placebo|HIV-1 infected participants receiving 3 doses of placebo at intervals of 4-10 weeks with the third dose administered by 32 weeks of age
62226615|NCT02637973|PLACEBO_COMPARATOR|Placebo|Placebo, once daily
62226616|NCT06050187|ACTIVE_COMPARATOR|Group I conventional stone cast|Mandibular stone cast with 4 parallel implants analogues in canines and second premolar regions will be fabricated conventionally.
62419584|NCT05165368|ACTIVE_COMPARATOR|Intraneural Facilitation® Therapy (INF® Therapy)|"INF® Therapy is a manual therapy technique that consists of three components. The first is the pressurization or facilitation hold which biases circulation more consistently in the nerves, which is thought to pressurize the entire system The secondary hold attempts to stretch the innervated structure, pulling apart the tough dividing membrane and allowing the pressurized blood flow to transport from the outside holding chamber to the endoneurium and push open the closed capillary beds next to the nerve axons. Once capillaries surrounding the nerves are pressurized, the circulation needs to be induced up the neural connective tissue. A separate set of pressure points or holds are performed distal to the secondary holds to ensure the circulation is drawn up the inflamed capillary beds using the Bernoulli principle."
62419585|NCT02720094|EXPERIMENTAL|Arm A|In Step 1, participants will receive daily oral CAB and daily oral TDF/FTC placebo for 5 weeks. In Step 2, participants will receive CAB LA and daily oral TDF/FTC placebo to Week 153. In Step 3, participants will receive daily oral TDF/FTC starting at Week 153 and for 48 weeks.
62419586|NCT02720094|EXPERIMENTAL|Arm B|In Step 1, participants will receive daily oral TDF/FTC and daily oral CAB placebo for 5 weeks. In Step 2, participants will receive daily oral TDF/FTC and placebo for CAB LA to Week 153. In Step 3, participants will receive daily oral TDF/FTC starting at Week 153 and for 48 weeks.
62419587|NCT06703788|EXPERIMENTAL|Integrated traditional Chinese medicine care program|Integrated traditional Chinese medicine (TCM) care program for metabolic syndrome, including herbal medicine, laser acupuncture, and diet and lifestyle education based on TCM theory.
62419588|NCT05174559|ACTIVE_COMPARATOR|Active LNAA|Active LNAA tablets are given to each participant in 3 multiple crossovers for a total exposure to the Active Comparator 3 times. The allocation is randomized within each cycle of two treatments (active/inactive). There are 3 total cycles for each participant. The intervention is PreKUnil® tablets.
62801579|NCT03041948|ACTIVE_COMPARATOR|Caudal-epidural nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The CE group will receive an US-confirmed CE nerve block with 0.8 mL/kg of 0.2% ropivacaine (maximum 15 mL).
62419589|NCT05174559|PLACEBO_COMPARATOR|Inactive LNAA|Inactive LNAA tablets (placebos) are given to each participant in 3 multiple crossovers for a total exposure to the Inactive Comparator 3 times. The allocation is randomized within each cycle of two treatments (inactive/active). There are 3 total cycles for each participant. The placebo intervention is PreKUnil® placebo tablets.
62419590|NCT02532023|ACTIVE_COMPARATOR|omega 3 fatty acid supplementation|patients with migraine receive 2 capsules 1000 mg omega3, 2 times a day, for 2 months.
62027481|NCT01757964|EXPERIMENTAL|Bacteriotherapy|Study stool recipient's will receive approximately 30 grams of processed donor stool through a tube into their stomach for the transplant.
62226617|NCT06050187|ACTIVE_COMPARATOR|Group II 3D printed implant cast|3D printed implant mandibular cast with 4 parallel digital implants analogues in canines and second premolar regions will be fabricated digitally.
62027482|NCT04759820|EXPERIMENTAL|Nano carbon group|Injection of carbon nanoparticle
62027483|NCT04759820|ACTIVE_COMPARATOR|Indocyanine green group|Injection of indocyanine green
62226618|NCT06382025|ACTIVE_COMPARATOR|storybook|
62226619|NCT06382025|PLACEBO_COMPARATOR|standart|
62226620|NCT02443090|EXPERIMENTAL|Fispemifene 450 mg|Fispemifene capsules will be taken orally each morning immediately after eating a meal
62226621|NCT02443090|PLACEBO_COMPARATOR|Placebo|Placebo capsules will be taken orally each morning immediately after eating a meal
62226622|NCT03371381|EXPERIMENTAL|Nivolumab + JNJ-64041757|Phase 1b and Phase 2 Group A/Arm 1: Participants will receive separate intravenous (IV) infusions of nivolumab and JNJ-64041757 over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
62226623|NCT03371381|ACTIVE_COMPARATOR|Nivolumab|Phase 2 Group B/Arm 2: Participants will receive intravenous (IV) infusions of nivolumab over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
62226624|NCT02011087|EXPERIMENTAL|Diagnostic (bioelectric impedance analysis)|Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment.
62226625|NCT02667977|ACTIVE_COMPARATOR|Group 1|These patients will receive Dextrose 5% and 0.9 NS in their maintenance IV fluids
62419591|NCT02532023|ACTIVE_COMPARATOR|curcumin supplementation|patients with migraine receive 2 capsules 1000 mg curcumin, 2 times a day, for 2 months.
62419592|NCT02532023|PLACEBO_COMPARATOR|omega 3 fatty acid Placebo|patients with migraine receive 2 capsules of omega 3 fatty acid placebo for 2 months.
62419593|NCT02532023|PLACEBO_COMPARATOR|curcumin placebo|patients with migraine receive 2 capsules of curcumin placebo for 2 months.
62419594|NCT05587686||Intubated patient during their stay in the IUCPQ-UL emergency or intensive care department|
62226626|NCT02667977|ACTIVE_COMPARATOR|Group 2|These patients will receive Dextrose 5% and 0.45 NS in their maintenance IV fluids
62226627|NCT02770456|EXPERIMENTAL|High dose fish oil|Women will be offered 4 capsules per day containing fish oil
62419595|NCT05016310|EXPERIMENTAL|High Vit D|High Dose Vitamin D
62419596|NCT05016310|ACTIVE_COMPARATOR|SOC Vit D|Standard of Care Vitamin D
62419597|NCT05500456|EXPERIMENTAL|Clear aligners|The patients in this group will be treated using clear aligners.
62419598|NCT05500456|ACTIVE_COMPARATOR|Fixed appliances.|The patients in this group will be treated using fixed appliances.
62801580|NCT03041948|EXPERIMENTAL|ilioinguinal/iliohypogastric nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The IIG/IHG group will receive a unilateral US guided IIG/IHG with 0.4mL/kg of ropivacaine 0.2% (max 12 mL).
62801581|NCT06129643|ACTIVE_COMPARATOR|Conventional group A|
62801582|NCT06129643|EXPERIMENTAL|Dual laser group (Er,Cr:YSGG/Diode)|
62801583|NCT06129643|EXPERIMENTAL|Combined group (EDTA/Diode):|
62801584|NCT01914640||Healthy adults living in Turkey|The group was enrolled from the 24 provinces of the 7 regions of Turkey. At least 3 provinces were selected from each region by a random sampling method. The populations of these 7 regions were obtained from the records of the 2000 census. The study sample included males and non-pregnant females aged between 20 and 83 years. The populations of city centers, districts, and villages were classified by using the stratified sampling method and then were selected from the data collected from the household identification forms by random sampling. The geography of Turkey was classified into three groups according to altitude. Sea level was accepted as zero. 0-300 m was taken as coastal, 300-900 m as moderate
62027484|NCT00344123|OTHER|Tipranavir/ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin.~Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
62027485|NCT06310161|EXPERIMENTAL|Bright Light|Light therapy will be delivered by the Re-Timer glasses for 60 minutes during dialysis sessions.
62027486|NCT06310161|PLACEBO_COMPARATOR|Dim Light|Dim light therapy will be delivered by the Re-Timer glasses for 60 minutes during dialysis sessions.
62419599|NCT04018937|EXPERIMENTAL|Reduced Intensity Conditioning with FAM|Children with SCD will received reduced intensity conditioning with fludarabine, alemtuzumab and melphalan (FAM) during HSCT with a HLA matched sibling donor
62419600|NCT06096116|EXPERIMENTAL|Low-dose Atenativ|
62801585|NCT01952886|EXPERIMENTAL|Granisetron patch|Granisetron transdermal delivery system (supplied as a 52 cm\^2 patch containing 34.3 mg of granisetron - 3.1 mg/day) is applied once per week.
62027487|NCT05773859|EXPERIMENTAL|XP-DC vaccinations|Patients in this arm will receive XP-DC vaccination in addition to standard-of-care treatment.
62027488|NCT03305016|EXPERIMENTAL|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
62027489|NCT01829412|EXPERIMENTAL|DW- MRI|"The patients will perform the DW-MRI, WB-MRI and MRI of the spine in the same session with the following timing:~1. Patients at first-line treatment for MM:~   1. Within 15 days before the start of the treatment~  2. Within one month after the end of the first-line treatment~  3. Six (6) months after the end of the first-line treatment~2. Patients at relapse after disease response (CR or PR) lasting at least 6 months~   1. At relapse~  2. Within 15 days after the end of the treatment of relapse~  3. Six (6) months after the end of the treatment of relapse Each DW-MRI, WB-MRI, MRI of the spine and skeletal X-Ray will be independently read and interpreted by two radiologists with proven experience in MM. ."
62027490|NCT06670066|EXPERIMENTAL|Adolescents receiving Let's Talk Birth Control|Participants in the Let's Talk Birth Control condition receive access to the CDA materials, contraceptive counseling with trained healthcare providers, and asynchronous access to the Bedsider ME web platform.
62226628|NCT02770456|EXPERIMENTAL|Low dose fish oil|Women will be offered 4 capsules per day containing mixed fish oil and olive oil
62226629|NCT02770456|PLACEBO_COMPARATOR|Control|Women will be offered 4 capsules per day containing olive oil
62226630|NCT00513643|EXPERIMENTAL|1|6 U insulin aspart
62226631|NCT00513643|EXPERIMENTAL|2|12 U insulin aspart
62226632|NCT00513643|EXPERIMENTAL|3|24 U insulin aspart
62419601|NCT06096116|EXPERIMENTAL|High-dose Atenativ|
62419602|NCT06096116|PLACEBO_COMPARATOR|Placebo|Patients will receive a saline bolus dose
62419603|NCT03072329|EXPERIMENTAL|Pudendal nerve block|Bilateral pudendal nerve block with the administration of 0.1 mL/kg Bupivacaïne 0.5%, regardless of neurostimulation response.
62801586|NCT01952886|ACTIVE_COMPARATOR|Ondansetron tablet|Ondansetron 8 mg oral tablet is prescribed for once a day.
62801587|NCT02931019|EXPERIMENTAL|neck flexion first|"With specific head posture, intubation is done under flexible fiberoscopy guide.~In this arm, at the position with neck flexion, fiberoscopy is pulled into the mouth and get the photo of laryngeal view. After then, neck position is changed to neck extension, And the laryngeal view is gotten in the same way."
62801588|NCT02931019|EXPERIMENTAL|neck extension first|In this arm, at the position with neck extension, fiberoscopy is pulled into the mouth and get the photo of laryngeal view. After then, neck position is changed to neck flexion, And the laryngeal view is gotten in the same way.
62226633|NCT00513643|ACTIVE_COMPARATOR|4|6 IU human regular insulin
62226634|NCT00513643|ACTIVE_COMPARATOR|5|12 IU human regular insulin
62419604|NCT03722849|EXPERIMENTAL|Chronic cough participant|"Twenty-five (25) Idiopathic chronic cough patients, defined as refractory to disease modifying therapies (eg anti-asthma medications), will be recruited.~Participants will attend two sessions. In the first they will inhale in a single breath a nebulized solutions of increasing doses of Adenosine Triphosphate (ATP; 0.2-300 milliM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds. In the second session, participants will undergo functional brain imaging (fMRI) for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin."
62419605|NCT03722849|EXPERIMENTAL|Healthy control participant|"Twenty-five (25) appropriately age and sex matched healthy non-smoking individuals will be recruited as the comparison group.~Participants will attend two sessions. In the first they will inhale in a single breath a nebulized solutions of increasing doses of ATP (0.2-300 milliM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds. In the second session, participants will undergo fMRI for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin."
62419606|NCT06102707|EXPERIMENTAL|Fluzopril Combined With Apatinib Group|
62801589|NCT05109780|EXPERIMENTAL|App + Unified Protocol Arm|"Participants at this condition will be daily monitored by the app (My Emi, Emotional Well-being) while they are administered a self-applied online transdiagnostic intervention for their emotional disorders. Alarms will be generated in the face of certain pre-set undesired events.~Therapists will receive pre-set clinical alarms in real time in the presence of relevant clinical events previously determined by the clinical staff (e.g., clinical worsening or no improvement of functionality, mood or psychological mechanisms worked in therapy). This information will be used to make clinical decisions in a short period of time (e.g., call the patient, or send additional therapeutic material by mail or through the app (momentary ecological intervention), or for its implementation during the course of psychological therapy in order to make the therapy more efficient, safe, personalized and adapted to the needs of the patient."
62801590|NCT04318769|EXPERIMENTAL|AFFIRM|AFFIRM is an 8-session psychoeducational weekly group intervention
62419607|NCT01413152|EXPERIMENTAL|0|
62419608|NCT03354962|ACTIVE_COMPARATOR|ARM A|
62589893|NCT06376565|EXPERIMENTAL|Arm I(Multilevel intervention)|"Aim 1: Participants complete an interview over 20-30 minutes.~Aim 2: Clinics have the automatic addition of HRN to the medical problem list and indication of surveillance interval is added to the health maintenance portion of the electronic health records (EHR). Clinics also call patients to schedule their colonoscopy. Providers receive reminders and pending orders for the colonoscopy in the electronic health record. Patients receive a reminder 6 months in advance via their patient portal and mail to schedule a colonoscopy, and also receive a phone call from the patient communication center."
62801591|NCT04318769|NO_INTERVENTION|Waitlisted control|Waitlisted control
62801592|NCT05852080|EXPERIMENTAL|intervention arm|Hospitals in the intervention arm will receive a multilevel system intervention based on information platform
62801593|NCT05852080|NO_INTERVENTION|control arm|Hospitals in the control arm will receive no intervention
62801594|NCT05897008|EXPERIMENTAL|CMAB007|150 mg Subcutaneous injection
62801595|NCT05897008|ACTIVE_COMPARATOR|Xolair|150 mg Subcutaneous injection
62801596|NCT00957879|ACTIVE_COMPARATOR|ergocalciferol|Weekly ergocalciferol for 12 weeks
62801597|NCT00957879|ACTIVE_COMPARATOR|calcitriol|Daily calcitriol for 12 weeks
62801598|NCT06466694|OTHER|Modified Dialectical Behavioural Therapy|
62027491|NCT06670066|NO_INTERVENTION|Adolescents receiving standard reproductive and sexual health care services|Participants in the control condition receive standard health care services from their medical provider. Health centers in the control condition will not be using an adolescent-focused sexual and reproductive health CDA or contraceptive counseling initiative.
62419609|NCT03354962|EXPERIMENTAL|ARM B|
62589894|NCT06376565|ACTIVE_COMPARATOR|Arm II (Standard follow up)|Patients receive care according to the clinics' usual care practices.
62589895|NCT04198038|EXPERIMENTAL|cognitively impaired children|This is a single-group study; all participants will be offered the songwriting intervention.
62801599|NCT05557344|ACTIVE_COMPARATOR|Oral acetaminophen arm|they will receive oral acetaminophen, placebo (saline) IV
62801600|NCT05557344|ACTIVE_COMPARATOR|IV acetaminophen arm|they will receive IV acetaminophen, placebo oral
62801601|NCT02711124||Group with hemoglobin A1c < 7|There will be no intervention administered to the group. The group will be observed for platelet function pre- and postoperatively.
62801602|NCT02711124||Group with hemoglobin A1c ≥ 7%|There will be no intervention administered to the group. The group will be observed for platelet function pre- and postoperatively.
62801603|NCT05456737||Unilateral Group|"Participants with a diagnosis of unilateral clubfoot treated with the Ponseti method were evaluated once with the following evaluation methods:~Anthropometric measurements FPI-6 Fizyosoft Balance System Functional Activity and Skills Form. OxAFQ-C and OxAFQ-P Kiddy-Kid-Kiddo KINDL"
62027492|NCT03912259|PLACEBO_COMPARATOR|Placebo Q2W|Placebo matched to dupilumab 600 milligrams (mg) (loading dose), subcutaneously (SC) on Day 1 followed by placebo matched to dupilumab 300 mg once every 2 weeks (Q2W) for 16 weeks.
62226635|NCT00513643|ACTIVE_COMPARATOR|6|24 IU human regular insulin
62226636|NCT05960617|EXPERIMENTAL|Oral administration of Empagliflozin|All subjects will have a baseline assessment and be prospectively followed up for 12 months to examine their outcome after receiving empagliflozin.
62226637|NCT00890487|OTHER|hyaluroni acid pill|
62419610|NCT01691261|EXPERIMENTAL|Treatment|PF-05206388 Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane
62419611|NCT06043219|ACTIVE_COMPARATOR|Traditional Teaching|Traditional anatomical teaching provided by a powerpoint lecture.
62027493|NCT03912259|EXPERIMENTAL|Dupilumab 300 mg Q2W|Dupilumab at a loading dose of 600 mg, SC on Day 1 followed by 300 mg, Q2W for 16 weeks.
62027494|NCT03590301|EXPERIMENTAL|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup will enable and inspire parents to encourage their children to improve their diet and activity behaviors through general authoritative parenting, structured feeding practices, and a healthy home environment. Parents and toddlers will participate in the FUNPALs Playgroup together where they will be led through a series of open but structured activities including free play, exercise, snack preparation, discussion, singing, and yoga stretches.
62801604|NCT05456737||Bilateral Group|"Participants with a diagnosis of bilateral clubfoot treated with the Ponseti method were evaluated once with the following evaluation methods:~Anthropometric measurements FPI-6 Fizyosoft Balance System Functional Activity and Skills Form. OxAFQ-C and OxAFQ-P Kiddy-Kid-Kiddo KINDL"
62801605|NCT05456737||Healty Group (Control)|"Healthy participants with normal development were evaluated once with the following evaluation methods:~Anthropometric measurements FPI-6 Fizyosoft Balance System Functional Activity and Skills Form. OxAFQ-C and OxAFQ-P Kiddy-Kid-Kiddo KINDL"
62801606|NCT01290757|EXPERIMENTAL|Dabigatran etexilate 150 mg (T)|Capsugel (T), oral administration
62027495|NCT03590301|ACTIVE_COMPARATOR|Healthy Toddlers Parent Group|The goal of the Healthy Toddlers Parent Group is to deliver the same nutrition and activity messages to parents as those delivered in the FUNPALs Playgroup. In the Healthy Toddlers Parent Group, parents (without children) will meet in groups to receive information on nutrition and activity as it relates to their toddlers and they will engage in a discussion around how they do or can implement these behaviors. No experiential learning, children, play, or parenting instruction will be included in this control condition.
62801607|NCT01290757|EXPERIMENTAL|Dabigatran etexilate 150 mg (R)|Qualicaps (R), oral administration
62419612|NCT06043219|EXPERIMENTAL|Action Observational|Traditional anatomical teaching via a recorded powerpoint and additionally receiving practice of the task via action observation.
62419613|NCT06043219|EXPERIMENTAL|Action Observational and Motor Imagery|Traditional anatomical teaching via a recorded powerpoint and additionally receiving practice of the task via action observation and at the same time imagine themselves executing the same action
62419614|NCT05224297||breast|
62801608|NCT04983277||Diabetes|patients with diagnosed Diabetes Mellitus
62801609|NCT01078441|EXPERIMENTAL|Treatment (combination chemotherapy)|Patients receive bortezomib 1.3 mg/m2 subcutaneously on days 1, 8, and 15; liposomal doxorubicin 30 mg/m2 intravenously (IV) over 1 hour on day 4; oral dexamethasone 20mg on days 1, 2, 8, 9, 15 and 16; and cyclophosphamide 750 mg/m2 IV over 2 hours on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62801610|NCT00497445|EXPERIMENTAL|Angioplasty / surgery and exercise therapy|Angioplasty / surgery followed by supervised exercise therapy
62801611|NCT00497445|NO_INTERVENTION|Angioplasty / surgery|Angioplasty / surgery alone
62027496|NCT06276855|NO_INTERVENTION|Control group|The DIF, PSQI, VAS, and BDI were also administered to individuals in the control group during the first interview, but no education was provided to them. The participants were given an appointment to meet at the hospital one month later. At the final polyclinic appointment one month later, the VAS, PSQI, and BDI were administered for the second time and took an average of 15-20 minutes to complete. In line with ethical principles, they were provided with individual education on sleep hygiene and sleep hygiene education booklets at the final polyclinic appointment. The same researcher collected the data and provided the education to avoid bias.
62419615|NCT05224297||thorax|
62419616|NCT05224297||skin|
62419617|NCT05224297||abdomen|
62419618|NCT05224297||skull|
62419619|NCT05224297||head and neck|
62419620|NCT05224297||pelvis male|
62419621|NCT05224297||pelvis female|
62027497|NCT06276855|EXPERIMENTAL|Experimental group|During the first interview, the DIF, PSQI, VAS, and BDI were administered to individuals in the experimental group. Each education session lasted an average of 30 minutes and was conducted face-to-face. Sleep hygiene education booklets were provided to individuals at the end of the education session. Studies suggest that at least one month should pass for behavioral change to occur after the education session. Therefore, the participants were given an appointment to meet at the hospital one month later. At the final interview one month after the education, the VAS, PSQI, and BDI were administered for the second and final time and took an average of 15-20 minutes to complete.
62027498|NCT06031246|EXPERIMENTAL|Selective Lymph Node Dissection|Selective Lymph Node Dissection is performed for cT1N0M0 Invasive Non-small Cell Lung Cancer With CTR\>0.5 Located in the Apical Segment
62419622|NCT05224297||extremities|
62027499|NCT06464393|ACTIVE_COMPARATOR|ketamine-lidocaine-dexmedetomidine group|combination of ketamine-lidocaine-dexmedetomidine
62027500|NCT06464393|ACTIVE_COMPARATOR|fentanyl group|fentanyl
62226638|NCT02192021|EXPERIMENTAL|Micro needle array-Doxorubicin (MNA-D)|MNA-D application for all subjects
62419623|NCT03614065|PLACEBO_COMPARATOR|arm a|This group is a placebo control group, and we will use radiation therapy plus Placebos as the control group for the study
62419624|NCT03614065|EXPERIMENTAL|arm b|This group belongs to the experimental group. We will use radiotherapy combined with endostar for treatment, so as to judge the efficacy of the medicine
62419625|NCT04934332|EXPERIMENTAL|Newly hospitalized patients|Patients admitted for the first time to a post intensive care rehabilitation unit after severe neurological trauma.
62589896|NCT01062243|EXPERIMENTAL|Brain Injury Education|The Brain Injury Inpatient Guide for Families and Caregivers (BIIG-FACS), developed by J. Niemeier and J. Kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation.
62589897|NCT03513809||Acute hypoxemic respiratory failure|Patients with acute hypoxemic respiratory failure breathing spontaneously with no requirements of immediate intubation connected to thoracic electrical impedance tomography.
62419626|NCT06567899||Non-pregnant with previous normal pregnancy|Non pregnant females
62419627|NCT06567899||Non-pregnant with previous known preeclampsia|Women with known preeclampsia in previous pregnancy
62801612|NCT01775774|EXPERIMENTAL|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|A dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 1, 5 and 10 million cells/kg predicted body weight (PBW). Proceed from lower dose to next higher dose if no safety concerns for each cohort.
62801613|NCT01569841|EXPERIMENTAL|IDeg|
62027501|NCT03725982|EXPERIMENTAL|With exoskeleton, then without exoskeleton|Subject will first perform the conditions (simulated, simplified, industrial standing work) with the exoskeleton, then without the exoskeleton.
62027502|NCT03725982|EXPERIMENTAL|Without exoskeleton, then with exoskeleton|Subject will first perform the conditions (simulated, simplified, industrial standing work) without the exoskeleton, then with the exoskeleton.
62027503|NCT04287374|EXPERIMENTAL|Multi-component Well-being Intervention|Reading and writing activities based on cognitive restructuring (rephrasing automatic negative thoughts), gratitude (noticing and appreciating good things in life), and behavioral activation (identifying and scheduling positive activities)
62027504|NCT04287374|SHAM_COMPARATOR|Study Skills Control|Reading and writing activities designed to teach evidence-based study strategies.
62027505|NCT00893932||SIRS|
62027506|NCT01753024||Sepsis-PEST|septic patients with enteral nutrition and pancreatic enzyme supplementation therapy
62027507|NCT01753024||Sepsis-NPEST|Septic patients with enteral nutrition only
62226639|NCT05302388|EXPERIMENTAL|Experimental group|Drug: SIBP-R002 \& Dexamethasone/Methyl prednisolone \& Diphenhydramine Starting from the lowest dose, when the former dose does not meet the termination criteria, then start the next dose group study until Maximum Tolerated Dose (MTD).
62226640|NCT05302388|PLACEBO_COMPARATOR|Placebo control group|Placebo control: The same volume of placebo as SIBP-R002 \& Dexamethasone/Methyl prednisolone \& Diphenhydramine The rule and dose of placebo were the same as SIBP-R002.
62419628|NCT06567899||First Trimester Pregnant (First antenatal visit)|Women in first trimester
62419629|NCT06567899||Second Trimester Pregnant|Women in second trimester
62419630|NCT06567899||Third Trimester with known preeclampsia|Women in third trimester with diagnosis of preeclampsia
62419631|NCT06567899||Third Trimester with Normal Pregnancy|Women in third trimester with no complications.
62419632|NCT00122031|EXPERIMENTAL|DBS|
62801614|NCT01569841|ACTIVE_COMPARATOR|IGlar|
62027508|NCT01753024||DM-PEST|Diabetic patients with enteral nutrition and pancreatic enzyme supplementation therapy
62027509|NCT01753024||DM-NPEST|Diabetic patients with enteral nutrition only
62226641|NCT06319456|EXPERIMENTAL|Lisaftoclax (APG-2575) combined with Acalabrutinib|
62226642|NCT06319456|ACTIVE_COMPARATOR|Immunochemotherapy regimens|
62419633|NCT04792281||Patients with suspected native valve endocarditis|
62226643|NCT04320394|OTHER|Septic shock patients|Patients with septic shock will be taken from an additional tube to analyze their immune response
62419634|NCT06684613|EXPERIMENTAL|PrEP Decision Aid|Participants randomized to the decision aid (active intervention arm), will interact with the enhanced PrEP decision aid in REDCap. This is an individualized, patient-facing decision aid that supports informed patient choice and is interactive. In contrast to shared decision aids that guide a clinical encounter, the participants uses the individualized decision aid prior to the clinical encounter to discretely assess HIV risk and build awareness before discussing with their clinician
62419635|NCT06684613|OTHER|Generic Information|"Participants randomized to this arm will be asked to watch a CDC-produced video, PrEP (Pre-Exposure Prophylaxis) (available online free of charge through CDC website) that will serve as a time- and attention-based control."
62801615|NCT03415204|EXPERIMENTAL|acupuncture|
62801616|NCT03415204|NO_INTERVENTION|no acupuncture|
62801617|NCT00556998|EXPERIMENTAL|1|
62801618|NCT03493295||Levonogestrel IntraUterine System (LNG-IUS)|Women in childbearing age between 18 to 30 years old and who have freely chosen a LNG-IUS for contraception after being adequately counselled and informed of all contraceptive options by their physician at the routine clinical practice setting in Spain
62801619|NCT00952458|EXPERIMENTAL|BIS monitoring|Dosing of sedatives with BIS monitoring
62027510|NCT01753024||PCAS-PEST|Patients suffering from cardiac arrest receive both enteral nutrition and pancreatic enzyme supplementation therapy
62589898|NCT04072393|EXPERIMENTAL|Home-based cardiac rehabilitation|"* The intervention consists of a prescribed course of home-based cardiac rehabilitation: 36 sessions, three times a week, one hour each, over a period of 12 weeks.~* Each customized exercise session includes three phases:~  * a 5- to 10-minute warm-up which consists of stretching, flexibility movements, and aerobic activity which gradually raises the heart rate to the desired level~ * a conditioning or training phase, which consists of 20 to 45 minutes of continuous or discontinuous aerobic activity~ * a cool down for 5 to 10 minutes consisting of low-intensity exercise that permits a gradual recovery from the conditioning phase~* The patient will complete a brief questionnaire on the teleHeart application after completing each exercise session on how well they tolerated the exercise. The patient's CR team will receive daily updates from the patient's teleHeart application. Based on feedback from the application, the CR team may modify the patient's exercise program going forward."
62027511|NCT01753024||PCAS-NPEST|Patients suffering from cardiac arrest receive enteral nutrition only
62027512|NCT01753024||ARF-PEST|Patients with acute renal failure receive both enteral nutrition and pancreatic enzyme supplementation therapy
62589899|NCT03879980|PLACEBO_COMPARATOR|Non-QL block|The control (non-QL block) group only received fentanyl IV during surgery.
62027513|NCT01753024||ARF-NPEST|Patients with acute renal failure receive enteral nutrition only
62589900|NCT03879980|EXPERIMENTAL|Bilateral QL block|The patients were in the semi-lateral supine position to show up the side to be blocked. Using USG and 1-6 MHz convex transducer placed in the transverse plane above the iliac crest at the level of the umbilicus. A Stimuplex® 20G 100-mm needle was advanced in anteroposterior direction toward the junction of tapered abdominal muscle layer and QL muscle, and 20 ml of 0.25% bupivacaine was deposited in the anterolateral border of QL muscle at the junction with the transversalis fascia reach outside the anterior layer of transversalis fascia. The lateral approach QL (type I) blocks were performed at both sides of patients. The total amount of bupivacaine was 100 mg for each patient
62589901|NCT03655093||Patients with multiple sclerosis|Patients with MS according to the diagnostic criteria of 2010 Validation of AMSQ questionnaire
62589902|NCT06278883|EXPERIMENTAL|Intervention|Risk assessment pipeline
62419636|NCT04444362|EXPERIMENTAL|Intestinal Microbial Transformation (IMT)|The Intestinal Microbial Transformation (IMT) group received Probacine, in addition to standard treatment and care, including prophylactic antibiotics , fluid therapy, and enteral nutrition supports.
62589903|NCT02759055|EXPERIMENTAL|Clinical Decision Support (CV Wizard)|In the Intervention arm, primary care providers will be provided with an EHR-linked, Web-based clinical decision support system that identifies patients with prediabetes and provides patients and their primary care providers personalized, evidence-based CDS and follow up to reduce risk of heart attacks or stroke, optimizing management and follow up of pre-diabetes patients with uncontrolled CV risk factors.
62589904|NCT02759055|NO_INTERVENTION|Usual Care|In the No Intervention arm, patients receive usual care from their primary care clinic and care providers.
62801620|NCT00952458|NO_INTERVENTION|Standard monitoring|Dosing of sedatives without BIS monitoring
62419637|NCT04444362|NO_INTERVENTION|Control|The control group received standard treatment and care, including prophylactic antibiotics , fluid therapy, and enteral nutrition supports.
62027514|NCT01159691||Neupro|Routine treatment as per approved label in Europe/ in accordance with the terms of the local marketing authorization for Neupro® transdermal patch.
62589905|NCT06465199|EXPERIMENTAL|Phase I- Dose level 1|"Dose Level 1: AMXT-1501 400mg/m2 twice daily and DFMO 1 g/m2 IV (intravenous) daily.~Each patient will receive DFMO by continuous infusion pump at the dose determined by their assigned dose level in addition to the AMXT-1501. At least three and up to six patients per dose level with an estimated three dose levels (based on safety), as well as a confirmation group of the final dose may be enrolled for a projected total of 12 to 24 patients in the Phase I. Subjects may continue to receive this combination until progression or twenty-four (24), 28-day cycles, whichever occurs first."
62801621|NCT05373446|EXPERIMENTAL|SSD8432 300mg|SSD8432 300mg in combination with ritonavir 100mg
62801622|NCT05373446|EXPERIMENTAL|SSD8432 750mg|SSD8432 750mg in combination with ritonavir 100mg
62801623|NCT05373446|PLACEBO_COMPARATOR|SSD8432 placebo|SSD8432 placebo in combination with ritonavir placebo
62801624|NCT05508022|EXPERIMENTAL|Breathing Exercise|Breathing exercises will be applied to the participants in the experimental group.
62027515|NCT05627128|EXPERIMENTAL|Arm1: Crohn's disease patients + DAIN|Participants will have 10 weeks of DAIN intervention (From week 1 to week 10)
62801625|NCT00108862|EXPERIMENTAL|Immediate ART|The intervention is the strategy of initiating antiretroviral therapy (ART) after approximately 2 weeks of tuberculosis (TB) treatment.
62801626|NCT00108862|ACTIVE_COMPARATOR|Deferred ART|The intervention is the strategy of initiating ART after 8 to 12 weeks of TB treatment.
62801627|NCT02186275|EXPERIMENTAL|Vitamin D3 3000 or 4000 UI/day then 2,000 UI/day|"3000 UI or 4,000 UI/day as induction therapy (according to weight) for 4 weeks then 2,000 UIday as maintenance therapy for 48 weeks.~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA))."
62027516|NCT05627128|NO_INTERVENTION|Arm 2: Crohn's disease patients no intervention|Participants will continue consuming their usual diet, with no intervention
62226644|NCT01597453|OTHER|Lifestyle counseling|There are no different arms, NOR-SYS is an observational study
62226645|NCT02637960|EXPERIMENTAL|Fedovapagon 2 mg|One daily dose of 2 mg fedovapagon for 12 weeks
62226646|NCT02637960|EXPERIMENTAL|Placebo matched to fedovapagon|One daily dose of placebo (matched to fedovapagon) for 12 weeks
62027517|NCT01788904||Patients with acute mesenteric ischemia|Patients with acute mesenteric ischemia meeting the in-/exclusion criteria
62243045|NCT04351763|EXPERIMENTAL|Verapamil|"Verapamil - administered intravenously~Bolus of 0.075-0.15 mg/kg (5-10 mg) over at least 3 minutes, then switch to oral administration.~Oral administration~120 to 480 mg/day in divided doses every 6-8 hours (adjust dosage based on cardiac response and age) up to discharge."
62243046|NCT04351763|NO_INTERVENTION|Usual Care|
62419638|NCT05837130|EXPERIMENTAL|Cohort A|Cohort A will include LRRK2 G2019S symptomatic carriers, idiopathic PD patients, and healthy volunteers. It will involve a blood sample collection and an optional cerebrospinal fluid (CSF) collection.
62589906|NCT06465199|EXPERIMENTAL|Phase I- Dose level 2|"Dose Level 2: AMXT-1501 600mg/m2 twice daily and DFMO 1 g/m2 IV (intravenous) daily.~Each patient will receive DFMO by continuous infusion pump at the dose determined by their assigned dose level in addition to the AMXT-1501. At least three and up to six patients per dose level with an estimated three dose levels (based on safety), as well as a confirmation group of the final dose may be enrolled for a projected total of 12 to 24 patients in the Phase I. Subjects may continue to receive this combination until progression or twenty-four (24), 28-day cycles, whichever occurs first."
62589907|NCT06465199|EXPERIMENTAL|Phase I- Dose level 3|Dose Level 3: AMXT-1501 RP2D and DFMO 1.5 g/m2 IV (intravenous) daily. Each patient will receive DFMO by continuous infusion pump at the dose determined by their assigned dose level in addition to the AMXT-1501. At least three and up to six patients per dose level with an estimated three dose levels (based on safety), as well as a confirmation group of the final dose may be enrolled for a projected total of 12 to 24 patients in the Phase I. Subjects may continue to receive this combination until progression or twenty-four (24), 28-day cycles, whichever occurs first.
62589908|NCT06465199|EXPERIMENTAL|Phase II- Arm A: AMXT-1501 + DFMO|"In this portion of the study, cohort 1 will be randomized to either receive Arm A: oral AMXT-1501 at the RP2D found in the Phase I along with continuous infusion pump DFMO at the recommended phase 2 dose (RP2D) found in the Phase I on each day of study or Arm B: continuous infusion pump DFMO alone at the recommended phase 2 dose (RP2D) found in the Phase I. Subjects will receive up to twenty-four (24), 28-day cycles of their assigned treatment. Cohorts 2 (ATRT/ETMR), 3 (DIPG), and 4 (Sarcomas) will automatically be assigned to Arm A with AMXT-1501.~Patients who progress on DFMO alone (and have met the primary PFS endpoint) may crossover to AMXT-1501 +DFMO."
62589909|NCT06465199|ACTIVE_COMPARATOR|Phase II- Arm B: DFMO Alone|"In this portion of the study, cohort 1 will be randomized to either receive Arm A: oral AMXT-1501 at the RP2D found in the Phase I along with continuous infusion pump DFMO at the recommended phase 2 dose (RP2D) found in the Phase I on each day of study or Arm B: continuous infusion pump DFMO alone at the recommended phase 2 dose (RP2D) found in the Phase I. Subjects will receive up to twenty-four (24), 28-day cycles of their assigned treatment. Cohorts 2 (ATRT/ETMR), 3 (DIPG), and 4 (Sarcomas) will automatically be assigned to Arm A with AMXT-1501.~Patients who progress on DFMO alone (and have met the primary PFS endpoint) may crossover to AMXT-1501 +DFMO."
62589910|NCT01558856|ACTIVE_COMPARATOR|Unilateral testing|"Following standard procedures, patients in this group will have unilateral testing for neuromodulation of the sacral nerves.~Intervention: Unilateral electrode placement and testing"
62589911|NCT01558856|EXPERIMENTAL|Bilateral testing|"Patients in this group will have bilateral testing for neuromodulation of the sacral nerves.~Intervention: Bilateral electrode placement and testing"
62589912|NCT03152838||Autism Cases|"20 confirmed autism cases will be involved in this study.~1. The autism patients will be diagnosed according to:Gilliam Autism Rating Scale Arabic version: An assessment of the severity of autism using the Gilliam autism rating scale Arabic version: This test was used for diagnosis and assessment of the severity of autistic features for ages 3-22 years. It consists of 56 items, subdivided into 4 subscales: communication, social interaction, stereotyped behaviors, development and total score.~2. Fasting blood samples will be collected from autism children for DNA Methylation-and quantitative Real-time Polymerase Chain Reaction Analysis"
62589913|NCT03152838||Control|"20 age-gender matched typical development children that will be assigned to the normal control group.~1. Control children will be examined by a psychiatrist to exclude any sub-clinical autistic features.~2. Fasting blood samples will be collected from control children for DNA Methylation-and quantitative Real-time Polymerase Chain Reaction Analysis"
62589914|NCT00613691|EXPERIMENTAL|SPI-1620|SPI-1620 an endothelin B agonist
62589915|NCT05665075|EXPERIMENTAL|QN-023a|QN-023a in adult subjects with r/r AML
62419639|NCT05837130|EXPERIMENTAL|Cohort B|Cohort B will include LRRK2 G2019S carriers, idiopathic PD patients, and heathy volunteers. It will involve only a blood sample collection.
62419640|NCT02487368|EXPERIMENTAL|Needle stimulation pad|a self-administered treatment with a mechanical needle stimulation pad, a mechanical device to be used for 30 minutes daily for 14 days.
62419641|NCT06639854||Hematopoietic Cell Transplant|"Participants choices may include to receive standard post-transplant virus prevention with letermovir or other standard drugs without being part of this study. Participants may choose to receive other investigational therapy, if available.~These alternative treatments have risks and benefits that may be the same or different than those in this research study. The study doctor can discuss these alternative treatments, including their risks and benefits, with you."
62419642|NCT03901027|EXPERIMENTAL|Parents of children with chronic illnesses|psycho-educational intervention for parents
62419643|NCT03081195|EXPERIMENTAL|MFG-delivered by trained family peers|"MFG delivered by trained parent peers drawn from local school planning councils:~10 schools; 60 parent peers (6 per school x 10); 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
62419644|NCT03081195|EXPERIMENTAL|MFG-delivered by CHWs|"MFG delivered by community health workers (CHW) drawn from local primary care clinics:~10 schools; 60 community health workers (6 assigned to children per school x 10); 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
62589916|NCT06667726|EXPERIMENTAL|Diagnostic (18F-DOPA)|Patients receive 18F-DOPA IV and undergo PET/CT over 30 minutes on day 1.
62589917|NCT02353442|PLACEBO_COMPARATOR|Control group|"This group will perform during 4 weeks:~* placebo ultrasound during 5min ;~* scapular squeezing in the sitting position (3x10repetitions);~* upper trapezius stretching (in sitting position, 3x30s and 30s of rest)."
62589918|NCT02353442|ACTIVE_COMPARATOR|Experimental group|"This group will perform during 4 weeks:~* posterior shoulder mobilizations during 5min (mobilizations during 30s and 30s of rest);~* external rotators strengthening in sidelying positions with load (3x10repetitions);~* posterior capsule stretching (sleeper stretch in sidelying position, 3x30s and 30s of rest)."
62589919|NCT02798289|EXPERIMENTAL|Active - Device|The Oculeve Intranasal Neurostimulator will be administered once to induce aqueous tear production once following study enrollment.
62589920|NCT06666543||Women Living with HIV|Women Living with HIV Who Have Given Birth to HIV-Exposed, Uninfected Children
62589921|NCT01707108|EXPERIMENTAL|Dental Implants|Rehabilitation of missing teeth with Dental Implant (MIS Technologies)
62589922|NCT01945970|EXPERIMENTAL|Black tea extract|Spray dried aqueous extract of a representative batch of black tea
62589923|NCT01945970|ACTIVE_COMPARATOR|Positive control|Spray dried aqueous extract of a batch of tea extract that has shown to improve FMD previously
62589924|NCT01945970|PLACEBO_COMPARATOR|Placebo|Food grade colouring, artificial tea flavour and an amount of caffeine matched to the caffeine in the Black tea extract
62589925|NCT03969563|EXPERIMENTAL|MBSR|8-week Mindfulness-based Stress Reduction class that trains participants in mindfulness, meditation, and yoga.
62589926|NCT03969563|ACTIVE_COMPARATOR|Brain Health Education|8-week Brain Health education class that teaches participants about brain-behavior relationships, nutrition, aging facts, sleep, and memory.
62589927|NCT05413369|EXPERIMENTAL|iGlarLixi|Participants self-administered iGlarLixi (100 units per milliliter \[U/mL\] insulin glargine + 100 or 50 microgram \[mcg\]/mL lixisenatide respectively) subcutaneous (SC) injection once daily on top of metformin +/- sodium-glucose co-transporter 2 inhibitor (SGLT-2i) for 24 weeks. Dose was individually adjusted.
62589928|NCT05413369|ACTIVE_COMPARATOR|IDegAsp|Participants self-administered IDegAsp (100 U/mL of insulin degludec + insulin aspart with a ratio of 70:30) SC injection once daily on top of metformin +/- SGLT-2i for 24 weeks. Dose was individually adjusted.
62589929|NCT06420557|EXPERIMENTAL|1 Session|1 neuro-reinforcement session
62589930|NCT06420557|EXPERIMENTAL|3 Sessions|3 neuro-reinforcement sessions
62226647|NCT05441709|NO_INTERVENTION|Standard of care|Standard lactation care is provided by postpartum RNs on the inpatient unit and RNs who are board certified in lactation (IBCLCs).Postpartum RNs provide support to all patients post delivery with direct breastfeeding, breast pump use, and addressing routine breastfeeding concerns. IBCLCs provide direct lactation care for more complicated lactation problems and is delivered in a dosed manner based on the nature of the lactation problem, with low-risk patients often having no encounters.
62801628|NCT02186275|ACTIVE_COMPARATOR|Vitamin D3 800 UI/day then 800 UI/day|800 UI/day as induction therapy for 4 weeks, then 800 UI/day as maintenance therapy for 48 weeks. The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA)).
62419645|NCT03081195|NO_INTERVENTION|Bolstered care|"Comparison (Bolstered care): Mental health wellness materials and educational supports (e.g. books, uniforms)~10 schools; 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
62419646|NCT06703216|EXPERIMENTAL|Treatment Arm|
62419647|NCT05414019|ACTIVE_COMPARATOR|Mini-screw|7 patients will receive an intrusive force delivered by elastics from 2 mini-screws between mandibular lateral incisor and mandibular canine.
62419648|NCT05414019|ACTIVE_COMPARATOR|Utility arch|7 patients will receive an intrusive force delivered by intrusive utility arch.
62419649|NCT05414019|ACTIVE_COMPARATOR|Nitinol reverse curve wire|7 patients will receive an intrusive force delivered by Nitinol reverse curve wire.
62419650|NCT06702540||Positive for respiratory viruses|79 retrospective samples tested positive for respiratory viruses
62589931|NCT06420557|EXPERIMENTAL|5 sessions|5 neuro-reinforcement sessions
62589932|NCT04722510|EXPERIMENTAL|Effect of repeated TMS on aggressive impulse behavior in patients with BPD.|A protocol of 15 sessions of repeated Transcranial Magnetic Stimulation at 1 Hz on right dorsolateral prefrontal cortex.
62589933|NCT06429345|EXPERIMENTAL|Coenzyme Q10 100 Milligrams Oral Capsule|Coenzyme Group received coenzyme Q10 in addition to the the standard preventive measures
62589934|NCT06429345|PLACEBO_COMPARATOR|Placebo group|Placebo Group received only the standard preventive measures
62589935|NCT04925258|NO_INTERVENTION|Services-as-usual|Services-as-usual (referral list for online and telehealth parenting and family mental health services).
62589936|NCT04925258|EXPERIMENTAL|SPACE Parenting Program|"The experimental groups of Manitoba-based parent-child dyads (children ages 3-4 years old) include:~1. Weekly parenting materials, including online videos and mailed out parenting activities, that were developed for the Building Regulation in Dual Generations (BRIDGE) Therapy program. Also included are weekly drop-in group sessions with other parents facilitated by trained MA-level or higher psychology students or psychologists."
62801629|NCT01726894|EXPERIMENTAL|Irreversible Electroporation|
62801630|NCT00305435|EXPERIMENTAL|romiplostim (AMG-531)|
62801631|NCT02372578|EXPERIMENTAL|ASP3662|ASP3662 once daily (QD) and pregabalin placebo 3 times daily (TID) for Weeks 1 - 6. ASP3662 placebo QD and pregabalin placebo TID for Week 7.
62801632|NCT02372578|ACTIVE_COMPARATOR|pregabalin|pregabalin TID and ASP3662 placebo QD for Weeks 1 - 7.
62801633|NCT02372578|PLACEBO_COMPARATOR|Placebo|ASP3662 placebo QD and pregabalin placebo TID for Weeks 1 - 7.
62226648|NCT05441709|ACTIVE_COMPARATOR|ci-BPC with Standard of Care|"In addtion to normal standard of care (as described above), patients will also receive clinically-integrated breastfeeding peer counseling (ci-BPC) from a Peer Counselor at four timepoints throughout the perinatal period. The encounters will take place either in person or virtually and include: an intake encounter between 2- and 30 weeks gestation, a dedicated prenatal infant feeding education encounter, at least one inpatient encounter post-delivery during the delivery admission, and at least one postpartum encounter. Patients will also have access to a warmline that will include phone follow up by the next business day."
62226649|NCT02305537|EXPERIMENTAL|Treatment (Cognitive-Behavioral Therapy)|Participants in the McLean Anxiety Mastery Program
62226650|NCT02305537|NO_INTERVENTION|Waitlist|Participants on the waitlist for the McLean Anxiety Mastery Program
62226651|NCT01919814|ACTIVE_COMPARATOR|Appethyl™, then Placebo|Participants receive Appethyl™ liquid once four hours after breakfast. After a washout period of at least one week, they received the placebo drink once four hours after breakfast.
62589937|NCT05073341|EXPERIMENTAL|experimental and control group and intervention is given in the experimental group|Nurse-led family intervention is given in the experimental group having three components i.e infarmation about the patient condition , guidance, and emotional support
62589938|NCT05073341|OTHER|control group|No intervention will be given in the control group
62589939|NCT06411535|ACTIVE_COMPARATOR|Control Group|"Patients answer the OHIP 14 and the Food Frequency Questionnaires, and are classified according to the NOVA classification. A full-mouth periodontal chart is performed.~After 8 weeks, Questionnaires are re-administered. A full-mouth periodontal chart is performed, along with a session of full-mouth ultrasonic debridement.~After 16 weeks from baseline, administration of the OHIP 14 and the FFQ is repeated. Clinical variables are re-evaluated."
62589940|NCT06411535|EXPERIMENTAL|Nutritional Counseling Group|"Patients answer the OHIP 14 and a Food Frequency Questionnaires, and are classified according to the NOVA classification. A full-mouth periodontal chart is perfomed. Patients receive a nutritional counseling on the significance of reducing ultra-processed food intake. Patients receive weekly motivational emails, as part of the dietary counseling.~After 8 weeks, Questionnaires are readministered. A full-mouth periodontal chart is performed, along with a session of full-mouth ultrasonic debridement. Nutritional counseling is reinforced. Patients receive weekly motivational emails, as part of the dietary counseling.~After 16 weeks from baseline, administration of the OHIP 14 and the FFQ is repeated. Clinical variables are re-evaluated."
62589941|NCT04641962|EXPERIMENTAL|Low dose ASP0367|Participants will receive ASP0367 once daily in the morning for 24 weeks.
62589942|NCT04641962|EXPERIMENTAL|High dose ASP0367|Participants will receive ASP0367 once daily in the morning for 24 weeks.
62801634|NCT00902681|OTHER|Reference|a single dose of 8 mg fesoterodine (Toviaz™ 8 mg) tablet manufactured at Zwickau
62801635|NCT00902681|OTHER|Test|a single dose of 8 mg fesoterodine (Toviaz™ 8 mg) tablet manufactured at Vega Baja (Test)
62801636|NCT01717872|ACTIVE_COMPARATOR|Macintosh laryngoscope blade|A photo of the larynx will be taken with the Macintosh laryngoscope blade lifting and not lifting the epiglottis. The view of the larynx will be assessed using the Percent of Glottic Opening (POGO) score by a blinded assessor.
62801637|NCT01717872|ACTIVE_COMPARATOR|Miller laryngoscope blade|A photo of the larynx will be taken with the Miller laryngoscope blade lifting and not lifting the epiglottis. The view of the larynx will be assessed using the percent of glottic opening score by a blinded assessor.
62801638|NCT04581226||Lung ultrasound|Sonographic assessments including the lung consolidation score, B-line score and Lung aeration score will be recorded 1min. after intubation, at end of surgery and 2h postoperatively.
62801639|NCT01172626||epileptic patients|epileptic patients receiving treatment with continuous Sodium Valproate
62801640|NCT05092672|EXPERIMENTAL|High traffic-related air pollution first|Participants will exercise in an environment with high levels of traffic-related air pollution first. Afterwards, participants will complete the same exercise in an environment with low levels of traffic-related air pollution.
62226652|NCT01919814|PLACEBO_COMPARATOR|Placebo, then Appethyl™|Participants receive the placebo drink once four hours after breakfast. After a washout period of at least one week, they received Appethyl™ liquid once four hours after breakfast.
62589943|NCT04641962|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo once daily in the morning for 24 weeks.
62589944|NCT01190358|PLACEBO_COMPARATOR|Placebo|Sugar pill
62589945|NCT01190358|ACTIVE_COMPARATOR|Grape seed extract|300mg of grape seed extract.
62226653|NCT02293915|EXPERIMENTAL|sodium oligo-mannurarate 900mg|
62589946|NCT05494008|EXPERIMENTAL|Korean herbal medicine treatment|"The Korean herbal medicine treatment group received Korean herbal medicine treatment for 28 days. A trained doctor of Korean medicine with at least 3 years of clinical experience prescribed Korean herbal medicine.~The Korean herbal medicine treatment group were also treated with other Korean medical treatment for twice a week for 4 weeks: acupuncture, pharmacoacupuncture, cupping, and chuna."
62801641|NCT05092672|EXPERIMENTAL|Low traffic-related air pollution|Participants will exercise in an environment with low levels of traffic-related air pollution first. Afterwards, participants will complete the same exercise in an environment with high levels of traffic-related air pollution.
62801642|NCT01064934|EXPERIMENTAL|Lipid apheresis|Lipid apheresis
62801643|NCT01064934|ACTIVE_COMPARATOR|Standard care|Standard care
62801644|NCT01683539|EXPERIMENTAL|The Thinking Skills for Work Program|The Thinking Skills for Work Program includes 5 components delivered by a Cognitive Specialist who works collaboratively with the consumer's Employment Specialist: a) assessing the consumer's strengths and weaknesses in cognitive functioning, and analysis of the contribution of cognitive impairments and other factors to job losses and difficulties obtaining a job; b) teaching coping strategies for dealing with cognitive challenges associated with job search or maintaining a job; c) computer cognitive training involving cognitive exercises with a commercially available software program, which is designed to improve the broad range of cognitive skills through a combination of practice and strategy coaching by the Cognitive Specialist; d) job search planning; and e) job support consultation.
62589947|NCT05494008|ACTIVE_COMPARATOR|Non-Korean herbal medicine treatment|The control group received Korean medical treatment for twice a week for 4 weeks: acupuncture, pharmacoacupuncture, cupping and chuna. (except Korean herbal medicine)
62589948|NCT04303026|ACTIVE_COMPARATOR|Treatment Group|Participants receiving active treatment with two infusions of Zoledronic Acid 5 mg with 3 months interval mixed in 100 ml 0.9% saline
62589949|NCT04303026|PLACEBO_COMPARATOR|Placebo Group|Participants receiving Placebo with two infusions of 100 ml 0.9% saline with 3 months interval.
62589950|NCT02894125||old subject|
62589951|NCT02207842||Volatile anesthesia exposure|
62226654|NCT02293915|PLACEBO_COMPARATOR|Placebo|
62226655|NCT00810394|EXPERIMENTAL|Sorafenib|Dose Re-Escalation Following a Dose Reduction
62419651|NCT06702540||Negative to respiratory viruses|79 retrospective samples tested negative to respiratory viruses
62419652|NCT05262023|EXPERIMENTAL|DNL593 (Healthy Participant)|
62419653|NCT05262023|PLACEBO_COMPARATOR|Placebo (Healthy Participant)|
62419654|NCT05262023|EXPERIMENTAL|DNL593 (Participants with FTD)|
62419655|NCT05262023|PLACEBO_COMPARATOR|Placebo (Participants with FTD)|
62801645|NCT01683539|ACTIVE_COMPARATOR|The Cognitive Skills for Work Program|The Cognitive Skills for Work Program includes 4 components delivered by a Cognitive Specialist who works with the consumer's Employment Specialist: a) assessing the consumer's cognitive strengths and weaknesses their relation to job history b) teaching coping strategies for cognitive challenges associated with job search or maintenance c)job search planning, in which the consumer and the Cognitive and Employment Specialists help identify job leads based on the consumer's interests, and identify cognitive coping strategies and supports the consumer may need to succeed at the workplace; and d) job support consultation, in which the Cognitive and Employment Specialists consult with the consumer on additional cognitive coping strategies to enable the consumer to meet the demands of the job.
62801646|NCT06527326|EXPERIMENTAL|receiving Bifidobacterium supplements|
62801647|NCT06527326|PLACEBO_COMPARATOR|receiving placebo|
62801648|NCT01105208|EXPERIMENTAL|Arm 1|
62801649|NCT01105208|ACTIVE_COMPARATOR|Arm 2|
62801650|NCT02911974|ACTIVE_COMPARATOR|Acquire EUS Biopsy Device|All patients will undergo sampling of pancreatic masses using the Acquire EUS Biopsy Device. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
62226656|NCT01251185|EXPERIMENTAL|CHF|Single-arm, open label, subjects with Congestive Heart Failure, with ischemic etiology.
62226657|NCT05469984|ACTIVE_COMPARATOR|women with term prolonged>18h rupture of membrane|women with term prolonged \>18 h prom or in preterm delivery will be treated with IV ampicillin 2 gr every 6 hours until delivery
62801651|NCT02911974|ACTIVE_COMPARATOR|Expect EUS Aspiration Needle|All patients will undergo sampling of pancreatic masses using the Expect EUS Aspiration Needle. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types
62027518|NCT05319327|ACTIVE_COMPARATOR|Control Group|Participants in the control group will be provided with nutritional guidelines to follow a healthy diet based on a Mediterranean diet.
62226658|NCT05469984|ACTIVE_COMPARATOR|women with preterm labor|women with term prolonged \>18 h prom or in preterm delivery will be treated with IV ampicillin 2 gr every 6 hours until delivery plus IV gentamicin 5 mg/kg every 24 hours
62226659|NCT01111747|EXPERIMENTAL|PRP|In this group PRP will be used in the patellar tendon donor site.
62226660|NCT01111747|SHAM_COMPARATOR|Control|In this group PRP will not be aded to the patellar tendon donor site
62419656|NCT02344914|EXPERIMENTAL|receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
62419657|NCT02344914|NO_INTERVENTION|do not receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the control group.
62419658|NCT06146504|EXPERIMENTAL|CanXida Supplement|"All participants will adhere to the following treatment regime:~Day 1-7: 1 tablet per day Day 8-22: 2 tablets per day Day 23- 84: 3 tablets per day~The product should always be taken with the first meal of the day."
62419659|NCT06146504|PLACEBO_COMPARATOR|Placebo|"All participants will adhere to the following treatment regime:~Day 1-7: 1 tablet per day Day 8-22: 2 tablets per day Day 23- 84: 3 tablets per day~The product should always be taken with the first meal of the day."
62419660|NCT04418115|EXPERIMENTAL|Acupuncture + usual care|Participants randomized to acupuncture treatment will receive 12 acupuncture treatments during 8-12 weeks.
62589952|NCT02207842||No volatile anesthesia exposure|
62589953|NCT05069402|EXPERIMENTAL|Immunonutrition|Oral immunonutrition containing arginine, omega-PUFAs and antioxidants
62589954|NCT05069402|ACTIVE_COMPARATOR|High-protein diet|Oral nutrition with high-protein content
62589955|NCT05069402|ACTIVE_COMPARATOR|Standard nutrition|Oral nutrition with standard components
62589956|NCT04016779|PLACEBO_COMPARATOR|Placebo|Placebo, qd, oral capsule
62589957|NCT04016779|EXPERIMENTAL|SPN-812|SPN-812, qd, oral capsule
62589958|NCT02329067|EXPERIMENTAL|walnut-CH|Western type diet including walnuts (43g/day); Walnuts substitute carbohydrates
62589959|NCT02329067|EXPERIMENTAL|Walnut-SFA|Western type diet including walnuts (43g/day); Walnuts substitute saturated fatty acids
62589960|NCT02329067|EXPERIMENTAL|Walnut-LIB|Western type diet including walnuts (43g/day); no specific recommendation
62589961|NCT02329067|NO_INTERVENTION|Control|Isocaloric western type diet w/o nuts, nut butters or nut oils of any kind
62589962|NCT02880774|EXPERIMENTAL|Mandibular Nonspecific mobilization|GA: Mandibular Nonspecific mobilization on the region of the face with presence of TMD.
62589963|NCT02880774|PLACEBO_COMPARATOR|ultrasound detuned|Group B: Used ultrasound equipment detuned on the region of the face with presence of TMD.
62589964|NCT06668454|OTHER|Surgical Arm|Surgical resection followed by preoperative chemoimmunotherapy for oligometastatic esophagogastric cancer
62589965|NCT05793450|EXPERIMENTAL|IBI362 - Mild and Moderate Renal Impairment|Group 2 - IBI362 administered SC to participants with mild and moderate renal impairment.
62801652|NCT05084430|EXPERIMENTAL|Recurrent MG|To determine the safety and tolerability of M032 at the doses examined when given in combinations with pembrolizumab in patients with recurrent MG.
62801653|NCT05084430|EXPERIMENTAL|Newly Diagnosed MG|To determine Overall Survival at 12 and 24 months, and Progression Free Survival at 6 months (PFS-6) in patients with newly diagnosed glioblastoma multiforme of M032 when given in combinations with pembrolizumab (while maintaining safety).
62801654|NCT01713959|EXPERIMENTAL|Group A - Split Body Treatment|Active treatment of one axilla with the Ulthera System Treatment; Sham treatment of one axilla.
62027519|NCT05319327|EXPERIMENTAL|Intervention group|Participants in the intervention group will follow a nutritional intervention program aimed to reduce UPF consumption. Nutritional intervention will not modify basal caloric intake but will record energy intake along the intervention. Nutritional counseling will be based on nutritional educational material such as encouraged and discouraged food items, recipes, menus and food shopping lists based on unprocessed or minimally processed foods.
62027520|NCT01369342|PLACEBO_COMPARATOR|Placebo IV|Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
62027521|NCT01369342|EXPERIMENTAL|Ustekinumab 130 milligram (mg)|Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
62419661|NCT04418115|NO_INTERVENTION|Usual care|"Our control group will receive business as usual. Hence, they will continue with their usual care for their CRF. By inclusion in the study and by the end of it, the participants in the control group will fill in the requested and similar instruments as the participants in the acupuncture group. Further, we will document any medical care they have received during the study period. This includes also life styles advice, and to which point they have followed such advices."
62419662|NCT06703476|EXPERIMENTAL|Stent vs No Stent|For patients treated by a surgeon randomized to use ureteral stents, the operating surgeon may choose to use a single or double J ureteral stent (6- to 8.5-fr in size) or an alternative ureteral stent of the surgeon's choice to be placed across the ureteroenteric anastomosis intraoperatively. Because there is no standard ureteral stent size or type, the surgeon will select a stent type and size according to their experience and will document the stent size and type used. This is already routinely recorded as part of the standard of care at MSK.
62419663|NCT06703476|EXPERIMENTAL|Alvimopan vs No Alvimopan|For patients randomized to receive alvimopan, the patient will receive alvimopan as a fixed 12-mg dose, with the first dose administered 0.5 to 5 h before the start of surgery; administration will be continued with twice daily oral doses postoperatively until hospital discharge or a maximum of 7 days (15 in-hospital doses), as indicated on the medication's FDA label. This is the current standard of care for most cases at MSK.
62419664|NCT06419803|ACTIVE_COMPARATOR|Strict Arm|The Strict study arm target range will be 65-120 mg/dL, with time in range goal of 70%.
62419665|NCT06419803|ACTIVE_COMPARATOR|Permissive|The permissive study arm target range will be 65-140 mg/dL, with target time in range goal of 70%.
62419666|NCT03408236|EXPERIMENTAL|Botulax|Single dose
62419667|NCT03408236|ACTIVE_COMPARATOR|Botox|Single dose
62419668|NCT06401603|EXPERIMENTAL|Phase 1|Participants enrolled in Phase I, the dose of lisaftoclax you receive will depend on when a participants join this study. Up to 2 dose levels of lisaftoclax will be tested. Between 3-12 participants will be enrolled at each dose level.
62419669|NCT06401603|EXPERIMENTAL|Phase 2|Participants enrolled in Phase II, participants will receive lisaftoclax at the recommended dose that was found in Phase I
62801655|NCT01713959|ACTIVE_COMPARATOR|Group B: Ulthera System Treatment w lido|Subjects receive a bilateral Ulthera System Treatment, with one axilla receiving a subcutaneous lidocaine injection.
62801656|NCT02792231|EXPERIMENTAL|OMG 20 mg|"Ofatumumab 20 mg pre-filled syringes for subcutaneous injectionon on days 1~,7 ,14, week 4 and every 4 weeks thereafter and a teriflunomide-matching placebo, taken orally once daily"
62801657|NCT02792231|ACTIVE_COMPARATOR|TER 14 mg|Teriflunomide 14 mg oral capsule taken once daily and matching placebo for subcutaneous injections to ofatumumab on days 1, 7, 14, week 4 and every 4 weeks thereafter
62801658|NCT02646631|EXPERIMENTAL|Usual Treatment|
62801659|NCT02646631|EXPERIMENTAL|MORE|
62801660|NCT02646631|ACTIVE_COMPARATOR|MORE + MI|
62027522|NCT01369342|EXPERIMENTAL|Ustekinumab approximately (~) 6 milligram per kilogram (mg/kg)|Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg) 390 mg (weight \> 55 kg and \<= 85 kg) and 520 mg (weight \> 85 kg).
62226661|NCT04644562|EXPERIMENTAL|patients undergoing Lower Limb vascular Surgery|Ultrasound-guided lumbar Erector Spinae plane block in patients undergoing Lower Limb vascular Surgery
62226662|NCT05004051||Patients who are booked for and then subsequently have undergone endovascular repair.|Patients who are scheduled and ultimately receive on-IFU endovascular infrarenal aortic aneurysm repair (EVAR)
62801661|NCT05424016|EXPERIMENTAL|Experimental arm|Patients with no contraindications will be included and randomized to receive propranolol orally for 24 months
62801662|NCT05424016|OTHER|control arm|Patient included with a routine follow-up
62801663|NCT03883581|EXPERIMENTAL|ALS individuals with bulbar dysfunction|Participants enrolled in this group will be prescribed dextromethorphan HBr and quinidine sulfate (Nuedexta) as recommended by their treating neurologist. 20 mg dextromethorphan HBr and 10mg quinidine sulfate will be administered orally with 1 capsule every day for the initial 7 days followed by 1 capsule every 12 hours for the remaining 23 days of the study. Participants will be evaluated 30 days apart to determine the impact of treatment.
62589966|NCT05793450|EXPERIMENTAL|IBI362 - Healthy|Group 1 - IBI362 administered subcutaneously (SC) to healthy participants with normal renal function.
62589967|NCT05793450|EXPERIMENTAL|IBI362 - Severe Renal Impairment|Group 3 - IBI362 administered SC to participants with severe renal impairment.
62589968|NCT02344251|OTHER|Group 1|Adherence measured by MEMS Cap
62801664|NCT00704938|EXPERIMENTAL|anti-p53 TCR PBL + DC + IL-2: Melanoma/RCC|Patients with melanoma and renal cell cancer will receive anti-p53 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + dendritic cells (DC) + interleukin-2 (IL-2)
62801665|NCT00704938|EXPERIMENTAL|anti-p53 TCR PBL + DC + IL-2: Other histology|Patients with other histologies, such as breast cancer, will receive anti-p53 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + dendritic cells (DC) + interleukin-2 (IL-2)
62801666|NCT05094726|EXPERIMENTAL|Group A|the participant will received photobiomodulation session.
62226663|NCT05004051||Patients with infrarenal AA without indications for repair undergoing serial monitoring|Patients who do not yet qualify for the aortic aneurysm repair who are enrolled in a serial monitoring program
62226664|NCT05507905|EXPERIMENTAL|Dance 3 Times Weekly (3xD)|Participants in this arm will attend classes 3 times a week for 24 weeks. During the 24 weeks, four different dance forms will be practiced. Each dance form will be taught for 6 weeks.
62589969|NCT02344251|OTHER|Group 2|Adherence measured by ID-Cap technology.
62589970|NCT02269228|EXPERIMENTAL|Asasantin ER|Administered once daily (days 1 to 7), followed by twice daily administration (days 8 to 14)
62589971|NCT02269228|EXPERIMENTAL|Asasantin ER, administered twice daily from day 1 to day 14|
62589972|NCT02269228|PLACEBO_COMPARATOR|Placebo|
62589973|NCT02663102||Fluarix Tetra Group 1|Subjects aged between 6-35 months old who received Fluarix Tetra as per locally approved PI (which is not part of the drug use investigation).
62589974|NCT02663102||Fluarix Tetra Group 2|Subjects aged 3 years and above who received Fluarix Tetra as per locally approved PI (which is not part of the drug use investigation).
62801667|NCT05094726|PLACEBO_COMPARATOR|Group B|the participant will received placebo photobiomodulation session.
62801668|NCT01149928||C/S delivered, wet lung|
62801669|NCT01149928||C/S delivered, healthy infants|
62801670|NCT03501472|EXPERIMENTAL|Text-only PWL, immediate post|"Exposure to 4 FDA-mandated warning labels and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
62801671|NCT03501472|EXPERIMENTAL|Text-only PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
62589975|NCT01773161||Cerebral palsy, post hip surgery|Children between the ages of 4-18 undergoing surgical treatment for hip subluxation or dislocation secondary to cerebral palsy.
62589976|NCT06025513|EXPERIMENTAL|embrace patch treatment|Insulin PK/PD before and after treatment with embrace patch
62801672|NCT03501472|EXPERIMENTAL|Low-emot PWL, immed post|"Exposure to 4 FDA-mandated warning labels paired with images that elicit little emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
62801673|NCT03501472|EXPERIMENTAL|Low-emot PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit little emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
62801674|NCT03501472|EXPERIMENTAL|High-emot PWL, immed posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit high emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
62589977|NCT05500638|EXPERIMENTAL|Virtual Reality Group|Firstly, the intervention group was administered the pretest, then the training program (VR-ESMEPP), and a posttest immediately following the training. The participants were monitored on the 15th day.
62589978|NCT05500638|NO_INTERVENTION|Control Group|For the control group, a pretest, routine outpatient clinical practices, and a posttest were carried out; and the participants were monitored on day 15. They took usual care.
62801675|NCT03501472|EXPERIMENTAL|High-emot PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit high emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
62801676|NCT02727218|EXPERIMENTAL|chest tube removal after 3 hours|30 patients, post thoracoscopic lobectomy, segmentectomy, thoracoscopic mediastinal biopsy, will undergo chest tube removal after 3 hours.
62801677|NCT02727218|ACTIVE_COMPARATOR|delayed chest tube removal|30 patients, post thoracoscopic lobectomy, segmentectomy, thoracoscopic mediastinal biopsy, will undergo chest tube removal according to the department's protocol, most probably post operative day 1 (POD1)
62589979|NCT01623843|ACTIVE_COMPARATOR|Arthroscopic Lavage|Participants have three hip portals (antero-lateral, mid anterior, distal antero-lateral) with limited capsulotomy allowing for a complete assessment of the central and peripheral compartments. The participant has a diagnostic arthroscopy and lavage of the hip joint with three litres of normal saline. No osteochondroplasty or rim resection is completed in this group. No instruments are used to treat minor cartilage or labral damage. The labrum should only be repaired if mechanically unstable once probed with visible displacement or chondrolabral separation. The labrum will be refixated only if the above criteria for labral instability is met.
62801678|NCT03217955|EXPERIMENTAL|CBT-SA|"1. Group sessions for 4 weeks, two sessions per week, 60 minutes per session, two trainers (a CBT therapist and a CBT assistant); eight participants, and;~2. Individual sessions (crystallizing learned skills, focus on individual needs) during 6-8 weeks, one session per week, 45 minutes per session"
62801679|NCT03217955|ACTIVE_COMPARATOR|Standard Treatment|Participants in both study conditions will receive ST. Participants are hospitalized or attending day-treatment at the Department of Early Psychosis, Amsterdam, the psychosis department of the ABC team, Utrecht, Parnassia Den Haag and collaborating (local community) mental health centers.
62801680|NCT04374461|EXPERIMENTAL|mechanically ventilated &/or managed in a critical-care|"This arm is closed to accrual as of September 2020. Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician.~Patients will receive treatment for a maximum of 3 weeks or until one of the following:~Arm A:~* Transfer out of the critical-care unit~* Extubation~* Toxicity~* Death"
62801681|NCT04374461|EXPERIMENTAL|non-mechanically ventilated, non-critical-care|"Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician.~Patients will receive treatment for a maximum of 3 weeks or until one of the following:~Arm B:~* Discharge from hospital~* Admission to a critical-care unit~* Intubation~* Toxicity~* Death"
62801682|NCT01061359||Non-Interventional Study|Chemotherapy containing Epirubicin
62801683|NCT03351517|EXPERIMENTAL|Tapentadol arm|Single dose of 100 mg of extended release oral tapentadol will be administered 1 hour before surgery.
62801684|NCT03351517|PLACEBO_COMPARATOR|Placebo arm|A comparable placebo will be administered 1 hour before surgery.
62801685|NCT06061822|EXPERIMENTAL|AI-planned images acquired|
62801686|NCT06061822|ACTIVE_COMPARATOR|Radiographer-planned images acquired|
62801687|NCT01592071|EXPERIMENTAL|Replace reactive w/ non-reactive foods|Test results, individual dietary plan: 'Replace reactive foods with non-reactive foods'
62801688|NCT04590807|ACTIVE_COMPARATOR|Posterior spinal fusion with pedicle screws|
62801689|NCT04590807|ACTIVE_COMPARATOR|Anterior vertebral body tethering|
62226665|NCT05507905|EXPERIMENTAL|Dance 2 Times Weekly (2xD)|Participants in this arm will attend classes 2 times a week for 24 weeks. During the 24 weeks, four different dance forms will be practiced. Each dance form will be taught for 6 weeks.
62226666|NCT05507905|EXPERIMENTAL|Dance 1 Time Weekly (1xD)|Participants in this arm will attend a class 1 time a week for 24 weeks. During the 24 weeks, four different dance forms will be practiced. Each dance form will be taught for 6 weeks.
62226667|NCT05507905|ACTIVE_COMPARATOR|Music Appreciation Classes (MAC)|In the MAC, the music associated with that dance form will be used as the subject for classes and will also change every 6 weeks.
62226668|NCT04773197|EXPERIMENTAL|Coach-assisted C-CBT with BtB|Participants will receive coach- assisted Beating the Blues (BtB), a C- CBT program, which contains 8 weekly sessions. A coach will provide between session support throughout the 8 sessions.
62226669|NCT04773197|ACTIVE_COMPARATOR|Coach-assisted animated C-CBT with EMW|Participants will receive coach- assisted Entertain Me Well (EMW), an animated C-CBT program, which contains 8 weekly sessions. A coach will provide between session support throughout the 8 sessions.
62801690|NCT04851912||General|Participants with or without psychiatric disorders
62801691|NCT03530397|EXPERIMENTAL|Arm A: MEDI5752|MEDI5752
62801692|NCT03530397|EXPERIMENTAL|Arm B: MEDI5752 and chemotherapy|MEDI5752, pemetrexed, carboplatin and paclitaxel.
62801693|NCT03530397|ACTIVE_COMPARATOR|Arm C: Pembrolizumab and chemotherapy|pembrolizumab, pemetrexed, and carboplatin
62801694|NCT05134558|EXPERIMENTAL|Xenon-enhanced Ventilation CT-guided Radiotherapy|Patients will be receiving Xenon-enhanced Ventilation CT-guided Radiotherapy for functional lung avoidance. The doses for the tumors, lungs, and organs at risk will be examined and evaluated.
62801695|NCT03781661|EXPERIMENTAL|Intervention Group|The participants in the intervention group will be provided with extended information of the advantages of the CT examination of the heart's arteries. This will be given to the participants both orally and written in form of a leaflet. In addition will they be given the opportunity for a visual go-through of their own calcium score images. After this they will be informed of the normal examination result.
62226670|NCT04773197|ACTIVE_COMPARATOR|Standard stand-alone C-CBT with BtB|Participants will use the stand-alone BtB for 8 weekly sessions, without coach assistance.
62226671|NCT01443715|EXPERIMENTAL|Stepped Care IPT-A - Interpersonal Psychotherapy|IPT-A focuses on communication and problem-solving skills.
62801696|NCT03781661|NO_INTERVENTION|Control group|Control Group receives standard care.
62801697|NCT01603303|OTHER|Usual Care + Education Materials|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Water-based vaginal lubricant used during sexual activity.
62226672|NCT01443715|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as Usual is the standard treatment received in the community
62226673|NCT02695303|EXPERIMENTAL|BAY 987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62226674|NCT02345785||Group 1|pediatric patients who need urologic surgery and caudal block
62226675|NCT00681785|ACTIVE_COMPARATOR|A|5000IE dalteparine
62589980|NCT01623843|EXPERIMENTAL|Arthroscopic Osteochondroplasty|After establishing standard portals, an inter-portal capsulotomy will be completed to allow for complete evaluation of the central compartment of the hip. Significant and obvious labral tears and cartilage damage will be addressed. The labrum will be repaired if mechanically unstable once probed with visible displacement or chondrolabral separation. The acetabular rim will be evaluated and any evident Pincer lesion will be resected using an arthroscopic burr under fluoroscopic guidance. Following this resection, the labrum will be refixated only if the criteria for labral instability is met. Following this, a limited capsulotomy will be completed along the head-neck junction of the femoral neck to allow for visualization and treatment of the impingement lesion in the peripheral compartment. For the FIRST-EPIC sub-study, participants will receive the osteochondroplasty intervention as per standard of care.
62589981|NCT03290456|EXPERIMENTAL|Prednisone 5mg/day extended of 12 additional months|Prednisone 5mg/day will be administered from Day 1 to Month 12
62589982|NCT03290456|PLACEBO_COMPARATOR|Placebo 5mg/day extended of 12 additional months|Placebo 5mg/day will be administered from Day 1 to Month 12
62226676|NCT00681785|PLACEBO_COMPARATOR|B|NaCL 0.9%
62226677|NCT03334136|ACTIVE_COMPARATOR|Vitamin D|25-hydroxyvitamin D 20.000 IU capsule given orally. Five capsules the first day and thereafter one capsule every week for 4 months.
62226678|NCT03334136|PLACEBO_COMPARATOR|Placebo|Placebo oral capsules. Five capsules the first day and thereafter one capsule every week for 4 months.
62226679|NCT03527368|EXPERIMENTAL|Time-restricted feeding|
62226680|NCT03527368|OTHER|Usual feeding pattern|Comparison
62226681|NCT05810987|EXPERIMENTAL|ELMs and virtual SP encounters|A virtual communication curriculum featuring electronic learning modules (ELMs) and skills sessions with standardized patients (SPs) along with coaching feedback.
62226682|NCT05810987|ACTIVE_COMPARATOR|ELMs alone|A virtual communication curriculum featuring electronic learning modules (ELMs) only.
62226683|NCT05220384|OTHER|Personalized In-person therapy|
62226684|NCT05220384|OTHER|Generalized, Video-based therapy|
62226685|NCT04463017|ACTIVE_COMPARATOR|Active Treatment: HU6|Planned doses of HU6; N = 74
62226686|NCT04463017|PLACEBO_COMPARATOR|Placebo Comparator|Non-active study drug N = 14
62226687|NCT05125666|EXPERIMENTAL|Dual Task Training|
62226688|NCT05125666|ACTIVE_COMPARATOR|Ordinary Physical Therapy for Ataxia|
62589983|NCT00761670|ACTIVE_COMPARATOR|1|
62226689|NCT02645955||Control group, disease history|people who didn't have disease history of Maintenance Hemodialysis
62226690|NCT02645955||The MHD patient group, diseases history|Maintenance Hemodialysis Patients
62226691|NCT04407871|EXPERIMENTAL|acupuncture and CHM|Women will receive acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after embryo transfer (ET). They will also take CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
62226692|NCT04407871|PLACEBO_COMPARATOR|acupuncture and placebo CHM|Women will receive acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take placebo CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, placebo CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
62243047|NCT05483309|EXPERIMENTAL|Diagnostic Treatment Regimen 1|Patients will receive a chest x-ray and their sputum sample will be analysed using the FilmArray Pneumonia Panel.
62243048|NCT05483309|NO_INTERVENTION|Diagnostic Treatment Regimen 2|Patients will receive a chest x-ray and their sputum sample will not be analysed using the FilmArray Pneumonia Panel.
62589984|NCT00761670|ACTIVE_COMPARATOR|2|
62589985|NCT06277271|EXPERIMENTAL|E-cigarette|Participants will be supplied with an e-cigarette along with a 4-week supply of e-liquid. Participants will receive training on how to use the device and practice puffing with the e-cigarette during the research visit. They will be instructed to self-regulate administration according to their craving and withdrawal symptoms and to refrain from using other nicotine and tobacco products.
62801698|NCT01603303|EXPERIMENTAL|Luvena Group|Luvena used vaginally 2 or 3 times a week. Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs. Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
62027523|NCT00365859|EXPERIMENTAL|De Novo|De novo participants (those who did not participate in protocol (CN138-178 \[NCT00332241\] or CN138-179 \[NCT00337571\]) assigned to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
62801699|NCT01603303|EXPERIMENTAL|Hyalo-Gyn Group|Hyalo-Gyn used vaginally 2 - 3 times a week. Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs. Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
62801700|NCT04669808|EXPERIMENTAL|Cohort A: STP705 30 μg dose|Cohort A: STP705 30 μg dose, localized injection, given once a week for 6 weeks
62589986|NCT01469832|EXPERIMENTAL|Subretinal injection of MA09-hRPE|"* Cohort 1 50,000 cells~* Cohort 2 100,000 cells~* Cohort 2a Better Vision 100,000 cells~* Cohort 3 150,000 cells~* Cohort 4 200,000 cells"
62589987|NCT06223971|EXPERIMENTAL|Patients with history of COVID-19 infection and still experiencing symptoms (Long-COVID)|Participants with a diagnosis of Long- COVID will receive a single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
62027524|NCT00365859|EXPERIMENTAL|Rollover Placebo|Participants who completed participation in protocol (CN138-178 \[NCT00332241\] or CN138-179 \[NCT00337571\]) on placebo treatment and continued to meet all of the inclusion criteria and none of the exclusion criteria. Assigned in this study to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
62243049|NCT05483309|EXPERIMENTAL|Diagnostic Treatment Regimen 3|Patients will receive a CT scan and their sputum sample will be analysed using the FilmArray Pneumonia Panel.
62243050|NCT05483309|EXPERIMENTAL|Diagnostic Treatment Regimen 4|Patients will receive a CT scan and their sputum sample will not be analysed using the FilmArray Pneumonia Panel.
62243051|NCT03483467|EXPERIMENTAL|1|Application of Omnigen
62801701|NCT04669808|EXPERIMENTAL|Cohort B: STP705 60 μg dose|Cohort B: STP705 60 μg dose, localized injection, given once a week for 6 weeks
62801702|NCT04669808|EXPERIMENTAL|Cohort C: STP705 90 μg dose|Cohort C: STP705 90 μg dose, localized injection, given once a week for 6 weeks
62801703|NCT04669808|EXPERIMENTAL|Cohort D: STP705 120 μg dose|Cohort D: STP705 120 μg dose, localized injection, given once a week for 6 weeks
62801704|NCT04669808|EXPERIMENTAL|Cohort E: STP705 180 μg dose|Cohort E: STP705 180 μg dose, localized injection, given once a week for 6 weeks
62801705|NCT04669808|EXPERIMENTAL|Cohort F: STP705 240 μg dose|Cohort F: STP705 240 μg dose, localized injection, given once a week for 6 weeks
62801706|NCT04669808|EXPERIMENTAL|Cohort G: STP705 320 μg dose|Cohort G: STP705 320 μg dose, localized injection, given once a week for 6 weeks
62801707|NCT01618669|EXPERIMENTAL|Regadenoson After Peak Exercise|On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
62027525|NCT00365859|EXPERIMENTAL|Rollover Aripiprazole|Participants who completed participation in protocol CN138-178 \[NCT00332241\] or CN138-179 \[NCT00337571\] on aripiprazole treatment and continued to meet all of the inclusion criteria and none of the exclusion criteria. Assigned in this study to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
62027526|NCT06577532|EXPERIMENTAL|ABO2102|Prat I: Monotherapy
62226693|NCT04407871|PLACEBO_COMPARATOR|control acupuncture and CHM|Women will receive control acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
62226694|NCT04407871|PLACEBO_COMPARATOR|control acupuncture and placebo CHM|Women will receive control acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take placebo CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, placebo CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
62589988|NCT06223971|EXPERIMENTAL|Healthy Participants with history of COVID-19 infection but not experiencing any symptoms.|Healthy participants (without any history of post-COVID symptoms) will receive a single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
62589989|NCT06666686|NO_INTERVENTION|Control group|Control group
62027527|NCT06577532|EXPERIMENTAL|ABO2102 and Toripalimab|Part I\&II: ABO2102 in combination with Toripalimab
62801708|NCT01618669|ACTIVE_COMPARATOR|Regadenoson Alone|On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus (1 hour after exercise recovery), and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
62226695|NCT03546322||Registry|Head and neck cancer patients monitored on registry
62226696|NCT00552240|ACTIVE_COMPARATOR|NVP 200mg bis indie (BID)|after receiving nevirapine (NVP) 200 mg quaue die (QD) for 2 weeks, pt titrated to NVP 200 mg bis in die (BID) combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks
62226697|NCT00552240|ACTIVE_COMPARATOR|Atazanavir 300 mg QD/ritonavir 100 mg QD|patients to receive atazanavir 300 mg QD boosted with ritonavir 100 mg QD combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks
62589990|NCT06666686|EXPERIMENTAL|Active noise control|This is the group where active noise control headphones are applied. Headphones will be applied to patients from the beginning to the end of anesthesia induction.
62801709|NCT02921659|PLACEBO_COMPARATOR|Placebo|placebo, 500 mg, 2x/day for 6 weeks
62801710|NCT02921659|ACTIVE_COMPARATOR|Niagen™|Niagen™ (nicotinamide riboside chloride, ChromaDex, Inc.) 500mg, 2x/day for 6 weeks.
62801711|NCT00003425|EXPERIMENTAL|Amifostine trihydrate|
62801712|NCT01555372|ACTIVE_COMPARATOR|Hook Plate|20 participants will be enrolled in this group.
62801713|NCT01555372|EXPERIMENTAL|Locking Plates|20 paticipants will be enrolled in this group
62801714|NCT06409065|EXPERIMENTAL|Attention Control|Participants will take part in a meditation program. As part of this program, participants will complete up to 4 meditation sessions with a trained counselor. Participants should attend each session together as a family. All sessions will be online by videoconference using Zoom.
62801715|NCT06409065|EXPERIMENTAL|Behavioral Intervention (FFM Program)|Participants will take part in a discussion program. Participants will be asked to complete 4 discussion sessions with a trained counselor over a course of a 4 week period. Participants should attend each session together as a family.
62801716|NCT06409065|EXPERIMENTAL|Usual Care|All participants will receive cancer treatment per usual care (UC).
62801717|NCT00327106|ACTIVE_COMPARATOR|1|Exacyl
62801718|NCT00327106|PLACEBO_COMPARATOR|2|Physiologic serum
62801719|NCT03111836|SHAM_COMPARATOR|Control group|The Control group received limited to general information on blood pressure management
62801720|NCT03111836|ACTIVE_COMPARATOR|Expert-driven group|The intervention will consisted of pre-determined exercise and dietary goals (e.g. increase daily steps by 1000 steps, consuming 2-3 servings of fruit and vegetables per day).
62801721|NCT03111836|ACTIVE_COMPARATOR|User-driven group|The User-driven group received an intervention that enabled participants to select their areas of lifestyle change using text and video web links embedded in the email. The trans-theoretical model was used to inform the design of the User-driven program.
62801722|NCT05437523|EXPERIMENTAL|Study group participants received a constipation action plan (USCAP)|"Received a personalized, pictographic, constipation action plan which detailed the subjects medications to manage functional constipation. The action plan was downloaded from:~https://wrnmmc.libguides.com/pediatrics/USAP~Watched a study group, specific, education video. Followed up in 4 months."
62801723|NCT05437523|ACTIVE_COMPARATOR|Control|Received medications to treat functional constipation Did not receive a written action plan. Watched a control group, specific, education video. Followed up in 4 months.
62801724|NCT05665894||Breast hematoma group|Patients of age between 18 and 75 years old after breast conservative surgery (BCS), VAB or vacuum-assisted excision (VAE) procedure in our facility, who developed clinically significant and large hematoma (\>25 mm). In our institution, we routinely offer a trial of Vacuum-Assisted Evacuation (VAEv) for \>25 mm hematoma that does not fulfill the criteria for immediate surgery and causes discomfort, pressure symptoms, infection, or pain classified on VAS \> 3.
62226698|NCT03433079||Acute Kidney Injury|Patients \> 18 years of age with acute kidney injury were enroled into the study. Arterial levels of neutrophil gelatinase-associated lipocalin (NGAL), arterial lactate, interleukin-6 (IL-6), procalcitonin (PCT) and myoglobin were investigated in all patients.
62801725|NCT04899622|EXPERIMENTAL|Combined MBSR and exercise|Group A will take part in live online weekly mindfulness sessions based on the Mindfulness Based Stress Reduction (MBSR) programme, in addition to supervised exercise classes.
62226699|NCT03243877||Breast Cancer Positive|"A 5cc blood sample will be collected from subjects who were screened for breast cancer at the treating facility and results were positive.~MammoAlert Screening Test will be performed on plasma obtained from the blood sample."
62226700|NCT03243877||Breast Cancer Negative|"A 5cc blood sample will be collected from subjects who were screened for breast cancer at the treating facility and results were negative.~MammoAlert Screening Test will be performed on plasma obtained from the blood sample."
62226701|NCT00561054|NO_INTERVENTION|1|CISPLATIN gENCITABINE cETUXIMAB
62226702|NCT00190411|EXPERIMENTAL|Treatment|Celiprolol
62226703|NCT01952223|EXPERIMENTAL|ADT + pelvic RT|"ADT for a total duration of 3 years i.e. luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist +/-Peripheral anti-androgen~Pelvic RT (by IMRT or IGRT protocol):~* Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
62801726|NCT04899622|ACTIVE_COMPARATOR|Online Self-Management Guide|Group B will be invited to interact with an online self-management guide accessible in the members area of the study website.
62801727|NCT05491408||patients exposed to cough assist device|the first group will include patients with COPD who received conventional management in addition to cough assist device
62226704|NCT01952223|EXPERIMENTAL|ADT + Cabazitaxel + prostate RT|"ADT Cabazitaxel: 4 CT cycles~Prostate-only RT (IMRT or IGRT):~* Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
62226705|NCT01952223|EXPERIMENTAL|ADT + cabazitaxel + pelvic RT|"ADT Cabazitaxel: 4 CT cycles~Pelvic RT (IMRT or IGRT):~* Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
62226706|NCT01952223|ACTIVE_COMPARATOR|ADT + prostate radiotherapy|"ADT for a total duration of 3 years: LHRH agonist or LHRH antagonist +/- anti-androgen~Prostate-only RT (IMRt or IGRT):~* Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
62226707|NCT02851927|EXPERIMENTAL|Mini Thoracoscopy|Thoracoscopy procedure shall be performed using the Rigid Mini Thoracoscope
62226708|NCT02851927|ACTIVE_COMPARATOR|Semirigid Thoracoscopy|Thoracoscopy procedure shall be performed using the SemiRigid Thoracoscope
62226709|NCT00110110|EXPERIMENTAL|CEV Chemo + Cyclosporine & Focal Therapy|Systemic carboplatin (28 mg/kg/dose), etoposide (12 mg/kg/dose) and vincristine sulfate (0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated) chemotherapy given with cyclosporin A (33 mg/kg/dose). Following 4-6 cycles CEV chemotherapy (depending on tumor stage) given every 3 weeks, focal laser therapy and/or cryosurgery are applied for tumor consolidation. Filgrastim is given after each chemotherapy cycle to prevent severe neutropenia.
62226710|NCT04265313||Head and Neck Cancer patients|Turkish patients diagnosed with Head and Neck Cancer
62801728|NCT05491408||patients not exposed to cough assist device|the second group will include COPD patients who received conventional management only.
62801729|NCT03178435|NO_INTERVENTION|Observational|patients will be recruited to this arm to observe prospectively the incidence of AKI among critically ill patients.patients will receive the standard care.No other intervention will be delivered
62801730|NCT03178435|ACTIVE_COMPARATOR|Interventional|Patients in this arm will be subject to AKI risk score. This risk score was recently developed and validated in Mayo clinic the intervention will be Measures to prevent AKI among critically ill patients
62226711|NCT00815685|EXPERIMENTAL|Eicosapentaenoic Acid|
62226712|NCT01372865|EXPERIMENTAL|Mometasone|
62226713|NCT01372865|ACTIVE_COMPARATOR|Nasonex®|
62226714|NCT04830397|EXPERIMENTAL|QLS-101 0.5%|
62226715|NCT04830397|EXPERIMENTAL|QLS-101 1%|
62226716|NCT04830397|EXPERIMENTAL|QLS-101 2%|
62226717|NCT04830397|ACTIVE_COMPARATOR|Timolol Maleate 0.5% preservative free ophthalmic solution|
62226718|NCT03945825|EXPERIMENTAL|Group 1|0.5 mL of 2018/2019 Fluzone QIV intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Fluzone QIV intramuscular injection on Day 90, n=40
62226719|NCT03945825|EXPERIMENTAL|Group 2|0.5 mL of 2018/2019 Fluzone QIV + 0.25 mL of AF03 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Fluzone QIV intramuscular injection on Day 90, n=40
62226720|NCT03945825|EXPERIMENTAL|Group 3|0.5 mL of 2018/2019 Fluzone QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 2019/2020 of Fluzone QIV intramuscular injection on Day 90, n=40
62226721|NCT03945825|EXPERIMENTAL|Group 4|0.5 mL of 2018/2019 Flublok QIV intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
62589991|NCT06666686|EXPERIMENTAL|Passive noise control|This is the group where passive noise control headphones are applied. Headphones will be applied to patients from the beginning to the end of anesthesia induction.
62801731|NCT02398240|EXPERIMENTAL|Low Risk|Low Risk Patients (Stage IA, IIA; no bulky disease or extension): 3 cycles of chemotherapy
62801732|NCT02398240|EXPERIMENTAL|Intermediate Risk|Intermediate Risk Patients (Stage IA bulk/E, IB, IIA bulk/E, IIB, IIIA): 4 cycles of chemotherapy
62801733|NCT02398240|EXPERIMENTAL|High Risk|High Risk Patients (Stage IIIA bulk/ E, IIIB, IVA/B): 6 cycles of chemotherapy
62801734|NCT04674007||Healthy basketball, volleyball and handball players|Healthy basketball, volleyball and handball players
62801735|NCT02316080|EXPERIMENTAL|Desensitizing therapy|14 groups (7 treated with in-office dental bleaching and 7 treated with home-use dental bleaching) . There will be 7 different types of dessensitizing agents that will be used together with the dental bleaching treatment
62801736|NCT02316080|EXPERIMENTAL|Dental Bleaching|2 groups of dental bleaching treatment - 16% carbamide peroxide and 35% peroxide
62801737|NCT01242917|PLACEBO_COMPARATOR|Placebo|
62801738|NCT01242917|EXPERIMENTAL|CCX354-C 100mg twice daily|
62801739|NCT01242917|EXPERIMENTAL|CCX354-C 200mg once daily|
62801740|NCT06330740|EXPERIMENTAL|Intervention Arm|
62801741|NCT06330740|NO_INTERVENTION|Control Arm|
62226722|NCT03945825|EXPERIMENTAL|Group 5|0.5 mL of 2018/2019 Flublok QIV + 0.25 mL AF03 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
62226723|NCT03945825|EXPERIMENTAL|Group 6|0.5 mL of 2018/2019 Flublok QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
62226724|NCT00969410|EXPERIMENTAL|AV-299 administered IV (monotherapy)|Subjects will be enrolled sequentially and treated with AV-299 (formerly SCH 900105) in dose escalating cohorts. Accrual to the next cohort will occur only if \<= 1 out of 6 subjects experiences a dose-limiting toxicity (DLT) during the first 2 cycles. If \>= 2 subjects in the same dose cohort experience a DLT during the first 2 cycles, dose-escalation will be terminated.
62226725|NCT02936167|EXPERIMENTAL|Ringer Lactate|fluid
62226726|NCT02936167|EXPERIMENTAL|Plasmalyte|fluid
62226727|NCT04451538|EXPERIMENTAL|Nutritional intervention group|Supplemental nutritional support is provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase). For non-diabetic patients, ENSURE is provided (Abbott; 112.6 g \[12 spoon, 500 kcal\]/day, twice a day); for diabetic patients, GLUCERNA SR is provided (Abbott; 104 g \[12 spoon, 440 kcal\]/day, twice a day).
62226728|NCT04451538|PLACEBO_COMPARATOR|Control group|Supplemental nutritional support is not provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase).
62226729|NCT06057675|ACTIVE_COMPARATOR|Control|The control arm will receive the current standard of care. Before incision, local anesthetic (1% lidocaine with 1:100,000 epinephrine) will be injected subcutaneously into the surgical site. The surgical team will inject approximately 0.8mL per square centimeter of the surgical site area (defect area and undermined tissue area).
62589992|NCT06500065|EXPERIMENTAL|Diagnostic (68Ga-DOTATATE dPET/CT)|Patients receive gallium Ga 68-HA-DOTA-TATE intravenously (IV) and undergo dPET/CT over 60 minutes up to two weeks after starting standard chemotherapy. Beginning 24 hours after gallium Ga 68-HA-DOTA-TATE dPET/CT, patients also receive fludeoxyglucose F-18 IV and undergo dPET/CT over 60 minutes..
62589993|NCT04971148|ACTIVE_COMPARATOR|HFNC flow set at patient peak tidal inspiratory flow|HFNC flow will be set at the level that matches patient peak tidal inspiratory flow
62801742|NCT05586919|ACTIVE_COMPARATOR|Direct Puncture Repair / Ethanol|
62801743|NCT05586919|ACTIVE_COMPARATOR|Direct Puncture Repair / Polidocanol|
62801744|NCT00800566|EXPERIMENTAL|Oral Clofarabine|
62801745|NCT04948047||Malignant pulmonary nodules|Patients with pulmonary nodule diagnosed as malignant cancer by pathological examinations after surgical resection.
62801746|NCT04948047||Benign pulmonary nodules|Patients with pulmonary nodule diagnosed as benign disease by pathological examinations after surgical resection.
62801747|NCT06362096|EXPERIMENTAL|ARM1|
62801748|NCT02490449|EXPERIMENTAL|Exprerimental group|medication after diet
62801749|NCT02490449|ACTIVE_COMPARATOR|control group|medication before diet
62801750|NCT04934566|EXPERIMENTAL|patients|patients receiving temporary veno-arterial assistance whose weaning, or transfer to a heart transplant, or to long-term assistance or discontinuation is envisaged.
62801751|NCT02029911|EXPERIMENTAL|Aurora Treatment Arm|Endometrial Ablation
62801752|NCT03997461|EXPERIMENTAL|BPro vs Oscar 2|Blood pressure measurement with BPro and Oscar 2 simultaneously during 24 hours under ambulatory conditions
62801753|NCT04339816|EXPERIMENTAL|HC-A group|"* Day 1: Patients receive two doses 400 mg of Hydrochloroquine in 12 hours interval and 500 mg of Azithromycin once in 24 hours (with the first dose of hydrochloroquine)~* Days 2-5: Patients receive two doses 200 mg of Hydrochloroquine in 12 hours interval 250 mg of Azithromycin once in 24 hours (with the first daily dose of hydrochloroquine)"
62801754|NCT04339816|ACTIVE_COMPARATOR|HC group|"* Day 1: Patients receive two doses 400 mg of Hydrochloroquine in 12 hours interval and placebo once in 24 hours (with the first dose of hydrochloroquine)~* Days 2-5: Patients receive two doses 200 mg of Hydrochloroquine in 12 hours interval and placebo once in 24 hours (with the first dose of hydrochloroquine)"
62226730|NCT06057675|EXPERIMENTAL|Experimental|The experimental arm will receive local anesthetic (1% lidocaine with 1:100,000 epinephrine) and TXA (1g/10mL) in a 9:1 volume ratio. This will be injected subcutaneously into the surgical site. The surgical team will inject approximately 0.8mL per square centimeter of the surgical site area (defect area and undermined tissue area).
62226731|NCT04361942|EXPERIMENTAL|Mesenchymal Stem Cells (MSCs)|Intravenous injection of 1 million MSCs (MSV cells)/Kg suspended in 100 ml of physiological saline solution.
62801755|NCT04339816|PLACEBO_COMPARATOR|C group|• Day 1-5: Patients receive two doses of placebo in 12 hours interval and 1 extra dose of placebo once in 24 hours
62801756|NCT03715803||Calistar A|Calistar A mesh to treat anterior and apical POP
62801757|NCT03715803||Calistar S|Calistar S mesh to treat anterior and apical POP
62801758|NCT01220804||NPDR|Type 2 diabetic patients with nonproliferative diabetic retinopathy (NPDR)
62801759|NCT01220804||Control Population|Healthy volunteers
62226732|NCT04361942|PLACEBO_COMPARATOR|Placebo|Intravenous injection of 100 ml of physiological saline solution containing no cells
62226733|NCT01517646|NO_INTERVENTION|Fat Reduction|
62226734|NCT02238353|EXPERIMENTAL|azelastine + fluticasone|azelastine 137 µg + fluticasone 50 µg combined applied twice daily one puff in each nostril duration: 4 weeks
62243052|NCT03483467|PLACEBO_COMPARATOR|2|Dummy Omnigen Packaging
62801760|NCT05513339||Cardiology Fellows|Cardiology fellows at Thomas Jefferson University Hospital (PGY4-PGY6)
62801761|NCT03679065|ACTIVE_COMPARATOR|P (Paracetamol) group:(n=100)|
62801762|NCT03679065|ACTIVE_COMPARATOR|D (Dexamethasone) (Dex) group: (n=100)|
62801763|NCT03679065|PLACEBO_COMPARATOR|Placebo|
62801764|NCT04410094|EXPERIMENTAL|Cohort 1: Lazertinib plus Itraconazole|Participants will receive a single oral dose of lazertinib tablets in Treatment Period 1 followed by itraconazole capsules orally along with a single oral dose of lazertinib tablet in Treatment Period 2.
62801765|NCT04410094|EXPERIMENTAL|Cohort 2: Lazertinib plus Rifampin|Participants will receive a single oral dose of lazertinib tablets in Treatment Period 1 followed by rifampin capsules orally along with a single oral dose of lazertinib tablet in Treatment Period 2.
62801766|NCT05520632||Children without autism spectrum disorder|Children without autism spectrum disorder undergoing BAEP
62801767|NCT05520632||Children with autism spectrum disorder|Children with autism spectrum disorder undergoing BAEP
62801768|NCT02146794|EXPERIMENTAL|Renal denervation|renal denervation
62801769|NCT03469466||untrained|Volunteers untrained in bedside ultrasound technique
62801770|NCT03469466||trained|Volunteers previously trained and experienced in bedside ultrasound technique
62801771|NCT03469466||healthy volunteer|Standardized patient who will undergo ultrasound study
62801772|NCT05771649|EXPERIMENTAL|Mindfulness-based intervention (MBI)|A 4-week mindfulness-based intervention comprised of focused attention meditations. From 15 to 30 minutes of practice per session, four times/week through audio guides.
62801773|NCT05771649|ACTIVE_COMPARATOR|Physical exercise (PE)|A 4-week physical exercise intervention comprised of running with mental association strategies. From 15 to 30 minutes of practice per session, three times/week through workout audio guides.
62801774|NCT05771649|NO_INTERVENTION|Treatment as Usual (TAU)|The participants will continue their daily activity and obligations in the academy as usual.
62801775|NCT00547651|EXPERIMENTAL|Amrubicin|Amrubicin
62801776|NCT00547651|ACTIVE_COMPARATOR|Topotecan|Topotecan
62027528|NCT04215029|EXPERIMENTAL|Group I (exercise plan, coaching calls, nutrition counseling)|Patients and their partners receive an exercise plan and printed materials that includes instructions for walking or other moderate-intensity activities. Patients and their partners also receive coaching calls discussing physical activity and diet related questions, each lasting 45-60 minutes and occurring every 2 weeks for 6 months. In addition, patients and their partners complete 2 nutrition counseling sessions over 1 hour each at baseline and before month 3 with an MD Anderson registered dietitian.
62027529|NCT04215029|ACTIVE_COMPARATOR|Group II (physical activity/healthy eating information)|Patients and their partners receive information/materials regarding physical activity and healthy eating.
62027530|NCT04215029|EXPERIMENTAL|Provider Interviews (interviews)|Healthcare providers participate in an interview regarding their opinions on family-focused care and its ability to improve health behaviors.
62027531|NCT04032847|EXPERIMENTAL|Cohort A|Following lymphodepletion with enhanced host conditioning, infusion of cell therapy product ATL001, followed by a low dose regimen of IL- 2.
62027532|NCT04032847|EXPERIMENTAL|Cohort B|Following lymphodepletion with enhanced host conditioning, infusion of cell therapy product ATL001 in combination with a checkpoint inhibitor, followed by a low dose regimen of IL- 2.
62027533|NCT04032847|EXPERIMENTAL|Cohort C|Following lymphodepletion with enhanced host conditioning, infusion of cell therapy product ATL001, followed by a higher dose regimen of IL-2.
62027534|NCT02353923|EXPERIMENTAL|OcuStem Supplementation|Twice daily supplementation with OcuStem. Subjects will take 2 capsules in the morning and 2 capsules at night for a total of 2800 mg/day of active ingredients.
62027535|NCT01631032|PLACEBO_COMPARATOR|Control|control group receive placebo capsule with same look, smell and flavor compared with experiment group. The scheme for medication is 3 times a day, 3gm each time, total 9gm per day.
62801777|NCT05926934|EXPERIMENTAL|Single strand β-Ti fixed retainer|Single strand β-Ti fixed retainer 0.011in diameter, bonded on each tooth separately from #33-43
62801778|NCT05926934|EXPERIMENTAL|SS fixed retainer|SS fixed retainer 0.028in diameter, bonded on each tooth separately from #33-43
62027536|NCT01631032|EXPERIMENTAL|Chinese herbal products (CHP)|CHP group receive Qi-tonifying Chinese herbal products capsule, 3 times a day, 3gm each time, total 9gm per day
62801779|NCT05926934|EXPERIMENTAL|Twisted fixed retainer|Twisted fixed retainer 0.027in diameter, bonded on each tooth separately from #33-43
62801780|NCT02205671|EXPERIMENTAL|Intervention|Building Better Caregivers Small-group Workshop
62801781|NCT01775371|EXPERIMENTAL|Patient Controlled Analgesia|PCA (loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes)
62801782|NCT01775371|ACTIVE_COMPARATOR|Usual Care|Usual opioid analgesia determined by the provider
62801783|NCT05191693||patients with CBD stones up to 8-12mm|72 patients (mean age: 67 years, 52.8% males) were included, of whom 22 (30.5%) had multiple CBD stones, 23 (31.9%) had a history of cholecystectomy, 13 (18.1%) had a periampullary diverticulum and 22 (30.5%) had a previous EST
62801784|NCT02346045|EXPERIMENTAL|Renal sympathetic denervation|Renal sympathetic denervation procedure plus antihypertensive medication (doses and types of medication are maintained as previously prescribed)
62027537|NCT02575846|ACTIVE_COMPARATOR|Human Milk|Neonates fed human milk
62027538|NCT02575846|PLACEBO_COMPARATOR|Formula|Neonates fed formula
62027539|NCT04593888|NO_INTERVENTION|No intervention|The group will be followed without any intervention, with regular visits at the research clinic.
62589994|NCT04971148|EXPERIMENTAL|HFNC flow set at 1.33 times of patient peak tidal inspiratory flow|HFNC flow will be set at the level that is 1.33 times of patient peak tidal inspiratory flow
62589995|NCT04971148|EXPERIMENTAL|HFNC flow set at 1.67 times of patient peak tidal inspiratory flow|HFNC flow will be set at the level that is 1.67 times of patient peak tidal inspiratory flow
62589996|NCT04971148|EXPERIMENTAL|HFNC flow set at 2 times of patient peak tidal inspiratory flow|HFNC flow will be set at the level that is 2 times of patient peak tidal inspiratory flow
62801785|NCT02346045|SHAM_COMPARATOR|Medical therapy|renal angiogram plus antihypertensive medications (doses and types of medication are maintained as previously prescribed)
62801786|NCT03479086|EXPERIMENTAL|Topiramate|Topiramate 200mg/day
62801787|NCT03479086|EXPERIMENTAL|Naltrexone|Naltrexone 50mg/day
62801788|NCT05377853|EXPERIMENTAL|Blindness history|Since this is a regression analysis, all participants are assigned to the same Arm with blindness history and the demographics as covariates.
62801789|NCT04001348|EXPERIMENTAL|HTL-STREFA S.A.safety lancet type 610|
62801790|NCT04001348|EXPERIMENTAL|HTL-STREFA S.A.safety lancet type 553-556|
62801791|NCT04001348|EXPERIMENTAL|HTL-STREFA S.A.safety lancet type 430|
62801792|NCT04001348|EXPERIMENTAL|HTL-STREFA S.A.safety lancet type 520|
62801793|NCT01933308|EXPERIMENTAL|Continuous high intensity training-CT80|All arms will receive standardized comprehensive self-management teaching from health care practitioners. At program completion, all subjects will receive the same standardized exercise recommendations. The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The duration of the training phase will be adjusted such that the total amount of work performed per session will be comparable between the three interventions. The training phase for the CT80 will consist of exercising at 80% of peak work rate (target training intensity) for 25 minutes, for a total session duration of 40 minutes.
62027540|NCT04593888|EXPERIMENTAL|Gluten reduced diet|"Subjects will follow a diet that does not exceed a daily intake of 3 gram gluten.~The group will be followed with regular visits at the research clinic."
62027541|NCT00644722|ACTIVE_COMPARATOR|1|Single use metallic blades
62027542|NCT00644722|ACTIVE_COMPARATOR|2|Classic reusable metallic blades
62027543|NCT04108091||Treatment for TTR amyloidosis|Transthyretin amyloid cardiomyopathy (wild-type or variants) patients administered Vyndaqel and Vynmac.
62589997|NCT03432793|EXPERIMENTAL|TD-9855 + Fluvoxamine + Caffeine|Male smokers will receive TD-9855, fluvoxamine, and caffeine
62801794|NCT01933308|EXPERIMENTAL|Training at ventilatory threshold-CTVT|The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The duration of the training phase will be adjusted such that the total amount of work performed per session will be comparable between the three interventions. The training phase for the CTVT will consist of exercising at the ventilatory threshold for a duration that will result in a total amount of work equivalent to the work that each patient would have done if he/she had been assigned to the CT80 arm. This approach has been used successfully in the past to isolate the effect of training intensity from that of total training dose.
62801795|NCT01933308|EXPERIMENTAL|Interval training-IT|The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The training phase for the IT will consist of intervals of 30 seconds of exercise at 100% of work peak interspersed with intervals of 30 seconds of rest. This approach to IT was selected because it was successfully used by Vogiatzis et al. \[33\] and was shown to be as effective as continuous exercise training at a moderate intensity. As with the CTVT and CT80 arms, the duration of the training phase will be adjusted for the IT arm such that the total amount of work will be equivalent.
62801796|NCT00965666|EXPERIMENTAL|Open Label|
62801797|NCT01425801|EXPERIMENTAL|LAS100977 0.625 μg|Single-dose LAS100977 0.625 μg, during double-blind treatment period
62801798|NCT01425801|EXPERIMENTAL|LAS100977 1.25 μg|Single-dose LAS100977 1.25 μg, during double-blind treatment period
62801799|NCT01425801|EXPERIMENTAL|LAS100977 2.5 μg|Single-dose LAS100977 2.5 μg, during double-blind treatment period
62801800|NCT01425801|ACTIVE_COMPARATOR|Salbutamol|Single-dose salbutamol 400 μg, during double-blind treatment period
62801801|NCT01425801|PLACEBO_COMPARATOR|Placebo|Placebo to LAS100977, and placebo to salbutamol
62801802|NCT01425801|EXPERIMENTAL|LAS100977 0.313 μg|Single-dose LAS100977 0.313 μg, during double-blind treatment period
62801803|NCT06410898|ACTIVE_COMPARATOR|skin biopsy from vitiligo lesion in vitiligo patient|punch biopsy 5mm from vitiligo patch in vitiligo patient
62801804|NCT06410898|ACTIVE_COMPARATOR|skin biopsy from normal skin in vitiligo patient|punch biopsy 5mm from normal skin patch in vitiligo patient
62801805|NCT06410898|ACTIVE_COMPARATOR|skin biopsy from normal skin in normal person|punch biopsy 5mm from normal skin patch in normal person
62027544|NCT04711564||Provision of olive oil emulsions in PN|Olive oil-based (Oliclinomel: 80% OO, 20% LCT provided in a complete all-in-one PN bag by Baxter) parenteral nutrition
62027545|NCT04711564||Provision of soybean emulsions in PN|Soybean-based (Kabiven: 100% LCT provided in a complete all-in-one PN bag)
62027546|NCT04325659|ACTIVE_COMPARATOR|Lofexidine/Sham Bridge Device|Lofexidine (Lucemyra) encapsulated
62027547|NCT04325659|PLACEBO_COMPARATOR|Sham Bridge Device /Placebo Study Drug|Inactive Bridge Device and placebo study drug
62589998|NCT03432793|EXPERIMENTAL|TD-9855 + Itraconazole + Caffeine|Male non-smokers will receive TD-9855, itraconazole, and caffeine
62801806|NCT01272232|EXPERIMENTAL|Lira 3.0 mg|
62801807|NCT01272232|EXPERIMENTAL|Lira 1.8 mg|
62801808|NCT01272232|EXPERIMENTAL|Placebo|
62027548|NCT04325659|EXPERIMENTAL|Active Bridge Device/ Placebo Study Drug|Active Bridge Device and placebo study drug
62027549|NCT05191576||epileptic children|All patients were diagnosed based on the International League Against Epilepsy (ILAE) operational clinical definition criteria for epilepsy and pediatric neurologists made the diagnosis. The patients had been receiving treatment for at least one year. Epileptic patients were grouped into idiopathic generalized or self-limiting focal epilepsy syndromes according to the International League Against Epilepsy (ILAE) criteria for epileptic seizures and syndromes and guidelines for epidemiological studies for diagnosis and classification.
62027550|NCT05191576||healthy controls|healthy controls without any complaint (e.g., behavior problems, depression, or anxiety) that could interfere with sleep.
62027551|NCT02983734|ACTIVE_COMPARATOR|D-cycloserine|"To compare efficacy of the novel therapeutic approach of DCS in improving cognitive functioning in GW veterans with GWI.~DCS = d-cycloserine~Dosage: 100mg~Dosage form: Pill, administered orally~Frequency: Daily for four weeks"
62589999|NCT00825461||1|Anorexia with tube feeding
62027552|NCT02983734|PLACEBO_COMPARATOR|Placebos|To provide a control group to compare efficacy of the novel therapeutic approach of DCS in improving cognitive functioning in GW veterans with GWI.
62226735|NCT02238353|PLACEBO_COMPARATOR|placebo|twice daily one puff in each nostril duration: 4 weeks
62226736|NCT03970460|ACTIVE_COMPARATOR|45-54 y.o / cemented modular metal-backed tibial implant|This group will undergo a surgery for a knee arthroplasty following standard procedure at our center
62419670|NCT02406365|EXPERIMENTAL|Standard of care plus imaging with research devices|"Eligible patients who consent to participate in the research study will receive their standard of care colposcopy or treatment with the Loop Electrosurgical Excision Procedure (LEEP). Additionally, cervical images will be taken using the diagnostic imaging aid. The cervical images will be compared to the histopathology from the biopsies taken as part of the patients' standard of care for colposcopy. If the patient is presenting for the LEEP procedure, then she will be asked if one or two biopsies can be obtained prior to the procedure but after anesthesia has been administered.~The imaging device is not being used to make a diagnosis, but rather to develop an algorithm to make more efficacious and timely diagnoses of cervical neoplasias in the future."
62590000|NCT00825461||2|Anorexia without tube feeding
62590001|NCT00825461||3|Control
62801809|NCT04645446|EXPERIMENTAL|Pro-ocular™ 1% Progesterone EP topical gel|Multidose formulation despensing unit doses of 0.07 g of topical gel containing 0.7 mg of progesterone
62801810|NCT04645446|EXPERIMENTAL|Pro-ocular™ 0.5% Progesterone EP topical gel|Multidose formulation despensing unit doses of 0.07 g of topical gel containing 0.35 mg of progesterone
62801811|NCT04645446|PLACEBO_COMPARATOR|Placebo topical gel|Multidose formulation identical in appearance to Experimental Products despensing unit doses of 0.07 g of topical gel containing 0 mg of progesterone
62801812|NCT05716074|EXPERIMENTAL|Supervised-exercise group|This group will be given combined low-intensity exercises under the supervision of a physiotherapist.
62801813|NCT05716074|EXPERIMENTAL|Home-exercise group|This group will exercise at home without the supervision of a physiotherapist.
62801814|NCT06313164|EXPERIMENTAL|enhanced L-gluthathione group|
62801815|NCT06313164|PLACEBO_COMPARATOR|placebo group|
62801816|NCT04874935|ACTIVE_COMPARATOR|Lansoprazole arm|33 patients who will receive neoadjuvant chemotherapy and lansoprazole 60 mg twice daily four days before starting chemotherapy regimen and then the same dose will be used during chemotherapy cycles
62801817|NCT04874935|PLACEBO_COMPARATOR|Placebo arm|33 patients who will receive neoadjuvant chemotherapy and placebo capsules.
62801818|NCT00931931|EXPERIMENTAL|HSV1716 - Intratumoral route|Research participants with localized disease receiving HSV1716 as an intratumoral injection
62801819|NCT00931931|EXPERIMENTAL|HSV1716 - intravenous|Research participants with metastatic disease receiving HSV1716 intravenously
62801820|NCT05672290|EXPERIMENTAL|Group 1|Group 1 will be applied external electric stimulation three days per week
62226737|NCT03970460|ACTIVE_COMPARATOR|55-59 y.o / cemented modular metal-backed tibial implant|This group will undergo a surgery for a knee arthroplasty following standard procedure at our center
62226738|NCT03970460|EXPERIMENTAL|45-54 y.o / uncemented Trabecular Metal modular tibial implant|This group will undergo a surgery for a knee arthroplasty with a trabecular metal of the tibial implant
62590002|NCT01188824|ACTIVE_COMPARATOR|Cilostazol|Pletaal® (Cilostazol) 100 mg, bid p.o.
62590003|NCT01188824|PLACEBO_COMPARATOR|placebo|"Placebo~1 tablet, bid p.o."
62590004|NCT03654716|EXPERIMENTAL|ALRN-6924 -- Cohort A|"* Participants will receive ALRN-6924 monotherapy on days 1, 4 (± 1 day), 8 (± 1 day), and 11 (± 1 day) of a 21-day cycle.~* ALRN-6924 will be administered intravenously.~* Participants with otherwise unselected TP53 wild type solid tumors and lymphoma will participate in this cohort."
62590005|NCT03654716|EXPERIMENTAL|ALRN-6924 -- Cohort B|"* Participants will receive ALRN-6924 monotherapy on days 1, 4 (± 1 day), 8 (± 1 day), and 11 (± 1 day) of a 21-day cycle.~* ALRN-6924 will be administered intravenously.~* Participants with solid and CNS tumors and lymphoma with specific diagnoses or molecular features will participate in this cohort."
62801821|NCT05672290|ACTIVE_COMPARATOR|Group 2|Group 2 will be applied external electric stimulation one day per week
62801822|NCT00825201|EXPERIMENTAL|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation given IP on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62801823|NCT00775099|EXPERIMENTAL|Filtered Air Exposure|1 hour exposure to filtered air during intermittent exercise
62801824|NCT00775099|EXPERIMENTAL|Diesel Exhaust Exposure|1 hour exposure to dilute diesel exhaust at a concentration of 300 µg/m3 during intermittent exercise
62801825|NCT00775099|EXPERIMENTAL|Filtered Diesel Exposure|1 hour exposure to diesel exhaust with all particulates filtered out using teflon filter with intermittent exercise
62801826|NCT00775099|EXPERIMENTAL|PALAS Exposure|1 hour exposure to pure carbon particles produced by PALAS generator during intermittent exercise
62801827|NCT06060795||Experimental Group|Patient infected by COVID19
62801828|NCT06060795||Control group|Patient non infected by COVID19
62801829|NCT04816084|EXPERIMENTAL|Population|Voluntary people over 18 from the staff of the University of Reims Champagne Ardenne
62801830|NCT05888675|OTHER|Clinical Study of Weifuchun Treatment on Gastric Cancer|72 patients with gastric cancer were randomly divided into a treatment group of 36 cases and a control group of 36 cases. The treatment group received combination chemotherapy with Weifuchun tablets, while the control group received monotherapy chemotherapy.
62801831|NCT01521130|NO_INTERVENTION|Healthy Control|Healthy Control
62801832|NCT01521130|NO_INTERVENTION|BECTS, no medication|BECTS, no medication
62419671|NCT06424704||Chronic suppurative otitis media with cholesteatoma (Chole)|Patients who applied to Selçuk University Faculty of Medicine Hospital, Department of Ear, Nose and Throat Diseases \& Head and Neck Surgery with complaints of ear discharge and were diagnosed with chronic suppurative otitis media with cholesteatoma were included in the study.
62801833|NCT01521130|EXPERIMENTAL|Levetiracetam Higher dose|Levetiracetam Higher dose
62419672|NCT06424704||Chronic suppurative otitis media without cholesteatoma (CSOM)|The study included patients who applied to Selçuk University Faculty of Medicine Hospital, Department of Ear, Nose and Throat Diseases \& Head and Neck Surgery, with complaints of ear discharge and were diagnosed with chronic suppurative otitis media without cholesteatoma.
62590006|NCT03654716|EXPERIMENTAL|ALRN-6924 -- Cohort C|"* Patients will receive ALRN-6924 in combination with cytarabine on days 1, 8 (± 1 day), and 15 (± 1 day) of a 28-day cycle.~* Cytarabine is administered intravenously.~* ALRN-6924 will be administered intravenously.~* Participants with TP53 wild type acute leukemia will participate in this cohort."
62027553|NCT01410448|ACTIVE_COMPARATOR|Immediate Everolimus (IE)|Everolimus was started within 48 hours after graft reperfusion at a starting dose of 0.75 mg twice daily in combination with low-dose cyclosporine and steroids for 3 months.
62027554|NCT01410448|EXPERIMENTAL|Delayed Everolimus|The standard dose of mycophenolate sodium was administered within 48 hours after graft reperfusion in combination with a full dose of cyclosporine and steroids. After28 +/- 4 days of treatment, mycophenolate sodium was discontinued and everolimus was introduced at a starting dose of 0.75 mg twice daily for 3 months.
62027555|NCT02494791|OTHER|Endometrial and Ovarian Cancer Participants|All study subjects will be offered the same options for screening and follow-up.
62027556|NCT06486740|EXPERIMENTAL|mesofiller aox|The investigated product M-AOX-2021 was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. The both sessions was conducted within 14 days interval.
62027557|NCT05853913|NO_INTERVENTION|Rest|Individuals will rest for about 1 hour in the seated position to mimic time exercising.
62027558|NCT05853913|EXPERIMENTAL|Exercise|Individuals will exercise for at medium to hard intensity for 1 hour.
62027559|NCT01813799|EXPERIMENTAL|DA-9801 300mg|
62027560|NCT01813799|EXPERIMENTAL|DA-9801 600mg|
62590007|NCT06338488|ACTIVE_COMPARATOR|Dry needling group (study group)|Real dry needling into the muscle under ultrasound guidance.
62027561|NCT01813799|EXPERIMENTAL|DA-9801 900mg|
62590008|NCT06338488|SHAM_COMPARATOR|Sham dry needling group (control group)|Sham dry needling into the subcutaneous fatty tissue under ultrasound guidance.
62226739|NCT03970460|EXPERIMENTAL|55-59 y.o / uncemented Trabecular Metal modular tibial implant|This group will undergo a surgery for a knee arthroplasty with a trabecular metal of the tibial implant
62243053|NCT05945927||Participants with HER2-positive Advanced Breast Cancer|Participants will be prospectively followed from the index date (the first treatment of T-DM1) for up to 1 year.
62419673|NCT05092451|EXPERIMENTAL|Cyclophosphamide|Cyclophosphamide is dosed per adjusted body weight for patients weighing \> 20% above their ideal body weight using the calculation.
62027562|NCT01813799|PLACEBO_COMPARATOR|Placebo|
62419674|NCT05092451|EXPERIMENTAL|CAR.70/IL15-transduced CB-NK cells|Patients will receive a single flat dose of CAR-NK.
62801834|NCT04724408|EXPERIMENTAL|VieScope|intubation with the VieScope laryngoscope
62801835|NCT04724408|ACTIVE_COMPARATOR|Conventional|intubation with MacIntosh-type laryngoscope
62801836|NCT00615017|EXPERIMENTAL|AZD9773 cohort 1 (50 units/kg)|AZD9773: single infusion of 50 units/kg
62801837|NCT00615017|EXPERIMENTAL|AZD9773 cohort 2 (250 units/kg)|AZD9773: single infusion of 250 units/kg
62027563|NCT03408912|OTHER|CMR and angiography FFR|Patients will undergo both CMR and angiography to acquired FFR.
62027564|NCT03932565|EXPERIMENTAL|The fourth-generation CAR-T therapy|Clinical trial study of Interventional therapy sequential with the fourth-generation CAR-T cells (IL7 and CCL19 or / and IL12) targeting Nectin4/FAP in the treatment of advanced malignant solid tumors with Nectin4-positive .
62027565|NCT05685108|ACTIVE_COMPARATOR|Group 1|"In Subgroup 1, individuals will receive pulsed ultrasound with a mechanical index of 0.6 and 1.4 delivered to the splenic hilum.~In Subgroup 2, individuals will receive pulsed ultrasound with a mechanical index of 1.0 and 1.8 delivered to the splenic hilum. The two doses will be administered in separate visits with min. 14 days between each stimulation.~In both Subgroups, the two doses will be administered in separate visits with min. 14 days between each stimulation."
62027566|NCT05685108|ACTIVE_COMPARATOR|Group 2|Individuals will receive pulsed ultrasound with a mechanical index of 1.4 delivered to the splenic hilum and the cervical vagus nerve. The two doses will be administered in separate visits with min. 14 days between each stimulation.
62027567|NCT06669130|EXPERIMENTAL|Xiangtong TM full degradation sinus drug stent system|
62027568|NCT06669130|PLACEBO_COMPARATOR|nasopore|
62419675|NCT05092451|EXPERIMENTAL|Fludarabine phosphate|Fludarabine is dosed using actual body weight.
62027569|NCT05735106||Group A (predicted easy intubation)|Group A labelled as predicted easy intubation on the basis of NC/TM distance ratio \<5
62027570|NCT05735106||Group B (predicted difficult intubation)|Group B labelled as predicted Difficult intubation on the basis of NC/TM distance ratio ≥ 5
62027571|NCT05234892||EVAR group|All consecutive eligible patients submitted to EVAR by Alto Endovascular AAA implantation will be included in analysis. Patients will be submitted to EVAR procedures on the basis of their own preferences, anatomical features, and operators experience.
62027572|NCT04078282|EXPERIMENTAL|Active treatment group|Patients will meet in a joint consultation with their family physician and a psychiatrist for evaluation. Then it follows three treatment sessions with the family physician before a new joint consultation with the psychiatrist. The intervention ends with three more treatment sessions with the family physician.
62027573|NCT04078282|ACTIVE_COMPARATOR|Control group|Patients belonging to family physicians who constitute the control group will be assessed and given treatment according to usual care. This may include treatment by the family physician, medication, referrals to specialized care.
62027574|NCT02282501|ACTIVE_COMPARATOR|intermittent feeding|Bolus infusion - The total daily feeding period was also 4-6 times a day.
62419676|NCT06203340|EXPERIMENTAL|Lumbar school training|"Lumbar back school is a programme for patient groups that provides information about the anatomy, biomechanics, optimal posture, ergonomics and lumbar exercises.~The aim of the lumbar lumbar school school is to reduce low back pain and to teach the individual to take care of his lumbar. It is applied to increase the skills of individuals to solve the problems they encounter in daily life and to teach them ways of coping. Assessment of the patient, explanation of the anatomy, functions and pathophysiology of low back pain, appropriate posture, use of correct body mechanics and theoretical explanation of exercise."
62590009|NCT03788408|EXPERIMENTAL|Intensive Psychotherapy Case Management|Treatment group received Intensive Psychotherapy and Case Management (IPCM) delivered by psychotherapists and social worker with expertise in refugee trauma and mental health.
62027575|NCT02282501|ACTIVE_COMPARATOR|continuous feeding|Continuous infusion - The daily desired amount was offered continuously for 20 hours a day.
62027576|NCT06393452|ACTIVE_COMPARATOR|PP405 0.05% Topical Gel|0.05% Topical Gel applied once daily
62027577|NCT06393452|PLACEBO_COMPARATOR|PP405 Topical Vehicle Gel|Placebo Topical Gel applied once daily
62027578|NCT05251753|EXPERIMENTAL|A K-Lock left|A) left side K-Lock with right side suture-based technique
62027579|NCT05251753|EXPERIMENTAL|B K-Lock right|B) right side K-Lock with left side suture-based technique.
62027580|NCT01407185|EXPERIMENTAL|Resistive Training|Subjects will be working at 30-60% of 1 RM. The therapist selects theraband that will produce muscle fatigue \~ 15 reps. Subjects should report that the exercise was somewhat light to somewhat hard 11 to 14 on RPE scale. Increase or decrease resistance until the desired RPE is obtained. Continues until momentary fatigue is evidenced. Fatigue is defined as the inability to move through the full ROM in a slow controlled fashion. Record the exercise performed, amount of resistance, and # of good quality reps performed before fatigue was reached. A single set will be done for each muscle group.
62027581|NCT05854381|EXPERIMENTAL|VIR-1388, 5×10^4 ffu|Study intervention will be administered at Day 1 and Day 85 via subcutaneous (SC) injections.
62027582|NCT05854381|EXPERIMENTAL|VIR-1388, 5×10^5 ffu|Study intervention will be administered at Day 1 and Day 85 via subcutaneous (SC) injections.
62027583|NCT05854381|EXPERIMENTAL|VIR-1388, 5×10^6 ffu|Study intervention will be administered at Day 1 and Day 85 via subcutaneous (SC) injections.
62027584|NCT05854381|PLACEBO_COMPARATOR|Placebo|Study intervention will be administered at Day 1 and Day 85 via subcutaneous (SC) injections.
62027585|NCT03538626|EXPERIMENTAL|Group 1: N6LS (5 mg/kg IV) single dose|N6LS (5 mg/kg) administered by intravenous (IV) infusion (Day 0)
62027586|NCT03538626|EXPERIMENTAL|Group 2: N6LS (5 mg/kg SC) single dose|N6LS (5 mg/kg) administered by subcutaneous (SC) injection (Day 0)
62027587|NCT03538626|EXPERIMENTAL|Group 3: N6LS (20 mg/kg IV) single dose|N6LS (20 mg/kg) administered by IV infusion (Day 0)
62027588|NCT03538626|EXPERIMENTAL|Group 4: N6LS (40 mg/kg IV) single dose|N6LS (40 mg/kg) administered by IV infusion (Day 0)
62027589|NCT03538626|EXPERIMENTAL|Group 5: N6LS (5 mg/kg SC) repeat dose|N6LS (5 mg/kg) administered by SC injection (Day 0, Week 12 and Week 24)
62027590|NCT03538626|EXPERIMENTAL|Group 6: N6LS (20 mg/kg IV) repeat dose|N6LS (20 mg/kg) administered by IV infusion (Day 0, Week 12 and Week 24)
62027591|NCT03538626|EXPERIMENTAL|Group 7: N6LS (5 mg/kg SC) + rHuPH20 (2000 U/ml SC) single dose|N6LS (5 mg/kg) + rHuPH20 (2000 U/ml) administered by SC injection (Day 0)
62027592|NCT03538626|EXPERIMENTAL|Group 8: N6LS (20 mg/kg SC) + rHuPH20 (2000 U/ml SC) single dose|N6LS (20 mg/kg) + rHuPH20 (2000 U/ml) administered by SC injection (Day 0)
62027593|NCT03165526||First Cohort|All available Emergency and Compassionate PIVSD Occluder subject data from 2011 until the end of 2016 will be utilized to determine technical success and acute survival. All subjects belonging to this cohort must have undergone an attempt to close a post-infarct VSD using the AMPLATZER™ PIVSD Occluder.
62027594|NCT03165526||Second Cohort|"This cohort will consist of subjects over the age of 18 years who have previously been successfully implanted with the PIVSD Occluder and~* For living subjects, the subject or subject's legally authorized representative has provided consent to participate in this study.~* Subject's post-procedure echocardiogram is evaluable and can be sent to the echocardiography core laboratory for residual shunt assessment.~Therefore, this cohort will be composed of retrospectively enrolled subjects. This cohort will be utilized to determine acute and chronic closure and chronic survival."
62027595|NCT06669598|EXPERIMENTAL|Experimental Training Group|The ETG group underwent in two 20-minute training sessions per week, with 72 hours of rest between sessions. Each session included aerobic activities such as rowing and treadmill exercises, combined with supervised WB-EMS stimulation. This stimulation utilised a rectangular waveform at 35 Hz, 350 μs, with continuous pulse duration. The intensity of this training modality was set based on heart rate reserve (HRR), starting at 60% HRR in the first week and increasing by 5% every 3 weeks, reaching 80% HRR by the twelfth week.
62027596|NCT06669598|ACTIVE_COMPARATOR|Control group|The CON group underwent three weekly training sessions for twelve weeks, con-sisting of 20 minutes of aerobic activity, performed on a treadmill and rowing machine, without the WB-EMS superimposition.
62027597|NCT02486224|EXPERIMENTAL|Kona Deep|Subjects will receive Kona Deep post-exercise
62027598|NCT02486224|PLACEBO_COMPARATOR|Spring Water|Subjects will receive commercially available Spring Water post-exercise
62027599|NCT02486224|ACTIVE_COMPARATOR|Sports Drink|Subjects will receive commercially available Sports Drink post-exercise
62027600|NCT06465420|ACTIVE_COMPARATOR|Vaccine arm|This arm receives 0.5 mL of a 10 µg dose of Hia Conjugate Vaccine with AdjuPhos.
62027601|NCT06465420|PLACEBO_COMPARATOR|Placebo arm|This arm receives 0.5 mL placebo (normal saline).
62027602|NCT00748046|EXPERIMENTAL|Radium-223 chloride (Xofigo, BAY88-8223)|The patients will receive Radium-223 chloride as an escalating dose of either 50, 100 or 200 kBq/kg b.w. (0.0014, 0.0027 or 0.0054 mCi/kg).
62027603|NCT06634550|EXPERIMENTAL|Mulligan technique group|The participants will receive Mulligan technique and lifestyle modification advice for 4 weeks
62027604|NCT06634550|EXPERIMENTAL|Core stability exercise group|The participants will receive core stability exercises and lifestyle modification advice for 4 weeks
62027605|NCT06634550|ACTIVE_COMPARATOR|Lifestyle modification advice group|The participants will receive lifestyle modification advice only for 4 weeks
62027606|NCT06457009|EXPERIMENTAL|Intervention arm|Within the intervention arm, all medical practitioners will be incentivized by a pay-for-population mechanism within their township. First, finish a ECRHS questionnaire with notification of suspected asthma risk status. Those noticed will be given a face-to-face survey, simple physical examination, pulmonary function tests, and provide a multi-component intervention at baseline. For suspected asthma population, we provide community-based spirometry PFT and education; If individuals whose FEV1 improved by ≥12% and ≥200 mL, they will be undiagnosed asthma patients and encouraged to seek treatment to the superior hospitals. We provide (1) two digital health intervention programs to smokers and individuals with mental health issues; (2) CBT-based health education for study participants with abnormal BMI; (3) active recruitment into National Essential Public Health Program for those with abnormal blood pressure and glucose. Intensive follow-ups will be conducted at month 3, 6, 12.
62027607|NCT06457009|NO_INTERVENTION|Control Arm|Those who are assigned in the control arm, we will ask them to finish the same ECRHS asthma screening online questionnaire with notification of his or her suspected asthma status and a face-to-face survey. No physical examinations, community-based pulmonary function tests will be given.
62243054|NCT02764450|EXPERIMENTAL|Astralis 10 HPM|Polymerization High-power mode: 1300 mW/cm2 for 10 s
62590010|NCT03788408|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Treatment as Usual group received ongoing care from their primary care providers without the involvement of CVT (except for the collection of outcomes). TAU patients could be referred to a full range of outpatient and community-based behavioral health services by their primary care physician.
62590011|NCT06601569||diplegic cerebral palsy|
62590012|NCT06601569||quadripledic cerebral palsy|
62027608|NCT04612361||non impaired sleep group|about 200-250 patients
62027609|NCT04612361||insomnia group|about 200 patients
62027610|NCT04612361||sleep deprived group|about 200-250 patients
62027611|NCT00880932|EXPERIMENTAL|customized electronic alert|"This intervention was not targeted to patients with a disease but to the providers. The intervention was not a drug but a customized electronic alert, requesting the prescriber to specify a reason for override whenever the combination drugs of warfarin and NSAID were ordered together."
62243055|NCT02764450|EXPERIMENTAL|Astralis 10 RM|Polymerisation regular mode: 650 mW/cm2 for 20
62243056|NCT02031783|EXPERIMENTAL|mixture of glucose and fructose|mixture of glucose and fructose
62590013|NCT06601569||hemiplegic cerebral palsy|
62027612|NCT00880932|NO_INTERVENTION|Standard practice|The control group was not patients but the providers. Providers in the control group continued with the standard practice of receiving passive alerts in the form of message boxes warning the provider not to prescribe the combination drugs warfarin and NSAID.
62027613|NCT05916742|EXPERIMENTAL|CAF+VCMX+i-PRF|The surgical procedure for root coverage will be the trapezoidal-type of coronally advanced flap previously described (de Sanctis \& Zucchelli 2007). Thus, it will start with two divergent releasing incisions lateral to the gingival recession defect. These releasing incisions will then be united by a sulcular incision, and the flap will be raised beyond the mucogingival junction. Subsequently, a VCMX functionalized with injectable platelet rich-fibrin (I-PRF) will be placed at the cemento-enamel junction (CEJ) level and stabilized in the adjacent interdental connective beds by interrupted sutures. Then, sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
62027614|NCT05916742|EXPERIMENTAL|CAF+VCMX|The surgical procedure for root coverage will be the trapezoidal-type of coronally advanced flap previously described (de Sanctis \& Zucchelli 2007). Thus, it will start with two divergent releasing incisions lateral to the gingival recession defect. These releasing incisions will then be united by a sulcular incision, and the flap will be raised beyond the mucogingival junction. Subsequently, a VCMX will be placed at the cemento-enamel junction (CEJ) level and stabilized in the adjacent interdental connective beds by interrupted sutures. Then, sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
62027615|NCT05916742|ACTIVE_COMPARATOR|CAF|The surgical procedure for root coverage will be the trapezoidal-type of coronally advanced flap previously described (de Sanctis \& Zucchelli 2007). Thus, it will start with two divergent releasing incisions lateral to the gingival recession defect. These releasing incisions will then be united by a sulcular incision, and the flap will be raised beyond the mucogingival junction. Then, sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
62027616|NCT00784043|EXPERIMENTAL|Bilateral|Bilaterally implanted simultaneously
62027617|NCT00784043|EXPERIMENTAL|Unilateral|Unilaterally implanted
62801838|NCT00615017|EXPERIMENTAL|AZD9773 cohort 3 (250/50 units/kg)|AZD9773: loading infusion of 250 units/kg then 9 maintenance doses of 50 units/kg q12hrs
62801839|NCT00615017|EXPERIMENTAL|AZD9773 cohort 4 (500/100 units/kg)|AZD9773: loading infusion of 500 units/kg then 9 maintenance doses of 100 units/kg q12hrs
62027618|NCT05156138||study group|patients with pseudoexfoliation fulfilling the inclusion criteria
62027619|NCT05156138||control group|patients without pseudoexfoliation fulfilling the inclusion criteria
62027620|NCT03806985|EXPERIMENTAL|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
62027621|NCT03806985|EXPERIMENTAL|Placebo/High Dose Psilocybin|Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
62027622|NCT03806985|EXPERIMENTAL|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
62027623|NCT03806985|EXPERIMENTAL|High Dose Psilocybin/Placebo|Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.
62226740|NCT02268474|EXPERIMENTAL|532nm KTP Laser vs 595nm Pulse Dye Laser|"This is a single-center prospective, randomized, controlled split-face study in 20 subjects diagnosed with Erythematotelangiectatic Rosacea and/or Papulopustular Rosacea.~This two arm, split-face study will consist of:~1. Treatment arm involving treatments with 532nm KTP laser~2. Active control arm involving treatments with 595nm Pulse Dye Laser (PDL)~Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of treatment (532nm KTP laser) and active control treatment (595nm PDL) arms will be determined by randomization."
62226741|NCT01548079|NO_INTERVENTION|Control|Untreated controls
62590014|NCT06601569||dyskinetic cerebral palsy|
62801840|NCT00615017|EXPERIMENTAL|AZD9773 cohort 5 (750/250 units/kg)|AZD9773: loading infusion of 750 units/kg then 9 maintenance doses of 250 units/kg q12hrs
62027624|NCT03806985|EXPERIMENTAL|High Dose Psilocybin/Low Dose Psilocybin|Subjects in this arm receive high dose psilocybin in the first session and low dose psilocybin in the second session.
62243057|NCT02031783|ACTIVE_COMPARATOR|Glucose|Single glucose
62801841|NCT00615017|PLACEBO_COMPARATOR|Placebo|Placebo
62801842|NCT05381363|EXPERIMENTAL|Intervention: Inhaled Interferon α2b|Inhaled Interferon α2b (10U/ml)
62801843|NCT05381363|OTHER|Intervention: Standard of Care|Standard of care treatment will be provided according to management guideline.
62801844|NCT05774639|EXPERIMENTAL|ADL-018 300 mg Main Treatment period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
62801845|NCT05774639|ACTIVE_COMPARATOR|Xolair-300 mg Main Treatment Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
62801846|NCT05774639|EXPERIMENTAL|ADL-018 150 mg Main Treatment period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
62801847|NCT05774639|ACTIVE_COMPARATOR|Xolair-150 mg Main Treatment Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
62801848|NCT05774639|EXPERIMENTAL|ADL-018 300 mg Main / ADL-018 300 mg Transition Period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to ADL-018 300 mg in the Main Treatment period.
62590015|NCT02409563|EXPERIMENTAL|Budesonide nasal (100 mcg bid)|The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: N1 (n = 8) = Budesonide nasal spray 100 mcg, 2 v / d; Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)
62226742|NCT01548079|ACTIVE_COMPARATOR|Ursodeoxycholic acid|Oral ursodeoxycholic acid 20 mg/kg/day in three weeks
62801849|NCT05774639|EXPERIMENTAL|Xolair-300 mg Main / ADL-018 300 mg Transition Period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
62801850|NCT05774639|ACTIVE_COMPARATOR|Xolair-300 mg Main / Xolair-300 mg Transition Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
62801851|NCT05774639|EXPERIMENTAL|ADL-018 150 mg Main / ADL-018 150 mg Transition Period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to ADL-018150 mg in the main treatment period.
62801852|NCT05774639|EXPERIMENTAL|Xolair-150 mg Main / ADL-018150 mg Transition Period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR-150 mg in the main treatment period.
62226743|NCT02526147|NO_INTERVENTION|Control|Receives no intervention
62801853|NCT05774639|ACTIVE_COMPARATOR|Xolair-150 mg Main / Xolair-150 mg Transition Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR -150 mg in the main treatment period.
62801854|NCT02995980|EXPERIMENTAL|Contrast enhanced mammography vs standard digital mammogram|Contrast-enhanced spectral mammography for the detection breast cancer .
62801855|NCT00506350|EXPERIMENTAL|GSK1562902A non-AD F1 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
62801856|NCT00506350|EXPERIMENTAL|GSK1562902A non-AD F2 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
62801857|NCT00506350|EXPERIMENTAL|GSK1562902A non-AD F3 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
62801858|NCT00506350|EXPERIMENTAL|GSK1562902A non-AD F4 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
62801859|NCT00506350|EXPERIMENTAL|GSK1562902A AD F1 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
62801860|NCT00506350|EXPERIMENTAL|GSK1562902A AD F2 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
62801861|NCT00506350|EXPERIMENTAL|GSK1562902A AD F3 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
62801862|NCT00506350|EXPERIMENTAL|GSK1562902A AD Approved F4 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
62801863|NCT00506350|EXPERIMENTAL|Control Group|Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
62801864|NCT01410513|EXPERIMENTAL|SAR245409 + rituximab|Subjects will receive oral SAR245409 twice daily continuously and weekly rituximab intravenously
62801865|NCT01410513|EXPERIMENTAL|SAR245409 + rituximab + bendamustine (iNHL, MCL)|Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine intravenously.
62226744|NCT02526147|EXPERIMENTAL|Cash|Household receives cash transfer monthly for 6 months
62226745|NCT02526147|EXPERIMENTAL|Voucher|Household receives food voucher to use at local supermarket monthly for 6 months
62226746|NCT02526147|EXPERIMENTAL|Food|Household receives food transfer composed of rice, lentils, canned sardines, and vegetable oil, monthly for 6 months
62243058|NCT00775736||A|
62027625|NCT03806985|EXPERIMENTAL|Low Dose Psilocybin/High Dose Psilocybin|Subjects in this arm receive low dose psilocybin in the first session and high dose psilocybin in the second session.
62027626|NCT02138591|EXPERIMENTAL|Vitamin D3|"Vitamin D3 (cholecalciferol) 50,000 IU by mouth daily for each of the five days prior to surgery.~Blood draw pre-operatively Blood draw post-operative Day 1 Blood draw post-operative Day 2"
62027627|NCT02138591|PLACEBO_COMPARATOR|Placebo pill|Placebo pill by mouth daily for each of the five days prior to surgery. Blood draw pre-operatively Blood draw post-operative Day 1 Blood draw post-operative Day 2
62027628|NCT00936390|ACTIVE_COMPARATOR|Dose-Escalated Radiation Therapy Alone|Radiation therapy consists of 79.2 Gy EBRT only or 45 Gy EBRT followed by low- or high-dose rate brachytherapy. EBRT is delivered in 1.8 Gy daily fractions.
62027629|NCT00936390|EXPERIMENTAL|Dose-Escalated Radiation Therapy and Short-Term Androgen-Deprivation|"Radiation therapy consists of 79.2 Gy EBRT only or 45 Gy EBRT followed by low- or high-dose rate brachytherapy. EBRT is delivered in 1.8 Gy daily fractions.~Six months of androgen-deprivation therapy starts 8 weeks prior to start of radiation therapy and consists of luteinizing-hormone releasing-hormone (LHRH) agonist (antagonist) therapy (leuprolide, goserelin, buserelin. triptorelin, or degarelix) and anti-androgen therapy (bicalutamide or flutamide)."
62027630|NCT04065438|EXPERIMENTAL|LIPOSORBER® LA-15 System|All study patients who meet the study eligibility criteria will undergo the extracorporeal treatment using LIPOSORBER® LA-15 System. The participants are to be treated with the system twice weekly for the 3weeks and then once weekly for the following 6 weeks.
62027631|NCT06074666|EXPERIMENTAL|CareMeds Intervention|Participants complete the CareMeds parent training sessions during weeks 2, 3 and 4.
62027632|NCT06074666|ACTIVE_COMPARATOR|Usual Care|Usual care consists of medical consultations and supportive care, The usual care group will serve as a delayed intervention/wait list group for which 3 parent training sessions will be offered during weeks 13 through 15.
62801866|NCT01410513|EXPERIMENTAL|SAR245409 + rituximab+ bendamustine (CLL)|Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine and rituximab intravenously
62801867|NCT05311735|OTHER|Freeze-Dried Bone Allograft Control|-Control group (FDBA): extracted teeth will be discarded and sites will be grafted with FDBA.
62801868|NCT05311735|EXPERIMENTAL|Mineralized Dentin Graft|-Test group I (mineralized tooth graft): extracted teeth will undergo the mineralization process according to the manufacture's guidelines. Procedure will be done in a specialized equipment for tooth graft preparation (Smart Dentin Grinder® (SDG) (KometaBio), and then sites will be grafted. Remaining graft will be stored appropriately for future grafting in the same patient (according to the guidelines)
62027633|NCT04617028|EXPERIMENTAL|Jaktinib|Participants will receive Jaktinib plus placebo to match Hydroxycarbamide.
62027634|NCT04617028|ACTIVE_COMPARATOR|Hydroxycarbamide|Participants will receive Hydroxycarbamide plus placebo to match Jaktinib.
62027635|NCT01899976|OTHER|X-Suit NIR Covered Biliary Stent|Stent implantation in the biliary tree
62027636|NCT04015648|EXPERIMENTAL|Group 1|Volunteers will receive standalone dose of ChAdOx1 Zika 5 x 10\^9 vp vaccination intramuscularly.
62027637|NCT04015648|EXPERIMENTAL|Group 2|Volunteers will receive standalone dose of ChAdOx1 Zika 2.5 x 10\^10 vp vaccination intramuscularly.
62027638|NCT04015648|EXPERIMENTAL|Group 3|Volunteers will receive standalone dose of ChAdOx1 Zika 5 x 10\^10 vp vaccination intramuscularly.
62027639|NCT05383248|EXPERIMENTAL|High Reward - High Variance|
62027640|NCT05383248|ACTIVE_COMPARATOR|High Reward - Low Variance|
62801869|NCT05311735|EXPERIMENTAL|Partial-Demineralized Dentin Graft|-Test group II (partial-demineralized tooth graft): extracted teeth will be undergone to partial-demineralized process, according to the manufacture's guidelines. Procedures will be done in a specialized equipment for tooth graft preparation (Smart Dentin Grinder® (SDG) (KometaBio), and then sites will be grafted. Remaining graft will be stored appropriately for future grafting in the same patient (according to the guidelines).
62801870|NCT03609996||PDR treated with Laser|
62027641|NCT03188939|ACTIVE_COMPARATOR|G s|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction, local anesthetic (30 ml bupivacaine) is injected at the point where the subclavian artery meets the first rib
62027642|NCT03188939|ACTIVE_COMPARATOR|G ic|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction,the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
62027643|NCT03188939|ACTIVE_COMPARATOR|G d|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction,half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
62027644|NCT04667117|EXPERIMENTAL|Cohort 1|Patients with relapsing multiple sclerosis (MS) receiving a 2020-2021, 2021-2022, or 2022-2023 inactivated influenza vaccine two weeks prior to ofatumumab start
62027645|NCT04667117|EXPERIMENTAL|Cohort 2|Patients with relapsing MS receiving a 2020-2021, 2021-2022, 2022-2023 inactivated influenza vaccine at least 4 weeks after ofatumumab start
62801871|NCT03609996||PDR treated with Lucentis|
62027646|NCT04667117|ACTIVE_COMPARATOR|Cohort 3|Patients with relapsing MS currently on iDMT receiving a 2020-2021, 2021-2022, or 2022-2023 inactivated influenza vaccine
62027647|NCT04245891||Control group|boli of ephedrine phenylephrine (45μg/mL-3mg/mL) if the variation of MAP \< 20% of baseline (MAP before spinal anaesthesia).
62027648|NCT04245891||Protocol group|continuous infusion of norepinepineprhine at 20 μg/mL, started at 0.05 μg/kg/min. The dosage of norepinephrine was then adjusted to maintain a variation in MAP \< 20% of baseline. In case of failure, the use of a control group boli injection was possible.
62027649|NCT03790176|OTHER|A - patients on automated peritoneal dialysis|each of n=8 patients will receive one single intravenous infusion of ceftazidime/avibactam (CAZ/AVI) 2g/0.5g over two hours. Subsequently, PK of CAZ/AVI will be determined in plasma and peritoneal dialysis fluid (and urine, if applicable) at protocol-defined time points over 24 hours.
62027650|NCT03790176|OTHER|B - critically ill patients with pneumonia|following one intravenous dose of 2g/0.5g CAZ/AVI (which patients will receive based on clinical indication by their treating physician), PK of CAZ/AVI will be determined at protocol-defined time points over one dosing interval in plasma and in epithelial lining fluid (ELF).
62801872|NCT02043938|EXPERIMENTAL|Healthy Volunteers|All healthy volunteers will receive four sessions of anesthesia with different common drug combinations while having SedLine EEG sensors placed on their forehead during these sessions to study the effects of these drugs on the brain. The sessions were: propofol (P), sevoflurane (S), propofol with remifentanil (PR), and sevoflurane with remifentanil (SR).
62801873|NCT06063044||Respiratory system group|the patients who diagnosed as rhinitis, asthma and conjunctivitis were assigned to the respiratory system group
62226747|NCT03742921||Relapsed or Refractory T-Cell Lymphoma patients with Istodax|Among patients with relapsed or refractory peripheral T-Cell lymphoma, patients who received Istodax will be targeted in this surveillance
62027651|NCT06627842||Global cohort|All patients admitted to intensive care during the study period
62027652|NCT04667455|NO_INTERVENTION|Control subjects|Infants and Children with no evidence of congenital heart disease based on clinical examination and echocardiography / standard ECG assessment where necessary.
62027653|NCT04667455|ACTIVE_COMPARATOR|Congenital heart disease subjects|Infants and Children with evidence of predefined congenital heart disease lesions based on clinical examination, echocardiography and standard ECG assessment
62027654|NCT04635722|EXPERIMENTAL|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating. Participants will be followed by daily self-weighing for 1 year after intervention.
62027655|NCT04294810|EXPERIMENTAL|Tiragolumab + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
62226748|NCT02790268||Lens Subluxation|Pediatric eyes with lens subluxation undergoing Cionni Ring Bag fixation with in-the-bag IOL Implantation
62226749|NCT04885452||Patients treated with casirivimab/imdevimab according to the ATU protocol|
62801874|NCT06063044||Skin system group|the patients who diagnosed as urticaria and atopic dermatitis were assigned to the skin system group
62226750|NCT04885452||Patients treated with bamlanivimab/etesevimab according to the ATU protocol|
62226751|NCT04885452||Patients treated with Xevudy according to the authorisation for early access (AAP) protocol|
62226752|NCT04885452||Patients treated with Paxlovid according to the authorisation for early access (AAP) protocol|
62801875|NCT06063044||Multiple systems group|the patients who diagnosed with a combination of symptoms from different systems were assigned to the multiple systems group
62801876|NCT05760859|EXPERIMENTAL|Chest pain|"Patient answers the initial question of history taking on why he had come to the hospital with Chest pain"
62801877|NCT05760859|EXPERIMENTAL|Dyspnoea|"Patient answers the initial question of history taking on why he had come to the hospital with Dyspnoea"
62801878|NCT05760859|EXPERIMENTAL|Chest pain AND Dyspnoea|"Patient answers the initial question of history taking on why he had come to the hospital with Chest pain, and Dyspnoea"
62801879|NCT05760859|EXPERIMENTAL|Chest pain AND dyspnoea, AND leg pain|"Patient answers the initial question of history taking on why he had come to the hospital with Chest pain, and Dyspnoea, and leg pain"
62027656|NCT04294810|PLACEBO_COMPARATOR|Placebo + Atezolizumab|Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
62027657|NCT05867446|EXPERIMENTAL|Experimental:|pecha kucha will be practiced
62590016|NCT02409563|EXPERIMENTAL|Budesonide nasal (50 mcg bid)|The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: ; N2 (n = 31) = Budesonide nasal spray 50 mcg, 2 v / d. Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)
62590017|NCT01708486||Adolescents' with asthma using inhalation devices|Asthmatic adolescents will record their opinion for their inhalation devices by replying to FSI-10 questionnaire
62027658|NCT05867446|NO_INTERVENTION|control|Routine maintenance will be applied.
62027659|NCT06205524|EXPERIMENTAL|cohort 1|Participants will receive 2 intramuscular (IM) injections of either TI-0010 or Placebo at Dose Level 1 on Day 0 and Day 28
62027660|NCT06205524|EXPERIMENTAL|cohort 2|Participants will receive 1 intramuscular (IM) injection of either TI-0010 or Placebo at Dose Level 1 on Day 0
62027661|NCT06205524|EXPERIMENTAL|cohort 3|Participants will receive 2 intramuscular (IM) injections of either TI-0010 or Placebo at Dose Level 2 on Day 0 and Day 28
62027662|NCT06205524|EXPERIMENTAL|cohort 4|Participants will receive 1 intramuscular (IM) injection of either TI-0010 or Placebo at Dose Level 2 on Day 0
62027663|NCT01289912|EXPERIMENTAL|RAD001|RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis.
62027664|NCT01289912|PLACEBO_COMPARATOR|Placebo|Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10.
62027665|NCT01636882|EXPERIMENTAL|CVA21|Dose of CAVATAK up to 3 x 10⁸ TCID50 for an additional 9 treatments at 3-week intervals
62027666|NCT04412395|ACTIVE_COMPARATOR|Arm 01 (SOC + Lactoferrin 1200 mg QID)|Patients randomized to this group will receive two 600 mg Lactoferrin tablets QID plus the Standard of Care (SOC) treatment(s).
62027667|NCT04412395|PLACEBO_COMPARATOR|Arm 02 (SOC + Placebo QID)|Patients randomized to this group will receive two placebo tablets QID plus the SOC treatment(s).
62027668|NCT02116465|ACTIVE_COMPARATOR|Levodopa Carbidopa 100/25 tablets Test 1|single oral dose of levodopa carbidopa immediate release tablets
62027669|NCT02116465|ACTIVE_COMPARATOR|Levodopa Carbidopa 100/25 tablets Ref. 1|single oral dose of levodopa carbidopa immediate release tablets
62801880|NCT05760859|EXPERIMENTAL|Chest pain AND dyspnoea, AND immobilization|"Patient answers the initial question of history taking on why he had come to the hospital with Chest pain, and Dyspnoea, and immobilization"
62801881|NCT05760859|EXPERIMENTAL|Chest pain AND dyspnoea, AND leg pain AND immobilization|"Patient answers the initial question of history taking on why he had come to the hospital with Chest pain, and Dyspnoea, and leg pain, and immobilization"
62027670|NCT02116465|ACTIVE_COMPARATOR|Levodopa Carbidopa 100/25 tablets Test 2|single oral dose of levodopa carbidopa immediate release tablets
62226753|NCT04698642|EXPERIMENTAL|CBL-514 180 mg, 1.2 mg/cm^2|CBL-514 will be administrated with the grid spacing of 2.5 cm\^2
62801882|NCT06194214|EXPERIMENTAL|Pirtobrutinib|Pirtobrutinib in multiple oral doses will be administered on Days 8 through Day 16.
62801883|NCT06194214|EXPERIMENTAL|Digoxin|Digoxin will be administered from Day 1 to Day 16.
62027671|NCT02116465|ACTIVE_COMPARATOR|Levodopa Carbidopa 100/25 tablets Ref. 2|single oral dose of levodopa carbidopa immediate release tablets
62027672|NCT02579642|PLACEBO_COMPARATOR|Placebo|Propofol at usual induction doses for ECT (0.75 - 1 mg/kg IV bolus) with placebo (normal saline)
62027673|NCT02579642|EXPERIMENTAL|Ketamine|Propofol at usual induction doses for ECT (0.75 - 1 mg/kg IV bolus) with the addition of low-dose ketamine 0.2 mg/kg (or 0.5 mg/kg - see interim analysis)
62027674|NCT04481048|EXPERIMENTAL|N-Acetylcysteine (NAC)|"Each subject will be dosed with approximately 70 mg/kg/day of NAC for 8 weeks. To facilitate drug compounding, three tiers of drug dose will be administered based on body weight as described in Table 3.~Table 3: NAC Dosing Participant's weight (kg) Dose (BID) \< 20 700 mg 21-39 1050 mg \> 40 1350 mg~\*Max dose not to exceed 2700mg/day (1350mg BID)"
62027675|NCT04481048|PLACEBO_COMPARATOR|Placebo|Each subject will be dosed with placebo for 8 weeks.
62801884|NCT03951272|EXPERIMENTAL|Lyoplant® Onlay|All the model including 2.5cm×2.5cm, 5.0cm×5.0cm,2.5cm×7.5cm,7.5cm×7.5cm,10.0cm×12.5cm will be used in this study
62027676|NCT04481048|NO_INTERVENTION|Single Visit/Non-Treatment Arm|"Based on preliminary data, an additional Single visit, non-treatment cohort will include 40 individuals with NF1 for a single biomarker study visit. These individuals will undergo motor function (PANESS) and brain-based measures (TMS, MRI-MRS, DTI) as biomarkers of impaired executive function (ADHD-RS; BRIEF-2; TOVA) but will not be assigned to receive NAC/Placebo."
62027677|NCT00380068|EXPERIMENTAL|Ambrisentan|
62027678|NCT00033254|ACTIVE_COMPARATOR|Arm I (radiation therapy)|Patients undergo radiotherapy once daily 5 days a week for 3 weeks.
62027679|NCT00033254|EXPERIMENTAL|Arm II (radiation therapy, thalidomide)|Patients undergo radiotherapy as in arm I. Beginning on the first day of radiotherapy, patients receive oral thalidomide once daily.
62027680|NCT03263377|ACTIVE_COMPARATOR|2|The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.
62027681|NCT03263377|OTHER|Non Intervention|A control group will be included in study design consisting of 7 schools selected randomly from 7 comparable yet adjacent Upazilas not slated for inclusion in the feeding programme. Use of a control group will enable later evaluations to attribute possible improvements in key impact/outcome variables to the intervention itself. An equal number of boys and girls will be selected from each class to enable gender analysis. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.No intervention had given in this group.
62226754|NCT04698642|EXPERIMENTAL|CBL-514 240 mg, 1.6 mg/cm^2|CBL-514 will be administrated with the grid spacing of 2.5 cm\^2
62226755|NCT04698642|EXPERIMENTAL|CBL-514 300 mg, 2 mg/cm^2|CBL-514 will be administrated with the grid spacing of 2.5 cm\^2
62801885|NCT03951272|ACTIVE_COMPARATOR|DURAFORM™ Dural Graft Implant|All the model including 2.54cm×2.54cm,5.08cm×5.08cm, 2.54cm×7.62cm, 7.62cm×7.62cm,10.16cm×12.70cm will be used in this study
62801886|NCT00027170||Participants with cardiovascular diseases|Patients may receive an intravenous injection of gadobutrol (Gadavist) not to exceed 0.2 mmol/kg of Gd per bolus injection and per examination.
62801887|NCT00027170||Healthy Participants|Patients may receive an intravenous injection of gadobutrol (Gadavist) not to exceed 0.2 mmol/kg of Gd per bolus injection and per examination.
62226756|NCT01466634||permanent polymer DES|
62226757|NCT01466634||bioabsorbable polymer DES|
62226758|NCT01052922|ACTIVE_COMPARATOR|2 sample InSure|
62419677|NCT06203340|EXPERIMENTAL|Core stabilisation training|Core exercise programmes are designed to improve stabilisation, strength and power. Core exercise programmes are aimed to improve the sense of bodily movement and position (proprioception), which systematically progresses, prepares for activities and goals. Patients are started from the beginning level of the core exercises and in the following weeks, to the extent that the patients can do will be made more difficult.
62801888|NCT01122602|EXPERIMENTAL|Arm 1|
62801889|NCT01122602|ACTIVE_COMPARATOR|Arm 2|
62801890|NCT01122602|PLACEBO_COMPARATOR|Arm 3|
62590018|NCT05468242|EXPERIMENTAL|Neoadjuvant Chemotherapy Plus Tislelizumab + Bevacizumab|Patients in experimental group will receive Tislelizumab consolidation (200 mg/q3w) after the neoadjuvant chemotherapy plus Tislelizumab + Bevacizumab and concurrent chemoradiotherapy.
62027682|NCT04601155||AlloSure Group|Patients will have quarterly AlloSure cfDNA testing (every 3 months) and DSA as part of their post-transplant surveillance for a period of 5 years. For the quarterly AlloSure tests, approximately 20 mL of blood will be obtained in Streck Cell-Free DNA BCT tubes and shipped to CareDx, Inc. (Brisbane, CA) to analyze the presence of donor-derived cell-free DNA.
62027683|NCT04601155||Control Group|The control group was never followed with AlloSure as part of their post-transplant follow-up care. Matched control data will originate from UNOS SRTR data.
62027684|NCT00611091|EXPERIMENTAL|I|Intervention Group - (receive intervention) randomized at patient level - includes all health plan members, aged 65+, hospitalized at the study site hospital and discharged to an outpatient health plan clinic provider.
62027685|NCT00611091|NO_INTERVENTION|C|Control Group - (do not receive intervention) randomized at patient level - includes all health plan members, aged 65+, hospitalized at the study site hospital and discharged to an outpatient health plan clinic provider.
62027686|NCT01761435|EXPERIMENTAL|Influenza vaccine, second administration after 5 weeks|Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first one.
62027687|NCT01761435|ACTIVE_COMPARATOR|Influenza vaccine|Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.
62027688|NCT00620477|EXPERIMENTAL|1|injection in the knee joint with 20 ml of chirocaine 0.125%
62419678|NCT06203340|NO_INTERVENTION|Control group|Patients with a previous diagnosis of pain in the lumbar region will be sought. Patients will be invited to the institution and will be informed about low back pain. Patients with low back pain will be evaluated with self-report scales and functional tests. No treatment will be applied as a treatment.
62590019|NCT05468242|ACTIVE_COMPARATOR|Neoadjuvant Chemotherapy Plus Tislelizumab|Patients in this group will receive Tislelizumab consolidation (200 mg/q3w) after the neoadjuvant chemotherapy plus Tislelizumab and concurrent chemoradiotherapy.
62590020|NCT03474016||Patients with early breast cancer(30)|
62027689|NCT00620477|PLACEBO_COMPARATOR|2|injection in the knee joint with 20 ml of physiological fluid
62027690|NCT03914157|ACTIVE_COMPARATOR|15 patients with ARAS randomized to SWT|We will study 15 patients with ARAS randomized to SWT twice a week over 3 weeks. We will measure before and again 3 months after a 3-wk regimen renal cortical and medullary perfusion and function (multi-detector computed tomography \[MDCT\]), oxygenation, and fibrosis (magnetic resonance imaging \[MRI\]), urinary and plasma levels of renal injury markers, systemic endothelial function, and heart rate variability, an index of sympathetic activation.
62027691|NCT03914157|SHAM_COMPARATOR|15 patients with ARAS sham|we will study 15 patients with ARAS randomized to or sham twice a week over 3 weeks. We will measure before and again 3 months after a 3-wk regimen renal cortical and medullary perfusion and function (multi-detector computed tomography \[MDCT\]), oxygenation, and fibrosis (magnetic resonance imaging \[MRI\]), urinary and plasma levels of renal injury markers, systemic endothelial function, and heart rate variability, an index of sympathetic activation.
62027692|NCT00823082|EXPERIMENTAL|Antithrombin III treatment group|Preoperative ATIII supplementation administered immediately after anesthesia induction
62226759|NCT01052922|ACTIVE_COMPARATOR|1 sample OC-Micron|
62226760|NCT01052922|ACTIVE_COMPARATOR|3 sample g-SENSA|
62226761|NCT02202005|EXPERIMENTAL|Nevirapine|
62226762|NCT02202005|ACTIVE_COMPARATOR|Viramune®|
62590021|NCT03474016||Patients with advanced breast cancer(30)|
62590022|NCT03474016||Patients with benign breast diseases(20)|
62590023|NCT03474016||Apparently healthy females as a control group(36)|
62590024|NCT01348308|ACTIVE_COMPARATOR|Maraviroc|Maraviroc 300, 600 or 1200mg per day
62590025|NCT01348308|PLACEBO_COMPARATOR|Placebo|Placebo 300, 600 or 1200mg per day
62226763|NCT01822236|EXPERIMENTAL|Craniosacral Therapy Program|A program of 10 craniosacral therapy techniques
62226764|NCT01822236|ACTIVE_COMPARATOR|One technique of craniosacral therapy|Decompression L5-S1.
62419679|NCT03035981|EXPERIMENTAL|White rice, low amylose|Cooked white rice with low amylose content
62419680|NCT03035981|EXPERIMENTAL|White rice, high amylose|Cooked white rice with high amylose content
62590026|NCT04257032|EXPERIMENTAL|Reference 1 (R1)|
62590027|NCT04257032|EXPERIMENTAL|Test 1 (T1)|
62590028|NCT04257032|EXPERIMENTAL|Reference 2 (R2)|
62590029|NCT04257032|EXPERIMENTAL|Test 2 (T2)|
62590030|NCT04519320|OTHER|SARS-COV 2 Patients|
62027693|NCT00823082|NO_INTERVENTION|Control group|No preoperative ATIII supplementation administered
62027694|NCT02953626|EXPERIMENTAL|Immediate Treatment Condition (ITC)|Mother Matters Online Postpartum Support Group. Participants will be assigned to begin immediately after randomization.
62801891|NCT03300557|EXPERIMENTAL|Treatment (exemestane)|Patients receive exemestane PO QD over 21-42 days in the absence of disease progression or unaccepted toxicity. Patients undergo standard of care surgery between days 22-43.
62027695|NCT02953626|NO_INTERVENTION|Waitlist Control Condition (WLC)|Mother Matters Online Postpartum Support Group. Participants will receive the intervention after the Immediate Treatment Condition group completes the intervention, and after follow-up data are collected from both groups.
62419681|NCT03035981|EXPERIMENTAL|White rice, slow|Cooked white rice with slow digesting starch
62419682|NCT03035981|EXPERIMENTAL|White rice, resistant|Cooked white rice with resistant starch
62801892|NCT01685567|EXPERIMENTAL|MICHI NPS+f|The MICHI™ NPS+f is a flow reversal circuit consisting of two proprietary sheaths connected by standard surgical tubing. The sheaths each have a standard hemostasis valve and sidearm. An in-line flow regulator allows the clinician to modify to the flow through the circuit (either high flow or low flow) in addition to permitting temporary cessation of flow.
62801893|NCT02103491|ACTIVE_COMPARATOR|Salt administration|Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol).
62027696|NCT01006044|EXPERIMENTAL|Vaccination|Autologous Dendritic cells loaded with tumor lysate
62027697|NCT06558318||"TMJ Dysfunction for the group with TMJ dysfunction."|This group consists of young adults aged 18-25 who have been diagnosed with temporomandibular joint (TMJ) dysfunction. The diagnosis was determined using the Fonseca Amnestic Index, where participants with a score greater than 20 were classified into this group. The participants in this group are being analyzed for proprioception, body awareness, and pain-related parameters, including pain threshold, pain tolerance, and temporal summation.
62027698|NCT06558318||"No TMJ Dysfunction for the group without TMJ dysfunction."|This group includes young adults aged 18-25 who do not exhibit temporomandibular joint (TMJ) dysfunction. Participants in this group have a Fonseca Amnestic Index score of 20 or lower. Similar to the TMJ dysfunction group, these participants are being evaluated for proprioception, body awareness, and pain-related parameters such as pain threshold, pain tolerance, and temporal summation.
62027699|NCT06114823|ACTIVE_COMPARATOR|mini incision group|Patients were subjected to a longitudinal mini-incision started just above the proximal flexor wrist crease and then extended for 1.5 - 2 cm in a proximal direction.
62027700|NCT06114823|ACTIVE_COMPARATOR|conventional group|Patients were subjected a longitudinal incision which was created between the thenar and hypothenar eminences along the longitudinal axis of the ring finger. Then, it was extended to the proximal flexor wrist crease.
62027701|NCT03429426||Rheumatoid arthritis|"Patients with Rheumatoid arthritis ≥5 years according to the ACR/EULAR 2010 classification criteria or the American Rheumatism Association 1987 revised criteria.~ICD-10: M059 Seropositive rheumatoid arthritis UNS, M060 Seronegative rheumatoid arthritis, M069 Rheumatoid arthritis UNS."
62226765|NCT05285930|EXPERIMENTAL|group A|received phonophoresis with Bee Venom gel in form of a noncontact low-frequency pulsed ultrasound delivered through Bee Venom gel as a topical treatment at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
62226766|NCT05285930|EXPERIMENTAL|group B|received phonophoresis with Bee Venom gel in form of a noncontact low-frequency pulsed ultrasound delivered through Bee Venom gel as a topical treatment at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
62590031|NCT04084834|EXPERIMENTAL|Intervention group|Participants allocated to the intervention group will be familiarized with exercise intensity levels (heart rate and Borg RPE) during the assessment at Diakonhjemmet Hospital. Further, the patients will be offered to take part in a 5-hour Learning and Mastery-course at Diakonhjemmet Hospital. Thereafter, the participants will get access to a web-based exercise program and guided to choose the appropriate exercise-level. Weekly, based on the individual progression, all participants will receive an exercise program by email consisting of individually tailored exercise sessions and motivational messages. At the end of each week, the participants complete an electronic exercise diary for monitoring adherence. All participants will be offered the possibility to seek peer-support; however, if preferred they may also follow the exercise program by themselves.
62027702|NCT03429426||Pre-Rheumatoid arthritis|Patients with joint pain, but no swelling and Anti-CCP 3 times above the upper limit.
62027703|NCT03429426||Healthy Subjects|Healthy age- and sex-matched Individuals are recruited, as a control group.
62226767|NCT05285930|SHAM_COMPARATOR|group C|received a noncontact low-frequency pulsed ultrasound delivered through only plain gel without BV gel at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
62226768|NCT02594683||Key Group of Interest|Exclusively formula fed subjects since 1 month of age
62590032|NCT02891434|EXPERIMENTAL|Acquisition on TouchScreen|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
62590033|NCT02891434|EXPERIMENTAL|Acquisition on Kinect|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
62801894|NCT02103491|PLACEBO_COMPARATOR|Placebo administration|In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose).
62801895|NCT02588326|ACTIVE_COMPARATOR|MFF 1, then MFF 2|Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray. After a wash out period then Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray. All formulations will be a 200 mcg single dose.
62801896|NCT02588326|ACTIVE_COMPARATOR|MFF 2, then MFF 1|Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray. After a wash out period then Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray. All formulations will be a 200 mcg single dose.
62801897|NCT00182039|EXPERIMENTAL|A|metoprolol
62801898|NCT00182039|PLACEBO_COMPARATOR|B|placebo
62027704|NCT05889247|EXPERIMENTAL|ctDNA monitoring|Treatment monitoring by longitudinal circulating tumor DNA measurements and Quality of Life assessments
62027705|NCT05889247|NO_INTERVENTION|CT scan monitoring|Treatment monitoring by longitudinal CT scans (standard) and Quality of Life Assessments
62027706|NCT06081309|EXPERIMENTAL|Open-Label active EEG-based personalized TMS treatment|20 sessions of EEG-based personalized TMS over a maximum of 21 days. Two sessions per treatment day. Each session consists of TMS treatment at 50% Motor Threshold, pulse frequency between 8-13 Hz. TMS delivery of 5 second pulse train, with an inter-train interval of 20 seconds. Session duration is 15 minutes. A rest period of at least 30 minutes is required between the 2 sessions in a treatment day.
62027707|NCT02044510|EXPERIMENTAL|Mirabegron|Patients randomised to this arm start with mirabegron 25mg PO daily for two weeks, and then at 2 weeks titrate to 50mg PO daily, and maintain that dose for the duration of the study (8 additional weeks).
62027708|NCT02044510|PLACEBO_COMPARATOR|Placebo|Inert placebo pill, matching active treatment pill.
62027709|NCT05935540|EXPERIMENTAL|ACP-Family|It is a ACP discussion intervention consisting of two sessions (45-60 mins) and to be delivered within one month in a face-to-face format as long as the patient is still in the hospital by a trained ACP facilitator.
62027710|NCT05935540|NO_INTERVENTION|ACP-UC|Usual care that is available to all palliative care patients in the hospital.
62226769|NCT02594683||Other-Fed Group|Mixed feeding of formula and breast milk
62226770|NCT02594683||Breastfeeding Group|Exclusively breastfeeding at least until 4 months of age
62226771|NCT00936546|EXPERIMENTAL|Rituximab|
62226772|NCT05943223|EXPERIMENTAL|Piperacillin/tazobactam|
62027711|NCT04954339|EXPERIMENTAL|Atezolizumab plus Bevacizumab|Two cycles of naeoadjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) prior to surgical resection and four cycles of adjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) after the surgery will be administered.
62027712|NCT01953926|EXPERIMENTAL|Neratinib monotherapy|"Neratinib monotherapy in HER2 mutated cancers including cervical, salivary gland, and lung cancers containing EGFR exon 18 mutations.~Cohorts closed to enrollment in prior amendments: HER2 mutant cancers including bladder/urinary, colorectal, endometrial, breast HR-positive, TNBC HR-negative, lung, gastroesophageal, biliary, and ovarian; HER3 mutant solid tumor NOS; HER4 mutant solid tumor NOS; fibrolamellar carcinoma and EGFR brain."
62027713|NCT01953926|EXPERIMENTAL|Neratinib and Trastuzumab|"Neratinib and Trastuzumab in HER2 mutated (TNBC, HR-negative) breast cancers.~Cohorts closed to enrollment in in prior amendments: colorectal, lung cancer HER2 mutant."
62027714|NCT01953926|EXPERIMENTAL|Neratinib, Fulvestrant and Trastuzumab (Randomized)|Neratinib, Fulvestrant and Trastuzumab or Fulvestrant and Trastuzumab or Fulvestrant alone in HER2 mutated (HR-positive with prior CDK4/6i) breast cancers.
62027715|NCT01953926|EXPERIMENTAL|Neratinib, Fulvestrant and Trastuzumab (Non-Randomized)|Neratinib, Fulvestrant and Trastuzumab in HER2 mutated (HR-positive with or without CDK4/6i) breast cancers.
62027716|NCT01953926|EXPERIMENTAL|Neratinib and Paclitaxel|Neratinib and Paclitaxel in HER2 mutated bladder/urinary tract cancers.
62027717|NCT01953926|EXPERIMENTAL|Neratinib and Fulvestrant|Neratinib and Fulvestrant in HER2 mutated (HR-positive) breast cancers.
62226773|NCT05943223|ACTIVE_COMPARATOR|Ceftriaxone and metronidazole|
62226774|NCT00775463|EXPERIMENTAL|treprostinil diethanolamine|Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
62590034|NCT02891434|EXPERIMENTAL|Acquisition on LeapMotion|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
62027718|NCT01764984|EXPERIMENTAL|Trabecular metal|Primary Total Knee Arthroplasty is performed with a non cemented trabecular metal tibial baseplate.
62590035|NCT02891434|ACTIVE_COMPARATOR|Acquisition on TouchScreen Control Group|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
62226775|NCT00775463|PLACEBO_COMPARATOR|placebo (sugar pill)|Matching placebo sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
62801899|NCT06216067||Group 1 (Operating Room #1) CALLISTO eye|Group 1 (Operating Room #1) will have preoperative measurements with the IOL Master 700 and lens selection will be based on Veracity. The subjects in group 1 will have LenSx surgery and placement of the lens will be based on the CALLISTO eye.
62801900|NCT06216067||Group 2 (Operating Room #2) Wavetec AnalyzOR|Group 2 (Operating Room #2) will also have preoperative measurements with the IOL Master700, but lens selection will be based on the Wavetec AnalyzOR. The subjects in group 2 will have LenSx surgery and placement of the lens will be based on the Wavetec AnalyzOR.
62226776|NCT01707225|EXPERIMENTAL|Octreotide LAR Depot|Once enrolled in the study subjects will receive a monthly intra-muscular injection of 20mg of octreotide LAR at each study visit for 24 weeks and will be followed for a total of 36 weeks.
62226777|NCT04433273|NO_INTERVENTION|Group A: Healthy control group|Neither placebo nor vestibular stimulation is administered
62590036|NCT02891434|ACTIVE_COMPARATOR|Acquisition on Kinect Control Group|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
62801901|NCT01125982|ACTIVE_COMPARATOR|Desflurane|Patients will receive Desflurane to provide sleep during anaesthesia for laparoscopic cholecystectomy. Analgesia will be provided by remifentanil.
62801902|NCT01125982|ACTIVE_COMPARATOR|Propofol|Patients will receive Propofol to provide sleep during anaesthesia for laparoscopic cholecystectomy. Analgesia will be provided by remifentanil.
62226778|NCT04433273|PLACEBO_COMPARATOR|Group B: Placebo control group|Placebo stimulation along with regular treatment
62226779|NCT04433273|ACTIVE_COMPARATOR|Group C: Intervention group|Electrical vestibular nerve stimulation along with regular treatment
62226780|NCT00596778|OTHER|C, CP|Thirty-one adults were randomly assigned to control (C) and chest physiotherapy (CP) groups. Chest physiotherapy group received treatment at the post-anesthesia unit care and control group did not.
62226781|NCT03407443|EXPERIMENTAL|Exposure to Make the Connection messages|
62226782|NCT03407443|ACTIVE_COMPARATOR|Active Control group|
62226783|NCT03407443|NO_INTERVENTION|No exposure control group|
62226784|NCT02764918||Children|
62226785|NCT02764918||Mothers|
62226786|NCT06044974|ACTIVE_COMPARATOR|Group I (n=15): combined therapy sessions using 1064 nm Nd-YAG laser (once/week)|"Each treatment session will include: a first pass, which will be performed using cold Piano Level Laser Therapy PLLT settings for photo biomodulation - MSP pulse (100 µs), P = 2W, 10 Hz, with 1 minute treatment duration per spot. A second pass, higher warm PLLT settings that causes mild heating of the tissue, aimed at pain relief - MSP pulses 5 W, 60 Hz, where the handpiece will be held at each spot from 30 seconds to 1 minute, depending on patient heat tolerance~. Both the masseter and temporalis muscles will be divided into 3 spots: insertion, body, and origin for the masseter muscle and anterior, middle, and posterior for temporalis muscle. A stamping technique will be carried out for both passes."
62419683|NCT03035981|EXPERIMENTAL|Brown rice, low amylose|Cooked brown rice with low amylose content
62590037|NCT02891434|ACTIVE_COMPARATOR|Acquisition on LeapMotion Control Group|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
62590038|NCT03473366|EXPERIMENTAL|Tao Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Tao Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
62590039|NCT03473366|ACTIVE_COMPARATOR|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
62027719|NCT01764984|ACTIVE_COMPARATOR|Titanium|Primary total knee arthroplasty is performed with cemented titanium traditional tibial base plate
62027720|NCT00158379|EXPERIMENTAL|Paclitaxel|
62027721|NCT02522533|EXPERIMENTAL|Physical Therapy|Patients will be receiving 6 weeks of an exercise program.
62027722|NCT05806801|EXPERIMENTAL|Moderate Intensity Continuous Training (MICT) exercise group|45 minutes of continuous steady-state exercise at 70% maximal heart rate throughout the 10% weight loss phase of the study
62027723|NCT05806801|EXPERIMENTAL|No exercise (Control)|to remain sedentary (no planned physical exercise) throughout the duration of the 10% weight loss phase of the study
62027724|NCT00354705||Colon Cancer Patients|Patients with colon cancer recently removed by surgery.
62027725|NCT04657146||Patients with suspected newly-diagnosed Glioblastoma (GBM)|Patients, ≥18 years of age, with newly diagnosed GBM, World Health Organization (WHO) Grade IV, undergoing gross total resection (defined as \>90% of contrast enhancing volume removed on post-operative MRI) and collection of blood, bone marrow, and tumor.
62027726|NCT04536636|ACTIVE_COMPARATOR|Control|The patients on this arm received usual medical care
62801903|NCT04623788||Myocarditis|Twenty patients with acute myocarditis will be recruited if the diagnosis has been made by a cardiologist based on clinical, biochemical, electrographic and imaging data. This reflects the diagnostic criteria set out by the European Society of Cardiology (ESC) Task force 2013.
62801904|NCT04623788||Takotsubo Cardiomyopathy|Twenty patients with takotsubo cardiomyopathy will be recruited. The diagnosis will be made according to the Mayo clinic and the European Society of Cardiology (ESC) Heart Failure Association criteria, including a normal coronary angiogram, typical appearances on cardiac imaging including ventriculography, and no evidence of fibrosis on cardiac magnetic resonance imaging.
62801905|NCT04623788||Reversible Ischaemia|Forty patients who have undergone stress echocardiography or magnetic resonance imaging; twenty with positive (areas of reversible akinesis/hypokinesis during pharmacological stress), and twenty with a negative stress result (no reversible wall motion abnormalities during pharmacological stress) as per international guidelines. They will be matched for age and sex.
62801906|NCT04623788||Healthy Volunteer|Twenty healthy volunteers of comparable age and sex to the other cohorts.
62419684|NCT03035981|EXPERIMENTAL|Brown rice, high amylose|Cooked brown rice with high amylose content
62590040|NCT02643797|EXPERIMENTAL|Intervention Group: MA Health Coaching|"Patients in the intervention group will receive the MA Health Coaching intervention during their primary care visits, as well a follow-up calls to encourage/monitor progress and offer support."
62590041|NCT02643797|NO_INTERVENTION|Usual Care|"Patients in this group will receive treatment as usual during their primary care visits."
62590042|NCT01859117|EXPERIMENTAL|3 x 10^6 cells|3 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
62590043|NCT01859117|EXPERIMENTAL|10 x 10^6 cells|10 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
62590044|NCT01859117|EXPERIMENTAL|30 x 10^6 cells|30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
62027727|NCT04536636|ACTIVE_COMPARATOR|DHA supplementation|The patients on this arm received DHA supplementation (650 mg DHA/3 times/wk/post-HD session)
62027728|NCT04225208|EXPERIMENTAL|[14C]-AZD4205|A single dose of \[14C\]-AZD4205
62027729|NCT01597544|NO_INTERVENTION|CISC instruction post-operatively|For those patients that are randomized to CISC instruction before surgery, instruction will begin on post-operative day one. One of the nurses from the hospital gynecology unit will teach and supervise the patients until they feel comfortable with the technique or until catheterization is no longer required (e.g. when the patient passes her voiding trial on two separate occasions). This is the protocol currently in use at our institution.
62027730|NCT01597544|ACTIVE_COMPARATOR|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
62027731|NCT06326606|ACTIVE_COMPARATOR|MLS101|MLS101 capsule(s) administered orally as a once a day dose
62027732|NCT06326606|PLACEBO_COMPARATOR|Placebo|Active treatment matching capsules will be administered orally as a once a day dose
62590045|NCT01859117|EXPERIMENTAL|100 x 10^6 cells|100 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
62590046|NCT05848492|EXPERIMENTAL|Prophylactic Fluconazole|12 mg/Kg loading dose of fluconazole given intravenously followed by 6 mg/Kg every 48 hours till 14 days of life, and then 6 mg/kg/day thereafter, for a total duration of 6 weeks (42 days).
62590047|NCT05848492|PLACEBO_COMPARATOR|placebo group|Normal Saline 2cc given intravenously
62590048|NCT02982174||Normal Eyes|Subjects with no known ocular diseases will be imaged on the 3D OCT-1 Maestro and DRI OCT Triton
62226787|NCT06044974|ACTIVE_COMPARATOR|Group II (n=15): Epidermal Growth factor (EGF) injection|"Epidermal Growth factor (EGF) injection into masseter and temporalis muscles. Each muscle will be divided into 3 zones; origin, body and insertion for masseter muscle, anterior, middle, and posterior for temporalis muscle~* For masseter muscle injection, 3-point injection technique will be followed: 1 injection point in each zone. For temporalis muscle injection, 3-point injection technique will be followed: 1 in each zone~* Each point will receive 0.1 ml of EGF"
62027733|NCT04058769|OTHER|Software first|Patients that are pre-operatively assessed first software-guided and then traditional
62419685|NCT03035981|EXPERIMENTAL|Fructooligosaccharide (FOS)|Fermentable carbohydrate solution
62419686|NCT05211037|EXPERIMENTAL|Kidney function assessment|
62590049|NCT01710189|EXPERIMENTAL|TicoVac immunisation - right deltoid muscle|IM immunisation right deltoid muscle
62801907|NCT04820244||No intervention|Otherwise healthy human volunteers, 16-55 years old, with a confirmed genetic diagnosis of Usher Syndrome type 2 or non-syndromal USH2A related retinitis pigmentosa
62801908|NCT03354117|EXPERIMENTAL|Ulipristal 30mg plus Meloxicam 15mg|Each study participant will complete one menstrual cycle without medication. Her second menstrual cycle, each study participant will receive ulipristal acetate plus meloxicam at peak fertility.
62027734|NCT04058769|OTHER|Traditional|Patients that are first pre-operatively assessed in the traditional way and then with aid of the software
62027735|NCT04465006|EXPERIMENTAL|Hippotherapy Simulator Group|Getting a diagnosis of stroke by a specialist physician, Being between the ages of 18-65, Having a stroke history of 3- 36 months, To be able to sit without support while both soles are in contact with the floor, To be able to walk independently with or without using walking aid, To be able to understand and follow audio and visual warnings, Scoring 24 points or more from the Mini Mental State Exam.
62027736|NCT04465006|EXPERIMENTAL|Conventional Exercise Group|Getting a diagnosis of stroke by a specialist physician, Being between the ages of 18-65, Having a stroke history of 3- 36 months, To be able to sit without support while both soles are in contact with the floor, To be able to walk independently with or without using walking aid, To be able to understand and follow audio and visual warnings, Scoring 24 points or more from the Mini Mental State Exam.
62027737|NCT02684422||Cystic Fibrosis with MRSA infection|"Cystic Fibrosis patients that are admitted to the hospital for IV therapy targeting MRSA will give a sputum sample and complete symptom diaries at the beginning and end of therapy. There will be no intervention administered.~Inclusion criteria are ability to produce sputum and having a chronic i.e. \> 2 years of positive respiratory cultures, MRSA CF lung infection."
62027738|NCT03989804|EXPERIMENTAL|Targeted follow-up|
62027739|NCT03989804|NO_INTERVENTION|Usual practice|Usual practice at the fitness center is self-directed use
62027740|NCT01792089||non-obese healthy subjects|subjects with BMI\<25 and no known disease
62027741|NCT01792089||post-gastric bypass|post-obese subjects 12-48 months after Roux-en-Y gastric bypass
62027742|NCT01792089||matched control subjects|Nonobese, healthy subjects of similar age, weight, and gender ratio, than post-bypass subjects
62226788|NCT06415006||Group Sepsis|The group consists of 1,522 patients treated in the intensive care unit for sepsis/septic shock.
62226789|NCT04466826|EXPERIMENTAL|Minors with chronic migraines|
62419687|NCT02499406|OTHER|Skills group|Dialectical behavior therapy skills group
62419688|NCT04741945|EXPERIMENTAL|Metformin|2000 mg/day metformin for 12 months.
62419689|NCT06704113|ACTIVE_COMPARATOR|Group A control. Ibuprofen|Ibuprofen 400mg tablets, 1 every 8 hours for 3 days will be administered for post-surgical pain.
62419690|NCT06704113|ACTIVE_COMPARATOR|Group B experimental. Meloxicam|Meloxicam 7.5mg tablets, 1 every 12 hours for 3 days will be administered for post-surgical pain.
62419691|NCT00424931|EXPERIMENTAL|001|JNJ-17216498 10mg one time
62419692|NCT00424931|EXPERIMENTAL|002|JNJ-17216498 50mg one time
62419693|NCT00424931|ACTIVE_COMPARATOR|003|Modafinil 200 mg X 2
62419694|NCT05218317||MS-Relapse|"Twenty-seven patients (MS-Relapse) for whom the administration of intravenous corticosteroids was decided due to the diagnosis of new relapse.~The diagnosis of RRMS and the new relapse was confirmed and decided by a senior neurologist (K.A) of Marmara University Department of Neurology, according to the revised McDonald criteria, based on clinical and radiological findings These subjects underwent Corneal Confocal Microscopy (IVCM)."
62419695|NCT05218317||MS-Control|"Thirty-one patients (MS-Control) who were followed up with the diagnosis of RRMS The diagnosis of RRMS and the new relapse was confirmed and decided by a senior neurologist (K.A) of Marmara University Department of Neurology, according to the revised McDonald criteria, based on clinical and radiological findings.~These subjects underwent Corneal Confocal Microscopy (IVCM)."
62419696|NCT05218317||Healthy Controls|Thirty healthy age and gender similar population These subjects underwent Corneal Confocal Microscopy (IVCM).
62419697|NCT05077904|EXPERIMENTAL|Staccato alprazolam Arm|Participants randomized to this arm will receive a single dose of Staccato alprazolam by inhalation.
62419698|NCT05077904|PLACEBO_COMPARATOR|Placebo Arm|Participants randomized to this arm will receive a single dose of placebo by inhalation.
62590050|NCT01710189|EXPERIMENTAL|TicoVac immunisation - upper anterolateral thigh|IM: right upper anterolateral thigh
62801909|NCT05718856|ACTIVE_COMPARATOR|efficacy of TPO-RAs|"After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag administration was an oral 37.5 mg (6-11 years old) or 50 mg (12-17 years old) once daily. The initial dose of hetrombopag administration was an oral 3.75 mg (6-11 years old) or 5mg (12-17 years old) once daily in all participants. The initial dose of avatrombopag administration was an oral 10 mg (\<30kg) or 20mg (≥30kg) once daily in all participants. Complete blood count including platelet count was done once a week. The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the TPO-RAs will stop until the platelet count \<100×10\^9/L.~Efficacy and safety will be evaluated at Week 4, Week 8, Week 12 and Week 24."
62027743|NCT00475059|EXPERIMENTAL|1|patients who received cimétidine
62027744|NCT02511431|EXPERIMENTAL|Group 1|Lonafarnib/Ritonavir at 50 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
62027745|NCT02511431|EXPERIMENTAL|Group 2|Lonafarnib/Ritonavir at 75 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
62027746|NCT02511431|EXPERIMENTAL|Group 3|Lonafarnib/Ritonavir at 100 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
62419699|NCT03567330|EXPERIMENTAL|Experimental|Family-based attachment-focused intervention for families where parent/caregiver is within 12 months of first diagnosis of a stage I-III solid tumor cancer.
62027747|NCT02511431|EXPERIMENTAL|Group 4|Placebo for 12 weeks then Lonafarnib/Ritonavir at 50 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
62027748|NCT02511431|EXPERIMENTAL|Group 5|Placebo for 12 weeks then Lonafarnib/Ritonavir at 75 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
62419700|NCT03567330|ACTIVE_COMPARATOR|Psychoeducation|Provides equivalent number of American Cancer Society psychoeducational sessions.
62419701|NCT05121779|EXPERIMENTAL|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT|All patients diagnosed with Lung fibrosis underwent 68Ga-FAPI PET/CT and 18F-FDG PET/CT.
62419702|NCT06701643||Patients undergoing adenoidectomy, tonsillectomy and/or ventilation tube application|Patients undergoing adenoidectomy, tonsillectomy and/or ventilation tube application either premedicated or not, with ASA I-III risk group, followed up for 30 minutes postoperatively.
62419703|NCT06580184|EXPERIMENTAL|LEARN 2 Platform|The intervention arm in this study involves participants engaging with the LEARN2 virtual environment, designed to provide tailored prevention education for HIV-related comorbidities with shared risk factors. Participants will navigate a virtual platform focused on health education related to body systems, utilizing customizable avatars for anonymity and comfort.
62419704|NCT06580184|ACTIVE_COMPARATOR|Waitlist Control|The waitlist control group will not have immediate access to the LEARN2 intervention but will receive a welcome packet with information on how to contact the study team and the date they will gain access to the intervention after a waiting period. This design helps to ensure that all participants eventually receive the intervention while allowing researchers to assess the efficacy of the LEARN2 platform.
62419705|NCT04380701|EXPERIMENTAL|BNT162a1 (P/B) - Part A 18-55 years of age|Escalating dose levels
62419706|NCT04380701|EXPERIMENTAL|BNT162b1 (P/B) - Part A 18-55 years of age|Escalating dose levels
62419707|NCT04380701|EXPERIMENTAL|BNT162b2 (P/B) - Part A 18-55 years of age|Escalating dose levels
62419708|NCT04380701|EXPERIMENTAL|BNT162c2 (P/B) - Part A 18-55 years of age|Escalating dose levels
62419709|NCT04380701|EXPERIMENTAL|BNT162c2 (prime only) - Part A 18-55 years of age|Single dose
62419710|NCT04380701|EXPERIMENTAL|BNT162b1 (P/B) - Part A 56-85 years of age|Escalating dose levels
62419711|NCT04380701|EXPERIMENTAL|BNT162b2 (P/B) - Part A 56-85 years of age|Escalating dose levels
62419712|NCT04380701|EXPERIMENTAL|BNT162b2 (P/B) - Part A 18-85 years of age (Expansion cohorts 11 to 13)|Fixed doses used; cohort 11: alternative posology dose group expansion cohort; cohort 12: adaptive immune response dose group expansion cohort; cohort 13: immunocompromised (IC) participants expansion cohort
62419713|NCT04380701|EXPERIMENTAL|BNT162b2 (P/B) - Part A 18-85 years of age (Expansion cohort 14)|fixed doses used; B-cell immune response dose group expansion cohort
62419714|NCT05151822|EXPERIMENTAL|Virtual reality mask|"Realization of the following examinations with virtual reality mask :~* Training session~* Acceptability of the device before and after surgery~* Monitoring of the device during surgery"
62419715|NCT03740828||Women undergoing IVF treatment|Device: KIDScore D3 study
62590051|NCT03788434|EXPERIMENTAL|VE303 High Dose|Study subjects assigned the high dose VE303 arm took 10 capsules (dosage: 8.0 × 10\^9 CFU daily) containing VE303 per day for 14 days.
62027749|NCT02511431|EXPERIMENTAL|Group 6|Placebo for 12 weeks then Lonafarnib/Ritonavir at 100 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
62027750|NCT06669793|EXPERIMENTAL|biolimus-coated balloon group|
62027751|NCT06669793|EXPERIMENTAL|paclitaxel-coated balloon group|
62027752|NCT03037385|EXPERIMENTAL|Phase 1 Dose Escalation|Multiple doses of pralsetinib (BLU-667) for oral administration.
62027753|NCT03037385|EXPERIMENTAL|Phase 2 Dose Expansion|Oral dose of pralsetinib (BLU-667) as determined during Dose Escalation.
62027754|NCT01803997|OTHER|STRIDE|12 cooking classes offered over 6 weeks (approximately 2 classes/week)
62027755|NCT01803997|OTHER|SPARK|12 physical activity classes offered over 6 weeks (approximately 2 classes/week)
62027756|NCT04579263|EXPERIMENTAL|Patient with diabetes mellitus type 1 (T1DM)|Treatment by transplantation of fecal microbiota
62590052|NCT03788434|EXPERIMENTAL|VE303 Low Dose|Study subjects assigned to the low dose VE303 arm took 2 capsules (dosage: 1.6 × 10\^9 CFU daily) containing VE303 per day for 14 days.
62226790|NCT01719926|EXPERIMENTAL|Capecitabine/Oxaliplatin|Patients receiving Capecitabine/Oxaliplatin chemotherapy
62226791|NCT01719926|EXPERIMENTAL|Cisplatin + Xeloda(Capecitabine) or Gemcitabine|Patients receiving Cisplatin regimen
62226792|NCT01767805|OTHER|Type of incubator|Embryos are cultured in a standard incubator or a mini-incubator
62419716|NCT06585943|ACTIVE_COMPARATOR|Forced Rate Exercise + Rehabilitation|The forced rate exercise+rehab group (N=33) will complete FE on the cycle designed to augment pedaling rate to \>75 revolutions per minute (RPM). Target heart rate zone will be set to 60-80% of heart rate (HR) reserve. The session will consist of a 5-min warm-up, 35-min main exercise set, and 5-min cool down. Following FE, abbreviated sessions of motor learning-based training will be administered by a neurologic OT and PT experienced in stroke rehabilitation, with 30 min focused on restoration of UE function (OT) and 15 min focused on LE motor function/ gait training (PT).
62419717|NCT06585943|ACTIVE_COMPARATOR|Rehabilitation|The rehab group will receive consecutive, full-length sessions of motor learning-based training, administered by a neurologic OT and PT experienced in stroke rehabilitation, with 45 min focused on restoration of UE function (OT) and 45 min focused on LE motor function/ gait training (PT).
62419718|NCT06311565|EXPERIMENTAL|Education|People who have undergone colorectal cancer screening will be given training on colorectal cancer prevention. Training will be carried out face to face and individually. The training will take approximately 25-30 minutes.
62419719|NCT06311565|NO_INTERVENTION|Control|Individuals in this group will be screened for colorectal cancer. However, this group will not be given any training on cancer prevention.
62027757|NCT04579263|EXPERIMENTAL|Patient with diabetes mellitus type 2 (T2DM)|Treatment by transplantation of fecal microbiota
62027758|NCT00492349|EXPERIMENTAL|1|Varenicline
62226793|NCT01767805|OTHER|Oxygen concentration|Embryos are cultured in an incubator with a gas mixture with 20% oxygen or with 5% oxygen
62226794|NCT06071260|EXPERIMENTAL|Study group|Participants will receive 0.01% atropine (0.1 mg/ml)
62226795|NCT02921308||With BPD|No intervention will be administered. After informed consent is obtained, children will undergo ultra-short echo time pulmonary MRI, followed by PFT and completion of questionnaires.
62226796|NCT02921308||Without BPD|No intervention will be administered. After informed consent is obtained, children will undergo ultra-short echo time pulmonary MRI, followed by PFT and completion of questionnaires.
62226797|NCT00669526|ACTIVE_COMPARATOR|SMHC referral|Referral to local Specialty Mental Health Care Services
62226798|NCT00669526|EXPERIMENTAL|BCBT|Brief Cognitive Behavioral Therapy
62226799|NCT02763787|EXPERIMENTAL|Placebo|Matched placebo was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
62226800|NCT02763787|EXPERIMENTAL|10 mg|1 x 10 mg BIA 3-202 tablet BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
62226801|NCT02763787|EXPERIMENTAL|30 mg|3 x 10 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
62226802|NCT02763787|EXPERIMENTAL|50 mg|5 x 10 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
62419720|NCT03275168|ACTIVE_COMPARATOR|Control|Participants will receive individual evidence-based STI/HIV prevention intervention (Sister to Sister Teen for female participants and Focus on the Future for male participants) for STI prevention
62419721|NCT03275168|EXPERIMENTAL|Intervention|Participants will receive individual evidence-based STI/HIV prevention intervention (Sister to Sister Teen for female participants and Focus on the Future for male participants) for STI prevention plus dyadic counseling and negotiation practice with partner
62419722|NCT06206421|EXPERIMENTAL|Fezolinetant|Participants will receive fezolinetant once daily for 52 weeks.
62419723|NCT06206421|EXPERIMENTAL|Placebo|Participants will receive matching placebo once daily for 52 weeks.
62027759|NCT00492349|PLACEBO_COMPARATOR|2|Placebo
62027760|NCT01689116|EXPERIMENTAL|Bardoxolone Methyl 20mg|
62027761|NCT01689116|EXPERIMENTAL|Bardoxolone Methyl 80mg|
62027762|NCT01689116|PLACEBO_COMPARATOR|Bardoxolone Methyl Placebo|
62226803|NCT02763787|EXPERIMENTAL|100 mg|1 x 100 mg BIA 3-202 tablet BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
62226804|NCT02763787|EXPERIMENTAL|200 mg|2 x 100 mg BIA 3-202 tablets
62226805|NCT02763787|EXPERIMENTAL|400 mg|4 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
62226806|NCT02763787|EXPERIMENTAL|800 mg|8 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
62226807|NCT02763787|EXPERIMENTAL|Food Effect (fed/fasted)|400 mg BIA 3-202: 4 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
62226808|NCT02636179||448 children|Children aged 11-15 years from a historical cohort born after In Vitro Fertilization or Intracytoplasmic Sperm Injection at Hospital Saint Joseph of Marseille
62419724|NCT01785472|EXPERIMENTAL|LCZ696 200 mg|Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.
62027763|NCT01689116|ACTIVE_COMPARATOR|Moxifloxacin|
62027764|NCT06534515|EXPERIMENTAL|Intervention/Treatment|Tomatis Auditory stimulation.
62027765|NCT06534515|NO_INTERVENTION|No intervention|Waitlist control.
62226809|NCT02636179||1344 children|Children aged 11-15 years born spontaneously schooling in the same geographic area as case
62226810|NCT04623970|EXPERIMENTAL|Propofol sedation group|Patients in this experimental group received propofol sedation agent.
62226811|NCT04623970|EXPERIMENTAL|Ketofol 1:3 sedation group|Patients in this experimental group received ketofol sedation agent as a 1:3 mixture.
62226812|NCT04623970|EXPERIMENTAL|Ketofol 1:4 sedation group|Patients in this experimental group received ketofol sedation agent as a 1:4 mixture.
62226813|NCT04040504|EXPERIMENTAL|Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)|Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)
62226814|NCT04040504|ACTIVE_COMPARATOR|Pentax ED-34i10T Duodenoscope|Pentax ED-34i10T Duodenoscope
62226815|NCT06204874|EXPERIMENTAL|Pulsed Radiofrequency Ablation Arm|18 total subjects in this arm. Subjects will be laid in the prone position. Local anesthesia will be administered. The appropriate spinal interspace will be identified under fluoroscopic guidance and hollow-tip needles will be inserted through the back into the retroperitoneal space adjacent to the superior hypogastric plexus. A microelectrode will be inserted through the hollow needle. A test pulse will be delivered. When proper positioning has been confirmed, 4mL of 1% lidocaine without epinephrine will be administered to reduce discomfort associated with radiofrequency ablation. Pulsed radiofrequency ablation will be performed at a pulse frequency of 2Hz, pulse width of 20ms, temperature of 42 degrees Celsius, total duration 120 seconds. The microelectrode and hollow-tip needle will then be withdrawn.
62226816|NCT06204874|SHAM_COMPARATOR|Sham Arm|18 total subjects in this arm. Subjects will be laid in the prone position. Local anesthesia will be administered. The appropriate spinal interspace will be identified under fluoroscopic guidance and hollow-tip needles will be inserted through the back into the retroperitoneal space adjacent to the superior hypogastric plexus. A microelectrode will be inserted through the hollow needle. A test pulse will be delivered. Sham pulsed radiofrequency ablation will then be performed with the radiofrequency generator disconnected from the microelectrode. The duration of the sham procedure will be 120 seconds. The microelectrode and hollow-tip needle will then be withdrawn.
62226817|NCT01189084||Observational immunotherapy follow-up|
62226818|NCT01543126||pleural effusion|patients with pleural effusion
62419725|NCT01785472|EXPERIMENTAL|LCZ696 400 mg|Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.
62226819|NCT01210118|EXPERIMENTAL|High intensity intervention|"Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the 5 Αs (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided."
62419726|NCT01785472|ACTIVE_COMPARATOR|Olmesartan 20 mg|Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.
62419727|NCT00050752||1 / Patients|Patients with known or suspected Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)
62419728|NCT00050752||2 / Family Members|Family members (related by blood) of patients who have or are suspected of having Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)
62419729|NCT00050752||3 / Non-Biologic Family Members|Spouses enrolled primarily for linkage analysis (Spouses have been removed from the inclusion criteria for this study. This closed cohort is for spouses previously enrolled on study.)
62590053|NCT03788434|PLACEBO_COMPARATOR|Placebo|Study subjects assigned to the placebo dose arm took placebo capsules each day for 14 days. The capsules did not contain any VE303.
62590054|NCT05591222|PLACEBO_COMPARATOR|Placebo/Daxdilimab Arm 1|Administration of placebo Q4W from Day 1 through Week 20 and administration of Daxdilimab Q4W from Week 24 through Week 44.
62590055|NCT05591222|EXPERIMENTAL|Daxdilimab Arm 2|Administration of Daxdilimab Q4W from Day 1 through Week 44.
62027766|NCT06530953|ACTIVE_COMPARATOR|Patient Navigator/ Community Health Worker|The community health worker will contact the participant two days after their initial clinic visit. They will call the participant to offer support and counseling on accessing their follow-up visits with local healthcare system. Additionally, the PN will call 1 day prior to the scheduled appointment to offer support and information to the patient followed by a reminder text the morning of the appointment.
62027767|NCT06530953|ACTIVE_COMPARATOR|Patient Navigator/Clinic Staff|Clinic staff will contact the participant two days after their initial clinic visit. They will call the participant to offer support and counseling on accessing their follow-up visits with local healthcare system. Additionally, the clinic staff will call 1 day prior to the scheduled appointment to offer support and information to the patient followed by a reminder text the morning of the appointment.
62226820|NCT01210118|OTHER|Low intensity intervention|Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
62226821|NCT00738582|EXPERIMENTAL|Open Label|Pemetrexed, Cisplatin and MORAb-009 (Amatuximab)
62027768|NCT00690521|EXPERIMENTAL|Furosemide and hydrochlorothiazide|A randomized, double-blind, crossover study designed to compare the efficacy of hydrochlorothiazide in combination with stable doses of furosemide in congestive heart failure patients.
62590056|NCT05591222|EXPERIMENTAL|Daxdilimab Arm 3|Administration of Daxdilimab Q4W from Day 1 through Week 44.
62226822|NCT00418626|EXPERIMENTAL|Nilotinib|
62226823|NCT04278157|EXPERIMENTAL|SCBT-SB|A culturally centered CBT treatment protocol called Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)
62226824|NCT04278157|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as usual is base on the standard care for teens and their parents under a community mental health center.
62419730|NCT01822964|ACTIVE_COMPARATOR|targeted brain cooling|In these 15 pts, targeted brain cooling (tympanic temperature of 33°C) will be applied during the TAVI intervention by the use of the RhinoChill device (Benechill Inc, San Diego cA)
62419731|NCT01822964|PLACEBO_COMPARATOR|no use of targeted brain cooling|In these 15 pts, no cooling techniques will be applied and current clinical practice as to maintenance of normothermia will be followed during these TAVI interventions
62419732|NCT00099320|EXPERIMENTAL|Exenatide|After a 2-week placebo lead-in period, exenatide will be given in an esclating dose along with the subject's current therapy regimen
62419733|NCT00099320|PLACEBO_COMPARATOR|Placebo|After a 2-week placebo lead-in period, subjects will be given placebo (in equivalent amounts to exenatide) in addition to their current therapy regimen.
62590057|NCT01343277|EXPERIMENTAL|Trabectedin|
62590058|NCT01343277|ACTIVE_COMPARATOR|Dacarbazine|
62590059|NCT05102474||Moderate to Severe Psoriasis|Moderate to severe psoriasis will be defined as affected body surface area (BSA) ≥3%.
62027769|NCT00690521|EXPERIMENTAL|Furosemide and metolazone|A randomized, double-blind, crossover study designed to compare the efficacy of metolazone in combination with stable doses of furosemide in congestive heart failure patients.
62027770|NCT01985126|EXPERIMENTAL|Part 1|During Stage 1 of Part 1, participants will be randomized to receive daratumumab treatment regimens in Group A and Group B. If in Stage 1, 1 or both of the treatment groups is considered to be ineffective and/or not well tolerated, then that treatment group will be terminated. Participants in Group B will be given the option to cross over to Group A if the investigator deems it in the best interest of the participants.
62027771|NCT01985126|EXPERIMENTAL|Part 2|Based on the Part 1 response rate, Group A or B daratumumab treatment will be selected as the treatment regimen for participants enrolled in Part 2.
62027772|NCT03080129|EXPERIMENTAL|Cirrhosis + sarcopenia|Patients with cirrhosis will receive 200ml of an oral nutritional supplement daily for 7 days.
62027773|NCT03080129|NO_INTERVENTION|Control|Patients with sarcopenia and no evidence of cirrhosis and healthy controls
62590060|NCT05102474||Healthy Controls|Healthy controls will be age and sex matched subjects with no prior or current history of psoriasis.
62590061|NCT05280457|EXPERIMENTAL|nivolumab-GX-188E-GX-I7|
62590062|NCT06251635|EXPERIMENTAL|Follicular Phase Visits|Participants will undergo two visits during the follicular phase of the menstrual cycle (they will be scanned between day 4-10 of their menstrual cycle). Each of the study periods will involve administration of OLA 5 mg HS (or PL) on day 0, OLA 10 mg HS (or PL) on day 1, and cognitive testing and MRI scanning on day 2. MRI assessments will occur 15 minutes after administering 160 International Units (IU) INI/INP.
62027774|NCT02979535|EXPERIMENTAL|CYD Dengue Vaccine + Cervarix (Concomitant Administration)|Participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12 and 2 doses of Cervarix vaccine 0.5 mL Intramuscularly (IM) concomitantly with the 2 first doses of CYD dengue vaccine.
62027775|NCT02979535|EXPERIMENTAL|CYD Dengue Vaccine + Cervarix (Sequential Administration)|Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Month 1, Month 7, and Month 13 along with the 2 doses of Cervarix vaccine 0.5 mL IM at Day 0 and Month 6 sequentially (i.e., one month before) to each of the 2 first doses of CYD dengue vaccine.
62419734|NCT05048342|EXPERIMENTAL|LOU064 25 mg b.i.d.|Patients were treated with remibrutinib 25 mg bis in die/twice a day (b.i.d.). LOU064 open-label treatment taken orally for 52 weeks.
62419735|NCT00479739|EXPERIMENTAL|Arm 1|
62419736|NCT04404530||Palynziq Therapy for PKU|Participants with PKU who are starting Palynziq therapy, or have recently started Palynziq therapy but have not achieved response.
62419737|NCT01266915||Control group|Normal disease free (non lupus) subjects
62419738|NCT01266915||Diseased Control|
62027776|NCT03140436|EXPERIMENTAL|sodium bicarbonate powders (65 µm)|sodium bicarbonate powders with grain size 65 µm
62226825|NCT03300115|EXPERIMENTAL|AC0010|Each participant will be given AC0010 300mg bid.
62226826|NCT02777723|EXPERIMENTAL|CKD-350|Xenobella
62419739|NCT01266915||Diseased group 1|Those subjects with systemic lupus erythematosus.
62419740|NCT01266915||Diseased group 2|Subjects diagnosed with cutaneous lupus.
62419741|NCT00364273|EXPERIMENTAL|Subjects receiving treatment sequence 1 : Cohort 1|Eligible subjects will receive placebo, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms.
62419742|NCT00364273|EXPERIMENTAL|Subjects receiving treatment sequence 2 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, placebo, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms.
62419743|NCT00364273|EXPERIMENTAL|Subjects receiving treatment sequence 3 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, placebo, GSK159802 900 micrograms and GSK159802 1200 micrograms.
62027777|NCT03140436|EXPERIMENTAL|sodium bicarbonate powders (40 µm)|sodium bicarbonate powders with grain size 40 µm
62027778|NCT06197893|EXPERIMENTAL|1. GUG+MSS|The GUG was obtained from the maxillary premolar area. The dissected graft was fixed to the recipient site using a modified sling suture technique.
62226827|NCT02777723|ACTIVE_COMPARATOR|Sodium Hyaluronate|Isotonic 0.3% Sodium Hyaluronate
62226828|NCT00900744||Tamoxifen|20mg daily
62226829|NCT02027220|EXPERIMENTAL|G-CSF/Bortez/Cyc/Dex|G-CSF IC on days 0, 1, 7, 8, 14, 15, 21 and 22. Bortezomib IV on days 1, 8, 15 and 22. Cyclophosphamide CIV on days 1, 8, 15 and 22. Dexamethasone IV on days 1, 2, 8, 9, 15, 16, 22 and 23.
62226830|NCT02049164|EXPERIMENTAL|AR08 0.5 mg/day|AR08 QD oral dosing for 14 weeks
62226831|NCT02049164|EXPERIMENTAL|AR08 1.0 mg/day|AR08 QD oral dosing for 14 weeks
62226832|NCT02049164|EXPERIMENTAL|AR08 2.0 mg/day|AR08 QD oral dosing for 14 weeks
62226833|NCT02049164|PLACEBO_COMPARATOR|Placebo|Placebo QD oral dosing for 14 weeks
62419744|NCT00364273|EXPERIMENTAL|Subjects receiving treatment sequence 4 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, placebo and GSK159802 1200 micrograms.
62419745|NCT00364273|EXPERIMENTAL|Subjects receiving treatment sequence 5 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and placebo.
62226834|NCT03131583|EXPERIMENTAL|Cohort 1|Colchicine 0.5 mg Oral Tablet Day-14\~Day16 qd, Febuxostat 80 mg Oral Tablet Day1 and Day8 qd, SHR4640 10 mg Oral Tablet Day3\~Day8 qd.
62801910|NCT05718856|EXPERIMENTAL|efficacy of TPO-RAs combining anti-CD 20 monoclonal antibody|After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as patients in TPO-RAs monotherapy group. The dose of TPO-RAs was adjusted according to the subject platelet count. Two kinds of anti-CD 20 monoclonal antibody could be used in this study. All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment. Subjects weighing less than 30kg will be given rituximab 100 mg once a week for four times. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater. Ps. Participants in the eltrombopag monotherapy group who have platelet count \< 20×10\^9/L or significant skin and mucosal bleeding at the end of 12 weeks of treatment will be given a single dose of rituximab 375mg/m2. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater. Efficacy and safety will be evaluated at Week 4, Week 8, Week 12 and Week 24.
62590063|NCT06251635|EXPERIMENTAL|Luteal Phase Visits|Participants will undergo two visits during the luteal phase of the menstrual cycle (they will be scanned between day 16-22, or within 5 days of next expected menses depending on individual cycle duration). Each of the study periods will involve administration of OLA 5 mg HS (or PL) on day 0, OLA 10 mg HS (or PL) on day 1, and cognitive testing and MRI scanning on day 2. MRI assessments will occur 15 minutes after administering 160 International Units (IU) INI/INP.
62801911|NCT05391035||Symptomatic patients attending a sexual health clinic.|A cohort of 160 symptomatic people attending a sexual health clinic in the UK will be recruited to this observational study.
62419746|NCT00364273|EXPERIMENTAL|Subjects receiving treatment sequence 1 : Cohort 2|Eligible subjects will receive placebo, salmeterol, GSK159802 low dose (LD) and GSK159802 maximum tolerated dose (MTD).
62226835|NCT03790319||Single Workshop 'The Emotional Backpack'|Subjects of this group are participating in one single workshop over three days.
62419747|NCT00364273|EXPERIMENTAL|Subjects receiving treatment sequence 2 : Cohort 2|Eligible subjects will receive salmeterol, GSK159802 MTD, placebo and GSK159802 LD.
62419748|NCT00364273|EXPERIMENTAL|Subjects receiving treatment sequence 3 : Cohort 2|Eligible subjects will receive GSK159802 LD, placebo, GSK159802 MTD and salmeterol.
62419749|NCT00364273|EXPERIMENTAL|Subjects receiving treatment sequence 4 : Cohort 2|Eligible subjects will receive GSK159802 MTD, GSK159802 LD, salmeterol and placebo.
62419750|NCT00364273|EXPERIMENTAL|Subjects receiving treatment sequence 1 : Cohort 3|Eligible subjects will receive placebo, salmeterol, GSK159802 300 micrograms and GSK159802 1200 micrograms.
62419751|NCT00364273|EXPERIMENTAL|Subjects receiving treatment sequence 2 : Cohort 3|Eligible subjects will receive salmeterol, GSK159802 1200 micrograms, placebo and GSK159802 300 micrograms.
62801912|NCT03512171|EXPERIMENTAL|Amphetamine|One oral dose of dextroamphetamine (0.43 mg/kg) up to a maximum dose of 45mg. The dose is administered in 10mg and 2.5mg capsules prepared by the Vanderbilt Investigational Drug Services (IDS). Note: We are not testing the effect of dextro-amphetamine on a symptom. Rather it is part of the diagnostic intervention that is used to measure dopamine release assessed as the decline in \[18F\]fallypride binding relative to baseline.
62801913|NCT03512171|PLACEBO_COMPARATOR|Placebo|One oral placebo dose, with capsules prepared by the Vanderbilt Investigational Drug Services (IDS). This provides the baseline against which dopamine release is measured.
62801914|NCT03512171|EXPERIMENTAL|[18F]-FE-PE2I|\[18F\]-FE-PE2I is a radioligand for measuring dopamine transporters with positron emission tomography (PET). All participants complete this arm. The arm does not include administration of amphetamine or placebo.
62801915|NCT02696265|ACTIVE_COMPARATOR|CFAE guided ablation|CFAE/spatiotemporal dispersion guided ablation: CFAE mapping and ablation during AF aimed at restoring sinus rhythm during ablation.
62801916|NCT02696265|ACTIVE_COMPARATOR|PVI guided ablation|PVI guided ablation: wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals.
62801917|NCT03113032|EXPERIMENTAL|Exercise group 1|This group of patients will receive the P-SEC exercise intervention protocol on their 'surgical' leg in addition to their normal pre-surgical care.
62226836|NCT03790319||Year Program 'The Power of Feelings'|Subjects of this group are participating in three workshops of over 3 days each in a continuing group over nine months. They are animated to deal with the content inbetween the workshops through biweekly e-mails and to exchange in couples.
62226837|NCT01990209|EXPERIMENTAL|Orteronel|The planned dose of orteronel is 300mg orally (PO) twice daily (BID), for a total daily dose of 600mg.
62419752|NCT00364273|EXPERIMENTAL|Subjects receiving treatment sequence 3 : Cohort 3|Eligible subjects will receive GSK159802 300 micrograms, placebo, GSK159802 1200 micrograms and salmeterol.
62226838|NCT04256577||patients proven having (SLE)|20 patients proven to have systemic lupus Erthematosus without renal impairment (eGFR) ≥ 80 ml/min/1.73 m2 and albumin / creatinine ≤ 30 mg/g)
62027779|NCT06197893|EXPERIMENTAL|2. GUG+CS|The GUG was obtained from the maxillary premolar area, as detailed experimental GUG+MSS group. The dissected graft was fixed to the recipient site using conventional suture technique.
62419753|NCT00364273|EXPERIMENTAL|Subjects receiving treatment sequence 4 : Cohort 3|Eligible subjects will receive GSK159802 1200 micrograms, GSK159802 300 micrograms, salmeterol and placebo.
62801918|NCT03113032|EXPERIMENTAL|Exercise group 2|This group of patients will receive the P-SEC exercise intervention protocol on their 'non-surgical' leg in addition to their normal pre-surgical care.
62801919|NCT03113032|ACTIVE_COMPARATOR|Control group|This group of patients will not receive the P-SEC protocol but will follow normal pre-surgical care along with the other two groups of patients.
62801920|NCT04183374|EXPERIMENTAL|Intervention|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
62801921|NCT03982641||Colon surgery|patients diagnosed with colon cancer, who undergone at least one surgical procedure at one of participating hospitals during the observational period
62801922|NCT03982641||Rectal surgery|patients diagnosed with rectal cancer, who undergone at least one surgical procedure at one of participating hospitals during the observational period
62801923|NCT03854838|EXPERIMENTAL|Toripalimab +Radiotherapy|Radiotherapy, intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks. Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks ) will be administered as an intravenous infusion over 60 minutes.
62801924|NCT03076762|EXPERIMENTAL|Intravesical suburothelial injection|Patients assigned for suburothelial injections received 100 U of onabotulinumtoxinA in 20 sites injected in the bladder body on treatment day and follow-up
62801925|NCT03076762|ACTIVE_COMPARATOR|Intravesical trigonal injection|Patients assigned trigonal injections will receive 100U of onabotulinumtoxinA at 10 sites injected at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone) on treatment day and follow-up.
62801926|NCT05579977|EXPERIMENTAL|PF-07081532 20 mg T2DM|PF-07081532 20 mg daily in T2DM
62801927|NCT05579977|EXPERIMENTAL|PF-07081532 40 mg T2DM|PF-07081532 40 mg daily in T2DM
62226839|NCT04256577||patients proven to have (LN) by renal biopsy|Group (2) 25 patients proven to have LN by renal biopsy before starting treatment and after 3 cycle of treatment (eGFR \< 80 ml/min/1.73 m2 and albumin/creatinine ratio \> 30 mg/g)
62801928|NCT05579977|EXPERIMENTAL|PF-07081532 80 mg T2DM|PF-07081532 80 mg daily in T2DM
62801929|NCT05579977|EXPERIMENTAL|PF-07081532 160 mg T2DM|PF-07081532 160 mg daily in T2DM
62801930|NCT05579977|EXPERIMENTAL|PF-07081532 260 mg T2DM|PF-07081532 260 mg daily in T2DM
62801931|NCT05579977|PLACEBO_COMPARATOR|Placebo T2DM|Placebo daily in T2DM
62801932|NCT05579977|EXPERIMENTAL|PF-07081532 80 mg Obesity|PF-07081532 80 mg daily in Obesity
62226840|NCT04256577||healthy control|(20) patients healthy control matched in age and sex
62226841|NCT05127629|PLACEBO_COMPARATOR|Control|
62226842|NCT05127629|EXPERIMENTAL|Collagen matrix|
62226843|NCT05423886|EXPERIMENTAL|Intervention arm|Participants receive a personalized screening invitation interval (1,2 or 3 years) based on their fecal Hemoglobin concentration of the negative fecal immunochemical test in previous round.
62226844|NCT05423886|NO_INTERVENTION|Control arm|Participants receive a standard screening invitation interval (2 years).
62226845|NCT00722930|EXPERIMENTAL|1. Consolidation with Y90 Ibritumomab Tiuxetan|1. Consolidation with Y90 Ibritumomab Tiuxetan
62226846|NCT05249829|EXPERIMENTAL|Part 1: mRNA-1273.529|"Phase A: Participants will receive 1 intramuscular (IM) dose of mRNA-1273.529 on Day 1.~Phase B: After Day 179, eligible participants may choose to be unblinded and to receive an additional booster outside of the study."
62801933|NCT05579977|EXPERIMENTAL|PF-07081532 140 mg Obesity|PF-07081532 140 mg daily in Obesity
62801934|NCT05579977|EXPERIMENTAL|PF-07081532 200 mg Obesity (Option 1)|PF-07081532 200 mg daily in Obesity
62801935|NCT05579977|EXPERIMENTAL|PF-07081532 200 mg Obesity (Option 2)|PF-07081532 200 mg daily in Obesity
62801936|NCT05579977|EXPERIMENTAL|PF-07081532 260 mg Obesity|PF-07081532 260 mg daily in Obesity
62801937|NCT05579977|ACTIVE_COMPARATOR|Rybelsus 14 mg T2DM|Semaglutide 14 mg daily in T2DM
62801938|NCT05579977|PLACEBO_COMPARATOR|Placebo Obesity|Placebo in Obesity
62027780|NCT06197893|EXPERIMENTAL|3. CG+MSS|Conventional graft dimensions were determined with aluminum foil and the foil was placed in the palatial region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique, as detailed experimental GUG+MSS group.
62027781|NCT06197893|EXPERIMENTAL|4. CG+CS|The dissected conventional graft, as detailed experimental CS+MSS group, fixed recipient bed with conventional suture technique, as detailed experimental GUG+CS group.
62027782|NCT02543346|OTHER|cetirizine hydrochloride|
62419754|NCT00364273|EXPERIMENTAL|Subjects receiving treatment sequence 5 : Cohort 3|Eligible subjects will receive GSK159802 1200 micrograms, salmeterol, GSK159802 300 micrograms and placebo.
62801939|NCT01722539|EXPERIMENTAL|Sulfadoxine-Pyrimethamine|"Sulfadoxine-Pyrimethamine every Four months Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more; Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
62801940|NCT01722539|EXPERIMENTAL|Sulfadoxine-Pyrimethamine+Piperaquine|"Sulfadoxine-Pyrimethamine every 4 months Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more; Piperaquine every four months Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.~Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
62419755|NCT06383143||Patients with MGUS and aFLCR and with SMM|"Part A: Patients with MGUS and aFLCR and patients with SMM undergoing an active, biomarker-based screening of presymptomatic amyloid organ involvement.~Part B: Newly diagnosed patients with AL amyloidosis identified through Part A or with clinically overt AL amyloidosis evaluated in the frame of routine clinical assessments and referred to the Amyloidosis Research and Treatment Center in Pavia or managed locally at the participating Italian Hematologic Departments"
62027783|NCT02543346|PLACEBO_COMPARATOR|placebo|
62027784|NCT00288587|ACTIVE_COMPARATOR|Ultrafiltration|Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
62027785|NCT00288587|ACTIVE_COMPARATOR|Usual & Customary|Patients treated with conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
62027786|NCT01183377||1|Female athlete Triad syndrom was based on menstrual disorder,Eating Disorder and bone loss
62226847|NCT05249829|ACTIVE_COMPARATOR|Part 1: mRNA-1273|"Phase A: Participants will receive 1 IM dose of mRNA-1273 on Day 1.~Phase B: After Day 179, eligible participants may choose to be unblinded and to receive an additional booster outside of the study."
62419756|NCT05359003|EXPERIMENTAL|Arm 1: Exercise Intervention|Participants in this arm will undergo a 12-week physical activity program aimed to achieve the equivalent of 8,000 steps per day (56,000 weekly steps).
62027787|NCT06270823|EXPERIMENTAL|interventional arm|As soon as the infant is out of the uterus a Knee-to-chest flexion (KCF) maneuver is performed for 30 seconds while the infant remains attached to the cord. When applying KCF, we essentially bring the newborn back into the fetal position, flexing the knees to the chest. This is similar to the holding position applied for performing lumbar puncture in neonates. Except for KCF, the infant will receive normal routine care and there are no co-interventions.
62027788|NCT06270823|NO_INTERVENTION|control|As soon as the infant is out of the uterus normal routine care is given
62027789|NCT03447782|EXPERIMENTAL|NDPH Persistent|"Patients will be evaluated in clinic 1 month after the phone call evaluation. At this time, patients will begin a 3 month trial of low-dose naltrexone (Naltrexone HCL powder compounded to provide 4.5mg once per day orally).~Patients will be evaluated in clinic 3 months after beginning treatment with naltrexone."
62027790|NCT03447782|NO_INTERVENTION|Healthy Controls|These participants will be in the research study for the initial visit only. They will be evaluated by a physician or nurse practitioner
62226848|NCT05249829|EXPERIMENTAL|Part 2: mRNA-1273.214|"Phase A: Participants will receive 1 IM dose of mRNA-1273.214 on Day 1.~Phase B: After Day 85, eligible participants may choose to be unblinded and to receive an additional booster outside of the study."
62419757|NCT05359003|NO_INTERVENTION|Arm 2 Control|Participants randomized to the wait-list attention control group will continue to undergo standard care for 12 weeks.
62801941|NCT01722539|ACTIVE_COMPARATOR|Control|"Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
62801942|NCT01336933|EXPERIMENTAL|Treatment|"A Treatment: Cyclophosphamide,Etoposide, Vincristine and Prednisone (CEOP) B Treatment: Pralatrexate (P)~A cycles (CEOP) of the treatment regimen are 14 days, followed by  B cycles (P) which are 21 days, followed by 7 days of rest for a total of 42 days per course, unless criteria are met for stopping or holding treatment or to a maximum of 6 courses.~Patients with Complete Response (CR) or Partial Response (PR), per investigators discretion, may then undergo hematopoietic stem cell collection and administration of standard preparative regimen followed by hematopoietic stem cell transplantation."
62801943|NCT04035252||1. Young healthy group|Male or female between the age of 18 and 40 years old. No presence of systolic blood pressure \>140 and/or diastolic blood pressure \>90, cardiovascular history or antihypertensive medication
62801944|NCT04035252||2. Patients with an AAA|Individuals (\>60 years) with a small, stable, abdominal aortic aneurysm (i.e. AAA diameter of 30-50 mm)
62801945|NCT04035252||3. Healthy older group|Healthy age- and sex- matched with group 2 with no presence of systolic blood pressure \>140 and/or diastolic blood pressure \>90, cardiovascular history or antihypertensive medication
62801946|NCT01239069|EXPERIMENTAL|DE-110 ophthalmic suspension high dose|
62801947|NCT01239069|EXPERIMENTAL|DE-110 ophthalmic suspension low dose|
62801948|NCT01239069|PLACEBO_COMPARATOR|Placebo|
62801949|NCT01527968|ACTIVE_COMPARATOR|Tranexamic Acid|TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)
62801950|NCT01527968|ACTIVE_COMPARATOR|Epsilon Aminocaproic Acid|eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
62801951|NCT01527968|PLACEBO_COMPARATOR|Placebo|Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
62801952|NCT04282252|EXPERIMENTAL|IV fluid restriction group|"No IV fluids should be given unless one of the below occurs; in these cases, IV fluid may be given:~1. In case of severe hypoperfusion or severe circulatory impairment defined by:~   Lactate 4 mmol/L or above or mean arterial blood pressure below 50 mm Hg or mottling beyond the kneecap or urinary output less than 0.1 mL/kg bodyweight/h, but only in the first 2 hours after randomisation. A bolus of 250-500 mL of IV crystalloid solution may be given.~2. In case of overt fluid losses (eg, vomiting, large aspirates, diarrhoea, drain losses, bleeding or ascites tap) IV fluid may be given to correct for the loss.~3. In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to correct dehydration or electrolyte imbalances and/or to ensure a total fluid input of 1 L per 24 hours."
62027791|NCT04053764|EXPERIMENTAL|crizanlizumab + standard of care|5 mg/kg by intravenous (i.v.) infusion at Week 1 Day 1, Week 3 Day 1 and Day 1 of every 4-week cycle until Week 51 in addition to their usual standard of care treatment.
62027792|NCT04053764|ACTIVE_COMPARATOR|standard of care|Patients in the standard of care alone arm will continue to receive their usual standard of care treatment.
62419758|NCT06290739||Intrahepatic cholangiocarcinoma patients who underwent lymph nodes dissection|
62419759|NCT06290739||Intrahepatic cholangiocarcinoma patients who didn't undergo lymph nodes dissection|
62226849|NCT05249829|ACTIVE_COMPARATOR|Part 2: mRNA-1273|"Phase A: Participants will receive 1 IM dose of mRNA-1273 on Day 1.~Phase B: After Day 85, eligible participants may choose to be unblinded and to receive an additional booster outside of the study."
62419760|NCT01031134|EXPERIMENTAL|Shared Decision Making|1 in person session followed by 2 telephone calls 1 and 2 weeks later.
62226850|NCT02256137||Childhood Cancer Survivors|This study will evaluate 1493 members of the St. Jude Lifetime Cohort Study (SJLIFE) who have completed a baseline functional assessment six or less years ago when 18-45 years of age.
62419761|NCT01031134|ACTIVE_COMPARATOR|Usual Care|Physician Usual Care of depressed patients.
62419762|NCT03402945|ACTIVE_COMPARATOR|Arm 1|"cefazolin prophylaxis plus Prevena negative-pressure wound management system . Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h.~Prevena will be applied to all diabetic and/or obese patients (BMI \>30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 day"
62801953|NCT04282252|ACTIVE_COMPARATOR|Standard care group|There will be no upper limit for the use of IV or oral/enteral fluids. In particular: IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline. IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid. IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte imbalances.
62419763|NCT03402945|ACTIVE_COMPARATOR|Arm 2|"cefazolin and vancomycin prophylaxis plus Prevena negative-pressure wound management system. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hrs after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose.~Prevena will be applied to all diabetic and/or obese patients (BMI \>30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 days."
62419764|NCT03402945|ACTIVE_COMPARATOR|Arm 3|"cefazolin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h.~Standard wound dressing: non-negative wound dressing as standard of care at the study site."
62419765|NCT03402945|ACTIVE_COMPARATOR|Arm 4|"cefazolin and vancomycin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose.~Standard wound dressing: non-negative wound dressing as standard of care at the study site."
62419766|NCT01596049||Self-fixating Mesh|patients attributed to that arm, undergoing surgery of open inguinal unilateral hernia repair, using Self-fixating Mesh which is acceptable in the literature.
62419767|NCT05218031|EXPERIMENTAL|ACT Intervention|"5-week ACT Group Intervention based on the Self-Help Booklet by the World Health Organization Doing What Matters in Times of Stress: An Illustrated Guide."
62419768|NCT05218031|NO_INTERVENTION|Control group|Waiting-list
62419769|NCT02802007|EXPERIMENTAL|Elipse Intragastric Balloon|Patients seeking weight loss received the Elipse Intragastric Balloon.
62590064|NCT06482684|EXPERIMENTAL|Arm A|The abbreviated induction phase consists of 2 cycles of Ibrutinib + Rituximab and 2 cycles of Ibrutinib + R-CHOP for primary tumor reduction followed by CAR-T-cell treatment. In case of good clinical response (PR or CR) after 2 cycles of Ibrutinib + Rituximab, Ibrutinib + R-CHOP can be omitted. In this case, one cycle of Ibrutinib monotherapy will be applied. T cell apheresis will be performed after the initial 2 cycles. Application of KTE-X19 will be performed after lymphodepleting chemotherapy with Fludarabine and Cyclophosphamide (FC). After stable hematopoietic recovery, maintenance with Ibrutinib will be applied for 6 months but not prior to day 60 post CAR. The follow-up period starts after the completion of Ibrutinib maintenance and takes 4.5 up to 7 years.
62801954|NCT04001634||Dual anti-HER2 group|Dual anti-HER2 therapy (lapatinib and trastuzumab) plus chemotherapy
62801955|NCT00996463|ACTIVE_COMPARATOR|IL SSG|Intralesional sodium stibogluconate
62801956|NCT00996463|EXPERIMENTAL|ETC+MWT|Electro-thermo-coagulation with subsequent moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
62801957|NCT00996463|EXPERIMENTAL|MWT|Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
62801958|NCT05057481|ACTIVE_COMPARATOR|MMF arm|
62801959|NCT05057481|ACTIVE_COMPARATOR|Rituximab arm|
62226851|NCT02995577||Feeding tolerant|Patients that are able to reach 80-100% of full enteral feeds (whether fed by mouth or through a nasogastric tube) 7 days after the initiation of feeds. Patients will be excluded from this group if they are ever diagnosed with NEC at any time during this hospitalization.
62243059|NCT04669288|ACTIVE_COMPARATOR|Treatment - Active|Eligible patients will be randomly assigned to one of two treatment groups (1:1) and one arm will be administered the active drug per the randomization schedule. Study medication will be provided to parents/guardians, along with instructions, for home-based administration. The first dose of the study medication will be administered before discharge from the ED.
62027793|NCT05605119|EXPERIMENTAL|AUR105 50mg to 750mg|Currently planned dose levels in Part 1 are 50mg, 100mg, 200mg, 300mg, 450mg, 600mg and 740mg once daily
62419770|NCT02377687||elderly >75 years|all patients aged ≥ 75 having an emergency GI laparotomy or laparoscopy
62027794|NCT04709536|EXPERIMENTAL|IBI306|IBI306 administered subcutaneously (SC)
62801960|NCT06332066|EXPERIMENTAL|Oxytocin|24IU (12IU\*2) of Oxytocin, Sorbitol, Benzyl, alcohol glycerol, distilled water.
62801961|NCT06332066|PLACEBO_COMPARATOR|Placebo|24IU (12IU\*2) of Sorbitol, Benzyl, alcohol glycerol, distilled water.
62226852|NCT02995577||Feeding intolerant|Patients with GI symptoms (vomiting, abdominal distention, diarrhea, hematemesis, and/or hematochezia) that persist for 48 hours or longer while needing to be NPO, this patient is retrospectively categorized into the feeding intolerance group. Patients with feeding intolerance may also include infants that are made NPO, placed on bowel rest, and are started on antibiotics to rule out NEC, but are never diagnosed with NEC. Exclusion criteria include patients that are continued on antibiotics for greater than 48 hours due to diagnosed bacterial sepsis or diagnosed NEC, and those that have a positive blood, urine, or sputum culture.
62226853|NCT02995577||Necrotizing enterocolitis|Any infant that is diagnosed (radiographically, by Bell's criteria) with and treated for NEC.
62226854|NCT01768117|EXPERIMENTAL|rLP2086|
62226855|NCT01097382|EXPERIMENTAL|AMBIEN CR|AMBIEN CR 12.5 mg once daily immediately before bedtime or in elderly/hepatically impaired patients: 6.25 mg once daily immediately before bedtime
62226856|NCT05764993|EXPERIMENTAL|Group #1|SCIgR with Cuvitru 125 mg/kg/week + standard of care management
62226857|NCT05764993|PLACEBO_COMPARATOR|Group #2|Standard of care management = 20 patients
62226858|NCT02120131||test envelope|envelope flap
62419771|NCT06386185||Diagnostic Test|Patients referred for initial PH investigations, who underwent ECG and echo screening prior to RHC.
62419772|NCT06220838|EXPERIMENTAL|SC-101|
62419773|NCT03470896|ACTIVE_COMPARATOR|Preanesthesia teleconsultation|Preanesthesia teleconsultation through video-conference, between an anesthesiologist of the surgical center Emile Galle, in a medical consulting room in the surgical center Emile Galle, and a patient at home or at work. The patient must be in a quiet area, which allows the confidential medical contact.
62419774|NCT03470896|ACTIVE_COMPARATOR|Preanesthesia traditional consultation|Preanesthesia traditional consultation between an anesthesiologist of the surgical center Emile Galle, and a patient, in a medical consulting room in the surgical center Emile Galle.
62419775|NCT03470896|OTHER|Bis traditional consultation|"If a patient, in the group  preanesthesia teleconsultation  cannot realized his teleconsultation because of technical problem, he will be assigned on the sub group  bis traditional preanesthesia consultation ."
62419776|NCT05988411|EXPERIMENTAL|Catheter ablation + renal denervation|Catheter ablation + renal denervation
62419777|NCT05988411|ACTIVE_COMPARATOR|Catheter ablation only|Catheter ablation
62419778|NCT01258452|EXPERIMENTAL|CHF 5074 (fed group)|oral tablet, single dose
62419779|NCT01258452|EXPERIMENTAL|CHF 5074 (fasting group)|oral tablet, single dose
62419780|NCT06540482||Stroke patients|The participants consisted of stroke patients aged 50 years and older who were followed up and treated by Pamukkale University Adult Neurological Rehabilitation - Outpatient Unit.
62419781|NCT03596086|EXPERIMENTAL|ADV/HSV-tk (gene therapy)|"The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 10 sessions (over 2 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent or after completion of the radiotherapy dependent on patient status based on best clinical judgment.~Patient can receive second treatment of HSV-tk after 6 months"
62419782|NCT02786186||Secikinumab|Patients treated with secukinumab
62419783|NCT02786186||Approved standard of care|Patients treated with other indicated therapies (systemic, phototherapy, or biologic therapy)
62419784|NCT06245369|EXPERIMENTAL|SWITCH tracking healthy nutrients|Participants allocated to this group will be given goals to reach a recommended daily intake of nutrients in which US adults tend to not consume enough. Recommended amounts will be based off of age and sex, in line with the US Dietary Guidelines.
62801962|NCT06096649|EXPERIMENTAL|Topical Vehicle + Zinc Di-(dibutyryl lisinate)|Topical cream containing Zinc Di-(dibutyryl listinate)
62801963|NCT06096649|PLACEBO_COMPARATOR|Topical Vehicle|Topical cream
62801964|NCT00304174||Subjects with bulimia nervosa|Participants with bulimia nervosa
62801965|NCT00304174||Controls between 80-120% of ideal weight|Controls without bulimia nervosa
62027795|NCT04709536|PLACEBO_COMPARATOR|Placebo|administered subcutaneously (SC)
62027796|NCT04304833|ACTIVE_COMPARATOR|Provider-Based Care Model Arm|Non-connected home vital sign equipment will be given to patients in this group. The patients in the group will be instructed to record their daily readings on a paper log provided by the research team. These monitoring devices will not transmit readings to a centralized location and no one will be alerted to out-of-range readings or compliance with taking daily vital sign measures. At the front page of the log, normal ranges will be described with brief instructions about what participants/caregivers should do if their readings are out-of-range. Logs will be collected at baseline, 3-months and 6-months.
62226859|NCT02120131||control, trapezodal|standard incision
62226860|NCT00002570|ACTIVE_COMPARATOR|Fluorouracil and folinic acid|
62226861|NCT00002570|NO_INTERVENTION|Observation|
62226862|NCT02619149|ACTIVE_COMPARATOR|Intervention|Piperacillin-tazobactam combination product
62226863|NCT02619149|PLACEBO_COMPARATOR|Control|Saline solution
62226864|NCT02976701|EXPERIMENTAL|DLBS1033|DLBS1033 enteric-coated tablet is administered at the dose of 980 mg (two tablets@490 mg) three times daily, everyday for four weeks of study period
62801966|NCT03703778||bilateral orchidectomy|Patients with advanced prostate cancer who receive surgical androgen deprivation therapy - bilateral orchidectomy
62801967|NCT03703778||GnRH agonist|Patients with advanced prostate cancer who receive medical androgen deprivation therapy - GnRH agonist
62801968|NCT03703778||GnRH antagonist|Patients with advanced prostate cancer who receive medical androgen deprivation therapy - GnRH antagonist
62801969|NCT04791436||Mild Illness|Recovered COVID-19 patients who experienced a mild clinical course
62801970|NCT04791436||Moderate Illness|Recovered COVID-19 patients who experienced a moderate clinical course
62226865|NCT02976701|PLACEBO_COMPARATOR|Placebo|Placebo is administered two tablets three times daily, everyday for four weeks of study period
62226866|NCT06107725|NO_INTERVENTION|Standard Stroke Care without Minocycline|560 Patients will receive standard stroke care.
62226867|NCT06107725|EXPERIMENTAL|Standard Stroke Care with Minocycline|560 patients in the Minocycline arm will receive Minocycline 200 mg every 24 hours for five days with standard stroke care
62226868|NCT01362660||Infants with potential exposure in utero|
62226869|NCT01007448|EXPERIMENTAL|Bexarotene 150 milligrams (mg)/square meter (m^2)/day|Participants will receive bexarotene 150 mg/m\^2/day once daily for 24 weeks.
62226870|NCT01007448|EXPERIMENTAL|Bexarotene 300 mg/m^2/day|Participants will receive bexarotene 300 mg/m\^2/day once daily for 24 weeks.
62226871|NCT03720743|EXPERIMENTAL|Biodanza|Intervention group received a total of 10 sessions, once a week, over the course of two months. Each session lasted 60 minutes. All sessions began with a 10-minute warm-up period combining music and low-intensity movements as a welcome round, followed individual exercises, in pairs and/or groups, which included dance combined with exercises based on the five lines of Biodanza (vitality, sexuality, creativity, affectivity and transcendence). Finally, a celebration and farewell round of 10 minutes was held. At the end of each session, the participants were asked to share their experiences with the rest of the group.
62226872|NCT03720743|NO_INTERVENTION|Control Group|The study allowed control group subjects to participate in Biodanza sessions after the follow-up period.
62226873|NCT00912691|EXPERIMENTAL|1|CM-AT
62226874|NCT02520284|EXPERIMENTAL|Andecaliximab Every 2 Weeks|Participants will receive andecaliximab 150 mg administered via subcutaneous (SC) injection alternating with matching placebo weekly for a total of 4 doses of andecaliximab. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
62226875|NCT02520284|EXPERIMENTAL|Andecaliximab Weekly|Participants will receive andecaliximab 150 mg administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
62801971|NCT04791436||Severe Illness|Recovered COVID-19 patients who experienced a severe clinical course
62801972|NCT04272346|EXPERIMENTAL|Peer helping condition|Participants in the peer helping condition will be asked to write about their cancer experience with an emphasis on using the experience to benefit a newly-diagnosed AYA cancer patient.
62226876|NCT02520284|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to andecaliximab administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
62243060|NCT04669288|PLACEBO_COMPARATOR|Treatment - Placebo|Eligible patients will be randomly assigned to one of two treatment groups (1:1) and one arm will be administered placebo per the randomization schedule. Study medication will be provided to parents/guardians, along with instructions, for home-based administration. The first dose of the study medication will be administered before discharge from the ED.
62243061|NCT05920356|EXPERIMENTAL|Sotorasib combined with carboplatin and pemetrexed|Sotorasib administered in combination with carboplatin and pemetrexed.
62801973|NCT04272346|EXPERIMENTAL|Processing + peer helping condition|Participants in the processing + peer helping condition will be asked to first write about their deepest thoughts and feelings about their cancer experience (3 writings), then share advice to a newly-diagnosed AYA cancer patient (final writing).
62243062|NCT05920356|ACTIVE_COMPARATOR|Pembrolizumab combined with carboplatin and pemetrexed|Pembrolizumab administered in combination with carboplatin and pemetrexed.
62419785|NCT06245369|ACTIVE_COMPARATOR|standard SWITCH app|Participants in this group will be given goals to reduce intake of nutrients in which US adults tend to consume too much. Personalized daily intake goals for nutrients will be based on age, weight, sex, and the US Dietary Guidelines.
62419786|NCT06540898|EXPERIMENTAL|Experimental Group|Participants in this arm engage in an 8-week program that integrates mindful eating and mindful movement practices into their regular physical education classes. Each class includes a 10-minute mindful eating practice focused on enhancing awareness of hunger and fullness cues, sensory experiences of food, and emotional responses to eating. Following this, the final 10 minutes of each class are dedicated to mindful movement exercises, which combine physical postures and movement with mindfulness techniques to promote food literacy, physical literacy and social emotional competencies.
62801974|NCT04272346|PLACEBO_COMPARATOR|Facts-only writing condition|Participants in the facts-only writing condition will be asked to write about their cancer experience. Unlike the previous conditions, they will not be instructed to write for the benefit of a newly-diagnosed AYA cancer patient.
62801975|NCT06217848|EXPERIMENTAL|Patients diagnosed with a hypothalamic tumor.|
62419787|NCT06540898|NO_INTERVENTION|Control Group|Standard Physical Education Participants in this arm continue with their regular physical education classes as usual, without the integration of any mindfulness practices. This control arm involves the standard activities and curriculum designed for physical education classes at the university, which may include a variety of physical exercises, sports, and theoretical instruction related to health and fitness.
62027797|NCT04304833|EXPERIMENTAL|mHealth Model Arm|Connected home vital sign equipment (mHealth) will be given to patients in this group. The patients will be instructed to take their daily readings, which will automatically be sent to the secure cloud-based software. If the readings are out-of-range, the Registered Nurse (RN) Call Center will be automatically alerted and the event will be triaged. Daily measures and medical follow-up from the measures will be counted and collected at baseline, 3-months, and 6-months.
62027798|NCT03176680|EXPERIMENTAL|Fluid therapy optimization|Fluid loading to optimize stroke volume after induction.
62027799|NCT03176680|NO_INTERVENTION|Fluid therapy normalization|No fluid loading after induction.
62801976|NCT05890768|EXPERIMENTAL|Lumateperone|Lumateperone 42 mg capsule 1 PO QD for 6 weeks
62590065|NCT06482684|ACTIVE_COMPARATOR|Arm B|Younger patients (≤ 65 years) will receive 3 cycles R-CHOP + Ibrutinib/ 3 cycles R-DHAP alternating, followed by autologous stem cell transplantation (ASCT). Elderly patients (≥ 65 years) will receive 6 cycles of Bendamustine and Rituximab + Ibrutinib or R-CHOP + Ibrutinib without ASCT. Independently of age, control patients receive 2 years of maintenance therapy with Ibrutinib and 3 years of Rituximab maintenance if foreseen by national guidelines, in addition to Ibrutinib maintenance.
62801977|NCT05890768|ACTIVE_COMPARATOR|Risperidone|Risperidone starts 1 mg capsule PO QD for 1 week; then titrated blindly per clinical response and tolerability up to: 2 mg capsule QD starting in week 2; up to 3 mg capsule QD starting in week 3; and up to 4 mg capsule QD starting in week 4. Total risperidone exposure of 6 weeks.
62801978|NCT05691894|EXPERIMENTAL|18F-FAPI|
62801979|NCT05691894|EXPERIMENTAL|68Ga-FAPI|
62801980|NCT03445884|EXPERIMENTAL|Acute myocardial infarctions group|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV. three times. 1-3 days after intervention, 7-10 days after intervention and 30-35 days after intervention.
62801981|NCT03445884|ACTIVE_COMPARATOR|Control group|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV. one time.
62801982|NCT03973359|NO_INTERVENTION|Epidemiology|HCMV-seropositive pregnant women receiving standard care
62590066|NCT00287196|ACTIVE_COMPARATOR|Post-operative RADIOTHERAPY|Immediate post-operative RADIOTHERAPY
62226877|NCT06382454|EXPERIMENTAL|Treatment Group|30 minutes of individualized trunk, lower extremity and upper extremity exercises; the other 30 minutes will be treated with the robotic system. In the robot-assisted treatment, a total of 12 movements will be used, including the movement patterns that patients have the most difficulty in daily life and two movement patterns used in the Proprioceptive Neuromuscular Facilitation approach. Individual-specific rehabilitation program; individual-specific trunk, lower extremity and upper extremity exercises to be applied in both groups will consist of the following exercises according to the needs of the patients, and the degree of difficulty will be planned according to the needs of the patients. All patients will be treated for 8 weeks, 3 days a week, 60 minutes a day.
62801983|NCT03973359|EXPERIMENTAL|Prevention|HCMV-seropositive pregnant women receiving hygienic information
62801984|NCT01914263|EXPERIMENTAL|cytokine induced killer cell|The eligible patients are infused a single dose of 8x10\^9 CIK cells.
62801985|NCT01914263|NO_INTERVENTION|Control|The eligible patients are followed up for 30 days without any treatment.
62801986|NCT00844012|EXPERIMENTAL|Experimental group|
62801987|NCT00844012|ACTIVE_COMPARATOR|Control|
62801988|NCT00999544|EXPERIMENTAL|Placebo aprepitant/0 mg oxycodone IN PO|Placebo aprepitant/Placebo oxycodone IN/PO
62801989|NCT00999544|EXPERIMENTAL|Placebo aprepitant/ oxycodone 15 IN 0 PO|Placebo aprepitant/ oxycodone 15 IN 0 PO
62801990|NCT00999544|EXPERIMENTAL|Placebo aprepitant/ oxycodone 30 IN 0 PO|Placebo aprepitant/ oxycodone 30 IN 0 PO
62801991|NCT00999544|EXPERIMENTAL|Placebo aprepitant/ oxycodone 0 IN 20 PO|Placebo aprepitant/ oxycodone 0 IN 20 PO
62801992|NCT00999544|EXPERIMENTAL|Placebo aprepitant/ oxycodone 0 IN 40 PO|Placebo aprepitant/ oxycodone 0 IN 40 PO
62801993|NCT00999544|EXPERIMENTAL|Aprepitant 40 mg/ oxycodone 0 IN 0 PO|Aprepitant 40 mg/ oxycodone 0 IN 0 PO
62801994|NCT00999544|EXPERIMENTAL|Aprepitant 40 mg/ oxycodone 0 IN 20 PO|Aprepitant 40 mg/ oxycodone 0 IN 20 PO
62801995|NCT00999544|EXPERIMENTAL|Aprepitant 40 mg/ oxycodone 0 IN 40 PO|Aprepitant 40 mg/ oxycodone 0 IN 40 PO
62801996|NCT00999544|EXPERIMENTAL|Aprepitant 40 mg/ oxycodone 15 IN 0 PO|Aprepitant 40 mg/ oxycodone 15 IN 0 PO
62801997|NCT00999544|EXPERIMENTAL|Aprepitant 40 mg/ oxycodone 30 IN 0 PO|Aprepitant 40 mg/ oxycodone 30 IN 0 PO
62801998|NCT00999544|EXPERIMENTAL|Aprepitant 200 mg/ oxycodone 0 IN 0 PO|Aprepitant 200 mg/ oxycodone 0 IN 0 PO
62801999|NCT00999544|EXPERIMENTAL|Aprepitant 200 mg/ oxycodone 0 IN 20 PO|Aprepitant 200 mg/ oxycodone 0 IN 20 PO
62802000|NCT00999544|EXPERIMENTAL|Aprepitant 200 mg/ oxycodone 0 IN 40 PO|Aprepitant 200 mg/ oxycodone 0 IN 40 PO
62802001|NCT00999544|EXPERIMENTAL|Aprepitant 200 mg/ oxycodone 15 IN 0 PO|Aprepitant 200 mg/ oxycodone 15 IN 0 PO
62802002|NCT00999544|EXPERIMENTAL|Aprepitant 200 mg/ oxycodone 30 IN 0 PO|Aprepitant 200 mg/ oxycodone 30 IN 0 PO
62802003|NCT06033066|ACTIVE_COMPARATOR|Messaging Only|16,000 participants will be randomized to Arm 1 where no monetary incentive is offered.
62802004|NCT06033066|EXPERIMENTAL|Small Incentive|16,000 participants will be randomized to Arm 2 where a small one-time monetary incentive is offered.
62802005|NCT06033066|EXPERIMENTAL|Prize Incentive|16,000 participants will be randomized to Arm 3 where an opportunity based incentive (or a drawing with a prize) with a single winner will be offered.
62802006|NCT02581306|OTHER|Exercise session|All subjects will exercise for 1 hour at a moderate intensity. There are no different arms in this study
62802007|NCT03592316|EXPERIMENTAL|Lower Extremity Amputation Pathway|Patients will follow the Lower Extremity Amputation Pathway, which will include pre-operative consultations and earlier progression with physical therapy post-operatively.
62802008|NCT01978496|PLACEBO_COMPARATOR|Placebo|
62802009|NCT01978496|EXPERIMENTAL|Eletriptan 20 mg|
62802010|NCT01978496|EXPERIMENTAL|Eletriptan 40 mg|
62802011|NCT01978496|EXPERIMENTAL|Eletriptan 80 mg|
62802012|NCT03488836|ACTIVE_COMPARATOR|race|race rotation protocol
62802013|NCT03488836|ACTIVE_COMPARATOR|reciproc|reciprocal endodontic treatment group
62226878|NCT06382454|ACTIVE_COMPARATOR|Control Group|For 30 minutes, exercises including trunk, lower extremity and upper extremity exercises specific to the individual will be practiced, while the movement patterns to be used in the robotic system will be practiced in the other 30 minutes with the physiotherapist. Individual-specific rehabilitation program; individual-specific trunk, lower extremity and upper extremity exercises to be applied in both groups will consist of the following exercises according to the needs of the patients, and the degree of difficulty will be planned according to the needs of the patients. All patients will be treated for 8 weeks, 3 days a week, 60 minutes a day.
62419788|NCT01938742|EXPERIMENTAL|Group 1|100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
62802014|NCT01550536|EXPERIMENTAL|Training|Sedentary women who exercised \<2 hours per week and who had never engaged in a regular exercise program were enrolled in an exercise training intervention, following baseline measurements. See intervention below.
62590067|NCT00287196|EXPERIMENTAL|Delayed Radiotherapy|OBSERVATION with delayed radiotherapy for relapse
62590068|NCT02233296|EXPERIMENTAL|Group A|Dosing Sequence: Administration of lasmiditan 200 mg in fed state in Dosing Period 1 followed by administration of lasmiditan 200 mg in fasted state in Dosing Period 2
62590069|NCT02233296|EXPERIMENTAL|Group B|Dosing Sequence: Administration of lasmiditan 200 mg in fasted state in Dosing Period 1 followed by administration in lasmiditan 200 mg fed state in Dosing Period 2.
62590070|NCT02111785|ACTIVE_COMPARATOR|Burr Hole Craniostomy randomized|Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
62590071|NCT02111785|EXPERIMENTAL|Dexamethasone randomized|Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
62802015|NCT01550536|NO_INTERVENTION|Active|Postmenopausal women who exercised \>5 hours per week and had been doing so for at least the past 10 years. These women were asked to maintain their normal activity habits for the duration of the study.
62027800|NCT06636097||Patients Rehabilitated with full-arch implant-supported prosthesis|All patients that are rehabilitated with full-arch implant-supported prosthesis
62226879|NCT02717403|EXPERIMENTAL|Facebook + Website Group|Participants complete a self response electronic questionnaire at baseline. Participant shown how to access the Educational Website and the Facebook page on the internet about rheumatoid arthritis. Patients assessed at three and six months after baseline via email self response electronic questionnaires.
62226880|NCT02717403|EXPERIMENTAL|Educational Website Group|Participants complete a self response electronic questionnaire at baseline. Participant shown how to access the Educational Website on the internet about rheumatoid arthritis. Content includes the following: (i) a learning center; (ii) relevant links to other evidence-based web pages; (iii) news released by major rheumatology and dermatology organizations/societies; and (iv) chronic disease management strategies. Participants assessed at three and six months after baseline via email self response electronic questionnaires.
62226881|NCT02717403|EXPERIMENTAL|Pilot Testing Group|Participants access the Educational Website and Facebook page about rheumatoid arthritis for a period of one week. After 1 week, research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
62590072|NCT02111785|OTHER|Burr hole craniostomy observational|Observational cohort of patients selecting burr hole craniostomy
62802016|NCT02794649||healthy|Individuals without a history of kidney or bowel disease
62802017|NCT02794649||primary hyperoxaluria|Patients diagnosed with type I PH by genetic testing
62802018|NCT02794649||enteric hyperoxaluria|Patients with Roux-en-Y-gastric-bypass.
62802019|NCT02794649||calcium oxalate stone formers|History of passing or having surgically removed a calcium oxalate kidney stone within 5 years of recruitment.
62802020|NCT06124365|EXPERIMENTAL|study group|
62027801|NCT01664845|ACTIVE_COMPARATOR|metformin, pegylated-IFN, ribavirin|metformin,pegylated-IFN and ribavirin
62027802|NCT01664845|PLACEBO_COMPARATOR|Pegylated-IFN and ribavirin|pegylated -IFN and ribavirin
62226882|NCT01847469|EXPERIMENTAL|Zonisamide|Participants in this arm will receive zonisamide for 12 weeks.
62419789|NCT01938742|EXPERIMENTAL|Group 2|100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
62419790|NCT01938742|EXPERIMENTAL|Group 3|100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
62419791|NCT01938742|EXPERIMENTAL|Group 4|100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21
62590073|NCT02111785|OTHER|Dexamethasone observational|Observational cohort of patients treated with dexamethasone protocol
62802021|NCT06124365|ACTIVE_COMPARATOR|Control group|
62802022|NCT01759420||IV Ondansetron|Adult emergency department patients receiving 4mg of IV ondansetron as part of their treatment plan.
62802023|NCT00563030||1|Patients undergoing CABG with CPB
62027803|NCT01311102|EXPERIMENTAL|2% Lidocaine liquid|1.33cc of 2% liquid lidocaine infused in endo cervix and endometrium
62027804|NCT01311102|PLACEBO_COMPARATOR|Normal Saline|1.33cc of normal saline infused in endo cervix and endometrium
62027805|NCT06568302|EXPERIMENTAL|SerpinPC|Participants will receive SerpinPC 1.2 milligrams/kilograms (mg/kg) subcutaneous injection every 2 weeks (Q2W) once they have completed treatment in a SerpinPC parent study.
62590074|NCT06667050|EXPERIMENTAL|chemotherapy plus sintilimab and bevacizumab biosimilar|"capecitabine: 100 mg/m2, Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; sintilimab: 200 mg, iv drip, d1, bevacizumab biosimilar (IBI305) 10mg~/Kg, iv drip, d1, q3w."
62590075|NCT06668805|EXPERIMENTAL|Vosoritide Dose 1 - Low Dose|"Drug: Vosoritide - Dose 1 Injection~• Experimental Drug Lyophilized powder for reconstitution"
62802024|NCT00563030||2|Patients undergoing off-pump CABG
62802025|NCT03929107|EXPERIMENTAL|Intervention group|In this group, patients will be treated with Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T, and the safety and efficacy will be evaluated.
62802026|NCT02098746||Pioglitazone/glimepiride|Pioglitazone/glimepiride 15 mg/1 mg, orally once daily before or after breakfast.
62802027|NCT02893709|EXPERIMENTAL|Omeprazole|A course of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
62802028|NCT01155336|EXPERIMENTAL|Lovaza®|Lovaza® is a prescription grade EPA+DHA fish oil supplement. Four capsules (each containing 1 gram of fish oil) were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
62590076|NCT06668805|EXPERIMENTAL|Vosoritide Dose 2 - Medium Dose|"Drug: Vosoritide - Dose 2 Injection~• Experimental Drug Lyophilized powder for reconstitution"
62590077|NCT06668805|EXPERIMENTAL|Vosoritide Dose 3- High Dose|"Drug: Vosoritide Dose 3 Injection~• Experimental Drug Lyophilized powder for reconstitution"
62419792|NCT01938742|EXPERIMENTAL|Group 5|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 21
62419793|NCT01938742|EXPERIMENTAL|Group 6|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21
62590078|NCT06668805|ACTIVE_COMPARATOR|Human Growth Hormone|Drug: Human Growth Hormone
62590079|NCT01197625|EXPERIMENTAL|DC-vaccine|
62590080|NCT06663956|NO_INTERVENTION|Control group|The conventional treatment paradigm is in the current paradigm of standard antitumor cancer pain treatment and follow-up with no warning and no patient feedback.
62590081|NCT06663956|EXPERIMENTAL|Experimental group|"We propose to develop a patient self-reporting applet that is easy to use and simple to operate. The program is embedded with questionnaires related to cancer pain and quality of life assessment, so that patients can fill out the questionnaires to report their symptoms and changes in their conditions to primary care doctors in a timely manner. At the same time, the background of the program will monitor the patient's indicators in real time. When the patient's pain reaches moderate-to-severe level, or when the patient experiences side effects of drugs, or when the patient's adherence to medication is poor, the primary care doctor can immediately receive relevant alerts through the app, so as to intervene in the patient's cancer pain treatment. When the patient has an alarm value, primary care doctors can provide feedback to doctors in higher-level hospitals and implement comprehensive and standardized treatment for cancer pain patients."
62590082|NCT05318092|EXPERIMENTAL|AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE|Single Arm Study - Use of AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for the treatment of acute pulmonary embolism
62590083|NCT00630721|OTHER|IFNbeta-1b|no drug was given under study. patients already taking IFNbeta-1b were enrolled for blood draw only.
62590084|NCT06337890||CO2 FEVAR|Use of automated CO2 angiographies combined with Fusion Imaging in patients with complex aortic aneurysms to obtain zero- or near zero- contrast FEVAR
62590085|NCT01287949|EXPERIMENTAL|REPEVAX followed by REVAXIS administration|
62590086|NCT03279939|EXPERIMENTAL|Subjects with Normal Eyes|OCT Angiography, Color Fundus Photography, and Fluorescein Angiography as per protocol in subjects without ophthalmic pathology.
62027806|NCT04686448|ACTIVE_COMPARATOR|propofol-ketamine|patients will receive IV ketofol (0.5 mg/kg ketamine and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
62027807|NCT04686448|ACTIVE_COMPARATOR|propofol-fentanyl|patients will receive IV fenofol (1 µg/kg fentanyl and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
62419794|NCT01938742|EXPERIMENTAL|Group 7|100 subjects receive 45mcg sanofi A/H7N9 antigen on Day 0 and 21
62419795|NCT04586569|NO_INTERVENTION|Standard Education|This group will receive the standard of care pre-operative education that all children get prior to ORL surgery at BCH Waltham.
62419796|NCT04586569|EXPERIMENTAL|Pediatric Interactive Relational Agent (PIRA)|This group will receive the standard of care pre-operative education that all children get prior to ORL surgery at BCH Waltham and will be given access to an interactive, online educational tool for use prior to surgery. This Pediatric Interactive Relational Agent (PIRA) will be able to be accessed as many times as the family would like prior to surgery.
62590087|NCT03279939|EXPERIMENTAL|Subjects with Pathology|OCT Angiography, Color Fundus Photography, Fluorescein Angiography, and when clinically indicated, Indocyaine Green Angiography as per protocol in subjects with retinal vascular pathology.
62590088|NCT02855229||Phase 1 Participants [No Study Drug]|Phase 1 participants are not being assigned to any study drug.
62590089|NCT02855229||Phase 2 Participants [Placebo]|Phase 2 participants that are randomly assigned to the placebo.
62590090|NCT02855229||Phase 2 Participants [Methylphenidate]|Phase 2 participants that are randomly assigned to take methylphenidate.
62590091|NCT02855229||Phase 2 Participants [Modafinil]|Phase 2 participants that are randomly assigned to take modafinil.
62590092|NCT03224416|EXPERIMENTAL|Alcohol|In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
62027808|NCT03116594|EXPERIMENTAL|Low potency of NBP608|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
62027809|NCT03116594|EXPERIMENTAL|High potency of NBP608|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
62027810|NCT03116594|ACTIVE_COMPARATOR|Zostavax|Single dose 0.65mL Zostavax by subcutaneous injection into the outer aspect of the upper arm
62027811|NCT03652311|EXPERIMENTAL|TNM Device Group|In this arm participants will receive 5 sessions of twice daily treatments of 15 minutes of caloric vestibular stimulation (CVS) using the ThermoNeuroModulation TNM Device. In addition, participants will continue with the standard therapy that they are receiving.
62027812|NCT03652311|SHAM_COMPARATOR|Sham CVS Group|In this arm participants will receive 5 sessions of twice daily sessions of 15 minutes of sham stimulation with the ThermoNeuroModulation TNM Device. The ThermoNeuroModulation TNM device will be fitted and turned on in a random paradigm that has no demonstrated efficacy. Participants will continue with the standard therapy that they are receiving.
62027813|NCT03273439|EXPERIMENTAL|repetitive TMS|Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
62027814|NCT03273439|SHAM_COMPARATOR|Sham rTMS|all procedures were identical except they were the unmagnetized steel cylinders, instead of cylindrical magnets, that were rotated. Participants were, therefore, unable to distinguish between active and sham rTMS.
62027815|NCT01737112|EXPERIMENTAL|99mTc-3PRGD2 SPECT/CT scanning|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and evaluation of lung cancer patients.
62027816|NCT02504658|EXPERIMENTAL|Text Message Group|Subjects will set 2 lifestyle goals (exercise and nutrition) and receive health tips and goal status check in messages over 1 month.
62226883|NCT01847469|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive placebo medication for 12 weeks.
62226884|NCT06352164|EXPERIMENTAL|Acupuncture group|Subjects receiving acupuncture and moxibustion treatment.
62590093|NCT03224416|PLACEBO_COMPARATOR|Placebo|"In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims."
62590094|NCT03224416|SHAM_COMPARATOR|True Control|In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
62590095|NCT01598090|EXPERIMENTAL|Part A: Peginterferon Lambda-1a + RBV + TVR|
62590096|NCT01598090|EXPERIMENTAL|Part B (Arm 1): Peginterferon Lambda-1a + RBV + TVR|
62027817|NCT02504658|ACTIVE_COMPARATOR|Control Group|"The control subjects will set 2 lifestyle goals and receive a educational booklet to review.They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over. The approximate procedure time will be 20-25 minutes."
62027818|NCT05316038||Belatacept cohort|Kidney transplanted patients for whom a conversion from Tacrolimus to belatacept has been decided will be included in this cohort.
62027819|NCT04986553||50 subjects, male and female, at least 18 years of age|50 subjects who are candidates for surgery using the Arthrex Clavicle Plate for treatment of clavicle fractures.
62027820|NCT02794402|ACTIVE_COMPARATOR|Bydureon|s.c. once Weekly
62590097|NCT01598090|EXPERIMENTAL|Part B (Arm 2): Peginterferon Lambda-2a + RBV + TVR|
62590098|NCT06544096|ACTIVE_COMPARATOR|the control group|Routine health education
62590099|NCT06544096|EXPERIMENTAL|"UsingWeChat platform+health care group"|"UseWeChat platform+health care"
62027821|NCT02794402|PLACEBO_COMPARATOR|Placebo|s.c. once Weekly
62027822|NCT04941755|EXPERIMENTAL|Sequence AB|
62027823|NCT04941755|EXPERIMENTAL|Sequence BA|
62027824|NCT02630667|EXPERIMENTAL|SLOW Carbohydrate|Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response.
62590100|NCT04915768|EXPERIMENTAL|Group 1:Treatment|CH505 TF chTrimer 300 mcg admixed with (5 mcg) 3M-052-AF + (500 mcg) Aluminum Hydroxide suspension, administered at months 0, 2, 4, 8 and 12.
62027825|NCT02630667|EXPERIMENTAL|MEDIUM Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response.
62027826|NCT02630667|EXPERIMENTAL|FAST Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response.
62027827|NCT02630667|PLACEBO_COMPARATOR|Non-Caloric Placebo|Non-caloric placebo consisting of artificial sweeteners
62027828|NCT04139317|EXPERIMENTAL|Capmatinib 400mg BID + pembrolizumab 200mg Q3W|Capmatinib (INC280) 400 mg orally twice daily (BID) in combination with pembrolizumab 200 mg intravenously every 3 weeks (Q3W)
62027829|NCT04139317|ACTIVE_COMPARATOR|Pembrolizumab 200mg Q3W|Pembrolizumab 200 mg intravenously every 3 weeks (Q3W)
62590101|NCT04915768|EXPERIMENTAL|Group 2: Treatment|CH505 TF chTrimer 300 mcg admixed with (3 mcg) 3M-052-AF administered at months 0, 2, 4, 8 and 12.
62419797|NCT05037292|EXPERIMENTAL|PAUSE|"Surgical specialty clinics that completed an onboarding training for team members to use the standardized frailty screening incorporated in Veterans' medical records. Veterans identified as frail upon screening will be referred to a multidisciplinary PAUSE Board comprised of members from surgery, anesthesia, geriatrics, palliative care, case management, rehabilitation, nutrition."
62419798|NCT05037292|NO_INTERVENTION|Usual Care|Surgical specialty clinics that have not yet implemented the PAUSE Intervention. Veterans at these clinics will receive usual perioperative assessment and management by the clinical team.
62802029|NCT01155336|PLACEBO_COMPARATOR|Corn Oil|The placebo contained 1 gram of corn oil in each capsule. Four capsules were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
62802030|NCT00748345|EXPERIMENTAL|1|Caspofungin (drug)
62802031|NCT05770817||6-20-year-old youth|6-20-year-old youth
62802032|NCT03818750|EXPERIMENTAL|Experimental arm|"Patients (60) will be selected from the Alcohol Use Disorders Identification Test (AUDIT-C) :~* light drinkers (score between 1 to 3)~* heavy drinkers (score between 4 to 7) Two clinical visits will be realized in less than 4 weeks"
62802033|NCT03714724|ACTIVE_COMPARATOR|Group 4|"Patients who received 0-4 cmH2O PEEP in mechanical ventilation were referred to as Group 4.~Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded."
62802034|NCT03714724|ACTIVE_COMPARATOR|Group 8|Patients who received 5-8 cmH2O PEEP in mechanical ventilation were referred to as Group 8. Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded.
62802035|NCT03714724|ACTIVE_COMPARATOR|Group 12|Patients who received 9-12 cmH2O PEEP in mechanical ventilation were referred to as Group 12. Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded.
62590102|NCT04915768|EXPERIMENTAL|Group 3: Treatment|CH505 cTrimer, 300 mcg admixed with (3 mcg) 3M-052-AF + (500 mcg) Aluminum Hydroxide Ssuspension (Alum) administered at months 0, 2, 4, 8 and 12.
62590103|NCT04915768|EXPERIMENTAL|Group 4: Treatment|CH505 chTrimer 300 mcg admixed with (5 mcg) 3M-052-AF administered at months 0, 2, 4, 8 and 12.
62802036|NCT00869752|EXPERIMENTAL|Arm 1|MK-0646, a monoclonial antibody in combination with etoposide and cisplatin.
62802037|NCT05927766|ACTIVE_COMPARATOR|patients with chronic kidney disease|
62590104|NCT02339324|EXPERIMENTAL|This study has one arm that consists of 3 phases or steps.|"Induction phase (first 6 weeks): Pembrolizumab and High Dose IFNα-2b (HDI) Pembrolizumab I.V. every 3-4 weeks for 2 doses concurrently with HDI I.V. x 5 consecutive days every week for 4 weeks, followed by S.C. every other day 3x each week for 2 weeks.~Surgery phase (week 6-8).~Maintenance phase (following recovery from surgery): Pembrolizumab I.V. infusion every 3 weeks given concurrently with HDI S.C. QOD (e.g. M,W,F) TIW every week for 46 additional weeks"
62802038|NCT05927766|ACTIVE_COMPARATOR|patients without chronic kidneys disease|
62802039|NCT02041481|EXPERIMENTAL|Arm I (continuous MEK inhibitor MEK162, FOLFOX)|Patients receive MEK inhibitor MEK162 PO BID on days 1-14, and leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62027830|NCT06457542|OTHER|Active Release Technique|Active release technique is a technique used for to treat impingment syndrome.
62590105|NCT04411277||T2DM Elderly on Insulin CGM|70 patients with type 2 diabetes \> 65 years of age taking insulin as treatment. The sample size was calculated to estimate the minimal number of patients necessary to describe the mean TIR (minutes/day).
62226885|NCT05898256|EXPERIMENTAL|Bispecific Antibody + GP Group|"Cadonilimab will be administered once every 3 weeks (Q3W), for up to 2 years；~Gemcitabine on Day 1, Day 8 of each 3 weeks cycle, for 4 to 6 cycles；~Cisplatin on Day 1 of each 3 weeks cycle, for 4 to 6 cycles."
62226886|NCT03720054|EXPERIMENTAL|MapTrek|Veterans in the intervention group receive a Fitbit and MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required prior to enrollment). Each week, veterans are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. MapTrek also supports Street View on Google Maps, so veterans can explore what they would see if they were in that location. Throughout each race, patients will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
62802040|NCT02041481|EXPERIMENTAL|Arm II (intermittent MEK inhibitor MEK162, FOLFOX)|Patients receive MEK inhibitor MEK162 PO BID on days 1-5, and leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 6 and 7. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62226887|NCT03720054|ACTIVE_COMPARATOR|Fitbit Only|Veterans randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to MapTrek or simply by giving the veterans a Fitbit.
62226888|NCT01597141|EXPERIMENTAL|Family-aided Assertive Community Treatment|The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
62226889|NCT01597141|ACTIVE_COMPARATOR|Enhanced standard treatment|In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention.
62027831|NCT06457542|OTHER|Soft Tissue Mobilization|Soft Tissue Moboilization is techniques used for to treat shoulder pain. Soft tissue mobilization (STM) targeting the subscapularis muscle.
62590106|NCT06126029|EXPERIMENTAL|Metformin group|This group will receive metformin 500mg extended release oral tablet daily along with standard of care for 8 weeks.
62226890|NCT00666523|EXPERIMENTAL|1|
62226891|NCT00666523|PLACEBO_COMPARATOR|2|
62226892|NCT05039528|EXPERIMENTAL|Intervention|Participants will receive the personalized OSA messages.
62226893|NCT05039528|PLACEBO_COMPARATOR|Control|Placebo participants will receive no treatment during the experiment.
62226894|NCT02301715|ACTIVE_COMPARATOR|Oxytocin|24 IU Oxytocin, 3 puffs per nostril, each with 4 IU OXT, intranasal application 45 min prior to the experiment
62226895|NCT02301715|PLACEBO_COMPARATOR|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril, 45 min prior to the experiment
62802041|NCT05378321|OTHER|ACS risk gropu|Group of patients with an acute-cardiovascular syndrome.
62802042|NCT04036981||Brachialis|Targeted muscle for BoNT A injection
62419799|NCT06701058||Cancer patients|Oral and oropharyngeal cancer patients
62419800|NCT06701058||Control patients|Control participants with no history of any type of cancer cancer in the past five years
62590107|NCT06126029|PLACEBO_COMPARATOR|Placebo group|This group will receive placebo oral tablet daily along with standard of care for 8 weeks.
62590108|NCT04699513|EXPERIMENTAL|P-SIMV+PS group|The reason behind using P-SIMV+PS as a conventional mode was that it is a pressure controlled mode like APRV.
62590109|NCT04699513|EXPERIMENTAL|APRV group|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that alternates between two levels of continuous positive airway pressure (CPAP) support and allows spontaneous respiratory effort at either CPAP level. It is considered as an alternative, life-saving modality in patients with acute respiratory distress syndrome (ARDS) that struggle for oxygenation.
62590110|NCT00937586||Newly diagnosed patients|Patients with newly diagnosed prostate cancer.
62802043|NCT04036981||Biceps|Targeted muscle for BoNT A injection
62802044|NCT04036981||Brachialis plus Brachioradialis|Targeted muscles for BoNT A injection
62027832|NCT01529957|ACTIVE_COMPARATOR|Nemonoxacin Malate Sodium Chloride 25 mg|Nemonoxacin Malate Sodium Chloride 25 mg
62027833|NCT01529957|ACTIVE_COMPARATOR|Nemonoxacin Malate Sodium Chloride 50 mg|Nemonoxacin Malate Sodium Chloride 50 mg
62027834|NCT01529957|ACTIVE_COMPARATOR|Nemonoxacin Malate Sodium Chloride 125 mg|Nemonoxacin Malate Sodium Chloride 125 mg
62027835|NCT01529957|PLACEBO_COMPARATOR|placebol|placebol
62590111|NCT02676817||Group 1|Group 1 (n=70) = UC in remission regardless of the medication that allowed remission nor taken by the patient (Mayo' sub-score 0 or 1) and who require colonoscopy regardless of the study according to current guidelines (screening for dysplasia, monitoring during treatment etc).
62590112|NCT02676817||Group 2|Group 2 (n=30) = Active UC (Mayo' sub-score 2 or 3) requiring adalimumab and for whom a rectosigmoidoscopy will be performed 8 to 12 weeks after starting therapy, according to current French guidelines and routine practice. Eight weeks after the treatment is the minimum time necessary to evaluate the effects of this treatment according the current practice in France. Then, investigators chose in our study to assess the effects in the group 2 at 8 weeks. All the 30 patients in group 2 will receive adalimumab and they will be anti-TNF naïve patients.
62802045|NCT06376578|EXPERIMENTAL|Partly supervised, prescribed exercise group|The partly-supervised, prescribed exercise group will be required to undertake two supervised exercise sessions and one unsupervised exercise session at home or in your local area each week. Supervised sessions will consist of exercising on both a treadmill and a stationary exercise bike. The intervention will be progressive, increasing in intensity and duration.
62226896|NCT03854045|EXPERIMENTAL|Home-based|Clinicians at the FQHC will identify and offer the opportunity to receive telepsychiatry in the home with 2 clinicians present. The patients are not required to agree to the evaluation to receive the services. The services are entered into their EHR but are not eligible for Medicaid reimbursement.
62590113|NCT04858490|EXPERIMENTAL|Symptom-triggered diazepam treatment|Participants will be treated for a period of 3 days using a symptom-triggered withdrawal management protocol delivered over telemedicine. Participants who score 10 or above on the modified CIWA-Ar will be advised to take a specific dose of diazepam (either 10 or 20mg, at the clinician's discretion). Participants will be reassessed regularly over the 3-day period.
62226897|NCT03854045|ACTIVE_COMPARATOR|Clinic-based|Clinicians at the FQHC will identify and offer the opportunity to receive telepsychiatry in the clinic with 1 clinican present. The patients are not required to agree to the evaluation to receive the services. The services are entered into their EHR and eligible for Medicaid reimbursement.
62419801|NCT06700447|ACTIVE_COMPARATOR|Control|Participants enrolled in the control group will receive unrelated information on nutrition topics of the same length as the inoculation messages. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study.
62590114|NCT01133002||VTE management registry|Patients receiving enoxaparin, with or without oral anticoagulation, within Day 0-10 after diagnosis of VTE
62590115|NCT04709692|OTHER|Arm 1 A (cohort 1)|Combination of 600 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.vivax
62590116|NCT04709692|OTHER|Arm 1 B (cohort 1)|Combination of 600 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.falciparum
62590117|NCT04709692|OTHER|Arm 2 A (cohort 2)|600 mg SJ733 administered orally once every day for three consecutive days for patients with P.vivax
62590118|NCT04709692|OTHER|Arm 2 B (cohort 2)|600 mg SJ733 administered orally once every day for three consecutive days for patients with P.falciparum
62590119|NCT04709692|OTHER|Arm 3 A (cohort 3)|Combination of 300 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.vivax
62590120|NCT04709692|OTHER|Arm 3 B (cohort 3)|Combination of 300 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.falciparum
62590121|NCT06668558|EXPERIMENTAL|Cohort 1|Patients diagnosed with a favorable ELN subtype AML, not intended for alloHCT in CR1, but who present an MRD failure by after frontline intensive chemotherapy, as defined in the 2021 update on MRD guidelines elaborated by the European LeukemiaNet MRD Working Party (Heuser et al. 2021)
62590122|NCT06668558|EXPERIMENTAL|Cohort 2|Patients diagnosed with a non-favorable ELN AML subtype, intended to undergo alloHCT, in first complete morphological remission but harboring detectable MRD at time of alloHCT (\>0.1%)
62590123|NCT05408871|EXPERIMENTAL|Head and neck cancer|Participants with head and neck squamous cell carcinoma who plan to undergo tumor resection and lymph node resection.
62590124|NCT05408871|EXPERIMENTAL|Brain Metastases|Participants with metastases to the brain from melanoma, lung cancer, breast cancer.
62590125|NCT00593359||A|Lactated Ringer's replacement for blood loss and placebo eye drops
62590126|NCT00593359||B|Lactated Ringer's replacement for blood loss and brimonidine eye drops
62802046|NCT06376578|EXPERIMENTAL|Technology enabled, remotely delivered exercise group|The technology enabled, remotely delivered exercise group will receive information and advice about exercise that could be undertaken at home or in their local area. In addition, participants will received a Polar A370 fitness tracker wristwatch with heart rate monitoring chest strap. Participants will take part in exercise each week (most likely walking) which will increase in duration over 8-weeks from 105 minutes each week to 150 minutes each week. Each week a member of the research team will have a telephone call with the participant to discuss the exercise prescription.
62226898|NCT01605292|ACTIVE_COMPARATOR|Palpation|Manual palpation of radial pulse, as sole guide to needle cannulation.
62226899|NCT01605292|EXPERIMENTAL|Ultrasound|Real-time ultrasound guidance to facilitate needle cannulation of artery.
62590127|NCT00593359||C|Albumin replacement for blood loss and placebo eye drops;
62590128|NCT00593359||D|Albumin replacement for blood loss and brimonidine eye drops
62802047|NCT05191394|OTHER|Evolution of anti-SARS-CoV-2 titer over time in vaccinated adult patients treated with TPE.|"Assessment of the possible variation of anti-SARS-CoV-2 antibody titer in adult patients regularly treated with therapeutic plasma exchange.~For each patient included in this study, 3 blood samples of 5 ml(serum) will be collected at well-defined time points: at the beginning of an TPE session, at the end of the same session, and at the beginning of the consecutive TPE session."
62226900|NCT02939170|EXPERIMENTAL|DT1 MF MM|Delefilcon A multifocal contact lenses with molded marks on back surface worn bilaterally (in both eyes) for 9 hours
62419802|NCT06700447|OTHER|Enhanced inoculation message|Participants enrolled in the enhanced inoculation message arm will receive a similar inoculation message that is enhanced with insights from behavioural economics. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime. Following this message delivery, all participants will view/watch claims about the HIV vaccine some of which will be false or misleading. The vaccine misinformation claims will be presented using language (and in some cases, visual imagery) consistent with how misinformation exposure will occur in the information ecology (i.e., through social networks and in traditional and social media in real-world settings).
62419803|NCT06700447|OTHER|Standard inoculation message|Participants enrolled in the standard inoculation message arm will receive a message that warns them about impending HIV vaccine misinformation and explains why that claim is false or misleading. Following this message delivery, all participants will view/watch claims about the HIV vaccine some of which will be false or misleading. The vaccine misinformation claims will be presented using language (and in some cases, visual imagery) consistent with how misinformation exposure will occur in the information ecology (i.e., through social networks and in traditional and social media in real-world settings).
62419804|NCT03739684|EXPERIMENTAL|18F-DCFPyL Injection|9 mCi (333 MBq) IV injection of 18F-DCFPyL
62419805|NCT06533904|PLACEBO_COMPARATOR|Standard multi-modal pain regimen alone|
62590129|NCT02343445|EXPERIMENTAL|P-1037 in Hypertonic Saline (HS)|P-1037 Solution for Inhalation, 85 μg twice daily (BID) (28.3 μg/mL) in hypertonic saline (4.2% saline) BID
62590130|NCT02343445|EXPERIMENTAL|P-1037 in Saline|P-1037 Solution for Inhalation, 85 μg BID (28.3 μg/mL) in 0.17% saline BID
62590131|NCT02343445|PLACEBO_COMPARATOR|Saline|Placebo (0.17% saline) BID
62590132|NCT02343445|SHAM_COMPARATOR|Hypertonic Saline|Hypertonic saline (4.2% saline) BID
62802048|NCT01576432|EXPERIMENTAL|Breastfeeding + skin-to-skin contact|In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; breastfeeding (BF) was started at least 5 minutes before heel lance and maintained during sampling
62419806|NCT06533904|EXPERIMENTAL|Standard multi-modal pain regimen with percutaneous cryoablation|
62419807|NCT03568929||Idelalisib|Participants who have been or are currently being treated with 100 or 150 mg of idelalisib
62419808|NCT05077683|ACTIVE_COMPARATOR|DAPT|aspirin (≤100mg per day) and P2Y12 inhibitors (i.e. clopidogrel 75mg per day or ticagrelor 90mg twice a day), as per current guidelines
62419809|NCT05077683|EXPERIMENTAL|DAPT + Direct Oral AntiCoagulants (DOAC)|aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily) and rivaroxaban 2.5mg twice daily.
62590133|NCT05733702||Single arm study:|Patients with IBD requiring a treatment change at the time of inclusion
62590134|NCT04614610|ACTIVE_COMPARATOR|Lidocaine|Lidocaine 1.5mg/kg (Max: 200mg) in dextrose 5% 100mL over 10 minutes along with either morphine 0.1-0.15mg/kg IV OR hydromorphone 0.01-0.02mg/kg IV.
62590135|NCT04614610|PLACEBO_COMPARATOR|Placebo|Dextrose 5% 100mL (placebo) over 10 minutes along with either morphine 0.1-0.15mg/kg IV OR hydromorphone 0.01-0.02mg/kg IV.
62226901|NCT02939170|ACTIVE_COMPARATOR|DT1 MF|Delefilcon A multifocal contact lenses worn bilaterally for 9 hours
62226902|NCT04513184|ACTIVE_COMPARATOR|Standard therapy (ST) only|Control. Standard care and treatment only
62226903|NCT04513184|EXPERIMENTAL|DXM|Nasal dexamethasone plus Standard care and treatment
62419810|NCT05600933||1 - premalignant, primary or metastatic solid tumor|Participants \>= 18 with a suspected or confirmed solid tumor malignancy that requires surgery or biopsy.
62419811|NCT05600933||2 - known or suspected hematologic malignancy|Participants \>= 18 who have a known or suspected hematologic malignancy that requires surgery or biopsy.
62590136|NCT00582504|EXPERIMENTAL|Vaccination|VEE TC-83
62226904|NCT04062968|EXPERIMENTAL|Video education|"Women randomized to the intervention group (video education) will view the prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos .7 They will then complete the study related surveys at their initial obstetric visit."
62802049|NCT01576432|EXPERIMENTAL|Sucrose + skin-to-skin contact|In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance.
62802050|NCT01576432|EXPERIMENTAL|Skin-to-skin contact|In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given.
62802051|NCT01576432|ACTIVE_COMPARATOR|Sucrose|In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother
62802052|NCT00100789|EXPERIMENTAL|gemcitabine paclitaxel combination|
62802053|NCT01774799|EXPERIMENTAL|Advance care planning intervention|At baseline, health care proxies in the intervention arm will be shown a 12-minute Advance Care planning video that describes 3 levels of treatment in advanced dementia: comfort basic and intensive. After viewing the video, the proxies will be asked their preferred level of care for the resident and this choice will be communicated to the residents primary care team in a written form.
62802054|NCT01774799|ACTIVE_COMPARATOR|Usual care|Residents in control nursing homes with receive the usual advance care planning that occurs in their nursing home.
62802055|NCT01708512|EXPERIMENTAL|Ultherapy™ study treatment|Each subject will receive a customized, high-density, vectored Ulthera System Treatment.
62226905|NCT04062968|NO_INTERVENTION|Usual care|Women randomized to the control group will receive routine prenatal care with no additional study intervention other than completion of the study related surveys at baseline (initial prenatal testing).
62419812|NCT03782688||Single-arm cohort|Patients with significant coronary stenosis by invasive fractional flow reserve (FFR≤0.80)
62802056|NCT01535807|ACTIVE_COMPARATOR|CorMatrix Group|"The treatment Cormatrix group will receive the CorMatrix ECM during surgery for the closure of the pericardium according to the specific recommended surgical technique."
62802057|NCT01535807|NO_INTERVENTION|Control|"The control No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care."
62226906|NCT04503343|OTHER|intervention group|subjects are randomly divided into the intervention group. and they will be given a one-time non-drug intervention(mindfulness training, relaxation training or electrical cerebellar stimulation).
62802058|NCT03890588|EXPERIMENTAL|CKD enhanced clinical decision support (CKD-CDS Intervention)|Priority Wizard CDS tool is enhanced to incorporate chronic kidney disease(CKD) management. This presents patients and their primary care providers (PCPs) multiple opportunities to consider an evolving array of timely, evidence-based treatment options to improve CKD care. The CDS also provides CV risk factor management like the basic Priority Wizard present in the usual care arm.
62802059|NCT03890588|NO_INTERVENTION|Usual Care|A basic Priority Wizard CDS tool for cardiovascular (CV) risk factor management (previously know as the CV Wizard) includes algorithmically derived identification of high CV risk patients and prioritized treatment suggestions for lipids, Blood Pressure (BP), glycemic control, weight, tobacco, and aspirin use based on distance from goal, current medications, labs, allergies, and safety considerations. Has no decision support specific to CKD care.
62802060|NCT05415358||Single Arm|Biomarkers and ctDNA data generated from patients with metastatic non-small cell lung carcinoma who have completed first line pembrolizumab monotherapy or pembrolizumab-platinum doublet combination therapy, and have, at immunotherapy discontinuation, completed at least 20 of an anticipated 24 months of pembrolizumab.
62802061|NCT06157866|EXPERIMENTAL|Cognitive Training|Participants will meet with a pain specialist who will conduct a specific form of cognitive training targeting fibromyalgia.
62802062|NCT06157866|ACTIVE_COMPARATOR|Education Training|Participants will meet with a pain specialist to receive education training related to fibromyalgia.
62802063|NCT04410185|EXPERIMENTAL|MEDITATION|Meditation sessions will take place over 12 weekly sessions of 1.5 hours. A retreat (3 hours) will be realized after the 9th session
62802064|NCT02544568|EXPERIMENTAL|High-Carb Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
62802065|NCT02544568|EXPERIMENTAL|High-Protein Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
62802066|NCT02544568|EXPERIMENTAL|High-Fat Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
62802067|NCT02544568|EXPERIMENTAL|High-Fibre Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr).
62802068|NCT06376630|ACTIVE_COMPARATOR|Substudy evaluating cardioprotective effects of early iv administration of esmolol|100 pts with STEMI will be randomized 1:1 in arms receiving esmolol or no IV beta-blockers. In the esmolol arm the infusion will begin immediately on admission
62802069|NCT06376630|NO_INTERVENTION|Substudy investigating coronary physiology|50 stable patients with MI will undergo invasive measurements of coronary physiology. Those will also undergo cardiac MRI. Other 150 pts will not undergo invasive measurements of coronary physiology during initial hospitalization. Pts in both groups will be hospitalized again in 30-40 days after MI. They will undergo stress SPECT or stress echocardiography. All patients will undergo a follow-up coronary angiography with invasive measurement of coronary physiology
62802070|NCT00488488||A|
62419813|NCT05337514|EXPERIMENTAL|EngAGE|Older adult subjects will receive an Alexa Echo Show that runs an exercise app called EngAGE.
62419814|NCT05337514|ACTIVE_COMPARATOR|Physical Exercise Handouts|Older adults subjects will receive a paper booklet containing exercise instructions.
62802071|NCT05147376|EXPERIMENTAL|Curcumin mouthwash|The curcumin mouthwash contains the final concentration of 1 μM curcumin, water, xylitol, and food coloring agent.
62802072|NCT05147376|SHAM_COMPARATOR|Placebo mouthwash|The placebo mouthwash contains water, xylitol, and food coloring agent.
62419815|NCT05070169||Early Surgical Fixation|Prospective cohort of patients with intertrochanteric fractures with DOAC (direct oral anticoagulation) therapy undergoing early surgical fixation (within 24 hours).
62802073|NCT04138992|EXPERIMENTAL|study group A|"bevacizumab combined with neoadjuvant chemotherapy and concurrent chemoradiotherapy：~1. bevacizumab combined with neoadjuvant chemotherapy for 2 cycles: Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week; Docetaxel 75mg/m2, intravenous injection，once three week;~2. bevacizumab combined with concurrent chemoradiotherapy: Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor"
62802074|NCT04138992|EXPERIMENTAL|study group B|study arm: bevacizumab combined with concurrent chemoradiotherapy： Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week; pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor
62802075|NCT04138992|ACTIVE_COMPARATOR|control|standard concurrent chemoradiotherapy: DDP 40mg/m2, intravenous injection，once a week; pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor
62802076|NCT03833726|EXPERIMENTAL|LED group|Participants who will submitted to active procedure with LED. Both groups will be submitted to kinesiotherapy.
62027836|NCT01529957|ACTIVE_COMPARATOR|Nemonoxacin Malate Sodium Chloride 250 mg|Nemonoxacin Malate Sodium Chloride 250 mg
62027837|NCT01529957|ACTIVE_COMPARATOR|Nemonoxacin Malate Sodium Chloride 500 mg|Nemonoxacin Malate Sodium Chloride 500 mg
62027838|NCT01529957|ACTIVE_COMPARATOR|Nemonoxacin Malate Sodium Chloride 650 mg|Nemonoxacin Malate Sodium Chloride 650 mg
62419816|NCT05070169||Delayed Surgical Fixation|Retrospective control group of patients with intertrochanteric fractures with DOAC medication who underwent delayed surgical fixation (≥48 hours) from January 2014 to December 2018.
62419817|NCT06213311|EXPERIMENTAL|Axicabtagene Ciloleucel (axi-cel) and Glofitamab|Participants will receive glofitamab based on a step-up dosing regimen.
62419818|NCT06299631||Crohn's disease patients undergoing ICR|Crohn's disease patients undergoing ICR treated with TNF inhibitors
62027839|NCT01529957|ACTIVE_COMPARATOR|Nemonoxacin Malate Sodium Chloride 750 mg|Nemonoxacin Malate Sodium Chloride 750 mg
62027840|NCT01529957|ACTIVE_COMPARATOR|Nemonoxacin Malate Sodium Chloride 1000 mg|Nemonoxacin Malate Sodium Chloride 1000 mg
62419819|NCT06678191||Asthmatic patients switched to Trimbow (BDP/FF/G 172/5/9 μg)|Asthmatic patients who had been switched to BDP/FF/G 172/5/9 μg before study enrollment, due to uncontrolled asthma.
62419820|NCT05308576|EXPERIMENTAL|SCTV01E|one dose of SCTV01E on D0
62027841|NCT01529957|ACTIVE_COMPARATOR|Nemonoxacin Malate Sodium Chloride 1250 mg|Nemonoxacin Malate Sodium Chloride 1250 mg
62027842|NCT04972955||Pregnant women diagnosed with gestational diabetes|Pregnant individuals who have been diagnosed with gestational diabetes during the current pregnancy
62027843|NCT06328647|EXPERIMENTAL|POC Quantra QPlus System|Perfusion team or trained (certified for POC testing) research personnel will perform hemostasis testing using the Quantra QPlus POC System, results will be interpreted by the primary anesthesia team that will decide if transfusion of blood components is necessary in the operating room and up to 12 hours after surgery in the cardiac surgery intensive care unit (ICU).
62027844|NCT06328647|ACTIVE_COMPARATOR|Routine Care|The primary anesthesia provider will determine the need for blood and blood component transfusion with or without guidance from central laboratory testing for hemostatic abnormalities in the operating room and up to 12 hours after surgery in the cardiac surgery intensive care unit (ICU).
62027845|NCT05659290|EXPERIMENTAL|Arm A|Efficacy of Fruquintinib alternating Bevacizumab plus Capecitabine as maintenance therapy after first-line treatment
62027846|NCT05659290|ACTIVE_COMPARATOR|Arm B|Efficacy of Bevacizumab plus Capecitabine as maintenance therapy after first-line treatment
62027847|NCT06467045||Pediatric patients who received sedation for magnetic resonance imaging|All pediatric patients who received sedation for magnetic resonance imaging(MRI) in radiology unit will be added to this study. In the study, there is only one group. No comparisons are being made.
62027848|NCT04419493|EXPERIMENTAL|Part B: Alteplase, TPA-02 then Alteplase, TPA-05|
62027849|NCT04419493|ACTIVE_COMPARATOR|Part B: Alteplase, TPA-05 then Alteplase, TPA-02|
62027850|NCT04419493|EXPERIMENTAL|Part A: Alteplase, TPA-05 then Alteplase, TPA-02|Open-label
62027851|NCT04419493|ACTIVE_COMPARATOR|Part A: Alteplase, TPA-02 then Alteplase, TPA-05|
62419821|NCT05308576|PLACEBO_COMPARATOR|Placebo|one dose of Placebo on D0
62419822|NCT03974516|EXPERIMENTAL|Careseng 1370 Level A|Level A (1 sachet): 1 sachet before breakfast. Careseng 1370 granule 4,000 mg sachet consisted of 652 mg (16.3%, w/w) DS-1370 drug substance powder (dry extracts of Panax notoginseng stems and leaves)
62802077|NCT03833726|SHAM_COMPARATOR|Control group|Participants who will submitted to sham procedure with heated gel. Both groups will be submitted to kinesiotherapy.
62802078|NCT02405156|EXPERIMENTAL|letrozole + misoprostol|Women will receive three tablets of letrozole vaginal as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) for three days and will be followed by 200 mcg vaginal misoprostol or 100mcg vaginal misoprostol (according gestational age) soaked with saline every six hours up to maximum four doses.
62802079|NCT02405156|PLACEBO_COMPARATOR|placebo + misoprostol|Women will receive three tablets of placebo vaginal as a single dose, for three days and will be followed by 200 mcg vaginal misoprostol or 100 mcg vaginal misoprostol (according gestational age) soaked with saline every six hours up to maximum four doses.
62802080|NCT01678378|EXPERIMENTAL|SHARP Intervention|School health centers randomized to the SHARP Intervention will be trained to address adolescent relationship abuse with school health center clients.
62802081|NCT01678378|NO_INTERVENTION|Control|School health centers randomized to Control will provide standard of care.
62419823|NCT03974516|EXPERIMENTAL|Careseng 1370 Level B|Level B (2 sachets): 1 sachet before breakfast, 1 sachet before lunch. Careseng 1370 granule 4,000 mg sachet consisted of 652 mg (16.3%, w/w) DS-1370 drug substance powder (dry extracts of Panax notoginseng stems and leaves)
62802082|NCT02071966|ACTIVE_COMPARATOR|Ticagrelor|Ticagrelor: oral, 180 mg once for the first dose then 90 mg twice a day
62226907|NCT04503343|NO_INTERVENTION|control group|subjects are randomly divided into the control group and regularly followed up.
62226908|NCT02941250|EXPERIMENTAL|treatment|patients receiving ISSD emulator
62419824|NCT03974516|EXPERIMENTAL|Careseng 1370 Level C|Level C (3 sachets): 1 sachet before breakfast, 2 sachets before lunch. Careseng 1370 granule 4,000 mg sachet consisted of 652 mg (16.3%, w/w) DS-1370 drug substance powder (dry extracts of Panax notoginseng stems and leaves)
62802083|NCT02071966|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel: oral, 300 or 600 mg once for the first dose, 75 mg once a day
62802084|NCT03010527|PLACEBO_COMPARATOR|Placebo|Subjects with a PASI90 response at Week 12 and receiving Placebo in PS0010 entering PS0011 will receive Placebo.
62802085|NCT03010527|EXPERIMENTAL|Bimekizumab dosing regimen 1|"Subjects with a PASI90 response at Week 12 receiving dosing regimen 1 in PS0010 entering PS0011 will receive the same dosing regimen.~Subjects who do not achieve PASI90 response at Week 12 receiving dosing regimen 1 in PS0010 will be assigned to a higher dosing regimen."
62802086|NCT03010527|EXPERIMENTAL|Bimekizumab dosing regimen 2|"Subjects with a PASI90 response at Week 12 receiving dosing regimen 2 in PS0010 entering PS0011 will receive the same dosing regimen.~Subjects who do not achieve PASI90 response at Week 12 receiving dosing regimen 2 in PS0010 will be assigned to a higher dosing regimen."
62226909|NCT03200015|EXPERIMENTAL|Metformin arm|Metformin 850 mg tablets. Initial dose 425 mg twice a day for 1 week, followed by 850 mg twice a day for 1 week, titrated to a maximum dose 850 mg every 8 hours until disease response evaluation study date (Computed tomography or positron emission tomography)
62590137|NCT06482788|EXPERIMENTAL|Experimental arm|Patients will receive Immunotherapy (Adebrelimab, PD-L1 inhibitor) combined with XELOX chemotherapy (Capecitabine + Oxaliplatin) therapy in four 3-week treatment cycles with imaging assessment every 2 cycles. After treatment response evaluation, patients will receive resection within 4-8 weeks. Following surgery, patients will receive four further 3-week cycles of Adebrelimab + XELOX after 4-12 weeks of resection. Patients will then receive 10 additional 3-week treatment cycles with Adebrelimab alone.
62419825|NCT03974516|EXPERIMENTAL|Careseng 1370 Level D|"Level D (1 sachet)(modified cohort): 1 sachet before breakfast on 1st, 3rd and 5th days.~Careseng 1370 granule 4,000 mg sachet consisted of 652 mg (16.3%, w/w) DS-1370 drug substance powder (dry extracts of Panax notoginseng stems and leaves)"
62419826|NCT05166421|EXPERIMENTAL|AZD7442 (co-formulation)|Participants will receive single dose of AZD7442 (co-formulation of AZD8895 + AZD1061) on Day 1.
62419827|NCT05166421|ACTIVE_COMPARATOR|AZD8895 and AZD1061 (clonal cell line material)|Participants will receive two separate doses of the individual mAbs (AZD8895 and then AZD1061) on Day 1.
62419828|NCT05166421|ACTIVE_COMPARATOR|AZD8895 and AZD1061 (cell pool material)|Participants will receive two separate doses of the individual mAbs (AZD8895 and then AZD1061) on Day 1.
62419829|NCT06033703|EXPERIMENTAL|Primary retinal detachment, Phakic group|"Phakic patients with primary rhegmatogenous retinal detachment repair within 7 days of symptom onset, undergoing vitrectomy or vitrectomy with scleral buckle will be included.~Patients will receive topical Netarsudil ophthalmic solution 0.02%: once per day, from time of diagnosis of retinal detachment to 16 weeks post-operatively."
62419830|NCT06033703|EXPERIMENTAL|Primary retinal detachment, Pseudophakic group|"Pseudophakic patients with primary rhegmatogenous retinal detachment repair within 7 days of symptom onset, undergoing vitrectomy or vitrectomy with scleral buckle will be included.~Patients will receive topical Netarsudil ophthalmic solution 0.02%: once per day, from time of diagnosis of retinal detachment to 16 weeks post-operatively."
62419831|NCT06033703|EXPERIMENTAL|Secondary retinal detachment, Phakic group|"Phakic patients with retinal detachment due with proliferative vitreoretinopathy (grade C or higher) or retinal detachment associated with open globe trauma, undergoing vitrectomy or vitrectomy with scleral buckle will be included.~Patients will receive topical Netarsudil ophthalmic solution 0.02%: once per day, from time of diagnosis of retinal detachment to 16 weeks post-operatively."
62590138|NCT02210130||patients HIV+ CSVD+|patients with HIV and cerebral small vessel disease
62419832|NCT06033703|EXPERIMENTAL|Secondary retinal detachment, Pseudophakic group|"Pseudophakic patients with retinal detachment due with proliferative vitreoretinopathy (grade C or higher) or retinal detachment associated with open globe trauma, undergoing vitrectomy or vitrectomy with scleral buckle will be included.~Patients will receive topical Netarsudil ophthalmic solution 0.02%: once per day, from time of diagnosis of retinal detachment to 16 weeks post-operatively."
62590139|NCT02210130||control HIV+ CSVD-|patients with HIV and without cerebral small vessel disease
62590140|NCT04286581|EXPERIMENTAL|Igel Larnygeal Mask Airway|Group 1 will receive the I-Gel Laryngeal Mask Airway for airway maintenance during general anesthesia
62590141|NCT04286581|ACTIVE_COMPARATOR|Ambu Auragain Laryngeal mask airway|Group 2 will receive the Ambu Auragain Laryngeal Mask Airway for airway maintenance during general anesthesia
62590142|NCT02878265|PLACEBO_COMPARATOR|Vitamin A|A single dose of 20,000IU Vitamin A for the whole study period
62226910|NCT06158685|ACTIVE_COMPARATOR|control group|The control group subjects were applied with 15 sessions of conventional physiotherapy consisting of hotpack, ultrasound, and TENS.
62226911|NCT06158685|EXPERIMENTAL|study group|The study group subjects received 15 sessions of McKenzie hyperextension exercises in addition to the conventional physiotherapy program.
62226912|NCT05812287||Case|The case group includes high-grade intraepithelial neoplasia of the stomach, early gastric cancer, and advanced gastric cancer. According to the anatomical location of the tumors, they were divided into two groups: gastric cardia cancer and non-cardia gastric cancer.
62226913|NCT05812287||Control|Pathological findings in the control group showed no malignant changes in the stomach, including normal gastric mucosa, superficial gastritis, non atrophic gastritis, and gastric polyps, etc.
62590143|NCT02878265|ACTIVE_COMPARATOR|Vitamin A and zinc|A single dose of 20,000IU Vitamin A and 10mg of elemental zinc each day for 5 months
62226914|NCT04220697|EXPERIMENTAL|patients undergo lateral thoracotomy for primary lung cancer|"1. Electroencephalography (EEG) will be acquired before surgery~2. Questionnaires assessing psychological status of the patients before and after surgery~3. High frequency electrical stimulation of the skin (HFS) will be delivered before surgery~4. Quantification of mechanical sensitivity after HFS and after surgery"
62226915|NCT06443554|EXPERIMENTAL|Intervention group|
62226916|NCT06443554|PLACEBO_COMPARATOR|Control group|
62802087|NCT03010527|EXPERIMENTAL|Bimekizumab dosing regimen 3|Subjects that were initially randomized to bimekizumab dosage regimen 3, 4 and 5 in PS0010 will receive bimekizumab dosing regimen 3.
62802088|NCT04762732|EXPERIMENTAL|Experimental: negative pressure wound therapy (PREVENA™ Incision Management System)|Wound of ALT donor site will be cared under PREVENA™ Incision Management System
62802089|NCT04762732|PLACEBO_COMPARATOR|Placebo Comparator: conventional dressing|Wound of ALT donor site will be cared by traditional dressing and care.
62802090|NCT01165983|PLACEBO_COMPARATOR|Placebo|
62802091|NCT01165983|EXPERIMENTAL|Aliskiren|
62802092|NCT02953600|EXPERIMENTAL|Standard Dose Spirulina Platensis|Spirulina platensis pill/500mg, 3 pills before each meal /6 pills per day
62802093|NCT02953600|ACTIVE_COMPARATOR|Zero Spirulina Platensis|Spirulina platensis pill/500mg, 6 pills before each meal /12 pills per day
62802094|NCT02953600|ACTIVE_COMPARATOR|Double Dose Spirulina Platensis|same as usual, non pill taken
62802095|NCT06000124|EXPERIMENTAL|Plyometric exercises training|High knee lifts, squat jumps, lunge cross jumps, squat jumping lunges, and squat jump twists are examples of plyometric exercises suitable for older adults.
62226917|NCT02680002|EXPERIMENTAL|7.5 mcg H5N1 (monobulk) Plus MF59 (monobulk)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long-term as monobulk inactivated
62226918|NCT02680002|EXPERIMENTAL|15 mcg H5N1 (monobulk) Plus MF59 (monobulk)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long-term as monobulk MF59 adjuvant
62226919|NCT02680002|EXPERIMENTAL|7.5 mcg H5N1 (monobulk) Plus MF59 (vials)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
62226920|NCT02680002|EXPERIMENTAL|15 mcg H5N1 (monobulk) Plus MF59 (vials)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
62226921|NCT02680002|EXPERIMENTAL|90 mcg H5N1 (monobulk) without MF59|Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59
62226922|NCT02680002|EXPERIMENTAL|90 mcg H5N1 (vials) without MF59|Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59
62226923|NCT04208945|EXPERIMENTAL|Inhaled colistin|Inhaled colistin three times daily for 10 days
62226924|NCT04208945|NO_INTERVENTION|Standard management|
62226925|NCT01202214|EXPERIMENTAL|Active drug|
62802096|NCT06000124|ACTIVE_COMPARATOR|Regulation exercises program|The regulated exercise program includes the use of elastic bands, Qigong, and dance et al.
62802097|NCT06106113|OTHER|Mild hepatic impairment|150 mg GST-HG171
62802098|NCT06106113|OTHER|Moderate hepatic impairment|150 mg GST-HG171
62802099|NCT06106113|OTHER|healthy subjects with normal hepatic function|150 mg GST-HG171
62802100|NCT03077542|EXPERIMENTAL|Participants with Sickle Cell Disease with Nonmyeloablative Haplo Transplants|Participants will receive pentostatin on days -21, -17, -13, and -9 and oral cyclophosphamide from days -21 to -8. Alemtuzumab to be infused on days -7 to -3, followed by 400 cGy TBI on day -1. Donor-derived peripheral blood stem cells will be given on Day 0 then cyclophosphamide will be given at 50 mg/kg on day +3. Sirolimus loading dose of 5mg PO q4h x three doses at one day after the completion of cyclophosphamide (on day +4) and continued the following day at 5mg PO q24h to maintain trough levels between 5-15 ng/ml.
62802101|NCT03077542|OTHER|Human Leukocyte Antigens (HLA) Haploidentical Related Stem Cell Donor|A haploidentical relative donor will receive filgrastim (G-CSF) 10 to 16 µg/kg/d subcutaneously or intravenously for up to 6 days with apheresis collections of peripheral blood hematopoietic progenitor cells (PBPC) after the 5th day (and after the 6th day if required).
62802102|NCT02041507|ACTIVE_COMPARATOR|Air insufflation method.|Colonoscopy performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
62802103|NCT02041507|EXPERIMENTAL|Water Immersion method.|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Withdrawal phase done using air insufflation.
62226926|NCT01202214|PLACEBO_COMPARATOR|Placebo|
62226927|NCT05559008|EXPERIMENTAL|T1 subtypes based on next generation sequencing results|T1 subtypes based on next generation sequencing results
62226928|NCT05559008|EXPERIMENTAL|T2 subtypes based on next generation sequencing results|T2 subtypes based on next generation sequencing results
62226929|NCT05559008|EXPERIMENTAL|T3.1 subtypes based on next generation sequencing results|T3.1 subtypes based on next generation sequencing results
62226930|NCT05559008|EXPERIMENTAL|T3.2 subtypes based on next generation sequencing results|T3.2 subtypes based on next generation sequencing results
62226931|NCT05125705|EXPERIMENTAL|Platelet rich plasma injection|Patients will be treated with a single PRP injection, where 8 mL of whole blood will be collected and 2.5 mL of PRP will be given to the patient. Routine physiotherapy regimens will be implemented, similar to placebo arm.
62226932|NCT05125705|PLACEBO_COMPARATOR|Saline injection|Patients will be treated with 2.5 mL saline 0.9%. Routine physiotherapy regimens will be implemented, similar to intervention arm.
62226933|NCT05631431|PLACEBO_COMPARATOR|Placebo|
62419833|NCT01308073||EMIC 2 dialysis|Patients on ICU requiring dialysis for acute renal insufficiency
62419834|NCT03029000|EXPERIMENTAL|Tbo-filgrastim (GRANIX)|"Participants will receive tbo-filgrastim 10 mcg/kg of body weight, subcutaneously on the morning of Days 1 to 5.~The actual dose of tbo-filgrastim administered to each, individual participant will be calculated at baseline according to his or her body weight and that specific dose (10 mcg/kg of body weight) for each, individual participant will remain the same for all consecutive daily doses.~If the collection goal will not meet after the first apheresis on Day 5, tbo-filgrastim 10 mcg/kg of body weight will be administered subcutaneously for up to 3 additional days (Days 6 to 8) followed by daily apheresis to reach the cumulative collection goal."
62419835|NCT05286983||K0 - baseline cohort|45 preterm infants and their parents (average number of patient admissions per 6 months during the last 5 years)
62226934|NCT05631431|ACTIVE_COMPARATOR|Treatment|
62226935|NCT04121195|OTHER|Dose escalation sequence (all participants)|The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.
62226936|NCT04639141|ACTIVE_COMPARATOR|Synbiotic|"Dosing: one sachet/dose per day for 12 weeks. The combination includes: Lactobacillus rhamnosus (1x10\^10 CFU/dose), Lactobacillus plantarum (4 x 10\^9 CFU/dose), Bifidobacterium animalis subsp. lactis (5 x 10\^9 CFU/dose), Bifidobacterium longum (1 x 10\^9 CFU/dose) + 4g/dose of partially hydrolysed guar gum (PHGG).~Mode of administration: oral."
62226937|NCT04639141|EXPERIMENTAL|Synbiotic + gut-directed hypnotherapy|"Includes the daily oral synbiotic (as pervious described) + a home-based therapy program.~Home-based therapy program: based on the Manchester model of gut-directed hypnotherapy (GDH) adapted for use in children with ASD. The GDH core therapy focus areas will be relaxation, control of gut function and ego-strengthening.~Schedule: daily use of a home-based audio recordings. The program will consist of six (6) therapy sessions/recordings over 12 weeks. Each recording (sessions 1 through 6) is to be used daily for a fortnight. Each session is approximately 15-20 minutes in duration."
62226938|NCT01543529|ACTIVE_COMPARATOR|RO4917838 + non-alcoholic drink|
62226939|NCT01543529|EXPERIMENTAL|RO4917838 + alcohol|
62226940|NCT01543529|PLACEBO_COMPARATOR|RO4917838 placebo + alcohol|
62226941|NCT01543529|PLACEBO_COMPARATOR|RO4917838 placebo + non-alcoholic drink|
62226942|NCT05822219|ACTIVE_COMPARATOR|COVID-19 vaccine and booster training|Group training involving COVID-19 vaccine and booster information, including background, development, and myths.
62226943|NCT05822219|EXPERIMENTAL|COVID-19 vaccine and booster training with extra undisclosed component|Group training involving COVID-19 vaccine and booster information, including background, development, and myths. Contains extra training component that is undisclosed until the end of the study so as not to introduce bias.
62419836|NCT05286983||K1 - 1st intervention cohort|All preterm infants and their parents enrolled during the first 6 months period after completion of the baseline cohort and who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
62226944|NCT01874301|EXPERIMENTAL|High quantity probiotic food product|
62226945|NCT01874301|EXPERIMENTAL|Low quantity probiotic food product|
62226946|NCT01874301|PLACEBO_COMPARATOR|Placebo|
62226947|NCT03542773|EXPERIMENTAL|18F-DCFPyL|A bolus of less than or equal to 9 mCi (331 MBq) of IV injection of 18F-DCFPyL
62226948|NCT04967534|EXPERIMENTAL|WB-EMS|
62226949|NCT04967534|SHAM_COMPARATOR|social contact control group|
62590144|NCT02878265|ACTIVE_COMPARATOR|Vitamin A , Zinc and Multivitamin|A single dose of 20,000IU Vitamin A , 10mg of elemental zinc each day and 0.5ml/kg multivitamin syrup for 5 months
62802104|NCT02041507|EXPERIMENTAL|Water Exchange method.|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using air insufflation.
62590145|NCT01246869|EXPERIMENTAL|All Participants|All enrolled participants will complete three imaging sessions on separate days, beginning with a research MRI, then a PET scan with FDG and \[15O\]water, and a PET scan with FMISO. The two PET scans will be in any order on different days within one week of each other, and preferably on consecutive days. The research MRI will be within 14 days of the first PET scan.
62027852|NCT03778294|EXPERIMENTAL|Treatment (18F-DOPA, PET/MRI, PET/CT, temozolomide)|Patients receive 18F-DOPA IV and undergo PET/MRI or PET/CT imaging scan. Patients then receive proton beam radiotherapy over 5 or 10 consecutive days excluding weekend and standard of care temozolomide on days 1-7 or 1-14. Beginning cycles 2, patients receive standard of care temozolomide on days 1-5. Cycles with temozolomide repeat every 28 days for up to 7 cycles in the in the absence of disease progression or unacceptable toxicity.
62027853|NCT01673139|EXPERIMENTAL|Moderate exercise|Moderate exercise
62027854|NCT01673139|EXPERIMENTAL|Control|Control group
62027855|NCT01673139|EXPERIMENTAL|Interval exercise|interval exercise
62027856|NCT01847846|EXPERIMENTAL|Prototype mask|Participants will be randomised to trial the new prototype mask for 4 and 8 weeks. The prototype mask will be used in conjunction with the participant's home CPAP machine. The participant's will be instructed to use the prototype mask every night until the completion of the trial. No changes will be made to the participant's prescribed CPAP settings.
62226950|NCT05727787|EXPERIMENTAL|Single fraction SBRT 27 Gy|vGRID SBRT 3+3 dose escalation, single fraction, one day cycle length
62226951|NCT00645047|EXPERIMENTAL|Telemedicine CBT|Cognitive behaviour therapy (CBT) delivered using videoconference telemedicine.
62590146|NCT05109884|OTHER|newly diagnosed very high risk locally advanced and/or oligometastatic prostate cancer|
62590147|NCT05109884|OTHER|metastatic, castration resistant prostate cancer|
62590148|NCT05109884|OTHER|newly diagnosed prostate cancer with planned radical prostatectomy|
62590149|NCT05109884|OTHER|primary bladder cancer with planned radical cystectomy|
62802105|NCT02214641|EXPERIMENTAL|Lifestyle intervention|Resilient, Empowered, Active Living (REAL) Diabetes
62802106|NCT02214641|ACTIVE_COMPARATOR|Information Control|Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose.
62802107|NCT04648319|EXPERIMENTAL|locally advanced, metastatic or recurrent cholangiocarcinoma|D1: Compound: BMS-936558 treatment d8: radiotherapy D 20: CT guided Biopsy D 28: BMS-936558 treatment monthly: BMS-936558 treatment CT CAP: after 4doses
62802108|NCT02526602|EXPERIMENTAL|Preservation (endopelvic fascia)|During robotic assisted laparoscopic radical prostatectomy endopelvic fascia are preserved.
62027857|NCT02599792|EXPERIMENTAL|CTP-656, 150 mg|Single Oral Dose
62027858|NCT02599792|ACTIVE_COMPARATOR|Kalydeco, 150 mg|Single oral dose
62027859|NCT02599792|EXPERIMENTAL|CTP-656, 75 mg or matching placebo|Subjects will be administered 75 mg CTP-656 for 7 days.
62027860|NCT02599792|EXPERIMENTAL|CTP-656, 150 mg or matching placebo|Subjects will be administered 150 mg CTP-656 for 7 days.
62027861|NCT02599792|EXPERIMENTAL|CTP-656, high dose or matching placebo|Subjects will be administered up to 300 mg CTP-656 for 7 days.
62027862|NCT02025777|EXPERIMENTAL|capsule endoscopy and colonoscopy|
62027863|NCT06636058|EXPERIMENTAL|Early VCare Intervention (6-month active treatment followed by 6-month maintenance)|Participants randomized to the early-intervention arm will receive active treatment for 6 months, followed by maintenance for another 6 months.
62419837|NCT05286983||K2 - 2nd intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
62226952|NCT00645047|ACTIVE_COMPARATOR|In-Person CBT|Cognitive behaviour therapy (CBT) delivered using in-person consultation.
62802109|NCT02526602|ACTIVE_COMPARATOR|Opening (endopelvic fascia)|During robotic assisted laparoscopic radical prostatectomy endopelvic fascia are opened.
62802110|NCT01271725|EXPERIMENTAL|Afatinib 40mg once daily (OD)|Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
62802111|NCT01271725|EXPERIMENTAL|Paclitaxel 80 mg/m2 weekly|Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
62802112|NCT01271725|EXPERIMENTAL|Vinorelbine 25 mg/m2 weekly|Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
62802113|NCT03214861||Nurses Health Study|The Nurses' Health Study (NHS) was initiated in 1976 as a prospective cohort study, where 121,701 female registered nurses between the ages of 30 and 55 years were recruited from 11 US states.
62802114|NCT03214861||Health Professionals Follow-Up Study|The Health Professionals Follow-up Study (HPFS) was initiated in 1986 and recruited 51,529 US men between the ages of 40-75.
62802115|NCT03518294|NO_INTERVENTION|Standard of Care|Subjects in the control condition will be instructed to continue their medical care at the discretion of their treating medical professional. They will be informed to maintain their current physical activity level. Weekly phone calls will be performed by study personnel to ensure adherence to the protocol (no changes in activity). Subjects will report to Penn State on a monthly basis for anthropometric assessment to confirm their self-reports and study investigators will perform and interim history and physical examination at that time.
62419838|NCT05286983||K3 - 3rd intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
62419839|NCT05286983||K4 - 4th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
62419840|NCT05286983||K5 - 5th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
62226953|NCT05149911|EXPERIMENTAL|Coaching|Participants randomized to the coaching group will receive a 1-hour initial professional coaching session followed by five 30-minute professional coaching sessions occurring at a goal frequency of every 2 to 3 weeks within 5 months (total of 3.5 coaching hours). All coaching sessions will be conducted individually (i.e. between one coach and one participant). Participants will be able to request coaching on any topic to individualize the intervention, but the general structure of the sessions will be standardized across participants. All coaching sessions will be performed over the phone or virtual web meeting as standard in coaching practices.
62226954|NCT05149911|NO_INTERVENTION|Control|"Participants randomized to the control group will receive no intervention but will be asked to complete the distress and wellness survey at the same time points as participants in the intervention group. Participants in the control group will receive the life coaching intervention after the statistical analysis is completed."
62226955|NCT01275131|ACTIVE_COMPARATOR|Stage 1: Insulin aspart first, then insulin aspart-rHuPH20|"Participants first received 0.15 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4.~After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8."
62419841|NCT05286983||K6 - 6th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
62419842|NCT05286983||K7 - 7th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
62590150|NCT06623123|ACTIVE_COMPARATOR|Tinnitus Retraining Therapy (TRT) Arm|Tinnitus-retraining therapy will be offered in the control arm which represents the standard evidence-based intervention on the NHS. (2) Participants enrolled to this arm will undertake tinnitus retraining therapy with a trained audiologist. The sessions will last 30 minutes with the option for further sessions should the patient which to have more support with their tinnitus to mimic the NHS programme as much as possible. These sessions will encompass a brief audiological history followed by therapy tailored to the patient's needs allowing for patient-centred optimisation of tinnitus burden and secondary comorbidities. This may include relaxation, CBT and advice surrounding sound as well as white noise masking therapy.
62802116|NCT03518294|EXPERIMENTAL|Aerobic Exercise|Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
62802117|NCT02019732||Study Group|Applicable subjects less than 65 years of age identified in the Marketscan Commercial database during the period from July 2000 through April 2009, and October 2010 to May 2011 and subjects 65 years of age and older identified in MarketScan Medicare Supplemental database during the period from July 2006 through April 2009, and October 2010 to May 2011.
62802118|NCT04531761|EXPERIMENTAL|Immediate Access to Parent Support Program|
62802119|NCT04531761|NO_INTERVENTION|Waitlist Control|
62802120|NCT00694655|EXPERIMENTAL|HLA-A202+: Yellow Fever Vaccine and Post-vaccination Blood Draws|HLA-A202+ participants receiving Yellow Fever Vaccine plus post-vaccination blood draws.
62802121|NCT00694655|EXPERIMENTAL|HLA-A202+: Yellow Fever Vaccine, Post-vaccination Blood Draws and Leukapheresis|HLA-A202+ participants receiving Yellow Fever Vaccine plus post-vaccination blood draws and leukapheresis.
62027864|NCT06636058|ACTIVE_COMPARATOR|Later Waitlist VCare Intervention (active treatment after 6 months)|Participants in the later-intervention arm will be waitlisted for 6 months and then receive active treatment in the second 6 months.
62027865|NCT00936858|EXPERIMENTAL|Arm A|RAD001 will be administered orally as once daily dose of 10 mg (one 10mg tablet or two 5mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity.
62027866|NCT02395562||OTR and viral reactivation|Organ transplant recipients with and without viral reactivation and skin cancer
62027867|NCT06513897|EXPERIMENTAL|Acupressure|
62027868|NCT06513897|EXPERIMENTAL|Paternal Holding|
62226956|NCT01275131|ACTIVE_COMPARATOR|Stage 1: Insulin aspart-rHuPH20 first, then insulin aspart|"Participants first received 0.15 units per kilogram (U/kg) insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4.~After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart alone as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8."
62419843|NCT05286983||K8 - 8th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
62419844|NCT05286983||K9 - 9th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
62419845|NCT05286983||K10 - 10th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
62590151|NCT06623123|EXPERIMENTAL|Oto Smartphone Application|The smartphone application delivers personalized tinnitus therapy combining evidence-based CBT with mindfulness, patient education as well as physical therapy such as stretches and exercises. There are additional sounds available to listen to from the sound library. There will be a structured programme that the participants can work through however they are encouraged to personalise their own therapy.
62027869|NCT06513897|NO_INTERVENTION|Control|
62419846|NCT04774809|ACTIVE_COMPARATOR|SHR0302 Low Dose|Drug: SHR0302 SHR0302 Ointment BID Low Dose
62027870|NCT00875836|EXPERIMENTAL|Buspirone|Buspirone
62027871|NCT00875836|PLACEBO_COMPARATOR|Placebo|Placebo
62027872|NCT05457946|EXPERIMENTAL|Test group 1|Low dose of candidate hexavalent vaccine (DTwPHepB-Sabin IPV-Hib) for Stage 1/ selected dose of hexavalent vaccine Lot A for Stage 2
62027873|NCT05457946|EXPERIMENTAL|Test group 2|Middle dose of candidate hexavalent vaccine (DTwPHepB-Sabin IPV-Hib) for Stage 1/ selected dose of hexavalent vaccine Lot B for Stage 2
62027874|NCT05457946|EXPERIMENTAL|Test group 3|High dose of candidate hexavalent vaccine (DTwPHepB-Sabin IPV-Hib)for Stage 1/ selected dose of hexavalent vaccine Lot C for Stage 2
62027875|NCT05457946|ACTIVE_COMPARATOR|Control group|Co-administration of Pentavalent vaccine and Inactivated Polio vaccine for both stages
62419847|NCT04774809|ACTIVE_COMPARATOR|SHR0302 High Dose|Drug: SHR0302 SHR0302 Ointment BID High Dose
62419848|NCT04774809|PLACEBO_COMPARATOR|Placebo Comparator: Vehicle|Drug: vehicle Vehicle BID Placebo
62590152|NCT05826288|EXPERIMENTAL|Post BMT or CAR-T patients receiving care at UCHealth|"Participants will be recruited for this study from among three discrete patient populations:~* Allogeneic BMT patients receiving care at UCHealth who are planning to reside in the Denver metro area within 45 minutes of the Anschutz Medical Campus (AMC) for at least 90 days post-transplant.~* Autologous BMT patients receiving care at UCHealth who are planning to reside in the Denver metro Area within 45 minutes of the AMC for at least 30 days post-transplant.~* CAR-T patients receiving care at UCHealth who are planning to reside in the Denver metro area within 45 minutes of the AMC for at least 30 days post treatment."
62590153|NCT06320236||Emergency department patients tested for pulmonary embolism.|
62590154|NCT06432075|EXPERIMENTAL|Neoantigen Reactive T Cells|Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory;nab-paclitaxel 100-200mg/m2/D will be i.v. for 7 days before cell infusion; Cyclophosphamide 300mg/m2/D will be i.v. for 2 and 3 days before cell infusion; NRTs 0.5\~1 x 10\^10, will be i.v.Q3 weeks for total 4 doses;Interleukin-2 (IL-2) will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 1000,000 international unit per day.All Patients will receive a total of 4 cycles of treatment.
62590155|NCT04339647|EXPERIMENTAL|The SIMS Programme|The SIMS programme is a community-based intervention which improvised the usual care (defined as the existing preschool oral health programme) offered by the Ministry of Health. The target group is 5-6-year-old preschool children and their parents. Apart from the usual care, the 5-6-year-old children receive interventions carried out by teacher in school and home tooth brushing supervision by parents. In addition, parents/guardians will receive OHE from the DT team, free toothbrush and toothpaste (1000ppm F) for child home tooth brushing and supervised child home tooth brushing for 6 months.
62590156|NCT04339647|NO_INTERVENTION|Control|The control group receives the usual care from the preschool oral health programme. The usual care is described as a DT team visiting the school to do an oral examination, provides OHE to the children, and applies fluoride varnish (20,000 ppmF) twice/year.
62802122|NCT00694655|EXPERIMENTAL|HLA-A202+: Yellow Fever Vaccine, Post-vaccination Blood Draws and Fine Needle Aspirate|HLA-A202+ participants receiving Yellow Fever Vaccine plus post-vaccination blood draws and fine needle aspirate.
62802123|NCT00694655|EXPERIMENTAL|HLA-A202-: Yellow Fever Vaccine and Post-vaccination Blood Draws|HLA-A202- participants receiving Yellow Fever Vaccine plus post-vaccination blood draws.
62802124|NCT03666871|EXPERIMENTAL|Arm 1|Arm 1 (n=20) will be pretreated with cyclophosphamide 1 g/m2 and will receive a single intravenous infusion of 0.5 to 4x1010 ex vivo expanded autologous CD4+ T cells that have been transduced with a zinc finger nuclease designed to cleave CCR5.
62802125|NCT03666871|ACTIVE_COMPARATOR|Arm 2|Arm 2 (n=10) will be pretreated with cyclophosphamide 1 g/m2 and will receive a single intravenous infusion of 0.5 to 4x1010 ex vivo expanded autologous CD4+ T cells that have not been modified by zinc finger nucleases.
62226957|NCT01275131|ACTIVE_COMPARATOR|Stage 3: Insulin aspart first, then insulin aspart + rHuPH20|"Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a sham injection was administered 2.5 hr prior to the 6-hr euglycemic clamp.~After a 5- to 14-day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the 6-hr euglycemic clamp."
62419849|NCT06537102|OTHER|Unilateral laparoscopic ovarian drilling group|"Patients underwent unilateral laparoscopic ovarian drilling Laparoscopic drilling was performed under general anesthesia as follows: 10-mm subumbilical entry and two 5-mm secondary ports in the lower part of the abdomen just above the anterior superior iliac spine. The laparoscope is introduced through the subumbilical port, and secondary ports was used for introduction of the instruments,the type of needle was an insulated unipolar needle electrode with a non-insulated distal end. We are planning to use the least thermal effective dose which is 60 J/cm3 of ovarian tissue.~The number of punctures (Np) per ovary was calculated according to the following formula: N p = 60 J/cm3/40 W × 4 s, with 3 mm diameter and 4 mm depth for each puncture using power setting of 300 W for 2-4 s. Unilateral: was done on the larger ovary."
62590157|NCT03253289|EXPERIMENTAL|Meclizine 100 mg|Meclizine 50 mg will be taken by the patient orally twice daily for a total of 28 days(up to 35 days).
62590158|NCT01423396|OTHER|standard care|Follow up with city doctor with recommendation HAS French guidelines
62590159|NCT01423396|EXPERIMENTAL|optimal care of VRF|Monitoring according to the strict recommendations of the HAS French guidelines
62590160|NCT01471340|EXPERIMENTAL|Mometasone Furoate/Formoterol MDI BID|MF/F MDI BID (pooled MF/F MDI 200/10 mcg BID and MF/F MDI 400/10 mcg BID treatments)
62590161|NCT01471340|ACTIVE_COMPARATOR|Mometasone Furoate MDI BID|MF MDI BID (pooled from MF MDI 200 mcg BID and MF MDI 400 mcg BID treatments)
62590162|NCT04079517|EXPERIMENTAL|Tamoxifen 10mg|Randomised dose of daily oral Tamoxifen 10mg, for 180 days
62590163|NCT04079517|ACTIVE_COMPARATOR|Tamoxifen 20mg|Randomised dose of daily oral Tamoxifen 20mg, for 180 days
62590164|NCT06327503||T2DM patients|patients with diagnosed controlled Type 2 Diabetes Mellitus with or without systemic complications
62590165|NCT06327503||non-T2DM patients|age and general health matched control group without Type 2 Diabetes Mellitus
62802126|NCT03247257|ACTIVE_COMPARATOR|Group A: General Anesthesia|35 patients will be randomized to receive general anesthesia during their laparoendoscopic single site incision cholecystectomy.
62802127|NCT03247257|ACTIVE_COMPARATOR|Group B: Epidural Anesthesia|35 patients will be randomized to receive epidural anesthesia during their laparoendoscopic single site incision cholecystectomy.
62802128|NCT02553057|ACTIVE_COMPARATOR|Group 1|mechanical ventilation with Tidal volume 4 ml/kg and PEEP 8-10 cm H2o
62802129|NCT02553057|ACTIVE_COMPARATOR|Group2|mechanical ventilation with Tidal volume 6 ml/kg and PEEP 8-10 cm H2o
62590166|NCT01511874|EXPERIMENTAL|ELIGRAD 22.5mg|a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
62027876|NCT05834608||Group M|Manual ventilation
62027877|NCT05834608||Group A|AutoFlow mechanical ventilation
62027878|NCT00814203||Chronic obstructive lung disease|those with a condition
62027879|NCT04291963|ACTIVE_COMPARATOR|DGG + TUN|The multiple adjacent gingival recession sites were treated with DGG in conjunction with TUN technique.
62226958|NCT01275131|ACTIVE_COMPARATOR|Stage 3: Insulin aspart + rHuPH20 first, then insulin aspart|"Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6- hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the euglycemic clamp .~After a 5- to 14- day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a sham injection was administered 2.5 hr prior to the 6-hour euglycemic clamp."
62226959|NCT03372707|EXPERIMENTAL|Intervention Arm|Patients randomized to the intervention arm will have the results of the Cuff Leak Test (CLT) (whether failed or passed) communicated to the treating physician; the treating physician will decide whether to proceed with extubation or not based on the CLT results. It is at the discretion of the treating physician to provide corticosteroids (4-5 mg of intravenous dexamethasone every six hours for up to 24 hours, with the last dose given one hour preceding extubation) and/or delay extubation by 24 hours should the patient fail the CLT.
62226960|NCT03372707|NO_INTERVENTION|Control Arm|In the control arm of this trial; the treating physicians and healthcare workers will be blinded to the results of the Cuff Leak Test (CLT); therefore, the Respiratory Therapist (RT) will proceed with extubation without delay or administering systemic steroid, regardless to the CLT results.
62226961|NCT04685057|PLACEBO_COMPARATOR|Placebo|This arm will receive placebo for 6 months then probiotic for 6 more months.
62590167|NCT06191328|EXPERIMENTAL|Intervention group|
62802130|NCT02553057|ACTIVE_COMPARATOR|Group 3|mechanical ventilation with Tidal volume 8 ml/kg and PEEP 8-10 cm H2o
62802131|NCT05137964||Vitamin D Deficient|deficiency (\<20ng/ml)
62027880|NCT04291963|ACTIVE_COMPARATOR|SCTG + TUN|The multiple adjacent gingival recession sites were treated with SCTG in conjunction with TUN technique.
62027881|NCT01658787||Endovascular aortic repair|Patients treated with Gore Endovascular Aortic Products.
62802132|NCT05137964||Vitamin D Sufficient|sufficiency (\>30ng/ml)
62802133|NCT00613496|PLACEBO_COMPARATOR|2|Placebo treatment in each patient during the study (9 weeks) using an intraindividual cross-over design
62802134|NCT00613496|ACTIVE_COMPARATOR|1|Irbesartan treatment in each patient during the study (9 weeks) using an intraindividual cross-over design
62027882|NCT02079805|EXPERIMENTAL|Azilsartan 20 mg|Participants will receive azilsartan 20 mg once daily in the morning before or after breakfast.
62027883|NCT02079805|ACTIVE_COMPARATOR|Telmisartan 40 mg|Participants will receive telmisartan 40 mg once daily in the morning before or after breakfast.
62027884|NCT01316926|ACTIVE_COMPARATOR|Paxil CR Reference|Reference drug administration followed by test drug administration
62027885|NCT01316926|ACTIVE_COMPARATOR|Paxil CR Test|Test drug administration followed by Reference drug administration
62027886|NCT00823719|EXPERIMENTAL|ofatumumab + DHAP or ICE chemotherapy regimen|This study is a single arm study, but the Investigators are required to prospectively choose to treat all of their subjects with either ICE or DHAP chemotherapy regimens in combination with ofatumumab. Regardless of whether the subject receives ICE or DHAP chemotherapy, all subjects will receive the same ofatumumab regimen and dose.
62027887|NCT05617716|EXPERIMENTAL|Standard dose SBRT|Participants will undergo standard dose Stereotactic Body Radiation Therapy
62027888|NCT05617716|EXPERIMENTAL|High dose SBRT|Participants will undergo high dose Stereotactic Body Radiation Therapy
62027889|NCT05617716|EXPERIMENTAL|Conventional EBRT|Participants will undergo External Beam Radiation Therapy
62027890|NCT00742703|EXPERIMENTAL|1|
62027891|NCT00742703|ACTIVE_COMPARATOR|2|
62027892|NCT02541929|EXPERIMENTAL|DHA|DHA (2grams/day) for 26 weeks
62027893|NCT02541929|PLACEBO_COMPARATOR|placebo|placebo (4 capsules per day) for 26 weeks
62027894|NCT00628771|ACTIVE_COMPARATOR|Usual Care|Participants will receive usual care for their prenatal visits.
62027895|NCT00628771|EXPERIMENTAL|CenteringPregnancy Plus|Participants will receive the CenteringPregnancy Plus treatment program, which includes an HIV/STD prevention component.
62802135|NCT05301517|EXPERIMENTAL|Roxadustat|Participants will receive roxadustat, administered orally 3 times per week (TIW) for 12 weeks to achieve Hb levels of 100-120 g/L. The starting dose will be based on the participant's weight group. The maximum dose for individual participants may not exceed 3.5 milligrams (mg)/kilogram (kg) or 400 mg TIW whichever is lower.
62027896|NCT04236349||CO1TB: observational|patients with pulmonary and extrapulmonary tuberculosis
62027897|NCT04236349||CO2TB: immunogenetics|"patient with pulmonary and extrapulmonary tuberculosis and meet the following criteria:~* informed consent form signed by the patient or by the representative of parental authority~* affiliation to social security (beneficiary or assignee)~* HIV negative"
62027898|NCT04842955|EXPERIMENTAL|real tACS|Single session of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus)
62802136|NCT05301517|ACTIVE_COMPARATOR|SEPO®|Participants will receive SEPO®, injected subcutaneously TIW for 12 weeks to achieve Hb levels of 100-120 g/L. The starting dose will be 150 international units (IU)/kg subcutaneously TIW.
62802137|NCT03331900|PLACEBO_COMPARATOR|Placebo|
62802138|NCT03331900|ACTIVE_COMPARATOR|COR388 TBD mg|
62802139|NCT01929226|EXPERIMENTAL|ETI-204|A single intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1
62802140|NCT01929226|PLACEBO_COMPARATOR|Placebo for ETI-204|A single intravenous dose of ETI-204-placebo infused over 90 minutes on Day 1
62802141|NCT01798966|EXPERIMENTAL|SENSIMED Triggerfish|Sensimed Triggerfish device will be worn by each subject for 24h
62802142|NCT01559181||Exposure to intrauterine hyperglycemia|The study group includes the offspring of women with type 1 diabetes from the national diabetes birth registry (1993-99, n=900) with information of HbA1c prior to conception and/or 1st trimester HbA1c.
62802143|NCT01559181||Control group|The control group including offspring of women without diabetes who delivered during the same period matched with respect to gender and age of offspring and the family's postcode as an indirect marker of the socioeconomic background.
62419850|NCT06537102|OTHER|Bilateral laparoscopic ovarian drilling group|"Laparoscopic drilling was performed under general anesthesia as follows: 10-mm subumbilical entry and two 5-mm secondary ports in the lower part of the abdomen just above the anterior superior iliac spine. The laparoscope is introduced through the subumbilical port, and secondary ports was used for introduction of the instruments,the type of needle was e an insulated unipolar needle electrode with a non-insulated distal end. We are planning to use the least thermal effective dose which is 60 J/cm3 of ovarian tissue.~The number of punctures (Np) per ovary was calculated according to the following formula: N p = 60 J/cm3/40 W × 4 s, with 3 mm diameter and 4 mm depth for each puncture using power setting of 300 W for 2-4 s. Bilateral : using dose adjusted according to ovarian volume."
62419851|NCT05587517|EXPERIMENTAL|EMPOWER arm|"The EMPOWER arm includes six 15 minute modules delivered in a 1-on-1 format with the same interventionist, and 2 boosters (approximately 45 minutes each) conducted by phone.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the EMPOWER intervention within 3 months conducted in person and by phone."
62419852|NCT05587517|PLACEBO_COMPARATOR|Supportive Conversation arm|"The Supportive Conversation (SC) arm includes a supportive, empathic encounter without specific skill-building for approximately the same amount of time as EMPOWER.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after SC within 3 months conducted in person and by phone."
62419853|NCT04424407|OTHER|CBT-I|
62419854|NCT00000135|EXPERIMENTAL|MSL-109|The dose MSL-109 administered by intravenous infusion every 2 weeks 60 mg.
62590168|NCT02272907|EXPERIMENTAL|Non-buttressed, non-imbricated oversewing|Along the staple line, the surgical attending will oversew the length of the staple line using a 2-0 Vicryl suture in a continuous fashion.
62802144|NCT05662098|EXPERIMENTAL|Treatment|All participants will receive an individualized PK hydroxyurea assessment. Participants for whom the PK-process successfully generates a dose in the predicted treatment range of 15-35 mg/kg/day, will start on that personalized dose. Participants for whom the process does not generate a starting hydroxyurea dose in the predicted treatment range, due to potential pitfalls in lab draws, serum storage, sample processing, or hydroxyurea analysis, will start at a default dose of 20.0 ± 2.5 mg/kg/day. For all participants, the hydroxyurea dose will be adjusted as needed based on blood counts to establish the optimal dose. Where necessary, a weekly dosing average will be determined, so that treatment can occur solely with locally available and affordable 500mg hydroxyurea capsules.
62802145|NCT01315171|EXPERIMENTAL|Medium chain supplemented diet|Subjects will have a diet during which all meals are supplemented with 4 tablespoons of medium chain triglyceride oil.
62802146|NCT01315171|NO_INTERVENTION|Standard group|Subjects will continue with a standard western diabetes diet.
62802147|NCT04266808|EXPERIMENTAL|An interactive telehealth monitoring and biofeedback system|Participants in this group will receive feedback of pressure relief maneuvers and wheelchair propulsion activity. Feedback for pressure relief will include information during the activity to identify adequate duration and magnitude of pressure relief activity, reminders of when the next pressure relief is due, and daily aggregate information regarding the number of successful pressure relief maneuvers performed.
62802148|NCT04266808|SHAM_COMPARATOR|Education Control|Participants will receive education on the importance and recommended frequency of pressure relief maneuver for prevention of pressure ulcer/injury and on the importance and recommended amounts of physical activity for health.
62802149|NCT05113511|EXPERIMENTAL|SCT510|SCT510
62802150|NCT05113511|ACTIVE_COMPARATOR|bevacizumab|bevacizumab
62802151|NCT04676620||CK surgery|Conductive keratoplasty (CK) had shown to be a safe and effective procedure for the treatment of low to moderate hypeopia. It had been approved by the U.S. Food and Drug Administration (FDA) to treat presbyope in early 2004. CK appeals to both surgeons and patients as it avoids the need for flap creation, the use of high intraocular pressure (IOP), or tissue ablation.
62802152|NCT04676620||LASIK surgery|LASIK surgery is femtosecond laser assisted conventional refractive surgery and has also been proved to offer many advantages in terms of visual acuity, corneal sensitivity, and corneal biomechanics compared with traditional refractive surgeries.
62027899|NCT04842955|SHAM_COMPARATOR|sham tACS|Single session of sham tACS over the superior parietal cortex (Precuneus)
62802153|NCT04175730|OTHER|MRI and Ultrasound|men with elevated PSA or abnormal DRE for which prostate biopsy is indicated and mpMRI positive for suspected prostate cancer followed by MRI/ultrasound fusion directed prostate needle biopsies
62802154|NCT04175730|OTHER|Ultrasound|men with elevated PSA or abnormal DRE for which prostate biopsy is indicated and mpMRI negative for suspected prostate cancer followed by standard ultrasound guided prostate needle biospies
62802155|NCT05374239|OTHER|Hospital 1|First hospital in the allocation sequence to cross from control to intervention arm.
62802156|NCT05374239|OTHER|Hospital 2|Second hospital in the allocation sequence to cross from control to intervention arm.
62802157|NCT05374239|OTHER|Hospital 3|Third hospital in the allocation sequence to cross from control to intervention arm.
62802158|NCT05374239|OTHER|Hospital 4|Fourth hospital in the allocation sequence to cross from control to intervention arm.
62802159|NCT02884024||lean|healthy subject undergoing routine screening colonoscopy, BMI\< or = 25
62802160|NCT02884024||mildly obese|healthy subject undergoing routine screening colonoscopy, BMI 30-33.9
62802161|NCT02884024||moderate-to-severe obese|healthy subject undergoing routine screening colonoscopy, BMI 34+
62802162|NCT03560336||Overall Population|Patients will be treated with commercially available liraglutide 3.0 mg according to routine clinical practice at the discretion of the treating physician
62802163|NCT03168620|ACTIVE_COMPARATOR|ITR group|In ITR group after partial caries removal(PCR), interim therapeutic restoration of glass ionomer cement (GIC) Ketac molar was placed for one month before definitive adhesive restoration
62802164|NCT03168620|ACTIVE_COMPARATOR|Non ITR group|In NON-ITR group, cavity preparation was similar to ITR group, but definitive restoration was done in the same visit
62802165|NCT01745367|ACTIVE_COMPARATOR|Placebo in combination with paclitaxel|Placebo orally once daily on a 3 weeks on/1 week off schedule with 90 mg/m2 of paclitaxel administered intravenously 3 weeks on (Day 1, Day 8 and Day 15)/1 week off (4 weeks = 1 Cycle).
62802166|NCT01745367|EXPERIMENTAL|Tivo in combination with paclitaxel|1.5 mg tivozanib hydrochloride orally once daily on a 3 weeks on/1 week off schedule with 90 mg/m2 of paclitaxel administered intravenously 3 weeks on (Day 1, Day 8 and Day 15)/1 week off (4 weeks = 1 Cycle).
62802167|NCT01111695|EXPERIMENTAL|Honey and ionic silver dressing|
62802168|NCT00239733|EXPERIMENTAL|1|Participants will be given anti-D in an outpatient setting. Participants will be observed for any adverse effects for 1 hour postinfusion. Some participants may require additional doses of anti-D later in the study, depending on individual response to the drug; participants may receive 1 to 6 doses of anti-D.
62802169|NCT03847844|EXPERIMENTAL|Group A|Cyto-MSC (5 million UCMSCs per kg bodyweight) and standard treatment
62802170|NCT03847844|PLACEBO_COMPARATOR|Group B|Placebo (normal saline) and standard treatment
62802171|NCT00726648|EXPERIMENTAL|1|
62802172|NCT00726648|EXPERIMENTAL|2|
62802173|NCT00726648|EXPERIMENTAL|3|
62419855|NCT00000135|PLACEBO_COMPARATOR|Placebo|Placebo administered intravenous infusion every 2 weeks 60 mg.
62590169|NCT02272907|EXPERIMENTAL|Non-buttressed, imbricated suture line|Along the staple line, the surgical attending will oversew the staple line using a 2-0 Vicryl suture in a continuous, imbricating fashion.
62802174|NCT00726648|EXPERIMENTAL|4|
62802175|NCT00726648|PLACEBO_COMPARATOR|5|
62802176|NCT02714569|EXPERIMENTAL|Part A: LY3202328 (LY)|Single ascending doses of 1 milligram (mg), 3 mg, 10 mg, 30 mg, 100 mg, 300mg, 600 mg LY3202328 orally while fasting, or 30 mg LY3202328 orally while fed in 4 periods.
62802177|NCT02714569|PLACEBO_COMPARATOR|Part A: Placebo|A single ascending dose of placebo orally, in 1 period while fasting, and up to one period while fed.
62802178|NCT02714569|EXPERIMENTAL|Part B: LY3202328 (LY)|A multiple ascending dose of 5 mg, 20 mg, 100 mg, and 300 mg LY3202328 at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
62802179|NCT02714569|PLACEBO_COMPARATOR|Part B: Placebo|A multiple ascending dose of placebo at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
62802180|NCT04262726|EXPERIMENTAL|REMOTION + TAU|Participants in the REMOTION group receive REMOTION in addition to psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
62802181|NCT04262726|ACTIVE_COMPARATOR|TAU|Participants in TAU receive psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
62802182|NCT03121508|OTHER|TODAY Project|All participants will attend individualized self-management sessions led by an occupational therapist. The classes will focus on promoting modifying daily activities, habits, roles, and routines to promote healthy lifestyles for individuals with type 2 diabetes.
62802183|NCT04758702|EXPERIMENTAL|GROUP 1|L-PRF membranes will be placed on the palatal donor site to help stabilizing the blood clot and release of growth factors that help in deceasing the discomfort wound healing.
62802184|NCT04758702|EXPERIMENTAL|GROUP 2|H-PRF membranes will be placed on the palatal donor site to help stabilizing the blood clot and release of growth factors that help in deceasing the discomfort wound healing.
62802185|NCT04758702|EXPERIMENTAL|GROUP 3|A surgical stent will be delivered to cover the surgical site and apply pressure on the wound site.
62802186|NCT06396234|EXPERIMENTAL|Safe VLM|The device will be placed after patient is anesthetized. Following placement, the glottis will be observed and endotracheal tube will be placed.
62802187|NCT06396234|ACTIVE_COMPARATOR|Video laryngoscopy|Following anesthetic induction, endotracheal intubation will be performed with a video laryngoscope.
62802188|NCT06396234|EXPERIMENTAL|SaCo VLM|The device will be placed after patient is anesthetized. Following placement, the glottis will be observed and endotracheal tube will be placed.
62027900|NCT05382416|EXPERIMENTAL|Peer Toolkit Training|Participants assigned to this arm will attend online or in-person trainings on the SHARE! Peer Toolkit, which requires 60 hours of time to be completed over 10 weeks.
62027901|NCT05382416|NO_INTERVENTION|Wait-list Control|The wait-list control will continue practice as usual and not receive peer toolkit training until after the follow-up data collection.
62027902|NCT04800029|EXPERIMENTAL|TIPS Alone|The TIPS synchronous telehealth protocol will consist of (a) two-way televideo evaluation with enhanced suicide risk components, performed by a Masters-level evaluator from Community HealthLink, and (b) telephone consultation and, in some cases, televideo evaluation by a psychiatrist for patients the evaluator judges should be admitted. The primary evaluation will gather data form the ED providers, patient, and any other collateral sources available. The core of the evaluation itself will consist of Community HealthLink's existing standard adult emergency mental health evaluation, which is a semi-structured evaluation focused primarily on informing a disposition decision on whether to admit the patient to a psychiatric unit. The evaluators will use this same evaluation to guide the telehealth evaluation.
62027903|NCT04800029|EXPERIMENTAL|TIPS and ED-SAFE|"Half of the ED discharged patients with suicide risk will also be invited to receive post-discharge telephone counseling originally developed by Principal Investigator in a previous study, Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE). The participant will receive three calls, clustered within three months of the index visit, with some flexibility to continue beyond that if desired. These coaching calls will still follow the original structure and content from ED-SAFE, with modifications guided by study investigators."
62027904|NCT04800029|ACTIVE_COMPARATOR|No intervention, Treatment as Usual|No study related intervention, just monitoring of current practices used to provide suicide-related care in the non-intervention EDs.
62027905|NCT04985591|EXPERIMENTAL|liposuction group|
62027906|NCT04985591|PLACEBO_COMPARATOR|Other plastic surgery group|
62027907|NCT01318187|EXPERIMENTAL|Paracetamol|
62027908|NCT01318187|ACTIVE_COMPARATOR|Morphine|
62027909|NCT01427075|EXPERIMENTAL|lateral pharyngoplasty|lateral pharyngoplasty
62027910|NCT01752192|EXPERIMENTAL|Telerehabilitation programme|Telerehabilitation programme: Each patient will use a telehealth monitor and measure blood pressure, pulse and weight once or twice a week over a 3 months periods with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital step-counter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with healthcare professionals. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound. The patients are randomised in block of different sizes to follow rehabilitation from hospital, healthcare center or a callcenter.
62027911|NCT01752192|NO_INTERVENTION|Control group traditional rehabilitation|The control group of heart patients follow traditional rehabilitation activities for a period of 3 months.The patients are randomised in block of different sizes to follow rehabilitation from hospital, healthcare center or a callcenter.
62027912|NCT05132699|ACTIVE_COMPARATOR|Cannabidiol (CBD)|Epidiolex oral solution 500mg (5ml) per day
62027913|NCT05132699|PLACEBO_COMPARATOR|Placebo|Placebo oral solution 5ml per day
62027914|NCT06279221||Japanese participants with alopecia areata|Japanese participants with alopecia areata
62590170|NCT02272907|EXPERIMENTAL|Buttressed stapling|"The specimen will be stapled utilizing the same stapling device, with Seamguard applied as a buttress. We will use the standard methodology to apply Seamguard as illustrated in the company's Instructions for Use."
62226962|NCT04685057|EXPERIMENTAL|Probiotic|This arm will receive probiotic for 6 months then will keep receiving probiotic for 6 more months.
62226963|NCT04805190|EXPERIMENTAL|Pain Catastrophizing Reduction Group|This group will be assigned to a 30-minute, single-session cognitive-behavioral intervention designed to reduce pain catastrophizing.
62590171|NCT02272907|ACTIVE_COMPARATOR|No reinforcement|Data will be collected on staple lines without any reinforcement as a baseline for leak pressure.
62226964|NCT04805190|ACTIVE_COMPARATOR|Pain Education Group|This group will receive general information about the neurobiology of pain and knee OA.
62226965|NCT00839657|EXPERIMENTAL|1|Genotype-guided dosing algorithm for warfarin
62226966|NCT00839657|ACTIVE_COMPARATOR|2|Clinical-guided dosing algorithm for warfarin
62419856|NCT06636721|EXPERIMENTAL|Behavioral Intervention|Participants will engage in a 5-session protocol, to be delivered in an individual therapy setting, via telehealth or in-person. The program will integrate aspects of Cognitive Behavioral Therapy and Acceptance and Commitment Therapy.
62419857|NCT03634007|EXPERIMENTAL|Cohort 1: 1.4 x 10^10 gc/mL CSF|Participants will receive 1.4 x 10\^10 gc/mL CSF of LX1001.
62590172|NCT04588051|EXPERIMENTAL|Cabozantinib|
62590173|NCT06668844|EXPERIMENTAL|First arm|Endoscopic direct Draf IIa (Carolyn' window approach) frontal sinusotomy
62802189|NCT00587158|OTHER|Immunosuppression without paricalcitol (control)|Subjects will receive the standard immunosuppressive therapies consisting of induction therapy with Alemtuzumab (Campath®) and Methylprednisolone (Solumedrol®), then maintained with corticosteroid avoidance using Mycophenolate Mofetil (Cellcept®) and Tacrolimus (Prograf®).
62590174|NCT06668844|ACTIVE_COMPARATOR|Second arm|Endoscopic angled Draf IIa frontal sinuaotomy
62802190|NCT00587158|ACTIVE_COMPARATOR|Immunosuppression with paricalcitol|Subjects will receive the standard immunosuppressive therapy consisting of induction therapy with Alemtuzumab (Campath®) and Methylprednisolone (Solumedrol®), then maintained with corticosteroid avoidance using Mycophenolate Mofetil (Cellcept®) and Tacrolimus (Prograf®). In addition, subjects will receive the study medication paricalcitol (Zemplar®).
62802191|NCT01522716|EXPERIMENTAL|Mesenchymal stromal cell treatment|
62419858|NCT03634007|EXPERIMENTAL|Cohort 2: 4.4 x 10^10 gc/mL CSF|Participants will receive 4.4 x 10\^10 gc/mL CSF of LX1001.
62590175|NCT05061277|EXPERIMENTAL|Recifercept|A 300 mg single subcutaneous (SC) dose of recifercept for the treatment phase of study
62802192|NCT05743803||Before|This group will undergo their preoperative fasting period as standard care.
62590176|NCT00767728|ACTIVE_COMPARATOR|1|Mesalamine pellets
62590177|NCT00767728|PLACEBO_COMPARATOR|2|Placebo
62802193|NCT05743803||After|This group will undergo their preoperative fasting period after the sensitization campaign about preoperative fasting rules.
62802194|NCT02610777|ACTIVE_COMPARATOR|Azacitidine 75 mg/m^2|Azacitidine 75 mg/m\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).
62802195|NCT02610777|EXPERIMENTAL|Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2|Azacitidine 75 mg/m\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 and pevonedistat 20 mg/m\^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).
62419859|NCT03634007|EXPERIMENTAL|Cohort 3: 1.4 x 10^11 gc/mL CSF|Participants will receive 1.4 x 10\^11 gc/mL CSF of LX1001.
62419860|NCT03634007|EXPERIMENTAL|Cohort 4: 1.4 x 10^14 gc (fixed dose)|Participants will receive 1.4 x 10\^14 gc (fixed dose; approximately 3.4 × 10\^11 gc/mL CSF based on an average CSF volume of 409 mL) of LX1001.
62590178|NCT05046379||Patients with Fabry disease|Adult men and women with well characterized Fabry disease
62590179|NCT05046379||Healthy controls (with no Fabry disease)|Adult men and women from the endocrinology and nephrology in- or out-patient clinic
62590180|NCT05622058|EXPERIMENTAL|ALRN-6924 Dose plus TAC|ALRN-6924 plus Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
62590181|NCT01062542||Breast Cancer Survivors|
62590182|NCT01062542||Pediatric Cancer Survivors|
62590183|NCT01062542||Control group|
62590184|NCT05452499|EXPERIMENTAL|Intervention group|
62590185|NCT06216808|EXPERIMENTAL|Laparoscopic Renal Denervation|"Intervention:~Device: HyperQure Renal Denervation System"
62590186|NCT03476408|EXPERIMENTAL|Single Group Correlation|Correlation between these topics.
62419861|NCT05047237|NO_INTERVENTION|Control|Subjects in this arm will receive standard of care treatment with no intervention. They will receive month 6 follow up.
62419862|NCT05047237|NO_INTERVENTION|Active Decliners|Subjects who decline intervention. Standard of care treatment with month 6 follow up.
62590187|NCT00964990|EXPERIMENTAL|001|JNJ-42160443 SC injection (1 3 or 10 milligrams) once every 28 days
62590188|NCT00964990|PLACEBO_COMPARATOR|002|Placebo SC injection once every 28 days
62590189|NCT06445842|EXPERIMENTAL|Exercise Group|This group will perform exercises three times a week for eight weeks, with each session lasting approximately 45 minutes.
62590190|NCT06445842|ACTIVE_COMPARATOR|Non-Exercise Group|This group will maintain their sedentary lifestyle and will not make any changes to their diet or activity levels during this period
62802196|NCT05617508|PLACEBO_COMPARATOR|Placebo|Placebo, no active ingredients. Administered in capsule form twice daily for the duration of the trial (12 weeks).
62027915|NCT05168241|EXPERIMENTAL|1.the song/melodica group|"15 patients in the song/melodica group. Pre-tests were applied to the song/melodica group in the first interview, and training was given according to Pender's Health Promotion Model. In addition to the trainings, the experimental group was given a total of 40 minutes twice a day, a total of 2 sessions, melodica training for the melodica group, and song activity for the singing group. In addition, the song/melodica group was encouraged to work at home for at least 20 minutes every day by providing the necessary motivation for singing or playing the melodica. The patient was asked to record his practices by keeping a diary.~Two follow-ups were made by phone every 15 days, and the final tests were done face-to-face after 15 days. It tooks 10 weeks in total."
62590191|NCT04614922|EXPERIMENTAL|Acceptance and Commitment Therapy|Participation in a 4 week group program based on Acceptance and Commitment Therapy, individual councelling and home lessions.
62027916|NCT05168241|OTHER|2. the control group|15 patients in the control group. The control group was given pre-tests in the first interview, they were trained according to Pender's Health Promotion Model, they were followed up twice every 15 days by phone, and the post-tests were done face-to-face after 15 days, It tooks 10 weeks in total.
62027917|NCT03411655|ACTIVE_COMPARATOR|Ambu® Aura-ITM|
62027918|NCT03411655|ACTIVE_COMPARATOR|Ambu Aura GainTM|
62027919|NCT04084808|EXPERIMENTAL|Maple Syrup|A maple syrup solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
62027920|NCT04084808|EXPERIMENTAL|Maple sap|A maple sap solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
62419863|NCT05047237|EXPERIMENTAL|Active Intervention|Subjects are mailed Information about Type 2 Diabetes Mellitus (T2DM) Guidelines and Appointment Information (Face to face \[F2F\] or Telehealth). They attend up to 3 pharmacist visits, depending on if they reach target glucose levels. And they attend interviews. They also have month 6 follow up.
62590192|NCT04614922|NO_INTERVENTION|control group|Standard care, i.e. follow-up as needed, to some degree dependent on current capacity of therapists.
62590193|NCT05044546|EXPERIMENTAL|Aim 1 and secondary aim 2 (focus group)|Participants participate in focus group over 60-90 minutes. Participants who completed and dropped out of postpartum treatment also participate in a focus group.
62590194|NCT05044546|EXPERIMENTAL|Aim 3 Group I (BA)|Participants participate in smoking cessation counseling over 15 minutes and BA counseling sessions over 45 minutes once a week for 10 weeks to pilot test delivery via smartphone videoconferencing and to conduct process evaluation of technical issues in use of smartphones.
62590195|NCT05044546|EXPERIMENTAL|Aim 3 Group II (HW)|Participants participate in smoking cessation counseling over 15 minutes and health and wellness education counseling sessions over 45 minutes once a week for 10 weeks to pilot test delivery via smartphone videoconferencing and to conduct process evaluation of technical issues in use of smartphones.
62590196|NCT05044546|EXPERIMENTAL|Aim 4 Group III (BA)|Participants participate in 8-14 smoking cessation counseling over 15 minutes and BA counseling sessions over 45 minutes every 2-3 weeks till the end of the pregnancy. Following birth, participants also participate in 4 additional sessions within the first 6 weeks, then that last 4 evenly distributed across 10 weeks.
62802197|NCT05617508|EXPERIMENTAL|Dietary Supplement: NR 1000 mg group|Nicotinamide Riboside (NR) 1000mg total daily. Administered in capsule form in doses of 500mg twice daily for the duration of the trial (12 weeks).
62802198|NCT05617508|EXPERIMENTAL|Dietary Supplement: NR dose escalation group|Nicotinamide Riboside (NR) dose escalation group: 1000mg NR daily in doses of 500mg twice daily (week 1 - week 4), 2000mg NR daily in doses of 1000mg twice daily (week 5 - week 8), 3000mg NR daily in doses of 1500mg twice daily (week 9 - week 12).
62802199|NCT04701333|EXPERIMENTAL|Cabergoline|After the completion of the surgical procedure or medical induction for the second-trimester abortion or fetal loss, the participant will be administered cabergoline 1mg orally with juice or water by the clinician or study investigator.
62802200|NCT04701333|PLACEBO_COMPARATOR|Placebo|After the completion of the surgical procedure or medical induction for the second-trimester abortion or fetal loss, the participant will be administered a placebo pill orally with juice or water by the clinician or study investigator.
62802201|NCT00555880|EXPERIMENTAL|1|
62802202|NCT00555880|PLACEBO_COMPARATOR|2|
62802203|NCT02535143|EXPERIMENTAL|Test Group|Group will prepare a test cavity in an acrylic block. They will receive 250 ml of a commercially available energy drink containing caffeine and taurine (Red Bull, Red Bull GmBh Austria) three hours after the last meal. The participants will then be required to perform a post intervention test cavity preparation 30 minutes after consuming the drink.
62802204|NCT02535143|PLACEBO_COMPARATOR|Control Group|Group will prepare a test cavity in an acrylic block. They will receive 250ml of a commercially available carbonated apple juice (Appy Fizz, Parle Agro, Mumbai, India) three hours after the last meal. The participants will then be required to perform a post intervention test cavity preparation 30 minutes after consuming the drink.
62802205|NCT00436995|OTHER|Single|
62802206|NCT00487357||MATCh Parents' Supplemental Survey|Parent/Guardian Survey
62027921|NCT04084808|ACTIVE_COMPARATOR|Glucose|A glucose solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
62802207|NCT04627155|EXPERIMENTAL|7mg dose group|
62027922|NCT04084808|ACTIVE_COMPARATOR|Sports drink|A commercial sports drink of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
62802208|NCT04627155|EXPERIMENTAL|14mg dose group|
62802209|NCT00985465|EXPERIMENTAL|Pn-Pn group|subjects from the Pn-Pn group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in the Malian centre of study NCT00678301, receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A
62802210|NCT00985465|EXPERIMENTAL|Zil-Pn group|subjects from the unprimed group of the NCT00678301 Malian study centre, not previously vaccinated with any pneumococcal vaccine, receiving two doses of pneumococcal conjugate vaccine GSK1024850A
62027923|NCT04084808|PLACEBO_COMPARATOR|Water|A solution containing stevia (sugar substitute) labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
62419864|NCT06307678|EXPERIMENTAL|calcium silicate based medicament|"Root canal lengths were determined by an electronic apex locator with a 15-K file R25 and R50 Reciproc files were used at working lengths to complete the canal preparation. During instrumentation, the root canals were irrigated with 2 mL 1% NaOCl. To obtain the first samples, 3 sterile paper points were placed into the root canals beyond the 2-mm root apex and were kept in position for 60 seconds. Thereafter, the paper points were cut 4 mm from the tip30.~Afterward, root canals were dried with paper points, and calcium silicate based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length. Next, the coronal cavities were restored with temporary material.~Seven days later, the medication was mechanically removed using a master apical file. Subsequently, root canals were irrigated.The final samples were collected from the interstitial fluid of the apical tissue as previously described."
62590197|NCT05044546|EXPERIMENTAL|Aim 4 Group IV (HW)|Participants participate in 8-14 smoking cessation counseling over 15 minutes and health and wellness education counseling sessions over 45 minutes every 2-3 weeks till the end of the pregnancy. Following birth, participants also participate in 4 additional sessions within the first 6 weeks, then that last 4 evenly distributed across 10 weeks.
62590198|NCT03933696|ACTIVE_COMPARATOR|Active Lighting Intervention|"The TLI will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. Combining spectrum and light level, TLI will allow us to: (a) use a light source that will stimulate the circadian system, and (b) provide the participants with options as to how the light treatment will be delivered. The investigators will deliver at least 300-400 lux at the eye of the bluish-white light during the day (CS of 0.4 or greater).~The lighting intervention will be in place for 24 weeks"
62590199|NCT03933696|PLACEBO_COMPARATOR|Placebo Lighting Intervention|The placebo condition light source will be a warm yellow - white (2700 - 3000 K) source providing 50 -100 lux at the eye. The lighting intervention will be in place for 24 weeks.
62802211|NCT00872599|PLACEBO_COMPARATOR|Placebo, then fenofibrate|Randomized study of fenofibrate versus placebo during high salt diet
62802212|NCT00872599|PLACEBO_COMPARATOR|Fenofibrate, then placebo|Randomized study of fenofibrate versus placebo during high salt intake.
62802213|NCT05874024||Placement 6 hours|double balloon catheter placement for 6 hours
62802214|NCT05874024||Placement 12 hours|double balloon catheter placement for 12 hours
62590200|NCT03677336|OTHER|Group l: 1st cycle MVP/placebo OD|"2 cycles of controlled ovarian stimulation, dual triggering, oocyte retrieval (OR) and LPS, with an interval period of 2 to 12 months. The only difference of the second cycle being the other LPS study medication as compared to the first cycle.~* 1st cycle: Start on day of oocyte retrieval (OR) (=d1): Dydrogesterone Oral Tablet 10 mg 3 times daily + Placebo micronized vaginal progesterone 200 mg capsules 3 times daily, for 8 days.~* 2nd cycle: Start on day of oocyte retrieval (OR) (=day 1): 'Micronized Progesterone 200 mg intravaginal capsules 3 times daily + placebo 'Dydrogesterone Oral Tablet 10 mg 3 times daily, for 8 days."
62802215|NCT01463462||Electronic Catheter Stethoscope|
62802216|NCT01303939|OTHER|Glaucoma Patients|Patients who were outliers from two previous studies: Assessment of Ability Related to Vision (AARV) or Assessment of Disability Related to Vision (ADREV) with mini mental status exam score of 25 or higher underwent magnetic resonance imaging (MRI) of the brain to look at structures and volume.
62802217|NCT01303939|OTHER|Control Patients|Age, gender and race matched (to each glaucoma patient) group of healthy individuals with no ocular diseases with mini mental status exam score of 25 or higher underwent magnetic resonance imaging (MRI) of the brain to look at structures and volume.
62802218|NCT02059226|EXPERIMENTAL|Internet-based CBT|Internet-based cognitive behavioural therapy
62802219|NCT02059226|ACTIVE_COMPARATOR|Internet-based resource page|Static webpage
62802220|NCT02507388|EXPERIMENTAL|Brolucizumab 3 mg|Brolucizumab 3 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
62027924|NCT01638923|EXPERIMENTAL|Arm 1|
62027925|NCT01638923|PLACEBO_COMPARATOR|Arm 2|
62027926|NCT02084966|EXPERIMENTAL|OCT Imaging|OCT imaging of the kidneys prior to and following their transplant
62802221|NCT02507388|EXPERIMENTAL|Brolucizumab 6 mg|Brolucizumab 6 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
62802222|NCT05912764|EXPERIMENTAL|Early home return arm|Nurses will coordinate the patients' care prior to their intervention and when they leave the Clinics.
62802223|NCT05912764|NO_INTERVENTION|Standard Of Care arm|Patients will not receive any support before and after intervention and hospital leave
62802224|NCT02673918|EXPERIMENTAL|Part 1: Rehabilitation after surgery for breast cancer|Home-based upper-body rehabilitation with online support
62802225|NCT02673918|EXPERIMENTAL|Part 2: Rehabilitation after radiation for breast cancer|Home-based upper-body rehabilitation with online support
62802226|NCT00818792|ACTIVE_COMPARATOR|Drug-eluting stent Xience V|
62802227|NCT00818792|ACTIVE_COMPARATOR|Bare-metal stent Vision|
62027927|NCT00158743|ACTIVE_COMPARATOR|Digoxin immune fab|Digibind treatment plus standard of care
62027928|NCT00158743|PLACEBO_COMPARATOR|placebo (sodium chloride)|
62027929|NCT01756625||First line WT KRAS mCRC|
62027930|NCT05062928|EXPERIMENTAL|Virtual coaching group|In this group, the virtual coach will train and assess.
62419865|NCT06307678|ACTIVE_COMPARATOR|calcium hydroxide based medicament|"Root canal lengths were determined by an electronic apex locator with a 15-K file R25 and R50 Reciproc files were used at working lengths to complete the canal preparation. During instrumentation, the root canals were irrigated with 2 mL 1% NaOCl. To obtain the first samples, 3 sterile paper points were placed into the root canals beyond the 2-mm root apex and were kept in position for 60 seconds. Thereafter, the paper points were cut 4 mm from the tip30.~Afterward, root canals were dried with paper points, and calcium hydroxide based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length. Next, the coronal cavities were restored with temporary material.~Seven days later, the medication was mechanically removed using a master apical file. Subsequently, root canals were irrigated.The final samples were collected from the interstitial fluid of the apical tissue as previously described."
62419866|NCT04275388||Xiyanping injection +other drugs|Drug: Xiyanping injection Xiyanping injection: 10-20ml daily, Qd, the maximum daily dose does not exceed 500mg (20mL) Other drugs: Lopinavir tablet or Ritonavir tablet;Alpha-interferon nebulization;Abidor Hydrochloride
62590201|NCT03677336|OTHER|Group ll: 1st cycle placebo MVP/OD|"2 cycles of controlled ovarian stimulation, dual triggering, oocyte retrieval (OR) and LPS, with an interval period of 2 to 12 months. The only difference of the second cycle being the other LPS study medication as compared to the first cycle.~* 1st cycle: Start on day of oocyte retrieval (OR) (=day 1): Micronized Progesterone 200 mg intravaginal capsules 3 times daily + placebo Dydrogesterone Oral Tablet 10 mg 3 times daily, for 8 days.~* 2nd cycle: Start on day of oocyte retrieval (OR) (=day 1): Dydrogesterone Oral Tablet 10 mg 3 times daily + Placebo micronized progesterone 200 mg intravaginal capsules 3 times daily, for 8 days."
62590202|NCT05238870||Clinicians (interviewees) from Ghent University Hospital, Belgium|Semi-structured interviews with clinicians
62590203|NCT05238870||Clinicians (interviewees) from Brussels University Hospital, Belgium|Semi-structured interviews with clinicians
62590204|NCT05238870||Clinicians (interviewees) from Orebro University Hospital, Sweden|Semi-structured interviews with clinicians
62802228|NCT02726620|EXPERIMENTAL|Hypotension decision support|"The intervention period. Several decision support elements are implemented to notify anesthesia providers: attending anesthesiologists and in-room anesthesia providers of intraoperative hypotension (threshold of a mean arterial pressure below 60 mmHg). Two types of decision support will be implemented: near real-time decision support and feedback emails.~Near real-time decision support elements will notify the anesthesia providers of a blood pressure drop below the threshold and display the associated increased risk of acute kidney injury. The notification is presented through the pager system for attending anesthesiologists and through the anesthesia information management system for the in-room anesthesia provider.~All providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension that is associated with an increased risk of organ injury due to organ ischemia."
62802229|NCT02726620|ACTIVE_COMPARATOR|Usual care group|The 'before' period - or historic control group - during which no decision support for intraoperative hypotension was being used, also known as 'usual care'. This is the three year period prior to the intervention period (the 'Intraoperative hypotension decision support' arm).
62802230|NCT01226225|EXPERIMENTAL|Aerobic interval training|
62802231|NCT01226225|ACTIVE_COMPARATOR|Moderate endurance training|
62802232|NCT01116401|EXPERIMENTAL|GnRH Agonist Injection|We will be administering an injection of leuprolide acetate (a GnRH agonist) to all participants.
62802233|NCT04797039||MR guided cryoablation|Focal MR guided cryoablation for low- to intermediate-grade prostate cancer
62802234|NCT03823183|EXPERIMENTAL|Multi-domain training|Group that receives cognitive training and physical training
62027931|NCT05062928|NO_INTERVENTION|Human instructor group|In this group, a human instructor will train, but the virtual coach will assess.
62027932|NCT01130766|EXPERIMENTAL|stereotactic radiosurgery (SRS)|
62027933|NCT01130766|NO_INTERVENTION|observation|
62027934|NCT04740294|EXPERIMENTAL|Magnesium Sulfate|The patient will receive a bolus of 50mg/kg MgSO4 over twenty minutes.
62590205|NCT06024096|ACTIVE_COMPARATOR|seasonal quadrivalent influenza vaccine (QIV)|Participants will receive the seasonal QIV
62802235|NCT03823183|EXPERIMENTAL|Cognitive training|Group that receives cognitive training and physical control activity
62802236|NCT03823183|EXPERIMENTAL|Physical activity|Group that receives control cognitive activity and physical training
62027935|NCT04740294|PLACEBO_COMPARATOR|Placebo|The patient will receive a bolus of Normal Saline over twenty minutes.
62419867|NCT04275388||other drugs|Lopinavir tablet or Ritonavir tablet;Alpha-interferon nebulization;Abidor Hydrochloride
62802237|NCT03823183|ACTIVE_COMPARATOR|Active control|Group that receives cognitive control activity and physical control activity
62802238|NCT04929535|EXPERIMENTAL|30% hydrogen peroxide|30% hydrogen peroxide liquid topical application. 2 drops (0.10 ml) of hydrogen peroxide solution per centimeter of lesion. Once every week for continuous 4 weeks. If there is complete clinical response, further hydrogen peroxide will not be done.
62027936|NCT03885453||Panic Disorder / Agoraphobia|Patients with Panic Disorder / Agoraphobia as major diagnosis
62027937|NCT03885453||Depression|Patients with Depression as major diagnosis
62027938|NCT04729855||colorectal cancer patients|"Colorectal cancer patients( n = 30 ) from stage I-III with the following criteria:-~a. Inclusion criteria:~* No sex predilection.~* Age (25-65 yr).~* Colorectal carcinoma confirmed by histopathological examination"
62027939|NCT04729855||Healthy controls ( n = 30)|matched as regarding age and sex as much as possible with cases.
62419868|NCT05903924|EXPERIMENTAL|Tradipitant High Dose|
62419869|NCT05903924|PLACEBO_COMPARATOR|Placebo|
62419870|NCT05903924|EXPERIMENTAL|Tradipitant Low Dose|
62419871|NCT00981019||mortality*incidence*5-year survival*early stage|Physicians will be faced in scenarios about screening with information on mortality and 5-year survival, followed by information on mortality\*incidence and 5-year survival\*early stage in a random order.
62419872|NCT06700369||Taxanes combined with carboplatin|Taxane (paclitaxel, liposome paclitaxel, docetaxel, albumin paclitaxel), carboplatin combined with trastuzumab and pertuzumab, 6 cycles in total
62419873|NCT06700369||Taxanes|Taxane (paclitaxel, liposome paclitaxel, docetaxel, albumin paclitaxel) with trastuzumab and pertuzumab, 6 cycles in total
62419874|NCT03647280|EXPERIMENTAL|Abraxane Combined With Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
62419875|NCT01053078|EXPERIMENTAL|Naltrexone|
62419876|NCT01053078|PLACEBO_COMPARATOR|Placebo|
62802239|NCT04929535|PLACEBO_COMPARATOR|3% hydrogen peroxide|3% hydrogen peroxide liquid topical application. 2 drops (0.10 ml) of hydrogen peroxide solution per centimeter of lesion. Once every week for continuous 4 weeks. If there is complete clinical response, further hydrogen peroxide will not be done.
62802240|NCT01685775|EXPERIMENTAL|Transvaginal/transumbilical cholecystectomy|Transvaginal/transumbilical group: we will use a 5 mm trocar in the umbilicus and a 10 mm trocar together with a 5 mm seizing forceps through the posterior vaginal vault to perform the cholecystectomy in the Zornig style
62802241|NCT01685775|ACTIVE_COMPARATOR|Needlescopic cholecystectomy|Needlescopic cholecystectomy with 3 trocars: we will use two 2-3 mm working trocars and one 10 mm optic trocar, its access is also used for extraction of the gallbladder
62802242|NCT02677935|EXPERIMENTAL|Intervention|community support program
62802243|NCT00631605||1|
62802244|NCT00631605||2|
62027940|NCT05524194|EXPERIMENTAL|Experimental: 6MW3511|Subjects will receive 6MW3511 by intravenous administration.
62419877|NCT06033183|EXPERIMENTAL|Radiosensitivity|Patients who agree to participate in this research study will have blood sample collected to perform the RadioDtect test
62419878|NCT05343793|EXPERIMENTAL|Path 1|Enhanced Monitoring and Feedback
62419879|NCT05343793|EXPERIMENTAL|Path 2|Enhanced Monitoring and Feedback + NIATx/MAT Academy
62419880|NCT05343793|EXPERIMENTAL|Path 3|Enhanced Monitoring and Feedback + NIATx/MAT Academy + NIATx External Facilitation
62419881|NCT05343793|EXPERIMENTAL|Path 4|Enhanced Monitoring and Feedback + NIATx/MAT Academy + NIATx Internal Facilitation
62419882|NCT05343793|EXPERIMENTAL|Path 5|Enhanced Monitoring and Feedback + NIATx/MAT Academy + NIATx Internal Facilitation + NIATx External Facilitation
62419883|NCT00585039|EXPERIMENTAL|A|levalbuterol nebulization
62419884|NCT05919329|EXPERIMENTAL|Cohort 1: CRPC|Patients with CRPC will receive 18F-DCFPyL PET prior to start of therapy (standard of care), then again 8 days and 28 days after initiation of hormonal therapy.
62419885|NCT05919329|EXPERIMENTAL|Cohort 2: CSPC|Patients with CSPC will receive 18F-DCFPyL PET prior to start of therapy (standard of care), then again 8 days and 28 days after initiation of hormonal therapy.
62419886|NCT01984619||Blunt Tip Cannula|
62419887|NCT04917029|ACTIVE_COMPARATOR|Active:Group A|Group A: receive 40 ml bupivacaine 0.25% +5 ml placebo in FICB perineurally in generally anaesthetized patients with intravenous infusion of 0.5 µg/kg/h of Dexmedetomidine.
62802245|NCT01347528|EXPERIMENTAL|TELEmonitoring intervention|
62027941|NCT05641493|EXPERIMENTAL|HLX208 combined HLX10|"For the phase Ib study, HLX208 is administered orally at two dose levels of 600mg BID or 900 mg BID. And HLX10 is administered intravenously at a fixed dose of 300mg every 3 weeks.~For the phase II study, HLX208 is administered orally with the RP2D dose. And HLX10 is administered intravenously at a fixed dose of 300mg every 3 weeks."
62027942|NCT01470755|OTHER|salbutamol - dose 1|Metered dose inhaler, 100µg+300µg per puff, administered one day
62027943|NCT01470755|OTHER|Salbutamol - dose2|Metered dose inhaler, 100µg+500µg per puff, administered one day
62027944|NCT01470755|OTHER|Salbutamol - dose3|Metered dose inhaler, 200µg+600µg per puff, administered one day
62802246|NCT01347528|NO_INTERVENTION|Usual care|
62027945|NCT01470755|OTHER|salbutamol - dose4|Metered dose inhaler, 200µg+200µg per puff, administered one day
62027946|NCT05591352|PLACEBO_COMPARATOR|Placebo sachet|consume 1 sachet per day
62419888|NCT04917029|ACTIVE_COMPARATOR|(Group B|Group B: receive FICB with dexmedetomidine 80µg diluted in 5 ml normal saline and 40 ml bupivacaine 0.25% added perineurally in generally anaesthetized patients without dexmedetomidine infusion.
62419889|NCT03438474|ACTIVE_COMPARATOR|Arm A standard surgical procedure|"Standard surgical procedure for endometrial cancer:~total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)"
62419890|NCT03438474|EXPERIMENTAL|Arm B systematic lymphadenectomy (LNE)|"In addition to standard procedures as defined for Arm A:~systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels"
62419891|NCT03797573|ACTIVE_COMPARATOR|active tDCS|Patients will receive tDCS (bilateral fronto-central stimulation) during 20 minutes preceded and followed by a clinical assessment (Modified Ashworth Scale and Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
62802247|NCT04936061|EXPERIMENTAL|High flow treatment|15 minute transnasal air flow therapy with the CoolStat active device as an abortive treatment for migraine attack.
62802248|NCT04936061|EXPERIMENTAL|Low flow treatment|15 minute transnasal air flow therapy with the CoolStat active device as an abortive treatment for migraine attack.
62802249|NCT04936061|SHAM_COMPARATOR|Sham flow ambient air|15 minute transnasal air flow therapy with the CoolStat sham device as an abortive treatment for migraine attack.
62027947|NCT05591352|EXPERIMENTAL|Chenopodium formosanum extracts sachet|consume 1 sachet per day
62027948|NCT06669260||TEThA technique|TEThA technique
62027949|NCT05499741|EXPERIMENTAL|Forehead Temperature-Regulating Therapy|Forehead Temperature-Regulating Therapy
62419892|NCT03797573|SHAM_COMPARATOR|sham tDCS|Patients will receive sham tDCS (5 seconds of stimulation) during 20 minutes preceded and followed by a clinical assessment (Modified Ashworth Scale and Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
62419893|NCT05495425|EXPERIMENTAL|NPC-12Y gel|NPC-12Y gel is containing 0.2% Sirolimus
62419894|NCT05495425|PLACEBO_COMPARATOR|NPC-12Y placebo gel|Placebo gel matched NPC-12Y gel
62802250|NCT04911894|EXPERIMENTAL|Phase Ia Dose-Escalation Stage: IBI321|
62802251|NCT03195816|EXPERIMENTAL|computerized Cognitive training|Experimental group will receive 1 year of a computer-based cognitive stimulation program.
62802252|NCT03195816|NO_INTERVENTION|MCI control group|The control group will receive a usual standard care without engagement in intervention
62802253|NCT02299726|EXPERIMENTAL|Active|spironolactone
62027950|NCT02073331||CorMatrix ECM|Data collection for information on the use of CorMatrix ECM for pericardial reconstruction
62027951|NCT02194049|EXPERIMENTAL|BKM 120, cisplatin, etoposide|Patients receive PI3K Inhibitor BKM120 PO QD on days 1-21, cisplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62027952|NCT02662842||FlowSmart Infusion set, then current set|Subjects will use the FlowSmart Infusion Set for a period of 9 to 11 days, then switch to their current infusion set for another period of 9 to 11 days. Subjects must use at least 3 sets during each Study Period then - Subjects will use their current infusion set for a period of 9 to 11 days, then switch to the FlowSmart infusion set for another period of 9 to 11 days. Subjects must use at least 3 sets during each Study Period.
62027953|NCT03935386|ACTIVE_COMPARATOR|Standard Compression|Standard multi-layer compression dressing with no graft or biologic material added
62027954|NCT03935386|ACTIVE_COMPARATOR|Standard Compression with application of human allograft|standard compression with application of a cryopreserved skin allograft (TheraSkin)
62027955|NCT00870805|EXPERIMENTAL|bilateral-ultrabrief ECT|Patients will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 3-4 times seizure threshold.
62027956|NCT00870805|ACTIVE_COMPARATOR|bilateral standard ECT|Patients will be treated with a standard (1.0ms) pulse with a bilateral placement at 1.5 times seizure threshold.
62027957|NCT00870805|EXPERIMENTAL|right-unilateral ultrabrief ECT|Patients will be treated with an ultrabrief (0.3ms) pulse with a right unilateral placement at 8 times seizure threshold.
62802254|NCT02299726|PLACEBO_COMPARATOR|Placebo|matching placebo to active study drug
62802255|NCT01088334||IVTE, follow-up|no malignancy at basal screening, no extensive screening
62802256|NCT01088334||IVTE, screening|No malignancy at basal screening, screening by means of CT-Chest/abdomen and mammography in women
62226967|NCT06337526||Children & Adolescents with Active CRPS|"Subjects between the ages of 10 and 18 years, who have CRPS diagnosed in a pediatric pain center or clinic and whose CRPS is presently active (i.e. unresolved), of either gender, and any ethnicity or racial group.~For 6 months subjects will wear an Apple Watch, transmitting physiologic and movement data to the investigators, will photograph their meals for AI analysis of content, and log their pain scores and episodes of pain flares, and independently the investigators will collect weather and environmental data in the subject's location. These data will be analyzed by AI to identify chronologic triggers of pain flares."
62226968|NCT02504944|EXPERIMENTAL|Propranolol 0.2% eye drops|Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%). The treatment will be started as soon as the diagnosis of stage 1 ROP is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days. Cardiovascular and respiratory parameters will be continuously monitored. Blood samplings checking metabolic, renal and liver functions will be performed periodically, as well as cardiac function, in order to verify the treatment safety. Propranolol concentrations will be measured on dried blood spots at the steady state (10th day). Serial ophthalmological evaluations will be planned to monitor the efficacy of the treatment, the ROP progression and the possible complications.
62802257|NCT04470635||Type 1 diabetes with gingivitis|Children with type 1 diabetes mellitus and gingivitis
62802258|NCT04470635||Type 1 diabetes with healthy gingiva|Children with type 1 diabetes mellitus and healthy gingiva
62419895|NCT05847569|ACTIVE_COMPARATOR|Group I (low dose belantamab mafodotin)|Patients receive low dose belantamab mafodotin intravenously (IV) on day 1 of each cycle. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. All patients undergo a CT scan, a MRI scan, or a PET/CT scan during screening and patients with plasmacytoma (a MM tumor in bone or soft tissue) also undergo imaging scans on study. Patients undergo bone marrow aspirate and biopsy during screening and on study as well as collection of blood samples throughout the trial.
62802259|NCT04470635||Healthy children with gingivitis|Systemically healthy children with gingivitis
62802260|NCT04470635||Healthy children and healthy gingiva|Systemically healthy children with healthy gingiva
62802261|NCT02232217|EXPERIMENTAL|Cognitive Behavior Therapy Sleep|Children in this arm will receive instructions on the use of 'coping thoughts.' Common elements across the CBTcs sessions include reviewing progress, setting goals for change, problem solving to address challenges/barriers, and reinforcing progress
62802262|NCT02232217|ACTIVE_COMPARATOR|Education Control|Children in this arm will receive sleep and dietary education, as well as general coping strategies and controls for staff attention and seasonal effects that could influence changes in sleep and health outcomes.
62802263|NCT01345760||Basal Cell Carcinoma|
62027958|NCT00870805|ACTIVE_COMPARATOR|right-unilateral standard ECT|Patients will be treated with a standard (1.0ms) pulse with a right unilateral placement at 5 times seizure threshold.
62027959|NCT03152552|EXPERIMENTAL|LIK066 2.5mg|Eligible participants randomized to this treatment arm received the LIK066 2.5mg dose regimen once daily for 36 weeks.
62027960|NCT03152552|EXPERIMENTAL|LIK066 10mg|Eligible participants randomized to this treatment arm received the LIK066 10mg dose regimen once daily for 36 weeks.
62802264|NCT01345760||Squamous Cell Carcinoma|
62802265|NCT01345760||Actinic Keratosis|
62802266|NCT01345760||healthy non-lesional skin|
62802267|NCT05625659|OTHER|DBT and CESM Diagnostic Imaging in Women with Dense Breasts|Interventional Diagnostic
62802268|NCT01290614|EXPERIMENTAL|Pharmacist intervention|
62802269|NCT01290614|ACTIVE_COMPARATOR|Control - usual care|Patients assigned to control will continue to receive care from their VA provider.
62802270|NCT02474563||Bortezomib, Melphalan, Prednisone (VMP) Group|Participants will not receive any intervention in this study. Participants receiving VMP therapy for MM that was not eligible for autologous stem cell transplantation will be enrolled in the study.
62027961|NCT03152552|EXPERIMENTAL|LIK066 50mg|Eligible participants randomized to this treatment arm received the LIK066 50mg dose regimen once daily for 36 weeks.
62027962|NCT03152552|ACTIVE_COMPARATOR|Empagliflozin|Participants randomized to this treatment arm received empagliflozin once daily for 36 weeks.
62027963|NCT03152552|PLACEBO_COMPARATOR|Placebo|Participants randomized to this treatment arm received LIK066 matching placebo and empagliflozin matching placebo.
62802271|NCT06263374|EXPERIMENTAL|Physiotherapy with self-rehabilitation including motor imagery|Patients will undergo maxillofacial rehabilitation, comprising a single 30-minute session per week during the first month post-surgery, followed by one session every two weeks for up to three months. In between these sessions, patients will participate in a self-rehabilitation program at home, involving jaw and tongue movements as well as massages, each lasting 5 minutes, three times a day. Compliance with the program will be monitored by the physiotherapist. The program has been standardized across all centers, ensuring consistency in this multicentric study.
62027964|NCT01184066|EXPERIMENTAL|ACTS Intervention|The intervention arm are the women who received the ACTS Intervention. It is a 45 minute intervention provided by a breast cancer survivor. The intervention includes a discussion of the patient's attitudes towards chemotherapy, communication strategies with providers, the recommended treatment in accordance with tumor size and tumor characteristics
62027965|NCT01184066|ACTIVE_COMPARATOR|Usual Care|This group receives care as usual.
62027966|NCT01032967|ACTIVE_COMPARATOR|Surgery, esophagectomy|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
62027967|NCT01032967|ACTIVE_COMPARATOR|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
62802272|NCT06263374|SHAM_COMPARATOR|Physiotherapy with self-rehabilitation including control task|Patients allocated to the control group will receive physiotherapy along with self-rehabilitation, incorporating a control task. The delivery of physiotherapy and self-rehabilitation will mirror that of the experimental group. The control task, substituting motor imagery, will involve completing Sudoku or crossword puzzles based on patient preference. (i.e., an equivalent duration to the motor imagery practice of the experimental group). The physiotherapist will ensure adherence to the rehabilitation and intervention protocols.
62802273|NCT01168349||Cohort|
62027968|NCT04587440|EXPERIMENTAL|Patient|"All patients will have a clinical examination before surgery and another 3 months after surgery, each including :~* A medical examination~* 3 pelvic inclination measurements (1 sitting, 1 lying and 1 standing). These measurements will be done by ultrasound devices.~* 2 EOS X-rays (1 standing and 1 sitting) of the lower limbs and spine~* Harris hip score~* Pain quantification thanks to an EVA scale~* hand-ground distance"
62027969|NCT02411721|EXPERIMENTAL|Animal assisted intervention|The Effects of Dog Intervention on Anxiety Levels in Children. The experimental group will receive standard training on the imaging process by the MRI technician plus intervention activity with a dog
62027970|NCT02411721|NO_INTERVENTION|control group|The control group will receive the standard training on the imaging process by the MRI technician.
62027971|NCT04032899|EXPERIMENTAL|L. fermentum CECT5716 3x109 ufc|Volunteers will take 1 capsule per day with L. fermentum CECT5716 3x109 cfu mixed with maltodextrin from week 28-32 of gestation up to 16 weeks after delivery.
62226969|NCT02748720|EXPERIMENTAL|RFM Visible|Patients will be randomize in other Group 1, where these parameters (from the device Respiratory Function Monitor) of lung mechanics would be visible by the rescuer (the usual parameters of PIP and PEEP will be visible). We adapt or change PIP using visible TVe.
62802274|NCT05404087||Pre-operative staging of breast cancer with CEBCT|Women who have been diagnosed with breast cancer and need to have a pre-operative staging and this will be done with contrast-enhanced breast CT.
62027972|NCT04032899|PLACEBO_COMPARATOR|Maltodextrin|Volunteers will take 1 capsule per day with maltodextrin from week 28-32 of gestation up to 16 weeks after delivery.
62027973|NCT02960529||extra-peritoneal high ligation of hernia|the 150 patients were subjected trans-umbilical single-port laparoscopic extra-peritoneal approach repair for inguinal hernia
62226970|NCT02748720|NO_INTERVENTION|RFM No Visible|Patients will be randomize in a Group 2, where the parameters of TVe and respiratory flow would not be visible by the rescuer (the usual parameters of PIP and PEEP will be visible). Always, in both groups, current recommendations ventilation measures included in cardiopulmonary resuscitation of newborns of the Spanish Society of Neonatology, based on international recommendations (1-3.5) apply. In turn, the results analyzed in two subgroups between 24 and 27 + 6 weeks gestational age and 28 to 32 + 6 weeks
62802275|NCT05404087||Follow-up of women with breast cancer treated with neo-adjuvant chemotherapy|Women who are selected for neo-adjuvant chemotherapy to reduce the size of the tumor need to be followed-up in order to evaluate the treatment response.
62802276|NCT02403999|EXPERIMENTAL|Test shampoo|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
62802277|NCT02403999|EXPERIMENTAL|Test bath foam|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
62802278|NCT02403999|EXPERIMENTAL|Test head to toe Wash|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
62802279|NCT04449627||Naturalistic cohort|Patients who were hospitalised between March and June from Covid19, who did not require treatment in intensive care, who at 8 weeks post discharge have symptoms of anxiety or depression. All patients are offered access to an audio based self help programme based on applied relaxation and mindfulness based cognitive therapy.
62802280|NCT03360435||Participants with transdermal patches|All study subjects will belong to the same group. This group will undergo bariatric surgery and will use a transdermal patch for vitamin and mineral supplementation post operatively. The transdermal patch will be the Patch MD MultiVitamin Plus patch
62027974|NCT02960529||intraabdominal high ligation of hernia|the 150 patients were subjected trans-umbilical single-port laparoscopic intraabdominal approach repair for inguinal hernia
62802281|NCT00415129|EXPERIMENTAL|Study Group 1|Vaccine with adjuvant
62802282|NCT00415129|EXPERIMENTAL|Study Group 2|Vaccine without adjuvant
62027975|NCT00740545|PLACEBO_COMPARATOR|2|
62027976|NCT00740545|EXPERIMENTAL|1|
62027977|NCT04838301|EXPERIMENTAL|Allo group|Allopregnanolone 4mg IV 30-minute infusion once per week for 12 months.
62027978|NCT04838301|PLACEBO_COMPARATOR|Control group|Placebo (normal saline) IV 30-minute infusion once per week for 12 months.
62027979|NCT00490646|EXPERIMENTAL|Arm A|trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m\^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.
62027980|NCT00490646|ACTIVE_COMPARATOR|Arm B|trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + docetaxel 100 mg/m\^2 IV over 1 hour once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.
62027981|NCT05222230|EXPERIMENTAL|FFP3 Respirator|Participants will wear FFP3 respirators during the study.
62027982|NCT04820673||Sarecycline|Eligible patients prescribed with commercially available sarecycline will be followed-up for 12 weeks post-initiation of treatment.
62027983|NCT01220557|EXPERIMENTAL|PRIMAS group|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
62027984|NCT01220557|ACTIVE_COMPARATOR|Control group|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
62590206|NCT06024096|ACTIVE_COMPARATOR|statin therapy and a seasonal quadrivalent influenza vaccine (QIV)|Participants randomized to the Statin + QIV arm will be asked to come back for an extra visit one month prior to the date of vaccination to start statin therapy.
62027985|NCT02000245|ACTIVE_COMPARATOR|verbal expression for compassion|verbal expression for compassion
62027986|NCT02000245|ACTIVE_COMPARATOR|verbal expression and touch|verbal expression and touch
62027987|NCT02000245|NO_INTERVENTION|control|control
62027988|NCT03882684||Cancer patients|The patients receive the surgery according to the indication of surgery. The diagnosis is confirmed by pathology of removed tissue. The result of imprinting detection are used as cancer group.
62027989|NCT03882684||Benign tumor and other disease patients|Patients ruled out the possibility of malignancy according to biopsy pathology are used as negative control.
62027990|NCT04584112|EXPERIMENTAL|Cohort A: Tiragolumab and Atezolizumab + Nab-paclitaxel|Participants with first-line metastatic TNBC will receive tiragolumab and atezolizumab on Day 1 of every 28-day cycle plus nab-paclitaxel on Days 1, 8, and 15 of every 28-day cycle.
62027991|NCT04584112|EXPERIMENTAL|Cohort B: Tiragolumab and Atezolizumab + Nab-pac-carbo-AC|Participants with early TNBC in the neoadjuvant setting, who are eligible for surgery, will receive tiragolumab and atezolizumab every 2 weeks (Q2W) in combination with nab-paclitaxel weekly (QW) and carboplatin every 3 weeks (Q3W) for four cycles, followed by tiragolumab and atezolizumab in combination with doxorubicin and cyclophosphamide Q2W with granulocyte colony-stimulating factor (G-CSF; filgrastim or pegfilgrastim) or granulocyte-macrophage colony-stimulating factor (GM-CSF) support for four doses.
62802283|NCT04184830|EXPERIMENTAL|tDCS arm|"Active stimulation:~Direct current will be transferred using a pair of saline-soaked surface sponge electrodes (5x7). For anodal stimulation of the left DLPFC the anode will be placed over the site of F3, according to the 10-20 international system for electroencephalogram electrode placement. The cathode will be placed over the right supraorbital area. A constant current of 2mA will be applied for 30 minutes, which will result in current density of 0.08 mA/cm².In order to avoid side effects, as a result of electrical transient (e.g. tingling and burning sensation), the current will be ramped for 10 seconds at the beginning and end of stimulation (Nitsche et al., 2008)."
62027992|NCT04584112|EXPERIMENTAL|Cohort B: Tiragolumab and Atezolizumab + Nab-pac-AC|Participantswith early TNBC in the neoadjuvant setting, who are eligible for surgery, will receive tiragolumab and atezolizumab Q2W in combination with nab-paclitaxel QW for 12 weeks, followed by tiragolumab and atezolizumab in combination with doxorubicin and cyclophosphamide Q2W with G-CSF (filgrastim or pegfilgrastim) or GM-CSF support for four doses.
62027993|NCT06636032|EXPERIMENTAL|AdMSC (CellReady®)|Different doses of AdMSC will be tested for a dose escalation (5.10\*7 and 10.10\*7 cells) and injected in the in the wall of the fistula
62027994|NCT04712812||Proband with Hereditary Spastic Paraplegia|The study population consists of male and female patients up to the age of 30 years old with a clinical and molecular diagnosis of hereditary spastic paraplegia and/or their family members of interest (if applicable).
62027995|NCT04236557|EXPERIMENTAL|Intervention|
62027996|NCT04236557|PLACEBO_COMPARATOR|Wait-list Control|
62027997|NCT05253625|EXPERIMENTAL|lullaby mother|The participant will listen to a lullaby recorded with his mothers voice.
62027998|NCT05253625|EXPERIMENTAL|lullaby female|The participant will listen to a lullaby recorded with a foreign female voice.
62027999|NCT05253625|NO_INTERVENTION|no lullaby|The participant will not listen to a lullaby.
62028000|NCT00991250|EXPERIMENTAL|SentoClone®|SentoClone®: Specific tumour-reactive lymphocytes located in lymph nodes directly draining primary tumours or metastases are identified and expanded. These lymphocytes are infused to the patient to treat metastatic disease.
62802284|NCT04184830|SHAM_COMPARATOR|tDCS sham|"Sham stimulation:~During the sham stimulation a pair of saline-soaked surface sponge electrodes (5x7) will be places on the scalp For sham stimulation of the left DLPFC the anode will be placed over the site of F3, according to the 10-20 international system for electroencephalogram electrode placement. The cathode will be placed over the right supraorbital area. A constant current of 2mA will be applied for 30 seconds.In order to avoid side effects, as a result of electrical transient (e.g. tingling and burning sensation), the current will be ramped for 10 seconds at the beginning and end of stimulation (Nitsche et al., 2008)."
62802285|NCT03940729|OTHER|PWID colonized with S aureus|Repeated chlorhexidin showers for PWID colonized with S aureus
62802286|NCT03579940|EXPERIMENTAL|Lasmiditan - Japanese|Single (50 milligram (mg), 100 mg, 200 mg, 400 mg) and repeated (2 × 200 mg) doses of Lasmiditan administered orally in up to three of three study periods.
62802287|NCT03579940|PLACEBO_COMPARATOR|Placebo - Japanese|Single and repeated (2 X placebo) doses of Placebo administered orally in up to one of three study periods.
62802288|NCT03579940|EXPERIMENTAL|Lasmiditan - Caucasian|Single (50 mg, 100 mg, 200 mg) dose of Lasmiditan administered orally in up to three of three study periods.
62802289|NCT03579940|PLACEBO_COMPARATOR|Placebo - Caucasian|Single dose of Placebo administered orally in up to one of three study periods.
62802290|NCT04171531|ACTIVE_COMPARATOR|Botox A® injection|A dose of 100 units of Botulinum toxin A will be injected into the bladder. Follow up visits at 2 weeks, 3 and 6 months post intervention to collect clinical and patient-reported outcomes.
62802291|NCT04171531|ACTIVE_COMPARATOR|Mid-urethral sling|Mid-urethral Sling Procedure includes retropubic as well as transobturator full length slings. Follow up visits at 2 weeks, 3 and 6 months post intervention to collect clinical and patient-reported outcomes.
62802292|NCT02181309|EXPERIMENTAL|Meloxicam low dose, fasted|
62802293|NCT02181309|EXPERIMENTAL|Meloxicam medium dose, fasted|
62802294|NCT02181309|EXPERIMENTAL|Meloxicam high dose, fed|
62802295|NCT02181309|ACTIVE_COMPARATOR|Meloxicam high dose, fasted|
62802296|NCT02892526||Vital wounds|from abdominoplasty of alive persons
62802297|NCT02892526||Post-mortem wounds|from autopsy of deceased persons
62802298|NCT04006093|EXPERIMENTAL|participants with normal renal function|
62802299|NCT04006093|EXPERIMENTAL|participants with end-stage renal disease|
62802300|NCT01593124|ACTIVE_COMPARATOR|Imiquimod, 2 doses, vaginally|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
62802301|NCT01593124|PLACEBO_COMPARATOR|Placebo|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
62802302|NCT01593124|ACTIVE_COMPARATOR|Nonoxynol-9|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
62028001|NCT00991250|ACTIVE_COMPARATOR|Temodal® or Dacarbazine Medac®|"To be decided by each centre as one of the following:~1. Temodal® (temozolomide)~2. Dacarbazine Medac® (dacarbazine) The reference treatment regimen should follow the general guiding principles for each of the two reference treatments."
62028002|NCT06162520||Congenital biliary dilatation|Patients with congenital biliary dilatation diagnosed according to the Japanese Study Group on Congenital Biliary Dilatation (JSCBD) guideline.
62028003|NCT06162520||Secondary biliary dilatation|Patients with secondary biliary dilatation attributed to choledocholithiasis or malignancies (hilar cholangiocarcinoma, pancreatic carcinoma, and distal cholangiocarcinoma).
62028004|NCT01947946|EXPERIMENTAL|Benra 30 mg q.4 Weeks|Fixed 30 mg dose of benralizumab (every 4 weeks)
62028005|NCT01947946|EXPERIMENTAL|Benra 30 mg - Placebo q.8 Weeks|Fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administered at the 4 week interim treatment visits to maintain blind).
62028006|NCT01947946|PLACEBO_COMPARATOR|Placebo|A (Dummy) injection
62028007|NCT02078323|ACTIVE_COMPARATOR|Linaclotide|Linaclotide 290micrograms q day 30 min before meal for a 10 week period
62590207|NCT05709028|EXPERIMENTAL|Oral fosfomycin|"* Children who have been diagnosed with an uncomplicated UTI will be administered a single dose of oral fosfomycin trometamol. Then, on Day 2 either;~  1. Stop if the child has clinically improved, or~ 2. Give a second dose of oral fosfomycin trometamol if the child has ongoing fever or clinical symptoms consistent with an uncomplicated UTI, or~ 3. Give an additional 8 days of oral fosfomycin trometamol with repeat doses every 48 hours (to make up a total 10-day treatment duration) if the child has evidence of a complicated UTI.~* Children who have been diagnosed with a complicated UTI will be administered repeat doses of oral fosfomycin trometamol every 48 hours until the child has received a total 10-day course of antibiotics with presumed or proven efficacy against the urinary pathogen."
62028008|NCT02078323|PLACEBO_COMPARATOR|placebo|Placebo q day 30 min before meal for a 10 week period
62028009|NCT01308216|EXPERIMENTAL|Transcranial low level laser therapy|Transcranial laser therapy is applied by automatic scanning over both hemispheres and the patients undergoing also a standard rehabilitation program based on therapeutic exercises.
62590208|NCT05709028|ACTIVE_COMPARATOR|Standard of Care antibiotics|"* Children who have been diagnosed with an uncomplicated UTI will be administered a 3-day course of standard of care (SOC) antibiotics with known efficacy against the urinary pathogen. Then, on Day 3 either;~  1. Stop of the child has clinically improved, or~ 2. Give an additional 48 hours of SOC antibiotics if the child has ongoing fever or clinical symptoms consistent with an uncomplicated UTI, or~ 3. Give an additional 7 days of SOC antibiotics (to make up a total 10-day duration) if the child has evidence of a complicated UTI.~* Children who have been diagnosed with a complicated UTI will be administered a total 10-day course of SOC antibiotics with known efficacy against the urinary pathogen."
62590209|NCT01902810|ACTIVE_COMPARATOR|Propranolol|Propranolol by mouth given daily throughout hospitalization
62028010|NCT01308216|ACTIVE_COMPARATOR|Control|The patients undergoing only a standard rehabilitation program based on therapeutic exercises.
62028011|NCT05427786|EXPERIMENTAL|Pre-PCI IC Nicorandil|"If the lipid core burden index at the main lesion site on vascular ultrasound exceeds 353, randomization was performed.~Nicorandil group will be administrated 8cc or more of the prescribed drug (Nicroandil) according to randomization into the coronary artery before starting balloon therapy."
62028012|NCT05427786|NO_INTERVENTION|Standard PCI|"If the lipid core burden index at the main lesion site on vascular ultrasound exceeds 353, randomization was performed.~Standard PCI group will be performed coronary intervention including starting balloon therapy without pre-administrated nicorandil."
62028013|NCT00598689|EXPERIMENTAL|Lubricant|Patients scheduled to receive LASIK surgery and randomized to receive 0.3% hypromellose ophthalmic solution prior to surgery.
62226971|NCT06280625|EXPERIMENTAL|Bread|Bread will be prepared with 100 % of wheat flour and with some replacements by different % of soy flour (at three concentrations)
62590210|NCT01902810|PLACEBO_COMPARATOR|Sugar Pill|Placebo by mouth given daily throughout hospitalization
62590211|NCT01985607|EXPERIMENTAL|Thickened|
62590212|NCT01985607|ACTIVE_COMPARATOR|Control|
62802303|NCT00973453|OTHER|Slow regimen|
62028014|NCT00598689|NO_INTERVENTION|No Lubricant|Patients scheduled to receive LASIK surgery and randomized to receive no intervention of 0.3% hypromellose ophthalmic solution prior to surgery
62028015|NCT03579563|ACTIVE_COMPARATOR|AUD/High-end|In this group, the audiologist-based fitting will be used to provide high-end hearing aids.
62028016|NCT03579563|EXPERIMENTAL|OTC+/High-end|In this group, audiologists will provide brief services to fit high-end OTC hearing aids
62028017|NCT03579563|EXPERIMENTAL|OTC/High-end|In this group, high-end OTC hearing aids will be provided to subjects.
62028018|NCT03579563|ACTIVE_COMPARATOR|AUD/Low-end|In this group, the audiologist-based fitting will be used to provide low-end hearing aids.
62226972|NCT06280625|EXPERIMENTAL|Tortilla|Bread will be prepared with 100 % of wheat flour and with some replacements by different % of soy flour (at three concentrations)
62802304|NCT00973453|OTHER|Intermediate regimen|
62802305|NCT00973453|OTHER|Fast regimen|
62028019|NCT03579563|EXPERIMENTAL|OTC+/Low-end|In this group, audiologists will provide brief services to fit low-end OTC hearing aids.
62028020|NCT03579563|EXPERIMENTAL|OTC/Low-end|In this group, low-end OTC hearing aids will be provided to subjects.
62028021|NCT05739747||Women undergoing cesarean section|This study is designed with a single cohort of women who will undergo a scheduled cesarean section
62590213|NCT02586519|EXPERIMENTAL|Active SurroSense Rx System + RCW|Patients randomized to the experimental group will be fitted with an active (alerting) version of the SurroSense R® smart insole System. This device will be placed in the RCW, underneath the liner. The device tab will be fed up the instep, through a hole in the liner, and affixed to the dorsum of the RCW by way of a tie.
62802306|NCT00651339||A|
62028022|NCT05169658|EXPERIMENTAL|Treatment (mosunetuzumab, obinutuzumab, polatuzumab vedotin)|"PART A: Patients receive mosunetuzumab SC over 30 seconds - 2 minutes on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET/CT, PET/CT and CT scans, bone marrow biopsy, bone marrow aspirate, and collection of blood samples throughout the study.~PART B: Beginning cycle 9, patients who do not achieve a CR receive obinutuzumab IV on day 1, 8, and 15 of cycle 9 and day 1 of subsequent cycles and polatuzumab vedotin IV on day 1. Treatment repeats every 21 day for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, PET/CT, and FDG-PET scans, bone marrow biopsy, bone marrow aspirate, and collection of blood samples throughout the study."
62028023|NCT01714219|EXPERIMENTAL|Posterior reconstruction|"* New posterior reconstruction, which entails opposition of the median dorsal fibrous raphe solely to the posterior counterpart of the detrusor apron~* Vesicourethral anastomosis using the van Velthoven method~* Anterior reconstruction, which involved opposing the anterior detrusor apron to the remaining puboprostatic ligaments and dorsal vascular complex"
62028024|NCT01714219|NO_INTERVENTION|No posterior reconstruction|"* No posterior reconstruction~* Vesicourethral anastomosis using the van Velthoven method~* Anterior reconstruction, which involved opposing the anterior detrusor apron to the remaining puboprostatic ligaments and dorsal vascular complex"
62028025|NCT04381026|PLACEBO_COMPARATOR|Placebo Group|Pill of 500 mg containing filler agent, two pills daily for eight weeks.
62802307|NCT05217160|EXPERIMENTAL|KeraStat® Gel with Morphine|"Administration and application of KeraStat® Gel with Morphine (Bi-Weekly):~KeraStat® Gel with Morphine will be formulated by mixing liquid Morphine 25mg/mL into 5mg of KeraStat, this will be individually packaged in 5mL tubes at a concentration of 5mg/mL. Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel with Morphine (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel with Morphine in 5mL tubes.~Instructions for application as above will be taught to subjects and instructions will be provided as subjects themselves or designated caretakers or home-care personnel will change their dressings as instructed by their physician with the addition of KeraStat® Gel administration as outlined above."
62802308|NCT05217160|ACTIVE_COMPARATOR|KeraStat® Gel|"Administration and application of KeraStat® Gel (Bi-Weekly):~Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel 5mL tubes.~Instructions for application as above will be taught to subjects and instructions will be provided as subjects themselves or designated caretakers or home-care personnel will change their dressings as instructed by their physician with the addition of KeraStat® Gel administration as outlined above."
62802309|NCT04926649|SHAM_COMPARATOR|Conventional ventilation group|Conventional SLV and complementary with DLV when necessary. When SLV was initiated, the patient was ventilated with left lung. FiO2 of 1.0, tidal volume of 6ml/kg, respiratory rate of 16-24 bpm, PEEP of 5-10 cmH2O. The right lung was totally collapsed. If the SpO2 decreased lower than 90%, DLV was started and the operation was paused until the SpO2 increased to 100%. Then the operation was restarted.
62590214|NCT02586519|SHAM_COMPARATOR|Inactive SurroSense Rx System + RCW|Patients randomized to this group will be fitted with an inactive (non-alerting) version of the device in an identical fashion.
62028026|NCT04381026|EXPERIMENTAL|Treatment Group with botanical extracts|Pill of 500 mg containing botanicals and filler agent, two pills daily for eight weeks.
62028027|NCT05741125|EXPERIMENTAL|DSMES + ASE intervention Appetite Self-Regulation (Centering Appetite)|The Diabetes Self-Management Education and Support (DSMES) + Appetite Self-Regulation (ASE) intervention includes two, 45-60-minute group sessions delivered via telehealth. These sessions will enable participants to relearn their stomach's hunger and fullness signals and monitor their appetite. Participants will also learn strategies for glucose monitoring and carbohydrate management. Monthly booster sessions will be devoted to problem-solving, addressing barriers to emotion management, and self-monitoring type 2 diabetes mellitus symptoms. Participants will also receive weekly lessons with interactive activities delivered via a digital app.
62028028|NCT05741125|NO_INTERVENTION|Control|Control group participants will attend two remotely delivered DSMES sessions that will offer content commonly. They will also receive weekly emails providing content from the American Association of Diabetes Educators.
62028029|NCT04495374|PLACEBO_COMPARATOR|Group P(0) - Placebo|Patients were randomly allocated to Group P(0) - Placebo by a double blind randomized study. Group P(0) received two placebo tablets as medication, 02h before the start of the anesthesic-surgical procedure in identical sealed envelops, only identified as medication A or B
62028030|NCT04495374|EXPERIMENTAL|Group P(1) - Pregabalin 300mg|Patients were randomly allocated to Group P(1) - Pregabalin 300mg by a double blind randomized study. Group P(1) received two tablets of pregabalin 150mg, 02h before the start of the anesthesic-surgical procedure in identical sealed envelops, only identified as medication A or B
62028031|NCT03834064|EXPERIMENTAL|Intervention|Homes where participants with intellectual/developmental disabilities reside will be randomly assigned to the intervention arm. Caregivers working in that home will receive the oral health promotion strategy/intervention over the course of a year.
62028032|NCT03834064|NO_INTERVENTION|Control|Homes where participants with intellectual/developmental disabilities reside will be randomly assigned to the control arm. Caregivers in that home will not receive the oral health promotion strategy/intervention over the course of a year but will be offered a compressed intervention after a year.
62028033|NCT00832923|NO_INTERVENTION|Routine IMPACT DC care|Participants receive standard asthma education as routine for IMPACT DC
62028034|NCT00832923|EXPERIMENTAL|Enhanced care PEPAC Intervention|
62802310|NCT04926649|ACTIVE_COMPARATOR|CPAP group|"SLV of left lung and CPAP of right lung, and complementary with DLV when necessary.~When SLV was initiated, the patient was ventilated with left lung. FiO2 of 1.0, tidal volume of 6ml/kg, respiratory rate of 16-24 bpm, PEEP of 5-10 cmH2O. After the right lung was totally collapsed, CPAP was started with the pressure less than 8 cmH2O. If SpO2 decreased lower than 90%, DLV was started and the operation was paused until the SpO2 increased to 100%. Then the operation was restarted."
62028035|NCT01602848|EXPERIMENTAL|Intervention enrollee|HIgh risk fee for service Medicaid recipients identified as eligible by the New York State Dept of Health and enrolled in the intensive care management and coordination intervention
62226973|NCT06280625|EXPERIMENTAL|Arepa|Arepa will be prepared with 100 % of wheat flour and with some replacements by different % of soy flour (at three concentrations)
62590215|NCT02586519|SHAM_COMPARATOR|Inactive SurroSense Rx System + iTCC|Patients in this group will be fitted with an inactive (non-alerting) version of the device in an identical fashion. The RCW will be further secured using a device specific tie such that it acts as an iTCC.
62590216|NCT02357706|ACTIVE_COMPARATOR|Group 1|Patients will be randomised to either Group 1 or Group 2. Patients in this group (group 1) will use APAP A on the first night of the evaluation, and APAP B on the second night.
62028036|NCT01602848|NO_INTERVENTION|Eligible, not enrolled|Medicaid fee-for-service patients who are identified as eligible for the intervention but are not enrolled. These patients receive usual services provided by Medicaid.
62590217|NCT02357706|ACTIVE_COMPARATOR|Group 2|Patients will be randomised to either Group 1 or Group 2. Patients in this group (group 2) will use APAP B on the first night of the evaluation and APAP A on the second night.
62028037|NCT03821376|EXPERIMENTAL|Renal malignancy|Patients with renal mass(es) identified by cross sectional imaging, specifically ultrasound following the intravenous injection of Lumason
62028038|NCT03473886|EXPERIMENTAL|Intervention Arm: PP-MI|Participants will complete an 8-week group physical activity and positive psychology program, in which they will complete exercises related to increasing positive emotions and physical activity during and between the group sessions. They will track their activity (steps) and set personalized physical activity goals each week, as complete a group walk or indoor exercise during the group sessions. We will ask questions about participants' health and health behaviors, and ask them to wear a physical activity monitor at the beginning and end of the program.
62226974|NCT00865969|EXPERIMENTAL|Belinostat|Belinostat 1000 mg/m\^2 administered as a 30 minute IV infusion on Days 1-5 of every 3-week cycle until disease progression or unmanageable treatment-related toxicities.
62226975|NCT00831285|EXPERIMENTAL|tortilla with high amylose flour|
62226976|NCT00831285|EXPERIMENTAL|barley tortilla with low amylose flour|
62226977|NCT00831285|EXPERIMENTAL|barley tortilla with low amylose flour and soluble fibre|
62226978|NCT00831285|EXPERIMENTAL|barley tortilla with low amylose flour and insoluble fibre|
62226979|NCT00831285|ACTIVE_COMPARATOR|glucose|
62226980|NCT00831285|EXPERIMENTAL|barley tortilla with low amylose flour and low soluble fibre|
62226981|NCT02445950|EXPERIMENTAL|Technology-aided counseling|Customers receive intervention via technology-aided phone wellness counseling. The intensive phase lasts 13 weeks and includes 5 phone calls. The customers are able to view their change change needs and choose tasks/goals for the coaching. The independent phase lasts 13 weeks and coaching is done via a digital tool.
62226982|NCT02445950|ACTIVE_COMPARATOR|Traditional counseling|Customers receive intervention via traditional phone wellness counseling. The intensive phase lasts 13 weeks and includes 5 phone calls. Change needs and goals are set during the phone calls. The independent phase lasts 13 weeks and includes 3 phone calls.
62226983|NCT04928001|OTHER|Youth Thrive iCBT program|Youth Thrive iCBT online program
62226984|NCT05227105|ACTIVE_COMPARATOR|Physical Activity intervention|Five physical activity coaching calls with MoveLine and weekly physical activity. Objective tracking of activity with an accelerometer will occur at baseline, after 12 months, and after 24 months.
62419896|NCT05847569|EXPERIMENTAL|Group II (low dose and high dose belantamab mafodotin)|Patients receive belantamab mafodotin IV on day 1. Cycle repeats at 3 weeks for the next cycle and then every 6 weeks for subsequent cycles in the absence of disease progression or unacceptable toxicity. All patients undergo a CT scan, a MRI scan, or a PET/CT scan during screening and patients with plasmacytoma (a MM tumor in bone or soft tissue) also undergo imaging scans on study. Patients undergo bone marrow aspirate and biopsy during screening and on study as well as collection of blood samples throughout the trial.
62419897|NCT05619627|EXPERIMENTAL|Dexmedetomidine 12 mcg/kg|Group One: Subjects will receive oral dexmedetomidine 12 mcg/kg 2 hours prior to MRI
62590218|NCT05280925|EXPERIMENTAL|Episodic Future Thinking|Participants will generate vivid, episodic events and be prompted via a guided smartphone app to engage in EFT in their daily lives. EFT will be paired with diet and physical activity support.
62226985|NCT05227105|PLACEBO_COMPARATOR|Delayed intervention|Objective tracking of activity with an accelerometer will occur at baseline, after 12 months, and after 24 months.
62802311|NCT04926649|EXPERIMENTAL|HFLVV group|"SLV of left lung and HFLVV of right lung, and complementary with DLV when necessary.~When SLV was initiated, the patient was ventilated with left lung. FiO2 of 1.0, tidal volume of 6ml/kg, respiratory rate of 16-24 bpm, PEEP of 5-10 cmH2O. After the right lung was totally collapsed, HFLVV was started with tidal volume of 2ml/kg, respiratory rate of 60 bpm. If SpO2 decreased lower than 90%, DLV was started and the operation was paused until the SpO2 increased to 100%. Then the operation was restarted."
62028039|NCT04166019|EXPERIMENTAL|Peer-led self-management program|Peer-led self-management program (PLSMI) consists of 10 weekly/biweekly, 1.5-hour sessions (4 months), based on the modified Crisis-resolution-team Optimization and Relapse Prevention (CORE) program workbook/manual and psycho-education programs developed by the research team. The program based on completion of a self-management workbook, consisting of the main components: personal recovery goals, plans to re-establish community functioning and support networks following a crisis, identifying early warning signs and creating a relapse prevention plan, and strategies and coping resources to problem-solving and maintain well-being. Participants work through the workbook at their own pace, with the support from the peer support worker, to facilitate/support their recovery. They will meet in group with a trained peer support worker on 10 sessions, usually at 7-12 days intervals over 4 months.
62028040|NCT04166019|ACTIVE_COMPARATOR|Psycho-education group|Psycho-education groups (12-18 members/group; 10 two-hour sessions, weekly/biweekly), 4-month duration similar to the PLSMI, will be led by one trained advanced practice psychiatric nurse in each center experienced in psychiatric rehabilitation, and are guided by a validated group-intervention protocol based on the research team's and McFarlane et al.'s psycho-education programs for psychosis.
62028041|NCT04166019|OTHER|Usual care only|Usual care (control) participants (and treatment groups) will receive routine psychiatric outpatient and community mental healthcare services.
62028042|NCT05266911|EXPERIMENTAL|High-intensity strength training (HIFST) program|Home-based high-intensity strength training program
62028043|NCT05266911|ACTIVE_COMPARATOR|Lower extremity stretching program|Lower extremity stretching program
62028044|NCT04464304|ACTIVE_COMPARATOR|Virtual Reality|Patients will be provided with a commercially-available VR device for use up to 15 minutes at bedside.
62028045|NCT04464304|SHAM_COMPARATOR|Smartphone|Patients will be provided with a commercially-available smartphone device for use up to 15 minutes at bedside.
62028046|NCT04968938|EXPERIMENTAL|MDMA-assisted therapy|Two sessions of MDMA-assisted therapy with an initial dose of 80 mg or 120 mg midomafetamine HCl and optional supplemental dose of 40 mg 1.5 to 2 hours later
62028047|NCT00562159|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62028048|NCT00562159|EXPERIMENTAL|SCH 697243|
62028049|NCT02828111|EXPERIMENTAL|Patidegib gel 2% - Cohort 1|Patidegib gel 2%, applied topically, once daily for 12 weeks (Cohort 1)
62028050|NCT02828111|EXPERIMENTAL|Patidegib gel 4% - Cohort 2|Patidegib gel 4%, applied topically, once daily for 12 weeks (Cohort 2)
62028051|NCT02828111|PLACEBO_COMPARATOR|Vehicle gel - Cohort 1|Vehicle gel, applied topically, once daily for 12 weeks (Cohort 1)
62419898|NCT05619627|EXPERIMENTAL|Dexmedetomidine 18 mcg/kg|Group Two: Subjects will receive oral dexmedetomidine 18 mcg/kg 2 hours prior to MRI
62028052|NCT02828111|EXPERIMENTAL|Patidegib gel 2% - Cohort 3|Patidegib gel 2%, applied topically, twice daily for 12 weeks (Cohort 3)
62419899|NCT05619627|EXPERIMENTAL|Dexmedetomidine 24 mcg/kg|Group Three: Subjects will receive oral dexmedetomidine 24 mcg/kg 2 hours prior to MRI
62419900|NCT05619627|ACTIVE_COMPARATOR|General anesthesia control|Control group: Subjects will receive general anesthesia for their MRI
62419901|NCT06396533||Non- neoadjuvant chemotherapy patients|"Archival (FFPE) specimen of prior diagnostic TUR will be obtained.~For patients receiving neoadjuvant chemotherapy: Blood will be collected at pre-treatment/baseline, mid-treatment(C3D1), day of cystectomy, and then only serum/plasma 4-6 weeks (±2 weeks) post-cystectomy, and 6 months (±1 month) post-cystectomy.~For patients not receiving neoadjuvant chemotherapy: Freshly voided mid-stream urine will be collected on the day of cystectomy."
62419902|NCT06396533||Neoadjuvant Chemotherapy (NAC) Patients|"Archival (FFPE) specimen of prior diagnostic TUR will be obtained.~For patients not receiving neoadjuvant chemotherapy: Serum/plasma will be collected on the day of cystectomy, and only serum/plasma 4-6 weeks (±2 weeks) post-cystectomy, and 6 months (±1 month) post-cystectomy.~For patients receiving neoadjuvant chemotherapy: Freshly voided mid-stream urine will be collected from each subject at pre-treatment, mid-treatment (C3D1), and the day of cystectomy.~Stool samples will be collected in OMNIgene GUT kits. Patients who are not undergoing NAC, will be provided one kit for stool collection prior to cystectomy at baseline. All stool samples will be sent to Case Western Microbiome Core for analysis."
62419903|NCT04929522|ACTIVE_COMPARATOR|IANB/inferior alveolar nerve block|patients will be given standard IANB with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
62419904|NCT04929522|ACTIVE_COMPARATOR|IANB+IO|patients will be given standard IANB plus an intra-osseous with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
62419905|NCT04929522|ACTIVE_COMPARATOR|IANB+PDL|patients will be given standard IANB plus a PDL injection with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
62028053|NCT02828111|EXPERIMENTAL|Patidegib gel 4% - Cohort 4|Patidegib gel 4%, applied topically, twice daily for 12 weeks (Cohort 4)
62028054|NCT02828111|PLACEBO_COMPARATOR|Vehicle gel - Cohort 2|Vehicle gel, applied topically, once daily for 12 weeks (Cohort 2)
62028055|NCT02828111|PLACEBO_COMPARATOR|Vehicle gel - Cohort 3|Vehicle gel, applied topically, twice daily for 12 weeks (Cohort 3)
62028056|NCT02828111|PLACEBO_COMPARATOR|Vehicle gel - Cohort 4|Vehicle gel, applied topically, twice daily for 12 weeks (Cohort 4)
62028057|NCT04365946||Complete type|Patients with complete-type intestinal metaplasia
62028058|NCT04365946||Incomplete type|Patients with incomplete-type intestinal metaplasia
62028059|NCT04365946||Controls|Healthy subjects
62028060|NCT00317239|EXPERIMENTAL|Ferric Carboxymaltose (FCM)|A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
62028061|NCT00317239|ACTIVE_COMPARATOR|Ferrous Sulfate tablets|325 mg/TID x 8 weeks
62028062|NCT00618475|EXPERIMENTAL|Treatment|Individual cognitive behavioral therapy (CBT)
62028063|NCT00618475|OTHER|Wait-list control|Individual cognitive behavioral therapy (CBT) after 3 month wait-list period
62028064|NCT03696121|EXPERIMENTAL|Intervention|Desmopressin injection
62226986|NCT03522480|OTHER|Group A: Education & Gaming|Children will participate in 1 initial training session where they will be taught by a RT to use autogenic drainage (AD). Patients will be sent home \& prescribed to practice the technique 15 minutes 3 times / week. At week 8 +/- 1 week patients will return and will be tested by a software program designed to evaluate their ability to perform the AD sequence (percent accuracy). At the 8 week visit, the Jamboxx gaming device will be introduced, which will contain a game to guide them through the proper sequence of breathing for the AD technique. Patients will be sent home with a Jamboxx device and requested to do 15 minutes of AD training 3 times / week. Patients will return at week 16 and again will be tested via software program for ability to perform the AD technique.
62028065|NCT03696121|PLACEBO_COMPARATOR|Control|Normal Saline
62028066|NCT00869232|EXPERIMENTAL|MEL--VTD-PACE|Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide and Etoposide
62028067|NCT06457750|EXPERIMENTAL|Intervention Arm (Exposed to FLAGs Digital Health Application)|Participants in the intervention group will have access to the FLAGs assessment tool together with the real-time feedback and advisory provided by the digital application, complete with mobile nudges.
62028068|NCT06457750|NO_INTERVENTION|Control Arm|Participants in the control group will not have access to the FLAGs advisory and monitoring functions will not be made available on their digital application. Participants will not receive any automated notifications or nudges.
62028069|NCT03523533|EXPERIMENTAL|Peripherally-inserted internal jugular catheter|All enrolled patients will receive a peripheral angiocatheter in the internal jugular vein, under dynamic ultrasound guidance.
62028070|NCT04351438||Centrifuge TPE with citrate|These participants were undergoing centrifuge TPE using citrate anticoagulant
62028071|NCT04351438||Filter TPE with heparin|These participants were undergoing filter TPE using filter-based heparin anticoagulant
62028072|NCT04351438||Filter TPE with citrate|These participants were undergoing filter TPE using filter-based citrate anticoagulant
62028073|NCT02247505|OTHER|Group1: Treatment A + Treatment B, PO|Treatment A : Tamsulosin 0.2mg\*1t for 5days, Treatment B : Tamsulosin 0.2mg\*1t/day and Tadalafil 5mg\*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
62028074|NCT02247505|OTHER|Group2: Treatment B + Treatment A, PO|Treatment A : Tamsulosin 0.2mg\*1t for 5days, Treatment B : Tamsulosin 0.2mg\*1t/day and Tadalafil 5mg\*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
62028075|NCT01721018|EXPERIMENTAL|HSV1716|Single Arm Phase I/II study of intra-pleural HSV1716 administration.
62028076|NCT05509972||Columbus® DD Primary CoCr|Columbus® Deep Dish (DD) Primary Cobalt Chromium (CoCr)
62028077|NCT05509972||Columbus® DD Primary CoCr AS coated|Columbus® Deep Dish (DD) Primary Cobalt Chromium (CoCr) Advanced Surface
62226987|NCT03522480|EXPERIMENTAL|Group B: Gaming Only|Children will participate in an initial training session at Albany Med where they will be taught by a RT to use the Jamboxx respiratory therapy device to guide them through autogenic drainage (AD): a series of controlled breathing exercises that mobilizes mucous without inducing wheezing in patients with reactive airways. Patients will be sent home and prescribed to use the Jamboxx respiratory therapy device 15 minutes three times per week. At week 8 and week 16 +/- 1 week patients will return and will be tested by a software program designed to evaluate their ability to perform AD sequence (percent accuracy).
62419906|NCT04929522|ACTIVE_COMPARATOR|IANB+BI|patients will be given standard IANB plus a BI injection with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
62028078|NCT03726346|EXPERIMENTAL|Toffee Full Face Mask|Participants will be placed on this arm for a total of 14+- 4 days from visit 2. Participants will be using the Toffee mask during this treatment arm.
62028079|NCT05520905|EXPERIMENTAL|Telemedicine for pre-exposure prophylaxis of HIV|"1. We will identify youth potentially eligibile for PrEP using tenfovir alefenamide/emtricitabine (TAF/FTC).~2. Eligible youth will be contacted for rapid (same day) consenting and enrollment.~3. Participants who consent to the study will undergo a PrEP initiation visit either the same day or within two weeks with a provider. The initial visit may be in-person or via Telemedicine.~4. TelePrEP visits may be carried out in the setting of the participant's choosing and may include home or at a community organization.~5. Recommended laboratory testing will be arranged as part of the PrEP initiation visit. HIV testing will be carried out as well as Centers for Disease Control and Prevention (CDC)-recommended laboratory testing will be obtained.~6. TelePrEP(or in-person visits as needed) will be conducted by a skilled multidisciplinary team one month after initiation and then every three months."
62028080|NCT02883725||Esophageal atresia|
62028081|NCT03080519|EXPERIMENTAL|Endovascular Therapy|Renal artery revascularization
62028082|NCT00428454|EXPERIMENTAL|Zotarolimus eluting stent|Zotarolimus eluting stent
62028083|NCT00428454|ACTIVE_COMPARATOR|Sirolimus eluting stent|Sirolimus eluting stent
62028084|NCT04757753|EXPERIMENTAL|ready-to-use root canal sealer: PA1704|PA1704 is used in combination with gutta percha points for the permanent obturation of root canals.
62028085|NCT04757753|OTHER|root canal sealer: BioRoot™ RCS|BioRoot™ RCS is used in combination with gutta percha points for the permanent obturation of root canals.
62028086|NCT06668948||patients with acute leukemia|
62028087|NCT04598477|EXPERIMENTAL|efgartigimod PH20 SC|patients receiving efgartigimod PH20 SC on top of prednisone
62028088|NCT06551519||Ofatumumab|Patients who have received treatment with category 1 DMTs and decided to switch to ofatumumab
62028089|NCT06551519||Category 1 DMTs|Patients who continued with DMT category 1 treatment. According to local treatment guidelines, DMT category 1 include dimethylfumarate/diroximelfumarate, glatirameroids, Interferon beta and teriflunomide.
62028090|NCT01380483|EXPERIMENTAL|A|Subjects received the Par formulated product
62028091|NCT01380483|ACTIVE_COMPARATOR|B|Subjects received the Oclassen Pharmaceuticals formulated product.
62028092|NCT02084953|EXPERIMENTAL|ARM A: BMS-791325|BMS-791325 600 mg tablet orally on 1st and 2nd day, then 900 mg on the 3rd day once a day for 3 days
62028093|NCT02084953|ACTIVE_COMPARATOR|ARM B: Moxifloxacin|Moxifloxacin 400mg tablet orally once on third day
62028094|NCT02084953|PLACEBO_COMPARATOR|ARM C: Placebo matching BMS-791325|Placebo matching BMS-791325 0 mg tablet orally once daily for 3 days
62028095|NCT06388577|EXPERIMENTAL|Education|Participants in the intervention group (n = 36) will be administered the Epilepsy Education Programme based on Pender's Health Promotion Model by the researcher and will be given the education booklet developed by the researcher in line with the literature. The training topics of the intervention programme are: General information about epilepsy, seizure moment management, management of antiepileptic drug treatments, controlling the factors that may trigger seizures, and recommendations to parents about health promoting and protective behaviours. In the training, learning and teaching techniques such as presentation, video demonstration, question and answer sections, lecture and discussion will be applied. The training will last approximately one hour.
62028096|NCT06388577|NO_INTERVENTION|Control|No intervention will be made to the control group, only the data will be collected at the same time as the study group.
62028097|NCT02938416|EXPERIMENTAL|Isokinetic training|Ten times, three sets of isokinetic strengthening exercise using 30 degree/sec and 120 degree/sec
62028098|NCT02938416|ACTIVE_COMPARATOR|Isotonic training|Ten times, three sets of isotonic strengthening exercise using consistent resistance of 60% of 1-repetition maximum of hip or knee
62028099|NCT02938416|PLACEBO_COMPARATOR|isometric training|home exercise education on isometric quadriceps strengthening on the day of out-patient appointment
62028100|NCT00426504|EXPERIMENTAL|radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
62028101|NCT01637012|EXPERIMENTAL|ALEX stent arm|implantation of ALEX stent during index procedure
62226988|NCT01729143|ACTIVE_COMPARATOR|Black pepper|During the black pepper study day, subjects consumed 1.5g of black pepper (0.5g/meal) in 60.8g of vegetable juice. Black pepper was consumed was a meal on each occasion. 24-hour energy expenditure and substrate utilization will be measured.
62226989|NCT01729143|PLACEBO_COMPARATOR|No pepper control|During the no pepper control study day, subjects consumed an identical menu without black pepper. 60.8g of vegetable juice (vehicle) was consumed at each of the three study meals. 24-hour energy expenditure and substrate utilization will be measured.
62419907|NCT06072131|ACTIVE_COMPARATOR|Group 1a|Group 1a Belinostat 600 mg/m2 + CHOP
62419908|NCT06072131|ACTIVE_COMPARATOR|Group 1b|Group 1b Belinostat 1000 mg/m2 + CHOP
62419909|NCT06072131|ACTIVE_COMPARATOR|Group 2a|Group 2a Pralatrexate 20 mg/m2 + COP
62419910|NCT06072131|ACTIVE_COMPARATOR|Group 2b|Group 2b Pralatrexate 30 mg/m2 + COP
62419911|NCT06072131|ACTIVE_COMPARATOR|Group 3|CHOP
62419912|NCT00547209|ACTIVE_COMPARATOR|1|ventilation with air and oxygen
62028102|NCT05106231|EXPERIMENTAL|PICC arm|Participants assigned to the intervention group will attend the PICC program, which will take four-month and each session 2.5 hours.
62028103|NCT05106231|ACTIVE_COMPARATOR|Control arm|Participants assigned to the DMTAC group will receive a standard intervention of pharmacist-led education.
62419913|NCT00547209|EXPERIMENTAL|2|ventilation with nitrous oxide and oxygen
62419914|NCT04230785||AIS before EVT group|This group includes patients with acute ischemic stroke (AIS) before endovascular treatment (EVT)
62419915|NCT04230785||AIS after EVT group|This group includes patients with acute ischemic stroke (AIS) after endovascular treatment (EVT)
62028104|NCT06310772||Children with CAE or Controls|Pediatric Epilepsy Side Effect Questionnaire Continuous Performance Test Children's Sleep Questionnaire Anxiety/Depression Screening Eye tracking during active tasks- saccade/antisaccade task, and passive tasks
62028105|NCT02920905|EXPERIMENTAL|lidocaine|• Patients in group A will receive 3 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
62802312|NCT01378988|EXPERIMENTAL|Dose level 1|Dexmedetomidine 0.7 mcg/kg loading dose and 0.5 mcg/kg/hr maintenance infusion
62802313|NCT01378988|EXPERIMENTAL|Dose level 2|Dexmedetomidine 1.0 mcg/kg loading dose and 0.75 mcg/kg/hr maintenance infusion
62028106|NCT02920905|EXPERIMENTAL|lidocaine & atracurium|• Patients in group B receive 3 mg/kg of lidocaine 2% + 2 mg atracurium diluted with saline to a total volume of 40 ml.
62802314|NCT00479713|EXPERIMENTAL|1|Arm 1: drug
62028107|NCT02920905|EXPERIMENTAL|lidocaine & atracurium & Mg sulphate|• Patients in group C will receive 3 mg/kg of lidocaine 2% + 2 mg atracurium mixed with 10 mg /kg magnesium sulphate diluted with saline to a total volume of 40 ml.
62028108|NCT04445805|ACTIVE_COMPARATOR|CBTI Treatment Group|Telemedicine Cognitive Behavioral Therapy for Insomnia (CBTI)
62028109|NCT04445805|EXPERIMENTAL|Perinatal-enhanced behavioral therapy for insomnia|Telemedicine Mindfulness Based Therapy for Insomnia (MBTI)
62028110|NCT04445805|PLACEBO_COMPARATOR|Attention Control Treatment Group|Minimal intervention control
62028111|NCT05126797|OTHER|3D printed stent+ MDASI-3D Oral Stents Questionnaire|Patients wear a customized 3D printed oral stent over 5-10 minutes in the supine position at the time of radiation simulation, before starting radiation therapy, and in the 3rd to 5th week of radiation therapy. Patients may also optionally wear the commercially-made stent called TruGuard at these timepoints. Ancillary Studies (MDASI-3D Oral Stents Questionnaire)
62028112|NCT05369650|EXPERIMENTAL|Lidocaine 1 group|After induction of anesthesia, 1% lidocaine 1.5mg/kg (ideal body weight, 10min pumped) was injected intravenously with a micro pump, and then 1% lidocaine 1mg/kg.h (ideal body weight) was continuously pumped until the end of the operation , connected to patient-controlled intravenous analgesia (PCIA) pump containing lidocaine 0.3-1.5mg/kg.h after operation to 72h after operation.
62028113|NCT05369650|EXPERIMENTAL|Lidocaine 1.5 group|After induction of anesthesia, 1% lidocaine 1.5mg/kg (ideal body weight, 10min pumped) was injected intravenously with a micro pump, and then 1% lidocaine 1.5mg/kg.h (ideal body weight) was continuously pumped until the end of the operation , connected to patient-controlled intravenous analgesia (PCIA) pump containing lidocaine 0.3-1.5mg/kg.h after operation to 72h after operation.
62028114|NCT05369650|EXPERIMENTAL|Lidocaine 2 group|After induction of anesthesia, 1% lidocaine 1.5mg/kg (ideal body weight, 10min pumped) was injected intravenously with a micro pump, and then 1% lidocaine 2mg/kg.h (ideal body weight) was continuously pumped until the end of the operation , connected to patient-controlled intravenous analgesia (PCIA) pump containing lidocaine 0.3-1.5mg/kg.h after operation to 72h after operation.
62226990|NCT00978653|EXPERIMENTAL|Allopurinol|Hyperuricemic (uric acid (UA)\>7 mg/dL), nondiabetic CKD patients without any comorbidity, age\<60 years with creatinine clearance (CrCl) between 20 and 60ml/min were evaluated.
62590219|NCT05280925|ACTIVE_COMPARATOR|Healthy Information Thinking|Participants will be prompted via a guided smartphone app to thinking about their written responses to informational health vignettes during their daily lives. The HIT condition will be paired with diet and physical activity support.
62802315|NCT00479713|ACTIVE_COMPARATOR|2|Arm 2: active comparator
62802316|NCT02040740||Observation|Healthy early pubertal boys
62802317|NCT00402168|EXPERIMENTAL|A: Belatacept|
62802318|NCT00402168|ACTIVE_COMPARATOR|B: calcineurin inhibitor (CNI)-based immunosuppressive regimen|
62802319|NCT00795704|PLACEBO_COMPARATOR|Placebo|Control Group
62802320|NCT00795704|ACTIVE_COMPARATOR|Mulberry Leaf Extract|
62802321|NCT01276639|EXPERIMENTAL|Active Treatment 10 mg BID|
62802322|NCT01276639|EXPERIMENTAL|ActiveTreatment 5 mg BID|
62802323|NCT01276639|PLACEBO_COMPARATOR|Placebo Treatment|
62802324|NCT05362968|NO_INTERVENTION|Control arm|Each participants on usual diet and lifestyle for 12 weeks
62028115|NCT02521090|EXPERIMENTAL|Treatment (EGFRBi-armed autologous T cells)|"PHASE I: Patients receive EGFRBi-armed autologous T cells IT twice weekly for 4 weeks.~PHASE II: Patients receive EGFRBi-armed autologous T cells\* IT twice weekly for 4 weeks and then IV over 15-30 minutes twice weekly for 2 weeks.~\*NOTE: Six selected patients receive EGFRBi-armed autologous T cells IV on day -3, -2, or -1 prior to first IT infusion."
62226991|NCT01596621|EXPERIMENTAL|Bendamustine|Participants will receive bendamustine hydrochloride administered at 120 milligrams (mg)/square meter (m\^2) intravenously (IV) as a 60-minute infusion, and not more than 120 minutes, on Days 1 and 2 in each 21-day treatment cycle for 6 planned cycles and up to 8 total cycles.
62226992|NCT00495586|PLACEBO_COMPARATOR|Placebo|Placebo pills t.i.d. for 8 days
62226993|NCT00495586|ACTIVE_COMPARATOR|Amoxycillin and clavulanic acid|Amoxycillin and clavulanate t.i.d. for 8 days
62802325|NCT05362968|EXPERIMENTAL|Strawberry intervention|Each participants will consume freeze-dried strawberry powder (32g/day) for 12 weeks
62802326|NCT04538937||Subjects with eosinophilia and respiratory manifestation|
62802327|NCT04538937||Healthy subjects|
62226994|NCT01793311|SHAM_COMPARATOR|Group1: Decaffeinated coffee|contains 0.5-2 mg of caffeine
62226995|NCT01793311|ACTIVE_COMPARATOR|Group2: regular dose coffee|contains 91.8 mg of caffeine
62590220|NCT05183308||patients treated with Vitamin D|
62590221|NCT05183308||patients treated with Vitamin D and Clodronic Acid|
62590222|NCT04975750|EXPERIMENTAL|Problem solving intervention|Problem solving as developed by Nexu and colleguages. First-line managers are trained in the problem solving intervention (1 1/2 day). Thereafter, they apply the problem-solving in 2 - 5 meetings (about 30 - 45 min each) with employees at risk of future sick leave due to common mental disorders.
62590223|NCT04975750|ACTIVE_COMPARATOR|Care as usual|First-line managers participate in a 3 hour lectur including a brief overview about worker health, occupational stress and the mismatch model and self-efficacy. Thereafter, they provide care-as-usual to employees at risk of future sick leave due to common mental disorders.
62028116|NCT05207059|EXPERIMENTAL|Study Arm|The intervention will comprise four modules, namely the HELMS Journey, HELMS Model, HELMS Lifestyle and HELMS Community. The HELMS Journey will provide anticipatory guidance for both HELMS and routine clinic visits. The HELMS Model will deliver the 4S ('Screening', 'Size', 'Supplementation' and 'Specific case management') care plan, detailed below. The HELMS Lifestyle will provide lifestyle support in terms of healthy eating through the 6P tool ('Portion', 'Proportion', 'Pleasure', 'Phase', Physicality', 'Psychology'), physical activity, sleep and mental well-being. Finally, the HELMS Connection will provide community support and improve engagement with the program.
62226996|NCT01793311|ACTIVE_COMPARATOR|Group3: high dose coffee|contains 144 mg of caffeine
62590224|NCT03459898|OTHER|Active Breathing Control|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
62802328|NCT01508169|EXPERIMENTAL|Foot orthosis|Forty-seven women in treatment in the outpatient clinic of the Rheumatology Division of State University of Campinas(UNICAMP) who met the inclusion criteria for this study (being female with osteoporosis and aged 60 or above) were assigned, at random, to wear ethyl-vinyl-acetate insoles with medial arch supports and metatarsal pads over a four-week period. Balance, using the Berg Balance Scale (BBS) and the Timed Up and Go (TUG) indexes; pain, using a numeric pain scale (NPS); and disability of the feet, using the Manchester Foot Pain and Disability Index (MFPDI), were assessed at baseline and after four weeks.
62802329|NCT01508169|NO_INTERVENTION|Control Group|Forty-seven elderly women with osteoporosis (in treatment in the outpatient clinic of the Rheumatology Division of State University of Campinas- UNICAMP) were assigned, at random, to enter the control group with no foot intervention. Balance, using the Berg Balance Scale (BBS) and the Timed Up and Go (TUG) indexes; pain, using a numeric pain scale (NPS); and disability of the feet, using the Manchester Foot Pain and Disability Index (MFPDI), were assessed at baseline and after four weeks.
62226997|NCT04758689|EXPERIMENTAL|Laser acupuncture and aerobic exercise|
62590225|NCT03459898|OTHER|Deep Inspiration Breath Hold|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
62590226|NCT02177903|OTHER|Bair PawsPatient Adjustable Warming System|Bair PawsPatient Adjustable Warming System for active pre-warming
62590227|NCT02177903|OTHER|Passive pre-warming|Passive pre-warming
62590228|NCT06130579|EXPERIMENTAL|IFN-α application in TP53+ myeloid malignancy|
62802330|NCT01620086|EXPERIMENTAL|Patients|Patients with Schizophrenia who meet entry criteria for the study and first receive active repetitive transcranial magnetic stimulation for four days over a control site located at the vertex and then are randomized to receive repetitive Transcranial Magnetic Stimulation for four days over the temporal cortex at both 1 Hz and 10 Hz.
62802331|NCT01620086|EXPERIMENTAL|Controls|These subjects are normal controls without schizophrenia who receive sham, repetitive transcranial magnetic stimulation at 1 Hz for two days and then receive active, repetitive Transcranial Magnetic stimulation for two days. All stimulation is delivered at the control site located over the vertex.
62802332|NCT05661786||Observation cohort|
62802333|NCT05661786||Treatment cohort|
62802334|NCT06117865|SHAM_COMPARATOR|Patient education|
62590229|NCT06031688|EXPERIMENTAL|Arm A: (Ramucirumab and tepotinib)|Patients receive ramucirumab IV over 30-60 minutes on day 1 of each cycle and tepotinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo lymphoscintigraphy scan and CT scan and/or MRI throughout the trial. Patients also undergo blood sample collection while on study.
62802335|NCT06117865|ACTIVE_COMPARATOR|Behavioral therapy|
62802336|NCT06117865|ACTIVE_COMPARATOR|Low FODMAP-diet|
62802337|NCT06117865|ACTIVE_COMPARATOR|Combined treatment|Low FODMAP-diet and behavioral therapy
62802338|NCT02855034|OTHER|Blood sample|All the patients performed the same blood samples for dosage: copeptin, S-100B, GFAP, NFL and UCHL-1 proteins
62802339|NCT01492205||Human insulin|
62802340|NCT01671033|EXPERIMENTAL|Muscle Relaxation|The patients of this arm practice on-line muscle relaxation every day.They complete the Brief Symptom Rating Scale(BSRS), Family APGAR(APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Clinical Global Impression (CGI) were performed by well-trained clinicians.
62802341|NCT01671033|EXPERIMENTAL|Muscle Relaxation with Biofeedback|The patients of this arm practice on-line muscle relaxation with finger temperature biofeedback every day. They complete the Brief Symptom Rating Scale(BSRS), Family APGAR(APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Clinical Global Impression (CGI) were performed by well-trained clinicians.
62802342|NCT01671033|NO_INTERVENTION|Waiting-List|The patients of this arm waited for four weeks. They complete the Brief Symptom Rating Scale(BSRS), Family APGAR (APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Impressions-Improvement(CGI) were performed by well-trained clinicians.
62802343|NCT03242694||persistent atrial fibrillation|invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
62028117|NCT05860322|EXPERIMENTAL|Inulin group|Patients randomized to the intervention group will receive inulin supplementation for 14 days, preceding the surgery. Inulin will be given at a dosage of 10g/day divided in two doses.
62028118|NCT05860322|PLACEBO_COMPARATOR|Control group|Patients randomized to the control group will receive a placebo for 14 days, two times a day.
62028119|NCT01923727|EXPERIMENTAL|[89Zr]Df-IAB2M|A single intravenous infusion of 5 mCi of \[89Zr\]Df-IAB2M in mass doses of either 10 mg, 20 mg or 50 mg (optional).
62226998|NCT04758689|EXPERIMENTAL|Aerobic exercise|
62226999|NCT02523001||Naïve-S|Patients with hypercholesterolemia starting statin treatment for primary or secondary prevention of cardiovascular diseases.
62028120|NCT03151265|EXPERIMENTAL|Low Back Pain Group|"Low Back Pain (LBP) group will be assessed on two consecutive days. The first day will have no ThermaCare intervention applied, and is for a Baseline assessment of flexibility, muscle relaxation and low back pain.~The second day will have the ThermaCare Low Back Heat Wrap intervention applied, and will have the same assessments as the Baseline day."
62028121|NCT03151265|EXPERIMENTAL|Active in Sport Group|"Sport group will be assessed on two consecutive days. The first day will have no ThermaCare intervention applied, and is for a baseline assessment of flexibility, muscle relaxation and low back pain.~The second day will have the ThermaCare Low Back Heat Wrap intervention applied, and will have the same assessments as the Baseline day."
62028122|NCT03676062|ACTIVE_COMPARATOR|stabilization exercise group|Spinal stabilization exercise were applied all patients additional with hotpack, TENS application in this group accompanied by physiotherapist.
62227000|NCT02523001||ONC-S|Patients with hypercholesterolemia who had been treated with statin for at least one year and continued their previous therapy during the study period
62227001|NCT02523001||Naïve-MC|Patients with mild hypercholesterolemia either refusing initial statin treatment or intolerant to standard statin treatment and starting with monacolin K
62227002|NCT02523001||Naïve-Diet|Patients refusing an initial pharmacologic treatments and choosing the hypolipidic diet
62227003|NCT04634825|EXPERIMENTAL|Retifanlimab Cohort|Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles
62028123|NCT03676062|ACTIVE_COMPARATOR|yoga group|Yoga program were applied all patients in this group accompanied by physiotherapist. Sessions included selected breathing exercises, warm up, asana and relaxation.
62590230|NCT06031688|ACTIVE_COMPARATOR|Arm B: (Tepotinib)|Patients receive tepotinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo lymphoscintigraphy scan and CT scan and/or MRI throughout the trial. Patients also undergo blood sample collection while on study.
62590231|NCT02256982|EXPERIMENTAL|Resectable Disease|"* Consent and Registration~* 3 cycles of gemcitabine + cisplatin~* Evaluate for surgery\* (weeks 10-15)~  -- Patients who are eligible for surgery at restaging will receive surgery; patients not eligible for surgery at restaging will receive radiation therapy.~* Proceed to surgery~* Additional care as recommended; may include additional cycles of GEM + CDDP on a 21 day cycle and/or post-op radiation as recommended by treating medical oncologist and radiation oncologist"
62590232|NCT02256982|EXPERIMENTAL|Unresectable Disease|"* Consent and Registration~* 3 cycles of gemcitabine + cisplatin~* Evaluate for surgery\* (weeks 10-15)~* Patients who are eligible for surgery at restaging will receive surgery; patients not eligible for surgery at restaging will receive radiation therapy.~* Proceed to radiation therapy with protons or photons, determined by available resources~* Additional cycles of GEM + CDDP on a 21 day cycle as recommended by treating medical oncologist"
62590233|NCT05688033|EXPERIMENTAL|experimental arm|peritoneal space V15\<850cc，pelvic bone V10\<80% and normal dosimetric limitation
62590234|NCT05688033|NO_INTERVENTION|control arm|normal dosimetric limitation
62590235|NCT04588870|EXPERIMENTAL|Preoperative Cochlear Implant|The intervention will be the use of a surgical simulation system preoperatively by the surgeon to develop the surgical plan to optimize electrode array placement with respect to scalar location and modiolar distance.
62590236|NCT00965341|ACTIVE_COMPARATOR|Testosterone|Testosterone Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
62590237|NCT00965341|PLACEBO_COMPARATOR|Placebo|Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
62590238|NCT03467061|ACTIVE_COMPARATOR|Nitrate-rich beetroot juice|2 x 70mL concentrated juice per day for 14 days
62028124|NCT03676062|ACTIVE_COMPARATOR|home exercise group|Home exercise were applied all patients in this group supervised, controlled by physiotherapist every week.To make compliance easier for patients; a booklet including suggestions to prevent low back pain and description of exercises, were given. Prescribed exercises were selected in this booklet and checked\&progressed in each control sessions.
62227004|NCT04634825|EXPERIMENTAL|Tebotelimab Cohort|Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks for up to 35 cycles
62227005|NCT05576194||TauroPace irrigation group|every consecutive CIED placement, revision, extraction conducted with TauroPace
62227006|NCT05576194||antiseptic irrigation group|every procedure conducted with adjunct antiseptic irrigation, which could be Taurolidine, TauroPace or Hydrogen Peroxide 3%
62590239|NCT03467061|PLACEBO_COMPARATOR|Nitrate-depleted beetroot juice|2 x 70mL concentrated juice per day for 14 days
62590240|NCT03467061|OTHER|Antibacterial mouthwash|2 x 10mL antibacterial mouthwash per day for 14 days
62802344|NCT03852134|EXPERIMENTAL|MOCC Group|The OB provider will hold the baby at/below the placenta, provide warmth, stimulate the baby and suction the mouth/nose for 30 secs.S/He will then clamp and cut the cord about 5 cm from the the introitus (vaginal deliveries) or from the abdominal incision (C-Sections) before handing the baby with the long-cut cord to the neonatal team to resuscitate/ stabilize the baby. A member of the neonatal team will milk the long-cut cord slowly 1 time from the cut end toward the infant over 10 secs before clamping and cutting the cord 1-2 cm from the umbilical stump. The neonatal team will provide PPV to the baby (during the milking process) if the baby is not breathing. If the baby is breathing during the milking process the team will continue the stabilization as per standard NRP practice.
62802345|NCT03852134|ACTIVE_COMPARATOR|DCC group|"The OB provider will hold the baby at or below the level of placenta, provide warmth, stimulate the baby to breathe and suction the mouth/nose if needed for the first 30 seconds.~After these initial 30 seconds, if the baby is breathing then the obstetrician will continue DCC for a total of 60 seconds before clamping and cutting the cord close to the umbilicus and handing over the baby to the neonatal team for further stabilization as per standard NRP practice. If the baby is not breathing after the initial 30 seconds of DCC, then the OB provider will clamp and cut the cord close to the umbilicus and hand over the baby to the neonatal team to continue resuscitation of the baby as per the standard NRP guidelines."
62802346|NCT02864121|EXPERIMENTAL|arm 1|all patients included in IDAHO study
62802347|NCT05254106||Paclitaxel drug-eluting devices|Patients treated by at least one paclitaxel drug-eluting balloon or stent after an endovascular femoropopliteal artery revascularization between October 2011 and December 2019 in France.
62802348|NCT05254106||Non-drug-eluting devices|Patients exclusively treated by a non-drug-eluting balloon or stent after an endovascular femoropopliteal artery revascularization between October 2011 and December 2019 in France.
62802349|NCT02116881||Open colorectal surgery|Patients scheduled to undergo open colorectal surgery from Department of Colorectal Surgery at Cleveland Clinic
62802350|NCT02116881||Laparoscopic colorectal surgery|Patients scheduled to undergo laparoscopic colorectal surgery from Department of Colorectal Surgery at Cleveland Clinic
62802351|NCT01976052||Obstructive sleep apnea patients|Patients with obstructive sleep apnea that has not received CPAP treatment
62802352|NCT01976052||Matched volunteers with non OSA|Matched volunteers without OSA. Matched in respect to age and BMI
62802353|NCT01976052||Matched normal controls with normal BMI|Volunteers that are matched according to age but has a normal BMI
62802354|NCT05889715|EXPERIMENTAL|Green Wellness Program: Plants-2-Plate|The Green Wellness Program:Plants-2-Plate is an established program focusing on whole food plant-based predominant eating pattern in academic primary care setting.The dietary approach includes vegetables, fruits, legumes, whole grains, seeds, nuts in small portion, elimination of all or most of animal foods, and reduction of processed foods. Participants will eat ad libitum. In addition, they will receive support to manage stress, improve quality of sleep, and increase physical activity during the SMA.
62802355|NCT04353245||Arm treatment (HCQ + Azithro)|Participants that used HCQ + Azithro in their treatment for COVID19
62802356|NCT04353245||Arm control (without HCQ + Azithro)|Participants that did not used HCQ + Azithro in their treatment for COVID19
62802357|NCT05951946|ACTIVE_COMPARATOR|Treatment 1(T1)|BR3006-1 + BR3006-2 administered in combination once daily for 7 days.
62802358|NCT05951946|ACTIVE_COMPARATOR|Treatment 2(T2)|BR3006-3 administered alone once daily for 7 days.
62802359|NCT05951946|EXPERIMENTAL|Treatment 3(T3)|BR3006-1 + BR3006-2 + BR3006-3 administered in combination once daily for 7 days.
62802360|NCT02535325|EXPERIMENTAL|Treatment (pemetrexed, methoxyamine, cisplatin, RT)|"CYCLES 1-2: Patients receive pemetrexed disodium IV over 10 minutes and methoxyamine hydrochloride PO day 1; and cisplatin IV over 0.5-24 hours on day 3. Patients also undergo 3-D conformal RT or IMRT QD 5 days a week (3 days of week 1 and 4 days of week 4) for 30 fractions total.~CYCLES 3-4: Beginning at least 10 days after RT completion, patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 0.5-24 hours on day 1.~Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity."
62802361|NCT03382990||STEMI|Patients with STEMI treated with PCI and stent placement (DES or BMS)
62802362|NCT03382990||NSTEMI|Patients with NSTEMI treated with PCI and stent placement (DES or BMS)
62802363|NCT03214107|ACTIVE_COMPARATOR|Full snack given before exercise|A snack containing \~0.5g of carbohydrates per kilogram of body weight will be given 5 minutes before exercise
62802364|NCT03214107|ACTIVE_COMPARATOR|Distributed snack over exercise period|A snack containing \~0.5g of carbohydrates per kilogram of body weight distributed this way will be given: \~40% given 5 minutes before exercise, \~30% after 20 minutes of exercise and the last \~30% after 40 minutes of exercise.
62802365|NCT01633788|EXPERIMENTAL|AGN-195263 0.1%|1 drop of AGN-195263 0.1% instilled in each eye twice daily.
62802366|NCT01633788|EXPERIMENTAL|AGN-195263 0.03%|1 drop of AGN-195263 0.03% instilled in each eye twice daily.
62802367|NCT01633788|EXPERIMENTAL|AGN-195263 0.01%|1 drop of AGN-195263 0.01% instilled in each eye twice daily.
62802368|NCT01633788|PLACEBO_COMPARATOR|AGN-195263 Vehicle|1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
62802369|NCT02268734||Sporadic Medullary Thyroid Cancer|Patients with diagnosis of locally relapsed and or metastatic sporadic MTC surgically treated (total thyroidectomy)
62802370|NCT05676502|ACTIVE_COMPARATOR|Nasal High Flow with Optiflow M cannula|Nasal high flow treatment 35L/min with the standard symmetric nasal cannula (Optiflow M)
62802371|NCT05676502|ACTIVE_COMPARATOR|Nasal High Flow with Optiflow Duet Cannula|Nasal high flow treatment 35L/min with the asymmetric nasal cannula (Optiflow Duet)
62227007|NCT03276325|PLACEBO_COMPARATOR|Placebo-nalbuphine|Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
62227008|NCT03276325|ACTIVE_COMPARATOR|Dexamethasone-nalbuphine|Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
62227009|NCT00657670|EXPERIMENTAL|1|Ready-made spectacles
62227010|NCT00657670|ACTIVE_COMPARATOR|2|Spectacles
62802372|NCT06206538|EXPERIMENTAL|The observation group|"The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided.~Based on the invention above, the patients in the observation group were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)"
62227011|NCT03013660|NO_INTERVENTION|Comparison|Participants will be provided with standard information about the benefits of STSC and breastfeeding and will be encouraged to come into the NICU every day for at least 1 hour of STSC. To facilitate increased let down of breast milk, all participants will be provided a hospital grade breast pump free of charge during the stay of their babies in the NICU and assistance will be provided to the mothers in procuring a Medicaid covered breast pump to keep when the baby leaves the NICU. The hospital grade breast pump will be provided to her as soon as she enrolls into the study and will remain with her until her baby is discharged or transferred.
62227012|NCT03013660|EXPERIMENTAL|Treatment: Limited Financial Support|Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment. The participants selected for the intervention arm will be asked not to discuss the payment with any other study participants (such as the members of any other families they may see at the NICU) or other health care staff at the NICU. Participants will also receive everything that the Comparison group receives.
62227013|NCT03076333|EXPERIMENTAL|Single Arm: PET/MR|Each patient will undergo three combined PET/MR scans. The pre-treatment PET, mid-treatment PET and MR, and post-treatment PET are for research purposes and not part of the patient's standard of care (pre-treatment MR and post-treatment MR).
62227014|NCT01374373|OTHER|Open Label|One arm open label
62227015|NCT05037877|ACTIVE_COMPARATOR|Intervention group|HUM supplement - 1 capsule per day
62802373|NCT06206538|ACTIVE_COMPARATOR|The control group|"The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
62802374|NCT02744365||Prediction Group|The women recruited in the biobank through the Prediction Study (NCT02189148) are low-risk pregnant women between 11 and 13 6/7 weeks of gestation (N=7600 maximum).
62802375|NCT02744365||PEARL Group|"The women recruited in the biobank through the PEARL Study (NCT02379832) are :~1. low-risk pregnant women between 11 and 13 6/7 weeks of gestation (controls, N=45)~2. pregnant women with diagnosis of preeclampsia between 20 and 41 6/7 weeks of gestation (cases, N=45)"
62802376|NCT02744365||GAP Group|The women recruited in the biobank through the GAP Trial (NCT02280031) are women pregnant with twins between 11 3/7 and 13 6/7 weeks of gestation(N=50 maximum) randomized for placebo or aspirin.
62802377|NCT02744365||PREDICTION 2 Group|The women recruited in the biobank through the Prediction-2 Study (NCT03067298) are nulliparous pregnant women between 14 and 15 6/7 weeks of gestation (N=1000 maximum).
62802378|NCT02744365||HAUPE Study|Women that are at risk of pre-eclampsia and great obstetrical syndroms (elevated maternal age, invitro fertilization, chronic disease) (N=60) and a control group not at risk (N=60)
62227016|NCT05037877|PLACEBO_COMPARATOR|Placebo group|Placebo supplement - 1 capsule per day
62227017|NCT00551941|ACTIVE_COMPARATOR|2|non-union of diaphysary tibial fractures will be treated with allograft together with DBM
62227018|NCT00551941|EXPERIMENTAL|1|non-union of diaphysary tibial fractures will be treated with BMP-7 in adjunct to fresh frozen allograft
62227019|NCT05751772|EXPERIMENTAL|"Patient therapeutic education group"|The intervention group will benefit from a pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients and usual hospital care (medical and nursing care)
62802379|NCT02471235|EXPERIMENTAL|Intervention group|The physiotherapist will provide every patient an individualized physical training programme that fits their cardiopulmonary status. Patients will have the training as out-patient in the physiotherapy department for 4-8 sessions, 2 hours each time, 1-2 times weekly. Home exercise will be taught. Our case manager will give phone calls to the subject every 2 weeks to provide support and reinforcement for having continuous exercise at home for one year. Patients will be invited to attend reinforcement out-patient physiotherapy training once very month or every 2 months if they are willing to attend.
62802380|NCT02471235|NO_INTERVENTION|Control group|The control group will receive no physiotherapy training by physiotherapist and no phone calls from case manager for reinforcement of home exercise. .
62802381|NCT05659823|ACTIVE_COMPARATOR|Control group|Elective CS patients receiving current analgesia.
62802382|NCT05659823|EXPERIMENTAL|Intervention group|Elective CS patients receiving guideline recommended analgesia.
62802383|NCT05659823|EXPERIMENTAL|Emergency group|Emergency CS receiving current analgesia.
62802384|NCT04821258|EXPERIMENTAL|MICODIGEST 2.0 supplement|Treatment with MICODIGEST 2.0 will initiate with 10mL/day (before breakfast or before lunch) for 7 days, and rise to 20mL/day (10mL before breakfast and 10 mL before dinner) for 4-6 weeks.
62802385|NCT04821258|PLACEBO_COMPARATOR|Placebo|Treatment with placebo will initiate with 10mL/day (before breakfast or before lunch) for 7 days, and rise to 20 mL/day (before breakfast and before dinner) for 4-6 weeks.
62227020|NCT05751772|NO_INTERVENTION|"Usual hospital care group"|The control group do only benefit from the usual hospital care (any medical and nursing care giving to an acute heart failure inpatient) and won't benefit from the pharmacist's educational intervention.
62419916|NCT06568809||0-2 weeks; 3-4 weeks; 5-6 weeks; 7-8 weeks|"The time between body temperature recovery and surgery was collected as categorical factor and was scheduled to be analyzed in the following categories: 0-2 weeks; 3-4 weeks; 5-6 weeks; 7-8 weeks.~1. Before operation:~   ① Ask the children about the history of upper respiratory tract infection complicated with fever, and record the symptoms of upper respiratory tract infection.~   ② The symptoms of upper respiratory tract infection were collected on the day of operation.~   ③ Record the patient's age, sex, height, weight and ASA grade.~   ④ The preoperative chest X-ray imaging examination was collected.~2. During the operation:~   * Record the average arterial pressure and heart rate before and after entering the room, intubation, extubation and operation room.~     ② Record the lowest value of oxygen saturation of hypoxemia during intubation and extubation.~     ③ Record the treatment process when PRAEs appear.~     ④ Record all anesthetic dosage.~     ⑤ Record the total operation time."
62802386|NCT03612778|EXPERIMENTAL|Plant-based diet|Participants will receive a meal plan based on unrefined plant-based foods with the following macronutrient composition: approximately 15% of calories from vegetable protein, \<15% from fat, and 70-75% from carbohydrates. Additionally, to ensure adequate intake of n-3 polyunsaturated fatty acids, they will receive a supplement in the form of one 840 mg n-3 acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily. Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.
62802387|NCT03612778|ACTIVE_COMPARATOR|Mediterranean diet|Participants will receive a meal plan, based on the recommendations by the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology and European Atherosclerosis Society, based on Mediterranean diet pattern with the following macronutrient composition: approximately 15% of calories from animal and vegetable protein, up to 30% of calories from fat, 50-65% from carbohydrates. Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.
62802388|NCT01673828|EXPERIMENTAL|Allopregnanolone|Allopregnanolone injection (intravenous solution) continuous infusion for 5 days
62802389|NCT01673828|PLACEBO_COMPARATOR|Placebo|Placebo injection (intravenous solution) continuous infusion for 5 days
62802390|NCT03314701|ACTIVE_COMPARATOR|Group 1|"Biphasic Intermittent Positive Airway Pressure (BIPAP) group:~Following endotracheal intubation BIPAP mode will be started with:~* Inspiratory positive airway pressure \[IPAP\] at 20 cmH2O~* Expiratory positive airway pressure \[EPAP\] at 5 cmH2O~* PRESSURE SUPPORT is difference between these two pressures \[IPAP\]- \[EPAP\]~* Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed"
62227021|NCT02667847||Preoperative patients|Preoperative patients were asked to verbally rate their anxiety 1=on a scale from 0-10 and 2=using the new smiley scale
62227022|NCT03513588|PLACEBO_COMPARATOR|Placebo|
62227023|NCT03513588|EXPERIMENTAL|PF-06865571 100 mg|
62227024|NCT03513588|EXPERIMENTAL|PF-06865571 600 mg|
62227025|NCT01442818|EXPERIMENTAL|Scheduled IV post op|Patient's will receive scheduled nurse administered IV pain medications post operatively.
62227026|NCT01442818|EXPERIMENTAL|PCA post op|Patients will receive PCA for pain control post operatively.
62227027|NCT02621125|EXPERIMENTAL|Fertilix|Fertilix supplementation
62028125|NCT05558059||Cohort 1|"16 preterm infants undergoing ROP screening to optimize methods to acquire and process beside infant perifoveal vascular imaging and assess rigor and reproducibility.~The visits in the ICN (Intensive Care Nursery) will occur between 32 and 43 weeks post menstrual age at the time of ROP screening exams. Study visits will include, but are not limited to:~* Ocular examination~* OCT imaging of retinal microanatomy~* OCTA imaging of retinal microvasculature~* Medical and ocular history~* Adverse event documentation"
62028126|NCT04055948|NO_INTERVENTION|Control - Standard of Care|- All participants will be screened for health literacy using a 4-item Brief Health Literacy Screening Tool (BRIEF)
62028127|NCT04055948|EXPERIMENTAL|Intervention|"* All participants will be screened for health literacy using a 4-item Brief Health Literacy Screening Tool (BRIEF)~* Three in-person, one-on-one teaching sessions with the caregiver during radiation treatments, followed by a telephone booster contact 2 weeks post-treatment."
62028128|NCT00803647|EXPERIMENTAL|treatment|mFOLFOX7 (5-FU, leucovorin, oxaliplatin) + cetuximab
62028129|NCT02239718|EXPERIMENTAL|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
62028130|NCT02239718|ACTIVE_COMPARATOR|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
62028131|NCT02961140|EXPERIMENTAL|Cardiac Output Maximization|maximize stroke volume, and maintain cardiac index and stroke volume variation during the whole operation
62028132|NCT02961140|ACTIVE_COMPARATOR|Cardiac Output Normalization|keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation
62227028|NCT02621125|PLACEBO_COMPARATOR|Placebo|Placebo
62227029|NCT05949112|EXPERIMENTAL|Manual|Manual toothbrush
62227030|NCT05949112|EXPERIMENTAL|Mechanical|Mechanical toothbrush
62590241|NCT01676896|EXPERIMENTAL|Asthma in-school class|Provided in 16 15-minute sessions (4 hours total didactic time); scheduled 3 sessions/week. The content is provided by trained asthma educators. The Asthma Plan for Kids (AP-K) is a 7-step curriculum for children to use when responding to asthma symptoms. Skills practice with placebo metered dose inhaler (MDI) and peak expiratory flow (PEF) meters with PEF score interpretation. Topics include (a) identifying lung function, asthma warning signs, symptoms, and triggers; (b) learning skills to manage symptoms, including PEF meter score interpretation, communication with adults (e.g. teachers, coaches, family members), medication use and MDI technique; (c) evaluating asthma symptoms and the effectiveness of management; and (d) discussing how to stay active in a safe manner.
62802391|NCT03314701|ACTIVE_COMPARATOR|Group 2|"Airway Pressure Release Ventilation (APRV) group:~* high airway pressure (Phigh) will be set at 20 cmH2O~* low airway pressure ( Plow) will be set at 5 cmH2O~* the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min~* T high at 4.5-6 seconds~* T low at 0.5 to 0.8 second"
62227031|NCT01947985||Rivaroxoban|Patients who have been prescribed Rivaroxaban for the first time
62227032|NCT01947985||Standard of care|Patients who have been prescribed standard of care for the first time
62227033|NCT04206930|NO_INTERVENTION|Control|Standard support: information on alcoholic pathology, medico-psycho-social assessment, relapse prevention program
62227034|NCT04206930|EXPERIMENTAL|Art-Therapy|in addition to standard treatment, art therapy treatment program: 1 session of 2 hours per week in a closed group for 10 weeks
62227035|NCT00552487|OTHER|1|healthy people without Hashimoto disease receive a 1µg ACTH stimulation test
62227036|NCT00552487|OTHER|2|patients with Hashimoto disease with well being receive a 1 µg ACTH stimulation test
62227037|NCT00552487|OTHER|3|patients with Hashimoto disease an impaired well-being receive a 1 µg ACTH stimulation test
62028133|NCT00747799|EXPERIMENTAL|1|Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)
62028134|NCT06360835||cases of recurrent fractures of the proximal end of the femur following surgical treatment failure|
62028135|NCT01953796|EXPERIMENTAL|Study of Stair-step Clomiphene Protocol|50 mg clomiphene given for 5 days beginning on day 2 of the cycle. Tv USS done at days 11-14. When there is no response (no follicle \>10 mm), 100 mg clomiphene is initiated immediately for 5 days, and U/S is repeated 1 week after the first tvUSS at day 21. If there is no response, another 150 mg clomiphene is initiated immediately for 5 days and U/S is performed 1week after the second U/S (day28). Ovulation for the stair-step cycles was confirmed by folliculometry (follicle tracing) by tvUSS.
62227038|NCT00552487|OTHER|4|patients with Hashimoto disease and negative TPO antibodies receive a 1µg ACTH stimulation test
62227039|NCT03322748|EXPERIMENTAL|Experimental group|Usual physical therapy+ strengthening of lower limbs muscles
62227040|NCT03322748|OTHER|Control group|Usual physical therapy
62227041|NCT02299492|EXPERIMENTAL|Person-Centered Care Planning|Arm will receive provider level training in Person Centered Care Planning
62227042|NCT02299492|NO_INTERVENTION|Treatment as Usual|Arm will receive treatment as usual in community mental health clinic
62227043|NCT04923074||DTI group|the patient in this group will receive DTI evaluation
62433554|NCT05157607|EXPERIMENTAL|Family Connections Protocol for Relatives of Patients with SBD.|"The intervention lasts three months and includes 12 sessions with a weekly two-hour group format. The FC program is divided into six modules:~Module 1: Up-to-date information and research on suicide (Epidemiology, frequency, Risk factors, protective factors).~Module 2: Psychoeducation on the development of suicide, explanatory theories, available treatments, comorbidity.~Module 3: Emotional regulation skills, skills of acceptance, validation, approach, awareness, and to decrease emotional reactivity.~Module 4: Skills to improve the quality of relationships in family interactions (letting go of guilt and anger, acceptance skills in relationships).~Module 5: Communication skills and effective self-expression. Module 6: Problem management and making safe plans for crisis management."
62802392|NCT02333357|EXPERIMENTAL|Toolkit|Counselors randomized to the toolkit (TK) condition will receive a one to three hour standardized toolkit orientation that will include a description of the overall goal of the toolkit curriculum comprised of five modules, the purpose of each individual element of the toolkit, and an introduction to the toolkit teaching aids such as counselor guides, posters, and patient materials (hand-outs, sampling menus, worksheets, etc). TK counselor participants then conduct group treatment sessions using the toolkit materials with their patient participants.
62802393|NCT02333357|ACTIVE_COMPARATOR|Treatment as Usual|Counselors assigned to the Treatment as Usual (TAU) attention control condition complete a training that reviews the same five 12-step topics that are included in the toolkit, but they do not receive any toolkit materials. TAU counselor participants then conduct group treatment sessions on the 12-step topics without using toolkit materials.
62802394|NCT03482531||before group|"In the before group, the investigators retrospectively included 405 patients who had a dinoprostone vaginal insert for cervical ripening before induction of labor, between January 2015 and September 2016.~Multivariate and regression analysis showed that the factors significantly increasing the time to delivery were: Nulliparity, obesity, a closed cervix on initial examination, and intact membranes at the time of insertion. The investigators also described a regression equation that allows to calculate the mean time from insert placement to delivery for each patient."
62227044|NCT04923074||routine group|the patient in this group will receive routine evaluation
62227045|NCT00611312|EXPERIMENTAL|1|Cognitive Training
62028136|NCT01953796|ACTIVE_COMPARATOR|Traditional Protocol.|Clomiphene medication was initiated at day two of the cycle. The starting dose was 50 mg/day for 5 consecutive days. In case of absent response, the patient was treated with 10 mg medroxyprogesterone acetate (MPA) for10 days. Daily doses of clomiphene citrate were increased by 50 mg in the next cycle up to 3 treatment cycle. In each cycle monitoring of follicular growth was done by tvUSS at day 11-14 of each cycle. First ovulation was used as the endpoint and the duration of follow-up was three treatment cycles (up to 150mg). Ovulation was assessed by tvUSS monitoring of follicle growth.
62802395|NCT03482531||after group|"The investigators will prospectively include all eligible patients with a vaginal dinoprostone insert for cervical ripening during the next two years, starting on April 1st, 2018. At Angers hospital, there are around 600 cases of dinoprostone vaginal inserts per year, so the investigators will be able to include 400 to 500 patients during the study's duration.~The equation will be incorporated when scheduling patients for cervical ripening with vaginal dinoprostone insert. The main objective of this study is to analyze to evaluate our mathematical model. One of the secondary objectives is to analyze whether the use of the personalized scheduling based on the mathematical model would decrease the rate of nocturnal deliveries (between midnight and 6 a.m.)."
62028137|NCT05078944|EXPERIMENTAL|Active acupuncture + Donepezil|Active acupuncture treatment is to be taken 3 sessions weekly over a period of 14 weeks. Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily over 32 weeks (including 4-week run-in) Intervention: Device: Acupuncture + Drug: Donepezil hydrochloride
62028138|NCT05078944|SHAM_COMPARATOR|Sham acupuncture + Donepezil|Sham acupuncture treatment with no skin penetration and no current output on sham acupoints is to be taken 3 sessions weekly over a period of 14 weeks. Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily over 32 weeks (including 4-week run-in) Intervention: Device: Sham acupuncture + Drug: Donepezil hydrochloride
62028139|NCT04305613||Cohort|Patients with locally advanced non-small cell lung cancer
62028140|NCT03125304|EXPERIMENTAL|treatment group|Treatment group will receive acupuncture at Sanyinjiao (SP 6), Zhaohai (KI 6) ,Taichong (LR 3) ,Qichong (ST 30) and Guanyuan.
62028141|NCT03125304|PLACEBO_COMPARATOR|control group|Control group will receive acupuncture at non-acupoints.
62802396|NCT05543902|EXPERIMENTAL|Intervention group: Breastfeeding Problems Management Model (BPMM)|The women in the intervention group were provided with nursing interventions according to the BPMM by the researcher. LATCH (pre-test) was administered before discharge from the hospital; women were given the education booklet; and their contact information was recorded. After discharge from the hospital, the women were called by phone in the 1st, 2nd, and 6th weeks, BES was read, and the scale was filled in by the researcher based on the women's responses. Women who were found to experience breastfeeding problems in these phone calls were provided with consultancy and home visits. In the 8th week, home visits were done and the education was repeated. The women were administered the BES, LATCH (post-test), and BMS.
62802397|NCT05543902|NO_INTERVENTION|No Intervention: Standard care group|The women in standard care group were not provided with any interventions by the researcher. They were provided with standard care at the hospital. Before discharge from the hospital, the LATCH (pre-test) was administered and women's contact information was recorded. After discharge from the hospital, the women were called by phone in the 1st, 2nd, and 6th weeks. BES were read on the phone, and the scale was filled in by the researcher based on the women's responses. Home visits were performed in the 8th week, and the women were administered the BES, LATCH (post-test), and BMS
62802398|NCT02857608|EXPERIMENTAL|Lymphoseek - 0.5 mCi, 50 ug|A single dose of 50 µg Lymphoseek radiolabeled with 0.5 millicurie (mCi) (18.5 MBq) 99m Tc
62802399|NCT01145846|EXPERIMENTAL|Arm I (AI regimen)|Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Idarubicin 12 mg/m2/day iv daily for 3 days (D 1-3)
62802400|NCT01496235|ACTIVE_COMPARATOR|Dark chocolate|Presence of 70% cocoa solids
62028142|NCT04156308|EXPERIMENTAL|Combined exercises+OMT weekly|"* This group will conduct a home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality~* This group will also receive Osteopathic Manipulative Treatment (OMT): exactly 3 sessions with a weekly frequency (with + -2 days of margin: between 5 and 9 days)."
62028143|NCT04156308|EXPERIMENTAL|Combined exercises+OMT once every 3 weeks|"* This group will conduct a home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality~* This group will also receive Osteopathic Manipulative Treatment (OMT): exactly 3 sessions at the rate of one session every 3 weeks (with + -2 days of margin: between 19-23 days)."
62028144|NCT04156308|EXPERIMENTAL|Combined exercises|This group will conduct a home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality.
62028145|NCT00778466|EXPERIMENTAL|1|metformin hydrochloride 1000 mg tablets of ranbaxy
62028146|NCT00778466|ACTIVE_COMPARATOR|2|GLUCOPHAGE® (metformin hydrochloride) 1000 mg tablets
62227046|NCT04438577|EXPERIMENTAL|Efficacy of Lidocaine mucilage-ICG|Efficacy of Lidocaine mucilage-ICG for intraoperative tumor delineation
62590242|NCT01676896|EXPERIMENTAL|Asthma Day Camp|The asthma day camp is provided in a single day session (5.5 hours total) by trained camp staff. The same skills (i.e., placebo metered dose inhaler (MDI) and peak expiratory flow (PEF) meters) and topics \[a) identifying lung function, asthma warning signs, symptoms, and triggers; (b) learning skills to manage symptoms, including PEF meter score interpretation, communication with adults (e.g. teachers, coaches, family members), medication use and MDI technique; (c) evaluating asthma symptoms and the effectiveness of management; and (d) discussing how to stay active in a safe manner\] are covered as those in the asthma in-school classes.
62802401|NCT01496235|PLACEBO_COMPARATOR|White chocolate|
62028147|NCT02075593|EXPERIMENTAL|DTG/ABC/3TC|All subjects will be administered DTG 50 milligrams (mg)/ABC 600 mg/3TC 300 mg FDC tablet once daily, with or without food.
62227047|NCT03948724|EXPERIMENTAL|Therapeutic patient education|Patient will receive 5 therapeutic education sessions.
62227048|NCT03948724|ACTIVE_COMPARATOR|Standard Care|Patient will receive usual informations
62227049|NCT03568331|EXPERIMENTAL|Tradipitant|
62227050|NCT03568331|PLACEBO_COMPARATOR|Placebo|
62227051|NCT01436188|OTHER|001 (Healthy Elderly Cohort 1)|standard frequent CSF sampling procedure for 36 hours
62419917|NCT06568809||≥3 month(control group)|"The time between body temperature recovery and surgery was collected as categorical factor and was scheduled to be analyzed in the following categories≥ 3 months (control group).~1. Before operation:~   ① Ask the children about the history of upper respiratory tract infection complicated with fever, and record the symptoms of upper respiratory tract infection.~   ② The symptoms of upper respiratory tract infection were collected on the day of operation.~   ③ Record the patient's age, sex, height, weight and ASA grade.~   ④ The preoperative chest X-ray imaging examination was collected.~2. During the operation:~   * Record the average arterial pressure and heart rate before and after entering the room, intubation, extubation and operation room.~     ② Record the lowest value of oxygen saturation of hypoxemia during intubation and extubation.~     ③ Record the treatment process when PRAEs appear.~     ④ Record all anesthetic dosage.~     ⑤ Record the total operation time."
62028148|NCT03285282|ACTIVE_COMPARATOR|Intervention|Thoracolumber interfascial plane block
62227052|NCT01436188|OTHER|002 (Healthy Elderly Cohort 2)|an alternative frequency of CSF sampling procedure for 36 hours
62028149|NCT03285282|NO_INTERVENTION|Control|
62227053|NCT01436188|OTHER|003 (Healthy Elderly Cohort 3)|standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
62227054|NCT01436188|OTHER|004 (Elderly Volunteers with MCI or AD)|standard CSF sampling procedure for 36 hours
62227055|NCT01436188|OTHER|005 (Healthy Eldely Cohort 5)|an alternative lower frequency of CSF sampling in comparison to Cohort 1
62227056|NCT06207331|EXPERIMENTAL|Dexmedetomidine 0.5 μg/kg|Participants inhale 0.5 μg/kg dexmedetomidine prepared in 2 ml 0.9% saline.
62227057|NCT06207331|EXPERIMENTAL|Dexmedetomidine 1 μg/kg|Participants inhale 1 μg/kg dexmedetomidine prepared in 2 ml 0.9% saline.
62227058|NCT06207331|PLACEBO_COMPARATOR|Placebo|Participants inhale 2 ml atomized 0.9% saline.
62802402|NCT04006951|EXPERIMENTAL|Biological collection|"For all the patients include in the study :~* Paraffin tissue samples (if applicable) collected during pre-therapeutic rectal biopsy~* Blood samples collected at different times : Before any treatment and Before surgery if the patient received pre-operative radiochemotherapy~In parallel to this biological collection, standardized clinical data will be entered into a database"
62227059|NCT00680589|EXPERIMENTAL|1|Injection of mouse TYRP2 DNA in patients with highrisk melanoma.
62227060|NCT01574391|ACTIVE_COMPARATOR|EPIDRUM|EPIDRUM DEVICE IS USED TO SITE THE EPIDURALS IN THE PATIENTS RANDOMISED TO THIS ARM
62227061|NCT01574391|NO_INTERVENTION|Control|This arm is the control where normal technique is used
62227062|NCT00665912|OTHER|1|Standard post-lobectomy wound care plus use of PRP and PPPc in the thoracic cavity.
62028150|NCT01745861|ACTIVE_COMPARATOR|Lipidem® (BBraun)|Lipid emulsion containing medium chain triglycerides (MCT), long chain triglyceride (LCT) and Omega-3 fatty acid (fish oil)
62028151|NCT01745861|PLACEBO_COMPARATOR|Lipofundin® MCT/LCT 20%|Lipid emulsion containing medium and long chain triglycerides
62227063|NCT00665912|ACTIVE_COMPARATOR|2|Standard post-lobectomy wound care in the thoracic cavity
62227064|NCT02678247|ACTIVE_COMPARATOR|NU-FlexSIV Socket|The Northwestern University Flexible Sub-Ischial Vacuum Socket is a novel socket design for transfemoral amputees.
62227065|NCT02678247|ACTIVE_COMPARATOR|IC Socket|The Ischial Containment Socket is the standard of care socket design for transfemoral amputees.
62227066|NCT01976351||Barrett's esophagus|Patients were eligible for the study if they were scheduled for endoscopic examination at the National Taiwan University Hospital and its Yun-Lin branch, because of a BE, with or without a previous history of dysplasia. Exclusion criteria included patients who are younger than 20 years of age or patients with esophageal or cardiac varices or pregnant women.
62227067|NCT00202293|EXPERIMENTAL|Lithium and olanzapine|
62227068|NCT00202293|ACTIVE_COMPARATOR|Lithium and chlorpormazine|
62227069|NCT01140711|EXPERIMENTAL|Gastric bypass|Patients submitted to gastric bypass for treatment of morbid obesity
62227070|NCT01140711|EXPERIMENTAL|Sleeve gastrectomy|Patients submitted to sleeve gastrectomy for treatment of morbid obesity
62227071|NCT05279001|EXPERIMENTAL|Jaktinib|
62802403|NCT03583853||patients|take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of Ribonucleic acid (RNA) to determine the expression of autophagy genes by real time polymerase chain reaction (real time PCR)
62028152|NCT04597320|ACTIVE_COMPARATOR|Fentanyl group|"The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer. Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
62028153|NCT04597320|EXPERIMENTAL|Esketamine group|"The esketamine group was prepared by 0.5mg/kg esketamine in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer. Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
62028154|NCT03521635|EXPERIMENTAL|Pramipexole SR|
62028155|NCT03521635|ACTIVE_COMPARATOR|Pramipexole IR|
62802404|NCT03583853||control|take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of RNA to determine the expression of autophagy genes real time polymerase chain reaction
62802405|NCT01769963|EXPERIMENTAL|Dietary intervention|All participants will be fed a high AGE diet followed by a low AGE diet (single arm study)
62802406|NCT05931926||Patients with adrenal insufficiency|10 patients with adrenal insufficiency due to pituitary desease will be recruited for this arm.
62802407|NCT05931926||Healthy controls|10 healthy controls will be recruited for this arm.
62802408|NCT02510625|ACTIVE_COMPARATOR|Bankart repair|Arthroscopic bankart repair
62802409|NCT02510625|EXPERIMENTAL|Anatomic Glenoid Reconstruction|Arthroscopic distal tibia bone graft
62802410|NCT06007183|ACTIVE_COMPARATOR|Group 1a|CHIKV VLP vaccine booster, 3 years post initial vaccination
62028156|NCT02616094|EXPERIMENTAL|Treatment Seeking Alcohol Dependent Adults|Group consists of 100 treatment seeking alcohol dependent (AD) men and women (ages 18-60). AD subjects will complete either 8 weeks of outpatient treatment at the Yale Stress Center, or the first 4 weeks as inpatient treatment at the CNRU, followed by 4 weeks of outpatient treatment at the Yale Stress Center. While in outpatient treatment, AD subjects may be admitted to the CNRU or HRU for the 1-5 days prior to one or both of their scans, to ensure abstinence for their scans.
62802411|NCT06007183|PLACEBO_COMPARATOR|Group 1b|Placebo booster, 3 years post initial vaccination
62802412|NCT06007183|ACTIVE_COMPARATOR|Group 2a|CHIKV VLP vaccine booster, 4 years post initial vaccination
62802413|NCT06007183|PLACEBO_COMPARATOR|Group 2b|Placebo booster, 4 years post initial vaccination
62802414|NCT06007183|ACTIVE_COMPARATOR|Group 3a|CHIKV VLP vaccine booster, 5 years post initial vaccination
62802415|NCT06007183|PLACEBO_COMPARATOR|Group 3b|Placebo booster, 5 years post initial vaccination
62028157|NCT02616094|ACTIVE_COMPARATOR|Social Drinking Controls|Group consists of demographically and handedness matched 50 socially drinking controls. Healthy controls will be moderate and binge/heavy social drinkers who will participate in a single MRI session after baseline assessments. Healthy controls may be admitted to the HRU overnight prior to their scan.
62227072|NCT02270515|EXPERIMENTAL|PCMH-KD dialysis care|Dialysis care team is expanded to include a primary care doctor, nurse coordinator, community health worker, and pharmacist. Enrolled patients are observed for an initial baseline period receiving care under the usual dialysis care model called the 'usual dialysis care phase'.
62227073|NCT04871854|EXPERIMENTAL|Svere infected Covid-19 control|Arm one confirmed sever COVID 19 infection admitted to ICU including with or without breast cancer patients comorbidity receive traditional therapy
62227074|NCT04871854|ACTIVE_COMPARATOR|sever infected Covid -19 pateints study|Arm two patients with confirmed sever COVID 19 infection admitted to ICU with or without breast cancer patients comorbidity tocilizumab
62802416|NCT06007183|NO_INTERVENTION|Group 4|Unrandomized or unboosted participants, for any reason
62802417|NCT00359996|ACTIVE_COMPARATOR|Health disparities collaborative|The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.
62802418|NCT00359996|ACTIVE_COMPARATOR|Control|No additional educational sessions added to usual care of patients.
62802419|NCT02343393|EXPERIMENTAL|H-ISDN|Eligible patients randomised to treatment arm will be initiated on a starting dose of hydralazine 60mg and ISDN 30mg daily (20/10mg three times daily). After 7 days following the first dose, if the starting medication is well-tolerated, the patient is instructed to double the dose of study medication to the target maintenance dose of hydralazine 120mg and ISDN 60mg daily for 24 weeks
62227075|NCT02309255||coronary heart disease patients|
62227076|NCT01689337|EXPERIMENTAL|Sprifermin (AS902330), 30 mcg|
62419918|NCT00756652||MemoryGel Breast Implant Participants|MemoryGel Breast Implant Participants received Mentor Silicone Gel-Filled Breast Implants (MemoryGel) during their Breast Augmentation, Breast Reconstruction, or Revision surgery
62802420|NCT02343393|NO_INTERVENTION|Standard Medical Therapy|Current standard HF therapy include the use of beta-blockers, ACE inhibitors/ARBs and diuretics.
62802421|NCT03326778||AVR + CABG|Patient receiving AVR combined with CABG
62802422|NCT01858792||Baseline Health-Related Quality of Life (HRQOL)|Quality of life assessment tools were similar across the treatment groups and indicated that there was impairment in quality of life of subjects in the Low C+anti-dsDNA Population
62028158|NCT02616094|ACTIVE_COMPARATOR|Prazosin/Placebo Group|This is a separate group of 60 treatment seeking AD subjects in a NIAAA-funded RCT of Prazosin vs placebo for alcohol dependence ( PI: Sinha, Hic protocol 0705002691, NCT00585780) to assess target primary and secondary predictors of alcohol treatment outcomes in the context of a currently ongoing RCT. AD subjects enrolled in the PZ/PL RCT will NOT be given drugs as part of this study. That study and intervention is listed elsewhere (NCT00585780). Subjects will participate in a baseline scan and a second scan between weeks 10-12 of the 12-week RCT with follow-ups. PZ/PL is only given to subjects enrolled in 0705002691, not the current protocol.
62802423|NCT01858792||SLE Medication Usage at Baseline|All subjects in the Low C+anti-dsDNA Population
62802424|NCT02489071|EXPERIMENTAL|Brain Training|8-session cognitive training program
62802425|NCT02489071|EXPERIMENTAL|Brain Health|8-session cognitive education program
62802426|NCT02489071|NO_INTERVENTION|Control|Wait-list control group
62802427|NCT05876507|EXPERIMENTAL|exercise|Participants will receive a training about progressive relaxation exercises on the first day, then given an audio-record containing instructions about exercises. They will perform exercises at home for 4 week and revisited by the principal investigator at the 2nd and 4th week.
62419919|NCT00756652||Saline Breast Implant Control Participants|Saline Breast Implant Control Participants received Saline Filled Breast Implants during their Breast Augmentation, Breast Reconstruction, or Revision surgery
62419920|NCT03933982|EXPERIMENTAL|Pyrotinib plus Vinorelbine|
62802428|NCT05876507|NO_INTERVENTION|Control|Participants will receive routine care.
62802429|NCT05482828|EXPERIMENTAL|JGT group|Treatment group: JGT (Jaeumgeonbi-Tang) tablet. 8 g t.i.d. for 28 days
62802430|NCT05482828|PLACEBO_COMPARATOR|Placebo group|Placebo group: Corn starch tablet, 8 g t.i.d. for 28 days
62802431|NCT01881516|ACTIVE_COMPARATOR|Acupuncture|Participants will receive 30-min sessions of true acupuncture per week after randomization for 6 weeks
62802432|NCT01881516|SHAM_COMPARATOR|sham acupuncture|Participants will receive 30-min sessions of sham acupuncture per week after randomization for 6 weeks.
62802433|NCT01599000|ACTIVE_COMPARATOR|Efficacy arm|Supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
62419921|NCT04288323|EXPERIMENTAL|Single arm|This is a single arm study in which all participants have one ultrasound and one abbreviated MR exam
62419922|NCT06419855||Human collagen matrix graft|Is a porous cross-linked human collagen Matrix or Sponge, used as a scaffold in the repair and restoration of dura mater defects, following craniotomy, laminectomy or in general when there is intentional (surgical procedure) or accidental damage to the dura mater.
62802434|NCT01599000|EXPERIMENTAL|Effectiveness arm|Un-supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
62802435|NCT00743249|EXPERIMENTAL|Canalicular stent, 10 mm|MINI MONOKA canalicular stent (tube), 10 mm, inserted in the lower lacrimal canaliculus (tear duct) of one eye for up to 3 months
62419923|NCT06419855||Bovine collagen matrix graft|Is a porous type 1 collagen matrix derived from bovine Achilles tendon, this matrix is absorbed after 8 weeks and is used for the repair and restoration of dura mater defects.
62419924|NCT04272255|ACTIVE_COMPARATOR|DPI-386 nasal gel|"DPI-386 Nasal Gel is formulated to contain 0.2 mg scopolamine HBr per 0.1 g dose, with each dose therefore described as 0.2 mg / 0.1 g"
62227077|NCT01689337|EXPERIMENTAL|Sprifermin (AS902330), 100 mcg|
62227078|NCT01689337|PLACEBO_COMPARATOR|Placebo|
62227079|NCT04991792|EXPERIMENTAL|Standard Infant Formula with synbiotics (CS-born)|CS born infants, randomized to receive infant formula with synbiotics
62227080|NCT04991792|EXPERIMENTAL|Standard Infant Formula with prebiotics (CS-born)|CS born infants, randomized to receive infant formula with prebiotics
62227081|NCT04991792|ACTIVE_COMPARATOR|Control Group 1: Standard Infant Formula (CS-born)|CS born infants, randomized to receive standard infant formula without synbiotics
62227082|NCT04991792|ACTIVE_COMPARATOR|Control Group 2 : Standard Infant Formula (VD-born)|VD born infants, receiving standard infant formula without synbiotics (self-selected for formula-feeding = non-randomized)
62227083|NCT04991792|NO_INTERVENTION|Reference Group 1: Breastfed (CS-born)|CS-born infants, receiving exclusive breast-feeding with mother's own breast milk (non-randomized)
62227084|NCT04991792|NO_INTERVENTION|Reference Group 2: Breastfed (VD-born)|VD-born infants, receiving exclusive breast-feeding with mother's own breast milk (non-randomized)
62802436|NCT00743249|EXPERIMENTAL|Canalicular stent, 20 mm|MINI MONOKA canalicular stent (tube), 20 mm, inserted in the lower lacrimal canaliculus (tear duct) of one eye for up to 3 months
62802437|NCT00390767|EXPERIMENTAL|MultiGeneAngio|Escalating doses of MultiGeneAngio
62419925|NCT04272255|PLACEBO_COMPARATOR|placebo nasal gel|Placebo nasal gel product is the same but does not contain scopolamine HBr
62419926|NCT04272255|EXPERIMENTAL|Transderm Scop®|TDS patch delivers 1.5 mg of scopolamine over a 72-hour period. TDS arm will apply two TDS patches over the six treatment days.
62419927|NCT02629380|EXPERIMENTAL|Hyaluronic acid group|Single injection of 3 ml HA (Hymovis, Fidia Farmaceutici SpA, Padova, Italy) at the end of the arthroscopic meniscectomy
62802438|NCT01432405|EXPERIMENTAL|Pioglitazone and exenatide|Exenatide 10 micrograms injected subcutaneously twice daily plus pioglitazone 45 mg daily orally for 12 months.
62028159|NCT03477448|ACTIVE_COMPARATOR|PPD group|"This group will include 20 patients who will be treated with IL injection of PPD at a dose of 10 IU (0.1 ml) supplied an insulin syringe in the largest wart.~Injections will be repeated for all patients into the same lesion (largest wart) every 2 weeks for three treatment sessions"
62028160|NCT03477448|ACTIVE_COMPARATOR|Bleomycin group|"This group will include 20 patients who will be treated with IL injection of bleomycin.~Injections will be repeated for all patients into the same lesion (largest wart) every 2 weeks for three treatment sessions, if needed."
62028161|NCT04297540|EXPERIMENTAL|Active-tDCS group|8 sessions (in two weeks) of active tDCS combined with a virtual reality training
62028162|NCT04297540|SHAM_COMPARATOR|Sham-tDCS group|8 sessions (in two weeks) of sham tDCS combined with a virtual reality training
62028163|NCT03727750|EXPERIMENTAL|Gemtuzumab Ozogamicin (GO)|Patients will receive three doses of Gemtuzumab Ozogamicin (GO) 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
62227085|NCT02080741|OTHER|Type A behaviour profile|
62227086|NCT02080741|OTHER|Type B behaviour profile|
62419928|NCT02629380|OTHER|meniscectomy alone|Arthroscopic meniscectomy alone
62802439|NCT01432405|EXPERIMENTAL|Pioglitazone|Pioglitazone 45 mg daily orally for 12 months
62802440|NCT02524171|EXPERIMENTAL|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
62802441|NCT02524171|NO_INTERVENTION|Usual Care (UC)|Usual care provided by the mental health residential rehabilitation treatment programs, which patients in both groups are in.
62802442|NCT04632771||Pilot survey: non-pregnant, non-lactating women|Survey of non-pregnant, non-lactating women 15-49 years of age (n=250)
62802443|NCT04632771||Pilot survey: lactating women|Survey of lactating women 15-49 years of age who are currently breastfeeding a child 4-18 months of age (n=250)
62802444|NCT04632771||Pilot survey: children|Survey of children 2-5 years of age (n=250)
62802445|NCT04632771||RID Pilot 1|Two-week study to assess total body vitamin A stores in a sample of non-pregnant, non-lactating women 15-49 years of age (n=30)
62802446|NCT04632771||RID Pilot 2|"Kinetic study with Super-woman design to develop a prediction equation to assess total body vitamin A stores among non-pregnant, non-lactating women 15-49 years of age (n=123)"
62802447|NCT04632771||Focus group discussions|Focus group discussions conducted among women of reproductive age, older women, and men (n=120 total)
62227087|NCT05742022|EXPERIMENTAL|"Phospholipovit"|Powder for preparing a solution for oral administration. 500 mg orally 2 times a day, for 12 weeks
62227088|NCT05742022|EXPERIMENTAL|Placebo|Powder for preparing a solution for oral administration. 500 mg orally 2 times a day, for 12 weeks
62419929|NCT05706311|EXPERIMENTAL|Intervention Pharmacy Site|"Pharmacies randomized to the experimental arm will be exposed to the intervention condition.~Patients at the intervention pharmacy identified as at elevated risk will receive confirmatory screening for opioid risk. Those with confirmed moderate risk will receive a brief motivational intervention for medication misuse and an offer of naloxone dispensation. Those with high risk will receive a brief motivational intervention leading to warm handoff treatment linkage intervention to primary or specialty substance use care with an offer for naloxone dispensation."
62433555|NCT05157607|ACTIVE_COMPARATOR|Treatment as Usual Optimized Protocol (TAU-O).|"Family members in this condition will continue to receive their treatment as usual in their care center of reference. In addition, we will optimize the treatment based on the recommendations of the international guidelines for the treatment of suicide. There will be one three-hour session in group format with the following component:~Module 1: Updated information and research on suicide (Epidemiology, frequency, Risk factors, protective factors). Psychoeducation on the development of Suicide, Explanatory theories. Available treatments, and comorbidity."
62802448|NCT04632771||Market assessment|Survey of retail outlets selling fortified staple foods and/or bouillon (n=50 shop owners or operators)
62802449|NCT04632771||Recipe observations|Observations of cooking of local dishes by selected participants (n=50) enrolled in the pilot survey.
62802450|NCT04657874|ACTIVE_COMPARATOR|Bromelain and Escin|
62802451|NCT04657874|PLACEBO_COMPARATOR|Placebo|
62802452|NCT06154564||Observed group|No intervention will be administered on behalf of the project. The participants will be tested using ALBA and PICNIR (non-invasive) cognitive tests, and further FAQ-CZ and GDS-CZ questionnaires will be administered.
62802453|NCT04011657|EXPERIMENTAL|Voluntary CDSS|Voluntary use of computerized decision support with prospective review and feedback
62802454|NCT04011657|NO_INTERVENTION|Compulsory CDSS|Compulsory use of computerized decision support with prospective review and feedback
62802455|NCT04335617|EXPERIMENTAL|Investigational|Patients receive MMPF 500mg for one year
62802456|NCT04335617|PLACEBO_COMPARATOR|Placebo|Patients receive Placebo for one year
62802457|NCT02864563|EXPERIMENTAL|Prospective cohort|Experimental arm, prospective cohort
62802458|NCT04995575||all MINDACT patients who relapse|
62802459|NCT00643968|ACTIVE_COMPARATOR|1|TDF+EFV
62802460|NCT00643968|EXPERIMENTAL|2|TDF+3TC+EFV
62802461|NCT00972101|EXPERIMENTAL|Regimen 1: No TBI|High Dose Chemotherapy without Total Body Irradiation (TBI)
62227089|NCT05049954|EXPERIMENTAL|Healthy Ketogenic Diet (HKD)|"Participants in the HKD group will be advised to follow a calorie-restricted healthy ketogenic diet (n=35), with a maximum of 50g net carbohydrate intake daily, with calorie prescriptions calculated based on the Schofield equation, adjusted with a deficit of 500 kcal daily to promote weight loss.~Participants will attend group workshops conducted by dietitians at weeks 1, 3, 5, 7, and thereafter at 6-week intervals over the course of a 6-month period (total of 7 workshops). Participants will also be recommended to use the Nutritionist Buddy (nBuddy) mobile application to facilitate monitoring of diet intake, steps count and to aid in their adherence to the diet and physical activity recommendations during the 6 months period. The participants will be recommended to achieve their incremental daily step count goal from 3,000, 7,000 to 10,000 to promote increased physical activity, as per their tolerance."
62227090|NCT05049954|ACTIVE_COMPARATOR|Low Fat caloric-restricted Diet (LFD)|"Participants in the reference group will be instructed to follow a calorie-restricted low fat diet (LFD) (n=35), with calorie prescriptions calculated based on the Schofield equation, adjusted with a deficit of 500 kcal daily to promote weight loss.~Similar to the experimental group, participants will attend group workshops conducted by dietitians at weeks 1, 3, 5, 7, and thereafter at 6-week intervals over the course of a 6-month period (total of 7 workshops). Participants will also be recommended to use the Nutritionist Buddy (nBuddy) mobile application to facilitate monitoring of diet intake, steps count and to aid in their adherence to the diet and physical activity recommendations during the 6 months period. The participants will be recommended to achieve their incremental daily step count goal from 3,000, 7,000 to 10,000 to promote increased physical activity, as per their tolerance."
62227091|NCT04256629|EXPERIMENTAL|Treatment ABC|Subjects will receive a single dose of all 3 treatments (A, B, and C) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
62227092|NCT04256629|EXPERIMENTAL|Treatment BCA|Subjects will receive a single dose of all 3 treatments (B, C, and A) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
62227093|NCT04256629|EXPERIMENTAL|Treatment CAB|Subjects will receive a single dose of all 3 treatments (C, A, and B) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
62227094|NCT04256629|EXPERIMENTAL|Treatment ACB|Subjects will receive a single dose of all 3 treatments (A, C, and B) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
62227095|NCT04256629|EXPERIMENTAL|Treatment BAC|Subjects will receive a single dose of all 3 treatments (B, A, and C) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
62227096|NCT04256629|EXPERIMENTAL|Treatment CBA|Subjects will receive a single dose of all 3 treatments (C, B and A) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
62419930|NCT05706311|OTHER|Control Pharmacy Site|Standard of Care is the treatment as usual condition, which follows federal and Ohio state pharmacy requirements for pharmacists where in patients filling prescriptions receive information and opt-in counseling. Ohio State law requires pharmacist to not dispense an opioid supply \>90 days, with a specific prohibition on dispensations ≥14 days after prescriptions are issued. Pharmacists are also required to perform a universal prescription drug medication review before initial dispensation and offer brief counseling (e.g., unstandardized information about medication safety) for new/modified prescription therapies.
62419931|NCT06132412|EXPERIMENTAL|active tDCS+PT|For those participants assigned to the active or sham tDCS groups, the overall set-up will be identical between groups and will use the Mini-CT device. However, the sham tDCS group will have the tDCS device turned off after 30 seconds of stimulation. Saline-soaked sponge electrodes that are 35 cm\^2 in size will be used for both the active and sham tDCS groups. For electrode placement, the active electrode (anode) will be placed over M1 contralateral to the side of primary knee pain (over C3/4 using the 10-20 system for electrode placement), while the reference electrode (cathode) will be over the contralateral supraorbital region, which is ipsilateral to the painful knee (Fp2 using the 10-20 system). The intensity will be set at 2mA for the active tDCS group, following a 30 second ramp-up time. The participants in the active tDCS group will undergo 20 minutes of tDCS treatment prior to receiving individualized PT intervention.
62433556|NCT04699643|EXPERIMENTAL|EVER4010001 combination with Pembrolizumab|EVER4010001 combination with Pembrolizumab, EVER4010001 started dose escalation from 40mg bid, and then to 60mg bid, 80mg bid, 100mg bid and 120 mg bid if applicable, dose escalation decision will be made by safety monitoring committee which is composed of the study team members. After phase II dose was recommended by safety monitoring committee, this dose will be applied to phase II patients. Pembrolizumab will be administered at 200mg every 3 weeks through the study.
62802462|NCT00972101|EXPERIMENTAL|Regimen 2: TBI|High Dose Chemotherapy with Total Body Irradiation (TBI)
62802463|NCT04221724|EXPERIMENTAL|Intervention Group|Multicomponent physical exercise intervention
62802464|NCT01165541|ACTIVE_COMPARATOR|Quetiapine fumarate extended release (Quetiapine XR)|Quetiapine XR 50-400mg
62802465|NCT01165541|EXPERIMENTAL|Quetiapine XR and Mirtazapine|Quetiapine XR 50-400mg + Mirtazapine 7.5-45mg
62419932|NCT06132412|SHAM_COMPARATOR|sham tDCS+PT|For those participants assigned to the active or sham tDCS groups, the overall set-up will be identical between groups and will use the Mini-CT tDCS device. However, the sham tDCS group will have the tDCS device turned off after 30 seconds of stimulation. Saline-soaked sponge electrodes that are 35 cm\^2 in size will be used for both the active and sham tDCS groups. For electrode placement, the active electrode (anode) will be placed over M1 contralateral to the side of primary knee pain (over C3/4 using the 10-20 system for electrode placement), while the reference electrode (cathode) will be over the contralateral supraorbital region, which is ipsilateral to the painful knee (Fp2 using the 10-20 system). The participants in the sham tDCS group will undergo 20 minutes of sham tDCS treatment prior to receiving individualized PT intervention.
62419933|NCT04640909|OTHER|CAR T Cells generation|CAR T Cells generation at baseline and after 6 and 12 months of treatment
62227097|NCT02831803|EXPERIMENTAL|Intervention|All participants will receive an 8-week supply of walnuts and Extra Virgin Olive Oil (EVOO). Study supplements will consist of 28 gm of walnuts and 32 gm of EVOO per day. Participants will be instructed how to consume the proper amount of walnuts and EVOO and to report their consumption using a compliance diary. The walnuts are pre-packaged in daily servings (one 28 g packet per day) and measuring spoons will be provided with the olive oil to assist participants in consuming it appropriately. Participants will also receive recipes and other written information that will assist them in incorporating both the nuts and olive oil into their existing dietary patterns.
62419934|NCT01910597|EXPERIMENTAL|SBG|
62590243|NCT01676896|SHAM_COMPARATOR|Health Promotion in-school class|The mock comparison follows the in-school format of 16 15-minute sessions; scheduled 3 sessions/week. The content is provided by trained health educators and includes skills practice (i.e., handwashing and brushing teeth) and health promotion topics of nutrition, healthy snacks, preventing colds, and safe exercise.
62590244|NCT05204862|EXPERIMENTAL|TU2218 Phase 1a|Escalating doses of TU2218 orally administered daily for two weeks followed by one week of rest for up to 21-day cycles
62590245|NCT05204862|EXPERIMENTAL|TU2218 Food Effect|TU2218 orally administered at a one dose level below MTD under fasting condition on -Day 2, followed by the same dose orally administered with meals on -Day 1 and then continued under fasted condition for two weeks followed by one week of rest for up to 21-day cycles
62227098|NCT03991819|EXPERIMENTAL|Phase 1|"Cycle 1 = 28 days and Cycle 2 and Future Cycles = 21 days~Binimetinib, by mouth (orally): Level 1: 45 mg, twice a day, continuously; Level -1: 30 mg, twice a day, continuously; Level -2: 30 mg, twice a day, for Days 1-14 of each cycle only~Pembrolizumab, by vein (intravenously), at a dose of 200 mg on Day 8 of Cycle 1, then Day 1 of Cycle 2 and future cycles."
62227099|NCT03991819|EXPERIMENTAL|Phase 1b|"All Cycles = 21 days~Binimetinib, by mouth (orally), at the best dose found in Phase 1 of the study, twice a day, continuously.~Pembrolizumab, by vein (intravenously), at a dose of 200 mg on Day 1 of every cycle."
62227100|NCT02823366|EXPERIMENTAL|Fenofibrate + UDCA|Fenofibrate in combination with ursodeoxycholic acid
62227101|NCT02823366|ACTIVE_COMPARATOR|Monotherapy|UDCA alone
62227102|NCT01614197|EXPERIMENTAL|Dose Level 1|This is the starting dose of temsirolimus at 7.5 mg/m\^2 given IV. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m\^2) and cyclophosphamide (440 mg/m\^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
62227103|NCT01614197|EXPERIMENTAL|Dose Level 2|If Dose Level 1 is tolerated, the study will escalate to Dose Level 2 following the dose escalation schedule. Dose Level 2 will be administered via IV at 10 mg/m\^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m\^2) and cyclophosphamide (440 mg/m\^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
62227104|NCT01614197|EXPERIMENTAL|Dose Level 3|If Dose Level 2 is tolerated, the study will escalate to Dose Level 3 following the dose escalation schedule. Dose Level 3 will be administered via IV at 15 mg/m\^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m\^2) and cyclophosphamide (440 mg/m\^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
62227105|NCT01614197|EXPERIMENTAL|Dose Level 4|If Dose Level 3 is tolerated, the study will escalate to Dose Level 4 following the dose escalation schedule. Dose Level 4 will be administered via IV at 25 mg/m\^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m\^2) and cyclophosphamide (440 mg/m\^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8. Temsirolimus will not be escalated beyond Dose Level 4.
62419935|NCT06438159|EXPERIMENTAL|Cardiac rehabilitation with Mindfulness-Based Stress Reduction (MBSR)|Conventional cardiac rehabilitation over 4 weeks with the introduction of MBSR over 8 weeks
62419936|NCT06438159|ACTIVE_COMPARATOR|Conventional cardiac rehabilitation|Conventional cardiac rehabilitation over 4 weeks
62419937|NCT00808015||Patients in routine practice|Patients prescribed Champix by treating physician and then entered into trial
62419938|NCT05120752|EXPERIMENTAL|FODMAP diet|
62419939|NCT06111417||Standard arm|Analysis carried out using the gold standard with BRCA1/2 results provided on average in 2 months + ultrafast BRCA1/2 test (nanopore test) with no communication of results to the patient at 1-2 weeks.
62433557|NCT03198637|EXPERIMENTAL|Monitoring|Neuromuscular Blockade's monitoring
62433558|NCT03198637|ACTIVE_COMPARATOR|Clinical assessment|No active monitoring of cisatracurium
62802466|NCT01749969|EXPERIMENTAL|SAR650984 (isatuximab)|"SAR650984 (isatuximab) (escalating dose) plus lenalidomide 25 mg on Days 1 to 21 plus dexamethasone 40 mg on Days 1, 8, 15, 22 in 28-day cycles for all cohorts up to disease progression.~For Q2W cohorts: SAR650984 (isatuximab) on Days 1 and 15 of every cycle. For QW/Q2W cohorts: SAR650984 (isatuximab) on Days 1, 8, 15, and 22 of first cycle and Days 1 and 15 of every subsequent cycle."
62802467|NCT03558919|EXPERIMENTAL|Mirabegron|Mirabegron 25mg will give daily at night for 12 weeks
62227106|NCT06016673|EXPERIMENTAL|Intermittent theta burst stimulation to right dorsolateral prefrontal cortex|Participants will receive intermittent theta burst stimulation (iTBS) to the experimental target area, the right dorsolateral prefrontal cortex (rDLPFC)
62227107|NCT06016673|ACTIVE_COMPARATOR|Intermittent theta burst stimulation to vertex of the skull|Participants will receive intermittent theta burst stimulation (iTBS) to the active comparator area, the vertex of the skull
62227108|NCT05325580|PLACEBO_COMPARATOR|Placebo Group|1g paracetamol + 20 min infusion of 150ml of saline serum
62227109|NCT05325580|EXPERIMENTAL|magnesium group|1g paracetamol + 20 min infusion of 2g magnesium in 150 ml of serum saline
62227110|NCT04984954|EXPERIMENTAL|Experimental group|This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
62802468|NCT03558919|ACTIVE_COMPARATOR|Solifenacin|Solifenacin Succinate 5mg will give daily at night for 12 weeks
62802469|NCT04644211|EXPERIMENTAL|Ruxolitinib Stage 1|"In stage 1, participants will be divided into two cohorts:~* Very low, Low, and Intermediate-risk ETpatients with significant symptom burden and Low-risk PV patients with significant symptom burden~* Study cycles are 28 days long, participants in both cohorts will receive:~  * Ruxolitinib 2x daily for 6 study cycles."
62227111|NCT04984954|PLACEBO_COMPARATOR|Placebo group|The control group was given placebo 4 capsules / day, 3 times / day, until the end of follow-up.
62227112|NCT01798121|EXPERIMENTAL|Aplisol|To compare new PPD to reference standard material
62227113|NCT01798121|PLACEBO_COMPARATOR|Reference standard|Response of standard material
62419940|NCT06111417||Experimental arm|Analysis carried out using the gold standard with BRCA1/2 results provided in an average of 2 months + ultra-rapid BRCA1/2 test (nanopore test) with results communicated to the patient in 1-2 weeks. This communication will be accompanied by the necessary explanations to enable the patient to understand that this is a preliminary result and that only the gold standard will constitute a definitive result.
62028164|NCT00798798|EXPERIMENTAL|Implantable Tissue Expansion Device|Will apply externally implantable tissue expansion device for 2 days
62802470|NCT04644211|EXPERIMENTAL|Ruxolitinib Stage 2|"Stage 2 will commence based on 3 or more participants in Stage 1 showing a predetermined positive response to Ruxolitinib.~In stage 2, participants will be divided into two cohorts:~* Very low, Low, and Intermediate-risk ET patients with significant symptom burden and Low-risk PV patients with significant symptom burden~* Study cycles are 28 days long, participants in both cohorts will receive:~  * Ruxolitinib 2x daily for 6 study cycles."
62802471|NCT03264365|EXPERIMENTAL|Intervention|Relatives participated actively in the one out of three consultation conducted by trained study nurses at two months after intensive care superimposed on standard care.
62028165|NCT05459844|EXPERIMENTAL|Lutetium[177Lu] Oxodotreotide Injection|"Treatment consisted of a cumulative administered radioactivity of 29.6 Giga Becquerel (GBq) (800 mCi) Lutetium\[177Lu\] Oxodotreotide Injection: Four administrations of 7.4 GBq (200 mCi).~Concomitant amino acids were given with each administration for kidney protection.~Lutetium\[177Lu\] Oxodotreotide Injection was administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.~In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections were allowed."
62227114|NCT04141969|ACTIVE_COMPARATOR|RLP|ReaLife+
62227115|NCT04141969|PLACEBO_COMPARATOR|Inert|Inert brown powder to look similar to RLP
62227116|NCT04141969|NO_INTERVENTION|Control|Not given RLP or the placebo
62227117|NCT02077569|EXPERIMENTAL|AZD5363 480mg|STAGE 1 ONLY AZD5363 480mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
62227118|NCT02077569|PLACEBO_COMPARATOR|Placebo|STAGE 1 ONLY Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
62227119|NCT02077569|EXPERIMENTAL|AZD360mg|STAGE 2 AZD5363 360mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
62227120|NCT02077569|EXPERIMENTAL|AZD5363 240mg|STAGE 2 AZD5363 240mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
62227121|NCT06414694|EXPERIMENTAL|Direct Challenge|Patients who met enrollment criteria proceed to direct oral challenge with penicillin with one hour observation, 48 hour phone call, six month follow-up.
62227122|NCT01809002|EXPERIMENTAL|Processed Nerve Allograft|Processed Nerve Allograft
62227123|NCT01809002|ACTIVE_COMPARATOR|Collagen Nerve Cuff|
62227124|NCT02913417|EXPERIMENTAL|hepatic radiation followed by immunotherapy|SIR-Spheres Yttrium 90 will be given by injection into the hepatic artery in two treatments, one for each lobe. 3-5 weeks later patients receive concurrent ipilimumab 1mg/kg q 3 wk x 4 and nivolumab 3mg/kg q 3 weeks x 4, all followed by nivolumab 240mg/kg q 2 weeks or 480 mg q 4 weeks until progression or 3 years
62227125|NCT03257020||Normal subject|Measure BMO-MRW and RNFL with SD-OCT. If the BMO-MRW and RNFL is within the normal range and those with no history of ocular disease, an intraocular pressure \< 21 mmHg, an absence of glaucomatous optic disc appearance, and a normal visual field, they will be classified into normal group.
62227126|NCT03257020||Glaucoma patients|Measure BMO-MRW and RNFL with SD-OCT. If the BMO-MRW and RNFL is below the normal range and those with glaucomatous optic disc and two consecutive abnormal visual field test results with open angles on gonioscopy, glaucomatous optic neuropathy, RNFL defects congruent with visual field defects, they will be classified into glaucoma patients.
62802472|NCT03264365|NO_INTERVENTION|Standard care|Relatives to former ICU patients, who had received standard care (SC) completed a questionnaire package at 3 and 12 months after the patient was discharged from intensive care. After enrollment were all contract handled by primary investigator.
62802473|NCT05154084||Audit only|This group of sites will participate in the audit. No performance feedback will be provided during the period under study. Feedback will be provided at the end of the study period.
62419941|NCT03394794|ACTIVE_COMPARATOR|Kegel exercises|Pelvic floor exercises designed in the 1950s' by Arnold Kegel.
62802474|NCT05154084||Audit with feedback|This group of sites will participate in the audit, and receive a feedback intervention about their practice based on retrospective data about surgery performed before the start of the study period.
62802475|NCT00165672|EXPERIMENTAL|1|
62802476|NCT00165672|EXPERIMENTAL|2|
62802477|NCT00603330|EXPERIMENTAL|1|MSC infusion for steroid-refractory grade II-IV acute GVHD. In this arm, 4 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
62802478|NCT00603330|EXPERIMENTAL|2|MSC infusion for poor graft function. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
62802479|NCT00603330|EXPERIMENTAL|3|MSC + DLI for poor donor T-cell chimerism after allogeneic HCT. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
62802480|NCT03145311|ACTIVE_COMPARATOR|Real rTMS|Each patient received real repititive transcranial magnetic stimulation (rTMS) 20 HZ at 100% RMT (a total of 2000 pulses to each hand area consisting of 10 trains of 200 pulses with intertrain interval 30 s), over the hand motor area area for 10 consecutive days
62227127|NCT05493241|OTHER|Open trial|In Aim 2, all 10 participants will receive the ACTIVaTE intervention.
62227128|NCT05493241|EXPERIMENTAL|ACTIVaTE intervention|In Aim 3, 24 participants will be randomized to receive the ACTIVaTE intervention.
62590246|NCT05204862|EXPERIMENTAL|TU2218 + Anti-PD-1 antibody Phase 1b|Escalating doses of TU2218 in combination with anti-PD-1 antibody up to 21-day cycles
62590247|NCT05204862|EXPERIMENTAL|TU2218 Phase 2a|TU2218 at a RP2D orally administered daily for two weeks followed by on week of rest for up to 21-day cycles
62802481|NCT03145311|SHAM_COMPARATOR|Sham rTMS|Each patient received repetitive transcranial magnetic stimulation (rTMS) with the same pulse delivery as the 1st group but with the coil placed perpendicular to the scalp.
62028166|NCT05459844|ACTIVE_COMPARATOR|Octreotide LAR|"60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.~In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections were allowed."
62227129|NCT05493241|ACTIVE_COMPARATOR|Attention control|In Aim 3, 24 participants will be randomized to an attention control arm.
62227130|NCT01729325|EXPERIMENTAL|Preventive Narrative Exposure Therapy|Treatment with Pre-NET before deployment in peace-keeping mission
62590248|NCT05204862|EXPERIMENTAL|TU2218 + Anti-PD-1 antibody Phase 2b|TU2218 at a RP2DC in combination with anti-PD-1 antibody up to 21-day cycles
62590249|NCT05013151|EXPERIMENTAL|Date consumption|Consumption of 6 dates a day until 41 weeks of gestation
62590250|NCT05013151|EXPERIMENTAL|Castor oil consumption|One time consumption of 60 CC of Castor oil
62590251|NCT05013151|NO_INTERVENTION|Control Group|
62590252|NCT04278651|ACTIVE_COMPARATOR|Oral Iron|325mg oral iron (ferrous sulfate) twice daily
62802482|NCT05626101|ACTIVE_COMPARATOR|Inravesical BCG|Intravsical induction and maintenance BCG injections.
62802483|NCT05626101|ACTIVE_COMPARATOR|Inravesical Gemcitabin|Intravsical induction and maintenance gemcitabin injections.
62802484|NCT01793623||nonemergent heart surgery, atrial tissue|patients undergoing non-emergent heart surgery
62802485|NCT05887921|ACTIVE_COMPARATOR|Open inguinal Lymphadenectomy|- Groin 1: open lymphadenectomy performed by a surgical team with extensive experience in traditional surgery
62802486|NCT05887921|ACTIVE_COMPARATOR|Laparoscopic inguinal Lymphadenectomy|Groin 2: laparoscopic lymphadenectomy performed by a surgical team with extensive experience in minimally invasive surgery
62802487|NCT05724992|OTHER|Saliva testing swab|Subjects with familiarity with pancreatic cancer enrolled into the IRFARPC registry (NCT04095195) will be submitted to buccal swab for saliva-based genetic testing
62802488|NCT06184607||Maxillary anterior interdental papilla|Presence or loss of interdental papilla with intact maxillary central incisors in systemically healthy patients
62802489|NCT04839016|EXPERIMENTAL|Treatment group A|
62419942|NCT03394794|EXPERIMENTAL|biofeedback|Biofeeback therapy to improve neuromuscular coordination and strengthen sphincter contractility.
62802490|NCT04839016|PLACEBO_COMPARATOR|Treatment group B|
62802491|NCT00004092|EXPERIMENTAL|Arm I (ACT) (closed to accrual as of 4/6/2006)|Patients receive doxorubicin IV over 24 hours on days -9 to -6, cyclophosphamide IV over 2 hours on day -5, and paclitaxel IV over 24 hours on day -2. PBSC are reinfused on days -2 and 0. G-CSF is administered beginning on day 0 and continuing until blood counts recover.
62802492|NCT00004092|ACTIVE_COMPARATOR|Arm II (STAMP V)|Patients receive cyclophosphamide IV, carboplatin IV, and thiotepa IV over 24 hours on days -7 to -4. PBSC are reinfused and G-CSF is administered as in arm I.
62802493|NCT01966822|EXPERIMENTAL|Dolutegravir 50mg|Dolutegravir 50mg every 24 hours + Kivexa (ABC+3TC)
62802494|NCT01966822|ACTIVE_COMPARATOR|Protease Inhibitor/ritonavir|Protease Inhibitor/ritonavir + Kivexa (ABC+3TC)
62802495|NCT04648813|EXPERIMENTAL|tiotropium bromide monohydrate (Spiriva Respimat)|
62802496|NCT04648813|PLACEBO_COMPARATOR|matching placebo|
62802497|NCT06054100|EXPERIMENTAL|Colchicine group|Colchicine group, Colchicine oral tablets, loading dose 1mg every 12 hrs for 1 day, followed by 0.5 mg BID for 3 months
62802498|NCT06054100|NO_INTERVENTION|STEMI standard treatment group|Control group, STEMI standard treatment only
62802499|NCT05003466|EXPERIMENTAL|candidate vaccine|
62802500|NCT05003466|PLACEBO_COMPARATOR|Placebo|
62802501|NCT00880620|PLACEBO_COMPARATOR|Placebo|One Placebo capsule was given TID for the first 21 days. Two placebo capsules were given TID on days 22 till end of study (week 30).
62802502|NCT00880620|EXPERIMENTAL|IPX066 145 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-21. One IPX066 145 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).
62802503|NCT00880620|EXPERIMENTAL|IPX066 245 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. One IPX066 245 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).
62227131|NCT01729325|NO_INTERVENTION|No treatment control|
62227132|NCT03149718|ACTIVE_COMPARATOR|SMC (n=23)|Standard Medication Counseling.
62227133|NCT03149718|EXPERIMENTAL|BI-MTM (n=23)|Brief Intervention Medication Therapy Management.
62419943|NCT03394794|EXPERIMENTAL|electrostimulation|Administration of electric current with a specific device (stimulator) and through a vaginal prove, in order to improve pelvic floor contractility.
62802504|NCT00880620|EXPERIMENTAL|IPX066 390 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. Two IPX066 195 mg LD capsules were given TID on days 22 till end of study (week 30).
62802505|NCT02401347|EXPERIMENTAL|Cohort A - Triple-negative Breast Cancer|"Participants with advanced triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD) based on the Myriad HRD Assay.~Participants receive talazoparib 1 mg by mouth daily."
62802506|NCT02401347|EXPERIMENTAL|Cohort B - HER2-negative solid tumor|"Participants with advanced HER2-negative solid tumor with a deleterious hereditary or cancer somatic mutation in one of the following genes:~PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, RAD51C, RAD51D, MRE11, ATR, Fanconi anemia complementation group of genes.~Participants receive talazoparib 1 mg by mouth daily."
62802507|NCT02682147|EXPERIMENTAL|Hypoxia Administration study group|40 subjects will be recruited to study normoxia oxygen compared to hypoxia oxygen. 20M and 20F subjects will be evaluated under normoxia oxygen with low dose non-contrast CT scans at total lung capacity (TLC) and 20% vital capacity (VC) and then with contrast using dual energy CT scans to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normixia scans, hypoxia administration will be administered by breathing an inspired FIO2 of 15% oxygen and the non-contrast and contrast using DECT scans to evaluate heterogeneity of perfused blood volumen will be completed.
62227134|NCT02166125||Endoscopic suturing|Any patient who has undergone clinically indicated and/or standard of care endoscopic suturing within the Gastrointestinal tract.
62227135|NCT00549614|EXPERIMENTAL|1|
62227136|NCT00549614|PLACEBO_COMPARATOR|2|
62227137|NCT03059225|EXPERIMENTAL|Experimental|repetitive transcranial magnetic stimulation (rTMS) intervention of contralesional 1Hz-rTMS for 10 daily sessions.
62227138|NCT03059225|SHAM_COMPARATOR|Sham stimulation|Sham treatment for 2-week inhibitory non-dominate hemisphere rTMS program.
62227139|NCT03059225|EXPERIMENTAL|High frequency rTMS|High-frequency rTMS to ipsilesional region for 10 daily sessions.
62227140|NCT04061395|EXPERIMENTAL|Guselkumab|Guselkumab 200 mg Q4W; subcutaneous injections; duration of 16 weeks.
62227141|NCT03251781|EXPERIMENTAL|Pulmonary Rehabilitation|Pulmonary Rehabilitation
62227142|NCT04606043|EXPERIMENTAL|Sandblasting|The enamel surfaces will be subjected to sandblasting prior to acid etching
62419944|NCT03394794|EXPERIMENTAL|transcutaneous neuromodulation|Stimulation of tibial nerve with a specific electric current through a stimulator and surface electrodes
62419945|NCT04832984|EXPERIMENTAL|Intervention arm|Participants receiving the phone app together with a fitness tracker. All participants will receive the educational curriculum through the app over a period of 24 weeks. The mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve goals. The participants can use the app to log their food intake, weight, steps, exercise, in addition to participating in the peer support via the chat function. Participants will also receive regular care and follow up in community pharmacies for support.
62590253|NCT04278651|EXPERIMENTAL|Intravenous Iron|510mg ferumoxytol intravenous infusion for two doses total; second dose 3-8 days after first dose.
62802508|NCT02682147|EXPERIMENTAL|Hyperoxia Administration study group|40 subjects will recruited to study normoxia oxygen scans compared to hyperoxia scans. 20M and 20F subjects will be evaluated under normoxia with low dose non-contrast CT scans at TLC and 20% vital capacity (VC) and then with contrast scans using DECT to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normoxia scans, hyperoxia administration will be administered by breathing an inspired FIO2 of 100% oxygen and the non-contrast and contrast using DECT to evaluate heterogeneity of perfused blood volumen will be completed.
62802509|NCT02682147|EXPERIMENTAL|Sildenafil|40 subjects (20M and 20F) will be recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT scans to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
62802510|NCT00257699|PLACEBO_COMPARATOR|I|Ciprofloxacin placebo and Metronidazole placebo
62802511|NCT00257699|EXPERIMENTAL|II|Ciprofloxacin 500 mg bid po Metronidazole - total daily dose dependent on body weight
62802512|NCT04117204|EXPERIMENTAL|Fruits and Vegetables|This group will receive a prescribed amount of free fruits and vegetables (F\&V) for 6 weeks of pick-up at a farm stand or direct delivery. After 6 weekly pick-up/deliveries, participants will be provided vouchers and reminders to obtain F\&V at farm stands for an additional 6 weeks with minimal contact.
62227143|NCT04606043|ACTIVE_COMPARATOR|Acid Etching Alone|Acid etching will be applied alone before the rebounding procedures
62227144|NCT03543501|EXPERIMENTAL|Real-time ultrasound imaging group|See intervention
62419946|NCT04832984|ACTIVE_COMPARATOR|Usual care arm|"The control group will be a usual care condition in which participants are free to seek any assistance for their medical care during the study period. Participants will be given physical tracking sheets to record their food intake, weight, steps and exercises."
62419947|NCT05777369|EXPERIMENTAL|R-CMOP|R-CMOP：Rituximab, Cyclophosphamide, Mitoxantrone hydrochloride liposomes, Vincristine or Vindesine, Prednisone
62419948|NCT05976867|EXPERIMENTAL|PAT + Smart Parents|Participants in this arm will receive the additional Smart Parents module, added to Parents as Teachers (PAT) in which they are already enrolled. This is the experimental condition.
62419949|NCT05976867|ACTIVE_COMPARATOR|PAT as usual|Participants in this arm will continue to receive Parents as Teachers (PAT) as usual. This is the treatment as usual condition (comparison).
62419950|NCT06514118||Combined chemotherapy and immunotherapy plus residual lesion irradiation|Patients receive carboplatin 5/AUC intravenously (IV) on day 1, adebrelimab 1200mg IV on day 1, and etoposide100mg/m2 IV on days 1-3. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity; redsidual tumor irradiation for 50GY in 25 fraction.
62419951|NCT04706520|EXPERIMENTAL|Group 1: Vinegar|Participants will consume 400 mL/day vinegar beverage providing 1,500 mg/day acetic acid \[200 mL vinegar beverage, twice per day (prior to breakfast and dinner)\] for 12 weeks.
62227145|NCT03543501|EXPERIMENTAL|PBU group|See intervention
62419952|NCT04706520|EXPERIMENTAL|Group 2: Vinegar/Placebo Combination|Participants will consume 200 mL/day vinegar beverage and 200 mL/day placebo beverage providing 1,200 mg/day lactate \[200 mL placebo beverage 1x/day\] and 750 mg/day acetic acid \[200 mL vinegar beverage 1x/day\] (prior to breakfast and dinner) for 12 weeks.
62419953|NCT04706520|PLACEBO_COMPARATOR|Group 3: Placebo|Participants will consume 400 mL/day placebo beverage containing 1,250 mg/day lactate \[200 mL placebo beverage, and 200 mL placebo beverage (prior to breakfast and dinner) for 12 weeks.
62419954|NCT06525155|EXPERIMENTAL|Treatment 1|Triptorelin Embonate, 3 times dosing
62419955|NCT06525155|EXPERIMENTAL|Treatment 2|Triptorelin Embonate, 1 time dosing
62419956|NCT02913651||Idiopathic hypersomnia|Drug-free patients diagnosed with idiopathic hypersomnia from 01/01/11 to 15/09/15
62590254|NCT06187883||1|patients treated with PRFT
62590255|NCT05351879|EXPERIMENTAL|GAD-Alum (DIamyd) 40 μg/mL and Vitamin D|"Patients with a Vitamin D level \<100 nmol/L (40 ng/mL) at screening will receive oral Vitamin D supplementation (2000 IU daily) for 60 days, starting 30 days prior to the injection.~On Visit 2 (Day 0), patients eligible for the study will receive one intralymphatic injection of 4µg Diamyd."
62590256|NCT06665230|EXPERIMENTAL|MK-6552 + Modafinil|In Period 1, participants receive MK-6552 orally. In Period 2, participants receive MK-6552 orally plus low dose modafinil orally. In Period 3, participants receive MK-6552 orally plus high dose modafinil orally.
62802513|NCT04117204|NO_INTERVENTION|Wait List Control|This group will not receive a prescribed amount of free fruits and vegetables (F\&V) for 12 weeks. They will serve as the control group. After 12 weeks of control and data comparisons, they will be given 12 weeks of vouchers with minimal contact.
62802514|NCT04818619||chronic myeloid leukemia patients|
62802515|NCT04818619||Healthy individuals|
62802516|NCT02199366||Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
62802517|NCT05100615|OTHER|hydroxyappatite|hydroxyapatite powder used for enhancement of bone regeneration
62802518|NCT05100615|OTHER|nanohydroxyapatite|nanohydroxyapatite powder used for enhancement of bone regeneration
62802519|NCT05100615|OTHER|PRF with nanohydroxyapatite|platelet rich fibrin mixed with nanohydroxyapatite used for enhancement of bone regeneration
62802520|NCT03536585|EXPERIMENTAL|Vulvovaginal treatment|Internal vaginal treatment monthly for 3 treatments; External mons pubis treatment monthly for 3 treatments; External labia treatment monthly for 3 treatments.
62802521|NCT03536585|NO_INTERVENTION|Baseline|Subject's baseline photograph to act as their own control for the one-month and four-month post-treatment photograph of the mons pubis and labia.
62802522|NCT00584012|EXPERIMENTAL|Dose Esclation|Determine the maximum tolerated dose (MTD) of escalating doses of lovastatin in combination with docetaxel in patients with any type of solid tumor.
62028167|NCT03682094|EXPERIMENTAL|Probiotic|The treatment will consist of VSL#3, 3 grams (g), taken orally once a day for 4 weeks. The VSL#3 will be delivered in the form of a sachet of freeze-dried powder. Participants will be instructed to mix the sachets with water to consume. Those participants taking thickened liquids will mix the sachet with liquids thickened to the level (nectar versus honey) prescribed by their clinician. In order to facilitate delivery of the probiotic solution throughout the oral cavity, participants will be instructed to swish the solution in the mouth for up to 10 seconds (as tolerated) prior to each swallow.
62028168|NCT00113438|EXPERIMENTAL|45 mg/m2 Combretastatin A-4 Phosphate|
62802523|NCT04457765|EXPERIMENTAL|group 1|All participants will have PVP-I at 1.25% administered as an intranasal topical preparation prior undergoing rhinoplasty
62802524|NCT01854359|OTHER|Active treatment|Idebenone (150mg tablets) administered orally as five tablets, three times per day with food.
62802525|NCT03667755|EXPERIMENTAL|fast track recovery|Participants will attend dietitian clinic to have anthropometry \& dietary assessment on the same day of admission (before admission). Subjects are given a specific drink to their group on the evening prior to surgery and three hours before operation. The CHO-P group received 474ml (evening drink) or 237ml (3 hours prior to operation drink) of a lactose-free clear tea-colour fruit flavoured fluid contains 14% whey protein, 86% carbohydrates and 0% lipids. Participants fast for solids for 6 hours from the operation. Participants will be given clear fluid (2 packs Resource peach) within 24 hours post-surgery (without present of bowel sound) and reviewed by dietitian. Staff nurse in-charged will monitor anesthetic risk of drinking whey protein and ensure subject to finish specific drinks prior surgery. When they tolerated at least 500ml of clear fluids, they were given a regular solid diet.
62028169|NCT00113438|EXPERIMENTAL|60 mg/m2 Combretastatin A-4 Phosphate|
62802526|NCT03667755|NO_INTERVENTION|conventional|Participants will attend dietitian clinic to have anthropometry \& dietary assessment on the same day of admission (before admission). Participants followed conventional operation procedure whereby fasting start 12am until operation. On the first day of post-operation day, participants will be reviewed by gynaecologist and dietitian. They are allowed for clear fluid once there is bowel sound. After tolerated clear fluid, they will proceed for nourishing fluid, then soft diet and they were given a regular solid diet.
62028170|NCT06349161||Ureteropelvic junction obstruction|UPJO with severe hydronephrosis, with or without parenchymal atrophy (Society for Fetal Urology grade III or IV), recurrent urinary tract infections (UTI), prolonged drainage parameters with T1/2 \> 20 minutes, and/or differential renal function (DRF) less than 40%.
62419957|NCT02913651||Controls|Patients with no sleep complaints, having a 24-h ambulatory ad libitum polysomnography
62419958|NCT05551000|EXPERIMENTAL|Intervention|This group will use a functional training system developed specifically for elderlies to improve everyday movements, physical strength and balance.
62802527|NCT05668832|EXPERIMENTAL|oral intake of UVB-exposed mushrooms|Daily intake of 500 g of UVB-exposed button mushrooms over 7 days (provided as mushroom cream soup) and blood sampling (at baseline, 3 h postprandial, 6 h postprandial and at day 8)
62802528|NCT05668832|PLACEBO_COMPARATOR|oral intake of non-UVB-exposed mushrooms|Daily intake of 500 g of non-UVB-exposed button mushrooms over 7 days (provided as mushroom cream soup) and blood sampling (at baseline, 3 h postprandial, 6 h postprandial and at day 8)
62802529|NCT05792813|EXPERIMENTAL|Experimental group|LGYY+ WZYZ mimetic
62802530|NCT05792813|ACTIVE_COMPARATOR|Control group|WZYZ + LGYY mimetic
62802531|NCT04889508|EXPERIMENTAL|Socio-emotional mental training|The socio-emotional intervention will consist of 10 weeks of daily Affect Dyad practice with a partner.
62802532|NCT04889508|EXPERIMENTAL|Mindfulness-based mental training|The intervention will consist of 10 weeks of daily individual Breathing Meditation practice.
62028171|NCT02416791|ACTIVE_COMPARATOR|Active tDCS + robotic therapy + physical therapy|"Active tDCS (transcranial direct current stimulation) will be applied prior to the robotic training. After robot training, the patient will receive physical therapy for 40 minutes.~Number of treatment sessions: 18 (3 times a week, for 6 weeks)."
62028172|NCT02416791|ACTIVE_COMPARATOR|sham tDCS + robotic therapy + physical therapy|"Sham tDCS (transcranial direct current stimulation) will be applied prior to robotic training. After robot training, the patient will receive physical therapy for 40 minutes.~Number of treatment sessions: 18 (3 times a week, for 6 weeks)."
62227146|NCT06115681||Cohort 1|Patients with unresectable locally advanced or metastatic differentiated liposarcoma (DDLPS) who received at least one line of systemic antineoplastic treatment by the end of cohort identification period (index date = start date of first line (1L) treatment).
62227147|NCT06115681||Cohort 2|Patients with DDLPS who have not initiated 1L systemic antineoplastic treatment by the end of cohort identification period (index date = date of initial DDLPS diagnosis during cohort identification period). Patients initiated 1L treatment afterwards or patients received adjuvant and/or neoadjuvant therapy only through follow-up will be included in Cohort 2.
62419959|NCT05551000|ACTIVE_COMPARATOR|Positive control|This group will use a general training system developed for elderlies to improve everyday movements, physical strength and balance.
62028173|NCT02416791|EXPERIMENTAL|sham tDCS + physical therapy + occupational therapy|Sham tDCS (transcranial direct current stimulation) will be applied prior to conventional therapy (40 minutes of physical therapy and 40 minutes of occupational therapy) Number of treatment sessions: 18 (3 times a week, for 6 weeks).
62227148|NCT05737537|OTHER|infected pediatric cancer patients|
62227149|NCT00775320||Brain tumor FLT-PET|Those diagnosed with a brain tumor and are to undergo surgery
62419960|NCT05551000|NO_INTERVENTION|Negative control|Control group: A group that is not treated.
62028174|NCT00448539|EXPERIMENTAL|Rufinamide (Rufinamide During Core Study)|
62419961|NCT06567535|EXPERIMENTAL|Navigation and endoscopy Group|Preoperative copies of the patient's maxillofacial imaging data were digitally designed, professional software was used to segment cystic lesions and segment the inferior alveolar nerve together, and then the data was imported into the navigation system. The surgeon placed a mandibular reference frame in the anterior mandibular region, and used the navigation probe to accurately locate the difficult areas such as the anterior part of the capsule cavity, the apical part of the tooth root and the ascending branch of the mandible under the guidance of navigation. After accurate positioning was obtained, the navigation adapter was loaded onto the endoscope to locate the lesions in all directions and the inferior alveolar nerve under visual conditions, and further precisely curettage the lesions in the cystic cavity with the assistance of the adapter.
62419962|NCT04520594|ACTIVE_COMPARATOR|Resistant Starch|Once daily oral consumption of 7.5g/m2 of an individually optimized resistant starch for approximately 6 months
62028175|NCT00448539|EXPERIMENTAL|Rufinamide (Placebo During Core Study)|
62227150|NCT04618328|EXPERIMENTAL|ATRA treatment group|ATRA is given at a daily dose of 10 mg twice daily orally for 12 weeks
62227151|NCT05623722|NO_INTERVENTION|Control Group|Patients receive the same administration of acute gastrointestinal injury and enteral nutrition strategy according to the guidelines, and the routine practice of the ICU. The interventions end on day 7 or cease when the patients are discharged from the ICU, dead, or withdraw their consent.
62227152|NCT05623722|EXPERIMENTAL|Erector Spinae Plane Block Group|"1. Patients receive the same administration of acute gastrointestinal injury and enteral nutrition strategy according to the guidelines, and the routine practice of the ICU.~2. Ultrasound-guided erector spinae plane block is performed at thoracic (T) level 8. An 18F catheter is placed on both sides of the thoracic vertebra deep into the erector spinae, and a bolus of 20 ml of 0.375% ropivacaine is administered bilaterally. Then, a continuous infusion of 20 ml of 0.375% ropivacaine on each side is followed at a rate of 2 ml/h every 12 hours. The interventions end on day 7 or cease when the patients are discharged from the ICU, dead, or withdraw their consent."
62243063|NCT02441673|ACTIVE_COMPARATOR|Nefopam|"Premedication of IV (Intravenous)10mg Metoclopramide and 50mg Ranitidine would be given morning of surgery to all patients.~0.15mg/kg of Acupan(Nefopam) would be administered IV after the initiation of the subarachnoid block (Time 0) and presence and severity of shivering (the primary outcome) would be looked out for.~IV Ephedrine in 3mg alliquots would be given if hypotension occurs; IV oxytocin 30-50mg would be given after delivery of the baby to all patients and IV Pethidine 25mg would be given to abate any residual shivering if a repeat dose of Acupan is not satisfactory."
62590257|NCT06666712|EXPERIMENTAL|Long-term CED of Topotecan|Six patients will be treated with Topotecan by Convection-Enhanced Delivery. Four 48-hour Topotecan infusions will be carried out over the course of 23-29 days (with five to seven-day drug holiday after the first three infusions). Infusions will take place using Synchromed II infusion pumps with the same infusion parameters and experimental conditions used in our previous Phase I clinical trial and other short-term studies.
62028176|NCT06138574|ACTIVE_COMPARATOR|Effects of Dexmetomidine|Patients in this group will be given dexmedetomidine infusion during the intraoperative period to provide controlled hypotension.
62590258|NCT05050123|ACTIVE_COMPARATOR|First episode of anxiety: standard relaxation training|During a subject's first episode of anxiety the subject will be offered a session of standard relaxation training.
62028177|NCT06138574|ACTIVE_COMPARATOR|Effects of Remifentanil|Patients in this group will be given remifentanil infusion during the intraoperative period to provide controlled hypotension.
62028178|NCT04413890|ACTIVE_COMPARATOR|Classical administration|One prostaglandin vaginal gel every 24 hours
62028179|NCT04413890|EXPERIMENTAL|Experimental administration|One prostaglandin vaginal gel every 12 hours
62419963|NCT04520594|PLACEBO_COMPARATOR|Placebo|Once daily oral consumption of a food-grade cornstarch that is readily digestible for approximately 6 months
62590259|NCT05050123|EXPERIMENTAL|Second episode of anxiety: virtual reality relaxation|During a subject's second episode of anxiety the subject will be offered a session of virtual reality exposure available through the iPhone Google Cardboard virtual reality meditation/relaxation app.
62590260|NCT01719913|ACTIVE_COMPARATOR|Low gluten|Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
62590261|NCT01719913|PLACEBO_COMPARATOR|High gluten|Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
62590262|NCT03841162||Patients with suspected sepsis|Patients for whom blood cultures are drawn at the Emergency Department or the department of Infectious Diseases/Nephrology
62590263|NCT00745238|EXPERIMENTAL|Myotonic Dystrophy 1|
62028180|NCT06536348||Experimental group|Group of subjects with Parkinson's disease
62028181|NCT06536348||Control group|Neurological healthy subjects
62028182|NCT02875587|ACTIVE_COMPARATOR|Cabergoline group|Cabergoline is administered starting on the day of HCG administration.
62028183|NCT02875587|EXPERIMENTAL|Calcium gluconate infusion group|Calcium gluconate is administered starting on the day of HCG administration.
62028184|NCT03153280|EXPERIMENTAL|Lithium, Oxaliplatin & Capecitabine|Target serum concentrations of escalating doses of lithium (0.6, 0.9, 1.26 or 1.4 mmol/L) in combination standard chemotherapy - oxaliplatin and capecitabine.
62028185|NCT01866410|EXPERIMENTAL|Treatment (cabozantinib-s-malate, erlotinib hydrochloride)|Patients receive cabozantinib-s-malate PO daily and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62028186|NCT06635473|NO_INTERVENTION|control group|Routine nursing, discharge education
62590264|NCT00808639|EXPERIMENTAL|Dose Dense MVAC|Chemo therapy with methotrexate, vinblastine, Adriamycin, Cisplatin
62590265|NCT01754961|PLACEBO_COMPARATOR|Placebo|Placebo will be given on Day 1 orally
62590266|NCT01754961|ACTIVE_COMPARATOR|Vitamin D|Administration of 500,000 IU Vitamin D orally on Day 1
62590267|NCT06338917|EXPERIMENTAL|Intervention group|Participation in a vigorous-intensity physical activity program
62590268|NCT06338917|NO_INTERVENTION|Control group|Habitual caring
62590269|NCT00723255|EXPERIMENTAL|Treatment (bevacizumab, temsirolimus)|Patients receive bevacizumab IV on days 1 and 15 and temsirolimus IV on days 1, 8, 15, and 22.
62590270|NCT03201770|EXPERIMENTAL|Pyramax|Pyronaridine artesunate tablets (180/60mg) and granules (60/20mg)
62590271|NCT06480721|EXPERIMENTAL|Clinical management is based on the index MRI and an additional [¹⁸F] FET-PET together|
62590272|NCT06480721|NO_INTERVENTION|Standard of care|
62590273|NCT04674917|EXPERIMENTAL|Group A|Decompression + Hot pack, TENS, Mobilization, Exercise Therapy
62028187|NCT06635473|EXPERIMENTAL|intervention group|Intelligent interventions to enhance parents' hospital discharge readiness and self-efficacy.
62419964|NCT04992169|EXPERIMENTAL|Smartphone App with Video Self-Scoring Functionality|In this condition, after parents video-record their delivery of the intervention, they watch their video and are taught to score their own performance/fidelity through question prompts built into the app. When they are finished, the app will offer feedback and follow-up lessons based on the PRT strategies they have not demonstrated consistently.
62419965|NCT04992169|EXPERIMENTAL|Smartphone App without Video Self-Scoring Functionality|In this condition, after parents video-record their delivery of the intervention, they watch their own video but do not score their performance.
62419966|NCT05394428||Patients with female sexual organs treated with pelvic radiotherapy|Patients with female sexual organs treated with pelvic radiotherapy.
62419967|NCT04289467|EXPERIMENTAL|Fenfluramine treatment|Open label treatment with fenfluramine. Dosage will be titrated to 0.8 mg/kg/day, for an initial duration of 21 days. Patients with favorable response will have an option to continue treatment for up to 6 months.
62419968|NCT05800743|EXPERIMENTAL|ASG device only in Ascending Aorta|Ascending Aortic Isolated Lesions, Pseudoaneurysms and Penetrating Aortic Ulcers in subjects at high-risk for surgical repair, treated with endovascular repair using the ASG device alone.
62419969|NCT05800743|EXPERIMENTAL|ASG + TBE|Ascending Aorta/Aortic Arch Isolated Lesions and Chronic De Novo Dissections in subjects at high-risk for surgical repair, treated with endovascular repair using the ASG and TBE devices.
62028188|NCT02026700|EXPERIMENTAL|bariederm, barrier cream|one arm study: use of bariederm cream on hands twice daily for 21 days
62227153|NCT00685633|ACTIVE_COMPARATOR|Arm A|Patients are observed without treatment in weeks 1-12. Patients with a prostate-specific antigen (PSA) rise of \> 50% above baseline or nadir (whichever is lowest) and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. In weeks 13-44, patients with a rise PSA ≥ 50% above baseline or nadir, and a PSA rise of at least 5 ng/mL confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue to receive bicalutamide up to 72 weeks.
62227154|NCT00685633|ACTIVE_COMPARATOR|Arm B|In weeks 1-12, patients receive oral enzastaurin hydrochloride twice daily. Patients with a PSA rise of \> 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. In weeks 13-44, patients with a PSA rise of ≥ 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral enzastaurin twice daily and oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue on this combination therapy up to 72 weeks.
62227155|NCT05060068|PLACEBO_COMPARATOR|Placebo group|Patients in the placebo group will receive a bolus of 0.9% saline, followed by continuous infusion of 0.9% saline until 30 min prior to the end of the surgery.
62227156|NCT05060068|EXPERIMENTAL|Low-dose ketamine group|Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 2 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
62227157|NCT05060068|EXPERIMENTAL|High-dose ketamine group|Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 4 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
62227158|NCT00433459|ACTIVE_COMPARATOR|COPP|procarbazine-containing consolidation chemotherapy arm
62227159|NCT00433459|EXPERIMENTAL|COPDAC|procarbazine-free consolidation chemotherapy arm
62227160|NCT00116337|EXPERIMENTAL|Expiratory Muscle Stimulator|Procedure/Surgery: spinal cord stimulation to restore cough
62227161|NCT02076178|EXPERIMENTAL|Arm 1|Participants will receive daily oral 744 (30 mg tablets) for 4 weeks, followed by a one week washout period followed by intra-muscular (IM) injections of 800 mg of 744 LA at three time points at 12 week intervals as: Week 5, Week 17, and Week 29
62419970|NCT05800743|OTHER|Surgical Follow-up Cohort|Open surgical repair of ascending aorta in subjects at high-risk for surgical repair
62419971|NCT05653349|EXPERIMENTAL|Ianalumab Lower dose|Lower dose of ianalumab administered intravenously with corticosteroids oral or parental (if clinically justified)
62419972|NCT05653349|EXPERIMENTAL|Ianalumab Higher dose|Higher dose of ianalumab administered intravenously with corticosteroids oral or parental (if clinically justified)
62419973|NCT05653349|PLACEBO_COMPARATOR|Placebo|Placebo administered intravenously with corticosteroids oral or parental (if clinically justified)
62802533|NCT04889508|OTHER|Retest Control Group (Waitlist control)|"The retest control group, which is also a waitlist control group, will first not undergo an intervention, but will be tested prior to and after the 10-week period at Pre- and Post-test wherein other groups undergo the interventions.~In a second step, the waitlist control group will then also undergo a 10-week period of socio-emotional intervention.~During the first 10-week intervention period, this group will only be tested serving as a re-test control group. After Post-test, however, they will be given the chance to also enroll in a 10-week socio-emotional mental training with the exact same protocol as the socio-emotional intervention experimental group above.~Both the experimental intervention arm groups will be given the possibility to continue their daily assigned practices (respective socio-emotional and mindfulness-based training exercises) after post-test for the duration of the 10-weeks during which the waitlist control group undergoes the socio-emotional intervention."
62802534|NCT00940940|EXPERIMENTAL|Live attenuated herpes zoster vaccine|
62802535|NCT00940940|PLACEBO_COMPARATOR|Placebo|
62802536|NCT04332107|EXPERIMENTAL|Azithromycin|1.2g of oral azithromycin
62802537|NCT04332107|PLACEBO_COMPARATOR|Placebo|Matching placebo
62802538|NCT05122728||Concussed Cohort|Active duty Service Members and physically active civilians who have self-reported as asymptomatic post-concussion.
62802539|NCT05122728||Non-Concussed Cohort|Gender, age, occupation, and physical activity matched active duty Service Members and physically active civilians who have not sustained a concussion.
62802540|NCT05259735|EXPERIMENTAL|Intervention|Clinical guideline-based management of T2DM by Ayurvedic practitioners. The clinical guideline will cover topics like diagnostic criteria, blood glucose targets, lifestyle advice, Ayurvedic medicines, monitoring and follow-up (including screening for complications and referral to specialists for complications management). The clinical guideline will make recommendations based on the best available evidence. Ayurvedic practitioners will have at least a 5½ year undergraduate medical degree in Ayurveda. Regular training will be provided to Ayurvedic practitioners (in groups) in the use of clinical guideline which will involve roleplaying and structured and instructive feedback to improve their performance. The trainings will be recorded on the Training Attendance Log and they will be provided a Training Certificate for completing the training.
62227162|NCT02076178|EXPERIMENTAL|Arm 2|Participants will receive daily oral matching placebo for 4 weeks, followed by a one week washout period followed by intra-muscular (IM) injections of saline at three time points at 12 week intervals as: Week 5, Week 17, and Week 29
62419974|NCT05348018|EXPERIMENTAL|"test group"|"test group which accessed SGs during a four-week test period in addition to conventional lectures"
62590274|NCT04674917|EXPERIMENTAL|Group B|Decompression + Hot pack, TENS, Mobilization, Exercise Therapy
62590275|NCT04674917|OTHER|Group C|Hot pack , TENS, Mobilization, Exercise therapy
62802541|NCT05259735|ACTIVE_COMPARATOR|Comparator|"Comparator: Currently, no standard clinical guideline is used by Ayurvedic practitioners to manage T2DM in Nepal. Thus, the comparator will be the usual management of T2DM (i.e., without any clinical guideline) by Ayurvedic practitioners.~Participants will continue their medications for other systemic diseases, if any."
62802542|NCT01370902|EXPERIMENTAL|Single-dose (SD) trial part (i.v.)|
62590276|NCT06280274|EXPERIMENTAL|Treatment|Oral metformin hydrochloride
62802543|NCT01370902|EXPERIMENTAL|Single-dose (SD) trial part (s.c.)|
62802544|NCT01370902|EXPERIMENTAL|Multiple-dose (MD) trial part (s.c.)|
62802545|NCT05395637||Assessed with the remote assessment of Longshi Scale first and then with bedside assessment|
62802546|NCT05395637||Assessed with the bedside assessment of Longshi Scale first and then with remote assessment|
62802547|NCT01360320|EXPERIMENTAL|Green tea extract|Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG, bid for 3 years
62802548|NCT01360320|PLACEBO_COMPARATOR|Placebo|Placebo, packed in hard gelatine capsules, bid for 3 years
62802549|NCT03194906|ACTIVE_COMPARATOR|Memantine|Beginning at least two weeks prior to radiation therapy, participants receive memantine. Treatment continues for 12 weeks with periodic cognitive assessments and lab work.
62802550|NCT03194906|PLACEBO_COMPARATOR|Placebo|Beginning at least two weeks prior to radiation therapy, participants receive a placebo. Treatment and assessment are identical to the memantine group.
62802551|NCT00757237|EXPERIMENTAL|AZLI 75 mg 3 times a day (TID)|
62419975|NCT05348018|NO_INTERVENTION|"control group"|"control group which benefited solely from conventional lectures"
62419976|NCT06702241|ACTIVE_COMPARATOR|12 hours continuous double phototherapy with irradiance of over head light of 40 µW/cm2/nm|
62419977|NCT06702241|ACTIVE_COMPARATOR|12 hours continuous double phototherapy with irradiance of over head light of 55 µW/cm2/nm|
62419978|NCT06702241|ACTIVE_COMPARATOR|12 hours continuous double phototherapy with irradiance of over head light of 70 µW/cm2/nm|
62590277|NCT06280274|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62227163|NCT02892084|EXPERIMENTAL|Uphill COMa training|Walking on an inclined treadmill, thus manipulating the permissive environment to elicit COMa adaptation, while receiving either tDCS or sham tDCS.
62802552|NCT00757237|ACTIVE_COMPARATOR|TIS 300 mg 2 times a day (BID)|
62802553|NCT05829954||1st dentistry students|1st dentistry students
62419979|NCT06702241|ACTIVE_COMPARATOR|12 hours cycled double phototherapy with irradiance of over head light of 70 µW/cm2/nm|This group will receive 12 hours double phototherapy in cycles of 1,5 hours. Thus receiving 1,5 hours treatment, 1,5 hours pause, 1,5 hours treatment etc.
62802554|NCT05829954||Intern dentistry students|5th dentistry students
62802555|NCT05829954||working dentists|dentists who have worked for at least two years
62419980|NCT06560996|NO_INTERVENTION|Control|7 days isoenergetic (weight maintaining) diet
62419981|NCT06560996|EXPERIMENTAL|Very low calorie diet with low protein content (VLCD-LP group)|7 days very low-calorie diet (850 kcal per day) with low protein content (10% energy from protein, 45% from carbohydrate and 45% from plant-based fat)
62227164|NCT02892084|EXPERIMENTAL|Downhill COMa training|Walking on a declined treadmill, thus manipulating the permissive environment to elicit COMa adaptation, while receiving either tDCS or sham tDCS.
62419982|NCT06560996|EXPERIMENTAL|Very low calorie diet with high protein content (VLCD-HP group)|7 days very low-calorie diet with high protein content (30% energy from protein, 45% from carbohydrate and 25% from plant-based fat)
62802556|NCT04630665|OTHER|thin buccal bone|immediate implant placement in thin buccal bone wall socket
62802557|NCT04630665|OTHER|≥1 buccal bone|immediate implant placement in 1 mm or more buccal bone thickness socket
62227165|NCT03095690|OTHER|Idiopathic Parkinson's Disease patients|High resolution peripheral scanner (HRpQCT).
62227166|NCT03022279|ACTIVE_COMPARATOR|TAP blocks|TAP block group will receive three injections performed by an Anesthesiologist trained in the procedure, prior to initiation of the surgical procedure. Bilateral posterior transversalis fascial plane blocks and a right sided subcostal transverse abdominal plane block will be placed under ultrasound guidance. Normal saline will be used to confirm proper muscle layer placement before instillation of the local anesthesia. All patients will receive 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine with maximum of 60 mL (divided equally amongst the injection sites).
62028189|NCT02864082|EXPERIMENTAL|PAT-001 0.1%|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply only PAT-001, 0.1% to both Treatment Areas from Weeks 8-12.
62419983|NCT02480855|OTHER|Questionnaire and feedback|Patients that will see a doctor randomized to the intervention group will fill in the Work Stress Questionnaire prior to the visit. The doctor gets the results from the questionnaire and then gives consultation to the patient based on the results.
62419984|NCT02480855|NO_INTERVENTION|Control group|Patients that will see a doctor randomized to the control group get the usual treatment/consultation and after the visit fill in the Work Stress Questionnaire.
62419985|NCT01408407|ACTIVE_COMPARATOR|Arm A: standard of care|Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatment
62419986|NCT01408407|EXPERIMENTAL|Arm B: standard of care plus Alkagin paste|Patients will apply Alkagin Paste to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. They will also perform standard of care skin treatment.
62802558|NCT01796717|ACTIVE_COMPARATOR|C Group|Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
62802559|NCT01796717|EXPERIMENTAL|E Group|Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
62802560|NCT03969095|EXPERIMENTAL|Immediate|Participants in the immediate intervention arm will begin a 4-week intervention tongue pressure resistance training protocol within 10 days of their baseline Videofluoroscopic Swallowing Evaluation assessment, with 2 face-to-face 1-hour visits per week under direct supervision of a speech-language pathologist. These treatment sessions will be supplemented by daily home practice of the intervention.
62802561|NCT03969095|ACTIVE_COMPARATOR|Delayed|Participants in the delayed intervention arm will begin their involvement with a 4-week waiting period after the baseline Videofluoroscopic Swallowing Evaluation. Treatment will commence after the second Videofluoroscopic Swallowing Evaluation and will follow the same schedule for the tongue pressure resistance training, supplemented by daily home practice.
62802562|NCT05289843|EXPERIMENTAL|Experimental|Rosmarinus officinals will be used as root canal irrigant in treating aysymptomatic mandibular premolars.
62802563|NCT05289843|NO_INTERVENTION|Control Group|Sodium Hypochlorite used as control in root canal irrigations in treating a asymptomatic mandibular premoalrs.
62802564|NCT00967317|EXPERIMENTAL|Auris-Sedina|"Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor."
62802565|NCT00967317|ACTIVE_COMPARATOR|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
62590278|NCT01033955|EXPERIMENTAL|Drug (Rosuvastatin) Crestor|The first dose of encapsulated study drug or placebo (day 1) will be administered within 4 hours of randomization as a loading dose of 40 mg. The placebo will be identical in appearance to Rosuvastatin. Thereafter, doses of 20 mg will be administered daily starting on the next calendar day at 10 pm daily (+/- 4 hours) as a maintenance dose from days 2 to 14. If the patient is of Asian descent, is \<18 years, or serum creatinine is greater than or equal to 248 μmol/L (2.8 mg/dL) dose adjustments will be made according to a dose adjustment algorithm.
62590279|NCT01033955|PLACEBO_COMPARATOR|Placebo|An identical appearing placebo will be administered to patients in the second study arm.
62590280|NCT01187771|ACTIVE_COMPARATOR|Laparoscopic Gastric Banding|
62028190|NCT02864082|EXPERIMENTAL|PAT-001 0.2%|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply PAT-001, 0.2% to both Treatment Areas.
62028191|NCT02864082|PLACEBO_COMPARATOR|Vehicle for PAT-001 0.1% arm|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.
62802566|NCT03015766|EXPERIMENTAL|Auricular acupressure therapy|Participants in the treatment group will received AAT on five active acupoints including Acup.1. Shen Men (Spiritual Gate, TF4), Acup.2. Jiao Gan (Sympathetic autonomic, AH6a), Acup.3. Xin (Heart, CO15), Acup.4. Pi Zhi Xia (Subcortex, AT4), Acup.5. Nei Fen Mi (Endocrine, CO18)
62802567|NCT03015766|SHAM_COMPARATOR|sham auricular acupressure therapy|Participants in the control group (SAA group) will receive auricular acupressure on five Helix points (HX 5-9), which were clearly remote from the inner ear area. These points have no evidence for insomnia management.
62590281|NCT01187771|ACTIVE_COMPARATOR|Continuous Positive Airway Pressure|
62028192|NCT02864082|PLACEBO_COMPARATOR|Vehicle for PAT-001 0.2% arm|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.
62028193|NCT02693873|OTHER|Single Arm Study:|All participants will receive GLA:D Canada, an education and neuromuscular exercise program
62028194|NCT02795442|EXPERIMENTAL|Even protein|Menu to provide 90 g of protein per day in an even distribution of 30 g at each meal.
62028195|NCT02795442|EXPERIMENTAL|Skewed protein|Menu to provide 90 g of protein per day in a skewed distribution of 10 g at breakfast, 15 g at lunch and 65 g at dinner.
62419987|NCT05580588|EXPERIMENTAL|SPH4336|400 mg (2 - 200 mg tablets) PO QD
62419988|NCT06513988|EXPERIMENTAL|MI-BCI combined with tDCS|The MI-BCI combined with tDCS treatment was performed five days per week (in the late afternoon)
62802568|NCT02768766|EXPERIMENTAL|Dose Level 1: Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles at a dose of 100mg.
62802569|NCT02768766|EXPERIMENTAL|Dose Level 2: Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles at a dose of 125mg.
62802570|NCT02768766|EXPERIMENTAL|Dose Level 3: Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles at a dose of 150mg.
62028196|NCT03408158|NO_INTERVENTION|HPA antigen and antibodies|Investigate the positive rate of HPA antibodies, the distribution and the specificity of HPA antigen and antibodies in Chinese blood disease patients.
62028197|NCT03408158|NO_INTERVENTION|necessity of HPA antibodies screening|Investigate the connection between times of platelet transplantation and HPA antibody titer, which providing statistical data for evaluating the necessity and setting screening time and standards of HPA antibodies screening.
62028198|NCT03408158|EXPERIMENTAL|matched platlet infusion|Enable platelet donors'common HPA antigen to be typed and blood disease patients to be same type infusion of main HPA antigen as possible as early.The investigators compare the differences of platelet count between patients with same type infusion of main HPA antigen and not.
62419989|NCT01614808||Observational|Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance (NMR) spectroscopy and principal component analysis (PCA). Tumor tissue may also be examined by NMR and PCA.
62590282|NCT05733143||Symptom high/T2-biomarker low (20 participants)|\[ACQ≥ 1.5 FeNO\<20 ppb AND blood eosinophil count\<150 cells/µL\]. During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.
62802571|NCT02768766|EXPERIMENTAL|Dose Level 4: Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles at a dose of 175mg.
62802572|NCT02768766|EXPERIMENTAL|Dose Level 5: Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles at a dose of 200mg.
62802573|NCT02768766|EXPERIMENTAL|Dose Level 6: Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles at a dose of 225mg.
62802574|NCT01494948|PLACEBO_COMPARATOR|placebo|skin test negative
62802575|NCT01494948|ACTIVE_COMPARATOR|allergic|Skin test positive
62802576|NCT01825187|ACTIVE_COMPARATOR|Treatment Group 1|Patients in this group will be randomized to receive the ULTRAPRO mesh
62590283|NCT05733143||Symptom low/T2-biomarker high (20 participants)|\[ACQ\<1.5 AND FeNO≥20 ppb AND blood eosinophil count≥150 cells/µL\] During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.
62802577|NCT01825187|ACTIVE_COMPARATOR|Treatment Group 2|Patients in this group will be randomized to receive the 3DMAX Mesh
62590284|NCT05733143||Symptom low/T2-biomarker low (12 participants)|\[ACQ\<1.5 AND FeNO\<20 ppb AND blood eosinophil count\<150 cells/µL\] During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.
62802578|NCT01825187|OTHER|Evaluation of Surgical Residents|Surgical residents will be evaluated on the ease of use and the amount of time it takes for them to perform the surgery using these two different meshes.
62802579|NCT05262257|EXPERIMENTAL|Lifestyle intervention group|patients did not take any hypoglycemic drugs and adopted diet, exercise and other lifestyle intervention measures to control blood sugar.
62802580|NCT05262257|EXPERIMENTAL|Metformin treatment group|on the basis of lifestyle intervention, patients were given metformin 2-3 times a day (starting with 2times), 0.5g each time.
62802581|NCT05262257|EXPERIMENTAL|Dapagliflozin treatment group|on the basis of lifestyle intervention, patients took Dapagliflozin orally, once a day, 10mg at a time.
62028199|NCT00116805|EXPERIMENTAL|TDF-TDF|TDF plus ADV placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.
62028200|NCT00116805|ACTIVE_COMPARATOR|ADV-TDF|ADV plus TDF placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of FTC/TDF FDC tablet) to their treatment regimen in the open-label period.
62802582|NCT05262257|NO_INTERVENTION|Healthy control group|no intervention.
62802583|NCT00799266|EXPERIMENTAL|Zoledronic acid|Twice yearly 0.05 mg/kg (max 5 mg) i.v infusion (at least 30 minutes) of zoledronic acid
62802584|NCT00799266|PLACEBO_COMPARATOR|Placebo|Twice yearly i.v of infusion of Placebo (similar dosing as active drug)
62802585|NCT03103126|NO_INTERVENTION|Control|Standard care.
62802586|NCT03103126|EXPERIMENTAL|Combined resistance exercise and walking|Combined resistance exercise and walking.
62802587|NCT00569140|NO_INTERVENTION|1|E10030
62802588|NCT03865082|EXPERIMENTAL|IO Naive Subjects MSS CRC|8mg Tilsotolimod by intratumoral injection plus 3mg/kg Nivolumab (every three weeks for four doses followed by 480mg dose every four weeks) and 1mg/kg Ipilimumab every three weeks for four doses intravenous
62802589|NCT00623324|ACTIVE_COMPARATOR|1|Aplindore titrated to safe and tolerable dose
62802590|NCT00623324|PLACEBO_COMPARATOR|2|
62802591|NCT04689516|EXPERIMENTAL|Control Group|will receive a hypervolemic hemodilution with an IV infusion load of 6% HES.The infusion will be started preoperatively and will stop after completion of the infused volume. LUS evaluation will be done before start and after the end of the infusion.
62028201|NCT02543359|EXPERIMENTAL|Clinicians and Supervisors|After randomization clinicians and supervisors from community behavioral health agencies receive training in one of three PCIT training models: Train the Trainer (TTT), Learning Collaborative (LC) or Web-Supported Self Study (SS).
62802592|NCT04689516|EXPERIMENTAL|The TFC Group|will receive hypervolemic hemodilution with an IV infusion load of 6% HES.The infusion will be started preoperatively . The patient will be monitored for thoracic fluid content and LUS score. The infusion will stop if TFC reaches 40 k ohm-1 or after completion of the infused volume. LUS evaluation will be done before start and after the end of the infusion.
62802593|NCT00392392|EXPERIMENTAL|Intervention|Patients received treatment with nab-paclitaxel (100 mg/m2 IV days 1, 8, 15) and carboplatin (AUC 6 IV day 1) every 28 days for 6 cycles. Trastuzumab (4 mg/kg loading dose, followed by 2 mg/kg) and bevacizumab (5 mg/kg IV) were administered weekly for 23 weeks, beginning concurrently with chemotherapy. Patients then underwent either mastectomy or breast conserving surgery and pathologic treatment responses were assessed. After surgery, trastuzumab 6 mg/kg and bevacizumab 15 mg/kg were administered at 3 week intervals for a total of 52 weeks.
62028202|NCT02543359|EXPERIMENTAL|Administrators|After randomization administrators from participating community behavioral health agencies receive one of three treatments for PCIT (1/3 Learning Collaborative, 1/3 other treatment - none, and 1/3 other treatment - none).
62590285|NCT05733143||Symptom high/T2-biomarker high (12 participants)|\[ACQ≥ 1.5 AND FeNO≥20 ppb AND blood eosinophil count≥150 cells/µL\] During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.
62590286|NCT00150800|EXPERIMENTAL|Brivaracetam|Brivaracetam used as adjunctive treatment, flexible dosing up to 200 mg /day in b.i.d (twice daily) administration. Dose increase or decrease can be made in increments of maximum 50 mg/day on a weekly basis.
62802594|NCT01272570||Aromatase Inhibitor|"* Diagnosis of BCa- Histologic confirmed diagnosis of BCa: Stage 0, I, II, or III with no evidence of metastatic disease.~* Treatment- AI as clinically indicated (AI may be anastrozole, exemestane or letrozole). Subjects may have had prior tamoxifen or raloxifene. Subjects may have had chemotherapy and/or radiation therapy. Must be within the first year of consecutive AI therapy. If a subject started AI, discontinued, then restarted, they will be accepted into the study as long as the past therapy did not exceed 12 months and the current therapy has not exceeded 12 months."
62802595|NCT01272570||Control|• No Diagnosis of cancer.- Patients must not have a diagnosis of any cancer (Not including a history of thyroid or skin cancer).
62802596|NCT04509791|PLACEBO_COMPARATOR|placebo|placebo arm
62802597|NCT04509791|ACTIVE_COMPARATOR|2.5 mg ATG/kg|the trial consists of 7 cohorts. The first cohort of 30 participants will be randomised to placebo, 2.5 mg/kg, 1.5 mg/kg, 0.5 mg/kg en 0.1 mg/kg in a 1:1:1:1:1 allocation ratio
62802598|NCT04509791|ACTIVE_COMPARATOR|1.5 mg ATG/kg|the next two cohorts of 12 participants will be randomised to placebo, 2.5 mg/Kg, and 2 specified middle ATG total doses in a 1:1:1:1 allocation ratio
62802599|NCT04509791|ACTIVE_COMPARATOR|0.5 mg ATG/kg|The next four cohorts of 15 participants will be randomised to placebo, 2.5 mg/kg and a single selected middle ATG total dose in a 1:1:1 allocation ratio
62802600|NCT04509791|ACTIVE_COMPARATOR|0.1 mg ATG/kg|the trial consists of 7 cohorts. The first cohort of 30 participants will be randomised to placebo, 2.5 mg/kg, 1.5 mg/kg, 0.5 mg/kg en 0.1 mg/kg in a 1:1:1:1:1 allocation ratio
62802601|NCT03626792|OTHER|Hypertensive group|The Mat Pilates session was held lasting 50 minutes of exercises with the first 5 minutes heating and in each exercise performing 10 repetitions with 45 seconds of rest between one exercise and another. For practice, are used only mats, and alternative devices such as the Swiss ball and the flexible ring, as well as body weight and the force of gravity as resistance factors and Borg's subjective perception of effort scale for intensity parameters. The 20 exercises were chosen through the classic exercises thus classified by the creator of the Joseph Pilates method.During the sessions, volunteers were instructed on correct breathing without performing the valsalva maneuver.
62590287|NCT01290679|EXPERIMENTAL|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) (PegIFN alpha-2a/b) and ribavirin (Copegus or Rebetol) for 24 or 48 weeks
62590288|NCT01290679|PLACEBO_COMPARATOR|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) (PegIFN alpha-2a/b) and ribavirin (Copegus or Rebetol) for 48 weeks
62590289|NCT05212662|EXPERIMENTAL|TTI-0102|Cysteamine-pantetheine disulfide (TTI-0102) is supplied in a vial as a powder to be dissolved in water and administered orally.
62590290|NCT05212662|PLACEBO_COMPARATOR|Placebo|Placebo is supplied in a vial as a powder to be dissolved in water and administered orally.
62590291|NCT01041846||Decitabine|
62802602|NCT03626792|OTHER|Normotensive group|The Mat Pilates session was held lasting 50 minutes of exercises with the first 5 minutes heating and in each exercise performing 10 repetitions with 45 seconds of rest between one exercise and another. For practice, are used only mats, and alternative devices such as the Swiss ball and the flexible ring, as well as body weight and the force of gravity as resistance factors and Borg's subjective perception of effort scale for intensity parameters. The 20 exercises were chosen through the classic exercises thus classified by the creator of the Joseph Pilates method.During the sessions, volunteers were instructed on correct breathing without performing the valsalva maneuver.
62802603|NCT02399709|EXPERIMENTAL|simvastatin|oral administration, capsule of 20mg.
62227167|NCT03022279|ACTIVE_COMPARATOR|Local Wound Infiltration|Local wound infiltration (LWI) will be performed by the operative surgeon using 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine with maximum of 60 mL divided amongst the four port sites. 40% of the total dose will be given at the umbilicus, and 20% will be given at each of the other 3 ports. The majority of the anesthetic will be administered at the peritoneal level. Laparoscopic/robotic cholecystectomy will be performed with a port at the umbilicus and three smaller ports in a standard fashion in the subxiphoid and right upper quadrant regions. If conversion to open cholecystectomy occurs, the study data will still be collected, but the patient's data will be excluded from analysis.
62028203|NCT02543359|EXPERIMENTAL|Parent-Child Dyads|Parent-child dyads receive Parent-Child Interaction Therapy (PCIT) treatment from trained clinicians/supervisors.
62227168|NCT05406076|ACTIVE_COMPARATOR|Oral Motor Therapy/ABA|"Eighty subjects who met the inclusion/exclusion criteria were randomly divided into 2 groups according to a 1:1 ratio. The experimental group was first treated with 2 months of ABA + oral motor therapy, followed by 2 months of ABA treatment.~Oral motor therapy appliances can be used during mouth muscle training sessions, depending on the individual needs of the child. 30-40 min/session, 1 session/day, 5 sessions/week.~ABA training time is at least 20 hours per week. The therapist is fully aware of each stage of the child's training during the teaching process and can make an accurate assessment of the child."
62227169|NCT05406076|ACTIVE_COMPARATOR|ABA/Oral Motor Therapy|"Eighty subjects who met the inclusion/exclusion criteria were randomly divided into 2 groups according to a 1:1 ratio. The control group was treated with 2 months of ABA followed by 2 months of ABA + oral motor therapy.~Oral motor therapy appliances can be used during mouth muscle training sessions, depending on the individual needs of the child. 30-40 min/session, 1 session/day, 5 sessions/week.~ABA training time is at least 20 hours per week. The therapist is fully aware of each stage of the child's training during the teaching process and can make an accurate assessment of the child."
62227170|NCT00589680||2|Patients treated for DKA under DKA protocol implemented by hospital
62227171|NCT00589680||1|To establish a baseline on how patients are being treating with DKA in general and without a standardized DKA protocol
62802604|NCT02399709|PLACEBO_COMPARATOR|microcrystalline cellulose|oral administration, capsule of 20mg
62802605|NCT03617952|EXPERIMENTAL|S1 (Peer) group|"S1 group households located in 25 clusters that were included in a prior cookstove study: selected households are nearest neighbors (peers) of households who received free stoves in that prior study. This group is used to represent a potentially high peer influence on the adoption of improved cookstoves.~The P3 Bio Intervention is implemented in this group."
62802606|NCT03617952|EXPERIMENTAL|S2 (Non-Peer) Group|"S2 group households are located in 25 clusters randomly selected from the area of the K-N Districts more than 1 km from the S1 clusters. This group will have minimal prior knowledge of the cookstoves through peers.~The P3 Bio Intervention is implemented in this group."
62802607|NCT00548600|EXPERIMENTAL|1|Iridium implant plus external beam irradiation
62802608|NCT00548600|ACTIVE_COMPARATOR|2|Standard external beam irradiation alone
62802609|NCT00250341|ACTIVE_COMPARATOR|Advair|
62802610|NCT00250341|EXPERIMENTAL|QVAR|
62028204|NCT04408755|EXPERIMENTAL|AVP-786|Participants will be assigned to treatment with AVP-786 capsules administered twice a day over a 12-week period.
62028205|NCT04408755|PLACEBO_COMPARATOR|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
62028206|NCT05085600|ACTIVE_COMPARATOR|Exercise Group|20-minute session, composed of 2 blocks of 10 repetitions, holding each exercise for 10 seconds, a 40-second rest between each repetition and 2 minutes between blocks.
62028207|NCT05085600|EXPERIMENTAL|Exercise + Manual Therapy Group|20-minute session. In the first 5 minutes, muscle techniques will be performed to prepare the tissue of the upper cervical spine before applying joint techniques. In the next 15 minutes, manipulation and / or mobilization techniques of the upper cervical spine, including the C2-3 segment, will be combined with cervical exercise
62590292|NCT01878422|EXPERIMENTAL|Arm A: FOLFIRI or FOLFOX + Bevacizumab|"* BEVACIZUMAB: Day 1,1st cycle 5 mg/kg IV infusion of 90 min Day 1, 2nd cycle if well tolerated, 5 mg/kg IV infusion of 60 min Day 1, 3rd cycle and subsequent cycles if well tolerated, 5 mg/kg IV infusion of 30 min after 5-FU bolus~* FOLFIRI Day 1: Irinotecan 180 mg/m2 IV infusion 30-90 min~Day 1,2:~L-Folinic acid 100 mg/m2 IV infusion of 2 hours 5-Fluorouracil 400 mg/m2 as a bolus 5-Fluorouracil 600 mg/m2 continuous IV infusion of 22 hours~- FOLFOX Day 1: Oxaliplatin 85 mg/m2 IV infusion of 2hours~Day 1,2:~L-Folinic acid 100 mg/m2 IV infusion of 2 hours 5-Fluorouracil 400 mg/m2 as a bolus 5-Fluorouracil 600 mg/m2 continuous IV infusion of 22 hours"
62590293|NCT01878422|EXPERIMENTAL|Arm B: FOLFIRI or FOLFOX|If FOLFIRI: FOLFIRI as specified in arm A without Bevacizumab If FOLFOX: FOLFOX as specified in arm A without Bevacizumab
62590294|NCT01878422|EXPERIMENTAL|Arm C: FOLFIRI or FOLFOX|Arm C: FOLFIRI or FOLFOX: for patients from arm A: FOLFIRI or FOLFOX (the CT schedule not received in 1st line trial, as defined in arm B)
62028208|NCT05501860|EXPERIMENTAL|AG-920|Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%.
62590295|NCT01878422|EXPERIMENTAL|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB: for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in 1st line trial, as described in arm B) plus CETUXIMAB
62028209|NCT05501860|PLACEBO_COMPARATOR|Placebo|Placebo Sterile Topical Ophthalmic Solution
62028210|NCT01703455|EXPERIMENTAL|Sorafenib 400 mg twice daily|Sorafenib 400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
62028211|NCT02359396|EXPERIMENTAL|5.0g of MZRW|The participants will receive 5.0g of MZRW at 9 am .
62028212|NCT02359396|EXPERIMENTAL|7.5g of MZRW|The participants will receive 7.5g of MZRW at 9 am.
62028213|NCT02359396|EXPERIMENTAL|10g of MZRW|The participants will receive 10g of MZRW at 9 am.
62028214|NCT06429020||control group|non SARS-COV-2 vaccinated group
62028215|NCT06429020||vaccinated group|SARS-COV-2 vaccinated group
62028216|NCT04596254|OTHER|Juice Intake|
62028217|NCT02202473|ACTIVE_COMPARATOR|Lamivudine|Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd
62028218|NCT02202473|EXPERIMENTAL|Lamivudine+Oxymatrine Capsules|Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd; oxymatrine Capsules (Chia Tai Tianqing Pharmaceutical Group Co., Ltd) 200 mg, po, tid.
62028219|NCT06030245||Patients with Clostridioides infection|The following procedures are specific to this test: 8 additional stool swabs (or Fecal Swab in the absence of stool output) to that of the initial diagnosis, plus four saliva swabs. Rectal swabs may cause anal irritation. The patient must also complete a stool collection form.
62028220|NCT05853250|EXPERIMENTAL|Reiki/manual therapy|Reiki, a Japanese energy-based healing technique, is universal vital energy that flows throughout and encompasses all living forms (Rand, 1991). It is delivered by gentle hand placement either on/slightly above the body by certified Reiki practitioners. In this study, Reiki will be delivered first, for 15 min. and will involve light placement of hands on patients' head, chest, shoulders, hands, knees, and feet (\~ 3 minutes to each body part). Manual therapy (MT) includes light effleurage to head and feet (for 5 minutes; \~ 2.5 minutes to each body part) by the Reiki practitioner. MT techniques are defined as light circular stroking movements made with the hands. Reiki and MT will be delivered for 3 consecutive days beginning on the day after endotracheal tube removal. Reiki and MT will be delivered by 4 Reiki practitioners with training at a Level 2+. Reiki and manual therapy was delivered as one intervention. They are not two separate interventions.
62590296|NCT01878422|EXPERIMENTAL|Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB|for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in the 1st line trial, as defined in arm B) plus BEVACIZUMAB
62028221|NCT05853250|NO_INTERVENTION|Usual care quiet time|All usual care provided pre and post-operative management will continue, uninterrupted; including the 20 minute rest period. The only non-usual care component will be placement of a sign on the door to discourage visitors and providers from entering the room and disturbing the rest period.
62028222|NCT03921268|EXPERIMENTAL|Treatment A|Dose A estimated delivered single dose of AZD1402 nebuliser solution administered via a nebuliser.
62028223|NCT03921268|EXPERIMENTAL|Treatment B|Dose B estimated delivered single dose of AZD1402 inhalation powder administered via an inhaler.
62028224|NCT03921268|EXPERIMENTAL|Treatment C|Dose C estimated delivered single dose of AZD1402 inhalation powder administered via an inhaler.
62590297|NCT01878422|EXPERIMENTAL|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB;|for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in the first-line trial, as defined in arm B) plus BEVACIZUMAB and CETUXIMAB; cycle to be repeated every 2 weeks, whilst cetuximab will be administered weekly.
62590298|NCT06668298|EXPERIMENTAL|Oliceridine group|Oliceridine 0.4mg · kg-1+tropisetron 10mg, mixed with physiological saline to 100ml. PCIA is set to continuous infusion of 2ml/h, with a single dose of 2ml and a locking time of 15 minutes.
62590299|NCT06668298|ACTIVE_COMPARATOR|Sufentanil group|Sufentanil 2 µ g · kg-1+tropisetron 10mg, mixed with physiological saline to 100ml. PCIA is set to continuous infusion of 2ml/h, with a single dose of 2ml and a locking time of 15 minutes.
62590300|NCT05121103|EXPERIMENTAL|Open-label EZM0414|"Participants will receive EZM0414 in continuous 28-day cycles. EZM0414 will be administered orally once daily (QD) without food.~Participants who receive EZM0414 at Maximum tolerated dose (MTD) and do not have Dose limiting toxicities (DLT) in the dose escalation part of the study will be rolled over to a cohort of this dose expansion part.~Cohort 1 for R/R MM Participants. Cohort 2 for R/R MM Participants. Cohort 3 for Participants with R/R DLBCL."
62590301|NCT00836888|EXPERIMENTAL|Cohort|
62590302|NCT01542437|EXPERIMENTAL|BIBW 2992|Patients received a daily oral 40mg dose of afatinib. Treatment was continued until docu-mented disease progression, unacceptable toxicity or withdrawal of consent. The Common Terminology Criteria for Adverse Events (CTCAE) v4.0 was used to evaluate toxicity. In patients with severe toxicity (grade ≥3) afatinib was temporary discontinued until the patient recovery to at least grade 1 toxicity and continued with a dose reduction to 30 mg/day. Dose reduction below 30mg/day was not allowed. Patients experiencing more than one grade ≥3 event, those with grade ≥2 toxicity after dose reduction, and/or those showing no recovery within 14 days discontinued treatment.
62590303|NCT03359668|EXPERIMENTAL|Non-contrast-enhanced CT|Comparison of non-contrast CT to the standard-of-care contrast-enhanced CT of the head and neck in detection of suspicious lymph nodes
62590304|NCT03359668|ACTIVE_COMPARATOR|Contrast-enhanced CT|Comparison of non-contrast CT to the standard-of-care contrast-enhanced CT of the head and neck in detection of suspicious lymph nodes
62590305|NCT02805179|EXPERIMENTAL|High Dose Chemoradiation|Patients will receive high dose radiation based in part on advanced imaging, and concurrent temozolomide. Four weeks after the completion of chemoradiation, patients will receive adjuvant temozolomide.
62590306|NCT00611663|EXPERIMENTAL|1|Vaccination with conjugate vaccine Prevenar® (WYETH-LEDERLE) at week 0 and Poly Saccharidic vaccine Pneumo23® (Sanofi Pasteur MSD) after 6 months (W24)
62590307|NCT00611663|PLACEBO_COMPARATOR|2|Vaccination with placebo at W0 and Poly Saccharidic vaccine Pneumo23® at W24
62590308|NCT06307756|EXPERIMENTAL|Music group|"Mothers will be informed about the application before the procedure. Mothers who agree to participate in the study will be asked to listen to music that relaxes them for 20 minutes a day for 4 days. The mothers' state anxiety levels and milk quantities will be evaluated before starting the application and every day during the application. Mothers' anxiety levels will be evaluated with the State Anxiety Inventory. Mothers' anxiety levels and milk quantities will be evaluated every day at 11.45 when they come to the NICU to express milk."
62590309|NCT06307756|NO_INTERVENTION|Control group|"After mothers are informed about the study, mothers who agree to participate in the study will be included in the control group by randomization method. No intervention will be made to mothers in the control group. The mothers' state anxiety levels and milk quantities will be evaluated at the first meeting with the mothers and every day for four days. Mothers' anxiety levels will be evaluated with the State Anxiety Inventory. Mothers' anxiety levels and milk quantities will be evaluated every day at 11.45 when they come to the NICU to express milk."
62590310|NCT05194761|ACTIVE_COMPARATOR|using nebulization|extubated neonates will be divided in two group , one will receive saline nebulization for 3 days postextubation ,
62590311|NCT05194761|NO_INTERVENTION|No nebulization|the other group will only receive the standard only
62590312|NCT06074796||Transgender patients|"Patients included are transgender patients who have had routine consultations as part of the transition process for transgender patients, done in the reproductive medicine department of the regional university hospital centre in Nancy. Exclusion criteria : minors, patients under guardianship or trusteeship.~French laws allow embryo transfer until 45 years for women and sperm reuse up to 60 years for men, so patients older have been excluded."
62590313|NCT00832871|EXPERIMENTAL|Mifepristone|200 mg RU-486 (Mifepristone) daily
62590314|NCT03417089|EXPERIMENTAL|falciform ligament suspension|routine suspension of falciform ligament during mini gastric bypass,
62590315|NCT03417089|ACTIVE_COMPARATOR|No suspension|working without suspension of the falciform ligament
62590316|NCT00102531|EXPERIMENTAL|Cisplatin liposomal 24 mg/m2|Inhaled liposomal cisplatin was administered over 1 day in a 14-day treatment cycle by inhalation for a maximum of 6 cycles.
62590317|NCT00102531|EXPERIMENTAL|Cisplatin liposomal 36 mg/m2|The study allowed for a dose escalation of liposomal cisplatin to 36 mg/m2 if no adverse events of Grade 3 or higher occurred after at least 3 cycles of drug administration at 24 mg/m2
62590318|NCT04544696||Patients with chronic non cancer pain|Patients with chronic non cancer pain, treated with opioids and having completed the POMi questionnaire
62028225|NCT00407992|EXPERIMENTAL|Occipital nerve stimulation ON|
62590319|NCT02048566|EXPERIMENTAL|hTEEPM|Group hTEE protocolled monitoring (hTEEPM) will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, at the time of occurrence of defined new organ system deterioration (see below) and/or at least every 4 hours during the first 72h after study inclusion or until one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
62028226|NCT00407992|OTHER|Occipital nerve stimulation OFF|
62028227|NCT05014165||Ancillary-Correlative (Cord Blood collection)|Accrue patients with ALL and AML who indicate having banked cord blood at birth through the COG Project:EveryChild (APEC14B1)
62028228|NCT04391049|EXPERIMENTAL|Treatment (OBP-301, carboplatin, paclitaxel, radiation)|Patients receive OBP-301 by intratumoral injection on days -3, 12, and 26. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, and 29, and undergo radiation therapy on Monday through Friday beginning day 1 for 28 fractions over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity.
62419990|NCT03025659||Pediatric post-cardiac surgery|All immediately post-operative pediatric cardiac patients will be enrolled. Standard of care laboratory analysis will be performed based on current clinical protocols. Results for lactate, blood gases, liver enzymes, creatinine, glucose, hemoglobin, hematocrit and other direct and indirect measure of cardiac output will be collected. Investigators will also measure pyruvate levels at specific time points, which is not part of standard of care. To measure pyruvate, an additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw. The lactate/pyruvate ratio will be calculated and compared to direct and indirect measure of cardiac output described above.
62590320|NCT02048566|EXPERIMENTAL|hTEESM|Group hTEE standard monitoring (hTEESM) will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, follow-up assessment intervals are at the discretion of the treating physician for the first 72h after study inclusion. A follow up assessment is defined as any assessment that leads to significant changes in hemodynamic management in which case an hTEE assessment has to be performed. hTEE monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
62590321|NCT02048566|ACTIVE_COMPARATOR|ControlPM|Group Control protocolized monitoring (ControlPM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, at the time of occurrence of defined new organ system deterioration or at least every 4 hours for the first 72h after study inclusion. Protocolized monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
62590322|NCT02048566|ACTIVE_COMPARATOR|ControlSM|Group Control standard monitoring (ControlSM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, follow-up measurement intervals are at the discretion of the treating physician for the first 72h after study inclusion. A follow up assessment is defined as any assessment that leads to significant changes in hemodynamic management. Data collection from standard monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
62590323|NCT00890084||Group1|
62419991|NCT01466959|ACTIVE_COMPARATOR|AD- acetic acid dialysate|AD is a standard bicarbonate based dialysate with a small amount of acetic acid which is the standard of care for dialysis.
62419992|NCT01466959|EXPERIMENTAL|CD - citrasate dialysate|Dialysis with a citric acid based dialyasate.
62590324|NCT03915431|EXPERIMENTAL|NCS-01|human bone marrow derived cells
62590325|NCT03915431|SHAM_COMPARATOR|sham|sham procedure
62590326|NCT02960165|EXPERIMENTAL|Virtual interface group A|Older adults that started the practice on the virtual interface
62590327|NCT02960165|EXPERIMENTAL|Virtual interface group B|Older adults that started the practice on the virtual interface and then practiced on real task.
62590328|NCT02960165|ACTIVE_COMPARATOR|Real interface group A|Older adults that started the practice on the virtual interface
62590329|NCT02960165|ACTIVE_COMPARATOR|Real interface group B|Older adults that started the practice on the real interface and then practiced on virtual task.
62590330|NCT05864612|ACTIVE_COMPARATOR|Text Message|Subjects in this arm will be asked to complete standard care screening questionnaires on anxiety and depression, delivered by Twilio text message.
62590331|NCT05864612|ACTIVE_COMPARATOR|Customized Email Prompt|Subjects in this arm will be asked to complete standard care screening questionnaires on anxiety and depression, delivered by an email with a REDCap email survey link.
62028229|NCT00122018|EXPERIMENTAL|NAC|N-acetylcysteine started day prior to surgery, continued through night of surgery
62028230|NCT00122018|EXPERIMENTAL|fenoldopam|fenoldopam started at surgery continued for 24 hours
62028231|NCT00122018|EXPERIMENTAL|NAC and fenoldopam|Both N-acetylcysteine and fenoldopam as above
62028232|NCT00122018|PLACEBO_COMPARATOR|Control|Placebo
62028233|NCT03137147|OTHER|Cognitive-Behavioral Therapy|Intervention for Sleep and Pain in Youth, a 7-session cognitive-behavioral therapy intervention for co-morbid insomnia and headache
62028234|NCT04842357|OTHER|video - then self-study|Group A will be video recorded during the performance of the two skills on simulators (i.e. Donati suture and intraosseous venous access) (timepoint: T0). Then group A will watch a standardised video about the skills, then will be again video recorded during the performance of the two skills on simulators (timepoint: T1). After 1 to 2 weeks group A will do self-study, then will be again video recorded during the performance of the two skills on simulators (timepoint: T2).
62590332|NCT05864612|ACTIVE_COMPARATOR|Generic Electronic Health Record (EHR) portal email|Subjects in this arm will be prompted with customized EHR portal message after login to EHR portal.
62590333|NCT05864612|ACTIVE_COMPARATOR|EHR Portal with No Message|Subjects in this arm will not receive a reminder, but previsit questionnaires associated with a visit will be in their EHR portal.
62590334|NCT05803798|ACTIVE_COMPARATOR|treatment|preventive treatment by IPL+LLLT with EYE-LIGHT, Espansione group
62590335|NCT05803798|NO_INTERVENTION|standard|non preventive treatment by IPL+LLLT with EYE-LIGHT, Espansione group = standard care
62802611|NCT06288048|EXPERIMENTAL|Deep Dry Needling (DDN), Ischemic Compression, Cold Spray with Stretching + MFT|The intervention protocol in this study will target individuals experiencing Post-needling pain associated with lateral elbow pain. It will comprise a series of treatments including Deep Dry Needling (DDN) focused on the proximal third of the m. Brachioradialis (BR), was conducted with the patient seated and the therapist positioned on the same side as the needle insertion. Following DDN, ischemic compression (IC) will be applied using a sphygmomanometer on the seated subject's arm, along with three applications of cold spray synchronized with m. Brachioradialis (BR) stretching. The intervention will conclude with Mirror Therapy (MFT), where the patient will face a mirror covering the punctured side at a 45-degree angle for proper hand visualization, engaging in hand exercises and wrist movements while observing their reflection.
62802612|NCT06288048|ACTIVE_COMPARATOR|Deep Dry Needling (DDN), Ischemic Compression, Cold Spray with Stretching|The intervention protocol in this study will target individuals experiencing Post-needling pain associated with lateral elbow pain. It will comprise a series of treatments including Deep Dry Needling (DDN) focused on the proximal third of the m. Brachioradialis (BR), conducted with the patient seated and the therapist positioned on the same side as the needle insertion. Following DDN, ischemic compression (IC) will be applied using a sphygmomanometer on the seated subject's arm, along with three applications of cold spray synchronized with m. Brachioradialis (BR) stretching. The intervention will not conclude with Mirror Therapy (MFT).
62802613|NCT05753839|EXPERIMENTAL|Upfront cytoreductive nephrectomy|Cytoreductive nephrectomy±metastasectomy, followed by induction therapy with nivolumab plus ipilimumab combination and maintenance therapy with nivolumab.
62802614|NCT05753839|EXPERIMENTAL|Deferred cytoreductive nephrectomy|Cytoreductive nephrectomy±metastasectomy after induction therapy with nivolumab plus ipilimumab combination, followed by maintenance therapy with nivolumab.
62802615|NCT05753839|ACTIVE_COMPARATOR|No surgery|Induction therapy with nivolumab plus ipilimumab combination, followed by maintenance therapy with nivolumab.
62243064|NCT02441673|ACTIVE_COMPARATOR|Tramadol|"Premedication of IV (Intravenous)10mg Metoclopramide and 50mg Ranitidine would be given morning of surgery to all patients.~1mg/kg of tramadol would be administered after the initiation of the subarachnoid block (Time 0) and presence and severity of shivering (the primary outcome) would be looked out for.~IV Ephedrine in 3mg alliquots would be given if hypotension occurs; IV oxytocin 30-50mg would be given after delivery of the baby to all patients and IV Pethidine 25mg would be given to abate any residual shivering if a repeat dose of Tramadol is not satisfactory."
62419993|NCT06568978||Group 1|patients with upper limb lymphedema
62419994|NCT06568978||Group 2|healthy individuals
62419995|NCT06579196|EXPERIMENTAL|Arm I: Dose Finding|"Subjects receive either 140, 190, or 250 mg/m2 intravenous OT-101/Trabedersen for up to 12 weeks using a 4 days on 10 days off dosing schedule. The dose level is determined according to the Bayesian optimal interval (BOIN) design with cohort size 3.~Subjects receive concurrent administration of 400 mg intravenous Pembrolizumab every 6 weeks."
62419996|NCT06579196|EXPERIMENTAL|Arm II: Treatment|"Subjects receive the recommended phase II dose of intravenous OT-101/Trabedersen (140, 190, or 250 mg/m2) until progression using a 4 days on 10 days off dosing schedule.~Subjects receive concurrent administration of 400 mg intravenous Pembrolizumab every 6 weeks."
62419997|NCT04241068|EXPERIMENTAL|Aducanumab|Participants will be administered aducanumab 10 milligrams per kilogram (mg/kg) by intravenous (IV) infusions every four weeks (Q4W) for a duration of 100 weeks during the Core Treatment Period. Eligible participants will continue to receive aducanumab 10 mg/kg IV infusion, Q4W, for 52 weeks during the Long-Term Extension (LTE) Treatment Period.
62419998|NCT05875623|EXPERIMENTAL|Intervention|"In the intervention group, the clinical pharmacist will apply the MALPIP criteria on all the admission and discharge medications. The pharmacists can access the full MALPIP list at https://sites.google.com/moh.gov.my/malpip/home.~The intervention will consist of 4 steps: i) pharmacist review using MALPIP criteria to detect PIM, ii) discussion with doctors for deprescribing decision iii) discussion with patients and documentation of shared decision iv) follow up patients at 6, 12, and 18 months.~Pharmacists will perform the reviewing and checking by themselves and discuss the suggestions with doctors during daily medical ward rounds. The attending doctors will decide whether to deprescribe based-on pharmacists suggestions. Then, the pharmacists will discuss the deprescribing proposal with the patients and record the decision."
62419999|NCT05875623|NO_INTERVENTION|Control|"In the control arm, pharmacists, patients and doctors are not purposefully blinded but are not aware of the intervention (i.e. the MALPIP tool). Designated pharmacist at the control sites identifies patients who match the eligibility requirements and enroll them into the trial after obtaining consent.~Patients in the control arm will receive routine care and support that they entitled to from the medical team and clinical pharmacists. Preadmission medication will be reconciled by a clinical pharmacist using the standard procedures, including medication history assessment form (CP1), pharmacotherapy review (CP2) and the clinical pharmacy report form (CP3)."
62028235|NCT04842357|OTHER|self-study, then video|Group B will be video recorded during the performance of the two skills on simulators (i.e. Donati suture and intraosseous venous access) (timepoint: T0). Then group B will do self-study, then will be again video recorded during the performance of the two skills on simulators (timepoint: T1). After 1 to 2 weeks group B will watch the standardised video about the skills, then will be again video recorded during the performance of the two skills on simulators (timepoint: T2).
62028236|NCT03483636|EXPERIMENTAL|Lemborexant|Participants will be randomized to receive a 10 milligram (mg) lemborexant tablet administered with 50 milliliter (mL) water followed by a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
62802616|NCT05631561|EXPERIMENTAL|The endovascular denervation (EDN) group|Receive endovascular denervation (EDN)
62420000|NCT03771768|ACTIVE_COMPARATOR|Triamcinolone acetonide|Triamcinolone acetonide 0.1% 5 gm adhesive paste 4 times / day for 1 month.
62590336|NCT06468878|EXPERIMENTAL|Exposure Intervention with Non-Lyrical, Liked Background Music|Participants will be presented with a list of instrumental songs without lyrics from popular movies. Participants will then rank the songs in order of those they would like to hear the most. During VR heights exposure the participants' highest-ranked songs will be played in the background at a low volume.
62590337|NCT06468878|EXPERIMENTAL|Exposure Intervention without Background Music|Participants will undergo VR heights exposure without background music.
62802617|NCT00148759|ACTIVE_COMPARATOR|adult male subjects|LPV/r 800/200 mg once daily
62802618|NCT00148759|EXPERIMENTAL|Adult female subjects|LPV/r 800/200 mg once daily
62802619|NCT05982990|EXPERIMENTAL|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|Test
62802620|NCT05982990|ACTIVE_COMPARATOR|ADVAIR DISKUS® 250/50|Reference
62802621|NCT00858026|OTHER|1|Breastfed babies
62802622|NCT00858026|ACTIVE_COMPARATOR|2|Weaning with the standard milk
62802623|NCT00858026|EXPERIMENTAL|3|Weaning with the fermented milk
62028237|NCT03483636|EXPERIMENTAL|Lemborexant Plus Alcohol|Participants will be randomized to receive a 10 mg lemborexant tablet administered with 50 mL water followed by alcohol (0.6 grams per kilogram \[g/kg\] of alcohol for females or 0.7 g/kg of alcohol for males) for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
62243065|NCT04004429|EXPERIMENTAL|50 mg AP1189|50 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.
62420001|NCT03771768|EXPERIMENTAL|Diode laser|Diode laser 980 nm \& 100mWatt.
62420002|NCT01643928|EXPERIMENTAL|Rituximab-Pfizer|
62420003|NCT01643928|ACTIVE_COMPARATOR|Rituximab-EU+Rituximab-Pfizer|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses.
62420004|NCT01643928|ACTIVE_COMPARATOR|Rituximab-US+Rituximab-Pfizer|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses.
62420005|NCT06568068|EXPERIMENTAL|EDUCATION GROUP|"Procedures to be implemented in the Intervention Group:~The intervention group that will receive training determined after randomization; In Stage 1 An introductory meeting will be held, ERGEP will be announced and educational materials will be distributed. Pretest applications will be done. In Stage 2 A week consisting of four weeks and eight sessions on the following topics determined within the scope of ERGEP Trainings planned to be held in two sessions will be given once.~Educational Topics:~1. Developmental periods (oral, anal,a phallic, latent, genital)~2. Physical, psychological and social changes experienced in girls and boys during adolescence~3. Being an adolescent parent and healthy communication~4. Risky behaviors in life and sexual matters during adolescence In Stage 3 At the end of the training, measurement tools will be applied again. In Stage 4 Measuring tools will be repeated after 21 days."
62420006|NCT06568068|NO_INTERVENTION|CONTROL GROUP|"Procedures to be applied in the Control Group:~In this group, where no intervention was made, the pretest, interim follow-up and posttest were the same as the intervention group.~It will be implemented in weeks. It was aimed to present the program to the control group parents at the end of the study."
62420007|NCT00566969|PLACEBO_COMPARATOR|Sugar Pill|To be compared to active drug
62420008|NCT00566969|ACTIVE_COMPARATOR|Carvedilol 25 mg|To be compared to placebo and Carvedilol 50 mg
62420009|NCT00566969|ACTIVE_COMPARATOR|Carvedilol 50 mg|To be compared to placebo and Carvedilol 25 mg
62420010|NCT03593356|EXPERIMENTAL|Monthly cash gift payments of $333|These subjects receive $333 each month for 76 months via debit card.
62420011|NCT03593356|ACTIVE_COMPARATOR|Monthly cash gift payments of $20|These subjects receive $20 each month for 76 months via debit card.
62420012|NCT01563029|ACTIVE_COMPARATOR|Arm 1|Fluticasone Furoate 100mcg inhalation powder once daily in the evening ICS powder
62420013|NCT01563029|ACTIVE_COMPARATOR|Arm 2|Fluticasone Furoate 50mcg inhalation powder once daily in the evening ICS powder
62420014|NCT01563029|ACTIVE_COMPARATOR|Arm 3|Fluticasone Furoate 25mcg inhalation powder once daily in the evening ics powder
62420015|NCT01563029|ACTIVE_COMPARATOR|Arm 4|Fluticasone Propionate 100mcg inhalation powder twice daily ICS powder
62243066|NCT04004429|EXPERIMENTAL|100 mg AP1189|100 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.
62420016|NCT01563029|PLACEBO_COMPARATOR|Arm 5|Placebo inhalation powder once daily in the evening Placebo powder
62420017|NCT03006822|EXPERIMENTAL|Application 90 minutes pressure release|Subjects will receive a pressure release technique for 90 seconds in the levator scapula muscle
62802624|NCT04506541|EXPERIMENTAL|Kangaroo Care Group|"The pregnant women who were in the kangaroo care group of the study and who were 36-38 weeks of gestation were given 20 minutes of kangaroo care and breastfeeding training by the researcher. A video about kangaroo care and breastfeeding was sent to pregnant women to remind them two weeks after the training. Kangaroo care application started in the first minute after giving birth in mothers who were in the kangaroo care group and came to the delivery room. In the first, third, sixth, and ninth months after the discharge of the mothers who started applying kangaroo care, kangaroo care application status, breastfeeding status, baby's growth, and development status were evaluated. In each follow-up, the baby's height, weight, and head circumference were measured with a standard measuring tool."
62420018|NCT03006822|EXPERIMENTAL|Application 60 minutes pressure release|Subjects will receive a pressure release technique for 60 seconds in the levator scapula muscle
62420019|NCT03006822|EXPERIMENTAL|Application 30 minutes pressure release|Subjects will receive a pressure release technique for 30 seconds in the levator scapula muscle
62420020|NCT02077660|PLACEBO_COMPARATOR|4 daily placebo tea bags for 12 weeks|"All subjects will undergo a 12 weeks supplemented with four daily placebo maltodextrin tea-bags. The subjects will be instructed than to brew the placebo sachets for five minute in 240 mL boiling water without stirring and to drink 4 cups per day for 12 weeks period (Placebo period)."
62420021|NCT02077660|EXPERIMENTAL|Four green tea bags per day for 12 weeks|After the placebo period, all subjects will undergo a 12 weeks supplemented with four daily green tea bags. The subjects will be instructed than to brew the green tea sachets for five minute in 240 mL boiling water without stirring and to drink 4 cups per day for 12 weeks period (Green tea period).
62420022|NCT05171127||Glioblastoma|No intervention. Observation of diffuse reflectance spectroscopy patterna are made on ex-vivo tissue samples in patients undergoing surgery for glial tumors.
62802625|NCT04506541|NO_INTERVENTION|Control Group|The pregnant women in the control group were not trained other than breastfeeding training given in the hospital. In the maternity room, routine care practices were performed after delivery of the pregnant women. As in mothers in the kangaroo care group, in the first, third, sixth, and ninth months after the discharge of mothers, kangaroo care application situations, breastfeeding conditions, growth, and development of the baby were evaluated.
62802626|NCT06002217|ACTIVE_COMPARATOR|TAP Block|
62802627|NCT06002217|PLACEBO_COMPARATOR|saline solution|
62802628|NCT01338818|EXPERIMENTAL|Ritalin LA|All participants started with Ritalin LA 20 mg/day and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 40, 60 or 80 mg/day).
62802629|NCT05170451|ACTIVE_COMPARATOR|Active Comparator: Start with CBD|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of the CBD and then crossover to the other condition (Shea butter only) for 2 additional weeks. Patients will apply the topical cream to the affected body region or joint two times daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
62802630|NCT05170451|ACTIVE_COMPARATOR|Active Comparator: Start with control (Shea butter)|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of Shea butter and then crossover to the other condition (CBD) for 2 additional weeks. Patients will apply the topical cream to the affected body region or joint two times daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
62802631|NCT03790722|EXPERIMENTAL|Higher Blood Pressure|Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure. Intervention: Ergometry H
62802632|NCT03790722|EXPERIMENTAL|Lower Blood Pressure|Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure. Intervention: Ergometry L
62802633|NCT04440878|EXPERIMENTAL|Static stretching|Static stretching will be administered to the hamstring muscles in the first group.
62802634|NCT04440878|EXPERIMENTAL|Mulligan TSLR technique|The Mulligan TSLR technique will be administered on the same muscle in the second group.
62802635|NCT03231852||Study Population|Women with a gynecologic malignancy will complete several surveys to assess their willingness to participate in clinical trials.
62802636|NCT00700596|ACTIVE_COMPARATOR|1|Salvinorin A (SA)
62420023|NCT06573697|EXPERIMENTAL|low-frequency continuous wave group|In each treatment session, the patients will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2Hz continuous wave will be used for 20 min.
62243067|NCT04004429|PLACEBO_COMPARATOR|Placebo|Placebo. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension i e. the powder will be added 50 ml water.
62243068|NCT06724016|EXPERIMENTAL|HM16390 Monotherapy|
62590338|NCT03388645|EXPERIMENTAL|Low Dose 10^6.3 PFU of RSV A2|Single intranasal dose of 10\^6.3 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0
62590339|NCT03388645|EXPERIMENTAL|High Dose 10^7 PFU of RSV A2|Single intranasal dose of 10\^7 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0
62590340|NCT05120531||Down Syndrome patients undergoing otolaryngologic surgery with anesthesia|
62590341|NCT05120531||Non-Down Syndrome patients undergoing otolaryngologic surgery with anesthesia|
62590342|NCT03057054|EXPERIMENTAL|Arm I (Lactobacillus plantarum, alloHCT)|Patients receive Lactobacillus plantarum strains 299 and 299v PO or through NJ, NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
62590343|NCT03057054|PLACEBO_COMPARATOR|Arm II (placebo, alloHCT)|Patients receive placebo PO or through NJ, NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
62590344|NCT06502795|EXPERIMENTAL|Limited Range of Motion Quadriceps Strengthening group|The Limited-RoM Quadriceps Strengthening group will perform open-kinetic-chain quadriceps strengthening exercises within a range of 90° to 45° of knee flexion and closed-kinetic-chain within a range of 0° to 45°.
62802637|NCT00700596|PLACEBO_COMPARATOR|2|Control or Placebo SA
62227172|NCT01839487|EXPERIMENTAL|Run-in Phase - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 micrograms/kilogram (mcg/kg) PEGPH20 with 125 milligrams/square meter (mg/m\^2) NAB and 1000 mg/m\^2 GEM as intravenous (IV) infusion. In Cycle 1 Week 1, PEGPH20 will be administered alone on Days 1 and 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15 and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1 8 and 15. NAB+GEM will be given 2 to 4 hours after PEGPH20 dose. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior and 8 to 12 hours after completion of each PEGPH20 infusion.
62227173|NCT01839487|ACTIVE_COMPARATOR|Run-in Phase - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m\^2 NAB and 1000 mg/m\^2 GEM, as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion.
62227174|NCT01839487|EXPERIMENTAL|Phase 2: Stage 1 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 mcg/kg PEGPH20 with 125 mg/m\^2 NAB and 1000 mg/m\^2 GEM as an IV infusion. In Cycle 1 Week 1, PEGPH20 will be given alone on Days 1 and Day 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15, and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and 15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1, 8, and 15. NAB+GEM will be given 2 to 4 hours after dose of PEGPH20. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning and 8 to 12 hours after the completion of each PEGPH20 infusion.
62243069|NCT04219696|ACTIVE_COMPARATOR|1 session|Participants will complete one 45-minute session of reactive balance training. Participants will experience 40-60 perturbations during this session. Participants will also complete 5 45-minute 'traditional' balance training sessions.
62802638|NCT00961155|ACTIVE_COMPARATOR|cyklezonid|children will receive 160 mcg once daily cyklezonid for 3 months
62590345|NCT06502795|ACTIVE_COMPARATOR|Patient-Guided Range of Motion Quadriceps Strengthening group|The Patient-Guided-RoM Quadriceps Strengthening group will perform quadriceps strengthening exercises in both open and closed kinetic chains to the maximum tolerated by the patient based on their symptoms. The patient-guided maximum range of motion will be adjusted based on pain intensity, comfort, and patient response, following a shared decision-making approach with a clinician. The goal will be to maintain exercises at the greatest possible range of motion.
62590346|NCT00857168|ACTIVE_COMPARATOR|Group 1|
62590347|NCT00857168|ACTIVE_COMPARATOR|Group 2|
62590348|NCT00857168|ACTIVE_COMPARATOR|Group 3|
62590349|NCT00857168|ACTIVE_COMPARATOR|Group 4|
62802639|NCT00961155|ACTIVE_COMPARATOR|montelukast sodium|children will receive 5 or 10 mg montelukast sodium for 3 months
62802640|NCT00961155|PLACEBO_COMPARATOR|placebo|children will receive placebo for 8 weeks out of allergy season to house dust mite
62590350|NCT00857168|ACTIVE_COMPARATOR|Group 5|
62590351|NCT00857168|ACTIVE_COMPARATOR|Group 6|
62802641|NCT00961155|ACTIVE_COMPARATOR|formoterol|children will receive formoterol aerolzol 12mcg twice daily for 3 months
62802642|NCT04582786|ACTIVE_COMPARATOR|Standard group|Standard treatment (morphine) administered according to usual practice
62420024|NCT06573697|EXPERIMENTAL|discontinuous wave group|In each treatment session, the patientss will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 40Hz discontinuous wave will be used for 20 min.
62802643|NCT04582786|EXPERIMENTAL|Test group: Infusion with bolus|STR-324 or morphine HCl infusion started with a initial bolus
62802644|NCT04582786|EXPERIMENTAL|Test group: Infusion without bolus|STR-324 or morphine HCl infusion started without a initial bolus
62802645|NCT03857100|ACTIVE_COMPARATOR|Intervention|Receives letter and report
62802646|NCT03857100|NO_INTERVENTION|Control|Does not receive letter and report
62802647|NCT02185703|EXPERIMENTAL|Chordate System S020 in treatment mode|
62802648|NCT02185703|SHAM_COMPARATOR|Chordate System S020 in placebo mode|
62802649|NCT02859714||colorectal adenoma|
62802650|NCT04437901||COVID-19 patients|Patients admitted at one of the participating centres with highly suspected/confirmed infection with SARS-CoV-2.
62802651|NCT00205335|OTHER|glucose monitoring|Each participant received a Bayer Breeze Monitor and glucose test strips for monitoring blood sugar.
62227175|NCT01839487|ACTIVE_COMPARATOR|Phase 2: Stage 1 - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m\^2 NAB and 1000 mg/m\^2 GEM as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion.
62243070|NCT04219696|EXPERIMENTAL|3 sessions|Participants will complete three 45-minute sessions of reactive balance training. Participants will experience 40-60 perturbations during each session. Participants will also complete 3 45-minute 'traditional' balance training sessions.
62243071|NCT04219696|EXPERIMENTAL|6 sessions|Participants will complete six 45-minute sessions of reactive balance training. Participants will experience 40-60 perturbations during each session.
62243072|NCT05717478|EXPERIMENTAL|Experimental|Socket preservation after extraction with Proteo-Graft (Noricum S.L.) with a particle size of 0.25-1.00 mm, without using a barrier membrane.
62420025|NCT06573697|EXPERIMENTAL|dilatational wave group|In each treatment session, the patientss will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2/100Hz dilatational wave will be used for 20 min.
62802652|NCT02186613|EXPERIMENTAL|Experimental|These mothers and their babies will receive Primary Care standard care (office visits at 1, 2, 4 and 6 months) plus the telephone support
62802653|NCT02186613|NO_INTERVENTION|No intervention|Standard care (office visits at 1, 2, 4 and 6 months)
62802654|NCT00732212|EXPERIMENTAL|Doppler endoscopic probe hemostasis|In addition to stigmata of hemorrhage and visual cues, Doppler endoscopic probe will be used for detection of blood flow before and after standard endoscopic hemostasis. If residual blood flow in the lesion is found after standard treatment, further endoscopic treatment will be applied as deemed safe by the investigator-endoscopist.
62802655|NCT00732212|ACTIVE_COMPARATOR|Standard Endoscopic Hemostasis|Standard, visually guided endoscopic hemostasis based on visual cues of stigmata of hemorrhage and endoscopic control of bleeding or treatment of the stigmata according to current guidelines
62802656|NCT00358397|EXPERIMENTAL|Treatment arm|
62802657|NCT01253642|EXPERIMENTAL|Treatment (antiangiogenesis, chemosensitizer, chemotherapy)|Patients receive phenelzine sulfate PO QD on days -7 to -4, and then BID on days -3 to 21. Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for at least 12 weeks in the absence of disease progression or unacceptable toxicity.
62802658|NCT00644696|EXPERIMENTAL|Irinotecan and Bortezomib|Irinotecan and Bortezomib will both be administered
62420026|NCT06701955|OTHER|sequence of intervention|self administered questionnaires at different time points..
62802659|NCT03244917|EXPERIMENTAL|TRAIN-AD|The study intervention is a multi-component training and education program targeting direct care providers and healthcare proxies for advanced dementia NH residents, intended to improve the management of urinary and lower respiratory tract infections in advanced dementia patients. There are two components to this practice intervention: 1. Provider Training, and 2. Proxy Education.
62802660|NCT03244917|NO_INTERVENTION|CONTROL|Facility randomized to the control arm will employ usual care for the management for suspected infections in advanced dementia,
62802661|NCT03195283||Traditional meal service|TMS consists of three meals served by nutritional assistants throughout the day. Preference for dinner can be indicated in the morning by the individual patient from a menu list with predefined choices for meat, potatoes/rice/pasta and vegetables with various portion sizes.
62028238|NCT03483636|EXPERIMENTAL|Alcohol|Participants will be randomized to receive a 10 mg lemborexant-matched placebo tablet administered with 50 mL water followed by alcohol (0.6 g/kg of alcohol for females or 0.7 g/kg of alcohol for males) for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
62028239|NCT03483636|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive a 10 mg lemborexant-matched placebo tablet administered with 50 mL water followed by alcohol for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
62028240|NCT06583096|OTHER|Assessment Only|Weekly surveys only.
62590352|NCT06038344|EXPERIMENTAL|Standard of Care + Gluten-free food guide teaching|45-minute dietary counselling session using the novel gluten-free food guide conducted by a researcher over Zoom. This occurs after standard of care dietary education by an RD. The gluten free teaching session in the study protocol focuses on the GF plate model, the rationale for the GF plate model, and addressing the individual participants dietary needs based on a dietary intake assessment by a trained investigator using specific educational materials that are present in the guide.
62802662|NCT03195283||FoodforCare|FfC consists of a 6-meals per day service. At bedside, patients are offered one or more small protein-rich dishes from a choice of 3. Nutritional assistants play a key role in recommending and delivering these protein-rich meals and assist patient in choosing the most optimal dish, based on the patient's nutrition order in the electronic patient record.
62028241|NCT06583096|EXPERIMENTAL|Intervention - surveys, text messages, and feedback reports|"Participants in the intervention arm will be randomized to receive (or not receive) text messages in a given week, with a daily randomization to receive (or not receive) a text message if randomized to receive text messages that week.~Additionally, participants will be randomized each week to receive (or not receive) personalized feedback reports."
62028242|NCT04626791|EXPERIMENTAL|Treatment (modified VR-CAP, acalabrutinib)|"CYCLES 1, 3, AND 5: Patients receive acalabrutinib PO BID on days 1-21. Patients also receive bortezomib SC on days 1, 8, and 15, rituximab (or rituximab and hyaluronidase human) IV, cyclophosphamide IV, and doxorubicin hydrochloride IV on day 1, and prednisone PO on days 1-5.~CYCLES 2, 4, AND 6: Patients receive acalabrutinib PO BID on days 1-21. Patients also receive rituximab (or rituximab and hyaluronidase human) IV on day 1 and cytarabine IV on days 1-2.~Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
62028243|NCT05043649|EXPERIMENTAL|Camsirubicin + pegfilgrastim|Camsirubicin phase 1b dose escalating to determine MTD
62028244|NCT03136614|ACTIVE_COMPARATOR|Preoperative|A single measurement with an Arteriograph is performed a day before an elective surgical intervention.
62028245|NCT03136614|ACTIVE_COMPARATOR|Intraoperative|An arteriograph is put on the patient for the time of operation. The device is set to measure in every 5 minutes.
62028246|NCT03136614|ACTIVE_COMPARATOR|Intensive Care Unit|Three separate measurements are performed on the subject with an Arteriograph throughout every dayshift for 3 days.
62028247|NCT03808506||Ulcerative colitis patients|Patients with documented ulcerative colitis who are initiating adalimumab therapy will have baseline bowel ultrasound and fecal calprotectin completed.
62028248|NCT06374602|EXPERIMENTAL|Intervention group|Treatment-naive patients with BRAF-negative anaplastic thyroid cancer and previously treated patients, including patients with BRAF-positive anaplastic thyroid cancer (resistant to anti-BRAF therapy).
62028249|NCT02585895|EXPERIMENTAL|Evolocumab|Participants received 140 mg evolocumab every 2 weeks (Q2W) administered by subcutaneous injection for 6 weeks during the primary period of the study. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
62028250|NCT02585895|ACTIVE_COMPARATOR|Low Density Lipoprotein Cholesterol (LDL-C) Apheresis|Participants continued apheresis at the same schedule, every week (QW) or every two weeks (Q2W), as prior to study entry, for the first 6 weeks. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
62028251|NCT02873611|EXPERIMENTAL|MRI scanning and the genicular ablation|patients undergoing both MRI scanning and the genicular ablation procedure. additional MRI testing of apprx. 0.5-1 hour
62028252|NCT01178151|EXPERIMENTAL|afinitor|10mg afinitor daily orally
62243073|NCT05717478|ACTIVE_COMPARATOR|Control|Conventional treatment (socket preservation therapy). Post-extraction socket preservation with Bio-Oss® (Geistlich Pharma AG, Switzerland) with a particle size of 0.25-1.00 mm, hereinafter BO, and protection with a barrier membrane, Bio-Gide® ( Geistlich Pharma AG, Switzerland).
62590353|NCT06038344|NO_INTERVENTION|Standard of Care|45-minute group session on the gluten-free diet conducted by registered dietitians over Zoom. The registered dietitian's dietary education included a virtual group class focusing on gluten literacy, meal planning, food label reading and dietary intake based on Canada's Food Guide to Healthy Eating (2019).
62590354|NCT03104049|ACTIVE_COMPARATOR|the PD NMT Group|the NMT Group were treated with NMT
62590355|NCT03104049|NO_INTERVENTION|The PD Group without NMT|The patients received only their usual pharmacological PD therapy
62227176|NCT01839487|EXPERIMENTAL|Phase 2: Stage 2 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 mcg/kg PEGPH20 with 125 mg/m\^2 NAB and 1000 mg/m\^2 GEM as an IV infusion. In Cycle 1 Week 1, PEGPH20 will be given alone on Days 1 and 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15, and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and 15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1, 8, and 15. NAB+GEM will be given 2 to 4 hours after dose of PEGPH20. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to beginning and 8 to 12 hours after completion of each PEGPH20 infusion. Enoxaparin 40 mg/day or 1 mg/kg/day will be given subcutaneously (SC).
62227177|NCT01839487|ACTIVE_COMPARATOR|Phase 2: Stage 2 - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m\^2 NAB and 1000 mg/m\^2 GEM as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion. Enoxaparin 40 mg/day or 1 mg/kg/day will be given SC.
62243074|NCT00616434|EXPERIMENTAL|Interferon beta-1a|Interferon beta-1a 30 µg intramuscular (IM) injection twice weekly for 12 weeks
62420027|NCT05153590||Reimbursed|The reimbursed cohort includes only patients who received Saxenda® through mandatory basic insurance
62420028|NCT05153590||Non reimbursed|The non reimbursed cohort includes patients who received Saxenda® through additional private insurance or self-pay
62420029|NCT02812368|EXPERIMENTAL|Clonidine|Taken once a day at bedtime; with the dose titrated from 0.05mg to 0.20mg over the course of 6 weeks
62028253|NCT05260710|EXPERIMENTAL|Telemedicine intervention|Tele-critical care + continuing education activities
62028254|NCT05260710|NO_INTERVENTION|Usual Care|Usual Care
62028255|NCT04818346|EXPERIMENTAL|INCB054707 Dose A followed by Dose C|Participants will receive INCB054707 Dose A for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).
62028256|NCT04818346|EXPERIMENTAL|INCB054707 Dose B|Participants will receive INCB054707 Dose B for 52 weeks (Period 1 + Period 2).
62028257|NCT04818346|EXPERIMENTAL|INCB054707 Dose C|Participants will receive INCB054707 Dose C for 52 weeks (Period 1 + Period 2).
62028258|NCT04818346|PLACEBO_COMPARATOR|Placebo followed by INCB054707 Dose C|Participants will receive placebo for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).
62028259|NCT01432366||Rheumatoid arthritis patients treated with SC anti-TNF|
62028260|NCT05067491|EXPERIMENTAL|Intervention|The experimental group will go through an exposure therapy session using an augmented reality headset device. The participant will work with the therapist, who will control the augmented reality paradigm and cater the exposure to the needs of the participant. The duration of the exposure will be as long as is needed to reduce anxiety regarding the feared object until self-reported subjective distress is low and stable.
62420030|NCT02812368|PLACEBO_COMPARATOR|Placebo (for clonidine)|Taken once a day at bedtime
62420031|NCT06025500||EBV-patients|Patients who are scheduled for a bronchoscopic lung volume reduction treatment using endobronchial valves.
62420032|NCT04331418|NO_INTERVENTION|control group|"On arrival to operating room, Noninvasive monitors, such as electrocardiography, noninvasive blood pressure (NIBP), oxygen saturation (SpO2), will be attached and baseline parameters such as heart rate, mean arterial pressure, and peripheral oxygen saturation will be recorded .~General anesthesia will be induced with O2/sevo (FiO2 = 1 /sevoflurane 8% MAC), cis-atracurium 0.1 mg/kg iv, +/- fentanyl 1 mcg/kg iv. Trachea will be intubated with an appropriate sized, endotracheal tube and maintenance of anesthesia by O2/Air (FiO2 = 0.4), sevoflurane 2% MAC.~Dexamethasone 0.15 mg/kg iv will be given as PONV prophylaxis. Increments of fentanyl 0.5 mcg/kg iv and cis-atracurium 0.03 mg/kg iv will be given according to hemodynamics and capnography."
62802663|NCT04183114|EXPERIMENTAL|IP batch MRUK-0317|135 Subjects received Bio Farma's vaccine batch MRUK 0317
62802664|NCT04183114|EXPERIMENTAL|IP Batch MRUK-0417|135 Subjects received Bio Farma's vaccine batch MRUK 0417
62802665|NCT04183114|EXPERIMENTAL|IP Batch 550118|135 Subjects received Bio Farma's vaccine batch MRUK 0417
62028261|NCT05067491|NO_INTERVENTION|Non-intervention|The control group will not go through an exposure therapy session using an augmented reality headset device. This will be a no-intervention control group that can have some form of exposure therapy following the conclusion of the treatment/research period.
62028262|NCT03389802|EXPERIMENTAL|Stratum 1|The recurrent, progressive, or refractory primary malignant non-brainstem CNS tumor patients will be treated with APX005M.
62028263|NCT03389802|EXPERIMENTAL|Stratum 2|The newly diagnosed diffuse intrinsic pontine gliomas (DIPGs) patients will be treated with APX005M.
62028264|NCT01495767||females, males|females: patients of female sex males: patients of male sex
62028265|NCT02129738|EXPERIMENTAL|LoFric|LoFric catheters
62028266|NCT04323436|EXPERIMENTAL|Run-in part|capmatinib in combination with spartalizumab
62028267|NCT04323436|EXPERIMENTAL|Randomized part - Arm 1 spartalizumab|capmatinib in combination with spartalizumab
62028268|NCT04323436|EXPERIMENTAL|Randomized part - Arm 2 placebo|capmatinib in combination with placebo
62028269|NCT06465147|EXPERIMENTAL|SCRI-CAR19v3|Single infusion of SCRI-CAR19v3
62802666|NCT04183114|ACTIVE_COMPARATOR|Control|135 Subjects received SII's MR vaccine batch 012W72230Z
62802667|NCT04406896|EXPERIMENTAL|Participants with mild hepatic impairment (Group 1)|Participant with Child-Pugh Grade A Score of 5-6.
62802668|NCT04406896|EXPERIMENTAL|Participants with moderate hepatic impairment (Group 2)|Participant with moderate hepatic impairment with a Child-Pugh Grade B Score of 7-9.
62590356|NCT01140256||SGA infants|SGA infants were recruited at birth and zinc stable isotope was administered at birth and at 6 months of age .This was a longitudinal study whereby the growth trajectory and zinc pools were measured.
62590357|NCT01140256||AGA|AGA infants were recruited at birth and zinc stable isotope was administered at birth and at 6 months of age .This was a longitudinal study whereby the growth trajectory and zinc pools were measured.
62590358|NCT01140256||SGA infant|Infants who were born small for gestational age were recruited and zinc stable isotopes were administered at birth and at 6 months.
62590359|NCT02408289|PLACEBO_COMPARATOR|Lo-Flav|Low-flavonoid cocoa powder with 0 mg of procyanidins and 0 mg epicatechin per kg of body weight will be consumed as a beverage
62420033|NCT04331418|EXPERIMENTAL|caudal group|After negative aspiration of blood or cerebrospinal fluid, 2 mg/ kg of bupivacaine at concentration of 0.5% (volume 0.5ml/kg) was given as per the group assigned, then the site of injection was dressed, and the patient was turned supine.
62420034|NCT04331418|EXPERIMENTAL|dexmetomidine group|Children in this group will be received (1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr) with a suggested maximum dose of 2 mcg/kg.of dexmedetomidine is available in a 100 mcg/mL concentration in a 2 mL preservative-free vial. It may be prepared as a 2 to 4 mcg/mL solution using normal saline
62420035|NCT03890861|EXPERIMENTAL|Physical activity intervention|The intervention group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations. Participants will engage in 2 days per week of supervised activity at community facilities. These participants will be requested to engage in an additional 30 minutes of moderate to vigorous aerobic physical activity two days per week at home.
62420036|NCT03890861|ACTIVE_COMPARATOR|Active control|The active control group will be based on a low-intensity activity program and a healthy aging educational component. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avoiding scams, fall prevention, living wills, and dementia awareness.
62420037|NCT03735095|EXPERIMENTAL|Treatment (porfimer sodium, EBUS, and photodynamic therapy)|Patients receive porfimer sodium IV over 20 minutes 2-4 hours prior to the delivery of I-PDT. Patients then undergo EBUS-TBN guided I-PDT over 30-45 minutes.
62590360|NCT02408289|ACTIVE_COMPARATOR|Hi-Flav|Cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.
62590361|NCT02408289|ACTIVE_COMPARATOR|Epicatechin|Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage.
62802669|NCT04406896|EXPERIMENTAL|Healthy participants (Group 3)|
62802670|NCT05062005|OTHER|Induction Chemotherapy+Chemoradiotherapy|
62802671|NCT05062005|OTHER|Chemoradiotherapy|
62802672|NCT05084313|EXPERIMENTAL|Manual therapy group|This group of patients will receive manual therapy techniques to harmonize vegetative nervous system. PPG and GSR will be recorded during the intervention. The techniques consist of CV-4 technique, suboccipital decompression, lumbo-sacral decompression, release of the transverse diaphragms, frontal lift technique, parietal lift technique, temporal techniques, temporo-mandibular joint myofascial release, deep cervical fasciae technique as described in Upledger's protocol. In addition to the protocol; rib raising technique, larynx and sternocleidomastoid muscle fascial release and occipito-mastoid suture release will be applied. All intervention is planned to take approximately 20 minutes. The group will include 40 healthy individuals.
62420038|NCT06144827|ACTIVE_COMPARATOR|Multiparametric MRI scan group|Multiparametric MRI scans will be used to evaluate baseline degree of liver fibroinflammation and function as well as temporal changes in liver fibroinflammation and function using MRI-based LiverMultiScan software.
62590362|NCT02408289|ACTIVE_COMPARATOR|Procyanidins|Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.
62590363|NCT05830734|EXPERIMENTAL|BCL surgery with fatty cell injection arm|Patients will undergo BCL surgery and additionally have to small incisions made in the lumbar region from which 80 ml of fatty cells are harvested. After harvest local anesthetics are injected bilaterally and a compression bandage applied. The fatty cells are injected into the surgical wound before closure. All wounds are lateralized and close with a suction drain removed after 3 days
62590364|NCT05830734|SHAM_COMPARATOR|BCL surgery alone arm|Patients will undergo BCL surgery. Additionally two small incisions are made in the lumbar region, local anesthetics are injected bilaterally and a compression bandage applied. All wounds are lateralized and close with a suction drain removed after 3 days
62590365|NCT01337466|EXPERIMENTAL|[124I]FIAU|single dose study of \[124I\]FIAU in healthy volunteers or subjects with prosthetic joint infection who will undergo PET-CT scanning
62590366|NCT06668233||children from 3 years to 18 years with congenital heart disease|
62802673|NCT05084313|ACTIVE_COMPARATOR|Deep-slow breathing group|Patients in this group will do deep-slow paced breathing exercise. The patients will be able to cease the session in case of feeling uncomfortable. The main purpose will be that the individuals should breathe six breaths per minute to increase respiratory sinus arrhythmia which is also reflected at PPG waveforms and in reduction in GSR. The group will include forty healthy individuals.
62802674|NCT05084313|OTHER|Control|Control group patients will be attached to the sensors, and they will rest in a quiet and controlled indoor environment without any intervention. The aim of including this group is to to understand whether the parasympathetic effects expected in the manual therapy group were due to the intervention. The group will include forty healthy individuals.
62227178|NCT06065969|ACTIVE_COMPARATOR|Local photobiomodulation|Delivering an energy of 6J per point (60 seconds) at 2 points in the masseter muscle region, 1 point in the temporal muscle, and 1 point in the trapezius muscle in the cervical region. The total application will take 4 minutes per session
62227179|NCT06065969|EXPERIMENTAL|Vascular photobiomodulation|660 nm and 100 mW, directing the light beam towards the radial artery region, for 10 minutes per session. The participant will be seated in a comfortable chair with side support for resting their arms during the application
62420039|NCT06144827|EXPERIMENTAL|Multiparametric MRI scans + HepQuantShunt Test group|Eligible patients can have previously undergone any modality and number of prior treatments for their hepatic malignancies, must be considered for either liver photon or proton radiation in the de-novo or re-irradiation setting and can be simultaneously enrolled on parallel trials.
62420040|NCT03944538|EXPERIMENTAL|Lifestyle Physical Activity|"The primary content of the website will be delivered through interactive video courses. The courses will be released seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention.~The website Tracker feature will allow for tracking of daily step counts as well as setting goals and monitoring progress.~The one-on-one video chats will be conducted face to face through Zoom and will be semi-scripted. The chats will consist of an ongoing review of goal-setting and progress toward goal attainment through Tracker as well as discussion of strategies and facilitators of behavioral changes based on social cognitive theory and current website content. The chats will occur at the same frequency as the video course release. For the second 6 months of the study, participants will be asked to maintain their usual activities."
62590367|NCT01300416||With Gastro-Intestinal (GI) symptoms|
62590368|NCT01300416||Without GI symptoms|
62590369|NCT04695574|EXPERIMENTAL|Volunteer young adults|Healthy young adults
62802675|NCT05380063|ACTIVE_COMPARATOR|Dual Antiplatelet Therapy (DAPT)|DAPT with ticagrelor (90mg twice daily) + aspirin (100 mg once daily) for 1 year after CABG.
62802676|NCT05380063|EXPERIMENTAL|De-escalated Dual Antiplatelet Therapy (De-DAPT)|De-DAPT referred to ticagrelor (90mg twice daily) + aspirin (100 mg once daily) during first 3 months post CABG, then switch to aspirin (100 mg once daily) + placebo (twice daily) for 9 months.
62227180|NCT06065969|SHAM_COMPARATOR|sham local photobiomodulation|The same procedures described for local photobiomodulation will be followed; however, the equipment will emit only the sound signal, exactly like the equipment used in local photobiomodulation group, without emitting laser light.
62802677|NCT02356445||Cytotoxic drug|Patients treated for sarcoidosis
62802678|NCT02354534|EXPERIMENTAL|50 mg Artesunate suppositories, 1 cycle|Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
62802679|NCT02354534|EXPERIMENTAL|200 mg Artesunate suppositories, 1 cycle|Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
62227181|NCT06065969|SHAM_COMPARATOR|Sham Vascular photobiomodulation|The same procedures described for vascular photobiomodulation will be followed; however, the equipment will emit only the sound signal, exactly like the equipment used in vascular photobiomodulation group, without emitting laser light
62227182|NCT03453320|EXPERIMENTAL|Rapid - Slow|"Two infusions of 3 ml/kg bodyweight of hyperoncotic albumin 20%, with an interval of 3 to 20 weeks between.~First time rapid (30 minutes), second time slow (120 minutes). Albumin solution"
62243075|NCT00616434|PLACEBO_COMPARATOR|Placebo|Placebo IM injection twice weekly for 12 weeks
62243076|NCT02616445|PLACEBO_COMPARATOR|MAD Study|
62420041|NCT03944538|ACTIVE_COMPARATOR|General Wellness|The general wellness condition will focus on self-managing MS through means other than physical activity. The materials are transformations of brochures provided by the National Multiple Sclerosis Society. The delivery of the Internet materials and chat sessions will occur on the same schedule and frequency as the intervention condition, and will have a comparable time commitment. This condition will account for attention and social contact as well as other possible biases such as initial reactivity and time spent on the website and video chats. For the second 6 months of the study, participants will be asked to maintain their usual activities.
62802680|NCT02354534|EXPERIMENTAL|200 mg Artesunate suppositories,2 cycles|Subjects enrolled in this cohort will receive 2 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
62802681|NCT02354534|EXPERIMENTAL|200 mg Artesunate suppositories,3 cycles|Subjects enrolled in this cohort will receive 3 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
62802682|NCT01788917|EXPERIMENTAL|Vegetarians|Dietary supplement: 10 mL linseed oil per day
62802683|NCT01788917|PLACEBO_COMPARATOR|Omnivores|Dietary supplement: 10 mL linseed oil per day
62802684|NCT02179411|ACTIVE_COMPARATOR|healthy volunteers|healthy volunteers
62028270|NCT06040866|EXPERIMENTAL|Pain neuroscience education|In addition to the exercise training (stretching and relaxation exercises), which includes stretching and relaxation exercises routinely used in the field of physiotherapy and rehabilitation in primary dysmenorrhea, the patients in the pain neuroscience education arm will be given pain neuroscience education once a week for 2 weeks. Participants in the pain neuroscience education arm will be given pain neuroscience education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
62028271|NCT06040866|ACTIVE_COMPARATOR|Biomedical pain education|In the biomedical pain education arm, in addition to the exercise training (stretching and relaxation exercises) that includes stretching and relaxation exercises routinely applied in the field of physiotherapy and rehabilitation in primary dysmenorrhea, biomedical pain education will be given once a week for 2 weeks. Participants in the biomedical pain education arm will be given biomedical pain education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
62028272|NCT02977624|EXPERIMENTAL|Tele-CO-OP|The intervention included weekly videoconferencing sessions using the Cognitive Orientation to Daily Occupational Performance approach (tele-CO-OP) over a period of three months. Participant identified five functional goals, of which three were directly addressed.
62028273|NCT02977624|NO_INTERVENTION|Waitlist control|The waitlist control group did not receive the intervention during the same time period
62802685|NCT02179411|ACTIVE_COMPARATOR|renal transplant recipients|renal transplant recipients
62802686|NCT02179411|ACTIVE_COMPARATOR|renal transplant recipients grave|renal transplant recipients grave
62028274|NCT02243033||Visualase|MR-guided laser focal therapy
62028275|NCT04558710||CGM|CGM users
62028276|NCT04558710||SMBG|Non-CGM users
62028277|NCT06543979|OTHER|single arm as all participant will receive the treatment|all participant will receive lubiprostone
62802687|NCT03726957|EXPERIMENTAL|Intervention group|The intervention arm included households which received improved cookstoves
62802688|NCT03726957|NO_INTERVENTION|Control group|The control group included households, which did not receive improved cookstoves, and cooked in their usual traditional cookstoves.
62802689|NCT03393234|EXPERIMENTAL|A group|Patients who receive interphincteric resection (ISR) in this group will be given extra intraoperative radiation by INTRBEAM using low energy X-ray.
62802690|NCT03393234|NO_INTERVENTION|B group|Patients who only receive interphincteric resection (ISR) in this group without intraoperative radiation.
62802691|NCT03522792|EXPERIMENTAL|Saline + ad libitum meal|This will serve as the placebo / control day for the NT + ad libitum meal study day.
62802692|NCT03522792|EXPERIMENTAL|NT + ad libitum meal|Neurotensin (NT) infusion followed by an ad libitum meal to study the effect of NT on ad libitum food intake.
62227183|NCT03453320|EXPERIMENTAL|Slow - Rapid|"Two infusions of 3 ml/kg bodyweight of hyperoncotic albumin 20%, with an interval of 3 to 20 weeks between.~First time rapid (120 minutes), second time slow (30 minutes). Albumin solution"
62028278|NCT03916003|EXPERIMENTAL|PQ7|high dose primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)
62028279|NCT03916003|NO_INTERVENTION|standard care|As per national guidelines for P. falciparum treatment
62028280|NCT01823848|ACTIVE_COMPARATOR|Sodium phosphate enema|Administration of sodium phosphate (fleets) enema for functional constipation in children ages 4-12 years Age 4-5: 33ml per rectum Age 5-12: 66ml per rectum
62802693|NCT03522792|EXPERIMENTAL|Saline + liquid meal + ad libitum meal|Saline infusion followed a standardized liquid mixed meal followed by an ad libitum meal. This will serve as the placebo / control day for the NT + standardized liquid mixed meal + ad libitum meal study day. Investigating the effect of NT on the second meal effect.
62028281|NCT01823848|ACTIVE_COMPARATOR|Normal saline enema|Administration of normal saline enema for functional constipation in children ages 4-12 years Admininstered as 10ml/kg with maximum of 700ml
62028282|NCT01823848|EXPERIMENTAL|Mineral oil enema|Administration of mineral oil enema for functional constipation in children ages 4-12 years Administered as 66ml per rectum
62028283|NCT03290144||with diabetes|
62028284|NCT03290144||without diabetes|
62028285|NCT04331600|EXPERIMENTAL|CHLOROQUINE|Standard of care + chloroquine phosphate + telemedical approach.
62420042|NCT05809986||Cohort 1: Early treatment arm|All patients who initiated Ofatumumab within 3 years after MS diagnosis (can be treatment-naive or switch).
62028286|NCT04331600|OTHER|CONTROL GROUP|Standard of care + telemedical approach.
62227184|NCT02070887||Entacapone|
62227185|NCT02070887||No Entacapone|
62802694|NCT03522792|EXPERIMENTAL|NT + liquid meal + ad libitum meal|NT infusion followed a standardized liquid mixed meal followed by an ad libitum meal. This study day aims to study the effect of NT on the second meal effect.
62802695|NCT03522792|EXPERIMENTAL|Neurotensin|Acclimatization day
62802696|NCT01623479||Hypotrichosis of the Eyelashes|Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
62802697|NCT00430716|EXPERIMENTAL|Sildenafil High dose|
62028287|NCT03972488|EXPERIMENTAL|Lutathera® plus Octreotide LAR 30 mg (Investigational arm)|Lutathera treatment consisted of a cumulative administered radioactivity of 29.6 GBq (800mCi) (7.4 GBq/200 mCi x 4 administrations every 8 +/- 1 week). Participants in the Lutathera arm were concomitantly administered with octreotide LAR 30 mg (Sandostatin LAR Depot) the day after each administration of Lutathera and no earlier than 4 hours after completion of the Lutathera infusion. Once Lutathera treatment completed, participants continued the 4-week interval administrations of 30 mg octreotide LAR until the completion of the Treatment Phase. Concomitantly with Lutathera, sterile amino acid solution was administered to minimize renal radiation exposure during Lutathera treatment.
62028288|NCT03972488|ACTIVE_COMPARATOR|Octreotide LAR 60 mg (Control arm)|Participants were administered with octreotide LAR 60 mg (Sandostatin LAR Depot) at 4-week intervals until the completion of the Treatment Phase.
62028289|NCT03972488|EXPERIMENTAL|Optional post-progression re-treatment with Lutathera|Participants who received Lutathera in experimental arm and who progressed and met re-treatment eligibility criteria received additional 2 - 4 cycles of Lutathera (7.4 GBq/200 mCi x 4 cycles)
62028290|NCT03972488|ACTIVE_COMPARATOR|Optional post-progression cross-over to Lutathera|Participants who received Octreotide LAR in Active comparator arm and who progressed and met cross-over eligibility criteria received maximum 4 cycles of Lutaathera (7.4 GBq/200 mCi x 4 cycles) plus octreotide long-acting (30 mg every 8 weeks).
62227186|NCT06015178|EXPERIMENTAL|Intelligent Language Model Group|Subjects must use the intelligent language model to complete the retrieval and protocol design execution of an interdisciplinary task, in addition to Google search, literature search and book query.
62802698|NCT00430716|EXPERIMENTAL|Sildenafil Low dose|
62802699|NCT00430716|EXPERIMENTAL|Sildenafil medium dose|
62227187|NCT06015178|PLACEBO_COMPARATOR|Control Group|Subjects can only use Google search, literature retrieval and book query, and cannot use any AI-driven conversational natural language processing tools to complete the retrieval and protocol design execution of an interdisciplinary task.
62802700|NCT00430716|EXPERIMENTAL|Sildenafil - Open label Phase|Open label extension from week 12 to week 24.
62802701|NCT02637583|ACTIVE_COMPARATOR|Sequential vaccination PCV13 and PPV23|PCV13 0.5 ml intramuscular injection once on day 0 PPV23 0.5 ml intramuscular injection once 6 months later
62802702|NCT02637583|EXPERIMENTAL|Simultaneous vaccination PCV13 and PPV23|PCV13 0.5ml intramuscular injection once on day 0 followed by PPV23 0.5ml intramuscular injection on day 0
62802703|NCT02637583|ACTIVE_COMPARATOR|Single vaccinationPPV23|PPV23 0.5ml intramuscular injection on day 0
62028291|NCT03972488|ACTIVE_COMPARATOR|Optional post-progression re-treatment with Lutathera after cross-over|Participants who received Octreotide LAR in Active comparator arm subsequently entered cross-over, received Lutathera in cross-over, progressed for the second time and met re-treatment eligibility criteria could receive additional 2 - 4 cycles of Lutathera (7.4 GBq/200 mCi x 4 cycles).
62227188|NCT01319188|ACTIVE_COMPARATOR|0.5 mg of ranibizumab|
62227189|NCT01319188|ACTIVE_COMPARATOR|injection + photodynamic therapy|
62227190|NCT01319188|SHAM_COMPARATOR|Sham injection|
62227191|NCT01135407||group #1|Parkinson's disease patients at a disease's stage characterized by motor complications
62227192|NCT01135407||group #2|Parkinson's disease patients treated by subthalamic nucleus deep brain stimulation.
62420043|NCT05809986||Cohort 2: Late treatment arm|All patients who initiated Ofatumumab with more than 3 years of MS diagnosis.
62420044|NCT05385744|EXPERIMENTAL|BCD-132|IV infusion every 24 weeks in combination with daily placebo tablets. The total duration of the blinded therapy is 100 weeks (a total of 5 treatment cycles with BCD-132 in combination with the daily placebo tablets)
62590370|NCT00537316|EXPERIMENTAL|Infliximab (IFX)|Part 1: IFX 5 mg/kg of body weight intravenous (IV) infusions was to be administered at Weeks 0, 2, and 6 and placebo to AZA was to be taken orally every day for 16 weeks. Responders to IFX at Week 8, were to receive one more IFX infusion at Week 14; non-responders to IFX were to receive placebo IFX infusions at Weeks 8 and 10 and an additional IFX infusion at Week 14. Part 2: Participants in steroid-free remission at Week 16 of Part 1 were to be randomized to either maintenance (every 8 weeks \[q8w\]) or intermittent (upon relapse) open-label IFX (last IFX infusion administered at Week 86) plus double-blind oral AZA/placebo treatment as allocated in Part 1 (last dose at the final visit, Week 94). Responders at Week 16 who had not achieved steroid-free remission were to continue to receive IFX infusions every 8 weeks.
62802704|NCT03187132|EXPERIMENTAL|Digital Pain Reduction Kit|Participants in the experimental arm will be assigned the digital pain reduction kit consisting of a transcutaneous electrical nerve stimulation unit to be used as needed and a virtual reality headset to be used as needed or at least once a day. Remote clinical support is provided for patients who volunteer information to be viewed by clinicians.
62802705|NCT03187132|ACTIVE_COMPARATOR|Active Control|Participants in the active control arm will receive standard of care as provided by their physician in addition to a transcutaneous electrical nerve stimulation unit.
62420045|NCT05385744|ACTIVE_COMPARATOR|Teriflunomide, 14 mg orally|Teriflunomide, 14 mg orally daily, in combination with intravenous placebo infusions. The total duration of the blinded therapy is 100 weeks (a total of 5 treatment cycles with intravenous placebo infusions in combination with daily teriflunomide tablets).
62420046|NCT01933139|EXPERIMENTAL|Audio-visual presentation|The intervention group will watch a 10-minute scripted video explaining the procedure, risks, benefits, expectations, and long term complications that relate to hysterectomies before face-to-face interaction with the surgeon. Patients in both arms will then sign the same standard pre-surgical informed consent form before undergoing the procedure.
62028292|NCT04073043|EXPERIMENTAL|Intervention Group|The intervention group will have access to the web-based intervention along with telephone coaching. Participants in the intervention will receive 7 coach calls over a period of 12 weeks.
62028293|NCT04073043|NO_INTERVENTION|Control Group|The control group will have access only to the web-based intervention without telephone support
62227193|NCT01135407||group #3|healthy controls
62028294|NCT05997004|PLACEBO_COMPARATOR|Control|31 participants received 1ml of Normal Saline
62028295|NCT05997004|EXPERIMENTAL|Glyco|31 participants received 1ml (0.2mg) of Glycopyrrolate
62227194|NCT05610293||5mm surgical margin|Patients treated with a 5mm surgical margin for a T1 SCC of the lip.
62227195|NCT05610293||10mm surgical margin|Patients treated with a 10mm surgical margin for a T1 SCC of the lip.
62227196|NCT05685927||Non-obese participants with dysregulated type 1 diabetes|
62227197|NCT05685927||Non-obese participants with dysregulated type 2 diabetes|
62227198|NCT05685927||Obese participants with type 2 diabetes|
62227199|NCT05685927||Obese participants without type 2 diabetes|
62227200|NCT05685927||Healthy control participants|
62227201|NCT04175626||Orsiro sirolimus coronary stent system|Intervention with a Orsiro DES.
62227202|NCT02622815||Healthy blood donors|10,000 highly controlled blood donors in the age range 30-70 years
62227203|NCT02622815||Moli-sani subjects|A sample of 1,000 tumor cases have been identified so far and samples from these participants will be analyzed compared to 1,000 controls from randomly extracted from the Moli-sani cohort (parent cohort).
62227204|NCT02622815||Cancer patients|4,000 Patients with breast, lung, and gastrointestinal tumors.
62420047|NCT01933139|NO_INTERVENTION|Control|standard physician interaction (control arm)
62420048|NCT00423228|EXPERIMENTAL|ZT-1|ZT-1 (investigational product)
62420049|NCT00423228|ACTIVE_COMPARATOR|Donepezil|Donepezil
62420050|NCT02717624|EXPERIMENTAL|Part 1: Acalabrutinib+BR in TN patients|Part 1: Acalabrutinib in combination with drugs bendamustine and rituximab (BR) in treatment naive patients
62420051|NCT02717624|EXPERIMENTAL|Part 1: Acalabrutinib+BR in RR patients|Part 1: Acalabrutinib in combination with bendamustine and rituximab (BR) in relapse refractory patients
62420052|NCT02717624|EXPERIMENTAL|Part 2: Acalabrutinib+VR in TN patients|Part 2: Acalabrutinib in combination with venetoclax and rituximab (VR) in treatment naive patients
62028296|NCT02811029|EXPERIMENTAL|premature infants less than 32 weeks of age|measurement of phonology in premature infants less than 32 weeks of age who participated to LAMOPRESCO-1 study
62420053|NCT03338673|EXPERIMENTAL|Dual Therapy First|Participants receive 10 sessions of non-invasive brain stimulation (tDCS) plus 10 hours of computerized cognitive exercises (BrainHQ), followed by 10 hours of computerized cognitive exercises alone
62420054|NCT03338673|EXPERIMENTAL|Mono Therapy First|Participants complete 10 hours of computerized cognitive exercises (BrainHQ) alone, followed by 10 sessions of non-invasive brain stimulation (tDCS) plus 10 hours of computerized cognitive exercises
62802706|NCT03058692|EXPERIMENTAL|M-001 + IIV4|0.4 ml injection of M-001 (1 mg dose) intramuscularly on Day 1 and Day 22, followed by 0.5 ml injection of IIV4 (60 mcg HA) intramuscularly on Day 172 (n=60)
62028297|NCT06287359||Parents/carers|Parents or carers of children with severe motor disabilities complaining of spinal pain
62028298|NCT00599326|EXPERIMENTAL|A|
62028299|NCT04955639|ACTIVE_COMPARATOR|Control|A commercially available mobile phone app and program
62028300|NCT04955639|ACTIVE_COMPARATOR|Pivot|Pivot mobile phone app and program
62028301|NCT03840460||Pancreatic Cancer|Patients who are investigated for and subsequently diagnosed with early/advanced pancreatic adenocarcinoma or a precursor lesion or a pancreatic neuroendocrine tumour.
62420055|NCT01850108|EXPERIMENTAL|Non-Myeloablative Conditioning and Bone Marrow Transplantation|
62420056|NCT05431348||patients with glioblastoma treated with STUPP schema|
62420057|NCT05526443||Patient with locally advanced inoperable and/or metastatic pancreatic ductal adenocarcinoma|Patient with locally advanced inoperable and/or metastatic pancreatic ductal adenocarcinoma
62802707|NCT03058692|PLACEBO_COMPARATOR|Placebo+ IIV4|0.4 ml injection of placebo intramuscularly on Day 1 and Day 22, followed by 0.5 ml injection of IIV4 (60 mcg HA) intramuscularly on Day 172 (n=60)
62802708|NCT05994508|EXPERIMENTAL|Participants|A single group of participants with Parkinson disease will participate in a 6-week pickleball program with pre-test, post-test, and one month follow-up testing.
62802709|NCT05291793|NO_INTERVENTION|NSAID group|Group 1, patients only received non-steroid anti-inflammatory oral and topical treatment for 3 weeks. (ibuprofen 2x800 mg (1600 mg daily), 1% nimesulide + 5%Lidocain (3 times a day))
62802710|NCT05291793|ACTIVE_COMPARATOR|Tenoxicam|Group 2, patients received intraarticular tenoxicam ( 20 mg) once.
62802711|NCT05291793|ACTIVE_COMPARATOR|Methylprednisolone|Group 3, patients received intraarticular methylprednisolone once(40mg).
62802712|NCT05291793|SHAM_COMPARATOR|Saline|Group 4, patients received an intraarticular sterile saline injection(4ml).
62802713|NCT04811040|EXPERIMENTAL|Primary Cohorts: Lenacapavir (LEN), Teropavimab, Zinlirvimab Dose C|Participants will begin treatment by receiving LEN Dose A + LEN Dose B + teropavimab + zinlirvimab Dose C followed by LEN Dose A on the next day. The last treatment regimen will include LEN Dose B + teropavimab + zinlirvimab Dose C.
62802714|NCT04811040|EXPERIMENTAL|Primary Cohorts: LEN, Teropavimab, Zinlirvimab Dose D|Participants will begin treatment by receiving LEN Dose A + LEN Dose B + teropavimab + zinlirvimab Dose D followed by LEN Dose A on the next day. The last treatment regimen will include LEN Dose B + teropavimab + zinlirvimab Dose D.
62227205|NCT03030170|EXPERIMENTAL|Experimental|Stapling of the pancreas with ENDO GIA Reinforced reload
62420058|NCT06644755|EXPERIMENTAL|Part 1: Dose Escalation DS-2243a|Participants will receive DS-2243a at escalating doses. The recommended dose for expansion (RDE) will be calculated using data collected from this population.
62420059|NCT06644755|EXPERIMENTAL|Part 2: Dose Expansion SS/MRCLS|Participants with synovial sarcoma or myxoid/round cell liposarcoma will receive DS-2243a at the recommended dose for expansion (RDE)
62420060|NCT06644755|EXPERIMENTAL|Part 2: Dose Expansion Sq-NSCLC|Participants with squamous cell carcinoma-non-small cell lung cancer will receive DS-2243a at the recommended dose for expansion (RDE)
62420061|NCT06644755|EXPERIMENTAL|Part 2: Dose Expansion UC|Participants with urothelial carcinoma will receive DS-2243a at the recommended dose for expansion (RDE)
62420062|NCT06644755|EXPERIMENTAL|Part 2: Dose Expansion Ad-NSCLC|Participants with adenocarcinoma-non-small cell lung cancer will receive DS-2243a at the recommended dose for expansion (RDE)
62420063|NCT02625961|EXPERIMENTAL|Pembrolizumab|Participants with carcinoma-in-situ (CIS) with or without papillary tumors (Cohort A) and participants with papillary tumors only, without CIS (Cohort B) will receive pembrolizumab, 200 mg, intravenously, every 3 weeks (Q3W) for up to 24 months.
62420064|NCT02625961|EXPERIMENTAL|Pembrolizumab coformulation|Participants with CIS with or without papillary tumors (Cohort C) will receive either pembrolizumab/vibostolimab or favezelimab/pembrolizumab coformulation intravenously Q3W for up to 24 months
62802715|NCT04811040|EXPERIMENTAL|Optional Cohorts: Lenacapavir (LEN), Teropavimab, Zinlirvimab Dose C|Optional cohort included participants from primary cohort who could not qualify for primary cohort at the study start. Participants in optional cohort will begin treatment by receiving LEN Dose A + LEN Dose B + teropavimab + zinlirvimab Dose C followed by LEN Dose A on the next day. The last treatment regimen will include LEN Dose B + teropavimab + zinlirvimab Dose C.
62028302|NCT00320658|EXPERIMENTAL|A|3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm B.
62227206|NCT03030170|ACTIVE_COMPARATOR|Control|Stapling of the pancreas with ENDO GIA X-tra Thick reload
62227207|NCT04421833|ACTIVE_COMPARATOR|group starting with TOVERTAFEL activities|Participants will benefit from TOVERTAFEL activities for 6 weeks then the usual animation techniques for 6 weeks with a week of wash-out between the two periods.
62227208|NCT04421833|SHAM_COMPARATOR|group ending with TOVERTAFEL activities|Participants will benefit from the usual animation techniques for 6 weeks then from TOVERTAFEL activities for 6 weeks with a week of wash-out between the two periods.
62227209|NCT01393860||Aliskiren|Diabetic nephropathy
62227210|NCT04815967|EXPERIMENTAL|Phase 2; Low Dose MYOBLOC|Low Dose MYOBLOC is a single treatment and will be compared to volume-matched placebo
62227211|NCT04815967|EXPERIMENTAL|Phase 2; High Dose MYOBLOC|High Dose MYOBLOC is a single treatment and will be compared to volume-matched placebo
62227212|NCT04815967|PLACEBO_COMPARATOR|Phase 2; Placebo|Volume-matched placebo is a single treatment
62802716|NCT04811040|EXPERIMENTAL|Optional Cohorts: LEN, Teropavimab, Zinlirvimab Dose D|Optional cohort included participants screened for primary cohort but could not qualify for primary cohort at the study start. Participants in optional cohort will begin treatment by receiving LEN Dose A + LEN Dose B + teropavimab + zinlirvimab Dose D followed by LEN Dose A on the next day. The last treatment regimen will include LEN Dose B + teropavimab + zinlirvimab Dose D.
62227213|NCT04815967|EXPERIMENTAL|Phase 3; MYOBLOC|MYOBLOC is a single treatment and will be compared to volume-matched placebo
62227214|NCT04815967|PLACEBO_COMPARATOR|Phase 3; Placebo|Volume-matched placebo is a single treatment
62227215|NCT01556477|ACTIVE_COMPARATOR|azacitidine|
62227216|NCT01556477|EXPERIMENTAL|azacitidine + lenalidomide|
62227217|NCT00819520|EXPERIMENTAL|Ivermectin|ivermectin Stromectol®)
62227218|NCT00819520|ACTIVE_COMPARATOR|Malathion|malathion(Prioderm®)
62227219|NCT02178670|PLACEBO_COMPARATOR|non-cancer stem cell vaccine|There is no cancer stem cell vaccine in this group
62227220|NCT02178670|EXPERIMENTAL|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62227221|NCT02178670|EXPERIMENTAL|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62420065|NCT02446197|EXPERIMENTAL|Patient Directed Exercise Group|Participants will complete a combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
62420066|NCT02446197|NO_INTERVENTION|Standard of care|Standard of care comprehensive inpatient rehabilitation program.
62420067|NCT00394992|ACTIVE_COMPARATOR|1 oxaliplatin+capecitabine|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
62227222|NCT02178670|EXPERIMENTAL|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62227223|NCT05389085|OTHER|Prospective non-blinded clinical study|All patients enrolled with with suspicious pigmented skin tumours will be scanned with reflectance confocal microscopy and photoacoustic imaging by an experienced examiner in a 30 minutes to 1-hour session. Subsequently, material for RNA and lipid analysis is obtained from tape-stripped lesional skin at the bedside. The skin tumors in patients enrolled will subsequently be treated according to hospital and national guidelines.
62227224|NCT02240693|EXPERIMENTAL|BI 409306 dose 1|
62227225|NCT02240693|EXPERIMENTAL|BI 409306 dose 2|
62227226|NCT02240693|EXPERIMENTAL|BI 409306 dose 3|
62420068|NCT00394992|EXPERIMENTAL|2 oxaliplatin+capecitabine+bevacizumab|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
62590371|NCT00537316|ACTIVE_COMPARATOR|Azathioprine (AZA)|AZA 2.5 mg/kg of body weight orally every day for 16 weeks. Responders to AZA monotherapy at Week 8 were to continue on AZA therapy and receive one placebo infusion at Week 14; non-responders to AZA at Week 8 would be eligible to receive an IFX infusion at Weeks 8, 10, and 14. Participants in steroid-free remission at Week 16 were to continue on AZA monotherapy and were to be followed up for safety in Part 2. Participants who experienced a relapse of disease after Week 16 were to continue daily AZA monotherapy and receive 3 infusions of IFX (induction therapy at Weeks 0, 2, and 6) followed by infusions every 8 weeks (maintenance therapy).
62590372|NCT00537316|EXPERIMENTAL|IFX/AZA|IFX 5 mg/kg of body weight IV infusions at Weeks 0, 2, and 6 plus AZA 2.5 mg/kg orally every day for 16 weeks. Responders to IFX/AZA at Week 8 were to receive one more IFX infusion at Week 14; non-responders to IFX/AZA were to receive placebo infusions at Weeks 8 and 10 and one additional IFX infusion at Week 14. Part 2: Participants in steroid-free remission at Week 16 of Part 1 were to be randomized to either maintenance (every 8 weeks \[q8w\]) or intermittent (upon relapse) open-label IFX (last IFX infusion administered at Week 86) plus double-blind oral AZA/placebo treatment as allocated in Part 1 (last dose at the final visit, Week 94). Responders at Week 16 who had not achieved steroid-free remission were to continue to receive IFX infusions every 8 weeks.
62590373|NCT00537316|EXPERIMENTAL|Maintenance IFX/AZA (during Part 2)|Participants randomized to maintenance IFX/AZA in Part 2 of the study were to receive IFX 5 mg/kg of body weight IV infusions every 8 weeks (beginning at Week 22, Week 6 for direct entry) plus AZA 2.5 mg/kg of body weight daily. Four participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
62590374|NCT00537316|EXPERIMENTAL|Maintenance IFX (during Part 2)|Participants randomized to maintenance IFX were to receive IFX 5 mg/kg of body weight IV infusions every 8 weeks (beginning at Week 22, Week 6 for direct entry) in Part 2 of the study. Placebo to AZA therapy was to continue as allocated in Part 1 of the study. All participants were from Part 1 of the study.
62590375|NCT00537316|EXPERIMENTAL|Intermittent IFX/AZA (during Part 2)|Participants randomized to intermittent IFX/AZA were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained) plus AZA 2.5 mg/kg of body weight daily in Part 2 of the study. Three participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
62590376|NCT00537316|EXPERIMENTAL|Intermittent IFX (during Part 2)|Participants randomized to intermittent IFX were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained). Placebo to AZA therapy was to continue as allocated in Part 1 of the study. One participant was from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
62590377|NCT03680586|EXPERIMENTAL|Treatment (low-dose radiation therapy)|Patients undergo low-dose radiation therapy over 2 fractions for 2 consecutive days in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease at 12-16 weeks post-treatment, or persistent disease at 1 year may undergo higher-dose radiation therapy at the discretion of treating physician.
62590378|NCT01363453||Patients with Ulcerative Colitis|
62590379|NCT03192670|SHAM_COMPARATOR|Sham control group|Sham control group received same procedure without LED-T. Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)
62802717|NCT04327102|EXPERIMENTAL|Experimental : intervention group|Combination of health education tools and health literacy intervention: on the basis of the control group, the hypertension health education tools are used as the education media to encourage patients to find out the elements of the tool chart, use the picture content to guide the topic development, encourage patients to discuss with each other, realize heuristic questions, rather than a single indoctrination, so as to deepen the understanding and memory of patients. At the end of the course, patients are encouraged to set short-term goals to encourage behaviors that continue to achieve larger goals. At the same time, health literacy lectures were organized during the hospitalization. Health literacy lecture is mainly to learn the information that hypertension needs to pay attention to in order to improve the health literacy of hypertension patients and other indicators.
62802718|NCT04327102|NO_INTERVENTION|No intervention:The control group|No intervention except conventional care were performed for the control group
62420069|NCT02543229|EXPERIMENTAL|Part 1 Dose escalation - Cohort 1|Dose Level 1 of OPT-302 in combination with Lucentis™
62420070|NCT02543229|EXPERIMENTAL|Part 1 Dose escalation - Cohort 2|Dose Level 2 of OPT-302 in combination with Lucentis™
62420071|NCT02543229|EXPERIMENTAL|Part 1 Dose escalation - Cohort 3|Dose Level 3 of OPT-302 in combination with Lucentis™
62420072|NCT02543229|EXPERIMENTAL|Part 1 Dose escalation - Cohort 4|Dose Level 3 of OPT-302 monotherapy
62420073|NCT02543229|EXPERIMENTAL|Part 2 Dose expansion - Cohort 5|OPT-302 (at Maximum Tolerated Dose \[MTD\] or highest dose tested in Part 1) in combination with Lucentis™
62420074|NCT02543229|EXPERIMENTAL|Part 2 Dose expansion - Cohort 6|OPT-302 (at MTD or highest dose tested in Part 1) monotherapy
62420075|NCT02643810|ACTIVE_COMPARATOR|Interval training group|Patients to be randomized to the 'interval training group' will have exercise training sessions 3 times per week for a period of 12 weeks. During training, they will undergo interval exercise series composed of high-intensity intervals (80-90% of peak heart rate) and low-intensity intervals (50-70% of peak heart rate).
62420076|NCT02643810|ACTIVE_COMPARATOR|Continuous training group|Patients to be randomized to the 'continuous training group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo moderate continuous exercise training at 70-75% of peak heart rate.
62028303|NCT00320658|EXPERIMENTAL|B|3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel and CPG7909 given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm A.
62028304|NCT00320658|EXPERIMENTAL|C|3 vaccinations with a dose of 160 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm D after review of the results from Arms A and B.
62028305|NCT00320658|EXPERIMENTAL|D|3 vaccinations with a dose of 160 mcg MSP1 42-C1/Alhydrogel and CPG7909 given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm C after review of the results from Arms A and B.
62227227|NCT02240693|EXPERIMENTAL|BI 409306 dose 4|
62420077|NCT02643810|NO_INTERVENTION|Usual care group|Patients to be randomized to the 'usual care group' will undergo standard care for 12 weeks.
62420078|NCT02411110|EXPERIMENTAL|LiRIS® (Treatment Period 1)/LiRIS® (Treatment Period 2)|Treatment Period 1: continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 1. Treatment Period 2: optional continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 2.
62420079|NCT02411110|OTHER|LiRIS Placebo (Treatment Period 1)/LiRIS® (Treatment Period 2)|Treatment period 1: Matching placebo device to LiRIS inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 1. Treatment Period 2: optional continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 2.
62420080|NCT06702254|OTHER|Treament as usual|The in-ward patient are provided treatment as usual. This can include medication, routine brief conversation and ward activity.
62590380|NCT03192670|EXPERIMENTAL|CA(Carotid artery)-stimulation group|"In CA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
62590381|NCT03192670|EXPERIMENTAL|VA(Vertebral artery)-stimulation group|"In VA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
62802719|NCT00689312|ACTIVE_COMPARATOR|1|
62802720|NCT00689312|EXPERIMENTAL|2|
62802721|NCT00689312|EXPERIMENTAL|3|
62802722|NCT00228358|EXPERIMENTAL|Group A (cellular infusions after cyclophosphamide)|Patients receive low-dose cyclophosphamide IV on day -1 and 3 escalating doses of autologous ex vivo-expanded HER2-specific T cells IV over 30 minutes on days 1, 10, and 20.
62028306|NCT06293235||Subfertile couples|Couples who are not able to conceive for at least 12 months with female partners without infertility diagnosis.
62590382|NCT03192670|EXPERIMENTAL|CA+VA dual stimulation group|"In CA+VA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
62590383|NCT06622902|EXPERIMENTAL|start with 2LPM|start with 2LPM
62802723|NCT00228358|EXPERIMENTAL|Group B (cellular infusions after ONTAK conditioning)|Patients receive denileukin diftitox IV over 1 hour on day -1 and 3 escalating doses of autologous ex vivo-expanded HER2-specific T cells IV over 30 minutes on days 1, 10, and 20.
62802724|NCT01735266|ACTIVE_COMPARATOR|Air colonoscopy|Air was insufflated during whole procedure of colonoscope insertion.
62802725|NCT01735266|EXPERIMENTAL|Whole-colon water exchange colonoscopy|The air pump was turned off before colonoscopy. During the whole procedure of the scope insertion, residual air in lumen was suctioned and 37°C (maintained with a water bath) water was infused with a peristaltic pump to obtain lumen visualization. Air was insufflated until cecum was reached or appendix opening was seen.
62802726|NCT01735266|EXPERIMENTAL|left-colon water exchange colonoscopy|In the left side of colon (including descending colon, sigmoid colon and rectum), water was infused instead of air to obtain lumen visualization as described above in whole-colon water exchange colonoscopy group.
62802727|NCT01518556|EXPERIMENTAL|Idarubicin|Idarubicin dose intensification for remission induction in acute myeloid leukemia
62802728|NCT03649074|EXPERIMENTAL|AKL-T01|AKL-T01 digital treatment.
62802729|NCT05048316|EXPERIMENTAL|eHealth|Weekly video conference groups led by a trained facilitator
62802730|NCT02417883|EXPERIMENTAL|Furosemide Stress Test|Furosemide stress test will be perform to patients scheduled for kidney bipsy. The test consist in 1.5 miligrams per kilogram of weight of intravenous furosemide administration, along with urinary output follow up and measurement for 6 hours. The urinary output will be replaced intravenously with normal saline to avoid dehydration and/or hypotension.
62028307|NCT06293235||Fertile couples|Couples with attempted time to conceive within 12 months to achieve this pregnancy or with unplanned pregnancy, with female partners who are currently pregnant with viable intrauterine pregnancy.
62028308|NCT05827978|EXPERIMENTAL|mRNA-1010|Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
62028309|NCT05827978|ACTIVE_COMPARATOR|Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine|Participants will receive a single dose of licensed quadrivalent inactivated seasonal influenza vaccine by IM injection on Day 1.
62028310|NCT00633321|EXPERIMENTAL|1|TA-NIC 100 μg
62590384|NCT06622902|EXPERIMENTAL|start with 6LPM0|start with 6LPM
62590385|NCT01883050|OTHER|Self Monitoring of Software Application|log into self monitoring software application from a home computer. Log on 3-4 times weekly for 12 weeks for important reminders, care tips and educational materials.
62802731|NCT00352001|EXPERIMENTAL|Lenalidomide and Azacitidine|
62802732|NCT02936635|EXPERIMENTAL|Delayed Start Treatment|The Delayed Start Treatment group consisted of patients who received placebo in CY 4031 and tirasemtiv in CY 4033.
62802733|NCT02936635|EXPERIMENTAL|Early Start Treatment|The Early Start Treatment group consisted of patients who received tirasemtiv in both CY 4031 and CY 4033.
62802734|NCT04548466|NO_INTERVENTION|CONTROL group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization.
62802735|NCT04548466|EXPERIMENTAL|PEP group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Positive expiratory pressure breathing (PEP bottle)
62802736|NCT03152695|EXPERIMENTAL|High-intensity focused ultrasound therapy|Abdominal MRI will be used to target the tumor, and the tumor will be divided into slices with 5mm separation using MR images. By scanning the HIFU beam in successive sweeps from the deep to the shallow regions of the tumor.
62802737|NCT03073421|OTHER|HIV positive pregnant women|HIV positive pregnant women who took part in the P3 program will take part in a 2-hour qualitative interview.
62802738|NCT00187863||Exercise induced pain perception|
62802739|NCT00187863||Surgical pain perception|
62802740|NCT05237817||Cerebral infarction Group|Patients with cerebral infarction, and enrolled in our emergency or clinical department.
62802741|NCT05237817||Intracerebral hemorrhage Group|Patients with intracerebral hemorrhage, and enrolled in our emergency or clinical department.
62802742|NCT05237817||Subarachnoid hemorrhage Group|Patients with subarachnoid hemorrhage, and enrolled in our emergency or clinical department.
62802743|NCT02366351|EXPERIMENTAL|SHR3824 Placebo|once daily, 12 weeks
62802744|NCT02366351|EXPERIMENTAL|SHR3824 5 mg|once daily, 12 weeks
62802745|NCT02366351|EXPERIMENTAL|SHR3824 10 mg|once daily, 12 weeks
62802746|NCT02366351|EXPERIMENTAL|SHR3824 20 mg|once daily, 12 weeks
62802747|NCT02643459|NO_INTERVENTION|Conventional|no suPAR measurement. Standard care.
62802748|NCT02643459|EXPERIMENTAL|suPAR|suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR. Since suPAR is measured on all patients regardless of disease the investigators cannot define a single intervention. A possible intervention depends on the clinical situation.
62590386|NCT01883050|NO_INTERVENTION|No Intervention|No Intervention
62227228|NCT02240693|PLACEBO_COMPARATOR|Placebo|
62227229|NCT02796157|ACTIVE_COMPARATOR|absorb arm|PCI with Absorb everolimus-eluting bioresorbable vascular scaffold
62420081|NCT06702254|EXPERIMENTAL|Psychological manualized treatment with CBT and ACT|The intervention is based on a manual and is an add-on to treatment as usual. In-ward patients are offered a brief psychological treatment based on core features from CBT and ACT such as behavioral activation and work on values and unhelpful thoughts. Prior to the intervention nursing staff receive training in the manual followed by supervision during the treatment intervention. The treatment in this condition is an add-on to usual treatment given in the wards. The intervention is brief up to four sessions in the manual but can be shortened or extended to fit the patients admission time.
62420082|NCT04289571|EXPERIMENTAL|Participants|Participants with retinal disease, healthy volunteers
62420083|NCT02223598|EXPERIMENTAL|Dose Escalation - CB-5083|CB-5083 will be administered orally, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with lymphoid hematological malignancies
62420084|NCT02223598|EXPERIMENTAL|Dose Expansion - CB-5083, Dexamethasone|CB-5083 will be administered orally, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with relapsed and refractory multiple myeloma; in addition, subjects who develop progressive disease at the end of Cycle 1, or beyond, may receive their current dose of CB-5083 in combination with oral or IV low dose Dexamethasone (40 mg)
62590387|NCT06668415|ACTIVE_COMPARATOR|Group A (Hydrodilation+Spencer Technique )|Patients in this group will be followed by Spencer Technique after Hydrodilation for the duration of 4 weeks which includes 12 sessions in total. Spencer muscle energy technique is a seven 7 step procedure which consists of shoulder extension with elbow flexed, shoulder flexion with elbow flexed, circumduction with compression, circumduction with traction, Abduction then adduction with external rotation and glenohumeral pump. Following the complete action, patients will be encouraged to use their muscles for 3 to 5 seconds against little resistance provided by the therapist
62590388|NCT06668415|EXPERIMENTAL|Group B (Hydro dilation+ Passive Stretching)|This group will undergo Passive Stretching followed by Hydrodilation. The low intensity stretches will be given in supine for all the movements ie Flexion ,Abduction , Internal Rotation and External Rotation for 5 repititions with 30 sec hold. (7)
62590389|NCT05819112||Conventional prophylaxis|Participants hospitalized for acute medical illness receiving conventional (i.e., once daily for 7 days) enoxaparin VTE prophylaxis
62227230|NCT02796157|EXPERIMENTAL|Xience arm|PCI with Xience everolimus-eluting metallic stent
62590390|NCT05819112||Extended prophylaxis|Participants hospitalized for acute medical illness receiving extended duration (i.e., once daily for 14, 21 or 28 days) enoxaparin VTE prophylaxis
62227231|NCT03482583|OTHER|Cognitive Behavior Therapy with NRT|Cognitive Behavior Therapy (CBT) will be provided by a certified tobacco treatment specialist (CTTS) using vidyo, a HIPAA-compliant video based platform. Participants in this arm, if interested will be provided a 2 week supply of nicotine replacement therapy (NRT). The intervention in this arm would be NRT along with the CBT counseling.
62227232|NCT03482583|OTHER|Referral to Area Health Education Center|The Area Health Education Center (AHEC) is a locally available tobacco cessation program aimed at strengthening the capacity of Florida's healthcare system to deliver effective evidence based tobacco use treatment, and prevention services throughout the state. The intervention is education on the health effects related to tobacco use, and benefits of quitting and what to expect when quitting. A tobacco cessation specialist of trained facilitator guides participants as they identify triggers and withdrawal symptoms, and discuss ways to cope with them. The program offers free nicotine replacement therapy, educational materials, goodies for their quit day and follow up support.
62590391|NCT06617949|ACTIVE_COMPARATOR|Transverse abdominal Plane(TAP) Block with long acting Exparel|A subset of participants (n=15) will be divided into three different arms: A.) Postoperative Epidural infusion for 24-36hrs B.) Hydromorphone Patient Controlled Analgesia (PCA) with Preservative free Morphine via epidural for 36hrs C.) Transverse abdominal Plane(TAP) Block with long acting Exparel.
62227233|NCT03482583|OTHER|Referral to Qutiline|"Quitline is a local program in the state where smokers can call a toll free number to talk to coach who can help them quit. There is also an option of online program if they prefer to engage in online help to quit tobacco use.~The intervention in this arm is counseling support by phone or online with an option of Nicotine replacement therapy. If participants prefer this option, our nurse will refer them to locally available quitline service using EPIC."
62227234|NCT05368051||long course radiotherapy + capecitabine + PD-1 monoclonal antibody|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
62227235|NCT05169320||Case group|Patients with symptomatic persistent AF episodes after previous failure of ≥2 pulmonary vein isolation procedures
62227236|NCT04037904||H. pylori negative group|Subjects who have not have H. pylori infection, and had not receive H. pylori eradication
62227237|NCT04037904||H. pylorieradicated group|Subjects who have had H. pylori infection currently and received successful H. pylori eradication according to appropriated indication
62227238|NCT02862834||patients with poikiloderma|
62227239|NCT03784560||study group|anesthesia residents with 24 hours working shift
62028311|NCT00633321|EXPERIMENTAL|2|TA-NIC 250 μg
62028312|NCT00633321|PLACEBO_COMPARATOR|3|
62227240|NCT05880615||opioid reduced anesthesia with parasternal catheters inserted before sternotomy|Patients with opioid reduced anesthesia with parasternal catheters inserted before sternotomy will be included.
62243077|NCT02616445|PLACEBO_COMPARATOR|Fed-Fasted|
62028313|NCT02602808||Severe acute pancreatitis group|Severe acute pancreatitis is characterised by persistent organ failure.
62420085|NCT02223598|EXPERIMENTAL|Dose Expansion - CB-5083|CB-5083 will be administered orally, daily, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with diffuse large B-cell lymphoma (DLBCL) or Waldenstrom Macroglobulinemia, if such arm is opened, per Sponsor
62420086|NCT03214705||Patients with poor outcome|Follow up of patients is done for 21 days by combined clinical and radiological examination. Poor clinical outcome is associated with vasospasm leading to permanent neurological deficit, stroke or death.
62802749|NCT01682733|EXPERIMENTAL|Botulinum toxin at injection site|All subjects will have gastroplasty performed using the Overstitch Endoscopic Suturing System. Botulinum toxin will be injected in every other suture site in half of the randomly patients selected.
62802750|NCT03188107||Risky Infants|Infants that have risk of developing motor impairment, or infants diagnosed as Spina Bifida, Down Syndrome ect.
62802751|NCT03188107||Healthy Infants|Healthy infants that have normal motor development
62420087|NCT03214705||Patients without poor outcome|Patients who do not develop delayed cerebral ischemia or stroke, confirmed by combined clinical and radiological examination.
62420088|NCT06127979|EXPERIMENTAL|Breast Cancer|All study patients will receive standard ET for at least 2 weeks, which will be followed by standard of care surgical treatment. Surgical tumor tissue will be obtained at the time of surgery and will be assessed for Ki67; a portion of this specimen will be snap-frozen for future analysis.
62802752|NCT03068494||Coronary Bifurcation Lesion|
62802753|NCT05438719|EXPERIMENTAL|MOTUS|All subjects will be treated with the MOTUS Total Joint Replacement
62802754|NCT03639363|EXPERIMENTAL|Intervention Arm|daily bathing with 4% chlorhexidine gluconate soap-like solution followed by water rinsing
62802755|NCT03639363|ACTIVE_COMPARATOR|Control Arm|daily bathing with standard soap
62802756|NCT05724407||Standard of care|Female patient diagnosed for breast cancer
62028314|NCT02602808||Moderately severe acute pancreatitis|Moderately severe acute pancreatitis is characterised by the presence of transient organ failure or local or systemic complications in the absence of persistent organ failure.
62028315|NCT02602808||Mild acute pancreatitis|Mild acute pancreatitis is characterised by the absence of organ failure and the absence of local or systemic complications.
62028316|NCT02602808||post-ERCP pancreatitis|Patients with new onset of epigastric pain, an increase in pancreatic enzymes of at least three times the upper limit of the normal range within 24 hours after ERCP, and hospitalization for at least 2 nights.
62227241|NCT05880615||Opioid Anesthesia (OA)|Patients with Opioid Anesthesia (OA) will be included.
62227242|NCT04960735|EXPERIMENTAL|Patients with cancer (patients with breast cancer and patients with lung cancer)|"Health-related Quality of Life evidence was collected from patients with cancer (patients with breast cancer and patients with lung cancer) for six months. The evidence was collected by means of health related and patient reported questionnaires (ICHOM standard sets for breast cancer and lung cancer).~Patients were monitored for six months. Intervention outcomes were monitored at different times: for patients with breast cancer, at the start (on recruitment which coincided with diagnosis) and at six months; for patients with lung cancer, at the start (on recruitment which coincided with diagnosis), at three and at six months."
62028317|NCT00384228|EXPERIMENTAL|Nilotinib|
62028318|NCT03517774|EXPERIMENTAL|3D Printed Socket|All participants will received a 3D Printed Prosthetic
62227243|NCT02943226|EXPERIMENTAL|Becton Dickinson Nexiva Diffusics System|Intervention with the new Becton Dickinson Nexiva Diffusics System will be evaluated to see if it will improve image quality compared to the standard catheter.
62227244|NCT02943226|ACTIVE_COMPARATOR|Standard intravenous catheter|Standard catheter with one hole at the tip will be compared to novel 3 hole Becton Dickinson Nexiva Diffusics System to see which catheter provides the best image quality.
62227245|NCT03809429|EXPERIMENTAL|FE 999049 + GnRH agonist (GONAPEPTYL)|
62227246|NCT03809429|ACTIVE_COMPARATOR|FE 999049 + GnRH antagonist (CETROTIDE)|
62227247|NCT02038491||regional anesthesia|patients undergoing regional anesthesia procedures
62227248|NCT03008707||Group 1|Patients who undergo Laparoscopic Peritoneal Lavage
62227249|NCT03008707||Group 2|Patients who have a laparoscopically approached sigmoidectomy
62227250|NCT04461483|EXPERIMENTAL|Part 1, Cohort 1; TAK-935 200 mg|Part 1, Cohort 1; TAK-935 200 mg, tablets, orally once on Days 1 in fasted state.
62227251|NCT04461483|EXPERIMENTAL|Part 1, Cohort 2; TAK-935 600 mg|Part 1, Cohort 2; TAK-935 600 mg, tablets, orally once on Days 1 in fasted state.
62802757|NCT01771978|PLACEBO_COMPARATOR|Arm1: control group|Received 250 ml of a 5% dextrose solution as placebo drug
62802758|NCT01771978|EXPERIMENTAL|Arm 2: diltiazem group|Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution
62802759|NCT01771978|EXPERIMENTAL|Arm 3: acetylcystein group|Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
62227252|NCT04461483|EXPERIMENTAL|Part 1, Cohort 3; TAK-935 1200 mg|Part 1, Cohort 3; TAK-935 1200 mg, tablets, orally once on Days 1 in fasted state.
62243078|NCT02616445|EXPERIMENTAL|CSF|
62802760|NCT01771978|EXPERIMENTAL|Arm 4: diltiazem and acetylcystein group|"Received a combination of drug :~bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution and 150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution"
62802761|NCT04163029||preoperative oral care|
62802762|NCT02028481|EXPERIMENTAL|Postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
62802763|NCT02385851|EXPERIMENTAL|CHS-1701/Neulasta|CHS-1701 followed by Neulasta (crossover)
62802764|NCT02385851|EXPERIMENTAL|Neulasta/CHS-1701|Neulasta followed by CHS-1701 (crossover)
62028319|NCT03293940|EXPERIMENTAL|Cryoablation Group|"After an initial diagnostic visit to locate the pain causing nerve, participants randomized to this arm will receive the cryoablation procedure.~Participants will have the option to crossover to tPNB 90 days post the initial intervention."
62802765|NCT04945759|EXPERIMENTAL|Isokinetic Exercise (İE) Group:|"Isokinetic Exercise (IE) Group:~(Knee Joint Flexion / Extension, Hip Joint Internal / External Rotation and Abduction / Adduction Strengthening Program)~Patients will be seated on the isokinetic Cybex-Humac Norm device in a 90° upright sitting position. It will be fixed to the seat with torso, pelvis and thigh straps. During this training, patients will be told that the dynamometer arm will bring the knee from extension to flexion. During this exercise, the patient will be advised to resist the dynamometer as much as possible while moving the knee in flexion/extension, internal/external rotation, and abduction/adduction with the dynamometer."
62802766|NCT04945759|ACTIVE_COMPARATOR|Isokinetic Exercise + Aussie Current (IE+AC)Group:|Aussie Current and Isokinetic Exercise program will be applied to the patients. The distal electrode is placed on the anterior part of the thigh and superior to the patella. The proximal electrode will be placed on the thigh. One electrode will be placed between the anterior superior and posterior superior iliac spine of the PFPS(Patellofemoral Pain Syndrome) side and the other electrode will be placed in a triangle on the greater trochanter of the femur in the gluteus medius muscle. By contacting the Turkish authorities of the BTL 4825SPREMIUM device, the current was adjusted in the Aussie Current 1 kHz frequency, 400 ms phase time, 50 hz burst frequency, 4 ms duration device. This new burst modality medium frequency alternating current will be applied to the patient for 20 minutes.
62802767|NCT04945759|ACTIVE_COMPARATOR|Isokinetic Exercise + Russian Current (IE+RC) Group:|"Isokinetic Exercise program will be applied to the patients. Similarly, as with the Aussie Current, the Russian current will be applied to the vastus lateralis-medialis and gluteus medius muscles.~Russian current will be set as 2500 Hz sinusoidal current, 200 ms phase time, 50 hz burst frequency, 50% duty cycle, 10 ms duration.~The patient will be treated for 20 minutes."
62802768|NCT04945759|PLACEBO_COMPARATOR|Isokinetic Exercise + placebo Electrical Stimulation (IE+PES) Group:|Isokinetic Exercise program will be applied to the patients. The appropriate modalities will be set on the electrical stimulation device, but the device will not operate. It will be applied for 20 minutes.
62802769|NCT01946139|EXPERIMENTAL|Screening (HSIL detection)|Patients undergo screening for the detection of HSIL using anal cytology, HPV hybrid capture 2, HPV mRNA assays, and OncoHealth HPVE6/E7 oncoprotein at baseline, at 6, 12, 18, and 24 months.
62802770|NCT06420089|EXPERIMENTAL|Senza5 CART5 with standard of care lymphodepletion|"Four treatment arms with Standard of Care Lymphodepletion:~Fludarabine 25mg/m2 IV for 3 days Cyclophosphamide 250mg/m2 IV for 3 days"
62590392|NCT06617949|ACTIVE_COMPARATOR|Postoperative Epidural infusion for 24-36hrs|A subset of participants (n=15) will be divided into three different arms: A.) Postoperative Epidural infusion for 24-36hrs B.) Hydromorphone Patient Controlled Analgesia (PCA) with Preservative free Morphine via epidural for 36hrs C.) Transverse abdominal Plane(TAP) Block with long acting Exparel.
62227253|NCT04461483|PLACEBO_COMPARATOR|Part 1, Cohort 1-3; Placebo|Part 1, Cohort 1-3; TAK-935 placebo-matching tablets, orally once on Days 1 in fasted state.
62227254|NCT04461483|EXPERIMENTAL|Part 2, Cohort 4: TAK-935 100 mg|Part 2, Cohort 4: TAK-935 100 mg, tablets, orally twice on Days 1-7 in fasted state with multiple doses with titration.
62227255|NCT04461483|EXPERIMENTAL|Part 2, Cohort 4: TAK-935 200 mg|Part 2, Cohort 4: TAK-935 200 mg, tablets, orally twice on Days 8-14 in fasted state with multiple doses with titration.
62590393|NCT06617949|ACTIVE_COMPARATOR|Hydromorphone Patient Controlled Analgesia (PCA),Preservative free Morphine via epidural for 36hrs|A subset of participants (n=15) will be divided into three different arms: A.) Postoperative Epidural infusion for 24-36hrs B.) Hydromorphone Patient Controlled Analgesia (PCA) with Preservative free Morphine via epidural for 36hrs C.) Transverse abdominal Plane(TAP) Block with long acting Exparel.
62590394|NCT04180137|EXPERIMENTAL|Surgical treatment with subsequent pharmacotherapy|
62227256|NCT04461483|EXPERIMENTAL|Part 2, Cohort 4: TAK-935 300 mg|Part 2, Cohort 4: TAK-935 300 mg, tablets, orally twice on Days 15-21 in fasted state with multiple doses with titration.
62227257|NCT04461483|PLACEBO_COMPARATOR|Part 2, Cohort 4: Placebo|Part 2, Cohort 4: TAK-935 placebo-matching tablets, orally twice on Days 1-21 in fasted state.
62227258|NCT04153123|EXPERIMENTAL|Lidocaine with epinephrine|Peribulbar anesthesia with lidocaine and epinephrine
62227259|NCT04153123|NO_INTERVENTION|Lidocaine without epinephrine|Peribulbar anesthesia with lidocaine
62227260|NCT02207881|PLACEBO_COMPARATOR|placebo|placebo gel, 25mg, 3 times up to 10 days
62227261|NCT02207881|EXPERIMENTAL|VDO gel|VDO gel 25mg, 3 times a day up to 10 days
62227262|NCT04818333|EXPERIMENTAL|SHR-A1811|SHR-A1811 was administered intravenously every 3 weeks (Q3W) until discontinuation treatment
62227263|NCT06409520||Group (1)|patients with acute coronary syndrome and subclinical hypothyroidism
62227264|NCT06409520||Group (2)|(control group) patients with acute coronary syndrome and normal thyroid function
62227265|NCT05555056|ACTIVE_COMPARATOR|Active Stimulation|MxN-9 HD-tES Stimulator (Soterix Inc.) will be used to deliver direct current (High-Definition Transcranial Direct Current Stimulation) to the target brain areas via electrodes and conducive gels. A constant current will be applied for 20 minutes with peak current of 2 mA. The 9 electrodes (8 channels + 1 ground) positions and current intensity have been determined based on computer simulation using HDTargets software (Soterix Inc.) that results in maximum focal current on the left VLPFC (x=-50, y=+26, z=+8) and the PCC (x=1, y=-61, z=38) with inward field orientation.
62243079|NCT01535183|EXPERIMENTAL|Irinotecan|
62243080|NCT02597803|EXPERIMENTAL|High Dose RGN-259|High dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
62420089|NCT06118086|EXPERIMENTAL|REM-422|"* Dose Escalation: Participants will receive escalating doses of REM-422 to determine Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)-422, oral capsule administered once daily~* Dose Expansion: Participants will receive REM-422 at the identified RP2D~* Treatment will continue until disease progression, therapy intolerance, or participant withdrawal~* Safety evaluation will continue until 30 days of last administration of REM-422"
62590395|NCT04180137|OTHER|Isolated surgical treatment|
62590396|NCT04737798|EXPERIMENTAL|oil pulling with coconut oil|patients used oil pulling therapy with coconut oil for 4 days
62590397|NCT04737798|ACTIVE_COMPARATOR|oil pulling with sesame oil|patients used oil pulling therapy with sesame oil for 4 days
62590398|NCT02593578||Biomarker group|Advanced cancer undergoing genomic profiling
62590399|NCT02644720|EXPERIMENTAL|multifocal intraocular lens group|
62590400|NCT02644720|ACTIVE_COMPARATOR|monofocal intraocular lens group|
62590401|NCT03429244|EXPERIMENTAL|Prostate cancer- men being treated with radical prostatectomy|Men being treated for prostate cancer with radical prostatectromy were enrolled in this arm.
62590402|NCT03429244|EXPERIMENTAL|Prostate cancer- men undergoing cancer screening or active surveillance|Men undergoing cancer screening or active surveillance were enrolled in this arm.
62590403|NCT03429244|EXPERIMENTAL|Prostate cancer- focal therapy|Men undergoing focal therapy with high intensity focused ultrasound are in this group.
62590404|NCT04480671|OTHER|Sacrocolpopexy|This group will only receive the sacrocolpopexy for their pelvic organ prolapse repair.
62590405|NCT04480671|ACTIVE_COMPARATOR|Sacrocolpopexy and concomitant level III support procedure|This randomized group will receive an additional vaginal repair for level III support at the conclusion of the sacrocolpopexy.
62802771|NCT06420089|EXPERIMENTAL|Senza5 CART5 without standard of care lymphodepletion|Four treatment arms in patients are lymphopenic into the corresponding dose level.
62802772|NCT03075618||Acute Pancreatitis|Patients with Acute Pancreatitis.
62802773|NCT04581486|EXPERIMENTAL|OMI intervention|Multimodal intervention based on optimal fluid viscosity adaptation (with Nutilis Clear®), optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning)
62802774|NCT04581486|OTHER|Control intervention (standard clinical practice)|Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
62802775|NCT00549640|ACTIVE_COMPARATOR|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
62802776|NCT00549640|PLACEBO_COMPARATOR|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
62802777|NCT01329627|EXPERIMENTAL|Paclitaxel/doxorubicin/cyclophosphamide|
62802778|NCT02936674|EXPERIMENTAL|Light 1|Light 1 will have an altered color composition as compared with a standard LED bulb.
62802779|NCT02936674|ACTIVE_COMPARATOR|Light 2|Light 2 will be a standard LED bulb.
62590406|NCT03480191|EXPERIMENTAL|Patients|
62590407|NCT05039814||AKI|patients suffered postoperative acute kidney injury
62590408|NCT05039814||Non-AKI|patients did not suffer postoperative acute kidney injury
62590409|NCT05761561|EXPERIMENTAL|Exercise and medical nutrition|Over the intervention period (18 weeks on average - dependent on length of chemotherapy) women in the intervention arm will receive weekly counseling sessions, the study dietitian and exercise trainer will each conduct weekly sessions to assist the participants in achieving the diet and exercise study goals.
62802780|NCT03370042|ACTIVE_COMPARATOR|Semilunar Coronally Positiones Flap + Free Gingival Graft|semilunar coronally positioned flap with free gingival graft for root coverage
62802781|NCT03370042|SHAM_COMPARATOR|Semilunar Coronally Positioned Flap|semilunar coronally positioned flap alone without free gingival graft for root coverage
62802782|NCT03594682|EXPERIMENTAL|dose titration group|First of all, according to the patient's weight and ECOG score, patients were divided into three groups（the initial dose of 250 mg qd,250 mg/500 mg qd by turns, 500 mg qd）. in two weeks, if the patient who is intolerant of the initial dose,250mg qod,250mg qd ,250mg qd was selected. if the patient can tolerate the dose well,a high-dose was given,and the maximum dose does not exceeding 750mg qd.
62802783|NCT03594682|ACTIVE_COMPARATOR|non-titration group|Patients were given 750mg qd apatinib until disease progression or intolerance
62802784|NCT05502913|EXPERIMENTAL|standard of care (SoC) (IO±CTX) + FMT|"Subjects assigned to Arm 1 will be required to swallow FMT capsules in a regimen of ten capsules in the morning and ten capsules in the afternoon on day 1 of the first (chemo-)immunotherapy cycle, and then every three weeks.~abbreviation: Immuno-Oncology (IO) Chemotherapy (CTX)"
62420090|NCT05329558||Healthy Controls|
62420091|NCT05329558||Patients with ART without MRONJ|
62420092|NCT05329558||Patients with oral ART with MRONJ|
62420093|NCT05329558||Patients with intravenous ART with MRONJ|
62420094|NCT01506817||Fibromyalgia|patients with fibromyalgia fulfilling the 1990-ACR research criteria and with pain in the hands as a prominent clinical feature
62590410|NCT05761561|NO_INTERVENTION|Control|Contact limited to study assessments.
62590411|NCT05326347|EXPERIMENTAL|Rollover subjects|For rollover subjects, treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation at 24 mg. From Week 1 onward, 2 tablets of brexpiprazole QW formulation 24 mg (48 mg/week) will be orally administered for 51 weeks.
62802785|NCT05502913|NO_INTERVENTION|standard-of-care treatment|Subjects will receive standard-of-care treatment only.
62802786|NCT04045327|ACTIVE_COMPARATOR|Normal Saline|Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
62227266|NCT05555056|SHAM_COMPARATOR|Inactive Stimulation|The current will be applied for 30 seconds ramp-up followed by 30 seconds ramp-down, and thus no active stimulation will be administered except for the initial and last 1 minutes of 20 minute stimulation duration.
62227267|NCT02937064||Controls|Controls
62420095|NCT01506817||Controls|healthy aged matched pain-free controls
62028320|NCT03293940|ACTIVE_COMPARATOR|Control Group|"After an initial diagnostic visit to locate the pain causing nerve, participants randomized to this arm will receive the nerve block procedure.~Participants will have the option to crossover to cryoablation treatment 90 days post the initial intervention."
62028321|NCT01659723|ACTIVE_COMPARATOR|A - Immediate start|Start of treatment within 6 weeks of inclusion in the study. 100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
62028322|NCT01659723|NO_INTERVENTION|B - delayed start|Delayed start: Start of treatment not before 6 months of inclusion in the study. No intervention is given during the initial period.
62227268|NCT02937064||ACL subjects|Subjects with anterior cruciate ligament injuries.
62227269|NCT02937064||OA1, doubtful OA|Subjects with doubtful osteoarthritis.
62227270|NCT02937064||OA2, mild OA|Subjects with mild osteoarthritis.
62227271|NCT02937064||OA3, moderate OA|Subjects with moderate osteoarthritis.
62227272|NCT02937064||OA4, severe OA|Subjects with severe osteoarthritis.
62227273|NCT06524752||Observation group|The patient experience the postoperative nausea or vomiting
62802787|NCT04045327|EXPERIMENTAL|PMZ-2010 (centhaquine)|Hypovolemic shock patients will be provided the standard of care. Following randomization PMZ-2010 (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.
62802788|NCT03962179|EXPERIMENTAL|VACStent Group|Patient s who received a VACStent
62802789|NCT04071197|EXPERIMENTAL|Gastrostomy-biliary tube|The study group will be subjected to gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril
62802790|NCT04071197|EXPERIMENTAL|Other biliary diversion modalities|The control group will include those cases with other modalities of therapy as external biliary diversion, internal biliary diversion, and nasobiliary tube
62802791|NCT01544920|ACTIVE_COMPARATOR|Arm 1: peg-IFN + RBV|Participants received an initial 4 week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, participants with undetectable HCV RNA received open label peg-IFN + RBV for an additional 18 weeks (total of 24 weeks of peg-IFN/RBV therapy) \[Arm 1a\]. Participants with detectable HCV RNA at Week 4 had BOC added to the peg-IFN + RBV regimen at Week 6 and then followed the Response Guided Therapy (RGT) regimen for BOC + peg-IFN + RBV \[Arm 1b\].
62028323|NCT05808725|EXPERIMENTAL|T1 Fasting|Giving test product under fasting condition
62028324|NCT05808725|EXPERIMENTAL|T2 Fed|Giving test product under fed condition
62227274|NCT06524752||Control group|The patient did not experience postoperative nausea or vomiting
62227275|NCT04883437|EXPERIMENTAL|Treatment (acalabrutinib, obinutuzumab)|"INDUCTION PHASE: Patients receive acalabrutinib PO BID on days 1-28. Patients also receive obinutuzumab IV on days 1, 8, and 15 of cycle 3, then on day 1 of cycles 4-8. Treatments repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~FOLLOW-UP PHASE: After cycle 12, patients who are in CR are randomized to either discontinue acalabrutinib or to continue acalabrutinib monotherapy in the absence of disease progression or unacceptable toxicity. Patients with PR or SD after cycle 12 continue acalabrutinib monotherapy in the absence of disease progression or unacceptable toxicity. Patients with disease progression after cycle 12 discontinue study treatment. Patients with disease progression at any time prior to the conclusion of cycle 12 may continue study therapy if they are felt to be benefiting by the treating physician, but not past cycle 12."
62420096|NCT03285412|EXPERIMENTAL|Ribociclib + Endocrine Rx|Ribociclib will be administered. Endocrine therapy will be administered.
62420097|NCT03285412|ACTIVE_COMPARATOR|Endocrine Rx|Endocrine therapy will be administered.
62420098|NCT02228369|EXPERIMENTAL|Daily dose of AZD3759|Daily oral dose of AZD3759
62420099|NCT02228369|EXPERIMENTAL|Daily Dose of AZD9291|Daily oral dose of AZD9291
62028325|NCT05808725|ACTIVE_COMPARATOR|R Fasting|Giving reference product under fasting condition
62028326|NCT01106144||Acute myeloid leukemia|
62590412|NCT05326347|EXPERIMENTAL|New subjects|In medication switching period, treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation 24 mg, and the dose of the other antipsychotics will be gradually reduced, finally switching to monotherapy with 2 tablets of brexpiprazole QW formulation 24 mg (48 mg/week) by Week 4. In treatment period, 2 tablets of brexpiprazole QW formulation 24 mg (48 mg/week) will be orally administered for 52 weeks.
62028327|NCT02869217|EXPERIMENTAL|Cohort B (retreatment)|"Cyclophosphamide will be given intravenously (by vein) at a fixed dose of 750mg/m\^2/d for 2 days.~Fludarabine will be given intravenously at a fixed dose of 30mg/m\^2/d for 2 days.~TBI-1301 cells will be infused on Day 0 at a dose of 5x10\^9 cells.~\*Patients will only enter into this cohort if they have already been enrolled in another cohort prior"
62028328|NCT02869217|EXPERIMENTAL|Cohort C (double infusion)|"Cyclophosphamide will be given intravenously (by vein) at a fixed dose of 750mg/m\^2/d for 2 days.~Fludarabine will be given intravenously at a fixed dose of 30mg/m\^2/d for 2 days.~TBI-1301 cells will be infused on Day 0 and Day 14 at a dose of 5x10\^9 cells."
62028329|NCT00110617|EXPERIMENTAL|Deferasirox (ICL670)|Deferasirox (ICL670) 20 mg/kg orally once daily for 104 weeks.
62028330|NCT00110617|EXPERIMENTAL|Deferoxamine (DFO) then ICL670|Deferoxamine (DFO) subcutaneously for a weekly dose of 175 mg/kg for 24 weeks then crossed over to receive Deferasirox (ICL670) orally 20 mg/kg for a total of 104 weeks on therapy.
62802792|NCT01544920|EXPERIMENTAL|Arm 2: BOC + peg-IFN + RBV|Participants received an initial 4-week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, all participants had BOC added to the peg-IFN + RBV regimen at Week 6 regardless of HCV RNA levels. Participants who had undetectable HCV RNA at Week 4 continued on the BOC + peg-IFN + RBV regimen for an additional 20 weeks (total of 24 weeks of BOC + peg-IFN + RBV therapy) \[Arm 2a\]. Participants with detectable HCV RNA at Week 4 followed the RGT regimen for BOC + peg-IFN + RBV \[Arm 2b\].
62802793|NCT05219331|OTHER|Disorder of consciousness|Ventriculo peritoneal shunt
62028331|NCT05997693|EXPERIMENTAL|Ticagrelor 90 mg + Low-Dose Aspirin|
62028332|NCT05997693|ACTIVE_COMPARATOR|Low-Dose Aspirin Alone|
62802794|NCT04347863|EXPERIMENTAL|Experimental group|Group swallowing disorder diet preparation program
62802795|NCT04347863|NO_INTERVENTION|Control group|No Intervention
62028333|NCT03425149|EXPERIMENTAL|Treatment Group I|0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.5 ml Placebo on Day 7
62802796|NCT06134219|EXPERIMENTAL|Intervention|Mental Fatigue course + Usual care in clinical care
62028334|NCT03425149|EXPERIMENTAL|Treatment Group II|0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.5 ml Placebo on Day 28
62590413|NCT02406079|EXPERIMENTAL|tracheotomy|
62028335|NCT03425149|EXPERIMENTAL|Treatment Group III|0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.25 ml Placebo on Day 7
62028336|NCT03425149|EXPERIMENTAL|Treatment Group IV|0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.25 ml Placebo on Day 28
62028337|NCT03425149|PLACEBO_COMPARATOR|Treatment Group V|0.5 ml Placebo on Day 0, 7 and 28
62028338|NCT06130059|EXPERIMENTAL|Low dose colchicine|Low dose colchicine 0.5 mg once a day orally for 3 months
62028339|NCT06130059|PLACEBO_COMPARATOR|Placebo|Placebo once a day orally for 3 months
62028340|NCT06635265|EXPERIMENTAL|Target stimulation|Stimulation of a combination of targets: Hypoglossal nerve (HGN) and Ansa Cervicalis (AC), Genioglossus (GG) and AC, HGN and strap muscles, or GG and strap muscles, during an acute and sub-acute phase.
62028341|NCT04942106|OTHER|Side-lying position followed by Supine position|In this arm, infants will be bottle-fed in the side-lying position first followed by the supine position.
62028342|NCT04942106|OTHER|Supine position followed by Side-lying position|In this arm, infants will be bottle-fed in the supine position first followed by the side-lying position.
62590414|NCT03528369|EXPERIMENTAL|CGS-200-1|CGS-200-1 (1% Capsaicin content), a topical analgesic liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
62802797|NCT06134219|ACTIVE_COMPARATOR|Control Group|Usual care in clinical care
62802798|NCT05354908||Colombian research groups in surgery|Colombian research groups in surgery
62802799|NCT05051579|EXPERIMENTAL|12 milligram (mg) LY3502970|Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
62802800|NCT05051579|EXPERIMENTAL|24 mg LY3502970|Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
62802801|NCT05051579|EXPERIMENTAL|36 mg-1 LY3502970|Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
62802802|NCT05051579|EXPERIMENTAL|36 mg-2 LY3502970|Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
62028343|NCT00093769|EXPERIMENTAL|bortezomib + rituximab|"Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.~Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients in either arm may crossover to the other arm if treatment is found to be ineffective."
62028344|NCT06322472|EXPERIMENTAL|23 children with cochlear implants|The children with cochlear implants was applied The Early Childhood Phonological Sensitivity Scale and The Turkish Early Language Development Test.
62028345|NCT06322472|OTHER|23 parents|Demographic Questionaries, Family Literacy Scale and ELHES were applied to the families of the participants
62028346|NCT05797285|EXPERIMENTAL|Weekly Human Keratin Graft Application|Patients randomized into this arm will receive standard of care (offloading, debridement, and three-layer outer dressing) with the test material, the human keratin graft, reapplied weekly to the target wound.
62028347|NCT05797285|EXPERIMENTAL|Bi-Weekly Human Keratin Graft Application|Patients randomized into this arm will receive standard of care (offloading, debridement, and three-layer outer dressing) with the test material, the human keratin graft, reapplied every other week to the target wound.
62028348|NCT04980053|EXPERIMENTAL|Back Massage|"Back massage will be initiated in the first 2 hours after birth and it will be performed every 6 hours for 15 minutes until the mother is discharged from the hospital. After the mother's outfits are removed and the mother is situated in a suitable position, the back of the mother will be massaged by euphlorage, petrissage, friction methods. Then, the participants breast will be milked by hand every 3 hours and will be measured in the breast milk storage bag and delivered to the baby nurses until the 5th-7th day."
62028349|NCT04980053|EXPERIMENTAL|Breast Massage|Breast massage will be initiated in the first 2 hours after delivery and it will be practised every 6 hours until being discharged. After the researcher washes her hands, the participant's outfits are removed and she is situated in a sitting position, the massage will be practised on both breasts for 10 minutes by the researcher herself. After the mother's breast will be milked by hand every 3 hours and the milk obtained from the breast will be measured in the breast milk storage bag and delivered to the baby nurses.
62590415|NCT03528369|EXPERIMENTAL|CGS-200-5|CGS-200-5 (5% Capsaicin content), a topical analgesic liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
62590416|NCT03528369|SHAM_COMPARATOR|CGS-200 Vehicle|CGS-200 Vehicle (no Capsaicin), a topical liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
62028350|NCT04980053|NO_INTERVENTION|Control Group|No intervention will be made to the control group, standard hospital procedures will be applied and the relevant forms will be filled out. Until the mother is discharged from the hospital, the amount of milk obtained from the mother will be measured every 3 hours by the researcher.
62590417|NCT05196867|EXPERIMENTAL|Arm 1: Immediate Intervention|participants will receive the 6 months intervention immediately
62590418|NCT05196867|EXPERIMENTAL|Arm 2: Delayed Intervention|participants will receive the intervention after the 6-month follow-up visit
62590419|NCT01704690|EXPERIMENTAL|S-1 and Paclitaxel|Patients in these arm will receive combination treatment of S-1 and paclitaxel. S-1, 80-120mg po, bid, from day 1 to day 14 Paclitaxel, 175mg/m2, IV infusion on day 1 Repeated every 21 days
62802803|NCT05051579|EXPERIMENTAL|45 mg-1 LY3502970|Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
62227276|NCT05979454||Rheumatoid Arthritis-associated Interstitial Lung Disease|Krebs von den Lungen-6 (KL6)
62227277|NCT03111251|EXPERIMENTAL|Provider-only intervention|New provider- and system-level evidence-based strategies for increasing HPV vaccination rates are being implemented throughout the entire clinic network. This includes provider assessment and feedback, provider reminders, provider education, and patient reminders.
62590420|NCT01704690|ACTIVE_COMPARATOR|Paclitaxel and Cisplatin|"Patients in these arm will receive combination treatment of paclitaxel and cisplatin.~Paclitaxel, 175mg/m2, IV infusion on day 1 Cisplatin, 30 mg/m2, IV infusion on day 1 and day 2 Repeated every 21 days"
62802804|NCT05051579|EXPERIMENTAL|45 mg-2 LY3502970|Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
62802805|NCT05051579|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered orally once daily until 36 weeks.
62802806|NCT00974753|PLACEBO_COMPARATOR|PPV-MP + Placebo (Saline drops)|PPV-MP= pars plana vitrectomy membrane peel
62802807|NCT00974753|ACTIVE_COMPARATOR|PPV-MP + Ketorolac 0.5%|PPV-MP= pars plana vitrectomy membrane peel
62802808|NCT00974753|PLACEBO_COMPARATOR|PhacoVit-MP + Placebo (Saline drops)|PhacoVit-MP= phacovitrectomy membrane peel
62802809|NCT00974753|ACTIVE_COMPARATOR|PhacoVit-MP + Ketorolac 0.5%.|PhacoVit-MP= phacovitrectomy membrane peel
62802810|NCT03946748|EXPERIMENTAL|REGN3918|"Cohort A (Dose Confirmation) If a decision is made to expand Cohort A, patients will be assigned to Cohort A.~Cohort B (Dose Expansion) If a decision is made to progress to Cohort B, patients will be assigned to Cohort B."
62802811|NCT02836652|EXPERIMENTAL|Treatment Arm|Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + placebo (1 pill/day) post HeartMate II implant
62802812|NCT02836652|ACTIVE_COMPARATOR|Control Arm|Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + acetylsalicylic acid (ASA) therapy (81mg/day) post HeartMate II implant
62802813|NCT02098330|ACTIVE_COMPARATOR|: Ginkgo biloba & methylprednisolone|Patients receive Ginkgo biloba \& methylprednisolone per oral.
62802814|NCT02098330|PLACEBO_COMPARATOR|Ginkgo biloba|Patients receive Ginkgo biloba per oral.
62227278|NCT03111251|EXPERIMENTAL|Provider plus parent intervention|Clinics randomized to the provider plus parent intervention will receive both the provider intervention and the parent education intervention.
62590421|NCT01704690|ACTIVE_COMPARATOR|5-FU and Cisplatin|Patients in these arm will receive combination treatment of 5-FU and cisplatin. 5-FU, 2500mg/m2, continue iv infusion for 120 hours Cisplatin, 35 mg/m2, IV infusion on day 1 and day 2 Repeated every 21 days
62028351|NCT06220448||BAGI|patients suffering from thoraco-abdominal blunt trauma with and without blunt adrenal gland injury
62590422|NCT00672581|EXPERIMENTAL|1|Control (healthy volunteers)
62590423|NCT00672581|EXPERIMENTAL|2|Mild Hepatic Impairment
62590424|NCT00672581|EXPERIMENTAL|3|Moderate Hepatic Impairment
62590425|NCT00672581|EXPERIMENTAL|4|Severe Hepatic Impairment
62590426|NCT04809740|OTHER|Patient Group|7,500 Patients from UAB/MCI
62028352|NCT03722160|OTHER|Solo Tympanostomy Tube Device|The Solo Tympanostomy Tube Device is a disposable surgical tool designed to deliver a tympanostomy tube (grommet) into the tympanic membrane of patients undergoing a tympanostomy tube placement procedure
62028353|NCT04471818|EXPERIMENTAL|Ketamine|Patients allocated to the ketamine arm will receive 0.5 mg/kg of ketamine every week administered intravenously for 4 weeks.
62028354|NCT04471818|PLACEBO_COMPARATOR|Placebo|Patients allocated to the ketamine arm will receive 0.5 mg/kg of ketamine every week administered intravenously for 4 weeks.
62227279|NCT04160767|ACTIVE_COMPARATOR|Probiotic|
62227280|NCT04160767|PLACEBO_COMPARATOR|Placebo|
62227281|NCT05882097|EXPERIMENTAL|Treatment arm receiving the Transform program|"Transform: Participants will receive ICM's Transform program.~In the treatment arm, the full 15-session Transform program will be delivered once a week for 15 consecutive weeks in a venue located within the community. In each session, there will be 90 minutes lessons on livelihood and health delivered by trained ICM staff. Separately, a voluntary values lesson will be delivered by the host community leader."
62227282|NCT05882097|NO_INTERVENTION|Control arm receiving no Transform program|Control: Participants will not receive any intervention during the study period.
62227283|NCT03794167|EXPERIMENTAL|busulfan cyclophosphamide etoposide|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6, cyclophosphamide 50mg/kg/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4
62227284|NCT03794167|ACTIVE_COMPARATOR|busulfan melphalan etoposide|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6 melphalan 50mg/m2/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4
62590427|NCT04535531|EXPERIMENTAL|SB206 10.3% berdazimer|SB206 10.3% berdazimer topically once daily
62590428|NCT04535531|PLACEBO_COMPARATOR|vehicle gel|Vehicle gel topically once daily
62590429|NCT05484440|EXPERIMENTAL|Group cognitive-behavioral intervention plus individual Motivational Interviewing|Group participants will participate in six individual sessions based on Motivational Interviewing techniques (60 minutes each) and then in 18 group sessions based on psychoeducational and cognitive-behavioral techniques (90 to 120 minutes each). Groups will be composed of 6 to 10 participants. The intervention will be delivered weekly.
62590430|NCT05484440|EXPERIMENTAL|Group cognitive-behavioral intervention|Group participants will participate in 18 group sessions based on psychoeducational and cognitive-behavioral techniques (90 to 120 minutes each). Groups will be composed of 6 to 10 participants. The intervention will be delivered weekly.
62590431|NCT05484440|NO_INTERVENTION|Treatment as usual (TAU)|Group participants will receive the usual treatment delivered by different institutions (e.g., correctional services, probation services, child protection services) as the participants of this study are justice-involved individuals (i.e., perpetrators of intimate partner violence).
62590432|NCT05522205|EXPERIMENTAL|Experimental group|Immediately regulated cannabis access in pharmacies.
62028355|NCT01793064|EXPERIMENTAL|Adaptive Intervention Group (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
62028356|NCT01793064|ACTIVE_COMPARATOR|Static Intervention group (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
62028357|NCT00974857|ACTIVE_COMPARATOR|Study group|"Pre-dialytic overhydration(OH) will be estimated by Body Composition Monitor (BCM) at least once a month.~1. If OH is positive, dry weight will be reached by ultrafiltration without regard to the level of blood pressure.~2. If OH is negative and:~   * Systolic blood pressure(SBP)\< 100 mmHg with/or intradialytic hypotension episodes(IDHE) and/or clothing and/or erythrocytosis(htc\>36%);dry weight will be increased.~  * SBP normal(100-150 mmHg) w/o IDHE and clothing and erythrocytosis;dry weight will not be changed.~  * SBP normal(100-150 mmHg) with IDHE and/or clothing and/or erythrocytosis;dry weight will be increased.~  * SBP\>150 mmHg captopril test(CT)will be done. If CT is positive, ACEI/ ARBs will be used and dry weight will be increased if IDHE and/or clothing and/or erythrocytosis(htc\>36%) are present.~If CT is negative, BCM measurement will be repeated and if same,ABPM will be performed for confirmation."
62028358|NCT00974857|OTHER|Control Group|BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
62028359|NCT05585424|EXPERIMENTAL|Experimental Group|Patients in the experimental group were paired so that each patient with MCI faced a patient with ModCI. During the sessions, two therapists performed the upper limb activities that only the MCI patients could see and they performed them by imitation
62028360|NCT05585424|NO_INTERVENTION|Control group|The CG was assessed at baseline and after one month and continued with their usual activities in the nursing home.
62227285|NCT00420433||1|Patients with breast cancer that has spread to the bones.
62227286|NCT03363763|ACTIVE_COMPARATOR|Arm 1|Sirolimus 0.2% ointment applied topically hs x 12 weeks
62227287|NCT03363763|ACTIVE_COMPARATOR|Arm 2|Sirolimus 0.4% ointment applied topically hs x 12 weeks
62227288|NCT03363763|PLACEBO_COMPARATOR|Arm 3|Placebo ointment applied topically hs x 12 weeks
62227289|NCT04464954|EXPERIMENTAL|Auricular semi-permanent (ASP gold) needles|
62590433|NCT05522205|NO_INTERVENTION|Control group|During the first six months participants of the control group have to continue to buy their cannabis on the illicit market. Afterthese six months they also have access to regulated cannabis access.
62590434|NCT01388244|ACTIVE_COMPARATOR|Screening|Two-step screening process using FRAX risk score assessment followed by DXA scanning for high risk participants.
62590435|NCT01388244|OTHER|Control|Control arm - Fracture risk assessment by FRAX without any intervention
62590436|NCT01447082||Quetiapine XR group|
62028361|NCT00550225|EXPERIMENTAL|Sequence 1|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by placebo in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and 1500 micrograms of GSK961081 edisylate in session 4.
62028362|NCT00550225|EXPERIMENTAL|Sequence 2|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by 1500 micrograms of GSK961081 edisylate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and placebo in session 4.
62028363|NCT00550225|EXPERIMENTAL|Sequence 3|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by placebo in session 2. The subjects will receive 1500 micrograms of GSK961081edisylate in session 3 and an additional dose of GSK961081 succinate in session 4.
62590437|NCT01447082||Non-quetiapine comparison group|
62227290|NCT04464954|EXPERIMENTAL|Intradermal (long) needles using J-type No. 2 (.18)x 15mm|
62227291|NCT04464954|EXPERIMENTAL|Pyonex needles (Seirin Yellow 0.2 x 0.6mm)|
62227292|NCT04398953|EXPERIMENTAL|TQ-B3525 tablet|TQ-B3525 tablet administered orally.
62227293|NCT00582686|ACTIVE_COMPARATOR|ORIF with Bone Grafting|This study will be designed as a randomized, prospective, blinded evaluation of patients who have sustained an intra-articular calcaneous fracture that would require open reduction with internal fixation as the preferred method of treatment. Group A will be made up of patients that undergo ORIF and Tricortical iliac crest bone grafting.
62227294|NCT00582686|ACTIVE_COMPARATOR|ORIF without Bone Grafting|This study will be designed as a randomized, prospective, blinded evaluation of patients who have sustained an intra-articular calcaneous fracture that would require open reduction with internal fixation as the preferred method of treatment. Group B will consist of patients that undergo open reduction with internal fixation without bone grafting
62802815|NCT02459119|EXPERIMENTAL|Regorafenib|Regorafenib will be administered orally to all patients on study. The drug will be taken once a day for 3 of every 4 week cycle (3 weeks on/1 week off). The dose is 120 mg once daily for the first cycle, then 160 mg once daily from the second cycle if no significant Regorafenib-associated toxicities occur during the first cycle. Drug dosage may be modified if toxicities occur. Patients will undergo up to 4 cycles of treatment and may continue on additional at the discretion of the investigator.
62028364|NCT00550225|EXPERIMENTAL|Sequence 4|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by 1500 micrograms of GSK961081 edisylate in session 2. The subjects will receive placebo in session 3 and an additional dose of GSK961081 succinate in session 4.
62227295|NCT04261491|EXPERIMENTAL|postmenopausal women with chronic periodontitis|postmenopausal women with chronic periodontitis will be evaluated after SRP for serum bone resorption markers- CTX and inflammatory markers IL-6
62590438|NCT05566574|EXPERIMENTAL|RP-3500 in Combination With Standard Radiation Therapy|Patients with metastatic cancers with identified mutations in ATM will be enrolled. All patients will receive a standard palliative RT (4Gy x 5 fractions) on Days 1-5 in combination with RP-3500 on Days 1-5. In the first phase of the study, a 3+3 study design will be used to identify a safe dose of RP-3500 (starting at 80 mg QD) in combination with palliative RT.
62420100|NCT02233465|EXPERIMENTAL|IPOM Mesh-repair parastomal hernia|Mesh-repair of para-stomal hernia. Patients with para-stomal hernia requiring surgery are offererd enrollment in the study. Preoperatively a CT-scan of the abdomen and or a 3D ultrasonography of the stoma is performed. All patients in the stydy are operated with IPOM-mesh designed for treatment of parastomal hernia.
62590439|NCT05566574|EXPERIMENTAL|Pilot subcohort|The primary objective is to assess 6 month local control rate of patients of new metastatic lesions with pathogenic ATM who haves received prior RP-3500 and palliative RT.
62028365|NCT00550225|EXPERIMENTAL|Sequence 5|In session 1, subjects will receive 1500 micrograms of GSK961081 edisylate followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and placebo in session 4.
62227296|NCT02057523|EXPERIMENTAL|Acthar|Acthar 80 units twice weekly for 6 months. If endpoint is not reached, duration may be increased to 12 months.
62420101|NCT02233465|NO_INTERVENTION|No mesh-repair|Patients not attending the study
62590440|NCT03109665||Glaucoma within NICOLA|NICOLA study Participants Eligible for GwNICOLA by meeting inclusion criteria
62590441|NCT04293029|EXPERIMENTAL|Normal liver function|Patients will receive single dose of SHR0302
62590442|NCT04293029|EXPERIMENTAL|Mild Hepatic Impairment|Patients will receive single dose of SHR0302
62590443|NCT04293029|EXPERIMENTAL|Moderate Hepatic Impairment|Patients will receive single dose of SHR0302
62802816|NCT02848963|ACTIVE_COMPARATOR|ketamine-propofol mixture 5/1|Ketamine-propofol mixture will be compare for every groups.
62802817|NCT02848963|ACTIVE_COMPARATOR|ketamine-propofol mixture 10/1|Ketamine-propofol mixture will be compare for every groups.
62802818|NCT02848963|ACTIVE_COMPARATOR|Ketamine-propofol mixture 6,7/1|Ketamine-propofol mixture will be compare for every groups
62802819|NCT04388683|EXPERIMENTAL|Intervention|Will receive study drug treatment.
62802820|NCT04388683|NO_INTERVENTION|Control|Will receive standard of care.
62028366|NCT00550225|EXPERIMENTAL|Sequence 6|In session 1, subjects will receive placebo followed by 900 micrograms of GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and 1500 micrograms of GSK961081 edisylate in session 4.
62227297|NCT02683005|EXPERIMENTAL|Ledipasvir/Sofosbuvir|Hepatitis C treatment will be initiated with ledipasvir (400 mg) and sofosbuvir (90mg) fixed dose combination, one pill, once daily for 12 weeks.
62243081|NCT02597803|PLACEBO_COMPARATOR|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
62243082|NCT02597803|EXPERIMENTAL|Low Dose RGN-259|Low dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
62420102|NCT02258399|ACTIVE_COMPARATOR|Breakfast Rest|
62802821|NCT02018341|EXPERIMENTAL|homeopathic remedy in 30C potency|5 lactose globules containing a commonly used homeopathic remedy in the potency of 30C will be administered twice daily for 3 days
62802822|NCT02018341|PLACEBO_COMPARATOR|placebo|5 lactose globules without any homeopathic remedy will be administered twice daily for 3 days
62420103|NCT02258399|ACTIVE_COMPARATOR|Breakfast Exercise|
62420104|NCT02258399|EXPERIMENTAL|Fasted Exercise|
62420105|NCT05705531||Observational (blood samples, surveys, MRI, record review)|Patients undergo collection of blood samples, complete surveys, and undergo cardiac MRI on study. Patients also have their medical records reviewed.
62802823|NCT00350571|ACTIVE_COMPARATOR|Standard care follow up|Standard care counselor follow up care phone calls or letters.
62802824|NCT00350571|EXPERIMENTAL|Drop out reengagement motivational intervention|Single session office based or phone based motivational counseling session designed to promote participant re-engagement in standard treatment.
62028367|NCT00550225|EXPERIMENTAL|Sequence 7|In session 1, subjects will receive 1500 micrograms of GSK961081 edisylate followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive placebo in session 3 and an additional dose of GSK961081 succinate in session 4.
62028368|NCT00550225|EXPERIMENTAL|Sequence 8|In session 1, subjects will receive placebo followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 edisylate in session 3 and an additional dose of GSK961081 succinate in session 4.
62028369|NCT02014857||Periodonatlly healthy smokers|Gingival crevicular fluid sampling
62028370|NCT02014857||Periodontally healhty non-smokers|Gingival crevicular fluid sampling
62028371|NCT04618354||LADA group|The patient was diagnosed with late-onset autoimmune diabetes (LADA).
62028372|NCT04618354||T2DM group|The patient was diagnosed with type 2 diabetes (T2DM).
62028373|NCT04618354||T1DM group|The patient was diagnosed with type 1 diabetes (T1DM).
62420106|NCT06702969|ACTIVE_COMPARATOR|Digital impression with intraoral scanner|included seven participants with non-restorable tooth in esthetic zone replaced by immediate implants receiving a single all ceramic crown fabricated with full digital procedure consisting of digital impression with intraoral scanner, and Computer Aided Design/ Computer Aided Manufacture (CAD/CAM) procedure.
62420107|NCT06702969|ACTIVE_COMPARATOR|conventional impression technique|included seven participants with non-restorable tooth in esthetic zone replaced by immediate implants receiving a single all ceramic crown fabricated with Conventional impression-taking with polyvinyl siloxane, plaster model pouring and lost-wax casting technique
62420108|NCT04982718|EXPERIMENTAL|Oral fluid-based HCV ST|In the intervention group, participants will receive a HCV self-test (ST) kit delivered in non-identifiable packaging to their home or a preferred mailing address. The kit will include the test, instructions for use, and information about additional supporting materials, such as access to live chat and a call center for questions about testing. In order to evaluate two sampling methods for HCV self-testing, the first 250 participants in the intervention group will receive an oral fluid-based HCV ST.
62420109|NCT04982718|EXPERIMENTAL|Blood-based HCV ST|In the intervention group, participants will receive a HCV self-test (ST) kit delivered in non-identifiable packaging to their home or a preferred mailing address. The kit will include the test, instructions for use, and information about additional supporting materials, such as access to live chat and a call center for questions about testing. In order to evaluate two sampling methods for HCV self-testing, the next 250 participants will receive a blood-based fingerstick HCV ST.
62420110|NCT04982718|NO_INTERVENTION|Control standard of care|In the control group, participants will receive information about standard of care HCV antibody testing available at local testing sites in their community and information about additional supporting materials, such as access to live chat and a call center for questions about testing.
62420111|NCT02314949||intestinal transplantation|all performed intestinal transplants underwent the same Leuven intestinal transplant protocol
62420112|NCT06257966|EXPERIMENTAL|Exendin-4 Fc fusion protein injection(1.2mg）+Metformin|1.2mg,Subcutaneous injection in the abdomen,Bi-weekly for 54 weeks.
62420113|NCT06257966|EXPERIMENTAL|Exendin-4 Fc fusion protein injection(2.4mg）+Metformin|The first dose of 1.2 mg of JY09 injection was administered, the dose was adjusted to 2.4 mg after two weeks, after which 2.4 mg was maintained to continue subcutaneous injection in the abdomen, bi-weekly treatment for 52 weeks.
62420114|NCT06257966|ACTIVE_COMPARATOR|Dulaglutide+Metformin|1.5 mg dulaglutide injection subcutaneously once a week for 26 weeks.
62590444|NCT04245540|EXPERIMENTAL|Active|1,050 mg per day of encapsulated Pau d' Arco taken orally for 2 months.
62028374|NCT06046573|EXPERIMENTAL|Internet-delivered psychological treatment, arm #1|Support and information + Behavioral activation
62028375|NCT06046573|EXPERIMENTAL|Internet-delivered psychological treatment, arm #2|Support and information + Systematic exposure with mindfulness training
62028376|NCT06046573|EXPERIMENTAL|Internet-delivered psychological treatment, arm #3|Support and information + Promotion of health behaviors
62227298|NCT05065333|EXPERIMENTAL|Septic Shock Clinical Decision Support|Emergency Department sites in this arm will have Clinical Decision Support (CDS) alerts active in the Electronic Health Record during clinical ED care of patients with suspected sepsis, in addition to following usual institutional standard of care for sepsis. The CDS will alert providers to patients at high risk for developing septic shock.
62028377|NCT06046573|EXPERIMENTAL|Internet-delivered psychological treatment, arm #4|Support and information + Behavioral activation + Systematic exposure with mindfulness training
62028378|NCT06046573|EXPERIMENTAL|Internet-delivered psychological treatment, arm #5|Support and information + Behavioral activation + Promotion of health behaviors
62028379|NCT06046573|EXPERIMENTAL|Internet-delivered psychological treatment, arm #6|Support and information + Systematic exposure with mindfulness training + Promotion of health behaviors
62028380|NCT06046573|EXPERIMENTAL|Internet-delivered psychological treatment, arm #7|Support and information + Behavioral activation + Systematic exposure with mindfulness training + Promotion of health behaviors
62028381|NCT06046573|EXPERIMENTAL|Internet-delivered psychological treatment, arm #8|Support and information
62028382|NCT03537924|ACTIVE_COMPARATOR|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
62028383|NCT03537924|PLACEBO_COMPARATOR|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
62420115|NCT06356038|EXPERIMENTAL|Group A (phrenic nerve infiltration)|Patients received intra-operative phrenic nerve infiltration with local anesthetic
62420116|NCT06356038|NO_INTERVENTION|Group B (no phrenic nerve infiltration)|Patients did not receive intra-operative infiltration
62420117|NCT06673550|EXPERIMENTAL|Fluid filled intragastric balloon at a volume of 500 ml|This arm will undergo a fluid-filled intragastric balloon palcement at a volume of 500 ml
62420118|NCT06673550|EXPERIMENTAL|Fluid filled intragastric balloon at a volume of 600 ml|This arm will undergo a fluid-filled intragastric balloon palcement at a volume of 600 ml
62028384|NCT04287049|EXPERIMENTAL|14 Day Azithromycin Monotherapy|For the first 14 days of therapy, participants will receive Azithromycin 250mg PO daily as monotherapy. Beyond day 14, all participants will receive guideline-based standard multi-drug therapy for Mycobacterium avium lung disease, as dictated by the physicians treating the participants.
62420119|NCT06673550|EXPERIMENTAL|Fluid filled intragastric balloon at a volume of 700 ml|This arm will undergo a fluid-filled intragastric balloon palcement at a volume of 700 ml
62028385|NCT01634698|EXPERIMENTAL|RDR test (1500 UI vitamin A)|81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 1500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).
62802825|NCT01454596|EXPERIMENTAL|1/Phase I Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of epidermal growth factor receptor (EGFRv)III Chimeric antigen receptor (CAR) transduced peripheral blood lymphocytes (PBL) + aldesleukin
62028386|NCT01634698|EXPERIMENTAL|RDR test (2500 IU vitamin A)|81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 2500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).
62028387|NCT04433767|EXPERIMENTAL|Transdermal Nicotine Patch|Participants will wear open label transdermal nicotine patch daily for 12-15 weeks. They will apply study patch each morning and remove at bedtime. Dosage will begin at 3.5mg patch / day, increasing to a possible maximum of 21mg patch / day.
62028388|NCT00706121|EXPERIMENTAL|Vitamin E + selenium placebo|Vitamin E and selenium placebo daily for 7 - 12 years
62420120|NCT06701981|EXPERIMENTAL|Glare discomfort measures with filters|
62420121|NCT05413850|EXPERIMENTAL|Phase 1, Cohort A|Subjects with PSMA positive disease will receive 5.55GBq of 177Lu-rhPSMA-10.1 (maximum of 3 cycles).
62802826|NCT01454596|EXPERIMENTAL|2/Phase II Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + maximum tolerated dose (MTD) of anti-EGFRvIII CAR transduced PBL established in Phase I + aldesleukin
62802827|NCT01429493|ACTIVE_COMPARATOR|Conventional radiotherapy|
62802828|NCT01429493|EXPERIMENTAL|Biological image-guided radiotherapy with conventional dose.|
62802829|NCT01429493|EXPERIMENTAL|Biological image-guided SBRT with dose-escalation.|
62802830|NCT03169166|EXPERIMENTAL|"Repeated 3-dose GnRHa  Triptorelin"|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart (0.3/0.2/0.2mg) when at least three follicles 18 mm in diameter have been observed by ultrasound examination.
62802831|NCT03169166|NO_INTERVENTION|"Conventional 1-dose GnRHa  Triptorelin"|Triptorelin pre-filled syringes will be administered subcutaneously in a single dose (0.3 mg) when at least three follicles 18 mm in diameter have been observed by ultrasound examination.
62028389|NCT00706121|EXPERIMENTAL|Selenium + vitamin E placebo|Selenium and vitamin E placebo daily for 7 - 12 years
62028390|NCT00706121|EXPERIMENTAL|Vitamin E + selenium|Vitamin E and selenium daily for 7 - 12 years
62802832|NCT00128895|ACTIVE_COMPARATOR|azathioprine, standard|standard azathioprine maintenance upto one year after diagnosis, subsequently tapering of azathioprine with 25 mg per 3 months
62028391|NCT00706121|PLACEBO_COMPARATOR|Vitamin E placebo + selenium placebo|Vitamin E placebo and selenium placebo daily for 7 - 12 years
62227299|NCT05065333|ACTIVE_COMPARATOR|Clinical Diagnosis Only|Emergency Department sites in this arm will follow the institutional standard for sepsis care without Clinical Decision Support. Standard care includes clinical diagnosis of sepsis supported by institutional sepsis education, a sepsis pathway and orderset.
62420122|NCT05413850|EXPERIMENTAL|Phase 1, Cohort B|Subjects with PSMA positive disease will receive 7.4GBq of 177Lu-rhPSMA-10.1 (maximum of 3 cycles).
62420123|NCT05413850|EXPERIMENTAL|Phase 2, Cohort 1, post-chemotherapy mCRPC|Subjects with PSMA positive disease will receive up to 6 cycles of the Therapeutic IMP at the Recommended Phase 2 dose \[RP2D\]
62420124|NCT05413850|EXPERIMENTAL|Phase 2, Cohort 2, Taxane-naïve mCRPC|Subjects with PSMA positive disease will receive up to 6 cycles of the Therapeutic IMP at the Recommended Phase 2 dose \[RP2D\] .
62420125|NCT06236165|NO_INTERVENTION|Control arm|22 patients who will receive supportive treatment for jaundice only, for 3 months.
62420126|NCT06236165|EXPERIMENTAL|NAC arm|22 patients who will receive oral N-acetylcysteine 600 mg twice daily in addition to supportive treatment, for 3 months.
62420127|NCT06236165|EXPERIMENTAL|PTX arm|22 patients who will receive oral Pentoxifylline 400 mg twice daily in addition to supportive treatment, for 3 months.
62227300|NCT00284986|EXPERIMENTAL|Prochymal®|
62227301|NCT00235547|ACTIVE_COMPARATOR|contraception-Immediate start|contraception after abortion and before leaving the clinic, observed by clinic staff
62802833|NCT00128895|EXPERIMENTAL|azathioprine, longterm|longterm maintenance with azathioprine upto four years after diagnosis, subsequently azathioprine will be tapered with 25 mg per 3 months
62802834|NCT06027203||transrectal biopsy|
62227302|NCT00235547|ACTIVE_COMPARATOR|Contraception-Delayed start|instructed to begin contraception the first Sunday after leaving the clinic
62227303|NCT05102604|ACTIVE_COMPARATOR|Avocado|one avocado per day
62420128|NCT05312255|EXPERIMENTAL|Module A (strength training, behavioral intervention)|Patients undergo strength training sessions twice weekly supervised by a licensed and specialized personal trainer via the internet (e.g., remote access) for 6 months. Patients also wear a FitBit device and receive prompts via email or text on a cell phone or other electronic device to incrementally increase physical activity over 6 months.
62420129|NCT05312255|EXPERIMENTAL|Module B (intermittent fasting)|Patients undergo intermittent fasting for 1 month. This consists of restricting all eating to a consecutive 8-hour time period each day followed by 16 consecutive hours of not eating.
62420130|NCT05312255|EXPERIMENTAL|Module C Group I (propranolol)|Patients receive propranolol PO BID for 3 months.
62420131|NCT05312255|ACTIVE_COMPARATOR|Module C Group II (propranolol)|Patients continue receiving beta-blocker regimen as per SOC for 3 months.
62420132|NCT05312255|EXPERIMENTAL|Module D|MDS Patients undergo strength training for 6 months.
62802835|NCT06027203||transperineal biopsy|
62802836|NCT04376216|NO_INTERVENTION|Control|No treatment
62028392|NCT03727191|ACTIVE_COMPARATOR|Control Group|Nutritional education, guidelines for the consumption of a completed shreded diet and recommendations for physical activity.
62028393|NCT03727191|EXPERIMENTAL|Experimental Group|Nutritional education and guidelines for the consumption of a completed shreded diet including: 2 packets of 90 grams every day (One salted packet for lunch/dinner and one sweet packet for breakfast/afternoon snack) and recommendations for physical activity for one month.
62227304|NCT05102604|PLACEBO_COMPARATOR|Habitual Diet|maintain habitual diet
62227305|NCT00947557|ACTIVE_COMPARATOR|Dutogliptin|Dutogliptin
62802837|NCT04376216|ACTIVE_COMPARATOR|Prednisone|Oral prednisone. Starting dose of 60 mg with tapering for 2 months
62802838|NCT01594931|EXPERIMENTAL|pyronaridine/artesunate (6:2 mg/kg)|pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg
62802839|NCT01594931|EXPERIMENTAL|pyronaridine/artesunate (9:3 mg/kg)|pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg
62802840|NCT01594931|EXPERIMENTAL|pyronaridine/artesunate (12:4 mg/kg)|pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg
62590445|NCT06462950|EXPERIMENTAL|Ostracism|Ostracism is manipulated by randomly assigning people to the inclusion condition (they play an online ball tossing game and get the ball passed a third of the time) or exclusion condition (they get the ball passed twice in the beginning of the game and then not again).
62227306|NCT00947557|PLACEBO_COMPARATOR|Placebo|Placebo
62227307|NCT02801968|EXPERIMENTAL|Tap block|Tap block with ropivacaine 2 mg/kg at the end of cesarean delivery. Postoperative analgesia with acetaminophen and tramadol plus NSAIDs (nonsteroidal anti-inflammatory drugs) as rescue dose.
62227308|NCT02801968|ACTIVE_COMPARATOR|control group|Postoperative analgesia after cesarean delivery with acetaminophen and tramadol plus NSAIDs (nonsteroidal anti-inflammatory drugs) as rescue dose.
62420133|NCT03713294|EXPERIMENTAL|Treatment (dexamethasone, elotuzumab, pomalidomide)|Patients receive dexamethasone IV on days 1, 8, 15, and 22 of cycles 1-2 and IV on day 1 and PO on days 8, 15, and 22 of subsequent cycles and elotuzumab IV on days 1, 8, 15, and 22 of cycles 1-2 and day 1 of subsequent cycles. Patients also receive pomalidomide PO on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62227309|NCT03457038|EXPERIMENTAL|Patient with Septic Shock|Patient Hospitalized in Intensive Care Unit for sepsis of any etiology. The number of follow-up visits will not be changed compared to usual patient follow-up hospitalized in the intensive care unit but there will be blood testing more frequently
62420134|NCT03403712|EXPERIMENTAL|Test group|"intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination, administered as a 30-minute infusion of a 50 mL solution, on Day 1 of each cycle.~Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)"
62420135|NCT03403712|ACTIVE_COMPARATOR|Control group|"oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.~Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)"
62420136|NCT05904769|EXPERIMENTAL|Hospitalized Diabetic Group|Subjects hospitalized and diabetic on insulin, undergoing four times daily blood sugar checks, will wear the LIFELEAF Smartwatch for the duration of their hospital stay.
62802841|NCT00088140|PLACEBO_COMPARATOR|Placebo|
62802842|NCT00088140|ACTIVE_COMPARATOR|IDN-6556 5 mg twice a day (BID)|
62227310|NCT05872360|ACTIVE_COMPARATOR|Bundle Group 1 with Nutrilite Lifestyle|"Amway All-plant protein booster: 450g/bottle, containing the following active ingredients and with the guideline of Nutrilite Lifestyle:~* All-plant protein~* Peptide~* HA (hyaluronicacid)~* Calcium~* Magnesium~* Glucosamine~Facility: EMS (electric muscle stimulation)~Nutrition Guideline: Nutrilite Lifestyle"
62227311|NCT05872360|ACTIVE_COMPARATOR|Bundle Group 2 without Nutrilite Lifestyle|"Amway All-plant protein booster: 450g/bottle, containing the following active ingredients:~* All-plant protein~* Peptide~* HA (hyaluronicacid)~* Calcium~* Magnesium~* Glucosamine~Facility: EMS (electric muscle stimulation)"
62227312|NCT05872360|PLACEBO_COMPARATOR|Control Group 1|Placebo for all-plant protein booster: 450g/bottle, containing the following ingredients: Maltodextrin
62227313|NCT05872360|PLACEBO_COMPARATOR|Control Group 2 with Nutrilite Lifestyle|"Placebo for all-plant protein booster: 450g/bottle, containing the following ingredients: Maltodextrin~Nutrition Guideline: Nutrilite Lifestyle"
62227314|NCT04876677|EXPERIMENTAL|CHF5993|Beclometasone Dipropionate (BDP) 100 μg/inhalation + Formoterol Fumarate (FF) 6 μg/inhalation + Glycopyrronium Bromide (GB) 12.5 µg/inhalation
62227315|NCT02874339|EXPERIMENTAL|Optiflow Group|High flow nasal oxygen therapy
62227316|NCT02874339|ACTIVE_COMPARATOR|NIV group|
62227317|NCT01401192|EXPERIMENTAL|TS positive cohort & Gem/Cis Tx arm|Among TS expression positive patients, some will be randomized to Gem/cis therapy
62420137|NCT05904769|EXPERIMENTAL|Electrophysiologic (EP) Group|Subjects undergoing an EP procedure will wear he LIFELEAF Smartwatch for the duration of the procedure.
62590446|NCT06462950|EXPERIMENTAL|Concealment|Concealment is manipulated by randomly assigning the participants to information that the other players did (revealed condition) or did not know (concealed condition) the gender of the participant.
62802843|NCT00088140|ACTIVE_COMPARATOR|IDN-6556 25mg twice a day (BID)|
62802844|NCT00088140|ACTIVE_COMPARATOR|IDN-6556 50 mg twice a day (BID)|
62802845|NCT03018444|EXPERIMENTAL|Atorvastatin|2 weeks treatment with Atorvastatin (1st week 40 mg once daily on day, 2nd week 80 mg (2x40mg) once daily)
62802846|NCT03018444|PLACEBO_COMPARATOR|Placebo|2 weeks treatment with placebo tablets of comparable sizes and color to the Atorvastatin tablets (1st week one tablet once daily, 2nd week two tablets once daily)
62802847|NCT02750774|EXPERIMENTAL|Low-Glycemic Index Group|Women in the low- glycaemic index group received a dietary intervention based on 3 main meals and 3 snacks, with a precise macronutrient composition, and a physical activity counseling according to the ACOG and ACSM recommendations.
62802848|NCT02750774|OTHER|Standard Care Group|Women in the Standard Care Group received a simple nutritional booklet regarding lifestyle, which was in agreement with the Italian Guidelines for a healthy diet during pregnancy that included general advice regarding food consumption and physical activity.
62802849|NCT05915845|EXPERIMENTAL|Laura Mitchell's Relaxation technique|
62802850|NCT05915845|ACTIVE_COMPARATOR|Papworth exercise|
62802851|NCT03923894|EXPERIMENTAL|Blueberry Yeast Fermentation Freeze Dying Powder Extract|Blueberry Yeast Fermentation Freeze Dying Powder Extract 2.07 g/day for 8 weeks.
62802852|NCT03923894|PLACEBO_COMPARATOR|Placebo|Placebo 2.07 g/day for 8 weeks.
62802853|NCT05355064|EXPERIMENTAL|Single arm|Single treatment, no placebo.
62802854|NCT04765514|ACTIVE_COMPARATOR|Standard Arm: TMZ with concurrent RT (combined modality arm)|"Patients will receive a total of 21 days of Temozolomide (TMZ), with 15 days of TMZ administered daily with concurrent RT. TMZ will be delivered at a dose of 75 mg/m2, given daily with RT for 15 days, one hour before each session of RT.~After a 4-week break, patients will receive six cycles of adjuvant TMZ according to the standard 5-day schedule (days 1-5) every 28 days, up to 6 cycles as tolerated by the patient. The dose will be 150 mg/m2 for the first cycle and increased to 200 mg/m2 beginning with the second cycle, so long as there are no hematologic adverse events, intractable nausea or fatigue."
62420138|NCT06410118|EXPERIMENTAL|DreamChanger combined with Imagery Rehearsal Therapy|Families will receive the DreamChanger remote along with 3 instructional videos for parents, explaining how to present the remote to children, and how to rehearse alternative dream imagery using the DreamChanger remote.
62420139|NCT06410118|NO_INTERVENTION|Waitlist control|Families will be placed on a waitlist, and receive the intervention 6 weeks after baseline
62802855|NCT04765514|EXPERIMENTAL|Biomarker based treatment|"MGMT (+) Temozolomide monotherapy: Patients will receive Temozolomide (TMZ) at a dose of 75 mg/m2 daily for 21 consecutive days. This will be followed by six cycles of TMZ according to the standard 5-day schedule (days 1-5) every 28 days. The dose will be 150 mg/m2 for the first cycle and increased to 200 mg/m2 beginning with the second cycle, so long as there are no hematologic adverse events. Dose will be determined using body surface area (BSA) calculation.~MGMT methylation (-) RT monotherapy: Participants will receive radiation treatment with 40Gy / 15 fractions over a period of 21 days (3 weeks)."
62802856|NCT05361694||Participants with MGUS or SMM|Participants with either Monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM) will be followed for disease progression to active multiple myeloma (MM) for up to 5 years.
62802857|NCT00481819|EXPERIMENTAL|1|In combination with MMF and steroids
62802858|NCT00481819|ACTIVE_COMPARATOR|2|In combination with MMF and steroids
62802859|NCT05551858|PLACEBO_COMPARATOR|Placebo|"Arm 1. Placebo for first 12 weeks. Placebo is a fiber filler called Avicel and is given by mouth three times daily.~Note: After 12 weeks on placebo, these subjects will receive proglumide 400 mg orally three times daily open labeled for 12 additional weeks."
62802860|NCT05551858|EXPERIMENTAL|Proglumide|Proglumide therapy 400 mg by mouth three times daily for 12 weeks in a blinded fashion followed by continued proglumide 400 mg by mouth three times daily for 12 additional weeks in an open labeled fashion. Hence this arm receives proglumide for a total of 24 weeks.
62590447|NCT06271707|EXPERIMENTAL|Group 1|ultrasound with bupivacaine
62028394|NCT01330797||LOCS III|Cohort is composed of cases with a diagnosis of wet age-related macular degeneration and those that received intravitreal ranibizumab
62802861|NCT02931032|EXPERIMENTAL|Patients of Student Dental clinic|"Enrolled patients of the student dental clinic in Hadassah Faculty of Dental Medicine, who came to receive scheduled dental treatment and agreed to participate in the trial.~The patients sampled will originate at the students' clinics, and the samples will be taken as part of their dental treatment, namely: removal of caries and infected dentin for future restoration, and dental calculus and plaque removal for the treatment of periodontal disease."
62028395|NCT05700682||Diagnostic|The investigators will target VA patients with clinically-ordered knee, hip and shoulder MRIs for recruitment (40 for each joint). Patients who elect to participate will undergo perfusion MRI add-on sequence at the end of their clinical MRI. Arterial-phase maximum intensity projection images from the perfusion MR data will be generated, and the presence of abnormal vascularity about each joint will be assessed by the study principal investigators. Participants who have focal or generalized peri-articular hypervascularity will be offered enrollment in the Therapeutic Arm of the study. Those participants who decline enrollment into the Therapeutic Arm, and those without significant peri-articular vascularity on perfusion MRI, will be asked to return for follow-up clinical and imaging visits so that the natural history of pain/imaging parameters in the absence of treatment can be evaluated.
62028396|NCT05700682||Therapeutic|"Of 40 participants enrolled for each joint, the investigators anticipate 20 will choose to enroll in an embolization pilot study. Participants must have peri-articular hypervascularity on perfusion MRI and must have failed at least one first line therapy for their pain to be eligible.~Embolization will be performed as an outpatient procedure under conscious sedation. Further description of this procedure is available in the study protocol and literature. Technical success will be defined as selective embolization of at least one abnormal peri-articular artery.~After embolization, participants will return for clinical follow-up at 1, 3, 6 and 12 months with perfusion MRI performed at the 3- and 12-month visits. Clinical follow-up at 3, 6 and 12 months will consist only of surveys (WOMAC/WORC). Participants will be instructed to avoid additional treatments for their joint pain when possible, and if a second treatment is initiated to report it to the study investigators."
62802862|NCT00580736|EXPERIMENTAL|Optical Clearing|Optical Clearing
62028397|NCT06534242||CRC cases|Inclusion is adult and confirmed pathological examination of newly diagnosed CRC of no specific type. Exclusion attributes that prevent a person from being included in the study were blood diseases, patients with HBV, schistosomiasis, HIV, alcohol intake, thyroid dysfunction, inflammatory diseases, diabetes mellitus, and cardiovascular disorders. Subjects receiving any chemotherapy or radiotherapy, or had undergone a GIT surgical operation, patients with blood disorder diseases, any cancer other than CRC, patients with neuronal diseases, respiratory diseases, uterine diseases, kidney diseases, cirrhosis of the liver, prolonged use of corticosteroids or sex hormones.
62028398|NCT06534242||Controls|Apparently healthy, age and sex matched, 100 volunteers, not suffering from any disease or taking any medication. Control subjects with normal kidney functions and liver enzyme levels, absence of any clinical or laboratory evidence of CRC, were recruited during routine checkup examinations for themselves or their relatives or from the Chronic Diseases Screening National Presidential Program.
62028399|NCT03400540|EXPERIMENTAL|Group A|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:~1. squeeze the pelvic floor muscles~2. squeeze and lift the pelvic floor muscles as if stopping the flow of urine~3. Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.~4. contract all of the above together"
62028400|NCT03400540|EXPERIMENTAL|Group B|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:~1. squeeze the pelvic floor muscles~2. squeeze the anus~3. Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.~4. contract all of the above together"
62028401|NCT04661995|EXPERIMENTAL|Amplification + Notched Noise Therapy|"Following the baseline assessment, participants will be randomly assigned to one of the study groups. This treatment group will include a Notched Noise Therapy, a 1-10 kHz noise notched within a 1-octave range centered around the psychoacoustic tinnitus pitch match measured. Randomized participants will wear their hearing aids with this loaded software for 8 weeks. They will be seen at a baseline, 4 week, and 8 week visits for outcome measures and any adjustments in hearing aid comfort."
62028402|NCT04661995|ACTIVE_COMPARATOR|Amplification + Broadband Noise|"Following the baseline assessment, participants will be randomly assigned to one of the study groups. A popular and commonly used sound therapy treatment, this treatment group will listen to a broadband noise, or white noise, that is housed on the manufacturer's hearing aid tinnitus program. They will be seen at a baseline, 4 week, and 8 week visits for outcome measures and any adjustments in hearing aid comfort."
62028403|NCT04661995|PLACEBO_COMPARATOR|Amplification Only|Following the baseline assessment, participants will be randomly assigned to one of the study groups. Hearing aids are ear-level, self-contained, FDA-approved hearing device. Hearing aids help individuals with hearing loss and provide safe amplification/gain to frequencies that have loss.
62028404|NCT01040104||Regular wound healing, young|Regular skin repair, controlled wound healing conditions in young individuals
62227318|NCT01401192|ACTIVE_COMPARATOR|TS+ cohort & Pem/Cis arm|Among patients with TS+, randomised to Pem/cis chemotherapy
62227319|NCT01401192|ACTIVE_COMPARATOR|TS negative cohort & Pem/Cis Tx arm|Among patients with TS-, some will be randomised to Pem/cis Tx arm
62227320|NCT01401192|EXPERIMENTAL|TS negative cohort & Gem/Cis Tx arm|Among patients with TS-, some will be randomised to Gem/Cis Tx arm
62227321|NCT00627211|NO_INTERVENTION|Room air insufflation|Air used for insufflation during gastroscopy to expand the lumen for inspection of the mucosal lining. This is current standard procedure, i.e. no experimental intervention.
62590448|NCT06271707|SHAM_COMPARATOR|Group 2|Ultrasound with saline
62802863|NCT00878956|ACTIVE_COMPARATOR|1|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
62028405|NCT01040104||Regular wound healing, aged|Regular skin repair, controlled wound healing conditions in aged individuals
62028406|NCT01040104||Hypertrophic scarring, young|Skin repair with and without hypertrophic scarring in young individuals
62028407|NCT01040104||Hypertrophic scarring, aged|Skin repair with and without hypertrophic scarring in aged individuals
62028408|NCT01040104||Non-diabetic, young|Skin repair in non-diabetic young individuals
62028409|NCT01040104||Non-diabetic, aged|Skin repair in non-diabetic aged individuals
62227322|NCT00627211|EXPERIMENTAL|CO2 insufflation|CO2 used for insufflation during gastroscopy to expand the lumen for inspection of the mucosal lining. This is not standard procedure and therefore experimental intervention.
62028410|NCT01040104||Diabetic, young|Skin repair in young diabetic individuals
62028411|NCT01040104||Diabetic, aged|Skin repair in aged diabetic individuals
62028412|NCT04477980||Culture positive empyema|Patients with empyema confirmed by a positive pleural fluid culture, irrespective of its gross fluid appearance
62028413|NCT04477980||Culture negative empyema|Patients with empyema confirmed by a gross pus appearance AND a negative pleural fluid culture
62028414|NCT04743908|NO_INTERVENTION|Social Network Strategy (SNS Condition)|"Study staff will describe the Social Network Strategy, construct a plan for successfully referring network members into the study, and discuss compensation for the recruitment efforts. Study staff will specifically discuss network members of interest: friend, family, coworker or someone you spend time with on a regular basis. Walkthrough and scenario play will be strategies to assist with planning regarding: (1) how the conversation will be raised, (2) how potential barriers to testing will be addressed, (3) how the screening by phone or web survey will be conducted, (4) how network members will have the option to bring others into the study visit with them, (5) what information about the study will be shared."
62028415|NCT04743908|EXPERIMENTAL|Social Network Strategy + Messaging|"Study staff will describe the Social Network Strategy, construct a plan for successfully referring network members into the study, and discuss compensation for the recruitment efforts. Study staff will specifically discuss network members of interest: friend, family, coworker or someone you spend time with on a regular basis. Walk through and scenario play will be strategies to assist with planning regarding: (1) how the conversation will be raised, (2) how potential barriers to testing will be addressed, (3) how the screening by phone or web survey will be conducted, (4) how network members will have the option to bring others into the study visit with them, (5) what information about the study will be shared. Finally, community developed COVID-19 public health messages will be shared in the participant's preferred language."
62028416|NCT04411108|ACTIVE_COMPARATOR|Exercise Instruction by PT and written handout|
62028417|NCT04411108|EXPERIMENTAL|Exercise Instruction by Motion Coach Technology|
62227323|NCT02466633|EXPERIMENTAL|Change in in-hospital cardiac monitoring method|Pre- and post-intervention, where the intervention is a change in in-hospital cardiac monitoring method
62227324|NCT02874274|ACTIVE_COMPARATOR|100 Non-Homebound Subjects|outpatient healthcare utilization and self-reported illness.
62227325|NCT02874274|ACTIVE_COMPARATOR|60 Homebound Subjects|Will test the feasibility of offering influenza and pneumococcal vaccinations, as appropriate, to the homebound individuals in our HVP cohort
62420140|NCT02564952|EXPERIMENTAL|GWP42003-P|"Participants who transferred from the DB phase (NCT02565108) to the OLE (still blinded at that stage) tapered off their GWP42003-P or placebo treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P to 20 mg/kg/day initially for the OLE; doses could then be adjusted up or down, dependent on investigator opinion, to a maximum of 30 mg/kg/day GWP42003-P.~Clobazam (CLB) was administered in line with the physician's preferred CLB dosing regimen for each participant."
62227326|NCT05132283|EXPERIMENTAL|Urologic Lymphadenectomy in AMIGO|Participants will undergo Lymphadenectomy per standard of care with the navigation systems (3D Slicer and Monaco) used to locate the abnormal lymph node(s).
62227327|NCT00887432|EXPERIMENTAL|Arm I (cholecalciferol and placebo)|Patients receive cholecalciferol PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm II.
62227328|NCT00887432|EXPERIMENTAL|Arm II (placebo and cholecalciferol)|Patients receive placebo PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm I.
62420141|NCT06119373|EXPERIMENTAL|Single daily icodextrin exchange group|For incident peritoneal dialysis (PD) patients assigned to the experimental arm, PD is initiated with single daily exchange of 2-liter icodextrin-based dialysis solution. The daily dwell time ranges from 8-24 hours per day, depending on the patient's clinical conditions. Additional exchange(s) of glucose-based dialysis solution will be added to increase uremic toxins and fluid removal if necessary during the follow-up.
62590449|NCT06411925|EXPERIMENTAL|Atock Dry Syrup|
62590450|NCT06411925|PLACEBO_COMPARATOR|Placebo|
62028418|NCT00758953|EXPERIMENTAL|1|
62028419|NCT00758953|EXPERIMENTAL|2|
62028420|NCT00758953|PLACEBO_COMPARATOR|3|
62028421|NCT00758953|PLACEBO_COMPARATOR|4|
62028422|NCT03126838||diaphragmatic dysfunction|diaphragmatic displacement \< 10 ml, and / OR diaphragmatic thickening fraction \< 36 %.
62028423|NCT03126838||non diaphragmatic dysfunction|diaphragmatic displacement \> 10 ml, and / OR diaphragmatic thickening fraction \> 36 %.
62028424|NCT05958342|EXPERIMENTAL|Prehospital Intervention Arm|1 gram calcium gluconate provided via intravenous or intraosseous access over approximately 2-5 minutes, initiated prior to trauma bay arrival and infused to completion following arrival if needed
62802864|NCT00878956|PLACEBO_COMPARATOR|2|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
62802865|NCT00521287|OTHER|Early (E)|Early stage cancer
62802866|NCT00521287|OTHER|Advanced (A)|Advanced stage cancer (Stage IV without treatment)
62802867|NCT00521287|OTHER|Terminal (T)|Terminal stage cancer (Stage IV with chemotherapy)
62028425|NCT05958342|PLACEBO_COMPARATOR|Prehospital Control Arm|Identical volume saline placebo to prehospital intervention arm provided via intravenous or intraosseous access over approximately 2-5 minutes, initiated prior to trauma bay arrival and infused to completion following arrival if needed
62802868|NCT01012986||2nd Grade|students of 2nd grade
62802869|NCT01012986||4th Grade|students of 4th Grade
62802870|NCT02108249||Annex Group|Patients prospectively treated with Annex™ Adjacent Level System
62028426|NCT05958342|EXPERIMENTAL|Early In-Hospital Intervention Arm|4 unit vasopressin bolus followed by a vasopressin infusion at 0.04 U/min for eight hours, initiated within approximately two hours of enrollment
62028427|NCT05958342|PLACEBO_COMPARATOR|Early In-Hospital Control Arm|volume matched saline bolus followed by volume matched normal saline placebo infusion for eight hours initiated within approximately two hours of enrollment
62227329|NCT01576653|ACTIVE_COMPARATOR|No IFI|Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do not fulfill EORTC/MSG IFI criteria will serve as negative controls.
62802871|NCT02108249||Retrospective Control|Patients previously treated for adjacent level disease using other systems
62227330|NCT01576653|ACTIVE_COMPARATOR|IFI|Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do fulfill EORTC/MSG criteria of possible/probable/proven IFI will serve as study group.
62227331|NCT00304525|EXPERIMENTAL|RAF265 - Arm 1|Patients received 10mg RAF265 as a once weekly dose until progressive disease was confirmed.
62802872|NCT03915171|EXPERIMENTAL|MSI-H|IHC/PCR tested as dMMR/ MSI-H
62802873|NCT03915171|EXPERIMENTAL|MSS|IHC/PCR tested as pMMR/ MSS
62802874|NCT01250366|EXPERIMENTAL|Arm 1: INX-08189 (9 mg) or Placebo|
62802875|NCT01250366|EXPERIMENTAL|Arm 2: INX-08189 (25 mg) or Placebo|
62802876|NCT01250366|EXPERIMENTAL|Arm 3: INX-08189 (50 mg + 9 mg) or Placebo|
62802877|NCT01250366|EXPERIMENTAL|Arm 4: INX-08189 (50 mg) or Placebo|
62802878|NCT01250366|EXPERIMENTAL|Arm 5: INX-08189 (9 mg) or Placebo + Ribavirin|
62802879|NCT01250366|EXPERIMENTAL|Arm 6: INX-08189 (25 mg) or Placebo + Ribavirin|
62028428|NCT02005471|ACTIVE_COMPARATOR|Bendamustine + Rituximab|Participants will receive bendamustine 70 milligrams per meter square (mg/m\^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m\^2 on Day 1 of Cycles 2-6.
62028429|NCT02005471|EXPERIMENTAL|Venetoclax + Rituximab|Participants will be initially placed on a venetoclax 5 weeks ramp-up period, and will receive an initial dose of 20 milligrams (mg) via tablet orally once daily (QD). Then the dose will be incremented weekly up to a maximum dose of 400 mg. Participants will then continue receiving venetoclax 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards, as directed by the investigator, in combination with rituximab 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m\^2 on Day 1 of Cycles 2-6.
62028430|NCT02005471|EXPERIMENTAL|Bendamustine + Rituximab Crossover Substudy|Participants entering the Crossover Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Crossover Day 1 of the Substudy.
62227332|NCT00304525|EXPERIMENTAL|RAF265 - Arm 2|"RAF265 is given as a single PK run-in dose, a single loading dose on day 1 of cycle 1, followed by once daily maintenance doses."
62802880|NCT01250366|EXPERIMENTAL|Arm 7: INX-08189 (100 mg) or Placebo|
62802881|NCT05220878|EXPERIMENTAL|GNR-069|Main group (80 patients) - multiple weekly subcutaneous injections of GNR-069, doses are calculated individually.
62802882|NCT05220878|ACTIVE_COMPARATOR|Nplate|Control group (80 patients) - multiple weekly subcutaneous injections of Nplate, doses are calculated individually.
62802883|NCT02501252|EXPERIMENTAL|CORN Based at health post|Trained CORN based at health post will provide SBA and other RH services on demand at health post or household levels on an outreach bases.
62802884|NCT02501252|ACTIVE_COMPARATOR|CORN Based at health center|Trained CORN based at health center, but working in the community in an outreach basis will provide SBA and other RH services
62802885|NCT02501252|NO_INTERVENTION|Control|will be composed of a randomly selected comparable controls clusters. Control clusters (arm) will be similar with the other two arms (groups) except for the intervention.
62802886|NCT01384734|EXPERIMENTAL|Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir|Treatment Group 1
62802887|NCT01384734|EXPERIMENTAL|Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir|Treatment Group 2
62802888|NCT01384734|EXPERIMENTAL|Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir|Treatment Group 3
62802889|NCT01384734|EXPERIMENTAL|Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir|Treatment Group 4
62802890|NCT01384734|ACTIVE_COMPARATOR|Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir|Treatment Group 1 (reference arm)
62802891|NCT05659771|EXPERIMENTAL|low energy density, hard texture|Sandwich with a hard texture (slow eating rate) and relatively low energy density (kcal/g)
62802892|NCT05659771|EXPERIMENTAL|low energy density, soft texture|Sandwich with a soft texture (fast eating rate) and relatively low energy density (kcal/g)
62028431|NCT02005471|EXPERIMENTAL|Venetoclax + Rituximab Re-Treatment|Participants entering the Re-Treatment Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Re-Treatment Day 1 of the Substudy.
62028432|NCT02649868|EXPERIMENTAL|Hepatic tumors bead embolization|Participants with diagnosed hepatic malignancy underwent transarterial embolization (TAE) with or without thermal ablation under general anesthesia. The LC LUMI bead were used in the transarterial embolization procedure.
62028433|NCT03179839|EXPERIMENTAL|Mindfulness-based Cognitive Therapy|MBCT group is a treatment group used mindfulness-based cognitive therapy, and guided by two therapists for 10 sessions. Every collection of about 6-8 patients is a closed structural group. Each session lasts 2.5 hours once a week, and has daily homework assignments.
62028434|NCT03179839|PLACEBO_COMPARATOR|Psycho-education Program|The program is consists of the information and principle of treatment for OCD, group sharing, supporting and discussion.
62028435|NCT03179839|ACTIVE_COMPARATOR|SSRIs Therapy|This is a control group that can choose to use SSRI drugs which the SFDA approved for the treatment of OCD (Sertraline, Fluvoxamine, initial dose of 50 mg).
62028436|NCT06635174|PLACEBO_COMPARATOR|control group|in this arm participant will receive oral 2ml of normal water
62028437|NCT06635174|EXPERIMENTAL|50% dextrose group|this arm will include the participant who will receive 50% oral dextrose
62028438|NCT01352598|OTHER|Stereotactic Body Radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
62028439|NCT03422003|EXPERIMENTAL|Arm 1: Hypofractionation|16 fractions of radiation therapy (daily, Monday through Friday) to the chest wall with or without internal mammary nodes, and 15 fractions to the supraclavicular (with or without axillary) lymph nodes.
62028440|NCT03422003|ACTIVE_COMPARATOR|Arm 2: Conventional Radiation Therapy|25 fractions of radiation therapy (daily, Monday through Friday) to the chest wall with or without internal mammary nodes, and 23-25 fractions to the supraclavicular (with or without axillary) lymph nodes.
62028441|NCT03719105|EXPERIMENTAL|Cohort 1|"Patients with aggressive NK cell leukemia or stage III or IV extranodal NK/T-cell lymphoma, nasal type.~Chemotherapy Regimen:~mSMILE: Methotrexate Day 1, Ifosfamide Days 2-4, Dexamethasone Days 2-4, Etoposide Days 2-4, calaspargase pegol Day 8. For patients in CR and no available allogeneic SCT can receive up to 2 additional cycles of mSMILE.~Pembrolizumab: For patients in PR/MR/NR/PD after 2 cycles of mSMILE.~Allogeneic Stem Cell Transplant if donor available and not in PD."
62227333|NCT00304525|EXPERIMENTAL|RAF265 - Arm 3|Patients were treated with once weekly dosing of RAF265
62227334|NCT00304525|EXPERIMENTAL|RAF265 - Arm 4|Patients with locally advanced or metastatic melanoma will utilize a dose close to or at the MTD/RPTD of the liquid formulation that was determined in Arm 2.
62227335|NCT00304525|EXPERIMENTAL|RAF265 - Arm 5|RAF265 was administered as a continuous dose for 2 weeks followed by a dose holiday of 1 week.
62802893|NCT05659771|EXPERIMENTAL|High energy density, hard texture|Sandwich with a hard texture (slow eating rate) and relatively high energy density (kcal/g)
62802894|NCT05659771|EXPERIMENTAL|High energy density, soft texture|Sandwich with a soft texture (fast eating rate) and relatively high energy density (kcal/g)
62802895|NCT05659771|ACTIVE_COMPARATOR|Average energy density and medium hard texture (control)|Sandwich with a medium texture (medium eating rate) and medium energy density (kcal/g)
62028442|NCT03719105|EXPERIMENTAL|Cohort 2|"Patients with stage III or IV peripheral T-cell lymphoma-NOS, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, or enteropathy-associated T-cell lymphoma (other histologies will be considered after case-by-case discussion with Study Chairs and Executive Vice-Chairs).~Chemotherapy Regimen:~Cycle 1 \& 2: Pralatrexate Days 1, 8, and 15, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Cycle 3 \& 5: Brentuximab vedotin Day 1, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Cycle 4 \& 6: Pralatrexate Days 1, 8, and 15, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Allogeneic Stem Cell Transplant if donor available and not in PD."
62028443|NCT06636214|EXPERIMENTAL|CHATO Inclusive Intervention|
62028444|NCT06636214|NO_INTERVENTION|Waitlist Control|
62028445|NCT05684965|EXPERIMENTAL|Phase 1 - XTX301 Monotherapy Dose Escalation and Pharmacodynamics Expansion|"Part 1A Dose Escalation of XTX301 administered in ascending doses to patients with advanced solid tumors to assess the safety and tolerability and determine/define MTD and/or the highest recommended Phase 2 dose (RP2D).~Part 1B Evaluation of XTX301 in patients with selected advanced solid tumors to further characterize the pharmacodynamics profile of XTX301."
62028446|NCT05684965|EXPERIMENTAL|Phase 2 - XTX301 Monotherapy Dose Expansion in Disease-Specific Cohorts|"Phase 2 will further evaluate the safety and antitumor activity/efficacy of XTX301 monotherapy in disease-specific expansion cohorts of patients with select tumors, namely:~* Cohort 2A: head and neck squamous cell carcinoma (HNSCC)~* Cohort 2B: melanoma~* Cohort 2C: non-small cell lung cancer (NSCLC)~* Cohort 2D: ovarian cancer~* Cohort 2E: castrate-resistant prostate cancer (CRPC)~* Cohort 2F: triple-negative breast cancer (TNBC)"
62028447|NCT03088384||Combat Veterans|Eligible participants must be military veterans who have served in a combat zone as evidenced by documentation on the subject's DD214 (or equivalent if he/she served in a foreign military). Participants must have a diagnosis of post traumatic stress disorder that was as a result of their military combat experience.
62028448|NCT05028660||Cohort 1|At least 76 patients with MIBC and elected for NAC
62028449|NCT06636448||obese patients undergoing low-flow anaesthesia|Low-flow anaesthesia was performed in patients with a body mass index between 30-40
62028450|NCT01073618||A.|Patients who are indicated for VFEND according to drug package insert.
62802896|NCT02257034|EXPERIMENTAL|Taichi|patients exercise with Tai chi
62802897|NCT02257034|SHAM_COMPARATOR|Control|patients under exercise of dance
62802898|NCT00716963|ACTIVE_COMPARATOR|1|Fluticasone propionate (Flovent Diskus) 250 mcg
62802899|NCT00716963|ACTIVE_COMPARATOR|2|budesonide 400mcg
62802900|NCT00716963|PLACEBO_COMPARATOR|3|placebo
62802901|NCT00821652|OTHER|Dose-esclation|Part I represents a dose-escalation part with topical resiquimod in an open-label fashion.
62802902|NCT00821652|EXPERIMENTAL|2|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I.
62802903|NCT04283071||Patient|Progressive MS patients administered clinical examination measures including EDSS, nine-hole PEG test, patient reported outcomes measures and kinematic assessment of upper limb function
62590451|NCT02877810|EXPERIMENTAL|Telemedicine|A consultation will be given for the care of a critically ill pediatric patient to a remote hospital emergency department physician by telemedicine, a live, interactive, audiovisual teleconferencing system, from a pediatric critical care physician.
62590452|NCT02877810|ACTIVE_COMPARATOR|Telephone|A consultation will be given for the care of a critically ill pediatric patient to a remote hospital emergency department physician by telephone, from a pediatric critical care physician..
62028451|NCT04105023|EXPERIMENTAL|genistein|Genistein capsules of 25 mg each, 50mg/day
62028452|NCT04105023|PLACEBO_COMPARATOR|placebo|Maltodextrin capsules, administered orally once every 12 hours
62028453|NCT03205995|EXPERIMENTAL|OMS721|Administration of OMS721
62028454|NCT03239379|PLACEBO_COMPARATOR|Placebo|Normal saline
62420142|NCT06119373|ACTIVE_COMPARATOR|Conventional PD group|For incident peritoneal dialysis (PD) patients assigned to this arm, PD is initiated with 2 to 3 exchanges of 2-liter glucose-based solution. The daily dwell time ranges from 8-24 hours per day, depending on the patient's clinical conditions. Additional exchange(s) of glucose-based dialysis solution will be added to increase uremic toxins and fluid removal if necessary during the follow-up.
62590453|NCT00329537|EXPERIMENTAL|Arm 1|
62590454|NCT00329537|PLACEBO_COMPARATOR|Arm 2|
62590455|NCT03917316||ADHD|
62028455|NCT03239379|EXPERIMENTAL|BNZ132-1-40|PEGylated BNZ-1 for Injection
62028456|NCT01999504|EXPERIMENTAL|PAL-2|Based on WHO dietary guidelines for protein, fat and carbohydrate but made with ingredients that would have been available in palaeolithic times (e.g. no cereals, no dairy).
62028457|NCT01999504|EXPERIMENTAL|TFH-1|Based on WHO dietary guidelines for protein, fat and carbohydrate but made with ingredients that would have been available in palaeolithic times, (e.g. no cereals, no dairy).
62028458|NCT01999504|PLACEBO_COMPARATOR|Reference|Meal based on WHO dietary guidelines for protein, fat and carbohydrate.
62028459|NCT03551938|NO_INTERVENTION|Control|Receive only the standard HIV Counseling, Testing, and Referral or Couples HIV Testing and Counseling (CHTC) Session.
62420143|NCT01022177|ACTIVE_COMPARATOR|diabetics|subjects with HbA1c \>7,0 and pathological glucose tolerance testing
62420144|NCT01022177|ACTIVE_COMPARATOR|healthy|healthy subjects with HbA1c \<7,0 and negative glucose tolerance testing
62420145|NCT01465074|ACTIVE_COMPARATOR|Nicotine gum (4 mg)|Nicotine gum will be given once on one of the two test days in a randomized, double-blinded fashion. Gum will be chewed for 30 min before the plasticity induction occurs.
62028460|NCT03551938|EXPERIMENTAL|Intervention|Receive one 45-minute Relationship skills session for YMSM individuals and couples (the intervention) as an addition to the standard HIV Counseling, Testing, and Referral (CTR) or Couples HIV Testing and Counseling (CHTC) Session.
62028461|NCT01989650|ACTIVE_COMPARATOR|Break|A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
62028462|NCT01989650|NO_INTERVENTION|No break|No break will be provided
62028463|NCT06451068|EXPERIMENTAL|Group 1 - Healthy adult volunteers|Healthy adult volunteers recruited from the patient population, students or employees of Duke University or Duke Eye Center (n=7)
62028464|NCT06451068|EXPERIMENTAL|"Group 2 - Adult participants with flashers and floaters"|"Adult participants recruited from the patient population of Duke Eye Center with complaints of flashers and floaters undergoing clinical examination (n=7)"
62028465|NCT06451068|EXPERIMENTAL|Group 3 - Adult participants with flashers and floaters with no diagnosed peripheral retinal breaks|"Adult participants recruited from the patient population of Duke Eye Center with complaints of flashers and floaters and a clinical examination showing no breaks in the peripheral retina (n=22)"
62028466|NCT06451068|EXPERIMENTAL|Group 4 - Adult participants with flashers and floaters with diagnosed peripheral retinal breaks|"Adult participants recruited from the patient population of Duke Eye Center with complaints of flashers and floaters and a clinical examination showing one or more breaks in the peripheral retinal (n=22)"
62227336|NCT04156854|EXPERIMENTAL|Subjects with heart failure|Subjects admitted to the hospital for acute decompensation of chronic systolic heart failure will have a Quantitated Blood Volume Analysis blood test done
62227337|NCT02995954|ACTIVE_COMPARATOR|Fixed|The Fixed group received one single tablet containing Perindopril/Amlodipine (Reaptan) at the appropriate dose
62420146|NCT01465074|PLACEBO_COMPARATOR|Regular Mint Gum|Regular, taste-, texture- and color matched with the Nicotine Gum will be ingested once on one of the two testing days, 30 min before plasticity induction.
62420147|NCT00685048|EXPERIMENTAL|1|psychoeducation
62420148|NCT00685048|EXPERIMENTAL|2|brief advice
62028467|NCT00647712|EXPERIMENTAL|1|Divalproex Sodium Extended-Release Tablets 500 mg
62028468|NCT00647712|ACTIVE_COMPARATOR|2|Depakote ER® Tablets 500 mg
62227338|NCT02995954|ACTIVE_COMPARATOR|Free|The Free group, received Perindopril and Amlodipine in separate tablets at the appropriate dose
62420149|NCT00685048|EXPERIMENTAL|3|Motivational Enhancement Therapy (MET)/Cognitive-Behavioral Therapy (CBT)
62420150|NCT01770639||MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
62420151|NCT01879709|EXPERIMENTAL|Yoga Training Group|Yoga Training: Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols).
62420152|NCT01879709|PLACEBO_COMPARATOR|Treatment as Usual Group|Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided
62590456|NCT03917316||Control|
62227339|NCT00679237|ACTIVE_COMPARATOR|Multifactorial intervention|Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin
62227340|NCT00679237|NO_INTERVENTION|Control|no intervention
62227341|NCT06063785||CF with liver affection|CF patients with proven CF hepatopathy
62028469|NCT01093794|EXPERIMENTAL|1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~* Co-administration of 50 mg sitagliptin and 500 mg metformin~* sitagliptin/metformin 50 mg/500 mg FDC tablet~* sitagliptin/metformin 50 mg/850 mg FDC tablet~* Co-administration of 50 mg sitagliptin and 850 mg metformin"
62028470|NCT01093794|EXPERIMENTAL|2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~* sitagliptin/metformin 50 mg/500 mg FDC tablet~* Co-administration of 50 mg sitagliptin and 850 mg metformin~* Co-administration of 50 mg sitagliptin and 500mg metformin~* sitagliptin/metformin 50 mg/850 mg FDC tablet"
62028471|NCT01093794|EXPERIMENTAL|3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~* Co-administration of 50 mg sitagliptin and 850 mg metformin~* sitagliptin/metformin 50 mg/850 mg FDC tablet~* sitagliptin/metformin 50 mg/500 mg FDC tablet~* Co-administration of 50 mg sitagliptin and 500mg metformin"
62028472|NCT01093794|EXPERIMENTAL|4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~* sitagliptin/metformin 50 mg/850 mg FDC tablet~* Co-administration of 50 mg sitagliptin and 500 mg metformin~* Co-administration of 50 mg sitagliptin and 850 mg metformin~* sitagliptin/metformin 50 mg/500 mg FDC tablet"
62028473|NCT05472714|NO_INTERVENTION|Without Video|In year 1, we will recruit families of patients receiving the current standard-of-care approach to tumor-normal genetic testing with provider based education.
62028474|NCT05472714|EXPERIMENTAL|With Video|In year 2, we will recruit families of patients receiving the updated standard-of-care approach to tumor-normal genetic testing with provider based education and an educational video.
62028475|NCT04191057|EXPERIMENTAL|Healthy twin|Free light chains of twins compared to non-twin siblings
62028476|NCT05343702||standard|standard rapid sequence intubation group (paralysis following induction)
62420153|NCT01879709|ACTIVE_COMPARATOR|Physical Exercise Group|Physical Exercise: This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises.
62420154|NCT05166655|EXPERIMENTAL|Parkinson disease patients|Parkinson disease patients undergoing DBS Surgery of the Globus Pallidus Internus (GPi) for clinical indications
62420155|NCT06393738|EXPERIMENTAL|Dose escalation|Dose escalation will begin at Dose Level 1. Dose escalation or de-escalation decision will be recommended by the cohort review committee.
62420156|NCT00833976|EXPERIMENTAL|open-label Lovaza (omega-3 fatty acids)|4g per day (4g once a day or 2g two times a day) for 16 weeks
62420157|NCT03127943|ACTIVE_COMPARATOR|Buffered 1% lidocaine|"In week One, Each subject would be injected intraorally with either anesthetic (Buffered 1% lidocaine with 1/100,00 epinephrine) or (Non-buffered 1% lidocaine with 1/100,00 epinephrine to block the Inferior alveolar, Lingual and Buccal nerves.~At least a week later injections for the same nerves would involve the alternate anesthetic. Mandibular molar and canine tested for pulpal anesthesia."
62802904|NCT04283071||Control|Healthy volunteers administered nine-hole PEG test and kinematic assessment of upper limb function
62802905|NCT00514358||gestational age|
62802906|NCT02870998|EXPERIMENTAL|Active learning|Educational strategies will be used to foster active learning.
62802907|NCT02870998|ACTIVE_COMPARATOR|Passive learning|Traditional educational strategies (lecture) will be used.
62590457|NCT06666218|EXPERIMENTAL|Aim 1 (HOPE intervention workshop, survey, interview)|Patients complete the HOPE intervention workshop virtually or in person. The workshop consists of three weekly sessions, each lasting 60 to 90 minutes, along with a survey and an interview for HOPE Intervention refinement during follow up.
62802908|NCT06472492|EXPERIMENTAL|Adjuvant yoga intervention group|The yoga group will attend the yoga under the guidance of a therapist for 6 weeks (6 days a week).yoga group, the participant needs to attend Specific Yoga Practices of duration around 1 Hour every day under a trained therapist for about 6 days in a week for 6 weeks, along with your ongoing medications (online/offline).. It includes warme up exercises and asanas.
62802909|NCT06472492|NO_INTERVENTION|Treatment as usual group|The treatment-as-usual group will continue with usual treatment.the treatment as usual group will continue the ongoing medications for next 6 weeks. But participants will be coming for cognitive assessments at the end of 6 weeks and 4 weeks later. After the final assessment they will be given an option for joining yoga sessions provided in the yoga center at NIMHANS. But this will not be the part of this study.
62802910|NCT05152758|NO_INTERVENTION|Usual Care|Patients will receive the usual care.
62802911|NCT05152758|EXPERIMENTAL|Physical Activity Prescription (PARx)|Patients will be prescribed technology-based physical activity programming.
62028477|NCT05343702||priming|group primed with rocuronium before induction
62028478|NCT04962464|EXPERIMENTAL|Fasting Mimicking Diet + Supplement / Usual Routine|Participants in will be asked to begin the Peak Human Labs calorie mimetic supplement. They will also begin on day 1 the 5 day Fasting Mimicking Diet Program. Participants will continue the supplementation for the 90 days and repeat the 5 day Fasting Mimicking Diet Program on days 1, 29 and 57. Starting at day 91, they will return to their usual daily routine.
62028479|NCT04962464|EXPERIMENTAL|Supplement / Usual Routine|Participants will be asked to begin the Peak Human Labs calorie mimetic supplement. Participants will continue the supplementation for 90 days. Starting at day 91, they will return to their usual daily routine.
62802912|NCT01363700|EXPERIMENTAL|1|
62802913|NCT01363700|PLACEBO_COMPARATOR|2|
62802914|NCT01363700|ACTIVE_COMPARATOR|3|
62802915|NCT03741686|EXPERIMENTAL|Konjac-mannan|Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet.
62028480|NCT04962464|EXPERIMENTAL|Usual Routine / Fasting Mimicking Diet + Supplement|Participants will have no intervention for the first 90 days, during which they will be asked not to start a new fasting program supplement. At day 91, they will begin the 5-day Fasting Mimicking Diet Program and start the Peak Human Labs calorie mimetic supplement. Participants will continue the supplementation for 90 days and repeat the 5-day Fasting Mimicking Diet Program on days 91, 120, and 148.
62028481|NCT04962464|EXPERIMENTAL|Usual Routine / Supplement|Participants will have no intervention for the first 90 days, during which they will be asked not to start a new fasting program supplement. At day 91,start the Peak Human Labs calorie mimetic supplement. Participants will continue the supplementation for 90 days.
62028482|NCT02096900|ACTIVE_COMPARATOR|zolpidem|zolpidem given orally 0.25mg/kg pre-operatively single dose
62028483|NCT02096900|ACTIVE_COMPARATOR|midazolam|midazolam will be given at 0.5mg/kg, pre-operatively single dose
62028484|NCT05556408|OTHER|High-Resolution Solid-State Manometry|Before catheterization, the patients were monitored by pulse oximetry, electrocardiogram, automatic noninvasive arterial blood pressure and bispectral index (BIS). Before the insertion of the manometric catheter an intravenous cannula was inserted. The manometric catheter was placed through the nose until the pressure from the lower esophageal sphincter to the stomach could be recorded. After confirming the position of the catheter, the catheter was taped to the nose.
62590458|NCT06666218|EXPERIMENTAL|Aim 2, Group I (HOPE intervention workshop)|Patients complete the HOPE intervention workshop either virtually or in person, with three weekly sessions, each lasting 60 to 90 minutes.
62590459|NCT06666218|ACTIVE_COMPARATOR|Aim 2, Group II (usual care)|Patients receive usual care on study.
62590460|NCT05283343||Adults 20 years old or older|
62802916|NCT03741686|PLACEBO_COMPARATOR|Placebo|wheat bran fiber biscuits with NCEP Step II metabolically controlled diet.
62802917|NCT00717249|EXPERIMENTAL|Test Lens|galyfilcon A contact lens with a silver additive
62802918|NCT00717249|ACTIVE_COMPARATOR|Control Lens|galyfilcon A control contact lens
62802919|NCT02568514|NO_INTERVENTION|Usual care|Patients admitted to hospital floors without any other intervention.
62802920|NCT02568514|EXPERIMENTAL|Secure text messaging|Patients admitted to hospital floors on which physicians and other staff are able to communicate with each other (not to the patient) using mobile secure text messaging.
62802921|NCT05663021|EXPERIMENTAL|Ultrasound-Guided Biopsy of Tumor Site during neoadjuvant chemotherapy|For patients who were not evaluated as progressive disease by the latest imaging measurement, repeated CNB (RCNB) was performed after 2-4 cycles of NAC, depending on the total cycles of NAC. Tissue is acquired from different sections of the lesion from different angles to minimize the impact of tumor heterogeneity. For each patient, 3 to 4 tissue specimens are collected and sent for pathological review to examine whether there is residual malignancy (residual cancer, pleomorphic tissue) in the tumor site that is tattooed.
62028485|NCT04104581|PLACEBO_COMPARATOR|Control|Volunteers will consume a diet in which all grain foods are made from refined grains.
62028486|NCT04104581|EXPERIMENTAL|Low Whole Grain Oat Diet|Volunteers will consume a diet with a low level of whole grain oat incorporated into some of the foods.
62028487|NCT04104581|EXPERIMENTAL|High Whole Grain Oat Diet|Volunteers will consume a diet with a high level of whole grain oat incorporated into some of the foods.
62028488|NCT04104581|EXPERIMENTAL|Low Whole Grain Wheat Diet|Volunteers will consume a diet with a low level of whole grain wheat incorporated into some of the foods.
62028489|NCT04104581|EXPERIMENTAL|High Whole Grain Wheat Diet|Volunteers will consume a diet with a high level of whole grain wheat incorporated into some of the foods.
62028490|NCT01571362|EXPERIMENTAL|ALO-02|
62420158|NCT03127943|ACTIVE_COMPARATOR|Non-buffered 1% lidocaine|"In week Two, Each subject would be injected intraorally with the alternate anesthetic (Buffered 1% lidocaine with 1/100,00 epinephrine) or (Non-buffered 1% lidocaine with 1/100,00 epinephrine to block the Inferior alveolar, Lingual and Buccal nerves.~At least a week later injections for the same nerves would involve the alternate anesthetic. Mandibular molar and canine tested for pulpal anesthesia."
62028491|NCT01571362|PLACEBO_COMPARATOR|Placebo|
62028492|NCT06054724|EXPERIMENTAL|Yoga-based Respiration Group|This group will be given yoga-based breathing exercises
62028493|NCT06054724|EXPERIMENTAL|Pilates-based Respiration Group|This group will be given pilates-based breathing exercises
62028494|NCT03044067|EXPERIMENTAL|Pain neuroscience education + Exercise|Pain neuroscience education can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system. It will be applied three times (at baseline, one week and one month after intervention). Exercise will be based on a set of 4 exercise implicating flexion, extension, lateral rotation and abduction of lower and upper extremities.
62420159|NCT04250896|OTHER|Control|Control group will receive standard child care in health units plus exposure to EsIAN (Strategy of Integral Attention to Nutrition)
62420160|NCT04250896|EXPERIMENTAL|Intervention|Intervention group will receive SMS messages sent through a cell pone in addition to the control group receive (standard child care in health units plus exposure to EsIAN)
62420161|NCT06083220|EXPERIMENTAL|School Readiness Intervention Program|The School Readiness Program is a 64 hour intensive therapy program focused on school readiness skills for young children with unilateral cerebral palsy (UCP). The program will include 64 hours of intervention supporting the development and goal attainment across 5 school readiness domains: (1) health and physical development, (2) emotional well-being and social competence, (3) approaches to learning, (4) communication skills, and (5) cognitive skills and general knowledge.
62028495|NCT03044067|ACTIVE_COMPARATOR|Exercise|Exercise will be based on a set of 4 exercise implicating flexion, extension, lateral rotation and abduction of lower and upper extremities. Participants will attend three appointments per week over three weeks. They will complete three sets of 10 repetitions, with the exercises progressed in difficulty at each appointment.
62028496|NCT06088654|EXPERIMENTAL|IPH6501 monotherapy|
62028497|NCT02132611|EXPERIMENTAL|Diamondback 360® Coronary OAS Micro Crown|Diamondback 360® Coronary Orbital Atherectomy System Micro Crown
62028498|NCT06516757|EXPERIMENTAL|Boric Acid Suppository Group|Participants will use 600 mg Boric Acid Gelatin Capsules (The Killer®) once daily for 7 consecutive days when they feel they are experiencing any signs of vaginal imbalance such as vaginal malodor, irritation, and/or itching.
62028499|NCT02152267|EXPERIMENTAL|tDCS 1mA|the parameters used in the TDCS will be 1mA, cathodal over right DLPFC and anodal over supraorbital contralateral area.
62028500|NCT02152267|EXPERIMENTAL|tDCS 2mA|the parameters used in the TDCS will be 2mA, cathodal over right DLPFC and anodal over supraorbital contralateral area.
62028501|NCT02152267|SHAM_COMPARATOR|tDCS Sham|the parameters used in the TDCS will be sham, cathodal over right DLPFC and anodal over supraorbital contralateral area.
62028502|NCT06634693||Heathy adult|healthy adult without pulmonary or cardiovascular disease
62028503|NCT02264067|EXPERIMENTAL|Talsaclidine|single rising doses
62028504|NCT02264067|PLACEBO_COMPARATOR|Placebo|
62227342|NCT06063785||CF without liver affection|CF patients without proven CF hepatopathy
62420162|NCT05617625|EXPERIMENTAL|CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen|"1. Cytoreduction therapy:~   1. 0.8 mg/kg q6h x 12 doses busulfan via IV injection~  2. 70 mg/m\^2/day x 2 days melphalan via IV infusion over 30 minutes~  3. 25 mg/m\^2/day x 5 days fludarabine vis IV infusion over 30 minutes~2. CD34+ selected, T-cell depleted, allogeneic PBSC transplant using CliniMACS system to select CD34+ cells"
62420163|NCT06204536|EXPERIMENTAL|technology integrated care planning cohort|This cohort will consist of 15 BCBAs that will receive a minimum of 3 technology-based tools (2 proprietary tools and at least 1 non-proprietary tool) for use in conjunction with the standard of care to develop and manage ABA treatment plans for active patients.
62590461|NCT03925233||HER2+ Breast Cancer|
62028505|NCT05023252|EXPERIMENTAL|mobile application|Participants use a mobile application on their smartphone
62028506|NCT02709954|EXPERIMENTAL|Active THC and Placebo Ethanol|
62227343|NCT06063785||Healthy volunteers|Healthy volunteers without liver affection
62028507|NCT02709954|EXPERIMENTAL|Active THC and Active Ethanol|
62028508|NCT02709954|EXPERIMENTAL|Placebo THC and Active Ethanol|
62028509|NCT02709954|PLACEBO_COMPARATOR|Placebo THC and Placebo Ethanol|
62028510|NCT04697758|EXPERIMENTAL|Low Dose|AXT107 0.1 mg/eye
62028511|NCT04697758|EXPERIMENTAL|Mid Dose|AXT107 0.25 mg/eye
62028512|NCT04697758|EXPERIMENTAL|High Dose|AXT107 0.5 mg/eye
62028513|NCT05309161|PLACEBO_COMPARATOR|A group (placebo)|Placebo
62028514|NCT05309161|ACTIVE_COMPARATOR|B group (experimental)|Crassocephalum rabens extract
62227344|NCT00106145|EXPERIMENTAL|Part I - Arm 1|
62420164|NCT06204536|NO_INTERVENTION|non-technology integrated care cohort|This cohort will consist of 5 BCBAs that will follow the standard of care that does not involve the use of the tech-based tools to develop and manage ABA treatment plans for active patients receiving ABA.
62420165|NCT05963360||Frailty in Older people|Older people, 50 and above.
62420166|NCT05221476||polytraumatized patients|Patients with an ISS \>16 points, an AIS \>3 in one body region and at least 2 different body regions affected were included.
62420167|NCT00378482|EXPERIMENTAL|1|Drug: CP-675,206 (Tremelimumab)
62420168|NCT06283771|EXPERIMENTAL|EXPERIMENTAL GROUP|The study group will wear heated socks to be developed with wearable technology
62420169|NCT06283771|NO_INTERVENTION|CONTROL GROUP|The control group will wear socks that look exactly the same as the heated socks developed with wearable technology worn by the study group, but with a closed heating circuit.
62420170|NCT03967418|OTHER|Patients with behavioral addictions|Patients suffering from behavioural addiction (sexual addiction and eating disorders with bulimia episodes) will be recruited
62420171|NCT03967418|OTHER|Healthy volunteers|Healthy volunteers will be matched on gender, age and education level to patients
62420172|NCT05137262|EXPERIMENTAL|Arm A: Standard of Care with dose-dense MVAC|The patient will receive treatment every 14 days for up to 6 cycles in the neoadjuvant setting.
62420173|NCT05137262|EXPERIMENTAL|Arm B: Intervention with dose-dense MVAC plus Durvalumab|Durvalumab will be administered one week prior to the initial cycle of dose-dense MVAC and then with each additional cycle of dose-dense MVAC on Arm B
62420174|NCT04920565|EXPERIMENTAL|cardiac surgery patients with multiple organ dysfunction|hemoperfusion procedure with polymyxin B will be performed for 12 hours
62420175|NCT04920565|NO_INTERVENTION|cardiac surgery patients|without hemoperfusion with polymyxin B
62420176|NCT06233175|ACTIVE_COMPARATOR|conventional group|patients take conventional trans cutaneous electrical stimulation (tens) with a frequency of 100 Hz , a pulse duration of 60 micro seconds for 20 min. ,hot backs for 15 min,stretching exercises for hamstring ,quadriceps ,calf muscles
62028515|NCT02808455|EXPERIMENTAL|Sequence I: A/B|Treatment A: pacritinib 400 mg capsule
62028516|NCT02808455|EXPERIMENTAL|Sequence II: B/A|Treatment B: pacritinib 80 mg solution
62028517|NCT04156607|EXPERIMENTAL|Kinesio taping group (KT)|"Kinesio taping applied to plantar soles of these children with Down Syndrome. Epidermis-Dermis-Fascia technique was used for providing sensory input from soles.~The application was performed on both feet."
62028518|NCT04156607|SHAM_COMPARATOR|Sham taping group (ST)|A random taping was performed using Kinesio tape but without using Kinesiotaping techniques for sham taping. The application was performed on both feet
62028519|NCT04156607|NO_INTERVENTION|Healty control group|This group took no intervention but all balance assessments once.
62028520|NCT01627249|ACTIVE_COMPARATOR|Ranibizumab|
62028521|NCT01627249|EXPERIMENTAL|Aflibercept|
62028522|NCT01627249|EXPERIMENTAL|Bevacizumab|
62028523|NCT03178357|OTHER|HCM patients with CR|30 HCM patients treated as standard subjected to 4-week hospital cardiac rehabilitation (CR) including psychological care (counseling and / or psychoeducation) and physical training followed by 8 weeks of telerehabilitation in the patient's home (cardiac rehabilitation + standard therapy)
62028524|NCT03178357|OTHER|HCM patients without CR (control group)|30 HCM patients in control group - standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling (standard therapy)
62028525|NCT03969069||Fistula/chronic perianal conditions|Participants symptomatic of FI with chronic perianal disease
62028526|NCT03969069||Obstetric injury <12 months|Participants symptomatic of FI \< 12 months following obstetric injury.
62227345|NCT00106145|EXPERIMENTAL|Part II - Arm 1|
62227346|NCT00106145|EXPERIMENTAL|Part III - Arm 1|
62227347|NCT00106145|EXPERIMENTAL|Part IV - Arm 1|
62227348|NCT00106145|EXPERIMENTAL|Part V - Arm 1|
62227349|NCT01122095||Psoriasis|Children with psoriasis Age matched controls without psoriasis or other significant inflammatory disease
62227350|NCT01122095||Control patient|Age matched, without psoriasis or significant inflammatory disease
62227351|NCT01131234|EXPERIMENTAL|Treatment (cediranib maleate and RO4929097)|Patients receive gamma-secretase inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17 (days 1-3, 8-10, 15-17 22-24, 29-31, and 36-38 of course 1 only) and cediranib maleate PO QD on days 1-21 (days 22-42 course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
62590462|NCT03925233||ER+ Breast Cancer|
62590463|NCT03925233||Triple Negative Breast Cancer|
62802922|NCT03022396|OTHER|Group A: age 8-17 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
62802923|NCT03022396|OTHER|Group B: age 18-30 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
62028527|NCT03969069||Obstetric injury >12 months|Participants symptomatic of FI \>12 months following obstetric injury.
62028528|NCT03969069||Neurogenic|Participants symptomatic of FI with evidence/history of neurological condition.
62028529|NCT04837482|EXPERIMENTAL|AGN-190584 Sequence 1|AGN-190584 Sequence 1 (Participants will receive AGN-190584 from Visit 2 through Visit 3 followed by Vehicle from Visit 4 through Visit 5).
62028530|NCT04837482|EXPERIMENTAL|AGN-190584 Sequence 2|AGN-190584 Sequence 2 (Participants will receive Vehicle from Visit 2 through Visit 3 followed by AGN-190584 from Visit 4 through Visit 5).
62028531|NCT03820661|OTHER|High Resolution Ultasound|Diagnostic high resolution ultrasound pre-operatively and intraoperatively
62028532|NCT04725721|EXPERIMENTAL|FIRST|FIRST is built upon five empirically supported principles of change (ESPCs-i.e., feeling calm, increasing motivation, repairing thoughts, solving problems, trying the opposite). Each principle can be applied to treatment of problems spanning depression, anxiety (including OCD and PTS), and conduct problems-thus encompassing a majority of the youths seen in outpatient care. Its design addresses breadth of problem coverage, youth comorbidity, and flux in youth treatment needs during episodes of care. It is used in conjunction with performance feedback via a web-based tracking system that gives clinicians weekly data on youth treatment response. FIRST has treatment and training efficiency, and efficient clinician skill-building is supported by group consultation.
62028533|NCT04725721|ACTIVE_COMPARATOR|Usual Care|Treatment in the usual care (UC) condition will use the clinical procedures therapists consider appropriate and believe to be effective.
62420177|NCT06233175|EXPERIMENTAL|interventional group|patients take conventional tens with a frequency of 100 Hz , a pulse duration of 60 micro seconds for 20 min. ,hot backs for 15 min,stretching exercises for hamstring ,quadriceps ,calf muscles with combined kinetic chain exercises (terminal knee extension,semi squat (wall slide) ,foreword step up and down ,straight leg raise ,seated knee extension )
62420178|NCT01635127|EXPERIMENTAL|Canakinumab|Monoclonal antibody inhibiting interleukin 1 beta
62802924|NCT03022396|OTHER|Group C: age 18-30 yo fraternal twins|Individual twins to receive Fluzone® (intramuscular)
62028534|NCT04947111|OTHER|Serological survey|A blood sample will be taken to estimate the specific serotype prevalence for dengue virus in groups of 5 to 35 years in areas of low and high dengue endemicity.
62227352|NCT04780347|EXPERIMENTAL|Albumin-bound paclitaxel plus capecitabine|Albumin-bound paclitaxel combined with capecitabine
62420179|NCT01635127|PLACEBO_COMPARATOR|Placebo|Constituent, inactive
62420180|NCT06012175|EXPERIMENTAL|Oral melatonin supplementation|Participants in the intervention arm will receive one 3 mg melatonin tablet every night before going to bed
62802925|NCT03022396|OTHER|Group D: age 40 - 59 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
62802926|NCT03022396|OTHER|Group E: age 40 - 59 yo fraternal twins|Individual twins to receive Fluzone® (intramuscular)
62802927|NCT03022396|OTHER|Group F: age 70 - 100 yo identical twins|Individual twins to receive Fluzone® (intramuscular) or High Dose Fluzone® (intramuscular)
62802928|NCT03826719|EXPERIMENTAL|NBP607QIV|1 dose of 0.5mL by Intramuscular injection
62227353|NCT04780347|ACTIVE_COMPARATOR|Capecitabine|Capecitabine
62227354|NCT06223204|OTHER|Controlled euglycemia, hypoglycemia and hyperglycemia|
62227355|NCT02607696|EXPERIMENTAL|Zolpidem 1.75 mg|Zolpidem Hemitartarate 1.75 mg Orodispersible Tablets Once daily
62802929|NCT03826719|ACTIVE_COMPARATOR|Agrippal|1 dose of 0.5mL by Intramuscular injection
62802930|NCT04215536||DPP4i|Reference group
62802931|NCT04215536||Empagliflozin|Exposure group
62802932|NCT03112265|EXPERIMENTAL|Child STEPS|Child STEPs includes (1) a treatment protocol, Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems (MATCH-ADTC), and (2) a youth monitoring and feedback system (MFS).
62028535|NCT02126293|EXPERIMENTAL|Zinc deficient patients|If the patient is found to be zinc deficient (serum zinc \< 11.5 μmol/L), the family will be contacted by the RA to commence zinc supplement: zinc citrate (Zinc Lozenges, manufactured by Douglas Laboratories Inc, London, ON, Health Canada NPN 80032476) for 3 months. As per the NPN licence the dose is 10 mg (1 lozenge) orally once a day for children age 4-8 years, and 10 mg twice a day for children age 9-18 years. This should give enough time to restore serum zinc to normal in most patients.
62028536|NCT02126293|ACTIVE_COMPARATOR|Zinc sufficient patients|Zinc sufficient patients will repeat blood and urine tests in 3 month time to compare the changes with intervention arm.
62590464|NCT01727544|ACTIVE_COMPARATOR|Surgical Group|patients will undergo a primary transmastoid and tegmen mini-craniotomy cartilage cap occlusion surgery.
62028537|NCT06491121|EXPERIMENTAL|TECHNO-HIT group|Technology supported High Intensity Training
62028538|NCT06491121|EXPERIMENTAL|HIT group|High Intensity Training
62028539|NCT06491121|ACTIVE_COMPARATOR|MIT group|Moderate Intensity Training
62028540|NCT04883671|ACTIVE_COMPARATOR|Standard of Care (Cohort 1)|Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).
62028541|NCT04883671|EXPERIMENTAL|Stereotactic Body Radiotherapy (SBRT) 1-5 Metastatic Sites (Cohort 1)|"Participants will be randomly assigned and receive SBRT to 1-5 sites of metastatic disease over the course of 1-8 business days to each area of cancer.~After SBRT is completed participant may go on to receive systemic therapy (like chemotherapy, immunotherapy, or targeted therapies) per discretion of their treating physician."
62028542|NCT04883671|NO_INTERVENTION|Local Ablative Therapy (Cohort 2)|Participants embarking on standard of care local ablative therapy (not limited to radiofrequency, microwave, or cryoablation, bland or chemoembolization, palliative radiotherapy, or surgical metastasectomy) not eligible for cohort 1 will be enrolled and followed.
62028543|NCT03689010|ACTIVE_COMPARATOR|Azelaic acid foam 15%|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
62028544|NCT03689010|ACTIVE_COMPARATOR|Finacea® (azelaic acid) Foam, 15%|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
62028545|NCT03689010|PLACEBO_COMPARATOR|Vehicle of the test product|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
62028546|NCT06507566|ACTIVE_COMPARATOR|Cohort A|Samples centrifuged/aliquoted after arrival at central lab.
62028547|NCT06507566|ACTIVE_COMPARATOR|Cohort B|Samples centrifuged/aliquoted at collection Site before shipment to central lab.
62028548|NCT02612402|EXPERIMENTAL|Learning algorithm|The app will be installed on the patients's phone. The app will measure the amount of activity performed. THE INTERVENTION IS THAT the Patients will receive daily messages, a learning algorithm will study the exercise response to each type of message and personalize the best message sequence for each patient.
62028549|NCT02612402|ACTIVE_COMPARATOR|control|The app will be installed on the patients's phone. The app will measure the amount of activity performed. THE INTERVENTION IS THAT THE Patients will receive a weekly reminder to exercise.
62028550|NCT00050310||Acute Infection (confirmed or suspected)|adults and children with acute anthrax infection
62227356|NCT02607696|EXPERIMENTAL|Zolpidem 3.50 mg|Zolpidem Hemitartarate 3.50 mg Orodispersible Tablets Once daily
62420181|NCT06012175|PLACEBO_COMPARATOR|Placebo|The control group will receive an identical-looking inert placebo tablet every night before going to bed
62590465|NCT01727544|NO_INTERVENTION|Non Surgical Group|patients meet the same criteria but will elect not to undergo surgery
62802933|NCT03112265|ACTIVE_COMPARATOR|Usual Care|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective, and researchers will not influence their work.
62802934|NCT02763644|EXPERIMENTAL|LFG316 plus SoC|LFG316 plus SoC (excluding plasmapheresis and prohibited treatment)
62802935|NCT02763644|EXPERIMENTAL|All SoC first|Standard of Care then LFG316 plus SoC
62802936|NCT01529073|EXPERIMENTAL|Nitazoxanide|
62028551|NCT00050310||AVA Recipient/Healthy Volunteer|healthy adults who have received AVA vaccine
62028552|NCT00050310||Recovered|adults and children in recovering phase of anthrax infection
62028553|NCT00050310||Suspected Exposure|adults and children with suspected exposure to anthrax
62028554|NCT06531954|ACTIVE_COMPARATOR|Breathing exercise group (BE)|The content of breathing exercises was planned as thoracic expansion exercises. These exercises were applied to the lower, middle, and upper lobes in 3 sets of 3x10 (90 times breathing in one area) and lasted for an average of 20 minutes. These exercises were first taught by the physiotherapist and performed under her supervision. Participants were asked to inhale as deeply as possible into the relevant area, hold their breath for 3 seconds, and then slowly exhale the entire breath.
62227357|NCT01788098||Rheumatoid Arthritis|Patients with rheumatoid arthritis
62227358|NCT01788098||Healthy controls|Healthy control subjects
62420182|NCT05090722|EXPERIMENTAL|The PureWick Urine Collection System|The PureWick Urine Collection System is intended for non-invasive urine output management. It pulls urine through tubing that is connected to a collection canister for proper disposal. It is designed to be used by patients, caregivers, or healthcare professionals in both home environments and professional care facilities.
62590466|NCT00784303|EXPERIMENTAL|DTC cohort|This arm will enroll participants with radioiodine (131 I)-refractory/resistant differentiated thyroid cancer.
62590467|NCT00784303|EXPERIMENTAL|MTC cohort|This arm will enroll participants with medullary thyroid cancer.
62802937|NCT04879693|EXPERIMENTAL|Hospitalized Patients|To assess performance of CGM compared to comparator measurement.
62420183|NCT06056531|EXPERIMENTAL|NIR light visualization|The participant performing PVC carried out the procedure on the arm vein of another volunteer classmate with the help of vein imaging by NIR. All interventions were conducted under the observation of the researchers. The researchers used a chronometer to measure and record how long the PVC took. Participants were asked about the degree of vein prominence under NIR light after the tourniquet was applied, using inspection and palpation. The chronometer was started after the tourniquet was applied and stopped when the catheter plaster was applied. The time that it took to choose the materials needed for the PVC was not added to this time. The researchers recorded whether the PVC procedure was successful or unsuccessful. The cannula's placement during PVC was evaluated by drawing blood and returning it to the vein with a syringe. The PVC procedure was considered a failure if the vein was not opened or no blood reached the syringe.
62028555|NCT06531954|EXPERIMENTAL|Vagus nerve stimulation group (VNS)|Vagus stimulation was applied bilaterally through the ear. taVNS was performed with the Vagustim device. The stimulation pulse width was 300 microseconds, the frequency was 10 Hz, and it was biphasic with a 20-minute duration. Electrodes were placed on the concha and tragus parts of the ear, and the current was increased through these electrodes until the participant felt pain. When the participant felt pain, the intensity was reduced to a comfortable sensation.
62028556|NCT06486168|EXPERIMENTAL|Diaphragmatic Dysfunction evaluation|
62028557|NCT00765193|OTHER|Skin cancer screening|
62802938|NCT00052585|EXPERIMENTAL|Treatment (irinotecan, gefitinib, leucovorin, fluorouracil)|Patients receive oral gefitinib daily beginning on day 1, irinotecan IV over 90 minutes on days 1 and 15, and leucovorin calcium IV over 2 hours and fluorouracil IV over 3-5 seconds followed by a 22-hour infusion on days 1, 2, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62028558|NCT06670352|PLACEBO_COMPARATOR|Placebo|
62028559|NCT06670352|EXPERIMENTAL|HSK39297 50mg BID|
62028560|NCT06670352|EXPERIMENTAL|HSK39297 100mg BID|
62028561|NCT06670352|EXPERIMENTAL|HSK39297 200mg QD|
62028562|NCT02848417|EXPERIMENTAL|Curcumin|12 weeks 400mg orally twice a day
62028563|NCT02848417|EXPERIMENTAL|Liposomal Glutathione|12 weeks 630mg orally twice a day
62028564|NCT02848417|EXPERIMENTAL|Placebo Liquid or Capsules|"Placebo liquid for Glutathione 120 ml per/ bottle 420 mg/5 ml~Placebo capsules for Curcumin 60 capsules per bottle 400 mg /cap"
62028565|NCT00386906|OTHER|Sentinel Lymph Node (SLN) Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
62420184|NCT06056531|EXPERIMENTAL|isometric hand exercise|In this group, the participants performing PVC carried out the procedure by observing vein dilation after isometric exercise. Before the procedure, the students on whom PVC was to be performed were given two stress balls, and they were told how to use them for 15 minutes. The stress balls used in the study were 6 cm in diameter and yellow in color. They were of medium hardness and made of high-quality silicone. The participants were told to squeeze and relax the stress ball in the palm of their hands after counting from one to three, to continue doing this until the procedure began, and to concentrate on squeezing the ball. Participants were asked about the degree of vein prominence after the isometric exercise and tourniquet was applied, using inspection and palpation. The remaining stages were carried out in the same way as with all of the groups.
62802939|NCT04429191|EXPERIMENTAL|Blood Stem Cell Transplant w/ anti-CD117 conditioning|"The phase 1a portion of the study plans to assess approximately 3 planned dose cohorts of JSP191: 0.3 mg/kg, 0.6 mg/kg, and 1.0 mg/kg to determine the maximum tolerated dose for expansion. Subjects will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery.~The phase 1b portion of the study will enroll additional subjects at the expansion dose in order to further explore the safety, feasibility, and PK of that dose."
62420185|NCT06056531|NO_INTERVENTION|Control group: no intervention|The students in this group performed the PVC procedure directly on each other's arm veins without NIR or isometric exercise. Participants were asked about the degree of vein prominence after the tourniquet was applied, using inspection and palpation. The remaining stages were carried out in the same way as with all of the groups.
62420186|NCT05442515|EXPERIMENTAL|1/Phase I Dose Escalation-with standard LD - CLOSED|CD19/CD22-CAR-transduced T cells at escalating dose + standard LD
62420187|NCT05442515|EXPERIMENTAL|1b/Phase 1 Dose Escalation - low disease burden|CD19/CD22-CAR-transduced T cells
62028566|NCT02727101|ACTIVE_COMPARATOR|phenobarbital|"After 12 weeks of baseline observation on phenobarbital medication, the treatment with perampanel will introduced as add on medication."
62028567|NCT02727101|ACTIVE_COMPARATOR|valproate|"After 12 weeks of baseline observation on valproate medication, the treatment with perampanel will introduced as add on medication."
62028568|NCT02727101|ACTIVE_COMPARATOR|lamotrigine|"After 12 weeks of baseline observation on lamotrigine medication, the treatment with perampanel will introduced as add on medication."
62028569|NCT02727101|ACTIVE_COMPARATOR|levetiracetam|"After 12 weeks of baseline observation on levetiracetam medication, the treatment with perampanel will introduced as add on medication."
62420188|NCT05442515|EXPERIMENTAL|2/Phase I Dose Escalation- with intensified LD - CLOSED|CD19/CD22-CAR-transduced T cells + standard LD
62420189|NCT05442515|EXPERIMENTAL|2b/Phase 1 Dose Escalation - high disease burden|CD19/CD22-CAR-transduced T cells
62420190|NCT05442515|EXPERIMENTAL|3/Phase II Dose Expansion- with low disease burden|CD19/CD22-CAR-transduced T cells at MTD/or highest dose administered with LD
62227359|NCT02932007|EXPERIMENTAL|Chloroquine Phosphate|Chloroquine Phosphate will be provided at 500 mg dosage strength for oral administration. Patient will be instructed to take 2 tablets per day on the first two days and 1 tablet each day for the next 12 days for a total of 14 days treatment.
62227360|NCT01209143|EXPERIMENTAL|Vismodegib + rosiglitazone|Participants received rosiglitazone 4 mg orally on Days 1 and 8 of the study. Participants also received vismodegib 150 mg orally once a day beginning on Day 2 until one of the following occurred; disease progression, intolerable toxicity, most probably attributable to vismodegib, or patient withdrawal of consent.
62590468|NCT05845021|EXPERIMENTAL|Surgeon-Initiated Bone Health Referral Pathway|Patients assigned in the endocrinology bone health referral pathway would be formally referred by the surgeon to see endocrinology for clearance before undergoing lower extremity arthroplasty. In addition to normal labs, the surgeon will initiate additional bone health labs in these patients before consultation with endocrinology. Endocrinology providers will be available for a virtual consultation to review the patients DEXA and bone health labs; start the patient on the appropriate medication; and provide patient education regarding osteoporosis and bone health. For those undergoing evaluation by endocrinology, these providers will let the surgical team know when and whether the patient has initiated treatment.
62802940|NCT03228771|ACTIVE_COMPARATOR|PRGF/ATV|"Group I (PRGF/ATV) : It was included 10 patients undergoing single tooth extraction followed by socket fill with 1.2% Atorvastatin loaded in PRGF derived fibrin scaffold then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.~Intervention: Atorvastatin drug loaded in platelets rich in growth factors (PRGF)."
62802941|NCT03228771|ACTIVE_COMPARATOR|ATV gel|Group II (ATV gel) : Will include 10 patients undergoing single tooth extraction followed by socket fill with 1.2% Atorvastatin in methyl cellulose gel then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.
62802942|NCT03228771|NO_INTERVENTION|Empty socket|Group III Empty socket( control) : Will include 10 patients undergoing single tooth extraction then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.
62802943|NCT06049329|EXPERIMENTAL|NNC0487-0111|Once-daily oral administration - 1 of 3 different doses
62802944|NCT06049329|PLACEBO_COMPARATOR|Placebo|Once-daily oral administration - 1 of 3 different doses
62802945|NCT02169986|NO_INTERVENTION|control group|Parents/caregivers will receive the standard of care.
62227361|NCT01209143|EXPERIMENTAL|Vismodegib + oral contraceptive|Participants received the oral contraceptive norethindrone 1 mg/ethinyl estradiol 35 µg (Ortho-Novum 1/35®) orally on Days 1 and 8 of the study. Participants also received vismodegib 150 mg orally once a day beginning on Day 2 until one of the following occurred; disease progression, intolerable toxicity, most probably attributable to vismodegib, or patient withdrawal of consent.
62227362|NCT03890718|EXPERIMENTAL|Photorefractive keratectomy in mile keratoconus|Photorefractive keratectomy in mile keratoconus type of corneal surface ablation in for correct refractive error
62227363|NCT00502021|EXPERIMENTAL|1|Supplement of flaxseed powder (60 g/day)during 12 weeks
62227364|NCT00502021|PLACEBO_COMPARATOR|2|Placebo powder supplement 60 g/day during 12 weeks
62227365|NCT00502021|EXPERIMENTAL|3|Flaxseed oil 30 ml/day (10 g ALA)during 12 weeks
62802946|NCT02169986|EXPERIMENTAL|electronic reminders|In this group, the parents/caregivers will receive two daily electronic reminders in addition to the standard of care.
62802947|NCT00134303|EXPERIMENTAL|NASH|
62802948|NCT06109363|EXPERIMENTAL|Stepped-care CBT-I group|"A total of 3 steps of CBT-I intervention will be provided, with the objectives to increase the awareness of sleep health, increase sleep literacy, establish good sleep hygiene and treat insomnia.~Step 1: self-help digital CBT-I program; Step 2: guided CBT-I program; Step 3: individualized consultation."
62802949|NCT06109363|NO_INTERVENTION|Control group|Participants in the control group remain unexposed to the stepped-care CBT-I intervention.
62227366|NCT00502021|PLACEBO_COMPARATOR|4|Safflower oil 30 ml/day (no ALA) during 12 weeks
62227367|NCT06137014|EXPERIMENTAL|Amino acid-fortified oral rehydration therapy|"Participants will consume the amino acid-fortified oral rehydration therapy (fORT) according to the World Health Organization (WHO) Treatment Plan A for ORT administration:~* Child under 24 months: 50 to 100 ml ORT after each loose stool (approximately 500 ml daily)~* Child from 2 to 10 years: 100 to 200 ml ORT after each loose stool (approximately 1000 ml daily)"
62420191|NCT05442515|EXPERIMENTAL|4/Phase II Dose Expansion- with high disease burden|CD19/CD22-CAR-transduced T cells at MTD/or highest dose administered with LD regimen #2
62420192|NCT01093482||mechanically ventilated patients|"1. Patients who are admitted to the participating intensive care units and require invasive mechanical ventilation (endotracheal tube or tracheostomy) for more than 12 hours.~2. Patients who are admitted to the participating intensive care units and require non-invasive mechanical ventilation (Bilevel positive airway pressure (BIPAP) or continuous positive airway pressure (CPAP) with nasal or facial mask) for more than 1 hour."
62227368|NCT06137014|PLACEBO_COMPARATOR|Standard of care oral rehydration therapy|"Participants will consume the standard of care oral rehydration therapy according to the WHO Treatment Plan A for ORT administration:~* Child under 24 months: 50 to 100 ml after each loose stool (approximately 500 ml daily)~* Child from 2 to 10 years: 100 to 200 ml after each loose stool (approximately 1000 ml daily)"
62590469|NCT05845021|NO_INTERVENTION|Standard of Care|The control arm will be composed of patients identified in the osteoporotic range like the endocrinology bone health referral pathway. These patients will be told by the surgeon that the patient has osteoporosis based on the DEXA scan and will be told to follow-up these results with the patient's primary care provider. These patients do not need bone health clearance before undergoing surgery. Only serum 25-hydroxyvitamin D levels will be added on to the patient's standard of care pre-operative labs. The control arm is the current standard of care. Comparing this pathway to the endocrinology referral pathway permits an assessment on the efficacy of the new pathway.
62590470|NCT03310801||LAAO with DAPT|patients with AF who underwent PCI and treated with LAAO(either ACP or Watchman) and DAPT
62802950|NCT02614729|EXPERIMENTAL|Energy Balance Comparison|"Participants will randomly consume 4 eucaloric diets for 7 consecutive days/treatment. Energy levels for all diets are established according to needs for energy balance.~Interventions:~Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN); Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN); High Protein-Beef, Even Distribution (HP-BEEF-EVEN); High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)"
62802951|NCT02614729|EXPERIMENTAL|Energy Restriction Comparison|"Participants will randomly consume 3 energy restriction diets (1250 kcal/day) for 7 consecutive days/treatment. Energy levels for all diets are established according to needs for energy restriction.~Interventions:~Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN); Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN); High Protein-Beef, Even Distribution (HP-BEEF-EVEN)"
62227369|NCT04617210||Surgical Cohort|Elderly patients aged 65 and above who are planned for major non-cardiac surgery predicted to be at least 2 hours in duration and requiring at least 1 postoperative stay in hospital.
62227370|NCT01468129|ACTIVE_COMPARATOR|Cell Saver|
62420193|NCT05802342|EXPERIMENTAL|A|GM1 (100 mg) + albumin paclitaxel
62590471|NCT03310801||Conventional antithrombotic therapy|patients with AF who underwent PCI and treated with conventional antithrombotic therapy
62590472|NCT01629290|ACTIVE_COMPARATOR|Enamel Pro|Varnish containing 5%NaF
62590473|NCT01629290|ACTIVE_COMPARATOR|Duraphat|Varnish containing 5%NaF
62590474|NCT01629290|ACTIVE_COMPARATOR|Vanish|Varnish containing 5%NaF
62802952|NCT05487521|NO_INTERVENTION|Patients without EEG changes or clinical seizures|
62802953|NCT05487521|EXPERIMENTAL|Patients with EEG changes or clinical seizures|
62227371|NCT01468129|NO_INTERVENTION|Non Cell Saver|
62420194|NCT05802342|EXPERIMENTAL|B|GM1 (400 mg) + albumin paclitaxel
62420195|NCT05802342|PLACEBO_COMPARATOR|C|placebo + albumin paclitaxel
62420196|NCT01057160|EXPERIMENTAL|intake of rizatriptan 10 mg|
62420197|NCT01057160|ACTIVE_COMPARATOR|previous used analgesic|
62590475|NCT01629290|PLACEBO_COMPARATOR|Placebo|Bland varnish containing no NaF
62590476|NCT05948501||mTBI w/ Visual Impairment|Individuals 18 years or older, current patient of Gaylord Hospital Outpatient Services, within the last 6 months have been diagnosed with a mTBI/concussion with visual field loss of greater than or equal to 20% as determined by a perimetry screening
62590477|NCT05948501||mTBI w/o Visual Impairment|Individuals 18 years or older, current patient of Gaylord Hospital Outpatient Services, within the last 6 months have been diagnosed with a mTBI/concussion currently presenting with no symptoms consistent with peripheral vision loss.
62227372|NCT04997759|EXPERIMENTAL|Neostigmine group|This group will administered neostigmine for reverse the efficacy of neuromuscular blocking agent and stabilize the patient's vital signs.
62802954|NCT06307418|EXPERIMENTAL|Internet-based support (Carer eSupport)|The internet-based support is developed in collaboration with clinical expertise within head and neck cancer care and an expert group of informal caregivers to patients with head and neck cancer. The support comprise text, lectures, films, discussion forum and real-time video meetings with clinical experts. The support will last for 18 weeks.
62802955|NCT06307418|NO_INTERVENTION|Support as usual|Support as usual comprise a possibility for informal caregivers to contact a specified nurse with expertise in head and neck , at the head and neck or oncology clinic, to ask for support. Healthcare counsellors at the clinics is also available for ICs on request. Group support providing emotional and social support for ICs to patients with various cancer diagnoses may also be arranged at the clinics occasionally. Also, the Swedish healthcare is always responsible for recognizing the need for support for children (\< 18 years) of patients with cancer.
62802956|NCT05266612|EXPERIMENTAL|Monotherapy Arm|This is an open label trial using standard 3+3 design, in up to 24 HSV seropositive subjects. This rule-based design proceeds with cohorts of three patients.
62802957|NCT05266612|EXPERIMENTAL|Combination Arm|The starting dose of VG2025 in the combination cohorts will be a dose of 1.0 x108 PFU for combination cohort 1 on days 1 and 15 of every cycle. Combination cohort 2 will be dosed at 1.0 x108 PFU on Day 1 and either Day 2 or 3 in cycle 1 and 2. Day 1 only in subsequent cycles
62590478|NCT05948501||Healthy Control|Community dwelling adults aged 18 years or older with no diagnosis of mTBI/concussion within the last 6 months. Population will be matched to the concussion population within the age, gender, and height range of the concussion population.
62802958|NCT03006380|EXPERIMENTAL|oxytocin before placental delivery|patients who will receive 10 IU of oxytocin (syntocinon®, NOVARTIS, Egypt) intramuscularly at delivery of anterior shoulder of the fetus and an identical placebo injection (normal saline, NACL 0.9%) intramuscularly following delivery of the placenta.
62227373|NCT04997759|EXPERIMENTAL|Sugammadex group|This group will administered Sugammadex for reverse the efficacy of neuromuscular blocking agent and stabilize the patient's vital signs.
62227374|NCT05740735||Disorder of consciousness patients - Prospective group|DOC defined either by a coma (Glasgow Coma Scale \<8), a vegetative state (VS) or a minimal state of consciousness (MCS) according to the Coma recovery scale-revised (CRS-r) after a primary brain injury: severe traumatic brain injury (TBI)), subarachnoid hemorrhage, stroke or cardiac arrest (CA)
62802959|NCT03006380|EXPERIMENTAL|oxytocin after placental delivery|patients who will receive placebo injection (normal saline, NACL 0.9%) intramuscularly at delivery of anterior shoulder of the fetus and 10 IU of oxytocin (syntocinon®, NOVARTIS, Egypt) intramuscularly following delivery of the placenta.(opposite medication sequence)
62227375|NCT05740735||Disorder of consciousness patients - Retrospective group|
62227376|NCT01684332|EXPERIMENTAL|High Sugar (HS)|Study of the postprandial effects after consuming 60g of strawberry jam with high sugar content
62227377|NCT01684332|EXPERIMENTAL|Low Sugar (LS)|Study of the postprandial effects after consuming 60g of strawberry jam with low sugar content
62227378|NCT01684332|EXPERIMENTAL|Low Sugar + Antioxidant (LSA)|Study of the postprandial effects after consuming 60g of strawberry jam with low sugar content and an antioxidant extract from strawberry pulp
62227379|NCT03797261|EXPERIMENTAL|Venetoclax + AMG 176|Venetoclax and AMG 176 will be administered in combination. Different combinations of dose levels for venetoclax and AMG 176 will be explored.
62227380|NCT01079741|EXPERIMENTAL|Dose-escalation component|Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen and Montanide will be held constant.
62590479|NCT06122870|EXPERIMENTAL|CampETEC HBC group|CampETEC HBC (hyper immune bovine colostrum) and challenge strain C. jejuni CG8421
62590480|NCT06122870|PLACEBO_COMPARATOR|Placebo ProMilk 85 group|ProMilk 85 (placebo) and challenge strain C.jejuni CG8421
62227381|NCT01079741|ACTIVE_COMPARATOR|Phase II is the randomized component.|The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B).
62227382|NCT04107376|EXPERIMENTAL|Retroviewing endoscopy (RVE)|Withdrawal in every colonic segment with SFV (standard forward view) followed by another withdrawal with the retroviewing endoscope. Allocation of patients to each arm (RVE or SFVE) is done by randomization using sealed envelopes.
62227383|NCT04107376|ACTIVE_COMPARATOR|standard forward viewing endoscopy (SFVE)|Withdrawal in every colonic segment with SFV followed by another withdrawal with SFV. Allocation of patients to each arm (RVE or SFVE) is done by randomization using sealed envelopes.
62028570|NCT02727101|ACTIVE_COMPARATOR|zonisamide|"After 12 weeks of baseline observation on zonisamide medication, the treatment with perampanel will introduced as add on medication."
62028571|NCT02727101|ACTIVE_COMPARATOR|pregabalin|"After 12 weeks of baseline observation on pregabaline medication, the treatment with perampanel will introduced as add on medication."
62227384|NCT03701815|EXPERIMENTAL|Post-stroke|Patients will receive a 12-week lifestyle medicine program.
62227385|NCT03309306|NO_INTERVENTION|Phase 1: Lab Testing (Visit 1, Day 0)|Participants will test the FoodImage App and Pen-and-paper Records with in a Laboratory Kitchen. Participants will use the FoodImage app and food records to measure food waste during simulated shopping trip and kitchen clean-out. Measurements will be collected by participants with both methods while lab personnel directly weigh foods to provide the criterion value.
62227386|NCT03309306|ACTIVE_COMPARATOR|Phase 2: RCT Stress Management|Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will capture baseline data for 4-7 days. After a 1-week break, participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also receive information on stress management
62227387|NCT03309306|EXPERIMENTAL|Phase 2: RCT Food Waste Reduction|"Phase 2 will occur in participants' natural environment (free-living conditions). Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges. Participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also be provided with the following:~1. Feedback on the amount of food waste their household created during the first week,~2. A goal to reduce the next week's food waste by 20% or more, and~3. Tips on how to reduce household food waste adapted from current consumer campaigns"
62028572|NCT02727101|ACTIVE_COMPARATOR|lacosamide|"After 12 weeks of baseline observation on lacosasmide medication, the treatment with perampanel will introduced as add on medication."
62028573|NCT02727101|ACTIVE_COMPARATOR|clobazam|"After 12 weeks of baseline observation on clobazam medication, the treatment with perampanel will introduced as add on medication."
62028574|NCT02727101|ACTIVE_COMPARATOR|ezogabine|"After 12 weeks of baseline observation on ezogabine medication, the treatment with perampanel will introduced as add on medication."
62028575|NCT02727101|ACTIVE_COMPARATOR|eslicarbazepine|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
62028576|NCT02727101|ACTIVE_COMPARATOR|topiramate|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
62227388|NCT04188691|EXPERIMENTAL|vaccine group 1|vaccine produced by NVSI , Specification: GI.1 / GII.4 (low), 0.5ml / dose
62227389|NCT04188691|EXPERIMENTAL|vaccine group 2|vaccine produced by NVSI , Specification: GI.1 / GII.4 (middle), 0.5ml / dose
62227390|NCT04188691|EXPERIMENTAL|vaccine group 3|vaccine produced by NVSI , Specification: GI.1 / GII.4 (high), 0.5ml / dose
62227391|NCT04188691|PLACEBO_COMPARATOR|Normal saline|（0.5ml / dose）produced by NVSI
62227392|NCT04188691|PLACEBO_COMPARATOR|Aluminum adjuvant|（0.5ml / dose）produced by NVSI
62802960|NCT01028105|NO_INTERVENTION|No MRSA screening, Group b|Standard of care
62802961|NCT01028105|OTHER|MRSA screening, Group a|MRSA preoperative screening
62802962|NCT03584165|EXPERIMENTAL|BIIB111|Participants previously treated with sub-retinal injection of BIIB111 in antecedent studies 273CH301 (NCT03496012) and 273CH203 (NCT03507686) will be enrolled. Participants previously treated with this same sub-retinal injection (rAAV2-REP1) in antecedent studies 20150371 (NCT02553135), Pro00028599 (NCT02077361), THOR-TUE-01 (NCT02671539), CHM09/01 (NCT01461213) and REGEN2015 (NCT02407678) will also be invited for enrollment. This is a follow-up study, investigational product was administered in the previous study.
62802963|NCT03584165|EXPERIMENTAL|BIIB112|Participants previously treated with sub-retinal injection of BIIB112 in the antecedent study 274RP101 (NCT03116113) will be enrolled. This is a follow-up study, investigational product was administered in the previous study.
62028577|NCT02727101|ACTIVE_COMPARATOR|tiagabine|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
62028578|NCT06030726|NO_INTERVENTION|Usual Care|No letter
62028579|NCT06030726|EXPERIMENTAL|Standard Letter|This group will receive a standard letter on the benefits of influenza vaccination without behavioral economic enhancement
62028580|NCT06030726|EXPERIMENTAL|Repeated Letter|The standard letter sent out two times instead of once
62028581|NCT06030726|EXPERIMENTAL|Cardiovascular Gain-Framing Letter|Text added to the standard letter highlighting potential cardiovascular benefits of influenza vaccination
62028582|NCT06030726|EXPERIMENTAL|Respiratory Gain-Framing Letter|Text added to the standard letter highlighting potential respiratory disease-related benefits of influenza vaccination
62028583|NCT06030726|EXPERIMENTAL|Implementation Intention Prompt Letter|Implementation intention prompt added to the standard letter
62028584|NCT06030726|EXPERIMENTAL|Loss-Framing Letter|Text added to the standard letter highlighting potential risks of not receiving influenza vaccination
62028585|NCT03551015|EXPERIMENTAL|Intervention|The intervention arm will have outpatient review at 3 weeks and start 8 sessions of cardiac rehabilitation from 4 weeks, after hospital discharge following CABG.
62028586|NCT03551015|NO_INTERVENTION|Control|This arm will have outpatient review 6 weeks after hospital discharge and start 8 sessions of cardiac rehabilitation from 8 weeks.
62028587|NCT05956340|EXPERIMENTAL|Recording Session During Hospitalization|While inpatient, participants will undergo a research interview with recorded audio.
62028588|NCT04402177|EXPERIMENTAL|Hypersensitivity Pneumonitis patients showing lung fibrosis|hypersensitivity Pneumonitis patients that shows lung fibrosis after CT scan ( fibrotic patients ) methyl prednisolone 0.5mg/kg /day orally for 8 weeks
62028589|NCT04402177|ACTIVE_COMPARATOR|hypersensitivity Pneumonitis patients without lung fibrosis|hypersensitivity Pneumonitis patients that doesn't show lung fibrosis after CT ( non-fibrotic patients ) will be given also methyl prednisolone 0.5mg/kg /day orally for 8 weeks
62028590|NCT04833647|OTHER|Term|7-10 years old born at 37-42 weeks gestation
62028591|NCT04833647|OTHER|Late preterms|7-10 years old born at 34.0-36.6 weeks gestation
62028592|NCT04833647|OTHER|Preterms with BPD|7-10 years old born before 30 weeks gestation with the diagnosis of BPD: the need for oxygen at 36 weeks gestation and/or flow or 3LPM or more, and/or the need for CPAP or invasive ventilation
62028593|NCT04833647|OTHER|pretermas without BPD|7-10 years old born before 30 weeks gestation without the diagnosis of BPD (without the need for oxygen at 36 weeks gestation and/or flow or 3LPM or more, and/or the need for CPAP or invasive ventilation)
62028594|NCT04777565|EXPERIMENTAL|CI surgery|cochlear implant surgery
62028595|NCT06262529|EXPERIMENTAL|Acute ischemic stroke|
62227393|NCT01676909|EXPERIMENTAL|Living Well|This study will involve a clinical trial of Living Well (LW), a 12-session, peer co-led, group intervention designed to help veterans with co-occurring Serious Mental Illnesses and Chronic Medical Conditions learn techniques for better health management and ways to live a healthier lifestyle. Key topics that will be discussed are medication side effects, how symptoms of mental illness may affect veterans' ability to manage their medical conditions, effects of substance use on medical and mental health functioning, learning ways to eat healthier and exercise, and how to communicate more effectively with care providers. After completing the 12 weekly groups, participants will return to complete once monthly booster group sessions for the next three months.
62227394|NCT01676909|ACTIVE_COMPARATOR|Medical Illness Education & Support Group|We selected a comparison condition that would provide parallel focus (i.e. medical illness) but not include use of the core ingredients undergirding the Living Well intervention including behavioral action planning, problem solving, in-session and between session practice using specific disease self-management techniques and involvement of peer co-facilitators to enhance modeling and improve self-efficacy and activation. As with Living Well, the content of the intervention will have broad applicability across diverse chronic disease conditions. The comparison condition will be a once-weekly support and education group focusing on living with a chronic medical condition.
62227395|NCT05517837|EXPERIMENTAL|BMS-986421 Under Fasted Conditions|
62420198|NCT03105089|ACTIVE_COMPARATOR|ischemic preconditioning|ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
62420199|NCT03105089|NO_INTERVENTION|control|no intervention will be done
62420200|NCT00704990|EXPERIMENTAL|A|All study participants take part in the experimental arm
62802964|NCT03584165|NO_INTERVENTION|Untreated|Untreated participants who served as controls in the antecedent study 273CH301 (NCT03496012), investigating treatment with BIIB111, will be enrolled. This is a follow-up study, participants will not be administered study medication nor receive a sham surgery.
62802965|NCT06434883|ACTIVE_COMPARATOR|Anxiety/Depression Program|
62420201|NCT03105882|EXPERIMENTAL|Neuro-Spinal Scaffold|
62420202|NCT06701110|EXPERIMENTAL|Single Oral Dose of [U-14C] WX-081|Participants will receive a single oral dose of approximately 450 mg (100 μCi) of \[U-14C\] WX-081. The study involves collecting biological samples, including blood, plasma, urine, and feces, at specified time points to evaluate pharmacokinetics, metabolism, mass balance, and excretion pathways.
62802966|NCT06434883|OTHER|Waitlist|
62420203|NCT04199104|EXPERIMENTAL|Pembrolizumab with Lenvatinib|Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
62802967|NCT00887549|EXPERIMENTAL|Pemetrexed|
62802968|NCT01425684||schizophrenia|smokers and nonsmokers
62802969|NCT01425684||control|smokers and nonsmokers
62028596|NCT05064969|EXPERIMENTAL|Single-arm non-randomised|This study includes a baseline assessment, a 9-week (with the possibility of extension to 12 weeks) blended intervention period, a post-intervention assessment, and two follow-ups at 3 and 6 months. Informal caregivers of people with dementia (with at least 18-year-old) with no restriction in terms of sex, educational level, or ethnic background will be included.
62028597|NCT05282381||Cohort of renal transplant recipients|
62028598|NCT06328361|EXPERIMENTAL|Nonoperative management|The patients presenting with complete clinical response undergo nonoperative management (i.e. watch \& wait) as surveillance for local regrowth or distant spread.
62028599|NCT01248650|ACTIVE_COMPARATOR|TRK-820 5 μg|Taking TRK-820 5μg(two 2.5μg soft capsules) once on the first day of hospitalization by oral route
62227396|NCT05517837|PLACEBO_COMPARATOR|Placebo|
62227397|NCT02480153|EXPERIMENTAL|PF-06410293|
62227398|NCT02480153|ACTIVE_COMPARATOR|Adalimumab|
62802970|NCT05343858|EXPERIMENTAL|Group 1: Spirulina platensis|10 volunteers will consume 16g / day (in 2 doses of 8g) of a nutritional supplement of Spirulina platensis
62802971|NCT05343858|EXPERIMENTAL|Group 2: Chlorella vulgaris|10 volunteers will consume 16g / day (in 2 doses of 8g) of a nutritional supplement of Chlorella vulgaris
62802972|NCT05343858|PLACEBO_COMPARATOR|Group 3: Control|10 volunteers will consume 16g / day (in 2 doses of 8g) of a control supplement
62028600|NCT01248650|ACTIVE_COMPARATOR|TRK-820 2.5μg|Taking TRK-820 2.5μg(one 2.5μg soft capsule) once on the first day of hospitalization by oral route
62028601|NCT02785406|EXPERIMENTAL|suvorexant|Subjects will receive suvorexant (10 mg week 1, 20 mg week 2), once daily at 10 PM.
62028602|NCT02785406|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo once daily at 10 PM.
62028603|NCT05014594|ACTIVE_COMPARATOR|Group A (Dapaglifozin)|Group A will receive oral Dapaglifozin (10 mg/day) along with standard medical therapy for 6 months
62028604|NCT05014594|PLACEBO_COMPARATOR|Group B (Placebo)|Group B will receive placebo of Dapaglifozin along with standard medical therapy for 6 months
62028605|NCT02253693||Patients with haemophilia|Adult patients with haemophilia A presenting joint disease.
62028606|NCT02529774|EXPERIMENTAL|Systemic Chemotherapy plus Hepatic Artery Infusion (HAI)|
62028607|NCT02529774|ACTIVE_COMPARATOR|Systemic Chemotherapy|
62227399|NCT04989413|ACTIVE_COMPARATOR|Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg|Cannabidiol + Cannabigerol + Tetrahydrocannabinol in the maximum dosage of 133/66/4mg, divided in 2 doses of 66.5/33/2mg a day for 12 weeks. Each drop contain CBD/CBG/THC 1.66/0.8/0.05 mg, and medication will be titrated up as follow: day 1 to day 3 - 10 drops twice a day day 4 to day 6 - 20 drrops twice a day day 7 to day 9 - 30 drops twice a day from day 10 to the end of the study 40 drops twice a day
62028608|NCT04790981|ACTIVE_COMPARATOR|selected physical therapy program group|The Control group received the selected physical therapy program for one hour, three times weekly for three successive months including facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern
62227400|NCT04989413|PLACEBO_COMPARATOR|Placebo|"Placebo capsules will be titrated up as follow:~day 1 to day 3 - 10 drops twice a day day 4 to day 6 - 20 drops twice a day day 7 to day 9 - 30 drops twice a day from day 10 to the end of the study 40 drops twice a day"
62802973|NCT06289933|EXPERIMENTAL|BR3005|
62028609|NCT04790981|ACTIVE_COMPARATOR|motor imaginary training and selected physical therapy program group|"The study group received the selected physical therapy program for one hour, three times weekly for three successive months in addition to motor imagery program for 30 minutes as the following.~Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi-reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise"
62028610|NCT04201548|ACTIVE_COMPARATOR|Active Comparator|This is the constant-load Endurance Training (ET) group which will constitute the control group.
62028611|NCT04201548|EXPERIMENTAL|Long High Intensity Interval Training|This is the Long High Intensity Interval Training (Long-HIIT) group.
62028612|NCT04201548|EXPERIMENTAL|Short High Intensity Interval Training|This is the Short High Intensity Interval Training (Short-HIIT) group.
62227401|NCT05681858||CT coronary angiography and [12N] NH3 PET-MR|All patients will undergo CT coronary angiography and stress \[12N\] NH3 PET-MR
62227402|NCT03426254|EXPERIMENTAL|Injections Subcutaneously Talazoparib|"Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Auto-Injector delivers a single dose of 1 mg Talazoparib injection (subcutaneous)"
62227403|NCT03426254|ACTIVE_COMPARATOR|Oral capsules Talazoparib|Patients receive 1 mg of Talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62420204|NCT04199104|ACTIVE_COMPARATOR|Pembrolizumab with Placebo|Participants receive lenvatinib-matching placebo orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months).
62420205|NCT00689273|EXPERIMENTAL|PF-04136309|
62227404|NCT03775070|EXPERIMENTAL|Simvastatin|Simvastatin, 0.5mg/kg/d(maximum 20mg), once daily
62420206|NCT00689273|PLACEBO_COMPARATOR|Placebo|
62802974|NCT06289933|ACTIVE_COMPARATOR|BR3005-1+BR3005-2|
62802975|NCT03275740|EXPERIMENTAL|PF-06755347 intravenous healthy participant|intravenous administration
62802976|NCT03275740|PLACEBO_COMPARATOR|Placebo intravenous healthy participant|intravenous administration
62802977|NCT03275740|EXPERIMENTAL|PF-06755347 subcutaneous healthy participant|subcutaneous administration
62802978|NCT03275740|PLACEBO_COMPARATOR|Placebo subcutaneous healthy participant|subcutaneous administration
62420207|NCT04060927|EXPERIMENTAL|Group 1|Freebreathing SBRT with SGRT
62420208|NCT04060927|EXPERIMENTAL|Group 2|Breath hold SBRT with SGRT
62802979|NCT03275740|EXPERIMENTAL|PF-06755347 subcutaneous ITP|subcutaneous
62802980|NCT00619515|EXPERIMENTAL|CyberKnife® stereotactic radiosurgery|
62028613|NCT06670274|EXPERIMENTAL|Part 1 SAD|
62028614|NCT06670274|EXPERIMENTAL|Part 2 MAD|
62028615|NCT06670274|PLACEBO_COMPARATOR|Placebo|
62028616|NCT05209282|EXPERIMENTAL|Grup I|Conventional physiotherapy program, Video-based action observation training
62028617|NCT05209282|EXPERIMENTAL|Grup II|Conventional physiotherapy program, Live Action Observation Training
62028618|NCT05209282|OTHER|Grup III|Conventional physiotherapy program
62227405|NCT00252733|NO_INTERVENTION|1|Placebo
62420209|NCT04060927|EXPERIMENTAL|Group 3|Breath hold SBRT with SGRT in combination with implanted fiducials
62802981|NCT02986126|ACTIVE_COMPARATOR|Resources for Services|Resources for Services (RS) is an evidence-based depression QI toolkit developed for primary care, but adapted for health- and community-based programs. Protocols support training licensed providers in clinical assessment, medication management, and CBT; all staff in team management; and non-clinical staff in addressing patient safety, screening, behavioral management skills (behavioral activation, problem solving) to enable education, coordination, and referral. RS is offered as an initial 1-day / 8-hour training with follow-up through 12 webinars, 3 each on team management, medication management, psychotherapy, and case management. Programs will be invited to have a staff lead per training component, with no limit on number of staff at trainings. Training experts include a psychiatrist, psychologist/CBT trainer, case manager, support staff, and patient / community advocate liaison. All enrolled study participants will be nested within programs participating in RS.
62802982|NCT02986126|ACTIVE_COMPARATOR|Resiliency Class +|"Resiliency Classes (RC) are a manualized, 7-session, CBT, psychoeducation class, lead by community health workers, that teaches skills to enhance mood. The RC manual covers: Session 1 - What Affects Your Mood and Resilience; Session 2 - Pleasant Activities Can Help Improve Your Mood and Make You Resilient; Session 3 - What Gets In The Way of Pleasant Activities: Harmful Thoughts and How to Change Them; Session 4 - How to Increase Your Resilience Through Support from Others; Session 5 - My Personal Resiliency Plan: Goal Setting; Session 6 - Celebrate Your Resiliency: Graduation Each RC will be 90-120 minutes in duration; once a week in community settings with up to 10 participants. RC will be supplemented with automated mobile text reminders about basic concepts and follow-up for care. Half of enrolled participants will be randomized to the Resiliency Class +. As of July 12, 2018, we will be offering bus tokens and $5 for completion of a satisfaction survey."
62802983|NCT02180581|EXPERIMENTAL|Probiotic (2 * 10^9 cfu/d)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12) and Lactobacillus Rhamnosus GG (LGG) in a dosage of 10\^9 cfu/day of each strain. The probiotics are provided as powder in a sachet, and can be added to food or drink
62420210|NCT03904498|EXPERIMENTAL|Tolcapone then Placebo|Participants in this arm will receive tolcapone during the first medication period (1 capsule containing 200 mg tolcapone on study days 1 and 2; 3 capsules containing a total of 600 mg tolcapone on study days 3-8), and placebo during the second medication period (1 capsule on study days 1 and 2; 3 capsules on study days 3-8).
62420211|NCT03904498|EXPERIMENTAL|Placebo then Tolcapone|Participants in this arm will receive placebo during the first medication period (1 capsule on study days 1 and 2; 3 capsules on study days 3-8), and tolcapone during the second medication period (1 capsule containing 200 mg tolcapone on study days 1 and 2; 3 capsules containing a total of 600 mg tolcapone on study days 3-8).
62028619|NCT06630871|EXPERIMENTAL|Experimental group|High risk and extremely high risk NMIBC for HER2 2 2+or 3+treated with combination therapy of trastuzumab, Distitamab Vedotin, and re-TURBt
62028620|NCT00549926|ACTIVE_COMPARATOR|1|
62420212|NCT02858167|EXPERIMENTAL|FDG-PET|
62028621|NCT00549926|ACTIVE_COMPARATOR|2|
62028622|NCT00549926|ACTIVE_COMPARATOR|3|
62227406|NCT00252733|EXPERIMENTAL|2|candesartan cilexetil
62420213|NCT00883259|EXPERIMENTAL|Experimental|Metformin treatment
62420214|NCT00883259|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62420215|NCT03633773|EXPERIMENTAL|MUC-1 CART|Patients are given fludarabine and cyclophosphamide as pretreatment before MUC-1 CART immunotherapy. After treatment, specific antibodies, CART cells and serum levels of cytokines will be assessed.
62420216|NCT04808427|EXPERIMENTAL|1/Arm 1|Ultrasound ablation of focal prostate cancer
62420217|NCT00950378||CVI|Varicose veins, varicose veins with leg swelling, venous stasis skin color changes, no open ulcers
62028623|NCT00549926|ACTIVE_COMPARATOR|4|
62028624|NCT04506970||Intrauterine Growth Restriction|Pregnant women carrying a fetus identified with intrauterine growth restriction during the third trimester (\>28 weeks gestation)
62028625|NCT04506970||Normal pregnancy|Pregnant women identified with an uncomplicated pregnancy during the third trimester (\>28 weeks), matched for fetal sex and gestational age with women enrolled in the IUGR group.
62028626|NCT02091999|EXPERIMENTAL|Part A enfortumab vedotin Dose Escalation (Dose Levels 1-4)|All subjects will receive a single 30 minute intravenous (IV) infusion of enfortumab vedotin once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
62028627|NCT02091999|EXPERIMENTAL|Part B enfortumab vedotin Renal Insufficiency Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at a dose level below and escalated up to the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
62028628|NCT02091999|EXPERIMENTAL|Part B enfortumab vedotin NSCLC Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
62028629|NCT02091999|EXPERIMENTAL|Part B enfortumab vedotin Ovarian Cancer Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
62227407|NCT03314597|ACTIVE_COMPARATOR|Balance exercise group|Each of the ten sessions was composed of 45 minutes of balance exercises, each treatment being followed by a 15-min final phase of lower limb stretching, performed with the assistance of a physiotherapist. Sessions were repeated two or three times a week, with at least one rest day between one session and the next, over four successive weeks. Each patient was treated on-phase, at the same time of the day across sessions.
62420218|NCT00950378||No treatment|Subjects with no venous disease CEAP (clinical etiology antomy pathophysiology)Class 0
62420219|NCT01612052|ACTIVE_COMPARATOR|Cefazolin plus Daptomycin|
62802984|NCT02180581|PLACEBO_COMPARATOR|Placebo|provided as powder in a sachet, and can be added to food or drink
62802985|NCT01434173||Group 1|
62802986|NCT01434173||Group 2|
62590481|NCT06592508|EXPERIMENTAL|Experimental: Remote Virtual Cardiology Program|The Ventricle Health program will remotely receive daily vital signs directly from a blood pressure cuff and scale provided to the participant. In addition, the program will also remotely receive oxygen levels and electrical heart activity directly from a Pulse Ox and an EKG Single-Lead monitor, provided to the participant. All of this data will be transmitted to the Ventricle Health program. The Ventricle Health team, consisting of Cardiologists and clinical staff, will use this data to titrate medications and make clinical decisions.
62802987|NCT05460455|ACTIVE_COMPARATOR|HB0034 dose group 1|8 subjects receive a multi-dose of HB0034 and 2 subjects receive a multi-dose placebo
62802988|NCT05460455|ACTIVE_COMPARATOR|HB0034 dose group 2|8 subjects receive a multi-dose of HB0034 and 2 subjects receive a multi-dose placebo
62802989|NCT05460455|ACTIVE_COMPARATOR|HB0034 dose group 3|8 subjects receive a multi-dose of HB0034 and 2 subjects receive a multi-dose placebo
62420220|NCT01612052|ACTIVE_COMPARATOR|Cefazolin plus Vancomycin|
62420221|NCT06360523|EXPERIMENTAL|AI review (index)|self-paired design, AI review (index)
62420222|NCT06360523|ACTIVE_COMPARATOR|Radiologist review (Standard)|self-paired design, radiologist review (standard)
62420223|NCT04586023|EXPERIMENTAL|Fenebrutinib|Participants will receive oral fenebrutinib with teriflunomide-matching placebo.
62420224|NCT04586023|ACTIVE_COMPARATOR|Teriflunomide|Participants will receive oral teriflunomide with fenebrutinib-matching placebo in a blinded fashion.
62420225|NCT00597727|ACTIVE_COMPARATOR|Blinded Peanut SLIT|Blinded subjects who received peanut sublingual drops for the initial 12 month blinded phase of the study.
62420226|NCT00597727|PLACEBO_COMPARATOR|Blinded Placebo SLIT|Blinded subjects who received placebo sublingual drops for the initial 12 month blinded phase of the study.
62590482|NCT06592508|NO_INTERVENTION|Usual Care|Routine clinical care will be followed. Participants should be recommended for the best possible outpatient heart failure care at each site.
62590483|NCT00369070|EXPERIMENTAL|A|AMG 706 125 mg once daily (QD) and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.
62802990|NCT03914417|EXPERIMENTAL|Imiquimod 3.75% cream|applied topically
62802991|NCT00874146||1|HER2-positive advanced breast cancer
62802992|NCT02928315|ACTIVE_COMPARATOR|magnesium|Five ampules of 500 mg of magnesium sulfate will be dissolved in 100 ml of normal saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
62802993|NCT02928315|PLACEBO_COMPARATOR|control|100 ml of normal saline solution infused intravenously over 4 hours once daily , for 3 days
62227408|NCT03314597|EXPERIMENTAL|Mobile platform exercise group|Each of the ten sessions was composed of 45 minutes mobile platform training, each treatment being followed by a 15-min final phase of lower limb stretching, performed with the assistance of a physiotherapist. Sessions were repeated two or three times a week, with at least one rest day between one session and the next, over four successive weeks. Each patient was treated on-phase, at the same time of the day across sessions.
62227409|NCT01166867||Infant Development|Photo-plethysmography monitoring
62227410|NCT01680068|EXPERIMENTAL|Pars plana vitrectomy and postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
62802994|NCT05289115|EXPERIMENTAL|Experimental Group/ Active HD-tDCS|Patients who will be randomly enrolled in this group. They will receive 10 sessions of anodal stimulation on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS associated to respiratory training; for 20 minutes (each session) with a 3mA intensity. The electrical current will be delivered with a ramp-up time of 30 s, held at 3mA for 20 min, and then ramped down over 30 s.
62802995|NCT05289115|SHAM_COMPARATOR|Control Group / Sham Group|Patients enrolled in this group condition will receive 10 sessions of anodal stimulation on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS associated to respiratory training; for 20 minutes (each session) with a 3mA intensity. In the sham condition, the device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
62802996|NCT03053947|OTHER|Ketamine IN|All participants will receive intranasal Ketamine between 3mg/kg up to 9 mg/kg, once.
62802997|NCT03049761|ACTIVE_COMPARATOR|Water Flosser|Power interdental Cleaning Device
62802998|NCT03049761|ACTIVE_COMPARATOR|String floss|Manual interdental cleaning device
62802999|NCT03049761|ACTIVE_COMPARATOR|Manual Toothbrush|ADA standard manual toothbrush
62590484|NCT00369070|EXPERIMENTAL|B|AMG 706 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.
62028630|NCT02091999|EXPERIMENTAL|Part C enfortumab vedotin CPI Treated Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15). A cycle is 4 weeks. Subjects will continue treatment until disease progression, intolerability of enfortumab vedotin, Investigator decision or consent withdrawal.
62028631|NCT05553691|EXPERIMENTAL|Test Cohort|Patients who are currently taking an SSRI that is not effective in fully relieving their depression (prescribed outside of study). Patients will be administered a single dose of SPL026 by intravenous infusion.
62028632|NCT05553691|EXPERIMENTAL|Control Cohort|Patients who are not currently taking any pharmacological treatment for their depression. Patients will be administered a single dose of SPL026 by intravenous infusion.
62590485|NCT00369070|ACTIVE_COMPARATOR|C|Bevacizumab 15 mg/kg bevacizumab, delivered via intravenous (IV) infusion once every 3 weeks and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.
62803000|NCT02551068|EXPERIMENTAL|60% Oxgyen|While participants are exercising, they will be breathing 60% oxygen through a mask.
62803001|NCT02551068|PLACEBO_COMPARATOR|Standard of Care|While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
62803002|NCT00954993|EXPERIMENTAL|Vaniprevir 600 mg - 300 mg|For each participant in period 1, 600 mg of Vaniprevir was taken twice daily on Days 1-3 and a single dose of Vaniprevir 600 mg was taken on Day 4. Period 1 was followed by a minimum 30-day, up to approximately 140 day, washout interval. In period 2, 300 mg of Vaniprevir was taken twice daily by each participant on Days 1-3 and a single dose of Vaniprevir 300 mg was taken on Day 4.
62803003|NCT02535455|EXPERIMENTAL|ACES Pilot|This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
62803004|NCT04932928|EXPERIMENTAL|FreeStyle Libre (CGM) Group|Device: FreeStyle Libre (ver 1.0) Education on lifestyle modification
62803005|NCT04932928|ACTIVE_COMPARATOR|Self Monitoring of Blood Glucose (SMBG) Group|Device: Blood glucose meter Education on lifestyle modification
62803006|NCT01059409|EXPERIMENTAL|Meniscal Allograft|
62028633|NCT02870790|EXPERIMENTAL|treatment|A single open-label arm. All participants receive daily oral pill containing TDF/FTC
62028634|NCT00997165||Metabolic syndrome (MS)|Patients suspected of metabolic syndrome without sleep apnea or liver steatosis
62028635|NCT00997165||MS with sleep apnea|Metabolic syndrome with sleep apnea
62028636|NCT00997165||MS with Liver steatosis|Metabolic syndrome with liver steatosis
62028637|NCT01107574|EXPERIMENTAL|Gabapentin and Osteopathic Manipulative Medicine|6 weeks of both Gabapentin 900 mg HS given orally was accompanied with Osteopathic Manipulative Medicine treatment 30 minutes weekly to the tender points of the musculoskeletal system of each patient for 6 weeks.
62028638|NCT01107574|EXPERIMENTAL|Gabapentin|Gabapentin was given orally at 900 mg at HS weekly for 6 weeks.
62028639|NCT01107574|EXPERIMENTAL|Osteopathic Manipulative Medicine|6 weeks of Osteopathic Manipulative Medicine Treatment was applied to the patients tender points in the musculoskeletal system weekly by a 30 minute treatment.
62028640|NCT04763122||Thyroid Cancer Cases|
62803007|NCT02760966|EXPERIMENTAL|Alcohol 70º|Umbilical cord care will be carried out using alcohol 70º at least 3 times a day. Firstly, there must be a proper hand hygiene. Then, with sterile gauzes alcohol will be applied from the abdominal part to the end of the stump.
62803008|NCT02760966|ACTIVE_COMPARATOR|Soap|Umbilical cord care will be carried out using soap at least 3 times a day. Firstly, there must be a proper hand hygiene. Then, with sterile gauzes alcohol will be applied from the abdominal part to the end of the stump.
62803009|NCT01759797|EXPERIMENTAL|stem cell reciepient|the patients with ALS who underwent intravenous injection of mesenchymal stem cell.
62028641|NCT06352853|ACTIVE_COMPARATOR|Group 1: Scalpel Group|A skin incision is made by traditional method, with proper homeostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeding as well as using of diathermy on coagulation mode. Then,the scalpel was used to reach peritoneum.
62028642|NCT06352853|ACTIVE_COMPARATOR|Group 2: Diathermy Group|A skin incision is made using a small flat blade pen electrode, set on cutting mode and delivering a 120-wat (maximum) sinusoidal current, electrosurgical cutting performed without pressure or mechanical displacement. Then, we used the scalpel to reach peritoneum.
62028643|NCT02487563|EXPERIMENTAL|Experimental Group 1|Decitabine in combination with rhTPO.
62028644|NCT02487563|EXPERIMENTAL|Experimental Group 2|Decitabine
62028645|NCT02487563|ACTIVE_COMPARATOR|Control Group|Conventional treatment except decitabine.
62028646|NCT00959517|EXPERIMENTAL|CQ|
62028647|NCT00959517|EXPERIMENTAL|CQ+PQ|
62028648|NCT00959517|EXPERIMENTAL|CQ + AS|
62028649|NCT00959517|EXPERIMENTAL|SP|
62028650|NCT00959517|EXPERIMENTAL|SP + PQ|
62028651|NCT00959517|EXPERIMENTAL|SP + AS|
62028652|NCT04514315||Minimally invasive aortic valve surgery|Patients undergoing minimally invasive aortic valve surgery
62590486|NCT03303573||recombinant human erythropoietin group|cerebral palsy patients who had received erythropoietin from January 2013 to November 2016
62803010|NCT04301466|EXPERIMENTAL|Qi Zhi Tong Luo group|Patients were receiveed Qi Zhi Tong Luo Capsule 4 capsules, 2 times per day for 24 weeks. Each capsule was weighted 0.5g. Qi Zhi Tong Luo capsule (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
62803011|NCT04301466|PLACEBO_COMPARATOR|Placebo group|Patients were allocated to placebo, 4 capsules, 2 times per day for 24 weeks. Placebo (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
62803012|NCT00154297|ACTIVE_COMPARATOR|Immediate Everolimus|Patients received Everolimus starting within 48 hours of kidney transplant through to the end of the study, administered orally twice a day. Dose was adjusted in order to maintain a trough level between 3-8 ng/mL.
62590487|NCT01107808|NO_INTERVENTION|Control|The adolescents randomized to Standard of care group will receive the medical and behavioral counseling regarding their obesity as a patient of the Children's Center for Weight Management (CCWM). They will not receive any pharmacological treatment for their vitamin D deficiency or insulin resistance. Calcium and vitamin D dietary intake will be determined using a specific food frequency questionnaire at each study visit for all groups. This will be used to determine effect of nutrition counseling.
62590488|NCT01107808|EXPERIMENTAL|Calcium and Vit D|The participants in the vitamin D/calcium group will receive standard of care through the CCWM along with the addition of treatment with ergocalciferol (vitamin D2) and calcium carbonate for their vitamin D deficiency. The vitamin D treatment will be 50,000 IU orally weekly for 8 weeks. This treatment regimen for vitamin D deficiency has been found to be safe to children and adolescents. 32 33The dose of calcium supplementation will be calcium carbonate orally 1200mg daily. This is the daily recommended intake of calcium for adolescents
62590489|NCT01107808|EXPERIMENTAL|Metformin/ Vit D|The participants randomized into the vitamin D/calcium/Metformin treatment group will receive standard of care through the CCWM in addition to treatment for their Vitamin D deficiency with the same doses of ergocalciferol (vitamin D2) and calcium carbonate as previously outlined. Additionally, these participants will receive Metformin ER to treat insulin resistance. The Metformin ER will be started at 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks).
62803013|NCT00154297|EXPERIMENTAL|Delayed Everolimus|Patients received Everolimus 4 weeks after kidney transplant until the end of the study, administered orally twice a day. The dose was adjusted in order to maintain a trough level between 3-8 ng/mL. Patients received mycophenolic acid until everolimus was initiated.
62803014|NCT00255190|EXPERIMENTAL|Dexlansoprazole MR 60 mg QD|
62803015|NCT00255190|EXPERIMENTAL|Dexlansoprazole MR 90 mg QD|
62803016|NCT05022459||Emicizumab Prophylaxis|This group will include patients on standard of care Emicizumab prophylaxis for Hemophilia A
62028653|NCT04514315||Minimally invasive mitral valve surgery|Patients undergoing minimally invasive mitral valve surgery
62028654|NCT04514315||Conventional aortic valve surgery|Patients undergoing conventional aortic valve surgery
62028655|NCT03266250||spinal anesthesia Hypotensive patients|Transthoracic echocardiography of IVC before spinal anaesthesia
62803017|NCT05022459||FVIII Prophylaxis|This group will include patients on standard of care FVIII prophylaxis for Hemophilia A
62803018|NCT02058953||Craniotomy scheduled|"Patients who have scheduled craniotomy with melanoma brain metastases will have the following specimens collected:~1. CNS tumor specimens, specifically the remaining portion from the resected melanoma CNS metastasis~2. the remaining portion from the adjacent normal CNS tissue. No additional normal brain tissue will be collected for research purposes only, however the routinely collect peritumoral tissue will be retained.~3. melanoma specimens from other extracranial, clinically palpable metastatic sites.~4. CSF taken at around the time of the craniotomy procedure~5. peripheral blood prior to craniotomy."
62028656|NCT03266250||spinal anesthesia Normotensive patients|Transthoracic echocardiography of IVC before spinal anaesthesia
62028657|NCT04821596|EXPERIMENTAL|Multiple Sclerosis Patients|Multiple Sclerosis Patients usually followed by Dr. Bourre as part of his consultation at the Rouen University Hospital will be offered the opportunity to participate in this study if they meet the selection criteria.
62028658|NCT01693432|EXPERIMENTAL|DS (docetaxel+S-1)|"Treatment will be delivered as a 3-week cycle.~1. Docetaxel 60 mg/m²IV on day 1~2. S-1 80 mg/m2/day PO on day 1-14"
62028659|NCT03539562||Accepted Morphine Sulfate|Patients accepted morphine and promethazine as a method for pain management in early or prodromal labor.
62803019|NCT02058953||Collection for non-craniotomy|"For those eligible patients who are not having a craniotomy:~1. collection of CSF will be performed by lumbar puncture or from the patient's Ommaya reservoir, if present.~2. collection of peripheral blood.~NOTE: Only patients who have no absolute contraindications or up to two relative contraindications will be considered for lumbar puncture"
62803020|NCT03469063|EXPERIMENTAL|AferBio|Daily oral AferBio (20 g/day, in sachets)
62803021|NCT03469063|PLACEBO_COMPARATOR|Placebo|Daily oral placebo (20 g/day, in sachets)
62803022|NCT01316874|EXPERIMENTAL|AD32 (valrubicin)|800mg, once weekly for 6 weeks
62803023|NCT01262079||Group 1: 6-15 years old|
62028660|NCT03539562||Declined Morphine Sulfate|Patients declined morphine and promethazine as a method for pain management in early or prodromal labor.
62803024|NCT01262079||Group 2: 16-25 years old|
62803025|NCT01262079||Group 3: 26-35 years old|
62803026|NCT01262079||Group 4: 36-45 years old|
62803027|NCT01262079||Group 5: 46-55 years old|
62028661|NCT05982522|EXPERIMENTAL|Experimental Group|IN10018 + nab-paclitaxel + Tislelizumab in previously-treated NSCLC
62028662|NCT05982522|ACTIVE_COMPARATOR|Control Group|Nab-paclitaxel + Tislelizumab in previously-treated NSCLC
62028663|NCT04482751||Infertile women|the group consists of 80 infertile patients undergoing IVF
62028664|NCT01193803||Spondylodiscitis control group|Patients needing vertebral biopsy looking for tumoral etiology
62028665|NCT01193803||Prosthetic Joint Infection control group|Patients with primary prosthetic arthrosis surgery
62028666|NCT01193803||Septic arthritis control group|Arthrosic patients needing evacuating articular punction with leucocytes infiltration less than 1000 /mm3
62803028|NCT01262079||Group 6: 56-65 years old|
62803029|NCT01262079||Group 7: 66-75 years old|
62803030|NCT01262079||Group 8: 76-85 years old|
62803031|NCT01262079||Group 9: > 85 years old|
62420227|NCT00597727|OTHER|Ext. maint. open label peanut SLIT|After completing the blinded phase of the study, subjects receiving Blinded Peanut SLIT continued on extended maintenance open-label peanut SLIT for the duration of the study. Subjects receiving Blinded Placebo SLIT were crossed over and underwent the 12 month buildup protocol on open label peanut SLIT and then continued on extended maintenance treatment for the duration of the study.
62028667|NCT01193803||Spondylodiscitis case group|Patients suspected of Discitis and/or Vertebral Osteomyelitis is defined by the need of spinal biopsy in infectious context.
62028668|NCT01193803||Prosthetic Joint Infection case group|Patients suspected of Prosthetic Joint Infection defined by the need of surgical revision for diagnostic or therapeutic aiming in infectious context.
62028669|NCT01193803||Septic arthritis case group|Patients suspected of Septic arthritis without prosthesis were defined by the need of synovial punction and/or biopsy
62028670|NCT00672048|OTHER|1|
62028671|NCT00672048|OTHER|2|Control group to receive annual continuing education
62028672|NCT01206244||Normal|Normal subjects
62028673|NCT01206244||Dry eye|clinically diagnosed dry eye with aqueous tear deficiency
62028674|NCT06495801|EXPERIMENTAL|Intervention|
62028675|NCT06495801|NO_INTERVENTION|Wait-list controls|The group will have access to the mobile application after the six-month follow-up period.
62420228|NCT00597727|OTHER|Early unblinded peanut SLIT|Subjects who were unblinded prematurely during the blinded phase of the study and then re-enrolled as an open label cohort.
62420229|NCT00597727|OTHER|Pilot peanut SLIT rollover cohort|Subjects from the original phase 1 study of peanut SLIT (NCT00429429) who were rolled over into the current protocol as an open label peanut SLIT cohort.
62420230|NCT06442137|EXPERIMENTAL|Treatment group|"These medicines of Chazhu Xiaozhi decoction are uniformly decocted, prepared, and packaged by the Pharmacy of Shanghai Municipal Hospital of Traditional Chinese Medicine. The administration is oral, taken twice daily, one packet each time, for a treatment period of 8 weeks.~In addition, following the guidelines, all participants will receive lifestyle interventions, including diet and exercise health education before enrollment to ensure calorie control and exercise compliance."
62803032|NCT04340635||Multi-center data collection|Without intervention
62803033|NCT01014130|ACTIVE_COMPARATOR|Arm 2|Conventionally Fractionated Radiotherapy (ConRT) - Standard of Care
62803034|NCT01014130|EXPERIMENTAL|Arm 1|Hypofractionated radiotherapy (HypoRT) - Investigational
62803035|NCT03371472|OTHER|VALE - PVL leak sizing balloon - mitral|Placement and inflation of PVL leak sizing balloon for visualisation and measuring of paravalvular leak located in mitral position - Balton developed investigational balloon
62803036|NCT03371472|OTHER|VALE - PVL leak sizing balloon - aortic|'Placement and inflation of PVL leak sizing balloon for visualisation and measuring of paravalvular leak located in aortic position - Balton developed investigational balloon
62803037|NCT06378034|ACTIVE_COMPARATOR|Lactium|
62803038|NCT06378034|PLACEBO_COMPARATOR|Placebo|
62803039|NCT01935635|EXPERIMENTAL|HPDCs-T immune therapy combined with IFN|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2\*105-1\*106 cells per time,total 12 times; IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks
62803040|NCT01935635|EXPERIMENTAL|HPDCs-T immune therapy combined with ETV|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2\*105-1\*106 cells per time,total 12 times; Entecavir(ETV)therapy:0.5mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
62803041|NCT01935635|EXPERIMENTAL|HPDCs-T immune therapy combined with LdT|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2\*105-1\*106 cells per time,total 12 times; Telbivudine(LdT)therapy:600mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
62803042|NCT01935635|NO_INTERVENTION|IFN treatment|IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks
62590490|NCT03638999|ACTIVE_COMPARATOR|Intervention Group - Ketorlac (NSAID)|Subjects will receive a one-time intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure. After consent and during screening visit demographic information, medical/surgical history, and height and weight will be collected. On Day 0 subject will be randomized to NSAID or Saline using inclusion/exclusion criteria and the procedure data will be collected. On Day 1 subject will receive a follow up phone call and complete AUA Symptom Score, USS Questionnaire 1 and USS Questionnaire 2 and any adverse events will be assessed. These questionnaires will again be administered on the day of stent removal and again 1 to 2 months post stent removal.
62590491|NCT03638999|PLACEBO_COMPARATOR|Placebo Group - Normal Saline|Subjects in the control group will receive a one-time 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure. After consent and during screening visit demographic information, medical/surgical history, and height and weight will be collected. On Day 0 subject will be randomized to NSAID or Saline using inclusion/exclusion criteria and the procedure data will be collected. On Day 1 subject will receive a follow up phone call and complete AUA Symptom Score, USS Questionnaire 1 and USS Questionnaire 2 and any adverse events will be assessed. These questionnaires will again be administered on the day of stent removal and again 1 to 2 months post stent removal.
62590492|NCT00831714||Group 1|
62803043|NCT01935635|NO_INTERVENTION|ETV treatment|Entecavir(ETV)therapy:0.5mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
62420231|NCT06442137|PLACEBO_COMPARATOR|Control group|"These placebo medicines are uniformly decocted, prepared, and packaged by the Pharmacy of Shanghai Municipal Hospital of Traditional Chinese Medicine. The administration is oral, taken twice daily, one packet each time, for a treatment period of 8 weeks.~In addition, following the guidelines, all participants will receive lifestyle interventions, including diet and exercise health education before enrollment to ensure calorie control and exercise compliance."
62420232|NCT02987504|EXPERIMENTAL|Samalizumab 10, 15, 20 milligrams (mg)/kilogram (kg) Dose|"Participants received escalating doses of 10, 15, and 20 mg/kg of samalizumab IV every 21 days. Enrollment at each dose level and safety assessments were completed prior to enrolling at the next dose level; intra-participant dose escalation was not allowed.~3 participants were enrolled into a dose cohort: If 0/3 participants developed dose limiting toxicities (DLT) within Cycle 1, enrollment began at the next higher dose to a maximum of 20 mg/kg. If 1/3 participants developed a DLT, the dose cohort was expanded to include 3 new participants. If 0/3 new participants developed a DLT within Cycle 1, enrolment began at the next higher dose level. If ≥1 of 3 new participants developed a DLT within Cycle 1, dose-escalation was terminated, and the dose level 5 mg/kg below the current dose was considered the MTD. If ≥2 of 3 participants developed DLTs within Cycle 1, dose-escalation was terminated, and the dose level 5 mg/kg below the current dose was considered the MTD."
62420233|NCT05485571|ACTIVE_COMPARATOR|GROUP 1|15 patient with alopecia areata treated by microneedling only one session weekly for 12 weeks
62420234|NCT05485571|ACTIVE_COMPARATOR|GROUP 2|15 patient with alopecia areata treated by combined therapy with Microneedling and methotrexate After microneedling we applied methotrexate topically (25mg/ml) at dose 0.02ml/cm2 , A maximum of 0.1-0.2ml (2.5-5 mg) on the affected areas and rub it gently then Microneedling again, patient will take session weekly for 12 weeks.
62420235|NCT06234605|EXPERIMENTAL|Monotherapy|Participants will receive HC-7366 monotherapy \[dose to be determined\] daily
62420236|NCT06234605|EXPERIMENTAL|Combination|Participants will receive HC-7366 monotherapy \[dose to be determined\] in combination with belzutifan \[120 mg\] daily
62420237|NCT02367781|EXPERIMENTAL|Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)|Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurred first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
62420238|NCT02367781|ACTIVE_COMPARATOR|Arm B (Nab-Paclitaxel+Carboplatin)|Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurred first during induction treatment phase. Participants received best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed was also permitted. Participants who were consented prior to approval of protocol Version 5 were given the option to cross over to receive atezolizumab as monotherapy until disease progression.
62590493|NCT00831714||Group 2|
62803044|NCT01935635|NO_INTERVENTION|LdT treatment|Telbivudine(LdT)therapy:600mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
62803045|NCT03266133|EXPERIMENTAL|Sleep Education Intervention|This is a two-session program designed to educate patients about healthy sleep in respect to timing, regularity, efficiency, and duration in order to promote sleep during pregnancy.
62803046|NCT03266133|NO_INTERVENTION|Routine Care|Usual care
62803047|NCT04524858|EXPERIMENTAL|ATI-450|Oral, small molecule MK2 inhibitor will be administered twice daily (BID) at a dose of 50 mg
62803048|NCT01517932|EXPERIMENTAL|Group-DEX|Patients in this arm received dexmedetomidine 0.2 microgram per kg i.v. during 10 minutes 1 hour before the end of surgery
62803049|NCT01517932|PLACEBO_COMPARATOR|Group-PLB|Patients in this arm received saline placebo 0.05 ml per kilogram i.v. during 10 minutes 1 hour before the end of surgery
62803050|NCT05268640|EXPERIMENTAL|Double-level cerclage|double-level cervical cerclage placement with one suture above the other approximately 1 cm higher. Suture will be placed analogous to McDonald technique
62803051|NCT05268640|ACTIVE_COMPARATOR|Single-level cerclage|single-level cervical cerclage of McDonald technique
62803052|NCT00381004|EXPERIMENTAL|FCR + Sargramostim|Fludarabine + Cyclophosphamide + Rituximab (FCR) = Fludarabine - Course 1: 25 mg/m\^2 IV Days 2-4; Course 2-6: 25 mg/m\^2 IV Days 1-3. Cyclophosphamide - Course 1: 250 mg/m\^2 intravenous (IV) Days 2-4; Course 2-6: 250 mg/m\^2 Days 1-3. Rituximab - Course 1: 375 mg/m\^2 IV over 2-6 hours Day 1; Course 2-6: 500 mg/m\^2 IV Day 1. Sargramostim - Course 1: 250 mcg/m\^2 subcutaneous (SQ) Days -1 and 5-11; Course 2-6: 250 mcg/m\^2 SQ Days -1 and 4-10.
62803053|NCT03494920|OTHER|Direct endovascular clot retrieval|Endovascular clot retrieval (ECR) within 4.5 hours stroke
62803054|NCT03494920|OTHER|Bridging thrombolysis followed by ECR|Intravenous tPA (at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour) followed by ECR
62028676|NCT00889213|EXPERIMENTAL|Patch and glue arm|Randomized patients to the patch and glue arm will undergo placement of a falciform ligament tissue patch and fibrin glue to the resection margin of the remnant pancreas following distal pancreatectomy
62227411|NCT03450967|EXPERIMENTAL|Durvalumab Plus Tremelimumab|Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.).
62803055|NCT04533386|EXPERIMENTAL|BSMM|Intervention arm will include motivational interview-consistent discussion with a peer change agent and use of a mobile application to record and review sexual risk behaviors with participants.
62227412|NCT02739373|EXPERIMENTAL|BMS-986189|Specified Dose on Specified Day
62803056|NCT01774201|EXPERIMENTAL|Breathing exercises|Daily deep breathing exercises during two month
62227413|NCT02739373|PLACEBO_COMPARATOR|Placebo|Specified Dose on Specified Day
62227414|NCT02312388|EXPERIMENTAL|Catheter-over-the-needle technique|to use the 22G angiocatheter for central venous catheterization
62590494|NCT06668636|NO_INTERVENTION|Pre-Implementation|This arm of the study will occur before ED-PATCH has been implemented. Patients will receive usual discharge communication.
62028677|NCT00889213|ACTIVE_COMPARATOR|stapled /sutured pancreatic closure|
62028678|NCT05623150||Descriptive study|"The patients included in this observational study are patients with hepatic steatosis either related to NAFLD or to alcohol-related liver disease.~Patients included in the study may have hepatocellular carcinoma.~Thus, 4 groups of patients can be recruited:~* patients with NAFLD without hepatocellular carcinoma,~* patients with NAFLD with hepatocellular carcinoma,~* patients with alcohol-related liver disease without hepatocellular carcinoma, -patients with alcohol-related liver disease with hepatocellular carcinoma."
62590495|NCT06668636|EXPERIMENTAL|Post-Implementation|This arm of the study will occur after ED-PATCH has been implemented.
62227415|NCT02312388|EXPERIMENTAL|Thin-wall needle technique|to use the sharp hollow 23G needle for central venous catheterization
62227416|NCT04386187|EXPERIMENTAL|Arm 1: Experimental Feeding|Small glutathione-rich meals will be prepared and delivered to participants for 12 weeks.
62227417|NCT04386187|ACTIVE_COMPARATOR|Arm 2: Education Control|Standard of care medical nutrition education for type 2 diabetes will be provided in the form of electronic handouts and web-based resources.
62227418|NCT03626519|EXPERIMENTAL|Test with Menthol|Patients will chew a menthol flavored chewing gum 5 minutes before perform one Six-minute Walk Test
62227419|NCT03626519|PLACEBO_COMPARATOR|Test with placebo|Patients will chew a strawberry flavored chewing gum 5 minutes before perform one Six-minute Walk Test
62227420|NCT05925179|EXPERIMENTAL|antibiotic prophylaxis|per os 2 g augmentin one hour prior to surgery
62803057|NCT01774201|NO_INTERVENTION|Control|Control group
62803058|NCT01329237|OTHER|dynamic physical exercise OCT|dynamic physical exercise and optical coherence tomography imaging
62803059|NCT02423655|EXPERIMENTAL|Deffered Dialysis Initiation|"Algorithm for deferred dialysis intervention:~initiating dialysis in the absence of symptoms in patients with an eGFR of 5 ml/min /1.73 m2 or less"
62803060|NCT02423655|ACTIVE_COMPARATOR|Routine dialysis Initiation|"Algorithm for routine dialysis intervention:~initiating dialysis in the absence of symptoms in patients with an eGFR of 7 ml/min /1.73 m2 (which is the average GFR for patients in Beijing to start dialysis )"
62803061|NCT01501266||Faslodex|
62803062|NCT00931034|ACTIVE_COMPARATOR|South Beach Diet with SBD Products|
62803063|NCT00931034|ACTIVE_COMPARATOR|ADA Diabetes meal plan|
62227421|NCT05925179|PLACEBO_COMPARATOR|placebo control|per os placebo one hour prior to surgery
62803064|NCT03843086|ACTIVE_COMPARATOR|720 Low Intensity shockwave therapy|Five daily sessions within a week, Monday thru Friday, in which 720 shocks of treatment energy applied every session to each treated region (left and right corpora cavernosa and crura)
62590496|NCT00003407|EXPERIMENTAL|Effectiveness of amifostine &high-dose combination chemotherapy in treating patients with AML or CML|Treatment of Newly Diagnosed High Risk And Relapsed Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Ethyol and High-Dose Cytarabine + Mitoxantroni, followed by Maintenance Phase Using Low-Dose ARA-C, rhGM-CSF, Pentoxifylline, Ciprofloxacin, and Decadron
62590497|NCT00692471||1|Patients meeting the diagnostic criteria for the Postural Tachycardia Syndrome, a form of Orthostatic Intolerance
62803065|NCT03843086|ACTIVE_COMPARATOR|600 Low Intensity shockwaves therapy|"Three weekly sessions for 2 consecutive weeks, Monday-Wednesday-Friday, in which 600 shocks of treatment energy applied every session to each treated region (left and right corpora cavernosa and crura)~Following the last treatment session, each patient will resume his baseline consumption of phosphodiesterase 5 inhibitor in terms of type and dose of drug, for the remainder of study duration."
62803066|NCT01067274|EXPERIMENTAL|R1 Arm A : ATRA|"Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN \>1G/l over 2 days at minimum~All-trans retinoic acid (ATRA): 45mg/m2/day in two divided doses from D8 to D28"
62803067|NCT01067274|NO_INTERVENTION|R1 Arm B : no ATRA|Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN \>1G/l over 2 days at minimum
62803068|NCT01067274|EXPERIMENTAL|R2 Arm 1A : AZACITIDINE and ATRA|Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5 All-trans retinoic acid (ATRA): 45mg/m2/d in two divided doses from D8 to D21
62803069|NCT01067274|EXPERIMENTAL|R2 Arm 1B : AZACITIDINE and No ATRA|Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5
62803070|NCT01067274|EXPERIMENTAL|R2 Arm 2A : ATRA|Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5 All-trans retinoic acid (ATRA): 45mg/ m2/d in two divided doses from D8 to D21
62803071|NCT01067274|EXPERIMENTAL|R2 Arm 2B : no ATRA|Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5
62803072|NCT04143685|ACTIVE_COMPARATOR|misoprostol|misoprostol 50 mcg tablet by mouth every four hours for maximum dosage of six
62803073|NCT04143685|ACTIVE_COMPARATOR|oxytocin|Oxytocin 10 IU in 1000 mL Standard solution. Starting with 10 mL/hr infusion rate and increasing by 10mL/hr every 20 minutes until achieving 3-5 regular uterine contractions every 10 minutes (as recorded by cardiotocography)
62803074|NCT04803643||Patients|"Upper extremity exercise capacity will be assessed using six minute pegboard ring test, functional exercise capacity using six minute walk test, muscle oxygenation using Moxy monitor, balance using Biodex Balance System® and Y balance test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, life quality using The Revised Cystic Fibrosis Questionnaire (CFQ-R) (Turkish version)."
62803075|NCT04803643||Healthy controls|"Upper extremity exercise capacity will be assessed using six minute pegboard ring test, functional exercise capacity using six minute walk test, muscle oxygenation using Moxy monitor, balance using Biodex Balance System® and Y balance test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, life quality using The Revised Cystic Fibrosis Questionnaire (CFQ-R) (Turkish version)."
62803076|NCT03200834|ACTIVE_COMPARATOR|D2 lymph node dissection for right colon cancer|Hemicolectomy for right colon cancer with D2 lymph node dissection
62803077|NCT03200834|EXPERIMENTAL|D3 lymph node dissection for right colon cancer|Hemicolectomy for right colon cancer with D3 lymph node dissection
62803078|NCT02430090|EXPERIMENTAL|Levobupivacaine|"Levobupivacaine, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.~Injection Surgical anaesthesia~Adult: Epidural block: 50-100 mg (10-20 ml) of a 0.5% solution or 75-150 mg (10-20 ml) of a 0.75% solution. Caesarean section: 75-150 mg (15-30 ml) of a 0.5% solution. Spinal block: 15 mg (3 ml) of a 0.5% solution. Max: 150 mg/dose; 400 mg/day. Injection Peripheral nerve block~Read more: http://www.ndrugs.com/?s=levobupivacaine#ixzz3Xvp0iS5T"
62227422|NCT04361188|EXPERIMENTAL|MAC anesthesia group|Parkinson's disease patients receiving deep brain stimulation under MAC anesthesia.
62590498|NCT00692471||2|Healthy control subjects who do not meet the criteria for the Postural Tachycardia Syndrome
62590499|NCT00714012||1 Visualization users|End users of the domain specific visualizations.
62227423|NCT04361188|ACTIVE_COMPARATOR|AAA anesthesia group|Parkinson's disease patients receiving deep brain stimulation under AAA anesthesia.
62243083|NCT04654585|EXPERIMENTAL|The STOP intervention|The stop intervention is a heath professional (medical doctor) led intervention assisting smokers with low socioeconomic position in their smoking cessation attempt. It consists of routine care and adapted advice supplemented with a free delivery of any or several type(s) of nicotine replacement therapy (NRT) (patches, inhalers, gum, tablets, etc.) and/or an e-cigarette + e-liquid. The delivery of those smoking aids is based on the smokers' preference and choice.
62590500|NCT03514485|ACTIVE_COMPARATOR|P+S- (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the primary care intervention Yes We Can Children's Asthma Program.
62227424|NCT05397184|EXPERIMENTAL|Single-dose intravenous infusion of a banded dose of CAR7+ T cells/kg BECAR7|Single-dose intravenous infusion (weight-based dosing) of CAR7+ T cells/kg BECAR7 Total duration of treatment: 28 days Follow-up: 12 months Patients will undergo careful screening to confirm that this treatment is adequate for them. Chemotherapy will be given prior to BE CAR-7 infusion. Patients will then receive a single infusion of the BE CAR-7 cells and will be closely monitored in hospital via blood and bone marrow tests for safety and to check the levels of BE CAR-7 and leukaemia cells. Patients are expected to be in hospital for 4-6 weeks for the BE CAR-7 therapy and the transplant will be scheduled 2-4 weeks after the end of BE CAR7 if leukaemia cells are no longer detectable. Patients will be monitored on the study for 1 year every month for the first 3 months and then every 6 months and then long term in routine clinics.
62227425|NCT02647294|EXPERIMENTAL|Polyunsaturated omega-3 fatty acids|Patients will receive n-3 fatty acids (Maxicor) 3,6 g/day.
62227426|NCT02647294|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo (soya oil)
62227427|NCT02754817||Insulin degludec/liraglutide|
62227428|NCT01718353|EXPERIMENTAL|Docetaxel + Prednisone (Treatment A)|Docetaxel 75 mg/m\^2 intravenous (IV) infusion on Day 1 of Cycle 1 and every 3 weeks (q3w) thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily. Participants with \<30% PSA reduction from baseline at the end of Cycle 4 switched to Cabazitaxel 25mg/m\^2 IV infusion on Day 1 of Cycle 5 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), death, unacceptable toxicity or participant's refusal of further study treatment. Participants with ≥30% PSA reduction from baseline at the end of Cycle 4, continued on the same treatment which they received before switching until DP, death, unacceptable toxicity or participant's refusal of further study treatment.
62803079|NCT02430090|EXPERIMENTAL|Levobupivacaine + fentanyl|"Fentanyl - Used for: Producing anesthesia for surgery and treating pain before, during, and after surgery.Fentanyl is a narcotic (opioid) analgesic. It works in the brain and nervous system to cause anesthesia and decrease pain.~Indications:~Adult: PO Breakthrough cancer pain As a loz: Initially, 200 mcg over 15 minutes for an episode of breakthrough pain; may repeat once after 15 minutes if needed. Not more than 4 unit doses/day. IV Adjunct to general anesth Patients w/ spontaneous resp: Initial: 50-200 mcg, w/ supplements of 50 mcg. Patients w/ assisted ventilation: Initial: 300-3,500 mcg (up to 50 mcg/kg), w/ supplements of 100-200 mcg depending on response.~Read more: http://www.ndrugs.com/?s=fentanyl#ixzz3XvpAcULL"
62420239|NCT06410573|EXPERIMENTAL|Training on Breast Self-Examination|In the training, women will be divided into 5 groups and the training will be held in 5 separate sessions in one day. A training program will be completed with 9 women. All trainings will be conducted under the same conditions in the school's training room. Before the training, women will be informed about the training and their permission and consent will be obtained. The training prepared by the researcher will be presented to the women in the experimental group of the study. The presentation used in the training will include information about breast cancer, breast cancer screening programs and breast self-examination.
62803080|NCT02430090|EXPERIMENTAL|Levobupivacaine + sufentanil|"Sufentanil is a synthetic opioid analgesic. Sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation.~Maintenance: Additional doses of 0.5-10 mcg/kg may be given if needed. Max (total dose): 30 mcg/kg. Post-op pain Initial: 30-60 mcg. Additional doses of up to 25 mcg may be given at intervals of ≥1 hr if needed. Epidural Pain relief during labour and delivery W/ bupivacaine: 10-15 mcg w/ or w/o epinephrine. May repeat dose twice at intervals of ≥1 hr till delivery. Max (total dose): 30 mcg.~Read more: http://www.ndrugs.com/?s=sufentanil#ixzz3XvqVyLzx"
62803081|NCT06403462|ACTIVE_COMPARATOR|transversus abdominis plane block|
62803082|NCT06403462|EXPERIMENTAL|transversalis fascial plane block|
62803083|NCT00631358|EXPERIMENTAL|Maxidex|Maxidex
62028679|NCT00967850|EXPERIMENTAL|Intravitreal Bevacizumab|Intravitreal injections of bevacizumab
62803084|NCT00631358|SHAM_COMPARATOR|No treatment|Healthy normal control group receiving no treatment
62803085|NCT01748097|EXPERIMENTAL|IV bicarbonate 4.2% 20 cc|injecting 20cc 4.2% to a newly administered IV line
62028680|NCT00967850|ACTIVE_COMPARATOR|Visudyne|Photodynamic Therapy with Visudyne
62420240|NCT06410573|NO_INTERVENTION|Control|1 week follow-up.
62420241|NCT01766973||Chronic back pain|Adults, \>6months duration
62420242|NCT01766973||Control|Age and sex matched controls
62420243|NCT04323449|EXPERIMENTAL|Vision-guided control|New custom control method
62803086|NCT01748097|PLACEBO_COMPARATOR|IV normal saline|injecting 20 cc normal saline to a newly administered IV line
62803087|NCT05045261|NO_INTERVENTION|A - Standard of care NUC|Patients will continue their standard of care NUC treatment
62803088|NCT05045261|EXPERIMENTAL|B - NUC discontinuation|Patients will stop their NUC treatment 28 weeks after enrolment
62803089|NCT05045261|EXPERIMENTAL|C - NUC discontinuation after SLGN treatment|"Patients will take from enrolment~* their standard of care NUC treatment for 28 weeks then stop~* 3mg SLGN weekly for 24 weeks then stop"
62028681|NCT01434602|EXPERIMENTAL|1/Phase I|Daily everolimus (days 1- 28) in combination with sorafenib as per the Phase I dosing table. Maximum tolerated dose. Dose Escalation.
62028682|NCT01434602|EXPERIMENTAL|2/Phase II|Combination of sorafenib and everolimus. Sorafenib 400mg twice daily will be taken for 7 days on, then 7 days off. Everolimus 5mg will be taken daily. Determined from dose escalation in phase I, maximum tolerated dose -1.
62803090|NCT01929590|ACTIVE_COMPARATOR|PEG-3350 group 3|group 3: low-volume 2 L PEG-3350 solution (same day of the procedure 06:00-08:00 am).
62803091|NCT01929590|ACTIVE_COMPARATOR|PEG-3350 group 1|group 1 single dose (PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h)
62803092|NCT01929590|EXPERIMENTAL|PEG-3350 group 2|group 2: split-dose (PEG-3350 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
62803093|NCT00599066||Study cases|Application of a second M-Entropy probe on the forehead of the patient; at the end the patient will have 2 probes on the forehead, one in the right and one in the left.
62803094|NCT06392724|EXPERIMENTAL|GEN6050X|"* A single IV infusion of GEN6050X at a dose of 5×10\^13 vector genome(VG)/kg body weight~* Interventions:~  * Genetic: GEN6050X"
62803095|NCT01841905||Observational Study|Pre-Symptomatic Alzheimers' Disease
62803096|NCT01779232|PLACEBO_COMPARATOR|control|patients treated with placebo for at least 4 months before IVF attempt
62803097|NCT01779232|ACTIVE_COMPARATOR|danazol|patients treated with danazol (100mg/day)for at least 4 months before IVF attempt
62028683|NCT04353869||Group 1|"Patients with uncomplicated diabetes and low cardiovascular risk~During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA (Éthylènediaminetétraacétique) tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
62028684|NCT04353869||Group 2|"Patients with uncomplicated diabetes and high cardiovascular risk~During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
62028685|NCT04353869||Group 3|"Patients with complicated diabetes~During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
62028686|NCT03318575|EXPERIMENTAL|autoRIC|The autoRIC device will be used on subjects randomized to the treatment group.
62028687|NCT03318575|SHAM_COMPARATOR|autoRIC Sham|The autoRIC Sham device will be used on subjects randomized to the control group.
62028688|NCT03140748|OTHER|Patients with fungal peritonitis|
62028689|NCT03140748|OTHER|Patients with peritonitis without yeast|
62227429|NCT01718353|EXPERIMENTAL|Cabazitaxel + Prednisone (Treatment B)|Cabazitaxel 25 mg/m\^2 IV infusion on Day 1 of Cycle 1 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily. Participants with \<30% PSA reduction from baseline at the end of Cycle 4 switched to Docetaxel 75mg/m\^2 IV infusion on Day 1 of Cycle 5 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, death, unacceptable toxicity or participant's refusal of further study treatment. Participants with ≥30% PSA reduction from baseline at the end of Cycle 4, continued on the same treatment which they received before switching until DP, death, unacceptable toxicity or participant's refusal of further study treatment.
62227430|NCT02409368|EXPERIMENTAL|Cohort A: Treatment - Nivolumab|Nivolumab IV infusion
62803098|NCT03196804|EXPERIMENTAL|LC28-0126|LC28-0126(IV)
62803099|NCT03196804|PLACEBO_COMPARATOR|Placebo|Placebo of LC28-0126
62803100|NCT03375034|EXPERIMENTAL|NDMC 20mg|oral single dose
62590501|NCT03514485|ACTIVE_COMPARATOR|P-S+ (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the school intervention Open Airways for Schools Plus.
62590502|NCT03514485|ACTIVE_COMPARATOR|P+S+ (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the enhanced school intervention Open Airways for Schools Plus, School-Based Asthma Therapy and the primary care intervention Yes We Can Children's Asthma Program.
62803101|NCT03375034|EXPERIMENTAL|NDMC 60mg|oral single dose
62803102|NCT03375034|ACTIVE_COMPARATOR|Clonazepam 1.5mg|oral single dose
62803103|NCT03375034|PLACEBO_COMPARATOR|Placebo|oral single dose
62803104|NCT03556163|EXPERIMENTAL|Test Group|Modified vertical internal mattress sutures + MWF surgery.
62803105|NCT03556163|ACTIVE_COMPARATOR|Control Group|Simple loop interrupted sutures + MWF surgery.
62803106|NCT05977400|ACTIVE_COMPARATOR|Very preterm infants that receive empiric antibiotic treatment in the first 48 hours of life|Neonates in this group will have been enrolled and randomized into the NANO trial and received a blinded 48 hour course of empiric antibiotic treatment.
62803107|NCT05977400|PLACEBO_COMPARATOR|Very preterm infants that do not receive empiric antibiotic treatment in the first 48 hours of life|Neonates in this group will have been enrolled and randomized into the NANO trial and received a blinded 48 hour course of placebo.
62803108|NCT00062179|EXPERIMENTAL|paclitaxel/carboplatin/celecoxib|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion Carboplatin: dosed at an AUC of 6 by the Calvert Formula Celecoxib: 400 mg po BID 3 cycles of paclitaxel and carboplatin 21 days apart celecoxib 3-7 days before first dose of chemotherapy
62028690|NCT04481347||Patients undergoing general anesthesia|Patients eligible for interventional neuroradiology or surgery performed under general anesthesia. Patients will be included if they are admitted for a non-emergency scheduled procedure.
62028691|NCT03621384||Bb Genotype|Subjects with Bb genotype of BsmI polymorphisms in vitamin D receptor gene
62803109|NCT00062179|PLACEBO_COMPARATOR|paclitaxel/Carboplatin/Placebo|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion Carboplatin: dosed at an AUC of 6 by the Calvert Formula Placebo 3 cycles of paclitaxel and carboplatin 21 days apart Placebo 3-7 days before first dose of chemotherapy
62803110|NCT02585362|ACTIVE_COMPARATOR|Intervention group|Participants will receive physical exercise, nutrition counseling and a whey protein Supplement over 12 weeks
62803111|NCT02585362|NO_INTERVENTION|Control group|Participants will receive standard care
62803112|NCT02576639|PLACEBO_COMPARATOR|Placebo|Matching placebo to CNP520 was taken once daily (qd) orally for 13 weeks.
62803113|NCT02576639|EXPERIMENTAL|CNP520 2 mg|CNP520 2 mg was taken qd orally for 13 weeks.
62803114|NCT02576639|EXPERIMENTAL|CNP520 10 mg|CNP520 10 mg was taken qd orally for 13 weeks.
62803115|NCT02576639|EXPERIMENTAL|CNP520 35 mg|CNP520 35 mg was taken qd orally for 13 weeks.
62803116|NCT02576639|EXPERIMENTAL|CNP520 85 mg|CNP520 85 mg was taken qd orally for 13 weeks.
62803117|NCT01514019|EXPERIMENTAL|Acebutolol|Acebutolol 200 mg capsule (Acetanol®)
62803118|NCT01514019|PLACEBO_COMPARATOR|Placebo|
62227431|NCT02303522||All subjects|All subjects will be included in a unique cohort
62803119|NCT00878163|EXPERIMENTAL|Treatment (vismodegib, erlotinib hydrochloride, gemcitabine)|Patients receive Hedgehog antagonist GDC-0449 PO QD and erlotinib hydrochloride PO QD on days 1-28. Some patients also receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62803120|NCT04395807|ACTIVE_COMPARATOR|Helmet CPAP|Helmet Continuous Positive Airway Pressure (CaStar hood for CPAP therapy by Starmed/Intersurgical) driven by high-flow blender (Bio-Med Devices).
62803121|NCT04395807|ACTIVE_COMPARATOR|HFNC|High-Flow Nasal Cannula (OptiflowTM nasal high-flow interface) driven by AIRVO 2 humidification system (Fisher and Paykel)
62803122|NCT02905266|EXPERIMENTAL|Nivolumab and Ipilimumab Concomitant Administration|Followed by Nivolumab monotherapy
62803123|NCT02905266|EXPERIMENTAL|Nivolumab and Ipilimumab Sequential Administration|Followed by Nivolumab monotherapy
62803124|NCT05385666|EXPERIMENTAL|group experimental|
62803125|NCT04804917||Participants in the MindMyMind RCT|"The study participants comprise the 396 youths (and their parents) who participated in the Mind My Mind RCT. The study participants were randomized to the experimental MMM intervention (n=197) or MAU (n=199) and followed in the trial until 26 weeks after randomization, from September 7, 2017, to August 28, 2019.~The MMM consisted of 9-13 weekly, individual therapy sessions. The CBT methods were organized in modules for anxiety, depression and behavioral problems. Flowcharts described the sequencing and dosing of modules to match the problems at hand. The therapy was completed within 17 weeks, followed by a booster session after four weeks.~The MAU was enhanced by two care-coordination visits (week 2 and 17). The MAU interventions included anonymous counseling, pedagogical advice, network meetings, educational support, psychological treatment, or no treatment."
62803126|NCT02602886|EXPERIMENTAL|Exposure and Response Prevention Therapy|
62803127|NCT05527041||Concussed|Subjects age 17-34 years within 72 hours of injury.
62590503|NCT03514485|NO_INTERVENTION|P-S- (Partner School)|This arm includes children who attend one of the partnering schools, and are randomized to the control group (no primary care or school intervention).
62803128|NCT05527041||Non-concussed|In Phase I, uninjured, matched controls. In Phase II, subjects completing baseline concussion testing as part of the standard of care or athletics pre-season.
62227432|NCT03753659|EXPERIMENTAL|Pembrolizumab with local ablation|"* Pembrolizumab 200mg IV Q3W on day 1 of cycle 1 and 2~* Radio Frequency Ablation (RFA) / Microwave Ablation (MWA) / brachytherapy or combination of TACE with RFA, MWA or brachytherapy will be performed on day 1 of cycle 3~* Pembrolizumab 200mg IV administration 2 days after local ablation~* Pembrolizumab 200mg IV Q3W for up to 12 months total treatment duration"
62227433|NCT04291820|EXPERIMENTAL|Intravenous induction with desflurane maintenance|The EMLA patch will be removed, and intravenous induction with propofol + opioid will be performed. The anaesthesia will be maintained with desflurane according to the levels of Bispectral index (BIS). Neuromuscular blockade is optional based on operator decision.
62803129|NCT02579213||women candidates for amniocentesis|pregnant women candidates for amniocentesis between 17-33 gestational weeks
62420244|NCT04323449|EXPERIMENTAL|Default control|Default control method (joystick or switch)
62420245|NCT04541992||Airborne Group|Participants in this group will be tested for balance and agility within a 20 minute time frame.
62803130|NCT04675333|EXPERIMENTAL|evorpacept (ALX148) + pembrolizumab + Chemotherapy|evorpacept (ALX148) 45 mg/kg IV, pembrolizumab 200 mg IV, and chemotherapy given every 3 weeks.
62803131|NCT04675333|ACTIVE_COMPARATOR|pembrolizumab + Chemotherapy|pembrolizumab 200 mg IV and chemotherapy given every 3 weeks.
62803132|NCT04781166|EXPERIMENTAL|Intervention|Participants will be immediately assigned to the intervention.
62803133|NCT04781166|OTHER|Waitlist control|Participants will complete measures before and after a waitlist equivalent to the duration of the intervention, to assess whether change is observed with time and repeated assessment. After the waitlist control, participants will be provided the opportunity to take part in the intervention. In this RDICT design, the pre- post- treatment data will be included in analyses.
62803134|NCT03232996|EXPERIMENTAL|Experimental Group|Computer Game based balance and walk rehabilitation
62803135|NCT06340308|EXPERIMENTAL|1 tablet|
62803136|NCT06340308|ACTIVE_COMPARATOR|2 tablets|
62803137|NCT03369418|ACTIVE_COMPARATOR|Active|Subjects will be given an Alpha-Stim active device for daily treatment. The electrodes attached to the device will be active. The device frequency is preset to 0.5 Hz and 100 microampere and treatment is one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur.
62803138|NCT03369418|SHAM_COMPARATOR|Inactive|"Subjects will be given an Alpha-Stim inactive device for daily treatment. The electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive. The frequency on the device will state 0.5 Hz and 100 microampere but it will not actually emit anything. Subjects in this group will receive treatment one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur."
62803139|NCT01051674|EXPERIMENTAL|High fiber diet|
62227434|NCT04291820|ACTIVE_COMPARATOR|Inhalation induction with sevoflurane,sevoflurane maintenance|The EMLA patch will be removed, and inhalation induction with the sevoflurane will be performed. After peripheral vein cannulation, the opioid will be administered. The neuromuscular blockade is optional based on operator decision. Anaesthesia will be maintained with sevoflurane according to the set BIS levels.
62420246|NCT05327023|NO_INTERVENTION|Donor Arm|Donors for Recipients in Arms 1-4
62420247|NCT05327023|EXPERIMENTAL|Phase I Dose Escalation, Cohort 1 (matched)|DLI at escalating doses (1 x 10\^6 CD3+ cells/kg, 3 x 10\^6 CD3+ cells/kg, and 1 x 10\^7 CD3+ cells/kg) on day +7 or +21 to assess for safety and determine Phase II dose (up to 18 evaluable patients)
62420248|NCT05327023|EXPERIMENTAL|Phase I Dose Escalation, Cohort 2 (haploidentical)|DLI at escalating doses (1 x 10\^5 CD3+ cells/kg, 3 x 10\^5 CD3+ cells/kg, and 1 x 10\^6 CD3+ cells/kg) on day +7 or +21 to assess for safety and determine Phase II dose (up to 18 evaluable patients)
62420249|NCT05327023|EXPERIMENTAL|Phase II Efficacy, Cohort 1 (matched)|DLI at maximally tolerated, safe dose (from Phase I) to assess secondary clinical outcomes at this dosing level (up to 14 additional evaluable patients in each cohort)
62420250|NCT05327023|EXPERIMENTAL|Phase II Efficacy, Cohort 2 (haploidentical)|DLI at maximally tolerated, safe dose (from Phase I) to assess secondary clinical outcomes at this dosing level (up to 14 additional evaluable patients in each cohort)
62590504|NCT03514485|ACTIVE_COMPARATOR|P+ (Non-Partner School)|This arm includes children who do not attend one of the partnering schools and who are randomized to receive the primary care intervention Yes We Can Children's Asthma Program.
62590505|NCT03514485|NO_INTERVENTION|P- (Non-Partner School)|This arm includes children who do not attend one of the partnering schools and who are randomized to the control group (no primary care intervention and ineligible for the school intervention).
62803140|NCT01051674|EXPERIMENTAL|Low-carbohydrate diet|
62803141|NCT02668497|EXPERIMENTAL|De-novo PD|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined by biomechanical analysis of tremulous movements for tremor therapy in both upper extremity every 12 weeks over 42 weeks. BoNT-A dose will range from 50-300 U per arm
62803142|NCT02668497|EXPERIMENTAL|L-dopa PD|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined by biomechanical analysis of tremulous movements for tremor therapy in both upper extremity every 12 weeks over 42 weeks. BoNT-A dose will range from 50-300 U per arm
62803143|NCT01694381|EXPERIMENTAL|mutant pro-urokinase (M5) alone|In the first study part subjects in cohorts of 4 will receive ascending doses of either M5 (3 subjects) or M5-placebo (1 subject) without C1-inhibitor.
62803144|NCT01694381|EXPERIMENTAL|Mutant pro-urokinase (M5) and its inhibitor, C1 inhibitor|"In the second study part subjects in cohorts of 5 will receive ascending doses of either M5 or M5-placebo, preceded by a single intravenous dose of C1-inhibitor or C1-inhibitor-placebo. Each subject will randomly be allocated to one of the following treatment arms within one cohort:~* C1-inhibitor followed by M5 (3 subjects);~* C1-inhibitor followed by M5-placebo (1 subject);~* C1-inhibitor-placebo followed by M5-placebo (1 subject).~Dose levels of both M5 and C1-inhibitor within each cohort will be chosen based on the available safety, pharmacokinetic and pharmacodynamic data of the preceding cohorts."
62803145|NCT03449966|EXPERIMENTAL|Target biopsy under pCLE|(Cellvisio® with confocal minoprobe™, Mauna Kea Technologies, France)
62803146|NCT03449966|ACTIVE_COMPARATOR|Random biopsy at cancer lesion under WLE|WLE (GIF-HQ290, Olympus, Japan) group
62028692|NCT03621384||bb Genotype|Subjects with bb genotype of BsmI polymorphisms in vitamin D receptor gene
62420251|NCT04820335|EXPERIMENTAL|Immediate Treatment Group|Participants will complete 7, 60-minute SEMAT sessions over 7 weeks with their group.
62420252|NCT04820335|NO_INTERVENTION|Delayed Treatment Control|Participants will not receive the intervention immediately. After 8 weeks, participants in this arm will complete the SEMAT. This is not a crossover design, because the treatment effects from those in the immediate treatment group can not be taken away.
62590506|NCT00286780|EXPERIMENTAL|1|
62590507|NCT04696354|OTHER|Interrogation Arm|patients will first be evaluated with MPV (limited to 3 views). The prescribed course of treatment based on the MPV results will be documented and patients will then be evaluated using IVUS. A treatment plan based on IVUS results will be compared with the MPV guided treatment plan and any differences will be documented. Any patients determined to still require venous stenting based on IVUS results will be stented accordingly using IVUS to guide stent placement.
62803147|NCT01611038|PLACEBO_COMPARATOR|Placebo|Placebo given daily
62803148|NCT01611038|EXPERIMENTAL|Methylselenocysteine|Methylselenocysteine given daily
62803149|NCT05737914|ACTIVE_COMPARATOR|Endoscopic thoracic T3 sympathectomy|
62803150|NCT05737914|ACTIVE_COMPARATOR|ThoracicT3 radiofrequency ablation|
62803151|NCT01493193|ACTIVE_COMPARATOR|Endurance training with constant work load|
62803152|NCT01493193|EXPERIMENTAL|Pyramid-Training|
62803153|NCT01493193|EXPERIMENTAL|High-intensity interval training|
62227435|NCT01907360|EXPERIMENTAL|HLD200 (methylphenidate hydrochloride) in Adolescents|HLD200 (B formulation, 54 mg, oral capsules) administered as a single treatment in the evening to children aged 13-17 years.
62227436|NCT01907360|EXPERIMENTAL|HLD200 (methylphenidate hydrochloride) in Children|HLD200 (B formulation, 54 mg, oral capsules) administered as a single treatment in the evening to children aged 6-12 years.
62227437|NCT03897244|EXPERIMENTAL|High-dose dual therapy|group A - HDDT (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)
62420253|NCT01365676|EXPERIMENTAL|GAMALINE® + HIPERICIN® 25-44 years old|Fertile women 24-44 years old with PMS symptoms
62227438|NCT03897244|EXPERIMENTAL|Bismuth High-dose dual therapy|group B - Bis-HDDT (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)
62227439|NCT03897244|ACTIVE_COMPARATOR|Amoxicillin-Metronidazole Bismuth quadruple therapy|group C - AM-BQT (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)
62420254|NCT01365676|ACTIVE_COMPARATOR|GAMALINE® 25-44 years old|Fertile women 24-44 years old with PMS symptoms
62590508|NCT04696354|OTHER|Deferred Interrogation Arm|"Deferred Interrogation Guidelines for this study are as follows:~Mandate:~• Continued compression therapy/stockings as prescribed.~Allow:~* Periodic leg elevation.~* Sclerotherapy under ulcer bed.~* Recommend mechanical debridement as needed.~* Wound biopsy if evidence of infection.~* Systemic antibiotics if patient is diagnosed with an infection, avoid prophylactic prescription.~* Pain management medication (Pentoxifylline/Trental) allowed but not recommended~* Topical antimicrobial as needed.~Prohibit:~* Negative pressure systems.~* Artificial and/or autologous skin grafting within first 3 months after randomization and within the first 3 months for subjects that crossover from deferred interrogation to the interrogation arm."
62803154|NCT03567031|EXPERIMENTAL|Main Arm|In each patient, under ongoing standard general anesthesia in a stable state, EtCO2 is manually modified to reach predefined values, and after waiting until cerebral blood flow has reached steady state, NIRS and DTC values are noted.
62803155|NCT04604041||Relapsing-remmitting MS group treated with corticosteroids|"1. Clinical testing~2. Neurophysiological examination (TMS, EMNG)~3. Psychomotor examination~4. Neuropsychological evaluation~5. Flow cytometry~6. ELISA"
62803156|NCT04604041||Relapsing-remmitting MS group treated with immunomodulation|1. Clinical testing 2. Neurophysiological examination (TMS, EMNG) 4. Neuropsychological evaluation 5. Flow cytometry
62803157|NCT04604041||Healthy control group|5. Flow cytometry
62803158|NCT06265181|EXPERIMENTAL|Intervention Group|"Diabetes coaching will be provided to experimental group participants. In this study, one chemistry interview and eight diabetes coaching meetings are planned to be held.~Interviews will be conducted in accordance with the standards of the GROW technique, which is based on a scientific framework. Interviews will be held every 10 days, via a video-free phone call, and will last between 45-60 minutes."
62803159|NCT06265181|NO_INTERVENTION|Control Group|Diabetes treatment and care of the participants in this group will continue routinely, and no additional intervention will be performed.
62227440|NCT05353673|EXPERIMENTAL|Sitagliptin and Danazol|Sitagliptin is given at a dose of 100 mg/m2 qd for 12 weeks. Danazol is given at 200mg bid for 12 weeks.
62227441|NCT05353673|ACTIVE_COMPARATOR|Danazol|Danazol is given at 200mg bid for 12 weeks.
62227442|NCT00605644|PLACEBO_COMPARATOR|Placebo|Placebo
62420255|NCT01365676|EXPERIMENTAL|GAMALINE® + HIPERICIN® 45-55 years old|Climacteric women with PMS symptoms
62420256|NCT01365676|ACTIVE_COMPARATOR|GAMALINE® 45-55 years old|Climacteric women with PMS symptoms
62803160|NCT02066766||Subjects with diabetes mellitus (type 2)|
62803161|NCT01163526||neuroendocrine metastases|15 patients with neuroendocrine metastases
62803162|NCT01163526||colon cancer metastases|15 patients with colon cancer metastases
62803163|NCT01163526||HCC treated with cyberknife radiation and chemotherapy|15 patients with HCC treated with cyberknife radiation and chemotherapy
62227443|NCT00605644|EXPERIMENTAL|150 mg|MOA-728
62227444|NCT00605644|EXPERIMENTAL|300 mg|MOA-728
62227445|NCT00605644|EXPERIMENTAL|450 mg|MOA-728
62803164|NCT01163526||HCC treated with Sirsphere embolization and chemotherapy|15 patients with HCC treated with Sirsphere embolization and chemotherapy
62803165|NCT03524482|EXPERIMENTAL|Path2Quit|Culturally specific text message intervention
62803166|NCT03524482|ACTIVE_COMPARATOR|SmokeFreeText|The National Cancer Institute's publicly available, standard text messaging program for tobacco cessation
62803167|NCT03782233|EXPERIMENTAL|deep neuromuscular blockade group (Group D)|Patients undergoing elective laparoscopic surgery for gastrectomy will be randomized to receive deep neuromuscular blockade (post-tetanic count = 1-2) using high dose rocuronium.
62420257|NCT04000529|EXPERIMENTAL|TNO155 in combination with spartalizumab|TNO155 in combination with spartalizumab
62420258|NCT04000529|EXPERIMENTAL|TNO155 in combination with ribociclib|TNO155 in combination with ribociclib
62590509|NCT05891223|EXPERIMENTAL|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"* A breath break with kindness is practiced.~* Encourage them to think about how threat, impulse and sedative systems have developed in their own lives.~* A safe place application is made.~* Courtesy meditation is done."
62803168|NCT03782233|OTHER|moderate neuromuscular blockade group (Group M)|Patients undergoing elective laparoscopic surgery for gastrectomy will be randomized to receive moderate neuromuscular blockade (train-of-four count = 1-2) using moderate dose rocuronium.
62803169|NCT04442542|EXPERIMENTAL|Respiratory exercises plus method JaPer|Respiratory exercises plus the new intervention protocol with an inspirometer (JaPer Method)
62803170|NCT04442542|ACTIVE_COMPARATOR|Protocol of use of inspirometer in a conventional way|Respiratory exercises plus conventional use of the inspirometer.
62227446|NCT00605644|EXPERIMENTAL|600 mg|MOA-728
62227447|NCT05219474|EXPERIMENTAL|Cochlear implant subjects|Participates in 7 visits over a six-month duration. Subjects will be given several tests that require them to listen to sounds presented to their cochlear implant and answer questions about those sounds.
62227448|NCT05219474|NO_INTERVENTION|Normal hearing subjects|Participates in 1 visit lasting 3 hours. Will be given several tests that require you to listen to sounds and answer questions about those sounds. The sounds will be distorted in ways that approximate how a cochlear implant sounds.
62803171|NCT01601535|EXPERIMENTAL|Treatment|"Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.~Irinotecan will be administered intravenously during each course on study day 1 through day 5.~Temozolomide will be administered orally during each course on study day 1 through day 5."
62803172|NCT02913482|EXPERIMENTAL|Part 1 (Dose Finding): Risdiplam (RO7034067)|Participants will receive multiple ascending doses of risdiplam (RO7034067), administered orally once daily for a minimum of 4 weeks to select the dose for Part 2. During the first year of treatment, most participants will switch to the Part 2 dose. During the second year of treatment, all Part 1 participants will be receiving the Part 2 dose. They will thereafter enter a 3-year open-label extension phase and continue to receive risdiplam at the same dose.
62590510|NCT05891223|EXPERIMENTAL|Session 2: Threat and Self-Compassion|"* A breath break with kindness is practiced.~* Building a compassionate relationship with resilience and kindness meditation: a benevolent practices are made.~* A hand on your heart and a compassionate comrade practices are made."
62227449|NCT06294054||Patients enrolled in VESPER study|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort
62227450|NCT06294054||Patients from St Louis cohort not enrolled in VESPER study|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort
62227451|NCT06294054||Patients from COBLAnCE cohort not enrolled in VESPER study|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in COBLAnCE cohort
62227452|NCT05172349|EXPERIMENTAL|LV-Visio-AMTRIX|Sutureless amniotic membrane supported by a biological ring positioned by the investigator during patients' hospital visits.
62420259|NCT06562335|EXPERIMENTAL|Booster intervention|"* Start conversation: participant personalises the Booster app, supported by the Booster practitioner~* Measurement period: the participant fills out short repeated questionnaires 5 times daily for 4 weeks in the Booster app. This method is called experience sampling methodology (ESM). Questions are partially personalised to reflect factors that the participants believes are related to fatigue. Questions cover thoughts, feelings, and activities.~* Insight conversation: the Booster practitioner discusses the analysed questionnaires with the participant. Together they set lifestyle goals based on the insight obtained.~* Experiment period: the participant works on the lifestyle goals supported by the goal attainment module in the Booster app."
62227453|NCT03686748|EXPERIMENTAL|Two-point intervention|Two point discrimination training.
62227454|NCT03686748|ACTIVE_COMPARATOR|One-point intervention|One point discrimination of size of probe
62420260|NCT06568354|ACTIVE_COMPARATOR|Yoga Group|A yoga exercise program will be applied in two sessions per week, a total of eight weeks.
62227455|NCT03686748|NO_INTERVENTION|Healthy Controls|Observational component of differences in discrimination between chronic pain patients and healthy controls.
62227456|NCT02569203|PLACEBO_COMPARATOR|control group|standard enteral nutrition
62227457|NCT02569203|EXPERIMENTAL|test group I|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
62227458|NCT02569203|EXPERIMENTAL|test group II|high-protein enteral nutrition of immune modulating nutrients without β-glucan
62420261|NCT06568354|ACTIVE_COMPARATOR|Motor Control Exercise Group|Motor control exercise program will be applied two sessions per week, totally eight week.
62420262|NCT03539939|EXPERIMENTAL|Smoker Group|This group included smoker gingival recession patients.
62420263|NCT03539939|ACTIVE_COMPARATOR|Non-smoker Group|This group included non-smoker gingival recession patients.
62590511|NCT05891223|EXPERIMENTAL|Session 3: Unraveling the Knots of Desire and Patterns Agenda|"* Talk about homework.~* A breath break with kindness is practiced.~* Establishing a compassionate relationship with desire, guided meditation to discover the inner pattern, courtesy meditation: a good friend practices are made."
62227459|NCT01669876|ACTIVE_COMPARATOR|Dietary Supplement: Anatabloc(R)|Study product, as mint-flavored lozenge (3 mg anatabine per lozenge) to be taken 2-3 times each day
62227460|NCT01669876|PLACEBO_COMPARATOR|Placebo|Placebo, as mint-flavored lozenge, to be taken 2-3 times each day
62227461|NCT01995851||Intervention (LAIV)|Healthy children and adolescents between Junior Kindergarten (JK) and Grade 8 in the intervention schools will be immunized with LAIV (FluMist influenza vaccine) recommended for the 2013-14 the influenza season.
62028693|NCT01962493|OTHER|Sodium bicarbonate/ Sodium Fluoride toothpaste|Marketed Sodium bicarbonate toothpaste containing 1400 parts per million (ppm) fluoride as Sodium fluoride (NaF)
62420264|NCT03086980|ACTIVE_COMPARATOR|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.Research suggests that ASTM may help reduce depression and anxiety.
62420265|NCT03086980|PLACEBO_COMPARATOR|Treatment as Usual (TAU)|The usual standard of care for patients with glaucoma includes starting them on first line of drugs. Participants will be initiated and maintained on appropriate dosages of such medications as part of standard of care. The usual standard of care also includes an ophthalmic examination measuring best-corrected Snellen VA and pinhole acuities and a follow-up visit once a year.
62803173|NCT02913482|EXPERIMENTAL|Part 2 (Confirmatory): Risdiplam (RO7034067)|Participants will receive risdiplam (RO7034067), administered orally once daily at the dose defined in Part 1 of the study, for a duration of 24 months. They will thereafter enter a 3-year open-label extension phase and continue to receive risdiplam at the same dose.
62803174|NCT05597774|EXPERIMENTAL|Exercise training + Inspiratory and expiratory muscle training group|Participants will perform a cardiovascular exercise program 2 days per week during 8 weeks in the hospital, combined with an inspiratory and expiratory muscle training by a threshold device at home, twice a day, 3 days per week, for 8 weeks supervised by a physiotherapist through a virtual platform.
62803175|NCT05597774|SHAM_COMPARATOR|Exercise training + Inspiratory and expiratory muscle training sham group|Participants will perform a cardiovascular exercise program 2 days per week during 8 weeks in the hospital, combined with an inspiratory and expiratory muscle training by a sham threshold device at home, twice a day, 3 days per week, for 8 weeks supervised by a physiotherapist through a virtual platform.
62803176|NCT03356275|EXPERIMENTAL|Mobile application|Psychosocial support for parents, including: brief audio mindfulness recordings, videos, and psychoeducational materials.
62803177|NCT00411749|EXPERIMENTAL|V501|"V501 vaccination Quadrivalent HPV (Types 6, 11, 16,~18) L1 VLP Vaccine Injection~cervix cancer exgenlesion Vaccination at Day 1, Month 2, and Month 6. Total 3 vaccinations. 0.5 mL intramuscular dose of V501 (HPV L1 Virus-Like Particle \[VLP\] Type 6,~Type 11, Type 16, Type 18) or placebo at Day 1, Month 2 and Month 6."
62803178|NCT00411749|PLACEBO_COMPARATOR|Placebo|Placebo vaccination, Placebo 0.5 ml injection in 3 dosing regimen
62803179|NCT02147743|EXPERIMENTAL|CCP+MDFT|Multidimensional Family Therapy (MDFT) is a multisystemic, flexible intervention system (Liddle, 2002). It is a strengths-based approach promoting protective factors and reducing risk factors for delinquency, substance use, and school problems. MDFT organizes interventions in key areas of the teen's life: self of the adolescent (includes HIV-STD risk behaviors), parenting, family environment, and school/vocational functioning.
62803180|NCT02147743|OTHER|CCP+SAU|Services as Usual (SAU) are determined on a case-by-case basis by the CCP Case Manager. SAU includes a variety of services offered by a number of community partners.
62803181|NCT03259555|EXPERIMENTAL|Brexpiprazole|Participants received a starting dose of 2 milligrams (mg)/day brexpiprazole from Days 1 to 3, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
62420266|NCT04715737|EXPERIMENTAL|Vasopressin|Vasopressin (20IU) intranasally
62420267|NCT04715737|EXPERIMENTAL|Oxytocin|Oxytocin (24IU) intranasally
62420268|NCT04715737|PLACEBO_COMPARATOR|Placebo|Placebo intranasally
62420269|NCT03622086|EXPERIMENTAL|7-10 years old|Children-caregiver pairs will participate in a 24-week pilot that includes 2 phases, 12 weeks of usual care, followed by 12 weeks of Foundations of Fitness Program.
62803182|NCT03259555|PLACEBO_COMPARATOR|Placebo|Matching placebo was administered in the same way as brexpiprazole to maintain the blind.
62803183|NCT04520607|EXPERIMENTAL|Arm 1|Subjects assigned to this arm will receive one intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle (same treatment as in the parent-study) into their target knee (the same target knee injected in the parent study); performed on Day 1, at Week 48 and every 52 weeks thereafter.
62028694|NCT01962493|ACTIVE_COMPARATOR|Sodium fluoride toothpaste|Non-sodium bicarbonate toothpaste containing 1450ppm fluoride as NaF
62028695|NCT01962493|OTHER|Chlorhexidine digluconate mouthwash|0.2% w/v Chlorhexidine digluconate mouthwash for rinsing post-brushing with study toothpastes
62420270|NCT03622086|EXPERIMENTAL|11-13 years old|Children-caregiver pairs will participate in a 24-week pilot that includes 2 phases, 12 weeks of usual care, followed by 12 weeks of Foundations of Fitness Program.
62590512|NCT05891223|EXPERIMENTAL|Session 4: Internalizing compassion|"* Pretend-to-pretend practice is made for participants to observe themselves.~* In addition to the previous practices, the practice of internalizing compassion is made in order to increase their expanded mindfulness.~* Courtesy meditation: a neutral person, kindness towards your body, which is based on mindfulness practices and increases body awareness and mindful movement, is carried out. During the day, they will be informed that they should do the walking with kindness practice on their own."
62803184|NCT04520607|EXPERIMENTAL|Arm 2|Subjects assigned to this arm will receive one intra-articular injection of 0 mg lorecivivint in 2 ml vehicle (same treatment as in the parent-study) into their target knee (the same target knee injected in the parent study) on Day 1, followed by one intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle at Week 48 and every 52 weeks thereafter.
62803185|NCT03406273|EXPERIMENTAL|≥ 5 years of age|Cerebral Spinal (CS) radiation
62803186|NCT03406273|EXPERIMENTAL|< 5 yo and ≥ 3 yo and CSF +|Cerebral Spinal (CS) radiation
62420271|NCT06588413|EXPERIMENTAL|Olanzapine 2.5 mg|Olanzapine 2.5 mg dose to be given on the day of high-dose melphalan and three days after
62420272|NCT06588413|ACTIVE_COMPARATOR|Olanzapine 5 mg|Olanzapine 5 mg dose to be given on the day of high-dose melphalan and three days after
62420273|NCT05807217||Group A|12 patients (receiving meropenem) without acute kidney injury
62420274|NCT05807217||Group B|12 patients (receiving meropenem) without renal replacement therapy for acute kidney injury
62803187|NCT03406273|EXPERIMENTAL|All < 3 yo & < 5 yo/≥ 3 yo CSF neg|Focal radiotherapy (SRS)
62803188|NCT04125043||RRT Group|Pediatric patients undergoing ocular screening tests
62028696|NCT05794464|EXPERIMENTAL|Catheter ablation and/or electrical cardioversion|Study subjects indicated for catheter ablation and/or electrical cardioversion will be enrolled in this study arm.
62028697|NCT00305058|EXPERIMENTAL|Hydromorphone|0.0075 mg/kg IV hydromorphone
62420275|NCT05807217||Group C|12 patients (receiving meropenem) with intermittent renal replacement therapy for acute kidney injury
62420276|NCT05807217||Group D|4 patients (receiving meropenem) with continuous renal replacement therapy for acute kidney injury
62420277|NCT05807217||Group E|4 patients (receiving piperacillin) with intermittent renal replacement therapy for acute kidney injury
62420278|NCT01327807||Cystinsosis patients|Those with a diagnosis of cystinosis.
62590513|NCT05891223|EXPERIMENTAL|Session 5: Me and others - Expanding the circle|"* A compassionate letter application is made by asking participants to think about a situation they encountered recently or some time ago and is still causing distress. It is explained that they can gain insight with this application.~* Courtesy meditation: the 'difficult' person, compassion and breathing: yourself and compassionate breathing: others practices are made."
62590514|NCT05891223|EXPERIMENTAL|Session 6: Growing happiness|"* Revisiting the good practice is carried out to define the five sense organs for the participants.~* Forgiveness, Asking for forgiveness, forgiving others, gratitude practices are carried out.~* The practice is expanded as kindness meditation: groups and all beings."
62803189|NCT03881111|EXPERIMENTAL|Pembrolizumab + Cisplatin + 5-FU|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W), cisplatin 80 mg/m\^2 IV Q3W, and 5-FU 800 mg/m\^2/day continuous IV infusion on Days 1 to 5 (120 hours). All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
62028698|NCT00305058|ACTIVE_COMPARATOR|Morphine|0.05 mg/kg IV morphine
62420279|NCT04190966|ACTIVE_COMPARATOR|Integrated smoking cessation|Integrated smoking cessation delivered by trained health-care practitioners in the thoracic surgical pathway: a three part package of behaviour interventions and pharmacotherapy as per NICE/NCSCT guidance which is supported by an adjunct web-based application.
62420280|NCT04190966|NO_INTERVENTION|Usual care smoking cessation|Usual care of standard community/hospital based NHS smoking cessation.
62420281|NCT02360124|PLACEBO_COMPARATOR|control|instructions on oral hygiene (OHI) tailored to the individual's condition will be given, and a tube of toothpaste containing 1,000 ppm fluoride (the most popular type of adult toothpaste in the Hong Kong market) will be provided. The OHI and provision of toothpaste will be repeated at 6-month intervals. In addition, distilled water as placebo with a bitter flavor added (to mimic the bitter metallic taste of SDF) will be painted onto all exposed tooth root surfaces using a small disposable brush. This procedure will be repeated after 12 and 24 months.
62028699|NCT06634706|OTHER|Cohort 1 - Head and Neck Tumors|Tumors in the following regions: Larynx, Salivary glands, Thyroid gland, Head and Neck lymph nodes, Oral cavity, Oropharynx, Nasopharynx, and Hypopharynx
62028700|NCT06634706|OTHER|Cohort 2 - Thoracic Tumors|Tumors in the following regions: Thoracic lymph nodes, Thymus, Esophagus, and Breast,
62227462|NCT01995851||Control (TIV)|Healthy children and adolescents between JK and Grade 8 in schools assigned to TIV will be immunized with inactivated influenza vaccine (Vaxigrip vaccine) recommended for the 2013-14 influenza season.
62420282|NCT02360124|EXPERIMENTAL|silver diammine fluoride|the subjects will receive the same intervention as those provided to subjects in the control group except that a 38% SDF solution (Saforide, Toyo Seiyaku Kasei Co. Ltd, Osaka, Japan) instead of the placebo solution will be painted onto the exposed tooth root surfaces. This treatment will be repeated after 12 and 24 months.
62420283|NCT02360124|ACTIVE_COMPARATOR|silver diammine fluoride and KI|the subjects will receive the same treatment as those provided to subjects in the control group except that a 38% SDF solution instead of the placebo solution will be painted onto the exposed tooth root surfaces and followed by painting of a saturated potassium iodide solution. This treatment will be repeated after 12 and 24 months.
62420284|NCT01406769|EXPERIMENTAL|Diagnostic (bioimpedance to measure lymphedema)|Patients undergo preoperative and postoperative lower-extremity lymphedema assessment comprising serial circumferential measurements, bioimpedance spectroscopy measurements, and clinical evaluation using the Stemmer sign. Patients undergo radical vulvectomy or radical local excision as prescribed by GOG-0244, and unilateral or bilateral inguinal or inguinal-femoral lymphadenectomy.
62420285|NCT04723173|EXPERIMENTAL|Experimental device: Noise reduction on|The noise reduction is activated. The feature shall support the hearing aid user in noisy situation and shall reduce the listening effort in these special situations.
62420286|NCT04723173|ACTIVE_COMPARATOR|Experimental device: Noise reduction off|To compare the advantage of the special noise reduction feature the tests will be done additionally with the deactivated feature.
62420287|NCT05340517|EXPERIMENTAL|video-assisted rib planting|
62420288|NCT06544473|ACTIVE_COMPARATOR|Oral estrogen treatment|Turner syndrome patients receiving oral estrogen treatment (Estrofem®)
62803190|NCT03881111|PLACEBO_COMPARATOR|Placebo + Cisplatin + 5-FU|Participants receive placebo to pembrolizumab (saline) IV Q3W, cisplatin 80 mg/m\^2 IV Q3W, and 5-FU 800 mg/m\^2/day continuous IV infusion on Days 1 to 5 (120 hours). All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
62803191|NCT00930891|ACTIVE_COMPARATOR|Arm A|4 additional cycles of chemotherapy
62803192|NCT00930891|EXPERIMENTAL|Arm B|4 additional cycles of chemotherapy + bevacizumab
62803193|NCT02341235|EXPERIMENTAL|Game intervention|Participants will receive narrative-based games on a mobile device and telephone counseling (weekly for the first 12 weeks, then once per month until 6 months)
62803194|NCT02341235|ACTIVE_COMPARATOR|Standard intervention|Participants will receive an electronic activity monitor with a mobile device and telephone counseling (weekly for the first 12 weeks, then once per month until 6 months)
62803195|NCT05768100|EXPERIMENTAL|1,3-Butanediol|
62420289|NCT06544473|ACTIVE_COMPARATOR|Transdermal estrogen treatment|Turner syndrome patients receiving transdermal estrogen treatment (Divigel)
62420290|NCT05478499|EXPERIMENTAL|Deucravacitinib|
62420291|NCT05478499|PLACEBO_COMPARATOR|Placebo then Deucravacitinib|
62420292|NCT00951899|EXPERIMENTAL|Colesevelam|Treatment with colesevelam hydrochloride in addition to Metformin and Diet
62420293|NCT00951899|PLACEBO_COMPARATOR|Placebo|Treatment with placebo in addition to Metformin and Diet
62420294|NCT05267184|EXPERIMENTAL|Embolization of middle meningeal artery|Participants receive endovascular treatment with embolization of the middle meningeal artery ipsilaterally to the chronic subdural hematoma(s).
62420295|NCT05267184|ACTIVE_COMPARATOR|Standard neurosurgical hematoma evacuation and drainage|Participants receive standard neurosurgical hematoma evacuation via burr hole or mini craniotomy and post-operative subdural or subgaleal drainage.
62803196|NCT05768100|PLACEBO_COMPARATOR|Placebo|
62803197|NCT03479229|EXPERIMENTAL|Geneveve Treatment|Active Treatment
62803198|NCT03479229|PLACEBO_COMPARATOR|Sham Treatment|Sham Treatment
62803199|NCT05090735|ACTIVE_COMPARATOR|SPIP Block|50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
62803200|NCT05090735|ACTIVE_COMPARATOR|SPIP Block with TAP Block|50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib. This group of patients will also receive unilateral TAP block by injecting 20 mL of 0.25% bupivacaine in the plane between the internal oblique and transversus abdominis muscles.
62227463|NCT06340399|EXPERIMENTAL|patients receiving BCAA|patients undergoing BCAA before surgery to postoperative day 30
62227464|NCT06340399|PLACEBO_COMPARATOR|patients not receiving BCAA|patient not undergoing BCAA
62028701|NCT06634706|OTHER|Cohort 3 - Hepatobiliary Tumors|Tumors in the following regions: Liver and intrahepatic ducts, Gallbladder, Extrahepatic bile ducts, and Hepatic lymph nodes,
62227465|NCT03215810|EXPERIMENTAL|TIL+ Nivolumab|Tumor-infiltrating Lymphocyte Therapy (TIL) + Nivolumab Treatment Plan: Tumor harvest, Tumor-infiltrating Lymphocytes growth, 4 cycles of nivolumab, cytoreductive chemotherapy with cyclophosphamide and fludarabine, TIL infusion, Interleukin-2 treatment.
62028702|NCT06634706|OTHER|Cohort 4 - Retroperitoneal Tumors & non-Hepatobiliary Abdominal Tumors|Tumors in the following regions: Kidneys, Adrenal gland, Pancreas, Retroperitoneal lymph nodes, Stomach, Spleen, Small intestine, and Colon
62028703|NCT06634706|OTHER|Cohort 5 - Pelvic Tumors|Tumors in the following regions: Prostate, Bladder, Ureter, Urethra, Cervix, Ovaries, Fallopian tubes, Vagina, Colon \[Sigmoid\], Rectum, Anus, and Pelvic lymph nodes.
62803201|NCT05144100|EXPERIMENTAL|Arm 1 - Surgery +/- Neck Dissection|Patients would undergo appropriate surgery via open, endoscopic, TLM, TORS or a combination. The primary and the neck would be addressed. For N0 neck, clearance of levels II-IV will be required, with levels I and/or V electively dissected at the discretion of the operating surgeon and based on extension of nodal disease. For N+ neck and tumors approaching to within 1cm of the midline, we recommend a contralateral neck dissection be performed as well of levels II-IV but to be done as per operating team's discretion. For lateralized lesions of the BOT and tonsil, ipsilateral neck dissection will be performed. A minimum of 18 lymph nodes per dissected side of the neck is required and will be subject to quality assurance review
62028704|NCT06634706|OTHER|Cohort 6 - Other and Orphan Tumors|Tumors in the following regions: \* Locations not listed in Cohorts 1-5, however; considered at physicians discretion i.e. Lymphoma \[Head and Neck\], Thorax, Abdomen, and Pelvis
62028705|NCT00586105|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006)|400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
62028706|NCT03432624||Experiment Subgroup, Group One|Experiment Subgroup, Group One consists of pancreatic cancer patients, in which 120 are operable, and 120 are not operable.
62028707|NCT03432624||Control Subgroup, Group One|Control Subgroup, Group One consists of 150 patients, in which 30 are of gallbladder carcinoma, 60 are of biliary tract lower segment carcinoma, 60 are of gastrointestinal carcinoma.
62803202|NCT05144100|EXPERIMENTAL|Arm 2 - Chemoradiation|"Patients will receive IMRT with normal tissue sparing techniques (70Gy/35# or 66Gy/ 30#) along with concurrent weekly cisplatin. Weekly cisplatin will be administered during IMRT at a dose of 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36, and 43 for a total of up to 7 weekly doses, administered during the course of IMRT.~For patients with T1-2 lateralized tonsil tumors with \<1 cm invasion into the soft palate, no invasion of BOT, and N1 neck involvement, unilateral neck will be irradiated. The contralateral neck will be addressed for some BOT tumors\<1cm or at the midline and may be considered in patients with N2 and N3status. For patients with residual neck disease after CCRT, a formal neck dissection will be performed. For patients with residual primary disease after CCRT, surgery for the primary will be performed if feasible."
62028708|NCT03432624||Interference Subgroup, Group One|Interference Subgroup, Group One consists of 150 patients, in which 60 are of chronic pancreatitis, 90 are of other types of pancreatic tumor, in which 30 are of IPMN (intraductal papillary mucinous neoplasm), 30 are of SPT (solid pseudopapillary tumor of pancreas), and 30 pancreatic cystic adenoma.
62028709|NCT03432624||Experiment Subgroup, Group Two|Group Two consists of 210 patients selected from Group One, of which the Experiment Subgroup, Group Two consists of the 120 operable pancreatic cancer patients who have had successful surgery.
62028710|NCT03432624||Control Subgroup, Group Two|Control Subgroup, Group Two consists of 90 patients of other cancers who have had successful surgery, in which 30 are of gallbladder carcinoma, and 60 are of biliary tract lower segment carcinoma.
62028711|NCT03498248|EXPERIMENTAL|Neutropenia in chemotherapy|Neutropenia after cytotoxic chemotherapy
62028712|NCT06143215|EXPERIMENTAL|Two weeks revision group|Patients will be clinically revised in a 2-weeks basis
62028713|NCT06143215|ACTIVE_COMPARATOR|Four weeks revision group|Patients will be clinically revised in a 4-weeks basis
62227466|NCT00407277|EXPERIMENTAL|1A|
62227467|NCT00407277|PLACEBO_COMPARATOR|1B|
62227468|NCT00407277|EXPERIMENTAL|2A|
62028714|NCT06143215|EXPERIMENTAL|Six weeks revision group|Patients will be clinically revised in a 6-weeks basis
62028715|NCT04371900|EXPERIMENTAL|Experimental Group|Mothers randomized to receive a voucher to be used at Planned Parenthood to cover the cost of contraceptives
62803203|NCT02140515|ACTIVE_COMPARATOR|Luveris|Evaluation the effect of Luveris protocol on Induction of ovulation in Patients with Hypogonadotropic Hypogonadism
62803204|NCT02140515|ACTIVE_COMPARATOR|Gonal-F& Luveris|Evaluation the effect of Gonal-F\& Luveris protocols of Induction of ovulation in Patients with Hypogonadotropic Hypogonadism
62803205|NCT01178463||I. Obstructive Azoospermia|
62803206|NCT01178463||II. Non-Obstructive Azoospermia Patients|
62803207|NCT01913951|EXPERIMENTAL|Treatment (vosaroxin, azacitidine)|Patients receive vosaroxin IV over 10 minutes on days 1 and 4 and azacitidine SC or IV over 15 minutes on days 1-7. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62803208|NCT03850366|EXPERIMENTAL|Bortezomib|
62803209|NCT02260934|ACTIVE_COMPARATOR|Rituximab/Cyclophosphamide (RC)|Prednisone taper to 10 mg/day by week 12 and continue prednisone 10 mg/day to week 96.
62028716|NCT04371900|NO_INTERVENTION|Control Group|Mothers randomized to NOT receive a voucher. Mothers in this arm receive the Planned Parenthood standard of care priced according to the Planned Parenthood sliding scale.
62028717|NCT06038721|EXPERIMENTAL|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children|The participants in this group will receive the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children (UP-C) in up to 15 sessions through a group format, attended over up to 24 weeks. Sessions will include parent and child strategies to manage strong emotions.
62420296|NCT03203265|OTHER|A:Offline HIV testing and counseling|Participants in Group A will be invited to come to the Thai Red Cross Anonymous Clinic, RSAT or SWING drop-in centers in Bangkok, or SWING or Sisters drop-in centers in Pattaya. After registration, they will receive standard HIV Testing and Counseling (HTC) services.
62803210|NCT02260934|EXPERIMENTAL|Rituximab/Cyclophosphamide/Belimumab (RCB)|"1. Belimumab (10 mg/kg IV) at weeks 4, 6, 8, and every 4 weeks to week 48.~2. Prednisone taper to 10 mg/day by week 12, and continue prednisone 10 mg/day to week 96."
62420297|NCT03203265|OTHER|B1:Offline|participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only.
62420298|NCT03203265|OTHER|B2: Online|participants will be mailed a rapid HIV test kit. A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit, obtaining blood through finger prick, performing the testing steps, and reading the test result.
62420299|NCT00713622|ACTIVE_COMPARATOR|1|
62420300|NCT00713622|ACTIVE_COMPARATOR|2|
62803211|NCT05067517|ACTIVE_COMPARATOR|Nintedanib|Nintedanib 150 mg administered PO twice daily
62803212|NCT05067517|PLACEBO_COMPARATOR|Placebo|Placebo administered PO twice daily
62803213|NCT02635607|OTHER|Fixed Protocol|Patients will start Follitropin beta stimulation on menstrual cycle day 3 and the daily dose will be fixed for the first 5 days of stimulation, a modification of the rFSH dose will be allowed from stimulation day 6 onward. Ganirelix will start fixedly on stimulation Day 5. rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed, and triptorelin trigger will be used as a replacement in case of OHSS high risk
62227469|NCT05021094|EXPERIMENTAL|POI patients who taking Kuntai capsule|Patients in this group will take Kuntai capsule orally, 4 capsules each time, 3 times a day, and take the medicine for 3 courses.
62227470|NCT05021094|ACTIVE_COMPARATOR|POI patients who accepting hormone therapy|The estrogen and progesterone sequential regimen was adopted. The drug was estradiol tablets/estradiol didroxyprogesterone tablets (Femoston). Red tablets (estradiol, 2mg/d) were taken in the first 14 days, and gray tablets (estradiol, 2mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and 3 courses of treatment were taken.
62420301|NCT06568900|ACTIVE_COMPARATOR|(control) continue smoking their usual brand of CC|
62420302|NCT06568900|ACTIVE_COMPARATOR|tobacco flavor and unflavored options of ZYN|
62420303|NCT06568900|ACTIVE_COMPARATOR|unrestricted flavor options of ZYN|
62420304|NCT03610646|EXPERIMENTAL|MYL-1701P|MYL-1701P
62420305|NCT03610646|ACTIVE_COMPARATOR|Eylea|Eylea
62420306|NCT03582059|OTHER|Patient group meeting inclusion criteria group 1|Patients meeting the inclusion criteria in the first 10 days of entering trial and are randomised to first intervention.
62420307|NCT03582059|OTHER|Patient group meeting inclusion criteria group 2|Patient group meeting inclusion criteria after 10 days and are allocated second intervention.
62420308|NCT04012008|ACTIVE_COMPARATOR|Standard care|"* Regular follow-up by internists every 3 month~* May consult nephrologists case-by-case"
62420309|NCT04012008|EXPERIMENTAL|Comprehensive care|"* Regular follow-up by nephrologists every 1-3 month~* Multidisciplinary team consisting pharmacists, nurses, and dieticians"
62420310|NCT00696631|EXPERIMENTAL|Dronedarone 400mg bid|dronedarone 400mg tablets
62420311|NCT00696631|PLACEBO_COMPARATOR|Placebo|matching placebo tablets
62420312|NCT01732666|PLACEBO_COMPARATOR|group L|receives 100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
62420313|NCT01732666|PLACEBO_COMPARATOR|group H|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
62420314|NCT01732666|EXPERIMENTAL|group N|20mg of nefopam mixed in 100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
62420315|NCT02816749|EXPERIMENTAL|Maggot debridement therapy(MDT)|Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
62420316|NCT02816749|ACTIVE_COMPARATOR|Conventional Dressing Therapy(CDT)|Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
62420317|NCT03216681||Hoat Huyet Nhat Nhat|Administered orally twice a day, 2 tablets each time, for 45 days.
62227471|NCT05021094|EXPERIMENTAL|POI patients who taking Kuntai capsule combined with hormone therapy|Kuntai capsule was taken at the same dose as Kuntai group on the basis of hormone therapy for 3 courses.
62420318|NCT03216681||Tanakan 40mg|Administered orally three times a day, one tablet each time, for 45 days.
62420319|NCT02594137|EXPERIMENTAL|Without Watertight Duraplasty|"After standard craniectomy (12x15cm) and dural opening, the intervention, which is to not perform watertight duraplasty is carried out. The exposed brain parenchyma is covered with Surgicel. Usual closure is then performed."
62227472|NCT05021094|EXPERIMENTAL|Subclinical POI patients who taking Kuntai capsule|Subclinical POI patients in this group which with Kuntai capsule intervention. This group is a self-controlled experiment before and after treatment
62227473|NCT04009915|EXPERIMENTAL|VATS|Patients undergo a standard VATS operation for stage II-III lung cancer
62227474|NCT04009915|ACTIVE_COMPARATOR|open surgery|Patients undergo a standard open operation for stage II-III lung cancer
62420320|NCT02594137|NO_INTERVENTION|With Watertight Duraplasty|After standard craniectomy (12x15cm) and dural opening, watertight duraplasty with pericranium or an artificial graft is performed. Usual closure is then performed. This kind of duraplasty is performed by most neurosurgeons and this group will be used as a control.
62420321|NCT02719015|EXPERIMENTAL|rAd.CD40L + Pembrolizumab|"The dose escalation phase will include rAd.CD40L dose escalation and increase in the number of injected sites/lesions. Once patients tolerate dose level 1 (1 injection site and 1x1011vp-MTD) in Dose Escalation cohort, Expansion cohort will open with same maximum number of injection sites at maximum tolerated dose from Dose Escalation cohort.~All participants receive same dosage of Pembrolizumab in both phases."
62420322|NCT04253379|EXPERIMENTAL|pediatric epilepsy children|
62420323|NCT04253379|ACTIVE_COMPARATOR|healthy children|
62420324|NCT05494580|EXPERIMENTAL|Pamiparib + Surufatinib (Phase Ib/II)|"Phase Ib:~A dose de-escalation schedule is used in the phase Ib dose finding part. Dose Level 1 (starting dose): pamiparib 40 mg administered orally twice daily (fixed dose) and surufatinib 250 mg administered orally once daily on a 21-day treatment cycle. If ≥2/6 patients experience a dose limiting toxicity (DLT), we will de-escalate to Dose Level 2: pamiparib 40 mg administered orally twice daily (fixed dose) and surufatinib 200 mg administered orally once daily on a 21-day treatment cycle. Approximately 3-12 patients will be enrolled in phase Ib study.~Phase II:~The phase II part will begin once the recommended phase 2 dose (RP2D) of surufatinib have been determined in the Phase Ib in order to assess antitumor activity of pamiparib and surufatinib combination. In phase II study, pamiparib 40 mg orally twice daily and surufatinib PR2D will be administered."
62420325|NCT02275039|EXPERIMENTAL|Treatment (MVA-p53 vaccine and gemcitabine hydrochloride)|Patients receive modified vaccinia virus ankara vaccine expressing p53 SC on day 15 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then continue to receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 every 21 days in the absence of disease progression or unacceptable toxicity.
62803214|NCT02635607|OTHER|Flexible protocol|Patients will start Follitropin beta stimulation on menstrual cycle day 3 and the daily dose will be fixed for the first 5 days of stimulation, a modification of the rFSH dose will be allowed from stimulation day 6 onward. Ganirelix will start flexibly by the promissory criterion in the flexible group. rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed, and triptorelin trigger will be used as a replacement in case of OHSS high risk
62028718|NCT06038721|EXPERIMENTAL|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents|The participants in this group will receive the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) in an individual format for up to 24 weeks.
62227475|NCT01911065|EXPERIMENTAL|Zostavax™ vaccine group|Participants \> 50 years will receive a single dose 0.65 ml Zostavax™ (live, attenuated zoster vaccine) administered by subcutaneous injection.
62227476|NCT01911065|NO_INTERVENTION|Natural-acquired VZV immunity|Participants 40-49 years of age will not receive any intervention with the objective of examining the influence of age and inherited factors on the varicella zoster virus (VZV)-specific immune response in those with a naturally-acquired VZV immunity (a prior history of chicken pox).
62227477|NCT00883077||Inflammation|Patients with long standing history or short onset of ulcerative colitis.
62227478|NCT00883077||Healthy controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
62227479|NCT00883077||Irritable bowel syndrome|Patients admitted to outpatient department with symptoms meeting ROME III criteria of irritable bowel syndrome.
62803215|NCT03917797|EXPERIMENTAL|MSC treatment|Intervention: a previously selected dose of MSCs (Phase IIa) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate.
62028719|NCT03829904|EXPERIMENTAL|VGH-BPH1 group|VGH-BPH1 includes Ji Sheng Shen Qi Wan 2.5g, Sangpiaoxiao powder 1.0g, Wuyao 0.3g, Yizhiren 0.3g, Danshen 0.3g, Yinyanghuo 0.3g, Fupenzi 0.1g, Huangbo 0.25g and Zhimu 0.25g, three times per day, each serving a small packet of 5.3 grams of concentrated granules.
62028720|NCT03829904|PLACEBO_COMPARATOR|Control group|Placebo includes corn starch plus caramel coloring, and added 1/100 VGH-BHP1 compound, three times per day, each serving a small packet of 5.3 grams of concentrated granules.
62590515|NCT05891223|EXPERIMENTAL|Session 7: Weaving Wisdom and Compassion into Daily Life|"* Participants are made to choose a day in their life and allow a few minutes to pause in a mindful way.~* A breather for wise and compassionate action, calmness meditation and joy sharing meditation practices are carried out."
62028721|NCT03020420|EXPERIMENTAL|treatment arm|receive cicatricell cream
62028722|NCT03020420|NO_INTERVENTION|control arm|to treatment
62028723|NCT04349787||Colorectal polyp patients|Patients who have a colonoscopy in regular care as part of the Dutch colorectal screening program, in the context of complaints or in the context of the follow-up of previously diagnosed bowel diseases. And who have at least one colorectal polyp found and resected during the examination.
62227480|NCT02835326|EXPERIMENTAL|Exercise and Dietary Weight Loss|For the first 6 months, participants will meet at a community center for 3 group-based sessions and 1 individual session each month. Sessions include a 45 minute exercise component and a 45 minute dietary weight loss component. Exercise will consist of progressive aerobic and strength training. The dietary component will focus on decreasing caloric intake, while being nutritionally safe. All diets will be monitored by a Registered Dietitian. During months 7-12, participants will meet for 1 group session and 1 individual session per month. The final 12-24 months, bimonthly phone calls are provided to the participants to aid in retention efforts.
62227481|NCT02835326|ACTIVE_COMPARATOR|Walk with Ease|The Arthritis Foundation's (AF) WWE is a self-management program for symptoms of arthritis (pain, fatigue, stiffness,etc.) through exercise. It is a 6 week program involving 3 sessions per week each lasting about 60 minutes. The WWE sessions are comprised of walking, stretching and strengthening exercises, and health education lectures. These group classes will be lead by an AF instructor. Each participant will complete 2 consecutive WWE classes for a total of 12 weeks in the program. During the final week of the program, participants will be trained and transitioin to the self-directed version of WWE for maintenance of exercise. To aid in retention efforts, phone contacts are provided to participants on a monthly basis from 4-12 months and bi-monthly from 12 to 24 months
62227482|NCT01313689|EXPERIMENTAL|Ofatumumab|Biological
62227483|NCT01313689|ACTIVE_COMPARATOR|Physicians' Choice|Physicians' choice of treatment
62803216|NCT03917797|PLACEBO_COMPARATOR|Placebo|Intervention: A Placebo (infusion vehicle) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate.
62227484|NCT00330265|EXPERIMENTAL|1|KC-002
62227485|NCT00330265|OTHER|2|Conventional Wound Therapy
62803217|NCT01368250||1|Patients with native aortic stenosis undergoing TAVI
62803218|NCT01368250||2|Patients with native aortic regurgitation undergoing TAVI
62227486|NCT06333262|EXPERIMENTAL|Pirtobrutinib-Obinutuzumab|Eligible participants will receive initial treatment with pirtobrutinib and obinutuzumab for 12 cycles. Participants with progressive chronic lymphocytuc leukemia or small lymphocytic lymphoma during the off-treatment follow-up will receive continuous pirtobrutinib monotherapy.
62590516|NCT05891223|EXPERIMENTAL|Session 8: Living with the Heart|"* The participants are told about the applications that they can apply for, where they need help to develop compassion towards self-healing skills, and the whole training is evaluated.~* The river of life application, which evaluates mindfulness in depth, is carried out.~* An overall summary of the 8-session study is made and feedback is received."
62590517|NCT03724877||Subjects with Chronic obstructive pulmonary disease (COPD)|
62803219|NCT01368250||3|Patients with degenerative surgical bioprosthesis undergoing TAV-in-SAV
62803220|NCT04742907|EXPERIMENTAL|TU-100 15 g/day|Subjects will receive a total daily dose of TU-100 5 g TID until hospital discharge or ≤ 10 days (whichever is earlier).
62803221|NCT04742907|EXPERIMENTAL|TU-100 7.5 g/day|Subjects will receive a total daily dose of TU-100 2.5 g TID until hospital discharge or ≤ 10 days (whichever is earlier).
62803222|NCT04742907|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo TID until hospital discharge or ≤ 10 days (whichever is earlier).
62803223|NCT01034514|EXPERIMENTAL|4DCT arm|Patients breathe in 99mTc-DTPA and then undergo ventilation scans using a SPECT scanner over 2 hours. Patients also receive 99mTc-MAA IV and then undergo perfusion scans using a SPECT scanner over 2 hours. Patients may also undergo a pre- and post-treatment Xe-CT ventilation scan over 15 minutes and a pre-treatment 4D-CT scan over 5-10 minutes.
62028724|NCT04644354||Group A - Advanced Preterm Labor (aPL)|Singleton pregnant women with spontaneous preterm labor at their 23-36 weeks: regular contractions 4 or more in 20 minutes and cervical dilatation at 2 cm and above
62028725|NCT04644354||Group B - Threatened Preterm Labor (tPL)|Singleton pregnant women with spontaneous preterm labor at their 23-36 weeks: regular contractions less then 4 in 20 minutes and cervical dilatation less then 2 cm
62028726|NCT05300308||transperitoneal pelvic lymph node dissection for treatment of urogenital cancer|patients planned for transperitoneal pelvic lymph node dissection for treatment of urogenital cancer (including prostate or bladder cancer)
62028727|NCT01517698|EXPERIMENTAL|RO4917523 0.5 mg|
62028728|NCT01517698|EXPERIMENTAL|RO4917523 1.5 mg|
62028729|NCT01517698|PLACEBO_COMPARATOR|Placebo|
62028730|NCT04216108|EXPERIMENTAL|23G gauge needle vitrectomy surgery|
62028731|NCT04216108|EXPERIMENTAL|27G gauge needle vitrectomy surgery|
62028732|NCT02706158|EXPERIMENTAL|supplement and balanced diet|"Woman at high risk of pre-eclampsia:~supplements. 1500 mg Calcium and 1200 IU Vitamin D for 2 months. balanced diet."
62227487|NCT06086925|EXPERIMENTAL|BRB treatment|Day 1 of BRB will be determined based upon the anticipated surgery day. Subjects will be instructed to consume a total dose of 5 Gm/day (orally) by taking one BRB five times a day: one upon waking in the morning, one in the morning, one at noon, one in the evening, and one at bedtime. BRB should not be given during meals and drinking. The subject should avoid eating for about 30 minutes before and after taking a BRB.
62590518|NCT06069999|EXPERIMENTAL|TR Bedside Telerehabilitation|"Participants will be assigned 45-minutes of therapy training exercises each day for 7 days a week up to 4 weeks or until discharge.~Participants will use the HandyMotion device to interact with the telerehabilitation program displayed on the TV set in the patient room."
62803224|NCT05944406||Audit Cycle 1|These are the patients included in the first cycle of the clinical audit. The study collected data from a sample of 256 patients who visited the Medical Unit I of Benazir Bhutto Hospital, Rawalpindi, during the specified period. The patients were triaged by the triage nurses using the Manchester Triage System (MTS). Their age, gender, registration time, time of consultation, triage category assigned by the triage nurse, and admission decision were recorded for analysis. The accuracy of triage and waiting times were assessed for these patients.
62227488|NCT03975738||A GP Surgery|A selection of healthcare workers from a GP Surgery to be recruited
62227489|NCT03975738||A Patient and Public Involvement and Engagement Group|A selection of healthcare workers from a Patient and Public Involvement and Engagement Group to be recruited
62803225|NCT05944406||Audit Cycle 2|These are the patients included in the second cycle of the clinical audit, conducted after an educational intervention for the triage nurses. The study collected data from a sample of 238 patients who visited the same Medical Unit I of Benazir Bhutto Hospital, Rawalpindi. Similar to audit cycle 1, these patients were triaged using the MTS, and their demographic information, triage category, and admission decision were recorded. The study aimed to evaluate any improvements in triage accuracy and waiting times compared to audit cycle 1 after the intervention and training of the triage nurses.
62803226|NCT03226002|ACTIVE_COMPARATOR|Airtraq NT right nostril|nasotracheal intubation with Airtraq NT through the right nostril
62803227|NCT03226002|ACTIVE_COMPARATOR|Airtraq NT left nostril|nasotracheal intubation with Airtraq NT through the left nostril
62227490|NCT03975738||Young Person's Steering Group|A selection of patients from a Young Person's Steering Group to be recruited
62227491|NCT03975738||An Acute Trust|A selection of healthcare workers from an Acute Trust to be recruited
62803228|NCT02919761|EXPERIMENTAL|Part 1: All Enrolled Participants|All participants receive Acthar Gel 1 mL twice weekly for 12 weeks
62227492|NCT03975738||Hayward Hospital Social Care Team|A selection of healthcare workers from the Hayward Hospital Social Care Team to be recruited
62227493|NCT03975738||A Hospice|A selection of healthcare workers from a Hospice to be recruited
62227494|NCT03975738||West Midlands Cares|A selection of healthcare workers from a the West Midlands Cares Group to be recruited
62227495|NCT03975738||CRN Clinical Research Speciality Leads (CRSL)|A selection of healthcare workers from a group of CRN (Clinical Research Network) Clinical Research Speciality Leads (CRSL) to be recruited
62227496|NCT03975738||CRN Sub Speciality Leads (SSL)|A selection of healthcare workers from a CRN Sub Speciality Leads (SSL) to be recruited
62227497|NCT03975738||A District General Hospital|A selection of healthcare workers from a A District General Hospital to be recruited
62227498|NCT05536011||Pitolisant-exposed participants with narcolepsy|Pregnant women with a diagnosis of narcolepsy who are exposed to pitolisant at any time during pregnancy
62227499|NCT05536011||Unexposed participants with narcolepsy|Pregnant women with a diagnosis of narcolepsy who are not exposed to pitolisant or a comparator product at any time during pregnancy
62803229|NCT02919761|EXPERIMENTAL|Part 2: Acthar Gel|Participants receive Acthar Gel 1 mL twice weekly for an additional 12 weeks
62803230|NCT02919761|PLACEBO_COMPARATOR|Part 2: Placebo|Participants receive Placebo 1 mL twice weekly for an additional 12 weeks
62803231|NCT03863288|PLACEBO_COMPARATOR|Intranasal Spray Placebo|Nasal spray of placebo liquid solution as a single dose. fMRI scan pre and post-administration.
62803232|NCT03863288|ACTIVE_COMPARATOR|Oxytocin Intranasal Spray 8 International Unit (IU)|Nasal spray of Oxytocin 8 International Unit (8IU) liquid solution as a single dose. fMRI scan pre and post administration.
62803233|NCT03863288|ACTIVE_COMPARATOR|Oxytocin Intranasal Spray 24 International Unit (IU)|Nasal spray of Oxytocin 24 International Unit (24IU) liquid solution as a single dose. fMRI scan pre and post administration.
62803234|NCT03863288|ACTIVE_COMPARATOR|Oxytocin Intranasal Spray 48 International Unit (IU)|Nasal spray of Oxytocin 48 International Unit (48IU) liquid solution as a single dose. fMRI scan pre and post administration.
62803235|NCT03863288|ACTIVE_COMPARATOR|Oxytocin Intranasal Spray 80 International Unit (IU)|Nasal spray of Oxytocin 80 International Unit (80IU) liquid solution as a single dose. fMRI scan pre and post-administration.
62803236|NCT04393493|EXPERIMENTAL|GROUP A|"Furosemide 80 mg every 24 hrs (morning) intravenously every 24 hrs for 4 consecutive days, additionally:~* Day 1 furosemide 100mg / day infused with 100cc of Hartmann solution~* Day 2 Furosemide 200mg / day infused with 100cc of Hartmann solution~* Day 3 Furosemide 300mg / day infused with 100cc of Hartmann solution~* Day 4 Furosemide 400mg / day infused with 100cc of Hartmann solution"
62420326|NCT06536582||Normal weight patients|23 subjects with body mass index (BMI) between 18.5 and 25 therefore considered normal weight, who undergo treatment with PRGF.
62420327|NCT06536582||Over weight patients|23 subjects with BMI values that exceed the considered range normal weight, therefore with BMI\>25, who undergo the PRGF treatment
62227500|NCT05536011||Comparator-exposed participants with narcolepsy|Pregnant women with a diagnosis of narcolepsy who are not exposed to pitolisant at any time during pregnancy but who are exposed to comparator products at any time during pregnancy
62227501|NCT05536011||Pitolisant-exposed participants without narcolepsy|Pregnant women without a diagnosis of narcolepsy who are exposed to pitolisant at any time during pregnancy
62590519|NCT04764370|EXPERIMENTAL|WeFlow-Arch Moduler Embedded Branch Stent Graft System|
62590520|NCT05161975|PLACEBO_COMPARATOR|Placebo|Food supplement tablets do not contain vitamin K2
62590521|NCT05161975|EXPERIMENTAL|Vitamin K2|Food supplement tablets contain vitamin K2
62227502|NCT05536011||Comparator-exposed participants without narcolepsy|Pregnant women without a diagnosis of narcolepsy who are not exposed to pitolisant at any time during pregnancy but who are exposed to a comparator product at any time during pregnancy
62227503|NCT02661087|EXPERIMENTAL|Bipolar energy|Hysteroscopic resection of symptomatic sub mucosal myomas with the use of bipolar energy
62227504|NCT02661087|ACTIVE_COMPARATOR|Monopolar energy|Hysteroscopic resection of symptomatic sub mucosal myomas with the use of monopolar energy
62420328|NCT05302414|EXPERIMENTAL|Board game-based learning (experience group-I)|The team of PGY doctors and nurses receive training in resuscitation teamwork skills through a board game-based teaching approach.
62590522|NCT05679531|NO_INTERVENTION|Control group|Children in the control group, who met the research criteria, were not applied any procedure other than clinical routine protocol and nursing care. After being brought to the pediatric surgery service, patients with nausea and vomiting were filled out with a questionnaire. The severity of nausea was evaluated with the BARF Scale during nausea and vomiting and 30, 60 and 120 minutes after nausea and vomiting in patients with nausea and vomiting.
62227505|NCT02675868|EXPERIMENTAL|Norepinephrine|The noradrenaline group: a group of 10 subjects that will receive noradrenaline 0.05 μg/kg/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
62420329|NCT05302414|EXPERIMENTAL|Simulation-based learning (experience group-II)|The team of PGY doctors and nurses receive training in resuscitation teamwork skills through a simulation-based teaching approach.
62420330|NCT05302414|OTHER|Lecture-based learning (control group)|The team of PGY doctors and nurses receive training in resuscitation teamwork skills through an interactive lecture-based learning approach.
62420331|NCT04895696|EXPERIMENTAL|Afimetoran: Dose 1|
62420332|NCT04895696|EXPERIMENTAL|Afimetoran: Dose 2|
62420333|NCT04895696|EXPERIMENTAL|Afimetoran: Dose 3|
62735296|NCT01802580|EXPERIMENTAL|Standard of care, no internet survey|Standard treatment for psoriasis. If it is felt that their psoriasis could be suitably treated with fluocinonide, then they will be asked to participate in the study. At the initial study visit, fluocinonide will be dispensed to the subjects in a small jar with a MEMS® electronic monitoring cap attached. Subjects will be asked to apply the medication twice daily. All subjects will be assigned to treatment with topical fluocinonide to the entire affected area, excluding face and genitals. Subjects will be instructed to apply the smallest amount of study medication sufficient to cover the affected areas. At the end of the treatment phase, subjects will have a feedback session with specific results of adherence behavior revealed.
62803237|NCT04393493|EXPERIMENTAL|GROUP B|"Furosemide 80 mg every 24 hrs (morning) intravenously every 24 hrs for 4 consecutive days, additionally:~* Day 1 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.~* Day 2 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.~* Day 3 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.~* Day 3 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs."
62803238|NCT05011812|EXPERIMENTAL|Part 1, Treatment A|Dose level 1 of PBI-0451
62227506|NCT02675868|ACTIVE_COMPARATOR|Vasopressins|The vasopressin group: a group of 10 subjects that will receive vasopressin 0.04 IU/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
62227507|NCT02675868|ACTIVE_COMPARATOR|Phenylephrine|The phenylephrine group: a group of 10 subjects that will receive phenylephrine 0.5 μg/kg/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
62420334|NCT04895696|PLACEBO_COMPARATOR|Placebo|
62420335|NCT05810974|ACTIVE_COMPARATOR|Concentrated beetroot juice|
62420336|NCT05810974|ACTIVE_COMPARATOR|Nitrate depleted beetroot juice + potassium nitrate (KNO3)|
62420337|NCT05810974|PLACEBO_COMPARATOR|Nitrate-depleted beetroot juice|
62420338|NCT05207176|EXPERIMENTAL|DWP16001|Total number of subjects: 24 (8 Korean, 8 Caucasian, and 8 Hispanic)
62420339|NCT06701474||high PhA|"* Patients diagnosed with knee osteoarthritis and scheduled for total knee arthroplasty.~* Among these, patients are classified into the high PhA group if their preoperative PhA is above 4.95 for males or 4.35 for females"
62227508|NCT02675868|PLACEBO_COMPARATOR|Placebo|The placebo group: a group of 10 subjects that will receive NaCl 0.9% infusion for 5 hours, starting 60 minutes before endotoxin administration.
62420340|NCT06701474||low PhA|"* Patients diagnosed with knee osteoarthritis and scheduled for total knee arthroplasty.~* Among these, patients are classified into the low PhA group if their preoperative PhA is below 4.95 for males or 4.35 for females"
62420341|NCT01336218|EXPERIMENTAL|1|Fostamatinib
62420342|NCT01336218|EXPERIMENTAL|2|Rifampicin
62420343|NCT06399263|EXPERIMENTAL|Psilocybin Therapy|The psilocybin therapy will include three preparatory sessions, psilocybin dosing session one (20mg), two integration sessions, psilocybin dosing session two (30mg), and four final integration sessions
62420344|NCT06393816|EXPERIMENTAL|Experimental : Durvalumab with etoposide and Carboplatin/Cisplatin|Combination of durvalumab with etoposide and platinum (either cisplatin or carboplatin) for the first-line treatment of patients with advanced LCNEC
62420345|NCT01528046|EXPERIMENTAL|Metformin in Combination with VIT|Participants will receive metformin in combination with vincristine, irinotecan and temozolomide (VIT).
62420346|NCT02484404|EXPERIMENTAL|P1 Durvalumab+C|Ph I Durvalumab + cediranib dose escalation
62420347|NCT02484404|EXPERIMENTAL|P1 Durvalumab+O|Ph I Durvalumab + olaparib dose escalation
62420348|NCT02484404|EXPERIMENTAL|P1 Durvalumab+O+C|Ph I Durvalumab + olaparib + cediranib dose escalation
62420349|NCT02484404|EXPERIMENTAL|P2 Durvalumab+C|Ph II Durvalumab + cediranib at RP2D
62590523|NCT05679531|EXPERIMENTAL|Chewing gum group|Starting from the second hour after the child was brought to the clinic after appendectomy, menthol sugar free gum was given to children with nausea and vomiting outside the clinical routine nursing care, as soon as they could chew gum and follow the instructions, and were asked to chew for an average of 15 minutes. The product of a single brand of gum was used. In the first stage, the patient's nausea was evaluated with the BARF nausea scale before the intervention. After filling out the patient information form, the patients who met the research criteria were chewed gum for an average of 15 minutes. During the intervention (between 5-10 minutes), the patient was re-evaluated for nausea with the BARF nausea scale at 30.,60. and 120 minutes after the intervention. Episodes of vomiting were recorded in patients with vomiting.After the quantitative stages of the study were completed, the patient's level of relief was evaluated using a verbal descriptive scale.
62590524|NCT00819559|ACTIVE_COMPARATOR|Open PCRT group|Patients who underwent preoperative chemoradiotherapy and open resection
62803239|NCT05011812|EXPERIMENTAL|Part 1, Treatment B|Dose level 2 of PBI-0451
62028733|NCT02706158|NO_INTERVENTION|women without nutrition or supplement intervention|usual follow-up in the gynecology out patient clinic, without nutrition or supplement intervention.
62227509|NCT02054988|EXPERIMENTAL|caffeine|"three cups of coffee will be administered for 10 days (on chronic phase) and two cups of coffee will be consecutively administered for acute evaluation."
62420350|NCT02484404|EXPERIMENTAL|P2 Durvalumab+O|Ph II Durvalumab + olaparib at RP2D
62420351|NCT02484404|EXPERIMENTAL|P2 Durvalumab+O+C|Ph II Durvalumab + olaparib + cediranib at RP2D
62590525|NCT00819559|EXPERIMENTAL|Open no PCRT group|Patients who did not undergo preoperative chemoradiotherapy and open resection
62590526|NCT00819559|ACTIVE_COMPARATOR|LAP PCRT group|Patients who underwent preoperative chemoradiotherapy and laparoscopic resection
62590527|NCT00819559|EXPERIMENTAL|LAP no PCRT group|Patients who did not undergo preoperative chemoradiotherapy and laparoscopic resection
62590528|NCT01712867|EXPERIMENTAL|Phytosterol esters of omega-3|4 capsules/day for 12 weeks
62803240|NCT05011812|EXPERIMENTAL|Part 1, Treatment C|Dose level 3 of PBI-0451
62227510|NCT02054988|ACTIVE_COMPARATOR|not caffeine|not caffeine will be administered for the duration of the study
62590529|NCT01712867|ACTIVE_COMPARATOR|Omega-3 acid ethyl esters|4 capsules/day for 12 weeks
62803241|NCT05011812|EXPERIMENTAL|Part 1, Treatment D|Dose level 4 of PBI-0451
62803242|NCT05011812|EXPERIMENTAL|Part 2, Treatment E|PBI-0451 =/\< Dose level 1
62803243|NCT05011812|EXPERIMENTAL|Part 2, Treatment F|PBI-0451 =/\< Dose level 2
62803244|NCT05011812|EXPERIMENTAL|Part 2, Treatment G|PBI-0451 =/\< Dose level 3
62803245|NCT05011812|EXPERIMENTAL|Part 2, Treatment H|PBI-0451 =/\< Dose level 4
62803246|NCT05011812|EXPERIMENTAL|Part 3, Treatment J|PBI-0451 + ritonavir (a CYP450 3A inhibitor)
62227511|NCT05251467||People with CF age 12 years and over|Participants will be identified through one of the 6 participating UK CF centres as well as recruiting via social media. Participants outside the 6 listed CF centres as well as outside the UK are also eligible.
62420352|NCT05864235|ACTIVE_COMPARATOR|Control|Each week for 6-weeks, control group participants will receive the following weekly text message assessments (without receiving any feedback or support): (1) Thursdays (3pm): weekend plans to drink and desire to get drunk; (2) Sundays (12pm): most drinks consumed on any weekend day and peer pressure to drink.
62590530|NCT06666647||Patients in need of treatment by emergency medical services|All patients in Denmark to whom an ambulance or helicopter has been disapatched
62803247|NCT05011812|EXPERIMENTAL|Part 3, Treatment K|PBI-0451 + ritonavir
62028734|NCT05741736|OTHER|Group|A structured 5-day lifestyle modification program led by endocrinologists-diabetologists together with a nutritionist, a psychologist, and a kinesiologist is aiming to educate on lifestyle modification necessary to lose weight.
62227512|NCT00323856|EXPERIMENTAL|Coagulation factor VIII (Human)|Anti-Hemophilic coagulation factor VIII (Human) Alphanate SD/HT
62227513|NCT01937156|EXPERIMENTAL|SP-01|
62227514|NCT01937156|ACTIVE_COMPARATOR|Granisetron Hydrochloride Tablet|
62227515|NCT03326453|EXPERIMENTAL|Mini Dental implant|2 mini dental implant of diameter 2.8 mm with length 10 mm will be inserted mandiblular ridge ≥5 mm mesial to the mental foraminato support overdentures for the intervention group.
62590531|NCT01080469|ACTIVE_COMPARATOR|Prograf® Capsule 1 mg|
62590532|NCT01080469|EXPERIMENTAL|Tacrolimus Capsule 1 mg|
62590533|NCT03377504|EXPERIMENTAL|mirror group|Routine physical therapy and exercise program will be applied to all patients for a total of 4 weeks, 5 days a week, 1 hour/day. Mirror therapy will be applied to the mirror group for 30 minutes per day in addition to this routine treatment.
62590534|NCT03377504|ACTIVE_COMPARATOR|control group|Routine physical therapy and exercise program will be applied to all patients for a total of 4 weeks, 5 days a week, 1 hour/day. A total of 20 sessions of treatment will be given to each patient.
62590535|NCT04450524|EXPERIMENTAL|Hypnosis|Hypnosis formed from hypnotic induction (an adapted version from Harvard Group Scale of Hypnotic Susceptibility) together with hypnotic suggestions about a future where they will control their eating behaviors by choosing the low-calorie food instead of dense calorie one.
62590536|NCT04450524|EXPERIMENTAL|Food Inhibition Training|Participants will perform an online computer go-no-go task. They will be shown pictures of dense and low-calorie food together with neutral pictures, followed by the instruction to press or not a button when the pictures are framed in a bold frame (dense calorie food).
62803248|NCT05011812|EXPERIMENTAL|Part 3, Treatment L|"PBI-0451 dose TBD~+ midazolam (a sensitive CYP450 3A substrate)"
62803249|NCT05011812|EXPERIMENTAL|Part 1, Treatment M|Dose level 2 of PBI-0451 with food
62803250|NCT05011812|EXPERIMENTAL|Part 2, Treatment I|PBI-0451 =/\< Dose level 5
62803251|NCT05011812|EXPERIMENTAL|Part 1, Treatment N|Dose Level 5 of PBI-0451
62803252|NCT03627871|EXPERIMENTAL|Trending majority norm|Participants receive information about exercise-related norms that apply to the majority of the population and are told this norm has been increasing recently.
62803253|NCT03627871|EXPERIMENTAL|Non-trending majority norm|Participants receive information about exercise-related norms that apply to the majority of the population but are not told about recent trends.
62803254|NCT03627871|EXPERIMENTAL|Trending minority norm|Participants receive information about exercise-related norms that apply to a minority of the population and are told this norm has been increasing recently
62803255|NCT03627871|EXPERIMENTAL|Non-trending minority norm|Participants receive information about exercise-related norms that apply to a minority of the population but are not told about recent trends.
62028735|NCT02575092|ACTIVE_COMPARATOR|Group A, without hypertension|The patients who will not be taken the drugs of antihypertension and antihomocysteine.
62028736|NCT02575092|EXPERIMENTAL|Group B, hypertension|The hypertensive patients with their plasma Hcy levels \<10 umol/L will be taken the drugs of antihypertension(Enalapril Maleate Tablets,as the program-based antihypertension)
62028737|NCT02575092|EXPERIMENTAL|Group C,hypertension and hyperhomocysteinemia|The hypertensive patients with their plasma Hcy levels ≥10 umol/L will be taken the drugs of antihypertension and antihomocysteine( Enalapril Maleate and Folic Acid Tablets,as the program-based antihypertension)
62028738|NCT02446561|ACTIVE_COMPARATOR|MRXXX|Active comparator
62028739|NCT02446561|EXPERIMENTAL|MR1XXX|MR1XXX
62028740|NCT02446561|EXPERIMENTAL|MR2XXX|MR2XXX
62420353|NCT05864235|EXPERIMENTAL|Goal Support (GS)|Each week for 6-weeks, GS group participants will compete identical weekly text message assessments to the control group and receive further prompts and tailored feedback and support focused on weekly drinking limit goal commitment \& confidence assessments and subsequently receive tailored feedback on goal success to either bolster future goal striving or reframe goal failure.
62420354|NCT05864235|EXPERIMENTAL|GS + Coaching for Context-specific Peer Support (CCPS)|Each week for 6-weeks, CCPS group participants will compete identical weekly text message assessments and feedback to GS plus additionally will receive weekly motivation and strategies to enlist peer support during drinking episodes.
62420355|NCT06515496|EXPERIMENTAL|Intervention|Participants in this arm will take the Scale HLV Clinical Formula Hair Vitamins.
62420356|NCT06515496|PLACEBO_COMPARATOR|Placebo|Participants in this arm will take a placebo product consisting of rice flour in vegetable cellulose capsules.
62028741|NCT02446561|EXPERIMENTAL|MR3XXX|MR3XXX
62028742|NCT05893654|EXPERIMENTAL|Single Arm|Participants will undergo intra-arterial catheterization of the ophthalmic artery, with administration of 7.5mg of melphalan. After 4±1 weeks, they will receive Ru-106 plaque brachytherapy, which will be performed using a 24-mm notched plaque. Due to tumor thickness and the previous IAC, the target dose to the tumor apex shall be as close as possible to 80 Gy, respecting the safety limits regarding the risk of excessive dosage to the tumor base and scleral melting.
62028743|NCT05934734||Cohort 1 (Mild)|Participants with mild self-reported thoracic outlet syndrome symptoms (visual analog scale score 1-3).
62028744|NCT05934734||Cohort 2 (Moderate)|Participants with moderate self-reported thoracic outlet syndrome symptoms (visual analog scale score 4-6). No intervention will be provided.
62028745|NCT05934734||Cohort 3 (Severe)|participants with severe self-reported thoracic outlet syndrome symptoms (visual analog scale score 7-9). No intervention will be provided
62028746|NCT05934734||Cohort 4 (Very Severe)|Participants with very severe self-reported thoracic outlet syndrome symptoms (visual analog scale score 10). No intervention will be provided.
62028747|NCT03516318|EXPERIMENTAL|SMART Connections|"The intervention components include:~* Informational messages that reflect the content of the structured group counseling curriculum and are posted to the Facebook group wall on a regular basis for approximately 4 to 5 months~* Moderated, closed group chats in a secret Facebook group where YLHIV can interact with their peers and with a trained support group facilitator~* Access to a trained facilitator via Facebook Messenger for the duration of the intervention who will be able to provide information or basic counseling on ART/HIV care related issues, with referral to health care services as needed"
62028748|NCT03516318|NO_INTERVENTION|Control|All study participants, in both study arms, will receive standard services currently available to YLHIV in these facilities and communities. The services currently include: routine clinical care for HIV treatment including laboratory testing (CD4, viral load tests); active case management by community volunteers with intensive adherence support during the first 4 weeks of ART; adherence support through phone calls and SMS (short messaging service) reminders; and enhanced adherence counseling for patients with unsuppressed viral loads.
62028749|NCT06436053||LBBAP with SyncAV|
62028750|NCT05497284|EXPERIMENTAL|LTP001|Participants will receive LTP001 orally once daily in the morning for approximately 26 weeks
62420357|NCT01432782|PLACEBO_COMPARATOR|Placebo|Placebo arm: per-endoscopic injection of saline
62735297|NCT01732510|EXPERIMENTAL|Part 1: MK-8226 0.3 mg/kg|MK-8226 administered intravenously (IV) at a weight-based dose every 2 weeks for a period of 12 weeks.
62420358|NCT01432782|ACTIVE_COMPARATOR|Botulinum toxin|Botulinum toxin (Botox) 100 u in 4 ml, injected per-endoscopically
62803256|NCT03627871|EXPERIMENTAL|Control|Participants receive information about exercise unrelated to social norms or recent trends.
62803257|NCT00449124|EXPERIMENTAL|Part I-group 1|Part I/Group 1: Cycle 1-TG4040 10\^6 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14; Cycle 3-Placebo days 0, 7 and 14.
62803258|NCT00449124|EXPERIMENTAL|Part IIa-group 1|Part IIa/Group 1: Cycle 1-TG4040 10\^8 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14.
62803259|NCT00449124|EXPERIMENTAL|Part IIa-group 2|Part IIa/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10\^8 PFU days 0, 7 and 14.
62803260|NCT00449124|EXPERIMENTAL|Part I-group 3|Part I/Group 3: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14; Cycle 3-TG4040 10\^8 PFU days 0, 7 and 14.
62803261|NCT00449124|EXPERIMENTAL|Part I-group 2|Part I/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10\^7 PFU days 0, 7 and 14; Cycle 3-Placebo days 0, 7 and 14.
62803262|NCT00449124|EXPERIMENTAL|Part IIb-group 1|Part IIb/Group 1: Cycle 1-TG4040 10\^8 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14.
62803263|NCT00449124|EXPERIMENTAL|Part IIb-group 2|Part IIa/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10\^8 PFU days 0, 7 and 14.
62028751|NCT05497284|EXPERIMENTAL|Placebo|Participants will receive LTP001 placebo capsules matching LTP001 orally once daily in the morning for approximately 26 weeks
62227516|NCT03326453|NO_INTERVENTION|conventional implant|two slandered implant diameter 3.7 mm and length 10 mm will be placed in interforaminal region of mandiblular ridge support overdenture for the compartor group.
62227517|NCT04832282|OTHER|Roux-en-Y gastric bypass patients with weight regain|The study population is Roux-en-Y gastric bypass (RYGB) patients with weight regain undergoing an endoscopy at Bellevue Hospital Center or Brigham and Women's Hospital.
62420359|NCT03291847|EXPERIMENTAL|Buprenorphine-naloxone treated|Participants receiving buprenorphine-naloxone treatment for opioid use disorder during pregnancy
62420360|NCT05884333|EXPERIMENTAL|Cord Blood Transplant|Adult patients with high-risk hematologic malignancies and a suitable double-unit CB graft will undergo work-up to assess protocol eligibility. CB graft selection will be based on established MSKCC guidelines. Patients will receive standard conditioning with Cy 50 mg/kg, Flu 150 mg/m2, Thio 10 mg/kg, and TBI 400 cGy according to the eligibility criteria. GVHD prophylaxis will consist of CSA and MMF starting day -3. The double-unit CB graft will be infused on day 0 per standard practice. Optimized CBT practices, will be implemented in this protocol.
62420361|NCT04201834|EXPERIMENTAL|Risperidone|Participants will initiate risperidone 0.5 mg nightly the day after the baseline visit. Dose assessment will occur at pre-specified intervals during the titration phase (week 2, 3, 4, 6, 7). The investigator will increase the dose by 0.5 mg at the week 2, week 3, week 4, and week 6 visits until either optimal chorea benefit has been obtained, an intolerable adverse event occurs, or the maximum allowable dose (3.0 mg) is reached.
62420362|NCT00357565|EXPERIMENTAL|Double Unit UCB Transplantation|Patients that receive 2 units of umbilical cord blood transplantation (UCBT).
62420363|NCT00357565|EXPERIMENTAL|Single Unit UCB Transplantation|Patients that receive one unit of umbilical cord blood transplantation (only if 2 adequate size and matched units are not available).
62420364|NCT05951959|EXPERIMENTAL|Acalabrutinib + Venetoclax + Rituximab|Acalabrutinib + Venetoclax + Rituximab (AVR)
62420365|NCT06352840|OTHER|Monitoring progress plus usual care|Participants will have access to the monitoring progress web-based symptom monitoring program.
62803264|NCT01839435|EXPERIMENTAL|outpatient patients|Outpatient surgery will be proposed to all patients
62803265|NCT02398305|ACTIVE_COMPARATOR|TR Band accelerated|Diminishing air pressure in the TR Band using accelerated protocol
62420366|NCT06352840|EXPERIMENTAL|My Pelvic Plan plus usual care|Participants will have access to My Pelvic Plan program.
62803266|NCT02398305|OTHER|TR band standard|Diminishing air pressure in the TR band according to standard care
62227518|NCT04480125|EXPERIMENTAL|Aza+Chida|Azacitidine ivgtt D1-7 Chindamide 30mg,PO,twice a week Every 21 days for total 6 courses
62420367|NCT02557568|EXPERIMENTAL|Hemodialysis patients (HPs)|staphylococcus aureus carriage is measured in nose
62420368|NCT02557568|EXPERIMENTAL|Healthcare Workers (HCWs)|staphylococcus aureus carriage is measured in nose
62420369|NCT00279149|EXPERIMENTAL|surgery|surgery
62803267|NCT05787665||With Lung Ultrasonography|Patient who meet inclusions criteria, and which lung ultrasonography were performed during their medical care in Emergency Department
62803268|NCT05787665||Without Lung Ultrasonography|Patient who meet inclusions criteria, and which lung ultrasonography were not performed during their medical care in Emergency Department.
62803269|NCT03395899|ACTIVE_COMPARATOR|Atezolizumab alone|1200mg of Atezolizumab D1 C1
62803270|NCT03395899|EXPERIMENTAL|Atezolizumab + Cobimetinib|Atezolizumab (1200mg IV D1 C1) + Cobimetinib (60mg PO D1 - 21 of C1)
62803271|NCT03395899|EXPERIMENTAL|Atezolizumab + Ipatasertib|Atezolizumab (1200mg IV D1 C1)+ Ipatasertib (400mg OD D1 - 21 of C1)
62803272|NCT03395899|EXPERIMENTAL|Atezolizumab + Ipatasertib + Bevacizumab|Atezolizumab (1200mg IV D1 C1)+ Cobimetinib (60mg PO D1 - 21 of C1) + Bevacizumab (10mg/kg IV D1 C1)
62803273|NCT05448339||PVHA|Patients undergo tumor feeding vessels deprivation
62803274|NCT05448339||TACE|Patients undergo TACE therapy
62803275|NCT01433016|EXPERIMENTAL|Octanaote Breath Test|A Octanoate breath test will be performed on this single arm population
62803276|NCT01696370|ACTIVE_COMPARATOR|Trimetazidine|
62803277|NCT01696370|PLACEBO_COMPARATOR|Placebo capsule|
62803278|NCT02210000|PLACEBO_COMPARATOR|Placebo|Subjects will receive camicinal matching placebo orally once daily (QD) from Day 1 to Day 84
62227519|NCT03466996|EXPERIMENTAL|Intervention group|The intervention group will participate in face-to-face video telemedicine visits, in addition to routine annual visits to the Spina Bifida Clinic. These 30-minute visits will occur at 2 weeks, 3 months, 6 months and 9 months from last in-person clinic appointment. The visits will consist of structured counseling using a plan-do-study-act cycle approach to incrementally adopt elements of a well-planned transition. Using qualitative notes from each session, we will identify common themes or challenges across patients and develop adjunctive education, support, and monitoring tools for patients and families in transition.
62420370|NCT06703099|EXPERIMENTAL|Magnesium Supplementation|Life Extension® Extend Release Magnesium 250 mg/day of oral magnesium in capsule form to be taken once a day at breakfast/morning.
62227520|NCT03466996|ACTIVE_COMPARATOR|Standard of care group|The control group will receive the current standard of care transition program. In addition to this, they will receive encouraging text messages and e-mails relating to their transition goals. These messages will be sent 2 weeks, 3 months, 6 months and 9 months from the last in-person clinic appointment.
62420371|NCT06438354|EXPERIMENTAL|Group A|Test arm, patients undergo subgingival instrumentation of residual active site together with an adjunctive treatment protocol.
62420372|NCT06438354|PLACEBO_COMPARATOR|Group B|Control arm, patients undergo subgingival instrumentation of residual active site only.
62420373|NCT00590785|EXPERIMENTAL|1|
62420374|NCT00590785|EXPERIMENTAL|2|
62420375|NCT00981409|EXPERIMENTAL|Fondaparinux|
62420376|NCT00981409|OTHER|unfractionated heparin|
62420377|NCT04933903|EXPERIMENTAL|Protocol Therapy|Ipilimumab: 1mg/kg IV day 1. Nivolumab: 3mg/kg IV days 1, 15, 29. SBRT delivered as 1-2 fractions to the gross primary tumor and nodal disease following day 1 infusion and completed by day 3 (7Gy x 1; 4Gy x 2).
62420378|NCT00759174||Case Group|
62028752|NCT06669065|EXPERIMENTAL|patients rehabilitated with dental implants in upper edentulous jaws|patients rehabilitated with dental implants in upper edentulous jaws, then different data acquisition techniques will be applied to the patients using conventional impressions versus intra-oral scanning methods
62803279|NCT02210000|EXPERIMENTAL|Camicinal 25mg|Subjects will receive camicinal 25 mg orally QD from Day 1 to Day 84
62028753|NCT01972516|EXPERIMENTAL|Tivozanib|Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.
62420379|NCT05875064|ACTIVE_COMPARATOR|conventional restoration group (control)|The teeth allocated in the conventional restoration group (control) will receive restorations in resin composed by incremental technique, using opaque resin. For this, 37% phosphoric acid (Condac37, FGM) will be applied for 15 seconds, and then, after washing and relative drying of the surface, application of universal adhesive (Universal Beautibond Adhesive, Shofu) with the aid of microbrush on the entire dental surface, photoactivation of the adhesive and restoration by incremental technique and photoactivation of each layer of resin for 20 seconds. The tooth will receive finishing and polishing through rotating instruments and abrasive discs (Supersnap, Shofu).
62420380|NCT05875064|EXPERIMENTAL|polyvinyl crown - experimental group|The teeth allocated in the experimental group will have the restorations carried out through monochromatic composite resin with chameleon effect in single insertion through polyvinyl crown. For this, 37% phosphoric acid (Condac37, FGM) will be applied for 15 seconds, and then, after washing and relative drying of the surface, application of universal adhesive (Universal Beautibond Adhesive, Shofu) with the aid of microbrush on the entire tooth surface, photoactivation of the adhesive and adaptation of the crown matrix in acetate filled with resin in the tooth. Photoactivation will be done for 20 seconds per dental face, and the acetate matrix is then removed. The tooth will receive finishing and polishing through rotating instruments and abrasive discs (Supersnap, Shofu).
62420381|NCT00593099|EXPERIMENTAL|1|Buproprion
62420382|NCT00593099|PLACEBO_COMPARATOR|2|Placebo
62420383|NCT03785600|EXPERIMENTAL|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 90 minutes of waking up.
62420384|NCT03785600|SHAM_COMPARATOR|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 90 minutes of waking up.
62420385|NCT06173128||Antibody deficient participants|Provider referred patients that have antibody deficiency.
62420386|NCT06173128||Controls|Patients without antibody deficiency from the allergy and immunology clinic at Boston Medical Center and from healthy volunteers at the BU School of Medicine.
62420387|NCT03405389||Patients|Patients diagnosis of a mandibular fracture requiring Open Reduction and Internal Fixation (ORIF) and use of Mandibulo-Maxillary fixation (MMF) during or subsequent to surgical intervention for a minimum of two weeks
62420388|NCT01468974|OTHER|ESPRIT BVS|Subjects receiving the ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries.
62028754|NCT01972516|NO_INTERVENTION|Standard Care|Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.
62028755|NCT04458584||Ligament Reconstruction - Tendon Interposition (LRTI)|Patients undergoing thumb basal joint arthroplasty using LRTI procedure as treatment of osteoarthritis.
62420389|NCT03128047|EXPERIMENTAL|Recurrent high grade gliomas and ependymomas|"Recurrent high-grade glioma and ependamoma patients will receive treatment with the Optune NovoTTF-200A system as monotherapy.~Interventions: Device: Optune NovoTTF-200A System Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles combined with Temozolomide and Bevacizumab."
62420390|NCT02793375|PLACEBO_COMPARATOR|Control|Patients receiving placebo preoperatively (blinded)
62590537|NCT04450524|PLACEBO_COMPARATOR|Control|Participants will perform an online computer go-no-go task. They will be shown pictures of dense and low-calorie food together with neutral pictures, followed by the instruction to press the button to indicate the position of the picture - left or right.
62420391|NCT02793375|EXPERIMENTAL|Study group|Patients receiving montelukast preoperatively (blinded)
62420392|NCT06568328|EXPERIMENTAL|CNK-UT cells therapy|"1. Dose Escalation：Single-dose intravenous injection of CNK-UT cells (1\~10×10\^7 CNK+ cells/kg).~2. Dose Expansion：Multiple-dose intravenous injection of CNK-UT cells according to the results of dose escalation."
62420393|NCT05756413|EXPERIMENTAL|SDT|Pregnant mothers will be randomly assigned to either an experimental group (Group 1) where mothers will receive autonomy-supportive messages informed by the SDT or a control group (Group 2) where mothers will receive the same oral health care messages delivered using a neutral style. All mothers will be exposed to oral health messages - one during pregnancy, one later when their child is 12 months of age, and one when their child is 24 months of age. Three months after receiving the oral health messages at each time point, mothers will be sent a follow-up booster message.
62590538|NCT04106895||Fibryga|
62590539|NCT05777902|EXPERIMENTAL|Patient|
62590540|NCT00644410|ACTIVE_COMPARATOR|1|The number of mesenchymal stromal cells reached after two culture expansion passages.
62590541|NCT00644410|PLACEBO_COMPARATOR|2|Saline
62803280|NCT05839574|ACTIVE_COMPARATOR|MTX in monotherapy|Combined treatment with MTX followed by hysteroscopic evacuation of POC
62803281|NCT05839574|ACTIVE_COMPARATOR|MTX + letrozole add-on|Combined treatment with MTX + letrozole add-on followed by hysteroscopic evacuation of POC
62803282|NCT01402401|EXPERIMENTAL|AUY922 + Trastuzumab|
62803283|NCT04670341|EXPERIMENTAL|chewing tapioca pearls in the bubble tea drinks|In the first week, the subjects drink as much as 100 ml of bubble tea over a span of 5 minutes once a day for 3 days
62803284|NCT04670341|PLACEBO_COMPARATOR|drink tea without chewing tapioca pearls|In the second week, the subjects drink tea without tapioca pearls as much as 100 ml for 5 minutes per day for 3 days.
62803285|NCT01307436|EXPERIMENTAL|Group A|Epaxal + concomitant administration of DTPaHibIPV, MMR, OPV
62803286|NCT01307436|EXPERIMENTAL|Group B|Epaxal, with administration of DTPaHibIPV, MMR, OPV one month later
62803287|NCT01307436|ACTIVE_COMPARATOR|Group C|Havrix 720 + concomitant administration of DTPaHibIPV, MMR
62803288|NCT03833739|EXPERIMENTAL|Upper Arch Treatment First|"Intervention : using fixed orthodontic pre-adjusted edgewise appliance in the upper and lower arches.~starting treatment in the upper arch The upper ach was bonded for 28 patients and teeth alignment was started using round 0.014NiTi arch wire. The 0.014NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. Orthodontic treatment was continued in the upper arch with arch wire sequence of 0.014NiTi, 0.018NiTi, 0.016X0.022NiTi, 0.019X0.025NiTi, and 0.019X0.025stainless steel arch wires. The patients were followed up on a monthly basis until sufficient proclination of the upper incisors achieved to establish an overjet of at least 4 mm. After reaching the full working arch wire in lower arch (0.019 X 0.025stainless steel wire), lateral cephalogram and study models were taken."
62803289|NCT03833739|EXPERIMENTAL|Lower Arch Treatment First|"Intervention : using fixed orthodontic pre-adjusted edgewise appliance in the lower arch and anterior bite plate in the upper arch.~The lower arch was bonded after taking the pretreatment records. At the same appointment an anterior bite plate in the upper arch was delivered to prevent shearing off the mandibular incisor brackets and help in correction of anterior deep bite .After lower arch alignment and leveling in the same arch wire sequence as the other group and 0.019 X 0.025stainless steel arch wire was reached, the anterior bite plate was removed and the upper arch was bonded. The same arch wire sequence was used in the upper arch as was used in the lower arch. When the full working arch wire (0.019 X 0.025stainless steel arch wire) was reached in the upper arch, study models and lateral cephalogram were taken."
62803290|NCT04057066|EXPERIMENTAL|Intervention|Participants receive physical activity counseling as well as an individualized exercise plan.
62803291|NCT01676987|EXPERIMENTAL|Fixed Combination of Budesonide and formoterol|Group 1 (experimental): Fixed Combination of Budesonide and formoterol
62803292|NCT01676987|ACTIVE_COMPARATOR|Budesonide|Group 2 (comparator): Budesonide
62803293|NCT04730765||Surgical Experimental Group|Patient operated between 01/02/2021 and 30/07/2021, in elective situation of sigmoid diverticulitis
62803294|NCT04730765||Medical Control Group|Patient not operated and medically treated
62803295|NCT03476148|EXPERIMENTAL|Interactive Device Rehabilitation|
62803296|NCT03476148|ACTIVE_COMPARATOR|Inpatient Rehabilitation|
62803297|NCT06256588|EXPERIMENTAL|Arm A: Dostarlimab|
62028756|NCT04458584||Suture Suspensionplasty (SS)|Patients undergoing thumb basal joint arthroplasty using suture suspensionplasty (SS) procedure as treatment of osteoarthritis.
62590542|NCT06666595|ACTIVE_COMPARATOR|Subcrestal short implant|Evaluation the amount of bone loss after one, two, and three years of function.
62590543|NCT06666595|ACTIVE_COMPARATOR|crestal standard length implant|Evaluation the amount of bone loss after one, two, and three years of function.
62590544|NCT05646381|EXPERIMENTAL|Pelacarsen (TQJ230) 80mg|Pelacarsen (TQJ230) 80 mg prefilled syringe injected monthly, administered subcutaneously
62803298|NCT06256588|PLACEBO_COMPARATOR|Arm B: Placebo|
62803299|NCT00421057||Exercise Group|Taught to perform a specific regimen for strength-training and walking exercises.
62803300|NCT00421057||Nonexercise Group|Follow usual routines of standard care but not taught to perform a specific regimen for strength-training and walking exercises; will keep record of any exercises done that are not a part of this study.
62803301|NCT06063694|NO_INTERVENTION|Transmetatarsal amputation with primary closure|Transmetatarsal amputation with primary closure and no application of synthetic electrospun fiber matrix.
62803302|NCT06063694|EXPERIMENTAL|Transmetatarsal amputation with application of synthetic electrospun fiber matrix|Transmetatarsal amputation with application of synthetic electrospun fiber matrix
62803303|NCT05153577|ACTIVE_COMPARATOR|Group A: Free produce box|Participants receive free weekly produce boxes for the first 4 weeks of the study and are then randomized to pay $5 per box (with continued free weekly delivery) for the remaining 4 weeks of the study.
62420394|NCT05756413|OTHER|Control|Pregnant mothers will be randomly assigned to either an experimental group (Group 1) where mothers will receive autonomy-supportive messages informed by the SDT or a control group (Group 2) where mothers will receive the same oral health care messages delivered using a neutral style. All mothers will be exposed to oral health messages - one during pregnancy, one later when their child is 12 months of age, and one when their child is 24 months of age. Three months after receiving the oral health messages at each time point, mothers will be sent a follow-up booster message.
62590545|NCT05646381|PLACEBO_COMPARATOR|Matching placebo|Placebo to match pelacarsen (TQJ230) prefilled syringe injected monthly, administered subcutaneously
62803304|NCT05153577|ACTIVE_COMPARATOR|Group B: Free produce box|Participants receive free weekly produce boxes for the first 4 weeks of the study and are then randomized to pay $10 per box (with continued free weekly delivery) for the remaining 4 weeks of the study.
62803305|NCT03820882|EXPERIMENTAL|stent retriever(Catfish)|Mechanical thrombectomy with Catfish flow restoration device
62803306|NCT03820882|ACTIVE_COMPARATOR|stent retriever(Solitaire FR)|Mechanical thrombectomy with Solitaire FR flow restoration device
62803307|NCT03899298|EXPERIMENTAL|Amniotic and Umbilical Cord Tissue for Autoimmune Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for autoimmune conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
62420395|NCT05847504|EXPERIMENTAL|mSTARS|mHealth-supported Skills Training for Alcohol-Related Suicidality, or mSTARS, is an intervention that combines a cognitive-behavioral skills training intervention in emotion regulation skills with a post-discharge mobile health (mHealth) app that encourages application of these skills to real life.
62590546|NCT01927549|ACTIVE_COMPARATOR|Immediate multivessel PCI|After diagnostic angiography the culprit lesion is identified and PCI should be performed using standard techniques. The use of drug-eluting stents is recommended but not mandatory. All additional lesions in other major coronary arteries defined by a diameter \>2 mm with high grade stenoses (\>70% by visual assessment) should be intervened using standard techniques. Other major coronary arteries are defined by stenoses of other vessels and are not confined to a diagonal branch if the left anterior descending coronary artery was identified as the culprit lesion.
62590547|NCT01927549|ACTIVE_COMPARATOR|Culprit lesion only PCI|After diagnostic angiography the culprit lesion is identified and PCI of the culprit lesion should be performed using standard techniques. The use of drug-eluting stents is recommended but not mandatory. All other lesions should be left untreated in the acute setting. Complete revascularization of the non-culprit lesions may be performed at a later time point as staged procedure depending on remaining ischemia (as per guideline recommendations either by PCI or CABG).
62735298|NCT01732510|EXPERIMENTAL|Part 1: MK-8226 1 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
62803308|NCT03899298|EXPERIMENTAL|Amniotic and Umbilical Cord Tissue for Orthopedic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for orthopedic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
62803309|NCT03899298|EXPERIMENTAL|Amniotic and Umbilical Cord Tissue for Neurologic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for neurologic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
62803310|NCT03899298|EXPERIMENTAL|Amniotic and Umbilical Cord Tissue for Urologic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for urologic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
62803311|NCT03899298|EXPERIMENTAL|Amniotic and Umbilical Cord Tissue for Cardiac Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for cardiac conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
62803312|NCT03899298|EXPERIMENTAL|Amniotic and Umbilical Cord Tissue for Renal Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for renal conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
62028757|NCT04458584||Arthroscopic Trapeziectomy (AT)|Patients undergoing thumb basal joint arthroplasty using arthroscopic trapeziectomy (AT) procedure as treatment of osteoarthritis.
62028758|NCT06316986|EXPERIMENTAL|Patients requiring an orogastric or nasogastric tube|
62028759|NCT01023100|EXPERIMENTAL|Open label|
62028760|NCT01361412|EXPERIMENTAL|ToleroMune Ragweed 4|
62028761|NCT01361412|EXPERIMENTAL|ToleroMune Ragweed Regimen 3|
62028762|NCT01361412|EXPERIMENTAL|ToleroMune Ragweed Regimen 2|
62803313|NCT03899298|EXPERIMENTAL|Amniotic and Umbilical Cord Tissue for Pulmonary Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for pulmonary conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
62227521|NCT00319839|EXPERIMENTAL|Abraxane plus Cetuximab|Drug: Abraxane-260 mg/m2 IV over 30 minutes every 3 weeks. Drug: Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles.
62227522|NCT00580346|EXPERIMENTAL|2|
62227523|NCT02216045|ACTIVE_COMPARATOR|Peginterferon ,Ribavirin|drug :Peginterferon, Ribavirin,
62227524|NCT02216045|EXPERIMENTAL|Peginterferon, Ribavirin, camel milk|drug :Peginterferon, Ribavirin, camel milk
62227525|NCT01355653|EXPERIMENTAL|Treatment A|thermal therapy
62420396|NCT04961112|EXPERIMENTAL|Experimental - Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. Participants will be told they may receive additional shocks for poor performance during cognitive assessments.~Participants will be administered cranial electrotherapy stimulation with a frequency of .5 Hz and a current of 100 microamps during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
62420397|NCT04961112|EXPERIMENTAL|Experimental - No Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. After this procedure, the shock belt will be turned off. Participants will be told they will not receive additional shocks during cognitive assessments.~Participants will be administered cranial electrotherapy stimulation with a frequency of .5 Hz and a current of 100 microamps during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
62420398|NCT04961112|SHAM_COMPARATOR|Sham - Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. Participants will be told they may receive additional shocks for poor performance during cognitive assessments.~Participants will be administered sham cranial electrotherapy stimulation with no current during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
62420399|NCT04961112|SHAM_COMPARATOR|Sham - No Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. After this procedure, the shock belt will be turned off. Participants will be told they will not receive additional shocks during cognitive assessments.~Participants will be administered sham cranial electrotherapy stimulation with no current during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
62227526|NCT01355653|ACTIVE_COMPARATOR|Treatment B|ThermaCare Lower Back/Hip heatwrap
62227527|NCT01234753|NO_INTERVENTION|Usulal care|Usual care by a visit to physician at the hospital out-patient clinic
62227528|NCT00234806|EXPERIMENTAL|Telemedicine intervention group|
62227529|NCT00234806|PLACEBO_COMPARATOR|Control group|
62227530|NCT05252650||regional block|epidural / peripheral nerve block
62590548|NCT01259349|EXPERIMENTAL|one percent ultrasound|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at one percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
62735299|NCT01732510|EXPERIMENTAL|Part 1: MK-8226 3 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
62803314|NCT06059235|EXPERIMENTAL|intervention|"Package of clinical pharmacy activities including :~* Medication history (during assessment consultation)~* Medication review and consultation with the geriatrician~* Therapeutic education (during results consultation)~* Shared decision (at results consultation)~* One-week follow-up call + usual care"
62803315|NCT06059235|NO_INTERVENTION|controle|Medication history (during assessment consultation) + usual care
62028763|NCT01361412|PLACEBO_COMPARATOR|Placebo|Placebo
62227531|NCT05252650||intravenous|intravenous analgesia
62227532|NCT01130584||Cancer patient|
62227533|NCT00530907|EXPERIMENTAL|Valproic Acid + Bevacizumab|"Valproic acid administered at a dose of 5.3 mg/Kg/day on days 1 - 28. Depending on the calculated dose, patients will take capsules once or twice a day per mouth.~Bevacizumab administered at a dose of 2.5 mg/kg by vein every 2 weeks."
62227534|NCT02501070||Pre-PROGALIAM|Patients treated for myocardial infarction before the implementation of the network for acute myocardial infarction care (2001 to 2005).
62227535|NCT02501070||PROGALIAM|Patients treated for myocardial infarction after the implementation of the network for acute myocardial infarction care (2005 to 2011).
62227536|NCT01127269|EXPERIMENTAL|Insulin Glargine|"Patients will receive insulin glargine titrated based on standard of care as recommended by the ADA/EASD Consensus Algorithm. Step 1: insulin glargine initiation regimen for insulin naive patients/ Switch to insulin glargine for patient already treated with basal insulin.~Step 2: the insulin dosage of patients will be titrated according to the ADA/EASD Consensus Algorithm."
62227537|NCT05938374|EXPERIMENTAL|Preoperative moderately fractionated RT with Fluzoparib|"Patients will receive preoperative moderately fractionated radiotherapy (RT)(43.5Gy/15fr). One week before RT onset, during radiotherapy and 5 weeks post-RT, patients also take oral Fluzoparib (100mg, BID, five days per week).~Wide resection surgery would be done around 6 -10 weeks post-RT."
62227538|NCT05938374|EXPERIMENTAL|Preoperative moderately fractionated RT without Fluzoparib|"Patients will receive preoperative moderately fractionated radiotherapy (RT)(43.5Gy/15fr). No radio-sensitizing drugs was given.~Wide resection surgery would be done around 6 -10 weeks post-RT."
62028764|NCT01361412|EXPERIMENTAL|ToleroMune Ragweed Regimen 1|
62028765|NCT06635304||Deep vault|All digital models with deep palatal vault will be included in this group. The depth of the vaults will be assessed according to the Korkhaus index, which sets the cutoff for determining the depth of the palatal vault at 42%. Below this percentage, the vault is considered deep; above this percentage, it is considered flat.
62028766|NCT06635304||Flat vault|All digital models with flat palatal vault will be included in this group. The depth of the vaults will be assessed according to the Korkhaus index, which sets the cutoff for determining the depth of the palatal vault at 42%. Below this percentage, the vault is considered deep; above this percentage, it is considered flat.
62227539|NCT03172182|EXPERIMENTAL|Virtual reality (VR) group|Immersive education using a 360-degree VR video tour at operation day
62227540|NCT03172182|NO_INTERVENTION|Control Group|Conventional verbal education of preoperative proceudres
62227541|NCT04514666|EXPERIMENTAL|Liver/kidney transplant|The breath of patients undergoing liver or kidney transplant will be sampled and analysed
62590549|NCT01259349|ACTIVE_COMPARATOR|40 percent ultrasound|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at 40 percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
62590550|NCT04564378||Mild Fuchs Dystrophy|
62590551|NCT04564378||Severe Fuchs Dystrophy|
62590552|NCT06668090|EXPERIMENTAL|Exercise|"Moderate intensity bike exercise thrice weekly for 12 week added to the usual activity level.~Each participant receive an individual exercise program based on their maximum heart rate.~Exercise is not supervised, but compliance is monitored. It will either be performed at home or at gyms.~No changes in diet."
62803316|NCT03527472|EXPERIMENTAL|Memantine|At randomization, subjects will receive 5 mg twice per day for one week. They will escalate their dose to 10 mg twice per day for one week, then 10 mg in the morning and 20 mg at night for one week, and finally 20 mg twice per day for three weeks. Maximum tolerated will be determined at this time and this dose will be continued for an additional six weeks.
62227542|NCT05871177|EXPERIMENTAL|HiLow hyaluronic acid sodium salt for intralesional penile injection|"Five intralesional injections of HiLow hyaluronic acid sodium salt will be administered in total to men affected by PD every two weeks (for a total period of 2.5 months). Patients will be then followed-up for 3 months.~The following visits are scheduled:~Day 0: basal visit Day 15: injection n.1 Day 30: injection n.2 Day 45: injection n.3 Day 60: injection n.4 Day 75: injection n.5 Day 180: end of follow up"
62227543|NCT05241457||Standard of care group|Patients will receive the standard physical therapy sessions that they would normally receive during their IRF stay, (60 to 90 min sessions, 5 to 6 days/week). This group will not receive Ekso exoskeleton gait training.
62227544|NCT05241457||Ekso exoskeleton gait training group|Patients in the Ekso group will have several (2 to 3) of their standard of care sessions replaced with Ekso gait training sessions each week.
62227545|NCT02121834|EXPERIMENTAL|LY3050258|Daily dose of LY3050258 for 28 days: Cohort A 10 mg, Cohort B 30 mg, Cohort C 90 mg, Cohort D 180 mg and Cohort E 360 mg.
62227546|NCT02121834|PLACEBO_COMPARATOR|Placebo|Daily dose of placebo matching LY3050258 for 28 days.
62227547|NCT01672723|EXPERIMENTAL|Naltrexone|"Participants will take 4 doses of naltrexone over 4 days (25mg/day for days 1 and 2, 50mg/day for days 3 and 4) as well as 4 matched placebo pills for a total of 8 days. Capsules will be packaged into blister packs.~Participants will be asked to take the first drug, either naltrexone or placebo, once a day for three days prior to the first experimental session and when they arrive at the lab for the experimental procedure . After the first session, participants will take the second study drug for three days prior to the second experimental session and when they arrive for the second experimental procedure."
62590553|NCT06668090|NO_INTERVENTION|Control/no intervention|"12 weeks with usual activity level.~No changes in diet."
62803317|NCT03527472|PLACEBO_COMPARATOR|Placebo|At randomization, subjects will receive one matching placebo capsule twice per day for one week. They will also take one matching placebo capsule twice per day for the next week (week 2), then one matching placebo capsule in the morning and two capsules at night for one week (week three), and finally two capsules twice per day for three weeks (weeks 4-6). Maximum tolerated number of capsules will be determined at this time and this dose will be continued for an additional six weeks.
62028767|NCT01739829|EXPERIMENTAL|DIABECELL group 1|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
62028768|NCT01739829|EXPERIMENTAL|DIABECELL group 2|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
62028769|NCT05734846|EXPERIMENTAL|Control Lenses, then Test Lenses|Participants wore the Control Lenses for 1 week, then crossed over to the Test Lenses for 1 week.
62028770|NCT05734846|EXPERIMENTAL|Test Lenses, then Control Lens|Participants wore the Test Lenses for 1 week, then crossed over to the Control Lenses for 1 week.
62028771|NCT04331366|EXPERIMENTAL|Treatment with GO2 PEEP MOUTHPIECE|Participants receiving treatment with the GO2 PEEP MOUTHPIECE
62028772|NCT03671603||Iodixanol|Participants will receive Iodixanol 270 mg I/ml or Iodixanol 320 mg I/ml injection as a part of routine clinical practice at the medical discretion of the physician.
62028773|NCT05709743|EXPERIMENTAL|Within-Subjects Attentional Information|Within-Subjects, all participants receive all interventions
62028774|NCT01260233|NO_INTERVENTION|Control|No intervention. Patients will receive standard of care.
62028775|NCT01260233|EXPERIMENTAL|Smoking cessation program|Receives smoking cessation program
62028776|NCT05577429|PLACEBO_COMPARATOR|Moderate intensity exercise under normoxia|The participants will perform low-moderate intensity cycling exercise at 90% lactate threshold (LT) (determined during LT test) under normoxia (FiO2: 20.9%) for 60 minutes on a cycle ergometer. Immediately after exercise oral glucose tolerance test (OGTT) will be determined with 24-hour glucose concentration will be monitored continuously. Circulatory factors will be determined pre, immediately after exercise and 24 hours after exercise.
62028777|NCT05577429|EXPERIMENTAL|Moderate intensity exercise under hypoxia|The participants will perform low-moderate intensity cycling exercise at 90% lactate threshold (LT) (determined during LT test) under hypoxia (FiO2: 16.5-14.8%) for 60 minutes on a cycle ergometer. Immediately after exercise oral glucose tolerance test (OGTT) will be determined with 24-hour glucose concentration will be monitored continuously. Circulatory factors will be determined pre, immediately after exercise and 24 hours after exercise.
62590554|NCT02559596||Cases|Adults (aged 16+) with stored serum samples collected for the Health Survey for England (HSE) between 2009 and 2013, who have a record of hospitalisation for stroke, transient ischaemic attack or myocardial infarction occurring after their participation in the HSE.
62590555|NCT02559596||Controls|Adults (aged 16+) with stored serum samples collected for the Health Survey for England (HSE) between 2009 and 2013, who do not have a record of hospitalisation for stroke, transient ischaemic attack or myocardial infarction and are matched to cases on age, gender and year of participation in the HSE.
62590556|NCT01154348|EXPERIMENTAL|Washout period, S-707106 tablet|14-day washout of metformin, followed by S-707106 once daily for 14 days under fed conditions
62590557|NCT01154348|PLACEBO_COMPARATOR|Washout, placebo|14-day washout of metformin followed by placebo for S-707106 once daily for 14 days under fed conditions
62803318|NCT05510089|EXPERIMENTAL|EAP regimen|The combination regimen of etoposide, cytarabine and PEG-rhG-CSF.
62803319|NCT04589871|EXPERIMENTAL|Group A|Group A received a taping technique in addition to the supervised exercises protocol
62803320|NCT04589871|ACTIVE_COMPARATOR|Group B|Group B received supervised exercises protocol only
62227548|NCT01672723|PLACEBO_COMPARATOR|Placebi|"Participants will take 4 doses of naltrexone over 4 days (25mg/day for days 1 and 2, 50mg/day for days 3 and 4) as well as 4 matched placebo pills for a total of 8 days. Capsules will be packaged into blister packs.~Participants will be asked to take the first drug, either naltrexone or placebo, once a day for three days prior to the first experimental session and when they arrive at the lab for the experimental procedure . After the first session, participants will take the second study drug for three days prior to the second experimental session and when they arrive for the second experimental procedure."
62420400|NCT06267118|ACTIVE_COMPARATOR|Hypertonic saline nebulization group|First group of patients diagnosed as acute bronchiolitis will be nebulized with hypertonic saline every 6 hours and data will be recorded on a Performa
62227549|NCT00014131|EXPERIMENTAL|Biological/Vaccine|Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
62803321|NCT05981508|ACTIVE_COMPARATOR|In-person Family Skills Training|The index partner will participate in intervention as a dyad with a family member with an in-person skills training.
62803322|NCT05981508|EXPERIMENTAL|Online Family Skills Training|The index partner will participate in intervention as a dyad with a family member with an online skills training.
62227550|NCT04707651|EXPERIMENTAL|Lifestyle intervention|Nutrition advices and formula diet
62420401|NCT06267118|ACTIVE_COMPARATOR|Adrenaline nebulization group|Second group of patients will be nebulized with adrenaline every 6 hours and data will be recorded on a Performa
62420402|NCT06547814|EXPERIMENTAL|Standard implementation (Stage 1)|Participants begin with the standard implementation interventions for 8-16 weeks, depending on random block assignment.
62420403|NCT06547814|EXPERIMENTAL|Virtual facilitation (Stage 2)|After completing the standard implementation, participants then complete the virtual facilitation intervention for 8-16 weeks, depending on random block assignment.
62420404|NCT01986400|EXPERIMENTAL|Virtual Peer-to-Peer Support Mentoring|In addition to standard medical care, adolescents in the experimental group will receive the VP2P support program, a manualized peer-mentorship program that will provide modeling and reinforcement by peers (young adults with JIA aged 16-25 years who have learned to function successfully with their JIA to the mentored participants).
62420405|NCT01986400|NO_INTERVENTION|Wait-list Control|The control group will receive usual care but without the mentorship intervention. They will be offered the VP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
62420406|NCT04862650|EXPERIMENTAL|Treatment (cemiplimab, paclitaxel, carboplatin)|Patients will be treated with a combination of cemiplimab 350 mg every three weeks, with weekly combination of paclitaxel 25 mg/m2 and carboplatin AUC 1. Treatment will continue for a total of 24 months or until disease progression or unacceptable toxicity. Weekly chemotherapy will stop after six months of treatment (24 weeks). A ten patient safety run-in phase will be initially performed.
62803323|NCT03782519|EXPERIMENTAL|Incremental hemodialysis|Patients who will begin HD with two treatment sessions per week
62420407|NCT06350331|EXPERIMENTAL|mVTEA Management Group|Patients randomly assigned to the mVTEA management group will be discharged with mVTEA-assisted patient-centered VTE management.
62227551|NCT03706313|ACTIVE_COMPARATOR|Genicular nerve block with bupivacaine|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
62420408|NCT06350331|NO_INTERVENTION|Routine Management Group|Patients randomly assigned to the routine management group will be given routine post-discharge management in accordance with local clinical practice.
62420409|NCT01579292|EXPERIMENTAL|Physical Activity and Diet Intervention|5-month physical activity and diet intervention which includes 6 in-person sessions, mobile app, and pedometer
62420410|NCT01579292|ACTIVE_COMPARATOR|Pedometer only|Pedometer only
62590558|NCT01154348|EXPERIMENTAL|Maintenance, S-707106 tablet plus metformin|14-day maintenance of metformin, followed by S-707106 once daily plus open-label metformin twice daily for 14 days under fed conditions
62590559|NCT01154348|PLACEBO_COMPARATOR|Maintenance, placebo plus metformin|14-day maintenance of metformin, followed by placebo for S-707106 once daily plus open-label metformin twice daily for 14 days under fed conditions
62803324|NCT03782519|ACTIVE_COMPARATOR|Conventional hemodialysis|Patients who will begin HD three times a week
62590560|NCT03734146|EXPERIMENTAL|Aerobic exercise (AE)|Engage in supervised aerobic exercise for 60 minutes on 3 days per week for 8 weeks. Exercise is performed on a recumbent bike or treadmill at 50-80% of their heart rate reserve.
62227552|NCT03706313|PLACEBO_COMPARATOR|Genicular nerve block with saline|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane (in-plane approach). Once satisfactory position of the needle time is confirmed, 5mL of a saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
62590561|NCT03734146|EXPERIMENTAL|Resistance exercise (RE)|Engage in supervised resistance exercise for 60 minutes on 3 days per week for 8 weeks. Exercise consists of 3 sets of 8-12 repetitions of 12 exercises for the major muscle groups.
62227553|NCT06011174||post-stroke patient|"1. Being 18 years of age or older,~2. being diagnosed with hemorrhagic or ischemic stroke,~3. No cooperation and communication problems~4. Being able to walk independently"
62227554|NCT01945541|NO_INTERVENTION|standard fluid management|postoperative BMC measurements
62227555|NCT01945541|ACTIVE_COMPARATOR|body composition monitoring preoperative|pre and postoperative BCM measurements
62420411|NCT05290272|EXPERIMENTAL|ViFIVE Digital Care Program|AI based digital care program that is individually tailored for each user depending on need. ViFive DCP includes illustration, voice guidance, and pose correction features of AI coach. Participants will required to complete the program.
62420412|NCT06251154|EXPERIMENTAL|Lens 1|All participants wore Lens 1 for 15 minutes (Period 1)
62590562|NCT03734146|EXPERIMENTAL|Combined Resistance and Aerobic Exercise|Engage in supervised aerobic resistance exercise for 60 minutes on 3 days per week for 8 weeks. Exercise consists of 30 min aerobic exercise at 50-80% heart rate reserve and 30 min of resistance exercise comprising 2 sets of 8-12 repetitions of 9 exercises for the major muscle groups.
62227556|NCT02372656|PLACEBO_COMPARATOR|Placebo Group|Placebo gel without active ingredient to be delivered at baseline, 3, 6 and 9 months.
62227557|NCT02372656|ACTIVE_COMPARATOR|1% Metformin|1% metformin gel to be delivered at baseline, 3, 6 and 9 months.
62227558|NCT02372656|ACTIVE_COMPARATOR|1.2% Simvastatin|1.2% Simvastatin to be delivered at baseline, 3, 6 and 9 months.
62227559|NCT04890925|NO_INTERVENTION|Control group|Women who have experienced intimate partner violence but no sustained brain injury (Brain Injury Severity Assessment; BISA = 0)
62227560|NCT04890925|EXPERIMENTAL|Community Support Network (CSN) intervention group|The SOAR Community Support Network (CSN) intervention includes cognitive training, aerobic exercise, mindfulness meditation, counselling, quality of life tracking.
62227561|NCT04890925|ACTIVE_COMPARATOR|Usual care|Participants in this group will receive dose-equivalent usual care
62227562|NCT05236478||CoviMouv' program|Patients who have benefited from the CoviMouv' program (supervised physical activity program + therapeutic education program) will be included.
62227563|NCT05236478||control group|Patients with autonomous physical activity at home or with a community-based physiotherapist will be included. They will have support for the resumption of an adapted physical activity in autonomy, according to the results of the aerobic and anaerobic tests carried out during the initial evaluation (delivery of a training booklet).
62420413|NCT06251154|EXPERIMENTAL|Lens 2|All participants wore Lens 2 for 15 minutes (Period 2)
62420414|NCT01687400|EXPERIMENTAL|Decitabine|Patients receive decitabine IV over 1 hour on days 1-10 of a 28-day cycle. Treatment continues for 2 cycles. Patients then receive decitabine IV over 1 hour on days 1-10, 1-5, or 1-3 (depending on response). Treatment continues in the absence of disease progression or unacceptable toxicity.
62590563|NCT03734146|NO_INTERVENTION|No training control|No exercise training. Participants will refrain from any moderate-vigorous exercise or resistance training for 8 weeks.
62590564|NCT00068393|EXPERIMENTAL|Doxorubicin/Gemcitabine|Doxorubicin was given at 50 mg/m² by IV slow push, followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life. Cycles were repeated every 2 weeks.
62590565|NCT03634995|EXPERIMENTAL|Single Dose|Ascending single doses of BMS-986256
62590566|NCT03634995|EXPERIMENTAL|Multiple Dose|Ascending multiple doses of BMS-986256
62590567|NCT03634995|EXPERIMENTAL|Sequential Dose|Sequential multiple doses of BMS-986256
62590568|NCT06033430|EXPERIMENTAL|True dry needling of the hypertrophic scar tissue|Participants with hypertrophic linear scar tissue in the true dry needling group will undergo authentic dry needling interventions targeted at the scar tissue, in conjunction with routine physiotherapy.
62590569|NCT06033430|SHAM_COMPARATOR|Sham dry needling of the hypertrophic scar tissue|In the sham dry needling group, participants presenting with hypertrophic linear scar tissue will receive superficial dry needling of the skin, performed at a location distinct from the scar tissue. This will be administered alongside routine physiotherapy.
62420415|NCT05076617|EXPERIMENTAL|Staccato alprazolam|Participants will receive Staccato alprazolam by inhalation.
62420416|NCT00445458|EXPERIMENTAL|HKI-272 dose level 1|Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 160 mg daily by mouth in combination with paclitaxel 80 mg/m\^2 weekly IV.
62420417|NCT00445458|EXPERIMENTAL|HKI-272 dose level 2|Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m\^2 weekly IV.
62028778|NCT02268838|EXPERIMENTAL|50 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 1, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
62028779|NCT02268838|EXPERIMENTAL|100 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 2, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
62227564|NCT05635981|ACTIVE_COMPARATOR|Clearfil S3 Bond Plus|"After selective etching is applied to the enamel surface, Clearfil S3 Bond Plus is applied according to the manufacturer's instructions, restorations are completed with Clearfil Majesty ES-2.~Clearfil S3 Bond Plus: one-step self-etch adhesive with HEMA"
62590570|NCT03124407|ACTIVE_COMPARATOR|Once daily-Active|40 subjects receiving once daily application of complete drug product (contains 0.25% capsaicin) to the knee
62590571|NCT03124407|PLACEBO_COMPARATOR|Once daily-Vehicle|20 subjects receiving once daily application of drug product vehicle (i.e., with no capsaicin) to the knee
62420418|NCT00445458|EXPERIMENTAL|HKI-272 expanded MTD cohort, arm A|Part 2: Subjects with metastatic breast cancer who have not received more than 1 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m\^2 weekly IV.
62420419|NCT00445458|EXPERIMENTAL|HKI-272 expanded MTD cohort, arm B|Part 2: Subjects with metastatic breast cancer who have not received more than 3 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m\^2 weekly IV.
62420420|NCT03742245|EXPERIMENTAL|Olaparib and Vorinostat|"Phase I: Olaparib and vorinostat will be orally administered for 4 28-day cycles. Dose levels (DLs) are as follows: DL -1, 100 mg twice daily (b.i.d.) olaparib and 300 mg for 5 consecutive days per week vorinostat; DL 0 (starting dose), 200 mg twice daily (b.i.d.) olaparib and 300 mg once daily (q.d.) vorinostat; DL 1, 300 mg b.i.d. olaparib and 300 mg q.d. vorinostat; and DL 2, 300 mg b.i.d. olaparib and 400 mg q.d. vorinostat. . Patients who derive clinical benefit (CR, PR, or SD) after 4 cycles of treatment can continue to receive the study treatment until they experience unacceptable AEs or disease progression.~Phase Ib: Olaparib and vorinostat will be administered at the maximum tolerated dose (MTD) determined in the Phase I portion of the study for 4 28-day cycles. Participants who derive clinical benefit (complete response, partial response, or stable disease) after 4 cycles will continue to receive study treatment until unacceptable toxicity or disease progression."
62420421|NCT05293743|ACTIVE_COMPARATOR|Standard Bar|This group will continue using the Standard Bar as part of their brace, per their current treatment.
62420422|NCT05293743|EXPERIMENTAL|Dynamic Bar|This group will use the Dynamic Bar for 30 days instead of their Standard Bar.
62420423|NCT04425369|NO_INTERVENTION|inner side approaches for iliac crest bone graft|An anterior approach was used to expose the inner table of the ilium.
62420424|NCT04425369|EXPERIMENTAL|two-sided approaches for iliac crest bone graft|both sides of the ilium were totally exposed of the ilium.
62420425|NCT05399186|NO_INTERVENTION|Control group|Usual care group - receiving traditional preoperative preparation and assessment (1 week) prior to total joint arthroplastic surgery
62420426|NCT05399186|EXPERIMENTAL|Early preoperative assessment and optimization|Interventional group - receiving early preoperative assessment and optimization (6-12 months) in wait of total joint arthroplastic surgery
62420427|NCT05083091|ACTIVE_COMPARATOR|Monitor & Accept (MA-MBI)|14-day smartphone based mindfulness meditation attention monitoring and acceptance skills training intervention consisting of a 5-minute introductory video, a 20-minute audio-guided lesson, plus daily life homework practice (3-10 minutes) each day.
62590572|NCT03124407|ACTIVE_COMPARATOR|Twice daily-Active|40 subjects receiving twice daily application of complete drug product (contains 0.25% capsaicin) to the knee
62590573|NCT03124407|PLACEBO_COMPARATOR|Twice daily-Vehicle|20 subjects receiving twice daily application of drug product vehicle (i.e., with no capsaicin) to the knee
62590574|NCT03395184|EXPERIMENTAL|PF-06700841 or placebo|
62590575|NCT03395184|EXPERIMENTAL|PF-06651600 or placebo|
62590576|NCT03339726|EXPERIMENTAL|New Formulation Phenylephrine HCl|
62590577|NCT03339726|ACTIVE_COMPARATOR|Marketed Phenylephrine HCl|
62590578|NCT03339726|PLACEBO_COMPARATOR|Placebo|
62590579|NCT05448417|EXPERIMENTAL|non-invasive high-frequency oscillatory ventilation|Patients were titrated for relevant parameters of noninvasive ventilation the day before the trial. In the non-invasive high-frequency oscillation ventilation mode, the support pressure is consistent with the noninvasive bi-level positive pressure mode, and the highfrequency airway pressure oscillation driven by the solenoid valve is added during the expiratory phase. The amplitude is about 4cmH2O, and the oscillation frequency is about 8HZ.
62735300|NCT01732510|EXPERIMENTAL|Part 1: MK-8226 10 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
62028780|NCT02268838|EXPERIMENTAL|200 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 4, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
62028781|NCT02268838|EXPERIMENTAL|400 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 8, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
62028782|NCT02268838|EXPERIMENTAL|200 mg E6007 fed condition|E6007 50mg or E6007 matching placebo x 4, orally once daily in the morning under fed condition. Drug administration on 1 day (Day 1).
62028783|NCT06442553|EXPERIMENTAL|GRR laser|patients received 15 sessions GRR laser treatment for 3 weeks
62028784|NCT06442553|EXPERIMENTAL|Nd:YAG Laser|patients received 10 sessions Nd:YAG laser treatment for 2 weeks
62028785|NCT06442553|PLACEBO_COMPARATOR|placebo|patients received 10 sessions emission-free laser treatment for 2 weeks
62227565|NCT05635981|EXPERIMENTAL|Clearfil S3 Bond Plus with Additional Hydrophobic Adhesive Layer Application|"After selective etching is applied to the enamel surface, Clearfil S3 Bond Plus is applied according to the manufacturer's instructions. Heliobond is applied as an additional hydrophobic adhesive layer and restorations are completed with Clearfil Majesty ES-2.~Clearfil S3 Bond Plus: one-step self-etch adhesive with HEMA Heliobond: hydrophobic adhesive with Bis-GMA and TEGDMA"
62227566|NCT05635981|ACTIVE_COMPARATOR|G-Premio Bond|"After selective etching is applied to the enamel surface, G-Premio Bond is applied according to the manufacturer's instructions, restorations are completed with Clearfil Majesty ES-2.~G-Premio Bond: universal adhesive without HEMA"
62227567|NCT05635981|EXPERIMENTAL|G-Premio Bond with Additional Hydrophobic Adhesive Layer Application|"After selective etching is applied to the enamel surface, G-Premio Bond is applied according to the manufacturer's instructions. Heliobond is applied as an additional hydrophobic adhesive layer and restorations are completed with Clearfil Majesty ES-2.~G-Premio Bond: universal adhesive without HEMA Heliobond: hydrophobic adhesive with Bis-GMA and TEGDMA"
62227568|NCT05629481|EXPERIMENTAL|CO2 laser group|Participants in the CO2 laser group underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) treatment sessions with 4-6 weeks intervals.
62227569|NCT05629481|SHAM_COMPARATOR|Sham group|Participants in the sham group underwent three sham treatment sessions with 4-6 weeks intervals.
62420428|NCT05083091|ACTIVE_COMPARATOR|Monitor Only (MO-MBI)|14-day smartphone based mindfulness meditation training intervention consisting of a 5-minute introductory video, a 20-minute audio-guided lesson, plus daily life homework practice (3-10 minutes) each day.
62735301|NCT01732510|PLACEBO_COMPARATOR|Part 1: Placebo (pooled)|Dose-matched placebo administered IV every 2 weeks for a period of 12 weeks.
62227570|NCT03866304|EXPERIMENTAL|Picosecond Laser|Treatment with investigational wavelengths of the S2 laser for tattoo removal.
62227571|NCT03050255|EXPERIMENTAL|ESWT order 1|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~1. medical air (MA)~2. Oxygen (2 Liter/min)~3. Oxygen (4 Liter/min)"
62227572|NCT03050255|EXPERIMENTAL|ESWT order 2|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~1. medical air (MA)~2. Oxygen (4 Liter/min)~3. Oxygen (2 Liter/min)"
62735302|NCT01732510|EXPERIMENTAL|Part 2: MK-8226 3 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
62028786|NCT04240821|EXPERIMENTAL|Open-label theophylline|Oral theophylline - either once daily capsule or q6h elixir.
62590580|NCT05448417|ACTIVE_COMPARATOR|Bilevel positive pressure ventilation|Bilevel positive pressure ventilation Patients were titrated for relevant parameters of non-invasive ventilation the day before the trial. Noninvasive bilevel positive pressure ventilation mode pressure titration follows previous studies.
62590581|NCT01243216|EXPERIMENTAL|Ultrasound Group|Patients in the Ultrasound Group will have a pre-procedure ultrasound of the spine prior to needle placement
62590582|NCT01243216|NO_INTERVENTION|No Ultrasound Group|Patients in the No Ultrasound Group will not have a pre-procedure ultrasound of the spine performed prior to needle placement.
62590583|NCT01363752|ACTIVE_COMPARATOR|Advagraf + MMF + Steroids|Without sirolimus
62590584|NCT01363752|EXPERIMENTAL|Advagraf + MMF + Steroids + Sirolimus|With sirolimus; MMF withdrawn on Day 28; Sirolimus introduced on Day 28
62590585|NCT06203132|EXPERIMENTAL|Doravirine arm|Doravirine (100 mg) + tenofovir DF (300 mg) + lamivudine (300mg) administered daily
62420429|NCT05083091|ACTIVE_COMPARATOR|Coping Condition (CC)|14-day smartphone based training intervention focused on coping strategies consisting of a 5-minute introductory video, a 20-minute audio-guided lesson, plus daily life homework practice (3-10 minutes) each day.
62420430|NCT05350358||Patients who have undergone surgical treatment with LeMaitre Cardial Dialine II|Subject who has undergone surgical treatment for the replacement or bypass in aneurysmal and/or occlusive diseases and for arterial reconstruction in patients requiring systemic heparinization with LeMaitre Cardial Dialine II.
62420431|NCT06612255|EXPERIMENTAL|Regimen A then B: Delafloxacin Tablet then Powder|Participants will receive delafloxacin tablet in the fasted state, followed by delafloxacin powder in the fasted state.
62590586|NCT06203132|ACTIVE_COMPARATOR|Dolutegravir arm|Dolutegravir (50 mg) + tenofovir DF 300 mg + XTC (300 mg if lamivudine ou 200 mg if emtricitabine) administered daily
62590587|NCT00254176|ACTIVE_COMPARATOR|Cysteine|Subjects that receive cysteine
62803325|NCT00360412|EXPERIMENTAL|E2007|During the first two weeks of the study, Patients received 1 x 2mg E2007 tablet. At the week 2 visit, patients who tolerated the 2 mg/day dose were up-titrated to receive 4mg/day (2 x 2 mg E2007 tablets). Patients not tolerating the 4 mg dose were allowed to down titrate to 2 mg. Patients who did not tolerate the 2 mg dose were withdrawn from the study. Patients returned at week 4, if their tolerance to the 4 mg/day dose was acceptable they remained on this dose for the maintenance phase of the study. If at any time their tolerance declined, they were to return for an unscheduled visit and the daily dose was reduced to 2 mg. If at any stage, 2 mg day wass not tolerated, the patient was withdrawn from the study.
62803326|NCT03471247|EXPERIMENTAL|In-Bed Cycle Ergometer + Routine PT|Patients will receive 30 minutes of in-bed cycling once per day, 5 days per week, while they remain in the ICU, for up to a maximum of 28 days. They will also receive routine physiotherapy.
62590588|NCT00254176|PLACEBO_COMPARATOR|No-cysteine placebo|Subjects that do not receive cysteine but an isonitrogenous placebo
62590589|NCT05838430|EXPERIMENTAL|Solriamfetol+ CBT-I|
62590590|NCT05838430|EXPERIMENTAL|Solriamfetol Only|
62803327|NCT03471247|ACTIVE_COMPARATOR|Routine PT|Patients will receive routine physiotherapy interventions per current institutional practice
62803328|NCT01029184|ACTIVE_COMPARATOR|complete non allergenic cereals|existing commercialized product
62803329|NCT01029184|EXPERIMENTAL|complete non allergenic cereals plus|commercialised product with the addition of a novel ingredient
62420432|NCT06612255|EXPERIMENTAL|Regimen B then A: Delafloxacin Powder then Tablet|Participants will receive delafloxacin powder in the fasted state, followed by delafloxacin tablet in the fasted state.
62420433|NCT06612255|EXPERIMENTAL|Regimen C: Delafloxacin Powder|Participants will receive delafloxacin powder in fasted or fed states.
62420434|NCT06612255|EXPERIMENTAL|Regimen D (Optional): Delafloxacin Powder|Participants will receive delafloxacin powder in fasted or fed states.
62590591|NCT05838430|ACTIVE_COMPARATOR|Placebo + CBT-I|
62590592|NCT05838430|PLACEBO_COMPARATOR|Placebo Only|
62590593|NCT05365672|EXPERIMENTAL|MIC with low immunosuppression|"Patients in MIC Arm A receive the investigational medicinal product MIC plus immunosuppression consisting of tacrolimus, mycophenolic acid derivative and corticosteroids (without IL-2 receptor antibody induction therapy).~Tacrolimus dose will be gradually reduced to 4-8 μg/L at Day 183 and the corticosteroid treatment will be stopped at Day 92 after gradual dose reduction."
62028787|NCT04210687|ACTIVE_COMPARATOR|Trapeziectomy|Standard simple trapeziectomy, no pins.
62028788|NCT04210687|ACTIVE_COMPARATOR|trapeziometacarpal limited excision|Trapeziometacarpal limited excision; Narrow pseudarthrosis of the trapeziometacarpal joint.
62028789|NCT05408494|SHAM_COMPARATOR|Non-gamified program with sham ICT|One group will be assigned to a 12-month mobile weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets (to align with neurotraining and promote autonomy , and behavioral strategies with sham.
62227573|NCT03050255|EXPERIMENTAL|ESWT order 3|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~1. Oxygen (2 Liter/min)~2. Medical air (MA)~3. Oxygen (4 Liter/min)"
62590594|NCT05365672|EXPERIMENTAL|MIC with minimal immunosuppression|"Patients in MIC Arm B receive the investigational medicinal product MIC plus immunosuppression consisting of tacrolimus, mycophenolic acid derivative and corticosteroids (without IL-2 receptor antibody induction therapy).~Tacrolimus dose will be gradually reduced to 4-8 μg/L at Day 183 and the corticosteroid treatment will be stopped at Day 92 after gradual dose reduction.~The mycophenolic acid derivative will be stopped between Days 141 and 182."
62590595|NCT05365672|OTHER|Standard of care immunosuppression for transplantation|Patients of the Control Arm receive standard of care immunosuppression for kidney transplantations according to the Efficacy Limiting Toxicity Elimination (ELITE) symphony scheme (interleukin \[IL\]-2 receptor antibody induction therapy, tacrolimus, mycophenolic acid derivative and corticosteroids) without the investigational medicinal product MIC.
62735303|NCT01732510|PLACEBO_COMPARATOR|Part 2: Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
62735304|NCT05135559|EXPERIMENTAL|Concizumab-naïve patients|Concizumab-naïve participants below 12 years of age at the time of consent/assent
62227574|NCT03050255|EXPERIMENTAL|ESWT order 4|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~1. Oxygen (2 Liter/min)~2. Oxygen (4 Liter/min)~3. Medical air (MA)"
62803330|NCT03136471||EMR data extraction|"EMR Data extraction from the Louisiana Clinical Data Research Network (LaCDRN). The Louisiana Clinical Data Research Network (LaCDRN) data will be requested, including patients' records of pharmacy, inpatient, outpatient and lab results from January 01, 2016 to December 31, 2021. It is a retrospective data analysis without interaction with any participants. All data is de-identified and the study participants will not be contacted in any way.~Inclusion criteria: Patients with type 2 diabetes, whose age\>=18 years old will be extracted from database of LaCDRN.~Exclusion criteria: Patients without type 2 diabetes or age\<18 years old."
62803331|NCT03136471||Healthcare Professionals|"Healthcare professionals (physician, nurse) will be randomly selected from LaCDRN partner health system. An email will be distributed to the registered clinicians at partner health systems.~Inclusion criteria: physicians and nurses who treat diabetes patients and work at clinic settings within LaCDRN network and consent to participate the study.~Exclusion criteria: physicians and nurses who do not treat diabetes patients or not work at clinic settings within LaCDRN network; refuse to participate the study."
62803332|NCT03136471||Patients for Qualitative Study|"Patients with diabetes who are a members of Diabetes Advisory Group or partner LaCDRN health system will be contacted via email, letter or phone call.~Inclusion criteria:~* Diabetes patients who consent to participate the study.~* Age 65+;~* Diagnosis code for diabetes in the last 2 years;~* Diagnosis code for at least one additional chronic condition in the last 2 years.~Exclusion criteria: age\<65; patient with diabetes without other chronic conditions."
62803333|NCT03136471||LaCDRN partner health system's medical directors|Face-to-face semi-structured interviews will be used to explore organizational cultures, their social architecture, resources, capacity, communication networks, assess barriers, and refine the data collection for the assessing the RE-AIM framework. The one time interview will take 1 hour. A 10 minutes questionnaire of Diabetes care coordination readiness assessment (DCCRA) will be emailed to them annually during entire 5 years of study period.
62803334|NCT03136471||PROMIS® survey|"Patients for PROMIS® survey (National Institutes of Health's Patient-Reported Outcome Measurement Information System Global Health Measures). Patients will be administered the surveys at the point-of-care visit (in exam rooms) using REACHnet's tablet-based application.~Inclusion criteria:~* All patients age 18+ who registered at REACHnet.~* Able to provide informed consent~Exclusion criteria: patients who do not provide inform consent or age\<18 years old."
62803335|NCT03136471||PACIC+ survey|"Patients for PACIC+ survey (Group Health Research Institute's Patient Assessment of Care for Chronic Conditions+). Patients will be administered the surveys at the point-of-care visit (in exam rooms) using REACHnet's tablet-based application.~Inclusion criteria:~* All patients age 18+ with a Diabetes diagnosis and who registered at REACHnet.~* Able to provide informed consent~Exclusion criteria: patients who do not provide inform consent or without diabetes diagnosis or age\<18 years old"
62803336|NCT03136471||Telehealth Services using HCPCS/CPT for COVID-19 Patients|Study population with versus without telehealth services. Telehealth services using the HCPCS/CPT codes will be defined in the following categories: Medicare telehealth visits (CPT codes: 99201-99215; HCPCS codes: G0425-G0427, G0406-G0408), virtual check-in (HCPCS codes: G2010, G2012), and e-visits (CPT codes: 99421-99423, HCPCS codes: G2061-G2063). Propensity score-matching will be used to ensure comparison groups are comparable at baseline.
62803337|NCT01768507|PLACEBO_COMPARATOR|Placebo|no medication
62803338|NCT01768507|EXPERIMENTAL|Resveratrol|Trans-resveratrol (Resveratrol - Terraternal®): 5 g (10 capsules) as single oral dose on day 1 of the investigation period.
62227575|NCT03050255|EXPERIMENTAL|ESWT order 5|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~1. Oxygen (4 Liter/min)~2. Medical air (MA)~3. Oxygen (2 Liter/min)"
62420435|NCT06703073|EXPERIMENTAL|Cohort A: vilobelimab|
62420436|NCT06703073|PLACEBO_COMPARATOR|Cohort A: placebo|
62227576|NCT03050255|EXPERIMENTAL|ESWT order 6|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~1. Oxygen (4 Liter/min)~2. Oxygen (2 Liter/min)~3. Medical air (MA)"
62227577|NCT05432726||Elderly patients|Elderly patients (aged ≥65 year's old) planned to receive first-line chemotherapy for advanced solid tumor malignancies, presenting to the clinical oncology department, Assiut University Hospitals, Assiut, Egypt.
62227578|NCT02086123|ACTIVE_COMPARATOR|Epidural Analgesia|Subjects randomized to this arm will receive Bupivacaine + Fentanyl Epidural Analgesia. Subjects on this group could be allowed to receive Toradol Intravenously (IV) + Acetaminophen Orally (PO) if needed.
62227579|NCT02086123|ACTIVE_COMPARATOR|Parenteral Analgesia (Intravenous)|Subjects randomized to this arm will receive Analgesia with Dilaudid 0.2 -0.4 mg Intravenously (IV) every 3 hours. Subjects on this group could be allowed to receive Toradol Intravenously (IV) + Acetaminophen Orally (PO) if needed.
62227580|NCT02631512|OTHER|Woulgan Gel|Primary dressing with Woulgan Gel with Soluble Beta-Glucan (SBG)
62227581|NCT02631512|OTHER|Intrasite Hydrogel|Primary dressing with Intrasite Hydrogel
62803339|NCT03854058||OHS or elevated OHS-risk (stages 0-IV)|"stage 0: OHS-risk (OSA / no hypercapnia)~stage I: obesity associated hypoventilation (intermittent hypercapnia during sleep, arterial carbon dioxide partial pressure (PaCO2) or transcutaneous carbon dioxide partial pressure (PtcCO2) morning \~ evening), bicarbonate \< 27 mmol/L awake)~stage II: obesity associated hypoventilation (intermittent hypercapnia during sleep, PaCO2 or PtcCO2 morning \> evening, bicarbonate ≥ 27 mmol/L awake)~stage III: OHS (hypercapnia, carbon dioxide partial pressure (PCO2) \> 45 mmHg awake)~stage IV: OHS with end organ damage (hypercapnia , PCO2 \> 45 mmHg awake, cardiometabolic comorbidities)~diagnostic tests: magnetic phrenic nerve stimulation, diaphragmatic ultrasound"
62803340|NCT02816697|ACTIVE_COMPARATOR|Cease-Aim 1|"* Cease Implementation~* 100 Patients after CEASE Implementation~  * Exit Interview and Tobacco Use Survey"
62803341|NCT02816697|ACTIVE_COMPARATOR|Pre Cease Implementation Aim 2|"50 Current or former smokers (3 months +/-2 month) patients in usual care (before CEASE implementation)~* Tobacco Use Survey (Baseline,1- 6 Months)~* Biochemical verification"
62803342|NCT02816697|EXPERIMENTAL|After Cease Implementation Aim 2|"50 Current or former smokers (3 months +/-2 month)~* Tobacco Use Survey (Baseline,1- 6 Months)~* Biochemical verification"
62803343|NCT02816697|ACTIVE_COMPARATOR|Usual Care-Aim 1|"Usual Care Tobacco Treatment Services~* 100 patients in usual care~* Exit Interview and Tobacco Use Survey"
62803344|NCT02816697|NO_INTERVENTION|Clinician and Staff Survey|- Interview clinicians and support staff (40)
62803345|NCT03650491|EXPERIMENTAL|Experimental: FOR46 (Dose Escalation)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
62803346|NCT03650491|EXPERIMENTAL|Experimental: FOR46 (Dose Expansion)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
62803347|NCT02043353||Winter Vs. Summer|All children that underwent PSG evaluation at the Tel Aviv Medical center between 2005-2010
62803348|NCT02043353||Primary snoring|All children that were diagosed with primary snoring at the Tel Aviv Medical center between 2005-2010
62803349|NCT02043353||Adenotonsillectomy Vs. Adenoidectomy|All children that underwent adenotonsillectomy or tonsillectomy at the Tel Aviv Medical center between 2005-2008
62803350|NCT02043353||repeated PSG|All children that underwent Adenoidectomy / Adenotonsillectomy and two PSG evaluations at the Tel Aviv Medical center between 2005-2012
62803351|NCT03073239||ALS epidemiological characterization|epidemiological characterization
62803352|NCT03073239||Genetic findings in ALS patients|genética characterization
62803353|NCT00670280|EXPERIMENTAL|Intervention Group|Those randomized to the Intervention group will meet twice over a two-week period with a trained counselor while visiting the neonatal intensive care unit.
62803354|NCT00670280|ACTIVE_COMPARATOR|UC Group|Those randomized to the Usual Care group will receive written information on secondary smoke and infant health and will be assessed at 1 month, 3 months, and 6 months post-intervention.
62803355|NCT00670280|ACTIVE_COMPARATOR|UC-RM Group|Those randomized to the Usual Care - Reduced Measurement group will receive the same information as the Usual Care group but will be measured less often (only at 6 months post-intervention).
62803356|NCT04452630||Covid 19 Patients|patients having presented an episode of Covid-19 diagnosed by at least one positive nasopharyngeal RT-PCR test for SARS-Cov-2 and considered recovered.
62803357|NCT01135134|EXPERIMENTAL|Mometasone furoate nasal spray (MFNS) (50 μg spray device)|"The dose will be as follows:~* 5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks"
62803358|NCT01135134|PLACEBO_COMPARATOR|MF placebo nasal spray|"Administration will be as follows:~* 5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks"
62803359|NCT01527123|EXPERIMENTAL|GSK2585823|External Preparation
62803360|NCT03458312|NO_INTERVENTION|Family and Network support measurements|"The perceived 'Family support' and 'Caregiver burden' (FNC) will be measured among 30 families.~Test time points:~Post 1. FNC (week 1-2), post FNC 2 (week 8-10) and post FNC 3 (week 28-30) and post the 4. FNC (week 50-52)"
62227582|NCT00390182|EXPERIMENTAL|Single Arm|"Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.~Radiation: External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy."
62227583|NCT05745831|EXPERIMENTAL|Women with a less active ectopic pregnancy using a therapeutic decision tool for treatment decision|Women will have a therapeutic decision tool to help medical decision making and women and doctors will have to fill a questionnaire about the tool and the decision made
62227584|NCT03107104||Medical need for FA imaging|Subjects deemed to have a medical need for FA imaging will be imaged on the Topcon DRI OCT Triton (plus) and TRC-50DX retinal camera
62227585|NCT03785171||Moyamoya disease|The cohort includes patients with Moyamoya disease diagnosed by DSA examination who are treated by surgical revascularization.
62028790|NCT05408494|ACTIVE_COMPARATOR|Non-gamified program with Active ICT|One group will be assigned to a 12-month mobile weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets (to align with neurotraining and promote autonomy , and behavioral strategies with active neurotraining.
62028791|NCT05408494|EXPERIMENTAL|Gamified program with sham ICT|One group will receive fully-gamified version of the program with a sham.
62028792|NCT05408494|EXPERIMENTAL|Gamified program with Active ICT|One group will receive fully-gamified version of the program with active neurotraining.
62028793|NCT04797858|EXPERIMENTAL|Self-Test kit distribution|Participants in the self-test arm receive multiple COVID-19 self-test kits to distribute to others in their social networks.
62028794|NCT04797858|ACTIVE_COMPARATOR|Test referral distribution|Participants in the test referral arm receive multiple COVID-19 test referral cards and text messages to distribute to others in their social networks.
62420437|NCT06703073|EXPERIMENTAL|Cohort B: paridiprubart|
62590596|NCT00729157|EXPERIMENTAL|Treatment (ziv-aflibercept and fludeoxyglucose F 18)|Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients experiencing clear clinical benefit with aflibercept may continue treatment beyond 12 months, at the discretion of the study sponsor. Patients undergo FDG-PET scans at baseline and after 8 weeks of study therapy to evaluate changes in FDG avidity on FDG-PET scan. Blood samples are obtained at baseline and periodically during study for laboratory correlative studies. Samples are examined for pretreatment serum VEGF concentration, thyroglobulin levels (when elevated), serum pharmacokinetics of aflibercept by ELISA, and anti-aflibercept antibodies.
62028795|NCT01949480|ACTIVE_COMPARATOR|Traditional approach paravertebral nerve block|After final needle placement, a hanging drop technique will be used to rule out intrapleural placement while the patient inhales and exhales deeply. After correct needle placement, 10 mL of 0.5% Ropivacaine will be injected incrementally through each needle after negative aspiration, followed by insertion of the nerve block catheter to a depth 5 cm beyond the tip of the needle. An additional 10 mL of 0.5% Ropivacaine will then be injected in 5 mL increments with negative aspiration in between, through the catheter yielding a total activation dose of 20 ml of 0.5% Ropivacaine. The catheter will be secured with Steri-strips and a transparent occlusive dressing.
62028796|NCT01949480|EXPERIMENTAL|Ultrasound assisted paravertebral nerve block|The 22 gauge catheter will be threaded through the needle and placed at previously found distance to paravertebral space on obtained ultrasound image. An additional 10 ml of 0.5% Ropivacaine will be administered through the catheter yielding a total activation dose of 20 ml of 0.5% Ropivacaine. The catheter will be secured with Steri-strips and a transparent occlusive dressing.
62028797|NCT03116139|NO_INTERVENTION|Low risk for kidney injury with use of CT|No randomization due to low risk for kidney injury. 100 patients undergoing CTPA with an estimated risk of CIN \<10% (CINRisk Score \<2)
62028798|NCT03116139|ACTIVE_COMPARATOR|Randomized to V/Q|300 patients with \> 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to VQ imaging (unexposed control)
62028799|NCT03116139|ACTIVE_COMPARATOR|Randomized to CT|300 patients with \> 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to CT (exposure to iodinated contrast media)
62028800|NCT05218005|NO_INTERVENTION|Observation|Those admitted in the first 6 months of the study that meet the inclusion criteria. Patients will be treated according to the normal standard of care for acute coronary syndrome.
62028801|NCT05218005|EXPERIMENTAL|Active-testing|Those admitted between 6-18 months of the study meeting the inclusion criteria. Saliva samples will be collected for DNA testing.
62028802|NCT05035719||Group 1|Cardiac patients
62028803|NCT05518929|ACTIVE_COMPARATOR|Control group(Propofol group)|Anesthesia induction:Propofol 1.5mg/kg Anesthesia maintenance: Propofol 0.75mg/kg
62028804|NCT05518929|EXPERIMENTAL|Experimental group(ciprofol group)|Anesthesia induction:ciprofol 0.4mg/kg Anesthesia maintenance: ciprofol 0.2mg/kg
62028805|NCT03564379|EXPERIMENTAL|Part 1: Single Dose Part|Participants will receive a single oral dose of 25 mg JNJ-42165279 or placebo tablet under fasted condition in the morning on Day 1.
62028806|NCT03564379|EXPERIMENTAL|Part 2: Multiple Dose Part|After a washout period of at least 10 days, same participants from Part 1 will receive multiple daily dosing of 25 mg JNJ-42165279 or placebo tablet for 10 days.
62028807|NCT02824913|EXPERIMENTAL|P-321 Ophthalmic Solution|0.017% P-321 Ophthalmic Solution will be administered to approximately 8 patients in Phase I and either 0.05% P-321 Ophthalmic Solution or 0.01% P-321 Ophthalmic Solution or additional 0.017% P-321 Ophthalmic Solution will be administered to approximately 16 patients in Phase II
62420438|NCT06703073|PLACEBO_COMPARATOR|Cohort B: placebo|
62420439|NCT06703073|EXPERIMENTAL|Cohort C: bevacizumab|
62590597|NCT01698242|EXPERIMENTAL|Enhanced Training|The Enhanced Training intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. Randomization occurs at the PCP-level, that is, patients are assigned to the Enhanced Training group only if their PCP has been enrolled and randomized to this group. Descriptions of the intervention on the PCP-level and patient-level are provided in the intervention section.
62590598|NCT01698242|ACTIVE_COMPARATOR|Enhanced Education|The Enhanced Education intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention strategy revolves around providing nominal information through the mail. Randomization occurs at the PCP-level; that is, patients are assigned to the Enhanced Education group only if their PCP already has been enrolled and randomized to this group. Description of the intervention on the PCP-level and patient-level is provided in the intervention section.
62227586|NCT02224677||Children with Craniofacial Microsomia|125 children with craniofacial microsomia will be asked to come in for two study visits - when they are about 12 months old and again when they are about 36 months old. Procedures for children at the first visit include: assessment of development, video, photographs, and a hearing evaluation. Procedures for the final study visit include: assessment of development, photographs (2D \& 3D), video, saliva sample, hearing evaluation, speech assessment.
62227587|NCT02224677||Children without Craniofacial Microsomia|Please note: we are not recruiting this group through ClinicalTrials.gov 100 children without craniofacial microsomia will be asked to come in for two study visits - when they are about 12 months old and again when they are about 36 months old. Procedures for the first visit include: assessment of development, video, and photographs. Procedures for the final study visit include: assessment of development, photographs (2D \& 3D), video, and speech assessment.
62420440|NCT06703073|PLACEBO_COMPARATOR|Cohort C: placebo|
62420441|NCT06297941|EXPERIMENTAL|REM-422|"Dose Escalation: Participants will receive escalating doses of REM-422 to determine Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)-422, oral capsule administered once daily~Dose Expansion: Participants will receive REM-422 at the identified RP2D Treatment will continue until disease progression, therapy intolerance, or participant withdrawal Safety evaluation will continue until 30 days of last administration of REM-422"
62420442|NCT06123494|EXPERIMENTAL|SHR-A1811|
62420443|NCT06123494|ACTIVE_COMPARATOR|The investigators' choice|
62420444|NCT06701396|EXPERIMENTAL|Tasimelteon|
62420445|NCT06701396|PLACEBO_COMPARATOR|Placebo|
62420446|NCT06038149||Low PH probability|Individuals identified as being of a low risk of pulmonary hypertension on routine echocardiography through existing British Society of Echocardiography/ European Society of Cardiology guidelines will undergo a research echocardiogram on the day of their planned right heart catheter.
62420447|NCT06038149||Intermediate PH probability|Individuals identified as being of an intermediate risk of pulmonary hypertension on routine echocardiography through existing British Society of Echocardiography/ European Society of Cardiology guidelines will undergo a research echocardiogram on the day of their planned right heart catheter.
62420448|NCT04264273||Participants with Parkinson´s disease.|Participants who fulfilled the diagnostic criteria of Parkinson´s disease.
62590599|NCT04349462|OTHER|VFSS and Water Sip Test|Enrolled patients will undergo a water sip test and Videofluroscopy Swallow Test (VFSS)
62803361|NCT03458312|EXPERIMENTAL|Family and network consultations|Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns.
62803362|NCT02724098|ACTIVE_COMPARATOR|intravenous|1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) diluted in 10 ml of sodium chloride will be administered intravenously in 10 min at a constant rate using an infusion pump.
62803363|NCT02724098|ACTIVE_COMPARATOR|subcutaneous|1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) will be administered subcutaneously undiluted.
62803364|NCT05898217|ACTIVE_COMPARATOR|Dairy Milk|Participants will drink 16 oz of dairy milk daily for the duration of the study.
62803365|NCT05898217|ACTIVE_COMPARATOR|Soy Milk|Participants will drink 16 oz of soy milk daily for the duration of the study.
62227588|NCT02224677||Parents of Children with Craniofacial Microsomia|125-250 parents of children with craniofacial microsomia will be asked to complete three visits - when their child is about 12 months old, 24 months old, and 36 months old. Parents will be asked to complete an interview at the first visit. The second visit consists of a telephone interview where parents will be asked about their child's hearing and health history. At the final study visit, parents will be asked to complete more questionnaires, have their picture taken, and donate saliva.
62227589|NCT02224677||Parents of Children without Craniofacial Microsomia|Please note: we are not recruiting this group through ClinicalTrials.gov 100 parents of children without craniofacial microsomia will be asked to complete three visits - when their child is about 12 months old, 24 months old, and 36 months old. Parents will be asked to complete an interview at the first visit. The second visit consists of a telephone interview where parents will be asked about their child's hearing and health history. At the final study visit, parents will be asked to complete questionnaires and an interview.
62420449|NCT04264273||Participants without a neurological disease|25 neurologically healthy patients of the local otolaryngological clinic, in whom submandibular gland needle biopsy was performed due to a clinical indication.
62420450|NCT00005879|PLACEBO_COMPARATOR|Placebo|Placebo
62590600|NCT02130804|EXPERIMENTAL|Salsalate|Salsalate (4 g/day)
62590601|NCT02130804|PLACEBO_COMPARATOR|Placebo|Placebo (4 g/day)
62590602|NCT01663779|EXPERIMENTAL|Ultrasound radial artery catheter|Ultrasound guided radial artery catheterization.
62590603|NCT01663779|ACTIVE_COMPARATOR|Palpation based artery catheterization|Blind insertion of radial artery catheterization
62227590|NCT02224677||Teacher/Day Care Provider|When the children participants are around 36 months old, we will ask parents for permission to contact their child's teacher/day care provider. We would like the teacher/day care provider to fill out a questionnaire.
62227591|NCT04595383|NO_INTERVENTION|Control|Usual care and usual communication with health professional
62227592|NCT04595383|EXPERIMENTAL|Intervention|They will be trained to use the ti.care platform and will be able to use it as a communication channel for any questions or clarification they require during the time elapsed between routine control visits. This platform will be a complement to the visits, but in no case will it replace them or be used as a diagnostic or therapeutic method. The platform does not have any treatment algorithm and only aims to facilitate communication between the patient at home and the health professional, both the doctor and the nurse educator. It will be used in a preventive and advisory manner for the patient for follow-up. In no case it will be used for emergencies. Daily during working hours from Monday to Friday, health professionals will review patient requests and respond to them.
62227593|NCT04288765|EXPERIMENTAL|Group A - Non transplant|Carfilzomib Lenalidomide Daratumumab Dexamethasone
62420451|NCT00005879|EXPERIMENTAL|Arzoxifene|LY353381, 20 mg daily
62420452|NCT05292313|OTHER|Single distal femur implant|Single implant constructs will be either a retrograde intramedullary nail with interlocking screws or a single plate and screw construct.
62420453|NCT05292313|OTHER|Dual distal femur implants|Dual implant constructs will either be an intramedullary nail with an additional plate and screw construct or dual (two plates in any orientation) plate and screw construct.
62420454|NCT00128518|EXPERIMENTAL|Group A : T1+P2 ● P1+P2 ● T2+P1 ● P1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
62420455|NCT00128518|EXPERIMENTAL|Group B : P1+P2 ● T1+P2 ● P1+P2 ● T2+P1|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
62420456|NCT00128518|EXPERIMENTAL|Group C : T2+P1 ● P1+P2 ● T1+P2 ● P1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
62420457|NCT00128518|EXPERIMENTAL|Group D : P1+P2 ● T2+P1 ● P1+P2 ● T1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
62420458|NCT06463756||training cohort|No interventions
62803366|NCT05898217|ACTIVE_COMPARATOR|Almond Milk|Participants will drink 16 oz of almond milk daily for the duration of the study.
62803367|NCT05898217|ACTIVE_COMPARATOR|Oat Milk|Participants will drink 16 oz of oat milk daily for the duration of the study.
62803368|NCT02541812|EXPERIMENTAL|Patients|Ten sessions of 1Hz repetitive Transcranial Magnetic Stimulation of the dorsal anterior cingulate cortex in patients with obsessive compulsive disorder
62803369|NCT02541812|ACTIVE_COMPARATOR|Healthy Control Subjects|One session of 1Hz repetitive Transcranial Magnetic Stimulation of the dorsal anterior cingulate cortex in healthy control individuals
62420459|NCT06463756||internal validation cohort|No interventions
62420460|NCT06463756||external validation cohort|No interventions
62420461|NCT06610279|PLACEBO_COMPARATOR|Part 1: Pooled Placebo|Participants will receive a single SC dose of TAK-951 matching placebo on Day 1.
62420462|NCT06610279|EXPERIMENTAL|Part 1, Cohort 1: TAK-951 Dose 1|Participants will receive a single SC dose of TAK-951 Dose 1 on Day 1.
62420463|NCT06610279|EXPERIMENTAL|Part 1, Cohort 2: TAK-951 Dose 2|Participants will receive a single SC dose of TAK-951 Dose 2 on Day 1.
62420464|NCT06610279|EXPERIMENTAL|Part 1, Cohort 3: TAK-951 Dose 3|Participants will receive a single SC dose of TAK-951 Dose 3 on Day 1.
62420465|NCT06610279|EXPERIMENTAL|Part 1, Cohort 4: TAK-951 Dose 4|Participants will receive a single SC dose of TAK-951 Dose 4 on Day 1.
62420466|NCT06610279|EXPERIMENTAL|Part 1, Cohort 5: TAK-951 Dose 5|Participants will receive a single SC dose of TAK-951 Dose 5 on Day 1.
62420467|NCT06610279|EXPERIMENTAL|Part 1, Cohort 6: TAK-951 Dose 6|Participants will receive a single SC dose of TAK-951 Dose 6 on Day 1.
62803370|NCT05339022|EXPERIMENTAL|Arm I (ROAR-LCT intervention)|Patients receive ROAR-LCT intervention weekly for 12 weeks consisting of physical therapy visits and an exercise intervention. Patients also undergo progressive muscles relaxation exercises over 20 minutes for 12 weeks.
62803371|NCT05339022|ACTIVE_COMPARATOR|Arm II (standard of care)|Patients receive standard of care for 12 weeks.
62420468|NCT06610279|EXPERIMENTAL|Part 2: TAK-951 Multiple Rising Doses|Participants will receive multiple rising SC doses of TAK-951 twice daily (BID) or 3 times a day (TID) in Part 2.
62420469|NCT06610279|EXPERIMENTAL|Part 3: TAK-951 Multiple Dose Titration|Participants will receive multiple rising SC doses of TAK-951 once daily (QD), BID, or TID from Days 1 to 5 followed by a washout period of 2 to 7 days and a single redose on any day from Days 8 to 13 in Part 3.
62420470|NCT04451109||Cases in which Dilapan-S was used for cervical ripening.|Every participating site will select 50 cases of pregnant women who underwent cervical ripening by Dilapan-S prior to induction of labor. These cases has to fulfill inclusion/exclusion criteria defined in the protocol.
62590604|NCT03186274|NO_INTERVENTION|Control Group|Those in the control group (CG) will write a pre and post-study reflection essay discussing their experiences with end of life discussions.
62590605|NCT03186274|EXPERIMENTAL|Facilitated Group Session|Participants in Facilitated Group Session (previously called Intervention Group 1) will watch a pre-recorded video describing the SPIKES model and then take part of a facilitated guided group session reviewing the model and group interview of standardized/simulated patient encounter.
62590606|NCT03186274|EXPERIMENTAL|CELA Session|Participants in the CELA Session (previously called Intervention Group 2) will watch a pre-recorded video describing the SPIKES model and then participate in an individualized standardized/simulated patient scenario that will be filmed at the Center for Experiential Learning and Assessment (CELA).
62590607|NCT04002882||Subjects with Cystic Fibrosis|n=60 patients with CF ages 16-30
62420471|NCT04057118|EXPERIMENTAL|SKI-O-703 100 mg|
62420472|NCT04057118|EXPERIMENTAL|SKI-O-703 200 mg|
62420473|NCT04057118|EXPERIMENTAL|SKI-O-703 400 mg|
62420474|NCT04057118|PLACEBO_COMPARATOR|Placebo|
62420475|NCT06575270||Pediatric Patients with Congenital Heart Disease|No intervention will take place in this observational study. All patients will have their skin pigment measured using a color spectrophotometer and color matching techniques (Fitzpatrick Scale, Monk Skin Tone Scale). Two pulse oximeters will be utilized and pulse oximeter readings will be compared to simultaneous measured arterial saturations. After cardiopulmonary bypass is initiated for the surgery, the subject's involvement in the study will be completed.
62420476|NCT06693336|EXPERIMENTAL|Dose Escalation and Confirmation|All participants will receive a one-time administration of SMS001 undergoing their scheduled lung cancer surgery. Participants are given SMS001 and are watched very closely for side effects. If the side effects are manageable, then more participants are asked to join the study and are given a higher dose of SMS001, until a pre-defined suitable dose is reached.
62590608|NCT04002882||Healthy Controls|n=30 healthy controls matched to participants with CF for age, sex, BMI, and race.
62590609|NCT02233920||Chronic obstructive bronchitis patients|
62590610|NCT05981261|OTHER|Experimental pain|Experimental pain
62590611|NCT05918484||Type 1 diabetes patients|All type 1 diabetes patients using intermittently scanned continuous glucose monitoring (isCGM) in Castilla-La Mancha (Spain).
62590612|NCT02416882|OTHER|Aerobic Exercise vs Sedentary Option|Relative Reinforcing Value of aerobic exercise versus sedentary activity will be determined.
62590613|NCT02416882|OTHER|Resistance Exercise vs Sedentary Option|Relative Reinforcing Value of resistance exercise versus sedentary activity will be determined.
62590614|NCT02980341|EXPERIMENTAL|Dose Escalation Part|Participants receive U3-1402 from 1.6 mg/kg to 8.0 mg/kg, administered via intravenous (IV) solution at 3-week intervals.
62590615|NCT02980341|EXPERIMENTAL|Dose Finding Part|Participants receive 1 of 5 different U3-1402 dosing regimens, administered via IV solution at 2 or 3-week intervals at doses at or lower than those studied in the Dose Escalation Part.
62590616|NCT02980341|EXPERIMENTAL|Dose Expansion Part|Participants with HER3 high, HER2 negative, HR positive status receive 4.8 mg/kg or 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals. Participants with HER3 low, HER2 negative, HR positive status receive 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals. Participants with HER3 high, HER2 negative, HR negative status receive 6.4 mg/kg of U3-1402 administration via intravenous (IV) solution at 3-week intervals.
62590617|NCT05793879|EXPERIMENTAL|Video 360|"Patients will watch spherical videos displaying everyday actions towards objects; an audio is embedded describing the action and the object represented (i.e. I'm cutting the potatoes)."
62590618|NCT05793879|ACTIVE_COMPARATOR|Standard video|"Patients will watch standard videos displaying everyday actions towards objects; an audio is embedded describing the action and the object represented (i.e. I'm cutting the potatoes)"
62590619|NCT04529785|ACTIVE_COMPARATOR|SVC only|Patients in Group 1 will receive an SVC isolation only
62803372|NCT02201680||parents and children|Anxiety tests
62590620|NCT04529785|ACTIVE_COMPARATOR|SVC isolation with substrate modification and VoM inf|Patients in Group 2 will receive an SVC isolation with substrate modification and vein of Marshal ethanol infusion
62590621|NCT06460883|EXPERIMENTAL|eccentric cable leg curls|Group A players will perform eccentric cable leg curls
62227594|NCT04288765|ACTIVE_COMPARATOR|Group B - transplant|Carfilzomib Lenalidomide Daratumumab Dexamethasone Autologous stem cell transplantation (ASCT)
62227595|NCT00889668|EXPERIMENTAL|Experimental|subjects with a diagnosis of type 1 or 2 diabetes; GlucoTrack results will be compared with the readings from approved invasive glucose meter device.
62420477|NCT01838863|EXPERIMENTAL|Plasma|If the patient is randomized to experimental arm, 2 units of frozen type AB plasma (FP24) will be thawed in the Plasmatherm Dry Thawing and Warming Device according to the operator manual as approved by the FDA in the ambulance and infusion will commence as soon as the type AB plasma is ready, and will continue during transport to the emergency department (ED). After infusion of 2 units of type AB plasma is completed, subsequent care will proceed per institutional, Advanced Trauma Life Support (ATLS) guided resuscitation with acute packed red blood cells (pRBC) administration determined by the hemodynamic response and additional blood component administration guided by rapid thrombelastography (rTEG) and coagulation panel assessment in conjunction with clinical scenario.
62590622|NCT06460883|ACTIVE_COMPARATOR|eccentric banded leg curls|Group A players will perform eccentric banded leg curls
62803373|NCT05583123|EXPERIMENTAL|OPZAs group (OG)|one-piece zirconia abutments (OPZAs)
62590623|NCT05827042|EXPERIMENTAL|Endovascular thrombectomy alone|Patients will receive endovascular thrombectomy without intravenous thrombolysis.
62803374|NCT05583123|ACTIVE_COMPARATOR|TPZAs group (TG)|two-piece zirconia abutments (TPZAs) with friction-fitted titanium bases
62590624|NCT05827042|ACTIVE_COMPARATOR|Intravenous thrombolysis plus endovascular thrombectomy|Patients will receive intravenous alteplase (0.9mg/kg, maximum 90mg) or tenecteplase (0.25mg/kg, maximum 25mg) before endovascular thrombectomy.
62590625|NCT01671046||Cohort|
62803375|NCT03071263|EXPERIMENTAL|Group 1 - Patiromer|spironolactone + blinded patiromer
62803376|NCT03071263|EXPERIMENTAL|Group 2 - Placebo|spironolactone + blinded placebo
62803377|NCT04641845|EXPERIMENTAL|Heel height increases|All participants consecutively walked with four heel height conditions (0 millimeter, 3 millimeter, 5 millimeter and 8 millimeter). The order of the heel height conditions was randomized.
62227596|NCT06327932|ACTIVE_COMPARATOR|Matched control|Patients undergo Transurethral Resection of Bladder Tumors (TURBT) and receive Intravesical Chemotherapy.
62227597|NCT06327932|EXPERIMENTAL|HIVEC|Patients undergo Transurethral Resection of Bladder Tumors (TURBT) and Hyperthermic Intravesical Chemotherapy (HIVEC)
62227598|NCT01848951||Epidural|The skin will be disinfected with 2% chlorhexidine. Under sterile technique, the epidural will be placed. Epidural catheter will be placed at thoracic vertebral levels T5 to T10. Level chosen as clinically indicated. The epidural solution should contain institution's standard solution of Bupivicaine 0.05% and hydromorphone 10 mcg/cc. However, solution type should be clinically indicated.
62420478|NCT01838863|ACTIVE_COMPARATOR|Standard|If the patient is randomized to the standard arm, the patient will be given intravenous crystalloid fluid (normal saline) as the initial resuscitation fluid with 2 large bore IVs based on the current ATLS guidelines, the standard of care. Subsequent care will proceed per institutional, ATLS guided resuscitation with acute packed red blood cells pRBC administration determined by the hemodynamic response and additional blood component administration guided by rTEG and coagulation panel assessment in conjunction with clinical scenario.
62420479|NCT02470962||Patients with muscular dystrophy|Boys aged 8 to 18 years with muscular dystrophy of the Duchenne / Becker type
62590626|NCT03808597|EXPERIMENTAL|Intervention group|The participants in this group will be exposed to digital health promotion. Please note that the participants are not randomly chosen, but stratified after the project villages. The participants in this group belong to the villages: Izazi and Migoli.
62590627|NCT03808597|NO_INTERVENTION|Control group|"The participants in this group will be not be exposed to digital health promotion, but the villages will receive the intervention after one year. Please note that the participants are not randomly chosen, but stratified after the project villages.~The participants in this group belong to the villages: Kimande and Idodi."
62590628|NCT04815265|EXPERIMENTAL|Experimental group|Participants in the experimental group received remimazolam for sedation
62803378|NCT03501563||Case Group|"Participants with ASA 1-2, aged 18-60 years, undergoing hypotensive anesthesia in the operation of the septoplasty in Recep Tayyip Erdoğan University Medical Faculty Training and Research Hospital. Participants with uncontrolled hypertension, diabetes mellitus, cerebrovascular disease, cogulopathy, morbid obesity (BMI ≥35) and renal disease will not be taken.~Participants were first pre-medicated with an infusion of midazolam 0.05 mg/kg, fentanyl 1 µg/kg, lidocaine 1 mg/kg. Induction of anesthesia was achieved with an infusion of propofol 1-2 mg/kg and vecuronium bromide 0.6 mg/kg and after 2 to 3 minutes participants were intubated with the appropriate tube size. Anesthesia was maintained with an infusion of remi fentanyl (0.05 - 1 µg/Kg/min), with oxygen (O2) in air with desflurane."
62803379|NCT01082835||the group of Jiangzhuo Qinggan prescription|
62803380|NCT01082835||the group of irbesartan|
62803381|NCT01111708|EXPERIMENTAL|Close Rectal-Ileo Pouch Anal Anastomosis|
62803382|NCT01111708|ACTIVE_COMPARATOR|Conventional Ileo Pouch Anal Anastomosis|
62803383|NCT01111708|ACTIVE_COMPARATOR|Ileo Neo Rectal Anastomosis|
62227599|NCT01848951||TAP Block|The skin will be disinfected with 2% chlorhexidine. The bilateral dual TAP infiltrative blocks will be placed using high-frequency ultrasound. The TAP blocks will be performed using lipospheric bupivacaine (Exparel) with the following dosing regimen.A 266mg (20cc) vial of lipospheric bupivacaine will be equally into 2 30 ml syringes using strict sterile technique. The solution will be diluted in each syringe with 20cc preservative free sterile 0.9% normal saline to a total volume of 30 ml in each syringe. Once the transversus abdominal plane is identified then a 5-10 ml of plain 0.9% normal saline will be injected to open the fascial plane. Once the plane is opened then the 15cc of diluted lipospheric bupivacaine will be administered under direct ultrasound visualization in all 4 TAP quadrants (subcostal position x2 and lateral position x2)
62420480|NCT02470962||Children without heart disease|Children without heart disease, aged 8-18 years, as CMR comparison group
62803384|NCT06155422||Cadonilimab-treated Recurrent or Metastatic Cervical Cancer|
62803385|NCT00325715|EXPERIMENTAL|1|
62803386|NCT00325715|ACTIVE_COMPARATOR|2|
62803387|NCT02336607|EXPERIMENTAL|Felodipine tablet (Plendil)|
62803388|NCT02336607|ACTIVE_COMPARATOR|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|
62803389|NCT02336607|ACTIVE_COMPARATOR|Felodipine tablets (Plendil)+Lisinopril (Zestril)|
62803390|NCT02336607|ACTIVE_COMPARATOR|Felodipine tablet (Plendil)+Hydrochlorothiazide|
62803391|NCT00363844|EXPERIMENTAL|E|
62803392|NCT02961959|EXPERIMENTAL|Surgery|Arthrodesis of SI-joint/s, physiotherapy
62803393|NCT02961959|ACTIVE_COMPARATOR|Non-surgery|Non-surgery, physiotherapy
62803394|NCT05711043|EXPERIMENTAL|Intervention group|Endoscopic sutured gastroplasty with endomina device
62803395|NCT05711043|NO_INTERVENTION|Control group|Standard diabetes care
62803396|NCT03626259|OTHER|losartan and amlodipine|Individuals with SAH grade 1 or 2 without triple pharmacological therapy.
62803397|NCT03626259|ACTIVE_COMPARATOR|Losartan|Individuals with SAH grade 1 or 2 without triple pharmacological therapy.
62803398|NCT03959163|OTHER|DMSA/Quick MRI|All participants will go through DMSA and Quick MRI scan to help determine the validity of the Quick Renal MRI in pediatric kidney disease.
62803399|NCT00362648|EXPERIMENTAL|1|RotaTeq™
62803400|NCT00362648|PLACEBO_COMPARATOR|2|Placebo
62803401|NCT02572323|ACTIVE_COMPARATOR|Immediate group|1.4mg of tesamorelin is injected once a day for 6 months, then no treatment is given for 6 months
62803402|NCT02572323|PLACEBO_COMPARATOR|Deferred group|No treatment is given for 6 months, then 1.4mg of tesamorelin is injected once a day for 6 months
62803403|NCT00726414|EXPERIMENTAL|Quinine Sulfate Capsules 2 x 324 mg Capsules - Fasting|A single dose of Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
62227600|NCT01750203||No treatment|No cohort as this study is not using a treatment or intervention only swabs are being collected.
62420481|NCT06143683|EXPERIMENTAL|Early Mobilization|
62420482|NCT06143683|ACTIVE_COMPARATOR|Usual Care|
62420483|NCT00664417|EXPERIMENTAL|1|
62420484|NCT00664417|EXPERIMENTAL|2|
62803404|NCT00726414|EXPERIMENTAL|Quinine Sulfate Capsules 2 x 324 mg Capsules - Fed|A single dose of Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
62420485|NCT00664417|EXPERIMENTAL|3|
62420486|NCT00664417|EXPERIMENTAL|4|
62420487|NCT00664417|EXPERIMENTAL|5|
62420488|NCT00664417|EXPERIMENTAL|6|
62420489|NCT00664417|ACTIVE_COMPARATOR|7|
62420490|NCT00664417|ACTIVE_COMPARATOR|8|
62420491|NCT00664417|PLACEBO_COMPARATOR|9|
62420492|NCT03932838|EXPERIMENTAL|clinical and radiologic evaluation|Follow up post surgery: clinical and radiologic evaluation
62803405|NCT03653858|EXPERIMENTAL|Group A: DBS onset in week 1|"Implantation of Vercise GEVIA deep brain stimulation (DBS) system. DBS onset in week 1.~2ND STAGE: After 6 months DBS ON, patients will be assessed whether they are responders or non-responders. In the subgroup of eligible responders, patients will be randomized to either DBS OFF\* (for max. 3 months) or continued DBS for another 6 months. \*DBS OFF until worsening of clinical depression, event (defined as \> 5 points augmentation in MADRS in two consecutive visits) or for a maximum of 3 months. After DBS OFF, re-onset of DBS will be performed, followed by 6 months continuous DBS.~Non-responders will also receive another 6 months DBS therapy in the 2nd stage. At sites other than Freiburg/Bonn, the 2nd stage consists of 6 months DBS therapy only."
62803406|NCT03653858|SHAM_COMPARATOR|Group B: DBS off, followed by DBS onset in week 17|"Implantation of Vercise GEVIA deep brain stimulation (DBS) system. 4 months OFF after implantation followed by DBS onset in first week of month 5.~2ND STAGE: See group A."
62803407|NCT00988598|ACTIVE_COMPARATOR|PF-04447943|
62803408|NCT00988598|PLACEBO_COMPARATOR|Placebo|
62803409|NCT04190914|ACTIVE_COMPARATOR|necrotic primary molar treated with pulpectomy followed by SSC|control group treated by pulpectomy under rubber dam isolation access cavity will be prepared by a round bur then filling and irrigation will be performed and the tooth will be restored with a temporary filling. After one week all signs and symptoms will be assessed in case of absence of signs and symptoms the tooth will be restored with zin oxide and eugenol and SSC
62420493|NCT05769153|EXPERIMENTAL|Cohort 1 (Stage 1)|One intravitreal (IVT) injection of aflibercept 2 mg at Week -1 and one IVT insertion of AR-14034 SR lower dose at Baseline. Up to one retreatment with AR-14034 SR will be administered between Weeks 4 and 36 according to protocol-specified disease activity criteria.
62420494|NCT05769153|EXPERIMENTAL|Cohort 2 (Stage 1)|One IVT injection of aflibercept 2 mg at Week -1 and one IVT insertion of AR-14034 SR higher dose at Baseline. Up to one retreatment with AR-14034 SR will be administered between Weeks 4 and 36 according to protocol-specified disease activity criteria.
62420495|NCT05769153|EXPERIMENTAL|AR-14034 SR lower dose (Stage 2)|One IVT injection of aflibercept 2 mg at Baseline, Week 4, and Week 8, with one IVT insertion of AR-14034 SR lower dose at Week 6. Up to one retreatment of AR-14034 SR will be administered between Weeks 16 and 52 according to protocol-specified disease activity criteria. Sham procedures will be performed between Weeks 16 and 52 except when AR-14034 SR repeat treatment is administered.
62420496|NCT05769153|EXPERIMENTAL|AR-14034 SR higher dose (Stage 2)|One IVT injection of aflibercept 2 mg at Baseline, Week 4, and Week 8, with one IVT insertion of AR-14034 SR higher dose at Week 6. Up to one retreatment of AR-14034 SR will be administered between Weeks 16 and 52 according to protocol-specified disease activity criteria. Sham procedures will be performed between Weeks 16 and 52 except when AR-14034 SR repeat treatment is administered.
62420497|NCT05769153|ACTIVE_COMPARATOR|Aflibercept (Stage 2)|One IVT injection of aflibercept 2 mg at Baseline, Week 4, Week 8, Week 16, Week 24, Week 32, Week 40, and Week 48. Sham procedures will be performed between Weeks 16 and 52.
62420498|NCT05503797|EXPERIMENTAL|Subprotocol A|Participants with unresectable, locally advanced or metastatic solid tumors or primary CNS tumors harboring BRAF fusions will receive plixorafenib 900 mg BID, which will be increased as tolerated, continuously in 3-week cycles until disease progression, unacceptable toxicity, or other reason for withdrawal.
62590629|NCT04815265|ACTIVE_COMPARATOR|Control group|participants in the control group received dexmedetomidine for sedation
62803410|NCT04190914|EXPERIMENTAL|necrotic primary molar treated with regeneration using triple|under rubber dam isolation access cavity will be prepared by a round bur then minimal filling and irrigation will be performed then triple antibiotic paste will be inserted into the canals and the tooth will be restored by a glass ionomer (GI) as a temporary filling. After2-4 weeks all signs and symptoms will be assessed in case of absence of signs and symptoms an endodontic file will be used to induce bleeding from the periapical area after hemostasis mineral trioxide aggregate will be applied followed by SSC
62227601|NCT03178539|ACTIVE_COMPARATOR|diclofenac|patients will receive intra-operative diclofenac sodium at dose of 0.3 mg/kg intravenously then will continue postoperatively on the same drug received intra-operative.
62227602|NCT03178539|ACTIVE_COMPARATOR|ketorolac|patients will receive intra-operative ketorolac tromethamine at dose of 0.5 mg/kg intravenously then will continue postoperatively on the same drug received intra-operative.
62227603|NCT00348855|EXPERIMENTAL|1|"Intervention with one day training, electronic device to measure bood pressure, leaflet with goals and drug strategies according to guidelines, six specific cardiovascular consultations during two years, feed back on results of the intervention group at inclusion, year 1 and year 2.~Specific consultations will be focused on goals to be reach, compliance, exercise and diet."
62028808|NCT02824913|PLACEBO_COMPARATOR|Drug: P-321 Ophthalmic Solution placebo|Placebo treatment administered to approximately 8 patients in Phase I and approximately 16 patients in Phase II
62227604|NCT00348855|NO_INTERVENTION|2|
62227605|NCT02068209|ACTIVE_COMPARATOR|Tramadol|Patients will receive Tramadol 50mg 1 hour before outpatient hysteroscopy
62227606|NCT02068209|PLACEBO_COMPARATOR|Placebo|Patients will receive a placebo 1 hour before the procedure.
62803411|NCT04190914|EXPERIMENTAL|necrotic primary molar treated with regeneration using metape|under rubber dam isolation access cavity will be prepared by a round bur then minimal filling and irrigation will be performed then calcium hydroxide with iodoform (metapex) will be inserted into the canals and the tooth will be restored by a glass ionomer (GI) as a temporary filling. After 2-4 weeks all signs and symptoms will be assessed in case of absence of signs and symptoms an endodontic file will be used to induce bleeding from the periapical area after hemostasis mineral trioxide aggregate will be applied followed by SSC
62227607|NCT00063154|EXPERIMENTAL|Pertuzumab|Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). Subjects received pertuzumab at a loading dose of 840 mg in Cycle 1 followed by a dose of 420 mg in Cycles 2 and beyond.
62227608|NCT02314767|ACTIVE_COMPARATOR|Interpersonal Psychotherapy|Interpersonal Psychotherapy treatment for MDD patients was implemented with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression. Intervention:Interpersonal psychotherapy as ADD-on method. Outcome was compared with patients in treatment as usual group.
62227609|NCT02314767|ACTIVE_COMPARATOR|Psychoeducational Group Therapy|Psychoeducational Group Therapy arm for MDD patients with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression. Intervention: Psychoeducational Group Treatment as ADD-on method.
62227610|NCT02314767|NO_INTERVENTION|Treatment as Usual|Treatment as usual ( consisting of supportive psychodynamic-oriented treatment) with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression
62227611|NCT05466773|EXPERIMENTAL|CN group|Giving nutrition education for nurse, but not for patients
62227612|NCT05466773|EXPERIMENTAL|CP group|Giving nutrition education for patients, but not for nurses
62227613|NCT05466773|EXPERIMENTAL|CNP group|Giving nutrition education for both patients and nurses
62227614|NCT05466773|NO_INTERVENTION|NC group|No nutrition education for patients and nurses
62227615|NCT01193920|EXPERIMENTAL|1: GBS Trivalent Vaccine with aluminium - 20/20/20 μg|Non-pregnant women who received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
62227616|NCT01193920|PLACEBO_COMPARATOR|2: Placebo - Sterile saline|Non-Pregnant Women who received two injection of saline solution.
62420499|NCT05503797|EXPERIMENTAL|Subprotocol B|Participants with recurrent primary CNS tumors harboring BRAF V600E mutations will receive 900 mg of plixorafenib administered with 150 mg of cobicistat QD, continuously in 3-week cycles until disease progression, unacceptable toxicity, or other reason for withdrawal.
62803412|NCT00429559|EXPERIMENTAL|A|
62803413|NCT02753803|EXPERIMENTAL|A group|Evogliptin Pioglitazone Evogliptin+Pioglitazone
62803414|NCT02753803|EXPERIMENTAL|B group|Pioglitazone Evogliptin Evogliptin+Pioglitazone
62803415|NCT02753803|EXPERIMENTAL|C group|Evogliptin Evogliptin+Pioglitazone Pioglitazone
62227617|NCT01193920|EXPERIMENTAL|3: GBS Trivalent Vaccine - 0.5/0.5/0.5 µg|Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
62227618|NCT01193920|EXPERIMENTAL|4: GBS Trivalent Vaccine - 2.5/2.5/2.5 µg|Pregnant Women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
62227619|NCT01193920|EXPERIMENTAL|5: GBS Trivalent Vaccine - 5/5/5 µg|Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
62227620|NCT01193920|PLACEBO_COMPARATOR|6: Placebo - Sterile saline|Pregnant Women who received one injection of saline solution.
62227621|NCT00562133|EXPERIMENTAL|1|One Day Treatment with Insulin Glulisine
62028809|NCT02872259|EXPERIMENTAL|BGB324 + pembrolizumab|"BGB324 capsules, 200 mg once daily + pembrolizumab 2 mg/kg IV every 3. week~Treatment until disease progression, or unacceptable toxicity"
62227622|NCT00562133|ACTIVE_COMPARATOR|2|One day Treatment with Human insulin
62227623|NCT01544660||Scanning|no treatment
62227624|NCT01544660||scanning|no treatment
62227625|NCT04342793|PLACEBO_COMPARATOR|Placebo|Placebo
62227626|NCT04342793|EXPERIMENTAL|ALS-L1023 1,200mg|ALS-L1023 600mg twice a day
62028810|NCT02872259|EXPERIMENTAL|BGB324 + dabrafenib and trametinib|"BGB324 capsules: Dose finding part of the study will determine if 100 mg once daily should be used for main part of the study or if 200 mg once daily once daily should be used.~Dabrafenib capsules: 150 mg twice daily Trametinib tablets: 2 mg once daily~Treatment until disease progression, or unacceptable toxicity"
62028811|NCT02872259|ACTIVE_COMPARATOR|pembrolizumab|"Pembrolizumab 2 mg/kg IV every 3. week~Treatment until disease progression, or unacceptable toxicity"
62028812|NCT02872259|ACTIVE_COMPARATOR|dabrafenib and trametinib|"Dabrafenib capsules:150 mg twice daily Trametinib tablets: 2 mg once daily~Treatment until disease progression, or unacceptable toxicity"
62028813|NCT05625906|EXPERIMENTAL|Intervention group|will receive a multi-media experiential training programme.
62028814|NCT05625906|NO_INTERVENTION|control group|will NOT receive a multi-media experiential training programme
62028815|NCT05881668|EXPERIMENTAL|MSC-EV group|After liver transplantation, on the basis of postoperative standard treatment (anti-infection treatment, immunosuppressive treatment, nutritional support treatment, etc.), an additional injection of MSC-EV will be received between the 1st and 5th days after transplantation
62028816|NCT05881668|NO_INTERVENTION|Non-MSC-EV group|After liver transplantation, patients will receive postoperative standard treatment (anti-infection treatment, immunosuppressive treatment, nutritional support treatment, etc.)
62028817|NCT03421691|OTHER|Excel V laser|excel V Laser Genesis procedure utilizing 1064 nm laser
62028818|NCT00583726|ACTIVE_COMPARATOR|1|The control arm receives written information and pedometers
62028819|NCT00583726|EXPERIMENTAL|2|This arm also receives telephone counseling.
62227627|NCT04342793|EXPERIMENTAL|ALS-L1023 1,800mg|ALS-L1023 900mg twice a day
62227628|NCT06349928||Dancers|Dancers or dance students who pracitce at least 8 hours/week
62028820|NCT06636539|EXPERIMENTAL|CEM Investigational Exam|All subjects enrolled in this study will undergo a CEM exam using Investigational Device
62028821|NCT03146169|EXPERIMENTAL|Training group|Four two-hour training sessions were conducted at baseline, and one week, one month and three months after the first session.
62028822|NCT02053350|EXPERIMENTAL|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days.
62028823|NCT04972513||Prevention (survey, breathe tests, biospecimen collection)|Participants undergo computer-based spirometry testing, nitric oxide breath testing, airwave oscillometry, and an assessment of endothelial function. Participants will undergo collection of blood. Current e-cigarette users also vape their own e-cigarette device for 30 minutes.
62028824|NCT02431039|EXPERIMENTAL|NEOSORB PLUS|Subjects who are treated by NEOSORB PLUS
62028825|NCT02431039|ACTIVE_COMPARATOR|NEOSORB|Subjects who are treated by NEOSORB
62028826|NCT06668987|EXPERIMENTAL|BNCT, recurrent meningioma.|Single arm treated by BNCT only
62028827|NCT03077724|EXPERIMENTAL|Fish Oil|4.2 grams per day of n-3 long chain polyunsaturated fatty acids (LCPUFA)
62028828|NCT03077724|PLACEBO_COMPARATOR|Placebos|Olive oil supplements
62227629|NCT03160651|ACTIVE_COMPARATOR|methylprednisolone|Patients will receive 28 days of methylprednisolone 32 mg/day
62803416|NCT02753803|EXPERIMENTAL|D group|Pioglitazone Evogliptin+Pioglitazone Evogliptin
62227630|NCT03160651|PLACEBO_COMPARATOR|placebo|Patients will receive 28 days of matching placebo
62227631|NCT05052554|EXPERIMENTAL|30 µg cohort|Open label single dose cohort: Dose level 1
62227632|NCT05052554|EXPERIMENTAL|60 µg cohort|Open label single dose cohort: Dose level 2
62227633|NCT02091453|EXPERIMENTAL|attention training acute|20 hours of attention training, APT training, or multiprofessional rehabilitation
62803417|NCT02753803|EXPERIMENTAL|E group|Evogliptin+Pioglitazone Evogliptin Pioglitazone
62803418|NCT02753803|EXPERIMENTAL|F group|Evogliptin+Pioglitazone Pioglitazone Evogliptin
62803419|NCT02414308|EXPERIMENTAL|Adipose tissue stem cell injection|The stem cell will be harvested by liposuction and injection will be at corpora cavernosa and dorsal penile artery
62803420|NCT00247403|EXPERIMENTAL|2DG|
62803421|NCT05694039|NO_INTERVENTION|Control Group|Procedure: no intervention
62803422|NCT05694039|ACTIVE_COMPARATOR|Intervention Group|Procedure: a intervention via hearing aids for 5 years
62227634|NCT02091453|EXPERIMENTAL|attention training subacute|20 hours of attention training, APT training, or multiprofessional rehabilitation
62227635|NCT05954520|EXPERIMENTAL|Perceptual measures|Perception will be measured for different algorithm settings and environmental variables (type of noise and signal-to-noise ratio)
62420500|NCT05503797|EXPERIMENTAL|Subprotocol C|Participants with advanced, rare, non-CNS solid tumors harboring BRAF V600E mutations will receive 900 mg of plixorafenib administered with 150 mg of cobicistat QD, continuously in 3-week cycles until disease progression, unacceptable toxicity, or other reason for withdrawal.
62803423|NCT00644046|NO_INTERVENTION|1|Chronic kidney disease patient with standardized nephrology care
62803424|NCT00644046|ACTIVE_COMPARATOR|2|chronic kidney disease patient with multidisciplinary predialysis care
62803425|NCT00890825|ACTIVE_COMPARATOR|AZD6244 + Docetaxel|AZD6244 75 mg bd + Docetaxel 75 mg/m\^2
62803426|NCT00890825|PLACEBO_COMPARATOR|Placebo + Docetaxel|Placebo + Docetaxel 75 mg/m\^2
62803427|NCT02252146|EXPERIMENTAL|IMO-8400|IMO-8400 0.3 mg/kg twice weekly, 0.6 mg/kg twice weekly, or 1.2 mg/kg twice weekly
62803428|NCT04033367|EXPERIMENTAL|Dupilumab/Dupilumab|Participants received dupilumab 600 milligrams (mg) (loading dose) injection subcutaneously (SC) on Day 1 followed by dupilumab 300 mg injection SC every 2 weeks (q2w) up to Week 10 in the double-blind (DB) period of 12 weeks. After completion of DB period, participants entered in the open-label extension (OLE) period (Week 12 to 24) and continued to receive dupilumab 300 mg injection SC q2w from Week 12 up to Week 22.
62803429|NCT04033367|PLACEBO_COMPARATOR|Placebo/Dupilumab|Participants received placebo matching to dupilumab injection SC on Day 1 then followed by placebo injection SC q2w up to Week 10 in the DB period of 12 weeks. After completion of DB period, participants entered in the OLE period (Week 12 to 24) and received dupilumab 600 mg (loading dose) at Week 12 followed by dupilumab 300 mg injection SC q2w up to Week 22.
62803430|NCT03036410|OTHER|bimodal user|wearing one hearing aid and one CI Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
62227636|NCT04784260||Group A (normozoospermic): >15 mill/ml and >32% progressive mobility.|Analysis of the microbiome by extracting DNA from ejaculates, amplification of bacterial DNA with feeders aimed at the regions of the bacterial rRNA 16 S gene, sequencing, library preparation and bioinformatic analysis.
62420501|NCT05503797|EXPERIMENTAL|Subprotocol D|Participants with BRAF V600E-mutated cutaneous melanoma and BRAF V600E-mutated thyroid cancer (MAPK inhibitor naïve) will be randomized to one of two treatment arms.
62803431|NCT03036410|OTHER|unilateral hearing aid users|wearing one hearing aid Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
62803432|NCT03036410|OTHER|bilateral hearing aid users|wearing two hearing aids Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
62420502|NCT01929148|EXPERIMENTAL|Laparoscopic myomectomy plus PBS|A Laparoscopic myomectomy plus Prophylactic bilateral salpingectomy will be performed in women which have accomplished their reproductive desire
62420503|NCT01929148|ACTIVE_COMPARATOR|Laparoscopic myomectomy without PBS|A standard laparoscopic myomectomy without any prophylactic salpingectomy will be performed
62420504|NCT03973086|EXPERIMENTAL|Citrus flavonone-O-glycosides (Low dose)|
62803433|NCT03036410|OTHER|CI users|wearing CI Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
62803434|NCT01458639|EXPERIMENTAL|Technegas|Technegas V SPECT imaging with Technetium-99m (Tc-99m) labeled carbon particles; approximately 1.1 milliCuries of Technegas, compared with the results of Xenon-133 ventilation scan
62803435|NCT01458639|ACTIVE_COMPARATOR|Xenon-133|Xenon-133 ventilation Planar imaging compared with the results of the Technegas scan.
62803436|NCT06024070|EXPERIMENTAL|study group|this study group assessed by 3 functional tests (Figure of 8 hopping , single leg stance test and y balance test) pre and post receiving rigid ankle tapping
62803437|NCT03576326|EXPERIMENTAL|Incentive Drawing|Eligible to earn a weekly drawing entry with different winning probabilities during the 6-month incentive intervention period. Possible winnings depend on toothbrushing performance: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will have an 18% chance of winning $25 and a 1% chance of winning $50 (expected $5 payout); high adherence threshold (brushing twice per day for 14 days in a week) will have a 34% chance of winning $25 and a 3% chance of winning $50 (expected $10 payout).
62803438|NCT03576326|NO_INTERVENTION|Control - Delayed Incentive|No rewards during the first 12 months, but information on toothbrushing performance. After the Month 12 follow-up visit, may opt to participate in a delayed 6-month open label extension to earn the same monetary rewards the intervention group could earn Baseline through Month 6. Not a formal part of this trial, but rather a necessary condition to assure all participating parents/caregivers have the chance to earn the same monetary incentives.
62420505|NCT03973086|EXPERIMENTAL|Citrus flavonone-O-glycosides (High dose)|
62420506|NCT03973086|PLACEBO_COMPARATOR|Microcrystaline Cellulose- 400mg|
62420507|NCT06461234||pelvic floor muscle training (PFMT)|Control group
62803439|NCT02735967|EXPERIMENTAL|Group manual therapy + diadynamic|"Initially, the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.~Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minutes short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient."
62227637|NCT04784260||Group B (normozoospérmic): <15 mill/ml and <32% progressive mobility.|Analysis of the microbiome by extracting DNA from ejaculates, amplification of bacterial DNA with feeders aimed at the regions of the bacterial rRNA 16 S gene, sequencing,library preparation and bioinformatic analysis.
62420508|NCT06461234||pelvic floor biofeedback electrical stimulation|Observation Group 1
62420509|NCT06461234||pelvic floor magnetic stimulation|Observation Group 2
62420510|NCT06461234||Magnetic stimulation combined with biofeedback electrical stimulation|Observation Group 3
62420511|NCT05557487||Previous heavy smokers|Age 50 to 80 years who have at least a 20-pack-year smoking history with successful smoking cessation history (stopping smoking for more than 6 months), but less than 15 years
62420512|NCT05557487||First degree relatives of lung cancer patients|"First-degree relatives of lung cancer patients~1. aged more than 50 years~2. age less than 50 years old, but older than the age at diagnosis of the youngest lung cancer proband in the family"
62420513|NCT05557487||With other high-risk occupational or environmental factors|"Age 50 to 80 years, meet one or more of the following criteria.~1. air-pollution exposed occupations (such as traffic policeman, street cleaners....) for at least 10 years~2. cooking index ≥ 110, defined as 2/7 \* days cooking by pan frying, stir frying, or deep frying in one week \* years cooking.~3. cooking without using ventilation for more than 20 years~4. history of pulmonary tuberculosis and complete anti-tuberculosis treatment with interval more than 5 years before this study"
62590630|NCT03024203|EXPERIMENTAL|Executive Training|Executive Training (ET) involves training on computerized cognitive exercises that have graded increases in difficulty so that the participant is always challenged. A therapist will be in the room with participants to address any difficulties with the program and facilitate generation of strategies. ET will be delivered in both individual and group settings.
62028829|NCT00971048|EXPERIMENTAL|HP828-101|
62028830|NCT00971048|ACTIVE_COMPARATOR|Standard of Care|For DFU SoC is a hydrogel. For PU SoC is a hydrocolloid gel.
62028831|NCT04639453||Stroke|Individuals with post-stroke hemiparesis in subacute phase will be included in the study.
62028832|NCT02169687|EXPERIMENTAL|Hifu|
62028833|NCT06670547||Patients with biliopancreatic pathology undergoing ERCP|Patients with biliopancreatic pathology who undergo ERCP are over 18 years of age and sign the informed consent.
62227638|NCT02970877|EXPERIMENTAL|Allogenic treatment group|Fecal filtrate from 150 g stool from healthy lean donors
62227639|NCT02970877|PLACEBO_COMPARATOR|Autologous control group|Fecal filtrate from 150 g of the recipient's own stool
62420514|NCT01261429|EXPERIMENTAL|Nilotinib|
62803440|NCT02735967|ACTIVE_COMPARATOR|Group manual therapy|Initially, the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
62227640|NCT04268524|EXPERIMENTAL|monotherapy miltefosine|Miltefosine capsules (Impavido®) 2.5 mg/kg daily PO for 28 days \<30 kg BW allometric miltefosine dose based on fat-free mass. (approx. 2.5 mg/kg); \>30 - ≤44kg BW: 100 mg/day BID; ≥45kg BW 150mg TDS
62227641|NCT04268524|EXPERIMENTAL|Thermotherapy|Thermotherapy (ThermoMed 1.8 ®) 50°C for 30 seconds, 1 session
62227642|NCT04268524|EXPERIMENTAL|Combination miltefosine and thermotherapy|Miltefosine capsules 2.5 mg/kg daily PO for 21days, and thermotherapy 50°C for 30 seconds, one session on day 1 of the miltefosine.
62227643|NCT04268524|ACTIVE_COMPARATOR|° Meglumine antimoniate (Glucantime®) intralesional|Meglumine antimoniate (Glucantime®) intralesional injections 0.5-3ml, 8 sessions, bi-weekly
62227644|NCT04275401||patients|patients with clinical presentions of change in muscle tone
62227645|NCT04275401||volunteers|healthy volunteers with normal muscle tone
62420515|NCT03574571|EXPERIMENTAL|Docetaxel|Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses. Prednisone will be given at a dose of 5mg orally twice daily.
62420516|NCT03574571|EXPERIMENTAL|Docetaxel with Radium-223|Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses. Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
62590631|NCT03024203|EXPERIMENTAL|Perceptual Training|Perceptual Training (PT) involves training on computerized cognitive exercises that have graded increases in difficulty so that the participant is always challenged. A therapist will be in the room with participants to address any difficulties with the program and facilitate generation of strategies. PT will be delivered in both individual and group settings.
62803441|NCT02735967|ACTIVE_COMPARATOR|Group diadynamic|An electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF),4 minutes long periods (LP) and 4 minutes short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
62803442|NCT02987725|ACTIVE_COMPARATOR|Attention Control|Participants will listen to a 30-minute historical story.
62803443|NCT02987725|EXPERIMENTAL|Hypnosis|Participants will receive a 30-minute hypnosis session
62803444|NCT05258604|EXPERIMENTAL|argon plasma coagulation (APC).|APC Standard APC equipment will be used, consisting of a high-frequency electrosurgical generator (ICC 350; ERBE, Tübingen, Germany), an argon source which is regulated automatically (APC 300) and APC probe.
62803445|NCT05258604|EXPERIMENTAL|endoscopic band ligation.|endoscopic band ligation will be carried out using a Saeed Multi-Band Ligator (Cook Medical, WinstonSalem, NC), and ligation bands were placed on the GAVE.
62803446|NCT00483470|EXPERIMENTAL|1|
62803447|NCT00483470|ACTIVE_COMPARATOR|2|
62803448|NCT00760955|EXPERIMENTAL|TAK-583 5 mg QD|
62227646|NCT01385813||Pregnant women who develop preeclampsia|pregnant women who develop preeclampsia (n =43) compared to pregnant women fulfilling a normotensive pregnancy (n= 86).
62227647|NCT02960854|EXPERIMENTAL|Nivolumab 1|Dose 1
62227648|NCT02960854|EXPERIMENTAL|Nivolumab 2|Dose 2
62803449|NCT00760955|EXPERIMENTAL|TAK-583 50 mg QD|
62803450|NCT00760955|EXPERIMENTAL|TAK-583 100 mg QD|
62803451|NCT00760955|PLACEBO_COMPARATOR|Placebo QD|
62803452|NCT00988078|EXPERIMENTAL|Metformin|Metformin 500mg three times a day for six months
62227649|NCT05611008|EXPERIMENTAL|Intervention condition|
62227650|NCT05611008|NO_INTERVENTION|Control condition|
62227651|NCT04409353|EXPERIMENTAL|Virtual Reality Program A|This arm will include software that provides immersive skills-based content for pain reduction.
62227652|NCT04409353|ACTIVE_COMPARATOR|Virtual Reality Program B|This arm will include software that provides immersive distraction based content for pain reduction.
62227653|NCT04409353|SHAM_COMPARATOR|Virtual Reality Program C|This arm will include software that provides nonimmersive distraction based content for pain reduction.
62227654|NCT00828880||DRX9000|
62227655|NCT02727127||Healthy Volunteers|MRI on 3 Tesla (3T) or 7 Tesla (7T) scanner, without contrast
62227656|NCT02727127||Bipolar Patients|MRI on 3 Tesla (3T) or 7 Tesla (7T) scanner, without contrast
62227657|NCT04345835|ACTIVE_COMPARATOR|prone flexed|prone flexed PCNL position
62227658|NCT04345835|ACTIVE_COMPARATOR|prone|prone position PCNL
62227659|NCT01414374|ACTIVE_COMPARATOR|Iron|
62227660|NCT01414374|EXPERIMENTAL|Herbal|
62227661|NCT04879771||Morning GIE|
62227662|NCT04879771||Afternoon GIE|
62227663|NCT03868488|EXPERIMENTAL|Visual imagery tasks group|During the intervention, each participant of this group will be asked to create visual mental images.
62227664|NCT03868488|EXPERIMENTAL|Auditory imagery tasks group|During the intervention, each participant of this group will be asked to create auditory mental images.
62227665|NCT04217733|ACTIVE_COMPARATOR|Mebeverine|Mebeverine 3 times daily for 3 months
62227666|NCT04217733|EXPERIMENTAL|Ethosuximide|Ethosuxemide 3 times daily for 3 months
62803453|NCT00988078|PLACEBO_COMPARATOR|Placebo|1 capsule three times a day for six months
62227667|NCT04217733|EXPERIMENTAL|Pentoxyifylline|pentoxyifylline 2 times daily for 3 months
62028834|NCT06380231|EXPERIMENTAL|kangaroo mother care (KMC) for experimental group|Examined physiological parameters of both groups were measured before, during and after KMC and traditional mother's bosom. This measurement was made at 15-minute intervals for 45 minutes (0-01,15,30,45 minutes). Physiological parameters before and after KMC and traditional mother's bosom represent incubator conditions.
62803454|NCT04881916||Sample Collection|"Participation In:~* Initial data completion: Telephone collection of information on disease, treatment and testing~* Medical record collection: Collection of medical records regarding cancer, testing, and treatment history~* Archival tissue collection: Collection of tumor from prior standard of care procedure~* Saliva collection: Saliva collection with at home kit~* Follow up data completion: Telephone collection of medical condition every 3-6 months up to 2 years."
62028835|NCT06380231|NO_INTERVENTION|control group|"The control group received only traditional mother's bosom. In the control group, unlike the experimental group, the mother's clothes were not removed. The hands of the mothers were cleaned with 0.4% chlorhexidine, and the mothers were seated in the KMC chair. The same chair was used for the experimental and control groups.~A hospital shirt was placed over the mother's own clothes for hygiene purposes only. The baby was not naked, was given to his mother wrapped in a blanket. The infant spent 45 minutes in traditional mother's bosom without skin-to-skin contact. There were no restrictions placed on the position of the mother holding the infant, and she could hold the infant upright, horizontally, and to the right or left. In control groups, all mothers were permitted to sing lullabies or talk to their infants if they chose to do so."
62028836|NCT03625193||Ambulatory patients with SCI|"* Age at least 18 years~* Body mass index (BMI) between 18.5 - 29.9 kg/m2~* Having an incomplete SCI from traumatic or non-traumatic causes~* Ability of independent standing up from a chair with or without hand support~* Ability of independent walking with or without walking device over at least 10 meters continuously.~* Ability to follow commands used in the studies"
62028837|NCT04458350|EXPERIMENTAL|Digital Promotions Group|Eligible zip codes (n=96) will be randomized using stratified randomization at the state level. The intervention will last 13 weeks (Summer 2020 market season) and consist of receiving digital ads on the Fresh EBT app and Facebook for SNAP fruit and vegetable incentive programs at farmers' markets.
62028838|NCT04458350|NO_INTERVENTION|Control Group|No intervention administered. Eligible zip codes (n=96) will be randomized using stratified randomization at the state level.
62227668|NCT01588496|EXPERIMENTAL|Part A: Evolocumab|Participants received open-label evolocumab 420 mg subcutaneously once a month for 12 weeks.
62227669|NCT01588496|EXPERIMENTAL|Part B: Evolocumab|Participants received double-blind evolocumab 420 mg subcutaneously once a month for 12 weeks.
62227670|NCT01588496|PLACEBO_COMPARATOR|Part B: Placebo|Participants received double-blind placebo subcutaneously once a month for 12 weeks.
62227671|NCT03747198|EXPERIMENTAL|methylsulfonylmethane|Subjects will be given 2 g/day of methylsulfonylmethane (MSM). Salivary estrogen will be measured around ovulation and menstruation each month for 3 months. Knee laxity will be measures 2 times per month at the same time points (ovulation, menstruation).
62227672|NCT03747198|PLACEBO_COMPARATOR|Placebo|Subjects will be given 2 g/day placebo (rice flour). Salivary estrogen will be measured around ovulation and menstruation each month for 3 months. Knee laxity will be measures 2 times per month at the same time points as the intervention arm (ovulation, menstruation).
62420517|NCT05274568|EXPERIMENTAL|[18F]UCB-2897|"Administration of Investigational Agent:~Study center personnel will administer \[18F\]UCB-2897 as an IV injection. Prior to PET imaging, participants will have an IV catheter (for radiopharmaceutical administration) inserted according to standard clinical practice. Each participant will receive a single injection of \[18F\]UCB-2897. \[18F\]UCB-2897 will be injected IV at a dose of not more than 10 mCi, with a maximum mass dose of 10 μg and maximum volume of 10 mL. The injection will be followed by a 10 mL saline flush. Qualified study staff will accompany participants during PET imaging procedures."
62420518|NCT03692078|NO_INTERVENTION|GROUP 1: Continue Smoking|Subjects will be asked to continue smoking their own brand (OB) cigarettes ad libitum for 7 days.
62420519|NCT03692078|EXPERIMENTAL|GROUP 2: OTDN product 1|Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline cigarettes per day (CPD) and use at least 3 oral tobacco-derived nicotine (OTDN) product units per day for 7 days.
62420520|NCT03692078|EXPERIMENTAL|GROUP 3: OTDN product 2|Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 oral tobacco-derived nicotine (OTDN) product units per day for 7 days.
62420521|NCT03692078|EXPERIMENTAL|GROUP 4: OTDN product 1|Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine (OTDN) product, using at least 3 OTDN product units per day for 7 days.
62420522|NCT03692078|EXPERIMENTAL|GROUP 5: OTDN product 2|Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine (OTDN) product, using at least 3 OTDN product units per day for 7 days.
62420523|NCT03692078|EXPERIMENTAL|GROUP 6: Tobacco Cessation|Subjects will completely stop all tobacco product usage for 7 days.
62420524|NCT03257137|EXPERIMENTAL|Healthy Diet|This dietary pattern will represent recommendations for fiber and added sugar set forth in the 2015 Dietary Guidelines for Americans and saturated fat guidelines from the American Heart Association
62420525|NCT03257137|EXPERIMENTAL|Simulated Fast Food (SFF)|This dietary pattern will represent the typical American diet for fiber, added sugar, and saturated fat intake.
62028839|NCT04271709|ACTIVE_COMPARATOR|Enhanced Intervention|Consented subjects living in buildings randomized to the Enhanced Intervention arm who fail the screening and need vision correction will receive free eyeglasses, which will be fitted by an optician at the housing building. If they are referred to an ophthalmologist for a follow-up eye exam, they will receive enhanced support with patient navigators to assist with all aspects of follow-up eye care and ocular surgery at either Harkness Eye Institute or Harlem Hospital, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.
62028840|NCT04271709|PLACEBO_COMPARATOR|Usual Care|Consented subjects living in buildings randomized to Usual Care arm who fail the screening and need vision correction will be given an eyeglasses prescription and a list of optical shops within 1 mile from their home. These subjects who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment at either Harkness Eye Institute or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence.
62028841|NCT03149783|EXPERIMENTAL|Ropivacaine|Participants will have bilateral TAP catheters placed along with continuous infusion of ropivacaine.
62028842|NCT03149783|PLACEBO_COMPARATOR|Placebo|Participants will have bilateral TAP catheters placed along with continuous infusion of placebo.
62028843|NCT01335243|EXPERIMENTAL|TLIF surgery|
62028844|NCT01872169|OTHER|Disordered eating screening questionnaire|
62028845|NCT03380962|EXPERIMENTAL|Clazakizumab|All twenty patients will receive clazakizumab monthly. Patients will receive up to 6 doses pre-transplantation. If patients are transplanted during the study, they will then receive 6 doses of clazakizumab (monthly) and a 6 month protocol biopsy will be performed. Based on the biopsy results and clinical labs PI will determine if patients should continue monthly doses for up to another 6 doses and day 330 post-transplantation. Patients who received 12 post-transplant doses of clazakizumab will then undergo a 12 month protocol biopsy.
62028846|NCT05219240||Program participants|
62028847|NCT01257867|EXPERIMENTAL|Lithia spring water|Lithia water (active) for 4 weeks then placebo water for 4 weeks
62028848|NCT01257867|PLACEBO_COMPARATOR|Natural spring water|Placebo water for 4 weeks then lithia water (active) for 4 weeks
62028849|NCT01381328||RAL Group|HIV-1 infected patients failing to a RALTEGRAVIR-containing regimen
62028850|NCT01917526|ACTIVE_COMPARATOR|oxygen mask|Oxygen mask with oxygen flow 5 L/min will be given to allocated post general anesthesia patients. The incidence and causes of hypoxemia will be recorded.
62028851|NCT01917526|ACTIVE_COMPARATOR|Oxygen cannula|Oxygen cannula with oxygen flow 4 L/min will be given to allocated post general anesthesia patients. The incidence and causes of hypoxemia will be recorded.
62028852|NCT02357628||Research Group I|Wound treatment with RO-NPT 40%
62028853|NCT02357628||Research Group II|Wound treatment with RO-NPT 60%
62227673|NCT02952287|EXPERIMENTAL|Study Participants|4D PC MRI acquisition
62420526|NCT05872503||Cohort 1|Participants of African Ancestry with elevated serum prostate specific antigen of (Bullet)3ng/ml or positive digital rectal examination or strong family history.
62028854|NCT02357628||Research Group III|Wound treatment with RO-NPT 40% and irrigation
62028855|NCT03904472|EXPERIMENTAL|Web-based CBTI|Participants will have 8 weeks to receive 6 therapy sessions. Content is dynamically driven by an animated therapist who guides the user through the program.
62028856|NCT06164262||Individuals with CSVD|This does not entail the application of interventions.
62028857|NCT01495065|EXPERIMENTAL|Part A|Japanese subjects in cohort 1 and 2 will receive treatments A, B and C. Caucasian subjects in cohort 3 will receive treatment B and C.
62028858|NCT01495065|EXPERIMENTAL|Part B|Subjects in cohort 4 and 5 will receive repeat doses of IV GSK2251052 for 10 days.
62028859|NCT04785404|EXPERIMENTAL|primary skin closure|in this group, skin wound will be primarily closed
62028860|NCT04785404|NO_INTERVENTION|secondary skin closure|skin will be left open to heal by secondary intention
62227674|NCT05884151|ACTIVE_COMPARATOR|Intralesional tranexamic acid in the treatment of melasma|Group A 30 patients treated with Intradermal Tranexamic acid injection (4mg/ml) for preparation an insulin syringe was used with a volume of 1ml containing 0.04 ml of TXA and the reminder being normal saline to ensure 4mg preparation in each insulin syringe
62028861|NCT02458105|EXPERIMENTAL|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
62028862|NCT02458105|ACTIVE_COMPARATOR|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
62227675|NCT05884151|ACTIVE_COMPARATOR|Intrlesional platelets rich plasma in the treatment of melasma|Group B 30 patients prescribed with PRP (1ml) intra-dermally PRP was obtained manually by a two-step procedure using a centrifuge machine. First spin was performed at 1500 RPM for 10 minutes. Second spin was performed at 4000 RPM for 10 minutes. Thus, obtaining a two-part plasma. Upper two third was platelet poor plasma and was discarded. Lower one third was platelets rich plasma. Before injection applying 0.1 ml calcium chloride was added for each 1 ml of PRP to activate the platelets. PRP was injected 1 ml by using 30 G needle (insulin syringe) in each cm2 of melasma.
62227676|NCT05323201|EXPERIMENTAL|fhB7H3.CAR-T cells|In phase I study , 9 enrolled patients diagnosed with advanced liver cancer will receive one-time transhepatic arterial infusion of fhB7H3.CAR-Ts at the doses of 1×10\^6/kg, 3×10\^6/kg and 5×10\^6/kg, 3 patients for each dose. To further confirm the therapeutic efficacy, in phase II study, 6 enrolled patients will receive an optimal dose (balancing effectiveness and toxicity) of fhB7H3.CAR-Ts.
62227677|NCT02714387||ICU patients|Patients with Non Traumatic Neuro-Vascular Diseases. Medical data concerning ICU stay will be collected.
62227678|NCT02325427|EXPERIMENTAL|real tDCS|Subjects will receive tDCS stimulation at the intensity of 1 mA and last for 20 minutes. The anode will be placed over the affected primary motor cortex (M1) of cortical representation of the hand, while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
62227679|NCT02325427|SHAM_COMPARATOR|sham tDCS|Subjects will receive sham tDCS stimulation. The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
62227680|NCT02325427|NO_INTERVENTION|no stimulation|Subjects will not received any intervention.
62028863|NCT03712917|ACTIVE_COMPARATOR|Greater Occipital Nerve Block|"The GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg), and 1 ml 0,9% NaCl. The solution is administered using a 22G × 1¼ (0.7 × 40mm) injector with the patient lying prone on the table. Injection is applied to medial of the occipital artery localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp is cleaned with iodine before the procedure, and the injections are performed bilaterally at a volume of 2 mL after negative aspiration for blood."
62028864|NCT03712917|ACTIVE_COMPARATOR|Topiramate|Topiramate is administered twice a day at a dose of 25 mg/day, which is increased to 100 mg/day in the second week.
62028865|NCT03712917|ACTIVE_COMPARATOR|Flunarizine|Flunarizine is introduced with a single dose of 10 mg/day.
62028866|NCT05935501|EXPERIMENTAL|Formaderm Young|Formaderm Young was randomly administered to subjects. The injection volume was limited to 2c.c.
62028867|NCT05935501|ACTIVE_COMPARATOR|Restylane|Restylane was randomly administered to subjects. The injection volume was limited to 2c.c.
62028868|NCT02797925||Tendinopathy|Long slow strength training for 3 months that are performed at home or gym. Participants receive initial guidance to the exercises from a physiotherapist assigned to Bispebjerg H.
62028869|NCT02797925||Healthy|No intervention. No training
62028870|NCT05924919|EXPERIMENTAL|Experimental Arm: Whole-body Passive Heat Therapy (HT)|Heat therapy will be administered using an infrared sauna. The intervention duration will last 25 minutes at a temperature of 60°C.
62028871|NCT04488536||Frail patients|Clinical Frailty Scale level 5-9
62028872|NCT04488536||Nonfrail patients|Clinical Frailty Scale level 1-4
62803455|NCT03868254||Implant|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until the last visit was extracted from existing medical records.
62028873|NCT04897893|EXPERIMENTAL|Experimental Treatment|All subjects enrolled in the study will receive an identical dose of 2g/day (4 capsules of MAG-EPA) which will be taken by the subject at home. The duration of treatment should not be prolonged in the event of missed doses, that is, treatment should end on the 84th day as planned. A deviation of ± 3 days is acceptable, which means that treatment can be stopped from day 81 to day 87 of subject's participation.
62028874|NCT06196762|EXPERIMENTAL|XKH002|A total of 5 dose cohorts will be enrolled and treated: 0.3, 1.0, 3.0, 10, and 20 mg/kg. The dose-escalation process will utilize both the accelerated titration and the conventional 3+3 methods.
62028875|NCT04826354|EXPERIMENTAL|Rosuvastatin|Rosuvastatin 20mg
62028876|NCT04826354|ACTIVE_COMPARATOR|Rosuvamibe|Rosuvastatin plus ezetimibe 10/5
62028877|NCT01325948||Patients with COPD|
62028878|NCT03397212|EXPERIMENTAL|NADA and Clonidine|NADA acupuncture and treatment with tbl Clonidine
62028879|NCT03397212|SHAM_COMPARATOR|Sham acupuncture and Clonidine|Sham ear acupuncture and treatment with tbl Clonidine
62028880|NCT01714128|OTHER|Optional Diagnostic Imaging|Optional diagnostic imaging FES-PET/CT imaging
62028881|NCT03351374||Temple Physicians Incorporated|A community-based provider, operating 32 primary care sites
62028882|NCT03351374||WhiteBark|For profit entity created by the Indiana Rural Health Association
62028883|NCT03351374||Drexel Family Intervention Science|Academic center that developed and deployed Attachment Based Family Therapy (ABFT) assessment, treatment, and prevention models with an interest in adolescents struggling with substance abuse, depression, trauma, and suicidality.
62028884|NCT03351374||Bon Secours Health System|A primary care clinic in Baltimore that provides care services to a population in a lower socioeconomic status in downtown Baltimore.
62028885|NCT03351374||Howard University Hospital CARES|A project provides free outpatient medical, dental, mental health, nutrition and social services for HIV positive uninsured and underinsured residents of the District of Columbia.
62028886|NCT02194426|EXPERIMENTAL|MP0250|"see section intervention description below"
62028887|NCT03577002|ACTIVE_COMPARATOR|Clinician SICP|Advance care planning between primary care clinician and the patient/family using the Serious Illness Care Program (SICP)
62028888|NCT03577002|ACTIVE_COMPARATOR|Team SICP|Advance care planning between team members and the patient/family using the Serious Illness Care Program (SICP)
62227681|NCT02705287||Vitamin D dynamics-pregnant|Pregnant women recruited to measure Vitamin D dynamics during pregnancy.
62803456|NCT03868254||Implant + Phaco|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until the last visit was extracted from existing medical records.
62227682|NCT02705287||Vitamin D dynamics-nonpregnant|Non-pregnant women recruited to measure Vitamin D dynamics.
62227683|NCT03109145|EXPERIMENTAL|Menopause educational secure messaging|Secure messages that provide information about menopause and treatment option for menopause symptoms.
62028889|NCT03006250|EXPERIMENTAL|Desflurane|Desflurane group: The rule of 24 will be applied, which means that the fresh gas flow (l/ min) multiplied by volume percent of desflurane must not exceed 24. Therefore, once the patients return of spontaneous ventilation, an anesthesiologist turns on oxygen 1 l/ min, nitrous oxide 1 l/ min, and desflurane 12 vol% for 1-2 minutes. When the end-tidal desflurane reaches 3-3.5% (approximately 0.5 MAC), the anesthesiologist will decrease oxygen and nitrous oxide to each 0.5 l/ min and desflurane to 6 vol% (1 MAC). Desflurane concentration will be adjusted to maintain the end-tidal desflurane around 3-6% (0.5-1 MAC).
62028890|NCT03006250|ACTIVE_COMPARATOR|Sevoflurane|Sevoflurane group: The oxygen and nitrous oxide each 1 l/min will be turned on with sevoflurane 4 vol% for 1-2 minutes or until the end-tidal sevoflurane reach 1-1.2% (approximately 0.5 MAC). After that, the flow of oxygen and nitrous oxide is reduced to each 0.5 l/ min and concentration dial of sevoflurane is set to 2 vol% (1 MAC). During the operation, sevoflurane concentration will be adjusted to maintain the end-tidal sevoflurane around 1-2% (0.5-1 MAC)
62028891|NCT02516618|EXPERIMENTAL|Cohort 1|Participants in this cohort will receive dose 1 of Fasinumab or placebo
62028892|NCT02516618|EXPERIMENTAL|Cohort 2|Participants in this cohort will receive dose 2 of Fasinumab or placebo
62028893|NCT02516618|EXPERIMENTAL|Cohort 3|Participants in this cohort will receive dose 3 of Fasinumab or placebo
62028894|NCT02516618|EXPERIMENTAL|Cohort 4|Participants in this cohort will receive dose 4 of Fasinumab or placebo
62028895|NCT02516618|EXPERIMENTAL|Cohort 5|Participants in this cohort will receive dose 5 of Fasinumab or placebo
62735305|NCT05135559|EXPERIMENTAL|Patients coming from compassionate use|Patients previously treated with concizumab via compassionate use, either on an individual patient basis or through the concizumab compassionate use programme NN7415-4807
62028896|NCT04094454|EXPERIMENTAL|Tampon with extended vaginal dilatation|Patients in arm A will use a special tampon with extended vaginal dilatation during radiotherapy
62028897|NCT04094454|ACTIVE_COMPARATOR|Commercially available tampon|Patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
62028898|NCT05544994|EXPERIMENTAL|Aerobic Exercise Training Group|"Aerobic training will be performed 3 days a week for 12 weeks at 60% -%75 of their maximum hearth rate with 30 minutes total duration consisting of 5 min warm up and 5 min cool down period in treatment group.~Home exercise program will be given. This home program will include stretching, breathing, normal joint movement for 3 to 5 days a week"
62803457|NCT03435185|ACTIVE_COMPARATOR|Blockade Group|Lidocaine injections. Procedure. Grater occipital nerve and supraorbital nerve were blocked with %2 lidocaine. These injections were repeated weekly for three weeks. After treatment was completed, patients were followed up for 2 months at the polyclinic to assess the clinical response.
62028899|NCT05544994|ACTIVE_COMPARATOR|Control Group|Home exercise program will be given. This home program will include stretching, breathing, normal joint movement, for 3 or 5 days a week.
62028900|NCT01316133|EXPERIMENTAL|Tacrolimus group|Oral
62028901|NCT04719793|EXPERIMENTAL|Wharton's Jelly|Intraarticular injection of Umbilical Cord-derived Wharton's Jelly
62028902|NCT04691765|EXPERIMENTAL|100 mg SC|100 mg of Kineret (anakinra) will be administered sub-subcutaneously once a day for 28 days (1 cycle) with a maximum of 7 cycles (28 weeks of treatment)
62420527|NCT04735406||Multiple Sclerosis (MS)|Data from the participants with diagnosed MS treated and untreated will be part of this study. Medical records of participants will be used to collect demographics and data pertaining to Multiple Sclerosis (MS) management.
62420528|NCT01921725|EXPERIMENTAL|Hydrophilic-based dressing (KoCarbonTM)|The wound is first cleansed with normal saline, and then applied with hydrophilic-based dressing (KoCarbonTM) and covered by sterile gauze. The frequency of dressing chang is depend on the amount of exudate.
62028903|NCT04691765|EXPERIMENTAL|100 mg SC BID|100 mg of Kineret (anakinra) will be administered sub-subcutaneously twice a day for 28 days (1 cycle) with a maximum of 7 cycles (28 weeks of treatment)
62028904|NCT04691765|EXPERIMENTAL|200 mg SC BID|200 mg of Kineret (anakinra) will be administered sub-subcutaneously twice a day for 28 days (1 cycle) with a maximum of 7 cycles (28 weeks of treatment)
62803458|NCT03435185|PLACEBO_COMPARATOR|Placebo Group|Saline injections. Procedure. Grater occipital nerve and supraorbital nerve were injected with saline.These injections were repeated weekly for three weeks. After treatment was completed, patients were followed up for 2 months at the polyclinic to assess the clinical response.
62028905|NCT02269293|EXPERIMENTAL|Regimen 1|Paclitaxel 175 mg/m\^2 IV, Day 1 (administered over approximately 3 hours) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor (to be taken orally once daily on days 1, 4, 8, 11, 15, and 18 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
62028906|NCT02269293|EXPERIMENTAL|Regimen 2|Paclitaxel 80 mg/m\^2 IV, Days 1, 8, 15 (administered over approximately 1 hour) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor orally (to be taken orally once daily on days 1, 4, 8, 11, 15, and 18 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
62028907|NCT02269293|EXPERIMENTAL|Regimen 3|Paclitaxel 80 mg/m\^2 IV, Days 1, 8, 15 (administered over approximately 1 hour) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor orally (to be taken orally once weekly on days 1, 8, and 15 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
62028908|NCT02269293|EXPERIMENTAL|Regimen 4|Paclitaxel and carboplatin will be delivered intravenously (IV) on day 1 of each cycle. Selinexor will be taken orally once a week on days 1, 8 and 15 of each chemotherapy cycle.
62227684|NCT03109145|NO_INTERVENTION|Usual care: Control|Control group of eligible women patients between 45-60 years who do not receive the intervention at the West Palm Beach and Orlando Veterans Healthcare System. Usual care participants did not receive the educational secure messages.
62227685|NCT03618654|EXPERIMENTAL|Arm A (durvalumab, metformin)|"Patients will take Metformin 500mg/day for 3 days. From day 4, 500mg twice daily and then in 3 days (day 7) dose escalation to 1000mg twice daily will be achieved. This will be taken until the day before surgery after dinner.~Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion"
62420529|NCT03543046|EXPERIMENTAL|Tortle Midliner|The use of the Tortle Midliner will be in addition to the NICU department process guidelines for positioning relevant to the gestational age of the subject. The Tortle Midliner will be applied no later than 3 hours following birth under the supervision of a study investigator. The size/fit and application of the device will be according to the manufacturer's guidelines. The neutral midline head position, supine or slightly side-lying, with a bed elevation between 15° and 30° will be maintained during the first 72 hours of life.
62227686|NCT03618654|EXPERIMENTAL|Arm B (durvalumab)|Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion. Participants receive durvalumab as in Arm A in the absence of disease progression or unacceptable toxicity.
62420530|NCT03543046|NO_INTERVENTION|Control Group|All clinical care for the control group will be within NICU department process guidelines relevant to the gestational age of the subject and as ordered by physician and/or ARNP providers. The neutral midline head position with the aid of nesting and/or rolls with a bed elevation between 15° and 30° will be maintained throughout position changes during the first 72 hours of life, which is standard practice. Caregivers will document the NICU integrated flowsheet and the Sunrise electronic record with interventions regarding positioning, handling, skin assessment etc. per standard practice requirements.
62420531|NCT00945971|EXPERIMENTAL|Physical activity|The intervention group will participate in an exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be performed at the start and in the end of this study.
62803459|NCT06342817|EXPERIMENTAL|Intervention|Participants in the intervention group will attend 8 weekly online meetings lasting approximately 60 minutes each (generally structured in an initial 10 minutes for questions about the practices, 15-20 minutes of exposition on the central theme of the meeting, 5-10 minutes for class practice, 10-15 minutes for post-practice inquiry, 5 minutes for explanation of the week's informal practice and audios for daily practice). Audio in mp3 of the practice carried out at each meeting will be provided to maintain daily individual practice during the week. An online questionnaire related to weekly practices will also be left at the beginning of each meeting.
62028909|NCT05975190|EXPERIMENTAL|R&R arm (interventional arm)|The training program in the experimental arm includes relaxation techniques, breath hold training, music, and nature sounds that patients can listen to on an MP3 player. The training is offered one week before the planning CT scan and patients are encouraged to practice independently. Patients complete standardized questionnaires about their well-being and satisfaction at prospective time points before, during the radiation treatment course, as well as at 6 weeks follow-up.
62420532|NCT03190018|EXPERIMENTAL|Single group with CLS PD device|Aim of the intervention is to evaluate the adsorbs of uremic toxins and certain ions with Purcart and the evaluation of the glucose-salt solution ability to achieve stable osmolality. The intervention is during an eight hour study session.
62028910|NCT05975190|NO_INTERVENTION|Standard arm|Patients in the standard arm receive current conventional DIBH instruction without an extended R\&R training. Patients complete standardized questionnaires about their well-being and satisfaction at prospective time points before, during the radiation treatment course, as well as at 6 weeks follow-up.
62028911|NCT06635512|EXPERIMENTAL|Stress Ball Impact on Post-Transurethral Resection Recovery.|Participants will use stress balls regularly, and outcomes such as physical strength, pain levels, and psychological well-being will be assessed to evaluate the intervention's impact.
62028912|NCT06635512|EXPERIMENTAL|The effect of the stress ball on patients' discharge time.|This arm of the study examines how the use of stress balls during recovery affects the length of hospital stay and discharge time for patients
62227687|NCT04509115||Patients given short-acting opioid prescription|Patients not currently using opioids who receive a new short-acting opioid prescription for acute pain will be recruited.
62227688|NCT02941562|EXPERIMENTAL|Preoperative chemotherapy with short-course radiotherapy|Preoperative treatment:4 course of FOLFOX4 therapy combined with short-course radiotherapy
62227689|NCT02941562|ACTIVE_COMPARATOR|Preoperative neo-adjuvant therapy|Preoperative treatment:neo-adjuvant therapy
62420533|NCT03300232|EXPERIMENTAL|Computer-based VC-CBT|Computer-based VC-CBT: Three, one-hour computerized therapy sessions delivered on an interactive computerized platform with therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
62420534|NCT05606159|EXPERIMENTAL|Bacillus velezensis DSM 33864|"This arm will receive a single strain probiotic capsule containing Bacillus velezensis DSM 33864.~The probiotic will be taken orally, once a day, for 8 weeks."
62028913|NCT06031701|EXPERIMENTAL|Intervention|Neuro-psychosocial intervention with 12 grupal sessions is offered
62028914|NCT06031701|EXPERIMENTAL|Control|Waiting list control group
62028915|NCT02180646|ACTIVE_COMPARATOR|High Carb then High Protein Breakfast|A high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat) followed by a 7-day washout period, and then 7 days of eating a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat).
62028916|NCT02180646|ACTIVE_COMPARATOR|High Protein then High Carb Breakfast|A high protein breakfast - 500 kcal followed by a 7-day washout period, and then 7 days of eating a high carbohydrate breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
62028917|NCT05088213|EXPERIMENTAL|Patients in Group 1 undergo suction mini percutaneous nephrolithotomy|
62028918|NCT05088213|EXPERIMENTAL|Patients in Group 2 undergo standard percutaneous nephrolithotomy|
62028919|NCT02105363||Age 11-15|
62028920|NCT02105363||Age 16-20|
62028921|NCT02105363||Age 21-25|
62028922|NCT02105363||Age 26-30|
62028923|NCT02105363||Age 31-35|
62028924|NCT02105363||Age 36-40|
62028925|NCT02105363||Age 41-45|
62028926|NCT02105363||Age 46-50|
62028927|NCT02105363||Age 51-55|
62028928|NCT02105363||Age 56-60|
62028929|NCT02105363||age 61-65|
62028930|NCT02105363||Age 66-70|
62028931|NCT02105363||Age 71-75|
62028932|NCT02105363||Age 76-80|
62227690|NCT03188757|EXPERIMENTAL|hyperglycaemic clamp|
62227691|NCT05134350|EXPERIMENTAL|Arm A (LOXO-305 - Fasted)|LOXO-305 administered orally while fasting
62227692|NCT05134350|EXPERIMENTAL|Arm B (LOXO-305 - Fed)|LOXO-305 administered orally with standard meal
62028933|NCT02105363||Age 81-85|
62028934|NCT02105363||Age 86-90|
62028935|NCT02105363||Age 91-95|
62028936|NCT02105363||Age 96-100|
62028937|NCT02105363||Age 0-5|
62028938|NCT02105363||Age 6-10|
62028939|NCT01719952|EXPERIMENTAL|Carbetocin|Carbetocin 100 µg, given as an intravenous bolus over 30 seconds others names are: duratocin, pabal
62420535|NCT05606159|PLACEBO_COMPARATOR|Placebo control group|A placebo capsule containing microcrystalline cellulose will be taken orally, once a day, for 8 weeks.
62420536|NCT05801991|EXPERIMENTAL|Neurolens Treatment|Participants will receive Neurolens lenses (measured with the Neurolens device while wearing their habitual contact lenses) in their study spectacles
62028940|NCT01719952|ACTIVE_COMPARATOR|Oxytocin|Other names are Pitocin, syntocinon given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
62028941|NCT04789421|ACTIVE_COMPARATOR|Arm 1 (interventional)|Patients with equivocal skin lesions suspicious for melanoma, randomised to adjunctive RCM evaluation, following clinical and dermoscopy evaluation.
62028942|NCT04789421|PLACEBO_COMPARATOR|Arm 2 (control)|Patients with equivocal skin lesions suspicious for melanoma, randomised to clinical and dermoscopy evaluation only; adjunctive RCM evaluation refused.
62028943|NCT06315218|EXPERIMENTAL|Intervention Arm|iTHRIVE 365 is a multicomponent intervention that combines mHealth features and institutional to support community priorities identified in formative CBPR. In line with best-practices for trials of intervention principles (TIPs) with mHealth interventions, iTHRIVE 365 deploys intervention elements that serve to accomplish intervention strategies. iTHRIVE 365 intervention strategies are to promote: 1)Health knowledge and motivation; 2)Social support coping; 3)Access to culturally-affirming healthcare; and 4)Housing and other economic resources. iTHRIVE 365 pursues these strategies via these intervention elements: 1)Weekly HIV and psychological health information and motivation content and daily health notifications; 2)Online moderated forums, interpersonal chats, and community calendars; 3)Linkage to biopsychosocial healthcare via THRIVE SS's network of Black SGLM-affirming providers; and 4)Housing and economic resources through THRIVE SS's direct support and referral network.
62028944|NCT06315218|NO_INTERVENTION|Control Arm|The 6-month waitlist control group will only have access to THRIVE SS services not encompassed by iTHRIVE 365, such as in-person events. The investigators will ensure the control group does not access the iTHRIVE 365 mHealth app portion by screening all new app users, giving the intervention group unique private log-ins, and explaining the importance of securing those log-ins to ensure the accuracy of study results.
62028945|NCT01314118|EXPERIMENTAL|001|abiraterone acetate in combination with prednisone Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
62028946|NCT03453606|ACTIVE_COMPARATOR|home group|
62028947|NCT03453606|ACTIVE_COMPARATOR|center group|
62028948|NCT05515159||ECT group|patients undergoing electroconvulsive therapy for depression
62028949|NCT05515159||control group|healthy controls; patients undergoing electroconversion for atrial fibrillation
62028950|NCT05204355||Scleroderma|Patients with Scleroderma will be imaged with UTE MRI to compare MRI with CT for identifying Interstitial Lung Disease
62028951|NCT05204355||Scleroderma ILD|Patients with Scleroderma ILD who are initiating treatment will be imaged using hyperpolarized 129Xe MRI to assess treatment efficacy.
62028952|NCT00593372|EXPERIMENTAL|I|Drug Plus Behavioral Therapy
62028953|NCT00593372|NO_INTERVENTION|II|Drug Therapy Only
62028954|NCT04254900||Male wheelchair athletes|Other
62028955|NCT04254900||Female wheelchair athletes|Other
62028956|NCT02059694|EXPERIMENTAL|Hyaluronidase|"Dilutions (Blocks):~0.5 mL of lidocaine 2% with epinephrine 1:100,000 and 0.5 mL of marcaine 0.75% and 1 mL (150 U) of rHuPH20 for a total of 75 U/ml"
62420537|NCT05801991|PLACEBO_COMPARATOR|Placebo Lens|Participants will receive plano (no power) lenses in their study spectacles
62420538|NCT00710086|ACTIVE_COMPARATOR|1|Intravenous administration of hydromorphone intermittently
62028957|NCT02059694|OTHER|Comparitor|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20
62028958|NCT00919243|EXPERIMENTAL|prednisone|
62028959|NCT00919243|ACTIVE_COMPARATOR|allopurinol|
62028960|NCT04452708||HFNC at 30-60L/min|HFNC at 50-60L/min with humidification at 37C (Airvo 2, Fisher \& Paykel, Auckland, New Zealand) will be applied for patients with moderate type 1 respiratory failure
62028961|NCT04452708||NIV|NIV (Respironics V60) via oronasal mask (Quattro, ResMed) will be reserved for patients with type 2 respiratory failure
62028962|NCT04452708||Conventional nasal oxygen|Oxygen 1-5 L/min via nasal cannula for those with mild type 1 respiratory failure
62227693|NCT05134350|EXPERIMENTAL|Arm C (Omeprazole + LOXO-305 Fasted)|Omeprazole + LOXO-305 administered orally while fasting
62420539|NCT00710086|EXPERIMENTAL|2|Remifentanil intravenous patient-controlled analgesia
62227694|NCT02707237|OTHER|Verbal counseling|Parents with threatened delivery will receive verbal counseling only
62227695|NCT02707237|OTHER|Verbal, pictorial, written counseling|Parents with threatened delivery will receive verbal counseling supplemented with pictorial and written information
62227696|NCT01706887|EXPERIMENTAL|Diet Amiloride|One week Low Na diet (10 mmol/d) followed by ine week high Na diet (200 mmol/d) followed by 2 weeks administration of amiloride (10 mg the 1 st week and the 20mg).
62227697|NCT00645801|ACTIVE_COMPARATOR|Ingested 4 tablets of lubiprostone in divided doses + 1 gallon of polyethylene glycol|"First dose of lubiprostone 24 micrograms or placebo was administered 2 nights before colonoscopy and subsequent doses at breakfast, lunch, and dinner on the day before the procedure. Patients were on a clear liquid diet on the day before the procedure and were instructed to initiate drinking PEG (immediately after the last dose of lubiprostone) at 6 PM the evening before the colonoscopy and continued drinking the solution until at least 2 bowel movements were clear yellow or green. All study patients were educated and instructed to observe for clear stool, which was defined as watery consistency without any solid fecal material or dark liquid stools. Patients were instructed to return the unused PEG solution on the day of colonoscopy. After completing the preparation but before colonoscopy, patients were also required to fill a questionnaire to assess the tolerability of tablets and solution."
62420540|NCT06222411|OTHER|Physicians in Methodist Health System (MHS)|All Current physicians who are older than 18 years of age who are literate in English
62420541|NCT01552005||Population of patients treated with Saxagliptin|
62590632|NCT02410434|EXPERIMENTAL|LGBT Stigma Reduction Intervention|Participants will complete a pre-test, followed by a performance ethnography where they will watch theatre performances that illustrate stigma experienced by LGBT persons in Swaziland and Lesotho. They will have the opportunity to participate in these theatre performances to demonstrate reduced stigma and increased acceptance of LGBT persons. They will then complete a post-test, followed by a 6 week follow up survey.
62590633|NCT06206577|EXPERIMENTAL|Group A|Seven horizontal anterior maxillary ridge augmentation was done with symphyseal autogenous bone block, which was placed buccally as onlay graft.
62590634|NCT06206577|EXPERIMENTAL|Group B|Seven horizontal anterior maxillary ridge augmentation was done with symphyseal autogenous bone block, which was interpositioned in space created between buccal and lingual cortex as inlay graft.
62590635|NCT00487006|ACTIVE_COMPARATOR|At risk for CIH/with CIH|In hyperglycemic patients who will be starting insulin infusions to control hyperglycemia, blood will be drawn just prior to initiation of insulin infusion for the following levels: insulin, glucose, and C-peptide. These levels will be re-drawn upon achieving euglycemia, at 24 hours following that, then every three days. Levels will be again drawn once the insulin infusion is stopped/when CIH has resolved, and 24 hours following discontinuation of insulin infusion. At each timepoint the patient's clinical status will be documented and significant interval changes (intubation/extubation, change in pressor need), amount of dextrose (mg/kg/hour) supplied, and other concurrent medicines and doses will be recorded.
62590636|NCT00487006|ACTIVE_COMPARATOR|At risk for CIH/without CIH|"For comparative controls, insulin, C-peptide, and glucose levels will be drawn from ICU patients aged 2-12 years at similar risk (mechanical ventilation or vasoactive medications) but without CIH. The above labs will be drawn and data gathered near the time of risk, 24 hours later, then in 3 days following, for a total of three timepoints."
62590637|NCT00487006|ACTIVE_COMPARATOR|Not at risk for CIH/without CIH|"In addition, other ICU patients aged 2-12 years that are deemed NOT at risk for critical illness hyperglycemia will also be evaluated to serve as a group not at risk but admitted to the PICU as a further control population. Like Group B, the above labs will be drawn and data gathered at the time consent is obtained, 24 hours later, then in 3 days following, for a total of three timepoints"
62243084|NCT04654585|ACTIVE_COMPARATOR|Standard Care|"Participants randomised to the standard care group will be given standard care in assisting their smoking cessation attempt, but without free delivery of NRT or e-cigarettes.~Standard care includes motivational interviewing, advice to quit and prescription for NRTs. The number and online address of the French smoking cessation support helpline could also be provided. Health professionals will also be in position to prescribe NRT or other treatments (for example: Varenicline or Bupropion) which can help with smoking cessation, according to routine practice. The health professional could also give advice on e-cigarette use if he or she finds it suitable."
62028963|NCT05672992|EXPERIMENTAL|Scleroderma Participants|Participants in this arm will be asked to complete the Fitzpatrick skin type questionnaire to quantify skin tone and will have measurements taken with a colorimeter on the right and left forearms, hands, and fingers to quantify skin tone at the first study visit. Participants will be asked to complete the SSPRO questionnaire at the time of enrollment and every three months for the first 12 months and then every six months until the end of the study. At each study visit, a physician will measure the mRSS, which is a method of quantifying skin fibrosis; SFDI measurements, ultrasound, and durometry will then be done. Skin biopsies will be collected from the forearm of each subject annually. A small amount of blood will also be collected from subjects once per year to explore serum biomarkers of fibrosis.
62028964|NCT05672992|ACTIVE_COMPARATOR|Healthy controls|Participants in this arm will be asked to complete the Fitzpatrick skin type questionnaire to quantify skin tone and will have measurements taken with a colorimeter on the right and left forearms, hands, and fingers to quantify skin tone at the first study visit. At each study visit, SFDI measurements, ultrasound, and durometry will be done. Skin biopsies will be collected from the forearm of each subject annually. A small amount of blood will also be collected from subjects once per year to explore serum biomarkers of fibrosis.
62028965|NCT03862404|PLACEBO_COMPARATOR|Control group|Patients in this group receive Normal Saline injection in the inter pleural space
62420542|NCT05633095|EXPERIMENTAL|Treatment group|The patient with mild cognitive disorder and early dementia who will be treated with the medical device-Neuclare
62420543|NCT03456973|EXPERIMENTAL|Nurse AMIE|
62420544|NCT03377387|EXPERIMENTAL|capecitabine 7/7 with neratinib|"In the phase I portion of the study, a 3+3 design will be used. Once the MTD is reached, the phase II portion will enroll up to 24 patients. Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Patients will be seen on Day 1 of each cycle (+/- 3 days).~The MD has been determined as 240mg of neratinib and 1000mg BID of capecitabine."
62420545|NCT01614158||acute N-AION (< 7 d)|"physical, intellectual and linguistic abilities, in order to understand the test requirements~* willingness to comply with the protocol (4 visits)~* 45 - 80 years, informed consent~* acute N-AION (\< 7 d)~* D-BCVA \> 0.1 (2/20)~* RAPD ≥ 0.3 logE steps (neutral density filters)"
62420546|NCT01785043|EXPERIMENTAL|Liraglutide|Liraglutide will be administered once a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given independently of meals and preferably at the same each day. The starting dose will be 0.6 mg. After one week, the dose will be increased to 1.2 mg, and then it will be increased to 1.8 mg one week later to achieve better control of blood glucose. When Liraglutide is added to existing treatment containing metformin, as it is our scenario, the dose of metformin does not have to be changed.
62420547|NCT01785043|ACTIVE_COMPARATOR|Sitagliptin|"Sitagliptin will be administered once daily at a 100 mg dose. When Sitagliptin is used in combination with metformin, as it is our scenario, the dose of metformin should be maintained. If a dose of Sitagliptin is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.~Sitagliptin will be used daily during the study period of 12 weeks."
62420548|NCT04169425||Group 1|patients who underwent to laparoscopic TME, with elective diverting ileostomy for rectal cancer
62420549|NCT04169425||Group 2|patients who underwent to laparoscopic TME, without elective diverting ileostomy for rectal cancer
62420550|NCT04156282|ACTIVE_COMPARATOR|classical closure.|In this group, the rectus sheath closure will be done by simple running continuous sutures with the knots beneath the subcutaneous layer.
62420551|NCT04156282|ACTIVE_COMPARATOR|knot burial technique|The surgeon holds the left angle of the rectus sheath incision with an Allis. Using (Polyglactin 910) suture,The needle is taken from the inside outward on the upper edge.The needle is then taken lateral to the Allis and brought back into the wound by taking it through the inferior edge from outside to inside . A square knot is tied with three or four throws. The needle is then taken out of the wound through the upper edge and continuous running stitches . As the right angle is approached, the angle is held with an Allis. the suture, will be taken through the lower edge, is brought outside the wound and passed between the blades of a closed Allis before taking it inside out on the upper edge. One more bite is taken but this time just lateral to the Allis holding the angle, and the needle is brought back into the wound and to the outside between the edges of the rectus sheath. Using the loop of polyglactin held with the Allis , an Aberdeen knot is tied after removing the Allis.
62243085|NCT04808986|OTHER|serology COVID-19|Serology of COVID-19 will be proposed to all health professionels and household members included in the study
62227698|NCT00645801|PLACEBO_COMPARATOR|Ingested 4 tablets of placebo in divided doses + 1 gallon of polyethylene glycol|"First dose of look alike placebo was administered 2 nights before colonoscopy and subsequent doses at breakfast, lunch, and dinner on the day before the procedure. Patients were on a clear liquid diet on the day before the procedure and were instructed to initiate drinking PEG (immediately after the last dose of lubiprostone) at 6 PM the evening before the colonoscopy and continued drinking the solution until at least 2 bowel movements were clear yellow or green. All study patients were educated and instructed to observe for clear stool, which was defined as watery consistency without any solid fecal material or dark liquid stools. Patients were instructed to return the unused PEG solution on the day of colonoscopy. After completing the preparation but before colonoscopy, patients were also required to fill a questionnaire to assess the tolerability of tablets and solution."
62227699|NCT00562705|EXPERIMENTAL|1|Growth hormone and nutritional intervention
62227700|NCT00562705|ACTIVE_COMPARATOR|2|growth hormone
62227701|NCT01768520|EXPERIMENTAL|Entelon tab. 150mg|
62227702|NCT01768520|ACTIVE_COMPARATOR|Celebrex cap.|
62227703|NCT01768520|PLACEBO_COMPARATOR|Placebo|
62227704|NCT01658722||Observational|Long term follow-up
62227705|NCT03327428||Patients with Sickle Cell Disease|Patients with any sickling condition, including among others Sickle Cell Anemia, HbSC Disease, HbS-betaThal, excluding Sickle Cell Trait.
62227706|NCT02787889|EXPERIMENTAL|Uneven Protein Intake Pattern|Subjects consumed either dietary protein intake at 1.1g protein/kg/day over 8 weeks.Each participant will consume 15%/2-%/65% of total protein in breakfast, lunch, and dinner, respectively)\] on net protein synthesis over 8 weeks.
62227707|NCT02787889|EXPERIMENTAL|Even Protein Intake Pattern|Subjects consumed either dietary protein intake at 1.1g protein/kg/day over 8 weeks. Each participant will consume 33% of total protein consumed each meal
62227708|NCT01944150|ACTIVE_COMPARATOR|TENS|Patients with only transcutaneous electrical nerve stimulation (TENS),
62227709|NCT01944150|EXPERIMENTAL|TENS and hypnosis.|Patients with transcutaneous electrical nerve stimulation (TENS) and hypnosis simultaneously
62227710|NCT04176302|ACTIVE_COMPARATOR|Parkinson Holter|The neurologists in the study will receive information from the Parkinson Holter (device being studied)
62590638|NCT00006007|EXPERIMENTAL|gemcitabine + pemetrexed|"Patients receive gemcitabine IV over 30 minutes on days 1 and 8. pemetrexed disodium IV is administered over 10 minutes 90 minutes following gemcitabine on day 8. Treatment continues every 21 days for a minimum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients achieving a complete response receive 2 additional courses.~Patients are followed every 3 months for 5 years."
62028966|NCT03862404|EXPERIMENTAL|Experimental group|Patients in this group receive Bupivacaine 0.25% + Epinephrine 5 mcg/ml injection in the inter pleural space
62227711|NCT04176302|ACTIVE_COMPARATOR|Parkinson's diary|The neurologists in the study will receive information from a motor fluctuations diary
62227712|NCT04176302|PLACEBO_COMPARATOR|Traditional clinical practice|The neurologists in the study will receive no additional information other than what is obtained during the visit
62227713|NCT05063825|EXPERIMENTAL|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
62227714|NCT05063825|PLACEBO_COMPARATOR|Attention placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
62227715|NCT03879837|EXPERIMENTAL|Investigational Test Product|Fluticasone propionate pressurized metered dose inhaler, 110 mcg per actuation
62227716|NCT03879837|ACTIVE_COMPARATOR|Reference Listed Drug|Flovent HFA pressurized metered dose inhaler, 110 mcg per actuation
62227717|NCT03879837|PLACEBO_COMPARATOR|Placebo|Placebo pressurized metered dose inhaler, no active content
62227718|NCT03753620|EXPERIMENTAL|Music listening|The participants listens to their favorite emotional musical extracts. While listening, their Hemodynamic activity (with fMRI), their cerebral electric activity (with EEG) and their peripheral physiological parameters are recorded simultaneously
62227719|NCT02687022|EXPERIMENTAL|Myopia (Peramis)|Peramis aberrometry: 30 consecutive LASIK candidates with myopia and regular astigmatism who agree to participate in the study will have up to 4 aberrometry scans acquired consecutively using the Peramis (test) aberrometer.
62227720|NCT02687022|ACTIVE_COMPARATOR|Myopia (iDesign)|iDesign aberrometry: The same 30 consecutive LASIK candidates scanned in the Myopia (Peramis) arm will also have up to 4 aberrometry scans acquired consecutively using the iDesign aberrometer (control) aberrometer. The order of scans (Peramis and iDesign) will be randomised.
62227721|NCT02687022|EXPERIMENTAL|Irregular astigmatism (Peramis)|Peramis aberrometry: 30 consecutive cases with stage II-III keratoconus or post corneal transplantation cases with irregular astigmatism will have up to 4 aberrometry scans acquired consecutively using the Peramis (test) aberrometer
62227722|NCT02687022|ACTIVE_COMPARATOR|Irregular astigmatism (iDesign)|iDesign aberrometry: 30 consecutive cases with stage II-III keratoconus or post corneal transplantation cases with irregular astigmatism will also have up to 4 aberrometry scans acquired consecutively using the iDesign aberrometer (control) aberrometer. The order of scans (Peramis and iDesign) will be randomised.
62227723|NCT03501641|EXPERIMENTAL|image-based virtual reality learning|The participants will undergo 10-minute image-based virtual reality learning for history taking and physical examination of otolaryngology.
62227724|NCT03501641|ACTIVE_COMPARATOR|video-based learning|The participants will undergo 10-minute video-based learning for history taking and physical examination of otolaryngology.
62243086|NCT00235820|ACTIVE_COMPARATOR|A|
62243087|NCT00235820|ACTIVE_COMPARATOR|B|
62243088|NCT00235820|PLACEBO_COMPARATOR|C|
62028967|NCT00782340|ACTIVE_COMPARATOR|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
62028968|NCT00782340|PLACEBO_COMPARATOR|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
62227725|NCT02835833|EXPERIMENTAL|Nintedanib 150 mg + Bevacizumab 15 mg/kg|"The first three patients on study will be treated with 150 mg orally of Nintedanib two times daily plus 15 mg/kg of Bevacizumab administered intravenously on day one of each three week cycle.~If one dose limiting toxicity occurs in the first cohort, then three more patients will be treated at that same starting dose and assessed for toxicity after cycle two. If two or more patients have dose limiting toxicity, then dose escalation will end and the maximum tolerated dose will be reached."
62227726|NCT02835833|EXPERIMENTAL|Nintedanib 200 mg + Bevacizumab 15 mg/kg|If no patients experience dose limiting toxicity, then three additional patients will be treated with 200 mg orally of Nintedanib two times daily plus 15 mg/kg of Bevacizumab administered intravenously on day one of each three week cycle.
62227727|NCT01988766||Thrombosis|incidence of thrombosis in subjects who had PICC line placement
62227728|NCT01988766||No Thrombosis|no incidence of thrombosis in subjects who had PICC line placement
62227729|NCT00852540|EXPERIMENTAL|Retapamulin|
62227730|NCT00852540|ACTIVE_COMPARATOR|Linezolid|
62227731|NCT02856828|EXPERIMENTAL|Digital Image Enhancement (DIE) Group|A novel digital image enhancement technology will be used intraoperatively
62227732|NCT02856828|NO_INTERVENTION|Control Group|Standard intraoperative imaging will be used intraoperatively
62227733|NCT02206594|EXPERIMENTAL|Descemetorhexis|
62227734|NCT05304468|EXPERIMENTAL|Reduced-dose group|After 2 cycles of induction chemotherapy, patients with favorable response undergo low-dose (60Gy) intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (30 fractions). Patients also receive concurrent cisplatin once every three weeks for 2 cycles.
62227735|NCT05304468|ACTIVE_COMPARATOR|Standard dose group|After 2 cycles of induction chemotherapy, patients with favorable response undergo standard-dose (70Gy) intensity modulated radiotherapy (IMRT) 5 days per week for approximately 7 weeks (33 fractions). Patients also receive concurrent cisplatin once every three weeks for 3 cycles.
62227736|NCT00194519|ACTIVE_COMPARATOR|Acyclovir|
62227737|NCT00194519|PLACEBO_COMPARATOR|Placebo|
62227738|NCT04374344||Medical professionals|Medical professionals including cardiologists and cardiology residents.
62227739|NCT01124409|ACTIVE_COMPARATOR|3DCRT with EPID|this patients randomised to this arm will be planned by 3DCRT and during treatment setup error will be identified and corrected by weekly EPID if error \>3mm.Weekly CBCT will be done for this arm to note the setup error but will not be corrected.
62227740|NCT01124409|ACTIVE_COMPARATOR|IGRT with CBCT|The patients randomised to this arm will be planned by 3DCRT and set up error during RT will be verified by CBCT and error corrected if \>3mm.Weekly EPID will be done for setup error documentation but no correction based on EPID in this arm.
62227741|NCT05916573|EXPERIMENTAL|Mild Renal Impairment|
62227742|NCT05916573|EXPERIMENTAL|Moderate Renal Impairment|
62227743|NCT05916573|EXPERIMENTAL|Severe Renal Impairment|
62227744|NCT05916573|EXPERIMENTAL|Normal Renal function|
62227745|NCT06322953|ACTIVE_COMPARATOR|Start/Restart DOAC at 1 week|Participants will be restarted/started on DOAC 1 week post traumatic intracranial hemorrhage (tICrH).
62227746|NCT06322953|ACTIVE_COMPARATOR|Start/Restart DOAC at 4 weeks|Participants will be restarted/started on DOAC 4 weeks post traumatic intracranial hemorrhage (tICrH).
62227747|NCT03942809|EXPERIMENTAL|Effectiveness|Evaluate the Effectiveness in insertion success, insertion times, influence of respiratory, cardiac and cerebral circulation
62227748|NCT05624320|EXPERIMENTAL|single center open label, single arm study with no control and no randomization|Investigators will enroll 30 presbyopic patients between the ages of 40-55 years old who have undergone successful contact lens fitting in single-use, daily, contact lenses between the spectacle lens powers of -4.00 -to +1.00, in both eyes for best distance correction by the primary investigator
62227749|NCT04115085|EXPERIMENTAL|Hand therapy|9 weeks of standard hand therapy including two 20 min slots per week.
62227750|NCT04115085|EXPERIMENTAL|Therapeutic ultrasound|9 weeks of standard ultra sound therapy including two 10 min slots per week.
62227751|NCT04115085|EXPERIMENTAL|Combined hand therapy and therapeutic ultrasound|9 weeks of standard hand therapy plus therapeutic ultrasound including two 30 min slots per week.
62227752|NCT04115085|SHAM_COMPARATOR|Sham ultrasound group|9 weeks of sham ultrasound therapy including two 10 min slots per week.
62227753|NCT00824356|ACTIVE_COMPARATOR|GSK1004726 (1000mg)|1000mg aqueous suspension
62227754|NCT00824356|PLACEBO_COMPARATOR|Placebo|Intranasal spray
62227755|NCT00824356|ACTIVE_COMPARATOR|GSK1004723 (200mg)|200 mg aqueous suspension
62227756|NCT04833699|NO_INTERVENTION|Control|Group A or the control group did not pick up any therapy except our clinical standard postoperative care (ERAS protocol)
62590639|NCT05590897|EXPERIMENTAL|Antimicrobial Photodynamic Therapy Group|Participants in this group will receive treatment with tooth brushing, dental flossing and antimicrobial photodynamic therapy in the tongue.
62590640|NCT05590897|EXPERIMENTAL|Tongue Scraping Group|Participants in this group will receive treatment with tooth brushing, dental flossing and tongue scraping.
62803460|NCT06342817|NO_INTERVENTION|control group|In the control group there will be no intervention. Participants will only participate in the initial meeting explaining the study design and their role in it, inviting them to complete the questionnaires at the same time as the intervention group. They will commit to not receiving any intervention and will be asked not to participate in any meditation or mindfulness sessions during the period of application of the POMBM to the intervention group (8 weeks). After the end of this period, it will be offered the possibility to take the POMBM as they wish.
62028969|NCT01704092||Group High-dose|Dexmedetomidine loading dose 1μg/kg Dexmedetomidine maintenance dose 0.6μg/kg/h
62590641|NCT02295020|ACTIVE_COMPARATOR|Standard Treatment Only|Group A will receive standard treatment only such as NSAIDs and injections
62803461|NCT00934635|ACTIVE_COMPARATOR|002|Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 2 hours
62803462|NCT00934635|ACTIVE_COMPARATOR|003|Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 2 hours
62803463|NCT00934635|ACTIVE_COMPARATOR|004|Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 2 hours
62803464|NCT00934635|ACTIVE_COMPARATOR|005|Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 24 hours
62803465|NCT00934635|ACTIVE_COMPARATOR|006|Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 24 hours
62803466|NCT00934635|ACTIVE_COMPARATOR|007|Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 24 hours
62803467|NCT00934635|ACTIVE_COMPARATOR|008|Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 24 hours
62028970|NCT01704092||Group Low-dose|Dexmedetomidine loading dose 0.6μg/kg Dexmedetomidine maintenance dose 0.3μg/kg/h
62590642|NCT02295020|EXPERIMENTAL|Standard Treatment plus Bioskin Ten-7|Group B will receive standard treatment such as NSAIDs and injections and the Bioskin Ten-7 knee brace.
62803468|NCT00934635|OTHER|009|PET Scan PET Scan
62803469|NCT00934635|ACTIVE_COMPARATOR|001|Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 2 hours
62803470|NCT04012541|EXPERIMENTAL|treatment group|"1. post-myocardial infarction management~2. basic periodontal examinations~3. active dental procedure"
62803471|NCT04012541|ACTIVE_COMPARATOR|control group|"1. post-myocardial infarction management~2. basic periodontal examinations"
62803472|NCT02894671||male under 45y|blood exams performed on males under 45years (in a range of 20-90 years) not wearing articular devices, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb\<9)
62803473|NCT02894671||male over 45y|blood exams performed on males over 45years (in a range of 20-90 years) not wearing articular devices, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb\<9)
62803474|NCT02894671||fertile female|blood exams performed on fertile females (in a range of 20-90 years) not wearing articular devices, no pregnant, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb\<9)
62803475|NCT02894671||infertile female|blood exams performed on infertile females (in a range of 20-90 years) not wearing articular devices, no pregnant, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb\<9)
62803476|NCT06262789|EXPERIMENTAL|"Experimental arm with return-to-work after cancer consultation"|
62028971|NCT01704092||Group Control|Dexmedetomidine loading dose and Dexmedetomidine maintenance dose were placed with the same amount of 0.9% saline as placebo
62028972|NCT03631979|EXPERIMENTAL|Intervention group|Regular intestinal lavage with normal saline twice per day, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. The intervention will be applied at a maximum of 2 weeks from birth.
62590643|NCT05742360||OSA subjects with the excessively sleepy symptom subtype treated with CPAP|Patients with the excessively sleepy symptom subtype who accept CPAP therapy
62028973|NCT03631979|NO_INTERVENTION|Control group|Current routine for extremely preterm infants that do not defecate adequately will be applied.
62028974|NCT05445427|EXPERIMENTAL|VNS Treatment|Subjects with post COVID syndrome with fatigue and headache will have vagal nerve stimulator applied to the neck for 2 minute intervals with two sets administered three times daily
62028975|NCT05445427|NO_INTERVENTION|Non-VNS Treatment|Subjects with post COVID syndrome with fatigue and headache will receive current standard of care
62028976|NCT00321919|EXPERIMENTAL|Early Epoetin Beta Therapy|Participants received immediate epoetin beta therapy starting at 2000 IU, subcutaneously once weekly up to four years to reach a target Hb level of 13-15 g/dL; with an individual Hb increase of at least 2 g/dL within approximately 3 months.
62227757|NCT04833699|EXPERIMENTAL|Study|Group B served as the hot pack group boiled tap water (80 °C) was put in a rubber water bag with a fluffy cover (Fig. 1), and placed on the patient's abdomen at 3, 6, 9, and 12 h after the surgical procedure for 30 minutes in addition to clinical standard postoperative care (ERAS protocol).
62028977|NCT00321919|ACTIVE_COMPARATOR|Late Epoetin Beta Therapy|Participants received epoetin beta treatment starting at 2000 IU, subcutaneously once weekly up to four years only when a decline in Hb levels to \<10.5 g/dL had occurred in order to reach a target Hb of 10.5-11.5 g/dL.
62227758|NCT00591045|EXPERIMENTAL|1|The patients will undergo neoadjuvant chemotherapy with mFOLFOX and then an operation and then individualized adjuvant chemotherapy.
62227759|NCT00591045|NO_INTERVENTION|2|No neoadjuvant chemotherapy and surgery and then adjuvant chemotherapy.
62227760|NCT06525909||Untreated group|The untreated patients who met the staging subgroups of the Chinese Guidelines for the Prevention and Control of Chronic Hepatitis B, 2022 edition or lost HBsAg spontaneously.
62227761|NCT06525909||NA treatment group|The patients who achieved HBV DNA suppression by NA.
62590644|NCT03512717|EXPERIMENTAL|Potenfill|
62028978|NCT05399953|ACTIVE_COMPARATOR|Control Group|Participants in the control group will receive usual care ( standard physical therapy program)
62227762|NCT03290209|EXPERIMENTAL|Laparoscopic D1 Lymphadenectomy|Laparoscopic D1 Lymphadenectomy will be performed for the treatment of patients assigned to this group.
62227763|NCT03290209|ACTIVE_COMPARATOR|Laparoscopic D2 Lymphadenectomy|Laparoscopic D2 Lymphadenectomy will be performed for the treatment of patients assigned to this group.
62227764|NCT04236505|EXPERIMENTAL|ACT group intervention|4 weekly 2hour group therapy interventions drawing from an Acceptance and Commitment Therapy (ACT) based protocol.
62227765|NCT04236505|EXPERIMENTAL|Mindfulness skills group intervention|4 weekly 2 hour group therapy interventions drawing from an Mindfulness based stress reduction (MBSR) based protocol
62227766|NCT04236505|PLACEBO_COMPARATOR|Wait list control group|Wait list control group who at the time of the experimental group interventions are not attending a group and receiving treatment as usual. This group are offered a Mindfulness skills group intervention after the follow up data has been collected.
62590645|NCT03512717|ACTIVE_COMPARATOR|Powerfill|
62590646|NCT00979875|EXPERIMENTAL|Lispro+PH20, Lispro, Glulis+PH20, Glulis, Aspart+PH20, Aspart|"All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C). Each intervention was separated by a 3- to 14-day washout.~Intervention A: Participants received a single, subcutaneous (SC) injection of 95 units per milliliter (U/mL) Lispro + 5 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20 (PH20) and a single, SC injection of 95 U/mL Lispro alone 3 to 14 days apart.~Intervention B: Participants received a single, SC injection of 95 U/mL Glulisine (Glulis) + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Glulis alone 3 to 14 days apart.~Intervention C: Participants received a single, SC injection of 95 U/mL Aspart + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Aspart alone 3 to 14 days apart."
62590647|NCT04459715|EXPERIMENTAL|Xevinapant (Debio 1143)|"Participants will receive:~Concomitant chemo-radiation therapy period (Cycles 1-3):~* Radiotherapy~* Cisplatin~* Xevinapant (Debio 1143)~Monotherapy period (Cycles 4-6):~• Xevinapant (Debio 1143)"
62590648|NCT04459715|ACTIVE_COMPARATOR|Placebo|"Participants will receive:~Concomitant chemo-radiation therapy period (Cycles 1-3):~* Radiotherapy~* Cisplatin~* Matched placebo~Monotherapy period (Cycles 4-6):~• Matched placebo"
62803477|NCT06262789|NO_INTERVENTION|"Standard arm without with return-to-work after cancer consultation"|Patient are treated according to usual care, according to local practice.
62028979|NCT05399953|EXPERIMENTAL|Intervention Group|Particiapnts in intervevention group will receive both usual care and myofascial release techniques
62028980|NCT04230408|EXPERIMENTAL|DURVALUMAB (MEDI4736) + carboplatin-paclitaxel|"Induction chemo-immunotherapy phase:~Two cycles of Paclitaxel 200 mg/m2, Carboplatin AUC 6 and Durvalumab 1500 mg intravenously every 21 days.~Concurrent chemo-immuno-radiotherapy phase:~Radiation therapy concomitantly with: paclitaxel 50 mg/m2 intravenously every 7 days (+/- 3 days) until completion of radiation therapy, carboplatin AUC 2 intravenously every 7 days (+/- 3 days) until completion of radiation therapy and durvalumab 1500 mg intravenously every 21 days (+/- 6 days) for a maximum of 2 doses.~Concurrent chemo-immuno-radiotherapy:~Durvalumab 1500 mg intravenously every 28 days (+/- 7 days) for a maximum of 12 doses"
62028981|NCT02626715|ACTIVE_COMPARATOR|Reduced-Intensity Conditioning|"Campath (alemtuzumab), Droxia (hydroxyurea), Fludara (fludarabine), Alkeran (melphalan), Thiotepa (triethylenethiophosphoramide)~Trade Name (generic name)"
62227767|NCT00584597|PLACEBO_COMPARATOR|1|Saline
62227768|NCT00584597|EXPERIMENTAL|2|Traumeel S 1 mL
62227769|NCT00584597|EXPERIMENTAL|3|Traumeel S 2 mL
62227770|NCT00584597|EXPERIMENTAL|4|Traumeel S 3 mL
62227771|NCT00923533|ACTIVE_COMPARATOR|Part A|Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
62227772|NCT00923533|ACTIVE_COMPARATOR|Part B|Hydrochlorothiazide (7day) Hydrochlorothiazide + Fimasartan (7day)
62028982|NCT02626715|ACTIVE_COMPARATOR|Myeloablative Conditioning|"Campath (alemtuzumab), Thiotepa (triethylenethiophosphoramide) , Fludara (fludarabine), Busulfex (busulfan)~Trade Name (generic name)"
62028983|NCT06034405||ATTR Negative|Participants who have undergone previous lumbar spinal, and/or carpel tunnel surgery will provide medical record data and spinal specimen for analysis of presence of ATTR amyloid.
62243089|NCT02885948|EXPERIMENTAL|Naloxone|"The naloxone arm of the study will receive naloxone at a rate of 5mcg/kg/hr which equates to 0.25ml/kg/hr. Each 1 ml ampoule of solution contains 400 micrograms (0.4mg) naloxone hydrochloride present as naloxone hydrochloride dihydrate.~Excipients: each 1ml contains 3.55mg sodium. This will be diluted to a concentration of 20mcg/ml with 0.9% NaCl. Presented as solution for injection or infusion. Clear colourless sterile solution."
62803478|NCT02289495|EXPERIMENTAL|GSK2838232 without RTV|Subjects will receive 20 mg of GSK2838232/ placebo (3:1) in cohort 1 and 50 mg of GSK2838232/ placebo (3:1) in cohort 2, administered QD for 8 days. There will be a minimum period of 7 days between successive cohorts to establish safety and PK for dose escalation; enrollment into a cohort will commence following review of interim PK and safety data from at least 4 subjects in the preceding cohort
62803479|NCT02289495|EXPERIMENTAL|GSK2838232 with RTV|Subjects will receive 10 mg of GSK2838232/ placebo (3:1) in cohort 3, 20 mg of GSK2838232/ placebo (3:1) in cohort 4 and 50 mg of GSK2838232/ placebo (3:1) in cohort 5, co administered with RTV 100 mg, QD for 11 days. There will be a minimum period of 7 days between successive cohorts to establish safety and PK for dose escalation; enrollment into a cohort will commence following review of interim PK and safety data from at least 4 subjects in the preceding cohort
62803480|NCT01467544|NO_INTERVENTION|wait list control group|After completing time three data collection, wait-listed participants will be provided with the complete tai chi intervention (8 weeks).
62803481|NCT01467544|EXPERIMENTAL|Tai Chi intervention group|This participant group completes the 8-week tai chi group intervention.
62803482|NCT05626166|PLACEBO_COMPARATOR|control group|Group I (Control group; n=30) which will receive mesalamine 1000 mg three times daily plus placebo tablets twice daily for 3 months.
62803483|NCT05626166|EXPERIMENTAL|diosmin group|Group II: (Diosmin group; n=30) which will receive mesalamine 1000 mg three times daily plus diosmin 600 mg twice daily for 3 months.
62803484|NCT04394923|EXPERIMENTAL|"Intervention group or PRINT group"|The ablation line previously drawn will be modified regarding the esophageal print position in order to avoid RF application within the red layer of the esophageal print, which is the zone where the atrioesophageal distance is shorter. The maximal distance and the area between the original line and the modified line will be noted. In cases when ablation through the red layer is unavoidable, the delivered energy can be lowered to an ablation index (AI) of 300 regardless of the local wall thickness. If the temperature rises above 39℃, ablation will be immediately stopped, and energy will be reduced.
62028984|NCT06034405||ATTR Positive|Participants who have undergone previous lumbar spinal, and/or carpel tunnel surgery will provide medical record data, spinal specimen, prospective data from cardiac workup with confirmed ATTR amyloid in spinal specimen then undergo cardiac workup for cardiac phenotyping/genotyping.
62243090|NCT02885948|PLACEBO_COMPARATOR|Saline|The placebo arm of the study will receive an infusion of normal saline at a rate of 0.25ml/kg/hr.
62227773|NCT03034304|EXPERIMENTAL|MASCT-I alone or in combination with chemical drugs or in combination with PD-1 antibody|"Group 1: MASCT-I alone;~Group 2: Advanced urothelial carcinoma and cholangiocarcinoma treatment with MASCT-I alone,Advanced soft tissue sarcoma and osteosarcoma treatment with MASCT-I alone or combination with ifosfamide. In the event of disease progression, treatment with MASCT-I +PD1 antibody;~Group 3: Advanced metastatic or recurrent urothelial carcinoma, soft tissue sarcoma/osteosarcoma, and cholangiocarcinoma that progressed after first line chemotherapy were treated with MASCT-I combined with PD1 antibody;~Group 4: Recurrent metastatic solid tumors that had failed previous treatment with PD1 antibody were treated with MASCT-I + PD1 antibody;~Group 5: Untreated advanced soft tissue sarcom treatment with MASCT-I+AI (Adriamycin+ifosfamide);~Group 6: Untreated advanced urothelial carcinoma treatment with MASCT-I+GP/GC(Gemcitabine+cisplatin/ Gemcitabine+carboplatin);"
62227774|NCT01001832|ACTIVE_COMPARATOR|Subcutaneous (SC) abatacept, 125 mg|
62227775|NCT01001832|ACTIVE_COMPARATOR|Intravenous (IV) abatacept, 125 mg|
62590649|NCT05616507|EXPERIMENTAL|Arm A|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
62590650|NCT05616507|NO_INTERVENTION|Arm B|observation
62590651|NCT00444041|EXPERIMENTAL|Xelox, Bev|
62420552|NCT05698524|EXPERIMENTAL|Single arm|"Patients will receive a combination of PCI-24781/Abexinostat and temozolomide. Patients will receive a loading dose of PCI-24781/Abexinostat prior to the start of Cycle 1; patients will take PCI-24781/Abexinostat by mouth twice a day starting 7 days prior to Cycle 1, Day 1 and ending 4 days prior to Cycle 1, Day 1.~Patients will continue taking PCI-24781/Abexinostat on days 1-4, 8-11, 15-18, and 22-25 of each 28 day cycle, starting with Cycle 1, Day 1. The initial dose level is 60 mg of PCI-2478/Abexinostat 1 by mouth twice daily. The dose level may be escalated based on results of interim data analysis.~Patients will additionally initiate metronomic temozolomide on Cycle 1, Day 1 at a dose of 50 mg/m2, taken by mouth twice daily. Patients will continue the PCI-24781/Abexinostat and metronomic temozolomide regimen until disease progression or intolerance."
62590652|NCT06137963|OTHER|Transform10 Waitlist|"The control group will receive access to the Transform10 website at 6 months.~Patients in this group will report their active minutes and weight via the Transform10 website throughout the 6 month-long programs. In addition, participants will take an Hba1c blood test at pre surgical screening, 6 months after their day of surgery and 1 year after their day of surgery as part of routine procedures."
62590653|NCT06137963|EXPERIMENTAL|Transform10|"Patients in this group will get access to the Transform10 website on their day of surgery.~Patients in this group will report their active minutes and weight via the Transform10 website throughout the 6 month-long program. In addition, participants will have a repeat Hba1c test ordered at 6 months after their day of surgery and 1 year after their day of surgery as part of routine procedures."
62590654|NCT02825758|EXPERIMENTAL|ZestiVits|"Supplement for use in ketogenic and restricted therapeutic diets, from the age of 11.~Daily use for 7 days. Daily intake level for each subject will be determined and prescribed by a dietitian."
62590655|NCT05420298|EXPERIMENTAL|cervical mobilization|session will include3-5 repetitions of muscle energy technique in combination of facet joint mobilization of unilateral antro-posterior glide and extension repetitions
62590656|NCT05420298|ACTIVE_COMPARATOR|cervical manipulation|patients will receive high velocity low amplitude thrust
62590657|NCT03547063||Sleeve Gastrectomy (SG)|25 participants, male and female, aged 18-50 years, body mass index (BMI) 35-50 kg/m2, due to undergo primary SG
62590658|NCT03547063||Lifestyle Intervention|25 participants, male and female, aged 18-50 years, BMI 35-50 kg/m2
62590659|NCT03547063||Normal Weight|25 participants, aged 18-50 years BMI 18.5-24.9 kg/m2, age and gender matched to group with severe obesity
62420553|NCT03909971|EXPERIMENTAL|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
62420554|NCT03976843|EXPERIMENTAL|1/18F-DCFPyL PET/CT + radical prostatectomy|18F-DCFPyL PET/CT with radical prostatectomy and lymphadenectomy
62590660|NCT02716116|EXPERIMENTAL|Part 1: Dose Escalation Component|TAK-788 treatment for participants with advanced NSCLC.
62590661|NCT02716116|EXPERIMENTAL|Part 2: Expansion Cohort 1|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions, who have either not received or not shown an objective response to an EGFR tyrosine kinase inhibitors (TKI), and who have no active, measurable central nervous system (CNS) metastases.
62590662|NCT02716116|EXPERIMENTAL|Part 2: Expansion Cohort 2|TAK-788 treatment for NSCLC participants with HER2 exon 20 activating insertions or point mutations and no active, measurable CNS metastases.
62590663|NCT02716116|EXPERIMENTAL|Part 2: Expansion Cohort 3|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions or HER2 exon 20 activating insertions or point mutations and active, measurable CNS metastases.
62590664|NCT02716116|EXPERIMENTAL|Part 2: Expansion Cohort 4|TAK-788 treatment for NSCLC participants with other targets against which TAK-788 is active (examples include EGFR exon 19 deletions or exon 21 substitutions \[with or without T790M mutations\] and other uncommon EGFR activating mutations), without active CNS metastases.
62227776|NCT05438017|EXPERIMENTAL|Dreem + PSG|
62227777|NCT05534256|EXPERIMENTAL|Intervention Group|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth.
62227778|NCT05534256|NO_INTERVENTION|Control Group|The control group will receive usual medical care and American Heart Association's Healthy Living booklet
62243091|NCT03099239|EXPERIMENTAL|Single hCT-MSC infusion|Subjects 1-3 will receive a single infusion of hCT-MSCs.
62420555|NCT04318249|EXPERIMENTAL|Assisted Relaxation Therapy|This group will be receiving an assisted relaxation therapy intervention
62590665|NCT02716116|EXPERIMENTAL|Part 2: Expansion Cohort 5|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions, who have previously shown an objective response to an EGFR TKI and subsequently progressed without active CNS metastases.
62590666|NCT02716116|EXPERIMENTAL|Part 2: Expansion Cohort 6|TAK-788 treatment NSCLC participants with EGFR exon 20 activating insertions, who have not received prior systemic anticancer treatment for locally advanced or metastatic disease without active CNS metastases
62590667|NCT02716116|EXPERIMENTAL|Part 2: Expansion Cohort 7|TAK-788 treatment for participants with solid tumors other than NSCLC with EGFR/HER2 mutations against which TAK-788 is active without active CNS metastases.
62803485|NCT04394923|OTHER|Control group|The ablation line will not be modified from the original one drawn before randomization and RF applications will follow the regular path. If the temperature rises above 39℃, ablation will be immediately stopped, and energy will be reduced.
62803486|NCT02232022|EXPERIMENTAL|NonCryptogenic Ischemic Stroke Patients|Patients with non-cryptogenic ischemic stroke will be enrolled within 10 days of stroke onset
62803487|NCT01356537||Gaucher's Disease under VPRIV|
62420556|NCT04318249|EXPERIMENTAL|Modified Assisted Relaxation Therapy|This group will be receiving a modified version of an assisted relaxation therapy intervention
62590668|NCT02716116|EXPERIMENTAL|Part 3: Extension Cohort|TAK-788 treatment for participants with previously treated locally advanced or metastatic NSCLC whose tumors harbor EGFR exon 20 insertion mutations.
62590669|NCT03813784|EXPERIMENTAL|A|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m\^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m\^2, IV q3w; for 4-6 cycles followed by SHR-1210 plus apatinib 250 mg PO qd.
62803488|NCT02124733|ACTIVE_COMPARATOR|Group 1: 30 minutes|The first 4 patients enrolled will be considered Group 1, and will receive 30 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated in terms of erythema immediately post-PDT (Day 1) and on Day 4 . If there is no clinical reaction on Side A after 2 patients, then the dose will be advanced to the next Group. If the post-PDT reaction (erythema at Day 4) on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of the 4 patients, then the protocol will advance to Group 2
62420557|NCT03235973|EXPERIMENTAL|Fludarabine-Cladribine-Busulfan conditioning regimen|
62420558|NCT06102499||Pediatric population|Pediatric population \< 18 years old (estimated 100 patients)
62420559|NCT06102499||Adult population|Adult population \>or= 18 years old (estimated 100 patients)
62420560|NCT06538441||Severe pneumonia|"Severe pneumonia patients will be continuously recruited in ICU department in Shanghai General Hospital (n=450) and RICU in the First Affiliated Hospital of Chongqing Medical University (n=150) during June 1, 2022 to April 28, 2024.~Severe pneumonia was defined as meeting either one major criteria (septic shock with need of vasopressors or respiratory failure requiring mechanical ventilation) or three minor (laboratory and physiologic markers such as uremia or hypothermia) criteria according to the ATS/IDSA major criteria."
62420561|NCT05155046|EXPERIMENTAL|18F-DCFPyL imaging|18F-DCFPyL imaging with routine imaging (mpMRI)
62420562|NCT05189860|EXPERIMENTAL|C-MIC Device|Device plus Standard of Care
62420563|NCT05489523|EXPERIMENTAL|Treatment Arm|Tafamidis 61 mg
62420564|NCT04106947||Patients with Hirschsprung and anorectal malformation|Patients with Hirschsprung and anorectal malformation living in Norway
62420565|NCT00295308|EXPERIMENTAL|Arm 1|
62243092|NCT03099239|EXPERIMENTAL|Two hCT-MSC infusions|Subjects 4-6 will receive two infusions of hCT-MSCs.
62243093|NCT03099239|EXPERIMENTAL|Three hCT-MSC infusions|Subjects 6-12 will receive three infusions of hCT-MSCs.
62243094|NCT05712057|EXPERIMENTAL|Cognitive Restructuring + Repetitive Transcranial Magnetic Stimulation (rTMS)|Group 1 (G1)- 80 eligible participants will receive training in Cognitive Restructuring (CR). These participants will use CR while receiving rTMS over their individual dlPFC target and will partake in short term and long term follow up testing.
62243095|NCT05712057|ACTIVE_COMPARATOR|Cognitive Restructuring + scalp electrical stimulation|Group 2 (G2) - 80 eligible participants will receive training in CR. These participants will use CR while receiving scalp electrical stimulation over their individual dlPFC target and will partake in short term and long term follow up testing.
62243096|NCT05712057|ACTIVE_COMPARATOR|Emotional Awareness Training + Repetitive Transcranial Magnetic Stimulation (rTMS)|Group 3 (G3) - 80 eligible participants will receive emotional awareness training. These participants will receive rTMS over their individual dlPFC target and will partake in short term and long term follow up testing.
62243097|NCT02187614|EXPERIMENTAL|Diclofenac and Placebos|Participants in this group will receive a Diclofenac 75 mg intramuscular injection, and two placebo saline solutions intravenously.
62243098|NCT02187614|ACTIVE_COMPARATOR|Morphine and Placebos|Participants in this group will receive Morphine 0.1 mg/kg intravenously, along with an additional intravenous placebo and an intramuscular placebo injection.
62243099|NCT02187614|ACTIVE_COMPARATOR|Paracetamol and Placebos|participants in this group will receive intravenous Paracetamol 1 gm solution, along with an additional intravenous placebo and an intramuscular placebo injection.
62590670|NCT03813784|ACTIVE_COMPARATOR|B|Capecitabine 1000 mg/m\^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus Oxaliplatin 130 mg/m\^2, IV q3w
62590671|NCT03813784|EXPERIMENTAL|C|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m\^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m\^2, IV q3w; for 4-6 cycles followed by SHR-1210
62590672|NCT05655286|EXPERIMENTAL|Group A- immediately rinse mouth|Children are instructed to rinse their teeth with a cup of water containing about 50 ml immediately after SDF treatment. Afterwards, no post-treatment protocol is given to children.
62590673|NCT05655286|EXPERIMENTAL|Group B- not to rinse for at least 30 minutes|Children are instructed not to eat and drink for at least 30 minutes.
62735306|NCT02793973|ACTIVE_COMPARATOR|80% discrepancy lift height correction|Each participant will be given 80% discrepancy shoe lift height correction through analyzing kinematic performance of center mass of body and will be required to wear the lifts in their shoes when they are walking or standing for 6 month.
62803489|NCT02124733|ACTIVE_COMPARATOR|Group 2: 45 minutes|Patients in this group will receive 45 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated for erythema response immediately post-PDT and at Day 4. If there is no clinical reaction on Side A after 2 patients, then the dose will be advanced to the next Group. If the post-PDT reaction (erythema at Day 4) on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of the 4 patients, then the protocol will advance to Group 3.
62227779|NCT05441254|EXPERIMENTAL|Experimental group|"Camrelizumab: 200 mg, intravenous infusion, d1, q3w;~Nab-paclitaxel: 130 mg/m2 intraperitoneal and 130 mg/m2 intravenously, d1, q3w;~S-1: calculated based on body surface area Dosage, twice a day, orally, d1-d14, q3w;"
62227780|NCT00515320|EXPERIMENTAL|Fluoxetine|
62227781|NCT00515320|PLACEBO_COMPARATOR|Placebo|
62227782|NCT04429997|EXPERIMENTAL|Removal of fibrosynovial tissue|Removal of fibrosynovial tissue in patellar non-resurfacing TKA
62227783|NCT04429997|EXPERIMENTAL|Non-removal of fibrosynovial tissue|Non-removal of fibrosynovial tissue in patellar non-resurfacing TKA
62227784|NCT01924520|EXPERIMENTAL|Group 1 (FK949E lower dose)|Oral
62227785|NCT01924520|EXPERIMENTAL|Group 2 (FK949E middle dose)|Oral
62227786|NCT01924520|EXPERIMENTAL|Group 3 (FK949E higher dose)|Oral
62227787|NCT06164067||Pregnant women who abort within 24 hours|Group 1 treatment was completed in the first 24 hours ( who were completely aborted and removed the fetal material and its attachments )
62227788|NCT06164067||Pregnant women who abort within 24- 48 hours|Group 2 consisted of patients who needed additional cycles and aborted within 24-48 hours.
62227789|NCT04552756|EXPERIMENTAL|Patients irradiated for high-grade glioma|Participants who receive radiotherapy or radiochemotherapy for glioblastoma (grade IV), anaplastic astrocytoma (grade III) or anaplastic oligodendroglioma (grade III).
62227790|NCT03410615|ACTIVE_COMPARATOR|Radiation/Cisplatin|"All patients will receive standard fractionation radiation therapy (RT) scheme: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)~Cisplatin IV 100 mg/m2 days 1, 22, 43 concurrently with RT"
62227791|NCT03410615|EXPERIMENTAL|Radiation/Durvalumab + Adjuvant Durvalumab|"All patients will receive standard fractionation radiation therapy (RT) scheme: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)~Concurrent Phase: Durvalumab IV 1500 mg, days -7 and 22 (the second dose is given concurrently with RT).~Adjuvant Phase (to start 4 weeks after completion of concurrent phase): Durvalumab IV 1500 mg q4 weekly for 6 doses."
62227792|NCT03410615|EXPERIMENTAL|Radiation/Durvalumab + Adjuvant Durvalumab/Tremelimumab|ARM CLOSED TO ACCRUAL WITH AMENDMENT #1
62227793|NCT04115553|EXPERIMENTAL|idiopathic intracranial hypertension|patients with idiopathic intracranial hypertension
62227794|NCT04115553|SHAM_COMPARATOR|healthy subjects|Healthy subjects
62227795|NCT04553198|EXPERIMENTAL|Backward Locomotion Treadmill Training (BLTT)|Participants train on a reverse treadmill (no bodyweight support), three times per week x 3 weeks.
62227796|NCT04553198|SHAM_COMPARATOR|Forward Locomotion Treadmill Training (FLTT)|Participants train on a treadmill (no bodyweight support), three times per week x 3 weeks.
62227797|NCT02035592|ACTIVE_COMPARATOR|Full dose blueberry|"26g of freeze dried blueberry powder; equivalent to 2 portions of fresh blueberries per day.~Frequency: 26g per day.~Total duration: 6-month."
62803490|NCT02124733|ACTIVE_COMPARATOR|Group 3: 60 minutes|Patients in this group will receive 60 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated for erythema responses immediately post-PDT and at Day 4. If the post-PDT reaction on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of patients, then the protocol will terminate after 15 patients (total for all groups) have been treated.
62803491|NCT05182788|PLACEBO_COMPARATOR|Placebo pressed candy|
62735307|NCT02793973|EXPERIMENTAL|optimal lift height correction|Each participant will be given the optimal shoe lift height correction through analyzing kinematic performance of center mass of body and will be required to wear the lifts in their shoes when they are walking or standing for 6 month.
62803492|NCT05182788|EXPERIMENTAL|CHOLESWISE pressed candy|
62803493|NCT02052544||Study patients|Patients receiving unfractionated heparin (UFH)
62803494|NCT05648266|ACTIVE_COMPARATOR|Continuous SAPB|postoperative serratus-anterior-plane-block 20ml Ropivacain 0,75%, pain catheter with continous administered Ropivacain (5ml/h 0,2% for 48h)
62803495|NCT05648266|PLACEBO_COMPARATOR|Placebo|standard of care
62803496|NCT03864939|EXPERIMENTAL|dHAM|dHAM wrap is placed during RRP.
62803497|NCT03864939|PLACEBO_COMPARATOR|Standard|A standard RRP is performed.
62803498|NCT04636281|EXPERIMENTAL|Passive static stretching exercise|Group 1 will receive passive static stretching. All subjects will be assessed before the intervention through likert muscle soreness scale, Numeric Rating Pain Scale and range of motion for Shoulder, elbow, and wrist by a Goniometer. After that all subjects will perform eccentric exhaust weight exercises in the gym of all mentioned joints, three sets at each joint. Before giving the intervention they will assess of all mentioned parameters.
62803499|NCT04636281|EXPERIMENTAL|Active static stretching|Group 2 will receive active static stretching. All subjects will be assessed before the intervention through likert muscle soreness scale, Numeric Rating Pain Scale and range of motion for Shoulder, elbow, and wrist by a Goniometer. After that all subjects will perform eccentric exhaust weight exercises in the gym of all mentioned joints, three sets at each joint. Before giving the intervention they will assess of all mentioned parameters.
62803500|NCT00890734|EXPERIMENTAL|1|
62803501|NCT00890734|PLACEBO_COMPARATOR|2|
62803502|NCT02477124|ACTIVE_COMPARATOR|transvaginal digital colposcope (TVCD)|Each enrolled patient will undergo the standard of care for cervical cancer screening at her institution, and then the trans-vaginal colposcope will be used to collect digital images of the cervix.
62227798|NCT02035592|ACTIVE_COMPARATOR|Half dose blueberry|"26g of freeze dried powder; containing 13g of freeze dried blueberry powder and 13g of placebo comparator material; equivalent to 1 portion of fresh blueberries per day.~Frequency: 26g per day.~Total duration: 6-month."
62735308|NCT00190229|EXPERIMENTAL|1|Cyclophosphamide
62735309|NCT03346421||diet and physical activity|
62735310|NCT02200926|EXPERIMENTAL|Placebo|The breathing was performed normally in this groups.
62803503|NCT02477124|ACTIVE_COMPARATOR|standard of care screening|Each enrolled patient will undergo the standard of care for cervical cancer screening at her institution, and then the trans-vaginal colposcope will be used to collect digital images of the cervix.
62803504|NCT04890379|EXPERIMENTAL|standard management plus Dimethyl Fumarate|
62803505|NCT04890379|PLACEBO_COMPARATOR|standard management plus placebo|
62803506|NCT03880292|OTHER|Intraoperative Maneuvers|To document intraoperative maneuvers performed in repsonse to alerts
62803507|NCT03242486|EXPERIMENTAL|toric intraocular lens|toric intraocular lens is implanted to all subjects
62803508|NCT03010319|EXPERIMENTAL|PriMatrix|Arm will receive PriMatrix Dermal Repair Scaffold plus secondary dressings to maintain a moist wound healing environment and an appropriate off-loading device.
62803509|NCT03010319|ACTIVE_COMPARATOR|Standard of Care|Arm will receive moist wound therapy consisting of 0.9% Sodium Chloride gel plus secondary dressings and an appropriate off-loading device.
62803510|NCT01022281||Normal Controls|Normal age matched controls without exfoliation
62803511|NCT01022281||Exfoliation Syndrome|Patients with exfoliation syndrome
62803512|NCT05416866|EXPERIMENTAL|TR group|ultrasound-guided transversus abdominis plane block with 20 ml mixture 0.20% ropivacaine + dexamethasone 5 mg and retrolaminar block with 30-40 ml mixture 0.20% ropivacaine + dexamethasone 5 mg
62803513|NCT05416866|EXPERIMENTAL|TQ group|ultrasound-guided transversus abdominis plane block with 20 ml mixture 0.20% ropivacaine + dexamethasone 5 mg and quadratus lumborum block with 30 ml mixture 0.20% ropivacaine + dexamethasone 5 mg
62028985|NCT05996159|EXPERIMENTAL|vHPSD ablation only for PVI|Pulmonary vein encirclement is achieved using contiguous applications of very high power and short duration (90 W over 4 seconds). The inter-lesion distance is set at 3-4mm for the roofs and anterior segments, and 5-6mm for other segments. If the esophageal temperature rises \> 38 for segments near the esophagus, encirclement will be applied at 25 W for 15 seconds.
62590674|NCT05919225|EXPERIMENTAL|INTERVENTION|Once AHF has been diagnosed at ED, and before decision-making about hospitalize/discharge home is taken, physicians will objectively measure the severity of decompensation, based on risk of 30-day death using MEESSI scale. As result, patient can be allocated to low, intermediate, high or very-high risk. For patients classified as low-risk, the propocol recommendation will be discharge patient to home. For patients classified as increased risk (i.e., intermediate, high or very-high risk categories), the protocol recommendation will be to hospitalize patient. Nonetheless, final decission will be left to emergency physician, and overruling (disposition against recommendation) will be allowed. For discharged patients, there is no follow up intervention planned, and it will be based on current centre protocols.For hospitalized patients, department of admission will be based on current centre protocols, with no intervention at this level.
62803514|NCT04306614|EXPERIMENTAL|Capillary technique|
62590675|NCT05919225|NO_INTERVENTION|USUAL CARE|Once AHF has been diagnosed at ED, emergency physicians will decide patient disposition according to their usual strategies of care, that currently do not include risk stratification. For discharged patients, there is no follow up intervention planned, and it will be based on current centre protocols. For hospitalized patients, department of admission will be based on current centre protocols, with no intervention at this level.
62590676|NCT06546956|EXPERIMENTAL|Integrative Breathwork Intervention|The integrative, multicomponent breathwork intervention that will be tested in this study is called Guided Respiration Mindfulness Therapy. Participants will receive a 60 minute breathwork session once a week for 8 weeks.
62803515|NCT04306614|PLACEBO_COMPARATOR|Suction technique|
62803516|NCT02494960|PLACEBO_COMPARATOR|Control Group|The doctor will offer a placebo intervention.
62803517|NCT02494960|EXPERIMENTAL|Intervention Group A|"The doctor will offer the brief smoking cessation AWARD model .~At 1-month follow-up survey, trained study personnel will repeat the brief smoking cessation AWARD model ."
62227799|NCT02035592|PLACEBO_COMPARATOR|Control|"Matched control powder; matched for appearance, taste and sugar content.~Frequency: 26g per day.~Total duration: 6-month."
62227800|NCT04054752|EXPERIMENTAL|1/ Arm 1|NT-I7 administered at 720 and 960g/kg to select the OBD of NT-I7
62227801|NCT04054752|ACTIVE_COMPARATOR|2/ Arm 2a|Administration of 4 vaccines according to Sequence 1 + NT-I7 administration at OBD to assess vaccine response
62227802|NCT04054752|ACTIVE_COMPARATOR|3/ Arm 2b|Administration of 4 vaccines according to Sequence 2 + NT-I7 administration at OBD to assess vaccine response
62227803|NCT04025580|EXPERIMENTAL|Flucelvax, Fluvirin, or Fluzone High Dose|Healthy Volunteer between ages 18-65 receiving Flucelvax
62227804|NCT02009254|EXPERIMENTAL|Mashed Potatoes (as produced)|
62227805|NCT02009254|EXPERIMENTAL|Mashed Potatoes (with no added butter during production)|
62227806|NCT02009254|EXPERIMENTAL|glucose control (50 g)|
62420566|NCT00295308|PLACEBO_COMPARATOR|Arm 2|
62028986|NCT05996159|EXPERIMENTAL|vHPSD and AI-guided ablation for PVI|"At the anterior segments, pulmonary vein encirclement is achieved through contiguous applications using AI-guided ablation (40-50 W, AI target 500, and an inter-lesion distance of 4mm).~In the other segments, pulmonary vein encirclement is achieved through contiguous applications using very high-power and short-duration techniques (90 W over 4 seconds, inter-lesion distance of 3-4mm; if the segments are near the esophagus, encirclement will be applied at 25 W for 15 seconds)."
62227807|NCT04119258||Psychiatric patients|Psychiatric outpatient care patients with major depressive disorder, anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, or illness anxiety disorder who have just completed cognitive-behavioral therapy.
62420567|NCT00609063|EXPERIMENTAL|1|Participants will receive atorvastatin for 6 months.
62420568|NCT00609063|PLACEBO_COMPARATOR|2|Participants will receive matching placebo for 6 months.
62803518|NCT02494960|EXPERIMENTAL|Intervention Group B|The doctor will offer the brief smoking cessation AWARD model.
62803519|NCT03049917|NO_INTERVENTION|No incentive|No incentive
62803520|NCT03049917|EXPERIMENTAL|KES financial incentive 1|Kenyan Shillings conditional cash transfer upon HIV testing
62803521|NCT03049917|EXPERIMENTAL|KES financial incentive 2|Kenyan Shillings conditional cash transfer upon HIV testing
62227808|NCT00842270|EXPERIMENTAL|2|4,5 mg/kg/day
62803522|NCT03049917|EXPERIMENTAL|KES financial incentive 3|Kenyan Shillings conditional cash transfer upon HIV testing
62803523|NCT03049917|EXPERIMENTAL|KES financial incentive 4|Kenyan Shillings conditional cash transfer upon HIV testing
62803524|NCT03830359|EXPERIMENTAL|T2769|T2769 Ophthalmic solution patients treated with 1 drop in each eye 3 to 6 times daily
62227809|NCT00842270|EXPERIMENTAL|3|6 mg/kg/day
62227810|NCT00842270|PLACEBO_COMPARATOR|4|matching placebo for AB1010 3, 4,5 and 6 mg/kg/day
62227811|NCT00842270|EXPERIMENTAL|1|AB1010 3 mg/kg/day
62420569|NCT06368778||"Group 1 Verbal Advice"|The participant will receive verbal instructions following the standard of care physical therapy. A member of the study team will observe and provide comments on the participant's exercises.
62420570|NCT06368778||"Group 2 Bathroom Scale"|In this group, the participant is given a sense of what a 20 kg load feels like using a scale. Subsequently, the same exercises as in Group 1 will be conducted.
62420571|NCT06368778||"Group 3 Biofeedback"|In this group, the biofeedback function of the sensor insoles is activated. This feature provides both visual (a bar graph on the iPad) and auditory feedback (an audible signal when the load exceeds 20 kg). Through this feedback, the participant is expected to develop an understanding of partial weight-bearing.
62420572|NCT05330143|EXPERIMENTAL|ASC22 1mg/kg|ASC22 Injection of 1mg/kg and anti-retroviral therapy for 12 weeks
62420573|NCT05330143|EXPERIMENTAL|ASC22 2.5mg/kg|ASC22 Injection of 2.5mg/kg and anti-retroviral therapy for 12 weeks
62420574|NCT05330143|PLACEBO_COMPARATOR|Placebo|0.9% Saline and anti-retroviral therapy for 12 weeks
62420575|NCT03939403|EXPERIMENTAL|7-days pill free interval|
62420576|NCT03939403|NO_INTERVENTION|5-days pill free interval|
62420577|NCT06563050|EXPERIMENTAL|Nebulized lidocaine|Subjects in group A underwent nebulization with 5 mL of 2% lidocaine for 15 minutes by using a jet nebulizer.
62420578|NCT06563050|EXPERIMENTAL|Lidocaine spray|In group B will underwent 10% lidocaine spray solution will be sprayed 10 times at the oropharynx at 5 s interval.
62803525|NCT00515151|ACTIVE_COMPARATOR|Oct/Alc|
62803526|NCT00515151|ACTIVE_COMPARATOR|Alc|
62227812|NCT03073265||Patients on apixaban|Patients currently on apixaban who meet inclusion/exclusion criteria A blood draw will be done on each patient to measure apixaban concentration in plasma using anti-Xa assay and LCMS.
62227813|NCT03231930|EXPERIMENTAL|Intervention group|Rapid point of care testing will be done using the OraQuick HCV Ab test and the Xpert HCV RNA viral load test. All participants will undergo rapid point of care testing for hepatitis C antibodies using the OraQuick test with oral fluid, followed by point of care testing for the detection of hepatitis C virus RNA using the Cepheid Xpert HCV viral load test on the GeneXpert system. Participants who are found to have current HCV infection will be worked up for treatment at the clinic and referred to appropriate practitioners for HCV treatment. As these tests are not yet licensed for diagnostic use in Australia, confirmatory testing using standard laboratory tests will be performed for all participants.
62227814|NCT01217957|EXPERIMENTAL|Phase 1: Ixazomib 1.68 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 1.68 mg/m\^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 1.68 mg/m\^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
62227815|NCT01217957|EXPERIMENTAL|Phase 1: Ixazomib 2.23 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 2.23 mg/m\^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 2.23 mg/m\^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
62243100|NCT05315453|EXPERIMENTAL|Brief Cognitive Rehabilitation|5-session Cognitive Rehabilitation intervention administered over telehealth
62420579|NCT06563050|EXPERIMENTAL|Combination( Nebulized lidocaine and lidocaine spray)|Group C: both nebulization and spray will be performed in the same manner except the number of spray will be 2 instead 10.
62420580|NCT02105597|EXPERIMENTAL|Mobile application|
62420581|NCT02105597|NO_INTERVENTION|Standard care|
62420582|NCT03794999||Benralizumab-exposed group|Pregnant women with asthma exposed to benralizumab anytime during pregnancy or within 8 weeks prior to last menstrual period
62420583|NCT03794999||Asthmatic comparison group|Pregnant women currently treated for asthma not exposed to benralizumab during pregnancy or within 8 weeks prior to last menstrual period
62590677|NCT06451562|NO_INTERVENTION|Control|This group will serve as a control - the patients will receive general anesthesia according to the standard protocol for general anesthesia in this study. Upon the end of the surgery, patients will begin receiving analgesics and anti-nausea treatment according to the standard protocol in this study.
62803527|NCT03167333|EXPERIMENTAL|PRP group|the patients received PRP(platelet-rich-plasma) injection twice at 2-week intervals
62420584|NCT03794999||Non-asthmatic comparison group|Pregnant women who are not diagnosed with asthma, have not had exposure to a known human teratogen, and have not taken benralizumab during pregnancy.
62420585|NCT06701227|EXPERIMENTAL|In Situ Simulation|"The educational intervention consists of applying the in situ simulation scenario entitled Breastfeeding the Newborn, previously structured and validated among experts, through individual home visits, with pregnant people."
62803528|NCT03167333|ACTIVE_COMPARATOR|HA group|the patients received HA(hyaluronic acid) injection twice at 2-week intervals
62803529|NCT05730296|EXPERIMENTAL|group 1|rTMS active + training
62803530|NCT05730296|EXPERIMENTAL|group 2|rTMS active
62420586|NCT06701227|NO_INTERVENTION|Routine Prenatal Care|Routine prenatal guidance on breastfeeding. Currently, prenatal education provided by the Unified Health System (UHS) is being carried out through individual counseling during prenatal consultations and in groups for pregnant people organized by the FHUs and also by the local maternity hospital.
62803531|NCT05730296|SHAM_COMPARATOR|sham coil|rTMS sham
62803532|NCT04984967|EXPERIMENTAL|Insertion of peripheral venous catheter with micro-guide|
62803533|NCT04984967|OTHER|Classic insertion of peripheral venous catheter, without micro-guide|
62028987|NCT05996159|EXPERIMENTAL|AI-guided ablation only for PVI|Pulmonary vein encirclement is achieved through contiguous applications using AI-guided ablation (40-50 W, AI target 500 for anterior segments and 400 for other segments, with an inter-lesion distance of 4mm; if the segments are near the esophagus, encirclement will be applied at 25 W for 15 seconds)
62227816|NCT01217957|EXPERIMENTAL|Phase 1: Ixazomib 2.97 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 2.97 mg/m\^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 2.97 mg/m\^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
62227817|NCT01217957|EXPERIMENTAL|Phase 1: Ixazomib 3.95 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 3.95 mg/m\^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 3.95 mg/m\^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
62803534|NCT03065322||Women with PCOS|Women with confirmed diagnosis of PCOS, based on the Rotterdam Criteria. To assess risk of OSA: the risk of OSA will be assessed using the Berlin questionnaire and the Epworth Sleepiness Scale (ESS). Women with at high risk of OSA will have home-based sleep studies performed.
62803535|NCT02950740||Center 01 (SA)|Toddlers from Santo André Early Childhood Public School
62803536|NCT02950740||Center 02 (POA)|Toddlers from Porto Alegre Early Childhood Public School
62420587|NCT05098444|EXPERIMENTAL|Cognitive behavioral psychotherapy|"Internet-based CBT for patients with endometriosis:~The experimental group has access to an online training consisting of 8 modules, one per week.~Modules comprise of 1) psychoeducation (e.g., information about endometriosis and its treatment); 2) \& 3) cognitive strategies (e.g., identifying and modifying dysfunctional cognitions); 4\&5) pain and stress management (e.g. activity plans, relaxation techniques); 6) emotion regulation strategies (e.g. recognition and acceptance of emotions); 7) communication training (e.g. detection and communication of needs); 8) prophylaxis (e.g. summary of intervention, plans for the future).~Participants are in weekly written contact with their assigned therapist via the news function of the training platform, receiving feedback on the content or getting answers to open questions."
62028988|NCT01965834|EXPERIMENTAL|Fenofibrate Therapy|Fenofibrate orally daily for each 28 day cycle, per study protocol.
62028989|NCT00484705|EXPERIMENTAL|Low-frequency electro-acupuncture|
62028990|NCT00484705|EXPERIMENTAL|Physical exercise|
62227818|NCT01217957|EXPERIMENTAL|Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone|In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 4.0 mg fixed dose, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
62227819|NCT01813370||Pts with prostate cancer|Patients who have progressed or hit their 36 month post treatment date between the closure of TAX3503 and the activation of this TAX3503 Registry protocol will be permitted on the study to capture their date of progression or their 36 month post treatment progression free date.
62803537|NCT02950740||Center 03 (MG)|Toddlers from Uberaba Early Childhood Public School
62803538|NCT02950740||Center 04 (RN)|Toddlers from Natal Early Childhood Public School
62803539|NCT05931757|EXPERIMENTAL|Treatment Group|The patients would be treated with Olverembatinib, Given PO, combined with Blinatumomab, Given intravenously
62803540|NCT01718457|EXPERIMENTAL|Endobarrier device insertion|
62803541|NCT01931423|PLACEBO_COMPARATOR|Drainage Group|early placental drainage plus cord traction
62803542|NCT01931423|NO_INTERVENTION|Controlled Group|spontaneous removal placenta
62803543|NCT02800863||Dorsal Root Ganglion (DRG) Stimulation|
62803544|NCT04535635|EXPERIMENTAL|Active Release Techniques®|The ART® procedure will consist of identifying and treating manipulatable lesions as per their protocols, while the sham group will receive a passable version of this technique. This information is under copyright and cannot be copied or outlined specifically in any form, including a research paper. The overarching procedure used by ART® will be explained however specific details referring to each protocol cannot be described. Muscles are shortened, and the therapist applies sufficient digital pressure to be in contact with the tissue in question. Directional tension is applied proximally along the muscle fiber direction, and then the structure is lengthened while the contact remains as described.
62028991|NCT00484705|ACTIVE_COMPARATOR|Untreated control|
62028992|NCT06635746|EXPERIMENTAL|Vinpocetine|Participants will take increasing, single doses of vinpocetine.
62028993|NCT02658643|EXPERIMENTAL|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
62028994|NCT02658643|ACTIVE_COMPARATOR|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
62028995|NCT03034577|ACTIVE_COMPARATOR|ModNMB|"Moderate Neuromuscular block: participants will receive moderate neuromuscular blockade with rocuronium aiming for TOF 0-2 twitches, with neostigmine reversal when the TOF at least 3 twitches. The depth of neuromuscular block may be reduced after completion of the majority of surgical excision to TOF 3 or more~Neostigmine"
62227820|NCT02105623|ACTIVE_COMPARATOR|Standard Therapy|Risk factor control Diet Exercise
62227821|NCT02105623|EXPERIMENTAL|Rosuvastatin therapy|Risk factor control Rosuvastatin
62227822|NCT04822285|EXPERIMENTAL|Psychological Triaging Intervention|The PTI intervention followed the path of RAPID Psychological First Aid model of John Hopkins University (Everly\& Lating 2012). The content of the PTI represents a simple structure that is revolved around five core phases including (R: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition\& follow up).
62420588|NCT05098444|OTHER|Waiting list|During the waiting period, patients receive no treatment. After a waiting time of 5 months, patients of the waitlist receive the same iCBT treatment as the experimental group.
62420589|NCT02650609|EXPERIMENTAL|Methylprednisolone|"Methylprednisolone will be supplied as powder and stored in capsules containing 16 mg with lactose as excipient.~Capsules will be administered orally in the morning, during breakfast with a glass of water.~Dose is adapted according to the weight of the patient (1mg/kg):~* \<60 kg: 3 pills of 16 mg/day~* 60-80kg: 4 pills of 16 mg/day~* \>80kg: 5 pills of 16 mg/day The duration of the treatment is 21 days."
62420590|NCT02650609|PLACEBO_COMPARATOR|Placebo|"Placebo capsules will only contain lactose. Capsules will be administered orally in the morning, during breakfast with a glass of water.~Dose is adapted according to the weight of the patient (1mg/kg):~* \<60 kg: 3 pills of 16 mg/day~* 60-80kg: 4 pills of 16 mg/day~* \>80kg: 5 pills of 16 mg/day The duration of the treatment is 21 days."
62803545|NCT04535635|PLACEBO_COMPARATOR|Sham Active Release Techniques®|"For the sham treatment, the muscle(s) in question will be taken from a lengthened to a shortened position (opposite of the protocol direction as per the ART® manual) with a broad light contact on the skin - the treating therapist will not achieve tissue depth as specified by ART® and will not attempt to take tension as is outlined in the ART® manual."
62803546|NCT04467086|NO_INTERVENTION|Control Arm - Usual Care|"Participants in the control group will receive usual intravenous sedation according to practices already in place at each participating site. The choice of agent, route of delivery, method of monitoring, and target levels of sedation will be determined by the treating team; however, we will recommend best practice clinical guidelines be followed. Current guidelines recommend analgesia first sedation titrated to relief of pain and dyspnea and sedative infusions if need for anxiety or agitation titrated to a prescribed level of sedation using a validated sedation scale. Patients may receive adjunct sedative/analgesic medications (e.g., enteral benzodiazepines) but propranolol use in the control group will be considered a protocol violation."
62028996|NCT03034577|ACTIVE_COMPARATOR|DeepNB|Deep Neuromuscular block: participants will receive DNB aiming for a post tetanic count of 1-2, which will be maintained until removal of the laparoscopic ports, with reversal using sugammadex
62028997|NCT06634979|EXPERIMENTAL|Arm Selective lymph node dissection|Lower mediastinal lymph node clearance is not required for upper lobe tumors and upper mediastinal lymph node clearance is not required for lower lobe tumors in the group
62028998|NCT02365467|EXPERIMENTAL|Treatment with Valiant Mona LSA device|Treatment with Valiant Mona LSA device
62028999|NCT06286631||Past Medical Records Group|Sample size:500 Whether control group:No Name of exposure factor:papillary thyroid cancer Exposure factor type:Other Description of exposure factor:None
62243101|NCT03298568|EXPERIMENTAL|DAOsin treatment|Patients suffering from histamine intolerance and a diamin oxidase activity below 10 Units/ml get a DAOsin treatment for one month 3 times a day.
62420591|NCT06568640|EXPERIMENTAL|Interventional treatment group|superselective adrenal arterial embolization
62420592|NCT03380182|EXPERIMENTAL|Acupuncture/Acupressure Group|Bilateral P6 point acupuncture will be performed intra-operatively by the PI, who has UC Davis Medical Center privilege for this specific acupuncture, while the patient is under anesthesia. Patient will be sent home with an acupressure band, which is to remain on for 24 hours post operatively.
62420593|NCT03380182|SHAM_COMPARATOR|Control Group|Bilateral sham point acupuncture will be performed intra-operatively. Patient will be sent home with a wrist sham band matching in appearance of acupressure bands without the acupressure function, which is to remain on for 24 hours post operatively.
62803547|NCT04467086|EXPERIMENTAL|Intervention Arm - Propranolol hydrochloride|"Participants in the control arm will received sedation as described for the control arm, but with the addition of propranolol hydrochloride (titrated up as described under Intervention Description) and a corresponding reduction in sedatives as appropriate and described under Intervention Description."
62803548|NCT02758717|EXPERIMENTAL|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for 7 cycles and 6-8 weeks in cycle 8 in the absence of disease progression or unacceptable toxicity.
62803549|NCT04365712|ACTIVE_COMPARATOR|Oscillating saw|Patients treated for hallux valgus with 1st metatarsal osteotomy obtained by common oscillating saw
62803550|NCT04365712|EXPERIMENTAL|Piezoelectric tool|Patients treated for hallux valgus with 1st metatarsal osteotomy obtained by piezoelectric tool
62803551|NCT04891016|EXPERIMENTAL|experimental group|patients received FLOT regimen on day 1 and toripalimab on day 3.
62803552|NCT02166892|ACTIVE_COMPARATOR|Normal weight|Normal weight children will be served food in two different occasions using two sets of plates (same size). One set will be plane and the second is a specially designed plate that demonstrate the recommended food consumption and portion.
62803553|NCT02166892|ACTIVE_COMPARATOR|Overweight children|Overweight children will be served food in two different occasions using two sets of plates (same size). One set will be plane and the second is a specially designed plate that demonstrate the recommended food consumption and portion.
62803554|NCT03669614|EXPERIMENTAL|AR-501 inhaled|Four doses (low, medium, high, top) of inhaled AR-501 will be used.
62803555|NCT03669614|PLACEBO_COMPARATOR|inhaled AR-501 Placebo|Four doses (low, medium, high, top) of inhaled placebo will be used
62803556|NCT06106126|OTHER|Mild renal impairment|
62803557|NCT06106126|OTHER|Moderate renal impairment|
62803558|NCT06106126|OTHER|Severe renal impairment|
62803559|NCT06106126|OTHER|Normal Renal Function|
62590678|NCT06451562|ACTIVE_COMPARATOR|Erector spinae plane block|Patients will receive general anesthesia according to the standard protocol for general anesthesia in this study. After induction for anesthesia, before the start of the surgery, the anesthesiologist will perform an ultrasound guided ESP block, according to the ultrasound guided erector spinae plane block protocol
62590679|NCT06451562|ACTIVE_COMPARATOR|Lidocaine|Patients will receive general anesthesia according to the standard general anesthesia protocol for this study. In addition, after induction of anesthesia, patients will begin receiving an intravenous infusion of lidocaine at a dose of 0.5 mg per kg per hour, and will continue to receive the infusion after surgery for a total of 24 hours.
62590680|NCT01077037|EXPERIMENTAL|Decision Aid|Receives Decision Aid
62590681|NCT01077037|NO_INTERVENTION|Control|Patient receives usual care.
62803560|NCT02088450|ACTIVE_COMPARATOR|Active treatment|Active treatment with nitrendipine (10-40 mg/day). If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
62029000|NCT06286631||Clinical Validation Group|Sample size:300 Whether control group:No Name of exposure factor:papillary thyroid cancer Exposure factor type:Other Description of exposure factor:None
62803561|NCT02088450|PLACEBO_COMPARATOR|Placebo|Placebo tablets were identical to the study drugs with a similar schedule.
62227823|NCT04822285|ACTIVE_COMPARATOR|Routine Psychological support|For the comparison group, the researchers provided them with routine psychological support that mainly revolved around enhancing their self-compassion, practicing mindfulness exercises, keeping them socially connected with their family and peers. Moreover, adopt a healthy lifestyle such as; engage in physical activity, eating a well-balanced diet, and sleeping well.
62420594|NCT05673018|EXPERIMENTAL|(Galleri + UC)|Medicare beneficiaries who receive the Galleri test plus usual care (Galleri + UC).
62420595|NCT05673018|NO_INTERVENTION|(UC) alone|Passively-enrolled Contemporaneous Comparator Arm of Medicare beneficiaries who receive usual care (UC) alone.
62420596|NCT05777174|EXPERIMENTAL|Participants with eGFR ≥ 70 mL/min/1.73 m^2|MB-102 (130 mg) will be administered to participants with estimated glomerular filtration rate (eGFR) eGFR ≥ 70 mL/min/1.73 m\^2, and fluorescence measured using the MediBeacon Transdermal GFR Measurement System. Approximately half of the participants are to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
62420597|NCT05777174|EXPERIMENTAL|Participants with eGFR < 70 mL/min/1.73 m^2|MB-102 (130 mg) will be administered to participants with estimated glomerular filtration rate (eGFR) eGFR \< 70 mL/min/1.73 m\^2, and fluorescence measured using the MediBeacon Transdermal GFR Measurement System. Approximately half of the participants are to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
62420598|NCT04616079|EXPERIMENTAL|IV Cohort 1|Single intravenous (IV) dose 1 of REGN6490 or matching placebo
62420599|NCT04616079|EXPERIMENTAL|IV Cohort 2|Single IV dose 2 of REGN6490 or matching placebo
62420600|NCT04616079|EXPERIMENTAL|IV Cohort 3|Single IV dose 3 of REGN6490 or matching placebo
62420601|NCT04616079|EXPERIMENTAL|IV Cohort 4|Single IV dose 4 of REGN6490 or matching placebo
62590682|NCT03036865|EXPERIMENTAL|Cohort 1: 1 mg, IV BOS161721|Each participant will receive a single intravenous (IV) dose of BOS161721 1 milligram (mg).
62590683|NCT03036865|PLACEBO_COMPARATOR|Cohort 1: matching placebo|Each participant will receive matching IV placebo.
62590684|NCT03036865|EXPERIMENTAL|Cohort 2: 3 mg, SC BOS161721|Each participant will receive a single subcutaneous (SC) dose of BOS161721 3 mg.
62803562|NCT05806437|EXPERIMENTAL|Long assumption|Assumpion of SideremilVita for 30 days
62803563|NCT05806437|ACTIVE_COMPARATOR|Standard assumption|Assumpion of SideremilVita for 15 days
62803564|NCT00648635||PET + QOL|Survey of how recurrent rectal cancer treatment affects well being + QOL
62227824|NCT00000263|PLACEBO_COMPARATOR|0 g/Kg ethanol +/- 30% nitrous oxide|
62227825|NCT00000263|ACTIVE_COMPARATOR|0.25 g/Kg ethanol +/- 30% nitrous oxide|
62227826|NCT00000263|ACTIVE_COMPARATOR|0.5 g/Kg ethanol +/- 30% nitrous oxide|
62590685|NCT03036865|PLACEBO_COMPARATOR|Cohort 2: matching placebo|Each participant will receive matching SC placebo.
62590686|NCT03036865|EXPERIMENTAL|Cohort 3: 10 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 10 mg.
62590687|NCT03036865|PLACEBO_COMPARATOR|Cohort 3: matching placebo|Each participant will receive matching SC placebo.
62590688|NCT03036865|EXPERIMENTAL|Cohort 4: 30 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 30 mg.
62590689|NCT03036865|PLACEBO_COMPARATOR|Cohort 4: matching placebo|Each participant will receive matching SC placebo.
62803565|NCT02539771|OTHER|Nocturnal VOC|
62803566|NCT02539771|OTHER|Diurnal VOC|
62420602|NCT04616079|EXPERIMENTAL|IV Cohort 5|Single IV dose 5 of REGN6490 or matching placebo
62420603|NCT04616079|EXPERIMENTAL|SC Cohort 1|Single subcutaneous (SC) dose 1 of REGN6490 or matching placebo
62420604|NCT04616079|EXPERIMENTAL|SC Cohort 2|Single SC dose 2 of REGN6490 or matching placebo
62590690|NCT03036865|EXPERIMENTAL|Cohort 5: 60 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 60 mg.
62590691|NCT03036865|PLACEBO_COMPARATOR|Cohort 5: matching placebo|Each participant will receive matching SC placebo.
62590692|NCT03036865|EXPERIMENTAL|Cohort 6: 22 mg, IV BOS161721|Each participant will receive a single IV dose of BOS161721 22 mg.
62803567|NCT02539771|OTHER|Slightly symptomatic|
62029001|NCT04023695|ACTIVE_COMPARATOR|Corticosteroid with lidocaine with epinephrine|This arm includes an injection mixture of corticosteroid and lidocaine with epinephrine
62227827|NCT02436785|ACTIVE_COMPARATOR|Music Therapy|The music therapy group will run for approximately an hour (twice a week) and will involve in-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.
62227828|NCT02436785|ACTIVE_COMPARATOR|Music Listening|The control group will also run for approximately an hour (twice a week) and will involve listening to relaxing music on a CD player.
62227829|NCT04834349|EXPERIMENTAL|Cohort I (NBTXR3, SBRT, pembrolizumab)|Patients receive NBTXR3 IT on day 1. Patients then undergo SBRT QOD on days 15-29. Beginning the first day of radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
62227830|NCT04834349|EXPERIMENTAL|Cohort II (NBTXR3, IMRT/IMPT, pembrolizumab)|Patients receive NBTXR3 IT on day 1. Patients then undergo IMRT/IMPT QD on days 15-50. Beginning the first day of radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
62420605|NCT04616079|EXPERIMENTAL|SC Cohort 3|Single SC dose 2 of REGN6490 or matching placebo
62029002|NCT04023695|EXPERIMENTAL|Corticosteroid with normal saline|This arm includes a mixture of corticosteroid and normal saline. The purpose of normal saline is the keep the volume and concentration similar when compared to the injections containing lidocaine.
62420606|NCT03756207|EXPERIMENTAL|Multidisciplinary Therapy|Multidisciplinary bladder-preservation therapy: Maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy
62029003|NCT04050293|EXPERIMENTAL|SPN-538|Patients will be treated with SPN-538 as a single dose once a day
62029004|NCT04050293|PLACEBO_COMPARATOR|Placebo|Patients will be treated with Placebo once a day
62590693|NCT03036865|EXPERIMENTAL|Cohort 7: 120 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 120 mg.
62029005|NCT03181360|ACTIVE_COMPARATOR|Tenecteplase|Tenecteplase + Best standard treatment
62029006|NCT03181360|OTHER|Control|No tenecteplase + Best standard treatment
62227831|NCT05204745||Case|Subjects with subjective gait impariment according to questionnaire answers.
62227832|NCT05204745||Control|Subjects without subjective gait impariment according to questionnaire answers.
62227833|NCT03129880|PLACEBO_COMPARATOR|Weekly Voice Therapy|Participants are randomized to receiving weekly voice therapy sessions
62420607|NCT06328543|EXPERIMENTAL|1st pruritogen|The subproject is conducted in 1 session (approx. 3 hours in total) divided into two parts. In the first part, 3 test areas (3x3 cm) will be selected on one forearm of the subject. The 3 areas will be randomly treated with 1 application of cowhage, 2 applications of cowhage (the second application will be conducted 90 seconds after the first one in the same area), and 2 applications of cowhage (the second application will be conducted 180 seconds after the first one in the same area). Itch will be monitored using a VAS (visual analog scale) for 15 min in each session. After the removal of cowhage, FLPI, alloknesis, and mechanically evoked itch will be measured.
62420608|NCT06328543|EXPERIMENTAL|2nd pruritogen|The second part will be conducted 20 minutes after the first part, and the procedure will be the same, but using histamine instead of cowhage. The two parts will be randomized between subjects.
62590694|NCT03036865|PLACEBO_COMPARATOR|Cohort 7: matching placebo|Each participant will receive matching SC placebo.
62029007|NCT01659021|EXPERIMENTAL|Idelalisib+ofatumumab|"Randomized Initial Therapy (24 weeks): Idelalisib + ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 1000 mg weekly for 7 weeks, and then 1000 mg every 4 weeks for 4 doses)~Continuing Therapy/Observation: Idelalisib 150 mg tablets twice daily until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation.~Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone."
62227834|NCT03129880|ACTIVE_COMPARATOR|Intensive Voice Therapy|Participants are randomized to receiving multiple sessions of voice therapy in one day
62227835|NCT01190137|ACTIVE_COMPARATOR|400 IU Vitamin D3|
62227836|NCT01190137|EXPERIMENTAL|400 IU Vitamin D2|
62420609|NCT02270840|ACTIVE_COMPARATOR|CRT-D|Patients currently implanted with a single or dual chamber pacemaker or ICD will be upgraded to CRT.
62227837|NCT05663437|ACTIVE_COMPARATOR|Control group|Core stabilization exercises
62227838|NCT05663437|EXPERIMENTAL|Experimental group|Core stabilization exercises and Neural mobilization technique
62227839|NCT01341756|EXPERIMENTAL|Radiotherapy for gastric cancer|Single arm study
62227840|NCT01111474|ACTIVE_COMPARATOR|Cyanoacrylate|3 applications of cyanoacrylate (48 hours interval)at the cervical region of the sensitive tooth
62590695|NCT03036865|EXPERIMENTAL|Cohort 8: 240 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 240 mg.
62590696|NCT03036865|PLACEBO_COMPARATOR|Cohort 8: matching placebo|Each participant will receive matching SC placebo.
62590697|NCT03699280|EXPERIMENTAL|Virtual Reality|VR video to be played during the procedure
62590698|NCT03699280|NO_INTERVENTION|Standard Procedure|Routine protocol outpatient hysteroscopy
62590699|NCT05642962|EXPERIMENTAL|Arm 1|Participants with stage 4 Pancreatic Ductal Adenocarcinoma / PDAC will receive 384 units lipase/kg of body weight per meal or snack
62590700|NCT05642962|EXPERIMENTAL|Arm 2|Participants with stage 4 Pancreatic Ductal Adenocarcinoma / PDAC will receive 1350 units lipase/kg of body weight per meal or snack
62590701|NCT01273623|EXPERIMENTAL|Patients with PAD|Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention who have moderate to severe obstructive intraluminal calcium
62590702|NCT04411979|NO_INTERVENTION|treatment-as-usual|
62590703|NCT04411979|EXPERIMENTAL|treatment-as-usual plus aerobic walking|
62803568|NCT05833529|EXPERIMENTAL|VRCET for Cocaine Craving then MFCT|3 weeks treatment consisting of 10 meetings of Virtual Reality Cue Exposure Therapy (VRCET) for cocaine craving, followed by 5 meetings of Memory Focused Cognitive Therapy (MFCT). All meetings will last 90 minutes. VRCET meetings will take place in a 2 weeks period (weeks 1 and 2) at a daily frequency from monday to friday included. MFCT meetings will take place in the 1 week period following VRCET (week 3) at a daily frequency from monday to friday included.
62803569|NCT05833529|ACTIVE_COMPARATOR|PCET for Cocaine Craving|3 weeks treatment consisting of 15 meetings of Picture-based Cue Exposure Therapy (PCET) for cocaine craving. All meetings will last 90 minutes. PCET meetings will take place in a 3 weeks period (weeks 1 to week 3) at a daily frequency from monday to friday included.
62803570|NCT02366195|EXPERIMENTAL|Talimogene Laherparepvec|Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL on day 1 followed by a dose of 10⁸ PFU/mL 21 days after the initial dose and every 14 days thereafter. Participants were treated with talimogene laherparepvec until they achieved a complete response, all injectable tumors had disappeared, clinically significant (resulting in clinical deterioration or requiring change of therapy) disease progression beyond 6 months of treatment, per modified World Health Organization (WHO) response criteria, or intolerance of study treatment, whichever occurred first.
62803571|NCT04941495|ACTIVE_COMPARATOR|Control Group|It Includes the TENS, Infrared, Isometric and stretching exercises along with the home plan and postural education
62803572|NCT04941495|EXPERIMENTAL|Experimental Group|It Includes the TENS, Infrared, Isometric and stretching exercises along with the home plan and postural education. It also include the cervical proprioceptive training
62803573|NCT03498807|EXPERIMENTAL|Control group_Use Ventilator P/V tool|Use the Pressure/Volume Loop
62803574|NCT03498807|ACTIVE_COMPARATOR|Study group_Use EIT|Use the Electrical Impedance Tomography
62803575|NCT00617175|EXPERIMENTAL|Long NID|Programming a number of 30 out of 40 intervals to detect (NID)ventricular arrhythmia
62227841|NCT01111474|ACTIVE_COMPARATOR|Laser|3 Low intensity laser application (48 hour interval). The application of 1Joule/cm\^2 was performed for eight seconds at three points along the dental neck, using the infrared wavelength (795nm)
62227842|NCT03422354|ACTIVE_COMPARATOR|Paravertebral block Group|Patients will receive single shot L1-L2 PVB before undergoing GA Full monitoring with ECG , NIBP , puls oximetry will be applied. The level between L1 and L2 will be identified using U/S as well as transverse processes depth. Insertion points will be marked 2.5 cm lateral to the superior aspect of corresponding spinous processes, A 22-gauge Tuohy needle will be advanced until it made contact with the transverse process. The needle will be withdrawn slightly and walked off caudally to an additional depth of 1 cm. Once this is reached, 20cc of bupivacaine 0.25% will be injected slowly To control intraoperative blood pressure, fentanyl will be used as well as hypotensive drugs ( propranolol and nitroglycerine and the total dose will be recorded.
62243102|NCT02231021|EXPERIMENTAL|alogliptin + pioglitazone|alogliptin 25 mg 1 tablet daily for 24 weeks pioglitazone 30 mg 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
62420610|NCT02270840|NO_INTERVENTION|Only ICD|"In the ICD arm, choosing single or dual chamber device is based upon the investigator's discretion.~Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only)."
62420611|NCT06692166|EXPERIMENTAL|9MW2821|
62420612|NCT06692166|ACTIVE_COMPARATOR|Treatment of Physician's Choice|
62243103|NCT02231021|ACTIVE_COMPARATOR|alogliptin|alogliptin 25 mg 1 tablet daily for 24 weeks pioglitazone matching placebo 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
62420613|NCT05785754|EXPERIMENTAL|Phase 1a Dose Escalation Monotherapy|Dose escalation to investigate the safety and tolerability of DCSZ11.
62420614|NCT05785754|EXPERIMENTAL|Phase 1a Dose Escalation Combination|Dose escalation to investigate safety and tolerability, and determine DCSZ11 Phase 1b doses in combination with pembrolizumab.
62420615|NCT05785754|EXPERIMENTAL|Phase 1b Dose Expansions|Dose expansion to further investigate the safety, tolerability, and preliminary evidence of antitumor activity of the combination with pembrolizumab in select tumor indications.
62420616|NCT02865642|EXPERIMENTAL|Serotonin Uptake Inhibitors|"Treatment 1: Starting with Escitalopram 5mg/day at the baseline-visit (day 14 (+-7) post stroke) for 7 days followed by a weekly dosage increase of 5mg/day till target dose of Escitalopram 20mg/day.~Subjects will remain on Escitalopram 20mg/day until visit 3 (day 90 (+-14) post stroke) followed by dosage reduction of Escitalopram 10mg/day for one week."
62420617|NCT02865642|PLACEBO_COMPARATOR|Placebo|"Treatment 2: Starting with Placebo 5mg/day at the baseline-visit (day 14 (+-7) post stroke) for 7 days followed by a weekly dosage of 5mg/day till target dose of Placebo 20mg/day.~Subjects will remain on Placebo 20mg/day until visit 3 (day 90 (+-14) post stroke) followed by Placebo 10mg/day for one week."
62420618|NCT06555562|EXPERIMENTAL|Treatment|Participants will receive active treatment during the visit. There will be a total of 4 visits involving ultrasound, with 1 being a sham and 3 being active. Patient is blinded to the treatment. The visit in which the sham is administered will be determined according to the Randomization Table
62590704|NCT02996123|EXPERIMENTAL|cad/cam maxillary dentures|single maxillary dentures fabricated by cad/cam method
62590705|NCT02996123|ACTIVE_COMPARATOR|conventional dentures|heat cured single maxillary dentures
62590706|NCT05451953|EXPERIMENTAL|Apneic Oxygenation|
62590707|NCT05451953|ACTIVE_COMPARATOR|Standard of Care|
62803576|NCT00617175|ACTIVE_COMPARATOR|Short NID|Programming a number of 18 out of 24 intervals to detect (NID)ventricular arrhythmia
62803577|NCT04640649|EXPERIMENTAL|Prediction Algorithm|Patients in the test arm will have a screening visit, then will come for two follow-up visits, at 3 months (if the algorithm determines high-risk of conversion within 3 months) and 6 months.
62803578|NCT04640649|NO_INTERVENTION|Control|Patients in the control arm will have a screening visit, then will come for one follow-up visit, at 6 months (standard care) only.
62420619|NCT06555562|SHAM_COMPARATOR|Control|Participants will receive a non-active treatment during the visit. There will be a total of 4 visits involving ultrasound, with 1 being a sham and 3 being active. Patient is blinded to the treatment. The visit in which the sham is administered will be determined according to the Randomization Table
62420620|NCT05957913|EXPERIMENTAL|Treatment arm|After a one-month baseline period where patients will not take any study drug, all patients will receive Truvada (tenofovir/emtricitabine) for three months. The study drug will be Truvada (tenofovir/emtricitabine), an antiviral drug that is approved by the Food \& Drug Administration (FDA) for the treatment of chronic hepatitis B virus and for the treatment and prevention of human immunodeficiency virus (HIV) infection. The study drug will be administered at the standard dose used for the treatment and prevention of HIV (300mg tenofovir disoproxil fumarate, 200mg emtricitabine). Since extensive safety and tolerability data already exists for this standard dose, the selection of this dose also allows us to use existing data to inform strategies for safety and tolerability monitoring to minimize risk, as detailed in the study design.
62803579|NCT04295317|EXPERIMENTAL|Combined the therapy using Capecitabine and PD-1|PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis) Capecitabine 2500mg / m2, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
62029008|NCT01659021|ACTIVE_COMPARATOR|Ofatumumab|"Randomized Initial Therapy (24 weeks): Ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 2000 mg weekly for 7 weeks, and then 2000 mg every 4 weeks for 4 doses)~Continuing Therapy/Observation: Observation until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation.~Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone."
62029009|NCT01404572|ACTIVE_COMPARATOR|Atazanavir + 10% aspartame|
62029010|NCT01404572|ACTIVE_COMPARATOR|Atazanavir + 4.2% aspartame|
62803580|NCT01482026|EXPERIMENTAL|Treated patients|Patients for whom ADHD treatment is introduced at enrolment. Evolution of the ADHD Rating Scale-IV inattention subscore
62029011|NCT01404572|ACTIVE_COMPARATOR|Atazanavir + 4.2% aspartame and sucralose|
62227843|NCT03422354|ACTIVE_COMPARATOR|General anesthesia Group|"Patients will receive only GA All patients in the study will receive GA in the form of propofol 2mg/kg , atracurium 0.5ml/kg ,fentanyl 100 microgram in induction with ETT and mechanical ventilation , full monitoring with ECG , NIBP and puls oximetry will be applied.~To control intraoperative BP,fentanyl will be used as well as,hypotensive drugs ( propranolol and nitroglycerine and the total dose will be recorded.~To achieve post operative analgesia, intravenous paracetamol( 1gram ) and pethidine IV (50 mg ) will be added when needed"
62227844|NCT04894487|NO_INTERVENTION|Control Group|The babies have got sternum incision after the pediatric cardiac surgery. Experiment is about the dressing of the sternum incision. There is no extra intervention during sternum dressing at control group like routine of pediatric cardiovascular surgery intensive care clinic. Saved pain scores and physiological parameters and pain scores; just before the sternum dressing, just after sternum dressing and after the 15 minutes sternum dressing.
62227845|NCT04894487|EXPERIMENTAL|THE USE OF BABY MOBILE ACCOMPANIED WITH BRAHMS LULLABIES GROUP|Baby mobile and Brahms Lullaby started before the 10 minutes of sternum dressing process and controlled permanence of the baby mobile and Brahms Lullaby during sternum dressing. Saved pain scores and physiological parameters and pain scores; just before the sternum dressing, just after sternum dressing and after the 15 minutes sternum dressing.
62227846|NCT06436027||Development cohort|Random selection of 80% of the overall cohort.
62227847|NCT06436027||Validation cohort|Random selection of 20% of the overall cohort.
62227848|NCT01801735|EXPERIMENTAL|Meloxicam Test Capsules|One Capsule QD
62803581|NCT01482026|EXPERIMENTAL|Non treated patients|Patients for whom no ADHD treatment is required at enrolment. Evolution of the ADHD Rating Scale-IV inattention subscore
62803582|NCT03523884|EXPERIMENTAL|Exercise Program plus Education.|Rotator cuff stretching and strengthening exercises outlined in the American Academy of Orthopedic Surgeons (AAOS) guidelines on management of rotator cuff problems.
62029012|NCT02254447|EXPERIMENTAL|Sequence ABC|Subjects in this arm will receive single dose of treatment A in period 1, treatment B in period 2 and treatment C in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
62029013|NCT02254447|EXPERIMENTAL|Sequence ACB|Subjects in this arm will receive single dose of treatment A in period 1, treatment C in period 2 and treatment B in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
62803583|NCT03523884|ACTIVE_COMPARATOR|Educational Program (EP).|An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions
62803584|NCT04179006|ACTIVE_COMPARATOR|LF chocolate + antidepressant(s)|Participants with LF chocolate add-on to their antidepressants regimen.
62227849|NCT02052830|EXPERIMENTAL|Wise Guys|A sexual health and male responsibility program for adolescent males
62029014|NCT02254447|EXPERIMENTAL|Sequence BAC|Subjects in this arm will receive single dose of treatment B in period 1, treatment A in period 2 and treatment C in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
62803585|NCT04179006|ACTIVE_COMPARATOR|Erinacine A-enriched Hericium chocolate + antidepressant(s)|Participants with Erinacine A-enriched Hericium chocolate add-on to their antidepressants regimen.
62029015|NCT02254447|EXPERIMENTAL|Sequence BCA|Subjects in this arm will receive single dose of treatment B in period 1, treatment C in period 2 and treatment A in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
62029016|NCT02254447|EXPERIMENTAL|Sequence CAB|Subjects in this arm will receive single dose of treatment C in period 1, treatment A in period 2 and treatment B in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
62029017|NCT02254447|EXPERIMENTAL|Sequence CBA|Subjects in this arm will receive single dose of treatment C in period 1, treatment B in period 2 and treatment A in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
62029018|NCT03024073||SG|Study group (patients who underwent pseudophakic presbyopic correction with bilateral bifocal lenses implantation
62029019|NCT03024073||CG|Control group (age-matched participants without pseudophakic presbyopic correction)
62227850|NCT02052830|NO_INTERVENTION|Control|Business as usual sexual education in schools
62227851|NCT06004947|EXPERIMENTAL|Cohort A|A single dose of 2 mg midazolam (a Cytochrome P450 \[CYP\]3A4 probe drug) and a single dose of 200 mg celecoxib (a CYP2C9 probe drug) will be given orally concurrently on Day 1 and Day 13. On Day 3 through Day 18, CCX168 will be given orally at 30 mg twice daily (b.i.d.), and a single dose of 30 mg CCX168 will be given in the morning on Day 19. On Day 16 through Day 19, a once daily (q.d.) dose of 200 mg itraconazole (a CYP3A4 inhibitor) will be given orally.
62227852|NCT06004947|EXPERIMENTAL|Cohort B|A single dose of 30 mg CCX168 will be given on Day 1 and Day 14, while rifampicin (a CYP3A4 inducer) will be given at 600 mg once daily from Day 4 through Day 17.
62590708|NCT01942356|EXPERIMENTAL|RL-TIVA Group|Propofol, ketamine and sufentanil administration for a TIVA (total intravenous anesthetic) will be administered using a Harvard 33 syringe pump connected via a RS 232 interface to the study computer running the RL (Reinforcement Learning) control software. This software platform will collect real time vitals and BIS valises and steer the target controlled infusion pumps and the closed loop controllers. The anesthesiologist will provide interventions based on protocol for TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia and TIVA - Tachycardia .
62029020|NCT02848508|EXPERIMENTAL|moderate impairment, CKD stage 3a|(12 subjects): GFR 59-45 (moderate impairment, CKD stage 3a) Metformin : 1500mg/day
62029021|NCT02848508|EXPERIMENTAL|moderate impairment, CKD stage 3a)|(12subjects): GFR 44-30 (moderate impairment, CKD stage 3b) Metformin : 1000mg/day
62029022|NCT02848508|EXPERIMENTAL|severe impairment|(12 subjects): GFR 29-15 (severe impairment, CKD stage 4) Metformin : 500mg/day
62029023|NCT02722746|PLACEBO_COMPARATOR|Ropivacaine only Control group|The participants in this group will receive standard anesthesia, epidural analgesia with 0.2% ropivacaine with no epinephrine added during the procedure.
62227853|NCT02391272|EXPERIMENTAL|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10\^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
62227854|NCT05272956|NO_INTERVENTION|control group|Enteral feeding is carried out with a syringe pump
62590709|NCT01942356|ACTIVE_COMPARATOR|Manual TIVA Group|Manually titrated TIVA (total intravenous anesethetic) with proposal, ketamine and sufentanil will be administered using an Alaris infusion pump titrated by the anesthesiologist based on blood pressure and heart-rate as is traditionally done and is standard of care with intravenous anesthetics. The anesthesiologist will provide interventions based on protocol for TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia and TIVA - Tachycardia .
62803586|NCT04179006|PLACEBO_COMPARATOR|Plain chocolate + antidepressant(s)|Participants with plain chocolate add-on to their antidepressants regimen.
62803587|NCT00911248|EXPERIMENTAL|PTC299|PTC299 administered at 100 mg/dose twice per day
62803588|NCT05914948|OTHER|Subjects implanted with a Medtronic 8-contact Vectris subcompact or compact electrode.|Subjects meeting study eligibility criteria will be implanted with a Medtronic 8-contact Vectris subcompact or compact electrode.
62803589|NCT00409539|PLACEBO_COMPARATOR|1|Placebo run-in phase. 2 week duration.
62803590|NCT00409539|PLACEBO_COMPARATOR|2|To be taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
62590710|NCT01942356|ACTIVE_COMPARATOR|Inhaled Sevofluorane Group|An inhaled anesthetic with Sevofluorane will be titrated between 0.8-1.5 MAC (minimum alveolar concentration) by the anesthesiologist based on heart rate and blood pressure which is standard of care for inhaled anesthetics. The anesthesiologist will provide interventions based on protocol for INH - Hypotension, INH - Hypertension, INH - Bradycardia and INH - Tachycardia .
62803591|NCT00409539|EXPERIMENTAL|3|20mg dose of SMP-986 to be taken once daily for 8 week duration.
62803592|NCT00409539|EXPERIMENTAL|4|40mg dose of SMP-986 to be taken for 8 week duration.
62029024|NCT02722746|ACTIVE_COMPARATOR|Ropivacaine + 2 mcg/mL epinephrine|The participants in this group will receive standard anesthesia (Ropivacaine 0.2%) with the addition of 2mcg/mL of epinephrine during the procedure.
62029025|NCT02722746|ACTIVE_COMPARATOR|Ropivacaine + 5 mcg/mL epinephrine|The participants in this group will receive standard anesthesia (Ropivacaine 0.2%) with the addition of 5mcg/mL of epinephrine during the procedure.
62029026|NCT03667053|EXPERIMENTAL|dasiglucagon|Single fixed dose (s.c.injection) of dasiglucagon
62227855|NCT05272956|EXPERIMENTAL|intervention group|the first enteral feeding is pushed with a syringe by the nurse. Following enteral feeding attempts are pushed with a syringe by the parents. Bolus feeding speed is at the discretion of the person pushing the syringe (nurse or parent) and is adjusted to the child's signs of discomfort. When the parents are absent, enteral feeding is carried out with a syringe pump
62420621|NCT01992770|EXPERIMENTAL|Tailored behavioural medicine|After having received a minimal intervention (step 1) comprising 'stay-active advice', participants scoring \>90 on the Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) are randomly allocated to an eight-week treatment in step 2, depending on risk profile. The experimental condition includes supervised physical exercises integrated with either (a) graded activity, or (b) hierarchical graded exposure depending on risk profile, i.e. absence or presence of pain catastrophizing and fear-avoidance beliefs.
62029027|NCT03667053|PLACEBO_COMPARATOR|placebo|Single fixed dose (s.c.injection) of placebo
62029028|NCT03667053|ACTIVE_COMPARATOR|GlucaGen®|Single fixed dose (s.c.injection) of GlucaGen®
62029029|NCT04117932|EXPERIMENTAL|"Arm ustekinumab"|Patients with bullous pemphigoid, treated using ustekinumab in association during 8 weeks with superpotent topical corticosteroids
62029030|NCT01910129|ACTIVE_COMPARATOR|gammaCore|Active stimulation treatment
62227856|NCT05532943|EXPERIMENTAL|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of diagnosis of multiple sclerosis.
62227857|NCT05532943|SHAM_COMPARATOR|Placebo|For IV administration, normal saline will be administered to patients after the onset of diagnosis of multiple sclerosis. For IT administration, sham puncture procedure will partially penetrate without reaching subarachnoid space, and no spinal fluid will be drawn.
62420622|NCT01992770|ACTIVE_COMPARATOR|Control group|"Participants will be scheduled for supervised, regular Physical exercises twice a week during eight weeks 8. Participants with a moderate to high disability risk profile will receive: Tailored graded activities training."
62590711|NCT01923298|EXPERIMENTAL|Estradiol|ESTRING® (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days.
62803593|NCT00409539|EXPERIMENTAL|5|80mg dose of SMP-986 to be taken for 8 week duration.
62803594|NCT00409539|EXPERIMENTAL|6|120mg dose of SMP-986 to be taken for 8 week duration.
62029031|NCT01910129|PLACEBO_COMPARATOR|sham gammaCore|Inactive stimulation treatment
62029032|NCT04060394|EXPERIMENTAL|Phase I Cohort 1|LAE001 (capsules) 75mg Twice Daily (BID) + prednisone (tablet) 5mg BID +afuresertib (tablet) 100mg Once Daily (QD) will be administered in Cycles of 28 days.
62803595|NCT02507323|ACTIVE_COMPARATOR|ticagrelor or matching placebo|ticagrelor (180 mg loading followed by 90 mg twice daily) or matching placebo
62803596|NCT02507323|ACTIVE_COMPARATOR|prasugrel or matching placebo|prasugrel (60 mg loading followed by 5-10 mg/d) or matching placebo
62803597|NCT02926989|EXPERIMENTAL|Isotonic solution|Plasmalyte Glucos 50 mg/mL; total daily fluid requirements are estimated using the Holiday-Segar method plus possible dehydration (according to child's weight loss during acute illness); intravenous fluids are administered using delivery pumps programmed for an hourly infusion rate (mL/hour); intravenous fluids are administered as long as needed during hospitalization, but no longer than seven days after admission.
62590712|NCT01913535|ACTIVE_COMPARATOR|Low Dose Drug-Drug Arm|Patients in this arm will receive CERC-501 10.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
62029033|NCT04060394|EXPERIMENTAL|Phase I Cohort 2|LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 100mg QD will be administered in Cycles of 28 days.
62590713|NCT01913535|ACTIVE_COMPARATOR|High Dose Drug-Drug Arm|Patients in this arm will receive CERC-501 20.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
62029034|NCT04060394|EXPERIMENTAL|Phase I Cohort 3|LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 125mg QD will be administered in Cycles of 28 days.
62227858|NCT04080908|EXPERIMENTAL|Ferumoxytol injection treatment|
62227859|NCT04022551||Observational|"At Emergency nurses will carry out a test called: Emergency Room Evaluation and Recommendation which contents the following statements:~1. Being 85 years older and over (Yes/No)~2. Male (Yes/No)~3. Home services (Yes/No)~4. Taking 5 different medication daily (Yes/No)~5. Use of walking aid (Yes/No)~6. Disoriented (Yes/No)"
62227860|NCT04840641|NO_INTERVENTION|Baseline|The investigators measure the baseline of flucloxacillin and cocktaildrugs.
62227861|NCT04840641|EXPERIMENTAL|Flucloxacillin treatment|The investigators measure the concentration of flucloxacillin after 9 and 27 days and the concentration of cocktaildrugs after 10 and 28 days.
62227862|NCT00367887|ACTIVE_COMPARATOR|1|
62227863|NCT00367887|ACTIVE_COMPARATOR|2|
62227864|NCT00367887|ACTIVE_COMPARATOR|3|
62420623|NCT06541977|EXPERIMENTAL|Pre and Post Intervention|Participants in this group will receive the usual hospital care, which includes psychology visits, nutritional advice, and a physical activity protocol plan. In addition, participants will be referral form the Hospital to the Unviersity to undertake supervised physical activity sessions and health behavior change techniques aimed at reducing sedentary behavior and improving quality of life. This intervention will start 8 months before surgery and continue for 12 months post-surgery, with regular monitoring and support to sustain life-changing behaviors.
62420624|NCT06541977|EXPERIMENTAL|Post Intervention|Participants in this group will receive the usual hospital care, including psychology visits, nutritional advice, and a physical activity protocol plan. Additionally, participants in this group will be referral from the Hospital to the Unviersity to begin supervised physical activity sessions and health behavior change techniques 12 months post-surgery, designed to reduce sedentary behavior and improve quality of life, with continuous professional support throughout the intervention period.
62590714|NCT01913535|OTHER|Placebo/Low-Dose Drug Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and CERC-501 10.0 mg/day for 3 days (in Phase 2)
62590715|NCT01913535|OTHER|Placebo/High-Dose Drug Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and CERC-501 20.0 mg/day for 3 days (in Phase 2)
62590716|NCT01913535|PLACEBO_COMPARATOR|Placebo/Placebo Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
62590717|NCT00160706|EXPERIMENTAL|Certolizumab Pegol|3-dose induction regimen of Certolizumab Pegol 400 mg at Weeks 0, 2, 4. Subsequently continue on 4-weekly treatment with Certolizumab Pegol 400 mg until Week 360.
62590718|NCT04287855|EXPERIMENTAL|Intervention|Isatuximab, Carfilzomib, Pomalidomide and Dexamethasone
62590719|NCT02143154||GBS positive women|Women wih GBS positive bacteruria with plan for treatment with vancomycin in labor, or women with positive GBS screening cultures with a plan to receive vancomycin in labor
62590720|NCT05713396|EXPERIMENTAL|Quinapril (Q)|Patients receiving Quinapril
62590721|NCT05713396|EXPERIMENTAL|Losartan (L)|Patients receiving Losartan
62590722|NCT05713396|EXPERIMENTAL|Quinapril + Losartan (Q+L)|Patients receiving both Quinapril and Losartan
62029035|NCT04060394|EXPERIMENTAL|Phase I Cohort 4|LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 150mg QD will be administered in Cycles of 28 days.
62029036|NCT04060394|EXPERIMENTAL|Phase II Cohort 1|LAE001 (capsules) + prednisone (tablet) +afuresertib at the Recommended Phase II Dose (RP2D)
62029037|NCT04060394|EXPERIMENTAL|Phase II Cohort 2|Docetaxel/prednisone + afuresertib
62029038|NCT02457221|EXPERIMENTAL|Tacrolimus group|Tacrolimus capsules + steroid
62227865|NCT01704131||children > 6 months|children \> 6 months of age
62590723|NCT02274870|EXPERIMENTAL|Liposome Bupivacaine,|Liposome Bupivacaine 266mg, Knee Infiltration
62590724|NCT02274870|ACTIVE_COMPARATOR|Bupivacaine HCl|Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
62590725|NCT02819180||Healthy adults group|Healthy men and women between 18 and 59 years of age.
62590726|NCT02819180||Elderly group|Elderly over 60 years old.
62590727|NCT01813214|EXPERIMENTAL|Vemurafenib Monotherapy|Vemurafenib 960 mg po BID until unacceptable toxicity or progression of disease
62590728|NCT01813214|EXPERIMENTAL|Vemurafenib + Cobimetinib Combination Therapy|"Vemurafenib 960 mg po BID until unacceptable toxicity or progression of disease~Cobimetinib will be given 60mg QD for 21 days on, then 7 days off, in a 28-day treatment cycle."
62227866|NCT01704131||children < 6 months|children \< 6 months
62227867|NCT03788083|PLACEBO_COMPARATOR|placebo|
62227868|NCT03788083|ACTIVE_COMPARATOR|TriMix|
62227869|NCT03356457|ACTIVE_COMPARATOR|DCA in T1DM with severe hypoglycemia|12 T1DM subjects (C-peptide negative, HbA1c \<7.5%) with a history of severe hypoglycemia and hypoglycemia unawareness as assessed by the Guy's and Thomas' Minimally Modified Clarke Hypoglycemia Survey, the Gold Score and the Edinburgh Hypoglycemia Survey and as evidenced by interview and glucose log and/or continuous glucose monitoring will receive a single dose of 12.5mg/kg dichloroacetate (DCA).
62227870|NCT03356457|PLACEBO_COMPARATOR|Placebo in T1DM with severe hypoglycemia|12 T1DM subjects (C-peptide negative, HbA1c \<7.5%) with a history of severe hypoglycemia and hypoglycemia unawareness as assessed by the Guy's and Thomas' Minimally Modified Clarke Hypoglycemia Survey, the Gold Score and the Edinburgh Hypoglycemia Survey and as evidenced by interview and glucose log and/or continuous glucose monitoring will receive a placebo oral capsule.
62227871|NCT03356457|ACTIVE_COMPARATOR|DCA in healthy control subjects|12 non-diabetic healthy subjects (fasting plasma glucose \< 100 mg/dL, HbA1c \< 6.0%), who are matched for age, gender, and weight to T1DM subjects, to serve as controls for the study. Each subject will receive a single dose of 12.5mg/kg dichloroacetate (DCA).
62029039|NCT02457221|ACTIVE_COMPARATOR|Cyclophosphamide group|Cyclophosphamide injections + steroid
62420625|NCT06541977|ACTIVE_COMPARATOR|Comparision|Participants in this group will receive the usual hospital care, which includes psychology visits, nutritional advice, and a physical activity protocol plan provided on a sheet. There will be no additional supervised physical activity sessions or health behavior change techniques beyond the standard care currently provided by the hospital.
62735311|NCT02200926|EXPERIMENTAL|Loaded breathing training|subjects will trained to inspire deeply against the resistance setting by using BreathMAX® at the loaded of 18 cmH2O with breathing frequency control at 6 breaths/minute. Breathing pattern will be controlled at duty cycle of 0.4 (inspiratory time = 4 sec and total respiratory time = 10 sec). The training program will be performed at home for 30 minutes/day, 7 days/week for 8 weeks.
62803598|NCT02926989|ACTIVE_COMPARATOR|Hypotonic solution|0.45% saline in 5% dextrose; total daily fluid requirements are estimated using the Holiday-Segar method plus possible dehydration (according to child's weight loss during acute illness); intravenous fluids are administered using delivery pumps programmed for an hourly infusion rate (mL/hour); intravenous fluids are administered as long as needed during hospitalization, but no longer than seven days after admission.
62803599|NCT06233188|ACTIVE_COMPARATOR|study group|In the study group, lateral nasal osteotomy was performed 2 mm less than the measured distance in the axial section
62227872|NCT03356457|PLACEBO_COMPARATOR|Placebo in healthy control subjects|12 non-diabetic healthy subjects (fasting plasma glucose \< 100 mg/dL, HbA1c \< 6.0%), who are matched for age, gender, and weight to T1DM subjects, to serve as controls for the study will receive a placebo oral capsule.
62227873|NCT02772406|EXPERIMENTAL|Experimental group|(With LCI endoscopy and 1 month later with white light endoscopy) The patients will be evaluated by Linked Color Imaging and 1 month later evaluated by White Light endoscopy
62227874|NCT02772406|ACTIVE_COMPARATOR|Control group|(With white light endoscopy and 1 month later with LCI endoscopy) The patients will be evaluated by White Light endoscopy and 1 month later evaluated by Linked Color Imaging
62227875|NCT04651517|EXPERIMENTAL|Study arm|Subjects undergoing procedures with the XACT ACE Robotic system.
62227876|NCT01491672|EXPERIMENTAL|RAD001|Participants, received RAD001 10 mg orally once daily.
62227877|NCT00960531|EXPERIMENTAL|ACC-001 (3mcg) + QS-21|ACC-001 (3mcg) + QS-21
62227878|NCT00960531|EXPERIMENTAL|ACC-001 (10mcg) + QS-21|ACC-001 (10mcg) + QS-21
62420626|NCT06375837|EXPERIMENTAL|an alkasite-based restorative material|Cention N, Ivoclar Vivadent, Schaan, Liechtenstein (CN) The liquid and powder will be mixed and then applied according to manufacturer's instructions.
62420627|NCT06375837|EXPERIMENTAL|hybrid resin composite|Gradia Direct Anterior, GC, Tokyo, Japan (GR) After applying 37% orthophosphoric acid to the enamel of the lesions for 30 seconds and to the dentin for 15 seconds, the acid will be washed with water and then dried with light air. A universal adhesive (G-Premio Bond, GC, Tokyo, Japan) and then the composite will be applied according to the manufacturer's instructions.
62420628|NCT06375837|EXPERIMENTAL|a highly filled flowable resin composite|G-aenial Universal Flo, GC, Tokyo, Japan (GF) After applying 37% orthophosphoric acid to the enamel of the lesions for 30 seconds and to the dentin for 15 seconds, the acid will be washed with water and then dried with light air. A universal adhesive (G-Premio Bond, GC, Tokyo, Japan) and then the composite will be applied according to the manufacturer's instructions.
62803600|NCT06233188|ACTIVE_COMPARATOR|conventional group|n the conventional osteotomy group, lateral nasal osteotomy was performed 25 mm for female and 30 mm for male patients, as suggested in the literature.
62029040|NCT01710072|EXPERIMENTAL|aspirin|aspirin 81 mg po every day
62029041|NCT01710072|NO_INTERVENTION|no aspirin|
62227879|NCT00960531|EXPERIMENTAL|ACC-001 (30mcg) + QS-21|ACC-001 (30mcg) + QS-21
62227880|NCT03722147|EXPERIMENTAL|AK105|AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
62420629|NCT03569566||Elite endurance athletes|Cross-country skiers at high national level
62803601|NCT00730977|EXPERIMENTAL|single|single arm, open label, 4 doses tested.
62029042|NCT03460223|EXPERIMENTAL|Conventional plus MSC treatment|
62029043|NCT05981443|EXPERIMENTAL|Active Comparator: Dermabond|The surgical wound over one eyebrow will be closed with Dermabond.
62227881|NCT00610467|EXPERIMENTAL|Disease Group|Patients with suspicious breast diseases
62227882|NCT00610467|EXPERIMENTAL|Control Group|Healthy volunteers for system testing
62227883|NCT05333770|EXPERIMENTAL|SCI Group|"Complete testing at Baseline, Post, and 6 month follow up. Intervention includes 15 treatment sessions (3-5 times per week) with HF-rTMS \& 6 month follow-up. Following HF-rTMS, there will be 30 minutes of arm and hand training. Each session will last for approximately 60 mins.~At baseline, post and 6 months, the following evaluations to evaluate safety and other related measures. These measures include a safety and pain questionnaire, spasticity measurement, a physician or clinician evaluation to determine motor and sensory neurological level of injury, hand and arm function measurement, evaluation of ability to perform everyday tasks, and measures to determine level of brain function."
62227884|NCT03107897|NO_INTERVENTION|Pre-procedure standard of care|No prehab prior to TAVR.
62227885|NCT03107897|ACTIVE_COMPARATOR|Prehab prior to TAVR procedure.|Individuals participate in prehabilitation prior to TAVR.
62227886|NCT02054741|EXPERIMENTAL|Arm I (GA intervention)|Patients complete a geriatric assessment. Patients and physicians are provided with the geriatric assessment information and recommendations.
62227887|NCT02054741|NO_INTERVENTION|Arm II (usual care)|Patients complete a geriatric assessment, but information other than clinically significant cognitive impairment and depression is not provided to the oncology teams.
62227888|NCT00220753|ACTIVE_COMPARATOR|Active air cleaner|Two Icleen IQAir air cleaners with active filters supplied
62227889|NCT00220753|PLACEBO_COMPARATOR|Placebo air cleaner|Two Icleen IQAir air cleaners with placebo filters supplied
62227890|NCT02966301|EXPERIMENTAL|interventional|Single arm : Arsenic trioxide
62227891|NCT01063660|EXPERIMENTAL|Treosulfan|Patients with acute myeloid leukaemia (AML) according to WHO classification (\> 20% myeloblasts in peripheral blood or bone marrow at initial diagnosis) with \< 5% myeloblasts in the bone marrow, indicated for allogeneic transplantation
62803602|NCT00003239|EXPERIMENTAL|Chemotherapy with Cytarabine + Homoharringtonine|Interferon alfa and cytarabine daily by subcutaneous injection. Homoharringtonine is administered by continuous infusion on days 1-5.
62803603|NCT00938678|EXPERIMENTAL|Treatment Group 1|
62803604|NCT00938678|ACTIVE_COMPARATOR|Treatment Group 2|
62227892|NCT04250441|EXPERIMENTAL|Treatment|All patients enrolled will receive transcranial focused ultrasound. Target location is dependent on patient condition.
62227893|NCT04593316||Exertional heatstroke group|Patients presenting or having presented exertional heatstroke.
62227894|NCT04593316||Control group|Healthy people who never experienced exertional heatstroke.
62227895|NCT00346268|ACTIVE_COMPARATOR|Morphine plus Parecoxib|
62227896|NCT00346268|ACTIVE_COMPARATOR|Morphine and Placebo|
62227897|NCT01501760|EXPERIMENTAL|bevacizumab|Three subconjunctival injections of 0.5 ml of bevacizumab at inclusion, 1 month, 2 month.
62735312|NCT02200926|EXPERIMENTAL|Unloaded breathing training|subjects will trained to inspire deeply (no resistance) with breathing frequency control at 6 breaths/minute. Breathing pattern will be controlled at duty cycle of 0.4 (inspiratory time = 4 sec and total respiratory time = 10 sec). The training program will be performed at home for 30 minutes/day, 7 days/week for 8 weeks.
62227898|NCT01501760|PLACEBO_COMPARATOR|Placebo|Three subconjunctival injections of 0.5 ml of Nacl at inclusion, 1 month, 2 month.
62227899|NCT02943486|EXPERIMENTAL|dac-MSCs and Fitostimoline|Intradermic application of dac-MSCs (1 mL ) in four equidistant points around the ulcer (twice: day 0 and 7) and topical application of fitostimoline every other day
62227900|NCT02943486|ACTIVE_COMPARATOR|MSCs and Fitostimoline|Intradermic application of MSCs (500,000 cells/mL) in four equidistant points around the ulcer (once: day 0 ) and topical application of fitostimoline every other day
62227901|NCT02943486|ACTIVE_COMPARATOR|Fitostimoline|Topical application of fitostimoline every other day
62735313|NCT02263326|EXPERIMENTAL|dolutegravir plus lamivudine|dolutegravir 50 mg plus lamivudine 300 mg once daily
62227902|NCT05515380|EXPERIMENTAL|8-stage model based exercise training|8-stage model based exercise training
62227903|NCT05515380|ACTIVE_COMPARATOR|Conventional exercise training|Conventional exercise training
62803605|NCT02975050||Side location|u-Cor device will be applied on side location
62227904|NCT03275844||Group 1|Children with congenital heart disease
62803606|NCT02975050||Front location|u-Cor device will be applied on front location
62227905|NCT03275844||Group 2|Control healthy subjects
62735314|NCT02263326|ACTIVE_COMPARATOR|Continue current ART regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
62735315|NCT03813758||finger after digital nerve cut|
62735316|NCT03813758||healthy finger|
62735317|NCT01447498|NO_INTERVENTION|Control group|
62735318|NCT01447498|ACTIVE_COMPARATOR|Screening and risk assessment|
62735319|NCT03949452|ACTIVE_COMPARATOR|Subcostal Transversus Abdominis Plane catheter|This group includes patients who will receive subcostal Transversus abdominis plane block analgesia
62735320|NCT03949452|PLACEBO_COMPARATOR|Epidural catheter|This group includes patients who will receive epidural analgesia using a catheter technique
62029044|NCT05981443|ACTIVE_COMPARATOR|Active Comparator: Non-Absorbable Sutures|The surgical wound over one eyebrow will be closed with non-absorbable sutures.
62029045|NCT03185975|PLACEBO_COMPARATOR|Control arm|Each participant will receive an at-home test kit and will be asked to test and return results to investigator.
62029046|NCT03185975|ACTIVE_COMPARATOR|Intervention Arm|Each participant will receive an at-home test kit and will be asked to take the test in conjunction with an online Motivational interviewing/certified testing and referral (MI/CTR).
62029047|NCT05568888|EXPERIMENTAL|BE1116|Administration by IV infusion
62227906|NCT04229251|EXPERIMENTAL|Online Mindfulness-based Intervention|iMBI will be delivered to participants in 8 online sessions, approximately 2 hours per session.
62227907|NCT04229251|SHAM_COMPARATOR|Online Introductory Psychology Program|An online introductory psychology courses will be delivered to participants in 8 online sessions, approximately 2 hours per session.
62227908|NCT00315900|EXPERIMENTAL|Depakote ER|Depakote ER
62420630|NCT04844931|EXPERIMENTAL|RIC + PostC in addition to standard treatment|RIC by arm ischemia initiated on hospital admission plus local PostC by re-inflating the angioplasty balloon after re-opening the infarct-related artery in addition to standard treatment.
62227909|NCT00315900|ACTIVE_COMPARATOR|Seroquel|Seroquel
62227910|NCT03527173|EXPERIMENTAL|S. sonnei Group|Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the S. sonnei study vaccine at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally.
62243104|NCT02231021|ACTIVE_COMPARATOR|Pioglitazone|alogliptin matching placebo 1 tablet daily for 24 weeks pioglitazone 30 mg 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
62420631|NCT04844931|ACTIVE_COMPARATOR|Standard treatment|
62420632|NCT06122649|EXPERIMENTAL|Placebo-controlled Treatment Phas|Participants are randomized in a 1:1 ratio to take either apremilast or placebo BID for 16 weeks.
62735321|NCT04294459|EXPERIMENTAL|Cohort A: Participants with cPRA >=99.90%|Participants with calculated panel reactive antibodies (cPRA) \>=99.90% (indicating active candidates on kidney transplant waitlist) received isatuximab 10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, once weekly (QW) for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1) and then every 2 weeks (Q2W) for subsequent treatment cycles (each cycle of 28 days) until unacceptable adverse events (AEs) or participant's decision to stop the treatment (maximum treatment duration: 13 weeks).
62803607|NCT02434822|EXPERIMENTAL|Study Group 1|Participants aged 1 through 4 years at enrollment
62029048|NCT05568888|PLACEBO_COMPARATOR|Placebo|Administration by IV infusion
62029049|NCT03238937|OTHER|Phrenic Nerve Stimulator|Phrenic Nerve Stimlator
62029050|NCT03238937|NO_INTERVENTION|no intervention|Patients without phrenic nerve stimulation
62803608|NCT02434822|EXPERIMENTAL|Study Group 2|Participants aged 5 through 14 years at enrollment
62029051|NCT03879720|ACTIVE_COMPARATOR|Standard Endotracheal Intubation (SEI)|the patient will be positioned supine on the gurney for intubation, with eventual position in the standard semi-prone ERCP position on the fluoroscopy table. Anesthesiologist-determined doses of Fentanyl, Versed, Propofol and Succinylcholine will be administered per standard of care and intubation will be accomplished by direct laryngoscopy or glidescope, with confirmation of endotracheal tube placement by auscultation.
62029052|NCT03879720|EXPERIMENTAL|Endoscope assisted endotracheal intubation [EAEI]|the patients will position themselves in the semi-prone position on the fluoroscopy table. Anesthesiologist-determined doses of Fentanyl, Versed and Propofol will be administered per standard of care. Succinylcholine will not be administered and therefore the patient will not be paralyzed. The endotracheal tube will be positioned on the mid-distal aspect of the ultra-slim endoscope and the ultra-slim endoscope will then be advanced into the trachea under direct endoscopic visualization to the level of the carina. The anesthesiologist will then advance the endotracheal tube over the endoscope into the trachea, and its position above the carina will be simultaneously confirmed endoscopically with the ultra-slim endoscope.
62029053|NCT03955393||LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS|Twenty patients candidates to radical nephrectomy and extended lymphadenectomy for clinical T4 cancers (clinical Nany) or renal masses with evidence of lymphadenopathies at preoperative CT scan (clinical Tany N1) or larger tumor (clinical Tany Nany and max diameter\>10 cm). RCC candidates to surgery will receive a single intravenous infusion of 18F-FAZA. Surgery will be scheduled within 1 week after infusion. PET and CT scanning of the abdomen will be planned before surgery.
62420633|NCT06122649|EXPERIMENTAL|Active Treatment Phase|Participants who received placebo during the placebo-controlled treatment phase will receive apremilast BID for 36 weeks. Participants who took apremilast will continue receiving it BID for 36 weeks.
62803609|NCT02434822|EXPERIMENTAL|Study Group 3|Participants aged 15 years and above at enrollment
62029054|NCT02000284||General ASD|150 general ASD children
62029055|NCT02000284||ASD/MD|50 children Diagnosed with an Autism Spectrum Disorder and a Mitochondrial Disorder
62029056|NCT02000284||ASD/noMD|50 children with ASD that have been r/o as having a mitochondrial disorder
62029057|NCT02000284||MD/noASD|50 children with a mitochondrial disorder and without an ASD
62590729|NCT06586788|EXPERIMENTAL|Children Undergoing Developmental Evaluation|Participating EE Hubs referred a prospective, consecutive sample of children who received an EE Hub evaluation. Next, the study team traveled to the EE Hub to conduct a follow-up gold-standard autism diagnostic assessment (reference standard diagnosis) and eye-tracking biomarker battery (index test; Aim 2) within 16 weeks of EE Hub evaluation. Reference standard diagnosis was made by a licensed clinical psychologist with expertise in autism diagnosis based upon a research evaluation including the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), Vineland Adaptive Behaviors Scale, Third Edition (VABS-3), Mullen Scales of Early Learning (MSEL), and a caregiver interview to assess for DSM-5 autism criteria. Children also completed a short (\< 15min) eye-tracking activity where the children view a series of different images/videos while the children's eye movements and pupil diameter was measured.
62590730|NCT06254001|ACTIVE_COMPARATOR|Nicotine replacement therapy|Nicotine replacement therapy (Nicotine patches) plus counseling and cognitive behavioral therapy
62590731|NCT06254001|EXPERIMENTAL|Nicotine replacement therapy and Bupropion|Nicotine replacement therapy (Nicotine patches) plus Bupropion and counseling and cognitive behavioral therapy
62590732|NCT06618196|EXPERIMENTAL|Test group 1|Low dose of candidate hexavalent vaccine (DTaP-HepB-IPV-Hib)
62590733|NCT06618196|EXPERIMENTAL|Test group 2|Middle dose of candidate hexavalent vaccine (DTaP-HepB-IPV-Hib)
62590734|NCT06618196|EXPERIMENTAL|Test group 3|High dose of candidate hexavalent vaccine (DTaP-HepB-IPV-Hib)
62590735|NCT06618196|ACTIVE_COMPARATOR|Test group 4|Control hexavalent vaccine (DTaP-HepB-IPV-Hib)
62420634|NCT04138602|ACTIVE_COMPARATOR|Emsella Chair Active Treatment with Dietary Counseling|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%. During the visit the subject will also receive dietary counseling.
62029058|NCT02000284||Developmental Delay|50 children without a mitochondrial disorder or autism spectrum disorder, but with general developmental delays
62029059|NCT02000284||Typically Developing|100 children with no history of medical, behavioral, or immunological disorders
62420635|NCT04138602|PLACEBO_COMPARATOR|Emsella Sham Treatment with Dietary Counseling|Sham subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (\<10% power). During the visit the subject will also receive dietary counseling.
62590736|NCT04875702|ACTIVE_COMPARATOR|TTT-SU|The participants randomized to the Treat-to-Target-Serum Urate (TTT-SU) group will be counseled about gout, generalized lifestyle and dietary issues and will be provided with a three-month supply of allopurinol as well as a treatment to prophylax against attacks that might occur during the up-titration of urate lowering therapy. Allopurinol dose increases will occur until SU concentrations achieve a target level \< 6.0 mg/dL.
62803610|NCT01112397|EXPERIMENTAL|1|AZD1480 until Maximum Tolerated Dose (MTD) is reached
62420636|NCT06606899|EXPERIMENTAL|Group Melatonin|Group A: will receive oral Melatonin and nasal Sevoflurane.
62420637|NCT06606899|EXPERIMENTAL|Group Chloral-Hydrate|Group B: will receive oral Chloral Hydrate and nasal Sevoflurane.
62803611|NCT01112397|EXPERIMENTAL|2|AZD1480 dose expansion of MTD
62803612|NCT01730521||Difference in Iron bioavailabilty exercise and resting phase|the subjects will act as their own control during the study
62803613|NCT02783365|EXPERIMENTAL|Intervention|The intervention uses photo-elicitation and online group support (via Facebook) to improve patients' overall experience of chronic pain and patient-identified areas of function. This intervention was informed by the Photovoice methodology developed by Wang and Burris (1994). Photovoice participants will utilize cameras that enable them to record issues related to their experiences, and subsequently display them in office visits with their physician or mid-level clinician.
62803614|NCT02783365|NO_INTERVENTION|Control|Patients in the control practices will receive usual care and will be eligible to participate in the intervention after their participation in the study is completed at 12 months.
62420638|NCT06065475|EXPERIMENTAL|Thyroid Cartilage Plane Block Group (T Group)|All patients received topical oral and pharyngeal anesthesia using 2.4% lidocaine spray. The pharyngeal surface was sprayed twice, with each spray lasting one second, and repeated after a 5-minute interval. Ultrasound-guided bilateral Thyroid Cartilage Plane Block is performed using the thyroid cartilage plate as an anatomical landmark. 2.5ml of 2% lidocaine is injected on the surface of the thyroid cartilage each side. Subsequently, perform fiberoptic bronchoscope-guided subglottis and tracheal surface topical anesthesia using 5ml of 2% lidocaine. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
62590737|NCT04875702|ACTIVE_COMPARATOR|TTASx|Subjects randomized to the treat-to-avoid-symptoms (TTASx) group will receive the same education as the TTT-SU group. In addition, they will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone); enough to treat up to six flares over the ensuing three months.
62803615|NCT05432713|EXPERIMENTAL|LP-168 tablet|After confirmation of inclusion, subjects will be randomized into the LP-168 tablet or LP-168 placebo tablet arm and receive single or multiple doses of LP-168 tablet or LP-168 placebo tablet.
62590738|NCT04622514|EXPERIMENTAL|Village doctor-led telemedicine integrated care|To empower village doctors, a new technology-based model of AF care was established in the intervention group. A digital health support platform was developed by our research team, and a network of teams consisting of village doctors and AF specialists in our research team was established in the intervention group. With the aid of this telemedicine platform, village doctors can receive more support from AF specialists in providing integrated AF care to the rural elderly with AF.
62803616|NCT05432713|PLACEBO_COMPARATOR|LP-168 Placebo tablet|After confirmation of inclusion, subjects will be randomized into the LP-168 tablet or LP-168 placebo tablet arm and receive single or multiple doses of LP-168 tablet or LP-168 placebo tablet.
62803617|NCT02962167|EXPERIMENTAL|Locally Recurrent Medulloblastoma/ATRT|Patients must have local recurrent disease (defined as negative spine MRI and negative cytology within 21 days prior to study registration) and undergo resection of local recurrence as part of their standard of care. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, directly into the tumor bed during standard of care resection.
62803618|NCT02962167|EXPERIMENTAL|Disseminated Recurrent MB/ATRT|Patients must have disseminated recurrent medulloblastoma (MB) or ATRT (defined as multifocal disease, positive spine MRI including leptomeningeal disease and/or positive cytology within 21 days prior to study registration) and have adequate CSF flow based on spine MRI with no evidence of bulky disease or if bulky disease is present based on a CSF flow study per institutional guidelines. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, via lumbar puncture (modified measles virus lumbar puncture).
62227911|NCT03527173|PLACEBO_COMPARATOR|Placebo Group|Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the placebo at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally.
62227912|NCT02499770|EXPERIMENTAL|trilaciclib + carboplatin/etoposide|All patients in part 1 will receive trilaciclib (G1T28) prior to standard chemotherapy- carboplatin and etoposide. Patients will have PK assessments completed on days 1 and 3 in cycle 1 only. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
62227913|NCT02499770|EXPERIMENTAL|trilaciclib/placebo + carboplatin/etoposide|All patients enrolled in part 2 will be randomized to receive either trilaciclib (G1T28) or placebo administered prior to standard chemotherapy- carboplatin and etoposide. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
62420639|NCT06065475|NO_INTERVENTION|the Control Group （C Group）|Patients in the C Group received topical oral and pharyngeal anesthesia using 2.4% lidocaine spray. The pharyngeal surface was sprayed twice, with each spray lasting one second, and repeated after a 5-minute interval. Patients in the C Group receive airway topical anesthesia using the fiberoptic bronchoscope-guided local anesthetic spray method throughout the vocal cord and tracheal with 5 ml 2% lidocaine respectively.
62227914|NCT02094755||Single cohort|Single cohort will receive Blood draw only.
62420640|NCT05612178|EXPERIMENTAL|3BNC117-LS and 10-1074-LS|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) at weeks 0, 20 and 40.
62590739|NCT04622514|ACTIVE_COMPARATOR|Enhanced usual care|Usual care plus intensified education to patients, their family members, and their village doctors.
62227915|NCT01122862|ACTIVE_COMPARATOR|0.12% Chlorhexidine Mouthrinse|Commercially available 0.12% Chlorhexidine mouthrinse
62227916|NCT01122862|ACTIVE_COMPARATOR|Cosmetic mouthrinse|Commercially available cosmetic mouthrinse
62227917|NCT01122862|PLACEBO_COMPARATOR|Sterile Water|Sterile Water
62420641|NCT05612178|PLACEBO_COMPARATOR|Placebo|Participants will receive three intravenous infusions of placebo (Sterile Saline) at weeks 0, 20 and 40.
62590740|NCT03199807|EXPERIMENTAL|NRT + radiotherapy|HCC received NRT and radiotherapy
62029060|NCT00354523|EXPERIMENTAL|Capecitabine + Dacarbazine + Imatinib|Capecitabine starting Dose 500 mg/m\^2 twice a day Days 1-14 of 21 Day Cycle. Dacarbazine starting Dose 250 mg/m\^2 a day on Days 1-3 of 21 Day Cycle. Imatinib starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
62029061|NCT00709280|EXPERIMENTAL|Active treatment group|7% Hypertonic Saline administered via inhalation twice daily for 48 ± 4 weeks
62420642|NCT06083051|ACTIVE_COMPARATOR|6Fr Percuflex ureteral stents|
62420643|NCT06083051|ACTIVE_COMPARATOR|6Fr Tria ureteral stents|
62420644|NCT06083051|ACTIVE_COMPARATOR|4.8Fr Tria ureteral stents|
62227918|NCT03086525||Musculoskeletal pain|Participants Healthy male and female students, students of the University of Málaga, will be recruited. . The inclusion criteria are as follows: (i) men / women over 18 years; (ii) students of the University of Málaga.
62227919|NCT02154789|EXPERIMENTAL|polidocanol|
62227920|NCT02154789|ACTIVE_COMPARATOR|cryotherapy|
62227921|NCT02154789|ACTIVE_COMPARATOR|infra-red coagulation|
62420645|NCT06083051|ACTIVE_COMPARATOR|4.8Fr Percuflex ureteral stents|
62420646|NCT06703411|EXPERIMENTAL|Iron sucrose|IV iron sucrose 200mg per visit
62420647|NCT06703411|ACTIVE_COMPARATOR|Standard of care|Standard of care (HFrEF4 pillars treatment)
62227922|NCT00569595|EXPERIMENTAL|1|Multi-Level, Patient-Directed, Lifestyle Change, Health Promotion Program
62227923|NCT00569595|SHAM_COMPARATOR|2|"Patient health counseling program by lay health educators Entitled Fighting Cancer with Advice."
62227924|NCT04371653|EXPERIMENTAL|Active group|Patients with NAFLD will receive orally fecal microbiota capsules from healthy donors
62227925|NCT04371653|PLACEBO_COMPARATOR|Placebo group|Placebo capsules will be identical to the active capsules, but not contain intestinal bacteria
62227926|NCT04612374|EXPERIMENTAL|Phase 1: Unified Protocol, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
62227927|NCT04612374|EXPERIMENTAL|Phase 1: Experimental: Unified Protocol, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
62227928|NCT04612374|EXPERIMENTAL|Phase 2: Revised Unified Protocol, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the revised Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences and will be revised based on patient feedback in Phase 1.
62227929|NCT04612374|EXPERIMENTAL|Phase 2: Revised Unified Protocol, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the revised Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences and will be revised based on patient feedback in Phase 1.
62227930|NCT02434939|EXPERIMENTAL|Low dose ketamine|Low dose ketamine 1mg/kg given as an IV infusion via syringe pump over 10 minutes. Maximum of 2 doses to be given during study period that will last 2 hours.
62227931|NCT02434939|ACTIVE_COMPARATOR|Morphine|Morphine 0.1mg/kg given as an IV infusion via a syringe pump over 10 minutes. Maximum of 2 doses to be given during the study period that will last 2 hours.
62227932|NCT00355199|EXPERIMENTAL|R-HDS|R-HDS : Rituximab supplemented high-dose (Cyclophosphamide,Ara-C, Methotrexate, Etoposide, Cis-Platin) sequential chemotherapy with autografting.
62227933|NCT00355199|ACTIVE_COMPARATOR|R-CHOP|Rituximab-CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone).
62227934|NCT01795664|ACTIVE_COMPARATOR|Seretide Evohaler|"Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Seretide Evohaler, Allen \& Hanburys, UK)~Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg"
62227935|NCT01795664|EXPERIMENTAL|Salmeterol xinafoate and Fluticasone propionate HFA pMDI|"Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Cipla Ltd., India)~Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg"
62227936|NCT02648165|EXPERIMENTAL|ABM +|Attention Bias Modification
62227937|NCT02648165|SHAM_COMPARATOR|ABM -|Sham Attention Bias Modification
62227938|NCT02648165|EXPERIMENTAL|ABM + and ACT|Attention Bias Modification followed by Group Acceptance and Commitment Therapy
62227939|NCT02648165|SHAM_COMPARATOR|ABM - and ACT|Sham Attention Bias Modification followed by Group Acceptance and Commitment Therapy
62227940|NCT06107608|EXPERIMENTAL|FAPI PET/CT|The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is injected intravenously for molecular imaging of FAP expression with FAPI PET/CT in patients with NSCLC with an indication for immunotherapy
62227941|NCT04752982|ACTIVE_COMPARATOR|c-SIGHT intervention|Grasp, lift and balance three wooden rods of different lengths.
62227942|NCT04752982|SHAM_COMPARATOR|c-SIGHT attentional control|Grasp and lift three wooden rods of different lengths from one end only (no attempt to balance rods).
62227943|NCT04700020|OTHER|Patients above the age of 18 years|"In the context of this study, we will take two blood samples. In addition to the second blood sample, an insulin tolerance test (ITT) is also performed, even if the result of the blood values is normal.~MRI will only be performed if the previous imaging was done more than two years ago or when the quality of the MRI was not good enough to measure the volume of the pituitary gland."
62227944|NCT03418948|ACTIVE_COMPARATOR|2 x CC|2 x conventional colonoscopy (CC), back-to-back design
62227945|NCT03418948|ACTIVE_COMPARATOR|CC followed by EC|Conventional colonoscopy followed by Endocuff Vision- assisted colonoscopy, back-to-back design
62227946|NCT03418948|ACTIVE_COMPARATOR|EC followed by CC|Endocuff Vision-assisted colonoscopy followed by conventional colonoscopy, back-to-back design
62227947|NCT03418948|ACTIVE_COMPARATOR|2 x EC|2 x Endocuff Vision-assisted colonoscopy
62227948|NCT02273817|EXPERIMENTAL|Ciclesonide Nasal Spray (Apotex, Inc.)|"Ciclesonide nasal spray~* Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide.~* Strength: 50 μg per actuation.~* Batch/Lot number (Expiry date): JM6697 (May 2012)~* Manufacturer: Apotex, Inc."
62227949|NCT02273817|ACTIVE_COMPARATOR|Omnaris™ nasal spray|"Omnaris™ Nasal Spray,~* Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide~* Strength: 50 μg per actuation~* Batch/Lot number (Expiry date): 131657 (03/2012)~* Manufacturer: Sepracor, Inc."
62227950|NCT02273817|PLACEBO_COMPARATOR|Placebo|"Placebo~* Dosage form: Contain the aqueous medium of each metered-dose pump spray formulation unit minus the active ingredient, ciclesonide.~* Batch/Lot number (Expiry date): JR3808 (Nov 2012)~* Manufacturer: Apotex, Inc."
62590741|NCT01311375|EXPERIMENTAL|w3 supplement + capsule CA-D|Mor DHA :w3 supp will be given to this group + capsule Ca(500 mg)-D(200 micro gram)
62590742|NCT01311375|PLACEBO_COMPARATOR|placebo+ CA-D|placebo in the same color,shape,size
62590743|NCT06253390|ACTIVE_COMPARATOR|D-MCT group|
62590744|NCT06253390|OTHER|DPN group|
62590745|NCT03644823|EXPERIMENTAL|PDL1-inhibitor and radiotherapy|PDL1-inhibitor (Atezolizumab) and Radiotherapy (6 Gy x 3)
62227951|NCT03503344|EXPERIMENTAL|Arm I (apalutamide, SBRT)|Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Beginning 60 days after first dose of apalutamide, participants also undergo stereotactic body radiation therapy for 1-5 fractions.
62227952|NCT03503344|ACTIVE_COMPARATOR|Arm II (SBRT)|Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
62029062|NCT00709280|ACTIVE_COMPARATOR|Control group|0.9% Isotonic Saline administered via inhalation twice daily for 48 ± 4 weeks
62029063|NCT00655980|EXPERIMENTAL|Treatment|Vitamin B12 and folic acid
62227953|NCT00446667|EXPERIMENTAL|1|
62590746|NCT01871493|EXPERIMENTAL|LY2605541-Part A|1.42 units per kilogram (U/kg) of LY2605541 given once daily (QD) for 1 day, subcutaneously (SQ) in 1 of 4 treatment periods.
62590747|NCT01871493|ACTIVE_COMPARATOR|Insulin Lispro-Part A|Single dose 0.36 U/kg of insulin lispro given QD for 1 day, SQ in 1 of 4 treatment periods.
62590748|NCT01871493|EXPERIMENTAL|LY2605541/Lispro Mix 1-Part A|Single dose 0.54 U/kg of LY2605541 and 0.36 U/kg insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.
62590749|NCT01871493|EXPERIMENTAL|LY2605541/Lispro Mix 2-Part A|Single dose 1.42 U/kg of LY2605541 and 0.36 insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.
62590750|NCT01871493|ACTIVE_COMPARATOR|Insulin Lispro-Part B|0.18 U/kg insulin lispro given twice daily (BID) for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
62029064|NCT00655980|PLACEBO_COMPARATOR|Comparator|Nitrous oxide and placebo
62029065|NCT00655980|OTHER|Standard of care|standard of care
62029066|NCT03009526|ACTIVE_COMPARATOR|Sulfadoxine-pyrimethamine|Intermittent preventive treatment with Sulfadoxine-pyrimethamine: Monthly dose of 3 co-formulated tablets containing 500 mg sulfadoxine and 25 mg pyrimethamine
62029067|NCT03009526|EXPERIMENTAL|dihydroartemisinin-piperaquine|"Intermittent preventive treatment with dihydroartemisinin-piperaquine: Monthly course of daily doses of co-formulated DP tablets containing 40 mg dihydroartemisinin and 320 mg piperaquine, dosed based on the woman's weight, for 3 days:~* 24-35.9 kg: Two tablets~* 36-59.9 kg: Three tablets~* 60-79.9 kg: Four tablets~* ≥80 kg: Five tablets"
62227954|NCT05186194|EXPERIMENTAL|Experimental (Treatment) Group|Oral vitamin D1000IU, 1/day, calcium 1200mg, 1/day, for 8 weeks.
62227955|NCT05186194|PLACEBO_COMPARATOR|Control Group|Oral placebo, for 8 weeks.
62227956|NCT05674331|ACTIVE_COMPARATOR|socket seal group|After tooth extraction a soft tissue pounch is sutured above the extraction socket.
62227957|NCT05674331|EXPERIMENTAL|XSD+ socket seal group|After tooth extraction for the reconstruction of the buccal bony wall a xenograft membrane with a long absorption rate is fixed with titanium pins to the buccal side. A soft tissue pounch is sutured above the extraction socket.
62227958|NCT05674331|EXPERIMENTAL|XSD+ ATB+socket seal group|After tooth extraction, the tooth will be grinded and after the sterilization procedure it will be filled back to the extraction socket. For the reconstruction of the buccal bony wall a xenograft membrane with a long absorption rate is fixed with titanium pins to the buccal side. A soft tissue pounch is sutured above the extraction socket.
62227959|NCT03373695|EXPERIMENTAL|Dissolve™|
62227960|NCT03373695|ACTIVE_COMPARATOR|SeQuent®Please|
62227961|NCT05810337|EXPERIMENTAL|Splenda drink|Drink containing 4.5g Splenda dissolved on 250ml water.
62227962|NCT05810337|PLACEBO_COMPARATOR|Maltodextrin drink|Drink containing 4.5g maltodextrin dissolved on 250ml water.
62227963|NCT03714425|ACTIVE_COMPARATOR|High frequency device|Subjects will use high frequency Quell devices.
62227964|NCT03714425|SHAM_COMPARATOR|Low frequency device|Subjects will use low frequency Quell devices.
62590751|NCT01871493|EXPERIMENTAL|LY2605541/Lispro Mix-Part B|0.71 U/kg LY2605541 and 0.18 U/kg insulin lispro mixture given BID for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
62590752|NCT01871493|EXPERIMENTAL|LY2605541 QD-Part B|0.54 U/kg of LY2605541 given QD for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
62590753|NCT01871493|EXPERIMENTAL|LY2605541 BID-Part B|0.71 U/kg of LY2605541 given BID for 1 day SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
62590754|NCT03177031|ACTIVE_COMPARATOR|Stay Safe (STS)|CAPD system produced by Fresenius Medical Care in Germany
62590755|NCT03177031|EXPERIMENTAL|Stay Safe Link (SSL)|CAPD system produced by Fresenius Medical Care in Malaysia
62029068|NCT02790853|EXPERIMENTAL|Diagnostic (multimodal imaging, biopsy)|Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and incisional biopsy. Procedures are repeated every 3-4 months for 2 years.
62029069|NCT01494402|EXPERIMENTAL|D961S|2 way crossover
62227965|NCT03324451|EXPERIMENTAL|Intervention arm|"The arm that receives TTM Intervention for Insulin Initiation. The intervention contains two parts: (1) individual intervention; (2) insulin injection follow-up management"
62227966|NCT03324451|PLACEBO_COMPARATOR|Control arm|The arm that receives usual care from the hospital that hosts the control arm. Participants in the control arm receives regular patient education.
62029070|NCT01494402|EXPERIMENTAL|esomeprazole + buffered acetylsalicylic acid|2 way crossover
62227967|NCT01558895|EXPERIMENTAL|Conventional Treatment and Infrared ray heat treatment group|conventional treatment consist of antiviral drugs, lowering aminotransferase and jaundice medicine.
62227968|NCT01558895|ACTIVE_COMPARATOR|conventional treatment group|conventional treatment consist of antiviral drugs, lowering aminotransferase and jaundice medicine.
62227969|NCT00879112|EXPERIMENTAL|1|MB07811 Cohort 1
62227970|NCT00879112|EXPERIMENTAL|2|MB07811 Cohort 2
62227971|NCT00879112|EXPERIMENTAL|3|MB07811 Cohort 3
62227972|NCT00879112|PLACEBO_COMPARATOR|4|Cohort 4
62227973|NCT02710903|EXPERIMENTAL|Healthy with Dominant IL28B and IL29|Stent-induced biofilm overgrowth model will be used in dominant IL28B and IL29 allelic with probing depths (PD) ≤4mm, no evidence of inter proximal clinical attachment loss (CAL), and \<20% of sites with bleeding on probing (BOP).
62227974|NCT02710903|EXPERIMENTAL|Periodontal Disease with Dominant IL28B and IL29|Stent-induced biofilm overgrowth model will be used in dominant IL28B and IL29 allelic with the presence of at least four periodontal sites with PD ≥ 5mm, evidence of interproximal CAL, and ≥20% of sites with BOP.
62227975|NCT02710903|EXPERIMENTAL|Healthy with IL28B and/or IL29 SNP variants|Stent-induced biofilm overgrowth model will be used in IL28B or IL29 SNP variants with PD ≤4mm, no evidence of interproximal CAL, and \<20% of sites with BOP.
62227976|NCT02710903|EXPERIMENTAL|Periodontal Disease with IL28B and/or IL29 SNP variants|Stent-induced biofilm overgrowth model will be used in IL28B or IL29 SNP variants with the presence of at least four periodontal sites with PD ≥ 5mm, evidence of interproximal CAL, and ≥20% of sites with BOP.
62227977|NCT00512317|EXPERIMENTAL|ganaxolone|active experimental drug
62227978|NCT03434782|EXPERIMENTAL|G1- Negative Control|Group with no desensitizing treatment. Prior to bleaching therapy, a water-soluble placebo gel, with non-active agent will be applied to dental vestibular surfaces. After bleaching therapy, the LASER tip will be positioned in two points (apical and cervical), without light emission (placebo).
62227979|NCT03434782|EXPERIMENTAL|G2- LASER (Positive Control)|Group treated with placebo gel before bleaching and with LLLT after in-office bleaching.
62227980|NCT03434782|EXPERIMENTAL|G3- KNO3 (Positive Control)|Group treated with desensitizing gel before bleaching and after in-office bleaching, the LASER tip will be positioned in two points (apical and cervical), without light emission (placebo).
62227981|NCT03434782|EXPERIMENTAL|G4- KNO3 + LASER|Group treated with desensitizing gel before bleaching and with LLLT after in-office bleaching.
62420648|NCT02836704|ACTIVE_COMPARATOR|Standard initial dose of insulin glargine|Dose 1 of insulin glargine will be administered subcutaneously once a day at the same time every day. Previous non-sulfonylurea OADs (eg, metformin, acarbose) are background treatment and will be continued at the same dosage and dosing frequency as before.
62420649|NCT02836704|EXPERIMENTAL|Higher initial dose of insulin glargine|Dose 2 of insulin glargine will be administered subcutaneously once a day at the same time every day. Previous non-sulfonylurea OADs (eg, metformin, acarbose) are background treatment and will be continued at the same dosage and dosing frequency as before.
62227982|NCT05508620|EXPERIMENTAL|Sirolimus for Injection (Albumin-bound)|Treatment with Sirolimus for Injection (Albumin-bound) will continue until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurs first.
62227983|NCT03507465|EXPERIMENTAL|Letrozole Plus Low-Dose Metronomic Capecitabine|
62227984|NCT03507465|ACTIVE_COMPARATOR|EC-T|
62420650|NCT05681520|EXPERIMENTAL|peer specialist|Work with a peer specialist for six 30-minute sessions
62420651|NCT01010230|PLACEBO_COMPARATOR|LMHF mechanical stimulation placebo device|The placebo device is identical in appearance and function to the active platform; except when activated, it emits the same sound as the active device but does not deliver the vibration.
62420652|NCT01010230|ACTIVE_COMPARATOR|LMHF mechanical stimulation|"Low magnitude, high frequency mechanical stimulation device (vibrating) platform"
62420653|NCT01283373|EXPERIMENTAL|A|Dose escalation cohorts
62420654|NCT01283373|EXPERIMENTAL|B|Dose expansion cohorts
62420655|NCT01929837|EXPERIMENTAL|E-fied navigated rTMS|Electrical field navigated transcranial magnetic stimulation
62420656|NCT01929837|SHAM_COMPARATOR|sham E-field navigated rTMS|Sham electrical field navigated rTMS
62420657|NCT01929837|EXPERIMENTAL|non-navigated rTMS|non-navigated rTMS
62420658|NCT01929837|EXPERIMENTAL|Experimental, Navigated rTMS|Navigated rTMS,
62420659|NCT02845973||test cohort|The test cohort was from Fudan University Shanghai Cancer Center (August 2016 to December 2016) and ECRJ-East Campus of Renji hospital (January 2012 to March 2017);
62420660|NCT02845973||validation cohort|The validation cohort was from Shanghai Tenth People's Hospital (October 2015 to November 2016) and WCRJ-West Campus of Renji hospital (July 2016 to March 2017)
62420661|NCT06541743|ACTIVE_COMPARATOR|Regular Toothbrush|Oral-B Chhota Bheem Toothbrush.
62420662|NCT06541743|ACTIVE_COMPARATOR|Musical Toothbrush|Aqua White Musical Chhota Bheem Toothbrush.
62420663|NCT06541743|ACTIVE_COMPARATOR|Electric Toothbrush|Oral-B Star Wars Kids Electric Toothbrush.
62420664|NCT06541093|EXPERIMENTAL|UVAX-1107 half dose + UVAX-1197 half dose boost|
62420665|NCT06541093|EXPERIMENTAL|UVAX-1107 full dose + UVAX-1197 full dose boost|
62803619|NCT02962167|EXPERIMENTAL|Disseminated Recurrent Medulloblastoma|Patients must have disseminated recurrent medulloblastoma (defined as multifocal disease, positive spine MRI including leptomeningeal disease and/or positive cytology within 21 days prior to study registration) and have adequate CSF flow based on spine MRI with no evidence of bulky disease or if bulky disease is present based on a CSF flow study per institutional guidelines. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, via lumbar puncture (modified measles virus lumbar puncture).
62029071|NCT04880304|EXPERIMENTAL|ADHD diagnosis and subconcussive head impacts|"ADHD Group: Individuals clinically diagnosed with ADHD, currently taking his/her prescribed ADHD medication.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
62420666|NCT06541093|EXPERIMENTAL|UVAX-1107 full dose + UVAX-1107 full dose boost|
62420667|NCT06541093|PLACEBO_COMPARATOR|Placebo|
62420668|NCT01019278|EXPERIMENTAL|Arm I|Patients undergo external proton beam radiotherapy once daily, 5 times per week, for up to 9 weeks. Patients also receive cisplatin IV once weekly for 6 weeks during radiotherapy.
62227985|NCT03390374|EXPERIMENTAL|Nystatin group|Nystatin oral 1 mL (0.5 mL coated in oral cavity and the rest was given through orogastric tube) three times a day
62420669|NCT06173765|EXPERIMENTAL|36g of strawberry|High dose intervention
62590756|NCT05311436|EXPERIMENTAL|Experimental|"1. Pregnant women will receive monthly intensive dietary counseling, daily iron-folate, calcium supplementation, and at least four antenatal visits to local ANC service providers from enrollment before 16 weeks of gestation to delivery of the baby will be ensured.~2. Adolescent girls will receive twice-monthly nutrition education sessions to improve dietary diversity scores from enrolment to 6 months of enrollment.~3. Under 2y children will receive monthly growth monitoring and promotion, IYCF counseling~4. Under 2y children for WASH counseling group will receive twice-monthly nutrition education sessions for 6months to improve maternal WASH practices~5. Severely stunted children: Daily 1 egg for 3 consecutive months and 1 sachet of multiple micronutrient powder supplementation for 2 months."
62227986|NCT03390374|NO_INTERVENTION|Control group|Sterile water 1 mL three times a day for oral hygiene
62227987|NCT00655863|PLACEBO_COMPARATOR|Placebo QD|
62420670|NCT06173765|EXPERIMENTAL|12g of strawberry|Low dose intervention
62420671|NCT06173765|PLACEBO_COMPARATOR|0g of strawberry|Control
62420672|NCT05917093|EXPERIMENTAL|Culturally tailored HLWD|
62590757|NCT05311436|NO_INTERVENTION|Control|Participants will receive the standard of care in the area
62590758|NCT01817582|EXPERIMENTAL|Lotemax Gel 0.5% and Restasis 0.05%|Participants will administer lotemax gel 0.5 % BID in both eyes (OU) for 2 weeks, then administer both lotemax gel 0.5% and restasis emulsion 0.05% BID OU for 2 weeks, then administer restasis emulsion 0.05% BID OU for 8 weeks. Participants will also receive preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day).
62029072|NCT04880304|EXPERIMENTAL|No history or current diagnosis of ADHD and subconcussive head impacts|"Non-ADHD Group: Individuals with no current or prior diagnosis of ADHD.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
62029073|NCT01713218|EXPERIMENTAL|Gemcitabine+Vismodegib|Neoadjuvant chemotherapy combining gemcitabine and Vismodegib during 4 weeks before surgery
62803620|NCT03324802|EXPERIMENTAL|Arm 2 (hypofractionated radiation therapy, 5 fractions)|Within 12 weeks of breast cancer surgery or adjuvant chemotherapy, patients undergo hypofractionated radiation therapy in 5 daily fractions for 5 days.
62803621|NCT03324802|EXPERIMENTAL|Arm I (radiation therapy, 15 fractions)|Within 12 weeks of breast cancer surgery or adjuvant chemotherapy, patients undergo standard radiation therapy in 15 daily fractions for 10 days.
62803622|NCT02182934|EXPERIMENTAL|Ginsana|
62420673|NCT00534521|ACTIVE_COMPARATOR|Active Treatment Arm|Subjects will have their leg and foot draped to remain blinded to the test. They will be in a supine position with the knees abducted and flexed. The medial aspect of the lower extremity is palpated and a needle insertion site is identified. Between the posterior margin of the tibia and the soleus muscle, an acupuncture-like needle is inserted. An adhesive grounding pad is placed on the bottom of the foot just below the smallest toe. The needle and grounding pad are connected to the stimulator and the stimulation is increased as tolerated.
62803623|NCT02182934|PLACEBO_COMPARATOR|Placebo|
62227988|NCT00655863|EXPERIMENTAL|Alogliptin 25 mg QD|
62590759|NCT01817582|EXPERIMENTAL|Lotemax Gel 0.5%|Participants will administer lotemax gel 0.5% BID OU for 12 weeks. Participants will also receive preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day).
62590760|NCT01817582|ACTIVE_COMPARATOR|Restasis 0.05%|Participants will administer restasis emulsion 0.05% BID OU for 12 weeks. Participants will also receive preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day).
62803624|NCT06015386|EXPERIMENTAL|inclined plane|group treated with inclined plane
62803625|NCT06015386|EXPERIMENTAL|clear aligner|group treated with clear aligner
62803626|NCT03923257|EXPERIMENTAL|PRRT with 177Lu-DOTA-tyr3-OCTREOTATE|"177Lu-DOTA-tyr3-OCTREOTATE (177Lu-DOTATATE) and amino acid will be administered intravenously (IV) on Day 1 of each of four treatment cycles, 8 weeks apart.~This study will consist of children and adolescents ages 1-20 years with relapsed or refractory neuroendocrine tumors and pheochromocytoma or paraganglioma. Children and adolescents with neuroendocrine tumor, pheochromocytoma or paraganglioma will not have had any previous endoradiotherapy with 90Y-DOTATOC, 131I-MIBG, or 177Lu-DOTATATE."
62803627|NCT02685306|ACTIVE_COMPARATOR|Taxane|Taxane (Paclitaxel) weekly on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
62803628|NCT02685306|EXPERIMENTAL|Bavituximab plus Taxane|Bavituximab 3 mg/kg weekly PLUS Taxane (Paclitaxel) on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
62803629|NCT01674088||Irritable Bowel Syndrome|Subjects meeting Rome III criteria will be included as the group Irritable Bowel Syndrome
62803630|NCT01674088||Healthy Controls|Subjects not meeting Rome III criteria and meeting clinical definitions of general good health will be considered as Healthy Controls
62803631|NCT06136364|EXPERIMENTAL|CD 7 CAR-T|
62803632|NCT00724178|EXPERIMENTAL|A|Oral cholecalciferol (100,000 IU) administered orally every 60 days plus calcium carbonate (1 gram)given daily
62803633|NCT00724178|PLACEBO_COMPARATOR|B|Double placebo
62803634|NCT03840863|EXPERIMENTAL|Commercially-Available Energy drink|Healthy volunteers willing to consume two cans of energy drinks (16 oz./can) daily for 4 weeks
62227989|NCT00655863|EXPERIMENTAL|Alogliptin 25 mg QD + Pioglitazone 30 mg QD|
62227990|NCT02791945|EXPERIMENTAL|N-acetylcysteine|N-acetylcysteine capsules daily - up to 3200 mg
62803635|NCT00961181|EXPERIMENTAL|Paclitaxel Releasing Balloon|Percutaneous coronary intervention with paclitaxel releasing balloon
62803636|NCT02246595|ACTIVE_COMPARATOR|CaCP29|dose escalating i.v. administration of CaCP29 (verum)
62227991|NCT02791945|PLACEBO_COMPARATOR|Placebo|Placebo capsules daily - up to 3200 mg
62227992|NCT05748496|EXPERIMENTAL|Intervention|
62227993|NCT05748496|NO_INTERVENTION|Controle|
62227994|NCT04975477||Training cohort|A cohort was used to develop the novel score for predicting liver decompensation
62227995|NCT04975477||Validation cohort|A cohort was used to validate the performance of novel score for predicting liver decompensation
62227996|NCT04975477||Exploratory cohort|A cohort was used to study the diagnostic value of novel score for clinically significant portal hypertension
62227997|NCT04869423|NO_INTERVENTION|Control group|Participants in this group will simply continue with their daily living and therapies. Assessments will be conducted before and after the 7wk program but patients in this group will not take part in it
62227998|NCT04869423|EXPERIMENTAL|Experimental group|Participants in this group will take part in 7 dog-assisted therapy sessions (1 per week). This therapy will be added to their usual daily living and therapies. Assessments will be conducted before and after the 7-week program.
62227999|NCT03170453|EXPERIMENTAL|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
62420674|NCT00534521|SHAM_COMPARATOR|Sham Arm|"Since subjects with the PTNS will feel foot stimulation, the sham was devised to mimic this feeling without the tibial nerve being stimulated. Again the leg and foot will be draped and out of view from the subject. The medial aspect of the lower extremity is palpated (Figure 4) and the tibial nerve site is identified approximately 5 cm cephalad from the medial malleolus. A Streitberger needle is used at the tibial nerve insertion site to simulate needle placement without puncturing the skin. The needle will be taped in place as in the PTNS procedure. The grounding pad will be a gel electrode pad from a TENS unit device that is placed on the bottom of the foot just below the smallest toe."
62420675|NCT04676386||PD1/PD-L1|Standard of Care: PD1/PD-L1 monotherapy
62420676|NCT04676386||PD1/PD-L1 + chemo|Standard of Care: Platinum doublet-based chemotherapy plus PD-1/PD-L1 combination
62420677|NCT06007209|ACTIVE_COMPARATOR|Ultrasound guided|Pressure on the subclavian artery against the 1st rib and on the common femoral artery against the pelvis for 3 minutes using an ultrasound probe visualizing the arteries, the underlying bones and the compression of the arteries.
62803637|NCT02246595|PLACEBO_COMPARATOR|Placebo|dose escalation mimicing i.v. placebo treatment:
62803638|NCT02254473|EXPERIMENTAL|Wedge Insert|Patients will receive a wedge insert
62803639|NCT02254473|PLACEBO_COMPARATOR|Flat insert|Patients will receive a flat insert
62803640|NCT04738981|EXPERIMENTAL|UC-MSC and anti-CD25 mAb|UC-MSC, iv, 1×10\^6 cells/kg, once a week, for 4 weeks. Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after the first 4 weeks of treatment.
62803641|NCT04738981|ACTIVE_COMPARATOR|Anti-CD25 mAb|Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after first 4 weeks of treatment.
62803642|NCT05835765|EXPERIMENTAL|Dynamic Elastometric Body and neurological evaluation|Use of dynamic elastometric body for one week and neurological evaluation before use of body, at 30 minutes after application, at one week after using the device and at 1th months since discharge
62803643|NCT05835765|NO_INTERVENTION|Neurological evaluation|Neurological evaluation at enrollment, at one week after enrollment and at 1th months since discharge
62803644|NCT05289063|ACTIVE_COMPARATOR|Treatment|OSA patients who adhered or did not adhere with CPAP who are randomized to receive atorvastatin 10 mg daily.
62803645|NCT05289063|PLACEBO_COMPARATOR|Control|OSA patients who adhered or did not adhere with CPAP who are randomized to receive placebo daily.
62803646|NCT03585478|ACTIVE_COMPARATOR|Latiglutenase|IMGX003
62803647|NCT03585478|PLACEBO_COMPARATOR|Placebo|Placebo
62803648|NCT06081543|EXPERIMENTAL|Ketogenic Diet|This arm will be provided food to induce a state of nutritional ketosis in each person as defined as blood Beta-hydroxybutyrate (3-OHB) ≥0.5 millimoles (mM), which will require most participants to consume \<50 g/day carbohydrate and 1.5g/kg reference weight protein. Fat will comprise the remaining calories with an emphasis on monounsaturated and saturated sources from whole foods.
62803649|NCT06081543|EXPERIMENTAL|Low-fat mixed Diet|This arm will be provided food consisting of \~25% fat, and the remaining calories from carbohydrate (\~55% after accounting for protein at \~20%).
62803650|NCT05824130||B/F/TAF group|B/F/TAF
62420678|NCT06007209|ACTIVE_COMPARATOR|Blind techniques|Pressure on the subclavian artery against the 1st rib and on the common femoral artery against the pelvis for 3 minutes using the medic's hand based on anatomical land marks and palpation of pulse.
62803651|NCT05824130||other INSTI-based ART regimen|1-2 NRTI(s) plus an INSTI other than bictegravir
62228000|NCT03170453|ACTIVE_COMPARATOR|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.~Time commitment: about 1 hour per week; Location: Pittsburgh, PA only"
62228001|NCT02937454|ACTIVE_COMPARATOR|ferric carboxymaltose|The first dose of study treatment will be administered for all randomised subjects while the patient is still hospitalised for the Index hospitalisation. The subsequent administrations of study treatment will be done as part of the outpatient clinic visits.
62029074|NCT02832323|OTHER|Reticera|A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) and 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.
62029075|NCT02638662||First time IVF patients. Observational|Those who are doing IVF for the first time.
62029076|NCT02638662||Donors Observational|Those who are doing IVF for the sole purpose of donating their eggs.
62029077|NCT02638662||2 or more IVF cycles Obervational|Those who have done IVF 2 or more times with no success.
62029078|NCT03419169|EXPERIMENTAL|Light load BFR resistance training|This arm of the clinical trial will involve eight weeks of twice weekly light load resistance training with BFR. Patients in this arm will complete four sets (30, 15, 15 and 15 repetitions, respectively) of unilateral leg press exercise at 30% of predicted one repetition maximum. BFR will be applied at 80% of total limb arterial occlusive pressure. Both legs will be trained, with the affected limb trained first and the unaffected limb matched for volume at a relative percentage of one repetition maximum. Both legs will be trained with BFR.
62029079|NCT03419169|ACTIVE_COMPARATOR|Heavy load resistance training|This arm of the clinical trial will involve eight weeks of twice weekly heavy load resistance training. Patients in this arm will complete three sets of ten repetitions of unilateral leg press exercise at 70% of predicted one repetition maximum. Both legs will be trained, with the affected limb trained first and the unaffected limb matched for volume at a relative percentage of one repetition maximum.
62029080|NCT00833989|PLACEBO_COMPARATOR|PLACEBO|
62029081|NCT00833989|EXPERIMENTAL|ACTIVE|
62029082|NCT04571619|ACTIVE_COMPARATOR|Pain Coping Skills Training|
62029083|NCT04571619|NO_INTERVENTION|Usual Care|
62029084|NCT04571619|ACTIVE_COMPARATOR|Buprenorphine|
62420679|NCT03715660|EXPERIMENTAL|Xpert monitor- evaluated patients|Xpert Bladder Cancer Monitor performance shall be established in recurrence patients relative to cystoscopy (for disease negative patients) or histology (for disease positive patients)and relative to a currently used diagnostic assay (urine cytology)which is the standard of care used for detecting recurrent bladder cancer at the site. In this study, clinical sensitivity shall be established in patients who have been previously diagnosed with bladder cancer and are scheduled for a standard of care (SOC) surveillance cystoscopy.
62420680|NCT03254537|EXPERIMENTAL|Mediterranean Organic|
62803652|NCT05824130||non-INSTI-based ART regimen|2 NRTIs plus NNRTI or protease inhibitor
62029085|NCT04571619|NO_INTERVENTION|No Buprenorphine|
62029086|NCT03057119|EXPERIMENTAL|SBIRT Intervention|The interventionist will discuss substance use and misuse, HIV, and the interaction of aging and substance use; will give the patient feedback on their NM-ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change; motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues. Identifying and prioritizing need; problem-solving techniques to help patients identify which services may best help them work towards their goals; will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
62228002|NCT02937454|PLACEBO_COMPARATOR|normal saline 0.9%|The first dose of study treatment will be administered for all randomised subjects on the same day as randomisation.
62420681|NCT03254537|EXPERIMENTAL|Mediterranean conventional|
62420682|NCT03932474|EXPERIMENTAL|SAMEUp|SAMEUp, the Investigational Food Supplement (IFS), is an oral formulation (tablet) containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
62803653|NCT03318588||Case|Patients undergoing vitrectomy for primary retinal detachment
62803654|NCT03318588||Control|Patients undergoing vitrectomy for idiopathic macular hole
62420683|NCT03932474|PLACEBO_COMPARATOR|Placebo|Placebo is an oral formulation of inert tablet. Placebo and SAMEUp are identical in shape, size, colour and taste.
62803655|NCT02513121|ACTIVE_COMPARATOR|Dietary modification|Low free sugar diet
62803656|NCT02513121|NO_INTERVENTION|Observational Arm|Standard of care
62228003|NCT04581954|ACTIVE_COMPARATOR|Standard of care|
62228004|NCT04581954|ACTIVE_COMPARATOR|Fostamatinib|
62803657|NCT01671761||young adults|19-24 years old
62803658|NCT01671761||adolescents|15-18 years old
62228005|NCT04581954|ACTIVE_COMPARATOR|Ruxolitinib|
62803659|NCT03796637|EXPERIMENTAL|nmDMD Participants|Participants who have been receiving ataluren, will be dosed daily 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening, for \>=9 months from ongoing PTC-sponsored nmDMD clinical trials.
62029087|NCT03057119|NO_INTERVENTION|Treatment as Usual|Participants in the enhanced care treatment as usual group will receive the same illustrated handout depicting their substance use screening score and the same referral resource guide provided to those in the control group. These will be provided with only a quick introduction by the research assistant to minimize intervention elements in the control condition and to resemble the notification and referral strategy that would be standard care.
62803660|NCT05269160|EXPERIMENTAL|Dermaprazole 1% (Arm A:Head and neck)|Dermaprazole cream at a concentration of 1% will be applied to the skin twice daily starting from CT simulation throughout the radiation treatment period.
62803661|NCT05269160|EXPERIMENTAL|Dermaprazole 1% (ArmB: Breast)|Dermaprazole cream at a concentration of 1% will be applied to the skin twice daily starting from CT simulation throughout the radiation treatment period.
62029088|NCT00783744|EXPERIMENTAL|1|Insulin Glargine + Glimepiride + Metformin
62029089|NCT00783744|ACTIVE_COMPARATOR|2|Insulin monotherapy with premixed insulin NPH 30/70
62803662|NCT05269160|EXPERIMENTAL|Dermaprazole 2% (Arm A: Head and neck)|Dermaprazole cream at a concentration of 2% will be applied to the skin twice daily starting from CT simulation throughout the radiation treatment period.
62803663|NCT05269160|EXPERIMENTAL|Dermaprazole 2% (Arm B: Breast)|Dermaprazole cream at a concentration of 2% will be applied to the skin twice daily starting from CT simulation throughout the radiation treatment period.
62803664|NCT06032910|EXPERIMENTAL|Study group|Patients who receive prophylactic mesh during the surgery.
62803665|NCT02619474|EXPERIMENTAL|Experimental|Patients who have been admitted to the 3F or 3M wards under the care of the clinical teaching unit (CTU) after the introduction of the new, labelled whiteboard.
62803666|NCT02619474|NO_INTERVENTION|Control|Patients who have been admitted to the 3R surgical ward under the care of any of the nursing groups without the introduction of the new labelled whiteboard.
62803667|NCT04104386|EXPERIMENTAL|Disclosure of Telomere Length Arm|Telomere Length results were provided (personal value, means, and standard deviation of the group), and categorized as 'short' telomere length (bottom quartile) and 'not short' (above the bottom quartile) based on age related norms available from research literature.
62803668|NCT04104386|NO_INTERVENTION|Non-Disclosure|Telomere Length results were not provided.
62803669|NCT01606709|EXPERIMENTAL|GnRH agonist trigger|Induction of oocyte maturation with GnRH agonist
62803670|NCT01606709|ACTIVE_COMPARATOR|hCG trigger|Induction of oocyte maturation with hCG
62029090|NCT02486926|PLACEBO_COMPARATOR|Sevoflurane|Anesthesia was maintained with sevoflurane,and the incidence and severity of emergence agitation was investigated.
62420684|NCT03519360|EXPERIMENTAL|Restricted ultrafiltration rate (UFR)|UFR ≤10 ml/kg/hr
62803671|NCT00498914|EXPERIMENTAL|1|
62803672|NCT00040443|EXPERIMENTAL|CX516|CX516 - 900 mg
62803673|NCT00040443|PLACEBO_COMPARATOR|Placebo|Placebo
62803674|NCT00372268|ACTIVE_COMPARATOR|B|Administration of ropivacaïne 0,2% by direct intra-abdominal administration at the end of the surgery
62803675|NCT00372268|ACTIVE_COMPARATOR|C|Administration of ropivacaïne 0,75% by nebulization in the insufflated gas during all the surgical procedure with direct intra-abdominal administration of Nacl 0,9%
62803676|NCT00372268|PLACEBO_COMPARATOR|A|Administration of Nacl 0,9% by nebulization in the insufflated gas during all the surgical procedure with direct intra-abdominal administration of Nacl 0,9%
62803677|NCT00372268|PLACEBO_COMPARATOR|D|Administration of Nacl 0,9% by direct intra-abdominal administration at the end of the surgery
62029091|NCT02486926|ACTIVE_COMPARATOR|Remifentanil|Anesthesia was maintained with sevoflurane and remifentanil. The incidence and severity of emergence agitation was compared with sevoflurane group.
62029092|NCT02486926|ACTIVE_COMPARATOR|Alfentanil|"Anesthesia was maintained with sevoflurane and remifentanil, and alfentanil was administered 10 min before the end of surgery.~The incidence and severity of emergence agitation was compared with sevoflurane group."
62029093|NCT02486926|OTHER|Thiopental|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
62228006|NCT02730741|EXPERIMENTAL|Lcr restituo® sachet and placebo|The active treatment (Total freeze-dried culture of Lcr restituo® sachet) at a rate of 2 sachets of 1.5 grams per day (one sachet in the morning and one in the evening) and the placebo at a rate of 2 sachets of 1.5 grams per day (one sachet in the morning and one in the evening).
62228007|NCT02730741|EXPERIMENTAL|Lcr restituo® sachet|The active treatment (Total freeze-dried culture of Lcr restituo® sachet) at a rate of 4 sachets of 1.5 grams per day (two sachets in the morning and two in the evening).
62228008|NCT02730741|PLACEBO_COMPARATOR|Placebo|The placebo at a rate of 4 sachets of 1.5 grams per day (two sachets in the morning and two in the evening).
62228009|NCT02574754|EXPERIMENTAL|warfarin|Subjects will receive a single dose of warfarin 10 mg PO at each of 3 visits. The study days will be separated by at least 14 days to allow adequate time for the drug to reach washout.
62228010|NCT00271960|ACTIVE_COMPARATOR|Individual Care|Participants will receive usual care for their prenatal visits
62029094|NCT02486926|OTHER|Rocuronium|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
62029095|NCT05603273|NO_INTERVENTION|standard wound care|normal wound care according to current clinical practice
62029096|NCT05603273|EXPERIMENTAL|non-weight bearing exercise + standard wound care|normal wound care according to current clinical practice with the addition of a weekly exercise routine
62029097|NCT04679467|EXPERIMENTAL|Experimental - single arm|All patients to recieve PKU sphere as part of their dietary management for phenylketonuria (PKU)
62029098|NCT01090804|EXPERIMENTAL|breathing exercise|BreatheMAX breathing device is Water pressure Threshold Bottle. The level of water in the cylinder determines the load for treatment. In the treatment using 20% PNIP (Peak negative inspiratory pressure) was performed with 6-10 breaths/set; 10 set/day
62029099|NCT02529319|EXPERIMENTAL|MRI-Guided Ablation|"Surgery~Patients will undergo catheter ablation using DE-MRI as a guide for fibrosis imaging."
62029100|NCT02529319|ACTIVE_COMPARATOR|Conventional Ablation|"Surgery~Patients will undergo conventional catheter ablation as described by the HRS guidelines."
62228011|NCT00271960|ACTIVE_COMPARATOR|CenteringPregnancy|Participants will receive CenteringPregnancy(R) group prenatal care
62228012|NCT00271960|EXPERIMENTAL|CenteringPregnancyPlus|Participants will receive CenteringPregancy with an HIV/STD prevention component
62228013|NCT01614743|EXPERIMENTAL|IncobotulinumtoxinA|
62228014|NCT01614743|PLACEBO_COMPARATOR|Placebo|
62228015|NCT03617341||Brain MRI|Regular brain MRI can detect early brain metastases in metastatic Breast cancer with high risk subgroups, such as HER2-positive and triple negative.
62228016|NCT00577473|ACTIVE_COMPARATOR|1|mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
62228017|NCT00577473|EXPERIMENTAL|2|mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
62228018|NCT05837494|ACTIVE_COMPARATOR|Group ozone|
62228019|NCT05837494|ACTIVE_COMPARATOR|Group PRGF(plasma rich in growth factors)|
62228020|NCT04581668|OTHER|Neurally adjusted ventilatory assist first|Ventilation in NAVA mode then ventilation in conventional mode
62228021|NCT04581668|OTHER|Conventional ventilation first|Ventilation in conventional mode then ventilation in NAVA mode
62228022|NCT02664727|EXPERIMENTAL|Heavy drinkers|The effects of acute exercise in heavy drinkers. Participants will cycle on ergometer for 30 min at 50-60% of Heart Rate Reserve (HRR).
62228023|NCT02664727|EXPERIMENTAL|Alcoholic patients|The effects of acute exercise in alcoholic patients. Participants will cycle on ergometer for 30 min at 55-60% of Heart Rate maximal (HRmax).
62803678|NCT03476135|EXPERIMENTAL|Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW)|Participants who received a single dose of MenACYW conjugate vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).
62803679|NCT03476135|EXPERIMENTAL|Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix)|Participants who received a single dose of Nimenrix® vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).
62590761|NCT00004465|EXPERIMENTAL|SYNSORB Pk|Oral Shiga toxin-binding agent (500 mg/kg/day)
62590762|NCT00004465|PLACEBO_COMPARATOR|Placebo|Cornmeal placebo
62590763|NCT06055413|EXPERIMENTAL|Intervention Arm|Patients receiving the intervention.
62590764|NCT03133182||Polypharmacy|People taking \>=5 unique prescription drugs in the 3 months prior to surgery
62803680|NCT01702558|EXPERIMENTAL|Phase 1 (mBC) Cohort 1: T-DM1 + Capecitabine|In Phase 1, Cohort 1 participants (with mBC) will receive trastuzumab emtansine (T-DM1) at a dose of 3.6 milligrams per kilogram (mg/kg) via intravenous (IV) infusion (on Day 1 \[on Day 2 for Cycle 1\] of each 21-day cycle) along with capecitabine at de-escalating dose levels (starting from 750 milligrams per meter squared \[mg/m\^2\]) via tablet orally twice daily on Days 1-14 of each 21-day cycle until unacceptable toxicity, withdrawal of consent, disease progression (PD), death, or study end.
62803681|NCT01702558|EXPERIMENTAL|Phase 1 (LA/mGC) Cohort 2: T-DM1 + Capecitabine|In Phase 1, Cohort 2 participants (with LA/mGC) will receive trastuzumab emtansine at a dose of 2.4 mg/kg via IV infusion on Day 1 (on Day 2 of first week) of every week along with capecitabine at MTD (determined in Cohort 1) via tablet orally twice daily on Days 1-14 followed by a 7-day rest period, in each 21-day cycle until unacceptable toxicity, withdrawal of consent, PD, death, or study end.
62803682|NCT01702558|ACTIVE_COMPARATOR|Phase 2 (mBC): T-DM1 + Capecitabine|In Phase 2, participants (with mBC) who will be randomized to this group, will receive trastuzumab emtansine at a dose of 3.6 mg/kg via IV infusion on Day 1 of each 21-day cycle along with capecitabine at MTD via tablet orally twice daily on Days 1-14 of each 21-day cycle until unacceptable toxicity, withdrawal of consent, PD, death, or study end.
62029101|NCT03248739|ACTIVE_COMPARATOR|Clear Bactiseal 'large' catheter (EVD)|All EVDs will be placed by neurological surgeons in either the major operating suite or in an ICU setting using a previously published protocol. This protocol includes using a burr hole entry point 1 cm anterior to the coronal suture in the mid-pupillary line, prep and sterile drape, pre-procedural antibiotic administration, and tunneling the catheter to an exit site at least 5 cm from the incision. In general, physicians are instructed to first attempt distal irrigation of the drainage chamber using sterile techniques (rarely effective), followed by gentle aspiration of the proximal system and catheter if distal flushing is not effective. If these do not restore patency, a small volume of sterile saline, 3 ml or less, is flushed proximally into the catheter. Patency is checked by lowering the EVD drainage system and evaluating for spontaneous flow through the EVD.
62029102|NCT03248739|ACTIVE_COMPARATOR|Orange Bactiseal 'small' catheter (EVD)|All EVDs will be placed by neurological surgeons in either the major operating suite or in an ICU setting using a previously published protocol. This protocol includes using a burr hole entry point 1 cm anterior to the coronal suture in the mid-pupillary line, prep and sterile drape, pre-procedural antibiotic administration, and tunneling the catheter to an exit site at least 5 cm from the incision. In general, physicians are instructed to first attempt distal irrigation of the drainage chamber using sterile techniques (rarely effective), followed by gentle aspiration of the proximal system and catheter if distal flushing is not effective. If these do not restore patency, a small volume of sterile saline, 3 ml or less, is flushed proximally into the catheter. Patency is checked by lowering the EVD drainage system and evaluating for spontaneous flow through the EVD.
62420685|NCT03519360|EXPERIMENTAL|Standard of Care/ Unrestricted UFR|UFR as needed
62420686|NCT06594094|EXPERIMENTAL|HG302|The study will enroll up to 2 dose cohorts
62420687|NCT01976637|EXPERIMENTAL|no compression|no compression stockings worn during a 3 weeks period
62420688|NCT01976637|ACTIVE_COMPARATOR|compression stockings|compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
62420689|NCT02924337|EXPERIMENTAL|Imeglimin therapeutic dose|Tablet, oral, single dose
62590765|NCT03133182||No polypharmacy|People taking \<5 unique prescription drugs in the 3 months prior to surgery
62803683|NCT01702558|EXPERIMENTAL|Phase 2 (mBC): T-DM1|In Phase 2, participants (with mBC) who will be randomized to this group, will receive trastuzumab emtansine at a dose of 3.6 mg/kg via IV infusion on Day 1 of each 21-day cycle until investigator-assessed PD, unacceptable toxicity, withdrawal of consent, death, or study end.
62420690|NCT02924337|EXPERIMENTAL|Imeglimin supratherapeutic dose|Tablet, oral, single dose
62420691|NCT02924337|PLACEBO_COMPARATOR|Placebo|Tablet, oral, single dose
62803684|NCT05703750||CEPH group|CEPH was defined when at least one following factor was present: 1) esophageal/gastric varices on upper endoscopy or CT imaging, 2) ascites requiring diuretic treatment, 3) splenomegaly (largest diameter on CT \>12 cm) with a low platelet count (\<100,000/mm3).
62420692|NCT02924337|ACTIVE_COMPARATOR|Moxifloxacin|Tablet, oral, single dose (400 mg)
62420693|NCT02155231||previous enrolled|
62420694|NCT02155231||New Enrolled|
62590766|NCT02808728|ACTIVE_COMPARATOR|Pain Cocktail with Ropivacaine|"patients given the standard intra-articular pain cocktail injection, consisting of ropivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 100cc preparation.~given in one single dose"
62590767|NCT02808728|EXPERIMENTAL|Pain Cocktail with Exparel|"patients given a similar intra-articular injection consisting of bupivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 80cc preparation as well as an injection of Exparel, 20cc of 1.3% Exparel, to total 100cc.~given in one single dose"
62590768|NCT06244056|NO_INTERVENTION|Narrow QRS complex Heart failure patients|Narrow QRS complex Heart failure patients with optimal medical treatment.
62590769|NCT06244056|ACTIVE_COMPARATOR|: Narrow QRS complex Heart failure patients|: Narrow QRS complex Heart failure patients with optimal medical treatment with stellate ganglion block.
62590770|NCT06244056|ACTIVE_COMPARATOR|Wide QRS complex heart failure patients|Wide QRS complex heart failure patients with optimal medical treatment who were non responders to CRT( retrospective and prospective) with stellate ganglion block.
62590771|NCT06094660|ACTIVE_COMPARATOR|Chemical ablation of the genicular nerves with Phenol 6%|Chemical ablation with phenol is done by injection of 1,5ml of phenol 6 % at the superomedial, the superolateral and the inferomedial genicular nerve.
62228024|NCT05237661|EXPERIMENTAL|Dietary supplement|Dietary supplement: Moon Balance
62228025|NCT02593409|OTHER|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
62228026|NCT02258165||Advanced ovarian cancer|gated PET/CT imaging
62228027|NCT04485182||First|Patients receiving Transcutaneous Electrical Nerve Stimulation + underwater massage + spine gymnastics +
62590772|NCT06094660|ACTIVE_COMPARATOR|Radiofrequency ablation (RFA) of the genicular nerves|In our study we will make two RFA lesions at every target with 80°C for 90 seconds with a 5mm active tip. So we will make 6 lesions in total. The targets are the superomedial, the superolateral and the inferomedial genicular nerve.
62803685|NCT05703750||non-CEPH group|Non-CEPH was defined when none of the following factor was present: 1) esophageal/gastric varices on upper endoscopy or CT imaging, 2) ascites requiring diuretic treatment, 3) splenomegaly (largest diameter on CT \>12 cm) with a low platelet count (\<100,000/mm3).
62803686|NCT05279287||Minimally invasive surgical procedure|Patients undergoing any minimally invasive procedure can be included in the study. Initial focus will be on robotic prostatectomy and robotic TME (rectal cancer removal).
62803687|NCT04725253|EXPERIMENTAL|Nicotinamide|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the experimental group:They will continue to receive standard prevention measures: Detection of delirium, education of health care team and the patient's family, sleep hygiene plan, early mobilization, resolve sensory impairments, and delivery of information of temporal-spatial reorientation in continuously. Study medication will be managed by nurses and administered daily at 7 a.m. This regimen will be continued up to 7 days after admission. The dosage of nicotinamide will be 1,5 gr per day.
62803688|NCT04725253|PLACEBO_COMPARATOR|Control|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the Control group: They will continue to receive the standard prevention measures: delirium detection, treatment health team education and the patient's family, sleep hygiene plan, early mobilization, resolve sensorial deterioration, and delivery of information of temporal-spatial reorientation in a continuous manner. Study medication will be managed by nurses and administered daily at 7 a.m. (in these case placebo tablets). This regimen will be continued up to 7 days after admission.
62803689|NCT02339753|EXPERIMENTAL|Carboplatin-treatment arm|"Arm description : Carboplatin intravenous administration once daily for 3 to 4 days~* Topotecan + Thiotepa + Carboplatin : carboplatin 500mg/m2/day, for 3 days~* MEC for 2nd PBSCT : carboplatin 350 mg/m2/day, for 4 days~* MEC for other solid tumor : carboplatin 400 mg/m2/day, for 4 days~* MEC + MIBG Tx for 2nd PBSCT (neuroblastoma) : carboplatin 300 mg/m2/day, for 4 days"
62803690|NCT02394535|EXPERIMENTAL|Treatment (chemotherapy, radiation therapy)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, 15, 22, and 29 and capecitabine PO BID on days 1-5 (Monday-Friday). Patients also undergo radiation therapy QD on days 1-5 (Monday-Friday). Treatment continues for 51/2 weeks in the absence of disease progression or unacceptable toxicity.
62803691|NCT04001413|NO_INTERVENTION|Arm A: Observational|No intervention, observational arm.
62803692|NCT04001413|EXPERIMENTAL|Arm B: Durvalumab Alone|Durvalumab will be administered as an IV Infusion.
62803693|NCT04001413|EXPERIMENTAL|Arm C: MEDI0457 and Durvalumab|MEDI0457 is an injection. Durvalumab will be administered as an IV Infusion.
62228028|NCT04485182||controll group|Patients receiving Transcutaneous Electrical Nerve Stimulation + spine gymnastics
62228029|NCT03756246|EXPERIMENTAL|Depression Subjects: Influenza Vaccine|Subjects will receive a quadrivalent inactivated influenza vaccine, for the appropriate season/year of enrollment. The vaccine will be administered by the PI or similarly trained clinician, into the deltoid muscle as directed
62420695|NCT03371680|EXPERIMENTAL|Injection of stable isotopes|Injection of 1-13 Carbon Leucine and deuterated water: all patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
62420696|NCT06200259|EXPERIMENTAL|"Spot Delete"|"A unique technique called Spot Delete will be utilized to control the placement of spots during treatment planning, to prohibit proton spots from being placed in the rectum, sigmoid, and small bowel. A specialized computer model will be used to study how the energy of the proton beam (linear energy transfer) is related to rectal and bladder side effects."
62420697|NCT06200259|ACTIVE_COMPARATOR|Control Arm|The proton spots that are placed by the treatment planning system are not modified
62420698|NCT03686137||Institut Paoli-Calmettes patients undergoing liver surgery|
62590773|NCT06094660|NO_INTERVENTION|Conservative treatment|Examples of allowed conservative treatments during the study are patient education, physical therapy, weight loss and different pharmacological treatments.
62803694|NCT03367728|PLACEBO_COMPARATOR|TAP and Rectus Sheath Normal Saline|TAP and Rectus Sheath Block of 60 mL Normal Saline divided into 4 injections administered as in Experimental Arm.
62590774|NCT06029452||ATTRwt-CM and non-amyloid heart failure patients|
62590775|NCT04995250|EXPERIMENTAL|Corrective exercise training for knee Osteoarthritis|
62228030|NCT03756246|ACTIVE_COMPARATOR|Healthy Subjects: Influenza Vaccine|Subjects will receive a quadrivalent inactivated influenza vaccine, for the appropriate season/year of enrollment. The vaccine will be administered by the PI or similarly trained clinician, into the deltoid muscle as directed
62228031|NCT06105268|EXPERIMENTAL|flipped learning group|In addition to the traditional theory training to be given within the scope of the study, two hours of video-supported shoulder dystocia training will be given using the university's corporate Microsoft teams program, one day before the simulation application. The videos used in the training consist of previously shot training videos. There is no copyright or legal problem in using the videos.
62228032|NCT06105268|NO_INTERVENTION|routine training group- control group|The control group will be given shoulder dystocia theory training before the simulation training within the routine course protocol within the scope of the routine risky birth and postpartum period course.
62590776|NCT03413956||NSCLC patients with lymph metastases|Pathologically diagnosed patients with T1 non-small cell lung cancer complicated with lymph metastases after surgeries
62228033|NCT05709015|OTHER|1|Based on a randomisation table, each participant will use either a mouthwash containing neutral electrolyzed water, placebo, or chlorhexidine digluconate twice a day instead of tooth brushing and flossing for 4 days. Each subject will receive each mouthwash type only once during the study period (he/she will receive a different mouthwash type in every arm of the study based on a randomisation table).
62228034|NCT05709015|OTHER|2|Based on a randomisation table, each participant will use either a mouthwash containing neutral electrolyzed water, placebo, or chlorhexidine digluconate twice a day instead of tooth brushing and flossing for 4 days. Each subject will receive each mouthwash type only once during the study period (he/she will receive a different mouthwash type in every arm of the study based on a randomisation table).
62228035|NCT05709015|OTHER|3|Based on a randomisation table, each participant will use either a mouthwash containing neutral electrolyzed water, placebo, or chlorhexidine digluconate twice a day instead of tooth brushing and flossing for 4 days. Each subject will receive each mouthwash type only once during the study period (he/she will receive a different mouthwash type in every arm of the study based on a randomisation table).
62228036|NCT05997368||young group|Participants aged 18-39
62228037|NCT05997368||middle-aged group|Participants aged 40-56
62228038|NCT05997368||elderly group|Participants aged 57-79
62590777|NCT04216693|EXPERIMENTAL|Digoxin tablet|Patients will be given digoxin orally daily for 24 weeks. The initial dose will be selected with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml, a dose range recommended for heart failure patients. A dose of 0.0625, 0.125 or 0.25 mg daily will be selected based on a normogram.
62590778|NCT04216693|PLACEBO_COMPARATOR|Placebo|Digoxin-like oral placebo
62590779|NCT01198288|ACTIVE_COMPARATOR|Standard Care|"Drugs for COPD (as prescribed), oxygen therapy if needed\*, check-up by the general practitioner and/or respirologist as usual.~Educational leaflet regarding optimization of oxygen therapy and drugs; Benefits of physical activity and proposal of a programme of exercise training; Energy conservation techniques; Nutritional counselling; Activity of daily Living (ADL) diary; Prevention and management of acute exacerbation~Monthly phone call with the aim of verifying:~* the patients' clinical conditions;~* the patient's adherence to the pharmacological treatments prescribed~* the patient's compliance in filling out the clinical diary and the ADL diary"
62803695|NCT03367728|EXPERIMENTAL|TAP and Rectus Sheath ropivacaine|The block will be administered in the anterior abdominal wall. For the TAP block, the standard technique will be followed- at the anterior axillary line midway between the subcostal margin and iliac crest. For the rectus sheath block, a bilateral sub-xiphoid approach will be used. There will be 4 injection sites in total and the size of the needle will be standardized to an 18g spinal needle 10cms. Using laparoscopic visualization, the transversus abdominis muscles were identified lateral to the semilunar line. Ropivacaine to be infiltrated will be divided into 4 equal amounts. The procedure is then repeated 2 times in the transversus abdominis plane (20mL each) and 2 times as a Rectus Sheath Block (10mL each) with a total amount of 60 mL.
62590780|NCT01198288|EXPERIMENTAL|domiciliary rehabilitation|"Same as the standard care group plus 10 (ten) home-based visits supervised by a specifically trained respiratory therapist (education+exercise training) Autonomous home-based programme: The patients will be given instructions and training in order to continue the exercise training programme on the days the respiratory therapist is not visiting them.~Counselling addressed at the outdoor activities."
62590781|NCT00276991|OTHER|"Kallunk oxide (Immunotherapy)"|"The participants were received a daily regimen of Kallunk oxide(Immunotherapy) ."
62590782|NCT04199078|EXPERIMENTAL|A - papilocare alternative days treatment|Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)
62803696|NCT03378817|ACTIVE_COMPARATOR|Conventional cold storage|Conventional static cold storage (CCS) on temperature 0-4 °C from organ procurement (historical case matched group)
62803697|NCT03378817|EXPERIMENTAL|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the renal artery in a recirculating and pressure controlled system, Belzer (UW) machine perfusion solution, perfusate temperature 0-4 °C, perfusate oxygenation pO2 of 60-80 kPa Other Name: Hypothermic machine perfusion (HMP)
62803698|NCT06426953||History of diabetes ≥2 years and Glycated hemoglobin ≥6.5%|Diabetic patients with a history of more than 2 years
62803699|NCT06426953||No history of diabetes and normal blood glucose|Patients without a history of diabetes
62803700|NCT04946890|EXPERIMENTAL|MRX2843 orally 80 mg/d|"Participants received 80 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days~1 to 21 of a 21-day cycle."
62803701|NCT04946890|EXPERIMENTAL|MRX2843 orally 120 mg/d|"Participants received 120 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days~1 to 21 of a 21-day cycle."
62803702|NCT04946890|EXPERIMENTAL|MRX2843 orally 180 mg/d|"Participants received 180 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days~1 to 21 of a 21-day cycle."
62803703|NCT02736201|EXPERIMENTAL|IMT+ T-CaRe®on; n = 10|The instrumental manual therapy with the switched on capacitive diathermy electrode
62803704|NCT02736201|SHAM_COMPARATOR|IMT+ T-CaRe® off; n = 10|The instrumental manual therapy with the switched off capacitive diathermy electrode
62803705|NCT03847766|EXPERIMENTAL|PRO-based follow-up|Patients will receive a questionnaire every 3 months. The PRO questionnaire is used as decision aid together with other available clinical data to decide whether the patient needs a visit or not. Hence, patients only visit the outpatient clinic if there is a clinical need or a patient's wish. The actual response for each questionnaire automatically results in a colour code (green, yellow or red). A red or yellow response indicates that the patient needs to be contacted. A green colour indicates no need for a visit. Based on an overview of the questionnaire and the patient's blood samples a physician decides whether this patient should have a telephone consultation or the patient needs to be seen in the clinic.
62228039|NCT00763867|PLACEBO_COMPARATOR|Placebo|Placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks
62228040|NCT00763867|EXPERIMENTAL|Sildenafil|Sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks
62029103|NCT06188364|OTHER|Standard of Care|Transition Supports and Services (USS) that prepare care partners of persons with TBI for post-rehabilitation discharge
62029104|NCT06188364|EXPERIMENTAL|Experimental|USS supplemented with community health services delivered by a certified CHW (CHW+USS) for care partners
62029105|NCT02951104|EXPERIMENTAL|USCOM|
62420699|NCT02805673|EXPERIMENTAL|OSTEO group|usual medical treatment + 6 osteopathic interventions
62420700|NCT02805673|NO_INTERVENTION|witness group|usual medical treatment
62590783|NCT04199078|EXPERIMENTAL|B - papilocare semiintensive treatment|Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)
62420701|NCT05027945|EXPERIMENTAL|Arm A|Reduced intensity regimen (Fludarabine, busulfan)+HSCT+GVHD prophylaxis
62420702|NCT05027945|EXPERIMENTAL|Arm B|Reduced intensity regimen (Fludarabine, low dose cyclophosphamide, 200cGY TBI, busulfan)+HSCT+GVHD prophylaxis
62420703|NCT06454630|EXPERIMENTAL|REGN7508|
62420704|NCT06454630|ACTIVE_COMPARATOR|Enoxaparin|
62029106|NCT02365051|NO_INTERVENTION|usual care|Older adults with dementia and their family caregivers receive all services for which they are eligible in the Connecticut Home Care Program for Elders.
62029107|NCT02365051|EXPERIMENTAL|COPE plus usual care|Older adults with dementia and their family caregivers receive Usual care plus the intervention: Care of Persons with Dementia in their Environments.
62029108|NCT02494284|EXPERIMENTAL|Short term dual therapy|
62029109|NCT02494284|ACTIVE_COMPARATOR|Long term dual therapy|
62029110|NCT00851214||Acute CHF/COPD|Patients presenting with shortness of breath secondary to acute exacerbation of CHF/COPD
62029111|NCT00851214||Acute Trauma|Acute trauma patients with a trauma ISS\>15
62029112|NCT00851214||Sepsis|Patients presenting with a suspicion of acute sepsis (fever, tachycardia, tachypnea)
62029113|NCT00851214||Stroke|Patients presenting with symptoms and signs of acute stroke (thrombotic or hemorrhagic)
62029114|NCT01951430||Myelodysplastic syndrome patients|Patients affected by myelodysplastic syndrome enrolled in the observational study
62029115|NCT05268666|EXPERIMENTAL|JBI-802|10 mg JBI-802 once daily as the starting dose with 4 days on/3 days off cycle
62029116|NCT04070573|ACTIVE_COMPARATOR|81mg ASA|Patients in Arm 1, will be instructed to take one tablet of 81mg aspirin per day.
62420705|NCT03464786|EXPERIMENTAL|absorbable collagen membrane|Subjects randomized in this arm will receive Lando® absorbable collagen membrane after tooth extraction.
62420706|NCT03464786|ACTIVE_COMPARATOR|Bio-Gide resorbable bilayer membrane|Subjects randomized in this arm will receive Bio-Gide resorbable bilayer membrane after tooth extraction.
62803706|NCT03847766|EXPERIMENTAL|PRO-based telephone consultations|Patients receive an electronic questionnaire every 3 months prior to a scheduled telephone consultation.The PRO questionnaire is used as dialogue support during the telephone consultation. The actual response for each item automatically results in a colour code (green, yellow or red). A red response indicates that the patient has a problem; a yellow colour indicates a potential problem, while a green colour indicates no problems.
62803707|NCT03847766|NO_INTERVENTION|Usual outpatient follow-up visits|Patients in the control group will continue to have usual scheduled outpatient follow-up visits at the hospital initiated by the physician every 3 months. These patients do not use the clinical PRO questionnaire, but complete the research questionnaires.
62803708|NCT01957878|EXPERIMENTAL|HPV therapeutic vaccine|ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod
62803709|NCT01957878|PLACEBO_COMPARATOR|Placebo matching ProCervix|Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod
62803710|NCT03101254|EXPERIMENTAL|Phase I: Dose Level 1: LY3022855 (50mg) + Vemurafenib + Cobimetinib|"* Starting dose level of LY3022855 50mg IV administered intravenously every week~* Vemurafenib 960 mg BID administered by mouth twice daily~* Cobimetinib 60 mg administered by mouth once daily on days 1-21of each cycle"
62803711|NCT03101254|EXPERIMENTAL|Phase I: Dose Level 2: LY3022855 (75mg) + Vemurafenib + Cobimetinib|"* LY3022855 50mg IV administered intravenously every week~* Vemurafenib 960 mg BID administered by mouth twice daily~* Cobimetinib 60 mg administered by mouth once daily on days 1-21of each cycle"
62803712|NCT03101254|EXPERIMENTAL|Phase I: Dose Level 3: LY3022855 (100mg) + Vemurafenib + Cobimetinib|"* LY3022855 100mg IV administered intravenously every week~* Vemurafenib 960 mg BID administered by mouth twice daily~* Cobimetinib 60 mg administered by mouth once daily on days 1-21of each cycle"
62803713|NCT03101254|EXPERIMENTAL|Phase II: LY3022855 (MTD) + Vemurafenib + Cobimetinib|"* MTD of LY3022855 was not established~* Vemurafenib planned 960 mg BID administered by mouth twice daily~* Cobimetinib planned 60 mg administered by mouth once daily on days 1-21of each cycle"
62029117|NCT04070573|ACTIVE_COMPARATOR|162mg ASA|Patients in Arm 2, will be instructed to take two tablets simultaneously orally once per day.
62029118|NCT03297840||Treatment|Patients with Borderline Personality Disorder receiving DBT treatment. Measurement takes place at the beginning of the treatment and a second time after 12-weeks treatment.
62590784|NCT04199078|EXPERIMENTAL|C - papilocare intensive treatment|Arm C: scheme C (21 days / 1 cannula per day + 7 days rest) x 6 months
62029119|NCT03297840||Waitlist|Patients with Borderline Personality Disorder on the waitlist for inpatient DBT treatment. Measurement takes place twice at baseline and after 12-weeks waiting.
62029120|NCT05190393||Convex resection group|Patients were used hemivertebra resection procedure on convex side to treat congenital cervical scoliosis.
62029121|NCT05190393||Concave distraction group|Patients were used distraction and lateral opening procedure on concave side to treat congenital cervical scoliosis, without hemivertebra resection.
62029122|NCT01278277|PLACEBO_COMPARATOR|placebo supplementation|patients will be assigned, in a cross-over design, to placebo or supplement administration
62029123|NCT01278277|ACTIVE_COMPARATOR|Saffron|Saffron Supplementation 20 mg/die
62029124|NCT05175963||High Risk|"Nurses (auxiliary nurses, enrolled nurses and professional nurses), medical doctors (interns, medical officers, registrars and consultants) and auxiliary/para-medical staff involved in the care of patients admitted for respiratory illnesses at Chris Hani Baragwanath Academic Hospital (CHBAH). This will include staff that have been assigned to work in:~Internal Medicine: Staff working in the Ambulatory and Emergency Department, staff in the pneumonia-admission ward (ward 24), and staff in the COVID-19 confirmed case wards.~Paediatrics: Staff involved in-hospital care of patients admitted to the dedicated pneumonia ward and COVID-19 cases wards.~Intensive Care Unit: All medical staff working in the intensive care unit."
62029125|NCT05175963||Low Risk|Nursing and medical-doctor staff that are working in the neonatal high-care and intensive care unit; who are likely to be at lower risk from SARS-CoV-2 acquisition in the health-care facility compared to their peers listed in Group 1.
62029126|NCT05175963||Intermediate Risk|"A third group, with a likely intermediate risk for hospital-facility based SARS-CoV-2 infection, are:~VIDA staff involved in sample collection related to COVID-19, and laboratory personnel that will be involved in sample collection at VIDA.~Nurses and medical doctors from the Obstetrics \& Gynaecology."
62590785|NCT04199078|NO_INTERVENTION|D - standard of care|Arm D: usual clinical practice - no treatment
62590786|NCT05525585|EXPERIMENTAL|Early human milk fortification (HMF) group|A human milk fortifier will be added to the feeds between days 4 to 7, after a total feeding volume greater than 120 ml/kg/day is achieved.
62029127|NCT05175963||Mixed Risk|In 2021 with an eminent 3rd wave spreading across the country an additional group will be included comprising of any person working at CHBAH even if not in direct contact with patients.
62029128|NCT05175963||TND group|Any person working at CHBAH or Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) and Helen Joseph Hospital (HJH) even if not in direct contact with patients.
62029129|NCT05302466|ACTIVE_COMPARATOR|gymnastic (control group)|"usual care home gymnastics programme for 12 weeks, which consists of three different 3-minute sequences to be performed daily."
62590787|NCT05525585|ACTIVE_COMPARATOR|Delayed human milk fortification (HMF) group|A human milk fortifier will be added to the feeds between days 10 to 14, after a total feeding volume greater than 120 ml/kg/day is achieved.
62803714|NCT03491826||ROM before 34 weeks (A)|premature rupture of membrane before 34 weeks
62803715|NCT03491826||ROM after 34 weeks (B)|premature rupture of membrane after 34 weeks
62803716|NCT00657644|EXPERIMENTAL|Arm 1|
62803717|NCT06142539||SDCT group|
62803718|NCT06142539||LDCT group|
62029130|NCT05302466|EXPERIMENTAL|gymnastic plus dental bite pads (intervention group)|Identical home gymnastics programme for 12 weeks, which consists of three different 3-minute sequences to be performed daily plus dental bite pads during exercise. The dental bite pads are placed on the back molars of the lower jaw and remain in this position in the mouth for 3 minutes during the exercise.
62803719|NCT06427408||Villi RNASeq|There is only one study group : patients with placental transcriptomic analysis by single nucleus RNA-seq approach
62803720|NCT00828971|EXPERIMENTAL|Arm 1|
62420707|NCT05246111|EXPERIMENTAL|[14C]Berzosertib|Participants received single intravenous infusion of\[14C\]Berzosertib at a dose of 210 milligrams per square meter (mg/m\^2) on Day 1 in Period 1 and stay in clinical research unit (CRU) is required until the discharge criteria are met with a maximum confinement period of 15 days.
62420708|NCT05246111|EXPERIMENTAL|Berzosertib + Topotecan|Participants received single intravenous infusion of Berzosertib at a dose of 210 mg/m\^2 on Day 2 and Day 5 in combination with topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation were met.
62420709|NCT05653518|EXPERIMENTAL|Closed-loop artificial pancreas (AP)|FDA approved Tandem t:slim insulin pump with Control-IQ Technology and the Dexcom G6 CGM
62803721|NCT00828971|ACTIVE_COMPARATOR|Arm 2|
62803722|NCT02864693|ACTIVE_COMPARATOR|Configuration A (Kinnex)|
62803723|NCT02864693|ACTIVE_COMPARATOR|Configuration B (Pacifica LP)|
62803724|NCT01094678|EXPERIMENTAL|Stent|
62803725|NCT00443417|PLACEBO_COMPARATOR|1|
62803726|NCT00443417|ACTIVE_COMPARATOR|2|200mg qd
62803727|NCT00443417|ACTIVE_COMPARATOR|3|200mg bid
62803728|NCT00443417|ACTIVE_COMPARATOR|4|400mg qd
62803729|NCT02096016||Human Papilloma Virus test|"Patients treated with surgery alone for uterine cervical neoplasms attending surveillance at Dept. of Obstetrics and Gynecology, Oncogynecological unit, Aarhus University Hospital from 01.01.14 From 01.01.15 patients will be recruited from Oncogynecologic units at Aalborg University Hospital and Rigshospitalet. Recruitment of patients from these institutions has not been successful and has been closed.~It is expected due to political decisions that the cervical cancer patients from the uptake area of Aalborg University Hospital will be treated at Aarhus University Hospital and they will then be eligible for the study"
62420710|NCT05653518|EXPERIMENTAL|Sensor Augmented Pump (SAP) therapy|Sensor augmented pump (SAP) therapy that includes the use of a study CGM and the participant's current insulin therapy (i.e., either insulin pump or multiple daily injections)
62803730|NCT01916382|EXPERIMENTAL|Nitisinone|Homogentisic acid lowering drug intervention
62803731|NCT01916382|NO_INTERVENTION|No treatment|comparrator
62803732|NCT06008392||Participants with a confirmed cancer diagnosis|Potential participants may be identified through the following sources: patients who will undergo or are currently undergoing clinical evaluation in practices such as, but not limited to, hematology-oncology, gastroenterology-hepatology, radiation-oncology and surgery. Participants will be enrolled in the study indefinitely unless a request to withdraw is made.
62803733|NCT03526744|EXPERIMENTAL|marine protein hydrolysate 1234|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with up to 7 days wash-out in between. Random sequence of arms.
62803734|NCT03526744|EXPERIMENTAL|marine protein hydrolysate 2134|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with up to 7 days wash-out in between. Random sequence of arms.
62803735|NCT03526744|EXPERIMENTAL|marine protein hydrolysate 3124|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with with up to 7 days-out in between. Random sequence of arms.
62803736|NCT03526744|EXPERIMENTAL|marine protein hydrolysate 4123|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with up to 7 days wash-out in between. Random sequence of arms.
62803737|NCT00764361|EXPERIMENTAL|NanoDOX™ Hydrogel|1.0% doxycycline gel
62228041|NCT03295110|EXPERIMENTAL|Functionalities of the Lili Smart Solution activated|Lili Smart solution consists of an application for caregivers (web / mobile), a GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 / 24 and 7/7.
62803738|NCT00764361|PLACEBO_COMPARATOR|Placebo|placebo gel
62420711|NCT04460521|EXPERIMENTAL|NAC Group|Participants in this group will given an N-acetylcysteine 500mg oral tablet daily in addition to wearing a standard carpal tunnel splint nightly (worn approximately 6-8 hours/day). Both interventions will take place concurrently for a total of 8 consecutive weeks.
62420712|NCT04460521|PLACEBO_COMPARATOR|Placebo Group|Participants in this group will be given a placebo table to be taken orally daily in addition to wearing a standard carpal tunnel splint nightly (worn approximately 6-8 hours/day). Both interventions will take place concurrently for a total of 8 consecutive weeks.
62420713|NCT05452642|ACTIVE_COMPARATOR|DASH diet|12-month DASH diet intervention with psychological support
62420714|NCT05452642|EXPERIMENTAL|Very low-carbohydrate diet|12-month very low-carbohydrate diet intervention with psychological support
62420715|NCT04941274|EXPERIMENTAL|1/Dose Determination/De-Escalation|Abemaciclib (de-escalating dose)
62420716|NCT04941274|EXPERIMENTAL|2/Dose Expansion: Group 2a|Abemaciclib (at optimal dose determined in dose escalation portion of the study) for up to 15 participants previously treated with at least 1 line of systemic therapy.
62803739|NCT06262308|EXPERIMENTAL|Psychological intervention|Women will be given psychological intervention
62029131|NCT03958344|EXPERIMENTAL|Intraorbital injection of steroid|"2 mL of steroid will be ready for each injection session:~1 mL Triamcinolone (40 mg) + 1 mL Betamethasone (6 mg) = 2 mL~For Dacryoadenitis without myositis , 1 mL of this compound will be injected at lacrimal gland through 1 site of injection.~For Dacryoadenitis plus 1 rectus muscles myositis 1 mL of this compound will be injected at lacrimal gland and 0.5 mL of this compound will be injected at the rectus muscle through 2 separate sites of injection.~For Dacryoadenitis plus 2 rectus muscles myositis 1 mL of this compound will be injected at lacrimal gland and 0.5 mL of this compound will be injected at either recti muscles through 3 separate sites of injection."
62803740|NCT05230628|EXPERIMENTAL|Active TENS|Active will be performed with using a TENS device with an ear clip attached to the tragus of the right ear (which is innervated by auricular branch of the vagus nerve) at 25 Hz, 200ms at a current just below discomfort threshold.
62029132|NCT03958344|ACTIVE_COMPARATOR|Oral Steroid|"Each patient will receive oral Prednisolone, 1 mg/kg, for 5-7 days, followed by tapered dose in 12 weeks (according to a pre-defined table of oral administration dose).~Daily Omeprazole 40mg p.o and daily Calcium Supplement will also be recommended to avoid complications."
62029133|NCT02086357||SWUE|
62029134|NCT06479629|ACTIVE_COMPARATOR|Piracetam Group|receiving standard care according to the institution's protocol, along with 800mg oral tablet of Piracetam three times every day for the whole duration of the study ( 3 Months) Standard care includes insulin therapy with or without oral hypoglycemics and vitamin b complex.
62029135|NCT06479629|PLACEBO_COMPARATOR|Control Group|"will receive standard care in accordance with the institution protocol in addition to placebo for 3 months.~Standard care includes insulin therapy with or without oral hypoglycemics and vitamin b complex."
62029136|NCT06059196|ACTIVE_COMPARATOR|Control - Standard contraceptive counseling|Standard contraceptive counseling, includes provider training on standard BCS+ counseling protocol and use of a companion mobile application to guide counseling
62029137|NCT06059196|EXPERIMENTAL|Intervention - Integrated contraceptive counseling|Integrated contraceptive counseling, includes provider training on ARCHES integrated in BCS+ counseling protocol and use of a companion mobile application to guide counseling
62029138|NCT06389604|EXPERIMENTAL|Heat acclimation|Passive heat exposure (29-35ºC; 6h/day for 7 days) in combination with 30min/day low-to-moderate intensity cycling.
62420717|NCT04941274|EXPERIMENTAL|2/Dose Expansion: Group 2b|Abemaciclib (at optimal dose determined in dose escalation portion of the study) for up to 10 previously untreated participants.
62590788|NCT05742269||PD-L1 positive disease (on PET and/or IHC)|"Nab-paclitaxel at a dose of 100 mg per square meter of body-surface area, administered intravenously, on days 1, 8, and 15, and carboplatin at a dose of Area Under the Curve (AUC) 5 on day 1 of every 28-day cycle.~The patients with a PD-L1+ tumour, according to IHC with the SP142 antibody (≥ 1% on immune cells) and/or 89Zr-atezolizumab tracer uptake on PET-imaging, will receive atezolizumab at a dose of 840 mg, administered intravenously, on days 1 and 15."
62029139|NCT06529679|EXPERIMENTAL|Early Stance Training|This study arm will complete both a 20-minute split-belt \& tied-belt session. During the split-belt session, the ACL limb will walk at a faster speed (150-170% of 1.1 m/s) than the non-ACL limb (1.1 m/s). During the tied-belt session both limbs will walk at the same speed which will be set to match the faster speed of the ACL leg from the split-belt training day.
62029140|NCT06529679|EXPERIMENTAL|Mid-Stance Training|This study arm will complete both a 20-minute split-belt \& tied-belt session. During the split-belt session, the ACL limb will walk at a slower speed (30-50% of 1.1 m/s) than the non-ACL limb (1.1 m/s). During the tied-belt session both limbs will walk at the same speed which will be set to match the slower speed of the ACL leg from the split-belt training day.
62420718|NCT02964078|EXPERIMENTAL|Pembrolizumab and Interleukin-2|Outpatient Intravenous (IV) infusion of Pembrolizumab and Inpatient IV infusion of Interleukin-2.
62803741|NCT05230628|SHAM_COMPARATOR|Sham TENS|Sham TENS will be performed to the ear lobe, which is devoid of vagal innervation.
62803742|NCT06122623|OTHER|A single-arm pre-post approach will be employed in this study;|There will be no control group. All participants will receive the same treatment. The intervention to be used will be a gaming education program conducted once with each participant.
62029141|NCT05711524|ACTIVE_COMPARATOR|Patients given Traditional Cryo|These are the liver transplant and cardiothoracic (LT and CT) patients that will be given traditional cryo based on the randomization protocol. The blood bank will alternate use of PR cryo and regular cryo each month for all patients with a cryo order. All patients will receive either traditional cryo or PR cryo in a given month.
62029142|NCT05711524|EXPERIMENTAL|Patients given PR Cryo|These are the liver transplant and cardiothoracic (LT and CT) patients that will be given PR cryo based on the randomization protocol. The blood bank will alternate use of PR cryo and regular cryo each month for all patients with a cryo order. All patients will receive either traditional cryo or PR cryo in a given month.
62029143|NCT05307055|EXPERIMENTAL|Group A|double-blinded randomization into theta burst stimulation followed by baseline stimulation
62029144|NCT05307055|EXPERIMENTAL|Group B|double blinded randomization into baseline stimulation followed by theta burst stimulation
62029145|NCT01906294||Type 2 Diabetes Mellitus|Patients with antidiabetic treatment for Type 2 Diabetes Mellitus
62029146|NCT01063257|EXPERIMENTAL|Cohort A|Clofarabine treatment at D1-D5
62029147|NCT01063257|EXPERIMENTAL|Cohort B|Clofarabine treatment at D1, D3, D5, D8, D10
62029148|NCT03806829|ACTIVE_COMPARATOR|Water + Meal|250 ml Water and a high calorie, high fat meal (\>900 kcal, 50g fat)
62029149|NCT03806829|EXPERIMENTAL|Red Wine + Meal|250 ml Red Wine and a high calorie, high fat meal (\>900 kcal, 50g fat)
62029150|NCT03806829|EXPERIMENTAL|Green Tea + Meal|250 ml Green Tea and a high calorie, high fat meal (\>900 kcal, 50g fat)
62029151|NCT03806829|EXPERIMENTAL|Orange Juice + Meal|250 ml Orange Juice and a high calorie, high fat meal (\>900 kcal, 50g fat)
62029152|NCT00803465||Cohort Group 1|Subjects number 1 to 24
62029153|NCT00803465||Cohort Group 2|Subjects number 25 to 44
62029154|NCT00803465||Cohort Group 3|Subjects number 45 to 68
62029155|NCT00803465||Cohort Group 4|Subjects number 69 to 91
62029156|NCT00803465||Cohort Group 5|Subjects Number 92 to 115
62029157|NCT06529588||Head and neck cancer post-radiotherapy|Head and Neck cancer patients who received radiotherapy (32-35 fractions) exposure (5700-7000 Gys) addition chemotherapy (cisplatin or cetuximab (2-3 dosages).
62029158|NCT00605241|OTHER|GSK598809|Drug
62029159|NCT06636045||BFR Group|Blood Flow Restriction (BFR) will be administered in conjunction with regular physical therapy exercises. BFR training will begin as early as 2 weeks post-op. For 2-3 times/week, as indicated by the patient's physical therapist. This is part of standard practice. Each session will consist of 4 sets (30, 15, 15, and 15 reps) at 80% limb occlusion pressure.
62029160|NCT06636045||Control Group|This group will perform physical therapy without the use of BFR
62029161|NCT06502171|EXPERIMENTAL|Phase 1 cabozantinib and selumetinib combination|"The first enrolled participants will start at dose level one with a starting dose of cabozantinib of 20 mg once daily and a starting dose of selumetinib of 15 mg/m2 twice daily.~The doses of drug a participant receives will depend on when the participant enrolls on the study. The first group of participants (3 - 6) will receive selumetinib and cabozantinib at half of the typical dose when given separately. If the side effects are tolerable, the second group of 3 to 6 participants will receive a higher dose of selumetinib and cabozantinib. If the drug combination is well-tolerated, there could be up to 5 groups (maximum 6 participants in each group) with each group taking an increased dose from the previous group's dose. If this is tolerated, then this will be the recommended dose of this combination for the Phase 1b of this study. If the side effects are too severe, the participants will receive a lower dose of both drugs."
62228042|NCT03295110|OTHER|Functionalities of the Lili Smart Solution non activated|Lili Smart watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
62228043|NCT05160792|EXPERIMENTAL|Volunteers|Index leg - compression with GraduCheck Control leg - compression without Graducheck
62228044|NCT00292162|ACTIVE_COMPARATOR|medical therapy|Standard therapy for heart failure with angiotensin converting enzyme inhibitors(ACE) - (Ramipril, enalapril, lisinopril, captopril, perindopril), beta-blocker (BB) - (carvedilol, bisoprolol, metoprolol), Aldosterone antagonists (spironolactone) +/- diuretics and digoxin
62228045|NCT00292162|ACTIVE_COMPARATOR|Radiofrequency ablation (RFA)|Isolation of the pulmonary veins using radiofrequency ablation
62228046|NCT04759664|EXPERIMENTAL|LUT014 Gel (Dose 1)|
62029162|NCT01517451|EXPERIMENTAL|Radiation with Androgen Deprivation Therapy (ADT)|This will be a Phase I/II study evaluating the effectiveness and toxicity of a combined regimen of 7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions) with androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT (stereotactic body radiation therapy). This choice of daily dose is based on the prior published experience showing safety and efficacy of hypofractionated regimens.
62029163|NCT03347500||obese OA patients|"Use of patient-derived biological samples~Inclusion Criteria:~* Subscription of informed consent~* BMI ≥ 30~* age between 60-80 years included~* Kelgrenn-Lawrence equal or superior to grade III~* presence of synovitis~* patients undergoing knee replacement~* suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice~Exclusion criteria:~- HCV, HIV, HBV, TPHA infection"
62029164|NCT03347500||Non-obese OA patients|"Use of patient-derived biological samples~Inclusion criteria:~* Subscription of informed consent~* BMI ≤ 28~* age between 60-80 years included~* Kelgrenn-Lawrence equal or superior to grade III~* presence of synovitis~* patients undergoing knee replacement~* suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice~Exclusion criteria:~- HCV, HIV, HBV, TPHA infection"
62029165|NCT02233829|ACTIVE_COMPARATOR|Evening MRI/PET/Raclopride/IV Methylphenidate Session|The PET \[11C\] raclopride scan will be done between 5-7 PM. After iv catheters are inserted blood sampling starts and continues throughout study. Cardiac monitoring is initiated and continues until physician discontinues post PET scan. Bolus-plus-infusion method for \[11C\]raclopride and the administration of intravenous MP (0.5 mg/kg) forty-five minutes after initial bolus injection of \[11C\]raclopride. Scan to be done for a total of 100 minutes.
62029166|NCT02233829|ACTIVE_COMPARATOR|Morning MRI/PET/Raclopride/IV Methylphenidate Session|Morning Session \[11C\]raclopride PET scan: To be started between 7-8 AM. After iv catheters are inserted, genetic blood samples are drawn and then blood sampling starts and continues throughout study. Cardiac monitoring is initiated and continues until physician discontinues post PET scan. Bolus-plusinfusion method for \[11C\]raclopride and the administration of intravenous MP (0.25 mg/kg) fortyfive minutes after initial bolus injection of \[11C\]raclopride. Scan to be done for a total of 100 minutes.
62029167|NCT01629355||Schizophrenia|Five patients with diagnosed schizophrenia will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern. Twelve patients with schizophrenia will then be studied blindly to evaluate the predictive value of the test.
62029168|NCT01629355||ADHD|Five patients with diagnosed ADHD will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern.
62029169|NCT01629355||Bipolar disorder|Five patients with diagnosed Bipolar disorder will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern. Twelve patients with Bipolar disorder will then be studied blindly to evaluate the predictive value of the test.
62029170|NCT01629355||Healthy controls|Fifteen healthy controls will be used to define normal pattern of ABR/SD-BERA potentials. Another twelve normal controls will be studied blindly to evaluate the predictive value of the test.
62029171|NCT01204151|EXPERIMENTAL|Math intervention|
62029172|NCT00153764|PLACEBO_COMPARATOR|multivitamin|1 tablet morning and evening
62228047|NCT04759664|EXPERIMENTAL|LUT014 Gel (Dose 2)|
62228048|NCT04759664|PLACEBO_COMPARATOR|Placebo|
62228049|NCT03325920|EXPERIMENTAL|Sleep bruxism group|25 sleep bruxism subjects wear the DIABRUX for five consecutive nights.
62228050|NCT03325920|EXPERIMENTAL|non-sleep bruxism group|25 non-sleep bruxism subjects wear the DIABRUX for five consecutive nights.
62803743|NCT02318563|EXPERIMENTAL|Cannabidiol Oral Solution|Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
62803744|NCT02318563|PLACEBO_COMPARATOR|Placebo Solution|Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
62228051|NCT02097641|EXPERIMENTAL|Human Mesenchymal Stromal Cells (hMSCs)|A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.
62228052|NCT02097641|PLACEBO_COMPARATOR|Plasma-Lyte A (placebo)|A single dose of Plasma-Lyte A was administered intravenously over approximately 60-80 minutes.
62228053|NCT03401229|EXPERIMENTAL|Benralizumab 30mg SC + MF|SC - subcutaneously MF - Mometasone Furoate
62228054|NCT03401229|PLACEBO_COMPARATOR|Placebo SC + MF|
62420719|NCT01148927||Adult acute lymphoblastic leukemia patients|
62803745|NCT04924985|EXPERIMENTAL|Physiological Feedback CPR|
62803746|NCT04924985|ACTIVE_COMPARATOR|Non-Physiological (Audiovisual) Feedback CPR|
62803747|NCT05616923|EXPERIMENTAL|Trametinib|Cheek describing the active compound (topical cream containing 0.1 mg/g trametinib)
62029173|NCT06218667|EXPERIMENTAL|Copanlisib in Combination With Degarelix|"Phase 1b: The starting Dose level 1 will be 45 mg with the intent of dose escalating to the standard dose of 60 mg approved for heme malignancy. In the event of \> =2 DLT at Dose level 1 (45 mg) the study will be terminated. If \>= 2 DLT in patients at Dose level 2 (60 mg), Dose level 1 (45 mg) will be the RP2D if \<= 1 DLT out of 6 patients at this dose.~Phase 2: Patients may dose reduce at the discretion of the investigator to the lowest dose of 45 mg. Participants who do not tolerate the copanlisib dose of 45 mg must discontinue study treatment permanently."
62029174|NCT03910257|EXPERIMENTAL|nutrition education module|12 activities of the nutrition education module pre and post test
62228055|NCT03435757|EXPERIMENTAL|Test Group OFD+IMP+CPS|OFD+IMP+CPS; open flap debridement (OFD) and intramarrow penetration (IMP) plus calcium phosphosilicate putty (CPS)
62228056|NCT03435757|ACTIVE_COMPARATOR|Control group (OFD+IMP)|OFD+IMP;open flap debridement (OFD) and intramarrow penetration (IMP)
62228057|NCT00882154|EXPERIMENTAL|1|Cefdinir 300 mg Capsule (Sandoz, Austria)
62228058|NCT00882154|ACTIVE_COMPARATOR|2|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
62228059|NCT04290169|OTHER|Adults with hemiplegic spastic cerebral palsy|Adults (\> 18 years old) with hemiplegic spastic cerebral palsy, with reduced hand function and spasticity as prevalent finding under clinical examination. Also these patients can walk but have problems with balance. Participants' cognitive function does not limit them to perform video game training.
62420720|NCT03284424|EXPERIMENTAL|R/M cSCC cohort|Participants with R/M cSCC receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
62420721|NCT03284424|EXPERIMENTAL|LA cSCC cohort|Participants with LA cSCC receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
62420722|NCT02163629|EXPERIMENTAL|psychotherapeutic intervention|"The psychotherapeutic intervention stress management is based on therapeutic, behavioral and cognitive strategies. They are active and put the patient actor of his adaptation of the heart transplantation entire process. The approached components are emotional, cognitive and behavioral (techniques of communication and problem solving)."
62803748|NCT05616923|PLACEBO_COMPARATOR|Vehicle|Cheek receiving cream without active compound (topical cream lacking active ingredient)
62420723|NCT02163629|NO_INTERVENTION|Usual medical care|
62803749|NCT02136966|EXPERIMENTAL|Programme|"* Distribution of Micronutrients powders (MNP)~* Intensive counseling on Infant and Young Child Nutrition~* Cooking demonstrations"
62803750|NCT02136966|NO_INTERVENTION|Controle|"* Usual Infant growth monitoring and promotion activities~* No distribution of micronutrients powders~* No Intensive counseling~* No cooking demonstrations"
62803751|NCT03254199|EXPERIMENTAL|Experimental|
62803752|NCT03254199|PLACEBO_COMPARATOR|Placebo Comparator|
62803753|NCT00596986|ACTIVE_COMPARATOR|AD|Antidepressant Duloxetine
62803754|NCT00596986|ACTIVE_COMPARATOR|PT|Psychotherapy (CBASP) - Cognitive Behavioural Analysis System of Psychotherapy
62803755|NCT06346834|EXPERIMENTAL|experimental group|sIPV: Sinovac Biotech Co., Ltd., Beijing
62803756|NCT06346834|ACTIVE_COMPARATOR|control group|sIPV: Beijing Institute of Biological Products Co., LTD.
62803757|NCT06400914|EXPERIMENTAL|Lens A (ocufilcon D)|All participants will wear lens A for 15 minutes (Period 1).
62803758|NCT06400914|EXPERIMENTAL|Lens B (fanfilcon A)|All participants will wear lens B for 15 minutes (Period 2).
62803759|NCT06474078|EXPERIMENTAL|Tofacitinib treatment|"1. Meet the conditions of inclusion and exclusion, seek the consent of the patient~2. Fill out the case report form~3. Blood test and physiological assessment, and do serum granulysin concentration and peripheral blood mononuclear spherical granulysin expression analysis~4. Tofacitinib administration: The experimental group received tofacitinib 5mg-10mg, twice daily, for the first week; and maintained tofacitinib 5mg-10mg, daily, for the second week."
62803760|NCT06273150||DRPLA-mutation carrier|Subjects with a positive genetic test for a pathological expansion in the ATN1 gene.
62803761|NCT06273150||Volunteer control|Subjects without neurological conditions (other than primary headache disorders), without a family history of DRPLA or a previous negative genetic test for pathological expansions in the ATN1 gene.
62803762|NCT02537249|EXPERIMENTAL|Dexmedetomidine|
62803763|NCT02537249|SHAM_COMPARATOR|Saline 0.9%|
62803764|NCT03680820||Ages 5-9, gastroparesis|Participants 5-9 years of age at screening with documented gastroparesis (delayed gastric emptying)
62803765|NCT03680820||Ages 5-9, gastroparesis-like syndrome|Participants 5-9 years of age at screening with cardinal symptoms of gastroparesis, but who have normal gastric emptying
62803766|NCT03680820||Ages 10-17, gastroparesis|Participants 10-17 years of age at screening with documented gastroparesis (delayed gastric emptying)
62803767|NCT03680820||Ages 10-17, gastroparesis-like syndrome|Participants 10-17 years of age at screening with cardinal symptoms of gastroparesis, but who have normal gastric emptying
62803768|NCT00485017|EXPERIMENTAL|1|THR-4109: 115 mg orally in am, 115 mg orally in pm for 24 weeks
62803769|NCT00485017|EXPERIMENTAL|2|THR-4109: 100 mg orally in am, 100 mg orally in pm for 24 weeks
62803770|NCT00485017|EXPERIMENTAL|3|THR-4109: 15 mg orally in am, 15 mg orally in pm for 24 weeks
62803771|NCT00485017|PLACEBO_COMPARATOR|4|
62803772|NCT02966808||Clinical measures|multiple sclerosis patients in treatment with fampridine
62803773|NCT02763839|EXPERIMENTAL|BIA 3-202 50 mg|BIA 3-202 single-dose plus 1 tablet of Sinemet 25/100 BIA 3-202 50 mg: 5 tablets of 10 mg. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
62803774|NCT02763839|EXPERIMENTAL|BIA 3-202 100 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 100 mg: 1 tablet of 100 mg + 4 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
62803775|NCT02763839|EXPERIMENTAL|BIA 3-202 200 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 200 mg: 2 tablet of 100 mg + 3 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
62029175|NCT03910257|NO_INTERVENTION|control group|no intervention pre and post test
62029176|NCT03722251|EXPERIMENTAL|Glucose Beverage|50 g of glucose in solution
62029177|NCT03722251|EXPERIMENTAL|Control Beverage|Sucralose in solution
62029178|NCT03722251|EXPERIMENTAL|Glucose beverage and active video game playing|50 g of glucose in solution and 30 min of active video game playing
62029179|NCT03722251|EXPERIMENTAL|Control Beverage and active video game playing|Sucralose in solution and 30 min of active video game playing
62029180|NCT01351285|EXPERIMENTAL|Sevo group|undergoing sevoflurane-remifentanil anesthesia
62029181|NCT01351285|ACTIVE_COMPARATOR|Des group|undergoing desflurane-remifentanil anesthesia
62029182|NCT01351285|ACTIVE_COMPARATOR|Pro group|undergoing propofol-remifentanil anesthesia
62228060|NCT02635360|EXPERIMENTAL|Following chemoradiation|Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. After chemoradiation is complete, subjects will receive the study drug, pembrolizumab.
62029183|NCT06104215|EXPERIMENTAL|BGT007H Cell Injection|"This is an exploratory study of single-arm, open, modified 3+3 dose escalation. The BGT007H cell therapy group received five progressively increased dose levels (2.0× 10\^8,5.0 ×10\^8, 1.0× 10\^9,3.0 × 10\^9,6.0 ×10\^9) of BGT007H cells. Each subject was observed for at least 4 weeks after cell transfusion (DLT observation period). The first two dose groups (2.0×10\^8 cells and 5.0×10\^8 cells) included 1 subject each, and the other three dose groups were followed by conventional 3+3 dose increments."
62228061|NCT02635360|EXPERIMENTAL|Concurrent to chemoradiation|Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. While subjects are receiving chemotherapy and radiation, they will also receive the study drug, pembrolizumab.
62228062|NCT02617849|EXPERIMENTAL|Pembrolizumab, Carboplatin, Paclitaxel|Carboplatin will be administered at AUC = 6, IV over 60 minutes every 3 weeks for up to 4 doses. Paclitaxel will be administered at 175mg/m2, IV over 3 hours every 3 weeks for up to 4 doses. Pembrolizumab will be administered at 200 mg, IV over 30 minutes every 3 weeks.
62029184|NCT02038673|EXPERIMENTAL|Dose escalation part 0.5 mg QD|Oral
62228063|NCT06153953|ACTIVE_COMPARATOR|group A|
62420724|NCT03906773||Intervention|The investigators seek to conduct a pragmatic trial including 2 sister clinical sites to test an innovation using a patient portal framework for Advance Care Planning. The intervention site implemented the intervention (secure patient portal delivered pre-visit planning framework for Advance Care Planning communication). The presence of ACP and the quality of documentation will be assessed through post-intervention chart review. Practice level enrollment was sought for the trial, and the framework will be delivered to all patients during a period of roll out. About 250 patients will receive the intervention.
62228064|NCT06153953|ACTIVE_COMPARATOR|group B|
62420725|NCT03906773||control|The control site delivered usual care during the same period of roll out.
62803776|NCT02763839|EXPERIMENTAL|BIA 3-202 300 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 300 mg: 3 tablet of 100 mg + 2 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
62029185|NCT02038673|EXPERIMENTAL|Dose escalation part 1.0 mg QD|Oral
62420726|NCT00342797||Retinoblastoma cohort|Retinoblastoma patients treated at two hospitals in New York and one hospital in Boston from 1914-2006.
62803777|NCT02763839|EXPERIMENTAL|BIA 3-202 400 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 400 mg: 4 tablet of 100 mg + 1 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
62029186|NCT02038673|EXPERIMENTAL|Dose escalation part 2.0 mg QD|Oral
62029187|NCT02038673|EXPERIMENTAL|Dose escalation part 2.0 mg BID|Oral
62029188|NCT02038673|EXPERIMENTAL|Dose escalation part 4.0 mg BID|Oral
62228065|NCT01313637|EXPERIMENTAL|GSK573719/GW642444|125/25mcg
62228066|NCT01313637|EXPERIMENTAL|GSK573719|125mcg
62803778|NCT02599363|EXPERIMENTAL|Dose Escalation Treatment Arm|
62029189|NCT02038673|EXPERIMENTAL|Dose escalation part 6.0 mg BID|Oral
62029190|NCT02038673|EXPERIMENTAL|Dose escalation part 10.0 mg BID|Oral
62029191|NCT02038673|EXPERIMENTAL|Dose escalation part 20.0 mg BID|Oral
62029192|NCT02038673|EXPERIMENTAL|Dose escalation part 16.0 mg BID|Oral
62029193|NCT02038673|EXPERIMENTAL|Expansion part Urothelial Carcinoma|Oral
62029194|NCT02038673|EXPERIMENTAL|Expansion part Hepatocellular Carcinoma|Oral
62029195|NCT02038673|EXPERIMENTAL|Expansion part Squamous Cell Lung Carcinoma|Oral
62029196|NCT03216876|EXPERIMENTAL|Healthy Controls|Healthy subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg
62029197|NCT03216876|EXPERIMENTAL|PSC Single Dose|PSC subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg
62228067|NCT01313637|EXPERIMENTAL|GW642444|25mcg
62228068|NCT01313637|PLACEBO_COMPARATOR|Placebo|Placebo
62228069|NCT06244446||SBRT+Atezolizumab+Bevacizumab|
62228070|NCT06244446||Atezolizumab+Bevacizumab|
62228071|NCT00044031|PLACEBO_COMPARATOR|B|Placebo (immunogen vehicle) combined with gemcitabine.
62228072|NCT00044031|EXPERIMENTAL|A|500 µg G17DT immunogen combined with gemcitabine.
62029198|NCT03216876|EXPERIMENTAL|PSC Multiple Dose|PSC subjects assigned to treatment with daily oral ursolic acid at the dose determined to be optimal in the first phase of the study. The treatment will last for 24 weeks with an off-treatment follow up of 28 weeks
62029199|NCT04233099||Healthy Subjects|20 Healthy subjects in a good state of health comparable by age and sex with the other selected groups
62803779|NCT04075344|EXPERIMENTAL|Experimental RCHEs staff|Experimental RCHEs staff will received a multimodal ICP regarding the NG tube feeding. Knowledge and skills of NG tube feeding will be measured before and after the multimodal ICP. In addition, 10 fingertips of RCHEs staff, enteral milk and NG tube hubs of residents will be taken for bacterial counts before and after the intervnetion.
62029200|NCT04233099||Amyotrophic Lateral Sclerosis with Bulbar onset|20 subjects affected by Amyotrophic Lateral Sclerosis with Bulbar onset, comparable by age and sex with the other selected groups
62029201|NCT04233099||Amyotrophic Lateral Sclerosis with Spinal onset|20 subjects affected by Amyotrophic Lateral Sclerosis with Spinal onset, comparable by age and sex with the other selected groups
62029202|NCT04233099||Parkinson's Disease|20 subjects affected by Parkinson's Disease comparable by age and sex with the other selected groups
62029203|NCT04233099||Alzheimer's Disease|20 subjects affected by Alzheimer's Disease comparable by age and sex with the other selected groups
62029204|NCT03689322|EXPERIMENTAL|WBV + IMT|Whole body vibration training associated with respiratory muscle training (WBV + IMT)
62029205|NCT03689322|ACTIVE_COMPARATOR|WBV + IMTsham|Whole body vibration training associated with respiratory muscle training sham (WBV + IMTsham)
62029206|NCT03689322|SHAM_COMPARATOR|WBVsham + IMTsham|Whole body vibration training sham associated with respiratory muscle training sham (WBVsham + IMTsham)
62029207|NCT00360529|EXPERIMENTAL|fibanserin|flibanserin 50 mg q.h.s.
62029208|NCT00360529|EXPERIMENTAL|flibanserin|flibanserin 100 mg q.h.s.
62029209|NCT00360529|PLACEBO_COMPARATOR|placebo|placebo q.h.s.
62420727|NCT04137406||T1 tumor with lymph node metastasis|patients with T1 tumor and lymphnode positive
62420728|NCT04137406||T2 or T3 tumor with lymph node negative|patients with T2 or T3,lymph node negative
62803780|NCT04075344|NO_INTERVENTION|Control RCHEs staff|No multimodal ICP will be offered to the staff of control RCHEs.
62803781|NCT03992352||Age 60+ with planned HCT for Hematologic Malignancy|Subjects 60 years or older with a planned allogeneic transplantation for a hematologic malignancy.
62803782|NCT04537793|EXPERIMENTAL|Part A: ELX/TEZ/IVA|Participants weighing greater than or equal to (\>=)14 kilograms (kg) at screening received elexacaftor (ELX) 100 milligrams (mg) once daily (qd)/tezacaftor (TEZ) 50 mg qd/ivacaftor (IVA) 75 mg every 12 hours (q12h) in the treatment period for 15 days.
62029210|NCT04992260|EXPERIMENTAL|Experimental Group|subjects will receive two doses of inactivated COVID-19 vaccine on day 0 and day 28.
62029211|NCT04992260|PLACEBO_COMPARATOR|Control Group|subjects will receive two doses of placebo on day 0 and day 28.
62029212|NCT04034641|EXPERIMENTAL|probiotics plus standard therapy|
62029213|NCT04034641|PLACEBO_COMPARATOR|placebo plus standard therapy|
62029214|NCT00821418|EXPERIMENTAL|PulsHaler first|
62029215|NCT00821418|PLACEBO_COMPARATOR|Placebo first|
62803783|NCT04537793|EXPERIMENTAL|Part B: ELX/TEZ/IVA|Participants weighing (\>=)14 kg at screening received ELX 100 mg qd/TEZ 50 mg qd/IVA 75 mg q12h. Participants weighing (\>=)10 kg to less than (\<)14 kg received ELX 80 mg qd/TEZ 40 mg qd/IVA 60 mg once every morning (qAM) and 59.5 mg once every evening (qPM) in the treatment period for 24 weeks.
62420729|NCT03987737|EXPERIMENTAL|small catheter|In the study arm, a small catheter will be placed in the rectum by the MRI technician and the examination will be executed with the small catheter in situ.
62420730|NCT03987737|NO_INTERVENTION|control group|In the control arm, subjects will be scanned immediately after rectal evacuation on the toilet without small catheter in situ.
62420731|NCT01226654|OTHER|MS Patients|All subjects enrolled in this study will undergo MRI studies. A computerized neuropsychological battery of tests will be administered.
62420732|NCT01226654|OTHER|Healthy Patients|Patients enrolled in this study will undergo MRI studies. A computerized neuropsychological battery of tests will be administered.
62420733|NCT02462239|EXPERIMENTAL|Whole-body FDG PET-CT|Whole-body FDG PET-CT (Experimental arm)
62420734|NCT02462239|NO_INTERVENTION|No PET-CT|No PET-CT (Control arm)
62420735|NCT04577456|EXPERIMENTAL|Active|Reinfusion of chyme using the Insides System for subjects with Type II intestinal failure dependent on PN
62420736|NCT04577456|NO_INTERVENTION|Control|Standard of care therapies in accordance with ASPEN and ESPEN treatment guidelines
62420737|NCT03648385|EXPERIMENTAL|DHEA|DHEA tablet (50 mg) taken by mouth once a day for 18 weeks
62420738|NCT03648385|PLACEBO_COMPARATOR|Placebo|1 placebo tablet taken by mouth once a day for 18 weeks
62420739|NCT04671303|EXPERIMENTAL|Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets|"Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Allitinib Tablets：The dose of allitinib mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.~Take medicine continuously for 3 weeks (21 days) for 1 cycle."
62803784|NCT01693549|EXPERIMENTAL|Cabazitaxel|Cabazitaxel(XRP6258) will be administered on day 1 of each cycle, every 21 days, at a dose of 25 mg/m² by i.v. route in 1 hour. Treatment can be continued until patient's consent withdrawal, intolerable toxicity or documented disease progression.
62803785|NCT05661344|EXPERIMENTAL|Group 1: participants with mild hepatic impairment (Child-Pugh A)|
62803786|NCT05661344|EXPERIMENTAL|Group 2: participants with moderate hepatic impairment (Child-Pugh B)|
62803787|NCT05661344|EXPERIMENTAL|Group 3: participants with normal hepatic function individually matched to participants of Group 1|"One participant with normal hepatic function may match one participant in one or both groups of participants with hepatic impairment.~The matching criteria of the participants with normal hepatic function to the participants with hepatic impairment:~Age (± 10 years) Gender Weight (± 15%)"
62803788|NCT05661344|EXPERIMENTAL|Group 4: participants with normal hepatic function individually matched to participants of Group 2|"One participant with normal hepatic function may match one participant in one or both groups of participants with hepatic impairment.~The matching criteria of the participants with normal hepatic function to the participants with hepatic impairment:~Age (± 10 years) Gender Weight (± 15%)"
62803789|NCT03586713|OTHER|ICDAS-II|According to the international caries detection and assessment system (ICDAS-II). The visual examination was performed using the ICDAS-II criteria, which provides a standardized method of lesion detection. The ICDAS-II detection codes for coronal categories the score will be 0 =surface not restored or sealant then according to caries categories range from 0 to 6 depending on the severity of the lesion with the corresponding clinical views.
62803790|NCT01207258|EXPERIMENTAL|Brief Intervention Group|Participants randomly assigned to this group receive a brief motivational enhancement therapy intervention group and are assessed at baseline, weekly for 12 weeks, and at 3, 6 and 12 months.
62803791|NCT01207258|NO_INTERVENTION|Assessed Control Group|This group does not receive the intervention and is assessed at baseline, weekly for 12 weeks, and at 3, 6 and 12 months.
62420740|NCT06216301|EXPERIMENTAL|Arm 1: NovoTTF-200T, Pembrolizumab, and Platinum-based Chemotherapy|Subjects in this arm receive three treatments - TTFields using the NovoTTF-200T device, pembrolizumab, and platinum-based chemotherapy.
62420741|NCT06216301|ACTIVE_COMPARATOR|Arm 2: Pembrolizumab and Platinum-based Chemotherapy|Subjects in this arm receive two treatments - pembrolizumab and platinum-based chemotherapy.
62803792|NCT01207258|NO_INTERVENTION|No Contact Control Group|This group does not receive the intervention and is assessed only at 3 months.
62803793|NCT01450501||Patients with vascular chronic Q-fever|All patients with chronic Q-fever and an aneurysm or vascular reconstruction
62803794|NCT05612308|EXPERIMENTAL|Verical Oscillatory Pressure (VOP)|Vertical Oscillatory Pressure (VOP) will be administered with the patient lying prone on a couch. The researcher will place the thumb reinforced with the other thumb on the implicated lumbar vertebra, then apply pressure posterior anteriorly on the spinous process and oscillate for a maximum of 60 seconds. This will be done on each patient in this group twice a week for 6 weeks after an initial assessment both subjective and objective (Egwu et al, 2007).
62228073|NCT02991131||Tedizolid|Hospitalized ABSSSI patients treated with tedizolid
62420742|NCT01669759||fatigue|
62590789|NCT05742269||PD-L1 negative disease (on PET and IHC)|Nab-paclitaxel at a dose of 100 mg per square meter of body-surface area, administered intravenously, on days 1, 8, and 15, and carboplatin at a dose of Area Under the Curve (AUC) 5 on day 1 of every 28-day cycle.
62590790|NCT02568020|NO_INTERVENTION|low-protein diet(LPD)|All patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
62228074|NCT02991131||Linezolid|Hospitalized ABSSSI patients treated with linezolid
62590791|NCT02568020|EXPERIMENTAL|LPD+KA|LPD+KA group will be supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
62803795|NCT05612308|EXPERIMENTAL|Sustained Natural Apophyzeal Glides|Participant in this group will undergo SNAG technique on lumbar vertebra with active spinal movement according to Mulligan, (2004). Participants will be in a sitting position on the edge of the couch while both feet will be on a footrest. A stabilization belt will be used around the patient's waist and the therapist's hips and the researcher standing behind the patient well supported with stabilization belt. The researcher places one thumb or hypothenar eminence (pisiform bone) reinforced by the other on the spinous process of the implicated lumbar vertebra and then apply pressure posterior-anteriorly on the spinous process, the pressure will be sustained and the patient concurrently performs active spinal movement. SNAGS will be applied with 3 repetitions on the first day and 10 repetitions from next visit. SNAG will be used twice a week for 6 weeks.
62803796|NCT01794000|EXPERIMENTAL|Prasugrel|Participants will be titrated from initial daily dose of 0.08 milligram per kilogram (mg/kg) of orally administered prasugrel monotherapy at randomization to a dose that will achieve a P2Y12 reaction units (PRU) level of 231 to 136, as measured by VerifyNow instrument. This corresponds to a range of platelet inhibition of approximately 30% to 60%. The maximum possible dose allowed is 0.12 mg/kg daily, not to exceed 10 mg daily.
62803797|NCT01794000|PLACEBO_COMPARATOR|Placebo|Participants in this treatment group will receive daily orally administered placebo and will follow visit schedule identical to that in the active treatment group.
62228075|NCT03511313|EXPERIMENTAL|Renal denervation|Renal angiography and renal denervation (with sterile irrigated deflectable ablation catheter in renal artery), and maintaining anti-hypertensive medications
62228076|NCT03511313|SHAM_COMPARATOR|Renal angiography|Renal angiography and maintaining anti-hypertensive medications
62590792|NCT04550975|EXPERIMENTAL|Advanced Cognitive Stimulation Therapy|Advanced Cognitive Stimulation Therapy (ACST), a psychosocial intervention, is the modified version of CST for people with moderate and severe dementia. Activities consist of more multisensory stimulation elements than the original CST. ACST will be prescribed to participants 45-minutes per week, biweekly for 7 weeks. The intervention will be delivered by two facilitators, such as a research staff, clinical psychologist trainee or care home staff.
62590793|NCT04550975|NO_INTERVENTION|Treatment as usual|Standard care in care homes
62803798|NCT01204177|EXPERIMENTAL|Arm 1|
62228077|NCT04040816|EXPERIMENTAL|Dose A|Dose A SAP-001 versus placebo
62228078|NCT04040816|EXPERIMENTAL|Dose B|Dose B SAP-001 versus placebo
62228079|NCT04040816|EXPERIMENTAL|Dose C|Dose C SAP-001 versus placebo
62803799|NCT05555875|EXPERIMENTAL|IntelliCare with Automated Motivational Messaging and Coach Support|IntelliCare Plus mobile application intervention with two engagement strategies, automated motivational messaging and coach support.
62803800|NCT05555875|EXPERIMENTAL|IntelliCare with Automated Motivational Messaging|IntelliCare Plus mobile application intervention with one engagement strategy, automated motivational messaging.
62803801|NCT05555875|EXPERIMENTAL|IntelliCare with Coach Support|IntelliCare Plus mobile application intervention with one engagement strategy, coach support.
62803802|NCT05555875|ACTIVE_COMPARATOR|IntelliCare Alone|IntelliCare Plus mobile application intervention with no additional engagement strategy applied.
62803803|NCT03669367|EXPERIMENTAL|abatacept|abatacept monotherapy (subcutaneous route).: 125 mg solution for injection in pre-filled syringe. In the first year (0-12 months) at a a dose of 125 mg per week (full dose) and in the second year (12-24 months) at a dose of 125 mg every other week (q2w) (optimized dose) injection) - 125 mg x week - subcutaneous use.
62803804|NCT03669367|ACTIVE_COMPARATOR|hydroxycloroquina|Hydroxyclorquina (Coated tablet)- (5 mg/Kg/day) monotherapy for 2 years (0-48 months)
62803805|NCT03189537|EXPERIMENTAL|Ingavirin|Ingavirin (Imidazolyl Ethanamide Pentandioic Acid) capsules, 90 mg once daily for 7 days
62803806|NCT03189537|PLACEBO_COMPARATOR|Placebo|Placebo oral capsule, once daily for 7 days
62228080|NCT04040816|EXPERIMENTAL|Dose D (allopurinol patients)|Dose D SAP-001 versus placebo in gout patients who remain on allopurinol
62228081|NCT03769012|EXPERIMENTAL|Treatment|Beta-Glucan
62228082|NCT03769012|PLACEBO_COMPARATOR|Placebo|Placebo
62228083|NCT02541760|EXPERIMENTAL|Montelukast|4 ml monteleukast daily for one month
62228084|NCT02541760|ACTIVE_COMPARATOR|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
62228085|NCT02541760|NO_INTERVENTION|Control|No intervention
62228086|NCT02132013|EXPERIMENTAL|Intervention SUBLIME|Intervention group
62420743|NCT03173521|EXPERIMENTAL|open label|"Adeno-associated viral vector serotype 8 with liver-specific thyroxine-binding globulin (TBG) promoter driving the expression of the human ARSB gene diluted in its final formulation medium \[Drug product (DP) diluted in 0.9% saline solution and 0.25% of human serum albumin\].~Four dose levels are available:~* 'Starting dose' is 6x1011 gc of vector per kg of body weight.~* 'High dose' is 2x1012 gc of vector per kg of body weight.~* 'Very high dose' is 6x1012 gc of vector per kg of body weight.~* 'Low dose' is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein (e.g. median cubital vein) over 2-4 hours using an infusion pump. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg."
62029216|NCT01258114|ACTIVE_COMPARATOR|SPA treatment (ST)|"Drug : spa treatment during 18 days soon after randomization the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises) ;~* nutritional counseling (french nutritional recommendations booklet) ;~* caloric restriction and physical training on demand (non mandatory)."
62803807|NCT01906333|EXPERIMENTAL|Exercise & Glucose|2 hour exercise while getting glucose-supplementation
62803808|NCT01906333|EXPERIMENTAL|Exercise & Fasted|2 hour exercise while staying fasted
62803809|NCT01473290|EXPERIMENTAL|Arm I|Patients receive live freeze-dried lactic acid bacteria probiotic (VSL#3®) orally (PO) 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
62029217|NCT01258114|SHAM_COMPARATOR|Non SPA treatment (NST)|"Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)"
62029218|NCT02740127|EXPERIMENTAL|Caudal Nerve Block + General Anesthesia Group|"Participants receive a caudal nerve block (CNB) prior to surgery and receive general anesthesia during surgery.~Study staff calls participant about 3 days after surgery."
62029219|NCT02740127|ACTIVE_COMPARATOR|General Anesthesia Alone Group|"Participants receive general anesthesia (GA) during surgery without a caudal nerve block.~Study staff calls participant about 3 days after surgery."
62228087|NCT02132013|NO_INTERVENTION|Control|Regular care
62803810|NCT01473290|PLACEBO_COMPARATOR|Arm II|Patients receive placebo PO 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
62803811|NCT02602093|ACTIVE_COMPARATOR|Transforaminal Endoscopic Discectomy|Surgery: Patients will undergo Percutaneous Transforaminal Endoscopic Discectomy.
62803812|NCT02602093|ACTIVE_COMPARATOR|Open Microdiscectomy|Surgery: Patients will undergo conventional micro discectomy.
62803813|NCT04337424||Participants with active infection test to SARS-COV2|Sampling of saliva (1 to 2 ml)
62803814|NCT04337424||Convalescent participants for SARS-COV2|Sampling of saliva (1 to 2 ml)
62803815|NCT04337424||Participants cured to SARS-COV2|Sampling of saliva (1 to 2 ml)
62803816|NCT04337424||Participants with negative test to SARS-COV2|Sampling of saliva (1 to 2 ml)
62803817|NCT00082498|PLACEBO_COMPARATOR|1|Group 1 will receive placebo
62803818|NCT00082498|EXPERIMENTAL|2|Group 2 will receive 5 mg vicriviroc daily
62803819|NCT00082498|EXPERIMENTAL|3|Group 3 will receive 10 mg vicriviroc daily
62803820|NCT00082498|EXPERIMENTAL|4|Group 4 will receive 15 mg vicriviroc daily
62803821|NCT05772819|EXPERIMENTAL|Imaging arm|Participants are subjected to in-magnet exercise test consisting of in vivo exercise cardiac magnetic resonance (exCMR) imaging and 31P-magnetic resonance spectroscopy (31P-MRS) during exercise testing in a MR-compatible ergometer, before and after the 4-week prehabilitation program.
62803822|NCT02109640|EXPERIMENTAL|Targinact|Oral Targinact 10-20mg bd following laparoscopic segmental colectomy
62803823|NCT02109640|ACTIVE_COMPARATOR|Oxycodone|Oral oxycodone 10-20mg bd following laparoscopic segmental colectomy
62803824|NCT05084586|ACTIVE_COMPARATOR|Continuous Intravesical Infusion of Epirubicin|Patients who received continuous epirubicin infusion into the bladder in the early postoperative period.
62228088|NCT02026310|EXPERIMENTAL|glimepiride|on the basis of metformin and glargine, the initial dose of glimepiride is 2 mg,qd (before breakfast), and adjust the dosage for fasting plasma glucose, dosage-adding indicator is the FPG≥7.2, maximum dose of glimepiride is 4 mg/d per day.
62029220|NCT06636474|OTHER|patients with mental disorders|administration of standardized questionnaires and scales, upon entering the research, then annually, and finally upon leaving the research
62029221|NCT04295733||Cohort 1|Hematopoietic Stem Celi Transplant (HSCT) patients
62029222|NCT04295733||Cohort 2|HIV infected subjects
62029223|NCT04295733||Cohort 3|Patients candidates for / in treatment with biological drugs such as monoclonal antibodies anti CD-20 (rituximab or ocrelizumab)
62228089|NCT02026310|ACTIVE_COMPARATOR|Metformin and glargine|on the basis of Metformin and glargine,no glempiride addition. dose of glargine was adjust according to the FPG, with the target less than 7.2mmol/l
62228090|NCT00116727||Drug|etanercept 50 mg/wk SC
62228091|NCT02237313|EXPERIMENTAL|prevalent cases|"40 prevalent cases correspond to patients with known pemphigus. Emphasis will be on included patients at different times of the course of their disease.~8 incident cases recruited through the center of Rouen and following an intervention program with psychological support and therapeutic education program"
62803825|NCT05084586|SHAM_COMPARATOR|Single-Dose Instillation of Epirubicin|Patients who received single-dose epirubicin into the bladder in the early postoperative period.
62029224|NCT02412930|ACTIVE_COMPARATOR|Group Paravertebral Block|With ultrasound guidance at T10 to L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. 5 mL bupivacaine 0.5% was injected in each dermatome level.
62029225|NCT02412930|PLACEBO_COMPARATOR|Group tramadol|Patients in group T were given a loading dose of tramadol of 1 mgkg-1
62029226|NCT05618353|ACTIVE_COMPARATOR|Colchicine|One day before surgery: Colchicine 1.2 mg with 0.6 mg PO one hour later. This load will be followed by colchicine 0.6 mg twice daily for a total of 14 days.
62029227|NCT05618353|PLACEBO_COMPARATOR|Placebo|Matching placebo at same time points as active comparator
62029228|NCT04829344|EXPERIMENTAL|AG-920|Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%, Boric Acid, Mannitol, Sodium Acetate Trihydrate, Glacial Acetic Acid, and Edetate Disodium Dihydrate. The product formulation is adjusted to pH 4.5 to 5.0. Each subject randomized to AG-920 will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
62029229|NCT04829344|PLACEBO_COMPARATOR|Placebo|Placebo ophthalmic solution is identical to the active product, with the exception of the active ingredient. Each subject randomized to placebo will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
62029230|NCT02277782|ACTIVE_COMPARATOR|No Hydromorphone|1.7 mg bupivacaine + 17 mcg fentanyl + 0.05 ml of 0.9% normal saline.
62228092|NCT04312217|ACTIVE_COMPARATOR|Medical clowning|Preoperative medical clown exposure
62228093|NCT04312217|NO_INTERVENTION|Control|Normal preop care
62228094|NCT01098097||Peginterferon alpha and ribavirin|Peginterferon alpha and ribavirin will be administered at the discretion of the treating physician, in accordance per label according to local guidelines for all participating countries.
62228095|NCT01722110|EXPERIMENTAL|Indomethacin Extended-Release Capsules USP 75 mg|Indomethacin Extended-Release Capsules USP 75 mg of Ipca Laboratories Limited, India
62228096|NCT01722110|ACTIVE_COMPARATOR|Indomethacin Extended Release Capsules USP 75 mg|Indomethacin Extended Release Capsules USP 75 mg of Epic Pharma, USA.
62228097|NCT01777269|EXPERIMENTAL|Duodart|Fixed dose combination of dutasteride 0.5mg and tamsulosin 0.4mg. A capsule once daily during 12 months
62228098|NCT01777269|PLACEBO_COMPARATOR|Sugar Pill|A capsule once daily during 12 months
62803826|NCT06344403|ACTIVE_COMPARATOR|Standard gorup|Patients will receive standard oral medicine for herpes zoster.
62228099|NCT04781088|EXPERIMENTAL|Treatment (paclitaxel, lenvatinib, pembrolizumab)|Patients receive paclitaxel IV over 1 hour on days -15 and -8 and lenvatinib PO QD on days -15 to 0. Beginning cycle 1 day 1, patients receive lenvatinib PO QD, pembrolizumab IV over 30 minutes on day 1, and paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles with pembrolizumab repeats every 3 weeks for up to 2 years, and cycles with paclitaxel and lenvatinib repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
62228100|NCT02968732|EXPERIMENTAL|Surgical|
62228101|NCT00580268||H|Pregnant women with bipolar disorder
62228102|NCT06266884|EXPERIMENTAL|Kangaroo care group|The contact numbers of the prospective fathers will be taken and a training video and presentation on kangaroo care will be sent via WhatsApp. Kangaroo care will be applied to the fathers in the experimental group during birth.
62803827|NCT06344403|EXPERIMENTAL|TPI group|Patients will receive standard medicine treatment and tender point infiltrations therapy.
62420744|NCT05809115||Neurocognitive Outcomes|"* Surveys~* General behavioral, economic, and household resources"
62590794|NCT02247440|EXPERIMENTAL|PegINF-ribavirin|"Peg-interferon + ribavirin under HIV physician supervision Peg-interferon alpha 2-b initial dosing is 1.5 micrograms/kg (subcutaneous injection) once a week~Ribavirin initial dosing in the morning and in the evening:~1. For genotypes 2, 3: ribavirin 400 mg (i.e. 800 mg daily).~2. For genotypes 1, 4, 5 and 6:~   * 800 mg/day, if bodyweight \<65 kg,~  * 1000 mg/day, if bodyweight between 66-80 kg,~  * 1200 mg/day, if bodyweight between 81-105 kg,~  * 1400 mg/day, if bodyweight \>105 kg.~Duration: 48 weeks"
62590795|NCT03118492|EXPERIMENTAL|Treatment (combination chemotherapy, TBI, HCT)|Patients receive melphalan IV over 30 minutes on day -5, fludarabine IV over 30-60 minutes on days -5 to -2. Patients undergo TBI on day -1 and HCT on day 0. Patients receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Starting on day 5, patients receive tacrolimus IV then PO for 6 months followed by a taper, mycophenolate mofetil PO TID until day 35, and G-CSF IV daily until absolute neutrophil count \> 1,500/mm\^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
62803828|NCT04665271|EXPERIMENTAL|Immediate Treatment - Zemedy App|Participants will be given immediate access to the Zemedy app for IBS.
62228103|NCT06266884|NO_INTERVENTION|Control Group|After the fathers are informed that the birth has started, the postpartum questions prepared for the control group will be sent via WhatsApp and filled in by the fathers within the first 24 hours after birth. No other application will be applied to the control group. Father-Baby Attachment Scale questions will be sent to fathers via WhatsApp in the first and fourth months after birth and their answers will be received.
62228104|NCT04790019|EXPERIMENTAL|Low energy availability|Intervention involves three of dietary energy restriction providing 15 kilo-calories per kilogram of fat-free mass per day.
62803829|NCT04665271|ACTIVE_COMPARATOR|Active Control - Education and Relaxation Training App|Participants will be given access to a education and relaxation training app. After 8 weeks they will then be crossed over to the Zemedy app.
62420745|NCT05809115||Neurodevelopmental Outcomes|"* Surveys~* Individualized behavioral, economic, and household resources"
62420746|NCT04503707||Follitropin Delta|Treatment according to routine clinical practice.
62420747|NCT05725577|OTHER|Care via the telemedicine system|Intervention
62420748|NCT05725577|OTHER|Standard care|Control
62420749|NCT02591316||Breast cancer survivor|Inclusion criteria: Female breast cancer survivors (30-70yrs of age) that have completed primary treatment (chemotherapy, radiation therapy or both) within past 60 months
62420750|NCT02591316||Control|Females (30-70yrs of age) with no previous cancer diagnosis.
62420751|NCT05399407|EXPERIMENTAL|Experimental group: health e-coaching|"* Personalised and secure access to the health e-coaching platform for 12 months.~* Follow-up by professionals who are specialized in the subject matter (at a distance): a psychologist, a dietician and a teacher of adapted physical activity.~* Personalised activities offered to each young adult throughout their follow-up: synchronous and asynchronous activities (video, animation, quizzes, etc.), individual and collective on different themes (expression of emotions, my weight and me, eating well to start with, my image and me, making choices, my way of moving, etc.). The personalisation of the activities will be done in consultation between the professionals and the young adult according to the needs expressed and identified."
62029231|NCT02277782|EXPERIMENTAL|Hydromorphone|1.7 mg bupivacaine + 17 mcg fentanyl + 50 mcg preservative-free hydromorphone (0.05 ml)
62420752|NCT05399407|NO_INTERVENTION|Control group: Usual Care System|"Control group : - Referral to health professionals in the health care system and, in priority, to the GP declared by the young adult.~- Transmission of the data collected during follow-up visit No. 3 / 0 (T3/T0) to the GP with relay for the implementation of a care plan."
62420753|NCT01615640||Osteosarcoma patients|Patients with an histologically proven osteosarcoma will be entered into the study.
62590796|NCT02775149||Reflux patients|Patients who are treated at the Clinic for Gastroenterology and Gastrointestinal Oncology and have a 24-hours pH monitoring or impedance measurement performed for medical reasons
62590797|NCT05325489|EXPERIMENTAL|Nebulized Budesonide|Drug: budesonide 0.5mg/2ml Pulmicort Respules budesonide inhalation suspension(BIS) once a day (QD) oral montelukast sodium chewable tablets 4mg QD
62803830|NCT06392958|NO_INTERVENTION|Control group|Routine nursing: including pre-operation and 1d before discharge self-health management lectures on cardiac rehabilitation, mainly according to the essentials of China's Guidelines for Cardiac Rehabilitation and Secondary Prevention 2018, and the distribution of the knowledge manual of five major prescriptions for cardiac rehabilitation; After discharge, patients were followed up 1 month, 3 months and 6 months after surgery, including medication compliance, exercise diet, review reminder and other issues, and provided guidance on the problems existing in patients.
62803831|NCT06392958|EXPERIMENTAL|Test group A|Conventional intervention means + Internet platform improved Baduanjin intervention method
62029232|NCT03550313|EXPERIMENTAL|Group 1 - Coadministration|Multivalent pneumococcal conjugate vaccine coadministered with Prevnar 13
62803832|NCT06392958|EXPERIMENTAL|Test group B|Family empowering cardiac rehabilitation management under conventional intervention + cross-theoretical model
62029233|NCT03550313|EXPERIMENTAL|Group 2 - Staggered Administration|Multivalent pneumococcal conjugate vaccine given 1 month after Prevnar 13
62029234|NCT03550313|ACTIVE_COMPARATOR|Group 3 - Control with Supplemental Dose|Prevnar 13 with a single dose of multivalent pneumococcal conjugate vaccine
62420754|NCT05685693|ACTIVE_COMPARATOR|Conventional TKA|Conventional TKA, with no patient-specific instrumentation or robotic assistance
62420755|NCT05685693|EXPERIMENTAL|Robotic-assisted TKA|ROSA Knee System assisted TKA
62420756|NCT06702163|ACTIVE_COMPARATOR|Experimental Condition|"Active sessions will last 1 hour each. The following parameters will be used for electric stimulation: low frequency (20 Hz), low current intensity (2 mA), with a small pulse width of 25-170 microseconds. These parameters were previously found to be safe in human studies. Based on the clinical exam of each patient, the spastic muscles will be targeted.~EXOPULSE Mollii Suit is used for activation of weak muscles or relaxation of spastic muscles mediated by a physiological reflex mechanism referred to as reciprocal inhibition. By sending an electrical signal to an antagonistic muscle, the spastic muscle will subsequently relax."
62420757|NCT06702163|SHAM_COMPARATOR|Control Condition|In the control condition, the patients will receive a sham stimulation, for which the control unit will be programmed to start stimulating for 1 minute then it will shut off. There is no risk related to the sham intervention since it consists of applying the same parameters used for the active session (low frequency: 20 Hz; current intensity: 2 mA; pulse width ranging from 25 to 170 µs) but for a shorter duration of time (1 minute instead of 1 hour).
62420758|NCT01256398|EXPERIMENTAL|Treatment (chemotherapy, transplant)|See Detailed Description
62420759|NCT02420665|EXPERIMENTAL|High-Resolution Microendoscopy (HRME) + Colposcopy|Visual inspection of cervix performed using 3 - 5% acetic acid to the cervix. Participants undergo standard colposcopy and abnormal lesions noted by quadrant. Then 0.01% proflavine applied topically to the cervix. High-resolution microendoscopy (HRME) then performed. HRME images obtained from one visually normal site and from up to 3 visually abnormal lesions based on visual exam and/or colposcopic findings. Study staff follow up with participant by phone one month after procedure.
62420760|NCT06503523|EXPERIMENTAL|Experimental:Healthy volunteers|
62420761|NCT01356186|EXPERIMENTAL|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Sessions of Post Admission Cognitive Therapy Delivered Preferably Over 3 Consecutive Days of Inpatient Stay
62420762|NCT01356186|NO_INTERVENTION|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services
62420763|NCT04861415|ACTIVE_COMPARATOR|Conventional Fractionated Radiation|"* Prostate Only Radiation - 37.5Gy in 15 daily fractions to the prostate and proximal/entire seminal vesicle~* Prostate + Nodal Radiation - 46Gy in 23 daily fractions to the prostate, seminal vesicle and regional lymph nodes"
62803833|NCT06392958|EXPERIMENTAL|Test group C|Conventional intervention means + Internet platform improvement Baduanjin + cross-theoretical model of family empowerment cardiac rehabilitation management
62803834|NCT02506712|EXPERIMENTAL|spinal cord injury|use a wheelchair with and without a assisting device to power manuel wheelchair
62029235|NCT02020954||Dystrophinopathy|Patients with mutations in the DMD gene and Becker muscular dystrophy and/or dilated cardiomyopathy
62029236|NCT04226924|EXPERIMENTAL|Trehalose|Trehalose 9% solution: The dose is 0.75 g/kg administered IV over 60 ± 5 minutes once weekly.
62029237|NCT04226924|PLACEBO_COMPARATOR|0.9% Normal Saline|Normal saline: weight-based volume administered IV over 60 ± 5 minutes once weekly.
62228105|NCT04790019|EXPERIMENTAL|Low energy availability and high impact jumping|Intervention involves three days of dietary energy restriction providing 15 kilo-calories per kilogram of fat-free mass per day and brief high impact jumping exercise performed daily in the morning and in the evening.
62420764|NCT04861415|EXPERIMENTAL|Stereotactic Body Radiotherapy|"* Prostate Only Radiation - 25Gy in 5 fractions to the prostate and proximal/entire seminal vesicle~* Prostate + Nodal Radiation - 25Gy in 5 fractions to the prostate, seminal vesicle and regional lymph nodes"
62029238|NCT03272633|EXPERIMENTAL|Cohort I (initial IHC within 42 days)|Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.
62029239|NCT03272633|EXPERIMENTAL|Cohort II (initial IHC within 70 days or after relapse)|Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.
62803835|NCT02506712|OTHER|volunteer|push a wheelchair with and without a assisting device to power manuel wheelchair
62029240|NCT05677334|EXPERIMENTAL|Henagliflozin+ Continuous Subcutaneous Insulin Infusion|Combination therapy of Henagliflozin and Continuous Subcutaneous Insulin Infusion
62029241|NCT05677334|ACTIVE_COMPARATOR|Continuous Subcutaneous Insulin Infusion|Continuous Subcutaneous Insulin Infusion therapy alone
62029242|NCT04183322||Women of childbearing age|Healthy non-pregnant women between 18 and 45 years old living in Goroka, Papua New Guinea, will receive one dose of 13-valent pneumococcal conjugate vaccine (PCV).
62029243|NCT05320822|ACTIVE_COMPARATOR|Progressive Return to Activity (Group 1)|The current practice, Progressive Return to Activity (PRA) based on Traumatic Brain Injury Center of Excellence (TBICoE) protocols, provides a framework for activity progression based on participant symptom reports and recovery. PRA TBICoE includes a graded approach for clinicians to return participants to pre-injury activities based on the severity of the participant symptoms with and without physical exertion.
62228106|NCT03453437|NO_INTERVENTION|Control group|Receiving no intervention (control groups will be offered the intervention after the experimental group has completed the course)
62228107|NCT03453437|EXPERIMENTAL|Active group|Receiving Mindful Self-Compassion intervention
62228108|NCT01600521|ACTIVE_COMPARATOR|Paeoniflorin + Polypeptides (PAE + CCPI)|Paeoniflorin (PAE), the extract from peony (Paeonia lactiflora), is an active ingredient with anti-inflammation properties. Polypeptides (3,000 - 10,000 dalton) in Cervus \& Cucumis polypeptide injection (CCPI), the extract from Sika deer (Cervus nippon Temmick) bones and muskmelon (Cucumis melo L) seeds, are the active ingredients with bone healing, pain relieving, and anti-inflammation properties. PAE was administrated orally 600 mg twice a day for at least 12 months. CCPI was administered intravenously 8\~12 mL daily with 250 mL 5% dextrose injection solution or 0.9% NaCl IV solution for 2 weeks, discontinued 1 week, and restarted for another 2 weeks.
62228109|NCT01600521|ACTIVE_COMPARATOR|Methotrexate (MTX) + Leflunomide (LEF)|DMARDs (methotrexate: MTX, leflunomide: LEF) were taken orally for at least 12 months. MTX dose: 7.5 mg \~ 10mg / week, LEF dose: 10 mg \~ 20mg daily.
62228110|NCT01600521|ACTIVE_COMPARATOR|MTX + LEF + CCPI|The DMARDs and CCPI were administrated as in the above two groups.
62420765|NCT00817869|EXPERIMENTAL|New Flooring|Will receive 8.3mm thick floor covering (Omnisports EXCEL) to replace previous floor covering.
62420766|NCT00817869|NO_INTERVENTION|Standard Flooring|Ward will remain with standard floor covering. The overlay will have a comparable slip resistance rating to the new flooring. The sub-floor will also be comparable.
62803836|NCT01841879|EXPERIMENTAL|Intervention Program|Receives the full Healthy, Safe, and Tobacco-Free Worksites intervention
62803837|NCT01841879|OTHER|Delayed Intervention Control|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
62803838|NCT02428192|EXPERIMENTAL|Cohort A (nivolumab - closed to accrual on 21-Oct-2015)|Patients receive nivolumab IV over approximately 60 minutes once every 2 weeks for up to 46 doses in the absence of disease progression or unacceptable toxicity.
62803839|NCT02428192|EXPERIMENTAL|Cohort B (nivolumab and Ipilimumab)|Patients receive nivolumab IV over approximately 60 minutes followed by a saline flush and ipilimumab IV over 90 minutes. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62420767|NCT05480384|EXPERIMENTAL|Starting Trastuzumab Deruxtecan Dose|Trastuzumab deruxtecan, 6.4 mg/kg IV every 3 weeks for 17 doses (12 months)
62420768|NCT05480384|EXPERIMENTAL|First Trastuzumab Deruxtecan Dose Reduction|Trastuzumab deruxtecan, 5.4 mg/kg IV every 3 weeks for 17 doses (12 months)
62803840|NCT01262807|EXPERIMENTAL|Exercise|This group will receive instructions on specific exercises to perform after randomization.
62803841|NCT01262807|NO_INTERVENTION|Standard Care|This group will receive standard care
62420769|NCT05480384|EXPERIMENTAL|Second Trastuzumab Deruxtecan Dose Reduction|Trastuzumab deruxtecan, 4.4 mg/kg IV every 3 weeks for 17 doses (12 months)
62420770|NCT01031225|EXPERIMENTAL|1|
62420771|NCT03313154||Neuropsychiatric screening (treatment+)|Subjects affected by chronic hepatitis HCV-related, undergoing new antiviral drugs treatment, will be screened by psychiatric and neuropsychological questionnaires/tests
62590798|NCT05325489|ACTIVE_COMPARATOR|Intranasal Budesonide Spray|Drug: budesonide nasal spray 100μg QD oral montelukast sodium chewable tablets 4mg QD
62228111|NCT02132546|EXPERIMENTAL|Chlorhexidine 0,2%|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.2% CHX.
62228112|NCT02132546|EXPERIMENTAL|Chlorhexidine 0,2% with ADS|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.2% CHX with ADS.
62228113|NCT02132546|EXPERIMENTAL|Chlorhexidine 0,12%|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.12% CHX.
62228114|NCT02066285|EXPERIMENTAL|Pazopanib|Single arm of pazopanib 800 mg (2x400 mg or 4x200 mg) given as a single agent once daily continuously.
62228115|NCT02225951|ACTIVE_COMPARATOR|Test group|Nutritional product as breakfast.
62228116|NCT02225951|OTHER|Control Group|Standard breakfast according to ADA recommendations for pregnant women diagnosed with Gestational Diabetes Mellitus.
62228117|NCT05535933|EXPERIMENTAL|HMPL-523|"Phase II: Eligible subjects will receive 300 mg HMPL-523 treatment once daily for 8 weeks and at least 16 weeks open-label treatment.~Phase III: Eligible subjects will receive 300 mg HMPL-523 treatment once daily for 24 weeks and enter open-label phase in the opinion of the Investigator."
62228118|NCT05535933|PLACEBO_COMPARATOR|Placebo|"Phase II: Eligible subjects will receive 300 mg HMPL-523 treatment once daily for 8 weeks and at least 16 weeks open-label treatment.~Phase III: Eligible subjects will receive 300 mg HMPL-523 treatment once daily for 24 weeks and enter open-label phase in the opinion of the Investigator."
62228119|NCT05506657|OTHER|State Counselor-Coordinated Services|In this program, services are coordinated by a counselor employed by the New Jersey State Division of Vocational Rehabilitation Services (NJDVRS), a state-based agency that assists people with disabilities who are interested in pursuing employment. While the participant is in inpatient rehabilitation or soon after their discharge, a member of the research team will assist them in completing the necessary documentation to apply for services from this agency. Services for which they are eligible will be provided directly through NJDVRS.
62228120|NCT05506657|OTHER|Center Facilitator-Coordinated Services|In this program, services are coordinated by a facilitator who is employed by Kessler Institute for Rehabilitation and works cooperatively with NJDVRS. The facilitator will begin working with the participant during inpatient rehabilitation, or soon after discharge, depending on when they enroll in the study. Some services for which they are eligible will be provided through NJDVRS and others will be provided to them by the facilitator.
62228121|NCT00585377|OTHER|1|
62228122|NCT05663879|EXPERIMENTAL|ID120040002 A mg|Single dose 8 volunteers will be administered ID120040002 Amg or placebo comparators (ID120040002: placebo = 6:2)
62228123|NCT05663879|EXPERIMENTAL|ID120040002 Bmg|Single dose 8 volunteers will be administered ID120040002 Bmg or placebo comparators (ID120040002: placebo = 6:2)
62228124|NCT05663879|EXPERIMENTAL|ID120040002 Cmg|Single dose 8 volunteers will be administered ID120040002 Cmg or placebo comparators (ID120040002: placebo = 6:2)
62228125|NCT05663879|EXPERIMENTAL|ID120040002 Dmg|"Period1:~Single dose 8 volunteers will be administered ID120040002 Dmg or placebo comparators (ID120040002: placebo = 6:2)~Period2:~Single dose 8 volunteers will be administered ID120040002 Dmg or placebo comparators (ID120040002: placebo = 6:2)"
62420772|NCT03313154||Neuropsychiatric screening (treatment-)|Subjects affected by chronic hepatitis HCV-related, in wait list for new antiviral drugs treatment, will be screened by psychiatric and neuropsychological questionnaires/tests
62420773|NCT05113862|SHAM_COMPARATOR|LD Vehicle GNP|Low dose (LD) comparator (2.5nmol) - gold nanoparticle (12.8ug) without peptides
62420774|NCT05113862|EXPERIMENTAL|LD PepGNP-Covid19|Low dose (LD) peptide vaccine (2.5nmol) - gold nanoparticle (12.8ug) plus peptides
62420775|NCT05113862|SHAM_COMPARATOR|HD Vehicle GNP|High dose (HD) comparator (7.5nmol) - gold nanoparticle (38.3ug) without peptides
62228126|NCT05663879|EXPERIMENTAL|ID120040002 Emg|Single dose 8 volunteers will be administered ID120040002 Emg or placebo comparators (ID120040002: placebo = 6:2)
62228127|NCT05663879|EXPERIMENTAL|ID120040002 Fmg|Multiple dose 10 volunteers will be administered ID120040004 F mg or placebo comparators (ID120040002: placebo: 8:2)
62228128|NCT05663879|EXPERIMENTAL|ID120040002 Gmg|Multiple dose 10 volunteers will be administered ID120040004 G mg or placebo comparators (ID120040002: placebo: 8:2)
62420776|NCT05113862|EXPERIMENTAL|HD PepGNP-Covid19|High Dose (HD) peptide vaccine (7.5nmol) - gold nanoparticle (38.3ug) plus peptides
62420777|NCT01040546|EXPERIMENTAL|Individualized education|Individualized consultation of health problem, dietary intake and exercise
62228129|NCT05663879|EXPERIMENTAL|ID120040002 Hmg|Multiple dose 10 volunteers will be administered ID120040004 H mg or placebo comparators (ID120040002: placebo: 8:2)
62420778|NCT01040546|EXPERIMENTAL|Grouped education|Grouped consultation of health problem, dietary intake and exercise
62420779|NCT02604186|EXPERIMENTAL|Botulinum Toxin Injections|Botulinum Toxin injections at adductors and triceps surae
62420780|NCT02604186|PLACEBO_COMPARATOR|Placebo Injections|Placebo injections at adductors and triceps surae
62803842|NCT05187819|EXPERIMENTAL|Patients with positive blood test for biomarkers for Alzheimer's disease|"The positive blood tests results for this group will be compared with the results from the investigation at the at the memory outpatient clinic to calculate the number of false positive blood tests (using the results from the outpatient clinic as a gold standard for the diagnosis)"
62590799|NCT00256854|EXPERIMENTAL|Ropinirole cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR|Participants received Placebo in the evening and Ropinirole 1 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 2 mg controlled release for Restless Legs Syndrome (CR-RLS) in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 1 mg IR at bedtime and continued to receive the same till the end of Week 4.
62590800|NCT00256854|EXPERIMENTAL|Ropinirole cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS|Participants received Placebo in the evening and Ropinirole 1 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 2 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4.
62590801|NCT00256854|EXPERIMENTAL|Ropinirole cohort B1: 2 mg IR/3 mg CR-RLS/2 mg IR/2 mg IR|Participants received Placebo in the evening and Ropinirole 2 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 3 mg CR-RLS in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 2 mg IR at bedtime and continued to receive the same till the end of Week 4.
62590802|NCT00256854|EXPERIMENTAL|Ropinirole cohort B2: 2 mg IR/2 mg IR/2 mg IR/3 mg CR-RLS|Participants received Placebo in the evening and Ropinirole 2 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 3 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4.
62590803|NCT00256854|EXPERIMENTAL|Ropinirole cohort C1: 4 mg IR/6 mg CR-RLS/4 mg IR/4 mg IR|Participants received Placebo in the evening and Ropinirole 4 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 6 mg CR-RLS in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 4 mg IR at bedtime and continued to receive the same till the end of Week 4.
62590804|NCT00256854|EXPERIMENTAL|Ropinirole cohort C2: 4 mg IR/4 mg IR/4 mg IR/6 mg CR-RLS|Participants received Placebo in the evening and Ropinirole 4 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 6 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4.
62590805|NCT05133271|EXPERIMENTAL|Scheduled cesarean section|Patient with scheduled cesarean section under spinal anesthesia.
62590806|NCT04677751|EXPERIMENTAL|Experimental group|
62590807|NCT06667531|ACTIVE_COMPARATOR|Group 1 (height 3; surgery 1)|Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 3 mm.
62803843|NCT05187819|ACTIVE_COMPARATOR|Patients with negative blood test for biomarkers for Alzheimer's disease|"The negative blood tests results for this group will be compared with the results from the investigation at the at the memory outpatient clinic to calculate the number of false negative blood tests (using the results from the outpatient clinic as a gold standard for the diagnosis)"
62803844|NCT04550637||Anticoagulant therapy after percutaneous left atrial appendage|Oral apixaban
62228130|NCT05663879|EXPERIMENTAL|ID120040002 Img|Multiple dose 10 volunteers will be administered ID120040004 I mg or placebo comparators (ID120040002: placebo: 8:2)
62228131|NCT05663879|ACTIVE_COMPARATOR|Compound-X Jmg|Multiple dose 8 volunteers will be administered compound-X J mg
62228132|NCT03637985|EXPERIMENTAL|resistive exercise|resistive exercises using elastic band(Thera Band) Sets were at moderate intensity, 8-10 repetitions for every motion for 12 weeks
62228133|NCT03637985|EXPERIMENTAL|Aerobic exercise|Aerobic exercise in form of treadmill walking for 45 minutes for 12 weeks
62228134|NCT00187668||African American|Must self identify as African American with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
62228135|NCT00187668||Cuacasian|Must self identify as Caucasian with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
62803845|NCT00424944|EXPERIMENTAL|I, GMZ2 vaccine arm|20 volunteers will receive GMZ2 vaccine on days 0, 28, and 56
62803846|NCT00424944|ACTIVE_COMPARATOR|II, Rabies vaccine arm|20 volunteers will receive standard vaccine against rabies on the similar schedule on days 0, 28, and 56
62803847|NCT04194268|EXPERIMENTAL|Interventional arm|Carbon Ion Radiation 12 x 4 Gy (RBE) within 2 weeks
62590808|NCT06667531|ACTIVE_COMPARATOR|Group 2 (height 2; surgery 1)|Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 2 mm.
62228136|NCT00187668||Hispanic|Must self identify as Hispanic with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
62803848|NCT02677168|EXPERIMENTAL|cNEP|Subjects with OSA will be treated with cNEP (continuous negative external pressure) at home for three weeks
62228137|NCT00187668||Asian|Must self identify as Asian with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
62803849|NCT01191723|OTHER|Treatment A, then Treatment B, then Treatment C|"There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.~Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
62803850|NCT01191723|OTHER|Treatment A, then Treatment C, then Treatment B|"There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.~Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
62228138|NCT03237351|ACTIVE_COMPARATOR|Conventional therapy group|Patients in Conventional therapy group were received fluid therapy: intraoperative transfusion volume=maintenance fluids+deficit replacement+restoration of losses and with heart rate, mean arterial pressure, urine measurement ect.
62228139|NCT03237351|EXPERIMENTAL|Low value of PPV group|Patients in low value of PPV group were received fluid therapy according to PPV (3% ≤PPV \< 5%) .
62228140|NCT03237351|EXPERIMENTAL|High value of PPV group|Patients in high value of PPV group were received fluid therapy according to PPV (5% ≤PPV \< 8%) .
62228141|NCT00894153|EXPERIMENTAL|chemo plus p53|chemotherapy plus p53
62228142|NCT00894153|ACTIVE_COMPARATOR|chemo only|chemotherapy group
62420781|NCT06465706|EXPERIMENTAL|LAmbre Device|LAmbre Plus LAAO is a second-generation device intended for investigational use only in the United States.
62420782|NCT06465706|ACTIVE_COMPARATOR|FDA approved LAAO devices|The control devices for the study will be commercially available transcatheter LAAO devices. Currently, there are three FDA approved devices (WATCHMAN FLX and WATCHMAN FLX Pro from Boston Scientific and Amplatzer Amulet from Abbott Laboratories) all of which can be used in subjects assigned to the control group.
62228143|NCT00894153|ACTIVE_COMPARATOR|radio|radiotherapy
62228144|NCT04246567|ACTIVE_COMPARATOR|Total intravenous anesthesia technique for group 1 patients|"Procedure/Surgery:Mean Blood Pressure (MBP) Mean blood pressure (MBP) 50-65 mmHg was applied with 6-10 mg / kg / h propofol and 0.0,4mcg / kg remifentanyl infusion / min. When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS,TOF and SpO2 were recorded at 5 minute intervals.~Blood samples were taken from patients during preop preparation (t0), 30th minute (t1), 1st hour (t2) and 2nd hour (t3) of the operation. 5 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
62803851|NCT01191723|OTHER|Treatment B, then Treatment A, then Treatment C|"There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.~Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
62243105|NCT02704338|EXPERIMENTAL|Regulatory T cells|CD4(cluster of differentiation)+CD25+CD127- T cells isolated from peripheral blood mononuclear cells were be expanded with GMP(Good Manufacturing Practice) anti-CD3/CD28 coated beads in the presence of IL-2 and all-trans retinoid acid.
62243106|NCT01050413||1|colon cancer, prostate cancer, lung cancer, ovarian cancer
62243107|NCT02017639|EXPERIMENTAL|Sarilumab SAR153191 (REGN88)|Single dose of simvastatin before and after sarilumab administration
62243108|NCT01699854|ACTIVE_COMPARATOR|capsaicin patch|
62420783|NCT02680730|EXPERIMENTAL|Intervention only|Participants will be included in 1 pre-intervention and 2 post-assessment measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 60 minutes per day, for 5 consecutive days.
62803852|NCT01191723|OTHER|Treatment B, then Treatment C, then Treatment A|"There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.~Tablets were orally administered after oral inhalation dosing."
62420784|NCT02680730|EXPERIMENTAL|Intervention + Stability|Participants will be included in 2 pre-intervention and 2 post-assessment measures. The additional pre-intervention assessment will allow for assessment of stability of measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 60 minutes per day, for 5 consecutive days.
62803853|NCT01191723|OTHER|Treatment C, then Treatment A, then Treatment B|"There was 48 hour wash-out between treatment visits. Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.~Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
62228145|NCT04246567|ACTIVE_COMPARATOR|Inhalation anesthesia technique for group 2 patients|"Procedure/Surgery:Mean Blood Pressure (MBP) Mean blood pressure (MBP) 50-65 mmHg was applied with 40% Oxygen 60% N2O2 and Sevoflurane at a concentration of 1.5-3.5% with 2 L / minTGA to provide a value of BIS between 40-60. When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS,TOF and SpO2 were recorded at 5 minute intervals.~Blood samples were taken from patients during preop preparation (t0), 30th minute (t1), 1st hour (t2) and 2nd hour (t3) of the operation. 5 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
62420785|NCT01305265|ACTIVE_COMPARATOR|intervention|Endotracheal tube will be adjusted to 22-26 cm H20 pressure immediately post intubation using a cuff manometer
62803854|NCT01191723|OTHER|Treatment C, then Treatment B, then Treatment A|"There was 48 hour wash-out between treatment visits.~Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.~Tablets were orally administered after oral inhalation dosing."
62803855|NCT03564717|EXPERIMENTAL|Segmented Three dimensionally printed transfer tray|
62803856|NCT03564717|NO_INTERVENTION|Full arch three dimensionally printed transfer tray|
62228146|NCT00816348|OTHER|Omegaven|All subjects will receive Omegaven
62228147|NCT02647229|ACTIVE_COMPARATOR|Isosmotic bowel cleansing preparation|Isosmotic solution ingested prior to colonoscopy
62243109|NCT01699854|PLACEBO_COMPARATOR|placebo patch|
62420786|NCT01305265|NO_INTERVENTION|control|endotracheal tube cuff will be inflated using standard technique
62803857|NCT01896024|ACTIVE_COMPARATOR|General Psychiatric Management (GPM; Gunderson & Links, 2008)|psychodynamic-psychiatric treatment for borderline personality disorder
62803858|NCT01896024|EXPERIMENTAL|GPM plus Motive-Oriented Therapeutic Relationship|use of Plan Analysis and Motive-oriented therapeutic relationship, as add-on variable to GPM
62803859|NCT01860287|PLACEBO_COMPARATOR|Placebo group|Healthy volunteers receive placebo during session (within-subjects design).
62803860|NCT01860287|EXPERIMENTAL|buprenorphine (0.2 mg) group|Healthy volunteers receive buprenorphine (0.2 mg) during session (within-subjects design).
62803861|NCT01860287|EXPERIMENTAL|buprenorphine (0.4 mg) group|Healthy volunteers receive buprenorphine (0.4 mg) during session (within-subjects design).
62803862|NCT01576289||Patients undergoing uppper endoscopy|Consecutive patients with and without symptoms of reflux disease who routinely undergo upper endoscopy from November 2011 through May 2012.
62803863|NCT04593108||Letrozole misoprostol|"Group (A):~A participant will receive three tablets of letrozole (Letrozole®, Technopharma) as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) on day One, then she took the second dose herself on day Two and will be told to bring back the empty pack. The third dose will be given on admission to hospital on day Three followed by 4 tablets of vaginal misoprostol (200 μg) (Cytotec®, Pfizer) soaked with saline every three hours for maximum two doses.then give antibiotics when abortion start"
62803864|NCT04593108||Misoprostol,placebo|"Group (B):~A participant will receive three tablets of placebo as a single dose on day One, then she took the second dose herself on day Two and will be told to bring back the empty pack. The third dose will be given on admission to hospital on day Three followed by 4 tablets of vaginal misoprostol (200 μg) (Cytotec®, Pfizer) soaked with saline every three hours for maximum two doses.then give antibiotics when abortion start"
62803865|NCT05006235|ACTIVE_COMPARATOR|Salbutamol Group|included babies who had received nebulized B2 agonist salbutamol (0.15 mg/kg) + 4ml normal saline
62803866|NCT05006235|ACTIVE_COMPARATOR|Epinephrine Group|included babies who had received nebulized epinephrine (0, 05 ml/Kg) + 4ml normal saline
62420787|NCT01491373|EXPERIMENTAL|rhBMP-2/ACS|
62420788|NCT01491373|ACTIVE_COMPARATOR|Autograft|
62420789|NCT05602974|EXPERIMENTAL|adjuvant stereotactic body radiation therapy|adjuvant stereotactic body radiation therapy after hepatectomy with narrow margin
62420790|NCT05602974|ACTIVE_COMPARATOR|regular follow-up|regular follow-up after hepatectomy with narrow margin
62803867|NCT05006235|PLACEBO_COMPARATOR|Saline Group|include babies who had received nebulized 0.9% saline
62803868|NCT04662008|ACTIVE_COMPARATOR|High resource tailored intervention|Tele-coaching arm
62420791|NCT06376773||mesenchymal|Based on RNA-seq transcriptome, patients were divided into mesenchymal, and received neoadjuvant chemotherapy with apatinib or not
62420792|NCT06376773||immunogenic|Based on RNA-seq transcriptome, patients were divided into immunogenic, and received neoadjuvant chemotherapy with Camrelizumab or not
62803869|NCT04662008|ACTIVE_COMPARATOR|Low-resource web-only intervention|Website arm
62803870|NCT03306667|EXPERIMENTAL|Normal group|Healthy control subjects
62803871|NCT03306667|EXPERIMENTAL|Mild hepatic-insufficient group|Patients with mild hepatic impaired function (Child-Pugh A)
62803872|NCT03306667|EXPERIMENTAL|Moderate hepatic-insufficient group|Patients with moderate hepatic impaired function (Child-Pugh B)
62803873|NCT03306667|EXPERIMENTAL|Severe hepatic-insufficient group|Patients with severe hepatic impaired function (Child-Pugh C)
62029244|NCT05320822|EXPERIMENTAL|Active Rehab (Group 2)|"Active Rehab includes an adaptive paradigm based on personal characteristics, symptom presentation, and duty requirements that integrate with current progressive return to activity (PRA TBICoE) guidelines. Activity progressions consider the initial presentation and changes in participant status during treatment, with the goal of safely accelerating recovery. Severity and presence of symptoms will guide progression as reported by the participant.~The intervention consists of 5 phases designed to facilitate an active approach to concussion rehabilitation. Phases are symptom stabilization, impairment reduction, activity integration, recovery acceleration, and military duty specific application. Participants complete phase specific activities under direction of a clinical professional, and progress upon meeting specific requirements."
62029245|NCT05859100|EXPERIMENTAL|Early Intervention|Participants are expected to begin intervention immediately after the completion of treatment for a period of 8 weeks.
62029246|NCT05859100|OTHER|Delayed Intervention|Participants are expected to begin intervention 4 weeks after the completion of the treatment, for a period of 4 weeks (weeks 5-8).
62029247|NCT03230916|EXPERIMENTAL|IMI/REL FDC|Imipenem/Cilastatin/Relebactam (IMI/REL) administered as a single fixed 2:1 ratio of imipenem/cilastatin to relebactam, with a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
62029248|NCT00650741||1|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), no repetition of test
62029249|NCT00650741||2|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), Repetition with Nitroglycerin
62029250|NCT00650741||3|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), repetition of test with the Endotect
62029251|NCT03456908|EXPERIMENTAL|myeloma before MV-NIS treatment|"Perform \[18F\]BF4-PET and \[99mTc\]pertechnetate-SPECT imaging in 10 patients with myeloma before MV-NIS treatment, and at Day 8-9 to monitor NIS activity in the tumors. To show the correlation of positive regional uptake with tissue histopathology for NIS, biopsies will be taken, when accessible, after the day 8 scan. Patients will be selected from subjects electing to participate in IRB 06-005263 at Mayo Clinic: Phase I/II Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma,"
62420793|NCT06376773||metabolic|Based on RNA-seq transcriptome, patients were divided into metabolic, and received neoadjuvant chemotherapy with apatinib, Camrelizumab or not
62803874|NCT03832348|EXPERIMENTAL|PET scan imaging|PET scan will be performed each of three first cycles of pembrolizumab to describe the early tumour metabolic changes during the first line of treatment.
62803875|NCT01934257|OTHER|Marketed milk-based lactose-containing infant formula|
62803876|NCT01934257|OTHER|Marketed milk-based lactose-free infant formula|
62420794|NCT06376773||classic|Based on RNA-seq transcriptome, patients were divided into classic, and received neoadjuvant chemotherapy with apatinib, Camrelizumab or not
62228148|NCT02647229|ACTIVE_COMPARATOR|Colonic Hyrdrotherapy|Colonic hydrotherapy is an FDA approved method of colon cleansing using constant warm water lavage with a contained temperature and pressure controlled device administered by a trained technician.2 There
62228149|NCT01577745|EXPERIMENTAL|MEDI0639 Cohort 1|Participants received MEDI0639 dose level 1 as a 60-minute intravenous (IV) infusion on Day 1 of each 21-day cycle.
62420795|NCT06336174||Surgery Group|Symptomatic intracranial stenosis patients who receive endovascular therapy combined with standard medical treatment
62590809|NCT06667531|ACTIVE_COMPARATOR|Group 3 (height 1.5; surgery 1)|Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 1.5 mm.
62803877|NCT01934257|OTHER|Marketed soy-based lactose-free infant formula|
62803878|NCT04062110|ACTIVE_COMPARATOR|Long plaster casts for type AO 2R3A2.2|Closed reduction of the fracture and immobilization with long plaster casts (above-elbow, Long plaster casts).
62803879|NCT04062110|ACTIVE_COMPARATOR|Short plaster casts for type AO 2R3A2.2|Closed reduction of the fracture and immobilization with short plaster casts (below-elbow, Short plaster casts)
62420796|NCT06336174||Medical group|Symptomatic intracranial stenosis patients who receive standard medical treatment without endovascular therapy
62420797|NCT01115699|EXPERIMENTAL|Repetitive Transcranial Magnetic Stimulation|All subjects will receive 10 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for a fixed-flexible period of 5 treatments per week for up to 6 weeks.
62590810|NCT06667531|ACTIVE_COMPARATOR|Group 4 (height 3; surgery 2)|Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 3 mm.
62590811|NCT06667531|ACTIVE_COMPARATOR|Group 5 (height 2; surgery 2)|Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 2 mm.
62590812|NCT06667531|ACTIVE_COMPARATOR|Group 6 (height 1.5; surgery 2)|Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 1.5 mm.
62803880|NCT02360826|EXPERIMENTAL|Pravastatin|Pravastatin 20mg tablet (age 8-13 years), 40mg tablet (\>14 years); 1 time dose given per oral at at the start of the study day.
62803881|NCT02360826|EXPERIMENTAL|Simvastatin|Simvastatin 10mg tablet (ages 8-13 years), 20mg tablet (\>14 years); 1 time dose given per oral at the start of the study day.
62228150|NCT01577745|EXPERIMENTAL|MEDI0639 Cohort 2|Participants received MEDI0639 dose level 2 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
62228151|NCT01577745|EXPERIMENTAL|MEDI0639 Cohort 3|Participants received MEDI0639 dose level 3 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
62228152|NCT01577745|EXPERIMENTAL|MEDI0639 Cohort 4|Participants received MEDI0639 dose level 4 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
62803882|NCT03487731|PLACEBO_COMPARATOR|Group 1 - Placebo|Group 1 - Five (5) subjects will be treated with a single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection. These subjects will be part of the control (Standard care) group.
62803883|NCT03487731|EXPERIMENTAL|Group 2 - Allogeneic Human Mesenchymal Stem Cells (hMSCs)|Group 2 - Five (5) subjects will be treated with a single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml. These subjects will be part of the experimental group.
62803884|NCT03487731|EXPERIMENTAL|Group A - Allogeneic Human Mesenchymal Stem Cells (hMSCs)|Group A will consist of 15 subjects that will receive 20 million Allogeneic hMSCs delivered via lumbar level injection based on pain originator.
62029252|NCT03456908|EXPERIMENTAL|endometrial cancer before VSV-hINF-NIS treatment|"Perform \[18F\]BF4-PET and \[99mTc\]pertechnetate-SPECT imaging in 10 patients with endometrial cancer before VSV-hINF-NIS treatment, and at Day 3-5 to monitor NIS activity in the tumors. To show the correlation of positive regional uptake with tissue histopathology for NIS, biopsies will be taken, when accessible, after the day 3-5 scan. Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Metastatic and/or Incurable Endometrial and Epithelial Ovarian Cancer, IRB 15-007000"
62228153|NCT01577745|EXPERIMENTAL|MEDI0639 Cohort 5|Participants received MEDI0639 dose level 5 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
62228154|NCT01577745|EXPERIMENTAL|MEDI0639 Cohort 6|Participants received MEDI0639 dose level 6 as a 60-minute IV infusion on Day 1 of each 21 day cycle.
62228155|NCT02738944|ACTIVE_COMPARATOR|Integrated Care|Telepsychiatry Collaborative Care
62228156|NCT02738944|ACTIVE_COMPARATOR|Referral Care|Telepsychiatry Enhanced Referral
62228157|NCT01845051||Migraine group|Patients diagnosed with migraine
62228158|NCT01845051||Healthy group|Healthy subjects with no migraine as control
62228159|NCT02911415||the dosage of 0.25 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac-Combi in the dosages of 0.25 ml, during the study under Protocol 01-COMBI-2015 in October-November 2015.
62803885|NCT03487731|PLACEBO_COMPARATOR|Group B - Placebo|Group B will consist of 15 subjects who will receive 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution via lumbar level injection based on pain originator.
62029253|NCT05435612|EXPERIMENTAL|single-sided deafness group（SSD Group）|The single-sided group（SSD group）consists of 20 SSD patients voluntarily enrolled in the study and plan to undergo cochlear implantation.
62228160|NCT02911415||the dosage of 0.5 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac-Combi in the dosages of 0.5 ml, during the study under Protocol 01-COMBI-2015 in October-November 2015
62228161|NCT02893930|EXPERIMENTAL|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62243110|NCT03932825|PLACEBO_COMPARATOR|Air oxygen mixture|participants in this arm inhale mixed oxygen-air gas (inspired oxygen concentration \~50%).
62243111|NCT03932825|EXPERIMENTAL|Nitrous oxide|Participants in this group inhale mixed 50% nitrous oxide and 50% oxygen.
62029254|NCT05435612|EXPERIMENTAL|asymmetric hearing loss group（AHL Group）|The asymmetric hearing loss group（AHL group）consists of 10 AHL patients voluntarily enrolled in the study and plan to undergo cochlear implantation.
62029255|NCT01600157|EXPERIMENTAL|Laparoscopic Nephrectomy|
62803886|NCT01495208|EXPERIMENTAL|aflibercept|
62228162|NCT05401760|ACTIVE_COMPARATOR|Group A: includes eyes for whom combined phacoaspiration & angle surgery will be done.|"Group A: for whom combined phacoaspiration \& angle surgery trabeculotomy will be done.~* continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~* The nucleus and cortex will be aspirated.~* Posterior capsulrehxis and limited anterior vitrectomy will be done.~* Corneal incisions will be sutured with 10-0 Nylon suture.~* Using metal trabeculotomes to open thetrabecular meshwork after accessing the canal of schlemm.~* Suturing of scleral flap with 10-0 Nylon suture."
62803887|NCT00622037|ACTIVE_COMPARATOR|1|PEG-400 based artificial tear
62420798|NCT00227734|ACTIVE_COMPARATOR|Arm I|Patients receive oral capecitabine twice daily on days 1-15 and oxaliplatin IV over 2 hours on day 1.
62420799|NCT00227734|ACTIVE_COMPARATOR|Arm II|Patients receive capecitabine and oxaliplatin as in arm I and cetuximab IV over 1-2 hours on days 1 and 8
62803888|NCT00622037|ACTIVE_COMPARATOR|2|Systane
62029256|NCT05904847|EXPERIMENTAL|Intervention|
62029257|NCT05904847|NO_INTERVENTION|Control|
62029258|NCT00604981|EXPERIMENTAL|1|Multisystemic Therapy (MST)
62029259|NCT00604981|ACTIVE_COMPARATOR|2|Shapedown
62029260|NCT01781572|EXPERIMENTAL|Phase Ib|"The phase Ib is the dose escalation part where successive cohorts of 3-6 newly enrolled patients receiving various dose pairs considering the recommendation from an adaptive BLRM incorporating the EWOC principle until MTD(s)/RP2D is defined. If multiple alternate dosing schedules are explored in parallel, the allocation of patients will proceed in an alternating fashion. Approximately 40 patients are expected to be treated during the phase Ib part of the study.~Dosing Schedule 1: MEK162 administered orally twice daily on a continuous dosing schedule. LEE011 administered orally once daily for 21 days followed by a 1 week break (28-day cycle).~Dosing Schedule 2: MEK162 administered orally twice daily and LEE011 administered orally once daily for 3 weeks followed by a 1 week break (28-day cycle).~Dosing Schedule 3: MEK162 administered orally twice daily and LEE011 administered once daily for 2 weeks followed by a 1 week break (21-day cycle)."
62803889|NCT00720590|EXPERIMENTAL|1|Participants will receive treatment with atazanavir and placebo lopinavir/ritonavir.
62803890|NCT00720590|EXPERIMENTAL|2|Participants will receive treatment with lopinavir/ritonavir and placebo atazanavir.
62803891|NCT00720590|PLACEBO_COMPARATOR|3|Participants will receive treatment with placebos for both drugs.
62803892|NCT04073121|EXPERIMENTAL|Luminor DCB and Angiolite DES|Study Devices
62420800|NCT01485588|EXPERIMENTAL|hI-con1™ 60µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
62420801|NCT01485588|EXPERIMENTAL|hI-con1™ 150µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
62420802|NCT01485588|EXPERIMENTAL|hI-con1™ 300µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
62420803|NCT06457204|EXPERIMENTAL|Treatment sequence A|First reference treatment, then test treatment
62803893|NCT01667289|ACTIVE_COMPARATOR|Radiotherapy alone|Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
62803894|NCT01667289|EXPERIMENTAL|Concurrent chemoradiation|"Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy"
62029261|NCT01781572|EXPERIMENTAL|Phase II|"The Phase II part will begin once the MTD(s)/RP2D have been determined in the Phase Ib in order to assess antitumor activity of the LEE011and MEK162 combination. Patients enrolled in the Phase II part of the study are required to have measurable disease. Approximately 40 patients will be treated in this part.~Phase II part will begin at the RP2D on the chosen schedule in order to assess antitumor activity of the LEE011 and MEK162 combination."
62029262|NCT03859843|ACTIVE_COMPARATOR|PRP|
62029263|NCT03859843|ACTIVE_COMPARATOR|Chemical peeling (Salycilic acid)|
62029264|NCT03859843|ACTIVE_COMPARATOR|Chemical peeling (Jessenr's solution)|
62029265|NCT03877523|EXPERIMENTAL|Cocarnit|disodium adenosine triphosphate trihydrate 10mg, cocarboxylase 50mg, cyanocobalamin 500mg and nicotinamide 20mg
62029266|NCT00321854|EXPERIMENTAL|Early Pramipexole|Patients were treated with pramipexole for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
62803895|NCT04468581||Community sample|We plan to recruit a representative sample of the Singapore population.
62803896|NCT02911870|EXPERIMENTAL|Part A, SNAC|Single dose of 1.2mg, 2.4mg or 3.6mg increasing for each cohort of trial participants.
62803897|NCT02911870|PLACEBO_COMPARATOR|Part A, placebo|Single dose at corresponding dose levels.
62029267|NCT00321854|EXPERIMENTAL|Delayed Pramipexole|Patients were treated with placebo for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
62029268|NCT01012869|EXPERIMENTAL|everolimus-eluting stent|patients undergoing treatment of a coronary chronic total occlusion (at least 3-months old) using everolimus-eluting stents (Xience, Abbott Vascular) or Promus (Boston Scientific)
62029269|NCT03297268||Phase 1-Controlled Validation & Study Planning|Phase 1 is focused on refining and ultimately verifying BESI's basic sensing and notification functionality and validating BESI's environmental assessments in a controlled setting - namely the laboratory and homes of two healthy volunteers. This phase also serves to support further requirements gathering to refine BESI for community-based deployment. No interventions are delivered.
62029270|NCT03297268||Phase 2 - In-situ Validation and Ethnographic Analysis|Phase 2 starts the deployment of the technology within a community context, with the goals of validating the system's ability to assess agitation and environmental events in-situ and developing the cyber-sociophysical system models based on the dyad-specific relationship between agitation and the environment. A hybrid remote ethnographic methodology will be used, combining remote BESI measurement and caregiver diaries and a time-series design for the administration of the assessment battery.
62228163|NCT05401760|ACTIVE_COMPARATOR|Group B : includes eyes with only phacoaspiration will be done|"Group B: for whom phacoaspiration only will be done.~* 2 side ports will be fashioned.~* Trypan blue will be injected to aid visualization of the anterior capsule \& continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~* The nucleus and cortex will be aspirated.~* Posterior capsulrehxis and limited anterior vitrectomy will be done.~* Corneal incisions will be sutured with 10-0 Nylon suture."
62420804|NCT06457204|EXPERIMENTAL|Treatment sequence B|First test treatment, then reference treatment
62420805|NCT00668109|EXPERIMENTAL|Arm 1|
62420806|NCT00668109|ACTIVE_COMPARATOR|Arm 2|
62420807|NCT02665026|EXPERIMENTAL|stoma closure at different times|choose different times to do stoma closure after surgery for rectal cancer
62420808|NCT04668118|EXPERIMENTAL|Diquafosol group|The treatment period is 12 weeks. The day after subjects who meet the inclusion criteria undergo baseline examination is the day starting the medication. Dosing frequency was six times daily for 3% Diquafosol Ophthalmic Solution. The follow-up time points are 2, 4, 8, 12 weeks, and no other medication is required on the follow-up day.
62420809|NCT01466673|EXPERIMENTAL|Ethinyl estradiol/Norgestimate (EE/NGM)|
62420810|NCT01466673|ACTIVE_COMPARATOR|Ethinyl estradiol/Desogestrel (EE/DSG)|
62420811|NCT01618903|EXPERIMENTAL|Levetiracetam iv infusion|Levetiracetam intravenous (iv) 45 min infusion administered as one single dose.
62420812|NCT01618903|EXPERIMENTAL|Levetiracetam oral tablet|Levetiracetam oral tablet administered as one single dose.
62803898|NCT02911870|EXPERIMENTAL|Part B, SNAC, Placebo, Moxifloxacin|Subjects will receive 4 different treatments in random order. SNAC dose between 1.2-3.6 mg, Placebo in two different periods, moxifloxacin 400mg.
62420813|NCT04721327|EXPERIMENTAL|Pediatric Arm|Patient ages 1-17 years who are current cochlear implant (CI) users will receive CI programming in person for the first visit and remotely for the second visit.
62420814|NCT04721327|EXPERIMENTAL|Adult Arm|Patient ages 18-90 years who are current cochlear implant (CI) users will receive CI programming in person for the first visit and remotely for the second visit.
62590813|NCT06459349|EXPERIMENTAL|exteroceptive and proprioceptive sensory stimulation|Patients in this group will receive exteroceptive and proprioceptive sensory stimulation
62590814|NCT06459349|ACTIVE_COMPARATOR|sensorimotor therapy group|Patients in this group will receive sensorimotor therapy
62803899|NCT02163824|ACTIVE_COMPARATOR|KPI-121 0.25% QID|KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
62803900|NCT02163824|ACTIVE_COMPARATOR|KPI-121 1.0% BID|KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
62803901|NCT02163824|PLACEBO_COMPARATOR|Vehicle of KPI-121 0.25%|Vehicle of KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
62803902|NCT02163824|PLACEBO_COMPARATOR|Vehicle of KPI-121 1.0%|Vehicle of KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
62803903|NCT03767621||Patients with intermediate lesions.|Patients with intermediate lesions (stenosis in angiography between 25% and 60%) in LMCA.
62029271|NCT03297268||Phase 3 - Intervention with Home-Based Caregivers|Phase 3 is the intervention phase and the full realization of BESI. The goal is to employ the validated assessment capabilities and the developed modeling techniques to enable real-time, dyad-specific caregiver notifications that empower a caregiver to intervene with the PWD and/or environment before agitation escalation. In addition to validation of the BESI's ability to provide such appropriate notifications, Phase 3 will also serve as a pilot study about the effect that these notifications have on caregiver empowerment (as measured by self-efficacy) and the frequency and severity of PWD agitation, thus providing proof-of-concept for BESI's potential to improve dyad outcomes and motivating a larger-scale followup study to establish proof-of-practice.
62420815|NCT05323409|EXPERIMENTAL|OPTIMISE|OPTIMISE components to facilitate Patient self-management support are: 1) a bilingual oncology nurse navigator (ONN) and care coordination; 2) distress screening; 3) tailored comorbidity self-management action planning, 4) tailored survivorship action planning, and 5) surveillance reminders and follow-up. OPTIMISE components to facilitate provider decision support are: 1) when the initial referral is made, the ONN will send the PCP treatment plan summary (based on the ASCO treatment plan template) and standardized fact sheets on treatment toxicities; 2) throughout treatment, there will be bi-directional and structured communication between oncologist and PCP facilitated by the ONN; 3) The ONN will send the SCP to the PCP describing surveillance guidelines and summary of late effects. Finally, OPTIMISE will adopt a risk-stratified shared care model of post-treatment survivorship care.
62803904|NCT06061939|NO_INTERVENTION|Control Group|A control group (CG) that will not undergo treatment, which will be evaluated in the pre and post phase of the study. Participants assigned to this group will receive general advice on the positive effects of regular physical activity, and they will be given the guide of recommendations for the promotion of physical activity.
62590815|NCT05002673|EXPERIMENTAL|SLEEPERONE|
62590816|NCT05002673|EXPERIMENTAL|COMFORTIN|
62803905|NCT06061939|EXPERIMENTAL|Intervention Group|An experimental group (EG) that after an initial evaluation and with their consent, will be subjected to a directed physical training program, based on strength training with blood flow restriction, applied for 12 weeks with 3 weekly sessions (Monday, Wednesday and Friday), with a duration of 30-45 minutes per session. The exercises to be performed will be divided into three different phases: warm-up during the first 10 minutes; the main part with a duration of 15 minutes (where each exercise must be performed doing 4 series with a pattern of 30-15-15-15 repetitions, resting 30-45 seconds between series and 1-2 minutes between exercises); and the return to calm, based above all on stretching exercises with a total duration of 10 minutes.
62029272|NCT06383975|EXPERIMENTAL|Pulsed field ablation with posterior wall isolation|
62029273|NCT06383975|ACTIVE_COMPARATOR|Radiofrequency ablation and vein of Marshall ethanolization|
62029274|NCT06370598|EXPERIMENTAL|TP-122A with SOC|Enrolled subjects in the TP-122A+SoC arm will receive IP every 8 hours for 7 days by nebulization and will be followed-up for 28 days after the last IP administration.
62029275|NCT06370598|NO_INTERVENTION|SOC alone|Just standard of care will be given to patient
62029276|NCT04604587|EXPERIMENTAL|amyloid PET、T807 PET|PET/CT
62803906|NCT03385655|EXPERIMENTAL|WEE-1 inhibitor - ARM CLOSED|
62803907|NCT03385655|EXPERIMENTAL|cMET inhibitor|
62803908|NCT03385655|EXPERIMENTAL|novel non-steroidal androgen receptor (AR) antagonist|
62803909|NCT03385655|EXPERIMENTAL|CFI400945 PLK4 inhibitor - ARM CLOSED|
62803910|NCT03385655|EXPERIMENTAL|Ipatasertib AKT inhibitor|
62803911|NCT03385655|EXPERIMENTAL|Durvalumab and Tremelimumab immunotherapy|
62803912|NCT03385655|EXPERIMENTAL|Carboplatin platinum based chemotherapy|
62803913|NCT01271556|EXPERIMENTAL|1, salmeterol, saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to each test day. Salmeterol 50 mcg on days A was administered between 8 AM and 10 AM. Patients and healthy subjects underwent a rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment (salmeterol 50 mcg MDI), and mixed venous blood was withdrawn for measurements of hematocrit (Htc), Hb, and albumin concentration 10 minutes before and 10 minutes after the infusion. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
62803914|NCT01271556|PLACEBO_COMPARATOR|2, placebo, saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Placebo was administered between 8 AM and 10 AM. Patients and healthy subjects underwent a rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment (placeboI), and mixed venous blood was withdrawn for measurements of hematocrit (Htc), Hb, and albumin concentration 10 minutes before and 10 minutes after the infusion. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
62803915|NCT01271556|ACTIVE_COMPARATOR|3, salmeterol, no saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Salmeterol 50 mcg on days A was administered between 8 AM and 10 AM. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
62029277|NCT03690869|EXPERIMENTAL|Phase 1|Patients in both the Solid Tumor Cohort and the CNS Cohort will receive cemiplimab monotherapy. Each Cohort will have 2 subgroups by age (0 to \<12 years, 12 to \<18 years).
62029278|NCT03690869|EXPERIMENTAL|Efficacy with Newly Diagnosed DIPG|≥ 3 to \< 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy
62590817|NCT05641285||Otosight, Otoscope, and Tympanogram|Prospective study using a convenience sample. There will be no group assignment or randomization. There is no intervention planned and therefore, no placebo group or use of controls.
62590818|NCT00879346|EXPERIMENTAL|1|160mg oral dose of AZD8931
62590819|NCT04210388|EXPERIMENTAL|AZD5718 tablet, Treatment A|Volunteers will receive single doses of AZD5718 tablet, Formulation A under fasted conditions.
62590820|NCT04210388|EXPERIMENTAL|AZD5718 tablet, Treatment B|Volunteers will receive single doses of AZD5718 tablet, Formulation B under fasted conditions.
62029279|NCT03690869|EXPERIMENTAL|Efficacy with Newly Diagnosed HGG|≥ 3 to \< 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy
62029280|NCT03690869|EXPERIMENTAL|Efficacy with Recurrent HGG|≥ 3 to \< 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy
62420816|NCT05323409|NO_INTERVENTION|Usual Medical Care (UMC)|UMC consists of standard oncologic care from point of diagnosis. Cancer patients with comorbidities are encouraged by their oncologist to follow up with their PCP regarding comorbidity management but no formal referral process is in place. At the end of cancer treatment (with standard, definitive therapies), patients meet with a nurse (Survivorship Nurse Practitioner, NP) to review the SCP, which is based on ASCO templates and populated from the EHR. The Survivorship NP also reviews therapies received, recommended surveillance, common late effects, and recommended lifestyle behaviors. Patients are given a printed copy of the SCP and are encouraged to share this information with their PCP. Cancer surveillance follows the traditional oncologist led model regardless of patient risk for recurrence.
62420817|NCT03402126||TPD RAMWare Download|Subjects who qualify and consent to participate in the TPD study will have TPD RAMWare injected into their device to collect data.
62420818|NCT04947059|ACTIVE_COMPARATOR|Gemcitabine|Bladder cancer patients, who are treated with a transurethral resection of a bladder tumor, receive postoperatively, within 6 hours after the resection, an immediate single intravesical instillation with gemcitabine hydrochloride 2gr in 100ml of saline for 45-60 minutes and continuous saline irrigation for 24 hours
62420819|NCT04947059|ACTIVE_COMPARATOR|Epirubicin|Bladder cancer patients, who are treated with a transurethral resection of a bladder tumor, receive postoperatively, within 6 hours after the resection, an immediate single intravesical instillation with epirubicine hydrochloride 50mg in 50ml of saline for 45-60 minutes and continuous saline irrigation for 24 hours
62420820|NCT06564337|EXPERIMENTAL|Patients recruited for intervention|A combination of 3Y-TZP and 5Y-TZP (IPS e.max ZirCAD Prime, Ivoclar AG) with a flexural strength of 1200MPa will be utilized for the crowns. Tooth preparation will include occlusal reduction of 1.0 to 1.2mm and rounded line angles for the rest seats within the zirconia crown and buccal and lingual reduction of 1 to 1.5mm to allow for adequate buccal and lingual contour to accommodate retentive clasp arms and minor connectors. Impressions for zirconia crowns will be made with polyvinyl siloxane on a full arch custom tray. After clinical verification crowns will be cemented with resin or resin modified glass ionomer cement
62420821|NCT06398080||Naïve nAMD|Treatment-naive patients with nAMD
62420822|NCT06398080||Pretreated nAMD|Patients with nAMD who have been previously treated with anti-VEGF and/or laser
62420823|NCT06398080||Naïve DME|Treatment-naive patients with DME
62420824|NCT06398080||Pretreated DME|Patients with DME who have been previously treated with anti-VEGF, laser treatment, and/or intravitreal steroids
62029281|NCT06635902|EXPERIMENTAL|Low dose intravenous L-citrulline|
62029282|NCT06635902|EXPERIMENTAL|High dose intravenous L-citrulline|
62029283|NCT06635902|PLACEBO_COMPARATOR|Placebo|
62029284|NCT00933231|ACTIVE_COMPARATOR|Tacrolimus Standard Dose with ACEi/ARB|Participants receive a standard dose of tacrolimus with ACEi/ARB.
62029285|NCT00933231|ACTIVE_COMPARATOR|Tacrolimus Standard Dose without ACEi/ARB|Participants receive a standard dose of tacrolimus without ACEi/ARB.
62029286|NCT00933231|EXPERIMENTAL|Tacrolimus Low Dose with ACEi/ARB|Participants receive a low dose of tacrolimus with ACEi/ARB.
62228164|NCT01014260|PLACEBO_COMPARATOR|Placebo|placebo
62029287|NCT00933231|EXPERIMENTAL|Tacrolimus Low Dose without ACEi/ARB|Participants receive a low dose of tacrolimus without ACEi/ARB.
62803916|NCT01271556|PLACEBO_COMPARATOR|4, placebo, no saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Placebo was administered between 8 AM and 10 AM. 240 and 290 minutes after inhalatory treatment (placebo), pulmonary function tests were performed.
62590821|NCT04210388|EXPERIMENTAL|AZD5718 tablet, Treatment C|Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions.
62803917|NCT00371592|EXPERIMENTAL|1|Participants will receive acyclovir for 24 weeks
62029288|NCT04002934|EXPERIMENTAL|Group A|"Group A is the early-start group and will receive a total of 6 months of BZA -- 3 months of BZA, followed by 3 months BZA"
62029289|NCT04002934|EXPERIMENTAL|Group B|"Group B is the delayed-start group and will receive a total of 3 months of BZA -- 3 months of placebo, followed by 3 months of BZA"
62803918|NCT00371592|PLACEBO_COMPARATOR|2|Participants will receive acyclovir placebo for 24 weeks
62803919|NCT04830930|EXPERIMENTAL|Sequence 1|Period 1: fasted condition/ Period 2: fed condition
62029290|NCT04885829|EXPERIMENTAL|DRL_TC|Subcutaneous injection of DRL's Tocilizumab
62420825|NCT04691739|ACTIVE_COMPARATOR|In-person occupational therapy|occupational therapy delivered in-person
62803920|NCT04830930|EXPERIMENTAL|Sequence 2|Period 1: fed condition/ Period 2: fasted condition
62803921|NCT04766463|EXPERIMENTAL|Treatment group A|
62803922|NCT04766463|EXPERIMENTAL|Treatment group B|
62029291|NCT04885829|ACTIVE_COMPARATOR|RP and RMP|Subcutaneous injection of Actemra and RoActemra (Commercially available Tocilizumab)
62029292|NCT03849755|OTHER|PEPPER/Control|Group with intervention applied (PEPPER system) during the first three months and then, after wash -out period, swap to control group (using standard bolus calculator) for the next 3 months.
62029293|NCT03849755|OTHER|Control/PEPPER|Group without intervention applied (using standard bolus calculator) during the first three months and then, after wash -out period, swap to intervention group (using PEPPER system) for the next 3 months.
62029294|NCT05131100||Participants receiving Somavert|
62420826|NCT04691739|ACTIVE_COMPARATOR|Teletherapy|Video-conferencing occupational therapy
62590822|NCT04210388|EXPERIMENTAL|AZD5718 tablet, Treatment D|Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions.
62029295|NCT02401191|EXPERIMENTAL|FEX60/PE10|Internal use of FEX60/PE10 combination tablet will be administered twice daily (1 tablet per intake) for 2 weeks
62029296|NCT00244504|ACTIVE_COMPARATOR|I|moxonidine group
62029297|NCT00244504|PLACEBO_COMPARATOR|II|placebo group
62029298|NCT04208022||Healthy Musician|At least 15 hypermobile musicians and at least 15 non-hypermobile musicians will be included in the study.
62420827|NCT03091218||The individuals taking RZZY Capsule|The overall individuals taking RZZY Capsule with recommended dosage and achieving the inclusion criteria.
62590823|NCT04210388|ACTIVE_COMPARATOR|AZD5718 film-coated tablet|Volunteers will receive single doses of AZD5718 film-coated tablet, Reference treatment under fasted conditions.
62590824|NCT05770271|EXPERIMENTAL|The mild senile groin eczema, neurodermatitis and psoriasis and one treatment|Participants with itching of mild senile groin eczema, neurodermatitis and psoriasis will receive one treatment with the device and complete the questionnaire.
62590825|NCT00570427|EXPERIMENTAL|1.|All participants
62803923|NCT04766463|PLACEBO_COMPARATOR|Treatment group C|
62803924|NCT04766463|ACTIVE_COMPARATOR|Treatment group D|
62803925|NCT04168658|EXPERIMENTAL|Physical activity and education intervention|
62803926|NCT04168658|ACTIVE_COMPARATOR|Education intervention|
62803927|NCT04344808|EXPERIMENTAL|Navigation group|Dental implants will be placed using a dynamic computer assisted surgery system
62803928|NCT04344808|ACTIVE_COMPARATOR|Freehand group|Dental implants will be place without any guidance. Only virtually planning the ideal position on a 3D image (Cone beam computed tomography)
62803929|NCT04474678|OTHER|All Patients|Since this is a single-group study, all patients are within the same arm
62803930|NCT04234620||Toripalimab injection|Use of Toripalimab injection in the real world
62803931|NCT01180465|EXPERIMENTAL|LIPO-102 High|
62029299|NCT04208022||Healthy Individuals|The study will include at least 15 healthy non-hypermobile individuals who do not deal with music and at least 15 healthy hypermobile individuals who do not deal with music.
62803932|NCT01180465|EXPERIMENTAL|LIPO-102, Low|
62420828|NCT06248073|EXPERIMENTAL|on-line self-management group|The investigators plan to conduct 12 sessions of intervention, one hour per session, 2 sessions per week, for a total of 6 weeks. Participants will receive interventions in their home via online meetings with a certified occupational therapist. The training will be related to functional tasks in daily life. In addition, the investigators will guide participants to use self-management skills in their daily routines. Participants will receive booklets to conduct their self-practice and exercise for 30 minutes per session, two sessions per week, for a total of 6 weeks.
62420829|NCT06248073|EXPERIMENTAL|on-site task-related group|The investigators plan to conduct 12 sessions of intervention, one hour per session, 2 sessions per week, for a total of 6 weeks. Participants will receive interventions at Chang Gung Memorial Hospital. A certified occupational therapist will conduct the interventions. The training will include motor function of upper extremities, balance training and functional tasks. The level of difficulty of the tasks will be adjusted based on the participants' abilities.
62420830|NCT06248073|NO_INTERVENTION|control group|To compare the two experimental groups in the context of early Parkinson's disease, the control group will not receive any additional intervention and will continue their regular daily activities without changes.
62029300|NCT00863096||Gardasil|
62029301|NCT06395350|OTHER|Spire Medical Health Tag|Health Monitor Use
62029302|NCT03753165|EXPERIMENTAL|High Intensity Interval Exercise group|Patients suffering from chronic low back pain perform 12 sessions of high intensity interval exercise (HIIE) over a period of 6 weeks at an intensity of 80% of their maximal Heart rate. In addition they also receive conventional physiotherapy in the form of hot pack or TENS
62029303|NCT03753165|NO_INTERVENTION|Conventional physiotherapy|Patients suffering from chronic low back pain will receive conventional physiotherapy such as TENS and hot packs applied over appropriate areas over a period of 6 weeks
62029304|NCT03385018|EXPERIMENTAL|Laparoscopic group|Arm Description: Laparoscopic radical total gastrectomy with D2 (or D2-#10) lymph node dissection
62029305|NCT03385018|ACTIVE_COMPARATOR|Open group|Open radical total gastrectomy with D2 (or D2-#10) lymph node dissection
62029306|NCT04724655|OTHER|control group|gastric lavage with saline and bicarbonate and standard treatment :inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
62029307|NCT04724655|ACTIVE_COMPARATOR|paraffin group|gastric lavage with paraffin oil and bicarbonate and standard treatment :inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
62029308|NCT04724655|ACTIVE_COMPARATOR|coconut group|gastric lavage with coconut oil and bicarbonate and standard treatment :inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
62228165|NCT01014260|ACTIVE_COMPARATOR|Doxycycline|Doxycycline
62590826|NCT05236777||Natalizumab Cohort|The cohort will include participants with MS who are newly treated with natalizumab (administered as a standard of care/routine clinical practice) from 1st January 2019 including those participants who terminate or discontinue the treatment during the observational period.
62803933|NCT01180465|PLACEBO_COMPARATOR|LIPO-102; Placebo|
62803934|NCT04908085|EXPERIMENTAL|OPC|Occupational Performance Coaching delivered by telephone
62803935|NCT04908085|NO_INTERVENTION|Waitlist control|Intervention provided after post intervention assessment
62803936|NCT05245201|ACTIVE_COMPARATOR|Arm 1 - Standard of care|Standard of care
62803937|NCT05245201|ACTIVE_COMPARATOR|Arm 2 - Clinical decision support for PrEP|EHR-based decision support tools to support PrEP discussions and prescribing for patients who have increased predicted HIV risk
62803938|NCT01835717||Cognitively normal individuals|
62803939|NCT03813888|EXPERIMENTAL|Arsha Vidya Group|After school, children joined regular sessions in Arsha Vidya study centre to practice, vedic chants, vedanta reading, yoga and group activities within the ashram.
62803940|NCT03813888|OTHER|Usual Activity Group|After school, control group were asked to conitue their usual routine.
62803941|NCT04039126|EXPERIMENTAL|PATIENTS WITH MALIGNANT PLEURAL EFFUSION|PARTICIPANTS WITH MALIGNANT PLEURAL EFFUSIONS REQUIRING PLEURODESIS, COMBINATION OD POVIDONE IODOONE-TETRCYCLINE TO BE USED.
62420831|NCT03412994|EXPERIMENTAL|Apatinib group|"Apatinib combined with second-line chemotherapy (5-Fu combined with irinotecan or oxaliplatin standard regimen ) Apatinib tablets: 500 mg po qd . Continuous medication, the cycle is consistent with the chemotherapy cycle.~Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.（Take CAPEOX for example）"
62420832|NCT03412994|PLACEBO_COMPARATOR|Control group|Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.（Take CAPEOX for example）
62420833|NCT03155061|EXPERIMENTAL|Part A (Dose Escalation Part): ONO-4578 monotherapy|ONO-4578 specified dose on specified days in advanced or metastatic solid tumors
62803942|NCT04039126|ACTIVE_COMPARATOR|PATEINT WITH MALIGANT PLEURAL EFFUSION REQUIRNG PLEURODESIS|TO USE POVIDONE IODINE ALONE IN THIS GROUP
62803943|NCT01766453|NO_INTERVENTION|Non exercise control|Non exercise control will undergo baseline testing and follow up testing but will not participate in an exercise intervention.
62803944|NCT01766453|EXPERIMENTAL|Standard Exercise|The standard exercise group will attend exercise sessions under the supervision of a Certified Personal Trainer. Intensity will increase every four weeks by 10% from 50-80% of maximal heart rate to ensure that exercise is progressive in nature. Participants will be provided with a heart rate monitor during their exercise sessions and have the option to perform the aerobic training on a treadmill, upright bike, elliptical machine or recumbent bike as long as heart rate is kept within the prescribed training intensity. Intensity, duration, resting and exercise heart rates will be recorded for each exercise session for the duration of the intervention to ensure compliance to the exercise program.
62803945|NCT01766453|EXPERIMENTAL|Bhangra Dance Exercise|Bhangra dance classes taught be a certified instructor progressing in difficulty over the 12 week period. Bhangra dance is an Indian folk dance that consists of jumping and kicking of a high intensity. This group will attend exercise sessions under the supervision of a Bhangra Dance Instructor. The intensity of bhangra dance will be tracked through heart rate monitors worn by participants.
62803946|NCT06079333|EXPERIMENTAL|neo-adjuvant and adjuvant braf/mek-inhibition|Participants will undergo neo-adjuvant treatment with dabrafenib/trametinib. After 6 weeks of BRAF/MEK inhibitors, participants will undergo an evaluation of resectability. If the tumor is resectable, patients undergo tumor resection. If not resectable, neo-adjuvant treatment continues for another 6 weeks followed by a new evaluation. All resected patients receive adjuvant dabrafenib/trametinib up to a total treatment duration of 52 weeks. If resection is not possible, patients will continue on dabrafenib/trametinib.
62803947|NCT04333368|EXPERIMENTAL|MSC|
62803948|NCT04333368|PLACEBO_COMPARATOR|NaCl|
62803949|NCT03635463|EXPERIMENTAL|twin block appliance|this group will receive conventional twin block appliance and followed up every month for 9 months.
62803950|NCT03635463|EXPERIMENTAL|modified twin block appliance group|modified twin block appliance group , this group will receive the modified appliance and followed up every month for 9 months
62803951|NCT06368258|ACTIVE_COMPARATOR|Dietary supplement|
62803952|NCT06368258|PLACEBO_COMPARATOR|Placebo|
62803953|NCT02401685|EXPERIMENTAL|Adjuvant therapy alone|Women in this arm will have adjuvant therapy but no treatment to their armpit after surgery. Axillary and supraclavicular fossa radiotherapy is not allowed when randomised to this arm.
62803954|NCT02401685|ACTIVE_COMPARATOR|Adjuvant therapy plus axillary treatment|Women in this arm will have adjuvant therapy plus treatment to their armpit after surgery. Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
62803955|NCT02730728|ACTIVE_COMPARATOR|Single shot adductor canal block|adductor canal block group will receive single shot adductor canal block with 20ml bolus of 0.5% ropivicaine for analgesia after TKA
62803956|NCT02730728|ACTIVE_COMPARATOR|24 hour continuous adductor canal block|adductor canal block group will receive 24 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
62803957|NCT02730728|ACTIVE_COMPARATOR|48 hour continuous adductor canal block|adductor canal block group will receive 48 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
62029309|NCT03726034|EXPERIMENTAL|Life story book training|The migrant caregivers will receive training (six weekly 1.5-hour sessions) about life story approach by a part-time trained interventionist with psychology or social work background with at least three years of working experience working with older people and have basic knowledge about the life story work. After training, the migrant caregivers will be asked to produce the life story book individually at home with the older adults
62029310|NCT03726034|ACTIVE_COMPARATOR|Communication skills training|The migrant caregivers who have randomly assigned into the control group will receive communication skills training (two 1.5-hour sessions) offered by another trained interventionist with psychology or social work background with at least three years of working experience working with older people. They would not receive any additional training on life story work.
62029311|NCT05295498|EXPERIMENTAL|Active repetitive transcranial magnetic stimulation|10 hertz (Hz) rTMS will be administered over the primary motor area. Therapy will include 6 sessions (three sessions in two consecutive days). In every sessions 1500 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
62029312|NCT05295498|SHAM_COMPARATOR|Sham repetitive transcranial magnetic stimulation|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
62029313|NCT02291614|EXPERIMENTAL|AMG 211 200 μg/day for 7/14 Days|In cycle 1 participants receive 200 µg/day AMG 211 administered as a continuous intravenous infusion (cIV) infusion at a constant flow rate for 7 days followed by a 3-week treatment-free interval. In cycle 2 and thereafter, participants receive 200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
62420834|NCT03155061|EXPERIMENTAL|Part B: ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in advanced or metastatic solid tumors
62420835|NCT03155061|EXPERIMENTAL|Part C (Expansion Part): ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in unresectable, advanced or recurrent gastric cancer
62420836|NCT03155061|EXPERIMENTAL|Part D (Expansion Part): ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in unresectable, advanced or recurrent colorectal cancer
62803958|NCT05694455|OTHER|Septic Patient Interventions|Septic Patients will have all interventions performed: Urine collection, Passive Leg Raise, Ultrasound and sublingual microscopy
62029314|NCT02291614|EXPERIMENTAL|AMG 211 200 μg/day for 14 Days|Participants receive 200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
62420837|NCT02398500|EXPERIMENTAL|LMG324|SAD: LMG324 administered as a single IVT injection in 1 eye (study eye) in 1 of 4 doses, with 15-day follow-up
62420838|NCT02398500|EXPERIMENTAL|LMG324 + sham|Expansion: LMG324 administered as a single IVT injection in 1 eye (study eye), followed by sham injections, until implementation of SoC therapy as specified in the protocol, for 24 weeks
62420839|NCT02398500|ACTIVE_COMPARATOR|Lucentis + sham|Expansion: Ranibizumab 0.5 mg administered as monthly IVT injections in 1 eye (study eye) with interim sham injections, for 24 weeks
62420840|NCT00812227|EXPERIMENTAL|Psychodynamic psychotherapy|
62420841|NCT05775536|EXPERIMENTAL|Aspirin® 500 mg tablets|Dose: 1 tablet per day starting from visit 2 until visit 3, intake in the evening Ingredients: 500 mg acetylsalicylic acid, Cellulose powder, maize starche
62420842|NCT05775536|EXPERIMENTAL|Dr. Böhm® Omega 3 complex 870 mg|Dose: 2 tablets per day starting from visit 2 until visit 3, intake in the evening
62420843|NCT05407675|EXPERIMENTAL|Part 1: BMS-986408 Monotherapy|
62803959|NCT05694455|OTHER|Control Patient Interventions|Control patients will have urine collection and sublingual microscopy performed when intubated
62029315|NCT02291614|EXPERIMENTAL|AMG 211 400 μg/day for 14 Days|Participants receive 400 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
62029316|NCT02291614|EXPERIMENTAL|AMG 211 800 μg/day for 14 Days|Participants receive 800 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
62029317|NCT02291614|EXPERIMENTAL|AMG 211 1600 μg/day for 14 Days|Participants receive 1600 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
62029318|NCT02291614|EXPERIMENTAL|AMG 211 1600 µg/day for 28 Days|Participants receive 1600 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
62029319|NCT02291614|EXPERIMENTAL|AMG 211 3200 µg/day for 14 Days|Participants receive 3200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
62029320|NCT02291614|EXPERIMENTAL|AMG 211 3200 µg/day for 28 Days|Participants receive 3200 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
62029321|NCT02291614|EXPERIMENTAL|AMG 211 6400 µg/day for 14 Days|Participants receive 6400 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
62803960|NCT05004831|EXPERIMENTAL|fruquintinib plus TAS-102|fruquintinib plus TAS-102, orally given, Q4W
62803961|NCT06543901|EXPERIMENTAL|Submuscular plate|The patient underwent open reduction and internal fixation by being fixed with a submuscular plate
62803962|NCT06543901|ACTIVE_COMPARATOR|traction with a thomas splint and then casting|the patient was placed on traction with a thomas splint and then was casted in a spica cast
62029322|NCT02291614|EXPERIMENTAL|AMG 211 6400 µg/day for 28 Days|Participants receive 6400 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
62803963|NCT01735448||Aboriginal smoker, male, Adelaide|Focus group: Aboriginal smoker, male from Adelaide
62803964|NCT01735448||Aboriginal smoker, female, Adelaide|Focus group: Aboriginal smoker, female, from Adelaide
62803965|NCT01735448||Aboriginal ex/non-smoker, male, Adelaide|Focus group: Aboriginal ex/non-smoker, male, from Adelaide
62803966|NCT01735448||Aboriginal ex/non-smoker, female, Adelaide|Focus group: Aboriginal ex/non-smoker, female, from Adelaide
62803967|NCT01735448||Healthcare workers, Adelaide|Focus group: Healthcare workers who are based in Adelaide and work with Aboriginal patients
62803968|NCT01735448||Healthcare workers, Murray Bridge|Focus group: Healthcare workers who are based in Murray Bridge and work with Aboriginal patients
62803969|NCT01735448||Aboriginal smoker, male, Murray Bridge|Focus group: Aboriginal smoker, male, from Murray Bridge
62803970|NCT01735448||Aboriginal smoker, female, Murray Bridge|Focus group: Aboriginal smoker, female, from Murray Bridge
62029323|NCT02291614|EXPERIMENTAL|AMG 211 12,800 µg/day for 28 Days|Participants receive 12,800 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
62029324|NCT04388020|EXPERIMENTAL|Test Arm|
62029325|NCT03339050|EXPERIMENTAL|Health for Hearts United|Health for Hearts United (HHU) is a 18-month church-based intervention to reduce CVD risk in mid-life and older African Americans.
62029326|NCT06635720|EXPERIMENTAL|Reduced-dose steroids|Reduced-dose steroid protocol (intervention): oral prednisone or prednisolone 30mg/m2 (1mg/kg; max 40mg) daily until remission, then 20mg/m2 (0.66mg/kg; max 25mg) on alternate days for four weeks.
62029327|NCT06635720|ACTIVE_COMPARATOR|Standard-dose steroids|Standard-dose steroid protocol (control): oral prednisone or prednisolone 60mg/m2 (2mg/kg; max 60mg) daily until remission, then 40mg/m2 (1.5mg/kg; max 50mg) on alternate days for four weeks.
62029328|NCT06670443|EXPERIMENTAL|experimental group|"Electrical neuromuscular stimulation electrode patches will be applied over the intercostal respiratory muscles and leg muscles (placed superficially just below each knee, over the head of the fibula, in close proximity to the common peroneal nerve).~Active stimulation consisted of a ∼30-second ramp-up to the titrated intensity value at the start of stimulation, ∼30 minutes at the titrated intensity, and a 10-second ramp-down at the end of stimulation."
62029329|NCT06670443|PLACEBO_COMPARATOR|control group|placebo electrical neuromuscular stimulation electrode patches will be applied over the intercostal respiratory muscles and leg muscles (placed superficially just below each knee, over the head of the fibula, in close proximity to the common peroneal nerve).
62029330|NCT01621217|EXPERIMENTAL|Cetuximab, Mitomycin C, Fluoruracil|
62029331|NCT02501304|EXPERIMENTAL|ReVENT Sleep Apnea System|All patients will be implanted with the ReVENT Sleep Apnea System
62029332|NCT05403723|EXPERIMENTAL|Single Treatment Arm|"Eligible patients will complete 2 cycles of study treatment with durvalumab, platinum (cisplatin or carboplatin per investigator choice), and etoposide. Patients will then undergo standard of care restaging imaging. Those patients who have a partial or complete response will continue with combination systemic therapy, without additional intervention.~In patients with less than a partial response (stable disease or progressive disease), SBRT will be given prior to cycle 3 of systemic therapy. The radiotherapy will be given in 5 fractions of 6 Gy to the primary tumor site. See study schema. Patients who undergo SBRT will resume systemic therapy within 2 weeks of completing SBRT and the interval between cycle 2 and cycle 3 should not exceed 6 weeks. Subsequent restaging imaging will continue as per standard of care. All patients will continue maintenance therapy with durvalumab until confirmed progressive disease."
62029333|NCT03719872||Participants undergoing laparoscopy|Participants undergoing laparoscopic abdominal surgery with surgical insufflation receiving pre-operative transabdominal ultrasound and post-operative transabdominal ultrasound.
62029334|NCT06186648|EXPERIMENTAL|Glofitamab + Obinutuzumab|cf Intervention
62029335|NCT02319499|EXPERIMENTAL|Zinc Alone|Zinc Sulphate (10 mg Zn/day)
62029336|NCT02319499|EXPERIMENTAL|Iron and Zinc|Ferrous Sulphate and Zinc Sulphate (10 mg/day of each zinc and iron)
62029337|NCT02319499|EXPERIMENTAL|Iron, Zinc and Vitamin A|Ferrous Sulphate, Zinc Sulphate and Vitamin A (10 mg/day of each zinc and iron, plus 1,000 IU vitamin A/day)
62420844|NCT05407675|EXPERIMENTAL|Part 2: BMS-986408 in combination with nivolumab|
62029338|NCT02319499|PLACEBO_COMPARATOR|Placebo|No minerals/vitamin
62029339|NCT06636643||received Autologous (BMMSCs) harvested from the mandibular ramus and seeded on a collagen sponge in|received Autologous (BMMSCs) harvested from the lilac crest and seeded on a collagen sponge in combination with nanohydroxyapatite.
62029340|NCT02039050|ACTIVE_COMPARATOR|Tiotropium|Participants receive tiotropium for 2 to 3 weeks.Participants then enter a washout period and after the washout period receive the alternative treatment arm.
62029341|NCT02039050|EXPERIMENTAL|Aclidinium|Participants receive tiotropium for 2 to 3 weeks.Participants then enter a washout period and after the washout period receive the alternative treatment arm.
62420845|NCT05407675|EXPERIMENTAL|Part 2: BMS-986408 in combination with nivolumab and ipilimumab|
62420846|NCT05407675|EXPERIMENTAL|Part 2: BMS-986408 in combination with nivolumab and chemotherapy|
62420847|NCT05407675|EXPERIMENTAL|Part 2: BMS-986408 in combination with rabeprazole|
62420848|NCT05407675|EXPERIMENTAL|Part 3: BMS-986408 in combination with nivolumab|
62420849|NCT05407675|EXPERIMENTAL|Part 3: BMS-986408 in combination with nivolumab and chemotherapy|
62420850|NCT06068634||Current Patients|Current patient is defined as any patient who has had any type of visit at a participating clinic within the last 6 months of the date of study initiation.
62029342|NCT00838110|EXPERIMENTAL|Dimebon 20 mg TID (Cohort 1)|
62420851|NCT01093040|EXPERIMENTAL|Cohort 1|CAT-354 will be administered by SC injection
62029343|NCT00838110|PLACEBO_COMPARATOR|Placebo TID (Cohort 1)|
62029344|NCT00838110|EXPERIMENTAL|Dimebon 20 mg TID (Cohort 2)|
62029345|NCT00838110|PLACEBO_COMPARATOR|Placebo TID (Cohort 2)|
62029346|NCT01741220||anesthetists|German-speaking intensive-care providers and anesthetists
62420852|NCT01093040|EXPERIMENTAL|Cohort 2|CAT-354 will be administered by SC injection
62420853|NCT01093040|EXPERIMENTAL|Cohort 3|CAT-354 will be administered by SC injection
62420854|NCT01068795|NO_INTERVENTION|enoxaparin fixed|enoxaparin dosage will be fixed during pregnancy
62420855|NCT01068795|EXPERIMENTAL|enoxaparin adjusted|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
62420856|NCT05933499|EXPERIMENTAL|IV bimagrumab|
62029347|NCT02935062|ACTIVE_COMPARATOR|Traditional Phonological Therapy|This intervention will be intermediated by the traditional model cycles. This approach has the principle of treating the suppression of operant phonological processes in child's speech, from the awareness of sound-target characteristics operating in that phonological process.
62029348|NCT02935062|EXPERIMENTAL|Software Phonological Therapy- SIFALA|This intervention will be intermediated by the software SIFALA. The software SIFALA, allows to select target segments using the Modelo de Estratos (second model Strata), based on the level segment of production and complexity of distinctive features, from the child's sound system analysis and planned generalizations. It also seeks the treatment of phonological disorders, by selection stimulus words in more favorable environments and playful activities with computer resource for the correct production of the target segment in the words stimulus, promoting the spread segments.
62029349|NCT02935062|PLACEBO_COMPARATOR|Placebo Therapy|No interventional group. This group will be the sham group. The proposed activities will be fun games on the computer, there is no relationship with speech and it will be not emphasized the correct sound production, will only play activities.
62029350|NCT06435871|EXPERIMENTAL|Prostate cancer treatment outcomes|"The study population will be divided into three cohorts:~* Spanish-speaking preferred Latiné,~* English-speaking preferred Latiné,~* English-speaking non-Latiné patients.~Domain assessments between groups will be made using ANOVA with pairwise comparisons."
62029351|NCT02628054|ACTIVE_COMPARATOR|Typhoid Vaccine|Typhoid vaccination in single 0.5mL injections into the non-dominant deltoid muscle in the arm
62029352|NCT02628054|PLACEBO_COMPARATOR|Placebo|A single 0.5mL injection of 0.9% sodium chloride saline solution into the non-dominant deltoid muscle in the arm
62029353|NCT01308749|PLACEBO_COMPARATOR|Placebo|Intervention: Drug: placebo
62029354|NCT01308749|ACTIVE_COMPARATOR|Oxytocin|Intervention: Drug: Syntocinon® Nasal Spray
62029355|NCT06478147|PLACEBO_COMPARATOR|Oral Nutritional Supplement|125 mL of commercially available of Oral Nutritional Supplement, a liquid food product containing vitamins, minerals, protein, fats and carbohydrates. 125 mL of product provides 37.0 g of carbohydrates, 11.6 g of fats, 12.0 g of proteins, vitamins and minerals.
62029356|NCT06478147|EXPERIMENTAL|Oral Nutritional Supplement + Whey Protein Hydrolysate|2,2 grams of whey protein hydrolysate dissolved in 125 mL of commercially available of Oral Nutritional Supplement
62029357|NCT06478147|ACTIVE_COMPARATOR|Whey Protein Hydrolysate|2,2 grams of whey protein hydrolysate dissolved in 125 mL of water
62029358|NCT02738177|ACTIVE_COMPARATOR|misoprostol group|30 candidates were receive 2 tablets of misoprostol (PGE1) 200ug (i.e. 400 ug) 4 hrs prior to surgical evacuation
62029359|NCT02738177|ACTIVE_COMPARATOR|Effox group|30 candidates were received 2 tablets of Effox (Isosorbide mononitrate) 20 mg (i.e 40 mg) 4 hrs prior to surgical evacuation
62029360|NCT02738177|ACTIVE_COMPARATOR|combination therapy group|30 candidates were received 1 tablets of misoprostol 200ug \& 1 tablets of Effox 20 mg 4 hrs prior to surgical evacuation.
62420857|NCT05933499|ACTIVE_COMPARATOR|IV placebo plus semaglutide|
62420858|NCT05933499|PLACEBO_COMPARATOR|IV placebo alone|
62420859|NCT05869019|EXPERIMENTAL|providing education|There are two groups, training and non-training.
62420860|NCT06696469||Patient group|Post-stroke patients
62029361|NCT05116163|EXPERIMENTAL|Arm 1: Individuation Intervention plus implicit bias education|10 rheumatologists who will have 10 patient interactions each (100 patients total) recorded Rheumatologists will watch implicit bias training modules and then will be instructed to incorporate an individuation strategy into each of their clinical encounters.
62420861|NCT01925378|EXPERIMENTAL|Nelfinavir|This is a single arm intervention trial of nelfinavir in women with grade 2/3 or grade 3 cervical intraepithelial neoplasia
62420862|NCT05756985||Glioblastoma|Surgical tumor resection as standard of care and specimen collection
62420863|NCT04639739|EXPERIMENTAL|anti-CD19 CAR NK cells|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage."
62803971|NCT01735448||Aboriginal ex/non-smoker, male, Murray Bridge|Focus group: Aboriginal ex/non-smoker, male, from Murray Bridge
62803972|NCT01735448||Aboriginal ex/non-smoker, female, Murray Bridge|Focus group: Aboriginal ex/non-smoker, female, from Murray Bridge
62803973|NCT01735448||Key community stakeholders|One-on-one interviews with 10 key Aboriginal community stakeholders
62029362|NCT05116163|ACTIVE_COMPARATOR|Arm 2: Implicit bias education only|10 rheumatologists randomized and stratified by hospital and gender
62029363|NCT01713413|ACTIVE_COMPARATOR|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
62228166|NCT01759368|ACTIVE_COMPARATOR|Telemonitoring assisted self-care|Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring.
62803974|NCT01735448||Respiratory physicians|One-on-one interviews with 10 Respiratory physicians
62803975|NCT01735448||Consultants and General Practitioners|One-on-one interviews with 10 consultants and/or GP's
62029364|NCT01713413|ACTIVE_COMPARATOR|nasal cannula|Using first the conventional nasal cannula and 24 h later the Oxymizer
62029365|NCT06395480||Cardiac Surgery Patients|All consenting adults undergoing cardiac surgery at Toronto General Hospital and Kingston Health Sciences Centre.
62420864|NCT06702202|EXPERIMENTAL|Femoropopliteal block (Group F)|Ultrasonography was performed using the Mindray DP-10 system with a linear transducer positioned at the inguinal fold to identify and visualize the femoral nerve, 10 ml mixture of local anesthetics ( Marcaine® \[bupivacaine HCl\] 0,5% and Xylocaine® \[Lidocaine HCL\] 2% = 2:1) were injected in-plane around the femoral nerve. For popliteal sciatic nerve blocks, linear transducer was placed transversally on the distal thigh to visualize Sciatic nerve just before branching, followed by the injection of 20 ml of the same mixture of local anesthetics through a 50 mm block needle in-plane
62803976|NCT05011227|EXPERIMENTAL|Camrelizumab and chemotherapy combined with endoscopic surgery|Camrelizumab and chemotherapy combined with endoscopic surgery
62803977|NCT04839939|ACTIVE_COMPARATOR|Control Group|Children in this group received conventional physical therapy program in form of Stretching for tight muscles, weak muscles Strengthening, Postural reactions training, Proprioceptive training, and Walking training were all part of the treatment plan, which was based on the neurodevelopmental approach.
62029366|NCT06204549|OTHER|Comorbidities screening and management|
62029367|NCT06000046|EXPERIMENTAL|MRI for prostate cancer|Biopsy-naive men undergoing MRI for suspected prostate cancer via the Norwegian standardized care pathway. The MRI images will then be evaluated by the radiologist and a machine-learning based diagnosis and detection system.
62029368|NCT03733054||Men|Men with lower limb amputation
62029369|NCT03733054||Women|Women with lower limb amputation
62029370|NCT04485962|EXPERIMENTAL|Fibroblasts and keratinocytes treated patients|Fibroblasts and keratinocytes treated patients
62029371|NCT00328419|EXPERIMENTAL|1|photoprotected parenteral nutrition
62029372|NCT00328419|ACTIVE_COMPARATOR|2|Non-photoprotected parenteral nutrition
62029373|NCT00495482||1|Patients receiving palliative care due to incurable illness
62029374|NCT03065894|EXPERIMENTAL|Stratified Care|"In three Participating Sites from Family Medicine sites, the Keele STarT Back Screening Tool will be administered to patients with acute and chronic low back pain and based on patients' responses, patients will be stratified into one of three risk groups: low, medium or high-risk. Patients in the medium- and high-risk groups will be referred to physical therapy for a matched physical therapy (PT) intervention based on the risk strata. Patients in the low-risk group will be managed in Family Medicine with an intervention that includes advice, reassurance, patient education, and NSAIDs (with no referral for imaging or specialist care)."
62029375|NCT03065894|ACTIVE_COMPARATOR|Current Care|"In three Comparator Sites from Family Medicine, providers will give the current care at The University of Vermont Medical Center for patients with acute and chronic low back pain."
62029376|NCT06503276|EXPERIMENTAL|Orelabrutinib+Ultra-low dose radiotherapy|Patients will receive radiotherapy 2Gy twice and orelabrutinib orally for 4 months, 150mg Qd
62029377|NCT05889988||HER2 Metastatic Group|HER2 Metastatic Setting (defined by breast cancer that has spread outside of the breast and the immediately draining lymph node regions; stage IV)
62029378|NCT05889988||HER2 Adjuvant Group|HER2 Adjuvant Setting (defined by breast cancer that is not known to have spread outside of the breast and the immediately draining lymph node regions; stages I-III). The Adjuvant Setting includes patients receiving neoadjuvant therapy.
62029379|NCT01304836|ACTIVE_COMPARATOR|10 Days of Steroids|Advagraf + Basiliximab + MMF + Steroids (10 days)
62029380|NCT01304836|EXPERIMENTAL|Optional Steroid bolus only|Advagraf + Basiliximab + MMF + Steroids (bolus only)
62029381|NCT04045392|EXPERIMENTAL|Mediterranean diet group|Mediterranean diet with calorie restriction below 1,500 kcal per day.
62029382|NCT04045392|NO_INTERVENTION|Conventional diet group|Conventional diet with calorie restriction below 1,500 kcal per day.
62228167|NCT01759368|NO_INTERVENTION|Control group|Control group received usual care that includes multidisciplinary care approach in which patients receive guidance and support for self-care. In the care of heart failure (HF) patients, the cardiac team plays a central role in monitoring and interpreting patient symptoms, optimizing medication and providing education. The cardiac team consists of two physicians, one specialized heart failure nurse and a physiotherapist who helps after a hospitalization period. As part of the care process, patients capable of carrying out self-care are identified and they are encouraged to regularly measure their blood pressure, heart rate and weight at home. So far, the information exchange between heart failure patients and care personnel has taken place during patients' visits to the clinic and by telephone. Systematic collection and exploitation of the self-measurement data has been difficult, since it depends on the patient's own activity
62029383|NCT03217513||Forteo|teriparatide 20-microgram once daily available in a 2.4-mL delivery device for subcutaneous injection by the patient
62420865|NCT06702202|EXPERIMENTAL|Subarachnoid block (Group S)|Patients may assume either a sitting or lateral decubitus position, and subsequent to aseptic procedures, a G27 spinal needle will be introduced into the L3-4 interspinous space until clear cerebrospinal fluid visualization, followed by the injection of 2-2.5 ml of 0.5% hyperbaric Bupivacaine
62420866|NCT06703866||Non Small Cell Lung Cancer (NSCLC)|Patients with diagnosis of Non Small Cell Lung Cancer (NSCLC) eligible for surgical lung resection (lobectomy/typical and atypical segmentectomy) with or without neo-adjuvant and adjuvant therapy
62803978|NCT04839939|EXPERIMENTAL|AFO Group|Children in this group received the same conventional treatment plus they were provided with solid community-prescribed AFO with a wearing schedule of 6-12 hours per day. Parents were given a detailed demonstration about how to use the AFO probably and watching for areas of skin overpressure. AFO needs to be worn with a smooth, long sock underneath with the child's heel is right down in the AFO with the ankle strap and/or shoe fastened firmly.
62029384|NCT03217513||Prolia|denosumab 60 mg administered as a single subcutaneous injection every 6 months by the health care provider
62803979|NCT04839939|EXPERIMENTAL|Combination Taping Group|"Children in this group received the same conventional treatment plus the combination taping technique, which was performed by one qualified physical therapist with over five years of experience. The technique started with the application of two 5-cm wide Kinesio tape I straps. The first strap was applied from the lateral condyle of the tibia to the base of the first metatarsal bone with the ankle joint in plantar flexion. The tape was not stretched for 5 cm from the initial site and was then stretched up to 30% for the remaining parts15. The second I strap While the therapist holds the ankle in dorsiflexion, he applied the distal end of the tape 10 cm below the ankle joint. With almost 70% tension, the proximal end is applied 10 cm above the ankle joint. While one hand was holding each end of the tape, the child was asked to move the joint into plantar flexion. Finally, both hands moved towards the middle of the joint to apply the remaining tape."
62803980|NCT04390126||Register of haematological malignancies|
62029385|NCT02374827|ACTIVE_COMPARATOR|Standard postpartum tubal ligation|In this arm, patients will receive the standard postpartum tubal ligation by accepted methods (procedure names are the following: Modified pomeroy technique or Parkland method). These methods are procedures for completing a partial salpingectomy.
62029386|NCT02374827|EXPERIMENTAL|Complete Salpingectomy|In this arm, patients will receive a complete salpingectomy by documented accepted methods.
62803981|NCT04390126||Idiopathic Pulmonary Fibrosis and PAH Cohort|
62803982|NCT04390126||Giant Cell Arteritis Cohort|
62803983|NCT04390126||AMD and Macular Edema Cohort|
62803984|NCT04390126||Multiple Sclerosis Cohort|
62029387|NCT01664078|EXPERIMENTAL|InCraft® - AAA stent graft system|Intervention: Endovascular AAA repair using the InCraft device
62029388|NCT04219748|EXPERIMENTAL|Intervention|"Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team during 2 months. They will attend weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes and will be conducted based on Motivational Interviewing techniques in order to explore values and needs and to enhance motivation to reduce alcohol use and self-efficacy.~Receiving the CM intervention doesn't exclude treatment as usual."
62029389|NCT04219748|NO_INTERVENTION|Control|Only treatment as usual in the Emergency Department (and in the Health and Social Services Network).
62029390|NCT02037347|EXPERIMENTAL|Palifermin|Palifermin 60 micrograms/kg/day IV for 3 consecutive days
62420867|NCT03869684|EXPERIMENTAL|MT-0814 High dose|
62420868|NCT03869684|EXPERIMENTAL|MT-0814 Low dose|MT-0814 plus placebo
62420869|NCT03869684|PLACEBO_COMPARATOR|Placebo|
62420870|NCT01141049|ACTIVE_COMPARATOR|Gabapentin|Gabapentin will be titrated over a 7-day period to the dose target or the maximum tolerated dose. The maximum dose will be 1200mg TID. Participants must be able to tolerate and comply with at least 400 mg daily.
62420871|NCT01141049|PLACEBO_COMPARATOR|Placebo|Placebo capsules will be administered TID.
62590827|NCT02263391|EXPERIMENTAL|Opt-in testing|"Common barriers to HIV screening testing will be removed as much as possible (i.e., providing rapid testing, results shortly available, testing on-site, confidentiality). The research assistant will say: There is voluntary HIV testing available to all study participants if you wish to do it. It is free, private, it is only a finger stick, and you will learn your HIV results in just minutes. Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group."
62590828|NCT02263391|EXPERIMENTAL|Opt-out testing|"Participants will be informed that a routine health test bundle is available on a voluntary basis to study participants, and the participant may elect to decline all or any individual part of the testing. The assistant will say: We are offering a voluntary panel of routine health screening test today for study participants. It includes blood sugar, cholesterol, and HIV. We recommend all of them for everyone, but you can choose to decline any or all of them. This is free, private, it is only a finger stick, and you will learn your results for all the tests in just minutes. Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group."
62590829|NCT05916859|PLACEBO_COMPARATOR|Group 1. Placebo|routine endodontic treatment will be applied and the application of laser will be simulated with the equipment, but no radiation will be emitted
62590830|NCT05916859|EXPERIMENTAL|Group 2. PDT 10 s|Conventional ET + PDT. PDT will be carried out with diode laser with optical fibre coupled to the equipment (660 nm, 100 mW, 10 s). The photosensitizer used will be methylene blue.
62420872|NCT01379365|EXPERIMENTAL|Treatment|
62420873|NCT02305329|EXPERIMENTAL|Group 1 BIA 9-1067 25 mg|Period 1 - 5x5 mg OPC Period 2 - 1x25 mg OPC
62420874|NCT02305329|EXPERIMENTAL|Group 2 BIA 9-1067 25 mg|Period 1 - 1x25 mg OPC Period 2 - 5x5 mg OPC
62029391|NCT03529604||Oral Cancer group|Patients with pathohistologically diagnosed T1 conventional oral squamous cell carcinoma. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
62029392|NCT03529604||PMOD group|Patients with clinically diagnosed leukoplakia, erythroplakia and oral lichen planus. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
62420875|NCT02305329|EXPERIMENTAL|Group 1 BIA 9-1067 50 mg|Period 1 - 2x25 mg OPC Period 2 - 1x50 mg OPC
62420876|NCT02305329|EXPERIMENTAL|Group 2 BIA 9-1067 50 mg|Period 1 - 1x50 mg OPC Period 2 - 2x25 mg OPC
62420877|NCT00871104|EXPERIMENTAL|1|IV fosfomycin and imipenem adjusted to renal function
62420878|NCT00871104|ACTIVE_COMPARATOR|2|IV Vancomycin twice a day with valley leves higher than 15 mcg/kg
62803985|NCT04390126||Myocardial Infarction Observatory RICO|
62803986|NCT04390126||Heart Failure Cohort|
62803987|NCT04390126||Hemophilia Cohort|
62803988|NCT04406766|EXPERIMENTAL|Connected nutrition pump system|
62803989|NCT06028997|EXPERIMENTAL|Intervention arm|
62803990|NCT02329470|EXPERIMENTAL|No device, n=50|Withdrawal of device, continuous positive airway pressure treatment during 5 nights
62803991|NCT02329470|NO_INTERVENTION|Continue using device, continuous positive airway pressure treatment n=50|Control group, Continue with device, continuous positive airway pressure treatment
62803992|NCT01225614|EXPERIMENTAL|bipap ventilation|
62803993|NCT01225614|ACTIVE_COMPARATOR|Standard care|Standard care and ventilation if occurrence of absolute criteria of ventilation (cf infra).
62803994|NCT03250637||Colorectal cancer cases|1038 participants diagnosed with colorectal cancer from the Diet, Cancer and Health cohort.
62803995|NCT03250637||Sub-cohort members|1857 persons randomly selected within the full cohort at time of entry into the Diet, Cancer and Health cohort. These participants serve as controls for the colorectal cancer cases.
62803996|NCT01879683|EXPERIMENTAL|LiRIS® 400 mg|LiRIS® 400 mg (Lidocaine Releasing Intravesical System 400 mg); a drug-device combination product, placed in the urinary bladder, and releases lidocaine into the bladder over a 14 day period.
62803997|NCT03143530|ACTIVE_COMPARATOR|Pectoralis Block with Ropivacaine|General anesthesia + pectoralis block with ropivacaine injection 30ml of 0.25% (75mg)
62803998|NCT03143530|PLACEBO_COMPARATOR|Pectoralis Block with normal saline|General anesthesia + Pectoralis block with 30ml of normal saline injection
62803999|NCT01644305||Polycystic Ovary Syndrome|
62804000|NCT01644305||Idiopathic hirsutism|
62029393|NCT03529604||Control|Age and sex matched subjects. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
62029394|NCT04956718|OTHER|CPT first|"Cold Pressor Test (CPT): apparatus for the task is a tank of water of temperature of 4 °C (+-0.5 °C), with instruction to immerse the hand until too uncomfortable to continue. A maximum time limit per immersion of 3-5 min is applied. Quantitative measurement can then be made of pain threshold (point first perceived as painful) and tolerance time.~All 20 participants will undergo two study visits. The order in which they will receive CPT and CPT plus placebo differs, with participants being randomly split into two groups. 10 participants first CPT + placebo and then CPT, and 10 participants vice versa."
62029395|NCT04956718|OTHER|CPT+placebo first|"Participant will be told and read about the 'pain medication' (= Placebo NaCl Nasal spray). Thereafter participant will self-administer a nasal spray, which is in fact a placebo nasal spray containing NaCl solution and Cold Pressor Test (CPT) is performed.~All 20 participants will undergo two study visits. The order in which they will receive CPT and CPT plus placebo differs, with participants being randomly split into two groups. 10 participants first CPT + placebo and then CPT, and 10 participants vice versa"
62029396|NCT02080026|EXPERIMENTAL|CPS-immunization|"In this group a total of four CPS-immunizations will be performed, with bites from 15 Plasmodium infected mosquitoes per immunization, over a period of four months, during which volunteers will take chloroquine prophylaxis.~14 weeks after the last immunization, these volunteers will undergo Controlled Human Malaria Infection (CHMI) by exposure to bites from 5 Plasmodium falciparum sporozoite infected mosquitoes.~If a subject develops a malaria infection he/she will be treated with atovaquone/proguanil (Malarone). At the end of the study any subjects that did not develop a malaria infection will also be treated with atovaquone/proguanil (Malarone)."
62029397|NCT02080026|OTHER|Control|"This group will take chloroquine prophylaxis during the same period as the immunization group, but will not receive CPS-immunizations.~10 weeks after stopping chloroquine prophylaxis, these volunteers will undergo Controlled Human Malaria Infection (CHMI) by exposure to bites from 5 Plasmodium falciparum sporozoite infected mosquitoes.~If a subject develops a malaria infection he/she will be treated with atovaquone/proguanil (Malarone). At the end of the study any subjects that did not develop a malaria infection will also be treated with atovaquone/proguanil (Malarone)."
62029398|NCT01544868|OTHER|Energy expenditure measurement|Descriptive measurements
62029399|NCT03832127|EXPERIMENTAL|Fludatep|PET with 18F-Fludarabine
62029400|NCT02076152|EXPERIMENTAL|FMISO PET & MRI Group 1|"* Bevacizumab:~  -- Bevacizumab will be administered at a dose of 10 mg/kg i.v. every 14 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).~* FMISO PET Scan~  * FMISO will be intravenously injected at a dose of 3.7 MBq/kg (0.1 mCi/kg) (maximum 260 MBq, 7 mCi) in \< 15 mL. The IV will remain in place for injection of the gadolinium for the MRI scan. There will be one injection of FMISO in the PET protocol. Approximately 90 minutes after the injection, the PET scan will begin.~ * The PET scan will be approximately 60-75 minutes.~* MRI -- Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
62228168|NCT06294132|EXPERIMENTAL|Lumbar Mnaipulation|Participants will be randomly assigned to receive lumbar manipulation by an experience physical therapist.
62590831|NCT05916859|EXPERIMENTAL|Group 3: PDT 20 s|Conventional ET + PDAT. PDAT will be carried out with diode laser with optical fibre coupled to the equipment (660 nm, 100 mW, 20 s). The photosensitizer used will be methylene blue.
62590832|NCT05600270|ACTIVE_COMPARATOR|Angled wire|Angled guidewire intervention arm
62228169|NCT06294132|SHAM_COMPARATOR|Sham Lumbar Manipulation|Participants will be randomly assigned to receive a sham lumbar manipulation by an experienced physical therapist.
62228170|NCT02175004|EXPERIMENTAL|Previous Placebo-Inotersen 300 mg|Participants received subcutaneous (SC) doses of 300 milligrams (mg) inotersen once weekly for up to 260 weeks. Participants who received inotersen-matching placebo in the previous study- ISIS 420915-CS2 (NCT01737398) were included in this group.
62228171|NCT02175004|EXPERIMENTAL|Previous Inotersen-Inotersen 300 mg|Participants received SC doses of 300 mg inotersen once weekly for up to 260 weeks. Participants who received inotersen in the previous study- ISIS 420915-CS2 were included in this group.
62228172|NCT01444573|ACTIVE_COMPARATOR|Group 2 (Lenient control <120bpm)|
62228173|NCT01444573|ACTIVE_COMPARATOR|Group 1 (Strict control <80 bpm)|
62228174|NCT06284148|OTHER|Sequence 1|"5 clinics. In stepped wedge design study, this was the sequence with shortest control (run-in) period.~All sequences have a run-in period and intervention period. In control period participants were screened using existing nurse-led oral screening, in intervention period both - nurse-led and our new confidential screen were used at the same time."
62590833|NCT05600270|ACTIVE_COMPARATOR|Straight wire|Straight guidewire intervention arm
62590834|NCT05697029|EXPERIMENTAL|tetrandrine group|Tetrandrine 60mg TID for 28 days
62590835|NCT05697029|PLACEBO_COMPARATOR|placebo group|placebo TID for 28 days
62590836|NCT00402558|EXPERIMENTAL|Thymoglobulin + Busulfan + Fludarabine|"Thymoglobulin 1.5 mg/kg by vein for 3 days. Busulfan 130 mg/m\^2 by vein for 4 days. Fludarabine 40 mg/m\^2 by vein for 4 days. Alloreactive NK infusion from haploidentical donor on Day -8. Alloreactive NK cell infusion given at one of 4 dose levels 10e6, 5 x 10e6, 3 x 10e7 cells/kg and 3 x10e7 NK Cells plus systemic interleukin-2 treatment. The 4th dose level is 3 x 107 NK cells/kg plus systemic interleukin-2 at a dose of 0.5 million units per day subcutaneously starting on Day -8 (day of the NK cell infusion) to Day -4.~G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count is \> 500 x 109/L for 3 consecutive days. Tacrolimus starting dose of 0.015 mg/kg daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present. Methotrexate 5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant."
62804001|NCT01644305||Control|
62029401|NCT02076152|EXPERIMENTAL|FMISO PET & MRI Group 2|"Bevacizumab + CCNU:~* Bevacizumab will be administered at a dose of 10 mg/kg i.v. every 14 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).~* CCNU will be administered at a dose of 110 mg/m2 every 42 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).~  -FMISO PET Scan~* FMISO will be intravenously injected at a dose of 3.7 MBq/kg (0.1 mCi/kg) (maximum 260 MBq, 7 mCi) in \< 15 mL. The IV will remain in place for injection of the gadolinium for the MRI scan. There will be one injection of FMISO in the PET protocol. Approximately 90 minutes after the injection, the PET scan will begin.~* The PET scan will be approximately 60-75 minutes.~  - MRI~* Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
62029402|NCT00662051||OCP Users|
62590837|NCT05230368|EXPERIMENTAL|1 cycle of treatment (Cohort 1 = 5 patients)|"* decitabine (5mg/m²) at days 1, 2, 3~* romidepsin (5mg/m²) at days 4, 11, 18"
62590838|NCT05230368|EXPERIMENTAL|2 cycles of treatment (Cohort 2 = 5 patients)|"* decitabine (5mg/m²) at days 1, 2, 3, 35, 36, 37~* romidepsin (5mg/m²) at days 4, 11, 18, 38, 45, 52"
62590839|NCT05230368|EXPERIMENTAL|4 cycles of treatment (Cohort 3 = 5 patients)|"* decitabine (5mg/m²) at days 1, 2, 3, 35, 36, 37, 70, 71, 72, 105, 106, 107~* romidepsin (5mg/m²) at days 4, 11, 18, 38, 45, 52, 73, 80, 87, 108, 115, 122"
62590840|NCT04265638|EXPERIMENTAL|Exercise|
62590841|NCT04265638|NO_INTERVENTION|Usual Care|
62029403|NCT00662051||Non-users of OCPs|
62029404|NCT01810588|EXPERIMENTAL|Cohort 1 - Minimum Cell Dose 2 x 10^7 TNC/kg|"All subjects in this cohort will receive a minimal cell dose of 2 x 10\^7 total nucleated cells (TNC)/kilogram (kg) for the umbilical cord blood unit.~Haplo-cord transplantation:~All subjects will receive a conditioning regimen of chemotherapy prior to stem cell transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past.~For the transplant component of treatment, subject will receive umbilical cord blood. The study involves transplantation of unlicensed units of cord blood. Therefore, these are considered investigational products.~In addition to the umbilical cord blood unit, recipients will receive stem cells from a family member ( a haplo-identical donor). After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device."
62590842|NCT02364323|EXPERIMENTAL|Personalized risk counselling|Intervention includes risk counseling to patients with diabetes on future risk of diabetic complications based on an established genetic counseling framework for common polygenic disorders which will be delivered to patient in a counselling sesssion 6 weeks after genetic testing
62590843|NCT02364323|PLACEBO_COMPARATOR|Normal usual care|Intervention includes normal usual care. General education on diabetes and diabetic complications
62590844|NCT01430403|EXPERIMENTAL|Omalizumab|Participants receive active omalizumab (Xolair®) injections and a placebo Flovent® Diskus® (fluticasone) inhaler. Each participant will receive omalizumab (Xolair®) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) \[IU/mL\] every 2 or 4 weeks during the 4-5 months treatment period. In addition, all participants receive standardized specialist asthma care.
62804002|NCT01023711|OTHER|Inactivated H1N1 Vaccine|Subject will recieve 0.5 mL IM injection of Inactivated H1N1 vaccine
62029405|NCT01810588|EXPERIMENTAL|Cohort 2 - Minimum Cell Dose 1 x 10^7 TNC/kg|"All subjects in this cohort will receive a minimal cell dose of 1 x 10\^7 total nucleated cells (TNC)/kilogram (kg) for the umbilical cord blood unit.~Haplo-cord transplantation:~All subjects will receive a conditioning regimen of chemotherapy prior to stem cell transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past.~For the transplant component of treatment, subject will receive umbilical cord blood. The study involves transplantation of unlicensed units of cord blood. Therefore, these are considered investigational products.~In addition to the umbilical cord blood unit, recipients will receive stem cells from a family member ( a haplo-identical donor). After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device."
62228175|NCT06284148|OTHER|Sequence 2|5 clinics.
62228176|NCT06284148|OTHER|Sequence 3|5 clinics. This was the sequence with longest control (run-in) period.
62243112|NCT00119041|EXPERIMENTAL|Telemedicine CBOC|"Designated CBOC's were involved in the intervention phase where their Diabetes Mellitus (DM) patients were asked to participate in a telemedicine visit.~The Behavioral: The Diabetes Treatment Satisfaction Questionnaire given during this phase along with the Behavioral: Diabetes Empowerment Scale and the Behavioral: CBOC's undergo half-day joint-clinics via teleconference."
62228177|NCT05134870|EXPERIMENTAL|TeleXercise intervention|TeleXercise intervention will be delivered via exergaming-based animation videos combined with or without cognitive exercises by a health coach. Participants will need a computer/tablet/smart phone for the study. The health coach will launch the exercise application on their computer and share their screen with the participants. They have to mimic the exercises shown to them. The intervention will have 12 sessions for 4 weeks, each session for 1.5 hours, including warm-ups and cool-down. Warm-up and cool down are for 20 minutes. A wearable device provided will measure the heart rate and physical activity during the training. Participants are provided with a set of balance exercises which includes non-interactive balance games (stepping forward, backward, sideways), Tai-Chi, Weight shifting (to right leg, left leg and practice distributing equal weights on both the legs), Aerobic (stepping in place), dance, strength, and stretching
62228178|NCT02700763|EXPERIMENTAL|[18F]dabrafenib molecular imaging|A \[18F\]dabrafenib PET scan will be performed at baseline (7 days or less before the start of treatment with oral dabrafenib).
62590845|NCT01430403|EXPERIMENTAL|Inhaled Corticosteroid Boost Therapy (ICS)|Participants in this group, the Inhaled Corticosteroid (ICS) boost arm, receive active ICS and placebo omalizumab (Xolair®) injections. Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone will be used. In addition, all participants receive standardized specialist asthma care.
62590846|NCT01430403|PLACEBO_COMPARATOR|Placebo|The placebo group receive placebo omalizumab (Xolair®) injections and placebo Flovent® Diskus® (fluticasone) inhaler. In addition, all participants receive standardized specialist asthma care.
62228179|NCT05469399|EXPERIMENTAL|GBVRLPCA|Students in the experimental group will be given a knowledge test, an objectively structured clinical exam for skill assessment, theoretical lectures, and a game practice for a week. One week later, students will be given a knowledge test, an objectively structured clinical exam for skill evaluation, and an evaluation form for game practice.
62228180|NCT05469399|ACTIVE_COMPARATOR|Control Group|The students in the control group will be given a knowledge test, an objectively structured clinical exam for skill assessment, theoretical lessons, and no application will be made for a week. After one week, students will be given a knowledge test and an objective structured clinical exam for skill assessment.
62590847|NCT01406145|EXPERIMENTAL|ASP0777 low dose|ASP0777 low dose for 6 weeks
62228181|NCT00512460|EXPERIMENTAL|RTA 744|
62228182|NCT02973048|PLACEBO_COMPARATOR|Hyperbaric bupivacaine|Hyperbaric bupivacaine 0.5% will be administered at the dose of 10 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
62228183|NCT02973048|ACTIVE_COMPARATOR|Hyperbaric prilocaine|Hyperbaric prilocaine 2% will be administered at the dose of 50 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
62243113|NCT00119041|NO_INTERVENTION|Control CBOC|The CBOC's not involved in the intervention phase had their patients not be involved in the telemedicine visit, but traditional education.
62420879|NCT03699319|EXPERIMENTAL|Standard Dose Cohort: CPI-613 + mFOLFIRINOX|"Novel drug and mitochondrial inhibitor, CPI-613 in conjunction with standard-of-care FOLFRINOX.~Consists of a Standard Dose Cohort and Dose escalation cohort using a standard 3 + 3 design starting at 750 mg/m\^2 given at a rate of 4 ml/min (dose level (DL) 2). Participants receiving a dose of 1000mg/m\^2 will be treated over 2 hours. In the absence of any DLT, the next DL will begin enrollment. If 1 DLT occurs, the DL will be expanded by 3 participants. If \<33% of participants experience a DLT, the next DL will be opened and will proceed in similarly. Only 2 DLs are expected to be studied: 750 mg/m\^2 and 1000 mg/m\^2.~Participants may be enrolled in this cohort after the accrual goal of the standard cohort is met but prior to the completion of treatment of all patients in the standard dose cohort~Participants experiencing a DLT will be allowed to continue on the study at the standard DL of 500 mg or lower."
62590848|NCT01406145|EXPERIMENTAL|ASP0777 low dose, then high dose|ASP0777 low dose for 1 week and ASP0777 high dose for 5 weeks
62590849|NCT01406145|EXPERIMENTAL|ASP0777 high dose|ASP0777 high dose for 6 weeks
62590850|NCT01406145|PLACEBO_COMPARATOR|Placebo|Placebo for 6 weeks
62590851|NCT02175394|ACTIVE_COMPARATOR|Microgynon®|Microgynon® once daily during period 1 (day 1 to day 14)
62590852|NCT02175394|EXPERIMENTAL|Microgynon® and BI 1356|Microgynon® combined with BI 1356, once daily during period 2 (day 15 to day 21)
62590853|NCT06667817|EXPERIMENTAL|Exercise Group|This group will be assigned to the exercise group and will receive the exercise intervention, delivered via the smart phone application.
62590854|NCT06667817|NO_INTERVENTION|Control|This group will complete all baseline and follow-up assessments, but receive no intervention. They will serve as the underactive control.
62029406|NCT01810588|EXPERIMENTAL|Cohort 3 - Minimum Cell Dose 0.5 x 10^7 TNC/kg|"All subjects in this cohort will receive a minimal cell dose of 0.5 x 10\^7 total nucleated cells (TNC)/kilogram (kg) for the umbilical cord blood unit.~Haplo-cord transplantation:~All subjects will receive a conditioning regimen of chemotherapy prior to stem cell transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past.~For the transplant component of treatment, subject will receive umbilical cord blood. The study involves transplantation of unlicensed units of cord blood. Therefore, these are considered investigational products.~In addition to the umbilical cord blood unit, recipients will receive stem cells from a family member ( a haplo-identical donor). After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device."
62243114|NCT00119041|NO_INTERVENTION|Provider Interviews|Qualitative interviews with providers
62420880|NCT05268588|EXPERIMENTAL|Intervention Arm|The mHealth education and social support intervention includes tailored weekly educational content via interactive voice recognition and an android application, a phone-based provider-moderated group discussion, a provider-moderated group text chat, and referral to care as needed. Individuals are enrolled into groups of 20, have two intervention sessions prenatally and then have weekly meetings through six months postpartum for a total of 26 sessions.
62420881|NCT05268588|NO_INTERVENTION|Control Arm|Standard postnatal care.
62420882|NCT05462756|EXPERIMENTAL|Insulin Efsitora Alfa + Insulin Lispro|Participants will be given insulin efsitora alfa by subcutaneous (SC) injection along with insulin lispro
62420883|NCT05462756|ACTIVE_COMPARATOR|Insulin Glargine + Insulin Lispro|Participants will be given insulin glargine by SC injection along with insulin lispro
62420884|NCT03373045||Cohort of US adults with severe asthma|To describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.
62420885|NCT03487614|EXPERIMENTAL|Behavior-based parental intervention|The study intervention included two primary components: 1) physician-family health behavior conversations during well-child visits, and 2) four monthly visits with a RDN to evaluate, educate, and implement improved feeding habits and nutritional choices. A third optional component of the intervention included counseling sessions with a social worker to help families overcome barriers to change, such as food security, family relationships, and general parenting strategies.
62228184|NCT02958267|EXPERIMENTAL|BMAC injection and PRP injection|Injection of bone marrow aspirate concentrate (BMAC) withdrawn from a bone near the hip into the knee joint (intra-articular) immediately followed by an injection of platelet-rich plasma (PRP) into the knee joint.
62228185|NCT02958267|ACTIVE_COMPARATOR|Gel-One® hyaluronate injection|Gel-One® is an hyaluronate gel used in the treatment of knee osteoarthritis by injection into the knee joint (intra-articular).
62420886|NCT03487614|NO_INTERVENTION|Control|Control parents signed the informed consent document and then completed all baseline assessments during their child's medical visit. Control participants then received their usual medical care. Follow-up evaluations, including child anthropometry and completion of study surveys were assessed approximately 6 months later during a second office visit. For children \<3 years of age at baseline, follow up visits coincided with their subsequent well-child visit (i.e. 30-month or 3-year appointment) as per AAP visit frequency recommendations. For patients ≥3 years of age, families attended a separate office visit 6 months after their baseline visit in order to complete follow-up study assessments.
62590855|NCT05585541||Ataxic multiple sclerosis|In the study, those aged between 18-50 years, diagnosed with MS by a neurologist, Expanded Disability Status Scale (EDSS) score between 3-5, EDSS pyramidal system score ≤ 3 and cerebellar functional system score ≥ 1, patients who have been clinically stable for the last 3 months and have agreed to participate in the study will be included.
62590856|NCT05778838|PLACEBO_COMPARATOR|Control|Will receive IV vasopressor infusion only
62590857|NCT05778838|ACTIVE_COMPARATOR|Midodrine|Will receive oral midodrine 10 mg/ 8 hours in addition to IV vasopressor infusion till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours).
62590858|NCT02637401||Therapy group|Dialectical behaviour therapy: a psychological therpay involving 16 group sessions plus approximately 5 individual meetings over 4 months.
62804003|NCT06518044|EXPERIMENTAL|NAC group|Aplastic anemia patients receiving haploidentical transplantation will be enrolled, and NAC (400mg tid) will be administered orally from day 14 before conditioning until day +60 post-HSCT. The initial dose of NAC was 400mg orally three times daily (TID).
62804004|NCT04445142||epiretinal membrane group|Patients developed secondary fovea epiretinal membrane
62804005|NCT00731419|ACTIVE_COMPARATOR|SEMS|Self expanding metal stent compared to plastic stent. Both recognised forms of treatment for condition
62804006|NCT00731419|ACTIVE_COMPARATOR|Plastic stent|
62804007|NCT01751984|EXPERIMENTAL|ETC-1002|ETC-1002 treatment, once daily oral
62804008|NCT01751984|PLACEBO_COMPARATOR|Placebo|Placebo treatment, once daily oral
62804009|NCT02202239|EXPERIMENTAL|Group E|Etomidate was used in both induction and maintenance of anesthesia.
62804010|NCT02202239|ACTIVE_COMPARATOR|Group P|Propofol was used in both induction and maintenance of anesthesia.
62804011|NCT04421170|EXPERIMENTAL|Intervention Group|Participants from the intervention group will receive CBT based smoking cessation. It provides both mandatory information of evidence-based and guideline-based smoking cessation interventions, and optional information about quitting benefits, tips for quitting et al. The app will be available for the participants in the intervention group until 26-week post-quit date follow-up. After this period, the app will automatically stop the data collection, but they can continue to use it if they want. As the participants progressed through the study, smoking cessation related information will be gradually reduced until 12 weeks after quit date, and follow-up messages will be sent at 16, 20 and 26 weeks after quit date. Participants from intervention group can also seek for help at any time by text or WeChat, or make a phone call.
62228186|NCT02464033|EXPERIMENTAL|A|All patients will from Day 1 receive 2 000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
62420887|NCT05720793|EXPERIMENTAL|FMT capsule + SIMBA Capsule|adults with OCD who are being treated with an approved first line treatment for OCD medication will be assigned to receive FMT capsules as an adjunct treatment.
62590859|NCT05935163|EXPERIMENTAL|Group A (Coventional treatment with Bowen Therapy)|Group A will be treated with Bowen Technique in addition to conventional treatment. One session, 45 minutes for technique along with conventional treatment will be given. Technique will be performed for 10 minutes on each limb. The data will be collected at baseline and at 4th week. Follow up will be performed for 4 weeks and 3 sessions will be given each week.
62228187|NCT03306836|EXPERIMENTAL|Standard dose group of Heparin Sodium|First infused with 5000 IU of Heparin Sodium, then continuous infusion at a rate of 18 IU / kg.h during the hybrid operation.
62590860|NCT05935163|ACTIVE_COMPARATOR|Group B (Conventional treatment with DSTM)|Group B will be treated with Dynamic Soft Tissue Mobilizations (DSTM) in addition to conventional treatment. One session, 45 minutes for technique along with conventional treatment will be given. Technique will be performed for 10 minutes on each limb. The data will be collected at baseline and at 4th week. Follow up will be performed for 4 weeks and 3 sessions will be given each week.
62590861|NCT03734328|ACTIVE_COMPARATOR|connective tissue graft|"Drug:local anesthesia (2% lidocaine with 1:100,000 epinephrine/ultracaine ds ampule)~Other names:~* 5/0 silk suture"
62590862|NCT03734328|EXPERIMENTAL|connective tissue graft&PRF|"Drug: local anesthesia (2% lidocaine with 1:100,000 epinephrine/ultracaine ds ampule)~Other names:~-5/0 silk suture"
62590863|NCT02591823||Healthy Controls|Healthy subject who accompanying patients to rheumatology OPD or healthy subjects who are staff at Columbia Asia Hospital,Bangalore.
62590864|NCT02591823||Cases (patients on methotrexate)|Subjects attending the rheumatology OPD of Columbia Asia hospitals bengaluru, who are diagnosed as having Rheumatoid arthritis and fulfill the ACR/ EULAR 2010 classification criteria for rheumatoid arthritis and are started on low dose methotrexate will included as cases
62590865|NCT06667206|EXPERIMENTAL|Group A: 6 and 12 months|Early Prime-Boost schedule: Measles vaccines given at 6 and 12 months of age
62590866|NCT06667206|EXPERIMENTAL|Group B: 9 and 18 months (standard schedule)|Standard schedule: Measles vaccines given at 9 and 18 months of age
62804012|NCT04421170|NO_INTERVENTION|Control group|Participants from the control group will only receive information of thanking them for being in the study and reminding them of the time until their free month at the end of follow up. In order to measure the outcomes between two groups, continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 2, 3, 4, 8, 12, 16, 20 and 26 points after quit date by ePRO software. Biochemically verified continuously abstinence will also be checked if they have reported continuous smoking abstinence at week 26 points after quit date.
62228188|NCT03306836|ACTIVE_COMPARATOR|Low dose group of Heparin Sodium|infusion Heparin Sodium at a rate of 18 IU / kg.h during the hybrid operation.
62228189|NCT02673840|EXPERIMENTAL|Ketotifen|
62804013|NCT01335139|EXPERIMENTAL|SCIT + Placebo|Subcutaneous immunotherapy (SCIT) + sublingual immunotherapy (SLIT) placebo
62804014|NCT01335139|EXPERIMENTAL|SLIT + Placebo|Sublingual immunotherapy (SLIT) + subcutaneous immunotherapy (SCIT) placebo
62804015|NCT01335139|PLACEBO_COMPARATOR|Placebo + Placebo|Sublingual immunotherapy (SLIT) placebo + subcutaneous immunotherapy (SCIT) placebo
62804016|NCT03011788|ACTIVE_COMPARATOR|Single day|Single day Golytely purge 4L purge
62804017|NCT03011788|ACTIVE_COMPARATOR|2 day colon purge|Two days of Golytely purge 8L purge
62804018|NCT05406011|EXPERIMENTAL|Age groups|Participants grouped by their age (Age group I: patients aged between 18-30, age group II: patients aged between 31-45).
62804019|NCT05406011|EXPERIMENTAL|Groups by toothbrush change|Half of the group change the toothbrush after scaling and the other half not.
62804020|NCT05406011|EXPERIMENTAL|Experimental period|"Control: Control period without sour cherry chewing gum usage, with saliva sampling on fixed appointments (between 12:00 and 14:00, 0th, 4th and 7th day of the week) of the week. At the beginning oral and basic periodontal examinations performed. Plaque and calculus index at every sampling occasions.~Prevention: After a full mouth scaling sour cherry chewing gum usage, for a week. Saliva sampling on the same days. Plaque and calculus index at every sampling occasions.~Therapeutic: Sour cherry chewing gum usage, for one more week. Saliva sampling on the same days. Plaque and calculus index at every sampling occasions.~Control (without sour cherry chewing gum usage), prevention and therapeutic periods takes 3 weeks together."
62804021|NCT04585425|OTHER|Control|Treatment as usual including sleep hygiene advice
62228190|NCT02673840|PLACEBO_COMPARATOR|Placebo|
62228191|NCT02012764||Musculoskeletal symptoms - Pre diagnosis|Patients presenting with non-specific musculoskeletal complaints at risk of development of RA.
62590867|NCT06667206|EXPERIMENTAL|Group C: 6 and 18 months|Early Prime schedule: Measles vaccines given at 6 and 18 months of age
62590868|NCT01728662|EXPERIMENTAL|ELVR Procedure|A single subsegmental AeriSeal System treatment consists of the administration of 10 mL Foam Sealant administered through a standard fiberoptic bronchoscope via an administration syringe and bronchoscopic catheter into the target area of damaged lung
62228192|NCT03572478|EXPERIMENTAL|Combination Therapy (Phase 1b Cohort)|Participants will receive rucaparib plus nivolumab in 4 week cycles.
62228193|NCT03572478|EXPERIMENTAL|Rucaparib (Phase 2b Randomized Cohort)|Participants randomized to receive rucaparib alone in 4 week cycles.
62228194|NCT03572478|EXPERIMENTAL|Nivolumab (Phase 2b Randomized Cohort)|Participants randomized to receive nivolumab alone in 4 week cycles.
62228195|NCT03572478|EXPERIMENTAL|Combination Therapy (Phase 2b Randomized Cohort)|Participants randomized to receive rucaparib plus nivolumab in 4 week cycles. Participants will receive rucaparib alone in cycle 1 and begin nivolumab on day 1 of Cycle 2.
62228196|NCT04235933|EXPERIMENTAL|Tai Ai(RC18) 80mg|·Experimental: Tai Ai 80mg: Injection: subcutaneous injection on abdomen; Intervention:Biological: RC18
62420888|NCT03746080|EXPERIMENTAL|Whole Brain Radiotherapy + Plerixafor +Chemoradiotherapy|After completion maximal safe surgical resection, patients undergo radiation therapy for 42 days, initiating whole brain radiation therapy at day 21 (dose 16 of radiation therapy) and receive temozolomide daily on days 1 to 42. Beginning 7 days before the completion of whole brain radiation therapy, patients receive plerixafor by continuous infusion on days to 1 to 28. Beginning 1 week after completion of plerixafor infusion and 35 days after completion of whole brain radiation therapy, patients receive temozolomide monthly for 6 to 12 courses in the absence of disease progression or unacceptable toxicity.
62420889|NCT06568926|EXPERIMENTAL|patient group|Beta thalassemia patients on oral chelation therapy
62420890|NCT04188405|EXPERIMENTAL|Treatment (ponatinib, venetoclax, decitabine)|See Detailed Description.
62228197|NCT04235933|EXPERIMENTAL|Tai Ai(RC18) 160mg|·Experimental: RC18 160mg: Injection: subcutaneous injection on abdomen; Intervention:Biological: RC18
62228198|NCT04235933|EXPERIMENTAL|RC18 240mg|·Experimental: RC18 240mg Injection: subcutaneous injection on abdomen; Intervention: Biological: RC18
62420891|NCT04896918||Cohort of adult client of public dental clinics in Region Stockholm|Tobacco use (cigarette smoking and/or snus use) will be considered as exposure. Information on tobacco use will be extracted by public dental clinic records in Stockholm Region (October 2015-January 2020). Any diagnosis of COVID-19, hospitalization, receiving intensive care, and death because of COVID-19 will be examined as outcomes. Diagnoses of COVID-19 will be obtained through record linkage with health care registers of inpatient and outpatient care (February 2020-August 2021).
62420892|NCT00951717|NO_INTERVENTION|Treatment as usual|Participants will receive standard postpartum education and discharge materials provided by the hospital and a list of community and Internet resources by mail.
62804022|NCT04585425|EXPERIMENTAL|Intervention|Treatment as usual (sleep hygiene advice) and bedtime music listening
62804023|NCT04325334|EXPERIMENTAL|Running volume increase|Participants will be be given a running program based on their running mileage on inclusion and supported by regular contacts with the study trainer.
62228199|NCT01201317|EXPERIMENTAL|AZD2423, 150 mg|Tablets, 150 mg once daily in the morning.
62228200|NCT01201317|EXPERIMENTAL|AZD2423, 20 mg|Tablets, 20 mg once daily in the morning.
62228201|NCT01201317|PLACEBO_COMPARATOR|Placebo|Tablets, placebo, once daily in the morning.
62228202|NCT05391477|NO_INTERVENTION|Human optical diagnosis (HOD)|The examinator will provide a HOD for every lesion (regardless of their size) found during the examination (adenoma vs non-adenoma) following one of the available validated classifications (NICE, JNET, BASIC). He/she will also give a level of confidence in his/her diagnosis (high/low confidence). However, only diminutive lesions will be considered when analyzing the main outcome. The time to get a HOD will be recorded. An in situ surveillance interval will be provided if possible.
62228203|NCT05391477|EXPERIMENTAL|Artificial intelligence optical diagnosis (AIOD):|GI-Genius will provide an artificial intelligence diagnosis (AIOD) for every lesion detected (adenoma vs non-adenoma). Only diminutive lesions will be considered for the analysis of the main outcome. However, data on larger lesions will be recorded to describe GI-Genius´ performance in detail (secondary outcome). The time to get an AIOD will be recorded. An in situ surveillance interval will be provided if possible
62420893|NCT00951717|EXPERIMENTAL|Behavioral education|Participants will receive behavioral education on postpartum depression and a list of community and Internet resources by mail.
62420894|NCT04245397|EXPERIMENTAL|Dose Escalation of SX-682|Escalating oral doses of SX-682 (study drug) of 25, 50, 100, 200 and 400 mg twice-daily (i.e., 50, 100, 200, 400 and 800 mg total each day.
62804024|NCT01392131|ACTIVE_COMPARATOR|Oncoxin will be administered orally|20 patients will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
62804025|NCT01392131|ACTIVE_COMPARATOR|Supportive treatment|20 patients with hepatocellular carcinoma will receive supportive treatment only
62804026|NCT05162183||Glimepiride|Reference Group
62228204|NCT04067648|EXPERIMENTAL|S1 group|Sufentanil 0.3 μg/kg was intravenously given during anesthesia induction
62228205|NCT04067648|EXPERIMENTAL|S2 group|Sufentanil 0.4 μg/kg was intravenously given during anesthesia induction
62228206|NCT04067648|EXPERIMENTAL|S3 group|Sufentanil 0.5 μg/kg was intravenously given during anesthesia induction
62228207|NCT01532726||Eslicarbazepine Acetate (ESL)|ESL and concomitant medication should be managed by the neurologist according to the respective SPC.Summary of Product Characteristics
62228208|NCT06250556|EXPERIMENTAL|creatine supplementation|
62228209|NCT00959647|EXPERIMENTAL|Vismodegib 150 mg|Participants received 150 mg vismodegib orally once a day until disease progression, intolerable toxicity, or withdrawal from the study. If a participant had been receiving combination chemotherapy and/or biotherapy (FOLFOX, FOLFIRI, bevacizumab) in a parent study, the same combination chemotherapy and/or biotherapy as specified in the parent study could be continued in this study at the discretion of the investigator.
62590869|NCT02556294|EXPERIMENTAL|Self-acceptance behavioral intervention|The intervention will consist of individual and 4 group counseling sessions and 6 individual counseling sessions. The individual sessions are focused on specific individualized risk reduction plans, whereas the group sessions are focused on increasing self-acceptance and reducing HIV risk. Additionally, participants in this arm will receive HIV and STI counseling and testing.
62804027|NCT05162183||Liraglutide|Exposure group
62804028|NCT04281615|EXPERIMENTAL|Intervention (Generic Message)|Receives promotional materials that feature a generic messaging approach.
62420895|NCT04245397|EXPERIMENTAL|Expansion of SX-682 alone (lower risk patients, naive to hypomethylating agents)|Expansion of oral doses of SX-682 (study drug) at 200 mg twice daily (recommended phase 2 dose) in lower risk patients who have never received hypomethylating agents.
62420896|NCT04245397|EXPERIMENTAL|Expansion of SX-682 alone (lower risk patients, failed on hypomethylating agents)|Expansion of oral doses of SX-682 (study drug) at 200 mg twice daily (recommended phase 2 dose) in lower risk patients who failed on hypomethylating agents.
62804029|NCT04281615|NO_INTERVENTION|Control (Threshold Message)|Receives promotional materials that use traditional, threshold messages.
62804030|NCT02601157|EXPERIMENTAL|Orsiro SES or CX-ISAR/3-months DAPT|Patients allocated to this group will be implanted with Orisro sirolimus-eluting stents or Corflex ISAR stents for their coronary lesions, and then will be followed with 3-month dual antiplatelet therapy (DAPT) schedule.
62804031|NCT02601157|ACTIVE_COMPARATOR|Orsiro SES or CX-ISAR/1-year DAPT|Patients allocated to this group will be implanted with Orisro sirolimus-eluting stents or Coroflex ISAR stents for their coronary lesions, and then will be followed with 1-year dual antiplatelet therapy (DAPT) schedule.
62420897|NCT04245397|EXPERIMENTAL|Expansion of SX-682 with decitabine (lower risk patients, naive to hypomethylating agents)|Expansion of oral doses of SX-682 (study drug) at 100 mg twice daily with decitabine in lower risk patients who have never received hypomethylating agents.
62590870|NCT02556294|OTHER|Comparison/Control|The comparison group will receive HIV and STI counseling and testing.
62228210|NCT04568460|EXPERIMENTAL|Intervention Group Sessions|Intervention group sessions will be delivered by lay health counselors. The sessions will reflect principles of co-learning, participatory design, and empowerment to promote engagement of young people in critical thinking and problem solving - including modeling, roleplaying, and interactive activities.
62590871|NCT04885179||Individuals with SPLIS|Individuals diagnosed with SPLIS based on genetic testing that confirms bi-allelic pathogenic variants in SGPL1
62590872|NCT04885179||Parents of individuals with SPLIS|Parents of individuals diagnosed with SPLIS based on genetic testing that confirms bi-allelic pathogenic variants in SGPL1
62590873|NCT04885179||age and gender-matched controls|The investigators will attempt to collect biological specimens from individuals closely matched to SPLIS patient cohort by age and gender. This group may include siblings, cousins, and unrelated healthy children and adults.
62804032|NCT02960386|OTHER|Machine Learning Algorithm|Single group participants that will use the algorithm to be engaged in using their fitness tracker.
62804033|NCT05202678|OTHER|AGN1 LOEP|Subjects treated with AGN1 LOEP in proximal femur
62804034|NCT01104896|ACTIVE_COMPARATOR|Nicotine|One or two 15mg nicotine patch(es) applied from 6am to 10pm according to the patients tobacco dependence measured by the Fagerström scale.
62804035|NCT01104896|PLACEBO_COMPARATOR|Placebo|One or two patch(es) with placebo
62804036|NCT06006650|EXPERIMENTAL|Pembrolizumab Plus Albumin Paclitaxel and Cisplatin|Preoperative neoadjuvant (pembrolizumab 200mg, d1 intravenously, q3w+ albumin paclitaxel 100mg/m2, d1/d8/d15 intravenously, q3w+ cisplatin 75mg/m2, d1 intravenously, q3w) 3 cycles + surgery + 16 cycles of postoperative pembrolizumab adjuvant therapy
62804037|NCT06006650|ACTIVE_COMPARATOR|Pembrolizumab Plus 5-fluorouracil and Cisplatin|Preoperative neoadjuvant (pembrolizumab 200mg, d1 intravenously, q3w+ 5-fluorouracil 800mg/m2, d1-5 intravenously, q3w+ cisplatin 75mg/m2, d1 intravenously, q3w) 3 cycles + surgery + 16 cycles of postoperative pembrolizumab adjuvant therapy
62228211|NCT04568460|NO_INTERVENTION|Standard of Care|This is the standard of care arm. Participants newly diagnosed with HIV will get a referral to the local primary health care setting of their choice for further management, including ART.
62228212|NCT00947674|EXPERIMENTAL|Cellsorba EX|
62228213|NCT00947674|SHAM_COMPARATOR|Sham treatment|
62228214|NCT01187472||Treated subjects|Subjects treated on a previous study of locally advanced head and neck cancer
62228215|NCT03133546|EXPERIMENTAL|Osimertinib plus Bevacizumab|Patients will receive treatment with osimertinib and bevacizumab until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.
62228216|NCT03133546|ACTIVE_COMPARATOR|Osimertinib alone|Patients will receive treatment with osimertinib until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.
62228217|NCT03584568|EXPERIMENTAL|Perspective Taking Reappraisal|This arm focuses on reappraisals with perspective taking with a limited amount of basic skill building
62228218|NCT03584568|OTHER|Basic Skill Building|This arm focuses on basic skill building only.
62228219|NCT04354896|EXPERIMENTAL|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily with regular blinded dosis titration.
62228220|NCT04354896|PLACEBO_COMPARATOR|Placebo|Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
62420898|NCT04245397|EXPERIMENTAL|Expansion of SX-682 with decitabine (lower risk patients, failed on hypomethylating agents)|Expansion of oral doses of SX-682 (study drug) at 100 mg twice daily with decitabine in lower risk patients who failed on hypomethylating agents.
62804038|NCT06006650|ACTIVE_COMPARATOR|5-fluorouracil and Cisplatin|Preoperative neoadjuvant (5-fluorouracil 800mg/m2, d1-5 intravenously, q3w+ cisplatin 75mg/m2, d1 intravenously, q3w) 3 cycles + surgery + 16 cycles of postoperative pembrolizumab adjuvant therapy
62804039|NCT04435483|EXPERIMENTAL|Treatment Sequence 1|Participants will receive Treatment A (100 mg acalabrutinib suspension via NG administration plus 20 mg rabeprazole) in Period 1, Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 2, and Treatment C (100 mg acalabrutinib capsule) in Period 3.
62228221|NCT04076839|EXPERIMENTAL|Goal Management Training (GMT)|Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors. The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments. Participants assigned to this group will attend 9 weeks of GMT group sessions, each 2 hours in length, occurring once per week.
62228222|NCT04076839|NO_INTERVENTION|Wait-list Control|Following baseline testing, participants randomly assigned to the wait-list control group will have no intervention during the 9 weeks that the GMT group attends their group sessions. Following the completion of the GMT group intervention, the wait-list control will attend a a testing session, and subsequently, a 3 month follow-up testing session, the results of which will be compared to those of the GMT group. This group will then be offered a complimentary 9-week GMT program once the final testing session is complete. Again, during these sessions participants will be required to complete questionnaires every third session in order to monitor their progress and symptoms. Following the completion of the complimentary 9-week GMT program, individuals in the WLC will complete post-intervention testing
62228223|NCT01759407|ACTIVE_COMPARATOR|Femoral Nerve Block|Ropivicaine 0.2% with epinephrine 1:200,000 will be used for patients between 10kg and up to 25kg in weight; ropivicaine 0.5% with epinephrine 1:200,000 will be used for patients greater than or equal to 25kg
62228224|NCT01759407|NO_INTERVENTION|Standard Anesthetic Management|
62228225|NCT04460274||Model Building|Number of Covid-19 cases from December 31, 2019 to June 1, 2020 were used to build ARIMA model using Hyndman-Khandakar algorithm.
62804040|NCT04435483|EXPERIMENTAL|Treatment Sequence 2|Participants will receive Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 1, Treatment C (100 mg acalabrutinib capsule) in Period 2, and Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 3.
62804041|NCT00611689|EXPERIMENTAL|A|Imatinib and PTK/ZK222584
62804042|NCT01546558|EXPERIMENTAL|Metformin, Ranolazine|"Single cohort, 2-period study:~* Period 1, metformin 1000 mg bid on Days 1-5~* Period 2, metformin 1000 mg bid + ranolazine 500 mg bid on Days 6-10"
62228226|NCT04460274||Model Validation|Number of Covid-19 cases from June 2, 2020 to June 15, 2020 were used to forecast cases using the ARIMA model
62228227|NCT02709096|EXPERIMENTAL|BPX-01, 1% Topical Gel|BPX-01, 1% Topical Gel; applied once daily to the face for four weeks.
62590874|NCT04696185|ACTIVE_COMPARATOR|Dapagliflozin|Sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy with daily oral dose of dapagliflozin 10 mg
62420899|NCT04245397|EXPERIMENTAL|Expansion of SX-682 alone (higher risk patients, failed on hypomethylating agents)|Expansion of oral doses of SX-682 (study drug) at 200 mg twice daily (recommended phase 2 dose) in higher risk patients who failed on hypomethylating agents.
62228228|NCT02709096|PLACEBO_COMPARATOR|BPX-01, Vehicle Gel|BPX-01, Vehicle Gel; applied once daily to the face for four weeks.
62228229|NCT02236104|EXPERIMENTAL|cough assist session|Mechanical insufflation-exsufflation contains 15 cycles durea 2-3 seconds. pressure level fixed +/-30 cm H2O.
62228230|NCT05218187|ACTIVE_COMPARATOR|Conventional Physical Therapy (CPT) Group|CPT sessions will involve a warm-up using a cycle ergometer or treadmill walking, stretching, progressive strength training exercises, and balance training. Gait training will be provided using traditional over-ground walking. Additional strategies for home exercises, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided. Training will be administered 2 times per week for 40-60 minutes for six weeks.
62228231|NCT05218187|EXPERIMENTAL|Conventional Physical Therapy (CPT) Group with G-EO Training (CPT-GEO)|CPT-GEO sessions will involve a warm-up using a cycle ergometer or treadmill walking, stretching, progressive strength training exercises, and balance training. Gait training will be administered using end-effector gait training protocols (G-EO trainer). Training will be administered 2 times per week for 40-60 minutes for six weeks.
62804043|NCT02802839|EXPERIMENTAL|Sperimental|The patient will be shown the headset for VR and a selection of age appropriate virtual realities to immerge in by the nurse not performing the procedure. There will be two lists of VRs to choose from, one for age 6 to 12 and one for age 12 to 18 with the following themes: amusement rides /carousel, space rides, zoo, safari, dinosaurs, city touring, landscapes, caverns. Once the patient is ready to wear the headset the application will start and 120 seconds later the procedure will take place. The nurse performing venipuncture will be a different one than the one handling distraction. Once the procedure ends the video will last for one more minute or up to the child' s desire. Only the first venipuncture attempt will be observed.
62804044|NCT02802839|NO_INTERVENTION|Observational|Control intervention When arriving to the CF centre for routine visit that implies also the taking of blood samples, after having obtained the informed consent, a trained nurse of the CF Centre, will apply to each child recruited -in the presence of the parent, who may hold the child- the anesthetic cream. Only the first venipuncture attempt will be observed.
62804045|NCT05005663|ACTIVE_COMPARATOR|group A|patients younger than 2 years
62804046|NCT05005663|ACTIVE_COMPARATOR|group B|patients older than 2 years
62804047|NCT05120427|NO_INTERVENTION|Control|Access to standard care.
62228232|NCT03958786|EXPERIMENTAL|single arm|500 HIV-1 infected patients, aged 70 years and older
62228233|NCT04612959|EXPERIMENTAL|Psychosexual care|The psychosexual caring program will be conducted online psychoeducation as a group intervention. The program includes four sessions with home assignments and home readings papers.
62228234|NCT04612959|NO_INTERVENTION|Standard care|Standard care includes the information given by the nurse about the treatment methods to be applied once.
62420900|NCT04245397|EXPERIMENTAL|Expansion of SX-682 with decitabine (higher risk patients, naive to hypomethylating agents)|Expansion of oral doses of SX-682 (study drug) at 100 mg twice daily with decitabine in higher risk patients who have never received hypomethylating agents.
62590875|NCT04696185|NO_INTERVENTION|Standard care|No SGLT-2 inhibitor therapy with dapagliflozin
62804048|NCT05120427|EXPERIMENTAL|LNS only|Children in this arm will receive lipid-based nutrient supplements (LNS) for 12-18 months. LNS are 20 g/\~110 calorie nutrient supplements that provide energy, protein, essential fatty acids and a wide range of micronutrients critical for children ages 6 to 24 months of age. They are designed to complement diets without displacing breastmilk and local dietary preferences and can be mixed into the child's meal or eaten directly from the sachet. The LNS used in this study will be Nutributter plus.
62590876|NCT04091412|EXPERIMENTAL|Long-term administration of Butylphthalide Soft Capsules|In addition to standard secondary preventive drugs, such as atorvastatin calcium tablets, aspirin enteric-coated tablets and/or clopidogrel hydrogen sulphate tablets, patients in this group take Butylphthalide Soft Capsules orally, 0.2g per serving, three times a day for one year.
62243115|NCT01883479|EXPERIMENTAL|Exercise|Telephone-based intervention designed to increase exercise among postpartum women.
62590877|NCT04091412|NO_INTERVENTION|Standard secondary prevention group|patients in this group take atorvastatin calcium tablets, aspirin enteric-coated tablets and/or clopidogrel hydrogen sulphate tablets as standard secondary prevention.
62590878|NCT04738617|EXPERIMENTAL|Warm-up based on small-sided games|Intervention A is based on football-specific small-sided games (SSGs), consisting of 4 versus 4 matches (with mini-goals), performed in a 30 m by 24 m court (Giménez et al., 2018), using five sets of 90 seconds of work interspersed with 30 seconds of pause, in a total duration of 10 minutes.
62804049|NCT05120427|EXPERIMENTAL|Growth Charts Only|Children in this arm will receive a growth chart that can be installed at children's homes. Growth charts have been locally developed to allow parents an easy assessment of their children's height at their home. Charts will be placed on walls inside homes and will provide parents the opportunity to measure their child whenever they want, and will also contain information on the most suitable local foods as well as the importance of diverse diets and frequent feeding. After the home installation of growth charts, caregivers will be given a short introduction on how to use them and on how to interpret the measurements by study staff.
62804050|NCT05120427|EXPERIMENTAL|LNS and Growth Charts|Children in the combined arm will receive both growth charts and LNS.
62804051|NCT04118465|ACTIVE_COMPARATOR|ECV with Full urinary bladder|ECV with Full urinary bladder
62804052|NCT04118465|ACTIVE_COMPARATOR|ECV with empty urinary bladder|ECV with empty urinary bladder
62804053|NCT01187940|EXPERIMENTAL|PEGASUS|PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
62804054|NCT01187940|NO_INTERVENTION|Placebo|Will receive managment as usual from their local educational and NHS services
62804055|NCT05054140|EXPERIMENTAL|IMU-838|IMU-838 as tablet; Administration: Oral - daily
62804056|NCT05054140|PLACEBO_COMPARATOR|Placebo|Matching placebo as tablet; Administration: Oral - daily
62804057|NCT01819155|EXPERIMENTAL|adjTIV|Children randomized to receive adjTIV
62804058|NCT01819155|EXPERIMENTAL|TIV|Children randomized to receive TIV
62804059|NCT01819155|PLACEBO_COMPARATOR|Placebo|Children randomized to receive Placebo
62804060|NCT01546857|PLACEBO_COMPARATOR|placebo|Placebo one dose in the evening of surgery and post op day #1.
62804061|NCT01546857|ACTIVE_COMPARATOR|Gabapentin|Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively
62804062|NCT01908686|ACTIVE_COMPARATOR|Pivotal Response Training|Pivotal Response Training with children ages 4-35 years of age with an Autism Spectrum Disorder diagnosis
62804063|NCT01908686|NO_INTERVENTION|Waitlist Control|Children in WL will be offered treatment following WL condition.
62804064|NCT05184192|EXPERIMENTAL|Gabapentin|"This arm will be given the active treatment, oral Letco (gabapentin) gelatin capsules of 300mg each.~Up to the first four weeks will be a titration period (week 1 300mg TID, week 2 600mg TID, week 3 900mg TID, week 4 1,200mg TID) as tolerated. If intolerable adverse reactions occur, the dosage will be decreased to prior tolerable dose (e.g., if 900mg TID is intolerable, dose will be decreased to 600mg TID).~The following eight weeks will be fixed dose, the highest tolerable dose from the titration period.~Up to two weeks will be a taper down tailored to the maximum dose the participant reached during the titration and fixed periods.~A maximum 14 weeks will mark the end of active treatment. Follow-up assessments will be conducted 4 weeks after completion of the taper-down period."
62804065|NCT05184192|PLACEBO_COMPARATOR|Placebo|"Placebo gelatin capsules that look, smell, and taste like gabapentin capsules will be given to the placebo arm.~To preserve double-blinding of the study, subjects will receive one capsule TID the first week, the second week two capsules TID, the third week three capsules TID, and fourth week four capsules TID as tolerated. If intolerable, the dose will be decreased to prior tolerable dose.~The next eight weeks will be a fixed amount of placebo based on the highest tolerable amount from the titration period.~Subjects will then taper-down placebo to imitate the gabapentin arm for maximum two weeks based on highest dose achieved during study.~4 weeks after completion of taper-down, follow-up assessments will be conducted."
62804066|NCT06076148|EXPERIMENTAL|Individual then multiplayer games|Participants of this group will conduct the sessions in the following order : Focus group about individual virtual reality games then Focus group about multiplayer virtual reality games.
62804067|NCT06076148|EXPERIMENTAL|Multiplayer then individual games|Participants of this group will conduct the sessions in the following order : Focus group about multiplayer virtual reality games then Focus group about individual virtual reality games.
62804068|NCT03070080|ACTIVE_COMPARATOR|restrictive group|restrictive fluid strategy, 6 ml/kg/hour of lactated Ringer, during intraoperative period
62804069|NCT03070080|ACTIVE_COMPARATOR|conservative group|conservative fluid strategy, 12 ml/kg/hour of lactated Ringer, during intraoperative period
62804070|NCT00665665|EXPERIMENTAL|A|
62804071|NCT00665665|EXPERIMENTAL|B|
62804072|NCT00665665|EXPERIMENTAL|C|
62804073|NCT00665665|EXPERIMENTAL|D|
62804074|NCT03430778|EXPERIMENTAL|High CO2 group|end tidal CO2 : 40-45 mmHg
62804075|NCT03430778|PLACEBO_COMPARATOR|Low CO2 group|end tidal CO2 : 30-35 mmHg
62804076|NCT02631551|EXPERIMENTAL|GSP 301 NS|
62804077|NCT02631551|ACTIVE_COMPARATOR|Olopatadine HCl NS|
62804078|NCT02631551|ACTIVE_COMPARATOR|Mometasone furoate NS|
62804079|NCT02631551|PLACEBO_COMPARATOR|GSP 301 Placebo NS|
62029407|NCT01810588|EXPERIMENTAL|Cohort 4|"All subjects in this cohort will receive the minimum required cell dose that is determined following the dose de-escalation portion of the study (cohorts 1 through 3)~Haplo-cord transplantation:~All subjects will receive a conditioning regimen of chemotherapy prior to stem cell transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past.~For the transplant component of treatment, subject will receive umbilical cord blood. The study involves transplantation of unlicensed units of cord blood. Therefore, these are considered investigational products.~In addition to the umbilical cord blood unit, recipients will receive stem cells from a family member ( a haplo-identical donor). After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device."
62804080|NCT00421681|EXPERIMENTAL|A|"Treatment Arm A will develop tailored/negotiated contracts with the exercise instructor to maintain post intervention exercise adherence at home or in the community. Half of the participants in this negotiated maintenance arm will be randomly assigned to receive telephone calls to reinforce adherence and half will be assigned to a no telephone calls group."
62735322|NCT04294459|EXPERIMENTAL|Cohort B: Participants with cPRA 80.00% to 99.89%|Participants with cPRA between 80.00% to 99.89% (indicating active candidates on kidney transplant waitlist with no living donor cleared for donation) received isatuximab 10 mg/kg, IV infusion, QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1) and then Q2W for subsequent treatment cycles (each cycle of 28 days) until unacceptable AEs or participant's decision to stop the treatment (maximum treatment duration: 13 weeks).
62735323|NCT02471534|EXPERIMENTAL|Pediatric patients with hypovolemia|Right upper abdominal compression is performed in patients with hypovolemic signs including hypotension, decreased urine output and central venous pressure less than 5 mmHg. Changes of blood pressure during abdominal compression is continuously recorded.
62735324|NCT02236325|EXPERIMENTAL|DBT Brief Suicide Intervention|
62804081|NCT00421681|EXPERIMENTAL|B|"Treatment Arm B will be mainstreamed into an ongoing facility-based exercise program for post intervention exercise adherence. Persons in this mainstream follow up arm will be randomly assigned such that half will receive regular telephone reinforcement follow up and half will not."
62804082|NCT02136017||Changchun biologial's vaccine|Changchun Biological's vaccine group is the population injected with this vaccine.
62804083|NCT03471273|OTHER|endoscopic management|
62804084|NCT03471273|OTHER|follow up|
62804085|NCT03471273|OTHER|surgery|
62735325|NCT02236325|ACTIVE_COMPARATOR|Relaxation Training|
62735326|NCT01109615|EXPERIMENTAL|Chemotherapy|
62735327|NCT06314854|EXPERIMENTAL|Experimental Group|During the cannulation process, the experimental group will listen to the sound of flowing water throughout the process through the researcher's smartphone. The experimental and control groups will be administered VAS before, during and after each cannulation, and the State and Trait Anxiety Scale will be administered before the dialysis session and after the 12th first session.
62804086|NCT04099966|EXPERIMENTAL|alpha beta cell depletion|Matched allogeneic donor stem cells will be processed utilizing α/β CD3+/CD19+ cell depletion with the Prodigy system. Standard pre-conditioning and post-transplant motioning will be given.
62804087|NCT03043885|EXPERIMENTAL|PRF|
62804088|NCT03043885|EXPERIMENTAL|PRF+FDBA|
62804089|NCT03043885|ACTIVE_COMPARATOR|FDBA|
62804090|NCT03043885|ACTIVE_COMPARATOR|Blood Clot|
62804091|NCT04867551|EXPERIMENTAL|KDT-3594|
62804092|NCT03200119|EXPERIMENTAL|Mobile application user group|In the active group, participants were educated to modify their lifestyle to lose weight by using a smart phone-based lifestyle app which was designed to collect daily activity and dietary information. The app was composed of two main modules: a diet module, and a physical activity module.
62804093|NCT03200119|NO_INTERVENTION|Control group|Conventional lifestyle modification
62804094|NCT03373149|EXPERIMENTAL|Growth hormone/HPuFSH/GnRH antagonist|The patients receive growth hormone
62029408|NCT03776136|EXPERIMENTAL|lenvatinib plus pembrolizumab|Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
62029409|NCT04480112|EXPERIMENTAL|Group A Intervention|Participants in Group A will receive an intervention designed to provide participants with more social interaction during a time of social distancing and highly limited in-person social interactions
62029410|NCT04480112|ACTIVE_COMPARATOR|Group B Control|Participants in Group B will not receive any new interventions.
62029411|NCT01865591|EXPERIMENTAL|Renal denervation|Subjects are treated with unfocussed ultrasound-based renal denervation and are maintained on baseline anti-hypertensive medications.
62228235|NCT01163916||Patients with RA, PsA and AS|Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) prescribed adalimumab as part of Routine Clinical Care in Russia.
62228236|NCT06088212|NO_INTERVENTION|Usual care|Usual care patients will continue with the hospital follow-up plan and routine preventive care after hospital discharge.
62228237|NCT06088212|EXPERIMENTAL|Intervention|Intervention patients will receive a disease management program in addition to the usual care.
62228238|NCT06035679|EXPERIMENTAL|Pyrotinib Combined With Trastuzumab and Chemotherapy|T1cN0M0 HER2+ breast cancer Patients received 2 cycles (pyrotinib + trastuzumab + taxoid) regimen and were evaluated to continue with the original regimen if PR, and 4 cycles (pyrotinib + trastuzumab + taxoid + carboplatin) regimen if SD/PD. Phase II-III HER2+ breast cancer Patients received 6 cycles of treatment (pyrotinib + trastuzumab + taxoid + carboplatin)
62228239|NCT05914441||Thrombotic thrombocytopenic purpura patients|Including all patients enrolled in the study
62228240|NCT04446533|EXPERIMENTAL|Hydrogen Peroxide and Hyaluronic acid (BMG0703)|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with BMG0703 by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of BMG0703 will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
62228241|NCT04446533|ACTIVE_COMPARATOR|Chlorhexidine 0.2%|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with Chlorhexidine 0.2% by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of Chlorhexidine 0.2% will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
62228242|NCT04446533|PLACEBO_COMPARATOR|Placebo product|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with a placebo product by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of the placebo product will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
62228243|NCT04084470|ACTIVE_COMPARATOR|Bread types 1, 2 and 3|Daily consumption of 5 slices of allocated bread type for three intervention days (separated by a wash-out period of at least 7 days).
62228244|NCT04084470|ACTIVE_COMPARATOR|Bread types 4, 5 and 6|Daily consumption of 5 slices of allocated bread type for three intervention days (separated by a wash-out period of at least 7 days).
62029412|NCT05734508|EXPERIMENTAL|MVA-BN vaccine|2 doses of 0.5 mL MVA-BN vaccine injected subcutaneously and given at least 28 days apart
62228245|NCT00639353|ACTIVE_COMPARATOR|spherical contact lens|Subjects will wear and evaluate a spherical soft contact lens daily for 2 weeks
62228246|NCT00639353|EXPERIMENTAL|toric contact lens|Subjects will wear and evaluate a toric soft contact lens daily for 2 weeks
62029413|NCT01765634|EXPERIMENTAL|Mesenchymal stem cells|Mesenchymal stem cell group refers to treatment with mesenchymal stem cells (1×10\^6 cells/kg, intravenously)each week, four times for a cycle
62029414|NCT01765634|EXPERIMENTAL|Non-mesenchymal stem cells|Non-mesenchymal stem cell group refers to treatment with other second line drugs
62029415|NCT03750318|EXPERIMENTAL|Aingeal|All patients will wear the Aingeal device as part of the vital sign monitoring with opioid delivery system at ward setting.
62029416|NCT04211714|EXPERIMENTAL|EXG34217|single autologous CD34+ cells contacted ex vivo with EXG-001
62029417|NCT02356380|EXPERIMENTAL|Mobilization|"Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.~Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae."
62029418|NCT03950765|EXPERIMENTAL|Ecological Momentary Intervention|This group will receive three intervention prompts and three assessment prompts on their smartphone each day.
62029419|NCT01026974|EXPERIMENTAL|4rMenB|Subjects received three primary doses of rMenB vaccine (at the age of 6-8 months; 2 months after and at 12 months) in parent study (NCT00433914) and one booster dose of rMenB vaccine at 40 months of age in the present study.
62029420|NCT01026974|EXPERIMENTAL|4rMenB+OMV NZ|Subjects received three primary doses of rMenB+OMV NZ vaccine (at the age of 6-8months; 2 months after and at 12 months) in parent study (NCT00433914) and one booster dose of rMenB+OMV NZ vaccine at 40 months of age in the present study.
62029421|NCT01026974|EXPERIMENTAL|Naive_4042|Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.
62029422|NCT01026974|EXPERIMENTAL|Naive_6062|Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study.
62029423|NCT03152747||A|"Group A with pre-operative complete posterior vitreous detachment Group A will be invited for one follow-up visit (two months post-operatively) followed up by telephone interviews at one, two, three and five years after surgery to determine occurrence of pseudophakic retinal detachment.~Examinations: Best corrected Visual Acuity (BCVA) , SD-OCT (spectral domain optical coherence tomography), Ultrasound B-scan (substudy only), Slit lamp examination, telephone interview"
62029424|NCT03152747||B|"Group B with no/partial PVD~Group B will be invited for follow-up examinations at two months, six months and one year after surgery to document occurrence of PVD (if a PVD is present at one of the follow-ups, no more visits are necessary). Two, three and five years after surgery, all patients from group B will be interviewed by telephone, as in group A, to document the occurrence of pseudophakic retinal detachment.~Examinations: BCVA, SD-OCT, Ultrasound B-scan (substudy only), Slit lamp examination, telephone interview"
62029425|NCT06630299|EXPERIMENTAL|ISL/LEN|Participants will receive an initial dose of ISL/LEN (Dose A), followed by once weekly ISL/LEN (Dose B) from Day 8 onwards up to Week 96.
62029426|NCT06630299|ACTIVE_COMPARATOR|Standard of Care Treatment|"Participants will continue standard of care treatment with 2-3 ARVs up to Week 96:~* Integrase Strand Transfer Inhibitor (INSTI) class: INSTI combined with 1 or 2 nucleoside reverse transcriptase inhibitors (NRTIs; bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF; coformulated; Biktarvy®), dolutegravir (DTG)/abacavir (ABC)/lamivudine (3TC), DTG+ TAF or TDF (TXF)/emtricitabine (FTC; Emtriva®), DTG/tenofovir disoproxil fumarate (TDF; Viread®)/3TC, DTG/3TC, raltegravir (RAL) + TXF/FTC, RAL+TDF/3TC, elvitegravir (EVG; Vitekta®)/cobicistat (c; Tybost®)/TXF/FTC), or~* PI class: Boosted protease inhibitor (PI) combined with 2 NRTIs (darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF; coformulated), boosted darunavir (DRV)+TXF/FTC, boosted DRV+TDF/3TC), or~* NNRTI class: Nonnucleoside reverse transcriptase inhibitor (NNRTI) combined with 2 NRTIs (doravirine (DOR)/TDF/3TC, DOR+TXF/FTC, DOR+TDF/3TC, rilpivirine (RPV)/TXF/FTC, RPV+TXF/FTC, RPV+TDF/3TC)"
62029427|NCT06630299|EXPERIMENTAL|Extension Phase|"At the end of randomized treatment visit, if safety and efficacy of ISL/LEN are demonstrated following review of randomized data, participants will be given the option to receive ISL/LEN tablets in an extension phase until ISL/LEN becomes available or until the sponsor elects to discontinue the study, whichever occurs first.~Participants receiving ISL/LEN during the randomized phase will continue to take ISL/LEN weekly.~Participants receiving standard of care during the randomized phase will take an initial dose of ISL/LEN (Dose A), followed by once weekly ISL/LEN (Dose B) from Day 8 onwards."
62029428|NCT02188433|EXPERIMENTAL|Cut down to quit (CDTQ)|"For those subjects who claim that they cannot quit smoking ≤7 days, they will receive a leaflet (i.e. include a roadmap of smoking reduction strategy) plus a brief intervention using the AWARD model: (a) Ask about smoking history, (b) Warn about the high risk, (c) Advise to quit as quitting can greatly reduce risks, and participants will be advised to cut down cigarette consumption at their own pace, but the process should not exceed 3 months. (d) Refer smokers to a smoking cessation clinic, and (e) Do it again: repeat the intervention and encourage smokers who fail to quit or relapse to reduce again during each telephone follow-up.~For the subjects have intention to quit smoking ≤7 days, the investigator will follow-up them after a week. For those who report quitted, they will be followed up as other participants. However, if they report failed to quit, they will receive the same interventions and will be followed-up as other participants in the experimental group."
62029429|NCT02188433|ACTIVE_COMPARATOR|Quit Immediately (QI)|QI group subjects will receive a smoking cessation booklet (provided by COSH) plus brief intervention using AWARD model similar to CDTQ group. For the subsequent telephone follow-up repeat the health warning that 'one in two smokers will be killed by smoking' and encourage smokers who fail to quit or relapse to try again.
62029430|NCT00611143|EXPERIMENTAL|1|Atorvastatin group
62029431|NCT00611143|NO_INTERVENTION|2|Control group
62029432|NCT03540927|EXPERIMENTAL|PM+ for entrepreneurs|The intervention arm participants will receive a cash transfer to support them in their businesses PLUS 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement, provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 discusses problem solving technique.Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
62735328|NCT06314854|NO_INTERVENTION|Control Group|The control group will be provided with standard care and no intervention will be made. A total of 12 sessions will be followed in both groups.
62029433|NCT03540927|ACTIVE_COMPARATOR|Control|The control arm will receive a cash transfer only to support them in their businesses.
62029434|NCT05930327|EXPERIMENTAL|High-Value Cash Transfer|Participants in the treatment group will receive four $325 payments. The first payment will be disbursed at the time of enrollment (between birth and 4 weeks of age), and second payment on the infant's one-month birthday, third payment on the infant's two-month birthday, and the fourth payment on the infant's three-month birthdays.
62029435|NCT05930327|ACTIVE_COMPARATOR|Low-Value Cash Transfer|Participants in the control group will receive four $25 payments. The first payment will be disbursed at the time of enrollment (between birth and 4 weeks of age), and second payment on the infant's one-month birthday, third payment on the infant's two-month birthday, and the fourth payment on the infant's three-month birthdays.
62029436|NCT05225818|EXPERIMENTAL|Experimental: PLAN - Home|Trained NPs will deliver the PLAN-Home to the enrolled participants, which consists of home-based dementia evaluation, education, and care planning for older adults with probable dementia.
62029437|NCT05225818|NO_INTERVENTION|No intervention: Control Group|The control group will receive a copy of the publicly available educational material on 10 warning signs and symptoms of Alzheimer's disease and action steps prepared by Alzheimer's Association.
62228247|NCT01592500|EXPERIMENTAL|MOD-4023 low dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
62804095|NCT03373149|ACTIVE_COMPARATOR|HPuFSH/GnRH antagonist|Growth hormone is not used
62029438|NCT05754450|EXPERIMENTAL|AVTX-803|AVTX-803 at a dose specified by the investigator up to 5 times a day not to exceed 1700 mg/kg/day
62029439|NCT06028230|EXPERIMENTAL|SAR444656 dose 1|Participants will receive SAR444656 dose 1 orally
62029440|NCT06028230|EXPERIMENTAL|SAR444656 dose 2|Participants will receive SAR444656 dose 2 orally
62804096|NCT01794988|EXPERIMENTAL|Group Cognitive Behavioral Therapy|Participants will undergo 11 weeks of group cognitive behavioral therapy (CBT) and a pre- and post-intervention MRI brain scan.
62029441|NCT06028230|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo orally
62029442|NCT04479618|ACTIVE_COMPARATOR|Usual practice (negative control)|After a member of the UHWI surgical team performs the initial cleansing/debriding, the control group (1) will have their ulcer dressed as usually done at UHWI. Wounds are dressed with saline-soaked gauze, covered with dry gauze. One wrap of stretch gauze will hold the dressing in place. Patients will clean the wound by vigorously wiping with gauze soaked in homemade normal saline (1 tsp salt/500ml water bottle), center to edges, at each dressing change, unless already very clean. Clean wounds will simply be irrigated with normal saline at each dressing change. Patients experienced with using papaya for debridement of their ulcers may apply it only to the open wound, avoiding contact with the periwound, to remove slough or eschar. If patients observe green exudate, they are permitted to add one teaspoon of vinegar to their bottle of saline. Dressings in group (1) will be changed daily. The dressings will be soaked off if they become adherent.
62228248|NCT01592500|EXPERIMENTAL|MOD-4023 middle dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
62228249|NCT01592500|EXPERIMENTAL|MOD-4023 high dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
62804097|NCT01794988|ACTIVE_COMPARATOR|Pain Education|Participants will receive 11 weeks of pain education and a pre- and post-intervention MRI brain scan.
62804098|NCT01794988|EXPERIMENTAL|Therapeutic Interactive Voice Response|Four months of therapeutic interactive voice response (TIVR).
62804099|NCT01794988|ACTIVE_COMPARATOR|No TIVR|Control - no intervention
62228250|NCT01592500|ACTIVE_COMPARATOR|Genotropin|Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)
62243116|NCT01883479|EXPERIMENTAL|Wellness/Support|Telephone-based intervention designed to provide support to postpartum women.
62243117|NCT01883479|NO_INTERVENTION|Usual care|Participants receive usual care and will receive their choice of the interventions at 9 months.
62804100|NCT01553903|EXPERIMENTAL|Tamoxifen,|Current hormonotherapy treatment in hormone dependent breast cancer
62804101|NCT01553903|EXPERIMENTAL|Exemestane|Current hormonotherapy treatment in hormone dependent breast cancer
62804102|NCT01553903|EXPERIMENTAL|Anastrozole|Current hormonotherapy treatment in hormone dependent breast cancer
62804103|NCT01553903|EXPERIMENTAL|Letrozole|Current hormonotherapy treatment in hormone dependent breast cancer
62804104|NCT05013424|EXPERIMENTAL|OnabotulinumtoxinA|Participants will receive one dose of OnabotA X administered as 5 injections to the corrugator and procerus muscles on Day 1.
62804105|NCT03621657|EXPERIMENTAL|Low dose FMT Capsule DE|FMT Capsule double-encapsulated (DE) by mouth, 5 capsules once daily with antibiotic, followed by 5 capsules daily for 7 days post-antibiotic
62228251|NCT05380778|EXPERIMENTAL|Shallow Anesthesia|Experimental: Shallow Anesthesia Standard anesthesia with fentanyl, propofol for shoulder surgery together with an interscalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS ≥ 55 (group 2, shallow anesthesia). Anesthesia depth as measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes above a BIS level of 45 were counted.
62590879|NCT04738617|EXPERIMENTAL|Warm-up based on potentiation principles (e.g., speed, change of direction, plyometrics)|"Intervention B is based on speed, COD and plyometrics (i.e., a potentiation protocol), inspired by ideas presented by Howe, Coward, and Price (2017). Participants will perform five repetitions of the following exercises, in this order: unilateral hurdle hops and lateral hurdle hops with each lower limb; CMJ; broad jump; forward in and out; slalom jumps; lateral scissor jumps; single leg linear hops. Each intervention will last \~10 minutes and will be applied in the football field."
62590880|NCT06192927|EXPERIMENTAL|TenoMiR intralesional injection|"Drug: TenoMiR (Low Dose), Single injection Mimic of miR29a~Other Names:~• CWT-001~Drug: TenoMiR (High Dose), Single injection Mimic of miR29a~Other Names:~• CWT-001"
62804106|NCT03621657|ACTIVE_COMPARATOR|Single dose FMT Capsule DE|FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.
62228252|NCT05380778|EXPERIMENTAL|Deep Anesthesia|Experimental: Deep Anesthesia Standard anesthesia with fentanyl, propofol for shoulder surgery together with an interscalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS \< 45 (group 1, deep anesthesia). Anesthesia depth as measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes below a BIS level of 45 were counted.
62228253|NCT01847053|PLACEBO_COMPARATOR|Oatmeal control|Oatmeal control, around 70g; without cinnamon
62228254|NCT01847053|ACTIVE_COMPARATOR|Ground cinnamon, 3g|3 g ground cinnamon in Oatmeal (\~70 g)
62590881|NCT06192927|SHAM_COMPARATOR|0.9% saline subcutaneous sham injection|Drug: 0.9% saline Subcutaneous single injection
62590882|NCT01210196||mild affected Fabry patients|
62590883|NCT01010295|EXPERIMENTAL|doxycycline|doxycycline 100 mg twice daily for 3 weeks
62804107|NCT03621657|PLACEBO_COMPARATOR|Placebo Oral Capsule|Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic
62804108|NCT05724745|OTHER|Healthy volunteers, Asthmatic patients and COPD patients|This arm of the study is essential to establish nominal flow-volume maps of nominal flow-volume curves and to determine the dependence of normal breathing on gravity and response to a bronchodilator in order to evaluate the sensitivity and specificity of the technique for the known lung diseases asthma and COPD by comparing data from healthy the data from healthy subjects with those from sick subjects.
62029443|NCT04479618|EXPERIMENTAL|improvised dressings (experimental)|After initial cleansing/debriding, patients in the improvised dressing group (2) will then have a thin layer zinc oxide paste applied to the dried periwound, carefully avoiding the open wound. A piece of a clean new plastic bag (food-grade World Star 1 mil LD bags, or the equivalent, purchased from the Papine Market across John Golding Road from the University of the West Indies), cut slightly larger than the ulcer will be gently conformed to the moist wound contours and sealed onto the zinc oxide paste. The bag will be fenestrated with a small slit using a number 11 scalpel or clean scissors prior to placing it on the ulcer in order to allow excess fluid to escape. The edges of the slit will be approximated. Clean gauze will be placed lightly over the slit to capture escaping fluid. One wrap of stretch gauze will hold the dressing in place. Patients will be instructed to change the dressings daily, irrigating with normal saline at each dressing change.
62804109|NCT05706948|EXPERIMENTAL|High Intensity Interval Training (With Face Mask)|
62228255|NCT01847053|ACTIVE_COMPARATOR|Cinnamon extract, 3 g|3 g cinnamon extract in Oatmeal (\~70 g)
62228256|NCT01847053|ACTIVE_COMPARATOR|Cinnamon extract, 6 g|6 g cinnamon extract in Oatmeal (\~70 g)
62228257|NCT05782452||Bilateral congenital cataract probands who were consecutively enrolled|
62228258|NCT02683876||Subjects with malodor|individuals with self-reported odor issues suspected to be associated with microbial imbalance on or inside the body and inefficient metabolism as evidenced from other laboratory tests
62228259|NCT02683876||Healthy control|individuals not complaining of uncontrollable or unpredictable malodor episodes
62228260|NCT05466565||Nucleoside analog alone group|planning or ongoing treatment with entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and no addition or switch Patients on the pegylated interferon alfa-2b program
62228261|NCT05466565||In the continuous treatment group of peginterferon|the subjects started oral antiviral drugs from the 2nd day after operation, and simultaneously took peginterferon alfa-2b in combination from the 4th to 8th week after operation, and stopped after 96 weeks. Continue oral antiviral drugs with peginterferon
62420901|NCT04245397|EXPERIMENTAL|Expansion of SX-682 with decitabine (higher risk patients, failed on hypomethylating agents)|Expansion of oral doses of SX-682 (study drug) at 100 mg twice daily with decitabine in higher risk patients who failed on hypomethylating agents.
62420902|NCT04709029|ACTIVE_COMPARATOR|intravenous dexamethazone group|Patients receive intrathecal 3 ml heavy bupivacaine 0. 5% +1 ml normal saline + intravenous 8 mg dexamethazone in 10 ml saline,to prevent postdural puncture headache. Spinal anesthesia will be done in a sitting position under complete aseptic techniques, 25 G Quincke needle was inserted intrathecally at L3-L4 or L4-L5 interspace through midline approach. The study drugs were given by an anesthesiologist not aware of the type of medications injected.
62590884|NCT06668051||IPF|Inclusion Criteria: Being over 18 years old -having a clinical, radiological and/or pathological diagnosis of IPF -volunteering to participate in the study -not having had a respiratory tract infection in the last month -not having an accompanying airway disease such as COPD -being in the stable phase of the disease Exclusion Criteria: Patients who have had an IPF attack within the last three months and/or are in the acute exacerbation of the disease; who use a walking aid; who have unstable angina or class III-IV heart failure according to the New York Heart Association congestive heart failure classification; who have orthopedic, neuromuscular, neurological and cardiac diseases that may affect walking and balance; who have serious comorbid conditions such as cancer or neoplasm; who have a history of sarcoidosis, tuberculosis, emphysema and/or lung surgery; who have communication problems, mental and cognitive problems, and who cannot adapt to the applied assessment methods will be
62590885|NCT06668051||HEALTHY GROUP|Being over 18 years old -having a clinical, radiological and/or pathological volunteering to participate in the study -not having had a respiratory tract infection in the last month -not having an accompanying airway disease such as COPD
62804110|NCT05706948|EXPERIMENTAL|High Intensity Interval Training (Without Face Mask)|
62029444|NCT04479618|ACTIVE_COMPARATOR|advanced dressings (positive control)|"After initial cleansing/debriding, the advanced dressing group (3) will have a cut piece of a 4x24 standard (pink) polymeric membrane dressing roll large enough to extend at least 0.5 cm beyond all open and closed (inflamed or damaged) wound edges applied as per the Instructions for Use (the periwound is blotted dry, but the wound bed remains moist from the final saline rinse). One wrap of stretch gauze will hold the polymeric membrane dressing in place. The approximate open wound edges will be marked on the dressing backing. As per the manufacturer's instructions for use, patients will change the dressings when saturation reaches any of the wound edges, as indicated by a change in color on the backing of the dressing, visible through the stretch gauze. Routine rinsing will not be performed; the wounds will be rinsed at dressing changes only if visible loose debris is present."
62804111|NCT02777658||Primary Study Cohort|Patients with prior confirmed EGFR mutation-positive locally advanced or advanced NSCLC (Non-Small Cell Lung Cancer) who have progressed on or after EGFR-TKI (Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitor) therapy
62804112|NCT02777658||Secondary Study Cohort|Patients diagnosed with de-novo (wild-type) EGFR T790M mutation-positive (alone or in combination with other mutations) locally advanced or advanced NSCLC
62228262|NCT05466565||In the pegylated interferon pulse medication group|the subjects started oral antiviral drugs from the second day after the operation, and at any time point from the 4th to the 8th week after the operation, the subjects were combined with peginterferon alfa-2b. After every 8 weeks of combined use, stop for 4 weeks (continuous oral NA is maintained during the period), and perform periodically until pegylated interferon is stopped after 96 weeks, and oral antiviral drugs are continued
62735329|NCT04737434|EXPERIMENTAL|Extremely low frequency electromagnetic field device|with extremely low frequency electromagnetic wave
62804113|NCT03980899||Patients with PPI|
62804114|NCT04592588|EXPERIMENTAL|Common Elements Toolbox (COMET)|The Common Elements Toolbox is an online intervention consisting of modules from empirically supported treatments for common mental health problems.
62804115|NCT04592588|SHAM_COMPARATOR|Wait-list control condition|
62804116|NCT03965013|EXPERIMENTAL|Part 1 (healthy): NNC0268-0965|A single dose of NNC0268-0965 given s.c. (subcutaneously, under the skin)
62804117|NCT03965013|PLACEBO_COMPARATOR|Part 1 (healthy): placebo|A single dose of placebo (NNC0268-0965) given s.c.
62804118|NCT03965013|EXPERIMENTAL|Part 2 (type 1 diabetes): NNC0268-0965|A single dose of NNC0268-0965 given s.c.
62804119|NCT03965013|ACTIVE_COMPARATOR|Part 2 (type 1 diabetes): insulin glargine|A single dose of insulin glargine given s.c.
62804120|NCT02385747|EXPERIMENTAL|women with anbormal bleeding|women with perimenopausal and postmenopausal bleeding who will be evaluated with transvaginal ultrasound, saline sonohysterography,hystroscopy and endometrial currettage
62804121|NCT02624440|EXPERIMENTAL|Clarithromycin|p.o. clarithromycin 250 mg twice daily for 180 days
62804122|NCT02624440|EXPERIMENTAL|Sulfamethoxazole/trimethoprim|p.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily for 180 days
62804123|NCT02624440|EXPERIMENTAL|Observation|Observation without prophylactic antibiotic treatment
62804124|NCT02884648|EXPERIMENTAL|Bevacizumab|Participants receive Bevacizumab by vein on Day 1 of every 21-day study cycle, for as long as study doctor thinks it is in participant's best interest.
62804125|NCT02719496|EXPERIMENTAL|IBEROGAST|Dose of 20 drops three times a day for 28 days, on constipation parkinsonian patients with disorders intestinal transit.
62804126|NCT03255135|EXPERIMENTAL|HIFU|Patients with untreated recent diagnosed localized prostate cancer candidates of focal therapy.
62029445|NCT05832437|EXPERIMENTAL|BREATHE-Peds intervention|The patient's primary care provider (PCP) will deliver a brief intervention using motivational interviewing and shared decision making, in a one time 9-minute intervention integrated into an office visit for asthma. PCPs will follow a 4-step script tailored to erroneous asthma and inhaled corticosteroid (ICS) beliefs, as well as ACQ score, measured just prior to the office visit. PCPs will follow a 4-step script tailored to erroneous asthma and inhaled corticosteroid (ICS) beliefs, as well as ACQ score, measured just prior to the office visit.
62029446|NCT05832437|ACTIVE_COMPARATOR|Control Intervention|The patient's primary care provider (PCP) will deliver a 9-minute scripted intervention on credible nutrition and lifestyle information. The control intervention is designed to not be specific enough to change strategies related to asthma control.
62029447|NCT01734681|EXPERIMENTAL|Treatment with G-202|G-202 will be administered by intravenous infusion over one hour on Days 1, 2 and 3 of a 28-day treatment cycle. The G-202 dose will be 40 mg/m2 on Day 1 and 66.8 mg/m2 on Days 2 and 3.
62029448|NCT04831736|EXPERIMENTAL|Treatment|
62029449|NCT04831736|PLACEBO_COMPARATOR|Control|
62029450|NCT04134442|EXPERIMENTAL|Bupivacaine Liposome|"1. Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist).~2. Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%"
62029451|NCT04134442|ACTIVE_COMPARATOR|Standard therapy|"1. Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist).~2. Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000."
62029452|NCT06184984|EXPERIMENTAL|Methionine metabolic availability in mung beans|"Participants will be seen initially for pre-study assessment. They will then be studied for up to 7 times.~The participants will be expected to participate in 7 different sets of experiments which will take 2 to 3 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or cooked mung bean, which will be provided by the investigators."
62029453|NCT02156674|EXPERIMENTAL|Naglazyme®|weekly Naglazyme® infusion for 2 years
62029454|NCT00392561|EXPERIMENTAL|1|Selenium
62029455|NCT00392561|EXPERIMENTAL|2|Vitamin E
62804127|NCT04934501||PAD patients|The entire cohort exists of patients recently treated with an endovascular stent placement in the superficial femoral artery (SFA).
62804128|NCT03015168||Observational Group|Patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
62029456|NCT00392561|EXPERIMENTAL|3|Vitamin E + Selenium
62029457|NCT00392561|NO_INTERVENTION|Arm 4|
62029458|NCT06634589|EXPERIMENTAL|Substudy 1 Part 1a: Dose Escalation|Sequential cohorts of increasing dose level combinations of BGB-16673 and sonrotoclax will be evaluated.
62029459|NCT06634589|EXPERIMENTAL|Substudy 1 Part 1b: Safety Expansion|Cohorts of select dose level combinations of BGB-16673 and sonrotoclax will be evaluated in participants with selected B-cell histologies.
62029460|NCT06634589|EXPERIMENTAL|Substudy 2 Part 1a: Dose Escalation|Sequential cohorts of increasing dose level combinations of BGB-16673 and zanubrutinib will be evaluated.
62029461|NCT06634589|EXPERIMENTAL|Substudy 2 Part 1b: Safety Expansion|Cohorts of select dose level combinations of BGB-16673 and zanubrutinib will be evaluated in participants with selected B-cell histologies.
62029462|NCT01562756|EXPERIMENTAL|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
62029463|NCT02451800|EXPERIMENTAL|in-class yoga|"The intervention is a in-class yoga course taught by yoga instructors for 3 times per week for 3 months. This class is based on Peggy Cappy's Program: More Yoga for Every Body. Class is taught at Sanford Wellness Centers in Sioux Falls, South Dakota and Fargo, North Dakota. Each class in 1 hour in length."
62029464|NCT02451800|ACTIVE_COMPARATOR|yoga by DVD|"For the intervention participants are asked to do yoga at home following the Peggy Cappy's Program: More Yoga for Every Body DVD. They are asked to complete these exercises 3 times per week for 3 months. The DVD is 1 hour in length."
62029465|NCT02451800|ACTIVE_COMPARATOR|stretching by DVD|"For the intervention participants are asked to do stretching exercises at home following Bob Anderson's DVD-Stretching: the DVD. They are asked to complete these exercises 3 times per week for 3 months. The DVD is 1 hour in length."
62804129|NCT05851196||Patients with non-specific low back pain|Individuals with chronic non-specific ow back pain
62804130|NCT05851196||Healthy controls|Healthy, age- and sex-matched individuals without low back pain
62228263|NCT03821441|EXPERIMENTAL|bOPV(Candy)|"bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.~1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
62228264|NCT03821441|EXPERIMENTAL|bOPV(Liquid)|"bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.~0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops each person;be be equivalent to 0.1ml each person )"
62228265|NCT03821441|EXPERIMENTAL|bOPV（liquid）|bOPV(Liquid):Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral Produced by Beijing Tiantan Biological Products Co., Ltd. 1.0ml each bottle,2 drops each person(be be equivalent to 0.1ml each person).(total content of polio virus≥6.12lgCCID50，type1 polio virus≥6.0 lgCCID50，type 3 polio virus ≥5.5lgCCID50 in each 0.1 ml)
62804131|NCT02426515|EXPERIMENTAL|Hilotherm® Device|Patients undergo removal of lower third molar with Hilotherm® cooling device applied.
62804132|NCT02426515|NO_INTERVENTION|Control|Patients undergo removal of lower third molar without the Hilotherm® cooling device applied.
62804133|NCT02856048|EXPERIMENTAL|Triptorelin (GnRHa) + Chemotherapy|Triptorelin LP 3 mg (DECAPEPTYL LP 3 mg, IPSEN) 3 mg every 28±3 days, intramuscular during chemotherapy
62804134|NCT02856048|NO_INTERVENTION|Chemotherapy alone|Patient having a chemotherapy without drug injection for fertility preservation
62804135|NCT03568240||30 men suffering from apnea|
62804136|NCT03568240||15 men defined as snorers|
62804137|NCT03568240||15 men without complaints|
62804138|NCT00740207|ACTIVE_COMPARATOR|Isovue 250|
62804139|NCT00740207|ACTIVE_COMPARATOR|VISIPAQUE 270|
62804140|NCT01509235|EXPERIMENTAL|1. Exercise testing and self drainage session|
62804141|NCT01509235|ACTIVE_COMPARATOR|2. Chest physiotherapy (CP) session|
62804142|NCT01437280|EXPERIMENTAL|CGTG-102|CGTG-102 is an oncolytic adenovirus
62804143|NCT05229185|EXPERIMENTAL|DeXtreme (Error-enhacement)|Training (error-enhancement): 5 consecutive days, 1 hour per day
62804144|NCT05014672|EXPERIMENTAL|Setanaxib 1200 mg/day|Participants will be administered setanaxib at a dose of 1200 mg/day for the 24-week double-blind treatment period.
62804145|NCT05014672|EXPERIMENTAL|Setanaxib 1600 mg/day|Participants will be administered setanaxib at a dose of 1600 mg/day for the 24-week double-blind treatment period.
62804146|NCT05014672|PLACEBO_COMPARATOR|Placebo|Participants will be administered a placebo for the 24-week double-blind treatment period.
62804147|NCT02631096|EXPERIMENTAL|0.2 mg/kg ARB-001467 or Placebo|HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.2 mg/kg versus placebo once a month for 3 months
62804148|NCT02631096|EXPERIMENTAL|0.4 mg/kg ARB-001467 or Placebo|HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
62804149|NCT02631096|EXPERIMENTAL|ARB-001467 or Placebo|HBeAg-positive subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
62029466|NCT01126593|PLACEBO_COMPARATOR|Placebo group|The placebo group will receive the same subacromial infusion catheter as the study group.However, the reservoir will be filled with 200cc of 0.9% normal saline.
62029467|NCT01126593|NO_INTERVENTION|Control group|The control group patients will receive no continuous infusion catheter.
62804150|NCT02631096|EXPERIMENTAL|0.4 mg/kg ARB-001467|HBeAg-negative subjects receive ARB-001467 at. 0.4 mg/kg (open label) bi-weekly for 5 treatments and then subjects with HBsAg ≤1000 IU/mL AND ≥1.0 log10 decrease from baseline at Day 71 will continue monthly dosing through 48 weeks
62804151|NCT04034823|EXPERIMENTAL|KN035 in combination with trastuzumab and docetaxel|
62029468|NCT01126593|EXPERIMENTAL|Study Group|Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The infusion rate will be 4cc per hour.
62029469|NCT02501343|EXPERIMENTAL|Sodium bicarbonate|High acid load meal (Western style meal) with Sodium bicarbonate (Sodibic 840mg\*2)
62804152|NCT02838108||patients with COPD|
62029470|NCT02501343|PLACEBO_COMPARATOR|Placebo|High acid load meal (Western style meal) with sodibic-matching placebo
62029471|NCT01899846|EXPERIMENTAL|Cohort 1|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation following first dose
62590886|NCT06654141|EXPERIMENTAL|Implant placement 3 months after tooth extraction|Alveolar ridge preservation using xenograft (Bio-Oss Collagen®) and implant placement 3 months after tooth extraction
62590887|NCT06654141|ACTIVE_COMPARATOR|Implant placement 6 months after tooth extraction|Alveolar ridge preservation using xenograft (Bio-Oss Collagen®) and implant placement 6 months after tooth extraction
62029472|NCT01899846|EXPERIMENTAL|Cohort 2|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation 24 - 28 weeks gestation
62228266|NCT04969978|ACTIVE_COMPARATOR|Arm I (Quitline eReferral)|Clinics are notified via email that the Quitline eReferral system is available with a link to an online publication that includes an overview of Quitline services, information on Quitline effectiveness, and a detailed eReferral workflow with corresponding EHR screenshots, including how to identify eligible patients, create an eReferral, and access Quitline follow-up data in the EHR. Clinics also gain access to technological assistance, as needed.
62590888|NCT03817905|EXPERIMENTAL|Patient navigator|Participant meets the patient navigator at their colonoscopy appointment and discusses any problems they experienced in getting the colonoscopy done. Participant will tell navigator in their own words their experience and whether they faced any barriers to scheduling and colonoscopy completion.
62590889|NCT03105635|OTHER|Patients|"Participating primary care providers will be encouraged to refer their patients who could benefit from community resources to these services. They will complete the study referral form for all patients referred to a resource. They will briefly mention the study to patients who are referred to a community resource, and ask for their verbal consent to be contacted by a member of the research team to learn more about the study, and leave a patient recruitment package with them."
62228267|NCT04969978|EXPERIMENTAL|ARM II (Quitline eReferral plus enhanced AD)|Clinics receive standard online materials access to remote technological assistance as in Arm I. Clinics also receive group training of clinic staff prior to activation of the eReferral system and 12 months post-activation, follow-up booster sessions and monthly performance audit and feedback.
62228268|NCT00610103|ACTIVE_COMPARATOR|KW-6500|Drug: KW-6500 (apomorphine hydrochloride (USAN))
62420903|NCT04709029|ACTIVE_COMPARATOR|intrathecal dexamethazone group|Patients receive intrathecal 3 ml heavy bupivacaine 0.5% + 4 mg (1 ml) dexamethazone + intravenous 10 ml normal saline to prevent postdural puncture headache. Spinal anesthesia will be done in a sitting position under complete aseptic techniques, 25 G Quincke needle was inserted intrathecally at L3-L4 or L4-L5 interspace through midline approach. The study drugs were given by an anesthesiologist not aware of the type of medications injected.
62420904|NCT02356250||PORTAL HYPERTENSION|PAIEBT WITH PORTAL HYPERTENSION
62420905|NCT00486577|EXPERIMENTAL|1|
62420906|NCT00486577|EXPERIMENTAL|2|
62590890|NCT03105635|OTHER|Practice and Provider|"Four to six practices will be recruited to participate in this feasibility study. Primary care members working in a participating practice will be invited to participate in the study.~All primary care providers will be encouraged to participate and at least one primary care provider is required to participate to include the practice in the study.~After the obtaining an interest from a practice member to whom the invitation email was sent, we will offer all practice members eligible for the study an information session during which the study is described and participation offered. The practice manager or lead will be provided with the Practice Information and Consent Form"
62590891|NCT02222350|EXPERIMENTAL|DS-8500a 10mg once daily|10mg DS-8500a tablet given orally once daily
62590892|NCT02222350|EXPERIMENTAL|DS8500a 75 mg once daily|75mg DS-8500a tablet given orally once daily
62029473|NCT01899846|EXPERIMENTAL|Cohort 3|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation 32 - 36 weeks gestation
62228269|NCT00610103|PLACEBO_COMPARATOR|Placebo|Placebo
62420907|NCT05848687|EXPERIMENTAL|Treatment|"Participants who meet eligibility criteria will receive remission induction, induction intensification, consolidation I, reinduction block I, reinduction block II, consolidation II, and Maintenance.~Interventions: Dexamethasone, Mitoxantrone, PEG-asparaginase, Bortezomib, Vorinostat, Mercaptopurine, Methotrexate and Vincristine, Blinatumomab, Ziftomenib"
62420908|NCT06453005|EXPERIMENTAL|Single Arm Split-Mouth Design|Our study involves comparing two different dental treatment modalities, the SMART Hall technique and standard Stainless Steel Crown (SSC) restoration, in a split-mouth design. In this design, each participant serves as their own control, receiving both interventions sequentially. The 'Single Arm' model aligns with our study structure, indicating that all participants receive both treatment modalities. This approach is consistent with our split-mouth study design, where each participant acts as their own control.
62420909|NCT00572156|ACTIVE_COMPARATOR|1. rhGH Alone|
62420910|NCT00572156|EXPERIMENTAL|2. Combination Dose|
62420911|NCT00572156|EXPERIMENTAL|3. Combination Dose|
62420912|NCT00572156|EXPERIMENTAL|4. Combination Dose|
62420913|NCT04946071|NO_INTERVENTION|Control|Period in which each group will not receive the arts-based HIV stigma intervention.
62420914|NCT04946071|EXPERIMENTAL|Group 1|"Arts-based HIV stigma intervention for three 8-week periods (24 weeks). The intervention will begin with 5 weeks of two 2 interrelated activities: 1) Transformative educational activities that will engage learners in problem-based discussions; 2) Arts-based activities that will focus on addressing the problem through finding solutions and encouraging action will be accomplished by learning traditional Ugandan songs, dance, told and acted stories, proverbs and sayings that incorporate empowering messages and moral teachings connected with self and community, respect for self, peers and authority, and responsibility for others. These activities will be followed by 3 weeks of a participatory theatre intervention (PTI) developed by students that will summarize the learnings and cultural traditions from the weekly sessions."
62590893|NCT02222350|PLACEBO_COMPARATOR|placebo to match DS-8500a tablet|placebo matching DS-8500a tablet
62590894|NCT03046316|OTHER|local consolidative treatment|Patients will be referred to multiple disciplinary treatment discussion for the decision of local consolidative treatment to primary or metastatic lesions including surgery, radiotherapy or interventional therapy.
62029474|NCT04781153|EXPERIMENTAL|Immediate intervention (A)|Subjects will receive the full mouth disinfection treatment protocol (scaling and rootplaning of all periodontal pockets with adjunctive use of chlorhexidine mouthwash) immediately after baseline.
62420915|NCT04946071|EXPERIMENTAL|Group 2|"Arts-based HIV stigma intervention for two 8-week periods (16 weeks). Each intervention period will begin with 5 weeks of two 2 interrelated activities: 1) Transformative educational activities that will engage learners in problem-based discussions; 2) Arts-based activities that will focus on addressing the problem through finding solutions and encouraging action will be accomplished by learning traditional Ugandan songs, dance, told and acted stories, proverbs and sayings that incorporate empowering messages and moral teachings connected with self and community, respect for self, peers and authority, and responsibility for others. These activities will be followed by 3 weeks of a participatory theatre intervention (PTI) developed by students that will summarize the learnings and cultural traditions from the weekly sessions."
62420916|NCT04946071|EXPERIMENTAL|Group 3|"Arts-based HIV stigma intervention for one 8-week period. The intervention period will begin with 5 weeks of two 2 interrelated activities: 1) Transformative educational activities that will engage learners in problem-based discussions; 2) Arts-based activities that will focus on addressing the problem through finding solutions and encouraging action will be accomplished by learning traditional Ugandan songs, dance, told and acted stories, proverbs and sayings that incorporate empowering messages and moral teachings connected with self and community, respect for self, peers and authority, and responsibility for others. These activities will be followed by 3 weeks of a participatory theatre intervention (PTI) developed by students that will summarize the learnings and cultural traditions from the weekly sessions."
62029475|NCT04781153|EXPERIMENTAL|Delayed intervention (B)|"Subjects will receive a full mouth disinfection treatment protocol (scaling and rootplaning of all periodontal pockets with adjunctive use of chlorhexidine mouthwash) 3-4 weeks after baseline. The delayed intervention will enable the study team to explore the effect of the participants change in behavior due to participation in a research project, and furthermore how change in oral hygiene habits might affect the lung function."
62029476|NCT03579745|ACTIVE_COMPARATOR|Conventional lingual mechanics|
62590895|NCT01720498|EXPERIMENTAL|Male|To find out the effect site concentration of remifentanil for preventing QTc prolongation \< 15 sec during intubation : Dixon's up-and-down method
62029477|NCT03579745|EXPERIMENTAL|Lever arm lingual mechanics|
62029478|NCT00547391|NO_INTERVENTION|1|patients on waiting list for a minimum of 5 months. These patients receive no prophylactic intervention for their recurrent pharyngitis episodes.
62029479|NCT00547391|ACTIVE_COMPARATOR|2|Tonsillectomy as soon as possible after randomization (within 2-3 weeks).
62029480|NCT02544243|EXPERIMENTAL|A|Vinorelbine 25 mg/m2 d1, 8; Gemcitabine 1000 mg/m2 d1, 8 q 3 weeks
62029481|NCT02544243|EXPERIMENTAL|B|Vinorelbine 25 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1,2,3 q 3 weeks
62029482|NCT06161844|EXPERIMENTAL|Semaglutide injection (HD1916)|Up to 1.0 mg semaglutide (HD1916) Metformin ≥ 1500 mg/day
62420917|NCT05035407|EXPERIMENTAL|Treatment at dose levels 1 through 7|Non-myeloablative, lymphocyte depleting preparative regimen, followed by KK-LC-1 TCR T cells plus aldesleukin at escalating doses
62420918|NCT06567964|ACTIVE_COMPARATOR|Erector Spinae Plane Block (Group E)|"ESPB was administered preoperatively under ultrasound guidance via a high-frequency linear probe (Sonosite M-Turbo, Fujifilm Sonosite Inc., USA) (Figure 1). The procedure was as follows:~1. Patient Positioning: The patient was positioned in the lateral decubitus position, with the side to be blocked uppermost.~2. Ultrasound Setup: A high-frequency linear ultrasound probe was placed in a parasagittal orientation over the transverse process of the lumbar vertebra at the level of surgery.~3. Needle Insertion: After skin disinfection with chlorhexidine, a 22-gauge, 100-mm needle (Stimuplex A, B. Braun Melsungen AG, Germany) was inserted in-plane to the ultrasound probe. The needle was advanced until the tip contacted the transverse process.~4. Injection: Following negative aspiration to ensure no vascular puncture, 20 mL of 0.5% bupivacaine was injected incrementally, with real-time ultrasound visualization to confirm the correct spread of the anesthetic solution."
62590896|NCT01720498|EXPERIMENTAL|Female|To find out the effect site concentration of remifentanil for preventing QTc prolongation \< 15 sec during intubation : Dixon's up-and-down method
62590897|NCT02348151|EXPERIMENTAL|Treadmill|The Shuttle is going to play on treadmill
62590898|NCT02348151|ACTIVE_COMPARATOR|Corridor|The Shuttle is going to play on corridor
62590899|NCT03793673|OTHER|Standard Care: Standard appointments|"Usual in-person medical appointments. See previous detailed description.~COVID-19 Update: Current clinic appointments consist of telehealth appointments only. Any additional community and CHLA based educational and support events will be following COVID-19 guidelines."
62029483|NCT06161844|ACTIVE_COMPARATOR|Ozempic®|Up to 1.0 mg semaglutide (Ozempic®) Metformin ≥ 1500 mg/day
62029484|NCT04976738|EXPERIMENTAL|Treatment arm: Cybis™ 10:25 THC:CBD oil|Cybis™ 10:25 THC:CBD oil administered oromucosally at doses varying from 0.5 mL once daily to 1.5 mL twice daily. Total duration of dosing is 28 days.
62029485|NCT03506516|EXPERIMENTAL|single type|Restricted to drinking only one type of alcohol
62029486|NCT03506516|ACTIVE_COMPARATOR|mixed type|Drinking and mixing different types of alcohols freely
62029487|NCT05983601|ACTIVE_COMPARATOR|Active tDCS+Balance training|The current intensity will be 2mA and the duration of stimulation will be 20 minutes with direct current stimulation. In the beginning and end of the tDCS stimulation, there will be 30 second ascent and descent period.
62029488|NCT05983601|SHAM_COMPARATOR|Sham tDCS+Balance Training|In sham stimulation, the current will increase to 2 mA in the first thirty second, following by 30 second active stimulation, then it will be dropped to 0 mA. Brief electric current will be given in order to create a tingling sensation under electrodes.
62029489|NCT06448871||group 1, pws group|Individuals with PWS, aged 7 to 65 years, and able to follow simple instructions in chinese language.
62029490|NCT05932069|EXPERIMENTAL|SPIN|Exercise 3 times a week on a stationary ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes per session
62029491|NCT05932069|ACTIVE_COMPARATOR|Non-aerobic, stretching/balance intervention Control|For this arm of the intervention, randomized participants followed the same guidelines as the SPIN group but did not partake in aerobic exercise. To equalize contact/monitoring of the groups this group met for the same total duration time as the SPIN group; however, instead of aerobic exercise, progressive whole body stretching and toning exercises
62029492|NCT01863277|ACTIVE_COMPARATOR|Melatonin|Melatonin 14mg/daily given over 14 days
62029493|NCT01863277|PLACEBO_COMPARATOR|sugar pill|sugar pill given over 14 days
62029494|NCT04348604|EXPERIMENTAL|Customized Adherence Enhancement for AYA|This arm will receive the experimental intervention, Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA).
62029495|NCT04348604|ACTIVE_COMPARATOR|Enhanced Treatment as Usual (ETAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (ETAU).
62029496|NCT05135910|EXPERIMENTAL|HSG|Hallux terbinafine subungual gel
62029497|NCT05078190||Doxorubicin|Patients treated with doxorubicin (Adriamycin) for breast cancer
62029498|NCT05078190||Trastuzumab|Patients treated with trastuzumab (Herceptin) for breast cancer
62029499|NCT05078190||Doxorubicin and Trastuzumab|Patients treated with both doxorubicin (Adriamycin) and trastuzumab (Herceptin) for breast cancer
62029500|NCT03892772|EXPERIMENTAL|SAS0421a, SAS0421b and SAS0421c|Participants will take SAS0421a, SAS0421b and SAS0421c for 3 days. Half doses will be given on the first night.
62029501|NCT03892772|ACTIVE_COMPARATOR|SAS0421a and SAS0421b|Participants will take SAS0421a and SAS0421b for 3 days. Half doses will be given on the first night.
62029502|NCT03892772|ACTIVE_COMPARATOR|SAS0421c|Participants will take SAS0421c for 3 days. Half doses will be given on the first night.
62590900|NCT03793673|OTHER|Standard Care: Telehealth appointments|Telehealth - with provider and/or team. See previous detailed description.
62029503|NCT03892772|PLACEBO_COMPARATOR|Placebo|Participants will take placebos for 3 days.
62029504|NCT05409014|EXPERIMENTAL|PFMT|The exercises of this protocol were performed at home, but with face-to-face meetings in the first phase of the protocol (awareness) and every 15 days, where the physical therapist taught the new exercises to be performed in the next phase. All protocol meetings were performed by a trained physical therapist/researcher. In situations where it was not possible to hold the meetings in person, due to the Covid-19 pandemic, they were held online through video calls with the responsible researcher. The PFMT protocol lasts for eight weeks and was divided into five phases: awareness, stabilization, strength, potency and potency complement. Each phase is 2 weeks long.
62029505|NCT02535208|EXPERIMENTAL|Restrictive transfusion group|
62029506|NCT02535208|ACTIVE_COMPARATOR|Liberal transfusion group|
62029507|NCT03487835|EXPERIMENTAL|Kinesiotape group|
62029508|NCT03487835|EXPERIMENTAL|Control group|
62029509|NCT04728243|EXPERIMENTAL|WHO QualityRights|Mental health professionals assigned to the experimental arm will be enrolled in the WHO QualityRights online training.
62029510|NCT04728243|PLACEBO_COMPARATOR|WHO Coronavirus Disease of 2019 (COVID19)|Mental health professionals assigned to the control arm will be enrolled in the WHO novel coronavirus 2019 online training series.
62029511|NCT00982358|PLACEBO_COMPARATOR|Placebo|
62029512|NCT00982358|ACTIVE_COMPARATOR|Valsartan|
62029513|NCT05892354|EXPERIMENTAL|Immunonutrition Group|"Induction chemotherapy (IC) + Concurrent chemoradiotherapy (CCRT) and enteral immunonutrition~Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2-3 cycles before radiotherapy and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin (100mg/m² d1) every 3 weeks for 2-3 cycles.~Patients receive enteral immunonutrition, Oral Impact®, Nestle, 250ml/ bottle, 2 bottles per day, from 5 days before radiotherapy to the end of radiotherapy."
62243118|NCT05634252|EXPERIMENTAL|Education + Action Plan + UV Photo + MC1R Test|Students in this intervention will receive education on skin cancer and prevention strategies, complete an individualized sun protection and tanning worksheet for situations in which they receive UVR exposure, receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system, and provide a saliva sample using an Oragene® clinical-grade saliva kit and receive individualized results following MC1R sequencing.
62420919|NCT06567964|ACTIVE_COMPARATOR|Wound infiltration (Group WI)|"Wound infiltration was performed by the surgeon at the end of the surgery via the following procedure:~1. Preparation: After hemostasis was achieved and before skin closure, 20 mL of 0.5% bupivacaine was prepared in a sterile syringe.~2. For infiltration, the anesthetic mixture was infiltrated into multiple layers of the surgical wound. This included the subcutaneous tissue and muscle layers, ensuring the even distribution of the anesthetic solution to cover the entire surgical area."
62590901|NCT03793673|OTHER|CoYoT1 Care: Standard Appointment|"In-person - medical appointments with provider and/or team. See previous detailed description.~COVID-19 Update: Current clinic appointments consist of telehealth appointments only. Any additional community and CHLA based educational and support events will be following COVID-19 guidelines."
62804153|NCT00721396|EXPERIMENTAL|B+R246|Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations.
62804154|NCT00721396|EXPERIMENTAL|B246_R357|Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age.
62590902|NCT03793673|OTHER|CoYoT1 Care: Telehealth appointments|Telehealth - with provider and/or team. See previous detailed description.
62735330|NCT04737434|PLACEBO_COMPARATOR|electromagnetic field with no wave|electromagnetic field with no wave
62804155|NCT00721396|EXPERIMENTAL|B+R234|Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations.
62804156|NCT00721396|ACTIVE_COMPARATOR|R234|Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.
62804157|NCT03974386|EXPERIMENTAL|Blood Purification|Patients will receive resuscitation and treatment according to current guidelines for septic shock. In addition to standard care, the patients will receive continuous venovenous hemofiltration and adsorption with oXiris blood purification set.
62804158|NCT03974386|NO_INTERVENTION|Conventional Treatment|Patients will receive standard care, including resuscitation and treatment according to current guidelines for septic shock.
62804159|NCT02843906|ACTIVE_COMPARATOR|BD/CD +|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
62804160|NCT02843906|ACTIVE_COMPARATOR|BD/CD -|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
62804161|NCT02843906|ACTIVE_COMPARATOR|a-MCI|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
62029514|NCT05892354|ACTIVE_COMPARATOR|Control Group|"Induction chemotherapy+Concurrent chemoradiotherapy and standard enteral nutrition~Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2-3 cycles before radiotherapy and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin(100mg/m² d1) every 3 weeks for 2-3 cycles.~Patients receive isocaloric standard enteral nutrition formula (ENSURE®), 250 mL per administration, 3 times per day, from 5 days before radiotherapy to the end of radiotherapy. Preparation of the 250 mL dose involves adding 200 mL of potable water to a cup and slowly stirring in 52.7 g of ENSURE powder (approximately 6 scoops)."
62029515|NCT04223193|EXPERIMENTAL|Tavapadon|Participants will receive tavapadon tablet titrated up to 15 milligram (mg) once daily (QD) orally for 27 weeks.
62029516|NCT04223193|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
62029517|NCT06312839||Control group|Esophagectomy alone
62029518|NCT06312839||Study Group|Preoperative ischemic conditioning before esophagectomy
62029519|NCT03222518|ACTIVE_COMPARATOR|Parcetamol Group|The patient receives an envelope containing Paracetamol 1000 mg at the dose of 3 times / day + follow-up sheet + appointment card.
62029520|NCT03222518|ACTIVE_COMPARATOR|NSAID Group|The patient receives an envelope containing NSAID 20 mg piroxicam twice daily / day + follow-up sheet + appointment card.
62029521|NCT03222518|ACTIVE_COMPARATOR|NSAID + Paracetamol Group|The patient receives an envelope containing NSAID 20 mg piroxicam at a dose of 2 times/day + Paracetamol 1000 mg at a dose of 3 times / day + follow-up sheet + appointment card.
62029522|NCT04006977|PLACEBO_COMPARATOR|Arm 1: placebo plus standard therapy|placebo plus standard therapy
62029523|NCT04006977|EXPERIMENTAL|Arm 2: DSF plus standard therapy|DSF (4 sachets/day) plus standard therapy
62029524|NCT01417312|ACTIVE_COMPARATOR|Green tea extract|
62029525|NCT01417312|PLACEBO_COMPARATOR|Placebo|
62029526|NCT04846608||Nursing home residents with behavioural problems|Nursing home residents from Grand Nancy aged 75 and over referred to emergency departments for disorientation, agitation, dementia or behavioural problems during the study period
62029527|NCT04846608||Nursing home residents with other problems|Nursing home residents from Grand Nancy aged 75 and over referred to emergency departments for other reasons
62029528|NCT00546728|EXPERIMENTAL|Exenatide|Subjects were randomlly assigned to treatment arm: Exenatide 10 mcg twice daily vs. Metformin 500 mg twice daily.
62029529|NCT00546728|ACTIVE_COMPARATOR|Metformin|Subjects were randomlly assigned to treatment arm: Exenatide 10 mcg twice daily vs. Metformin 500 mg twice daily.
62029530|NCT04561479|ACTIVE_COMPARATOR|Training Group|Intervention:Training group will receive upper extremity aerobic exercise training, inspiratory muscle training and progressive resistance training
62029531|NCT04561479|SHAM_COMPARATOR|Control Group|Control group will receive alternative upper extremity exercises and breathing exercises.
62029532|NCT03929146|EXPERIMENTAL|Liposomal Bupivacaine|Patients in this group will receive a single intra-operative injection of liposomal bupivacaine near the surgical site (40 ml total: consisting of 20 ml 1.3% liposomal bupivacaine and 20 ml normal saline).
62029533|NCT03929146|OTHER|Interscalene Nerve Block|Patients in this group will receive a single pre-operative interscalene nerve block in the neck/shoulder consisting of 30 ml 0.5% ropivacaine.
62029534|NCT01774565|EXPERIMENTAL|Fully Automated Closed-Loop Insulin Delivery (phase 1-4)|The control algorithm will automatically direct between meals and meal-related subcutaneous insulin delivery utilizing real-time continuous glucose monitoring (RT-CGM) data. The subcutaneous insulin pump will deliver insulin Aspart or similar. In phase 1, a once daily basal insulin analogue will also be given subcutaneously at 20% the patient's usual total daily dose. In phase 3 and 4 faster-acting insulin aspart (Fiasp) is applied.
62029535|NCT01774565|ACTIVE_COMPARATOR|Usual care/ fully-automated closed-loop using Iasp|"Phase 1-3: During usual care (conventional therapy), subject's s.c. insulin dose and regimen on admission will be adjusted as necessary by the clinical team according to local centres' usual clinical practice. Subjects will have masked CGM sensors inserted during the study (CGM readings will be masked throughout the study).~Phase 4: subjects will receive fully-automated insulin delivery using standard insulin aspart (Iasp)"
62029536|NCT00848679|ACTIVE_COMPARATOR|Epidural lidocaine|30 women to receive 5 x 5mL boluses of epidural lidocaine 2%. 10 pre-eclampsia, 10 term pregnancy, 10 non-pregnant.
62029537|NCT00848679|PLACEBO_COMPARATOR|Epidural saline|30 women to receive 5 x 5 mL boluses of epidural saline. 10 pre-eclamptics, 10 normal term pregnancy, 10 non-pregnant
62029538|NCT05969067|PLACEBO_COMPARATOR|Dissection Technique|The peritoneum is incised superficially and opened longitudinally from the sacral promontory, downward to the posterior cul-de-sac and the posterior vaginal wall to create retroperitoneal space for the SCP mesh.
62420920|NCT06702852|NO_INTERVENTION|Control|The control group will receive the standard of care per the facility Standard Operating Procedures (SOP)
62735331|NCT05580770|EXPERIMENTAL|Phase 1 Dose Escalation Cohorts Ranging in Dose|Participants with an oncogenic mutation or other genomic aberration of the MAPK pathway
62029539|NCT05969067|EXPERIMENTAL|Tunneling Technique|A retroperitoneal tunnel is created by undermining the peritoneum with the robotic scissors and/or needle driver which is placed in the peritoneal opening over the sacral promontory. The tunnel is created just medial to the right uterosacral ligament and toward the posterior vaginal wall by using forward pressure and a sweeping motion to create a space within the retroperitoneum
62029540|NCT00845572|EXPERIMENTAL|Consta Club|
62029541|NCT04695834|ACTIVE_COMPARATOR|Conservative treatment|"Patients that are randomized to the conservative arm of the trial. These patients will not be operated until primary endpoint is reached.~If necessary, cross-over can occur after primary endpoint is reached.~Conservative treatment is considered standard of care."
62029542|NCT04695834|ACTIVE_COMPARATOR|Surgical treatment|"Patients randomized to the surgical arm will be operated within 1 week after randomization (if possible within 2 days).~Neurolysis is considered standard of care."
62029543|NCT04005183||All patients|Patients undergoing nephrectomy at the University Health Network are eligible for enrolment. All renal cell carcinoma histological subtypes and stages are eligible. Tumor, blood and urine samples are acquired at the time of nephrectomy.
62029544|NCT00749151|NO_INTERVENTION|Literature|
62029545|NCT00749151|EXPERIMENTAL|Lit + Counseling|
62029546|NCT02700282|EXPERIMENTAL|Cystic Fibrosis children|"Children with Cystic Fibrosis will experience lung function measurement while backpack carrying.~Aerobic Capacities will also be assessed during treadmill gait."
62029547|NCT02700282|ACTIVE_COMPARATOR|Healthy Children|"Healthy Children will experience lung function measurement while backpack carrying.~Aerobic Capacities will also be assessed during treadmill gait."
62029548|NCT06636305|EXPERIMENTAL|physical activity intervention|Women in the intervention group were instructed to obtain 10,000 steps per day and 150 minutes of MVPA (defined as physical activity that resulted in a heart rate in the range of 120-170 bmp) per week and were given a physical activity tracker (FitBit Charge HR 2, Fitbit, San Francisco, USA) to self-monitor progress.
62029549|NCT06636305|NO_INTERVENTION|control group|Women in the control group were given a physical activity tracker (FitBit Charge HR 2, Fitbit, San Francisco, USA) but no other physical activity instructions.
62029550|NCT06223828|EXPERIMENTAL|Azithromycin Intervention|Participants in this arm will receive Azithromycin 10mg/kg/dose (max dose 500mg) once daily for 3 days.
62029551|NCT06223828|NO_INTERVENTION|Standard Care|Participants will receive standard care without Azithromycin.
62029552|NCT06470529||PCI|Post PCI patients with drug eluting stents
62029553|NCT06530017|EXPERIMENTAL|Subjects in the Study group will be treated with Ingested, Space Occupying hydrogel capsules, which|During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water.
62029554|NCT06530017|PLACEBO_COMPARATOR|Subjects in the Placebo group will be treated with placebo of the control medical device.|During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water.
62029555|NCT05493553|NO_INTERVENTION|Baseline|A baseline period (no supplements or intermittent fasting).
62029556|NCT05493553|EXPERIMENTAL|Phase 1|A four-day period during which subjects will take a yerba mate supplement once per day in the morning and a fiber-based supplement twice per day prior to two meals.
62029557|NCT05493553|EXPERIMENTAL|Phase 2|A four-day period during which subjects will take a yerba mate supplement once per day in the morning and a fiber-based supplement twice per day prior to two meals, while also practicing daily intermittent fasting (16 hours fasting, 8 hours eating window).
62029558|NCT04993326|OTHER|Intervention|"emPOWERed to Change~Online Courses:~4 Critical Step to Manage Diabetes modules~* Step 1 Learn about diabetes~* Step 2 Know your diabetes ABCs~* Step 3 Learn how to live with diabetes~* Step 4 Get routine care to stay healthy Diabetes + COVID-19 Protection and Prevention modules~* Introduction to understanding COVID-19 and the risks specific to T2DM~* Learn preventive and protective measures to avoid COVID-19~* COVID-19 Vaccine education and Discussion guide~* Community resource guide to access COVID-19 testing and vaccination Stress Management modules~* Understanding of the relationship between diabetes and stress~* Learn stress management techniques for diabetes Ongoing Program Support: Motivation for participation, medication adherence, accountability and peer-to-peer interaction and support (bi-weekly text messages \& private and closed Facebook community support group with peers and professionals)"
62029559|NCT04993326|NO_INTERVENTION|Control|Usual Standard of Care as deemed by participants provider(s)
62029560|NCT05061264|EXPERIMENTAL|Active infection group|A cohort of 38 patients carrying an active infection (mesh sinus, exposed mesh or enteric fistulas) resulting from a previous hernia repair, with or without an associated recurrent ventral hernia, and submitted to abdominal wall reconstruction with PVDF mesh.
62029561|NCT05061264|ACTIVE_COMPARATOR|Clean control group|A cohort of 38 patients with ventral hernias, and submitted to clean ventral hernia repair with PVDF mesh.
62029562|NCT01412723|ACTIVE_COMPARATOR|Ferrous sulphate|Preschool children with depleted levels of iron enrolled in FAN Foundation of Medellin, which will be supplied with ferrous sulfate-fortified milk
62029563|NCT01412723|EXPERIMENTAL|Iron Amino acid chelate|Preschool children with depleted levels of iron enrolled in FAN Foundation of Medellin , which will be supplied with iron amino acid chelate-fortified milk
62029564|NCT06535594|EXPERIMENTAL|Laser acupuncture + Physical therapy|Laser acupuncture five times a week for a total of four weeks (20 sessions). Physical therapy three times a day, five times a week for a total of four weeks.
62420921|NCT06702852|EXPERIMENTAL|Intervention|The intervention group will receive the standard of care per the facility Standard Operating Procedures (SOP) with the addition of NIRS imaging utilizing the SnapshotNIR
62029565|NCT03081455||Women meeting guidelines for genetic testing|Women who present for an OB/GYN office visit (new patient visit, well woman visit, or problem visit) and who meet guidelines for genetic diagnostic testing will provide a blood or saliva sample for genetic diagnostic testing and complete a satisfaction survey.
62029566|NCT05253898|ACTIVE_COMPARATOR|Pelvic Floor Physical Therapy|"Group 1 includes a training program about correctly using pelvic floor muscles. At the first session, an educational program will be given to all women about the anatomy and function of the pelvic floor muscles. Then, the pelvic floor muscles contractions will be controlled by vaginal palpation for approximately 10 minutes.~Then it will follow with 5 minutes of warm-up exercises, 30 minutes of fast and slow pelvic floor muscles contractions in different positions, and 10 minutes of abdominal breathing, general relaxation, stretching, and cool-down exercises.~It is planned to teach contractions with internal palpation for 10 minutes before the first session to ensure that the patients' pelvic floor contractions are performed correctly. PFT treatment will be given as two sessions per week, 45 minutes, and 8 weeks as group sessions."
62029567|NCT05253898|ACTIVE_COMPARATOR|Therapeutic Yoga Training|"Group 2 program includes therapeutic yoga training. It will begin with education about the positive effects of yoga on the body and pelvic floor.~Then it will follow with 5 minutes of warm-up exercises, 30 minutes of different asanas coordinated with breathing, and 10 minutes of yogi breathing and cool-down exercises.~Also, a home exercise program will be given based on yoga sessions. Participants will receive a detailed description of the home program."
62804162|NCT00754585||I|"All participants will perform the five Chair Support tasks: (1) quiet standing, sitting, (2) upper back unsupported, (3) sitting, upper back unsupported with Logic Back in place, (4) sitting in a standard ergonomic chair, and (5) sitting in a standard ergonomic chair with Logic Back in place. Aside from the Quiet Standing trials which will be performed first, the order of Chair Support will be randomized. Participants will perform the Chair Support task for 30 minutes while quietly watching a movie DVD of their choice. The DVDs provided will the light in content without a lot of suspense or emotion. Data will be collected for the final two minutes of each 30-minute trial."
62228270|NCT04660604|EXPERIMENTAL|Graston Technique® Group|Participants were asked to warm up at a speed that they felt comfortable for 5 minutes at a gentle tempo with an ergometer. Time was followed by a stopwatch. Participants who completed warm-up were taken to GT® application. Application was implemented by a GT® certified therapist with 13 years of experience in orthopedic rehabilitation. Intervention dosage was determined as 2 times a week, 12 sessions over 6 weeks. GMed muscle was scanned between crista iliaca and trochanter major, and a fascial release was applied. Each session lasted 5 minutes. At the end of sessions, iliotibial band stretching exercises (30 seconds, 3 repetitions) was given to the treated side. Application protocol has been determined with reference to GT® manual
62804163|NCT05222828|EXPERIMENTAL|Mepivacaine arm|mepivacaine injection
62804164|NCT02807623|EXPERIMENTAL|Ibuprofen|Randomized and double blinded study participants assigned to Group A intervention will receive an oral NSAID of ibuprofen 800 mgs three times a day for 48 hours.
62228271|NCT04660604|NO_INTERVENTION|Control Group|Control group is followed up for 6 weeks without intervention.
62228272|NCT02534038|PLACEBO_COMPARATOR|Placebo|Placebo drug to be taken twice a day for 6 weeks
62804165|NCT02807623|PLACEBO_COMPARATOR|Placebo|Randomized and double blinded study participants assigned to Group B intervention will receive an oral placebo three times a day for 48 hours starting immediately after influenza vaccine receipt.
62804166|NCT02807623|EXPERIMENTAL|Compound Exercise of Push-ups|Randomized study participants assigned to Group C will perform an exercise intervention of push-ups immediately after influenza vaccine receipt.
62804167|NCT04082234|EXPERIMENTAL|Integrated Individualized Behavioral Parent Training|Partnering to Achieve School Success (PASS) is a personalized, enhanced behavioral intervention for ADHD that includes evidence-based behavior therapy strategies and enhancements to promote family engagement in treatment, team-based care, and high quality therapy. Caregivers engage in up to 12 sessions with a behavioral health provider over the course of 16 weeks that are specifically tailored to caregiver goals and values.
62804168|NCT04082234|ACTIVE_COMPARATOR|Treatment as Usual|The control condition will be TAU informed by AAP guidelines for managing ADHD and facilitated by electronic practice supports, which have been successfully incorporated into the electronic health record (EHR) to guide primary care providers (PCPs) in implementing ADHD guidelines. At CHOP, PCPs across the primary care network were invited to participate in a distance learning, quality improvement initiative to promote implementation of AAP guidelines, including strategies to educate families about ADHD and evidence-based treatments, engage families in shared decision making, titrate medication, and monitor treatment effects. The six practices participating in this study participated in that project.
62228273|NCT02534038|ACTIVE_COMPARATOR|AVP-786|Participants randomized to AVP-786 will take one dose of AVP-786 once a day and one dose of placebo once a day for the first 7 days; from day 8, participants will receive AVP-786 twice a day for 5 weeks.
62228274|NCT03377426|EXPERIMENTAL|LYS228|IV infusion
62228275|NCT03377426|ACTIVE_COMPARATOR|Standard of care|IV infusion of standard of care antibiotics for at least 5 days
62228276|NCT02102477|EXPERIMENTAL|Prostatectomy/Surgery|Patients with locally advanced prostate adenocarcinoma recieves Prostatectomy/Surgery with or without adjuvant or salvage radiotherapy
62804169|NCT01013051||Post Gastric Bypass|
62804170|NCT01013051||Obese Controls|age, BMI, gender matched
62029568|NCT04274608|EXPERIMENTAL|Intervention Arm|"Patients in the intervention arm will receive 300units of Botulinum Toxin A (Botox; Allergan Inc., Irvine, Ca, USA) diluted to 10mls of saline. Endoscopy will be performed using a single-lumen gastroscope. Injection of the solution will be done using a 23Gauge Interject needle catheter. 20 separate injections of 0.5ml each will be performed in a concentric ring 1cm apart. 10 injections will be performed into the body of the stomach, and 10 injections into the fundus, from the level of the CEJ and above~Patients will undergo a 12-week weight management program approximately 2 weeks after the injection of Botox."
62029569|NCT04274608|ACTIVE_COMPARATOR|Control Arm|Patients will undergo a 12-week weight management program.
62228277|NCT02102477|ACTIVE_COMPARATOR|Radiotherapy with adjuvant androgen deprivation therapy|Patients with locally advanced prostate adenocarcinoma treated with adjuvant androgen deprivation therapy
62590903|NCT01901354|ACTIVE_COMPARATOR|Low-tidal-volume ventilation|Subjects will be ventilated with a goal tidal volume of 6 cc/kg predicted body weight (PBW), a goal plateau pressure of \<30 cm H2O, and a goal respiratory rate of 6-35 bpm to achieve a goal arterial pH of 7.30 to 7.45. Positive end-expiratory pressure is set as per the ARDSNet Positive end-expiratory pressure table
62735332|NCT05580770|EXPERIMENTAL|Phase 2 Dose Expansion A|Participants with cutaneous melanoma harboring NRAS mutations
62804171|NCT02488837||DBS subjects|deep brain stimulation (DBS) in patients with Parkinson's disease, tremor, dystonia, and Tourette's syndrome
62420922|NCT04192786|EXPERIMENTAL|Treatment Group 50 Hz|
62804172|NCT06027866||Tracheostomy patients|All consenting participants will receive access to SRAVI (Speech Recognition Application for the Voice Impaired), a communication aid for speech-impaired patients. SRAVI is a software-based mobile application ('app') and can be downloaded onto any device with a standard forward facing camera (e.g., smartphone, tablet). SRAVI has been registered with the Medical and Healthcare products Regulatory Agency (MHRA) and CE marked for intended use. SRAVI is based on Visual Speech Recognition (VSR) technology. Specifically, the LipRead technology can determine speech by analysing the movements of a user's lips as they speak into a camera.
62804173|NCT01156480|EXPERIMENTAL|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via intravenous (IV) route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. Subjects in placebo group will receive equal volume of placebo on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
62804174|NCT01156480|PLACEBO_COMPARATOR|Placebo|Subjects in placebo group will receive equal volume of placebo (as compared to hydrocortisone arm) on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
62804175|NCT01654926||Heart Failure patients|
62804176|NCT02843269|ACTIVE_COMPARATOR|Multi-component lifestyle intervention 1|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
62029570|NCT02352948|EXPERIMENTAL|MEDI4736 (durvalumab) monotherapy in Sub-study A|MEDI4736 (durvalumab) by intravenous infusion. Sub-study A for patients with PD-L1 positive tumors.
62420923|NCT04192786|EXPERIMENTAL|Treatment Group 100 Hz|
62029571|NCT02352948|ACTIVE_COMPARATOR|Standard of Care in Sub-study A|Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study A for patients with PD-L1 positive tumors.
62735333|NCT05580770|EXPERIMENTAL|Phase 2 Dose Expansion B|Participants with NSCLC harboring KRAS mutations
62420924|NCT04192786|ACTIVE_COMPARATOR|Control Group|
62420925|NCT00411762|EXPERIMENTAL|PHY906 Administration|PHY906 800mg, orally, twice a day for days 1-4 and capecitabine 1500mg/m\^2 days 1-7 of a 14-day cycle
62420926|NCT06611475||MMSE ≤26|339 participants
62420927|NCT06611475||MMSE 30|354 participants
62420928|NCT00921765|PLACEBO_COMPARATOR|Placebo + Placebo|Saline single bolus dose iv + saline single bolus dose iv
62420929|NCT00921765|ACTIVE_COMPARATOR|Placebo + Ketamine|Saline single bolus dose followed by single bolus dose of ketamine 0.2 mg/kg bw
62420930|NCT00921765|ACTIVE_COMPARATOR|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
62029572|NCT02352948|EXPERIMENTAL|MEDI4736 (durvalumab) + tremelimumab in Sub-study B|MEDI4736 (durvalumab) by intravenous infusion and tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
62029573|NCT02352948|ACTIVE_COMPARATOR|Standard of Care in Sub-study B|Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study B for patients with PD-L1 negative tumors.
62029574|NCT02352948|EXPERIMENTAL|MEDI4736 (durvalumab) monotherapy in Sub-study B|MEDI4736 (durvalumab) by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
62029575|NCT02352948|EXPERIMENTAL|tremelimumab in Sub-study B|tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
62029576|NCT00060450|EXPERIMENTAL|1|Inhaled Nitric Oxide
62029577|NCT00060450|PLACEBO_COMPARATOR|2|Placebo gas
62029578|NCT04724317|SHAM_COMPARATOR|Steroid Group|shoulder intra-articular injection of 5 ml of Bupivacaine 0.125% added to triamcinolone 40 mg under the ultrasound guidance
62029579|NCT04724317|ACTIVE_COMPARATOR|Ozone Group|shoulder intra-articular injection of 5 ml of Bupivacaine 0.125% followed by injection of 10 ml of Oxygen-Ozone mixture (15 µg/ml) under the ultrasound guidance
62420931|NCT00921765|ACTIVE_COMPARATOR|Naloxone + Ketamine|Single bolus dose of ketamine 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
62804177|NCT02843269|ACTIVE_COMPARATOR|Multi-component lifestyle intervention 2|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
62804178|NCT02843269|ACTIVE_COMPARATOR|Multi-component lifestyle intervention 3|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
62804179|NCT05720910|EXPERIMENTAL|GERONTE|The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway;
62804180|NCT05720910|NO_INTERVENTION|CONTROL ARM|Patients included in the control arm will be managed according to the standard of care.
62029580|NCT04724317|ACTIVE_COMPARATOR|PRF Group|shoulder intra-articular injection of 5 ml of Bupivacaine 0.125% followed by pulsed radiofrequency application under the ultrasound guidance
62804181|NCT00945282|EXPERIMENTAL|Cohort 1|In Cohort 1 subjects will receive either GSK2248761 30 mg or placebo once a day for 7 days. On Day 8 subjects will receive either Kaletra or HAART for 28 days. The doctor will choose the most appropriate medications for HAART.
62804182|NCT00945282|EXPERIMENTAL|Cohort 2|In Cohort 2 subjects will receive either GSK2248761 in the range of 10 mg - 20 mg or 40 mg - 90 mg or placebo once a day for 7 days. On Day 8 subjects will receive either Kaletra or HAART for 28 days. The doctor will choose the most appropriate medications for HAART. The dose for Cohort 2 will be determined following evaluation of results from Cohort 1. Cohort 2 may not be done.
62804183|NCT05938621|NO_INTERVENTION|Standard of Care|Health care providers in this arm will receive no intervention
62804184|NCT05938621|EXPERIMENTAL|Resilience intervention|Providers in this arm will receive training to improve their resilience and well-being
62029581|NCT00626522|EXPERIMENTAL|1|
62029582|NCT00626522|EXPERIMENTAL|2|
62029583|NCT00626522|EXPERIMENTAL|3|
62029584|NCT00626522|PLACEBO_COMPARATOR|4|
62029585|NCT00626522|PLACEBO_COMPARATOR|5|
62029586|NCT00626522|PLACEBO_COMPARATOR|6|
62029587|NCT05424068|NO_INTERVENTION|Standard best cancer practice|All participants (intervention arms 1 and 2, and control) will receive usual oncology care by their health care providers which includes recommendations for general aerobic and resistance exercise. Participants in the control group will be of recommended to work towards the recommended 90 minutes moderate to vigorous aerobic exercise, and two days a week of large muscle group strength training as recommended by the ACSM. A general brochure will be provided to all control participants providing education in line with current standard of care. This safety precautions noted these will be indicated brochure will have an open text field on the back which will allow the kinesiologist to provide and general advice at each time point. If there are particular here. Participants in all study arms may also be referred by treating health care providers to usual supportive care or early palliative care services at any time deemed necessary, and will be recorded as part of monthly data collection.
62029588|NCT05424068|EXPERIMENTAL|In-person Intervention arm|The in-person intervention arm is an 8-week program and four week short maintenance period. This includes 1 hr of in-person, group-based exercise guided by a qualified exercise professional followed by 1 hr of in-person, group based, self-management education provided by a rehabilitation expert to occur immediately following the exercise session. Each participant is given a FitBit® to track steps, heart rate and sleep. Each site (i.e., Toronto and Vancouver) will run independent, in-person exercise and educational programs based on local referrals. Self management sessions include 8 high priority topics for advanced cancer patients including: 1) goal setting, 2) managing pain, 3) reducing fatigue and improving sleep, 4) boosting brain health, 5) eating and cooking for wellness, 6) managing emotions, 7) being mindful, and 8) planning for the future. Education sessions will be run by local experts at each site.
62029589|NCT05424068|EXPERIMENTAL|Virtual Intervention arm|The virtual intervention arm will be an 8-week program plus four week short maintenance period but will include two separate 1 hour sessions per week. This includes: 1) 60 minutes of virtual, group-based, synchronous exercise over a virtual secure platform; and, 2) A separate 60 min virtual synchronous education session provided on a separate day (to prevent virtual fatigue). 3) Encouragement to participate in a home program the other days of the week, striving for the recommended 90 min of moderate to vigorous aerobic exercise and 2 days of week or resistance exercise. The virtual intervention group will combine participants across both study locations and run sessions when sufficient numbers are recruited. Self-management education content will be unchanged to the in-person sessions but conducted over a virtual platform (i.e., videoconferencing) with participants also attending virtually.
62029590|NCT01606449||Group 1|Group 1 = Patients with type II Hiatal Hernia submitted to surgical therapy
62029591|NCT01606449||Group 2|Group 2 = Patients with type III Hiatal Hernia submitted to surgical therapy
62029592|NCT01606449||Group 3|Group 3 = Patients with type IV Hiatal Hernia submitted to surgical therapy
62420932|NCT05892965|EXPERIMENTAL|Intervention group|Receive iCBT based EMI with message content, delivery frequency and timing personalised to participants' preferences.
62804185|NCT05938621|EXPERIMENTAL|Resilience and Stigma group|Providers in this group will receive training to improve their resilience and well-being as well as receive sessions about the impact of stigmatizing their patients.
62029593|NCT06316362|OTHER|control group|The first group constitutes the control group that was administered the standard treatment protocol for carbamazepine toxicity.
62029594|NCT06316362|ACTIVE_COMPARATOR|SMOF lipid treated group|The second group received the SMOF lipid infusion in addition to the standard protocol.
62420933|NCT05892965|NO_INTERVENTION|Control group|Receive general mental health information through instant message.
62420934|NCT02233881||Chronic obstructive pulmonary disease patients|
62420935|NCT01892605|EXPERIMENTAL|music listening, no music|The clinical application and mechanism of music therapy The clinical application and mechanism of music therapy (Mozart's effect) on epilepsy (Mozart's effect) on epilepsy
62804186|NCT05938621|EXPERIMENTAL|Anti-stigma group|Providers in this group will receive sessions focusing on the impact that stigmatizing patients can have on themselves and their patients. Strategies to minimize negative feelings will be developed.
62804187|NCT00928902|ACTIVE_COMPARATOR|Peptides with GM-CSF-in-adjuvant, with upfront IL-2|Each of the peptides plus tetanus toxoid peptide, plus GM-CSF in adjuvant, administered subcutaneously and intradermally. Systemic low-dose IL-2 will be administered daily for 6 weeks, beginning at week 1 and ending at week 7.
62804188|NCT00928902|ACTIVE_COMPARATOR|Peptides plus GM-CSF-in-adjuvant, delayed IL-2|"Peptides plus GMCSF-in-adjuvant, with delayed IL-2.~Each of the peptides plus tetanus toxoid peptide, plus GM-CSF in adjuvant, administered subcutaneously and intradermally. Systemic low-dose IL-2 will be administered daily for 6 weeks, beginning at week 4 and ending at week 10."
62804189|NCT04365621|OTHER|ultra-high risk of psychosis patient|patient with ultra -high risk of psychosis will be enrolled to the study
62029595|NCT01310036|EXPERIMENTAL|Erlotinib|Erlotinib 150 mg daily
62029596|NCT06670014|EXPERIMENTAL|'repeech' Intervention Group|Participants in this group will use the 'repeech' for treatment.
62029597|NCT06670014|OTHER|Control Group|Participants in the control group will use a workbook provided by the sponsor for the treatment of dysarthria.
62029598|NCT05584215|EXPERIMENTAL|Treatment|Treatment group will receive cognitive behavioural therapy informed groups for psychosis.
62029599|NCT05584215|NO_INTERVENTION|Control|Control group will be put on a waitlist to receive cognitive behavioural therapy informed groups for psychosis.
62029600|NCT03082963|OTHER|EMR Feasibility|In this feasibility study, all ten patients will undergo EMR mapping which will be used to guide ablation.
62029601|NCT04965844|EXPERIMENTAL|Oxygen close-loop|Four hours period where the fraction of inspired oxygen delivered will be automatically titrated based on SpO2 values.
62420936|NCT04252326|ACTIVE_COMPARATOR|Doctor|Knowledge, Attitudes and Practices on Drug Hypersensitivity Reactions in Children
62420937|NCT04252326|ACTIVE_COMPARATOR|Nurse|Knowledge, Attitudes and Practices on Drug Hypersensitivity Reactions in Children
62804190|NCT00872235|EXPERIMENTAL|1|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc.(division of Ranbaxy Laboratories Limited)
62804191|NCT00872235|ACTIVE_COMPARATOR|2|Accuretic tablets (fixed dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg)
62804192|NCT00872235|EXPERIMENTAL|3|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc.(division of Ranbaxy Laboratories Limited)
62029602|NCT04965844|ACTIVE_COMPARATOR|Manual FiO2 adjustment|Four hours period where the fraction of inspired oxygen delivered will be manually adjusted by the healthcare personnel based on SpO2 values.
62804193|NCT00872235|ACTIVE_COMPARATOR|4|Accuretic tablets (fixed dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg)
62804194|NCT05331560|EXPERIMENTAL|Treatment Group|A 2-week intervention TPS intervention will result in a significant improvement in the Montreal Cognitive Assessment (HK-MoCA; Hong Kong Chinese version), which will be maintained for 12 weeks.
62029603|NCT02599194|EXPERIMENTAL|18F-FSPG and 18F-FDG Intragroup Comparision|Participants sequentially receive radioimaging agents 18F-FSPG and 18F-FDG IV followed by PET/CT scan with 60 minutes.
62029604|NCT01573845|EXPERIMENTAL|Healthy Eating + Eco-Friendly Campaign|
62029605|NCT01573845|ACTIVE_COMPARATOR|Healthy Eating Campaign|
62029606|NCT01573845|NO_INTERVENTION|Control/Delayed Intervention|
62029607|NCT05665777|EXPERIMENTAL|Active treatment (Qingyan Lihou Decoction)|It consists of 22 kinds of Chinese medicine as ingredients. It was prepared in granule form.
62029608|NCT05665777|PLACEBO_COMPARATOR|Placebo|The placebo medication is composed of starch and an edible pigment and will be matched as closely as possible to the appearance and taste of Qingyan Lihou Decoction granules.
62420938|NCT04252326|ACTIVE_COMPARATOR|Dentist|Knowledge, Attitudes and Practices on Drug Hypersensitivity Reactions in Children
62420939|NCT06017011||Acute charcot neuroarthropathy or Acute on Chronic charcot neuroarthropathy|Patients diagnosed with Acute charcot neuroarthropathy or Acute on Chronic charcot neuroarthropathy will be put on Total contact cast and followed till clinical remission and then after that till 6 months post clinical remission.
62420940|NCT03894293||ventilator group|It's a observational study. Participants entry the Respiratory Care Center and are evaluated. If the participant meet the inclusion criteria, the first assessments will be collected. After the weaning training, the second assessment will be collected before the the endotracheal tube is removed.
62029609|NCT05985486|EXPERIMENTAL|Weight Loss|"* Follow a reduced calorie diet daily for 12 months.~* Attend monthly behavioral counseling/education"
62029610|NCT05985486|ACTIVE_COMPARATOR|General Health Education Control|- Attend monthly health education sessions about general health.
62029611|NCT06239168|EXPERIMENTAL|Citrus extract|Daily Citrus extract supplementation for 8 weeks.
62029612|NCT06239168|PLACEBO_COMPARATOR|Control|Daily Maltodextrin supplementation for 8 weeks.
62029613|NCT02370602|EXPERIMENTAL|Pilot Cohort: [^11C]T-773 + TAK-063|\[\^11C\]T-773 \<8 μg; 400MBq ± 10%, intravenous (IV), once on Days 1 and 2 prior to PET scans and TAK-063 30 mg or 1000 mg, tablets, orally, once on Day 2 and after PET scan #2 and prior to PET scan #3 and \[\^11C\]T-773 IV after TAK-063 and prior to PET scan #3 on Day 2.
62420941|NCT04918810|EXPERIMENTAL|Arm 1: Intermittent docetaxel treatment|suspend docetaxel prior to cycle 4, recommencement based on mGSTP1 monitoring
62029614|NCT02370602|EXPERIMENTAL|Main Cohort: TAK-063 + [^11C]T-773|TAK-063 3 to 100 mg, tablets, orally, once, on Day 1, and \[\^11C\]T-773 \<8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2 .
62029615|NCT01718769|ACTIVE_COMPARATOR|STAMP using|100 boys and girls aged 1 to 6, attending Clalit Health Care Services Pediatric Centers, will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
62420942|NCT01635686|EXPERIMENTAL|DWP422|
62420943|NCT01635686|ACTIVE_COMPARATOR|ENBREL|
62420944|NCT06392321|ACTIVE_COMPARATOR|Fentanyl|Bupivacaine 3,75 mg + 2.5 ml saline added to fentanyl 20 microgram + 2.3 ml saline
62420945|NCT06392321|ACTIVE_COMPARATOR|Dexmedetomidine|Bupivacaine 3,75 mg + 2.5 ml saline added to dexmedetomedine 5 microgram + 2.3 ml saline
62804195|NCT02347397|EXPERIMENTAL|SS Bipolar Head + SL-TWIN Stem|Subject will be implanted with the SS Bipolar Head \& SL-TWIN Stem
62804196|NCT02347397|ACTIVE_COMPARATOR|Bipolar Head + SL-PLUS Stem|Subject will be implanted with the Bipolar Head \& SL-PLUS Stem
62804197|NCT03767946||Group 1|"Children both genders according to age:~\*1-year old children (12 months -1/+4 months); n=125 at the date of recruitment."
62804198|NCT03767946||Group 2|"Children both genders according to age:~\*2-year-old children (24 months -1/+4 months); n=125 at the date of recruitment."
62804199|NCT03767946||Group 3|"Children both genders according to age:~\*5-year old children (60 months +/- 6 months); n=125 at the date of recruitment."
62804200|NCT03767946||Group 4|"Children both genders according to age:~\*12-years old children (12 years old +/- 6 months); n=125 at the date of recruitment."
62804201|NCT03412396|EXPERIMENTAL|Treatment (apalutamide, radical prostatectomy)|Patients receive apalutamide PO daily for 24 weeks in the absence of disease progression or unacceptable toxicity. Within 2 weeks of completing apalutamide, patients undergo radical prostatectomy.
62804202|NCT00935740||Age-Matched Healthy Controls|Age-Matched Healthy Controls
62029616|NCT01718769|PLACEBO_COMPARATOR|No STAMP using|150 files shall be reviewed in the beginning of the research and after 6 months in order to estimate the change in medical staff's attention to nutritional status, by way of noting relevant diagnoses, reference to nutritional status- related tests and recording of anthropometric measurements.
62029617|NCT04099069|PLACEBO_COMPARATOR|trachial intubation|patient was insert trachial intubation with normal frequency jet ventilation
62029618|NCT04099069|EXPERIMENTAL|rigid bronchoscopy|patient was insert trachial intubation with high frequency jet ventilation
62420946|NCT06392321|NO_INTERVENTION|control|Bupivacaine 3,75 mg + 2.5 ml saline
62420947|NCT01059552|EXPERIMENTAL|vorinostat|Dose escalation of vorinostat, cisplatin, pemetrexed and radiation
62420948|NCT03906786|EXPERIMENTAL|motivacional interviewing group|
62420949|NCT03906786|NO_INTERVENTION|control group|
62735334|NCT05580770|EXPERIMENTAL|Phase 2 Dose Expansion C|Participants with NSCLC or cutaneous melanoma harboring BRAF Class II or Class III mutation or BRAF Fusion mutation
62804203|NCT00935740||Heart Failure|Subjects with LVEF \< 40%
62804204|NCT04277559|ACTIVE_COMPARATOR|Patient preferential music|The preference of the patients will be listened to preoperatively through the headphones.
62804205|NCT04277559|ACTIVE_COMPARATOR|Classical music|Classical music (Four Seasons from Vivaldi) will be listened to preoperatively through the headphones.
62804206|NCT04277559|PLACEBO_COMPARATOR|No music|the patients will not listen.
62804207|NCT01423968|EXPERIMENTAL|Lipopolysaccharide infusion|Lipopolysaccharide infusion; dosage 4ng/kg body weight
62804208|NCT01423968|PLACEBO_COMPARATOR|saline|0.9% saline infusion
62804209|NCT00571155|OTHER|1|
62804210|NCT04469972|EXPERIMENTAL|Implementation in the intervention group|This group of elderly were subjected to a pursed-lip breathing exercise (using a windmill toy), a diaphragmatic breathing exercise and a coughing exercise three times a week (Mondays, Tuesdays and Thursdays) for 12 weeks in groups of 5-6 individuals (2 groups of 6 persons, and 4 groups of 5 persons: 6 groups in total) between 10:00 and 15:30, at the same time of the day for each group in 30-minute sessions. All breathing exercises were taught to the elderly individuals on the first day of implementation and demonstrated again prior to practice by the researcher throughout the implementation phase.
62804211|NCT04469972|NO_INTERVENTION|Implementation in the control group|None of the elderly in the control group were subjected to breathing exercises. They continued their daily lives as normal.
62804212|NCT01623115|PLACEBO_COMPARATOR|Placebo|Placebo for alirocumab every 2 weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
62029619|NCT03249922||Treatment Group|"All patients who are considered candidates for spinal cord stimulator implant will be assigned to the Treatment Group. Participiants will be clinically evaluated and given the Owenstry low back disability index, WHODAS 12, Beck depression index and SF-36."
62420950|NCT06359418|EXPERIMENTAL|Acupuncture|"The participants in the acupuncture group will receive treatment that consists of 28 acupuncture sessions over a 12-week (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 8 weeks) period after baseline, each for 30 minutes. Hwato brand disposable acupuncture needles (size 0.30 x75mm; size 0.30 x 50mm; size 0.30 x 40mm) will be used. BaiHui(DU20), YinTang(EX-HN3), ShuaiGu(GB8), QuChi ( LI11), ZhongWan(RN12), XiaWan(RN10), TianShu(ST25), GuanYuan(RN4), FengLong(ST40), Daimai(GB26) and Fujie(SP14) were selected as acupoints protocol.~At the same time, all participants will receive standardized lifestyle intervention counseling from randomization to end of whole study period, about once a month. Participants were advised to achieve a reduced-calorie diet (500-kcal deficit per day relative to the energy expenditure estimated at the time they underwent randomization) and increased physical activity (with 150 minutes per week of physical activity)."
62029620|NCT01028573|ACTIVE_COMPARATOR|Group 1|4L of PEG-ELS (Golytely) consumed on the evening before colonoscopy
62029621|NCT01028573|EXPERIMENTAL|Group 2|2L of PEG-ELS (Golytely) consumed on the evening before and 2L consumed on the morning of colonoscopy
62804213|NCT01623115|EXPERIMENTAL|Alirocumab 75 mg/Up to 150 mg Q2W|Alirocumab 75 mg Q2W on top of stable LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when low-density lipoprotein cholesterol (LDL-C) levels ≥ 70 mg/dL (1.81 mmol/L) at Week 8.
62029622|NCT01028573|EXPERIMENTAL|Group 3|238g of PEG-3350 mixed with 2L of Gatorade
62804214|NCT05430958|EXPERIMENTAL|Group 1|Single injection of 0.8 mg of INO-4800 followed by EP administered at Day 0
62804215|NCT05430958|EXPERIMENTAL|Group 2|Single injection of 0.8 mg of INO-4800 plus 0.05 mg of INO-9112 followed by EP administered at Day 0
62804216|NCT05430958|EXPERIMENTAL|Group 3|Single injection of 0.8 mg of INO-4800 plus 0.10 mg of INO-9112 followed by EP administered at Day 0
62804217|NCT05430958|EXPERIMENTAL|Group 4|Single injection of 0.8 mg of INO-4800 plus 0.20 mg of INO-9112 followed by EP administered at Day 0
62804218|NCT05430958|EXPERIMENTAL|Group 5|Two injections of 0.8 mg (1.6 mg total) of INO-4800 followed by EP administered at Day 0
62029623|NCT01028573|EXPERIMENTAL|Group 4|1L of PEG-3350 + Gatorade
62029624|NCT02032511||RAM Cannula Nasal Continuous Positive Airway Pressure|
62029625|NCT02032511||Infant Flow Nasal Continuous Positive Airway Pressure (NCPAP)|
62029626|NCT03822013|EXPERIMENTAL|Miglustat|"Miglustat is administered, dose is adjusted according to Body Surface Area as below:~\>1.25 : 200 mg TDS 0.88-1.25 : 200mg BID 0.73-0.88 :100mg TDS 0.47-0.73 : 100mg BID \<0.47 :100mg daily"
62029627|NCT03822013|NO_INTERVENTION|No Miglustat|
62029628|NCT03405870|EXPERIMENTAL|Lipid|Infusion of drug (Smoflipid) will occur over a 16.5 hour period given once per day for the first two days of study enrollment.
62029629|NCT03405870|NO_INTERVENTION|Control|Control patients will receive no experimental drug (ie, usual care)
62029630|NCT00071487|PLACEBO_COMPARATOR|Placebo plus SOC|
62029631|NCT00071487|EXPERIMENTAL|Belimumab 1 mg/kg plus SOC|
62029632|NCT00071487|EXPERIMENTAL|Belimumab 4 mg/kg plus SOC|
62029633|NCT00071487|EXPERIMENTAL|Belimumab 10 mg/kg plus SOC|
62029634|NCT01360151|EXPERIMENTAL|experimental|Arm 1 : combination treatment of ranibizumab(Lucentis) and verteporfin(Visudyne) injection
62029635|NCT01360151|ACTIVE_COMPARATOR|active comparator|Arm 2 : Treatment of verteporfin(Visudyne)
62029636|NCT01360151|NO_INTERVENTION|normal control group|Arm 3 : normal control group
62029637|NCT06202378|EXPERIMENTAL|SHPL-49 Injection，3 ampoules|1mL/ampoule
62029638|NCT06202378|EXPERIMENTAL|SHPL-49 Injection，6 ampoules|1mL/ampoule
62029639|NCT06202378|PLACEBO_COMPARATOR|Placebo|1mL/ampoule
62029640|NCT05972720|EXPERIMENTAL|Experimental Drug (Cohort 1)|Single infusion of firi-cel following conditioning chemotherapy
62029641|NCT05972720|EXPERIMENTAL|Experimental Drug (Cohort 2: non-conforming product)|Single infusion of firi-cel following conditioning chemotherapy (patients in this cohort will receive non-conforming firi-cel that is deemed safe to administer).
62029642|NCT05972720|EXPERIMENTAL|Experimental Drug (Cohort 3)|Patients with relapsed or refractory Large B-cell lymphoma who have previously been treated with bispecific T-cell engaging antibody therapy will receive a single infusion of firi-cel following conditioning chemotherapy.
62029643|NCT01060761|ACTIVE_COMPARATOR|Rehabilitation program|Counselling (supportive conversation with patient and their relatives together) Retreat Weekend (patient and their relatives together)
62029644|NCT01060761|NO_INTERVENTION|Ususal treatment and support|Usual support and treatment at the hospital, no retreat Weekend.
62029645|NCT00295750|EXPERIMENTAL|degarelix 240/160 mg|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.
62029646|NCT00295750|EXPERIMENTAL|degarelix 240/80 mg|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.
62029647|NCT00295750|ACTIVE_COMPARATOR|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5 mg IM (in the muscle) every 28 days starting at day 0.
62029648|NCT03099850||Chronic Pancreatitis|
62804219|NCT05430958|EXPERIMENTAL|Group 6|Two injections of 0.8 mg (1.6 mg total) of INO-4800 + 0.05 mg (0.1 mg total) of INO-9112 followed by EP administered at Day 0
62804220|NCT05430958|EXPERIMENTAL|Group 7|Two injections of 0.8 mg (1.6 mg total) of INO-4800 + 0.1 mg (0.20 mg total) of INO-9112 followed by EP administered at Day 0
62804221|NCT05430958|EXPERIMENTAL|Group 8|Two injections of 0.8 mg (1.6 mg total) of INO-4800 + 0.20 mg (0.40 mg total) of INO-9112 followed by EP administered at Day 0
62228278|NCT03601988|ACTIVE_COMPARATOR|Chemotherapy|Adjuvant chemotherapy group receive 8 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1,capecitabine 1000mg po, Bid, D1-14, Q21D)
62804222|NCT01119469|EXPERIMENTAL|Cognitive Therapy (CT)|There will be 12 50-minute individual sessions conducted at weekly intervals. Booster sessions will be conducted one, three and six months after treatment. Sessions include psychoeducation, attention training, cognitive restructuring, behavioral experiments, imagery rescripting and relapse prevention.
62029649|NCT05161858||Primary Ciliary Dyskinesia (PCD) - Well State|Subjects with confirmed PCD in Well State
62228279|NCT03601988|EXPERIMENTAL|Chemo-radiotherapy|Adjuvant chemo-radiotherapy group receive 6 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1, capecitabine 1000mg po, Bid, D1-14, Q21D) and concurrent chemo-radiotherapy (capecitabine 825mg po, Bid, d1-5, QW)
62228280|NCT01966471|ACTIVE_COMPARATOR|Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane|Trastuzumab and pertuzumab will be administered concurrently for up to a total duration of 1 year (up to 18 cycles \[1 Cycle = 21 days\]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline \[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\] based chemotherapy.
62590904|NCT01901354|ACTIVE_COMPARATOR|Airway pressure release ventilation (APRV)|"Airway Pressure Release Ventilation (APRV) is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing throughout the respiratory cycle.~Initial settings: Pressure high will be set initially to equal the plateau pressure on baseline ARDSNet settings. Time low will be set to 0.5-0.8 seconds to achieve an end expiratory flow 25-50% of peak expiratory flow, and Time high will be set to obtain a set respiratory rate 60%-70% that of baseline settings. Time high will be adjusted to achieve similar continuous exhaled carbon dioxide levels as baseline ARDSNet settings. Low pressure will be set at \<5 cm H20."
62804223|NCT01119469|EXPERIMENTAL|Exposure Therapy (ET)|There will be 12 50-minute individual sessions conducted at weekly intervals. Booster sessions will be conducted one, three and six months after treatment. Sessions include change of safety behavior, exposition (in sensu and in vivo), and response prevention.
62804224|NCT01119469|NO_INTERVENTION|Waiting List (WL)|12 weeks waiting time
62804225|NCT03515525||Hematoma side|Drain secretion volume prior to revision surgery on the breast side affected by hematoma.
62804226|NCT03515525||Non-hematoma side|Drain secretion volume prior to revision surgery on the breast side not affected by hematoma.
62804227|NCT01474941|EXPERIMENTAL|5 mg QD PF-04620110 or Placebo|
62804228|NCT01474941|EXPERIMENTAL|5 mg BID PF-04620110 or Placebo|
62804229|NCT01474941|EXPERIMENTAL|Optional Arm, PF-04620110 or Placebo|
62804230|NCT05851833||Early MobilizatioN|
62804231|NCT05851833||conventional Mobilization|
62804232|NCT00997958|EXPERIMENTAL|CellCept|Administered in tablet form twice daily one hour after eating.
62804233|NCT02310412|EXPERIMENTAL|Amicus platelet components|The two stages of this pilot study consist of the following: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT treatment, storage for 7 days, collection of fresh platelets, radiolabeling, infusion of fresh and stored INTERCEPT treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). In Stage 1, apheresis platelets will be collected using the Amicus separator and stored for 7 days in 35% Plasma and 65% InterSol
62804234|NCT02310412|EXPERIMENTAL|Trima platelet components|The two stages of this pilot study consist of the following: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT treatment, storage for 7 days, collection of fresh platelets, radiolabeling, infusion of fresh and stored INTERCEPT treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). In Stage 2, apheresis platelets will be collected using the Trima separator and stored for 7 days in 100% plasma.
62590905|NCT00688675||Treated GERD pts|Previously diagnosed GERD patients on treatment in Switzerland
62590906|NCT03619083||Breast cancer patients treated with chemotherapy|
62804235|NCT03117816|EXPERIMENTAL|investigational arm A|There will be an overlapping treatment with AOP2014 and TKI for one month. After one month, the TKI therapy will be stopped and patient will receive only AOP2014 treatment for the next 14 months.
62804236|NCT03117816|OTHER|surveillance arm B|"This is an open-label study with a surveillance group as comparator arm. Similar as in the arm A, patient will discontinue TKI therapy one month after randomization. From then on patient will receive no further CML treatment."
62804237|NCT04493996|EXPERIMENTAL|Cognitive training group|
62804238|NCT04493996|NO_INTERVENTION|Control group|
62804239|NCT03572452|EXPERIMENTAL|McKenzie - method group|Participants will be sent to an experienced MDT therapist for therapy. They are 1) assessed clinically, 2) treated according the MDT-approach which includes home exercise program, consisting i) an educational component, and ii) an active therapy component with directional preference exercises, several times a day with sustained end range positions according to symptom response, and with avoiding aggravating positions. Participants have a maximum of 7 treatment visits. They will also have physiotherapy counselling at study entry about the good prognosis of sciatica.
62590907|NCT03619083||patients not exposed to chemotherapy|
62590908|NCT03619083||healthy controls|
62590909|NCT03227146|EXPERIMENTAL|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
62029650|NCT05161858||Primary Ciliary Dyskinesia (PCD) - Sick State|Subjects with confirmed PCD in Sick State
62029651|NCT04942171|EXPERIMENTAL|Atrial fibrillation catheter ablation group|catheter ablation
62029652|NCT04942171|ACTIVE_COMPARATOR|Medical therapy group|standard treatment include anti-arrhythmic drug
62029653|NCT06560970|EXPERIMENTAL|COPPEhR Intervention|Participants will have access to the COPPEhR system which will provide social support and engagement among older adults diagnosed with HIV.
62029654|NCT06560970|PLACEBO_COMPARATOR|Device-only Control Condition|Participants will have access to a device only without the COPPEhR system.
62029655|NCT05580991|EXPERIMENTAL|CAN1012|CAN1012 intratumoral injection given alone
62420951|NCT06359418|SHAM_COMPARATOR|Sham acupuncture|"The participants in the sham acupuncture group will receive shallow needling at sham DU20, EX-HN3, GB8, LI11, RN12, RN10, ST25, RN4, ST40, GB26 and SP14. The protocol includes the same duration and frequency of sessions as for the acupuncture treatment, but the treatment was delivered superficially at non-acupuncture points 10-20 mm to the lateral of corresponding acupuncture and not above a meridian line. The Hwato brand disposable acupuncture needles(size 0.20 x25mm) will be inserted.~At the same time, all participants will receive standardized lifestyle intervention counseling from randomization to end of whole study period, about once a month. Participants were advised to achieve a reduced-calorie diet (500-kcal deficit per day relative to the energy expenditure estimated at the time they underwent randomization) and increased physical activity (with 150 minutes per week of physical activity)."
62029656|NCT02763527|EXPERIMENTAL|Smoking reduction|"Subjects will receive a brief intervention on smoking reduction with a warning message plus a smoking reduction leaflet. They will be asked to think about a tailored smoking reduction schedule for themselves after the negotiation with the trained counsellor. The trained counsellor will negotiate a schedule with subjects to reduce their smoking over an acceptable level. For the subsequent telephone follow up in the intervention group, information on reduction and cessation will be collected, followed by a booster intervention, which will repeat the health warning to positively encourage them to reinforce their efforts and the next reduction target. Four consecutive (1, 3, 6 and 12 months) follow-ups will be conducted over the telephone by trained interviewers."
62029657|NCT02763527|PLACEBO_COMPARATOR|Smoking Cessation|"Subjects in the QI group will always be advised to quit immediately rather than to quit progressively. Subjects will receive a brief advice on quitting with a warning message similar to subjects in the QP group. In addition, subjects will receive a self-help quitting pamphlet published by the Hong Kong Council on Smoking and Health (COSH). Unlike the QP group, subjects in the QI group will not receive smoking reduction intervention and leaflet, and booster intervention during telephone follow-ups. However, they will undergo a similar schedule of telephone follow-up as those in the QP group."
62029658|NCT04327466|EXPERIMENTAL|Osciflow|Crossover sequence of experimental treatment and active comparator.
62029659|NCT04327466|ACTIVE_COMPARATOR|Highflow|Crossover sequence of experimental treatment and active comparator.
62029660|NCT05887193||Group 1|Order of saddle testing: Joyseat saddle - Specialized Power saddle - Fizik Tundra M5 saddle
62029661|NCT05887193||Group 2|Order of saddle testing: Joyseat saddle - Fizik Tundra M5 saddle - Specialized Power saddle
62029662|NCT05887193||Group 3|Order of saddle testing: Specialized Power saddle - Fizik Tundra M5 saddle - Joyseat saddle
62420952|NCT02606370|EXPERIMENTAL|Unstable shoes|Wearing unstable shoes during 1 month
62420953|NCT02606370|NO_INTERVENTION|Control Group|Not Wearing unstable shoes
62029663|NCT05887193||Group 4|Order of saddle testing: Specialized Power saddle - Joyseat saddle - Fizik Tundra M5 saddle
62029664|NCT05887193||Group 5|Order of saddle testing: Fizik Tundra M5 saddle - Joyseat saddle - Specialized Power saddle
62029665|NCT05887193||Group 6|Order of saddle testing: Fizik Tundra M5 saddle - Specialized Power saddle - Joyseat saddle
62029666|NCT05369585|EXPERIMENTAL|TOTUM-63|Experimental active are supplemented with TOTUM-63, taken 3 times per day.
62420954|NCT03555500|NO_INTERVENTION|Fasting Group|Clear fluids up to the time of the procedure and no food for at least 2 hours before the procedure.
62420955|NCT03555500|EXPERIMENTAL|Non fasting group|Clear fluids and food up to the time of the procedure.
62420956|NCT05194280||Robotic-assisted group|Group of patients that underwent a robotic-assisted donornephrectomy
62420957|NCT05194280||Hand-assisted laparoscopic group|Group of patients that underwent a hand-assisted laparoscopic donornephrectomy.
62420958|NCT06565819||Patients with type 2 diabetes who had not been diagnosed with lower peripheral artery disease|Patients received NIR-II and DUS six months and one year after the first NIR-II examination
62590910|NCT04630236|OTHER|Ultrasound|
62029667|NCT00710047|EXPERIMENTAL|1|Fasting state
62029668|NCT00710047|EXPERIMENTAL|2|after high-fat breakfast
62029669|NCT03341390|ACTIVE_COMPARATOR|Aspirin|325 mg tablet, once daily for 5 days (Day -5 to -1)
62029670|NCT03341390|EXPERIMENTAL|BMS-986177 plus aspirin|200 mg BMS-986177 twice daily and 325 mg tablet aspirin once daily (Day 1-7)
62029671|NCT03341390|PLACEBO_COMPARATOR|Placebo plus aspirin|200 mg Placebo twice daily and 325 mg tablet aspirin once daily (Day 1-7)
62029672|NCT02635958||Group 1|BMI 18.5 to 24.9
62029673|NCT02635958||Group 2|BMI 25 to 29.9
62804240|NCT03572452|ACTIVE_COMPARATOR|Advice to stay active group|"Participants enrolled into this group will receive physiotherapist's counselling at study entry for at least 60 minutes time about the good prognosis of sciatica, the spontaneous regression of the intervertebral disc herniation and pain tolerance (natural healing). In addition, they will get ergonomic advice and advice to stay normally active. The participants are also told to avoid bed rest and advised to continue their normal routines as actively as possible including exercise activities with limits permitted by their signs and symptoms. A two-page summary booklet related to these items will be given to them."
62029674|NCT02635958||Group 3|BMI 30 to 34.9
62029675|NCT02635958||Group 4|BMI ≥ 35
62228281|NCT01966471|EXPERIMENTAL|Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab|Trastuzumab emtansine and pertuzumab will continue for up to a total duration of 1 year (up to 18 cycles \[1 Cycle = 21 days\]) following anthracycline \[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\] based chemotherapy.
62228282|NCT04088487|EXPERIMENTAL|Experimental group|Participants gain access to the internet intervention after the baseline measurement (pre-test).
62228283|NCT04088487|OTHER|Waitlist control group|Participants gain access to the internet intervention 8 weeks after the baseline measurement (pre-test).
62029676|NCT02864433||Controls for non-cholera diarrhea cases|- Community members that did not have diarrhea between date of study commencement, and time of presentation of the case
62029677|NCT02864433||Non-cholera diarrhea cases|- Cases of acute watery diarrhea that present for healthcare at the study sites, but that test negative for cholera
62228284|NCT04295876|NO_INTERVENTION|Standard of Care|Women assigned to the control arm will receive self-directed (non-PN supported) treatment as usual at the HIV care service provider of choice following the Ryan White standard of care (i.e., referrals to physical, dental and mental health services; case management; and ancillary services. Annual assessments (e.g., updates on insurance, housing, referrals needed, behavioral assessment \[e.g., depression, substance use\]) are conducted by a case manager. For women who have fallen out of care and re-engage care, case management begins with an interview and assessment of current needs. Goals are set to create an individual care plan related to medical care, housing, and other resources, as needed. Referrals are made to appropriate services (e.g., primary care, housing, benefits counseling, food, support services) based on the intake assessment.
62228285|NCT04295876|EXPERIMENTAL|BRIDGES Arm|Women assigned to The BRIDGES Project intervention arm will be connected with and receive Ryan White HIV/AIDS Program services (see above as described under Control Arm), as well as receive Peer Navigation support via one-on-one sessions, phone/text-based check-ins, and 6 unique syndemic-responsive 120 -minute group sessions designed to build coping skills (3 sessions) and assertive communication and behavior (3 sessions).
62228286|NCT02665637|ACTIVE_COMPARATOR|CT-P6|Trastuzumab
62804241|NCT01149317|EXPERIMENTAL|Acupuncture|Weekly acupuncture treatment for up to 14 weeks
62804242|NCT00296816|EXPERIMENTAL|Oxaliplatin/Docetaxel/Bevacizumab|Participants with International Federation of Gynecology and Obstetrics (FIGO) stage IB through IV ovarian, primary peritoneal, or fallopian tube carcinoma treated with Oxaliplatin, Docetaxel, and Bevacizumab - 28 days after initial surgery
62029678|NCT02864433||Controls for cholera cases|- Community members that did not have diarrhea between date of study commencement, and time of presentation of the case
62029679|NCT02864433||Cholera cases|- Those with cholera-related diarrhea who present to healthcare at the study sites.
62029680|NCT03812796|EXPERIMENTAL|Domatinostat plus Avelumab|This is a multicentre open-label, phase II non-randomised clinical trial domatinostat plus avelumab (two separate cohorts in phase IIB part of trial).
62029681|NCT03332862|EXPERIMENTAL|Discontinuous ablation|perform discontinuous ablation of ipsilateral pulmunary veins.
62029682|NCT03332862|ACTIVE_COMPARATOR|Continuous ablation|perform continuous ablation of ipsilateral pulmunary veins.
62029683|NCT00566267|EXPERIMENTAL|2|Low carb diet plus simvastatin 20 mg/ezetimibe 10 mg
62029684|NCT03105362|EXPERIMENTAL|Amino Acid-ORS arm|Patients consumed an amino acid based oral rehydration solution (enterade®) as part of their oral rehydration care plan. Enterade® oral rehydration solution volumes varied from patient to patient depending on baseline clinical need.
62228287|NCT02665637|ACTIVE_COMPARATOR|US-licensed Herceptin|Trastuzumab
62420959|NCT01988493|EXPERIMENTAL|Phase 1b: Tepotinib 300 mg|Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
62590911|NCT00924495|ACTIVE_COMPARATOR|Cortical function|Activity/inhibition of the cortex
62804243|NCT01936675|NO_INTERVENTION|Framingham Risk Score|Patients in this arm will receive their Framingham Risk Score of having a heart attack.
62228288|NCT04300686|ACTIVE_COMPARATOR|Tocilizumab|This group of 20 TAK cases are prescribed with tocilizumab (Dose: 8mg/kg. qm. ivgtt.) for 24 weeks.
62228289|NCT04300686|EXPERIMENTAL|Adalimumab|This group of 20 TAK cases are prescribed with adalimumab (Dose: 40mg.bim.IH.) for 24 weeks.
62228290|NCT02939547|ACTIVE_COMPARATOR|Hydroxypropyl-beta-cyclodextrin IV 1500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8 - 9h every 2 weeks
62420960|NCT01988493|EXPERIMENTAL|Phase 1b: Tepotinib 500 mg|Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
62804244|NCT01936675|ACTIVE_COMPARATOR|Framingham and Genetic Risk Score|Patients in this arm will receive their Framingham Risk Score as well as their Genetic Risk Score of having a heart attack.
62804245|NCT01218763||ICD patients|Candidates may come from the investigator's general population, who require DR ICD or CRT-D therapy for primary or secondary ICD indication and meet all study eligibility criteria
62804246|NCT01169948||Patients awaiting cardiac surgery|
62804247|NCT00687180|ACTIVE_COMPARATOR|I|MMF
62804248|NCT00687180|ACTIVE_COMPARATOR|II|
62804249|NCT03904212|ACTIVE_COMPARATOR|Adipose tissue injection|Patients will be treated with freshly harvested autologous adipose tissue
62804250|NCT03904212|PLACEBO_COMPARATOR|Placebo|Patients will be treated with saline
62804251|NCT00771199|EXPERIMENTAL|Transdermal Therapeutic System (TTS)-Fentanyl|
62228291|NCT02939547|ACTIVE_COMPARATOR|Hydroxypropyl-beta-cyclodextrin IV 2500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8 - 9h every 2 weeks
62228292|NCT00633724|EXPERIMENTAL|1|
62804252|NCT03560310|EXPERIMENTAL|Dual antiplatelet therapy|Ticagrelor 90 mg twice daily and ASA 75-100 mg daily for 12 months
62804253|NCT03560310|ACTIVE_COMPARATOR|Acetylsalicylic acid|ASA 75-160 mg daily for 12 months
62804254|NCT06522789|ACTIVE_COMPARATOR|Group 1|The total number of patients who underwent CXL was seventy-seven; 23 were females, and 54 were males of the mean (±sd, range) age 24.2 (±7.0, 11-44) years.
62804255|NCT06522789|NO_INTERVENTION|Group 2|Twenty-three patients, six females and 17 males of mean age 27.3 (±7.0, 17-44) years, were untreated.
62804256|NCT06522789|NO_INTERVENTION|Group 3|Twenty-four subjects, nine females and 15 males of mean age 24.7 (±7.6, 17-45) years, were recruited as controls.
62804257|NCT05980728||Connective Tissue Disease Patients With Pulmonary Hypertension|Connective Tissue Disease Patients With Pulmonary Hypertension
62804258|NCT05980728||Connective Tissue Disease Patients Without Pulmonary Hypertension|Connective Tissue Disease Patients Without Pulmonary Hypertension
62804259|NCT05980728||healthy|healthy people
62228293|NCT00040677|EXPERIMENTAL|ICA-17043 Low Dose 6 mg/day|Active study medication: 100 mg loading dose; 6 mg maintenance dose per day
62228294|NCT00040677|PLACEBO_COMPARATOR|Placebo|
62804260|NCT06317753|EXPERIMENTAL|Experimental condition 1|Participants allocated to the Experimental condition 1 will be following a aerobic exercise training program.
62804261|NCT06317753|EXPERIMENTAL|Experimental condition 2|Participants allocated to the Experimental condition 2 will be following an agility-cognitive exercise training program.
62804262|NCT06317753|ACTIVE_COMPARATOR|Control condition|Participants allocated to the Control condition will be following a stretching/relaxation training program.
62228295|NCT00040677|EXPERIMENTAL|ICA-17043 High Dose 10 mg/day|Active study medication: 150 mg loading dose; 10 mg maintenance dose per day
62243119|NCT05634252|EXPERIMENTAL|Education + Action Plan + UV Photo|Students in this intervention will receive education on skin cancer and prevention strategies, complete an individualized sun protection and tanning worksheet for situations in which they receive UVR exposure, and receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system.
62420961|NCT01988493|EXPERIMENTAL|Phase 1b: Tepotinib 1000 mg|Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
62420962|NCT01988493|EXPERIMENTAL|Phase 2: Tepotinib|Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
62420963|NCT01988493|EXPERIMENTAL|Phase 2 Sorafenib|Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
62420964|NCT04900415|EXPERIMENTAL|Vitamin A and smell training|14-day course of daily oral vitamin A 7500µg RAE in combination with smell training three times per day for 4 weeks
62420965|NCT04900415|ACTIVE_COMPARATOR|Smell training|Smell training three times per day for 4 weeks
62420966|NCT04900415|NO_INTERVENTION|Control|Observation
62420967|NCT05880420|EXPERIMENTAL|Arm 1 - home group|
62420968|NCT05880420|ACTIVE_COMPARATOR|Arm 2 - outpatient calibration|
62590912|NCT00924495|ACTIVE_COMPARATOR|Cortical regulation|
62590913|NCT06439381|EXPERIMENTAL|300mg/600mg of TQH2722 injection in Part A or B|For Part A or Part B, 300mg/600mg of TQH2722 injection was administered every 2 weeks until week 22, combined with Mometasone furoate nasal spray of 100-200μg/ day until week 32.
62804263|NCT02431988|EXPERIMENTAL|CAR19 T-cells|"Patients will receive a single infusion of CAR19 T-cells following standard pre-conditioning with cyclophosphamide and fludarabine.~The CAR19 T-cells are to be administered on day 0."
62804264|NCT03192826|ACTIVE_COMPARATOR|Brinzolamide/Brimonidine FC|1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy
62804265|NCT03192826|ACTIVE_COMPARATOR|Brimonidine 0.2%|1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy
62590914|NCT03261050|EXPERIMENTAL|Body Project Treatment|An 8-session group-delivered eating disorder treatment that seeks to reduce valuation of the thin ideal and eating disordered behaviors used to pursue this ideal.
62420969|NCT05377866||Study population|Patients undergoing percutaneus coronary intervention for chronic total occlusion. The procedures will all be done using mixed reality to enable remote proctoring. The study is a feasibility trial.
62590915|NCT03261050|ACTIVE_COMPARATOR|Interpersonal Psychotherapy|An 8-session group-delivered eating disorder treatment that seeks to improve interpersonal functioning because this is theorized to maintain eating pathology.
62804266|NCT03192826|PLACEBO_COMPARATOR|Artificial tears|1 drop of artificial tears 1 hour before Nd-YAG capsulotomy
62420970|NCT06479746|EXPERIMENTAL|Emotional support group|Empathetic approach, listening to the feelings and thoughts, welcoming the woman's behavior and expressions, telling her that she is breathing correctly, etc.), not judging the woman, being honest, using a soft and calm tone of voice, taking the baby or asking her opinion, encouraging her to endure the birth process, touching the woman and making physical contact, allowing her to practice her beliefs, showing the baby to the mother as soon as it is born and placing it in her arms.
62804267|NCT02324283|ACTIVE_COMPARATOR|Desflurane|Desflurane group: this group of patients receives desflurane as the main anesthetic agent in addition to remifentanil infusion at 0.1\~0.3 mcg/kg/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
62804268|NCT02324283|ACTIVE_COMPARATOR|Propofol|Propofol group: this group of patients receives propofol as the main anesthetic agent in addition to remifentanil infusion at the rate of 0.1\~0.3 mcg./g/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
62804269|NCT01739036|ACTIVE_COMPARATOR|Group 4|Unvaccinated control volunteers who undergo controlled human malaria infection.
62804270|NCT01739036|ACTIVE_COMPARATOR|Group 3|Controlled human malaria infection administered at an interval of approximately 8-12 months after the initial controlled human malaria infection that the volunteers received in the VAC045 clinical trial.
62804271|NCT01739036|ACTIVE_COMPARATOR|Group 2|Intramuscular administration of a mixture of ChAd63 ME-TRAP 5 x 1010 vp and ChAd63 CS 5 x 1010 vp and ChAd63 AMA1 5 x 1010 vp followed by intramuscular administration of a mixture of MVA ME-TRAP 1.33 x 108 pfu and MVA CS 1.33 x 108 pfu and MVA AMA1 1.33 x 108 pfu eight weeks later, followed by controlled human malaria infection 17-24 days later.
62804272|NCT01739036|ACTIVE_COMPARATOR|Group 1|Intramuscular administration of a mixture of ChAd63 ME-TRAP 5 x 1010 vp and ChAd63 CS 5 x 1010 vp, followed by intramuscular administration of a mixture of MVA ME-TRAP 2 x 108 pfu and MVA CS 2 x 108 pfu eight weeks later, followed by controlled human malaria infection 17-24 days later.
62804273|NCT03537846||Osteoporosis and women|Patient women over thirty years old
62804274|NCT03857919|EXPERIMENTAL|TearCare|Subjects will have heat applied to the eyelids for 15 minutes followed by manual expression of the meibomian glands.
62804275|NCT03857919|ACTIVE_COMPARATOR|LipiFlow|Subjects will have heat and pressure applied to the eyelids for 12 minutes.
62804276|NCT04154046|EXPERIMENTAL|Tenotomy|Patients allocated to this arm receive tenotomy treatment of affected toes, and standard care including offloading treatment
62804277|NCT04154046|NO_INTERVENTION|standard care|Patient who are randomized to this arm receive standard care including offloading treatment
62804278|NCT00496015|EXPERIMENTAL|Synflorix I Group|Subjects were vaccinated with 3 primary vaccination doses of Synflorix™ vaccine with prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa along with prophylactic antipyretic treatment.
62590916|NCT04886219||Healthy individual|Healthy individual
62590917|NCT05301283|EXPERIMENTAL|Treatment|"Participants will receive pretreatment diagnostic MRIs to generate MRI habitats (images of tumor regions/subregions in different sequences). These images will identify radioresistant cells within the tumor to allow for more precise and higher doses of radiation to the resistant cells.~Participants will then be treated with neoadjuvant external beam radiation by using the intensity modulated radiation (IMRT) technique, with dose painting (simultaneous integrated boost/SIB) to 70 Gray Units (Gy), 60 Gy, and 50 Gy in 25 fractions for habitats 1, 2, and 3, respectively."
62590918|NCT00750139|EXPERIMENTAL|1|Naftin 2% cream applied daily for 2 weeks
62590919|NCT00750139|PLACEBO_COMPARATOR|2|Placebo cream applied daily for two weeks
62590920|NCT00750139|ACTIVE_COMPARATOR|3|Active comparator applied daily for 4 weeks
62590921|NCT00750139|PLACEBO_COMPARATOR|4|placebo cream applied daily for 4 weeks
62590922|NCT04082117|OTHER|Open Label|Educational genetic counseling video
62029685|NCT06109038|EXPERIMENTAL|: Conventional PT + ITB release with graston technique|"An emollient will be applied to the leg from the lateral joint line along the tibial condyle to just below the iliac crest. The instrument GT-4 will be used for treatment. The tool was used to assess the soft tissue in three locations on the lateral leg: anterior to the ITB, over the ITB, and posterior to the ITB. Brushing and strumming strokes were performed to the tissue utilising the instrument's convex surface. Treatment time with the instrument is 8 -10 mins .~Conventional PT including Hot Pack for 5mins. Quadriceps setting exercises, short arc terminal knee extension, straight leg raise, ROM excercises, hamstring curls in prone lying position, quadriceps strengthening in high sitting position, gastrocnemius muscle stretching (10reps × 5sec × 2sets). Maitland mobilization (Grade 1, 2 and 3 for 10 repititions)."
62029686|NCT06109038|OTHER|Conventional PT|Conventional PT including Hot Pack for 5mins. Quadriceps setting exercises, short arc terminal knee extension, straight leg raise, ROM excercises, hamstring curls in prone lying position, quadriceps strengthening in high sitting position, gastrocnemius muscle stretching (10reps × 5sec × 2sets). Maitland mobilization (Grade 1, 2 and 3 for 10 repititions).
62029687|NCT01109992|ACTIVE_COMPARATOR|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
62029688|NCT01109992|EXPERIMENTAL|Exercise + Regadenoson (Lexercise)|Exercise plus Regadenoson (Lexercise) Rubidium-82 Positron Emission Tomography
62029689|NCT05465889|EXPERIMENTAL|OSS group|Bowel preparation for colonoscopy was performed using oral sulfate solution as laxative
62029690|NCT05465889|ACTIVE_COMPARATOR|Polyethylene glycol group|Bowel preparation for colonoscopy was performed using polyethylene glycol as laxative
62029691|NCT01015989|ACTIVE_COMPARATOR|CARE+ Kenya brief computer risk assessment session (control)|
62029692|NCT01015989|ACTIVE_COMPARATOR|Full CARE+ Spanish computer-counseling group|
62029693|NCT06454357|EXPERIMENTAL|B007|
62029694|NCT06042647|ACTIVE_COMPARATOR|0.01% Halobetasol and 0.045% Tazarotene Lotion|0.01% Halobetasol and 0.045% Tazarotene Lotion (Duobrii)Applied to designated target plaque at bedtime.
62029695|NCT06042647|ACTIVE_COMPARATOR|Clobetasol Propionate 0.05% Cream (generic)|Clobetasol Propionate 0.05% Cream (generic)Applied to designated target plaque at bedtime.
62029696|NCT03322865|EXPERIMENTAL|One Arm|Obinutuzumab i.v.
62029697|NCT04230473|EXPERIMENTAL|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
62029698|NCT05918094|EXPERIMENTAL|Modified XELOX + sintilimab|The treatment option for the modified XELOX group (study group) is 200 mg of sintilimab IV Drip Q3W, 600 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 78 mg/m2 IV Drip Q3W. After 6 cycles of treatment, patients could choose capecitabine + sintilimab maintenance with a maximum treatment duration of 2 years.
62029699|NCT05918094|ACTIVE_COMPARATOR|Standard XELOX + sintilimab|The treatment option for the standard XELOX group (control group) is 200 mg of sintilimab IV Drip Q3W, 1000 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 130 mg/m2 IV Drip Q3W. After 6 cycles of treatment, patients could choose capecitabine + sintilimab maintenance with a maximum treatment duration of 2 years.
62029700|NCT05403762|EXPERIMENTAL|ESENTA™ Skin Barrier Spray|In the intervention group I, standardized mild skin cleansing regimen and daily topical application of a film-forming skin protectant at the exposed skin areas will be applied by nursing staff.
62029701|NCT05403762|EXPERIMENTAL|Hydrophobes Basisgel DAC|In the intervention group II, standardized mild skin cleansing regimen and daily topical application of a hydrophobic skin protectant at the exposed skin areas will be applied by nursing staff.
62029702|NCT05403762|NO_INTERVENTION|Standard Care|In the control group, standardized mild skin cleansing regimen without application of an additional skin protectant will be conducted by nursing staff.
62029703|NCT06177340||Sacrospinofixation|patient who benefited from anterior and/or posterior sacrospinofixation using the Nanoscope system
62029704|NCT06308159|EXPERIMENTAL|Vebeglogene autotemcel|One-time infusion of≥5×10\^6/kg beta-globin lentiviral vector transduced HSPCs
62029705|NCT00820768|EXPERIMENTAL|ABI-010|
62029706|NCT06230757|EXPERIMENTAL|Psilocybin|Participants receive Psilocybin 25mg capsule orally, administered with psychological support, on dosing day.
62029707|NCT06230757|PLACEBO_COMPARATOR|Active Placebo|Participants receive Psilocybin 1mg capsule (identical to the Psilocybin 25mg capsule) orally, administered with psychological support, on dosing day.
62029708|NCT00208793|EXPERIMENTAL|Calcium|Calcium 2,000 mg/day as calcium carbonate in two divided doses with food
62029709|NCT00208793|EXPERIMENTAL|Vitamin D3|Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
62029710|NCT00208793|EXPERIMENTAL|Calcium and vitamin D3 combined|Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with meals over 6 months
62029711|NCT00208793|PLACEBO_COMPARATOR|Placebo|
62029712|NCT06578234|ACTIVE_COMPARATOR|Start standard dose adenosine followed by high dose adenosine|Subjects randomized to this arm will undergo the first stress perfusion acquisition with a dose of 140 μg/kg/min adenosine, followed by a second stress perfusion acquisition with the dose of 210 μg/kg/min adenosine.
62420971|NCT06479746|NO_INTERVENTION|Standard of care Group|The control group did not receive any treatment.
62590923|NCT04223635|EXPERIMENTAL|Hepatic impaired|Participants with moderate hepatic impairment who will receive a single oral dose of pexidartinib.
62590924|NCT04223635|EXPERIMENTAL|Healthy controls|Sex-, age-, and weight-matched healthy participants who will receive a single oral dose of pexidartinib.
62804279|NCT00496015|EXPERIMENTAL|Synflorix II Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment
62804280|NCT00496015|EXPERIMENTAL|Synflorix PRE Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study (before the implementation of the protocol amendment) at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment.
62804281|NCT00496015|EXPERIMENTAL|Synflorix POST Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study (after the implementation of the protocol amendment) at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment.
62420972|NCT04389619|EXPERIMENTAL|Fractional Microneedling Radiofrequency|In every patient, each one of the two scars, or each side of a large scar will be assigned to fractional microneedling radiofrequency parameters; Power: 6 v, Exposure time: 800 ms. Depth: 2.5 mm (using non-insulated micro-needles), Frequency: 2 Hz for 5 treatment sessions 4 weeks apart.
62420973|NCT04389619|ACTIVE_COMPARATOR|Intralesional Steroid Injection with and without Microneedling|In every patient, each one of the two scars, or the other side of a large scar will be assigned to intralesional steroids injection, Triamcinolone acetonide will be injected in concentration 1:2 (20 mg/dl) using insulin syringe. Microneedling will be done using the same tip of the fractional microneedling radiofrequency at same depth. Patients will receive 5 treatment sessions 4 weeks apart.
62804282|NCT00496015|ACTIVE_COMPARATOR|Mencevax + Infanrix Hexa Group|Age-matched pneumococcal vaccine unprimed group receiving a single dose of Mencevax™ vaccine co-administered with Infanrix™ hexa vaccine.
62420974|NCT06703931|EXPERIMENTAL|Temperature Monitor|Patients included in the study will have their temperature measured simultaneously during their stay in intensive care, with Thermodiag(R) and with the reference medical device.
62420975|NCT05953883|EXPERIMENTAL|Interventional|
62420976|NCT06684405|ACTIVE_COMPARATOR|Intervention|The subjects in the intervention group received individually packaged daily doses of sodium fluoride solution in 0.5 ml sterile water to be added to 200 ml of milk
62420977|NCT06684405|PLACEBO_COMPARATOR|Control group|Subjects in the control group received a daily dose of 0.5 ml sterile water to be added to 200 ml of milk.
62420978|NCT06539988|EXPERIMENTAL|Receiving the optimized ADviSE Intervention|6 months of selected text messages from a library developed and refined in previous study aims.
62804283|NCT04551118|EXPERIMENTAL|tACS group|Participants receive 20 min sessions of 1.5 mA alternating current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
62420979|NCT06539988|NO_INTERVENTION|Control period|Usual care.
62420980|NCT02256319|EXPERIMENTAL|Dexmedetomidine recording|Recording registered through the deep brain stimulation electrodes with dexmedetomidine at 0.2 μg/kg/h.
62804284|NCT04551118|EXPERIMENTAL|tDCS group|Participants receive 20 min sessions of 1.5 mA direct current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
62804285|NCT04551118|SHAM_COMPARATOR|Sham group|Participants receive sham stimulation that administered similarly, but with current continued less than 30s.
62804286|NCT04561895||control group|healthy volunteers with absence of NAFLD
62804287|NCT04561895||test group|patients with confirmed NAFLD diagnosis
62804288|NCT01070589||Group 1: Obese|BMI\>30
62804289|NCT01070589||Group 2: control|Group 2:Normal weight (BMI \<25). age and gender matched.
62804290|NCT03287817|EXPERIMENTAL|AUTO3|Patient with relapsed or refractory DLBCL
62804291|NCT01513408|EXPERIMENTAL|CD8/Foxp3|patient suffering from non-metastatic breast cancer
62804292|NCT00990106|ACTIVE_COMPARATOR|prazosin hydrochloride|"prazosin Pfizer Minipress~oral capsules~Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose."
62804293|NCT00990106|PLACEBO_COMPARATOR|placebo|"placebo~oral capsules~Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose."
62029713|NCT06578234|ACTIVE_COMPARATOR|Start high dose adenosine followed by standard dose adenosine|Subjects randomized to this arm will undergo the first stress perfusion acquisition with a dose of 210 μg/kg/min adenosine, followed by a second stress perfusion acquisition with the dose of 140 μg/kg/min adenosine.
62029714|NCT06252129|EXPERIMENTAL|1. Interventional group|subjects who are being consented to this study and undergoing lymph node dissection as outlined in this protocol
62029715|NCT06252129|NO_INTERVENTION|Concurrent non-interventional group|
62029716|NCT06252129|OTHER|Retrospective cohort from 2021-2020|
62420981|NCT02256319|ACTIVE_COMPARATOR|Propofol recording|Recording registered through the deep brain stimulation electrodes with propofol at plasmatic levels of 0.5, 1, 1.5, 2, 2.5 μg/mL.
62029717|NCT03953027||Health Services Research (surveys about drug shortages)|At baseline, practice sites complete a Baseline Drug Shortage Survey and Pharmacy Baseline Survey; Drug Shortage Incident Reports are completed in real time as cancer care delivery problems occur; and the Quarterly Follow-Up Survey Number Treated Report every 3 months for one year (4 total).
62029718|NCT01821664||Prosthetic vascular graft implantation, follow up|
62029719|NCT01875926|EXPERIMENTAL|ALX-0171 Oral Inhalation - Single Dose (SD)|
62029720|NCT01875926|EXPERIMENTAL|ALX-0171 Oral Inhalation - Multiple Dose (MD)|
62420982|NCT02256319|NO_INTERVENTION|Basal recording|Recording registered through the deep brain stimulation electrodes with no sedation .
62420983|NCT05445830|EXPERIMENTAL|Post-covid patients|
62804294|NCT01467505|EXPERIMENTAL|T/PR + Immunosuppressant Regimen (Tacrolimus)|Participants who were receiving tacrolimus (TAC) based immunosuppressant regimen at baseline, received telaprevir (T) 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
62804295|NCT01467505|EXPERIMENTAL|T/PR + Immunosuppressant Regimen (Cyclosporine)|Participants who were receiving cyclosporine (CsA) based immunosuppressant regimen at baseline, received telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
62804296|NCT01658748|ACTIVE_COMPARATOR|Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Patients randomized to this arm will have stimulators turned on approximately 1 week after the 3-4 week post-surgery EEG telemetry session that determines safety parameters for stimulator settings. Subjects will be followed weekly for the next 12 weeks, with adjustments in stimulator settings according to prescribed protocol based on changes in rating scale scores (CAPS, CGI-I, ADIPS, LFIPS, HAMA, MADRS, YMRS).
62804297|NCT01658748|SHAM_COMPARATOR|Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS|Patients randomized to this arm will undergo the same procedures and same visit frequency as those in the week 0 stimulation arm, except that the actual stimulation settings will be kept at 0 V, 0 Hz, and the patient, study psychiatrist who does the ratings, and study neurosurgeon who does neurological clinical assessments will be blind to whether the subject is receiving actual or sham stimulation. Only the study neurophysiologist will know whether the patient is in the active or sham stimulation arm during these 12 weeks. After week 12, subjects in this week will begin to receive active stimulation according to pre-specified protocol.
62804298|NCT02371824||MRI Sequence|
62804299|NCT00295191|ACTIVE_COMPARATOR|1|high-flux dialyser
62804300|NCT00295191|ACTIVE_COMPARATOR|2|low-flux dialyser
62804301|NCT00295191|ACTIVE_COMPARATOR|3|conventional dialysate
62804302|NCT00295191|ACTIVE_COMPARATOR|4|ultrapure dialysate
62804303|NCT02456155|EXPERIMENTAL|ultrasound group|using B ultrasound as a instruction technique to place Nasal Jejunal Tube
62804304|NCT02456155|PLACEBO_COMPARATOR|endoscope group|Conventional methods for placing Nasal Jejunal Tube
62804305|NCT03326804||Cohort 1 - Safety|"Cohort 1 will consist of the first 20 participants recruited into the study for H1 Hip Resurfacing Arthroplasty. These patients will receive additional CT scans preoperatively and then post-operatively at these time points: immediately postoperatively (2days), at 6 weeks, 3 months, 6 months, 1 year and 2 years. They will have metal-ion measurements for safety analysis. Blood samples will be taken preoperatively and postoperatively at 3 months, 6 months, 1 year and 2 years.~A safety analysis of Cohort 1 will be performed at the 6 week, 3 month and 6 month post-operative stage by independent assessors. Yearly clinical evaluations will be performed until 10 years, and radiographs at 3,5,10 years. If the investigation supports the safety of the implant, the study will proceed with recruitment into Cohort 2."
62029721|NCT01875926|EXPERIMENTAL|ALX-0171 Intravenous (IV)|
62029722|NCT06170008|EXPERIMENTAL|Second-degree burn wounds covered with silicone film sheet group|After routine clinical treatment of second-degree burn wounds, the innermost layer is covered with physical microstructure-modified transparent silicone film sheet , and the outer dressing is changed every 3 to 4 days to observe and record the wounds, and the innermost dressing is changed weekly or as necessary and the number of times is recorded to observe the wound healing rate, dressing transparency, dressing-wound adhesion, pain level, wound infection rate and incidence of adverse reactions.
62420984|NCT05445830|EXPERIMENTAL|Control|
62420985|NCT00731601|EXPERIMENTAL|1|pantoprazole 40mg/q6h IV infusion for three days
62420986|NCT00731601|ACTIVE_COMPARATOR|2|pantoprazole 8mg/h for three days
62029723|NCT06170008|ACTIVE_COMPARATOR|Second-degree burn wounds covered with decellularized pig skin group|After routine clinical treatment of second-degree burn wounds, the innermost layer was covered with decellularized pig skin, the outer dressing was changed every 3 to 4 days, the wounds were observed and recorded, and the innermost dressing was changed weekly or as necessary and the number of times was recorded to observe the wound healing rate, dressing transparency, dressing-wound adhesion, pain level, wound infection rate and incidence of adverse reactions.
62228296|NCT02145247|ACTIVE_COMPARATOR|Normal adult women|"1. Images of the both ovaries will be obtained using vaginal ultrasound and the number, size, and spatial arrangement of ovarian follicles will be noted for both ovaries in each subject.~2. On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~3. Blood samples will be obtained at T = -0.5, 0, and +24 hours.~4. Blood sample will be used for DNA testing to identify genes that may be associated with androgen production.~5. One to two weeks after hCG stimulation testing each subject will come to the CTRI for an Oral Glucose Tolerance Test (OGTT). Each subject will ingest 75 gm of a glucose solution and blood samples will be obtained at 0, 15, 30, 60, 120 and 180 minutes after the glucose load."
62228297|NCT02145247|ACTIVE_COMPARATOR|Women with PCOS|"1. Images of the both ovaries will be obtained using vaginal ultrasound and the number, size, and spatial arrangement of ovarian follicles will be noted for both ovaries in each subject.~2. On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~3. Blood samples will be obtained at T = -0.5, 0, and +24 hours.~4. Blood sample will be used for DNA testing to identify genes that may be associated with androgen production.~5. One to two weeks after hCG stimulation testing each subject will come to the CTRI for an Oral Glucose Tolerance Test (OGTT). Each subject will ingest 75 gm of a glucose solution and blood samples will be obtained at 0, 15, 30, 60, 120 and 180 minutes after the glucose load."
62228298|NCT01740141|OTHER|Plexus before surgery|Plexus brachialis before surgery
62228299|NCT01740141|OTHER|Plexus after surgery|Plexus brachialis performed after surgery
62420987|NCT02703454|EXPERIMENTAL|FIRM-only|Subjects in this arm will be treated with FIRM-guided RF ablation without pulmonary vein isolation (PVI).
62420988|NCT02703454|ACTIVE_COMPARATOR|Conventional|Subjects in this arm will undergo conventional radio frequency (RF) ablation with confirmation of PVI.
62420989|NCT02554344|EXPERIMENTAL|All Patients|Fourteen subjects with histologically confirmed squamous CIN3 will be enrolled in a single arm study. All patients will receive 500 mg of curcumin administered orally, twice a day for 12 weeks upon enrollment on trial.
62804306|NCT03326804||Cohort 2 - Efficacy|Cohort 2 will consist of the remaining target size population of 230 patients for H1 Hip Resurfacing Arthroplasty. They will undergo the same intervention as previously described for Cohort 1, but will not undergo metal-ion testing and reduced frequency CT-scans.
62420990|NCT01781689|EXPERIMENTAL|Functional Electric Stimulation|perform arm cranking with functional electrical stimulation
62420991|NCT01781689|SHAM_COMPARATOR|traditional rehabilitation program|Receive traditional rehabilitation programs
62804307|NCT04426318|EXPERIMENTAL|Healthy Minds Program Foundations Training|"Healthy Minds Program (HMP) Description:~The HMP app was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on the work of Richard Davidson, PhD. HMP is designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of high-quality guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). HMP has \>100 guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose."
62420992|NCT01781689|NO_INTERVENTION|Health|with no motor function impairment
62420993|NCT01973270|EXPERIMENTAL|Targeted Cognitive Training - TCT|Neuroadaptive cognitive training
62420994|NCT01973270|EXPERIMENTAL|General Cognitive Exercises (GCE)|Neuroadaptive cognitive training
62420995|NCT01973270|NO_INTERVENTION|Treatment as Usual|Treatment as Usual
62420996|NCT06640023|NO_INTERVENTION|Guideline Education Control|Clinicians randomized to this arm receive guideline education prior to the trial.
62420997|NCT06640023|EXPERIMENTAL|Default Intervention|Clinicians randomized to this arm receive guideline education + 10 pill dispense quantity defaults.
62420998|NCT06640023|EXPERIMENTAL|Accountable Justification|Clinicians randomized to this arm receive guideline education + alerts requiring justification of orders discordant with guidelines. Justifications are entered in the patient's medical record.
62420999|NCT06640023|EXPERIMENTAL|Default and Accountable Justification|Clinicians randomized to this arm receive guideline education + 10 pill dispense quantity defaults + alerts requiring justification of orders discordant with guidelines. Justifications are entered in the patient's medical record.
62421000|NCT01508325|EXPERIMENTAL|Bisoprolol|
62421001|NCT01508325|ACTIVE_COMPARATOR|Metoprolol|
62421002|NCT05309031|EXPERIMENTAL|Immersion|This group will receive the immersion intervention
62421003|NCT04772469|EXPERIMENTAL|Promoter training, multiple self-test kits, and incentives|Promoters in the intervention group will receive HIVST training, multiple HIVST for distribution to other men, and a small amount of remuneration (transport voucher) for themselves and to distribute to men in their networks.
62421004|NCT04772469|NO_INTERVENTION|Short training and referral for testing|Promoters in the control group will a short training on the basics of HIV prevention and treatment and will be encouraged to refer men in their networks for standard of care testing at the local health facilities- this may include HIV testing with a counselor or HIV self-test from the local health clinic, depending on what is available.
62421005|NCT04363931|EXPERIMENTAL|Manual Therapy|Manual Therapy is a widely used physiotherapy modality which is known to be effective in the management of musculoskeletal problems . Manual Therapy is a passive, therapeutic approach used to target a variety of anatomical structures with the intent to create beneficial changes in the amount of pain a patient experiences. Manual Therapy includes joint mobilization, manipulation, or treatment of the soft tissues and is widely used to break fibrous adhesions, restore normal range of motion, reduce local ischemia, stimulate synovial fluid production, and reduce pain .
62421006|NCT04363931|EXPERIMENTAL|Kinesio Taping|Kinesio tape is a type of elastic therapeutic tape that was developed which is used in many different situations with various aims. Advocates of Kinesio Tape state that it may promote different therapeutic objectives such as; improved circulation and lymphatic drainage, pain inhibition, reduction of delayed onset of muscle soreness or improvement in performance and coordination .
62421007|NCT02397174|EXPERIMENTAL|Mediterranean Diet|The diet programme will be characterized by carbohydrates (60 %); proteins (20 %, half comprised of vegetable proteins); total fat (20 %; saturated fat \< 10 %). After calculating the patient's energy need, the amount of calories will be successively adjusted to create an 800 kcal deficit per day.
62228300|NCT04924543|ACTIVE_COMPARATOR|Received short refresher training on optical diagnosis|All participants receive access to the training module, with assessments at baseline, week 2 and week 8-12 Half of participants randomized 1:1 will also receive access to brief refresher training by week 8
62421008|NCT02397174|ACTIVE_COMPARATOR|hypocaloric diet|The diet programme will be characterized by carbohydrates (50%),total lipids (30%) and proteins (20%). After calculating the patient's energy need, the amount of calories will be successively adjusted to create an 800 kcal deficit per day.
62421009|NCT03764592||VF BrS/ERS patients|Only patients that diagnosed with BrS or ERS based on ECG criteria
62421010|NCT03199846||advanced melanoma patients|Part 1 will consist of a representative sample of advanced melanoma patients, irrespective of date of diagnosis of stage III unresectable and metastatic/stage IV, to address information objectives on treatment patterns, clinical outcomes, and resource use after the start of treatment post-launch of new drugs, ie, since 2011 for ipi and 2015 for ipi + nivo in advanced melanoma
62421011|NCT03199846||Ipi monotherapy|Part 2: patients must have been prescribed Ipi monotherapy during the index period between 01-Jan-2015 and 31-May-2016.
62590925|NCT02932774|EXPERIMENTAL|Cetirizine 10 mg|Cetirizine HCl 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive cetirizine HCl syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
62228301|NCT04924543|ACTIVE_COMPARATOR|No refresher training|All participants receive access to the training module, with assessments at baseline, week 2 and week 8-12 This arm does not also receive access to brief refresher training
62590926|NCT02932774|ACTIVE_COMPARATOR|loratadine 10 mg|Loratadine 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive loratadine syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
62804308|NCT04426318|NO_INTERVENTION|Wait-list control|Participants assigned to the wait-list control will not receive treatment for the intervention and follow-up period. They will be provided access to the HMP Foundations training after completing follow-up testing.
62228302|NCT01419457|EXPERIMENTAL|Group 1|Normal hepatic function
62804309|NCT05921435|EXPERIMENTAL|Sequence A|"* Period 1: D958~* Period 2: CKD-341~* Period 3: D958~* Period 4: CKD-341"
62804310|NCT05921435|EXPERIMENTAL|Sequence B|"* Period 1: CKD-341~* Period 2: D958~* Period 3: CKD-341~* Period 4: D958"
62804311|NCT04934371|ACTIVE_COMPARATOR|active TDCS and listening therapy|TDCS will be administered with NeurConn1 Channel DC-Stimulator Plus (neuroCare Group, München, Germany) according to established guidelines and procedures. The active tDCS will be delivered for 20 minutes at 2mA with a 15-s ramp-up and ramp-down period. Excitatory/anodal tDCS or sham will be administered alongside active listening therapy 5 times a week for 2 weeks.
62228303|NCT01419457|EXPERIMENTAL|Group 2|Mild hepatic impairment
62228304|NCT01419457|EXPERIMENTAL|Group 3|Moderate hepatic impairment
62228305|NCT01419457|EXPERIMENTAL|Group 4|Severe hepatic impairment
62228306|NCT00862628|EXPERIMENTAL|Rebamipide|
62228307|NCT02416804|EXPERIMENTAL|Buprenorphine|Buprenorphine group : They will apply 3 days after the spine operation.
62228308|NCT02416804|ACTIVE_COMPARATOR|Tramadol|Tramadol group : They will take a pill of tramadol analgesics.
62228309|NCT00123552|EXPERIMENTAL|1|
62228310|NCT00123552|EXPERIMENTAL|2|
62228311|NCT00123552|EXPERIMENTAL|3|
62421012|NCT03199846||Ipi + nivo combination therapy|Part 2: patients must have been prescribed Ipi + nivo combination therapy during the index period between 01-Jan-2015 and 31-May-2016.
62421013|NCT03199846||Dabrafenib + trametinib combination therapy|Part 2: patients must have been prescribed Dabrafenib + trametinib combination therapy during the index period between 01-Jan-2015 and 31-May-2016.
62421014|NCT03199846||Pembro monotherapy|Part 2: patients must have been prescribed Pembro monotherapy during the index period between 01-Jan-2015 and 31-May-2016
62590927|NCT02932774|PLACEBO_COMPARATOR|placebo|Placebo syrup once daily for 2 weeks. Both placebo syrups were received by subjects who were randomized to receive placebo. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
62228312|NCT05493670||DBS-STN|The DBS-STN group will consist of individuals with Parkinson's disease who have already elected to undergo deep brain stimulation surgery.
62228313|NCT05493670||Control|The control group will consist of individuals with Parkinson's disease who are not undergoing deep brain stimulation placement. No interventions will be completed with the control group.
62590928|NCT02838719|EXPERIMENTAL|Perineural group|Group 1: perineural dexamethasone acetate added to bilateral transverse abdominis plane block with levobupivacaine
62590929|NCT02838719|ACTIVE_COMPARATOR|Intravenous group|Group 2: Intravenous dexamethasone acetate added with bilateral transverse abdominal plane block with levobupivacaine
62590930|NCT01075646|EXPERIMENTAL|Ropivacaine|After a bolus administration of Ropivacaine a perfusion ot the same anesthetic is initiated through an elastomeric wound during 48 hours
62590931|NCT01075646|PLACEBO_COMPARATOR|saline solution|After a bolus administration of saline solution a perfusion ot saline solution is initiated through an elastomeric wound during 48 hours
62590932|NCT05764538|EXPERIMENTAL|DAOIB|
62228314|NCT01145755|EXPERIMENTAL|AZD2066|
62228315|NCT01145755|PLACEBO_COMPARATOR|Placebo|
62228316|NCT01145755|ACTIVE_COMPARATOR|Duloxetine|Duloxetine
62228317|NCT03336996|EXPERIMENTAL|evaluation|To characterize and evaluate functional and anatomical changes of nerve fiber injuries after umbilical cord mesenchymal stem cells transplantation with BOLD drived-DTI
62228318|NCT03336996|EXPERIMENTAL|BOLD-fMRI and DTI|To determine the therapeutic efficiency of umbilical cord mesenchymal stem cells and also the utility of the integration of BOLD-fMRI and DTI.
62228319|NCT03336996|EXPERIMENTAL|correlate the imaging results|To correlate the imaging results with the electrophysiology outcomes
62228320|NCT05354180|EXPERIMENTAL|navicular mobilization|Plantar glide combined with rotation of navicular bone against the talus The glide will be given in 20 repetitions of 3 sets, for 5 days a week
62228321|NCT05354180|EXPERIMENTAL|rigid tapping|"A non-elastic zinc oxide sports tape will be applied to patients. Patient will be advised to protect the tape from getting wet.~Tape will be changed on every 3rd day (48 hours) on Wednesday and Friday."
62590933|NCT03683693|NO_INTERVENTION|Standard of Care group|Historical Group = Standard of Care group. Decision for stopping antibiotics taken by ICU physician: assessment on the basis of the clinical picture and traditional inflammatory biomarkers such as crp and leucocytosis
62590934|NCT03683693|EXPERIMENTAL|Procalcitonin group|ICU physician gets on regular base PCT value, what can be used as additive tool in the decision-making for stopping antibiotics.
62590935|NCT02545478||Infected Group|subjects with suspected infection
62590936|NCT02545478||Non-infected group|subjects without any infection
62590937|NCT03387228|EXPERIMENTAL|Pain education group (PEG)|Pain education based on Explain Pain developed by Moseley and Butler in 2003.
62590938|NCT03387228|ACTIVE_COMPARATOR|Control group (CG)|Evidence based physiotherapy care brief education, superficial heat, massage, and exercise.
62590939|NCT03453879||1: Study population|Participants in this study are working staff (junior and senior doctors, midwifes and other health personal) in the maternity wards of two hospitals in Central Region Denmark: Horsens Regional Hospital and Aarhus University Hospital, Skejby.
62590940|NCT00656851|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone (Actos, 30mg/day for 16 weeks)
62590941|NCT00656851|ACTIVE_COMPARATOR|Exercise Training|Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks
62590942|NCT06372249|NO_INTERVENTION|Fiber Consumption and the Gut Microbiome Composition in a Pediatric Asthma Cohort|Participants are asked to complete a dietary recall questionnaire (ASA 24) that evaluates dietary intake in the last 24 hours. Participants are also sent home with a stool kit and instructions to collect a fecal sample for microbiome analysis. The purpose of the study is to better understand the pathways that connect diet and asthma.
62228322|NCT05354180|EXPERIMENTAL|"Navicular Mobilization and Rigid Taping|"|"Plantar glide combined with rotation of navicular bone against the talus The glide will be given in 20 repetitions of 3 sets, for 5 days a week.~A non-elastic zinc oxide sports tape will be applied to patients. Patient will be advised to protect the tape from getting wet.~Tape will be changed on every 3rd day (48 hours) on Wednesday and Friday."
62228323|NCT02867319|EXPERIMENTAL|age of 18-50 years old|
62228324|NCT02867319|EXPERIMENTAL|age of 7-17 years old|
62228325|NCT02867319|EXPERIMENTAL|age of 2-6 years old|
62228326|NCT04810754|EXPERIMENTAL|Daratumumab subcutaneous|open label daratumumab s.c., unblinded
62228327|NCT02722733|ACTIVE_COMPARATOR|G-CSF (filgrastim)|1.G-CSF at 10 μg/kg per day (divided into two doses every 12 hours) subcutaneously for up to 7 days.
62228328|NCT02722733|ACTIVE_COMPARATOR|Cytosine arabinoside + G-CSF (filgrastim)|"1. Cytosine arabinoside will be administered as a 2-hour i.v. infusion at a dose of 0.4 g/m2 twice daily on days 1 and 2 (total dose 1.6 g/m2).~2. G-CSF 5-10 μg/kg per day (divided into two doses every 12 hours) will be started on day 5 subcutaneously and continued until last leukapheresis."
62228329|NCT02486133|EXPERIMENTAL|A: boosted darunavir (bDRV) plus dolutegravir (DTG; 2DR)|Prezista \& Norvir \& Tivicay
62228330|NCT02486133|ACTIVE_COMPARATOR|B: bDRV plus 2 nucleoside reverse-transcriptase inhibitors (NRTIs; 3DR)|Prezista \& Norvir \& Truvada or Prezista \& Norvir \& Kivexa or Prezista \& Norvir \& Descovy
62228331|NCT06222385|EXPERIMENTAL|Sleep Opportunity-Sleep Deprivation|Participant randomized to overnight sleep period with a morning wake period on first visit of cross-over study.
62228332|NCT06222385|EXPERIMENTAL|Sleep Deprivation-Sleep Opportunity|Participant randomized to overnight sleep deprivation period with a morning recovery sleep period on first visit of cross-over study.
62243120|NCT05634252|EXPERIMENTAL|Education + Action Plan + MC1R Test|Students in this intervention will receive education on skin cancer and prevention strategies, complete an individualized sun protection and tanning worksheet for situations in which they receive UVR exposure, and provide a saliva sample using an Oragene® clinical-grade saliva kit and receive individualized results following MC1R sequencing.
62590943|NCT06372249|PLACEBO_COMPARATOR|A Phase II Randomized Controlled Trial of Soluble Fiber for Asthma|Participants are asked to fill out a dietary recall questionnaire (ASA 24) to determine eligibility in the study. If eligible, a nasal wash and blood sample will be collected at the first visit. Study drug or placebo will be given to participant after their visit in a randomized double-blinded nature. The participant will also fil out an Asthma Control Questionnaire (ACQ) and be sent home with 3 stool kits for analysis. Participant will turn in one sample after first visit, the second in three weeks, and the last one after the second study visit. At this second study visit, procedures from the first study visit will be repeated.
62029724|NCT06170008|EXPERIMENTAL|Post-operative skin grafting wounds covered with silicone film sheet group|After skin grafting, the innermost layer is covered with physical microstructure-modified transparent silicone film sheet , and the outer dressing is changed every 3 to 4 days to observe and record the wound. The innermost layer is changed weekly or as necessary and the number of times is recorded to observe the wound healing rate, transparency of the dressing, adhesion of the dressing to the wound, pain, wound infection rate and incidence of adverse reactions.
62029725|NCT06170008|ACTIVE_COMPARATOR|Post-operative skin grafting wounds covered with vaseline gauze group|After skin grafting, the innermost layer was covered with vaseline gauze, and the outer layer was changed every 3 to 4 days to observe and record the wound. The innermost layer was changed weekly or as necessary and the number of times was recorded to observe the wound healing rate, transparency of the dressing, adhesion of the dressing to the wound, pain, wound infection rate and incidence of adverse reactions.
62029726|NCT02934373|ACTIVE_COMPARATOR|A New Sound Processor|Sound Processor is the next generation sound processor.
62421015|NCT03199846||Nivo monotherapy|Part 2: patients must have been prescribed Nivo monotherapy during the index period between 01-Jan-2015 and 31-May-2016
62421016|NCT00753909|EXPERIMENTAL|1|Paclitaxel/Carboplatin/Bevacizumab
62029727|NCT02934373|NO_INTERVENTION|Subject's own sound processor|
62421017|NCT05789511||Medically refractory Non-transplanted gastroparesis|"Etiology of gastroparesis deemed on clinical grounds to NOT be secondary to lung transplantation process ( diabetes, post-surgery, idiopathic, neuromuscular etc.)~Gastroparesis defined as \> 10% radiotracer remains in the stomach after 4 hour gastric scintigraphy study.~Medically refractory is defined as lack of clinical response to trial of diet and lifestyle modifications such as small frequent low fat and low fiber meals and trial or contraindications to prokinetic medications for the treatment of gastroparesis~Case Cohort: Assessment of HR-EGG comparing controls (non lung transplant induced gastroparesis) vs lung transplant induced gastroparesis~Investigators will further categorize patients into sub- groups based on HR-EGG phenotypes:, such as High Frequency, Low Frequency, High Amplitude, Low Amplitude, Continuous Symptoms, Sensorimotor Symptoms, Mixed Symptoms and Normal on Day."
62421018|NCT05789511||Medically refractory Post Lung transplant gastroparesis|"Etiology of gastroparesis deemed on clinical grounds to be secondary to lung transplantation process.~Gastroparesis defined as \> 10% radiotracer remains in the stomach after 4 hour gastric scintigraphy study.~Medically refractory is defined as lack of clinical response to trial of diet and lifestyle modifications such as small frequent low fat and low fiber meals and trial or contraindications to prokinetic medications for the treatment of gastroparesis~Case Cohort: Assessment of HR-EGG comparing controls (non lung transplant induced gastroparesis) vs lung transplant induced gastroparesis~Investigators will further categorize patients into sub- groups based on HR-EGG phenotypes:, such as High Frequency, Low Frequency, High Amplitude, Low Amplitude, Continuous Symptoms, Sensorimotor Symptoms, Mixed Symptoms and Normal on Day."
62421019|NCT03576131|EXPERIMENTAL|GEN1029 (HexaBody®-DR5/DR5)|
62804312|NCT04934371|SHAM_COMPARATOR|sham TDCS and listening therapy|The sham stimulation will also last for 20 min with 15 sec ramp-up and ramp-down, except the current will be turned down gradually to 0 milliamperes (mA) after 30 seconds. The sham procedure provides the same tingling and itching sensation felt during active tDCS. The sham parameters were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade out in the first 30 s of tDCS
62804313|NCT00495729|EXPERIMENTAL|Cohort 1|Subjects in Cohort 1 will be randomized to receive 5 milligram (mg) of SB-649868 or Placebo along with 10 mg of simvastatin.
62029728|NCT04153266||Patients with oral epithelial dysplasia|"INCLUSION CRITERIA~These include:~* Adults aged 18 or above at the time of the screening visit.~* Good command of English language both written and spoken \[this is necessary as questionnaires are in English and cannot be translated unless through a cross-cultural validation study\].~* Being able to consent.~* Diagnosed with OED as per current standard diagnostic criteria.~* No concurrent malignancy in the head and neck or elsewhere."
62029729|NCT00352729|ACTIVE_COMPARATOR|A|
62421020|NCT01883518|EXPERIMENTAL|Autologous dendritic cell vaccine|Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
62804314|NCT00495729|EXPERIMENTAL|Cohort 2|Subjects in Cohort 2 will be randomized to receive two or three times higher than the starting dose of SB-649868 or Placebo along with 10 mg of simvastatin.
62804315|NCT00495729|EXPERIMENTAL|Cohort 3|Subjects in Cohort 3 will be randomized to dose higher than that administered in Cohort 2 of SB-649868 or Placebo along with 10 mg of simvastatin.
62804316|NCT04353128|EXPERIMENTAL|Melatonin|2 mg of melatonin orally before bedtime for 12 weeks
62804317|NCT04353128|PLACEBO_COMPARATOR|Placebo|Identically looking placebo orally before bedtime for 12 weeks
62804318|NCT04092153|ACTIVE_COMPARATOR|Mechanically aligned|Neutral limb alignment irrespective of the patient's native knee anatomy and joint mechanics
62804319|NCT04092153|EXPERIMENTAL|Functionally aligned|Restore the patient's own pre-arthritic knee anatomy
62804320|NCT03767647|EXPERIMENTAL|Intervention group|Receives 6 lessons in 6 different weeks on Emotional Intelligence
62804321|NCT03767647|NO_INTERVENTION|Control group|Receives no intervention.
62804322|NCT01175863|ACTIVE_COMPARATOR|Intravascular ultrasound|
62804323|NCT01175863|ACTIVE_COMPARATOR|Fractional flow reserve|
62804324|NCT01777074||Generalist physicians Cohort|
62804325|NCT01777074||Paediatricians Cohort|
62804326|NCT03746626||Hospice 1|Strathcarron Hospice, Scotland. All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
62804327|NCT03746626||Hospice 2|Arthur Rank Hospice, England. All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
62804328|NCT03746626||Hospice 3|All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
62804329|NCT02447965|ACTIVE_COMPARATOR|Bupivacaine|Will have 20ml of bupivacaine injected into each rectus sheath.
62804330|NCT02447965|PLACEBO_COMPARATOR|Normal Saline|Will have 20ml of normal saline injected into each rectus sheath.
62804331|NCT03111563|OTHER|warm saline|case group ,
62029730|NCT06199921|EXPERIMENTAL|20mg atorvastatin with standard of care (SOC) for TB|Trial of 20mg atorvastatin with standard of care (SOC) for TB
62421021|NCT01854515|ACTIVE_COMPARATOR|Budesonide|1 mg diluted in 4 cc of sterile water for 20 minutes, one hour preceding extubation. After extubation patients received nebulizing Budesonide via oxygen mask at the same dose every 12 h. for 48 h.
62421022|NCT01854515|EXPERIMENTAL|Dexamethasone|0.15 mg/kg before extubation. After extubation, the administration of intravenous Dexamethasone continued at the same dose every 12 h. for 48 h.
62804332|NCT03111563|OTHER|room temperature|control group
62804333|NCT03729648|EXPERIMENTAL|Intervention|This arm of participants will be receiving Expressive Arts Therapy as intervention
62804334|NCT03729648|NO_INTERVENTION|Control|This arm of participants will not receive any intervention and are allocated as a wait-list control group
62421023|NCT02229487|ACTIVE_COMPARATOR|Normal Sleepers|Prediabetes patients with normal sleep duration (7-8 hours/ night) as measured objectively
62421024|NCT02229487|EXPERIMENTAL|Short Sleepers|Prediabetes patients with short sleep duration (\<6 hours/night) as measured objectively
62421025|NCT04861831|EXPERIMENTAL|Immediate PCS Intervention|After the pre-intervention clinical assessments, immediate (within one week) begin with the PCS exercise program (75-minute group class, twice weekly for 12 weeks; home practice of exercises recommended but not required). Post-intervention clinical assessments within one week after the last intervention class, followed by a 12-week follow-up period (continuation of exercise program at home recommended but not required). Final clinical assessments within one week after the 12-week follow-up period.
62421026|NCT04861831|EXPERIMENTAL|Delayed PCS Intervention|During the 12 weeks that the Immediate Intervention (II) group participates in the PCS intervention, the Delayed Intervention (DI) group waits (there is no control intervention) and serves as a control arm comparison for the II group during this time. After the 12 weeks, the DI group will undergo a second pre-intervention assessment to document any change in baseline measures that may have occurred in those 12 weeks. No significant changes are expected. The DI group then begins the same exercise intervention (75-minute group class, twice weekly for 12 weeks; home practice of exercises recommended but not required) that the II group underwent, given by the same instructors. Post-intervention clinical assessments, 12-week follow-up period, and final clinical assessments after the follow-up period as described for the II group. After the trial, pooled data from both groups will provide results on the overall changes in outcome measures post- versus pre-intervention.
62421027|NCT05366153||Survivor Screening/Management Plan|"In cancer survivors;~1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease,~2. A clinical review to ensure optimal risk factor control and cardiac protection."
62804335|NCT01544725|EXPERIMENTAL|Ketamine-propofol|
62804336|NCT01544725|ACTIVE_COMPARATOR|Ketamine alone|
62804337|NCT03882892|PLACEBO_COMPARATOR|Placebo + Atorvastatin|Participants who received placebo in the parent study (P00692) receive placebo (blinded) + atorvastatin (10 mg/day; open-label) in this study.
62804338|NCT03882892|EXPERIMENTAL|Ezetimibe + Atorvastatin|Participants who received ezetimibe + atorvastatin, or atorvastatin alone, in the parent study (P00692) receive ezetimibe (blinded) + atorvastatin (10 mg/day; open-label) in this study.
62804339|NCT02055898|EXPERIMENTAL|Placebo first, then sodium oxybate|Subjects received a single dose of placebo comparator (fresh potable water) at bedtime on 4 nights during an inpatient stay of 5 days in the research centre. This was followed by an interval of at least 2 weeks. They were then admitted again and received a single dose of sodium oxybate (3.0g as liquid) at bedtime for 4 nights
62804340|NCT02055898|EXPERIMENTAL|Sodium oxybate first, then placebo|Subjects received a single dose of sodium oxybate (3.0g as liquid) at bedtime on 4 nights during an inpatient stay of 5 days in the research centre. This was followed by an interval of at least 2 weeks. They were then admitted again and received a single dose of placebo comparator (fresh potable water) at bedtime for 4 nights
62421028|NCT05366153||Non-cancer Screening/Management Plan|"In matched non-cancer patients (from EDCAD trial);~1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease,~2. A clinical review to ensure optimal risk factor control and cardiac protection."
62804341|NCT05083689|ACTIVE_COMPARATOR|Injections of 1.25 mg of intravitreal bevacizumab with topical drops of Timolol and Dorzolamide|31 cases in intervention group receive injections of 1.25 mg of intravitreal bevacizumab monthly for 3 months (months 0, 1 and 2) with topical drops of Timolol twice a day and Dorzolamide twice a day
62804342|NCT05083689|PLACEBO_COMPARATOR|Injections of 1.25 mg of intravitreal bevacizumab with artificial tears|31 cases in control group receive intravitreal injection of 1.25 mg bevacizumab monthly for 3 months (months 0, 1 and 2) plus artificial tears (twice a day as a placebo)
62029731|NCT06199921|EXPERIMENTAL|40mg atorvastatin with standard of care (SOC) for TB|Trial of 40mg atorvastatin with standard of care (SOC) for TB
62228333|NCT05261048|EXPERIMENTAL|Pelvic Proprioceptive neuromuscular facilitation in addition to Conventional Physical Therapy|"The experimental group received both conventional and Pelvic PNF for 30 minutes each, once in a day, 4 days per week.~The experimental group will be given anterior elevation-Posterior depression pattern with the techniques of Rhythmic initiation, Slow reversal and Stabilizing reversal.~These techniques will be given on affected side for total 30 minutes with 15 minutes of pelvic PNF in one session with rest periods in between.~Participants will be positioned into side lying with both hip flexion 1000 and knee flexion 450, neck supported by a pillow with flexion of 300.~Hand placement for anterior elevation over the crest of the ilium one hand overlaps other for posterior depression heel of the one hand hold with other hand on the ischial tuberosity.~Pull up and Push down command will be given along with the techniques of rhythmic initiation, slow reversal and stabilizing reversal."
62228334|NCT05261048|PLACEBO_COMPARATOR|Conventional Physical Therapy|"Patient will perform conventional physiotherapy in form of truncal exercises, which consist of upper and lower part of trunk in spine and sitting position for total 30 minutes and then participants will be asked to take some rest. In supine position, pelvic bridging, unilateral pelvic bridging, upper trunk rotation (clasped hand), lower trunk rotation (crook lying) with 3 repetitions for each exercise.~In sitting position, exercises included flexion and extension of lower trunk, rotation of upper and lower trunk, forward and lateral reach with 3 repetitions for each exercise."
62228335|NCT00104559|EXPERIMENTAL|1|Participants will receive the computer-based tutorial for VT and then the standard paper consent form for AT
62228336|NCT00104559|EXPERIMENTAL|2|Participants will receive the standard paper consent form for VT and then the computer-based tutorial for AT
62228337|NCT00104559|EXPERIMENTAL|3|Participants will receive the computer-based tutorial for AT and then the standard paper consent form for VT
62421029|NCT01262404||HealthEd,Minfdulness,Compassion|HealthEd receives training health education. Mindfulness receives training in mindfulness meditation. Compassion receives training in compassion meditation.
62421030|NCT02574260|EXPERIMENTAL|Talimogene Laherparepvec|Participants received talimogene laherparepvec 10⁸ plaque forming units (PFU)/mL (up to 4 mL depending on tumor size) administered intratumorally every 2 weeks, on Day 1 and Day 15 of 28-day cycles until discontinuation criteria were met.
62421031|NCT04179123|EXPERIMENTAL|Healthy|Conventional and customised PAP interfaces
62421032|NCT04179123|EXPERIMENTAL|Patients|Conventional and customised PAP interfaces
62421033|NCT01734213|EXPERIMENTAL|Eriobotyra Japonica Lindley Extract|
62421034|NCT01734213|PLACEBO_COMPARATOR|Placebo|
62421035|NCT01805258|EXPERIMENTAL|Intervention 2: Nevirapine|HIV and Tuberculosis co-infected patients on standard dose nevirapine (Intervention) based ART and Rifampicin based ATT.
62421036|NCT01805258|ACTIVE_COMPARATOR|Intervention 2: Efavirenz|HIV and Tuberculosis co-infected patients on standard dose Efavirenz(Intervention)based ART and Rifampicin based ATT.
62421037|NCT05270109|EXPERIMENTAL|BiZact|
62421038|NCT05270109|ACTIVE_COMPARATOR|Cold Steel|
62421039|NCT00022126|EXPERIMENTAL|Modified Augmented BFM Therapy|
62421040|NCT02343497|EXPERIMENTAL|Astaxanthin|Astaxanthin supplement from Phaffia rhodozyma, 6mg in lipid capsules, 2 caps per day, duration 12 weeks
62228338|NCT00104559|EXPERIMENTAL|4|Participants will receive the standard paper consent form for AT and then the computer-based tutorial for VT
62421041|NCT02343497|PLACEBO_COMPARATOR|Placebo|filling agent, in lipid capsules, 2 caps per day, duration 12 weeks
62421042|NCT05357742|EXPERIMENTAL|Intervention Group|Participants randomized to the intervention group will receive the manualized study intervention delivered by a health educator via telephone weekly for 12-weeks, followed by three monthly booster sessions resulting in a total of 6 months intervention.
62421043|NCT05357742|ACTIVE_COMPARATOR|Control group|Participants randomized to the control group will receive the manualized study intervention delivered by a health educator via telephone weekly for 12-weeks, followed by three monthly booster sessions resulting in a total of 6 months intervention.
62590944|NCT01640769|ACTIVE_COMPARATOR|Image guided delivery of pacing leads|Patients will be blindly randomized to image guided delivery of pacing leads during cardiac resynchronization therapy device implantation (study arm) versus standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
62590945|NCT01640769|PLACEBO_COMPARATOR|Standard delivery of pacing leads|Patients will be blindly randomized to standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
62590946|NCT05044936|EXPERIMENTAL|Training|Visit 1: sign consent form, pregnancy tests for females, resting blood pressure, height/weight, body composition, and VO2max test. Visit 2: 1-repetition maximum (RM) test and protocol familiarization. Visit 3: perform a muscle-damaging exercise protocol. Pre-exercise soreness and blood samples will be collected. After, they will perform the pre-exercise testing to assess baselines levels of power and sprint times. Upon completion, they will undergo the muscle-damaging exercise protocol. Post-exercise blood samples and soreness will be collected. The participant will then be given either placebo or CBD cream to rub into their quadriceps. Visit 4 \& 5: collect blood samples and soreness scale measurements. Participants will then be given the same treatment (placebo or CBD cream) as they had on visit 3. Visit 6 will be similar to visit 3, except the participant will be given the opposite treatment (placebo or CBD cream). Visits 7 \& 8 will be similar to visits 4 \& 5, respectively.
62590947|NCT05283226|EXPERIMENTAL|NRC-2694-A In Combination with paclitaxel|Patients will receive NRC-2694-A 300 mg orally once daily and paclitaxel 175 mg/m² IV infusion over approximately 3 hours once in 21 days for 6 cycles or more.
62029732|NCT06199921|EXPERIMENTAL|60mg atorvastatin with standard of care (SOC) for TB|Trial of 60mg atorvastatin with standard of care (SOC) for TB
62029733|NCT06199921|NO_INTERVENTION|Standard of care (SOC) for TB|Standard of care (SOC) for TB
62590948|NCT01582633|EXPERIMENTAL|0.1 ml ID dose|Dose of 0.1 ml ID trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
62029734|NCT04590703||ALLO-ASC-DFU|Subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial of ALLO-ASC-DFU-301
62029735|NCT04590703||Vehicle sheet|Subjects with Vehicle sheet treatment in phase 3 clinical trial of ALLO-ASC-DFU-301
62029736|NCT05846594|OTHER|Basic Workup: Metastatic Lung Cancer Cohort|This cohort will enroll approximately 160 participants who have clinical evidence of de novo metastatic lung cancer and who have not had tissue biopsy performed prior to enrollment (classified as 'basic workup').
62590949|NCT01582633|EXPERIMENTAL|0.2 ml ID dose|Dose of 0.2 ml ID trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
62590950|NCT01582633|EXPERIMENTAL|0.5 ml IM dose - needle-free|Dose of 0.5 ml IM trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
62029737|NCT05846594|OTHER|Basic Workup: Metastatic Gastrointestinal Cancer Cohort|This cohort will enroll approximately 160 participants who have clinical evidence of de novo metastatic gastrointestinal cancer and who have not had tissue biopsy performed prior to enrollment (classified as 'basic workup').
62029738|NCT05846594|OTHER|Extended Workup: Metastatic Lung Cancer Cohort|This cohort will enroll approximately 100 participants who have clinical evidence of de novo metastatic lung cancer and who have had tissue biopsy performed prior to enrollment (classified as 'extended workup').
62029739|NCT05846594|OTHER|Extended Workup: Metastatic Gastrointestinal Cancer Cohort|This cohort will enroll approximately 100 participants who have clinical evidence of de novo metastatic gastrointestinal cancer and who have had tissue biopsy performed prior to enrollment (classified as 'extended workup').
62029740|NCT06305572||QFR group|Patients suspected with coronary artery disease undergoing diagnostic coronary angiography with an indication for to perform invasive FFR
62590951|NCT01582633|ACTIVE_COMPARATOR|0.5 ml IM - needle and syringe|Dose of 0.5 ml IM trivalent 2012 influenza vaccine administered by needle and syringe
62590952|NCT02715362|EXPERIMENTAL|TAI-GPC3-CART cells|A single dose of GPC3-CART cells will be administered by transcatheter arterial infusion(TAI) mediated as one dose infusion. The dose is 1-10x106/kg GPC3-CAR positive T cells. The infusion will be scheduled to occur 2 days after a single dose of 1.5 grams/m2 of cyclophosphamide. Patients will undergo cannula--DSA radiography--CAR-T cells perfused into hepatic artery. The cells perfusion process would last 15min to 2 h, and the specific time depends on patent's tumor-burdened state.
62590953|NCT05929729|EXPERIMENTAL|Intravenous (IV) iron|This group will receive intravenous iron (Ferric Derisomaltose) in a single dose of 20 mg/kg (max individual dose of 1000 mg). The drug is administered as an infusion over 30 minutes. 3 months after the infusion, they will receive a 9-month supply of Novaferrum pill to be taken once a day.
62029741|NCT03449030|EXPERIMENTAL|Part A Escalation Stage: TAK-164 Q3W|TAK-164 0.004 milligram per kilogram (mg/kg) starting dose, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. Dose escalation will be performed to determine the MTD and/or RP2D.
62029742|NCT03449030|EXPERIMENTAL|Part B Expansion Stage: TAK-164 Q3W|TAK-164, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. TAK-164 RP2D dose to be decided based on safety, PK, pharmacodynamics and antitumor response data observed in Part A escalation stage.
62029743|NCT03449030|EXPERIMENTAL|Part C Imaging Substudy: 89Zr-TAK-164 and TAK-164|89Zr-TAK-164, intravenous infusion, followed by unlabeled TAK-164, intravenous infusion in combination with 89Zr-TAK-164, intravenous infusion, and further followed by unlabeled TAK-164, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. TAK-164 recommended imaging dose (RID) or RP2D dose to be decided based on safety, PK, PD and antitumor response data observed in Part A escalation stage.
62421044|NCT06543186|EXPERIMENTAL|Conventional oral health education|For the conventional oral health education, the trained and calibrated dentist will provide health education to the selected participants in this group by chalk and talk method, PowerPoint presentations, models and charts so that it can make the sessions more interactive. The duration of the session will be around 60-90 minutes. Pre-assessment will be taken prior to the lecture. Post assessment will be taken after the lecture to assess the oral health knowledge, practise and attitude.
62804343|NCT04690140|ACTIVE_COMPARATOR|modified coronally advanced tunnel technique|Initial sulcular incisions and flap separation were then carried out with tunnel knives. Dissection was extended at least 8 mm apically to the mucogingival junction and the muscle attachments were removed with curettes so that the flap could be moved in a coronal direction without tension. Interdental papillae were undermined to prepare the bed for connective tissue graft placement. Connective tissue graft was then inserted under the tunnel at the sites of recession and retracted laterally by sutures towards each end of the tunnel. After connective tissue graft positioning, the flap was gently stretched coronally to obtain passive flap closure. The exposed connective tissue was covered by connecting the adjacent flap margins with additional sutures.
62804344|NCT04690140|ACTIVE_COMPARATOR|epithelialized free gingival graft|A partial-thickness flap was elevated (blade #15c) with horizontal incisions at the cemento-enamel junction level of the adjacent teeth. Then, two vertical incisions extending to the apical were made from two ends of the horizontal incision. The epithelium in the framed region was removed with a scalpel and the underlying connective tissue was exposed. To achieve the best vascularization from the recipient site, bed preparation was completed with a split-thickness horizontal incision that joins the vertical incisions in the apical region.
62804345|NCT04021095|EXPERIMENTAL|Decompressive craniectomy|3D printed skull replacement piece will be fitted to subject.
62804346|NCT00276510|EXPERIMENTAL|1|
62804347|NCT00276510|PLACEBO_COMPARATOR|2|
62029744|NCT05520229||Pre- Preanaesthesia assessment clinic|Patients who have been to surgery for an elective laparoscopic or open partial intestine from 2014-2017.
62228339|NCT03525288|EXPERIMENTAL|PSMA-PETgRT|PSMA-PET/CT imaging is performed during treatment planning. Treating physicians are informed of test results and advised to include up to 5 PSMA-PET avid sites distant to the prostate gland, if present, in the radiotherapy treatment plan.
62228340|NCT03525288|ACTIVE_COMPARATOR|Standard|Patient's receive standard care radiotherapy and do not undergo PSMA-PET/CT imaging.
62228341|NCT01360931||Lung Cancer group|Subject with histological confirmation of lung cancer
62590954|NCT05929729|NO_INTERVENTION|Standard of care iron|This group will be referred to their primary care provider for oral iron therapy. If a participant cannot obtain care from a physician
62590955|NCT05929729|NO_INTERVENTION|Healthy Controls|This group will only be participating in the observational part of the study and serve as our controls.
62029745|NCT05520229||Post- Preanaesthesia assessment clinic|Patients who have been to surgery for an elective laparoscopic or open partial intestine from 2017 and have attended a preanesthesia clinic.
62029746|NCT00675740|EXPERIMENTAL|1|
62590956|NCT00831298|OTHER|1|Behavioral Questionnaire Sleep Recordings Genetic analysis
62029747|NCT00675740|ACTIVE_COMPARATOR|2|physical exercise
62590957|NCT06666881|NO_INTERVENTION|control|No Intervention: Head and Neck patients after CCRT treatment. After CCRT treatment, participants keep follow the skeletal muscle mass evaluation
62029748|NCT00675740|NO_INTERVENTION|3|control
62029749|NCT03179228|EXPERIMENTAL|Prostate Embolization|Prostate Embolization with acrylic polymer microspheres impregnated with porcine gelatin
62029750|NCT05660265|EXPERIMENTAL|Cohort 1|Participants in this arm will receive either single dose of GSK4172239D (Dose 1) or matching placebo.
62029751|NCT05660265|EXPERIMENTAL|Cohort 2|Participants in this arm will receive either single dose of GSK4172239D (Dose 2) or matching placebo.
62029752|NCT05660265|EXPERIMENTAL|Cohort 3|Participants in this arm will receive either single dose of GSK4172239D (Dose 3) or matching placebo.
62029753|NCT05660265|EXPERIMENTAL|Cohort 4|Participants in this arm will receive either single dose of GSK4172239D (Dose 4) or matching placebo.
62029754|NCT05660265|EXPERIMENTAL|Cohort 5|Participants in this arm will receive either single dose of GSK4172239D (Dose 5) or matching placebo.
62029755|NCT05660265|EXPERIMENTAL|Food effect cohort|One selected cohort will also receive an additional single dose of GSK4172239D (or matching placebo) under fed (high calorie and high fat) conditions.
62029756|NCT06356610|EXPERIMENTAL|Randomization Sequence 1: ABFCED|"Usage of Test and Reference study products in controlled use and ad libitum use sessions during the 6 day in-clinic period in following order:~Test Product A Test Product B Reference Product F Test Product C Reference Product E Test Product D"
62029757|NCT06356610|EXPERIMENTAL|Randomization Sequence 2: BCADFE|"Usage of Test and Reference study products in controlled use and ad libitum use sessions during the 6 day in-clinic period in following order:~Test Product B Test Product C Test Product A Test Product D Reference Product F Reference Product E"
62029758|NCT06356610|EXPERIMENTAL|Randomization Sequence 3: CDBEAF|"Usage of Test and Reference study products in controlled use and ad libitum use sessions during the 6 day in-clinic period in following order:~Test Product C Test Product D Test Product B Reference Product E Test Product A Reference Product F"
62029759|NCT06356610|EXPERIMENTAL|Randomization Sequence 4: DECFBA|"Usage of Test and Reference study products in controlled use and ad libitum use sessions during the 6 day in-clinic period in following order:~Test Product D Reference Product E Test Product C Reference Product F Test Product B Test Product A"
62029760|NCT06356610|EXPERIMENTAL|Randomization Sequence 5: EFDACB|"Usage of Test and Reference study products in controlled use and ad libitum use sessions during the 6 day in-clinic period in following order:~Reference Product E Reference Product F Test Product D Test Product A Test Product C Test Product B"
62029761|NCT06356610|EXPERIMENTAL|Randomization Sequence 6: FAEBDC|"Usage of Test and Reference study products in controlled use and ad libitum use sessions during the 6 day in-clinic period in following order:~Reference Product F Test Product A Reference Product E Test Product B Test Product D Test Product C"
62029762|NCT03149094|EXPERIMENTAL|CBSM-SMI|The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
62029763|NCT03149094|ACTIVE_COMPARATOR|CBSM-SMI control|The control group will receive an app called LifeSum, which focuses on healthy lifestyles.
62029764|NCT06006520|ACTIVE_COMPARATOR|control group|No exercises will be given.
62029765|NCT06006520|EXPERIMENTAL|oropharyngeal|oropharyngeal exercises will be given.
62029766|NCT06006520|EXPERIMENTAL|aerobic|In addition to oropharyngeal exercises, 50 minutes of moderate-intensity aerobic exercise will be given at least 3 days a week.
62029767|NCT01726192|ACTIVE_COMPARATOR|HLOC|Placement of a femoral catheter with the hydrolocalization technique
62029768|NCT01726192|ACTIVE_COMPARATOR|NS|Placement of a femoral neurostimulating catheter
62029769|NCT06670898|EXPERIMENTAL|Administration of [14C] NS-580|
62590958|NCT06666881|EXPERIMENTAL|experimental|"Experimental: Head and Neck patients after CCRT treatment with exercise training.~After CCRT treatment 4-5 week, arrange participants do the exercise training for patient. Two to three times a week ,total 24-36 times. Participants keep follow the skeletal muscle mass evaluation."
62029770|NCT00493766|EXPERIMENTAL|oral LBH589 alone|
62029771|NCT00493766|EXPERIMENTAL|oral LBH589 + IV docetaxel + oral prednisone|
62029772|NCT02313142|EXPERIMENTAL|Subjects|
62029773|NCT06636162|EXPERIMENTAL|DSP-0390 120 mg|The first 10 patients will be assigned to DSP-0390 120 mg once daily by mouth for 2 weeks prior to surgical resection, with the final dose being administered the morning of surgery.
62029774|NCT06636162|EXPERIMENTAL|DSP-0390 240 mg|The next 10 patients will be assigned to DSP-0390 240 mg once daily by mouth for 2 weeks prior to surgical resection, with the final dose being administered the morning of surgery.
62228342|NCT01360931||Control group|Subjects with no diagnosis of lung cancer
62228343|NCT04538456||used electronic Patient Reported Outcome Measures|Lung cancer patients who have used the electronic Patient Reported Outcome Measures system before and after COVID-19 lock down or new patients who have completed their first electronic Patient Reported Outcome Measures after COVID-19 lock down.
62590959|NCT00438100|ACTIVE_COMPARATOR|Capecitabine arm|Capecitabine (Xeloda): 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
62029775|NCT04607967|NO_INTERVENTION|"Conventional oxygen-therapy (study group CO)"|"Patients randomized in the Conventional Oxygen group will be treated according to the national and international recommendations with a conventional oxygen-therapy device (nasal cannula or nasal-oral mask).~Treatment failure will be evaluated after 4 hours by the need for a therapeutic escalation."
62228344|NCT04538456||never used electronic Patient Reported Outcome Measures|Lung cancer patients who have never completed electronic Patient Reported Outcome Measures.
62804348|NCT03932877||late-onset preeclampsia, group1|30 late-onset preeclampsia patients as group1 (gestational age≥34 weeks). The diagnosis of preeclampsia, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will establish based on the presence of proteinuria (urinary excretion of 300 mg protein or higher, or at least 1+in dipstick in a 24-h urine specimen) and a blood pressure level of ≥140/90mmHg (two blood pressure measurements 6 h apart) that occurs after 20 weeks of gestation in a previously normotensive woman. Diastolic and/or systolic blood pressure up to 110/160 mm Hg will consider mild, and higher values will consider to being severe.
62228345|NCT03618121|EXPERIMENTAL|Biofeedback plus gaming (Nevermind)|1) Group A is a biofeedback plus gaming group. Participants in this group play a horror videogame called Nevermind, while also wearing a chest strap heart rate monitor. The object of the videogame is to assist a patient by entering his/her mind and helping him/her work through some trauma memories. The way the game works is that the more anxious players are, the faster their heart beats, and the faster the heart beats, the harder and scarier the game gets. Thus, in order for one to do well in the game, he or she has to learn how to control the heartbeat and stress through relaxation. A therapist will help people in this group to learn relaxation techniques to help calm their body and finish the game.
62228346|NCT03618121|ACTIVE_COMPARATOR|Gaming only|2) Group B is a gaming only group. Like Group A, participants in this group play a Nevermind, but this time they do not wear a heart rate monitor. A therapist will still be present to help people in this group to learn relaxation techniques to help calm themselves during game play, but in this case the game does not change based on heart rate.
62228347|NCT03618121|ACTIVE_COMPARATOR|Biofeedback only (The Pip)|3) Group C is a biofeedback only group. In Group C, participants use a device called The Pip that measures Galvanic Skin Response. The Pip interacts with a few basic apps used in this study to teach relaxation. In one app, players control flying dragons. The more relaxed players are (as measured by GSR), the higher and faster their dragon flies. In another app, players control the changing of seasons. The more relaxed players are, the faster they can make seasons change from winter to spring. In another app, players can watch a simple graph of their stress over a period of time. Participants can learn to decrease stress by learning to make the line on the graph go down. In Group C, a therapist will also be present with participants to help them learn techniques to reduce stress.
62590960|NCT00438100|EXPERIMENTAL|S-1 arm|S-1: 80 mg/m2 orally bid daily for day 1 through day28 followed by 14-day washout; repeat this as a course.
62590961|NCT05028127|EXPERIMENTAL|Bimekizumab dosage regimen 1|Subjects participating in the study will be receiving assigned bimekizumab dosage regimen 1 during the Treatment Period.
62590962|NCT05028127|EXPERIMENTAL|Bimekizumab dosage regimen 2|Subjects participating in the study will be receiving assigned bimekizumab dosage regimen 2 during the Treatment Period.
62590963|NCT02411058|EXPERIMENTAL|Uninformed|Condition 1
62590964|NCT02411058|EXPERIMENTAL|Informed about Incentives and Purpose|Condition 2
62590965|NCT00465803|OTHER|DuoTrav|One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months, as recorded by dosing aid
62029776|NCT04607967|EXPERIMENTAL|"High Flow Nasal Oxygen (study group HNFO)"|"Patients randomized in the HNFO group will be treated according to the CE Marking with the high flow nasal oxygen device.~Treatment failure will be evaluated after 4 hours by the need for a therapeutic escalation."
62029777|NCT00653809||A, 1, I|Caucasian women without preeclampsia or PIH, delivering their first child
62029778|NCT00653809||A, 1, II|Caucasian women with preeclampsia or PIH, delivering their first child
62228348|NCT03618121|ACTIVE_COMPARATOR|Relaxation training only|4) Group D is a relaxation training only group. In Group D, participants receive relaxation training from a trained therapist. Participants in this group learn and practice with their therapist different techniques to help them relax and reduce stress.
62804349|NCT03932877||Control, group 2|33 patients with normal pregnancies as group2 (gestational age≥34 weeks). The control groups' samples obtained during the routine obstetrical care examination in the third trimester of pregnancy. Then these pregnant women followed-up until the delivery.
62590966|NCT00465803|OTHER|Travatan/Timolol|One drop Timolol in the study eye(s) once daily at 8 AM; one drop of Travatan in the study eye(s) once daily at 8 PM. Both products dosed for twelve months, as recorded by separate dosing aid for each product.
62590967|NCT02538887||Radio Frequency Surgical Detection|
62228349|NCT03730857|ACTIVE_COMPARATOR|olanzapine|olanzapine has a dose of 10 to 20 mg daily for 12 weeks
62590968|NCT03089697|EXPERIMENTAL|N-Rephasin® SAL200|To assign the study group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with N-Rephasin® SAL200 (3mg/kg); N-Rephasin® SAL 200 is given by intravenous only once at Day 1.
62590969|NCT03089697|PLACEBO_COMPARATOR|Placebo|To assign the control group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with Formulation buffer (placebo); Placebo (INT200) is given by intravenous only once at Day 1 (same way with Experimental group)
62029779|NCT00653809||A, 2, I|African-american women without preeclampsia or PIH, delivering their first child
62029780|NCT00653809||A, 2, II|African-American women with preeclampsia or PIH, delivering their first child
62029781|NCT00653809||B, 1, I|Caucasian women without preeclampsia or PIH, delivering at least their second child
62590970|NCT00738790|EXPERIMENTAL|1|Preoperative radiotherapy with five fractions of 5 Gy during one week and boost 4 Gy after 1 week interval, total dose 29 Gy; after 6 weeks full-thickness local excision
62590971|NCT00738790|ACTIVE_COMPARATOR|2|"Radiochemotherapy with 28 fractions of 1,8 Gy plus boost 5,4 Gy in 3 fractions~+ simultaneous bolus 5-Fluorouracil and leucovorin; after 6 weeks full-thickness local excision"
62029782|NCT00653809||B, 1, II|Caucasian women with preeclampsia or PIH, delivering at least their second child
62029783|NCT00653809||B, 2, I|African-american women without preeclampsia or PIH, delivering at least their second child
62228350|NCT03730857|ACTIVE_COMPARATOR|risperidone|risperidone at a dose of 4 to 6 mg daily for 12 weeks
62804350|NCT03932877||early-onset preeclampsia, group 3|31 early-onset preeclampsia patients as group3 (gestational age\<34 weeks). The diagnosis of preeclampsia, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will establish based on the presence of proteinuria (urinary excretion of 300 mg protein or higher, or at least 1+in dipstick in a 24-h urine specimen) and a blood pressure level of ≥140/90mmHg (two blood pressure measurements 6 h apart) that occurs after 20 weeks of gestation in a previously normotensive woman. Diastolic and/or systolic blood pressure up to 110/160 mm Hg considered mild, and higher values considered to being severe.
62029784|NCT00653809||B, 2, II|African-american women with preeclampsia or PIH, delivering at least their second child
62590972|NCT02818985|ACTIVE_COMPARATOR|Dexamethasone|patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.
62804351|NCT03932877||Control, group 4|31 patients with normal pregnancies as group 4 (gestational age\<34 weeks). The control groups' samples obtained during the routine obstetrical care examination in the third trimester of pregnancy. Then these pregnant women followed-up until the delivery.
62029785|NCT06417099|EXPERIMENTAL|Dihydroartemisinin Treatment Arm|The subjects take dihydroartemisinin, 40mg tid for 90 days
62228351|NCT03730857|ACTIVE_COMPARATOR|paliperidone|paliperidone at a dose of 6 to 12 mg daily for 12 weeks.
62029786|NCT03399734|EXPERIMENTAL|Treatment A|4 milligrams (mg) perampanel tablet
62029787|NCT03399734|EXPERIMENTAL|Treatment B|4 mg perampanel fine granules
62029788|NCT02053948|EXPERIMENTAL|Pursestring Wound Closure group|use Pursestring Wound Closure technique to close the stoma
62590973|NCT02818985|ACTIVE_COMPARATOR|Dexmedetomidine|patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.
62804352|NCT01618032|EXPERIMENTAL|HVLA|High velocity and low amplitude traction manipulation on the ankle joint
62804353|NCT01618032|EXPERIMENTAL|MWM|Mobilization with movement on ankle joint as Mulligan
62804354|NCT01618032|SHAM_COMPARATOR|placebo|Contact without therapeutic effect
62029789|NCT02053948|EXPERIMENTAL|Gunsight Skin Incision and Closure group|use Gunsight Skin Incision and Closure Technique to close the stoma
62029790|NCT02866253|EXPERIMENTAL|DHEA Group|DHEA 25mg t.i.d. for more than 12weeks
62228352|NCT02457208|EXPERIMENTAL|2HRZE/4HR|"2HRZE/4HR~* Intensive phase: 2 months HRZE - once daily~* Continuation phase: 4 months HR - once daily~Adults will be treated with fixed dose combination (FDC) tablets containing:~Intensive phase (content per tablet)~Isoniazid -75 mg,~Rifampicin - 150 mg,~Pyrazinamide - 400 mg,~Ethambutol - 275 mg~Continuation phase (content per tablet)~Isoniazid 150 mg~Rifampicin 300 mg~\*Drug dosing will be adjusted by patient body weight."
62228353|NCT02952807|ACTIVE_COMPARATOR|sequential|sequential use of vaginal misoprotol Plus Foley Catheter for Induction of Labor.
62804355|NCT00556907|OTHER|1|Patients will receive IORT
62804356|NCT00992758|EXPERIMENTAL|Treatment, Non-Randomized, Open Label|Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
62804357|NCT01107951|OTHER|Rituximab -dexamethasone|only one arm receive four doses weekly rituximab and four dosis daily dexamethasona
62804358|NCT02828761|EXPERIMENTAL|Coronary Calcium Scoring|Coronary calcium scoring by multidetector row computed tomography (MDCT).
62804359|NCT02828761|ACTIVE_COMPARATOR|Standard Care|Standard evaluation of chest pain patient which often includes immediate non-invasive imaging.
62029791|NCT02866253|NO_INTERVENTION|Control Group|patients without any DHEA
62029792|NCT05712291|OTHER|total knee arthroplasty using the active robotic system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
62029793|NCT05712291|OTHER|total knee arthroplasty using the standard manual technic|Primary total knee arthroplasty using the standard recommended set of instruments
62029794|NCT02334800|EXPERIMENTAL|Healthy Volunteers|Cohort of Healthy Volunteers
62228354|NCT02952807|ACTIVE_COMPARATOR|Concurrent|Concurrent Use of Vaginal misoprostol Plus Foley Catheter for Induction of Labor.
62029795|NCT02334800|EXPERIMENTAL|Mild Hepatic Impairment|Cohort of mild hepatic impairment subjects meeting the criteria for Child-Pugh Class A
62228355|NCT00006420||Observational, no interventions|
62228356|NCT01786733|EXPERIMENTAL|Behavioral Activation|Behavioral Activation + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at increased activation towards goals and personal values and decreased avoidance behaviors.
62228357|NCT01786733|ACTIVE_COMPARATOR|Supportive Therapy|Supportive Therapy + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at providing psychological non-directive support.
62228358|NCT02295657|EXPERIMENTAL|ETI intubation|endotracheal intubation in manikin
62243121|NCT05634252|EXPERIMENTAL|Education + Action Plan|Students in this intervention will receive education on skin cancer and prevention strategies and complete an individualized sun protection and tanning worksheet for situations in which they receive UVR exposure.
62243122|NCT05634252|EXPERIMENTAL|Education + UV Photo + MC1R Test|Students in this intervention will receive education on skin cancer and prevention strategies, receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system, and provide a saliva sample using an Oragene® clinical-grade saliva kit and receive individualized results following MC1R sequencing.
62590974|NCT02818985|PLACEBO_COMPARATOR|Control|patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.
62590975|NCT05438004|EXPERIMENTAL|Ambulatory nice birth|Discharge from the maternity ward from the 2nd hour and before the 24th hour following an uncomplicated delivery
62590976|NCT00804102|ACTIVE_COMPARATOR|Retinitis pigmentosa|
62590977|NCT00804102|ACTIVE_COMPARATOR|Macula off|condition after treatment of retinal detachment
62590978|NCT00804102|ACTIVE_COMPARATOR|Primary open angle Glaucoma|
62804360|NCT03065777|EXPERIMENTAL|ONE ENDO|Single file rotary system
62804361|NCT03065777|EXPERIMENTAL|F6 SKYTaper|Single file rotary system
62804362|NCT03065777|ACTIVE_COMPARATOR|ProTaper Universal|Muti-file rotary system
62804363|NCT05738265||Shocked patients who take crystalloids|Impact of crystalloids on shocked patients in trauma
62804364|NCT05738265||Shocked patients who take colloids|Impact of colloids on shocked patients in trauma
62804365|NCT05505448|EXPERIMENTAL|Cohort 1 Mid IV Dose|Randomized 3:1 for single ascending dose
62029796|NCT02334800|EXPERIMENTAL|Moderate Hepatic Impairment|Cohort of moderate hepatic impairment subjects meeting the criteria for Child-Pugh Class B
62029797|NCT02334800|EXPERIMENTAL|Severe Hepatic Impairment|Cohort of severe hepatic impairment subjects meeting the criteria for Child-Pugh Class C
62804366|NCT05505448|EXPERIMENTAL|Cohort 2 Mid SC Dose|Randomized 3:1 for single ascending dose
62804367|NCT05505448|EXPERIMENTAL|Cohort 3 High IV Dose|Randomized 3:1 for single ascending dose
62228359|NCT04265833|ACTIVE_COMPARATOR|calcium hydroxide|Thirty six primary molar teeth with deep caries lesion were selected to apply indirect pulp therapy with calcium hydroxide. The carious peripheral dentin was removed at the enamel-dentin junction using a high-speed tungsten-carbide bur and the infected and necrotic soft dentin layer in the center was carefully removed to prevent pulp exposure. Cavity excavation was stopped when the residual dentin over the pulp tissue showed increased resistance to manual instrumentation, and the demineralized dentin (affected dentin) was left at the floor of the cavity.The residual demineralized dentin was covered with a thin layer of Ca(OH)2 (approximately 1 mm2) in accordance with the recommendations of the manufacturer. Afterwards capsule glass ionomer cement was placed on each capping material. Following the etching and bonding process, permanent restoration was finished with composite resin.
62421045|NCT06543186|EXPERIMENTAL|Oral health education via mHealth using WhatsApp|For the oral health education intervention via mHealth, WhatsApp medium will be used to disseminate oral health educational material. Before the commencement of the study, the participants will be asked for their phone number in the respondent sheet and permission will be sought from both participants and their teachers and parents/guardians. Then, a WhatsApp group will be created consisting of the selected participants for this intervention. The participants in WhatsApp group will further receive WhatsApp instant messages. These participants will grouped and placed in class. These messages will be sent in both Malay and English language. The duration of the session will be around 60-90 minutes. Pre-assessment will be taken prior to the dissemination of oral health education on WhatsApp. Post assessment will be taken afterwards to assess the oral health knowledge, practise and attitude.
62804368|NCT05505448|EXPERIMENTAL|Cohort 4 High SC Dose|Randomized 3:1 for single ascending dose
62804369|NCT05505448|EXPERIMENTAL|Cohort 5 Higher IV Dose|Randomized 3:1 for single ascending dose
62228360|NCT04265833|EXPERIMENTAL|Biodentine|Thirty seven primary molar teeth were selected to apply indirect pulp therapy with Biodentine. The carious peripheral dentin was removed at the enamel-dentin junction using a high-speed tungsten-carbide-bur and the infected and necrotic soft dentin layer in the center was carefully removed. Cavity excavation was stopped when the residual dentin over the pulp tissue showed increased resistance to manual instrumentation, and the demineralized dentin (affected dentin) was left at the floor of the cavity. A thin layer of tricalcium silicate-containing pulp-capping material (Biodentine) (approximately 1 mm2) consisting of powder and liquid was applied to the demineralized dentin tissue and a 12-min setting time was allowed for hardening, in accordance with the recommendations of the manufacturer. Afterwards capsule glass ionomer cement was placed on each capping material. Following the etching and bonding process, permanent restoration was finished with composite resin.
62243123|NCT05634252|EXPERIMENTAL|Education + UV Photo|Students in this intervention will receive education on skin cancer and prevention strategies and receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system.
62590979|NCT00804102|ACTIVE_COMPARATOR|Hereditary Macular Degeneration|
62590980|NCT00804102|ACTIVE_COMPARATOR|Treated Retina detachment|
62590981|NCT00804102|ACTIVE_COMPARATOR|Retinal Artery Occlusion|
62804370|NCT05505448|EXPERIMENTAL|Cohort 6 Highest IV Dose|Randomized 3:1 for single ascending dose
62804371|NCT05505448|EXPERIMENTAL|Cohort 7 Low IV Dose|Randomized 3:1 for single ascending dose
62804372|NCT05505448|EXPERIMENTAL|Cohort 8 Low SC Dose|Randomized 3:1 for single ascending dose
62804373|NCT01476007|EXPERIMENTAL|oral Cobalamin (vitamin B12)|oral Cobalamin (vitamin B12)
62804374|NCT01476007|EXPERIMENTAL|intramuscular Cobalamin (vitamin B12)|intramuscular Cobalamin (vitamin B12)
62804375|NCT06156371|EXPERIMENTAL|Lymphatic drainage massage|In the lymphatic drainage massage group, a patient will receive a total of 12 treatments, 20 minutes a day, 3 days a week for 4 weeks. Face-to-face manual lymphatic drainage massage will be performed at least 1 hour after the patient starts hemodialysis treatment, according to the morning and afternoon work schedules of the institutions. Manual lymphatic drainage massage will be performed by a certified researcher in accordance with the application steps.
62804376|NCT06156371|ACTIVE_COMPARATOR|Classic massage|"A patient in the classical massage group will receive a total of 12 treatments, 15 minutes a day, 3 days a week for 4 weeks. The classical face-to-face massage application will be performed at least 1 hour after the patient starts hemodialysis treatment, according to the morning and afternoon work schedules of the institutions.~Classical massage application will be performed by the researcher. The order of application is upper leg, lower leg and feet. During the application, appropriate methods such as effleurage (stroking), kneading, friction, impact and vibration, which are frequently used in classical massage, will be used. Olive oil will be used as essential oil during application."
62243124|NCT05634252|EXPERIMENTAL|Education + MC1R Test|Students in this intervention will receive education on skin cancer and prevention strategies and provide a saliva sample using an Oragene® clinical-grade saliva kit and receive individualized results following MC1R sequencing.
62590982|NCT00804102|ACTIVE_COMPARATOR|Retinal Vein Occlusion|
62590983|NCT00804102|ACTIVE_COMPARATOR|Non-Arteriitic-Anterior-Ischemic Optic-Neuropathy|
62590984|NCT00804102|ACTIVE_COMPARATOR|Hereditary autosomal dominant Optic atrophy|
62590985|NCT00804102|ACTIVE_COMPARATOR|dry Age-related Macular Degeneration|
62590986|NCT00804102|ACTIVE_COMPARATOR|Ischemic Macula edema|
62029798|NCT02610062|EXPERIMENTAL|AGS67E 1.2 mg/kg Schedule 1|Participants will receive 1.2 mg/kg of AGS67E as an intravenous infusion once every three weeks (Q3).
62590987|NCT00804102|SHAM_COMPARATOR|Non-stimulated|
62735335|NCT05521191|EXPERIMENTAL|RGLS8429|"The randomized,double blind part of the study (Part A) will consist of three sequential cohorts of approximately 12 subjects each randomized centrally to receive RGLS8429 or placebo by subcutaneous injection every other week (Q2W) x 7 doses (36 subjects total).~* Cohort 1: first dose level of RGLS8429 or placebo~* Cohort 2: second dose level of RGLS8429 or placebo~* Cohort 3: third dose level of RGLS8429 or placebo"
62029799|NCT02610062|EXPERIMENTAL|AGS67E 1.8 mg/kg Schedule 1|Participants will receive 1.8 mg/kg of AGS67E as an intravenous infusion once every three weeks.
62029800|NCT02610062|EXPERIMENTAL|AGS67E 2.4 mg/kg Schedule 1|Participants will receive 2.4 mg/kg of AGS67E as an intravenous infusion once every three weeks.
62804377|NCT06156371|NO_INTERVENTION|Control|No intervention other than the first and last evaluation will be applied to the control group. Patients in this group will continue to receive their usual hemodialysis treatment and care.
62029801|NCT02610062|EXPERIMENTAL|AGS67E 0.6 mg/kg Schedule 2|Participants will receive 0.6 mg/kg of AGS67E once weekly for three weeks.
62228361|NCT04265833|EXPERIMENTAL|TheraCal LC|Thirty six primary molar teeth with deep caries lesion were selected to apply indirect pulp therapy with TheraCal LC. The carious peripheral dentin was removed at the enamel-dentin junction using a high-speed tungsten-carbide bur and the infected and necrotic soft dentin layer in the center was carefully removed. Cavity excavation was stopped when the residual dentin over the pulp tissue showed increased resistance to manual instrumentation, and the demineralized dentin (affected dentin) was left at the floor of the cavity. Flowable form of resin-reinforced tricalcium silicate-containing material (TheraCal LC) was applied directly onto the demineralized dentin at a maximum thickness of 1 mm and was polymerized for 20 sec (Valo LED), in accordance with the recommendations of the manufacturer. Afterwards capsule glass ionomer cement was placed on each capping material. Following the etching and bonding process, permanent restoration was finished with composite resin.
62421046|NCT06543186|EXPERIMENTAL|Metaverse platform called Metaverse for Oral Health Education (Meta-OHE)|For oral health education intervention via Meta-OHE, it will be done via computer in a computer lab. The participants will be gathered in their school's computer lab with the health of the teacher. Participants will be assigned a computer to each of them. Then, they will be asked to sign in into Mitoworld platform using their respective email address on https://mitoworld.io/world/w/2808/meta-ohe to access Meta-OHE. They will be asked to enter the Meta-OHE portal. The students are permitted to freely explore and follow the instruction to visit each section of the Meta OHE and interact with each other. They will also be assigned a few tasks for them to complete on the platform to ensure all the oral health education materials are being covered. The duration of the session will be around 60-90 minutes. Pre-assessment will be taken prior to their access to Meta-OHE. Post assessment will be taken afterwards to assess the oral health knowledge, practise and attitude.
62804378|NCT05971550|EXPERIMENTAL|Patients : Absence of antibiotic treatment|
62590988|NCT03881696|EXPERIMENTAL|Stage 1:Omalizumab as Monotherapy|"Eligible participants are randomized to receive omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After 16 weeks of treatment, each participant will complete double-blind placebo-controlled food challenge (DBPCFCs) to each of their three specific foods to a cumulative dose of 6044 mg protein of each food.~Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic.~The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 Open Label Extension (OLE).All other participants who complete all four DBPCFCs will move Stage 2 of the study."
62029802|NCT02610062|EXPERIMENTAL|AGS67E 0.9 mg/kg Schedule 2|Participants will receive 0.9 mg/kg of AGS67E once weekly for three weeks.
62029803|NCT06019468|EXPERIMENTAL|Neoadjuvant immunotherapy combined with radiotherapy|Treatment arms comprise 10-20 cycles of radiotherapy and 2-4 cycles of maintenance therapy with Envolizumab
62228362|NCT03426267|EXPERIMENTAL|SDN-037|
62228363|NCT03426267|PLACEBO_COMPARATOR|vehicle|
62228364|NCT01059123|EXPERIMENTAL|1:Short treatment|amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day 6 days.
62228365|NCT01059123|ACTIVE_COMPARATOR|2:Usual treatment|amoxicillin 50 mg/kg/24H ; I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day up to day 14.
62228366|NCT01892826|EXPERIMENTAL|hCG group|
62804379|NCT05971550|ACTIVE_COMPARATOR|Patients : Ceftriaxone|
62228367|NCT01892826|NO_INTERVENTION|LH pic|
62228368|NCT06282614|EXPERIMENTAL|Mucogyne treatment|"2 planned visits for each eligible patient :~* Screening/Baseline visit : V1 at Day 0. Patient receive Mucogyne Ovule.~* End-of-study visit : V2 at Day 35 ± 3"
62421047|NCT02838329|ACTIVE_COMPARATOR|room temperature - RT|Ropivacaine used for Epidural top-up administered at room temperature
62421048|NCT02838329|EXPERIMENTAL|body temperature BT|Ropivacaine used for Epidural top-up administered warmed to body temperature
62029804|NCT02378168||cohort of RCT (StV 5-2007; NCT00924222)|Patient group with either sevoflurane or propofol sedation of the RCT (StV 5-2007; NCT00924222)
62029805|NCT05771753|EXPERIMENTAL|Stretching Exercises|6 stretching exercise for 8 weeks
62029806|NCT05771753|EXPERIMENTAL|Dynamic core stabilizing exercises|6 strengthening exercises for 8 weeks
62029807|NCT03743038|EXPERIMENTAL|FMX101 vehicle|FMX101 hydrophobic oil based vehicle (Test Article A) topically applied daily for six weeks on one side of the face (in a split-face model)
62029808|NCT03743038|EXPERIMENTAL|Hydro-alcohol solution base|Hydro-alcohol solution based vehicle (Test Article B) topically applied daily for six weeks on the contralateral side of the face (in a split-face model)
62228369|NCT04565379|ACTIVE_COMPARATOR|NuSepin® 0.1 mg|NuSepin® 0.1 mg/kg in 100 ml normal saline infusion
62228370|NCT04565379|ACTIVE_COMPARATOR|NuSepin® 0.2 mg|NuSepin® 0.2 mg/kg in 100 ml normal saline infusion
62804380|NCT06317571|EXPERIMENTAL|fertility support training|The group will receive fertility support training.
62804381|NCT06317571|NO_INTERVENTION|routine care|They will receive routine care.
62804382|NCT06042959|NO_INTERVENTION|Control|
62804383|NCT06042959|EXPERIMENTAL|Intervention|
62804384|NCT04058041|EXPERIMENTAL|Neural mobilization|passive mobilization of the median nerve by the therapist following by an active movement of the fingers of the pathology hand
62804385|NCT04058041|ACTIVE_COMPARATOR|Surgery|the surgeon will release the median nerve in the tunnel carpal. After that the therapist will teach home exercises (no neural exercises) to the patients.
62804386|NCT04058041|ACTIVE_COMPARATOR|Surgery and Neural mobilization|the surgeon will release the median nerve in the tunnel carpal. After that the therapist will perform mobilizations of the median nerve just like the experimental group.
62804387|NCT00408850|ACTIVE_COMPARATOR|Pioglitazone|pioglitazone 15 mg for 6 weeks followed by 30 mg for 6 weeks
62735336|NCT05521191|EXPERIMENTAL|Placebo|"The randomized double blind part of the study (Part A) will consist of three sequential cohorts of approximately 12 subjects each randomized centrally to receive RGLS8429 or placebo by subcutaneous injection every other week (Q2W) x 7 doses (36 subjects total).~* Cohort 1: first dose level of RGLS8429 or placebo~* Cohort 2: second dose level of RGLS8429 or placebo~* Cohort 3: third dose level of RGLS8429 or placebo"
62029809|NCT02534857|EXPERIMENTAL|Intervention arm|Those allocated to the intervention arm, all the oocytes will be exposed to spermatozoa for 2 hours and gently wash through two organ dishes containing 1.5 ml of equilibrated medium, and then transferred to the corresponding microdroplet of equilibrated fresh medium. Surrounding cumulus cell will be retained, not removed from the ooctyes.
62029810|NCT02534857|PLACEBO_COMPARATOR|Control arm|Women who allocated to the control arm, all the oocytes will be exposed to spermatozoa for 20 hours, and checked for fertilization on day 1 (20 hours) after denuding
62029811|NCT02874482||Patients with schizophrenia|30 patients with schizophrenia (diagnosis based on the standard DSM criteria)
62029812|NCT02874482||Controls|30 healthy controls without any psychiatric or neurological diagnosis
62029813|NCT01820676||iUni G2+|iUni G2+ in all patients
62029814|NCT05004623|OTHER|Sentinel Lymph Node Biopsy|Sentinel lymph node biopsy by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device. Lymph node dissection in each hemipelvis should be performed as standard if no sentinel lymph node is detected. Decision of proceeding with complementary lymph node dissection after sentinel lymph node detection is a surgeon decision, according to his/her usual practice.
62029815|NCT01873365||Prospective Group|Japanese adults, aged greater than or equal to sixty years, diagnosed with HZ.
62029816|NCT05956964|EXPERIMENTAL|Sleep Restriction (SR)|"The research team will provide participants with a pair of shoes to wear throughout the study. The right shoe will be modified to include a 5cm (approximately 2) rocker-style platform which will keep the left leg suspended during walking. Participants will also be provided with a pair of short crutches to assist with walking. Participants in the SR group will sleep only 5 hours for three consecutive nights."
62029817|NCT05956964|ACTIVE_COMPARATOR|Sleep Adequate (SA)|"The research team will provide participants with a pair of shoes to wear throughout the study. The right shoe will be modified to include a 5cm (approximately 2) rocker-style platform which will keep the left leg suspended during walking. Participants will also be provided with a pair of short crutches to assist with walking. Participants in the SA group will sleep for 9 hours for three consecutive nights."
62029818|NCT03808675|EXPERIMENTAL|Aerobic|Participants randomized to aerobic exercise
62029819|NCT03808675|OTHER|Control|Participants randomized to usual care with PD specific health education
62029820|NCT04817280||Ice Swimmers Group.|No intervention. Data obtained from Polish ice swimmers reported by them retrospectively in the questionnaire.
62228371|NCT04565379|PLACEBO_COMPARATOR|Placebo|100 ml normal saline infusion
62804388|NCT00408850|PLACEBO_COMPARATOR|sugar pill|Placebo comparator
62804389|NCT03564652|NO_INTERVENTION|Arm A|Control arm: Lactating women (LW) randomized in this arm will only receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
62029821|NCT04433169|EXPERIMENTAL|Experimental group|ATRA 20 mg, three times a day (tid), for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles; combined with the treatment regimen chosen by the investigator since Day 6 of cycle 1.
62804390|NCT03564652|EXPERIMENTAL|Arm B|Intervention arm B: Lactating women (LW) randomized in this arm will receive ready-to-use nutritional supplement, 'Balanced energy-protein (BEP)' for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
62804391|NCT03564652|EXPERIMENTAL|Arm C|Intervention arm B: Lactating women (LW) randomized in this arm will receive ready-to-use nutritional supplement, 'Balanced energy-protein (BEP)' for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, the same infant of LW will receive a single dose of Azithromycin (20mg/kilogram) at day 42 of age. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
62804392|NCT04969029|EXPERIMENTAL|immunotherapy|In the immunotherapy group, the treatment regimen was Tirelizumab 200mg, intravenously infused once every 3 weeks until the end of 12 months of treatment, with a total of 17 infused times.
62804393|NCT04969029|NO_INTERVENTION|chemotherapy|The chemotherapy regimen of the standard chemotherapy group was XELOX regimen, oxaliplatin 130mg/m2, d1, capecitabine 1000mg/m2, orally, bid (half an hour after breakfast and dinner), d1-14, every 21 days. The duration of treatment was determined according to the patient's postoperative pathological stage (3 months for T4N0/ T1-3N1 and 6 months for T4N+/ T1-3N2).
62804394|NCT00230126|ACTIVE_COMPARATOR|A erlotinib 150 mg|erlotinib 150 mg/day cycles 1 - 3
62804395|NCT00230126|EXPERIMENTAL|B erlotinib modified according to weight|erlotinib Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to skin rash.
62804396|NCT00374439|EXPERIMENTAL|Cognitive-behavioral|Participants in this arm received a cognitive-behavioral program
62804397|NCT00374439|EXPERIMENTAL|Interpersonal Therapy|Participants in this arm received a prevention program based on interpersonal therapy for depression
62029822|NCT04433169|ACTIVE_COMPARATOR|Control group|The investigator chooses the treatment regimen based on the following regimens (including but not limited to: 1. VEGFR inhibitor; 2. chemotherapy).
62029823|NCT05772793||Group A|
62804398|NCT00374439|NO_INTERVENTION|No intervention|Participants in this arm did not receive an intervention, but complete assessments only
62804399|NCT04143867|EXPERIMENTAL|Nolix Device|Comparing use of device to non-treatment (pads only) phase
62804400|NCT05695807|EXPERIMENTAL|Carboxytherapy|Device
62804401|NCT05695807|ACTIVE_COMPARATOR|Fractional CO2 laser|Device
62804402|NCT05695807|ACTIVE_COMPARATOR|Platelet rich plasma|platelet rich plasma
62804403|NCT01038141|ACTIVE_COMPARATOR|Milligan Morgan|
62804404|NCT01038141|ACTIVE_COMPARATOR|Recto Anal Repair|
62804405|NCT06212297|EXPERIMENTAL|LX101 Subretinal Administration|
62804406|NCT04377217|EXPERIMENTAL|Video recording|The experimenter will make a standardized video of the patient during the inclusion process, and a second one after 18 months.
62804407|NCT01606072|EXPERIMENTAL|Desmopressin|
62804408|NCT01067677|EXPERIMENTAL|Metoclopramide|rescue emetic therapy
62804409|NCT01067677|EXPERIMENTAL|Ondansetron|Rescue emetic therapy
62804410|NCT01067677|EXPERIMENTAL|Diphenhydramine|Rescue emetic therapy
62804411|NCT01067677|PLACEBO_COMPARATOR|Saline|Placebo
62804412|NCT03279029|EXPERIMENTAL|patients with aortic valve disease (AVD).|
62029824|NCT01265069|ACTIVE_COMPARATOR|high dose dual therapy|Group A - high dose dual therapy (rabeprazole 20 mg qid, amoxicillin 750 mg qid for 14 days)
62029825|NCT01265069|EXPERIMENTAL|concomitant therapy|Group B - concomitant therapy (rabeprazole 20 mg, amoxicillin 1000 mg, metronidazole 500 mg, clarithromycin 500 mg, bid for 10 days).
62804413|NCT03279029|EXPERIMENTAL|patients with left ventricular assist device (LVAD|
62804414|NCT05418296|EXPERIMENTAL|Persons residing in long-term care homes|Subjects' ADLs are studied with intervention compared to baseline (without intervention).
62804415|NCT04154475|EXPERIMENTAL|yogurt diet|yogurt-diet (-500 kcal/day, 500 g yogurt, high calcium)
62804416|NCT04154475|ACTIVE_COMPARATOR|dairy diet|dairy diet: -500 kcal/day, high calcium, 500 g non-yogurt dairy products
62804417|NCT04154475|ACTIVE_COMPARATOR|standard diet|standard diet: -500 kcal/day, low calcium, 500 g soya-yogurt
62804418|NCT06533007||PDE3B LoF group|Individuals heterozygous for a loss-of-function variant in the PDE3B gene
62804419|NCT06533007||Wild type group|Individuals who do not carry the loss-of-function variant for PDE3B gene but otherwise matched for age, sex, race/ethnicity, and body fat percent.
62804420|NCT04787224||infected sockets|Signs of infection were periapical radiolucency only in 3 sites (2 patients), fistula in 2 sites (2 patients), sinus in 11 sites (7 patients) and finally swelling in 3 sites (2 patients)
62804421|NCT04787224||Non infected sockets|This is ensured by the absence of any clinical signs and symptoms of infection in addition to negative radiographic findings
62804422|NCT05041231|SHAM_COMPARATOR|Sham (group A)|Treatment procedure performed with the device that will not provide the bioactive light (laser)
62029826|NCT04320069|EXPERIMENTAL|Omnipod Horizon™ Automated Glucose Control System|All subjects using the Omnipod Horizon™ Automated Glucose Control System in Manual Mode without a connected CGM for 7 days and with a connected CGM for 7 days.
62029827|NCT00485485|EXPERIMENTAL|Imatinib Mesylate + Docetaxel|Imatinib 400 mg orally daily; Docetaxel 60 mg/m\^2 by vein over 1 hour every 3 weeks
62029828|NCT02047019|ACTIVE_COMPARATOR|Candesartan|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan 16 mg, Placebo combination A, Placebo combination B)
62029829|NCT02047019|EXPERIMENTAL|Nifedipine/Candesartan-30/16|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan placebo, Placebo combination A, Combination nifedipine / candesartan 30/16 mg)
62804423|NCT05041231|EXPERIMENTAL|PBT (group B)|Treatment procedure performed with the device that will provide the bioactive light (laser)
62228372|NCT06328803|EXPERIMENTAL|Rehabilitation training+Active Breathing Exercises|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Based on this, this group was given Active Breathing Exercises"
62243125|NCT05634252|EXPERIMENTAL|Education|Students in this intervention will receive education on skin cancer and prevention strategies.
62590989|NCT03881696|EXPERIMENTAL|Stage 1: Omalizumab OLE|"OLE: Open Label Extension, Long-Term Treatment with Omalizumab. Participants will receive 24 weeks of open label omalizumab in accordance with the omalizumab dosing table defined in the study protocol. Omalizumab is administered by subcutaneous injection either every 2 weeks or every 4 weeks for 24 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After 24 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 8044 mg protein of each food. Each participant who completes all four DBPCFCs at the end of the Stage 1 OLE will move on to Stage 3 of the study.~Throughout Stage 1 OLE, each participant will be instructed to strictly avoid all foods to which they are allergic."
62590990|NCT03881696|PLACEBO_COMPARATOR|Stage 1: Placebo for Omalizumab as Monotherapy|"Eligible participants are randomized to receive placebo for omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After 16 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 6044 mg protein of each food.~Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic.~The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 OLE. All other participants who complete all four DBPCFCs will move Stage 2 of the study."
62804424|NCT02451917|EXPERIMENTAL|Glargine insulin|This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin. At the end of the study, all data acquired during the use of insulin glargine, regardless of the sequence were grouped as glargine.
62804425|NCT02451917|ACTIVE_COMPARATOR|NPH insulin|"This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin.~At the end of the study, all data acquired during the use of NPH insulin, regardless of the sequence were grouped as NPH."
62804426|NCT01050634||Observational|
62804427|NCT03678701|EXPERIMENTAL|Protein group|The protein group will consume 30g of 100% whey protein shake 1 hour before lunch and before dinner, for 12 weeks
62804428|NCT03678701|NO_INTERVENTION|Control group|Control group will not consume any protein supplements. They will continue the usual feeding habits
62804429|NCT04453865|EXPERIMENTAL|Project EMPOWER|"Project EMPOWER is a web-based, self-administered SSI for parents that takes about 30 minutes to complete. The program includes 5 elements, based on current best-practices in SSI design (Schleider, Dobias, Sung, \& Mullarkey, 2020) and existing interventions targeting accommodation (Lebowitz \& Omer, 2014): (1) an introduction to the program's rationale; (2) psychoeducation around child anxiety and avoidance, along with how parental accommodation can inadvertently maintain child anxiety; (3) information on how parents can better identify children's patterns of avoidance and encourage brave behavior instead; (4) facilitating parents' creation of an action plan for promoting brave behavior and reduce avoidance in their own child; (5) a vignette exercise in which parents read about another family's difficulty managing their child's anxiety; parents identify the elements of the anxiety cycle and provide possible solutions to these parents based on what they learned."
62804430|NCT04453865|OTHER|Online Resources and Referrals (ORR)|Online Resources and Referrals (ORR) is an information sheet containing materials about the nature of child anxiety and a list of national resources related anxiety treatment. ORR does not include any psychoeducational components regarding parental accommodation.
62804431|NCT03960216|SHAM_COMPARATOR|Minimal Periodontal Treatment (MPT)|Once the hopeless teeth have been extracted, randomized patients will receive a periodontal prophylaxis, in the form of supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart. During this week the patients will be prescribed local antiseptics (chlorhexidine rinse, 2x, 10 days) and, after the last session, placebo capsules (one every 24 h for three days).
62804432|NCT03960216|EXPERIMENTAL|Intensive Periodontal Treatment (IPT)|Once the hopeless teeth have been extracted, randomized patients will receive non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia. During this week the patients will be prescribed local antiseptics (chlorhexidine rinse, 2x, 10 days) and after the last session, systemic antibiotics (azithromycin 500 mgrs, every 24 h for three days).
62804433|NCT01176032|EXPERIMENTAL|Aliskiren|"Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks. In addition to the study medication, amlodipine 5mg was given to patients who did not achieve the required blood pressure (\<140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication. At week 18 the dose of amlodipine was increased to 10mg if the required level (\<140/90 mmHg) was still not achieved.~HCTZ 12.5mg was prescribed at week 26 if the required values (\<140/90 mmHg) had not been reached."
62243126|NCT04881461|PLACEBO_COMPARATOR|Placebo|Glycerol, carbonate, sodium chloride One single-dose container (0.5 ml) once daily
62421049|NCT03541798|ACTIVE_COMPARATOR|Traditional sitting position|"Patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion before spinal anesthesia begun.~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
62029830|NCT02047019|EXPERIMENTAL|Nifedipine/Candesartan-60/16|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan placebo, Placebo combination B, Combination nifedipine / candesartan 60/16 mg)
62029831|NCT06039020||Anti-human thymocyte immunoglobulin, equine|Patients with moderate to severe aplastic anemia who receive ATGAM (Anti-human thymocyte immunoglobulin, equine)
62804434|NCT01176032|ACTIVE_COMPARATOR|Lostaran|"Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks. In addition to the study medication, amlodipine 5mg was given to patients who did not achieve the required blood pressure (\<140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication. At week 18 the dose of amlodipine was increased to 10mg if the required level (\<140/90 mmHg) was still not achieved.~HCTZ 12.5mg was prescribed at week 26 if the required values (\<140/90 mmHg) had not been reached."
62804435|NCT03780335||MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
62804436|NCT03780335||Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
62804437|NCT01662167|EXPERIMENTAL|Multiple dose mtx|mtx
62804438|NCT01662167|EXPERIMENTAL|Single Dose|In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
62804439|NCT04920955||G1, CRC Relapse|Patients with an actual relapse of CRC, within 5 years from primary surgery. A single blood sample is collected at relapse diagnosis.
62804440|NCT04920955||G2, CRC Disease-free|Patients previously diagnosed with CRC and declared disease-free for at least 36 months but less than 5 years. A single blood sample is collected at standard monitoring visit.
62804441|NCT04920955||G3, CRC Disease-free (longitudinal)|Patients declared disease-free for at least 3 months but less than 18 months. Longitudinal blood samples will be collected during standard monitoring visits up to relapse, or for a maximum of 4 time points.
62804442|NCT04920955||G4, Primary CRC (longitudinal)|Patients with an actual diagnosis of CRC who are eligible for a treatment with curative intent. Blood samples will be collected pre and post-surgery (\~6 weeks) and, eventually, at relapse.
62804443|NCT04916574|ACTIVE_COMPARATOR|BioBlock® concentration 0.2 mg/mL|BioBlock®: Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum
62804444|NCT04916574|ACTIVE_COMPARATOR|BioBlock® concentration 0.1 mg/mL|BioBlock®: Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum
62804445|NCT03535974|ACTIVE_COMPARATOR|Preparation with Spirulina|6 weeks bid Preparation with Spirulina
62804446|NCT03535974|PLACEBO_COMPARATOR|Placebo|6 weeks bid Placebo
62804447|NCT01003847|ACTIVE_COMPARATOR|fenofibrate|
62590991|NCT03881696|EXPERIMENTAL|Stage 2: Omalizumab|"Participants will receive eight weeks of treatment with open label omalizumab in accordance with the omalizumab dosing table specified in the study protocol, administered by subcutaneous injection. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After completion of eight weeks of open label omalizumab, participants will be randomized 1:1 to either:~* Omalizumab-facilitated oral immunotherapy (OIT): Open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks OR~* Omalizumab + placebo OIT: Open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks.~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
62804448|NCT01003847|ACTIVE_COMPARATOR|fatty acid|drug
62804449|NCT01003847|ACTIVE_COMPARATOR|Placebo|
62804450|NCT01102088|EXPERIMENTAL|Radiation + Chemotherapy|"Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.~For the phase II part of the study once the MTD has been achieved proton therapy will be allowed. Treatment dose will be identical to that of the photon treatment where the PTV is treated to 50.4 Gy(RBE) (RBE=1.1) while the CTV is boosted to 63 Gy(RBE) in 28 fractions.~Chemotherapy Administration: Schedule of chemotherapy, and modifications of chemotherapy drugs during chemoradiation treatment will be at the discretion of the treating medical oncologist per their standard of practice and with consideration to standard chemotherapy drugs in the treatment of esophageal cancer."
62804451|NCT03006146|EXPERIMENTAL|Sargramostim|Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
62804452|NCT02710656|EXPERIMENTAL|Drug Coated Balloon (DCB) - Legflow®|Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting Legflow® balloon.
62804453|NCT02710656|ACTIVE_COMPARATOR|Standard PTA - POBA|Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug eluting balloon (POBA, plain old balloon angioplasty).
62804454|NCT01400698|EXPERIMENTAL|Saizen® (Continuous or intermittent treatment)|
62804455|NCT01400698|EXPERIMENTAL|Saizen® (Observed and then continuous or no treatment)|
62804456|NCT01400698|OTHER|Observation only|
62804457|NCT03550378|EXPERIMENTAL|MEDI0382|Participants will receive subcutaneous (SC) dose of MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.
62804458|NCT03550378|PLACEBO_COMPARATOR|Placebo|Participants will receive SC dose of placebo matched to MEDI0382 once daily for 32 days.
62228373|NCT06328803|ACTIVE_COMPARATOR|Rehabilitation training|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
62228374|NCT01249274|PLACEBO_COMPARATOR|Placebo|Matched placebo pills to be taken twice daily
62228375|NCT01249274|EXPERIMENTAL|Progesterone|100 mgs progesterone twice daily
62228376|NCT01079338|EXPERIMENTAL|caffeine|
62029832|NCT05897099|EXPERIMENTAL|Comprehensive Tele-harm Reduction|Participants will have enhanced access to a physician and clinical psychologist via remote video technology wherever the participant is located and prefers engagement (SSP, home, shelter, encampment). Participants will be in this group for 12 months.
62804459|NCT02060435||EBER+ AMC|EBV+DLBCL patients in Asan Medical Center
62804460|NCT02060435||EBER+ SMC|EBV+DLBCL patients in Samsung Medical Center
62804461|NCT02060435||EBER- SMC|EBV-DLBCL patients in Samsung Medical Center
62804462|NCT05384340|EXPERIMENTAL|Beet protocol|Acute intervention: 1st day \[140 ml - Beet It Juice, 800mg nitrate/day\] Continued intervention: 2nd to 7th day \[70 ml - Beet It Juice, 400mg nitrate/day\] Exercise intervention \[Treadmill - 40 minutes duration, 65% - 70% VO2 Peak\]: Acute \[Just on day\] / Continued \[First and latest day\] Washout: 7 days
62029833|NCT05897099|ACTIVE_COMPARATOR|Off-site Linkage to HIV prevention|Participants in this group will receive off-site linkage to HIV care by having case management/social work services through our community engagement team. Participants will be in this group for 12 months.
62029834|NCT02107521|ACTIVE_COMPARATOR|ICSI group|In this group, sperm selected for injection will be morphologically evaluated under 400x magnification
62029835|NCT02107521|EXPERIMENTAL|IMSI group|In this group, sperm selected for injection will be morphologically evaluated under 6600x magnification
62029836|NCT04616625||Methamphetamine exposed|Infants born to mothers with prenatal history of MA use during current pregnancy and/or positive meconium toxicology positive for MA in infant.
62590992|NCT03881696|EXPERIMENTAL|Stage 2: Omalizumab-Facilitated OIT|"OIT: oral immunotherapy-Omalizumab as Adjunct Therapy to Multi-Allergen Oral Immunotherapy~Participants randomized to open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks.~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
62029837|NCT04616625||Methamphetamine non-exposed|Infants born to mothers without prenatal history of MA use during this pregnancy and negative meconium toxicology for MA in infant.
62029838|NCT01674036|EXPERIMENTAL|Part 1 (GZFD00111/TDU12766): Genz-682452|Participants will receive a single oral dose of Genz-682452. Six ascending single doses and an optional seventh dose under fasted conditions will be used.
62029839|NCT01674036|PLACEBO_COMPARATOR|Part 1 (GZFD00111/TDU12766): Placebo|Participants will receive a single oral dose of placebo.
62804463|NCT05384340|PLACEBO_COMPARATOR|Placebo protocol|Acute intervention (1st day): \[140 ml - Beet It Juice, 0mg nitrate/day\] Continued intervention (2nd to 7th day): \[70 ml - Beet It Juice, 0mg nitrate/day\] Exercise intervention \[Treadmill - 40 minutes duration, 65% - 70% VO2 Peak\]: Acute \[Just on day\] / Continued \[First and latest day\] Washout: 7 days
62804464|NCT02763423|EXPERIMENTAL|umbilical cord mesenchymal stem cell|single- or double-dose intravenous injection of umbilical cord mesenchymal stem cells for the treatment of severe type 1 diabetes patients
62804465|NCT01454791|EXPERIMENTAL|Diclofenac Sodium Topical Gel first then Placebo|1:1 randomization to either of two treatment phases of 2 weeks duration (active-placebo or placebo-active).
62029840|NCT01674036|EXPERIMENTAL|Part 2 (GZFD00211/FED12767): Genz-682452|Participants will receive two single doses of Genz-682452 separated by a 7-day wash-out period, one dose given under fed (standardized high-fat breakfast) and one under fasted conditions. The dose will be based on the blind review of the safety/tolerability/pharmacokinetic data of single dose level cohorts in Part 1.
62228377|NCT05767307||MRI-first|"Biopsy naïve men referred to MRI-first due to suspicion of PC (elevated PSA and/or suspect DRE) at one of the following three major urology/uroradiology centers in Denmark: Aarhus University Hospital (AUH), Herlev \& Gentofte Hospital (HH), and Odense University Hospital (OUH), where MRI and targeted biopsy is already implemented in clinical use."
62804466|NCT01454791|PLACEBO_COMPARATOR|Placebo first then Diclofenac Sodium Topical Gel|1:1 randomization to either of two treatment phases of 2 weeks duration (active-placebo or placebo-active).
62804467|NCT02632292|EXPERIMENTAL|Absorb GT1|Bioresorbable everolimus-eluting scaffolds
62804468|NCT02632292|ACTIVE_COMPARATOR|Promus|Everolimus-eluting stents
62804469|NCT01338337|NO_INTERVENTION|Support treatment|Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed.
62804470|NCT01338337|EXPERIMENTAL|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
62804471|NCT05627271||ocrelizumab|patients prescribed with ocrelizumab
62804472|NCT05627271||natalizumab|Patients prescribed with natalizumab
62804473|NCT05627271||ofatumumab|Patients prescribed with ofatumumab
62804474|NCT04508166|EXPERIMENTAL|Dexmedetomidine|Sublingual dose of dexmedetomidine
62029841|NCT03385876|EXPERIMENTAL|Enrollees|Enrollment of healthy and affected subjects to collect samples and data for a pediatric genomic biorepository. Data includes genomic sequencing and resultant molecular diagnostic results, if any.
62029842|NCT05829902|EXPERIMENTAL|Active product|The active product is a drink consisting of 600 mg of lemon balm extract, tea leaves, brown sugar and powdered flavoring agent that is mixed with lukewarm water. The volume per serving is 30 ml. The drink will be taken every night before sleep for a period of two weeks.
62804475|NCT04508166|ACTIVE_COMPARATOR|Gamma-hydroxybutyrate|Oral dose of gamma-hydroxybutyrate
62804476|NCT04508166|PLACEBO_COMPARATOR|Placebo|Oral (saline) and sublingual (orodispersible tablet) doses
62029843|NCT05829902|PLACEBO_COMPARATOR|Placebo|The placebo drink is maltodextrin mixed with water, and the same tea leaves, brown sugar and powdered flavoring agent as the test drink. The volume per serving is 30 ml. The drink will be taken every night before sleep for a period of two weeks.
62029844|NCT03821311|EXPERIMENTAL|Computed tomography examination|Each patient will undergo a low-dose supine position chest CT scan including end-inspiratory and expiratory acquisitions, corresponding to the routine protocol for COPD patients, except that this end-inspiratory/end-expiratory CT is repeated 3 times for total of 6 CT acquisitions.
62029845|NCT06669052||1 arm group, pregnant non-anemic females, second trimester.|Liposomal iron, capsules, 1 Capsule with food or few hours before or after taking other medication once daily. 1 arm group, Participants in this study will receive a daily oral dose of 30 mg Iron for a duration of 90 days. The liposomal formulation is designed to enhance the bioavailability of iron, potentially reducing gastrointestinal side effects.
62804477|NCT03933813|EXPERIMENTAL|IV Iron Sucrose|Four intravenous iron sucrose infusions prior to debulking surgery administered as four 200mg infusions, given no less than 7 days apart over a 30 day +/- 7 day period
62421050|NCT03541798|EXPERIMENTAL|Harmstring stretch position|"the patients sit up from supine position with the legs remaining on the operating table, knees are maximally extended.~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
62421051|NCT03541798|EXPERIMENTAL|Squatting position|"the patients sit up from supine position with the legs remaining on the operating table, hips and knees are maximally flexed .~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
62804478|NCT05932108||Staff|Educational intervention in TERMA. All staff are required to attend the education.
62804479|NCT05932108||Patients|Patients will not attend any education in TERMA. Data will be collected before and after the staffs education to se if the patients think the attitude of the staff have changed.
62029846|NCT03843918|EXPERIMENTAL|LAE001+ADT|LAE001+ADT
62029847|NCT03278665|EXPERIMENTAL|4SC-202 + Pembrolizumab|Single arm study of 4SC-202 in combination with Pembrolizumab
62029848|NCT03266588|EXPERIMENTAL|Rimegepant|
62029849|NCT05850689|EXPERIMENTAL|Lumateperone 42 mg|
62029850|NCT05850689|PLACEBO_COMPARATOR|Placebo|
62029851|NCT04152733|NO_INTERVENTION|Control group|Children in the control group receive oxygen via conventional nasal cannula during deep sedation. Oxygen flow is determined to set the fraction of inspired oxygen of 50%.
62029852|NCT04152733|EXPERIMENTAL|High flow (HF) group|Children in the HF group receive oxygen via high flow nasal cannula during deep sedation. Fraction of inspired oxygen is set to 50%.
62029853|NCT03664713|EXPERIMENTAL|EMDR plus TAU|Individual Eye Movement Desensitization and Reprocessing (EMDR) Therapy: This consists of 25 individual sessions of 60 minutes each, applying the standard protocol with the existing validated modifications for specific pathologies. The standard EMDR protocol consists of 8 phases: 1) Patient history; 2) Patient preparation; 3) Evaluation of the main aspects of the traumatic memory; 4) Desensitization of the memory; 5) Installation of the positive cognition; 6) Body scan; 7) Close and 8) Reevaluation.
62029854|NCT03664713|NO_INTERVENTION|TAU only|Treatment As Usual (TAU): The patients in this condition will participate in the psychosocial activities proposed by the inpatient unit (with a focus on autonomy, psychoeducation, treatment adherence, insight, functioning and family interventions). Patients who receive EMDR therapy will also participate in these activities.
62029855|NCT04181554||DRAM group|The post-partum women with DRAM
62029856|NCT02007577|ACTIVE_COMPARATOR|salsalate 3500mg in 2 divided doses a day|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
62029857|NCT02007577|PLACEBO_COMPARATOR|placebo|Participants will take 3 placebo tablets with breakfast and 4 placebo tablets with dinner
62029858|NCT02221934|EXPERIMENTAL|Test Treatment|Self-initiated high frequency bioelectric nerve block delivered to the nerve by Altius.
62029859|NCT02221934|ACTIVE_COMPARATOR|Active Sham Control Treatment|Self-initiated non-therapeutic electrical signal delivered to the nerve by Altius.
62029860|NCT05905952||patient group|to twenty five patient of Haglund syndrome as (patient group) after being diagnosed and referred by orthopedic surgeon and twenty
62029861|NCT05905952||control group|twenty five Healthy volunteers as (control group) based on the following inclusion and exclusion criteria
62029862|NCT02367911|EXPERIMENTAL|Active Arm|122-0551 Foam, topically applied twice daily for two weeks
62029863|NCT02367911|PLACEBO_COMPARATOR|Vehicle Arm|Vehicle Foam, topically applied twice daily for two weeks
62804480|NCT02986646||physical therapy (PT) and rest|This group of subjects will be prescribed a physical therapy home exercise program and rest (of the injured elbow).
62029864|NCT02220972|EXPERIMENTAL|Arm A: First on Perampanel with a crossover to Placebo|Treatment Arm A will initially receive perampanel 2 mg QD titrated up to 4 mg QD and finally to 6 mg QD with a crossover to placebo.
62029865|NCT02220972|EXPERIMENTAL|Arm B: First on Placebo with a crossover to Perampanel|Treatment Arm B will initially receive placebo with a crossover to perampanel 2 mg QD titrated up to 4 mg QD and finally to 6 mg QD.
62029866|NCT05289804|EXPERIMENTAL|Active NITESGON|One electrode each will be placed over the left and right C2 dermatomes. A constant current will be applied during the word association task.
62029867|NCT05289804|SHAM_COMPARATOR|Sham NITESGON|For sham NITESGON (inactive control), placement of the electrodes will be identical to active NITESGON. Current intensity (ramp down) will gradually be reduced as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain.
62735337|NCT05521191|EXPERIMENTAL|Open Label Fixed Dose RGLS8429|The open-label fixed dose part of the study (Part B and Cohort 4) will consist of a single cohort of up to 30 subjects each receiving 300 mg RGLS8429.
62804481|NCT02986646||PT and intra-tendinous steroid injection|This group of subjects will be prescribed a physical therapy home exercise program and will received an intra-tendinous corticosteroid injection into the area of the ECRB origin (of the injured elbow).
62421052|NCT04793165|EXPERIMENTAL|Non-hybrid closed-loop system|"To compare two types of treatments:~During the first 3 days: Previous or conventional, with CSII plus CGM in open loop.~During the second 3 day period: AP with CSII plus CGM in a closed-loop system, through the ARG algorithm."
62804482|NCT02986646||PT and intra-articular steroid injection|This group of subjects will be prescribed a physical therapy home exercise program and will received an intra-articular corticosteroid injection into the elbow joint (of the injured elbow).
62804483|NCT05777044|NO_INTERVENTION|Control- No Intervention/treatment|Participants in the control group will maintain their usual daily routine. The participants will complete the pre-test, 10 weeks of normal daily activities, and post-test. No changes to their daily schedule will be made by the researcher.
62804484|NCT05777044|ACTIVE_COMPARATOR|Active Comparator- 10-week, 2x/week, 45-minute sessions of guided meditation|The active comparator meditation group will complete a 10-week meditation yoga intervention (2x/week, 45 minutes per session). Each session will consist of yogic breathing, imagery, and meditation, specifically with a focus on each of the yogic limbs. The yogic limbs that will be incorporated during the meditation intervention are yamas, niyamas, pranayamas, and sense withdrawal/meditative techniques.
62804485|NCT05777044|EXPERIMENTAL|Experimental- 10-week, 2x/week, 45-minute Hatha yoga sessions|The experimental hatha yoga group will complete a 10-week yoga intervention (2x/week, 45 minutes per session). Each session will consist of a centering, integration, awakening, vitality, equanimity, grounding, igniting, opening, release, and deep rest; all of which are specific hatha yoga practice sections. This group will complete the pre-test and post-test measures.
62804486|NCT03520985|EXPERIMENTAL|Pomalidomide|The treatment in this trial consists of oral pomalidomide on alternate days (ad) plus Low-Dose Dexamethasone (adPOM + LD-DEX)
62421053|NCT02989610||Omnidirectional followed by directional DBS|"Omnidirectional DBS is used for the first 3 months in all subjects, unless not tolerated. Directional DBS is used for months 3-6 in all subjects with a directional DBS lead. Primary end point is based on double-blind testing of omnidirectional vs. directional DBS in randomized order at 3-month follow-up visit.~In this Observational study design, all interventions here are therapeutic interventions that are part of the standard of care, rather than assigned as part of an interventional study."
62421054|NCT01015456|EXPERIMENTAL|1|Oral mycophenolate sodium 1440 mg per day for 12 months
62590993|NCT03881696|EXPERIMENTAL|Stage 2: Omalizumab + Placebo OIT|"OIT: oral immunotherapy Participants randomized to open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks.~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
62735338|NCT02541058||Confirmed 22q.11.2 deletion/duplication|
62029868|NCT05289804|ACTIVE_COMPARATOR|Active NITESGON + local anesthesia|For active NITESGON + local anesthesia (active control; local nerve anesthesia group), patients will receive NITESGON, in combination with a topical skin anesthetic (lidocaine/prilocaine cream) to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. A current similar to active NITESGON will be applied.
62029869|NCT05289804|ACTIVE_COMPARATOR|Active C5/C6|For the active C5/C6 group (active control; same sensation different nerve), the electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location. A current similar to active NITESGON will be applied.
62421055|NCT01015456|ACTIVE_COMPARATOR|2|Intravenous cyclophosphamide monthly for 6 months
62421056|NCT03725722|EXPERIMENTAL|Delgocitinib cream 1 mg/g|Delgocitinib cream applied twice daily for 8 weeks
62421057|NCT03725722|EXPERIMENTAL|Delgocitinib cream 3 mg/g|Delgocitinib cream applied twice daily for 8 weeks
62421058|NCT03725722|EXPERIMENTAL|Delgocitinib cream 8 mg/g|Delgocitinib cream applied twice daily for 8 weeks
62735339|NCT02541058||Suspected 22q.11.2 deletion/duplication|
62735340|NCT02601430|EXPERIMENTAL|BOLD-MRI|Blood Oxygen Level Dependent (BOLD)-MRI assessment of limb perfusion before and after standard of care endovascular therapy.
62735341|NCT02330354|EXPERIMENTAL|Intervention group|Centers in this group will participate in the Healthy Me, Healthy We program.
62735342|NCT02330354|OTHER|Control Group|Centers in this group will participate in the Healthy Me, Healthy We program after follow-up measures are collected.
62735343|NCT03611816||Group 1a|Patient with atrial fibrillation and without stroke history.
62735344|NCT03611816||Group 1b|Patient with atrial fibrillation with scheduled electrophysiology exploration or ablation.
62735345|NCT03611816||Group 1c|Patient with atrial fibrillation and with stroke history.
62735346|NCT03611816||Group 2|Patients aged over 80 years old and without history of atrial fibrillation.
62735347|NCT03611816||Group 3|Patient with cryptogenic stroke or transient ischemic attack history before the age of 50.
62735348|NCT02758600|EXPERIMENTAL|LVEF < 45%|Patients with left ventricular dysfunction will be evaluated before and 6 days after after coronary arterial bypass graft surgery. Postoperatively, subjects will be submitted to a portable cycle ergometer exercise protocol from the first day until hospital discharge.
62735349|NCT02758600|EXPERIMENTAL|LVEF > 45%|Patients without left ventricular dysfunction will be evaluated before and 6 days after after coronary arterial bypass graft surgery. Postoperatively, subjects will be submitted to a portable cycle ergometer exercise protocol from the first day until hospital discharge.
62735350|NCT01800331|EXPERIMENTAL|Text2bHealthy|The intervention arm receives the Text2bHealthy program on a PDA
62735351|NCT01800331|NO_INTERVENTION|Control group|The control group will complete a paper dairy to keep track of their lifestyle behaviours
62735352|NCT05400603|EXPERIMENTAL|Dose Escalation Phase I cohort|"Subjects will be assigned a cell therapy dose level at time of registration. The entry dose level is Dose Level 1, with escalation up to Dose Level 3 following a 3 + 3 dose escalation design.~If there is no evidence of progression, patients may receive up to a maximum of 4 courses. Each course includes two administrations of γδ T cells, administered one week apart. Toxicity, for deciding dose escalation and defining the MTD, will be evaluated during Course 1. Disease response assessment will be done after Courses 2 and 4. Dinutuximab (17.5 mg/m2), temozolomide (100 mg/m2), irinotecan (50 mg/m2) and zoledronate (0.0125 mg/kg/dose) will be consistent across all dose levels.The same donor for γδ T cell will be used for both cell therapy product infusions per course. Treatment of the first two subjects in each dose escalation cohort will be staggered. The second subject will not be enrolled until the first subject completes the DLT observation interval (minimum of 21 days)."
62804487|NCT03228108|EXPERIMENTAL|Targeted antimicrobial prophylaxis|"Men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prior to biopsy (equal to the active comparator arm), and men whose swabs do show ciprofloxacin-resistant bacteria will receive alternative oral antibiotics, based on culture results, in the following order:~* trimethoprim/sulfamethoxazole (SXT) 960 mg orally 2 hours before and 12 hours after prostate biopsy, or~* fosfomycin 3 g orally 2 hours before prostate biopsy, or~* pivmecillinam/augmentin respectively 400 mg and 500/125 mg 2 hours before prostate biopsy followed by 2 days with three divided doses each day after prostate biopsy."
62228378|NCT01498679|ACTIVE_COMPARATOR|fluticasone furoate/vilanterol trifenatate|Inhaled corticosteroid (ICS)/Long-acting beta2-agonist (LABA) combination
62735353|NCT01050023|EXPERIMENTAL|1 - Active Treatment|Provant device activated to emit RF energy
62804488|NCT03228108|ACTIVE_COMPARATOR|Routine empirical prophylaxis|Ciprofloxacin 500 mg orally 2 hours before and 12 hours after transrectal prostate biopsy.
62804489|NCT03236441|ACTIVE_COMPARATOR|RIPC Group|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
62804490|NCT03236441|SHAM_COMPARATOR|Sham-RIPC Group|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 10 mmHg for 5 minutes and deflation for 5 minutes (Control)
62804491|NCT03901144|EXPERIMENTAL|Test cream (2% urea/20% glycerol)|Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
62804492|NCT03901144|ACTIVE_COMPARATOR|Reference cream 1: Miniderm® 20% cream (20% glycerol)|Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
62804493|NCT03901144|ACTIVE_COMPARATOR|Reference cream 2: Diprobase® cream (cream without humectants)|Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
62804494|NCT03901144|NO_INTERVENTION|Untreated|Untreated skin area on the volar forearm
62804495|NCT06383832|EXPERIMENTAL|Dapagliflozin|Dapagliflozin tablets oral 10mg/d qd. Treatment course:12 weeks. Then, subgroup analysis was conducted. According to the 24-hour dietary review on the 3rd day of each week during the introduction period, subjects with carbohydrate energy greater than or equal to 26% of their daily energy intake were included in the non low carbohydrate group (NCD group), while subjects with carbohydrate energy accounting for 10-25% of their daily energy intake were included in the low carbohydrate group (LCD group).
62804496|NCT02183857|OTHER|Ultrasound|Patients in group Ultrasound will have their femoral arterial lines inserted under the guidance of US. The Ultrasound equipment used is a SonoSite 180 PLUS with an L25/10- to 5-MHz linear array transducer (SonoSite, Inc., Bothell, WA)
62804497|NCT02183857|OTHER|Landmark|No Device is used. Patients in group Landmark will have their femoral line inserted using the blinded, external landmark-guided technique. After localization of the femoral artery by identifying the pulse in the femoral triangle immediately distal to the inguinal ligament.
62804498|NCT04718207||Patient with Alzheimer disease|Patients recruited retrospectively with the available nuclear medicine listing of patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.
62804499|NCT03318835|EXPERIMENTAL|Thalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21
62804500|NCT03318835|ACTIVE_COMPARATOR|R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
62804501|NCT01467011||Cases|de novo liver transplant recipients receiving Enteric-coated Mycophenolate Sodium
62804502|NCT02692937|EXPERIMENTAL|Surgery and exercise|Neurolysis of peripheral nerves in the back of the head and/or neck. Traditional neck-specific exercise program including five individual treatments sessions within 3 months plus home program over 9 months.
62804503|NCT02692937|ACTIVE_COMPARATOR|Exercise, Active Comparator|Traditional neck-specific exercise program including five individual treatments sessions within 3 months plus home program over 9 months.
62804504|NCT06413485||Beachgoers|Beachgoing families and households to one or more Canadian beaches during the summers of 2023 to 2026.
62804505|NCT04084717|EXPERIMENTAL|ROS1 Rearrangement|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented ROS1 rearrangement will be assigned to this arm.
62228379|NCT01498679|PLACEBO_COMPARATOR|Placebo|placebo comparator
62804506|NCT04084717|EXPERIMENTAL|MET-activating Mutation (exon 14)|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-activating mutation (exon 14) will be assigned to this arm.
62228380|NCT01586000|EXPERIMENTAL|10 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
62735354|NCT01050023|SHAM_COMPARATOR|2 - Inactive Treatment|Provant device not activated to emit RF energy
62735355|NCT05286476|EXPERIMENTAL|group A|received Whole-body Vibration, pelvic floor exercise and static abdominal exercises interventions In addition to diet instructions
62735356|NCT05286476|OTHER|group B|received pelvic floor exercises and static abdominal exercises in addition to diet instructions only
62735357|NCT06471959|EXPERIMENTAL|Active Group|"All participants will undergo a 12-week, group-based program (one session per week, for 12 weeks). The first group session, as well as the Week 10 session will occur in-person. The remainder of the sessions will occur remotely. Each week, trained facilitators will help create a trauma-informed safe space for the group to thrive and promote cognitive resilience. The topics covered throughout the 12-week program include breath-work, mindfulness, self-compassion, embodiment, and Internal Family Systems work.~During Week 10, participants will be provided with either psilocybin (active group) or complete a breathwork day (control group). For participants randomized to the active group, they will receive 10mg of psilocybin on Week 10. A clinician certified and trained in the therapeutic use of psilocybin will be on site for participants in the psilocybin group."
62735358|NCT01479751|EXPERIMENTAL|ketamine|Patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
62735359|NCT01479751|EXPERIMENTAL|priming|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
62735360|NCT01479751|NO_INTERVENTION|Roc 0.9|Patients receive Roc 0.9 mg/kg as an induction dose.
62804507|NCT04084717|EXPERIMENTAL|MET-amplification|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-amplification will be assigned to this arm.
62804508|NCT03222700||robotic thyroidectomy group|
62804509|NCT03222700||open thyroidectomy group|
62804510|NCT02663011||5YR boy|
62804511|NCT02663011||5YR girl|
62029870|NCT01730937|ACTIVE_COMPARATOR|Sorafenib Alone|400 mg sorafenib twice a day for 28-day cycle. Continue up to 5 years in the absence of disease progression or unacceptable toxicity.
62029871|NCT01730937|EXPERIMENTAL|SBRT followed by Sorafenib|27.5 Gy to 50 Gy stereotactic body radiation therapy (SBRT) in 5 fractions 24-72 hours apart over 5-15 days followed within 1-5 days by one cycle of 200 mg sorafenib twice a day. Starting with second cycle, if tolerable, increase to 400 mg sorafenib twice a day. Continue up to 5 years in the absence of disease progression or unacceptable toxicity.
62029872|NCT03832010|ACTIVE_COMPARATOR|Crisaborole|Participants will be instructed to apply emollient, topical steroid, and or crisaborole (blinded) to affected areas with eczema.
62029873|NCT03832010|PLACEBO_COMPARATOR|Vehicle|Participants will be instructed to apply emollient, topical steroid, and or vehicle (blinded) to affected areas with eczema.
62029874|NCT03832010|SHAM_COMPARATOR|Control|Participants will be instructed to apply emollient, topical steroid, and or emollient (blinded) to affected areas with eczema.
62029875|NCT02091726|EXPERIMENTAL|Unicirc with tissue adhesive|Circumcision with Unicirc instrument, followed by wound sealing with cyanoacrylate
62029876|NCT06227585|EXPERIMENTAL|Single Arm (Bevonescein)|All patients will receive a single administration of bevonescein 500mg via IV infusion and the REVEAL 475 system will be used on all patients.
62029877|NCT05054790|EXPERIMENTAL|"Autologous Neo-Bladder Construct"|All subjects enrolled will have non-neurogenic, fibrotic contracted bladder that is refractory to medical treatment and require augmentation cystoplasty for preventing long-term sequelae (i.e., kidney failure) that result from persistently high intravesical pressure.
62029878|NCT06489613||Clinical patients|Residual plasma specimens for iMS-LC Assay to detect M protein
62029879|NCT06489613||Individuals undergoing routine physical examinations|Residual plasma specimens for iMS-LC Assay to detect M protein
62029880|NCT05522803|OTHER|Sequence 1|TMS followed by sham TMS
62029881|NCT05522803|OTHER|Sequence 2|Sham TMS followed by TMS
62029882|NCT02703883|EXPERIMENTAL|Body Weight Support|Treatment protocol consisted of 18 training sessions on the BWST, three times a week, every session included three sets of six minutes of locomotion with rest intervals of 2 min of rest.
62029883|NCT03497923|ACTIVE_COMPARATOR|Neostigmine|Patients are anesthesized with Propofol and receive 0.6mg-1 of rocuronium for tracheal intubation. Neuromuscular monitoring will be done on the ulnar nerve by train-of-four (TOF) using a TOF-Watch-SX® acceleromyograph (Organon \[Ireland\] Ltd). After spontaneous recovery of 2 twitches at the train-of-four monitor (TOF), patients receive neostigmine 50 μg kg-1.
62029884|NCT03497923|EXPERIMENTAL|Sugammadex|Patients are anesthesized with Propofol and receive 0.6mg-1 of rocuronium for tracheal intubation. Neuromuscular monitoring will be done on the ulnar nerve by train-of-four (TOF) using a TOF-Watch-SX® acceleromyograph (Organon \[Ireland\] Ltd). After spontaneous recovery of 2 twitches at the train-of-four monitor (TOF), patients receive sugammadex (Bridion®) 2 mg kg-1.
62029885|NCT03811067|NO_INTERVENTION|Control group|
62029886|NCT03811067|ACTIVE_COMPARATOR|TAP group|Transversus abdominis plane block administered group
62029887|NCT03811067|ACTIVE_COMPARATOR|RS group|Rectus sheath block administered group
62735361|NCT01479751|NO_INTERVENTION|Control|Patients receive Roc 0.6 mg/kg without any pretreatments of Mg, ketamine, or priming.
62029888|NCT02011438|EXPERIMENTAL|UTalk Intervention|Active preventative intervention condition.
62029889|NCT02011438|NO_INTERVENTION|Control|Education/Support Condition
62029890|NCT02734342|EXPERIMENTAL|Exercise, Kinesiophobia and Knee Osteoarthritis|Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. During the hour, participants will complete a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improve aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted.
62228381|NCT01586000|EXPERIMENTAL|20 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
62735362|NCT01479751|EXPERIMENTAL|Mg|Patients receive magnesium sulfate (MgSO4) 50 mg/kg over 10 min before Roc injection.
62735363|NCT06351423|EXPERIMENTAL|MIND Diet and Forest Bathing (MIND-FB)|In this arm, participants will receive both the MIND diet and Forest Bathing (FB) intervention.
62735364|NCT06351423|ACTIVE_COMPARATOR|Forest bathing (FB)|In this arm, participants will receive Forest Bathing intervention only.
62735365|NCT06351423|NO_INTERVENTION|routine care group|The routine care group will be instructed to perform daily activities as usual and will receive a health talk and be given pamphlets about tips on maintaining mental well-being.
62735366|NCT03953248|NO_INTERVENTION|Non L-Carnitine|Subjects in this arm will receive standard treatment only (without LC). It consists of patient resuscitation, gastric decontamination (with sodium bicarbonate, and activated charcoal \[1 g/Kg, orally\] in the first 6 hours after onset of poisoning), adequate hydration and supportive treatment
62735367|NCT03953248|ACTIVE_COMPARATOR|L-Carnitine|Subjects in this arm will receive standard treatment in addition to LC IV, as a dose of 1 g/8 hours
62804512|NCT02663011||4YR boy|
62804513|NCT02663011||4YR girl|
62804514|NCT02663011||3YR boy|
62804515|NCT04215926||HIV-monoinfected outpatients|No intervention; cross-sectional study
62804516|NCT05467241|EXPERIMENTAL|Self-induced therapeutic tremor (SITT) combined with mindfulness|"This arm will consist of self-induced therapeutic tremor (SITT) training combined with mindfulness training that is performed during a 60 minute session, 2 times per week, for 4 weeks.~Self-induced therapeutic tremor (SITT) combined with mindfulness: SITT is a way to reduce stress by turning on a natural shaking response. This can calm the participant's body. It involves doing simple exercises. During SITT muscles will gently shake, and release built up stress. This shaking of muscles lets the participant's body physically let go of tension and stress. Mindfulness is the ability to be fully present in a moment so that the participant can focus on what the participant is sensing and feeling in the moment. It involves the acceptance of thoughts and feelings without judging them. Practicing mindfulness involves breathing methods, guided imagery, and other practices to relax the body and mind, help reduce stress, and not be overwhelmed."
62804517|NCT03462108|EXPERIMENTAL|Rotavirus (Bio Farma) Vaccine-Adult|1 doses of 1 ml of Rotavirus vaccine per oral
62029891|NCT06635707||Urapidil Group|Urapidil Injection (Shijiazhuang Sipharm Co., Ltd., National Medical Products Administration Approval No. H20233626): Initially, administer a loading dose of 10mg via slow intravenous injection, observe for 5 minutes, and then adjust the infusion rate based on the patient's blood pressure, generally not exceeding 2mg/min.
62029892|NCT06635707||Combination Group of Urapidil and Esmolol|"Urapidil Injection (Shijiazhuang Sipharm Co., Ltd., National Medical Products Administration Approval No. H20233626): Initially, administer a loading dose of 10mg via slow intravenous injection, observe for 5 minutes, and then adjust the infusion rate based on the patient's blood pressure, generally not exceeding 2mg/min.~Esmolol Injection (Qilu Pharmaceutical Co., Ltd., National Medical Products Administration Approval No. H19991058): Administer an intravenous bolus of 1mg/kg within 30 seconds, followed by a maintenance infusion rate not exceeding 300μg/kg/min, adjusted according to blood pressure readings."
62029893|NCT01657422|EXPERIMENTAL|PACE+ Intervention|Intervention Group
62029894|NCT01657422|NO_INTERVENTION|Sun Protection|Control / Comparison group. Patients assigned to the comparison group will receive intervention strategies over a the course of 2 years including: (1) completion of a 30-minute office-based computer program resulting in on-screen feedback to address excess sun exposure prevention, and (2) 4 phone calls and 4 mailings over a 24-month period conducted by PACE+ staff members.
62029895|NCT06295562|EXPERIMENTAL|atomoxetine 80mg combined with oxybutynin 5mg|Participants will receive atomoxetine 80mg combined with oxybutynin 5mg once (1 h before polysomnographic study).
62804518|NCT03462108|EXPERIMENTAL|Rotavirus (Bio Farma) Vaccine-Children|1 doses of 1 ml of Rotavirus vaccine per oral
62590994|NCT03881696|OTHER|Stage 3: DBPCFC Based Treatment|"DBPCFC Based Treatment-Long-term Follow-up Treatment Plan for Peanut and Each of the Two Other Participant-Specific Foods.~Upon completion of the DBPCFCs at the end of Stage 1 OLE or Stage 2, each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods based on the results of the DBPCFCs. A treatment plan will include instructions for one of the following:~* Long-term follow-up with dietary consumption of a food;~* Long-term follow-up with avoidance of a food; or~* Rescue OIT for a food.~The treatment plan for each food may change throughout Stage 3 depending on a participant's response to treatment. Once a participant enters Stage 3, the participant will have a minimum of 12 months follow-up until at least December 2022.~Note: Participants will be instructed to strictly avoid a food if they receive rescue OIT for the food during Stage 3."
62590995|NCT00847769|EXPERIMENTAL|High velocity, low amplitude stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
62590996|NCT00847769|ACTIVE_COMPARATOR|Slow, mobilization stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
62590997|NCT00847769|SHAM_COMPARATOR|Passive positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
62804519|NCT03462108|EXPERIMENTAL|Rotavirus (Bio Farma) Vaccine-Neonates|3 doses of 1 ml of Rotavirus vaccine per oral
62804520|NCT03462108|PLACEBO_COMPARATOR|Placebo-Neonates|3 doses of 1 ml of Placebo (contains 30% sucrose in DMEM) per oral
62804521|NCT01490775|EXPERIMENTAL|eMedonline access|patients will be followed for 3 months with access to eMedonline
62804522|NCT01490775|ACTIVE_COMPARATOR|no access to eMedonline|patients will be followed for 3 months with no access to eMedonline
62804523|NCT01156220|EXPERIMENTAL|female|"The healthy female volunteers receive furosemide and aminohippurate sodium PAH as single dose randomised on day 1 or day 2."
62804524|NCT01156220|EXPERIMENTAL|male|"The healthy male volunteers receive furosemide and aminohippurate sodium PAH as single dose randomised on day 1 or day 2"
62804525|NCT04715672||copper|
62804526|NCT04715672||no-copper|
62804527|NCT04715672||normal|
62590998|NCT04929288|EXPERIMENTAL|Males|Participants in this group will be adult male drinkers.
62590999|NCT04929288|EXPERIMENTAL|Females|Participants in this group will be adult female drinkers. Data will be segregated by menstrual cycle phase.
62591000|NCT05441111|EXPERIMENTAL|COMET + guided self-help bibliotherapy|"Participants are given access to a single session intervention the Common Elements Toolbox (COMET) and, a week after, are given access to the World Health Organization's (WHO) Doing what matters in times of stress: An illustrated guide (https://www.who.int/publications/i/item/9789240003927) virtually (i.e., as a pdf) and/or in print. Each participant is assigned an eCoach -- an undergraduate, post-baccalaureate, or graduate research assistant -- who will meet with the participant for a 60-minute welcome call describing the intervention and 3-6 sessions of guidance focused on promoting adherence to the manual and using skills in everyday life."
62804528|NCT02991638|OTHER|Ibrutinib|Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression
62804529|NCT04714567||Patients with severe asthma|Patients of all ages with severe asthma included in the RAG.
62804530|NCT03880058|ACTIVE_COMPARATOR|SLI-F06|Drug Product under investigation
62804531|NCT03880058|PLACEBO_COMPARATOR|Formulation Buffer|Placebo
62804532|NCT03061357|EXPERIMENTAL|Activity tracker group|Participants in intervention arm were provided with a small and lightweight activity tracker, Misfit Flash (Misfit Wearables Co., Burlingame, CA), that can be worn with a clasp or watch band. A handout detailing the step-by-step instructions for utilizing the activity tracker with Misfit App on their smartphone was provided. There was no intervention component mandated in the curriculum of intervention PAIP courses; rather, participants were continuously encouraged by the instructors to track their activity levels and use all the features in Misfit App on a daily basis as they learned health benefits of PA and as to how to develop individualized, life-long PA plan during the course of semester.
62804533|NCT03061357|NO_INTERVENTION|Control group|Participants in control arm did not receive any additional instructions other than the scheduled class activities based on the standardized core-curriculum of PAIP
62804534|NCT01827150|EXPERIMENTAL|Redbull, optic nerve|"15 subjects will each be drinking a can of Redbull (250 ml) and an equal amount of water (250 ml) in two different sessions. The order in which they will do so, is determined by randomization.~Intervention: Drug: Redbull, energy drink"
62804535|NCT05823402|EXPERIMENTAL|SPECT/CT|"All patients enrolled will undergo 5 additional (6 total) SPECT/CT scans per treatment cycle. Current FDA approved PSMA radioligand therapy is administered over 6 cycles, so there will be a total of 30 additional SPECT/CT scans during this study.~During each treatment cycle, patients will have a SPECT/CT scan at the following time points after administration of PRLT:~* 4 Hours~* 24 Hours (+/- 8 Hours)~* 48 Hours (+/- 8 Hours)~* 96 Hours (+/- 8 Hours)~* 168 Hours (+/- 24 Hours)~* 336 Hours (+/- 24 Hours)"
62804536|NCT04591938|OTHER|Single arm|Fantom Encore Bioresorbable scaffold implantation
62591001|NCT05441111|ACTIVE_COMPARATOR|COMET + unguided self-help bibliotherapy|"Participants are given access to a single session intervention the Common Elements Toolbox (COMET) and, a week after, are given access to the World Health Organization's (WHO) Doing what matters in times of stress: An illustrated guide (https://www.who.int/publications/i/item/9789240003927) virtually (i.e., as a pdf) and/or in print. Participants are left to read the book on their own (i.e., without an eCoach)"
62804537|NCT00628030|EXPERIMENTAL|NOURISH|The first 2 waves and second 2 waves of participants will receive a 12 and 6 week face-to-face intervention (NOURISH), respectively. The interventions differ only in duration. They cover the same concepts which are grounded in Social Cognitive Theory (SCT). Throughout the interventions the influence of social learning on behavioral outcomes (e.g., parent's modeling of healthy behavior) will be emphasized. Weekly topics provide information about implementing healthy lifestyle behaviors, authoritarian parenting approaches, and strategies for overcoming barriers to change. Parents will receive pedometers for themselves and 1 of their children. A one-hour booster session will be available for all intervention participants 2 months after completion of the interventions.
62804538|NCT00628030|PLACEBO_COMPARATOR|Wellness Group|The placebo control group will attend a group session moderated by an independent interventionist. This interventionist will be blinded to the Specific Aims and hypotheses of this study. The session will address the role of diet and exercise in pediatric overweight. In addition, control parents will receive pedometers (and instructions on their use) for themselves and 1 of their children. Finally, control participants will be mailed publicly available brochures on pediatric overweight on 2 occasions during the study. Control participants will also be sent home one additional packet of information (essentially a review of previous mail outs) 2 months after post-testing.
62804539|NCT02102789|EXPERIMENTAL|Systemic chemotherapy|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
62804540|NCT02102789|EXPERIMENTAL|Systemic chemotherapy combined with HAI|"Patients will receive mFOLFOX6+HAI every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15. 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
62804541|NCT02203695|EXPERIMENTAL|SRT plus Enzalutamide|Arm 2 (experimental): (SRT) Salvage radiation therapy (Three dimensional conformal radiation therapy (3D-CRT)/IMRT \[Intensity-modulated radiation therapy\]) 66.6-70.2 Gy as 1.8 Gy M-F for 37-39 fx PLUS Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
62804542|NCT02203695|PLACEBO_COMPARATOR|SRT plus placebo|Arm 1 (control): Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT (Intensity-modulated radiation therapy)) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx PLUS Placebo PO daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
62804543|NCT01065038|EXPERIMENTAL|Anagrelide|
62804544|NCT01065038|ACTIVE_COMPARATOR|Hydroxyurea|
62804545|NCT01998425||Non-small cell lung cancer|The cohort data of patients with NSCLC will follow up from diagnosis, treatment response and final survival. Fibrocytes will be checked on the date of diagnsis (before treatment), re-staing (3months after treatment) and disease progression.
62804546|NCT03258307|ACTIVE_COMPARATOR|omentectomy|Preoperative
62804547|NCT03258307|OTHER|Omentectomy|Postoperative
62804548|NCT03258307|OTHER|No omentectomy|Preoperative post operative
62029896|NCT06295562|EXPERIMENTAL|venlafaxine 37.5mg|Participants will receive venlafaxine 37.5mg once (1 h before polysomnographic study).
62029897|NCT06295562|EXPERIMENTAL|atomoxetine 80mg combined with trazodone 100mg|Participants will receive atomoxetine 80mg combined with trazodone 100mg once (1 h before polysomnographic study).
62591002|NCT02657213|EXPERIMENTAL|Minimed 640G with smartguard activated|"Group SmartGuard On: Patients will be equipped with a sensor augmented pump (SAP) therapy Minimed 640G insulin pump with SmartGuard activation"
62591003|NCT02657213|ACTIVE_COMPARATOR|Minimed 640G with smartguard off|"Group SmartGuard Off Patients will be equipped with a sensor augmented pump (SAP) therapy Minimed 640 insulin pump without SmartGuard activation"
62804549|NCT04475952||Oropharyngeal squamous cell carcinoma|
62804550|NCT04475952||Oesophageal squamous cell carcinoma|
62804551|NCT04475952||Control|
62804552|NCT01204749|EXPERIMENTAL|AMG 386|Arm A: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 15mg/kg IV QW
62804553|NCT01204749|PLACEBO_COMPARATOR|AMG 386 Placebo|Arm B: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 Placebo IV QW
62804554|NCT03345251|EXPERIMENTAL|manipulation of endometrium|The arm is physical manipulation to the endometrium prior to ICSI By one of these interventions )Hydrotubation , Sonohysterography or endometrial scratching
62804555|NCT03345251|PLACEBO_COMPARATOR|no manipulation to endometrium in ICSI|This is the control group , with no manipulation to endometrium prior to ICSI No intervention to this group
62804556|NCT00920751|EXPERIMENTAL|Water infusion|Water infusion in lieu of air insufflation during colonoscope insertion
62804557|NCT00920751|ACTIVE_COMPARATOR|Air insufflation|Conventional air insufflation colonoscopy
62804558|NCT01475877||Nepafenac|
62029898|NCT05734118|EXPERIMENTAL|Intraoperative perfusion assessment using ICG-FA|Surgical procedure within standard of care. Intraoperatively, the vitality of the bowel will be assessed visually (the conventional method). Afterwards, participants will be administered indocyanine green intravenously.
62029899|NCT01592032|EXPERIMENTAL|Vancomycin antimicrobial-lock|Vancomycin antimicrobial-lock solution. Dosage: 2 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
62029900|NCT01592032|EXPERIMENTAL|Teicoplanin antimicrobial-lock|Teicoplanin antimicrobial-lock solution. Dosage: 10 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
62029901|NCT01592032|EXPERIMENTAL|Linezolid antimicrobial-lock|Linezolid antimicrobial-lock solution. Dosage: 1.8 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
62228382|NCT01586000|EXPERIMENTAL|40 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
62804559|NCT05195229|EXPERIMENTAL|Arm 1|Aim: To estimate the viral load in aerosols generated from children with COVID-19 infection, and to compare the viral load contained in aerosols from children with aerosols from adults
62804560|NCT03596827|ACTIVE_COMPARATOR|1E10 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
62029902|NCT01592032|EXPERIMENTAL|Daptomycin antimicrobial-lock|Daptomycin antimicrobial-lock solution. Dosage: 5 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
62228383|NCT02833532|EXPERIMENTAL|Volus|Maxium: 22ml
62804561|NCT03596827|EXPERIMENTAL|1E9 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E9 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
62804562|NCT03596827|EXPERIMENTAL|1E8 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E8 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
62804563|NCT03596827|EXPERIMENTAL|1E7 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E7 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
62804564|NCT03596827|EXPERIMENTAL|1E6 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E6 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
62804565|NCT02724358|EXPERIMENTAL|TACE|iodized oil (5ml) + Pirarubicin (20mg)
62421059|NCT03725722|EXPERIMENTAL|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 8 weeks
62804566|NCT02724358|EXPERIMENTAL|Rg3|20mg, BID, maintained though Month 12
62804567|NCT02724358|EXPERIMENTAL|TACE + Rg3|the combination of the treatments for the above two groups. Rg3 will be stopped on the day performing TACE.
62804568|NCT02724358|EXPERIMENTAL|Control|standard liver protective therapy
62804569|NCT01460056||Peritoneal dialysis|
62804570|NCT00917475||Preterm infants|birth weight\<1500 grams and gestational age\<30 weeks
62029903|NCT01592032|EXPERIMENTAL|Tigecycline antimicrobial-lock|Tigecycline antimicrobial-lock solution. Dosage: 4.5 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
62228384|NCT02833532|ACTIVE_COMPARATOR|Powerfill|Maxium: 22ml
62228385|NCT05971667|EXPERIMENTAL|tadalafil|tadalafil 10 mg one tablet daily
62421060|NCT03725722|PLACEBO_COMPARATOR|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 8 weeks
62804571|NCT00763386|ACTIVE_COMPARATOR|1|Study arm will consist of patients that are treated with the NexGen LPS-Flex Fixed Bearing Knee.
62804572|NCT00763386|ACTIVE_COMPARATOR|2|Study arm will consist of patients that are treated with the NexGen Legacy Posterior Stabilized Knee.
62804573|NCT04140968|EXPERIMENTAL|Utrogestan|300mg Utrogestan (1 tablet 100mg + 1 tablet 200mg)by mouth,every day in the second and third menstrual cycle daily from cycle day 15 to 26.
62029904|NCT01415830|EXPERIMENTAL|Anti-scorpion venom serum Birmex|Patients 0 to 15 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex
62029905|NCT01415830|ACTIVE_COMPARATOR|Anti-scorpion venom serum Alacramyn|Patients 0 to 15 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)
62029906|NCT02653482|ACTIVE_COMPARATOR|Dapagliflozin|Dapagliflozin 10 mg daily
62029907|NCT02653482|PLACEBO_COMPARATOR|Dapagliflozin matching placebo|Dapagliflozin matching placebo 10 mg daily
62228386|NCT05971667|EXPERIMENTAL|pentoxifylline|pentoxyfilline 400 mg two tabs daily
62029908|NCT02778607||Progressive Supranuclear Palsy|Patients with a current clinical diagnosis of Progressive Supranuclear Palsy (PSP)
62029909|NCT02778607||Multiple System Atrophy|Patients with current clinical diagnosis of Multiple System Atrophy (MSA).
62228387|NCT05971667|EXPERIMENTAL|sildenafil|sildenafil 20 mg two tablets
62228388|NCT05971667|NO_INTERVENTION|control group.|no intervention is given
62228389|NCT04330885|EXPERIMENTAL|Prehab group|"The patients in the PREHAB group will meet with a PT for 6 weeks pre surgery. The PT will coach the patient in 1:1 visits with a graded activity program with the purpose to affect fear of movement and raising level of self-efficacy with physical activity. The intervention comprises; cycling on a stationary cycle. Instructions of exercises that strengthen the deep and the superficial abdominal muscles and the back muscles. Information to contract the abdominal muscles in posturally loaded position to support their back. Information on flexion exercises of their lumbar spine and to keep the back in a flexed position when standing and walking (as opposed to extension). Recommendation to use Nordic walk (stavar) for outdoor walking"
62421061|NCT05473247|EXPERIMENTAL|Ring-Fit Adventure Group|"In Phase 1, participants will be asked to play Ring-Fit Adventure for 60 minutes per week for 4 weeks. Participants will also be asked to attend a weekly, 90 minute health education session with a health educator on zoom.~In Phase 2, participants will be asked to play Ring-Fit Adventure for 60 (wk 1), 90 (wk 2), 120 (wk 3), and 150 (wk 4-12) minutes per week. Participants will also be asked to attend a weekly, 90 minute health education session with a health educator on zoom."
62421062|NCT06211803||J-PET group|The patient is referred for a PET/CT scan, in accordance with recognized indications for examining the brain or the entire body.
62804574|NCT03153696|EXPERIMENTAL|Cellie Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support. In this condition, children and parents will be introduced to the Cellie Intervention immediately following the completion of the T1 measures.
62804575|NCT03153696|OTHER|Cellie Wait-list Control|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support. In this condition, children and parents will be introduced to the Cellie Intervention via phone and mail following the completion of the T3 measures.
62228390|NCT04330885|NO_INTERVENTION|Care as usual|Control group will be treated with care as usual meaning information from a PT two weeks prior to the surgery with information on the surgery and to stay active. Both groups will be given information on to stay active and home exercises following the surgery.
62228391|NCT02737839|EXPERIMENTAL|Arm 1: STEPPING ON|"* Adaptation Waves is to adapt Stepping On to the oncology setting/Pilot Waves is to determine the feasibility \& acceptability of the program for older adults receiving cancer care/Gait \& Balance Waves is to determine whether the participants experience changes in their gait \& balance~  * Complete baseline questionnaires about Instrumental Activities of Daily Living, Medical Outcome Study Activities, Karnofsky Performance Status, falls in past 3 months, medications, comorbidities, vision \& hearing, The Falls Behavioral Scale, The Falls Efficacy Scale-International, Patient Reported Outcome pain, PRO neuropathy~ * 7 week STEPPING ON program is multi-component learning environment which has shown to help reduce falls~ * A home visit to gather any feedback on the experience of the program~ * Follow-up questionnaires up to 3 months after completion of the program~* Participants may elect to participate in a booster session to reinforce concepts 3-6 months after completion of the program"
62243127|NCT04881461|EXPERIMENTAL|5-grass mix SLIT-drops|Grass mix sublingual allergy immunotherapy drops One single-dose container (0.5 ml) once daily. 50 SRU/day for five consecutive days followed by 150 SRU/day for five additional consecutive days. Maintenance: 300 SRU/day from day 11.
62243128|NCT06734403||Ileocystoplasty|Urinary Calculi After Ileocystoplasty in Children
62421063|NCT06529276|EXPERIMENTAL|Augmented reality (AR) clinical learning arm|In the AR clinical learning arm, students will have one 3-hour session of AR clinical learning of emergency airway management. The PI will put on a HoloLens device and demonstrate endotracheal intubation using video laryngoscope (C-MAC®) and other AGPs, such as bag-valve-mask ventilation on a manikin in the resuscitation room. The students will be situated in another room and have a first-person view captured by the HoloLens during the demonstration.
62421064|NCT06529276|ACTIVE_COMPARATOR|Control clinical learning arm|In the control arm, students will have one 3-hour regular session of bedside learning of emergency airway management. The PI will demonstrate endotracheal intubation using video laryngoscope (C-MAC®) and other AGPs, such as bag-valve-mask ventilation on a manikin in the resuscitation room in front of the students there.
62421065|NCT05265624|EXPERIMENTAL|Early Genetic Results Disclosure|Early disclosure group receives results of genetic testing at Month 1
62804576|NCT00184223|EXPERIMENTAL|motivational interviewing|Manual guided motivational interviewing in addition to treatment as usual
62804577|NCT00184223|OTHER|control group|treatment as usual
62804578|NCT02344654|EXPERIMENTAL|Fluorescence cholangiography|After induction of anaesthesia 2.5-7.5 mg of indocyanine green (0.05 mg/kg) is injected intravenously. The operation field is routinely inspected in the fluorescence imaging mode before dissection of Calot´s triangle. During dissection, the fluorescence imaging mode is used when needed, before division of any tubular structure and after division of the cystic duct and artery.
62804579|NCT02344654|ACTIVE_COMPARATOR|X-ray cholangiography|The cholangiography is performed after dissection of the cystic duct by cannulation of the cystic duct with a catheter using either a Kumar- or Olsen grasper. A mobile X-ray C-arm system is used, and the monochrome X-ray image is shown on a separate screen. After satisfactory identification of the extra-hepatic biliary ducts, the intraoperative cholangiography is discontinued and the gallbladder is removed in a standardized manner.
62804580|NCT01691794|ACTIVE_COMPARATOR|Atazanavir, 150 mg + Ritonavir, 100 mg (weight:15 to <20 kg)|Participants with baseline weight of 15 to \<20 kg received 150 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
62804581|NCT01691794|ACTIVE_COMPARATOR|Atazanavir, 200 mg + Ritonavir, 100 mg (weight: 20 to <40 kg)|Participants with baseline weight of 20 to \<40 kg received 200 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 NRTIs for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
62804582|NCT01691794|ACTIVE_COMPARATOR|Atazanavir, 300 mg + Ritonavir, 100 mg (weight: ≥ 40 kg)|Participants with baseline weight ≥ 40 kg received 300 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 NRTIs for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
62804583|NCT02304939|ACTIVE_COMPARATOR|Quick change|"For this changeover : When the syringe of norepinephrine stops (pre alarm), start the second syringe pumps at the same speed of the first, wait for a first drop at the end of the tubing.~Close the first syringe, disconnect it and connect the second syringe, open the valve on and stop the first syringe."
62591004|NCT03200704|EXPERIMENTAL|IC2000/SPY-PHI|Per standard of care, each subject will receive an injection of Tc-99m radioactive colloid. Then the periareolar area of the breast(s) identified with breast cancer will be injected (intradermal) twice with 0.05 ml of a 2.5 mg/ml solution of IC2000. Following the injection lymph node mapping will occur based on intraoperative fluorescence visualization using IC2000 and SPY-PHI. Lymph nodes will be excised following identification with IC2000 and SPY-PHI. The Gamma Probe will then be used with Tc-99m for confirmation of the excised lymph nodes as well as in the area of LN excision to ensure all LNs have been identified and excised.
62591005|NCT05077176|ACTIVE_COMPARATOR|CoronaVac|Inactivated SARS-CoV-2 virus antigen, single intramuscular injection for boosting dose.
62591006|NCT05077176|EXPERIMENTAL|Turkovac|Inactivated SARS-CoV-2 virus antigen, single intramuscular injection for boosting dose.
62591007|NCT01106677|EXPERIMENTAL|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
62591008|NCT01106677|EXPERIMENTAL|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
62804584|NCT02304939|EXPERIMENTAL|Double Pumping|"For this changeover : When the syringe of norepinephrine stops (pre alarm), start the second syringe pumps, open the second syringe while leaving the first syringe open. Wait until the blood pressure rises 5 mmHg (SBP, DBP or MAP).~Once the blood pressure increased or 2 minutes from the start of the relay if no increase in blood pressure is observed, close the first syringe."
62804585|NCT02304939|EXPERIMENTAL|Smart infusion pump|For this automatic changeover : When the syringe of norepinephrine stops (pre alarm), oversee the progress of the automatic relay.
62804586|NCT01487135|EXPERIMENTAL|EVP-6124|A single low dose of 8-mg EVP-6124 and A single high dose of 80-mg EVP-6124
62804587|NCT01487135|PLACEBO_COMPARATOR|Placebo|Cranberry juice (180 mL)
62804588|NCT01487135|ACTIVE_COMPARATOR|Moxifloxacin|A single dose of 400-mg Moxifloxacin
62804589|NCT02277600|EXPERIMENTAL|Cohort 1, Treatment A, B|"Treatment A:~BMS-663068 orally twice daily (BID) on Days 1 through 4~Treatment B:~BMS-663068 orally BID plus DRV/COBI orally once daily (QD) on Days 5 through 14"
62804590|NCT02277600|EXPERIMENTAL|Cohort 2, Treatment C, D|"Treatment C:~BMS-663068 orally BID on Days 1 through 4~Treatment D:~BMS-663068 orally BID plus COBI QD on Days 5 through 14"
62804591|NCT01733875|EXPERIMENTAL|CC-220 0.03 mg|
62421066|NCT05265624|ACTIVE_COMPARATOR|Late Genetic Results Disclosure|Late disclosure group receives results of genetic testing at Month 12
62421067|NCT06301737|EXPERIMENTAL|comprehensive rehabilitation+stellate ganglion block|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 10 days.
62421068|NCT06301737|PLACEBO_COMPARATOR|comprehensive rehabilitation+placebo|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 10 days.
62421069|NCT04161118|EXPERIMENTAL|Tisagenlecleucel (CTL019)|All patients will receive a single target dose of 0.6 to 6.0 × 108 of autologous tisagenlecleucel (CTL019) transduced T-cells with a viability of at least 70% administered via IV infusion after optional bridging with chemo- or immunotherapy and lymphodepleting (LD) chemotherapy with cyclophosphamide and fludarabine.
62591009|NCT01106677|ACTIVE_COMPARATOR|Sitagliptin 100 mg|Each patient will receive 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
62591010|NCT01106677|OTHER|Placebo/Sitagliptin|Each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52. Placebo and sitagliptin will be given with protocol-specified doses of metformin immediate release.
62591011|NCT06668493|EXPERIMENTAL|Treatment|
62591012|NCT02984163|EXPERIMENTAL|Exercise Intervention|Participant exercise sessions will be conducted in groups of 10-15 under the direct supervision of the community-based exercise specialist. Sessions will be twice a week for 12-weeks. Participants will have the option to continue with the exercise program after the 12-weeks on a fee-for-service basis.
62591013|NCT03256058|ACTIVE_COMPARATOR|Reinflation after early deflation|The tourniquet would be inflated immediately before incision and deflated after the use of the cement, and 10 minutes later (after the hardening of the cement) , reinflate the tourniquet and deflate at the end of the operation.The total time of tourniquet inflation is controlled within 90 minutes.
62591014|NCT03256058|PLACEBO_COMPARATOR|Control|The tourniquet would be inflated immediately before incision and deflated at the end of the operation. The inflation of tourniquet should not last more than 90 minutes.
62804592|NCT01733875|EXPERIMENTAL|CC-220 0.1 mg|
62804593|NCT01733875|EXPERIMENTAL|CC-220 0.3 mg|
62804594|NCT01733875|EXPERIMENTAL|CC-220 1 mg|
62804595|NCT01733875|EXPERIMENTAL|CC-220 2 mg|
62804596|NCT01733875|EXPERIMENTAL|Placebo|In each arm, 6 subjects will receive a dose of CC-220 and 2 subjects will receive placebo depending on the randomization schedule.
62804597|NCT01733875|EXPERIMENTAL|CC-220 4 mg|
62804598|NCT01733875|EXPERIMENTAL|CC-220 6 mg|
62804599|NCT01733875|EXPERIMENTAL|CC-220 1 mg (Part 2 only)|
62804600|NCT02684773||Incentre Nocturnal Hemodialysis|These are patients who converted to incentre nocturnal hemodialysis (8 hours/session, 3 sessions/week) from conventional hemodialysis (4 hours/session, 3 sessions/week) at the inception of this study and are eligible for the long-term follow-up phase of the study.
62421070|NCT04095819|EXPERIMENTAL|Middle Meningeal Artery Embolization|Middle Meningeal Artery Embolization
62421071|NCT04095819|ACTIVE_COMPARATOR|Traditional Surgery|Craniotomy/Burr hole
62421072|NCT02792088|EXPERIMENTAL|Besifovir|Besifovir 150 mg q.d.
62421073|NCT02792088|ACTIVE_COMPARATOR|Tenofovir|Tenofovir 300 mg q.d.
62421074|NCT03567200|EXPERIMENTAL|Single-Arm Feasibility|9-week, 1x/week, 90-minute face-to-face sessions.
62421075|NCT03770832||Infants at Risk for Atypical Motor Development (high-risk)|
62591015|NCT05153200|EXPERIMENTAL|Upadacitinib(Rinvoq)|Upadacitinib(Rinvoq) 15 mg po daily
62591016|NCT05153200|ACTIVE_COMPARATOR|Adalimumab(Idacio)|
62591017|NCT03108586|ACTIVE_COMPARATOR|FDI - tradional group|Diagnosis and dental treatment decision based on the criteria of the International Dental Federation (FDI).
62591018|NCT03108586|EXPERIMENTAL|CARS - conservative group|Diagnosis and dental treatment decision according to CARS (Caries Associated with Restorations or Sealants) detection criteria.
62804601|NCT02684773||Conventional Hemodialysis|These are patients treated with conventional hemodialysis (4 hours/session, 3 session/week) who elected to remain on this dialysis schedule at the inception of this study and are eligible for the long term follow-up phase of the study.
62804602|NCT00487019||1|Neonates aged \<72 h and needing antibacterial therapy for early onset neonatal sepsis
62804603|NCT00487019||2|Same as group 1
62804604|NCT04827264||Return to Play Testing using Checklist|"Participants will be evaluated prospectively for return to play following ACL reconstruction by testing with the Safe return to play following ACL reconstruction checklist"
62804605|NCT04827264||Return to Play Testing using Clinical Judgment|Participants will be evaluated prospectively for return to play following ACL reconstruction by testing with clinical judgement
62804606|NCT02197117|ACTIVE_COMPARATOR|Remote ischemic conditioning|Standard blood pressure cuff placed on upper arm and inflated to 200 mmHg. The cuff is left inflated at this level for 5 minutes and then rapidly deflated to 0 mmHg left deflated for 5 minutes0 this cycle is repeated 4 times in total.
62804607|NCT02197117|SHAM_COMPARATOR|Control|Standard blood pressure cuff placed on upper arm and left un-inflated for 40 minutes, and then cuff is removed.
62804608|NCT01269866|OTHER|Cymbalta|Cymbalta 60 to 120 mg
62804609|NCT01380223|EXPERIMENTAL|Dose-escalation Cohort 1|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
62421076|NCT03770832||Infants Expected to Have Typical Motor Development (low-risk)|
62804610|NCT01380223|EXPERIMENTAL|Dose-escalation Cohort 2|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
62243129|NCT06734403||Sigmoidocystoplasty|Urinary Calculi After Sigmoidocystoplasty in Children
62243130|NCT03788395|EXPERIMENTAL|Symbicort Turbohaler plus Turbo+|10 asthmatic children
62421077|NCT01715259|EXPERIMENTAL|Abiraterone acetate|
62421078|NCT01992432||Single-group study: chemotherapy|Single-group study: chemotherapy
62421079|NCT05572424|EXPERIMENTAL|Adaptated Physical Activity + pedometer watch|Follow an Adapted Physical Activity program during 12 weeks and wear a pedometer watch during 1 year
62421080|NCT05572424|NO_INTERVENTION|Control group|Usual care
62591019|NCT01633684||Diabetes|patients with Type 1 Diabetes Mellitus
62591020|NCT01633684||Control|Age and sex matched control subjects
62421081|NCT04201418||Patisiran Prospective Cohort|Patients who are naive to patisiran at study enrollment with the intention to initiate commercial patisiran therapy.
62421082|NCT04201418||Patisiran Mixed Cohort|Patients who are currently on commercial patisiran therapy for less than 12 months at study enrollment.
62591021|NCT01159366|ACTIVE_COMPARATOR|occluded culprit artery|An occluded lesion was defined as a lesion with 100% stenosis or TIMI-flow grade 0 or 1.
62591022|NCT01159366|ACTIVE_COMPARATOR|non-occluded culprit artery|A non-occluded lesion was defined as a lesion without 100% stenosis or TIMI-flow grade 0 or 1.
62591023|NCT03890913||Observation|All childcare centers enrolled to Aim 1 will be observed. The physical activity environment will be examined before and after the implementation of playground stencils.
62591024|NCT03091036|OTHER|Proactive healthcare intervention|Participants who were included before (single-arm pre-post study), now a proactive and integrated intervention program for the health is performed of the complex chronic patient, based in an improvement of the care process.
62591025|NCT05283135|EXPERIMENTAL|risankizumab subcutaneous injection 600 mg (4x dosing) at Weeks 0, 4, and 16|
62591026|NCT05283135|EXPERIMENTAL|risankizumab subcutaneous injection 300 mg (2x dosing) at Weeks 0, 4, and 16|
62591027|NCT06207149|EXPERIMENTAL|Intervention|Participants will attend an advocacy program.
62591028|NCT06207149|ACTIVE_COMPARATOR|Waitlist-Control Group|Participants will receive the written materials of the advocacy program. After completing the intervention group completes the advocacy program, the waitlist-control group participants will be able to participate in the advocacy program.
62591029|NCT04597541|EXPERIMENTAL|1|AK112
62591030|NCT02465879|EXPERIMENTAL|Therapist Triage|All subjects in this group will be triaged by an extended role occupational or physical therapist prior to their visit with the rheumatologist.
62591031|NCT05407974|EXPERIMENTAL|Pleural abrasion Group|Mechanical pleural abrasion will be performed by rubbing the parietal pleura with gauze or a cleaning pad.
62591032|NCT05407974|EXPERIMENTAL|pleurectomy group|Pleurectomy will be performed by a small piece of gauze on grasper. The aim of pleurectomy is to remove the parietal pleural especially above the areas with blebs or bullae.
62591033|NCT03234517|EXPERIMENTAL|Vaginal Clindamycin Cream Plus continuous Vaginal Probiotic|Vaginal Clindamycin Cream followed by continuous Vaginal Probiotic use for 60 days
62591034|NCT03234517|ACTIVE_COMPARATOR|Vaginal Clindamycin Cream Plus interrupted Vaginal Probiotic|Vaginal Clindamycin Cream followed by interrupted Vaginal Probiotic use
62591035|NCT02340260|OTHER|High intensity interval training|High intensity interval training starts with warming up for 3 minutes at 70 % of maximum heart rate before treadmill training 10x1-minute intervals at 90 % of HRmax, with 75 seconds of active recovery at 70 % of HRmax between each interval. Exercise is completed with a three minute cool down. All training sessions are supervised by an exercise physiologist. Treadmill inclination and/or speed will be adjusted to make sure prescribed intensity is met throughout the intervention.
62228392|NCT04223427|ACTIVE_COMPARATOR|Single ring STN-DBS|The order of the five STN-DBS stimulation conditions will be randomized and assessments will be performed blinded from the stimulation condition. The effects of STN DBS on gait recordings will be assessed in 5 different conditions: with single ring DBS (1), and with current shaping for DBS of the gait 'hot spot' (2), of the dorsal STN (3) of the ventral STN (4) and of the DBS of narrow fiber tracts (5). The first condition will always be the single ring DBS.
62804611|NCT01380223|EXPERIMENTAL|Dose-escalation Cohort 3|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
62804612|NCT01380223|EXPERIMENTAL|Dose-escalation Cohort 4|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
62228393|NCT04223427|EXPERIMENTAL|Directional STN-DBS|The order of the five STN-DBS stimulation conditions will be randomized and assessments will be performed blinded from the stimulation condition. The effects of STN DBS on gait recordings will be assessed in 5 different conditions: with single ring DBS (1), and with current shaping for DBS of the gait 'hot spot' (2), of the dorsal STN (3) of the ventral STN (4) and of the DBS of narrow fiber tracts (5). The first condition will always be the single ring DBS.
62228394|NCT05539274||cervical cancer group, control group|
62228395|NCT03353831|PLACEBO_COMPARATOR|Arm A: Chemotherapy + Bevacizumab + Placebo|Chemotherapy: Paclitaxel 80 mg/m² d1, 8, 14, 22 q28 or pegylated liposomal doxorubicin 40 mg/m² q28 + Bevacizumab 10 mg/kg q14 + Placebos q14
62228396|NCT03353831|EXPERIMENTAL|Arm B: Chemotherapy + Bevacizumab + Atezolizumab|Chemotherapy: Paclitaxel 80 mg/m² d1, 8, 14, 22 q28 or pegylated liposomal doxorubicin 40 mg/m² q28 + Bevacizumab 10 mg/kg q14 + Atezolizumab 840 mg q14
62804613|NCT00872963||RABIES VACCINE|Those subjects who received the active comparator
62804614|NCT00872963||RTS,S/AS01E|The subjects who received investigational product
62804615|NCT03264274|OTHER|Aflibercept + DCE-US|Aflibercept: 4mg/kg IV every 2 weeks until discontinuation due to progression. DCE-US before treatment, and at 2 weeks and 8 weeks after the first Aflibercept administration.
62804616|NCT01064115|EXPERIMENTAL|Cetirizine|Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys Laboratories Limited
62804617|NCT01064115|ACTIVE_COMPARATOR|Zyrtec|Zyrtec Tablets 10 mg of Pfizer Labs
62804618|NCT06524128|EXPERIMENTAL|With Dreeft® wheels|The participant's wheelchair will be equipped with DREEFT wheels, to be used for 1 month.
62804619|NCT06524128|NO_INTERVENTION|without Dreeft® wheels|The participant's wheelchair will be equipped with its usual braking system, monitored over a period of 1 month.
62804620|NCT04361370|EXPERIMENTAL|Treatment group|BRCA mutation wild type, non-mucinous , platinum-sensitive recurrent ovarian cancer
62804621|NCT05022186|EXPERIMENTAL|Group receiving Cannabidiol|These patients will receive cannabidiol 5% without other medication for cognition and depression
62804622|NCT05022186|EXPERIMENTAL|Group receiving Homotaurine|These patients will receive Vivimind (homotaurine) without other medication for memory and depression
62804623|NCT05022186|NO_INTERVENTION|Control group|These patients will not receive treatment
62804624|NCT03055117|EXPERIMENTAL|Group-based exercise rehabilitation|Group-based rehabilitation: Group-based sessions (4-8 patients per group) with physiotherapist and home training for 8 weeks (maximum of 12 training sessions).
62804625|NCT03055117|ACTIVE_COMPARATOR|Individual exercise rehabilitation|Individual rehabilitation: One-on-one sessions with physiotherapist and home training for 8 weeks (maximum of 12 training sessions).
62228397|NCT00690443|ACTIVE_COMPARATOR|2|2.5 mg AEGR 733 plus atorvastatin 20 mg weeks 1-4 followed by 5 mg AEGR 733 plus atorvastatin 20 mg weeks 5-8
62228398|NCT00690443|ACTIVE_COMPARATOR|1|Following 35-day washout + diet run-in, subjects receive atorvastatin 20 mg for 8 wks.
62228399|NCT06185361|ACTIVE_COMPARATOR|fluoxetine|selective serotonin reuptake inhibitors fluoxetine 20 mg for 12 weeks
62228400|NCT06185361|ACTIVE_COMPARATOR|desmopressin|0.2 mg desmopressin tablet for 12 weeks
62421083|NCT04201418||Patisiran Retrospective Cohort|Patients who have been on commercial patisiran therapy for at least 12 months prior to study enrollment, regardless of current treatment status at enrollment.
62421084|NCT04989231||Experimental Group|Subjects who have received 4 doses of the experimental vaccine (including subjects at the age of 4 years (48 to 54 months) and 5 years (78 to 84 months) after the last vaccination ) will be collected venous blood about 3.0ml.
62421085|NCT04989231||Control Group|Subjects who have received 4 doses of control vaccine (including subjects at the age of 4 years (48 to 54 months) and 5 years (78 to 84 months) after the last vaccination ) will be collected venous blood about 3.0ml.
62421086|NCT01184378|PLACEBO_COMPARATOR|control formula|formula containing only vegetable fats
62421087|NCT01184378|EXPERIMENTAL|new formula|new formula with dairy lipids and soluble milk proteins
62421088|NCT04563416||Patients who need undergo magnifying endoscopy|
62421089|NCT04580173||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
62804626|NCT03055117|ACTIVE_COMPARATOR|Home exercise|Home exercise: Instruction in home exercise by physiotherapist, with maximum of 4 follow-up consultations over a period of 8 weeks.
62804627|NCT03642977||Allogeneic HSCT recipients|"Adult patients receiving allogeneic hematopoietic stem cell transplant (HSCT) at University Hospitals of Geneva and who are enrolled in the Cohort of infectious disease in hematopoietic stem cell transplant patients."
62804628|NCT02563314|EXPERIMENTAL|intervention|
62804629|NCT02563314|OTHER|control|
62804630|NCT03155126||Saline group|Patients resuscitated with saline
62804631|NCT03155126||Acetated Ringer's sodium group|Patients resuscitated with Acetated Ringer's sodium
62804632|NCT01307384||Continuum Acetabular System|Patients receiving primary hip arthroplasty using the Continuum Metal on Polyethylene Acetabular System
62804633|NCT00380055|EXPERIMENTAL|Screening Navigation|Individuals without a study cancer who receive services of a navigator.
62421090|NCT04580173||0 < SYNTAX score <=22|Low SYNTAX group
62228401|NCT06001086|EXPERIMENTAL|Disitamb Vedotin combined with pyrotinib|Disitamb Vedotin: 2 mg/kg，ivgtt，d1,14/28day/cycle pyrotinib:320mg, oral, every day.
62228402|NCT03089151|EXPERIMENTAL|Community Garden Intervention Group|Participants randomized to the Community Garden Intervention Group will receive the garden intervention. Participants will be assigned a plot for one season and will receive a standard package of services and amenities to support participation in the community garden, including seeds and transplants, tools, new garden classes and access to master community gardeners in Denver.
62228403|NCT03089151|NO_INTERVENTION|Wait List Control Group|The non-gardening group will remain on the DUG wait lists and will not receive the garden intervention.
62228404|NCT01379391|ACTIVE_COMPARATOR|TPO|Patients received myeloablative Allo-HSCT with platelet lower than 20G/L on +14d post-transplantation. Patient enrolled in TPO arm will recieved Recombinant Human Thrombopoietin (rHTPO) treatment fro 14 days.
62228405|NCT01379391|NO_INTERVENTION|TPO-Free Arm|No TPO intervention
62228406|NCT00589238|OTHER|Arm 1 (Standard Arm)|Arm 1 (Standard Arm) Preoperative (primary/ neoadjuvant) intravenous weekly paclitaxel 80 mg/m2 for 12 weeks followed by doxorubicin 60 mg/m2 in combination with cyclophosphamide 600 mg/m2 every 21 days for 4 cycles.
62421091|NCT04580173||23<=SYNTAX score<=32|Intermediate SYNTAX group
62421092|NCT04580173||SYNTAX score>=33|High SYNTAX group
62421093|NCT06701422|EXPERIMENTAL|Arm 1 - Intraoperative Participants|Motor evoked responses responses (MEPs) to epidural electrical stimulation (EES) will be tested at cervical segments with and without myelopathy in participants with cervical myelopathy.
62804634|NCT00380055|EXPERIMENTAL|Treatment Navigation|Individuals with a study cancer who receive navigation services.
62804635|NCT00380055|ACTIVE_COMPARATOR|Screening Education|Rather than receiving navigation, these participants receive general cancer education appropriate to Medicare enrollees.
62804636|NCT00380055|ACTIVE_COMPARATOR|Treatment Education|Rather than receiving navigation services, these participants receive cancer education appropriate to Medicare recipients.
62804637|NCT05952232|ACTIVE_COMPARATOR|PA-GH-01|1 capsule after breakfast once a day
62804638|NCT05952232|ACTIVE_COMPARATOR|MK-GH-04|1 capsule after breakfast once a day
62804639|NCT05952232|ACTIVE_COMPARATOR|TSH-GH-03|1 capsule after breakfast once a day
62029910|NCT02778607||Atypical Parkinsonian Syndrome|Atypical Parkinsonian Syndrome (APS) patients who do not fulfil existing criteria for PSP/CBD/MSA, but may represent variant clinical syndromes related to tau pathology including pure akinesia with gait freezing (PAGF), PSP-parkinsonism, overlap syndromes and atypical parkinsonian disorders not meeting clinical diagnostic criteria at entry
62029911|NCT02778607||Controls|Participants unaffected by neurological or psychiatric disease
62029912|NCT02778607||Corticobasal Degeneration|Patients with a current clinical diagnosis of Corticobasal Degeneration (CBD)
62029913|NCT03812146|EXPERIMENTAL|PC-TIME|PC-TIME consists of meeting with a behavioral health provider for 5, 30-minute sessions that will be delivered over the course of 8 weeks (spaced about 1-2 weeks apart). PC-TIME sessions integrate two effective treatments: motivational enhancement therapy approaches and brief Prolonged Exposure.
62228407|NCT00589238|EXPERIMENTAL|Arm 2 (Experimental Arm)|Arm 2 (Experimental Arm) Preoperative intravenous weekly paclitaxel 80 mg/m2 in combination with carboplatin AUC 2 on D1, D8 and D15 every 28 days for 4 cycles followed by doxorubicin 60 mg/m2 in combination with cyclophosphamide 600 mg/m2 every 21 days for 4 cycles.
62228408|NCT00780429||1|MMF+cyclosporine
62228409|NCT00780429||2|MMF+tacrolimus
62228410|NCT00780429||3|MMF+sirolimus
62421094|NCT02125617||Castration-resistant prostate cancer, Progression after taxane|Treated with abiraterone 1000 mg/day Prednisolone 10 mg/day
62421095|NCT02399059|EXPERIMENTAL|Antibiotic lavage|Peritoneal irrigation with Gentamycin - clndamycin solution
62421096|NCT02399059|ACTIVE_COMPARATOR|Normal saline lavage|Peritoneal irrigation with normal saline
62591036|NCT02340260|OTHER|Sprint interval training|Sprint interval training starts with warming up for 3 minutes at 70 % of maximum heart rate before treadmill training 2x20 seconds of maximum intensity intervals, with 3 minutes and 20 seconds of active recovery at 70 % of HRmax between each interval, followed by 3 minutes cooling down at the same intensity. All training sessions are supervised by an exercise physiologist. Treadmill inclination and/or speed will be adjusted to make sure prescribed intensity is met throughout the intervention.
62228411|NCT02424188|EXPERIMENTAL|TRIUMPH intervention|Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
62421097|NCT03795064|EXPERIMENTAL|Immediate Intervention|Patients in this group will be treated with foam sclerotherapy immediately in the first visit to outpatient clinic (immediate intervention).
62421098|NCT03795064|ACTIVE_COMPARATOR|Early Intervention|Patients in this group will be treated with foam sclerotherapy in the following visit to outpatient clinic at four weeks (early intervention).
62421099|NCT04171089|EXPERIMENTAL|Child-Safety Plan Intervention|A Child Safety Plan to prevent suicidal behavior will be developed with the children and their parents. The parents and child will complete feasibility and acceptability questionnaires.
62804640|NCT05952232|PLACEBO_COMPARATOR|PA-GH-02|1 capsule after breakfast once a day
62804641|NCT04002076|EXPERIMENTAL|Robot-assisted hand combined with occupational therapy|Ten participants in group A will undergo robot-assisted hand (with visual feedback) combined with occupational therapy. They will receive 60 minutes a day and 3 days a week robot-assisted hand and occupational therapy for six weeks.
62804642|NCT04002076|ACTIVE_COMPARATOR|Traditional occupational therapy|Another 10 participants allocated to the group B will receive 60 minutes a day and 3 days a week traditional occupational therapy for six weeks.
62804643|NCT01033539|ACTIVE_COMPARATOR|Placebo control|Placebo control without probiotics ATCC PTA 4659
62804644|NCT01033539|ACTIVE_COMPARATOR|ATCC PTA 4659 Low dose|
62804645|NCT01033539|ACTIVE_COMPARATOR|ATCC PTA 4659 high dose|
62228412|NCT02424188|NO_INTERVENTION|Treatment as Usual|referral to quit line
62421100|NCT01033201||Lung transplant|All lung transplant patients presenting for screening/surveillance and diagnostic bronchoscopies at Mayo Clinic Florida are eligible for participation.
62228413|NCT06036303|EXPERIMENTAL|Nasr Fascial Closure Device|
62228414|NCT06036303|ACTIVE_COMPARATOR|Berci Fascial Closure Device|
62228415|NCT05437185|ACTIVE_COMPARATOR|Active group|The investigators aimed for six sessions of anodal stimulation over the right DLPFC (F4 in 10-20 EEG system) with cathode above the left DLPFC (F3) using HDCstim by Newronika S.r.l., Italy. The therapy was administered over two weeks (Mon, Wed, Fri) to ensure a washout period of 48 to 72 hours between applications. The current of 1.5 mA was delivered via silicone electrodes inserted into saline (0.9%) filled cellulose sponges, both 5x5cm (Current Density of 0.6 A/m2), for 20 minutes with 20 seconds of both ramp-up and ramp-down. An International 10-20 EEG system was used to determine the stimulation location, and dedicated EEG caps were used to ensure consistency between applications.
62228416|NCT05437185|PLACEBO_COMPARATOR|Sham group|The sham (placebo) was administered using the same devices with a preprogrammed sham protocol (using HDCprog by Newronika S.r.l., Italy) of 20 minutes to be virtually indistinguishable from the active stimulation.
62228417|NCT02949258|EXPERIMENTAL|SEEOX group|A three-cycle neoadjuvant chemotherapy will be performed in all cases. In every cycle, oxaliplatin 150 mg, etoposide 100 mg and epirubicin 50 mg will be administered from the celiac artery on day 1. Oral S-1 120 mg per day will be given for days 1-14. The second cycle will be scheduled following a 1-week rest after the first cycle.After two courses of neoadjuvant chemotherapy, patients will be reevaluated and receive curative or palliative resection or exploratory laparotomy within 14 days after completing the second course of chemotherapy.
62804646|NCT04218617|EXPERIMENTAL|Arm 1 - Single fraction|sSRS 18 Gy in 1 fraction
62804647|NCT04218617|ACTIVE_COMPARATOR|Arm 2 - Two fraction|sSRS 24 Gy in 2 fractions
62804648|NCT05774301|EXPERIMENTAL|Nurses|A simulation-based training will be done for all nurses
62804649|NCT03776682||Acute inflammation|Patients with RA and active inflammation (by exam or inflammatory markers)
62804650|NCT03776682||Chronic remission|Patients with RA who are in remission (clinically)
62804651|NCT02568761|ACTIVE_COMPARATOR|Injection snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate. 0.5 ml of the solution will be implemented in three different regions of the submucosal layer of the soft palate, one median and two paramedians.
62029914|NCT03812146|ACTIVE_COMPARATOR|PC-TAU|Primary Care - treatment as usual. Participants in PC-TAU will be referred to the PCMHI mental health provider within their primary care team, and will receive whichever care or intervention is typically provided. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team.
62804652|NCT02568761|ACTIVE_COMPARATOR|Oropharyngeal Exercises|Weekly sessions of myofunctional exercises under the supervision of a qualified professional, lasting about 30 minutes each, combined with daily exercises without supervision for a period of three months.
62228418|NCT00521560|EXPERIMENTAL|1|
62421101|NCT03345953|EXPERIMENTAL|BP 1.4979|15 mg tablet BID
62591037|NCT06084884|EXPERIMENTAL|AZD5851|Subjects will receive AZD5851 following 3 consecutive doses of lymphodepleting chemotherapy (fludarabine and cyclophosphamide).
62804653|NCT01167803|ACTIVE_COMPARATOR|Reference - desflurane|The patients in this group will undergo anesthesia using remifentanil associated with desflurane.
62804654|NCT01167803|EXPERIMENTAL|Experimental - xenon|The patients in this group will undergo anesthesia using remifentanil associated with xenon
62804655|NCT00905450|EXPERIMENTAL|BOL-303242-X|BOL-303242-X (Mapracorat)
62804656|NCT00905450|PLACEBO_COMPARATOR|Vehicle|Vehicle for BOL-303242-X (Mapracorat)
62243131|NCT03788395|ACTIVE_COMPARATOR|Symbicort Turbohaler without Turbo+|10 asthmatic children
62421102|NCT03345953|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet
62421103|NCT03015909|OTHER|Eutropin pen inj.|
62421104|NCT01855321|ACTIVE_COMPARATOR|Vitamin D|the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
62421105|NCT01855321|PLACEBO_COMPARATOR|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
62804657|NCT02984488|EXPERIMENTAL|single visit endodontic treatment.|•single visit endodontic Treatment of necrotic teeth using Protaper next.
62421106|NCT02413879|EXPERIMENTAL|Treatment Group|All study subjects will be treated using the CleanCision device.
62421107|NCT03914937||Intervention Group: Virtual Reality|Patients will wear a virtual reality device in addition to standard lidocaine/novocaine numbing agent
62421108|NCT03914937||Control Group: Music|Patients will listen to music in addition to standard lidocaine/novocaine numbing agent
62804658|NCT02984488|ACTIVE_COMPARATOR|Two visits endodontic treatment|•Two visits endodontic Treatment of necrotic teeth using Protaper next.
62591038|NCT06159556|ACTIVE_COMPARATOR|Peanut group|Participants will be consuming 2 ounces of peanuts /peanut butter everyday for 12 weeks
62591039|NCT06159556|NO_INTERVENTION|control group|Participants will continue with habitual diet and abstain from eating peanuts
62591040|NCT06384001|EXPERIMENTAL|Active MBM|The active MBM is designed to be applied for 20 minutes per session daily.
62804659|NCT04130607|EXPERIMENTAL|Analytical|Students will receive brief instruction in probability, sensitivity, specificity, and likelihood ratios, with distributions and calculations. Pretest and posttest probabilities will be computed for two cases for each of the three conditions listed above.
62804660|NCT04130607|ACTIVE_COMPARATOR|Experiential|"Students will receive a brief instruction conceptually discussing sensitivity and specificity (e.g. a sensitive test will be positive at even low levels of disease. However, this can lead to a number of false positive errors, when the test is positive even when there is no disease. As a result, it is most useful for ruling out a diagnosis). They will then work through a total of 30 cases, 10 for each condition, in blocked sequence. For each brief written case they will be asked for a probability of diagnosis after the clinical information is presented. The test result will then be given and they will be asked for a post-test probability. Their estimate will be compared to the computed value based on published estimates of sensitivity and specificity and feedback provided."
62804661|NCT04130607|PLACEBO_COMPARATOR|No Explicit Instruction or Examples|Students will receive 3 passages from a clinical text related to each of the 3 conditions in the study and asked to study them for 15 min each.
62804662|NCT05772624|EXPERIMENTAL|LowN-AVD|classic Hodgkin's lymphoma patients receiving low dose nivolumab in combination with AVD
62421109|NCT04979078|EXPERIMENTAL|Experimental group|The experimental group receives 9 sessions of photobiomodulation therapy (3x/week for 3 weeks).
62421110|NCT05128331|EXPERIMENTAL|Spermidine supplementation|Study participants are provided with spermidine supplementation
62804663|NCT02539641|OTHER|Good responder RYGB|Good responders after Roux-en-Y gastric bypass (RYGB). EWL \> 50%. Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
62804664|NCT02539641|OTHER|Bad responder RYGB|Bad responders after Roux-en-Y gastric bypass (RYGB). EWL \< 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
62804665|NCT02539641|OTHER|Good responder SG|Good responders after sleeve gastrectomy (SG). EWL \> 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
62804666|NCT02539641|OTHER|Bad responder SG|Bad responders after sleeve gastrectomy (SG). EWL \< 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
62804667|NCT02539641|OTHER|Duodenal-jejunal bypass liner|Patients who will have a duodenal-jejunal bypass liner (DJBL) Intervention: Gastric emptying scintigraphy before and after implantation of DJBL
62804668|NCT02271698|ACTIVE_COMPARATOR|Dexamethasone 6mg|Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
62804669|NCT02271698|ACTIVE_COMPARATOR|Dexamethasone 12mg|Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
62421111|NCT05128331|PLACEBO_COMPARATOR|Placebo supplementation|Study participants are provided with a placebo supplementation
62029915|NCT05720806|EXPERIMENTAL|Weight bearing as tolerated (WBAT) immediately following surgery.|Subjects will be able to self-select weight bearing based on pain and confidence in surgical hip.
62421112|NCT05598463|EXPERIMENTAL|Augmented reality and wearable sensor-based home rehabilitation exercise|Experimental group performs augmented reality and wearable sensor-based home rehabilitation exercise for 4 weeks. And then, their exercise compliance is monitored by medical staff.
62421113|NCT05598463|NO_INTERVENTION|Control group|Control group is asked to maintain their own physical activity amount, not involve the regular exercise program additionally for 4 weeks after enrollment.
62804670|NCT02271698|ACTIVE_COMPARATOR|Dexamethasone 24mg|Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
62421114|NCT06567717|EXPERIMENTAL|Combination Supplements|Zinc and nicotinamide riboside
62421115|NCT06567717|PLACEBO_COMPARATOR|Placebo|Placebo-controls for both zinc and nicotinamide riboside
62421116|NCT01984931|EXPERIMENTAL|Trimebutine Maleate 300 mg Tab|A single dose of NEWBUTIN SR 300 mg Tab will be given orally one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
62591041|NCT06384001|SHAM_COMPARATOR|Sham MBM|The sham MBM intervention matches the active MBM
62591042|NCT06666751||Hydrus microstent|Participants in this group underwent Hydrus microstent placement at the Moran Eye Center.
62591043|NCT06666751||iStent Inject|Participants in this group underwent iStent Inject placement at the Moran Eye Center.
62591044|NCT00419601|ACTIVE_COMPARATOR|2|Fentanyl
62591045|NCT00419601|EXPERIMENTAL|1|Remifentanyl
62591046|NCT03722758|ACTIVE_COMPARATOR|Spectrum TPH3, tooth restoration|Restoration with micro hybrid resin composite
62591047|NCT03722758|ACTIVE_COMPARATOR|Riva LC, restorative material|Restoration with resin-modified glass ionomer cement
62591048|NCT04798989|EXPERIMENTAL|CY6463|CY6463 once daily (QD) for approximately 87 sequential days.
62591049|NCT04798989|PLACEBO_COMPARATOR|Placebo|Placebo QD for approximately 87 sequential days.
62591050|NCT00809640|ACTIVE_COMPARATOR|1|The intervention group will receive prevention of low back pain education through a Back Comic-Book, and their beliefs/knowledge will be tested twice after intervention.
62591051|NCT00809640|NO_INTERVENTION|2|The control group will receive no intervention, and their beliefs/knowledge on low back pain will be tested twice after the first assessment.
62421117|NCT01984931|ACTIVE_COMPARATOR|Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A|Anti-emetic medication protocol of Chungmu Hospital includes MACPERAN (Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A)thru IV twice in a day
62228419|NCT03226821|EXPERIMENTAL|Tesamorelin|Subjects will be treated with tesamorelin 2 mg by subcutaneous injection daily. Enrolled subjects will have 6 visits - a baseline visit before starting tesamorelin, a visit at 1 month, 3 months, 6 months, 9 months and at 1 year of tesamorelin (GHRH analogue) therapy. Blood sampling for safety labs and clinical examinations will be performed at each visit.
62421118|NCT05381883|OTHER|Epidemiology|"Participants will answer sociodemographic questions, questions about the experience of potentially traumatic lifelong events, the presence of a known psychological or medical disorder and the taking of drug treatment.~These questionnaires will make it possible to detect the main psychological disorders (post-traumatic stress disorder, depression, panic disorder, generalized anxiety disorder), to evaluate coping strategies, the presence of professional exhaustion (burnout), the consumption of psychoactive substances and quality of life."
62421119|NCT06096259|EXPERIMENTAL|Metformin|3x500mg metformin hydrochloride (HCl) extended-release (ER) tablets taken orally once a day for 1 year
62421120|NCT06096259|PLACEBO_COMPARATOR|Placebo|3x metformin placebo tablets matching metformin extended-release taken orally once a day for 1 year
62804671|NCT02271698|PLACEBO_COMPARATOR|Placebo|Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
62804672|NCT06379165|EXPERIMENTAL|Meloxicam Nanocrystal Injection|The eligible subjects will receive Meloxicam Nanocrystal Injection, administered as 30 mg (1 mL) every 24 h for 2 doses.
62804673|NCT06379165|PLACEBO_COMPARATOR|Placebo|The eligible subjects will receive Placebo, administered as 1 mL Placebo every 24 h for 2 doses.
62804674|NCT01960140|EXPERIMENTAL|Simvastatin|Single oral dose of 40 milligrams (mg) simvastatin on Day 1.
62804675|NCT01960140|EXPERIMENTAL|Baricitinib + Simvastatin|Oral doses of 10 mg baricitinib once daily (QD) on Days 3 to 7, with a single oral dose of 40 mg simvastatin coadministered on Day 6.
62804676|NCT04107714|EXPERIMENTAL|Intervention (STC)|"Study participants randomized to the experimental group receive the intervention (STC). STC is a peer-led and web-based group intervention containing four two-hour sessions within four weeks plus an additional booster session one month later.~Fidelity to manual is rated in each session by study staff."
62804677|NCT04107714|NO_INTERVENTION|No intervention|Participants randomized to the control group do not receive the group program but get the accompanying workbook at the end of the study.
62804678|NCT05757986||Experimental group|
62804679|NCT05757986||Control group|
62804680|NCT02995356||Doubt for ectopic pregnancy group|This group participants have doubt for ectopic pregnancy in terms of beta-HCG pregnancy follow-up results and ultrasonography results.
62804681|NCT02995356||Normal intrauterine pregnancy group|This groups participants have normal intrauterine pregnancy
62804682|NCT02484066|EXPERIMENTAL|VBN-EBUS-GS group|Fluoroscopy are not used in this group. EBUS and GS are inserted into bronchi in the assistance of VBN. The EBUS probe and GS are confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
62804683|NCT02484066|ACTIVE_COMPARATOR|VBN-EBUS-GS-X-ray group|EBUS and GS are inserted into bronchi in the assistance of VBN. The EBUS probe and GS are confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained with fluoroscopic guidance.
62804684|NCT02579200|ACTIVE_COMPARATOR|Inspiratory Muscle Training (IMT)|POWERbreathe®KHA (IMT group)
62804685|NCT02579200|SHAM_COMPARATOR|Sham Training|POWERbreathe®KH2 (sham group)
62804686|NCT02947386|EXPERIMENTAL|Treatment (nivolumab, nimotuzumab)|Patients receive nivolumab IV over 60 minutes and nimotuzumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62804687|NCT03008694|EXPERIMENTAL|1|PET/CT
62804688|NCT00395746|EXPERIMENTAL|0.6 mg + SU|Liraglutide 0.6 mg + sulphonylurea
62804689|NCT00395746|EXPERIMENTAL|0.9 mg + SU|Liraglutide 0.9 mg + sulphonylurea
62804690|NCT00395746|PLACEBO_COMPARATOR|SU Mono - 1|Liraglutide placebo 0.6 mg + sulphonylurea
62228420|NCT03287531|EXPERIMENTAL|conventional therapy (group I)|"1. Exercise therapy.~   For muscles around TMJ :~   Masetter Lateral Pterygoid Medial Pterygoid Temporalis Digastric~2. Pulsed ultrasound at 0.3 to 0.6 watts per sq cm over the lateral poles of the temporomandibular joint condyles with a small sound head for 2 to 3 minutes per side"
62804691|NCT00395746|PLACEBO_COMPARATOR|SU Mono - 2|Liraglutide placebo 0.9 mg + sulphonylurea
62804692|NCT03689023|EXPERIMENTAL|A controlled multimodal intervention|A uniform and systematic patient education about cardiovascular risk factors, physical activity and a healthy diet lifestyle starting early in the primary rehabilitation process with 6 months of follow up.
62228421|NCT03287531|EXPERIMENTAL|low level laser therapy (groupII)|LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.
62228422|NCT04094246|EXPERIMENTAL|Experimental Group|Participants in the experimental group will receive standard post-surgical rehabilitation protocol per their surgery in addition to Battlefield Acupuncture.
62804693|NCT02845817|OTHER|Qualitative research|Semi-structured interviews
62804694|NCT05223270|EXPERIMENTAL|intervention group-1|Hydrocolloid wound dressings were placed on the pressure areas under the NIMV mask of the patients in this group.
62804695|NCT05223270|EXPERIMENTAL|intervention group-2|Hydrocelluler wound dressings were placed on the pressure areas under the NIMV mask of the patients in this group.
62804696|NCT05223270|NO_INTERVENTION|control group|Patients in this group were treated without placing an additional dressing under the NIMV mask.
62804697|NCT04324502||Neuroendocrine neoplasms (tumours)|Patients with a diagnosis of neuroendocrine neoplasm who are due to undergo one of the following treatments: chemotherapy, everolimus, sunitinib, somatostatin analogues, peptide receptor targeted therapy, embolization/ ablative therapies or surgery.
62804698|NCT03563066|EXPERIMENTAL|Benralizumab|Fixed dose 30mg benralizumab.
62804699|NCT03563066|PLACEBO_COMPARATOR|Placebo Control|Will appear identical in form to benralizumab arm.
62804700|NCT04907981||Novel coronavirus infection|All patients were diagnosed according to the diagnostic criteria of the National Health Commission of China and confirmed by RT-PCR detection of viral nucleic acids.
62804701|NCT04907981||Not infected by novel coronavirus|Healthy controls and patients with liver disease
62804702|NCT04907981||Recovered patients with nucleic acid negative after infection with novel coronavirus|Novel coronavirus nucleic acid changed from positive to negative.
62228423|NCT04094246|ACTIVE_COMPARATOR|Control Group|Participants in the control group will receive standard post-surgical rehabilitation protocol per their surgery.
62421121|NCT03701490|EXPERIMENTAL|Prolutex|
62421122|NCT03701490|EXPERIMENTAL|Progeffik|
62421123|NCT05675930|ACTIVE_COMPARATOR|Adult and pediatric patients who received an allogeneic stem cell transplant (allo-HCT)|Participants are Allo-HCT recipients
62421124|NCT05675930|PLACEBO_COMPARATOR|Adult and pediatric patients who received a placebo treatment|Participants are Allo-HCT recipients
62421125|NCT05875974|EXPERIMENTAL|JZP258|Participants will self-administer an oral dose of JZP258 (XYWAV) as per label and titrate to an optimal dosage for each participant.
62421126|NCT01018342|EXPERIMENTAL|1|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
62421127|NCT01018342|ACTIVE_COMPARATOR|2|Macrobid® Capsules 100 mg
62804703|NCT04954508||P|patients suffering form shoulder pain and/or weakness or dislication
62804704|NCT04236102|EXPERIMENTAL|EGFR, KRAS, BRAF Lung adenocarcinoma LBC|Will use residual material from existing LBC cytology samples sent to the laboratory. Routine testing will take priority. Cases identified as non small cell lung carcinoma will have the residual LBC sample tested on the Idylla platform for EGFR, KRAS and BRAF. The EGFR, KRAS and BRAF mutation results obtained using the routine diagnostic procedure (FFPE samples) will be compared to those produced using the LBC samples.
62804705|NCT04236102|EXPERIMENTAL|KRAS Pancreatic adenocarcinoma|Will involve testing archived FFPE clot samples from confirmed pancreatic adenocarcinoma patients since 2014 (Approximately 20 cases per year). KRAS testing will be performed using the Idylla platform to establish if there is a KRAS codon 12 mutation present in 94% percent of the cases reported at RCHT. Patients will have consented to the use of their tissue at the time of procedure. Prospectively new patients diagnosed with pancreatic adenocarcinoma will have KRAS testing on the FFPE clot made as part of the routine diagnostic work up and KRAS testing on the LBC sample.
62804706|NCT04236102|EXPERIMENTAL|EGFR, KRAS, BRAF Blood plasma|Will involve a blood sample being taken at the time of the procedure from patients that have a clinical suspicion of having lung or pancreatic cancer. The single blood sample will be taken from the cannula inserted for the procedure. The blood sample will be processed using the Biocartis Idylla ™ circulating tumour cell cartridges (EFGR, KRAS and BRAF for lung and KRAS for pancreas).
62804707|NCT05347836||Children diagnosed to have T1DM with a minimum duration of five years|
62804708|NCT05347836||Healthy children|
62804709|NCT05624476||experimental group|Patients with urinary tract infection received treatments guided by both culture and mNGS
62228424|NCT05406830|EXPERIMENTAL|Verum acupuncture (VA)|Participants will be treated by real manual acupuncture and usual care. They will be treated twice a week for 8 weeks, to fulfill a 16-session treatment course. Each acupuncture treatment session for patients will be 30 minutes in duration.
62228425|NCT05406830|SHAM_COMPARATOR|Sham acupuncture (SA)|Participants will be treated by non-penetrating sham acupuncture and usual care. They will be treated twice a week for 8 weeks, to fulfill a 16-session treatment course. Each acupuncture treatment session for patients will be 30 minutes in duration.
62228426|NCT04651075|EXPERIMENTAL|music theraphy|One of the 4 music genres (Turkish Folk, Classical, Turkish Art and Sufi Music), which was determined by the researcher by scanning the literature 30 minutes before the CAG procedure, and the expert opinion was taken to the participants in this group was played with a 5-minute headset. The musical genres were arranged in instrumental, nonverbal, 70 decibels in terms of rhythm and duration and played according to the individual's choice.
62228427|NCT04651075|EXPERIMENTAL|information education|Participants in this group were trained to inform them about CAG in visual, audio and written form. Information training was provided by the researcher 30 minutes before the CAG procedure after the outpatient clinic controls of the patient. Information education prepared by the researcher by scanning the literature and getting expert opinion; It includes 7 minutes of video explanation about the CAG process, discussion after video watching, question and answer, and the delivery of a training book prepared in written form.
62421128|NCT05796531|ACTIVE_COMPARATOR|Active intervention arm|Participants will complete the intervention on a mobile device.
62421129|NCT05796531|SHAM_COMPARATOR|Control arm|Participants will complete the sham comparator on a mobile device.
62804710|NCT05624476||control group|Patients with urinary tract infection received treatments guided by culture first
62804711|NCT04811066|EXPERIMENTAL|Anodal tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
62804712|NCT04811066|EXPERIMENTAL|Cathodal tDCS|Cathodal electrode (35 cm2 sponge electrode) placed over C3. Anodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
62804713|NCT04811066|SHAM_COMPARATOR|Sham tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. Stimulation was phased in for 30 seconds up to 2 mA and then switched off. Stimulation was again phased in for 30 seconds following 20 minutes of no stimulation.
62421130|NCT05553600|OTHER|Regular Absorbency|Modified regular absorbency tampon versus regular absorbency reference tampon
62421131|NCT05553600|OTHER|Super Absorbency|Modified super absorbency tampon versus super absorbency reference tampon
62591052|NCT05026099|EXPERIMENTAL|Boxing training program|The program will start with a warm-up session involving breathing and stretching of the trunk and limbs for 5 minutes. The program will include mitt hitting and sand bag hitting for 10 minutes, with a 2-minute rest period. Thereafter, stretching of the trunk and limbs will be performed for 5minutes, similar to the warm-up
62735368|NCT02859285|ACTIVE_COMPARATOR|Estradiol vulvar cream|"The estradiol cream 0.5 grams will be placed on the clitoris/vestibule every night for 2 weeks, then 3 times a week thereafter on Monday, Wednesday, and Friday, for a total of 12 weeks.~In addition estradiol 10mcg tablet will be placed in the vaginal every night for 2 weeks, then 2x a week on Tuesday and Thursday, for a total of 12 weeks."
62421132|NCT06241794|ACTIVE_COMPARATOR|Group M-TAPA|"M-TAPA:~Aseptic conditions are ensured in the area where the block will be performed. Under ultrasound guidance, a linear probe at the sagittal plane and costochondral angle is used to identify the transversus abdominis, internal oblique, and external oblique muscles at the level of the 10th rib. To visualize the lower surface of the rib cartilage in the midline, a sagittal angle is applied with the probe in the direction of the costochondral angle at the edge of the 10th rib. Using a 22-G, 80-100 mm block needle with an in-plane technique, the needle is advanced cranially. The needle tip is directed towards the posterior surface of the 10th rib cartilage, underneath the condyle. Subsequently, 20 ml of 0.25% concentration bupivacaine is injected beneath the condyle. The same procedure will be applied to the opposite side using the same technique."
62421133|NCT06241794|ACTIVE_COMPARATOR|Group Serratus Intercostal Plane Block and Rectus Sheath Block|"Serratus intercostal plane block:The serratus anterior muscle and intercostal muscles are identified at the level of 8th rib along the right mid-axillary line.Using block needle,20 ml of 0.25% Bupivacaine is injected into the interfascial plane between these muscles.The SIPB will be performed only on right side.~Rectus sheath block:a linear probe is placed in a transverse position just above the umbilicus and slightly lateral to the midline.After visualizing the rectus abdominis muscle, posterior rectus sheath,and the hypoechoic space between them,block needle is advanced in-plane along the subcutaneous tissue.The needle is progressed until reaching the space between the epimysium of the muscle and the posterior rectus sheath, passing horizontally through the anterior rectus sheath of the rectus abdominis muscle.10 ml of 0.25% bupivacaine is injected.Adequate spread will lift the epimysium of the rectus abdominis muscle while displacing the posterior fascia and peritoneum downward"
62804714|NCT00688259|EXPERIMENTAL|Cognitive Behavioral Therapy for Psychosis (CBTp)|approximately 6 months of weekly individual manualized cognitive-behavioral psychotherapy for psychosis in which participants set personal goals, identify problematic/ illness-related beliefs and experiences that may interfere with achieving those goals, evaluate the data supporting those beliefs, and then modify the beliefs or behavior as warranted by the data to make progress on those goals.
62421134|NCT06422156|EXPERIMENTAL|SBRT+Nimotuzumab+ mono-chemotherapy|All eligible patients will receive SBRT combined with nimotuzumab and mono-chemotherapy.
62421135|NCT02056431|EXPERIMENTAL|IVR Intervention Group|Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
62421136|NCT02056431|NO_INTERVENTION|IVR Control Group|Participants will receive 3 non-interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) containing general messages regarding diabetic education.
62421137|NCT03210142|EXPERIMENTAL|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation for subjects undergoing an EP, cardiac catheterization or device procedure.
62421138|NCT00854386|ACTIVE_COMPARATOR|1|liberal fluid administration group
62421139|NCT00854386|EXPERIMENTAL|2|Restrictive fluid administration group
62421140|NCT04403386||non-smokers|Participants who have never smoked or do not currently reside with a smoker
62421141|NCT04403386||Smokers|Participants who currently smokes and has smoked for at least 5 years
62421142|NCT06453720||Patients with Crohn's disease|The study will include 75 consenting patients with Crohn's disease, varying in levels of severity depending on assigned SES-CD scoring from their gastroenterologist. These patients will be undergoing routine colonoscopy as per their normal care routine, with this study not requiring additional scheduling commitments. Blood, mucosal washing, and intestinal biopsy samples will be collected during routine colonoscopy procedure. The patient will have the option to send in their stool sample one week prior to their day of colonoscopy or two weeks after their scoping.
62421143|NCT06453720||Patients without inflammatory bowel disease|The study will include 25 non-IBD age and sex-matched controls to compare data alongside the CD patients. These patients will be undergoing routine colonoscopy as per their normal colon screening routine, with this study not requiring additional scheduling commitments. Blood, mucosal washing, and intestinal biopsy samples will be collected during routine colonoscopy procedure. The patient will have the option to send in their stool sample one week prior to their day of colonoscopy or two weeks after their scoping.
62804715|NCT00688259|ACTIVE_COMPARATOR|Supportive Therapy (ST)|approximately 6 months of weekly manualized supportive psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to the participants' lives and concerns
62804716|NCT00314743|ACTIVE_COMPARATOR|Control (No aprepitant)|"Regimen #1 (BEAM; NHL and HL)~Carmustine 300 mg/m2 IV on day -7 (premedicate with ondansetron 32 mg IV and dexamethasone 20 mg IV)~Etoposide 100 mg/m2 IV Q 12 hours x 8 doses on days -6 to -3 (premedicate first daily dose ondansetron 32 mg IV and dexamethasone 20 mg IV)~Cytarabine 100 mg/m2 IV Q 12 hours x 8 doses on days -6 and -3 (no additional premedication)~Melphalan 140 mg/m2 IV on day -2 (premedicate with ondansetron 32 mg IV and dexamethasone 20 mg IV)~Regimen #2 (MM and Amyloidosis)~Melphalan 100 mg/m2 IV on days -3 and -2 (premedicate each dose with ondansetron 32 mg IV and dexamethasone 20 mg IV)"
62804717|NCT00314743|EXPERIMENTAL|Experimental (with aprepitant)|"Aprepitant 125 mg PO will be given 30 minutes prior to the first dose of chemotherapy followed by Aprepitant 80 mg PO QD for the remainder of chemotherapy and continuing for a total of 2 days after completing the regimen.~Regimen #1 (BEAM; NHL and HL)~Carmustine 300 mg/m2 IV on day -7 (premedicate with ondansetron 32 mg IV and dexamethasone 10 mg IV)~Etoposide 100 mg/m2 IV Q 12 hours x 8 doses on days -6 to -3 (premedicate first daily dose ondansetron 32 mg IV and dexamethasone 10 mg IV)~Cytarabine 100 mg/m2 IV Q 12 hours x 8 doses on days -6 and -3 (no additional premedication)~Melphalan 140 mg/m2 IV on day -2 (premedicate with ondansetron 32 mg IV and dexamethasone 10 mg IV)~Regimen #2 (MM and Amyloidosis)~Melphalan 100 mg/m2 IV on days -3 and -2 (premedicate each dose with ondansetron 32 mg IV and dexamethasone 10 mg IV)"
62804718|NCT03326388|EXPERIMENTAL|Selumetinib Intermittent Dosing|Phase 1 of the study to evaluate Intermittent Dosing (Selumetinib given twice daily on 5 out of 7 days) in children with NF1 and inoperable plexiform neurofibromas. The Maximum tolerated dose will define the Recommended phase 2 dose of selumetinib.
62421144|NCT04567160|ACTIVE_COMPARATOR|Propofol group|Induction and maintenance of general anesthesia using propofol
62421145|NCT04567160|ACTIVE_COMPARATOR|Sevoflurane group|Induction and maintenance of general anesthesia using sevoflurane
62421146|NCT04245930|ACTIVE_COMPARATOR|Bovine Pericardial Patch|Immediate implant breast reconstruction using bovine pericardial patch. n=88
62591053|NCT05026099|ACTIVE_COMPARATOR|Task Oriented Training Program|Upper limb Exercises: Sitting position: open covered pots of different sizes and transfer the flour to a cup with a spoon, then close the pot.Sitting position: pick up coins and cards on the table and put the coins in a pot and gather the cards.Sitting position: write and/or draw pictures on a piece of paper.Sitting position: open a safe box with a key, pick up small objects inside the box, and transfer them to a pot, then lock the safe box Sitting position: pick up and transfer jars, bottles, and glasses of different sizes and weights located on a table. Transfer the liquid contents from jars and bottles to glasses Sitting position: throw and catch balls (in pairs)
62591054|NCT04633629||Patients with acute heart failure|Patients hospitalized for acute heart failure in medical department.
62421147|NCT04245930|EXPERIMENTAL|TiLOOP® Bra Mesh|Immediate implant breast reconstruction using TiLOOP® Bra Mesh. n=88
62591055|NCT00474201|SHAM_COMPARATOR|Gemfibrozil PK without LPV/r|"Subjects received a single 600 mg dose of gemfibrozil without concurrent lopinavir-ritonavir 400mg/100mg; this is the control arm of a crossover study design."
62591056|NCT00474201|EXPERIMENTAL|Gemfibrozil PK after 2 weeks of LPV/r|Single dose (600 mg) Gemfibrozil pharmacokinetics (i.e. plasma concentrations collected over time to calculate area under the concentration vs. time curve) assessed after 14.5 days of lopinavir/ritonavir (400/100 mg twice daily) administration.
62591057|NCT03864861||Elective Bariatric Surgery|Patients older than 18 undergoing elective bariatric surgery
62591058|NCT06667193|EXPERIMENTAL|Cold Tub Immersion Group (CI)|Participants will utilize the research cold tub area (10 ºC, 4-minutes), following a standardized protocol (see intervention description).
62591059|NCT06667193|EXPERIMENTAL|Cold Shower Group (CS)|Participants will utilize the research shower area (10 ºC, 4-minutes), following a standardized protocol (see intervention description).
62421148|NCT02854722|EXPERIMENTAL|Deferasirox and calcium-vitamin D3|"Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.~Calcium 500 mg and Vitamin D3 800 IU should also be taken daily as a basic therapy."
62421149|NCT02854722|PLACEBO_COMPARATOR|Calcium-vitamin D3|Calcium 500 mg and Vitamin D3 800 IU are taken daily as a basic therapy.
62421150|NCT06543004|ACTIVE_COMPARATOR|Control Group|The control group will be treated by using Resin based sealer during obturation which will be selected at random.
62421151|NCT06543004|ACTIVE_COMPARATOR|Intervention|The comparator group will receive Bioceramic sealer during obturation as intervention which will be selected at random.
62421152|NCT04196582|ACTIVE_COMPARATOR|Gastro-laryngeal tube Group (Group G)|Patients wear Gastro-laryngeal tube after receiving general anesthesia for biliopancreatic procedures
62421153|NCT04196582|ACTIVE_COMPARATOR|LMA Gastro Airway Group (Group L)|Patients wear LMA Gastro Airway® after receiving general anesthesia for biliopancreatic procedures
62421154|NCT02006355|ACTIVE_COMPARATOR|Continuous femoral nerve bloc|Continuous femoral nerve bloc
62421155|NCT02006355|EXPERIMENTAL|Continuous local anesthesia|Continuous local infiltration of local anesthetic in the operated knee.
62591060|NCT06667193|NO_INTERVENTION|Control Group (CO)|Participants will not participate in any cold water immersion.
62591061|NCT03076788||Athletes|"Professional and amateur athletes examined during the medical follow-up at the medical sport centre of Caen University Hospital.~The medical examination consists in a clinical exam, an electrocardiogram and an echocardiography."
62591062|NCT03076788||Sedentary controls|"Sedentary patients assessed in the cardiology unit with a normal heart function.~The medical examination consists in a clinical exam, an electrocardiogram and an echocardiography."
62591063|NCT03587883|EXPERIMENTAL|Cocoa Flavanol intervention|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 300 mg of cocoa flavanols per capsule: 900 mg of cocoa flavanols consumed daily for 2 weeks; 2 intervention periods: Cocoa flavanols I and cocoa flavanols II.
62591064|NCT03587883|PLACEBO_COMPARATOR|Control intervention|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks; 2 intervention periods: control I and control II.
62591065|NCT06014593|OTHER|Heart failure patients|Stable or relapsing heart failure patients aged between 25 and 85, diagnosed by a cardiologist and requiring respiratory and cardiac investigations at the Montpellier University Hospital.
62591066|NCT06014593|OTHER|Healthy voluntary|Volunteers Aged 25 to 85 with no previous cardiorespiratory history or treatment.
62591067|NCT06658405|EXPERIMENTAL|Vaccinated patients|Human papillomavirus vaccine, nonvalent, Gardasil 9
62591068|NCT06658405|NO_INTERVENTION|Non-vaccinated patients|no changes to standard care
62591069|NCT04673747|EXPERIMENTAL|Group 1 (Total Hip Arthroplasty with intraoperative manual correction)|Patients will undergo total hip arthroplasty with intraoperative manual correction of Iliosacral displacement of the sacroiliac joint
62591070|NCT04673747|ACTIVE_COMPARATOR|Group 2 (Total hip Arthroplasty: standard method)|Patients will undergo total hip arthroplasty according to the standard method
62591071|NCT03574142|EXPERIMENTAL|Epanova|Epanova® capsule, per oral
62591072|NCT04250532||Lifeguard|Lifeguards who work on the Atlantic coast of Gironde France.
62591073|NCT05706844|EXPERIMENTAL|Spinal Anaesthesia (SA)|"Patients undergoing total hip, total knee or unicompartmental knee arthroplasty are anaesthetized using:~Plain or heavy Bupivacaine hydrochloride 10 mg (2 mL)"
62591074|NCT05706844|EXPERIMENTAL|General Anaesthesia (GA)|"Patients undergoing total hip, total knee or unicompartmental knee arthroplasty are anaesthetized using:~Propofol (induction: 1.0-2.0 mg/kg. infusion: 3-5 mg/kg/hour) + Remifentanil (induction: 3-5 mcg/kg, infusion: 0.5 mcg/kg/min)"
62591075|NCT02118142|ACTIVE_COMPARATOR|Betaine|6 gram dose of betaine delivered in encapsulated form
62421156|NCT02069886|EXPERIMENTAL|deferasirox|single arm. all patients will receive deferasirox
62591076|NCT02118142|PLACEBO_COMPARATOR|Dextrose|6 gram dose of dextrose delivered in encapsulated form
62591077|NCT03701841||PEG-rhG-CSF primary prophylaxis|Patients receiving chemotherapy who have a overall FN risk \>=20% receive PEG-rhG-CSF for primary prophylaxis
62421157|NCT04740801|OTHER|PVI procedure|Subjects will undergo ablation treatment of the pulmonary veins with the Rhythmia HDx mapping system with DirectSense technology. Subjects indicated for ablation treatment of de-novo PAF will be selected based on the inclusion/exclusion criteria and if deemed to be eligible for participation, will be asked to sign the Informed Consent Form. For all enrolled subjects who undergo the ablation procedure, the subjects will be treated with the commercial Rhythmia HDx System with commercially available Software Version 4.0.1 or greater (commercially approved version) with DIRECTSENSE™ and Force Computation Software Module; the IntellaMap Orion mapping catheter and the IntellaNav StablePoint ablation catheter.
62804719|NCT01293279||HCV Patients who are treatment naive|Han ethnic Chinese male or female ≥ 18 years old with recent a confirmation of anti-HCV-antibody positive and HCV RNA positive but antiviral or interferon treatment naive at the time this study starts from 28 university affiliated hospital throughout China.
62804720|NCT00905463||Transplantation|Lung transplantation candidates
62029916|NCT05720806|ACTIVE_COMPARATOR|Flat foot weight bearing (FFWB) for 2 weeks after surgery.|Subjects will be limited to FFWB, approx 20lbs through the surgical hip.
62804721|NCT02604446|EXPERIMENTAL|Tapentadol|depot Tapentadol in addition to usual pain treatment
62029917|NCT01612403||Single group|Single group: all participants receive same intervention throughout study (Non-randomised)
62029918|NCT06532708|EXPERIMENTAL|5 Doses|Participants will receive 5 doses of prescription opioids following surgery.
62029919|NCT06532708|ACTIVE_COMPARATOR|16 Doses|Participants will receive 16 doses of prescription opioids following surgery.
62029920|NCT06082050|EXPERIMENTAL|YOLT-201|Phase 1a, which includes three dose cohorts (0.1 mg/kg, 0.3 mg/kg, 1.0 mg/kg) with a sample size of 1-2 subjects per cohort, aims to determine the optimal biologically active dose (OBD) of YOLT-201. Phase 1b will enroll an additional 8 subjects at the OBD to evaluate its safety and preliminary efficacy further
62029921|NCT04154124|EXPERIMENTAL|Rectal Cancer Patients|
62029922|NCT01844804|EXPERIMENTAL|A = PF-06438179|
62029923|NCT01844804|ACTIVE_COMPARATOR|B = Infliximab-EU|
62029924|NCT01844804|ACTIVE_COMPARATOR|C = Infliximab-US|
62029925|NCT06171945|EXPERIMENTAL|AYA Connect|Adolescent and young adult cancer survivors receive AYA Connect intervention.
62029926|NCT06171945|EXPERIMENTAL|AYA Connect-PP|Adolescent and young adult cancer survivors receive AYA Connect-PP intervention.
62029927|NCT06171945|EXPERIMENTAL|AYA Connect-PP+|Adolescent and young adult cancer survivors receive AYA Connect-PP+ intervention.
62029928|NCT01494051|ACTIVE_COMPARATOR|High carbohydrate diet|Diet composition of 10% long-chain fatty acids, 20% medium-chain triglycerides, 12% protein and 68% carbohydrate is the current standard of care in long-chain fatty acid oxidation disorders.
62029929|NCT01494051|EXPERIMENTAL|High protein diet|Diet composition of 10% long-chain fatty acids, 20% medium chain triglycerides, 25% protein and 45% carbohydrate is the comparison diet. Fat content is the same between treatments; only the carbohydrate to protein ratio varies.
62421158|NCT00817778|EXPERIMENTAL|AZD1656|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
62421159|NCT00817778|PLACEBO_COMPARATOR|Placebo|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
62421160|NCT04832178|PLACEBO_COMPARATOR|Placebo|
62421161|NCT04832178|EXPERIMENTAL|SUMOR|
62421162|NCT04778176|EXPERIMENTAL|DopaFuse Delivery System 50mg LD/hr or 68mg LD/hr flow rate|Either 50mg/13mg LD/CD per hour or 68mg/17mg LD/CD per hour flow rate based upon Subject's standard levodopa (LD) dose. Subjects will routinely wear each container for approximately 5 hours (3 containers per day).
62421163|NCT04135456|EXPERIMENTAL|Low dose group|0.5g/kg of 20% mannitol administered at skin incision.
62421164|NCT04135456|EXPERIMENTAL|Medium dose group|1.0g/kg of 20% mannitol administered at skin incision.
62421165|NCT04135456|EXPERIMENTAL|High dose group|1.5g/kg of 20% mannitol administered at skin incision.
62421166|NCT01424085||Those receiving antibiotics|Patients who received one prophylactic dose of antibiotics.
62421167|NCT01424085||Placebo|Patients who did not receive one prophylactic dose of antibiotics (received placebo).
62029930|NCT02624973|EXPERIMENTAL|A|ER/PGR\>50% TP53 wt
62029931|NCT02624973|EXPERIMENTAL|B|ER/PGR\>50% TP53 mutated
62804722|NCT02604446|ACTIVE_COMPARATOR|Oxycodone|depot Oxycodone in addition to usual pain treatment
62804723|NCT02604446|PLACEBO_COMPARATOR|Placebo|depot glucose placebo in addition to usual pain treatment.
62804724|NCT03710746|EXPERIMENTAL|Mixed Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in mixed-sex groups and will complete the food-focused response and attention training intervention.
62804725|NCT03710746|EXPERIMENTAL|Mixed Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in mixed-sex groups and will complete the generic response and attention training intervention.
62804726|NCT03710746|EXPERIMENTAL|Female Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in female-only groups and will complete the food-focused response and attention training intervention.
62804727|NCT03710746|EXPERIMENTAL|Female Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in female-only groups and will complete the generic response and attention training intervention.
62804728|NCT03710746|EXPERIMENTAL|Male Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in male-only groups and will complete the food-focused response and attention training intervention.
62804729|NCT03710746|EXPERIMENTAL|Male Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in male-only groups and will complete the generic response and attention training intervention.
62804730|NCT04369313|EXPERIMENTAL|delayed cord clamping|clamping the cord at least 30s at birth
62029932|NCT02624973|EXPERIMENTAL|C|ER/PGR\<50% TP53 wt
62029933|NCT02624973|EXPERIMENTAL|D|ER/PGR\<50% TP53 mutated
62029934|NCT02624973|EXPERIMENTAL|E|HER2+ TP53 wt
62228428|NCT04651075|NO_INTERVENTION|nursing care|Individuals in this group received routine nursing care and no intervention was made by the researcher. In routine nursing care for individuals who will receive CAG procedure in the clinic; Preparation for the CAG procedure, which involves opening the vascular access and dressing the surgical gown, is included in the pre-and post-procedure routine once and more frequently when there are deviations from normal, and if the patient asks questions about the procedure, measurement of blood pressure, heart rate and oxygen saturation.
62228429|NCT03369990|EXPERIMENTAL|Botulinum toxin type A|DWP450
62228430|NCT03369990|PLACEBO_COMPARATOR|Placebo|Normal Saline
62228431|NCT04017039|NO_INTERVENTION|Phase 1|Phase I is a cross-sectional study to compare endothelial vasodilator and fibrinolytic function in adults with elevated blood pressure who habitually sleep more than 7 hours/night (normal sleep) and those who habitually sleep less than 6.5 hr/night (short sleep)
62228432|NCT04017039|EXPERIMENTAL|Phase 2|Phase II is an intervention study to determine the effects of individualized targeted sleep interventions that increase sleep duration and improve sleep quality on endothelial vasodilator and fibrinolytic function in adults with elevated blood pressure who habitually sleep less than 6.5 hr/night (Specific Aims 3).
62228433|NCT03965611||Patients with isolated severe traumatic brain injury (TBI)|TBI with initial Glasgow Coma Scale (GCS) ≤ 8 and AISextrahead score ≤3. Oropharyngeal and rectal swabs will be performed for each patient within the first 24 hours after ICU admission (day 0), then 48 hours (day 2) and 7 days (day 7) after ICU admission and weekly thereafter until ICU discharge.
62228434|NCT03965611||Patients with severe trauma without TBI|Patients with severe trauma without TBI (AISextrahead score \> 3). Oropharyngeal and rectal swabs will be performed for each patient within the first 24 hours after ICU admission (day 0), then 48 hours (day 2) and 7 days (day 7) after ICU admission and weekly thereafter until ICU discharge.
62228435|NCT03965611||Healthy Controls|"Persons who have not had the conditions being studied or otherwise related conditions or symptoms, as specified in the eligibility requirements.~Oropharyngeal and rectal swabs will be taken only once, at inclusion, after that the participation of the control individual in the trial will be completed."
62228436|NCT00075647|EXPERIMENTAL|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62228437|NCT06486207|EXPERIMENTAL|Gong's mobilization|
62228438|NCT06486207|OTHER|Kendall Exercise|
62228439|NCT05318079|EXPERIMENTAL|Group virtual reality gaming|The intervention will include home-based exercise using the Oculus Quest 2. Participants will be prescribed two gaming goals to achieve across the 8-week intervention. The first goal will be to play with the Quest for at least ≥60 minutes, 5 days per week (Monday - Friday) across the 8-week intervention: a total of 300 minutes. Participants can achieve these goals through either single- or multiplayer gaming but will be prescribed to engage in online multiplayer or peer-to-peer gaming at least 2 days per week.
62228440|NCT05318079|NO_INTERVENTION|Wait-list Control|People who are randomized to the waitlist group will undergo 4-weeks of wait (habitual daily activities), followed by 8-weeks of VR intervention. People in the wait-group will be in the study for a total of 12 weeks.
62228441|NCT02447367|EXPERIMENTAL|JLP-1207, Fasted followed by fed|JLP-1207 dosing in the fasted state followed by fed dosing
62228442|NCT02447367|EXPERIMENTAL|JLP-1207, Fed followed by fasted|JLP-1207 dosing in the fed state followed by fasted dosing
62228443|NCT04259515|ACTIVE_COMPARATOR|Bukcberg|Buckberg cardioplegical solution administered antegrade and/or retrograde at 1-2ml/Kg for cardiac arrest induction. Arrest manteinance with antegrade and/or retrograde administration at 1-2ml/Kg every 15 to 20 minutes. Reperfusion dose with antegrade or retrograde administration at 15-20 ml/Kg before removing the aortic crossclamp.
62228444|NCT04259515|EXPERIMENTAL|Del Nido|Del Nido cardioplegic solution administered in a single dose at 15-20mg/Kg with a maximum dose of 1L of solution, administered antegrade or retrograde. In those patients in wich the crossclamping time exceed 90 to 120 minutes a manteinance dose of 500ml will be administered.
62228445|NCT03905954||Parkinson's Diagnosis|Usual care
62029935|NCT02624973|EXPERIMENTAL|F|HER2+ TP53 mutated
62029936|NCT02624973|EXPERIMENTAL|G|Triple negative breast cancer TP53 wt
62029937|NCT02624973|EXPERIMENTAL|H|Triple negative breast cancer TP53 mutated
62228446|NCT04227964|EXPERIMENTAL|Periodontal regeneration|Periodontal regeneration consisting of papilla preservation flaps, application of FDA approved CE marked periodontal regenerative devices, tooth splinting and root canal treatment as required.
62228447|NCT04227964|ACTIVE_COMPARATOR|Extraction and tooth replacement|Tooth extraction and replacement with a dental implant or a fixed partial denture following healing and reconstruction of the extraction area. Choice based on standard of practice.
62228448|NCT02054520|EXPERIMENTAL|Arm 1A HyperAcute®-Melanoma (HAM) + Ipilimumab|Arm 1A will receive ipilimumab at 3 mg/kg given every 3 weeks for 4 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
62228449|NCT02054520|ACTIVE_COMPARATOR|Arm 2A Ipilimumab Alone|Arm 2A will receive ipilimumab alone at 3 mg/kg every 3 weeks for a total of four doses.
62421168|NCT06703970|EXPERIMENTAL|Autologous Platelet Rich Plasma|\~3 milliliters (mL) injection of autologous PRP prepared with the Magellan Autologous Concentration System, ISTO Biologics
62591078|NCT03701841||PEG-rhG-CSF secondary prophylaxis|Patients receiving chemotherapy who had FN or dose-limited neutropenia receive PEG-rhG-CSF for secondary prophylaxis
62591079|NCT00004875||Standard Heparin|
62591080|NCT00004875||Enoxaprin|
62029938|NCT06669078|EXPERIMENTAL|NALIRINOX combined with PD-1 synchronous sequential SBRT group|Nal-IRI+Oxaliplatin+5- FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, SBRT is performed during the third and fourth cycle.
62804731|NCT04369313|OTHER|early cord clamping|umbilical cord clamping before 15 seconds
62804732|NCT01003041||lifestyle counseling|in the future parents will be advised to expose their infants to phonetic sounds in order to develop their phonetic categories in the future
62804733|NCT04748666|EXPERIMENTAL|3 PST sessions and no boosters|
62804734|NCT04748666|EXPERIMENTAL|3 PST sessions with monthly boosters for 6 months|
62029939|NCT06669078|EXPERIMENTAL|NALIRIFOX group|Nal-IRI+Oxaliplatin+5- FU, these drugs are given on d1, d15, 28 days as one cycle.
62804735|NCT04748666|EXPERIMENTAL|6 PST sessions, no boosters|
62421169|NCT06703970|ACTIVE_COMPARATOR|Corticosteroid|5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)
62804736|NCT04748666|EXPERIMENTAL|6 PST sessions with monthly boosters for 6 months|
62804737|NCT00264199|ACTIVE_COMPARATOR|1|
62804738|NCT00264199|PLACEBO_COMPARATOR|2|
62804739|NCT04581265|EXPERIMENTAL|nab-PTX, ifosfamide and cisplatin|albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin in the treatment of pediatric advanced, recurrent or refractory extracranial germ cell tumor.
62804740|NCT05356416|EXPERIMENTAL|Ischemic compression|Patients in Group B will receive a single session of ischemic compression technique for ischemic compression technique sustained pressure on the trigger points will be maintained for 30 seconds.
62228450|NCT02054520|EXPERIMENTAL|Arm 1B HyperAcute®-Melanoma (HAM) + nivolumab|Arm 1B will receive nivolumab alone at 3 mg/kg given every 2 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
62804741|NCT05356416|ACTIVE_COMPARATOR|Dry Needling|Patients in dry needling (DN) group will receive a single session of DN of 10 minutes with sterile needles insert on trigger points in scalene muscles as first twitch response will obtained needles will be manipulated in and out of the muscles to get 2 or 3 more local responses.
62804742|NCT02338635|EXPERIMENTAL|URSA group|Drug: Ursodeoxycholic acid Other Name: URSAⓇ (Daewoong Pharmaceutical Co., Ltd) Ursodeoxycholic acid (100 mg/tablet) 300 mg/day ( 100mg tid) for 6 months 3 times after meal
62804743|NCT02338635|PLACEBO_COMPARATOR|Placebo group|Placebo drug 1 tablet tid for 6 months
62804744|NCT00194805|EXPERIMENTAL|1|Subjects randomized into the treatment group received the computer treatment
62029940|NCT02647658|EXPERIMENTAL|GBC+PIPT|Guideline Based Care plus Psychologically Informed Physical Therapy (GBC+PIPT)
62029941|NCT02647658|ACTIVE_COMPARATOR|GBC|Guideline Based Care (GBC)
62029942|NCT04401579|EXPERIMENTAL|Remdesivir plus Baricitinib|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.
62804745|NCT02314663|EXPERIMENTAL|Intervention group|"COMBINED STRATEGY (a + b + c). Participants in the intervention group will be supplied with: a) printed matter; b) mobile-telephone text messages; and, c) self-report cards.~This group receive routine recommendations from their GPs, in accordance with current European clinical practice guidelines on the management of hypercholesterolaemia and cardiovascular risk"
62029943|NCT04401579|PLACEBO_COMPARATOR|Remdesivir plus Placebo|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.
62029944|NCT02812810|EXPERIMENTAL|active rTMS|
62029945|NCT02812810|PLACEBO_COMPARATOR|placebo rTMS|
62029946|NCT06198569|ACTIVE_COMPARATOR|Control Group|STRENGTH EXERCISE TRAINING
62029947|NCT06198569|EXPERIMENTAL|Study Group|PNF EXERCISE TRAINING
62029948|NCT02999776|ACTIVE_COMPARATOR|Standard of care|Daily self-administration of 1 to 5g Daivobet (Calcipotriol 50ug/g +Betamethasone, 0,5mg/g Gel) ointment, which is applied topically once per day for 8 weeks on one pre-selected randomized plaque.
62228451|NCT02054520|ACTIVE_COMPARATOR|Arm 2B Nivolumab alone|Arm 2B will receive nivolumab alone at 3 mg/kg given every 2 weeks
62421170|NCT04711512||Single Arm (All Participants)|Within this arm, participants are randomized to one of the interventions described below at each of 4 times per day.
62421171|NCT05243966||Myriad™|Ovine forestomach matrix sheet graft and morselized extracellular matrix
62421172|NCT06003673|EXPERIMENTAL|Neoadjuvant therapy group|Participants will receive a combination treatment of Tislelizumab, Lenvatinib, and Transarterial Chemoembolization (TACE).
62421173|NCT02780999|EXPERIMENTAL|Experimental group|It is a thumb orthotic that does not include wrist joint but includes the metacarpophalangeal joint.
62421174|NCT02780999|ACTIVE_COMPARATOR|Control group|It is a thumb orthotic that does not include wrist joint neither metacarpophalangeal joint.
62804746|NCT02314663|NO_INTERVENTION|Control group|This group receive routine recommendations from their GPs, in accordance with current European clinical practice guidelines on the management of hypercholesterolaemia and cardiovascular risk
62804747|NCT01982734|ACTIVE_COMPARATOR|Native curcumin|80 mg curcumin as native powder
62804748|NCT01982734|EXPERIMENTAL|Native curcumin plus phytochemicals|80 mg curcumin as native powder plus 80 mg sesamin, 40 mg naringenin, 40 mg ferulic acid and 40 mg xanthohumol
62804749|NCT01982734|EXPERIMENTAL|Curcumin micelles|80 mg curcumin incorporated into liquid micelles
62804750|NCT01982734|EXPERIMENTAL|Curcumin micelles plus phytochemicals|80 mg curcumin incorporated into liquid micelles plus 80 mg sesamin, 40 mg naringenin, 40 mg ferulic acid, 40 mg xanthohumol incorporated into micelles
62804751|NCT02374164|EXPERIMENTAL|Treatment Sequence ABC|Febuxostat extended release (XR) 80 mg, capsules, orally, once on Day 1 of Period 1 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.
62804752|NCT02374164|EXPERIMENTAL|Treatment Sequence BCA|Febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 3 after a high-fat meal.
62804753|NCT02374164|EXPERIMENTAL|Treatment Sequence CAB|Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.
62804754|NCT04019353||cf-DNA Collection|All patients undergoing kidney allograft biopsy for suspicion of an acute rejection episode will be approached for consent into the study. Patients who consent to the study will have the cf-DNA test drawn at time of biopsy to determine levels of cf-DNA. All consented patients will be followed for biopsy outcomes. Those whose biopsy shows acute rejection leading to treatment will have cf-DNA determination at 2, 4, 6, and 8 weeks post biopsy. Recipients with persistent high cf-DNA levels will undergo repeat biopsy at \~6 weeks after end of treatment per standard of care (this is not performed for purpose of the study, but for clinical care).
62029949|NCT02999776|EXPERIMENTAL|Laser plus etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
62804755|NCT00773162|PLACEBO_COMPARATOR|1|
62804756|NCT00773162|ACTIVE_COMPARATOR|2|
62228452|NCT02054520|EXPERIMENTAL|Arm 1C HyperAcute®-Melanoma (HAM) + pembrolizumab|Arm 1C will receive pembrolizumab at 2 mg/kg given every 3 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
62804757|NCT01095432||Main Study Group|All subjects who are undergoing a standard of care colonoscopy for flexible sigmoidoscopy and have a history of UC and agree to participate will be in the main study group.
62228453|NCT02054520|ACTIVE_COMPARATOR|Arm 2C Pembrolizumab alone|Arm 2C will receive pembrolizumab at 2 mg/kg given every 3 weeks
62421175|NCT01878500|EXPERIMENTAL|Intraoperative stereotactic imaging|Surgeon will use intraoperative stereotactic imaging with VectorVision® Cranial Guided Image System by Brainlab Inc. to assist in bladder exstrophy closure.
62804758|NCT04703088|EXPERIMENTAL|INTERVENTION GROUP - ONDANSETRON|2 mL of a solution of Ondansetron containing 2mg/ml in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
62421176|NCT02542722|ACTIVE_COMPARATOR|Control|General dietary and physical exercise recommendations
62421177|NCT02542722|EXPERIMENTAL|Intervention|Intensive intervention on dietary and physical exercise habits.
62029950|NCT02999776|ACTIVE_COMPARATOR|Laser alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
62029951|NCT01503034||Study cohort|This cohort is made up of pregnant women with a breast cancer diagnosed between 2000 and 2014.
62421178|NCT05875116|EXPERIMENTAL|Group I: virtual reality activities|The patient will practice the corresponding activities of the software indicated in the virtual reality equipment.
62421179|NCT05875116|EXPERIMENTAL|Group II: Modified Constraint-Induced Movement Therapy|"Patients will have the healthy upper limb fixed to the thorax with a sling and a horizontal shoulder immobilizer; The participants will practice physical and occupational therapy activities with the paretic upper limb."
62421180|NCT05875116|ACTIVE_COMPARATOR|Group III: Usual Physical and Occupational Therapy|The participants will practice physical and occupational therapy activities that are usually provided in the Medical Unit, without any restrictions on the upper extremities.
62591081|NCT02764801|EXPERIMENTAL|Contrast ultrasound arm|Patients receiving contrast-enhanced ultrasound for diagnosis of chemoembolization response.
62029952|NCT01503034||Compared cohort|This cohort is made up of non-pregnant women with a breast cancer diagnosed between 2000 and 2009.
62029953|NCT04082065|ACTIVE_COMPARATOR|conventional physical therapy|Myofacial release Stretching of hamstring and Piriformis
62228454|NCT02926079||Pregnant women diagnosed with gestational diabetes|
62228455|NCT02926079||Pregnant women with normal pregnancy|
62228456|NCT00519311|EXPERIMENTAL|School based health intervention|Educational intervention based on health diary + health check
62228457|NCT00519311|NO_INTERVENTION|Usual care|Normal school curriculum and usual medical care
62228458|NCT01313117|EXPERIMENTAL|Alpha lipoic acid|Oral administration three times daily (morning, mid-day, night)
62228459|NCT02913729|EXPERIMENTAL|radiotherapy in arm 1|pre-operative accelerated partial breast irradiation
62228460|NCT02913729|ACTIVE_COMPARATOR|radiotherapy in arm 2|post-operative accelerated partial breast irradiation
62421181|NCT05436184||Cincinnati IMPRINT birth cohort|mother-infant pairs enrolled at or after week 34 in pregnancy and followed over three flu seasons, up to four years of age.
62421182|NCT01453101|OTHER|Fludarabine, Melphalan, Bortezomib|
62591082|NCT00622661|OTHER|1|Normal weight
62591083|NCT00622661|OTHER|2|Overweight
62804759|NCT04703088|PLACEBO_COMPARATOR|CONTROL GROUP - NORMAL SALINE|2 mL of 0.9% Saline in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
62804760|NCT00443040|PLACEBO_COMPARATOR|Placebo|
62804761|NCT00443040|ACTIVE_COMPARATOR|Asimadoline 1.0 mg|Asimadoline 1.0 mg b.i.d.
62804762|NCT00443040|ACTIVE_COMPARATOR|Asimadoline 3.0 mg|Asimadoline 3.0 mg b.i.d.
62804763|NCT06271434|EXPERIMENTAL|Supplemented|"(n = 15), who will receive one capsule of a supplement called THYROX (Atlantic krill oil) four times a day. The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA - 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.~The supplementation period will be six weeks. Intervention: Drug: THYROX (Atlantic krill oil)."
62804764|NCT06271434|EXPERIMENTAL|Control|receiving placebo Intervention: Drug: Placebo
62804765|NCT03923790|EXPERIMENTAL|STOP model|Pharmacist evaluates patient prior to discharge and a nurse navigator contacts patient 72 hours after discharge. Patient receives educational packet and a blue tooth enabled BP monitor with an iPad. A video telehealth visit occurs 7 days after discharge attended by a nurse practitioner (NP) or MD , social worker (SW), and pharmacist. The NP and pharmacist review the BP data to determine the need for medication adjustment. The SW assesses the need for resources. BP is reviewed via an online portal every 2 weeks until average BP is \< 130/80mmHg, then monthly. Uncontrolled BP prompts a call from the pharmacist to discuss medication adherence and titration. Subsequent video telehealth visits occur 1 month, 3 months, and 5 months after enrollment.
62804766|NCT03923790|ACTIVE_COMPARATOR|Usual Care|Pharmacist evaluates patient prior to discharge and a nurse navigator contacts patient 72 hours after discharge. Patient receives educational packet.
62804767|NCT05255575||ertapenem treatment|
62804768|NCT01584141||Cases|Asian cases with lymphoid or myeloid neoplasma
62804769|NCT01584141||Controls|Controls with selected non-cancer diagnosis who were hospitalized in Hong Kong, Chengdu and Tianjin of Mainland China, and Taiwan
62804770|NCT00184795|EXPERIMENTAL|ALD 0.1|
62804771|NCT00184795|EXPERIMENTAL|ALD 0.25|
62804772|NCT00184795|PLACEBO_COMPARATOR|Placebo|
62804773|NCT04438694|ACTIVE_COMPARATOR|STANDARD OF COARE|Receiving SOC
62804774|NCT04438694|EXPERIMENTAL|STANDARD CP DOSE Adm (Two infusions)|Two infusions 48 hours apart
62804775|NCT00429949|EXPERIMENTAL|Dasatinib|"Dasatinib will be administered continuously at an oral dose of 70 mg BID on Days 1-28 of each 28 day cycle.~In patients with stable disease after 8 weeks on therapy the dasatinib will be increased to 100 mg BID on Days 1-28 on each 28 day cycle."
62804776|NCT03760991|EXPERIMENTAL|Insulin glargine (U300)|Insulin glargine (U300) (Gla-300) once daily for 26 weeks on top of any other antidiabetic treatment except other basal insulin
62804777|NCT05937763||Primary Care Paramedic (PCP) Block|A PCP will be staffed in the emergency department offload zone 3 days a week (Monday, Wednesday, and Friday) on a 10am - 10pm shift, in addition to the standard staffing model.
62228461|NCT03745482|EXPERIMENTAL|Mobilisations|"The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The plinth will rest on force plates to allow the authors to analyse the force placed through the vertebrae. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.~Following application of the mobilisations outcome measures including hamstring strength, sEMG activity and 3D motion analysis will take place."
62228462|NCT03745482|NO_INTERVENTION|Control|"The control condition will consist of the participant lying prone on a plinth for the same time if takes for intervention to be applied approximately 10 minutes.~Following the control condition outcome measures including hamstring strength, sEMG activity and 3D motion analysis will take place."
62228463|NCT02737709|EXPERIMENTAL|Paclitaxel and Carboplatin regimen|Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection. 21 days per cycle; 6 cycles in total.
62804778|NCT05937763||Registered Nurse (RN) Block|An experienced emergency department RN with triage training will be staffed in the emergency department offload zone 3 days a week (Monday, Wednesday, and Friday) in a 10am - 10pm shift, in addition to the standard staffing model
62804779|NCT05937763||Current Workflow Block|The currently hospitals staffing models of the emergency department offload zone.
62804780|NCT02264158|EXPERIMENTAL|Telmisartan high|
62804781|NCT02264158|EXPERIMENTAL|Telmisartan low|
62804782|NCT02264158|ACTIVE_COMPARATOR|Lacidipine high|
62804783|NCT02264158|ACTIVE_COMPARATOR|Lacidipine low|
62804784|NCT02264158|EXPERIMENTAL|Telmisartan+Lacidipine|
62804785|NCT02264158|PLACEBO_COMPARATOR|Placebo|
62804786|NCT04737278|EXPERIMENTAL|Cunermuspir|Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.
62804787|NCT04737278|PLACEBO_COMPARATOR|Placebo|Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm
62804788|NCT02356913|EXPERIMENTAL|Gum A|4 mg nicotine gum; single dose; chewed 30 minutes
62804789|NCT02356913|EXPERIMENTAL|Gum B|4 mg nicotine gum; single dose; chewed 30 minutes
62029954|NCT04082065|EXPERIMENTAL|cyriax lumber manipulation group|Myofacial Release stretching of hamstrings and Piriformis Cyriax Lumbar Manipulation Techniques
62804790|NCT02356913|EXPERIMENTAL|Gum C|4 mg nicotine gum; single dose; chewed 30 minutes
62804791|NCT02356913|ACTIVE_COMPARATOR|Nicorette Freshmint|4 mg nicotine gum; single dose; chewed 30 minutes
62804792|NCT02654548|EXPERIMENTAL|PCOS women and babies|Sebum output using Sebutape on post-partum PCOS women and new born babies.
62804793|NCT02654548|ACTIVE_COMPARATOR|Non-PCOS women and babies|Sebum output using Sebutape on post-partum non-PCOS women and new born babies.
62804794|NCT02776111||Healthy Controls|Participants in this group will have a one time blood sample taken.
62804795|NCT02776111||Kidney Transplant Group|Participants in this group have had a kidney transplant and blood samples will be obtained as described in study plan
62804796|NCT05296434||Control Group|Healthy volunteers undergoing MRI exam, ICG test and blood biochemical tests
62804797|NCT05296434||Child-Pugh A Group|Composed of patients with liver function of Child-Pugh A grade undergoing MRI exam, ICG test and blood biochemical tests
62804798|NCT05296434||Child-Pugh B Group|Composed of patients with liver function of Child-Pugh B grade undergoing MRI exam,ICG test and blood biochemical tests
62804799|NCT05296434||Child-Pugh C Group|Composed of patients with liver function of Child-Pugh C grade undergoing MRI exam
62228464|NCT01190514|EXPERIMENTAL|Bioequivalence and Food effect|
62228465|NCT00448123|PLACEBO_COMPARATOR|Placebo|Placebo
62804800|NCT04137913|EXPERIMENTAL|Music Group|Individuals in the music group will complete two assessment visit (pre-intervention and post-intervention). After their baseline visit, they will participate in a 6-week group music class, scheduled for 2 hours a day, 3 days a week. The daily music workshops will be led by a musician associated with the Rice Shepherd School of Music. Each week will be carefully scaled in difficulty, with the workshops becoming progressively more sophisticated. For instance, the first week's listening will focus on short and more familiar works such as instrumental etudes and folk songs. Gradually, the instructor will build towards symphonic movements, as well as more unfamiliar and experimental music. The course will culminate in creating a final composition.
62804801|NCT04137913|NO_INTERVENTION|Non-music group|Individuals in the non-music group will complete two assessment visits separated by 2-3 months. They will be asked not to participate in any other music-related courses during the time they are enrolled in the study. At the end of participation, participants will be given resources to seek out music classes.
62804802|NCT05238766|NO_INTERVENTION|Treatment as Usual|This arm does not receive any intervention. It will serve as a comparison for the experimental arm.
62804803|NCT05238766|EXPERIMENTAL|Treatment + DEAL|Parents in the Treatment plus Defuse Experience Accept Live (T+DEAL) arm will attend five 45-min DEAL sessions with a therapist. Across the five sessions, the therapist will 1) introduce caregivers to behavior change strategies that maximize contact with positive-maintaining contingencies related to adherence, while undermining the contingencies that maintain accommodation, and 2) provide caregivers with new treatment-related committed actions that are sensitive to positive changes in parent-child interactions.
62804804|NCT01693029|EXPERIMENTAL|HX575 epoetin alfa|HX575, recombinant human epoetin alfa
62804805|NCT01693029|ACTIVE_COMPARATOR|US-licensed epoetin alfa|US-licensed recombinant human epoetin alfa
62804806|NCT02803736|EXPERIMENTAL|Real acupuncture group|Patients in the real acupuncture group will receive true acupuncture 3 times a week for 4 weeks (12 sessions). A standardized prescription of six acupuncture points is used unilaterally. Needles are inserted and manipulated manually until needling sensation (de qi) is obtained, and are retained for 20 minutes with manual manipulation at 10 minutes. Acupuncturists are trained to inquire about specific needle sensations when providing true acupuncture.
62804807|NCT02803736|SHAM_COMPARATOR|Sham acupuncture group|Patients in the sham acupuncture group will receive sham acupuncture 3 times a week for 4 weeks (12 sessions).
62804808|NCT03897959|OTHER|Kohli vs Foley Study|Compare various performance characteristics of two urinary catheters.
62804809|NCT00701610||1|All infants born in our hospital between August 2007 and August 2009 will participate.
62591084|NCT05768763|EXPERIMENTAL|Precision Community Health|The Phase B precision community health intervention will consist of a three part intervention: 1) Community-enhanced reach activities 2) Person-centered care delivery; and, 3) Data system enhancement to improve reach and person-centered delivery
62804810|NCT03045874||30 parent-child dyads|Stratified purposive sampling will assure representation proportional to the minority representation in the community and will include equal subsamples (15 families each) of families with children 6-18 months of age and children aged 19-36 months.
62804811|NCT03045874||30 primary care providers|"Investigators will purposively recruit 30 primary care providers to assure proportional representation of physicians and NPs with a snowball method. The sample sizes should be sufficient to achieve saturation of the data for qualitative analyses, but we will recruit more participants if saturation is not obtained with the planned sample."
62804812|NCT03045874||focus groups|The investigators will hold separate focus groups for parents of the two age groups and clinicians. We anticipate conducting approximately 6 focus groups with 8-10 participants in each to review and refine the sleep program.
62804813|NCT03045874||22 parent-child dyads|The investigators will conduct feasibility testing of a 3 week sleep health promotion intervention. The intervention will be delivered to parents of children ages 12-36 months enrolled in one childcare center.
62804814|NCT03045874||5 childcare teachers|Teachers will be trained to deliver a brief sleep health intervention
62804815|NCT02813889|EXPERIMENTAL|Infants|Two populations will be involved in testing in the SmarToyGym: 1. Infants exhibiting typical development between 3 months and 11 months of age 2 . Infants exhibiting atypical development (at-risk for neuromotor delay) between 3 months and 11 months of age.
62804816|NCT05288647|EXPERIMENTAL|Group A|Patients treated with four computer-guided sodium hyaluronate injections in superior TMJ space.
62804817|NCT05288647|ACTIVE_COMPARATOR|Group B|Patients treated with four conventional sodium hyaluronate injections in superior TMJ space.
62804818|NCT01806220|ACTIVE_COMPARATOR|biopsy of retrocrycoid laryngeal mucosa|"During upper digestive endoscopy a biopsy specimen of the retrocrycoid laryngeal mucosa was obtained with a forceps introduced by the working channel of the scope.~Intervention: biopsy of retrocrycoid laryngeal mucosa"
62029955|NCT03301051|EXPERIMENTAL|Quadrivalent VLP Vaccine|Participants received one intramuscular (IM) injection of 0.5 mL of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.
62029956|NCT03301051|PLACEBO_COMPARATOR|Placebo|Participants received one IM injection of 0.5 mL of placebo on Day 0.
62228466|NCT00448123|ACTIVE_COMPARATOR|Tamsulosin|Intervention - Tamsulosin
62228467|NCT05729178||Pediatric acute lymphoblastic leukemia patients|pediatric patients of 1-16 years old affected by acute lymphoblastic leukemia
62228468|NCT05729178||healthy subjects|cord blood from healthy donors that cannot be used for clinical purposes
62591085|NCT05768763|ACTIVE_COMPARATOR|Control|Standard of Care
62228469|NCT02705560|EXPERIMENTAL|Cow´s milk (3.9% fat, pasteurized)|Cow´s milk (3.9% fat, pasteurized) Single dose, 600 ml milk
62228470|NCT02705560|EXPERIMENTAL|Hard, yellow cheese|"Hard, yellow cheese Single dose, 100 g cheese~+ 500 ml water"
62228471|NCT02705560|ACTIVE_COMPARATOR|Soy based drink|Soy based drink Single dose, 600 ml soy drink (soy drink + plant based cream)
62228472|NCT00867282|EXPERIMENTAL|Treatment A|
62228473|NCT00867282|ACTIVE_COMPARATOR|Treatment B|
62228474|NCT03728777|PLACEBO_COMPARATOR|Placebo|
62228475|NCT03728777|EXPERIMENTAL|Resveratrol|Over the counter supplement
62228476|NCT00690820|EXPERIMENTAL|A|
62228477|NCT00690820|PLACEBO_COMPARATOR|B|
62228478|NCT02926625|ACTIVE_COMPARATOR|Conditional follow-up|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, ie. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
62591086|NCT02009124|EXPERIMENTAL|Stem cell|autologous bone marrow mononuclear cell transplantation
62804819|NCT01806220|ACTIVE_COMPARATOR|biopsy of distal esophagus mucosa|"during upper digestive endoscopy a biopsy specimen of the distal esophageal mucosa was obtained~Intervention:biopsy of distal esophagus mucosa"
62804820|NCT05927844|EXPERIMENTAL|Treatment ARM1|Drugs1：XH30002 Capsual 300mg，Qd，28d; Drug2：Afatiinb tablets 30mg，Qd，28d
62804821|NCT05927844|EXPERIMENTAL|Treatment ARM2|Drugs1：XH30002 Capsual 400mg，Qd，28d; Drug2：Afatiinb tablets 30mg，Qd，28d
62804822|NCT02210728|ACTIVE_COMPARATOR|Medication only|Stimulant medication (methylphenidate or amphetamine product approved for clinical use in Canada), with dose optimized for each patient based on report of efficacy and side effects.
62804823|NCT02210728|ACTIVE_COMPARATOR|Cognitive behavioral therapy + medication|Patients are first titrated to an optimal dose of stimulant medication. They then undergo the 12 weeks of group cognitive behavioral therapy.
62804824|NCT02210728|EXPERIMENTAL|Cognitive behavioral therapy alone|12 weeks of structured group cognitive behavioral therapy, focusing on acquisition of skills in organization, time management, goal attainment, cognitive restructuring, stress management, anger management, impulse control, self-esteem, and relationship management.
62804825|NCT05072392|EXPERIMENTAL|Foley-assisted|"The tip of the nasal endotracheal tube will be telescoped onto a 16g Foley catheter. If a ballooned catheter is used then the inflation port may be cut off prior to use. The catheter tip is then fed through the pre-selected primary nare, until the tip of the endotracheal tube is in the oropharynx. The catheter is then removed from the tip of the nasal endotracheal tube through the mouth and disposed of. If the nasal endotracheal tube is inappropriately sized, a half size above or below may be used. If difficult to pass, the anesthetist may opt to use the other side nare.~Following this, the anesthetist will complete the rest of the intubation as usual."
62804826|NCT05072392|NO_INTERVENTION|Control|"The endotracheal tube is passed through the pre-selected primary nare, until the tip of the endotracheal tube is in the oropharynx. If the nasal endotracheal tube is inappropriately sized, a half size above or below may be used. If difficult to pass, the anesthetist may choose to use the other side nare.~Following this, the anesthetist will complete the rest of the intubation as usual."
62804827|NCT01638663|ACTIVE_COMPARATOR|Tolvaptan|Oral administration of 15 mg Tolvaptan on each examination day.
62804828|NCT01638663|PLACEBO_COMPARATOR|Placebo|Oral administration of 15 mg Unikalk tablet on each examination day.
62228479|NCT02926625|EXPERIMENTAL|Systematic follow-up arm|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should come back for a systematic follow-up visit after 2 days, even if the child has recovered.
62228480|NCT02802826|EXPERIMENTAL|Tailored Exercise Prescription|"Participants will have a discussion on the 'My Exercise Prescription' booklet on the benefits of increasing levels of physical activity. They will be encouraged to read this in more detail and guided through its completion. The participant will receive an exercise prescription using the Pre-Intervention Assessment Tool (PIAT) and following discussion with the participant on a realistic and achievable starting point.~The booklets provided will guide participants through the exercise programme which is a graduated walking-based activity intervention. Both booklets provide participants with a suggested starting point for walking distance per week based on their PIAT score as well as motivational and behaviour change strategies to encourage participation."
62228481|NCT02802826|NO_INTERVENTION|Standard Care|No sham or placebo conditions will be used in the study. At visit 1 standard care participants will be given the Standard Care Information Sheet and asked to simply continue with standard care.
62228482|NCT03794362||Local Anesthetics|Lidocaine
62591087|NCT02009124|NO_INTERVENTION|Control|Stem cell therapy is not done for this group of spinal cord injury patients
62591088|NCT06173635|OTHER|Maxi Move 5|24 healthy volunteers will evaluate all 5 devices
62591089|NCT03929601|ACTIVE_COMPARATOR|Rituximab-pvvr followed by Abatacept|"Rituximab-pvvr will be given by IV infusion over at least 3 hours, at a dose of 375mg/m2 on four visits each one week apart, starting at Week 0 of the study.~Abatacept will be given by a subcutaneous formulation weekly for 20 months, beginning at Week 16 (Month 4) of the study. Dosing will be determined by weight: Up to 25 kg: 50 mg (0.4 mL); 25 to \<50 kg receive 87.5 mg (0.7 mL), and \> 50 kg receive 125 mg (1.0 mL)."
62591090|NCT03929601|PLACEBO_COMPARATOR|Rituximab-pvvr followed by Placebo|"Rituximab-pvvr will be given by IV infusion over at least 3 hours, at a dose of 375mg/m2 on four visits each one week apart, starting at Week 0 of the study.~Placebo will be given by a subcutaneous isotonic saline formulation weekly for 20 months, beginning at Week 16 (Month 4) of the study. Dosing will be match to active comparator, determined by weight: Up to 25 kg: 0.4 mL; 25 to \<50 kg rec 0.7 mL, and \> 50 kg receive 1.0 mL."
62228483|NCT03794362||N-methyl-D-aspartate Antagonists|Ketamine
62228484|NCT03794362||SNRIs|Duloxetine
62228485|NCT03794362||Alpha-2 adrenergic agonists|Dexmedetomidine
62228486|NCT03794362||Oral Analgesics|NSAIDs, acetaminophen
62228487|NCT03794362||Non-pharmacologic interventions|Acupuncture
62228488|NCT02697292|PLACEBO_COMPARATOR|Placebo/Normal Saline Group|Subjects will receive placebo for 4 infusions. After completion of the blinded phase, subjects will receive IVIG for 4 infusions. Subjects will maintain their stable dose of antiepileptic meds.
62228489|NCT02697292|ACTIVE_COMPARATOR|Intravenous Immunoglobulin (IVIG) (Gamunex-C) Group|Subjects will receive IVIG for 4 infusions. Subjects will maintain their stable dose of antiepileptic meds.
62228490|NCT06046768|EXPERIMENTAL|Child with oral feeding disorder(s)|Child (boy or girl) with oral feeding disorder(s) diagnosed by a speech therapist as part of a speech therapy assessment.
62228491|NCT03253874|EXPERIMENTAL|Intervention Site-LAC+USC Medical Center|In this arm or study site,new guidelines are disseminated to all residents attending and faculty physicians within the department of Ophthalmology and Anesthesiology. New guidelines call for the across the board elimination of pre-operative testing and visits for patients undergoing cataract surgery.
62228492|NCT03253874|NO_INTERVENTION|Control Site--Harbor-UCLA Medical Center|In this arm or study site, patients will undergo standard of care for cataract surgery without any new guidelines.
62228493|NCT05898243||Humeral anterior dislocation|Patients presenting a first episode of humeral anterior dislocation and who are over 40 years old.
62228494|NCT02824666|EXPERIMENTAL|0.5 mg/kg|• Cohort 1: ATI-9242 - Single IV bolus dose of 0.5 mg/kg
62228495|NCT02824666|EXPERIMENTAL|ATI-9242 1.0 mg/kg|• Cohort 2: ATI-9242 - Single IV bolus dose of 1.0 mg/kg
62228496|NCT02926976|ACTIVE_COMPARATOR|risperidone with clozapine|risperidone, dosage form: 1 mg, dosage and frequency:3.0\~6.0 mg/d; clozapine, dosage and frequency:300\~600 mg/d; duration: 8 weeks
62228497|NCT02926976|ACTIVE_COMPARATOR|aripiprazole with clozapine|aripiprazole, dosage form: 5 mg, dosage and frequency:15\~30 mg/day; clozapine, dosage and frequency:300\~600 mg/d; duration: 8 weeks
62228498|NCT02926976|ACTIVE_COMPARATOR|sodium valproate with clozapine|sodium valproate, dosage form: 250 mg, dosage and frequency:600\~1200 mg/day; clozapine, dosage and frequency:300\~600 mg/d; duration: 3 months.
62228499|NCT02926976|ACTIVE_COMPARATOR|clozapine|only clozapine, dosage and frequency:300\~600 mg/d;
62228500|NCT02926976|ACTIVE_COMPARATOR|Modified electroconvulsive therapy with clozapine|10 times MECT for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.
62228501|NCT02926976|ACTIVE_COMPARATOR|Magnetic seizure therapy with clozapine|10 times MST for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.
62228502|NCT02343055|EXPERIMENTAL|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
62228503|NCT02343055|PLACEBO_COMPARATOR|Usual Care|A Certified Respiratory Educator (CRE) will meet with subjects to obtain a detailed COPD history and do a breathing test. Subjects will receive COPD care as usually provided by their physician.
62228504|NCT01458223|ACTIVE_COMPARATOR|Control|24 hours post-operative antibiotics
62228505|NCT01458223|EXPERIMENTAL|experimental|72 hours of post-operative antibiotics
62591091|NCT01539772||Becker|"BMD participants over 4 years of age with in-frame deletions in the dystrophin gene.~."
62228506|NCT04628819|EXPERIMENTAL|Babybiane Imedia|Patients receive Babybiane Imedia once daily during seven days.
62228507|NCT04628819|PLACEBO_COMPARATOR|Placebo|Patients receive a placebo with the same consistency and taste as the Babybiane Imedia once daily during seven days.
62228508|NCT01324440|EXPERIMENTAL|V710 without MAA|
62228509|NCT01324440|ACTIVE_COMPARATOR|V710 with MAA|
62228510|NCT00007345|EXPERIMENTAL|Peripheral T-cell Lymphoma (PTCL)|Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m\^2 and at 17.5 mg/m\^2 on days 1, 8, and 15 of a 28 day cycle.
62228511|NCT00007345|EXPERIMENTAL|Cutaneous T-cell Lymphoma (CTCL)|Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m\^2 and at 17.5 mg/m\^2 on days 1, 8, and 15 of a 28 day cycle.
62228512|NCT02709915|EXPERIMENTAL|Breakfast Diet (Bdiet)|The Bdiet will consist in 3 meals with distribution of calories: breakfast 50%, lunch 33% and dinner 17%.
62228513|NCT02709915|ACTIVE_COMPARATOR|6 small meals diet (6Mdiet)|The 6Mdiet will consist on 6 meals (breakfast, lunch and dinner and 3 snacks) with distribution of calories: breakfast 15%, lunch 25%, dinner 30% and 10% each of the three snacks.
62228514|NCT04078412||NTM pulmonary disease|Cohort Description: adults NTM pulmonary disease patients diagnose by criteria of American thoracic society guideline
62228515|NCT01045395|PLACEBO_COMPARATOR|Corn starch, 90mg/d|Corn starch, 90mg/d
62228516|NCT01045395|EXPERIMENTAL|Unique Marine Algae Concentrate (UMAC). 90mg/d|
62591092|NCT04895462||Ischemic Stroke and COVID-19|Ischemic stroke patients with COVID-19 receiving acute recanalization treatment (intravenous thrombolysis and/or endovascular treatment)
62029957|NCT06535451||Screening|Current smokers (\>20 pack-years) or have quit within the past 15 years, non-smokers exposed to wood smoke more than 100 hours/year, or participants diagnosed with Chronic Obstructive Pulmonary Disease (COPD).
62029958|NCT01278329|EXPERIMENTAL|Music|"Mothers in the music group were provided a pre-recorded Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India) with a running duration of approximately 50 minutes and a cassette player with headphones. They were asked to listen to the recorded music daily in the evening just before going to the bed with a minimum of ambient noise."
62029959|NCT01278329|NO_INTERVENTION|Control|Standard routine ante-natal care.
62029960|NCT01192906|EXPERIMENTAL|1|
62029961|NCT01192906|EXPERIMENTAL|2|
62029962|NCT01192906|PLACEBO_COMPARATOR|3|
62228517|NCT01045395|EXPERIMENTAL|Golden brown algae, 90mg/d|
62228518|NCT01137968|EXPERIMENTAL|imetelstat plus standard of care|imetelstat plus standard of care (bevacizumab or observation)
62228519|NCT01137968|OTHER|Standard of care|Bevacizumab or observation
62228520|NCT04211428||Bipolar Disorder|Patients with bipolar disorder
62228521|NCT00907790|EXPERIMENTAL|Comprehensive Self-Management (CSM)|"Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS~--------------------------------------------------------------------------------"
62228522|NCT00907790|OTHER|Usual Care (Control Group)|Includes the usual care provided by the person and their health care provider.
62228523|NCT04733742|EXPERIMENTAL|Conbined treatment group|intravenous tenecteplase bridging with endovascular treatment
62228524|NCT04733742|ACTIVE_COMPARATOR|Endovascular treatment alone group|endovascular treatment alone
62591093|NCT04895462||Control group: Ischemic Stroke without COVID-19|Ischemic stroke patients without COVID-19 receiving acute recanalization treatment (intravenous thrombolysis and/or endovascular treatment)
62029963|NCT02124967|EXPERIMENTAL|Exercise|A one hour exercise session which includes both aerobic activity and resistance training
62029964|NCT06670534|EXPERIMENTAL|low dose group|
62029965|NCT06670534|EXPERIMENTAL|median dose group|
62228525|NCT01959516|EXPERIMENTAL|Sequence A ⇒ B|Participants will receive sequence A = glycopyrronium + placebo to tiotropium during 28 days, followed by a 14 day washout period, then sequence B= tiotropium + placebo to glycopyrronium for 28 days.
62228526|NCT01959516|EXPERIMENTAL|Sequence B ⇒ A|Participants will receive sequence B= tiotropium + placebo to glycopyrronium during 28 days, followed by a 14 day washout period, then sequence A= glycopyrronium + placebo to tiotropium for 28 days.
62228527|NCT00406653|EXPERIMENTAL|1|"4 arms for induction period~2 arms for maintenance period"
62228528|NCT00406653|PLACEBO_COMPARATOR|2|"4 arms for induction period~2 arms for maintenance period"
62228529|NCT00406653|OTHER|abatacept|1 arm for open-label extension phase
62228530|NCT03183700|OTHER|Control arm 1|The women will receive the usual recall with a new invitation letter with a prefixed appointment.
62228531|NCT03183700|EXPERIMENTAL|Intervention arm 2|Dry one, where FloqSwab, with which perform the sampling is contained and will be preserved after sampling in a tube without preservation solutions
62228532|NCT03183700|EXPERIMENTAL|Intervention arm 3|Wet one in which, after sampling, the FloqSwab, will be dissolved in preservation solutions.
62029966|NCT06670534|EXPERIMENTAL|high dose group|
62029967|NCT06670534|ACTIVE_COMPARATOR|active comparator group|
62029968|NCT06670807|ACTIVE_COMPARATOR|Experimental group|Probiotic formulation that includes L. plantarum CECT 7481, L. plantarum CECT 7485 Y L. brevis CECT7480
62228533|NCT02578862|EXPERIMENTAL|Total Intravenous|Intravenous propofol for maintenance of anesthesia
62228534|NCT02578862|ACTIVE_COMPARATOR|Inhaled Anesthetic|Inhaled volatile anesthetic for maintenance of anesthesia
62228535|NCT02733393|EXPERIMENTAL|SPG Block|
62228536|NCT02912325|OTHER|FaseMetS ® a food supplement|Daily administration: 2 tablets FaseMETS a day
62591094|NCT04923581|EXPERIMENTAL|Condition 1|Participants will receive the constant component only.
62591095|NCT04923581|EXPERIMENTAL|Condition 2|Participants will receive the constant component and storytelling videos .
62029969|NCT06670807|PLACEBO_COMPARATOR|Control Group|Placebo comparator arm with identical pharmaceutical form and aspect, containing microcrystalline cellulose
62029970|NCT01914926|ACTIVE_COMPARATOR|Metoprolol Study Group|Patients Receiving metoprolol administered at a dose of 0.15 mg/kg (to a maximum dose of 10 mg)
62029971|NCT01914926|ACTIVE_COMPARATOR|Diltiazem Study Group|Patients receiving diltiazem administered parenterally at a dose of 0.25 mg/kg (to a maximum dose of 30 mg)
62029972|NCT03257462|EXPERIMENTAL|Cohort A|The first cohort of 9 patients will be administered SPR001 at dose strength of Dose A daily for 2 weeks, and escalating through Dose B per day for 2 weeks and Dose C per day for 2 weeks.
62029973|NCT03257462|EXPERIMENTAL|Cohort B|Cohort B will begin enrollment after Cohort A has been fully enrolled. Starting dose selection and the stepwise dosing paradigm for Cohort B will be determined by an interim review of safety and PK/PD data from from Cohort A.
62228537|NCT05001594|NO_INTERVENTION|Usual care+ Sham device|"Each participant will go through the normal rehabilitation process that follows ACL reconstruction+ a sham device used in the same was as the intervention group.~The sham device will look the same, will gave the same pressure around the leg, but will not vibrate."
62228538|NCT05001594|EXPERIMENTAL|Usual care+ knee vibratory device|Each participant will go through the normal rehabilitation process that follows ACL reconstruction. Additionally, each participant will receive the active device that applies non-invasive vibrational stimulation to the leg for two months, and will be asked to wear it during ambulation for at least an hour per day.
62228539|NCT05001594|NO_INTERVENTION|Normative data|"Healthy participants will go through one session of the full protocol (excluding blood tests):~* Questionnaires (IKDC, TSK, GAD-7).~* Biomechanical analysis during walking, stair ambulation, and hoping.~* Quadriceps and Hamstring strength testing"
62228540|NCT01520493|EXPERIMENTAL|Exercise|All patients are subject to this Arm.
62228541|NCT04641494|PLACEBO_COMPARATOR|Placebo|28 subject received 2 capsules 3times a day for 12 weeks Each capsule contain 1gm (High Oleic Acid Safflower oils)
62228542|NCT04641494|ACTIVE_COMPARATOR|CLA group|Participants received 2 capsules3 times a day for 12 weeks Each capsule is 1 gm and it provided 0.75 gm CLA in a 50:50 mixture
62228543|NCT02057978||EXCEL DES|Use EXCEL DES implatationas as control group,Implant DES for CAD cases
62228544|NCT02057978||EXCEL-II DES|EXCEL-II DES implantation as control group,Implant DES for CAD cases
62228545|NCT03682549||HCV positive Patients|"patients will be recruited from the outpatient's viral hepatitis clinic~The patients will be diagnosed as HCV positive through (antiHCV-Ab) and (HCV-PCR) tests"
62228546|NCT03682549||Successfully treated former HCV patients|Patients formerly diagnosed as HCV positive who received DAA treatment successfully.
62228547|NCT03682549||Normal Individuals|healthy volunteers recruited from the outpatient clinic of the Faculty of Dentistry- Cairo University
62228548|NCT04100642|ACTIVE_COMPARATOR|1% Hemay808 apply to 25%BSA|8 subjects use 1% Hemay808
62228549|NCT04100642|EXPERIMENTAL|3% Hemay808 apply to 25%BSA|8 subjects use 3% Hemay808
62228550|NCT04100642|EXPERIMENTAL|3% Hemay808 apply to 55%BSA|6 subjects use 3% Hemay808
62228551|NCT04100642|EXPERIMENTAL|7% Hemay808 apply to 25%BSA|8 subjects use 7% Hemay808
62228552|NCT04100642|PLACEBO_COMPARATOR|placebo apply to 25%BSA|6 subjects use placebo apply to 25%BSA
62228553|NCT04100642|PLACEBO_COMPARATOR|placebo apply to 55%BSA|2 subjects use placebo apply to 55%BSA
62228554|NCT00594360|ACTIVE_COMPARATOR|1|
62228555|NCT01047423|EXPERIMENTAL|Simvastatin|40mg Simvastatin once daily for 12 weeks followed by 4 week washout period followed by placebo for 12 weeks
62228556|NCT01047423|PLACEBO_COMPARATOR|Placebo|Placebo for 12 weeks followed by 4 week washout period followed by 40mg Simvastatin once daily for 12 weeks
62228557|NCT05560971|ACTIVE_COMPARATOR|Palmitoleic acid|The treatment arm will receive Palmitoleic acid (POA) supplement as Provinal® 420 mg capsules with at least 90% pure POA Ethyl Ester (less than 1% palmitic acid). Participants will be asked to consume 2 Provinal® 420 mg capsules twice a day for 8 weeks.
62228558|NCT05560971|PLACEBO_COMPARATOR|Placebo|The placebo is a medium chain fatty acid in triglyceride form. The placebo has no shown health effects, neither beneficial or detrimental. Participants will be asked to consume 2 placebo capsules daily twice a day for 8 weeks.
62228559|NCT04990479|EXPERIMENTAL|Cohort 1a|Cohort 1a: 3 patients (expandable to 9) with unresectable stage III / IV Cutaneous Melanoma.
62029974|NCT03257462|EXPERIMENTAL|Cohort C|Cohort C will begin enrollment after Cohort B has been fully enrolled. Starting dose selection and the stepwise dosing paradigm for Cohort C will be determined by an interim review of safety and PK/PD data from from Cohort A and B.
62029975|NCT06313762|EXPERIMENTAL|Intervention Group|
62029976|NCT06313762|ACTIVE_COMPARATOR|Control Group|
62029977|NCT00925158|EXPERIMENTAL|Surgical instrument (DAME)|Surgical dissector instrument created to malar elevation.
62029978|NCT03772080|EXPERIMENTAL|Early counseling of prematurity in high-risk pregnancies|
62029979|NCT03772080|NO_INTERVENTION|Standard counseling of prematurity in high-risk pregnancies|
62029980|NCT00810134|OTHER|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
62029981|NCT00810134|OTHER|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
62029982|NCT03196648|EXPERIMENTAL|Gingival health formulation in accelerating device|The interventional gingival health formulation is applied to the participant's mouth by means of an intra-oral accelerating device for a single eight-minute application, daily. Participants were instructed to brush their teeth with an OTC toothpaste twice daily, morning and night.
62029983|NCT03196648|EXPERIMENTAL|Gingival health formulation on a toothbrush|The interventional gingival health formulation is applied to the participant's mouth by means of a toothbrush and OTC toothpaste, together with the formulation in equal amounts, for two-minute applications twice daily, morning and night.
62029984|NCT03196648|ACTIVE_COMPARATOR|Control group (Split mouth design)|The control group did not receive the interventional gingival health formulation. Participants were instructed to brush their teeth with a toothbrush and OTC toothpaste twice daily, morning and night. In addition, participants were instructed to floss only half of their mouth daily, having the non-flossed half serve as an untreated comparative control of toothbrushing alone.
62228560|NCT04990479|EXPERIMENTAL|Cohort 2a|Cohort 2a:13 patients with unresectable stage III / IV Cutaneous Melanoma.
62228561|NCT04990479|EXPERIMENTAL|Cohort 2b|Cohort 2b: 12 patients with stage IV NSCLC (PDL1≥ 50%).
62591096|NCT04923581|EXPERIMENTAL|Condition 3|Participants will receive the constant component and oral health promotion messages.
62804829|NCT05077800|EXPERIMENTAL|Safety Run-In: FOLFIRINOX + 9-ING-41 + Losartan|"The study will begin with a Safety Run-In phase to establish the side effects from the study treatment to its safety before beginning the main part of the study, six (6) participants will receive 1-2 cycles of:~* FOLFIRINOX~  * 5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle~ * Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle~ * Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle~ * Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle~* 9-ING-41 on days on days 1, 3, 8, and 11 of every 14-day cycle~* Losartan daily of every 14-day cycle."
62804830|NCT05077800|EXPERIMENTAL|FOLFIRNINOX|"The study will be conducted in three parts depending on participant disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.~For initial complete therapy, participants will receive FOLFIRINOX as follows:~* 5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle up to 12 cycles (24 weeks)~* Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~* Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~* Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~For Maintenance therapy, participants will receive FOLFIRINOX as follows:~* 5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression~For Complete Therapy Round 2, participants will repeat initial complete therapy of FOLFIRINOX until further disease progression"
62804831|NCT05077800|EXPERIMENTAL|FOLFIRINOX + Losartan|"The study will be conducted in three parts depending on participant disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.~For initial complete therapy:~* FOLFIRINOX~  * 5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle up to 12 cycles (24 weeks)~ * Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~ * Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~ * Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~* Losartan daily up to 12 cycles (24 weeks)~For Maintenance therapy:~* 5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression~* Losartan daily until disease progression~For Complete Therapy Round 2, participants will repeat initial complete therapy of FOLFIRINOX + Losartan until further disease progression"
62804832|NCT05077800|EXPERIMENTAL|FOLFIRINOX + 9-ING-41|"The study conducted in 3 parts depending on disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.~For initial complete therapy:~* FOLFIRINOX~  * 5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle up to 12 cycles (24 weeks)~ * Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~ * Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~ * Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~* 9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle up to 12 cycles (24 weeks)~For Maintenance therapy:~* 5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression~* 9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle until disease progression~For Complete Therapy Round 2, repeat of initial complete therapy until further disease progression"
62421183|NCT04824300|ACTIVE_COMPARATOR|erector spinae plane block group|All patients were monitored with standard monitoring (electrocardiography (ECG), noninvasive blood pressure, peripheral oxygen saturation (SpO2)), bispectral index (BIS, Medtronic, Mineapolis) and ANI (analgesia nociception index) -90-120 min) data were recorded.Group ESPB was applied before general anesthesia by the same anesthesiologist with block experience. In the sitting position, using an ultrasound-guided linear probe (6-13 MHz) on the side to be operated, T3 is marked 3 cm from the lateral of the spinous processes and with the in-plane technique, a 22G block needle (100mm, B-Braun, Germany) in the cranio-caudal direction first After it was observed that the erector spina muscle was separated from the transverse process with -2 ml normal saline, 20 ml 0.5% bupivacaine and 100 mg lidocaine were administered. And the drug was found to spread to the craniocaudal line at the ESP on ultrasound.Postoperative pain of the patients was evaluated using VAS (visual analogue scale).
62421184|NCT04824300|NO_INTERVENTION|non block control group|All patients were monitored with standard monitoring (electrocardiography (ECG), noninvasive blood pressure, peripheral oxygen saturation (SpO2)), bispectral index (BIS, Medtronic, Mineapolis) and ANI (analgesia nociception index) -90-120 min) data were recorded.15 minutes before the end of the surgery, 1 gr paracetamol and 100 mg tramadol were given to the control group. Postoperative pain of the patients was evaluated using VAS (visual analogue scale).
62421185|NCT02321215|NO_INTERVENTION|Control|Usual care: This group will receive usual care from their physician without any special focus on education. At the end of the study period, patients that were assigned to the control group will receive the booklet at home and be offered two education sessions by phone or in-person if the patient is willing to return to the hospital.
62421186|NCT02321215|ACTIVE_COMPARATOR|Education Intervention|Introductory disease education: This group will attend two one-on-one education sessions. The educational content will be standardized and a checklist will be used to ensure that all topics are addressed. The sessions will focus on enhancing self-efficacy in areas that are thought to be important to individuals who recently had an AECOPD.
62591097|NCT04923581|EXPERIMENTAL|Condition 4|Participants will receive the constant component, oral health promotion messages, and storytelling videos.
62591098|NCT04923581|EXPERIMENTAL|Condition 5|Participants will receive the constant component and motivational interview session.
62591099|NCT04923581|EXPERIMENTAL|Condition 6|Participants will receive the constant component, motivational interview session, and storytelling videos.
62228562|NCT04309136|EXPERIMENTAL|Neoadjuvant Anlotinib|
62228563|NCT02417402|ACTIVE_COMPARATOR|Untrained Physical Therapists|The patients allocated to the Control group will be treated by physical therapists who did not receive any training about clinical practice guidelines and pain management. These patients will receive the usual care from their physical therapists.
62228564|NCT02417402|EXPERIMENTAL|Trained Physical Therapists|The patients allocated to the Experimental group will be treated by physical therapists who received training about clinical practice guidelines and pain management.
62029985|NCT03721991|ACTIVE_COMPARATOR|GABA|gamma Amino butyric acid (GABA) food supplement with 6 g per day
62029986|NCT03721991|PLACEBO_COMPARATOR|PLACEBO|Matching placebo capsules to GABA
62029987|NCT01178853|EXPERIMENTAL|Pitavastatin/Rosuvastatin|
62228565|NCT00282204|NO_INTERVENTION|Control|Usual care control
62228566|NCT00282204|EXPERIMENTAL|Hypnosis + CD|Hypnosis plus audio cd on hypnosis
62228567|NCT00282204|ACTIVE_COMPARATOR|Audio CD on Hypnosis|Audio CD on hypnosis sessions weekly on three occasions after 34 weeks gestation
62421187|NCT05654103|ACTIVE_COMPARATOR|surgAVF|Participant will undergo fistula creation through surgical means, which requires undergoing general anesthesia and opening the skin to create the fistula.
62421188|NCT05654103|ACTIVE_COMPARATOR|endoAVF|Participant will undergo fistula creation through endovascular surgical means, which does not require general anesthesia and is created by using a device that goes through the skin to create the fistula. The two devices that are currently FDA approved and used to create the endoAVF are the WavelinQ™ EndoAVF System and the Ellipsys® Vascular Access System.
62421189|NCT00741117|ACTIVE_COMPARATOR|Low Bilirubin Group|Low Bilirubin Group: subjects with a bilirubin level less than or equal to 10 mg/dl
62591100|NCT04923581|EXPERIMENTAL|Condition 7|Participants will receive the constant component, motivational interview session, and oral health promotion messages.
62591101|NCT04923581|EXPERIMENTAL|Condition 8|Participants will receive the constant component, motivational interview session, oral health promotion messages and storytelling videos
62591102|NCT04843124|EXPERIMENTAL|Intervention group|Remote hearing aid adjustment. All participants in this group are offered hearing aids possible to adjust remotely.
62591103|NCT04843124|ACTIVE_COMPARATOR|Control group|Traditional hearing aid adjustment
62591104|NCT02004886|EXPERIMENTAL|MK-0893 (40 mg)|MK-0893 40-mg q.d. (quaque die, once daily) group will receive MK-0893 40-mg tablets (after loading dose with 160 mg) and matching placebo to metformin and matching placebo to MK-0893.
62591105|NCT02004886|EXPERIMENTAL|MK-0893 (120 mg)|MK-0893 at 120 mg q.d. group will receive MK-0893 120 mg q.d. tablets (after loading dose of 500 mg on Day 1) and matching placebo tablets to metformin and matching placebo to MK-0893
62029988|NCT01178853|EXPERIMENTAL|Rosuvastatin/Pitavastatin|
62029989|NCT06534151||Patients undergoing implantation of cardiac resynchronisation therapy (CRT) device|These patients will have a diagnosis of heart failure with reduced ejection fraction (confirmed by a heart scan called an echocardiogram). A consultant cardiologist will advise they have a CRT device implanted to improve their symptoms and quality of life.
62029990|NCT02105948|EXPERIMENTAL|Arm 1|Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with optimized standard of care background therapy.
62029991|NCT02105948|PLACEBO_COMPARATOR|Arm 2|Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) along with optimized standard of care background therapy.
62029992|NCT06100497|EXPERIMENTAL|Stage IVB cohort|patients must undergo evaluation after receiving 2 cycles of PD-1 (pembrolizumab, 200mg, IV, Q3W) combined with platinum-based (cisplatin: 75 mg/m2, IV, Q3W) and albumin paclitaxel (260mg/m2, IV, Q3W) treatment (Arm 1 may receive a third cycle of treatment based on tumor regression). if achieving CR/PR on imaging, suitable for surgical treatment, not suitable for surgery or SD/PD patients, subsequent synchronous chemoradiotherapy or synchronous chemoradiotherapy combined with PD-1 (pembrolizumab) treatment (total of no more than 17 cycles).
62228568|NCT05695937|PLACEBO_COMPARATOR|DICA-HF + placebo|Participants allocated into this arm (n= 24) will receive the DICA Br adapted to FH (DICA-HF) plus placebo of both phytosterol and krill oil during 120 days.
62228569|NCT05695937|EXPERIMENTAL|DICA-HF + phytosterol|Participants allocated into this arm (n= 24) will receive the DICA Br adapted to FH (DICA-HF) plus 2g/day of phytosterol and placebo of the krill oil during 120 days.
62421190|NCT00741117|ACTIVE_COMPARATOR|Medium Bilirubin Group|Medium Bilirubin Group: subjects with a bilirubin level from 11mg/dl to 30 mg/dl
62421191|NCT00741117|ACTIVE_COMPARATOR|High Bilirubin Group|High Bilirubin Group: subjects with a bilirubin level greater than or equal to 30 mg/dl
62421192|NCT05538286|EXPERIMENTAL|transcranial ultrasonography through sonolucent cranioplasty|All surgical procedures and implants in this protocol are standard of care.
62421193|NCT05606913|EXPERIMENTAL|IBI362 6.0mg|①2mg, SC, once a week\* 4weeks; ②4mg, SC, once a week\* 4weeks；③6mg, SC, once a week\* 20weeks.
62421194|NCT05606913|EXPERIMENTAL|dulaglutide|1.5mg, SC, once a week\* 28weeks
62421195|NCT05606913|EXPERIMENTAL|IBI362 4.0mg|2mg, SC, once a week\* 4weeks; ②4mg, SC, once a week\* 24weeks.
62421196|NCT02199665|EXPERIMENTAL|Selinexor, carfilzomib, dexamethasone|Patients receive selinexor PO, carfilzomib IV, and dexamethasone PO QD or IV. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62421197|NCT05937750|EXPERIMENTAL|Imlifidase|Imlifidase administered in the 20-HMedIdeS-19 (PAES) study
62804833|NCT05077800|EXPERIMENTAL|FOLFIRINOX + 9-ING-41 + Losartan|"The study conducted in 3 parts depending on disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.~For initial complete therapy:~* FOLFIRINOX~  * 5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle~ * Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle~ * Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle~ * Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle~* 9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle~* Losartan daily~For Maintenance therapy:~* 5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression~* 9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle until disease progression~* Losartan daily until disease progression~For Complete Therapy Round 2, participants will repeat initial complete therapy of FOLFIRINOX + 9-ING-41+ Losartan until further disease progression"
62804834|NCT02531217|EXPERIMENTAL|ATYR1940|Participants will receive ATYR1940 3.0 milligrams per kilograms (mg/kg) intravenous (IV) infusion once weekly for 24 weeks.
62228570|NCT05695937|EXPERIMENTAL|DICA-HF + krill oil|Participants allocated into this arm (n= 24) will receive the DICA Br adapted to FH (DICA-HF) plus 2g/day of krill oil and placebo of phytosterol during 120 days.
62804835|NCT04513548|EXPERIMENTAL|Ligelizumab|test drug
62804836|NCT04513548|PLACEBO_COMPARATOR|Placebo|placebo
62804837|NCT00006252|EXPERIMENTAL|Allogeneic Stem Cell Tx|minimal ablation and cellular immune therapy with allogeneic donor stem cell therapy
62804838|NCT01246427|EXPERIMENTAL|BRN01|"A 2 to 4 weeks run-in period is planned, during which all patients receive single blinded hot flash evaluation treatment which is actually a placebo (2 tablets every morning and every evening during 2 to 4 weeks). At the end of this period, the hot flash score is calculated. If the score is ≥10, the patient can be randomized to one of the 2 arms:~* Experimental: BRN01~* Placebo Comparator: Placebo"
62804839|NCT01246427|PLACEBO_COMPARATOR|Placebo|"A 2 to 4 weeks run-in period is planned, during which all patients receive single blinded hot flash evaluation treatment which is actually a placebo (2 tablets every morning and every evening during 2 to 4 weeks). At the end of this period, the hot flash score is calculated. If the score is ≥10, the patient can be randomized to one of the 2 arms:~* Experimental: BRN01~* Placebo Comparator: Placebo"
62804840|NCT02952885|EXPERIMENTAL|Pegvisomant|Open-label, non-randomized single arm variable dose study of pegvisomant conducted in a real world setting.
62804841|NCT00796666|EXPERIMENTAL|Sitaxsentan and Placebo|Monotherapy arm
62804842|NCT00796666|EXPERIMENTAL|Sitaxsentan and Sildenafil|Combination treatment
62804843|NCT01919528|EXPERIMENTAL|axillary vein catheterization|central venous catheter placement into the axillary vein under ultrasound guidance
62804844|NCT02525653|EXPERIMENTAL|Albumin-Bound Paclitaxel and Gemcitabine|During each 21-day cycle, albumin-bound paclitaxel at 100mg/mg2 over 120 minutes and gemcitabine at 1000mg/m2 over 30 minutes will be given intravenously on days 1 and 8 of each 21 day cycle. Treatment will continue until disease progression or intolerable side effects. After the 4th cycle of treatment, patients will have the option of discontinuing gemcitabine and proceeding with weekly albumin-bound paclitaxel as maintenance therapy.
62804845|NCT01441843|ACTIVE_COMPARATOR|Lorazepam|Lorazepam 4mg/4ml
62228571|NCT05695937|EXPERIMENTAL|DICA-HF + phytosterol + krill oil|Participants allocated into this arm (n= 24) will receive the DICA Br adapted to FH (DICA-HF) plus 2g/day of phytosterol and 2g/day of krill oil during 120 days.
62228572|NCT04385420|EXPERIMENTAL|ATR-002 100 mg (SAD)|100 mg ATR-002 once (morning)
62228573|NCT04385420|EXPERIMENTAL|ATR-002 300 mg (SAD)|300 mg ATR-002 once (morning)
62228574|NCT04385420|EXPERIMENTAL|ATR-002 600 mg (SAD)|600 mg ATR-002 once (morning)
62228575|NCT04385420|EXPERIMENTAL|ATR-002 900 mg (SAD)|900 mg ATR-002 once (morning)
62228576|NCT04385420|PLACEBO_COMPARATOR|Placebo (SAD)|Placebo once (morning)
62228577|NCT04385420|EXPERIMENTAL|ATR-002 100 mg (MAD)|100 mg ATR-002 once daily (morning) for 7 days
62228578|NCT04385420|EXPERIMENTAL|ATR-002 300 mg (MAD)|300 mg ATR-002 once daily (morning) for 7 days
62228579|NCT04385420|EXPERIMENTAL|ATR-002 600 mg (MAD)|600 mg ATR-002 once daily (morning) for 7 days
62228580|NCT04385420|PLACEBO_COMPARATOR|Placebo (MAD)|Placebo once daily (morning) for 7 days
62421198|NCT05937750|EXPERIMENTAL|Non-Comparative Concurrent Reference Cohort|Best available treatment administered in the 20-HMedIdeS-19 (PAES) study
62591106|NCT02004886|ACTIVE_COMPARATOR|Metformin (2000 mg)|Metformin taken orally, 500 mg tablets, Day 1 to Day 6: 500 mg b.i.d. (bis in die, twice daily), Day 7 to Day 13: 1000 mg in the morning and 500 mg in the evening, and Day 14 to Day 28: 1000 mg. b.i.d. and matching placebo to MK-0893.
62591107|NCT02004886|PLACEBO_COMPARATOR|Placebo|Placebo tablets matching the MK-0893 and placebo tablets matching metformin.
62591108|NCT04692480|EXPERIMENTAL|Breastfeeding Video Education|"Participants will view a breastfeeding educational video entitled Breastfeeding in the First Hour, It's in Your Hands."
62228581|NCT01393327|EXPERIMENTAL|Respiratory and exercise therapy|Early after PEA postoperative three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks.
62228582|NCT01406951||SIRS|(1) temperature \> 38oC or \< 36oC; (2) pulse rate \> 90 beats/min; (3) ventilation rate \> 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) \< 32 mmHg; (4) white blood cell (WBC) count \>1 2,000μL-1 or \< 4000 μL-1 , or \> 10% immature cells.
62228583|NCT01406951||sepsis|SIRS + infection
62591109|NCT04692480|OTHER|Control|Participants will view a PDF of breastfeeding education materials available for inclusion in standard discharge paper work.
62029993|NCT06100497|EXPERIMENTAL|Stage III-IVA cohort|patients with stage III and IVA (T3NxM0, T4aNxM0) receive PD-1 (pembrolizumab, 200mg, IV, Q3W) combined with platinum-based chemotherapy (cisplatin: 75 mg/m2, IV, Q3W) and albumin-bound paclitaxel (260mg/m2, IV, Q3W) for 2 cycles. Patients who undergo surgery within 2 weeks based on pathological results are given PD-1 monotherapy maintenance treatment or low-dose radiotherapy followed by PD-1 monotherapy maintenance treatment if they achieve pathological complete response (pCR). Non-pCR patients with positive surgical margins or extracapsular extension after surgery receive PD-1 maintenance treatment after concurrent chemoradiotherapy (up to a maximum of 17 cycles). Patients without high-risk factors receive PD-1 maintenance treatment after radiotherapy (up to a maximum of 17 cycles).
62029994|NCT02682264|EXPERIMENTAL|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) Cream, 1%, applied twice daily to whole face (about 1 gram) and affected areas of trunk (if applicable) for up to an additional 9 months. Over the course of the study, treatment on the face and/or trunk may be discontinued if/when acne clears and re-started if/when acne worsens, according to the assessment of the investigator for each respective treatment area.
62029995|NCT04134819||Vaginally Delivered Babies- No antibiotic treatment|Adult healthy pregnant females (in total 400) as well as their infants will be recruited. It is expected 67% of babies will be vaginally delivered and that 60% will not have antibiotic treatment during pregnancy. This will be up to 161 mother/infant dyads.
62029996|NCT04134819||Vaginally Delivered Babies- antibiotic treatment|It is expected based from previous hospital statistics that 67% of babies will be vaginally delivered and 40% of these women will be treated with antibiotics during pregnancy. This could be up to 107 mother/infant dyads.
62228584|NCT01406951||VAP|(1) after 48-72h endotracheal intubation, X-ray film displays new or progressive infiltrating focus; (2)The patient is in two of the following conditions: a. fever (temperature \>38 ℃ or higher than basal temperature; b. peripheral WBC count≥10×10∧9/L，or \<4×10∧9/L; c. appearance or increase of purulent respiratory tract secretion. Besides the diagnostic norms above, it is suggested that lower respiratory tract secretions be collected under the bronchoscope and half-quantitative etiological culture be carried out through the medium of BALF samples (diagnostic threshold value:104cfu/mL ).
62804846|NCT01441843|PLACEBO_COMPARATOR|NaCl 0.9%|NaCl 0.9% 4ml
62804847|NCT06468956|EXPERIMENTAL|SHR-1819 injection dose 1|
62029997|NCT04134819||C-section Delivered Babies- No antibiotic treatment|It is expected based from previous hospital statistics that 33% of babies will be delivered by C section and that 60% will not have antibiotic treatment during pregnancy. This will be up to 80 mother/infant dyads All C Section women (including emergency C Section) will be treated with IV Cefazolin at the time of incision, in theatre, to prevent internal wound infection.
62029998|NCT04134819||C-section Delivered Babies- antibiotic treatment|It is expected based from previous hospital statistics that 33% of babies will be delivered by c section and 40% of these women will be treated with antibiotics during pregnancy. This could be up to 52 mother/infant dyads .All C Section women (including emergency C Section) will be treated with IV Cefazolin at the time of incision, in theatre, to prevent internal wound infection.
62228585|NCT00091169|EXPERIMENTAL|Arm I|Patients receive oral levocarnitine (L-carnitine) twice daily on weeks 1-4.
62228586|NCT00091169|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo twice daily on weeks 1-4.
62228587|NCT02618954|OTHER|Study patient|Articular ultrasound at each study follow-up
62228588|NCT02070588|ACTIVE_COMPARATOR|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
62228589|NCT02070588|PLACEBO_COMPARATOR|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
62735369|NCT02859285|PLACEBO_COMPARATOR|Placebo cream|"The placebo cream 0.5 grams will be placed on the clitoris/vestibule every night for 2 weeks, then 3 times a week thereafter on Monday, Wednesday, and Friday, for a total of 12 weeks.~In addition estradiol 10mcg tablet will be placed in the vaginal every night for 2 weeks, then 2x a week on Tuesday and Thursday, for a total of 12 weeks."
62735370|NCT04589572|EXPERIMENTAL|XLIF - group|
62804848|NCT06468956|EXPERIMENTAL|SHR-1819 injection dose 2|
62804849|NCT06468956|PLACEBO_COMPARATOR|placebo|
62804850|NCT02181465|EXPERIMENTAL|Group 1|One injection of G17DT followed by up to three booster injections depending on antibody response over 16 week period
62029999|NCT00040222||1|Individuals and families with known or suspected syndromes that include breast, ovarian or genetically-related cancers are enrolled in this family study.
62030000|NCT02264795|PLACEBO_COMPARATOR|Placebo|Intraperitoneal instillation of normal saline.
62030001|NCT02264795|ACTIVE_COMPARATOR|Lidocaine|Intraperitoneal instillation lidocaine 2% (400mg) with epinephrine 5mcg/ml.
62030002|NCT04044677|EXPERIMENTAL|tDSC-active|"The TDCS-active will be performed over ten consecutive sessions per weekday (i.e. one session daily, no stimulation during the weekend) during the practice of VR games, TDCS-active will be performed with a current of 1 mA and 20 min of duration (20 seconds of ramp-up and ramp-down). The stimulation target will be the M1 area, choosing the more functional side of the participant (C3 or C4).~This group will perform the tDCS-sham after one-month washout."
62030003|NCT04044677|SHAM_COMPARATOR|tDCS-sham|"The TDCS-sham will be performed over ten consecutive sessions per weekday (i.e. one session daily, no stimulation during the weekend). However, the electrodes will be positioned at the same sites of the tDCS-active and the device will be switched on for 20 seconds (with ramp-up and ramp-down), giving the children the initial sensation of the 1 mA current, but with no stimulation administered during the rest of the time. This sham protocol is already programmed in the device prior to data collection.~This group will perform the tDCS-active after one-month washout."
62735371|NCT04589572|ACTIVE_COMPARATOR|PLIF - Group|
62804851|NCT02181465|EXPERIMENTAL|Group 2|Three injections of G17DT with option of one booster after 16 weeks
62804852|NCT04862325|NO_INTERVENTION|Usual care|"Control group will follow the standard preoperative measures Enhanced Recovery After Surgery (ERAS®) established in the protocols of our hospital. Standard preoperative measures: recommendation of nutritional and physical activity and advice to stop smoking and reduce alcohol intake; optimization of preoperative pathologies including anaemia. An information document on ERAS® measures in our center will be attached to all of them."
62030004|NCT02057822||vernal keratoconjunctivitis|The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjonctivitis and in control subjects
62030005|NCT02057822||healthy children|The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjunctivitis and in control subjects
62030006|NCT06630455|EXPERIMENTAL|Meu-cinn group|This group takes Meu-cinn for 8 weeks.
62030007|NCT06630455|PLACEBO_COMPARATOR|Placebo group|This group takes placebo for 8 weeks.
62228590|NCT04196153|ACTIVE_COMPARATOR|Neuronavigation / O-arm group|Under neural navigation with the use of intraoperative three dimensional imaging quality O-arm , pedicle screws inserted at the thoraolumbar/lumbar spine after insertion of the reference frame at the spinous process above or below the level of instrumentation followed by O-Arm imaging and uploading the images to the stelth navigation system and pedicle tract identification using instrumented tools guided by the Navigation polyaxial screws is inserted.
62804853|NCT04862325|EXPERIMENTAL|Multimodal prehabilitation|Patients following the standard preoperative policies of our institution and the multimodal prehabilitation program
62804854|NCT02517034|EXPERIMENTAL|Arm I (geriatric assessment-driven treatment)|Patients follow an intervention plan created by the NP using the results of the geriatric assessment. The NP discusses the results of the assessment and treatment recommendations with the patient. They also share the treatment plan, proposed referrals, and specific vulnerabilities with the primary care physician and community oncologist. Some patients complete the intervention plan via Telehealth, which uses telecommunication technology to provide health services over a distance.
62804855|NCT02517034|ACTIVE_COMPARATOR|Arm II (standard of care)|Patients follow a standard of care treatment plan at the discretion of the primary oncologist. Beginning 6 months from the start of chemotherapy, patients undergo the geriatric assessment as in Arm I. Some patients complete the standard of care treatment plan via Telehealth.
62804856|NCT03898726|ACTIVE_COMPARATOR|laparoscopical l cuff closure|needle holder laparoscopic vaginal cuff closure
62804857|NCT03898726|ACTIVE_COMPARATOR|transvaginal cuff closure|transvaginal cuff closure
62804858|NCT01725490|EXPERIMENTAL|metformin 500mg daily (arm A)|
62804859|NCT01725490|EXPERIMENTAL|metformin 1500mg daily (arm B)|
62804860|NCT01725490|PLACEBO_COMPARATOR|an identical- appearing placebo (arm C)|
62804861|NCT04152226|ACTIVE_COMPARATOR|Cohort 1|Cohort 1 low dose of J. lividum
62804862|NCT04152226|ACTIVE_COMPARATOR|Cohort 2|Cohort 2 medium dose of J. lividum
62804863|NCT04152226|ACTIVE_COMPARATOR|Cohort 3|Cohort 3 - high dose of J. Lividum
62804864|NCT01177007|EXPERIMENTAL|TheraSphere|
62228591|NCT04196153|ACTIVE_COMPARATOR|Cervical distractor screws group|pedicle screws inserted using marker screws after posterior exposure of thoracolumbar /lumbar spine by either open midline posterior exposure or minimal invasive posterior wiltse style exposure with expandable tubular retractor, anatomical landmark for insertion of pedical screws identified and followed by inserting of a cervical distraction screw size 3 / 12 mm as a stable marker using high speed drill. C-arm floro is used to take antroposterior and lateral view to confirm the position of the marker screws at this stage.free hand technique supported by the images provided to cannulate the pedicle with the use of information on the images taken for all the marker screws simultaneously.
62228592|NCT02522351|ACTIVE_COMPARATOR|Thicken Up Clear concentration 1|Thicken Up Clear at concentration 1
62228593|NCT02522351|ACTIVE_COMPARATOR|Thicken Up Clear concentration 2|Thicken Up Clear at concentration 2
62228594|NCT02522351|ACTIVE_COMPARATOR|Thicken Up Clear concentration 3|Thicken Up Clear at concentration 3
62228595|NCT02522351|EXPERIMENTAL|Cereal extract concentration 1|Cereal extract at concentration 1
62228596|NCT02522351|EXPERIMENTAL|Cereal extract concentration 2|Cereal extract at concentration 2
62735372|NCT03352232|EXPERIMENTAL|Subacute Ischemic Stroke|Subacute stroke patients post stroke within 3 months of enrollment, have persistent neurological deficits despite conventional rehabilitation
62735373|NCT03352232|EXPERIMENTAL|Chronic Ischemic Stroke|Chronic stroke patients more than 6 months from stroke with persistent neurological deficits despite conventional rehabilitation
62735374|NCT03337867|ACTIVE_COMPARATOR|Real-iTBS|
62804865|NCT01043055||Breast Cancer Patients|
62804866|NCT01043055||Healthy Control Group|
62804867|NCT02828735|OTHER|Respiration assessment|
62030008|NCT05734794|EXPERIMENTAL|Rituximab Group|Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days).
62030009|NCT05734794|ACTIVE_COMPARATOR|Steroid Group|Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks.
62030010|NCT00907673|ACTIVE_COMPARATOR|Patient condition pre-implant|
62735375|NCT03337867|SHAM_COMPARATOR|Sham-iTBS|
62804868|NCT01579435|EXPERIMENTAL|Therapeutic tDCS|6 patients with essential tremor
62804869|NCT01579435|EXPERIMENTAL|Physiopathological tDCS|6 patients with essential tremor
62804870|NCT01176734|EXPERIMENTAL|active t-VNS|active t-VNS
62804871|NCT04899843|ACTIVE_COMPARATOR|Experimental|This arm includes 61 acne vulgaris patients receiving topical retinoids
62804872|NCT04899843|PLACEBO_COMPARATOR|Control|This arm includes 61 acne vulgaris patients receiving topical retinoids
62804873|NCT05055544|ACTIVE_COMPARATOR|Fosfomycin|a single dose of fosfomycin (3 g) powder dissolved in 75 ml water and 2 placebo tablets t.i.d. for 7 days (group A)
62804874|NCT05055544|ACTIVE_COMPARATOR|Bearberry|a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
62804875|NCT01876355|EXPERIMENTAL|Clonidine|
62804876|NCT01876355|PLACEBO_COMPARATOR|Sodium chloride|
62804877|NCT03115944|EXPERIMENTAL|UltraSpeed Treatment|UltraSpeed ultrasound treatments
62804878|NCT02609958|EXPERIMENTAL|Treatment Arm A|Varlitinib (ASLAN001) tablets
62591110|NCT04546399|EXPERIMENTAL|Arm G (dexamethasone, blinatumomab, nivolumab,MTX) DS patients|Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and day 3 of cycle 2, and MTX IT (for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with \< 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study.
62804879|NCT03980249|EXPERIMENTAL|Carvedilol + Standard Treatment|Subjects will receive carvedilol starting at 6.25 mg orally (PO) twice daily for 1-2 weeks and if tolerated will then be increased to 12.5 mg PO twice daily starting on day 1 of concurrent chemoradiotherapy and continue daily until the end of adjuvant cycle 6 of temozolomide and Tumor Treated Fields.
62804880|NCT04933071|EXPERIMENTAL|Podcast Education|Residents will be given access to podcasts during their rotation They will complete a survey after each obstetrics rotation
62804881|NCT04933071|NO_INTERVENTION|Usual Teaching|Residents will have usual teaching They will complete a survey after each obstetrics rotation
62804882|NCT03190395|EXPERIMENTAL|CPVI Group|CPVI Group: Pure Circumferential pulmonary vein isolation(CPVI)
62804883|NCT03190395|ACTIVE_COMPARATOR|CPVI+LARA Group|CPVI+LARA Group: Circumferential pulmonary vein isolation combine with Left Atrium Roofline Ablation
62591111|NCT04546399|EXPERIMENTAL|Group 1, Arm A (dexamethasone, blinatumomab, MTX)|ARM A: Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, MTX IT, cytarabine IT, or ITT IT on days 1, 15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given \< 7 days prior to the start of this cycle), and MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD \< 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD \>= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024)
62030011|NCT03720704||GORE VIABAHN VBX Balloon Expandable Endoprosthesis|The GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted according to the institution standard of practice in patients needing preservation of peripheral vessels due to multiple pathologies and conditions.
62030012|NCT06019312|EXPERIMENTAL|Lactobacillus plantarum 299v|15 patients will receive 2 capsules (per day - 1 capsule contains 10x10 CFU) of L. plantarum 299v for 4 weeks
62591112|NCT04546399|EXPERIMENTAL|Group 1, Arm B (dexamethasone, blinatumomab, MTX)|Patients receive dexamethasone, blinatumomab, and MTX, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD \< 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD \>= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024)
62591113|NCT04546399|EXPERIMENTAL|Group 2, Arm C (dexamethasone, blinatumomab, MTX)|Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and methotrexate IT on days 1 and 15 of cycles 1 and 2 (day 1 may be omitted from cycle 1 if intrathecal therapy is given \< 7 days prior to the start of this cycle). Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD \< 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD \>= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024)
62591114|NCT04546399|EXPERIMENTAL|Group 2, Arm D (dexamethasone, nivolumab, blinatumomab, MTX)|Patients receive dexamethasone, blinatumomab, and MTX as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD \< 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD \>= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024)
62591115|NCT04546399|EXPERIMENTAL|Group 3, Arm E (dexamethasone, blinatumomab, MTX)|See Outline section
62591116|NCT04546399|EXPERIMENTAL|Group 3, Arm F (dexamethasone, blinatumomab, nivolumab)|See Outline section
62591117|NCT04546399|EXPERIMENTAL|Group 4 Arm I (Dexamethasone, blinatumomab, nivolumab)|Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV, over 30 minutes on day 11 of cycle 1 and day 3 of cycle 2 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with \< 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study.
62804884|NCT05175092|EXPERIMENTAL|Intent to Treat: LDLT|Living Donor Liver Transplantation
62804885|NCT05175092|NO_INTERVENTION|Control Group|Enrolled but does not receive LDLT
62804886|NCT04836585|NO_INTERVENTION|Care As Usual|Participants in the control condition are followed by their RLS psychiatrists during the study as per usual care.
62804887|NCT04836585|EXPERIMENTAL|eMBC Intervention|Participants in the intervention arm are followed by their RLS psychiatrists during the study at clinically appropriate intervals with the addition of eMBC.
62804888|NCT04803266|EXPERIMENTAL|Internal mammary node irradiation|
62804889|NCT04803266|ACTIVE_COMPARATOR|No internal mammary node irradiation|
62228597|NCT02522351|EXPERIMENTAL|Cereal extract concentration 3|Cereal extract at concentration 3
62228598|NCT05155163|NO_INTERVENTION|Treatment as Usual|Treatment as usual for opioid use disorder
62030013|NCT06019312|EXPERIMENTAL|Lactobacillus plantarum 299v in combination with inulin|15 patients will receive 2 capsules (per day - 1 capsule contains 10x10 CFU) of L. plantarum 299v and inulin (4 g) for 4 weeks
62228599|NCT05155163|EXPERIMENTAL|SC-POWR|Treatment as usual for opioid use disorder with the addition of CBT with possible stepped care to exercise and stress reduction
62421199|NCT06468280|EXPERIMENTAL|Local Treatment Arm (Arm A)|In Phase 1, patients will receive four cycles of PD-1 antibody in combination with XELOX chemotherapy. Following this phase, a radiologic assessment will evaluate disease progression status. Patients identified as not experiencing progression will proceed with the study treatments. Subsequently, they will undergo surgeon-led local treatment, which may include standard D2 gastrectomy and metastasectomy when feasible. Non-surgical local treatments may also be administered to address unresected or unresectable metastatic lesions, either concurrently or sequentially with surgery. After surgical intervention, patients will receive up to four additional cycles of XELOX chemotherapy, followed by maintenance therapy consisting of tislelizumab and capecitabine during Phase 2 of the systemic treatment. The total treatment duration may extend up to two years from the date of enrollment.
62591118|NCT04546399|EXPERIMENTAL|Group 4, Arm H (dexamethasone bilinatumomab)|Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with \< 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study.
62591119|NCT05213884|EXPERIMENTAL|Camrelizumab plus chemoradiotherapy|Induction camrelizumab therapy at least one cycle (every 3 weeks) followed by definitive concurrent chemoradiotherapy. After 4\~6 weeks of the completion of radiotherapy, adjuvant camrelizumab therapy will begin every 3 weeks for 16 cycles (1 year) or continue until progression or unacceptable toxicity.
62591120|NCT06326996|EXPERIMENTAL|Post-CABG patients with Thiamine Treatment Intervention.|Assess cognition and evaluate blood thiamine, lactate, and inflammatory marker levels in patients receiving thiamine intervention treatment within 5 days (baseline) and one month after CABG.
62591121|NCT06326996|PLACEBO_COMPARATOR|Post-CABG patients without Thiamine Treatment Intervention.|Assess cognition and evaluate blood thiamine, lactate, and inflammatory marker levels in patients receiving placebo treatment within 5 days (baseline) and one month after CABG.
62804890|NCT01460108|EXPERIMENTAL|AeriSeal System Treatment|Candidates for the trial include patients with advanced non-bullous upper lobe predominant emphysema who have a DLco between 20 and 60% predicted and target sites in at least 1 upper lobe. Eligible and consented patients will undergo evaluation with the Chartis System, and only patients found to have significant collateral ventilation will be enrolled.
62804891|NCT03687788|EXPERIMENTAL|Intervention Group|Intervention group received laughter therapy twice a week for six weeks.
62804892|NCT03687788|NO_INTERVENTION|Control Group|The control group did not take part in the laughter therapy program. This group received the routine care given by the nurses in the center.
62804893|NCT04130321|EXPERIMENTAL|Camu camu|
62804894|NCT04130321|PLACEBO_COMPARATOR|Placebo|
62030014|NCT06019312|NO_INTERVENTION|Placebo in combination with inulin|15 patients will receive 2 capsules (per day) of placebo and inulin (4 g) for 4 weeks
62030015|NCT06019312|NO_INTERVENTION|Placebo|15 patients will receive 2 capsules (per day) of placebo for 4 weeks
62030016|NCT03302962|EXPERIMENTAL|Intensive Asthma Education|"One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted."
62030017|NCT03302962|NO_INTERVENTION|Routine Asthma Education Literature|"The remaining 54 cases were randomized to the control arm and received written materials related to patient-centered asthma control."
62030018|NCT01748929|EXPERIMENTAL|Albendazole|single dose 400 mg tablet of albendazole
62030019|NCT01748929|PLACEBO_COMPARATOR|Placebo|Placebo Manufactured by Hersil Laboratories in Lima, Peru
62228600|NCT04465760|EXPERIMENTAL|Supportive Care (xisomab 3G3)|Patients receive xisomab 3G3 IV or via catheter within 48 hours of catheter placement. Patients then receive standard of care chemotherapy 2 days later. After approximately 2 weeks, patients undergo standard of care ultrasound for possible CAT.
62228601|NCT05306769||Group 1|"* HIV positive~* ≥18 years old~* Currently registered to receive care under Harrison Wing (and thus potential candidates for Harrison Wing clinical studies)~* Has ≥ 1 demographic identified to be underrepresented as specified in 'trial statistics'~* Able and willing to provide written or witnessed informed consent to participate"
62228602|NCT05306769||Group 2|"HIV positive~* ≥18 years old~* Currently registered to receive care under Harrison Wing~* Currently participating in any clinical study in which Harrison Wing is the/ a participating centre1~* Able and willing to provide written or witnessed informed consent to participate"
62228603|NCT01525719|EXPERIMENTAL|RAD001|
62228604|NCT04681547|EXPERIMENTAL|Genicular nerve block|An ultrasound-assisted genicular nerve block will be performed. 4 ml of 0.2% ropivacaine will be administered, with adrenaline 1: 100 000 in each of the five nerves.
62228605|NCT04681547|ACTIVE_COMPARATOR|Local infiltration Analgesia|Administration of ropivacaine 0.2% 150 ml will be performed.
62030020|NCT06670833|ACTIVE_COMPARATOR|Routine Care Group|This group receives normal routine care. No intervention.
62228606|NCT04984733|EXPERIMENTAL|Treatment|"Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV until progression.~Metronomic TMZ 50mg/m2/day orally until progression then nivolumab 240mg IV until progression. Patients who progress on TMZ will start monotherapy with nivolumab.~Metronomic TMZ50mg/m2/day orally for 3 months, then nivolumab 240mg IV +/- TMZ until progression. Patients who don't progress on TMZ will commence with combination treatment; TMZ + Nivolumab at 3 mths until they progress~Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV +/- TMZ until 24 months. Patients will remain on combination therapy up to a maximum of 24mths."
62228607|NCT02743377|EXPERIMENTAL|Subjects with McCune-Albright syndrome (MAS)|Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans
62804895|NCT03321084|EXPERIMENTAL|MatPilates|In the beginning was nominated Contrology, but today is known as Pilates. Created by Joseph Humbertus Pilates. This technique is based on respiration, balance, flexibility, proprioception and muscular strength. One of the main work is on the power house (core), biomechanical axis of the body, composed of muscles: rectus abdominis, paravertebral, multifidus, diaphragm, and those of the perineal center.
62228608|NCT02743377|EXPERIMENTAL|Healthy control|Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans
62228609|NCT04986995|EXPERIMENTAL|Opicapone|50 mg hard capsules
62421200|NCT06468280|ACTIVE_COMPARATOR|Systemic Treatment Arm (Arm B)|In Phase 1, patients will receive four cycles of PD-1 antibody in conjunction with XELOX chemotherapy. Following this phase, a radiologic assessment will evaluate the disease progression status. Patients classified as not experiencing progression-defined as the absence of local progression, advancement of existing distant metastases, or the emergence of new distant metastatic lesions-will continue with the study treatments. In Phase 2, participants will receive an additional up to four cycles of PD-1 antibody and XELOX chemotherapy, followed by maintenance therapy consisting of PD-1 antibody and capecitabine. The total treatment duration could extend up to two years from the date of enrollment.
62421201|NCT06568029||Patient with rheumatoid arthritis|"18 years and older at the time of first included measurement. A diagnosis of RA. Complete registration of responses in the EQ-5D-3L descriptive system or EQ VAS on at least one time point in SRQ.~At least one measurement with Disease Activity Score 28 (DAS28) reported in relation to the same visit as EQ-5D-3L."
62804896|NCT03321084|OTHER|Control|It continues in your daily life with phone monitoring.
62804897|NCT04982939|EXPERIMENTAL|Experimental Group-Sintilimab in combination with SOX|Preoperative treatment: three cycles of sintilimab in combination with SOX. Radical gastrectomy and lymphadenectomy (D2). Postoperative treatment: five cycles of SOX, Sintilimab up to one year.
62804898|NCT04982939|ACTIVE_COMPARATOR|Active Comparator-SOX|Preoperative treatment: three cycles of SOX. Radical gastrectomy and lymphadenectomy (D2). Postoperative treatment: five cycles of SOX.
62804899|NCT05553795|EXPERIMENTAL|A - Early removal of chest drain|
62804900|NCT05553795|OTHER|B - Control|
62804901|NCT02907424|ACTIVE_COMPARATOR|BP-100|standard treatment
62804902|NCT02907424|EXPERIMENTAL|Num Trey|locally produced RUTF
62804903|NCT01885221|EXPERIMENTAL|Multimedia Support Intervention|(a) access to a website providing the content of our supporter guidebook, supplemented with interactive components, video elements, and a supporters' forum, and (b) a mailed copy of our supporter guidebook
62804904|NCT01885221|NO_INTERVENTION|Delayed Treatment Control|Access to the Multimedia Intervention after participant completes the final follow-up assessment
62804905|NCT03324490|ACTIVE_COMPARATOR|TSA group|Thoracic Spinal Anesthesia; Bupivacaine 0.5% (hyperbaric) 7.5mg, Fentanyl 25 µg \& Dexmedetomidine 5 µg by intrathecal injection
62804906|NCT03324490|ACTIVE_COMPARATOR|TEA group|Thoracic Epidural Anesthesia; Bupivacaine 0.5% (isobaric) 25-50 mg \& Fentanyl 10-20 µg by epidural injection
62228610|NCT01491893|EXPERIMENTAL|Dose Level 1 (dose escalation)|Participants received a single intratumoral infusion of 1.0 x 10\^8 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
62228611|NCT01491893|EXPERIMENTAL|Dose Level 2 (dose escalation)|Participants received a single intratumoral infusion of 3.3 x 10\^8 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convention-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
62228612|NCT01491893|EXPERIMENTAL|Dose Level 3 (dose escalation)|Participants received a single intratumoral infusion of 1.0 x 10\^9 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
62591122|NCT03374930|OTHER|Multiple rapid swallows test|Multiple rapid swallows test consists in giving to patient 4 to 6 sips of 2 mL of water, with an interval less than 4 seconds between the different sips.
62591123|NCT01246037|EXPERIMENTAL|First placebo|First half year placebo, second half year bisoprolol
62591124|NCT01246037|EXPERIMENTAL|First Bisoprolol|First half year bisoprolol, second half year placebo
62591125|NCT02846116|ACTIVE_COMPARATOR|lithium disilicate|The intervention will be: Prosthetic crown
62591126|NCT02846116|ACTIVE_COMPARATOR|Vita suprinity|The intervention will be: Prosthetic crown
62591127|NCT01927003|EXPERIMENTAL|Surgical flap|Dorsal digito-metacarpal flap is based on the dorsal digital artery and dorsal metacarpal artery.
62591128|NCT01188876|EXPERIMENTAL|Carboplatin/Pralatrexate|
62591129|NCT03549442|EXPERIMENTAL|Phase A|Safety Run-in to test the safety of CART-BCMA + huCART19 as split-dose infusions after lymphodepleting chemotherapy with cyclophosphamide + fludarabine in patients who have relapsed/refractory myeloma after two prior regimens but who are responding to their current therapy.
62591130|NCT03549442|EXPERIMENTAL|Phase B|Randomization Phase in which patients responding to first or second-line therapy will receive either CART-BCMA alone (Cohort 1) or CART-BCMA + huCART19 (Cohort 2) as split-doses after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
62804907|NCT02907151||pre-consultation survey group|The group completing a pre consultation survey filled the same questionnaire in post consultation but the doctor will see the result in the consultation.
62804908|NCT02907151||Group absence of pre-consultation survey|This group will be a control group to see if there is a difference between completing a pre-consultation survey before or not.
62804909|NCT02762695|EXPERIMENTAL|Case Management|
62804910|NCT02762695|ACTIVE_COMPARATOR|Control|Usual Care at Primary Health Care
62804911|NCT03706443|ACTIVE_COMPARATOR|Systane® Complete|All subjects are randomly assigned to arm one or arm two. Subjects are assigned to be treated with one drop of Systane® Complete, and the tear lipid layer thickness is to be measured at 15 minutes, 1, 2, 4, and 6 hours after instillation of the eye drop. Following a minimum of a 2-day washout, the same subjects will proceed to the second arm.
62030021|NCT06670833|EXPERIMENTAL|Intervention Group|"Participants will undergo lung ultrasound and the ultrasound images/videos will be reviewed by an expert and the findings, along with advice on whether or not an antibiotic should be used.~This means in this group there is a chance the participant will not be given an antibiotic if the ultrasound shows there is no need for it."
62030022|NCT02399579|EXPERIMENTAL|HypoScore|Provocation test. Recording symptoms of cat allergic participants with the cat owner's cat: Before and after petting the cat.
62030023|NCT02032472|NO_INTERVENTION|Health Center (usual practice)|Controlling arterial pressure in the health center (a common practice is carried out)
62030024|NCT02032472|EXPERIMENTAL|Collaboration of pharmacies|Pharmacies cooperate in Measurement of Arterial Pressure of patients
62421202|NCT06568029||Patient with polyarthritis|"18 years and older at the time of first included measurement. A diagnosis of polyarthritis. Complete registration of responses in the EQ-5D-3L descriptive system or EQ VAS on at least one time point in SRQ.~At least one measurement with DAS28 reported in relation to the same visit as EQ-5D-3L."
62591131|NCT03549442|EXPERIMENTAL|Phase C|Single-dose infusion phase to test the safety of single-dose infusion of CART-BCMA alone (Cohort 1) and CART-BCMA + huCART19 (Cohort 2) as single-dose infusions after lymphodepleting chemotherapy with cyclophosphamide + fludarabine in patients responding to first- or second-line therapy.
62591132|NCT03549442|EXPERIMENTAL|Phase A Expansion|Once safety of CART-BCMA/huCART19 combination therapy is established in Phase A, an expansion of Phase A will occur in which the Phase A target population (patients with relapsed/refractory multiple myeloma responding to a standard salvage therapy regimen) will receive both CART-BCMA and huCART19. Enrollment into the Phase A Expansion may occur concurrently with Phase B once opened.
62591133|NCT06602271|EXPERIMENTAL|PF614 25 mg|Oral administration every 12 hours
62804912|NCT03706443|ACTIVE_COMPARATOR|Systane® Ultra|All subjects are randomly assigned to arm one or arm two. Subjects are assigned to be treated with one drop of Systane® Ultra, and the tear lipid layer thickness is to be measured at 15 minutes, 1, 2, 4, and 6 hours after instillation of the eye drop. Following a minimum of a 2-day washout, the same subjects will proceed to the second arm.
62804913|NCT05714826|EXPERIMENTAL|Intervention Arm|Preop intervention Arm Referral to Perioperative Optimization of Senior Health (POSH) Program Remote patient monitoring device orientation, initial intake, and education UTSW ERAS protocol perioperatively Inpatient geriatrics co-management Monitored recovery Post-operative monitoring with Acticare for 90 days Post-op specialist continuity of care
62804914|NCT05714826|ACTIVE_COMPARATOR|Control Arm|Enhanced Recovery After Surgery Usual referral and recovery care as needed Standard follow-up protocol
62591134|NCT06602271|EXPERIMENTAL|PF614 37.5 mg|Oral administration every 12 hours
62421203|NCT06568029||Patients with psoriatic arthritis|"18 years and older at the time of first included measurement. A diagnosis of psoriatic arthritis. Complete registration of responses in the EQ-5D-3L descriptive system or EQ VAS on at least one time point in SRQ.~At least one measurement with DAS28 or Disease Activity in Psoriatic Arthritis (DAPSA) reported in relation to the same visit as EQ-5D-3L."
62591135|NCT06602271|EXPERIMENTAL|PF614 50 mg|Oral administration every 12 hours
62804915|NCT04879056||intra-system|reviewing selected features on images from three iterations of the same scanner.
62804916|NCT04879056||inter-system|reviewing selected features on images from three different scanners.
62804917|NCT00997919|EXPERIMENTAL|A|
62804918|NCT00997919|EXPERIMENTAL|B|
62804919|NCT02038153|EXPERIMENTAL|Treatment (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Courses repeat 4 weeks in the absence of disease progression or unacceptable toxicity.
62804920|NCT03649217|EXPERIMENTAL|wearing the iStride device|The training will consist of four weeks of training with three training sessions performed each week. The training sessions will consist of up to thirty minutes of training with the iStride on, with breaks between walking sessions and as needed if the subject requests an additional break. Subjects will place the device on their foot in which they have the shortest step length, as measured during the pre-training gait analysis. This is typically the healthy side foot. There will also be several follow up visits following the final testing session.
62804921|NCT02343146|EXPERIMENTAL|Type One Training (TOT)|The intervention group will receive the proposed intervention composed of peer parent consultants, telephone and in-person sessions with a trained interventionist, and SMS text messaging aimed at improving child glycemic control through improved nutrition and physical activity.
62030025|NCT04945174|ACTIVE_COMPARATOR|Exercise|12 weeks of supervised cardiorespiratory exercise twice a week (6 weeks at the hospital and 6 weeks in the local municipality) combined with patient education and individual follow-up sessions
62030026|NCT04945174|NO_INTERVENTION|Usual care|The usual care group is encouraged to perform home-based aerobic exercise on their own
62421204|NCT06568029||Patient with ankylosing spondylitis|"18 years and older at the time of first included measurement. A diagnosis of ankylosing spondylitis. Complete registration of responses in the EQ-5D-3L descriptive system or EQ VAS on at least one time point in SRQ.~At least one measurement with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) reported in relation to the same visit as EQ-5D-3L."
62421205|NCT05840601|EXPERIMENTAL|Pointdexter|The investigational device being tested is Pointdexter, a novel prosthetic finger with a built-in split gripper. The device is an index finger which can drop in place of existing fingers on a prosthetic hand. The investigational device is controlled with the same signals used to control the hand. Participants will use a commercially available prosthetic hand compatible with the Pointdexter device for this study.
62421206|NCT05840601|ACTIVE_COMPARATOR|Comparator|The comparator device is the same commercially available hand that is being used for the Pointdexter arm, except that it will be unmodified (i.e., it will have its usual index finger attached instead of the Pointdexter finger).
62421207|NCT03659617|EXPERIMENTAL|Implant placement 3 mo. after tooth ext.|Alveolar ridge preservation using xenograft (BioOss Collagen) and Implant placement 3 mo. after tooth ext.
62421208|NCT03659617|ACTIVE_COMPARATOR|Implant placement 6 mo. after tooth ext.|Alveolar ridge preservation using xenograft (BioOss Collagen) and Implant placement 6 mo. after tooth ext.
62421209|NCT03659617|ACTIVE_COMPARATOR|Implant placement 9 mo. after tooth ext.|Alveolar ridge preservation using xenograft (BioOss Collagen) and Implant placement 9 mo. after tooth ext.
62421210|NCT00950001|EXPERIMENTAL|Arm I (SRS)|Patients undergo stereotactic radiosurgery to the surgical cavity within 30 days of the craniotomy.
62421211|NCT00950001|NO_INTERVENTION|Arm II (observation)|Patients undergo clinical observation after craniotomy.
62591136|NCT06602271|ACTIVE_COMPARATOR|Oxycodone HCl 10 mg|Oral administration every 6 hours
62591137|NCT06602271|PLACEBO_COMPARATOR|Placebo|Oral administration every 6 hours
62804922|NCT02343146|NO_INTERVENTION|Comparison|The comparison group will receive usual care with the diabetes team.
62804923|NCT00286585|ACTIVE_COMPARATOR|Inhalational anesthetic|Sevoflurane will be used as the main anesthetic in this arm, and no propofol will be administered
62804924|NCT00286585|ACTIVE_COMPARATOR|Intravenous anesthetic, propofol|Propofol will be used as the main anesthetic in this arm, and no inhalational anesthetic will be administered
62591138|NCT06666335|EXPERIMENTAL|Anakinra|Anakinra, once daily s.c. injection, starting dose of 100 mg/day for patients with body weight ≥ 50 kg and 1-2 mg/kg/day for patients with body weight \< 50 kg for 6 months. For patients \< 16 years and \< 50 kg not responding sufficiently, the dose can be increased up to 4 mg/kg/day (max of 200 mg/day).
62804925|NCT01545726|EXPERIMENTAL|QAW039|Eligible patients will receive QAW039 po 450 mg daily dose.
62804926|NCT01545726|PLACEBO_COMPARATOR|Placebo|Placebo to QAW039 (oral capsules) will be administered to match QAW039 schedule.
62804927|NCT01260714|EXPERIMENTAL|Treatment (azacitidine, mitoxantrone hydrochloride, etoposide)|Patients receive induction therapy comprising azacitidine SC QD on days 1-7, mitoxantrone hydrochloride IV over 30 minutes, and etoposide IV over 1 hour on days 4-8. Patients may receive up to 2 additional courses of the same treatment as re-induction or consolidation therapy beginning 35-60 days from the start of the previous course.
62030027|NCT02459574|ACTIVE_COMPARATOR|Group 3-Conventional AF Ablation|This will involve an ablation procedure carried out in the usual manner. The patient will have three sheaths placed in the leg veins. Catheters will be passed up to the patient's heart from these veins. Two crossing are required into the left atrium. The ablation will involve freeze technology using the Advance Cryoballoon. It will include measuring the electrical signals and may also involve radiofrequency or 'burning' technology in addition.
62591139|NCT06487338|EXPERIMENTAL|Group A|Twenty patients will receive low-level laser therapy 3 times per week for a month
62591140|NCT06487338|EXPERIMENTAL|Group B|Twenty patients will receive shock wave therapy 3 times per week for a month
62804928|NCT00117637|EXPERIMENTAL|First Sorafenib (Nexavar, BAY43-9006) 400 mg then 600 mg|Subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (bid) (ie 12-hourly) orally until progression (= first intervention period, 5.7 months \[median\] ) and 3 tablets of Sorafenib twice daily (ie 12-hourly) orally until the following progression (= second intervention period, 3.6 months \[median\]) on a continuous basis.
62030028|NCT02459574|ACTIVE_COMPARATOR|Group 2-Anti-arrhythmic therapy|Anti-arrhythmic drugs: On the treatment start date the patient will have a new tablet prescribed or a change in the dosage of the medication. The patient will be reviewed at 8wks (visit 1) later to see if the medication is working. If the tablets are working, the patients medication will be left unchanged. If not, an alternative tablet or a higher dose will be used.
62228613|NCT01491893|EXPERIMENTAL|Dose Level 4 (dose escalation)|Participants received a single intratumoral infusion of 3.3 x 10\^9 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
62228614|NCT01491893|EXPERIMENTAL|Dose Level 5 (dose escalation)|Participants received a single intratumoral infusion of 1.0 x 10\^10 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
62421212|NCT03151226|OTHER|capnography monitoring|single arm, all subjects receiving duramorph will receive capnography monitoring
62804929|NCT00117637|ACTIVE_COMPARATOR|First Interferon then Sorafenib (Nexavar, BAY43-9006) 400 mg|Interferon (IFN) α-2a was administered at a dose of 9 million international units(MIU) subcutaneously three times a week until progression (= first intervention period, 5.6 months \[median\]). Subjects initially started with a single dose of 3 MIU IFN and increased the dose as rapidly as possible to 9 MIU IFN three times a week within 1 or 2 weeks in first intervention period.After first progression, subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (BID) (ie 12-hourly) until the next progression (=second intervention period, 5.3 months \[median\]).
62804930|NCT01847963|EXPERIMENTAL|Sindhuvallathy mezhugu|Sindhuvallathy mezhugu (SVM) 500 mg Twice daily per Oral 45 days duration
62804931|NCT01847963|EXPERIMENTAL|Kalladaippu Kudineer|Kalladaippu Kudineer (KK) 130 ml decoction Twice daily Per oral 45 days Duration
62804932|NCT01847963|EXPERIMENTAL|Sindhuvallathy + Kalladaippu Kudineer|Sindhuvallathy mezhu -500 mg capsules twice daily + Kalladaippu kudineer -130 ml decoction twice daily-per oral for 45 days.
62804933|NCT05661812||Patients|173 patients aged 18-75 years with self-reported allergic airways symptoms during autumn, primarily in August and September.
62804934|NCT05661812||Controls|114 controls aged 18-75, healthy, non-allergic individuals.
62804935|NCT04034706||PCOS females|Females diagnosed with PCOS with a BMI between 23 and 40 kg/m2.
62804936|NCT04034706||Non-PCOS control females|Females without PCOS with a BMI between 23 and 40 kg/m2 split into 2 groups- apple shaped and pear shaped.
62804937|NCT04734886|ACTIVE_COMPARATOR|L. reuteri DSM 17938|Probiotic compound
62804938|NCT04734886|PLACEBO_COMPARATOR|Placebo|Placebo compound
62804939|NCT03074565|EXPERIMENTAL|Ultrasonic alone|Sanative therapy using ultrasonic instrumentation only.
62804940|NCT03074565|ACTIVE_COMPARATOR|Ultrasonic+|Sanative therapy using ultrasonic plus hand instrumentation.
62804941|NCT01418430|EXPERIMENTAL|CHOP-daclizumab|
62804942|NCT01962441|EXPERIMENTAL|SOF+RBV 16 weeks|SOF+RBV for 16 weeks
62804943|NCT01962441|EXPERIMENTAL|SOF+RBV 24 weeks|SOF+RBV for 24 weeks
62804944|NCT01962441|EXPERIMENTAL|SOF+RBV+Peg-IFN 12 weeks|SOF+RBV+Peg-IFN for 12 weeks
62804945|NCT01962441|EXPERIMENTAL|Retreatment Substudy|Participants from the SOF+RBV arms (16 weeks or 24 weeks) who experienced virologic failure on treatment, or during the posttreatment period at or before Posttreatment Week 24 may be eligible to enroll into the Retreatment Substudy to receive SOF+RBV+Peg-IFN for 12 weeks.
62228615|NCT01491893|EXPERIMENTAL|Dose Level 4 (dose de-escalation)|Participants received a single intratumoral infusion of 3.3 x 10\^9 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
62228616|NCT01491893|EXPERIMENTAL|Dose Level 2 (dose expansion)|Participants received a single intratumoral infusion of 3.3 x 10\^8 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
62804946|NCT05734599||MAFLD-control group|Participants accepted health examinations including vibration-controlled transient elastography in Tongji and Union hospitals who are not MAFLD patients and are willing to participate in this study.
62228617|NCT01491893|EXPERIMENTAL|Dose Level -1 (dose expansion)|Participants received a single intratumoral infusion of 5.0 x 10\^7 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
62804947|NCT05734599||MAFLD-high hardness group|"Participants accepted health examinations including vibration-controlled transient elastography in Tongji and Union hospitals who are defined to have MAFLD and are willing to participate in this study.~The risk of advanced liver fibrosis was estimated based on the LSM value, FIB-4 score, and NAFLD fibrosis score (NFS), and patients were then divided into groups of low and high hardness according to the risk measured, as shown below:~High hardness group:~participants meet one of the following three requirements: LSM≥ 11.4 kPa；9.9\<LSM≤11.4 kPa and NFS≥0.676;9.9\<LSM≤11.4 kPa and FIB-4≥2.67.~NFS = -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) + 1.13 × Fasting blood glucose abnormalities / diabetes mellitus (with=1, none=0) + 0.99 × AST/ALT ratio - 0.013 × platelets (×109/L) - 0.66 × albumin (g/dl) FIB-4 = （age(years) x AST \[U/L\]) / ((PLT \[109/L\]) x (ALT \[U/L\])\^(1/2))"
62421213|NCT06440486|EXPERIMENTAL|Probiotics|Participants will receive a probiotic strip (3g/strip) daily alongside their standard clinical treatment for a continuous 12-week period.
62421214|NCT06440486|PLACEBO_COMPARATOR|Maltodextrin|Participants will take a daily placebo strip (3g/strip) in addition to their regular clinical treatment over a continuous 12-week period.
62421215|NCT00822679|EXPERIMENTAL|1: Eszopiclone|Subjects receive Eszopiclone for three consecutive nights to observe changes in sleep measures, and inflammatory and coagulation factors
62421216|NCT00822679|PLACEBO_COMPARATOR|2: Placebo|Subjects given placebo for 3 consecutive nights to observe changes in sleep measures, and inflammatory and coagulation factors
62804948|NCT05734599||MAFLD-low hardness group|"Participants accepted health examinations including vibration-controlled transient elastography in Tongji and Union hospitals who are defined to have MAFLD and are willing to participate in this study.~The risk of advanced liver fibrosis was estimated based on the LSM value, FIB-4 score, and NAFLD fibrosis score (NFS), and patients were then divided into groups of low and high hardness according to the risk measured, as shown below:~Low hardness group:~participants who do not meet the requirements of the high hardness group are low hardness group: LSM \< 9.9 kPa；9.9\<LSM≤11.4 kPa with NFS \< 0.676 and FIB-4\<2.67.~NFS = -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) + 1.13 × Fasting blood glucose abnormalities / diabetes mellitus (with=1, none=0) + 0.99 × AST/ALT ratio - 0.013 × platelets (×109/L) - 0.66 × albumin (g/dl) FIB-4 = （age(years) x AST \[U/L\]) / ((PLT \[109/L\]) x (ALT \[U/L\])\^(1/2))"
62804949|NCT05719649|EXPERIMENTAL|Probiotic NTU 101 Lactic Acid Bacteria Capsules|The subjects who meet the conditions of this test are randomly assigned according to the ratio of 1:1, and take the lactic acid bacteria NTU 101 (1.8 x 10 \^10 CFU) or Placebo in the test group for a total of 12 weeks of treatment. Once, after the treatment, the test physician evaluated the safety and efficacy of the subjects taking the test group lactobacillus NTU 101.
62804950|NCT05719649|PLACEBO_COMPARATOR|Placebo Capsules|Maltodextrin was used as a placebo.
62228618|NCT01491893|EXPERIMENTAL|Dose Level -2 (dose expansion)|Participants received a single intratumoral infusion of 1.0 x 10\^7 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
62804951|NCT00120016|EXPERIMENTAL|1|Mediterranean diet
62804952|NCT00120016|NO_INTERVENTION|2|non-intervention diet
62804953|NCT01046981|EXPERIMENTAL|Tumescent Antibiotic Delivery|TAD followed by sequential serum and interstitial tissue fluid sampling for antibiotic concentration of subsequent 24 hours
62804954|NCT01046981|EXPERIMENTAL|Intravenous Antibiotic Delivery|Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum and interstitial tissue fluid sampling for antibiotic concentration of subsequent 24 hours.
62228619|NCT01491893|EXPERIMENTAL|Dose Level -1 (selected dose expansion)|Participants received a single intratumoral infusion of 5.0 x 10\^7 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
62228620|NCT01600573|EXPERIMENTAL|pazopanib plus weekly topotecan|pazopanib in combination with weekly topotecan
62228621|NCT04328636|EXPERIMENTAL|NebMag|Neonates with PPHN receiving nebulized magnesium sulfate and intravenous placebo
62228622|NCT04328636|ACTIVE_COMPARATOR|IVMag|Neonates with PPHN receiving intravenous magnesium sulfate and nebulized placebo
62228623|NCT02182557|EXPERIMENTAL|WAL 801 CL Dry Syrup + Placebo|
62228624|NCT02182557|ACTIVE_COMPARATOR|Ketotifen Fumarate Dry Syrup + Placebo|
62228625|NCT00012623||Group 1|
62228626|NCT05050994|EXPERIMENTAL|Microwave ablation|Patients receiving microwave ablation of splenomegaly
62228627|NCT06081023|NO_INTERVENTION|Progressive Muscle Relaxation|This arm was provided with only a relaxing behavioral technique
62228628|NCT06081023|EXPERIMENTAL|Psycho-educational weight reduction program|This arm was provided with treatment of reducing emotional eating and obesity level
62228629|NCT02618031|OTHER|Favorable CIS|Patients with a favorable CIS (fCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines.
62228630|NCT02618031|EXPERIMENTAL|Poor CIS|Patients with a poor CIS (pCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines.
62228631|NCT04778423|EXPERIMENTAL|Avatar Therapy|AVATAR therapy for eating disorders
62228632|NCT03686319|NO_INTERVENTION|control groups|"Primiparas appropriate for the criteria, admitted to the clinic due to CS and accepting to participate in the study were randomly placed into groups. Reflexology was performed in the intervention group mothers, and the questionnaires and scales were self-reportingly filled in by the lead researcher (SC).~Different rooms were allocated for the participants in the intervention and control groups not to affect each other."
62228633|NCT03686319|EXPERIMENTAL|"intervention (foot reflexology)"|Reflexology was performed in those in the intervention group after CS on right foot for 10 min and left foot for 20 min as continuing 30-min seances three times per day every eight hours for three days. The procedure was started at mean 3rd hour after mothers became stable. Reflexology was performed for none of those in the control group.
62228634|NCT04671134|EXPERIMENTAL|Biomimetic remineralizing agent|
62228635|NCT04671134|ACTIVE_COMPARATOR|Resin modified glass ionomer varnish|
62228636|NCT00938860|EXPERIMENTAL|Neoral|Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
62228637|NCT00938860|ACTIVE_COMPARATOR|tacrolimus|Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
62228638|NCT03399487|EXPERIMENTAL|Arm 1|"This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.~This clinical study is targeted for the patients who harbor ROS1 rearrangement and all patients will be treated with LDK378 750mg daily. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.~Patients will be continued to receive study drug until the end of study unless the patients in disease progression, unacceptable toxicity, withdrawn consent, or by the investigator's judgment."
62030029|NCT02459574|EXPERIMENTAL|Group 1-AVATAR-AF Ablation Protocol|AF ablation with pulmonary vein isolation. The patient will have two sheaths in their leg veins instead of the usual three sheaths. Catheters will be passed up to the heart from these leg veins. The single crossing into the left atrium will be by the usual method. Veins will be ablated using freeze technology known as the Advance Cryoballoon. After the ablation is completed the patient will have scans on their heart and checks of the leg veins. If all the checks are satisfactory at six hours after the procedure the patient will be allowed to go home on the same day. The patient will be reviewed in clinic in 8 weeks (visit 1) after the procedure and if it has been successful, will be reviewed again a month later (visit 2) and if all is well, the patient will be discharged from clinic.
62030030|NCT00077025|ACTIVE_COMPARATOR|Anastrozole-placebo|Anastrozole (ZD1033, Arimidex)-Placebo
62030031|NCT00077025|ACTIVE_COMPARATOR|Anastrozole-ZD1839|Anastrozole (ZD1033, Arimidex)-ZD1839 (gefitinib, IRESSA)
62228639|NCT04187989|EXPERIMENTAL|Social Media Intervention|Facebook page that will deliver health information focused on increasing well-being and reducing risky behaviors.
62804955|NCT04960969|EXPERIMENTAL|Time-restricted Feeding Group|Participants will apply time-restricted feeding (8 hours/day) for 28 days.
62591141|NCT05548400||Criticaly ill patients who remained on invasive mechanical ventilation for at least 48 hours.|Criticaly ill patients who remained on invasive mechanical ventilation for at least 48 hours, and dietary followed up after ventilator withdrawal.
62804956|NCT04960969|NO_INTERVENTION|Control Group|No intervention will be applied.
62804957|NCT01698385|ACTIVE_COMPARATOR|Lifestyle counseling|
62591142|NCT06419543|EXPERIMENTAL|Group R1|The first induction dose of remimazolam is 0.1mg/kg.
62804958|NCT01698385|NO_INTERVENTION|Control, just measurements|
62804959|NCT04273334|EXPERIMENTAL|68Ga-NEB injection and PET/CT scan|Patients for lymphatic disorders imaging: The patients were subcutaneously injected with 68Ga-NEB and underwent PET/CT scan 20\~40min after the injection.
62804960|NCT04044469|EXPERIMENTAL|Immunization-enhancement|This group receives an immunization-promoting manipulation aimed at triggering negative appraisals of the medical information received and questioning the validity of the medical reassurance. For this purpose, a standardized information text is presented to the participants after receipt of the doctor's report, in which it is stated that the standard medical diagnosis in gastroenterology is often not particularly accurate and that serious diseases are from times to times overlooked. As a further factor contributing to the non-detection of diseases, it is mentioned that doctors are often under time pressure and thus do not have sufficient time to ask patients for all important information. It is believed that communicating this information will result in participants continuing to report high probabilities of serious illness despite the previously received findings report.
62804961|NCT04044469|EXPERIMENTAL|Immunization-inhibition|The aim of the immunization-inhibiting manipulation is to increase the probability that the normal test results obtained will be used to reduce worries about a serious illness. The participants of this group receive - analogous to the immunization-promoting group - a standardized information text which states that the standard medical diagnosis in gastroenterology is very accurate and that the physicians are very often correct in their initial diagnostic assessment, especially with regard to the assessment of a serious organic disease. This is supported by two scientific publications. The aim of this information is to increase the value of the results obtained, so that the participants are more reassured as a result of the inconspicuous test results and use them to correct their health-related concerns.
62030032|NCT03183427||Group of patients with pineal cyst|Group of patients with pineal cyst
62030033|NCT03183427||Control group|Group of subjects without pineal cyst
62030034|NCT00866840|EXPERIMENTAL|Riluzole|100 mg orally twice daily
62030035|NCT06627933||Low thromboembolic risk|
62030036|NCT06627933||Moderate thromboembolic risk|
62030037|NCT06627933||High thromboembolic risk|
62030038|NCT01201629|SHAM_COMPARATOR|t DC stimulation|Sham transcranial direct current stimulation tDCS induces slight short-lasting tingling with onset of the stimulation. These sensations usually fade away in seconds. Sham interventions are essential to blind the subject and the assessor in order to obtain unbiased assessment of intervention effects
62030039|NCT01201629|EXPERIMENTAL|tDC stimulation|Actual DC stimulation
62030040|NCT06636565||Hemophilia|Children with hemophilia
62591143|NCT06419543|EXPERIMENTAL|Group R2|The first induction dose of remimazolam is 0.2mg/kg.
62030041|NCT06636565||Healthy children|Healthy children
62228640|NCT04187989|NO_INTERVENTION|Control|An Attention-Control E-News (control) condition
62228641|NCT03005964|EXPERIMENTAL|AM001 Cream, 7.5%|A white to off-white Cream free from any foreign particles
62228642|NCT03005964|PLACEBO_COMPARATOR|Vehicle Cream|A white to off-white Cream free from any foreign particles.
62228643|NCT02470156|EXPERIMENTAL|High Intensity Arm (Intervention)|"Women in the High Intensity (intervention) arm are counseled by a wellness coach and have a group meeting each month. They are also interviewed four times (at baseline, 4 months, 8 months, and 12 months). Women in the high intensity group must have monthly contact with coaches during at least 9 of 12 months via participation in a group activity and/or monthly coaching to receive a full dose of the intervention."
62421217|NCT06611033|EXPERIMENTAL|V118C|Participants receive intramuscular (IM) injection of V118C in a 2-dose regimen administered on Day 1 and Day 29.
62591144|NCT06419543|EXPERIMENTAL|Group R3|The first induction dose of remimazolam is 0.3mg/kg.
62591145|NCT01550081|ACTIVE_COMPARATOR|Rate of perceived exertion|Exercise intensity controlled by Borg
62591146|NCT01550081|ACTIVE_COMPARATOR|Heart rate monitor|Exercise intensity controlled by heart rate monitors
62804962|NCT04044469|EXPERIMENTAL|Control group|This group does not receive additional information after the doctor's report.
62591147|NCT06410950||COPD subjects|"Individuals diagnosed with COPD based on GOLD spirometry criteria (post-bronchodilator FEV1/FVC ratio \< 0.70).~Stable COPD with no exacerbations requiring hospitalization in the past six months.~Age range: 45-75 years old."
62804963|NCT02104453|EXPERIMENTAL|E-C clamp mask holding technique|"the airway maneuver that press the mask against the patient's face (using the C of our thumb and forefinger) while pulling the jaw forward (using the E of our other fingers behind the mandible), and leaves one hand free to squeeze the bag."
62804964|NCT02104453|EXPERIMENTAL|two-handed ventilation with jaw thrust|the airway maneuver performed with thumbs point toward feet, palms press down and other fingers perform jaw thrust
62030042|NCT02166008|ACTIVE_COMPARATOR|Repamipide|Rebamipide (100) 1 tab oral tid for 1 year or peptic ulcer occurred
62804965|NCT02104453|EXPERIMENTAL|triple airway maneuver|the airway maneuver performed with two-handed mask ventilation, jaw thrust and head-tilt chin-lift technique
62030043|NCT02166008|PLACEBO_COMPARATOR|placebo|A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient. It will be prescribed as the same regimen of Rabamipide.
62030044|NCT01237002||Group 1|117 patients with cumulative clamping time between 60 and 120 minutes
62030045|NCT01237002||Group 2|72 patients with cumulative clamping time longer than 120 minutes
62030046|NCT01786967|EXPERIMENTAL|Fesoterodine Fumarate|Participants will receive 4 mg of study drug for first 2 weeks, and then 8 mg of study drugs for 2 weeks.
62030047|NCT04732403|NO_INTERVENTION|0 degree supine position|Surgical bed will be set to a 0 degree supine position
62228644|NCT02470156|ACTIVE_COMPARATOR|Low Intensity Arm (Comparison)|Women in the Low Intensity (comparison) arm are interviewed and coached four times during the study (at baseline, 4 months, 8 months, and 12 months).
62228645|NCT05311891||Retrospective|12000 participants positive for SARS-COV-2
62228646|NCT05311891||Prospective|600 participants positive for SARS-COV-2
62421218|NCT06611033|EXPERIMENTAL|V118|Participants receive IM injection of V118 in a 2-dose regimen administered on Day 1 and Day 29.
62421219|NCT06611033|ACTIVE_COMPARATOR|PREVNAR 20™ + Saline|Participants receive one dose of IM injection of PREVNAR 20™ in a 2-dose regimen on Day 1 followed by one dose of saline on Day 29.
62421220|NCT04083066|EXPERIMENTAL|Rituximab combined with formoterol, pemetrexed, dexamethasone|Rituximab 375mg/m2D0 is soluble in 0.9% NS, concentration 1mg/ml, micro pump is pumped for 4h Fotemustine 100mg/m2 D1 dissolved in 250mL 0.9% NS, intravenously for 1h, protected from light Pemetrexed 600mg/m2 D1 dissolved in 100ml 0.9% NS, intravenously 1h Dexamethasone 40mg D1-5 Dissolved in 100 ml 5% GS, intravenously (21 days is a cycle)
62421221|NCT06542731|EXPERIMENTAL|ONO-4578＋ONO-4538＋docetaxel ＋ ramucirumab|
62421222|NCT04466956|ACTIVE_COMPARATOR|Virtual reality for reduction of pain and anxiety during MVA|25 participants randomised to use VR headset during MVA and complete questionnaire and short interview regarding experience
62421223|NCT04466956|NO_INTERVENTION|Control group- no VR|25 participants randomised to not use VR headset during MVA and complete questionnaire and short interview regarding experience
62804966|NCT05448040|EXPERIMENTAL|Collagen|This group received a bone graft (xenograft) and had the socket covered with a collagen membrane, in order to protect the bone graft inserted and seal the socket.
62804967|NCT05448040|EXPERIMENTAL|Free gingival graft|This group received a bone graft (xenograft) biomaterial and had the socket covered with a free gingival graft material, in order to protect the bone graft inserted and seal the socket.
62804968|NCT00667888|ACTIVE_COMPARATOR|Intensity Modulated Radiotherapy (IMRT)|A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
62804969|NCT00667888|EXPERIMENTAL|Hypofractionated Intensity Modulated Radiotherapy (HIMRT)|A total dose of 72 Gy will be delivered in 30 fractions to the PTV.
62804970|NCT05715164|EXPERIMENTAL|E-cigarettes device plus liquid|The 200 participants will receive e-cigarettes along with basic care counseling for 48 weeks.
62804971|NCT05715164|EXPERIMENTAL|Nicotine Pouches|The 200 participants will receive nicotine pouches along with basic care counseling for 48 weeks.
62804972|NCT05715164|ACTIVE_COMPARATOR|Basic care counseling about smoking cessation|The 200 participants will receive basic care counseling for 48 weeks.
62804973|NCT06361563||Participants treated with adjuvant nivolumab|
62804974|NCT03494270|EXPERIMENTAL|Rosuvamibe Tab|Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks
62804975|NCT03494270|ACTIVE_COMPARATOR|Monorova Tab|Rosuvastatin 20mg qd for 24 weeks
62804976|NCT01274481|EXPERIMENTAL|Iloprost|All patients will have their response to Iloprost compared to baseline pre-treatment.
62030048|NCT04732403|EXPERIMENTAL|10-20 degree angle in reverse Trendelenburg|Surgical bed will be set to a 10-20 degree angle in reverse Trendelenburg
62030049|NCT01798953||UC/PSC with IPAA|Patients with ulcerative colitis and primary sclerosing cholangitis reconstructed with ileal pouch-anal anastomosis
62030050|NCT01798953||UC with IPAA|Patients with ulcerative colitis reconstructed with ileal pouch-anal anastomosis.
62030051|NCT01798953||UC/PSC with IRA|Patients with ulcerative colitis and primary sclerosing cholangitis reconstructed with ileorectal anastomosis.
62030052|NCT01798953||UC with IRA|Patients with ulcerative colitis reconstructed with ileorectal anastomosis.
62030053|NCT03981458|ACTIVE_COMPARATOR|Hyalofemme|Hyalofemme is a cream/gel containing hyaluronic acid, designed to be applied vaginally. This is primarily used in treatment of atrophic vaginitis and is applied by the patient once every three days. We intend treatment to continue for 6 months.
62030054|NCT03981458|ACTIVE_COMPARATOR|Ialuril|Ialuril is a bladder instillation designed to be delivered to the bladder via catheter. This is primarily used in patients suffering from recurrent UTI and acts to help rebuild the lining of the bladder, reducing irritation. Ialuril is applied weekly for 6 weeks, followed by every 2 weeks for 6 weeks, then once monthly for maintenance. Treatment will be continued for 6 months.
62030055|NCT02012491|ACTIVE_COMPARATOR|misoprostol plus mifepristone|800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior
62030056|NCT02012491|ACTIVE_COMPARATOR|misoprostol|800 micrograms of vaginal misoprostol alone
62030057|NCT04654416||Steroids|Dexamethasone 6mg intravenous OD for seven to ten days
62030058|NCT04654416||Colchicine|Patients treated with colchicine at a dose of 0.5 mg every 12 hours for 7 to 14 days.
62030059|NCT05437380|EXPERIMENTAL|CEUS|
62228647|NCT02584582|EXPERIMENTAL|Liraglutide + Liquid meal test|Liraglutide 1.2 mg once daily for 14 days (0.6 mg/day for one week, escalated to 1.2 mg/day after one week)
62228648|NCT02584582|EXPERIMENTAL|Exenatide + Liquid meal test|Exenatide 10 mcg twice daily for 14 days (5 mcg twice daily for one week, escalated to 10 mcg twice daily after one week)
62228649|NCT02584582|OTHER|Baseline + Liquid meal test|Baseline day with no additional medication
62804977|NCT05035758|NO_INTERVENTION|Control Goups|The control group (A) receives standard exercise therapy that is part of the rehabilitation at the center and no additional intervention
62421224|NCT05776732|EXPERIMENTAL|CaviionTM group|The first nursing is performed within 48 hours after PICC intubation, and each nursing is not more than 7 days thereafter. The nursing contents include skin disinfection, dressing replacement, flushing and locking venous catheters, needleless connector change. After the disinfectant was dried, the experimental group applied CaviionTM on the skin around the catheter and waited for 30 seconds before sticking the dressing.
62591148|NCT06410950||Healthy subjects|"Individuals with no history of chronic respiratory disease or recent infections.~Normal lung function on spirometry (post-bronchodilator FEV1/FVC ratio \> 0.70). Age range: 40-75 years old."
62591149|NCT04310605||Step 1 only|Participants in the study who only receive Step 1 of specialised CBT
62591150|NCT04310605||Step 1 and 2|Participants who receive both Step 1 and Step 2 of speciliased CBT for tinnitus.
62804978|NCT05035758|EXPERIMENTAL|Transcendental Meditation|The intervention group (B) receives transcendental meditation sessions (twice per day for 30 minutes) additionally to the standard rehabilitation therapy.
62804979|NCT05035758|EXPERIMENTAL|Yoga|The intervention group (C) receives yoga sessions (twice per day for 30 minutes) additionally to the standard rehabilitation therapy.
62804980|NCT05164081|EXPERIMENTAL|Dual antibiotic impregnated cement|Patients treated with a cemented hip hemiarthroplasty using dual antibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).
62591151|NCT04772196|NO_INTERVENTION|Control Group|Patients enrolled in the control group will receive standard of care.
62591152|NCT04772196|EXPERIMENTAL|Vitamin D Supplementation Group|Patients enrolled in the Vitamin D Supplementation Group will receive 50,000 IU Vitamin D3 weekly for 8 weeks.
62591153|NCT03153982|EXPERIMENTAL|Neoadjuvant Ruxolitinib|Participants will take 15 mg or 20 mg of ruxolitinib by mouth twice daily for up to 4 weeks during the pre-operative window for 14-21 days, or up to 28 days for delays in planned surgery. Dose will be assigned based on participant platelet count at baseline. The last dose will be taken the morning of planned surgery. Ruxolitinib will be dispensed in 5 mg tablets. Participants will either take three tables (15 mg) in the morning and evening, or four tablets in the morning and evening (20 mg). Participants will be asked to fill out a drug diary indicating when doses of study drug are taken and any side effects they experience.
62591154|NCT00832845|EXPERIMENTAL|CBSST plus treatment as usual|Subject randomized to the CBSST Group arm will attend 2 hour weekly Cognitive Behavioural Social Skills therapy sessions for 9 months. They will also be attending follow-up assessments q 4 months.
62591155|NCT00832845|ACTIVE_COMPARATOR|Treatment as Usual Group|Subjects randomized to the Treatment as Usual Group Arm will continue with their regular psychiatric treatment for 1 year. Like the CBSST Group Arm, they will have follow up assessments q 4 months. After completing the Treatment as Usual Group arm, they will automatically continue on with the CBSST Group Arm.
62591156|NCT05484349|EXPERIMENTAL|group A|Tizanidine Hydrochloride 1 mg Tid
62591157|NCT05484349|EXPERIMENTAL|group B|Tizanidine Hydrochloride 2 mg Tid
62591158|NCT05484349|PLACEBO_COMPARATOR|group C|placebo 1 tablet Tid
62591159|NCT02297776||CPC score 1 to 2|The patients with CPC score 1 to 2 judged half a year after cardiac arrest
62804981|NCT05164081|ACTIVE_COMPARATOR|Single antibiotic impregnated cement|Patients treated with a cemented hip hemiarthroplasty using single antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
62030060|NCT04207723|EXPERIMENTAL|TENS Therapy|Tens therapy + placebo drug therapy
62421225|NCT05776732|NO_INTERVENTION|Routine care group|The first nursing is performed within 48 hours after PICC intubation, and each nursing is not more than 7 days thereafter. The nursing contents include skin disinfection, dressing replacement, flushing and locking venous catheters, needleless connector change.
62591160|NCT02297776||CPC scores 3 to 5|The patients with CPC score 3 to 5 judged half a year after cardiac arrest
62591161|NCT02410798|EXPERIMENTAL|TransLoc electrode|Electrode placement
62804982|NCT05580822|EXPERIMENTAL|intra-arterial TNK infusion (0.4mg/min) via support/access catheter, over 15 minutes|
62804983|NCT05580822|EXPERIMENTAL|intra-arterial TNK infusion (0.25mg/min) via support/access catheter, over 15 minutes|
62804984|NCT05580822|PLACEBO_COMPARATOR|intra-arterial placebo infusion via support/access catheter, over 15 minutes|
62804985|NCT01288755|EXPERIMENTAL|001|TMC278 One 25 mg tablet once daily for 11 days (TrtA and C)
62421226|NCT01249690|EXPERIMENTAL|PAD|
62421227|NCT01249690|EXPERIMENTAL|TAD|
62421228|NCT03159611|EXPERIMENTAL|Tenoten for children|
62804986|NCT01288755|EXPERIMENTAL|002|Raltegravir One 400 mg tablet twice daily for 4 days (Trt B) and for 11 days (TrtC)
62804987|NCT05345353||The Aarhus Protocol, Aarhus municipality:|Children with obesity who participated in a family-centered multicomponent lifestyle intervention - The Aarhus Protocol, Aarhus Municipality
62804988|NCT05345353||The Randers Protocol, Randers municipality:|children with obesity who participated in a family-centered multicomponent lifestyle Intervention - The Randers Protocol: Randers Municipality
62804989|NCT05345353||No intervention|Children with obesity who didn't participate in a lifestyle intervention delivered by the municipality.
62421229|NCT03159611|PLACEBO_COMPARATOR|Placebo|
62421230|NCT04065386|ACTIVE_COMPARATOR|Active taVNS|"Patients will receive 5 days of transcutaneous auricular vagal nerve stimulation (taVNS) bilaterally, at the cymba conchae, the active localization.~It will be preceded and followed by a clinical assessment (Coma Recovery Scale- Revised) and a neurophysiological assessment (128/256 channels EEG and electrocardiograph) the first and last day of stimulation."
62421231|NCT04065386|PLACEBO_COMPARATOR|Sham taVNS|"Patients will receive 5 days of transcutaneous auricular vagal nerve stimulation (taVNS) bilaterally, at the ear lobe, the sham localization.~It will be preceded and followed by a clinical assessment (Coma Recovery Scale- Revised) and a neurophysiological assessment (128/256 channels EEG and electrocardiograph) the first and last day of stimulation."
62421232|NCT01728363|EXPERIMENTAL|Ticarcillin-clavulanate antibiotic|"Cohort Gestational Age (GA) Postnatal Age (PNA) Dose~1. \<30 weeks \<14 days: 75 mg/kg Q12 hrs x 6 doses~2. \<30 weeks ≥14 days-45 days 75 mg/kg Q 8 hours x 6 doses~3. \<30 weeks \>45 days-90 days 75 mg/kg Q 6 hours x 6 doses~Brand name is Timentin. This drug is an antibiotic used to treat a wide variety of bacterial infections. It is a combination of two drugs \& both treat bacterial infections. Ticarcillin is a penicillin-type antibiotic that stops bacterial growth \& clavulanate potassium is an enzyme inhibitor that helps the ticarcillin work better."
62228650|NCT03130803|NO_INTERVENTION|Baseline|9 hour sleep opportunity at habitual sleep/wake times for 14 days at home and 1 day in lab repeated for visit 1 and visit 2
62591162|NCT01985087|EXPERIMENTAL|Hypofractionated radiotherapy and temozolomide|All subjects will receive treatment as is a single arm study. Two weeks of combined hypofractionated radiotherapy with concurrent temozolomide followed by up to 6 cycles of adjuvant temozolomide treatment.
62804990|NCT01212562||Immunocryosurgery|2 weeks daily imiquimod application prior to a session of cryosurgery and subsequently 3 weeks continued daily imiquimod application
62804991|NCT02374749|ACTIVE_COMPARATOR|comorbidities|Evaluation of the prevalence and the presence of the risks factors of the four most frequently observed comorbidities in spondyloarthritis (cardiovascular diseases, cancers, infections osteoporosis and gastro-intestinal) as it is recommended by the French Society of Rheumatology.
62819470|NCT06704984|EXPERIMENTAL|Intervention group|Intervention group: A six-week intervention leveraging an online WeChat public account was implemented, integrating the IMB (Information-Motivation-Behavioral Skills) model into its design. Drawing from literature analysis, the intervention plan was structured into three distinct modules: information, motivation, and behavioral skills. The comprehensive intervention encompassed disseminating knowledge on Internet addiction, identifying and avoiding triggers, fostering withdrawal motivation, imparting coping strategies for cravings and challenging situations, enhancing self-efficacy, and facilitating access to personal and social support. Participants who followed the WeChat public account received automated push notifications containing articles or videos every two days. Throughout the intervention period, engagement was monitored by tracking the readership of the sent content through the WeChat public account's backend data.
62421233|NCT01728363|EXPERIMENTAL|Rifampin generic antibiotic|"Cohort GA PNA Dose~1. \<32 weeks \<14 days 10 mg/kg Q 24 hours x 4 doses~2. \<32 weeks ≥14 days-120 days 15 mg/kg Q 24 hours x 4 doses~3. ≥32 weeks \<14 days 15 mg/kg Q 24 hours x 4 doses~4. ≥32 weeks ≥14 days-120 days 20 mg/kg Q 24 hours x 4 doses~The brand name is Rifadin, Rimatane. This drug is an antibiotic and a first line antituberculotic and unlabeled use for infections caused by staphylococcus aureus \& staphylococcus epidermis."
62421234|NCT01728363|EXPERIMENTAL|Clindamycin Generic Antibiotic|"Cohort GA PNA Dose~1. \<30 weeks \<14 days 10 mg/kg Q 12 hours x 6 doses~2. \<30 weeks ≥14 days-45 days 10 mg/kg Q 8 hours x 6 doses~3. \<30 weeks \>45 days-120 days 10 mg/kg Q 6 hours x 6 doses~The brand name is Cleocin. This drug is an antibiotic used to treat a wide variety of bacterial infections and serious infections."
62591163|NCT04139512|OTHER|guided surgery|test group, using a full digital workflow procedure
62591164|NCT04139512|OTHER|conventional technic|free- hand technic to place implant
62591165|NCT06447662|EXPERIMENTAL|Part 1|PF-07934040 Monotherapy Dose Escalation PF-07934040 monotherapy at prescribed dose and frequency in 28-day cycles
62591166|NCT06447662|EXPERIMENTAL|Part 2a Cohort A1|Monotherapy dose expansion in 2-3L PDAC. PF-07934040 at prescribed dose and frequency in 28-day cycles
62591167|NCT06447662|EXPERIMENTAL|Part 2a Cohort B1|Monotherapy dose expansion in 2-3L CRC. PF-07934040 at prescribed dose and frequency in 28-day cycles
62591168|NCT06447662|EXPERIMENTAL|Part 2a Cohort C1|Monotherapy dose expansion in 2-3L NSCLC. PF-07934040 at prescribed dose and frequency in 28-day cycles
62591169|NCT06447662|EXPERIMENTAL|Part 2b Cohort A2|"Combination (PF-07934040 + Gemcitabine + Nab-paclitaxel) dose escalation/expansion in 1L PDAC.~Prescribed dose and frequency in 28-day cycles"
62591170|NCT06447662|EXPERIMENTAL|Part 2b Cohort B2|"Combination (PF-07934040 + Cetuximab) dose escalation/expansion in 2-3L CRC~Prescribed dose and frequency in 28-day cycles"
62228651|NCT03130803|EXPERIMENTAL|Insufficient Sleep|2 days with 5 hour sleep opportunities immediately following baseline on both visit 1 and visit 2.
62228652|NCT00640887|EXPERIMENTAL|1|RBT associated with EFV based ART
62228653|NCT00640887|EXPERIMENTAL|2|RBT associated with NVP based ART
62228654|NCT00640887|EXPERIMENTAL|3|RBT associated with LPV/r based ART
62228655|NCT02963103|EXPERIMENTAL|Tacrolimus group|oral
62228656|NCT01296685||oxygenator with arterial filter|
62228657|NCT01296685||arterial filter|
62228658|NCT02788903||Diabetes|During year 1 of the proposed project, the investigative team will identify a valid cohort of patients with type 2 diabetes using EHR data. The cohort of patients under study will be defined as all patients age 18 and older with an indication of type 2 diabetes during the proposed study time frame (2009-2019).
62421235|NCT04078659|EXPERIMENTAL|Propofol infusion|Patients received intravenous Propofol infusion
62421236|NCT04078659|EXPERIMENTAL|Magnesium Sulfate infusion|Patients received intravenous Magnesium Sulfate infusion
62421237|NCT01450150|EXPERIMENTAL|Active tDCS|
62421238|NCT01450150|SHAM_COMPARATOR|Sham tDCS|
62421239|NCT01519895|NO_INTERVENTION|Existing care|routine existing care
62421240|NCT01519895|EXPERIMENTAL|Telephone intervention|in addition to provide telephone intervention support
62421241|NCT04641273|EXPERIMENTAL|Part A: BAY1817080 150 mg BID|In Part A, Participants will be randomized to this arm with BAY1817080 150 mg BID.
62591171|NCT06447662|EXPERIMENTAL|Part 2b Cohort B3|"Combination (PF-07934040 + FOLFOX + Bevacizumab) dose escalation/expansion in 1L CRC~Prescribed dose and frequency in 28-day cycles"
62591172|NCT06447662|EXPERIMENTAL|Part 2b Cohort C2|"Combination (PF-07934040 + Pembro) dose escalation/expansion in 1L NSCLC (TPS ≥ 50%)~Prescribed dose and frequency in 21-day cycles"
62591173|NCT06447662|EXPERIMENTAL|Part 2b Cohort C3|"Combination (PF-07934040 + Pembro + Platinum Chemo) dose escalation/expansion in 1L NSCLC (any TPS)~Prescribed dose and frequency in 21-day cycles"
62591174|NCT02976779|EXPERIMENTAL|OWC MGC cream|Cannabis based topical cream 3% CBD and 3% THC. The cream was designed to treat Psoriasis . The cream will be applied twice daily.
62591175|NCT02976779|PLACEBO_COMPARATOR|OWC Control Cream|Carrier cream. CBD and THC were taken out from the formulation. The cream will be applied twice daily.
62591176|NCT05462860|EXPERIMENTAL|Suprathel® dressing|The Suprathel® dressing will be applied to the wound site after standard of care cleaning and debridement. The dressing will be maintained according to the manufacturer's instructions for use
62591177|NCT05462860|ACTIVE_COMPARATOR|Standard of Care|The Standard of care as prescribed will be followed for the dressing application for the wound site. Dressings will be applied to the wound site after standard of care cleaning and debridement.
62591178|NCT05872867|EXPERIMENTAL|Dose escalation (Stage 1)|WM-A1-3389 administered intravenously, weekly for 21 days of each cycle
62591179|NCT05872867|EXPERIMENTAL|Dose escalation (Stage 2)|WM-A1-3389 administered intravenously, weekly for 21 days of each cycle Pembrolizumab 200 mg administered intravenously, every 3 weeks for 21 days of each cycle
62819471|NCT06704984|NO_INTERVENTION|Control group|Control group: without any intervention, maintain normal life and study state.
62591180|NCT04589546|EXPERIMENTAL|Vitamin B3|
62228659|NCT02788903||Pre-Diabetes|The cohort of patients under study will be defined as patients age 18 and older who are at risk for the development of diabetes, based on being overweight. Patients seen at one of the six PaTH institutions will be included in the at-risk cohort if they have a BMI ≥ 25 kg/m2, based on most recent recorded weight and at least one recorded height.
62591181|NCT04589546|PLACEBO_COMPARATOR|Placebo|
62819472|NCT00497614|OTHER|No arm|
62228660|NCT01800981||Debrase|Patients previously treated with Debrase for burn debridement
62421242|NCT04641273|PLACEBO_COMPARATOR|Part A: Placebo BID|In Part A, Participants will be randomized to this arm with placebo for BAY1817080.
62421243|NCT04641273|EXPERIMENTAL|Part B: BAY1817080 25 mg BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with BAY1817080 25 mg BID and placebo for pregabalin.
62421244|NCT04641273|EXPERIMENTAL|Part B: BAY1817080 75 mg BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with BAY1817080 75 mg BID and placebo for pregabalin.
62421245|NCT04641273|EXPERIMENTAL|Part B: BAY1817080 150 mg BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with BAY1817080 150 mg BID and placebo for pregabalin.
62228661|NCT01800981||Standard of Care|Patients previously treated with local Standard of Care for burn debridement
62228662|NCT04589429|ACTIVE_COMPARATOR|MN group|intrathecal morphine 300 micrograms+2mg nalbuphine
62228663|NCT04589429|PLACEBO_COMPARATOR|M group|intrathecal morphine 300 micrograms
62228664|NCT04871100|EXPERIMENTAL|UP-A|Cognitive behavior therapy using the Unified Protocol for Emotional Disorders with supplemental skills-based alcohol modules.
62228665|NCT04871100|ACTIVE_COMPARATOR|Problem Solving therapy|Skills based approach for managing negative moods and stress.
62421246|NCT04641273|PLACEBO_COMPARATOR|Part B: Placebo BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with placebo for BAY1817080 and placebo for pregabalin.
62421247|NCT04641273|ACTIVE_COMPARATOR|Part B: Pregabalin|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with placebo for BAY1817080 and pregabalin.
62591182|NCT03215511|EXPERIMENTAL|Cancer participants <12 years|A Rolling-6 dose escalation design will be used. The starting dose for participants age \< 12 years will be 25% below the highest dose level cohort divided by 1.73 m\^2 cleared by the Safety Review Committee (SRC) for subjects age 12 years and older.
62591183|NCT03215511|EXPERIMENTAL|Cancer participants ≥12 years|A 3+3 dose escalation design will be used to determine the maximum tolerated dose (MTD)/recommended dose for further study, enrolling 3 to 6 participants per cohort with a starting dose level of 100 mg twice daily (BID).
62591184|NCT02923362||Laparoscopic Fundoplication Group|This group of patients are surgical candidates based on preoperative testing results for laparoscopic fundoplication antireflux procedure and possible hiatal hernia repair.
62228666|NCT02183597||Advanced breast cancer|Women with advanced breast cancer
62228667|NCT02709824|ACTIVE_COMPARATOR|Chlorhexidine gluconate with ADS|Chlorhexidine 0.12% plus Anti-Discoloration System Mouthwash
62228668|NCT02709824|ACTIVE_COMPARATOR|Chlorhexidine gluconate without ADS|Chlorhexidine 0.12% Mouthwash
62228669|NCT03940053|NO_INTERVENTION|Observation|Subjects only accept the routine treatment for underlying diseases.
62228670|NCT03940053|EXPERIMENTAL|Intervention|Based on the routine treatment for underlying diseases, subjects were administrated by arginine.
62421248|NCT02645266|EXPERIMENTAL|Aflibercept Injection [Eylea] group|Intervention: Subjects will be receiving a (2mg/ml) dose of VEGF-Trap, injected intravitreally at the start of every month, for the 4 months duration of the trial.
62421249|NCT03534830||eLASV > 38.5|exposed group of patients with an eLASV at or above 38.5 on a pre-operative MRI.
62421250|NCT03534830||eLASV < 38.5|non-exposed group of patients with an eLASV less than 38.5 of pre-operative MRIs
62228671|NCT04986085||GEP NET|GEP NET patients in Spain
62228672|NCT01414985|EXPERIMENTAL|Group A|Group A consists of 2 subjects who received 9x10\^11 molecules of AAVrh.10CUCLN2, the gene transfer vector carrying the CLN2 gene. This is equal to 900,000,000,000 molecules of the study drug. The drug will be administered only once in the study.
62228673|NCT01414985|EXPERIMENTAL|Group B|Group B will consist of 6 subjects who will receive 2.85x10\^11 molecules of AAVrh.10CUCLN2, the gene transfer vector carrying the CLN2 gene. This is equal to 285,000,000,000 molecules of the drug. The drug will be administered only once in the study.
62228674|NCT02325167|EXPERIMENTAL|EBT|
62591185|NCT02923362||LINX Antireflux Device Group|This group of patients are surgical candidates based on preoperative testing results for the laparoscopic LINX antireflux device placement and possible hiatal hernia repair.
62591186|NCT01880086|EXPERIMENTAL|Clomiphene citrate|The initial dose of clomiphene citrate will be 25 mg (po, pill by mouth) every other day. This will be started at visit 2, week 0 of the study following diagnosis of low baseline testosterone (serum total testosterone \<350 ng/dl in men \<55 years, \<300 ng/dl in men 55-65 years). Clomiphene citrate dose will be titrated up to a maximum of 50 mg daily according to serum total testosterone levels measured at follow-up visits during the 3 month duration of the study.
62228675|NCT02325167|EXPERIMENTAL|Treatment-as-usual|
62421251|NCT03271541|EXPERIMENTAL|Bitopertin|"Part 1 - The main study - 16 weeks in total:~Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose of bitopertin.~Part 2 - Open Label Extension (OLE) - up to an additional 12 months:~Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed.~Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period."
62804992|NCT02374749|ACTIVE_COMPARATOR|self-assessment|"During the initial visit, the clinical research nurse exempt a learning program of assessment of disease activity/severity :~* for assessing the activity in SpA;~* for the calculation of BASDAI and the ASDAS-CRP~* for the transfer technique and for the calculation of the disease activity on a monthly basis during the next 12 months.~* for the risk of tobacco exposure~* for the benefit of an NSAID intake in case of painful episode of the disease~* for the benefit of home exercises~* for the spine and indication of a treatment under the supervision of a physiotherapist in case of severe disease~* for learning the patient to calculate his BASDAI and ASDAS-CRP Then, the patient will return home with his calculator and his notebook. Each month, the patient will be asked to perform the BASDAI and ASDAS-CRP calculations and to report the data on the notebook. 12 months later, the patient comes for a visit in the current practice to assess both such program and comorbidities."
62804993|NCT05272371|EXPERIMENTAL|Intervention arm|Chemoimmunotherapy arm.
62804994|NCT02719171|PLACEBO_COMPARATOR|Placebo|Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection every 4 weeks for 16 weeks.
62804995|NCT02719171|EXPERIMENTAL|Risankizumab 150 mg Every 4 Weeks|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection every 4 weeks for 16 weeks.
62804996|NCT02719171|EXPERIMENTAL|Risankizumab 150 mg Weeks 0, 4, and 16|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0, 4, and 16.
62804997|NCT02719171|EXPERIMENTAL|Risankizumab 150 mg Weeks 0 and 12|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 12.
62804998|NCT02719171|EXPERIMENTAL|Risankizumab 75 mg Week 0|Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Week 0.
62804999|NCT05751746||Control|Control group with participants who do not get magnesium sulfate administration.
62805000|NCT05751746||Magnesium group|Intervention group with participants who get magnesium sulfate administration.
62805001|NCT05448495|EXPERIMENTAL|Posterior TAP block|
62805002|NCT05448495|ACTIVE_COMPARATOR|ESPB|
62805003|NCT03866655|EXPERIMENTAL|Intervention|
62805004|NCT03866655|NO_INTERVENTION|Control|
62421252|NCT00530088|EXPERIMENTAL|Porfimer Sodium|Patients receive porfimer sodium subcutaneously followed by photodynamic therapy (PDT) comprising laser light delivered by a single or a diffuser (i.e., for broad areas of dysplasia) fiberoptic lens fiber.
62421253|NCT05779488|EXPERIMENTAL|maca group|
62421254|NCT05779488|PLACEBO_COMPARATOR|Placebo group|
62421255|NCT02591017|OTHER|morphine drops solo and placebo spray|"morphine 2% drops~1. daily fixed dose of morphine equivalents \< 100 mg, 0.2 mg/kg Body weight morphine drops every hour in reserve due to international Standards~2. daily fixed dose of morphine equivalents =/\> 100 mg, 15% of the fixed daily dose in morphine drops every hour in reserve due to international standards"
62421256|NCT02591017|OTHER|ketamine/chitosan spray nasal and placebo drops|5 mg ketamine all 5 minutes, maximal 4 times an hour
62421257|NCT02591017|OTHER|morphine drops and ketamine/chitosan spray nasal|see above
62421258|NCT02378467|EXPERIMENTAL|Active Treatment Group|7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
62805005|NCT00893035||Intermediate prognosis prostate cancer|Intermediate prognosis prostate cancer
62805006|NCT00893035||Breast cancer|conservative treatment and age\<60 Boost irradiation and age\>60
62805007|NCT02736058|EXPERIMENTAL|Participants|the included pregnant females will undergo trans-abdominal sonography as well as trans-vaginal sonography , to diagnose the abnormal placentation and the results will be compared to the intra- operative as well as the pathological examination of the specimen.
62805008|NCT05940194|EXPERIMENTAL|COVIVAC 3 mcg|3 mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
62805009|NCT05940194|EXPERIMENTAL|COVIVAC 6 mcg|6 mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
62805010|NCT05940194|ACTIVE_COMPARATOR|AZD1222|AZD1222 (AstraZeneca) vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
62805011|NCT00276263|EXPERIMENTAL|1|
62805012|NCT03515759||hypertensive patients|60 pregnant women with singleton living fetus between 34 -38 wks gestation known to have severe hypertension in the current pregnancy were included
62805013|NCT03827135|ACTIVE_COMPARATOR|Traditional physical therapy|Cervical isometrics and Muscle Stretching
62805014|NCT03827135|EXPERIMENTAL|Cyriax manipulation|Experimental group was given cyriax manipulation protocol along with the cervical isometrics and muscle stretching.
62805015|NCT01949935|PLACEBO_COMPARATOR|Control|Placebo made from Glaxal base Applied once 1 day preoperatively and bid for 3 days postoperatively.
62805016|NCT01949935|EXPERIMENTAL|Mupirocin|Mupirocin ointment applied to nares once 1 day preoperatively and bid for 3 days postoperatively.
62805017|NCT02461381||Dr.Tang's research group|This group included diabetic participants with completed both the short-term HRV test and Ewing's test.
62805018|NCT01707836||Family|Families with a child with Neurofibromatosis Type 1 who has been diagnosed with a brain tumor.
62421259|NCT02378467|ACTIVE_COMPARATOR|Control Group|0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks
62805019|NCT04562181|EXPERIMENTAL|Interventions|Anesthesia will be induced with bolus infusion using propofol, sufentanil and cis-atracurium intravenously. The patients will be intubated subsequently. TOF (T4/T1) will be calculated continuously using muscle relaxation monitoring. Anesthesia are maintained with a combination of sevoflurane, propofol, sufentanil and cis-atracurium. Anti-emetic and opioids will be routinely administrated prior to abdominal closure. Neostigmine will be administrated for reversing the residual neuromuscular blockade after the patient get his breath. Tracheal extubating is indicated by a TOF value above 70% in addition to other physical signs.
62805020|NCT04325971|EXPERIMENTAL|Healthy Subjects|All healthy subject are gathered in one arm
62805021|NCT04585282|EXPERIMENTAL|intervention group|The study group was treated with intensive cognitive behavioral therapy for insomnia.
62805022|NCT04585282|ACTIVE_COMPARATOR|control group|The control group was treated with traditional cognitive behavioral therapy for insomnia.
62805023|NCT00744926|PLACEBO_COMPARATOR|placebo|
62805024|NCT00744926|EXPERIMENTAL|taspoglutide 10mg sc|
62805025|NCT00744926|EXPERIMENTAL|taspoglutide 10mg/20mg sc|
62805026|NCT01843036|EXPERIMENTAL|Durham Connects Eligible|From January 1, 2014 - June 30, 2014, all odd-birth-date residential births in Durham County, North Carolina will be randomly assigned to receive the Durham Connects nurse home visiting program.
62030061|NCT04207723|SHAM_COMPARATOR|Control|Standard treatment (paroxetine 20 mg) + sham therapy
62030062|NCT04207723|EXPERIMENTAL|Combination therapy|Tens therapy + standard treatment (paroxetine 20 mg)
62421260|NCT06412991|EXPERIMENTAL|Cycle therapy|The patient will either ambulate a short distance to recumbent bike which will be stored on the postsurgical 1 unit or be assisted out of bed to use floor cycle bike. After the patient demonstrates individual competency with either cycle modality, the patient may participate in this activity with nursing staff but will not require Physical Therapy (PT) presence at the time of use. This will allow the patient to participate multiple times a day if they choose.
62421261|NCT06412991|NO_INTERVENTION|ambulation as mobilization modality|ambulation by surgical team
62421262|NCT00788723|EXPERIMENTAL|1|Patients with severe brain injury, awake, but have cognitive problems
62591187|NCT01880086|PLACEBO_COMPARATOR|Placebo|Placebo pill will be administered (po, pill by mouth) every other day starting at week 0 of the study in men diagnosed with low testosterone. Treatment will be delayed in these men until the 3 month completion of the study, at which time this group may also receive testosterone replacement therapy.
62421263|NCT00788723|EXPERIMENTAL|2|Patients with severe brain injury and disorders of consciousness ( in minimally conscious or in vegetative state)
62421264|NCT00788723|EXPERIMENTAL|3|Healthy volunteers
62421265|NCT06176989|EXPERIMENTAL|1|Participants with IDH2 mutated (R140/R172) malignant sinonasal and skull base tumors.
62805027|NCT01843036|NO_INTERVENTION|Control|From January 1, 2014 - June 30, 2014, all even-birth-date residential births in Durham County, North Carolina will be randomly assigned to a control group condition. These families will be assigned to receive services as usual and serve as the randomized comparison group for evaluating Durham Connects program impact.
62421266|NCT01831596|EXPERIMENTAL|ciSNaP|
62421267|NCT02806622||Division II Collegiate Athletes|Student athletes (18-45) currently enrolled and participating on a sports team.
62421268|NCT05435872|EXPERIMENTAL|The intervention group (Artificial intelligence Cloud Platform Auxiliary Group)|The patients in this group would be examined by endoscopists with the Artificial intelligence Cloud Platform Auxiliary Device launched with gastrointestinal endoscopy.
62421269|NCT05435872|NO_INTERVENTION|The control group (Non-Auxiliary Group).|The patients in this group would be examined by endoscopists with the gastrointestinal endoscopy alone.
62805028|NCT01244841|NO_INTERVENTION|Standard care|Randomised to standard post MI care and length of hospital stay decided by treating physician.
62805029|NCT01244841|ACTIVE_COMPARATOR|Early discharge|Randomised patient where all post MI investigations, treatment, follow-up plans and information will be performed within 3 days, and the patients are thereafter discharged.
62030063|NCT02564575|EXPERIMENTAL|Cohort 1|Participants will receive two doses, separated by 4-8 weeks, of approximately 10\^6 PFU/mL of the HPIV3-EbovZ GP vaccine.
62030064|NCT02564575|EXPERIMENTAL|Cohort 2|Participants will receive two doses, separated by 4-8 weeks, of approximately 10\^7 PFU/mL of the HPIV3-EbovZ GP vaccine.
62421270|NCT05581199|EXPERIMENTAL|Treatment Period 1: Cohort A, Dose 1|
62421271|NCT05581199|EXPERIMENTAL|Treatment Period 1: Cohort A, Dose 2|
62421272|NCT05581199|EXPERIMENTAL|Treatment Period 1: Cohort B, Dose 1|
62421273|NCT05581199|EXPERIMENTAL|Treatment Period 1: Cohort B, Dose 2|
62591188|NCT04934189|OTHER|Empowerment Self-Defense Training- Pre-Post Single Arm Design Pilot Trial|Refinement and assessment of the feasibility and acceptability of the Empowerment Self-Defense curriculum will occur in Phase 2 through the delivery of the tailored ESD curriculum to 3 groups of 16 TW.
62805030|NCT00523757|EXPERIMENTAL|1|Spironolactone
62421274|NCT05581199|EXPERIMENTAL|Treatment Period 1: Cohort C, Dose 1|
62421275|NCT05581199|EXPERIMENTAL|Treatment Period 1: Cohort C, Dose 2|
62421276|NCT05581199|EXPERIMENTAL|Treatment Period 1: Cohort D, Dose 1|
62421277|NCT05581199|EXPERIMENTAL|Treatment Period 1: Cohort D, Dose 2|
62421278|NCT05581199|EXPERIMENTAL|Withdrawal Period 2: Cohort A, Dose 2|
62421279|NCT05581199|EXPERIMENTAL|Withdrawal Period 2: Cohort A, Placebo|
62421280|NCT05581199|EXPERIMENTAL|Withdrawal Period 2: Cohort B, Dose 2|
62805031|NCT00523757|PLACEBO_COMPARATOR|2|
62805032|NCT01983228|NO_INTERVENTION|Arm 1: Usual Care|Participants randomized to the usual care control condition will receive pedometers and an informational brochure.
62819473|NCT04678895|EXPERIMENTAL|Group A, Low-Dose Naltrexone, Then Placebo|Group A will receive active drug (Naltrexone 1 capsule by mouth daily, 1.5mg x1 week, 3mg x1 week, and 4.5 mg x6 weeks) for the first 8 weeks. Capsules of different dosages will be indistinguishable. Then followed by 4 weeks of placebo (placebo capsule will be matched with LDN capsule, microcrystalline cellulose filler, 1 capsule daily).
62421281|NCT05581199|EXPERIMENTAL|Withdrawal Period 2: Cohort B, Placebo|
62421282|NCT05581199|EXPERIMENTAL|Withdrawal Period 2: Cohort C, Dose 2|
62591189|NCT05317585|EXPERIMENTAL|Continuous Glucose Monitoring (CGM)|Patients will be randomized to application of a continuous glucose monitor (CGM). They will apply the device in the clinical setting and be instructed how to download their information onto their smartphones or using the CGM device reader. They will use the CGM for the duration of the pregnancy until delivery.
62591190|NCT05317585|ACTIVE_COMPARATOR|Fingerstick Glucose Monitoring|Patients will be randomized to checking their blood glucose with fingerstick monitors at time of fasting in the AM, and 2 hours after each meal. This is the standard of care for patients in the pregnancy diabetes clinic.
62591191|NCT03361969|ACTIVE_COMPARATOR|estetrol|
62591192|NCT03361969|PLACEBO_COMPARATOR|placebo|
62805033|NCT01983228|EXPERIMENTAL|Arm 2: Intervention Group|Participants assigned to the intervention group will receive personalized recruitment materials, including a letter and brochure describing the program and the benefits of walking for pain. They will also receive pedometers. Participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
62805034|NCT00292942|EXPERIMENTAL|2 mg/kg Intravenous Artesunate|2 mg/kg of Intravenous artesunate
62805035|NCT00292942|EXPERIMENTAL|4 mg/kg Intravenous Artesunate|4 mg/kg of Intravenous artesunate
62805036|NCT00292942|EXPERIMENTAL|8 mg/kg Intravenous Artesunate|8 mg/kg of Intravenous artesunate
62805037|NCT00292942|PLACEBO_COMPARATOR|Placebo|Mannitol (200 mg/vial) diluted in phosphate buffer and delivered in an equivalent volume by subject's weight as artesunate.
62805038|NCT02669342|ACTIVE_COMPARATOR|Group A: Sharklet Catheter for 2 weeks first|"Arm A will have catheters inserted according to the schedule below:~1. Sharklet catheter inserted for 2 weeks~2. Standard catheter inserted for 2 weeks~3. Sharklet catheter inserted for 4 weeks~4. Standard catheter inserted for 4 weeks"
62805039|NCT02669342|ACTIVE_COMPARATOR|Group B: Sharklet Catheter for 4 weeks first|"Arm B will have catheters inserted according to the schedule below:~1. Sharklet catheter inserted for 4 weeks~2. Standard catheter inserted for 4 weeks~3. Sharklet catheter inserted for 2 weeks~4. Standard catheter inserted for 2 weeks"
62805040|NCT01574586|ACTIVE_COMPARATOR|2-link stent Nobori|Bifurcation stenting
62805041|NCT01574586|ACTIVE_COMPARATOR|3-link stent Xience|Bifurcation stenting
62805042|NCT02334930||Patients|Patients who will have biopsy or surgery for Perivascular epithelioid cell tumor (PEComa) or vascular pediatric tumor (Rapidly Involuting Congenital Hemangioma (RICH), Non Involuting Congenital Hemangioma (NICH), hemangioma or pyogenic granuloma)
62421283|NCT05581199|EXPERIMENTAL|Withdrawal Period 2: Cohort C, Placebo|
62591193|NCT03344692|EXPERIMENTAL|Alirocumab|Alirocumab 75 mg for subcutaneous injection via a pre-filled pen. One injection every 2 weeks during a 10-weeks period (5 injections in total)
62591194|NCT03344692|PLACEBO_COMPARATOR|Placebo|"Placebo matching alirocumab is prepared in the same formulation as alirocumab, without the addition of protein, for subcutaneous injection via a pre-filled pen.~One injection every 2 weeks during a 10-weeks period (5 injections in total)"
62591195|NCT05313022|EXPERIMENTAL|ZR-202-CoV|Adult healthy subjects (60 years of age above, inclusive) receive ZR-202-CoV at Day 0 and Day 28
62591196|NCT05313022|PLACEBO_COMPARATOR|Placebo|Adult healthy subjects (60 years of age and above) receive 2 doses of placebo (saline) at Day 0 and Day 28
62805043|NCT03188146||PBC patients with liver biopsy|Ursodeoxycholic acid will be given compliance to the treatment guideline.
62805044|NCT01203735|OTHER|Valproic acid, Chemoradiotherapy|
62421284|NCT05581199|EXPERIMENTAL|Withdrawal Period 2: Cohort D, Dose 2|
62421285|NCT05581199|EXPERIMENTAL|Withdrawal Period 2: Cohort D, Placebo|
62421286|NCT05581199|EXPERIMENTAL|LTE Period: With Relapse in Period 2: Dose 1 and Dose 2|Participants will receive Dose 1 for the initial 4 weeks only and Dose 2 for the remaining 48 weeks.
62421287|NCT05581199|EXPERIMENTAL|LTE Period: Without Relapse in Period 2: Dose 2|Participants will receive Dose 2 for all 52 weeks.
62421288|NCT01220128|EXPERIMENTAL|Cohort A-GSK2302024A Group|This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of GSK2302024A according to the treatment schedule.
62591197|NCT02901275|PLACEBO_COMPARATOR|Placebo + Placebo|Within-subject double-blind, double-dummy administration of placebo + placebo. Order of dose randomized session days 2-5.
62591198|NCT02901275|ACTIVE_COMPARATOR|Hydromorphone (oral) 4mg + Placebo|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + placebo. Always administered during session 1.
62591199|NCT02901275|EXPERIMENTAL|Hydromorphone (oral) 4mg / Dronabinol (oral) 2.5mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 2.5mg. Order of dose randomized session days 2-5.
62591200|NCT02901275|EXPERIMENTAL|Hydromorphone (oral) 4mg / Dronabinol (oral) 5mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 5.0mg. Order of dose randomized session days 2-5.
62805045|NCT06172686|EXPERIMENTAL|Arm1|The first arm will receive Piperaquine tablets , that will be administered orally. Sub-curative regimen will be given as two tablets of 320mg and 160mg (total of 480mg).
62805046|NCT06172686|EXPERIMENTAL|Arm 2|The second arm will receive Doxycycline (100mg tablets strength as Doxycycline hyclate) that will also be administered orally. Sub-curative regimen will be given as 1 tablet (100mg) once daily for 7 days.
62805047|NCT02832934|EXPERIMENTAL|1|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
62030065|NCT05952141|EXPERIMENTAL|Stage 1 Clinic Outreach + Stage 2 Low Touch|All participants receive direct clinic outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging (stage 2).
62228676|NCT03748407|OTHER|dosages in Healthy volunteers|"Only one arm : healthy volunteer blood donors. Performing a blood test for the determination of parameters that explore thyroid status : only once.~Absence of other healthy volunteers group all healthy volunteers have a blood test performed in the same way."
62228677|NCT05864261|EXPERIMENTAL|JT1801|
62228678|NCT05864261|ACTIVE_COMPARATOR|NESP|
62228679|NCT02789527|EXPERIMENTAL|Healthy volunteers in Ethiopia|Phenotype and genotype of enzymes involved in drug metabolism in Ethiopia population
62228680|NCT02789527|EXPERIMENTAL|Healthy volunteers in Oman|Phenotype and genotype of enzymes involved in drug metabolism in Oman population
62228681|NCT02789527|EXPERIMENTAL|Healthy volunteers in the Czech Republic|Phenotype and genotype of enzymes involved in drug metabolism in Czech Republic population
62805048|NCT02832934|PLACEBO_COMPARATOR|2|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
62805049|NCT00269308|EXPERIMENTAL|1|Chiropractic Manual Treatment + Home Exercise
62591201|NCT02901275|EXPERIMENTAL|Hydromorphone (oral) 4mg / Dronabinol (oral) 10mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 10mg. Order of dose randomized session days 2-5 but was never the first hydromorphone 4mg + dronabinol combination dose.
62805050|NCT00269308|EXPERIMENTAL|2|Supervised Rehabilitative Exercise + Home Exercise
62805051|NCT00269308|ACTIVE_COMPARATOR|3|Home Exercise
62228682|NCT02789527|EXPERIMENTAL|Healthy volunteers in Greece|Phenotype and genotype of enzymes involved in drug metabolism in Greek population
62591202|NCT04090138|ACTIVE_COMPARATOR|Setria performance blend|l-citrulline + glutathione
62228683|NCT06254547|EXPERIMENTAL|Motivational messages and leaderboard|This group will receive daily reminders/motivational messages. They will be able to view their personal score and will be ranked on a daily updated leaderboard.
62591203|NCT04090138|PLACEBO_COMPARATOR|Placebo|
62805052|NCT02394314|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously
62228684|NCT06254547|EXPERIMENTAL|Only motivational messages|This group will receive daily reminders/motivational messages. They will be able to view their personal score, but they will not be ranked on a leaderboard.
62228685|NCT06254547|NO_INTERVENTION|Control|This group will be able to view their personal score, but will not be ranked on a leaderboard or receive daily reminders/motivational messages.
62228686|NCT01531647|ACTIVE_COMPARATOR|Period 1 Control|
62591204|NCT03431025|NO_INTERVENTION|Control|Participants in the Control Arm will wear sensors to monitor their upper limb movement but will not receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
62591205|NCT03431025|EXPERIMENTAL|Intervention|Participants in the Experimental Arm will wear sensors to monitor their upper limb movement and will receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
62591206|NCT04158882||Patients enrolled in differentiated service delivery models|
62228687|NCT01531647|EXPERIMENTAL|Period 2 danoprevir/ritonavir|
62228688|NCT01747525||NIRS/IVUS of coronary artery|All patients will have an epicardial coronary artery stenosis of intermediate severity (\>50% to \<70% stenosis) (stenosis ≥20% - ≤70%) by invasive angiography in whom IVUS is planned to further clinical evaluation of lesion severity; or a severe epicardial coronary artery stenosis by invasive angiography and percutaneous coronary intervention (PCI) is planned for definitive treatment.
62228689|NCT04525872|EXPERIMENTAL|Premature infants|Premature infants who are expected to receive TPN for a minimum of 5 days and infants with gastrointestinal surgical problems (e.g., ileal atresia, gastroschisis), expected to receive TPN for a minimum of 5 days
62228690|NCT02010008|EXPERIMENTAL|Motivational Interviewing Intervention|Motivational Interviewing (MI) Intervention includes in -person home visit that elicits behavior change by helping participants explore and resolve ambivalence. A telephone follow-up call also uses MI technique.
62228691|NCT02010008|NO_INTERVENTION|Comparison|Usual care
62228692|NCT00953407|EXPERIMENTAL|Nelfilcon A|Nelfilcon A contact lens
62228693|NCT00953407|ACTIVE_COMPARATOR|Narafilcon A|Narafilcon A contact lens
62228694|NCT00953407|ACTIVE_COMPARATOR|Etafilcon A|Etafilcon A contact lens
62228695|NCT00953407|ACTIVE_COMPARATOR|Omafilcon A|Omafilcon A contact lens
62805053|NCT02394314|EXPERIMENTAL|MEDI0382|MEDI0382 administered subcutaneously
62228696|NCT00953407|ACTIVE_COMPARATOR|Hilafilcon B|Hilafilcon B contact lens
62228697|NCT04490187|EXPERIMENTAL|Active tDCS stimulation|tDCS will be applied over the left motor cortex at 1 mA for 30 min. The current will be ramped up to 1 mA over 45-60 s, held for 30 min, and ramped down to 0 mA over 45-60 s.
62591207|NCT04158882||Patients not enrolled in DSD models|
62591208|NCT05404256|EXPERIMENTAL|The experimental group|Radical gastrectomy +D2 lymphadenectomy +TissuePatchTM to seal pancreatic tissue surface
62591209|NCT05404256|OTHER|The control group|Radical gastrectomy +D2 lymphadenectomy
62591210|NCT05094765|EXPERIMENTAL|FMT|60 capsules per day for 2 day
62805054|NCT05355103|NO_INTERVENTION|Control Group|Women having received epidural analgesia after a standard verbal consent provided by the anesthesiologist before doing the epidural technique, representing the standard of practice in our institution
62805055|NCT05355103|ACTIVE_COMPARATOR|Exposed group|Woman having received epidural analgesia after having received and read an educational tool at her admission to labour and delivery unit, in addition to the standard verbal consent.
62591211|NCT03098498|EXPERIMENTAL|Two-Stage Subgingival Debridement|Initially soft subgingival bacterial biofilms are removed from periodontal lesions by an airpolishing device and erythritol cleaning powder. 6 weeks later subgingival calculus is mechanically removed in a second step by mechanical scaling and root planing
62030066|NCT05952141|EXPERIMENTAL|Stage 1 Clinic Outreach + Stage 2 High Touch|All participants receive direct clinic outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging in combination with synchronous patient navigation (stage 2).
62805056|NCT02036047|EXPERIMENTAL|Exclusive cold polypectomy snare|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed using an exclusive cold polypectomy snare (Exacto cold snare). The technique is cold snare resection of the polyp without tenting without electrocautery and then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is not performed after cold snare polypectomy.
62591212|NCT03098498|ACTIVE_COMPARATOR|One-Stage Subgingival Debridement|Soft subgingival bacterial biofilms, as well as subgingival calculus are concomitantly removed from periodontal lesions by mechanical scaling and root planing
62805057|NCT02036047|ACTIVE_COMPARATOR|regular polypectomy snare|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed using a regular polypectomy snare. The technique is cold snare resection of the polyp without tenting without electrocautery and then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is not performed after cold snare polypectomy.
62228698|NCT04490187|SHAM_COMPARATOR|Sham tDCS stimulation|tDCS will be ramped up and held for only 60 s before it is slowly ramped down. This procedure, called the Fade-in-Short Stimulation-Fade out, has shown its reliability as an effective sham technique through making the same tolerability and transient scalp sensation as active stimulation in both adults (Ambrus 2012) and children (Ciechanski 2017).
62228699|NCT05504863||RAPIDIRON IV iron intervention arm 1|Maternal participants in this arm were given a single dose of an IV iron formulation - ferric carboxymaltose - during pregnancy as part of their participation in the parent RAPIDIRON Trial. Participants weighing 50kg and over received a single dose having 1000mg of iron, with others receiving a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This was given between 14 and 17 weeks fetal gestational age.
62591213|NCT04688528|EXPERIMENTAL|Arm A: Unilateral RT|If SPECT/CT shows ipsilateral drainage and the tumor does not cross the midline, the subject will automatically be assigned to Arm A, and will receive ipsilateral Radiotherapy with reduced prophylactic dose outside of the macroscopically involved nodes. The contralateral side of the neck will be spared according to the absence of sentinel lymph node drainage.
62591214|NCT04688528|EXPERIMENTAL|Arm B: Whole level|"If SPECT/CT shows contralateral drainage, the subject will be randomized between 'Whole level' and 'SLN alone'.~Arm B 'Whole Level': on the contralateral side of the neck, the whole level(s) containing the draining sentinel lymph node(s) will be irradiated at the reduced prophylactic dose. The ipsilateral side of the neck will be irradiated conform to arm A."
62805058|NCT04864639|EXPERIMENTAL|Transition of Care|Experimental: 32 participants will be discharged to a newly developed discharge/transition of care model.
62805059|NCT04539600|EXPERIMENTAL|induction chemotherapy + anti-PD-1 antibody|Camrelizumab (200 mg, Q3w, 2 cycles in total) combined with induction chemotherapy (taxane-containing regimen, Q3w, 2 cycles in total) followed by concurrent radiotherapy and chemotherapy.
62805060|NCT03901131||BAY98-7040|"Female adult patients of reproductive age, who want to use a contraceptive method, will be enrolled after the investigator has made the decision for treatment with Mesigyna.~Investigators should prescribe Mesigyna for medically approved indications as per the label of the medicine locally approved."
62805061|NCT01655758|ACTIVE_COMPARATOR|timolol|60-day treatment phase with 0.5% timolol eyedrops, b.i.d.
62805062|NCT01655758|ACTIVE_COMPARATOR|'timolol-dorzolamide fixed combination'|60-day treatment phase with the fixed combination of 0.5% timolol-2% dorzolamide, eyedrops, b.i.d.
62805063|NCT01655758|ACTIVE_COMPARATOR|xalatan|60-day treatment phase with 0.005% latanoprost, eyedrops, QD
62805064|NCT01655758|ACTIVE_COMPARATOR|travatan|60-day treatment phase with 0.004% travoprost, eyedrops, QD
62805065|NCT01655758|ACTIVE_COMPARATOR|lumigan|60-day treatment phase with 0.03% bimatoprost, eyedrops, QD
62030067|NCT05952141|EXPERIMENTAL|Stage 1 Enhanced Outreach + Stage 2 Low-Touch|All participants receive direct clinic outreach plus enhanced outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging (stage 2).
62030068|NCT05952141|EXPERIMENTAL|Stage 1 Enhanced Outreach + Stage 2 High-Touch|All participants receive direct clinic outreach plus enhanced outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging in combination with synchronous patient navigation.
62030069|NCT00762125|EXPERIMENTAL|Cognitive restructuring and coping skills training (CR+ST)|
62805066|NCT06264726|EXPERIMENTAL|Intervention Group|This group will receive the intervention
62805067|NCT02884388|EXPERIMENTAL|experimental group|Combined nerve block will be used, involving lower lumbar plexus, sciatic nerve, and paraspinal nerve L1-2.
62805068|NCT02884388|EXPERIMENTAL|control group|General anesthesia will be used in this group.
62805069|NCT01780116|EXPERIMENTAL|Medicaiton adherence therapy|"Adherence therapy, consisting of six, 2-hour sessions over 3 months, in three phases:~1. Engaging patients: assessing needs and concerns in medication adherence;~2. Reviewing strengths and barriers and developing coping strategies; and~3. Rationalizing beliefs and concerns and preventing relapse."
62805070|NCT01780116|NO_INTERVENTION|Routine community care|Routine Community psychiatric nursing services provided by the Community Psychiatric Nurses in the practice field
62805071|NCT04972786|SHAM_COMPARATOR|Sham rTMS|Participants will receive sham rTMS for 10-20 minutes.
62805072|NCT04972786|ACTIVE_COMPARATOR|Active rTMS|Participants will receive active rTMS for 10-20 minutes.
62805073|NCT05546151|EXPERIMENTAL|Cohort J1|
62805074|NCT05546151|EXPERIMENTAL|Cohort J2|
62805075|NCT05546151|EXPERIMENTAL|Cohort J3|
62591215|NCT04688528|EXPERIMENTAL|Arm C: SLN alone|"If SPECT/CT shows contralateral drainage, the subject will be randomized between 'Whole level' and 'SLN alone'.~Arm C 'SLN alone': on the contralateral side of the neck, only the sentinel node(s) will be irradiated at the reduced prophylactic dose. The ipsilateral side of the neck will be irradiated conform to arm A."
62030070|NCT00762125|EXPERIMENTAL|Exposure therapy (ET)|
62805076|NCT01001975|EXPERIMENTAL|SPF Testing|Following Food and Drug Administration (FDA) guidelines for SPF testing, exposure control and product-protected site erythema responses are scored after 16 to 24 hours post-exposure to full spectrum light (Ultraviolet B radiation \[UVB\] and UVA).
62228700|NCT05504863||RAPIDIRON IV iron intervention arm 2|Maternal participants in this arm were given a single dose of an IV iron formulation - iron isomaltoside - during pregnancy as part of their participation in the parent RAPIDIRON Trial. Participants weighing 50kg and over received a single dose having 1000mg of iron, with others receiving a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This was given between 14 and 17 weeks fetal gestational age.
62591216|NCT00950040|EXPERIMENTAL|Brief alcohol intervention|Brief alcohol intervention delivered in 2 15-minute in-person sessions and 2 5-minute telephone sessions.
62591217|NCT00950040|ACTIVE_COMPARATOR|General Health Education|General health education intervention delivered in 2 15-minute in-person sessions and 2 5-minute telephone sessions.
62805077|NCT01001975|EXPERIMENTAL|UVA Protection Testing|Determination of Ultraviolet A Protection Factor (PFA). Following FDA guidelines, test sites exposed to UVA are scored for pigmentation responses 2 to 4 hours post-exposure.
62805078|NCT04816474|EXPERIMENTAL|Education and Phone Counseling Service|Patients in this group will be trained online for 6 weeks. After the online training is over, a telephone consultation service will be provided once a week for 6 weeks.
62805079|NCT04816474|NO_INTERVENTION|Control|No application will be made to patients in this group for 12 weeks. Pre-test and post-test will be applied.
62805080|NCT04247230|EXPERIMENTAL|PET500 (0.1%)|"Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:~PET500 (0.1%) corresponding to a tetracaine total dose of 0.26mg"
62030071|NCT00762125|EXPERIMENTAL|Combination (COMB) treatment|
62030072|NCT00762125|ACTIVE_COMPARATOR|Attention control (AC) treatment|
62030073|NCT05495854|NO_INTERVENTION|National Health Authority (HAS) strategy control|
62030074|NCT05495854|EXPERIMENTAL|new strategy experimental|
62228701|NCT05504863||RAPIDIRON active comparator arm|Maternal participants in this arm of the RAPIDIRON Trial were given ferrous sulfate tablets with 60mg elemental iron each and instructed to take two per day (one in the morning and one at night) throughout their pregnancy.
62228702|NCT04970030|ACTIVE_COMPARATOR|mechanical intracanal (ML) lithotripsy|TTS mechanical lithotripter
62228703|NCT04970030|EXPERIMENTAL|electrohydraulic intracolangioscopic (EHL) lithotripsy|electrohydraulic lithotripsy with Autolith probe
62030075|NCT04386681|EXPERIMENTAL|RCBI|Receiving RCBI intervention, including BICS, ICAN, and RF.
62030076|NCT04386681|NO_INTERVENTION|Treatment as usual- Control group|Not receiving the RCBI intervention
62030077|NCT04669704|EXPERIMENTAL|Tablet application|"A protocol of exercises based on the current scientific evidence will be provided through a tablet application. A follow-up of the use of the application will be carried out. A minimum of 4-week home exercise intervention will be performed, which will have to be carried out daily by the patient autonomously at home for at least 5 days per week, starting after baseline measurement.~The exercise program will be individualized according to each pathology."
62228704|NCT01599715|OTHER|Instructional DVD Intervention|Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once
62228705|NCT01599715|OTHER|Bladder Health Class Intervention|Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
62228706|NCT02806388||tumor tissue for molecular profiling|
62228707|NCT05784220|OTHER|DPP|The CDC Diabetes Prevention Program (DPP) curriculum for lifestyle intervention, including 21 education topics delivered via text-based education module, and follow-up telephone health coaching call for each topic.
62591218|NCT04263896|EXPERIMENTAL|Participants receiving pre-operative laxative|Participants will receive 10 doses, 17g each, of polyethylene glycol 3350. They will be instructed to take 1 dose/packet each day for 10 days leading up to their surgery.
62591219|NCT04263896|NO_INTERVENTION|Participants not receiving pre-operative laxative|Participants will not be given any laxatives.
62805081|NCT04247230|EXPERIMENTAL|PET500 (0.25%)|"Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:~PET500 (0.25%) corresponding to a tetracaine total dose of 0.65mg"
62805082|NCT04247230|EXPERIMENTAL|PET500 (0.5%)|"Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:~PET500 (0.5%) corresponding to a tetracaine total dose of 1.3mg"
62805083|NCT04247230|EXPERIMENTAL|PET500 placebo comparator|Each actuation of the pump spray dispenses 130µl PET500 \[vehicle only\]. Two pumps will dispense 260µl
62805084|NCT04247230|ACTIVE_COMPARATOR|STUD100 (9.6%)|Each actuation of the pump spray dispenses 130µl, corresponding to a dose of 7.7mg lidocaine. Three pumps will dispense 390µl of a 9.6% solution, delivering a total dose of 23mg lidocaine. UK License Number PL/2294/5000R
62805085|NCT03416296||normal placenta|TA , TV ,TP us
62805086|NCT03416296||placenta previa and MAP|TA,TV.TP us
62805087|NCT02426333||Abiraterone Acetate|abiraterone treatment, 1000mg, tablets, once daily, treatment is not adapted for the study
62805088|NCT03584750|ACTIVE_COMPARATOR|Intervention group|Floating
62805089|NCT03584750|PLACEBO_COMPARATOR|Control group|Placebo floating
62805090|NCT03584750|NO_INTERVENTION|No-treatment group|Waiting list
62805091|NCT03379220||Subdural ECoG (Group 1)|For patients who require craniotomy to treat TBI, a subdural electrode strip will be placed intraoperatively following evacuation of a hematoma or contusion, as required. Electrode strips will be used for subsequent electrocorticography (ECoG) during intensive care. Patients will also undergo continuous scalp EEG monitoring.
62805092|NCT03379220||Burr Hole ECoG (Group 2)|For patients who do not require surgery but do require invasive monitoring, an intraparenchymal ECoG electrode array will be placed through a cranial burr hole. Depending on other monitoring needs, the location of injuries, and other clinical considerations, the burr hole may be the same as used for placement of other probes or may be separate. In cases of focal injury, the burr hole will be placed to allow electrode targeting to a lobe with significant primary lesion(s). Patients will also undergo continuous scalp EEG monitoring.
62030078|NCT04669704|ACTIVE_COMPARATOR|Conventional treatment|In the control condition, participants will receive a home exercise program on paper. The exercise program will be the conventionally prescribed one by the Andalusian Public Health Service. Participants will be told to perform exercises during a minimum of 4 week at home for at least 5 days per week, starting after baseline measurement.
62030079|NCT01360606|OTHER|SBRT|
62030080|NCT01915134|EXPERIMENTAL|EGP group|the group of participants who undergoing Recombinant Human Endostatin plus Gemcitabine and cisplatin chemotherapy
62030081|NCT01915134|ACTIVE_COMPARATOR|GP group|the group of participants who undergoing only Gemcitabine and cisplatin chemotherapy
62030082|NCT04315389||EXPERIMENTAL|OPEN LABEL USING HEALTHCARE ROBOTS IN PARALLEL (non comparison) EXPOSURE: 90 MINUTES 3 TIMES PER DAY FOR 3 DAYS, NON CONSECUTIVE
62030083|NCT03520634|EXPERIMENTAL|PD-L1 PET imaging in melanoma patients|The main intervention of this study is a \[18F\]PD-L1 PET scan. In both phase one and phase two a scan sequence will be performed both at baseline and 6 weeks after initiation of nivolumab treatment. The PET scans will be combined with either a low dose or diagnostic CT scan of chest, abdomen and pelvis and a MRI of the brain. In phase two, a biopsy of at least one accessible lesion will be performed to analyze PD-L1 expression using immunohistochemical staining after each PET scan.
62030084|NCT01134029|NO_INTERVENTION|Enhanced Usual Care|Control Group
62030085|NCT01134029|EXPERIMENTAL|Stepped Care|Intervention
62228708|NCT04848870||Sjögren patients|Patients in specialized consultations for Sjögren's patients in the oral medicine department of the Charles Foix Hospital AP-HP France
62228709|NCT04259645|ACTIVE_COMPARATOR|Low Volume group|30 subjects randomized to Low Volume will receive unilateral Quadratus Lumborum block type II. Each subject received 20mL Bupivacaine 0.375%.
62591220|NCT02161484|EXPERIMENTAL|Continuous Lumbar Plexus Block with Parasacral Nerve Block|"Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.~A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected."
62805093|NCT03379220||EEG (Groups 1-3)|Continuous EEG recordings will be made using Ag/AgCl electrodes placed on or beneath the scalp (subdermal wire) according to standard practice. The default montage will employ eight lead electrodes for each hemisphere following the 10/20 system (Right: Fp2, F4, C4, P4, O2, F8, T4, T6; left: Fp1, F3, C3, P3, O1, F7, T3, T5). Other montages with more dense placement of electrodes in the region of ECoG monitoring may also be used.
62030086|NCT00873795|EXPERIMENTAL|aripiprazole and sertraline|The patients of this arm receive ten weeks of treatment with a combination of sertraline 50mg/day and aripiprazole 2.5mg/day.The effect of this arm is assessed for HAM-D17, CGI, SF-36 and BSRS-50.
62030087|NCT00873795|PLACEBO_COMPARATOR|sertraline and placebo|The patients of this arm receive ten weeks of treatment with a combination of sertraline 50mg/day and placebo.The effect of this arm is assessed for HAM-D17, CGI, SF-36 and BSRS-50.
62030088|NCT00986167|EXPERIMENTAL|Quetiapine XR|The study population will be patients admitted to the acute psychiatry inpatient wards of St Vincent's or the Alfred and determined by a Psychiatrist to be experiencing a psychotic illness (including mania with psychotic features and drug-induced psychosis) and acting in an aggressive manner (determined by a score of at least 1 on the OAS).
62805094|NCT04930523|ACTIVE_COMPARATOR|Decompression|It include the pre- Physiotherapy treatment than decompression and post physiotherapy treatment.
62591221|NCT02161484|ACTIVE_COMPARATOR|Lumbar Plexus Nerve Block|"Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.~No sham/placebo parasacral (sciatic) blocks will be performed in this group."
62591222|NCT03264781|EXPERIMENTAL|Cyclofem group|Medroxyprogesterone Acetate 25 mg plus Estradiol Cypionate 5 mg (Cyclofem®) 0.5 ml IM injection single dose
62591223|NCT03264781|PLACEBO_COMPARATOR|Placebo group|normal saline 0.5 ml IM single dose
62591224|NCT01574638|EXPERIMENTAL|Arm 1B|Participants in Arm 1B will receive RPT based on weight at entry, at a dose of 20 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 10 mg/kg twice daily with low-fat meals.
62030089|NCT02629510|EXPERIMENTAL|Tachosil|The group composed of patients whose surgical margin of cervix will be treated with Tachosil® after a loop electrosurgical excisional procedure (LEEP)
62591225|NCT01574638|EXPERIMENTAL|Arm 1A|Participants in Arm 1A will receive RPT based on weight at entry, at a dose of 10 mg/kg twice daily with low-fat meals, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 20 mg/kg once daily with a low-fat breakfast.
62591226|NCT01574638|EXPERIMENTAL|Arm 2A|Participants in Arm 2A will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a boiled egg, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 70, at a dose of 15 mg/kg once daily with a low-fat breakfast.
62591227|NCT01574638|EXPERIMENTAL|Arm 2B|Participants in Arm 2B will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 15 mg/kg once daily with a boiled egg.
62591228|NCT05855174|ACTIVE_COMPARATOR|Low Protein|Protein intake at 0.15g/kg body weight
62591229|NCT05855174|EXPERIMENTAL|High Protein|Protein intake at 0.4 g/kg body weight
62030090|NCT02629510|NO_INTERVENTION|No Tachosil|The group composed of patients whose surgical margin of cervix will NOT be treated with Tachosil® after a loop electrosurgical excisional procedure (LEEP)
62030091|NCT03745664|ACTIVE_COMPARATOR|Treatment group|"Methylprednisolone Sodium Succinate (20mg/ml) will be given at the dose of 40 mg/day (20 mg x 2/day).~The treatment will last 7 days (or the time of hospitalization if the patient is discharged in a period less or more than 7 days)."
62591230|NCT00828074|EXPERIMENTAL|Treatment (vinorelbine tartrate and sorafenib tosylate)|Patients receive sorafenib tosylate PO twice daily on days 1-28 and vinorelbine ditartrate IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62591231|NCT04195620|EXPERIMENTAL|Low loneliness, low self-disclosure|Individuals in this arm report lower levels of loneliness than the mean level reported by similar individuals. They will start the study in the low self-disclosure group which involves questions that are unlikely to involve meaningful personal disclosure. All members of this group will also complete the high self-disclosure condition later in the study.
62591232|NCT04195620|EXPERIMENTAL|Low loneliness, high self-disclosure|Individuals in this arm report lower levels of loneliness than the mean level reported by similar individuals. They will start the study in the high self-disclosure group which involves questions that are likely to involve meaningful personal disclosure. All members of this group will also complete the low self-disclosure condition later in the study.
62591233|NCT04195620|EXPERIMENTAL|high loneliness, low self-disclosure|Individuals in this arm report higher levels of loneliness than the mean level reported by similar individuals. They will start the study in the low self-disclosure group which involves questions that are unlikely to involve meaningful personal disclosure. All members of this group will also complete the high self-disclosure condition later in the study.
62805095|NCT04930523|EXPERIMENTAL|Experimental|It includes the Pre physiotherapy treatment than ELDOA positions are guided and performed by patients before decompression Low back exercises guided i.e. knee to chest, pelvic rolling, bridging, SLR, piriformis exercises is guided for home plan along with precaution and Decoarctation of (C0/C1/C2),(C4/C5),(C5,C6),(C6/C7),(T4/T5),(T6/T7),(T8,/T9),(L4/L5),(L5/S1) then Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes and at last Post physiotherapy treatment
62805096|NCT03671941|ACTIVE_COMPARATOR|Group A|D578 Tab. 1T
62805097|NCT03671941|EXPERIMENTAL|Group B|CKD-357 Tab. 1T
62805098|NCT06217107|EXPERIMENTAL|C3 Coach plus H360x|Arm 1 will have 80 participants who will receive four weekly goal setting sessions with coach consisting of 45 min-1 hour recorded sessions. They will then receive another 4 sessions every 2 weeks, followed by three monthly goal setting sessions. Baseline surveys will be collected, in addition to surveys taken at 3 and 6 months.
62030092|NCT03745664|PLACEBO_COMPARATOR|Placebo group|Saline Solution for Injection will be given ath the dose of 2 ml/day. The treatment placebo will last 7 days (or the time of hospitalization if the patient is discharged in a period less or more than 7 days).
62030093|NCT05820724|EXPERIMENTAL|PSMA PET+mpMRI|PSMA PET+mpMRI guided prostate biopsy
62030094|NCT05820724|ACTIVE_COMPARATOR|mpMRI only|mpMRI only guided prostate biopsy
62030095|NCT02252211|EXPERIMENTAL|DS-8895a|Patients received infusions with DS-8895a on Days 1, 8, 22, and 36. Infusions on Days 1 and 36 were trace labelled with \^89Zr (\^89Zr-Df-DS-8895a). The Day 1 dose was 0.2 mg/kg, followed by subsequent doses calculated based on individual patient body weight and dosing cohort assignment.
62030096|NCT06156930|EXPERIMENTAL|Intervention group Lavander|The group will receive aromatherapy massage with a 5% mixture prepared with sesame oil and lavender oil for 10 minutes on both lower leg areas, three times a week for four weeks.
62030097|NCT06156930|PLACEBO_COMPARATOR|Placebo group sesame|The group will receive a massage with sesame oil on both lower leg areas for 10 minutes on each leg, three times a week for four weeks.
62805099|NCT06217107|ACTIVE_COMPARATOR|C3 Coach plus Health360x and micro-learning|Arm 2 will have 80 participants who will receive four weekly goal setting sessions with coach consisting of 45 min-1 hour recorded sessions, in addition to periodic micro-learning content delivered via an online technology platform. They will then receive another 4 sessions every 2 weeks, followed by three monthly goal setting sessions. Baseline surveys will be collected, in addition to surveys taken at 3 and 6 months. This arm will have learning augmented by micro-learning to test effectiveness in enhancing engagement and promoting retention of educational content.
62805100|NCT01332123|EXPERIMENTAL|Alignment perturbations|The following modifications will be applied to the prostheses: increased foot plantar flexion, increased foot dorsal flexion, increased foot supination, increased foot pronation (always 2 degrees from the neutral position)
62228710|NCT04259645|EXPERIMENTAL|High Volume group|30 subjects randomized to High Volume will receive unilateral Quadratus lumborum block Type II. Each subject was given 20mL Bupivacaine 0.375% diluted with 20mL normal saline to total 40mL (concentration decreased by half - 0.1875%).
62421289|NCT01220128|PLACEBO_COMPARATOR|Cohort A-Placebo Group|This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of placebo, according to the treatment schedule.
62805101|NCT00549692|EXPERIMENTAL|Omacor|
62228711|NCT03165929|ACTIVE_COMPARATOR|flurbiprofen-free gingival graft|
62805102|NCT00549692|PLACEBO_COMPARATOR|Placebo Omacor|
62421290|NCT01220128|EXPERIMENTAL|Cohort B-GSK2302024A Group|This group included breast cancer patients who received GSK2302024A, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
62591234|NCT04195620|EXPERIMENTAL|high loneliness, high self-disclosure|Individuals in this arm report higher levels of loneliness than the mean level reported by similar individuals. They will start the study in the high self-disclosure group which involves questions that are likely to involve meaningful personal disclosure. All members of this group will also complete the low self-disclosure condition later in the study.
62805103|NCT03546621|EXPERIMENTAL|Arm A|Myrcludex B, 2 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
62805104|NCT03546621|EXPERIMENTAL|Arm B|Myrcludex B, 5 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
62805105|NCT03546621|EXPERIMENTAL|Arm C|Myrcludex B, 10 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
62805106|NCT03546621|ACTIVE_COMPARATOR|Arm D|tenofovir treatment for 48 weeks
62805107|NCT04360746|ACTIVE_COMPARATOR|Clinical pharmacist intervention group|"all hip fractured patients admitted to D1 subunit in Beit rivka geriatric rehabilitation center. This group will get a clinical pharmacist review of their medication and a pharmaceutical counseling to the medical staff in the first few days of admission (1-5 days post admission)"
62805108|NCT04360746|OTHER|control group|"The control group will include all hip fractured patients admitted to D2 subunit in Beit rivka geriatric rehabilitation center. This group will not receive any pharmacist intervention during their rehabilitation."
62805109|NCT04228263|OTHER|hydroxychloroquine group|hydroxychloroquine 400 mg preconceptional
62805110|NCT04228263|OTHER|control group|not receive hydroxychloroquine
62805111|NCT04903782||Children and adolescents with newly diagnosed malignancy|
62805112|NCT05103826|EXPERIMENTAL|SHR6390+famitinib|Participants will receive SHR6390 in combination with famitinib.
62805113|NCT03007966|ACTIVE_COMPARATOR|Ilioinguinal / Iliohypogastric Block|Patient's randomized to receive an Ilioinguinal / Iliohypogastric nerve block (IINB) for post operative analgesia following inguinal herniorrhaphy will have said block performed in a supine position in a manner consistent with the technique described by Willschke, but modified to utilize an in-plane technique rather than an out-of-plane technique for needle to ultrasound probe orientation. Either a Sonosite linear HFL38x/13-6 MHz or Sonosite curvilinear C60x/5-2 MHz probe will be utilized to visualize the pertinent ultrasound anatomy. A Pajunk 21g x 100mm Sono Plex Stim Cannula will be utilized to appropriately deposit a single local anesthetic aliquot consisting of 25cc's of bupivacaine 0.25% with epinephrine 5mcg/cc and clonidine 1.66mcg/cc.
62228712|NCT03165929|PLACEBO_COMPARATOR|placebo-free gingival graft|
62228713|NCT03165929|ACTIVE_COMPARATOR|flurbiprofen-connective tissue graft|
62228714|NCT03165929|PLACEBO_COMPARATOR|placebo-connective tissue graft|
62228715|NCT01403610|EXPERIMENTAL|Cohort 1|Subjects received TH-302 single dose at 575 mg/m2 or placebo administered preoperative in a 2:1 randomization and were then administered 240 mg/m2 of TH-302 post-operative.
62421291|NCT01220128|PLACEBO_COMPARATOR|Cohort B-Placebo Group|This group included breast cancer patients who received placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
62421292|NCT01220128|EXPERIMENTAL|Cohort C-GSK2302024A Group|This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of GSK2302024A, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
62421293|NCT01220128|PLACEBO_COMPARATOR|Cohort C-Placebo Group|This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of placebo, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
62030098|NCT06156930|NO_INTERVENTION|Control group|Group of individuals receiving HD treatment who do not receive any treatment other than standard treatment
62228716|NCT01403610|EXPERIMENTAL|Cohort 2|Surgical subjects will receive TH-302 at 340 mg/m2 every 2 weeks (4 week cycles) starting after surgery from Cycle 1, Day 1 until disease progression.
62228717|NCT01403610|EXPERIMENTAL|Cohort 3|Surgical or Non-Surgical subjects will receive TH-302 at 480 mg/m2 every 2 weeks (4 week cycles) starting after surgery from Cycle 1, Day 1 until disease progression.
62228718|NCT01403610|EXPERIMENTAL|Cohort 4|Non-surgical subjects will receive a dose up to 670 mg/m2 of TH-302
62805114|NCT03007966|EXPERIMENTAL|Quadratus Lumborum Block|Patient's randomized to receive a Quadratus Lumborum block (QLB) for post operative analgesia following inguinal herniorrhaphy will have said block performed in a lateral position in a manner consistent with the technique described by Børglum. Either a Sonosite linear HFL38x/13-6 MHz or Sonosite curvilinear C60x/5-2 MHz probe will be utilized to visualize the pertinent ultrasound anatomy. A Pajunk 21g x 100mm Sono Plex Stim Cannula will be utilized to appropriately deposit a single local anesthetic aliquot consisting of 25cc's of bupivacaine 0.25% with epinephrine 5mcg/cc and clonidine 1.66mcg/cc.
62421294|NCT01220128|EXPERIMENTAL|Cohort D-GSK2302024A-D14 Group|This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer, who received GSK2302024A, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
62030099|NCT06670430|EXPERIMENTAL|experimental group|This group will include 30 type II diabetic patients with peripheral neuropathy Patients will receive TENS and NMES for 30 minutes 3 days per week,for 10 weeks with medical treatment
62805115|NCT03145740|EXPERIMENTAL|Intensive F.O.T.T.®|Intensive F.O.T.T.® intervention was given twice a day, approximately 20 minutes per intervention, exclusive time to position the patient. Before and after the intervention, the patient was positioned in a standardized way in side lying for 10 minutes to rest. Here, the Electromyographic Bioimpedance Measuring device (EMBI) measured the spontaneous swallowing frequency and -quality during both, the resting period and the intervention. In the intervention itself, the patient was facilitated with specific handling and interventions to swallow, according to F.O.T.T.®. The faciltation was embedded into a meaningful context for the patient, e.g. tooth brushing or eating small amounts of apple sauce, if safe.
62030100|NCT06670430|PLACEBO_COMPARATOR|control group|This group will include 30 type II diabetic patients with peripheral neuropathy Patients will receive placebo TENS and NMES for 30-min sessions, 3 days per week, for 10 weeks with medical treatment
62030101|NCT03171298|EXPERIMENTAL|transanal TME|Laparoscopic Assisted Transanal Total Mesorectal Excision
62030102|NCT00981591|EXPERIMENTAL|Inhaled Iloprost|
62030103|NCT00981591|PLACEBO_COMPARATOR|Inhaled Placebo|
62030104|NCT00864448|EXPERIMENTAL|A|Ramipril10 mg Capsules, single dose
62030105|NCT00864448|ACTIVE_COMPARATOR|B|Atlace® 10 mg capsules, single dose
62030106|NCT03418454||Oral Squamous Cell Carcinoma|Buccal mucosa samples for Extraction of BACTERIAL DNA
62030107|NCT03418454||Oral Epithelial Dysplasia|Buccal mucosa samples for Extraction of BACTERIAL DNA
62030108|NCT03418454||Control: Healthy age matched patients|Buccal mucosa samples for Extraction of BACTERIAL DNA
62030109|NCT03418454||Osteonecrosis of the Jaw|Buccal mucosa samples for Extraction of BACTERIAL DNA
62805116|NCT03145740|PLACEBO_COMPARATOR|Unspecific stimulation of face and mouth|The intervention in the control group was given twice a day, approximately 20 minutes per intervention, exclusive time to position the patient. Patients in the control group were before and after the intervention, positioned in a standardized way in side lying for 10 minutes to rest. The EMBI measured the spontaneous swallowing frequency and -quality during both, the resting period and the intervention. The intervention included unspecific stimulation of the hands and the face, without therapeutic interventions directed towards facilitation of swallowing.
62805117|NCT00286442|EXPERIMENTAL|Alogliptin 12.5 mg QD|
62805118|NCT00286442|EXPERIMENTAL|Alogliptin 25 mg QD|
62030110|NCT03418454||Underlying disease, no necrosis of the jaw|Buccal mucosa samples for Extraction of BACTERIAL DNA
62030111|NCT06634745|EXPERIMENTAL|Standard Needle Irrigation (SNI) with MB Activation|In this group, the activation of MB (Merck KgaA) was performed using a 30G NaviTip (Cermaked) with 1 activation cycle. The 30G NaviTip (Cermaked) was placed in the root canal 1 mm short of the working length and used with a 3-4 mm amplitude. The MB (Merck KgaA) solution was activated for 1 minute and renewed during the treatment
62030112|NCT06634745|EXPERIMENTAL|Passive Ultrasonic Irrigation (PUI) with MB Activation|In this group, the activation of MB (Merck KgaA) was performed using Ultra X (Eighteeth, Changzhou, China) and a #25 ultrasonic endodontic tip (Eighteeth) at a frequency of 45 kHz. The ultrasonic endodontic tip was placed in the root canal 1 mm short of the working length and the MB (Merck KgaA) solution was activated for 1 minute. During the activation process, care was taken to ensure the ultrasonic endodontic tip moved freely within the canal, and the MB solution was renewed during the treatment.
62030113|NCT06634745|EXPERIMENTAL|EndoActivator(EA) with MB Activation|In this group, the activation of MB (Merck KgaA) was performed using a polymer EA tip (Dentsply, Tulsa, OK) with a 25.04 tip diameter, which was placed into the canal 2 mm short of the working length. The activation procedure was carried out for 1 minute using the EA sonic irrigation device at 10,000 cycles, and the MB (Merck KgaA) solution was renewed during the treatment.
62030114|NCT06634745|EXPERIMENTAL|EDDY with MB Activation|In this group, the activation of MB (Merck KgaA) was performed using a polymer EDDY tip (VDW, Munich, Germany) with a 25.04 tip diameter and the Sonicmax sonic device (Maximum Dental Inc., Secaucus, NJ, USA) with one activation cycle. The EDDY (VDW) tip was placed in the canal 1 mm short of the working length and moved in a corono-apical direction at a frequency of 6 kHz and an amplitude of 5 mm for 1 minute to achieve MB activation. The MB (Merck KgaA) solution was renewed during the treatment.
62030115|NCT00005776|EXPERIMENTAL|Inhaled Nitric Oxide|Inhaled Nitric Oxide (iNO)
62030116|NCT00005776|PLACEBO_COMPARATOR|Oxygen|100% oxygen
62030117|NCT05916690|EXPERIMENTAL|Electrochemotherapy|
62030118|NCT03750201|EXPERIMENTAL|Direct Selective Trabeculoplasty|Treatment by the investigational device.
62030119|NCT03750201|ACTIVE_COMPARATOR|Selective Trabeculoplasty|Treatment by the comparator device.
62591235|NCT04744233|ACTIVE_COMPARATOR|Freshly squeezed orange juice (FS)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juice assayed was freshly squeezed (FS). Six subjects consumed FS-orange juice.
62805119|NCT00286442|PLACEBO_COMPARATOR|Metformin|
62805120|NCT04148534|ACTIVE_COMPARATOR|muscle relaxant|patient who will receive muscle relaxant, patients will receive rocronium infusion by (5 mcg/kg/min) , maintain partial NMB TOF count 2 and targeting BIS = (40-60)
62228719|NCT02731053|EXPERIMENTAL|Blues program|Participants will attend 6 weekly 1-hour sessions of group cognitive-behavioral therapy administered by school staff, and will do home practice between sessions and after the program individually using a web site (called the Blues App)
62805121|NCT04148534|PLACEBO_COMPARATOR|without muscle relaxant|patient who will not receive muscle relaxant, will recieve normal saline targeting BIS = 40-60.
62805122|NCT02072863|EXPERIMENTAL|Oprozomib with Melphalan and Prednisone (OMP)|"Subjects will receive oprozomib administered orally.~The combination of oprozomib, melphalan, and prednisone (OMP) will be administered until progression of disease, unacceptable toxicity, discontinuation of study treatment for reasons other than progression or toxicity, or a maximum of 9 cycles (54 weeks), whichever occurs first."
62228720|NCT02731053|NO_INTERVENTION|Control|Participants will receive a brochure describing the nature, causes, and consequences of depression, as well as available prevention/treatment options
62805123|NCT04872361|PLACEBO_COMPARATOR|Low PEEP|Low positive end-expiratory pressure (PEEP) and no recruitment maneuver (RM)
62805124|NCT04872361|ACTIVE_COMPARATOR|High PEEP|High positive end-expiratory pressure (PEEP)
62805125|NCT04872361|ACTIVE_COMPARATOR|High PEEP/RM|High positive end-expiratory pressure (PEEP) and recruitment maneuver (RM)
62805126|NCT04984239|OTHER|Acceptance and Commitment Therapy adapted for aphasia|There is only a single study arm, in which the adapted intervention will be developed using a successive cohort design.
62805127|NCT02255916|NO_INTERVENTION|Controll|No sound-bed intervention
62805128|NCT02255916|EXPERIMENTAL|Music|live sound-bed music intervention
62805129|NCT01138423|EXPERIMENTAL|Aliskiren|
62805130|NCT01138423|EXPERIMENTAL|Moxonidine|
62805131|NCT01138423|EXPERIMENTAL|Hydrochlorothiazide|
62805132|NCT01138423|PLACEBO_COMPARATOR|Placebo|
62805133|NCT02572544|EXPERIMENTAL|Participants|All participants perform all exams under 3 conditions, that is baseline, single pinhole glasses, and multiple pinhole glasses
62805134|NCT00139074|ACTIVE_COMPARATOR|1|quetiapine fumarate monotherapy
62805135|NCT00139074|EXPERIMENTAL|2|Quetiapine + sodium valproate
62805136|NCT01753622|NO_INTERVENTION|Control group|Sedentary Obese and overweight pregnant women
62805137|NCT01753622|EXPERIMENTAL|Exercise group|Physical exercise program
62805138|NCT06069258||Bahraini adults with type 2 diabetes|Male and female Bahraini adults aged 20-75 years with controlled type 2 diabetes (i.e. HbA1c \<9 on medication).
62805139|NCT02433886|EXPERIMENTAL|Gamma Ventral Capsulotomy|
62805140|NCT03705052|OTHER|Intervention|Patients and caregivers were asked to complete a questionnaire
62805141|NCT06512350||Breast Cancer Cohort|Subjects with mammography-confirmed dense breast tissue (BI-RADS density score of C or D) and with biopsy-proven primary breast cancer.
62805142|NCT06512350||Control Cohort|Subjects with mammography-confirmed dense breast tissue (BI-RADS density score of C or D) and a negative MRI (for surveillance or diagnostic purposes with BI-RADS 1 or 2) that confirms the absence of breast cancer.
62805143|NCT02729220|OTHER|Healthy controls|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
62228721|NCT03936582|EXPERIMENTAL|Treatment|All owners/managers of small businesses in 10 treatment neighborhoods will receive a request to support youth physical activity. The owners/managers will be able to direct support to specific programs, get recognized for their support, receive added information on the benefits of supporting such programs, have the oversight of an advisory board and interface with a local program representative
62228722|NCT03936582|ACTIVE_COMPARATOR|control|All owners/managers of small businesses in 10 control neighborhoods will will receive a request to support youth physical activity. None of the other components of the treatment arm (e.g., direct support to specific programs, advisory board) will be provided.
62228723|NCT03435497|EXPERIMENTAL|Game Changers Intervention|Game Changers is an intervention that aims to empower and mobilize people living with HIV to be agents for HIV prevention and behavioral change in their social networks.
62228724|NCT03435497|NO_INTERVENTION|Control|The control group will receive standard of care during the intervention assessment period. All control participants will be offered the Game Changers program once all assessments for the primary study outcomes have been completed.
62228725|NCT00547365|EXPERIMENTAL|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
62805144|NCT02729220|OTHER|Smokers|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
62805145|NCT02729220|OTHER|COPD rapid decline|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
62805146|NCT02729220|OTHER|COPD slow decline|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
62805147|NCT05488639||Football players at the FIFA U-20 Women's World Cup 2022.|"* Upper age limit: all players must be a maximum of 20 years old by the end of the calendar year in which the World Cup 2022 is played (i.e. all players of the teams were born on or after 1 January 2002).~* Lower age limit: all players must be at least 16 years old by the end of the calendar year in which the World Cup 2022 is played (i.e. all players of the teams were born on or before 31 December 2006)."
62805148|NCT05488639||Football players at the FIFA U-17 Women's World Cup 2022.|"* Upper age limit: all players must be a maximum of 17 years old by the end of the calendar year in which the World Cup 2022 is played (i.e. all players of the teams were born on or after 1 January 2005).~* Lower age limit: all players must be at least 15 years old by the end of the calendar year in which the World Cup 2022 is played (i.e. all players of the teams were born on or before 31 December 2007)."
62805149|NCT03038321|ACTIVE_COMPARATOR|solifenacin|(Sofenacin ''solifenacin 10 m'') \[Marcyrl Pharmaceutical Industries - Egypt\]
62805150|NCT03038321|ACTIVE_COMPARATOR|levofloxacin|(Tavanic ''levofloxacin 500 mg'') \[Sanofi-Aventis - Egypt\]
62805151|NCT03038321|ACTIVE_COMPARATOR|lornoxicam|(Xefo ''lornoxicam 8 mg'') \[Multi-Apex - Egypt, under license of: NYCOMED, Austria\]
62805152|NCT01484210|EXPERIMENTAL|Elpenhaler Active - Diskus Placebo|Patients on treatment with both devices, Elpenhaler and Diskus, first active substance, second placebo.
62805153|NCT01724866|EXPERIMENTAL|Arm 1: SPI-2012 45 µg/kg and Docetaxel + Cyclophosphamide (TC)|"Participants received SPI-2012 45 microgram/kilogram (µg/kg), subcutaneously (SC) once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 milligram/ square metre (mg/m\^2) intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes."
62805154|NCT01724866|EXPERIMENTAL|Arm 2: SPI-2012 135 µg/kg and Docetaxel + Cyclophosphamide (TC)|"Participants received SPI-2012 135 µg/kg, SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 mg/m\^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes."
62805155|NCT01724866|EXPERIMENTAL|Arm 3: SPI-2012 270 µg/kg and Docetaxel + Cyclophosphamide (TC)|"Participants received SPI-2012 270 µg/kg, SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 mg/m\^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes."
62805156|NCT01724866|EXPERIMENTAL|Arm 4: Pegfilgrastim and Docetaxel + Cyclophosphamide (TC)|"Participants received Pegfilgrastim 6 milligram (mg), SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 mg/m\^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes."
62805157|NCT05869435|OTHER|FastWire System - Peripheral|This study is to assess the safety and efficacy of the FastWire System. It is intended to assess that the FastWire System can facilitate the intra-luminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions (CTOs). This is a First in Human study
62805158|NCT04852861|EXPERIMENTAL|Comirnaty®; Pfizer-BioNTech BNT162b2 mRNA 20 mcg|In this arm participants will receive two doses of Comirnaty BNT162b2 mRNA 20 mcg.
62805159|NCT04852861|ACTIVE_COMPARATOR|Comirnaty®; Pfizer-BioNTech BNT162b2 mRNA 30 mcg|In this arm participants will receive two doses of Comirnaty BNT162b2 mRNA 30 mcg.
62805160|NCT01668303|EXPERIMENTAL|Miami Juvenile Drug Court-MDFT|Multidimensional family therapy (MDFT) is primarily a family-based approach (Liddle, 2002)which conducts individual sessions with the teen and parent\[s\] but not peer-group sessions.
62805161|NCT01668303|OTHER|Miami Juvenile Drug Court -TAU|The Treatment as Usual (TAU) condition is primarily a peer group-based and individual approach that uses cognitive-behavioral principles and interventions.
62030120|NCT06299397|EXPERIMENTAL|Breastfeeding-Humor group|32 pregnant women were included in the experimental group determined by randomization method. Consent to participate in the study was obtained from these pregnant women. After obtaining consent, a pre-test was conducted. Afterwards, pregnant women were given breastfeeding education and humor practice. The application was applied once a week, twice a week. An interim test was administered 1 month after the application, and a final test was administered 3 months later.
62805162|NCT02972203|EXPERIMENTAL|Mindfulness Training for Primary Care|• Mindfulness Training for Primary Care (MPTC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements. MTPC is a referral-based, insurance-reimbursable 8-week group psychotherapy delivered primarily by Patient-Centered Medical Home-integrated behavioral clinicians. MTPC groups are 2 hours long for 8 weeks, with a 7-hour day of silent group practice on a weekend. MTPC also emphasizes psychoeducational skills for self-regulation including a collaborative primary care provider (PCP) action-planning appointment during week 6.
62805163|NCT02972203|ACTIVE_COMPARATOR|Mindfulness Intro. +resources +waitlist|Control arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month waitlist for a Cambridge Health Alliance (CHA) mindfulness-based intervention group. All participants are scheduled to meet with their primary care provider during week 6 for a collaborative action planning visit.
62805164|NCT00803283|EXPERIMENTAL|Hydromprphone Hydrochloride (HCl) OROS|Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
62805165|NCT00803283|ACTIVE_COMPARATOR|Morphine Sustain Release (SR)|Participants will receive morphine SR 8 mg every 24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
62421295|NCT04807634|OTHER|Group A (control)|Group A (control): that will receive the traditional supportive treatment for acute antipsychotic drugs overdose
62030121|NCT06299397|SHAM_COMPARATOR|Control Group|After randomization, consent was obtained from the pregnant women determined that they agreed to participate in the study. The pregnant women in the control group were given a pre-test before starting the study, an interim test 1 month after the start, and a final test 3 months later.
62030122|NCT06235216|EXPERIMENTAL|Experimental|Sacituzumab govitecan (10 mg/kg) administered intravenously on Days 1 and 8 of a 21-day cycle. Patients will be treated until progression, death, study withdrawal, or unacceptable toxicity.
62030123|NCT02123693|EXPERIMENTAL|Osteopathic Manipulative Treatment|5 sessions of treatment will be carried out: the first 3 weekly, and the remaining 2 after 15 days. The type of treatment will be based on indirect techniques
62030124|NCT02123693|SHAM_COMPARATOR|Sham therapy|5 sessions of treatment will be carried out: the first 3 weekly, and the remaining 2 after 15 days. The type of treatment will be based on specific parameters set out previously based on a predetermined protocol
62030125|NCT02123693|OTHER|No intervention|Patients in this group will not receive any type of intervention, both therapeutic than fictitious, and will not be evaluated by any operator
62421296|NCT04807634|OTHER|Group B (case)|that will receive the traditional supportive treatment for acute antipsychotic drugs overdose plus administration of 1.5 ml/kg ILE (20%) as a bolus over 1-2 minutes, followed by a continuous rate infusion of 0.25 ml/kg/min for the next 30 to 60 minutes
62421297|NCT03911960|EXPERIMENTAL|Acceptance and Commitment Therapy|2 in person and 5 telephone sessions of Acceptance and Commitment Therapy for tobacco cessation plus up to 8 weeks of nicotine patch.
62421298|NCT03911960|ACTIVE_COMPARATOR|Enhanced Usual Care|2 in-person sessions of tobacco cessation counseling, electronic referral to state quitline, up to 8 weeks of nicotine patch
62591236|NCT04744233|ACTIVE_COMPARATOR|Commercially available low pasteurized orange juice (LP)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed was commercially available low pasteurized juice (LP). All participants consumed the LP orange juices.
62591237|NCT04744233|ACTIVE_COMPARATOR|High-pressure processed orange juice(HPP)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed was high-pressure processed (HPP). All participants consumed the HPP orange juices.
62591238|NCT04744233|ACTIVE_COMPARATOR|Pulsed electric fields treated orange juice (PEF)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed was those treated with pulsed electric fields (PEF). Six participants consumed the PEF-orange juice.
62805166|NCT00216671|EXPERIMENTAL|001|early initiation of treatment with Risperdal Consta 25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at baseline. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
62030126|NCT03355079|EXPERIMENTAL|SmofKabiven® E + standard oral nutrition|SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit® will be administered at 5-7 days per week for up to 9 +/-1 weeks in addition to standard of care oral nutrition as per routine dietary counseling, to reach the patient's target energy intake.
62805167|NCT00216671|ACTIVE_COMPARATOR|002|routine initiation of treatment with Risperdal Consta 25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at week 12. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
62421299|NCT04215120|ACTIVE_COMPARATOR|Desidustat oral tablet|Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.
62805168|NCT05237648|EXPERIMENTAL|Experimental Group|Participants will complete an online module with content focusing on patient self-rating of vocal quality within 24 hours of evaluation, approximately 1-2 weeks prior to their first therapy session, and within 24 hours after each therapy session;
62805169|NCT05237648|SHAM_COMPARATOR|Sham Control Group|Participants will complete an online module within 24 hours of evaluation, approximately 1-2 weeks prior to their first therapy session, and within 24 hours after each therapy session with content focusing on vocal hygiene.
62805170|NCT05237648|NO_INTERVENTION|Control group|Participants will not complete an online module. The groups will be compared in terms of attendance, self-efficacy, and treatment outcome measures based on the data collected within the NYU Voice Center standard of care
62030127|NCT03355079|NO_INTERVENTION|Standard oral nutrition|The patients will consume standard of care oral nutrition as per routine dietary counseling, to reach their target energy intake. Standard of care tube feeding or parenteral nutrition is allowed to start earliest 3 weeks after baseline visit, if required.
62030128|NCT05411965|EXPERIMENTAL|Sequence Group A|"The investigational products will be administered according to the treatment groups assigned to each sequence group in Period 1 and Period 2.~\*Sequence A \[Period 1\] Co-administration of BR3003B(R1) and BR3003C(R2) (single dose)~- Wash out for 7 days \[Period 2\] Administration of BR3003(T) (single dose)"
62421300|NCT04215120|EXPERIMENTAL|Epoetin Injection|Randomly assigned to receive Epoetin in a 1:1 ratio for 24 weeks.
62805171|NCT04072913|OTHER|Control group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
62805172|NCT04072913|OTHER|Low grade lesion group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
62805173|NCT04072913|OTHER|High grade lesions group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
62805174|NCT04072913|OTHER|Cancer group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
62805175|NCT01536717|ACTIVE_COMPARATOR|Bupivacaine hydrochloride 0.5%|Bupivacaine hydrochloride is related chemically and pharmacologically to the aminoacyl local anesthetics. Bupivacaine hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
62805176|NCT01536717|PLACEBO_COMPARATOR|Sodium chloride 0,9%|
62819474|NCT04678895|EXPERIMENTAL|Group B, Placebo, Then Low-Dose Naltrexone|Group B will receive 4 weeks of placebo (placebo capsule will be matched with LDN capsule, microcrystalline cellulose filler, 1 capsule daily). Then followed by active drug (Naltrexone 1 capsule by mouth daily, 1.5mg x1 week, 3mg x1 week, and 4.5 mg x6 weeks) for the last 8 weeks. Capsules of different dosages will be indistinguishable.
62030129|NCT05411965|EXPERIMENTAL|Sequence Group B|"The investigational products will be administered according to the treatment groups assigned to each sequence group in Period 1 and Period 2.~\*Sequence B \[Period 1\] Administration of BR3003(T) (single dose)~- Wash out for 7 days \[Period 2\] Co-administration of BR3003B(R1) and BR3003C(R2) (single dose)"
62421301|NCT00545441|EXPERIMENTAL|1|Surgisis® AFP
62421302|NCT00545441|ACTIVE_COMPARATOR|2|Flap
62421303|NCT00883740|EXPERIMENTAL|Lyrica|flexible dosing Lyrica 300-450mg/day
62421304|NCT00883740|PLACEBO_COMPARATOR|Placebo|Placebo
62421305|NCT05614479|OTHER|Intervention group|Use of the MAHA mobile application
62591239|NCT03083561|EXPERIMENTAL|LY3337641 Multiple Dose|Multiple doses of 30 mg LY3337641 tablet administered orally every day for two weeks, with a two week follow-up period.
62591240|NCT03083561|PLACEBO_COMPARATOR|Placebo Multiple Dose|Multiple doses of placebo administered orally every day for two weeks, with a two week follow-up period.
62591241|NCT03083561|EXPERIMENTAL|LY3337641 Single Dose|Single dose of 5 mg, 80 mg and 160 mg LY3337641 tablet administered orally, with a two week follow-up period.
62030130|NCT05834504|NO_INTERVENTION|Control group|"The control group will practice four basic skills and one procedural module on the Laparoscopic Lapsim Virtual Reality Simulator. They will practice with 6-8 days of break in between training sessions until proficiency level is achieved."
62228726|NCT03975205|ACTIVE_COMPARATOR|Doxil|This group of patients will receive Intravenous Doxil of 50mgm/m2 over 15 minutes and plasma concentration will be measured at time Frame: 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours. Cycle is defined as 28 days
62805177|NCT04472949|EXPERIMENTAL|Durvalumab & thoratic radiotherapy|"Patients will start with an induction phase (part 1). Patients with CR; PR or SD after the induction phase, will transfer to the maintenance phase (part 2). Patients with PD after the induction phase will transfer to the follow-up phase.~Induction phase (part 1):~Patients will receive durvalumab in combination with carboplatin and etoposide for 4 cycles of 21 days:~Maintenance phase (part 2):~Patients will receive durvalumab treatment up to PD or max. 2 years, i.e. 26 maintenance cycles, in combination with tRT:~Follow up phase:~Patients will be followed up for 24 months, every 8 weeks."
62591242|NCT03083561|PLACEBO_COMPARATOR|Placebo Single Dose|Single dose of placebo administered orally, with a two week follow-up period.
62805178|NCT04314908|EXPERIMENTAL|Apical enlargement|"Routine retreatment procedure will be performed at working length according to the apex locator at point 0."
62805179|NCT04314908|EXPERIMENTAL|Apical enlargement + Sonic Activation Assisted Irrigation|"Routine retreatment procedure will be performed at working length according to the apex locator at point 0 and sonic activation assisted irrigation will be applied."
62805180|NCT04314908|EXPERIMENTAL|Non Apical enlargement|"Routine retreatment procedure will be performed at working length according to the apex locator at 1mm shorter than 0 point."
62805181|NCT04314908|EXPERIMENTAL|Non Apical enlargement + Sonic Activation Assisted Irrigation|"Routine retreatment procedure will be performed at working length according to the apex locator at 1mm shorter than 0 point and sonic activation assisted irrigation will be applied."
62805182|NCT02223780|PLACEBO_COMPARATOR|control|standard management
62805183|NCT02223780|ACTIVE_COMPARATOR|early palliative care|early palliative care
62805184|NCT05195567|EXPERIMENTAL|Subject glucometer measurement|
62805185|NCT03480152|EXPERIMENTAL|1/Phase - Escalating doses of mRNA vaccine|Escalating doses of messenger ribonucleic acid (mRNA) vaccine
62805186|NCT03480152|EXPERIMENTAL|2/Phase II -MTD of mRNA vaccine established in Phase I|Maximum tolerated dose (MTD) of messenger ribonucleic acid (mRNA) vaccine established in Phase I
62805187|NCT03531671|EXPERIMENTAL|Presence of age related cataract|Binocular-OCT used to assess the eye pre and post-operatively.
62805188|NCT02372526||10 Roux-en-Y gastric bypass patients|Isocaloric amounts of specific macronutrients is mixed with 4 g vegetable bouillon and tested against each others ability to induce GLP-1 secretion. The mealtest takes place at 4 different days with 3-14 days separation.
62805189|NCT02372526||10 Healthy Control subjects|Isocaloric amounts of specific macronutrients is mixed with 4 g vegetable bouillon and tested against each others ability to induce GLP-1 secretion. The mealtest takes place at 4 different days with 3-14 days separation.
62591243|NCT01893216||with depression or anxiety|Hospital Anxiety and Depression Scale score over 9 points
62805190|NCT03735836|EXPERIMENTAL|MaxSimil 2 capsules daily|Subjects will receive two (2) capsules per day of MAG-EPA/MAG-DHA omega-3 oils for a total of 600mg of MAG-EPA and 260mg of MAG-DHA daily during 20 consecutive weeks of treatment.
62805191|NCT03735836|EXPERIMENTAL|MaxSimil 3 capsules daily|Subjects will receive two (3) capsules per day of of MAG-EPA/MAG-DHA omega-3 oils for a total of 900mg of MAG-EPA and 390mg of MAG-DHA daily during 20 consecutive weeks of treatment.
62228727|NCT03975205|EXPERIMENTAL|doxorubicin|This group of patients will receive Intravenous Doxorubicin of 50mgm/m2 over 15 minutes and plasma concentration will be measured at time Frame: 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours. Cycle is defined as 28 days
62591244|NCT01893216||without depression or anxiety|Hospital Anxiety and Depression Scale score less than 8 points
62591245|NCT04960683|EXPERIMENTAL|Robotic -assisted gait training group using Lokomat device|"* 5 sessions of 40 minutes of conventional therapy and~* 5 sessions of 40 minutes on Lokomat per week"
62591246|NCT04960683|ACTIVE_COMPARATOR|Traditional therapy group|• 5 sessions of 40 minutes of conventional therapy
62591247|NCT02697123||antepartum and postpartum|This prospective, observational cohort study was designed to assess the incidence of VTE in patients hospitalized for Cesarean Section, Vaginal delivery or any antepartum indication.
62591248|NCT06668675|EXPERIMENTAL|Digital intervention arm|This intervention arm will receive the serious game known as 'Happy Heart'. The game will be installed in their mobile devices through a link. The adolescents in this arm will play the game on their mobiles for 2 weeks.
62591249|NCT06668675|OTHER|No digital intervention arm|The control group adolescents will receive the same serious game 'Happy Heart' but after the study period is over
62591250|NCT03250767||Integra Titan Modular Shoulder System 2.5|
62591251|NCT04069832|OTHER|Intervention|SINGLE-SESSION CONSULTATION
62591252|NCT05669430|EXPERIMENTAL|Part A - Dose Escalation in up to 7 dose levels|A 3+3 dose escalation scheme will be used to evaluate the safety and tolerability of GV20-0251, and to establish the maximum tolerated dose (MTD) or the preliminary recommended Phase 2 dose (RP2D).
62805192|NCT01573546|EXPERIMENTAL|Aerobic Exercise|
62805193|NCT01573546|EXPERIMENTAL|DASH diet|
62805194|NCT01573546|EXPERIMENTAL|Combined aerobic exercise and DASH diet|
62805195|NCT01573546|ACTIVE_COMPARATOR|Health education control|
62805196|NCT05646134|EXPERIMENTAL|Low Frequency Experimental Group|Participants in this Arm will receive 10 sessions of Low Frequency (1 Hz) rTMS Participants in this Arm will receive 10 sessions of High Frequency (10 Hz) rTMS
62228728|NCT04891822||E (ERAS protocol)|receive ERAS protocol 8 hours of fasting and ingestion of oral carbohydrate 2 hour before surgery TIVA(Total intra-venous anesthesia) TAP(transversus abdominis plane) block IV-PCA using NSAIDs after surgery Resuming oral intake 2 hours after surgery.
62228729|NCT04891822||C (Control)|receive standard perioperative care 8 hours of fasting before surgery Inhalation anesthesia IV-PCA using NSAIDs Resuming oral intake 6 hours after surgery.
62805197|NCT05646134|EXPERIMENTAL|High Frequency Experimental Group|Participants in this Arm will receive 10 sessions of High Frequency (10 Hz) rTMS
62228730|NCT04862871|NO_INTERVENTION|Healthy Controls|A cohort (n=10) of participants will be recruited who do not have any neurological conditions and are age and sex-matched to participants in Arms 2 and 3.
62591253|NCT05669430|EXPERIMENTAL|Part B - Multiple Expansion Cohorts in up to 4 tumor indications|The Bayesian optimal design for Phase II (BOP2) will be utilized to further characterize the anti-tumor activities, safety, tolerability, pharmacokinetics, and pharmacodynamics of GV20-0251 at the preliminary RP2D in up to 4 expansion cohorts involving eligible participants.
62228731|NCT04862871|NO_INTERVENTION|Chronic Widespread Pain|A cohort (n=10) of participants who have not yet begun the exercise program and are currently on the waitlist for the exercise program at the PPRC
62805198|NCT05646134|SHAM_COMPARATOR|Sham Stimulation Control Group|Participants in this Arm will receive 10 sessions of Sham rTMS
62805199|NCT03546946|EXPERIMENTAL|Gaze-Contingent Music Reward Training|GCMRT for eight 20-minute sessions - twice per week over 4 weeks.
62805200|NCT03546946|PLACEBO_COMPARATOR|Control Training|Passive viewing task with continuous music for eight 20-minute sessions - twice per week over 4 weeks.
62030131|NCT05834504|EXPERIMENTAL|Intervention Group|"The intervention group will practice four basic skills and one procedural module on the Laparoscopic Lapsim Virtual Reality Simulator. They will practice with 1-2 days of break in between training sessions until proficiency level is achieved."
62030132|NCT04278144|EXPERIMENTAL|Single agent BDC-1001|Escalating doses followed by expansion targeting HER2-expressing advanced malignancies
62030133|NCT04278144|EXPERIMENTAL|Combination BDC-1001 plus nivolumab|Escalating doses followed by expansion targeting HER2-expressing advanced malignancies
62228732|NCT04862871|ACTIVE_COMPARATOR|Chronic Widespread Pain - Exercise|A cohort (n=10) of participants who have completed the exercise program at the PPRC. These individuals will be evaluated the day of their last treatment visit
62228733|NCT04253574||Patients with malignant melanoma|258 patients (w: 112, m: 146 age: 61±16 years) met the primary inclusion criteria. They were all examined by 18F-FDG PET/CT, 176 patients additionally by US (peripheral lymph nodes (pUS) and/or abdomen (aUS)).
62228734|NCT01222273|OTHER|Open label|open label Vitamin D
62591254|NCT05669430|EXPERIMENTAL|Part C - GV20-0251 in Combination with Pembrolizumab Dose Escalation in 2-4 dose levels|The Bayesian optimal interval (BOIN) design will be employed to evaluate the safety and tolerability of GV20-0251 in combination with pembrolizumab, and to determine the MTD or the preliminary RP2D of this combination in selected tumor indications.
62591255|NCT05669430|EXPERIMENTAL|Part D - GV20-0251 in Combination with Pembrolizumab Dose Expansion in up to 5 indications|The BOP2 will be applied to further characterize the anti-tumor activities, safety, tolerability, pharmacokinetics, and pharmacodynamics of GV20-0251 in combination with pembrolizumab at the preliminary RP2D in up to 5 expansion cohorts involving eligible participants.
62591256|NCT02303223|OTHER|Propofol|Single intravenous bolus dose of Propofol 2.5mg/kg for induction of anesthesia
62805201|NCT03546946|NO_INTERVENTION|No-Train Group|No active training.
62805202|NCT02121379|NO_INTERVENTION|control|stretching exercise
62805203|NCT02121379|EXPERIMENTAL|pulmonary rehablitation|warming up exercise strengthening exercise aerobic exercise cool down
62805204|NCT00867230|EXPERIMENTAL|FTS (S-trans, trans-farnesylthiosalicylic acid)|
62805205|NCT05528055|EXPERIMENTAL|Dose escalation|Participants will receive SCR-6920 capsule orally at escalating doses, till the maximum tolerated dose level is reached, and the recommended phase 2 dose(RP2D) will be determined.
62805206|NCT05528055|EXPERIMENTAL|Dose expansion: non small cell lung cancer(NSCLC)|Participants will receive SCR-6920 capsule orally at the recommended phase 2 dose
62228735|NCT04398420|ACTIVE_COMPARATOR|TVERP|
62228736|NCT04398420|ACTIVE_COMPARATOR|TURis|
62228737|NCT04398420|ACTIVE_COMPARATOR|HoLEP|
62228738|NCT02668185|EXPERIMENTAL|Active drug first|Baseline period - 2 weeks NK3R antagonist - AZD4901 - 40mg bd - 4 weeks Washout period - 2 weeks Matched placebo orally bd - 2 weeks Monitoring period - 2 weeks
62421306|NCT04662086|EXPERIMENTAL|Acebilustat|Participants are randomized to receive either active acebilustat or matching placebo for 28 days.
62805207|NCT05528055|EXPERIMENTAL|Dose expansion: NHL|Participants will receive SCR-6920 capsule orally at the recommended phase 2 dose on a continuous basis
62805208|NCT05528055|EXPERIMENTAL|Dose expansion: solid tumors|Participants will receive SCR-6920 capsule orally at the recommended phase 2 dose on a continuous basis
62805209|NCT05281666|ACTIVE_COMPARATOR|Absorbable Surgical Gut Suture|Ethicon Chromic Surgical Gut Suture Is an absorbable, sterile surgical suture composed of purified connective tissue (mostly collagen) derived from either the serosal layer of beef (bovine) or the submucosal fibrous layer of sheep (ovine) Intestines. Surgical Gut Suture is Indicated for use In general soft tissue approximation and/or ligation, including use In ophthalmic procedures, but not for use in cardiovascular and neurologic tissues.
62030134|NCT00497302|EXPERIMENTAL|1|receives housing based on drug abstinence
62030135|NCT00497302|ACTIVE_COMPARATOR|2|Usual care treatment at the Center for Addiction and Pregnancy
62030136|NCT06670742|EXPERIMENTAL|Marathon running group|Run 10 kilometers on a treadmill.
62030137|NCT06670742|NO_INTERVENTION|General healthy adult group|No intervention will be conducted.
62030138|NCT06304233||Diagnosed with Schizophrenia|Patients with a ICD-10 diagnosis of Schizophrenia will undergo investigations to assess cardiac function, cardiovascular disease risk factors and DISC1 mRNA expression. Participants eligible for MRI will be invited to undergo cardiac MRI in addition to echocardiography.
62228739|NCT02668185|PLACEBO_COMPARATOR|Placebo|Baseline period - 2 weeks Matched placebo orally bd - 2 weeks Washout period - 2 weeks NK3R antagonist - AZD4901 - 40mg bd - 4 weeks Monitoring period - 2 weeks
62228740|NCT01530165|NO_INTERVENTION|Standard|Pre diabetics randomized to control arm will receive standard life style advice which is given to all pre diabetics seeking medical advice. Group counselling (30 min to 1 hour) will be provided to participants enrolled in control arm in which they will attend one group class at baseline where they will be given basic information on diabetes prevention , weight loss, diet, and exercise consitent with expert recommendations for a healthy life style inclusing losing 5-10% of their excess body weight to reduce their calorie and fat intake and exercising at least 150 minutes per week.
62228741|NCT01530165|OTHER|life style intervention arm|"This arm would be given aggressive life style intervention in comparison to standard (control) arm. The intervention would consist of nutritional and physical activity advice.~Consists of 5 sessions during the two years course of follow up. Three sessions in the first year (intensive phase), two sessions (maintenance phase) in second year. Overall sessions have a theme with simple selected theoretical background information. Sessions are to be interactive. Selected handouts and pamphlets are given after the session. Teaching material is both available in English and Urdu (local) language."
62228742|NCT05919160|EXPERIMENTAL|Neuronal Recording and Behavioral Testing|Neuronal Recording and Behavioral Testing
62228743|NCT01542931|NO_INTERVENTION|Surgery and radiotherapy|Surgery and post-operative radiotherapy.
62228744|NCT01542931|EXPERIMENTAL|TPF induction chemotherapy|Induction chemotherapy before surgery: docetaxel, cisplatin, and 5-fluorouracil.
62805210|NCT05281666|ACTIVE_COMPARATOR|Non-absorbable Nylon Suture|Ethicon ETHILON\* nylon suture is a nonabsorbab\\e, sterile surgical monofi\\ament suture composed of the long-chain aliphatic polymers Nylon 6 and Nylon 6,6. ETHILON sutures are dyed black or green to enhance visibility in tissue. The suture is also available undyed (clear). ETHILON suture is indicated for use in general soft tissue approximation and/or ligation, including use in cardiovascular, ophthalmic and neurological procedures.
62805211|NCT05686785||Chronic viral hepatitis|
62591257|NCT00381043|ACTIVE_COMPARATOR|1- Acamprosate|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
62591258|NCT00381043|PLACEBO_COMPARATOR|2 - Sugar Pill - Placebo|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
62805212|NCT06079385|EXPERIMENTAL|Acupuncture group|The patients who received acupuncture treatment in addition to a standard rehabilitation program
62805213|NCT06079385|NO_INTERVENTION|Control group|The patients who received the standard rehabilitation program.
62805214|NCT06077045||LAIV Vaccinated cohort|All individuals receiving LAIV between 2 and \<18 years within a given flu season between 2012 and 2020.
62805215|NCT06077045||Unvaccinated cohort|All individuals between 2 and \<18 years with no record of influenza vaccinations in a given flu season
62805216|NCT01406301||Patients with a discharge diagnosis of ACS (UA/NSTEMI or STEMI|Patients with a discharge diagnosis of ACS (UA/NSTEMI or STEMI)
62805217|NCT02949609|EXPERIMENTAL|Mirror Therapy (MT)|Standard therapy + 30 min/day of mirror therapy, 5 days/week, for 4 weeks, administered by experienced physical and occupational therapists.
62805218|NCT02949609|ACTIVE_COMPARATOR|Control Therapy (CT)|Standard therapy + 30 min/day of CT.
62805219|NCT05046223|EXPERIMENTAL|high-flow nasal oxygen|THRIVE( Transnasal humidified rapid-insufflation ventilatory exchange), a method of high-flow nasal oxygen (HFNO), is planned to applied for bronchoscopic interventions
62805220|NCT05046223|ACTIVE_COMPARATOR|supraglottic devise|iGel, a supraglottic devise with tip in upper esophagus, is planned to applied for bronchoscopic interventions
62228745|NCT02012114|NO_INTERVENTION|Cysteamine Bitartrate|Single arm study. Subjects receive their current oral form of cysteamine bitartrate treatment : Cystagon® or RP103
62228746|NCT04450160|PLACEBO_COMPARATOR|Standard of Care|Current GBM Treatment of surgery, radiation and chemotherapy with temozolomide.
62228747|NCT04450160|EXPERIMENTAL|AEO with Standard of Care|Anhydrous Enol-Oxaloacetate added to the Standard of Care (surgery, radiation and chemotherapy with temozolomide).
62228748|NCT02935452|ACTIVE_COMPARATOR|Genie|This group will have the Genie social tool delivered on a one to one basis at discharge points in the study.
62228749|NCT02935452|NO_INTERVENTION|Normal Care|This group will have the same questionaires at discharge, but will be offered normal care
62591259|NCT04392388||SAPRIS-SERO|SAPRIS-SERO enrolls participants from cohorts entitled: Constances, E3N-E4N, ELFE, Epipage 2 and NutriNet-Santé.
62805221|NCT00942565|ACTIVE_COMPARATOR|Tramadol/acetaminophen|The tramadol and acetaminophen combination was given to patients at the same day after surgery.
62805222|NCT00942565|ACTIVE_COMPARATOR|acetaminophen|Acetaminophen was used as active control.
62805223|NCT02775188|EXPERIMENTAL|Physical Therapy with InterACTION|After ACL Reconstruction, subjects will undergo physical therapy 1 time per week supplemented by home exercise program with InterACTION device.
62805224|NCT02775188|OTHER|Physical Therapy|After ACL Reconstruction, subjects will undergo physical therapy 1 time per week
62805225|NCT03689582|EXPERIMENTAL|68Ga-PSMA|PET/CT imaging with 68Ga-PSMA
62228750|NCT01284686|ACTIVE_COMPARATOR|dopamine|ON DOPA:The patient will take his usual treatment with dopamine
62228751|NCT01284686|EXPERIMENTAL|without dopa|OFF Dopa: The patient will be deprived of his treatment usual dopaminergique for at least 12 hours
62421307|NCT04662086|EXPERIMENTAL|Camostat|Participants are randomized to receive either active camostat or matching placebo for 10 days.
62421308|NCT06385145|EXPERIMENTAL|TR|Administration order: PEG-rhGH with new preparation (T), PEG-rhGH with present preparation (R)
62805226|NCT02723812|EXPERIMENTAL|GCFLU® Influenza vaccine (Split virion, Inactivated)|One dose 0.5 mL vaccine GCFLU® administered intramuscularly.
62805227|NCT05932277|EXPERIMENTAL|Cocktail Probe Substrates + BMS-986419|
62805228|NCT01300728|EXPERIMENTAL|intravenous immunoglobulin (IVIG)|IVIG (NewGam 10%)at 0.4 g/kg
62805229|NCT01300728|PLACEBO_COMPARATOR|Saline solution|0.9% saline solution
62805230|NCT05608746|EXPERIMENTAL|Intervention Group|
62805231|NCT05608746|OTHER|Control Group|
62805232|NCT01849601|EXPERIMENTAL|PTA catheter|
62805233|NCT05754853|EXPERIMENTAL|MRG002|MRG002 will be administrated by an IV infusion of 2.2 mg/kg on Day 1 of every 3 weeks (21-day cycle).
62805234|NCT05754853|ACTIVE_COMPARATOR|Docetaxel /Paclitaxel /Gemcitabine Hydrochloride /Pemetrexed Disodium Injection|"Docetaxel injection will be administered by an IV infusion of 75 mg/m2 on Day 1 of every 3 weeks (21-day cycle); Paclitaxel will be administrated by an IV infusion of 175 mg/m2 on Day 1 of every 3 weeks (21-day cycle).~Gemcitabine Hydrochloride will be administrated by an IV infusion of 1000 mg/m2 on Day 1 and Day 8 of every 3 weeks (21-day cycle).~Pemetrexed Disodium will be administrated by an IV infusion of 500 mg/m2 on Day 1 of every 3 weeks (21-day cycle)."
62805235|NCT01778790|SHAM_COMPARATOR|Sham Stimulation for 8 weeks|Implantation of internal pulse generator (IPG), Sham Stimulation
62805236|NCT01778790|ACTIVE_COMPARATOR|Stimulation for 8 weeks|Implantation of IPG and active stimulation
62805237|NCT03841110|EXPERIMENTAL|FT500 Monotherapy|FT500 administered once weekly for 3 weeks as a monotherapy
62805238|NCT03841110|EXPERIMENTAL|FT500 in Combination with Immune Checkpoint Inhibitor|FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.
62805239|NCT03841110|EXPERIMENTAL|FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor|FT500 + IL-2 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.
62805240|NCT01311882|EXPERIMENTAL|MK-4305 40 mg|Day 1 and Day 8- 4 x 10 mg MK-4305 and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 4 x 10 mg MK-4305
62805241|NCT01311882|EXPERIMENTAL|MK-4305 20 mg|Day 1 and Day 8- 2 x 10 mg MK-4305 and 2 x 10 mg MK-4305 matching placebo and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 2 x 10 mg MK-4305 and 2 x 10 mg MK-4305 matching placebo
62805242|NCT01311882|ACTIVE_COMPARATOR|Zopiclone 7.5 mg|Day 1 and Day 8- 1 x 7.5 mg zopiclone and 4 x 10 mg MK-4305 matching placebo; Days 2-7- 4 x 10 mg MK-4305 matching placebo
62805243|NCT01311882|PLACEBO_COMPARATOR|Placebo|Day 1 and Day 8- 4 x 10 mg MK-4305 matching placebo and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 4 x 10 mg MK-4305 matching placebo
62805244|NCT02106000||Arm 1: Non-pregnant females|Inhalation profiles will be recorded for non-pregnant females
62805245|NCT02106000||Arm 2: Pregnant females|Inhalation profiles will be recorded for the women in the 3rd stage of labour
62805246|NCT05003479|EXPERIMENTAL|candidate vaccine|
62805247|NCT05003479|PLACEBO_COMPARATOR|Placebo|
62805248|NCT00925262|EXPERIMENTAL|Cognitive Processing Therapy|An adaptation of cognitive behavioral therapy, focusing on treatment for persons suffering mental health effects of trauma
62805249|NCT00925262|EXPERIMENTAL|Behavioral Activation|A form of counseling therapy that emphasizes enhancing pleasurable behaviors and minimizing negative behaviors as a means to reducing depression symptomatology.
62805250|NCT00925262|EXPERIMENTAL|non-specific counseling|a collection of counseling skills suitable for a broad range of mental health and psychosocial problems and not designed for specific disorders. This particular version was developed by a collaborator -Heartland Alliance - for use with torture survivors.
62805251|NCT00925262|NO_INTERVENTION|wait control|persons in this study arm will not receive active treatment as part of the study but will be monitored during the study and offered treatment after 3-5 months of waiting.
62805252|NCT03795116|EXPERIMENTAL|LED-RL phototherapy|Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week after surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks.
62805253|NCT03795116|SHAM_COMPARATOR|Mock irradiation|Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week after surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks.
62805254|NCT02939365|EXPERIMENTAL|Belatacept patients|"Forty patients who are previously enrolled in belatacept based regimens with a minimum of 7 years of follow up at 4 transplant centers and who are maintained on belatacept, an antiproliferative ± steroids will be approached for enrollment.~Drug withdrawal of steroids (in patients on steroids) and of antiproliferatives (MPAs or mTor inhibitors). Patients who continue to be stable for 3 months on belatacept monotherapy will be converted from q 4 weeks to q 8 weeks belatacept administrations."
62805255|NCT04585724|EXPERIMENTAL|Treatment (abemaciclib)|Beginning within 2 weeks prior to stereotactic radiosurgery, patients receive abemaciclib PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
62805256|NCT04585724|EXPERIMENTAL|Treatment (palbociclib)|Beginning within 2 weeks prior to stereotactic radiosurgery, patients receive palbociclib PO QD on days 1-21. Treatment continues in the absence of disease progression or unacceptable toxicity.
62805257|NCT04585724|EXPERIMENTAL|Treatment (ribociclib)|Beginning within 2 weeks prior to stereotactic radiosurgery, patients receive ribociclib PO QD on days 1-21. Treatment continues in the absence of disease progression or unacceptable toxicity.
62805258|NCT05189548|EXPERIMENTAL|Adsorbed a cell-free whitening break (three-component) combination vaccine|A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine.
62805259|NCT05850949|EXPERIMENTAL|Konjac-Grain|Without supplementation, followed by Supplementation with Konjac grain from PT. AMBICO
62591260|NCT04917861|EXPERIMENTAL|mRNA-1893 Low Dose (2-Dose Regimen)|Participants will receive mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).
62591261|NCT04917861|EXPERIMENTAL|mRNA-1893 High Dose (2-Dose Regimen)|Participants will receive mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).
62805260|NCT03210207||GASTROPLICATURE|"The procedure begins with division of the greater curve vessels from 4 to 5 cm proximal to the pylorus to the angle of His. Either ultrasonic energy or bipolar cautery is appropriate for this step.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum"
62805261|NCT02419365||PCD|Individuals with Primary Ciliary Dyskinesia will be assessed in a pure observational design without intervention
62805262|NCT06039553||Pulmonary Artery Banding Group|Patient in this group will undergo pulmonary artery banding surgery for congenital heart disease.
62805263|NCT05016466||Group I. Patients with DLCO <80%.|Patients with DLCO \<80% will be followed at baseline and once a year during the study
62805264|NCT05016466||Group II. Patients with DLCO ≥ 80%.|Patients with DLCO ≥80% only will be followed at baseline and year 5.
62805265|NCT01421017|EXPERIMENTAL|IMQ+RT|"This arm has been closed as of 6/4/2014.~* Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~* Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied to all skin sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.~* Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
62805266|NCT01421017|EXPERIMENTAL|CTX/IMQ/RT|"* Week -1 (day-7): cyclophosphamide 200mg/m2 IV as single infusion~* Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~* Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied all sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.~* Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
62805267|NCT01421017|EXPERIMENTAL|CTX/RT|"For patients with only non-skin metastatic sites~First cycle (Cycle 1):~* Week -1 (day -7): cyclophosphamide 200mg/m2 IV as single infusion~* Weeks 1-2: RT given to one site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~* Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
62805268|NCT00737776||A|
62805269|NCT06261177|EXPERIMENTAL|Active FES|300μs long charge-balanced biphasic pulses delivered at 40 Hz, with amplitudes in the range of 5-20 mA
62805270|NCT06261177|SHAM_COMPARATOR|Sham FES|Sensory stimulation (below 8 mA)
62805271|NCT02483806|EXPERIMENTAL|PEEP 0 cmH2O|PEEP 0 cmH2O (zero end expiratory pressure, ZEEP)
62421309|NCT06385145|EXPERIMENTAL|RT|Administration order: PEG-rhGH with present preparation (R), PEG-rhGH with new preparation (T)
62421310|NCT05472623|ACTIVE_COMPARATOR|Arm A|Arm A treatment: Oral Adagrasib 600 mg twice daily for 6 weeks prior to surgery. Surgical Resection, then standard postoperative therapy(chemo +/- RT).
62591262|NCT04917861|EXPERIMENTAL|mRNA-1893 High Dose (1-Dose Regimen)|Participants will receive placebo matching to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There will be 28-day (-3/+7 days) interval between vaccinations.
62591263|NCT04917861|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to mRNA-1893 administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).
62591264|NCT05146544||No limitation of exercise performance capacities|normal maximal oxygen uptake (greater than or equal to 80% of the reference value)
62805272|NCT02483806|EXPERIMENTAL|PEEP 5 cmH2O|
62805273|NCT02483806|EXPERIMENTAL|EEP 10 cmH2O|
62421311|NCT05472623|ACTIVE_COMPARATOR|Arm B|Arm B treatment: Oral Adagrasib 400 mg twice daily for 6 weeks and IV Nivolumab 240mg every 2 weeks for 3 doses prior to surgery. Surgical Resection, then standard postoperative therapy(chemo +/- RT).
62421312|NCT06389968|EXPERIMENTAL|Light stimulation|Experimental light stimulation (3 colors at 20 Hertz each for 80 seconds twice a day).
62421313|NCT06389968|SHAM_COMPARATOR|Sham light stimulation|Sham light stimulation (white screen for 80 seconds twice a day).
62421314|NCT01892020|EXPERIMENTAL|Treatment sequence 1 (Group A)|Group A will receive BIAsp 50 BID during the first 4 weeks (treatment period 1) then switch to BHI 50 BID for further 4 weeks (treatment period 2)
62421315|NCT01892020|EXPERIMENTAL|Treatment sequence 2 (Group B)|Group B will receive BHI 50 BID during the first 4 weeks (treatment period 1), then switch to BIAsp 50 BID for further 4 weeks (treatment period 2)
62805274|NCT04507243|EXPERIMENTAL|Active - HD tDCS|Participants randomized to this arm will receive 12 sessions of high definition tDCS (HD-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
62805275|NCT04507243|SHAM_COMPARATOR|Sham - HD tDCS|Participants randomized to this arm will receive 12 sessions of sham HD tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
62228752|NCT05955287|EXPERIMENTAL|Couple Intervention|"Patients will receive usual care. In addition, they will participate in virtual OSA support groups led by an African American peer-motivator patient with long-standing OSA and their bed partner. Peer-motivator couples will be trained and certified as competent prior to interacting with study participants. They will share their experiences with managing OSA including coping strategies to maximize CPAP adherence.~Telemonitoring. Patients and bed partners will receive text messages encouraging CPAP adherence."
62591265|NCT05146544||Limitation of exercise performance capacities|reduced maximal oxygen uptake (less than 80% of the reference value).
62591266|NCT06648031|EXPERIMENTAL|Arm 1 - DehydraTECH-CBD alone|
62805276|NCT01046565|ACTIVE_COMPARATOR|Differin® Cream 0.1%|Adapalene Cream 0.1% - apply once daily on one side of the face for 3 weeks
62805277|NCT01046565|ACTIVE_COMPARATOR|Differin® Lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face
62805278|NCT06071949|EXPERIMENTAL|Treatment group|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
62805279|NCT06071949|EXPERIMENTAL|Control group|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
62805280|NCT03308916|EXPERIMENTAL|Liver stiffness measurement|Transient elastography in fasting state
62805281|NCT02625792|EXPERIMENTAL|Endo-Clot(TM)|The intervention group
62805282|NCT01349517|OTHER|MIE Group|The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)
62805283|NCT01349517|OTHER|Three-incision esophagectomy group|The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)
62805284|NCT01349517|OTHER|Ivor-Lewis esophagectomy group|The patients in this group would underwent Ivor-Lewis esophagectomy
62805285|NCT01349517|OTHER|Sweet esophagectomy group|The patients in this group would underwent Sweet esophagectomy.
62805286|NCT01169129|ACTIVE_COMPARATOR|surgery+whole-brain irradiation|brain metastases is resected and the patient is submitted to whole-brain irradiation
62805287|NCT01169129|ACTIVE_COMPARATOR|whole-brain irradiation+radiosurgery|patients will be submitted to whole-brain irradiation and after, they will be submitted to radiosurgery.
62228753|NCT05955287|ACTIVE_COMPARATOR|Control|Patients with CPAP technical difficulties will be encouraged to contact the sleep technologist for assistance. Patients will also attend a 90-minute virtual webinar and question-answer session on hypertension management (1 month), cancer screening (3 months), and weight management (6 months) led by African American physicians with expertise in each topic.
62591267|NCT06648031|EXPERIMENTAL|Arm 2 - DehydraTECH-semaglutide alone|
62591268|NCT06648031|EXPERIMENTAL|Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide|
62591269|NCT06648031|ACTIVE_COMPARATOR|Arm 4 - Rybelsus medication (semaglutide) alone as a positive control.|
62591270|NCT00915408|EXPERIMENTAL|CRD|
62805288|NCT04804683|OTHER|Cohort of patients with Fibromuscular Dysplasia|Intervention consists in blood/urine sampling
62805289|NCT01247324|ACTIVE_COMPARATOR|Interferon beta-1a 44 mcg SC|Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
62805290|NCT01247324|EXPERIMENTAL|Ocrelizumab|Ocrelizumab 600 mg intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.
62805291|NCT03243617|ACTIVE_COMPARATOR|AO+Mist|Cosmetic Product AO+Mist
62805292|NCT03243617|PLACEBO_COMPARATOR|Placebo|Placebo
62805293|NCT00651781|EXPERIMENTAL|1|"Phase I:3 dose levels Cytarabine (200 mg/m2- 500 mg/m2-1000 mg/m2) with scheme Flag-Ida in combination with Velcade until determinate the appropriate dose.~Phase II:~Fludarabine, Cytarabine and Idarubicin in combination with 2 times per week of Velcade administration. Each 28-day treatment, patients will be evaluated, and in absence of disease progression or unacceptable toxicity, patients will start second cycle with Bortezomib in monotherapy two times per week followed by a 10 days rest period. That is, patients who response with acceptable toxicity will receive the combined sequential scheme twice (as induction and consolidation)."
62805294|NCT01121796|ACTIVE_COMPARATOR|Vitamin D|
62228754|NCT01898923|EXPERIMENTAL|ON101 Cream|ON101 Cream (1.25%),15g ointment per tube. Twice daily for up to 16 weeks.
62228755|NCT01898923|OTHER|Aquacel® Hydrofiber® dressing|Aquacel® Hydrofiber® dressings will be changed daily, on alternate days or three times a week according to need, but not longer than 7 days.
62591271|NCT00593710|EXPERIMENTAL|1|Losartan
62591272|NCT00593710|ACTIVE_COMPARATOR|2|Atenolol
62805295|NCT01121796|PLACEBO_COMPARATOR|Placebo|
62805296|NCT01121796|ACTIVE_COMPARATOR|Unique vehicle for Vitamin D supplementation|
62805297|NCT06202222|NO_INTERVENTION|standard rehabilitation|
62805298|NCT06202222|EXPERIMENTAL|standard rehabilitation and cycloergometer|
62805299|NCT01712126|EXPERIMENTAL|Irbesartan and Hydrochlorothiazide|300 mg and 25 mg tablet
62805300|NCT01712126|ACTIVE_COMPARATOR|Avalide|irbesartan 300 mg and hydrochlorothiazide 25 mg
62805301|NCT01480960|ACTIVE_COMPARATOR|Whole body vibration training|Whole body vibration training in addition to pulmonary rehabilitation
62805302|NCT01480960|NO_INTERVENTION|No whole body vibration training|Pulmonary rehabilitation without whole body vibration training
62805303|NCT02741622|EXPERIMENTAL|Exercise|Acute High aerobic intensity training (HIT) and long slow distance training (LSD)
62805304|NCT02967146|EXPERIMENTAL|Mediclore|
62805305|NCT02967146|NO_INTERVENTION|Not done|Standard treatment for surgery
62228756|NCT05190718||Dysphagia rehabilitation|All interventions are part of routine treatment of dysphagia.
62228757|NCT02652871|EXPERIMENTAL|LY2510924 + Idarubicin + Cytarabine|"Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients. On Day 8, LY2510924 administered after bone marrow aspiration and/or biopsy is performed.~Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase.~Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients \> 60 years of age Idarubicin given for 2 days.~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days.~Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age \< 60 years). In patients \> 60 years of age Cytarabine given for 3 days only.~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days."
62805306|NCT06034288|EXPERIMENTAL|Xeomin|100units xeomin dilated in 10mL injectable saline will be injected into the detrusor muscle to a depth of 3mm at 20 sites at 0.5mL volume each
62805307|NCT06034288|ACTIVE_COMPARATOR|Botox|100units Botox dilated in 10mL injectable saline will be injected into the detrusor muscle to a depth of 3mm at 20 sites at 0.5mL volume each
62228758|NCT04459247|EXPERIMENTAL|Intervention|Vitamin D high dose
62228759|NCT04459247|NO_INTERVENTION|Control arm|No Vitamin D supplementation
62805308|NCT05404152||Ederly|Elderly Admitted to Nursing homes
62228760|NCT04594447|OTHER|Physica KR|Subject that receive Physica Kinematic Retaining total Knee replacement system
62228761|NCT04594447|OTHER|Physica CR|Subject that receive Physica Cruciate Retaining total Knee replacement system
62805309|NCT03890068|EXPERIMENTAL|anlotinib|anlotinib for maintenance treatment a dose of 12 mg once daily (day1-14 PO) in 21-day cycles
62805310|NCT04400188|EXPERIMENTAL|Experimental A (part 1) : Fluzoparib + temozolomide|
62805311|NCT04400188|EXPERIMENTAL|Experimental B (part 2) : Fluzoparib + temozolomide + SHR-1316|
62805312|NCT02994563|EXPERIMENTAL|Open arm|Thrombectomy device to be used to retrieve clot and restore blood flow.
62805313|NCT03245125||HIIT subjects in HFrEF patients|heart failure patients with reduced ejection fraction (HFrEF) received at least 36 times of high-intensity interval training (HIIT)
62805314|NCT03245125||MDP subjects in HFrEF patients|heart failure patients with reduced ejection fraction (HFrEF) received only multidisciplinary disease management program (MDP) and underwent less than 36 times of high-intensity interval training (HIIT) or no exercise training
62805315|NCT03245125||HIIT subjects in HFpEF patients|heart failure patients with preserved ejection fraction (HFpEF) received at least 36 times of high-intensity interval training (HIIT)
62805316|NCT03245125||MDP subjects in HFpEF patients|heart failure patients with preserved ejection fraction (HFpEF) received only multidisciplinary disease management program (MDP) and underwent less than 36 times of high-intensity interval training (HIIT) or no exercise training
62805317|NCT00271375|EXPERIMENTAL|Arm 1: Caring for you, Caring for me Educational Intervention|Educational Intervention
62805318|NCT00271375|EXPERIMENTAL|Arm 2: Caring for you, caring for me + social worker|Educational + Social Work Intervention
62228762|NCT03849001|EXPERIMENTAL|Exercise Conditions|"Participants will undergo four Exercise Conditions (i.e., light intensity leg cycling, moderate intensity leg cycling, vigorous intensity leg cycling, and a seated, quiet rest) in a randomized, counterbalanced order."
62591273|NCT03662191|EXPERIMENTAL|Treatment A|4 × 20 mg commercial tafamidis meglumine administered as soft gelatin capsules under fasted conditions
62591274|NCT03662191|EXPERIMENTAL|Treatment B|10 mgA tafamidis free acid administered as a wet-milled suspension under fasted conditions
62805319|NCT00271375|PLACEBO_COMPARATOR|Arm 3: Control group usual care|Control group usual care
62805320|NCT01057849|EXPERIMENTAL|Risperidone, Intensive|risperidone and intensive psychosocial intervention
62805321|NCT01057849|ACTIVE_COMPARATOR|risperidone, basic|risperidone and basic psychosocial support
62805322|NCT01057849|EXPERIMENTAL|olanzapine, intensive|olanzapine and intensive psychosocial intervention
62805323|NCT01057849|ACTIVE_COMPARATOR|olanzapine, basic|olanzapine and basic psychosocial support
62805324|NCT01057849|EXPERIMENTAL|aripiprazole, intensive|aripiprazole and intensive psychosocial intervention
62805325|NCT01057849|ACTIVE_COMPARATOR|aripiprazole, basiv|aripiprazole and basic psychosocial support
62805326|NCT03490825|EXPERIMENTAL|Meal timing + Melatonin|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a 1mg melatonin supplementation given daily during the intervention.
62228763|NCT06445426||Simulataneous bladder pressure recording|In all patients recruited, the pressure will be recorded simultaneously with the conventional and novel pressure recording systems in the bladder. The procedure will be done according to the International Continence Society's (ICS) recommended indications for the procedure.
62805327|NCT03490825|EXPERIMENTAL|Meal timing + Placebo|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a melatonin placebo (Lactose/Starch) supplementation given daily during the intervention.
62805328|NCT03490825|EXPERIMENTAL|Melatonin|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No EOF will be imposed. This arm will include a 1mg melatonin supplementation given daily during the intervention.
62805329|NCT03490825|PLACEBO_COMPARATOR|Placebo|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No EOF will be imposed. This arm will also include a melatonin placebo (Lactose/Starch) supplementation given daily during the intervention.
62805330|NCT01889875|NO_INTERVENTION|Control group|
62805331|NCT01889875|ACTIVE_COMPARATOR|Subcutaneous Immunotherapy (SCIT)|"Treatment using ALK AluTard 225 Phleum pratense"
62805332|NCT01889875|ACTIVE_COMPARATOR|Sublingual Allergen Immunotherapy Tablets (AIT)|"Treatment using ALK Grazax 75,000 SQ-T Phleum pratense"
62805333|NCT05625984|EXPERIMENTAL|Fascigel injection application|Device is administered injected interfascially in the concerned place (low back) in multiple places laterally.
62421316|NCT01304563|ACTIVE_COMPARATOR|IM15|15 mcg TIV 2010/2011 influenza vaccine delivered via intramuscular injection (control)
62805334|NCT03201588|EXPERIMENTAL|Formulaid|Formulaid 2:1 Arachidonic acid/Docosahexaenoic acid (AA/DHA). Enteral supplement of AA (0,1-1ml) (100mg(kg/day) and DHA (50mg/kg/day) from birth to 40 weeks postmenstrual age in addition to conventional parenteral fatty acid treatment with Clinoleic
62805335|NCT03201588|NO_INTERVENTION|Clinoleic|"Sterile fat emulsion \[containing a mixture of refined olive oil (approximately 80%) and refined soya oil (approximately 20%)\] 200 g, egg lecithin (purified egg phospholipids) 12 g, glycerol 22.5 g, sodium oleate 0.3 g and Water for Injections to 1,000 mL (final pH between 6.0-8.0).~One of the active ingredients, soya oil, contains ascorbyl palmitate as an antioxidant (free radical scavenger), in the concentration of 0.15 mg/g of oil."
62805336|NCT03422029|EXPERIMENTAL|177Lu-Dotatate PRRT|177Lu-Dotatate A maximum of 8 cycles of 1000mCi 177Lu-Dotatate, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 8 cycles, every 8 weeks
62805337|NCT06189326|ACTIVE_COMPARATOR|non-penetrating deep sclerectomy|
62805338|NCT06189326|ACTIVE_COMPARATOR|primary combined trabeculotomy-trabeculectomy|
62805339|NCT04392726||patients with suspected DPLD|
62805340|NCT04392726||patients with known DPLD|
62805341|NCT05298202|EXPERIMENTAL|Capsaicin gel application|Capsaicin gel will be applied to the skin prior to exercise in the heat
62805342|NCT05298202|PLACEBO_COMPARATOR|Hypoallergenic gel application|A hypoallergenic gel will be applied to the skin prior to exercise in the heat
62805343|NCT05131425|EXPERIMENTAL|Cognitive Behavioral Intervention|The experimental condition is a CBT intervention which focuses on developing 1) emotion regulation skills, 2) somatic management skills individually tailored for sensory and regulatory needs; 3) cognitive strategies such as individualized helpful thoughts and mantras (I can do it); and 4) graded exposure (e.g., facing fears).
62805344|NCT05131425|OTHER|Treatment as Usual|The TAU condition will serve as the control condition and participants' medication use and outside therapies will be tracked monthly. Following completion of the 16-week wait period, the TAU group will be invited to enroll in FYF:ASD/ID.
62805345|NCT00466063||ICL670|ICL670
62805346|NCT05199051|EXPERIMENTAL|Gemtuzumab ozogamicine - Cytarabine - Gilteritinib|"For Gemtuzumab ozogamicine administrated during the induction phase at D1, D4 and D7, 3mg/m2/day (5mg max), IV, 2h of infusion.~For Cytarabine during induction and consolidation phase at D1 to D5, 1000 mg/m2, IV, 2h of infusion.~For Gilteritinib during induction phase from D10 for 14 consecutive days, per os, two doses level study with dose level 1 (80mg/d) in part 1 or dose level 2 (80 or 120mg/d depending of the result of part 1) in part 2.~During consolidation (2 cycles max) from D8 for 14 consecutive days, per os, 120mg/d or reduced dose of 80 mg/kg is planned to be used in patients receiving concomitantly CYP3A4 inhibitors.~During the maintenance (24 months max) dose level 2 (120mg/d), per os."
62805347|NCT06136780|EXPERIMENTAL|Experimental|Free reading glasses immediately after cataract surgery
62805348|NCT06136780|NO_INTERVENTION|Control|Free reading glasses will be given 4 months after cataract surgery
62805349|NCT03304561|EXPERIMENTAL|traditional rehabilitation|patients in this groups is going to recieve traditional rehabilitation programme for 3 months after ACL recontsruction
62030139|NCT06304233||No mental health diagnosis|Participants without a mental health diagnosis will be randomly selected from an existing population registered in the HUNT data and biobank for whom, echocardiographic data and biological samples are available.Those enrolled as controls will be invited to participate in the cardiac MRI portion of the study.
62030140|NCT03553589||Cases|Women older than 18 years and diagnosed with endometrial cancer will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
62030141|NCT03553589||controls|Women older than 18 years and with a benign endometrial disturbance will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
62030142|NCT05291208|EXPERIMENTAL|Treatment group|This group will receive a cognitive training intervention combined with alternating current electrical stimulation (i.e., treatment).
62030143|NCT05291208|SHAM_COMPARATOR|Control group|This group will receive a traditional cognitive training intervention with sham electrical stimulation.
62030144|NCT03782155|EXPERIMENTAL|HMB and glutamine supplementation|Patients with type 2 diabetes with supplementation HMB 3g, powder once a day and glutamine powder 14g once a day supplementation during 15 days.
62030145|NCT03782155|PLACEBO_COMPARATOR|placebo patients|Patients with type 2 diabetes with placebo( calcium caseinate) supplementation during 15 days 17g of powder once a day
62030146|NCT00634608|NO_INTERVENTION|Survey|Control group participants are sent a survey within one week of clinic visit
62030147|NCT00634608|EXPERIMENTAL|Health Information Prescription|Health Information Prescription is emailed to participants within 24 hours of clinic visit.
62030148|NCT01007591|ACTIVE_COMPARATOR|LEO 80190 ointment|
62030149|NCT01007591|ACTIVE_COMPARATOR|Hydrocortisone 10 mg/g ointment|
62421317|NCT01304563|ACTIVE_COMPARATOR|ID1|Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection (MicronJet)
62421318|NCT01304563|ACTIVE_COMPARATOR|ID2|Higher low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection (MicronJet)
62421319|NCT01304563|ACTIVE_COMPARATOR|INT|Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device
62421320|NCT04179773||Cirrhotic patients|Current care study. Data collection on oncological efficacy (Clinical, biological, imaging) Data collection on hepatology (clinical, biological, imaging)
62805350|NCT03304561|EXPERIMENTAL|Cross-over training|patients in this programme is going to recieve isokinetic exercise programme targeting unilvolved limb during rehabilitation. for the first 4 weeks after ACL reconstruction traditional rehabiitation programme is going to applied to the subjects. after 4 weeks, isokinetic strenghtening programme at 60˚/second angular velocity, between 0-90 degree knee flexion until 3 months after ACL reconstructon
62805351|NCT04912778||Persons who had a covid-19 infection.|Male and female adults who were previously infected with covid-19.
62805352|NCT06275555|EXPERIMENTAL|bivalirudin group|If the creatinine clearance rate \> 30ml/min, the initial dose of bivalirudin is 0.04mg/kg/h. If the creatinine clearance rate\<30ml/min or the patients who have received renal replacement therapy (CRRT), the initial dose of bivalirudin is 0.02mg/kg/h, and the dose is adjusted according to APPT to maintain APTT at 40-60s. After bivalirudin started, APTT was checked every 4 hours. If APTT was in the target range twice in a row, it was re-examined every 12 hours.
62805353|NCT06275555|OTHER|unfractionated heparin group|The initial dose of heparin was 8-12U/kg/h, and the dosage of heparin was adjusted according to the value of APTT. APTT was maintained at 40-60s, and APTT was reexamined every 4 hours.
62805354|NCT06179576|EXPERIMENTAL|EHS-CTB Hybrid|Dyads in the EHS-CTB hybrid condition will receive 6 individual sessions of CTB conducted by trained facilitators. The first session would be at the center, the 2nd through 5th would be remote, and 6th would be at the EHS center as a group session with other families. Sessions will occur approximately one to two weeks apart, allowing for program completion within 10 weeks. During the first in-person session, families will receive tablets with data plans and with the Zoom. They will receive a welcome pack that includes baby gifts that are used to support each session.
62805355|NCT06179576|NO_INTERVENTION|EHS-CTB Digital Only|Dyads in the EHS-CTB digital only group will receive EHS early education, as well as EHS home visitation, and will have access to the CTB content via text messages, but will receive no CTB sessions. Digital content includes videos of Baby Elmo and his father and suggested activities.
62421321|NCT04179773||Non-cirrhotic patients|Current care study. Data collection on oncological efficacy (Clinical, biological, imaging) Data collection on hepatology (clinical, biological, imaging)
62030150|NCT00201006|EXPERIMENTAL|Face-to-face counseling|26 biweekly face-to-face group counseling sessions
62421322|NCT00149773|EXPERIMENTAL|Cognitive Therapy + Enriched Usual Care|"The cognitive therapy intervention consists of approximately 12 (1-hour) sessions over the course of a 4-month period. The main therapy components include:~1. Using problem-solving and cognitive restructuring techniques to target hopelessness, reasons for living and dying, coping with loss, and perceived medical comorbidity that lead to suicidal ideation.~2. Improving social resources.~3. Improving adherence to medical regimen.~4. Targeting Suicidal Cognitions."
62591275|NCT03662191|EXPERIMENTAL|Treatment C|a dose of tafamidis free acid projected to be an equivalent of 4 × 20 mg commercial tafamidis meglumine administered as a wet-milled suspension under fasted conditions
62030151|NCT00201006|EXPERIMENTAL|Telephone Counseling|26 biweekly telephone counseling sessions
62030152|NCT00201006|ACTIVE_COMPARATOR|Mail contact|26 biweekly newsletters with weight management advice
62030153|NCT00896168|EXPERIMENTAL|Infliximab + Methotrexate (Moderate RA)|Participants with moderate RA (score greater than 3.2, but less than 5.1 on the disease activity score \[DAS\] 28) received infliximab 3 milligram per kilogram (mg/kg) intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) at Week 0, 2, 6, 14 and 22 along with oral MTX IN a stable dose of 7.5 to 20 mg per week (equal to the dose used before participation in the study) for 22 weeks.
62030154|NCT00896168|EXPERIMENTAL|Infliximab + Methotrexate (Severe RA)|Participants with severe RA (score greater than 5.1 on the DAS 28) received infliximab 3 mg/kg intravenous infusion at Week 0, 2, 6, 14 and 22 along with oral MTX in a stable dose of 7.5 to 20 mg per week (mg/week) equal to the dose used before participation in the study) for 22 weeks.
62030155|NCT01477827||Healthy volunteers|Healthy adolescents aged 12-15 years
62030156|NCT03114254|EXPERIMENTAL|Cabazitaxel|"Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days"
62030157|NCT06484244|EXPERIMENTAL|Split-beltTreadmill-based Locomotor Adaptation in Older Adults with MCI|Older adults with mild cognitive impairment (MCI) complete 5 split-belt treadmill walking exercise sessions over a 2-week period.
62030158|NCT06484244|EXPERIMENTAL|Split-beltTreadmill-based Locomotor Adaptation in Older Adults with AD|Older adults with Alzheimer's Disease (AD) complete 5 split-belt treadmill walking exercise sessions over a 2-week period.
62030159|NCT01155947|ACTIVE_COMPARATOR|Arimidex|Arimidex® Tablets 1 mg
62591276|NCT03662191|EXPERIMENTAL|Treatment D|a dose of tafamidis free acid projected to be an equivalent of 5 × 20 mg commercial tafamidis meglumine administered as a wet-milled suspension under fasted conditions
62591277|NCT00687479||1-NGT|normal glucose tolerance
62805356|NCT04256824|EXPERIMENTAL|Coated Polyglactin 910 with Triclosan|Coated vicryl plus
62805357|NCT04256824|ACTIVE_COMPARATOR|Coated Polyglactin 910 without Triclosan|Coated vicryl
62805358|NCT06264739|OTHER|group 1|Dexmedetomidine (dekstomid) infusion will be administered for intraoperative analgesia.
62805359|NCT06264739|OTHER|group 2|remifentanyl (ultiva) infusion will be administered for intraoperative analgesia.
62805360|NCT06290596|EXPERIMENTAL|Vasopressin group|patients in this group will be injected with a 10-ml syringe containing 10 units of vasopressin (5 mL bilaterally)
62030160|NCT01155947|EXPERIMENTAL|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
62030161|NCT00388843||Dose Increased|Patients presenting with symptoms of coronary artery disease or stroke/suspected stroke, with carotid plaque \> 1.1 mm, and whose statin dose is increased to moderate to high dose by their clinicians.
62030162|NCT00388843||Dose Maintained|Patients presenting with symptoms due to coronary artery disease or stroke/suspected stroke, with carotid plaque \> 1.1 mm, on no statins or whose statin dose was unchanged by their clinicians.
62030163|NCT01182753|EXPERIMENTAL|A|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E."
62030164|NCT01182753|ACTIVE_COMPARATOR|B|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E."
62030165|NCT03998618|EXPERIMENTAL|Acceptance and Commitment Therapy|Patients in the ACT arm will learn new and more adaptive ways to respond to fatigue.
62030166|NCT03998618|ACTIVE_COMPARATOR|Education/Support|Patients in the education/support arm will discuss their cancer-related concerns and receive education on services available in their medical center and community.
62030167|NCT00890955|EXPERIMENTAL|1|"Amrubicin + Cyclophosphamide 3+3 design with the following dose levels:~Dose Level -1: Amrubicin 20mg/m2, Cyclophosphamide 500mg/m2~Dose Level 1: Amrubicin 25mg/m2, Cyclophosphamide 500mg/m2~Dose Level 2: Amrubicin 30mg/m2, Cyclophosphamide 500mg/m2~Dose Level 3: Amrubicin 35mg/m2, Cyclophosphamide 500mg/m2~Dose Level 4: Amrubicin 40mg/m2, Cyclophosphamide 500mg/m2"
62805361|NCT06290596|EXPERIMENTAL|Tranexamic acid group|patients in this group will be injected with a 10-ml syringe containing 10 ml of tranexamic acid (5 mL bilaterally).
62030168|NCT00121238|EXPERIMENTAL|Experimental treatment: cilengitide|Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity. After 3 courses, patients undergo evaluation. Patients achieving a complete prostate-specific antigen (PSA) response (i.e., PSA \< 0.2 ng/mL) receive 2-3 additional courses of therapy. Patients with partial PSA response or stable disease continue treatment indefinitely in the absence of disease progression or unacceptable toxicity. Patients demonstrating disease progression by CT scan, MRI, or bone scan are removed from the study.
62030169|NCT05566301||Clopidogrel|Patients who undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel and whose aggregometry test shows correct response to the effect of clopidogrel
62030170|NCT05566301||Ticagrelor|Patients who undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel and whose aggregometry test shows incorrect response to the effect of clopidogrel, therefore therapy is switched to ASA + ticagrelor
62421323|NCT00149773|NO_INTERVENTION|EnrichedUsual Care Condition|"The Enriched Care (EC) condition will be used as the treatment comparison for this study. EC consists of usual care patients may obtain in the community as well as the assessment and referral services provided by the study case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health treatment in the community.~The primary role of the study case manager is to establish a strong relationship with patients in order to retain the patients in the study for the duration of the study period."
62805362|NCT06290596|PLACEBO_COMPARATOR|Control group|patients in this group will be injected with a 10-ml syringe containing 10 ml of normal saline (5 mL bilaterally).
62805363|NCT04364828|OTHER|Host Genome Analysis|For 150 patients from the extreme phenotypes - complementary to Whole Genome Analysis of each patient also Whole Transcriptome will performed Analysis; DNA methylation analysis using EPIC arrays will be performed in the pilot study (phase 1). Identically, in phase 2 starting from month 4, will be generated WGS, Whole transcriptome sequencing (WTS), and methylation data of the 500 patients. Epigenetic changes are likely to occur upon Corona infection. Subsequently, genome and epigenome data with RNA expression pattern will be correlated.
62805364|NCT04364828|OTHER|Host Response to SARS-CoV-2 Infection|Focus on longitudinal analysis of TCR repertoire of CD4+ and CD8+ T cells from blood samples (PBMCs) from clinically characterized patients (n = 24). The bulk- T-cell receptor (TCR) sequencing will be performed at different time points during the course of disease progression and recovery.
62030171|NCT05758064|ACTIVE_COMPARATOR|Oral dydrogesterone|60 patients in HRT frozen embryo transfer with low serum progesterone less than 10 ng/ml 24 hours before the embryo transfer will be given oral 10 mg dydrogesterone (Duphaston®, Abbott) twice daily
62030172|NCT05758064|ACTIVE_COMPARATOR|subcutaneous progesterone|60 patients in HRT frozen embryo transfer with low serum progesterone less than 10 ng/ml 24 hours before the embryo transfer will be subcutaneous injection 25mg daily (Prolutex®, IBSA).
62030173|NCT00846664|EXPERIMENTAL|Group 1|Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
62030174|NCT03157986|ACTIVE_COMPARATOR|Whole Body Vibration training|Balance Training on a Vibration platform
62030175|NCT03157986|ACTIVE_COMPARATOR|Conventional Balance training|Balance Training on a Balance board
62030176|NCT06635330|EXPERIMENTAL|Anti-CD19 CAR-T treatment group|
62030177|NCT05695183|EXPERIMENTAL|Emergency Department Nurses|Registered nurses will use the IV SafeLock Device on patients during care in the emergency department.
62030178|NCT02001480|OTHER|Echocardiography|"12 lead holter for 7 days~CGM = continuous Glucose Monitoring"
62030179|NCT06518577|EXPERIMENTAL|Flucelvax (ccIIV4)|Participants will receive Flucelvax (ccIIV4) at Visit 1.
62421324|NCT05277831|EXPERIMENTAL|Guided Imagery Intervention|Guided Imagery Intervention
62805365|NCT04364828|OTHER|Viral Sequence Composition|The Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) viral composition is determined by Next Generation sequencing (different protocols for enrichment are available, and are currently being tested to successfully analyse the virus from different isolates). It is known that SARS-CoV-2 sequence is changing at least one position every second passing from person to person. Numerous variants have been described deriving from 3 different ancestral viruses (named A, B, and C) reflecting different distributions in East Asia, Europeans and Americans. At it is anticipated that other (super)infections may add to the severity of the infection and disease course, the entire metagenome of the throat is being sequenced and analyzed as well.
62805366|NCT04646408||Participants with CKD|Recruitment is from a cohort of HIV positive individuals of African ancestry with Chronic Kidney Disease CKD defined as eGFR \<60 mL/min/1.73m2, and/or albumin/creatinine ratio \>30 mg/mmol or protein/creatinine ratio \>50 mg/mmol Anticipated n=75
62030180|NCT06518577|EXPERIMENTAL|Flublok (RIV) or Fluzone (IIV)|Participants will receive Flublok (RIV) or Fluzone (IIV) at Visit 1.
62030181|NCT00987467|EXPERIMENTAL|Cyclosporine 0.05% ophthalmic|cyclosporine 0.05% ophthalmic eye drops will be used starting with 1 drop in both eyes 6 times daily for first month, followed by 1 drop in both eyes 4 times daily for the following month, then will be adjusted by clinician as needed for appropriate disease control
62030182|NCT03652753|EXPERIMENTAL|N-acetylcysteine (NAC)|Injection of N-acetylcysteine at the time of external fixation
62030183|NCT03652753|PLACEBO_COMPARATOR|Saline|Injection of saline at the time of external fixation
62030184|NCT01585103|EXPERIMENTAL|Cytosponge/ brushing|Subjects with eosinophilic esophagitis undergoing clinically indicated endoscopy and biopsy either for initial diagnosis or for monitoring the activity of their disease will be asked to swallow the cytosponge two hours prior to endoscopy.
62030185|NCT01277965|OTHER|50% VO2 max, BFR reduced by 50%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%
62030186|NCT01277965|OTHER|50% VO2 max,BFR reduced by 80%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%
62421325|NCT05277831|ACTIVE_COMPARATOR|Standard Behavioral Control|Standard Behavioral Control
62805367|NCT04646408||Participants with diabetes|"Recruitment is from a cohort of HIV positive individuals of African ancestry with diabetes. Diabetes is defined as being on diabetic medications or HbA1c \>48 mmol/mol.~Anticipated n=75"
62805368|NCT04646408||Participants with ischaemic heart disease/stroke|Recruitment is from a cohort of HIV positive individuals of African ancestry with previous ischaemic heart disease or stroke Anticipated n=50
62805369|NCT04646408||No CKD/DM/CVD cohort|"Recruitment is from a cohort of HIV positive individuals of African ancestry who do not have CKD, diabetes or prior ischaemic heart disease/stroke.~Anticipated n=200"
62805370|NCT02954107||Absence epilepsy|Children aged 6-12 years of age primarily presenting with episodes of brief loss of consciousness (absences) in an otherwise normal child in the previous 2 years. With an EEG showing 3 Hz (2.5-4.5 Hz) generalized rhythmic spike-and-wave complexes with a discharge duration of at least 3 seconds on a present or former EEG.
62805371|NCT02954107||Controls|Overall healthy children aged 6-12 years of age following a regular school without major problems.
62805372|NCT02519608|ACTIVE_COMPARATOR|Aspirin 100 mg + Clopidogrel 75 mg|dual antiplatelet therapy as suggested by guidelines with aspirin 100 mg and clopidogrel 75 mg daily
62805373|NCT02519608|EXPERIMENTAL|Aspirin 100 mg + Ticagrelor 90 mg x2|dual antiplatelet therapy with aspirin 100 mg and ticagrelor 90 mg x 2 daily
62805374|NCT03366181||heart failure patients|
62805375|NCT06366178|EXPERIMENTAL|reshaping the orbito-naso-frontal band with a guide|
62805376|NCT00688584|EXPERIMENTAL|1|
62805377|NCT00688584|PLACEBO_COMPARATOR|2|
62805378|NCT00688584|NO_INTERVENTION|No intervention control|
62805379|NCT02316990||patients ≥18 ,Neurosurgical departments and whose GCS≤10[4]|"The subject population that will be included in the NIS are the consecutive discharged patients ≥18 years old who were hospitalized to Neurosurgical departments and whose GCS≤10\[4\] within 24 hours of lesion/admission.(GCS: Glasgow Coma Scale NIS: Non-Interventional Study~)"
62805380|NCT06322563|EXPERIMENTAL|Safety introduction trial：LTC004+regorafenib|LTC004 in combination with regorafenib safety introduction trial and completing a 28-day safety assessment
62805381|NCT06322563|EXPERIMENTAL|Formal trial phase：LTC004+regorafenib|After Safety introduction trial, safety will be confirmed before entering the formal trial phase.Further evaluation of the safety and efficacy of LTC004 in combination with regorafenib in the treatment of mCRC
62805382|NCT00423657|EXPERIMENTAL|Ceftaroline fosamil for Injection|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
62805383|NCT00423657|ACTIVE_COMPARATOR|IV Vancomycin plus IV Aztreonam|Vancomycin 1 g administered over 60 minutes every 12 hours followed by aztreonam 1 g administered over 60 minutes every 12 hours.
62805384|NCT06524687|EXPERIMENTAL|Imvotamab (Dose Escalation)|Imvotamab administered intravenously
62805385|NCT03367858|EXPERIMENTAL|Motivational Interviewing (MI)|This randomly assigned group receives two 60-minute 1:1 sessions of motivational interviewing.
62030187|NCT01277965|OTHER|75% VO2 max, BFR reduced by 80%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%.
62805386|NCT03367858|ACTIVE_COMPARATOR|Brief Adolescent Mindfulness (BAM)|This randomly assigned group receives two 60-minute 1:1 sessions of Brief Adolescent Mindfulness.
62805387|NCT05007522|EXPERIMENTAL|Study Drug|Ketotifen 2 mg administered in tablet form twice a day (every 12 hr). Indomethacin sustained-release (SR) 75 mg, twice a day (every 12 hr). Patients will be administered 28 doses in total of ketotifen/indomethacin combination.
62805388|NCT05007522|PLACEBO_COMPARATOR|Placebo|Placebo pills matching in appearance to study drug twice a day for 28 doses total.
62805389|NCT05541146|EXPERIMENTAL|Intraperitoneal chemotherapy|Intraperitoneal chemotherapy in gastric cancer patients with peritoneal carcinomatosis.
62805390|NCT02576223|ACTIVE_COMPARATOR|Ropivacaine hydrochloride|Ropivacain 7.5mg/ml, 5 ml injected perineural at the suprascapular nerve.
62805391|NCT02576223|PLACEBO_COMPARATOR|Isotonic Saline|0.9% Saline solution, 5 ml injected perineural at the suprascapular nerve.
62805392|NCT05682755|EXPERIMENTAL|Chidamide|
62805393|NCT02988778|EXPERIMENTAL|Budesonid 50mcg (Noex)|"Budesonid 50mcg (Noex), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.~Treatment of 28 days."
62805394|NCT02988778|ACTIVE_COMPARATOR|Budesonid 50mcg (Busonid)|"Budesonid 50mcg (Busonid), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.~Treatment of 28 days."
62805395|NCT00080665|EXPERIMENTAL|Imatinib mesylate and docetaxel|Imatinib mesylate (400-600 mg, oral, once daily) and docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
62805396|NCT01564069||IT opioids|Patients with IT pumps receiving IT opioids
62805397|NCT01564069||Systemic opioids|Patients taking oral or transdermal opioids for chronic pain
62805398|NCT01564069||Non-opioid management|Patients managing chronic pain without taking opioids
62805399|NCT01480622|EXPERIMENTAL|TDF tablets|Tenofovir disoproxil fumarate tablets
62805400|NCT03260179|EXPERIMENTAL|gastric carcinoma|20 gastric carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
62805401|NCT03260179|EXPERIMENTAL|hepatocellular carcinoma|20 hepatocellular carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
62805402|NCT03260179|EXPERIMENTAL|Nasopharyngeal carcinoma|20 Nasopharyngeal carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
62805403|NCT04694690|EXPERIMENTAL|RelyX U200 Automix Self Adhesive Resin Cement|Self Adhesive Resin Cement
62805404|NCT04694690|ACTIVE_COMPARATOR|G-Cem LinkForce Resin Cement|Resin Cement system used after surface treatment
62030188|NCT01277965|OTHER|75% VO2 max, pump switched off|Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed.
62030189|NCT01277965|OTHER|Rest|Patient will be in rest, basal insulin flow rate will not be change.
62030190|NCT02504294|OTHER|Epoetin Hospira|Epoetin Hospira Arm
62030191|NCT02504294|OTHER|Standard of Care|Standard of care arm
62421326|NCT03669640|EXPERIMENTAL|Part A: Monotherapy|Participants will receive RO6889450 or a dose-matched placebo. NOTE: Part A has completed enrollment.
62228764|NCT02764294|ACTIVE_COMPARATOR|Music Group|Music group was listened to a music of their choise with a headset. The music intervention was started about 10-15 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
62228765|NCT02764294|ACTIVE_COMPARATOR|Stress Ball Group|"Stress ball group was given stress ball into both their palms about 10-15 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure."
62228766|NCT02764294|ACTIVE_COMPARATOR|DVD Group|DVD group was watched a DVD of their choice (documentaries, interesting and amazing videos, comedies) on a ceiling-mounted monitor positioned at a comfortable distance to the participant.
62421327|NCT03669640|EXPERIMENTAL|Part B: Add-On Therapy|Participants will receive a low or high dose of RO6889450 or a dose-matched placebo in addition to their usual anti-psychotic treatment(s).
62421328|NCT00835068||BeneFIX|
62421329|NCT03469440|ACTIVE_COMPARATOR|Goal-directed therapy|Patients randomized to this group will be monitoring by continuous central venous oxygen saturation. Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.
62805405|NCT00804466|EXPERIMENTAL|Women referred to colposcopy clinic|Triage tests for diagnosis of cervical pre-cancer amongHPV positive women
62805406|NCT05532865||Adults with systemic sclerosis|It is a descriptive cohort of systemic sclerosis patients
62805407|NCT02719821|EXPERIMENTAL|Intervention|Individuals treated with HSCT will learn behavioral techniques to improve sleep and increase daytime activity with the goal of alleviating insomnia, fatigue, and depression. Study investigators will conduct semi-structured interviews after each session to determine participant satisfaction with and acceptability of the behavioral strategies, timing, delivery mode, assessment strategy, and time commitment. Participants will be asked to complete a daily checklist indicating which intervention strategies they used daily. Participants will be asked to complete self-report assessments, to wear a wrist-worn actigraphy device, and to complete a sleep log at three time points: prior to HSCT and approximately 9 and 18 weeks post-HSCT.
62805408|NCT05733858|EXPERIMENTAL|tRNS with digital MT|
62805409|NCT05733858|EXPERIMENTAL|tDCS with digital MT|
62805410|NCT05733858|SHAM_COMPARATOR|sham stimulation with digital MT|
62805411|NCT01792700|ACTIVE_COMPARATOR|MEA|MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.)
62805412|NCT01792700|ACTIVE_COMPARATOR|EBMT|EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d)
62805413|NCT03498950|NO_INTERVENTION|Placebo Group|submitted to the routine laser therapy protocol in addition to simulated laser irradiation on the taste papillae
62805414|NCT03498950|EXPERIMENTAL|Test Group|submitted to the same laser therapy protocol as that of the Placebo Group, however, laser irradiation on the taste papillae will be effective.
62805415|NCT04562454|EXPERIMENTAL|Normal group|Specific diet with CGM for 5days
62805416|NCT04562454|EXPERIMENTAL|T1DM group|Specific diet with CGM for 5days
62805417|NCT04562454|EXPERIMENTAL|T2DM group|Specific diet with CGM for 5days
62228767|NCT02764294|NO_INTERVENTION|Control Group|Participants received usual care from health professionals. They didn't receive any intervention.
62228768|NCT03841682|EXPERIMENTAL|I-CARE2 Intervention|"Participants should continue with their usual medical care. Additionally, participant receive the I-CARE2 intervention.~Trained health coaches deliver the I-CARE2 intervention over 6 months. The intervention provides 9 individual counseling sessions on problem solving treatment and behavior counselling to manage mood and lose weight (4 weekly, 2 biweekly, and then 3 monthly; 1 hour each), 11 home-viewed GLB videos (weekly; 20-30 minutes each), and self-study and self-monitoring activities. Throughout the intervention, participants are asked to wear and sync a study-provided Fitbit pedometer, and to log their weight, minutes of physical activity, and dietary intake using the Fitbit website or mobile app."
62228769|NCT03841682|NO_INTERVENTION|Usual Care|Participants should continue with their Usual Medical Care. Additionally, participants receive information on wellness and behavioral health promotion at UI Health and a Fitbit pedometer.
62228770|NCT02859363||Young stroke|Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing for the 26 common Fabry mutation types in Taiwan.
62228771|NCT02411357|ACTIVE_COMPARATOR|Treatment as usual|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
62421330|NCT03469440|OTHER|Standard protocol|The control group will keep the standard therapy.
62421331|NCT04561934|EXPERIMENTAL|resin modified glassionomer cement|Application of Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE)
62421332|NCT04561934|ACTIVE_COMPARATOR|silver diamine flouride|Application of 38% SDF (Riva Star, SDI, Bayswater, Australia), and Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE).
62421333|NCT06270459|EXPERIMENTAL|HMAN robot @ Home|4 weeks of daily HMAN robot training at participant's home (for up to 120 minutes per day with rest breaks) interspersed with 2 sessions of conventional therapy sessions (COTS) and 2 additional COTS upon completion of 4-week HMAN robot training at home.
62421334|NCT01399073||Patients with Neglect|
62805418|NCT04562454|EXPERIMENTAL|other type of diabetes group|Specific diet with CGM for 5days
62805419|NCT00348439|EXPERIMENTAL|Plasmin Injection|human-derived plasmin
62805420|NCT00348439|PLACEBO_COMPARATOR|Vehicle|Plasmin formulation, without active ingredient.
62805421|NCT00888017||PPI group|This group of infants have received treatment with a PPI as ordered by their neonatologist during their hospital stay.
62805422|NCT00888017||non-PPI group|These infants did not receive PPIs during their hospital stay.
62805423|NCT04951830||control group|NORMAL TMJ
62805424|NCT04951830||Study group|patients with TMJ internal derangement
62805425|NCT03327623||Hypertrophic Cardiomyopathy (HCM)|Subjects with a diagnosis of Hypertrophic Cardiomyopathy
62805426|NCT03327623||Control|Subjects who are healthy volunteers
62805427|NCT05117736|EXPERIMENTAL|Sacubitril/Valsartan|Treatment with Sacubitril/Valsartan
62805428|NCT05117736|PLACEBO_COMPARATOR|Placebo|Treatment with Placebo
62805429|NCT02534545|EXPERIMENTAL|Doctormate® (200mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) once daily for 12 months
62805430|NCT02534545|SHAM_COMPARATOR|Doctormate® (60mmHg)|Patients will be treated with the Renqiao Remote Ischemic Conditioning Device (Doctormate®) (60mmHg) once daily for 12 months
62030192|NCT03019536|EXPERIMENTAL|70 mg LY3303560|70 milligram (mg) LY3303560 administered intravenously (IV) every 4 weeks for 25 weeks with the option of continuing treatment up to 49 weeks (up to 6 further doses), followed by a 16-week follow-up period.
62030193|NCT03019536|EXPERIMENTAL|210 mg LY3303560|210 mg LY3303560 administered IV every 4 weeks for 25 weeks with the option of continuing treatment up to 49 weeks (up to 6 further doses), followed by a 16-week follow-up period.
62030194|NCT03019536|EXPERIMENTAL|Placebo IV|Placebo administered intravenously (IV) every 4 weeks for 25 weeks with the option of continuing treatment up to 49 weeks (up to 6 further doses),, followed by a 16-week follow-up period.
62030195|NCT05645588|EXPERIMENTAL|Pranayama assisted trauma-focused standard psychotherapy (TF-SPT).|Behavioral: Pranayama assisted trauma-focused standard psychotherapy (TF-SPT) The pranayama intervention is placed directly at the begin of the respective TF-SPT unit and will be repeated for 10 subsequent TF-SPT units.
62030196|NCT05645588|ACTIVE_COMPARATOR|Trauma-focused standard psychotherapy (TF-SPT)|Behavioral: Patients wait for 10 TF-SPT units and then are offered to learn pranayama.
62421335|NCT01399073||Patients with Hemianopsia|
62421336|NCT01399073||Healthy age-matched controls|
62421337|NCT06524401|EXPERIMENTAL|Limpet|Participants in this arm will utilize the subject device as intended to be used.
62421338|NCT06524401|ACTIVE_COMPARATOR|Control|Standard treatment with standard of care adhesive ostomy pouches.
62030197|NCT01561248|NO_INTERVENTION|SOC-treatment|Patients with EHEC associated bloody diarrhoea (n=12) receiving standard of care treatment, consisting of intravenous fluids (2-3 liters/daily), analgetics, including paracetamol and metamizol and metoclopramid, if required.
62030198|NCT01561248|EXPERIMENTAL|PEG-Solution, daily bowel lavage|Patients with EHEC associated bloody diarrhoea (n=21)receiving SOC-treatment, consisting of i.v. fluids (2-3 liter/day), analgetics ( paracetamol and metamizol) or metoclopramid and orally administered polyethylene glycol-solution daily during the clinical course.
62421339|NCT03976349|EXPERIMENTAL|Part A (SAD): BIIB094 Dose 1|Participants will receive a single IT injection of BIIB094 during Part A \[Single Ascending Dose (SAD)\].
62421340|NCT03976349|EXPERIMENTAL|Part A (SAD): BIIB094 Dose 2|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
62421341|NCT03976349|EXPERIMENTAL|Part A (SAD): BIIB094 Dose 3|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
62421342|NCT03976349|EXPERIMENTAL|Part A (SAD): BIIB094 Dose 4|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
62421343|NCT03976349|EXPERIMENTAL|Part A (SAD): BIIB094 Dose 5|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
62421344|NCT03976349|EXPERIMENTAL|Part A (SAD): BIIB094 Dose 6|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
62421345|NCT03976349|EXPERIMENTAL|Part B (MAD): BIIB094 Dose 1|Participants will receive a single IT injection of BIIB094 on multiple days during Part B \[Multiple Ascending Dose (MAD)\].
62421346|NCT03976349|EXPERIMENTAL|Part B (MAD): BIIB094 (Non LRRK2) Dose 2|Participants \[Non leucine-rich repeat kinase 2 (Non LRRK2)\] will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
62421347|NCT03976349|EXPERIMENTAL|Part B (MAD): BIIB094 (LRRK2) Dose 2|Participants (LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
62421348|NCT03976349|EXPERIMENTAL|Part B (MAD): BIIB094 (Non LRRK2) Dose 3|Participants (Non LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
62805431|NCT02408588||Childbirth and epidural|Pregnant women giving childbirth who receive an epidural.
62805432|NCT02408588||Childbirth and general anesthesia|Pregnant women giving childbirth who receive general anesthesia
62805433|NCT02408588||Fetal Intervention and epidural|Pregnant women receiving fetal intervention and an epidural
62030199|NCT02837341|OTHER|Volunteers|Monitoring of respiratory rates via camera-based System Monitoring of respiratory rate by Philips®Vital Sign Device - Camera-based system (Prototype) and capnography simultaneously.
62030200|NCT05553808|ACTIVE_COMPARATOR|Docetaxel|
62030201|NCT05553808|EXPERIMENTAL|Feladilimab plus Docetaxel|
62030202|NCT02987413|EXPERIMENTAL|Autologous Mesenchymal stem cells|Two escalated intrathecal infusions of autologous mesenchymal stem cell
62421349|NCT03976349|EXPERIMENTAL|Part B (MAD): BIIB094 (LRRK2) Dose 3|Participants (LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
62421350|NCT03976349|PLACEBO_COMPARATOR|Part A (SAD): Matching Placebo|Participants will receive matching placebo during Part A \[Single Ascending Dose (SAD)\].
62421351|NCT03976349|PLACEBO_COMPARATOR|Part B (MAD): Matching Placebo|Participants will receive matching placebo on multiple days during Part B (MAD).
62591278|NCT00687479||2-GDM|Gestational Diabetes mellitus
62805434|NCT02408588||Fetal Intervention and general anesthesia|Pregnant women receiving fetal intervention and general anesthesia
62805435|NCT01173016|EXPERIMENTAL|Laronidase After Transplantation|Patients with Mucopolysaccharidosis type IH (MPS I, Hurler syndrome) treated with a prior allogeneic transplant \>2 years previously and treated with Laronidase weekly for 2 years after transplant.
62805436|NCT06357117||No RLI vs RLI|No RLI: PHCC patients without RLI. RLI: PHCC patients with RLI.
62805437|NCT06357117||No DIHI vs DIHI|No DIHI: PHCC patients without DIHI. DIHI: PHCC patients with DIHI.
62805438|NCT00876616|EXPERIMENTAL|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d+MMF 1.0g/d
62805439|NCT00876616|ACTIVE_COMPARATOR|Cyclophosphamide|CTX iv 0.75 g/m2 body surface area (BSA)
62805440|NCT00963352||Patients operated for colon cancer|
62805441|NCT01556386||Pharmacogenetic analysis, ALL|
62805442|NCT06472674||Total|All subjects
62805443|NCT00627588|EXPERIMENTAL|Dose Evaluation|To assess the safety and efficacy of up to three dose levels of ProSavin
62805444|NCT00627588|SHAM_COMPARATOR|Sham element|The potential use of sham comparator to confirm efficacy
62805445|NCT04067323|PLACEBO_COMPARATOR|LCT consumption|20g soy oil (containing mainly long chain triglycerides - LCT) together with 100g yogurt) will be provided in lunch-daily meal for a period of 4 months.
62030203|NCT06669858|EXPERIMENTAL|Manual therapy standardized protocol group|This arm received 2 session of manual therapy (standardized protocol) 2-4 days after surgery and 90 days after surgery
62030204|NCT06669858|SHAM_COMPARATOR|Sham protocol group|The sham group received a standardized protocol of ligth touch with wide pressure of the 2 hands, without intention to treat.
62030205|NCT05713318|EXPERIMENTAL|Treatment Group 1|
62030206|NCT05713318|EXPERIMENTAL|Treatment Group 2|
62030207|NCT05713318|PLACEBO_COMPARATOR|Control Group 3|
62030208|NCT05713318|PLACEBO_COMPARATOR|Control Group 4|
62030209|NCT04969250|EXPERIMENTAL|Group I1|Immediate, one dose. Vaccination at study entry
62030210|NCT04969250|EXPERIMENTAL|Group I2|Immediate, two doses. Vaccination at study entry and Week 4
62030211|NCT04969250|EXPERIMENTAL|Group D1|Deferred, one dose. Vaccination at Week 12 only
62030212|NCT04969250|EXPERIMENTAL|Group D2|Deferred, two doses. Vaccination at Week 12 and Week 16
62030213|NCT04019847|EXPERIMENTAL|STAK Tool|The STAK Tool enables patients to apply a high intensity stretch to their knee independently. Patients are asked to do this for a maximum of 60 mins per day.
62030214|NCT04019847|ACTIVE_COMPARATOR|Standard treatment|Patients are treated as per their Clinician's prescription. Physiotherapists tailor treatment of arthrofibrosis to meet their patients' individual needs. Treatment may comprise the following: education, advice and a range of stretching exercises/techniques to change the length and density of the adhesions and shortened tissue. These include active range of movement (AROM), passive range of movement (PROM), strengthening exercises, hands-on high intensity passive physiological stretches, joint mobilisations and a home exercise programme involving full weight bearing exercises with the aim of enabling the patient to regain ROM and function.
62421352|NCT06537258|EXPERIMENTAL|Biofeedback Enhanced Treatment|Participants in this group will participate in biofeedback enhanced cognitive behaviorally based coping skills treatment. Treatment will consist of a 6-visit group intervention conducted online, via Emory zoom. Groups will include 5-8 patients. Groups will meet approximately each week for 6 weeks. Patients will also rate their disease symptoms and measures of clinical disease activity will be collected via chart review. Clinical assessments will occur at baseline within 1 week prior to starting treatment (T1), at treatment end or 6 weeks after baseline (T2), 14 weeks after baseline to capture 2-month follow-up after treatment (T3) and at 26 weeks after baseline (T4).
62421353|NCT06537258|NO_INTERVENTION|Wait-list control|Participants randomized to the waitlist control group will complete the same assessment protocol at the time of randomization (Baseline) and again 6 weeks later. They will then be invited to begin treatment and will repeat the assessments at posttest and again at 14 and 26-week follow-up (for a total of 5 assessments).
62421354|NCT02958774|EXPERIMENTAL|Hypofractionated Radiation Therapy|Daily for 4 weeks
62421355|NCT04624750|OTHER|Cohort 1 and 2|7 patients aged 12 to \< 18 years , inclusive in cohort-1 7 patients aged 6 to \< 12 years, inclusive in cohort-2
62421356|NCT00915473|EXPERIMENTAL|Active Injection|Subjects randomized to this arm will receive 2.5 mL 0.5% bupivicaine plus 0.5 mL 20 mg methylprednisolone injected over the ipsilateral (unilateral headache) or bilateral (bilateral headache) occipital nerve.
62421357|NCT00915473|PLACEBO_COMPARATOR|Placebo Injection|Subjects randomized to this arm will receive 2.75 mL normal saline plus 0.25 mL 1% lidocaine injected over the ipsilateral (unilateral headache) or bilateral (bilateral headache) occipital nerve.
62591279|NCT00687479||3.GIGT|Gestational Impaired glucose tolerance
62591280|NCT06668753||patients|Dapagliflozin or Empagliflozin 10 mg once daily for 6 months
62805446|NCT04067323|EXPERIMENTAL|MCT consumption|20g MCT oil (containing 100% MCT) together with 100g yogurt) will be provided in lunch-daily meal for a period of 4 months.
62805447|NCT05929521|EXPERIMENTAL|C-PrEP+|Sex Workers engaged in group PrEP care.
62805448|NCT04552769|EXPERIMENTAL|Abemaciclib|Each cycle of therapy will be 28 days long. A completed cycle will be twice daily abemaciclib. Number of Cycles: until progression or unacceptable toxicity develops
62030215|NCT01758692||Able-bodied Controls|"10 controls between the ages of 18 and 65 of either gender; free of cardiovascular disease and/or medication.~An addition 40 controls ages 18-89 of either gender, will perform the non-invasive manipulations only."
62030216|NCT01758692||Spinal Cord Injury|"40 subjects to perform the pharmacological and non-invasive manipulations; between the ages of 18 and 65 years old in stable health for the last 6 months, non-smoker, and level of injury from C1 - S4 for over 1 year and an AIS classification of A, B, C. Free of arrhythmia, hypertension, cardiovascular disease, kidney disease, diabetes, neuropathies, neuromuscular disease, and sulfite allergies or hypersensitivity.~60 subjects to perform the non-invasive manipulations only; between 18-89 years of age in stable condition (\>6 months), non-smoker. Level of injury from C1-S4 for over a year with a AIS classification of A, B, or C. No history of diabetes, autonomic neuropathy, parkinson's disease, or acute illness or infection. An additional 30 will perform the non-invasive testing before and after completion of an ambulatory training protocol."
62030217|NCT02288780||Control|BPH patients with normal diastolic function
62030218|NCT02288780||Diastolic dysfunction|BPH patients with preoperative diastolic dysfunction
62030219|NCT04298541|EXPERIMENTAL|Patients with Meningioma|Subjects with suspected meningioma planned for surgery who meet the inclusion and exclusion criteria.
62805449|NCT03011281||RA patients who start Tofacitinib|Korean RA patients who start Tofacitinib with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate or biologics.
62805450|NCT04837937|EXPERIMENTAL|Condition 1|(1) 'Caregiver vs. Patient \[Beginner\]' conflict negotiation/dispute resolution exercise. All participants will complete this exercise; it will serve as the constant.
62805451|NCT04837937|EXPERIMENTAL|Condition 2|(1) 'Caregiver vs. Patient \[Beginner\]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Patient \[Advanced\]' ' conflict negotiation/dispute resolution exercise
62228772|NCT02411357|EXPERIMENTAL|WHO contraception protocol|The WHO contraception protocol condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits.
62421358|NCT06471231|EXPERIMENTAL|Group A|Group A: when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min in the absence of adequate MAP (Mean arterial pressure \>65 mmhg), vasopressin infusion will be associated with the standard dosage of 0.3UI/min.
62228773|NCT02411357|EXPERIMENTAL|WHO contraception protocol + incentives|The WHO + incentives condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits, but will also receive financial incentives contingent on attending those follow-up visits.
62228774|NCT01659619|EXPERIMENTAL|erythromycin|
62421359|NCT06471231|ACTIVE_COMPARATOR|Group B|Group B (control): the infusion of vasopressin at a dosage of 0.3 IU/min will be associated if norepinephrine exceeds the dosage of 0.5 mcg/kg/min in the absence of adequate MAP.
62805452|NCT04837937|EXPERIMENTAL|Condition 3|(1) 'Caregiver vs. Patient \[Beginner\]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Physician' conflict negotiation/dispute resolution exercise
62421360|NCT05818332||before and after implementation cohort|"consecutive cohort of 1000 surgical patients (baseline)~consecutive cohort of 1000 surgical patients (after implementation with a multifaceted, tailored implementation strategy to improve adherence to the WHO SSC and routine recording of iAEs)"
62421361|NCT05742061|ACTIVE_COMPARATOR|OA group injected by corticosteroid|Group l include 50 patients who will be injected with one intra_articular injection of 2 ml of methylprednisolone acetate 40 mg/ml mixed with 2ml of lidocaine
62805453|NCT04837937|EXPERIMENTAL|Condition 4|(1) 'Caregiver vs. Patient \[Beginner\]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Physician' conflict negotiation/dispute resolution exercise; (3) 'Caregiver vs. Patient \[Advanced\]' conflict negotiation/dispute resolution exercise
62030220|NCT03400891|EXPERIMENTAL|Intervention|This group received 14 sessions (one every 15 days) of one hour in the classroom, to work TPB constructs: attitude; subjective norms; perceived behavioural control and intention.
62421362|NCT05742061|ACTIVE_COMPARATOR|OA group injected by Platelet Rich Plasma|Group lI include 50 patients who will be injected with a single 5 ml intra_articular injection of PRP prepared in our hospital
62421363|NCT02261974|ACTIVE_COMPARATOR|Active Viveve Treatment|Intervention in the active arm will be with the Viveve System using 90 Joules/cm2 active treatment with radiofrequency energy in the vaginal introitus
62421364|NCT02261974|PLACEBO_COMPARATOR|Sham Viveve Treatment|Intervention in the sham arm will be with the Viveve System using ≤1 Joule/cm2 sham treatment with radiofrequency energy in the vaginal introitus
62421365|NCT03300830||group 1|Viral-assoc. cancer; HIV-neg pts with cancer that occurs in HIV pos; KSHV-assoc. cancer or related diseases e.g. multicentric Castleman disease; retrovirus-induced cancer; Idiopathic Castleman disease
62421366|NCT05657873|EXPERIMENTAL|L-SABR Arm|Participants randomized to the experimental arm will continue with standard of care treatment but will also undergo radiation simulation for L-SABR/Liver Stereotactic Ablative Radiation Therapy.
62030221|NCT03400891|NO_INTERVENTION|Control|2 session of 1 hour each to give general information about fruit and vegetables intake and health.
62030222|NCT05328531|EXPERIMENTAL|Genakumab for injection 50mg (Ib)|subcutaneous injection, single dose
62030223|NCT05328531|EXPERIMENTAL|Genakumab for injection 100mg (Ib)|subcutaneous injection, single dose
62030224|NCT05328531|EXPERIMENTAL|Genakumab for injection 195mg (Ib)|subcutaneous injection, single dose
62421367|NCT05657873|ACTIVE_COMPARATOR|Control Arm|Participants randomized to the control arm will be treated according to the standard of care.
62421368|NCT06540157|EXPERIMENTAL|BBM and RPS group|All participants received 20-minute interventions daily from Monday to Friday for 12 weeks.
62421369|NCT06540157|SHAM_COMPARATOR|Sham group|All participants received 20-minute interventions daily from Monday to Friday for 12 weeks.
62421370|NCT05946382|EXPERIMENTAL|RNT-ACT protocol|Participants randomized to RNT-ACT will receive a total of 2 sessions of 60 minutes each as well as audio files to listen to between the occasions administered via internet. Previous studies have indicated that it doesn't make much of a difference whether the temporal distance between session 1 and session 2 is between 1 week and up to 3 months. At occasion 1, the time for occasion 2 is set. The temporal distance in days will noted for each patient. The treatment is inserted into the therapist's regular diary with 60 minutes session time and appropriate break before and after the treatment (e.g. at least 5-10 minutes) for preparation and post-administration where journal writing is included.
62421371|NCT05946382|ACTIVE_COMPARATOR|iCBT treatment|"The people randomized to Internet treatment will be offered based on M.I.N.I 7.0 a suitable iCBT program in the Stöd och Behandling (SoB) platform. The patients follow a structured self-help material which can be seen as a standard treatment option in Region Skåne, treatment as usual. The therapist has access to the material and the patient and the therapist can communicate via a chat function. The patients are matched to iCBT programs based on whether they are most likely to show symptoms of depression or anxiety. The main component of Internet processing consists of a structured self-help program in approximately eight modules, somewhat varying depending on which program in use. The program is based on proven CBT interventions for each problem area with a strong emphasis on psychoeducation but where different intervention elements is included."
62421372|NCT05920707|ACTIVE_COMPARATOR|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally.
62421373|NCT05920707|ACTIVE_COMPARATOR|Intranasal Arginine Vasopressin|Administer Arginine Vasopressin (20 IU) intranasally.
62421374|NCT05920707|PLACEBO_COMPARATOR|Intranasal placebo|Administer placebo intranasally.
62421375|NCT05920707|NO_INTERVENTION|Intranasal nothing (control)|Control condition
62805454|NCT04837937|EXPERIMENTAL|Condition 5|(1) 'Caregiver vs. Patient \[Beginner\]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Caregiver' conflict negotiation/dispute resolution exercise
62030225|NCT05328531|EXPERIMENTAL|Genakumab for injection 100mg (II)|Genakumab for injection, subcutaneous injection, single dose Placebo for Compound Betamethasone Injection, intramuscular injection, single dose
62030226|NCT05328531|EXPERIMENTAL|Genakumab for injection 195mg (II)|Genakumab for injection, subcutaneous injection, single dose Placebo for Compound Betamethasone Injection, intramuscular injection, single dose
62228775|NCT01659619|NO_INTERVENTION|saline|
62228776|NCT03111121|ACTIVE_COMPARATOR|Group 1|Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes:Group 1 will receive reversal with neostigmine (0.04 mg/kg and glycopyrrolate (0.01 mg/kg)
62228777|NCT03111121|ACTIVE_COMPARATOR|Group 2|Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes: Group2 will receive reversal with sugammadex 4mg/kg
62805455|NCT04837937|EXPERIMENTAL|Condition 6|(1) 'Caregiver vs. Patient \[Beginner\]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Caregiver' conflict negotiation/dispute resolution exercise; (3) 'Caregiver vs. Patient \[Advanced\]' conflict negotiation/dispute resolution exercise
62805456|NCT04837937|EXPERIMENTAL|Condition 7|(1) 'Caregiver vs. Patient \[Beginner\]' negotiation/dispute resolution exercise; (2) 'Caregiver vs. Caregiver' conflict negotiation/dispute resolution exercise; (3) 'Caregiver vs. Physician' conflict negotiation/dispute resolution exercise
62805457|NCT04837937|EXPERIMENTAL|Condition 8|(1) 'Caregiver vs. Patient \[Beginner\]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Caregiver' conflict negotiation/dispute resolution exercise; (3) 'Caregiver vs. Physician' conflict negotiation/dispute resolution exercise; (4) 'Caregiver vs. Patient \[Advanced\]' conflict negotiation/dispute resolution exercise
62805458|NCT03779542||open-angle group|ACD \> 2.68 measured by the swept source AS-OCT and angle \> Shaffer 2 in four quadrants under gonioscope
62805459|NCT03779542||narrow-angle group|ACD≤2.68 measured by the swept source AS-OCT and angle≤Shaffer 2 in four quadrants under gonioscope
62805460|NCT03656029|PLACEBO_COMPARATOR|Placebo|Participants will smoke a single smoked placebo (\<0.1% THC) cannabis cigarette
62228778|NCT01619150|OTHER|Etoricoxib, followed by placebo|4 weeks of treatment with etoricoxib, followed by a wash out period of at least 6 days, followed by another 4 weeks of treatment with placebo.
62228779|NCT01619150|OTHER|Placebo, followed by etoricoxib|4 weeks of treatment with placebo, followed by a wash out period of at least 6 days, followed by another 4 weeks of treatment with etoricoxib.
62228780|NCT03203395|EXPERIMENTAL|Heart patients|Screening and counselling
62805461|NCT03656029|ACTIVE_COMPARATOR|low dose|Participants will smoke a single low dose (6.25% THC) of smoked cannabis cigarette
62805462|NCT03656029|ACTIVE_COMPARATOR|middle dose|Participants will smoke a single intermediate dose (12.5% THC) of smoked cannabis cigarette
62805463|NCT03656029|ACTIVE_COMPARATOR|high dose|Participants will smoke a single high dose (22% THC) of smoked cannabis cigarette
62228781|NCT01242553||Normal|Normal results from clinical exam and free of ocular pathology.
62228782|NCT01242553||Retina|Clinical exam results consistent with retina pathology
62228783|NCT01242553||Glaucoma|Clinical exam results consistent with glaucoma and visual field defects consistent with glaucoma.
62228784|NCT01242553||Cornea|Clinical exam results consistent with cornea pathology.
62421376|NCT06462222|EXPERIMENTAL|Group|Immune checkpoint inhibitor combined with pemetrexed
62421377|NCT05307250|EXPERIMENTAL|Treatment Arm 1|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE
62421378|NCT05307250|EXPERIMENTAL|Treatment Arm 2|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR)
62805464|NCT01092728|ACTIVE_COMPARATOR|Group 1: Completely Resectable|Dasatinib 100 mg daily for 7 days and then surgical resection on Day 8. Afterwards, Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).
62805465|NCT01092728|ACTIVE_COMPARATOR|Group 2: Unresectable|100 mg Dasatinib daily continued up to 12 months/12 cycles (1 cycle = 4 weeks of treatment).
62805466|NCT02320006|ACTIVE_COMPARATOR|True acupuncture plus hydrotubation|The treatment group will receive true acupuncture and hydrotubation,Hydrotubation (80,000 U gentamicin , 400U chymotrypsin , 5mg dexamethasone , 50ml 0.9% saline) will be performedwithin 3 7 days after the menstruation\[12\].We use a manometer to measure the pressure and record the number on a card, then calculate the gap of the first and last time,it continues 3 menstrual cycles. The points (points used for every participant of treatment group) include bilateral RN4、CV6、CV3、EX-CA1、ST36、SP6,All the needles will be keep in positions for 30 min.Acupuncture will be performed three times per week,for a total of 36 sessions (12 wk)
62805467|NCT02320006|SHAM_COMPARATOR|control acupuncture plus hydrotubation|The control group will receive control acupuncture and hydrotubation.Hydrotubation (80,000 U gentamicin , 400U chymotrypsin , 5mg dexamethasone , 50ml 0.9% saline) will be performed within 3 7 days after the menstruation\[12\].We use a manometer to measure the pressure and record the number on a card, then calculate the gap of the first and last time,it continues 3 menstrual cycles.Two needles will be inserted in each arm, one in each shoulder and one in each upper arm at nonacupuncture pointsAll the needles will be keep in positions for 30 min. Acupuncture will be performed three times per week,for a total of 36 sessions (12 wk).
62805468|NCT05655663|EXPERIMENTAL|ICI|Patients under ICI treatment for their cancer will have vascular investigation and biological assessment
62805469|NCT04974255|EXPERIMENTAL|Operated Patients|Measurement of fibrosis degree and Anti-tTG levels
62805470|NCT02469623|EXPERIMENTAL|Dipole Density Mapping|
62805471|NCT05057663|ACTIVE_COMPARATOR|Bleomycin group|
62805472|NCT05057663|ACTIVE_COMPARATOR|5-Fluorouracil group|
62805473|NCT01801566|ACTIVE_COMPARATOR|Conventional implant loading protocol|Single implant-retained mandibular overdenture
62805474|NCT01801566|EXPERIMENTAL|Immediate loading implant protocol|Single implant-retained mandibular overdenture
62421379|NCT05307250|OTHER|Control Arm|Bolstered Standard of Care (BSOC)
62591281|NCT06668753||controls|patients with standard anti-proteinuric regimen
62591282|NCT05547295|OTHER|Paper Information|Patient will have classic paper information for prevention of pressure sores
62591283|NCT05547295|EXPERIMENTAL|Numeric information from MEDIASCREEN|Patient will have information for prevention of pressure sores throught the digital tool MEDIASCREEN
62591284|NCT06429215|EXPERIMENTAL|Multi-component Intervention (MC-I)|VR cognitive training + Psychoeducation program
62591285|NCT06429215|ACTIVE_COMPARATOR|Cognitive-only intervention (CO-I)|VR Cognitive training + Psychoeducation active control
62591286|NCT06429215|ACTIVE_COMPARATOR|Active control intervention (AC-I)|VR Cognitive active control + Psychoeducation active control
62591287|NCT06653608|EXPERIMENTAL|Group A (Nano-reinforced Calcium hydroxide)|Nano-reinforced Calcium hydroxide Medicament
62805475|NCT02421978||Chemotherapy-treated breast cancer group|Female subjects with Stage I-III breast cancer treated with chemotherapy will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
62805476|NCT02421978||Non-Chemotherapy-treated breast cancer group|Non-chemotherapy treated female subjects with Stage I-III breast cancer will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
62805477|NCT02421978||Control group|Age and race-matched healthy women will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
62421380|NCT06567795||HEMOTAG with Standard of Care in DM patients|HEMOTAG with Standard of Care: To evaluate the proportion of diabetic mellitus patients with cardiovascular events as identified by HEMOTAG measurements over a 12 month duration.
62421381|NCT06152341|EXPERIMENTAL|Patients with Acute Pulmonary Embolism|Patients undergoing mechanical thrombectomy for acute pulmonary embolism.
62421382|NCT04237779|EXPERIMENTAL|PRP injection into at least one testis|Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under local anesthesia. Sperm analysis, testicular volumes (using orchiometer), serum FSH and testosterone measurements will be re-evaluated at 8 weeks post-procedure. On the third month after the procedure, presence of spermatozoa will be reassessed in microTESE material.
62421383|NCT04275232|EXPERIMENTAL|Allogenic Plasma Aliquots|Allogenic Plasma Aliquots to be used as eye drops in the treatment of recurrences of ligneous conjunctivitis. Two drops will be administered to the affected eye, every 1 to 4 hours, depending on severity of the recurrence.
62421384|NCT00079963|EXPERIMENTAL|X|Vitamin C
62030227|NCT05328531|ACTIVE_COMPARATOR|Compound Betamethasone Injection 1ml (II)|Compound Betamethasone Injection, 1 ml, intramuscular injection, single dose Placebo for Genakumab for injection, 100mg, subcutaneous injection, single dose
62030228|NCT00906672|EXPERIMENTAL|INTEGRA®|
62030229|NCT00906672|ACTIVE_COMPARATOR|Flap technique|
62421385|NCT00079963|EXPERIMENTAL|Y|Vitamin E
62421386|NCT00079963|PLACEBO_COMPARATOR|Z|Placebo
62421387|NCT06566508|ACTIVE_COMPARATOR|Calcium Hydroxide|Intracanal medication
62421388|NCT06566508|ACTIVE_COMPARATOR|Leddermix|Intracanal medication
62591288|NCT06653608|EXPERIMENTAL|Group B (Conventional Calcium hydroxide)|Calcium hydroxide without nanoparticles
62591289|NCT00774254|EXPERIMENTAL|A|
62591290|NCT06223750|OTHER|Patient contact via mail with a letter and laboratory requisition|Patient contact via mail with a letter and laboratory requisition for serum creatinine and urine albumin to creatinine ratio
62591291|NCT06223750|OTHER|Patient and primary care network contact via mail with a letter but no laboratory requisition|
62591292|NCT00655707|EXPERIMENTAL|Autologous CD34+ cells|Autologous Cluster Designation 34+(CD34+) cells
62591293|NCT04662866|ACTIVE_COMPARATOR|Metformin|Metformin 500 mg x 1, morning, for 2 weeks, then Metformin 500 mg x 2, morning and evening for 10 weeks.
62591294|NCT04662866|ACTIVE_COMPARATOR|Empagliflozin|Empagliflozin 10 mg x 1, morning, for 2 weeks, then Empagliflozin 10 mg morning + Placebo evening for 10 weeks.
62591295|NCT04662866|ACTIVE_COMPARATOR|Linagliptin|Linagliptin 5 mg x 1, morning, for 2 weeks, then Linagliptin 5 mg morning + Placebo evening for 10 weeks.
62591296|NCT04662866|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone 30 mg x 1, morning, for 2 weeks, then Pioglitazone 30 mg morning + Placebo evening for 10 weeks.
62591297|NCT00737204|EXPERIMENTAL|Armodafinil|Participants will take armodafinil for 4 weeks. The dose will be titrated up from 50mg to 250mg per day as clinically indicated, using 50mg tablets. If responsive, participants will be offered 12 additional weeks of armodafinil.
62591298|NCT00737204|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo pills for 4 weeks. Placebo tablets that match the 50mg active medication tablets will given following the same dosing strategy as Arm 1. The dose will be titrated from 1 placebo tablet daily to 5 tablets daily as clinically indicated. Non-responders to placebo will then be offered 16 weeks of active medication.
62591299|NCT01954537||Professional football players|Offensive and defensive professional football players ranging in age from 22 to 30 years old.
62591300|NCT01954537||Collegiate Football Players|Division III collegiate football players ranging in age from 20 to 23 years old.
62591301|NCT01954537||High School Football Players|High school football players ranging in age from 16 to 18 years old.
62591302|NCT01369030||Deplin®|Subjects with depression who have been prescribed Deplin® daily.
62591303|NCT03317964||Saliva - cardiomyopathy|Saliva sample for genetic testing from subjects who developed cardiomyopathy
62591304|NCT03317964||Saliva - no cardiomyopathy|Saliva sample for genetic testing from subjects who do not have cariomyopathy
62591305|NCT02630225|EXPERIMENTAL|Intervention|"Participants in this arm will receive three intervention services in addition to treatment as usual services:~1. A brief intervention including a feedback session utilizing principles of Motivational Interviewing (MI).~2. Extended outreach services (6 months) using the Critical Time Intervention (CTI) approach.~3. Multi-agency attention."
62805478|NCT06528951|EXPERIMENTAL|Control Phase (6 Weeks)|All recruited participants will perform 6 weeks of resistance training with the same volume. The total training volume (sets x repetitions) will be 232 repetitions in the leg press and 160 repetitions in the chest press, with relative intensities ranging from 40% to 70% of 1RM.
62805479|NCT06528951|EXPERIMENTAL|15% increase in resistance training volume (10 Weeks)|The participants will perform 10 weeks of resistance training, increasing their initial volume by 15%.
62805480|NCT06528951|EXPERIMENTAL|30% increase in resistance training volume (10 Weeks)|The participants will perform 10 weeks of resistance training, increasing their initial volume by 30%.
62805481|NCT06528951|EXPERIMENTAL|15% + 15% increase in resistance training volume (10 Weeks)|The participants will perform 10 weeks of resistance training. The group that performed the 15% volume will increase to 30%.
62805482|NCT06528951|EXPERIMENTAL|30% + 15% increase in resistance training volume (10 Weeks)|The participants will perform 10 weeks of resistance training. The group that performed the 30% volume will increase to 15%.
62805483|NCT06528951|EXPERIMENTAL|Control group ( 29 Weeks)|The participants will not perform any form of physical exercise during the intervention period of twenty-nine weeks.
62805484|NCT03431441|EXPERIMENTAL|JJVC Marketed Contact Lens|ACUVUE 2 Vivid Style
62805485|NCT02230566|EXPERIMENTAL|Group A: 4 mg/kg UX003|4 mg/kg UX003 QOW through Week 46
62421389|NCT06566508|ACTIVE_COMPARATOR|Asiaticoside|Intracanal medication
62421390|NCT05078398|EXPERIMENTAL|POINT-B|Patients will receive perioperative counseling on opioid consumption following breast surgery, both preoperatively and postoperatively. Upon discharge, patients will be asked whether they would like to be discharged with narcotic pain medication or not.
62421391|NCT05078398|ACTIVE_COMPARATOR|Usual Care|Patients will receive equivalent of 5 tabs of Norco 5/325 mg upon discharge routinely
62030230|NCT06233318|ACTIVE_COMPARATOR|Pecto-intercostal fascial block|Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine injected to each side under ultrasound visualization.
62030231|NCT06233318|PLACEBO_COMPARATOR|Placebo|Pecto-intercostal Fascial Block with 20ml of normal saline injected to each side under ultrasound visualization.
62421392|NCT06359756|EXPERIMENTAL|Ischemic postconditioning group|Patients with ischemic postconditioning (IPCT) performed after standard eversion carotid endarterectomy (eCEA)
62421393|NCT06359756|ACTIVE_COMPARATOR|Control|Patients with standard eversion carotid endarterectomy (eCEA) performed with no ischemic postconditioning (IPCT)
62421394|NCT04750928|EXPERIMENTAL|1/ Phase I Dose Escalation|Abemaciclib orally twice daily at escalating doses to determine the MTD/RP2D
62421395|NCT04750928|EXPERIMENTAL|2/ Phase II Objective Response Rate|Abemaciclib orally twice daily at the RP2D
62421396|NCT05474573|EXPERIMENTAL|Fluorescence and Ultrasound|Extent of tumor resection will be intraoperatively assessed using both fluorescence with 5-aminolevulinic acid and sonography
62591306|NCT02630225|OTHER|Treatment as Usual|Participants in this arm will receive the usual care offered to victims of gun shot wounds.
62805486|NCT02230566|EXPERIMENTAL|Group B: 8 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 8 weeks followed by 4 mg/kg UX003 QOW through Week 46
62421397|NCT05474573|ACTIVE_COMPARATOR|Fluorescence|Extent of tumor resection will be intraoperatively assessed using fluorescence with 5-aminolevulinic acid
62805487|NCT02230566|EXPERIMENTAL|Group C: 16 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 16 weeks followed by 4 mg/kg UX003 QOW through Week 46
62805488|NCT02230566|EXPERIMENTAL|Group D: 24 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 24 weeks followed by 4 mg/kg UX003 QOW through Week 46
62805489|NCT05740488|EXPERIMENTAL|apalutamide combined with 89Sr and ADT|Neoadjuvant therapy with apalutamide in combination with 89Sr and ADT
62805490|NCT00557921|EXPERIMENTAL|1|
62805491|NCT00557921|ACTIVE_COMPARATOR|2|
62805492|NCT02977000|EXPERIMENTAL|Propranolol|Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h. investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.
62805493|NCT04958369|ACTIVE_COMPARATOR|Ultrasound-guided axillary venous access|Cardiac device implantation will be performed with ultrasound-guided axillary venous access.
62805494|NCT04958369|ACTIVE_COMPARATOR|Cephalic venous access|Cardiac device implantation will be performed with conventional cephalic venous access (cut-down technique).
62805495|NCT03863951||Patients with poststroke depression|No intervention
62805496|NCT03863951||Patients without poststroke depression|No intervention
62805497|NCT04230317|EXPERIMENTAL|Low dose chest CT simulation|VBN result driven using raw data acquired with low dose CTs taken with three different protocols
62805498|NCT04230317|ACTIVE_COMPARATOR|Standard protocol chest CT simulation|VBN result driven using raw data acquired with standard protocol CT
62805499|NCT01665469|PLACEBO_COMPARATOR|Placebo|Soft gel capsule without test material
62805500|NCT01665469|EXPERIMENTAL|Tomato extracted lycopene|Soft gel cups for oral use
62805501|NCT01918124|EXPERIMENTAL|radiotherapy combined with chemotherapy|"Arm Label: radiotherapy combined with chemotherapy:~Radiotherapy:~Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.~Cisplatin:~Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.~Cisplatin and Doxorubicin and Cyclophosphamide： Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) given at 3 week intervals following completion of radiotherapy.~Paclitaxel and Carboplatin： Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy."
62805502|NCT04294017||patients|participants undergoing a diagnostic laparoscopy and have a histologically confirmed Endometriosis
62805503|NCT04294017||controls|participants undergoing a diagnostic laparoscopy where no evidence of Endometriosis could be found
62805504|NCT03142529|NO_INTERVENTION|Integrated Therapy|This arm is an control group,in which participants will receive conventional integrated therapy on CRF.
62805505|NCT03142529|EXPERIMENTAL|Integrated Therapy and colonic dialysis|This arm is a treatment group,in which participants will receive integrated therapy on CRF and traditional Chinese medicine Colonic dialysis with traditional Chinese medicine colon lotion once a day.
62805506|NCT05048173||Sentinel lymph node group|woman who had sentinel lymph node mapping and biopsy
62805507|NCT05048173||Lymphadenectomy group|woman who underwent traditional pelvic lymphadenectomy without sentinel lymph node mapping
62805508|NCT02528825|EXPERIMENTAL|smooth emergence|ASA I-II, aged 19-65 years undergoing general anesthesia with DLT for lung wedge resection were enrolled in this study.After completing the surgery, the propofol infusion was stopped, and effect-site concentration of remifentanil was titrated to predetermined concentration ( initial concentration being 1.5ng/ml for the first patient).The predetermined concentration was maintained at least 10 min throughout emergence for the effect site concentration and plasma concentration can be expected stable. The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
62805509|NCT00088530|EXPERIMENTAL|Experimental Arm|Pixantrone (BBR2778)
62805510|NCT00088530|ACTIVE_COMPARATOR|Comparator Arm|To be chosen by the investigator, among vinorelbine, oxaliplatin, ifosfamide, etoposide or mitoxantrone
62805511|NCT02832544|EXPERIMENTAL|Rivaroxaban (20 mg)|Rivaroxaban 20 mg od (n \~ 2250); 15 mg od (once daily) in patients with creatinine clearance (CrCl) 15-49 ml/min
62805512|NCT02832544|ACTIVE_COMPARATOR|Vitamin K antagonists (VKA)|Any approved VKA in the participating country (n \~ 2250); VKA titrated to achieve an INR of 2.0-3.0
62805513|NCT04632888|EXPERIMENTAL|Study group/Telephone support for breastfeeding follow-up|"Study group: The women in the study group will be provided with a video call every day for the first week after discharge from the hospital, to provide consultancy to the mother on the matters she needs and to be recorded in the Baby Monitoring Form. The general appearance of the baby, observation during sucking, jaundice, drowsiness, reluctance to suck will be observed. The consultancy will be provided to the mother on these issues.~In the following weeks, the consultancy will continue to be given to the study group by making a video talk one week apart.~The researcher's phone will be given to the mothers in both groups and the incoming calls and their content will be recorded."
62805514|NCT04632888|NO_INTERVENTION|Control Group|"Control Group: No additional attempt or routine call will be made to mothers in the control group. The researcher's phone will be given to the mothers in both groups and the incoming calls and their content will be recorded.~The control group will be called to fill in the scales for monitoring purposes."
62805515|NCT05256680|EXPERIMENTAL|Gardening Activities|In the research, the elderly in the experimental group will have gardening activities once a week for 3 months.
62805516|NCT05256680|ACTIVE_COMPARATOR|Control|No intervention will be applied to the elderly in the control group during the research. They will participate in routine activities in the nursing home.
62805517|NCT01936714|OTHER|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 45ml/min, vacuum 600 mmHg, bottle height 100cm.
62805518|NCT01936714|OTHER|LF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 20ml/min, vacuum 400 mmHg, bottle height 100cm.
62805519|NCT04683835||Patients|Patients who are assessed by the clinical staff using Mini-Mental State Exam (MMSE)
62805520|NCT03936608|EXPERIMENTAL|Individualized RV-LV Pacing Offset|
62805521|NCT03936608|ACTIVE_COMPARATOR|No RV-LV Pacing Offset|
62030232|NCT01098006|OTHER|Immune tolerant patients Group|Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B viruss (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.
62228785|NCT01012739|EXPERIMENTAL|Indacaterol 150μg-placebo-Indacaterol 60μg-Indacaterol 120μg|In treatment period 1, patients received indacaterol 150 μg via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received placebo to indacaterol via the Concept1 DPI; in treatment period 3, patients received indacaterol 60 μg via the Simoon DPI; and in treatment period 4, patients received indacaterol 120 μg via the Simoon DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
62421398|NCT05111626|EXPERIMENTAL|Part 1 Safety Lead-in: Bemarituzumab with mFOLFOX6 and Nivolumab|Participants will be administered bemarituzumab at different doses with mFOLFOX6 and nivolumab to determine the recommended phase 3 dose (RP3D) based on occurrence of dose-limiting toxicities (DLTs), and on an evaluation of the overall safety, tolerability, and pharmacokinetics (PK).
62805522|NCT06011408|OTHER|Taking antipsychotic medication with Tardive Dyskinesia|
62805523|NCT06011408|OTHER|Taking antipsychotic medication without Tardive Dyskinesia|
62805524|NCT05299398|EXPERIMENTAL|Trazodone|Trazodone once daily for 24 weeks.
62805525|NCT05299398|PLACEBO_COMPARATOR|Placebo|Placebo once daily for 24 weeks
62805526|NCT05555966|EXPERIMENTAL|Tailor-made CRT delivery|Device placement based on Electrical Activation Mapping result
62805527|NCT01875159|EXPERIMENTAL|Caffeine|Caffeine citrate 6 mg/kg/day
62805528|NCT01875159|NO_INTERVENTION|Active Comparator: no caffeine|Compare extended use of caffeine citrate 6 mg/kg/day to no caffeine (usual care) in regard to extent of intermittent hypoxia from 35 weeks postmenstrual age (PMA) to 40 weeks PMA.
62805529|NCT06268054|EXPERIMENTAL|DEH113|The patient must take two (2) DEH113 tablets, if pain, up to three times a day.
62805530|NCT06268054|PLACEBO_COMPARATOR|Control|The patient must take two (2) DEH113 placebo tablets, if pain, up to three times a day.
62805531|NCT00524277|EXPERIMENTAL|Arm I|HLA-A2-positive patients receive GP2 peptide + GM-CSF vaccine intradermally (ID) every 3-4 weeks for a total of up to 6 inoculations.
62805532|NCT00524277|ACTIVE_COMPARATOR|Arm II|HLA-A2-positive patients receive GM-CSF ID every 3-4 weeks for a total of up to 6 inoculations.
62421399|NCT05111626|EXPERIMENTAL|Part 2: Bemarituzumab with chemotherapy (mFOLFOX6 or CAPOX) and Nivolumab|"Participants will be administered bemarituzumab at the RP3D determined from Part 1 in combination with mFOLFOX6 and nivolumab on a 14-day cycle.~Or participants will be administered bemarituzumab in combination with CAPOX and nivolumab on a 21-day cycle."
62421400|NCT05111626|PLACEBO_COMPARATOR|Part 2: Placebo with chemotherapy (mFOLFOX6 or CAPOX) and Nivolumab|"Participants will be administered placebo comparator in combination with mFOLFOX6 and nivolumab on a 14-day cycle.~Or participants will be administered placebo comparator in combination with CAPOX and nivolumab on a 21-day cycle."
62805533|NCT00524277|EXPERIMENTAL|Arm III|HLA-A2-negative patients receive AE37 peptide/GM-CSF vaccine ID every 3-4 weeks for a total of up to 6 inoculations.
62805534|NCT00524277|ACTIVE_COMPARATOR|Arm IV|HLA-A2-negative patients receive GM-CSF ID ID every 3-4 weeks for a total of up to 6 inoculations
62421401|NCT02808663|EXPERIMENTAL|Severe Alcoholic Hepatitis|
62421402|NCT06482437|EXPERIMENTAL|NMD670|
62421403|NCT06482437|PLACEBO_COMPARATOR|Placebo|
62805535|NCT05579015|EXPERIMENTAL|rMDD group|Participants with remitted MDD who will receive concurrent TBS/fNIRS with iTBS and followed by cTBS after one hour. This group will also receive follow-up telephone interviews every 3 months for 2 years to monitor major depressive episode recurrence.
62805536|NCT05579015|OTHER|Healthy control group|Healthy participants who will receive TBS/fNIRS with iTBS and followed by cTBS after one hour. No follow-up interviews will be conducted for this group.
62805537|NCT05277376|ACTIVE_COMPARATOR|BEMT Formulation SU-E-101413-85|PK evaluation of 6% BEMT after multiple applications of a topical sunscreen formulation.
62805538|NCT05277376|ACTIVE_COMPARATOR|BEMT Formulation SU-E-101413-87|PK evaluation of 6% BEMT after multiple applications of a topical sunscreen formulation.
62805539|NCT05277376|ACTIVE_COMPARATOR|BEMT Formulation SU-E-101413-89|PK evaluation of 6% BEMT after multiple applications of a topical sunscreen formulation.
62421404|NCT01494649|ACTIVE_COMPARATOR|Toothpaste containing 0.454% stannous fluoride|USA marketed toothpaste \[test\]
62421405|NCT01494649|OTHER|Toothpaste containing 0.76% sodium monofluorophosphate|USA marketed toothpaste \[negative control\]
62805540|NCT01732744|PLACEBO_COMPARATOR|Physiological solution|"1)Negative Control: physiological solution, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
62805541|NCT01732744|ACTIVE_COMPARATOR|Sodium hypochlorite|"2)active Comparator 1: Sodium hypochlorite, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
62805542|NCT01732744|ACTIVE_COMPARATOR|Peroxide alkaline|"2)Active Comparator 2: Alkaline peroxide (Polident), for 5 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
62591307|NCT00006251|EXPERIMENTAL|Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)|"CONDITIONING REGIMEN : Patients receive fludarabine phosphate IV on days - 4 to -2 and undergo low-dose TBI on day 0. (Note: Patients who have had an autologous transplant within 90 days prior to day 0 will not receive fludarabine phosphate.)~PBSC INFUSION: Patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 35 with a taper to day 56. Patients receive mycophenolate mofetil PO BID on days 0-27.~POST TRANSPLANT DLI: Patients with stable mixed chimerism on day 56, and without evidence of GVHD, undergo DLI IV over 30 minutes on day 65. Patients without a complete response, full donor chimerism, and GVHD after 2 months undergo further DLI at higher cell numbers. Up to 6 DLIs may be given 65 days apart."
62591308|NCT06666465|EXPERIMENTAL|Operating Room Environment Experienced by Patients|This study was planned as a randomized controlled experimental study in the pre-test post-test design in order to examine the effect of the operating room environment experience of patients using virtual reality glasses before surgery on the level of surgical fear experienced by patients before surgery and their perception of care.
62591309|NCT04241744|ACTIVE_COMPARATOR|vancomycin oral solution|vancomycin oral solution will be administered to consented patients \>65 years of age receiving IV antimicrobial(s) for a bacterial infection twice daily while hospitalized.
62591310|NCT04241744|PLACEBO_COMPARATOR|placebo oral solution|placebo oral solution will be administered to consented patients \>65 years of age receiving IV antimicrobial(s) for a bacterial infection twice daily while hospitalized.
62591311|NCT03358589|OTHER|MESTAR|All patients will have the same scans performed
62228786|NCT01012739|EXPERIMENTAL|Indacaterol 60μg-Indacaterol 150μg-Indacaterol 120μg-placebo|In treatment period 1, patients received indacaterol 60 μg via the Simoon dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 150 μg via the Concept1 DPI; in treatment period 3, patients received indacaterol 120 μg via the Simoon DPI; and in treatment period 4, patients received placebo to indacaterol via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
62243132|NCT06735209|EXPERIMENTAL|Arm 1 Part 1 Group 1|Healthy malaria-naïve participants aged between 18 and 45 years will receive 2x10\^5 PfSPZ of Plasmodium falciparum sporozoite vaccine (PfSPZ-LARC2) vaccine on Days 1, 29, and 57 followed by 3.2x10\^3 PfSPZ Challenge (7G8) Controlled Human Malaria Infection (CHMI) on Day 169 administered by direct venous inoculation (DVI). Placebo participants that drop out prior to CHMI will be replaced with infectivity controls. Infectivity controls will receive PfSPZ Challenge (7G8) CHMI N=3
62591312|NCT06342622||Patients with young-onset colorectal cancer|Patients were diagnosed with young-onset colorectal cancer after receiving colonoscopy examination.
62591313|NCT06342622||Patients without young-onset colorectal cancer|Patients were ruled out young-onset colorectal cancer after receiving colonoscopy examination.
62591314|NCT05969366||patients 85 yearsold or orlder who hab total hip replacement with uncemented femoral stem|
62591315|NCT03031249|ACTIVE_COMPARATOR|High Dose of Cytarabine|Patients receive high dose of cytarabine.
62591316|NCT03031249|EXPERIMENTAL|HDAC + ATRA + ATO|Patients receive high dose of cytarabine plus ATRA and ATO treatment.
62421406|NCT05839028||Patients with hypertension of stages 1 and 2|Individuals with stage 1 and 2 hypertension living in a temperate climate zone and doing rotational shiftwork in the Arctic.
62591317|NCT01595464|EXPERIMENTAL|Mind-Body Skills Groups|
62591318|NCT01595464|NO_INTERVENTION|Control Group|
62591319|NCT05017896||Normal Perfusion|
62591320|NCT05017896||Low Perfusion|
62591321|NCT04604509|EXPERIMENTAL|Group I (varenicline, counseling)|Participants receive varenicline PO daily or BID for 6 weeks in the absence of unacceptable toxicity. Participants who quit smoking continue treatment for 6 additional weeks in the absence of unacceptable toxicity. Participants also receive behavioral smoking cessation counseling.
62591322|NCT04604509|EXPERIMENTAL|Group II (NRT, counseling)|Participants receive NRT consisting of a patch, lozenges, or gum daily for 6 weeks in the absence of unacceptable toxicity. Participants who quit smoking continue treatment for 6 additional weeks in the absence of unacceptable toxicity. Participants also receive behavioral smoking cessation counseling.
62591323|NCT04604509|EXPERIMENTAL|Group III (varenicline or NRT, counseling)|Participants continue to receive varenicline as in Group I or NRT as in Group II for 6 additional weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
62591324|NCT04604509|EXPERIMENTAL|Group IV (varenicline or NRT, counseling)|Participants switch to a different therapy and receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
62591325|NCT04604509|EXPERIMENTAL|Group V (higher dose varenicline or NRT, counseling)|Participants receive a higher dose and continue to receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
62591326|NCT04604509|EXPERIMENTAL|Group VI (varenicline or NRT, bupropion, counseling)|Participants continue to receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive bupropion PO daily for 6 weeks and behavioral smoking cessation counseling.
62805543|NCT01732744|EXPERIMENTAL|Castor bean solution|"3)Experimental: castor bean solution, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
62030233|NCT01098006|OTHER|HBeAg positive Group|HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with activee inflammation and varying degrees of liver fibbrosis.
62030234|NCT01098006|OTHER|Inactive carriers Group|Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.
62805544|NCT02986711|EXPERIMENTAL|Motivational Text Messages|Motivational text messages to help participants stay quit when they leave the hospital.
62805545|NCT02986711|SHAM_COMPARATOR|Control|Text messages to ask about current smoking status.
62805546|NCT05697783||Methadone-treated group|
62805547|NCT05697783||Fentanyl-patch treated group|
62805548|NCT00226590|EXPERIMENTAL|Combined Therapy|In this trial we adopted the approach of using both induction and concurrent chemotherapy together with TRT planned conformally to a tumor dose of 74 Gy.
62030235|NCT01098006|OTHER|HBeAg negative Group|HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.
62030236|NCT02315157|EXPERIMENTAL|Bendamustine 200 mg/m2|Patients receive bendamustine hydrochloride IV over 60-180 minutes on days 1 and 2 (total dose 400 mg/m2).
62030237|NCT02315157|EXPERIMENTAL|Bendamustine 250 mg/m2|Patients receive bendamustine hydrochloride IV over 60-180 minutes on days 1 and 2 (total dose 500 mg/m2).
62030238|NCT05978765|EXPERIMENTAL|Inclinometer|Inclinometer : An inclinometer is a sensor used to measure the magnitude of the inclination angle or deformation of any structure
62030239|NCT05978765|EXPERIMENTAL|Back Pain Functional Scale|a subjective scale used to measure the patient's physical function after low back pain
62030240|NCT05978765|EXPERIMENTAL|Functional Mobility Scale|has been constructed to classify functional mobility
62030241|NCT05978765|EXPERIMENTAL|Numeric Pain Rating Scale|"A pain screening tool, commonly used to assess pain severity at that moment in time using a 0-10 scale, with zero meaning no pain and 10 meaning the worst pain imaginable"
62030242|NCT01666002|EXPERIMENTAL|Treatment|"1. st visit: Patient will come into clinic for initial laser treatment with Nd:YAG 1064 nm laser fitted with special handpiece.~2. nd visit: 2 weeks after initial laser treatment, patient will be seen for second treatment with Nd:YAG 1064 nm laser fitted with special handpiece."
62030243|NCT01666002|NO_INTERVENTION|Placebo|"1. st visit: For the control group, no treatment will be given.~2. nd visit: 2 weeks after initial visit, patient will be seen for second visit"
62030244|NCT06201182|EXPERIMENTAL|FMT rectal enema|Patients will receive FMT via rectal enema and placebo capsules.
62030245|NCT06201182|EXPERIMENTAL|Encapsulated FMT|Patients will receive FMT capsules and placebo via rectal enema.
62030246|NCT06201182|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo capsules and placebo via rectal enema.
62421407|NCT05839028||Healthy volunteers|Virtually healthy individuals living in a temperate climate zone and and doing rotational shiftwork in the Arctic.
62805549|NCT02120066|OTHER|Vitrectomy|
62805550|NCT03549975|EXPERIMENTAL|Botulinum toxin type A injection|Botulinum toxin type A injection followed by functional electrical stimulation
62030247|NCT05921877||Patients with functional hypothalamic amenorrhea|Women aged 15-34 years Diagnosis of functional hypothalamic amenorrhea (for at least 2 years) No interventions to be administered
62030248|NCT05921877||Healthy controls|Women aged 15-34 years Normal menstrual cycles No interventions to be administered
62030249|NCT02307929||Chronic Disease Management|Aging population with the need of Chronic Disease Management
62030250|NCT02938000|EXPERIMENTAL|Theraband group|This group will be furnished with Thera-band, and link to exercise video, with plans for regular exercise as described previously, in addition to usual post stroke care.
62421408|NCT01771419|EXPERIMENTAL|loop-tip arm|The cannulation of CBD will be obtained using the loop-tip wire (Cook Medical inc.)
62805551|NCT02306681||SAQ-Self-Assessment Questionnaire|
62805552|NCT01096836|EXPERIMENTAL|Diet counseling|Outcomes of the study may enhance diet counseling
62805553|NCT01096836|EXPERIMENTAL|exercise training|
62805554|NCT03056677|EXPERIMENTAL|Control|No Whey Protein
62805555|NCT03056677|EXPERIMENTAL|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
62805556|NCT03056677|EXPERIMENTAL|Modified Whey|Modified whey protein will be given
62805557|NCT06339151|ACTIVE_COMPARATOR|Group 1|"Preoperative - Dexamethasone 0.15 mg/kg injection by the anesthesiologist 30 minutes before surgery.~Postoperative 12 hr - Normal saline solution injection Postoperative 24 hr - Normal saline solution injection"
62805558|NCT06339151|ACTIVE_COMPARATOR|Group 2|"Preoperative - Dexamethasone 0.15 mg/kg injection by the anesthesiologist 30 minutes before surgery.~Postoperative 12 hr - Dexamethasone 0.15 mg/kg IV at 12 hours post operation Postoperative 24 hr - Normal saline solution injection"
62805559|NCT06339151|ACTIVE_COMPARATOR|Group 3|"Preoperative - Dexamethasone 0.15 mg/kg injection by the anesthesiologist 30 minutes before surgery.~Postoperative 12 hr - Normal saline solution injection Postoperative 24 hr - Dexamethasone 0.15 mg/kg IV at 24 hours post operation"
62030251|NCT02938000|PLACEBO_COMPARATOR|Usual Care Group|This group will have usual post stroke care, and will be advised to get regular exercise.
62030252|NCT02127801|EXPERIMENTAL|Group A|Participants in group A will receive REGN1908-1909
62030253|NCT02127801|EXPERIMENTAL|Group B|Participants in group B will receive placebo
62030254|NCT06146348||CVC confirmed by DRAUP|new mode of CVC confirmation for correct location and excluding pneumothorax
62030255|NCT06146348||CVC confirmed by CXR|traditional mode of CVC confirmation for correct location and excluding pneumothorax
62030256|NCT01597687|EXPERIMENTAL|Malaysia Group|Malaysian adults aged \>19 years with prolonged cough of 2 weeks or more.
62030257|NCT01597687|EXPERIMENTAL|Taiwan Group|Taiwanese adults aged \>19 years with prolonged cough of 2 weeks or more.
62030258|NCT01597687|EXPERIMENTAL|Thailand Group|Thailandese adults aged \>19 years with prolonged cough of 2 weeks or more.
62421409|NCT01771419|ACTIVE_COMPARATOR|Control arm|The cannulation of CBD will be obtained with a Cook Medical sphincterotome CT-25 mm (tradictional technique)
62421410|NCT02822807|OTHER|Q fever without valvular disease|Q fever without valvular disease
62421411|NCT02822807|OTHER|Q fever with valvular disease|Q fever with valvular disease
62421412|NCT02822807|OTHER|Q fever infective endocarditis|Q fever infective endocarditis
62421413|NCT02822807|OTHER|Other Coxiella burnetii infections (including pregnant women)|Other Coxiella burnetii infections (including pregnant women)
62421414|NCT00816517|EXPERIMENTAL|botulinum toxin|injection of botulinum toxin type A
62421415|NCT01561586|ACTIVE_COMPARATOR|A: Weekly cisplatin with RT|Weekly cisplatin 40mg/m2 six cycles concurrent to radiation therapy
62421416|NCT01561586|EXPERIMENTAL|B: Tri-weekly cisplatin with RT|Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy
62421417|NCT04955873|EXPERIMENTAL|Test - Group A - Dentsply biomaterials|"Dental extraction socket treated with the combined use of the xenogenic bone granules Dentsply Sirona Symbios Xenograft Granules and the resorbable collagen membrane Dentsply Sirona Symbios Collagen Membrane SR."
62421418|NCT04955873|ACTIVE_COMPARATOR|Active comparator - Group B - Geistlich biomaterials|"Dental extraction socket treated with the combined use of the xenogenic bone granules Geistlich Bio-oss Collagen and the resorbable collagen membrane Geistlich BioGide."
62421419|NCT04955873|NO_INTERVENTION|Control - Group C - Spontaneous healing|Spontaneous postextraction alveolar healing
62421420|NCT02043093|NO_INTERVENTION|Waiting|Surveys are administered to school students and staff, but Sources of Strength program is not implemented until the school year following two years of survey participation
62421421|NCT02043093|EXPERIMENTAL|Intervention|School receives Sources of Strength Peer Leader training and implementation for two school years, beginning in fall of enrollment year. Peer leaders are actively implementing program across two school years. Students and school staff participate in surveys across the two implementing school years.
62421422|NCT03755245|OTHER|[68Ga]Ga-DOTA-Siglec-9|Intravenous 140 MBq bolus injection of \[68Ga\]Ga-DOTA-Siglec-9 radiopharmaceutical
62421423|NCT06566898||Severe pneumonia|Patients clinically diagnosed as severe pneumonia are diagnosed according to the Guidelines for the diagnosis and Treatment of community-acquired pneumonia in Adults (2019 edition) formulated by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), who meet 1 of the following major criteria or ≥3 minor criteria can be diagnosed. The diagnostic criteria for severe pneumonia in children were adopted by the British Thoracic Society (BTS) in 2011.
62421424|NCT06566898||Mild pneumonia|Patients clinically diagnosed as severe pneumonia and mild pneumonia are diagnosed according to the Guidelines for the diagnosis and Treatment of community-acquired pneumonia in Adults (2019 edition) formulated by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA). The diagnostic criteria for severe and mild pneumonia in children were adopted by the British Thoracic Society (BTS) in 2011
62421425|NCT00343642|EXPERIMENTAL|Active Fructo-oligosaccharide|"Subjects received an active fructo-oligosaccharide supplement and a diet following the 2005 Dietary Guidelines for Americans.~The fructo-oligosaccharide supplement was administered orally in a powder form two teaspoons daily."
62421426|NCT00343642|PLACEBO_COMPARATOR|Placebo Fructo-oligosaccharide|Subjects received a placebo fructo-oligosaccharide supplement and a diet following the 2005 Dietary Guidelines for Americans.
62030259|NCT01669122|EXPERIMENTAL|Prototype 1|4mg nicotine lozenge administered orally as a single dose treatment per subject
62030260|NCT01669122|EXPERIMENTAL|Prototype 2|4mg nicotine lozenge administered orally as a single dose treatment per subject
62030261|NCT01669122|EXPERIMENTAL|Prototype 3|4mg nicotine lozenge administered orally as a single dose treatment per subject
62030262|NCT01669122|ACTIVE_COMPARATOR|Reference Therapy|4mg nicotine lozenge (internationally marketed) to be administered orally as a single dose treatment per subject.
62421427|NCT00343642|ACTIVE_COMPARATOR|Dietary Therapy|Subjects received a placebo fructo-oligosaccharide supplement and a restrictive anti-inflammatory diet developed by the research team.
62421428|NCT06079853|EXPERIMENTAL|Experimental|Single arm pilot sample will receive intervention
62591327|NCT04604509|EXPERIMENTAL|Group VII (varenicline and NRT, counseling)|Participants receive varenicline as in Group I and NRT as in Group II for 6 weeks. Participants also receive behavioral smoking cessation counseling.
62591328|NCT02105246|EXPERIMENTAL|Home-based|Referral to a home-based cardiac rehabilitation program (intervention).
62030263|NCT05542576|EXPERIMENTAL|AMDX2011P 25mg|25mg (1ml) single bolus injection intravenous for diagnostic review
62030264|NCT05542576|EXPERIMENTAL|AMDX2011P 50mg|AMDX2011P 50mg (2ml) single bolus injection intravenous for diagnostic review
62030265|NCT05542576|EXPERIMENTAL|AMDX2011P 100mg|AMDX2011P 100mg (4ml) single bolus injection intravenous for diagnostic review
62030266|NCT05542576|EXPERIMENTAL|AMDX2011P 200mg|AMDX2011P 200mg (6-8ml) single bolus injection intravenous for diagnostic review
62030267|NCT04695171||Prior Primary Large Hiatal Hernia with LINX Placement MSA|Patients who were previously implanted with the LINX device during repair of a hiatal hernia \>3 cm \>2 years prior will be asked to complete a quality of life questionnaire at about 3 years and 5 years post procedure. Each participant will complete a barium swallow at 3 and 5 years to determine recurrence of hiatal hernia.
62805560|NCT04612725|EXPERIMENTAL|Benralizumab Arm 1|Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)
62228787|NCT01012739|EXPERIMENTAL|Indacaterol 120μg-Indacaterol 60μg-placebo-Indacaterol 150μg|In treatment period 1, patients received indacaterol 120 μg via the Simoon dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 60 μg via the Simoon DPI; in treatment period 3, patients received placebo to indacaterol via the Concept1 DPI; and in treatment period 4, patients received indacaterol 150 μg via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
62228788|NCT01012739|EXPERIMENTAL|Placebo-Indacaterol 120μg- Indacaterol 150μg- Indacaterol 60μg|In treatment period 1, patients received placebo to indacaterol via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 120 μg via the Simoon DPI; in treatment period 3, patients received indacaterol 150 μg via the Concept1 DPI; and in treatment period 4, patients received indacaterol 60 μg via the Simoon DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
62805561|NCT04612725|EXPERIMENTAL|Benralizumab Arm 2|Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24,and Dose B regimen A during the extension period until Week 52 (n=30)
62805562|NCT04612725|EXPERIMENTAL|Benralizumab Arm 3|Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)
62805563|NCT04612725|EXPERIMENTAL|Benralizumab Arm 4|Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen A during the extension period until Week 52 (n=30)
62805564|NCT04612725|EXPERIMENTAL|Placebo and Benralizumab|Placebo regimen A until Week 24, benralizumab Dose B regiment A until Week 36, and Dose B regimen B until Week 52 (n=40).
62805565|NCT04456634|EXPERIMENTAL|AL&RUX|"Oral administration of:~• 20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)"
62805566|NCT04456634|PLACEBO_COMPARATOR|AL& Placebo|20 mg/120 mg artemether-lumefantrine (AL) + Placebo
62805567|NCT02155634|EXPERIMENTAL|Lenalidomide|Lenalidomide maintenance given until disease progression. Long term follow-up 5 years post last patient randomized.
62805568|NCT02155634|NO_INTERVENTION|Observation|Observation until disease progression. Long term follow-up 5 years post last patient randomized.
62228789|NCT05612763|EXPERIMENTAL|Method of fit|Devices are fit using either a clinician completed fitting process or a patient completed fitting process. Then the alternate fitting method is used to repeat the process. The order of which method used is counterbalanced.
62805569|NCT03990896|EXPERIMENTAL|Talazoparib|-Talazoparib will be provided as capsules for oral administration daily
62805570|NCT04076540|EXPERIMENTAL|AZD4041|
62805571|NCT04076540|PLACEBO_COMPARATOR|Placebo|
62805572|NCT06394986||Study group|
62805573|NCT03284606|EXPERIMENTAL|TAPING|taping in conjunction with common rehabilitation for hemiplegic patients
62805574|NCT03284606|PLACEBO_COMPARATOR|NO TAPING|Common rehabilitation for hemiplegic patients without taping
62805575|NCT05489341||Public Training and Development Set (1500 cases)|Available for all participants and researchers, to train and develop AI models. Includes multi-vendor (Siemens Healthineers, Philips Medical Systems) prostate bpMRI cases from three Dutch centers (Radboud University Medical Center, Ziekenhuisgroep Twente, University Medical Center Groningen), acquired between 2012-2021. All data is fully anonymized and made available under a non-commercial CC BY-NC 4.0 license. Includes 328 cases from the PROSTATEx challenge (prostatex.grand-challenge.org). Imaging data has been released via: zenodo.org/record/6624726 (DOI: 10.5281/zenodo.6624726). Lesion annotations of csPCa have been released and are maintained via: github.com/DIAGNijmegen/picai_labels.
62805576|NCT05489341||Private Training Set (7500-9500 cases)|Used exclusively by the organizers to retrain the top-ranking 5 AI algorithms, with large-scale data. Includes multi-vendor (Siemens Healthineers, Philips Medical Systems) prostate bpMRI cases from three Dutch centers (Radboud University Medical Center, Ziekenhuisgroep Twente, University Medical Center Groningen), acquired between 2012-2021.
62805577|NCT05489341||Hidden Validation and Tuning Cohort (100 cases)|Used for a live, public leaderboard that enables AI model selection and tuning throughout the open development phase of the challenge. Includes multi-vendor (Siemens Healthineers, Philips Medical Systems) prostate bpMRI cases from three Dutch centers (Radboud University Medical Center, Ziekenhuisgroep Twente, University Medical Center Groningen), acquired between 2012-2021, that remain fully hidden throughout the course of the challenge.
62228790|NCT06375707|ACTIVE_COMPARATOR|physician's choice of chemotherapy sequential Ribociclib combined with NSAI±OFS|
62228791|NCT06375707|EXPERIMENTAL|Ribociclib combined with NSAI±OFS|
62805578|NCT05489341||Hidden Testing Cohort (1000 cases)|Used to benchmark AI, radiologists, and test all hypotheses at the end of the PI-CAI challenge. A subset of 400 cases from this cohort is used to facilitate the PI-CAI: Reader Study. Includes multi-vendor (Siemens Healthineers, Philips Medical Systems) internal testing data (unseen prostate bpMRI cases from three seen Dutch centers {Radboud University Medical Center, Ziekenhuisgroep Twente, University Medical Center Groningen}) and external testing data (unseen prostate bpMRI cases from one unseen Norwegian center {Norwegian University of Science and Technology}), acquired between 2012-2021.
62805579|NCT04811742|EXPERIMENTAL|immersion bathing group|Immersion bathing was started by placing the baby's whole body, except for the head and neck, into a bathtub of warm water with a depth of 13-14 cm. The baby was shampooed and cleaned in the tub. Then, the baby was taken out of the water and rinsed over the tub. Finally, the baby was wrapped with a towel, taken to the radiant and dried, thus the process of bathing was completed.
62228792|NCT00368992|EXPERIMENTAL|Treatment (cetuximab, paclitaxel, bevacizumab)|"INDUCTION THERAPY: Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive cetuximab IV over 1 hour on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
62228793|NCT03982615|EXPERIMENTAL|Laser-Lok abutment|Laser-etched abutment
62228794|NCT03982615|ACTIVE_COMPARATOR|Standard Healing abutment|Standard abutment which is not laser-etched
62228795|NCT04278040|EXPERIMENTAL|Non-cystic fibrosis bronchiectasis (NCFB) patients|Inhalations with Melphalan 0,1 mg dissolved in 2 ml sodium chloride (NaCl) 0,9% 1 per day for 5 consequent days
62228796|NCT04293380|OTHER|normal karyotype|During the prenatal evaluation, IMA and cytokine values in amniotic fluid will be compared in cases with down syndrome and normal karyotype.
62228797|NCT04293380|OTHER|down syndrome|During the prenatal evaluation, IMA and cytokine values in amniotic fluid will be compared in cases with down syndrome and normal karyotype.
62228798|NCT02619487|EXPERIMENTAL|8-12 years old, parent receiving text|text message to parent only
62228799|NCT02619487|ACTIVE_COMPARATOR|13-18 years old, parent receiving text|text message to parent only
62228800|NCT02619487|ACTIVE_COMPARATOR|13-18 years, both receiving text|Text message to parent and adolescent
62228801|NCT02619487|NO_INTERVENTION|No text|No text will be sent
62228802|NCT01552525||acute kidney injury|Patients with acute kidney injury according to the definition of AKIN (Acute Kidney Injury Network)
62228803|NCT01426763|EXPERIMENTAL|SC CINRYZE with rHuPH20 Dose Level 1|Subcutaneous injection of 1000 Units of CINRYZE with 20,000 Units of rHuPH20 twice weekly for two weeks
62228804|NCT01426763|EXPERIMENTAL|SC CINRYZE with rHuPH20 Dose Level 2|Subcutaneous injection of 2000 Units of CINRYZE with 40,000 Units of rHuPH20 twice weekly for two weeks
62421429|NCT03233373||Otolaryngology Clinic Patients|Healthy subjects with no present complaints of nasal obstructions. Patients visiting the clinic, once consented, will be asked which nostril they breathe better from. They will then be asked to perform 3-4 normal respiration cycles through their nose which will be recorded using our thermal imaging device, the Seek CompactPro thermal imager
62805580|NCT04811742|EXPERIMENTAL|showering group|Shower was started by keeping the baby's face down and firmly gripping the baby from his/her armpit and head by one of the nurse's hands. The baby was washed under running water with the other hand. The second nurse assisted to ensure the flow of water. After the baby was rinsed, he/she was wrapped with a towel, taken to the radiant and dried, thus the process of bathing was completed.
62805581|NCT04967976|EXPERIMENTAL|Breast Reconstruction with breast mesh|The tissue expander-implant reconstruction with TiLoop Bra mesh.
62805582|NCT04967976|ACTIVE_COMPARATOR|Breast Reconstruction without breast mesh|The tissue expander-implant reconstruction without TiLoop Bra mesh. The tissue expander is placed sub-pectoral and covered by muscle/fascia.
62805583|NCT00416624|EXPERIMENTAL|Epoetin alfa - 40000 units|40,000 Units
62805584|NCT00416624|EXPERIMENTAL|Epoetin alfa - 80000 units|80,000 Units
62228805|NCT04988815|EXPERIMENTAL|Ropeginterferon alfa-2b|Eligible subjects will receive ropeg subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards until week 104. In patients achieving a clinical or molecular response at 24 months (week 104), treatment with ropeg will be continued until disease progression.
62421430|NCT06541483|EXPERIMENTAL|Ultra-Fast-Track Cardiac Anesthesia(UFTCA)|The researchers implemented an ultra-fast-track anesthesia protocol, and the tracheal tube was removed immediately or within 1 hour of awakening at the end of the operation.
62228806|NCT02348762|EXPERIMENTAL|Glycine and N-acetylcysteine|Older subjects will be studied before and after taking oral cysteine (as n-acetylcysteine) and glycine for 6 months
62228807|NCT06424626|EXPERIMENTAL|AK104 in Combination With Axitinib|The planned cohorts in part A were axitinib 5mg twice a day plus AK104 10mg/kg every 3 weeks. A minimum of three patients were initially enrolled at the first dose level. If a dose-limiting toxicity occurred, then the cohort would be expanded to a total of six patients. Responses were evaluated by investigators using both RECIST version 1.1 and Immune-Related RECIST (irRECIST).
62591329|NCT02105246|ACTIVE_COMPARATOR|Center-based|Referral to a center-based cardiac rehabilitation program (standard of care).
62591330|NCT05735587|EXPERIMENTAL|Freeze-dried Blueberry Powder|Randomized participants will be asked to consume 48 grams of freeze-dried blueberry powder each day for 12 weeks.
62591331|NCT05735587|PLACEBO_COMPARATOR|Placebo Powder|Randomized participants will be asked to consume 48 grams of a nutritionally matched placebo powder devoid of fiber and anthocyanins each day for 12 weeks.
62591332|NCT02039518|EXPERIMENTAL|gemcitabine|gemcitabine 1000mg/m2，d1，d8，Q3W
62805585|NCT00416624|EXPERIMENTAL|Epoetin alfa - 120000 Units|120,000 Units
62805586|NCT00416624|EXPERIMENTAL|Darbepoetin alfa***|500 mcg
62805587|NCT05979948|EXPERIMENTAL|zanubrutinib combined with BR regimen|Drug: zanubrutinib,160 mg oral capsules twice daily for 12 months Drug: Bendamustine,70-90 mg/m2 on days 1 and 2 of each cycle for 6 cycles. Drug: Rituximab,375 mg/m2 intravenously on day 0 of each cycle for 6 cycles.
62228808|NCT06424626|EXPERIMENTAL|AK112 in Combination With Axitinib|The planned cohorts in part A were axitinib 5mg twice a day plus AK112 20mg/kg every 3 weeks. A minimum of three patients were initially enrolled at the first dose level. If a dose-limiting toxicity occurred, then the cohort would be expanded to a total of six patients. Responses were evaluated by investigators using both RECIST version 1.1 and Immune-Related RECIST (irRECIST).
62228809|NCT00549809|ACTIVE_COMPARATOR|IMV, SIMV|
62228810|NCT03884205||test group|patients with PTCL who receive GDPE/CEOPE as the first-line therapy strategy
62228811|NCT03884205||control group|patients with PTCL who receive CEOPE as the first-line therapy strategy
62591333|NCT02039518|OTHER|observation group|observation
62228812|NCT04997473|EXPERIMENTAL|App Group|Participants will be receiving an addiction model based mobile health (mHealth) weight loss intervention with coaching for a total of 4 months duration
62421431|NCT06541483|OTHER|conventional general anesthesia (CGA)|The researcher implemented a conventional anesthesia protocol, and participants were not extubated at the end of the procedure and were admitted to the ICU under anesthesia with an endotracheal tube.
62421432|NCT01749618|NO_INTERVENTION|No education or feedback|Rheumatologists randomized to this treatment arm receive no additional education or feedback about their systematic assessments of patients
62805588|NCT02291146|EXPERIMENTAL|LA Sprouts intervention|"The intervention classes will be taught during a 90-minute session once a week for 12 weeks. Participants will receive a 45-minute gardening lesson, taught by a Master Gardener (supervised by Dr. Gatto). This lesson will include learning how to plant, maintain and harvest various fruits and vegetables. Supplementing the gardening lesson, a USC nutrition educator, with help from various graduate students (supervised by PI Dr. Davis), will lead a 45-minute cooking activity and nutrition education lesson. Every participant will participate in the cooking activity and sample the food. The program will include lessons on growing crops that have cultural significance to Latino youth such as nopales, beans, corn and squash (the latter three crops are commonly referred to as the three sisters)."
62805589|NCT02291146|NO_INTERVENTION|control|Approximately 200 students in the second region who are enrolled in LA's Best will serve as control participants. After the 12-week intervention is conducted and all post-testing measures are collected on controls, a vegetable/fruit garden will be built at both control schools and the LA Sprouts program will be taught to all 3rd, 4th and 5th graders in LAs Best and their parents at the control school as a delayed intervention.
62805590|NCT05418322|OTHER|Verbal Oral Hygiene Intervention|Each participant will be given oral hygiene instruction verbally by a clinician face to face.
62030268|NCT04695171||Prior Primary Large Hiatal Hernia with Fundoplication|Patients who previously underwent lower esophageal sphincter reconstruction by fundoplication during repair of a hiatal hernia \>3 cm \>2 years prior will be asked to complete a quality of life questionnaire at about 3 years and 5 years post procedure. Each participant will complete a barium swallow at about 3 and 5 years to determine recurrence of hiatal hernia.
62805591|NCT05418322|OTHER|Video-assisted Oral Hygiene Intervention|Each participant will be required to watch a pre-recorded oral hygiene instruction video via a tablet in a separate room away from the clinician
62805592|NCT00646646|ACTIVE_COMPARATOR|propofol|active drug
62228813|NCT01800825|ACTIVE_COMPARATOR|Clindamycin|Clindamycin 300mg orally twice daily for five days
62228814|NCT01800825|PLACEBO_COMPARATOR|placebo|This will be an identical placebot
62228815|NCT04283721|NO_INTERVENTION|No Video|These patients will not see the educational video on epidural/spinal analgesia and will receive the usual Irish standard of care.
62228816|NCT04283721|EXPERIMENTAL|Antenatal Video|These patients will see the educational video on epidural/spinal analgesia only at the antenatal classes.
62421433|NCT01749618|EXPERIMENTAL|Education and Feedback|Rheumatologists randomized to receive education and feedback participate in six web conferences designed to improve their systematic assessments of their patients, and are given feedback about their performances
62421434|NCT03053193||MammaPrint and BluePrint testing|All patients will receive MammaPrint and BluePrint testing using the full-genome testing data chip. Treatment will be at the discretion of the physician while adhering to NCCN guidelines.
62421435|NCT04701476|EXPERIMENTAL|colorectal cancer|metastatic colorectal cancer progressed on at least two lines of chemotherapy
62421436|NCT04701476|EXPERIMENTAL|NSCLC|Liver metastatic NSCLC progressed on immune checkpoint inhibitors and chemotherapy
62421437|NCT05222659||Urologic surgery patients|
62591334|NCT01955772|EXPERIMENTAL|EN (Enteral Nutrition)|"NE group: According to the HAS and SFNEP recommendations and the good practice rules, a polyurethane or silicone NGT, 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months.~PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments."
62805593|NCT00646646|ACTIVE_COMPARATOR|dexmedetomidine|sedative
62805594|NCT00646646|ACTIVE_COMPARATOR|midazolam|Sedative
62805595|NCT00646646|PLACEBO_COMPARATOR|placebo|placebo control
62805596|NCT04164134||Retinoblastoma patients (children)|Children that are currently diagnosed with a retinoblastoma. Blood will be collected and a short questionnaire has to be filled by the parent or legal guardian. Samples will be taken together with standard care blood draw, so no extra venepuncture is required.
62228817|NCT04283721|EXPERIMENTAL|Labour Video|These patients will see the educational video on epidural/spinal analgesia only at the beginning of labour.
62421438|NCT02238886|EXPERIMENTAL|Parenteral nutrition|Patients receives a goal-directed nutritional intervention combining oral intake and parenteral nutrition
62421439|NCT02238886|NO_INTERVENTION|Standard treatment|patients receives a standard nutritional strategy of resting the bowel till clear signs of bowel recovery and feeding orally after bowel recovery
62421440|NCT04569123|ACTIVE_COMPARATOR|Vibration|The device will deliver imperceptible vibration for the treatment group.
62421441|NCT04569123|SHAM_COMPARATOR|No Vibration|The device will deliver no vibration for the control group.
62421442|NCT05683496|EXPERIMENTAL|Cohort 1|Single SC injection of dose 1 of lonigutamab or placebo at Day 1 and Day 21
62228818|NCT04283721|EXPERIMENTAL|Video Twice|These patients will see the educational video on epidural/spinal analgesia twice (during antenatal classes and at the beginning of labour).
62421443|NCT05683496|EXPERIMENTAL|Cohort 2|multiple doses of dose 2 of lonigutamab administered SC injection weekly
62421444|NCT05683496|EXPERIMENTAL|Cohort 3|multiple doses of lonigutamab dose 3 administered SC injection every 4 weeks.
62421445|NCT05683496|EXPERIMENTAL|Cohort 4|multiple doses of lonigutamab dose 4 administered SC injection every 4 or 3 weeks.
62228819|NCT04025086||Study group|"44 patient undergoing spinal surgery in prone position at Gaspare Rodolico Presidium, in which the new Perioperative Goal Directed Therapy protocol has been used"
62228820|NCT04025086||Control group|44 patients who underwent spinal surgery in the period January 2016 - December 2017, in which was not used a Perioperative Goal Directed Therapy approach but a classical hemodynamic monitoring, according to the recommendations of good clinical practice and the international guidelines.
62591335|NCT01955772|OTHER|PN (Parenteral Nutrition)|"NE group: According to the HAS and SFNEP recommendations and the good practice rules, a polyurethane or silicone NGT, 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months.~PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments."
62591336|NCT03884517|EXPERIMENTAL|BAT8003 0.2mg/kg|BAT8003，0.2mg/kg，intravenous infusion, sample size 1-3
62591337|NCT03884517|EXPERIMENTAL|BAT8003 0.5mg/kg|BAT8003，0.5mg/kg，intravenous infusion, sample size 1-3
62591338|NCT03884517|EXPERIMENTAL|BAT8003 1mg/kg|BAT8003，1mg/kg，intravenous infusion, sample size 3
62591339|NCT03884517|EXPERIMENTAL|BAT8003 2mg/kg|BAT8003，2mg/kg，intravenous infusion, sample size 3
62591340|NCT03884517|EXPERIMENTAL|BAT8003 4mg/kg|BAT8003，4mg/kg，intravenous infusion, sample size 3
62591341|NCT03884517|EXPERIMENTAL|BAT8003 6mg/kg|BAT8003，6mg/kg，intravenous infusion, sample size 3
62591342|NCT03884517|EXPERIMENTAL|BAT8003 8mg/kg|BAT8003，8mg/kg，intravenous infusion, sample size 3
62591343|NCT03884517|EXPERIMENTAL|BAT8003 10mg/kg|BAT8003，10mg/kg，intravenous infusion, sample size 3
62591344|NCT03884517|EXPERIMENTAL|Amplification group|BAT8003，intravenous infusion，choose one proper dose from 0.2、0.5、1、2、4、6、8、10mg/kg
62228821|NCT00914264||COPD with OSA with CPAP treatment|COPD with OSA: CPAP treatment
62228822|NCT00914264||COPD without OSA|COPD without OSA, not treat with CPAP
62228823|NCT00914264||COPD with OSA but without CPAP treatment|COPD with OSA but patient refused CPAP treatment
62228824|NCT04927182|EXPERIMENTAL|Moderate Exercise Training (Age Group 1; Young adult 17 -30 years)|
62228825|NCT04927182|EXPERIMENTAL|Moderate Exercise Training (Age Group 2; 31 to 45 years)|
62228826|NCT04927182|EXPERIMENTAL|Moderate Exercise Training (Age Group 3; Above 45 years)|
62421446|NCT00881452|ACTIVE_COMPARATOR|CM-AT|CM-AT (Luminenz-AT)- 900mg CM-AT, pancreatic enzyme concentrate (720mg)
62421447|NCT00881452|PLACEBO_COMPARATOR|Placebo|Placebo 900mg (Sucanate (98% w/w), Citric Acid (2% w/w)
62421448|NCT01158976|EXPERIMENTAL|DHA supplementation|
62421449|NCT01158976|PLACEBO_COMPARATOR|Soybean Oil|
62421450|NCT01325701|EXPERIMENTAL|PCI-32765: 560 mg|Treatment Group 1: Subjects received 560 mg of ibrutinib once daily, on a continuous basis.
62421451|NCT01325701|EXPERIMENTAL|PCI-32765: 840 mg|Treatment Group 2: Subjects received 840 mg of ibrutinib once daily, on a continuous basis.
62421452|NCT02588742|EXPERIMENTAL|melatonin group|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
62421453|NCT02588742|PLACEBO_COMPARATOR|control group|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
62591345|NCT01620775|EXPERIMENTAL|Knee osteoarthritis (MRI, surveys, pain testing)|Subjects previously diagnosed with knee osteoarthritis will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
62591346|NCT01620775|ACTIVE_COMPARATOR|Healthy controls (MRI, surveys,pain testing)|Healthy volunteers will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
62591347|NCT01620775|EXPERIMENTAL|diabetic peripheral neuropathy|Subjects previously diagnosed with diabetic peripheral neuropathy will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
62591348|NCT01620775|EXPERIMENTAL|chronic low back pain|Subjects previously diagnosed with chronic low back pain will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
62591349|NCT02150733|EXPERIMENTAL|Group 1 - Normal hepatic function|Subjects with normal hepatic function
62421454|NCT03413969|EXPERIMENTAL|Behavioral Intervention|The study subjects will be recruited for approximately six weeks prior to the projected start date. The participants will attend the two-day weekend retreat. Follow-up assessments will be administered three months and six months after the retreat. The investigators will analyze the data and complete the study one month after the final assessment is administered.
62228827|NCT03846141|PLACEBO_COMPARATOR|Placebo|Room air for inhalation
62421455|NCT01286207|EXPERIMENTAL|Rizatriptan 5 mg|Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
62805597|NCT04164134||Controls (children)|Children with an unrelated problem/condition for which surgery is needed Blood will be collected and a short questionnaire has to be filled by the parent or legal guardian. Samples will be taken during standard care blood draw, so no extra venepuncture is required.
62228828|NCT03846141|EXPERIMENTAL|Hydrogen|Hydrogen (4%) for inhalation
62228829|NCT04895683|ACTIVE_COMPARATOR|Arm 1 - Control SMS|Control (current practice) text message invitation
62228830|NCT04895683|EXPERIMENTAL|Arm 2 - Behavioural Science informed SMS content|Experimental text message invitation
62228831|NCT04895683|EXPERIMENTAL|Arm 3 - Pre-alert and behavioural science informed SMS content|Two text messages, including a pre-alert SMS and the text message intervention in trial arm 2.
62228832|NCT05822778|EXPERIMENTAL|Formaderm(FD) group|Formaderm was randomly administered either side of subjects' facial areas once. The injection volume was limited to 2c.c.
62228833|NCT05822778|ACTIVE_COMPARATOR|control group|"As a self-controlled study, Q-MED RESTYLANE would be administered on the other side after injected Formaderm. The injection volume was limited to 2c.c."
62228834|NCT05319275|EXPERIMENTAL|Acetyllevocarnitine Hydrochloride Tablets|
62228835|NCT05319275|PLACEBO_COMPARATOR|Placebo|
62228836|NCT02645188|EXPERIMENTAL|Experimental|Cueing
62421456|NCT01286207|EXPERIMENTAL|Rizatriptan 10 mg|Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
62805598|NCT04164134||Retinoblastoma survivors (adults)|"Adults that carry a RB1 germline mutation and were diagnosed and treated for retinoblastoma in the past.~Blood will be collected and a short questionnaire has to be filled."
62421457|NCT01286207|ACTIVE_COMPARATOR|Standard Care|Standard care at onset of migraine attack
62421458|NCT05605184||Survey|Breast cancer patients complete questionnaire concerning their use of medical apps.
62421459|NCT01818414|EXPERIMENTAL|Misoprostol|Misoprostol 400 mcg buccal 3 hours prior to D\&E as an adjunct to same-day Dilapan-S.
62421460|NCT01818414|PLACEBO_COMPARATOR|Folic Acid|Folic acid 4 mg buccally 3 hours prior to D\&E as an adjunct to same-day Dilapan-S
62421461|NCT04389593||Single arm|This is a single arm study in which all participants have one MRI
62805599|NCT04164134||Controls (adults)|Healthy adult controls Blood will be collected and a short questionnaire has to be filled.
62805600|NCT04164134||Retinoblastoma survivors with Secondary primary malignancies|"Adults that carry a RB1 germline mutation, were treated for retinoblastoma in the past, and are currently diagnosed with a secondary primary malignancy.~Blood will be collected and a short questionnaire has to be filled. Tumor tissue will be collected during surgery."
62228837|NCT02645188|NO_INTERVENTION|Control|
62228838|NCT00421044|EXPERIMENTAL|Arm A (Normal liver function)|
62228839|NCT00421044|EXPERIMENTAL|Arm B (Mild liver dysfunction)|
62228840|NCT00421044|EXPERIMENTAL|Arm C (Moderate liver dysfunction)|
62228841|NCT04553250|ACTIVE_COMPARATOR|Conventional technique|"In this group, double-staple colorectal anastomosis will be performed following the technique described by Lee et al: Prior to firing the endostapler, a suture will be placed on the rectal stump that includes both dog ears. After the punch comes out of the endostapler, the point will be tied, which will invaginate the two corners of the staple line on the same punch. Subsequently, the endostapler will be closed and fired, including the dog ears in the anastomotic rims"
62228842|NCT04553250|ACTIVE_COMPARATOR|Lateral invagination technique|In this group, the circular endostapler will be fired in a conventional way, that is, without having invaginated the two corners of the staple line.
62228843|NCT06093854|EXPERIMENTAL|Decompression surgery + IORT|Decompression surgery + IORT (15-20 Gy, 20-50min）
62228844|NCT06093854|ACTIVE_COMPARATOR|Decompression surgery + postoperative SBRT|Decompression surgery + postoperative SBRT (30Gy, 5 fractions, 3 weeks)
62228845|NCT04721535|EXPERIMENTAL|DWJ1248|Camostat mesilate 200mg
62228846|NCT04721535|PLACEBO_COMPARATOR|Placebo|Placebo
62228847|NCT05584267|ACTIVE_COMPARATOR|cohort A|Chemotherapy + immunotherapy; Every three weeks, up to four cycles of chemotherapy
62228848|NCT05584267|EXPERIMENTAL|cohort B|Chemotherapy + immunotherapy; Once every three weeks, up to 4 cycles of chemotherapy; WBRT, 3 Gy/ time, 10 times in total
62228849|NCT05584267|EXPERIMENTAL|cohort C|Chemotherapy + immunotherapy; Once every three weeks, up to 4 cycles of chemotherapy; HFRT, 10 Gy/ time, 3 times in total
62228850|NCT04822974|EXPERIMENTAL|STUDY ARM|blood samples collection
62228851|NCT06463925|OTHER|acneic participants group|subjects with mild to moderate facial and truncal acne
62228852|NCT03013582|EXPERIMENTAL|Amnion wrapping + Tenolysis|Standard surgical tenolysis + wrapping of the released tendon with amnion.
62228853|NCT03013582|PLACEBO_COMPARATOR|Tenolysis control|Standard surgical tenolysis alone
62228854|NCT02679131|EXPERIMENTAL|Cohort A|Normal Renal function, Belinostat IV, Dose A
62228855|NCT02679131|EXPERIMENTAL|Cohort B|Mild Impairment, Belinostat IV, Dose A
62228856|NCT02679131|EXPERIMENTAL|Cohort C|Moderate Impairment, Belinostat IV, Dose B
62228857|NCT02679131|EXPERIMENTAL|Cohort D|Severe Impairment, Belinostat IV, Dose B
62228858|NCT03931031||Cardiac Surgery Patients|Patients taking antiplatelet medication who are scheduled for elective cardiac surgery.
62421462|NCT06621251|EXPERIMENTAL|TRL1068 + DAIR|TRL1068 will be administered at 15 mg/kg IV on Day 1 and subsequently at 7.5 mg/kg on Days 15, 29, and 43. Between Day 15-22, a DAIR procedure will be completed.
62591350|NCT02150733|EXPERIMENTAL|Group 2 - Mild hepatic impairment|Subjects with mild hepatic impairment by Child-Pugh classification scores
62030269|NCT03992755|EXPERIMENTAL|LIQ861 Inhaled Treprostinil|LIQ861 inhaled treprostinil at capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg. LIQ861 will be administered using the RS00 Model 8 dry powder inhalation (DPI) device (Plastiape S.p.A.; Osnago, Italy) at dose levels of 25 μg capsule strength to 200 μg capsule strength treprostinil four times a day (QID) in individual patients. Titrating to dose levels beyond 200 μg capsule strength QID, under clinical investigator supervision, requires review and approval from the Medical Monitor.
62030270|NCT01059760|OTHER|Fasting Day First|28±4 hours of water-only fasting followed by 28±4 hours fed
62030271|NCT01059760|OTHER|Fed Day First|28± 4 hours fed followed by 28± 4 hours of fasting
62805601|NCT05549817|EXPERIMENTAL|Synchronous Telerehabilitation Group|The exercise program was applied to groups that include three participants of the synchronous group 3 days per week by video conference method on an online platform (Zoom) with the supervision of a physiotherapist. The time of the group session was organized according to the availability of participants in that group and the physiotherapist using shared calendar availability (Doodle). The physiotherapist sent a reminder to participants one hour prior to each session including the video conference meeting link. Each exercise session lasted approximately 40 minutes. For 8 weeks, a total of 24 exercise sessions were performed. The physiotherapist demonstrated the exercises as needed, supervised the group by giving real-time feedback, and progressed the exercise program according to the needs of each group.
62591351|NCT02150733|EXPERIMENTAL|Group 3 - Moderate hepatic impairment|Subjects with moderate hepatic impairment by Child-Pugh classification scores
62591352|NCT02150733|EXPERIMENTAL|Group 4 - Severe hepatic impairment|Subjects with severe hepatic impairment by Child-Pugh classification scores
62030272|NCT06609239|EXPERIMENTAL|Lunsekimig|Participants will receive a subcutaneous injection of lunsekimig according to established dosing interval
62030273|NCT05593835|EXPERIMENTAL|METHIS Intervention|The METHIS intervention will consist of two components. The first component is a Goal-Oriented Care (GOC) Training Program for health professionals. The training program will include the concept of personalised care, methods of goal elation, implications of GOC in healthcare practice, and how METHIS platform can be used to support the application of GOC. The training will be implemented through a blended-learning, continuous education program that will be credited by Nova University of Lisbon. The second component is a GOC information system. This will be the digital platform METHIS, which will be designed to nudge clinicians to adopt a GOC and to encourage patients and caregivers to take an active role in healthcare. The investigators will adapt an existing platform that was developed for a pilot study during the COVID-19 pandemic, that promotes care coordination, optimises disease prioritisation, and patient self-management.
62030274|NCT05593835|NO_INTERVENTION|Control|"The control group in this trial will be the best usual care, using the standard Electronic Health Records available to the practice. Our understanding of what best usual care is for people with multimorbidity is informed by qualitative research in an earlier stage of this project. Our results suggest that healthcare professionals often provide disease-driven care. When faced with multiple healthcare problems, they prioritise based on 1) patient complaints; 2) which condition is less well controlled; or 3) which condition is more likely to adversely impact on patient Health Related-Quality of life. General practitioners and primary care nurses are often not familiar with the Goal-Oriented Care model. However, they already try to implement some of its principles such as identifying patient goals and supporting shared decision making."
62030275|NCT04189562|EXPERIMENTAL|SMS Intervention|All parents of participants will receive customized text messages once a day, Sunday through Friday, for a duration of 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
62030276|NCT04479150||Pandemic Covid-positive cohort|All Covid-positive patients operated on for emergency digestive pathology from March, 1st 2020 to June, 30th 2020
62030277|NCT04479150||Pandemic Covid-negative cohort|All Covid-negative patients operated on for emergency digestive pathology from March, 1st 2020 to June, 30th 2020
62030278|NCT04479150||Control cohort|Pre-pandemic cohort: all patients operated on for emergency digestive pathology from March, 1st 2020 to June, 30th 2019.
62030279|NCT02721238|ACTIVE_COMPARATOR|Resuscitation with 30ml/kg plasmalyte|
62030280|NCT02721238|EXPERIMENTAL|Resuscitation with 20% Albumin|
62030281|NCT01319448|ACTIVE_COMPARATOR|Daily proguanil|Standard policy of a supply of proguanil tablets to be taken daily
62591353|NCT02989779|EXPERIMENTAL|Active/Placebo crossover|NK1 Antagonist 7 days followed by placebo 7 days.
62591354|NCT02989779|ACTIVE_COMPARATOR|Placebo/Active Crossover|Placebo for 7 days followed by NK1 Antagonist 7 days.
62228859|NCT02074553|EXPERIMENTAL|Ro542-4802/F03;Ro542-4802/F07;Ro542-4802/F14;Ro542-4802/F08|Participants will receive Ro542-4802/F03 (containing 50% SLS) capsules orally on Day 1 of first intervention period; then Ro542-4802/F07 (containing 25% SLS) capsules orally on Day 1 of second intervention period; then Ro542-4802/F14 (containing 12.5% SLS) capsules orally on Day 1 of third intervention period; followed by Ro542-4802/F08 (containing 3% SLS) capsules orally on Day 1 of fourth intervention period during both fasted (Part 1) and fed (Part 2) conditions. A washout period of at least 10 days will be maintained between each period.
62421463|NCT06621251|NO_INTERVENTION|SoC|Standard of Care arm, receiving 2-stage surgery as is SoC for PJI. Reduced assessments will be done at the same timepoints as the experimental arm.
62591355|NCT06625307|EXPERIMENTAL|NNC0537-1482 Dose level 1|Participants will be administered a single dose of dose level 1 of NNC0537-1482 subcutaneously.
62591356|NCT06625307|EXPERIMENTAL|NNC0537-1482 Dose level 2|Participants will be administered a single dose of dose level 2 of NNC0537-1482 subcutaneously.
62591357|NCT06625307|EXPERIMENTAL|NNC0537-1482 Dose level 3|Participants will be administered a single dose of dose level 3 of NNC0537-1482 subcutaneously.
62591358|NCT06625307|EXPERIMENTAL|NNC0537-1482 Dose level 4|Participants will be administered a single dose of dose level 4 of NNC0537-1482 subcutaneously.
62228860|NCT02074553|EXPERIMENTAL|Ro542-4802/F07;Ro542-4802/F08;Ro542-4802/F03;Ro542-4802/F14|Participants will receive Ro542-4802/F07 (containing 25% SLS) capsules orally on Day 1 of first intervention period; then Ro542-4802/F08 (containing 3% SLS capsules orally on Day 1 in second intervention period; then Ro542-4802/F03 (containing 50% SLS) (containing 12.5% SLS) capsules orally on Day 1 of third intervention period; followed by Ro542-4802/F14 (containing 12.5% SLS) capsules orally on Day 1 of the fourth intervention period during both fasted (Part 1) and fed (Part 2) conditions. A washout period of at least 10 days will be maintained between each period.
62228861|NCT02074553|EXPERIMENTAL|Ro542-4802/F08;Ro542-4802/F14;Ro542-4802/F07;Ro542-4802/F03|Participants will receive Ro542-4802/F08 (containing 3% SLS) capsules orally on Day 1 of first intervention period; then Ro542-4802/F14 (containing 12.5% SLS) capsules orally on Day 1 in second intervention period; then Ro542-4802/F07 (containing 25% SLS) capsules orally on Day 1 of third intervention period; followed by Ro542-4802/F03 (containing 50% SLS) capsules orally on Day 1 of the fourth intervention period during both fasted (Part 1) and fed (Part 2) conditions. A washout period of at least 10 days will be maintained between each period.
62421464|NCT05563584|NO_INTERVENTION|Usual Care|Patients will continue Usual Care, which will include aspirin, a statin and routine lifestyle advice
62805602|NCT05549817|ACTIVE_COMPARATOR|Asynchronous Telerehabilitation Group|The exercise program was prescribed and followed up 3 days per week via the mobile application (FizyoTr). A notification was sent to participants' phones via mobile application prior to each session and attendance to the exercise program was recorded. For 8 weeks, a total of 24 exercise sessions were performed. The physiotherapist progressed the exercise program according to the assessment at 4 weeks and the needs of each participant.
62421465|NCT05563584|EXPERIMENTAL|Super Rehab plus Usual Care|12-month Super Rehab programme plus Usual Care
62421466|NCT04583631||Chronic adenoiditis|Patients with hypertrophy and those out of hypertrophy were determined and those who had purulant rhinorrhea signs and rate of adenoids-choana below 50% were categorized that chronic adenoiditis.
62421467|NCT04583631||Adenoid hypertrophy|Patients who have snoring and those whose adenoid choana rate is greater than 50% were categorized that adenoid hypertrophy group.
62421468|NCT03456843|EXPERIMENTAL|Arm I (ADT, docetaxel)|Participants receive antiandrogen therapy with or without docetaxel at the discretion of the treating physician.
62421469|NCT03456843|EXPERIMENTAL|Arm II (ADT, radical prostatectomy, docetaxel)|Participants receive antiandrogen therapy for at least 1 month, then undergo cytoreductive radical prostatectomy. Participants continue antiandrogen therapy and may receive docetaxel prior to surgery at the discretion of the treating physician.
62421470|NCT00752401|ACTIVE_COMPARATOR|1|6800 IU/day of Cholecalciferol (Vitamin D3) orally for one year
62421471|NCT00752401|PLACEBO_COMPARATOR|2|Oral placebo solution daily for one year
62805603|NCT04809012|EXPERIMENTAL|STI-3031|20 mg/kg STI-3031 administered intravenously Q2W
62805604|NCT03089021|EXPERIMENTAL|mulligan mobilization|mobilization for spinous process or facet with neck movement 10 repetetions for 3 times.
62805605|NCT03089021|EXPERIMENTAL|maitland mobilization|maitland mobilization for spinous process or facet joint for 2 min and repeated 3 times.
62805606|NCT03291938|EXPERIMENTAL|Treatment (oxidative phosphorylation inhibitor IACS-010759)|"INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7 of cycle 1 in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 8 and 15 of cycle 1 and then on days 1, 8, and 15 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
62805607|NCT05976516||pirffmann 2 grade|
62805608|NCT05976516||pirffmann 3 grade|
62805609|NCT05976516||pirffmann 4 grade|
62805610|NCT05976516||pirffmann 5 grade|
62805611|NCT06401369|EXPERIMENTAL|The lingual fixed orthodontic group (LA)|"This group received treatment with lingual brackets with 0.018-inch slots (DTC Orthodontics, Hangzhou, China) applied with the aid of a special, indirect bonding technique, the Modified HIRO® Technique. Individual lingual archwires (Forestadent®, Germany) were also used."
62591359|NCT06625307|EXPERIMENTAL|NNC0537-1482 Dose level 5|Participants will be administered a single dose of dose level 5 of NNC0537-1482 subcutaneously.
62591360|NCT06625307|EXPERIMENTAL|NNC0537-1482 Dose level 6|Participants will be administered a single dose of dose level 6 of NNC0537-1482 subcutaneously.
62591361|NCT06625307|PLACEBO_COMPARATOR|Placebo|Participants will be administered a single dose of Placebo matched to NNC0537-1482 subcutaneously
62591362|NCT04498689|EXPERIMENTAL|camrelizumab + nab-paclitaxel + gemcitabine|PD-1 Monoclonal Antibody Camrelizumab at 200 mg on Day 1 and 15 nab-paclitaxel at 100 mg/m2 on Day 1, 8, and 15; gemcitabine at 1000 mg/m2 on Day 1, 8, and 15
62805612|NCT06401369|ACTIVE_COMPARATOR|The labial fixed orthodontic group (BA)|Patients in this group received treatment with labial appliances with 0.018-inch slots (American Orthodontics brackets, Mini Master series, MBT prescription) directly bonded on both arches. Prefabricated archwires (American Orthodontics, Sheboygan, WI, USA) were also used.
62421472|NCT00535301|PLACEBO_COMPARATOR|Anterior Colporrhaphy (sutured repair)|Anterior vaginal prolapse repair with anterior colporrhaphy (no graft) using sutures.
62421473|NCT00535301|ACTIVE_COMPARATOR|Perigee (grafted repair)|Anterior vaginal prolapse repair with graft
62421474|NCT00874757||Rosuvastatin|Healthy subjects received rosuvastatin 20 mg orally for 3 weeks. Inflammatory markers measured pre and post rosuvastatin treatment.
62421475|NCT06568133|EXPERIMENTAL|Treatment A|UIC201603 and co-administration of UIC201603 and UIC201604
62421476|NCT06568133|EXPERIMENTAL|Treatment B|UIC201604 and co-administration of UIC201603 and UIC201604
62421477|NCT01980082|ACTIVE_COMPARATOR|Cefazolin|"Cefazolin~1 gram/2 gram if body mass index \> 40 - one time dose, 30-60 min prior to incision."
62421478|NCT01980082|PLACEBO_COMPARATOR|Placebo|1 dose of placebo - NaCl 0.9% with no drugs added to it.
62421479|NCT02343822|EXPERIMENTAL|Multiple PRP Injection|2 PRP Injections 2 months apart
62805613|NCT03947710|EXPERIMENTAL|High-protein meals|Patients with End Stage Renal disease on maintenance hemodialysis will consume high protein meals during their dialysis sessions for one week.
62805614|NCT03947710|EXPERIMENTAL|Low-protein meals|Patients with End Stage Renal disease on maintenance hemodialysis will consume low protein meals during their dialysis sessions for one week
62805615|NCT03947710|EXPERIMENTAL|No meals|Patients with End Stage Renal disease on maintenance hemodialysis will not consume meals during their dialysis sessions for one week
62030282|NCT01319448|EXPERIMENTAL|IPT with MQ+AS bimonthly|Intermittent Preventive Treatment (IPT) consisting of a bimonthly course of treatment with mefloquine-artesunate (MQ+AS)
62805616|NCT01894607|EXPERIMENTAL|Contrast Enhanced Intraoperative Ultrasound|"During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier.~Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having."
62228862|NCT02074553|EXPERIMENTAL|Ro542-4802/F14;Ro542-4802/F03;Ro542-4802/F08;Ro542-4802/F07|Participants will receive Ro542-4802/F14 (containing 12.5% SLS) capsules orally on Day 1 of first intervention period; then Ro542-4802/F03 (containing 50% SLS) capsules orally on Day 1 in second intervention period; then Ro542-4802/F08 (containing 3% SLS) capsules orally on Day 1 of third intervention period; followed by Ro542-4802/F07 (containing 25% SLS) capsules orally on Day 1 of the fourth intervention period during both fasted (Part 1) and fed (Part 2) conditions. A washout period of at least 10 days will be maintained between each period.
62805617|NCT03395483||Elective, adult colorectal surgical patients|All patients will be monitored by the non-invasive Masimo Radical7 pulseoximeter (Masimo, Irvine, CA, USA) measuring PPI and the MoorVMS-LDF (Moor Instruments Ldt., Axminster, UK) measuring mesenteric tissue blood flow using doppler flowmetry. Patients will be subjected to a haemodynamic challenge using anti-trendelenburg position.
62228863|NCT05552885||Stroke patients|General cognitive level will be evaluated with the Standardized Mini Mental Test to determine the eligibility of the participants for the study. The American National Institutes of Health Stroke Scale will be applied to determine the stroke severity and functional status of the participants. The reliability and validity of the eight-shape gait test and the double-task octagonal gait test will be examined. The reliability of the tests will be evaluated by calculating the test-retest method, standard error measurement and minimum detectable change values. The initial test and retest will be evaluated two days apart. The concurrent validity of the tests will be evaluated by the correlation between the timed get-and-go test, the 10-meter walk test, and the modified four-square step test.
62228864|NCT00448279|ACTIVE_COMPARATOR|Chemotherapy Alone|Chemotherapy, schedule and dose at the investigator's discretion.
62228865|NCT00448279|EXPERIMENTAL|Chemotherapy, Trastuzumab|Trastuzumab, at the investigator's discretion, either 2 milligrams per kilogram (mg/kg) intravenous (i.v.) every 7 days or 6 mg/kg i.v. every 3 weeks. Chemotherapy, schedule and dose at the investigator's discretion.
62228866|NCT02767128|EXPERIMENTAL|Fer-In-Sol Orally|Patients will receive A single oral dose of Fer-In-Sol at 3 mg Fe/kg body weight (bw).
62228867|NCT02767128|EXPERIMENTAL|Shohl's solution followed by Fer-In-Sol Orally|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7ml/kg bw) followed after 10 minutes by Fer-In-Sol at 3 mg Fe/kg bw.
62228868|NCT02767128|EXPERIMENTAL|Triferic Orally|Patients will receive a single oral dose of Triferic at 3 mg Fe/kg bw.
62228869|NCT02767128|EXPERIMENTAL|Shohl's solution followed by Triferic Orally|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7 ml/kg bw) administered 10 minutes prior to a single oral dose of Triferic at 3 mg Fe/kg bw.
62228870|NCT02767128|EXPERIMENTAL|Shohl's solution followed immediately by Triferic|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7 ml/kg bw) followed immediately by a single oral dose of Triferic at 3 mg Fe/kg bw.
62805618|NCT02090426|NO_INTERVENTION|Standard Care|Individuals in the standard care arm receive standard discharge planning from the hospital with no followup by Link2Care team members.
62805619|NCT02090426|EXPERIMENTAL|Link2Care|Participants are assigned to a multidisciplinary care team (Link2Care) comprised of a registered nurse, licensed practical nurse, social worker, intervention specialist, community health worker, and health coaches. A representative from the care team engages with the patient at bedside during the hospital admission and plans for the immediate period following discharge. The Program, as a whole, involves a series of home visits, scheduling of and accompaniment to initial primary care and specialty care visits, and support for individuals as they navigate various social service agencies to enroll in public programs including TANF, SNAP, and programs that promote housing stability.
62228871|NCT02767128|EXPERIMENTAL|Triferic via IV|Patients will receive IV Triferic iron 6.6 mg diluted in an appropriate amount of D5W administered as a 120 mL infusion intravenously for 4 hours.
62228872|NCT02767128|NO_INTERVENTION|Baseline|baseline serum iron profile will be determined for each patient. no study drug will be administered.
62228873|NCT00277706|EXPERIMENTAL|FORTEO|
62228874|NCT00277706|PLACEBO_COMPARATOR|Placebo|
62228875|NCT00658099||A|
62228876|NCT00658099||B|
62228877|NCT02294227|EXPERIMENTAL|Secukinumab 150 mg|Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
62228878|NCT02294227|EXPERIMENTAL|Secukinumab 150 mg No load|Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
62030283|NCT01319448|EXPERIMENTAL|IPT with SP+AQ bimonthly|IPT with bimonthly course of treatment with sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ)
62030284|NCT06634992||Group 1|Allergy to hazelnut, walnut, pistachio, cashew or peanut
62030285|NCT06634992||Group 2|Allergy to cow's milk, wheat or egg
62591363|NCT06617819|EXPERIMENTAL|experimental group|CR prosthesis for the left knee
62591364|NCT06617819|ACTIVE_COMPARATOR|control group|PS prosthesis for the left knee
62591365|NCT01128101|EXPERIMENTAL|Spironolactone|The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
62805620|NCT01788566|EXPERIMENTAL|Gemcitabine + Cisplatin + Necitumumab|"Necitumumab administered intravenously (IV) 800 milligram (mg) on Days 1 and 8 of each 3-week cycle.~Gemcitabine administered IV at 1250 milligram per square meter (mg/m\^2) on Days 1 and 8 of each 3 week cycle for a maximum of 6 cycles.~Cisplatin administered IV at 75 mg/m\^2 on Day 1 of each 3 week cycle for a maximum of 6 cycles."
62805621|NCT01068522|EXPERIMENTAL|ICP monitoring|Care based upon intracranial pressure.
62805622|NCT01068522|ACTIVE_COMPARATOR|Usual Care|Treatment based on clinical and imaging without intracranial pressure monitoring.
62805623|NCT01250106|EXPERIMENTAL|Probiotic capsule|
62030286|NCT06634992||Group 3|Allergy to unusual foods: sesame, celery, fenugreek, peas, lentils or others
62228879|NCT02294227|PLACEBO_COMPARATOR|Placebo|Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
62228880|NCT02325557|EXPERIMENTAL|Part A: ADXS31-142|"Participants received ADXS31-142 1 × 10\^9 colony-forming units (CFU), 5 × 10\^9 CFU, or~1 × 10\^10 CFU intravenously (IV) every 3 weeks (Q3W) in a 12-week cycle for up to 24 months or until disease progression or discontinuation."
62421480|NCT02343822|EXPERIMENTAL|Single PRP Injection|1 PRP Injection and Saline Injection 2 months apart
62421481|NCT02343822|ACTIVE_COMPARATOR|Saline Injection|2 Saline Injections 2 months apart
62421482|NCT05895214||patients who received primary surgery|preoperative CT scans available for assessing resectability criteria and presumed mesopancreatic infiltration status (CT scans are centrally evaluated) UICC 8th edition staging including CRM Tumor size in mm measured twice perpendicular Age Sex CA 19-9 values (preoperative) ECOG status BMI Type of PD (tail preserved vs total PD) simultaneous vessel resection (complete, partial; combined arterial and venous)
62591366|NCT02857400|OTHER|Arm A (standard)|
62591367|NCT02857400|EXPERIMENTAL|Arm B (experimental)|
62591368|NCT03837366|EXPERIMENTAL|Activity Tracker with Health Coaching|Participants assigned to this condition will receive a Fitbit activity tracker to use for 3 months. Also, they will be asked to come in for a visit approximately one week following baseline assessments. Using the principles of Motivational Interviewing and Habit Formation, participants will discuss their perceived benefits and barriers of becoming more physically active with a member of the research team. They will also be encouraged to set a goal related to using their Fitbit to increase their physical activity. Lastly, they will be given information regarding habit formation and encouraged to identify one or more cues that regularly occur in their daily life to check their Fitbit data as a prompt to engage in physical activity.
62421483|NCT05895214||patients who received neoadjuvant treatment prior to surgery|Peri-therapeutic CT scans available for assessing resectability criteria and presumed mesopancreatic infiltration status (CT scans are centrally evaluated) UICC 8th edition staging including CRM Tumor size in mm measured twice perpendicular Age Sex CA 19-9 values (peri-therapeutic) ECOG status BMI Type of neoadjuvant Therapy Type of PD (tail preserved vs total PD), simultaneous vessel resection (complete, partial; combined arterial and venous) Tumor response according to CAP
62591369|NCT03837366|ACTIVE_COMPARATOR|Activity Tracker alone|Participants assigned to this condition will use their Fitbit on their own for the duration of 3- month intervention, similar to the experience of participants buying the device off-the-shelf.
62421484|NCT05451134||patients with dysglycemia|Patients with dysglycemia in the included subjects with pheochromocytoma and paraganglioma
62421485|NCT05451134||patients without dysglycemia|Patients without dysglycemia in the included subjects with pheochromocytoma and paraganglioma
62591370|NCT04368039|EXPERIMENTAL|Normobaric Oxygen Therapy (40% FiO2)|4 weeks of nightly normobaric oxygen therapy (40% FiO2)
62591371|NCT04368039|PLACEBO_COMPARATOR|Placebo Condition|4 weeks of a placebo condition utilizing room air oxygen levels (21% FiO2)
62591372|NCT06069349|PLACEBO_COMPARATOR|usual treatment|
62591373|NCT06069349|EXPERIMENTAL|Early mobilization|early mobilization in the ICU
62591374|NCT00451893|ACTIVE_COMPARATOR|Heavy-weight|Lichtenstein operation performed with a heavy-weight mesh.
62591375|NCT00451893|ACTIVE_COMPARATOR|Light-weight|Lichtenstein operation performed with a light-weight mesh.
62591376|NCT02989649||Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)|Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first.
62591377|NCT00368784||1|Individuals ages 12-85 with an immune mediated skin disease, such as psoriasis, scleroderma, or mycosis fungoides. Peripheral blood and/or check swabs will be collected from participants ages 12- 85 years old. These samples will then be used to characterize the inflammatory cells as described above.
62805624|NCT01250106|PLACEBO_COMPARATOR|placebo capsule|
62805625|NCT03016572|EXPERIMENTAL|Enhanced Treatment As Usual (E-TAU)|The patient will be referred for regular (Standard of Care) outpatient psychiatry/ psychology services or continue with the services that they were receiving prior to admission. They will be followed up by calling patient families at 3 months (post their initial appointment) and at 12 months. They will also have 1 research visit at 6 months (with Dr. Falcone), which they will schedule during their 3 month follow-up call; the Suicide Ideation Questionnaire (SIQ) will be administered. The patients assigned to this group will also be receiving 10 caring follow-up post cards at the following weeks and months (post-discharge from the inpatient unit): 2 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 5 months, 7 months, 9 months, 12 months, and on the patient's birthday.
62591378|NCT00368784||2|Age-Matched Controls without immune mediated skin diseases. Peripheral blood and/or check swabs will be collected from participants ages 12- 85 years old. These samples will then be used to characterize the inflammatory cells as described above.
62591379|NCT04081090|EXPERIMENTAL|Brain HQ adaptive Cognitive Therapy Modules|Brain HQ licensed modules that adapt to each individuals unique strengths and weaknesses to address deficits and improve neuroplasticity.
62591380|NCT04081090|ACTIVE_COMPARATOR|Brain HQ Active Control Modules|Participants in this arm will complete puzzles such as crossword puzzles, Sudoku, etc.
62591381|NCT06228768|OTHER|Acupressure Arm 1|There are 5 acupoints with 4 of the acupoints performed on both the left and right sides of the body. Each of the 9 acupoints will be stimulated for 3 minutes per point with the AcuWand giving a total treatment time of 27 minutes daily. The relaxation acupoints are unlisted in order to maintain blinding.
62591382|NCT06228768|OTHER|Acupressure Arm 2|There are 5 acupoints with 4 of the acupoints performed on both the left and right sides of the body. Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes daily. The acupoints are unlisted in order to maintain blinding.
62591383|NCT05369208|OTHER|Avatrombopag|Avatrombopag 20 mg oral tablet
62591384|NCT01355198|EXPERIMENTAL|Cysteine/glycine|Subjects will be studied before and after receiving oral cysteine (as n-acetylcysteine) and glycine for 2 weeks
62591385|NCT06259903|EXPERIMENTAL|40 milligram (mg) MD-18 OR 40 milligram(mg) Placebo|A single dose of subcutaneous injection of 40mg MD-18 OR 40mg Placebo will be given on day zero.
62591386|NCT06259903|EXPERIMENTAL|80 milligram (mg) MD-18 OR 80 milligram (mg) Placebo|A single dose of subcutaneous injection of 80mg MD-18 OR 80mg Placebo will be given on day zero.
62805626|NCT03016572|EXPERIMENTAL|TAU + Crisis Center (CC) Follow Up|Frontline Services will be administering (at least 9) crisis intervention phone calls to the patients; more calls will be made if they feel it is necessary for the safety and health of the patient. Follow up calls will ask the patient questions about following up in the future, whether they have had thoughts about suicide, whether they are in imminent danger of suicide by the end of the call, and whether the patient is stable. At the end of the call, the patient will be asked to rate their suicidality on a scale of 1 to 10.
62421486|NCT04862052|ACTIVE_COMPARATOR|Xience chromium-cobalt everolimus eluting stent|The Xience chromium-cobalt everolimus eluting stent will be evaluated in prior implanted coronary drug eluting stent restenosis.
62421487|NCT04862052|EXPERIMENTAL|Emperor paclitaxel coated balloon|The Emperor paclitaxel coated balloon will be evaluated in prior implanted coronary drug eluting stent restenosis.
62421488|NCT04862052|EXPERIMENTAL|Magic Touch sirolimus coated balloon|The Magic Touch sirolimus coated balloon will be evaluated in prior implanted coronary drug eluting stent restenosis.
62421489|NCT02885974|EXPERIMENTAL|Celecoxib plus Gemcitabine/Cisplatin chemo|Celecoxib plus Gemcitabine/Cisplatin neoadjuvant chemotherapy
62591387|NCT06259903|EXPERIMENTAL|160 milligram (mg) MD-18 OR 160 milligram (mg) Placebo|A single dose of subcutaneous injection of 160mg MD-18 OR 160mg Placebo will be given on day zero.
62591388|NCT06259903|EXPERIMENTAL|240 milligram (mg) MD-18 OR 240 milligram (mg) Placebo|A single dose of subcutaneous injection of 240mg MD-18 OR 240mg Placebo will be given on day zero.
62591389|NCT06259903|EXPERIMENTAL|320 milligram (mg)MD-18 OR 320 milligram (mg) Placebo|A single dose of subcutaneous injection of 320mg MD-18 OR 320mg Placebo will be given on day zero.
62735376|NCT06139614|EXPERIMENTAL|Assistant Residents|At baseline, all participants will complete questionnaires related personal resilience, including professional fulfillment (professional fulfillment, work exhaustion, interpersonal disengagement), depression symptoms, anxiety, symptoms, self-valuation, flourishing, and psychosocial working conditions. At post-treatment (end of session 8), participants will complete the baseline questionnaires (with the exception of psychosocial working conditions), as well as a questionnaire assessing acceptability of the group experience and content. The post-treatment questionnaires will be repeated as a 3-month follow-up.
62735377|NCT00849355|EXPERIMENTAL|unique|RCOMP-14 with Rituximab
62735378|NCT01822899|EXPERIMENTAL|Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS|Subjects will receive UMEC/ VI 62.5/25 mcg, one inhalation administered once-daily in the morning via the NDPI and one placebo ACCUHALER/DISKUS administered as one inhalation each morning and evening.
62735379|NCT01822899|ACTIVE_COMPARATOR|Fluticasone propionate/Salmeterol + placebo NDPI|Subjects will receive FSC 500/50 mcg, administered as one inhalation each morning and evening via ACCUHALER/DISKUS + placebo administered once daily in the morning via NDPI.
62735380|NCT01769664|EXPERIMENTAL|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.)
62735381|NCT01769664|ACTIVE_COMPARATOR|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel)
62735382|NCT01769664|PLACEBO_COMPARATOR|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.)
62735383|NCT03777254|EXPERIMENTAL|RC28-E|"·Experimental:RC28-E 0.25mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E~* Experimental: RC28-E 0.5mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E~* Experimental: RC28-E 1.0mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E~* Experimental: RC28-E 2.0mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E"
62421490|NCT04621097|EXPERIMENTAL|pulsed electro magnetic field|30 patients will receive the physical therapy program in form of low frequency pulsed electro magnetic field application. with frequency 15hz, and low intensity with flux density of 20 Gauss (2mT), in pulse duration 200 usec , pulsed rectangular pulses for 60 min is applied to the dorsal surface of lower leg , ankle and foot in addition to their regular medications prescribed , 3 times per week for 8 week
62591390|NCT05628038|EXPERIMENTAL|Treatment arm|"The enrolled patients will receive 25-40Gy/5Fx irradiation or 15-30Gy/5Fx reirradiation (pelvic radiation history) for pelvic recurrence.~Cohort A patients will receive CAPOX, FOLFIRI or mFOLFOX6 chemotherapy andcohort B patients will receive CAPOX, FOLFIRI, mFOLFOX6, mXELIRI, irinotecan and raltitrexed, or oxaliplatin and raltitrexed chemotherapy, based on previous chemotherapy and adverse reactions to chemotherapy agents or at the discretion of the oncologist.~All metastasis sites will receive stereotactic ablative radiotherapy (SABR) between chemoimmunotherapy cycles. Five-fraction regimens (25-50Gy/5Fx) are delivered daily. Dose Constraints are based on SABR-COMET 10 trial.~Besides, according to the medical oncologist recommendation, patients with unresectable pelvic recurrence or distant metastasis will receive target therapy based on the KRAS/NRAS/BRAF mutation station."
62591391|NCT02058784|EXPERIMENTAL|Single-dose food effect in nonsmokers|Randomized, two-treatment design in nonsmoking healthy subjects. Single-dose pracinostat to be given under fasted and fed conditions followed by PK sampling for up to 48 hour post dose.
62591392|NCT02058784|EXPERIMENTAL|Single-dose food effect in smokers|Single-dose parallel treatment design in moderate to heavy smoking healthy subjects. Single-dose pracinostat will be given under fasted conditions followed by PK blood sampling up to 48 hours.
62591393|NCT04749654|EXPERIMENTAL|Fixed space maintainers|band-and-loop type fixed space maintainers were applied
62591394|NCT04749654|EXPERIMENTAL|Removable space maintainers|All removable space maintainers were produced of an acrylic base and retention elements that were a vestibule arch, (Adam's and C clasps).
62591395|NCT01095900||LIS group)|
62228881|NCT02325557|EXPERIMENTAL|Part B: ADXS31-142 + Pembrolizumab|Participants received ADXS31-142 1 × 10\^9 CFU) IV Q3W (in a 12-week cycle) in combination with 200 mg pembrolizumab IV Q3W for three times, with a fourth pembrolizumab dose 3 weeks later (in 12 week-cycles) for up to 24 months or until disease progression or discontinuation.
62228882|NCT04841356|EXPERIMENTAL|ICG|Immediate Compression Garment
62591396|NCT01095900||BT group|
62591397|NCT05978713|EXPERIMENTAL|Tirzepatide|A single dose of tirzepatide administered subcutaneously (SC)
62591398|NCT02429024|NO_INTERVENTION|Control|Subjects with type 1 and type 2 diabetes will be provided with the OneTouch Verio® Flex BGM system only over a period of 24 weeks.
62591399|NCT02429024|EXPERIMENTAL|Intervention|Subjects with type 1 and type 2 diabetes will be provided with the OneTouch Verio® Flex BGM and the OneTouch Reveal® Mobile APP system over a period of 24 weeks.
62591400|NCT03142542|EXPERIMENTAL|Udenafil 75mg|Drug: Udenafil 75mg by mouth, once daily, for 32 weeks
62228883|NCT02395874|EXPERIMENTAL|verum-tDCS|verum-tDCS+ speech therapy
62591401|NCT03142542|PLACEBO_COMPARATOR|Placebo|Drug: placebo by mouth, once daily, for 32 weeks
62591402|NCT01203761||Preoperative patients|ENT surgical patients, approximately 1 day before their procedure undertaken
62591403|NCT01203761||Postoperative patients|ENT surgical patients during their postoperative hospitalization
62228884|NCT02395874|SHAM_COMPARATOR|sham-tDCS|sham-tDCS + speech therapy
62228885|NCT00639210|OTHER|A|Supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.
62591404|NCT01203761||Family members|Family members of ENT surgical patients, during the perioperative period
62228886|NCT00639210|NO_INTERVENTION|B|
62228887|NCT05772494|EXPERIMENTAL|Assessment of activity limitation|Assessment and analysis of activity limitation by occupational therapist using 2 registered instruments (SDO and DOA).
62228888|NCT05772494|ACTIVE_COMPARATOR|Control group: treatment as usual|Assessment of activity limitations according to usual routines
62228889|NCT00706199||Group A|donors
62228890|NCT04716491|EXPERIMENTAL|Intervention group|Intervention to decrease disruptive sleep in patients undergoing percutaneous intervention to treat cardiac disorders admitted to the ICU: ear protector and eye mask.
62591405|NCT05160532|PLACEBO_COMPARATOR|Four injections of placebo|Subjects will receive four placebo intraarticular knee injections under ultrasound guidance. A placebo looks exactly like the study drug, but it contains no active ingredient.
62591406|NCT05160532|EXPERIMENTAL|One injection of DPT and three injections of placebo|Subjects will receive one intraarticular knee injection under ultrasound guidance of dextrose prolotherapy (DPT), followed by three intraarticular knee injections of placebo under ultrasound guidance.
62591407|NCT05160532|EXPERIMENTAL|Two injections of DPT and two injections of placebo|Subjects will receive two intraarticular knee injection under ultrasound guidance of dextrose prolotherapy (DPT), followed by two intraarticular knee injections of placebo under ultrasound guidance.
62591408|NCT05160532|EXPERIMENTAL|Four injections of DPT|Subjects will receive four intraarticular knee injection under ultrasound guidance of dextrose prolotherapy (DPT).
62228891|NCT04716491|NO_INTERVENTION|Control group|Participants will not use the devices at any time of admission to the intensive care unit
62228892|NCT02872883|EXPERIMENTAL|Expectant management and minimal vaginal examinations|Expectant management up to approximately 96hours and vaginal examinations only when necessary during active labour
62591409|NCT05514873|EXPERIMENTAL|0.3 mg/kg zilucoplan (RA101495)|Study participants will be treated with subcutaneous zilucoplan (0.3mg/kg/day)
62591410|NCT01833624|ACTIVE_COMPARATOR|Sondalis® HP|The Control Group that will receive Sondalis ® HP (a whole-peptide formula).
62591411|NCT01833624|EXPERIMENTAL|Peptamen® AF|In this arm, patients have enteral nutrition with Peptamen® AF
62591412|NCT01310634|EXPERIMENTAL|Comprehensive intervention|Parents of hospitalized neonates received Comprehensive intervention program.
62591413|NCT01310634|OTHER|Conventional treatment|Usual educational program
62735384|NCT04322409|EXPERIMENTAL|NMES|The experimental treatment of Neuromuscular Electrical Stimulation over the Peroneus Longus.
62591414|NCT06668532|EXPERIMENTAL|Flourish app condition|Participants in this condition will gain access to the Flourish app and be instructed to use it at least twice a week for 6 weeks.
62030287|NCT01518543||ASTUS|Patient candidate for an arthrodesis in the following joints:Ankle,1st MTP, Metatarso - Cuneiform (1st), Navicular - Cuneiform, Talo-Navicular, Calcaneum - Cuboid, and whose surgeon has recommended the implantation of an ASTUS Staple from Newdeal-INTEGRA.
62805627|NCT03016572|EXPERIMENTAL|TAU + CC Follow Up + Wraparound Services|This group will be linked with a care coordinator through Tapestry services. Wraparound is an intensive, individualized care coordination and treatment planning process that involves all of the important people in a child's life to work together to make the child successful in school, at home and in the community.
62228893|NCT02872883|EXPERIMENTAL|Expectant management and routine vaginal examinations|Expectant management up to approximately 96hours and routine vaginal examinations during active labour
62805628|NCT02462148|EXPERIMENTAL|4 mg Perineural Dexamethasone Group|4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
62228894|NCT02872883|EXPERIMENTAL|Active management and minimal vaginal examinations|Induction of labour at approximately 24hours and vaginal examinations only when necessary during active labour
62805629|NCT02462148|EXPERIMENTAL|1 mg Perineural Dexamethasone Group|1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
62805630|NCT02462148|PLACEBO_COMPARATOR|Placebo Group|This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
62805631|NCT01233596|ACTIVE_COMPARATOR|Monocanalicular intubation|Monocanalicular intubations (MCI; n=35 eyes) through the inferior canaliculus intubations performed under general anaeshesia in children between 10 and 36 months of age suffering from congenital nasolacrimal duct obstruction (CNLDO).
62805632|NCT01233596|ACTIVE_COMPARATOR|Bicanalicular intubation|Bicanalicular intubation (BCI; n=35 eyes) performed under general anaeshesia in children between 10 and 36 months of age suffering from congenital nasolacrimal duct obstruction (CNLDO).
62805633|NCT00760682|EXPERIMENTAL|1|30 preoperative HBO sessions, sequestrectomy and 10 postoperative HBO sessions. The duration of each session is 90 minutes. 100 % oxygen is inhaled during decompression to 2.4 ATA.
62805634|NCT00760682|NO_INTERVENTION|2|Sequestrectomy without HBO treatment
62591415|NCT06668532|ACTIVE_COMPARATOR|Control Condition|Participants in the control condition will gain access to mental health resources each week for 6 weeks and be instructed to reflect on how the information in the resources can be applied to their own lives.
62228895|NCT02872883|ACTIVE_COMPARATOR|Active management and routine vaginal examinations|Induction of labour at approximately 24hours and routine vaginal examinations
62228896|NCT02490202|EXPERIMENTAL|SANGUINATE|Two (2) infusions of SANGUINATE
62030288|NCT04313803||American Fork|CGM usage months 1 and 3
62228897|NCT02490202|PLACEBO_COMPARATOR|Normal Saline|Two (2) infusions of Normal Saline
62591416|NCT04008771|EXPERIMENTAL|Severe Disease|Subjects with baseline BCVA between 20/16000 and hand motion (HM). Subjects received 2.0 μM concentration intravitreal injections on each Day 0 and Day 21.
62591417|NCT04008771|EXPERIMENTAL|Moderate to Severe Disease|Subjects with baseline BCVA from 20/60 to 20/16000. The first five (5) to receive 2.0 μM concentration intravitreal at each Day 0 and Day 21, the subsequent five (5) to receive 0.2 μM intravitreal injection at each Day 0 and Day 21, additional subjects (up to ten \[10\]) to receive one of the dosing options (either 2.0 μM or 0.2 μM) at each Day 0 and Day 21, at the discretion of the Investigator and Sponsor.
62030289|NCT04313803||Central Orem|CGM usage for month 1
62030290|NCT04313803||North Canyon, Saratoga Springs, and Lehi|CGM usage for 1-3 months
62030291|NCT01060228|OTHER|001|paliperidone ER 1 tablet of 500 mg once daily on Day 1 and Day 15
62030292|NCT01060228|OTHER|002|divalproex sodium ER 2 tablets of 500 mg once daily from Days 5 through 18
62030293|NCT02907346|EXPERIMENTAL|Reinforcement for wearing CGM|The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
62228898|NCT02238665||Ulcerative colitis|
62228899|NCT02238665||Crohn's disease|
62735385|NCT04322409|PLACEBO_COMPARATOR|TENS|The placebo treatment of Transcutaneous Electrical Nerve Stimulation over the same region as the peroneus longus
62735386|NCT02180685|OTHER|Anchor fixation|Medial fixation of the reconstruction at the medial femural condyle with suture anchors.
62735387|NCT02180685|OTHER|Screw fixation|Medial fixation of the reconstruction at the medial femural condyle with a screw.
62735388|NCT04242576|EXPERIMENTAL|Action Observation|Subjects will watch 30-second videos, with a one-minute break between videos. The videos show the actions that subjects should imagine while watching the video.
62735389|NCT04242576|EXPERIMENTAL|Right/Left Judgment Task|"The laterality will be trained with the Recognize® application. Once the subjects have been trained, they are instructed to solve the different sections of the application, starting with the simplest tasks until reaching the most difficult ones.~These tasks would consist of indicating left or right, among the different images that appear on the iPad screen, indicating if the image's neck is rotated to the left or right. Being every level more complicated, so that people of different skin tones, with clothes or in a work environment are added."
62735390|NCT04242576|ACTIVE_COMPARATOR|Exercise|The subjects perform the exercises provided by the researchers. Which consist of neck exercises in all ranges of movement (inclinations and rotations to both sides), apart from flexion and extension.
62735391|NCT03051464|EXPERIMENTAL|Chemoradiation + EBRT Boost|standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5; Complete responders and Non-complete responders
62735392|NCT03051464|EXPERIMENTAL|Chemoradiation + HDRBT Boost|standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions; Complete responders and Non-complete responders
62228900|NCT02525757|EXPERIMENTAL|Group 1: Chemotherapy + Radiation|"Participants receive standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period when they receive no chemotherapy or radiation.~Consolidation Phase: After the rest period, participants receive MPDL3280A in addition to chemotherapy for 2 cycles.~Maintenance Phase: After completing the consolidation period, participants continue to receive MPDL3280A alone for up to 1 year."
62591418|NCT06392139|EXPERIMENTAL|Experimental: Intervention group|The Specific Therapy Program for Personality Disorders at the 1st Psychiatric Clinic, Medical School, National and Kapodistrian University of Athens, Eginition Hospital, established in 1999, offers outpatient, inpatient, and day care services with psychoanalytic interventions tailored for Borderline Personality Disorder. Group psychoanalytic psychotherapy sessions are predominant, supported by research. Patients undergo initial 6-8 months of closely monitored outpatient care, including monthly psychodynamically oriented sessions, psychiatric appointments, and psychological assessments, focusing on crisis management and personalized treatment plans. Subsequently, long-term psychodynamic psychotherapy interventions, often combined with psychiatric treatment, provide sustained therapeutic support.
62591419|NCT06392139|ACTIVE_COMPARATOR|Treatment As Usual (TAU) Group|"The TAU group receives the common practice treatment in the two Specific Outpatient Clinics for BPD patients:~1. The Outpatient Clinic for Borderline Personality Disorder Patients of the 2nd Psychiatric Clinic at the Medical School of National and Kapodistrian University of Athens called Attikon General University Hospital and~2. The Outpatient Clinic for Borderline Personality Disorder Patients of the Psychiatric Clinic of Sismanogleion General Hospital."
62591420|NCT05817617||Head and Neck cancer patients|candidate to receive definitive or adjuvant radiation therapy with bilateral neck irradiation
62805635|NCT04064658|SHAM_COMPARATOR|Sham RIPC group|"Treatment:Patients in this group received standard medical therapy and sham remote ischemic preconditioning treatment.~Device:Sham RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min, each patient in Sham RIPC group do it twice a day for at least five days before encephaloduroarteriosynangiosis.~Procedure: Encephaloduroarteriosynangiosis"
62805636|NCT04064658|EXPERIMENTAL|RIPC group|"Treatment:Patients in this group received standard medical therapy and remote ischemic preconditioning (RIPC) treatment.~Device:RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min,each patient in the RIPC group do it twice a day for at least five days before encephaloduroarteriosynangiosis.~Procedure: Encephaloduroarteriosynangiosis"
62228901|NCT02525757|EXPERIMENTAL|Group 2: MPDL3280A + Chemotherapy + Radiation|"Participants receive MPDL3280A, standard chemotherapy, and radiation therapy for 6-7 weeks. This will be followed by a rest period of 3-4 weeks, during which time participant receives 1 dose of MPDL3280A but no chemotherapy or radiation.~Consolidation Phase: After the rest period, participants receive MPDL3280A in addition to chemotherapy for 2 cycles.~Maintenance Phase: After completing the consolidation period, participants continue to receive MPDL3280A alone for up to 1 year."
62228902|NCT03495570||A|HIV-infected (chronic or acute infection) with a HIV viral load of \>1000 copies/mL in the 6 months prior to study entry and not (yet) in receipt of combination antiretroviral therapy (cART) at study entry.
62228903|NCT03495570||B|HIV-infected on cART with HIV viral load \<50 copies/mL within the 6 months prior to study entry, at least one measure of HCV (chronic or acute infection) showing a detectable HCV viral load and not in receipt of HCV treatment at study entry.
62228904|NCT03495570||C|HCV mono-infected (chronic or acute infection) with detectable HCV viral load (\>lower limit of quantification) in the prior 6 months and not in receipt of HCV treatment at study entry.
62228905|NCT03495570||D|HBV mono-infected (chronic or acute infection) patients with detectable HBV viral load in the prior 6 months and not in receipt of HBV treatment at study entry.
62228906|NCT04432246|EXPERIMENTAL|bilateral SMA|Continuous theta burst stimulation (cTBS) stimulation will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
62228907|NCT04281004|ACTIVE_COMPARATOR|Amniotic Fluid (AFED)|
62228908|NCT04281004|PLACEBO_COMPARATOR|Saline Solution|
62228909|NCT06148051||CADASIL cohort|
62228910|NCT06148051||Control Cohort|
62228911|NCT01553123|EXPERIMENTAL|Ulipristal with iron|
62228912|NCT01553123|PLACEBO_COMPARATOR|Placebo|Placebo with iron
62228913|NCT03720197||Participants aged less than 14 years old|
62228914|NCT03720197||Participants aged 14 years old and older|
62228915|NCT06436157|EXPERIMENTAL|Enhanced Education Intervention|Patients in the enhanced education intervention arm will be scheduled for a redesigned therapy education session with a trained oncology nurse.
62228916|NCT06436157|ACTIVE_COMPARATOR|Usual Care Education Arm|Patients in this arm will receive the usual care education provided to cancer patients undergoing systemic therapy, which includes information on treatment options, side effects, and support services without targeted genetic testing education.
62228917|NCT01944241||Women with cervical surgery|The cases will include women who have had cervical surgery, either LLETZ or cone biopsy
62228918|NCT01944241||women with no surgery|controls will be women who have attended colposcopy but who have not had surgery.
62591421|NCT04271839|EXPERIMENTAL|Fluticasone/formoterol k-haler (medium strength)|In this arm, uncontrolled patients who arrive at the consultation with their fixed combination of ICs (Inhaled CorticosteroidS) / LABA (Long-Acting Beta2-Agonist) (medium strength) will change their treatment to Fluticasone / formoterol k-haler (medium strength)
62735393|NCT03797963|ACTIVE_COMPARATOR|PBM+ACB|Porcine bone mineral (Symbios Xenograft) + autogenous cortical bone
62805637|NCT04496739|ACTIVE_COMPARATOR|Group I (educational materials)|Patients receive standard educational materials about breast cancer risk and chemoprevention in RealRisks via the patient portal or website.
62819475|NCT03821896|EXPERIMENTAL|Conversation Cards for Adolescents and Goal-Setting|Adolescents in the experimental arm will receive the tool 15 minutes prior to their appointment with their primary care provider. They will be instructed to familiarize themselves with the tool and to select the top 3 factors that resonate most with them in their attemps to change their lifestyle habits. They will then proceed to their clinical appointment to set one S.M.A.R.T. goal based on their selections and in collaboration with their primary care provider.
62228919|NCT04016467|EXPERIMENTAL|Thoracic Manipulation (ThM)|Will undergo spinal manipulation between pain assessment pre and post.
62228920|NCT04016467|SHAM_COMPARATOR|Sham thoracic treatment (ThS)|Sham manipulation between pain assessment pre and post
62228921|NCT03674567|EXPERIMENTAL|Part 1a: Monotherapy Dose Escalation|Eligible subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 as monotherapy.
62228922|NCT03674567|EXPERIMENTAL|Part 1b: Combination Dose Escalation|Eligible subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 in combination with pembrolizumab.
62228923|NCT03674567|EXPERIMENTAL|Part 2a: Monotherapy Expansion Cohorts|Eligible subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 as monotherapy; additional subjects in each cohort may be enrolled in Stage 2.
62591422|NCT04271839|ACTIVE_COMPARATOR|Standard of Care (SoC)|In this arm, uncontrolled patients arriving at the consultation with their fixed combination of ICs / LABA (medium strength) will change their treatment to the same fixed combination of ICs / LABA (high strength)
62819476|NCT03821896|ACTIVE_COMPARATOR|Goal-Setting|Adolescents in the control arm will not complete the tool activity, but will still set a S.M.A.R.T. goal with their primary care provider.
62228924|NCT03674567|EXPERIMENTAL|Part 2b: Combination Expansion Cohorts|Eligible subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 in combination with pembrolizumab; additional subjects in each cohort may be enrolled in Stage 2.
62228925|NCT00581815|EXPERIMENTAL|1|
62228926|NCT06459466|EXPERIMENTAL|Kinesiotherapy exercises with cervical mobilization|This group will receive kinesiotherapy exercises along with Cervical Mobilization
62228927|NCT06459466|ACTIVE_COMPARATOR|Cervical Mobilization|This group will receive Cervical lateral glide mobilization.
62819477|NCT06513910|EXPERIMENTAL|Component 2b. Social Music Study|Investigators will assess the neural mechanisms of feelings of subjective connectedness during communal music listening and creating between dyads of subjects who are both familiar and unfamiliar with each other
62228928|NCT01824160|OTHER|Repair of RV-PA Conduit Disruption|Covered stenting of RV-PA conduit injury
62228929|NCT00561951|EXPERIMENTAL|Fesoterodine fumarate 4 mg (Double-Blind)|
62819478|NCT04408313|EXPERIMENTAL|XR-B|Extended-release buprenorphine
62819479|NCT04408313|ACTIVE_COMPARATOR|XR-NTX|Extended-release naltrexone
62228930|NCT00561951|PLACEBO_COMPARATOR|Placebo (Double-Blind)|
62228931|NCT00561951|EXPERIMENTAL|Fesoterodine fumarate 8 mg (Double-Blind)|
62228932|NCT05560100||Patients|Must have participated in \>= 1 session of dry needling treatment and not be a healthcare provider.
62228933|NCT05560100||Dry Needling Experts|"(1) Must have \>= 5 years of clinical practice performing dry needling and at least ONE of the following secondary criteria:~1. Certification in Dry Needling~2. Completion of a manual therapy fellowship that included dry needling training~3. \>= 1 total scholarly product (poster presentation, author of a peer-reviewed publication) involving the use of dry needling"
62228934|NCT05560100||Policy Experts|"An individual who has a degree in bioethics with at least ONE of the following criteria:~1. \>= 5 years of experience in obtaining informed consent or an advanced graduate degree in bioethics~2. Has served on ethics related committee in a healthcare institution or healthcare society/professional association~3. Is or has been a member of a state licensing board"
62228935|NCT05560100||Legal Experts|"An individual who is an attorney and who has had training in health law as evidenced by at least ONE of the following criteria:~1. Evidence of training based on ONE of the follow:~   1. Concentration/Certification in Health Law~  2. L.L.M in health or medical law~  3. SJD in health law~2. Experience in litigating medical malpractice cases involving failure to obtain informed consent~3. Published scholarship on informed consent in an academic journal (\>= 1)"
62228936|NCT01610141|EXPERIMENTAL|Genotype-guided warfarin dosing|A pharmacogenetic dosing algorithm including clinical factors and genotype information (VKORC1, CYP2C9 and CYP4F2) will be used to determine warfarin doses.
62228937|NCT01610141|ACTIVE_COMPARATOR|Non-genotype guided warfarin dosing|A fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
62228938|NCT02279069|ACTIVE_COMPARATOR|4-point canne|Stroke patients walk with 4-point canne
62228939|NCT02279069|EXPERIMENTAL|4-roll canne|Stroke patients walk with 4-roll canne
62228940|NCT05260515|EXPERIMENTAL|Staying Sharp intervention|Staying Sharp is an online intervention to promote healthy behaviors through six health pillars (Be social, Engage your brain, Manage stress, Ongoing exercise, Restorative sleep, and Eat right).
62228941|NCT01405586|ACTIVE_COMPARATOR|gemcitabine|
62228942|NCT01405586|EXPERIMENTAL|gemcitabine + cisplatin|
62228943|NCT00661804||Thalassemia cohort|"Thalassemia as documented by clinical diagnosis, including:~thalassemia (intermedia or major); HbH disease; HbH with non-deletional mutations, e.g., HbH Constant Spring E beta-thalassemia; Homozygous alpha-thalassemia (i.e., 4-gene alpha deletion or equivalent null alpha mutation); Other thalassemic conditions not explicitly excluded; Thalassemia intermedia due to heterozygous beta mutation with alpha-gene excess."
62228944|NCT00661804||Successful SCT cohort|Individuals who have received a successful hematopoietic SCT, defined as engraftment of all three cell lines and transfusion independence by 100 days post-transplant, for any of the disorders listed above;Monitored for end-organ injury related to thalassemia prior to their successful SCT;Participants who were enrolled in TCRN Registry or had a successful SCT after 01 Jan 2002.
62228945|NCT04343638|ACTIVE_COMPARATOR|conventional nociception control arm|Intraoperative opioid will be administered by conventional clinical practice. ANI monitor readings will not be visible to the anesthesiologist.
62228946|NCT04343638|EXPERIMENTAL|ANI-monitor guided nociception control arm|Intraoperative opioid will be administered by maintaining the 4-minute moving average of ANI ≥50.
62591423|NCT04973540|EXPERIMENTAL|IBS Angel|Iron Bioresorbable Scaffold System
62591424|NCT03214380|EXPERIMENTAL|LY900014|LY900014 given subcutaneously (SC) with each meal with either 100 U/mL (U-100) basal insulin glargine given SC once or twice daily or U-100 or 200 U/mL (U-200) insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
62735394|NCT03797963|EXPERIMENTAL|ABB+ACB|Anorganic bovine bone (BioOss Xenograft) + autogenous cortical bone
62228947|NCT04470167|EXPERIMENTAL|TPX-115|Subjects receive ultrasound-guided intratendinous injection of TPX-115
62228948|NCT04470167|PLACEBO_COMPARATOR|Placebo|Subjects receive ultrasound-guided intratendinous placebo injection
62228949|NCT02832154|EXPERIMENTAL|Supportive Care|Patients complete an initial online questionnaire lasting about 25-30 minutes. Patients complete an internet-delivered PA program during weeks 3-8. Each week consists of didactic material and 20-30 minutes of daily online exercises.
62591425|NCT03214380|ACTIVE_COMPARATOR|Insulin Lispro (Humalog)|Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
62819480|NCT02743208|EXPERIMENTAL|Furlong Evolution femoral stem|Short stem hip arthroplasty (SHA) using a Furlong Evolution femoral stem, and a Furlong H-A.C. Cortical Scree Fit (CSF) plus acetabular cup system.
62030294|NCT01699243||Epidural|subjects under epidural anesthesia
62030295|NCT03220191|EXPERIMENTAL|palbociclib tablet with/without PPI|palbociclib tablet formulation alone in period 1 + palbociclib tablet formulation plus rabeprazole in period 2
62228950|NCT01340820|EXPERIMENTAL|AERAS-422 Low dose|\>=10\^5 to \< 10\^6 CFU
62228951|NCT01340820|EXPERIMENTAL|AERAS-422 High Dose|\>=10\^6 CFU
62591426|NCT03214380|EXPERIMENTAL|LY900014 Maximum Extended Enrollment (MEE)|LY900014 given subcutaneously (SC) with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
62735395|NCT05349968|EXPERIMENTAL|Dose 5 mg|Injected subcutaneously at room temperature into the abdomen (moles, scar tissue, bruises or areas other than the navel) and administered once a week for 4 weeks, with no more than 2.0 mL volume administered to a single site.
62735396|NCT05349968|EXPERIMENTAL|Dose 20 mg|Injected subcutaneously at room temperature into the abdomen (moles, scar tissue, bruises or areas other than the navel) and administered once a week for 4 weeks, with no more than 2.0 mL volume administered to a single site.
62735397|NCT05349968|EXPERIMENTAL|Dose 40 mg|Injected subcutaneously at room temperature into the abdomen (moles, scar tissue, bruises or areas other than the navel) and administered once a week for 4 weeks, with no more than 2.0 mL volume administered to a single site.
62030296|NCT05608629|EXPERIMENTAL|Transcutaneous Non-Invasive Vagus Nerve Stimulation|Application of electrode to left tragus with stimulus intensity at that which is just below pain threshold for 35 min a day
62228952|NCT01340820|ACTIVE_COMPARATOR|BCG Tice|BCG Tice 1-8 x 10\^5 CFU
62228953|NCT05316194||Participation in digital OA treatment|All participants that have participated in a digitally delivered first-line treatment program (Joint Academy) for hip or knee OA until May 2022.
62228954|NCT01551212|EXPERIMENTAL|EVR/TAC|Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: \< 5 ng/mL)
62228955|NCT01551212|ACTIVE_COMPARATOR|TAC|Tacrolimus (C0-h: 6-10 ng/ml)
62735398|NCT03879616|EXPERIMENTAL|An Enhanced Reminder|"Members randomized to this arm of the study will receive an enhanced reminder protocol, which will include multiple reminders, multiple modalities, and motivational messages. The timing of reminders will depend on the wait time between the date the appointment is made and the date of the appointment.~* An email reminder will be sent to all members who have provided their personal email information.~* Members will receive up to two text messages that roll over to an IVR automated phone call if the text cannot be delivered.~* Members scheduled for colonoscopy will also receive a single IVR-T reminder to begin their bowel prep the morning of the calendar day prior to the procedure."
62735399|NCT03879616|OTHER|Control|"Members randomized to this arm of the study will receive a single text message that rolls over to an IVR automated phone call if the text cannot be delivered. This message will be delivered 7 business days prior to the appointment. This replicates the current protocol for GI procedures. Of note, members who schedule appointments within 7 days of the procedure currently receive no reminders."
62735400|NCT05082519|EXPERIMENTAL|IDEAL2 intervention|"Focused and short-term intervention of diet and exercise during induction. Calorie goal is \>=15% daily deficit as determined by each subject's estimated energy requirement. Fat intake will make up \<25% of daily calories. Carbohydrate will make up \<55% of daily calories consisting of low glycemic load foods (\<100/2,000 kcal adjusted for daily calories). Protein will make up \>=20% of daily calories. Subjects will also perform moderate exercise 5 days per week for 30 minutes/session (total = 150 minutes per week). Subjects will have a step goal to decrease sedentary behavior, with a starting goal of \>=1000 steps/day and increasing by at least 1000 steps/day each week."
62735401|NCT05082519|NO_INTERVENTION|Control - Standard of Care|One-time education of diet and exercise, which is the standard of care for ALL patients during induction.
62735402|NCT01667133|EXPERIMENTAL|Phase 1 dose escalation|Phase 1
62735403|NCT01667133|EXPERIMENTAL|Phase 2 expansion|Phase 2
62735404|NCT03536481|EXPERIMENTAL|T-R cohort under fasted state|Subjects will be administered with one single dose of ensartinib capsules (test product) under fasted state, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (reference product) under fasted state.
62735405|NCT03536481|EXPERIMENTAL|R-T cohort under fasted state|Subjects will be administered with one single dose of ensartinib capsules (reference product) under fasted state, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (test product) under fasted state.
62735406|NCT03536481|EXPERIMENTAL|T-R cohort after meal|Subjects will be administered with one single dose of ensartinib capsules (test product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (reference product) after meal.
62735407|NCT03536481|EXPERIMENTAL|R-T cohort after meal|Subjects will be administered with one single dose of ensartinib capsules (reference product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (test product) after meal.
62735408|NCT04600726||older adults with known mild NCD|Older adults with known mild neuro-cognitive disorders
62735409|NCT04600726||older adults with non-communicable diseases|older adults with non-communicable diseases such as diabetics, hypertension and chronic obstructive airway diseases
62421491|NCT04621097|EXPERIMENTAL|Treadmilltraining|"* In this group, 30 patient will receive the physical therapy program in form of supervised treadmill walking exercise. The exercise program consists of intermittent walking bouts to moderate claudication pain alternating with periods of rest in between for a total of 40-50 minutes .~* At first , a 5 minutes- warm up period will be allowed, it will include stretching exercises for calf muscles , hamstrings and quadriceps (i.e. each for at least 10 -15 seconds) . Patients should start with walking on the treadmill at a comfortable speed, and should not stop at the onset of leg pain but instead , he/she would continue until moderate pain is reached. At this point, he/she has to rest until pain completely subsides, then walking is resumed again . The intensity of exercise will be determined by claudication pain scale, and should not exceed the score of 4 on this scale. The exercise can be progressed if the patient can walk continuously for 10 minutes without the need to stop."
62421492|NCT04621097|PLACEBO_COMPARATOR|medications|It includes 20 patients who will not receive any physiotherapy intervention. They will receive medical treatment only and will act as a control group.
62421493|NCT00646256|NO_INTERVENTION|no training|
62228956|NCT04520360|EXPERIMENTAL|Types of Carisbamate|"1. A single 300 mg oral dose of the Oral Suspension Type 1 under fasting conditions~2. A single 300 mg oral dose of Oral Suspension Type 2 under fasting conditions~3. A single 300 mg oral dose of Oral Suspension Type 2 under fed conditions~4. A single oral dose of the 300 mg Oral Tablet under fasting conditions~5. A single oral dose of the 300 mg Oral Tablet under fed conditions"
62591427|NCT03214380|ACTIVE_COMPARATOR|Insulin Lispro (Humalog) MEE|Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
62591428|NCT04323033|EXPERIMENTAL|PERS stent|20 Patients will receive PERS stent
62591429|NCT04323033|ACTIVE_COMPARATOR|NEPTUN C stent|20 Patients will receive NEPTUN C stent
62805638|NCT04496739|EXPERIMENTAL|Group II (educational materials, decision support, interview)|Patients receive standard educational materials about breast cancer risk and chemoprevention in RealRisks via the patient portal or website. Patients receive patient-centered decision support within the patient portal via an action plan summarizing their breast cancer risk profile, their risks and benefits of SERMs and AIs, and personal preferences for chemoprevention. Health care providers receive decision support and action plans based on their patients' interactions with RealRisks via the BNAV provider-centered support tool within the EHR. A sample of patients participate in an audio-recorded interview via telephone or video conference over 45-60 minutes at 12 months after registration. A sample of health care providers participate in 3 audio-recorded interviews via telephone or video conference over 45-60 minutes each at baseline, within 12-36 months after study activation, and within 12 months after study closure to accrual.
62421494|NCT00646256|EXPERIMENTAL|COGPACK training|
62421495|NCT05764200|ACTIVE_COMPARATOR|lean normoglycaemic individuals fiber mixture|Two day supplementation of 12 g (3 x 4 g) of the dietary fiber inulin in combination with 9.375 g (3 x 3.125 g (80% resistant starch (3 x 2.5 g)) granular potato starch
62421496|NCT05764200|PLACEBO_COMPARATOR|lean normoglycaemic placebo|Two day supplementation of 11.43 g (3 x 3.81 g) maltodextrin
62591430|NCT01646021|EXPERIMENTAL|Ibrutinib|
62591431|NCT01646021|EXPERIMENTAL|Temsirolimus|
62591432|NCT03324516|EXPERIMENTAL|Experimental Group|Patients included in this arm will undergo a traditional bony pterional approach for their craniotomy. A superior cuff of temporal muscle will be left attached to the temporal bone.
62591433|NCT03324516|ACTIVE_COMPARATOR|Control|Patients included into this arm will receive a traditional pterional approach for their craniotomy. The temporal muscle will be detached in its entirety.
62591434|NCT02121015|ACTIVE_COMPARATOR|Self-Directed|Access to the e-health intervention (an interactive website with didactic material and interactive tools) for participants to use at their own pace for 8 weeks (Self-Directed)
62591435|NCT02121015|EXPERIMENTAL|Share|Access to the same e-health intervention + an internet social networking component consisting of up to 12 other pregnant women (Share).
62805639|NCT02152826|EXPERIMENTAL|potassium oxalate gel|Professional application
62805640|NCT02152826|ACTIVE_COMPARATOR|Potassium oxalate liquid|Professional application
62805641|NCT03952013||Study group|"All eligible patients included into one of the three existing cohorts studies of Hospices Civils de Lyon's hospitals: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE~* LOOP-HF (Registry of Congestive Heart Failure, NCT03422991),~* HIBISCUS-STEMI (Prospective cohort with a heart attack from ST segment elevation myocardium admitted to the centre coronary angiography room participating investigators, NCT03070496)~* HIBISCUS-STROKE (Prospective cohort of Stroke patients, NCT03149705)"
62805642|NCT04268082|EXPERIMENTAL|Experimental Group|The Experimental Group followed the training wearing sensorized insoles that provided plantar pressures and shift of foot center of pressure images reported on monitors.
62805643|NCT04268082|ACTIVE_COMPARATOR|Control Group|The Control Group followed verbal instructions of physiotherapist during training.
62421497|NCT05764200|ACTIVE_COMPARATOR|overweight and/or obesity and prediabetes/insulin fiber mixture|Two day supplementation of 12 g (3 x 4 g) of the dietary fiber inulin in combination with 9.375 g (3 x 3.125 g (80% resistant starch (3 x 2.5 g)) granular potato starch
62228957|NCT01604707|NO_INTERVENTION|Control group|Standard care
62591436|NCT00482677|ACTIVE_COMPARATOR|Temozolomide|Temozolomide and short course radiation
62228958|NCT01604707|EXPERIMENTAL|Medical Yoga|Group training with medical yoga in primary health care.
62421498|NCT05764200|PLACEBO_COMPARATOR|overweight and/or obesity and prediabetes/insulin resistance placebo|Two day supplementation of 11.43 g (3 x 3.81 g) maltodextrin
62591437|NCT00482677|ACTIVE_COMPARATOR|Radiation|Short course radiation alone
62591438|NCT02490787|EXPERIMENTAL|Concizumab|
62591439|NCT02490787|PLACEBO_COMPARATOR|Placebo|
62591440|NCT02937142|EXPERIMENTAL|Cognitive behavior group therapy|Cognitive behavior group therapy in weekly 1,5 hour sessions during 12 weeks, 8 participants and 2 therapists per group, in addition to education on ADHD, and ADHD medication if indicated.
62591441|NCT02937142|OTHER|Controls|Treatment as usual: Education on ADHD, and ADHD medication if indicated.
62591442|NCT06622356||Rehabilitation Group|Rehabilitation Group (n = 268): mild/non pain group with VAS\<3 at 12-18 months after PLIF。The study was retrospective and did not design an intervention
62805644|NCT04098523|OTHER|Epidemiologic screening|All subjects are screened by duplex ultrasound for abdominal aortic aneurysm (AAA) and carotid artery stenosis (CAS). A questionnaire is completed to obtain information on demographic information, risk factors as well as prior treatment for AAA or CAS and current medication. No treatment is given.
62591443|NCT06622356||Recurrent pain group|Recurrent pain group (n = 184): recurrent pain group with VAS≥3 at 12-18 months after PLIF
62805645|NCT01917747|ACTIVE_COMPARATOR|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before and after any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test and any other follow up, as is standard practice.
62805646|NCT01917747|EXPERIMENTAL|Patient Navigator Group|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed.
62421499|NCT05212272|EXPERIMENTAL|PET-MRI In High-Grade Glioma Patients Undergoing Chemoradiation|PET scan and MRI scan of the brain, blood draw, and 1-hour of memory testing.
62421500|NCT05408728||Obese patients scheduled for Bariatric surgery|Subjects scheduled for Bariatric Surgery (BS) and will receive pre-BS Esophagogastroduodenoscopy (EGD) as a part of your standard care will have biopsies from the small intestine taken during the EGD procedure for this study.
62591444|NCT00288067|EXPERIMENTAL|Treatment (fenretinide, rituximab)|"PHASE I: Patients receive fenretinide PO BID on days 1-5. Treatment repeats weekly for at least 4 weeks in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive fenretinide PO BID on days 1-5 in weeks 1-8 and rituximab IV once weekly in weeks 5-8. Treatment continues in the absence of disease progression or unacceptable toxicity."
62591445|NCT03065764|OTHER|Patients|For the first 3 patients, PET scans will be obtained at 1, 72 and 120 hours post tracer injection to determine the optimal scan time point and to perform biodistribution measurements and dosimetry. All subsequent 7 patients receive only 1 PET scan post-injection (i.e. two PET scans).
62421501|NCT05408728||Lean controls naive to Bariatric surgery|Subjects presenting for surveillance/screening EGD procedure as part of their standard medical care will have biopsies from the small intestine taken during the EGD procedure for this study.
62591446|NCT02247492||Orsiro|
62591447|NCT05500274|ACTIVE_COMPARATOR|Education Arm|The Education condition will include COVID-19 prevention messaging and an interactive activity reinforcing the messages. Testimonial videos will be played including those that describe the testing experience and motivations for testing. This approach combines self-affirmation with misinformation correction to take advantage of the ability to promote adaptive COVID-19 prevention behaviors.
62591448|NCT05500274|ACTIVE_COMPARATOR|Motivational Arm|Study participants randomized to the Motivational Intervention will receive the intervention using a social network diffusion approach. This is a Type I network intervention that includes specific training on mobilization of network members. The Motivational intervention will be based upon a previous workshop divided into four learning and practice modules.
62591449|NCT06667752|EXPERIMENTAL|Advanced Antibacterial Wound Dressing|
62421502|NCT00820183|EXPERIMENTAL|quality improvement plan|It will be the group of primary health care teams who will undertake the quality improvement plan for hypertensive patients
62421503|NCT00820183|NO_INTERVENTION|non intervention|It will be the group of primary health care teams that will not undertake the quality improvement plan for hypertension control
62421504|NCT05575128|EXPERIMENTAL|Behavioral activation and medication optimization|"Behavioral activation (BA) will begin perioperatively and will span across 3 months postoperatively, with sessions approximately weekly or biweekly, depending on patient preference \& health condition.~Medications will be reviewed by a team of interventionists to minimize brain-toxic medications and optimize doses of antidepressants and other mental health medications. In-hospital and after discharge, the interventionists' role will include coordinating with the care teams to ensure that medication changes that were introduced preoperatively are maintained."
62591450|NCT06667752|ACTIVE_COMPARATOR|Aquacel Ag+ Extra|
62591451|NCT01672749||Spine based dual growing rod or VEPTR|Patients treated with the TROLLEY system will be compared with patients from the Chest Wall and Spine Deformity Study Group (CWSDSG) and the Growing Spine Study Group (GSSG) treated with a spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America). For each patient in the TROLLEY group a patient from each of the databases will be selected to be matched based on diagnosis, age, gender, and spine deformity classification.
62805647|NCT03748966|EXPERIMENTAL|Adults with XLH|Adults with X-linked hypophosphatemia will be treated with optimized doses of calcitriol (without phosphate supplementation) for one year
62805648|NCT03748966|EXPERIMENTAL|Children with XLH|Children (age 3-17) with X-linked hypophosphatemia will be treated with optimized doses of calcitriol (without phosphate supplementation) for one year
62805649|NCT06239740|EXPERIMENTAL|Electroacupuncture group|In the electroacupuncture group (EG), participants received acupuncture at 10 scalp points (Baihui \[GV20\], Ex-hn 1, 3 points of intelligence \[Shenting \[GV24\], Benshen \[GB13\] on both sides, Touwei \[ST8\] on both sides). Electroacupuncture was applied for 20 minutes at Benshen \[GB13\] and Touwei \[ST8\] on both sides. They also received acupuncture at Tai chong \[LV3\], Tai Yuan \[LU9\], and Tai Xi \[KI3\] on both sides, as shown in picture 1. Acupuncture sessions were weekly for 10 weeks.
62421505|NCT05575128|OTHER|Control (treatment as usual)|Participants in control arm will continue care as usual. They will receive printed resources for supporting sleep hygiene, stress reduction, cognitive and mental health exercises, as well as community resources for older adults.
62228959|NCT03558594|EXPERIMENTAL|Hypnosis|Participant will have one brief meeting with a clinician in which they will learn about hypnosis and be provided with an informational booklet and with audiorecordings of hypnosis exercises. Participants will be encouraged to listen to the hypnosis recordings as much as they would like, whenever they would like to listen. The recordings are short inductions followed by therapeutic suggestions, including post-hypnotic suggestions. Participants will relax in a comfortable position with their eyes closed and will simply listen to the audio recordings that will include an induction followed by suggestions for decreased pain and improvement in co-morbid symptoms (e.g., improved mood and optimism, relaxation, sleep quality).
62805650|NCT06239740|SHAM_COMPARATOR|Sham acupuncture|In the sham acupuncture control group (CG), participants received acupress or a brief needle insertion at He gu on both hands during the first and 10th weeks, marking the endpoint of the study
62805651|NCT06443372||Periodontitis|Periodontitis group (n = 23, generalized stage III) had interproximal CAL≥5 mm, along with PD≥6 mm and RBL extending to the mid-third of the root or beyond at 30% of the teeth or more. CAL was not originated from endodontic lesions draining through the marginal periodontium, dental caries extending into the cervical areas of the teeth, trauma-related gingival recession or distal bone loss in 2nd molars owing to extractions of 3rd molars. They had ≤4 teeth lost due to periodontitis.
62030297|NCT03649828|EXPERIMENTAL|kefir group|The kefir group (KG) received orally probiotic milk fermented with kefir grains and was compared with the control group (CG) that received only curd
62030298|NCT03649828|EXPERIMENTAL|control group|control group (CG) that received only curd
62030299|NCT04158375|EXPERIMENTAL|Insulin Resistant Exercise Group|Resistance (RE) training will be performed 4 days per week using a combination of upper and lower body exercises at 8-12 repetitions per set. Resistance training will be performed using a combination of upper and lower body exercises using machine and free weights. Upper body exercises are chest press, incline press, seated row, lat pull down, triceps extension, biceps curl and lateral raises. Major muscle groups for upper body exercises will include chest (pectoralis major and minor), arm (biceps and triceps), shoulder (deltoids) and back (latissimus dorsi and rhomboids). Lower body exercises are leg press, lunge (with body weight progressing to dumbbells), seated leg extension, seated leg curl, calf raises and abdominal crunches. Major muscle groups for the lower body exercises will be thighs (quadriceps and hamstrings), calves (gastrocnemius and soleus) and core (rectus abdominus and obliques).
62030300|NCT04158375|NO_INTERVENTION|Insulin Resistant Control Group|Participants in this group will perform no exercise for the 3 month study period.
62228960|NCT03558594|EXPERIMENTAL|Mindfulness|Participant will have one brief meeting with a clinician in which they will learn about mindfulness meditation and be provided with an informational booklet and with audio recordings of mindfulness exercises. Participants will learn Vipassana meditation by listening to audio recordings, which is the specific form of mindfulness meditation (MM) typically implemented in mindfulness research. The emphasis is placed upon developing focused attention on an object of awareness, such as the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.Participants will be encouraged to listen to the meditation recordings as much as they would like, whenever they would like to listen.
62421506|NCT05210998|ACTIVE_COMPARATOR|grup 1:|"Combined Exercise Group:~Gradual aerobic exercise training AND Respiratory muscle training"
62421507|NCT05210998|ACTIVE_COMPARATOR|grup 2:|"Aerobic Exercise Group:~Gradual Aerobic exercise training"
62421508|NCT04828629||Identification of prognostic factors in patients who have recovered from COVID-19|Selected prognosis factors will be analyzed in patients who have recovered from COVID-19
62805652|NCT06443372||Gingivitis|Gingivitis group (n = 26) exhibited PD was ≤3 mm and BOP was ≥30% in the entire mouth as well as no detectable interproximal CAL or RBL.
62805653|NCT06443372||Periodontal Health|Periodontally healthy controls (n = 26) had clinically healthy gingiva on intact periodontium with PD ≤3 mm and BOP \<10% and without detectable interproximal CAL and RBL.
62030301|NCT04158375|NO_INTERVENTION|Insulin Sensitive Lean Group|Participants in this group will have a baseline study for comparison to the insulin resistant groups.
62421509|NCT01222559|EXPERIMENTAL|co.don chondrosphere®|co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
62421510|NCT01222559|ACTIVE_COMPARATOR|Micofracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
62421511|NCT06672198||cesarean delivery|women undergoing elective caesarean section
62421512|NCT02224300|EXPERIMENTAL|Education|"Intervention group will receive the ELC for six weeks (15.9. - 26.10.2014) and comparison group will not receive it.~Members of the intervention group in will work in teams of 10 nurses with weekly questions (released in Mondays) based on patient-description existing in Moodle. One member of the team will send the solutions to questions once a week (in Thursdays) Moodle. Researcher will download the model-answer to Moodle once a week (in Fridays) and nurses will compare their answer to model answer (self-evaluation)."
62805654|NCT03693521|EXPERIMENTAL|Intervention group|Standard care at yearly check-up by diabetes-nurse in primary care. Handgrip strength measurement bilaterally. Measurement of physical activity level.
62805655|NCT03693521|ACTIVE_COMPARATOR|Control group|Standard care at yearly check-up by diabetes-nurse in primary care. Measurement of physical activity level.
62805656|NCT00141102|EXPERIMENTAL|A|
62805657|NCT00141102|ACTIVE_COMPARATOR|B|
62805658|NCT02840708|ACTIVE_COMPARATOR|125mcg|SK-1401 125mcg single inhalation
62805659|NCT02840708|ACTIVE_COMPARATOR|250mcg|SK-1401 250mcg single inhalation
62805660|NCT02840708|ACTIVE_COMPARATOR|500mcg|SK-1401 500mcg single inhalation
62805661|NCT03991845|EXPERIMENTAL|Low dose Vit D|All Patients belonging to arm 1 will be treated with low dose oral Vit D (2000 IU/day) for 12 weeks
62030302|NCT00715429|EXPERIMENTAL|vitamin D 50,000 U/d x 10d, + vitamin D 50,000 U weekly 7 wks|Vitamin D arm
62228961|NCT03558594|NO_INTERVENTION|No intervention|Participants will enroll in the study, but do not select a study intervention. They will complete study assessments on the same schedule as those participants who select either experimental arm.
62228962|NCT03680404|ACTIVE_COMPARATOR|Control (Phenylephrine)|Subjects will be administered phenylephrine at varying concentrations (10\^-2 to 10\^-8 M phenylephrine) at a rate of 2 microliters/minute for 10 minutes at each dose to construct a dose-response curve.
62228963|NCT03680404|EXPERIMENTAL|Phenylephrine + Apocynin|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and apocynin (10\^-4 M) at the same rate and for the same time as the control arm.
62228964|NCT03680404|EXPERIMENTAL|Phenylephrine + Allopurinol|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and allopurinol (10\^-5 M) at the same rate and for the same time as the control arm.
62228965|NCT03680404|EXPERIMENTAL|Phenylephrine + Tempol|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and Tempol (10\^-5 M) at the same rate and for the same time as the control arm.
62228966|NCT05787431||Unvaccinated individuals|COVID-19 recovered individuals who are not been vaccinated with any dose of COVID-19 vaccines.
62421513|NCT03909373||Cohort|patients with carpal tunnel syndrome
62421514|NCT03999229|ACTIVE_COMPARATOR|Blood transfusion with SNO agent|"Autologous blood transfusion packed red blood cells (RBCs) while inhaling S-nitrosylating agent (SNO)~A single intra venous blood transfusion of one unit of packed Red Blood Cells (RBCs) will be given over the standard transfusion flow rate of 5 ml/min under the direction of a physician or a licensed medical professional.~Inhalation of SNO agent, 20-40 parts per million will occur during the transfusion."
62591452|NCT01672749||TROLLEY system|Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs). The TROLLEY system is CE marked at the time of the study conduct.
62805662|NCT03991845|ACTIVE_COMPARATOR|High dose Vit D|All patients in this group will be treated with high dose oral Vit D (60,000 IU/week) for 12 weeks
62805663|NCT03991845|NO_INTERVENTION|Placebo|No Vit D supplementation will be given to patients in this group
62805664|NCT04844736|OTHER|Radiology Treatment Planning/Review|After patient consultation and enrollment, the patient will undergo routine CT simulation to initiate the radiation treatment planning process. The treating physician will contour the gross tumor volume (GTV) including the involved primary lung tumor and/or the involved lymph nodes. If the initial radiology review reflects concern for inadequate target volume delineation, the case will be flagged for multidisciplinary discussion between the radiation oncologist and radiologist.
62030303|NCT00715429|PLACEBO_COMPARATOR|placebo x 10d, + placebo weekly 7 wks|placebo
62228967|NCT05787431||Vaccinated individuals|COVID-19 recovered individuals who are vaccinated with one or more dose of COVID-19 vaccines, and stratified by sub-groups.
62228968|NCT00899548||Metastatic breast cancer patients|DNA methylation analysis, microarray analysis, polymerase chain reaction, laboratory biomarker analysis
62228969|NCT02201589|EXPERIMENTAL|Endovascular repair of ascending aorta|Endovascular repair with Valiant PS-IDE Stent Graft
62228970|NCT00504881|PLACEBO_COMPARATOR|Placebo|Matching Placebo tablets administered twice a day
62421515|NCT03999229|PLACEBO_COMPARATOR|Normal Saline with SNO agent|"Normal Saline Transfusion while inhaling S-nitrosylating agent (SNO)~A single intra venous infusion of one unit of normal saline, will be given over the standard transfusion flow rate of 5 ml/min under the direction of a physician or a licensed medical professional.~Inhalation of the SNO agent at 40 parts per million, will occur during the transfusion."
62421516|NCT06541730|EXPERIMENTAL|DA-302168S|
62421517|NCT06541730|PLACEBO_COMPARATOR|Placebo of DA-302168S|
62591453|NCT04532645||Patients with BRCA mutated ovarian cancer|BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting
62228971|NCT00504881|EXPERIMENTAL|Brivaracetam|A flexible dose of Brivaracetam tablets, administered twice a day, starting with a dose of 20 mg/day and could increase to 50 mg/day, 100 mg/day or 150 mg/day
62228972|NCT01966380|EXPERIMENTAL|Device, dressing|Intervention: Device, Leia dressing
62228973|NCT01966380|ACTIVE_COMPARATOR|Dressing , device|Intervention: Device: Hydroactive surgical dressing
62228974|NCT02179320|ACTIVE_COMPARATOR|Dry needling|Dry needling for myofascial pain syndrome, in the trapezius muscle.
62735410|NCT04600726||Older adults with healthy condition|Older adults who are free from neuro-cognitive disorders and non-communicable diseases
62805665|NCT00900510|EXPERIMENTAL|Drainage and placebo|Incision and drainage with placebo.
62805666|NCT00900510|ACTIVE_COMPARATOR|Drainage with TMP/SX|Drainage with Bactrim
62805667|NCT00833040|EXPERIMENTAL|Titration of sufentanil, the DBL sufentanil & PBO|"During the Titration Phase, patients titrated to the effective dosage of sublingual sufentanil NanoTab™(20, 30, 40, 60 or 80 mcg). One sublingual sufentanil NanoTab™ was taken as needed for breakthrough pain.~During the Double-Blind Phase, patients were then randomized to one of six treatment sequences, each of which included seven active doses of sublingual sufentanil (dosage determined in Titration Phase) and three placebo doses taken in random order. One NanoTab™ was taken as needed for breakthrough pain."
62805668|NCT00420576|EXPERIMENTAL|1|Low Dose Danggui Buxue Tang (1.5g)
62805669|NCT00420576|EXPERIMENTAL|2|Middle Dose Danggui Buxue Tang(3g)
62805670|NCT00420576|EXPERIMENTAL|3|High Dose Danggui Buxue Tang (6g)
62805671|NCT02122679|ACTIVE_COMPARATOR|Study group|Receive tranexamic acid in operating room.
62805672|NCT02122679|PLACEBO_COMPARATOR|Placebo group|Receive placebo in the operating room
62030304|NCT03699943|ACTIVE_COMPARATOR|CaverStem 1.0 - Low|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. low dose 30 cc
62030305|NCT03699943|ACTIVE_COMPARATOR|CaverStem 1.0 - High|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. high dose 60 cc
62228975|NCT02179320|SHAM_COMPARATOR|Sham needling|Superficial dry needling in the trapezius muscle
62228976|NCT06033651||Only 1 arm for the study|All participants shall receive the same treatment.
62228977|NCT02318797|ACTIVE_COMPARATOR|Patient Self-Directed Care|See intervention description
62228978|NCT02318797|ACTIVE_COMPARATOR|Provider-Supported Integrated Care|See intervention description
62805673|NCT00730158|EXPERIMENTAL|Arm A|irinotecan+ KD018
62805674|NCT00730158|EXPERIMENTAL|Arm B|irinotecan + placebo
62805675|NCT01915160|ACTIVE_COMPARATOR|treatment as usual|Trauma Focused- Cognitive Behavioral Therapy (TF-CBT)
62805676|NCT01915160|EXPERIMENTAL|tablet assisted therapy toolkit|electronically assisted Trauma Focused-Cognitive Behavioral Therapy (eTF-CBT)
62805677|NCT05754723|EXPERIMENTAL|e-Psychotherapy|Participants in the treatment group will receive access to the hub's services which begin with six weeks of online psychoeducation. Participants will be recruited through on-campus flyers, advertisements and wellness-center announcements, media advertisements, expert end-user referrals, and self-referrals. Participants will be excluded if they have active psychosis, acute mania, and/or active suicidal or homicidal ideation, and have received psychoeducation or psychotherapy like that offered by our proposed hub in the past six months. Participants with high disorder severity will be referred to other community resources determined by clinicians and therapists on the research team.
62805678|NCT05754723|NO_INTERVENTION|Treatment as Usual|TAU will consist of medications, regular physician or clinician visits, referrals or consultations that are conducted outside of the current research study.
62228979|NCT01097785|ACTIVE_COMPARATOR|Simvastatin|40 mg Simvastatin 1 pill every day for 30 days
62228980|NCT01097785|PLACEBO_COMPARATOR|Placebo|Placebo cap 1 pill every day for 30 days
62228981|NCT04260425|EXPERIMENTAL|High then low avenanthramides content oats|This arm will receive the high avenanthramides content oatmeal at the first session and the low avenanthramides content oatmeal at the second session. Sessions will be at least 5 days apart.
62228982|NCT04260425|EXPERIMENTAL|Low then high avenanthramides content oats|This arm will receive the low avenanthramides content oatmeal at the first session and the high avenanthramides content oatmeal at the second session. Sessions will be at least 5 days apart.
62735411|NCT06354348|EXPERIMENTAL|Total gastrectomy|Patients with esophagojejunostomy on endoscopic evaluation were considered as total gastrectomy.
62805679|NCT02798393|SHAM_COMPARATOR|HL-Sham|The placebo device (also referred to as the HL-SHAM device) will have an identical appearance to the HL-NIR device. Though the HL-NIR device will be applied, there will be no treatment administered.
62805680|NCT02798393|EXPERIMENTAL|HL-NIR|The device referred to as the HL-NIR device includes both a podiatric or foot and leg component, similar to a loose fitting boot, that is easily applied to all subjects (one size fits all). Application of the device is snug but comfortable without risk for constriction of soft tissue.
62805681|NCT05353322|EXPERIMENTAL|Sedentary Break Condition > Control Condition|Participants will be assigned to the sedentary break or control condition at each lab visit. If assigned to the sedentary break condition at lab visit 1, participants will be assigned to the control condition at visit 2 (and vice versa). During the lab visit, participants will wear a heart rate monitor and ambulatory blood pressure monitor, and eat a controlled diet. Participants will have an IV inserted and blood will be drawn 11 times throughout the visit. Participants will also eat a controlled diet for two days prior to the lab visit.
62228983|NCT06373029||Experimental group|
62228984|NCT00160784|ACTIVE_COMPARATOR|Arthroscopic Manipulation|Manipulation of Shoulder performed during arthroscopy
62228985|NCT00160784|ACTIVE_COMPARATOR|Home exercise program|Shoulder exercise program performed at home to increase shoulder function
62228986|NCT02148549|EXPERIMENTAL|Optimal chemotherapy courses|Neoadjuvant chemotherapy 4 courses of FIRINOX early 5 patients, and 8 courses of FIRINOX subsequent 5 patients
62805682|NCT05353322|EXPERIMENTAL|Control Condition > Sedentary Break Condition|Participants will be assigned to the sedentary break or control condition at each lab visit. If assigned to the sedentary break condition at lab visit 1, participants will be assigned to the control condition at visit 2 (and vice versa). During the lab visit, participants will wear a heart rate monitor and ambulatory blood pressure monitor, and eat a controlled diet. Participants will have an IV inserted and blood will be drawn 11 times throughout the visit. Participants will also eat a controlled diet for two days prior to the lab visit.
62228987|NCT01975974||Ultrasound|Ultrasound guided peripheral vascular access
62421518|NCT03853213|EXPERIMENTAL|Cognitive Bias Modification Training|"Participants in this intervention group complete two tasks, each repeated 8 times over the course of 4 weeks (twice per week). The first task is Cognitive Bias Modification Training for Attention. It is designed to reinforce attention away from ACS threat-related stimuli (e.g., death, chest pain) and toward neutral stimuli (e.g., curve, barn doors). The second task is Cognitive Bias Modification Training for Interpretation. It is designed to train participants to appraise ambiguous information that is potentially related to ACS threat as benign."
62421519|NCT03853213|SHAM_COMPARATOR|Attention Control Training|Participants in this placebo control group complete two tasks, each repeated 8 times over the course of 4 weeks (twice per week). The first task is the placebo version of Cognitive Bias Modification Training for Attention. It is designed NOT to train attention toward or away from threatening or neutral information. The second task is the placebo version of Cognitive Bias Modification Training for Interpretation. It is designed NOT to train the interpretation of information as either threatening or benign.
62421520|NCT00710060|EXPERIMENTAL|1|Participating communities will receive the Community Popular Opinion Leader intervention and HIV/STD educational materials.
62421521|NCT00710060|ACTIVE_COMPARATOR|2|Participating communities will receive HIV/STD educational materials only.
62421522|NCT04118855|EXPERIMENTAL|Neoadjuvant arm|Patients will receive axitinib 5 mg bid combined with Toripalimab 3mg/KG q3w for up to 12 wk.
62421523|NCT02177864|EXPERIMENTAL|Fiber|
62421524|NCT02177864|PLACEBO_COMPARATOR|Placebo|
62421525|NCT01281631|EXPERIMENTAL|Low dose NP001|Low drug dose
62421526|NCT01281631|EXPERIMENTAL|High dose NP001|High drug dose
62421527|NCT01281631|PLACEBO_COMPARATOR|Placebo|normal saline
62805683|NCT05787340|EXPERIMENTAL|BETY exercise group|"intervention group Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach) is a group exercise method that conforms to the biopsychosocial model via telerehabilitation~Exercise dosage is 60 minute three days a week."
62805684|NCT02899936|ACTIVE_COMPARATOR|2 drug dose - DA|Drug treatment with two-drug regimen diethylcarbamazine and albendazole (DA)
62805685|NCT02899936|EXPERIMENTAL|3 drug dose - IDA|Triple-drug regimen Ivermectin, diethylcarbamazine and albendazole (IDA)
62228988|NCT02652403|ACTIVE_COMPARATOR|Complete conventional dentures|Complete dentures fabricated by conventional technique.
62805686|NCT05157295|EXPERIMENTAL|Experimental Group|100 U of onabotulinumtoxinA toxin diluted in 10 mL of saline cystoscopically injected into approximately 4 different detrusor muscle sites along the posterior bladder wall and dome.
62805687|NCT05157295|ACTIVE_COMPARATOR|Control Group|100 U of onabotulinumtoxinA toxin diluted in 10 mL of saline cystoscopically injected into approximately 20 different detrusor muscle sites along the posterior bladder wall and dome.
62805688|NCT01412177|EXPERIMENTAL|OTO-104|
62805689|NCT01412177|PLACEBO_COMPARATOR|Placebo|
62805690|NCT05817565||intervention group|"Patients underwent physical therapy program 3days/week for three months in the form of~* Heat therapy by using infrared on the cervical region for relaxation of spasmed neck muscles, while the patient in sitting position.~* While the patient is sitting, the ultrasound was applied on the para spinal muscles of cervical region for controlling pain.~* Intermittent cervical traction (traction force equal 8% of body weight) was applied with the patient lying supine and the head in neutral position."
62805691|NCT01758809|ACTIVE_COMPARATOR|Bupivacaine|
62228989|NCT02652403|ACTIVE_COMPARATOR|Complete simplified dentures|Complete dentures fabricated by simplified technique
62228990|NCT06421610|EXPERIMENTAL|PITAC|"Malignant Pleural Effusion (MPE) from colorectal or appendix cancer will be treated with Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) using oxaliplatin 92 mg/m2 in 150 ml dextrose. MPE from non-colorectal or -appendix cancer will be treated with PITAC using cisplatin 10.5 mg/m2 in 150 ml saline and 2.1 mg/m2 in 50 ml saline.~PITAC is performed with a intrapleural pressure of 12 mmHg and the aerosolised chemotherapy will be nebulized at a maximum pressure of 300 PSI and a flow-rate of 0.5-1.8 ml/min. The PITAC directed treatment will be planned with 4 week intervals and patients may receive bi-directional systemic chemotherapy simultaneously."
62228991|NCT00905112|EXPERIMENTAL|MOMS|Receives manual therapy, stabilization exercise and patient education
62228992|NCT00905112|ACTIVE_COMPARATOR|STOB|Receive standard obstetrical care
62228993|NCT04044274|EXPERIMENTAL|IOPstim|
62805692|NCT01758809|OTHER|Intravenous Patient Controlled Analgesia|postoperative pain control with intravenous patient controlled analgesia
62228994|NCT04032587|EXPERIMENTAL|Non-treatment seeking subjects with Alcohol Use Disorder|AUD; mild vs. moderate to heavy
62421528|NCT04348292|EXPERIMENTAL|Treatment (sirolimus, durvalumab)|Patients receive sirolimus PO QD on days 1-21 in the absence of disease progression or unacceptable toxicity. Starting on day 22, patients receive durvalumab IV over 1 hour. Treatment with durvalumab repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Within a 2-3 week period after the second dose of durvalumab, but not earlier than two weeks after the administration of durvalumab, patients undergo standard of care surgery.
62805693|NCT02754570|EXPERIMENTAL|Pilocarpine group|Subjects with open-angle glaucoma and ocular hypertension that are currently taking latanoprost
62805694|NCT03066869|EXPERIMENTAL|H.P. ACTHAR GEL|
62805695|NCT05167435|EXPERIMENTAL|Group A (Intervention)|"Myofascial release (Following Cross-hand release techniques of myofascial release in a manner of 2 minutes approach:~Cross-Hand Release of Back \[For Thoracolumbar Fascia\] Cross-Hand Release of the Lumbosacral Junction \[L5-S1\] Cross-Hand Release of Lateral low back area \[for quadratus lumborum\]) will be provided with conventional therapy including stretching exercises (Stretching of Latissimus Dorsi \[10 seconds hold, 10 reps, 2 sets\], Quadratus Lumborum Stretching \[10 seconds hold, 3 reps, 1 set bilaterally\], Lower Back Stretching \[10 seconds hold, 10 reps, 2 sets\], Hamstring Stretching \[10 seconds hold, 10 reps, 2 sets bilaterally\], Tensor Fasciae Latae Stretching \[10 sec hold, 10 reps, 2 sets bilaterally\] with duration rest will be of thirty seconds after five minutes) and Thermotherapy will be given for 20 minutes"
62805696|NCT05167435|ACTIVE_COMPARATOR|Group B (Control)|Posterior-anterior glide: Grade 1-4 \[depending on tolerance\] (120 oscillations per minute x 3 sets, Duration of rest between each set: 30 seconds) will be provided with the same conventional therapy as in Group A (Intervention)
62805697|NCT03153514|EXPERIMENTAL|Obinutuzumab|"Obinutuzumab i.v.~Cycle 1: in the peri-transplant and transplantation phase~Cycle 2: if active disease and/or MRD positivity on day +60, +90, +180 or +270"
62228995|NCT04032587|ACTIVE_COMPARATOR|Healthy Controls|
62805698|NCT00841490||1|Intellectually \& Developmentally Disabled Adults
62805699|NCT00841490||2|Control Group of Adults without Intellectual \& Developmental Disabilities
62591454|NCT05660005|ACTIVE_COMPARATOR|Piriformis Muscle Stretching|Stretching based on the FAIR (flexion, adduction and internal rotation) position, which provides the most effective stretching on the piriformis muscle, was demonstrated, and a illustrated brochure containing the explanatory information of the application was given to the group participants. With the ipsilateral hip flexion, adduction and internal rotation, the foot is positioned to the lateral side of the contralateral knee, thus long-term passive stretching is targeted in this position. Individuals were asked to leave a 2-days gap between the two stretching exercise sessions by performing 10 repetitions (minimum duration of 15 s stretching, 30 s rest period between repetitions) 3 sets and 3 days of a week.
62591455|NCT05660005|ACTIVE_COMPARATOR|Piriformis Muscle Self Myofascial Release|The patient was presented with the anatomically localized area of the PiM on a visual anatomy map and they were encouraged to find this area on their body. They were asked to verify the trigger points along the PiM and then sat on the trigger points with the help of a tennis ball. Individuals were taught the PiM-SMR exercise, in which they would make forward-backward, right-left, diagonal and circular movements on the ball using their body weight. There was a continuation of the application with an interval of 2 days; 3 times a day with 10 repetitions (the application was for 1 min and 30s rest period between repetitions).
62228996|NCT02711111|EXPERIMENTAL|orthodontic bone anchor|new bone anchor device, which creates anterior traction on the upper jaw. Placed on the chin-region intra-orally.
62228997|NCT02711111|ACTIVE_COMPARATOR|face mask protraction|control group, conventional treatment method. Face mask creates anterior traction on the upper jaw
62591456|NCT05660005|EXPERIMENTAL|Control Group|The individuals who refused to apply stretching or releasing included to the control group. They perform only home exercises of hip strengthening
62591457|NCT01869699|PLACEBO_COMPARATOR|Normal saline placebo|Normal saline 100 mLs intravenous, administered over 15 minutes
62591458|NCT01869699|EXPERIMENTAL|Acetaminophen|Acetaminophen 1 gram/100 mLs intravenous, single dose administered over 15 minutes
62591459|NCT06277635|ACTIVE_COMPARATOR|Silymarin group|Silymarin 140 mg oral tid pc + methotrexate weekly + folic acid 5 mg oral OD pc for 12 weeks
62591460|NCT06277635|PLACEBO_COMPARATOR|Placebo group|Placebo + methotrexate weekly + folic acid 5 mg oral OD pc for 12 weeks
62805700|NCT02855281||NSCLC with pleural effusion|The population for selection of potential study participants is comprised of clinical routine patients presenting with (suspected malignant) pleural effusion. These patients must have an indication for pleural puncture. The cause and nature of the pleural effusion at this time point will be unknown in many cases. To establish this, further diagnostic procedures are required. Only patients with confirmed diagnosis of non-small cell lung cancer will be included in the data analysis.
62805701|NCT05899439||Subjects with diabetes age 0 to 100 years|People who have not been diagnosed with type 1 diabetes
62805702|NCT05899439||Subjects with type 1 diabetes age 0 to 100 years|People who have been diagnosed with type 1 diabetes
62805703|NCT01059097|ACTIVE_COMPARATOR|High volume surgeons|high volume surgeons performed at least 18 PD/year.
62805704|NCT01059097|ACTIVE_COMPARATOR|Low volume surgeons|low volume surgeons performed less than 18 PD/year.
62805705|NCT02579460|EXPERIMENTAL|Barrett's esophagus patients|Patients with Barrett's Esophagus will be enrolled. The intervention is cessation of acid-suppressing medications. Biopsies will be taken during endoscopy at Day 0, 7, and 14.
62805706|NCT01679496|EXPERIMENTAL|Food items|Food items low in saturated fat and high in polyunsaturated fat
62228998|NCT04455438|EXPERIMENTAL|SBRT Level 1|The starting dose level will be SBRT 30 Gy in 5 fractions (level 1 or L1).
62228999|NCT04455438|EXPERIMENTAL|SBRT Level 2|If the starting dose is tolerated in the first 5 patients, the next dose will be SBRT 40 Gy in 5 fractions (level 2 or L2)
62229000|NCT04455438|EXPERIMENTAL|SBRT Level 3|If the second dose is tolerated in the next 5 patients, the next dose will be SBRT 50 Gy in 5 fractions (level 3 or L3)
62229001|NCT05033171|EXPERIMENTAL|Study group|"Patients with scoliosis induced surgical indication (Cobb-degree\>45).~* Posterior screw-rod fixation segmentdesis~* Before the implantation, right after the implantation and after the in situ bending 3D scanning of the rod using Artec Eva Spider type manual 3D scanner will be performed. Scanning is possible from a more than 60 cm distance, so that means the operational area stays sterile.~* EOS Micro Dose imaging will be done on the third day after surgery, on the third, the sixth, the twelfth and twenty fourth month after surgery (as in the actual clinical protocal)."
62591461|NCT05380284|EXPERIMENTAL|Experimental Group|Senior Driving Simulation Training
62805707|NCT01679496|PLACEBO_COMPARATOR|Control food items|Food items containing saturated fat and polyunsaturated fat according to a traditional Norwegian diet
62591462|NCT05380284|OTHER|Control Group|Ｗaiting-list
62735412|NCT06354348|EXPERIMENTAL|Distal gastrectomy|Patients with resected mid-corpus with preserved corpus, fundus and cardia and gastrojejunostomy were considered as distal gastrectomy.
62735413|NCT06354348|EXPERIMENTAL|No gastrectomy status|Has not undergone a gastrectomy operation
62805708|NCT02522247|ACTIVE_COMPARATOR|Uvulopalatoplasty|Surgery with cold steel, single sutures of palate and tonsillar pillars including palatopharyngeal muscle
62805709|NCT02522247|NO_INTERVENTION|Controls|Only waiting 6 months
62805710|NCT00694616|OTHER|1|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
62805711|NCT00694616|OTHER|2|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
62805712|NCT03188159|EXPERIMENTAL|IV Vinorelbine|IV Vinorelbine 25mg/m2
62805713|NCT05450367||patients with a haematological malignancy treated with immunotherapy|
62229002|NCT01175447|EXPERIMENTAL|Chemoradiotherapy with S-1|radiation 54Gy over 30 fractions,and concurrent with s-1 on days 1-14 and 29-42
62805714|NCT06073808|EXPERIMENTAL|Assess dHACM viability|Implantation of dHACM in patients during Nipple Sparing Mastectomy; test arm. The device will be implanted in one breast per patient during bilateral nipple sparing mastectomy.
62805715|NCT06073808|ACTIVE_COMPARATOR|Assess dHACM effectiveness against control device|Implantation of control device in patients during Nipple Sparing Mastectomy; control arm. The device will be implanted in one breast per patient during bilateral nipple sparing mastectomy.
62805716|NCT00697931|EXPERIMENTAL|Group A|
62229003|NCT06143306|EXPERIMENTAL|Bupivacaine group|Patients undergoing total shoulder arthroplasty or reverse total shoulderarthroplasty aged 18- 85, randomized to the experimental group.
62229004|NCT06143306|PLACEBO_COMPARATOR|control group|Patients undergoing total shoulder arthroplasty or reverse total shoulderarthroplasty aged 18- 85, randomized to the control group.
62591463|NCT03280082|OTHER|MUAC Program|"At the CRENAS, MUAC as unique anthropometric criteria for admission, monitoring, and care for the SAM output will be used.~The criteria for admission include:~* MUAC \<120 mm~* Bilateral edema of grade + or ++~The criteria for release of care include:~* MUAC ≥ 125 mm at 2 consecutive visits~* Minimum stay 3 weeks in the program~* Absence of acute medical complications~* Absence of edema"
62805717|NCT00697931|ACTIVE_COMPARATOR|Group B|
62805718|NCT04983966|EXPERIMENTAL|Desflurane group|General anesthesia with volatile agent of desflurane
62805719|NCT04983966|ACTIVE_COMPARATOR|Remimazolam group|Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
62805720|NCT02292108|EXPERIMENTAL|Hypnosis and dietetic counselling|Patient will benefit of usual dietetic counselling and experimental hypnosis
62805721|NCT02292108|OTHER|dietetic counselling|Patient will only benefit of usual dietetic counselling
62805722|NCT02103309|OTHER|DACP, then 1DAM|Nelfilcon A contact lenses worn first, then etafilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable mode.
62805723|NCT02103309|OTHER|1DAM, then DACP|Etafilcon A contact lenses worn first, then nelfilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable mode.
62805724|NCT03633344|ACTIVE_COMPARATOR|Carbowhite|3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
62805725|NCT03633344|PLACEBO_COMPARATOR|Carbowhite placebo|3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
62805726|NCT03421522|EXPERIMENTAL|Intervention - ICBN preservation|For participants randomized to the ICBN preserving technique, surgeons will perform axillary dissection in which the second ICBN, just inferior to the axillary vein, will be preserved.
62805727|NCT03421522|NO_INTERVENTION|Control - Usual Care|For participants allocated to the usual surgical care arm, attending surgeons will perform a standard Level 1 and 2 axillary node dissection (sacrifice of the ICBN), either alone or with mastectomy or breast conserving surgery.
62805728|NCT03788174|EXPERIMENTAL|Apatinib plus POF|Apatinib (500 mg qd p.o.) plus POF until disease progression or intolerable toxicity or refused by the patients.
62805729|NCT03071068|EXPERIMENTAL|THR-317 4mg|anti-PlGF recombinant monoclonal antibody, 4mg dose
62805730|NCT03071068|EXPERIMENTAL|THR-317 8mg|anti-PlGF recombinant monoclonal antibody, 8mg dose
62805731|NCT02981368|EXPERIMENTAL|18F-DCFPyL Injection|9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
62805732|NCT00904813|ACTIVE_COMPARATOR|1. Short-course RT (5x5 Gy) + surgery within 1 week (SRT)|RT=Preoperative radiotherapy Gy=Gray
62805733|NCT00904813|ACTIVE_COMPARATOR|2. Short-course RT (5x5 Gy) + surgery after 4-8 weeks (SRT-delay)|RT=Preoperative radiotherapy Gy= Gray
62805734|NCT00904813|ACTIVE_COMPARATOR|3. Long-course RT (25x2 Gy) + surgery after 4-8 weeks (LRT-delay)|RT= Preoperative radiotherapy Gy= Gray
62805735|NCT03274908||Group|
62805736|NCT02454023|ACTIVE_COMPARATOR|Standard of care|Patients receive usual standard of care for investigating obstructive sleep apnea after stroke/transient ischemic attack, which is in-laboratory polysomnography.
62805737|NCT02454023|EXPERIMENTAL|Portable sleep monitor (ApneaLink Air)|Patients will undergo screening for obstructive sleep apnea using the ApneaLink Air portable sleep monitor.
62805738|NCT02967653|PLACEBO_COMPARATOR|Placebo|Patients will be randomized to a placebo a day using simple 1:1 randomization using random.org, for 12 weeks.
62805739|NCT02967653|EXPERIMENTAL|Atorvastatin|Patients will be randomized to Atorvastatin 20mg/day for 12 weeks or pill placebo.
62805740|NCT06035731|EXPERIMENTAL|group A: well-being care performed by SOCIO-AESTHETICS|"Group A will benefit from 4 sessions of well being care performed by a qualified socio-aesthetics, during 4 consecutive chemotherapy administrations.~Patients included will have following interventions :~quality of life: PCQ Pain: EVA Anxiety: HADS"
62229005|NCT00494481|PLACEBO_COMPARATOR|1|Docetaxel + placebo vandetanib
62229006|NCT00494481|EXPERIMENTAL|2|Vandetanib + Docetaxel
62229007|NCT05126433|EXPERIMENTAL|Urothelial Cancer Cohort|Participants with advanced (metastatic and/or unresectable) urothelial carcinoma who have progressed on platinum-containing regimen (prior therapies may include but are not limited to immune checkpoint inhibitor, enformumab vendotin, or sacituzumab govitecan) will receive Lurbinectedin 3.2 mg/m\^2 intravenous (IV) on Day 1 of every 3 weeks (Q3W) cycle until confirmed disease progression, withdrawal of participant consent, participant lost to follow-up, unacceptable toxicity, or the study or individual cohort may be terminated by the sponsor for lack of efficacy signal or any other reason.
62229008|NCT05126433|EXPERIMENTAL|Poorly Differentiated Neuroendocrine Carcinomas Cohort|Participants with advanced (metastatic and/or unresectable) poorly differentiated neuroendocrine carcinomas who received at least 1 prior line of therapy will receive Lurbinectedin 3.2 mg/m\^2 intravenous (IV) on Day 1 of every 3 weeks (Q3W) cycle until confirmed disease progression, withdrawal of participant consent, participant lost to follow-up, unacceptable toxicity, or the study or individual cohort may be terminated by the sponsor for lack of efficacy signal or any other reason.
62735414|NCT05441215|EXPERIMENTAL|nirmatrelvir/ritonavir|nirmatrelvir/ritonavir will be given by mouth two times a day as a tablet
62819481|NCT02743208|ACTIVE_COMPARATOR|Furlong H-A.C. femoral stem|Total hip arthroplasty (THA) using a Furlong H-A.C. femoral stem, and a Furlong H-A.C. CSF plus acetabular cup system.
62805741|NCT06035731|NO_INTERVENTION|group B: control|"Group B (control) will apply the dermo-cosmetic products themselves (self-care) without intervention of the socio-aesthetician, during 4 consecutive chemotherapy administrations.~quality of life: PCQ Pain: EVA Anxiety: HADS"
62229009|NCT05126433|EXPERIMENTAL|Homologous Recombination Deficient-Positive Malignancies Agnostic Cohort|Participants with advanced (metastatic and/or unresectable) endometrial, biliary tract, urothelial, breast (TNBC or HR+HER2- breast cancer), pancreas, gastric, or esophageal solid tumors with preidentified germline and/or somatic pathogenic mutation and received at least 1 prior line of therapy will receive Lurbinectedin 3.2 mg/m\^2 intravenous (IV) on Day 1 of every 3 weeks (Q3W) cycle until confirmed disease progression, withdrawal of participant consent, participant lost to follow-up, unacceptable toxicity, or the study or individual cohort may be terminated by the sponsor for lack of efficacy signal or any other reason.
62229010|NCT00824161|EXPERIMENTAL|1|TAS-109
62805742|NCT03540108|EXPERIMENTAL|Experimental: L. plantarum ECGC 13110402 (LPLDL®)|Lactobacillus plantarum ECGC 13110402 (LPLDL®) equivalent to 4 x10\^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
62229011|NCT00647725|ACTIVE_COMPARATOR|I|Active phrase analgesia
62229012|NCT00647725|ACTIVE_COMPARATOR|II|Latent phrase analgesia
62229013|NCT01502631|ACTIVE_COMPARATOR|SUN13837|
62229014|NCT01502631|PLACEBO_COMPARATOR|Placebo|
62229015|NCT04310423|PLACEBO_COMPARATOR|Placebo|Matched to endotoxin
62229016|NCT04310423|EXPERIMENTAL|Endotoxin|Bolus dose of endotoxin (0.8 ng/kg)
62229017|NCT06186570|EXPERIMENTAL|Online-Based Self-Help Intervention|The online-based self-help intervention is implemented as a six-week self-help intervention that is primarily based on Metacognitive Training (MKT), Mindfulness-Based Group Therapy (MBGT), and elements of cognitive behavioural therapy. It is conducted online and includes worksheets, audio, and interactive files. Participants work themselves through the intervention, based on their own needs and speed. All participants are allowed to continue parallel implemented standard scheduled treatment (TAU; for a description of TAU, see the section below).
62805743|NCT03540108|PLACEBO_COMPARATOR|Placebo Comparator: Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
62805744|NCT06185517|EXPERIMENTAL|Comprehension Phase|After an initial translation of the questionnaires into French, the aim of this phase is to ascertain the level of understanding of each questionnaire item and any suggestions, during a telephone or face-to-face interview.
62229018|NCT06186570|NO_INTERVENTION|Waitlist-Control Group|The waitlist control group will not receive any additional intervention but is allowed to continue standard scheduled treatment (WL-TAU). This includes various forms of psychotherapeutic, pharmacologic, psychosocial, online, and other self-help interventions, either carried out individually or within a group. After study completion, participants in the waitlist-control group will equally receive the online-based self-help intervention.
62229019|NCT03875846||Intraoperative Hemodynamic Improvement|The primary outcome will examine the magnitude of change in the Toe-Brachial Index (TBI) between the beginning and the end of the procedure. The two measurements will be taken before- and after- vascular sheaths had been placed.
62819482|NCT03670680|EXPERIMENTAL|Lina LibrataTM|Use of the Lina LibrataTM
62819483|NCT05678608|EXPERIMENTAL|spinal cord tumors group|
62229020|NCT03616197|ACTIVE_COMPARATOR|Group 1|"Thin Biotype group has described as Group 1. The biotypes of the terminal teeth adjacent to the free gingival graft region were determined by the Probe transparency method.~The mesial terminal tooth (MTT) was defined as the first tooth adjacent to the mesial side of the tooth / teeth to which the FGG will be applied. The distal terminal tooth (DTT) was defined as the first tooth adjacent to the distal side of the tooth / teeth to which the FGG will be applied. If MTT and DTT had thin biotype, the patient was assigned to the thin biotype group."
62229021|NCT03616197|ACTIVE_COMPARATOR|Group 2|"Thick biotype group has described as Group 2. The biotypes of the terminal teeth adjacent to the free gingival graft region were determined by the Probe transparency method.~The mesial terminal tooth (MTT) was defined as the first tooth adjacent to the mesial side of the tooth / teeth to which the FGG will be applied. The distal terminal tooth (DTT) was defined as the first tooth adjacent to the distal side of the tooth / teeth to which the FGG will be applied. If MTT and DTT had thick biotype, the patient was assigned to the thick biotype group."
62229022|NCT03105622|EXPERIMENTAL|Running+screen|Running on a treadmill at 60% VO2peak for 30 minutes while watching television.
62229023|NCT03105622|EXPERIMENTAL|Running+music|Running on a treadmill at 60% VO2peak for 30 minutes while listening to music.
62229024|NCT03105622|EXPERIMENTAL|Running without stimulus (control condition)|Running on a treadmill at 60% VO2peak for 30 minutes with no other stimuli.
62229025|NCT01943409|ACTIVE_COMPARATOR|Intralipid|Patients will receive Intralipid, which is the standard lipid emulsion used in the hospital
62229026|NCT01943409|EXPERIMENTAL|ClinOleic|Patients that are randomized to receive ClinOleic as a lipid emulsion in their PN, instead of Intralipid. ClinOleic is approved by Health Canada. The amount of calories from the lipid emulsion will be equivalent in the standard of care group and in the ClinOleic group.
62229027|NCT06085001||Women with preeclampsia|women with symptoms of preeclampsia from antenatal clinic or triage will be offered Lumella test along with traditional blood tests. If Lumella test is positive which will be compared with the traditional blood test results. Once 50 positive cases have been analysed the study results will be submitted to NICE.
62229028|NCT05034120|EXPERIMENTAL|MB:Single arm|10 subjects will be enrolled in this arm. The subjects will take a single dose XZP-3621 tablet after a low-fat meal and perform excretion collection consistently.
62229029|NCT05034120|EXPERIMENTAL|FE:Arm A|Cycle1 Day1: fasting; Cycle2 Day10: High-fat meal; Cycle3 Day19: Low-fat meal
62229030|NCT05034120|EXPERIMENTAL|FE:Arm B|Cycle1 Day1: High-fat meal; Cycle2 Day10: Low-fat meal; Cycle3 Day19: fasting
62229031|NCT05034120|EXPERIMENTAL|FE:Arm C|Cycle1 Day1: Low-fat meal; Cycle2 Day10: fasting; Cycle3 Day19: High-fat meal
62591464|NCT03280082|OTHER|Standard Program|"Regular screenings in the communities on children between 6 and 59 months of age. Children with MUAC\<125 mm will be referred to Nutrition Centers for admission.~The criteria for admission include:~* MUAC\<115 mm and/or~* Z score \<-3 and /or~* Bilateral edema of grade + or ++~The criteria for release of care include:~* MUAC ≥ 125 mm at 2 consecutive visits~* Minimum stay 3 weeks in the program~* Absence of acute medical complications~* Absence of edema"
62805745|NCT06185517|EXPERIMENTAL|Validation Phase|The aim is to validate the French translation of the Michigan Retinal Degeneration Questionnaire (MRDQ) and the Michigan Vision-Related Anxiety Questionnaire (MVAQ).
62229032|NCT05034120|EXPERIMENTAL|FE:Arm D|Cycle1 Day1: fasting; Cycle2 Day10: Low-fat meal; Cycle3 Day19: High-fat meal
62805746|NCT02567981|EXPERIMENTAL|21 micronutrient fortified supplement|21 micronutrient-fortified supplement
62805747|NCT02567981|ACTIVE_COMPARATOR|Current Standard of Nutritional Care|Cereal Fortificado (Fortified Cereal) Ferrous sulphate Vitamin A
62805748|NCT04178798|EXPERIMENTAL|Arm A_Acalabrutinib|Patients assigned to arm A, will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos schedule until disease progression, unacceptable toxicity or early withdrawal.
62805749|NCT04178798|NO_INTERVENTION|Arm B_Standard of care|"Patients assigned to arm B, will receive standard of care for the management of early Binet stage A patients clinical observation (watch \& wait) until disease progression or early withdrawal."
62805750|NCT04763395||non-severe COVID19|"* Patients with mild symptoms (i.e., fever, cough, expectoration, and other upper respiratory tract symptoms), and without abnormalities, or with mild changes on chest radiography, were classified as non-severe types.~* A mild change in chest radiography is defined by multiple small patchy shadows and interstitial changes, mainly in the outer zone of the lung and under the pleura."
62805751|NCT04763395||Severe Covid19|Severe COVID19 was defined by the presence of any of the following conditions: i) significantly increased respiration rate (RR): RR \>-30 times/minute; ii) hypoxia: oxygen saturation (resting state) \<-93%; iii) blood gas analysis: partial pressure of oxygen/fraction of inspired oxygen (PaO2) /FiO2) \<- 300 mmHg (millimeters of Mercury), or iv) the occurrence of respiratory or another organ failure that require Intensive care unit (ICU) monitoring and treatment, or shock
62805752|NCT00955214|EXPERIMENTAL|2.5mm Paclitaxel-eluting stent|
62805753|NCT05417750|EXPERIMENTAL|Experimental: Cohort 1|dose escalation group: participants with advanced solid tumors using cryopreserved GC101 TIL
62805754|NCT05417750|EXPERIMENTAL|Experimental: Cohort 2|participants with advanced cervix tumors using cryopreserved GC101 TIL
62805755|NCT05417750|EXPERIMENTAL|Experimental: Cohort 3|participants with advanced malignant melanoma using cryopreserved GC101 TIL
62805756|NCT05417750|EXPERIMENTAL|Experimental: Cohort 4|participants with advanced HNSCC using cryopreserved GC101 TIL
62229033|NCT05034120|EXPERIMENTAL|FE:Arm E|Cycle1 Day1: High-fat meal; Cycle2 Day10: fasting; Cycle3 Day19: Low-fat meal
62229034|NCT05034120|EXPERIMENTAL|FE:Arm F|Cycle1 Day1: Low-fat meal; Cycle2 Day10: High-fat meal; Cycle3 Day19:fasting
62591465|NCT01167543||Pediatric patients with symptoms or diagnosis of GER|
62805757|NCT02875535|NO_INTERVENTION|Usual Care|Standard school nurse care for suicide prevention.
62805758|NCT02875535|EXPERIMENTAL|RLAS|Through the RLAS, the investigators will train school nurses statewide. Using the Dynamic Adaptation Process, the nurses will then convene and lead Implementation Resource Teams (IRTs). With the assistance of RLAS coaches, the school nurse-led IRTs will engage in an iterative process of assessment and planning to build school capacity and implement up to six evidence-base strategies to reduce adolescent suicide.
62805759|NCT04731285||Pressure wire based FFR|Pressure wire based FFR was reference group
62805760|NCT04731285||CT-FFR|CFD-based RuiXin-FFR was test group
62805761|NCT05237349|EXPERIMENTAL|envafolimab plus chemotherapy|Envafolimab:300mg,sc,d1,Q3W; Chemotherapy:SOX(Oxaliplatin，130mg/m2, iv,d1,Q3W + S-1，40mg/m2, op,bid,d1-14,Q3W).
62805762|NCT03624673|EXPERIMENTAL|endoscopic robot-assisted simple enucleation|Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.
62805763|NCT03624673|ACTIVE_COMPARATOR|standard robot-assisted partial nephrectomy|Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.
62805764|NCT05225129|EXPERIMENTAL|Training Group|Resistance training will be applied to the training group, equivalent to 30% of 1 maximum repetition with blood flow restricted exercise for 8 weeks , 2 days in a week.
62805765|NCT05225129|NO_INTERVENTION|Control Group|Resistance training will be applied to the control group, equivalent to 30% of 1 maximum repetition without blood flow restriction for 8 weeks , 2 days in a week.
62591466|NCT01167543||Control group of pediatric subjects with no symptoms of GER.|
62591467|NCT05967988|EXPERIMENTAL|Atmospheric 3D video projection|Patients in the interventional arm will watch an immersive atmospheric video projection on the walls of their examination room.
62591468|NCT05967988|SHAM_COMPARATOR|Atmospheric 3D color projection|Patients in the interventional arm will look at a neutral color of their choice projected on the walls of their examination room.
62591469|NCT00774553|EXPERIMENTAL|1|AZD1656
62591470|NCT00774553|PLACEBO_COMPARATOR|2|Placebo
62805766|NCT01205100|ACTIVE_COMPARATOR|Biofeedback|Patients will be taught to control abdominal and diaphragmatic muscles by bio-feedback using EMG recordings.
62805767|NCT01205100|PLACEBO_COMPARATOR|Placebo medication|Electromyography will be recorded but not shown to the patients. Patients will take a pill of placebo.
62805768|NCT03262896||Patients with brain death|Ten patients with definite etiology, who were diagnosed with brain death because of Apnea test positive and / or cranial reflexes were not available and were male and female patients aged 18-72 years
62229035|NCT06189560|EXPERIMENTAL|The observation group|Patients enrolled were firstly numbered for privacy with software and divided into the observation group (n=33) and the control group (n=33) with a random number table. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasted 20 days.
62805769|NCT02416843|EXPERIMENTAL|Lean|Consumption of a mixed meal relative to individual resting metabolic rate.
62805770|NCT02416843|EXPERIMENTAL|Overweight|Consumption of a mixed meal relative to individual resting metabolic rate.
62805771|NCT02416843|EXPERIMENTAL|Obese|Consumption of a mixed meal relative to individual resting metabolic rate.
62805772|NCT00217425|EXPERIMENTAL|Treatment (A-CHOP followed by MA)|Patients receive 6-8 cycles of bevacizumab and combination chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (A-CHOP) followed by 8 cycles of maintenance bevacizumab (MA), as outlined below. Bevacizumab 15 mg/kg is administered on day 1 over 90 min (first cycle), 60 min (second cycle) and 30 min for the subsequent cycles. CHOP (cyclophosphamide 750 mg/m 2 ; doxorubicin 50 mg/m 2 ; vincristine 1.4 mg/m2 \[max. 2 mg\]; prednisone 100 mg daily on days 1-5) is administered on day 1 of a 21-day cycle. Radiographic response is assessed after cycles 3, 6 and 8 of ACHOP and after cycle 8 of MA. Patients receive six cycles of ACHOP if they achieve a complete response (CR) after three cycles, eight cycles if they achieve a partial response (PR) after three cycles. Non-responders are removed from the study. ACHOP responders receive maintenance bevacizumab 15 mg/kg every 21 days for eight cycles.
62805773|NCT01622959|ACTIVE_COMPARATOR|acupuncture|"Inclusion criteria:~Traumatic and non traumatic acute pain with visual analog pain scale ( VAPS) \> 40 (on a scale 0-100) Age ≥18 years Presigned consentement to participate in the study.~Exclusion criteria:~Temperature \> 37.7° C, Anticoagulation medication use or the presence of a mechanical heart valve, Skin infections that would preclude certain acupuncture points being used, Refusal, inability to consent or communication difficulties, Acute major trauma, Any form of analgesia up to 60 minutes prior to study start, An initial pain score ≤ 40 on the pain scale (score range 0-100), Opiate contraindication, Pregnancy, Presentation to the ED \> 4 times in the previous 3 months with the same condition."
62805774|NCT01622959|SHAM_COMPARATOR|morphine|drug:5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes \<30%.
62805775|NCT05697198||Cohort lung cancer|
62229036|NCT06189560|ACTIVE_COMPARATOR|The control group|Patients enrolled were firstly numbered for privacy with software and divided into the observation group (n=33) and the control group (n=33) with a random number table. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasted 20 days.
62229037|NCT05163587|PLACEBO_COMPARATOR|Control|control group will be provided with the commercially available whole-wheat flour for their consumption during the study period.
62229038|NCT05163587|EXPERIMENTAL|Intervention|intervention group will be provided with low GI composite flour for their chapatis during study period and they will be instructed to consume at least 4 chapatis each day.
62229039|NCT02634957|EXPERIMENTAL|3 day absolute voice rest|participants would begin initiation of voice/speaking 3 days post phonomicrosurgery for benign vocal fold lesions
62229040|NCT02634957|EXPERIMENTAL|7 day absolute voice rest|participants would begin initiation of voice/speaking 7 days post phonomicrosurgery for benign vocal fold lesions
62421529|NCT05780944|EXPERIMENTAL|Breastfeeding First, Bottle-feeding Second, PBF Third|Mother-infant dyads will visit the laboratory on three different days. During the first visit, they will be observed during breastfeeding. During the second visit, they will be observed during bottle-feeding. During the third visit, the mother will be taught the PBF approach and will be observed using it during bottle-feeding.
62805776|NCT05697198||Gyn malignancies|
62805777|NCT05697198||Gastrointestinal malignancies Cohort|
62805778|NCT05697198||Melanoma Cohort|
62805779|NCT05697198||Breast cancer Cohort|
62805780|NCT05697198||Head and neck cancer Cohort|
62805781|NCT05697198||Sarcoma and soft tissue cancer cohort|
62805782|NCT05697198||Prostate cancer|
62805783|NCT01813916|NO_INTERVENTION|proteomic analysis|
62229041|NCT03048643|NO_INTERVENTION|Standard of Care|Subjects will receive medication-assisted treatment for opioid use disorder and will complete IV antibiotic therapy for infective endocarditis according to usual care.
62229042|NCT03048643|EXPERIMENTAL|Outpatient Parenteral Antibiotic Therapy|Subjects will receive medication-assisted treatment for opioid use disorder and will complete IV antibiotic therapy via outpatient parenteral antibiotic therapy (OPAT).
62229043|NCT00940108|EXPERIMENTAL|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
62229044|NCT00940108|EXPERIMENTAL|CSL425 (30 mcg)|30 mcg of hemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
62421530|NCT05780944|EXPERIMENTAL|Bottle-feeding First, Breastfeeding Second, PBF Third|Mother-infant dyads will visit the laboratory on three different days. During the first visit, they will be observed during bottle-feeding. During the second visit, they will be observed during breastfeeding. During the third visit, the mother will be taught the PBF approach and will be observed using it during bottle-feeding.
62805784|NCT01392547|EXPERIMENTAL|rFVIIa|
62805785|NCT01392547|EXPERIMENTAL|vatreptocog alfa|
62805786|NCT03382886|EXPERIMENTAL|Nivolumab and bevacizumab, all patients|
62229045|NCT03774966|ACTIVE_COMPARATOR|Adductor Canal Block + Catheter|Adductor canal block: 15 mL of 0.25% ropivicaine, adductor canal catheter: 6 mL/hr of 0.2% ropivacaine
62229046|NCT03774966|EXPERIMENTAL|Adductor Canal Block + Catheter & IPACK|Adductor canal block: 15 mL of 0.25% ropivicaine, adductor canal catheter: 6 mL/hr of 0.2% ropivacaine, IPACK block: 15 ml of 0.25% ropivacaine.
62229047|NCT05647915|EXPERIMENTAL|berberine group|Berberine hydrochloride plus lifestyle intervention
62229048|NCT05647915|PLACEBO_COMPARATOR|placebo group|Placebo plus lifestyle intervention
62229049|NCT03169504|EXPERIMENTAL|Acupuncture|Patients in this arm will receive acupuncture.
62805787|NCT05569239|EXPERIMENTAL|OVX836 480µg|Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein in the influenza virus. One single administration intramuscularly of 480µg dose on Day1.
62805788|NCT05569239|PLACEBO_COMPARATOR|Placebo|Saline solution (B. Braun Ecoflac Plus) Saline solution (Nacl 0.9%), B. Braun Ecoflac Plus 50mL. One single administration intramuscularly of a 0.8mL dose on Day1.
62805789|NCT04125446||Cancer in pregnancy chemo treated|Patients that received at least one of the following treatments: Carboplatin, Cisplatin, Cyclophosphamide, Paclitaxel and/or anthracyclines, the latter being the most given type of CT during pregnancy
62030306|NCT03699943|ACTIVE_COMPARATOR|Caverstem 2.0 - Clinical Registry|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. 20 cc
62030307|NCT05831332|EXPERIMENTAL|BTL-785-7 Treatment|Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.
62229050|NCT03169504|EXPERIMENTAL|Conventional drug|Patients will be individually divided into Group A, Group B, Group C and Group D according to GOLD 2017. For Group A, Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd) will be used. For Group B and Group C, Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH) will be used. As for Group D, Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH) or Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline) will be used.
62229051|NCT03169504|EXPERIMENTAL|Acupuncture plus conventional drug|Patients in this arm will receive both acupuncture and conventional drug.
62229052|NCT01244776|EXPERIMENTAL|Acellular corneal matrix|
62229053|NCT00067587||HIV Negative|HIV negative subjects
62229054|NCT00067587||HIV Positive - NEVER had ARV therapy.|HIV Positive - NEVER had ARV therapy.
62805790|NCT04125446||Cancer in Pregnancy not chemo treated|Women who were not treated with CT during pregnancy, including those who were solely surgically treated or did not receive any treatment during pregnancy, will be included in the CT-unexposed control arm
62805791|NCT04125446||healthy pregnancies|A group of healthy pregnant women without cancer will form the second control group
62805792|NCT03336463||Controls|No intervention
62805793|NCT03336463||Cases|No intervention
62030308|NCT01432119|EXPERIMENTAL|Arm 1 SIR-Spheres + Cetuximab|"Arm 1: SIR-Spheres with yttrium-90 attached and cetuximab. SIR-Spheres Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
62030309|NCT01432119|EXPERIMENTAL|Arm 2 SIR-Spheres + Cetuximab + Erlotinib.|"Arm 2: SIR-Spheres with yttrium-90 attached, cetuximab, and erlotinib. Physicians will assign patients to Arm 1 or Arm 2 based on their discretion. SIR-Spheres on Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Erlotinib start 100 mg by mouth daily starting with Cycle 2. 28-day Cycles. Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
62030310|NCT04440553|ACTIVE_COMPARATOR|Uniform random|In this arm the types of messages were sent out randomly, i.e. with a uniform random distribution.
62229055|NCT00067587||HIV positive, on a NNRTI, non-PI regimen|HIV positive, currently on a NNRTI, non-PI regimen for at least 3 months. Must NEVER have received a total of more than SIX months of PI-containing regimen and at least ONE year must have passed since receipt of last PI-containing regimen.
62229056|NCT00067587||HIV positive, on a PI, non-NNRTI regimen|HIV positive, currently on a PI, non-NNRTI regimen for at least 3 months. Must NEVER have received a total of more than SIX months of NNRTI-containing regimen and at least ONE year must have passed since receipt of last NNRTIcontaining regimen.
62805794|NCT02867267|EXPERIMENTAL|thymosin alpha 1|1ml subcutaneous injection with 1.6 mg thymosin alpha 1, every 12±2 hours for not more than 7 days depending on the change of the subjects' condition
62805795|NCT02867267|PLACEBO_COMPARATOR|Placebo|1ml subcutaneous injection with placebo, every 12±2 hours for not more than 7 days depending on the change of the subjects' condition
62805796|NCT05759507||patients|Women undergo pregnancy from 5 SA to 41 SA with no limitation of age
62229057|NCT00067587||HIV positive, on a non-PI, non-NNRTI|HIV positive, currently on a non-PI, non-NNRTI containing regimen for at least 3 months. Must NEVER have received a total of more than SIX months of PI- and/or NNRTI- containing regimen and at least ONE year must have passed since receipt of last PI- and/or NNRTI-containing regimen.
62229058|NCT04634656|ACTIVE_COMPARATOR|Group L|Patients will receive lidocaine in a loading dose of 1 mg/ kg diluted in 10 ml of normal saline that will be infused over 5 minutes after induction of anesthesia then followed by a continuous infusion at 1.5 mg/ kg/ h diluted in normal saline to a volume of 50 ml until the end of surgery.
62229059|NCT04634656|PLACEBO_COMPARATOR|Group C|Patients will receive normal saline after induction of anesthesia with the same volume and rate changes as lidocaine group until the end of surgery.
62805797|NCT06104085|EXPERIMENTAL|99mTc-MY6349 SPECT/CT|Inject 99mTc-MY6349 and then perform SPECT/CT scan.
62229060|NCT06432608|EXPERIMENTAL|Experimental group|The single arm contemplates providing the study subjects diagnosed with functional constipation with a product based on fermented milk (80mL) daily for 4 weeks.
62805798|NCT00951366||Bronchopulmonary Dysplasia (BPD)|
62805799|NCT03096340|EXPERIMENTAL|IT-141|
62805800|NCT01239511|PLACEBO_COMPARATOR|Placebo group|placebo capsule 2# t.i.d./day
62805801|NCT01239511|EXPERIMENTAL|Treatment Group A|150 mg STA-2, 2 capsules t.i.d., after meal (900 mg STA-2 total dose per day)
62805802|NCT01239511|EXPERIMENTAL|Treatment Group B|300 mg STA-2, 2 capsules t.i.d., after meal (1800 mg STA-2 total dose per day)
62805803|NCT01239511|EXPERIMENTAL|Treatment Group C|450 mg STA-2, 2 capsules t.i.d., after meal (2700 mg STA-2 total dose per day)
62805804|NCT00830544|EXPERIMENTAL|1|Experimental chemotherapy using neoadjuvant approach
62805805|NCT01776658|EXPERIMENTAL|SYL1001 eye drops dose A|Ocular topical administration of SYL1001 eye drops dose A
62805806|NCT01776658|PLACEBO_COMPARATOR|Placebo|Ocular topical administration of placebo eye drops
62805807|NCT02448277|EXPERIMENTAL|Macintosh Laryngoscope|experimental Macintosh Laryngoscope group: laryngoscope is used to assist for nasotracheal intubation.
62819484|NCT05656534|PLACEBO_COMPARATOR|Control|Individuals will take a placebo pill during the Acute Drug Challenge and daily for 28 days.
62229061|NCT06429475|EXPERIMENTAL|budesonide/formoterol group|Budesonide-formoterol fumarate dihydrate at two dose strengths 80/4.5 and 160/4.5 administered via a pressurized metered dose inhaler (pMDI) or dry powder inhaler (DPI), respectively. The dosing will be dependent on asthma symptom severity ranging from 1 dose as needed and titrated up or down depending on asthma control.
62229062|NCT06429475|ACTIVE_COMPARATOR|comparator: standard of care group|Standard of care
62229063|NCT03802942|EXPERIMENTAL|Glucerna|2 bottles of Glucerna per day (237 ml per bottle for a total of 474 ml/d) on top of the meal plan supplied by the hospital.
62591471|NCT01597375|EXPERIMENTAL|Placebo then Prasugrel|"Subjects with AERD first received placebo oral tablet for 4 weeks prior to their aspirin challenge/desensitization. After aspirin challenge/desensitization subjects were discharged to home to washout the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to the alternate treatment for 4 weeks of Prasugrel oral tablets \[ (5 mg (for patients \<60kg) or 10mg (\> 60kg) daily, following a 60mg loading dose)\] and returned for the second aspirin challenge.~Because no period effect was observed, data obtained from all subjects while on placebo from either visit 2 or 3 were combined."
62805808|NCT02448277|EXPERIMENTAL|Pentax Airway scope|experimental Pentax Airway scope group:Pentax Airway scope is used to assist for nasotracheal intubation.
62805809|NCT02448277|EXPERIMENTAL|Glidescope|experimental Glidescope group:Glidescope is used to assist nasotracheal tube into trachea
62229064|NCT03802942|NO_INTERVENTION|Control|Regular meal plan supplied by the hospital
62229065|NCT06423209|EXPERIMENTAL|Vegan Intervention|The intervention group is composed of people who follow a vegan diet and who will be part of an intervention program for 16 weeks, consisting of a physical exercise program of strength resistance with 3 sessions per week. Each session will be guided by a physical activity professional and will last from 45 to 50 minutes.
62229066|NCT06423209|EXPERIMENTAL|omnivorous intervention|The intervention group is composed of people who follow a omnivorous diet and who will be part of an intervention program for 16 weeks, consisting of a physical exercise program of strength resistance with 3 sessions per week. Each session will be guided by a physical activity professional and will last from 45 to 50 minutes.
62229067|NCT06423209|NO_INTERVENTION|vegan control|People who follow an vegan diet who were part of the control group. They were evaluated before and after the intervention.
62229068|NCT06423209|NO_INTERVENTION|omnivorous control|People who follow an omnivorous diet who were part of the control group. They were evaluated before and after the intervention.
62735415|NCT02311036|OTHER|Comorbidity_Comprehensive Rehabilitation|Charlson Comorbidity Index contains 19 categories of comorbidity and predicts the ten-year mortality for a patient who may have a range of co-morbid conditions Each condition is assigned with a score of 1,2,3 or 6 depending on the risk of dying associated with this condition. For a physician, it is helpful in knowing how aggressively to treat a condition. Higher scores indicating greater comorbidity (patients with a score \> 5 have essentially a 100% risk of dying at one year).
62735416|NCT02311036|OTHER|MRS_Comprehensive Rehabilitation|The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.
62735417|NCT02311036|OTHER|MMSE_Comprehensive Rehabilitation|The mini mental state examination (MMSE) is the most commonly used instrument for screening cognitive function. This examination is not suitable for making a diagnosis but can be used to indicate the presence of cognitive impairment, such as in a person with suspected dementia or following a head injury. The examination has been validated in a number of populations. Scores of 25-30 out of 30 are considered normal; the National Institute for Health and Care Excellence (NICE) classifies 21-24 as mild, 10-20 as moderate and \<10 as severe impairment. The MMSE may not be an appropriate assessment if the patient has learning, linguistic/communication or other disabilities (eg, sensory impairments).
62229069|NCT01470313|EXPERIMENTAL|PD-0360324|
62229070|NCT01470313|PLACEBO_COMPARATOR|Placebo|
62229071|NCT05493085|ACTIVE_COMPARATOR|Quadratus Lumborum|Patients will receive Ultrasound-guided quadratus lumborum block
62229072|NCT05493085|ACTIVE_COMPARATOR|Caudal epidural|Patients will receive single Caudal epidural injection
62229073|NCT05430360|EXPERIMENTAL|GT201 treatment group|Autologous tumor infiltrating lymphocyte injection
62229074|NCT04094792|EXPERIMENTAL|Intervention|For the intervention group, baseline measures on depression and heart rate variability will be obtained at baseline and post-test (21 days later). Intervention group subjects will use the Breather app twice daily, five minutes each time, for a period of 21 days.
62229075|NCT04094792|NO_INTERVENTION|Control|For the control group, baseline measures on depression and heart rate variability will be obtained at baseline and post-test (21 days later).
62229076|NCT05057923|EXPERIMENTAL|generation of neutralizing antibody for unvaccinated participants|participants received vaccine 1 capsule of 1×10\^10 CFU of B. subtilis spore at day 0, 14, and 28 respectively.
62229077|NCT05057923|EXPERIMENTAL|neutralizing antibody booster for vaccinated participants|participants after 4-month vaccinated with Sinovac received 1 capsule of 1×10\^11 CFU of B. subtilis spore
62229078|NCT01119482|OTHER|Vaccination|Healthy volunteers before and after vaccination
62229079|NCT00419133|EXPERIMENTAL|1|Cholera Vaccine
62229080|NCT00419133|PLACEBO_COMPARATOR|2|Placebo
62229081|NCT00959166|OTHER|HIV/acute HCV coinfection|Subjects with HIV/acute HCV coinfection (aHCV cases) were required to have acute HCV, defined by a new positive plasma HCV RNA test within 12 months of a negative HCV RNA test.
62229082|NCT00959166|OTHER|HIV mono|HIV-infected individuals without hepatitis C co-infection
62735418|NCT02311036|OTHER|BSRS_Comprehensive Rehabilitation|Brief Symptom Rating Scale is a rating scale which a clinician or researcher may use to measure psychiatric symptoms such as depression, anxiety, hallucinations and unusual behavior. Each symptom is rated 1-7 and depending on the version between a total of 18-24 symptoms are scored. The scale is the one of the oldest, widely used scales to measure psychotic symptoms and was first published in 1962.
62735419|NCT05366127||Patient with bullous pemphigoid|IGA score and BPDAI score will be assessed to patient with bullous pemphigoid
62229083|NCT04200157||1|"Group assigned to the following answer combination:~1. 2 sessions~2. 4 sessions"
62229084|NCT04200157||2|"Group assigned to the following answer combination:~1. 2 sessions~2. 4 sessions~3. 7 sessions"
62805810|NCT00870181|EXPERIMENTAL|ADV-TK/GCV|ADV-TK was administered via intraarterial cerebral infusion. Systemic GCV therapy was delivered at a dose of 5mg/kg intravenous, every 12 h at 36 hours after ADV-TK therapy.
62229085|NCT04200157||3|"Group assigned to the following answer combination:~1. 2 sessions~2. 7 sessions"
62229086|NCT04200157||4|"Group assigned to the following answer combination:~1. 2 sessions~2. 7 sessions~3. 10 sessions"
62229087|NCT04200157||5|"Group assigned to the following answer combination:~1. 2 sessions (30 minutes)~2. 4 sessions (60 minutes)"
62229088|NCT04200157||6|"Group assigned to the following answer combination:~1. 2 sessions (30 minutes)~2. 4 sessions (60 minutes)~3. 7 sessions (105 minutes)"
62229089|NCT04200157||7|"Group assigned to the following answer combination:~1. 2 sessions (30 minutes)~2. 7 sessions (105 minutes)"
62229090|NCT04200157||8|"Group assigned to the following answer combination:~1. 2 sessions (30 minutes)~2. 7 sessions (105 minutes)~3. 10 sessions (150 minutes)"
62805811|NCT00870181|ACTIVE_COMPARATOR|Control group|Patients received surgery or systemic chemotherapy or palliative care.
62805812|NCT03636581|EXPERIMENTAL|Intervention|This group will receive a smart watch to track activity and diet. This group will also receive education on nutrition and exercise.
62805813|NCT03636581|NO_INTERVENTION|Control|This group will receive a smart watch to track activity only with no intervention.
62805814|NCT05572866||2019|No intervention will be carried out. The sum total of surgeries carried out during 2019 will be audited to see how the COVID-19 pandemic has impacted the surgical volume.
62229091|NCT04200157||9|"Group assigned to the following answer combination:~1. 2 sessions (30 minutes) - 10% chance of quitting~2. 4 sessions (60 minutes) - 30% chance of quitting"
62229092|NCT04200157||10|"Group assigned to the following answer combination:~1. 2 sessions (30 minutes) - 10% chance of quitting~2. 4 sessions (60 minutes) - 30% chance of quitting~3. 7 sessions (105 minutes) - 30% chance of quitting"
62229093|NCT04200157||11|"Group assigned to the following answer combination:~1. 2 sessions (30 minutes) - 10% chance of quitting~2. 7 sessions (105 minutes) - 30% chance of quitting"
62229094|NCT04200157||12|"Group assigned to the following answer combination:~1. 2 sessions (30 minutes) - 10% chance of quitting~2. 7 sessions (105 minutes) - 30% chance of quitting~3. 10 sessions (150 minutes) - 30% chance of quitting"
62229095|NCT01146626|ACTIVE_COMPARATOR|Peg+ Vitamin D+ Ribavirine|Peg+ Vitamin D+ Ribavirine
62229096|NCT01146626|EXPERIMENTAL|Peg+ Ribavirine|Peg+ Ribavirine
62229097|NCT03701867|EXPERIMENTAL|Metabolic Flexibility Tests Group|
62229098|NCT02019927|EXPERIMENTAL|Non-arthritic ischemic optic neuropathy|Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
62229099|NCT02019927|EXPERIMENTAL|Multiple Sclerosis|Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
62229100|NCT02019927|EXPERIMENTAL|Ocular Trauma|Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
62229101|NCT02019927|SHAM_COMPARATOR|Sham - Non-arthritic ischemic optic neuropathy|Sham treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
62805815|NCT05572866||2020|No intervention will be carried out. The sum total of surgeries carried out during 2020 will be audited to see how the COVID-19 pandemic has impacted the surgical volume.
62805816|NCT05572866||2021|No intervention will be carried out. The sum total of surgeries carried out during 2021 will be audited to see how the COVID-19 pandemic has impacted the surgical volume.
62805817|NCT05572866||2022|No intervention will be carried out. The sum total of surgeries carried out during 2022 will be audited to see how the COVID-19 pandemic has impacted the surgical volume.
62805818|NCT00377793|EXPERIMENTAL|Arm 1|
62805819|NCT00377793|PLACEBO_COMPARATOR|Arm 2|
62805820|NCT06020898|EXPERIMENTAL|Sodium valproate group|Within 3 days after admission, 20mg/kg sodium valproate will be given daily. Specifically, 400mg sodium valproate will be infused within 5 minutes, followed by intravenous drip with 1mg/kg/h.
62805821|NCT06020898|PLACEBO_COMPARATOR|Placebo group|Within 3 days after admission, normal saline will be given daily in the same way.
62805822|NCT00681629|EXPERIMENTAL|Quetiapine XR Alone|Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
62805823|NCT00681629|EXPERIMENTAL|Quetiapine XR With Integrated Care Program (ICP)|Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
62229102|NCT02019927|SHAM_COMPARATOR|Sham - Multiple Sclerosis|Sham treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
62229103|NCT02019927|SHAM_COMPARATOR|Sham - Ocular Trauma|Sham treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
62229104|NCT00599885|ACTIVE_COMPARATOR|1|
62229105|NCT00599885|ACTIVE_COMPARATOR|2|
62229106|NCT00555178||1|Patients with polymorphic light eruption without medical photohardening treatment
62229107|NCT00555178||2|Patients with polymorphic light eruption treated with medical photohardening
62229108|NCT00555178||3|Patients with other disorders (including psoriasis) treated with phototherapy
62229109|NCT00555178||4|Normal healthy subjects
62229110|NCT01657955|EXPERIMENTAL|Bendamustine Hydrochloride Injection|d1-d2,i.v.gtt, 100mg/m2/d, 28 days per cycle, at most 6 cycles.
62805824|NCT00895284|EXPERIMENTAL|Robot|Robotic hysterectomy
62805825|NCT00895284|ACTIVE_COMPARATOR|Standard|Standard hysterectomy
62805826|NCT00160186|EXPERIMENTAL|1|
62805827|NCT00160186|PLACEBO_COMPARATOR|2|
62819485|NCT05656534|EXPERIMENTAL|Suvorexant Treatment|Individuals will take 10mg of suvorexant (Merck \& Co Inc.) during the Acute Drug Challenge and daily for 28 days.
62591472|NCT01597375|EXPERIMENTAL|Prasugrel then Placebo|"Subjects with AERD first received prasugrel oral tablets \[ (5 mg (for patients \<60kg) or 10mg (\> 60kg) daily, following a 60mg loading dose)\] prior to their aspirin challenge/desensitization. After aspirin challenge/desensitization subjects were discharged to home to washout the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to the alternate treatment for 4 weeks of Placebo oral tablet.~Because no period effect was observed, data obtained from all subjects while on Prasugrel from either visit 2 or 3 were combined."
62591473|NCT02868567|EXPERIMENTAL|Ampyra|Ampyra open label
62591474|NCT05051267|NO_INTERVENTION|Routine Care Group|Before the application, the families will be informed by the researcher and the 'Informed Consent Form' will be signed. After the heel blood procedure, comfort will be provided with gentle touches. For ethical reasons, routine care will be provided when the baby cries.
62591475|NCT05051267|EXPERIMENTAL|Mothers Embrace|A mothers embrace is one of the earliest and most common care events that mothers offer to their babies. Close physical contact between mother and baby during hugs can reduce stress by facilitating co-regulation of mother and baby. In a study conducted in Turkey, it was stated that holding the baby on the lap for pain relief in painful interventions is a practical and easy method.
62591476|NCT05051267|EXPERIMENTAL|White Noise|Since white noise is a humming and continuous monotonous sound, it is similar to the sound in the womb (Balci, 2006). It will be explained that this sound is very similar to the sound that the baby hears in the mother's womb by making the white noise recordings listen to the mothers who will have their babies listen to white noise. by Orhan Osman; Dr. From the album 'Kolik', which was created by making use of the album 'The Happiest Baby' prepared by Harvery Karp, which consists only of uterus sounds; The song 'Don't Let Your Baby Cry, PT.2' will be played to babies (Karp, 2015). In addition, infants will be excluded from the study even though they meet the criteria, if they are not sedated, the procedure takes more than 2 minutes, the procedure is disrupted because someone enters the room loudly, or the mother changes the baby's position (Karakoç, \& Türker, 2014).
62030311|NCT04440553|EXPERIMENTAL|Reinforcement learning|In this arm the types of messages were chosen by a reinforcement learning algorithm. The decision about which message to send was based on several contextual variables, including data for the pedometer app, and consecutive days since messages from different categories were sent.
62030312|NCT06569056|EXPERIMENTAL|HRS-8427; Imipenem and Cilastatin Sodium placebo|
62030313|NCT06569056|ACTIVE_COMPARATOR|Imipenem and Cilastatin Sodium; HRS-8427 placebo|
62229111|NCT01657955|ACTIVE_COMPARATOR|Chlorambucil|d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC≥4×109 /L at d12-d14 ); d1-d2, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC\<4×109 /L at d12-d14 );
62591477|NCT05051267|EXPERIMENTAL|Mother's Voice|Auditory responses, fetal age 26-28. It develops in the auditory cortex and brain stem in weeks (Eskandari, Keshavarz, \& Jahdi, 2010). Hearing is one of the first senses a fetus develops and is 24-33. can recognize and remember the mother's voice after weeks (Djordjevic, 2010 ). The fetus memorizes the musical characteristics of the mother's voice, like tone, by listening to it (Arabin, 2002). It is stated that newborns exposed to their own mother's voice have a lower heart rate, higher sucking rate, a more relaxed appearance, and less crying and body movements (Campbell-Yeo, Fernandes, \& Johnston, 2011).
62421531|NCT05694156|EXPERIMENTAL|Music-based cognitive training|Music-based cognitive training sessions are derived from two Neurologic Music Therapy techniques: Musical Attention Control Training (MACT) and Musical Executive Function Training (MEFT). MACT exercises will focus on sustained and selective attention to emphasise flexibility and adaptability of the auditory attention system. MEFT exercises will provide opportunity for decision making, problem solving, reasoning, comprehending, organising, initiating, inhibiting, evaluating, analysing, and creating.
62421532|NCT02515461|EXPERIMENTAL|Intervention: Low energy shockwave therapy|Low energy shockwave therapy performed on both kidneys applying 3000 shocks on each kidney.
62805828|NCT02972060|ACTIVE_COMPARATOR|ADT|"The standard treatment for this stage of the disease is ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician."
62805829|NCT02972060|EXPERIMENTAL|ODM 201|"ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) bid for a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food.~Subjects who have clinical benefit at week 24 may continue to receive ODM-201 at the discretion of the investigator until disease progression, objective or clinical, or occurrence of an unacceptable toxicity. This includes those that will receive external beam radiation therapy.~Any anti-cancer therapy other than the study drug given as single agent will not be considered part of the protocol treatment."
62805830|NCT04248699|EXPERIMENTAL|Lumenato Supplement|tomato oleoresin
62805831|NCT03951077|PLACEBO_COMPARATOR|Placebo|Placebo taken orally twice a day (BID)
62030314|NCT04625543|EXPERIMENTAL|intervention group|Neoadjuvant immunotherapy (PD-1) plus concurrent chemotherapy (paclitaxel + Cisplatin) will be applied to patients with locally advanced esophageal squamous cell carcinoma with PD-L1\>=10% before surgery.
62030315|NCT04625543|ACTIVE_COMPARATOR|controll group|Neoadjuvant chemotherapy (paclitaxel + Cisplatin) will be applied to patients with locally advanced esophageal squamous cell carcinoma with PD-L1\>=10% before surgery.
62030316|NCT03900260|OTHER|Softec HP1 Intraocular Lens|The Softec HP1 IOL is a single-piece, biconvex, ultraviolet absorbing intraocular lens designed for insertion into the posterior chamber of the human eye for visual correction of Aphakia in adults over the age of 21, and as a replacement of a damaged (cataract) natural lens.
62030317|NCT05457608|EXPERIMENTAL|Lens A|All participants wore lens A for 15 minutes (Period 1)
62030318|NCT05457608|EXPERIMENTAL|Lens B|All participants wore lens B for 15 minutes (Period 2)
62229112|NCT03587974|EXPERIMENTAL|REACH-VN|In-home psychosocial intervention to enhance caregiver knowledge and skills and to reduce stress delivered in 4-6 sessions over the course of 2-3 months
62229113|NCT03587974|NO_INTERVENTION|Enhanced control|Single session with education about nature of dementia
62229114|NCT01745848|EXPERIMENTAL|Study Drug|Roflumilast 500 μcg, once daily, for 30 days
62421533|NCT06539039|EXPERIMENTAL|periodontitis with controlled diabetes|patients with generalized periodontitis and controlled diabetes mellitus with glycated haemoglobin (HbA1c) less than 7%.
62030319|NCT06486753|NO_INTERVENTION|Chevron osteotomy bunion surgery without LSTR|Participants randomized to this group will receive a standard Chevron osteotomy bunion surgery.
62229115|NCT05159869|EXPERIMENTAL|Experimental|After participants are recruited, participants will undergo neuropsychological testing prior to randomization in order to establish baseline cognitive functioning and verify that the participants are indeed in the early stages of dementia. Persons randomized to the User-Led Meaningful Activity intervention group will begin the treatment protocol right after randomization. The intervention will consist of 3-4 sessions lasting 60-90 minutes each in which participants receive feedback from the neuropsychological assessment, identify the basis/topic of the activity plan, receive dementia psychoeducation, and map out an activity gradation plan. A brief cognitive screening tool will be re-administered at six months and 12 months. The neuropsychological battery that was administered at baseline will be re-administered 12 months later. Follow-up will also involve solicitation of feedback from the person with dementia and his or her caregiver regarding participants' participation in the study.
62805832|NCT03951077|EXPERIMENTAL|Elagolix 25 mg BID|Elagolix 25 mg taken orally BID plus placebo
62805833|NCT03951077|EXPERIMENTAL|Elagolix 50 mg Once Daily (QD)|Elagolix 50 mg taken orally QD plus placebo
62805834|NCT03951077|EXPERIMENTAL|Elagolix 75 mg BID|Elagolix 75 mg taken orally BID plus placebo
62805835|NCT03951077|EXPERIMENTAL|Elagolix 150 mg QD|Elagolix 150 mg taken orally QD plus placebo
62030320|NCT06486753|EXPERIMENTAL|Chevron osteotomy bunion surgery with LSTR|Participants randomized to this group will receive a Chevron osteotomy bunion surgery and a lateral soft tissue release.
62030321|NCT02421614|EXPERIMENTAL|high olive oli|A high fat (45%) low carbohydrate (35%) enteral feeding will be administered to acute respiratory failure patients. The percentage of olive oil will be half of total fat.
62030322|NCT02421614|EXPERIMENTAL|high sunflower oil|A high fat (45%) low carbohydrate (35%) enteral feeding will be administered to acute respiratory failure patients. The total fat will be sunflower oil.
62030323|NCT02421614|NO_INTERVENTION|kitchen formula|A high protein kitchen diet for tube feeding will be administered to acute respiratory failure patients.
62229116|NCT05159869|ACTIVE_COMPARATOR|Wait-List Control|"After participants are recruited, participants will undergo neuropsychological testing prior to randomization in order to establish baseline cognitive functioning and verify that the participants are indeed in the early stages of dementia (i.e., mild dementia). Those who meet criteria will be randomly assigned. Persons randomized to the wait-list control group will begin the treatment protocol after four months' time."
62229117|NCT06082583|ACTIVE_COMPARATOR|Tibetan Medicine Group|
62229118|NCT06082583|EXPERIMENTAL|Tibetan Medicine-Remote Ischemic Conditioning Group|
62229119|NCT02770573|EXPERIMENTAL|Patients with dentin hypersensitivity|"Patients with evident clinical signs of dentin hypersensitivity The following dental materials will be used following the manufacturers' instructions: Cavex Bite\&White ExSense; Kuraray Teethmate™ Desensitizer; Ghimas Dentin Desensitizer.~In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.~The application of the materials will be made only once. The effectiveness will be evaluated: immediately after application and after 1, 4, 12 weeks."
62229120|NCT05540054|EXPERIMENTAL|Standard pulmonary rehabilitation group (PR)|Patients diagnosed with COPD and listed for bronchoscopic procedure.
62805836|NCT03951077|EXPERIMENTAL|Elagolix 300 mg QD|Elagolix 300 mg taken orally QD plus placebo
62805837|NCT01971541|EXPERIMENTAL|Mindfulness-Based Stress Reduction (MBSR)|An 8-week program designed to teach mindfulness skills
62805838|NCT01971541|ACTIVE_COMPARATOR|Cognitive Processing Therapy|A group-administered PTSD treatment program.
62805839|NCT05762497|EXPERIMENTAL|Laryngectomized patients|
62805840|NCT05229393|EXPERIMENTAL|Diaphragmatic Manual Therapy Group A|"Experimental: Diaphragmatic Manual Therapy plus Cervical Manual Therapy plus Breathing Reeducation Exercises group.~Cervical manual therapy will be the same as for the Manual Control Group (20 minutes).~Diaphragmatic Manual Therapy (10 minutes) and Breathing Reeducation Exercises (10 minutes). The program will be carried out three times per week lasting four weeks in total. Each session will last about 40 minutes."
62805841|NCT05229393|SHAM_COMPARATOR|Cervical Manual Therapy Group B|Sham Comparator: Sham Treatment group or Manual Control Group Patients included in this group will receive Cervical Manual Therapy (25 minutes) plus sham Diaphragmatic Manual techniques (15 minutes). The program will be carried out three times per week lasting four weeks in total. Each session will last about 40 minutes.
62805842|NCT05229393|ACTIVE_COMPARATOR|Conventional Physiotherapy Program Group C|"Active Comparator: Conventional Treatment group Patients included in this group will receive a conventional physiotherapy program with Transcutaneous Electrical Nerve Stimulation-TENS (15 minutes) plus Microwave pulsed Diathermy (10 minutes), and soft tissue techniques (15 minutes).~The program will be carried out three sessions per week during the four weeks. Each session will last about 40 minutes."
62229121|NCT05540054|EXPERIMENTAL|Inspiratory muscle training group (PR+IMT)|Patients diagnosed with COPD and listed for bronchoscopic procedure.
62805843|NCT01377584|EXPERIMENTAL|Patients in the Couple-oriented intervention|Patients randomly assigned to the couple-oriented (CO) group will attend two face to face sessions with their partner and participate in an individual telephone follow-up session.
62805844|NCT01377584|OTHER|Patients in Usual Care|Patients will not attend any intervention sessions.
62819486|NCT02537977|EXPERIMENTAL|CAR-T cells|Autologous 2nd generation CD19-directed CAR-T cells
62030324|NCT02352558|EXPERIMENTAL|Arm 1|Patients with multiple myeloma treated with BBI608
62030325|NCT02352558|EXPERIMENTAL|Arm 2|Patients with lymphoma treated with BBI608
62030326|NCT02352558|EXPERIMENTAL|Arm 3|Patients with acute myeloid leukemia or myelo-dysplastic syndrome treated with BBI608
62030327|NCT02352558|EXPERIMENTAL|Arm 4|Patients with chronic myeloid leukemia treated with BBI608
62030328|NCT02352558|EXPERIMENTAL|Arm 5|Patients with multiple myeloma treated with BBI608 and dexamethasone
62030329|NCT02352558|EXPERIMENTAL|Arm 6|Patients with multiple myeloma treated with BBI608 and bortezomib
62030330|NCT02352558|EXPERIMENTAL|Arm 7|Patients with chronic myeloid leukemia treated with BBI608 and imatinib
62030331|NCT02352558|EXPERIMENTAL|Arm 8|Patients with chronic lymphocytic leukemia treated with BBI608
62030332|NCT02352558|EXPERIMENTAL|Arm 9|Patients with chronic lymphocytic leukemia treated with BBI608 and ibrutinib
62229122|NCT06081582|EXPERIMENTAL|Toripalimab plus Cetuximab，chemotherapy group|"All subjects received 2-cycle conversion therapy with the PD-1 inhibitor toripalimab combined with cetuximab, cisplatin, and 5-FU~The dosage of medication used is as follows:~Toripalimab: 240mg, Day1, Q3W；Cisplatin: 25mg/m2, Day1-3, Q3W；5-FU: 1000mg/m2, Day1-3, Q3W Cetuximab Day 1, 8, 15, Q3W, 400 mg/m2 initial dose; Afterwards, 250 mg/m2 per week"
62229123|NCT01235104||Total nephrectomy|
62229124|NCT03883425||Case 1: formal home service recipients|Adults aged 65 or older living at home who receive formal home service (household, meal delivery, transportation, shopping) at least one a week
62805845|NCT01377584|EXPERIMENTAL|Patients in the Patient-oriented intervention|Patients randomly assigned to the patient-oriented (PT) group will attend two face to face sessions and participate in a telephone follow-up session.
62805846|NCT01377584|EXPERIMENTAL|Partners in the Couple-oriented intervention|Partners randomly assigned to the couple-oriented (CO) group will attend two face to face sessions with the patient and participate in an individual telephone follow-up session.
62805847|NCT01377584|OTHER|Partners in Usual Care|Partners will not attend any intervention sessions.
62229125|NCT03883425||Case 2: formal home care recipients|Adults aged 65 or older living at home who receive formal home care (shower/bath nursing assistance, nursing care) at least once a week
62229126|NCT03883425||Control: free of formal home care or home service|Adults aged 65 or older living at home who do not receive formal home care or home service.
62229127|NCT05960253|ACTIVE_COMPARATOR|PENG block group|
62229128|NCT05960253|EXPERIMENTAL|L-ESP group|
62421534|NCT06539039|EXPERIMENTAL|periodontitis with poorly controlled diabetes|patients with generalized periodontitis, and poorly controlled diabetes mellitus with HbA1c more than or equal 7%.
62421535|NCT06539039|EXPERIMENTAL|periodontitis|patients with generalized periodontitis
62229129|NCT02587468|EXPERIMENTAL|Juice Plus+(R)|Check of phenolic absorption between baseline and after 8wks of intake before-after comparison
62229130|NCT05399043|EXPERIMENTAL|Technology-based Rehabilitation Group|Patients will undergo conventional treatment and, additionally, robot-assisted therapy or virtual reality-based rehabilitation.
62229131|NCT05399043|ACTIVE_COMPARATOR|Conventional Rehabilitation Group|Patients will undergo conventional treatment exclusively.
62421536|NCT05980858|ACTIVE_COMPARATOR|KetoneAid KE4, then Placebo drink|For five days each subject will receive beta-hydroxybutyrate (KE4), then crossed over to receive placebo drink for 5 days.
62421537|NCT05980858|ACTIVE_COMPARATOR|Placebo drink, then KetoneAid KE4|For five days each subject will receive a placebo drink three times daily, then subjects are crossed over to receive beta-hydroxybutyrate (KE4).
62421538|NCT03141931|EXPERIMENTAL|Supplement|Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
62421539|NCT03141931|PLACEBO_COMPARATOR|Placebo|Polyethylene glycol, Oleic acid, Propylene glycol
62421540|NCT00774202|ACTIVE_COMPARATOR|Rituximab, Cyclophosphamide, Vincristine, Prednisone|"'Standard Dose of Rituximab administered with C, V, P (CVP)'~Interventions: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses at standard rates and use of premedication. The schedule will be to give the first rituximab infusion 5 days (± 3 days) prior to first administration of CVP, and the following 3 infusions will be given on the same day as the 3 cycles of C, V, P. On those days, the IV Cyclophosphamide and Vincristine will be given first so that the administration of fluids with the rituximab can be used as post-cyclophosphamide hydration, Cyclophosphamide dosing will be 750mg/m2 (maximum 2000mg), vincristine 1.4 mg/m2 (up to 1.6 mg), prednisone 100mg po daily for 5 days."
62591478|NCT05051267|EXPERIMENTAL|Mothers Embrace and White Noise Applied Group|One minute after the procedure, the baby's pain score will be evaluated. After the procedure, until the baby returns to basal values, the mother will be asked to hold her baby and the white noise will continue to be listened to. Video and audio recording will continue until the baby's oxygen saturation and heart rate return to pre-procedural basal values. When it returns to basal values, the baby's pain score will be re-evaluated.
62805848|NCT01377584|EXPERIMENTAL|Partners in the Patient-oriented intervention|Partners randomly assigned to the patient-oriented (PT) group will not attend any intervention sessions.
62805849|NCT02719548|EXPERIMENTAL|Breastshield treatment group A|"Participants will be treated with the following three breast shields:~Soft edge oval - Hard oval - Modified PF breast shield Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
62421541|NCT00774202|ACTIVE_COMPARATOR|Higher Dose of Rituximab|In this arm, Rituximab will be administered at a dose of 750 mg/m2 once a week x 4 consecutive weeks (4 infusions in total). We will perform EKG monitor tracings before, during and after Rituxan infusions. This will be a single-lead tracing that will allow us to look at the Q-T interval.
62421542|NCT05614765||Treatment group|statin+ezetimibe compound
62421543|NCT01491282||No treatment|
62805850|NCT02719548|EXPERIMENTAL|Breastshield treatment group B|"Participants will be treated with the following three breast shields:~Modified PF breast shield - Soft edge oval - Hard oval Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
62805851|NCT02719548|EXPERIMENTAL|Breastshield treatment group C|"Participants will be treated with the following three breast shields:~Hard oval - Soft edge oval - Modified PF breast shield Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
62229132|NCT06432894||observation|"Patients~* aged 20-80 years under general anaesthesia with remimazolam~* scheduled to undergo robotic surgery~* in American Society of Anesthesiologists physical class 1, 2 or 3"
62229133|NCT03063112|ACTIVE_COMPARATOR|Group 1( radiofrequency group )|Bilateral thoracic splanchnic nerves block will be performed by radiofrequency thermocoagulation at two level of vertebra T10 and T11 by using radiofrequency generator device and lidocaine 2% before thermal lesion
62229134|NCT03063112|PLACEBO_COMPARATOR|Group 2 ( alcohol group )|Bilateral thoracic splanchnic nerves block will be performed by ethyl alcohol at one level of vertebraT11 by using of C arm fluoroscopic device.
62229135|NCT01098565|EXPERIMENTAL|Study device arm|
62229136|NCT05786989|EXPERIMENTAL|Treatment|Patients will receive selinexor PO on days 1, 8, and 15 of a 21 week cycle. R-GemOx will be given at standard dosing every 21 days
62805852|NCT03133611|OTHER|Parkinson's disease|Speech assessment. Routine clinical assessment.
62229137|NCT03589092||GDM Current|"Currently pregnant women diagnosed with GDM.~Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes."
62229138|NCT03589092||GDM History|"Women with history of GDM (with negative GAD/IA2 antibodies if results available).~Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes."
62229139|NCT06351527|EXPERIMENTAL|ICP-248|
62229140|NCT05581667|EXPERIMENTAL|PIR Group|PIR Group participants will be given a one-time PIR Technique for each of the neck and upper back muscles, right after the classical Swedish massage is applied to the cervical region and upper back area.
62229141|NCT05581667|EXPERIMENTAL|Control Group|Control group participants will receive classical Swedish massage only to the cervical and upper thoracic region.
62229142|NCT05511792|EXPERIMENTAL|TAVR with down sizing strategy|"Balloon sizing will be used during procedural. Pre-dilation with balloon size just below the annular size. 20mm for annular size of 20-23mm. 23mm for annular size 23-26mm.~Waist sign with less than mild contrast regurgitation: Evolut PRO Valve one size smaller than manufacturer recommendation and Target implant depth 0-3mm.~No waist sign and/or contrast regurgitation or unable to finish supra-annular sizing: Evolut PRO annular sizing (per manufacturer recommendation) with implant depth 0-3mm."
62421544|NCT04594200|EXPERIMENTAL|Intervention Group: Harms Emphasis - Simple Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a simple comparator to represent a target or benchmark for antibiotic prescribing. For the simple comparator, we will rank the antibiotic prescribing outcomes for all Ontario family physicians and use the lowest quartile as the benchmark. The letter will also include information on both lack of benefit and potential harms caused by unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month post initial dissemination.
62030333|NCT04207190|EXPERIMENTAL|Treatment (talazoparib, gemtuzumab ozogamicin)|Patients receive talazoparib PO daily on days 1-21 and gemtuzumab ozogamicin IV over 2 hours on days 1, 4, and 7 or day 1 for patients who CR/CRi after cycles 1 or 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62421545|NCT04594200|EXPERIMENTAL|Intervention Group: Harms Emphasis - Complex Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a complex (adjusted) comparator to represent a target or benchmark for antibiotic prescribing. For the complex comparator, recipients will be compared only to top-performing 'like-peers' - the group of physicians with similar complexity and numbers of patients. We will adjust the prescribing indicators for patient sex, number of patients \>85 years, rurality, continuity of care score, proportion of emergency room practice, proportion nursing home practice, neighborhood income quintile of patients, and rates of common patient comorbidities. The letter will also include information on both lack of benefit and potential harms caused by unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month later.
62421546|NCT04594200|EXPERIMENTAL|Intervention Group: No Harms Emphasis - Simple Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a simple comparator to represent a target or benchmark for antibiotic prescribing. For the simple comparator we will rank the antibiotic prescribing outcomes for all Ontario family physicians and use the lowest quartile as the benchmark. The letter will also include information on lack of benefit of unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month post initial dissemination.
62421547|NCT04594200|EXPERIMENTAL|Intervention Group: No Harms Emphasis - Complex Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a complex (adjusted) comparator to represent a target or benchmark for antibiotic prescribing. For the complex comparator, recipients will be compared only to top-performing 'like-peers' - the group of physicians with similar complexity and numbers of patients. We will adjust the prescribing indicators for patient sex, number of patients \>85 years, rurality, continuity of care score, proportion of emergency room practice, proportion nursing home practice, neighborhood income quintile of patients, and rates of common patient comorbidities. The letter will also include information on lack of benefit of unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month later.
62805853|NCT03133611|OTHER|REM sleep behaviour disorder|Speech assessment. Routine clinical assessment.
62805854|NCT03133611|OTHER|Healthy controls|Speech assessment. Routine clinical assessment.
62805855|NCT05125159|EXPERIMENTAL|angioplasty guidewire-assisted transseptal group|Patients randomized to the angioplasty guidewire-assisted transseptal puncture (GW-TSP) group will undergo transseptal puncture with angioplasty guidewire-assistance.
62805856|NCT05125159|SHAM_COMPARATOR|Conventional transseptal group|Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with BRK needle (St. Jude Medical).
62805857|NCT00000928|EXPERIMENTAL|A|All study participants
62805858|NCT05258240|OTHER|Virtual Reality|Virtual reality workout session will be for about 50 minutes in which warm-up exercise will be for 5 minutes including relaxed breathing, selected exercises for dynamic balance and static balance will take 40 minutes of the session in which games; tilt city, soccer heading, table tilt game, and penguin tilt will be used for dynamic balance training. For static balance training games will be torso leg curl and single leg extension. After that 5 minutes will be given for cools down.
62819487|NCT06542029|EXPERIMENTAL|Groups 4 Health (G4H)|"Groups 4 Health (G4H, Ryhmät kuntoon) intervention is administered in this arm."
62229143|NCT05511792|ACTIVE_COMPARATOR|TAVR with standard sizing strategy|"Pre-dilation with balloon size just below the annular size. 20mm for annular size of 20-23mm. 23mm for annular size 23-26mm.~The prosthesis size of Evolut PRO will be chosen based on manufacturer recommendation. The target implant depth will be 0-3mm."
62030334|NCT05804877|EXPERIMENTAL|online mindfulness-based cognitive therapy program|The online mindfulness-based cognitive program was delivered on the platform of LINE to the experimental group 3 times a week for 8 weeks
62030335|NCT05804877|PLACEBO_COMPARATOR|mental health education|The mental health education was delivered on the platform of LINE to the control group 3 times a week for 8 weeks
62805859|NCT05258240|OTHER|Conventional Physical Therapy|Conventional physical therapy will be provided to this group for 50 minutes, with one minute of rest for every five minutes of exercise. Warm-up for 5 minutes, balancing-drills for 40 minutes, and cools down for five minutes. The session will include; slow and deep breathing exercise for about 3 minutes, patient will be asked to move both ankle joint to its complete range of movement for about five minutes, posture training for balance includes standing from sitting for five times, shifting the weight of the body while standing at one place for five times, move the body to the side and forward to aim the objective set by the therapist for five times, lift or raise the heels for five times of both foot for 20 seconds for each rise, to stand on one foot for 15 seconds, five times, to stand on one foot and bend the knee for about 15 seconds, five times. Wobble board preparation gait training and spot marching will be performed for about 5 to 6 minutes each.
62805860|NCT05892614|EXPERIMENTAL|efzofitimod 450 mg|Administered IV infusion
62030336|NCT01270451|OTHER|Lifestyle group counseling|Included patients will be randomised into two groups: to the intervention group or to the control group.
62229144|NCT05782426|EXPERIMENTAL|paclitaxel polymeric micelles for injection, platinum combined with sindilizumab injection|Patients will be treated with paclitaxel polymeric micelles for injection, platinum (cisplatin/carboplatin) in combination with sindilizumab for 4-6 cycles. If patient assessment is of clinical benefit, maintenance therapy with sindilizumab plus paclitaxel polymeric micelles for injection(≤230mg/m\^2) can be continued based on investor's evaluation and patient's own choice until disease progression (PD), unacceptable toxicity, withdrawal of consent, initiation of additional antineoplastic therapy, death, or other protocol-specified conditions for discontinuation of treatment, whichever comes first.
62229145|NCT03952494|EXPERIMENTAL|Intervention group|Intervention group will have the PGx test results available via Epic, three days after the biospecimen is received.
62805861|NCT05892614|EXPERIMENTAL|efzofitimod 270 mg|Administered IV infusion
62805862|NCT05892614|PLACEBO_COMPARATOR|Placebo|Administered IV infusion
62229146|NCT03952494|EXPERIMENTAL|Control group|"The control group will be considered in TAU(treatment as usual) group but will have the PGx test results available after 24 weeks.~Note: Patient in both the groups will be followed for 24 weeks and will take questionnaires every other week."
62229147|NCT02440230|EXPERIMENTAL|OFS + Anastrozole|Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Anastrozole.
62805863|NCT04498078|EXPERIMENTAL|Creatine|Twenty grams per day b.i.d.
62805864|NCT01020786|EXPERIMENTAL|Pemetrexed + Carboplatin|After four 21-day cycles of Pemetrexed plus Carboplatin treatment, Pemetrexed monotherapy is continued until study discontinuation.
62805865|NCT00677404|EXPERIMENTAL|stem cell recipient|the patients with peripheral vascular disease who receive bone marrow derived mono nuclear cells
62229148|NCT02440230|ACTIVE_COMPARATOR|OFS + Exemestane|Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Exemestane.
62229149|NCT01030198|EXPERIMENTAL|Fresh surgical scars|Treatment of scars
62229150|NCT01030198|EXPERIMENTAL|Mature scars|Treatment of scars
62421548|NCT04594200|NO_INTERVENTION|Control Group|Participants in this group will not receive a personalized antibiotic prescribing feedback letter and they will not receive a viral prescription pad.
62805866|NCT00764439|ACTIVE_COMPARATOR|1|Standard NRT user direction
62421549|NCT05254093|NO_INTERVENTION|group A|
62805867|NCT00764439|EXPERIMENTAL|2|Novel NRT user direction
62805868|NCT05854680||Long term|Tai Chi has been practiced for at least five years, regular practice, at least three times a week, each practice for at least 30 minutes.
62805869|NCT05854680||Short term|Tai Chi practice time is less than three months, regular practice, at least three times a week, each practice for at least 30 minutes.
62805870|NCT01980329|EXPERIMENTAL|Maraviroc|single oral administration of 300 mg maraviroc
62805871|NCT05642585|EXPERIMENTAL|Group 1: Dose1|Participants randomized to receive MY008211A tablets or placebo on Day 1.
62805872|NCT05642585|EXPERIMENTAL|Group 2: Dose2|Participants randomized to receive MY008211A tablets or placebo on Day 1.
62805873|NCT05642585|EXPERIMENTAL|Group 3: Dose3|Participants randomized to receive MY008211A tablets or placebo on Day 1.
62805874|NCT05642585|EXPERIMENTAL|Group 4: Dose4|Participants randomized to receive MY008211A tablets or placebo on Day 1.
62805875|NCT05642585|EXPERIMENTAL|Group 5: Dose5|Participants randomized to receive MY008211A tablets or placebo on Day 1.
62805876|NCT05642585|EXPERIMENTAL|Group 6: Dose6|Participants randomized to receive MY008211A tablets or placebo on Day 1.
62030337|NCT03830034|EXPERIMENTAL|Amino Acid chelated iron tab 15 mg group|Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) prepared by egyptian pharmaceutical company (nerhadou) once daily (a dose recommended by the company of the product).
62229151|NCT02301598|EXPERIMENTAL|FS-ALK|Femtosecond laser-assisted maximum thickness anterior lamellar keratoplasty (FS-ALK) was performed for 11 eyes of 11 patients with advanced keratoconus and 2 eyes of 2 patients with superficial corneal scattering.
62229152|NCT04271501|NO_INTERVENTION|Control|Area without surgical intervention. Ultraviolet Lamp (UVB)
62421550|NCT05254093|ACTIVE_COMPARATOR|group B|
62805877|NCT05642585|EXPERIMENTAL|Group 7: Dose7|Participants randomized to receive MY008211A tablets or placebo on Day 1.
62805878|NCT01180335|ACTIVE_COMPARATOR|Chemotherapy|4 cycles FEC followed by 4 cycles docetaxel
62805879|NCT01180335|EXPERIMENTAL|Genomic driven chemotherapy|High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
62805880|NCT05330013|OTHER|Control|Healthy volunteers who are age and sex matched
62805881|NCT05330013|EXPERIMENTAL|Subjects with HFpEF|Subjects are defined as patients with a diagnosis of HFpEF clinically confirmed by a licensed physician or advanced practitioner who meet the inclusion and exclusion criteria and are able to provide informed consent.
62229153|NCT04271501|ACTIVE_COMPARATOR|Melanocyte-Keratinocyte Transplantation|Autologous skin cell suspension prepared by laboratory based melanocyte-keratinocyte transplantation procedure technique applied to a surgically prepared area of depigmentation
62229154|NCT04271501|EXPERIMENTAL|RECELL 1:5|Regenerative epidermal suspension diluted 1:5 applied to a surgically prepared area of depigmentation
62421551|NCT05254093|ACTIVE_COMPARATOR|group C|
62229155|NCT04271501|EXPERIMENTAL|RECELL 1:10|Regenerative epidermal suspension diluted 1:10 applied to a surgically prepared area of depigmentation
62229156|NCT04271501|EXPERIMENTAL|RECELL 1:20|Regenerative epidermal suspension diluted 1:20 applied to a surgically prepared area of depigmentation
62229157|NCT04927117||high myopic group (group1:AL≥26.0 mm)|axial length≥26.0 mm)
62421552|NCT03690986|EXPERIMENTAL|Group A (VX15/2503)|Patients receive VX15/2503 IV over 60 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
62421553|NCT03690986|EXPERIMENTAL|Group B (VX15/2503, ipilimumab)|Patients receive VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
62229158|NCT04927117||age-matched control group|axial length\<26.0mm
62421554|NCT03690986|EXPERIMENTAL|Group C (VX15/2503, nivolumab)|Patients receive VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
62421555|NCT03690986|EXPERIMENTAL|Group D (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
62805882|NCT00259714|ACTIVE_COMPARATOR|standard dialysate sodium|In the control phase of the study, the prescribed dialysate sodium is 140 mEq/L
62229159|NCT03346161|EXPERIMENTAL|Arm 1: BREASTChoice (Decision Tool)|Investigators recruited patients scheduled for a plastic/reconstruction consult. Investigators identified patients who completed a mastectomy, or were scheduled for one, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home. Patients randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with the decision tool. They were asked to answer a survey. After the appointment, the team collected information consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes.
62243133|NCT06735209|EXPERIMENTAL|Arm 1 Part 1 Group 3|Healthy malaria-naïve participants aged between 18 and 45 years will receive 2x10\^5 PfSPZ of Plasmodium falciparum sporozoite vaccine (PfSPZ-LARC2) vaccine on Days 1, 29, and 57 followed by 3.2x10\^3 PfSPZ Challenge (7G8) Controlled Human Malaria Infection (CHMI) on Day 141 administered by direct venous inoculation (DVI). Placebo participants that drop out prior to CHMI will be replaced with infectivity controls. Infectivity controls will receive PfSPZ Challenge (7G8) CHMI N=12
62421556|NCT03690986|EXPERIMENTAL|Group E (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
62421557|NCT03690986|NO_INTERVENTION|Group F (no treatment)|Patients undergo standard of care surgery.
62421558|NCT05920018|ACTIVE_COMPARATOR|Dietary supplement|"1. Vivomixx®/VSL#3 sachets p.o. (1.800 bio bacteria/d) and~2. Conjugated linoleic acid (CLA/Tonalin® FFA 80) capsules p.o. (2 g/d)"
62421559|NCT05920018|PLACEBO_COMPARATOR|Placebo-control|"1. Maltose as Placebo to Vivomixx® and~2. Sunflower oil as Placebo to Conjugated linoleic acid (CLA/Tonalin® FFA 80)"
62421560|NCT01770197||recombinant tissue plasminogen activator|Stroke patients with rt-PA treatment in the 3-4.5 hour time window were compared with those within 3h.
62421561|NCT01770197||rt-PA|One group of was treated with standard recombinant tissue plasminogen activator therapy in 3h and the other group of stroke patients was treated within 3-4.5h.
62421562|NCT04648774|ACTIVE_COMPARATOR|Active serratus anterior plane (SAP) block with Ropivacaine 0.2%|
62421563|NCT04648774|PLACEBO_COMPARATOR|Placebo serratus anterior plane (SAP) block with normal saline|
62421564|NCT01307631|EXPERIMENTAL|Treatment (Akt inhibitor MK2206|Patients receive Akt inhibitor MK2206 PO once weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62421565|NCT05084209|EXPERIMENTAL|Parkinson's medical decision making support intervention group|All participants will complete an online medical decision making intervention, lasting about 60 minutes, and complete pre and post surveys.
62421566|NCT06374121|EXPERIMENTAL|Perfusion and concomitant adsorption|Kidneys eligible for perfusion will be treated with the PerLife PerKidney system. Kidneys allocated to the adsorption subgroup will receive concomitant treatment with PerSorb cartridge.
62421567|NCT06374121|ACTIVE_COMPARATOR|Perfusion alone|Kidneys eligible here will only be treated with the PerLife PerKidney system.
62421568|NCT05003895|EXPERIMENTAL|1/ Arm 1|Escalating doses of CAR-T cells
62421569|NCT05003895|EXPERIMENTAL|2/ Arm 2|MTD of CAR-T cells
62421570|NCT00396981|ACTIVE_COMPARATOR|Matrix 2® Coils|Matrix 2® Coils for endovascular aneurysm occlusion
62421571|NCT00396981|ACTIVE_COMPARATOR|GDC® Coils|GDC® Coils for endovascular aneurysm occlusion
62421572|NCT03674827|EXPERIMENTAL|Dose escalation (Part 1)|Participants with NSCLC or TNBC were enrolled at escalating dose levels s of the VBIR-2 regimen.
62805883|NCT00259714|EXPERIMENTAL|dialysate sodium individualization|".Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized)."
62805884|NCT04117113||Elderly, 60+ hospitalized with Invasive ExPEC Disease|Patients 60 years or older hospitalized with Invasive Extraintestinal Pathogenic Escherichia coli Disease.
62805885|NCT00637429||General Co-infection|Individuals with HIV infection and hepatitis B surface antigen positive results who are currently receiving or planning to commence HAART.
62819488|NCT06542029|ACTIVE_COMPARATOR|The study psychologists' group intervention|The study psychologists' group intervention is administered in this arm.
62229160|NCT03346161|ACTIVE_COMPARATOR|Arm 2: Enhanced Usual Care (Surgical Care Booklet)|"Investigators recruited patients scheduled for plastic/reconstruction consultation. Investigators identified patients who completed or scheduled a mastectomy, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or to complete the pre-appointment procedures at home. Patients were randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with American Society of Plastic Surgeons booklet Breast Reconstruction. They were asked to answer a survey. After the appointment, the team collected information about consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes."
62229161|NCT01730170||Pregnant Women without Epilepsy|Women in their first trimester of pregnancy who are not diagnosed with epilepsy
62229162|NCT01730170||Nonpregnant Women with Epilepsy|Women diagnosed with epilepsy and not currently pregnant.
62421573|NCT03674827|EXPERIMENTAL|Dose Expansion (Part 2)|Participants with metastatic NSCLC will be enrolled at the expansion dose level identified during Part 1 of the study.
62229163|NCT01730170||Pregnant Women with Epilepsy|Women in their first trimester of pregnancy and diagnosed with epilepsy
62229164|NCT06074965|EXPERIMENTAL|Arm 1|These subjects will be using infusion set A for the first 3 months and infusion set B for the following 3 months
62229165|NCT06074965|EXPERIMENTAL|Arm 2|These subjects will be using infusion set B for the first 3 months and infusion set A for the following 3 months
62229166|NCT04789278|EXPERIMENTAL|Notification|"Patients randomized to notification will receive a message sent by either the electronic health record (EHR) patient portal or postal mail that will inform them of the CAC identified on their previous chest CT. It will provide an overview of CAC, an image of their chest CT, and a recommendation that they discuss this finding with their clinician. These clinicians will be notified of these findings via an earlier EHR message. Any treatment decisions will be made by the patient and their clinician.~Patients randomized to notification who are not prescribed a statin medication and do not have a documented discussion regarding statin therapy within three months will be sent a second message at that time. Their primary care providers will receive a second EHR message concurrently."
62229167|NCT04789278|NO_INTERVENTION|Usual Care|Both arms have previously had their CT scans reported according to standard clinical practice. This may include notification of the CAC in the imaging report. The usual care arm will not receive any additional notification beyond this standard of care during the project.
62229168|NCT04483245||controls|persons free of hemorrhage or haemostasis disorder
62229169|NCT04483245||Haemorrhagic|Acute hemorrhagic patient
62421574|NCT02236390|ACTIVE_COMPARATOR|Cognitive Processing Therapy-Cognitive|12 sessions of cognitive processing therapy-Cognitive
62421575|NCT02236390|ACTIVE_COMPARATOR|ERRT + CPT-C|5 sessions of Exposure, Relaxation, and Rescripting Therapy, followed by 12 sessions of Cognitive Processing Therapy- Cognitive
62421576|NCT02236390|ACTIVE_COMPARATOR|CPT-C + ERRT|12 sessions of Cognitive Processing Therapy - Cognitive, followed by 5 sessions of Exposure, Relaxation, and Rescripting Therapy
62421577|NCT06578559|EXPERIMENTAL|Encorafenib + Cetuximab|
62421578|NCT03095963|ACTIVE_COMPARATOR|Probiotics|The study group took a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®) in addition to levothyroxine
62591479|NCT05051267|EXPERIMENTAL|Mothers Embrace and Mother's Voice Group|After the procedure, the baby will continue to listen to the baby who is in the mother's arms. One minute after the procedure, the baby's pain score will be evaluated and the HR and O2 values will be noted. After the procedure, until the baby returns to basal values, the mother will be asked to hold her baby and the mother's voice will continue to be listened to. Video and audio recording will continue until the baby's oxygen saturation and heart rate return to basal values. When it returns to basal values, the baby's pain score will be re-evaluated.
62229170|NCT04483245||ECMO|ECMO surgery patient with hemorrhagic complication
62229171|NCT04483245||polytrauma|
62229172|NCT04483245||Platelet disorder|Patient with an identified platelet disorder or treated with antiplatelet agents
62229173|NCT01046890|EXPERIMENTAL|darunavir/ritonavir + root of Echinacea purpurea|darunavir/ritonavir + root of Echinacea purpurea
62229174|NCT06033014|NO_INTERVENTION|Control|The one-year mortality prediction, calculated by the PM Heart algorithm, will not be available to the physician.
62229175|NCT06033014|EXPERIMENTAL|Intervention|The one-year mortality prediction, calculated by the PM Heart algorithm, will be available to the physician.
62229176|NCT00500162|ACTIVE_COMPARATOR|1|
62229177|NCT00500162|ACTIVE_COMPARATOR|2|
62229178|NCT03609684|EXPERIMENTAL|Gymnastic and Core Stabilization|This group consist people who regularly do gymnastics and also do 30-45 minutes core stabilization exercises.
62229179|NCT03609684|EXPERIMENTAL|Only Gymnastic Training|People can do gymnastics twice a week during 8 weeks but can't do core stabilization exercise.
62229180|NCT03609684|ACTIVE_COMPARATOR|Sedentary Group|This group consist individuals who are not interested in any sports and don't do any exercises during 8 weeks.
62229181|NCT04094025|EXPERIMENTAL|dATS patch|dATS, placebo and saline will be administered simultaneously
62421579|NCT03095963|ACTIVE_COMPARATOR|Levothyroxine|The control group took levothyroxine only
62421580|NCT03169660|EXPERIMENTAL|Treatment group|Eyes with submacular hemorrhage secondary to exudative age-related macular degeneration and were treated with vascular endothelial growth factor trap-eye.
62421581|NCT03496935|ACTIVE_COMPARATOR|Tunneled dialysis catheter|In this arm, patients will be randomized to undergo tunneled dialysis catheter insertion.
62591480|NCT02314260||Labour Induction|80 primigravidas undergoing bishop score calculation, trans-vaginal ultrasound assessment of cervical length \&, Modified bishop score calculation, then induction of labour at our hospital.
62229182|NCT00799513|EXPERIMENTAL|Lenalidomide|single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
62421582|NCT03496935|ACTIVE_COMPARATOR|Non-tunneled dialysis catheter|In this arm, patients will be randomized to undergo non-tunneled dialysis catheter insertion.
62591481|NCT03128177|EXPERIMENTAL|High sodium diet|High sodium diet is 6 g sodium per day for 10 days
62229183|NCT01852474|EXPERIMENTAL|Active tDCS|Subjects will receive active tDCS stimulation for 5 sessions (20m/each) over one week.
62229184|NCT04805775|EXPERIMENTAL|Desflurane Inhalation Group|Anesthesia maintenance: Desflurane inhalation (MAC 1.0-1.2) Sufentanil 0.3-0.5 μg / (kg·h) Cisatracurium 1-3 μg / (kg·min)
62229185|NCT04805775|ACTIVE_COMPARATOR|Propofol Group|Anesthesia maintenance: Propofol TCI: 3-4ug / ml Sufentanil 0.3-0.5 μg / (kg·h) Cisatracurium 1-3 μg / (kg·min)
62421583|NCT03751319|ACTIVE_COMPARATOR|Standard Emergency Care + CGA|Standard Care is provided for the acute condition as usual by the ED personnel. Besides the standard care provided by ED personnel, patients are systemically screened and assessed by physician trained for geriatrics or geriatric emergency medicine. Geriatric multi-discipline treatment plan and recommendations are given if suitable for the case.
62421584|NCT03751319|NO_INTERVENTION|Standard Emergency Care|Standard Care is provided for the acute condition as usual by the ED personnel.
62421585|NCT04070599|EXPERIMENTAL|Single arm|Study of lymphocyte subpopulations, cytokine assays, identification of autoantibodies, study of CD40 platelet ligand, thrombopoietin assay
62421586|NCT03940027|EXPERIMENTAL|ropivacaine|The patients will be carried on EUS-CPN with 10ml 0.75% ropivacaine with 10ml anhydrous alcohol
62421587|NCT03940027|ACTIVE_COMPARATOR|bupivacaine|The patients will be carried on EUS-CPN with 10ml 0.75% bupivacaine with 10ml anhydrous alcohol
62421588|NCT01545752|NO_INTERVENTION|coventional group|Teaching just by book
62421589|NCT01545752|EXPERIMENTAL|non-interactive CD|Teaching book with non-interactive CD
62421590|NCT01545752|EXPERIMENTAL|interactive CD|Teaching book with interactive CD
62591482|NCT03128177|EXPERIMENTAL|Low sodium diet|Low sodium diet is 1.5 g sodium per day for 10 days
62591483|NCT04982354|EXPERIMENTAL|Investigational Treatment|Daunorubicin-cytarabine liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) Induction Therapy followed by Busulfan/Melphalan/Fludarabine Conditioning therapy and CD34+-selected allografts.
62805886|NCT06218563|EXPERIMENTAL|vibration-induced illusion of movement|"The protocol consists of 4 or 2 different conditions (repeated 2 times) of vibration-induced illusion of movement in healthy and stroke participants respectively, resulting in 8 or 4 vibration blocks with 3 vibrations per block:~Healthy participants, 2 times each (24 vibrations):~* Right arm, eyes opened (no-illusion condition; RO)~* Right arm, eyes closed (illusion condition; RC)~* Left arm, eyes opened (no-illusion condition; LO)~* Left arm, eyes closed (illusion condition; LC)~Stroke participants, 2 times each (12 vibrations):~* Deficient side, eyes opened (no-illusion condition; DO)~* Deficient side, eyes closed (illusion condition; DC)"
62229186|NCT00855023||Asymptomatic Volunteers|healthy volunteer athletes and excluded those who had any of the following criteria: 1) counter-indications to magnetic resonance imaging (e.g., pregnancy or postsurgical hardware \[plates, screws, aneurysm clip, implanted cardiac pacemaker, etc.\]); (2) relevant medical problems (e.g., connective tissue problems, paralyzed hemidiaphragm, morbid obesity, claustrophobia, etc.); (3) clinical signs of an impairment or abnormality in the knee (e.g., abnormal range of motion, muscle weakness, or malalignment); (4) injury to the knee that required medical attention; (5) previous surgery on the knee; or (6) current pain in the knee.
62229187|NCT05293210|EXPERIMENTAL|Experimental arm|A daily dose of dexamethasone 20 mg intravenous for 3 days, followed by a daily dose of dexamethasone 6 mg intravenous or oral for 7 days.
62421591|NCT06542861|EXPERIMENTAL|Intervention|"Healthcare professionals (doctors and nurses) employed in one of four pediatric departments in the Central Denmark Region. N = approximately 600.~From April 1st 2023 to April 1st 2024 healthcare professionals in the intervention arm will be exposed to a high-frequency training program, in which each healthcare professional will attend four SBTT sessions in one year, approx. three months apart. Three-month intervals were chosen based on knowledge of retention of technical skills."
62421592|NCT06542861|NO_INTERVENTION|Control|"Healthcare professionals (doctors and nurses) employed in one of four pediatric departments in the Region of Southern Denmark. N = approximately 600.~No special training program. Participants in the control region will continue simulation-based team training as usual with no changes in training frequency."
62591484|NCT01883180|EXPERIMENTAL|ATG 7.5mg/kg|ATG 7.5mg/kg group refers to treatment with ATG in the total dose of 7.5mg/kg.
62229188|NCT05293210|ACTIVE_COMPARATOR|Standard treatment regimen|Dexamethasone 6 mg orally or intravenously for 10 days (with the possibility of escalation to doses of 20 mg daily of oral or intravenous dexamethasone for 3 days if clinical criteria of respiratory distress develop despite treatment with doses of dexamethasone 6 mg daily).
62229189|NCT01190982|EXPERIMENTAL|LEP-ETU|All patient will have baseline to confirm disease status. The disease progression/response is assessed inaccordance to the RECIST guidelines
62229190|NCT03488433|ACTIVE_COMPARATOR|Antirotation sling|Patients who undergo reverse shoulder arthroplasty or rotator cuff repair will be randomly assigned to this group.
62229191|NCT03488433|ACTIVE_COMPARATOR|abduction brace|Patients who undergo reverse shoulder arthroplasty or rotator cuff repair will be randomly assigned to this group.
62421593|NCT03496207|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo plus SOC by SC injection during the 24-week treatment period. Dosing will occur once every 3 weeks.
62229192|NCT00622349|EXPERIMENTAL|A|
62229193|NCT00622349|ACTIVE_COMPARATOR|B|
62421594|NCT03496207|EXPERIMENTAL|Sotatercept 0.3 mg/kg|Participants will receive sotatercept 0.3 mg/kg plus SOC by SC injection during the 24-week treatment period. Per protocol, participants may have their doses titrated. Dosing will occur once every 3 weeks.
62591485|NCT01883180|EXPERIMENTAL|ATG 10mg/kg|ATG 10mg/kg group refers to treatment with ATG in the total dose of 10mg/kg.
62591486|NCT05640726|EXPERIMENTAL|(SCRT) followed by PD-1+ standard therapy|
62591487|NCT00733239|EXPERIMENTAL|1|Receives 2-4 of the drugs listed under Intervention
62805887|NCT03976258||HIV-infected adults actively using heroin|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past.
62229194|NCT00622349|EXPERIMENTAL|C|
62229195|NCT02303691|EXPERIMENTAL|Computerized Attention Bias Modification|
62229196|NCT02303691|SHAM_COMPARATOR|Computerized Neutral Training|
62229197|NCT05776212||Work package 1 - Optimisation of 18F-fluoride PET in ATTR-CM|Optimise 18F-fluoride PET imaging of ATTR-CM with increased myocardial tissue to background ratio (TBR) uptake values to provide a state-of-the-art imaging modality for use in the other work packages. (n=15, ATTR-CM subjects)
62805888|NCT03976258||HIV-infected adults never having used heroin|HIV-infected adults on antiretroviral therapy matched to HIV-infected adults actively using heroin by age, sex and CD4+ count.
62805889|NCT03976258||HIV-infected adults initiating buprenorphine/naloxone|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with buprenorphine/naloxone.
62229198|NCT05776212||Work package 2 - Differentiation ATTR-CM from phenocopies|Establish the optimised 18F-fluoride TBR threshold that best differentiates ATTR-CM (n=100) from phenocopies (subjects with light chain amyloidosis, n=20 and subjects with hypertrophic cardiomyopathy, n=20).
62229199|NCT05776212||Work package 3 - In vivo calibration of 18F-fluoride PET|In vivo calibration of 18F-fluoride PET as a marker of the myocardial ATTR burden, calibrating optimised TBR values against the current imaging standard cardiac magnetic resonance imaging extracellular volume. (Subjects with ATTR-CM, n=100)
62421595|NCT03496207|EXPERIMENTAL|Sotatercept 0.7 mg/kg|Participants will receive sotatercept 0.7 mg/kg plus SOC by SC injection during the 24-week treatment period. Per protocol, participants may have their doses titrated. Dosing will occur once every 3 weeks.
62805890|NCT03976258||HIV-uninfected adults initiating buprenorphine/naloxone|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with buprenorphine/naloxone.
62805891|NCT03976258||HIV-infected adults initiating methadone|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with methadone
62805892|NCT03976258||HIV-infected adults initiating Vivitrol|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with Vivitrol.
62805893|NCT03976258||HIV-uninfected adults initiating methadone|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with methadone.
62805894|NCT03976258||HIV-uninfected adults initiating Vivitrol|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with Vivitrol.
62805895|NCT04959396|EXPERIMENTAL|Treatment|IUB SEAD procedure
62805896|NCT04945083|EXPERIMENTAL|Experimental Nutritional Pudding|2 servings per day
62805897|NCT03164811|EXPERIMENTAL|GDFT group|The GDFT group will receive 400 ml of 12.5% carbohydrate drink after 6 pm until the bed time in the day before surgery and 200 ml in the morning of the surgery day. Acetate ringer solution will be start at 7:00. After induction PPV will be measure and fluid bolus 200 ml in 10 minutes will be given if PPV \>13 before prone position. During the operation, the patient in GDFT group will receipt fluid therapy according to acceptable PPV
62229200|NCT05776212||Work package 4 - Disease progression and treatment response|Establish ability of 18F-fluoride PET to track disease progression and treatment response in ATTR-CM at one year follow up. (Subjects with ATTR-CM, n=100)
62421596|NCT06164431|EXPERIMENTAL|ZSP1273 Sequence 1|Single oral dose of 200mg ZSP1273 tablet administered under fasting conditions in first period and 200mg granules in second period，then 200mg ZSP1273 tablet administered under fasting conditions in third period and 200mg granules in fourth period.
62421597|NCT06164431|EXPERIMENTAL|ZSP1273 Sequence 2|Single oral dose of 200mg ZSP1273 granules administered under fasting conditions in first period and 200mg tablet in second period，then 200mg ZSP1273 granules administered under fasting conditions in third period and 200mg tablet in fourth period.
62421598|NCT05515627|EXPERIMENTAL|Atezolizumab|Atezolizumab 1200 mg IV every 3 weeks for 24 weeks
62421599|NCT01506063|EXPERIMENTAL|Levocetirizine DiHCl Tablets, 5 mg|Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
62421600|NCT01506063|ACTIVE_COMPARATOR|XYZAL|XYZAL Tablets 5 mg of UCB Farchim S.A.
62421601|NCT04465916|EXPERIMENTAL|Experimental Arm|Experimental Arm: EYP001a Dose A QD + NA daily (37 patients)
62421602|NCT04465916|PLACEBO_COMPARATOR|Control Arm|Control Arm: Placebo + NA daily (12 patients)
62421603|NCT06138678|EXPERIMENTAL|Accelerated iTBS protocol|Magnetic pulses of 120% of visual motor threshold applied in triplets of 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 1200 pulses per session; total duration of 6 min 40 s over the left DLPFC (F3), given in 2 sessions per day (50 min interval) on 15 week days.
62591488|NCT01687465|ACTIVE_COMPARATOR|Argon laser trabeculoplasty|Up to the year 2005, the vast majority of ophthalmologists used Argon laser trabeculoplasty (ALT) as the mode of laser therapy. ALT is effective but its most significant problem is that its effectiveness decreases with re-treatment since the tissue it targets (the trabecular meshwork) is changed by the laser rendering repeat treatments less effective.
62805898|NCT03164811|OTHER|controlled group|The carbohydrate drink will not be given. Fluid, blood and blood product administration will be under attending anesthesiologist order.
62805899|NCT03787186|EXPERIMENTAL|GLPG1690 oral and IV|GLPG1690 film-coated tablets followed by \[14C\]-GLPG1690 solution for infusion
62805900|NCT03787186|EXPERIMENTAL|[14C]-GLPG1690 capsules|\[14C\]-GLPG1690 capsules
62591489|NCT01687465|ACTIVE_COMPARATOR|selective laser trabeculoplasty|Post 2005, a newer mode of laser therapy, selective laser trabeculoplasty (SLT) has emerged as the standard of care laser. There are many potential advantages to SLT but to date these advantages are only theoretical. The most important potential clinical advantage of SLT is that it causes less damage to the tissue it targets.
62819489|NCT06542029|ACTIVE_COMPARATOR|Towards better well-being and studying -online course|"Online course for students' well-being and studying (Kohti parempaa opiskelua) is administered in this arm."
62421604|NCT06138678|ACTIVE_COMPARATOR|Routine iTBS protocol|Magnetic pulses of 120% of visual motor threshold applied in triplets of 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 20 s over the left DLPFC (F3), given in 1 session per day on 30 week days.
62591490|NCT05007990||Active|Participants include individuals who are caregivers of an individual with a chronic medical condition, OR individuals who support caregivers of an individual with a chronic medical condition.
62805901|NCT01863459|EXPERIMENTAL|Lidexamfetamine Dimesylate|"Lisdexamfetamine dimesylate (Vyvanse) is a central nervous system (CNS) stimulant, approved for the treatment of ADHD Lisdexamfetamine dimesylate is to be started at a dose of 30 mg/day for one week, increased to 50 mg/day for week 2 and to 70 mg/day for week 3. Doses are increased to the maximally tolerated/efficacious dose. Thirty milligrams of Lisdexamfetamine dimesylate per day, is the minimum dose that must be achieved.~Duration of treatment in this arm is 8 weeks; tablet is taken once per day"
62805902|NCT01863459|PLACEBO_COMPARATOR|Placebo|"Placebo will be dosed in the same fashion as the active intervention - 3 potential dose levels.~Placebo is taken once per day for 8 weeks"
62805903|NCT01422161|EXPERIMENTAL|Botulinum Toxin commonly known as BOTOX®|Some subjects will receive BOTOX® injections. Subject will not be informed of what injection they received.
62805904|NCT01422161|PLACEBO_COMPARATOR|Placebo|Some subject will receive a safe Placebo injection. Subjects will not be informed of what injection they have received.
62805905|NCT04722523|EXPERIMENTAL|Head and Neck Squamous Cell Cancer/HNSCC|Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible.
62229201|NCT02528383|EXPERIMENTAL|Vagifem|Postmenopausal women diagnosed with breast cancer, are currently on an anti-estrogen called an aromatase inhibitor and you have agreed to undergo treatment with Vagifem based on your physician's recommendation.
62229202|NCT05857631|EXPERIMENTAL|Hypofractionated Image guided External Beam Radiation|Adjuvant hypofractionated external beam radiotherapy for post operative patients with cervical or endometrial cancer.
62229203|NCT02573220|EXPERIMENTAL|Treatment (FOLFIRI and cetuximab)|Patients receive irinotecan hydrochloride IV over 1-2 hours, fluorouracil IV continuously over 46 hours, and leucovorin calcium IV on days 1 and 15. Patients also receive cetuximab IV over 2 hours on days 3 and 15 of course 1 and days 1 and 15 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62229204|NCT05390411|NO_INTERVENTION|Control Sites|No Intervention
62229205|NCT05390411|EXPERIMENTAL|Sites Randomized to SOCIAL HF|SOCIAL HF is composed of evidence-based bias reduction training, employment of objective measures of social support, and changes to facilitate group dynamics.
62229206|NCT00180323|EXPERIMENTAL|Renewal CRT (CRT ICD)|Single arm study only. All patients will undergo advanced echocardiographic examination pre-operative, pre-discharge after implantation and at 3 and 6-months follow-up. AV-delay optimization will be performed using aortic VTI (Velocity Time Integral) measured by continuous wave Doppler in a modified 4-chamber view. During optimisation aortic VTI will be measured at different heart rates reached by increasing atrial pacing 10, 20 and 30 beats above intrinsic heart rate (IHR).
62229207|NCT01535755|ACTIVE_COMPARATOR|protocol group|This group patients are weaned as the protocol which the investigators described.
62229208|NCT01535755|OTHER|clinicians' order group|This group patients are weaned as the clinicians' order.
62229209|NCT02877563||Patients with PAD|Patients with PAD who are to undergo surgical or percutaneous revascularization.
62229210|NCT05963529|OTHER|Humidity-ramp protocol|Healthy male and female volunteers. Participants will complete all exposures. The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.
62229211|NCT05963529|EXPERIMENTAL|Above-inflection fixed-condition exposure|Healthy male and female volunteers. Participants will complete all exposures. The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.
62229212|NCT05963529|EXPERIMENTAL|Below-inflection fixed-condition exposure|Healthy male and female volunteers. Participants will complete all exposures. The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.
62421605|NCT04707066|EXPERIMENTAL|1|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Responder, thus placed into ongoing Maintenance/Monitoring.
62421606|NCT04707066|EXPERIMENTAL|2|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 CAMS.
62421607|NCT04707066|EXPERIMENTAL|3|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 DBT.
62421608|NCT04707066|EXPERIMENTAL|4|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Responder, thus placed into ongoing Maintenance/Monitoring.
62421609|NCT04707066|EXPERIMENTAL|5|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 CAMS.
62421610|NCT04707066|EXPERIMENTAL|6|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 DBT.
62421611|NCT06514209|EXPERIMENTAL|Moderate-Severe ARDS patients|The dose of cisatracurium was gradually adjusted to achieve different depth of muscle relaxation
62421612|NCT01106118||Group 1|
62421613|NCT03706274|EXPERIMENTAL|CX-188 Escalation|
62421614|NCT03706274|EXPERIMENTAL|CX-188 Alternative Dosing Schedule|
62421615|NCT02368769||During tele-expertise|Remote site interpretation of frozen section
62805906|NCT04722523|EXPERIMENTAL|Secondary Cohort|Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible.
62805907|NCT00601497|EXPERIMENTAL|1|
62805908|NCT00601497|PLACEBO_COMPARATOR|2|
62805909|NCT05470335|NO_INTERVENTION|physician insertion|radial sheath insertion is performed by physicians
62421616|NCT02368769||Before tele-expertise|Usual (on site) frozen section
62421617|NCT03367273|EXPERIMENTAL|vitiligo patients|
62805910|NCT05470335|EXPERIMENTAL|nurse insertion|radial sheath insertion is performed by nurses
62421618|NCT03367273|EXPERIMENTAL|controls|
62421619|NCT03567239|EXPERIMENTAL|Using adaptive device|Participants will use a non-commercially available device, designed to meet their needs.
62421620|NCT05810181||Young Adult|15-25 parents/families of children (or young adults aged 18-35 years) with rare genetic diseases, who have recently received gene therapy
62229213|NCT05963529|ACTIVE_COMPARATOR|Control fixed-condition exposure|Healthy male and female volunteers. Participants will complete all exposures. The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.
62229214|NCT04151797|EXPERIMENTAL|Medication therapy management|Medication therapy management by pharmacist-led medication review
62229215|NCT04698941|EXPERIMENTAL|Simvastatin + Albumin Paclitaxel|received intravenous infusions of Paclitaxel 260 milligrams per square meter (mg/m\^2) on Day 1 of every 21-day cycle (4 cycles) in combination with oral simvastatin (20mg daily) (10 months)
62805911|NCT03267550|EXPERIMENTAL|remote programming system|
62229216|NCT04698941|ACTIVE_COMPARATOR|Albumin Paclitaxel|received intravenous infusions of Paclitaxel 260 milligrams per square meter (mg/m\^2) on Day 1 of every 21-day cycle (4 cycles)
62229217|NCT06262685|EXPERIMENTAL|Experimental Group|Patients in this Experimental Group will receive any of the statins authorized in Spain for lipid-lowering, both for primary and secondary prevention. Subjects in the Experimental Group will be administered the specific type and dosage of statins recommended by the Clinical Pharmacogenetics Consortium's genotype guidelines, utilizing the patient's pharmacogenetic information and characteristics
62805912|NCT04802811|EXPERIMENTAL|Treatment group A|
62805913|NCT04802811|EXPERIMENTAL|Treatment group B|
62421621|NCT05810181||Parent/caregiver|10-20 patients/families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or who were ultimately not eligible for a clinical trial.
62421622|NCT05810181||Healthcare Worker|10-20 health care workers' who provide care to patients receiving gene therapy.
62421623|NCT04045600|EXPERIMENTAL|Mult FCT/Trad FCT|Participants assigned to this condition will receive both traditional FCT (trad FCT) and FCT with multiple schedules (mult FCT) to evaluate the effects of mult FCT on renewal, super-resurgence, and reinstatement.
62421624|NCT04045600|EXPERIMENTAL|Mult FCT + Stimulus Fading/Trad FCT|Participants assigned to this condition will receive both traditional FCT (trad FCT) and FCT with multiple schedules and stimulus fading (mult FCT + stimulus fading) to evaluate the effects of mult FCT and gradual fading of contextual stimuli on renewal, super-resurgence, and reinstatement.
62805914|NCT04802811|EXPERIMENTAL|Treatment group C|
62805915|NCT04802811|EXPERIMENTAL|Treatment group D|
62421625|NCT01457729|NO_INTERVENTION|No Motivation|Patients are asked to complete a telemonitored Ergometer training for 4 Weeks, at least 30 minutes per day, no more intervention is done.
62421626|NCT01457729|OTHER|Motivation|Patients are asked to complete a telemonitored Ergometer training for 4 Weeks, at least 30 minutes every day. If training time declines to less than 20 minutes per day for one week, a motivation phone call will take place once a week.
62591491|NCT05007990||Bereaved|Participants include individuals who were caregivers of an individual with a chronic medical condition who has died, OR individuals who support the caregiver.
62805916|NCT04802811|EXPERIMENTAL|Treatment group E|
62805917|NCT02859259|EXPERIMENTAL|Treatment A: reference extended-release (ER) 1 tablet at 600mg|A single dose of BMS-663068 administered orally as specified
62805918|NCT02859259|EXPERIMENTAL|Treatment B: low-dose ER 4 tablets at 150mg|A single dose (4 tablets) of BMS-663068 administered orally as specified
62805919|NCT00629044|ACTIVE_COMPARATOR|G|
62805920|NCT00629044|ACTIVE_COMPARATOR|AMD|
62229218|NCT06262685|ACTIVE_COMPARATOR|Control Group|Patients in this Control Group will receive any of the authorized statins in Spain for lipid-lowering, whether for primary or secondary prevention. They will be administered statins according to clinical practice and the drug's product labeling, without exceeding the already authorized dosages
62229219|NCT00260663|OTHER|Arm 1|
62421627|NCT00949572|EXPERIMENTAL|Intramuscular administration|Intramuscular injection of HPV vaccine proteins
62421628|NCT00949572|EXPERIMENTAL|Sublingual administration|Sublingual administration of HPV vaccine proteins
62421629|NCT05031962||CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)|Implant-based breast reconstruction following mastectomy using the CELLIS Breast matrix
62805921|NCT00629044|ACTIVE_COMPARATOR|Healthy subjects|
62805922|NCT00622557||Surgical|All patients having surgery procedures
62805923|NCT01207375|EXPERIMENTAL|experimental group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
62805924|NCT01207375|PLACEBO_COMPARATOR|Placebo control group|The placebo control group will receive placebo memory exercises administered on a laptop computer twice a week for five weeks (10 placebo control sessions).
62805925|NCT05942144|EXPERIMENTAL|Exercise-snacks group|"They will perform a exercise-snacks program and receive information about physical activity"
62229220|NCT00589654||1|
62229221|NCT01005433|ACTIVE_COMPARATOR|Dexmedetomidine 0.6 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia
62229222|NCT01005433|ACTIVE_COMPARATOR|Dexmedetomidine 0.4 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 4 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia
62229223|NCT01005433|ACTIVE_COMPARATOR|Dexmedetomidine 0.2 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia.
62805926|NCT05942144|NO_INTERVENTION|Control group|They will maintain their usual lifestyle until the end of the study
62805927|NCT01118546||controls 2|patient without CAD, not on aspirin and without history of hypersensitivity
62805928|NCT01118546||case of hypersensitivity|patient with CAD on aspirin, with a history of hypersensitivity
62805929|NCT01118546||controls 1|patient with CAD on aspirin, without history of hypersensitivity
62805930|NCT04434417||Cohort tested|The cohort will include patients or health professionals who patients who were suspected of being infected with 2019-nCoV
62819490|NCT06542029|NO_INTERVENTION|No intervention control group|The no intervention control group consists of students who are not attending any active interventions for mental well-being or promotion of studying skills.
62819491|NCT03388346|EXPERIMENTAL|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET
62819492|NCT02432703|EXPERIMENTAL|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
62805931|NCT02752880|EXPERIMENTAL|YH1 group|YH1 with one batch number was manufactured by Sun Ten Pharmaceutical Co., Ltd., a renowned manufacturer of concentrated herbal extract granules conforming to the standards of good manufacturing practices (GMP) in New Taipei City, Taiwan. YH1 contains Rhizoma Coptidis (50 %) and Shen-Ling-Bai-Zhu-San (SLBZS) (50 %). SLBZS consists of Radix Ginseng, Poria, Rhizoma Atractylodis macrocephalae, Semen Lablab album, Rhizoma Dioscoreae, Embryo Nelumbinis, Radix Platycodonis, Semen Coicis, Fructus Amomi, Fructus Jujubae, and Radix Glycyrrhizae at a 3:3:3:2.3:3:1.5:1.5:1.5:1.5:1.5:3 ratio. Subjects in the YH1 group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.
62805932|NCT02752880|PLACEBO_COMPARATOR|placebo group|The placebo was also prepared as granules by Sun Ten Pharmaceutical Co., Ltd., and the packaging of the placebo was identical to that of YH1. Subjects in the placebo group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.
62229224|NCT01005433|PLACEBO_COMPARATOR|Placebo|The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 20 min before induction of anesthesia
62229225|NCT00484731|PLACEBO_COMPARATOR|Injection with Saline|Injection with Saline instead of Bupivacain
62229226|NCT00484731|ACTIVE_COMPARATOR|Injection with Bupivacaine|Injection with Bupivacaine
62229227|NCT05602831||operable treatment group|"After enrollment, patients will receive standard treatment and conventional follow-up strategy.~Peripheral blood samples will be collected before treatment and at different time points after starting treatment.~Baseline surgical tissue will be also obtained."
62421630|NCT01738009|EXPERIMENTAL|Induction of flow limitation|Flow limitation will be induced by sustained reductions in continuous positive airway pressure during sleep
62805933|NCT03658122|EXPERIMENTAL|Parent-Child Care Treatment|Participants receive PC-CARE treatment immediately following the pre-treatment assessment.
62805934|NCT03658122|OTHER|Waitlist Control then Parent-Child Care|Participants wait approximately 2 months with no intervention before completing another pre-treatment assessment (post-waitlist assessment) and receiving PC-CARE treatment.
62421631|NCT05643131|EXPERIMENTAL|Hyivy Intravaginal Device|Participants will receive a Hyivy intravaginal device for at-home use. Recommended use is three times per week for 12 weeks and consists of 10 minutes of heat (37-39ºC) and 10 minutes of dilation per session.
62805935|NCT05963620||percutaneous coronary intervention (PCI)|percutaneous coronary intervention (PCI) with sirolimus-eluting stents
62421632|NCT06232369|EXPERIMENTAL|Patient group + active stimulation intervention|Patient participants with anxiety disorders in this arm will first accept active repetitive stimulation on core brain regions and then complete the threat reversal learning paradigm.
62421633|NCT06232369|SHAM_COMPARATOR|Patient group + sham stimulation intervention|Patient participants with anxiety disorders in this arm will first accept sham repetitive stimulation on core brain regions and then complete the threat reversal learning paradigm.
62421634|NCT06232369|SHAM_COMPARATOR|Healthy control group + sham stimulation intervention|Healthy participants in this arm will first accept sham repetitive stimulation on core brain regions and then complete the threat reversal learning paradigm.
62421635|NCT03575611|EXPERIMENTAL|Treatment (SBRT)|Patients undergo SBRT over 1 day to 3 weeks based on the judgment of the treating radiation oncologist. If the disease spreads to a new lesion that can be treated with local therapy, patients may repeat SBRT over 1 day to 3 weeks based on the judgment of the treating radiation oncologist. Patients may undergo blood sample collection throughout the trial, as well as a tumor biopsy on study. Patients also undergo CT, PET/CT, and/or MRI throughout the trial.
62421636|NCT05854173|OTHER|Pendulum Exercises|
62421637|NCT05854173|EXPERIMENTAL|Kaltenborn Mobilization|
62421638|NCT05037175|EXPERIMENTAL|CPT-Text + Incentive|"CPT-Text. CPT is a 12-session, trauma-focused, cognitive therapy that teaches clients to examine and change problematic beliefs about themselves and the world that were altered as a result of trauma.~Retention Incentive (RI). Participants will be told at baseline that they can earn discounts for other users with PTSD if they message with their therapist regularly."
62805936|NCT05963620||coronary artery bypass grafting (CABG)|coronary artery bypass graft surgery
62805937|NCT03062735|EXPERIMENTAL|Inspiratory Muscle Training|Inspiratory Muscle Training intervention (Sham-IMT) groups during a 3 months training season. A pressure threshold device (POWERbreathe - HaB International Ltd., UK) will be used to IMT. The IMT group will perform 30 inspiratory efforts, 5 times a week, twice daily, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure (MIP).
62805938|NCT03062735|SHAM_COMPARATOR|Sham Inspiratory Muscle Training|Sham-IMT group will follow a similar protocol, except the inspiratory effort that will be made against 15% MIP. The duration of each IMT session will be 30 inspirations. After the initial setting of training loads, the IMT group will be instructed to periodically increase load so that only 30 maneuvers could be completed. The Sham-IMT group will not receive these instructions. All the IMT sessions, in both groups will take place before swimming training and will be supervised throughout the intervention period to ensure that technique and load will be appropriate.
62805939|NCT05487222||• Liberal fluid group (L group) using traditional technique of fluid administration|
62229228|NCT05602831||radical chemoradiotherapy group|"After enrollment, patients will receive standard treatment and conventional follow-up strategy.~Peripheral blood samples will be collected before treatment and at different time points after starting treatment.~Baseline puncture tissue will be also obtained before radical chemoradiotherapy."
62229229|NCT02210234|ACTIVE_COMPARATOR|50 grams of whole wheat bran cereal|This arm was randomized to eat 50 grams of whole wheat brand cereal during the day for 3 weeks.
62229230|NCT02210234|ACTIVE_COMPARATOR|100 grams of whole wheat bran cereal|This arm was randomized to eat 100 grams of whole wheat brand cereal the day for 3 weeks.
62229231|NCT06178406||dysmenorrhea|
62229232|NCT06178406||female healthy controls|
62229233|NCT02736773|EXPERIMENTAL|xenograft material to slow resorption|xenograft material to slow resorption (Bio-Oss®)
62229234|NCT01306097|EXPERIMENTAL|Zinc sulfate|daily zinc supplementation for 3 months. (10mg daily for under 1 years old children and 20mg daily for above 1 years old children)
62229235|NCT03328403|EXPERIMENTAL|Aspiration First|Aspiration thrombectomy with large bore catheters
62229236|NCT03328403|EXPERIMENTAL|Stent retriever first|Thrombectomy with a licensed stent retriever device
62805940|NCT05487222||• Goal directed fluid group(G group) using stroke volume optimization|
62805941|NCT00389844|NO_INTERVENTION|1|Routine care
62805942|NCT00389844|ACTIVE_COMPARATOR|2|Exercise only
62229237|NCT02853357|SHAM_COMPARATOR|Control|The control group includes randomized participants that will receive a sham manipulation. Participants will also complete the standard set of core strengthening exercises.
62805943|NCT00389844|ACTIVE_COMPARATOR|3|Motivation only
62229238|NCT02853357|EXPERIMENTAL|Manipulation|The manipulation group includes randomized participants that will receive a thoracic spine thrust manipulation. Participants will also complete the standard set of core strengthening exercises.
62030338|NCT03830034|ACTIVE_COMPARATOR|Ferrous Fumarate tab 350 mg( 115 mg elemental iron) group|Contain 75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb\<9g/dl) this dose can be doubled as recommended by the company of the product.
62030339|NCT01054820|EXPERIMENTAL|FLECTORA Patch (diclofenac epolamine topical patch) 1.3%|One patch applied every 12 hours
62030340|NCT01333124|EXPERIMENTAL|Radiation: chemoradiotherapy with Gemcitabine|Radiation: chemoradiotherapy with Gemcitabine All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.
62030341|NCT03546244|EXPERIMENTAL|musical treadmill|4-week daily musical treadmill training, consisting in two session, 20 minute per session
62229239|NCT03267160||Sepsis with cardiopulmonary failure|Patient with sepsis and also respiratory and heart involvement, confirmed by Hemodynamic parameters
62805944|NCT00389844|EXPERIMENTAL|4|Exercise plus motivation
62805945|NCT05172609|EXPERIMENTAL|Exposure Based Implementation Strategy (EBIS)|EBIS is informed by the latest science in exposure theory, borrowing heavily from brief exposure-based treatments that can be delivered in a single session. We anticipate that EBIS will occur in four phases that map on to standard exposure therapy practice for patients with anxiety disorders: psychoeducation, assessment, practice, and relapse prevention; however, the final version will depend on the outcomes of the preparatory phases of this study. Clinicians assigned to the EBIS arm will also receive all elements of IAU.
62805946|NCT05172609|ACTIVE_COMPARATOR|Implementation as Usual (IAU)|Gold-standard IAU for SSAIs typically comprises pre-implementation preparation, didactic training, knowledge tests, experiential role plays, ongoing expert consultation, and providing certification status to clinicians who attain established benchmarks. Pre-implementation preparation will include provision of materials. Didactic training will occur in two parts: (1) suicide screening and assessment, and (2) Safety Planning Intervention (SPI) use. Part one will consist of materials we previously developed based on community clinician feedback. Part two will follow established SPI guidelines, including didactic training about SPI rationale and evidence base and experiential practice. IAU also will include supports for electronic health record integration (e.g., previously developed templates). After training, clinicians will receive 8 weeks of expert consultation to discuss implementation barriers and receive more role play practice.
62229240|NCT03267160||Sepsis without cardiopulmonary failure|Patient with sepsis without respiratory and heart involvement
62229241|NCT00421707|EXPERIMENTAL|GW876008|GW876008
62229242|NCT00421707|PLACEBO_COMPARATOR|Placebo|Placebo
62229243|NCT01710332|EXPERIMENTAL|Intravitreal Aflibercept Injection (x4)|2 mg / Intravitreal / every 1 month x 3 months and at month 4 (Drug administered 4 times).
62805947|NCT02643108|EXPERIMENTAL|Lateral episiotomy|Lateral episiotomy (left or right) is performed by the attending physician or assisting midwife at crowning of the fetal head in operative vaginal delivery by vacuum extraction. Regular manual perineal support is applied.
62229244|NCT01710332|EXPERIMENTAL|Intravitreal Aflibercept Injection (x6)|2 mg / Intravitreal / every 1 month x 6 months ((Drug administered 6 times).
62030342|NCT03546244|ACTIVE_COMPARATOR|traditional session|4-week daily traditional treadmill training, consisting in two session, 20 minute per session
62229245|NCT06207513|EXPERIMENTAL|Intervention I group|Patient intubated with an endotracheal tube and on a mechanical ventilator will receive endotracheal suctioning procedure using a single-used open endotracheal suction catheter that is used only for one-time suctioning attempt and discarded after each endotracheal suction cycle. A new catheter will be used for each endotracheal suctioning procedure.
62229246|NCT06207513|EXPERIMENTAL|Intervention II group|Patient intubated with an endotracheal tube and on a mechanical ventilator will receive endotracheal suctioning procedure using an open endotracheal suction catheter that is used multiple times during a 12-hour nursing shift. Flushing of the suctioning circuit will be performed with 40 ml of chlorhexidine gluconate 0.2% after every endotracheal suction procedure
62030343|NCT05805397|EXPERIMENTAL|Motivation Skills Training (MST)|MST is a weekly group-based skills training intervention that aims to improve knowledge about one's level and sources of motivation, the ability to monitor and regulate (understand and manage) motivation so that one can better initiate and sustain goal-directed behavior
62229247|NCT06207513|OTHER|Control group|Patients intubated with an endotracheal tube and on a mechanical ventilator will receive standard care. This is the endotracheal suctioning procedure using an open endotracheal suction catheter that is used multiple times during a 12-hour nursing shift. Flushing of the suctioning circuit is standardised performed using normal saline after every endotracheal suction procedure.
62229248|NCT02159430||HereditaryAngioEdema|Patients from the Eastern Sicily HAE register
62229249|NCT03032393|EXPERIMENTAL|Dominant|Subjects in the experimental group were instructed to stand with hands on their hips, elbows pointing out and feet approximately one foot apart for 20 seconds.
62805948|NCT02643108|NO_INTERVENTION|No episiotomy|No episiotomy is performed during operative vaginal delivery, unless vitally indicated (for example severe fetal distress). The woman may tear spontaneously. Regular manual perineal support is applied.
62805949|NCT01324817||Hopitalized|Patients admitted to the hospital
62030344|NCT05805397|ACTIVE_COMPARATOR|Healthy Behaviors Control Group|HBC is a weekly group-based intervention that provides psychoeducation and skills training to help individuals improve physical health
62805950|NCT03499184|EXPERIMENTAL|Local Probiotics|P Flor (Lactobacillus reuteri 1.2 billion CFU) will be delivered locally every 12 hours for 12 weeks
62805951|NCT03499184|EXPERIMENTAL|Systemic Probiotics|P Flor (Lactobacillus reuteri 1.2 billion CFU) will be administered every 12 hours for 12 weeks
62805952|NCT03499184|ACTIVE_COMPARATOR|Systemic Antibiotics|Amoxil 500 mg capsule and Flagyl 400 mg tablet by mouth, will be given every 8 hours for 5 days
62805953|NCT05183945|EXPERIMENTAL|Localization needle insertion|Patients undergo localization needle insertion on day 1.
62805954|NCT05183945|ACTIVE_COMPARATOR|Coil insertion|Patients undergo coil insertion on day 1.
62805955|NCT05932615|EXPERIMENTAL|Navitor Transcatheter Aortic Valve Implantation (TAVI) System|TAVI with Abbott Navitor Transcatheter Aortic Valve Implantation (TAVI) System
62805956|NCT05932615|ACTIVE_COMPARATOR|Any Commercially Available Transcatheter Aortic Valve System (CAV)|TAVI with any FDA approved commercially available Transcatheter Aortic Valve System (CAV)
62805957|NCT03685955||Genitourinary Reconstruction with Amniotic Membranes|Patients who undergo genitourinary reconstruction with amniotic membranes
62805958|NCT04435444|EXPERIMENTAL|Masterful supportive care|This intervention uses teachings, discussions, and exercises about personal experiences that focus on specific topics related to meaning and cancer. For example, we may discuss what is meaningful in your life, how you identify yourself before and after cancer, and your hopes for the future. The Masterful intervention is available in both English and Arabic, and it will be delivered by a trained bilingual member of the study team. It includes 3 weekly (or at participant's preference) 1-hour sessions with a member of the study team. The sessions for either the treatment or the control arm will take place in-person in a private room at MSKCC or via teleconference, depending on the patients preference. Meeting one-on-one with an interventionist was feasible in our pilot study and will enhance relationship-building between interventionist and patient. Participants will have the option to meet with the interventionist via teleconference in order to reduce in-person contact burden.
62805959|NCT04435444|ACTIVE_COMPARATOR|Attention control supportive care|This intervention uses the American Cancer Society's patient education materials. These sessions will include discussions about managing a self-identified current problem in your life. The attention control supportive care intervention is available in both English and Arabic, and it will be delivered by a trained bilingual member of the study team. It includes 3 weekly (or at participant's preference) 1-hour sessions with a member of the study team. The sessions for either the treatment or the control arm will take place in-person in a private room at MSKCC or via teleconference, depending on the patients preference. Meeting one-on-one with an interventionist was feasible in our pilot study and will enhance relationship-building between interventionist and patient. Participants will have the option to meet with the interventionist via teleconference in order to reduce in-person contact burden.
62805960|NCT00690729|EXPERIMENTAL|1|Bibliotherapy - cognitive behavior therapy focusing on exposure and response prevention directed by the family
62805961|NCT00690729|ACTIVE_COMPARATOR|2|Cognitive Behavioral Therapy - therapist-directed exposure response prevention over a 12-week period
62805962|NCT04023526|EXPERIMENTAL|Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg|Participants will receive azacitidine 75 milligram per meter square (mg/m\^2) subcutaneously (SC) or intravenously (IV) on Day 1 through Day 7 and cusatuzumab 10 milligram per kilogram (mg/kg) IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee.
62805963|NCT04023526|EXPERIMENTAL|Azacitidine 75 mg/m^2 and Cusatuzumab 20 mg/kg|Participants will receive azacitidine 75 mg/m\^2 SC or IV on Day 1 through Day 7 and cusatuzumab 20 mg/kg IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee.
62805964|NCT03174353|EXPERIMENTAL|Lanreotide arm|Single arm study. A single deep subcutaneous dose of lanreotide (Somatuline Depot 120 Mg/0.5Ml) will be administered prior to planned resection on the day of surgery.
62805965|NCT03056417|EXPERIMENTAL|Intervention|Participants in the Complete Health Improvement Program.
62805966|NCT03056417|NO_INTERVENTION|No Change to Treatment|Participants who choose not to participate in the Complete Health Improvement Program.
62805967|NCT00960063|EXPERIMENTAL|Temozolomide+Irinotecan+Robatumumab|Participants receive temozolomide 100 mg/m\^2/day intravenously (IV) on Days 1-5 PLUS irinotecan 10 mg/m\^2/day IV on Days 1-5 and Days 8-12 PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
62805968|NCT00960063|EXPERIMENTAL|Vincristine+Doxorubicin+Cyclophosphamide+Robatumumab|Participants receive vincristine 2 mg/m\^2 (maximum 2 mg) IV on Day 1 PLUS cyclophosphamide 1200 mg/m\^2 IV on Day 1 PLUS doxorubicin hydrochloride 75 mg/m\^2 IV continuously over 48 hours PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
62805969|NCT00960063|EXPERIMENTAL|Ifosfamide+Etoposide+Robatumumab|Participants receive ifosfamide 1800 mg/m\^2 per day IV PLUS etoposide 100 mg/m\^2 per day IV on Days 1-5 PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
62030345|NCT06298539||Obesity|BMI \> 30 kg/m2
62030346|NCT06298539||Healthy weight|BMI range: 19 - 29 kg/m2
62030347|NCT01895387|EXPERIMENTAL|Whole grains and legumes|
62030348|NCT01895387|PLACEBO_COMPARATOR|Refined rice|
62805970|NCT01715168|ACTIVE_COMPARATOR|DOXIL/CAELYX or Doxorubicin Hydrochloride (Lipspome)|Current Standard of care and/or reference product in Europe (Caelyx) and US (Doxorubicin Hydrochloride (Liposome) and Doxil)
62229250|NCT03032393|ACTIVE_COMPARATOR|Submissive|Subjects in the control group were instructed to stand with hands and arms wrapping around the torso and feet together for 20 seconds.
62229251|NCT04977141||Under-represented minority|Non-English speaking and/or non-White
62229252|NCT04977141||Non-under-represented minority|English-speaking and/or White
62229253|NCT03280667|EXPERIMENTAL|Pembrolizumab plus Denosumab|Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D, continued until disease progression or prohibitive toxicity
62229254|NCT02156128|EXPERIMENTAL|Cogmed|Participants in a 3,5 week vocational rehabilitation program (containing cognitive therapy and physical exercise) are instructed to use a computer-based working memory training program (named CogMed) each weekday (5 days a week) for 5 weeks. Each training session consists of 8 different tasks and lasts 40-50 minutes.
62229255|NCT02156128|ACTIVE_COMPARATOR|Control group|These subjects will participate in the vocational rehabilitation program for 3,5 weeks. The program includes cognitive therapy (ACT) and physical activity, but no working memory training.
62229256|NCT02042612|EXPERIMENTAL|sevoflurane|Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in obese ICU patients
62030349|NCT02573519|ACTIVE_COMPARATOR|Diabetic patient|"The study consists of four different parts:~1. 11C Donepezil PET/CT scan~2. 3D-Transit~3. 3D-Transit during treatment with pyridostigmine~4. 3D-Transit after Malone appendicostomy (only diabetic patients who had a Malone-surgery for severe obstipation ordered during standard clinical practice)"
62805971|NCT01715168|EXPERIMENTAL|ATI-0918|Investigational drug arm which will be compared to Doxil/Caelyx and Hydrochloride Doxorubicin (Liposome) arms for bioequivalence analysis
62805972|NCT04257201|ACTIVE_COMPARATOR|Control -- no mushrooms|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
62229257|NCT02767713|EXPERIMENTAL|Dexamethasone|Dexamethasone dose of 0.1 mg/kg was administered intravenously 10h before surgery
62229258|NCT02767713|PLACEBO_COMPARATOR|Control|Equal volume of normal saline (placebo) was administered intravenously 10h before surgery
62229259|NCT03268122|ACTIVE_COMPARATOR|Standard Contact Isolation|Patients in the standard contact isolation arm will be under the standard contact isolation strategy during the entire time they are physically located in the Medical ICU.
62229260|NCT03268122|ACTIVE_COMPARATOR|Targeted Contact Isolation|Patients in the targeted contact isolation arm will be under the targeted contact isolation strategy during the entire time they are physically located in the Medical ICU.
62229261|NCT01377051|ACTIVE_COMPARATOR|Bronchodilator|Indacaterol maleate 300 mcg will be administered by a third independent investigator following a randomization list.
62229262|NCT01377051|PLACEBO_COMPARATOR|Placebo|Will be administered with the same device by a third independent investigator
62421639|NCT05037175|EXPERIMENTAL|CPT-Text + Reminder As Usual|"CPT-Text. CPT is a 12-session, trauma-focused, cognitive therapy that teaches clients to examine and change problematic beliefs about themselves and the world that were altered as a result of trauma.~Reminder as Usual (RAU). As per Talkspace guidelines, therapists are available to client participants twice per day, five days per week. In the event a client participant has not engaged or messaged in 48 hours, therapists send a personalized message to the client participant to encourage them to re-engage."
62805973|NCT04257201|EXPERIMENTAL|Yellow Oyster -- 84 g|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
62805974|NCT04257201|EXPERIMENTAL|Yellow Oyster -- 168 g|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
62805975|NCT04257201|EXPERIMENTAL|White button -- 84 g|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
62805976|NCT04257201|EXPERIMENTAL|White button 168 g|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
62819493|NCT02432703|PLACEBO_COMPARATOR|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
62819494|NCT01112826|EXPERIMENTAL|Capecitabine|Capecitabine 650 mg/m2 bid
62030350|NCT02573519|ACTIVE_COMPARATOR|Healthy subjects|"The study consists of two different parts:~1. 11C Donepezil PET/CT scan~2. 3D-Transit"
62030351|NCT04494152||Critically ill patients|Adult critically ill patients hospitalised in the intensive care unit.
62229263|NCT04819984|EXPERIMENTAL|Continuous PtC02 evaluation|Continuous PtC02 measured by TCM5 monitor during ventilatory weaning test of 30 minutes when available
62229264|NCT01544829|ACTIVE_COMPARATOR|Active Comparator: Single serving of theobromine|
62229265|NCT01544829|ACTIVE_COMPARATOR|Multiple servings of theobromine|
62229266|NCT01544829|PLACEBO_COMPARATOR|Placebo capsules|
62229267|NCT04771468||Sovratentorial ischemic stroke|
62229268|NCT03718533|EXPERIMENTAL|Eltrombopag|Patients received eltrombopag orally once daily up to 36 weeks.
62229269|NCT01720745||EUS FNA|Patients undergoing endoscopic ultrasound for solid mass lesions with a 22 G needle at University of Minnesota Medical center and Aurora St.Luke's Medical Center, Milwaukee, WI
62229270|NCT02271477|NO_INTERVENTION|Wild-Type|The setting is standard spinal anesthesia and corresponds to our first arm of the study, used as the control sample and statistical reference. During the induction phase, the patient is fitted with non-invasive blood pressure monitoring, three-lead ECG, pulse-oximetry and peripheral intravenous device. Data and vital signs are recorded and an infusion of crystalloid (NaCl 0.9% or Ringer's acetate) is given during the procedure until the beginning of the operation. Total amount of fluid is also recorded before and after the spinal anesthesia.
62421640|NCT05037175|ACTIVE_COMPARATOR|Culturally Informed Trauma Treatment (CITT) + Incentive|"CITT will be conducted by Talkspace therapists with a specialty in PTSD culturally informed PTSD treatment.~Retention Incentivefor other users with PTSD in subsequent months if they message with their therapist regularly."
62229271|NCT02271477|EXPERIMENTAL|Echocardiography|In addition to the current clinical standard, a Trans-Thoracic Echocardiography is performed before spinal anesthesia, with the aim of assessing the patient's volume status; the exam is performed to assess size and collapsing of the Inferior Vena Cava during breathing cycle. According to different pre-established parameters13, the patient is defined as fluid-responsive or unresponsive. If the patient is not responsive, investigators proceed to spinal anesthesia; otherwise they proceed to administration of crystalloid bolus (500 ml of NaCl 0.9% or Hartmann's solution). The patient may receive another bolus so as to reach a non-responsive pattern for echocardiographic evaluation.
62229272|NCT03439176|EXPERIMENTAL|Test of new adhesive strips|"The subjects will test adhesives strips made of 4 different adhesives:~Standard adhesive 1 Standard adhesive 2 PL4 PL16-L"
62229273|NCT01988623|EXPERIMENTAL|Pivotal Response Treatment (PRT)|
62229274|NCT05634525|EXPERIMENTAL|MRTX849 (Adagrasib)|Helps to control pancreatic cancer that has a KRAS G12 mutation.
62229275|NCT05029479|EXPERIMENTAL|Yamakin TMR-Aquabond0|Novel Moisture Resistant, M-TEG-P Phosphate Monomer Based Universal Adhesive (YAMAKIN TMR-Aquabond0)
62805977|NCT05058807|EXPERIMENTAL|Whole body vibration group|"Experimental Group will receive WBV training and balance exercises under the supervision of a physical therapist by using a vibration platform. Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps \* 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps, with 30 sec rest interval~WHOLE BODY VIBRATION:~The patient stood on the platform with his/her feet barefoot shoulder width and stared at the front, delivered on a side alternating vibration platform in an intermittent way: five repetitions of 1 min vibration followed by a 1 min rest. The vibration frequency and amplitude were 20 Hz and 3.0 mm respectively.~These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
62805978|NCT05058807|ACTIVE_COMPARATOR|TAI CHI Group|"Control group will receive Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps \* 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps ,with 30 sec rest interval Yang style Tai chi exercise which consist of 10 positions.~1. Hold the ball ward off 2: Grasping the sparrows tail left; 3.Grasping the sparrows tail Right;; 5.Repulse Monkey; 6. Part wild horse's Mane; 7.Brush knee Twist step; 8.Lift kick left;~.Lift kick Right; 10.Cross hands with double leg stance~1st and 2nd week will last for 5reps, 3rd and 4th week will last for 10reps,5th and 6th week will last for 15reps,7th and 8th week will last for 20reps, starting with 10 minutes warming- up and ending with 10 minutes cool-down. These outcomes will be evaluated at baseline, and after 4 week and at 8th week."
62030352|NCT02040402|ACTIVE_COMPARATOR|4-Dose Regimen|"3+1 schedule of 7-valent pneumococcal conjugated vaccine:~Infants who are randomized for 3+1 schedule will be administrated one dose of PCV7 at the age of 2 months old, 4months old and 6 months old. A booster dose will be administrated at the age of 12 months old.~Infants will be followed up for 12-16 months starting from vaccination of first dose. There is no restriction on the use of other medications before or during the follow-up period."
62805979|NCT04744961||Surgical site infections|
62805980|NCT04744961||Normal would healing|
62805981|NCT01683799|EXPERIMENTAL|Insomnia treatment|Cognitive Behavioral Therapy for Insomnia
62805982|NCT01683799|NO_INTERVENTION|Control|
62229276|NCT05029479|ACTIVE_COMPARATOR|3m ESPE Single Bond Universal Adhesive|Conventional Universal Adhesive
62229277|NCT04292678|EXPERIMENTAL|Relaxation|Caregivers of patients with advanced cancer will apply 20 minutes of progressive muscle relaxation exercise twice a week, for 8 weeks with a group session.
62229278|NCT04292678|ACTIVE_COMPARATOR|Attention matched control|Caregivers of patients with advanced cancer will receive only a training group session about general cancer information such as risk factors, treatment methods, and treatment-related side effects, lasting 20 minutes first week of the study.
62229279|NCT03054896|EXPERIMENTAL|VR-EPOCH|"* Standard chemotherapy regimen, DA-EPOCH-R, with a novel oral Bcl-2 inhibitor, venetoclax will be administered to patients~* Chemotherapy cycles will be administered approximately every 3 weeks~* Initial venetoclax dose ramp-up will be done in a condensed fashion over approximately 5 days, followed by continuous daily dosing"
62229280|NCT03054896|EXPERIMENTAL|VR-CHOP|"* Standard chemotherapy regimen, R-CHOP, with a novel oral Bcl-2 inhibitor, venetoclax will be administered to patients~* Chemotherapy cycles will be administered approximately every 3 weeks~* Initial venetoclax dose ramp-up will be done in a condensed fashion over approximately 5 days, followed by continuous daily dosing"
62805983|NCT01054664||impaired liver enzymes|
62805984|NCT01054664||normal liver enzymes|
62805985|NCT01054664||hepatitis C antibodies positive|
62229281|NCT01166321|EXPERIMENTAL|Carbon Ion Radiotherapy Boost|Carbon Ion Boost to the Macroscopic Tumor visible on contrast-enhanced MR-Imaging
62229282|NCT03194100||Diabetes Mellitus|
62229283|NCT03194100||Prediabetes|
62229284|NCT03194100||Normal glucose tolerance|
62229285|NCT02334774|EXPERIMENTAL|Participants receiving an SOC Program|Participants following prolonged endotracheal intubation receiving a up to 14-day daily Swallowing and Oral Care Program.
62229286|NCT01616056|EXPERIMENTAL|Bandage Contact Lenses|Patients wear bandage lenses continuously for at least 3 months in the absence of disease progression or unacceptable toxicity.
62229287|NCT01704924|ACTIVE_COMPARATOR|Prevena|Incision with prevena device overlying
62229288|NCT01704924|ACTIVE_COMPARATOR|Standard of Care dressing|Prevena device is not used
62229289|NCT04018235||localized disease or locally advanced disease|"Subgroups:~A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy"
62229290|NCT04018235||metastatic disease|"Subgroups:~A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy F: No Surgery"
62805986|NCT00953667|EXPERIMENTAL|Niacin and Endotoxin|All subjects are expected to have the same interventions- Niacin and Endotoxin.
62805987|NCT04376307|EXPERIMENTAL|minimal flow anesthesia|the patiennts who have thoracic sugery with one lung ventilaiton
62805988|NCT02749539|EXPERIMENTAL|Kinesio tape|The first 3 kinesio tape application was inhibition technique for supraspinatus, deltoid and teres minor muscles. the fourth Kinesio tape was mechanical correction for the shoulder joint. in addition to active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
62030353|NCT02040402|ACTIVE_COMPARATOR|3-Dose Regimen|"2+1 schedule of 7-valent pneumococcal conjugated vaccine:~Infants who are randomized for 2+1 schedule will be administrated with one dose of PCV7 at the age of 2 months old and 4months old. A booster dose will be administrated at the age of 12 months old.~Infants will be followed up for 12-16 months starting from vaccination of first dose. There is no restriction on the use of other medications before or during the follow-up period."
62805989|NCT02749539|ACTIVE_COMPARATOR|Physiotherapy program|active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
62030354|NCT00737087|OTHER|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
62030355|NCT00433069|EXPERIMENTAL|Intervention|Pioglitazone 15 mg QD + pegylated interferon Alfa-2a 180 μg QW + ribavirin 1000-1200 mg QD for 12 weeks, to be continued to a total of 48 weeks in case of complete early virological response, defined as undetectable serum HCV RNA after 12 weeks of triple therapy
62030356|NCT06670911|EXPERIMENTAL|Low-dose Pembrolizumab Plus Chemotherapy|pembrolizumab 100mg intravenous infusion plus chemotherapy every 3 weeks. Chemotherapy may consist of paclitaxel 175 mg/m² + carboplatina AUC 5 or paclitaxel 175 mg/m² + cisplatin 50 mg/m² for patients who have not been previously exposed to cisplatin.
62030357|NCT06669182|ACTIVE_COMPARATOR|Arms|Participants will receive iTBS-TMS once a day for 4 weeks, followed by once a week for 8 weeks.
62030358|NCT06669182|SHAM_COMPARATOR|Assigned Interventions|Participants will receive sham iTBS-TMS once a day for 4 weeks, followed by once a week for 8 weeks.
62030359|NCT00651508|EXPERIMENTAL|Single Arm 25mg/m2|KOS-1584 25mg/m2
62030360|NCT04564833|EXPERIMENTAL|Low Dose RBT-1|Single IV infusion prior to cardiac surgery
62030361|NCT04564833|EXPERIMENTAL|High Dose RBT-1|Single IV infusion prior to cardiac surgery
62030362|NCT04564833|PLACEBO_COMPARATOR|Placebo|Single IV infusion prior to cardiac surgery
62030363|NCT03215446|ACTIVE_COMPARATOR|propofol|
62030364|NCT03215446|EXPERIMENTAL|sevoflurane|
62030365|NCT06077227|EXPERIMENTAL|Virtual Reality (VR) Intervention|Individuals undergoing virtual reality therapy intervention
62030366|NCT06077227|SHAM_COMPARATOR|Matched Control|The matched controls will receive standard care without the VR intervention
62030367|NCT04405700||Cohort 1 (C1)|Prospective recruitment of pregnant women enrolling in antenatal clinic (ANC) at the site. All HIV+ pregnant women and a 1:1 systematic sample of HIV- pregnant women enrolling in ANC at the site will be prospectively enrolled. In addition, medical record data for the mother and infant will be collected at the time of delivery for all women who deliver at the site and as such will contribute to a subset of C2 (below). Women enrolled in C1 who do not deliver at the site will be contacted by phone and through field follow-up to ascertain their pregnancy and infant outcomes. Infants born to women enrolled in this component who are suspected of having congenital abnormalities (CAs) will be enrolled as outlined in C3 (below) if their mothers deliver at the site. If their mothers do not deliver at the site these infants will be enrolled in the field. Photos/videos of infants with CAs will also be taken for review and classification by a panel of experts (see C3 below).
62030368|NCT04405700||Cohort 2 (C2)|Cross-sectional data collection for deliveries at the site. Data will be collected retrospectively from medical records for all women who deliver at the site (including the women enrolled in C1 above), as well from the medical records of all newborn infants and stillbirths delivered at the site. Missing or incomplete information in the woman or her infant's medical record will be clarified by contacting the woman to provide this information.
62030369|NCT04405700||Cohort 3 (C3)|Photos/videos of infants with CAs. All newborn infants and stillbirths ≥ 24 weeks gestational age delivered at the site, as well as all infants born to women enrolled in C1, will be assessed by surface exam for the presence of CAs. Video and photographs will be taken of CAs identified on surface exam. These images will be reviewed and classified by panel of experts in genetics, dysmorphology and teratology. Mothers of infants with major CAs will be contacted by phone at 1, 6, and 12 months post-delivery to ascertain their infants' vital status and care engagement status.
62030370|NCT03800823|EXPERIMENTAL|Parent group & mHealth component|The intervention in the present study is a 10 week parent training group session (More and Less Program) followed by a 6-month mobile phone based intervention. Both components aim to develop healthy lifestyle behaviours regarding dietary habits and physical activity in 2-6 year olds. The intervention is delivered towards the parents.
62030371|NCT03800823|ACTIVE_COMPARATOR|Standard care|Standard care for overweight and obesity
62805990|NCT03347123|EXPERIMENTAL|Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BID|Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 50 mg BID orally in combination with nivolumab 240 mg on day 1 of each 14 day cycle and ipilimumab 1 mg/kg intravenous (IV) every 6 weeks thereafter on Day 1 of every third treatment cycle until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.
62030372|NCT04837248|ACTIVE_COMPARATOR|Group 1. Conventional treatment|Patients will be treated with a physiotherapy programme without digital support.
62030373|NCT04837248|EXPERIMENTAL|Group 2. Experimental treatment.|Patients will be treated using a digitally supported physiotherapy programme.
62030374|NCT01893242|EXPERIMENTAL|Aleglitazar Arm|
62030375|NCT01893242|PLACEBO_COMPARATOR|Placebo Arm|
62030376|NCT03446443|EXPERIMENTAL|Honghe Fujie lotion group|
62030377|NCT03446443|ACTIVE_COMPARATOR|Metronidazole Suppositories group|
62030378|NCT05051566|EXPERIMENTAL|LY3502970 Prototype (Part A)|Multiple doses of LY3502970 prototype administered orally.
62030379|NCT05051566|EXPERIMENTAL|LY3502970 Reference (Part A)|Multiple doses of LY3502970 reference administered orally.
62030380|NCT05051566|EXPERIMENTAL|LY3502970 Prototype (Part B)|Multiple doses of LY3502970 prototype administered orally.
62229291|NCT04018235||follow up disease|"Subgroups:~A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy F: No Surgery"
62229292|NCT00666809|ACTIVE_COMPARATOR|Arm 1|
62229293|NCT00666809|PLACEBO_COMPARATOR|Arm 2|
62030381|NCT05051566|EXPERIMENTAL|LY3502970 Reference (Part B)|Multiple doses of LY3502970 reference administered orally.
62030382|NCT05051566|ACTIVE_COMPARATOR|Esomeprazole (Part B)|Multiple doses of Esomeprazole (Proton Pump Inhibitor) administered orally.
62805991|NCT03347123|EXPERIMENTAL|Phase 1: Dose Escalation: Treatment Group A: Cohort 2 Epacadostat 100 mg BID|Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 100 mg BID orally in combination with nivolumab 240 mg on day 1 of each 14 day cycle and ipilimumab 1 mg/kg intravenous (IV) every 6 weeks thereafter on Day 1 of every third treatment cycle until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.
62805992|NCT03347123|EXPERIMENTAL|Phase 1: Dose Escalation: Treatment Group B: Cohort 1 Epacadostat 50 mg BID|Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 50 mg BID orally in combination with nivolumab 240 mg on day 1 of every 14 day cycle and lirilumab 240 mg IV every 4 weeks until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.
62805993|NCT03347123|EXPERIMENTAL|Phase 1: Dose Escalation: Treatment Group B: Cohort 2 Epacadostat 100 mg BID|Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 100 mg BID orally in combination with nivolumab 240 mg on day 1 of every 14 day cycle and lirilumab 240 mg IV every 4 weeks until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.
62030383|NCT00938873||Mindfulness Based Cognitive Therapy|The present study will use participants who have experienced more than three episodes of depression as judged by South London and Maudsley NHS Trust. No restrictions are placed in terms of participants' use of antidepressant medication. Participants will be 18 to 65 years old and would have participated in an MBCT course run by South London and Maudsley NHS Trust.
62030384|NCT05727605|OTHER|Primary brain and skull-base tumors|Primary brain and skull-base tumors who are amenable for radiotherapy (photon or proton therapy) will all be examined with neurocognitive tests, questionnaires and advanced MR imaging
62229294|NCT06042010|EXPERIMENTAL|Test group|
62229295|NCT06042010|ACTIVE_COMPARATOR|control group|
62229296|NCT05365477|ACTIVE_COMPARATOR|Empiric Therapy|Diet intervention and drug intervention not based on 24 hour urine results
62229297|NCT05365477|EXPERIMENTAL|Selective Therapy|Diet intervention and drug intervention based on 24 hour urine results
62421641|NCT05037175|ACTIVE_COMPARATOR|CITT+ Reminder as Usual|"CITT will be conducted by Talkspace therapists with a specialty in culturally informed PTSD treatment.~Reminder as Usual (RAU). As per Talkspace guidelines, therapists are available to client participants twice per day, five days per week. In the event a client participant has not engaged or messaged in 48 hours, therapists send a personalized message to the client participant to encourage them to re-engage."
62421642|NCT04208529|EXPERIMENTAL|CTX001|All participants who complete or discontinue one of the multiple parent studies (CTX001-111, CTX001-121, CTX001-141, CTX001-151, CTX001-161 and CTX001-171) after CTX001 infusion will be asked to participate in this long-term follow-up study.
62421643|NCT06541821||Urostomy Patients Group|
62805994|NCT03347123|EXPERIMENTAL|Phase 2: Dose Expansion: Treatment Group A: Cohort A1|Participants with unresectable or metastatic melanoma (MEL) were planned to be included in this cohort, who did not receive prior systemic therapy for advanced or metastatic disease to receive epacadostat in combination with nivolumab and ipilimumab at the MTD/PAD determined from dose escalation phase.
62421644|NCT06541821||Control Group|
62421645|NCT06512389|EXPERIMENTAL|Cannabidiol|10-day supply of 600 mg of CBD, taken orally twice daily
62421646|NCT06512389|PLACEBO_COMPARATOR|Placebo|10-day supply of 600 mg of placebo, taken orally twice daily
62421647|NCT01339000|EXPERIMENTAL|Arm A -Sequence 1 Immunizations|Receive vaccine of Sequence 1 first, then vaccines of Sequence 2, 7 weeks later, after receiving interleukin-7 (IL-7)
62421648|NCT01339000|EXPERIMENTAL|Arm B - Sequence 2 Immunizations|Receive vaccines of Sequence 2 first then vaccines of Sequence1, 7 weeks later, after receiving IL-7
62421649|NCT06472375||discharge|immediate discharge with ambulant HR monitoring (investigational treatment strategy) in low- and intermediate syncope patients in the setting of cardiac emergency room
62421650|NCT06472375||admission for 24 hours with rhythmobservation|discharge after 24-hour telemetric-observation (reference treatment strategy) in low- and intermediate syncope patients in the setting of cardiac emergency room
62805995|NCT03347123|EXPERIMENTAL|Phase 2: Dose Expansion: Treatment Group A: Cohort A2|Participants with advanced or metastatic non-small cell lung cancer (NSCLC) were planned to be included in this cohort, who have received no more than 1 prior line of platinum-based chemotherapy for advanced or metastatic disease to receive epacadostat in combination with nivolumab and ipilimumab at the MTD/PAD determined from dose escalation phase.
62819495|NCT01112826|NO_INTERVENTION|Standard treatment|Treatment according to National Comprehensive Cancer Network (NCCN) guideline.
62819496|NCT05614531|EXPERIMENTAL|Dose escalation- Cohort 1|dose 1 of EXG001-307 delivered one-time through a venous catheter inserted into a peripheral vein (n=3\~6)
62421651|NCT03596879|EXPERIMENTAL|dCBTI|Online access to the digital CBTI program Sleepio.
62030385|NCT06264050|OTHER|Patients in the psychological support group|Patients in neurorehabilitation attending a psychological support group
62030386|NCT05083247|ACTIVE_COMPARATOR|Arm A|mFOLFIRINOX (oxaliplatin: 85 mg/m2, CPT-11: 165-180 mg/m2, folinic acid: 400mg/m2 and 5FU 2000-2400 mg/m2/46 h) regimen for 8 cycles every 2 weeks; or\*Gemcitabine-Nab-P: gem: 1000 mg/m2 weekly 3 w/4; nab-P: 125 mg/m2 3 w/4 for 4 cycles in case of unfit for mFFX).
62229298|NCT04333927|EXPERIMENTAL|Treatment|Patients in treatment group will receive camrelizumab 200mg intravenously every 3 weeks until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal. After 1 or 2 courses of camrelizumab, patients went on to receive capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week) concurrent with radiotherapy (45 Gy to regional lymph nodes and 54 to 59.4 Gy to preoperative tumor bed).
62229299|NCT04333927|PLACEBO_COMPARATOR|Observation|Patients in observation group will not receive any anti-cancer therapy.
62229300|NCT00947739|EXPERIMENTAL|Cohort 1|80 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48)PO, DAILY
62229301|NCT00947739|EXPERIMENTAL|Cohort 2|160 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
62229302|NCT00947739|EXPERIMENTAL|Cohort 3|320 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
62229303|NCT00947739|EXPERIMENTAL|Cohort 4|640 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
62421652|NCT03596879|PLACEBO_COMPARATOR|Sleep Education|Weekly email messages with sleep hygiene recommendations.
62229304|NCT00947739|EXPERIMENTAL|Cohort 5a|1280 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
62229305|NCT00947739|EXPERIMENTAL|Cohort 6|2560 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
62229306|NCT00947739|EXPERIMENTAL|Cohort 7|18 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
62229307|NCT00947739|EXPERIMENTAL|Cohort 8|36 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
62229308|NCT00947739|EXPERIMENTAL|Cohort 9|72 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
62229309|NCT00947739|EXPERIMENTAL|Cohort 10|144 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
62805996|NCT03347123|EXPERIMENTAL|Phase 2: Dose Expansion: Treatment Group B: Cohort B1|Participants with recurrent or metastatic serotonin norepinephrine reuptake inhibitor (SCCHN) were planned to be included in this cohort, who received no more than 1 prior line of platinum-based chemotherapy for recurrent or metastatic disease to receive epacadostat in combination with nivolumab and lirilumab at the MTD/PAD determined from dose escalation phase.
62229310|NCT00947739|EXPERIMENTAL|Cohort 11|288 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
62805997|NCT02960217|EXPERIMENTAL|Double-Blind UX007 Followed by Placebo|"Participants will first receive UX007 (dosed according to an age- and weight-based strategy, up to a maximum daily administration of 130 g) for 10 weeks. After a washout period of 2 weeks, they will then receive placebo for 10 weeks.~Participants will have the option of rolling into the open label Extension Period, to continue UX007 treatment for up to 3 years."
62591492|NCT01729338|EXPERIMENTAL|Velcade, cyclophosphamide, Revlimid|"INDUCTION (28-day cycles for 8 cycles):~* VELCADE 1.3 mg/m2 subcutaneously (SC) days 1, 8 and 15~* Cyclophosphamide 300 mg/m2 orally (PO) days 1, 8 and 15~* Dexamethasone 40 mg PO days 1,8 and 15~MAINTENANCE (28-day alternating cycles until stopped for toxicity, relapse or death):~* Odd cycles (9, 11, 13, etc.) lenalidomide 10 mg PO days 1-21~* Even cycles (10, 12, 14, etc.) VELCADE 1.3 mg/m2 SC days 1, 15"
62591493|NCT05642312|EXPERIMENTAL|Arm A|Participants will receive 4 high-dose vamikibart intravitreal (IVT) injections every 4 weeks (Q4W) to Week 12, followed by as-needed (PRN) dosing from Week 20 to Week 48.
62229311|NCT00947739|EXPERIMENTAL|Cohort 12|576 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
62229312|NCT00947739|EXPERIMENTAL|Cohort 13|750mg/m2 PO Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
62229313|NCT00947739|EXPERIMENTAL|Cohort 14|1000mg/m2 PO Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
62229314|NCT00947739|EXPERIMENTAL|Cohort 5b|1280 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
62229315|NCT02640157|EXPERIMENTAL|Arm A|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
62229316|NCT02640157|ACTIVE_COMPARATOR|Arm B|Sofosbuvir 400 mg once daily (QD) co-administered with daclatasvir 60 mg QD for 12 weeks.
62229317|NCT02640157|EXPERIMENTAL|Arm C|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
62229318|NCT03127254|EXPERIMENTAL|Video Narrative with surveys|Participants will be asked to create a 10-15 minute video narrative on their experiences after being diagnosed with cancer. Participants will also be asked to complete surveys including pediatric quality of life (PedsQL), Ten Item Personality Inventory (TIPI), Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test, and The Cognitive Log (Cog-Log)
62805998|NCT02960217|EXPERIMENTAL|Double Blind Placebo Followed by UX007|"Participants will first receive Placebo for 10 weeks. After a washout period of 2 weeks, they will then receive UX007 (dosed according to an age- and weight-based strategy, up to a maximum daily administration of 130 g) for 10 weeks.~Participants will have the option of rolling into the open label Extension Period, to continue UX007 treatment for up to 3 years."
62805999|NCT02675907|EXPERIMENTAL|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
62806000|NCT02675907|PLACEBO_COMPARATOR|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
62229319|NCT04773496||Balance evaluation|patient's balance is evaluated with instrumental posturography
62229320|NCT01146054|EXPERIMENTAL|SBRT and Gemzar|Before stereotactic Body Radiotherapy (SBRT) 3-5 gold fiducials are placed by endoscopic ultrasound or CT guidance. A simulation FDG-PET/CT (Fludeoxyglucose (18F) - Positron emission tomography/Computerized tomography) scan will be used for treatment planning purposes (standard free-breathing CT and respiratory-correlated 4-D (4 dimensional) pancreatic protocol CT). Patients are treated by either respiratory gated (Trilogy, Elekta, Novalis) or by respiratory tracking (CyberKnife). SBRT is delivered in 5 fractions of 6.6 Gy by LINAC-based or CyberKnife based radiotherapy over a five-day period. Gemcitabine, cycles should resume/start up to 4 weeks following SBRT on a 3-week on, 1-week off schedule. Initial follow up is at 4, 6, 9 and 12 months and then for years 2-5 is every 3-6 months.
62229321|NCT05350579|EXPERIMENTAL|Yogurt Intervention|Participants assigned to the yogurt group were provided with a biweekly supply of yogurt at every other visit and were directed to consume one serving daily (5-ounce, 141 grams) and to store the remaining yogurt at 40˚ F or lower until consumed. Additionally, all participants were instructed to keep a log of any yogurt consumption time and changes to bowel health. The ingredients of the yogurt include Pasteurized Grade A Milk, Cane Sugar, Yogurt Cultures (L. bulgaricus, S. thermophilus), and Vanilla Extract. The intervention meets the Codex Alimentarius definition of yogurt. In addition, the yogurt lacked preservatives, added fruit or pectin, was not enriched with added prebiotics or probiotics.
62806001|NCT05003037|EXPERIMENTAL|Wild-type Genotype|
62229322|NCT05350579|NO_INTERVENTION|Diet Control|The control group was asked to abstain from yogurt consumption. Diet (including yogurt consumption) was monitored by weekly 24-hour dietary recalls throughout the study period.
62229323|NCT03726710|EXPERIMENTAL|Blood Pressure measurement and pharmacy|Blood Pressure measurement performed by barber and Blood pressure measurement and management visits with study pharmacist in person and through Telemedicine.
62591494|NCT05642312|EXPERIMENTAL|Arm B|Participants will receive 4 low-dose vamikibart IVT injections Q4W to Week 12, followed by PRN dosing from Week 20 to Week 48.
62806002|NCT05003037|EXPERIMENTAL|EGFR mutation|
62806003|NCT05030181|ACTIVE_COMPARATOR|kinesiotaping and exercise|'I'' strip kinesiotape will be applied with the space correction technique for the upper trapezius muscle, for a total of 4 sessions, 2 days a week, and the patients will be included in the 1-month home exercise program.
62806004|NCT05030181|ACTIVE_COMPARATOR|exercise|1-month home exercise program.
62806005|NCT04309110|NO_INTERVENTION|Standard care with geko™ T3 device|Current geko™ device incorporating hydrogel adhesive designated KM10T
62229324|NCT06018181||Exposure group|"The exposure group was defined as patients receiving Shuxuetong injection and guideline-standardized treatment after intravenous alteplase or tenecteplase.~Mainly based on the following guidelines:(1)Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018; (2)Guidelines for secondary prevention of ischemic stroke and transient ischemic attack in China 2022."
62229325|NCT06018181||Non-exposure group|The non-exposed group was defined as patients receiving guideline-standardized treatment after intravenous alteplase or tenecteplase.
62421653|NCT06565806||Retrospective cohort 2006-2019|
62806006|NCT04309110|ACTIVE_COMPARATOR|geko™ X-T3|Next generation geko™ device incorporating new hydrogel adhesive designated KM40C
62806007|NCT03803189|EXPERIMENTAL|Personalized eToolkit|The intervention arm will receive a personalized eToolkit with community and electronic supports each time they complete a survey, and their PCP will receive supports in the EMR to facilitate postpartum mental healthcare.
62229326|NCT02336750|EXPERIMENTAL|treatment group|D1:Chemotherapy Dexamethasone:7.5mg D2-4 Aprepitant:125mg D1, 80mg D2-3 Mirtazapine:15mg D2-4
62229327|NCT02336750|EXPERIMENTAL|control group|D1:Chemotherapy Dexamethasone:7.5mg D2-4 Aprepitant:125mg D1, 80mg D2-3
62229328|NCT03322787|NO_INTERVENTION|Oxygen|The training will be performed using oxygen by the Venturi mask with the FiO2 set during the run - in session.
62229329|NCT03322787|EXPERIMENTAL|HFO|The training will be performed using the HFO device during the run - in session at iso_FiO2 as in the Control Group (Oxygen by Venturi mask).
62229330|NCT05768633||Cases|Individuals diagnosed with obstructive sleep apnea (OSA) syndrome recruited at the beginning of rehabilitative treatment at the Istituto Auxologico Italiano, IRCCS, San Giuseppe Hospital (Italy).
62229331|NCT05768633||Controls|Age-matched healthy individuals recruited outside the hospital through personal contacts of the researchers and word-of-mouth.
62229332|NCT05992402|EXPERIMENTAL|Intervention|Participants in this arm will receive 2 one-on-one virtual education sessions as well as 4 virtual group education sessions prior to their epilepsy surgery.
62229333|NCT05992402|NO_INTERVENTION|Treatment-as-Usual|Treatment as usual but will also receive three brief 5-minute phone calls over 6-weeks after initial enrollment. These phone calls are not therapeutic in nature but provide control participants with brief engagement in study-related activities to ensure that any benefits seen between groups are not simply attributable to study participation.
62229334|NCT05003960|EXPERIMENTAL|Treatment Group|One intravenous infusion of 100 million cells
62421654|NCT06565806||Retrospective cohort of the CNR national register of Mycobacteria from 2020 to end of May 2024|
62421655|NCT06565806||Prospective cohort of the CNR national register of Mycobacteria from June 2024 to the end of 2029|
62806008|NCT03803189|NO_INTERVENTION|Usual care|The control arm will not receive intervention materials, unless they express suicidality, in which case they will receive a message with supports for suicidality including local emergency departments and crisis lines and an urgent message via EMR and fax will be sent to their PCP. Control arm participants will be asked to complete a baseline e-survey in their third trimester, and a follow-up e-survey 24-weeks after their baby is born.
62806009|NCT01372059|EXPERIMENTAL|Rhythm and music therapy|Since 1993 The RGRM Method is a concept launched in both health and medical care. The method is mainly designed to help people with injuries and diseases of the central nervous system.
62806010|NCT01372059|ACTIVE_COMPARATOR|Therapeutic riding|Therapeutic riding can be useful for individuals with neurological and muscular impairments. The goal of therapeutic riding as professional treatment is to improve neurological functioning and to achieve functional gains and enhance life skills.
62806011|NCT01372059|OTHER|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
62421656|NCT01836003|EXPERIMENTAL|Tokafatso programmatic intervention|Antenatal clinic receives the Tokafatso programmatic intervention, including educational session, SMS-based facilitation of CD4 result delivery, and patient tracing support.
62421657|NCT01836003|NO_INTERVENTION|Usual Care|Has not yet received Tokafatso combination programmatic intervention
62421658|NCT02151162|EXPERIMENTAL|Stress management plus omega-3|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
62229335|NCT03068663|EXPERIMENTAL|Pchir|"Non small cell lung carcinoma patients designated for immediate surgery. Intervention in this group is sampling. The sampling will be done for:~* blood and saliva: at consultations after inclusion in the study~* faeces: day before the surgery~* lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy"
62229336|NCT03068663|EXPERIMENTAL|Pct-chir|"Non small cell lung carcinoma patients who will receive neoadjuvant chemotherapy before the surgery. Intervention in this group is sampling. The sampling will be done for:~* blood and saliva: 1st time at consultations after inclusion in the study, 2nd time at consultations after chemotherapy and before surgery~* faeces: 1st time the day before the chemotherapy, 2nd time the day before the surgery~* lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy"
62591495|NCT05642312|SHAM_COMPARATOR|Arm C|Participants will receive 4 sham injections Q4W to Week 12, followed by PRN sham dosing from Week 20 to Week 48.
62421659|NCT02151162|ACTIVE_COMPARATOR|Stress management plus placebo|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
62591496|NCT00342381|ACTIVE_COMPARATOR|3.4 diaminopyridine|Single dose 3,4 diaminopyridine
62591497|NCT00342381|PLACEBO_COMPARATOR|Placebo|Two tablets identical to active treatment
62229337|NCT03170154|EXPERIMENTAL|Clareon IOL|Clareon aspheric hydrophobic acrylic monofocal IOL implanted in one eye during routine small incision cataract surgery
62229338|NCT02245672|EXPERIMENTAL|MGR001|MGR001 administered two times per day by inhalation throughout the study
62229339|NCT02245672|ACTIVE_COMPARATOR|Advair Diskus|Advair Diskus administered two times per day by inhalation throughout the study
62229340|NCT02245672|PLACEBO_COMPARATOR|Placebo|Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study
62229341|NCT01493011|EXPERIMENTAL|chemotherapy & WBH|Standard chemotherapy protocol combined with whole body hyperthermia
62229342|NCT01493011|NO_INTERVENTION|chemotherapy|standard chemotherapy protocol for advanced NSCLC
62229343|NCT02774161|EXPERIMENTAL|Diagnostic (B-mode ultrasound imaging)|Patients undergo B-mode ultrasound imaging of the liver over 15 minutes.
62229344|NCT03467503|NO_INTERVENTION|Prenatal Care/Nutrition Education|Participants were given nutrition educational counseling on healthy dietary habits and gestational weight gain as part of standard prenatal care.
62229345|NCT03467503|EXPERIMENTAL|Dietary Intervention|Participants were given dietary blueberries (2 cups) and soluble fiber (12g). They also received nutrition educational counseling on healthy dietary habits and gestational weight gain as part of standard prenatal care.
62229346|NCT01386788||Smoke Inhalation patients|Closed space fire, Soot deposits, Altered mental status Blood specimen before intravenous antidote treatment (cyanide measurement) Known delay between end of smoke exposure and blood sampling
62806012|NCT03244852||OCD Patients with Deep Brain Stimulators|Patients with deep brain stimulation for intractable obsessive compulsive disorder (OCD)
62591498|NCT06147063|EXPERIMENTAL|Arm 1: dosage 1 of AZD9838 18 to 64 years of age|Participants will receive 1 intramuscular dose of AZD9838.
62806013|NCT02644759|EXPERIMENTAL|Stem Cell Transplantation|Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
62229347|NCT05901662|EXPERIMENTAL|Competence training program|This group received a 3-hour weekly course training session in four consecutive weeks and provided services to community-dwelling older adults for two months.
62806014|NCT03495830||Carotid endarterectomy|Patients that underwent intervention (CEA or CAS) are followed by clinical examination and carotid duplex on 12, 24 and 36 month If there is coexisting contralateral carotid stenosis with grade greater than 50% and not requiring interventional treatment (CEA or CAS), patient should cross in optimal medical therapy group.
62806015|NCT03495830||Optimal medical therapy group|Patients not subjected to intervention (or in whom one carotid has been treated with CAS or CEA and contralateral has stenosis is greater than 50%) will be followed with carotid duplex (at 12, 24 and 36 months) and MRI imaging of carotid tree from aortic arch up to the circle of Willis after 12 and 36 months.
62806016|NCT00503750|ACTIVE_COMPARATOR|Trastuzumab and Abraxane followed Trastuzumab and Vinorelbine|Patients will be treated sequentially with preoperative trastuzumab and dose-dense ABI-007 followed by trastuzumab in combination with vinorelbine. Trastuzumab will be administered as a one-time loading dose of 4 mg/kg as a 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as a 30 minute infusion. ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8). Growth factor support with pegfilgrastim (Neulasta®) is required 24 to 48 hours following completion of each cycle of ABI-007. Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20). As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52.
62806017|NCT01227798|PLACEBO_COMPARATOR|Placebo|100 mM sodium Chloride and 25 mM sodium phosphate at pH 7.0 +/- 0.2
62229348|NCT05901662|ACTIVE_COMPARATOR|Control|This group provided their routine services at senior activity centers.
62806018|NCT01227798|ACTIVE_COMPARATOR|Infergen|15mcg subcutaneous injection at fill volume of 0.5mL
62806019|NCT02748863|PLACEBO_COMPARATOR|Placebo|Placebo, provided in a 2 mL pre-filled syringe Placebo, provided in a 1 mL pre-filled syringe
62806020|NCT02748863|EXPERIMENTAL|Secukinumab 2 mL form|Secukinumab 300 mg, provided in a 2 mL pre-filled syringe
62806021|NCT02748863|ACTIVE_COMPARATOR|Secukinumab 1 mL form|Secukinumab 300 mg provided in 2 pre-filled syringes of 1 mL/150 mg (current approved form)
62806022|NCT00752050|ACTIVE_COMPARATOR|1|Mentor Purified Toxin Botulinum Toxin Type A - Part II ONLY. (Part I is Single Group and all participants receive active drug and are not randomized)
62806023|NCT00752050|PLACEBO_COMPARATOR|2|Preservative-free Saline - Part II ONLY. (Part I is Single Group and all participants receive active drug and are not randomized)
62806024|NCT00884546|EXPERIMENTAL|Arm 1|BMS-833923 (Starting dose is a loading dose of 60 mg for 7 days with a 30 mg daily dose thereafter)
62806025|NCT00884546|ACTIVE_COMPARATOR|Arm 2|"BMS-833923 (MTD or below)~Lenalidomide (at or below the recommended prescribing dose)~Dexamethasone (40 mg)"
62806026|NCT00884546|ACTIVE_COMPARATOR|Arm 3|"BMS-833923 (MTD or below)~Bortezomib (at or below the recommended prescribing dose)"
62819497|NCT05614531|EXPERIMENTAL|Dose escalation-Cohort 2|dose 2 of EXG001-307 delivered one-time through a venous catheter inserted into a peripheral vein (n=6\~12)
62229349|NCT01133951|EXPERIMENTAL|OAC triple therapy|
62229350|NCT01133951|PLACEBO_COMPARATOR|Placebo|
62229351|NCT04242563|NO_INTERVENTION|CONTROL GROUP|No virtual reality
62229352|NCT04242563|EXPERIMENTAL|INTERVENTION GROUP|Patient equipped with Virtual reality in transfer room.
62421660|NCT02151162|ACTIVE_COMPARATOR|Psychoeducation leaflet plus omega-3|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
62591499|NCT06147063|EXPERIMENTAL|Arm 2: dosage 2 of AZD9838 18 to 64 years of age|Participants will receive 1 intramuscular dose of AZD9838.
62591500|NCT06147063|ACTIVE_COMPARATOR|Arm 3: licensed mRNA vaccine 18 to 64 years of age|Participants will receive 1 intramuscular dose of the licensed mRNA vaccine.
62591501|NCT06147063|EXPERIMENTAL|Arm 4: dosage 1 of AZD6563 18 to 64 years of age|Participants will receive 1 intramuscular dose of AZD6563.
62806027|NCT02068924|EXPERIMENTAL|slow freezing|Therefore, the aim of our study is to analyze whether extended culture of Day-2 top embryos to blastocyst-stage may improve the cumulative delivery rate in an in vitro fertilization program with Single Embryo Transfer policy in a prospective and randomized study integrating the transfer of fresh and frozen/thawed embryos using a slow freezing versus vitrification procedure.
62806028|NCT02068924|OTHER|vitrification|Therefore, the aim of our study is to analyze whether extended culture of Day-2 top embryos to blastocyst-stage may improve the cumulative delivery rate in an in vitro fertilization program with Single Embryo Transfer policy in a prospective and randomized study integrating the transfer of fresh and frozen/thawed embryos using a slow freezing versus vitrification procedure.
62806029|NCT02946281|EXPERIMENTAL|Intervention|
62806030|NCT02946281|NO_INTERVENTION|Care as usual|
62806031|NCT06440421|NO_INTERVENTION|Control Arm (Arm 1)|Participants will experience a default version of Bahrain e-Mart which replicates the traditional shopping experience of online grocery stores with no FOP labels.
62229353|NCT02841930|EXPERIMENTAL|Member|"The member group will be able to join ActionHealth NYC program, where they are assigned a primary care physician and have a standardized fee scale for services obtained in network. Laboratory, diagnostic, and specialty services can be obtained at network H+H locations. They will be offered recommended USPSTF A+B tests/screenings, HIV and TB screening (if indicated), and care coordination. If they are deemed high risk, enhanced care coordination services will be offered."
62421661|NCT02151162|ACTIVE_COMPARATOR|Psychoeducation leaflet plus placebo|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
62421662|NCT05686317|EXPERIMENTAL|APTURE shunt + medical therapy|
62806032|NCT06440421|EXPERIMENTAL|MTL Labels (Arm 2)|Same as Arm 1 Bahrain e-Mart except that Multiple-Traffic Light (MTL) labels are displayed on food and beverage products.
62806033|NCT00551759|EXPERIMENTAL|Neoadjuvant therapy, Surgery, adjuvant therapy|"Neoadjuvant chemoradiotherapy and cetuximab: Patients (pts) receive oxaliplatin IV over 2 hours on days 1, 15, and 29, cetuximab IV over 1-2 hours on days 1, 8, 15, 22, and 29, and 5-FU IV over 24 hours on days 1-35. Pts also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33. Pts then proceed to surgery.~Surgery: Pts undergo surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab. Pts with an R0 or R1 resection proceed to adjuvant therapy. Pts whose tumors have not been completely resected or who have metastatic disease discontinue protocol therapy and receive further therapy at the discretion of the treating physician.~Adjuvant therapy: Within 4-8 weeks after surgery, pts receive docetaxel IV over 1 hour on days 1, 8, 15, 22, and 29 and cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
62806034|NCT01599156|EXPERIMENTAL|Reflexology|reflexology treatment, x2-3/week for 12 weeks
62229354|NCT02841930|NO_INTERVENTION|Study|The study group will be counseled on their options to access health care, including at public hospitals and community health centers. They will receive no additional services from the study.
62229355|NCT00495287|ACTIVE_COMPARATOR|A|"Remission induction arm A is with conventional chemotherapy cycle (ICE: idarubicin, standard-dose cytarabine, etoposide)"
62229356|NCT00495287|EXPERIMENTAL|B|Remission induction therapy with high-dose cytarabine sequential regimen (HD-Ara-C, idarubicin)
62229357|NCT03731507|EXPERIMENTAL|Range of motion in upper extremity|Assessment of shoulder: flexion/extension, abduction/adduction, internal/external rotation, elbow flexion/extension, hip: flexion/extension, abduction/adduction, internal/external rotation, knee: flexion/extension, ankle: dorsal flexion/plantar flexion
62421663|NCT05686317|SHAM_COMPARATOR|Sham + medical therapy|
62421664|NCT00457418|EXPERIMENTAL|PEG-Intron|"6 ug/kg/week, SC (first 8 weeks)~3 ug/kg/week, SC (252 weeks \[weeks 9-260\], maintenance)"
62421665|NCT01396161|EXPERIMENTAL|30 mg PF-05175157 or Placebo QD|
62421666|NCT01396161|EXPERIMENTAL|100 mg PF-05175157 or Placebo QD|Planned dose might be modified based on emerging safety and PK data.
62421667|NCT01396161|EXPERIMENTAL|200 mg PF-05175157 or Placebo QD|Planned dose might be modified based on emerging safety and PK data.
62421668|NCT01396161|EXPERIMENTAL|100 mg PF-05175157 or Placebo BID|Planned dose might be modified based on emerging safety and PK data.
62421669|NCT01396161|EXPERIMENTAL|xxx mg PF-05175157|Dose will be determined based on results obtained from Arms 1 to 4.
62421670|NCT04152252||Baseline|No CPR feedback during CPR
62421671|NCT04152252||Real-time feedback|Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.
62421672|NCT04152252||Post-event debriefing|Structured oral post-event debriefing based on objective performance data from the resuscitation attempt. The debriefing is conducted as hot/immediate self-directed debriefing session with a maximum length of 10 minutes.
62591502|NCT06147063|EXPERIMENTAL|Arm 5: dosage 2 of AZD6563 18 to 64 years of age|Participants will receive 1 intramuscular dose of AZD6563.
62806035|NCT03282058|EXPERIMENTAL|Silastic Stent|"At the time of surgery, if the patient is identified in the silastic stent arm, dressing of the septal donor site with silastic stents will be performed after reconstruction has been achieved and the surgeon feels that the surgery proceeded routinely."
62806036|NCT03282058|NO_INTERVENTION|No Stent|"At the time of surgery, if the patient is identified in the no silastic stent arm, dressing of the septal donor site without the stent will be performed after reconstruction has been achieved and the surgeon feels that the surgery proceeded routinely - this is currently the standard of care."
62806037|NCT04750291|EXPERIMENTAL|Botulinum toxin|Infiltration with botulinum toxin
62806038|NCT04750291|PLACEBO_COMPARATOR|Placebo|Infiltration with placebo or sterile saline
62806039|NCT00802516|PLACEBO_COMPARATOR|1. placebo|placebo margarine
62806040|NCT00802516|EXPERIMENTAL|2. stanol ester|margarine with plant stanol ester
62806041|NCT00802516|EXPERIMENTAL|3. sterol ester|margarine with plant sterol ester
62806042|NCT05822934|EXPERIMENTAL|Carboplatin-gemcitabine|3-4 cycles of Carboplatin-Gemcitabine as a neoadjuvant treatment for Urinary bladder cancer Muscle invasive
62591503|NCT06147063|EXPERIMENTAL|Arm 6: dosage 1 of AZD6563 65 years of age and older|Participants will receive 1 intramuscular dose of AZD6563.
62229358|NCT02370082|EXPERIMENTAL|SAVI SCOUT device|SAVI SCOUT device used to localize breast lesion which will then be removed surgically. The SAVI SCOUT is the intervention for localization of breast lesions.
62229359|NCT04875676|ACTIVE_COMPARATOR|Cohort 1 (4-week boost vaccination)|(4-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU ± 0.5 log at Day 1 and Week 4
62229360|NCT04875676|ACTIVE_COMPARATOR|Cohort 2 (8-week boost vaccination)|(8-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU± 0.5 log at Day 1 and Week 8
62591504|NCT06147063|EXPERIMENTAL|Arm 7: dosage 2 of AZD6563 65 years of age and older|Participants will receive 1 intramuscular dose of AZD6563.
62591505|NCT06147063|ACTIVE_COMPARATOR|Arm 8: licensed mRNA vaccine 65 years of age and older|Participants will receive 1 intramuscular dose of the licensed mRNA vaccine.
62806043|NCT05822934|ACTIVE_COMPARATOR|cisplatin-gemcitabine|3-4 cycles of Cisplatin -Gemcitabine as a neoadjuvant treatment for Urinary bladder cancer Muscle invasive
62229361|NCT04875676|ACTIVE_COMPARATOR|Cohort 3 (12-week boost vaccination)|(12-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU± 0.5 log at Day 1 and Week 12
62229362|NCT02688959|EXPERIMENTAL|Tai Chi|Participants in this arm will attend 50-minute classes 2 times per week for 8 weeks. The course will emphasize experiential learning with 2 weeks of introductory sessions on gait, posture, and tai chi principles followed by instruction in the 24-form Yang style sequence. Students will be given a video to aid learning outside of class, and maintenance of practice post-intervention.
62229363|NCT02688959|ACTIVE_COMPARATOR|Exercise|Participants in the exercise arm will attend 50-minute classes 2 times per week for 8 weeks. The course will emphasize cardio-aerobic fitness training. Students will be given a video to aid practice outside of class, and maintenance of practice post-intervention.
62229364|NCT02688959|NO_INTERVENTION|Control|Participants in the control arm will not attend a class and not be given a video.
62229365|NCT00629330|EXPERIMENTAL|Multi-component Academic Detailing|Includes an interactive, digitized CDROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients.
62806044|NCT03495466|ACTIVE_COMPARATOR|Local only Anesthesia|The patient will receive local only anesthesia during the first surgery and local with sedation anesthesia for their second surgery.
62229366|NCT03730636|EXPERIMENTAL|PCT-guided strategy|Measurement of PCT concentration will be performed every two days and the ATB therapy will be stopped when PCT level reaches a value equal or below 0.5ng/mL.
62229367|NCT03730636|NO_INTERVENTION|Usual practice (control group)|Management of LOS and treatment is based on the attending clinician's practice and according to the usual practice.
62229368|NCT04708756|EXPERIMENTAL|Intervention Group A|Patients receive the Collabree mobile phone application with a specific set of functions and standard care.
62229369|NCT04708756|EXPERIMENTAL|Intervention Group B|Patients receive the Collabree mobile phone application with a specific set of functions and standard care.
62229370|NCT04708756|NO_INTERVENTION|Control Group|Patients will not receive the Collabree application and will continue to receive standard care.
62229371|NCT03742167|EXPERIMENTAL|Telemedicine|The telemedicine arm will have 2-way audiovisual connection with a pediatric medical control physician.
62229372|NCT03742167|NO_INTERVENTION|Control|The control arm will receive pediatric medical control physician consultation via telephone.
62229373|NCT01079130|EXPERIMENTAL|Indacaterol 18.75 µg|"Indacaterol 18.75 µg once daily in the morning via Concept1, a single-dose dry powder inhaler (SDDPI) and Placebo to Salmeterol in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI) for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
62591506|NCT03902522|EXPERIMENTAL|Leronlimab (PRO 140)|Subjects will be on existing ART for one week followed by PRO 140 700mg weekly SC Inj. + existing ART for the next week. Subsequently, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
62591507|NCT03335007|EXPERIMENTAL|Aceclofenac|Aceclofenac 100 mg tablet
62591508|NCT03335007|PLACEBO_COMPARATOR|Placebo|Placebo
62591509|NCT05379270|EXPERIMENTAL|Diet soda|Participants will be asked to ingest 24 of a commercially-available diet beverage sweetened with sucralose and acesulfame-potassium.
62591510|NCT05836740|ACTIVE_COMPARATOR|Minocycline treatment group|Minocycline Hydrochloride Capsules (50 mg per capsule) The first dose should be given immediately after randomization (within 30 minutes); 200mg (4 capsules) for the first dose; Subsequently, 100mg (2 capsules) will be administered once every 12 hours, a total of 9 times (lasting 4.5 days; the subject with dysphagia will be administrated through a nasal feeding tube)
62591511|NCT05836740|PLACEBO_COMPARATOR|Minocycline placebo-control group|Placebo of Minocycline Hydrochloride capsules (50mg per capsule, containing 0 mg of Minocycline) The method of administration was the same as that of treatment group.
62229374|NCT01079130|EXPERIMENTAL|Indacaterol 37.5 µg|"Indacaterol 37.5 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
62229375|NCT01079130|EXPERIMENTAL|Indacaterol 75 µg|"Indacaterol 75 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
62229376|NCT01079130|EXPERIMENTAL|Indacaterol 150 µg|"Indacaterol 150 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
62229377|NCT01079130|ACTIVE_COMPARATOR|Salmeterol|"Salmeterol 50 µg twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI) and Placebo to Indacaterol once daily in the morning via Concept1, a SDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
62591512|NCT01666743|EXPERIMENTAL|Ceftaroline fosamil|IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
62591513|NCT04128969|EXPERIMENTAL|Carnitine supplementation (CS+)|Carnitine supplementation in liquid form, sugar free.
62591514|NCT04128969|PLACEBO_COMPARATOR|Placebo (CS-)|Placebo comparator liquid similar in appearance and taste to CS+.
62591515|NCT00978250|EXPERIMENTAL|5-Fluro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)|FdCyd (100 mg/m(2)) + THU (350 mg/m(2)) administered 5 days/week for 2 weeks in 28-day cycles
62591516|NCT03517553|EXPERIMENTAL|EMS users in ESRD|Subjects then initiate passive electrical muscle stimulation (EMS) delivered by a commercially available FDA approved neuromuscular stimulator (EMPI 300PV or its replacement, EMPI Continuum device obtained from EMPI, Inc., St Paul MN) 3 times a week to the quadriceps muscle groups (15 minutes on each side, 30 minutes total) while on hemodialysis. The duration of training will last for 4 months. Subjects will be monitored at regular intervals during the training to make sure they are doing the training correctly and they are not experiencing any problems.
62591517|NCT04594226|EXPERIMENTAL|EA combined with medication group|Patients in this group will receive electroacupuncture combined with gabapentin.
62591518|NCT04594226|ACTIVE_COMPARATOR|Medication group|Participants in this group will only receive gabapentin.
62591519|NCT05257824|ACTIVE_COMPARATOR|short-term dual antiplatelet group|Patients with unruptured intracranial aneurysms received dual antiplatelet agents (100mg of aspirin and 75mg of clopidogrel) for at least five days before coil embolization. One day prior to coiling, aspirin reaction units (ARU) and P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with proper aspirin and clopidogrel reaction units (ARU \< 550 and PRU 85 \~219) will be enrolled in this study. After stent-assisted coiling, dual antiplatelet treatment continued for 6 months; after that time, this therapy will be exchanged for daily oral 100mg of aspirin for 18 months after coiling
62591520|NCT05257824|EXPERIMENTAL|long-term dual antiplatelet group|Patients with unruptured intracranial aneurysms received dual antiplatelet agents (100mg of aspirin and 75mg of clopidogrel) for at least five days before coil embolization. One day prior to coiling, aspirin reaction units (ARU) and P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with proper aspirin and clopidogrel reaction units (ARU \< 550 and PRU 85 \~219) will be enrolled in this study. After stent-assisted coiling, dual antiplatelet treatment continued for 12 months; after that time, this therapy will be exchanged for daily oral 100mg of aspirin for 18 months after coiling.
62591521|NCT01618123||All CPU subjects|All subjects admitted to the CPU with low to moderate probability for CAD and negative troponin, will undergo the following tests upon arrival following clinical evaluation and their consenting to the study: resting ECG, EndoPAT testing and then after stress nuclear imaging or stress echocardiography. Except for EndoPAT testing, all other tests were conducted according to the routine CPU protocol.
62806045|NCT03495466|ACTIVE_COMPARATOR|Local with sedation anesthesia|The patient will receive local with sedation anesthesia during the first surgery and local only anesthesia for their second surgery.
62421673|NCT04178018|EXPERIMENTAL|Transvaginal photoacoustic imaging/ultrasound|"* Baseline transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging for all participants enrolled~* Once the surgeon has surgically removed the ovary(ies), they will be imaged with the photoacoustic imaging/ultrasound~* For the exploratory outcome measure for high risk participants (approximately 50 participants), the transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging will be performed additionally at 6 months, 12 months, 18 months, 24 months, and at the time of surgery~* For the exploratory outcome measure for high risk participants (approximately 10 participants), the transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging will be performed additionally every 2 weeks at follicular phase and at the luteal phase for 3 months"
62421674|NCT05383976||Patients Residing in 18 zip codes in Western and Southwestern Philadelphia|The cohort will consist of patients residing in 18 zip codes in Western and Southwestern Philadelphia who have primary care providers in 4 Penn Medicine Internal Medicine practices and 3 Penn Medicine Family Medicine Practices.
62421675|NCT01550042||Intensive observation cohort|Patients \> 18 years of age diagnosed with a recent episode of cryptogenic stroke with long term rhythm observation using an implantable loop recorder for detecting atrial fibrillation.
62591522|NCT06184945|NO_INTERVENTION|Usual care|Usual ICU care
62421676|NCT01976663|EXPERIMENTAL|VOLIFT® XC NLFs|Nasolabial folds treated with JUVEDERM VOLIFT® XC.
62421677|NCT01976663|ACTIVE_COMPARATOR|Control NLFs|Nasolabial folds treated with Control.
62591523|NCT06184945|EXPERIMENTAL|Audit and Feedback|ICUs receive electronic dashboard that displays realtime ABCDEF bundle performance data
62591524|NCT06184945|EXPERIMENTAL|RN Implementation Facilitator|ICUs receive a extra RN who helps facilitate ABCDEF bundle implementation
62806046|NCT06136429|EXPERIMENTAL|TAVR Treatment Group|
62806047|NCT05665010||premature ovarian insufficiency|Patients with premature ovarian insufficiency (female age \<40 years, menopause or menstrual rarity for 4 months, basal FSH \> 25 IU / L for two consecutive intervals of more than 4 weeks)
62421678|NCT02494947|EXPERIMENTAL|interval training|high intensity interval-based aerobic exercise
62229378|NCT01079130|PLACEBO_COMPARATOR|Placebo|"Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
62229379|NCT02727465||meningitis cases|any individual with culture-confirmed IMD in England from 01 September 2015 to 31 August 2019 with written informed consent from the individual, the parent (for children aged \<16 years) or next-of-kin (for non-survivors)
62229380|NCT04789512||Covid-19 players|Female volleyball players with Covid-19
62421679|NCT02494947|OTHER|controls|usual care
62421680|NCT02525562|OTHER|Scorpio NRG Total Knee System|Patients eligible for Scorpio NRG Total Knee System with X3 insert
62421681|NCT02525562|OTHER|Triathlon Total Knee System|Patients eligible for Triathlon Total Knee System with X3 insert
62421682|NCT02525562|OTHER|Triathlon Partial Knee Resurfacing|Patients eligible for Triathlon PKR System with X3 insert
62591525|NCT00504699|EXPERIMENTAL|letrozole|ovarian stimulation after breast cancer diagnosis and before breast cancer treatment
62591526|NCT00504699|NO_INTERVENTION|control|No ovarian stimulation before breast cancer treatment
62591527|NCT01826565|NO_INTERVENTION|Control|i-gel will be inserted without rotation
62591528|NCT01826565|EXPERIMENTAL|Rotation|Rotational technique applied
62421683|NCT02426827|EXPERIMENTAL|SCS in CV|
62591529|NCT04562831|EXPERIMENTAL|Newly diagnosed ALS patients|"1. High dose EH301 (1500mg Nicotinamide riboside / 300mg Pterostilbene)~2. Single dose EH301 (1000mg Nicotinamide riboside / 200mg Pterostilbene)~3. Placebo"
62591530|NCT04562831|EXPERIMENTAL|Earlier diagnosed ALS patients|"1. High dose EH301 (1500mg Nicotinamide riboside / 300mg Pterostilbene)~2. Placebo"
62591531|NCT02222233|EXPERIMENTAL|BI 671800 HEA delayed release (enteric coated) tablet|
62591532|NCT02222233|EXPERIMENTAL|BI 671800 HEA solution released in jejunum|BI 671800 HEA solution in the Enterion® capsule released in the jejunum
62591533|NCT02222233|EXPERIMENTAL|BI 671800 HEA solution released in ascending colon|BI 671800 HEA solution in the Enterion® capsule released in the ascending colon
62591534|NCT02222233|EXPERIMENTAL|BI 671800 HEA solution released in descending colon|BI 671800 HEA solution in the Enterion® capsule released in the descending colon
62591535|NCT02222233|EXPERIMENTAL|BI 671800 HEA particulate released in ascending colon|BI 671800 HEA as particulate in the Enterion® capsule released in the ascending colon
62591536|NCT04724629|EXPERIMENTAL|IL-17 inhibitor (Ixekizumab)|Patients will receive study medication Ixekizumab 80 mg per week, (SC) once a week for 4 weeks or until discharge.
62591537|NCT04724629|EXPERIMENTAL|IL-2 (Aldesleukin)|1.5 million IU per day (SC) for 7 days or until discharge. Patients will receive study medication Aldesleukin 1.5 million IU per day (SC), for 7 days or until discharge.
62591538|NCT04724629|EXPERIMENTAL|Indirect IL-6 inhibitor (Colchicine)|Patients will receive study medication colchicine 0.5 mg every 8 hours for 3 days (PO), followed by 4 weeks (+/-7 days) 0.5 mg twice daily. If a dose is missed, it should not be replaced.
62591539|NCT04724629|ACTIVE_COMPARATOR|Standard of care|Standard treatment, supplementation of O2 ventilation + standard treatment of the institution, which may include Dexamethasone according to the institutional protocol.
62591540|NCT04217837||Major Depressive Disorder|Participants who meet the DSM-5 clinical diagnostic criteria, in the opinion of the treating clinician, for primary diagnosis of unipolar, non-psychotic MDD.
62591541|NCT04737824|EXPERIMENTAL|Experimental group A|"Participants executed two sets of twelve repetitions of an adaptation of the balloon-blowing exercise."
62229381|NCT04789512||non-Covid-19 players|Female volleyball players with non Covid-19
62229382|NCT02875093|OTHER|ADI-PEG 20 Plus Low Dose Cytarabine|This is a phase 1, open label trial of ADI-PEG 20 (18 and 36 mg/m2) weekly in combination with low-dose cytarabine (20 mg BID \[twice daily\] for 10 days, every 28 days)
62591542|NCT04737824|NO_INTERVENTION|Control group A|No intervention was applied.
62591543|NCT04737824|EXPERIMENTAL|Experimental group B|"Participants executed two sets of twelve repetitions of an adaptation of the balloon-blowing exercise for seven weeks, three times a week, at home."
62591544|NCT04737824|NO_INTERVENTION|Control group B|No intervention was applied.
62229383|NCT04851340|EXPERIMENTAL|Cow's Milk First|Participants in this group will eliminate all cow's milk products during the first 10 days of the study and receive the cow's milk intervention first and then will cross-over to eliminate soy products in the second 10 days of the study and receive the soy milk intervention during the second diet intervention.
62229384|NCT04851340|EXPERIMENTAL|Soy Milk First|Participants in this group will eliminate all soy products during the first 10 days of the study and receive the soy milk intervention first and then will cross-over to eliminate cow's milk products in the second 10 days of the study and receive the cow's milk intervention during the second diet intervention.
62229385|NCT01516593|EXPERIMENTAL|intensive short term immuno-chemotherapy|Experimental treatment consists of an induction phase followed by a consolidation or intensified phase according to tumor response.
62421684|NCT06063499|EXPERIMENTAL|6 weeks of sessions|Participants will be asked to attend 6 2-hour weekly in-person sessions
62421685|NCT04483427|EXPERIMENTAL|OSA patients after multilevel surgery|
62421686|NCT05727592|EXPERIMENTAL|Intervention Group|Intervention: Diabetic Brazilian spinach supplementation group Subjects in this group will be receiving Brazilian spinach for 12 weeks in which they must consume 15g of Brazilian spinach daily with lunch or dinner.
62421687|NCT05727592|EXPERIMENTAL|Control Group|No intervention: Diabetic control group Subjects in this group will not receive Brazilian spinach. However, they will be receiving standard dietary counselling and educated for the same lifestyle intervention as in the intervention group.
62421688|NCT02741752|EXPERIMENTAL|test group|decortication group
62421689|NCT02741752|NO_INTERVENTION|control|without decortication
62421690|NCT00887107|EXPERIMENTAL|sorafenib|30 patients with non-radioiodine avid differentiated thyroid carcinoma
62421691|NCT06539494|ACTIVE_COMPARATOR|Healthy volunteer|healthy volunteers who will get omeprazol daily 2dd40 mg for 4 weeks
62421692|NCT06539494|ACTIVE_COMPARATOR|Sujbects with MASLD|Patients with MASLD who will get omeprazol daily 2dd40 mg for 4 weeks
62421693|NCT00155259|EXPERIMENTAL|A|
62030387|NCT05083247|EXPERIMENTAL|Arm B|mFOLFIRINOX for 6 cycles (or for 3 cycles Gemcitabine-Nab-P: gem: 1000 mg/m2 weekly 3 w/4; nab-P: 125 mg/m2 3 w/4 in case of unfit for mFFX) +Isotoxic high-dose SBRT: 5 x 7Gy with Simultaneous Integrated Boost (SIB) up to maximum 55Gy (= 1 week; starting ideally 2 weeks and maximum within 4 weeks after the end of chemotherapy)
62030388|NCT04788667|EXPERIMENTAL|Experimental Group|A health education programme using a telerehabilitation platform
62030389|NCT04788667|ACTIVE_COMPARATOR|Control Group|General recommendations using a telerehabilitation platform
62030390|NCT01694537|PLACEBO_COMPARATOR|placebo|The comparison drug is placebo, which is made with same size and shape with study drug. DLBS1033 and placebo is produced by PT Dexa Medica. Placebo will taken 3 times 1 tablet per day for 7 days. Wash out period before enter another arm is 7 days.
62030391|NCT01694537|EXPERIMENTAL|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction. The drug will taken 3 times 490 mg per day for 7 days. Wash out period before enter another arm is 7 days.
62030392|NCT05947344|EXPERIMENTAL|STI-8591 in Advanced Acute Myeloid Leukemia (AML)|Subjects with Advanced primary AML or MDS secondary to AML or AML-MR.
62030393|NCT02937545|EXPERIMENTAL|PGx Only|Patients will receive pharmacogenetic testing. Pharmacists will make recommendations for drug/dose changes based on PGx results.
62229386|NCT05392153|EXPERIMENTAL|Myofascial therapy group|The myofascial therapy group (n=26) will receive 12 sessions of 6-weekly lower extremity posterior muscle myofascial therapy.
62229387|NCT05392153|NO_INTERVENTION|Control group|The control group (n=23) will not receive lower extremity posterior muscle myofascial therapy. They will continue the routine exercise program.
62229388|NCT03497754|EXPERIMENTAL|Cardiac output measurements|Cardiac output will be measured using TTE with and without the use of Probefix so not 2 arms but 2 consecutive measurements in the same patient
62229389|NCT04270630|NO_INTERVENTION|Standard of care|Patients in the control arm of the study will undergo standard of care treatment, discussing catheterization with their treating physicians.
62229390|NCT04270630|EXPERIMENTAL|Shared decision aid|Patients in the interventional arm of the study will discuss catheterization with their treating physicians, in addition to having access to the shared decision aid tool and a shared decision conversation with a co-investigator clinician.
62229391|NCT02066428|EXPERIMENTAL|AERAS-404(50mcg H4/0nmol IC31) or Placebo|1 dose
62421694|NCT05931952|EXPERIMENTAL|Buteyko breathing technique|"Buteyko breathing technique and conventional (chest physiotherapy) treatment for 5 times a week for about 20 minutes in one session for a period of 4 weeks. There are three steps involved in buteyko breathing technique.~Step 1; control pause breathing test (patient is asked to sit in an upright position and take normal breath. After this, asked the patient to take small breath-in for 2s and out for 3s. Control pause phase should not exceed for \>30 seconds).~Step 2; maximum pause or shallow breathing (patient is asked to place fingers under the nose to monitor inflow of air. 2 or 3 flickers of air is taken in and exhale as slowly as possible).~Step 3; combine step 1 and 2. Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus."
62421695|NCT05931952|EXPERIMENTAL|Papworth method|"Papworth method and conventional chest physiotherapy (bronchial drainage) treatment. Intervention will be given for a period of 5 sessions per week for 1 month. Duration of each session will be 20 minutes. This technique is performed particularly during remission period that make it feasible for respiratory physiotherapist to integrate this method into activities of daily living. Papworth method has five components including Papworth method ameliorates asthmatic symptoms breathing, education, relaxation, combination of breathing and relaxation exercise and home exercises and also improves quality of life.~Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus."
62421696|NCT06617013|EXPERIMENTAL|Child with CF on GERD therapy without severe GERD|The GSAS will be completed at baseline, GERD therapy will be discontinued, and GSAS will be repeated 12 weeks later.
62421697|NCT04075045|NO_INTERVENTION|"Group A. Standard Care (Control)"|Does not receive Wellth app.
62421698|NCT04075045|EXPERIMENTAL|"Group B. Wellth App (Treatment 1)"|Receives Wellth app without additional financial rewards tied to adherence.
62591545|NCT02728154||Normal control|The subjects in the normal heart function group will provide a blood sample and stool sample.
62030394|NCT02937545|EXPERIMENTAL|PGx + MTM|Patients will receive pharmacogenetic testing along with medication therapy management. Two MTM sessions will be conducted: one at the time testing is ordered and the testing sample is collected, and one when results are returned to the patient. Pharmacists will make recommendations for drug/dose changes based on medication action plan developed during MTM and the PGx results.
62030395|NCT06058156|EXPERIMENTAL|SAR444656 dose 1|Participants will receive SAR444656 dose 1 orally
62030396|NCT06058156|EXPERIMENTAL|SAR444656 dose 2|Participants will receive SAR444656 dose 2 orally
62229392|NCT02066428|EXPERIMENTAL|AERAS404 (50mcgH4/100nmol IC31) or Placebo|1 dose
62229393|NCT02066428|EXPERIMENTAL|AERAS404 (50mcgH4/0nmol IC31) or Placebo|2 dose
62229394|NCT02066428|EXPERIMENTAL|AERAS404 (150mcgH4/0nmol IC31) or Placebo|1 dose
62229395|NCT02066428|EXPERIMENTAL|AERAS404 (50mcgH4/5000nmol IC31) or Placebo|1 dose
62229396|NCT02066428|EXPERIMENTAL|AERAS404 (50mcgH4/500nmol IC31) or Placebo|2 dose
62229397|NCT02066428|EXPERIMENTAL|AERAS404|2 dose placebo
62229398|NCT02066428|EXPERIMENTAL|AERAS404 (50mcg H4/100nmol IC31) or Placebo|2 dose
62229399|NCT02641600|ACTIVE_COMPARATOR|Elastic stockings|Class 1 elastic stockings (18-21 mmHg)
62030397|NCT06058156|EXPERIMENTAL|SAR444656 dose 3|Participants will receive SAR444656 dose 3 orally
62030398|NCT06058156|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo orally
62229400|NCT02641600|PLACEBO_COMPARATOR|Placebo stockings|Placebo stockings (0 mmHg)
62229401|NCT03818685|EXPERIMENTAL|Nivolumab + Ipilimumab|Nivolumab (360 mg IV, every 3 weeks) for 8 doses and Ipilimumab (1 mg/kg, IV, every 6 weeks or every 2 doses of Nivolumab in case of dose delays) for 4 doses.
62229402|NCT03818685|ACTIVE_COMPARATOR|Capecitabine|Capecitabine (1000 mg/m2 twice a day, Bis In Die), 14 days on / 7 days off for 8 cycles.
62229403|NCT04223869|NO_INTERVENTION|periodontally healthy group|Control
62229404|NCT04223869|ACTIVE_COMPARATOR|Chronic Periodontitis|non-surgical periodontal treatment was performed
62030399|NCT03166618|EXPERIMENTAL|VOLUMA® XC Treatment|Participants will be treated with JUVÉDERM® VOLUMA® XC injectable gel in both temples (area above the eye). Participants are eligible for touch-up treatment 30 days later.
62030400|NCT03166618|NO_INTERVENTION|Control_No Treatment|No treatment is administered.
62229405|NCT04223869|ACTIVE_COMPARATOR|Aggressive Periodontitis|non-surgical periodontal treatment was performed
62229406|NCT05831930|EXPERIMENTAL|Treatment Group|
62229407|NCT04756388|ACTIVE_COMPARATOR|Executive Training|The Executive Training (ET) condition will consist of the ET intervention that Dr. Best previously developed and evaluated. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, at home between sessions. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.
62229408|NCT04756388|EXPERIMENTAL|Strategy Development only|In Strategy Development only participants will engage in cognitive strategy discussions to develop new executive function strategies that can be used in daily life. Between sessions, participants will be encouraged to practice their cognitive strategies in their daily life and track their strategies using the strategy worksheet. There will be no computerized cognitive training in this condition. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.
62229409|NCT04756388|EXPERIMENTAL|Computerized Cognitive Training only|In Computerized Cognitive Training only participants will spend the entire one-hour session practicing computerized training exercises. Between sessions participants will be encouraged to practice the computerized exercises at home for 40 minutes per day. There will be no strategy development in this condition. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.
62229410|NCT01816854||Patients with PAD|
62229411|NCT05418023||Autism Spectrum Disorder (ASD)|
62229412|NCT05418023||Non-ASD|
62229413|NCT01720173|EXPERIMENTAL|Treatment (dalantercept)|Patients receive dalantercept SC on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62229414|NCT05407922||Laparoscopy Group|The laparoscopy group included every pregnant woman having laparoscopic intervention because of acute abdominal pain during any trimester of her pregnancy.
62229415|NCT05407922||Non-laparoscopy Group|Non-laparoscopy Group included every pregnant woman having treatment approach other than the laparoscopic approach because of acute abdominal pain.
62229416|NCT03171077|ACTIVE_COMPARATOR|Virtual Rehabilitation|"A virtual rehabilitation program (G0) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The G0 treatment program consists of the following protocols: a) protocol 1 games (Balance Bubble Plus and Tennis); b) protocol 2 games (Rhythm Parade and Boxing)."
62591546|NCT02728154||heart failure|The subjects in history of heart failure group will provide a blood sample and stool sample.
62229417|NCT03171077|EXPERIMENTAL|PNF Method|A program of therapeutic exercises (G1) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The G1 treatment program consists of the following protocols: a) protocol 1 : 30 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation), and 10 minutes diagonal exercise scapula (anterior and posterior elevation); b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training;
62229418|NCT03171077|ACTIVE_COMPARATOR|Virtual Rehabilitation and PNF Method|In G2 program will be performed 20 minutes G0 protocol (1 or 2, used alternately between sessions a week) and 20 minutes G1 protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols.
62229419|NCT00888446|EXPERIMENTAL|Group A|"Number of Vaccine Recipients: 10~Dosage level 3 x 10\^10 DRP~Month 0 + 6"
62229420|NCT00888446|EXPERIMENTAL|Group B|"Number of Vaccine Recipients: 10~Dosage level 3 x 10\^10 DRP~Month 0+12"
62229421|NCT00888446|EXPERIMENTAL|Group C|"Number of Vaccine Recipients: 10~Dosage level 3 x 10\^11 DRP~Month 0+6"
62229422|NCT00888446|EXPERIMENTAL|Group D|"Number of Vaccine Recipients: 10~Dosage level 3 x 10\^11 DRP~Month 0+12"
62229423|NCT00888446|EXPERIMENTAL|Group E|"Number of Vaccine Recipients: 10~Dosage level 3 x 10\^12 DRP~Month 0+6"
62229424|NCT00888446|EXPERIMENTAL|Group F|"Number of Vaccine Recipients: 10~Dosage level 3 x 10\^12 DRP~Month 0+12"
62229425|NCT00888446|EXPERIMENTAL|Group G|"Number of Vaccine Recipients: 10~Preselected for baseline AAV neutralization titers of \<1/8~Dosage level 3 x 10\^12 DRP~Month 0+6"
62229426|NCT00888446|PLACEBO_COMPARATOR|Placebo|3 volunteers will receive placebo matched to each experimental group.
62591547|NCT02728154||pre-HFpEF|The subjects in history of diastolic dysfunction but not had heart failure clinical presentations group will provide a blood sample and stool sample.
62030401|NCT01445899|EXPERIMENTAL|PF-04523655 (Stratum II)|Stratum II, 6 monthly injections of PF-04523655 only
62030402|NCT01445899|EXPERIMENTAL|PF-04523655 and ranibizumab|Stratum II, 6 monthly injections of PF-0423655 and ranibizumab administered in combination
62030403|NCT01445899|ACTIVE_COMPARATOR|ranibizumab|Stratum II, 6 monthly IVT injections of ranibizumab only
62030404|NCT01445899|EXPERIMENTAL|PF-04523655 (Stratum I)|Stratum I
62030405|NCT04490746||active|patients with active tuberculosis
62030406|NCT04490746||latent|patients with latent tuberculosis infection
62030407|NCT04490746||negtive control|healthy volunteers
62030408|NCT00354874|EXPERIMENTAL|GW642444 50mcg|
62030409|NCT00354874|EXPERIMENTAL|GW642444 100mcg|
62806048|NCT05665010||declined ovarian function|Patients with diminished ovarian reserve(women before 40 years old; the number of antral follicles in both ovaries is less than 6, AMH \< 1.1ng/ml, and basal FSH \> 10 IU / L, which meets one of the three requirements)；Female with menopause between the age of 40 and 45.
62806049|NCT04088006|EXPERIMENTAL|Treated cheek and neckline area|Intra-individual study with one cheek and one side of neckline area treated
62591548|NCT05702242|EXPERIMENTAL|Removal with alligator forceps|Standard of care removal with passage of an intrauterine alligator forceps under ultrasound guidance to grasp and remove the IUD. If required, multiple attempts will be performed using this technique.
62591549|NCT05702242|EXPERIMENTAL|Removal with manual vacuum aspiration|Intrauterine placement of an MVA under ultrasound guidance adjacent to the IUD to remove the IUD. Multiple attempts will be performed up to a maximum of 3 unsuccessful MVA attempts, after which time, the provider will switch to the alligator forceps technique, given that this is the current standard of care.
62806050|NCT04088006|NO_INTERVENTION|Non-treated cheek and neckline area|Intra-individual study with one cheek and one side of neckline area non-treated
62806051|NCT01999452|EXPERIMENTAL|Paleolithic diet first|Starting with Paleolithic diet and then switching to Diabetes diet
62030410|NCT00354874|EXPERIMENTAL|GW642444 200mcg|
62030411|NCT00354874|ACTIVE_COMPARATOR|salmeterol 50mcg|
62030412|NCT00354874|PLACEBO_COMPARATOR|placebo|
62030413|NCT04885374||Amyotrophic lateral sclerosis patients|Amyotrophic lateral sclerosis patients with traditional Chinese medicine
62030414|NCT02898974||Regular Medical Marijuana users|People with MS that are regular Medical Marijuana users
62030415|NCT02898974||Non Users of Medical Marijuana|People with MS that are non users of Medical Marijuana
62030416|NCT04885686|EXPERIMENTAL|Endomethasone N RCS|Endomethasone N RCS is used in combination with gutta percha points for the permanent obturation of root canals.
62030417|NCT04885686|ACTIVE_COMPARATOR|Endomethasone SP RCS|Endomethasone SP RCS is used in combination with gutta percha points for the permanent obturation of root canals.
62030418|NCT03643952|EXPERIMENTAL|Daptomycin|Participants aged 1 to 17 years old with cSSTI or bacteremia will receive daptomycin intravenously every 24 hours for either 5-14 days for cSSTI or for 5-42 days for bacteremia.
62030419|NCT03744507||Uterine Fibroids|Premenopausal women with uterine fibroids confirmed by an ultrasound.
62229427|NCT03695666||Cycle 1|Counted number of patients booked into clinic. No individual patient data collected.
62229428|NCT03695666||Cycle 2|Counted number of patients booked into clinic. No individual patient data collected.
62591550|NCT03796416|ACTIVE_COMPARATOR|misoprostol|"Induction using misoprostol:~Insert misoprostol 25 micrograms in the posterior fornix of the vagina digitally Repeat cervical exam every 4 hours"
62030420|NCT03744507||Endometriosis|Premenopausal women with endometriosis diagnosed or confirmed by surgical or direct visualization, or histopathology within 10 years of the Screening visit.
62030421|NCT05317468|EXPERIMENTAL|Video|Patients will complete contraceptive counseling using a video-based platform. Patients and counselors will have an audio and video connection.
62030422|NCT05317468|EXPERIMENTAL|Telephone|Patients will complete contraceptive counseling on a telephone call. Patients and counselors will have an audio connection only.
62030423|NCT05558657|EXPERIMENTAL|Intervention group|The intervention group will receive home-based acupressure and nursing education.
62030424|NCT05558657|ACTIVE_COMPARATOR|Control group: Home-based sham group , acupressure combined with nursing interventions|The control group will receive home-based, manual light touch of the abdomen combined with nursing education.
62030425|NCT05554237|EXPERIMENTAL|PF-07612577|Part-1: Dose 1, Dose 2, Dose 4, Dose 5 Part-2: Cohort 2-5
62030426|NCT05554237|PLACEBO_COMPARATOR|Placebo|Part-1: Dose 1-5 Part-2: Cohort 2-4
62030427|NCT05554237|EXPERIMENTAL|PF-06264006|Part-1: Dose 3, Dose 5
62030428|NCT03570294|OTHER|Atosiban|Total oxidant status (TOS), total antioxidant status (TAS) and oxidative stress index (OSI) values as well as 3-nitrotyrosine, carbonyl and thiol groups levels weill be measure using ELISA test in serum and plasma of 64 pregnant women before and after 48 hours of continuous administration of Atosiban.
62030429|NCT05748405|EXPERIMENTAL|AEF0217|AEF0217 0.1 mg tablet 2 tablets in 10 ml of water per day during 28 days
62030430|NCT05748405|PLACEBO_COMPARATOR|Placebo|Placebo tablet 2 tablets in 10 ml of water per day during 28 days
62030431|NCT05369052|EXPERIMENTAL|contezolid acefosamil/contezolid|
62030432|NCT05369052|ACTIVE_COMPARATOR|linezolid|
62030433|NCT01895166|EXPERIMENTAL|EBUS-GS group|The EBUS probe and GS are confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
62421699|NCT04075045|EXPERIMENTAL|"Group C. Wellth App (Treatment 2) with targeted rewards"|Receives Wellth app with additional ability to earn up to $150 rewards usable at local pharmacies for using the app to track adherence.
62806052|NCT01999452|EXPERIMENTAL|Diabetes diet first|Starting with Diabetes diet and then switching to Paleolithic diet
62806053|NCT04519736|ACTIVE_COMPARATOR|Harmony Dye-VL 500-600nm|The left side of the face will be treated with the Single Band Alma Harmony Dye-VL 500-600nm device. Three treatments, administered in intervals of 21 +/- 2 days. Each full face treatment duration will be approximately 20-30 minutes .
62806054|NCT04519736|ACTIVE_COMPARATOR|Palomar MaxG|Right side of the face will be treated with the Dual Band Palomar MaxG device. Three treatments, administered in intervals of 21 +/- 2 days. Each full face treatment duration will be approximately 20-30 minutes .
62806055|NCT04338282|EXPERIMENTAL|treatment arm|anti-PD-1 antibody (toripalimab) 240mg/d, every 3 weeks, for up to one year or until disease progression.
62806056|NCT02589054||Patients|
62806057|NCT02485691|EXPERIMENTAL|Cabazitaxel|Participants received Cabazitaxel 25 mg/m\^2 intravenous (IV) infusion for over 1 hour on Day 1 of each 3 week treatment cycle in combination with Prednisone 10 mg orally once daily and primary prophylactic granulocyte-colony stimulating factor (G-CSF) as per investigator decision, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 22 weeks).
62229429|NCT04010825|EXPERIMENTAL|Hypnosis Arm|"In parallel with an inpatient pulmonary rehabilitation program, nine visits will be carried out :~* V0 : an inclusion visit~* V1 : a randomization visit~* V2 to V6 : five visits with hypnosis sessions~* V7 : a end-stay visit~* V8 : a 6-month post-rehabilitation visit ( by phone call)~The five hypnosis sessions (V2 to V6) will be spread over three weeks of rehabilitation program (1 to 2 hypnosis sessions per week).~For V1, V7 and V8 : questionnaires will be filled about : quality of life (CAT questionnaire), the three dimensions of dyspnea (mMRC, LCADL and MDP questionnaires), anxiety and depression (HADS questionnaire), post-traumatic stress ( PCLS questionnaire), sedentarity and physical activity (SIMPAQ questionnaire). Other data will be also collected on : previous experiences with hypnosis, self-hypnosis and relaxation, number of exacerbations and hospitalizations in the past 6 months, drug treatment, psychotropic drug use and dosage and psychological follow-up."
62229430|NCT04010825|NO_INTERVENTION|Control Arm|"In parallel with an inpatient pulmonary rehabilitation program, no additional intervention will be carry out and four visits will be carried out :~* V0 : an inclusion visit~* V1 : a randomization visit~* V7 : a end-stay visit~* V8 : a 6-month post-rehabilitation visit ( by phone call)~For V1, V7 and V8 : questionnaires will be filled about : quality of life (CAT questionnaire), the three dimensions of dyspnea (mMRC, LCADL and MDP questionnaires), anxiety and depression (HADS questionnaire), post-traumatic stress ( PCLS questionnaire), sedentarity and physical activity (SIMPAQ questionnaire). Other data will be also collected on : previous experiences with hypnosis, self-hypnosis and relaxation, number of exacerbations and hospitalizations in the past 6 months, drug treatment, psychotropic drug use and dosage and psychological follow-up."
62229431|NCT05830838|EXPERIMENTAL|Group I (daily adaptive online replanning, SBRT)|Patients undergo daily adaptive online replanning for SBRT to the prostate fossa on study. Patients also undergo MRI and may undergo PET/CT during screening.
62229432|NCT05830838|EXPERIMENTAL|Group II (daily adaptive online replanning, SBRT)|Patients undergo daily adaptive online replanning for SBRT to the prostate fossa and pelvic lymph nodes on study. Patients also undergo MRI and may undergo PET/CT during screening.
62229433|NCT04929548|EXPERIMENTAL|ECPy-THP Programs|Epirubicin 100 mg/m2, iv cyclophosphamide 600 mg/m2, iv + Pyrotinib 400 mg/d, po 4-week treatment, sequential docetaxel 80 mg/m2, iv + trastuzumab 6 mg/kg (first dose 8 mg/kg), iv + patuximab 420 mg (first dose 840 mg), iv ,po 4 weeks of treatment
62229434|NCT05916118|EXPERIMENTAL|Exercise and Oxaliplatin-induced peripheral neuropathy|A single arm to evaluate the feasibility and acceptability of having patients exercise during oxaliplatin infusions in the infusion center. Arm will enroll patients receiving oxaliplatin-containing chemotherapy for gastrointestinal cancer or for cancer of unknown primary.
62229435|NCT02925637|EXPERIMENTAL|FACoT group|treatment group will receive FACoT, that include one to one 10 treatment sessions. the treatment sessions will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
62229436|NCT02925637|NO_INTERVENTION|control group|control group receiving standard care - cognitive and functional assesment
62229437|NCT00295594|ACTIVE_COMPARATOR|1|
62229438|NCT00295594|EXPERIMENTAL|2|
62229439|NCT06109974||Participants with high risk of COPD|no intervention
62229440|NCT03904355|ACTIVE_COMPARATOR|Fiboroid group|Women with intramural myoma no reaching the cavity
62229441|NCT03904355|ACTIVE_COMPARATOR|Non fibroid group|Women without myomas
62229442|NCT00927160||MACE group|Elderly patients admitted to the Mobile Acute Care of the Elderly Unit.
62591551|NCT03796416|EXPERIMENTAL|Misoprostol and foley bulb|"Induction using Foley balloon combined with misoprostol:~A 26 French intracervical Foley balloon will be inserted above the internal os at the start of induction, inflated using 80cc of sterile water.~If a Foley balloon is not able to be inserted at the time of starting induction of labor, misoprostol 25microgram can be inserted in the posterior fornix of the vagina and the misoprostol protocol followed."
62591552|NCT05196984|EXPERIMENTAL|Down Syndrome Experimental|Experimental arm within Down Syndrome participant group: exposure to active 40Hz stimulation for 30-60 minutes.
62591553|NCT05196984|SHAM_COMPARATOR|Down Syndrome Sham|Sham arm within the Down Syndrome participant group: exposure to control stimulation for 30-60 minutes.
62591554|NCT05196984|EXPERIMENTAL|Cognitively Normal Experimental|Experimental arm within the cognitively normal control participant group: exposure to active 40Hz stimulation for 30-60 minutes.
62591555|NCT05196984|SHAM_COMPARATOR|Cognitively Normal Sham|Sham arm within the cognitively normal control participant group: exposure to control stimulation for 30-60 minutes.
62591556|NCT05538234||Non-living organ donors|Group of non-living donors
62229443|NCT00927160||Usual Care group|Elderly patients admitted to the general medicine service in the hospital
62229444|NCT04704011|EXPERIMENTAL|Arm 1: Basic Needs Assessment|-Patients will receive a phone call from a research team member 2-4 weeks before their colposcopy appointment. The team member will remind the patient of the date and time of their appointment and conduct a basic needs assessment. Those who have at least one unmet basic need or are unsure of their current needs will be referred to the 24-hr assistance hotline, 2-1-1 United Healthy Way Missouri. After the date of their appointment, patients will be contacted to ask whether they contacted 2-1-1 and used any recommended services.
62229445|NCT04704011|ACTIVE_COMPARATOR|Arm 2: Usual Care Cohort|-Patients will receive an automated phone call two weeks before their colposcopy appointment to remind them of the date and time of their visit.
62229446|NCT04751656|EXPERIMENTAL|Steady Intervention|Participants asked to engage in Steady Intervention for 12 months
62229447|NCT00567710|EXPERIMENTAL|I|BL - 1020 lowdose
62229448|NCT00567710|EXPERIMENTAL|II|BL 1020 high dose
62229449|NCT00567710|PLACEBO_COMPARATOR|III|
62229450|NCT00567710|ACTIVE_COMPARATOR|IV|Risperidone
62229451|NCT03556241|EXPERIMENTAL|Intervention: No change group|Case management consists keeping patient's current pacemaker mode during surgery
62229452|NCT03556241|NO_INTERVENTION|Control: Mode change group|Usual care consists changing pacemaker mode to VOO before surgery
62591557|NCT05538234||Living organ donors|Group of living organ donors
62591558|NCT05538234||Organ recipients|Group of organ recipients
62591559|NCT01354392|EXPERIMENTAL|AZD1152|
62591560|NCT06605989|EXPERIMENTAL|left nostril side|For nasotracheal intubation, the nasal RAE tube will be inserted through the left nostril and advanced into the oral cavity.
62030434|NCT01895166|ACTIVE_COMPARATOR|EBUS-GS-X-ray group|The EBUS probe and GS are confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained under fluoroscopic guidance.
62030435|NCT01625429|EXPERIMENTAL|neoadjuvant|
62229453|NCT05337852|EXPERIMENTAL|Experimental group|"To the pregnant women in the experimental group;~* Emotional freedom technique was applied online with the researcher twice a week.~* PUQE, PRAQ-2 tests will be applied before the intervention,~* SUE and PUQE will be applied before and after each session,~* After 2 sessions, post-test data will be obtained with PUQE, SUE, PRAQ-2."
62229454|NCT05337852|NO_INTERVENTION|Control group|"* After each intervention applied to the experimental group, SUE and PUQE will be applied to the control group over the phone, simultaneously.~* After 1 week, post-test data will be obtained with PUQE, SUE, PRAQ-2."
62229455|NCT00972452|EXPERIMENTAL|Exercise|5-10d exercise training
62591561|NCT06605989|EXPERIMENTAL|right nostril side|For nasotracheal intubation, the nasal RAE tube will be inserted through the right nostril and advanced into the oral cavity.
62591562|NCT00978081|EXPERIMENTAL|Arm I|Patients receive oral aminolevulinic acid and then undergo continuous photodynamic therapy 4-6 hours later.
62806058|NCT02485691|EXPERIMENTAL|Abiraterone acetate or enzalutamide|Participants received either abiraterone acetate 1000 mg orally once daily from Day 1 to Day 21 of each 3 week treatment cycle in combination with prednisone 5 mg orally twice daily; or enzalutamide 160 mg orally once daily continuously from Day 1 to Day 21 of each 3 week treatment cycle, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 12.5 weeks).
62229456|NCT06324565||Ovarian Torsion|All female patients under the age of 18 with suspicious signs and symptoms of ovarian torsion
62229457|NCT00709696|PLACEBO_COMPARATOR|1|Placebo Varenicline
62229458|NCT00709696|ACTIVE_COMPARATOR|2|Varenicline
62591563|NCT00978081|EXPERIMENTAL|Arm II|Patients receive aminolevulinic acid as in arm I and then undergo fractionated photodynamic therapy 4-6 hours later.
62806059|NCT05256485|ACTIVE_COMPARATOR|cognitive behavioral therapy|Standard CBT comprises an array of approaches directed toward modifying dysfunctional thinking and behavior. The two critical components are analysis of thoughts, feelings, and behaviors, as well as skills training for achieving active behavior and thought modification.
62806060|NCT05256485|ACTIVE_COMPARATOR|mindfulness based relapse prevention|"MBRP training is based on a two-component process:~1. Attention to present moment experience, even if it includes craving or negative emotion.~2. An accepting attitude towards this experience letting it be exactly as it is, without judging it or reacting to it."
62806061|NCT05256485|ACTIVE_COMPARATOR|twelve-step therapy|12-step therapy was based on strengthening conscious contact with God and awakening spirituality through prayer and meditation
62806062|NCT01379183|ACTIVE_COMPARATOR|Erythromycin|Erythromycin 200 mg i.v. suspension, Barium Sulfate Solution, and Magnetic Resonance Imaging
62806063|NCT01379183|PLACEBO_COMPARATOR|Placebo|Matching placebo i.v. suspension, Barium Sulfate Solution, and Magnetic Resonance Imaging
62806064|NCT04049487|ACTIVE_COMPARATOR|Generalized Exercise|General wellness/exercise program designed to replicate a generic wellness program that one would find in a gym setting. Will be led by an exercise instructor.
62229459|NCT03211910|PLACEBO_COMPARATOR|Standard Care of Treatment|Participants will be treated with standard of care treatment.
62229460|NCT03211910|ACTIVE_COMPARATOR|SacralSaver|SacralSaver
62229461|NCT04621591|EXPERIMENTAL|Saneso 360° gastroscope|Subjects will have a clinically indicated per standard of care EGD procedure performed using the Saneso 360° gastroscope. Immediately thereafter Patients will then have an EGD procedure using a standard Gastroscope (Olympus GIF 180) performed by a second endoscopist.
62421700|NCT04075045|EXPERIMENTAL|"Group D. Wellth App (Treatment 3) with non-targeted rewards"|Receives Wellth app with additional ability to earn up to $150 rewards usable at many stores for using the app to track adherence.
62591564|NCT02225366|EXPERIMENTAL|Intra-Tumoral Injection of LL37|LL37 administered intratumorally in cutaneous or subcutaneous tumors at least 1 cm in diameter. Patients will receive weekly intratumoral injections of LL37 for up to 8 weeks. The injections will be given every 7 days (+/- 48 hours). Starting dose 250 µg/tumor.
62030436|NCT05661331||Ascites|N = A target of 88 treated patients and thereof, a maximum of \~10 subjects with a pre-TIPS LVP frequency ≥ 2 LVP per month
62030437|NCT05661331||Variceal bleeding|N = At least 88 treated patients and thereof, a maximum of \~10 subjects enrolled with Child-Pugh class C
62030438|NCT05661331||Other Primary Indication|Portal vein obstruction or thrombosis, pre-operative TIPS, hepatorenal Syndrome Type 1, hepatorenal Syndrome Type 2, other) N = Approximately 20 treated patients
62030439|NCT06453226||Parkinson's group|Patients with confirmed Parkinson's disease undergoing neurological examination
62030440|NCT06453226||Healthy Controls|Patients will be asked to nominate a partner/carer that can be enrolled in the control group. Healthy controls will also be recruited using web-based adverts mainly via the Imperial Clinical Research Facility and Parkinson's disease charities.
62030441|NCT06453226||De-Novo|Patients undergoing neurological examination for suspected Parkinson's disease due to presence of symptoms
62030442|NCT06393465||Patients with mixed phenotype ATTR-CM|ATTR-CM patients presenting with mixed phenotype
62030443|NCT06259253||Observational Cohort 1 - Patient/Provider|Participant will complete a computer-based questionnaire about your age, gender, income, highest level of education, patient experience, medical mistrust, social support and health care access.
62229462|NCT00609765|EXPERIMENTAL|Protocol Specified Chemotherapy|"Protocol Specified Chemotherapy Every 28 Days: Avastin, Fluorouracil, Doxorubicin, Streptozocin.~Premedications: Dexamethasone, Ondansetron"
62229463|NCT03924739|EXPERIMENTAL|Intervention group|Participants in the intervention group will participate in a 13-week, nurse-coordinated integrated care model.
62229464|NCT03924739|NO_INTERVENTION|Control group|The control group will receive the conventional care provided by the study hospital.
62421701|NCT02040207|EXPERIMENTAL|AM-101 injection|AM-101 gel for intratympanic injection
62421702|NCT06417203|EXPERIMENTAL|Hyberbaric group|In this group, hyperbaric bupivacaine was planned to use in spinal anesthesia for partial hip replacement surgery
62421703|NCT06417203|EXPERIMENTAL|Hypobaric group|In this group, hypobaric bupivacaine was planned to use in spinal anesthesia for partial hip replacement surgery
62229465|NCT06249373|EXPERIMENTAL|LIPUS intervention group|Low intensity pulse ultrasound （LIPUS） intervenes at the anastomotic site, and if the ultrasound examination indicates the presence of a narrow site in the outflow tract, it also intervenes at the narrow site. It belongs to non-invasive extracorporeal intervention, with three times a week （during dialysis） for 20 minutes each time. The sound intensity is 350mW/cm2, the pulse frequency is 1MHz, the pulse repetition frequency is 100Hz, the pulse frequency is 100 times, and the treatment period is 12 weeks.
62229466|NCT06249373|NO_INTERVENTION|Simulated LIPUS control group|Using the same forearm wearable portable ultrasound as the LIPUS arteriovenous fistula intervention group, but not issuing low-intensity pulse ultrasound.
62229467|NCT04589208|EXPERIMENTAL|Ketamine|ketamine
62229468|NCT05331963|EXPERIMENTAL|Kinesio taping with rehabilitation program group|Rehabilitation program will be given to this group in addition to Kinesio taping on skin for 72 hour.
62229469|NCT05331963|NO_INTERVENTION|Rehabilitation plan group|The rehabilitation program will be provided individually to all participants (twice weekly during the first 4 weeks, then once weekly)
62229470|NCT00675090|EXPERIMENTAL|GSK239512|GSK239512 oral tablets
62229471|NCT00675090|PLACEBO_COMPARATOR|Placebo|Placebo to match tablets
62806065|NCT04049487|EXPERIMENTAL|Diastasis Specific Exercise|Diastasis specific exercise program incorporating multiple muscle groups and based on research findings of exercises that are shown to be effective for reducing size and impact of diastasis rectus.
62806066|NCT04292535|ACTIVE_COMPARATOR|Passive Control|20 minute sedentary control period during which participants watched an emotionally neutral video.
62229472|NCT05695625|ACTIVE_COMPARATOR|Group ESPB|Spinal anesthesia + bilateral ESPB (total of 40 ml, %0.5 bupivacaine)
62229473|NCT05695625|ACTIVE_COMPARATOR|Group SA|Only spinal anesthesia
62229474|NCT00925431|EXPERIMENTAL|Lifestyle Modification|Behavioral: cognitive-motivational enhancement to lifestyle management plus nutritional education.
62229475|NCT00925431|ACTIVE_COMPARATOR|Supportive education|General fibromyalgia education plus nutritional education.
62806067|NCT04292535|EXPERIMENTAL|Acute Exercise|20 minute physical activity period during which participants exercised on a treadmill at an intensity corresponding to 60-65% of maximum heart rate while watching an emotionally neutral video.
62806068|NCT02054585|ACTIVE_COMPARATOR|NaCl %0.9|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
62806069|NCT02054585|EXPERIMENTAL|NaCl 0.9% +5% dextrose|"Children will be included in each group in a randomized way using SAS program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% + 5% glucose. The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
62806070|NCT01332994|EXPERIMENTAL|1|
62806071|NCT01332994|EXPERIMENTAL|2|
62030444|NCT06259253||Observational Cohort 2 - Patient/Provider|Participant will complete a computer-based questionnaire about your age, gender, income, highest level of education, patient experience, medical mistrust, social support and health care access.
62229476|NCT03029312|EXPERIMENTAL|Whole Body Vibration|Twice daily WBVT at home using the Galileo M device, 3x3 min, with 3 minute breaks (total daily WBVT 18 min) for 5 months. Children stand upright on the device, with knees bent (10-45 degrees, semi-squat or squat position). A schedule of increasing intensity of vibration exercise was used over time, allowing some adjustment to the patient's physical capability. Amplitude 1 was used for the first 2 weeks, then increased to amplitude 2 and further increased up to amplitude 3, if individually possible, always using frequencies between 20-25Hz. Children also perform exercises on the platform, including shifting their weight from one side to the other, increase/decrease their knee and hip angle, weight shift with trunk rotation, and alternate flexion and extension of knees.
62030445|NCT01576562||Study Group - Control Group|VAD implantation (study group) or other cardiothoracic surgery (control group)
62229477|NCT03029312|NO_INTERVENTION|Regular Care|Regular Care, including physiotherapy for 5 months
62229478|NCT04633551|EXPERIMENTAL|Intervention|Participants in this arm will receive a commercially available anti-inflammatory supplement.
62229479|NCT04633551|NO_INTERVENTION|Control|Participants in this arm will not receive a commercially available anti-inflammatory supplement.
62229480|NCT01093521|EXPERIMENTAL|100 mg/m2 dose|Five day continuous IV Gallium Nitrate (Ganite®) infusion at 100 mg/m2
62030446|NCT02804542||Fascia Iliaca Block Cohort|Prospective patients receiving fascia iliaca blocks A prospective Observational study of Hip fracture patients that are offered fascia iliaca blocks as standard of care in the ED.
62030447|NCT02804542||Retrospective Control Cohort|No fascia iliaca block performed A retrospective review will be done of hip fracture patients that did not receive fascia iliaca blocks (before fascia iliaca blocks being offered in the ED as standard of care).
62229481|NCT01093521|EXPERIMENTAL|200 mg/m2 dose|Five day continuous IV Gallium Nitrate (Ganite®) infusion at 200 mg/m2
62229482|NCT02113930||Idiopathic CD4 lymphocytopenia|Constitution of a biobank of frozen cells, plasma and serum samples
62229483|NCT02113930||Genetic Study|High rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC)
62421704|NCT04212741|EXPERIMENTAL|A+ HA(tm)|20 ml oral solution of hyaluronic acid mixture in a bottle. Administration with 250\~500 ml water under fasting condition in the morning.
62421705|NCT04212741|PLACEBO_COMPARATOR|Placebo|20 ml oral solution without active ingredients in a bottle. Administration with 250\~500 ml water under fasting condition in the morning.
62806072|NCT02091817|OTHER|Control group|Control group will be administered oxytocin and placebo, in a double-blind randomized order.
62806073|NCT02091817|EXPERIMENTAL|congenital prosopagnosia|Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.
62806074|NCT02790996|EXPERIMENTAL|Vancomycin - Optimised Regimen|"A single loading dose of 25 mg/kg followed by a maintenance dose of:~Postmenstrual age ≤ 35 weeks - 15 mg/kg 12 hourly; Postmenstrual age \> 35 weeks - 15 mg/kg 8 hourly"
62591565|NCT04722744|EXPERIMENTAL|screwmented metal frameworks based on virtual implant position.|this group will receive a CAD CAM restoration based on virtually planned implant position.
62806075|NCT02790996|ACTIVE_COMPARATOR|Vancomycin - Standard Regimen|Postmenstrual age \< 29 weeks - 15 mg/kg given 24 hourly; Postmenstrual age 29 - 35 weeks - 15 mg/kg 12 hourly; Postmenstrual age \> 35 weeks - 15 mg/kg 8 hourly
62806076|NCT02222610|EXPERIMENTAL|Cohort A|"Subject's will receive monthly treatment of an intravitreal injection of 0.5 mg ranibizumab for 48 weeks.~Starting at week 52, subject's will enter a treat \& extend regime, if a subject achieves a dry macula. For a macula to be considered dry persistent or recurrent fluid must be resolved on spectral domain (SD)-optical coherence tomography (OCT). The interval between injections will not exceed 12 weeks. After a subject is extended beyond 4-weeks \& develops recurrent disease activity, the eye is treated \& the treatment interval for the next visit is reduced by 1 week, compared to the previous treatment interval. The interval between treatments will be reduced by 1-week intervals until a dry macula is again established. Once a dry macula is again achieved, the interval between visits will be extended by 1-week intervals again."
62806077|NCT02222610|EXPERIMENTAL|Cohort B|"Subject's receive monthly treatment of IVT of 0.5 mg ranibizumab for 48 weeks. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia based on 120° or greater wide field angiography. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks \& 24 weeks \& will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.~Starting at week 52, subject's will enter a treat \& extend regime as described in cohort A."
62806078|NCT02222610|EXPERIMENTAL|Cohort C|"Subject's will receive 3 consecutive monthly doses of IVT 0.5 mg ranibizumab followed by PRN treatment with 0.5 mg ranibizumab intravitreal injection. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks \& 24 weeks \& will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.~Starting at week 52, subject's will enter a treat \& extend regime as described in cohort A."
62030448|NCT03839953|ACTIVE_COMPARATOR|Best Medical Therapy|After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
62229484|NCT03274960|EXPERIMENTAL|Griess, Culture and antibiotic|Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
62229485|NCT03274960|NO_INTERVENTION|No Griess, culture, treatment|No Griess reagents added in urine sample, no culture test with blood agar and no treatment with antibiotic for every positive results every trimester
62229486|NCT00210470|EXPERIMENTAL|IRX-2 Regimen|The IRX-2 regimen is the combination of a 2-week course of IRX-2 itself, an initial dose of cyclophosphamide, and a 3-week course of indomethacin, zinc supplementation, and omeprazole.
62591566|NCT04722744|ACTIVE_COMPARATOR|screw-retained metal frameworks based on actual implant position.|this group will receive screw retained CAD CAM restoration based on actual implant position using conventional open tray impression.
62591567|NCT05887167|EXPERIMENTAL|CAR T Therapy with Autologous Hematopoietic Stem Cells (aHSCs)|
62591568|NCT06619314|EXPERIMENTAL|MK-1084 Treatment A|Participants will receive MK-1084 on Day 1 on an empty stomach
62591569|NCT06619314|EXPERIMENTAL|MK-1084 Treatment B|Participants will receive MK-1084 on Day 1 after a high-fat/high-calorie breakfast
62591570|NCT06619314|EXPERIMENTAL|MK-1084 Treatment C|Participants will receive MK-1084 Formulation 1 on Day 1
62806079|NCT04608721||Postpartum Anxiety|Postpartum anxiety will be assessed at 1-3 days (T1), 1(T2), 3 (T3), 6 (T4) and 12 months (T5) postpartum by using the State-Trait Anxiety Inventory (STAI).
62806080|NCT00646685|OTHER|1|
62806081|NCT00646685|OTHER|2|
62806082|NCT00956917|ACTIVE_COMPARATOR|Akern EFG|
62030449|NCT03839953|EXPERIMENTAL|Supervised Exercise Program|Patients will receive best medical therapy plus participation in a 12-week supervised exercise program.
62030450|NCT00439907|ACTIVE_COMPARATOR|End-to-end|End-to-end repair
62806083|NCT00956917|ACTIVE_COMPARATOR|RJL device|
62030451|NCT00439907|ACTIVE_COMPARATOR|Overlap|Overlap repair
62030452|NCT06476717||Prospective monitoring within 1 year follow-up|Patients after kidney transplantation from deceased donors (n=100) were prospectively enrolled and dd-cf DNA levels were measured at defined timepoints (0, D14, 1,2,3,4,6,9 and 12 months) within 12 months.
62229487|NCT04397341|EXPERIMENTAL|biweekly TPF induction|Docetaxel: 50 mg/m2 Cisplatin : 50 mg/m2 5-fluorouracil : 2,500 mg/m2 for 40-48 hrs Leucovorin: 250 mg/m2
62229488|NCT01203748|EXPERIMENTAL|PVI + Lines Ablation|
62229489|NCT01203748|ACTIVE_COMPARATOR|PVI Ablation|
62229490|NCT01203748|EXPERIMENTAL|PVI + CFE|
62229491|NCT03646201|EXPERIMENTAL|FFF|FFF teaches authoritative parenting skills for reducing children's exposure to and intakes of SoFAS, including changes to the family food environment, mothers' own eating behaviors, and food parenting practices.
62229492|NCT03646201|NO_INTERVENTION|Control Group|Data are collected at baseline and post intervention session.
62229493|NCT02430688|EXPERIMENTAL|IRE Group|irreversible electroporation for Unresectable Extremities Neoplasms
62229494|NCT02430688|NO_INTERVENTION|Control|The patients without treatment
62591571|NCT06619314|EXPERIMENTAL|MK-1084 Treatment D|Participants will receive MK-1084 Formulation 2 on Day 1
62591572|NCT06619314|EXPERIMENTAL|MK-1084 Treatment E|Participants will receive MK-1084 without a PPI on Day 1
62591573|NCT06619314|EXPERIMENTAL|MK-1084 Treatment F|Participants will receive MK-1084 with a PPI on Day 5
62591574|NCT00976820|EXPERIMENTAL|Arepanrix/F1 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh \[for children under (\<) 12 months of age\]. The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
62030453|NCT06476717||The effect of treatment cohort|Patients were enrolled at the time of biopsy with histologic and /or molecular signs of rejection. Donor-derived cell-free DNA (dd-cf DNA) were measured at the time of biopsy before centre standard of care treatment and then at weeks 1, 2 and 3 after biopsy.
62030454|NCT06058832|EXPERIMENTAL|Low-intensity Shockwave Therapy|patients will receive 6 sessions, once per week of low-intensity extracorporeal shock wave with the following parameters: - 3000 SWs (energy intensity of 0.09 mJ/mm2) to each of five different sites: three along the penile shaft and two at the crural level plus Sildenafil 25mg of daily dose and 50mg on-demand dose one hour before intercourse for 6 weeks.
62030455|NCT06058832|EXPERIMENTAL|Kegel Exercises|kegel exercises plus sildenafil 25mg of daily dose and 50mg on-demand dose one hour before intercourse for 6 weeks.
62229495|NCT01258335|ACTIVE_COMPARATOR|Omega 3 Fatty acids|"II. Study arms:~a. Participants in the dry AMD study group will be randomized into two arms with a 4:1 ratio: i. Omega-3-fatty acids 4 gm oral daily (Total:840mg EPA/2520mg DHA) (1:3 ratio of EPA to DHA) ( 6 capsules fatty acids)"
62229496|NCT01258335|PLACEBO_COMPARATOR|Olive Oil|ii. Placebo oral daily (6 softgel capsules, each contains 1100 mg olive oil)
62229497|NCT01640275|ACTIVE_COMPARATOR|Propofol based intravenous anesthesia|patients will receive propofol based intravenous anesthesia
62030456|NCT06058832|NO_INTERVENTION|control group|
62229498|NCT01640275|EXPERIMENTAL|Isoflurane Based Inhaled Anesthesia|patients will receive isoflurane based inhaled anesthesia
62229499|NCT00889317||healthy adults|
62229500|NCT05061784||MEN-1 patients who underwent routine thymectomy during parathyroidecotmy|A case series was built after review of available literature by searching four databases (PubMed, Embase, Medline and Cochrane Library) for observational studies or case reports on routine prophylactic TCT for MEN-1 and the development of thymic carcinoids.
62229501|NCT05507931|EXPERIMENTAL|1 Serving of broccoli sprouts|113 grams
62806084|NCT05161416|EXPERIMENTAL|Bubble Group|The children started to blow bubbles 3 minutes before the procedure. The procedure and the bubble blowing intervention were terminated simultaneously.
62806085|NCT05161416|EXPERIMENTAL|Cartoon Group|The children started to watch the cartoon 3 minutes before the procedure. The children were supported by their parents in holding the tablet. The procedure and the cartoon watching intervention were terminated simultaneously.
62806086|NCT05852067|EXPERIMENTAL|Active stimulation of M1|pcTBS was administered to the left M1 at 80% resting motor threshold (RMT), consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline.
62806087|NCT05852067|SHAM_COMPARATOR|SHAM stimulation|The Sham stimulation was delivered using the same protocol, with the coil being orientated at 90° to the scalp so that the magnetic field would be delivered away from the scal
62229502|NCT05507931|EXPERIMENTAL|3 Servings of broccoli sprouts|339 grams
62806088|NCT05940116|EXPERIMENTAL|HS-20117|Participants will receive IV infusion of HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days)
62806089|NCT01095393||Certolizumab pegol (CZP)|Patients with RA receiving treatment with certolizumab pegol (CZP; Cimzia®)
62806090|NCT01095393||Non-biologic DMARD|Subjects with RA receiving treatment with non-biologic DMARD
62806091|NCT02885688|OTHER|Standard-of-Care Treatment for Sepsis|Participants with diagnosis of septic shock in MD Anderson Cancer Center ICU receive standard of care treatment alone for up to 7 days.
62806092|NCT02885688|EXPERIMENTAL|Standard-of-Care Treatment Plus Liquid Nutrition for Sepsis|Participants with diagnosis of septic shock in MD Anderson Cancer Center ICU receive standard of care treatment plus plus liquid nutrition for up to 7 days.
62229503|NCT02150603||Adults with congenital heart disease|
62229504|NCT04528927|EXPERIMENTAL|HCQ+Azithromycin|"* Hydroxychloroquine (HCQ): 600 mg on the 1st day as a starting dose then 200 mg \* 2 / D for 9 days~* Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days~* Usual standard treatment"
62229505|NCT04528927|EXPERIMENTAL|HCQ+Azithromycin+Zinc|"* HCQ: 600 mg on the 1st day as a starting dose then 200 mg \* 2 / D for 9 days~* Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days~* Zinc: 220 mg per day for 10 days~* Usual standard treatment"
62229506|NCT04528927|EXPERIMENTAL|Azithromycin+Doxycycline|"* Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days~* Doxycycline: 200 mg per day for 10 days.~* Usual standard treatment"
62229507|NCT03434678|EXPERIMENTAL|Epidural-General Anesthesia|
62229508|NCT03434678|ACTIVE_COMPARATOR|General Anesthesia|
62229509|NCT03481023|EXPERIMENTAL|Esophageal thermal regulation device|
62229510|NCT03481023|ACTIVE_COMPARATOR|LET monitoring|
62229511|NCT05657483||Endometrial cancer patients|At least 18-year-old patients histologically diagnosed with endometrial cancer who will undergo surgical staging of disease after performing full-body CT-scan 30 days before the enrollment.
62229512|NCT03548246|PLACEBO_COMPARATOR|Placebo|Daily placebo, plus usual maintenance treatment with hydrocortisone and fludrocortisone.
62229513|NCT03548246|EXPERIMENTAL|Abiraterone acetate|Abiraterone acetate administered daily in dose determined in Phase 1, plus usual maintenance treatment with hydrocortisone and fludrocortisone..
62229514|NCT05344729|EXPERIMENTAL|TQB3616 Capsule- Fasted+ TQB3616 Capsule- After meal|Subjects in Arm A will take TQB3616 capsules under fasting and fed state in Cycle 1 and Cycle 2, respectively
62806093|NCT04528914|EXPERIMENTAL|Low-FODMAP diet|37 participants.
62806094|NCT04528914|NO_INTERVENTION|Regular diet|"37 participants. The regular diet will reflect the habitual FODMAP intake in a normal diet.~Diets in both groups will be matched in terms of total energy, fat, protein, carbohydrates and dietary fiber with the usual participant's diet."
62806095|NCT03571126|PLACEBO_COMPARATOR|Placebos group|"Patients will be administered with dexamethasone plus tropisetron from D1 to D3.~Patients will also be administrated with placebos from D1-D4"
62806096|NCT03571126|EXPERIMENTAL|Experimental group|Patients will receive a regimen with dexamethasone plus tropisetron from D1-D3. Patients will also be administrated with olanzapine from D1-D4.
62030457|NCT01024322||Ciprofloxicine or Vigamox or other.|
62030458|NCT01024322||Nonsteroidal (Acular, Voltaren Xibrom, etc)|
62030459|NCT01024322||Steroid (FML, Pred Forte, Flarex, etc.)|
62030460|NCT03797404||Mepolizumab|Patients receiving mepolizumab
62229515|NCT05344729|EXPERIMENTAL|TQB3616 Capsule- After meal + TQB3616 Capsule- Fasted|Subjects in Arm B will take TQB3616 capsules in Cycle 1 and Cycle 2 under fasting state, respectively
62806097|NCT02638766|OTHER|Unique arm|Regorafenib 160mg once a day, frequency: 3 weeks on/1 week off in cycles of 28 days
62806098|NCT05620316|EXPERIMENTAL|Injection group|In this group, patients will be injected with 10 MU of botulinum toxin type A in the masseter muscle.
62806099|NCT05620316|PLACEBO_COMPARATOR|Placebo group|In this group, patients will prick twice in the masseter muscle.
62806100|NCT03620266|EXPERIMENTAL|Bilberry|Dietary supplement with bilberry shakes 2 times daily for 3 months (containing in total 40g of dried bilberry powder equalling 480 g of fresh berries per day). Product development in collaboration with Glucanova AB.
62806101|NCT03620266|PLACEBO_COMPARATOR|Reference/Placebo|Dietary supplement with reference shakes 2 times daily for 3 months (containing no active bilberry or no active oats, but with similar texture and taste as both bilberry and oat). Product development in collaboration with Glucanova AB.
62806102|NCT03620266|EXPERIMENTAL|Bioprocessed oat bran|Dietary supplement with bioprocessed oat bran shakes 2 times daily for 3 months (containing beta glucans from the Glucanova® technology, invented by Glucanova AB).Product development in collaboration with Glucanova AB.
62806103|NCT03620266|EXPERIMENTAL|Combination of oat and bilberry|Dietary supplement with a combination of bioprocessed oat bran and dried bilberry (shakes) 2 times daily for 3 months. Product development in collaboration with Glucanova AB.
62806104|NCT02670577||stage I or II HR-positive, HER2-negative|"Histologically proven invasive stage I and II breast cancer and Hormone Receptor positive \& HER2 negative~\& Axillary lymph node status: 0-3 involved"
62229516|NCT01614535|EXPERIMENTAL|Female group|Female gender patients undergoing thyroidectomy
62229517|NCT01614535|ACTIVE_COMPARATOR|Male group|Male gender patients undergoing thyroidectomy
62421706|NCT01992068||Lung cancer patients ≥ 18 years of age|"Lung cancer patients age ≥ 18 years or older who have:~* Histologically confirmed lung cancer scheduled to undergo conventionally fractionated radiation treatment~* Absence of any severe disorders of esophageal motility (patients with reflux and/or a hiatal hernia are eligible)"
62421707|NCT05284474|NO_INTERVENTION|Control|"Small fetuses will be classified into 5 severity stages and managed as follows:~* SGA: Estimated fetal weight (EFW) between p3 and p10 with normal Dopplers. Ultrasound/2 weeks, elective vaginal delivery at ≥39-40 weeks.~* Stage I: EFW ≤p3 p or EFW p3-10 + UA PI \>p95 and/or UtA PI \>p95, and, at ≥32 weeks, CPR and/or MCA PI \<p5, in 2 occasions \>12 hours apart. Ultrasound weekly, elective vaginal delivery at ≥37 weeks.~* Stage II: AEDF UA in 2 occasions \>12 hours apart. Ultrasound every 48-72h, elective Cesarean delivery at ≥34 weeks.~* Stage III: DV PI \> p95 (or absent DV a wave) or reversed end-diastolic UA \>50% of cycles, in both cases in two occasions \> 6 hours apart. Ultrasound every 24-48h, elective Cesarean delivery at ≥30 weeks.~* Stage IV: reversed DV a wave in two occasions \> 6 hours apart. Elective Cesarean delivery at ≥26 weeks."
62421708|NCT05284474|EXPERIMENTAL|Study|"Doppler protocol (as in controls) + sFlt-1/PlGF ratio cutoffs will be incorporated as follows:~* \<38: Ultrasound biweekly in stage I FGR and every four weeks in SGA. In both cases delivery at ≥39-40 weeks.~* 38-110: In stage I FGR and SGA ultrasound weekly. Delivery at ≥37 weeks.~* \>110: In stage I FGR and SGA ultrasound weekly. Delivery at ≥36 weeks.~* \>110 and concurrent preeclampsia: In stage I FGR and SGA ultrasound every 48h-72h. Delivery at ≥34 weeks.~* \>201: Ultrasound every 48-72h, delivery at ≥34+0 weeks. If concurrent preeclampsia, delivery at ≥32+0 weeks.~* \>655: Ultrasound every 48-72h, delivery at ≥32+0 weeks. If concurrent preeclampsia, delivery at ≥30+0 weeks.~* \>1000: In cases with concurrent PE, delivery at ≥29+0 weeks."
62806105|NCT02670577||HER2+|"Histologically proven invasive T1a or T1b breast cancer~\& Hormone receptor negative or positive~\& HER2 positive~\& Axillary lymph node status: 0-1 involved"
62806106|NCT02670577||Triple Negative|"Histologically proven invasive T1a or T1b breast cancer~\& Hormone receptor negative~\& HER2 negative~\& Axillary lymph node status: 0-1 involved"
62806107|NCT02670577||Neoadjuvant|Stage I or II patients receiving neoadjuvant therapy.
62806108|NCT01859923|EXPERIMENTAL|Group 1: 12 to 17 Years of Age|Participants 12 to 17 years old (inclusive) received adult formulation of delamanid 100 milligrams (mg) (2x50 mg tablets), orally, twice daily (BID) plus optimized background regimen (OBR) up to Day 182. Participants continued to receive OBR up to Day 365.
62806109|NCT01859923|EXPERIMENTAL|Group 2: 6 to 11 Years of Age|Participants 6 to 11 years old (inclusive) received adult formulation delamanid 50 mg (1x50 mg tablet), orally, BID plus OBR up to Day 182. Participants continued to receive OBR up to Day 365.
62806110|NCT01859923|EXPERIMENTAL|Group 3: 3 to 5 Years of Age|Participants 3 to 5 years old (inclusive) received 25 mg pediatric formulation of delamanid (DPF - suspension prepared using dispersible tablet), orally, BID plus OBR up to Day 182. Participants continued to receive OBR up to Day 365.
62806111|NCT01859923|EXPERIMENTAL|Group 4: Birth to 2 Years of Age|"Participants from birth to 2 years old (inclusive) received DPF (suspension prepared using dispersible tablet) for 182 days plus OBR. Participants continued to receive OBR up to Day 365. The DPF dose was based on the participant's body weight during the baseline visit:~* Participants \>10 kilograms (kg) received DPF 10 mg BID plus OBR~* Participants \>8 kg and ≤10 kg received DPF 5 mg BID plus OBR~* Participants ≥5.5 kg and ≤8 kg received DPF 5 mg once per day (QD) plus OBR~Delamanid dose was adjusted as needed for Group 4 participants based on the weight measurement at specified study visits \[Visits 5 (Day 28), 7 (Day 56), 9 (Day 84), 11 (Day 126) and 12 (Day 154)\]."
62806112|NCT01361555|EXPERIMENTAL|Arm 1: Placebo + BMS-820836 (0.5 mg/day)|
62806113|NCT01361555|EXPERIMENTAL|Arm 2: Placebo + BMS-820836 (1 mg/day)|
62806114|NCT01361555|EXPERIMENTAL|Arm 3: Placebo + BMS-820836 (2 mg/day)|
62806115|NCT05449184|EXPERIMENTAL|Balloon Eustachian Tuboplasty with Tympanostomy Tube Insertion|
62806116|NCT05449184|OTHER|Tympanostomy Tube Insertion|
62229518|NCT00517582|EXPERIMENTAL|HOE-140|Administration of HOE-140 (icatibant) 30 mg at time 0 and at 6 hours
62229519|NCT00517582|PLACEBO_COMPARATOR|Placebo|Administration of placebo at time 0 and 6 hours
62229520|NCT02408276||dGEMERIC MRI technique|All tests and imaging are part of standard of care except follow up MRI, which will be performed in a random group from within the cohort and paid for through this grant.
62229521|NCT04481477||Patients COVID-19|Patients over the age of 18 who were admitted with a diagnosis of COVID-19 to any CCSPT unit between March 13, 2020 and April 30, 2020 and were discharged with a recovery result
62806117|NCT05490862|EXPERIMENTAL|Obese Weight Loss group|Low-calorie diet and regular physical trainings will be administered to obese participants (BMI \>30kg/m\^2).
62229522|NCT06476886|ACTIVE_COMPARATOR|Intensive Crisis Intervention (ICI)|ICI is a brief (Average Length of Stay \[ALOS\]: M±SD=4.5±1.4 days), intensive family-centered, skills-based alternative to traditional inpatient psychiatric care. Adolescents participate in 2-3 individual sessions and 1-2 family sessions daily. Based on the cognitive-behavioral model of suicidality, ICI emphasizes that learned, maladaptive cognitive, behavioral, and affective responses to stressors contributing to suicidal behavior can be changed. Master's-level clinicians facilitate this process by engaging adolescents and their families in developing more effective coping skills when faced with potential triggers to suicidal crises.
62229523|NCT06476886|ACTIVE_COMPARATOR|Adolescent Psychiatric Inpatient Unit (APIU)|APIU provides comprehensive assessment and treatment services to children and adolescents with significant psychiatric difficulties and to their families using a multidisciplinary approach. Symptoms and behaviors that led to admission are targeted through a milieu-based model of care and therapeutic group programming. The multidisciplinary treatment team includes a child and adolescent psychiatrist, often in collaboration with an advanced practice provider, psychologist, psychiatric nursing staff including trained mental health specialists, behavioral healthcare clinicians, care managers, rehabilitative care staff, teachers, and parent partners. Average length of stay is 9-11 days. An individualized treatment plan is developed by the entire treatment team, including the patient and caregivers, and includes initial planning for discharge with the primary treatment goal being stabilization of acute psychiatric symptoms. Programming is based on a trauma-informed biopsychosocial approach.
62229524|NCT02673424|ACTIVE_COMPARATOR|FFR-guided stenting|Percutaneous coronaryintervention using drug-eluting stent(s) will be performed by FFR-guided strategy.
62229525|NCT02673424|ACTIVE_COMPARATOR|IVUS-guided stenting|Percutaneous coronaryintervention using drug-eluting stent(s) will be performed by IVUS-guided strategy.
62229526|NCT03490526|EXPERIMENTAL|Root canal disinfection with XP-endo Finisher|
62229527|NCT03490526|ACTIVE_COMPARATOR|Root canal disinfection with passive ultrasonic irrigation|
62229528|NCT04776785|EXPERIMENTAL|Group 1|"In Group 1, one lesion will be received self-assembling peptide P11-4 solution (Curodont™ Repair, Credentis AG, Windisch, Switzerland) followed by 5% NaF varnish (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (test 1). The other lesion will be received 5% NaF varnish alone (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (control).~At the 6th and 12th months after the clinical applications, Profluorid® Varnish application will be repeated for test 1 and control lesions."
62229529|NCT04776785|EXPERIMENTAL|Group 2|"In Group 2, one lesion will be received self-assembling peptide P11-4 solution (Curodont™ Repair, Credentis AG, Windisch, Switzerland) followed by 5% NaF varnish (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (test 1). The other lesion will be received CPP-ACP varnish containing 5% NaF (MI Varnish™, GC America Inc., Alsip, IL, USA) (test 2).~At the 6th and 12th months after the clinical applications; Profluorid® Varnish application will be repeated for test 1 lesions, and MI Varnish™ application will be repeated for test 2 lesions."
62229530|NCT04776785|ACTIVE_COMPARATOR|Group 3|"In Group 3, one lesion will be received CPP-ACP varnish containing 5% NaF (MI Varnish™, GC America Inc., Alsip, IL, USA) (test 2). The other lesion will be received 5% NaF varnish alone (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (control).~At the 6th and 12th months after the clinical applications; MI Varnish™ application will be repeated for test 2 lesions, and Profluorid® Varnish application will be repeated for control lesions."
62229531|NCT04961723|EXPERIMENTAL|MSM Postal delivery|Participants who identify primarily as MSM will receive a home delivered HCV self-test kit in non-identifiable packaging. The kit will include the test, instructions for use (IFU), and information about additional supporting materials, such as access to live chat and a call center for questions about testing
62229532|NCT04961723|EXPERIMENTAL|MSM Peer delivery|Participants who identify primarily as MSM will schedule a peer delivery of the HCV self-test kit and IFU. The peer will provide basic information about the test, what to do if the test is reactive, and how to access to live chat and a call center for questions about testing
62229533|NCT04961723|NO_INTERVENTION|MSM control|Participants who identify primarily as MSM will receive information about standard of care HCV antibody testing available at local testing sites in their community. Participants will also have access to live chat and a call center for questions about HCV testing
62421709|NCT05730088|EXPERIMENTAL|intervention group|"Within the scope of the pre-test, the researcher to the patients who will explain the purpose of the research and agree to participate in the research; Inclusion Criteria Form; Socio-Demographic Information Form; Patient Descriptive Information Form, Modified British Medical Research Council (MRC) Questionnaire, St George Respiratory Questionnaire (Quality of Life Scale) will be used to evaluate patients' symptoms. In addition, the patients in the intervention group will be educated with the training booklet Educational Guide for COPD Patients prepared by the researcher by scanning the literature."
62421710|NCT05730088|NO_INTERVENTION|Not intervention group|The control group will be subjected to the standard COPD training given in the hospital and no intervention will be made by the researcher. After the trials of the experimental group are completed, the control group will be given a home visit, a COPD training booklet, and audio-visual materials.
62421711|NCT03283007|EXPERIMENTAL|Nintedanib|Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months
62806118|NCT05490862|ACTIVE_COMPARATOR|Obese Control group|Traditional weight loss recommendations will be provided to obese participants (BMI \>30kg/m\^2)
62806119|NCT05490862|NO_INTERVENTION|Lean Control group|The data of these subjects will be used as a control
62806120|NCT03641937|EXPERIMENTAL|INVSENSOR00011 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00011 investigational sensor.
62806121|NCT04868955|EXPERIMENTAL|Intervention group|Usual care and oral screen (IQoro®) training.
62229534|NCT04961723|EXPERIMENTAL|PWID peer delivery|Participants who identify primarily as PWID will schedule a peer delivery of the HCV self-test kit and IFU. The peer will provide basic information about the test, what to do if the test is reactive, and how to access to live chat and a call center for questions about testing
62421712|NCT03283007|PLACEBO_COMPARATOR|Placebo|Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
62806122|NCT04868955|NO_INTERVENTION|Control group|Usual care.
62806123|NCT01815944|ACTIVE_COMPARATOR|0.75% Ropivacaine and normal saline|Ultrasound-guided supraclavicular block using 0.75% ropivacaine diluted with normal saline
62030461|NCT03797404||Patients w/o mepolizumab (retrospective)|Retrospective control group of patients not exposed to mepolizumab, included in the COBRA cohort and the ASMATHERM protocol, who had 2 sets of biopsies and BAL within a 6 to 12 month-interval, without change in their treatment. Clinical data for this patients are available at inclusion and after 12 months.
62229535|NCT04961723|NO_INTERVENTION|PWID control|Participants who identify primarily as PWID will receive information about standard of care HCV antibody testing available at local testing sites in their community. Participants will also have access to live chat and a call center for questions about HCV testing
62229536|NCT05837715|EXPERIMENTAL|stabilization group|cervical stabilization exercises
62229537|NCT05837715|EXPERIMENTAL|vibration group|vibration application to the cervical region
62229538|NCT05837715|EXPERIMENTAL|telerehabilitation group|online exercise method
62229539|NCT03407820|ACTIVE_COMPARATOR|1st random 50% of cohort|Absorbable Chromic gut sutures
62229540|NCT03407820|ACTIVE_COMPARATOR|2nd random 50% of cohort|Non-absorbable Nylon sutures
62229541|NCT05621603|EXPERIMENTAL|Training|Participants receive the intervention, which is a training program.
62229542|NCT05621603|NO_INTERVENTION|Control|Participants do NOT receive the intervention, which is a training program. This is a waitlist control comparison model.
62421713|NCT03375996||FLACS group|Patient presenting cataract and scheduled for laser-assisted cataract surgery
62806124|NCT01815944|EXPERIMENTAL|0.75% ropivacaine and dextrose 5%|Ultrasound guided supraclavicular block using 0.75% ropivacaine diluted with dextrose 5%
62806125|NCT01769313|EXPERIMENTAL|Group A|In Group A the anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
62806126|NCT01769313|ACTIVE_COMPARATOR|Group B|Group B acts as a control group where the capsulotomy as well as the lens fragmentation is performed manually.
62229543|NCT00240045|EXPERIMENTAL|1|
62229544|NCT03728413|OTHER|Elderly Non-smoking|RSV A Memphis 37 will be given as intra-nasal drops.
62806127|NCT03507036|EXPERIMENTAL|Treatment|"All patients will undergo treatment with Profound system device. Using the radiofrequency and temperature setting within the FDA approved limits (460 +/- 5kHz and 65-75°C +/- 1°C), patients will be treated one time over the entire suprapatellar region bilaterally and followed for a 6 month period. The acute effect of the radiofrequency application will be determined by subjective and objective analysis using standard, close-up, 3D, cross-polarized, high resolution ultrasound, optical coherence tomography, transepidermal water loss measurements, and/or BTC 2000 measurements.~Biopsies will be taken using 0.33mm WellTech Rapid Core 0.33mm Biopsy Punch. Biopsies will allow investigators to correlate changes seen in skin measurements with histology and gene expression."
62806128|NCT06353594|EXPERIMENTAL|DCB-based|Reduced stent PCI strategy: Culprit lesion revascularization with DCB will be performed after coronary predilation if residual stenosis ≤30%, lack of dissections \>type B and TIMI 3 flow. If the aforementioned culprit-lesion characteristics are not achieved after DCB-PCI, a DES will be implanted.
62806129|NCT06353594|NO_INTERVENTION|DES-based|Control group
62229545|NCT03728413|OTHER|Elderly ex and current smokers|RSV A Memphis 37 will be given as intra-nasal drops.
62229546|NCT03728413|OTHER|Young non-smokers|RSV A Memphis 37 will be given as intra-nasal drops.
62229547|NCT05268874|ACTIVE_COMPARATOR|Group Clavipectoral = Clavipectoral block group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
62030462|NCT03895424|EXPERIMENTAL|Iron Fatty Acid Complex (IFAC)|The iron fatty acid complex encapsulated and administered to the participants
62030463|NCT03895424|EXPERIMENTAL|Micellarized iron fatty acid complex (MIFAC)|Micellarized form of the iron fatty acid complex which is enscapsulated and administered to the participants
62229548|NCT05268874|NO_INTERVENTION|Group Control = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
62229549|NCT01906554|EXPERIMENTAL|Egg Dose|
62229550|NCT04780022||Older patients with cryptogenic embolism and PFO closure|Data (clinical events at last follow-up) on patients older than 60 years who have experienced a previous paradoxical embolism of unknown origin and underwent transcatheter PFO closure will be collected.
62229551|NCT02719587|PLACEBO_COMPARATOR|control group|Control group (8 males, 7 females; 42.54±5.82 years) (SRP): SRP followed by administration of a placebo. The placebo was identical except for the fish oil.
62421714|NCT05188027|EXPERIMENTAL|All participants|All participants will take part in all three testing conditions
62421715|NCT05479760|EXPERIMENTAL|Implementation for anti-HCV reactive client|All clients who test anti-HCV positive at the study CBOs will be assessed for the inclusion criteria. Eligible clients will be informed and offered to participate in the study.
62806130|NCT01742195|OTHER|Nasal EBUS insertion|Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the nose.
62806131|NCT01742195|OTHER|Oral EBUS insertion|Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the mouth.
62806132|NCT06424444|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%)|
62806133|NCT06424444|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution|
62806134|NCT02649140|NO_INTERVENTION|Group 1|Group1 is control group and participants do not need intervention.
62806135|NCT02649140|EXPERIMENTAL|Group 2|Group 2 is vinegar Group and participants in this group are asked to drink 15ml vinegar(Ninghuafu, Sanxi, China)after dinner at noon and evening respectively for a period of four weeks.
62819498|NCT05614531|EXPERIMENTAL|Dose escalation-Cohort 3|dose 3 of EXG001-307 delivered one-time through a venous catheter inserted into a peripheral vein (n=3\~6)
62819499|NCT05442749|EXPERIMENTAL|Niraparib|
62819500|NCT05471076|EXPERIMENTAL|Bolus Delivery, Group 1: First injection - Medium dose, Final injection - Lower dose|The Bolus Delivery Arm Group 1 will receive injections at 2 visits scheduled 3 months apart. At each injection visit the patient will get one dose divided into 2 injections - one in the deltoid muscle of each arm.
62806136|NCT05459467|EXPERIMENTAL|Exercise|"Participants began exercising at 70% of their heart rate reserve (HRR). The Borg scale was used to monitor exertion during the programme. Participants were provided with watches to monitor their HR and also wore ECG monitors to assess for arrhythmias during exercise classes.~Sessions consisted of a circuit of set exercises alternating between aerobic/cardiovascular and resistance exercises. Participants were progressed in a graded fashion (up to a maximum of 85% HRR). Participants were also expected to participate in a predefined exercise session remotely.~Educational session took place in the half an hour following the exercise session. Examples of topics covered included: living with HCM, medications, diet, stress/anxiety management and mindfulness, ICD therapy- what to expect?."
62806137|NCT05459467|NO_INTERVENTION|Usual care|Patients exercised as per usual.
62030464|NCT03895424|ACTIVE_COMPARATOR|Control Ferrous Sulfate|Ferrous sulfate that is provided in the form of a solution along with a capsule that contains the same amount of fat that is present in the other two arms.
62030465|NCT06326801|ACTIVE_COMPARATOR|Treatment A|"1. Resistive Diaphragmatic breathing exercise~2. Pursed lips breathing exercise~3. Conventional stroke physiotherapy"
62030466|NCT06326801|ACTIVE_COMPARATOR|Treatment B|"1. Diaphragmatic breathing exercise~2. Pursed lips breathing exercise~3. Conventional stroke physiotherapy"
62030467|NCT06326801|ACTIVE_COMPARATOR|Control group|a) Conventional stroke physiotherapy
62030468|NCT02040480|EXPERIMENTAL|Sequence 1|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ABC
62030469|NCT02040480|EXPERIMENTAL|Sequence 2|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ACB
62030470|NCT02040480|EXPERIMENTAL|Sequence 3|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BAC
62030471|NCT02040480|EXPERIMENTAL|Sequence 4|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BCA
62030472|NCT02040480|EXPERIMENTAL|Sequence 5|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CAB
62030473|NCT02040480|EXPERIMENTAL|Sequence 6|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CBA
62030474|NCT02388386|EXPERIMENTAL|PROTEUS-SENSOR|The current study is a prospective interventional design with a single experimental arm. The intervention consists of two components: an edible sensor and a wearable receiver health monitor.
62030475|NCT02368353|EXPERIMENTAL|Cognitive behavioral therapy group|weekly group stress-management CBT (SM-CBT) - 1/week 3 months
62806138|NCT01599975|ACTIVE_COMPARATOR|Group A: 2 tabs of 18 mg Concerta daily|20 subjects to receive active study drug in a blinded fashion x 2 weeks, then washout x 2 weeks, then cross over to receive matched placebo x 2 weeks.
62030476|NCT02368353|ACTIVE_COMPARATOR|Reference group|weekly supportive therapy - 1/week 3 months
62030477|NCT06516588|SHAM_COMPARATOR|sham tDCS|Participants will receive sham (placebo) tDCS for 20 minutes, for 10 sessions
62030478|NCT06516588|EXPERIMENTAL|active tDCS|Participants will receive active tDCS for 20 minutes, for 10 sessions
62030479|NCT05358444|ACTIVE_COMPARATOR|Diabetes Prevention Program (DPP)|"Adult participants who are engaged in the Centers for Disease Control and Prevention's (CDC) National Diabetes Prevention Program lifestyle intervention (DPP) as delivered by the Johns Hopkins Brancati Center; this is a 12-month long, group-based lifestyle intervention, delivered by a certified lifestyle coach using a CDC-approved curriculum. This concurrent control group will consist of adults who are enrolled in the Brancati Center's DPP within 6 months of the intervention group start dates, who have children less than 18 years of age living in their households."
62030480|NCT05358444|EXPERIMENTAL|Family Diabetes Prevention Program (Family DPP)|"Adult participants will engage in the family-oriented Diabetes Prevention Program lifestyle intervention (Family DPP); this is an augmented version of the DPP lifestyle intervention. This 12-month, group-based lifestyle intervention will include all elements of the DPP lifestyle intervention as delivered by the Johns Hopkins Brancati Center using a CDC-approved curriculum, with additional child-focused sessions in which adult participants will learn about children's health-related behaviors. Children will be present at the child-focused sessions and family activities, and will be engaged in data collection. These groups will be mixed, in that non-study participants (adults who are eligible for the DPP), may also participate."
62030481|NCT05616533||focused group|Advanced gastric patients that will be treated with neoadjuvant therapy are enrolled. Every clinical decision such as regimen or dosage will be decided by their own doctors without any interventions. Tumor samples will be obtained before the first cycle of the treatment and will be transplanted to the zebrafish model. Compared results will be analyzed in future.
62030482|NCT05062239|ACTIVE_COMPARATOR|Continuance|Continuance prior statin therapy.
62030483|NCT05062239|EXPERIMENTAL|Discontinuance|Discontinuance prior statin therapy. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
62229552|NCT02719587|ACTIVE_COMPARATOR|test group|Test group (8 males, 7 females; 40.87±9.7 years) (SRP+omega-3 PUFAs): SRP followed by omega-3 PUFAs supplementation. The test drug contained omega-3 PUFAs including 6.25 mg EPA and 19.19 mg DHA obtained from the Atlantic salmon Salmo salar.Both test and placebo drugs were taken twice a day by the patients for six months. Subjects came to the clinic every 4 weeks during the 6 month course of the experiment to replenish their medication. Remaining medications were checked for compliance. At each evaluation visit (1, 3 and 6 months), oral soft and hard tissue examinations and adverse-event evaluations were performed.
62806139|NCT01599975|PLACEBO_COMPARATOR|Group B: Matched placebo, 2 tabs daily|Group B to receive matched placebo x 2 weeks, then washout x 2 weeks, then cross over to receive active drug in a blinded fashion x 2 weeks.
62030484|NCT03020147||early BCG|Children received BCG soon after their birth between 2008 and 2013.
62030485|NCT03020147||delayed BCG|Children received BCG when they are 2,5kg between 2008 and 2013.
62030486|NCT01508403||Shuxuetong injection|a cohort using Shuxuetong injection
62030487|NCT06669403|PLACEBO_COMPARATOR|0.9% Sodium Chloride Injection USP|Placebo will be 50mL normal saline (Sodium Chloride), USP sterile solution provided in a 50mL pre-packaged Intravenous (IV) bag.
62030488|NCT06669403|EXPERIMENTAL|OPT101|OPT101 (15-mer peptide) will be provided across 2 cohorts at 1.1 (cohort 1) and 2.8 mg/kg (cohort 2) doses . On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.
62229553|NCT04085406|EXPERIMENTAL|Active Stimulation|Patients will be randomized in a 1:1 ratio to one of two groups: Active Treatment (active stimulation programmed to the settings found to be optimal during the initial open-label period) and a Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V).
62591575|NCT00976820|EXPERIMENTAL|Arepanrix/F2 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
62591576|NCT00976820|EXPERIMENTAL|GSK2340273A/F1 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
62591577|NCT00976820|EXPERIMENTAL|GSK2340273A/F2 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
62591578|NCT03283644||Patients with a BMI over 40|Participants were aged between 27-65 years, BMI \>40 , Co-Morbidities associated with obesity including sleep apnoea, hypertension, depression, hypercholesterolaemia and type 2 diabetes, Undergoing Gastric Band surgery
62591579|NCT03283644||Lean, healthy individuals|Participants were aged between 27-65 years, BMI\<28 , Systemically healthy, taking no prescribed medication
62806140|NCT00769886|EXPERIMENTAL|KetoNaph|KetoNaph (ketotifen fumarate 0.025%, naphazoline HCl 0.05%) ophthalmic solution
62421716|NCT00629629|EXPERIMENTAL|Intervention|"Mothers in the intervention group received dietary advice based on Brazilian guidelines \[Ten steps for the healthy eating: Feeding guidelines for Brazilian children from birth to two years \] during monthly home visits from 2 weeks to 6 months postpartum and then every 2 months thereafter until 1 y postpartum."
62591580|NCT05658055|ACTIVE_COMPARATOR|Amoxicillin combined with vonoprazan|The subjects will be given 20mg vonoprazan twice a day and 1000mg amoxicillin three times a day. These two drugs were taken continuously for 14 days
62806141|NCT00769886|ACTIVE_COMPARATOR|Naphazoline|Naphazoline HCl 0.05% ophthalmic solution
62806142|NCT00769886|ACTIVE_COMPARATOR|Ketotifen|Ketotifen fumarate 0.025% ophthalmic solution
62806143|NCT00769886|PLACEBO_COMPARATOR|Vehicle|Vehicle of KetoNaph ophthalmic solution
62806144|NCT02102035|OTHER|Dorsal digital island flap|The flap is used to cover the soft-tissue defects of the fingers.
62806145|NCT02147886|EXPERIMENTAL|Cabaletta 15gr|Cabaletta 15gr
62806146|NCT02147886|EXPERIMENTAL|Cabaletta 30gr|Cabaletta 30gr
62806147|NCT05042700|EXPERIMENTAL|Melatonin-Placebo sequence|50% of the included patients will receive 4 weeks of treatment with melatonin, followed by a 4 week wash out period, and then 4 weeks of treatment with placebo. The treatments are blinded.
62806148|NCT05042700|EXPERIMENTAL|Placebo-Melatonin sequence|50% of the included patients will receive 4 weeks of treatment with placebo, followed by a 4 week wash out period, and then 4 weeks of treatment with melatonin. The treatments are blinded.
62421717|NCT00629629|NO_INTERVENTION|Control|Mothers in the control group received routine medical assistance without any involvement of the research team. The study staff provided no materials to mothers on the Control Arm.
62030489|NCT05008354|ACTIVE_COMPARATOR|Pyridoxine|
62030490|NCT05008354|PLACEBO_COMPARATOR|Placebo|
62421718|NCT02677402|EXPERIMENTAL|cold water immersion|Participants immersed their lower limbs in water of \~12°C
62030491|NCT03069222||Patient|SCI patients enrolled at Kessler Institute Rehabiliation
62030492|NCT03069222||Control|age and gender matched with patient enrolled
62421719|NCT02677402|EXPERIMENTAL|contrast water therapy|Participants immersed their lower limbs in water : alternated every 2 min between \~12°C and \~35°C for CWT
62421720|NCT02677402|EXPERIMENTAL|thermo neutral immersion|Participants immersed their lower limbs in water of \~35°C
62421721|NCT03628001|OTHER|A|ERCP with (Group A) ES before biliary SEMS placement
62421722|NCT03628001|OTHER|B|ERCP without (Group B) ES before biliary SEMS placement
62421723|NCT04506346||OSAHS|patients with OSAHS, undergoing UPPP
62421724|NCT00254488|EXPERIMENTAL|Lithium (LI)|Participants will receive 9 weeks of treatment with lithium
62806149|NCT05627973||Aortic valve replacement with mechanical valves|
62806150|NCT05627973||Aortic valve replacement with bioprostheses|
62806151|NCT04356495|SHAM_COMPARATOR|Vitamins|"Patients in this arm will receive a vitamin supplement (AZINC forme et vitalité®) during 10 days"
62806152|NCT04356495|EXPERIMENTAL|Telmisartan|Patients in this arm will receive Telmisartan (Micardis® 20 mg) during 10 days
62806153|NCT04356495|EXPERIMENTAL|Ciclesonide|Patients in this arm will receive ciclesonide (Alvesco® 160 µg ) during 10 days
62806154|NCT04356495|EXPERIMENTAL|interferon β-1b|Patients in this arm will receive interferon β-1b (Extavia® 9,6 MUI/300 µg ) during 5 days
62806155|NCT03102554|EXPERIMENTAL|Genetic Testing|Subjects will provide a DNA sample, which will be screened for variants in genes related to DSD/hypospadias. Probands/parents who wish to receive results of genetic testing related to DSD/hypospadias will receive these results directly from the research study. Parents who receive results of genetic testing for probands 17 years old or younger will complete questionnaires at the time of enrollment, right after receiving genetic results, and 3 months after receiving genetic results.
62421725|NCT00254488|EXPERIMENTAL|Divalproex (DV)|Participants will receive 9 weeks of treatment with divalproex
62421726|NCT03001869|EXPERIMENTAL|68Ga-PSMA PET/CT|68Ga-HBED-CC-PSMA PET/CT
62806156|NCT03827408|ACTIVE_COMPARATOR|Midazolam group (MDZ)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 0.5 mg/kg Midazolam.
62806157|NCT03827408|EXPERIMENTAL|Dexmedetomidine group (DEX)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 5µg/kg Dexmedetomidine.
62806158|NCT03827408|EXPERIMENTAL|Combination of Midazolam and Dexmedetomidine (MDZ/DEX)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 0.3 mg/kg Midazolam, and 3µg/kg Dexmedetomidine respectively.
62806159|NCT03992079|NO_INTERVENTION|Control|The control group will receive standard preoperative and postoperative directions, with the anesthesiologist and surgeon's preferences for analgesia during and after surgery.
62806160|NCT03992079|EXPERIMENTAL|Experimental|The experimental group will receive routine directions for surgery and a ReCOVER patient education document on the Enhanced Recovery protocol, with instructions on preoperative preparation, postoperative wound care, pain management, preventing and managing constipation, activity limitations, and return precautions. The information sheet will be provided to patients in clinic and reviewed with a member of the healthcare team to ensure an understanding of the plan.
62806161|NCT01775644||Metastatic Colorectal Cancer Participants|"Administration of treatment will be as used in normal daily routine under local labelling in 4 subgroups- participants with liver and/or lung metastases, potentially resectable after a response to a systemic therapy and clinically operable; participants with tumor related symptoms, risks for complications or fast progression for whom quick proliferation control is needed; asymptomatic participants (indolent tumor) without the option of a metastases resection (no pressure for remission) for whom the aim of the therapy is proliferation control and participants without classification."
62806162|NCT02800616|EXPERIMENTAL|Full intervention group|The full intervention ('The Healthy Primary School of the Future') is implemented in two schools involving extended school hours in which healthy nutrition, physical exercise, environmental, social, and educational activities are incorporated, during a period of four years.
62806163|NCT02800616|EXPERIMENTAL|Partial intervention group|The partial intervention ('The Physical Activity School') is implemented in two other schools: involving extended school hours in which healthy nutrition, physical exercise, environmental, social, and educational activities are incorporated, during a period of four years. Hence, this intervention only differs from the full intervention on the absence of nutritional intervention. Instead, children bring their own food from home, as they normally do.
62591581|NCT05658055|EXPERIMENTAL|Probiotics combined with vonoprazan and amoxicillin|The subjects will be given 20mg vonoprazan twice a day, 1000mg amoxicillin three times a day and probiotics three times a day. These three drugs were taken continuously for 14 days.
62591582|NCT01996410|ACTIVE_COMPARATOR|Chemotherapy 1 Acupuncture|"Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms."
62806164|NCT02800616|NO_INTERVENTION|Control group|Four primary schools will function as control schools. The control schools have a representative Dutch school environment in terms of lifestyle education, school hours and amount of Physical Education (PE) lessons.
62421727|NCT02238470||Oral anticoagulants|Patients who will receive oral anticoagulants indefinitely for the secondary prevention of cardioembolic stroke
62421728|NCT02908607|EXPERIMENTAL|experimental|3 groups of patients will be participated: women with cancer, women with premalignant lesions and women with a normal cervix. All patients will undergo the same examination
62421729|NCT06569680|EXPERIMENTAL|Mosunetuzumab Treatment Group|Participants in this group will receive Mosunetuzumab for eight (8) 21-day cycles. Total participation is about 3.5 years.
62421730|NCT04654286|ACTIVE_COMPARATOR|Control group (Nerve transfer procedure)|Patient will receive nerve transfer procedure without augmentation
62421731|NCT04654286|EXPERIMENTAL|Experimental group (Nerve transfer with HAM-AdMSC composite wrapping)|Following nerve transfer procedure, the end-to-end anastomosis will be wrapped with HAM-AdMSC composite as augmentation
62591583|NCT01996410|ACTIVE_COMPARATOR|Chemotherapy 2 Acupuncture|"Chemotherapy 2: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) on day 1 every 2 weeks for 4 cycles followed by Taxol (80mg/m2) on day 1 weekly for 12 cycles. Patients who randomize to the experimental (acupuncture) group will undergo acupuncture the morning of every treatment day of the adriamycin/cytoxan cycles; they will receive acupuncture for every third Taxol treatment, beginning with the first treatment. They will receive a total of 8 acupuncture sessions: 4 with the adriamycin/cytoxan cycles and 4 with the Taxol cycles. Both groups will fill out MDASI on day 3 (+/- 1 days) of each Adriamycin/Cytoxan cycle; they will also fill out the MDASI on day 3 (+/- 1 days) of every third Taxol treatment for a total of 8 MDASI forms."
62591584|NCT01996410|ACTIVE_COMPARATOR|Chemotherapy 3 Acupuncture|"Chemotherapy 3: In the adjuvant setting- This group will receive Taxotere (75mg/m2) and Cytoxan (600 mg/m2) on day 1 every 3 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Cytoxan for a total of 4 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 4 MDASI forms."
62806165|NCT01353404|EXPERIMENTAL|fenofibrate 65mg, fed condition, per oral|
62806166|NCT01353404|EXPERIMENTAL|fenofibrate 65mg, fasting condition, per oral|
62421732|NCT02670993|EXPERIMENTAL|Control group : Singing sessions.|Patients will participate to singing working sessions. They will continue to take their usual treatments during the study period.
62421733|NCT02670993|ACTIVE_COMPARATOR|Control group : Painting sessions.|Patients will continue to participate to painting work sessions, and to take their usual treatments during the study.
62806167|NCT01353404|ACTIVE_COMPARATOR|fenofibrate 160mg, fed condition, per oral|
62030493|NCT06557265|EXPERIMENTAL|NKX019 - CAR NK cell therapy|Phase 1: NKX019 plus cyclophosphamide
62030494|NCT02479412|EXPERIMENTAL|Sequence 1|Placebo once daily for 14 days in Period 1, 58 µg AZD7594 once daily for 14 days in Period 2 and 250 µg AZD7594 once daily for 14 days in Period 3
62030495|NCT02479412|EXPERIMENTAL|Sequence 2|Placebo once daily for 14 days in Period 1, 250 µg AZD7594 once daily for 14 days in Period 2 and 800 µg AZD7594 once daily for 14 days in Period 3
62030496|NCT02479412|EXPERIMENTAL|Sequence 3|Placebo once daily for 14 days in Period 1, 800 µg AZD7594 once daily for 14 days in Period 2 and 58 µg AZD7594 once daily for 14 days in Period 3
62030497|NCT02479412|EXPERIMENTAL|Sequence 4|58 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 800 µg AZD7594 once daily for 14 days in Period 3
62030498|NCT02479412|EXPERIMENTAL|Sequence 6|250 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 58 µg AZD7594 once daily for 14 days in Period 3
62030499|NCT02479412|EXPERIMENTAL|Sequence 8|800 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 250 µg AZD7594 once daily for 14 days in Period 3
62030500|NCT02479412|EXPERIMENTAL|Sequence 5|58 µg AZD7594 once daily for 14 days in Period 1, 800 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
62030501|NCT02479412|EXPERIMENTAL|Sequence 7|250 µg AZD7594 once daily for 14 days in Period 1, 58 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
62030502|NCT02479412|EXPERIMENTAL|Sequence 9|800 µg AZD7594 once daily for 14 days in Period 1, 250 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
62030503|NCT03392311|EXPERIMENTAL|AD-MSCs plus Calcipotriol ointment group|AD-MSCs（adipose-derived multipotent mesenchymal stem cells ） intravenous injection at a dose of 2 million cells/kg at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks. The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
62030504|NCT02921997|EXPERIMENTAL|Arm 1|10 Subjects: one dose of 15 µg of A/H3N2v, at Day 1
62030505|NCT02921997|EXPERIMENTAL|Arm 2|10 Subjects: two doses of 3.75 µg of AH7N9 AS03,at Day 1 and at Day 29
62030506|NCT02921997|EXPERIMENTAL|Arm 3|10 Subjects: two doses of 3.75 µg of A/H7N9, at Day 1 and Day 29
62030507|NCT04287023|EXPERIMENTAL|Group Physical therapy|1 physical therapists and groups of 10 patients during the sessions
62030508|NCT04287023|ACTIVE_COMPARATOR|Individual physical therapy|1 physical therapist and 1 patient during the sessions
62229554|NCT04085406|SHAM_COMPARATOR|Sham Stimulation|Patients will be randomized in a 1:1 ratio to one of two groups: Active Treatment (active stimulation programmed to the settings found to be optimal during the initial open-label phase) and a Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V).
62806168|NCT04735874||Children ages 10.0 to 18.0|
62030509|NCT03021226|EXPERIMENTAL|Group I: Adults|Participants in Group I will be adults ages 20 to 24 years of age, 50 hours of instruction provided over a six-week period, and address three major topic areas: Fatherhood Development, Relationship Enhancement, and Financial Literacy/Work.
62030510|NCT03021226|NO_INTERVENTION|Group II: No Intervention: Adults|Participants in Group II will be adults ages 20 to 24 years of age who do not receive any hours of intervention.
62030511|NCT06670976|EXPERIMENTAL|Treatment (propranolol, RT, surgery)|Patients receive propranolol PO BID for 2 weeks prior to standard of care RT (weeks 1 and 2) and then during and after standard of care RT (weeks 3-7). Treatment continues in the absence of disease progression or unacceptable toxicity until the time of standard of care surgery (week 8). Additionally, patients undergo PET scan and/or CT scan during screening and may undergo blood and tissue biopsy sample collection throughout the trial.
62030512|NCT02978274||experimental group|MMF withdrawal by engraftment post haplo-SCT
62030513|NCT02978274||control group|MMF withdrawal by 2 month post haplo-SCT
62030514|NCT05975268|EXPERIMENTAL|JS005 150mg (recombinant humanized monoclonal antibody against IL-17A)|
62030515|NCT05975268|EXPERIMENTAL|JS005 300mg (recombinant humanized monoclonal antibody against IL-17A)|
62030516|NCT05975268|PLACEBO_COMPARATOR|Placebo|
62030517|NCT05625048|EXPERIMENTAL|Intervention group|The intervention group receives same treatment as the control groups and in addition transperinal ultrasound guided instruction in pelvic floor muscle training at 2nd and 3rd session.
62030518|NCT05625048|NO_INTERVENTION|Control group 1|The patients recieve standard care including three physiotherapist sessions; within one week preoperatively, one week postoperatively at catheter removal, and six weeks postoperatively
62030519|NCT05625048|NO_INTERVENTION|Control group 2|The patients recieve standard care including three physiotherapist sessions; within one week preoperatively, one week postoperatively at catheter removal, and six weeks postoperatively
62030520|NCT06635382|ACTIVE_COMPARATOR|Universal single bond adhesive|
62030521|NCT06635382|EXPERIMENTAL|DMSO application before Universal single bond adhesive|
62030522|NCT04913363|EXPERIMENTAL|Walking|This contemplative activity will see users taken to a local green space area near their center and encouraged to walk around the space. It is anticipated walks will last around 15-20 minutes.
62030523|NCT04913363|EXPERIMENTAL|Citizen Science|This cerebral activity sees users engage with local green spaces, under the instruction of a citizen scientist, to learn about the intricacies of the space. This may include lichen counts (or similar) where the main outcome is learning based.
62229555|NCT01757808|EXPERIMENTAL|Ranolazine|
62806169|NCT02653326|EXPERIMENTAL|Telerehabilitation|In addition to routine care, patients in this arm will receive a telerehabilitation strategy comprised by a portable EKG monitor and a smartphone application.
62806170|NCT02653326|ACTIVE_COMPARATOR|Routine Care|Patients allocated to routine care will receive care as enforced by current practice guidelines. This care included nutritional counseling, depression screening, drug therapy for the management of comorbidities and physical exercise without telemonitoring.
62421734|NCT00287235|EXPERIMENTAL|Group 1: Standard Medical Therapy + MARS|Patients who were randomized to Group 1 received daily MARS treatments in addition to Standard Medical Therapy for 5 consecutive days.
62421735|NCT00287235|ACTIVE_COMPARATOR|Group 2: Standard Medical Therapy Only|Patients who were randomized to Group 2 received standard medical treatment only.
62591585|NCT01996410|ACTIVE_COMPARATOR|Chemotherapy 4 Acupuncture|"Chemotherapy 4: In the neoadjuvant setting- This group will receive Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose) day 1 every 3 weeks for 6 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Carboplatin/Perjeta treatment for a total of 6 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 6 MDASI forms."
62806171|NCT01948609||Treated with RRSO|Women with the BRCA gene 1/2 mutation who choose to undergo risk reducing salpingo-oophorectomy (RRSO) treatment.
62806172|NCT01948609||No RRSO treatment|Women with the BRCA gene 1/2 mutation who choose non-surgical treatment.
62030524|NCT04913363|EXPERIMENTAL|Planting|This physical activity will see users, lead by a local Master Gardener, engage with planting vegetables/fruit in raised beds. Not only will this allow users a chance to engage physically with nature, but it is anticipated that the grown produce will be used for center users.
62421736|NCT06265584|EXPERIMENTAL|phase II single arm study of 2 step ATG dosing in prevention of aGVHD|The primary outcome for the study is GRFS rate at one-year post transplant. GRFS will be estimated using Kaplan Meier method The reported GRFS with recent phase III trial of PTCY/tac/MMF in transplant from matched related and unrelated donors at 1 year follow up was 52%. We hypothesize that with 2 step ATG/Tac/Mini MTX regimen, we can achieve a one year GRFS of 69%.
62030525|NCT02279758|EXPERIMENTAL|METFORMIN|850mg of metformin every 12 hours.
62421737|NCT02163694|ACTIVE_COMPARATOR|Veliparib Placebo with Carboplatin and Paclitaxel|Placebo capsules for veliparib (120 mg) administered by mouth twice daily (BID) on Days -2 through 5 of a 21-day cycle. Carboplatin administered intravenously over approximately 15 to 30 minutes at AUC 6 mg/ml/min immediately following paclitaxel infusion on Day 1 of every cycle. Paclitaxel administered intravenously over approximately 1 hour at a dose of 80 mg/m² on Days 1, 8, and 15 of every cycle.
62421738|NCT02163694|EXPERIMENTAL|Veliparib with Carboplatin and Paclitaxel|Veliparib capsules (120 mg) administered by mouth twice daily (BID) on Days -2 through 5 of a 21-day cycle. Carboplatin administered intravenously over approximately 15 to 30 minutes at AUC 6 mg/ml/min immediately following paclitaxel infusion on Day 1 of every cycle. Paclitaxel administered intravenously over approximately 1 hour at a dose of 80 mg/m² on Days 1, 8, and 15 of every cycle.
62421739|NCT05860608|EXPERIMENTAL|ACTIVE investigational arm (NT-proBNP + AI-ECHO)|NT-proBNP will be performed in all individuals randomized to the ACTIVE arm at the same visit as informed consent; those with elevated NT-proBNP (≥125pg/ml) will undergo an Us2.ai (AI-enabled report) handheld echocardiogram within one month of NT-proBNP testing. A standard echocardiographic study will be performed if the AI-echo is non-diagnostic.
62421740|NCT05860608|OTHER|CONTROL routine care arm|Patients randomized to usual care will undergo standard clinical follow-up, with NT-proBNP and conventional echocardiography prescribed only as per usual practice.
62421741|NCT04142866|EXPERIMENTAL|A-tDCS & speech-language therapy|Anodal transcranial direct current stimulation (2 milliamps \[mA\]) plus aphasia therapy for 16 sessions (20-minutes per each 60-minute treatment session) over the course of 8 weeks. The electrical current will be administered over ventral inferior frontal gyrus. The stimulation will be delivered at an intensity of 2 milliamps (mA) for a maximum of 20 minutes.
62421742|NCT04142866|SHAM_COMPARATOR|Sham-tDCS & speech-language therapy|Sham transcranial direct current stimulation (2 milliamps \[mA\]) plus aphasia therapy for 16 sessions (20-minutes per each 60-minute treatment session) over the course of 8 weeks. Electrodes will be placed as in A-tDCS. Current will be ramped up for the first 30 seconds following which the intensity will drop to 0 milliamps (mA).
62421743|NCT06459076|NO_INTERVENTION|Routine Care group|After induction of general intravenous anesthesia, 100% oxygen mask ventilation was used for pre-oxygenation, wait 2-3 min to vecuronium take effect and reaching end-expiratory oxygen saturation \> 90%, the Optiflow THRIVETM system nasal plug is placed in the proper position, but without oxygen supply, and the tracheal intubation is started.
62421744|NCT06459076|EXPERIMENTAL|THRIVE group|After induction of general intravenous anesthesia, 100% oxygen mask ventilation was used for pre-oxygenation, wait 2-3 min to vecuronium take effect and reaching end-expiratory oxygen saturation \> 90%, Immediately after ceasing assisted ventilation, the age-appropriate nasal prongs were applied and weight-specific high flow rates delivered using the(Transnasal humidified rapid-insufflation ventilatory exchange, THRIVE) Optiflow THRIVE TM system. The flow rates applied were as follows: 0-15 kg, 2 litres kg-1 min-1；15-30 kg, 35 litres min-1; 30-50 kg, 40 litres min-1; and\>50 kg, 50 litres min-1,and the tracheal intubation is started
62030526|NCT03089086|ACTIVE_COMPARATOR|Group A|Students within schools randomised to group A will receive two doses of licensed 4CMenB vaccine after baseline oropharyngeal swab with an interval of 1 to 2 months between doses, with the first dose given at the baseline visit in 2017.
62030527|NCT03089086|NO_INTERVENTION|Group B|Students within schools randomised to group B will receive the licensed 4CMenB vaccine following completion of baseline and 12 month oropharyngeal swab in 2018.
62030528|NCT06369350|PLACEBO_COMPARATOR|Placebo|
62030529|NCT06369350|ACTIVE_COMPARATOR|Vitamin B6 25mg|
62030530|NCT06369350|ACTIVE_COMPARATOR|Vitamin B6 50mg|
62030531|NCT06369350|ACTIVE_COMPARATOR|Vitamin B6 100mg|
62806173|NCT01137032|EXPERIMENTAL|Pandel Cream 0.1%|Pandel Cream 0.1%
62806174|NCT01307319|EXPERIMENTAL|BDP HFA 80 mcg/day|Participants/parents administer 40 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
62806175|NCT01307319|EXPERIMENTAL|BDP HFA 160 mcg/day|Participants/parents administer 80 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
62806176|NCT01307319|PLACEBO_COMPARATOR|Placebo nasal aerosol once daily|Participants/parents administer placebo (a spray with no medication in each nostril) once daily for 15 days.
62030532|NCT00868023|EXPERIMENTAL|1|CHF 1535 DPI : BDP/Formo 400/24 µg
62030533|NCT00868023|ACTIVE_COMPARATOR|2|CHF 1535 pMDI HFA : BDP/Formo 400/24 µg
62806177|NCT04906122|EXPERIMENTAL|Experimental group|The grandmothers in the intervention group will be given breastfeeding counseling before discharge. Home monitoring will be performed in the 2nd week, 3rd and 6th months after the counseling. In each follow-up, breastfeeding knowledge and attitudes of the grandmothers, breastfeeding success of mothers, attitude towards breastfeeding, perception of postpartum support and newborn growth parameters will be determined. As a result of the research, the effect of breastfeeding training given to grandmothers will be evaluated breastfeeding status of the first 6 months, self-efficacy, attitude, social support perceptions, breastfeeding continuity and newborn growth parameters of primiparous mothers who have just given birth.
62806178|NCT04906122|NO_INTERVENTION|Control Group|Control Group: No additional attempt or routine call will be made to grandmother and mothers in the control group. The questionnaires will be given to the mothers at the same time for filling the surveys after birth, one month, 3 and 6 months follow up will be done with grandmothers and mothers.
62806179|NCT02611180||Arm 1: Acute skin GVHD|"* When clinically indicated, patients will undergo a skin biopsy to confirm a suspected diagnosis of acute or chronic GVHD, or to assess the status of their previously diagnosed acute or chronic GVHD. After the necessary samples are obtained for optimal medical care of the patient, two 6 mm punch biopsies (or four 4 mm punch biopsies) will be performed for research purposes, one (or two) of the affected area and one (or two) of a non-affected area (normal skin).~* Patients who have clinical resolution of their acute or chronic GVHD will undergo one additional 6 mm punch biopsy (or two additional 4 mm punch biopsies) of the previously affected area. This additional biopsy should occur within 10 cm of the previous affected area sample.~* With each skin biopsy, peripheral blood will be obtained by venipuncture or cannulation of an indwelling venous access device.~* Two optional skin biopsies. One on day 5-7 of treatment and one on day 28 from the start of treatment."
62806180|NCT02611180||Arm 2: Chronic skin GVHD|"* When clinically indicated, patients will undergo a skin biopsy to confirm a suspected diagnosis of acute or chronic GVHD, or to assess the status of their previously diagnosed acute or chronic GVHD. After the necessary samples are obtained for optimal medical care of the patient, two 6 mm punch biopsies (or four 4 mm punch biopsies) will be performed for research purposes, one (or two) of the affected area and one (or two) of a non-affected area (normal skin).~* Patients who have clinical resolution of their acute or chronic GVHD will undergo one additional 6 mm punch biopsy (or two additional 4 mm punch biopsies) of the previously affected area. This additional biopsy should occur within 10 cm of the previous affected area sample.~* With each skin biopsy, peripheral blood will be obtained by venipuncture or cannulation of an indwelling venous access device.~* Two optional skin biopsies. One on day 5-7 of treatment and one on day 28 from the start of treatment."
62806181|NCT02742961||Peripheral nerve block|Intervention arm. Participants who receive a peripheral nerve block identified through submission of an appropriate physician billing code
62806182|NCT02742961||No peripheral nerve block|Control arm. Participants who do not receive a peripheral nerve block identified through lack of a submission of an appropriate physician billing code
62806183|NCT00416208|EXPERIMENTAL|Bortezomib|Bortezomib 1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
62806184|NCT00416208|NO_INTERVENTION|Observation|Observational arm
62806185|NCT04968158|EXPERIMENTAL|Group A: Etoricoxib/Tramadol|Administered orally, one packet of etoricoxib / tramadol granules diluted in 100 ml of water, every 24 hours for 7 days.
62806186|NCT04968158|ACTIVE_COMPARATOR|Group B: Acetaminophen / Tramadol|Administered orally, one tablet, every 8 hours, for 7 days.
62806187|NCT02416999|EXPERIMENTAL|patient group|
62806188|NCT05515835||rocuronium|The patient will be given 50mg of rocuronium intravenously for induction.
62806189|NCT02222571|ACTIVE_COMPARATOR|Control|9-week parenting group focused on safety
62806190|NCT02222571|EXPERIMENTAL|Parents and Tots Together Program|Parents and Tots Together Program is a 9-week, group-based parenting intervention
62229556|NCT01757808|PLACEBO_COMPARATOR|Placebo|
62806191|NCT05927038|EXPERIMENTAL|Caffeinated coffee|4 sachets (1.8 grams each) of instant, caffeinated coffee
62806192|NCT05927038|EXPERIMENTAL|Decaffeinated coffee|4 sachets (1.8 grams each) of instant, decaffeinated coffee
62806193|NCT03675503|NO_INTERVENTION|Control|No change in the standard of care.
62806194|NCT03675503|EXPERIMENTAL|Fall Prevention Decision Support|"Nursing assesses patient using the Assistive Device Checklist and provides assistive devices to patients, if appropriate.~Decision support aimed at preventing hospital falls and empowering nurses."
62806195|NCT02053012||PVT-192|
62806196|NCT02464436|EXPERIMENTAL|human retinal progenitor cells (hRPC)|Single subretinal administration of human retinal progenitor cells (hRPC)
62806197|NCT02302768|PLACEBO_COMPARATOR|Placebo|Patients randomized to receive same pharmaceutical form (capsule) used for the two Semet groups, with the same excipients but the active drug.
62030534|NCT00868023|EXPERIMENTAL|3|CHF 1535 DPI : BDP/Formo 100/6 µg
62030535|NCT00868023|ACTIVE_COMPARATOR|4|CHF 1535 pMDI HFA : BDP/Formo 100/6 µg
62229557|NCT04436939|EXPERIMENTAL|PEEK healing abutment|Healing abutment made of polyetheretherketone (PEEK)
62030536|NCT00868023|PLACEBO_COMPARATOR|5|Placebo
62229558|NCT04436939|ACTIVE_COMPARATOR|Ti healing abutment|Healing abutment made of titanium (Ti)
62229559|NCT04168684|EXPERIMENTAL|Attachment and Biobehavioral Catch-up (ABC)|10 sessions that focused on parental nurturance, and sensitivity
62229560|NCT04168684|ACTIVE_COMPARATOR|Developmental Education for Families (DEF)|10 sessions that focused on cognitive development
62229561|NCT06164509|ACTIVE_COMPARATOR|Alphintern|Group A will receive (Alphintern® tablet, Amoun, Egypt),
62229562|NCT06164509|ACTIVE_COMPARATOR|Alzyme Max|Group B will receive (Limitless Allzyme Max®, tablet, Eva, Egypt)
62229563|NCT06164509|NO_INTERVENTION|Placebo|Group C will not receive medication
62229564|NCT00196404|EXPERIMENTAL|1|
62229565|NCT00196404|EXPERIMENTAL|2|
62229566|NCT00196404|PLACEBO_COMPARATOR|3|
62229567|NCT00985946|EXPERIMENTAL|panobinostat|This is a single arm trial. All patients will take panobinostat
62229568|NCT04121494|EXPERIMENTAL|Group A|BCG-vaccinated, 1x10\^9 vp, aerosol
62229569|NCT04121494|EXPERIMENTAL|Group B|BCG-vaccinated, 5x10\^9 vp, aerosol
62229570|NCT04121494|EXPERIMENTAL|Group C|BCG-vaccinated, 1x10\^10 vp, aerosol
62229571|NCT04121494|EXPERIMENTAL|Group D|BCG-vaccinated, highest tolerated dose aerosol + placebo IM; Randomized with Group E, blind
62229572|NCT04121494|EXPERIMENTAL|Group E|BCG-vaccinated, highest tolerated dose IM + placebo aerosol; Randomized with Group D, blind
62229573|NCT04121494|EXPERIMENTAL|Group F|BCG-non vaccinated, highest tolerated dose, aerosol
62229574|NCT05927857|EXPERIMENTAL|Phase 1b/II|"* Infusional nal-IRI (ONIVYDE, free form) 50/60/70 mg/m2 over 90 minutes day 1.~* Infusional Ramucirumab(Cyramza)8 mg/kg over 60 minutes day 1.~* oral Trifluridine/Tipiracil TAS-102 (LONSURF) 30 mg/m2/b.i.d. day 1-5.~* Every 14 days count as one cycle."
62806198|NCT02302768|ACTIVE_COMPARATOR|80-Semet|Patients randomized to receive selenomethionine at 80 mcg per day.
62806199|NCT02302768|ACTIVE_COMPARATOR|160-Semet|Patients randomized to receive selenomethionine at 160 mcg per day.
62806200|NCT03273673|EXPERIMENTAL|Biofeedback Intervention|The 6-week biofeedback training program is focused on altering loading and movement asymmetry during biweekly sessions on non-consecutive days (12 sessions). The biofeedback training program will provide sensory (visual and tactile) feedback to the subject to heighten awareness of asymmetrical movement strategies (e.g. load shift, movement asymmetry) during a squat. The two exercises that will be completed during the biofeedback training program will be a visual feedback squat and a resisted squat (tactile feedback). Each of these tasks will be completed 30 (3 sets of 10 repetitions) times per session. We will provide a 20 second rest between trials, and a 10 minute break between the visual and tactile feedback exercises to decrease the effect of fatigue.
62806201|NCT03273673|NO_INTERVENTION|Control|The 6-week attention control group program will focus on providing educational information to the participants related to the clinical and sports expectations as they are released to return to sport. These participants will be asked to meet 6 times during the 6-week intervention time period. Three of these visits will be completed in person and three will be completed using an online educational module (6 sessions). The online sessions will be completed in week 1, week 3, and week 5 while the in person sessions will be completed during week 2, week 4, and week 6.
62229575|NCT04309344|EXPERIMENTAL|RF|The bipolar radiofrequency-based chondroplasty device is used in the COBLATION mode (yellow) with The WEREWOLF system and the wand FLOW 50 in Lo mode (low) which are approved by the FDA for chondroplasty and debridement of the articular cartilage
62421745|NCT05974865|EXPERIMENTAL|Healthy Babies and Health Moms|Healthy Babies and Healthy Moms was designed as a 20-minute communication skills-based computer program based on key social learning principles designed to empower women to more actively and productively use targetted skills to improve the medical dialogue of their prenatal visits.
62591586|NCT01996410|NO_INTERVENTION|Chemotherapy 1 No Acupuncture|"Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms."
62806202|NCT03125226|EXPERIMENTAL|Supportive care (TracelT hydrogel)|Patients undergo transurethral resection of bladder tumors and receive TracelT hydrogel via injection. Patients undergo standard of care radiation therapy within 8 weeks of TracelT hydrogel placement.
62806203|NCT01145742|EXPERIMENTAL|self-management support and BP telemonitoring|collaborative intervention involving home BP monitoring, home behavior change counseling to enhance self management, and intensification of treatment by primary care doctors
62806204|NCT01145742|NO_INTERVENTION|usual care|usual primary care management of BP. lipids, and glucose
62806205|NCT05955846|EXPERIMENTAL|Z+ VAO IOL|FG-80030.1 hydrophobic
62229576|NCT04309344|ACTIVE_COMPARATOR|Control|The mechanical shaver is used to remove superficial fibrillations.
62421746|NCT05974865|ACTIVE_COMPARATOR|Baby Basics Prenatal Guide|The Baby Basics Prenatal Guide, published by the What to Expect Foundation, was used in a face-to-face educational session with a study research assistant during which pregnancy related information was personalized by reviewing relevant sections of the Baby Basics prenatal guide.
62806206|NCT03515577|EXPERIMENTAL|Diagnostic ([68]Ga-PSMA-11 PET/CT, Axumin PET/CT)|Participants receive (68)Ga-PSMA-11 IV and 60-90 minutes later, undergo PET/CT imaging over 3 hours. Participants also undergo best standard of care Axumin PET/CT within 2 weeks before or after (68)Ga-PSMA-11 PET/CT.
62806207|NCT01814527|ACTIVE_COMPARATOR|Docosahexaenoic acid|The experimental group will be given a standardized dose of omega-3 fatty acid containing 2200mg of DHA for 30 days after onset of concussion or longer for those with continued symptomatology. Brain Armor an over the counter DHA supplements that is independently tested and certified by the National Science Foundation Athletic Banned Substance Certified for Sport Program. The Docosahexaenoic acid supplement has 440mg of DHA per capsule and each subject will be given 5 capsules of Brain Armor once daily for a DHA dose of 2200mg/day.
62806208|NCT01814527|PLACEBO_COMPARATOR|Placebo|The placebo group will be given an equal amount of capsules.
62806209|NCT02454738|EXPERIMENTAL|Chest CT scan|Two follow-up ultralow dose chest CT scans will be taken 3 months and 1 year after the initial ultralow dose chest CT scan in close contact at high risk for developing multidrug- or extensively drug-resistant tuberculosis.
62421747|NCT04954209||Hospital program of resumption|Program of resumption with physical activities in the hospital
62030537|NCT05005975|EXPERIMENTAL|Dersimelagon 200mg|
62421748|NCT04954209||Non hospital program of resumption|Program of resumption outside hospital with discovery sessions
62421749|NCT00209495|PLACEBO_COMPARATOR|A|
62421750|NCT00209495|EXPERIMENTAL|B|Pregabalin
62421751|NCT00209495|EXPERIMENTAL|C|Pregabalin + dexamethasone
62421752|NCT06372379||Adults who attended the emergency department|
62030538|NCT01742767|ACTIVE_COMPARATOR|Cis (D1) + Pem (D1)|Cisplatinum 75 mg/m2 d 1 Pemetrexed 500 mg/m2 d 1 q d 21
62030539|NCT01742767|EXPERIMENTAL|CIS (D1+8) + Pem (D!)|Cisplatinum 40 mg/m2 d 1 + d 8 Pemetrexed 500 mg/m2 d 1 q d 21
62030540|NCT04137380|EXPERIMENTAL|Mirikizumab - Intravenous (IV)|Participants received a single dose of 300 milligram (mg), 600 mg and 1200 mg mirikizumab administered IV using a forearm vein infused over at least 30 minutes, 60 minutes and 2 hours.
62030541|NCT04137380|PLACEBO_COMPARATOR|Placebo - IV|Participants received a single dose of placebo administered IV using a forearm vein.
62030542|NCT04137380|EXPERIMENTAL|Mirikizumab - Subcutaneous (SC)|Participants received a single dose of 200 mg, 400 mg mirikizumab administered SC as 2 injections, 1 into the skinfold of each lower abdominal wall quadrant (left and right).
62030543|NCT04137380|PLACEBO_COMPARATOR|Placebo - SC|Participants received a single dose of placebo administered SC as 2 injections, 1 into the skinfold of each lower abdominal wall quadrant (left and right).
62030544|NCT05892679|EXPERIMENTAL|Acupressure|"Acupressure will be formulated according to the standards of the World Health Organization and applied to the determined points in a certain order. Since the reactions of individuals will be different from each other, the stiffness and pressure will be adjusted according to the sensitivity of the individual in order not to cause tissue damage. Pressures will be applied manually by a single practitioner. A total of 8 points with parallel points will be studied, with four points in each lower extremity. There will be a total of 12 minutes of pressure on 8 points, with an average of 90 seconds on each point, and approximately 10-15 seconds of warming and preparatory scrubbing before pressing on the area where the points are located.~Considering the studies done, a person will be given acupressure three times a week for four weeks."
62229577|NCT05253677|EXPERIMENTAL|CT-guided PCI strategy|"QAngio CT Research Edition is a software suite providing several functionalities for the analysis of coronary computed tomography angiography (CCTA) scans to extract and present relevant information on the coronary vasculature for further clinical investigation.~Also, QAngio CT Research Edition allows to export this information for later viewing during x-ray angiography (XA) procedures to help physicians plan and guide the interventional procedure."
62229578|NCT05253677|ACTIVE_COMPARATOR|intravascular ultrasound (IVUS)-guided PCI strategy|Intravascular ultrasound (IVUS) is an invasive intravascular imaging technique able to visualize the coronary vessel. The use of IVUS-guided PCI has been endorsed an recommended by the European Society of Cardiology. The device is considered part of standard of clinical care.
62229579|NCT04556461|EXPERIMENTAL|Tralokinumab|Tralokinumab 600mg loading dose s.c., followed by 300mg every other week.
62229580|NCT00671944|EXPERIMENTAL|1|Low protein diet
62591587|NCT01996410|NO_INTERVENTION|Chemotherapy 2 No Acupuncture|"Chemotherapy 2: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) on day 1 every 2 weeks for 4 cycles followed by Taxol (80mg/m2) on day 1 weekly for 12 cycles. Patients who randomize to the experimental (acupuncture) group will undergo acupuncture the morning of every treatment day of the adriamycin/cytoxan cycles; they will receive acupuncture for every third Taxol treatment, beginning with the first treatment. They will receive a total of 8 acupuncture sessions: 4 with the adriamycin/cytoxan cycles and 4 with the Taxol cycles. Both groups will fill out MDASI on day 3 (+/- 1 days) of each Adriamycin/Cytoxan cycle; they will also fill out the MDASI on day 3 (+/- 1 days) of every third Taxol treatment for a total of 8 MDASI forms."
62819501|NCT05471076|EXPERIMENTAL|Bolus Delivery, Group 2: First injection - Medium dose, Final injection - Higher dose|The Bolus Delivery Arm Group 2 will receive injections at 2 visits scheduled 3 months apart. At each injection visit the patient will get one dose divided into 2 injections - one in the deltoid muscle of each arm.
62030545|NCT05892679|NO_INTERVENTION|Control|No intervention will be made to the control group only the data will be collected at the same time as the study group.
62806210|NCT00972192|ACTIVE_COMPARATOR|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and counseling immediately after the baseline interview. Patients underwent phlebotomy and serologic testing and results were disclosed the following day with post-test counseling (before they were discharged from the hospital).
62030546|NCT05795595|EXPERIMENTAL|CTX131|Administered by IV infusion following lymphodepleting chemotherapy.
62030547|NCT03752229|EXPERIMENTAL|HTL-STREFA S.A.safety lancet type 610|
62806211|NCT00972192|NO_INTERVENTION|HIV testing post-discharge|Participants who were randomized to the control group were given a referral card and an appointment, by the interviewers, to return for free HIV testing and counseling at Mulago hospital one week after discharge. Participants who returned had their transport reimbursed.
62806212|NCT01290523|EXPERIMENTAL|Yttrium-90 liver radioembolization|Patients who receive liver-directed therapy with Yttrium-90 glass microspheres (TheraSphere)
62030548|NCT03752229|EXPERIMENTAL|HTL-STREFA S.A.safety lancet type 553-556|
62030549|NCT03752229|EXPERIMENTAL|HTL-STREFA S.A.safety lancet type 430|
62030550|NCT03752229|EXPERIMENTAL|HTL-STREFA S.A.safety lancet type 420|
62030551|NCT03752229|EXPERIMENTAL|HTL-STREFA S.A.safety lancet type 520|
62806213|NCT03918616||PD + AD|Patients with newly-diagnosed (onset of suggestive symptoms not later than 3 months) Parkinson disease (PD) or Alzheimer disease (AD) with no previous specific treatment, no anti-inflammatory drugs assumed in the three months preceding the enrolment and no chronic inflammatory diseases or cancer.
62030552|NCT03752229|EXPERIMENTAL|HTL-STREFA S.A.safety lancet type 450|
62229581|NCT03565120|EXPERIMENTAL|Arm-R|patients in this arm will receive aggressive thoracic radiotherapy.
62229582|NCT03034629|EXPERIMENTAL|Short-term aerobic exercise|One bout of moderate intensity exercise (75% of maximal predicated heart rate).
62229583|NCT01751074|EXPERIMENTAL|Part A|All subjects will be of Caucasian descent and will receive single dose of Rosuvastatin 10 mg for 1 day (Day 1) during treatment period 1, then will receive Darapladib 160 mg once daily (QD) for 10 days (Day 5 to 14) in treatment period 2. Immediately following this, all subjects will receive the combination of Darapladib 160 mg and Rosuvastatin 10 mg for 1 day (Day 15) and continued Darapladib dosing of 160 mg QD for additional 3 days (Days 16 to 18) in treatment period 2.
62030553|NCT03752229|EXPERIMENTAL|HTL-STREFA S.A.safety lancet type 545-549|
62030554|NCT03752229|EXPERIMENTAL|Owem Mumford lancet|
62030555|NCT03752229|EXPERIMENTAL|Medicore lancet|
62421753|NCT01227954|OTHER|WBRT with Hippocampal Avoidance|Whole brain radiotherapy (WBRT) with hippocampal avoidance using intensity-modulated radiation therapy (IMRT)
62421754|NCT04650516|EXPERIMENTAL|Endocare treatment|Patients will receive the treatment on a dedicated virtual reality headset to display the Endocare® application, with high quality headphones
62421755|NCT04650516|ACTIVE_COMPARATOR|Digital control treatment|Patients will receive the digital control on a dedicated tablet to display the digital control, with high quality headphones
62421756|NCT05877235|EXPERIMENTAL|Quercetin|Trans-quercetin, 1000 mg daily for 60 days
62806214|NCT03918616||Control group|An age and gender matched control group (n=50) was formed, on a volunteer basis, by the spouse of the probands participating in the study.
62806215|NCT04393415|ACTIVE_COMPARATOR|patients receiving LGF|
62806216|NCT04393415|NO_INTERVENTION|patients not receiving LGF nor PRP|
62030556|NCT03752229|EXPERIMENTAL|Arkray lancet|
62030557|NCT03752229|EXPERIMENTAL|Medipurpose lancet|
62030558|NCT03752229|EXPERIMENTAL|Sterilance lancet|
62030559|NCT03752229|EXPERIMENTAL|Dynarex lancet|
62030560|NCT03752229|EXPERIMENTAL|Ypsomed lancet|
62030561|NCT03752229|EXPERIMENTAL|Promismed lancet|
62030562|NCT03752229|EXPERIMENTAL|Cambridge Sensors lancet|
62030563|NCT02644460|EXPERIMENTAL|Stratum A|Appropriate dose RT will be administered in 30-33 fractions over approximately 6 weeks for Stratum A patients. Treatment with abemaciclib (LY2835219) will start on the same day as RT and continue twice daily during and after RT for a maximum treatment duration of 2 years. Investigators plan to treat a maximum of 4 cohorts of research participants (dosage levels 1, 2, 3, and 4) with escalating doses of abemaciclib (LY2835219) starting with dose level 1 (80% of adult dose). A cycle is defined as 28 days and the first 6 weeks of therapy will constitute the dose-limiting toxicity (DLT)-evaluation period. Participants must take abemaciclib by mouth as intact capsules.
62421757|NCT05877235|EXPERIMENTAL|Atorvastatin|Atorvastatin, 80mg daily for 60 days.
62421758|NCT05877235|PLACEBO_COMPARATOR|Control|Starch, 1000mg daily for 60 days.
62806217|NCT04393415|ACTIVE_COMPARATOR|patients receiving Platelet rich plasma|
62030564|NCT02644460|EXPERIMENTAL|Stratum B - enrollment is closed for this study arm|Abemaciclib (LY2835219) will be administered orally on a twice daily basis continuously for 28 days, which defines one cycle. The maximum treatment duration will be 2 years. Investigators plan to treat a maximum of 4 cohorts of research participants (dosage levels 1, 2, 3, and 4) with escalating doses of abemaciclib starting with dose level 1 (80% of adult dose). Dose escalation will be independent of Stratum A escalation. A cycle is defined as 28 days and the first 4 weeks of therapy will constitute the DLT-evaluation period. Participants must take abemaciclib by mouth as intact capsules.
62229584|NCT01751074|EXPERIMENTAL|Part B|The decision to initiate Part B will be made by the GSK study team based on an evaluation of data from Part A. Part B will consist of a cohort of healthy subjects of Far-East Asian descent and will be conducted similar to Part A.
62421759|NCT00819273||1|patients who have records of clinic visit with circulatory and endocrine internal medicines of nationwide tertiary hospitals within the last one year.
62421760|NCT06576089|OTHER|Traditional recruitment and enrollment processes (TRAD)|Traditional participant information letter and consent form only (TRAD)
62806218|NCT03018236|EXPERIMENTAL|Alcohol N-acetylcysteine|600 mg N-acetylcysteine capsule by mouth, every 12 hours for 8 weeks
62806219|NCT03018236|PLACEBO_COMPARATOR|Alcohol Placebo|A placebo capsule matching color and smell of the active medication
62030565|NCT01939028|EXPERIMENTAL|Diagnostic (SLN mapping, biopsy, surgery)|Patients undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.
62806220|NCT03018236|EXPERIMENTAL|Cocaine N-acetylcysteine|600 mg N-acetylcysteine capsule by mouth, every 12 hours for 8 weeks
62030566|NCT06635603||hypertension|patients admitted to emergency department with grade 3 (systolic ≥180 and/or diastolic ≥110 mmHg) blood pressure
62030567|NCT06114446|EXPERIMENTAL|Experimental group|Participants will be educated with immersive virtual reality simulation for postoperative nursing care of a patient who underwent colorectal surgery
62030568|NCT06114446|OTHER|Control group|Participants will be educated with simulation manikin for postoperative nursing care of a patient who underwent colorectal surgery
62030569|NCT01042457|OTHER|Mycophenolate mofetil|
62030570|NCT06433180|PLACEBO_COMPARATOR|Administration of the sham (PLACEBO)|Oral, capsulized, frozen capsules without fecal matter but containing cryopreservation solution will be administered at the same volume and same time point as in the experimental group. Taken in one day in two separate meals. Administration of the sham after colon cleaning.
62806221|NCT03018236|PLACEBO_COMPARATOR|Cocaine Placebo|A placebo capsule matching color and smell of the active medication
62421761|NCT06576089|EXPERIMENTAL|Supported, women-centred and aphasia-friendly recruitment and enrollment process (ORDER)|Supplementing traditional recruitment methods (detailed participant information letter and consent form) with women-centred, aphasia-friendly recruitment video and leaflet (ORDER)
62421762|NCT05969782||Endurant II|Patients with aortoiliac aneurysm submitted to EVAR with Endurant II.
62421763|NCT05969782||Zenith|Patients with aortoiliac aneurysm submitted to EVAR with Zenith.
62421764|NCT03159988|EXPERIMENTAL|Non-randomized treatment group|12 weeks of daily does subcutaneous injection of Angiotensin-(1-7) 100 mcg/kg/day
62421765|NCT04440007|EXPERIMENTAL|Abivertinib with Standard of Care|STI-5656 (abivertinib maleate) capsule administered orally 200 mg QD up to 28 days or until hospital discharge, in addition to standard of care
62421766|NCT04440007|ACTIVE_COMPARATOR|Standard of Care|Standard of care treatments for COVID-19 as determined appropriate by the Investigator
62421767|NCT04903717|EXPERIMENTAL|Intervention - Best Practice Alert|Providers randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record which alerts to the presence of HFrEF and the fact that the patient is not currently prescribed an MRA. A link to an order set for MRAs (or to potassium binders should a patient be hyperkalemic) will provided, along with a link to current best practices surrounding the use of MRAs.
62591588|NCT01996410|NO_INTERVENTION|Chemotherapy 3 No Acupuncture|"Chemotherapy 3: In the adjuvant setting- This group will receive Taxotere (75mg/m2) and Cytoxan (600 mg/m2) on day 1 every 3 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Cytoxan for a total of 4 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 4 MDASI forms."
62806222|NCT03708107|EXPERIMENTAL|Percutaneous Microelectrolysis (MEP)|"Principal MTrP will be detected by digital palpation in the upper trapezius. Algometry will be used to determine if the Pain Pressure Threshold (PPT) is equal or less than 3 KgF/cm2. If not, the patient will be not included. A mark will be done in the MTrP.~MEP® will be applied with a 0,30 x 25 mm acupuncture needle. The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.~Algometry will be done immediately finished the intervention, after 10 minutes and at 24 hs."
62806223|NCT03708107|EXPERIMENTAL|Ischemic compression|"Principal MTrP will be detected by digital palpation in the upper trapezius. Algometry will be used to determine if the Pain Pressure Threshold (PPT) is equal or less than 3 KgF/cm2. If not, the patient will be not included. A mark will be done in the MTrP with a marker.~Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.~Algometry will be done immediately finished the intervention, after 10 minutes and at 24 hs."
62030571|NCT06433180|EXPERIMENTAL|Administration of fecal microbiota transplantation ( FMT capsules)|Oral, capsulized, frozen fecal microbiota transplantation FMT delivering approximatively 24 g of stools taken in one day in two separate meals. Administration of the FMT after colon cleaning.
62030572|NCT00578994||Oxford® Meniscal Unicompartmental Knee|Patients with PKA using the Oxford® Meniscal Unicompartmental Knee System
62030573|NCT05637021||Control group|Healthy people were randomly divided into CO2 group and control group, with 20 cases in each group. After bowel preparation, volunteers underwent colonoscopy, with air routinely insufflated into the control group during colonoscopy.
62030574|NCT05637021||Carbon dioxide group|Healthy people were randomly divided into CO2 group and control group, with 20 cases in each group. After bowel preparation, volunteers underwent colonoscopy, with CO2 insufflated into the control group during colonoscopy.
62030575|NCT05637021||After appendectomy group|Volunteers after appendectomy were included in the appendectomy group. After bowel preparation, all volunteers underwent colonoscopy, air routinely insufflated into the appendectomy group.
62421768|NCT04903717|NO_INTERVENTION|Usual Care|Providers will not receive a best practice alert for eligible patients and will continue to care for patients as usual.
62421769|NCT03904667||Watson on oncology recommends surgery|
62421770|NCT03904667||Watson on oncology does not recommend surgery|
62421771|NCT03343054|EXPERIMENTAL|talazoparib|0.75 mg/day or 1.0 mg/day
62806224|NCT02337868|EXPERIMENTAL|High Dose Expanded|15 subjects will receive 4 mcg of HydroVax-001 IM and 4 subjects will receive placebo IM on Days 1 and 29.
62806225|NCT02337868|EXPERIMENTAL|High Dose Sentinel|5 subjects will receive 4 mcg of HydroVax-001 IM and 1 subject will receive placebo IM on Days 1 and 29.
62806226|NCT02337868|EXPERIMENTAL|Low Dose Expanded|15 subjects will receive 1 mcg of HydroVax-001 IM and 4 subjects will receive placebo IM on Days 1 and 29.
62030576|NCT03337529|EXPERIMENTAL|Vitamin C|RLS positive patients will be assessed for the severity. They will be given 200 mg Vitamin C for 8 weeks duration. Patients will be re-assessed for the severity of restless leg syndrome.
62229585|NCT03752918|EXPERIMENTAL|MDMA|MDMA (1.5mg/kg)
62229586|NCT03752918|PLACEBO_COMPARATOR|Niacin|Niacin (250mg)
62229587|NCT01385878|ACTIVE_COMPARATOR|Phacoemulsification with 1.8mm incision|Microcoaxial phacoemulsification was performed using a 1.8mm clear corneal incision
62229588|NCT01385878|ACTIVE_COMPARATOR|Phacoemulsification with 2.2mm incisi|Microcoaxial phacoemulsificaiton will be performed through 2.2mm incision
62229589|NCT01435330|EXPERIMENTAL|BVS857|
62229590|NCT01435330|PLACEBO_COMPARATOR|Placebo|
62229591|NCT00837551|PLACEBO_COMPARATOR|1 Placebo cream|0% cream 12 patients
62229592|NCT00837551|ACTIVE_COMPARATOR|2. Cream|0.5% WBI-1001 cream 12 patients
62229593|NCT00837551|ACTIVE_COMPARATOR|3. Cream|1.0% WBI-1001 cream 12 patients
62421772|NCT04457531|EXPERIMENTAL|LiuWeiLuoBi Group|Patients will receive the treatment of LiuWeiLuoBi Granule for 12 weeks,twice a day added to the standard medical treatment.
62421773|NCT04457531|OTHER|Control Group|Patients will receive the standard medical treatment for 12 weeks.
62421774|NCT00061945|EXPERIMENTAL|Treatment (alemtuzumab and combination chemotherapy)|See detailed description.
62421775|NCT06045832|PLACEBO_COMPARATOR|Control group|At the beginning of the study, the demographic characteristics of the study participants are recorded in detail, including sex, age, history of smoking, alcohol consumption, presence of bad breath and GI symptoms. The patients who are randomized into control group receive water gargle treatment (Gargle 3 times a day for 2 min each time for 7 days) Then, all patients were retested for oral H. pylori using H. pylori saliva test.
62421776|NCT06045832|ACTIVE_COMPARATOR|MAXPOWER Biological Antibacterial Liquid group|At the beginning of the study, the demographic characteristics of the study participants are recorded in detail, including sex, age, history of smoking, alcohol consumption, presence of bad breath and GI symptoms. The patients who are randomized into MAXPOWER Biological Antibacterial Liquid group receive MAXPOWER Biological Antibacterial Liquid gargle treatment (Gargle 3 times a day for 2 min each time for 7 days) Then, all patients were retested for oral H. pylori using H. pylori saliva test.
62421777|NCT01319305||BREATHE I participatants|
62421778|NCT04653701||Patients with hepatocellular carcinoma treated with TAMDEM® 100 micron and SEQURE® microcatheter|Patients included in this study and with chemoembolization indications will be superselective embolized using TAMDEM® 100 micron preloaded particles (Doxorubicin) and SEQURE® microcatheter combination (SYNERGIC EFFECT). Objective tumoral response and 30 days-complications (Safety) are primary outcomes.
62421779|NCT01058876|EXPERIMENTAL|Usual Cigarette|African American and White Smokers will smoke their usual cigarette and also undergo an oral pharmacokinetics protocol after administration of 3 mg deuteriumlabeled nicotine and 5 mg deuterium-labeled cotinine.
62421780|NCT01058876|EXPERIMENTAL|Low-yield Cigarette|"African American and White smokers will smoke a commercial cigarette with a machine-determined nicotine yield of approximately 50% of their usual brand."
62421781|NCT06703463|EXPERIMENTAL|MK-1167 Period 1|On Day 1 a single dose of MK-1167 will be administered.
62591589|NCT01996410|NO_INTERVENTION|Chemotherapy 4 No Acupuncture|"Chemotherapy 4: In the neoadjuvant setting- This group will receive Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose) day 1 every 3 weeks for 6 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Carboplatin/Perjeta treatment for a total of 6 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 6 MDASI forms."
62806227|NCT02337868|EXPERIMENTAL|Low Dose Sentinel|5 subjects will receive 1 mcg intramuscularly (IM) of HydroVax-001 and 1 subject will receive placebo IM on Days 1 and 29.
62806228|NCT01263964||stroke, troponin elevation|Patients with stroke (proven by cerebral imaging) and troponin elevation undergoing coronary angiogram
62806229|NCT01263964||non-stemi (controll group)|Patients with troponin elevation suggesting non-stemi undergoing coronary angiogram
62229594|NCT03364712||pregnant|Pregnant women receiving routine medical care, including venipuncture.
62229595|NCT03364712||non-pregnant|Women not pregnant receiving routine medical care, including venipuncture.
62229596|NCT05199220||Questionnaire|Participant must complete a questionnaire about injury during crossfit practice
62229597|NCT05494177||Premium monovision|Patients will undergo to implantation of an extended depth of field intraocular lens in the dominant eye and a trifocal diffractive intraocular lens in the non-dominant eye.
62229598|NCT05494177||Bilateral trifocal diffractive implantation|Patients will undergo to bilateral implantation of trifocal diffractive lenses.
62229599|NCT04258436|ACTIVE_COMPARATOR|Group 1-Block Arm|Group1 will receive an ultra-sound guided serratus anterior block after induction of general anesthesia
62229600|NCT04258436|NO_INTERVENTION|Group 2-No Block Arm|Group 2 will not receive a serratus block after induction of general anesthesia
62421782|NCT06703463|EXPERIMENTAL|MK-1167 Period 2|There will be a washout of at least 35 days between MK-1167 dosing in Period 1 and the first diltiazem dose in Period 2. In Period 2, diltiazem will be administered once daily (QD) for 49 consecutive days with a single dose of MK-1167 coadministered on Day 3.
62421783|NCT01932801|NO_INTERVENTION|Assessment-only|Assessment-only control condition
62421784|NCT01932801|ACTIVE_COMPARATOR|HRC|Harm reduction counseling, which entails provision of feedback and support of harm reduction goals and safer drinking provided at one-month intervals over a 3-month period.
62421785|NCT01932801|EXPERIMENTAL|XR-NTX+HRC|3 doses of active medication (380 mg injection/month) + Harm reduction counseling at one-month intervals over three months.
62591590|NCT05402969||Patients with long-term implantation|Patients undergone CI more than 6 months ago. After the study is presented to the patient and the egligibility criterias are verified, the patient is proposed to sign a consent form (visit 0). Once the consent form is signed, the visit 1 is scheduled (0 to 90 days after the visit 0). During the visit 1 TIM measurements are performed, including depth sounding and spectroscopy, and adversed affects if any are collected.
62591591|NCT05402969||Recently implanted patients|Patients enrolled at their pre-op appointments (visit 0 - egligibilty criterias are verified and the consent collected). Visit 1 (0 to 90 days after visit 0) is a surgery. TIM measurements, icluding deep sound and spectroscopy, are performed after the CI and all adverse events are noted. CBCT is routinely done the next day after CI. TIM measurements (as well as adverse event collection) are repeated during visits 2, 3, 4, 5 and 6 (appoitments 15 days, 1, 2, 3 and 6 months after the surgery).
62591592|NCT03089268||Group 1|"Individuals scheduled for colonoscopy at Hospital Universitari i Politècnic La Fe, participating in the Valencian CRC screening program, will be recruited.~Polypectomy or biopsy will be performed if necessary (following current guidelines).~Specific molecular analysis of serrated lesions and CRC will be carried out."
62229601|NCT04832425|EXPERIMENTAL|PRAX-114|40 mg PRAX-114 once daily
62229602|NCT04832425|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62229603|NCT01765465|EXPERIMENTAL|Rowachol|Rowachol treatment with 200mg PO tid, on postoperative 1 days to 3 months
62806230|NCT05930652||Young adults|The population of Polish Students, who graduated from high schools/ passed leaving exams, started university studies between 2020 and 2023, and were living in Poland during this period (2020-2023: COVID-19, lockdown, economic crisis, political changes, climate changes, and the war in Ukraine).
62806231|NCT02016976|ACTIVE_COMPARATOR|EMLA analgesic cream|Patients who have had EMLA analgesic cream applied to area before pacemaker implantation
62229604|NCT01765465|PLACEBO_COMPARATOR|Placebo|Placebo treatment with 200mg PO tid, on postoperative 1 days to 3 months
62806232|NCT02016976|ACTIVE_COMPARATOR|Routine treatment|Patients who have received routine treatment (Dormicum 2.5 mg and Pethidine 25 mg) before and during pacemaker implantation
62421786|NCT01932801|PLACEBO_COMPARATOR|Placebo+HRC|3 doses of placebo + harm reduction counseling at one-month intervals over a three-month period
62806233|NCT05917912|ACTIVE_COMPARATOR|Sequence A|i)screening and randomization; ii) baseline period (3 weeks); iii) treatment period 1 with placebo(3 weeks); iv) wash-out period (3 weeks); v), treatment period 2 with ATX-01(3 weeks); vi) follow-up visit
62806234|NCT05917912|ACTIVE_COMPARATOR|Sequence B|i)screening and randomization; ii) baseline period (3 weeks); iii) treatment period 1 with ATX-01(3 weeks); iv) wash-out period (3 weeks); v), treatment period 2 with placebo (3 weeks); vi) follow-up visit
62030577|NCT03337529|PLACEBO_COMPARATOR|Placebo|RLS positive patients will be assessed for the severity. They will be given 200 mg placebo for 8 weeks duration. Patients will be re-assessed for the severity of restless leg syndrome.
62030578|NCT03135951|EXPERIMENTAL|SPI-2012|"* SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF per cycle)~* Supplied in 1 mL prefilled, single-use syringes for subcutaneous injection~* Administered on Day 2 of each cycle after TC administration"
62229605|NCT03772444|ACTIVE_COMPARATOR|Beetroot juice|
62229606|NCT03772444|PLACEBO_COMPARATOR|Control group 1|
62421787|NCT00828516|EXPERIMENTAL|Usual treatment plus acupuncture|Acupuncture and moxibustion, individualised according to participant priorities, delivered once weekly for 7 treatments (Series 1) followed by 6 treatments (Series 2) if participant wishes to continue treatment
62819502|NCT05471076|PLACEBO_COMPARATOR|Bolus Delivery, Group 3: First injection - Placebo, Final injection - Placebo|The Bolus Delivery Arm Group 2 will receive injections at 2 visits scheduled 3 months apart. At each injection visit the patient will get one dose divided into 2 injections - one in the deltoid muscle of each arm.
62229607|NCT03772444|SHAM_COMPARATOR|Control group 2|
62819503|NCT05471076|EXPERIMENTAL|Fractionated Delivery, Group 1: First injection - Medium dose, Final injection - Lower dose|The first dose for the Fractionated Delivery Arm Group 1 will be divided into 6 smaller amounts (2 visits per week for 3 weeks). The second dose will be given about 3 months later and will be given all at once. At each injection visit for the first dose, the patient will get one amount divided into 2 injections - one in the deltoid muscle of each arm.
62229608|NCT00354458|PLACEBO_COMPARATOR|1|
62229609|NCT00354458|EXPERIMENTAL|2|
62229610|NCT02314910||Failed implant|There is only one group, being the group of patients of which the oral implant needed to be removed for clinical reasons.
62229611|NCT03279263|EXPERIMENTAL|MLR-1023 25mg QD|MLR-1023 25mg QD Tablet
62229612|NCT03279263|EXPERIMENTAL|MLR-1023 50mg QD|MLR-1023 50mg QD Tablet
62421788|NCT02773446|EXPERIMENTAL|Cohort 1 group A|Volunteers will receive 8 logs of E. coli strain B7A after overnight fast
62421789|NCT02773446|EXPERIMENTAL|Cohort 1 group B|Volunteers will receive 9 logs of E. coli strain B7A after 90 minute fast
62229613|NCT03279263|EXPERIMENTAL|MLR-1023 100mg QD|MLR-1023 100mg QD Tablet
62229614|NCT03279263|PLACEBO_COMPARATOR|Placebo|Placebo QDTablet
62421790|NCT02773446|EXPERIMENTAL|Cohort 1 group C|Volunteers will receive 9 logs of E. coli strain B7A after overnight fast
62229615|NCT05220254|EXPERIMENTAL|MindCotine mobile app program|
62229616|NCT06001489|ACTIVE_COMPARATOR|Control group|"This patient group received A standard form of patient education, consisting of oral information and an informative flyer during their outpatient clinic visit. After this visit, patients were asked to fill out 2 validated questionnaires: Spielberger's State-Trait Anxiety Inventory (STAI) and the Amsterdam Preoperative Anxiety and Information Scale (APAIS).~1 day prior to surgery, during admission to the hospital, patients were asked to fill out the STAI and APAIS again."
62229617|NCT06001489|EXPERIMENTAL|Intervention group - VR|"This patient group first received a standard form of patient education, consisting of oral information and an informative flyer. Additionally, patients watched a 360-degree VR Tour using a Pico G2 4K VR headset, describing their entire clinical pathway in more detail.~After this visit, patients were asked to fill out 2 validated questionnaires: Spielberger's State-Trait Anxiety Inventory (STAI) and the Amsterdam Preoperative Anxiety and Information Scale (APAIS).~1 day prior to surgery, during admission to the hospital, patients were asked to fill out the STAI and APAIS again."
62421791|NCT02773446|EXPERIMENTAL|Cohort 1 group D|Volunteers will receive 10 logs of E. coli strain B7A after 90 minute fast
62229618|NCT00598143||Group A|Ten healthy smokers will provide a saliva sample used to genotype UGT1A7 and complete a questionnaire to assess understanding of and willingness to participate in molecular risk assessments.
62421792|NCT02773446|EXPERIMENTAL|Cohort 2 group A|subjects from Cohort 1 who met primary endpoint will receive optimal regimen as determined by analysis after Cohort 1.
62591593|NCT01876784|EXPERIMENTAL|Vandetanib/ Vandetanib|Participants received Vandetanib 300 mg tablet, orally once daily until disease progression or death, in randomized treatment period (up to maximum of 40 months). Participants who completed the randomized treatment period, were offered the opportunity to continue the same vandetanib treatment in the open label period, if in the investigator's opinion, they received benefit and if the participant agreed and provided their informed consent to continue the open-label period for up to additional 31 months.
62591594|NCT01876784|PLACEBO_COMPARATOR|Placebo/ Vandetanib|Participants received placebo matched to Vandetanib tablet, orally once daily until disease progression or death, in randomized treatment period (up to maximum of 40 months). Participants who completed the randomized treatment period, and experienced disease progression were offered the option of treatment in open-label period with vandetanib, if in the investigator's opinion, they received benefit and if the participant agreed and provided their informed consent to begin open-label vandetanib treatment i.e., 300 mg tablet, orally once daily for up to 31 months.
62591595|NCT03533114|EXPERIMENTAL|JZP-258|JZP-258 at the stable dose and regimen for 2 weeks.
62591596|NCT03533114|PLACEBO_COMPARATOR|Placebo|Placebo will be administered at a volume and regimen equivalent to the JZP-258 dose and regimen for 2 weeks.
62591597|NCT06450054|ACTIVE_COMPARATOR|Aerobic Exercise in diabetic post-stroke patients|
62591598|NCT06450054|SHAM_COMPARATOR|Aerobic Exercise in Non diabetic post-stroke patients|
62591599|NCT02562638|NO_INTERVENTION|Group 1 Fasting|Group 1(control group) Fasting for both solids and fluids for up to 4 hours pre-procedure
62421793|NCT02773446|EXPERIMENTAL|Cohort 2 group B|Naive subjects who will receive optimal regimen as determined by analysis after Cohort 1
62421794|NCT03757793||Reliability of NIRS in DIEP flap surgery|In patients who underwent DIEP flap surgery, monitoring of postoperative tissue oxygen saturation of the flap by use of the FORE-SIGHT Elite monitor will be compared to standard of care physical examination.
62591600|NCT02562638|EXPERIMENTAL|Group 2 Non-fasting|Group 2 (intervention arm) Clear fluids up to 1 hour before the procedure and fasting for solids up to 4 hours pre-procedure
62591601|NCT02556073|ACTIVE_COMPARATOR|Usual care|"Usual care means that intervention by fluticasone/salmeterol 125/25 2 puffs bid plus salbutamol as needed acts as asthma controller and patients will be scheduled to revisit clinics."
62591602|NCT02556073|EXPERIMENTAL|Usual care+Smartphone action|Intervention by fluticasone/salmeterol 125/25 2 puffs bid plus salbutamol as needed and Smartphone action, which provides the real-time health information of surroudings and actively remind the patients to use controller.
62030579|NCT01436994|ACTIVE_COMPARATOR|Block and Replace|Carbimazole is commenced in a dose of 0.75 mg/kg/day. The intention is to completely prevent endogenous thyroxine production. Thyroxine is then added in a replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principal measure of control during the first 6 months will be thyroid hormone levels rather than TSH.
62591603|NCT01669174|EXPERIMENTAL|BYM338|
62229619|NCT00598143||Group B|Thirty smokers will receive standard smoking cessation therapy and provide urine specimens for PGE-M analysis at approximate 3-monthly intervals over one year. Self-reported smoking status and expired-air carbon monoxide (CO) will also be recorded at 3-monthly clinic visits.
62591604|NCT01669174|PLACEBO_COMPARATOR|Placebo|
62591605|NCT01306318|EXPERIMENTAL|1|
62229620|NCT04681027|ACTIVE_COMPARATOR|Pediatric Age Groups: 7 to ≤12 years|Participants expected to require ATC opioids for an extended period of time
62591606|NCT01306318|ACTIVE_COMPARATOR|2|
62591607|NCT00191282|EXPERIMENTAL|1|Postprandial: Premeal insulin lispro +/- bedtime NPH
62591608|NCT00191282|ACTIVE_COMPARATOR|2|Fasting: NPH/insulin glargine or human insulin 30/70
62591609|NCT06604962|EXPERIMENTAL|Group I: IMES using IEP|Participants in this group has allocated to the Intramuscular electrical stimulation using inverse electrode placement
62591610|NCT06604962|ACTIVE_COMPARATOR|Group II: IMES using CEP|Participants in this group has allocated to the Intramuscular electrical stimulation using conventional electrode placement
62591611|NCT06604962|SHAM_COMPARATOR|Group III: Sham-IMES|Participants in this group has allocated to the Sham Intramuscular electrical stimulation
62591612|NCT05896566|EXPERIMENTAL|Arm A: Giredestrant|Giredestrant
62229621|NCT04681027|ACTIVE_COMPARATOR|Pediatric Age Groups: 13 to ≤17 years|Participants expected to require ATC opioids for an extended period of time
62591613|NCT05896566|EXPERIMENTAL|Arm B: Giredestrant plus triptorelin|Giredestrant plus triptorelin
62591614|NCT05896566|ACTIVE_COMPARATOR|Arm C: Anastrozole plus triptorelin|Anastrozole plus triptorelin
62591615|NCT01690728|ACTIVE_COMPARATOR|Physical Activity|40 min exercise supervised by physiotherapists two times weekly in six month.
62591616|NCT01690728|NO_INTERVENTION|Control Group|These participants follows the standard post surgery follow-up consisting of counseling by dietitians, nurses and doctors.
62229622|NCT02148614|PLACEBO_COMPARATOR|Placebo|Subjects will be randomly assigned to treatment with placebo or LibramedR with a double blind clinical trial.
62229623|NCT02148614|ACTIVE_COMPARATOR|Libramed|Subjects will be randomly assigned to treatment with placebo or LibramedR with a double blind clinical trial.
62229624|NCT03532087|NO_INTERVENTION|No denosumab|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are not additionally treated with denosumab.
62229625|NCT03532087|EXPERIMENTAL|Denosumab 120 mg|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are additionally treated with denosumab 120 mg every 3 weeks. First denosumab gift is before surgery, last denosumab gift is together with the last cycle of chemotherapy.
62229626|NCT03532087|EXPERIMENTAL|Denosumab 60 mg|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are additionally treated with denosumab 60 mg every 6 months. First denosumab gift is before surgery, last denosumab gift is together with the last cycle of chemotherapy.
62229627|NCT02208999||Neurostimulator Precision|Patients implanted or reimplanted with the neurostimulator Precision
62229628|NCT03240874|EXPERIMENTAL|Usability - Focus Group|"Mobile Application Usability Testing: SweetMama Focus Groups~Focus groups: Women with a confirmed intrauterine pregnancy or postpartum until 12 weeks after delivery with gestational diabetes mellitus or type 2 diabetes mellitus will be recruited to undergo a single 1-hour focus group."
62806235|NCT05107895|EXPERIMENTAL|Experimental: Intervention group|A 10-week coping skills training was given to the training group from the randomly separated groups. The Coping Skills Training program will take place in a total of 10 online sessions, and the entire program was implemented in 10 weeks. The duration of each session is between 40 and 50 minutes, and it is determined as 5 minutes of introduction to the session, recognizing the general topics, 5 minutes of briefly summarizing the previous session, and the subject of the session for 30-40 minutes. In all sessions, reflections previously prepared with the power point program were used. In the sessions, question-answer method, audio-visual (audio-visual) method, role-playing and performance feedback phases were used when necessary. In addition to knowledge, experiences were also emphasized in education and it was possible to make comparisons with the subject learned in education.
62806236|NCT05107895|ACTIVE_COMPARATOR|Comparator: Control group|The control group will be informed about their coping skills for a week. Both groups will receive a final evaluation 10 weeks later and a follow-up evaluation 1 month after the last evaluation.
62030580|NCT01436994|ACTIVE_COMPARATOR|Dose Titration|"Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining the euthyroid state. The principal measure of control during the first 6 months will be thyroid hormone levels rather than TSH.~Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.~Drug: Carbimazole 5mg and 20 mg tablets. Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry Drug: propylthiouracil 50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry."
62421795|NCT06701760|ACTIVE_COMPARATOR|intervention|sodium lactate
62030581|NCT01613248|EXPERIMENTAL|MK-1602 1 mg|MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
62030582|NCT01613248|EXPERIMENTAL|MK-1602 10 mg|MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
62421796|NCT06701760|PLACEBO_COMPARATOR|placebo|sodium cbloride infusion
62030583|NCT01613248|EXPERIMENTAL|MK-1602 25 mg|MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
62030584|NCT01613248|EXPERIMENTAL|MK-1602 50 mg|MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
62030585|NCT01613248|EXPERIMENTAL|MK-1602 100 mg|MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
62229629|NCT03240874|EXPERIMENTAL|Usability - Individual Testing|"Mobile Application Usability Testing: SweetMama Individual Testing~Individual testing: Women with a confirmed intrauterine pregnancy (any gestational age) or who are up to 4 weeks postpartum, with gestational diabetes mellitus or type 2 diabetes mellitus, will be recruited to use SweetMama for 2 weeks and provide feedback."
62229630|NCT03240874|EXPERIMENTAL|Feasibility - Pilot Randomized Trial, SweetMama arm|"Mobile Application Feasibility Testing: SweetMama Pilot Trial, SweetMama arm~Women recruited to the pilot RCT phase will enroll in the study upon initiation of prenatal care for diabetes, which could be early in pregnancy at the time of first prenatal visit, or at a later point if they have transferred care to this site. Women randomized to receive SweetMama care will be oriented to use of SweetMama and will then use the intervention (messages, library, goal setting, and appointment reminders) throughout pregnancy and the first 8 weeks postpartum, at which point they will undergo surveys and interviews."
62421797|NCT04557969||1/ Cohort 1|Patients with histologically confirmed or clinical presentation suspicious of GIST
62421798|NCT03859570|EXPERIMENTAL|Pentoxifylline|Pentoxifylline and standard of care therapy
62421799|NCT03859570|PLACEBO_COMPARATOR|Placebo|Placebo and standard of care therapy
62591617|NCT03984435||Patients|Patients with a diagnosed malignancy who have been referred for radiotherapy with extended treatment time (\>10 minutes)
62591618|NCT03984435||Radiographers|Radiographers from radiotherapy departments in the UK who deliver radiotherapy
62591619|NCT05154500|EXPERIMENTAL|Biofortified Potato with iron or zinc ('A')|Women volunteers will consume biofortified ('A') for one day in zinc study, and 10 days in iron study Zinc study and a local non-fortified Peruanita potato variety ('B') in a randomized order (either A-B or B-A). The potatoes have significantly different (p\<0.001) content of iron or zinc, but no significant differences in vitamin C or phenolics (p\>0.05). Based on this study design, every woman is her own control.
62591620|NCT05154500|PLACEBO_COMPARATOR|Non Biofortified potato with iron or zinc ('B')|Women volunteers will consume no biofortified ('B') for one day in zinc study, and 10 days in iron study
62591621|NCT06330792|OTHER|effect of biomechanical awareness and core stability exercises on mechanical low back pain|
62229631|NCT03240874|NO_INTERVENTION|Feasibility - Pilot Randomized Trial, usual care arm|"Mobile Application Feasibility Testing: SweetMama Pilot Trial, usual care arm~Women recruited to the pilot RCT phase will enroll in the study upon initiation of prenatal care for diabetes, which could be early in pregnancy at the time of first prenatal visit, or at a later point if they have transferred care to this site. Women randomized to usual care will be undergo entry and exit surveys (at 6-8 weeks postpartum) but will not interact with SweetMama."
62030586|NCT01613248|PLACEBO_COMPARATOR|Placebo|Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
62030587|NCT03671330|EXPERIMENTAL|Ribociclib|"Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm.~Premenopausal experimental arm: NSAI + Goserelin + Ribociclib; For pre-menopausal only, patient is an adult, female ≥ 18 years old and \< 60 years old at the time of informed consent.~It is the investigators choice for NSAI based on patient's past medical history.~Postmenopausal experimental arm:~Letrozole + Ribociclib~PK Cohort: Open-label ribociclib + Letrozole treatment combination.~For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent"
62030588|NCT03671330|PLACEBO_COMPARATOR|Ribociclib Placebo|"Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm.~Premenopausal control arm: NSAI + Goserelin + Placebo; For pre-menopausal only, patient is an adult, female ≥ 18 years old and \< 60 years old at the time of informed consent.~It is the investigators choice for NSAI based on patient's past medical history.~Postmenopausal control arm:~Letrozole + Placebo For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent"
62806237|NCT01832077||rural doctor|examine patient's fundus by 90D fundus pre-set lens
62030589|NCT06099613|EXPERIMENTAL|EG-COVII|
62030590|NCT01169467|ACTIVE_COMPARATOR|Standard-of-Care plus Precedex|Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment.
62030591|NCT01169467|PLACEBO_COMPARATOR|Standard-of-Care|Subjects who are treated with the standard of care sedation regiment only.
62030592|NCT04894604|EXPERIMENTAL|Subjects with a low to moderate exuding surgically closed incision|Up to 34 study Subjects with a low to moderate exuding surgically closed incision deemed adequate by the Principal Investigator and clinical team for NPWT treatment.
62030593|NCT04696731|EXPERIMENTAL|ALLO-647, ALLO-316|
62030594|NCT04775680|EXPERIMENTAL|ADG106 combined with PD-1 antibody Dose Escalation Level 1|
62030595|NCT04775680|EXPERIMENTAL|ADG106 combined with anti PD-1 antibody Dose Escalation Level 2|
62030596|NCT04775680|EXPERIMENTAL|ADG106 combined with anti PD-1 antibody Expansion Phase|
62030597|NCT02495753|EXPERIMENTAL|Abdominal and Vaginal Cleansing|In the treatment arm, the vagina will be cleansed prior to usual abdominal cleansing before cesarean section.
62030598|NCT02495753|ACTIVE_COMPARATOR|Abdominal Cleansing Alone|In the control arm, abdominal cleansing will be performed per routine with no vaginal cleansing.
62030599|NCT00074035|EXPERIMENTAL|Pentostatin|treatment of pts with refractory graft vs host disease
62030600|NCT03675022|EXPERIMENTAL|Dupilumab|Dupilumab injections every 2 weeks.
62030601|NCT03932643|EXPERIMENTAL|ONC-201 Treatment|A 3+3 dose escalation design will be followed. Given the safety profile in prior trials, A dose of 250 mg weekly will be the starting dose. The first 12-15 patients are expected to receive escalating doses of ONC 201, the remaining patients will go on the expansion cohort.
62030602|NCT03975348|OTHER|Baseline conventional facemask|The patients will receive oxygen therapy through conventional facemask for 10 minutes
62030603|NCT03975348|EXPERIMENTAL|HFNC 40 L/min up|The patients will receive oxygen/air mixture through high flow nasal cannula at incremental, then decremental flows, starting at 40 L/min for 10 minutes
62591622|NCT06330792|OTHER|effect core stability exercises on mechanical low back pain|
62030604|NCT03975348|EXPERIMENTAL|HFNC 60 L/min up|High flow nasal cannula at 60 L/min for 10 minutes
62030605|NCT03975348|EXPERIMENTAL|HFNC 80 L/min up|High flow nasal cannula at 80 L/min for 10 minutes
62030606|NCT03975348|EXPERIMENTAL|HFNC 100 L/min|High flow nasal cannula at 100 L/min for 10 minutes
62030607|NCT03975348|EXPERIMENTAL|HFNC 80 L/min down|High flow nasal cannula at 80 L/min for 10 minutes
62030608|NCT03975348|EXPERIMENTAL|HFNC 60 L/min down|High flow nasal cannula at 60 L/min for 10 minutes
62030609|NCT03975348|EXPERIMENTAL|HFNC 40 L/min down|High flow nasal cannula at 40 L/min for 10 minutes
62030610|NCT03975348|OTHER|Washout conventional facemask|Again, the patients will receive oxygen therapy through conventional facemask for 10 minutes, to reduce the influence of HFNC on CPAP therapy
62030611|NCT03975348|ACTIVE_COMPARATOR|CPAP|The patients will receive CPAP at 10 cmH2O for 10 minutes
62030612|NCT02310750|EXPERIMENTAL|PF-06700841 Oral Solution/Suspension|
62030613|NCT02310750|EXPERIMENTAL|PF-06700841 Tablet|
62030614|NCT02310750|PLACEBO_COMPARATOR|Placebo|Oral placebo comparator for the healthy subject single and multiple ascending dose periods, and the psoriasis multiple dose period. No placebo used for the bioavailability investigation.
62030615|NCT04786444|ACTIVE_COMPARATOR|VLA1553 Lot 1|
62030616|NCT04786444|ACTIVE_COMPARATOR|VLA1553 Lot 2|
62030617|NCT04786444|ACTIVE_COMPARATOR|VLA1553 Lot 3|
62030618|NCT06285812||Standard of Care #1|Prospective Randomized Control Trial (RCT)
62030619|NCT06285812||OtoSight #1|Prospective Randomized Control Trial (RCT)
62030620|NCT06285812||OtoSight #2|Case and provider match
62806238|NCT01832077||grader|grade fundus pictures in ZOC
62806239|NCT01141712|OTHER|Autologous transplant|Patients will receive BCNU 300 mg/m\^2 Day -6, Etoposide 100 mg/m\^2 BID Days -5 to -2, Cytarabine 100 mg/m\^2 BID Days -5 to -2, and Melphalan 140 mg/m\^2 Day -1 followed by autologous HCT.
62806240|NCT01934959|EXPERIMENTAL|Probiotics|
62229632|NCT00949208||A|The study population will consist of healthy volunteers who fulfill all the inclusion criteria and do not meet any of the exclusion criteria.
62229633|NCT00101881|ACTIVE_COMPARATOR|Monophasic Shock|Administration of monophasic waveform defibrillation
62229634|NCT00101881|ACTIVE_COMPARATOR|Biphasic Shock|Administration of biphasic waveform defibrillation
62229635|NCT02970331|EXPERIMENTAL|pefcalcitol|pefcalcitol 0.005% BID for 8 weeks
62229636|NCT05106829|ACTIVE_COMPARATOR|Physical therapy program with treadmill training without using of ankle weights.|Cerebral palsied children will receive the physical therapy program from 45- 60 min./ session in addition to gait training on treadmill for 30 min./ session.
62229637|NCT05106829|EXPERIMENTAL|Physical therapy program with treadmill training with using of ankle weights.|Cerebral palsied children will receive the physical therapy program from 45- 60 min./ session in addition to gait training on treadmill with ankle weights for 30 min./ session.
62229638|NCT03709420|PLACEBO_COMPARATOR|Placebo|Matching placebo capsule
62421800|NCT01860690|EXPERIMENTAL|MTX , treatment outcome|patient receiving MTX. in a dosage of 50 mg/m\^2 , IM , in single dose
62421801|NCT02341209|EXPERIMENTAL|Doxycycline monohydrate|Doxycycline in either capsules or tablets will be administered at 400mg total per day. Patients will be treated for five months, or up to one year for those with a partial response at 5 months.
62421802|NCT01456494|EXPERIMENTAL|Teach-to-Goal|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
62421803|NCT01456494|EXPERIMENTAL|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
62421804|NCT04145349|EXPERIMENTAL|Ramucirumab + Cyclophosphamide + Vinorelbine|Ramucirumab given intravenously (IV), Cyclophosphamide given orally and vinorelbine given IV.
62421805|NCT04145349|ACTIVE_COMPARATOR|Cyclophosphamide + Vinorelbine|Cyclophosphamide given orally and vinorelbine given IV.
62591623|NCT06054776|EXPERIMENTAL|Treatment (acalabrutinib, obinutuzumab, glofitamab)|Patients recieve acalabrutinib PO BID of each cycle, obinutuzumab IV on days 1 and 7 of cycle 1 only, and glofitamab IV over 2-4 hours on days 8 and 15 of cycle 1 and day 1 of each subsequent cycle. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with MRD positive CR, PR, or SD after 12 cycles of protocol therapy may continue receiving single agent acalabrutinib per standard of care during the follow-up phase of the study. Patients also undergo a ECHO or MUGA during screening, as well as PET/CT or CT, and blood specimen collection throughout the trial. Patients may also undergo bone marrow biopsies throughout the trial.
62030621|NCT06285812||Standard of Care #2|Retrospective case and provider matched controls
62229639|NCT03709420|EXPERIMENTAL|FOR-6219|"Part I (SAD): Single oral doses of 2 mg, 10 mg, 25 mg, 50 mg, 100 mg and 175 mg.~Part II (MAD): Multiple oral doses of 50 mg QD, 75 mg BID and 150 mg BID.~Part III: Multiple oral doses of 10 mg, 25 mg, 75 mg and 150 mg BID"
62229640|NCT05603091||Pressure guided cryoablation|Patients undergoing cryoablation of atrial fibrillation with catheter-balloon, where the evaluation of the pulmonary veins occlusion will be assessed by the analysis of the pressure waveforms obtained from the tip of the catheter (without injecting contrast).
62229641|NCT02238522|EXPERIMENTAL|Dose Escalation Stage - ZEN003365|ZEN003365 will be administered orally as a single agent, enrolling LPM patients and AML patients
62229642|NCT02238522|EXPERIMENTAL|Dose Expansion Stage - ZEN003365|ZEN003365 will be administered orally as a single agent, enrolling LPM patients and AML patients
62421806|NCT02060240|EXPERIMENTAL|High Activity Group|Subject randomized to High Activity group will have 36, one hour training sessions over 12 weeks.
62421807|NCT02060240|NO_INTERVENTION|Standard of Care Group|The standard of care group will maintain their baseline level of activity for 12 weeks
62421808|NCT01031342|EXPERIMENTAL|Early colonoscopy|Colonoscopy performed within 12 hours of presentation
62421809|NCT01031342|ACTIVE_COMPARATOR|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
62421810|NCT01803035|EXPERIMENTAL|1 % LTX-109|LTX-109 topical gel in 1 % strength
62421811|NCT01803035|EXPERIMENTAL|2 % LTX-109|LTX-109 topical gel in 2 % strength
62030622|NCT01572727|EXPERIMENTAL|BKM120 and paclitaxel|Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel.
62229643|NCT06450938|EXPERIMENTAL|participants using guidance from artificial Intelligence|the experimental arm refers to the group of participants who have access to the AI-based platform for detecting features associated with the technical quality of endodontic treatment. These participants will utilize the AI assistance during the study.
62229644|NCT06450938|NO_INTERVENTION|Control arm without any guidance from artificial Intelligence|the control arm consists of participants who do not have access to the AI-based platform. They will perform the same tasks or assessments as those in the experimental arm but without the assistance of AI.
62229645|NCT05144633||Acute Respiratory failure|Patients presenting to the Emergency Department in acute respiratory failure. These patients may or may not have a diagnosis of chronic lung disease.
62229646|NCT02283554|PLACEBO_COMPARATOR|ARM1- open flap debridement (OFD)|open flap debridement done for 30 subjects. After debridement, Metformin or PRF was not added into the intrabony defect.
62229647|NCT02283554|EXPERIMENTAL|ARM2- open flap debridement plus PRF(Platelet rich fibrin)|"After open flap debridement, PRF( Platelet rich fibrin) was added into the intrabony defect.~No. of subjects= 30"
62229648|NCT02283554|EXPERIMENTAL|ARM3- open flap debridement plus 1%Metformin|After open flap debridement, 1% metformin was added into the intrabony defect No. of subjects= 30
62229649|NCT02283554|EXPERIMENTAL|ARM4- open flap debridement plus PRF plus metformin|"After open flap debridement, PRF and 1% metformin was added into the intrabony defect.~No. of subject- 30"
62421812|NCT01803035|PLACEBO_COMPARATOR|Placebo|Placebo gel, containing all ingredients except LTX-109
62591624|NCT05372055||Indwelling Pleural Catheter|Patients with malignant pleural effusions managed by IPC insertion as per standard of care
62591625|NCT02062073|ACTIVE_COMPARATOR|Abametapir Lotion 0.74%|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
62591626|NCT02062073|PLACEBO_COMPARATOR|Vehicle Lotion|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
62806241|NCT01792310|EXPERIMENTAL|Dose Cohort 1|Intervention: LAM561. 7 dose cohorts of up to 6 patients have been performed in the dose escalation phase. The starting dose cohort received 250 mg twice daily.
62806242|NCT01792310|EXPERIMENTAL|Dose Cohort 2|Intervention: LAM561. 500 mg twice daily
62229650|NCT04953715||1 - This is a multicenter microbiome and pharmacokinetic study.|A prospective, observational microbiome study of adult kidney transplant recipients receiving mycophenolate mofetil and tacrolimus maintenance immunosuppression. Participants will be studied post-transplant for mycophenolate pharmacokinetics and microbiome samples collected. Clinically measured tacrolimus trough concentrations will also be evaluated. Associations among mycophenolic acid enterohepatic recycling and metabolite formation, tacrolimus troughs, immunosuppression adverse effects, diarrhea and microbiome will be studied. To assess the relationship between kidney graft outcomes and stool, oral, nasal and urine microbiome diversity. To assess the relationship between transplant graft outcomes and urinary transcriptome.
62421813|NCT04876807|EXPERIMENTAL|Part 1 (Acidic formulation)|In Part 1 of the study, the participants will receive Dose 1 of ACP-196 (reference or acidic formulation as applicable) with 240 mL water in 4 treatment schedules on Day 1, Day 3, Day 8 (with omeprazole), and Day 10 (with omeprazole).
62421814|NCT04876807|EXPERIMENTAL|Part 2 (Orange drink)|In Part 2 of the study, the participants will receive Dose 1 of ACP-196 (reference formulation) with 240 mL water or acidic beverage as applicable in 4 treatment schedules on Day 1, Day 3, Day 8 (with omeprazole), and Day 10 (with omeprazole).
62591627|NCT02062073|OTHER|0.1% sodium lauryl sulfate|Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
62591628|NCT02062073|OTHER|Saline 0.9%|Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
62591629|NCT04538547|EXPERIMENTAL|Accelerated Radiotherapy|Accelerated Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 6 days per week from Monday to Saturday
62806243|NCT01792310|EXPERIMENTAL|Dose Cohort 3|"Intervention: LAM561.~1g twice daily"
62030623|NCT01572727|ACTIVE_COMPARATOR|Placebo and paclitaxel|Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel.
62229651|NCT05724160|OTHER|NSLBP treated with Physiotherapy|32 patients with non-specific low back pain receiving routine protocol-based physiotherapy care by an expert.
62421815|NCT04876807|EXPERIMENTAL|Part 3 (Grapefruit juice)|In Part 3 of the study, the participants will receive Dose 1 of ACP-196 (reference formulation) with 240 mL water or grapefruit as applicable in 4 treatment schedules on Day 1, Day 3, Day 8 (with omeprazole), and Day 10 (with omeprazole).
62421816|NCT00500695|EXPERIMENTAL|Motivational Interviewing|Motivational Interviewing
62421817|NCT00500695|ACTIVE_COMPARATOR|Psychoeducation|Psychoeducation
62421818|NCT05787860|ACTIVE_COMPARATOR|Ruxolitinib Cream|Participants will receive topical ruxolitinib 1.5% cream
62421819|NCT05787860|NO_INTERVENTION|Healthy Control Subjects|Age- and gender-matched healthy control subjects
62421820|NCT00571220||Gastric bypass surgery|Surgical group of obese patients with type 2 diabetes undergoing gastric bypass surgery
62421821|NCT00571220||Diet induced weight loss|Diet group of obese patient with type 2 diabetes, matched with the surgical group for diabetes duration, diabetes control (HbA1C), BMI, age.
62421822|NCT01771835||Diabetes patients|Patients with diabetes mellitus type I + II, without diabetic retinopathy
62591630|NCT04538547|ACTIVE_COMPARATOR|Non Accelerated Radiotherapy|Concurrent Chemoradiotherapy followed by 3 cycles adjuvant chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to Friday.
62806244|NCT01792310|EXPERIMENTAL|LAM561 Dose Cohort 4|Intervention: LAM561. 2g twice daily
62806245|NCT01792310|EXPERIMENTAL|LAM561 Dose Cohort 5|Intervention: LAM561. 4g twice daily
62806246|NCT01792310|EXPERIMENTAL|LAM561Dose Cohort 6|Intervention: LAM561. 4g three times daily
62806247|NCT01792310|EXPERIMENTAL|LAM561 Dose Cohort 7|Intervention: LAM561. 8g twice daily
62806248|NCT01792310|EXPERIMENTAL|LAM561 Dose Expansion cohort. Glioma|Intervention: LAM561 at the MTD: 4g three times daily. Up to 10 patients with malignant glioma.
62806249|NCT01792310|EXPERIMENTAL|LAM561 Dose Expansion cohort. Non-glioma|Intervention: LAM561 at the MTD: 4g three times daily. Up to 10 patients with other advanced solid tumours that are suitable for biopsy.
62806250|NCT01619371||Lactating women|Lactating women willing to use a breast pump.
62806251|NCT05297877|EXPERIMENTAL|AI Machine|All study participants will undergo a full day (roughly 8 hours) training programme consisting of a pre-test MCQ, a didactic lecture, hands-on training session, a post-test MCQ, and a practical evaluation. They will be randomised to using an A.I. ultrasound machine for teaching.
62806252|NCT05297877|OTHER|Conventional Machine|All study participants will undergo a full day (roughly 8 hours) training programme consisting of a pre-test MCQ, a didactic lecture, hands-on training session, a post-test MCQ, and a practical evaluation. They will be randomised to using a conventional ultrasound machine for teaching.
62806253|NCT02914639|EXPERIMENTAL|SF0166 low dose BID|SF0166 low dose instilled in study eye BID for 28 days of treatment.
62030624|NCT02590354|EXPERIMENTAL|Treatment interruption|The ART treatment in patients with a very low viral reservoir will be interrupted.
62030625|NCT03759873|EXPERIMENTAL|Incentives|Patient earns incentives for completing cardiac rehabilitation sessions.
62030626|NCT03759873|EXPERIMENTAL|Case Management|Patient is assigned a case manager while in hospital.
62806254|NCT02914639|EXPERIMENTAL|SF0166 high dose BID|SF0166 high dose instilled in study eye BID for 28 days of treatment.
62229652|NCT05724160|OTHER|NSLBP treated with Physiotherapy + Sitting ellipticals|32 patients with non-specific low back pain receiving routine protocol-based physiotherapy care by an expert together with planned training using sitting ellipticals
62229653|NCT03467243|EXPERIMENTAL|CBSST|Veterans participate in 20 weekly group sessions using Cognitive Behavioral Social Skills Training model
62229654|NCT03467243|EXPERIMENTAL|SST|Veterans participate in 20 weekly group sessions using Social Skills Training model
62229655|NCT03467243|OTHER|Treatment as usual|Veterans receive treatment as usual
62229656|NCT00896051|EXPERIMENTAL|ATV/rtv 300/100 mg (Treatment A)|Treatment-experienced human immunodeficiency virus - type 1 (HIV-1) infected participants will take by mouth atazanavir (ATV)/low-dose ritonavir (rtv) 300/100 mg once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 2 weeks pre-treatment followed by ATV/rtv 300/100 mg once daily + etravirine (ETR) 200 mg twice daily + 1 NRTI for 48 weeks. If particpating in an optional substudy to assess the effect of adding tenofovir disoproxil fumarate (TDF) for 7 days on ATV and ETR pharmacokinetics, participants will receive TDF 300 mg once daily for 7 days in addition to their antiretroviral regimen (ETR+ATV/rtv+NRTI).
62229657|NCT00896051|EXPERIMENTAL|ATV/rtv 400/100 mg (Treatment B)|Treatment-experienced human immunodeficiency virus - type 1 (HIV-1) infected participants will take by mouth atazanavir (ATV)/low-dose ritonavir (rtv) 300/100 mg once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 2 weeks pretreatment followed by ATV/rtv 400/100 mg once daily + etravirine (ETR) 200 mg twice daily + 1 NRTI for 48 weeks. If particpating in an optional substudy to assess the effect of adding tenofovir disoproxil fumarate (TDF) for 7 days on ATV and ETR pharmacokinetics, participants will take TDF 300 mg once daily for 7 days in addition to their antiretroviral regimen (ETR+ATV/rtv+NRTI).
62229658|NCT02216357|ACTIVE_COMPARATOR|Ifetroban, Oral Capsule|Ifetroban, Oral Capsule; 200 mg per dose (four - 50 mg capsules), once per day on Study Days 1, 2, and 3.
62229659|NCT02216357|PLACEBO_COMPARATOR|Placebo, Oral Capsule|Placebo, Oral Capsule; matching capsules for oral ifetroban dosing, four capsules once per day on Study Days 1, 2, and 3.
62229660|NCT05682157|EXPERIMENTAL|Paula Method|12 weeks of the Paula Method of muscle exercises with standard care
62806255|NCT02970981|EXPERIMENTAL|Nivolumab and Ipilimumab|"Dosing during cycle 1 will consist of: 3 mg/kg of Nivolumab+ Ipilimumab at 1 mg/kg. Each induction treatment cycle is comprised of 4 doses of Nivolumab and 4 doses of Ipilimumab given every three weeks for a total of 12 weeks (cycle 1)~Dosing during cycles 2-5 will consist of flat dose Nivolumab at 480 mg every 4 weeks (Q4W) for 48 weeks."
62229661|NCT05682157|NO_INTERVENTION|Standard Care|standard care
62229662|NCT04428125||Healthy sporty subjects|Healthy sporty subjects that participate in the following sports: baseball, tennis, swimming, rowing, volleyball, rugby football, weightlifting.
62229663|NCT04428125||Healthy non-sporty subjects|Healthy subjects that do not partecipate in sport activities.
62229664|NCT01008293|EXPERIMENTAL|VSL#3|
62229665|NCT01008293|ACTIVE_COMPARATOR|Lactulose|30-60 ml of lactulose per day (2 months) to ensure 2-3 soft stools
62421823|NCT02282826|EXPERIMENTAL|Dose 1 IV|GZ402668 dose 1 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
62591631|NCT03945370|ACTIVE_COMPARATOR|Intervention sequence 1|Ketone drink first - Placebo drink secondly
62591632|NCT03945370|PLACEBO_COMPARATOR|Intervention sequence 2|Placebo drink first - Ketone drink secondly
62806256|NCT05783206|EXPERIMENTAL|MIR 19 ®|"MIR 19 ® was used in a single dose of 1.85 mg for 3 inhalations per day at intervals of 6-7 hours for 7 days in addition to standard therapy without use of any etiotropic drugs.~Standard therapy included:~- paracetamol - 1-2 tablets (500-1000 mg) 2-3 times a day (if body temperature ≥38.0°)"
62229666|NCT05271292|EXPERIMENTAL|Study arm (35 mg)|Phase 1b: Patients will be enrolled sequentially in 3 dose-escalating cohorts (Chiauranib capsules 35, 50, and 65 mg, orally)
62229667|NCT05271292|EXPERIMENTAL|Study arm (50 mg)|Phase 1b: Patients will be enrolled sequentially in 3 dose-escalating cohorts (Chiauranib capsules 35, 50, and 65 mg, orally)
62421824|NCT02282826|EXPERIMENTAL|Dose 2 IV|GZ402668 dose 2 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
62421825|NCT02282826|EXPERIMENTAL|Dose 3 IV|GZ402668 dose 3 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
62421826|NCT02282826|EXPERIMENTAL|Dose 3 SC|GZ402668 dose 3 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
62591633|NCT06532864|EXPERIMENTAL|Practicing Mawangdui Guidance Exersize Group|The experimental group underwent the Mawangdui Guided Exercise, which consisted of five 45-minute sessions per week for 12 weeks.
62229668|NCT05271292|EXPERIMENTAL|Study arm (65 mg)|Phase 1b: Patients will be enrolled sequentially in 3 dose-escalating cohorts (Chiauranib capsules 35, 50, and 65 mg, orally)
62229669|NCT05008835|EXPERIMENTAL|Drug - ACP-044 Dose A|ACP-044 Dose A
62229670|NCT05008835|EXPERIMENTAL|Drug - ACP-044 Dose B|ACP-044 Dose B
62229671|NCT05008835|PLACEBO_COMPARATOR|Placebo|Placebo
62229672|NCT02940821|ACTIVE_COMPARATOR|Whitening and Dentifrice|
62229673|NCT02940821|ACTIVE_COMPARATOR|Whitening Dentifrice|
62229674|NCT02940821|ACTIVE_COMPARATOR|Dentifrice|
62229675|NCT03794570|SHAM_COMPARATOR|Control|Patients in this group will have BFR tourniquet applied but inflated to only minimal pressure.
62229676|NCT03794570|EXPERIMENTAL|Blood Flow Restriction (BFR) Therapy|Patients in this group will have BFR tourniquet applied and inflated to 80% limb occlusion pressure
62229677|NCT04977726|EXPERIMENTAL|STRIVE - Simulation Training for Resilience in Various Environments|
62229678|NCT04977726|SHAM_COMPARATOR|Control|
62229679|NCT00699920|EXPERIMENTAL|1|Coarsucam double-layer artesunate/amiodaquine tablets
62229680|NCT00699920|ACTIVE_COMPARATOR|2|Coartem (artemether/lumefantrine) fixed-dose combination tablets
62229681|NCT03333239|EXPERIMENTAL|psychodynamic psychotherapy|
62229682|NCT03333239|EXPERIMENTAL|cognitive behavioral psychotherapy|
62229683|NCT03333239|ACTIVE_COMPARATOR|psychodynamic family intervention|
62421827|NCT02282826|EXPERIMENTAL|Dose 4 SC|GZ402668 dose 4 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
62229684|NCT02739360|EXPERIMENTAL|Idelalisib|Participants will receive idelalisib until unacceptable toxicity, disease progression, study discontinuation, or death occurs.
62421828|NCT02282826|EXPERIMENTAL|Dose 5 SC|GZ402668 dose 5 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
62421829|NCT02282826|PLACEBO_COMPARATOR|Placebo SC|placebo subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
62421830|NCT02282826|PLACEBO_COMPARATOR|Placebo IV|placebo intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
62591634|NCT06532864|NO_INTERVENTION|Sleep Education Group|The control group maintained routine sleep education in addition to daily activities.
62806257|NCT05783206|ACTIVE_COMPARATOR|Standard therapy|"Standard therapy included:~* umifenovir (Arbidol®) - 200 mg 4 times per day for 7 days~* interferon-α, intranasal forms (Grippferon®),spray - in accordance with the instructions.~* paracetamol - 1-2 tablets (500-1000 mg) 2-3 times a day (if body temperature ≥38.0°)"
62806258|NCT01169025|EXPERIMENTAL|Ketamine|Subjects receive 0.3 mg/kg IV ketamine over 5 minutes and are evaluated every 10 minutes. Residual or recurring pain will be treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, subjects are asked if they need additional pain medication every 10 minutes, unless an earlier, spontaneous request is made by the subject or the provider determines that more is needed. For the potential of rare ketamine side effects (dysphoria, anxiety, or agitation), 2 mg IV midazolam is given every 5 minutes as needed for any of these symptoms. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
62806259|NCT01169025|ACTIVE_COMPARATOR|Fentanyl|Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
62806260|NCT00472225|EXPERIMENTAL|1|Rituximab treatment arm
62806261|NCT01742273|NO_INTERVENTION|standard treatment (usual care)|standard treatment (usual care)
62806262|NCT01742273|EXPERIMENTAL|Vitamin K1|Vitamin K1 (phylloquinone), thrice weekly p.o. (5mg)
62806263|NCT02107833|EXPERIMENTAL|2 mg|OPRX-106 2 mg oral once daily for 5 days
62806264|NCT02107833|EXPERIMENTAL|8 mg|OPRX-106 8 mg oral once daily for 5 days
62806265|NCT02107833|EXPERIMENTAL|16 mg|OPRX-106 16 mg oral once daily for 5 days
62806266|NCT02376634|ACTIVE_COMPARATOR|Hypnosis|"The hypnosis group will receive a semi-structured intervention by primary investigator. The intervention is somewhat individualized based on the recipients personal characteristics (e.g., age, gender, medical history). The intervention will begin with an induction phase during which the participant is guided to relax and to focus their attention on one stimuli. The intervention will then proceed with a suggestion phase. Suggestions used in this phase will all be directed toward decreasing the patient's anxiety and post-operative pain. Patients will be taught self-hypnosis to decrease distress and reframe painful experiences."
62806267|NCT02376634|NO_INTERVENTION|Control|This group will receive the standard of care of Nationwide Children's Hospital.
62806268|NCT06014346|NO_INTERVENTION|Control group|EFS usual standard practices for the whole blood donation
62806269|NCT06014346|EXPERIMENTAL|Test Group 1|"A psychological strategy is added to EFS standard practices before the whole blood donation~* flyer given at the interview presenting the 4 most frequent fears as well as a description of the recommended muscular and breathing exercises,~* followed by a training of these exercises and their execution"
62806270|NCT06014346|EXPERIMENTAL|Test Group 2|A physiological strategy is added to EFS standard practices before the whole blood donation : - Ingesting a salty snack.
62030627|NCT03759873|EXPERIMENTAL|Incentives and Case Management|Patient receives both the Incentives and Case Management interventions.
62030628|NCT03759873|NO_INTERVENTION|Usual care|This control condition does not receive either intervention.
62030629|NCT01764945|EXPERIMENTAL|1 BI 201335|low dose
62030630|NCT01764945|EXPERIMENTAL|2 BI 201335|high dose
62229685|NCT02669420|EXPERIMENTAL|extra amniotic misoprostol|misoprostol dissolved in warm saline , become dissolute misoprostol saline solution(200 microgram every 4 hours)
62229686|NCT02669420|EXPERIMENTAL|vaginal misoprostol|misoprostol tablet soaked with distilled water and inserted in the posterior fornix of the vagina( 200 microgram every 4 hours)
62229687|NCT00449553||Pioglitazone 15 mg QD + Sulphonylurea|
62229688|NCT00449553||Pioglitazone 30 mg QD + Sulphonylurea|
62229689|NCT00449553||Pioglitazone 15 mg QD + Metformin|
62229690|NCT00449553||Pioglitazone 30 mg QD + Metformin|
62229691|NCT02796560|EXPERIMENTAL|Brand name travoprost|Patients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks.
62229692|NCT02796560|EXPERIMENTAL|Generic travoprost|Patients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks.
62229693|NCT04647630||CAP|community acquired pneumonia
62229694|NCT00518791|EXPERIMENTAL|I|Multidisciplinary Care
62229695|NCT00518791|OTHER|II|Usual Care
62229696|NCT03153137|EXPERIMENTAL|Macitentan|Macitentan 10 mg per day; film-coated tablet; oral use
62229697|NCT03153137|PLACEBO_COMPARATOR|Placebo|film-coated tablet; oral use
62229698|NCT05428761|EXPERIMENTAL|TP1|Participants will receive TP1 during one experimental trial.
62229699|NCT05428761|EXPERIMENTAL|TP2|Participants will receive TP2 during one experimental trial.
62229700|NCT05428761|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo during one experimental trial.
62229701|NCT03692260|ACTIVE_COMPARATOR|intervention group|3D stent in Herbert screw insertion vs titanium plate
62229702|NCT03692260|NO_INTERVENTION|control group|titanium plate
62229703|NCT04506268|EXPERIMENTAL|Opt-in Recruitment Email|Participants will receive a recruitment email that describes the objectives of a new COVID-19 voluntary screening program, and invites them to enroll.
62806271|NCT06014346|EXPERIMENTAL|Test group 3|"The both psychological and physiological strategies are added to EFS standard practices before the whole blood donation~* flyer given at the interview presenting the 4 most frequent fears as well as a description of the recommended muscular and breathing exercises,~* followed by a training of these exercises and their execution Ingesting a salty snack."
62229704|NCT04506268|EXPERIMENTAL|Opt-out Recruitment Email|Participants will receive a recruitment email that describes the objectives of a new COVID-19 voluntary screening program, and informs them that they have been conditionally enrolled.
62229705|NCT04787250|EXPERIMENTAL|Arm 1, Phage Therapy with Antibiotic Treatment|Phage therapy will be administered in conjunction with antibiotic treatment.
62229706|NCT04787250|ACTIVE_COMPARATOR|Arm 2, Standard of Care|Two-stage exchange arthroplasty entails resection arthroplasty and placement of an antibiotic-loaded spacer, antibiotic therapy, an antibiotic-free observation period, and re-implantation of a new prosthesis.
62806272|NCT00626444|EXPERIMENTAL|1|Intravenous vitamin C
62229707|NCT00790764|PLACEBO_COMPARATOR|Placebo|20 individuals will receive placebo.
62229708|NCT00790764|EXPERIMENTAL|MESENDO|"Active combination autologous stem cell therapy. 40 individuals will receive MESENDO in either the high or low dose treatment groups."
62421831|NCT05189145|ACTIVE_COMPARATOR|Group I (control)|All patients given 8 mg estradiol valerate orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle. Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation. In all Patients progesterone supplements in form of two vaginal prontogest suppositories 400 mg each. Transfer of frozen embryo will be done on day 5 after progesterone supplementation.
62591635|NCT03834974|EXPERIMENTAL|Sun Safety Social Media Challenge|During this 4-week intervention, participants will be incentivized to create sun safety social media messages that will be distributed on our sun safety Twitter and Facebook feeds.
62806273|NCT00985673|EXPERIMENTAL|Flulaval/placebo/unadjuvanted Arepanrix Group|subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
62806274|NCT00985673|EXPERIMENTAL|Flulaval/placebo/Arepanrix Group|subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
62806275|NCT00985673|EXPERIMENTAL|Flulaval/unadjuvanted Arepanrix/placebo Group|subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
62806276|NCT00985673|EXPERIMENTAL|Flulaval/Arepanrix/placebo Group|subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
62806277|NCT00985673|EXPERIMENTAL|Unadjuvanted Arepanrix/placebo/Flulaval Group|subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
62229709|NCT06494891|EXPERIMENTAL|Intravenous Alcohol|Participants will receive 6% ethanol v/v in saline administered intravenously through the physiologically based pharmacokinetic model implemented in the Computerized Alcohol Infusion System.
62229710|NCT04168853|OTHER|Roller pump group|CABG was performed under normothermic (36-37°C) cardiopulmonary bypass (CPB). All components of the circuits were coated with phosphorylcholine inert surface (PHISIO, Sorin®). The pump manufacturer is Maquet® for the roller pumps.1.5 cm of ITA distality was sampled before blood flow interruption into the graft and before starting CPB (Time 1) and another segment (1.5 cm) before the last coronary anastomosis during aortic cross clamping (Time 2) (Figure 1). Each arterial segment was cut into three parts: a fresh part for arterial myography bathed and stored in a 50 ml organ bath containing a physiological salt solution (PSS). The other two parts were cooled in liquid nitrogen and stored at -80°C for immunohistochemistry and RT-PCR analysis.
62243134|NCT06735209|EXPERIMENTAL|Arm 1 Part 2 Group 5|Healthy malaria-naïve participants aged between 18 and 45 years will receive 2x10\^5 PfSPZ of Plasmodium falciparum sporozoite vaccine (PfSPZ-LARC2) vaccine on Days 1, 29 followed by 3.2x10\^3 PfSPZ Challenge (7G8) Controlled Human Malaria Infection (CHMI) on Day 113 administered by direct venous inoculation (DVI). Selection Criteria for Part 2 based on protection outcomes in Part 1 (protection = no evidence of infection by qRT-PCR endpoint after CHMI for vaccinated participants) N=15
62030631|NCT01325168|EXPERIMENTAL|study group|32 PTSD patients intervention: Drug: syntocinon nasal spray / placebo nasal spray nasal OT - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
62591636|NCT03834974|ACTIVE_COMPARATOR|Digital Health Social Media Challenge|During this 4-week intervention, participants will be incentivized to create posts that promote the use of technology to engage in healthy lifestyle behaviors (diet, exercise) on our digital health Twitter and Facebook feeds.
62030632|NCT01325168|OTHER|control group|control group - 30 healthy control subjects intervention: Drug: syntocinon nasal spray / placebo nasal spray nasal OT - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
62030633|NCT01973127|EXPERIMENTAL|Verum rTMS|"n=15. After detoxification of alcohol (maximum 4 days) rTMS treatment will start : 20 sessions (5 times during 4 weeks)of verum rTMS on the right dorsolateral prefrontal cortex.~Measurements of all objectives at baseline and 2,4,8 and 12 weeks after start treatment."
62591637|NCT01137110|OTHER|Brief LEV|Administration of three days of levetiracetam twice daily after SAH
62591638|NCT01137110|OTHER|Extended LEV|Administration of levetiracetam twice daily after SAH
62421832|NCT05189145|EXPERIMENTAL|group II (experimental)|"All patients given 8 mg estradiol valerate orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle. Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation. In all Patients progesterone supplements in form of two vaginal prontogest suppositories 400 mg each. Transfer of frozen embryo will be done on day 5 after progesterone supplementation.~progesterone (P4) and estradiol assessed and Progesterone supplement adjustments based on serum level of P4 on day of embryo transfer dividing Group II (Cases) into 3 groups:~* Group II A: If P4 levels \< 5ng/dl, one progesterone supplement in form of 100 mg intramuscular injection daily added~* Group II B: If P4 levels 5-10ng/dl, dydrogesterone three times daily added~* Group II C: If P4 levels \>10ng, continue on 400 mg prontogest suppositories twice daily"
62591639|NCT04522973|OTHER|Within group four condition comparison|On four separate occasions, participants will come to the research center and complete one of the four conditions. All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes.
62591640|NCT05723913|EXPERIMENTAL|Nutritional strategy based on functional foods|Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein, agave extract and genistein.
62591641|NCT03671109|EXPERIMENTAL|IPTp-DHA-PPQ|Monthly IPTp-DHA-PPQ over three days plus daily ARVs and cotrimoxazole prophylaxis
62591642|NCT03671109|PLACEBO_COMPARATOR|IPTp-Placebo|Monthly IPTp-placebo over three days plus daily ARVs and cotrimoxazole prophylaxis
62591643|NCT00555919|EXPERIMENTAL|Arm 1|
62591644|NCT00555919|EXPERIMENTAL|Arm 2|
62591645|NCT02180984|ACTIVE_COMPARATOR|BED randomized to rTMS|"30 obese individuals currently diagnosed with BED and meeting criteria for the study will be randomized to active rTMS treatment.~Intervention: Neurosoft device targeting the left DLPFC (neuro-navigational method).~Proposed schedule of treatment:~20 sessions of neuronavigated rTMS, one session per day, 3 days/week over approximately 7 weeks. Focal rTMS will be performed using a Neurosoft device and a 'figure of eight' coil. Brainscience Neuronavigation will be used to guide the placement of the coil to the target PFC region using a template MRI for all participants. The coil will be placed at a 45° angle to the mid-sagittal line to induce a posterior to anterior current in the underlying neural tissue. For the real treatment condition, stimulation will target the left DLPFC at 110% of the resting motor threshold. Each session of 10 Hz stimulation will apply 1000 pulses to the left hemisphere, with a duty cycle of 5s on and 55s off, for a total stimulation time of 20 min."
62806278|NCT00985673|EXPERIMENTAL|Arepanrix/placebo/Flulaval Group|subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
62806279|NCT01302717|ACTIVE_COMPARATOR|Right ventricular pacing|
62806280|NCT01302717|EXPERIMENTAL|Left ventricular pacing|
62030634|NCT01973127|SHAM_COMPARATOR|Sham TMS|"n=15. After detoxification of alcohol (maximum 4 days) rTMS treatment will start : 20 sessions (5 times during 4 weeks)of sham rTMS on the right dorsolateral prefrontal cortex.~Measurements of all objectives at basleine and 2,4,8 and 12 weeks after start treatment."
62030635|NCT00579917||1 Cognitive-behavioral therapy (CBT)|Cognitive-behavioral therapy (CBT) involves one-on-one counseling
62421833|NCT05943873||Control|Conventional mastectomy
62806281|NCT03301883|EXPERIMENTAL|Tocilizumab|Participants weighing greater than or equal to (\>/=) 30 kilograms (kg) will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion every 2 weeks (Q2W), and participants weighing less than (\<) 30 kg will receive tocilizumab 12 mg/kg IV infusion Q2W for 52 weeks. After Week 12, the dose of tocilizumab can be adjusted for non-transient changes in body weight (shifting from \<30 to \>/=30 kg) over a minimum of three consecutive dosing visits. MTX, NSAIDs, and oral corticosteroids (CSs) are permitted but not required during the study.
62806282|NCT00817726||1- RBD|polysomnographically diagnosed RBD patients. RBD is a sleep disorder diagnosed by a sleep lab in which the individual has muscle movements during the phase of deep sleep during which the muscles should be relaxed. Suspicion of RBD by history will be confirmed during screening.
62421834|NCT05943873||Minimally invasive|robotic-assisted or endoscopic assisted mastectomies
62421835|NCT02996448|EXPERIMENTAL|NDV 3A vaccine|Participants will receive a single dose of 0.5 mL (300 micrograms of rAls3) administered via IM injection.
62421836|NCT02624817|EXPERIMENTAL|Drug: Sulfonylurea|Sulfonylurea tablets (glibenclamide, other forms of sulfonylureas) were administered at the time of intervention (before November 1, 2006). The patients have been prospectively followed up. Sulfonylurea dose, insulin requirement, death of all causes, episodes of severe hypoglycemia, ketoacidosis, development of discoloured teeth and diarrhea have been recorded. For a small number of subjects, increment of insulin and C-peptide after either an oral or intravenous glucose load and/or response to glucagon have been tested.
62421837|NCT04554927|EXPERIMENTAL|WEB-application|
62030636|NCT00579917||2 Usual Care|Usual Care
62806283|NCT00817726||2 - control|"control:~* must not have any neurological degenerative diagnosis.~* must NOT have RBD.~* must be able to age and/or gender-match to RBD and PD subjects already enrolled."
62806284|NCT05569902|EXPERIMENTAL|Active tACS|Participants in this group received 20 minutes of active 6 Hz stimulation over the medial prefrontal cortex.
62806285|NCT05569902|SHAM_COMPARATOR|Sham tACS|Participants in this group received 20 minutes of sham stimulation over the medial prefrontal cortex.
62806286|NCT00285896|ACTIVE_COMPARATOR|Active|GLP-1
62806287|NCT00285896|PLACEBO_COMPARATOR|Placebo|Placebo
62806288|NCT03361085|EXPERIMENTAL|Intervention|nvHAP-Prevention Bundle
62806289|NCT01512134|EXPERIMENTAL|DBS Surgery|All patients enrolled will undergo DBS implantation in the targeted region to assess the safety of the procedure and the efficacy through weight loss.
62806290|NCT06350188|EXPERIMENTAL|experimental|the patient will receive kinsiotape therapy
62806291|NCT06350188|ACTIVE_COMPARATOR|traditional|the patient will receive traditional therapy
62806292|NCT04294121|EXPERIMENTAL|Children|"Children aged 5-13 years, all genders, will be exposed to a set of breakfast cereals displaying varying child-appealing and parent-appealing marketing techniques as well as varying degrees of child-appealing marketing power on their packaging. Children will be asked to determine if each individual cereal is child-appealing (i.e., yes or no). Children will also be asked to rank the cereals in order of their preference (i.e., Most (1) to Least (6)). Children will then participate in a focus group discussion about the why they classified/ranked the cereals the way that they did."
62421838|NCT04554927|ACTIVE_COMPARATOR|Standard accompaniment|
62806293|NCT04294121|EXPERIMENTAL|Parents|"Parents or guardians of the children in the study will be exposed to a set of breakfast cereals displaying varying child-appealing and parent-appealing marketing techniques as well as varying degrees of child-appealing marketing power on their packaging. Parents will be asked to determine if each individual cereal is child-appealing (i.e., yes or no). Parents will also be asked to rank the cereals in order of which they would be most likely to purchase for a child (i.e., Most (1) to Least (6)). Parents will then participate in a focus group discussion about the why they classified/ranked the cereals the way that they did."
62806294|NCT00637065|ACTIVE_COMPARATOR|1|Bosentan tablets (62.5mg bd for first 4 weeks, then 125mg bd as tolerated)
62806295|NCT00637065|PLACEBO_COMPARATOR|2|Placebo tablets
62806296|NCT04206735|EXPERIMENTAL|Interprofessional Education (IPE)|Each hospital needs to assign a 'COPD-NIV' team of champions to lead the implementation strategy at the local level. We will provide virtual or in-person (if safety permits) training for the COPD-NIV teams (one RT, one RN, and one MD). The training will consist of NIV knowledge and skills through the principles of IPE and teamwork. We will use the train the trainer method; after we train the COPD-NIV team champions, the champions will promote and hold training sessions for their peers in person (if safety permits, 2-3 times a month for 4 months). At present, we are providing these training sessions as prerecorded content available whenever the clinician is available. Champions will promote the training to their clinicians for the first 4 months and then at 6 and 12 months for new staff.
62806297|NCT02005016|EXPERIMENTAL|Intervention|All study participants will be assigned to this arm of this single-arm study. Participants will receive intensive behavioral therapy intended to improve their naming (word production) ability.
62806298|NCT00791388|PLACEBO_COMPARATOR|placebo|placebo capsule
62806299|NCT00791388|EXPERIMENTAL|50 mg PG 760564|50 mg PG 760564 active
62806300|NCT00791388|EXPERIMENTAL|100 mg PG 760564|100 mg PG 760564 active
62806301|NCT00791388|EXPERIMENTAL|200 mg PG 760564|200 mg PG 760564 active
62421839|NCT03875300|EXPERIMENTAL|Participants in the Intervention Group|Intervention Group - will undertake a programme of 7 x 2 hour group sessions, following the scripted 'Foodwise in Pregnancy' manual of nutrition information; practical cooking sessions; and information on low impact exercise.
62421840|NCT03875300|NO_INTERVENTION|Participants in the Control Group|Control Group - will continue with routine antenatal care, unchanged.
62421841|NCT02015299|EXPERIMENTAL|Linagliptin|Linagliptin 5 mg/day + lifestyle advise
62806302|NCT00791388|EXPERIMENTAL|400 mg PG 760564|400 mg PG 760564 active
62806303|NCT00405080|EXPERIMENTAL|Treatment Period 1|Subject will receive single oral dose of 150 milligram (mg) of Casopitant. There will be wash out period of 7 days.
62806304|NCT00405080|EXPERIMENTAL|Treatment Period 2|Subjects will receive rifampin 600 mg once daily on Days 1 - 9. On Day 8 subjects will receive a single dose of oral casopitant 150 mg along with rifampin.
62806305|NCT02738814|EXPERIMENTAL|PAED > 13|When severe emergence agitation(PAED is 14 or more) is occured, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.
62806306|NCT02738814|NO_INTERVENTION|PAED < 14|Caregivers must first try to reassure patients.
62806307|NCT01599663|EXPERIMENTAL|Intervention units|"A time period before the clinicians will be educated, trained and guided in the pain management algorithm, pre-test data will be collected in four ICU units.~The clinicians in three of the ICU units will be educated, trained and guided in the pain management algorithm. The algorithm will then be used to assess and treat pain in all consecutive ICU patients. Post-test data will be collected a time period after the intervention is implemented."
62806308|NCT01599663|NO_INTERVENTION|Control unit|The clinicians in the fourth ICU (control unit) will not be educated, trained and guided in the pain management algorithm. They will continue to assess and treat pain in all consecutive ICU patients as before. The unit, which will be used as a comparison unit, will collect the same post-test data at the same time as data in intervention ICUs were collected.
62806309|NCT02304900|EXPERIMENTAL|Group 1 : white implant|Randomization will determine the color of the implant to be used for each patient for interventions in both eyes, white or yellow to know.
62806310|NCT02304900|EXPERIMENTAL|Group 2 : yellow implant|Randomization will determine the color of the implant to be used for each patient for interventions in both eyes, white or yellow to know.
62806311|NCT03568981||Partial Breast Irradiation (PBI)|Patients receiving 5-fraction stereotactic partial breast irradiation for breast cancer
62806312|NCT03568981||Whole Breast Irradiation (WBI)|Patients receiving whole breast irradiation for breast cancer
62806313|NCT05507307|EXPERIMENTAL|MBSR group|mindfulness-based pregnancy education program group
62806314|NCT05507307|NO_INTERVENTION|Control group|control group standard care group
62243135|NCT06735209|EXPERIMENTAL|Arm 1 Part 2 Group 6|Healthy malaria-naïve participants aged between 18 and 45 years will receive 2x10\^5 PfSPZ of Plasmodium falciparum sporozoite vaccine (PfSPZ-LARC2) vaccine on Days 1, 29, and 57 followed by 3.2x10\^3 PfSPZ Challenge (7G8) Controlled Human Malaria Infection (CHMI) on Day 141 administered by direct venous inoculation (DVI). Selection Criteria for Part 2 based on protection outcomes in Part 1 (protection = no evidence of infection by qRT-PCR endpoint after CHMI for vaccinated participants) N=3
62421842|NCT02015299|PLACEBO_COMPARATOR|Placebo|Matching placebo + lifestyle advise
62735420|NCT05924581|EXPERIMENTAL|Clinical assessment of spinal stiffness|"Patients' back flexibility will be assessed during the medical examination or physiotherapy session through one of the following non-invasive tests:~* Thoracic Stiffness Test (TST)~* Scoliosis stiffness test (SST)~* Kyphosis Stiffness Test (KST) Each test will be carried out at the beginning of the visit and repeated at the end 2 times by different operators, or once by the same operator to verify that the measurements taken at different times are reliable and that the measurements taken by two different operators are reliable."
62735421|NCT03292874|OTHER|Paired imaging|Single arm, paired imaging of high resolution MRI (hrMRI) and stand MRI (sMRI)
62806315|NCT03714178|EXPERIMENTAL|FARAPULSE Endocardial Ablation|Subjects who are treated with the FARAPULSE Endocardial Ablation System for paroxysmal atrial fibrillation.
62806316|NCT05020509|ACTIVE_COMPARATOR|Touhy needle group|medial branch block with touhy needle
62806317|NCT05020509|PLACEBO_COMPARATOR|Quincke needle group|medial branch block with Quincke needle
62806318|NCT06086821|ACTIVE_COMPARATOR|3-Months|Periodontal Re-evaluation performed three months after Step 2 have been completed.
62806319|NCT06086821|EXPERIMENTAL|6-Months|Periodontal Re-evaluation performed six months after Step 2 have been completed.
62806320|NCT02307708|EXPERIMENTAL|8° incline shoe|"The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.~During the walk we will have:~In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).~In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction)."
62806321|NCT02307708|ACTIVE_COMPARATOR|kinesitherapy|The patient performs its home therapy and consults his physiotherapist once a week according to the protocol Stanish
62806322|NCT03947177|PLACEBO_COMPARATOR|Control|GMIT
62806323|NCT03947177|EXPERIMENTAL|Intervention|Modified GMIT + Parenting support groups
62806324|NCT00471692|PLACEBO_COMPARATOR|placebo|Normal saline placebo
62806325|NCT00471692|ACTIVE_COMPARATOR|Ropivocaine|Ilioinguinal nerve block with ropivocaine
62806326|NCT05677893|EXPERIMENTAL|Investigational drug|Eligible participants will be assigned to receive 0.3-1.2 mg/kg single or multiple doses of the investigational drug.
62806327|NCT05677893|PLACEBO_COMPARATOR|Placebo|Eligible participants will be assigned to single or multiple doses of the placebo.
62806328|NCT03980015||erythema migrans|patients with erythema migrans
62806329|NCT04048486||CAPA-IVM|Live babies born from CAPA-IVM
62806330|NCT04048486||IVF/ICSI|Live babies born from IVF/ICSI
62806331|NCT04048486||Natural conception|Live babies born from natural conception
62806332|NCT01990521|EXPERIMENTAL|MS3TMRI / TRUS Guided Biopsy|
62806333|NCT00793195|ACTIVE_COMPARATOR|1) Intralipid|Fat Emulsions for Intravenous Nutrition
62030637|NCT04805125|ACTIVE_COMPARATOR|Moderna mRNA COVID-19 vaccine|"The Moderna COVID-19 Vaccine, mRNA-1273 (100 μg) is administered intramuscularly as a series of two doses (0.5 mL each), given 28 days apart.~ARM CLOSED"
62030638|NCT04805125|ACTIVE_COMPARATOR|Comirnaty® (Pfizer / BioNTech) mRNA COVID-19 vaccine|"Active:~The comparator product is the first licensed vaccine against SARS-CoV-2 in Switzerland.~Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 (30 µg) Comirnaty®, is administered intramuscularly (IM) as a series of two 30 µg doses of the diluted vaccine solution (0.3 mL each) according to the following schedule: a single dose followed by a second dose 21 days later.~ARM CLOSED"
62030639|NCT03349450|EXPERIMENTAL|Single Arm-Investigational|"DPX-Survivac Priming dose of 0.5ml. DPX-Survivac Booster dose of 0.1ml.~Pembrolizumab 200mg Intravenously.~Cyclophosphamide 50mg Twice daily orally."
62243136|NCT06735209|EXPERIMENTAL|Arm 1 Part 2 Group 7|Healthy malaria-naïve participants aged between 18 and 45 years will receive 4x10\^5 PfSPZ of Plasmodium falciparum sporozoite vaccine (PfSPZ-LARC2) vaccine on Days 1, 29, and 57 followed by 3.2x10\^3 PfSPZ Challenge (7G8) Controlled Human Malaria Infection (CHMI) on Day 141 administered by direct venous inoculation (DVI). Selection Criteria for Part 2 based on protection outcomes in Part 1 (protection = no evidence of infection by qRT-PCR endpoint after CHMI for vaccinated participants) N=15
62243137|NCT06735209|PLACEBO_COMPARATOR|Arm 2 Part 1 Group 2|Healthy malaria-naïve participants aged between 18 and 45 years will receive saline placebo on Days 1, 29, and 57 followed by 3.2x10\^3 PfSPZ Challenge (7G8) Controlled Human Malaria Infection (CHMI) on Day 169 administered by direct venous inoculation (DVI). Placebo participants that drop out prior to CHMI will be replaced with infectivity controls. Infectivity controls will receive PfSPZ Challenge (7G8) CHMI N=1
62243138|NCT06735209|PLACEBO_COMPARATOR|Arm 2 Part 1 Group 4|Healthy malaria-naïve adult participants with no prior history of malaria vaccine study involvement and no exposure to Plasmodium parasites in the past two years, aged between 18 and 45 years will receive saline placebo on Days 1, 29, and 57 followed by 3.2x10\^3 PfSPZ Challenge (7G8) Controlled Human Malaria Infection (CHMI) on Day 141 administered by direct venous inoculation (DVI). Placebo participants that drop out prior to CHMI will be replaced with infectivity controls. Infectivity controls will receive PfSPZ Challenge (7G8) CHMI N=6
62806334|NCT00793195|EXPERIMENTAL|2) SMOFlipid|Fat Emulsions for Intravenous Nutrition
62806335|NCT00361881|EXPERIMENTAL|1|ME-609
62806336|NCT00361881|ACTIVE_COMPARATOR|2|Acyclovir in ME-609 vehicle
62806337|NCT00361881|PLACEBO_COMPARATOR|3|Vehicle
62806338|NCT01845935|EXPERIMENTAL|only one treatment group|Patients presenting inoperable venous vascular malformations in soft tissues with indication of cryoablation.
62806339|NCT06527170||Male patients|Male patients undergoing bariatric surgery
62806340|NCT00420485|EXPERIMENTAL|Daily times five schedule|
62806341|NCT00420485|EXPERIMENTAL|Continuous schedule, twice daily|
62806342|NCT05887986|EXPERIMENTAL|hand-held fan airflow stimulation|
62806343|NCT05887986|NO_INTERVENTION|control group|
62806344|NCT04900012||Distal pancreatectomy|All cases operated on performing distal pancreatectomy in involved Units
62806345|NCT05106881|EXPERIMENTAL|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 20-30 minutes functional gait training on varied environments with device.
62806346|NCT01746303|EXPERIMENTAL|Omega 3 and Blueberry powder|This group will receive omega-3 fatty acid and blueberry powder supplement for 24 weeks (6 months)
62806347|NCT01746303|EXPERIMENTAL|Omega-3 and placebo powder|This group will receive omega-3 fatty acid and placebo powder for 24 weeks (6 months)
62806348|NCT01746303|EXPERIMENTAL|Placebo oil and blueberry powder|This group will receive placebo oil and blueberry powder for 24 weeks (6 months).
62421843|NCT06263179|EXPERIMENTAL|Target Heartrate Aerobic Exercise (THRAE)|Participants will be asked to complete the Buffalo Concussion Treadmill Test (BCTT), a safe graded exercise test that is used to identify concussion-related exertion intolerance. Participants will wear a heart rate (HR) monitor for the collection of continuous HR data. The test is stopped when a participant's symptoms increase subjectively by an intensity of 3 points or more from the pre-exercise value on a scale from 0-10, or they report being physically exhausted. Their HR at the time of test termination constitutes the HR threshold (HRt). An individualized THRAE program will be prescribed based on 80% of the HRt on the BCTT. Participants will be given a Polar HR monitor to wear while performing their THRAE prescription, which will be performed at home for 20 minutes, 4-5 days per week, for 6 weeks or until medically cleared from their concussion.
62806349|NCT01746303|PLACEBO_COMPARATOR|Placebo oil and placebo powder|This group will receive placebo oil and placebo powder for 24 weeks (6 months)
62806350|NCT00857285|EXPERIMENTAL|1|olmesartan medoxomil
62735422|NCT03666520||Control Group|Clinician not prompted to change the drug from intravenous to oral equivalent.
62806351|NCT00857285|ACTIVE_COMPARATOR|2|losartan potassium
62806352|NCT05272618||MINOCA with CMD|MINOCA patients with CMD proven by invasive or non-invasive method
62806353|NCT05272618||MINOCA without CMD|MINOCA patients without CMD
62806354|NCT00798616|PLACEBO_COMPARATOR|Responders/Placebo|Albuterol responders being given placebo
62806355|NCT00798616|ACTIVE_COMPARATOR|Responders/Steroids|albuterol responders being given steroids
62806356|NCT00798616|PLACEBO_COMPARATOR|Non-responders/placebo|non-albuterol responders being given placebo
62806357|NCT00798616|ACTIVE_COMPARATOR|non-responders/steroids|non-albuterol responders being given steroids
62806358|NCT02305030|EXPERIMENTAL|BIA 9-1067 / Warfarin|BIA 9-1067 capsules of 25 mg or 50 mg Warfarin capsules of 5 mg
62806359|NCT02961608|EXPERIMENTAL|study group|
62806360|NCT05565287|EXPERIMENTAL|Brazelton and Prechtl Assessment Group|Parental advise and intervention based on the combination of neonatal neurobehaviourism (Brazelton) and motor behaviour (Prechtl)
62806361|NCT05565287|NO_INTERVENTION|No intervention group|Basic hospital guidelines
62806362|NCT05101447|EXPERIMENTAL|MMF PK|
62806363|NCT05101447|ACTIVE_COMPARATOR|MMF BSA|
62806364|NCT04721678|EXPERIMENTAL|Interpersonal psychotherapy (IPT)|10 weeks of internet-administered interpersonal psychotherapy with therapist support.
62806365|NCT04721678|NO_INTERVENTION|Wait-list control group|The participants in the control group will receive access to the treatment after the post-treatment assessment has been conducted.
62806366|NCT00597402|EXPERIMENTAL|Avastin, radiation, temozolomide, and irinotecan|
62806367|NCT01972581|EXPERIMENTAL|Reaction Time Training|
62806368|NCT01972581|NO_INTERVENTION|Control|
62806369|NCT06543667|EXPERIMENTAL|Limbal Stem Cell Derived Exosome Eye Drop treatment|Patients will receive artificial tears for 2 weeks to get the normalized baseline, followed by LSC-Exo eye drop intervention for 3 months.
62806370|NCT06112483||Children and adolescents with special education needs|Children and adolescents with special education needs, including (a) specific learning difficulties; (b) intellectual disability; (c) autism; (d) attention deficit hyperactivity disorder; (e) physical disabilities.
62806371|NCT01809821|EXPERIMENTAL|Online Sleep Education|The sleep intervention is a multi-component online intervention consisting of sleep information and sleep hygiene education, along with behavioural and cognitive components.
62806372|NCT01809821|NO_INTERVENTION|Usual CV care|Specialist nurses will administer the CV risk factor education intervention to participants in small groups over one hour.
62806373|NCT01489319|EXPERIMENTAL|Nl Wt PCOS - Nl Abdominal Adiposity|10 normal weight women with PCOS who have normal abdominal adiposity established by DEXA
62806374|NCT01489319|EXPERIMENTAL|Nl Wt PCOS - Increased Abdominal Adiposity|10 normal weight women with PCOS who have increased abdominal adiposity established by DEXA
62806375|NCT01489319|NO_INTERVENTION|Obese PCOS|10 obese women with PCOS
62806376|NCT01489319|NO_INTERVENTION|Nl Wt Controls - Nl Abdominal Adiposity|10 normal weight ovulatory women serving as controls who have normal abdominal adiposity established by DEXA
62806377|NCT01489319|NO_INTERVENTION|Nl Wt Controls - Increased Abdominal Adiposity|10 normal weight ovulatory women serving as controls who have increased abdominal adiposity established by DEXA
62806378|NCT01489319|NO_INTERVENTION|Obese Controls|10 obese ovulatory women serving as controls
62806379|NCT02921672|ACTIVE_COMPARATOR|Cognitively Normal|Persons who are considered to have normal cognitive function. A registered dietician will meet with each person to discuss the Mediterranean Diet.
62806380|NCT02921672|ACTIVE_COMPARATOR|Mild Cognitive Impairment|Persons diagnosed mild cognitive impairment (MCI). A registered dietician will meet with each person to discuss the Mediterranean Diet.
62806381|NCT02921672|EXPERIMENTAL|Mild to Moderate Alzheimer's Disease|Persons diagnosed with mild to moderate Alzheimer's disease (AD). A registered dietician will meet with each person to discuss the Mediterranean Diet.
62806382|NCT01248195|OTHER|Phase I: 1 arm 'amisulpride open label'|For 4 weeks, all patients will be treated with amisulpride open label.
62591646|NCT02180984|SHAM_COMPARATOR|Sham BED TMS|"30 obese individuals currently diagnosed with BED will be randomized to receive sham TMS treatment. Blinded to participants and study staff, except to the doctor applying the TMS treatment.~Intervention: Neurosoft device targeting the left DLPFC (neuro-navigational method).~Proposed schedule of treatment:~20 sessions of neuronavigated rTMS, one session per day, 3 days/week over approximately 7 weeks. Focal rTMS will be performed using a Neurosoft device and a 'figure of eight' coil. Brainscience Neuronavigation will be used to guide the placement of the coil to the target PFC region using a template MRI for all participants. The coil will be placed at a 45° angle to the mid-sagittal line to induce a posterior to anterior current in the underlying neural tissue. Sham treatment condition, will follow the same protocol however no real TMS will be delivered."
62421844|NCT04310735|EXPERIMENTAL|Experimental: Expect-Yes|Participants assigned to this condition will undergo a verbal smoking expectancy manipulation such that they will perceive an opportunity to smoke during the experimental session.
62591647|NCT02180984|NO_INTERVENTION|Control (obese non BED)|15 controls, obese but without a current or past diagnosis of BED will complete the baseline measurements only.
62806383|NCT01248195|ACTIVE_COMPARATOR|Phase II: 'amisulpride double blind'|Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'amisulpride double blind'
62806384|NCT01248195|ACTIVE_COMPARATOR|Phase II 'olanzapine double blind'|Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'olanzapine double blind'
62806385|NCT01248195|OTHER|Phase III: 1 arm 'clozapine open label'|Patients who do not meet remission criteria during phase II (6-week double blind amisulpride vs olanzapine), flow to phase III, where only 1 arm is available: 'clozapine open label'
62806386|NCT01248195|EXPERIMENTAL|Psychosocial intervention|Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Psychosocial Intervention' arm.
62806387|NCT01248195|NO_INTERVENTION|Psychosocial Intervention phase: 'TAU'|Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Treatment as usual' arm.
62806388|NCT01030029|ACTIVE_COMPARATOR|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
62806389|NCT01030029|PLACEBO_COMPARATOR|pstim device without acupuncture|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
62806390|NCT04959747|EXPERIMENTAL|acupuncture group|"Subject will be scheduled for a total of 8 sessions of acupuncture treatment, to be done by the 30 minutes for each session, twice per week over a 4-week period.~Body acupuncture will choose eight acupoints as Yingxiang (LI20),Shangxing (GV23), BiTong, Yintang, Hegu. Disposable acupuncture needle (0.25 mm in diameter and 25-30mm in length) are inserted at a depth of 10-25 mm obliquely into scalp acupuncture points (ShangXing, YinTang) and straightly into face/body acupuncture points (Yingxiang, BiTong, Hegu).~We will also deliver electro-acupuncture will be applied to the face points at fast and dispersed waves through electric needle stimulator which is provided by Chinese Medicine Clinic (ES-160 6-Channel Programmable electro-acupuncture) for 30 minutes."
62806391|NCT04959747|PLACEBO_COMPARATOR|sham-acupuncture group|"For subjects assigned to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to serve as sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin instead of insertion. Its validity and credibility have been well demonstrated."
62806392|NCT05259345|ACTIVE_COMPARATOR|Group SE-TAP block|Bilateral subcostal exterior semilunaris transverses abdominis plane (SE-TAP) block will be performed with 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline)
62806393|NCT05259345|ACTIVE_COMPARATOR|Group M-TAPA block|Bilateral modified thoracoabdominal nerves block through perichondrial approach (M-TAPA) will be performed with 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline)
62806394|NCT05259345|ACTIVE_COMPARATOR|Group RS block|Bilateral rectus sheath block will be performed with 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline)
62806395|NCT01645072|EXPERIMENTAL|Low glycemic index diet|The patients will be started on low glycemic index diet.
62030640|NCT01237639|EXPERIMENTAL|Restrictive Red blood cell Transfusion|Transfusion Trigger of 70g/L with an aim to maintain Hemoglobin between 80-90g/L
62421845|NCT04310735|EXPERIMENTAL|Experimental: Expect-No|Participants assigned to this condition will undergo a verbal smoking expectancy manipulation such that they will not perceive an opportunity to smoke during the experimental session.
62591648|NCT02180984|NO_INTERVENTION|Controls (normal weight)|15 controls, normal weight and without a current or past diagnosis of BED will complete baseline measures only.
62591649|NCT04875715|EXPERIMENTAL|Almond oil|Almond Oil Pressed Cold
62591650|NCT04875715|ACTIVE_COMPARATOR|Hydroquinone|Hydroquinone 2% cream
62591651|NCT01323010|EXPERIMENTAL|Albuterol - Experimental|Albuterol dosages during the first hour include 900 mcg (up to 15 kg), 1200 mcg (\> 15 to 20 kg), 1500 mcg (\> 20 to 25 kg) and 1800 mcg (\> 25 kg).
62591652|NCT01323010|ACTIVE_COMPARATOR|Albuterol - Control|Albuterol dosages during the first hour include either 600 mcg (up to 25 kg) or 1200 mcg (\> 25 kg).
62591653|NCT05113979|EXPERIMENTAL|IOPCL|Intraocular Pseudophakic Contact Lens (IOPCL) with +3.0D add
62030641|NCT01237639|ACTIVE_COMPARATOR|Liberal Red blood Cell Transfusion|Transfusion Trigger of 90g/L with an aim to maintain Hemoglobin between 100-110g/L
62030642|NCT00352365|EXPERIMENTAL|Treatment (lenalidomide)|"INDUCTION THERAPY: Patients receive oral lenalidomide once daily on days 1-14, 1-21, or 1-28 (course 1). Patients undergo bone marrow biopsy on day 28 or 35 to assess treatment efficacy. Patients with stable or improving disease (i.e., a decrease in blast percentage) without progressive disease proceed to maintenance therapy.~MAINTENANCE THERAPY: Beginning within 42 days after completion of induction therapy, patients receive oral lenalidomide once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62030643|NCT02345031|ACTIVE_COMPARATOR|AUT00063 (600 mg capsules)|3 capsules of 200 mg of the investigational drug AUT00063, to take orally once daily with food for 4 weeks
62030644|NCT02345031|PLACEBO_COMPARATOR|(AUT00063 placebo capsules)|3 capsules of placebo, to take orally once daily with food for 4 weeks
62030645|NCT04749420||Patients group|Individuals with cervical radiculopathy
62421846|NCT05065242|EXPERIMENTAL|Cognitive Behavioural Therapy|Cognitive Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles and to a lesser extent some cognitive exercises. focused on handling sleep disturbing thought activities.
62421847|NCT05065242|NO_INTERVENTION|Waitlist|The waitlist serves as a passive control which will receive the same measures as the cognitive behaviour therapy group.
62421848|NCT01979302|EXPERIMENTAL|Depression CAREPATH|Patients receiving care from Nurses trained in depression care management
62806396|NCT01645072|OTHER|Control group|Standard care. The control group will receive their usual diet without any alteration. No changes will be made to the patients' antiepileptic medication during the 4-week baseline or the 3-month study periods in both the intervention and control groups, unless medically indicated; e.g. drug side effects, or status epilepticus; in which case appropriate changes will be made to their medications and same will be documented.
62421849|NCT01979302|OTHER|Usual Care|Patients under the care of nurses who were trained in depression assessment and usual care
62806397|NCT06352541|EXPERIMENTAL|PRO-232|"* PRO-232. Moxifloxacin 0.5% y Dexamethasone Phosphate 0.1% Ophthalmic solution.~* Dosage: 1 drop QID \[4\] (four times per day) for 7 days on right eye."
62806398|NCT06352541|PLACEBO_COMPARATOR|Placebo|"* Placebo. Sodium Chloride.~* Dosage: 1 drop QID \[4\] (four times per day) for 7 days on right eye."
62806399|NCT02168114|EXPERIMENTAL|Duchenne Muscular Dystrophy|This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
62806400|NCT02168114|EXPERIMENTAL|Non-affected Subjects|This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
62806401|NCT04510649|EXPERIMENTAL|Surufatinib and Rabeprazole (Part A)|Part A: Surufatinib 300 mg on study days 1 and 11 Rabeprazole 40 mg on study days 5 - 11
62806402|NCT04510649|EXPERIMENTAL|Surufatinib and Rifampin (Part B)|Part B: Surufatinib 300 mg on study days 1 and 12 Rifampin 600 mg on study days 5-15
62806403|NCT06115616||Exercise|
62421850|NCT04164394|PLACEBO_COMPARATOR|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
62806404|NCT04014179|EXPERIMENTAL|Dried Blood Spot (Intervention)|Blood samples will be tested for HCV RNA from dried blood spot cards.
62806405|NCT04014179|EXPERIMENTAL|Point-of-care RNA (Intervention)|Blood samples will be tested for HCV RNA using the Xpert HCV Viral Load Fingerstick point-of-care assay.
62030646|NCT01309620|PLACEBO_COMPARATOR|Placebo|
62030647|NCT01309620|EXPERIMENTAL|Zinc supplement|
62421851|NCT04164394|EXPERIMENTAL|Probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
62421852|NCT03121989|ACTIVE_COMPARATOR|Hyperpolarized Pyruvate (13C) Injection|"The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.~After the injection research, MRI will be done and images evaluated."
62421853|NCT03121989|PLACEBO_COMPARATOR|Coil Testing|Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that acts as test object. It provides a signal that is used to ensure that the MRI system is functioning properly.
62030648|NCT02034578|EXPERIMENTAL|Arm A: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via oral syringe
62030649|NCT02034578|EXPERIMENTAL|Arm B: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via nasogastric tube (NGT) immediately followed by 60 mL of D5W via NGT
62030650|NCT02034578|EXPERIMENTAL|Arm C: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via NGT immediately followed by 60 mL of infant formula via NGT
62030651|NCT03560427|EXPERIMENTAL|duloxetine+morphine|
62030652|NCT03560427|PLACEBO_COMPARATOR|placebo+morphine|
62030653|NCT01943201|EXPERIMENTAL|new bedsheet|new bedsheet
62030654|NCT01943201|PLACEBO_COMPARATOR|conventional bedsheet|conventional bedsheet
62421854|NCT04908956|EXPERIMENTAL|Osimertinib & SBRT|Osimertinib 80mg once daily p.o., until progression or unacceptable toxicity \& locally ablative radiotherapy (SBRT) to the primary tumour and to all metastatic sites.
62806406|NCT04014179|NO_INTERVENTION|Standard of Care (Control)|Sites will continue with their standard of care for hepatitis C testing.
62030655|NCT03872349|EXPERIMENTAL|Monounsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in monounsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 7.1% from saturated fat; 20.7% from monounsaturated fat; 7.2% from n-6 polyunsaturated fat).
62229711|NCT04168853|OTHER|Centrifugal pump group|CABG was performed under normothermic (36-37°C) cardiopulmonary bypass (CPB). All components of the circuits were coated with phosphorylcholine inert surface (PHISIO, Sorin®). The pump manufacturer is Sorin® for the centrifugal pumps.1.5 cm of ITA distality was sampled before blood flow interruption into the graft and before starting CPB (Time 1) and another segment (1.5 cm) before the last coronary anastomosis during aortic cross clamping (Time 2) (Figure 1). Each arterial segment was cut into three parts: a fresh part for arterial myography bathed and stored in a 50 ml organ bath containing a physiological salt solution (PSS). The other two parts were cooled in liquid nitrogen and stored at -80°C for immunohistochemistry and RT-PCR analysis.
62229712|NCT00141726|EXPERIMENTAL|etanercept treatment|Etanercept for lung injury
62229713|NCT04386811|EXPERIMENTAL|Calcitriol|
62421855|NCT04479488||Hospitalized patients|Patient who are suspected or confirmed SARS-CoV2 infection need hospitalization.
62421856|NCT04479488||Non-hospitalized patients|Patient who are suspected or confirmed SARS-CoV2 infection non-hospitalized.
62421857|NCT02682173|ACTIVE_COMPARATOR|Laparoscopic gastric bypass|MR Abdomen in morbidly obese patients receiving gastric bypass
62421858|NCT02682173|ACTIVE_COMPARATOR|Laparoscopic sleeve gastrectomy|MR Abdomen morbidly obese patients receiving sleeve gastrectomy
62421859|NCT04359420|EXPERIMENTAL|BC-Predict|"Women will be sent an invitation letter one to two days after their breast screening invitation letter, directing prospective participants to the online risk assessment platform. Once participants have consented to the study online, they will be directed to the BC-Predict risk assessment questionnaire. Assessment of the online questionnaire during the pilot phase estimated that most women would be able to complete this within 30 minutes.~Women who complete the questionnaire will receive 10-year breast cancer risk estimates once they have screened negative for breast cancer, based on the Tyrer-Cuzick model, incorporating mammographic density, and for some women, SNPs (single nucleotide polymorphisms). Women who are identified as being at high (\>8%) or moderate (5% and \<8%) 10-year risk will be offered a consultation to discuss prevention options including prescription of chemoprevention drugs and/ or more frequent mammography as part of the NHS Breast Screening Programme."
62421860|NCT04359420|ACTIVE_COMPARATOR|NHS-Breast Screening Programme|Usual care in the NHS Breast Screening Programme, which involves mammography every 3 years for the majority of women
62229714|NCT04386811|PLACEBO_COMPARATOR|Placebo|
62229715|NCT03390920|EXPERIMENTAL|Umbilical Allograft|The study is nonrandomized with one arm. Depending on the body area being treated, the amount of the product utilized will be either 1.0cc's or 2cc's.
62229716|NCT03159533|ACTIVE_COMPARATOR|CHW Intervention|CHW lead Sessions Session1: BP and the Cardiovascular System Session 2: Nutrition and food labels Session 3: Physical Activity and Stress Management Session 4: CVD Risk factors: cholesterol, blood sugar, \& Smoking Session 5: Health Communication, Healthcare access \& Review
62229717|NCT03159533|PLACEBO_COMPARATOR|Control Group|Wait-list
62229718|NCT02139787|EXPERIMENTAL|Radio Story|Participants listen to a radio story about a family's' success with preventing or managing hypertension or obesity through diet and physical activity; the focus was for the entire family to implement healthful lifestyle behaviors so the children can learn as well.
62229719|NCT02139787|ACTIVE_COMPARATOR|Control -listened to a brochure|Participants received an audio version of a standard brochure about hypertension or obesity prevention.
62421861|NCT05684497|EXPERIMENTAL|experimental group|The intervention group was conducted a LBPSP
62421862|NCT05684497|NO_INTERVENTION|control group|the control group were not and were left to routine antenatal care.
62421863|NCT05171920|EXPERIMENTAL|Auxora|
62421864|NCT05171920|PLACEBO_COMPARATOR|Placebo|
62030656|NCT03872349|EXPERIMENTAL|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 14.4% from monounsaturated fat; 7.2% from n-6 polyunsaturated fat).
62030657|NCT06668311|EXPERIMENTAL|Play Dough Group|The child will be provided with play dough five minutes before the commencement of nebulizer treatment and will be allowed to continue playing with it throughout the treatment.
62229720|NCT01049971|ACTIVE_COMPARATOR|no wound protector|instead of wound protector, a woven drape is applied
62421865|NCT05359380||SG1 - Trifocal Group|Patients implanted bilaterally with trifocal diffractive IOLs
62421866|NCT05359380||SG2 - Bifocal Group|Patients implanted bilaterally with bifocal hybrid (diffractive - refractive) IOLs
62421867|NCT05359380||SG3 - Monofocal Group|Patients implanted bilaterally with monofocal IOLs
62421868|NCT05567588|EXPERIMENTAL|Pembrolizumab + RT (5 fractions, 8 Gy) + Pembrolizumab|"Pembrolizumab will be started. Stereotactic Body Radiation Therapy will be given before the 2nd course of pembrolizumab and pembrolizumab will be continued.~Pembrolizumab will continue until progression as per immune related response criteria (irRC)."
62421869|NCT03874585|ACTIVE_COMPARATOR|Standard Condition|Participants in the standard condition will receive a 30-minute group-based smoking cessation counseling session based on the 5 A's approach (Ask; Advise; Assess; Assist; Arrange) and free nicotine replacement.
62229721|NCT01049971|EXPERIMENTAL|wound protector|after minilaparotomy, wound protector is applied
62421870|NCT03874585|EXPERIMENTAL|Enhanced Condition|Participants in the standard condition will receive a 30-minute group-based smoking cessation counseling session based on the 5 A's approach (Ask; Advise; Assess; Assist; Arrange), free nicotine replacement, and the 6-week text messaging intervention.
62030658|NCT06668311|EXPERIMENTAL|Picture Book Reading group|Five minutes before the commencement of nebulizer treatment, the child will be provided with a picture book and will be allowed to continue reading it throughout the treatment.
62030659|NCT06668311|NO_INTERVENTION|Control Group|Nebulizer treatment of the child will be performed by the routine protocols currently applied in the emergency department.
62229722|NCT00615329||Soft tissue tumor|Any patient with soft tissue tumor will be asked to give a sample for this study
62806407|NCT04357535||Primary Cohort|"Patients enrolled in this study will have data collected from the beginning of their hospital stay until discharge.~Data collected will include:~* Patient demographics (age, sex, weight, and height)~* Indication for ACE-I, ARB therapy, duration and doses~* Use of any a non ACE-I/ ARB sntihypertensive agents~* Comorbidities, and COVID19 related markers: Including WBC, plateltes, ferritin, CRP, CK, and LD~* CT scan reports~* First positive COVID19 PCR~* Admission to the intensive care unit (ICU) and data relating to ICU stay."
62229723|NCT02826330||case Crohn disease|60 cases with Crohn's Disease
62229724|NCT02826330||first relative healthy|2 healthy relatives per CD case (total 120)
62229725|NCT02826330||controls|60 controls matched on gender and age with CD cases
62229726|NCT05877378|EXPERIMENTAL|Intervention|The intervention group measurements will be carried out every 7 days, since the PICO system lasts from 7 to 14 days, except when the ulcer presents infection, which will be cured every 2-3 days.
62806408|NCT02634385|NO_INTERVENTION|Small Renal Mass|Patient's with a small renal mass will be undergoing embolization prior to laparoscopic partial nephrectomy.
62806409|NCT05028192||Rectal cancer after neoadjuvant treatment|Rectal cancer patients, ycTNM stage II, III, and IV (AJCC 8th), clinically stratified in the pre-cachectic or cachectic stage according to Fearon K et al. definition. That will be subject to curative intent resection or palliative surgery through any approach (open, laparoscopic, or robotic).
62806410|NCT05028192||Control group|Patients who will undergo programmed abdominal surgery through any approach type for no neoplastic or inflammatory disease.
62806411|NCT02641847|EXPERIMENTAL|High risk group A|TA(E)C x 4 cycles to GP x 4 cycles (docetaxel + doxorubicin (epirubicin) + cyclophosphamide to gemcitabine + cisplatin), docetaxel: 75 mg/m2 IV on day 1; doxorubicin: 50 mg/m2 IV on day 1 or epirubicin 75 mg/m2 IV on day 1; cyclophosphamide: 500 mg/m2 IV on day 1; gemcitabine: 1250 mg/m2 IV on day 1 and 8; cisplatin: 75 mg/m2 IV on day 1, dosing interval is 21 days.
62229727|NCT05877378|NO_INTERVENTION|Control|The control group measurements will be carried out every 7 days, except when the ulcer is infected, when the cure will be carried out every 2-3 days. This group (GC) will be treated mainly with betadine and sugar, or other treatments such as alginate patches, corticosteroids, Aquacel, Celestoderm or Mepitel.
62806412|NCT02641847|ACTIVE_COMPARATOR|High risk group B|A(E)C x 4 cycles to T x 4 cycles (doxorubicin (epirubicin) + cyclophosphamide to docetaxel), doxorubicin: 60 mg/m2 IV on day 1 or epirubicin 90 mg/m2 IV on day 1; cyclophosphamide: 600 mg/m2 IV on day 1; docetaxel: 100 mg/m2 IV on day 1, dosing interval is 21 days.
62806413|NCT02641847|OTHER|Low risk group C|A(E)C x 4 cycles to T x 4 cycles (doxorubicin (epirubicin) + cyclophosphamide to docetaxel), doxorubicin: 60 mg/m2 IV on day 1 or epirubicin 90 mg/m2 IV on day 1; cyclophosphamide: 600 mg/m2 IV on day 1; docetaxel: 100 mg/m2 IV on day 1, dosing interval is 21 days.
62030660|NCT05331352|EXPERIMENTAL|Subjects following a psychotherapy|Domestic violence victims following a psychotherapy 15 subjets Aged from 20 to 55
62030661|NCT05331352|EXPERIMENTAL|Subjects unfollowing a psychotherapy|Domestic violence victims unfollowing a psychotherapy 15 subjects Aged from 20 to 55
62229728|NCT00526487|OTHER|1|Endovascular Repair
62229729|NCT05198908|EXPERIMENTAL|VR group|VR (virtual reality glasse) group
62229730|NCT05198908|EXPERIMENTAL|skin to skin group|skin to contact group
62229731|NCT05198908|NO_INTERVENTION|Control group-none|Women in this group will not be subjected to any treatment other than the routine hospital protocol. Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary.
62229732|NCT00796120|EXPERIMENTAL|Trabectedin|Trabectedin 1.5 milligram per square meter (mg/m\^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
62030662|NCT01168817|EXPERIMENTAL|Arm 1|
62030663|NCT01168817|ACTIVE_COMPARATOR|Arm 2|
62030664|NCT01168817|PLACEBO_COMPARATOR|Arm 3|
62030665|NCT03966976|EXPERIMENTAL|Vitaphone Arm|Follow-up via VITAPHONE in addition to conventional monitoring.
62030666|NCT03966976|ACTIVE_COMPARATOR|Conventional Arm|Conventional follow-up
62030667|NCT01221597|EXPERIMENTAL|AA4500|collagenase clostridium histolyticum
62229733|NCT00796120|ACTIVE_COMPARATOR|Doxorubicin plus Ifosfamide|Doxorubicin (as a monotherapy) 75 mg per m\^2 will be given intravenously every 3 weeks or Doxorubicin 60 mg per m\^2 will be given intravenously every 3 weeks followed by ifosfamide 6 to 9 gram (g)/m\^2 every 3 weeks until disease progression.
62229734|NCT03444753|EXPERIMENTAL|Arm A|BMS-986299
62229735|NCT03444753|EXPERIMENTAL|Arm B|BMS-986299 in combination with nivolumab and ipilimumab
62421871|NCT02751255|EXPERIMENTAL|daratumumab--> daratumumab + ATRA|In part A of the study patients will be treated with daratumumab as a single agent. In case patients have progressive disease after cycle 1, or in case patients achieve less than minimal response after cycle 2, or patients achieve less than PR after cycle 3, or in case patients experience progression during daratumumab therapy after having obtained a response, then ATRA will be added to daratumumab (part B).
62421872|NCT05940870||Nerivio treatment for migraine prevention|Patients with migraine who recieved the Nerivio device for migraine prevention therapy
62030668|NCT01221597|PLACEBO_COMPARATOR|Placebo|placebo
62421873|NCT04317053|NO_INTERVENTION|Site-Directed Care (SDC)|Site-specific existing interventions delivered to patients with OUD as part of ED care. At a minimum SDC arm patients will receive from the study research team OD education and naloxone distribution (OEND), a list of opioid treatment programs, and an informational flyer about Relay.
62591654|NCT03067688|EXPERIMENTAL|"Combination drug:Temisartan+Amlodipine+Rosuvastatin"|"60 subjects will be assigned and the subjects will be administered Temisartan+Amlodipine+Rosuvastatin for 8 weeks."
62591655|NCT03067688|ACTIVE_COMPARATOR|Temisartan+Amlodipine|"60 subjects will be assigned and the subjects will be administered Twynsta Tab.(Temisartan+Amlodipine) for 8 weeks."
62030669|NCT04729803|EXPERIMENTAL|Attention Guidance + Exposure|Participants will complete teleconferencing-based exposure trials with an attention guidance component.
62030670|NCT04729803|ACTIVE_COMPARATOR|Exposure Alone|Participants will complete teleconferencing-based exposure trials.
62806414|NCT04921566|OTHER|Sequence TR|13 subjects assigned to the sequence TR will receive a single 10 mg dose of the test product Torasemide (1 x 10 mg tablet), marked as T in the sequence, in Period 1 and a single 10 mg dose of the reference product Toradiur® (1 x 10 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62819504|NCT05471076|EXPERIMENTAL|Fractionated Delivery, Group 2: First injection - Medium dose, Final injection - Higher dose|The first dose for the Fractionated Delivery Arm Group 2 will be divided into 6 smaller amounts (2 visits per week for 3 weeks). The second dose will be given about 3 months later and will be given all at once. At each injection visit for the first dose, the patient will get one amount divided into 2 injections - one in the deltoid muscle of each arm.
62030671|NCT04729803|EXPERIMENTAL|Attention Control + Exposure|Participants will complete teleconferencing-based exposure trials with an attention control component.
62030672|NCT04936022|OTHER|Control|To receive standard care lifestyle advice only
62030673|NCT04936022|EXPERIMENTAL|Isometric Exercise|To receive standard care lifestyle advice plus 3 sessions of isometric exercise per week
62030674|NCT03525353||Patients undergoing ERCP by formally trained Endoscopists|Patients who undergo ERCP (Endoscopic Retrograde Cholangio Pancreatography) performed by Endoscopists who are trained on minimum use of fluoroscopy.
62030675|NCT03525353||Patients undergoing ERCP by Endoscopists not formally trained|Patients who undergo ERCP (Endoscopic Retrograde Cholangio Pancreatography) performed by Endoscopists who have not received formal training on minimum use of fluoroscopy.
62030676|NCT05764850||Case|100 patients followed in pediatric diabetology at the university hospital of Geneva: a cohort
62030677|NCT05764850||Control|50 control patients
62030678|NCT00035126|EXPERIMENTAL|EPO906|
62030679|NCT02186119|EXPERIMENTAL|abicipar pegol 2 mg (group A)|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, and 20, followed by a sham procedure at weeks 12, 16, and 24.
62030680|NCT02186119|EXPERIMENTAL|abicipar pegol 2 mg (group B)|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, 16, and 24, followed by a sham procedure at weeks 12 and 20.
62030681|NCT02186119|EXPERIMENTAL|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, 16, and 24, followed by a sham procedure at weeks 12 and 20.
62030682|NCT02186119|ACTIVE_COMPARATOR|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.
62030683|NCT04747977|EXPERIMENTAL|OTX-DED 0.2mg|Approximately 50 subjects
62030684|NCT04747977|EXPERIMENTAL|OTX-DED 0.3mg|Approximately 50 subjects
62229736|NCT00006177||Adult bipolar patients|Adult bipolar patients
62030685|NCT04747977|PLACEBO_COMPARATOR|Hydrogel Vehicle (HV)|Approximately 50 subjects
62030686|NCT06532175|EXPERIMENTAL|Su-jok Therapy Group /EXPERIMENTAL GROUP|"Providing a comfortable position considering the individual's limitations. In order for the hands not to be cold, the researcher will warm them by rubbing them together and will plan to grasp the patient's hand.~The individuals' pain areas will be determined and reflection points corresponding to these areas on the yin and yang sides will be determined.~The individual will be asked to state when they experience pain and pulling sensations at the points touched by the applicator.~Determining painful reflection points on the back of the individual's hand When each reflection point is determined, green mung bean will be placed on the relevant point and fixed with a plaster band. The same procedure will be applied to all painful points until the individual states that there are no more painful points The point where the seed is fixed will be massaged for 30 minutes. The individual will be helped to take a comfortable position."
62030687|NCT06532175|NO_INTERVENTION|Control Group|No intervention will be made. Data will only be collected when the participant participates in the study, one month after participating in the study, and 2 months after participating in the study.
62030688|NCT06171685|OTHER|Sub-protocol A|
62030689|NCT06171685|OTHER|Sub-protocol B|
62229737|NCT00006177||Adult Extended Relatives of BD probands|Adult Extended Relatives of BD probands
62229738|NCT00006177||Bipolar Children and Youth|Bipolar Children and Youth
62229739|NCT00006177||Child/Adolescent Extended Relatives of BD probands|Child/Adolescent Extended Relatives of BD probands
62229740|NCT00006177||Children with ADHD only (controls)|Children with ADHD only (controls)
62229741|NCT00006177||First degree relatives of BD patients|First degree relatives of BD patients
62229742|NCT00006177||Healthy volunteer adults (parents or not)|Healthy volunteer adults (parents or not)
62229743|NCT00006177||Healthy volunteer children and youth|Healthy volunteer children and youth
62229744|NCT02915393||Healthy Volunteers (BC)|Healthy Volunteers with Balanced Constitution(n=10).
62591656|NCT03067688|ACTIVE_COMPARATOR|Temisartan+Rosuvastatin|"60 subjects will be assigned and the subjects will be administered Micardis Tab. and Crestor Tab.(Temisartan+Rosuvastatin) for 8 weeks."
62591657|NCT04080557||AAA patients that went to the ICU postoperatively|An retrospective cohort study was conducted that included all patients treated electively for an abdominal aortic aneurysm (AAA) by open repair and patients undergoing emergency treatment for a ruptured AAA between 2013 and 2018.
62421874|NCT04317053|EXPERIMENTAL|Relay program (peer navigation)|Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.
62806415|NCT04921566|OTHER|Sequence RT|13 subjects assigned to the sequence RT will receive a single 10 mg dose of the reference product Toradiur® (1 x 10 mg tablet), marked as R in the sequence, in Period 1 and a single 10 mg dose of the test product Torasemide (1 x 10 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62229745|NCT02915393||Healthy Volunteers(QC)|Healthy Volunteers with Qi Deficiency Constitution(n=10).
62806416|NCT03728465|EXPERIMENTAL|Treatment Phase|"Treatment phase is divided into the Induction Phase and Maintenance Phase. During the induction phase patients are treated with 1 mg/kg nivolumab and 3 mg/kg ipilimumab, during the maintenance phase with nivolumab 3 mg/kg only ."
62806417|NCT00527735|EXPERIMENTAL|Ipilimumab/ placebo + paclitaxel + carboplatin (concurrent)|
62806418|NCT00527735|EXPERIMENTAL|Ipilimumab/ placebo + paclitaxel + carboplatin (sequential)|
62229746|NCT02915393||Healthy Volunteers(DC)|Healthy Volunteers with Damp-heat Constitution(n=10).
62591658|NCT00751049|EXPERIMENTAL|PhXA41|
62806419|NCT00527735|ACTIVE_COMPARATOR|Ipilimumab placebo + paclitaxel + carboplatin|
62806420|NCT04702412|EXPERIMENTAL|Opal patient portal|Exposure to routine use of a patient portal (Opal) through which HIV patients are expected to complete a measure on barriers to ART adherence for screening purposes, before each HIV care visit.
62806421|NCT06440473|ACTIVE_COMPARATOR|Roflumilast|
62806422|NCT06440473|PLACEBO_COMPARATOR|Vehicle|
62806423|NCT03358277|EXPERIMENTAL|ADHD+DMDD Group|The subjects with comorbid ADHD and DMDD received pharmacological intervention with combination treatment of MPH+ APZ with flexible dosage according to clinical judgment for six weeks.
62806424|NCT05918796|ACTIVE_COMPARATOR|bupivacaine|ultrasound guided quadratus lumborum perineural injection of 18 ml bupivacaine (0.25%) combined with 2 ml normal saline bilaterally.
62806425|NCT05918796|ACTIVE_COMPARATOR|bupivacaine and dexamethasone|ultrasound guided quadratus lumborum perineural injection of 18 ml bupivacaine (0.25%) combined with 2ml volume of dexamethasone (8mg) bilaterally.
62806426|NCT00963391|EXPERIMENTAL|ABHS use|Centers assigned to the intervention group were provided with ABHS dispensers with a gel solution with ethyl alcohol at 62% as active ingredient (Purell®, GOJO Industries, Dayton, Ohio). Proper safety measures were followed. Standardized ABHS training workshops for staff and children in centers allocated to the intervention were carried out simultaneously with dispenser installation. Thirty minute refresher sessions about ABHS technique were provided to staff and children on a monthly basis, for a total of 8 sessions per center.
62806427|NCT00963391|NO_INTERVENTION|No treatment|Centers assigned to the control group received no hand hygiene recommendations other than to continue with current hand hygiene practices and no further information on hand hygiene other than the general information received before trial initiation was provided.
62229747|NCT02915393||Superficial Gastritis(SDS)|Superficial Gastritis with Spleen-qi Deficiency Syndrome(n=10).
62229748|NCT02915393||Superficial Gastritis(DS)|Superficial Gastritis with Damp-heat Syndrome(n=10).
62806428|NCT04291612||Part 1|Participants will have endometrioid adenocarcinoma histological diagnosis with planned surgical treatment including hysterectomy in combination with SLN biopsy.
62229749|NCT02915393||Atrophic Gastritis(SDS)|Atrophic Gastritis with Spleen-qi Deficiency Syndrome(n=10).
62229750|NCT02915393||Atrophic Gastritis(DS)|Atrophic Gastritis with Damp-heat Syndrome(n=10).
62229751|NCT02915393||Gastric Cancer(SDS)|Gastric Cancer with Spleen-qi Deficiency Syndrome(n=10).
62229752|NCT02915393||Gastric Cancer(DS)|Gastric Cancer with Damp-heat Syndrome(n=10).
62229753|NCT01454518|EXPERIMENTAL|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
62591659|NCT00751049|ACTIVE_COMPARATOR|timolol|
62735423|NCT03666520||Cohort with clinician being prompted to convert drug|This arm would include the provider being prompted to change the intravenous drug to the oral equivalent.
62806429|NCT04291612||Part 2|Participants will have undergone surgery and bilateral sentinel lymph node mapping (negative for malignancy)
62806430|NCT05221411|EXPERIMENTAL|Mycofenolate Mofetil|Patients in the mycophenolate mofetil (MMF) arm will receive MMF for a total of 12 months (if tolerated)
62030690|NCT04802733|EXPERIMENTAL|MSK-DA01|
62030691|NCT02087410||study|patients with polycystic ovary syndrome
62229754|NCT01454518|PLACEBO_COMPARATOR|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
62229755|NCT04778956|EXPERIMENTAL|Toripalimab plus salvage surgery|"1. Toripalimab: Toripalimab treatment before and after salvage surgery.~2. Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor, and selective neck dissection for recurrent regional lymph node."
62229756|NCT04778956|ACTIVE_COMPARATOR|Salvage surgery alone|1. Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor, and selective neck dissection for recurrent regional lymph node.
62421875|NCT04270552|EXPERIMENTAL|Ismigen|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
62421876|NCT04270552|PLACEBO_COMPARATOR|Placebo|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
62806431|NCT05221411|EXPERIMENTAL|Tacrolimus (Envarsus)|Patients in the tacrolimus (TAC) arm will receive treatment with meltdose TAC for a total of 12 months (if tolerated)
62806432|NCT02316730|EXPERIMENTAL|Sanchi-Tongshu Capsule (Enteric coated pellets)|Sanchi-Tongshu Capsule (Enteric coated pellets) is developed by pharmaceutical factory of Chengdu Huasun Group Inc., 0.35g/capsule, containing 100mg of panaxatriol saponins (PTS).
62591660|NCT04891770|EXPERIMENTAL|Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab|"Nucleos(t)ide(s) (NUC)-suppressed participants with chronic hepatitis B (CHB) will receive:~* Tenofovir alafenamide (TAF) 25 mg once daily for 36 weeks (up to 84 weeks).~* VIR-2218 200 mg once every 4 weeks for 24 weeks.~At Week 12 the following will be added:~* Selgantolimod (SLGN) 3 mg once a week on the same day for 24 weeks.~* Nivolumab 0.3 mg/kg once every 4 weeks for up to 24 weeks (Up to protocol amendment 2).~Participants who are on TAF treatment will continue TAF treatment over the duration of study follow-up.~After the implementation of protocol amendment 2, nivolumab treatment was no longer administered."
62421877|NCT06701604|EXPERIMENTAL|Milk Protein + Probiotic|Arm receiving investigational product (probiotic) in the form of a capsule with a dose of 1B Colony Forming Unit (CFU) per day + a 25-gram dose of milk protein concentrate given daily for 3 weeks
62229757|NCT00884494|EXPERIMENTAL|Roux-en-Y gastric bypass|
62421878|NCT06701604|PLACEBO_COMPARATOR|Milk Protein + Placebo|Arm receiving placebo matching investigational product + a 25-gram dose of milk protein concentrate given daily for 3 weeks
62421879|NCT05613920|EXPERIMENTAL|diet management program based on the nudge strategy|The intervention group will receive a diet management program based on the nudge strategy
62591661|NCT04891770|EXPERIMENTAL|Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab|"Viremic participants with CHB will receive:~* VIR-2218 200 mg once every 4 weeks for 24 weeks.~At Week 12, the following will be added:~* SLGN 3 mg once a week on the same day for 24 weeks~* Nivolumab 0.3 mg/kg once every 4 weeks for up to 24 weeks (Up to protocol amendment 2).~Viremic participants who meet criteria to initiate NUC treatment will receive TAF 25 mg once daily for up to 36 weeks during the study.~After the implementation of protocol amendment 2, nivolumab treatment was no longer administered."
62591662|NCT04891770|EXPERIMENTAL|Cohort 2 Group B: SLGN + Nivolumab|"Viremic participants with CHB will receive:~* SLGN 3 mg once a week on the same day for 24 weeks.~* Nivolumab 0.3 mg/kg once every 4 weeks for up to 24 weeks.~Viremic participants who meet criteria to initiate NUC treatment will receive TAF 25 mg once daily for up to 36 weeks during the study.~Cohort 2 Group B, all treatments were administered up to protocol amendment 2 and after the implementation of protocol amendment 2, the treatments were discontinued based on Sponsor decision due to low likelihood of efficacy."
62806433|NCT02316730|ACTIVE_COMPARATOR|Sanchi-Tongshu Capsule|Sanchi-Tongshu Capsule is developed by pharmaceutical factory of Chengdu Huasun Group Inc., 0.2g/capsule, containing 100mg of panaxatriol saponins (PTS).
62806434|NCT02863614|EXPERIMENTAL|Ibuprofen+Lorazepam|Oral ibuprofen (600 mg) + lorazepam (1 mg); one hour before endometrial scratching.
62806435|NCT02863614|ACTIVE_COMPARATOR|Ibuprofen|Oral ibuprofen (600 mg) + Placebo; one hour before endometrial scratching.
62229758|NCT00884494|EXPERIMENTAL|Lean|
62229759|NCT03316625|EXPERIMENTAL|Bone mineral density|Bone densitometry measurement : Measurement of bone mineral densitometry with bone densitometry
62229760|NCT00821574|EXPERIMENTAL|1|Fluvastatin: daily 80 mg, oral
62229761|NCT00821574|EXPERIMENTAL|2|Valsartan
62421880|NCT05613920|NO_INTERVENTION|routine dietary management program|The control group will receive a routine dietary management program
62421881|NCT01956123|EXPERIMENTAL|A|Follitropin Delta (FE 999049) (COS cycle 2)
62421882|NCT01956123|ACTIVE_COMPARATOR|B|Follitropin Alfa (GONAL-F) (COS cycle 2)
62421883|NCT01956123|EXPERIMENTAL|C|Follitropin Delta (FE 999049) (COS cycle 3)
62806436|NCT02863614|PLACEBO_COMPARATOR|Placebo|Placebo + Placebo; one hour before endometrial scratching.
62806437|NCT01885156|PLACEBO_COMPARATOR|Placebo Cream|Topically applied once daily
62806438|NCT01885156|EXPERIMENTAL|Naftin 1% Cream|Topically applied once daily
62229762|NCT00821574|EXPERIMENTAL|3|Hydrochlorothiazide
62229763|NCT01594307||blood pressure monitor|Cuff circumference:13.5cm-22cm
62229764|NCT01594307||stethoscopy|Cuff circumference: 13.5cm-22cm
62229765|NCT02349360|ACTIVE_COMPARATOR|Probiotic|L. johnsonii N6.2 10\^10 CFU in capsule form administered for 8 weeks
62421884|NCT01956123|ACTIVE_COMPARATOR|D|Follitropin Alfa (GONAL-F) (COS cycle 3)
62421885|NCT06619834|ACTIVE_COMPARATOR|Financial Navigation only|Financial navigation using software called TailorMed only. The professional Financial Navigator is from the TailorMed team.
62421886|NCT06619834|ACTIVE_COMPARATOR|Financial Navigation and Peer Support|Financial navigation using software called TailorMed combined with peer support. The professional Financial Navigator is from the TailorMed team. Peer Supporters will be trained community members recruited from Michigan Medicine.
62421887|NCT05226468|EXPERIMENTAL|NEI-01|Single Arm
62229766|NCT02349360|PLACEBO_COMPARATOR|Placebo|Encapsulated starch placebo administered for 8 weeks
62229767|NCT06193460|EXPERIMENTAL|laser group|The anaesthesia will be reversed by the photobiomodulation mode of the diode laser (low-level laser therapy).
62229768|NCT06193460|NO_INTERVENTION|control group|The anesthesia will be withdrawn without intervention.
62421888|NCT05728216||NEPHROCT cohort|Patients \> 18 years of age with suspected acute kidney injury or chronic kidney disease requiring biopsy in the nephrology department
62421889|NCT06520995|NO_INTERVENTION|Control Group|Patients in this group will only receive standard diabetes education.
62421890|NCT06520995|EXPERIMENTAL|Video Group|In addition to standard diabetes education, patients in this group will be educated with the mentioned video education program (a total of 12 diabetes education videos prepared by the researcher).
62421891|NCT06520995|EXPERIMENTAL|Video and Mobile application Group|In addition to standard diabetes education and video education, patients in this group will participate in cognitive exercises for 15-20 minutes a day for 3 months via a mobile application.
62421892|NCT05658107|EXPERIMENTAL|BI 765423 treatment group|BI 765423
62421893|NCT05658107|PLACEBO_COMPARATOR|Placebo group|Placebo
62421894|NCT01888978|EXPERIMENTAL|Modified FOLFOX-6|Oxaliplatin 85 mg/m2 day 1 and 5-fluorouracil 400 mg/m2 day 1 and Leucovorin 400 mg/m2 day 1 and 5-fluorouracil 2400 mg/m2 over 46 hours on day 1-3 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
62421895|NCT01888978|EXPERIMENTAL|Ox-Tax|Docetaxel 65 mg/m2 and Oxaliplatin 100 mg/m2 on day 1 every 3 weeks All drugs will be administered until disease progression or unacceptable toxicity are observed
62030692|NCT02087410||control|healthy patients serves as control group
62030693|NCT04992767|ACTIVE_COMPARATOR|Sunnyside|An online intervention to better manage mood during and after pregnancy.
62421896|NCT01888978|EXPERIMENTAL|FOLFIRI|Irinotecan 180 mg/m2 on day 1 and 5-FU 400 mg/m2 on day 1 and Leucovorin 400 mg/m2 day 1 and 5-FU 2400 mg/m2 over 46 hours, days 1-3 as a continuous infusion All drugs will be administered until disease progression or unacceptable toxicity are observed
62421897|NCT01888978|EXPERIMENTAL|Tax-Iri|2 weeks on, 1 week off of Docetaxel 35 mg/m2/week and Irinotecan 50 mg/m2/week Both administered on day 1 of each week of treatment All drugs will be administered until disease progression or unacceptable toxicity are observed
62591663|NCT00861848||12-50 with heart disease|12-50 with heart disease
62591664|NCT00861848||12-50 normal controls|12-50 normal controls
62591665|NCT03808324|EXPERIMENTAL|Heart transplant recipients|
62591666|NCT05938829|OTHER|Ultrasound using SMFM guidelines, then ultrasound using ISUOG guidelines|Each site will utilize SMFM guidelines for the first 12 months and then there will be a 2 week washout period, after which each site will utilize ISUOG guidelines for 12 months
62591667|NCT02810470|EXPERIMENTAL|Cream appreciation tests|
62591668|NCT02810470|EXPERIMENTAL|Beverages appreciation tests|
62591669|NCT04874233|ACTIVE_COMPARATOR|Active Treatment: HU6 150 mg; N = 20|HU6 is Active Study Drug
62591670|NCT04874233|ACTIVE_COMPARATOR|Active Treatment: HU6 300 mg; N = 20|HU6 is Active Study Drug
62591671|NCT04874233|ACTIVE_COMPARATOR|Active Treatment: HU6 450 mg; N = 20|HU6 is Active Study Drug
62591672|NCT04874233|PLACEBO_COMPARATOR|Placebo Comparator Non-active study drug N = 20|Non-active Study Drug
62591673|NCT04187625|EXPERIMENTAL|Intervention|Patients will be given autologous endothelial progenitor cells
62591674|NCT05354102|EXPERIMENTAL|BMC128 in combination with Nivolumab|"Four 28-day treatment cycles of the standard Nivolumab treatment protocol (480 mg on Day 1 of each cycle) together with a QD regimen of BMC128, followed by a Iong-term Nivolumab monotherapy.~Prior to starting this combination treatment, patients will undergo:~I. Native microbiota depletion stage - patients will be treated with oral Vancomycin 500mg in combination with Neomycin 1000mg, q6h for 72 hours.~II. BMC128 monotherapy induction stage - One BMC128 capsule will be administered once daily QD for a period of 14 days."
62591675|NCT02543372|EXPERIMENTAL|Behavioral Couples Therapy|The participants receive 10 modules each containing treatment focusing on gambling and relationship functioning. The modules consist of text, videos, images and assignments. The participants receive support from an assigned therapist via email and telephone. Both the gamblers and the CSOs receive 10 modules each.
62591676|NCT02543372|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|The participants receive 10 modules each containing treatment focusing on gambling and relationship functioning. The modules consist of text, videos, images and assignments. The participants receive support from an assigned therapist via email and telephone. The gamblers receive 10 modules, but the CSOs do not receive any modules.
62591677|NCT02463929|EXPERIMENTAL|diphenhydramine|Subject sedated with sevoflurane, and given bilateral extraoral infraorbital block with 0,125% bupivacaine. Subject injected 0,5mg/kg diphenhydramine intravenously, 15 minutes prior to discontinuation of sevoflurane. If subject develop agitation, 0,1 mg/kg ketamine is administered
62229769|NCT05510752|ACTIVE_COMPARATOR|Psychoeducation Group|Psychoeducation is the most commonly offered non-pharmacological treatment for perinatal distress, with the assumption that an understanding of perinatal distress, self-care and infant milestones will improve mental health outcomes. Psychoeducation has been shown to be effective in reducing the severity of perinatal anxiety and depression.
62421898|NCT01888978|EXPERIMENTAL|Gem-Ox|Gemcitabine: 1000 mg/m2 over 100 minutes on Day 1 Oxaliplatin: 100 mg/m2 over 120 minutes on Day 2 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
62806439|NCT03824041|PLACEBO_COMPARATOR|Placebo|Formulation containing inert artificially colored maltodextrin, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
62030694|NCT04992767|EXPERIMENTAL|SunnysideFlex|An online intervention to treat symptoms of PTSD and better manage mood during and after pregnancy.
62243139|NCT06735209|PLACEBO_COMPARATOR|Arm 2 Part 2 Group 8|Healthy malaria-naïve participants aged between 18 and 45 years will receive saline placebo on Days 1, 29, and 57 followed by 3.2x10\^3 Challenge (7G8) Controlled Human Malaria Infection (CHMI) on Day 141 administered by direct venous inoculation (DVI). Selection Criteria for Part 2 based on protection outcomes in Part 1 (protection = no evidence of infection by qRT-PCR endpoint after CHMI for vaccinated participants) N=3
62421899|NCT01888978|EXPERIMENTAL|Gem-5FU|Gemcitabine: 1000 mg/m2 over 30 minutes 5-FU 2000/m6 as a 24 hour infusion on days 1, 8, and 15 of every 28 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
62591678|NCT02463929|PLACEBO_COMPARATOR|control|Subject sedated with sevoflurane, and given bilateral extraoral infraorbital block with 0,125% bupivacaine. Subject injected 0,5cc/kg normal saline intravenously, 15 minutes prior to discontinuation of sevoflurane. If subject develop agitation, 0,1 mg/kg ketamine is administered
62030695|NCT04992767|NO_INTERVENTION|Treatment as Usual|A control condition consisting of standard prenatal medical care, without provision of the SunnysideFlex or Sunnyside intervention
62591679|NCT01793480|EXPERIMENTAL|patient-controlled dose of methadone|The titration will be done on the patient's request (patient-controlled dose of methadone), with no overlapping with the previous opioid treatment, under the investigator's supervision.
62806440|NCT03824041|EXPERIMENTAL|Aronia full spectrum - half dose|Formulation containing 50% Aronia full spectrum and 50% placebo, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
62806441|NCT03824041|EXPERIMENTAL|Aronia full spectrum - full dose|Formulation of 100% Aronia full spectrum, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
62030696|NCT04566029||Cases|Patients who have been responding to treatment for a long time
62030697|NCT04566029||Controls|Patients who do not respond to treatment
62030698|NCT00911872|EXPERIMENTAL|aging|
62030699|NCT03923959|ACTIVE_COMPARATOR|Intervention|100 cc normal saline with 1g of tranexamic acid in solution
62030700|NCT03923959|PLACEBO_COMPARATOR|Placebo|100 cc normal saline
62806442|NCT04503746|PLACEBO_COMPARATOR|Placebo|Placebo twice a day
62806443|NCT04503746|EXPERIMENTAL|ALH-L1005 600 mg|ALH-L1005 300 mg twice a day
62806444|NCT04503746|EXPERIMENTAL|ALH-L1005 1,200 mg|ALH-L1005 600 mg twice a day
62030701|NCT05947474|EXPERIMENTAL|Dose Escalation ORB-011|ORB-011 Dose Escalation Participants will be administered study drug at dose levels corresponding to their Cohort. Cohort 1 will be treated with the lowest dose, and the dose will be escalated for future cohorts once the previous dose has been observed not to be associated with DLTs. Up to 7 dose cohorts have been pre-specified. Doses from the escalation arms will be selected as RP2D candidates.
62591680|NCT01793480|EXPERIMENTAL|fixed-dose of methadone|The titration will be done with fixed-dose of methadone, on a progressive switch with overlapping with the previous opioid treatment, to avoid withdrawal syndrome when the opioid is discontinued.
62591681|NCT03692793|EXPERIMENTAL|Pulmonary rehabilitation|The PRP (24-session, three times for week) will be delivered according to ATS/ERS (Spruit et al, 2013),
62030702|NCT01811550||SHINE study subjects|Subjects enrolled in the SHINE trial who are not receiving intra-arterial therapy nor systemic anticoagulation; have no known moderate/severe hepatic insufficiency; have no known history of hypercoaguable or thrombotic condition; have INR =\<1.5 (if known) at baseline and provide informed consent (self or LAR) will be enrolled in the I-SPOT study.
62229770|NCT05510752|EXPERIMENTAL|Cognitive Behavioural Group Therapy|Cognitive Behavioural Group Therapy (CBGT) is a well-established psychological treatment for anxiety and other mental health disorders. CBGT treatment for perinatal anxiety has shown significant reductions in anxiety (primary outcome), worry and depression from pre- to post-treatment when compared to a waitlist control condition. However, to be considered well-established, a treatment must be at least as effective as other active interventions. As such, the present study will compare CBGT to what is most commonly offered to perinatal women with a principal anxiety disorder (i.e., psychoeducation).
62421900|NCT01888978|EXPERIMENTAL|Gem-Tax|Gemcitabine 1000 mg/m2 over 30 minutes and Docetaxel 35 mg/m2 over 60 minutes on days 1, 8, and 15 of every 28 day cycle
62421901|NCT02515552|OTHER|All applicants|Study applicants who consented and completed the application to participate in the Fibromyalgia Wellness Project. From that point forward all subjects used the intervention program to at whatever frequency they chose voluntarily. It was recommended subjects complete a SMARTLog at least three times per week for at least three months.
62421902|NCT06320093|EXPERIMENTAL|Sound intervention|the SOUND intervention is a new and innovative method of applying musical activities in a circle consisting of elderly people with mild-to-moderate dementia, caregivers, family caregivers and young people.
62806445|NCT06154811||Extubation Success Group|Extubation success is defined as the successful completion of a Spontaneous Breathing Trial (SBT) and the maintenance of spontaneous breathing without respiratory distress for at least 48 hours, without the need for non-invasive or invasive ventilation.
62806446|NCT06154811||Extubation Failure Group|Extubation failure is defined as successful Spontaneous Breathing Trial (SBT) but an inability to sustain independent breathing for more than 48 hours without non-invasive or invasive ventilation.
62030703|NCT01725646|ACTIVE_COMPARATOR|Omacor® 4 g|Subjects in this group will take 4 g of Omacor® everyday.
62030704|NCT01725646|ACTIVE_COMPARATOR|Omacor® 2 g|Subjects in this group will take 2 g of Omacor® and 2 g of placebo everyday.
62030705|NCT01725646|PLACEBO_COMPARATOR|Placebo|Subjects in this group will take 4 g of placebo everyday.
62030706|NCT05359523|ACTIVE_COMPARATOR|Patients diagnosed with myofascial pain syndrome|Ultrasound measurements will be made while the upper back is at rest and during arm movements.
62421903|NCT04064359|EXPERIMENTAL|OBT076 Dose Escalation and Expansion|OBT076 administered intravenously (IV) every 3 weeks in escalating dose cohorts during Part A and OBT076 administered at or below the MTD in the Part B expansion cohort. In Part C sequential administration of OBT076 administered at the recommended phase 2 dose (RP2D) followed by Balstilmab. Part D will evaluate the safety, tolerability, preliminary efficacy of OBT-076 in combination with Balstilmab.
62421904|NCT05478486|EXPERIMENTAL|MSP008-22 treatment arm|"Oral Escalating doses of MSP008-22- total five doses, each in form of a single dose oral formulation/tablet.~Each trial participant will receive only one single oral dose of 05 identified dose levels of MSP008-22. Intra-patient dose escalation will not be carried out"
62421905|NCT06541106||Conservative management group|Patients with unruptured VBDAs did not receive any interventional therapy (including endovascular therapy and microsurgery).
62421906|NCT06541106||Stent-assisted coiling group|Patients with unruptured VBDAs receive common stent and coils embolization.
62421907|NCT06541106||Flow diverter group|Patients with unruptured VBDAs receive flow diverter treatment.
62591682|NCT02548351|EXPERIMENTAL|10 mg Obeticholic Acid|10 mg Obeticholic Acid daily for the remainder of the study
62591683|NCT02548351|EXPERIMENTAL|25 mg Obeticholic Acid|25 mg Obeticholic Acid daily for the remainder of the study
62591684|NCT02548351|PLACEBO_COMPARATOR|Placebo|One tablet daily for the remainder of the study
62591685|NCT00611949|ACTIVE_COMPARATOR|1 Geranium Oil|
62591686|NCT00611949|ACTIVE_COMPARATOR|2 Geramium Oil|
62591687|NCT00760695|ACTIVE_COMPARATOR|A|the patients in this arm are receiving 2,5 mg dronabinol twice daily
62591688|NCT00760695|PLACEBO_COMPARATOR|B|the patients in this arm are receiving 2,5 mg placebo twice daily
62806447|NCT04019899|ACTIVE_COMPARATOR|Control group|
62030707|NCT05359523|ACTIVE_COMPARATOR|Healthy volunteers|Ultrasound measurements will be made while the upper back is at rest and during arm movements.
62030708|NCT01792011|EXPERIMENTAL|PVI|A new non-invasive device (Radical-7 pulse oximeter monitor, Masimo Corp.) has been introduced that continuously detects changes in the plethysmograph waveform and computes a Plethysmography Variability Index (PVI) reflecting alteration in preload and fluid management.
62806448|NCT04019899|EXPERIMENTAL|Study group|
62806449|NCT01357226||All patients over the age of 18|
62806450|NCT06372626|EXPERIMENTAL|Part 1: Dose Escalation|Dose-escalation study of ZG005 in combination with Etoposide and Cisplatin.
62806451|NCT06372626|EXPERIMENTAL|Part 2: Dose Expansion|Group A: ZG005 in combination with Etoposide and Cisplatin; Group B: Placebo in combination with Etoposide and Cisplatin.
62806452|NCT01747512|ACTIVE_COMPARATOR|C-PERT|45 patients with cancer
62806453|NCT01747512|ACTIVE_COMPARATOR|G-PERT|65 patients with cancer
62030709|NCT05042219||COPD (ICS)|COPD before initiation of inhaled corticosteroid therapy
62421908|NCT06104592|EXPERIMENTAL|Radiation Therapy and CAR T-Cell Infusion|Following T-cell apheresis for CD19 CAR T-cell therapy, eligible enrolled study participants patients will undergo Comprehensive Ablative Bridging Irradiation (CABI) to all pretreatments lesions that are able to be feasibly and safely treated by the treating radiation oncologist. Upon completion of bridging radiotherapy, patients will undergo lymphodepleting chemotherapy period (Days -5, -4, -3) followed by axi-cel infusion (Day 0).
62806454|NCT05583487|ACTIVE_COMPARATOR|Control/non-experimental group|The control/nonexperimental group will consist of multidisciplinary teams, who will not be given the nurse-led protocol and will be asked to mobilize the assigned ventilated neurosurgery patient according the facility's standard mobility procedures.
62806455|NCT05583487|EXPERIMENTAL|Experimental/interventional group|The experimental/interventional group will consist of multidisciplinary teams who will use a given nurse-led protocol (intervention) to mobilize the assigned patient.
62806456|NCT04616755|ACTIVE_COMPARATOR|Bonded retainer 13-23|This group have bonded retainer behind six front teeth in the maxilla to keep front teeth stable.
62806457|NCT04616755|ACTIVE_COMPARATOR|Bonded retainer 12-22|This group have bonded retainer behind four front teeth in the maxilla to keep front teeth stable.
62806458|NCT04616755|ACTIVE_COMPARATOR|Vacuum-formed retainer|This group have Vacuum-formed retainer covering all erupted teeth in maxilla to keep front teeth stable
62806459|NCT02789059|EXPERIMENTAL|muscle oxygenation|assesment of muscle oxygenation and gas exchanges
62806460|NCT04147689|EXPERIMENTAL|Treated labia majora|Labia majora are treated at Baseline visit (V1) and a touch-up may be performed 4 weeks after Baseline (V2) if needed
62806461|NCT06227871||Penetrating intra-abdominal injury|Patients diagnosed with a pancreatic injury secondary to penetrating intra-abdominal injury subdivided by pancreatic injury grade
62806462|NCT06227871||Blunt intra-abdominal injury|Patients diagnosed with a pancreatic injury secondary to blunt intra-abdominal injury subdivided by pancreatic injury grade
62806463|NCT04400357|EXPERIMENTAL|Robotic pancreaticoduodenectomy|Patients randomized in this arm will undergo a robotic pancreaticoduodenectomy.
62229771|NCT00977054|EXPERIMENTAL|DFPP and Peg-IFN + RBV|Double filtration plasmapheresis (Day 1, Day 2, Day 4, Day 8, and Day 9 from the onset of treatment; overall 5 session, each session for 4 hours) and weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1 to week 48; body weight \< 75 kg, 1,000 mg/day and body weight \>= 75 kg, 1,200 mg/day)
62229772|NCT00977054|ACTIVE_COMPARATOR|Peg-IFN + RBV|Weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1-48; body weight \< 75 kg, 1,000 mg/day and body weight \>=75 kg, 1,200 mg/day)
62229773|NCT03541382|ACTIVE_COMPARATOR|HIVST campaign arm|Community representatives will be supported to plan and administer an HIVST campaign linked to HIV care and prevention services in their communities.
62421909|NCT02803190|EXPERIMENTAL|ICG- integrated care group|Integraded Care Group
62806464|NCT04400357|ACTIVE_COMPARATOR|Open pancreaticoduodenectomy|Patients randomized in this arm will undergo a routine open pancreaticoduodenectomy.
62806465|NCT03614117|ACTIVE_COMPARATOR|L.salivarius PS7 6-months|Lactobacillus salivarius PS7 during 6-months; approximately 1\*10E9 colony forming unit (CFU) of L. salivarius PS7 in 1 sachet per day to be diluted in water by mouth for 6-months.
62806466|NCT03614117|ACTIVE_COMPARATOR|L. salivarius PS7 + placebo (3+3)|Lactobacillus salivarius PS7 during 3 months; approximately 1\*10E9 CFU of L. salivarius PS7 in 1 sachet per day to be diluted in water by mouth for 3-months followed by 3 months oral administration of 1sachet per day of placebo supplement to be diluted in water.
62421910|NCT02803190|EXPERIMENTAL|MTG- muscle training group|Muscle Traing Group
62421911|NCT00665704|EXPERIMENTAL|Tobacco Tactics Website|Nine veteran smokers who will pilot test the Tobacco Tactics website
62421912|NCT05269316|EXPERIMENTAL|IMP9064 Monotherapy|Dose-escalation IMP9064 administered orally on empty stomach once/twice daily
62421913|NCT05829473|EXPERIMENTAL|Breathing Exercise Group|A total of 1 times day diaphragmatic breathing exercise will be made on 3 consecutive days (5 minutes diaphragmatic breathing exercise, 5 minutes relaxation exercise). Diaphragmatic breathing exercises will be performed at least 4 hours after the use of antiemetic drugs in the service. 20 minutes from the diaphragmatic breathing exercise application. Afterward, post-test data will be obtained using the Nausea-Vomiting Severity Evaluation Test During Pregnancy and Pregnancy-Related Anxiety scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
62806467|NCT03614117|PLACEBO_COMPARATOR|Control group|Placebo supplement in 1 sachet per day to be diluted in water by mouth for 6-months.
62806468|NCT06056492|ACTIVE_COMPARATOR|Control Group|Participants assigned to the control group received assessment without experience N2O/O2 sedation and they tried the mask with O2 only.
62030710|NCT05042219||COPD (LTOT-NIV)|COPD before initiation of long term oxygen therapy or domiciliary long-term non-invasive ventilation
62229774|NCT03541382|NO_INTERVENTION|SOC arm|Standard HTS will be provided by MoH at health facilities.
62229775|NCT00690235|OTHER|Placebo|Patients will be given the Placebo for injection twice daily
62591689|NCT06667154|EXPERIMENTAL|Low-dose nivolumab combined with platinum-based doublet chemotherapy|
62806469|NCT06056492|EXPERIMENTAL|Study Group|Participants assigned to the study group received assessment with experience of N2O/O2 sedation
62806470|NCT02314052|EXPERIMENTAL|DCR-MYC|Patient groups (cohorts) will receive a single dose level of DCR-MYC; the dose level of DCR-MYC will be increased in subsequent cohorts
62806471|NCT00343265|ACTIVE_COMPARATOR|1|Progesterone gel
62806472|NCT00343265|PLACEBO_COMPARATOR|2|Vaginal gel with no medication
62806473|NCT02798250|ACTIVE_COMPARATOR|Dual-hormone CL with overestimation of meal size category|A regular size standardized meal of 45g of carbohydrates will be provided to the patient and the meal size will be overestimated by one category, which will result in a meal insulin bolus for a meal of 65g of carbohydrates.
62229776|NCT00690235|OTHER|Pramlintide|volunteers are given 180mg of pramlintide, twice daily
62229777|NCT01647269|EXPERIMENTAL|DBS Off first|
62229778|NCT01647269|EXPERIMENTAL|DBS On First|
62229779|NCT01003197||complication group < III|
62806474|NCT02798250|ACTIVE_COMPARATOR|Dual-hormone CL with adequate estimation of meal size category|A regular size standardized meal of 45g of carbohydrates will be provided to the patient and the meal size will be adequately estimated, which will result in a meal insulin bolus for a meal of 35g of carbohydrates.
62806475|NCT06360822|EXPERIMENTAL|Intervention|Patients will be shown a modified version of LungTalk.
62229780|NCT01003197||complication group >= III|
62229781|NCT01560689|ACTIVE_COMPARATOR|BUDESONIDE/FORMOTEROL|
62229782|NCT01560689|PLACEBO_COMPARATOR|control|
62229783|NCT02471833|EXPERIMENTAL|Telmisartan 20mg|African American participants with untreated or treated hypertension and at high risk for Alzheimer's disease who are randomly assigned to receive telmisartan 20mg once a day orally.
62229784|NCT02471833|EXPERIMENTAL|Telmisartan 40mg|African American participants with untreated or treated hypertension and at high risk for Alzheimer's disease who are randomly assigned to receive telmisartan 40mg once a day orally.
62806476|NCT06360822|NO_INTERVENTION|Usual Care|Patients will receive usual care.
62806477|NCT05904561|ACTIVE_COMPARATOR|Group (A) (Study group A)|It will be consisted of 16 women complaining from mild to moderate Carpel Tunnel Syndrome after 6 weeks from delivery diagnosed by electrophysiological study. They will receive low level laser therapy, for 10 minutes, three times per week for 4 weeks (total of 12 sessions), in addition to wrist exercises and home advices.
62421914|NCT05829473|EXPERIMENTAL|Guided Imagery Group|10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service.10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service. Afterward, 20 minutes from the application post-test data will be obtained by using the Nausea-Vomiting Severity Assessment Test in Pregnancy and Pregnancy-Related Anxiety Scale-R2 scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
62421915|NCT05829473|NO_INTERVENTION|Control Group|No intervention will be made to the pregnant women in the control group, other than their routine daily care. Pre-test data will be obtained by applying the Nausea-Vomiting Severity Evaluation Test During Pregnancy and Pregnancy-Related Anxiety scales at least 4 hours after the use of antiemetic drugs in the service. 20 min from the pre-test data. Afterward, the final test data will be obtained by applying the Nausea-Vomiting Severity Evaluation Test During Pregnancy and Pregnancy-Related Anxiety scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
62421916|NCT00334828|EXPERIMENTAL|1|
62421917|NCT00334828|PLACEBO_COMPARATOR|2|
62421918|NCT04539158|ACTIVE_COMPARATOR|single-DCCV group|"Patients randomized to single-DCCV will be given a single 200J shock using the primary (or right anterior-left posterior) pair of pads."
62421919|NCT04539158|EXPERIMENTAL|dual-DCCV group|"Patients assigned to dual-DCCV will receive two simultaneous 200J shocks (from both the primary and secondary set of defibrillator pads), totaling 400J delivered."
62421920|NCT03620760|EXPERIMENTAL|Lower dose ticagrelor|Subjects will be treated with ticagrelor 45 mg twice daily in combination with aspirin 100mg once daily.
62421921|NCT03620760|ACTIVE_COMPARATOR|Standard dose ticagrelor|Subjects will be treated with ticagrelor 90 mg twice daily in combination with aspirin 100mg once daily.
62421922|NCT04341207|EXPERIMENTAL|Cohort 1|Advanced Cancer Patients with SARS-CoV-2 positive test \& Covid19 symptoms
62421923|NCT04341207|NO_INTERVENTION|Cohort 2|Advanced Cancer Patients with SARS-CoV-2 negative test \& Covid19 symptoms. Patients with a chest CT-scan compatible with Covid19 disease shall be treated in part B.
62806478|NCT05904561|EXPERIMENTAL|Group (B) (study group B)|It will be consisted of 16 women complaining from mild to moderate Carpel Tunnel Syndrome after 6 weeks from delivery diagnosed by electrophysiological study. They will receive pulsed ultrasound therapy, for 10 minutes, three times per week for 4 weeks (total of 12 sessions), in addition to wrist exercises and home advices
62806479|NCT05904561|ACTIVE_COMPARATOR|Group (C) (control):|It will be consisted of 16 women complaining from mild to moderate Carpel Tunnel Syndrome after 6 weeks from delivery diagnosed by electrophysiological study. They will receive wrist exercises (strengthening exercises for thenar muscles, wrist flexors. Extensors, grip strengthening, stretching, nerve glide, neurodynamic technique and tendon glide) for 15 minutes, three times per week for 4 weeks (total of 12 sessions) and home advices only.
62229785|NCT02471833|PLACEBO_COMPARATOR|Placebo|African American participants with untreated or treated hypertension and at high risk for Alzheimer's disease who are randomly assigned to receive a placebo to match telmisartan once a day orally.
62421924|NCT04341207|NO_INTERVENTION|Cohort 3|Advanced Cancer Patients with SARS-CoV-2 positive or negative test \& no Covid19 symptoms
62421925|NCT04341207|EXPERIMENTAL|Cohort 4|Advanced Cancer Patients with SARS-CoV-2 positive test AND chest CT-scan compatible with Covid19 disease \& no Covid19 symptoms \& Pretreated or with frail conditions following the HCSP definition
62421926|NCT06239467|EXPERIMENTAL|Phase 1a: Part A Dose Escalation|OKI-219 Monotherapy Dose Escalation in participants with advanced solid tumors with the PI3Kα1047R mutation
62229786|NCT03294746|OTHER|Clinical evaluations and Thoracic CT scan scoring of DIILD|
62229787|NCT04320797||Active lupus nephritis|Patients with proliferative lupus nephritis (Class III and IV)
62229788|NCT04320797||Control|Patients with systemic lupus erythematodes without lupus nephritis or lupus nephritis I, II or VI
62229789|NCT04047589||Subjects|Cancer patients with curable or previously treated malignancies
62229790|NCT04047589||Providers|Physicians seeing patients in the outpatient clinics at the IU Simon Cancer Center
62229791|NCT05053438|ACTIVE_COMPARATOR|Intensive Multidisciplinary Intervention (Standard Care)|Children with a history of chronic food refusal will be randomized to receive the standard of care. The standard of care for tube wean is to accomplish the balance between enteral supplementation and oral intake, the tube feeding regimen will follow the schedule of therapeutic meals (e.g., mid-day supplementation occurs after morning therapeutic meals).
62421927|NCT06239467|EXPERIMENTAL|Phase 1b: Part B Dose Escalation|OKI-219 + Fulvestrant Dose Escalation in participants with HR+/HER2- locally advanced, unresectable or metastatic breast cancer with the PI3KαH1047R mutation
62806480|NCT01664910|EXPERIMENTAL|Treatment (transplant)|Patients receive inotuzumab ozogamicin IV over 1 hour on day -13, and fludarabine phosphate IV over 1 hour and bendamustine hydrochloride IV over 30 minutes to 1 hour on days -5 to -3. Patients with CD20-positive disease also receive rituximab IV over 4-6 hours on days -6, 1, and 8 and patients with MUD receive anti-thymocyte globulin IV over 3-4 hours on days -2 to -1. All patients also receive tacrolimus IV over 24 hours continuously or PO daily beginning on days -2 to 180 followed by taper in the absence of GVHD and methotrexate IV over 30 minutes on days 1, 3, and 6 (1, 3, 6, and 11 in patients with MUD). Patients undergo allogeneic BM or PBSC transplant on day 0.
62806481|NCT01773317|EXPERIMENTAL|Perturbation|Subjects complete the training protocol and peturbation training exercises
62229792|NCT05053438|EXPERIMENTAL|Intensive Multidisciplinary Intervention (Standard Care) + Hunger provocation (Rapid Tube Wean)|"Children with a history of chronic food refusal will be randomized to receive the experimental arm that combines standard care with rapid tube wean.~All schedules and documents will be updated accordingly. After the 50% tube wean cut, the dietitian will use regular tube wean sheet to provide credit for oral intake for remainder of admission."
62229793|NCT02784197|OTHER|Enrolled Subjects (PSR)|Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.
62229794|NCT05680064|NO_INTERVENTION|Control|Patients who are routinely followed up will be included in the control group. At the end of 15 days, all patients will come to the second interview. The same data collection methods will be repeated after 15 days.
62806482|NCT01773317|EXPERIMENTAL|Control|Subjects will complete the training protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
62806483|NCT02028923|EXPERIMENTAL|Morphine gel|morphine 30 mg, quantity of gel per application: 15mg (15ml)
62806484|NCT02028923|PLACEBO_COMPARATOR|Neutral gel|water for injection, quantity of gel per application: 15mg (15ml)
62806485|NCT02584179|EXPERIMENTAL|Biparametric MRI before biopsy|"Biparametric MRI is a reduced Multiparametric MRI using less scan sequences and no intravenous contrast.~All men will have standard transrectal ultrasound guided biopsies"
62806486|NCT06236971||MRI scanning|The subjects are receiving MRI scanning first in the supine position, and then in the lateral position. The field of view was determined from the length and girth of each patient's head, at least including the skull base to the level of tracheal bifurcation.
62229795|NCT05680064|EXPERIMENTAL|Gum-Chewing Group|In the gum-chewing group, routine follow-up and additional gum-chewing training will be given (at least 10 minutes 4 times a day, preferably before meals and with sugar-free gum). Patients in the Gum Chewing Group will chew gum as recommended for 15 days. At the end of 15 days, all patients will come to the second interview. The same data collection methods will be repeated after 15 days. In the study, the chewing gum group will chew Vivident Xylit Full Fresh Mint Flavored Liquid Filled Sugar-Free Sweetener Gum. The contents of the gum; Sweeteners (Xylitol, Sorbitols, Mannitol, Maltitols, Aspartame, Acesulfame-K), Gum Yeast, Stabilizer (Glycerol), Flavorings, Natural Mint Flavoring, Maltodextrin, Starch, Emulsifiers (E473, Soy Lecithin), Green Tea Extract, Consistency Enhancers (Cellulose Gum, Xanthan Gum), Coconut Oil, Antioxidant (E321), Brightener (Carnauba Wax), Colorant (E133). There is no allergen warning.
62229796|NCT05680064|EXPERIMENTAL|Tongue, lip, chin exercise group|In the tongue, lip and chin exercise group, patients who are routinely followed up and who will be given additional tongue, lip and jaw exercises training (at least 10 minutes 4 times a day and preferably before meals) will take place. Patients in Tongue, Lip, Chin Exercise Group will do the tongue, lip and chin exercises as recommended for 15 days. At the end of 15 days, all patients will come the second interview. The same data collection methods are repeated after 15 days. content of the training to be given to the tongue, lip and chin exercise group and the exercise brochure to be given to the patients T.C. Oral-Motor Exercises Brochure published by the Ministry of Health Istanbul Provincial Health Directorate, Basic Evaluation Principles in Treatment Movements book and Specialist. It was determined and prepared in line with the recommendations of physiotherapist İbrahim ÖZDEMİR.
62229797|NCT01828073||Cohort 1: Full term infants exposed in utero to maternal RAL|Infants, who were expected to be ≥2000 grams at birth (i.e. full-term) at time of enrollment, born to women with HIV-1 infection who received RAL 400 mg twice daily for at least two weeks prior to delivery and continued to receive ARVs during labor. The group also includes the mothers of these infants.
62243140|NCT06286254||The control group|Basic therapy of ARVI1 + Cycloferone®. Cycloferone® is administered according to the instruction for medical use: 600 mg (4 tablets) once daily on day 1, 2, 4, 6 and 8.
62421928|NCT06239467|EXPERIMENTAL|Phase 1b: Part B Dose Optimization|OKI-219 + Fulvestrant Dose Optimization in participants with HR+/HER2- locally advanced, unresectable or metastatic breast cancer with the PI3KαH1047R mutation
62806487|NCT03798613|ACTIVE_COMPARATOR|Apple Watch 4 Series Device|Apple watch 4 series heart rate monitoring device
62030711|NCT05042219||COPD (Roflumilast )|COPD before initiation of Roflumilast therapy
62591690|NCT04544293|EXPERIMENTAL|Molgramostim|Double-blind treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks, followed by open-label treatment with molgramostim nebulizer solution 300 µg once daily for 96 weeks
62806488|NCT03798613|ACTIVE_COMPARATOR|Continuous Telemetry|Standard continuous telemetry monitoring device
62806489|NCT04807998||Group EA|Serum and Urine samples were collected before anesthesia and immediately after surgery from children who enrolled in part I and undergoing the adenoidectomy or adenotonsillectomy. A PAED score of 12 or greater was defined as EA. The serum and urine samples were analyzed by UHPLC-Q-TOF/MS separately.
62030712|NCT05042219||Bronchial asthma (antibody)|Bronchial asthma before initiation of antibody therapy
62030713|NCT05042219||Bronchial asthma (ICS)|Bronchial asthma before initiation of inhaled corticosteroid therapy
62030714|NCT05042219||Pulmonary fibrosis|Pulmonary fibrosis before initiation of antifibrotic therapy
62030715|NCT00377819|EXPERIMENTAL|denosumab|
62030716|NCT00377819|ACTIVE_COMPARATOR|alendronate|
62030717|NCT06316427|EXPERIMENTAL|Arm-1|Autologous CD7 CAR T-cell treatment
62030718|NCT06316427|EXPERIMENTAL|Arm-2|Prior-HSCT donor-derived CD7 CAR T-cell treatment
62030719|NCT06316427|EXPERIMENTAL|Arm-3|New donor-derived CD7 CAR T-cell treatment
62806490|NCT04807998||Group non-EA|Serum and Urine samples were collected before anesthesia and immediately after surgery from children who enrolled in part I and undergoing the adenoidectomy or adenotonsillectomy. A PAED score less than 12 was defined as non-EA. The serum and urine samples were analyzed by UHPLC-Q-TOF/MS separately.
62806491|NCT06002269|EXPERIMENTAL|BOOST Box Intervention|"Baseline: Questionnaires (FACT-Bl-Cys, mPG-SGA, Short 2012, FAACT, Godin, TCC), exercise prescription, compensation.~Pre-Surgery: Dietitian consultation, at least 3-weeks and up to 6-weeks of Boost Box deliveries and check-ins (nutritional intervention), up to 6 weeks of exercise intervention and logs, ASA Food Record (x2), compensation Post-Surgery: post-surgery surveys once (FACT-Bl-Cys, mPG-SGA, FAACT, Godin), 6 weeks of Boost Box deliveries and check-ins (nutritional intervention), 6 weeks of exercise intervention and logs, weekly hunger check-in, ASA Food Record (x2), Dietitian consultation, compensation.~Follow-up (estimated 6 months after baseline) : 6-month questionnaire, compensation.~Compensation total: up to $100 via electronic gift card."
62229798|NCT01828073||Cohort 2: LBW infants exposed in utero to maternal RAL|Infants, who were expected to be ≤2500 grams at birth (i.e. LBW) at time of enrollment, born to women with HIV-1 infection who received at least one dose of RAL 400 mg within 2 to 24 hours prior to delivery. The group also includes the mothers of these infants.
62229799|NCT02795429|EXPERIMENTAL|Phase Ib: Capmatinib 200 mg BID + Spartalizumab 300 mg Q3W|Capmatinib 200 mg administered orally on a continuous twice daily (BID) dosing schedule in combination with spartalizumab 300 mg administered intravenously once every 3 weeks (Q3W) in Phase Ib
62229800|NCT02795429|EXPERIMENTAL|Phase Ib: Capmatinib 300 mg BID + Spartalizumab 300 mg Q3W|Capmatinib 300 mg administered orally on a continuous twice daily (BID) dosing schedule in combination with spartalizumab 300 mg administered intravenously once every 3 weeks (Q3W) in Phase Ib
62591691|NCT04544293|PLACEBO_COMPARATOR|Placebo|Double-blind treatment with placebo nebulizer solution once daily for 48 weeks, followed by open-label treatment with molgramostim nebulizer solution 300 µg once daily for 96 weeks
62591692|NCT02900651|EXPERIMENTAL|Phase I - All|advanced stage (relapsed/refractory or recurrent/metastatic) malignancy limited to the following malignancies; DLBCL, nasopharyngeal carcinoma, gastric cancer, ovarian cancer, prostate cancer and sarcoma.
62229801|NCT02795429|EXPERIMENTAL|Phase Ib: Capmatinib 400 mg BID + Spartalizumab 300 mg Q3W|Capmatinib 400 mg administered orally on a continuous twice daily (BID) dosing schedule in combination with spartalizumab 300 mg administered intravenously once every 3 weeks (Q3W) in Phase Ib
62229802|NCT02795429|EXPERIMENTAL|Phase II: Capmatinib 400 mg BID + Spartalizumab 300 mg Q3W|Capmatinib 400 mg administered orally on a continuous twice daily (BID) dosing schedule in combination with spartalizumab 300 mg administered intravenously once every 3 weeks (Q3W) in Phase II
62421929|NCT06239467|EXPERIMENTAL|Phase 1b: Part C Dose Escalation|OKI-219 + Trastuzumab Dose Escalation in participants with HR±/HER2+ locally advanced, unresectable or metastatic breast cancer with the PI3KαH1047R mutation
62591693|NCT04641663|EXPERIMENTAL|100 RDD|100% of recommended daily dose (RDD) of the MORNING tablet dose (5 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
62591694|NCT04641663|EXPERIMENTAL|80 RDD|80% of recommended daily dose of the MORNING tablet dose (4 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
62030720|NCT04851613|EXPERIMENTAL|Phase I: Afuresertib and Fulvestrant Safety Run In|Phase I: Safety run-in Cycle 1 (a cycle is 28 days) will be performed in the first 6 patients of the phase Ib. Combination regimens during the safety run-in period are: afuresertib 125 mg QD (once daily) or 125 mg Day1-21 Q4W + fulvestrant 500 mg or 250 mg Intra Muscular (IM) on Day 1, 15 of Cycle 1, and on Day 1 of the subsequent 28-day cycles.
62229803|NCT02795429|EXPERIMENTAL|Phase II: Spartalizumab 300 mg Q3W|Spartalizumab 300 mg administered intravenously once every 3 weeks (Q3W) in Phase II
62229804|NCT00901277|NO_INTERVENTION|Control|Usual Care
62229805|NCT00901277|EXPERIMENTAL|Web Intervention|Web-based: interactive web-based tool based on Microsoft's HealthVault technology for data transmission, tracking and communication of cardiac risk factors (e.g. home BP monitors for all in this intervention arm)
62421930|NCT06239467|EXPERIMENTAL|Phase 1b: Part C Dose Optimization|OKI-219 + Trastuzumab Dose Optimization in participants with HR±/HER2+ locally advanced, unresectable or metastatic breast cancer with the PI3KαH1047R mutation
62591695|NCT04641663|EXPERIMENTAL|60 RDD|60% of recommended daily dose of the MORNING tablet dose (3 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
62243141|NCT06286254||The test group|Basic therapy of ARVI1 + Arbidol®. Arbidol® is administered according to the instruction for medical use: 200 mg (4 capsules) 4 times/day for 5 days.
62735424|NCT04092803|NO_INTERVENTION|GA for LP|Patients who decline to undergo an LP with VR will be asked if they would be willing to participate by answering questionnaires specific to their pre procedure anxiety. This will include questionnaires 2 and 3 from above. The investigators will also plan to collect vital sign data if they agree to participate in that capacity.
62030721|NCT04851613|EXPERIMENTAL|Phase I: Afuresertib and Fulvestrant|Phase I: Combination regimens are: afuresertib 125 mg QD (once daily) or 125 mg Day1-21 Q4W + fulvestrant 500 mg or 250 mg Intra Muscular (IM) on Day 1, 15 of Cycle 1, and on Day 1 of the subsequent 28-day cycles.
62229806|NCT00901277|EXPERIMENTAL|Nurse Intervention|Nurse: an interactive web-based tool based on Microsoft's HealthVault technology for data transmission, tracking and communication of cardiac risk factors (e.g. home BP monitors for all in this intervention arm)
62229807|NCT05334745|EXPERIMENTAL|application of Alvogyl in the palatal wound with stent|
62229808|NCT05334745|OTHER|application of 0.2% Hyaluronic acid is placed in the palatal wound with stent .|
62229809|NCT01832233|EXPERIMENTAL|Renal Denervation|Patients with resistant hypertension and chronic kidney disease (GFR between 15 and 60) will receive Renal Denervation as a treatment
62229810|NCT01416415|EXPERIMENTAL|Educational intervention|The educational intervention arm will contain subjects who will watch a video on proper eye drop instillation technique.
62229811|NCT01416415|PLACEBO_COMPARATOR|Attention placebo|The attention control placebo group will receive an educational intervention that mimics the amount of time and attention received by the treatment group. The video chosen is regarding healthy eating tips.
62421931|NCT06540365|EXPERIMENTAL|Community-Based activity program|
62421932|NCT04529096|EXPERIMENTAL|750 Mg-500 mg LY3016859|Participants received LY3016859 every 2 weeks with 750 milligram (mg) as starting dose followed by 500 mg intravenous (IV) infusion for a total of 4 doses
62421933|NCT04529096|PLACEBO_COMPARATOR|Placebo|Participants received placebo every 2 weeks by IV infusion for a total of 4 doses.
62421934|NCT03733184||The Christie NHS FT|Patients treated by Cytoreduction and Heated Intraperitoneal Surgery at The Christie NHS Foundation Trust (one of the two initial, primary treatment centres) for Colorectal Peritoneal Metastasis.
62421935|NCT03733184||Hampshire Hospitals NHS FT|Patients treated by Cytoreduction and Heated Intraperitoneal Surgery at Hampshire Hospitals NHS Foundation Trust (one of the two initial, primary treatment centres) for Colorectal Peritoneal Metastasis.
62591696|NCT05622318|EXPERIMENTAL|Graft-versus-host disease prophylaxis|Following reduced intensity conditioning and 8/8-matched peripheral blood transplant on Day 0, all patients will receive a GVHD prophylaxis post-transplant composed of the following: (i) cyclophosphamide administered at 25 mg/kg on Day +3 and +4, (ii) tacrolimus beginning on Day +5 and through Day +180 and administered with a trough target of 5-10 ng/ml through Day +90 and tapered thereafter; (iii) mycophenolate mofetil (MMF) administered at 15 mg/kg thrice daily beginning on Day +5 through Day +35; and (iv) ruxolitinib administered at 5 mg twice daily starting after engraftment (between Days +30 and +60) and continuing through one year post transplant.
62591697|NCT01083186||Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism|Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)
62591698|NCT03425409|OTHER|Continuous Flow|Oxygen delivery at 4 liters per minute is the standard method
62806492|NCT06002269|NO_INTERVENTION|Usual Care|"Baseline: Questionnaires (FACT-Bl-Cys, mPG-SGA, Short 2012, FAACT, Godin, TCC), compensation.~Pre-Surgery: Dietitian consultation, ASA Food Record (x2), compensation. Post-Surgery: post-surgery surveys once (FACT-Bl-Cys, mPG-SGA, FAACT, Godin), Dietitian consultation, ASA Food Record (x2), compensation.~Follow-up (estimated 6 months after baseline): 6-month questionnaire, compensation.~Compensation total: up to $100 via electronic gift card."
62229812|NCT01169246||Paradym VR, DR and CRT models|
62806493|NCT02626585|NO_INTERVENTION|Control|Control group (n=20): Following removal of nasal cast on postoperative first week, no additional taping was applied to this group.
62806494|NCT02626585|EXPERIMENTAL|2-weeks of PRT|2-weeks of PRT (n=17): Following removal of nasal cast on postoperative first week, 2 weeks of additional postrhinoplasty taping was applied to this group (form 1st to 3rd week).
62806495|NCT02626585|EXPERIMENTAL|4-weeks of PRT|4-weeks of PRT (n=20): Following removal of nasal cast on postoperative first week, 4 weeks of additional postrhinoplasty taping was applied to this group (form 1st to 5th week).
62806496|NCT04274816|EXPERIMENTAL|Tremelimumab|Intradermal injection of tremelimumab at the primary melanoma excision site, 7 days prior to sentinel node biopsy (SNB), with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).
62806497|NCT04235517||Axial deviations in children|Children with axial deviations in the lower extremity treated with guided growth
62806498|NCT04235517||Limb length discrepancy in children|Children with limb length discrepancy treated with temporary epiphysiodesis
62229813|NCT03187340|ACTIVE_COMPARATOR|Sleep education and relaxation 1|Behavioral education intervention about sleep and relaxation
62229814|NCT03187340|EXPERIMENTAL|Sleep education and relaxation 2|Behavioral education intervention about sleep and relaxation
62229815|NCT05555407|EXPERIMENTAL|Wireless patch system (WPS)|Subjects scheduled for a gastric emptying scan will have a wireless patch system (WPS) placed.
62229816|NCT01487408||Insulin Aspart|
62229817|NCT04725396|EXPERIMENTAL|Patients undergoing PVP-assisted MR|PVP is based on CT-scan with millimetric thin slice acquisitions of the facial bone and fibulas. The surgeon defines the exact sites of the intended mandibular osteotomies. A single external subcontracted laboratory (Materialise®) produces the various cutting guides for mandibular resection, flap conformation and the preformed plates for flap osteosynthesis. Flap conformation is entirely performed at the donor site before section of the vascular pedicle (flap still vascularized).
62243142|NCT01133379|EXPERIMENTAL|PO-019|1.40% Potassium Oxalate Sensitive Mouthwash without fluoride (12027-019)
62243143|NCT01133379|EXPERIMENTAL|PO-020|1.40% Potassium Oxalate Sensitive Mouthwash with fluoride (12027-020)
62243144|NCT01133379|SHAM_COMPARATOR|PO-021|Vehicle Control Mouthrinse (without potassium oxalate and without fluoride) (12027-021)
62421936|NCT06360679|EXPERIMENTAL|BariTon™ System implantation|
62806499|NCT06276998|EXPERIMENTAL|LNK01001 12 mg|Period 1: Participants receive LNK01001 12 mg twice daily for 24 weeks. Period 2: Participants will continue on LNK01001 12 mg twice daily from Week 24 to Week 76.
62243145|NCT02289352|EXPERIMENTAL|brimonidine 0.33% gel|Brimonidine Topical Gel, 0.33%, 30 gram fill (Watson Laboratories, Inc., USA)
62591699|NCT03425409|OTHER|Pneumatic Pulsed Flow|Oxygen delivery using test method
62229818|NCT04725396|ACTIVE_COMPARATOR|Patients undergoing conventional (i.e. without PVP) MR|Flap modeling and positioning requires one or multiple cuneiform osteotomies. The bone transplant is shaped to restore the contours of the mandibular defect using preoperative imaging studies and the resection specimen. Flap conformation begins at the donor site and is generally completed at the recipient site after fibular pedicle section and before microvascular anastomosis (during ischemia time). The different bone fragments are fixed together and to the native mandible using either titanium miniplates or reconstruction plate and monocortical screws. Regardless of the material used for fixing the fibular flap to the native mandible, the use of a reconstruction plate adapted to the native mandible (or other similar techniques) prior to tumor resection is recommended to guide flap shaping and positioning, and to insure an accurate MR.
62229819|NCT02527343|EXPERIMENTAL|Placebo/Volanesorsen|"Randomized Period: Volanesorsen-matching placebo as SC, QW for Weeks 1-52. Participants who received volanesorsen-matching placebo in RT period and not enter in OLE period went straight to 13-week PT follow-up period. Dose adjustment based on monitoring rules were allowed.~OLE Period: Participants who received volanesorsen-matching placebo in RT period and completed RT period, were to receive 300 mg of volanesorsen as SC QW for 52 weeks (Weeks 53-104) in OLE period. Dose adjustment based on monitoring rules were allowed. After Week 104, participants had option of continuing treatment with 300 mg of volanesorsen as SC injection for up to additional 52 weeks (Weeks 105-156). Participants not entered in option for additional 52 weeks of dosing in OLE PT period went straight to 13-week PT follow-up period after completion of first 52 weeks (Weeks 53-104) of OLE. Participants entered in OLE PT period went straight to 13-week PT follow-up period after completion of Week 156 of OLE."
62806500|NCT06276998|PLACEBO_COMPARATOR|Placebo / LNK01001 12 mg|Period 1: Participants receive a placebo twice daily for 24 weeks. Period 2: Participants will switch to receive LNK01001 12 mg twice daily from Week 24 to Week 76.
62030722|NCT04851613|EXPERIMENTAL|Phase III: afuresertib combined with fulvestrant (experimental arm)|Phase III: afuresertib 125mg QD combined with fulvestrant 500mg Q4W (D1, 15 in cycle 1)
62030723|NCT04851613|PLACEBO_COMPARATOR|Phase III:placebo combined with fulvestrant (control arm)|PhaseIII：placebo combined with fulvestrant 500mg Q4W (D1, 15 in cycle 1)
62030724|NCT04256551|EXPERIMENTAL|Machine Learning App + Registered Dietitian facilitator|The ML-RD group will be provided access to the Heali mobile application as well as a personal RD to provide nutrition support and answer any questions through a real-time messaging system within the mobile app. Group will receive a link to resources regarding the Low FODMAP diet: website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System
62030725|NCT04256551|ACTIVE_COMPARATOR|Machine Learning App|The ML-APP group receives access to the Heali mobile dietary application. Group will receive a link to resources regarding the Low FODMAP diet: website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System
62243146|NCT02289352|ACTIVE_COMPARATOR|Mirvaso gel|Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA)
62243147|NCT02289352|PLACEBO_COMPARATOR|Placebo|Topical gel base only (Watson Laboratories Inc., USA)
62243148|NCT05870254|EXPERIMENTAL|ExeRVIEM Protocol|They will carry out the ExeRVIEM program for 8 weeks (2 times a week). Intervention based on exercise therapies with RVI software.
62243149|NCT05870254|ACTIVE_COMPARATOR|Usual Protocol|They will carry out the usual protocol of Association
62243150|NCT05476926||Cohort 1: Faricimab for nAMD|
62243151|NCT05476926||Cohort 2: Faricimab for DME|
62243152|NCT05476926||Cohort 3: Port Delivery System with Ranibizumab for nAMD|
62421937|NCT04373057|EXPERIMENTAL|Galacto-oligosaccharide|"Phase I: Subjects will receive GOS, at dose levels 0.75g, 1.5g, and 2.9 g/day administered once daily. GOS will be dosed per the following schedule using a modified 3+3 design: 0.75g x 4 days, followed by 1.5g x 4 days, followed by 2.9g for the duration of the study starting from about 30 days before transplant to about 4 weeks after transplant.~Phase II: Subjects will receive GOS, at dose levels 0.25\*MTD, 0.5\*MTD, and MTD with MTD determined by the phase 1 of the study, once daily from about 30 days before transplant to about 4 weeks after transplant."
62591700|NCT02741674||Roux-en-y gastric bypass (RYGB)|"1. Adults and children ages 12 ≤79 years at time of surgery~2. Had a primary (not revision) Roux-en-y gastric bypass from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)~3. Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
62806501|NCT05853341|EXPERIMENTAL|RID-TDS 13.3 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
62030726|NCT04256551|PLACEBO_COMPARATOR|Standard Dietary Education|Group will receive a link to resources regarding the Low FODMAP diet: website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System
62030727|NCT05210192|PLACEBO_COMPARATOR|placebo arm|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. Placebo group will be injected with 4ml of 0.9% saline. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
62243153|NCT05476926||Cohort 4: Faricimab for BRVO|
62229820|NCT02527343|EXPERIMENTAL|Volanesorsen|"Randomized Period: 300 mg of volanesorsen as SC, QW for Weeks 1-52. Participants who received 300 mg of volanesorsen in RT period and did not enter in OLE period went straight to 13-week PT follow-up period. Dose adjustment based on monitoring rules were allowed.~OLE Period: Participants who received volanesorsen in RT period and completed RT period, were to receive 300 mg of volanesorsen as SC QW for 52 weeks (Weeks 53-104) in OLE period. Dose adjustment based on monitoring rules were allowed. After Week 104, participants had option of continuing treatment with 300 mg of volanesorsen as SC injection for up to additional 52 weeks (Week 105-156). Participants who were not entered in option for additional 52 weeks of dosing in OLE PT period went straight to 13-week PT follow-up period after completion of first 52 weeks (Weeks 53-104) of OLE. Participants entered in OLE PT period went straight to 13-week PT follow-up period after completion of Week 156 of OLE."
62229821|NCT00722852|EXPERIMENTAL|1|
62229822|NCT00722852|PLACEBO_COMPARATOR|2|
62591701|NCT02741674||Adjustable gastric banding (AGB)|"1. Adults and children age 12 ≤79 years at time of surgery~2. Had a primary (not revision) adjustable gastric banding procedure from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)~3. Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
62229823|NCT03353350|EXPERIMENTAL|Efpeglenatide 2mg|Efpeglenatide low dose (Prefilled syringe) administered once weekly for 56 weeks
62229824|NCT03353350|EXPERIMENTAL|Efpeglenatide 4 mg|Efpeglenatide middle dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
62030728|NCT05210192|ACTIVE_COMPARATOR|lidocaine arm|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. Lidocaine group will be injected with 4ml of 0.1%Lidocaine. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
62030729|NCT01750268|EXPERIMENTAL|Topiramate|Topiramate capsules daily - up to 300 mg
62030730|NCT01750268|PLACEBO_COMPARATOR|Placebo|Placebo capsules daily - up 300 mg
62030731|NCT02363738|EXPERIMENTAL|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation
62030732|NCT02363738|PLACEBO_COMPARATOR|Saline (Placebo)|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.
62229825|NCT03353350|EXPERIMENTAL|Efpeglenatide 6 mg|Efpeglenatide high dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
62229826|NCT03353350|PLACEBO_COMPARATOR|Placebo|Matching placebo (Prefilled syringe) administered once weekly for 56 weeks
62421938|NCT04373057|PLACEBO_COMPARATOR|Maltodextrin|Phase II: Subjects will receive maltodextrin at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.
62421939|NCT05719129||DWD participants|Individuals that voluntarily chose to participate in DWD seminar.
62030733|NCT03646786|EXPERIMENTAL|visually impaired patients|
62030734|NCT00572234|EXPERIMENTAL|Receiving Bupropion SR|receiving bupropion SR 12 week course of bupropion SR 150 mg, BID (twice a day)
62030735|NCT00572234|NO_INTERVENTION|Treatment as Usual|Not receiving bupropion
62421940|NCT05719129||Matched control group|Individuals that voluntarily chose to from the US population matched by gender, age, education, ethnicity and income
62421941|NCT04776291|EXPERIMENTAL|Recruitment and image processing|
62421942|NCT03772184|ACTIVE_COMPARATOR|cervical inversion|
62421943|NCT03772184|NO_INTERVENTION|no cervical inversion|
62421944|NCT03535506|EXPERIMENTAL|Group A|Patients enrolled to Group A will receive a 12-day course of Palbociclib before surgery. They will receive Palbociclib 100mg PO daily x 12 days.
62421945|NCT03535506|NO_INTERVENTION|Group B|These patients will receive no pre-operative treatment. Core biopsies from diagnosis and material from definitive surgery will be collected for translational studies and tissue banking. They will also provide blood samples at screening and prior to definitive surgery.
62421946|NCT05942131|EXPERIMENTAL|Intervention Group (n:42)|Laughter yoga will be practiced to students in the intervention group
62591702|NCT02741674||Sleeve gastrectomy (SG)|"1. Adults and children age 12 ≤79 years at time of surgery~2. Had a primary (not revision) sleeve gastrectomy from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)~3. Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
62591703|NCT05568121|EXPERIMENTAL|A (L04RD1 -> L04TD1)|Administration of 1 tablet of L04RD1, and taking 7-day wash-out period, and then administration of 1 tablet of L04TD1
62030736|NCT06565507|EXPERIMENTAL|Intervention 1|OXF 20 mg/kg/d, single dose, orally
62030737|NCT06565507|EXPERIMENTAL|Intervention 2|OXF 20 mg/kg/d, for three days (1, 4 and 7), orally
62229827|NCT01137526|EXPERIMENTAL|ABT-384 Dose 1|
62591704|NCT05568121|EXPERIMENTAL|B (L04TD1 -> L04RD1)|Administration of 1 tablet of L04TD1, and taking 7-day wash-out period, and then administration of 1 tablet of L04RD1
62229828|NCT01137526|EXPERIMENTAL|ABT-384 Dose 2|
62229829|NCT01137526|ACTIVE_COMPARATOR|donepezil|
62229830|NCT01137526|PLACEBO_COMPARATOR|placebo|
62229831|NCT04751708|ACTIVE_COMPARATOR|best medical management|Unless contra-indicated patients are treated with a standard full dose of open-label IV rt-PA (0.9mg/kg; 90mg maximum). IVT has to be initiated within 4.5 hours of estimated time of basilar artery occlusion. For the patients in whom the rtPA is contraindicated, the standard medical treatment follows the current guidelines for the early management of patients with acute ischemic stroke from the American Heart Association/American Stroke Association.
62243154|NCT05476926||Cohort 5: Faricimab for CRVO/HRVO|
62243155|NCT01217216|ACTIVE_COMPARATOR|Group-based Intervention|We randomly assigned 30 individuals to a group-based intervention to promote weight loss through dietary restriction and physical activity.
62243156|NCT01217216|ACTIVE_COMPARATOR|Telephone-based Intervention|We randomly assigned 22 individuals to the telephone-based intervention to promote weight loss through dietary restriction and physical activity.
62243157|NCT04088383|OTHER|Amnios™ RT|
62806502|NCT05853341|ACTIVE_COMPARATOR|Exelon® 13.3 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
62806503|NCT04107246||Newly transplanted corneal patients|
62243158|NCT04088383|PLACEBO_COMPARATOR|Saline|
62421947|NCT05942131|NO_INTERVENTION|Control Group (n:42)|"No intervention will be applied to the control group midwives and Secondary Traumatic Stress Scale for Social Media Users and Beck Depression Inventory will be applied when they are included in the study and again after 4-6 weeks."
62421948|NCT03720522||Group 1: Patients suffering from acute myocardial infarction|Patients with positive gadolinium late enhancement and positive intramyocardial oedema in the short CMR have an acute myocardial infarction and will be allocated to group 1.
62421949|NCT03720522||Group 2: Patients suffering from chronic myocardial infarction|Patients with elevated (≥ 0.015 mg/L) high sensitive troponin T (hsTnT) levels, positive gadolinium late enhancement and/or positive myocardial infarction suffer from chronic myocardial infarction or significant coronary stenosis. They will be allocated to group 2 and receive coronary angiography in a timely manner according to clinical routine and current guidelines.
62591705|NCT05252390|EXPERIMENTAL|Phase 1 Monotherapy|NUV-868 will be administered at escalating dose levels until the maximum tolerated dose (MTD) is reached or a recommended Phase 2 dose (RP2D) is determined.
62591706|NCT05252390|EXPERIMENTAL|Phase 1b Combination: NUV-868 + Olaparib|"NUV-868 will be administered at escalating dose levels in combination with olaparib until the recommended Phase 2 combination dose (RP2cD) is determined.~300 mg olaparib will be administered orally twice daily throughout the 28-day cycles of NUV-868."
62591707|NCT05252390|EXPERIMENTAL|Phase 1b Combination: NUV-868 + Enzalutamide|"NUV-868 will be administered daily at escalating dose levels in combination with enzalutamide until the RP2cD is determined.~160 mg enzalutamide will be administered orally daily throughout the 28-day cycles of NUV-868."
62591708|NCT05252390|EXPERIMENTAL|Phase 2 Combination: NUV-868 + Olaparib|"NUV-868 will be administered at the RP2cD.~Olaparib will be administered at the RP2cD."
62591709|NCT05252390|EXPERIMENTAL|Phase 2 Combination: NUV-868 + Enzalutamide|"NUV-868 will be administered at the RP2cD.~Enzalutamide will be administered at the RP2cD."
62806504|NCT04792736||Survivors|Patients discharged alive from intensive care unit
62806505|NCT04792736||non survivors|Patients who succumbed during their ICU stay
62806506|NCT01548027|EXPERIMENTAL|No intervention|no injection of local anesthetic agents
62806507|NCT01548027|EXPERIMENTAL|Local infiltration group|patients would have 0.5 ml/kg of 0.25% bupivacaine if age \< 6 months or 1 ml/kg if age \> 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
62030738|NCT06565507|ACTIVE_COMPARATOR|Comparison regimen|Combined treatment with albendazole (15 mg/k/d) plus praziquantel (50 mg/k/d), for 10 days, orally.
62030739|NCT01749644||CF patients with chronic pseudomonas infection|
62030740|NCT00615966|EXPERIMENTAL|1|
62030741|NCT00615966|EXPERIMENTAL|2|
62030742|NCT00615966|PLACEBO_COMPARATOR|3|
62030743|NCT01605617|ACTIVE_COMPARATOR|PTNS + fesoterodine fumarate first, then PTNS + placebo|Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + 4mg of fesoterodine fumarate first for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + placebo.
62243159|NCT06632444|EXPERIMENTAL|Survodutide|
62243160|NCT06632444|PLACEBO_COMPARATOR|Placebo|
62591710|NCT05252390|EXPERIMENTAL|Phase 2: NUV-868 Monotherapy|NUV-868 will be administered at the RP2D in one arm of a randomized Phase 2 combination (NUV-868 + enzalutamide) cohort.
62806508|NCT01548027|EXPERIMENTAL|TAP block group|Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age \< 6 months or 1 ml/kg if age \> 6 months
62806509|NCT06387823|ACTIVE_COMPARATOR|Sivelestat sodium|Sivelestat sodium and dexamethasone placebo
62806510|NCT06387823|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone and Sivelestat sodium placebo
62806511|NCT06387823|PLACEBO_COMPARATOR|Placebo|Sivelestat sodium placebo and dexamethasone placebo
62806512|NCT02703298|EXPERIMENTAL|TRX-818|
62806513|NCT05822557|EXPERIMENTAL|Bolus Pouch Feed|A 250 ml feeding pouch containing 400 kcal.
62229832|NCT04751708|EXPERIMENTAL|endovascular treatment+ best medical management|Device: endovascular treatment For patients randomized to endovascular treatment arm, EVT has to be initiated within 12 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. The endovascular procedures allowed by the steering committee include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, or any combination of above procedures. We recommend applying ADAPT as the first choice of treatment. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
62229833|NCT02960841|EXPERIMENTAL|Intracavitary Manual Lymphatic Drainage|Intracavitary Manual Lymphatic Drainage technique.
62806514|NCT01331603||MDS and primary myelofibrosis patients|patients with in iron overloaded MDS patients (low and high risk ), and also patients with primary myelofibrosis. The risk stratification of these patients will be calculated according to the IPSS (International Prognostic Scoring System).
62591711|NCT05252390|ACTIVE_COMPARATOR|Phase 2: Enzalutamide Monotherapy|160 mg enzalutamide will be administered orally daily in one arm of a randomized Phase 2 combination (NUV-868 + enzalutamide) cohort.
62806515|NCT03481335|EXPERIMENTAL|Intervention Community|Intervention communities (barangays) will receive the intervention (CHAP-P sessions).
62591712|NCT05605496|EXPERIMENTAL|Stable Disease|Patients with a radiological documentation of SD according to RECIST V1.1 criteria following at least 12 weeks under standard PD-1/PD-L1 therapy. The initial evidence of SD is to be confirmed by a second assessment, no less than 4 weeks from the date of the first documented SD. Note : This treatment arm closed on 27/09/2024 due to non-feasibility.
62591713|NCT05605496|EXPERIMENTAL|Primary refractory|Patients with documented radiological PD according to RECIST V1.1 but with clinical benefit under PD-1/PD-L1 standard therapy.
62591714|NCT05605496|EXPERIMENTAL|Secondary refractory|Patients with documented radiological PD following an initial Objective Response according to RECIST V1.1, with clinical benefit under standard PD-1/PD-L1.
62591715|NCT02847494|ACTIVE_COMPARATOR|Control|Metoclopramide 10mg IV+ dexamethasone 10mg IM
62591716|NCT02847494|ACTIVE_COMPARATOR|Experimental|Metoclopramide 10mg IV + methylprednisolone acetate 160mg IM
62806516|NCT03481335|NO_INTERVENTION|Control Community|Control communities (barangays) will receive care as usual.
62806517|NCT04954755||RFS|
62229834|NCT02960841|ACTIVE_COMPARATOR|Conventional treatment|Conventional treatment active comparator
62591717|NCT00744549|EXPERIMENTAL|A|This group of men will be on active treatment (antioxidants) for one year and placebo for the second year.
62229835|NCT06135675|EXPERIMENTAL|TNP-2092 capsules 100mg Twice daily(BID)|
62229836|NCT06135675|EXPERIMENTAL|TNP-2092 capsules 300mg BID|
62229837|NCT06135675|EXPERIMENTAL|TNP-2092 capsules 600mg BID|
62229838|NCT06135675|PLACEBO_COMPARATOR|TNP-2092 capsules Placebo|
62229839|NCT02699983|EXPERIMENTAL|Group I (SparkPeople program)|"Participants receive one 30-minute session with the research assistant for training on how to use the SparkPeople website, and they may request additional training if needed.~Participants are instructed to self-monitor their diet at least weekly using the SparkPeople tool, and to self-monitor their activity daily using the Fitbit monitoring device.~Participants receive weekly motivational reminders to log into the website for 3 months via email, text, or phone, based on patient preference (active phase). Participants then enter the maintenance phase for 3 months without reminders.~All participants answer survey questions on quality of life and social cognitive theory variables and undergo anthropometric measurements at baseline, 3, and 6 months."
62591718|NCT00744549|EXPERIMENTAL|B|This group of men will be on placebo for one year and active treatment (antioxidants) for the second year.
62591719|NCT01322594|EXPERIMENTAL|MEDI2338 10 MG|MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump
62591720|NCT01322594|EXPERIMENTAL|MEDI2338 30 MG|MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
62591721|NCT01322594|EXPERIMENTAL|MEDI2338 100 MG|MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
62591722|NCT01322594|EXPERIMENTAL|MEDI2338 300 MG|MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
62591723|NCT01322594|EXPERIMENTAL|MEDI2338 1000 MG|MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
62591724|NCT01322594|PLACEBO_COMPARATOR|Placebo|Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
62806518|NCT04954755||non-RFS|
62806519|NCT02388581|EXPERIMENTAL|Anti-H. pylori Therapy|Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole
62806520|NCT05369663||no mask|no mask use
62806521|NCT05369663||surgical mask|surgical mask use
62806522|NCT05369663||N99 mask|N99 mask use
62806523|NCT05369663||face shield|face shield use
62806524|NCT05369663||surgical mask+ faceshield|surgical mask+ faceshield use
62806525|NCT05369663||N99 mask+ faceshield|N99 mask+ faceshield use
62806526|NCT01942096||Competitive swimmers|Swimmers performing at national or international level
62806527|NCT01942096||Competitive indoor athletes|Indoor athletes performing at national or international level
62806528|NCT01942096||Healthy control individuals|Individuals performing sports at a recreational level
62591725|NCT03784625|EXPERIMENTAL|therapeutic dose activity (level 1)|\[131\]ICF01012 at a therapeutic dose of 800 MBq/m² , single dose at D11 (intravenous administration)
62591726|NCT03784625|EXPERIMENTAL|therapeutic dose activity (level 2)|\[131\]ICF01012 at a therapeutic dose of 1600 MBq/m² , single dose at D11 (intravenous administration)
62229840|NCT02699983|ACTIVE_COMPARATOR|Group II (wait list)|Participants receive the weight loss handout and a Fitbit activity monitoring device and proceed with their usual life. After 6 months, patients receive the SparkPeople treatment as in Group I. All participants answer survey questions on quality of life and social cognitive theory variables and undergo anthropometric measurements at baseline, 3 and 6 months.
62229841|NCT05242185||COVID-19 survivors|All patients age 18years and more who have SARS-CoV-2 infection confirmed by reverse-transcriptase polymerase-chain-reaction assay (RT-PCR) following their discharge from Dhaka hospital or outpatient clinic or inpatient wards of BSMMU
62229842|NCT01943032||Primary Breast Tumor|Immunohistochemical staining of paraffin embedded tissue blocks of primary breast tumor for estrogen and progesterone receptors was performed.
62229843|NCT01943032||Axillary Lymph Nodes.|Immunohistochemical staining of paraffin embedded tissue blocks of axillary lymph nodes for estrogen and progesterone receptors was performed.
62030744|NCT01605617|PLACEBO_COMPARATOR|PTNS + placebo first, then PTNS + fesoterodine fumarate|Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + placebo for 12 weeks followed by 4 weeks of washout followed by 12 weeks of PTNS + 4mg of fesoterodine fumarate
62229844|NCT00517907|EXPERIMENTAL|1|6 steroid-resistant acute GVHD patients, post-matched BMT (serial)
62229845|NCT03931720|EXPERIMENTAL|anti-tumor response of BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)|Patients with relapsed and refractory cancer of ROBO1 expression will be treated with BiCAR-NK/T cells (ROBO1 CAR-NK/T cells).
62229846|NCT04942834|ACTIVE_COMPARATOR|Drug treatment group|receive class I or class III AAD to restore or maintain sinus rhythm.
62229847|NCT04942834|EXPERIMENTAL|cryoballoon ablation group|receive cryoballoon ablation to restore sinus rhythm.
62030745|NCT04333394|ACTIVE_COMPARATOR|Probiotic|The probiotics capsules contain 7 strains of friendly bacteria (Lactobacillus casei PXN 37, Lactobacillus rhamnosus PXN 54, Streptococcus thermophilus PXN 66, Bifidobacterium breve PXN 25, Lactobacillus acidophilus PXN 35, Bifidobacterium longum PXN 30, Lactobacillus bulgaricus PXN 39)
62229848|NCT03482154||With Malglycemia|
62229849|NCT03482154||Without Malglycemia|
62229850|NCT04166890|EXPERIMENTAL|NS Lower right molar|IANB Artheek SP Articaine EPINEPHrine Cartridge 4% 1:100000
62229851|NCT04166890|ACTIVE_COMPARATOR|SD Lower Left molar|IANB Septanest Articaine EPINEPHrine Cartridge 4% 1:100000
62229852|NCT04166890|EXPERIMENTAL|NS Lower left molar|IANB Artheek SP Articaine EPINEPHrine Cartridge 4% 1:100000
62421950|NCT03720522||Group 3: Patients suffering from stunned neurogenic myocardium|"Patients with elevated (≥ 0.015 mg/L) high sensitive troponin T (hsTnT) levels and presence of wall motion abnormalities (WMA) have potential WMA due to neurogenic myocardial stunning. They will be allocated to group 3.~These patients will undergo a follow-up CMR without adenosine-perfusion after 3 months to confirm improvement/normalization of WMA.~Patients with normal (\< 0.015mg/L) hsTnT levels and presence of WMA will also be allocated to group 3."
62421951|NCT03720522||Group 4: Control|Patients with normal (\< 0.015mg/L) high sensitive troponin T (hsTnT) levels without late enhancement, without myocardial infarction and without wall motion abnormalities will serve as control group and will be classified to group 4.
62229853|NCT04166890|ACTIVE_COMPARATOR|SD Lower right molar|IANB Septanest Articaine EPINEPHrine Cartridge 4% 1:100000
62421952|NCT01875991|EXPERIMENTAL|Autoinjector A|Participants self-injected 50 mg etanercept once a week (RA) or twice a week (PsO) using Autoinjector A for 4 weeks.
62421953|NCT01875991|EXPERIMENTAL|Autoinjector B|Participants self-injected 50 mg etanercept once a week (RA) or twice a week (PsO) using Autoinjector B for 4 weeks.
62421954|NCT00683904|ACTIVE_COMPARATOR|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|
62421955|NCT00683904|ACTIVE_COMPARATOR|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|
62421956|NCT02549833|EXPERIMENTAL|Vaccines before and after surgery|GBM6-AD lysate protein 1 mg and poly-ICLC 1.4 mg administered as one formulation every week leading up to standard-of-care surgery to remove the WHO grade II glioma (Days -23±2, -16±2, -9±2 and 24-48 hours prior to scheduled surgery), every 3 weeks after surgery (Weeks A1, A4, A7, A10, A13, A16; defining Week A1 as the first post-surgery vaccine), and two booster vaccines (Weeks A32 and A48).
62591727|NCT03784625|EXPERIMENTAL|therapeutic dose activity (level 3)|\[131\]ICF01012 at a therapeutic dose of 2700 MBq/m² , single dose at D11 (intravenous administration)
62591728|NCT03784625|EXPERIMENTAL|therapeutic dose activity (level 4)|\[131\]ICF01012 at a therapeutic dose of 4000 MBq/m² , single dose at D11 (intravenous administration)
62030746|NCT04333394|PLACEBO_COMPARATOR|Placebo|Placebo capsules have an identical appearance to probiotic capsules and contain microcrystal cellulose.
62229854|NCT01174160|EXPERIMENTAL|vernakalant HCl|vernakalant hydrochloride
62229855|NCT01174160|PLACEBO_COMPARATOR|placebo|placebo
62229856|NCT04626492||F0|Normal control group
62229857|NCT04626492||F1|Grade 1 of liver fibrosis
62229858|NCT04626492||F2|Grade 2 of liver fibrosis
62229859|NCT04626492||F3|Grade 3 of liver fibrosis
62229860|NCT04626492||F4|Hepatic cirrhosis
62591729|NCT02628457||Mild Subgroup|patients with supraspinatus tendon retracted upto medial 1/3rd of humerus head and arthroscopic rotator cuff repair done by single row.
62030747|NCT05859204|EXPERIMENTAL|OT-led Exercise Group on Inpatient Psychiatry Unit|Occupational therapist (OT) led group. Group includes education, warm-up, high intensity interval training cardio, strength, kick boxing, cool-down, yoga, and discussion. This group also receives the Treatment as Usual groups.
62030748|NCT05859204|PLACEBO_COMPARATOR|Treatment As Usual - OT Groups on Inpatient Psychiatry Unit|An occupational therapist (OT) will begin daily educational session about the topic of choice for that day.
62030749|NCT06129669||Debridement after radiotherapy|Debridement after radiotherapy
62030750|NCT06129669||Debridement after trauma|Debridement after trauma
62030751|NCT06129669||Reconstructive surgery using a fasciocutaneous flap|Reconstructive surgery using a fasciocutaneous flap
62030752|NCT06129669||Reconstructive surgery using a muscle flap|Reconstructive surgery using a muscle flap
62030753|NCT06129669||Reconstructive surgery using a osseous flap|Reconstructive surgery using a osseous flap
62030754|NCT06129669||Vaginaplasties|Vaginaplasties using a peritoneum flap or colon interposition
62030755|NCT06129669||Phalloplasties|Phalloplasties
62030756|NCT06129669||Finger replantation|Finger replantation
62030757|NCT05246423||Observation group|Patients with paroxysmal atrial fibrillation, recruited at least two weeks after the last paroxysm
62030758|NCT04447404|EXPERIMENTAL|DUR-928|
62030759|NCT04447404|PLACEBO_COMPARATOR|Placebo|
62030760|NCT04701398|EXPERIMENTAL|Multimodal intervention|supervised physical training (1-hour sessions, 24 sessions, 8 weeks) + nutritional supplementation + psychological advice
62030761|NCT04701398|NO_INTERVENTION|Standard Care|Healthy living recommendations
62030762|NCT02501460|ACTIVE_COMPARATOR|Supplement Group|Participants will receive educational handouts and complete research testing to evaluate their physical condition prior to beginning the resistance training and dietary supplementation. Adherence will be assured as described below.
62030763|NCT02501460|PLACEBO_COMPARATOR|Placebo Group|Participants will receive educational handouts and complete research testing to evaluate their physical condition prior to beginning the resistance training and placebo. Adherence will be assured as described below.
62030764|NCT05240014|EXPERIMENTAL|Exoskeleton|Participants in this arm of the study will perform various tasks while wearing the modular powered orthosis
62229861|NCT06266819|EXPERIMENTAL|the chewing of a mint-flavored gum group|In data collection, pregnant women will sign an informed consent form before the application. Personal Information Form, VAS Scale, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale will be filled out. In addition to the routine treatment plan, the application will begin at least 4 hours after the antiemetic administration. The application will continue by chewing mint-flavored gum twice a day for at least 15 minutes for 3 days. The VAS scale will be filled after the morning chewing application, and the VAS Scale, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale will be filled in after the evening application. The forms of patients discharged during this period will be filled in via phone.
62421957|NCT02549833|ACTIVE_COMPARATOR|Vaccines after surgery only|GBM6-AD lysate protein 1 mg and poly-ICLC 1.4 mg administered as one formulation every 3 weeks after standard-of-care surgery to remove the WHO grade II glioma only (Weeks A1, A4, A7, A10, A13, A16; defining Week A1 as the first post-surgery vaccine) and two booster vaccines (Weeks A32 and A48). Patients will not receive vaccines before surgery.
62421958|NCT04261322|EXPERIMENTAL|rabies patient 1|not received immunoglobulins and symptomatic
62421959|NCT04261322|EXPERIMENTAL|rabies patient 2|received immunoglobulins and symptomatic
62421960|NCT04261322|EXPERIMENTAL|rabies patient 3|not received immunoglobulins and not yet symptomatic
62806529|NCT02313259||AMD controls|15 patients with early to intermediate AMD (grade 2-8) were enrolled using the Age-Related Eye Disease Study (AREDS) severity scale for AMD.
62030765|NCT04154787|EXPERIMENTAL|LNP023|"As per protocol V00, participants took LNP023 10 mg orally b.i.d. for 4 weeks followed by LNP023 50 mg orally b.i.d. for 20 weeks.~As per protocol amendment V01, participants took LNP023 50mg orally b.i.d. for 4 weeks followed by LNP023 200mg for 20 weeks."
62421961|NCT04261322|EXPERIMENTAL|rabies patient 4|received immunoglobulins and not symptomatic
62030766|NCT04154787|ACTIVE_COMPARATOR|Rituximab|Rituximab 1 g i.v. at Day 1 and Day 15
62030767|NCT03103555|EXPERIMENTAL|Bortezomib and cyclophosphamide|Two cycles of bortezomib administered subcutaneously, followed by 4 months of low dose oral cyclophosphamide.
62030768|NCT01715805|OTHER|Placebo + ADT Lead-in|Antidepressant therapy (ADT) as prescribed by the investigator plus single-blind placebo for 8 weeks.
62030769|NCT01715805|PLACEBO_COMPARATOR|Placebo + ADT (Double-Blind)|Following the 8 week ADT plus single blind placebo lead-in period participants were randomized to dose-matched placebo, once per day, oral administration plus ADT for 8 weeks (up to Week 16).
62030770|NCT01715805|EXPERIMENTAL|Cariprazine + ADT (Double-Blind)|Following the 8 week ADT plus single blind placebo lead-in period participants were randomized to cariprazine, 1.5 to 4.5 milligrams (mg) per day, oral administration plus ADT for 8 weeks (up to Week 16).
62030771|NCT01715805|OTHER|Placebo + ADT (Continued Treatment)|Following the 8 week ADT plus single blind placebo lead-in period, participants who were ADT responders continued treatment with ADT plus placebo for an additional 8 weeks.
62030772|NCT01845610|EXPERIMENTAL|Fortified fat-based paste with EFAs, DHA, ARA and phytase|Complementary food supplement providing micronutrients and both essential fatty acids, DHA, ARA, phytase and L-lysine, potassium, phosphorous, magnesium and manganese
62030773|NCT01845610|EXPERIMENTAL|Fortified fat-based paste with essential fatty acids|Complementary food supplement providing micronutrients and essential fatty acids (EFAs)
62030774|NCT01845610|NO_INTERVENTION|Control group|The control group will receive a delayed intervention
62806530|NCT02313259||Age-matched controls|15 drivers without ocular disease.
62806531|NCT02313259||Young controls|15 drivers without ocular disease. Between 18 and 25 years old.
62806532|NCT02313259||Glaucoma patients|15 patients having a Humphrey visual field mean deviation between -10 and -12 (better eye).
62806533|NCT03408197|EXPERIMENTAL|EasyWarm|
62806534|NCT03408197|ACTIVE_COMPARATOR|BairHugger|
62030775|NCT06073574||Experimental: ION-682884-CS2 MRI Scan Sub-set|Participants enrolled in the parent study ION-682884-CS2 (NCT04136171) to receive either eplontersen or placebo and who consented to participate in this sub-study will undergo cardiac MRI at Baseline, Weeks 25, 49, 97 and 140.
62030776|NCT04020991||Doctors working in a tertiary hospital|Doctors working in a tertiary hospital
62030777|NCT01479920|ACTIVE_COMPARATOR|DCEAS|"Dense cranial electroacupuncture stimulation (DCEAS)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
62030778|NCT01479920|SHAM_COMPARATOR|n-CEA|"Non-invasive cranial electroacupuncture (n-CEA)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
62030779|NCT00540280|ACTIVE_COMPARATOR|Surgery alone|Surgery alone
62030780|NCT06589648|EXPERIMENTAL|intervention group|Participants in the intervention group will be given a set of colored markers and a mandala coloring page and will be asked to color them any time of the day and in any way they want during their hospital stay. Participants will be asked to take a picture of the mandala they colored and send it to the researcher after they are finished. Participants will be reminded daily so that they do not forget to do the activity.
62030781|NCT06589648|NO_INTERVENTION|control group|No intervention other than routine care will be made to the control group of the study, and research data will be collected at simultaneous intervals with the experimental group.
62030782|NCT00607425||1|Non-small cell lung cancer patients
62030783|NCT00607425||2|Healthy control subjects
62030784|NCT04568538|EXPERIMENTAL|İntervention group|"Randomization with a sealed envelope will be applied to mothers who have 2-4 months old babies who apply to Akdeniz University Hospital Pediatric Outpatient Clinic for health control and who accept the study. A pre-test application will be made in the intervention group. The Researcher will fill in the Personal Information Form and the Shaken baby syndrome assessment survey at this stage.~The training prepared to prevent shaken baby syndrome, which was prepared immediately after the end of the pre-test application, will be given to the mothers in the intervention group. The training will be given with mothers using one-to-one face-to-face interview method. Necessary equipment will be provided for training. At the end of the training, the questions of the mothers will be answered and a booklet prepared to prevent shaken baby syndrome will be given and tele-consultancy will be provided for 2 months."
62030785|NCT04568538|NO_INTERVENTION|Control group|No application will be made to the mothers in the control group after the pre-test application. After 2 months, the final test application will be made. After the last test, the mothers in the control group will be given a training and a booklet prepared to prevent shaken baby syndrome.
62030786|NCT03457532|EXPERIMENTAL|Dose escalation study of Gumarontinib|To determine the maximum tolerated dose (MTD) of Gumarontinib
62421962|NCT03023007|EXPERIMENTAL|Loco-regional anaesthesia|Loco-regional anaesthesia Anesthesia technique used : loco-regional PECS for patients requiring Mastectomy; And/or Axillary node dissection ; And/or Reconstruction of breast by prosthesis
62591730|NCT02628457||Moderate Subgroup|patients with supraspinatus tendon retracted between medial 1/3rd of humerus head and glenoid,and arthroscopic rotator cuff repair done by single row.
62591731|NCT02628457||Severe subgroup|patients with supraspinatus tendon retracted beyond glenoid and arthroscopic rotator cuff repair done by single row
62806535|NCT01745926||CPR|MECHANICAL CHEST COMPRESSION
62806536|NCT03309566|EXPERIMENTAL|Test - Reference|A new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).
62806537|NCT03309566|EXPERIMENTAL|Reference - Test|A branded formulation (R) followed by a new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T).
62806538|NCT04674891|ACTIVE_COMPARATOR|baseline physical therapy treatment|baseline physical therapy treatment ,Control group- Group A
62806539|NCT04674891|EXPERIMENTAL|Cervical Stabilization exercises|baseline physical therapy treatment along with Cervical Stabilization exercises- Experimental Group- Group B
62806540|NCT00633971|EXPERIMENTAL|A|Complex lymphedema therapy (which includes compression stocking use)
62030787|NCT05118854|EXPERIMENTAL|Sotorasib in Combination with Cisplatin/Carboplatin and Pemetrexed|4 cycles of at least one dose of sotorasib plus cisplatin (or carboplatin) and pemetrexed can be administered safely
62591732|NCT04582058|NO_INTERVENTION|Control Group (CG)|Control Group (CG): Standard of care, normally follow up, without mobile health
62806541|NCT00633971|OTHER|B|Standard of care (compression stocking use at 30-40 mm Hg)
62806542|NCT04664153|EXPERIMENTAL|atopic dermatitis - PF-07038124 ointment|
62806543|NCT04664153|PLACEBO_COMPARATOR|atopic dermatitis - vehicle ointment|
62806544|NCT04664153|EXPERIMENTAL|plaque psoriasis - PF-07038124 ointment|
62806545|NCT04664153|EXPERIMENTAL|plaque psoriasis - vehicle ointment|
62806546|NCT00181363|EXPERIMENTAL|Mamma board|use of the mamma board during radiotherapy
62806547|NCT04957797|OTHER|ROT-Group|reamed with round tunnel
62806548|NCT04957797|EXPERIMENTAL|FLT-Group|reamed with flat tunnel
62806549|NCT01317758|PLACEBO_COMPARATOR|Group 6|Two doses of sanofi H5N1 antigen 15 mcg plus PBS diluent
62806550|NCT01317758|PLACEBO_COMPARATOR|Group 5|Two doses of sanofi H5N1 antigen 7.5 mcg plus PBS diluent
62806551|NCT01317758|PLACEBO_COMPARATOR|Group 4|Two doses of sanofi H5N1 antigen 3.75 mcg plus Phosphate Buffered Saline (PBS) diluent
62806552|NCT01317758|EXPERIMENTAL|Group 3|Two doses of sanofi H5N1 antigen 15 mcg plus GSK AS03 adjuvant
62806553|NCT01317758|EXPERIMENTAL|Group 1|Two doses of sanofi H5N1 antigen 3.75 mcg plus GSK AS03 adjuvant
62030788|NCT00127075|EXPERIMENTAL|NOMA + estradiol|Oral NOMA (LUTENYL® 10 mg/day) combined with transdermal Estradiol (DERMESTRIL SEPTEM® 75 mcg, once a week),
62030789|NCT00127075|PLACEBO_COMPARATOR|placebo|Matching placebo treatments
62806554|NCT01317758|EXPERIMENTAL|Group 2|Two doses of sanofi H5N1 antigen 7.5 mcg plus GSK AS03 adjuvant
62030790|NCT03858205|EXPERIMENTAL|Treatment (low-dose radiation therapy)|Patients receive low-dose radiation therapy at consecutive business days 1 and 2 in the absence of disease progression or unacceptable toxicity. Patients with no pain relief may receive additional radiotherapy at 4 weeks following initial radiotherapy.
62806555|NCT05936112|OTHER|Infants < 4 months old with FGID|Infants \< 4 months old presenting one or several Functional GastroIntestinal Disorder(s)
62806556|NCT05936112|OTHER|Infants < 4 months old free from FGID|Infants \< 4 months old without any Functional GastroIntestinal Disorder
62806557|NCT06347198|EXPERIMENTAL|Intervention group (Fruquintinib combined with Sintilimab and inulin group)|
62806558|NCT06347198|OTHER|Control group (Fruquintinib combined with Sintilimab group)|
62806559|NCT04716426|EXPERIMENTAL|Tetracycline hydrochloride 3%|4 drops of tetracycline hydrochloride 3% (APT™ T3X) applied inside of the nasal channels and inside of nostrils, once a day, every day for 21 days (except health professionals that will be instructed to use 4 drops of APT™ T3X twice a day, every day for 21 days.
62030791|NCT06635018|EXPERIMENTAL|Determination of effect of pulse oximeters from different manufacturers on measured Perfusion index|Three finger pulse oximeter sensors from different manufacturers are placed on the middle fingers of one hand. Three interventions subsequently follow (Resting condition, Movement artifacts and Circulation constriction).
62030792|NCT02656797|EXPERIMENTAL|AM-B|Topical Amphotericin-B 0.4% liposomal gel
62806560|NCT04716426|PLACEBO_COMPARATOR|Placebo|4 drops of placebo applied inside of the nasal channels and inside of nostrils, once a day, every day for 21 days (except health professionals that will be instructed to use 4 drops of APT™ T3X twice a day, every day for 21 days.
62806561|NCT01774032|EXPERIMENTAL|Influenza Vaccine|One dose of the vaccine will be administered at a volume of 0.5 mL by intramuscular injection into the musculus deltoideus in the upper arm on Day 1 and 22.
62806562|NCT00809900||Dietary Supplement|Cranberry Juice Consumption
62806563|NCT04101071|EXPERIMENTAL|Modular ketogenic enteral feed|Ketogenic enteral feed to be administered continuously for 10 days.
62806564|NCT04101071|ACTIVE_COMPARATOR|Standard enteral feed|Standard enteral feed to be administered continuously for 10 days.
62806565|NCT01166841|EXPERIMENTAL|PSVC line clamped|Clamping of the percutaneously placed superior vena cava line placed for minimally invasive mitral valve repair/replacement.
62806566|NCT01166841|NO_INTERVENTION|Unclamped PSVC|Unclamped percutaneously placed superior vena cava line placed for minimally invasive mitral valve repair/replacement.
62806567|NCT04800250|EXPERIMENTAL|A - Mucogain matrix on right|The patient will receive mucogain matrix on right side and connective tissue graft on left side.
62806568|NCT04800250|EXPERIMENTAL|B - Mucogain matrix on left|The patient will receive mucogain matrix on left side and connective tissue graft on right side.
62806569|NCT05283551|EXPERIMENTAL|Single arm|
62030793|NCT02656797|PLACEBO_COMPARATOR|Placebo|Placebo gel preparation
62806570|NCT02110563|EXPERIMENTAL|DCR-MYC|Patient groups (cohorts) will receive a single dose level of DCR-MYC; the dose level of DCR-MYC will be increased in subsequent cohorts
62030794|NCT02952924|PLACEBO_COMPARATOR|Parts 1a and 1b: SAD in Healthy Volunteers (Placebo)|In Part 1a, participants will receive a single oral dose of placebo matching to RO7049389 film coated tablet on Day 1. In Part 1b, minimum 8 participants from Part 1a will be selected and 2 of whom will receive another single dose of placebo matching to RO7049389 on Day 16 after eating the standard United States - Food and Drug Administration (US FDA)-recommended high-fat and high-calorie breakfast.
62030795|NCT02952924|EXPERIMENTAL|Parts 1a and 1b: SAD in Healthy Volunteers (RO7049389)|In Part 1a, participants will receive a single oral dose of RO7049389 film coated tablet on Day 1 in dose-escalation cohorts with a starting dose of 150 milligrams (mg). The doses for subsequent cohorts will be defined by an adaptive approach based on the safety and PK data in previously-dosed healthy volunteers. In Part 1b, minimum 8 participants from Part 1a will be selected and 6 of whom will receive another single dose of RO7049389 on Day 16 after eating the standard US FDA-recommended high-fat and high-calorie breakfast.
62421963|NCT06255730|EXPERIMENTAL|Stellate Ganglion Block Group|Stellate Ganglion Block Group will be given Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day
62806571|NCT01844388|EXPERIMENTAL|Carboxymethylcellulose Based Eye Drop Formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
62806572|NCT01844388|ACTIVE_COMPARATOR|REFRESH CONTACTS®|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
62806573|NCT00815217|EXPERIMENTAL|1 lipoaspirate|wounds which have received the lipoaspirate
62806574|NCT00815217|PLACEBO_COMPARATOR|2 control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
62421964|NCT00630448||Group 1|Control Group. Normal (healthy) individuals without Von Willebrand Disease.
62806575|NCT05342558|ACTIVE_COMPARATOR|Biomass Smoke COPD|"Fluticasone Furoate/Vilanterol 100/25 mcgs. Dry powder inhaler with 30 blisters. 1 inhalation a day for 24 weeks.~Umeclidinium/Vilanterol 62.5/25 mcgs. Dry powder inhaler with 30 blisters. 1 inhalation a day for 24 weeks."
62806576|NCT05342558|ACTIVE_COMPARATOR|Tobacco Smoke COPD|"Fluticasone Furoate/Vilanterol 100/25 mcgs. Dry powder inhaler with 30 blisters. 1 inhalation a day for 24 weeks.~Umeclidinium/Vilanterol 62.5/25 mcgs. Dry powder inhaler with 30 blisters. 1 inhalation a day for 24 weeks."
62806577|NCT02932137|EXPERIMENTAL|Interleukin-2|Interleukin-2 to treat activated SLE.
62806578|NCT02932137|NO_INTERVENTION|Traditional therapy|Treat activated SLE with glucocorticoid or immunosuppressor.
62806579|NCT04404868||Enrolled patients|"Each patient (whether hospitalized or outpatient) included in the study underwent to a baseline evaluation in which near and remote pathological history were recorded (main concomitant pathologies, drug therapy in progress, previous major surgery) and the following evaluation scales were administered: modified Ashworth scale (MAS), MI (motricity index), FMA (Fughl Meyer assessment) and Modified Rankin' scale (MRS).~Each patient will subsequently undergo to a follow-up evaluation at 4, 12 and 24 weeks after the date of inoculation through the execution of a specialist visit (physiatric/neurological) and the administration of the following evaluation scales: MAS, MI, FMA and MRS. For the duration of the study, each patient may undergo integrated rehabilitation treatment at the discretion of each of the investigators of each centre involved in the study according to the guidelines and common clinical practice."
62030796|NCT02952924|PLACEBO_COMPARATOR|Part 1c: MAD in Healthy Volunteers (Placebo)|Participants will receive placebo matching to RO7049389 film coated tablet from Days 1 to 13 (either once a day \[QD\] or twice a day \[BID\]) and a single dose of placebo matching to RO7049389 film coated tablet in the morning of Day 14. Participants will also receive a single dose of midazolam solution (100 micrograms \[mcg\]) on Day -1 and Day 14.
62229862|NCT06266819|NO_INTERVENTION|control group|In data collection, pregnant women will sign an informed consent form before the application. At least 4 hours after the antiemetic administration, the Personal Information Form, VAS Scale, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale will be filled out. Routine treatment and nursing care will be applied to the control group, and no intervention will be performed. 1. After the forms are applied, the forms will continue to be filled for 3 days: VAS Scale in the morning, VAS Scale in the evening, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale. The forms of discharged patients will be filled in via phone.
62229863|NCT02284451|ACTIVE_COMPARATOR|English HIGH Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
62229864|NCT02284451|ACTIVE_COMPARATOR|English LOW Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
62229865|NCT02284451|ACTIVE_COMPARATOR|Spanish HIGH Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
62229866|NCT02284451|ACTIVE_COMPARATOR|Spanish LOW Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
62229867|NCT05077865|EXPERIMENTAL|Cohort 1 - Active|6 subjects, randomized to receive 150mg MYMD1 (Isomyosamine), administered as one 150mg capsule on Day 1.
62229868|NCT05077865|PLACEBO_COMPARATOR|Cohort 1 - Placebo|2 subjects, randomized to receive placebo, administered on Day 1, as one capsule matching the 150mg MYMD1 capsule in appearance.
62229869|NCT05077865|EXPERIMENTAL|Cohort 2 - Active|6 subjects, randomized to receive 300mg MYMD1 (Isomyosamine), administered as two 150mg capsules on Day 1.
62806580|NCT01113359||study group|hypertensive patients
62806581|NCT01113359||control group|healthy volunteer
62229870|NCT05077865|PLACEBO_COMPARATOR|Cohort 2 - Placebo|2 subjects, randomized to receive placebo, administered on Day 1, as two capsules matching the 150mg MYMD1 capsules in appearance.
62591733|NCT04582058|EXPERIMENTAL|Interventional Group (IG)|Interventional Group (IG): Mobile Health to patients with an orientation about daily activities and protocol of physical exercise
62806582|NCT03656939||Prevenar 13 cohort|This is a non-interventional study. Children in the study receive Prevenar 13 per normal medical practice.
62806583|NCT06260566|EXPERIMENTAL|Infants with Biliary Atresia|"* Administering applesauce alone~* Administering applesauce plus NAC (for infants who tolerate applesauce alone)"
62806584|NCT05588349|EXPERIMENTAL|Dry needling + stretching exercise|"After locating the MTrPs, hand hygiene of the physiotherapist will be done and the needling site will be disinfected with alcohol swab. 0.30 x 50 mm disposable stainless-steel needles (DongBang Acupuncture Inc., Boryeong, Korea) will be used. The needle will be inserted into the muscle and pistoned in an up-and-down fashion using the fast in and fast out technique in order to provoke the local twitch response (LTR). This will be repeated until either the LTRs are exhausted, or the participant's tolerance threshold is met. If the participant is sensitive to the needle stimulation, the manipulation will be reduced. The needle will be left in situ for five minutes (Cotchett et al., 2011). Participants will receive dry needling once per week for three weeks. Plantar fascia and calf stretching exercise will be taught"
62819505|NCT05471076|PLACEBO_COMPARATOR|Fractionated Delivery, Group 3: First injection - Placebo, Final injection - Placebo|The first dose for the Fractionated Delivery Arm Group 2 will be divided into 6 smaller amounts (2 visits per week for 3 weeks). The second dose will be given about 3 months later and will be given all at once. At each injection visit for the first dose, the patient will get one amount divided into 2 injections - one in the deltoid muscle of each arm.
62819506|NCT05471076|EXPERIMENTAL|Optional Boost Regimen with BG505|SOSIP.GT1.1 gp140
62229871|NCT05077865|EXPERIMENTAL|Cohort 3 - Active|6 subjects, randomized to receive 450mg MYMD1 (Isomyosamine), administered as three 150mg capsules on Day 1.
62229872|NCT05077865|PLACEBO_COMPARATOR|Cohort 3 - Placebo|2 subjects, randomized to receive placebo, administered on Day 1, as three capsules matching the 150mg MYMD1 capsules in appearance.
62229873|NCT05077865|EXPERIMENTAL|Cohort 4 - Active|6 subjects, randomized to receive 600mg MYMD1 (Isomyosamine), administered as four 150mg capsules each on Days 1, 2, 3, 4, and 5.
62229874|NCT05077865|PLACEBO_COMPARATOR|Cohort 4 - Placebo|2 subjects, randomized to receive placebo, administered on Days 1, 2, 3, 4, and 5 as four capsules each, matching the 150mg MYMD1 capsules in appearance.
62229875|NCT01280812|EXPERIMENTAL|PA intervention and Maintenance plus|3-month physical activity intervention and 6-month maintenance intervention-Plus program
62591734|NCT00799721||1|VLBW infants with erythropoietin therapy
62806585|NCT05588349|ACTIVE_COMPARATOR|Stretching exercise|"Plantar fascia stretching exercise:~Participants will be instructed to sit with the affected foot placed on the contralateral thigh with the toes being grasped and pulled into extension until a stretch is felt in the plantar fascia.~Calf stretching exercise:~To focus on stretching the gastrocnemius, participants will be taught to stand with both hands holding onto the wall and keep the affected leg back with knee straightened and heel in contact with the floor. Slowly lean forward to the wall until a stretch is felt in the calf. To focus on stretching the soleus, the same procedures will be taught except with the affected knee being bent."
62030797|NCT02952924|EXPERIMENTAL|Part 1c: MAD in Healthy Volunteers (RO7049389)|Participants will receive RO7049389 film coated tablet from Days 1 to 13 (either QD or BID; dose and regimen will be decided based on the available PK and safety data) and a single dose of RO7049389 film coated tablet in the morning of Day 14. Participants will also receive a single dose of midazolam solution (100 mcg) on Day -1 and Day 14.
62030798|NCT02952924|PLACEBO_COMPARATOR|Part 2: POM in Chronic HBV Participants (Placebo)|Participants will receive placebo matching to RO7049389 film coated tablet from Days 1 to 27 (either QD or BID) and a single dose of placebo matching to RO7049389 film coated tablet in the morning of Day 28.
62806586|NCT03416855||Overall population|Participants will be decided to be treated with Ryzodeg® FlexTouch® by physicians before the enrolment in the study based on clinical judgement in the diabetes management.
62806587|NCT02702466|EXPERIMENTAL|Immediate SPA Therapy|6 day immediate SPA treatment (soon after randomization) and written information with physical exercises adapted to their pathology and also a program of healthcare at the USB key
62030799|NCT02952924|EXPERIMENTAL|Part 2: POM in Chronic HBV Participants (RO7049389)|Participants will receive RO7049389 film coated tablet from Days 1 to 27 (either QD or BID; dose and regimen will be decided based on the available PK and safety data) and a single dose of RO7049389 film coated tablet in the morning of Day 28.
62806588|NCT02702466|ACTIVE_COMPARATOR|Late SPA Therapy|Written information with physical exercises adapted to their pathology and a program of healthcare at the USB key and late 6 day SPA treatment
62030800|NCT02952924|EXPERIMENTAL|Part 3: POM in NUC-Suppressed CHB Participants (Cohort A)|Participants will receive RO7049389 on top of a NUC for 48 weeks at a dose determined from Part 2. NUC therapy will be administered per local label or guidelines.
62030801|NCT02952924|EXPERIMENTAL|Part 3: POM in Treatment-Naive CHB Participants (Cohort B)|Participants will receive RO7049389 for 4 weeks, followed by RO7049389 with an added NUC for 44 weeks. RO7049389 will be administered at a dose determined from Part 2. NUC therapy will be administered per local label or guidelines.
62591735|NCT00799721||2|VLBW infants without erythropoietin therapy.
62591736|NCT05087966|EXPERIMENTAL|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
62806589|NCT03430791|EXPERIMENTAL|Nivolumab Monotherapy|Nivolumab 240 mg IV every 2 weeks for maximum of 24 months. TTF (Optune) for max of 24 months
62806590|NCT03430791|EXPERIMENTAL|Nivolumab+Ipilimumab|"Nivolumab 3 mg/kg IV with ipilimumab then 240 mg every 2 weeks for maximum of 24 months.~Ipilimumab 1 mg/kg IV every 6 weeks maximum of 4 times. NovoTTF200A (Optune) TTF for maximum 24 months"
62806591|NCT02724332|NO_INTERVENTION|control group|Patients will be treated with radical hepatectomy only.
62806592|NCT02724332|ACTIVE_COMPARATOR|transcatheter arterial chemoembolization|Patients will be treated with TACE
62806593|NCT02162550|EXPERIMENTAL|Bydureon|injectable medication Bydureon
62806594|NCT02162550|PLACEBO_COMPARATOR|Placebo|a similar looking injectable
62229876|NCT01280812|EXPERIMENTAL|PA intervention and Maintenance regular|3-month physical activity intervention and 6-month maintenance - Regular program
62229877|NCT01280812|ACTIVE_COMPARATOR|Pedometer|Non-intervention group
62591737|NCT00798668|EXPERIMENTAL|1|participants continue current exercise and take liquid supplement
62591738|NCT00798668|EXPERIMENTAL|2|Participants continue current exercise and take solid supplement
62591739|NCT00798668|EXPERIMENTAL|3|Participants continue current sedentary behavior and take liquid supplements
62591740|NCT00798668|EXPERIMENTAL|4|Participants continue current sedentary behavior and take solid supplements
62591741|NCT04440891|EXPERIMENTAL|TMS-Stimulation with X-Torp task|TMS with VR 1 experimental arm
62806595|NCT01842802|EXPERIMENTAL|Diode Laser Treatment Before Abdominoplasty|Patient will be treated with Diode Laser prior to abdominoplasty.
62030802|NCT02952924|EXPERIMENTAL|Part 3: POM in Treatment-Naive CHB Participants (Cohort C)|Participants will receive RO7049389 + NUC + Pegylated-Interferon (Peg-IFN) for 48 weeks. RO7049389 will be administered at a dose determined from Part 2. NUC and Peg-IFN therapy will be administered per local label or guidelines.
62229878|NCT04254302|NO_INTERVENTION|Control|Participants randomized into the control arm will receive usual care as per the service delivery models and pathways planned in their region. As a pragmatic trial, no attempt will be made to standardize practices which may vary across professionals. Usual practices may be categorised as either reference to online websites deemed appropriate by their healthcare professional, general recommendations, referral for services, or none of the above.
62806596|NCT01842802|EXPERIMENTAL|YAG Laser Treatment Before Abdominoplasty|Patients will be treated with YAG prior to abdominoplasty
62806597|NCT05439044||Patients who have received an anti-SARS-CoV-2 monoclonal antibody|Patients who have received an anti-SARS-CoV-2 monoclonal antibody, either prophylactically or curatively.
62806598|NCT02216708|EXPERIMENTAL|intravenous fluid for rehydration rapidly over 6 hours|intravenous fluid for rehydration rapidly over 6 hours
62806599|NCT02216708|EXPERIMENTAL|receive slow rehydration recommended by WHO (12 hours)|receive intravenous fluid followed by ORS (slow rehydration recommended by WHO) over 12 hours
62806600|NCT03255902|EXPERIMENTAL|Families attending parenting classes|Families attended 6 parenting sessions, filled out daily glucose screens, \& questionnaires
62229879|NCT04254302|EXPERIMENTAL|Experimental|WECARE intervention include: 1) 30-minute appointments with an occupational therapist or a physiotherapist, as part of a multidisciplinary team, to problem-solve the child's motor performance issues, provide recommendations to stimulate the child's motor development, and intervene online directly with the child, if needed; offered bimonthly during the first three months, then on a patient-identified needs-basis. 2) A chat function where participants can privately contact the therapist; flexible access as per participant needs. 3) A forum open to all intervention group participants where they can communicate with each other or with the therapist, who will also act as a forum moderator; flexible access as per participant needs. 4) Access to static online information via relevant websites and resources on child development; flexible access based on participant needs.
62229880|NCT00448409|EXPERIMENTAL|1|TroVax alone
62806601|NCT05308992|OTHER|Couples who use condom|The investigator will recruit heterosexual couples who have experience using silicone-lubricated latex condoms. All couples are required to have a backup birth control option and must be monogamous to participate in the study.
62229881|NCT00448409|EXPERIMENTAL|2|TroVax plus GM-CSF
62229882|NCT05786833|ACTIVE_COMPARATOR|Dexmedetomidine Group|
62229883|NCT05786833|ACTIVE_COMPARATOR|Ketofol Group|
62229884|NCT05786833|PLACEBO_COMPARATOR|Control Group|
62229885|NCT06267586|EXPERIMENTAL|PeptiSleep 250 mg/day|Low dose Given as 1 capsule 1 hour before bed
62229886|NCT06267586|EXPERIMENTAL|PeptiSleep 500 mg/day|Middle dose Given as 2 capsules 1 hour before bed
62229887|NCT06267586|EXPERIMENTAL|PeptiSleep 1000 mg/day|High dose Given as 4 capsules 1 hour before bed
62806602|NCT01836588|ACTIVE_COMPARATOR|gentle tissue extraction (curettage)|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
62806603|NCT01836588|ACTIVE_COMPARATOR|conventional cervix biopsy|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
62806604|NCT00675402||1|Patients referred to the vascularsurgeon with complaints of claudication for their first time, will be asked to participate with the study, with respect toward the in- and exclusion criteria.
62806605|NCT04696263|ACTIVE_COMPARATOR|Extraperitoneal SinglePort (SP) Robotic Radical Prostatectomy (Da Vinci ® SP system)|"All participants will undergo SOC robotic radical prostatectomy.~The procedure for this arm uses the Da Vinci ® SP system. Access point consists of one 3.5 cm single infraumbilical incision for the SP-RARP"
62806606|NCT04696263|ACTIVE_COMPARATOR|Extraperitoneal MultiPort (MP) Robotic Radical Prostatectomy (Da Vinci ® Xi system)|"All participants will undergo SOC robotic radical prostatectomy.~The procedure for this arm uses the Da Vinci ® Xi system, where four 8mm trocars will be used along with a 12 mm assistant trocar (a surgical instrument) to create six small incisions during the surgery"
62229888|NCT06267586|PLACEBO_COMPARATOR|Microcrystalline Cellulose 500mg/day|Placebo Given as 2 capsules 1 hour before bed
62229889|NCT03642951|ACTIVE_COMPARATOR|Active Treatment Group|"Each patient will receive daily 40 min treatment five days per week for two weeks. The procedure during each treatment session will consist of positioning the device centered at 15% of the nasion-inion distance anterior to the Cz electrode placement in standard EEGs, with the patient relaxing in a chair.~The stimulus parameters used will be 480 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 40 min. The investigator will measure the subject for accurate placement of the device prior to each visit. Once the placement of the device is confirmed, the study technician administering the treatment will tum on the device using an app downloaded to an electronic device connected by Bluetooth to the device."
62421965|NCT00630448||Group 2|Case Group. Individuals with known Von Willebrand Disease.
62229890|NCT03642951|SHAM_COMPARATOR|Sham Treatment Group|"Each patient will receive daily 40 min treatment five days per week for two weeks. The procedure during each treatment session will consist of positioning the device centered at 15% of the nasion-inion distance anterior to the Cz electrode placement in standard EEGs, with the patient relaxing in a chair.~The stimulus parameters used will be 480 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 40 min. The investigator will measure the subject for accurate placement of the device prior to each visit. Once the placement of the device is confirmed, the study technician administering the treatment will tum on the device using an app downloaded to an electronic device connected by Bluetooth to the device.~Note: While the device looks and is operated the same as the active device, subjects in this group will be stimulated with the placebo device so no active stimulation will be given."
62229891|NCT02159560|ACTIVE_COMPARATOR|End holed catheter|Single holed, end holed epidural catheter
62806607|NCT04080180|ACTIVE_COMPARATOR|Contingency Management (CM)|CM is a behavioral method that employs external rewards for target behavior. Participants will receive gift cards for adhering to treatment (attending physician visits and being adherent to buprenorphine-naloxone) for their first 4 clinic visits.
62030803|NCT05967572|EXPERIMENTAL|Experiment 1 (Rainstick)|The experimental group will start playing music 3 minutes before the start of the process. The examination begins with the insertion of the speculum into the eye. The duration of the examination depends on the visibility of the vascularity in the retina and the examination will end with the removal of the speculum from the eye. The rain bar will continue to play during the ROP inspection. The rain stick will be played 25cm away from the baby.
62229892|NCT02159560|ACTIVE_COMPARATOR|Three holed catheter|closed ended, three side holed epidural catheter
62229893|NCT01241097|EXPERIMENTAL|high-dose simvastatin, combined, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
62229894|NCT05050916|EXPERIMENTAL|1/High Dose Vitamin D|Deficient women will be assigned to the Endocrine Society recommendation for deficiency, 50,000 IU/week.
62229895|NCT05050916|PLACEBO_COMPARATOR|2/Placebo|Sufficient women who will receive placebo instead of Vitamin D supplementation.
62229896|NCT05455138|EXPERIMENTAL|Arterial bypass procedures using autologous venous graft|Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using autologous venous graft
62229897|NCT05455138|EXPERIMENTAL|Arterial bypass procedures using allogeneic venous graft|Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using allogeneic venous graft
62229898|NCT05455138|EXPERIMENTAL|Arterial bypass procedures using allogeneic arterial graft|Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using allogeneic arterial graft
62229899|NCT05455138|EXPERIMENTAL|Arterial bypass procedures using biologic bovine decellularized arterial graft|Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using biologic bovine decellularized arterial graft
62229900|NCT03082742|ACTIVE_COMPARATOR|Furosemide|Use of Furosemide, 40mg (1 tablet) per day, over 12 months
62421966|NCT03872440||EGFR T790M patients|EGFR T790M patients who have progressed on osimertinib or other third generation (mutant selective) EGFR TKI therapy
62806608|NCT04080180|ACTIVE_COMPARATOR|Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM)|Participants will receive the BSM intervention at 4 timepoints.
62806609|NCT04080180|ACTIVE_COMPARATOR|BSM+CM|BSM+CM is a combination of the two other arms. Participants may be randomized to this arm only in stage 2 of the SMART design.
62806610|NCT02229058|EXPERIMENTAL|Albumin Bound Paclitaxel plus S-1|Abraxane 120 mg/m2, D1,D8;S-1 40\~60mg QD D1-D14,every 3 weeks until disease progress or intolerable toxicity.
62806611|NCT01562080|EXPERIMENTAL|Dietary supplement|red yeast, astaxanthin, berberine, policosanol, coenzyme Q10, folic acid
62806612|NCT01562080|PLACEBO_COMPARATOR|microcrystalline cellulose|
62806613|NCT04428346|ACTIVE_COMPARATOR|Contigency Management (Intervention)|
62806614|NCT04428346|NO_INTERVENTION|Standard of Care (Control)|
62229901|NCT03082742|ACTIVE_COMPARATOR|Hydrochlorothiazide|Use of Hydrochlorothiazide, 25mg (1 tablet) per day, over 12 months
62229902|NCT05849948|EXPERIMENTAL|choronobiological nutrition group|newborns were fed according to chronobiological nutrition
62229903|NCT05849948|NO_INTERVENTION|control group|newborns will be fed in the order in which breastmilk is delivered to the hospital
62229904|NCT02808637|EXPERIMENTAL|Manual Pressure|
62229905|NCT02808637|EXPERIMENTAL|Rapid Injection without Aspiration|
62421967|NCT03872440||EGFR exon 19 del or L858R patients|EGFR exon 19 del or L858R patients who have progressed on first line osimertinib
62229906|NCT02808637|EXPERIMENTAL|Manual Pressure + Rapid Injection without Aspiration|
62229907|NCT02808637|EXPERIMENTAL|Control|
62421968|NCT03872440||Exon 20 insertion mutations patients|Patients with Exon 20 insertion mutations (n=10; regardless of drug therapy). Includes EGFR Exon 20 and up to two HER2 Exon20 patients
62421969|NCT02659826|EXPERIMENTAL|anodal tsDCS and gait training|Volunteers will be submitted to anodal transcutaneous spinal cord stimulation and gait training
62421970|NCT02659826|EXPERIMENTAL|cathodal tsDCS and gait training|Volunteers will be submitted to cathodal transcutaneous spinal cord stimulation and gait training
62806615|NCT03453905|EXPERIMENTAL|CTFEA|Decision on preventive surgery vs follow-up will be based on expert judgement, Mirels' score and CTFEA
62806616|NCT03453905|OTHER|Mirels|Decision on preventive surgery vs follow-up will be based on expert judgement and Mirels' score
62806617|NCT06133322|EXPERIMENTAL|Community health worker-led implementation strategy|CHW-led church-based multifaceted implementation strategy: CHWs will conduct individualized health coaching and healthcare navigation, organize church-based health promotion programs (e.g., nutrition education and exercise sessions), and train and assist the study participants in self-monitoring of BP. Nurse practitioners will see study participants at church settings, and community pharmacies will deliver antihypertensive medications to patients' homes.
62819507|NCT01243164|EXPERIMENTAL|Wheelchair Skills Training Program|A standardized wheelchair skills training program to teach 32 specific wheelchair skills.
62806618|NCT06133322|EXPERIMENTAL|Group-based Education Strategy|The investigator team will work with church leadership and wellness coordinators to organize group-based education sessions. Health education will be delivered by local primary care providers, dieticians, and health educators. Contact information for primary care providers and information on self-monitoring of BP will also be given at group sessions.
62229908|NCT01809223|EXPERIMENTAL|conbercept treatment group|Subjects will receive conbercept injections at a dose of 0.5 mg/eye, once a month for first 3 months. In the next 6 months, the investigator will decide whether repeat injections are needed base on the monthly assessment results.
62229909|NCT01809223|SHAM_COMPARATOR|sham injection group|Subjects will receive sham injections monthly for 3 months and will receive 0.5 mg/eye conbercept at month 4. The investigator will decide whether repeat injections are needed base on the monthly assessment results from month 5 to month 9.
62806619|NCT05361369|EXPERIMENTAL|EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule|Fixed dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule will be administered once as a single dose during a single-period.
62229910|NCT04779372|EXPERIMENTAL|Group of dCBT-I|participants will receive 6-week smartphone-based dCBT-I from a Wechat applet
62806620|NCT04782063|NO_INTERVENTION|No Intervention: Standard Infant Feed Group|Infants will receive human milk or formula milk ad libitum.
62806621|NCT04782063|OTHER|Calibrated Infant Feed Group|Infants will have reduced human milk or formula milk intake.
62806622|NCT02205996|ACTIVE_COMPARATOR|Controls|Weight-matched healthy controls. Euglycaemic Hypoglycaemic insulin clamp. Using hyperinsulinaemic clamps, blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
62806623|NCT02205996|ACTIVE_COMPARATOR|Type 2 diabetes|People with a known diagnosis of type 2 diabetes. Euglycaemic Hypoglycaemic Insulin clamp. Using hyperinsulinaemic clamps, blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
62806624|NCT06360146|EXPERIMENTAL|Group 1|The patients in early mobilization group underwent early mobilization and functional exercises program, while the patients served as the control group did not receive the therapy protocol applied in the early mobilization group
62806625|NCT06360146|ACTIVE_COMPARATOR|Group 2|The patients in early mobilization group underwent early mobilization and functional exercises program, while the patients served as the control group did not receive the therapy protocol applied in the early mobilization group
62806626|NCT02591810|ACTIVE_COMPARATOR|Serial Casting|Participants will receive the intervention of the placement of serial casting/splinting for the injured wrist. This is not a surgical intervention.
62806627|NCT02591810|ACTIVE_COMPARATOR|Kirschner wires|Participants will receive the intervention of percutaneous fixation with Kirschner wires for the injured wrist. This will be performed surgically.
62806628|NCT02591810|ACTIVE_COMPARATOR|Foveal repair|Participants will receive the intervention of open anatomic foveal repair of the ligaments of the injured wrist. This is a surgical intervention.
62806629|NCT01017185|EXPERIMENTAL|Oncolytic virotherapy, intratumoral injection of HF10|
62806630|NCT00881738|EXPERIMENTAL|1|Clarithromycin 250 mg Tablets (Geneva, USA)
62806631|NCT00881738|ACTIVE_COMPARATOR|2|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)
62806632|NCT02408133|NO_INTERVENTION|Control|The control group will be accompanied according to the service routine.
62030804|NCT05967572|EXPERIMENTAL|Experiment 2 (Music-The Happiest Baby)|"During the ROP examination, Dr. Harvery Karp's The Happiest Baby, which consists of only intrauterine sounds, is a group of babies who are listened to. The experimental group will start playing music 3 minutes before the start of the process. The examination begins with the insertion of the speculum into the eye. The duration of the examination depends on the visibility of the vascularity in the retina and the examination will end with the removal of the speculum from the eye. Music will continue to play during the ROP exam. The voice recorder that will play The Happiest Baby will be placed 25 cm away from the baby. In the study, the music volume will be set as 45-50 decibels."
62229911|NCT04779372|SHAM_COMPARATOR|Group of sleep education|Patients will receive sleep health education like the advices getting from common sleep clinic by the same applet as the group of CBT-I in smartphone
62229912|NCT01337115|ACTIVE_COMPARATOR|Continuous femoral nerve block (CFNB)|A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
62229913|NCT01337115|EXPERIMENTAL|Single shot SNB plus CFNB|A single shot sciatic nerve block (SNB) is performed before surgery with 25ml of 0.2% ropivacaine in addition to the continuous femoral nerve block (CFNB) performed in the control group before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in Post anesthesia care unit (PACU) and maintained for 48h
62421971|NCT02659826|SHAM_COMPARATOR|sham tsDCS and gait training|Volunteers will be submitted to sham transcutaneous spinal cord stimulation and gait training
62806633|NCT02408133|EXPERIMENTAL|Exercise|The group will be instructed to perform home exercises autonomously for range of motion and muscular fitness
62806634|NCT01436526|EXPERIMENTAL|Rivaroxaban (Xarelto, BAY59-7939) first 2*5 mg, then 1*10 mg|Single oral dose of rivaroxaban administered under fasting conditions 2\*5 mg tablet in first intervention period and 1\*10 mg tablet in second intervention period (after washout period)
62806635|NCT01436526|EXPERIMENTAL|Rivaroxaban (Xarelto, BAY59-7939) first 1*10 mg, then 2*5 mg|Single oral dose of rivaroxaban administered under fasting conditions 1\*10 mg tablet in first intervention period and 2\*5 mg tablet in second intervention period (after washout period)
62591742|NCT04440891|EXPERIMENTAL|TMS-Stimulation with MindMotion Go|TMS with VR 2 experimental arm
62229914|NCT02396043|EXPERIMENTAL|Modifed BFM-95|All patients received induction phase 1 and phase2, followed by the protocol M, reinduction phase 1 and phase2, and maintenance (mercaptopurine 50 mg/m2 daily and methotrexate \[MTX\] 20 mg/m2 weekly, both orally) for up to a total therapy duration of 24 months. Response to treatment was evaluated on day 33 and at the end of induction in Modifed BFM-95.Sufficient response was defined as at least 70% tumor regression, less than 5% BM blasts, and no CNS disease on day 33 and complete remission detected by PET / CT at the end of induction.For patients with insufficient response at day 33 or at the end of induction treatment was to be intensified according to the high-risk branch of trial ALL-BFM95, with local radiotherapy (30 Gy) and allogeneic blood stem-cell transplantation.
62229915|NCT00029172|EXPERIMENTAL|Nurse Case management|
62421972|NCT02659826|EXPERIMENTAL|High frequency rTMS and gait training|Volunteers will be submitted to high frequency transcranial magnetic stimulation and gait training
62421973|NCT02659826|EXPERIMENTAL|Low frequency rTMS and gait training|Volunteers will be submitted to low frequency transcranial magnetic stimulation and gait training
62806636|NCT04997499|EXPERIMENTAL|Teaching video|This is a single arm interventional study wherein the subjects enrolled will all participate in the study in the same way by watching the teaching video and then will be asked to self inject subcutaneous depot-medroxyprogesterone as per the protocol. All participants will then be asked to answer survey questions. All health care providers that participate in the study will likewise be asked to answer survey questions.
62806637|NCT04711785|ACTIVE_COMPARATOR|Intervention|Multicomponent exercise program twice a week (2 hours per week) during six months
62806638|NCT04711785|NO_INTERVENTION|Control Goup|Usual routine.
62806639|NCT06158334||Minor and major surgeries of patients with haemophilia A treated with Elocta®|Description of all surgical data (minor and major) on Elocta® (all dosage and treatment regimens)
62806640|NCT06158334||Minor and major surgeries of patients with haemophilia B treated with Alprolix®|Description of all surgical data (minor and major) on Alprolix® (all dosage and treatment regimens)
62806641|NCT04326920|ACTIVE_COMPARATOR|Active sargramostim treatment group|Inhaled sargramostim 125mcg twice daily for 5 days on top of standard of care. Upon progression to ARDS and initiation of mechanical ventilator support within the 5 day period, inhaled sargramostim will be replaced by intravenous sargramostim 125mcg/m2 body surface area once daily until the 5 day period is reached. From day 6 onwards, progressive patients in the active group will have the option to receive an additional 5 days of IV sargramostim, based on the treating physician's assessment
62806642|NCT04326920|PLACEBO_COMPARATOR|Control group|standard of care. Subjects progressing to ARDS and requiring invasive mechanical ventilatory support, from day 6 onwards, will have the option (clinician's decision) to initiate IV sargramostim 125mcg/m2 body surface area once daily for 5 days
62806643|NCT02944851||Prospective observational|The changes of IVC diameter, SpHb and vital signs of blood donors were observed after blood donation
62806644|NCT01808859|EXPERIMENTAL|Tourniquet|The Torniquet will be inflated to 100 mmHg over systolic pressure just before skin incision. The tourniquet will be deflated when the last stich/agraf is fixed
62806645|NCT01808859|NO_INTERVENTION|No tourniquet|"The patients operated on in the non-tourniquet group will have the same surgery and surgical technique but without tourniquet~hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks."
62806646|NCT03082248|OTHER|Physical Therapy Group|10-week supervised physiotherapeutic intervention; all patients will receive educational leaflets and folders for maintenance and adherence to the treatment program.
62806647|NCT03082248|OTHER|Spinal Surgery Group|Surgical procedures and techniques specific for the low back region, previously discussed and agreed upon among surgeons according to patients description.
62806648|NCT01903460|EXPERIMENTAL|LUM001|LUM001 administered orally once each day
62806649|NCT01903460|PLACEBO_COMPARATOR|Placebo|Placebo administered orally once each day
62806650|NCT03450863||Fast-acting insulin aspart|Participants will receive fast-acting insulin aspart at the treating physician's discretion as part of the usual clinical practice. The prescription and use of fast-acting insulin aspart is completely independent of this study. Total study duration for the individual patient will be approximately 24 weeks.
62806651|NCT01865266|EXPERIMENTAL|NUTIG|"The normal dose of ulinastatin for injection group(NUTIG):~Ulinastatin(Techpool inc,Guangdong,China) was administered to the group as a bolus of 100,000 U diluted in 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
62806652|NCT01865266|EXPERIMENTAL|HUTIG|"The high dose of ulinastatin for injection group(HUTIG):~Ulinastatin(Techpool inc,Guangdong,China) was administered to the group as a bolus of 200,000 U diluted in 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
62806653|NCT01865266|PLACEBO_COMPARATOR|CG|"The compare group(CG):~The group was given 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
62806654|NCT00983307|EXPERIMENTAL|Erlotinib and radiotherapy|Patients will be treated with Erlotinib and hypofractionated radiotherapy.
62806655|NCT02512549|ACTIVE_COMPARATOR|Rehabilitation|Patients with diagnosed Chronic Obstructive Pulmonary Disease with severe airflow obstruction (spirometric forced expiratory volume in one second (FEV1) below 50% of the normal) and modified medical research council (mMRC) dyspnea grading 1 to 3 will undergo pulmonary rehabilitation program thrice a week for 2 months.
62806656|NCT02512549|NO_INTERVENTION|Usual Care|Patients with COPD as described in rehabilitation arm, will be provided usual care from the hospital outpatient clinic.
62806657|NCT04350281|ACTIVE_COMPARATOR|Treatment group|Subcutaneous injection of interferon β-1b 1mL (0.25mg; 8 million IU) consecutively on day 1 to day 3 and hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days plus standard care
62806658|NCT04350281|ACTIVE_COMPARATOR|Control group|Hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days plus standard care alone.
62806659|NCT03122041|EXPERIMENTAL|SITA|Sitagliptin (SITA) Lifestyle intervention and sitagliptin 100mg per day for 12 weeks
62229916|NCT05694572||Pacemaker system|Patients implanted with ENO or ALIZEA family pacing systems
62229917|NCT05694572||ICD system|Patients implanted with ULYS family ICD systems
62229918|NCT05694572||CRT-D system|Patients implanted with GALI family CRT-D systems
62030805|NCT05967572|NO_INTERVENTION|Control|It is the group of infants who receive routine care during the ROP examination. In the control group, a routine ROP procedure will be performed without any music before, during and after the ROP examination.
62030806|NCT01227681|EXPERIMENTAL|high dose G-CSF|high dose group: 3.3ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
62229919|NCT02948374||Delirium positive|Patients with a positive CAM-ICU test
62030807|NCT01227681|ACTIVE_COMPARATOR|low dose G-CSF|low dose group: 1.65ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
62030808|NCT01227681|PLACEBO_COMPARATOR|placebo|Sodium Chloride (NaCl) 0.9 %
62030809|NCT06270901|EXPERIMENTAL|High Protein Planetary Health Diet|High Protein Planetary Health Diet Meal: This meal contains 62 g of protein primarily from plant origin (particularly legumes)
62030810|NCT06270901|EXPERIMENTAL|Low Protein Planetary Health Diet|Low Protein Planetary Health Diet Meal: This meal contains 36 g of protein from primarily plant origin (particularly legumes)
62030811|NCT06270901|EXPERIMENTAL|High Protein Western Diet|High Protein Western Diet Meal: This meal contains 62 g of protein primarily form animal origin
62030812|NCT06270901|EXPERIMENTAL|Low Protein Western Diet|Low Protein Western Diet Meal: This meal contains 36 g of protein primarily from animal origin
62030813|NCT00168025|EXPERIMENTAL|IgPro10|
62030814|NCT02907021|EXPERIMENTAL|Heart failure|Treat the HER-2 positive breast cancer patients experiencing mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
62030815|NCT03339986|EXPERIMENTAL|Reduction|Participants will be instructed to reduce all high energy dense snacks that they serve to thier children by 50%
62030816|NCT03339986|EXPERIMENTAL|Replacement|Participants will be instructed to replace all high energy dense snacks with fresh fruit and vegetables
62229920|NCT02948374||Delirium negative|Patient without delirium determined with the CAM-ICU test
62030817|NCT05308251|ACTIVE_COMPARATOR|high ligation|High ligation of the indirect hernia sac is traditional in inguinal hernia repairs. In this arm, patients with indirect inguinal hernia undergoing open mesh herniorrhaphy will have their hernia sac was opened and high ligated.
62030818|NCT05308251|EXPERIMENTAL|non-ligation|In this arm, the patients' hernia sac will be dissected high but not opened or ligated. The sac will be invaginated to the abdomen.
62030819|NCT00052468|EXPERIMENTAL|TCG|Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, Gemcitabine 800 mg/m2 day 1 + 8, q 21 days / 6 - 10 courses
62229921|NCT05344820|EXPERIMENTAL|Mandala Intervention|To the experimental group; Mandala practice will be done for 2 hours, once a week for 8 weeks.
62229922|NCT05344820|NO_INTERVENTION|Control|No intervention will be applied to the control group
62229923|NCT03902223|EXPERIMENTAL|Enhanced Screening Protocol For Cardiac Sarcoidosis|Arm will be randomly assigned to undergo enhanced screening methods (ambulatory ECG and echocardiogram) at month 0 and month 24, as well as a phone call/chart review at month 12.
62421974|NCT02659826|SHAM_COMPARATOR|sham rTMS and gait training|Volunteers will be submitted to sham transcranial magnetic stimulation and gait training
62421975|NCT03027973|EXPERIMENTAL|UPA Treatment Group|UPA 5mg capsule daily + Placebo 2 capsules 4 times a day
62421976|NCT03027973|ACTIVE_COMPARATOR|TEA Treatment Group|TEA 500mg 2 capsules 4 times a day + Placebo 1 capsule daily
62229924|NCT03902223|ACTIVE_COMPARATOR|Routine Screening for Suspected Cardiac Sarcoidosis|Arm will be randomly assigned for the routine standard of care/no intervention with enhanced screening methods. They will be offered the EKG and symptom check at months 0 and 24, as well as a phone call/chart review at month 12.
62421977|NCT04503031|ACTIVE_COMPARATOR|cylindrical tube group|The patient in cylindrical tube group (n=26) were intubated with cylindrical shaped endotracheal tube.
62030820|NCT00052468|ACTIVE_COMPARATOR|TC|Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, q 21 days / 6 - 10 courses
62030821|NCT03408717||Persistent post surgical pain (PPSP)|Questionnaires, Mechanical Temporal Summation assessment and pain threshold assessment will be assigned to patient. Within this cohort, some patients will have high pain score recorded (persistent pain) during the follow-up evaluations at 4 and 6 months.
62030822|NCT04003649|EXPERIMENTAL|Arm I (nivolumab, ipilimumab, IL13Ralpha2 CAR T cells)|Patients receive nivolumab intravenously (IV) over 60 minutes and ipilimumab IV over 90 minutes on day -14. Patients then receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/intracranital ICT) every week and nivolumab IV over 30 minutes every other week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.
62243161|NCT03312699|EXPERIMENTAL|Group A IIV4|Group A: Up to 30 healthy volunteers 18-40 years old, will be given seasonal quadrivalent inactivated influenza vaccine (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
62421978|NCT04503031|EXPERIMENTAL|tapergaurd tube group|The patient in taperguard tube group (n=26) was intubated with TaperGuard endotracheal tube.
62421979|NCT04068155|EXPERIMENTAL|DaRT Seeds Intratumoral Diffusing alpha-emitters|An intratumoral insertion of securely fixed seeds loaded with Radium-224. The seeds release by recoil short-lived alpha-emitting atoms into the tumor.
62421980|NCT05214599|EXPERIMENTAL|Group 1|Low dose
62421981|NCT05214599|EXPERIMENTAL|Group 2|Middle dose
62421982|NCT05214599|EXPERIMENTAL|Group 3|High dose
62591743|NCT04440891|SHAM_COMPARATOR|TMS-Sham with X-Torp task|TMS sham control with VR 1
62229925|NCT03498482|EXPERIMENTAL|FORNET|During FORNET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress and committed violence. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for the client's emotions, cognitions, physiological reactions, and sensory informations during traumatic and aggressive events to link them to an autobiographical context, namely time and place. In total the individuals receive 8 sessions of FORNET, every session lasting between 1.5 and 2 hours depending on the needs of the participant.
62229926|NCT04364009|ACTIVE_COMPARATOR|Optimized Standard of Care (oSOC)|The control group will receive optimized standard of care alone, including all treatments authorized for COVID-19 by the French Health Ministry and/or the center COVID-19 therapeutic committees at inclusion and during the follow-up.
62229927|NCT04364009|EXPERIMENTAL|Anakinra plus Optimized Standard of Care (oSOC)|The experimental group will receive Anakinra plus optimized Standard of Care. The patients will receive Intravenous injection (IV) of Anakinra 400mg/day (100mg IV every 6 hours) at Day 1, 2 and 3. From Day 4 to Day 10, the patient will receive IV injection of Anakinra 200mg/day (100mg every 12 hours). The total duration of Anakinra is 10 Days
62229928|NCT01553305|EXPERIMENTAL|Supervised exercise programme|Six-weeks supervised high-intensity exercise programme with training sessions twice a week followed by 6-weeks unsupervised exercise programme.
62806660|NCT03122041|EXPERIMENTAL|CON|Controls (CON) Lifestyle intervention
62229929|NCT01553305|NO_INTERVENTION|Unsupervised exercise programme|
62806661|NCT06236100|EXPERIMENTAL|Strengthening Families Program + Family Advocate|Families in the treatment group will be connected to clinically trained, trauma-informed FAs that will assess and refer families to community services. The intervention will provide wraparound supports to prevent ACEs and substance use and, critically, enable providers and community-based partners to align their services in a way that addresses the social determinants of health and other community-level factors that impact substance use and the relationship between social connection and ACEs. The FA component of the intervention will run concurrent to the Strengthening Families Program 7-17 sessions, with the FAs interacting weekly with families over the 10- to 14-week intervention period. On a weekly basis, FAs will conduct 1-hour, post-session check-ins with each family. This 1-hour period will consist of a 20-minute phone call with families to discuss their needs, with the remaining 40 minutes used to debrief, make service referrals, and complete documentation.
62229930|NCT02577731|OTHER|Severe Trauma|Bone marrow collection. Blood collection. Clinical data collection.
62229931|NCT02577731|OTHER|Elective Hip Repair|Bone marrow collection. Blood collection. Clinical data collection.
62229932|NCT02577731|OTHER|Healthy Young Bone Marrow Control|Deidentified freshly isolated bone marrow samples from healthy young control subjects will be purchased for a tissue bank.
62229933|NCT02822638||STEMI PATIENT Cohort|STEMI PATIENT Cohort
62229934|NCT02794168|EXPERIMENTAL|VAS203 (Ronopterin)|Intravenous infusion of 17 mg/kg VAS203 over 48 hours, daily dose 8.5 mg/kg
62806662|NCT06236100|ACTIVE_COMPARATOR|Strengthening Families Program-Only|Families in the control group will participate in the Strengthening Families Program 7-17 (SFP7-17) Group Class Curriculum for families with children ages 7-17. Parents and children participate in SFP7-17, both separately and together, as the curriculum has lessons for parents, teens, and children plus a joint Family Practice class. SFP7-17 meetings are 2 hours in length and are typically held in person (but families can participate remotely, during extenuating circumstances) with participating families completing 11 sessions over a 10- to 14-week period.
62806663|NCT03805802|EXPERIMENTAL|active product|Once daily ad libitum consumption of one package of the fiber product 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).
62806664|NCT03805802|PLACEBO_COMPARATOR|reference product|Once daily ad libitum consumption of one package of placebo during 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).
62806665|NCT02198365||Group 2|Group 1: normal pap smear Group 2: cervical neoplasia
62229935|NCT02794168|PLACEBO_COMPARATOR|Saline|Intravenous infusion of physiological saline over 48 hours
62229936|NCT02017951||Urban-Rural Classification 1: Large Urban Areas|Settlements of over 125,000 people.
62421983|NCT05103488|EXPERIMENTAL|Intervention|"Comprehensive palliative care (CPC) is multidisciplinary inpatient care that aims to respond to patients' suffering in many aspects: physical, psychological, social, and spiritual. It is basically a standard palliative care service in Vietnam with additional psychosocial and spiritual support with a multidisciplinary approach. CPC is provided by seven doctors, 20 nurses, two social workers, a pharmacist, and a psychologist. CPC could go parallel with oncology care or be the primary care for patients.~The psychosocial and spiritual supports are mainly provided by social workers. Psychologist and religious will get involved when patient need advance care. The psychosocial intervention is individualized for each patient based on their individual situation, issues, and decision."
62591744|NCT04440891|SHAM_COMPARATOR|TMS-Sham with MindMotion Go|TMS sham control with sham VR 2
62591745|NCT03992703||Standard strategy|This group has been treated with antibiotic susceptibility testing on a conventional Mueller-Hinton medium with reading after 24 hours of incubation (Period 1: from July 1, 2015 to December 31, 2016)
62806666|NCT02221869|EXPERIMENTAL|Xyrem|Active Xyrem at a dose ≤9 g/night
62806667|NCT02221869|PLACEBO_COMPARATOR|Xyrem Placebo|Xyrem placebo at a volume and regimen equivalent to the stable dose of Xyrem.
62229937|NCT02017951||Urban-Rural Classification 2: Other Urban Areas|Settlements of 10,000 to 125,000 people.
62229938|NCT02017951||Urban-Rural Classification 3: Accessible Small Towns|Settlements of between 3,000 and 10,000 people and within 30 minutes drive of a settlement of 10,000 or more.
62229939|NCT02017951||Urban-Rural Classification 4: Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more.
62229940|NCT02017951||Urban-Rural Classification 5: Very Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more.
62229941|NCT02017951||Urban-Rural Classification 6: Accessible Rural|Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 or more.
62806668|NCT06447558|NO_INTERVENTION|Breast milk droplets group|We fed the infants via OGT in the oral administration of breast milk droplets group after applying a total of 0.5 cc of breast milk in drops into their mouths for 5 minutes by using an insulin injector.Breast milk droplets group was 30 infants
62421984|NCT05103488|OTHER|Control|Patients who are randomized to the control group will receive the standard palliative care in Vietnam. They can assess to the same palliative care for their physical symptoms as patients in the intervention group do. They can also access psychosocial and spiritual support from the resources that available for them before entering to the study. If they request for social or financial support, their care team can reach out to the social work departments. Patients who are in need can receive mental health care from psychiatrists from the psychiatrist unit at UMC.
62421985|NCT02035683|OTHER|Advanced NSCLC patients undergoing first-line chemotherapy|single cohort
62806669|NCT06447558|OTHER|Palatal stimulation group|In the palatal stimulation group, following the necessary hygiene rules, we used the little finger of one of our hands with a glove on and stimulated the palate and gums of the infants with this finger by slow and peristalsis-like movements for 5 minutes while the infants were fed via OGT. Palatal stimulation group was 30 infants.
62806670|NCT06447558|NO_INTERVENTION|Control group|We fed the premature infants in the control group via OGT following all hygiene rules, but we performed no intervention. In the intervention groups, where we orally applied breast milk in droplets in one group and stimulated the palate of the newborns by using a finger in the other, we performed these interventions every 3 hours for 5 minutes for 7 days at feeding times.
62806671|NCT05212558|PLACEBO_COMPARATOR|Placebo group|This group received a conventional respiratory retraining program plus unloaded (placebo) respiratory muscle training
62806672|NCT05212558|ACTIVE_COMPARATOR|Inspiratory muscle training group|This group received a conventional respiratory retraining program plus inspiratory muscle training only
62806673|NCT05212558|EXPERIMENTAL|Combined training group|This group received a conventional respiratory retraining program plus inspiratory and expiratory muscle training in the same respiratory cycle.
62806674|NCT00447720|EXPERIMENTAL|PATH counseling|These participants received the PATH intervention
62806675|NCT00447720|ACTIVE_COMPARATOR|Treatment as Usual|These individuals receive treatment as they normally would receive in the community
62806676|NCT04945187|NO_INTERVENTION|Standard care|No intervention. This arm will continue standard clinical practice consisting of clinical assessment regarding side effects and management before each cycle of chemotherapy conducted by physicians.
62806677|NCT04945187|EXPERIMENTAL|Intervention group|Intervention: This arm will be assigned to the intervention which will be nurse-led consultations based on electronic patient-reported outcomes. The patients will report ePRO weekly during chemotherapy and the answers will be used proactively in the nurse-led consultations. Nurses will conduct the clinical assessment regarding side effects and management before each cycle of chemotherapy.
62806678|NCT04122326|EXPERIMENTAL|Posture Sequence|Participants will complete computer work on a provided monitor and keyboard for two hours. During the first hour, the research personnel will alter the workstation every ten minutes to test various different postures of the neck, shoulder, arms, and trunk. The sequence will include 3 seated postures and 3 standing postures. At the end of the first hour, the participant will be instructed to adjust the workstation independently and continue to work for 60 minutes for an observational session.
62806679|NCT03902691|EXPERIMENTAL|Pegol-Sihematide|Participants received Pegolsihematide by intravenous injection once every 4 weeks.
62806680|NCT03902691|ACTIVE_COMPARATOR|ESPO (Recombinant Human Erythropoietin Injection）|ESPO administration 1 to 3 times per week.
62806681|NCT04081922|EXPERIMENTAL|Regional analgesia using erector spinae plane block|After pectus excavatum is done, intravenous patient controlled analgesia device with fentanyl is connected. Then, regional analgesia is performed for additional analgesia; ultrasound guided erector spinae plane block is performed using 0.25% ropivacaine (total 1 ml/kg) bilaterally. Plasma concentration of ropivacaine at baseline, and 5, 10, 20, 30, 60, 120 minutes after ropivacaine injection will be measured.
62421986|NCT05362409|EXPERIMENTAL|5-ALA with CV01|5-aminolevulinic acid \[5-ALA\] with CV01-delivered ultrasound
62421987|NCT06016413|EXPERIMENTAL|intervention group|All patients received nab-paclitaxel 260 mg/m2, carboplatin AUC=5 and adelbelimumab 1200 mg intravenously on day 1 of each 3-week cycle for 3 cycles. All patients were given conventional drugs to prevent vomiting in each cycle, and intravenous dexamethasone was given to prevent allergy before each dose
62421988|NCT06701019|OTHER|Data collection|Semi-structured interview or focus group discussion.
62421989|NCT04514809|EXPERIMENTAL|Experimental|It consists of 15 mothers who meet the inclusion criteria
62421990|NCT04514809|EXPERIMENTAL|Control Groups|It consists of 15 mothers who meet the inclusion criteria
62421991|NCT01838291||Patients on Ferriprox therapy <1 month|
62421992|NCT00123305|EXPERIMENTAL|1|
62421993|NCT00123305|EXPERIMENTAL|2|
62421994|NCT00123305|EXPERIMENTAL|3|
62421995|NCT00123305|PLACEBO_COMPARATOR|4|
62421996|NCT02832739|EXPERIMENTAL|SENACA - self-management support system|Use of enhanced SENACA - ICT based self-management support system prototype by study participants at home for 75-100 days
62421997|NCT06338800|EXPERIMENTAL|One session VR Exposure|All participants will receive one session exposure therapy with virtual reality during ongoing treatment.
62421998|NCT06185556|ACTIVE_COMPARATOR|A: Irreversible electroporation|Irreversible electroporation (IRE) is a primarily non-thermal, local ablative technique that utilizes electrical pulses to destroy tumor tissue. Theoretically, IRE only affects viable tumor tissue, leaving surrounding vital structures relatively intact. It is therefore considered to cause less morbidity than thermal ablative strategies.
62591746|NCT03992703||Rapid strategy|This group has been treated with antibiotic susceptibility testing on a rapid Mueller-Hinton medium after 8 hours of incubation (period 2: January 1, 2017 to June 30, 2018)
62806682|NCT04081922|NO_INTERVENTION|Control|After pectus excavatum is done, intravenous patient controlled analgesia device with fentanyl is connected. No regional block is performed.
62806683|NCT03381521|EXPERIMENTAL|Group A|Ultrasound-guided nerve hydrodissection with 10cc normal saline
62229942|NCT02017951||Urban-Rural Classification 7: Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 10,000 or more.
62229943|NCT02017951||Urban-Rural Classification 8: Very Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 60 minutes to a settlement of 10,000 or more.
62229944|NCT02017951||Travel Time - see below|Travel time will be analysed as both a continuous and discrete variable.
62229945|NCT03413657|OTHER|Fluid responders|Patient's identified to have a significant increase in their cardiac output following a fluid bolus.
62591747|NCT04351373|EXPERIMENTAL|Fluorescein sodium (FS) and YELLOW 560 nm microscope filter (YE560) during surgery|Subjects undergoing clinically planned vestibular schwannoma, Meningioma, Head and Neck Paraganglioma, or Head and Neck Schwannoma, removal surgery will have contrast agent fluorescein sodium administered intravenously after tumor exposure, and a special filter called YELLOW560 will be used on the operating microscope to see the fluorescent coloring of the contrast.
62591748|NCT00856869|EXPERIMENTAL|1 YM|Healthy young males
62421999|NCT06185556|ACTIVE_COMPARATOR|B: Stereotactic body radiotherapy|Stereotactic body radiotherapy (SBRT) is a form of external beam radiation that has important advantages over conventional radiotherapy such as a more precise and greater biological dose delivery and hence less toxicity and presumably better outcome.
62422000|NCT06081283|EXPERIMENTAL|Seizure network Positive subjects|"Participants in this group include all SzNET-Positive subjects, whether EEG-Positive or EEG-Negative. Within six days of their initial rs-fMRI study, they will receive both loading and maintenance doses of two intervention drug regimens from the study's list. For participants with a GCS of 9 to 12, the research team will choose one of the two selected ASMs, and will omit its loading dose. Maintenance doses should be administered every 12 hours, starting 12 hours after the loading dose, with a maximum of 19 doses allowed.~A second rs-fMRI and EEG will occur after participants have received at least five maintenance doses. Following these assessments, the use of the intervention drugs as part of the research intervention will cease. However, if medically necessary, these drugs can continue as part of regular therapy. Note that repeat EEG and rs-fMRI assessments Must occur no longer than 72 hours after the last dose of the intervention drug regimen."
62806684|NCT03381521|ACTIVE_COMPARATOR|Group B|Ultrasound-guided nerve hydrodissection with 5cc normal saline
62806685|NCT00373581|EXPERIMENTAL|Vigabatrin, cocaine|
62229946|NCT03413657|OTHER|Fluid non-responders|Patient's identified to NOT have a significant increase in their cardiac output following a fluid bolus.
62229947|NCT01018121|EXPERIMENTAL|Clinic and Home Behavioral Intervention|
62229948|NCT01018121|ACTIVE_COMPARATOR|Pediatrician Counseling|
62229949|NCT02621671|EXPERIMENTAL|Arm 1: Cognitive Interviews|"* Participants will complete several survey items, view 1 of 8 disease risk pictures (selected at random), and then complete further survey questions.~* Participants will then be recorded giving their opinions on the remaining 7 disease risk pictures which depict the hypothetical risk of disease.~* The entire visit will take no more than 90 minutes with no follow-up.~* The first 10-20 participants will be randomized to this arm."
62243162|NCT03312699|EXPERIMENTAL|Group B High Dose IIV3|Group B: Up to 15 healthy volunteers 65 plus years old, will be given seasonal high dose trivalent inactivated influenza vaccine (Fluzone High Dose) Fluzone® high dose vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
62422001|NCT06081283|NO_INTERVENTION|Seizure network Negative subjects|Participants in this group encompass all SzNET-Negative subjects, including those who are EEG-Positive and EEG-Negative. These participants will not receive interventions after the initial study indicated rs-fMRI. They will neither receive repeat rs-fMRI or repeat EEG.
62422002|NCT02296788|NO_INTERVENTION|No Exercise Control|Healthy Living Control Group
62591749|NCT00856869|EXPERIMENTAL|2 EM|Healthy elderly males
62591750|NCT00856869|EXPERIMENTAL|3 YF|Healthy young females
62591751|NCT00856869|EXPERIMENTAL|4 EF|Healthy elderly females
62422003|NCT02296788|EXPERIMENTAL|Aerobic Exercise Group|8 kcal/kg of body weight/week (KKW) (\~900 kcal/wk)
62591752|NCT00856869|EXPERIMENTAL|5 NASH|Patients with presumed NASH
62591753|NCT00856869|EXPERIMENTAL|6 CTP-A|Patients with hepatic cirrhosis CTP-class A
62591754|NCT00856869|EXPERIMENTAL|7 CTP-BC|Patients with hepatic cirrhosis CTP-class B and C
62591755|NCT03743324||BR group|Breast reconstruction without radiation therapy
62591756|NCT03743324||Immediate BR +post-op radiation|Immediate breast reconstruction followed by surgical site radiation therapy
62591757|NCT03743324||Radiation +delayed BR|previous post-mastectomy radiation followed by delayed breast reconstruction
62806686|NCT00373581|PLACEBO_COMPARATOR|placebo, cocaine|
62806687|NCT05774535||Experimental|Patients who will undergo thyroidectomy
62806688|NCT06237959|EXPERIMENTAL|Keranat™|Keranat™ capsule will be administered orally twice daily for 24 weeks.
62806689|NCT06237959|PLACEBO_COMPARATOR|Placebo|Placebo capsule will be administered orally twice daily for 24 weeks.
62806690|NCT03845127|EXPERIMENTAL|Revivent TC Ventricular Enhancement System plus GDMT|Patients will receive treatment with the Revivent TC Ventricular Enhancement System while being maintained on Guideline Directed Medical Therapy for treatment of Heart Failure.
62806691|NCT03845127|ACTIVE_COMPARATOR|GDMT Only|Patients will be maintained on Guideline Directed Medical Therapy for treatment of Heart Failure.
62806692|NCT04563377|EXPERIMENTAL|ChAdOx1.HTI and MVA.HTI vaccination|"1x dose of ChAdOx1.HTI at 5 x 10\^10 vp~1x dose of MVA.HTI at 2 x 10\^8 pfu"
62229950|NCT02621671|EXPERIMENTAL|Arm 2: Experimental survey|"* Participants will be randomly assigned by GfK's computer to one of the 12 experimental conditions.~* After completing questions about information seeking and physical activity, the participants will read a short scenario that describes the purpose of a risk assessment tool and ask them to imagine that they had just entered their information into such a tool.~* Participants will see whichever risk ladder corresponds to the experimental condition to which they were assigned.~* The hypothetical display will be consistent with a display generated for an individual whose risk profile includes risk increasing and decreasing factors, but does not engage in the recommended amount of physical activity."
62806693|NCT05204446|EXPERIMENTAL|GROW Project|"(GROW Group): Live interactive telehealth-based group meetings will be held for 60 minutes per week over six weeks using Zoom for Telehealth, a HIPAA-compliant platform provided by the PI's institution. A teen group (n=8 per cohort) and a parent group (n=8 per cohort) will be run concurrently but separately, with coordinating topics. Each group meeting will introduce and facilitate discussion of information and CBT-oriented topics for coping and management of CD. Participants will be encouraged to use their audio and video to engage with the interventionist and each other. Between sessions, resources sent through text-based SMS messages using Twilio HIPAA-compliant software 3x/week as reminders of skills and goals for the week."
62806694|NCT05204446|NO_INTERVENTION|Care-As-Usual|Participants assigned to the control group (n=32 dyads) will receive care as usual, which consists of appointments in the Celiac Disease Clinic (at diagnosis, 3 months post-diagnosis, 6 months post-diagnosis, and annually after diagnosis thereafter). These appointments consist of a gastrointestinal physician or nurse practitioner, dietitian, GFD educator, and psychologist for 40-minute consultations each.
62806695|NCT05204446|EXPERIMENTAL|GROW+ Project|"(GROW+ Group): Will include the GROW Project with enhanced behavioral strategies and materials identified from phase 2 data (e.g., group discussion about GIP testing, text-based check-ins, etc.) In addition, teens in GROW+ will be encouraged to complete a minimum of 2 GlutenDetect tests per week (12 total) and report results in REDCap (Research Electronic Data Capture, a secure, web-based survey application) throughout the intervention."
62806696|NCT01373463|EXPERIMENTAL|Arm A|"1. Patients will be given the drugs pemetrexed and carboplatin~2. Radiation~3. Participants evaluated for response~4. Lobectomy surgery"
62806697|NCT01373463|EXPERIMENTAL|Arm B|"1. Patients will be given the drugs pemetrexed and cisplatin~2. Radiation~3. Participants evaluated for response~4. Lobectomy surgery"
62806698|NCT00922623|EXPERIMENTAL|Belotero®|
62806699|NCT00565734||Posterior surgical approaches|Posterior surgical approaches for symptomatic cervical spondylotic myelopathy (CSM)
62806700|NCT00565734||Anterior surgical approaches|Anterior surgical approaches for symptomatic cervical spondylotic myelopathy (CSM).
62806701|NCT00804700|ACTIVE_COMPARATOR|Control Group|Subjects will be given a 60 minute lecture on the benefits of regular exercise and how music can enhance the exercise experience. Subjects will be individually instructed how to use the Precor elliptical trainer at the Yates fitness center while listening to music. Subjects are instructed to exercise using the elliptical trainer for periods of 45 -55 minutes at a time as frequently as they like with a minimum frequency of once per week. Subjects will also be encouraged to exercise regularly by walking, jogging or engaging in other forms of physical activity during the intervention period. A fitness attendant will be on hand to supervise their exercise activity, but will not give specific advice how to exercise, other than to make sure they are exercising safely.
62806702|NCT00804700|EXPERIMENTAL|Intervention Arm|Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
62806703|NCT00823251|EXPERIMENTAL|IlluminOss device|IlluminOss bone-pin device
62806704|NCT06477159|EXPERIMENTAL|Pancrelipase|Pancrelipase (CREON) capsules taken orally with food, at a dose 36,000 units with snacks and 72,000 units with meals, for a total of 6 months (180 days)
62806705|NCT02304510||females|females aged between 18 and 50 years old living in Beijing
62422004|NCT02296788|EXPERIMENTAL|Aerobic Exercise Group 2|20 KKW (\~2250 kcal/wk)
62422005|NCT00538707|EXPERIMENTAL|Young subjects|
62422006|NCT00538707|EXPERIMENTAL|Older subjects|
62422007|NCT05924568|EXPERIMENTAL|Median Sternotomy|
62422008|NCT01916759|OTHER|HIV uninfected adults|25 HIV uninfected adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
62422009|NCT01916759|OTHER|HIV infected adults on HAART|25 HIV infected adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
62806706|NCT05797012|OTHER|Individuals with migraine|To assess headache severity, head posture, cervical muscle endurance and neck disorders.
62422010|NCT01916759|OTHER|HIV-infected long-term non-progressors|10 HIV-infected long-term non-progressor adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
62422011|NCT04108884|EXPERIMENTAL|App Group|In the app group, if an episode of arrhythmia is detected with the app, the local investigator will contact the respective patient to schedule an appointment for a 14 day Holter ECG.
62806707|NCT06249685|NO_INTERVENTION|Baseline-Unaided|No hearing aids.
62806708|NCT06249685|EXPERIMENTAL|Aided|Fitted with bilateral hearing devices.
62806709|NCT06249685|NO_INTERVENTION|Follow-up-Unaided|No hearing aids.
62422012|NCT04108884|OTHER|Standard Care Group|The control group will perform the same measurements as the intervention group, with the only difference that a cumulated Portable Document Format (PDF) report is provided after 6 months instead of the immediate feedback in the app group.
62422013|NCT06173986|EXPERIMENTAL|IC+ICRT group|2 cycles of PD-1 inhibitor + nab-paclitaxel + cisplatin followed by concurrent PD-1 inhibitor + radiotherapy (45-50Gy/25fx) + nab-paclitaxel + cisplatin
62591758|NCT04034251|EXPERIMENTAL|Paclitaxel Intraperitoneal 20mg & Intravenous 80mg Every 3Weeks & Capecitabine 825mg/m^2 Twice Daily|Intraperitoneal (IP) and intravenous (IV) paclitaxel administration with concomitant oral capecitabine
62591759|NCT04034251|EXPERIMENTAL|Paclitaxel Intraperitoneal 60mg & Intravenous 80mg Every 3Weeks &Capecitabine 825mg/m^2 Twice Daily|Intraperitoneal (IP) and intravenous (IV) paclitaxel administration with concomitant oral capecitabine
62591760|NCT04034251|EXPERIMENTAL|Paclitaxel Intraperitoneal & Intravenous Every 3 Weeks & Capecitabine Twice Daily|Intraperitoneal (IP) and intravenous (IV) paclitaxel administration with concomitant oral capecitabine
62806710|NCT05089799||Patients|"Older adults 60 years old or older They are referred to the day care hospital for memory problems or frailty and may present with various cognitive, behavioural, mental and physical disorders.~Persons in this group are diverse in socio-cultural levels. The investigators expect to include 100 patients (N = 100). Each patient will test 1 out of the 5 use cases, so 20 patients will test the same use case (n = 20)."
62806711|NCT05089799||Informal carers or family caregivers|"This group includes persons who accompany patients during the hospital visit, such as family members (spouses or children) and friends.~They provide support to the patient with various frequency and intensity (occasional / regular / continuous).~Persons in this group are diverse in age and socio-cultural levels. They may also suffer from physical and/or psychological disorders.~The investigators expect to include 100 informal or family caregivers (N = 100). Each one will test 1 out of the 5 use cases, so 20 informal or family caregivers will test the same use case (n= 20)."
62806712|NCT05089799||Professionals|"All categories of professionals working in the day care hospital. Persons in this group belong to different professional categories (administrative, health, technical). They have different levels of proximity with the public and have various positions in the hospital.~The investigators expect to include 50 professionals."
62030823|NCT04003649|EXPERIMENTAL|Arm II (nivolumab, IL13Ra2 CAR T cells)|Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/ICT) every week and nivolumab IV over 30 minutes every other week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.
62229951|NCT02293031|EXPERIMENTAL|"Gene-activated matrix Nucleostim"|"Implantation of gene-activated matrix Nucleostim into the bone defects or sites of bone atrophy"
62806713|NCT01089686|ACTIVE_COMPARATOR|Venoplasty (treatment)|Patients will be randomized to treatment or non-treatment arm with a 2:1 ratio. Patients who meet the inclusion/exclusion criteria and who are randomized to the treatment arm of the study will receive venoplasty at the time of the diagnostic venogram.
62806714|NCT01089686|SHAM_COMPARATOR|Sham procedure (non-treatment)|Patients will be randomized to treatment or non-treatment with a 2:1 ratio. Patients who meet the inclusion/exclusion criteria and who are randomized to the non-treatment arm of the study will receive the diagnostic venogram only.
62229952|NCT05939466|EXPERIMENTAL|FM patients treated with Bedrocan®|Medical cannabis was administered by herbal tea or decoction as described by the Ministry of Health through the Ministerial Decree of 9 November 2015.
62591761|NCT01562301|EXPERIMENTAL|Anvirzel + Carboplatin + Docetaxel|Anvirzel administered sublingually. A total of five dose cohorts evaluated (6, 12, 24, 36, 48 mg/m2/day; SL divided into 3 doses given every 8 hrs) with 3 patients per cohort. Patients receive the assigned dose (2, 4, 8, 12, or 16 mg/m2) of Anvirzel three times a day throughout each cycle for a total of 4 cycles of chemotherapy. Cycles occur every 21 days. Patients start with an AUC of 6 for Carboplatin and 75mg/m2 for docetaxel, and on subsequent cycles, modifications at the discretion of the treating team. Questionnaire completion regarding physical and mental at baseline, 7 days before chemotherapy, day 1 of chemotherapy, day 1 of cycles 2, 3, and 4, and at end of dosing visit.
62591762|NCT00589134|EXPERIMENTAL|1|type of beverage
62591763|NCT06647654||Cases (Test Negative Design and Cohort Design)|Infants who meet the respiratory case definition and test positive for RSV (result obtained from standard of care (SOC) testing).
62591764|NCT06647654||Controls (Test Negative Design)|Infants who meet the respiratory case definition and test negative for RSV (result obtained from standard of care (SOC) testing).
62591765|NCT06647654||Ecologic Cohort (Ecologic Before-and-After Design)|Aggregated data on study outcomes from five historical RSV seasons and from 2024-2026 RSV seasons (data during the COVID-19 pandemic are excluded).
62591766|NCT02014233|EXPERIMENTAL|Omega-3|Participants will consume 5 mL of omega-3 (2333 mg essential fatty acids) with 1000 IU vitamin D3 for 21 days.
62591767|NCT02014233|PLACEBO_COMPARATOR|Olive oil|Participants will consume 5 mL of olive oil with 1000 IU vitamin D3 for 21 days.
62591768|NCT06618560|ACTIVE_COMPARATOR|Test Group 1: EMD group|After submarginal instrumentation (i.e., titanium curettes plus oscillating chitosan brush), implant surfaces will be conditioned for 2 min with 24% ethylene-diaminetetraacetate EDTA (PrefGel®, Institut Straumann AG). Then, the sites will be completely rinsed with saline solution and thoroughly dried with air. Repeated irrigation and air-drying will be done in the area until complete bleeding control with sterile gauzes. Then EMD (Emdogain®, Institut Straumann AG) will be gently applied with a blunt-tipped sterile syringe until overflowing from the mucosal margin.
62229953|NCT02044211|ACTIVE_COMPARATOR|Collaborative Care for Heart Failure + Depression|"Collaborative care program for heart failure and depression involving a nurse care manager providing counseling and treatment advice via telephone~Interventions:~Behavioral:~Counseling for heart failure self-care Counseling for depression~Drug:~Pharmacotherapy for heart failure Pharmacotherapy for depression"
62229954|NCT02044211|ACTIVE_COMPARATOR|Collaborative Care for Heart Failure Only|"Collaborative care program for heart failure and depression involving a nurse care manager providing counseling and treatment advice via telephone~Interventions:~Behavioral:~Counseling for heart failure self-care Usual care for depression~Drug:~Pharmacotherapy for heart failure~Usual Care for depression"
62229955|NCT02044211|NO_INTERVENTION|Usual Care for Heart Failure and Depression|Control group will receive their doctors' usual care for heart failure and depression
62229956|NCT02044211|NO_INTERVENTION|Non-Depressed Comparison Cohort|Control group will receive their doctors' usual care for heart failure
62030824|NCT04003649|EXPERIMENTAL|Arm III (IL13Ra2 CAR T cells)|Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/ICT) every week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly at the discretion of the principal investigator and oncologist.
62591769|NCT06618560|ACTIVE_COMPARATOR|Test Group 2: HA group|After submarginal instrumentation of the implant surface (i.e., titanium curettes plus oscillating chitosan brush), the cross-linked hyaluronic acid gel composed of a mixture of cross-linked (1.6%) and natural (0.2%) will be will be implemented to the peri-implant pockets.
62806715|NCT04688658|EXPERIMENTAL|Duvelisib plus Nivolumab|"Phase 1: Duvelisib will be taken orally in doses from 15mg once a day, 25mg once a day or 25mg twice a day, 12 hours a part, to determine the recommended dose for the Phase II study when combined with nivolumab.~Nivolumab, 240mg, IV, every 2 weeks for the first four cycles; thereafter it may be switched to 480mg, IV, once every 4 weeks if deemed appropriate by the study doctor.~Phase II: The Recommended Phase II dosage of duvelisib administered will not be determined until Phase I is completed.~Nivolumab, 480mg, IV, every 4 weeks, for up to 1 year."
62806716|NCT01911611|PLACEBO_COMPARATOR|Placebo|
62806717|NCT01911611|EXPERIMENTAL|RO6870868|
62806718|NCT03116516|OTHER|ARM1|"In ARM1, 30 subjects will be assigned and the subjects will be administered telmisartan/amlodipine and rosuvastatin at Day1 and YHP1604 at Day22."
62806719|NCT03116516|OTHER|ARM2|"In ARM2, 30 subjects will be assigned and the subjects will be administered YHP1604 at Day1 and telmisartan/amlodipine and rosuvastatin at Day22."
62806720|NCT01210716|EXPERIMENTAL|AMICUS Therapeutic plasma exchange, TPE|Patients are randomized to either TPE on AMICUS or Spectra.
62806721|NCT01210716|ACTIVE_COMPARATOR|Spectra Therapeutic plasma exchange, TPE|Patients are randomized to either TPE on AMICUS or Spectra.
62806722|NCT04486235|EXPERIMENTAL|Intervention|Receive experiential pamphlet
62806723|NCT04486235|NO_INTERVENTION|Control|No materials, usual care
62806724|NCT05515731|EXPERIMENTAL|Autologous platelet-rich plasma eye drops|Autologous platelet-rich plasma eye drops are derived from treatment of patients plasma using special process.
62806725|NCT05416216|NO_INTERVENTION|Control|In the stepped wedge design, ECE centers start the trial at the same point in time and act as controls with no intervention until they are randomized to crossover from control to intervention conditions.
62806726|NCT05416216|EXPERIMENTAL|WELL intervention|'WELL intervention' is when implementation of the one-year, three-strategy WELL intervention begins (see description).
62806727|NCT05640440||children who stutter|assessment executive function and stuttering severity in 30 child with stuttering
62806728|NCT05640440||children who don't stutter|assessment executive function in 30 child with stuttering
62806729|NCT01622621|ACTIVE_COMPARATOR|Randomized Sublobar Resection|Randomized by computer to receive a sublobar resection.
62806730|NCT01622621|ACTIVE_COMPARATOR|Randomized SBRT|Randomized by computer to receive Stereotactic Body Radiotherapy (SBRT).
62806731|NCT01622621|ACTIVE_COMPARATOR|Observation Sublobar Resection|Patient decides with doctor to undergo a sublobar resection.
62806732|NCT01622621|ACTIVE_COMPARATOR|Observation SBRT|Patient decides with doctor to undergo SBRT.
62229957|NCT03126708|EXPERIMENTAL|chemotherapy (cisplatin plus paclitaxel) and cetuximab|
62806733|NCT02764463|OTHER|FRCFPDs|Fiber reenforced Composite Fixed Partial Dentures
62806734|NCT02075112|EXPERIMENTAL|Soy isoflavone|Study treatment: Soy isoflavone in combination with radiation therapy \& cisplatin
62806735|NCT02498301|EXPERIMENTAL|Rifaximin 550 mg once/day|rifaximin, 550 mg, once daily, by mouth
62806736|NCT02498301|EXPERIMENTAL|Rifaximin 550 mg twice/day|rifaximin, 550 mg, twice daily, by mouth
62806737|NCT02498301|PLACEBO_COMPARATOR|Placebo|Placebo pills, twice daily, by mouth
62806738|NCT06055179|EXPERIMENTAL|XCHT group|Patients will be administered with XCHT (9 g, qd, po) for 5 days each cycle of irinotecan chemotherapy for 3 cycles. The XCHT administration begins 3 days before chemotherapy in each cycle, that is the chemotherapy begins on the 4th day of XCHT administration. Plasma will be collected for pharmacokinetic testing (using raloxifene 60mg po as probe), on the day before chemotherapy, that is on the 3rd day of XCHT administration in each cycle.
62806739|NCT06055179|PLACEBO_COMPARATOR|Placebo group|Patients will be administered with placebo (9 g, qd, po) for 5 days each cycle of irinotecan chemotherapy for 3 cycles. The placebo administration begins 3 days before chemotherapy in each cycle, that is the chemotherapy begins on the 4th day of placebo administration. Plasma will be collected for pharmacokinetic testing (using raloxifene 60mg po as probe), on the day before chemotherapy, that is on the 3rd day of placebo administration in each cycle.
62806740|NCT01485094|PLACEBO_COMPARATOR|Matching placebo|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
62806741|NCT01485094|EXPERIMENTAL|GRT6010|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
62806742|NCT01485094|ACTIVE_COMPARATOR|Pregabalin|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
62806743|NCT00532662|EXPERIMENTAL|1|epidural s(+)-ketamine for supplementation of caudal anesthesia
62806744|NCT00532662|ACTIVE_COMPARATOR|2|intravenous ketamine for supplementation of caudal anesthesia
62806745|NCT04427319|EXPERIMENTAL|Experimental group|Product: β-Alanine Supplementation strategy: 5 g, four times a day with main meals, for 7 days after the initial evaluation and until the end of the study.
62806746|NCT04427319|PLACEBO_COMPARATOR|Placebo group|Product: wheat semolina Supplementation strategy: 5 g, four times a day with main meals, for 7 days after the initial evaluation and until the end of the study.
62806747|NCT04024891|EXPERIMENTAL|Phentolamine Mesylate Ophthalmic Solution 1%|1 drop in each eye, 1 hour post medically-induced mydriasis
62806748|NCT04024891|PLACEBO_COMPARATOR|Phentolamine Mesylate Ophthalmic Solution Vehicle|1 drop in each eye, 1 hour post medically-induced mydriasis
62030825|NCT03926091|EXPERIMENTAL|4 cycles of TC adjuvant chemotherapy|4 cycles of TC (Docetaxel 75 mg/m\^2 ivgtt d1+Cyclophosphamide 600 mg/m\^2 iv d1, 21 days per cycle).
62030826|NCT03926091|ACTIVE_COMPARATOR|6 cycles of TC adjuvant chemotherapy|6 cycles of TC (Docetaxel 75 mg/m\^2 ivgtt d1+Cyclophosphamide 600 mg/m\^2 iv d1, 21 days per cycle).
62229958|NCT03126708|ACTIVE_COMPARATOR|chemotherapy (cisplatin plus paclitaxel)|
62229959|NCT02253108|EXPERIMENTAL|SYNERGY drug eluting stent|Everolimus eluting bioresorbable polymer stent
62591770|NCT06618560|PLACEBO_COMPARATOR|Control group|Implants allocated to the control group will be treated with the same sub-marginal instrumentation (i.e., titanium curettes plus oscillating chitosan brush). Implant surface will be irrigated with with sterile saline.
62591771|NCT05870956||High nintedanib adherence|Community-dwelling Idiopathic Pulmonary Fibrosis (IPF) patients with 66 years of age or older at the time of the first nintedanib prescription (between 01-Oct-2014 and 31-Oct-2018), and continuous Medicare hospital (Part A), physician (Part B) and pharmacy (Part D) coverage (between 01-Oct-2013 to 31-12-2020). Patients in high adherence group presented a mean adherence estimate of 0.96 (proportion of days covered - PDC) in a period of 12 months after nintedanib first initiation.
62806749|NCT06159452|EXPERIMENTAL|Group A|SAR153191 - P3 drug product concentration 1 dose 1
62806750|NCT06159452|EXPERIMENTAL|Group B|SAR153191 - P2 drug product concentration 2 dose 2
62806751|NCT06159452|EXPERIMENTAL|Group C|SAR153191 - P3 drug product concentration 2 dose 2
62806752|NCT06159452|EXPERIMENTAL|Group D|SAR153191 - P3 drug product concentration 3 dose 3
62806753|NCT06159452|EXPERIMENTAL|Group B'|SAR153191 - P2 drug product concentration 2 dose 3
62806754|NCT06159452|EXPERIMENTAL|Group C'|SAR153191 - P3 drug product concentration 2 dose 3
62806755|NCT06159452|ACTIVE_COMPARATOR|Group E'|SAR153191 - CIF3 drug product concentration 2 dose 3
62806756|NCT02737007|EXPERIMENTAL|[14C]-GSK3191607 IV Microdose|Subjects will receive a single microdose of 100 micrograms (mcg) of \[14C\]-GSK3191607 by intravenous infusion over 15 minutes on Day 1 of the study.
62806757|NCT00079040|EXPERIMENTAL|Treatment (cisplatin, etoposide, bevacizumab)|"Chemotherapy: Patients receive cisplatin IV over 30-60 minutes on day 1 and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~Bevacizumab therapy: Beginning concurrently with chemotherapy, patients receive bevacizumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 17 courses (1 year) in the absence of disease progression or unacceptable toxicity."
62806758|NCT03799796|EXPERIMENTAL|Flash Glucose Monitoring with Online Peer Support|Pre-Test-Post-Test
62806759|NCT01682408|ACTIVE_COMPARATOR|Part A1|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), fed 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
62806760|NCT01682408|ACTIVE_COMPARATOR|Part A2|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference) 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed 150 mg ranitidine
62806761|NCT01682408|ACTIVE_COMPARATOR|Part B1|1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
62806762|NCT01682408|ACTIVE_COMPARATOR|Part B2|1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)
62806763|NCT01682408|ACTIVE_COMPARATOR|Part B3|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
62806764|NCT04443634|EXPERIMENTAL|Adductor 20|Ultrasound guided adductor canal block will be performed with injection of 20 ml bupivacaine
62806765|NCT04443634|EXPERIMENTAL|Adductor 30|Ultrasound guided adductor canal block will be performed with injection of 30ml bupivacaine
62806766|NCT04443634|EXPERIMENTAL|Adductor /Saphenous|Ultrasound guided adductor canal block will be performed by injection of 20 ml bupivacaine , combined with ultrasound guided saphenous nerve block at the distal third of the thigh in the intermuscular plane between Vastus Medialis and Sartorius muscle with injection of 10ml bupivacaine 0.5%.
62229960|NCT02253108|EXPERIMENTAL|Biomatrix NeoFlex drug eluting stent|Biolimus eluting bioresorbable polymer stent
62229961|NCT05635539|EXPERIMENTAL|patients with COVID|27 patients with COVID in comorbidity with NCDs as T2D, hypertension, and NASH
62229962|NCT05635539|EXPERIMENTAL|patients with Influenza|35 patients with Influenza in comorbidity with NCDs as T2D, hypertension, and NASH
62591772|NCT05870956||Moderate nintedanib adherence|Community-dwelling Idiopathic Pulmonary Fibrosis (IPF) patients with 66 years of age or older at the time of the first nintedanib prescription (between 01-Oct-2014 and 31-Oct-2018), and continuous Medicare hospital (Part A), physician (Part B) and pharmacy (Part D) coverage (between 01-Oct-2013 to 31-12-2020). Patients in moderate adherence group presented a mean adherence estimate of 0.71 (proportion of days covered - PDC) in a period of 12 months after nintedanib first initiation.
62806767|NCT01364584|EXPERIMENTAL|Exenatide|Pre-dosed inject-able pen (an automatic device which injects under the skin) 10 mcg twice a day of exenatide for 2.5 months
62806768|NCT01364584|PLACEBO_COMPARATOR|Placebo|Pre-dosed inject-able pen (an automatic device which injects under the skin) 10 mcg twice a day of placebo for 2.5 months
62806769|NCT03016312|EXPERIMENTAL|Atezolizumab + Enzalutamide|Participants will receive atezolizumab along with enzalutamide until investigator-assessed confirmed radiographic disease progression per PCWG3 criteria or unacceptable toxicity (up to approximately 42 months).
62806770|NCT03016312|ACTIVE_COMPARATOR|Enzalutamide|Participants will receive enzalutamide alone until investigator-assessed confirmed radiographic disease progression per PCWG3 criteria or unacceptable toxicity (up to approximately 42 months).
62806771|NCT06125834|EXPERIMENTAL|T-DM1 treatment group|Trastuzumab Emtansine (T-DM1), 3.6mg/kg, d1/21, IVD, until progressive diseases or intolerable adverse effects occurs
62806772|NCT01072188|ACTIVE_COMPARATOR|ProClude Prophylaxis paste-A|Arginine Bicarbonate prophylaxis paste
62806773|NCT01072188|PLACEBO_COMPARATOR|Nupro-M Prophylaxis paste -B|Control prophylaxis paste (Fluoride free - placebo)
62806774|NCT02812836|OTHER|Manometry|All patients will be investigated by anorectal manometry and after the procedure with balloon expulsion test as previously described.
62806775|NCT06349694|EXPERIMENTAL|BT plus T-MPNS|T-MPNS sessions will be performed twice a week for 6 weeks. Each session will be lasted 30 minutes. The intervention will be included a 12-session BT plus T-MPNS treatment program
62806776|NCT06349694|EXPERIMENTAL|BT plus TTNS|TTNS sessions will be performed twice a week for 6 weeks. Each session will be lasted 30 minutes. The intervention will be included a 12-session BT plus TTNS treatment program
62806777|NCT06349694|ACTIVE_COMPARATOR|BT (Control group)|Information about BT will be explained to patients for 30 min. Then written form about BT will be given to be implemented as a home program.
62806778|NCT02201524|EXPERIMENTAL|Cohort 1|200mg of PF-04965842 twice daily
62806779|NCT02201524|EXPERIMENTAL|Cohort 2|400mg of PF-04965842 once daily
62806780|NCT02201524|EXPERIMENTAL|Cohort 3|200mg of PF-04965842 once daily
62806781|NCT02201524|PLACEBO_COMPARATOR|Cohort 4|Placebo comparator daily
62030827|NCT04066114|EXPERIMENTAL|lulizumab pegol + novel ISR|lulizumab pegol + novel ISR: lulizumab pegol plus immunosuppressive regimen (anti-thymocyte globulin (rabbit), steroids,) belatacept, tocilizumab, and everolimus)
62030828|NCT00728819|ACTIVE_COMPARATOR|1|Tapered PICC
62030829|NCT00728819|ACTIVE_COMPARATOR|2|Non-tapered PICC
62030830|NCT03013114|EXPERIMENTAL|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
62030831|NCT04732962|EXPERIMENTAL|AposHealth|"Following the initial consultation and calibration of the Apos device in the clinic, the patients will receive from his therapist a home-based treatment plan. This usually includes wearing the device for about 20 minutes with about 20% of weight-bearing (patient is instructed to wear the Apos and just be with the device and go about his/her daily routine). A gradual increase in usage time is prescribed reaching up to 60 min wear time with about 40% weight-bearing.~Patients are requested to return to follow-up (FU) appointments after 1, 3, 6, 9 and 12 months. In addition, patients will have a remote FU after 1-week to confirm they use AposHealth as advised. During the follow-up appointment, re-assessment of clinical outcomes and gait patterns are performed and the calibration of the Apos device is adjusted as needed. The treatment plan is adjusted, and patients are encouraged to continue to wear the device regularly at home."
62806782|NCT02528708|PLACEBO_COMPARATOR|Placebo|At the same time of randomization code generation, blood samples for a baseline ROTEM® analysis will be drawn, and blood products will be ordered. Patients will be eligible to receive study drug (fibrinogen concentrate or 0.9% saline solution), according to the randomization code previously generated, only if FIBTEM® - A10 value is \<18 mm (corresponding to a MCF value of \<20 mm, that is a plasma fibrinogen level \<3 g/L).
62806783|NCT02528708|EXPERIMENTAL|Fibrinogen concentrate|At the same time of randomization code generation, blood samples for a baseline ROTEM® analysis will be drawn, and blood products will be ordered. Patients will be eligible to receive study drug (fibrinogen concentrate or 0.9% saline solution), according to the randomization code previously generated, only if FIBTEM® - A10 value is \<18 mm (corresponding to a MCF value of \<20 mm, that is a plasma fibrinogen level \<3 g/L).
62806784|NCT03538418|EXPERIMENTAL|WAT group|The WAT group will receive a 3-month WAT-based exercise training programme, which includes 12 weekly exercise training sessions (an hour each) in addition to 2 face-to-face sessions followed by weekly to monthly telephone sessions offering support on dealing with technical issues and BCTs (7 session in total). The WAT group will be left to use the WAT on their own for 3 months during the follow-up period.
62030832|NCT04732962|ACTIVE_COMPARATOR|Total Knee Replacement (TKR)|"Patients will undergo TKR according to Geisinger's policy, guidelines and care protocol.~The study baseline visit will occur 6 weeks postoperative for TKR groups."
62030833|NCT04732962|EXPERIMENTAL|Post TKR traditional physical therapy (PT) and AposHealth|"Patients who have had a knee replacement and were assigned to the traditional PT+ AposHealth group will follow Geisinger post-operative rehab protocol and will also receive AposHealth and follow the rehabilitation protocol.~AposHealth will start six weeks post-op and will continue for 12 months. Patients will receive AposHealth similar to the non-invasive group, i.e., will have an initial evaluation (IE) and calibration of the Apos device, have a remote FU after one week from IE and in-clinic FUs at 1, 3 6, 9 and 12 months."
62030834|NCT05685615|EXPERIMENTAL|BV100 (200 mg) plus Polymyxin B|BV100 (200 mg q12h) infused over 2 hours plus Polymyxin B (12 500-15 000 IU/kg) infused over 1h
62229963|NCT01506141|EXPERIMENTAL|Idursulfase-IT|Idursulfase-IT will be administered once monthly and weekly IV infusions of Elaprase at the dose used in study HGT-HIT-045 via intrathecal drug delivery device (IDDD).
62422014|NCT05135143|ACTIVE_COMPARATOR|Infertility male patients|Infertile male patients will receive the antioxidant formula for more than 172 days. Divided in two groups. One will take the active substance, to the other group placebo treatment will be given.
62229964|NCT02038543|EXPERIMENTAL|Primary hyperoxaluria patients|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the Clinical Research and Trials Unit (CRTU). The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
62422015|NCT05135143|PLACEBO_COMPARATOR|Control group|Placebo treatment and control and comparative variables will be measured.
62806785|NCT03538418|NO_INTERVENTION|Control group|The control group will receive a 3-month exercise training programme without a WAT, which also includes 12 weekly exercise training sessions (an hour each) in addition to 7 face-to-face and telephone sessions offering support for BCTs.
62806786|NCT05646498|ACTIVE_COMPARATOR|implant retained removable overdentures|"Procedure: Long implant and partial overdentures insertion of long implants anterior to the maxillary sinus to retain partial overdentures~Device: Partial overdentures Distal extension metallic partial dentures retained by attachments to the implants"
62806787|NCT05646498|ACTIVE_COMPARATOR|implant supported fixed screw retained prosthesis|"Procedure: Sinus lift and long implant performing sinus lift surgical procedure with simultaneous placement of limplants to support screw-retained prosthesis~Device: Metal ceramic prosthesis on long implants porcelain fused to metal fixed screw-retained prosthesis supported by implants"
62806788|NCT04243694|EXPERIMENTAL|Intervention group|mindfulness intervention administered
62229965|NCT02934425|PLACEBO_COMPARATOR|Refined carbohydrate-rich breakfast|Refined carbohydrate-rich breakfast
62229966|NCT02934425|EXPERIMENTAL|High pork protein breakfast|High pork protein breakfast
62735425|NCT04092803|EXPERIMENTAL|VR for LP|"The patients in this study will be presented the opportunity to use VR instead of undergo GA for a LP. Patients who agree to undergo an LP with VR will be assessed by a certified child life specialist (CCLS) to determine whether the patient is an appropriate candidate for using VR.The system includes a VR headset with VR software already loaded in to it. The VR software to be used is either a game called Pebbles the Penguin or SpacePups (Weightless Studios)."
62030835|NCT05685615|EXPERIMENTAL|BV100 (300 mg) plus Polymyxin B|BV100 (300 mg q12h) infused over 2 hours plus Polymyxin B (12 500-15 000 IU/kg) infused over 1h
62030836|NCT05685615|ACTIVE_COMPARATOR|Best Available Therapy|Best Available Antibiotic Therapy to Treat CRAB
62030837|NCT05685615|EXPERIMENTAL|Part B: BV100 plus BAT|BV100 (300 mg q12h) infused over 2 hours plus Best Avaialble Therapy to Treat Colistin resistant CRAB
62591773|NCT05870956||High-then-poor nintedanib adherence|Community-dwelling Idiopathic Pulmonary Fibrosis (IPF) patients with 66 years of age or older at the time of the first nintedanib prescription (between 01-Oct-2014 and 31-Oct-2018), and continuous Medicare hospital (Part A), physician (Part B) and pharmacy (Part D) coverage (between 01-Oct-2013 to 31-12-2020). Patients in high-then-poor adherence group presented a mean adherence estimate of 0.74 (proportion of days covered - PDC) in a period of 12 months after nintedanib first initiation, with a high adherence in the first 7 months followed by a sharp decline.
62591774|NCT05870956||Delayed-poor nintedanib adherence|Community-dwelling Idiopathic Pulmonary Fibrosis (IPF) patients with 66 years of age or older at the time of the first nintedanib prescription (between 01-Oct-2014 and 31-Oct-2018), and continuous Medicare hospital (Part A), physician (Part B) and pharmacy (Part D) coverage (between 01-Oct-2013 to 31-12-2020). Patients in delayed poor adherence group presented a mean adherence estimate of 0.36 (proportion of days covered - PDC) in a period of 12 months after nintedanib first initiation, with a high adherence in the first 2 months followed by a constant decline.
62806789|NCT04243694|NO_INTERVENTION|Control group|no intervention administered
62229967|NCT02783521|EXPERIMENTAL|Intervention|Includes changing eating behaviors, increasing physical activity, and attending regular in-person weight loss meetings for 12 weeks. To support additional weight loss/weight maintenance, participants will receive bi-weekly phone calls across a 12 week follow-up.
62806790|NCT00752700|NO_INTERVENTION|1|Control group
62806791|NCT00752700|ACTIVE_COMPARATOR|2|Conventional resistance training program (CRT)
62806792|NCT00752700|EXPERIMENTAL|3|Whole body vibration resistance training (WBV) on the FITVIBE-platform
62806793|NCT02182323|EXPERIMENTAL|BI 201335 in single rising doses|
62229968|NCT02783521|OTHER|Wait List Control|Wait-list control participants will not receive any intervention for the first 12 weeks. After 12 weeks, participants will receive the weight loss intervention plus mHealth technology support.
62229969|NCT02498496|EXPERIMENTAL|Magnesium Sulfate|Administration of a bolus dose of 2 g of MgSO4 in 100 mL of Normal Saline IV, in 20 min.
62422016|NCT05377359|EXPERIMENTAL|Participants with Hearing Loss|Individuals with hearing loss that meet the candidacy to wear hearing aids with various coupling methods. All interventions are associated with the fitting of binaural hearing aids with various coupling methods. All participants will be assessed under all interventions.
62422017|NCT01266473|EXPERIMENTAL|Physiotherapy techniques|Cough Technique vs Forced Expiration Technique
62591775|NCT05870956||Early-poor nintedanib adherence|Community-dwelling Idiopathic Pulmonary Fibrosis (IPF) patients with 66 years of age or older at the time of the first nintedanib prescription (between 01-Oct-2014 and 31-Oct-2018), and continuous Medicare hospital (Part A), physician (Part B) and pharmacy (Part D) coverage (between 01-Oct-2013 to 31-12-2020). Patients in early-poor adherence group presented a mean adherence estimate of 0.13 (proportion of days covered - PDC) in a period of 12 months after nintedanib first initiation, with a high adherence in the first month followed by a sharp decline.
62591776|NCT02818829||Cohort|Collection of biological samples
62591777|NCT02047656|PLACEBO_COMPARATOR|Placebo to LFF269 (Part 1)|Placebo to LFF269 twice daily (b.i.d) for 10 days in healthy volunteers
62591778|NCT02047656|EXPERIMENTAL|LFF269 (Part 1)|LFF269 twice daily (b.i.d) for 10 days in healthy volunteers
62591779|NCT02047656|EXPERIMENTAL|LFF269 (Part 2)|LFF269 twice daily (b.i.d) for 5 days in patients with hypertension
62806794|NCT02182323|PLACEBO_COMPARATOR|Placebo|
62806795|NCT02182323|EXPERIMENTAL|BI 201335 NA fasted or fed|"two randomized sequences:~1. BI 201335 NA or placebo fasted~2. BI 201335 NA or placebo after high-fat breakfast"
62806796|NCT02179008|EXPERIMENTAL|DE-117 Low Dose ophthalmic solution|One drop Low Dose DE-117 in each eye QD for 90 days
62806797|NCT02179008|EXPERIMENTAL|DE-117 Low/Middle Dose ophthalmic solution|One drop DE-117 Low/Middle Dose ophthalmic solution in each eye QD for 90 days
62806798|NCT02179008|EXPERIMENTAL|DE-117 Middle Dose ophthalmic solution|One drop Middle Dose DE-117 in each eye QD for 90 days
62806799|NCT02179008|EXPERIMENTAL|DE-117 Middle/High Dose ophthalmic solution|One drop Middle/High Dose DE-117 in each eye QD for 90 days
62806800|NCT02179008|EXPERIMENTAL|DE-117 High Dose ophthalmic solution|One drop High Dose DE-117 in each eye QD for 90 days
62806801|NCT02179008|ACTIVE_COMPARATOR|latanoprost ophthalmic solution 0.005%|One drop latanaprost in each eye QD for 90 days
62806802|NCT00629226|EXPERIMENTAL|Group I|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8, 11, 22, 25, 29, 32, 43, 46, 50, and 53. Beginning on day 8 or 9, patients undergo standard intensity-modulated radiotherapy (IMRT) once daily, 5 days a week, for up to 8 weeks.
62806803|NCT00629226|EXPERIMENTAL|Group II|Patients receive cetuximab, bortezomib (beginning at one dose level below the MTD determined in group I), and IMRT as in group I. Patients also receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, and 57.
62806804|NCT02997501|EXPERIMENTAL|AZD9291|Single arm of AZD9291, starting dose of 80mg
62030838|NCT02615223|EXPERIMENTAL|Arm1|"Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.~Patients receive cryoablation therapy."
62030839|NCT02615223|EXPERIMENTAL|Arm2|Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
62030840|NCT06634966|EXPERIMENTAL|Segmentectomy|Segmentectomy is performed for solid-dominant invasive lung cancer with size of 2-3cm.
62422018|NCT05220046|EXPERIMENTAL|Psilocybin Treatment Arm|Participant with pancreatobilliary cancer will receive 25mg of psilocybin in one 8-hour monitored session with supportive counseling before and after session.
62422019|NCT05220046|NO_INTERVENTION|Family Observation Group|The study participant will select a family member who will provide parallel data regarding distress related to pancreatobiliary cancer.
62422020|NCT04183218||Observational (cardiac monitoring)|Patients receive cardiac monitor implants then undergo standard of care RT or CRT at the discretion of the treating physician. Patients also undergo blood sample collection at baseline, 4 weeks, 3, 9, and 12 months.
62806805|NCT00896714|EXPERIMENTAL|Closed loop anesthesia|
62806806|NCT04139655|EXPERIMENTAL|Colchicine Group|Administration of oral colchicine at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
62806807|NCT04139655|PLACEBO_COMPARATOR|Placebo Group|Participants allocated to the control group will receive a placebo pill at the same dosing regimen as with treatment group. Perioperative and surgical care will not be different from standard clinical practice.
62229970|NCT02498496|PLACEBO_COMPARATOR|Placebo|Administration of a bolus dose of 100 mL of Normal Saline, in 20 min.
62229971|NCT05139433|EXPERIMENTAL|Intervention Group|Participants in this arm will receive 5 internet-delivered cognitive-behavioral intervention and will have access to 15 educational videos
62806808|NCT03572179|ACTIVE_COMPARATOR|Treatment Group|After finishing orthodontic treatment, all patient will receive a modified indirect technique for bonding fixed mandibular retainer and the key of modification is the fabrication of 3D printed digital positioning tray for placement of retainer with holes for composite pads for its direct application using 3 shape Ortho analyser Software ® instead of conventional indirect retainer fabrication method
62806809|NCT03572179|NO_INTERVENTION|Control Group|All patients of this group will follow conventional steps of direct bonding procedure of fixed mandibular retainer
62030841|NCT06669546|EXPERIMENTAL|PLAS first, sham second|In this study arm, participants will undergo a 4-week intervention period with real phase-locked auditory stimulation (PLAS) administered on nights from Monday to Friday. Following this initial intervention period, participants will have a 2-week washout phase. Finally, participants will enter the second intervention period, during which sham (soundless) PLAS will be administered.
62229972|NCT05139433|ACTIVE_COMPARATOR|Active Control Group|Participants in this arm will have access to 15 educational videos.
62229973|NCT00208923|ACTIVE_COMPARATOR|1|Chemotherapy-only conditioning regimen comprising busulfan (Bu), cyclophosphamide (Cy) and fludarabine (FLUDARA) followed by an allogeneic stem cell transplant.
62229974|NCT03341351|ACTIVE_COMPARATOR|Instructional video|The modified beef tongue video group will be given an instructional video created using the modified beef tongue model to show anatomy and proper repair of the laceration.
62229975|NCT03341351|ACTIVE_COMPARATOR|Instructional workshop|The group randomized to the modified beef tongue instructional workshop will undergo an interactive workshop using the modified beef tongue model to show anatomy and proper repair of the laceration.
62229976|NCT02261051||Non-concurrent control group|"A group of advanced cancer patients who received care at our Center before implementation of the LCCM model. They will receive current standard of care.~This current study is to collect data on the control group only. After system redesign, we will open an intervention arm study to collect data after implementation of the new care model (about 18-24 months from start of control phase)."
62229977|NCT04035174|EXPERIMENTAL|LTS-2 DEC patch|This is a transdermal device with diethylcarbamazine (DEC) applied directly on the skin. The reading will be done 24 hours after.
62422021|NCT06147609|ACTIVE_COMPARATOR|children with lower lingual holding arch space maintainer|non functional fixed space maintainer used in the mandibular arch to maintain arch length by prevention of mesial movement of permanent first molar
62591780|NCT06487221|EXPERIMENTAL|Avutometinib & Defactinib|"Avutometinib: Study participants will receive Avutometinib 3.2mg orally two times per week for three weeks in a row followed by one week of rest~Defactinib: Study participants will receive Defactinib 200mg twice daily for three weeks in a row followed by one week of rest"
62735426|NCT04136548|EXPERIMENTAL|Fentanyl|Fentanyl will be administered intravenously during one visit.
62806810|NCT06451302|EXPERIMENTAL|Arm Description: Participants receive the straified treatment according to assigned risk group|Patients with Ewing sarcoma are risk stratified according to definition. Patients with low risk receive 8 cycles of chemotherapy comprising low-dose cyclosphomide, adriamycin，vincristine(CAV) alternated with ifosfamide and etoposide(IE). Patients with moderate risk receive a total of 12 cycles of moderate-dose CAV and IE. Patients with high risk receive a total of 17 cycles of high-dose CAV and IE. Thereafter, maitenance therapy is administered to high-risk patients after chemotherapy.
62806811|NCT05024435|EXPERIMENTAL|Nasogastric Tube|
62229978|NCT04035174|ACTIVE_COMPARATOR|Skin snip|A skin snip will be performed using a 2 mm Holth corneoscleral's punch. Once done, the microfilariae of Onchocerca volvulus will be counted with a microscope.
62229979|NCT03343457|EXPERIMENTAL|Acceptance Commitment Therapy|Acceptance Commitment Therapy. Cognitive therapy
62229980|NCT03343457|EXPERIMENTAL|Multidisciplinary assessment|Assessment of a team. Cognitive therapy
62735427|NCT04136548|PLACEBO_COMPARATOR|Placebo|Placebo (saline) will be administered intravenously during one visit.
62806812|NCT05024435|EXPERIMENTAL|Lisacath|
62806813|NCT00786617||Nurse-driven|Mechanically ventilated patients weaned by nurse-driven ventilator weaning protocol
62806814|NCT00786617||Physician-initated|Mechanically ventilated patients weaned by physician-initiated, non-protocol methods
62806815|NCT03063463||Pneumatic Dilation|Subject with achalasia undergoing routine care EGD (Esophagogastroduodenoscopy) with pneumatic dilation
62806816|NCT03063463||Surgical Myotomy|Subject with achalasia undergoing routine care EGD with surgical myotomy
62806817|NCT00215111|EXPERIMENTAL|Low carbohydrate, reduced glycemic load, control diet|
62806818|NCT05513326|EXPERIMENTAL|Intervention Group|Intervention group will received education and a specific rehabilitation program (exercises).
62806819|NCT05513326|OTHER|Control Group|Control group will received education alone.
62422022|NCT06147609|ACTIVE_COMPARATOR|children with removable partial denture space maintainer|functional Removable space maintainer that not only maintain the mesiodistal space, but vertical dimension and masticatory function is also assured
62422023|NCT01637259|ACTIVE_COMPARATOR|NRTI + PI|arm 1
62422024|NCT01637259|ACTIVE_COMPARATOR|PI + maraviroc|arm 2
62229981|NCT03343457|NO_INTERVENTION|Control|Control group
62422025|NCT01637259|ACTIVE_COMPARATOR|NRTI + maraviroc|arm 3
62591781|NCT01740076|EXPERIMENTAL|soy nuts|25 g of soy nuts provided daily to the subjects and they were counseled to replace 25 g of protein in their therapeutic lifestyle change (TLC) diet with the soy. TLC diet consisted of 30% of energy from total fat (\<7% saturated fat, 12% monounsaturated fat and 11% polyunsaturated fat), 15% from protein and 55% from carbohydrate; less than 200 mg of cholesterol per day and 1200 mg of calcium and 2 fatty fish meals per week. Those ingesting suboptimal dietary calcium were given calcium carbonate supplementation.
62591782|NCT01740076|OTHER|Therapeutic lifestyle change diet|Counseling on therapeutic lifestyle change diet consisting of 30% of energy from total fat (\<7% saturated fat, 12% monounsaturated fat and 11% polyunsaturated fat), 15% from protein and 55% from carbohydrate; less than 200 mg of cholesterol per day and 1200 mg of calcium and 2 fatty fish meals per week. Those ingesting suboptimal dietary calcium were given calcium carbonate supplementation.
62591783|NCT02749994|ACTIVE_COMPARATOR|R5|Rosuvastatin 5mg
62591784|NCT02749994|ACTIVE_COMPARATOR|R10|Rosuvastatin 10mg
62806820|NCT04085549|EXPERIMENTAL|Berry Oil Cream|Study part 1: Administered to a chosen eczema lesion on randomized body half 1-2 times/d or more frequently (use reported to study logbook) for two weeks. Also administered to forearm (randomized body half) twice/d for two weeks. Study part 2: Administered to randomized body half 1-2 times/d for five weeks.
62591785|NCT02749994|ACTIVE_COMPARATOR|R20|Rosuvastatin 20mg
62591786|NCT02749994|EXPERIMENTAL|R5/E10|Rosuvastatin 5mg/Ezetimibe 10mg
62591787|NCT02749994|EXPERIMENTAL|R10/E10|Rosuvastatin 10mg/Ezetimibe 10mg
62591788|NCT02749994|EXPERIMENTAL|R20/E10|Rosuvastatin 20mg/Ezetimibe 10mg
62591789|NCT06623175|EXPERIMENTAL|Acupuncture group|This group of patients were randomly assigned to receive acupuncture in the first 24h after PROM, consisting in the insertion of sterile disposable acupuncture needles, stimulating specific acupoints able to enhance uterine activity, ripe the cervix and reduce anxiety.
62591790|NCT06623175|NO_INTERVENTION|Non acupuncture group|This group of patients were randomly assigned to the no acupuncture group, meaning they received no intervention in the first 24h after PROM.
62591791|NCT06317142||Healthy overweight volunteers|This group includes 15 healthy overweight volunteers. These participants will undergo two test days with one overnight stay. During these days several tests will be conducted including measurements such as muscle and liver glycogen, whole-body gluconeogenesis, substrate oxidation and postprandial hepatic and muscle glucose uptake will be assessed by 18F-FDG PET combined with an oral glucose tolerance test.
62591792|NCT06317142||Prediabetes volunteers-IFG|"This group will include 15 subjects with impaired fasting glucose (IFG). These participants will undergo two test days with one overnight stay. During these days several tests will be conducted including measurements such as muscle and liver glycogen, whole-body gluconeogenesis, substrate oxidation and postprandial hepatic and muscle glucose uptake will be assessed by 18F-FDG PET combined with an oral glucose tolerance test.~A subset of IFG prediabetes individuals with impaired fasting glucose (first 10 subjects enrolled) will receive a 4-day Acipimox treatment (3x 250mg capsules for three days (one with breakfast, one with lunch and one with snack) and 1x 250mg in the morning of day 4. After the intervention the participants will come to the university for two days with an overnight stay for tests (muscle and liver glycogen, whole-body gluconeogenesis, substrate oxidation, oral glucose tolerance test)."
62806821|NCT04085549|NO_INTERVENTION|Control|Study part 1: A chosen eczema lesion on randomized body half is an untreated control for two weeks. Also one forearm (on randomized body half) is a control with no treatment for two weeks.
62806822|NCT04085549|ACTIVE_COMPARATOR|Reference cream|A commercial reference cream, not containing berry and plant oils. Study part 2: Administered to randomized body half 1-2 times/d for five weeks.
62806823|NCT05644314|EXPERIMENTAL|Patients with vertebral atherosclerotic stenosis requiring stent implantation|"Referring to the 2015 Chinese Guidelines for Endovascular Interventional Treatment of Ischemic Cerebrovascular Disease, the 2015 Symptomatic Atherosclerotic Sclerotic vertebral artery initiation stenosis: Chinese expert consensus and Subclavian/extracranial vertebral artery stenosis: Chinese expert consensus in 2019 and other guidelines and expert consensus for the diagnosis of symptomatic vertebral artery atherosclerotic stenosis ≥ 50% and non-symptomatic vertebral artery atherosclerotic stenosis ≥ 70% in patients."
62229982|NCT00326469|EXPERIMENTAL|1|
62229983|NCT06027164||Study Subjects|Ultrasound scans conducted by novice users and experts on this cohort.
62229984|NCT04454177||SMART watch|Medical records from patients aged 18 years or older undergoing Transcatheter Aortic Valve Replacement
62229985|NCT00454766||Questionnaire|Questionnaire Regarding Tailored Educational Materials
62229986|NCT04431401|EXPERIMENTAL|rTMS treatment group|The participants will be divided into the rTMS treatment group and the sham treatment group by means of randomized methods.The protocol of the treatment is to use rTMS with high frequency 10/20Hz 120%RMT 20 times for one month. The device is Magtism rTMS made in London, UK
62229987|NCT04431401|SHAM_COMPARATOR|sham treatment group|The control group is to receive sham treatment. The device is the same as the one used in the real treatment group.
62229988|NCT01944813|EXPERIMENTAL|Intervention: ACP conversation|Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
62229989|NCT01944813|NO_INTERVENTION|No intervention: usual care|No intervention just usual care
62422026|NCT05288842||Group 1: Controls|
62422027|NCT05288842||Group 2: Alzheimer's Disease|
62422028|NCT05288842||Group 3: Frontotemporal Dementia|
62422029|NCT06317363|EXPERIMENTAL|Experimental Group A (ACAPELLA)|Group A (baseline treatment + acapella)
62422030|NCT06317363|EXPERIMENTAL|Experimental Group B (MANUAL CHEST PHYSIOTHERAPY)|Group B (baseline + manual chest physiotherapy)
62422031|NCT06480565|EXPERIMENTAL|Dose Escalation|ADI-270 is administered at ascending dose levels as a single dose to determine the maximum tolerated dose (MTD) or maximum assessed dose (MAD) of ADI-270
62806824|NCT02767271|EXPERIMENTAL|Tinea Pedis|Participants with tinea pedis received luliconazole cream 1% topically once daily in the morning for 15 days (Day 1 through 15). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas, including up to the ankles.
62806825|NCT02767271|EXPERIMENTAL|Tinea Cruris|Participants with tinea cruris received luliconazole cream 1% topically once daily in the morning for 8 days (Day 1 through 8). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas, including up to the groin, thighs, and abdomen.
62806826|NCT03694405|EXPERIMENTAL|Group 1A|3 doses prior MenC , randomized to receive MenACWY-CRM (Menveo)
62806827|NCT03694405|EXPERIMENTAL|Group 1B|3 doses prior MenC, randomized to receive MenACWY-DT (Menactra)
62806828|NCT03694405|EXPERIMENTAL|Group 1C|3 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)
62806829|NCT03694405|EXPERIMENTAL|Group 2A|2 doses prior MenC, randomized to receive MenACWY-CRM (Menveo)
62806830|NCT03694405|EXPERIMENTAL|Group 2B|2 doses prior MenC, randomized to receive MenACWY-DT (Menactra)
62806831|NCT03694405|EXPERIMENTAL|Group 2C|2 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)
62806832|NCT03694405|EXPERIMENTAL|Group 3A|1 dose prior MenC, randomized to receive MenACWY-CRM (Menveo)
62806833|NCT03694405|EXPERIMENTAL|Group 3B|1 dose prior MenC, randomized to receive MenACWY-DT (Menactra)
62806834|NCT03694405|EXPERIMENTAL|Group 3C|1 dose prior MenC, randomized to receive MenACWY-TT (Nimenrix)
62806835|NCT05605626||Simulator training before|group exposed directly to simulator training without knowing the topic of obstetric emergency
62806836|NCT05605626||lesson before simulation training|group undergoing formal lecture before the vacuum delivery simulation on mannequin
62806837|NCT04614896|EXPERIMENTAL|Ultrasound for measuring DOI in tongue tumors|All patients included with tongue carcinoma
62806838|NCT00962208|EXPERIMENTAL|orthokeratology lenses|Children wearing orthokeratology at night for correcting of refractive error will be study group
62806839|NCT00962208|OTHER|single-vision spectacle lenses|Children wearing single-vision spectacles in the daytime for correcting the refractive error will serve as control group
62806840|NCT04043117||Clinical Group|Group is composed by 12-19 years adolescents with a tumor (excluding brain tumor). Every patient included in the group complete the assessment including: evaluation of self-esteem (TMA test) and body image (BUT test, I-BICI test and Human Figure Drawing).
62806841|NCT01879917|ACTIVE_COMPARATOR|Liraglutide|1.8 mg
62806842|NCT01879917|PLACEBO_COMPARATOR|Saline|
62806843|NCT02253615|ACTIVE_COMPARATOR|Machine resistance training (MRT)|The machine resistance training will consist of four exercises for lower limbs and four exercises for upper limbs which will be alternately performed with a one-minute interval between them during familiarization and training periods. Lower limb exercises will consist of: hip extension and abduction, and knee flexion and extension. Upper limb exercises will consist of: bench press, rowing, triceps and high pulley exercise.
62806844|NCT02253615|EXPERIMENTAL|Elastic resistance training (ERT)|The elastic resistance training will consist of four exercises for lower limbs and four exercises for upper limbs which will be alternately performed with a one-minute interval between them during familiarization and training periods. Lower limb exercises will consist of: hip extension and abduction, and knee flexion and extension. Upper limb exercises will consist of: bench press, rowing, triceps and high pulley exercise.
62806845|NCT03685630|EXPERIMENTAL|Brivaracetam|Subjects in this arm will receive open-label Brivaracetam.
62806846|NCT00683111|ACTIVE_COMPARATOR|1|oral esomeprazole 20 mg daily
62806847|NCT00683111|ACTIVE_COMPARATOR|2|oral famotidine 40mg daily
62806848|NCT00499681|EXPERIMENTAL|Arm I|Patients receive Lapatinib and Letrozole once daily for two weeks, following tumor measurement patients receive Lapatinib and Letrozole once daily for 14 weeks.
62806849|NCT00499681|EXPERIMENTAL|Arm II|Patients receive Letrozole and placebo once daily for 2 weeks, following tumor measurement patients receive Letrozole and Lapatinib once daily for 14 weeks.
62806850|NCT00879021|PLACEBO_COMPARATOR|Pregabalin, (other name) Lyrica|Study subjects wil be randomized to either the Pregabalin or Placebo group. There is a 5o ,50 chance of being in either group.
62243163|NCT03312699|EXPERIMENTAL|Group B Fluad|Group B: Up to 15 healthy volunteers 65 plus years old, will be given seasonal adjuvanted trivalent inactivated influenza vaccine Fluad®. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
62806851|NCT00879021|PLACEBO_COMPARATOR|pregabalin, drug|study subjects that are randomized to the placebo group will receive matching placebo
62806852|NCT02196961|NO_INTERVENTION|Observation|After complete resection of Merkel cell carcinoma, patients randomized to the observational arm will be observed only
62806853|NCT02196961|EXPERIMENTAL|Nivolumab|After complete resection of Merkel cell carcinoma, patients randomized to the treatment arm will receive nivolumab at a fixed dose of 480 mg by IV infusion every 4 weeks for up to one year (i.e.13 doses).
62806854|NCT02178995|NO_INTERVENTION|Healthy Controls|"Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.~Healthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."
62806855|NCT02178995|EXPERIMENTAL|Participants With Epilepsy (Open-label)|Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After a four week treatment trial, their scores on the batteries and questionnaires were again assessed.
62819508|NCT04916990|ACTIVE_COMPARATOR|CARES Intervention|All participants will complete surveys to assess Quality of Care and Patient Reported outcomes at baseline, 3 months and 6 months. The CARES intervention will include a maximum of 10 navigation and 10 counseling sessions delivered over approximately a 6- month period delivered by oncology nurse navigators and master's level counselors. Sessions will be scheduled to correspond with key transition points during treatment and may be held in person, virtually, or by phone.
62422032|NCT06480565|EXPERIMENTAL|Dose Expansion|Dose Expansion with ADI-270 at the MTD/MAD to confirm recommended phase 2 dose (Part 2).
62806856|NCT02178995|EXPERIMENTAL|10mg, 20mg, Then Placebo (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
62806857|NCT02178995|EXPERIMENTAL|10mg, Placebo, Then 20mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
62806858|NCT02178995|EXPERIMENTAL|Placebo, 20mg, Then 10mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
62806859|NCT02178995|EXPERIMENTAL|Placebo, 10mg, Then 20mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
62806860|NCT02178995|EXPERIMENTAL|20mg, Placebo, Then 10mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
62806861|NCT02178995|EXPERIMENTAL|20mg, 10mg, Then Placebo - Double-blind|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
62819509|NCT04916990|NO_INTERVENTION|Usual Care|All participants will complete surveys to assess Quality of Care and Patient Reported Outcomes. Patients will receive a standardized list of resources.
62819510|NCT05844501|EXPERIMENTAL|Ondansetron|Patients with atrial fibrillation scheduled to undergo AF ablation will receive treatment with ondansetron 8 mg orally twice daily for 28 days (n=40)
62591793|NCT06317142||Prediabetes volunteers-IGT|"This group will include 15 subjects with impaired glucose tolerance (IGT). These participants will undergo two test days with one overnight stay. During these days several tests will be conducted including measurements such as muscle and liver glycogen, whole-body gluconeogenesis, substrate oxidation and postprandial hepatic and muscle glucose uptake will be assessed by 18F-FDG PET combined with an oral glucose tolerance test.~A subset of IGT prediabetes individuals with impaired fasting glucose (first 10 subjects enrolled) will receive a 4-day Acipimox treatment (3x 250mg capsules for three days (one with breakfast, one with lunch and one with snack) and 1x 250mg in the morning of day 4. After the intervention the participants will come to the university for two days with an overnight stay for tests (muscle and liver glycogen, whole-body gluconeogenesis, substrate oxidation, oral glucose tolerance test)."
62591794|NCT03348930|EXPERIMENTAL|Tolcapone|Each subject will have a 4 week treatment phase with Tolcapone
62229990|NCT04053530|EXPERIMENTAL|3M™ Ketac™ Universal Aplicap™|"3M™ Ketac™ Universal Aplicap™ Glass Ionomer Restorative Clean the cavity preparation with water. Rinse thoroughly and dry. Extrude the mixed ketac universal out of the capsule directly into the prepared cavity with a capsule gun. Please ensure that no air bubbles are included.~It is recommended that the finishing and polishing can be continued after approximately 4 minutes after the start of the mixing or earlier if heat is applied for faster setting. The finishing and polishing can be done immediately after final setting with Extra-Fine, Friction Grip diamonds under water-cooling."
62229991|NCT04053530|EXPERIMENTAL|Filtek™ Bulk Fill Flowable composite|"Filtek™ Bulk Fill Flowable Restorative is the 3M ESPE choice in the bulk fill flowable category.~Selective etching 15-20 s for enamel. The adhesive system (BISCO universal all bond) will be applied following the manufacturer's instructions (apply 2 coats 20 s before curing). Bulk fill flowable composite will be light cured for 40 s using a visible light curing unit."
62591795|NCT03348930|PLACEBO_COMPARATOR|Placebo|4 week placebo phase before or after Tolcapone phase depending on randomization.
62422033|NCT05775146|EXPERIMENTAL|SBRT to the metastatic liver +/- lung lesions|All rectal cancer patients included in the trial will receive short course radiation to the pelvis (with 25 Gy in 5 fractions) followed by chemotherapy with either 6 cycles of 3 weekly CAPOX chemotherapy or 9 cycles of 2 weekly FOLFOX. All colon cancer patients will receive 6 cycles of 3 weekly CAPOX or 9 cycles of 2 weekly FOLFOX. Patients will proceed for SBRT to the metastatic liver +/_ lung lesions and resection of the colorectal primary. Treatment planning is to be done using CT simulation or conventional simulation (Fluorocscopy) as per institutional practice. Simple beam arrangements, such as parallel opposed beams, are favored wherever possible.
62422034|NCT01856686|EXPERIMENTAL|BP22042013|This group of patients receive 2.000 kilocalories diet(60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
62229992|NCT04053530|ACTIVE_COMPARATOR|ketac N100|"Ketac™ Nano Light Curing Glass Ionomer Restorative. Primer will be applied to both enamel and dentinal surfaces for 15 seconds. The prepared tooth surfaces will be wet with the primer for the full application time.~Dispensing two clicks from the Clicker™ Dispenser will provide an adequate amount of material for most restorative filling applications.~It will be placed with a syringe system then will be placed in 2mm increments or less, and light cured after each increment. An LED curing light will cure all shades with a 20 second light exposure.~Finishing Ketac Nano restorative will be polished with conventional finishing and polishing instruments such as a diamond impregnated rubberized polishing system under water spray. A glaze such as Vitremer™ Finishing Gloss will be applied after polishing if desired."
62422035|NCT01856686|EXPERIMENTAL|Low carbohydrate Diet|the second group of patients receive diet of 2.000 Kilo calories without rapidly absorbed carbohydrates and without proteins supplements
62591796|NCT06666933|EXPERIMENTAL|Time restricted eating with metformin|TRE (eating is allowed from 8am to 4pm without limitation in calories) with metformin 1g bid po for 6 weeks
62591797|NCT06666933|OTHER|Metformin only|Taking metformin 1g bid po for 6 weeks only
62806862|NCT02178995|EXPERIMENTAL|40mg, 20mg, Then Placebo (One Participant)|This study was originally intended to use 40mg, 20mg, and placebo doses rather than 20mg, 10mg, and placebo. This individual developed tachycardia (see adverse events) on the 40mg dose, and was withdrawn from the double-blind portion as a result. We removed the 40mg doses from this study and replaced them with 10mg doses. No other participant received a 40mg dose. This participant rejoined the open-label portion after consultation with his PCP due to significant perceived benefit from the MPH dose.
62806863|NCT05853146||pregnant women|Healthy women in their third trimester of pregnancy with one fetus
62806864|NCT00971802|EXPERIMENTAL|Cohort 1|Healthy volunteers - PF-03882845 versus Placebo
62806865|NCT00971802|EXPERIMENTAL|Cohort 2|Healthy volunteers - PF-03882845 versus Placebo
62806866|NCT00971802|EXPERIMENTAL|Cohort 3|Healthy volunteers - PF-03882845 versus Placebo
62806867|NCT00971802|EXPERIMENTAL|Cohort 4|Healthy volunteers - PF-03882845 versus Placebo
62806868|NCT04092686|EXPERIMENTAL|SEP-363856 75mg|SEP-363856 75mg dosed once daily
62806869|NCT04092686|EXPERIMENTAL|SEP-363856 100mg|SEP-363856 100mg dosed once daily
62806870|NCT04092686|PLACEBO_COMPARATOR|Placebo|Placebo dosed once daily
62806871|NCT03179566|NO_INTERVENTION|Usual Care|For the first two weeks, there will be no intervention or changes to the usual discharge instructions
62806872|NCT03179566|ACTIVE_COMPARATOR|Information Sheet|At discharge, patients will receive an informational sheet detailing options for safe drug disposal
62806873|NCT03179566|ACTIVE_COMPARATOR|Deterra Drug Deactivation System|At discharge, patients will receive a Deterra Drug Deactivation System.
62806874|NCT04498715|ACTIVE_COMPARATOR|OSTEOSYNTHESIS+SYSTEMIC ZOLEDRONIC ACID|After osteosynthesis, systemic Zoledronic acid 4mg (or any other bisphosphonate) will be given intravenously between day 7-14 post operation.
62806875|NCT04498715|EXPERIMENTAL|OSTEOSYNTHESIS+LOCAL CERAMENT BONE VOID FILLER (BVF)+SYSTEMIC ZOLEDRONIC ACID|During osteosynthesis, cerament BVF will be used for the augmentation of the screw. Then systemic Zoledronic acid 4mg (or any other bisphosphonate) will be given intravenously between day 7-14 post operation.
62806876|NCT04283864||Group A|
62806877|NCT04283864||Group B|
62806878|NCT04283864||Group C|
62806879|NCT00851357|EXPERIMENTAL|Active patches and telephone counseling|Proactive Telephone Counseling and 8-weeks of nicotine patches
62806880|NCT00851357|PLACEBO_COMPARATOR|Placebo patches and telephone counseling|Proactive Telephone Counseling and 8-weeks of placebo patches
62806881|NCT00851357|ACTIVE_COMPARATOR|Telephone counseling|Proactive Telephone Counseling
62806882|NCT00851357|ACTIVE_COMPARATOR|Active patches and materials|8-weeks of nicotine patches and materials
62806883|NCT00851357|ACTIVE_COMPARATOR|Placebo patches and materials|8-weeks placebo patches and materials
62806884|NCT00851357|ACTIVE_COMPARATOR|Materials|Self-help materials
62806885|NCT01320358|EXPERIMENTAL|ECMPS-IEM|
62819511|NCT05844501|PLACEBO_COMPARATOR|Placebo|Patients with atrial fibrillation scheduled to undergo AF ablation will receive treatment with matching placebo orally twice daily for 28 days (n=40)
62806886|NCT02793336||infant cohort|"The study is designed as a continuation of a cohort of infants from 12 to 48 months of age. This follows on from two previous cohorts: STOP MIP, which is a cohort of pregnant women followed up until delivery and the Baby-Cohort study, which enrols babies from mothers in the STOP MIP trial and follows them until their first year of live. When participants of the Baby-cohort Study reach study end, they are offered to participate in this study."
62806887|NCT00917930||physical training|
62806888|NCT02428777|ACTIVE_COMPARATOR|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
62806889|NCT02428777|ACTIVE_COMPARATOR|Diclofenac|Women will receive oral diclofenac 100 mg 1 hour before the procedure
62806890|NCT02428777|PLACEBO_COMPARATOR|Placebo|Women will receive an oral placebo 1 hour before the procedure
62806891|NCT03074071|ACTIVE_COMPARATOR|Breast Cancer patient|Patients with Stage IV breast cancer will be taught to build hope by defining attainable goals for themselves in a Hope Enhancement Workshop.
62422036|NCT05104736|EXPERIMENTAL|PT-112|PT-112 will be administered intravenously in 28-day cycles, on Days 1 and 15 at a dose of 360 mg/m2 for cycle 1, and on day 1 at 250mg/m2 for each subsequent cycle, until disease progression, development of intolerable adverse events, or until 8 years after an individual participant has been on study
62422037|NCT06113263||Anterior cervical decompression surgery|Individuals underwent anterior cervical decompression surgery due to cervical radiculopathy
62422038|NCT06113263||Posterior cervical decompression surgery|Individuals underwent posterior cervical decompression surgery due to cervical radiculopathy
62422039|NCT05822024|EXPERIMENTAL|Intervention group|Two schools (grade 4-5) will be randomly assigned to recieve the 3PL intervention in their physical education classes during one school year.
62422040|NCT05822024|NO_INTERVENTION|Control group|Two schools (grade 4-5) will be randomly assigned to the control group and will continue their normal physical education classes.
62422041|NCT00965263|EXPERIMENTAL|Low dose Vaccine|All participants were vaccinated four times: in week 1, 3, 5, and 9. Dose: 82ul
62422042|NCT00965263|EXPERIMENTAL|High Dose Vaccine|All participants were vaccinated four times: in week 1, 3, 5, and 9. Dose: 360ul
62422043|NCT05115955|EXPERIMENTAL|DS group|Combination of routine analgesic regimen and preoperative administration of 2 ml NALDEBAIN® ER Injection (150 mg Dinalbuphine Sebacate, 75 mg/ml, 2 ml/vial).
62422044|NCT05115955|PLACEBO_COMPARATOR|Control group|Combination of routine analgesic regimen and preoperative administration of 2 ml sesame oil (2 ml/vial).
62422045|NCT05674266|EXPERIMENTAL|AN Active tDCS|"Treatment as usual plus experimental treatment"
62422046|NCT05674266|SHAM_COMPARATOR|AN Sham tDCS|"Treatment as usual plus placebo treatment"
62422047|NCT00486642|EXPERIMENTAL|Arm A (pazopanib hydrochloride)|"Patients receive pazopanib hydrochloride PO QD on days 1-28.~."
62422048|NCT00486642|EXPERIMENTAL|Arm B (pazopanib hydrochloride, bicalutamide)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Patients also receive bicalutamide PO QD on days 8-28 of course 1 and on days 1-28 in all subsequent courses.
62806892|NCT03074071|ACTIVE_COMPARATOR|Oncologists|Oncologists will will be taught to build hope by defining attainable goals for themselves and for their patients in a Hope Enhancement Workshop.
62806893|NCT02010268|EXPERIMENTAL|preterm neonates|Preterm neonates (birth before 33 weeks of gestation)
62806894|NCT03976765||Hospital discharge at day 7|
62806895|NCT02837900|PLACEBO_COMPARATOR|Previous LT TX knee and right placebo|Previous left treated knee will have placebo treatment in this protocol.
62806896|NCT02837900|PLACEBO_COMPARATOR|Previous RT TX knee and left placebo|Previous right treated knee will have placebo treatment in this protocol.
62806897|NCT02837900|ACTIVE_COMPARATOR|Both TX with Active|Both knees with receive Active
62806898|NCT02111447|ACTIVE_COMPARATOR|Sevoflurane, propofol, Nasal oxygen|After securing the IV, sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. A bolus of propofol will not be administered. Oxygen will be delivered via nasal prongs at 2 liters per minute. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min also after 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be administered if the child moves or if signs of light anesthesia are noticed. The propofol infusion may also be increased in response to light anesthesia.
62806899|NCT02111447|ACTIVE_COMPARATOR|Sevoflurane, Propofol, LMA|After securing the IV, weight appropriate LMA will be inserted and sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. Oxygen in air will be delivered via LMA. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min after another 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be given if the child moves or exhibits signs of light anesthesia. The propofol infusion may also be increased in response to light anesthesia.
62806900|NCT02111447|ACTIVE_COMPARATOR|Sevoflurane, sevoflurane, LMA|After securing the IV, weight appropriate LMA will be inserted and sevoflurane continued at 3% inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. The sevoflurane may be increased or decreased in 0.5% increments as needed.
62422049|NCT01581073|EXPERIMENTAL|High Hb group|Darbepoetin alfa is given to the patients. Target Hb level is 12.0g/dL and it should be maintained greater than or equal to 11.0g/dL and less than 13.0g/dL. If the patients do not have medical history of myocardial infarction, stroke, pulmonary embolism, unstable angina, or peripheral artery disease, the target Hb level will be greater than or equal to 12.0g/dL and less than 13.0g/dL. Maximum dose of darbepoetin alfa is 240 microgram per 4 weeks.
62422050|NCT01581073|ACTIVE_COMPARATOR|Low Hb group|Darbepoetin alfa is given to the patients. Target Hb level is 10.0g/dL and it should be maintained greater than or equal to 9.0g/dL and less than 11.0g/dL. If the Hb level exceeds 10.0g/dL in patients, reduce the dose amount or stop giving dose.
62422051|NCT04605029||Critically Ill patients|No Intervention
62422052|NCT05688670|ACTIVE_COMPARATOR|Regional Anesthesia|Ultrasound guided blocks
62422053|NCT05688670|ACTIVE_COMPARATOR|Wound Infiltration|Surgeon-delivered wound infiltration
62591798|NCT06647667|EXPERIMENTAL|group A|high intensity interval training
62422054|NCT05224206|SHAM_COMPARATOR|Sham iTBS/Active iTBS|Intermittent Theta Burst Stimulation (iTBS) or realistic sham iTBS will be applied to the left DLPFC. Both sessions will be one week apart.
62422055|NCT05224206|ACTIVE_COMPARATOR|Active iTBS|Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC. Participants will receive daily sessions (on weekdays) for 6 weeks.
62806901|NCT02111447|ACTIVE_COMPARATOR|Sevoflurane, isoflurane, LMA|After securing the IV, weight appropriate LMA will be inserted , sevoflurane will be discontinued and isoflurane will be administered at 2 % inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. Isoflurane may be increased or decreased in 0.5% increments as needed.
62422056|NCT06058507||Patients with carotid web detected|Patients in whom carotid web was detected by examining carotid CTA images
62422057|NCT06203288|EXPERIMENTAL|MBSEL program for educators|"Teachers randomized to this arm will receive a mindfulness-based social and emotional learning (MBSEL) program for educators training outside the classroom. These teachers will continue to teach their regular business as usual social and emotional learning (SEL) curriculum in the classroom.~Note: In the school district where this research study is being conducted, every teacher is required to allot at least one 50-min class period to implementing SEL programs and/or practices, and to embed SEL activities and practices throughout the school day."
62422058|NCT06203288|EXPERIMENTAL|MBSEL program for educators and MBSEL program for students|Teachers randomized to this arm will first receive training in a mindfulness-based social and emotional learning (MBSEL) program designed specifically for educators and will complete the program on their own outside the classroom. Following, they will receive training for implementing an MBSEL program for their students, and then they implement weekly lessons of this program in their classroom to their students.
62422059|NCT06203288|NO_INTERVENTION|"Comparison Business as Usual"|"Teachers randomized to this arm will teach their regular business as usual social and emotional learning (SEL) curriculum to their student in the classroom.~Note: In the school district where this research study is being conducted, every teacher is required to allot at least one 50-min class period to implementing SEL programs and/or practices, and to embed SEL activities and practices throughout the school day."
62422060|NCT00337129|EXPERIMENTAL|eribulin mesylate|eribulin mesylate
62422061|NCT01173588|EXPERIMENTAL|Yogurt+fiber+probiotic|Yogurt YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
62422062|NCT01173588|PLACEBO_COMPARATOR|regular yogurt|yogurt YR had no additional fiber or bifidobacterium
62422063|NCT00288119||Cases|Patients with Barrett's esophagus undergoing surveillance or patients with esophageal adenocarcinoma and esophagogastric junctional adenocarcinoma undergoing EGD
62422064|NCT00288119||EGD Screening|Patients scheduled for clinically indicated EGD for GERD who meet ACG criteria for BE screening
62422065|NCT00288119||Colon Screening|Patients scheduled for screening colonoscopy who have not had EGD and meet clinically indicated criteria for BE screening
62422066|NCT00288119||Controls|Patients scheduled for EGD who do not meet criteria for screening
62422067|NCT06408428|EXPERIMENTAL|Glioma Surgery - MicroECoG recording|
62806902|NCT03306966||Colon cancer patients|Patients with colon cancer (ascending colon) eligible for laparoscopic or open segmental colectomy.
62806903|NCT03310723|ACTIVE_COMPARATOR|Standard Face Mask Preoxygenation|Tidal volume breathing for via a face mask set at 100% oxygen and a rate of 15L/min.
62806904|NCT03310723|EXPERIMENTAL|Optiflow Preoxygenation|Tidal volume breathing with the OptiFlow system applied at 100% oxygen and a flow rate of 30-70L/min.
62806905|NCT01788995||Cohort|
62806906|NCT01212861|EXPERIMENTAL|Suprachoroidal Dissection Instrument|
62422068|NCT06563973|EXPERIMENTAL|Breast milk odor and pacifier group|A pacifier was given for 3 minutes one hour before feeding and for 2 minutes 10 minutes before feeding to support oral feeding. In contrast to the control group, 2 cc of breast milk was dripped onto a sterile sponge one hour before feeding and placed in the baby's incubator, close to the nose (3 cm away). Heart rate and oxygen saturation levels were recorded 10 minutes before feeding.
62422069|NCT06563973|ACTIVE_COMPARATOR|Pacifier group|A pacifier was provided for 3 minutes one hour before feeding and for 2 minutes 10 minutes before feeding to support oral feeding. Heart rate and oxygen saturation levels were recorded 10 minutes prior to feeding.
62422070|NCT02507258||PROFEMUR® Am Femoral Stem|Single study group previously implanted with a primary PROFEMUR® Am Femoral Stem and PROCOTYL® O HA Coated Acetabular Component
62422071|NCT05503264|EXPERIMENTAL|NMDAR autoimmune encephalitis (AIE) cohort|Adults and adolescents with definite or probable NMDAR encephalitis
62422072|NCT05503264|EXPERIMENTAL|LGI1 AIE cohort|Adults with LGI1 encephalitis
62422073|NCT05503264|PLACEBO_COMPARATOR|NMDAR autoimmune encephalitis (AIE) Placebo cohort|Adults and adolescents with definite or probable NMDAR encephalitis
62422074|NCT05503264|PLACEBO_COMPARATOR|LGI1 AIE Placebo cohort|Adults with LGI1 encephalitis
62806907|NCT02095470|EXPERIMENTAL|videolaryngoscope group|video laryngoscopy was done for them
62806908|NCT02095470|PLACEBO_COMPARATOR|traditional laryngoscope|comparison to active group with routine laryngoscope
62806909|NCT02320916|ACTIVE_COMPARATOR|23Gauge|Arterial blood puncture will be performed using a 23Gauge needle
62806910|NCT02320916|ACTIVE_COMPARATOR|25Gauge|Arterial blood puncture will be performed using a 25Gauge needle
62806911|NCT05329844|EXPERIMENTAL|Vildagliptin 50 mg Tablet|1 tablet of Vildagliptin 50 mg as single-dose administration
62806912|NCT05329844|ACTIVE_COMPARATOR|Galvus 50 mg Tablet|1 tablet of Galvus 50 mg (each tablet contains 50 mg Vildagliptin) as single-dose administration
62806913|NCT03078322|EXPERIMENTAL|AV-101|L-4-chlorokynurenine 1440 mg daily for 14 days
62806914|NCT03078322|PLACEBO_COMPARATOR|Placebo|Placebo
62806915|NCT06462053|EXPERIMENTAL|Short-course Radiotherapy plus immunochemotherapy group|The patients will receive short-course radiotherapy (25Gy/5Fx, SCRT), followed by 4 cycles of CAPOX and PD-1 antibody, finally receive the TEM or TME surgery or adopt WW option.
62806916|NCT06462053|EXPERIMENTAL|Long-course Radiotherapy plus chemotherapy group|The patients will receive long-course radiotherapy (50Gy/25Fx,LCRT, concurrent capecitabine), followed by 2 cycles of CAPOX, finally receive the TEM or TME surgery or adopt WW option.
62806917|NCT02949349|EXPERIMENTAL|MMF 500mg|Mycophenolate mofetil 500mg, PO BID
62806918|NCT02949349|EXPERIMENTAL|MMF 750mg|Mycophenolate mofetil 750mg, PO BID
62229993|NCT03861117|EXPERIMENTAL|Assisted strategy|Ability to be weaned is determined with pressure support and positive end-expiratory pressure.
62422075|NCT04426019|EXPERIMENTAL|CLS intervention|Community health workers (CHWs) assess women's breast and/or cervical cancer screening needs and deliver behavioral education designed to increase breast and/or cervical cancer screening. After completing the education, CHWs provide women with clinic referrals to local and affordable screening services. Participants also are offered telephone-delivered navigation support, which focuses on helping women overcome logistic and personal barriers to accessing screening services.
62806919|NCT02949349|ACTIVE_COMPARATOR|AZA|Azathioprine 1mg/kg, PO BID
62229994|NCT03861117|ACTIVE_COMPARATOR|Non assisted strategy|Ability to be weaned is determined with T-piece.
62806920|NCT02003326|OTHER|Inflammatory markers|All patients with inclusion criteria (ARDS moderate and severe: Berlin definition) and absence of non inclusion criteria will have a broncho alveolar wash at day 0 and blood sample every three day to measure inflammatory markers. All patients will receive protective ventilation with low tidal volume and pressures limited (Pplat \<30cmH2O). End-Expiratory Lung Volume and strain will be measured every 6 hours from the inclusion to the extubation.
62229995|NCT02949505|EXPERIMENTAL|Intervention arm|12-week home prehabilitation program
62229996|NCT04499274|EXPERIMENTAL|0 ng/ml|Blood specimen which was added 0 ul of ondansetron
62229997|NCT04499274|EXPERIMENTAL|200 ng/ml|Blood specimen which was added 0.20 ul of ondansetron
62422076|NCT04426019|ACTIVE_COMPARATOR|No CLS intervention|Community health workers (CHWs) assess women's breast and/or cervical cancer screening needs and deliver print materials to women describing cancer screening guidelines.
62422077|NCT06285643|EXPERIMENTAL|AAV2-GDNF|
62422078|NCT06285643|SHAM_COMPARATOR|Control Surgery|
62806921|NCT03571139||Diabetics type 2 with and without diabetic retinopathy|Patients with diabetes mellitus type 2 with and without diabetic retinopathy who needs cataract surgery by phacoemulsification. All patients will undergo OCT angiography examination prior to their cataract surgery and 4 weeks after the cataract surgery.
62806922|NCT00746070||A, primary aldosteronism|patients approved to be aldosteronism
62806923|NCT00746070||B, essential hypertension|patients approved to be essential hypertension
62806924|NCT01425502|OTHER|All practices|The design is a stepped-wedge cluster randomised trial. All participating practices therefore receive the intervention at a start time which is randomised.
62806925|NCT02794207||Participants|One qualitative, semi-structured interview will be conducted. Each interview will last approximately 30-45 minutes and may be audio recorded (if consent is provided). Interviews will consist of several open-ended questions focusing on having the participant reflect upon past experiences with neutropenia management and the impact of the participant's illness and treatment. Several close-ended questions regarding participant's thoughts on potential outcomes will also be included.
62806926|NCT02794207||Caregivers|One qualitative, semi-structured interview will be conducted. Each interview will last approximately 30-45 minutes and may be audio recorded (if consent is provided). Interviews will consist of several open-ended questions focusing on having the participant reflect upon past experiences with neutropenia management and the impact of their child's illness and treatment. Several close-ended questions regarding participant's thoughts on their child's potential outcomes will also be included.
62806927|NCT03566342||GROUP A|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 8ml Lockout ( number of doses per hour) 2 Lock out interval 30 minutes
62806928|NCT03566342||GROUP B|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 5ml Lockout ( number of doses per hour) 4 Lock out interval 15 minutes
62806929|NCT03566342||GROUP C|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 3ml Lockout ( number of doses per hour) 6 Lock out interval 10 minutes
62806930|NCT03566342||GROUP D|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 14 ml/hour Demand dose 0 ml Lockout ( number of doses per hour) 0 Lock out interval 0 minutes
62806931|NCT03566342||GROUP E|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 7ml Lockout ( number of doses per hour) 3 Lock out interval 20 minutes
62806932|NCT04412577|EXPERIMENTAL|TQB3473 tablets|TQB3473 tablets administered once daily in 28-day cycle .
62806933|NCT05043350|EXPERIMENTAL|Interventional group|107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
62806934|NCT05043350|ACTIVE_COMPARATOR|Control group|107 patients will receive standard drug therapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company)
62229998|NCT04499274|EXPERIMENTAL|2000 ng/ml|Blood specimen which was added 2 ul of ondansetron
62229999|NCT04499274|EXPERIMENTAL|20000 ng/ml|Blood specimen which was added 20 ul of ondansetron
62230000|NCT00491829|EXPERIMENTAL|flibanserin|50 mg qhs
62230001|NCT00491829|EXPERIMENTAL|flibanserin 100mg|100 mg qhs
62230002|NCT00491829|PLACEBO_COMPARATOR|placebo|placebo qhs
62230003|NCT00837408||Cases|Individuals with Type 2 Diabetes
62230004|NCT00837408||Controls|Individuals without Type 2 Diabetes
62230005|NCT00461487|EXPERIMENTAL|1|Participants will receive sex education information during the physical exam
62230006|NCT00461487|ACTIVE_COMPARATOR|2|Participants will receive information on hygiene and nutrition during the physical exam
62230007|NCT00461487|NO_INTERVENTION|3|Passive control participants will not receive any additional information during the physical exam
62230008|NCT01422226|EXPERIMENTAL|Experimental active comparator|"Drug: Misoprostol~Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion"
62230009|NCT01422226|PLACEBO_COMPARATOR|Placebo comparator|"Other: Placebo~Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion"
62422079|NCT01642693|EXPERIMENTAL|Teeth with intrusive movement and low power laser|Histological changes and root resorption were assesed in Teeth with intrusive movement after a low power laser application
62806935|NCT00227721|EXPERIMENTAL|Docetaxel & Gemcitabine hydrochloride|Docetaxel, 40 mg/m2, 30 min IV infusion on Days 1 and 8, of a 21 day cycle Gemcitabine hydrochloride, 800mg/m2 30 min IV infusion on Days1 and 8, of a 21 day cycle
62806936|NCT03268785|NO_INTERVENTION|Control|Previous admitted patients who were given conventional thyroidectomy combined with central neck lymph node dissection, without intra-operative nodes identification were enrolled into control group.
62806937|NCT03268785|EXPERIMENTAL|Experimental group|Newly admitted patients,from august 2016 to august 2018, who were given thyroidectomy combined with central neck lymph node dissection, with intra-operative identification of suspicious lymph nodes or parathyroid glands were regarded as experimental group.Intraoperative identification method includes Diff-quik staining and PTH test assay. 200 participants were planed for enrollment.
62230010|NCT05692297|EXPERIMENTAL|Denosumab group|Fifty-one patients were randomly assigned to the denosumab group, which received subcutaneous injection of denosumab 60mg once every 6 months. Serum calcium, phosphorus, alkaline phosphatase, iPTH, tPINP, 25(OH)VitD, DXA and qCT were measured before medication. Serum calcium, phosphorus and iPTH were examined at day 1, 7 and 14, alkaline phosphatase, tPINP and 25(OH)VitD at day 7 and 14, and electrocardiogram at day 1 and 7 after treatment. Intravenous calcium supplementation was required if muscle spasms and QT prolongation occurred. Six months after medication, subcutaneous injections of denosumab 60mg were repeated. The protocol was repeated every 6 months, totally 24 months. Bone mineral density, clinical parameters and adverse events were evaluated at 24 months.
62230011|NCT05692297|ACTIVE_COMPARATOR|Non-denosumab group|The other 51 patients did not use denosumab and used other medications, such as diphosphonates, active vitamin D and/or active vitamin D analogue, calcimimetics, calcitonin, estrogen receptor agonists, etc. At the same time, calcium and vitamin D were supplemented. The baseline serum calcium, phosphorus, alkaline phosphatase, iPTH, tPINP, 25(OH)VitD, DXA, and qCT were measured. The above parameters were rechecked every 6 months, and the medications was recorded, totally 24 months.
62230012|NCT05749289|EXPERIMENTAL|Al18F-octreotide PET/CT|Al18F-octreotide PET/CT will be performed on patients with suspected or clearly diagnosed Neuroendocrine Tumor. The patients were injected with Al18F-octreotide and underwent PET/CT scan 20\~40min after the injection.
62230013|NCT00001563|EXPERIMENTAL|1|EPOCH-R every 3 weeks for up to 6 cycle
62230014|NCT05251662|EXPERIMENTAL|experimental group1|Sintilimab Combined With GEMOX + IBI305
62230015|NCT05251662|EXPERIMENTAL|experimental group2|Sintilimab Combined With GEMOX
62230016|NCT05251662|ACTIVE_COMPARATOR|Comparator|GEMOX
62230017|NCT05624294|EXPERIMENTAL|2mg CS0159|One tablet daily for seven days.
62230018|NCT05624294|EXPERIMENTAL|4mg CS0159|Two tablet daily for seven days.
62230019|NCT05624294|EXPERIMENTAL|6mg CS0159|Three tablet daily for seven days.
62806938|NCT03287921||mono bronchodilatation|patients with COPD and features of hyperinflation and small airway disease
62806939|NCT03287921||dual bronchodilatation|patients with COPD and features of hyperinflation and small airway disease
62806940|NCT02898454|EXPERIMENTAL|Dupilumab 300 mg q2w|Dupilumab 300 mg subcutaneous (SC) injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose.
62806941|NCT02898454|EXPERIMENTAL|Dupilumab 300 mg q2w then q4w|Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 and then 300 mg q4w until Week 52 added to background therapy of intranasal MFNS at stable dose. After Week 24, Dupilumab administration was alternated with matched placebo injection every other week up to Week 50.
62806942|NCT02898454|PLACEBO_COMPARATOR|Placebo|Placebo (for dupilumab), 1 SC injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose.
62806943|NCT02539797|EXPERIMENTAL|tDCS anodal stimulation|anodal stimulation
62806944|NCT02539797|ACTIVE_COMPARATOR|tDCS cathodal stimulation|cathodal stimulation
62806945|NCT02539797|SHAM_COMPARATOR|Sham stimulation|Sham stimulation. Termination of electrical stimulation following 30 seconds
62230020|NCT04012996|EXPERIMENTAL|Investigational|Two-level prodisc C SK and/or prodisc C Vivo
62230021|NCT04012996|ACTIVE_COMPARATOR|Control|Two-level Mobi-C device
62230022|NCT04144504|ACTIVE_COMPARATOR|Plastic stenting|Patients with post-liver transplantation and suffer from biliary anastomotic stricture would be given balloon dilatation and plastic stenting for treatment.
62230023|NCT04144504|ACTIVE_COMPARATOR|Retrievable metallic stenting|Patients with post-liver transplantation and suffer from biliary anastomotic stricture would be given retrievable metallic stenting for treatment.
62230024|NCT01096134|EXPERIMENTAL|HPV Vaccine|Eligible girls were offered 3 doses of the HPV vaccine
62230025|NCT01321346|EXPERIMENTAL|Leukemia Patients|Patients with ALL and AML will be treated in one arm of the study.
62230026|NCT01321346|EXPERIMENTAL|Lymphoma Patients|Patients with NHL or HD will be treated in one arm of the study.
62230027|NCT02898844|NO_INTERVENTION|Control Condition|Neither roommate dieted.
62230028|NCT02898844|EXPERIMENTAL|Mixed Diet Condition|Low-calorie diet: One roommate in each pair was randomly assigned to a 1200-calorie/day diet, while the other roommate was instructed to eat normally.
62230029|NCT02898844|EXPERIMENTAL|Both Diet Condition|Low-calorie diet: Both roommates in each pair were randomly assigned to a 1200-calorie/day diet.
62806946|NCT00791063|EXPERIMENTAL|18F ML-10|Intervention - 18F ML-10 PET/CT imaging for early detection of response of brain metastases to WBRT
62806947|NCT02530346|ACTIVE_COMPARATOR|Mechanical Bowel Preparation|"Patients will receive enteric polyethylene glycol at 100 ml/kg/dose during 4 hours, and up to 3 times, prior to surgery.~Enemas with normal saline 20 ml/kg/do will be administered through the stomas 3 times a day"
62030842|NCT06669546|EXPERIMENTAL|Sham first, PLAS second|In this study arm, participants will undergo a 4-week intervention period with sham (soundless) phase-locked auditory stimulation (PLAS) administered on nights from Monday to Friday. Following this initial intervention period, participants will have a 2-week washout phase. Finally, participants will enter the second intervention period, during which real PLAS will be administered.
62030843|NCT04980833|EXPERIMENTAL|Alpelisib|All participants will receive alpelisib once a day
62030844|NCT01015742|EXPERIMENTAL|Experimental|Stem cell Transplant using two unrelated umbilical cord blood units.
62030845|NCT01138904|ACTIVE_COMPARATOR|IROX arm: FOLFIRI -> FOLFOX|"IROX arm: FOLFIRI -\> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr"
62030846|NCT01138904|ACTIVE_COMPARATOR|OXIR arm: FOLFIRI -> FOLFOX|"OXIR arm: FOLFIRI -\> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr"
62230030|NCT03503253|OTHER|Single-arm|LAA leak closure using detachable coils; Interlock-35 Fibered IDC Occlusion System, Concerto Helix Detachable Coil System
62030847|NCT05735951|EXPERIMENTAL|Mild renally impaired patients|Mild renally impaired patients
62230031|NCT05808504|EXPERIMENTAL|Patients with Parkinson disease|Patients with idiopathic PD. Will receive real or sham transcranial alternating current stimulation at the second visit according to the randomization order. The other stimulation condition will be applied at the third visit.
62230032|NCT05808504|EXPERIMENTAL|Healthy volunteers|Healthy volunteers with no major cognitive impairment. Will receive real or sham transcranial alternating current stimulation at the second visit according to the randomization order. The other stimulation condition will be applied at the third visit.
62230033|NCT00188175|EXPERIMENTAL|IMRT for lower limb soft tissue sarcoma|
62422080|NCT01642693|EXPERIMENTAL|Teeth with intrusive movements with no laser|Histological changes and root resorption in Teeth with intrusive movements with no laser
62591799|NCT06647667|EXPERIMENTAL|group B|moderate intensity continuous training
62591800|NCT05040087|ACTIVE_COMPARATOR|USE OF DIABETES Rx GUIDED LARGELY BY HbA1c LEVELS|Extended-release \[ER\] metformin will be added if HbA1c is ≥7.0% after 3 months; if already used and maximized, pioglitazone will be begun. Other Rx will be added each time HbA1c reaches ≥7.5%. The sequence of Rx will be the same as in intensive Rx subjects; those using insulin will also do prebreakfast SMBG, aiming for glucose \<100 mg/dl.
62591801|NCT05040087|EXPERIMENTAL|USE OF DIABETES Rx GUIDED BY SELF-MONITORED BLOOD GLUCOSE (SMBG)|"1. Guidance by SMBG:~2. Glucose goals: We will aim for \<100 mg/dl premeal (2), \<130 postmeal.~3. Monitoring will include pre-breakfast 2x/wk, and a 5-point profile 1x/wk (before and 1.5-2.5 hr after breakfast, before lunch, before supper, and bedtime).~4. Added Rx will be used if SMBG is \>goal ≥3x in 2 consecutive weeks after ≥4 weeks of MOVE! and/or the previous Rx \[e.g., any 3 of the 7 goals (\<100 mg/dl premeal, \<130 post)\]. Metformin ER will be given first (if not already on it), and increased to 2000 mg/day if there are no side effects. (If metformin is not tolerated, it will be stopped and the second Rx will become the first Rx and given instead. If other Rx are not tolerated, the next Rx will be used. The second Rx will be the TZD pioglitazone, followed by the GLP-1 RA semaglutide, then the SGLT-2 inhibitor empagliflozin. If still above goal, glargine insulin will be added, titrated to keep fasting glucose \<100 mg/dl."
62422081|NCT03512067|EXPERIMENTAL|Patients given EMV Ventilation|Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
62422082|NCT00896701||Patient samples from C9621, C9720 and C19808|This is a CALGB Leukemia Tissue Bank project that makes use of tissue from patients who have previously provided their consent. Diagnostic and follow-up samples from acute myeloid leukemia (AML) patients treated on CALGB protocols 9621, 9720 and 19808, and who have been registered on the mandatory companion Leukemia Tissue Bank Protocol CALGB 9665 will be used.
62591802|NCT05336396|EXPERIMENTAL|BMI|
62591803|NCT05336396|NO_INTERVENTION|Traditional Oral Hygiene Instruction|
62806948|NCT02530346|EXPERIMENTAL|No Mechanical Bowel Preparation|Patients will not receive any preparation prior to surgery
62806949|NCT06063174|NO_INTERVENTION|Baseline-Only|Baseline-only condition will be cross-sectional, and participants will be only completing the first portion of the study. Participants in this arm will be asked to wear a research-grade smartwatch for at least one week and complete the baseline package at one time point which includes self-reported questionnaires, micro-blood collection, and optional stool collection.
62806950|NCT06063174|ACTIVE_COMPARATOR|Active Control|Active control condition will be longitudinal. Participants in this arm will be asked to wear a research-grade smartwatch for at least 24 weeks and complete the baseline package as well as two follow-ups over a period of 24 weeks. After completing the baseline package, participants in the active control group will receive a 12 week psychoeducation training on stress and health called the Environmental Education Program.
62230034|NCT02475902|EXPERIMENTAL|Computer guided home exercise program|"A laptop computer \& MS Kinect camera will be connected to a 40 TV to deliver guided fall prevention exercises. Research staff will train the participants in the use of the computerized program and be supervised performing the exercises during the instruction period. Then participants will be instructed to exercise 3 times per week for 4 weeks. Half of the participants will begin the study with the computerized version of the home exercise program while the other half begins with the paper booklet version of the home exercise program. After one month the arms will cross over."
62422083|NCT05614466|EXPERIMENTAL|Patients living with hepatitis B|Patients living with hepatitis B will be managed at the GP clinic using the Simply B e-support package
62422084|NCT02163031|ACTIVE_COMPARATOR|right radial approach|devices used in the coronary angiography by right radial approach
62230035|NCT02475902|ACTIVE_COMPARATOR|Paper guided home exercise program|A paper booklet with pictures and written instructions, and an exercise log for the home exercise program will be given to half of the participants. Participants will be carefully instructed in performing the exercises correctly and then asked to perform the exercises 3 times per week for one month. Participants who began the study with the paper exercise program will switch to the computerized version of the exercise program for the second month.
62591804|NCT03156608|EXPERIMENTAL|Novii Device ECG/EMG System|These patients will have the Novii ECG/EMG system placed throughout labor and delivery, unless a provider or investigator determines that a different device (internal or external) is necessary for a better signal.
62591805|NCT03156608|ACTIVE_COMPARATOR|Standard of Care External Monitor|A standard external monitor will be placed throughout labor and delivery, unless a provider or investigator determines that an internal device is necessary for a better signal.
62806951|NCT06063174|NO_INTERVENTION|Nonactive Control|Nonactive control condition will be longitudinal. Participants in this arm will be asked to wear a research-grade smartwatch for at least 24 weeks and complete the baseline package as well as two follow-ups over a period of 24 weeks. After completing the baseline package, participants in the nonactive control group will not be receiving any forms of intervention. Participants in this program called the Follow-up Program will be tracked over 12 weeks in parallel to participants receiving an intervention and another 12 weeks after.
62806952|NCT06063174|EXPERIMENTAL|CAL STAR Personalized Intervention|CAL STAR Personalized Intervention condition will be longitudinal. Participants in this arm will be asked to wear a research-grade smartwatch for at least 24 weeks and complete the baseline package as well as two follow-ups over a period of 24 weeks. After completing the baseline package, participants will be assigned to one of the five CAL STAR Personalized Intervention training programs (Think Well, Be Well, Eat Well, Sleep Well, Move Well programs) depending on their score on a self-reported survey called Consequences of Stress Scale (CSS). Based on the CSS score, a participant will be assigned to one of the five programs to work on a domain that is dysregulated when they are stressed. When eligible for multiple, their availability to attend coaching sessions and preferences will be accounted for, or they will be randomly assigned to conditions for which they are eligible.
62806953|NCT04508881|ACTIVE_COMPARATOR|External ligation|External ligation of the valve tube by vicryl sutures
62806954|NCT04508881|ACTIVE_COMPARATOR|intraluminal stenting|stenting of the valve tube by prolene suture
62806955|NCT02123134|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered in 0.2 mL subcutaneous (SC) injections, up to 10 milliliters (mL) per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
62806956|NCT02123134|EXPERIMENTAL|ATX-101 deoxycholic acid injection|Participants received deoxycholic acid 2 mg/cm\^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
62806957|NCT05313035|EXPERIMENTAL|Vaccine Candidate Formula 1|2 doses of vaccine candidate formula 1 administered with 28 days interval (0.5 mL per dose)
62806958|NCT05313035|EXPERIMENTAL|Vaccine Candidate Formula 2|2 doses of vaccine candidate formula 2 administered with 28 days interval (0.5 mL per dose)
62230036|NCT03433911|EXPERIMENTAL|FemBloc|Investigational device and procedure
62806959|NCT05313035|PLACEBO_COMPARATOR|Control|2 doses of placebo administered with 28 days interval (0.5 mL per dose)
62806960|NCT00860808|EXPERIMENTAL|1 AM-101|low dose
62806961|NCT00860808|EXPERIMENTAL|2 AM-101|high dose
62806962|NCT00860808|PLACEBO_COMPARATOR|3 Placebo|
62806963|NCT01739166|EXPERIMENTAL|Practice-tailored intervention - Early/Phase 1|During the 6 month Intervention Phase the Practice Facilitator works with each practice to create changes that are tailored to their individual preferences and methods of operation. Sites randomized to Early/Phase 1 start their 6 month intervention immediately after randomization.
62806964|NCT01739166|EXPERIMENTAL|Practice-tailored intervention - Late/Phase 2|The Phase 2 group will start the practice-tailored intervention with the study facilitator 4 months post-randomization and continue through post-randomization month 10.
62806965|NCT03850860||empirical antibotherapy currently used|patients having had a vancomycin and piperacillin-tazobactam combination as empirical antibiotherapy
62806966|NCT03850860||another empirical antibotherapy|patients having had a vancomycin and cefepime combination as empirical antibiotherapy
62806967|NCT01442480|EXPERIMENTAL|Fish oil|
62806968|NCT01442480|EXPERIMENTAL|Olive oil|
62806969|NCT06453408|SHAM_COMPARATOR|Placebo, sin experiencia|Group of patients with no previous experience in dry needling, will be given placebo dry needling
62230037|NCT03433911|ACTIVE_COMPARATOR|Control|Laparoscopic bilateral tubal sterilization
62422085|NCT02163031|ACTIVE_COMPARATOR|left radial approach|devices used in the coronary angiography by left radial approach
62422086|NCT00791154|EXPERIMENTAL|ARM A|Blinded AMG 479 study drug and carboplatin or cisplatin and etoposide
62422087|NCT00791154|EXPERIMENTAL|ARM B|Blinded AMG 102 study drug and carboplatin or cisplatin and etoposide
62422088|NCT00791154|PLACEBO_COMPARATOR|ARM C|Blinded placebo and carboplatin or cisplatin and etoposide
62422089|NCT01441401||Gabapentin|Peadiatric subjects taking Gabapen Tablets and syrup.
62422090|NCT06527846||Patients with chronic kidney disease (CKD)|
62422091|NCT06425146|OTHER|Clinical-biological cohort|"A clinical-biological cohort of 30 patients with epidermoid carcinomas of the oral cavity.~Blood sample and cytobrush sample at inclusion and before anti-cancer treatment."
62230038|NCT03019185|EXPERIMENTAL|Phase 2 Bardoxolone Methyl|Patients in the Phase 2 cohort will receive bardoxolone methyl throughout the study. Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR \> 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR \>300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
62806970|NCT06453408|SHAM_COMPARATOR|Placebo, con experiencia|Group of patients with previous experience in dry needling, will be given placebo dry needling
62230039|NCT03019185|ACTIVE_COMPARATOR|Phase 3 Bardoxolone Methyl|Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR \> 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR \>300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
62230040|NCT03019185|PLACEBO_COMPARATOR|Phase 3 Placebo|Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.
62422092|NCT02041182|EXPERIMENTAL|Intervention Pre-visit Questionnaire|Adolescents receive PVQ that includes questions about youth violence/bullying
62422093|NCT02041182|ACTIVE_COMPARATOR|Control Pre-visit Questionnaire|Adolescents received PVQ without youth violence/bullying items
62806971|NCT06453408|EXPERIMENTAL|Real, sin experiencia|Group of patients with no previous experience in dry needling, real dry needling will be applied
62422094|NCT01396473|NO_INTERVENTION|control|
62422095|NCT01396473|EXPERIMENTAL|Policy and Environmental Change|
62806972|NCT06453408|EXPERIMENTAL|Real, con experiencia|Group of patients with previous experience in dry needling, real dry needling will be applied.
62806973|NCT01316016|EXPERIMENTAL|Rose hip|
62806974|NCT04897217|ACTIVE_COMPARATOR|Megestrol Acetate Arm - Control Arm|Megestrol Acetate 160 mg by mouth daily
62806975|NCT04897217|EXPERIMENTAL|Levonorgestrel IUD - Comparison Arm|Levonorgestrel intrauterine device with 52 mg progestin (Releases 20mcg/daily)
62806976|NCT03876717|EXPERIMENTAL|Colesevelam, active arm|"Colesevelam hydrochloride, 625mg tablets. Overencapsulated with DB caps AAA for blinding.~Oral use. Dose: 1, 2, or 3 capsules twice daily. Starting dose 2 capsules twice daily. Dose titration by specific criteria by a central study nurse Treatment duration 12 days"
62806977|NCT03876717|PLACEBO_COMPARATOR|Placebo|Inactive placebo tablets. Overencapsulated with DB caps AAA for blinding. Oral use. Dosage and treatment duration as specified for colesevelam
62422096|NCT02901509||CHIK +|People with chikungunya diagnosis (serodiagnosis)
62422097|NCT02901509||CHIK -|People without chikungunya diagnosis (negative serology)
62806978|NCT01155492||Subjects with Parkinson's disease|Male and female subjects with clinically diagnosed Parkinson's disease, Stage I-IV.
62806979|NCT01155492||Control subjects|Age- and gender-matched subjects who do not have Parkinson's disease
62806980|NCT01155492||Multiple system atrophy.|Men and women with clinically diagnosed multiple system atrophy.
62806981|NCT00471055|EXPERIMENTAL|A|Capsaicin and placebo controlled,Cross-over design study
62806982|NCT00471055|PLACEBO_COMPARATOR|B|Capsaicin and placebo controlled,Cross-over design study
62806983|NCT03691909|EXPERIMENTAL|Treatment Arm|Single IV administration of autologous adipose-derived mesenchymal stem cells Baseline laboratory data will be collected prior to infusion; follow up data will be compared against baseline at 1, 3, 6 and 12 months. Joint Assessment 68 will be administered at 1, 3, 6 and 12 months.
62806984|NCT01259206||diabetic patients|
62806985|NCT01259206||diabetic patients and healty controls|there are two groups in this study. One group is obese type 2 diabetic patiens and other group is healty controls.
62806986|NCT03558542|EXPERIMENTAL|Study Group|cardiopulmonary rehabilitation plus neurorehabilitation
62806987|NCT06202495|EXPERIMENTAL|Laser and Fluoride|The treatment group will be treated with amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States) in association 980nm diode laser (doctor smile wiser by Lambda s.p.a. Via dell'Impresa, 1, 36040 Brendola VI, Italy) 1.5 W, pulsed mode 2 mm from tooth surface. For treatment will be used 400 μm diameter and 5 mm long tips of for 4 minutes
62806988|NCT06202495|ACTIVE_COMPARATOR|Fluoride|The control group will be treated with amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States) for 4 minutes.
62806989|NCT00428038||1|"Group 1:~Infants born prematurely at a gestational age \< 32 weeks with a diagnosis of chronic lung disease. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for \> 3 weeks. Subjects will be excluded for the following reasons:~1. Oxygen requirements~2. Congenital heart disease"
62806990|NCT00428038||2|"Group 2:~Infants born prematurely at a gestational age \< 32 weeks without a diagnosis of chronic lung disease. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for \> 3 weeks. Subjects will be excluded for the following reasons:~1. Oxygen requirements~2. Congenital heart disease"
62806991|NCT00428038||3|"Group 3:~Infants born full term at a gestational age \> 37 weeks. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for \> 3 weeks. Subjects will be excluded for the following reasons:~1. Hospitalization for a respiratory illness~2. History of wheezing, asthma, or treatment with asthma medications~3. Congenital heart disease"
62806992|NCT06436118|EXPERIMENTAL|Group with RELAX® glasses|
62030848|NCT05735951|EXPERIMENTAL|Moderate renally impaired patients|Moderate renally impaired patients
62422098|NCT02465710||pelvic organ prolapse|All women who underwent surgical treatment of pelvic organ prolapse in this study.
62243164|NCT03312699|EXPERIMENTAL|Group A Hepatitis A (HepA)|Group A: Up to 30 healthy volunteers 18-40 years old, will be given inactivated Hepatitis A vaccine Vaqta® in year 1 of the study and a booster 12 months post primary Vaqta vaccination. Each volunteer will complete a total of 4 visits per vaccination: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
62806993|NCT06436118|NO_INTERVENTION|Group without RELAX® glasses|
62806994|NCT05052034||BAROQUE MUSIC|This group would listen to baroque music to control their anxiety level during their oral surgeries.
62422099|NCT01154673|EXPERIMENTAL|Intensive HAART|"Patients in this arm will receive the following HAART regimen:~Raltegravir 400 mg BID + Maraviroc 150mg BID + emtricitabine 200mg /tenofovir 300mg QD + lopinavir 400 mg/ritonavir 100mg BID for 96 weeks"
62422100|NCT01154673|PLACEBO_COMPARATOR|Placebo Arm|Placebo (in place of raltegravir and maraviroc) will be added to standard HAART (Emtricitabine 200mg /tenofovir 300mg QD + Lopinavir 400 mg/ritonavir 100mg BID) for 48 weeks and then offered open label Raltegravir and Maraviroc after 48 weeks
62422101|NCT02696018||Critically ill patients|Ultrasonography in critically ill patients in weaning from mechanical ventilation
62422102|NCT01502917|EXPERIMENTAL|Radioactive iodine-labeled monoclonal antibody omburtamab|This is a therapeutic Phase I study intended to assess the safety of convection-enhanced delivery (CED) of radioimmunotherapy in the treatment of children with diffuse pontine glioma.
62422103|NCT01293318||Acute pancreatitis|
62806995|NCT05052034||CLASSICISM MUSIC|this group would listen to classical music to control their anxiety level during their oral surgeries.
62806996|NCT05052034||CONTROL GROUP|This group would not listen to music during their oral intervention, acting as a control group.
62806997|NCT05979740|EXPERIMENTAL|RC48+Toripalimab+Radiotherapy|RC48: 2.0 mg/kg, Q2W, iv; Toripalimab: 3mg/kg, Q2W, iv; Radiotherapy: total dose was greater than 50Gy (about 30 times).
62806998|NCT06217939|EXPERIMENTAL|Early hydrocortisone|After randomization, low-dose hydrocortisone will be administered as soon as possible
62806999|NCT06217939|PLACEBO_COMPARATOR|Standard care|Low-dose hydrocortisone will be given when indicated according to the current Surviving Sepsis Campaign Guidelines
62807000|NCT05563129|NO_INTERVENTION|No first aid training|
62807001|NCT05563129|EXPERIMENTAL|First aid training|
62807002|NCT00788307|EXPERIMENTAL|Experimental Arm|
62807003|NCT05224115||[11C]CHDI-180R|Biodistribution and whole-body dosimetry for \[11C\]CHDI-00485180-R in 3 healthy volunteers.
62807004|NCT05224115||[11C]CHDI-626|Biodistribution and whole-body dosimetry for \[11C\]CHDI-00485626 in 3 healthy volunteers.
62807005|NCT03543761|SHAM_COMPARATOR|A|Sham group
62807006|NCT03543761|ACTIVE_COMPARATOR|B|LiST active treatment group
62030849|NCT05735951|EXPERIMENTAL|Severe renally impaired patients|Severe renally impaired patients
62030850|NCT05735951|EXPERIMENTAL|Matching controls|Matching volunteer without renal impairement
62807007|NCT03543761|ACTIVE_COMPARATOR|C|LiST active treatment group
62807008|NCT00723307|EXPERIMENTAL|Metformin|
62807009|NCT00723307|PLACEBO_COMPARATOR|Placebo|
62030851|NCT01973933|EXPERIMENTAL|Metformin and Pyrimethamine|Metformin 750mg(D1), Metformin 500mg(D2)/Metformin 750mg+Pyrimethamine 50mg(D7), Metformin 500mg+Pyrimethamine 50mg(D8)
62030852|NCT02242747|OTHER|ingenol mebutate|Patients assigned to ingenol mebutate gel received an application a day for three consecutive days in a pre-determined area
62030853|NCT02242747|OTHER|5% 5-FU|Patients assigned to 5% 5-FU received two applications a day for four weeks in a pre-determined area
62030854|NCT06424249|EXPERIMENTAL|Virtual Reality group|
62030855|NCT06424249|ACTIVE_COMPARATOR|Control group|
62243165|NCT03312699|EXPERIMENTAL|Group B Hepatitis A|Group B: Up to 30 healthy volunteers 65 plus years old, will be given inactivated Hepatitis A vaccine Vaqta® in year 1 of the study and a booster 12 months post primary Vaqta vaccination. Each volunteer will complete a total of 4 visits per vaccination: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
62243166|NCT03312699|EXPERIMENTAL|Group A Typhoid VI|Group A: Up to 15 healthy volunteers 18-40 years old, will be randomized to either Typhoid Vi Polysaccharide Vaccine (Typhoid VI), Typhim Vi®, or Typhoid Vaccine Live Oral Ty21a, Vivotif®. This arm represents those randomized to Typhoid VI. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
62807010|NCT01420861|EXPERIMENTAL|1000 mg GTx-758 BID|subjects will receive daily doses of 1000 mg GTx-758
62807011|NCT04204265|OTHER|Monovisc|
62807012|NCT00649844|ACTIVE_COMPARATOR|A|
62807013|NCT00649844|EXPERIMENTAL|B|
62807014|NCT06256172|EXPERIMENTAL|Medlink RPM|The 10 Patients enrolled in this arm tested the ue of Medlink in Measuring and reporting their Physiological Paramters in Oder to remotely obtain access to health care for the following diseases: Myasthenia Gravis, Hypertension, Chronic Heart Failure, Diabetes Mellitus, and Chronic Obstruction Pulmonary Disorder.
62807015|NCT05655884|EXPERIMENTAL|Music Listening Application|"Children in this group; 15 minutes before going to the surgery, the child's favorite and chosen music piece will be loaded onto the mp3 player and played by the researcher (who has received music therapy training) via the creatone music pillow for 15 minutes."
62807016|NCT05655884|EXPERIMENTAL|Foot Reflexology Practice|Children in this group; Before going to the surgery, foot reflexology will be applied by the researcher (who has received reflexology training), only to the left foot, for 10 minutes.
62807017|NCT05655884|NO_INTERVENTION|Control Group|Children in this group will not be subjected to any non-pharmacological application to reduce nausea, pain and anxiety before and after surgery. They will receive routine perioperative care administered in the clinic.
62230041|NCT06341348|OTHER|Effect of case management for rheumatoid arthritis cases|"Case management (CM) applied is multi-component interventions, that comprised the provision of health education and professional advice, referring the client to another health care team, discussing a daily life plan, making reservations, and follow-up by telephone.~As the control group, they received usual health education lasting for about 15 minutes per medical visit from ward nurses, which consisted of consultation in terms of disease symptoms, related treatments or the doctor's orders. They were also free to ask questions of the research team, their ward nurses and physicians at any time within the study period."
62230042|NCT02388867|EXPERIMENTAL|Group I|Intervention: Polytetrafluoroethylene (PTFE) bypass grafting.
62230043|NCT02388867|EXPERIMENTAL|Group II|Intervention: Autogenous vein bypass grafting.
62230044|NCT03021954|EXPERIMENTAL|Intervention Group|Platelet rich plasma injected intramuscularly in pelvic floor muscle immediately following labor and before perineoraphy, simultaneously with the injection of local anesthesia
62230045|NCT03021954|NO_INTERVENTION|Control Group|No intervention given, patient will only get local anesthesia injection before perineoraphy
62422104|NCT04929951|EXPERIMENTAL|MFAT (Micro Fragmented Adipose Tissue)|Intra-articular shoulder injection of autologous Micro Fragmented Adipose Tissue harvested from the thigh using tumescent lipoaspiration and processing with minimal manipulation. This harvested tissue will then be injected into the patient's shoulder.
62422105|NCT04929951|ACTIVE_COMPARATOR|Conventional Therapy|Intra-articular injection of corticosteroid (Triamcinolone 40mg)
62422106|NCT02218931|EXPERIMENTAL|Targeted ESTEEM diet|"The ESTEEM dietary pattern is similar to that in a Mediterranean diet associated with reduced risk of pre-eclampsia.~The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants"
62422107|NCT02218931|NO_INTERVENTION|Current clinical practice|The control group will be provided the usual antenatal dietary advice. This includes advice on healthy and physical activity in women with normal weight and obesity and overweight. Folic acid and vit D supplementation are provided as per national recommendations. Participants will provide outcome data at point of delivery and food frequency questionnaire at baseline and 36 weeks or delivery depending on which is sooner.
62422108|NCT02218931|OTHER|Non-randomised cohort|Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
62422109|NCT00116207|EXPERIMENTAL|ORAL ANTIOXIDANT|Allopurinol (300mg daily), ALA (600mg twice daily) nicotinamide (750 mg twice daily) Given orally These drugs were given together as a combination and not as individual treatment.
62422110|NCT00116207|PLACEBO_COMPARATOR|Placebo|Placebo administered twice daily.
62807018|NCT03180385|EXPERIMENTAL|Neurally-Adjusted Ventilatory Assist (NAVA)|Synchronized biphasic non-invasive respiratory support
62422111|NCT06445608|EXPERIMENTAL|KARDION Cory P4 System|
62807019|NCT03180385|ACTIVE_COMPARATOR|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional non-invasive respiratory support
62807020|NCT04368260|ACTIVE_COMPARATOR|Control swab|FDA cleared swab
62422112|NCT06445608|ACTIVE_COMPARATOR|Commercial Control|
62807021|NCT04368260|EXPERIMENTAL|Prototype swab|Injection molded polypropylene flocked nylon NP swab
62807022|NCT02982902|EXPERIMENTAL|CMV specific adoptive t-cells|This study involves a one-time infusion of the experimental CMV specific adoptive t-cells. After this infusion, patients will be followed for 4 weeks.
62422113|NCT00293475|EXPERIMENTAL|Treatment (rituximab, mannitol, methotrexate, carboplatin)|Patients receive rituximab IV over 5 hours on day 1, mannitol IA, methotrexate IA over 10 minutes, and carboplatin IA over 10 minutes on days 2 and 3. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats monthly for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62591806|NCT02754674|EXPERIMENTAL|Transportal|this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with transportal technique
62807023|NCT03110471||Glangarnant Care Home|This is a 'before and after' observational study involving 10 care homes, listed below as groups. The investigators will observe the changes in detection and management of adverse drug reactions between usual care and with administration of the West Wales ADR Profile. Usual care will be provided before and during the intervention period.
62807024|NCT03110471||Fieldbay Care Homes|All groups are having identical intervention, so the above text applies to all.
62807025|NCT03110471||Neuadd Drymmau Care Home|As above
62807026|NCT03110471||Monkstone House,|As above
62030856|NCT03200938|EXPERIMENTAL|PBS CIMMO|Intervention: PBS CIMMO cement
62807027|NCT03110471||Danygraig House|As above
62807028|NCT03110471||Ty Coch|As above
62807029|NCT03110471||Swn y mor|As above
62807030|NCT03110471||Hengoed court|As above
62807031|NCT03110471||Hengoed park|As above
62807032|NCT03110471||Cefn Lodge care home|As above
62807033|NCT03770312|ACTIVE_COMPARATOR|Low intensity statin group|Taking low intensity statin
62807034|NCT03770312|ACTIVE_COMPARATOR|Moderate intensity statin group|Taking moderate intensity statin
62807035|NCT04565626|EXPERIMENTAL|Intervention|Participants will receive additional exercise by independent use of a peddle bike on the weekends. This is in addition to their usual physiotherapy
62230046|NCT02846753|EXPERIMENTAL|Implantation of Venus P-Valve™|Implantation of the Venus P-Valve™ in the pulmonic position in patients with native outflow tracts; trans catheter heart valve replacement.
62230047|NCT00413296|PLACEBO_COMPARATOR|1|Tablets, no active ingredient, 1-6 tablets/day for 12 wks in the 2 nd phase of the trial.
62230048|NCT00413296|ACTIVE_COMPARATOR|2|Levetiracetam, 500mg (1-6 tablets /day) for 12 wks in the 2nd phase of the study.
62230049|NCT00629460||1|there is only one group/cohort. This is a non-therapeutic study.
62230050|NCT02270086||Sarcoma patient|Patient diagnosed with soft tissue sarcoma and receiving preoperative radiotherapy.
62230051|NCT04693494|EXPERIMENTAL|Intervention group|"Four training sessions (before the baby is 1 month old, at 3 months, at 6 and at 9 months old) teaching the main motor milestones to get in the next 3 months and how to help infants with the correct stimuli, positions or plays; triptychs containing the main points explained at the session and links to short videos about the given advices.~Three evaluations of motor milestones at the age of 9, 12, and 15 months old"
62807036|NCT04565626|NO_INTERVENTION|Control|This arm will receive usual physiotherapy
62030857|NCT03200938|ACTIVE_COMPARATOR|Zinc oxide|Intervention: Formocresol and zinc oxide
62030858|NCT02273141|EXPERIMENTAL|NER1006, Day Before-Only Dosing|NER1006 1-Day Day Before-Only Split-Dosing Regimen (to commence on the evening of the day before colonoscopy).
62030859|NCT02273141|ACTIVE_COMPARATOR|SP+MS, Day Before-Only Dosing|SP+MS 1-Day Day Before-Only Split-Dosing Regimen (to commence on the morning of the day before colonoscopy).
62030860|NCT03386123|EXPERIMENTAL|Cognitive Behaviour Therapy for Insomnia (CBTi)|"A standard CBTi programme for the treatment of primary insomnia, with six, 2 hour, group sessions over eight weeks. There will be minor adaptations for tinnitus, including making specific reference to tinnitus and psycho-education about tinnitus. Every session concludes with provision of a homework task and a sleep diary to complete over the next week. The CBTi course will be supported by providing participants with a CD with some relaxation exercises and a booklet that covers the information given in the session.~CBTi includes: Sleep restriction, stimulus control, Sleep hygiene, Relaxation training, Paradoxical intention, Cognitive therapy: Targeting unhelpful beliefs about sleep and worry, Behavioural experiments: Testing unhelpful beliefs and adjusting sleep related behaviour."
62807037|NCT03210935||Merkel cell carcinoma|
62807038|NCT03210935||Advanced basal cell carcinoma|
62807039|NCT03210935||Cutaneous adnexal carcinomas|
62230052|NCT04693494|NO_INTERVENTION|Control group|Three evaluations of motor milestones at the age of 9, 12, and 15 months old
62230053|NCT01492530|EXPERIMENTAL|6-session, small group|Men of African American Legacy Empowering Self (MAALES) Intervention, a six-session, theoretically grounded, small-group intervention held over 3 weeks. Includes an additional 2 booster sessions at 6 and 18 weeks following Session 6.
62230054|NCT01492530|ACTIVE_COMPARATOR|HIV Education & Risk Reduction Session|20-30 minute standard, client-centered HIV education and risk-reduction session administered over the phone or in person. Similar to that received during pre-test counseling for HIV testing.
62230055|NCT05205915|EXPERIMENTAL|Single arm|All patients will receive active treatment which consists of stimulation (tDCS) applied using the Starstim device, with current delivered via four Starstim Pi electrodes (circular electrodes with a contact of area of 3.14 cm2) embedded in the headpiece. All study subjects will use the same fixed montage (electrode locations and currents).
62422114|NCT06538545|EXPERIMENTAL|Arm 1:Vertical Position (Experimental Group-Primiparous)|All pregnant women in the experimental group were allowed to use a sitting position (sitting and rocking on a pilates ball or sitting on a bed) from the active phase until labor. They were allowed to lie down for 10-15 minutes when they were tired or when monitoring or intervention was needed.
62422115|NCT06538545|EXPERIMENTAL|Arm 2: Vertical Position (Experimental Group-Multiparous)|All pregnant women in the experimental group were allowed to use a sitting position (sitting and rocking on a pilates ball or sitting on a bed) from the active phase until labor. They were allowed to lie down for 10-15 minutes when they were tired or when monitoring or intervention was needed.
62422116|NCT06538545|ACTIVE_COMPARATOR|Arm 3: Lithotomy Position (Control Group-Primiparous)|All pregnant women in the control group were followed up with hospital procedures during labor. From the latent phase until labor, the pregnant woman was followed up with hospital procedures. At the end of the latent and active phases, pain assessment was requested and VAS (Appendix 6) was applied. The 2nd and 3rd stages of labor were performed on a normal delivery table in the lithotomy position.
62422117|NCT06538545|ACTIVE_COMPARATOR|Arm 4: Lithotomy Position (Control Group-multiparous)|The hospital procedure was applied to determine the birth rates of all pregnant women in the control group. From the latent stage until the birth, the pregnant woman is followed up by applying the hospital procedure. At the end of the latent and active phases, the alarm results were requested to be evaluated and VAS (Appendix 6) was developed. The 2nd and 3rd stages of labor were performed in the lithotomy positions on the normal delivery table.
62422118|NCT05862116||Patients with chronic non-specific low back pain|Patients with chronic non-specific low back pain.
62422119|NCT02231307|PLACEBO_COMPARATOR|SUBLIVAC FIX Birch 0 AUN/ml|
62422120|NCT02231307|EXPERIMENTAL|SUBLIVAC FIX Birch 40,000 AUN/ml|
62422121|NCT03663205|EXPERIMENTAL|Tislelizumab + Platinum + Pemetrexed|Tislelizumab 200 milligrams (mg) administered intravenously (IV) once every 3 weeks plus cisplatin 75 mg/m\^2 or carboplatin area under the plasma or serum concentration-time curve (AUC) 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)
62807040|NCT02915666|EXPERIMENTAL|Digoxin combination for Melanoma|Drugs: Dabrafenib 150mg PO 2x daily, Trametinib 2 mg PO daily, and Digoxin 0.25 mg PO daily for 8-week cycles.
62807041|NCT05979844|EXPERIMENTAL|Non-medicine sessions of bCBCT + Medicine Sessions with 3,4-methylenedioxymethamphetamine (MDMA)|"bCBCT Non-medicine sessions: 8 sessions~MDMA Medicine sessions:~Initial Dose 1: 80 mg MDMA HCl (\~68 mg MDMA) Supplementary Dose 1: 40 mg MDMA HCl (\~34 mg MDMA) Initial Dose 2: 100 mg MDMA HCl (\~84 mg MDMA) Supplementary Dose 2: 40 mg MDMA HCl (\~34 mg MDMA)"
62807042|NCT05936008|ACTIVE_COMPARATOR|Moderate intensity, continuous training (MICT)|After a 5-minute warm-up at 30% peak watts, MICT will consist of continuous exercise for 25 minutes at 55% of peak watts (range: 45%-65%). The average heart rate for each individual session should not exceed 70% (60-70%) of HR maximum to align with current exercise recommendations for stroke. An active cool-down (20% peak workload) at comfortable stepping pace occurs immediately after the intervention.
62230056|NCT03628898|EXPERIMENTAL|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00025 sensor
62230057|NCT01620255|PLACEBO_COMPARATOR|Placebo|
62230058|NCT01620255|EXPERIMENTAL|Drug Dose Level 1|
62230059|NCT01620255|EXPERIMENTAL|Drug Dose Level 2|
62230060|NCT01620255|EXPERIMENTAL|Drug Dose Level 3|
62230061|NCT01620255|EXPERIMENTAL|Drug Dose Level 4|
62030861|NCT03386123|ACTIVE_COMPARATOR|Standard Audiological Care (SAC)|"A group intervention that fits with reported audiological treatment of people with tinnitus and significant sleep impairment. This involves psycho-education about tinnitus, habituation, sleep and sleep hygiene. Relaxation will be advised and information provided. A bedside sound generator, as used in routine clinical practice will be provided. Information will be based on standard advice given by hearing therapists/audiologists and will not include specific psychological techniques which are not part of SAC. The group will be generally supportive.~SAC tends not to involve repeated meetings; after the initial session, there will be one follow up session 8 weeks later. Follow up will allow for question and answer, and reports on what has been useful. Both sessions will last for 2 hours"
62030862|NCT03386123|PLACEBO_COMPARATOR|Sleep Support Group (SSG)|"Participants will meet in a group, which will offer equivalent contact with therapists and a supportive group milieu as CBTi. It will focus on the potential benefits of a supportive group and will not include specific advice.~Participants will complete 2-week sleep diaries as baseline and outcome measures at the four time-points, which will be checked within the session to ensure that participants know how to complete them correctly. The SSG will meet in a group for six sessions, over eight weeks, each of 2 two hours duration."
62030863|NCT02243553|EXPERIMENTAL|Treatment A|tipranavir (TPV) capsule + ritonavir (RTV) capsule + cocktail + digoxin oral
62030864|NCT02243553|EXPERIMENTAL|Treatment B|TPV capsule + RTV capsule + cocktail + digoxin injection
62230062|NCT04648735|EXPERIMENTAL|Drivers with cognitive impairments|The participants firstly completed a questionnaire of driving history and perceived driving competence, followed with a clinical physical and cognitive-perceptual assessment battery conducted by an occupational therapist to note any potential deficits that might affect driving performance. The participants, on a separate visit, completed three practice runs of a closed-circuit standardized course that included 8 driving maneuvers, followed by an on-road driving in the community fir 30 minutes.
62230063|NCT04648735|ACTIVE_COMPARATOR|drivers with normal cognition|The participants firstly completed a questionnaire of driving history and perceived driving competence, followed with a clinical physical and cognitive-perceptual assessment battery conducted by an occupational therapist to note any potential deficits that might affect driving performance. The participants, on a separate visit, completed three practice runs of a closed-circuit standardized course that included 8 driving maneuvers, followed by an on-road driving in the community fir 30 minutes.
62230064|NCT06335043|NO_INTERVENTION|Mental Health Provider|Mental health provider's thoughts on pharmacogenetic testing for treatment planning and changes to treatment planning.
62422122|NCT03663205|ACTIVE_COMPARATOR|Platinum + Pemetrexed|Cisplatin 75 mg/m\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)
62422123|NCT03447054|EXPERIMENTAL|Combined TDCS active and ICT active|Five consecutive days: Twenty minutes of TDCS on the right dorsolateral prefrontal cortex while performing an alcohol-cue inhibitory control training consisting to systematically paired go responses with non-alcohol pictures and no-go responses with alcohol-related pictures.
62422124|NCT03447054|ACTIVE_COMPARATOR|Combined TDCS sham and ICT active|Five consecutive days: Twenty minutes of sham TDCS on the right dorsolateral prefrontal cortex, while performing a no-cue go/no-go training consisting to carry out a go/no-go paradigm with no alcohol-related content.
62422125|NCT03447054|ACTIVE_COMPARATOR|Combined TDCS active and ICT inactive|Five consecutive days: Twenty minutes of active TDCS in association with no-cue go/no-go training consisting to carry out a go/no-go paradigm with no alcohol-related content.
62591807|NCT02754674|EXPERIMENTAL|Outside in|this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with patients who underwent operation with outside in technique
62030865|NCT02243553|EXPERIMENTAL|Treatment C|TPV solution + RTV capsule + cocktail + digoxin oral
62030866|NCT02243553|EXPERIMENTAL|Treatment D|TPV solution + RTV capsule + cocktail + digoxin injection
62030867|NCT04214132|EXPERIMENTAL|virtual patients group|Only nursing undergraduates from AY2017/2018 cohort, who have completed the redesigned NUR1110 (Effective Communication for Health-Professionals) core module will receive additional training using Virtual Patients in each semester (2 semesters per year) of year 2 and year 3 before they go for the clinical posting. Students will have unlimited access to the Virtual Patients (available scenarios depend on which semester the student is in) by logging in through the school portal.
62030868|NCT04214132|NO_INTERVENTION|Blended learning group|Nursing undergraduates from AY2016/2017 cohort who who have completed the redesigned NUR1110 (Effective Communication for Health-Professionals) core module that comprised of weekly online e-lectures and face-to-face tutorials.
62030869|NCT04535401|EXPERIMENTAL|Treatment (elimusertib, FOLFIRI)|Patients receive elimusertib PO QD on days 2, 3, 16, and 17 and irinotecan hydrochloride IV over 90 minutes, fluorouracil IV over 46 hours, and leucovorin calcium IV on days 1 and 15. Cycles repeat every 28 day in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy during screening and on study and blood sample collection and imaging throughout the study.
62030870|NCT00472095|EXPERIMENTAL|diabetes fotonovela|spanish language comic book describing diabetes care and consequences
62030871|NCT00472095|PLACEBO_COMPARATOR|placebo fotonovela|
62030872|NCT05366322||Cohort A: mRNA-1273 COVID Vaccine|Participants who have received 2 doses of the mRNA-1273 vaccine at least 14 days apart.
62030873|NCT05366322||Cohort B: BNT1262b2 COVID Vaccine|Participants who have received 2 doses of the BNT1262b2 vaccine at least 14 days apart.
62807043|NCT05936008|ACTIVE_COMPARATOR|High intensity, interval exercise (HIIT)|"After the 5-minute warm-up at 30% peak watts, HIIT will consist of repeated 1-minute, high intensity bursts (on interval) alternated with 1-minute interval recovery (off interval) for 25 minutes. The on interval will begin at 70% of peak watts (range: 65%-95%) followed by the off interval at 10% of peak watts. The average HR for the on intervals will not exceed 85% age predicted maximum (75-85%). There will be 13 minutes of on and 12 minutes of off interval exercise. An active cool-down (20% peak workload) at comfortable stepping pace occurs immediately after the intervention."
62807044|NCT04415203|EXPERIMENTAL|TAVNS plus usual care|TAVNS on Erzhong and Xin (Auricular Acupuncture Point with Vagus nerve distribution); Usual Care: usual medicine treatment for PVCs.
62807045|NCT04415203|PLACEBO_COMPARATOR|Sham-TAVNS plus usual care|"Sham-TAVNS on Erzhong and Xin (Auricular Acupuncture Point); the same acupoints as the treatment group without any current.~Usual Care: usual medicine treatment for PVCs."
62807046|NCT01300234|EXPERIMENTAL|A (TDF tablets)|Tenofovir disoproxil fumarate (TDF) tablets
62030874|NCT06636604|EXPERIMENTAL|Experimental Group|Experimental Group: The effect of the decision support algorithm on pain and satisfaction during intramuscular injection will be examined.
62030875|NCT06636604|NO_INTERVENTION|Control Group|There is no intervention. Pain and satisfaction during intramuscular injection will be examined.
62230065|NCT06335043|EXPERIMENTAL|Patient with Pharmacogenetic Testing|For patient participants who opt-in to pharmacogenetic testing, a report summarizing the pharmacogenetic testing results will be sent to each patient participants' respective mental health provider.
62230066|NCT06335043|NO_INTERVENTION|Patient without Pharmacogenetic Testing|For patient participants who opt-out to pharmacogenetic testing will be followed to see if treatment course is maintained.
62230067|NCT00250679|ACTIVE_COMPARATOR|Formoterol 12 ųg 2x/day|
62230068|NCT00250679|EXPERIMENTAL|Arformoterol 15 ųg 2x/day|
62230069|NCT00250679|EXPERIMENTAL|Arformoterol 25 ųg 2x/day|
62422126|NCT03447054|SHAM_COMPARATOR|Combined Sham TDCS and inactive ICT|Five consecutive days: Twenty minutes of Inactive TDCS combined with an non alcohol-cue inhibitory control training consisting to carry out a go/no-go paradigm with no alcohol-related content.
62422127|NCT06537024||LPF|patients treated with locked plate fixation
62230070|NCT01048580|EXPERIMENTAL|Perifosine +Capecitabine|One cycle of therapy will be defined as 3 weeks (21 days). Perifosine 50 mg qd (Days 1-21) + Capecitabine 1000 mg/m2 BID (Days 1-14).
62230071|NCT05714631|NO_INTERVENTION|Standard of care group|Patients in the standard of care will not be receiving any lidocaine or placebo patches. The aim of this group is to control for the placebo effect
62422128|NCT06537024||RTSA|reverse total shoulder arthroplasty
62422129|NCT01578252|EXPERIMENTAL|Ondansetron Tablets USP 8 mg|Ondansetron Tablets USP 8 mg of M/s Ipca Laboratories Limited, India
62422130|NCT01578252|ACTIVE_COMPARATOR|Zofran®|Zofran® (Ondansetron Hydrochloride) Tablets 8 mg of M/s GlaxoSmithKline
62422131|NCT05117931|EXPERIMENTAL|Amivantamab|Patients will receive amivantamab intravenously weekly for the first cycle, and biweekly subsequently at a dose of 1050mg (patients \<80kg) or 1400mg (patients ≥80kg). The initial dose will be administered over 2 days in split doses in order to mitigate the risk of infusion reactions. Therapy will continue for up to 2 years or until progression of disease, initiation of alternative cancer therapy, unacceptable toxicity, or other reason to discontinue treatment occurs-whichever comes first.
62422132|NCT06004401|EXPERIMENTAL|Penicillin negative test group|（Vonopazan 20mg 2//day+Amoxicillin 1.0g 3/day）\*14 days
62807047|NCT01300234|ACTIVE_COMPARATOR|B (ADV tablets)|Adefovir dipivoxil (ADV) tablets
62807048|NCT00877240|OTHER|Lifestyle counseling|
62807049|NCT03958175||Patients with Parkinson's Disease|Patients with Parkinson's Disease (PD) were evaluated for reading disorders using a screening method validated for dyslexia.
62807050|NCT03958175||Patients without Parkinson's Disease = control group|Patients without Parkinson's Disease (PD) were evaluated for reading disorders using a screening method validated for dyslexia.
62807051|NCT04335643|EXPERIMENTAL|TEACH|Participants will undergo CBT and continue medical TAU.
62807052|NCT04335643|NO_INTERVENTION|Control|Participants will only continue medical TAU.
62807053|NCT03300401|EXPERIMENTAL|Diagnostic (CEUS)|Patients receive perflutren or sulfur hexafluoride lipid microspheres and undergo CEUS at baseline, 2 and 4 weeks, and 3 and 6 months. Patients also undergo PET/CT after standard of care 90Y radioembolization at baseline.
62030876|NCT06412120|EXPERIMENTAL|Niraparib Maintenance Group|"Participants in this group will receive Niraparib maintenance therapy for up to 24 cycles, 28 days per cycle. Participants will be followed for up to one (1) year after completion of Niraparib therapy.~Total participation is about three years."
62030877|NCT05516797|EXPERIMENTAL|Continuous Glucose Monitoring (CGM)|Participants in this arm will use the FreeStyle Libre 2 CGM sensor.
62030878|NCT05516797|NO_INTERVENTION|Blood Glucose Monitoring (BGM)|Participants in this arm will use the Precision Xtra fingerstick blood glucose meter throughout the study.
62030879|NCT06155968|ACTIVE_COMPARATOR|PCA group|: the PCA pump will be connected in a separate cannula. The pump contains 0.5 mg nalbuphine/ ml. the basal rate is 5ml/h and lock out time is 10 min.
62230072|NCT05714631|PLACEBO_COMPARATOR|Placebo group|
62230073|NCT05714631|EXPERIMENTAL|Intervention group|
62230074|NCT02787837||Abiraterone Acetate|Abiraterone Acetate 1000 mg/24h plus Prednisone 5mg/12h
62807054|NCT03009786||Elderly institutionalized subjects or outpatients|
62807055|NCT02005367|NO_INTERVENTION|DAP-CP|512 patients who elected to participate in the Drug Abuse Core Program alone (DAP-CP).
62230075|NCT01395979|EXPERIMENTAL|Cognitive Processing Therapy for Sexual Risk (CPT-SR)|The CPT-SR condition will be comprised of 10 individual therapy sessions fully integrating sexual risk reduction counseling into cognitive therapy for sexual abuse-related trauma.
62230076|NCT01395979|ACTIVE_COMPARATOR|Time-Matched Control (TMC)|The TMC will be comprised of sexual risk reduction counseling/education and supportive psychotherapy.
62807056|NCT02005367|EXPERIMENTAL|Natural Recovery-Horticulture|Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using one module per week with a staff facilitator and also pursued four hours of their hobby on each weekend day for up to 14 weeks.
62807057|NCT02005367|EXPERIMENTAL|Natural Recovery-Art/Music|Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using one module per week with a staff facilitator and also pursued four hours of their hobby on each weekend day for up to 14 weeks.
62230077|NCT01246934|NO_INTERVENTION|COMPLICATION|
62230078|NCT02799953|EXPERIMENTAL|Technology-based self-management model|Participants randomized to the intervention group will be given a tablet-based, interactive touch-screen self-monitoring system free of charge to perform disease self-monitoring in their homes.
62230079|NCT02799953|NO_INTERVENTION|Conventional self-management|Participants randomized to the usual care group will not be provided access to tablet computers but a 2-in-1 blood pressure and blood glucose monitor and a paper-based log book to perform conventional self-monitoring.
62230080|NCT01821716|EXPERIMENTAL|1|"Three concentrations of Dermatophagoides pteronyssinus allergen extract (10, 1, 0.1 mg/ml)~Positive control (10 mg/ml histamine dihydrochloride)~Negative control (glycerinated phenol saline solution)"
62230081|NCT05423626|EXPERIMENTAL|technologies of robotic mechanotherapy with FES|"In the course of this study, each patient will be given 10 sessions using the ExoAtlet I robotic simulator. The duration of the procedure, according to the patient's condition, is up to 1 hour (taking into account the time for reconfiguring the exoskeleton and positioning the patient). Measurement of pulse, pressure and saturation in the preparatory, main and final parts. The length of stay in an upright position depends on the patient's condition. In order to study and monitor the state of the cardiovascular system during the procedure, the system of remote monitoring of ECG, breathing and movement Accordis will be connected. If necessary, a pause is made to rest in a standing or sitting position. The transition to the formation of subsequent skills is recommended after mastering the skills of the previous procedure."
62807058|NCT05353595|EXPERIMENTAL|insect protein|0.38g insect protein / kg body mass with vanilla flavouring is provided. In the morning the participant is weighed and based on this weight an independent researcher prepares the protein drink.
62230082|NCT05423626|EXPERIMENTAL|biofeedback virtual reality technologies|"The group will have 10 classes on a simulator using the technology of virtual reality with biofeedback ReviVR. The total duration of the procedure is 30 minutes. Before the procedure, blood pressure and heart rate are measured, the size of the pneumatic cuffs on the feet is selected. After instructing the patient and selecting the virtual environment and the optimal speed of movement in VR, VR glasses are installed. Then rehabilitation exercises are carried out for 15 minutes. The patient moves in a virtual environment, receiving visual, auditory and tactile signals that form the correct walking pattern. At the end of the training, the VR glasses are dismantled. Then blood pressure and heart rate are measured and information about the state of health and sensations during the procedure is recorded."
62230083|NCT05423626|EXPERIMENTAL|Complex application of robotic mechanotherapy technologies with FES and VR with biological feedback|The group plans to carry out comprehensive rehabilitation with the use of robotic mechanotherapy and virtual reality with BOS. In this group, patients will first practice for 30 minutes on a VR simulator with a BFB (the duct is identical to group 2), then after 2 hours on an exoskeleton with a FES (the protocol of the lesson is identical to group 1)
62230084|NCT05423626|NO_INTERVENTION|Control group|control group with basic course of reabilitation
62422133|NCT06004401|ACTIVE_COMPARATOR|Penicillin negative contral group|（Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Amoxicillin 1g 2/day+Clarithromycin 500mg 2/day）\*14 days
62807059|NCT05353595|PLACEBO_COMPARATOR|placebo|participants receive the same amount of water (based on body weight) with vanilla flavouring. this drink is also prepared by an independent researcher.
62807060|NCT04759235||neoadjuvant chemoradiotherapy of local advanced ESCC|All the patients receive paclitaxel/cisplatin chemotherapy and concurrent radiotherapy. Each patient receives radiation of 41.4 Gy / 23 fractions complied by intensity modulated radiotherapy or volumetric modulated arc therapy. Patients without disease progression after nCRT will be scheduled for surgery and patients with disease progression (PD) will continue to receive chemoradiation or additional treatments. Surgery will be performed 6 to 8 weeks after completion of chemoradiotherapy.
62422134|NCT06004401|EXPERIMENTAL|Penicillin positive test group|（Vonopazan 20mg 2/day+Minocycline 100mg 2/day）\*14 days
62422135|NCT06004401|ACTIVE_COMPARATOR|Penicillin positive control group|（Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Metronidazole 0.4g 3/day+Clarithromycin 500mg 2/day）\*14 days
62807061|NCT06075979|EXPERIMENTAL|Lumbar disc herniation group|Patients undergoing surgery for lumbar disc herniation
62807062|NCT06075979|EXPERIMENTAL|Lumbar spinal stenosis group|Patients undergoing surgery for lumbar spinal stenosis
62230085|NCT05048433|EXPERIMENTAL|implementation strategy for active learning to promote physical activity|
62230086|NCT05048433|ACTIVE_COMPARATOR|Usual Implementation support|
62230087|NCT03991104|EXPERIMENTAL|SOX-based Chemoradiotherapy|IMRT is delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy over 5 weeks. Concurrent Oxaliplatin (3 levels for phase I: 110mg/m², 120 mg/m² and 130 mg/m², d1) and fixed dose of S-1 (80mg/ m², d1-14) are administered concurrently with IMRT, every 4 weeks. The recommended dose of Oxaliplatin are then further evaluated in the Phase II setting.
62422136|NCT02282007|NO_INTERVENTION|No Intervention:Control group|
62422137|NCT02282007|EXPERIMENTAL|Individual NPMP to the participants|This arm will receive NPMP for 6 months, individually adjusted to their problems.
62422138|NCT01816438||dysplasia or colorectal lesion|300 patients
62422139|NCT04057573|EXPERIMENTAL|Double-Blind Period: Ruxolitinib cream 1.5% BID|Participants applied ruxolitinib 1.5% cream twice daily (BID) for 24 weeks.
62422140|NCT04057573|PLACEBO_COMPARATOR|Double-Blind Period: Vehicle cream BID|Participants applied matching vehicle cream BID for 24 weeks.
62422141|NCT04057573|EXPERIMENTAL|Treatment-Extension Period: Ruxolitinib cream 1.5% BID|Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied ruxolitinib cream 1.5% BID during the Double-Blind Period continued to apply ruxolitinib cream 1.5% BID for an additional 28 weeks in the Treatment-Extension Period.
62807063|NCT00526292|EXPERIMENTAL|natural killer (NK) cells with salvage chemotherapy|This is a Phase II study, designed to determine the efficacy of natural killer (NK) cells isolated from HLA-haploidentical related donors when infused following a salvage chemotherapy regimen into patients who have relapsed or persistent leukemia following an allogeneic HLA-compatible HSCT and who are ineligible for a second HSCT.
62030880|NCT06155968|ACTIVE_COMPARATOR|QL block group|". Patients will receive bilateral ultrasonography (USG) guided block with 20 ml of 0.25 % bupivacaine on each side. The block is performed by anaesthesia consultants having experience of 5 years in ultrasound guided blocks. The procedure will be performed using aseptic technique (gown, gloves, facemask and protective sheath for the ultrasound probe).~The curvilinear probe (2 5 MHz, SonoSite Turbo M) is placed in the transverse axial plane just cranial to the iliac crest. The shamrock sign was visualised (viz., the transverse process (TP) of vertebra L4 is the stem, whereas the erector spinae muscle (ESM) posteriorly, quadratus lumborum (QL) muscle laterally and the psoas major (PM) muscle anteriorly represent the three leaves). The needle is introduced using an in plane technique from the posterior end of the transducer through the QL muscle. The target for injection is the fascial plane between the QL and PM muscles."
62030881|NCT05110196|EXPERIMENTAL|Capmatinib|Capmatinib (Rahika®) film-coated tablet administered as 400 mg orally twice daily on a continuous dosing schedule for 24 weeks.
62030882|NCT02268552|EXPERIMENTAL|branaplam|branaplam Treatment
62030883|NCT05146674|ACTIVE_COMPARATOR|Tadalafil group|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
62230088|NCT01327859|EXPERIMENTAL|Prior Donepezil 5mg|
62422142|NCT04057573|EXPERIMENTAL|Treatment-Extension Period: Vehicle cream to Ruxolitinib cream 1.5% BID|Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied vehicle cream BID during the Double-Blind Period applied ruxolitinib cream 1.5%m BID for 28 weeks in the Treatment-Extension Period.
62422143|NCT00003276|EXPERIMENTAL|irinotecan|Patients receive a 90 minute continuous infusion of irinotecan on days 1, 8, 15, and 22 for 4 weeks, followed by a 2 week rest period. Courses of treatment are repeated every 42 days. Patients continue treatment in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months for the next 4 years.
62422144|NCT00684216|ACTIVE_COMPARATOR|1|capecitabine followed by hormonal treatment
62422145|NCT00684216|ACTIVE_COMPARATOR|2|hormonal treatment followed by capecitabine
62422146|NCT05764837|EXPERIMENTAL|Intervention group|"Facilitation of the posterior chain was performed by foam rolling (BLACKROLL, standard hardness), where the left lower limb was rolled first, then the right lower limb and finally the spinal erectors. Rolling was performed with a sense of the highest intensity and at a high rolling speed, across the full length and width of the muscle with both cranial and caudal rolling directions. Facilitation was performed on each muscle group in the distoproximal direction, in the order of:~m. triceps surae, hamstrings, and m. gluteus maximus, with the proband attending to each muscle group for 30 s. Finally, bilateral facilitation of mm. erectores spinae in the lumbar and thoracic segments was performed, also for 30 s. The frequency of rolling was determined using a metronome at 1.5 Hz."
62422147|NCT05764837|NO_INTERVENTION|Control group|The control group of probands rested in a resting sitting position for 4 minutes after pre-tests, corresponding to the intervention period.
62807064|NCT04479085|EXPERIMENTAL|experimental group|The nursing attempt to organize the home environment for the experimental group will take 17 weeks. During this period, two home visits and two telephone calls will be made. During the first home visit, training will be organized to regulate the home environment. Temperature and humidity changes of the houses will be monitored during the operation with the heat-moisture meter device. Children in this group will be given an anti-allergic duvet cover. Home environment arrangements of mothers and changes in the quality of life of children will be examined at the beginning and end of the study. Children's symptoms will be monitored weekly for 17 weeks.
62807065|NCT04479085|NO_INTERVENTION|control group|No intervention will be made on the control group. The humidity and temperature changes in the home environment of the children in this group and their symptoms will be monitored on a weekly basis during the study.
62807066|NCT02495701||Patients|Patients having Hip arthroscopic surgery
62230089|NCT01327859|EXPERIMENTAL|Prior Donepezil 10mg|
62230090|NCT01327859|PLACEBO_COMPARATOR|Prior Placebo|
62230091|NCT00717067|EXPERIMENTAL|Healthy Subjects|Subjects with Normal Renal Function (Creatinine Clearance \> 80mL/min) (I) Maraviroc single dose, followed by (II) Maraviroc + Saquinavir/Ritonavir
62230092|NCT00717067|EXPERIMENTAL|Mild Renal Impairment|Subjects with Mild Renal Impairment (Creatinine Clearance \>50 and ≤80 mL/min)
62230093|NCT00717067|EXPERIMENTAL|Moderate Renal Impairment|Subjects with Moderate Renal Impairment (Creatinine Clearance ≥30 and ≤50 mL/min)
62230094|NCT00717067|EXPERIMENTAL|Severe Renal Impairment|Subjects with Severe Renal Impairment (Creatinine Clearance \<30 mL/min)
62230095|NCT00717067|EXPERIMENTAL|ESRD on Hemodialysis|Subjects with End Stage Renal Impairment receiving Hemodialysis(Creatinine Clearance \<30 mL/min) (I) Maraviroc single dose one hour following completion of hemodialysis, followed by (II) Maraviroc single dose three hours prior to start of hemodialysis
62230096|NCT05720988|ACTIVE_COMPARATOR|Cohort I (tagraxofusp-erzs)|Patients receive tagraxofusp-erzs IV QD over 15 minutes on days 1-5. Treatment repeats every 28-42 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
62422148|NCT05974293|EXPERIMENTAL|Nabiximols, then Placebo|During Period 1, participants receive daily nabiximols spray, delivered by a pump action oromucosal spray. The first 2 weeks of Period 1 are the titration period with participants following pre-specified uptitration schedule, until they reach their individualized optimum daily dosage, with a maximum of 12 daily sprays. Following these 2 weeks, they continue the optimum dose for 4 weeks. Then, they undergo a 2-week washout period, and then, enter Period 2 where they receive the matched placebo spray and again undergo a 2-week titration period, and a 4-week consistent daily dosage period.
62807067|NCT05809921||Single-IVT strategy (SIS) cohort|The SIS cohort included patients with MeVO strokes who received a single conventional alteplase IVT (IVT-1).
62422149|NCT05974293|EXPERIMENTAL|Placebo, then Nabiximols|During Period 1, participants receive daily matched placebo spray, delivered by a pump action oromucosal spray. The first 2 weeks of Period 1 are the titration period with participants following pre-specified uptitration schedule, until they reach their individualized optimum daily dosage, with a maximum of 12 daily sprays. Following these 2 weeks, they continue the optimum dose for 4 weeks. Then, they undergo a 2-week washout period, and then, enter Period 2 where they receive the active nabiximols spray and again undergo a 2-week titration period, and a 4-week consistent daily dosage period.
62422150|NCT02554825|EXPERIMENTAL|Healthy Futures|
62030884|NCT05146674|NO_INTERVENTION|Control group|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
62030885|NCT02509221||Less than 30 minutes|
62422151|NCT02554825|OTHER|Control|
62422152|NCT04871724|EXPERIMENTAL|EDP-938 and Fluconazole interaction|
62807068|NCT05809921||Dual-IVT strategy (DIS) cohort|"The DIS cohort included patients with alteplase-treated MeVO strokes for whom a repeat MRI (MRI-2) was planned 1-2h after alteplase IVT (IVT-1) to discuss a possible complementary IVT with tenecteplase (TNK-IVT-2).~Patients could be in the following situations: already recanalized at 1-2h post-alteplase IVT-1, persistent occlusion treated with TNK-IVT-2 or persistent occlusion but additional IVT contraindicated according to the study protocol."
62422153|NCT03966196|OTHER|Healthy Volunteers|oxymetry and finger pressure in Healthy subjects
62422154|NCT03966196|EXPERIMENTAL|COPD patients|oxymetry and finger pressure in COPD patients
62422155|NCT00265863|EXPERIMENTAL|Patients with Malignant Ascites|Patients meeting protocol criteria enrolled with malignant ascites.
62030886|NCT02509221||30-60 minutes|
62030887|NCT02509221||More than 60 minutes|
62030888|NCT06669273|EXPERIMENTAL|Group 1 : - Label : suspicion of prostate cancer|"Patients will be included:~* aged over 18~* with suspected prostate cancer identified by an increase in blood PSA concentration~* naïve to chemotherapy, radiotherapy or hormonal therapy~* affiliated to a Social Security system~* able to give informed consent to participate in research~* understanding and reading French well"
62030889|NCT01602536|EXPERIMENTAL|Twitter|Experimental participants are assigned a 20-person twitter quit-smoking group to interact with, are instructed to use Twitter-enabled interactive peer messaging,and are sent daily messages to encourage interaction. The baseline intervention 'smoking cessation aides' is also provided.
62030890|NCT01602536|ACTIVE_COMPARATOR|Control|Control participants are not assigned to a twitter group. The baseline intervention 'smoking cessation aides' is also provided.
62030891|NCT05436236||Control|People who self-report that they do not use cannabis.
62030892|NCT05436236||Cannabis|People who self-report that they use cannabis.
62030893|NCT06634576|EXPERIMENTAL|Health population|Used custom-made ocular motor system to adjust the neck postures of participants, to examine the reliability of data and compared the pursuit ability in three different neck motion planes, seven different neck postures.
62422156|NCT04221217|EXPERIMENTAL|MND-2119 2g|MND-2119 2 g, orally, once daily after breakfast for 52 weeks.
62422157|NCT04221217|EXPERIMENTAL|MND-2119 4g|MND-2119 4 g, orally, once daily after breakfast for 52 weeks.
62422158|NCT02742818|OTHER|Upper body blanket, Bair Hugger|Patients undergoing EVAR and LEA will use this type of warming blanket.
62422159|NCT02742818|OTHER|Underbody blanket, Bair Hugger|Patients undergoing EVAR and LEA will use this type of warming blanket.
62422160|NCT03870737|EXPERIMENTAL|Active TNS|Participants who previously underwent screening and determination of eligibility in a double-blind sham-controlled trial of TNS for ADHD, and randomized to sham, will be offered upon unblinding at the end of the 5-week controlled trial to receive 4-weeks open treatment with the active TNS condition.
62030894|NCT02877290|EXPERIMENTAL|cycling test first with NIV, then without NIV|patients in this arm will perform their first constant work rate test while using NIV and the second constant work rate test without NIV
62030895|NCT02877290|EXPERIMENTAL|cycling test first without NIV, then with NIV|patients in this arm will perform their first constant work rate test without NIV and the second constant work rate test with NIV
62030896|NCT05178082|EXPERIMENTAL|VP group|Participants are linked to online informative videos on chronic pain produced by the Multidisciplinary Pain Centre (Rigshospitalet, DK). Ten video-modules of 2-6 minutes each. 1. Chronic pain development in Denmark, treatment offered at the Centre. 2. How chronic pain can affect life in all its facets. Chronic complex pain explained. 3. Psychological models used to describe affected life domains. The role of dysfunctional thoughts on e.g. anxiety. 4. The connection between pain and factors that can reduce energy level. 5. Pain interference in the familiar dynamic and relations. 6. Information about how to balance activity and rest - and on daily breathing exercises. 7. The Rules and opportunities when health challenges working life e.g. work relocation. 8. The importance of healthy habits regarding eating, sleep, and self-treating. 9. Selection of medication according to the patient's quality of life. 10. Expected side effects of medication and on measures to counteract side effects.
62422161|NCT06542705|EXPERIMENTAL|Internal Brace|Patients will undergo ACL Reconstruction (ACLR) with an internal brace. Patients will undergo standard perioperative protocol and be followed at typical time points after surgery (2 weeks, 6 weeks, 3 months, 6 months, 12 months). At 12 months postoperative, a follow-up MRI will be obtained to evaluate healing and at 12 months and 24 months follow up KT-1000 testing will be conducted.
62422162|NCT06542705|ACTIVE_COMPARATOR|Standard ACLR|Patients will undergo ACLR without an internal brace. Patients will undergo standard perioperative protocol and be followed at typical time points after surgery (2 weeks, 6 weeks, 3 months, 6 months, 12 months). At 12 months postoperative, a follow-up MRI will be obtained to evaluate healing and at 12 months and 24 months follow up KT-1000 testing will be conducted.
62030897|NCT05178082|EXPERIMENTAL|ER group|Participants will attend a single-session, 2-hour online group class. The program has two main components: didactics and skills acquisition. Participants will learn about pain self-regulation and self-management. The program content includes strategies to empower individuals with chronic non-cancer pain as following: 1) the identification of unhelpful thought patterns in the moment, 2) regulation of cognition and emotion, including thought reframing and mindset, 3) how to decrease physiological hyperarousal using relaxation techniques (binaural relaxation audio file for diaphragmatic breathing and progressive muscle relaxation), and 4) establishing self-soothing actions. At the end of the class, participants will develop a self-tailored plan for implementing these skills/strategies in daily life to use behaviors that modulate attention and counteract helplessness (Darnall et al 2014). The online class will be delivered by a nurse certified in the ER.
62230097|NCT05720988|EXPERIMENTAL|Cohort II (azacitidine, tagraxofusp-erzs)|Patients receive azacitidine SC daily on days 1-5 and tagraxofusp-erzs IV QD over 15 minutes on days 8-12. Treatment repeats every 28-42 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
62230098|NCT01935180|NO_INTERVENTION|Standard colonoscopy|
62030898|NCT05178082|NO_INTERVENTION|Control group|Participants in the control group will not receive any of the interventions. This project will not interfere with any current or future pain treatment. After the end of collecting data, the Multidisciplinary Pain Centre will eventually make available the videos that compose VP to all patients.
62030899|NCT06026293||subjects that participates to a previous clinical trial|
62422163|NCT02866123|EXPERIMENTAL|patient with insertion of an NGT|
62422164|NCT05855525|EXPERIMENTAL|Real-time fMRI|Participants will repeatedly and intermittently report the content of their ongoing, self-generated experiences based on an experience-sampling protocol in which self-report ratings will be triggered based on real-time analysis of the participant's current brain state. The protocol will be conducted while participants are undergoing MRI scanning.
62422165|NCT02256059||Plate osteosynthesis|Patients with fracture of the lateral clavicle and indication for surgical treatment
62422166|NCT01887860|EXPERIMENTAL|Cetaphil Daily Facial Moisturizer SPF50|All subjects receive Cetaphil Daily Facial Moisturizer SPF 50
62422167|NCT02367729|EXPERIMENTAL|Neurostimulator|Auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
62422168|NCT02367729|SHAM_COMPARATOR|Sham Neurostimulator|Inactive auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
62422169|NCT05926544|EXPERIMENTAL|Standard implementation (Stage 1)|Participants begin with the standard implementation interventions for 8-16 weeks, depending on random block assignment.
62422170|NCT05926544|EXPERIMENTAL|Virtual facilitation (Stage 2)|After completing the standard implementation, participants then complete the virtual facilitation intervention for 8-16 weeks, depending on random block assignment.
62422171|NCT03165331|OTHER|Intervention group|The intervention group will go through the intervention programme (Ung Face IT) after T1 and randomisation. Programme takes 7 weeks to complete + Treatment as usual (local health care services). Questionnaires after the 7 weeks (T2) and after three months (T3) and 6 months (T4).
62422172|NCT03165331|OTHER|Control group|Treatment as usual for three months after T1 and randomisation, with local health care support if needed. Questionnaires at T2 and T3 before participants are given access to the intervention (Ung Face IT) after three months. Questionnaire at T4 (post-intervention).
62422173|NCT02476500|ACTIVE_COMPARATOR|Experts|Surgically experienced gynecologists with a personal history of at least 30 LLETZ procedures will undergo a Video Training and subsequently will perform LLETZ on a Training model. Their performance will be scored by using a 23-item OSATS scheme. The exact time Frame for the OSATS-assessment is within 1 hour after the Video Training.
62030900|NCT04674358|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%) administered QID over two consecutive days.|
62030901|NCT04674358|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution administered over two consecutive days.|
62030902|NCT05996003|EXPERIMENTAL|NS-089/NCNP-02|"Experimental: NS-089/NCNP-02~NS-089/NCNP-02 solution for infusion (Cohort 1)~NS-089/NCNP-02 solution for infusion (Cohort 2)"
62230099|NCT01935180|ACTIVE_COMPARATOR|Cap assisted colonoscopy|A transparent cap will be affixed to tip of the high-definition wide angle colonoscope.
62230100|NCT02307760|ACTIVE_COMPARATOR|Study Human Milk Fortifier A|Acidified processing method.
62230101|NCT02307760|EXPERIMENTAL|Study Human Milk Fortifier B|Non-acidified processing method.
62422174|NCT02476500|EXPERIMENTAL|Novices|Medical students with no previous experience in gynecological surgery will undergo a Video Training and subsequently will perform LLETZ on a Training model. Their performance will be scored by using a 23-item OSATS scheme. The exact time Frame for the OSATS-assessment is within 1 hour after the Video Training.
62422175|NCT06433986|EXPERIMENTAL|Modified Coronally Advanced Tunnel (MCAT)Technique|Scaling and root planing will be performed and after resolution of gingival inflammation, root coverage procedure will be done with Volume Stable Collagen Matrix(VCMX) using MCAT.
62422176|NCT06433986|ACTIVE_COMPARATOR|Vestibular Incision Subperiosteal Tunnel Access (VISTA)Technique|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with Volume Stable Collagen Matrix(VCMX) using VISTA.
62422177|NCT03649256||Conventional suture|closure of uterine incision with conventional suture (Vicryl, Ethicon)
62422178|NCT03649256||Barbed suture|closure of uterine incision with barbed suture (Stratafix, Ethicon)
62422179|NCT06583148|EXPERIMENTAL|Group I (smoke-free home program)|Participants receive the smoke-free home program, consisting of mailed educational information about smoke-free homes at enrollment and in weeks 4 and 6, and attend one coaching call in week 2.
62230102|NCT03523260|ACTIVE_COMPARATOR|Tunneled dialysis Split-tip catheter|High-flow tunneled Split-tip catheter for hemodialysis will be inserted by standard interventional technique
62230103|NCT03523260|ACTIVE_COMPARATOR|Tunneled dialysis Step-tip catheter|High-flow tunneled Step-tip catheter for hemodialysis will be inserted by standard interventional technique
62230104|NCT03523260|ACTIVE_COMPARATOR|Tunneled dialysis Symmetric tip catheter|High-flow tunneled Symmetric tip catheter for hemodialysis will be inserted by standard interventional technique
62230105|NCT03143816|ACTIVE_COMPARATOR|Technosphere insulin (TI, Afrezza) -Treatment arm|Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG ( post prandial blood glucose)
62230106|NCT03143816|NO_INTERVENTION|Insulin Aspart ( Novolog) -Control arm|Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals.
62230107|NCT03438786|EXPERIMENTAL|group A|Patients undergoing trans-inguinal pre-peritoneal (TIPP) hernioplasty
62230108|NCT03438786|EXPERIMENTAL|group B|Patients undergoing lichtnestein's hernioplasty
62230109|NCT04997733|EXPERIMENTAL|Fecal microbiota|Patients receiving the fecal microbiota transplantation (FMT) in 3 times after inclusion and randomisation (endoscopic and oral)
62230110|NCT04997733|SHAM_COMPARATOR|Sham-transplantation|Patients receiving the sham-transplantation in 3 times after inclusion and randomisation (endoscopic and oral)
62230111|NCT04541537|EXPERIMENTAL|Sorbstar®|Odour sampling : rub hands with Sorbstars® before and post-surgery
62230112|NCT04541537|EXPERIMENTAL|Dog Detection|Odour sampling :sleep over a night with a compress on the affected breast before and after surgery
62230113|NCT01139060|EXPERIMENTAL|Intervention Group|18-month organized treatment program focused on outreach and engagement for chronic or recurrent depression
62230114|NCT01139060|NO_INTERVENTION|Usual Care|
62230115|NCT05030987|EXPERIMENTAL|RDN|Renal Denervation
62230116|NCT05030987|SHAM_COMPARATOR|Sham|Sham Procedure
62230117|NCT01490671|EXPERIMENTAL|Group 1a (tenofovir gel)|Group 1a will include women with a gestational age range of 36 0/7 to 37 6/7 weeks; they will receive 1% tenofovir gel
62230118|NCT01490671|PLACEBO_COMPARATOR|Group 1b (placebo gel)|Group 1b will include women with a gestational age range of 36 0/7 to 37 6/7 weeks; they will receive placebo gel.
62230119|NCT01490671|EXPERIMENTAL|Group 2a (tenofovir gel)|Group 2a will include women with a gestational age range of 28 0/7 to 32 6/7 weeks; they will receive 1% tenofovir gel.
62230120|NCT01490671|PLACEBO_COMPARATOR|Group 2b (placebo gel)|Group 2b will include women with a gestational age range of 28 0/7 to 32 6/7 weeks; they will receive placebo gel.
62230121|NCT01490671|EXPERIMENTAL|Group 3a (tenofovir gel)|Group 3a will include women with a gestational age range of 20 0/7 to 24 6/7 weeks; they will receive 1% tenofovir gel.
62807069|NCT01414894|ACTIVE_COMPARATOR|Normal Fluids & Normal Blood Pressure|Patients are treated with conventional fluid replacement (Normovolemia) and maintenance of blood pressure in a normal range (Conventional Blood Pressure).
62230122|NCT01490671|PLACEBO_COMPARATOR|Group 3b (placebo gel)|Group 3b will include women with a gestational age range of 20 0/7 to 24 6/7 weeks; they will receive placebo gel.
62230123|NCT01490671|EXPERIMENTAL|Group 4a (tenofovir gel)|Group 4a will include women with a gestational age range of 12 0/7 to 16 6/7 weeks; they will receive 1% tenofovir gel.
62230124|NCT01490671|PLACEBO_COMPARATOR|Group 4b (placebo gel)|Group 4b will include women with a gestational age range of 12 0/7 to 16 6/7 weeks; they will receive placebo gel.
62230125|NCT00562211|EXPERIMENTAL|1|
62230126|NCT00562211|ACTIVE_COMPARATOR|2|
62230127|NCT01110876|EXPERIMENTAL|Phase I Group 1: Vorinostat + Erlotinib + Temozolomide|"Phase I 3-Drug Combination Vorinostat with Erlotinib + Temozolomide~Starting doses Vorinostat 200 mg orally twice daily on Days 1-7 and 15-21 of every cycle; Erlotinib 200 mg orally once daily on Days 1-21; Temozolomide 125 mg/m\^2 orally once daily on Days 1-7 and 15-21."
62230128|NCT01110876|EXPERIMENTAL|Phase I Group 2: Vorinostat + Erlotinib|"This Phase I arm to be activated only after completion of Part A of the Phase II trial of the 3-Drug combination. If part A of the Phase II trial shows lack of efficacy, trial will be terminated.~Vorinostat orally twice daily, Days 1-14; and Erlotinib orally once daily Days 1-21 of every cycle."
62807070|NCT01414894|ACTIVE_COMPARATOR|Increased Fluids & Normal Blood Pressure|Patients are treated with fluids to achieve higher volume expansion (Hypervolemia) and maintenance of blood pressure in a normal range (Conventional Blood Pressure)
62807071|NCT01414894|ACTIVE_COMPARATOR|Normal Fluids & Higher Blood Pressure|Patients are treated with conventional fluid replacement (Normovolemia) and maintenance of blood pressure in a higher range (Augmented Blood Pressure).
62807072|NCT01414894|ACTIVE_COMPARATOR|Increased Fluids & Higher Blood Pressure|Patients are treated with fluids to achieve higher volume expansion (Hypervolemia) and maintenance of blood pressure in a higher range (Augmented Blood Pressure).
62230129|NCT01110876|EXPERIMENTAL|Phase II Part A 3-Drug Combination|"Vorinostat+Erlotinib+Temozolomide where drug dosing based on the MTD identified in the Phase I portion of the study.~Vorinostat 200 mg orally twice daily on Days 1-7 and 15-21 of every cycle; Erlotinib 200 mg orally once daily on Days 1-21; Temozolomide 100 mg/m\^2 orally once daily on Days 1-7 and 15-21."
62230130|NCT01110876|EXPERIMENTAL|Phase II Part B 2-Drug Combination|"This Phase II Part B arm to be activated only after completion of Part A of the Phase I and II Part A trial of the 3-Drug combination. If part A of the Phase II trial shows lack of efficacy, trial will be terminated.~Vorinostat orally twice daily, Days 1-14; and Erlotinib orally once daily Days 1-21 of every cycle."
62230131|NCT03286322|EXPERIMENTAL|manual therapy cervical spine|
62230132|NCT03286322|SHAM_COMPARATOR|control group|
62230133|NCT01431222|ACTIVE_COMPARATOR|percutaneous treatment|
62230134|NCT01431222|NO_INTERVENTION|optimal medical treatment|
62230135|NCT03728322|EXPERIMENTAL|iHSCs treatment group|
62230136|NCT03425071||Healthy volunteers|"Healthy volunteers - subjects without exposure to tacrolimus. Blood samples from these subjects will be used in in vitro experiments."
62230137|NCT03425071||kidney transplant (KTx) months 1-2|"Kidney transplant recipients recruited during the months 1 to 2 of follow up after kidney transplantation surgery. These are subjects expected to be exposed to high blood levels of tacrolimus. Blood samples from these subjects will be used in ex vivo experiments."
62807073|NCT04699890||preserved ejection fraction|Patients with a preserved ejection fraction (HF / FEp)
62807074|NCT04699890||reduced ejection fraction|Patients with a reduced ejection fraction (HF / FEr)
62030903|NCT06470217|EXPERIMENTAL|Neoadjuvant treatment arm|tirilizumab administered by intravenous drip (no prophylaxis required) at a fixed dose of 200 mg. each infusion was given for 30 min (not less than 20 min and not more than 60 min) every 3 weeks, and 3 preoperative cycles of albumin-bound paclitaxel 260 mg/m2 and cisplatin 75 mg/m2 on d1, with 1 cycle every 21 days; 3 preoperative Cycles. After neoadjuvant therapy, patients underwent surgery and were stratified according to pathological conditions after surgery; if significant pathological remission (MPR) was achieved, 6 cycles of adjuvant therapy with tirilizumab monotherapy (concurrent radiochemotherapy was available for those with high-risk factors) were performed; if MPR was not achieved, concurrent radiochemotherapy was performed.
62591808|NCT03559049|EXPERIMENTAL|Rucaparib and Pembrolizumab Maintenance|"All patients will receive induction therapy with Pembrolizumab (200mg IV on day 1 of every 21 days), Pemetrexed (500mg/m\^2 IV on day 1 of every 21 days), and Carboplatin (AUC5 IV on day 1 of every 21 days).~This will be followed by maintenance therapy with Pembrolizumab (200mg IV on day 1 of every 21 days) and Rucaparib (600mg PO BID days 1-21 of each 21 day cycle)."
62591809|NCT02064322||SImmetry Implant|Subjects who are indicated for the SImmetry Device according to the approved product labeling and inclusion/exclusion criteria will receive a SImmetry implant.
62591810|NCT03727126|EXPERIMENTAL|Robotic esophagectomy|Esophagectomy performed for esophageal cancer using the da Vinci robotic surgical system
62807075|NCT04699890||without heart failure|Patient without heart failure
62807076|NCT03050801|EXPERIMENTAL|Parietal Cortex rTMS stimulation - 1 day|Experiment 1
62230138|NCT03425071||KTx months 4-5|"Kidney transplant recipients recruited during the months 4 to 5 of follow up after kidney transplantation surgery. These are subjects expected to be exposed to standard blood levels of tacrolimus. Blood samples from these subjects will be used in ex vivo experiments."
62030904|NCT06470217|ACTIVE_COMPARATOR|Standard treatment arm|patients underwent direct surgical treatment, with postoperative radiotherapy or radiochemotherapy depending on the presence or absence of histological or pathological high-risk factors.
62030905|NCT04357028|EXPERIMENTAL|MMR vaccine|0.5 ml subcutaneous of MMR vaccine will be injected in posterior triceps aspect of upper arm
62030906|NCT04357028|PLACEBO_COMPARATOR|Control|0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
62030907|NCT03274843|EXPERIMENTAL|Patient with stroke|
62030908|NCT02818881|EXPERIMENTAL|High-speed then low-speed yoga|Subjects received a single session of High-speed yoga and within one week a single session of Low-speed yoga
62030909|NCT02818881|EXPERIMENTAL|Low-speed then high-speed yoga|Subjects received a single session of Low-speed yoga and within one week a single session of High-speed yoga
62030910|NCT00108225|ACTIVE_COMPARATOR|Arm 1|30% carbohydrate, 30% protein, 40% fat
62230139|NCT03030703|EXPERIMENTAL|350 mg phytic acid|350 mg phytic acid (inositol hexaphosphate) at week 0 (before supplementation) and at week 4 (after supplementation)
62230140|NCT04942730|EXPERIMENTAL|FluBuBe|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days; Days -7 through -6: Bendamustine 130 mg/m2 iv x 2 days; Days -5 through -3: Busulfan 1 mg/kg po qid x 3 days; Days +3 through +4: Cyclophosphamide 50 mg/kg iv x 2 days; Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days; Days +5 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration
62591811|NCT03727126|ACTIVE_COMPARATOR|Thoracolaparoscopic esophagectomy|Esophagectomy performed for esophageal cancer using conventional thoracoscopic and laparoscopic techniques
62591812|NCT00464516|EXPERIMENTAL|estetrol|
62591813|NCT00464516|PLACEBO_COMPARATOR|placebo|
62591814|NCT03435952|EXPERIMENTAL|Pembrolizumab + Clostridium novyi-NT|"Participants receive Pembrolizumab by vein over about 30 minutes on Day 0 and then every 3 weeks for up to 12 months.~Clostridium novyi-NT injected into the tumor on Day 8.~Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT"
62030911|NCT00108225|PLACEBO_COMPARATOR|Arm 2|55% carbohydrate, 15% protein, 30% fat
62030912|NCT02921243||Stool Sample Collection|
62030913|NCT02921243||Prebiotic|
62030914|NCT04586101|EXPERIMENTAL|Training intervention|
62030915|NCT04586101|NO_INTERVENTION|Control interverntion|
62030916|NCT04376021|EXPERIMENTAL|Physical Contact|Baby carrier (and education) provided to mother to increase physical contact with baby
62030917|NCT04376021|NO_INTERVENTION|Control|No intervention
62230141|NCT04424797|EXPERIMENTAL|Prone Positioning|Prone positioning
62230142|NCT04424797|OTHER|Supine Positioning|Supine Positioning
62230143|NCT01485354|EXPERIMENTAL|Armeo Spring training|Subjects will participate in upper extremity rehabilitation using the Armeo Spring system for a period of 6 weeks. The intervention will consist of 18 training sessions (60 minute sessions, 3 times a week).
62230144|NCT00666679|ACTIVE_COMPARATOR|1|mometasone
62591815|NCT04403646|EXPERIMENTAL|TREATED|"Participants will receive a supply of 28 -- 390 mg ARBOX capsules for 14 days. Patients will be supplemented with 2 capsules of ARBOX per day and standard therapy.~Standard treatment includes: Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas that could undergo to modifications). In addition, if necessary: supplemental O2, non-invasive ventilation, antibiotic therapy."
62807077|NCT03050801|EXPERIMENTAL|Parietal Cortex rTMS stimulation - 3 days|Experiment 1
62807078|NCT03050801|EXPERIMENTAL|Parietal Cortex rTMS stimulation - 4 days|Experiment 1
62807079|NCT03050801|EXPERIMENTAL|Experiment 2 - Parietal Cortex rTMS stimulation - 3 days|Experiment 2
62807080|NCT03050801|EXPERIMENTAL|Experiment 2 - Vertex rTMS stimulation - 3 days|Experiment 2
62807081|NCT03050801|EXPERIMENTAL|Experiment 2 - Prefrontal Cortex rTMS stimulation - 3 days|Experiment 2
62807082|NCT02744092|ACTIVE_COMPARATOR|Randomized Arm 1 (DOACs)|Randomized Arm 1 will get anticoagulation therapy with a Direct Oral AntiCoagulant (DOAC). There are four FDA-approved DOAC drugs that may be used for this study: Rivaroxaban, Apixaban, Edoxaban, or Dabigatran. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.
62030918|NCT05086367|ACTIVE_COMPARATOR|Routine Physical Therapy|This group received only routine physical therapy. This includes thermotherapy, trans-cutaneous electrical nerve stimulation, neck isometrics and stretching that includes 12 sessions (3 sessions per week)
62030919|NCT05086367|EXPERIMENTAL|Breathing Exercises along with routine physical therapy|This group received routine physical therapy along with breathing exercises. This includes thermotherapy, trans-cutaneous electrical nerve stimulation, neck isometrics and stretching that includes 12 sessions (3 sessions per week).
62030920|NCT03618238|EXPERIMENTAL|Anlotinib|patients will be given anlotinib 12 mg daily for continus 14 days every 21 days until disease progression.
62230145|NCT00666679|PLACEBO_COMPARATOR|2|montelukast followed by placebo; or placebo followed by montelukast.
62230146|NCT02037841|EXPERIMENTAL|Nursing-driven Asthma protocol|Children randomized to the intervention group will have their β2-agonist medication weaned by the nurse, according to the steps outlined in the clinical pathway. The nurse will ensure that the patient's family is booked for asthma teaching, and will also remind the physicians to fill out an asthma action plan on discharge. Detailed information as to when to contact physicians in the event of an acute deterioration of the patient is included in the clinical pathway.
62230147|NCT02037841|NO_INTERVENTION|Physician-driven asthma management|Patients in the control group will continue receiving the current standard of care, which consists of physicians weaning the β2-agonist medication when called to the bedside by the nurse or when deemed necessary by a physician
62230148|NCT00676377|EXPERIMENTAL|1|Neostigmine
62230149|NCT00676377|PLACEBO_COMPARATOR|2|Placebo
62230150|NCT03412305|ACTIVE_COMPARATOR|Amoxicillin oral tablets|2 g amoxicillin tablets orally 1 hour before implant placement
62230151|NCT03412305|PLACEBO_COMPARATOR|Placebo|Placebo tablets orally 1 hour before implant placement
62230152|NCT02125708|OTHER|OvulaRing®|Twenty patients with verified PPROM between gestation week 22 and 27 should be included. After gynecological and physical examination within verification of PPROM women will be informed about the study and invited to participate in this study. Subsequently informed consent will be obtained and the OvulaRing® placed into the vaginal fornix.
62230153|NCT04278001|OTHER|Ambulatory blood pressure measurement|Dual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207).
62422180|NCT06583148|ACTIVE_COMPARATOR|Group II (waitlist control)|Participants receive usual care on study. Participants may optionally receive the smoke-free home program following the 6 months follow-up.
62422181|NCT05981612||NSSI|
62422182|NCT05981612||HC|
62230154|NCT04012138|EXPERIMENTAL|Salbutamol|Patients in this experimental group will receive : 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air);
62422183|NCT05486663|EXPERIMENTAL|Tactile/kinesthetic Group|After the stability of the general health status of the babies is ensured and the oral feeding decision is made, tactile / kinesthetic application will be made for 14 days, 2 times a day, for 15 minutes just before feeding.
62422184|NCT05486663|NO_INTERVENTION|Control Group|Tactile / kinesthetic applications will not be applied to the control group and these babies will be followed for 14 days and at discharge after the stability of the general health status of the babies is ensured and the oral feeding decision is made.
62807083|NCT02744092|ACTIVE_COMPARATOR|Randomized Arm 2 (LMWH)|Randomized Arm 2 will get anticoagulation therapy with low molecular weight heparin (LMWH) with or without a transition to warfarin. There are three FDA-approved LMWH drugs that may be used for this study: Dalteparin, Enoxaparin, or Fondaparinux. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.
62422185|NCT05070689|EXPERIMENTAL|Single Group|A. Chohan Continuous squeezing Suture (ACCSS): An obstetrical procedure using half circle 40mm round body polyglactin 910 suture # 1 (Vicryl plus by Ethicon ®) for control of haemorrhage from the lower segment, in patients with Placenta Accreta for the prevention of hysterectomy at caesarean section
62422186|NCT05110144|EXPERIMENTAL|Duloxetine and Placebo|Subjects will receive 30mg of Duloxetine for blinded period 1 (first 4 week treatment period) and 30mg of Duloxetine plus 30mg Placebo for blinded period 2 (additional 4 week treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
62807084|NCT02744092|ACTIVE_COMPARATOR|Preference Cohort 1 (DOACs)|"If an eligible participant is offered randomization and declines randomization, then a limited number of participants (up to N=190) will be allowed to enroll in the Preference Cohort. In this case, the treating physician and patient choose Arm 1 or Arm 2 (non-randomized).~Preference cohort: Non-randomized Arm 1 will get anticoagulation therapy with a Direct Oral AntiCoagulant (DOAC)."
62030921|NCT06439563|EXPERIMENTAL|JP-1366 10 mg|
62030922|NCT06439563|ACTIVE_COMPARATOR|Lanston Capsule 15 mg|
62030923|NCT05970861|EXPERIMENTAL|Main Group|Patients who had suffered from COVID-19 in the six months before the start of the study. Patients will receive Saumal (freeze-dried mare milk) for four weeks.
62030924|NCT05970861|NO_INTERVENTION|Control Group|Patients who had suffered from COVID-19 in the six months before the start of the study. There will be no intervention.
62230155|NCT04012138|ACTIVE_COMPARATOR|Insuline + dextrose|Patients in the experimental group will receive : 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period
62230156|NCT04012138|EXPERIMENTAL|Insuline + Dextrose + Salbutamol|"Patients in the experimental group will receive either:~1. 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~2. 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol."
62230157|NCT05703074|OTHER|MBRT and NR|Psychological therapy and dietary supplement
62230158|NCT05703074|OTHER|MBRT and placebo|Psychological therapy and placebo dietary supplement
62230159|NCT05703074|OTHER|Care as usual and NR|No psychological therapy (information only) and dietary supplement
62230160|NCT05703074|OTHER|Care as usual and placebo|No psychological therapy (information only) and placebo dietary supplement
62422187|NCT05110144|EXPERIMENTAL|Duloxetine dose escalation|Subjects will receive 30mg of Duloxetine for blinded period 1 (first 4 week treatment period) and 60mg of Duloxetine for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
62030925|NCT05073133|EXPERIMENTAL|OAV101|A single IV infusion at 1.1e14 vector genome (vg)/kg over approximately 60 minutes
62230161|NCT03613285|ACTIVE_COMPARATOR|conventional brackets|Conventional brackets with Mac Laughin bennette Trevisi (MBT) prescription
62230162|NCT03613285|ACTIVE_COMPARATOR|Smart clip passive self ligating brackets|Smart clip passive self ligating brackets with Mac Laughin bennette Trevisi (MBT) prescription
62230163|NCT03613285|ACTIVE_COMPARATOR|Empower active self ligating brackets|Empower active self ligating brackets with Mac Laughin bennette Trevisi (MBT) prescription
62230164|NCT03933930|EXPERIMENTAL|Lactate-directed therapy|
62230165|NCT03933930|EXPERIMENTAL|Goal-directed therapy|
62807085|NCT02744092|ACTIVE_COMPARATOR|Preference Cohort 2 (LMWH)|"If an eligible participant is offered randomization and declines randomization, then a limited number of participants (up to N=190) will be allowed to enroll in the Preference Cohort. In this case, the treating physician and patient choose Arm 1 or Arm 2 (non-randomized).~Preference cohort: Non-randomized Arm 2 will get anticoagulation therapy with Low Molecular Weight Heparin (LMWH) with or without a transition to warfarin."
62807086|NCT03477734|EXPERIMENTAL|CS1 & heart monitor - AF patients|Males and females diagnosed with atrial fibrillation will be fitted with the CardiacSense1 and Holter heart monitor for 24-48 hours while going about daily activities, results shall be compared and analysed
62807087|NCT03477734|ACTIVE_COMPARATOR|CS1 & heart monitor -Healthy volunteers|Males and females not diagnosed with atrial fibrillation will be fitted with the CardiacSense1 and Holter heart monitor for 24-48 hours while going about daily activities, results shall be compared and analysed
62807088|NCT02859246|OTHER|Mucinex|600 mg of Mucinex 2 times a day.
62807089|NCT04290039|ACTIVE_COMPARATOR|Low Dose Sublingual|"Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP. Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in dropper bottles containing 2 mL.~Each bottle will only be used to administer a single dose, to a single subject."
62807090|NCT04290039|ACTIVE_COMPARATOR|High Dose Sublingual|"Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP. Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in dropper bottles containing 2 mL.~Each bottle will only be used to administer a single dose, to a single subject."
62030926|NCT02485470|EXPERIMENTAL|MPACT|A 7-week (7 weeks x 3 sessions per week), on site, functional resistance training (FRT) as well as a walking program concurrent with CCRT will be followed by a 7-week post-CCRT home program. The protocol follows American College of Sports Medicine (ACSM) prescription guidelines for cancer patients.
62230166|NCT04388774|EXPERIMENTAL|Ketamine|Total dose administration or 0.5 mg/kg of ketamine
62030927|NCT02485470|NO_INTERVENTION|Usual Care|
62030928|NCT02010060|NO_INTERVENTION|Control|The goal of this group is to maintain their current lifestyle habits during the intervention. participants are asked to make no conscious changes to their physical activity or dietary habits.
62230167|NCT06485362||healthy patients|"Subjects healthy will rest barefoot for 15 minutes in a room at constant temperature (22-24°C).~Thermographic images of both feet will be taken in multiple views (dorsal, plantar, lateral).~Images will be analyzed to identify temperature differences between different areas of the foot and between study groups."
62230168|NCT06485362||diabetic foot patients|"Subjects with diabetic foot, diagnosed with diabetes mellitus for more than 5 years, will rest barefoot for 15 minutes in a room at a constant temperature (22-24°C).~Thermographic images of both feet will be taken in multiple views (dorsal, plantar, lateral).~The images will be analyzed to identify temperature differences between different areas of the foot and between the study groups."
62230169|NCT03139357||Primary care patients|Patients ages 20-65 who score 5 or greater on the GAD-7 will be given the SF12, GAD7, medial utilization, and helpfulness questionnaires at 6 month intervals for a 2 year period.
62230170|NCT02485054||Eligible patients|Adults having had a transient visual disturbance during the last 8 days, except a diplopia
62230171|NCT03968120|NO_INTERVENTION|Group Fix:One-lung ventilation with constant PEEP|Controll group: lung protective one-lung ventilation with fix positive end-expiratory pressure (PEEP)
62230172|NCT03968120|ACTIVE_COMPARATOR|Group Variable:One-lung ventilation with variable PEEP|Variable group: lung protective one-lung ventilation with variable positive end-expiratory pressure (PEEP)
62422188|NCT05110144|EXPERIMENTAL|Amitriptyline and Placebo|Subjects will receive 25mg of Amitriptyline for blinded period 1 (first 4 week treatment period) and 25mg of Amitriptyline plus 30mg Placebo for blinded period 2 (additional 4 week treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
62422189|NCT05110144|EXPERIMENTAL|Amitriptyline dose escalation|Subjects will receive 25mg of Amitriptyline for blinded period 1 (first 4 week treatment period) and 50mg of Amitriptyline for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
62230173|NCT01894633|EXPERIMENTAL|Chloroquine, radiosensitizer|The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the CLQ plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days.
62230174|NCT01894633|PLACEBO_COMPARATOR|Placebo|30 Gy of whole-brain radiotherapy in 10 daily fractions and an oral matching placebo for 28 days
62230175|NCT04507126|EXPERIMENTAL|BCG Immunization|All participants will receive two Bacillus Calmette-Guérin (Japan BCG) vaccine injections spaced four week apart. Each injection will have 1.8-3.9 x 10\^6 colony forming units (CFU) reconstituted in 0.1 mL saline.
62422190|NCT05110144|PLACEBO_COMPARATOR|Placebo|Subjects will receive 30mg of Placebo for blinded period 1 (first 4 week treatment period) and 60mg of Placebo for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
62422191|NCT05140863|EXPERIMENTAL|HSK16149 20mg BID|HSK16149 20mg, orally twice a day for 12 weeks
62230176|NCT01143974|EXPERIMENTAL|PC Regimen|
62807091|NCT04290039|ACTIVE_COMPARATOR|Intravenous (IV)|"Atropine sulfate injection is indicated for temporary blockade of severe or life-threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia.~Atropine sulfate injection, USP,8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).~Atropine sulfate injection will be supplied in multidose vials containing 20 mL.~Each vial will only be used to administer a single dose, to a single subject."
62807092|NCT02213835|EXPERIMENTAL|Specific Carbohydrate diet (SCD)|"The treatment for this study will be the Specific Carbohydrate diet (SCD). Intervention will be based upon standard dietary therapy as well as a nutritional handbook developed in the Gastroenterology division. Patients will receive one-on-one guidance by a Seattle Children's Dietician trained in the SCD during each visit. Prior to each visit patient will fill out a 3 day nutrition log which will be reviewed by the dietician during the clinic visit. Each patient will receive books on the SCD therapy which will include recipes and information about the diet The two books given will include Breaking the Vicious Cycle by Elaine Gottschall and Recipes for the Specific Carbohydrate Diet by Raman Prasad."
62807093|NCT04629755|EXPERIMENTAL|Intervention|The intervention was delivered via a series of daily text messages to mobile phones. Participants first were delivered an introductory text message at 6:00 pm on Day 7 of the study. This message alerted the participants to expect their first suggestion via text message at 8:00 am the following morning. For the next 14 days (Days 8 - 22), participants received one of 14 suggestions in random order. The specific daily suggestions varied in length and complexity: The simplest ones included text messages and a brief audiofile delivered via text; the more complex suggestions included text messages and a link to a web-page, which included text or embedded audiofiles describing why a suggestion was being made, how to engage in the suggested practice, and audiotaped exchanges between members of the production team describing what it was like to try the practices themselves. Some suggestions were supplemented with additional reminder and check-in text messages at noon and 4:00 pm.
62030929|NCT02010060|EXPERIMENTAL|Aerobic Exercise Training|The Aerobic training group will participate in 6 months of aerobic training and asked to make no conscious alterations in their physical activity outside of exercise session, or dietary habits
62030930|NCT02010060|EXPERIMENTAL|Aerobic Exercise+ Physical Activity|The goal of this group is to perform 6 months of aerobic exercise and increase the amount of physical activity outside of their training sessions. They will be asked to make no conscious changes to their dietary habits
62230177|NCT03674463|EXPERIMENTAL|LCAR-B4822M treatment group|r/r multiple myeloma patients will be treated with LCAR-B4822M CAR-T cells with a escalation approach, 0.5x10\^6- 2.0x10\^6 CAR-T cells/kg.
62807094|NCT04629755|NO_INTERVENTION|Control|Assessment only.
62807095|NCT05408962||OMNI - omnivorous|Healthy omnivorous adults with ages between 18 and 65 years and having the reported dietary regimen for at least 1 year, free from any chronic condition such as metabolic, digestive, renal, haematological, endocrine or oncological diseases and presenting no food intolerances or eating disorders.
62230178|NCT02536391|EXPERIMENTAL|Sequence 1: Tablet/Capsule/Tablet with food|Day 1: ipatasertib tablet administered after fast, Day 8: ipatasertib capsule administered after fast, Day 15: ipatasertib tablet administered after high-fat meal.
62030931|NCT03604081|EXPERIMENTAL|Intervention Group|One hour of intense massed practice of lower extremity either in the form of shaping or task practice
62230179|NCT02536391|EXPERIMENTAL|Sequence 2: Tablet/Tablet with food/Capsule|Day 1: ipatasertib tablet administered after fast, Day 8: ipatasertib tablet administered after high-fat meal, Day 15: ipatasertib capsule administered after fast.
62230180|NCT02536391|EXPERIMENTAL|Sequence 3: Capsule/Tablet/Tablet with food|Day 1: ipatasertib capsule administered after fast, Day 8: ipatasertib tablet administered after fast, Day 15: ipatasertib tablet administered after high-fat meal.
62230181|NCT02536391|EXPERIMENTAL|Sequence 4: Capsule/Tablet with food/Tablet|Day 1: ipatasertib capsule administered after fast, Day 8: ipatasertib tablet administered after high-fat meal, Day 15: ipatasertib tablet administered after fast.
62230182|NCT02536391|EXPERIMENTAL|Sequence 5: Tablet with food/Tablet/Capsule|Day 1: ipatasertib tablet administered after high-fat meal, Day 8: ipatasertib tablet administered after fast, Day 15: ipatasertib capsule administered after fast.
62422192|NCT05140863|EXPERIMENTAL|HSK16149 40mg BID|HSK16149 40mg, orally twice a day for 12 weeks
62422193|NCT05140863|PLACEBO_COMPARATOR|Placebo BID|placebo, orally twice a day for 12 weeks
62422194|NCT05632809|EXPERIMENTAL|NKTR-255 combination (Durvalumab)|"Participants will receive vein over about 30 minutes. Participants receive the first dose within 72 hours (3 days) after you complete CRT and the second dose at 3 weeks after you complete CRT. Then, you will receive NKTR-255 one (1) time every 4 weeks after that for up to 1 year.~Durvalumab Participants will receive durvalumab by vein over about 30 minutes. You will receive the first dose at 3 weeks after you complete CRT therapy. Then, you will receive durvalumab one (1) time every 4 weeks after that for up to 1 year"
62807096|NCT05408962||LOV - lacto-ovovegetarians|Healthy lacto-ovovegetarians adults with ages between 18 and 65 years and having the reported dietary regimen for at least 1 year, free from any chronic condition such as metabolic, digestive, renal, haematological, endocrine or oncological diseases and presenting no food intolerances or eating disorders.
62807097|NCT05408962||VEG - vegan|Healthy vegan adults with ages between 18 and 65 years and having the reported dietary regimen for at least 1 year, free from any chronic condition such as metabolic, digestive, renal, haematological, endocrine or oncological diseases and presenting no food intolerances or eating disorders.
62807098|NCT06314334|EXPERIMENTAL|Group A (synchronous treatment group)|Patients received 4 cycles of Sintilimab combined with pegaspargase therapy, with each cycle lasting 3 weeks, for a total of 4 cycles. Concurrently, they received radiotherapy treatment (IMRT, 50-56Gy, starting within 21 days after the first Sintilimab treatment).
62807099|NCT06314334|EXPERIMENTAL|Group B (sequential treatment group)|Patients received 4 cycles of the PGEMOX regimen chemotherapy. Each cycle lasted 3 weeks, with sequential radiotherapy (IMRT, 50-56Gy) administered within 4 weeks after the last chemotherapy cycle.
62807100|NCT06314334|EXPERIMENTAL|Group C (sandwiched radiotherapy group)|Patients received 2 cycles of the GELAD regimen chemotherapy initially, with each cycle lasting 3 weeks. After the second cycle of chemotherapy, radiotherapy (IMRT, 50-56Gy) was administered within 4 weeks. Following the completion of radiotherapy, they received an additional 2 cycles of the GELAD regimen chemotherapy.
62807101|NCT02113917||hemophagocytic syndrome|patient with hemophagocytic syndrome
62807102|NCT06201260|EXPERIMENTAL|IPC|a 30 min high-pressure IPC protocol
62807103|NCT06201260|PLACEBO_COMPARATOR|placebo|A 30 min placebo
62807104|NCT04694235|NO_INTERVENTION|Observational cohort (control group)|In the observational cohort, pregnant mothers in the 2nd trimester (n=500) will be recruited and they will be followed up until their children are 24 months old. The control group women will receive standard intervention in the form of Ante Natal Care from village midwives (Polindes) or Puskesmas (IFA tablet, calcium tablet, nutrition counselling).
62030932|NCT03604081|PLACEBO_COMPARATOR|Control Group|Conventional physical therapy for 1 hour as per current standard of care that follows stroke clinical practice guideline.
62030933|NCT05480566|EXPERIMENTAL|Functional strength training + NMES|The experimental group will receive the standard of care plus functional strength training and quadriceps neuromuscular electrical stimulation. Functional strength training will include lower limb (e.g. rising from chair, heel rises) and upper limb (e.g. push-ups from the chair and against the wall) exercises for 15 min/day. Target levels of dyspnoea and/or perceived exertion will be 4 to 6 in the modified Borg scale. For neuromuscular electrical stimulation, electrodes will be placed longitudinally on the vastus intermedius and vastus medialis and a symmetric biphasic pulse waveform, with a pulse duration of 400ms, a frequency of 50Hz, in cycles of 8s of contraction and 20s of rest, will be used for 30min/day. The highest intensity tolerated by the patient will be used and intensity will be increased every time the patient feels comfortable with increasing the intensity. The device Compex Pro Rehab (CE-0473) will be used.
62030934|NCT05480566|ACTIVE_COMPARATOR|Standard of care|The standard of care group will receive the common treatment delivered at the hospital, i.e., routine medical treatment and daily sessions of approximately 15 minutes consisting of airway clearance techniques and breathing exercises upon indication, mobilization, and low-intensity daily walking/cycling exercise (5 to 10 minutes) according to patients' tolerance.
62030935|NCT03340051|ACTIVE_COMPARATOR|EFT group|Episodic Future Thinking (EFT) is the intervention in this arm. EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.
62030936|NCT03340051|PLACEBO_COMPARATOR|ERT group|Episodic Recent Thinking (ERT) is the intervention in this arm. ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
62030937|NCT06669923|NO_INTERVENTION|Baseline|Baseline study collects baseline data and screens for potential participants for the follow-up study.
62030938|NCT06669923|SHAM_COMPARATOR|Follow Up - Patient Education Group|
62030939|NCT06669923|EXPERIMENTAL|Follow Up - iSIPsmarter Program Group|
62030940|NCT02241967|EXPERIMENTAL|tDCS Full Dose|4 active treatments
62030941|NCT02241967|EXPERIMENTAL|tDCS Half Dose|2 active treatments
62422195|NCT02795949|EXPERIMENTAL|Antipseudomonal beta-lactam antibiotic|"1. Ampicillin 2g IV/6h~2. Trimethoprim/sulfamethoxazole 160/800 mg IV/8 -12h~3. Cefuroxime 750-1000 mg IV/8h~4. Cefotaxime 1-2g IV/8h ó ceftriaxone 1 g/12-24h~5. Amoxicillin/clavulanate 1000/125 mg IV/8h~6. Ciprofloxacin 400 mg IV/12h~7. Ertapenem 1-2g/24h."
62422196|NCT02795949|ACTIVE_COMPARATOR|De-escalation(short-spectrum antibiotic)|"* Piperacillin/tazobactam 4/0.5 g IV/8h~* Meropenem 1-2 g IV/8h~* Imipenem 0.5 g IV/6h - 1g IV/6h~* Aztreonam 1-2 g IV/8h~* Ceftazidime 1-2 g IV/8h~* Cefepime 2 g IV/8-12h"
62422197|NCT03220152|EXPERIMENTAL|emtricitabine / tenofovir 200/300 mg|emtricitabine / tenofovir 200/300 mg Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year.
62422198|NCT01333475|EXPERIMENTAL|TAC1:MK-2206 & AZD6244 in Pts with Colorectal Ca|Cycle = 28 days:MK-2206:90 mg PO days 1, 8, 15, and 22 AZD6244 Hydrogen sulfate: 75 mg PO QD (every day) MK-2206 + AZD6244: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
62422199|NCT01333475|EXPERIMENTAL|TAC1A:MK-2206 & AZD6244 in Pts with Colorectal Ca|"Cycle = 28 days:MK-2206:135 mg PO days 1, 8, 15, and 22 AZD6244 Hydrogen sulfate: 100 mg PO QD~MK-2206 + AZD6244: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression."
62230183|NCT02536391|EXPERIMENTAL|Sequence 6: Tablet with food/Capsule/Tablet|Day 1: ipatasertib tablet administered after high-fat meal, Day 8: ipatasertib capsule administered after fast, Day 15: ipatasertib tablet administered after fast.
62230184|NCT03286257|EXPERIMENTAL|Exercise Intervention|Participants will complete a partially supervised 4 month exercise program consisting of 3-5 sessions/week at a moderate intensity (40-75% heart rate (HR) reserve) at Liverpool Lifestyles gyms. Participants will be given free access to the Wellness Key System© when using the Lifestyles exercise equipment which allows researchers to remotely track the exercise intensity of participants accurately.
62230185|NCT04154176||POD CAM Nu-DESC|Patients undergoing surgery under general anesthesia assessed for POD with CAM and Nu-DESC
62230186|NCT02019043|EXPERIMENTAL|Syphilis testing with routine HIV bloodwork|The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count.
62230187|NCT02019043|NO_INTERVENTION|Current care practice|The control condition will remain the current care practice, which is generally opportunistic screening or diagnostic testing for those presenting with signs/symptoms or who report sexual risk behaviour.
62230188|NCT03074760||Contaminated acequias|
62422200|NCT06426992|EXPERIMENTAL|Patients with malignant liver tumors|Following the existing procedure of our institute, we aim to treat the tumor by applying up to 150W of microwaves within the tumor using a StarWave microwave generator and a 13-gauge antenna under fusion ultrasound guidance. If necessary, the antenna is reinserted 1-2 times to create sufficient ablation lesions until an echogenic band of 5-10mm is formed around the tumor and its periphery, implementing overlapping microwave ablation (MWA). Afterward, the antenna is removed while applying microwave energy to prevent bleeding.
62422201|NCT03120520|EXPERIMENTAL|Plecanatide 0.5 mg|Taken orally once daily in the morning for 8 weeks
62422202|NCT03120520|EXPERIMENTAL|Plecanatide 1.0 mg|Taken orally once daily in the morning for 8 weeks
62230189|NCT03074760||Non-contaminated acequias|
62230190|NCT02838693||APT-2D (Normoglycemic)|800 Normoglycemic
62230191|NCT02838693||APT-2D (Pre-Diabetic)|1,500 Pre-Diabetic
62591816|NCT04403646|PLACEBO_COMPARATOR|CONTROL|"Participants will receive placebo supply for 14 days. The placebo will be administrated with the identical dose as described for the test product.~Beside patients will receive the standard theraphy, which includes Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas that could undergo to modifications). In addition, if necessary: supplemental O2, non-invasive ventilation, antibiotic therapy."
62030942|NCT02241967|EXPERIMENTAL|tDCS Minimal dose|1 active treatment
62807105|NCT04694235|EXPERIMENTAL|Intervention group|The intervention group women (n=153) will be provided one egg three times per week from recruitment (2nd trimester) until term along with the standard Ante Natal Care.
62030943|NCT02241967|SHAM_COMPARATOR|Sham tDCS|no active treatments
62422203|NCT03120520|EXPERIMENTAL|Plecanatide 1.5 mg|Taken orally once daily in the morning for 8 weeks
62422204|NCT03120520|PLACEBO_COMPARATOR|Matching placebo|Taken orally once daily in the morning for 8 weeks
62230192|NCT04256382|EXPERIMENTAL|experimental group|The experimental group took two-hour online course about dementia pain care in two weeks.
62591817|NCT06287827||Simplified protocol|"The first cohort will be composed of all children between 6 and 59 months of age who attend predefined outpatient care points in the states Distrito Capital, Miranda, and La Guaira. These children must meet the inclusion criteria for the research. For those selected in these centers, the method of nutritional treatment for acute malnutrition will be the simplified protocol. Adaptations in this protocol include:~1. Use of a single treatment product (Ready to use therapeutic food).~2. Reduced dose.~3. Expanded cut-offs."
62807106|NCT01360671|EXPERIMENTAL|Sildenafil|iv sildenafil
62807107|NCT04610047|EXPERIMENTAL|Norketotifen|Norketotifen oral capsules, twice daily for 7 days
62030944|NCT03835377|EXPERIMENTAL|Iron-biofortified beans|Iron-biofortified beans (Phaseolus vulgaris L MIB465)
62030945|NCT03835377|ACTIVE_COMPARATOR|Control beans|Control beans (Phaseolus vulgaris L Jamapa variety)
62030946|NCT02967302|EXPERIMENTAL|Morphine Sulfate|Morphine 3 mg intraarticular once at baseline
62422205|NCT00922337||MGuard|eligible patients implanted with minimum one MGuard stent
62422206|NCT03839784||Neurocognitive Assessment Arm|
62422207|NCT04696627||Dural puncture|Patients with well-documented recognized unintentional dural punctures during their labor epidural insertion at Mount Sinai Hospital from January 2015 to December 2019.
62591818|NCT06287827||Standard protocol|The second cohort will be composed of all children between 6 and 59 months of age who attend other predefined outpatient care points in the four states and met the inclusion criteria for this research. Nutritional treatment will be administered to these children, following the WHO Standard Protocol.
62591819|NCT06620640|EXPERIMENTAL|ARM A: Active VGuard device|Active VGuard device
62591820|NCT06620640|SHAM_COMPARATOR|ARM B: Sham VGuard device|Sham VGuard device
62807108|NCT04610047|PLACEBO_COMPARATOR|Placebo|Placebo oral capsules, twice daily for 7 days
62030947|NCT02967302|ACTIVE_COMPARATOR|Triamcinolone|Triamcinolone 40 mg intraarticular once at baseline
62030948|NCT02967302|PLACEBO_COMPARATOR|Placebo|NaCl 0,9% 5 ml intraarticular at baseline
62030949|NCT04398524|EXPERIMENTAL|single arm|ISA101b 4 times plus cemiplimab every 3 weeks for up to 24 months
62030950|NCT02562755|EXPERIMENTAL|Pexa-Vec followed by Sorafenib|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 1e9 pfu at day 1 and weeks 2 and 4, followed by sorafenib at Week 6.
62030951|NCT02562755|ACTIVE_COMPARATOR|Sorafenib|Sorafenib (400 mg twice daily) begins on Day 1.
62230193|NCT04256382|ACTIVE_COMPARATOR|comparison group|The comparison group took two-hour online course about dementia care in two weeks.
62591821|NCT05001516|EXPERIMENTAL|LM302 Dose Escalation Level 1, 0.2 mg/kilogram(kg),|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~first dose: 0.2mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=1;"
62807109|NCT05723224|EXPERIMENTAL|Endoscopic ultrasound-guided gallbladder treatment|Endoscoipc gallbladder drainage under EUS guide using lumen apposing metal stents (LAMS) followed when needed by endoscopic lithotripsy.
62422208|NCT04696627||Dural puncture with blood patch|Patients with well-documented recognized unintentional dural punctures during their labor epidural insertion at Mount Sinai Hospital from January 2015 to December 2019 that were treated with an epidural blood patch.
62807110|NCT01071057|ACTIVE_COMPARATOR|Naloxone/morphine|Naloxone (12 µg/ml) mixed in a single infusion with morphine (1 mg/ml). The study solutions will be prepared by a pharmacist and diluted in saline to produce equal volumes to ensure proper blinding.
62807111|NCT01071057|PLACEBO_COMPARATOR|saline/morphine|Patients will be randomly assigned to one of two groups (Naloxone/morphine or saline/morphine) using computer-generated random numbers. On arrival to the PACU patients will be started on IV PCA and randomized study drug
62422209|NCT04696627||No dural puncture|Patients who did not have recognized unintentional dural punctures during their labor epidural insertion at Mount Sinai Hospital from January 2015 to December 2019.
62422210|NCT00062452||A-1,2,3|The cohort (A) comprised of high risk infants. There were 3 sub groups studied within this cohort: (1) premature infants, (2) Infants with congenital gut anomalies, and (3) perinatal asphyxia.
62807112|NCT05772741|OTHER|Biological sample collection|Tumor tissue for glioma stem-like cell culture generation. Skin or PBMC for organoid generation
62807113|NCT00737646|OTHER|1|Usual care
62807114|NCT00737646|EXPERIMENTAL|2|Clinic-focused intervention: The clinicians and clinical staff in each of the clinics will be scheduled for training sessions. The provider trainings will be designed for clinicians and clinical staff and will be conducted in at least two separate sessions of approximately 3 hours total duration. The sessions will be scheduled to accommodate the clinic schedule, but will be held with no more than 1 month between them. Participants in clinic training sessions will receive continuing education credit.
62807115|NCT00737646|EXPERIMENTAL|3|"Clinic-focused and patient focused intervention: The clinic focused-intervention as described in Arm 2 will be combined with a patient-focused intervention.~Patient focused intervention: CRC education packets, based upon previously developed CDC CRC patient education materials, have been adapted for each study site. These CRC educational packets will be mailed to average-risk patients aged 50-80 years who are due for CRC screening (based on electronic records) and who schedule a non-acute ambulatory care visit in clinics assigned to the patient-focused intervention. A cover letter signed by the patient's physician will be included with each packet. The packets will be mailed approximately 1 week before the medical appointment."
62807116|NCT00450970|EXPERIMENTAL|1|Prednisone and Satraplatin (INN / USAN), also known as JM-216, or OC-6-43-bis(acetato-O)ammine dichloro (cyclohexanamine)-platinum (IV), is a member of a novel class of platinum (IV) compounds that are absorbed by the oral route. The lipophilic properties of these compounds, and hence their absorption, are largely determined by the nature of the axial acetate ligands.
62807117|NCT00450970|EXPERIMENTAL|2|Prednisone (17 alpha, 21-dihydroxypregna-1, 4-diene-3, 11, 20-trione) is commercially formulated as the acetate salt (prednisone 21-acetate). It is a biologically inert glucocorticoid, which is converted to active prednisolone in the liver.
62807118|NCT03826121|EXPERIMENTAL|Sesame Oil Cake Extract|Sesame Oil Cake Extract 1.5 g/day for 12 weeks
62422211|NCT06577090|EXPERIMENTAL|Nimacimab injection|Nimacimab injection 200 mg
62591822|NCT05001516|EXPERIMENTAL|LM302 Dose Escalation Level 2, 0.4 mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~second dose: 0.4mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=3;"
62591823|NCT05001516|EXPERIMENTAL|LM302 Dose Escalation Level 3, 0.8 mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~third dose: 0.8mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=6;"
62807119|NCT03826121|PLACEBO_COMPARATOR|Placebo|placebo for 12 weeks
62807120|NCT03028298|EXPERIMENTAL|Low dose sildenafil|Twelve patients with cerebral vasospasm following aneurysmal subarachnoid hemorrhage will be assigned to low dose sildenafil citrate and will receive a 20mg oral dose and a subsequent 10mg intravenous dose of sildenafil citrate.
62807121|NCT03028298|EXPERIMENTAL|High dose sildenafil|Twelve patients with cerebral vasospasm following aneurysmal subarachnoid hemorrhage will be assigned to high dose sildenafil citrate and will receive a 60mg oral dose and a subsequent 30mg intravenous dose of sildenafil citrate.
62807122|NCT01121146|ACTIVE_COMPARATOR|Crosslinked Marathon polyethylene|
62807123|NCT01121146|ACTIVE_COMPARATOR|Standard Enduron polyethylene|
62807124|NCT01096316|EXPERIMENTAL|Intervention|"The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:~* enhanced education of patients and providers~* engagement of patients~* depression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation."
62807125|NCT01096316|NO_INTERVENTION|Usual Care|Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.
62807126|NCT00601835|EXPERIMENTAL|Canadian Td Vaccine Group|Participants received Canadian manufactured Td vaccine
62422212|NCT06577090|PLACEBO_COMPARATOR|Nimacimab placebo injection|Matching nimacimab placebo injection
62422213|NCT06577090|EXPERIMENTAL|Semaglutide injection + Nimacimab injection 200 mg|Semaglutide injection administered according to dose escalation described in semaglutide prescribing information plus concomitant administration of Nimacimab Injection 200 mg
62422214|NCT06577090|ACTIVE_COMPARATOR|Semaglutide injection + Nimacimab placebo injection|Semaglutide injection administered according to dose escalation described in semaglutide Prescribing Information plus concomitant administration of Nimacimab Injection matching placebo injection
62422215|NCT06580353||COPD group|Patients with COPD who presented to the chest diseases polyclinic and whose symptoms of cough, sputum and/or dyspnoea accompanied by tachypnoea and/or tachycardia had not worsened in the last 14 days were defined as 'Stable COPD group' \[
62422216|NCT06580353||Control group|The control group was defined as those who did not have any systemic disease and who were normal at the end of the polyclinic examination who applied to the chest diseases polyclinic.
62422217|NCT01468168|EXPERIMENTAL|DE-101 Ophthalmic Suspension High Dose|
62422218|NCT01468168|EXPERIMENTAL|DE-101 Ophthalmic Suspension Low Dose|
62422219|NCT01468168|PLACEBO_COMPARATOR|DE-101 Ophthalmic Suspension Vehicle|
62807127|NCT00601835|ACTIVE_COMPARATOR|United States Td Vaccine Group|Participants received US manufactured Td vaccine
62807128|NCT00973752|EXPERIMENTAL|Experimental|All patients treated on same arm
62807129|NCT04458506|EXPERIMENTAL|Rapid Maxillary Expander (RME)|36 patients will be treated with RME in order to correct their unilateral posterior cross bite
62807130|NCT04458506|ACTIVE_COMPARATOR|Quad Helix (QH)|36 patients will be treated with QH in order to correct their unilateral posterior cross bite
62807131|NCT06084832|EXPERIMENTAL|Binge Drinking|
62807132|NCT06084832|ACTIVE_COMPARATOR|Binge Drinking-control|
62807133|NCT05254665|EXPERIMENTAL|Docetaxel Polymeric Micelles for Injection|Docetaxel Polymeric Micelles for Injection
62807134|NCT02519023|EXPERIMENTAL|TAP-Block with liposomal bupivacaine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side. In the same arm the surgeon infiltration into the incision will consist of 10 ml of normal saline per port site, 5 ml prior to incision and 5 ml prior to closure at each port site.
62030952|NCT05709730||Women aged 26-80 with atypical glandular cell (AGC) cytology result|Women in the capital region of Sweden with AGC, a concomitant human papillomavirus (HPV) analysis, and a histopathology.
62030953|NCT05530135|PLACEBO_COMPARATOR|Control Group|Takotsubo patients receiving standard care
62230194|NCT03719170|EXPERIMENTAL|De-prescribing Program|"The 9 Veterans Integrated Service Networks (VISNs) randomly assigned to the PPI de-prescribing program. VISNs are the 18 geographical regions that make up the VHA.~PPI De-prescribing Program: The PPI de-prescribing program included alerts to clinical pharmacy specialists and primary care providers informing them of individual patients scheduled for upcoming primary care visits who meet criteria for PPI de-prescription; activation of clinical pharmacy specialists; education of primary care providers; and patient education."
62422220|NCT01998035|EXPERIMENTAL|R/O: Level -1|Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2, Day 8), cycle length (28 days)
62422221|NCT01998035|EXPERIMENTAL|R/O: Level 1|Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2, Days 8 and 15), cycle length (28 days)
62422222|NCT01998035|EXPERIMENTAL|R/O: Level 2|Oral 5-Azacitidine 200 mg (Days 1-14) Romidepsin (10 mg/m2, Days 8 and 15), cycle length (28 days)
62422223|NCT01998035|EXPERIMENTAL|R/O: Level 3|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (10 mg/m2, Days 8 and 15), cycle length (28 days)
62422224|NCT01998035|EXPERIMENTAL|R/O: Level 4|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2, Days 8 and 15), cycle length (28 days)
62422225|NCT01998035|EXPERIMENTAL|R/O: Level 5|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2, Days 8, 15 and 22), cycle length (35 days)
62422226|NCT01998035|EXPERIMENTAL|R/O: Level 6|Oral 5-Azacitidine 300 mg (Days 1-21) Romidepsin (14 mg/m2, Days 8, 15 and 22), cycle length (35 days)
62422227|NCT06647420|EXPERIMENTAL|Sedative music followed by stimulative music group|The participants in this group will receive sedative music followed by stimulative music for up to 25 minutes each. Session two will occur two days after session one.
62422228|NCT06647420|EXPERIMENTAL|Stimulative music followed by sedative music group|The participants in this group will receive stimulative music followed by sedative music for up to 25 minutes each. Session two will occur two days after session one.
62422229|NCT04200781|EXPERIMENTAL|Shengdi Dahuang Decoction|To clarify the clinical effects of Shengdi Dahuang Decoction in the treatment of acute hemorrhagic stroke and to explore the possible mechanism. Participants will take the granules of Shengdi Dahuang Decoction that contains 15 grams of rehmannia and 5 grams of rhubarb, one pack per time, twice a day for 7 days.
62422230|NCT04200781|PLACEBO_COMPARATOR|Placebo|To explore the effective clinical therapy in acute hemorrhagic stroke. Participants will take placebo contains 2% rehmannia and rhubarb, one pack per time, twice a day for 7 days.
62422231|NCT06271837|EXPERIMENTAL|Part 1|HER2 IHC 3+ solid tumors (excluding breast and gastric cancer)
62422232|NCT06271837|EXPERIMENTAL|Part 2 Cohort A|HER2 IHC 2+ solid tumors (excluding breast and gastric cancer)
62422233|NCT06271837|EXPERIMENTAL|Part 2 Cohort B|HER2 IHC 1+ gynecologic cancers
62422234|NCT06271837|EXPERIMENTAL|Part 3|HER2 IHC 3+ or 2+ cervical cancer
62422235|NCT06157502|EXPERIMENTAL|Shuxuening injection|Shuxuening Injection + Intravenous Thrombolysis
62422236|NCT06157502|PLACEBO_COMPARATOR|Placebo|Placebo + Intravenous Thrombolysis
62422237|NCT05764434||Patients with Amyotrophic Lateral Sclerosis|Patients with a possible, probable, or definite diagnosis of Amyotrophic Lateral Sclerosis according to the El Escorial Criteria.
62422238|NCT05764434||Healthy Control Persons|Healthy control persons matching the ALS patient group in sex and age
62030954|NCT05530135|ACTIVE_COMPARATOR|Exercise Group|Takotsubo patients who will undergo an exercise program in addition to standard care
62030955|NCT05530135|ACTIVE_COMPARATOR|CBT Group|Takotsubo patients who will receive cognitive behavioural therapy in addition to standard care
62030956|NCT06495775|EXPERIMENTAL|admitted patients|fecal sampling
62230195|NCT03719170|NO_INTERVENTION|No De-prescribing Program|The 8 Veterans Integrated Service Networks (VISNs) randomly assigned to usual care and did not receive the national de-prescribing program. VISNs are the 19 geographical regions that make up the VHA.
62422239|NCT05764434||Patients with other Motor Neuron Diseases|Patients with Motor Neuron Diseases other than ALS
62591824|NCT05001516|EXPERIMENTAL|LM302 Dose Escalation Level 4, 1.6mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~fourth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=6;"
62807135|NCT02519023|ACTIVE_COMPARATOR|Surgical infiltration with bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
62422240|NCT03986645|EXPERIMENTAL|4DFLOW|Acquire MR 4DFLow data.
62807136|NCT06555185|EXPERIMENTAL|Experimental group|Potentiation warm-up protocol with jumps combined with sprints with change of direction.
62807137|NCT06555185|ACTIVE_COMPARATOR|Control group|Usual warm-up exercises as previously used by the whole team.
62230196|NCT05821231|EXPERIMENTAL|Patients with metastatic soft tissue sarcoma with lung metastases|
62230197|NCT02614573|EXPERIMENTAL|The study population|The clinical phases of this study will be held in the nursing home (EHPAD; principal building + 2 annexes) of Pont-Saint-Esprit, located in France. Patients are elderly dependents treated by anti-vitamin K for more than 6 months.
62422241|NCT06435598|EXPERIMENTAL|Intervention Group (Educational video and usual care)|Investigator will allocate sixty- three of the participants to the video-based health education and usual care
62591825|NCT05001516|EXPERIMENTAL|LM302 Dose Escalation Level 5, 2.4mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~fifth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=9;"
62591826|NCT05001516|EXPERIMENTAL|LM302 Dose Escalation Level 6, 2.8mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~sixth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=12;"
62230198|NCT01200420|EXPERIMENTAL|miravirsen|Dose escalation study with review of safety data following each cohort.
62230199|NCT01200420|PLACEBO_COMPARATOR|saline|Dose escalation study with review of safety data following each cohort.
62819512|NCT05661682|ACTIVE_COMPARATOR|Tralement|This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of parenteral nutrition formulation requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.
62030957|NCT05503108|EXPERIMENTAL|Fasting Mimicking Diet group|Fasting Mimicking Diet 3 days before and the day of neoadjuvant chemotherapy (ddAC, T)
62230200|NCT02164383|EXPERIMENTAL|Mobile Games|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine patch plus behavioral cessation counseling with access to Mobile Games."
62230201|NCT02164383|EXPERIMENTAL|No Mobile Games|"This arm of the project will address the following question:~How effective is the following intervention:~Nicotine patch plus behavioral cessation counseling without access to Mobile Games."
62230202|NCT00012298|EXPERIMENTAL|Treatment (radiolabeled monoclonal antibody therapy)|Patients receive rituximab IV on days 1 and 8, indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1, and yttrium Y 90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) and interleukin-11 SC until blood counts recover.
62591827|NCT04064411|ACTIVE_COMPARATOR|abaloparatide-SC|Participants self-administered daily doses of abaloparatide 80 mcg SC for 12 months using a single-participant, multiple-use, prefilled injection pen that delivers 30 doses. Participants received a new injection pen every 30 days.
62591828|NCT04064411|EXPERIMENTAL|abaloparatide-sMTS|Abaloparatide-sMTS 300 mcg applied to the thigh for 5 minutes once daily for 12 months.
62591829|NCT04930159|NO_INTERVENTION|Enhanced usual care|Written materials in an appealing package.
62030958|NCT05503108|NO_INTERVENTION|Normal Diet group|Standard neoadjuvant chemotherapy (ddAC, T)
62030959|NCT01904812|OTHER|Lupus erythematosus|
62030960|NCT05981274||Systematic joint and bone health assessments before and after enrollment|"1. Haemophilia Early Arthropathy Detection :HEAD-US, HJHS, and DEXA scan~2. serum markers : CTX-II, COMP, hsCRP, TNF-a, CTX-I, sRANKL, OPG, and Osteopontin (OPN)~3. Quality of life assessments (Haem-A-QoL, EQ-5D)"
62230203|NCT00264953|ACTIVE_COMPARATOR|A|4x ABVD plus 30Gy IF-RT
62230204|NCT00264953|EXPERIMENTAL|C|4x BEACOPP baseline plus 30Gy IF-RT
62230205|NCT00264953|EXPERIMENTAL|B|4x ABVD plus 20Gy IF-RT
62230206|NCT00264953|EXPERIMENTAL|D|4x BEACOPP baseline plus 20Gy IF-RT
62230207|NCT04647045|ACTIVE_COMPARATOR|IBS-C group|77 constipation-predominant IBS were given three bottles of 125 ml cultured milk drink daily for 30 days
62230208|NCT04647045|OTHER|Non-IBS group|88 non-IBS subjects (healthy individuals) were given similar probiotics for 30 days.
62230209|NCT04127890|EXPERIMENTAL|Intervention Arm|1.5 L of ELO Water to be drunk daily for 24 weeks
62230210|NCT04127890|PLACEBO_COMPARATOR|Control Arm|1.5 L of placebo bottled drinking water to be drunk daily for 24 weeks
62230211|NCT00573495|EXPERIMENTAL|hTERT/Survivin Multi-Peptide Vaccine|
62230212|NCT05570123|PLACEBO_COMPARATOR|Placebo|
62230213|NCT05570123|EXPERIMENTAL|Flexofytol Forte|
62230214|NCT05900882|EXPERIMENTAL|study group|SVRd induction treatment
62230215|NCT04664673|EXPERIMENTAL|HABIT-ILE|HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) intervention during two weeks adapted for adults stroke survivors
62230216|NCT04664673|ACTIVE_COMPARATOR|Regular care|Usual customary treatment for adults stroke survivors during two weeks
62230217|NCT05254574|EXPERIMENTAL|SAM Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
62230218|NCT05254574|PLACEBO_COMPARATOR|Placebo SAM Ultrasound Device and Diclofenac Patch|Patients receive placebo treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with 0% diclofenac patch.
62422242|NCT06435598|NO_INTERVENTION|Control Group (Usual Care)|Investigator will allocate sixty-three of the participants to usual care only
62422243|NCT06025487|ACTIVE_COMPARATOR|Patients|Asplenic patients receiving two doses of Bexsero (meningococcal B vaccine) with one-month interval between doses
62422244|NCT06025487|ACTIVE_COMPARATOR|Healthy controls|Healthy controls receiving two doses of Bexsero (meningococcal B vaccine) with one-month interval between doses
62422245|NCT05452616|ACTIVE_COMPARATOR|"ART first arm"|ART initiation on the day of enrolment independent of TB investigations
62422246|NCT05452616|ACTIVE_COMPARATOR|"TB results first arm"|ART initiation only after active TB has been refuted or confirmed
62030961|NCT04501315||ICU TBI|Patients treated on the ICU with brain injury
62030962|NCT04501315||ICU tumor|Patients treated on the ICU because of intracranial tumor
62230219|NCT05254574|ACTIVE_COMPARATOR|Over the Counter Arthritis Pain Gel|Patients apply topical 1% diclofenac gel three times per day, at least 5 days per week for 8 weeks.
62230220|NCT01895153||pentosan polysulfate cohort|pentosan polysulfate monotherapy
62230221|NCT01895153||hydrodistension(HD) cohort|hydrodistension(HD) monotherapy
62230222|NCT01895153||combination cohort|combination therapy of pentosan polysulfate and hydrodistension.
62030963|NCT04501315||ICU surgery|Patients treated on the ICU following surgery without brain injury
62030964|NCT04501315||ICU control|Patients treated on the ICU without TBI, tumor or surgery
62030965|NCT04523545|EXPERIMENTAL|Treatment|
62030966|NCT04533425||Patients with syncope|Patients who present to the ED with syncope
62230223|NCT05710861|EXPERIMENTAL|F-HIFU Group|50 to 75 years old patients fit for a Radical Prostatectomy when active surveillance is not recommended and who do not want a radiation therapy: harboring a non-treated localized PC, with a maximum Gleason score of 3+4 , ISUP 2 and less than 50% of positive prostate biopsy (favorable intermediate risk), with or without contralateral microfocus score 3+3 (ISUP 1) of less than 3 mm, with a tumor visible on MRI and biopsy-proven with systematic and targeted biopsy with at least 2 biopsies per target and 12 systematic biopsies, Tumor involving maximum 2 biopsy-proven contiguous sextants. Patients with multiple MRI targets may be included if only one target is biopsy-proven, T1c-T2 stage, PSA \<20 ng/ml, prostate volume less than 100 ml, fully informed patient accepting, after a decent reflexion time, to participate to the study by signing a consent form, affiliated or beneficiary patient to the French social security system
62230224|NCT05710861|ACTIVE_COMPARATOR|Prostatectomy Group|50 to 75 years old patients fit for a Radical Prostatectomy when active surveillance is not recommended and who do not want a radiation therapy: harboring a non-treated localized PC, with a maximum Gleason score of 3+4 , ISUP 2 and less than 50% of positive prostate biopsy (favorable intermediate risk), with or without contralateral microfocus score 3+3 (ISUP 1) of less than 3 mm, with a tumor visible on MRI and biopsy-proven with systematic and targeted biopsy with at least 2 biopsies per target and 12 systematic biopsies, Tumor involving maximum 2 biopsy-proven contiguous sextants. Patients with multiple MRI targets may be included if only one target is biopsy-proven, T1c-T2 stage, PSA \<20 ng/ml, prostate volume less than 100 ml, fully informed patient accepting, after a decent reflexion time, to participate to the study by signing a consent form, affiliated or beneficiary patient to the French social security system
62230225|NCT02855970|EXPERIMENTAL|patient|
62422247|NCT01999322|EXPERIMENTAL|FIAsp|The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period
62591830|NCT04930159|ACTIVE_COMPARATOR|Facilitated group support|Weekly group gatherings.
62030967|NCT02206503|EXPERIMENTAL|Cyclophosphamide; Lenalidomide; Dexamethasone|"MM Patients who experienced biochemical progression during Rd treatment without CRAB (signs of organ damage, multiple myeloma-related, as renal impairment and/or anemia and/or new bone lesions and/or hypercalcemia), will continue:~* Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days.~* Dexamethasone orally at the dose of 40 mg once a week.~Adding:~· Cyclophosphamide orally at the dose of 50 mg/day on days 1-21 every 28 days. CRd combination will be continued for 9-4week cycles. Patients will not receive any maintenance therapy."
62030968|NCT00717509||clozapine group|"* chronic schizophrenia~* have been taking clozapine at leaset one year~* without diabetes, pulmonary tuberculosis"
62030969|NCT02715921|EXPERIMENTAL|Cystic fibrosis patients|Receive tele-exercise training and undergo pulmonary function testing and exercise testing
62030970|NCT06669780|EXPERIMENTAL|Active|This arm will receive access to an online program that will guide them through cognitive behavioral therapy program.
62030971|NCT06669780|SHAM_COMPARATOR|Sham comparator|Participants will obtain access to an online program with activities not including the cognitive behavioral therapy
62030972|NCT01692535|EXPERIMENTAL|GlideScope|intubation
62230226|NCT02683941|EXPERIMENTAL|Lanreotide (Autogel formulation)|120mg every 28 days until disease progression, death, or unacceptable toxicity
62230227|NCT02683941|PLACEBO_COMPARATOR|Placebo|120mg every 28 days until disease progression, death, or unacceptable toxicity during the double-blind phase. The patient may enter open-label phase for treatment with Lanreotide.
62230228|NCT02202668|EXPERIMENTAL|TRS|
62230229|NCT02418273|EXPERIMENTAL|Denosumab|These subjects will receive two sequential doses of denosumab
62230230|NCT02418273|NO_INTERVENTION|No drug intervention|These subjects do not receive denosumab
62230231|NCT04299438|ACTIVE_COMPARATOR|Propranolol|IV Propranolol - 2mg; one possible repeat dose ≥2 hours later
62422248|NCT01999322|ACTIVE_COMPARATOR|Insulin Aspart|The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period
62422249|NCT03295968|NO_INTERVENTION|Water and Rest|
62422250|NCT03295968|EXPERIMENTAL|Water and High Intensity Exercise|
62030973|NCT01692535|EXPERIMENTAL|Airtraq|intubation
62030974|NCT01692535|EXPERIMENTAL|McGrath MAC|intubation
62030975|NCT01692535|EXPERIMENTAL|King Vision|intubation
62030976|NCT01692535|EXPERIMENTAL|A.P. Advance|intubation
62030977|NCT01692535|EXPERIMENTAL|C-MAC|intubation
62030978|NCT03562000|EXPERIMENTAL|Intervention group on cough and ventilation assistance|Mechanical cough assistance during physiotherapy post-extubation in ICU and systematic indication of NIV.
62030979|NCT03562000|OTHER|Control group on cough and ventilation assistance|Control group of extubated patients receiving the current gold standard strategy during physiotherapy after extubation in ICU and with selected indications of NIV.
62030980|NCT01328574|EXPERIMENTAL|Single Arm - TRC105 in Urothelial Carcinoma|TRC105 15 mg/kg/dose every two weeks
62030981|NCT01662882|EXPERIMENTAL|AD Subjects|
62030982|NCT01662882|EXPERIMENTAL|MCI|MCI (mild cognitive impairment)
62591831|NCT04930159|ACTIVE_COMPARATOR|1:1 Peer Support|Individual peer support calls.
62230232|NCT04299438|PLACEBO_COMPARATOR|Placebo|Normal saline placebo- 2 mL; one possible repeat dose ≥2 hours later
62230233|NCT05231031|ACTIVE_COMPARATOR|Aerobic exercise|This group received continuous aerobic exercise only in the form of walking on a treadmill 3 sessions/week for 6 weeks
62230234|NCT05231031|EXPERIMENTAL|Aerobic, Breathing exercises , and relaxation training|This group received continuous aerobic exercise only in the form of walking on a treadmill 3 sessions/week for 6 weeks in addition to breathing exercises and relaxation training for the same period
62230235|NCT00701779|EXPERIMENTAL|Dutasteride|"Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.~Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks."
62230236|NCT03405441|EXPERIMENTAL|Part 1 (Panel 1): JNJ-55375515 and placebo|Participants will receive dose level (DL) 1 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 3 (period 2) and a maximum of DL 5 (period 3) based on the safety and tolerability profile and pharmacodynamic (PD) profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations.
62230237|NCT03405441|EXPERIMENTAL|Part 1 (Panel 2): JNJ-55375515 and placebo|Participants will receive DL 2 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 4 (period 2) and a maximum of DL 6 (period 3) based on the safety and tolerability profile and PD profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations.
62230238|NCT03405441|EXPERIMENTAL|Part 2: JNJ-55375515 and placebo|Participants will randomly be assigned to one of four treatment sequences 1, 2, 3 or 4. In the first 3 sequences, participants will receive 2 doses of JNJ-55375515 and placebo. Participants assigned to sequence 4 will receive placebo only in all periods. 3 dose levels will be tested in Part 2 based on Part 1 and will not exceed those evaluated in Part 1. A wash-out period of at least 10 days will be maintained between study drug administrations in period 1, 2, 3 and 4. In period 4 (open-label pharmacokinetic (PK) assessment period) participants will be randomly assigned to one of two dose levels tested in periods 1 to 3.
62030983|NCT01662882|EXPERIMENTAL|Healthy Controls|
62030984|NCT05221164|EXPERIMENTAL|Intervention with 162 mg aspirin|Aspirin 162 mg daily for prevention of preeclampsia in pregnant patients at Family Medicine Clinic
62230239|NCT03271203||Subjects participating in the CE and CD interview|Thirty adult subjects from the US with erosive HOA will be asked to participate in CE and CD interviews.
62230240|NCT03271203||Subjects participating in interview and real time data capture|Ten adult subjects from the US (n=5 with erosive HOA, n=5 with non-erosive HOA) of the thirty subjects who are participating in the CE and CD interviews, will be asked to participate in the real-time data capture app task
62230241|NCT03218241|EXPERIMENTAL|PRT0064445 Dose 1|Dose 1 versus Placebo
62230242|NCT03218241|EXPERIMENTAL|PRT064445 Dose 2|Dose 2 versus Placebo
62230243|NCT03218241|EXPERIMENTAL|PRT064445 Dose 3|Dose 3 versus Placebo
62230244|NCT03218241|EXPERIMENTAL|PRT064445 Dose 4|Dose 4 versus Placebo
62030985|NCT06216691|OTHER|Coach-guided smartphone delivered CBT program|All eligible participants will be enrolled in an 8-week coach-guided smartphone delivered CBT program. The full duration of the program, with follow-up interview, will be 9 weeks.
62819513|NCT05661682|ACTIVE_COMPARATOR|a fixed-dose trace element combination product of zinc sulfate, copper sulfate, and selenious acid|This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of parenteral nutrition formulation requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.
62230245|NCT03218241|EXPERIMENTAL|PRT064445 Dose 5|Dose 5 versus Placebo
62819514|NCT05774353|OTHER|Patient questionnaire|Patients included in the study will complete an online questionnaire (LimeSurvey).
62030986|NCT05913622|EXPERIMENTAL|IABP unloading arm|This group of patients will receive an intra-aortic balloon pump (IABP) as an adjunct to VA ECMO support. When allocated to the IABP unloading arm, patients must receive an IABP within 8 hours after VA ECMO initiation.
62030987|NCT05913622|NO_INTERVENTION|ECMO alone arm|This group of patients will receive VA ECMO support without left ventricular unloading device after randomization.
62030988|NCT00628732|EXPERIMENTAL|1|
62030989|NCT03332524|EXPERIMENTAL|Arm 1 Product SP160412|oral route, 9 doses (Capsule) of SP160412 (Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg combined) in the 72 hours-period from first dose to last dose.
62030990|NCT03332524|PLACEBO_COMPARATOR|capsules Ibuprofen&placebo|2 capsules Ibuprofen and 1 placebo, oral route, 9 doses of Ibuprofen 400 mg with Placebo (Capsule) in the 72 hours-period from first dose to last dose,
62230246|NCT00121277|EXPERIMENTAL|SAHA (Suberoylanilide Acid) with Capecitabine|
62230247|NCT00275262|EXPERIMENTAL|LAD 11.25 mg 3 Month Depot|Three intramuscular injections LAD 11.25 mg 3 Month treatment administered approximately 3 months apart.
62230248|NCT00275262|PLACEBO_COMPARATOR|Placebo Comparator|Three intramuscular injections of matched placebo administered approximately 3 months apart.
62591832|NCT02877394|EXPERIMENTAL|Squatting Assist Device|The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.
62230249|NCT03126045|ACTIVE_COMPARATOR|Standard needle|Patients perform a spinal punction according to the usual practice, with a standard needle.
62230250|NCT03126045|EXPERIMENTAL|Atraumatic needle|Patients perform a spinal punction according to the usual practice, with an atraumatic needle.
62030991|NCT03332524|PLACEBO_COMPARATOR|Capsule Chlorpheniramin&placebo|capsule Chlorpheniramine 4mg and 1 Placebo, 3/72 hours-period from first dose to last dose, oral route
62030992|NCT01367327|EXPERIMENTAL|Exercise with music|Loaded sit-to-stand exercise with music for 6 weeks
62030993|NCT01367327|ACTIVE_COMPARATOR|Exercise without music|Loaded sit-to-stand exercise without music for 6 weeks
62591833|NCT02877394|SHAM_COMPARATOR|Sham Squatting Assist Device|This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
62807138|NCT05478941|ACTIVE_COMPARATOR|Progressive Muscle Relaxation training via Zoom and Guided Imagery exposure|"A standardized protocol regarding the information on the training background is shared with participants. Then, they are invited to participate in four individual PMRT sessions (two sessions per week) deployed via Zoom.~The fifth session after a week (T1; day 7) is administered in-presence at the Virtual Reality laboratory (A10-A11)- University of Padova; here an in-imagination relaxing scenario is built up with the support of the Psychotherapist; then, participants are exposed to an in-vivo PMRT relaxing session conducted by the Psychotherapist, with the request to think about the in-imagination relaxing scenario, created before, during the progressive relaxation procedure. After two weeks (T2; day 14), at the follow-up phase, the therapist asks to recover the in-imagination relaxing scenario and relax, giving participants the time allowed for the last guided relaxing session."
62591834|NCT03039855|EXPERIMENTAL|Treatment|Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system
62807139|NCT05478941|EXPERIMENTAL|Progressive Muscle Relaxation training via Zoom and personalized VR exposure|"PMRT sessions and expected time length are the same as for the first group. Differences regard the fifth session after a week (T1; day 7), where the relaxing scenario is built with the psychotherapist's support based on the VR's tools. Indeed, during the in-presence session, participants are exposed to a merged personalized relaxing VR scenario and PMRT session administered by the Oculus Quest 2 tool.~During the follow-up (T2; day 14), it is asked to recover the image and relax, making available the same time allowed for the last guided session."
62807140|NCT05478941|EXPERIMENTAL|Progressive Muscle Relaxation training based on audio-recording and personalized VR exposure|"A standardized protocol of information and the four PMRT sessions is administered individually based on an audio-track through the Moodle e-learning platform of the University of Padova.~During the fifth session after a week (T1; day 7), users are asked to participate in an in-presence session in which they are exposed to a merged personalized, relaxing VR scenario and a PMRT session administered based on the Oculus Quest 2 tool. The last follow-up session (T2; day 14) has the same features as the other groups."
62807141|NCT02584946|PLACEBO_COMPARATOR|Low-AVA oat flour cookies|
62807142|NCT02584946|EXPERIMENTAL|High-AVA oat flour cookies|
62807143|NCT01811888||Patients with knee osteoarthritis|
62230251|NCT05631301|EXPERIMENTAL|Move&Connect-Youth|"* Sessions run weekly at the Bloorview Research Institute by a registered physiotherapist and occupational therapist for one hour. Participants will provide electronic consent and complete the pre-intervention measures one week before the intervention begins. Data collection will also occur on week 8 (post intervention) and at 3-month follow-up.~* Weekly sessions will include an active rehabilitation component including exercises focused on cardiovascular fitness, balance, co-ordination and strength.~* Weekly sessions will also include an educational component through focused discussions on topics including headache management, stress coping skills, fatigue management, advocacy skills, and goal setting.~* Data collection sessions will include a series of questionnaires and surveys to acquire consent, demographic information, and assess pre-post changes in concussion symptoms, self-efficacy, quality of life, mental health and social support."
62591835|NCT04231500||patients with GVHD after allo-HSCT|Exploration of the skin-microbiota in patients with GVHD after allo-HSCT by sampling of skin swabs and a skin punch biopsy before conditioning procedure and additional skin biopsies from affected and healthy skin sites in case of GVHD
62591836|NCT04231500||patients without GVHD after allo-HSCT|Exploration of the skin-microbiota in patients without GVHD after allo-HSCT by sampling of skin swabs and a skin punch biopsy before conditioning procedure
62591837|NCT01913431|EXPERIMENTAL|Baracle Tab.®|(It can be also placebo) dosage: 2 tablets daily for 48 weeks
62591838|NCT01913431|EXPERIMENTAL|Baraclude Tab.®|(It can be also placebo) dosage: 2 tablets daily for 48 weeks
62591839|NCT03465618|EXPERIMENTAL|surgical patients|Patients will be i.v. injected with approximately 5 mCi (\~3.4-6.7 nanomoles) of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (specific activity range 750.0 - 1450 mCi/ µmol) and undergo the microdosing study for purposes of collecting particle tracer kinetic and dosimetry data. The patient's PET/CT Brain scans may be acquired prior to surgery. All non-surgical and some surgical patients (at the discretion of the physician) will undergo PET brain imaging.
62591840|NCT03465618|EXPERIMENTAL|non-surgical patients|Before the patient's PET Brain scans patients will be i.v. injected with approximately 5 mCi (\~3.4-6.7 nanomoles) of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (specific activity range 750.0 - 1450 mCi/ µmol) and undergo the microdosing study for purposes of collecting particle tracer kinetic and dosimetry data. All non-surgical and some surgical patients (at the discretion of the physician) will undergo PET brain imaging
62591841|NCT00643825|ACTIVE_COMPARATOR|A: prolonged adj TMZ|
62591842|NCT00643825|OTHER|B : Stop and Go|Rechallenging patients with TMZ at relapse
62591843|NCT03943264|EXPERIMENTAL|0.3 mg/kg XPro1595|0.3 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
62591844|NCT03943264|EXPERIMENTAL|0.6 mg/kg XPro1595|0.6 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
62591845|NCT03943264|EXPERIMENTAL|1.0 mg/kg XPro1595|1.0 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
62591846|NCT02345460|EXPERIMENTAL|Treatment (FOLFIRINOX)|Patients receive FOLFIRINOX regimen comprising irinotecan hydrochloride IV over 90 minutes, oxaliplatin IV over 120 minutes, leucovorin calcium IV over 120 minutes, and fluorouracil IV over 1-2 minutes and then continuously over 46 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62819515|NCT00907595|ACTIVE_COMPARATOR|Ramelteon|Subjects randomized to Ramelteon
62819516|NCT00907595|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo
62819517|NCT05720897|EXPERIMENTAL|Auditory Alone Brief Relaxation|Participants randomized to this arm will receive earphones to listen to a guided brief relaxation recording, focusing on breathing and a body scan, prior to their dental procedure.
62030994|NCT04372966|ACTIVE_COMPARATOR|Cemented|This group will receive a cemented Exeter stem and contemporary acetabular component (Stryker).
62030995|NCT04372966|ACTIVE_COMPARATOR|Uncemented|This group will receive an uncemented Corail stem and uncemented acetabular component (Depuy).
62030996|NCT05570526|EXPERIMENTAL|Intervention group:|20 patients will receive oral melatonin 5mg tablets 1-hour before bedtime for 12 weeks.
62030997|NCT05570526|PLACEBO_COMPARATOR|Placebo|20 patients will receive one tablet of placebo 1-hour before bedtime for 12 weeks.
62030998|NCT05462626|EXPERIMENTAL|the Holistic Occupational Performance Empowerment (HOPE) Lifestyle Program|The intervention will consist of six individualized sessions that will be conducted via a telehealth platform, each lasting about 45-60 minutes. Individual sessions allow for the participant's personal health factors to be discussed and reflected upon as the intervention is delivered weekly. Each week will comprise one or more lifestyle topics that are based on the twelve modules described in the Lifestyle Redesign® manual (Clark et al., 2015).
62819518|NCT05720897|EXPERIMENTAL|Relaxation Virtual Reality|Participants will receive virtual reality goggles and choose a scene of their liking to experience, prior to their dental procedure.
62819519|NCT01769742|EXPERIMENTAL|Early mobility bundle|Delivery of early targeted physiotherapy to patients on the interventional wards; to comprise assessment and communication of mobility to ward staff and patient, provision of mobility aids, guidance and encouragement to patient and staff to allow patient to dress and mobilise independently if clinically safe to do so
62030999|NCT00496665|EXPERIMENTAL|Vandetenib|Cyclophosphamide 50 mg daily, methotrexate 2.5 mg days 1-2 weekly, and daily vandetanib (zactima) in 3 dose-escalation cohorts (100mg=Cohort 1) (200mg=Cohort 2) (300mg=Cohort3)
62031000|NCT04317820|EXPERIMENTAL|DBR Condition|Involves 8 weekly sessions of DBR treatment.
62031001|NCT04317820|NO_INTERVENTION|Wait-list Condition|No intervention for approximately 8 weeks.
62031002|NCT05403008|OTHER|Zirconomer improved|a nano zirconia reinforced glass ionomer, which has improved the mechanical, esthetic and handling properties than its previous successor.
62031003|NCT05403008|ACTIVE_COMPARATOR|Nano hybird resin composite|Resin composite (RC) is the gold standard esthetic restoration in proximal cavities due to their high aesthetic properties, increased mechanical durability and enhanced adhesion to tooth structure.
62031004|NCT01850680|EXPERIMENTAL|Sarilumab (SAR153191, REGN88) Dose 1|First dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
62031005|NCT01850680|EXPERIMENTAL|Sarilumab (SAR153191, REGN88) Dose 2|Second dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
62230252|NCT05631301|EXPERIMENTAL|Move&Connect-Youth-Virtual|"* Sessions run weekly via Zoom videoconferencing by a registered physiotherapist and occupational therapist for one hour. Participants will provide electronic consent and complete the pre-intervention measures one week before the intervention begins. Data collection will also occur on week 8 (post intervention) and at 3-month follow-up.~* Weekly sessions taking place over Zoom will include an active rehabilitation component including exercises focused on cardiovascular fitness, balance, co-ordination and strength.~* Weekly sessions will also include an educational component through focused discussions on topics including headache management, stress coping skills, mood coping skills, fatigue management, advocacy skills, and goal setting.~* Data collection sessions will include a series of questionnaires and surveys to acquire consent, demographic information, and assess pre-post changes in concussion symptoms, self-efficacy, quality of life, mental health and social support."
62031006|NCT01850680|EXPERIMENTAL|Sarilumab (SAR153191, REGN88) Dose 3|Third dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
62422251|NCT03295968|EXPERIMENTAL|Ibuprofen and Rest|
62819520|NCT01769742|NO_INTERVENTION|Usual care|Usual physiotherapy service only
62031007|NCT01850680|EXPERIMENTAL|Sarilumab (SAR153191, REGN88) Dose 4|Fourth dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
62031008|NCT01850680|PLACEBO_COMPARATOR|Placebo Dose 5|Placebo to match Sarilumab (SAR153191, REGN88) in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
62031009|NCT04477603|EXPERIMENTAL|Subjects receiving the Impella ECP|
62031010|NCT02003001|EXPERIMENTAL|BT injection|
62031011|NCT01629004|OTHER|Non-responders|"Non-responders to an initial mailed CRC screening invitation from their family physician.~FOBT kit. Mailed invitation."
62031012|NCT01629004|OTHER|Recall patients|"Those who responded to the initial mailed CRC screening invitation and are now due for repeat screening (i.e., recall patients).~FOBT kit. Mailed invitation."
62031013|NCT06636136|OTHER|OPRA implant leg|The participants will have two stage surgical procedures to implant the OPRA device to the amputated leg.
62031014|NCT06113627|EXPERIMENTAL|Exercise group|The intervention group will receive a total of 24 sessions of Therapeutic Resistance Exercise, distributed in 2 weekly sessions of 50 minutes during 3 months.
62031015|NCT06113627|NO_INTERVENTION|Control group|The control group will receive an educational booklet containing generalized mobility exercises such as frontal and lateral shoulder raises and rotations (hands to head, hands behind back). This is usually the usual treatment, since in most centers, patients are only referred for treatment of LACM when it is already established.
62031016|NCT02267382|EXPERIMENTAL|VT-1161 Low-dose 3-month|1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
62031017|NCT02267382|EXPERIMENTAL|VT-1161 Low-dose 6-month|1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 23 weeks
62422252|NCT03295968|EXPERIMENTAL|Ibuprofen and High Intensity Exercise|
62422253|NCT01506570|EXPERIMENTAL|TetraVax-DV Vaccine - Admixture TV003|Participants will receive one SC injection of the TetraVax-DV Vaccine - Admixture TV003 in their upper arm at Day 0 and Day 180.
62422254|NCT01506570|EXPERIMENTAL|TetraVax-DV Vaccine - Admixture TV005|Participants will receive one SC injection of the TetraVax-DV Vaccine - Admixture TV005 in their upper arm at Day 0 and Day 180.
62422255|NCT01506570|PLACEBO_COMPARATOR|Placebo|Participants will receive one SC injection of placebo in their upper arm at Day 0 and Day 180.
62422256|NCT01067989|EXPERIMENTAL|intervention|same treatment for all patients
62422257|NCT03996980|EXPERIMENTAL|Custom-made foot orthoses|treatment intervention custom-made polypropylene foot orthoses for a period of 4 weeks
62807144|NCT02536898|EXPERIMENTAL|Fracture liaison service|"* Information, assessment \& lifestyle advice~* refer to DXA scan, except patients with dementia, difficulties laying on the back or short life exp.~* Blood samples~* Sufficient intake of Vitamin D \& calcium, combined with physical activity will be recommended with lifestyle advice (smoking \& alcohol intake)~* Patients With Hip, Vertebral or two or more low-trauma fractures are recommended treated with anti-osteoporosis drug~* Other fractures, treatment recommended if FRAX score≥20% for major fracture \& T-score≤-1.5~* Fracture patients with reduced kidney function will be treated with anti-RANKL~* Anti-osteoporosis drug prescribed by hospital physician~* Follow-up phone call after 3 months and visit to talk with coordinating nurse after 1 year~* Patients with spine or femoral neck T-scores≤-3.5, \>2 severe vertebral fractures \& those who suffer a second fracture while using anti-osteoporosis drug, will be referred for further examination and teriparatide treatment will be considered"
62807145|NCT02536898|OTHER|Current treatment|Treatment as offered before intervention.
62807146|NCT06340022|EXPERIMENTAL|Upper jaw|"* A half of upper jaw: Electronic local anesthesia technique (SleeperOne) A topical anesthetic spray containing 10% lidocaine was applied with a cotton pellet for 1 minute.The SleeperOne® 5 (Dentalhitec, Mazières-en-Mauges, France) device was used with 30 gauge-0.30x09 mm Effitec needle tips for intraosseous anesthesia. The anesthesia was applied in child mode according to the manufacturer.1 ml of local anesthetic solution (Ultracaine D-S Fort) was applied for 1 minute.~* The contralateral half of the upper jaw: Infiltrative anesthesia (conventional) After confirming the vitality of the tooth, a topical anesthetic spray was applied with a cotton pellet for 1 minute. A local anesthetic, Maxicaine Forte, was administered for 1.5 ml for 1 minute using buccal infiltration anesthesia technique using short syringes."
62807147|NCT06340022|EXPERIMENTAL|Lower jaw|"* A half of lower jaw: Electronic local anesthesia technique (SleeperOne) A topical anesthetic spray containing 10% lidocaine was applied with a cotton pellet for 1 minute.The SleeperOne® 5 (Dentalhitec, Mazières-en-Mauges, France) device was used with 30 gauge-0.30x09 mm Effitec needle tips for intraosseous anesthesia. The anesthesia was applied in child mode according to the manufacturer.1 ml of local anesthetic solution (Ultracaine D-S Fort) was applied for 1 minute.~* The contralateral half of the lower jaw: mandibular anesthesia (conventional) After topical anesthesia, mandibular anesthesia with Maxicaine Forte,in an amount of 1.8 ml was administered for 1 minute using long syringes."
62807148|NCT03999515|EXPERIMENTAL|Treatment (abiraterone acetate, enzalutamide, erdafitinib)|Patients receive abiraterone acetate orally PO QD or enzalutamide PO QD on days 1-21. Patients also receive erdafitinib PO QD on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
62807149|NCT04598022||vegan|subjects having a vegan nutrition pattern for at least the last 3 months
62807150|NCT04598022||vegetarian|subjects having a vegetarian nutrition pattern for at least the last 3 months
62807151|NCT04598022||omnivores|subjects having a omnivore nutrition pattern for at least the last 3 months
62031018|NCT02267382|EXPERIMENTAL|VT-1161 High-dose 3-month|2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
62031019|NCT02267382|EXPERIMENTAL|VT-1161 High-dose 24-week|2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 23 weeks
62031020|NCT02267382|PLACEBO_COMPARATOR|Placebo|2 placebo tablets once daily for 7 days, then once weekly for 23 weeks
62031021|NCT03411967|EXPERIMENTAL|apatinib combine with docetaxel|Docetaxel, 60 mg / m2, d1, iv + apatinib 500mg, po, qd
62422258|NCT03996980|PLACEBO_COMPARATOR|Placebo|a flat insole for a period of 4 weeks
62422259|NCT06138756||Pre-adolescence with migraine|Patients at the age of 9-11with migraines who used the Nerivio device at least once
62422260|NCT06551454|ACTIVE_COMPARATOR|Football Youth League Players group|Intervention for all participants: 12 weeks of prevention exercise program in football FIFA 11+ tasks of part 2: single leg stance and squats. Followed by exercise monitoring instructions in the FIFA 11+ user manual.
62422261|NCT06551454|EXPERIMENTAL|Smart Textile Biofeedback Football Youth League Players group|Using the biofeedback method provided by the DAid® smart sock system as the monitoring method of positioning the lower limb for the study group during 12 weeks of prevention exercise program in football FIFA 11+ tasks of part 2: single leg stance and squats.
62422262|NCT05385796|EXPERIMENTAL|Loop taping|Loop taping of the heel fat pad
62422263|NCT05385796|PLACEBO_COMPARATOR|Control taping|Control taping of the heel fat pad
62422264|NCT05649852|OTHER|Chemotherapy|Adjuvant chemotherapy treatment
62422265|NCT03928613|EXPERIMENTAL|Mild Cognitive Impairment|"* Clinical dementia rating 0 or 0.5~* Diagnosed by physicians as mild cognitive impairment according to the criteria of International Working Group on Mild Cognitive Impairment"
62422266|NCT06289335|ACTIVE_COMPARATOR|Dexmedetomidine|0.3 mcg Kg-1 (actual weight) of dexmedetomidine IV in 20 mL of saline
62422267|NCT06289335|SHAM_COMPARATOR|Ondansetron|8 mg ondansetron IV in 20 mL saline
62031022|NCT03591341||nursing women|women who gave birth and are breast feeding their baby- melatonin level in pumped breast milk have been checked
62031023|NCT02313012|EXPERIMENTAL|Dose Level 1 CC-90003|CC-90003 by mouth (PO) daily on days 1 -21 of every 28 day cycle; Cycle 1, Days 1 to 28 will constitute the dose limiting toxicity (DLT) assessment period for purposes of non-tolerated dose (NTD) and Maximum Tolerated Dose determination.
62031024|NCT03516331|EXPERIMENTAL|Part 1:FDL176 & FDL169 coadministration|To receive a single dose of FDL176 on Day 1, followed up FDL169 TID starting Day 8; and another single dose of FDL176 on Day 22.
62422268|NCT05019716|EXPERIMENTAL|Treatment (ZEN-3694, etoposide, cisplatin)|Patients receive ZEN003694 PO once or twice daily on days 1-14 or days 1-21 of each cycle depending upon dosage assignment. Patients also receive etoposide IV over 60 minutes on days 1-3 for cycles 1-4 or up to 8 cycles, and cisplatin IV over 60 minutes on day 1 of cycles 1-4 or up to 8 cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo radiologic evaluation (chest x-ray, CT, PET-CT, MRI, and/or FDG-PET), blood and urine sample collection and biopsy throughout the study.
62422269|NCT05147792|EXPERIMENTAL|CLAAS|Transcatheter left atrial occluder
62422270|NCT05147792|ACTIVE_COMPARATOR|WATCHMAN / Amulet|Transcatheter left atrial occluder
62422271|NCT01791127||Pacemaker Therapy|Patients with a market-released BIOTRONIK pacemaker system including one or two Siello S leads.
62031025|NCT03516331|EXPERIMENTAL|Part 2:FDL176 & FDL169 coadministration|To receive FDL176 QD starting Day 1, and FDL169 TID starting Day 8
62031026|NCT04454411|EXPERIMENTAL|Buprenorphine|Participants assigned to treatment with extended-release buprenorphine
62031027|NCT04454411|ACTIVE_COMPARATOR|Naltrexone|Participants assigned to treatment with extended-release naltrexone
62230253|NCT05631301|OTHER|Move&Connect-Youth Waitlist control|"The control group will be recruited from the waitlist for the Persistent Concussion Clinic and the Early Care Concussion Clinic at Holland Bloorview, in addition to partnered community medical offices and organizations.~For the control group, the research assistant will schedule the participants first session to obtain consent and provide youth/caregivers with week 1 questionnaires. At this time, the participants will be able to ask any questions related to the study. After eight weeks the control group will be asked to complete the post measures in order to mimic the length of the intervention. The control group will then be given the opportunity to enroll in one of the intervention arms of the Move\&Connect study. They will then follow the same approved procedures for the intervention treatment group. Youth and their caregivers will be able to participate as waitlist controls without completing the intervention, if they choose."
62807152|NCT03651037|EXPERIMENTAL|Thrivors+BH|For Thrivors+BH, a module will be developed for users to input pain and energy levels, enabling real-time customization of exercise regimens. Modules of clinically validated bone health exercises with instructional videos will be developed. Additionally, users will be able upload and send videos of themselves exercising for feedback and assessment. This version will contain bone health educational content, mindfulness and nutrition resources.
62807153|NCT03651037|EXPERIMENTAL|Thrivors Basic|A Thrivors Basic version that lacks customization and video content will be developed. This version will contain bone health educational content, mindfulness and nutrition resources.
62031028|NCT01279889||Cesarean Delivery|Healthy pregnant women having an elective cesarean delivery
62031029|NCT05802238|EXPERIMENTAL|Treatment Arm|Patients randomized to treatment arm of study will have TXA administered 10 minutes prior to surgery
62031030|NCT05802238|PLACEBO_COMPARATOR|Control Group|The control group will have saline administered 10 minutes prior to surgery.
62243167|NCT03312699|EXPERIMENTAL|Group A Oral Typhoid|Group A: Up to 15 healthy volunteers 18-40 years old, will be randomized to either Typhoid Vi Polysaccharide Vaccine, Typhim Vi®, or Typhoid Vaccine Live Oral Ty21a, Vivotif® (Oral Typhoid). This arm represents those randomized to Oral Typhoid. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8 (from date of last oral dose), Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
62422272|NCT01252446||ADHD|The sample of 187 children and adolescent in the age of 6 to 17 years referred to the Child and Adolescent Clinic, Haugesund, Norway during the period of one year and diagnosed in ICD 10 system as ADHD.
62422273|NCT03658356|PLACEBO_COMPARATOR|Verbal Instruction on Urine collection|"At initial prenatal visit, pregnant patients will be given verbal instructions on how to collect a urinary sample for culture.~Intervention: Pt will be given verbal instruction to collect urine"
62807154|NCT02793726||Symptomatic|Patients with pain and or other sign of prothesis failure
62591847|NCT05507476|ACTIVE_COMPARATOR|Desmopressin group|"The patient will receive two puffs of desmopressin acetate 10 µg/puff in the side of the nasal cavity ipsilateral to the obstructed lacrimal duct (20 μg totally) 60 minutes before surgery Minirin 10 μg/0.1 ml per spray, Ferring Pharmaceutical Company. Three normal saline-soaked packs will be placed in the middle meatus for 5 minutes immediately before the start of surgery."
62807155|NCT02793726||Asymptomatic|Patients with regular clinical and radiographic evolution of the implant. No pain
62807156|NCT05800223|EXPERIMENTAL|GroupA|Intracranial stereotactic radiotherapy (27-40 Gy/3-5f) was administered to all intracranial lesions on the first day of oral administration of Almonertinib
62807157|NCT05800223|EXPERIMENTAL|GroupB|Two successive MR enhancements after oral administration of Almonertinib suggest that intracranial lesions are maximally remission, and stereotactic body radiotherapy is given to all lesions (27-40Gy/3-5f)
62807158|NCT05800223|EXPERIMENTAL|GroupC|oral administration of Almonertinib
62807159|NCT03652012|EXPERIMENTAL|Mild Cognitive Impairment|"The following revised Mayo Clinic criteria for MCI (Petersen, et al. 2014) will be used: (1) cognitive concern expressed by a physician, informant, participant, or nurse; (2) impairment in 1 or more cognitive domains (memory, language, visuospatial skills, or executive functions); (3) essentially normal functional activities; and (4) absence of dementia. Individuals with MCI will have Mini-Mental State Exam (MMSE, Appendix 19) scores between 18 and 23 (inclusive) and have a Clinical Dementia Rating Scale score of 0.5.~This group will undergo Transcranial Magnetic Stimulation (TMS) protocol."
62807160|NCT03652012|ACTIVE_COMPARATOR|Healthy Controls|"Participants who are matched for age and gender.~This group will undergo Transcranial Magnetic Stimulation (TMS) protocol."
62807161|NCT04722874|ACTIVE_COMPARATOR|Ortho-k|Participants will continue to use ortho-k lenses alone.
62031031|NCT06388525||ERCP Group|All patients aged 18 years and over who underwent elective cholecystectomy surgery after a prior ERCP with a diagnosis of symptomatic cholelithiasis and whose surgery was started laparoscopically
62807162|NCT04722874|EXPERIMENTAL|RLRL+Ortho-k|Participants will be treated with RLRL twice a day in addition to ortho-k lenses.
62807163|NCT02008123|EXPERIMENTAL|Primidone|Participants will receive primidone in addition to their clopidogrel regimen. For the first 3 days of the study, participants will take 125 mg of primidone (one-half tablet). After 3 days of 125 mg, the primidone dose will be increased to 250 mg (1 tablet) taken at bedtime for the next 17-25 days. The participant will then be asked to return and be retested.
62807164|NCT02640638|EXPERIMENTAL|CenteringPregnancy group prenatal care|Pregnant women who were randomized to receive CenteringPregnancy group prenatal care
62807165|NCT02640638|NO_INTERVENTION|Traditional individual prenatal care|Pregnant women who were randomized to receive traditional individual prenatal care
62031032|NCT06388525||Standard/Non-ERCP Group|All patients aged 18 years and over who underwent elective cholecystectomy surgery without an ERCP history with a diagnosis of symptomatic cholelithiasis and whose surgery was started laparoscopically
62807166|NCT06304116|EXPERIMENTAL|Rehabilitation therapy+Stellate ganglion block|"The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Based on the invention above, the patients in the observation group were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)"
62807167|NCT06304116|PLACEBO_COMPARATOR|Rehabilitation therapy+Placebo|The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
62807168|NCT01192997|ACTIVE_COMPARATOR|Menveo-Meningitec|Subjects who were primed with Meningitec who will receive Novartis Menveo
62807169|NCT01192997|ACTIVE_COMPARATOR|MenACWY-TT-Meningitec|Subjects who were primed with Meningitec who will receive GSK MenACWY-TT
62807170|NCT01192997|ACTIVE_COMPARATOR|Menveo-Menjugate|Subjects who were primed with Menjugate who will receive Novartis Menveo
62807171|NCT01192997|ACTIVE_COMPARATOR|MenACWY-TT-Menjugate|Subjects who were primed with Menjugate who will receive GSK MenACWY-TT vaccine.
62807172|NCT01192997|ACTIVE_COMPARATOR|Menveo-NeisVac-C|Subjects who were primed with NeisVac-C who will receive Novartis Menveo
62591848|NCT05507476|ACTIVE_COMPARATOR|Epinephrine group|"The patient will receive topical 1:100,000 epinephrine in the side of the nasal cavity ipsilateral to the obstructed lacrimal duct via 3 soaked packs placed in the middle meatus for 5 minutes immediately before the start of surgery. The patient will also receive two puffs of normal saline prepared in emptied Minirin bottle in the same nasal cavity 60 minutes before surgery."
62591849|NCT06038461|EXPERIMENTAL|Surufatinib Combined With Temozolomide and S-1|"Patients will receive surufatinib combined with temozolomide and S-1 once every three weeks as the second-line treatment until disease progression or intolerable toxicity or patients withdrawal of consent.~Phase I: DLTs of surufatinib combined with temozolomide and S-1 will be evaluated based on NCI CTCAE v 5.0 in the first cycle."
62807173|NCT01192997|ACTIVE_COMPARATOR|MenACWY-TT-NeisVac-C|Subjects who were primed with NeisVac-C who will receive GSK MenACWY-TT vaccine
62807174|NCT02161796|EXPERIMENTAL|1: young male subjects|3x single dose of FG-4592 and a placebo
62031033|NCT03496038|EXPERIMENTAL|Leukocyte and Platelet Rich Fibrin (L-PRF)|"For the test group the sub-sinus cavity will be filled with Leukocyte en Platelet Rich Fibrin (L-PRF).~Before starting the surgery, 8 tubes (9 ml) of venous blood will be collected from the patients. A centrifugation standard L-PRF protocol will be followed followed (12 minutes centrifugation, 2700 rpm/408g RCF).~After full centrifugation of the tubes, the L-PRF clots will be removed from the tubes using surgical tweezers. The clots will be thereafter gently compressed into membranes using a sterile metal box (Xpression, Intra-Lock, Florida, USA)."
62422274|NCT03658356|ACTIVE_COMPARATOR|Video instruction on urine collection|"At initial prenatal visit, pregnant patients will watch a video on how to collect a urinary sample for culture~Intervention: Patient will be asked to watch a video on how to collect a urine sample"
62591850|NCT04433715||patients with UI symptoms|All participants completed all three questionnaires: ICIQ-SF, UDI-6 and IIQ-7.
62031034|NCT03496038|ACTIVE_COMPARATOR|Deproteinized Bovine Bone Mineral (DBBM)|For the test group the sub-sinus cavity will be filled with deproteinized bovine bone mineral (DBBM). The product used will be a xenograft (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland).
62031035|NCT05406687|OTHER|People experiencing homelessness|All homeless adults, aged 18 years and over, who visit the CANCERLESS pilot sites will be asked to participate (convenience sampling). We define individuals as being homeless if they fall under one of the categories listed in the European typology of homelessness and housing exclusion.
62591851|NCT04433715||patients without UI symptoms|All participants completed all three questionnaires: ICIQ-SF, UDI-6 and IIQ-7.
62591852|NCT05120466|ACTIVE_COMPARATOR|Usual Health Education Curriculum|Students will receive the school's usual health education curriculum.
62591853|NCT05120466|EXPERIMENTAL|Usual Health Education Curriculum plus Intervention|Students will receive the school's usual health education curriculum. Students will also receive the intervention. Delivery of the intervention (i.e., timing, frequency) will be determined by discussing the results of the Aim 1 focus groups with teachers and administrators.
62591854|NCT04794374|EXPERIMENTAL|Discharged COVID-19 survivors|"Telerehabilitation will be provided by physiotherapists including audio, video visits.~A brochure designed by physiotherapists for COVID-19 survivors will be used. Physiotherapists will call patients weekly and guide, design, modify the exercises accordingly to the patients."
62591855|NCT02238912|EXPERIMENTAL|Kandhaga Rasayanam- single arm|Kandhaga Rasayanam- 2grams twice a day for 45 days
62591856|NCT06247007|EXPERIMENTAL|EA (electroacupuncture)|Individuals who underwent electroacupuncture addition to non-surgical periodontal therapy
62591857|NCT06247007|NO_INTERVENTION|Control|Individuals who have non-surgical periodontal therapy only
62591858|NCT06616675|ACTIVE_COMPARATOR|Darifenacin Group|Anticholinergic treatment for OAB
62591859|NCT06616675|EXPERIMENTAL|PTENS Group|Neuromodulation using transcutaneous electrical sacral nerves stimulation
62591860|NCT05115214|EXPERIMENTAL|SpherePVI™ Catheter|Subjects treated with the SpherePVI™ Catheter
62591861|NCT01665222|EXPERIMENTAL|Morphine Sulfate 60mg Extended-release tablets|A single oral dose of Morphine Sulfate 60mg Extended-release tablets of Ohm Laboratories Inc.
62591862|NCT01665222|ACTIVE_COMPARATOR|MS Contin® 60 mg Controlled-release tablets|A single oral dose of MS Contin® 60 mg Controlled-release tablets of Purdue Pharma L.P.
62591863|NCT06623539|EXPERIMENTAL|Pemafibrate high dose group|
62591864|NCT06623539|EXPERIMENTAL|Pemafibrate low dose group|
62807175|NCT02161796|EXPERIMENTAL|2: young female subjects|3x single dose of FG-4592 and a placebo
62807176|NCT02161796|EXPERIMENTAL|3: elderly male subjects|3x single dose of FG-4592 and a placebo
62807177|NCT02161796|EXPERIMENTAL|4: elderly female subjects|3x single dose of FG-4592 and a placebo
62807178|NCT01687361|EXPERIMENTAL|branched-chain amino acids (BCAA) supplementation|
62807179|NCT01687361|PLACEBO_COMPARATOR|PLACEBO|
62807180|NCT02526277|ACTIVE_COMPARATOR|MMF07 Foot Massager device|Participants randomized to the MMF07 Foot Massager device arm will be provided the MMF07 Foot Massager device and instructed to set this device at setting 3, then increase or decrease the setting to their desired level of comfort, to be used for 30 minutes at bedtime.
62230254|NCT05631301|EXPERIMENTAL|Move&Connect-Caregiver|"* The treatment sessions run once a week at the Bloorview Research Institute and last approximately one hour. Participants will provide electronic consent and complete the pre-intervention measures one week before the intervention begins. Data collection will also occur on week 8 (post intervention) and at 3-month follow-up.~* Caregivers will participate in a group-based psychoeducational support group with sessions consisting of focused discussions on topics including: the ripple effect, school advocacy, child well-being, family functioning, parenting, and stress \& daily challenges. The sessions will be run by a clinical neuropsychologist and social worker.~* Data collection sessions will include a series of questionnaires and surveys to acquire consent, demographic information, and assess pre-post changes in their youth's concussion symptoms, and mental health, as well as parental self-efficacy, quality of life, mental health and social support."
62807181|NCT02526277|ACTIVE_COMPARATOR|Heat therapy|Participants randomized to heat therapy will be provided an electric heating pad and will be instructed to use this pad at a medium setting for 30 minutes at bedtime.
62031036|NCT05499429|ACTIVE_COMPARATOR|active stimulus group|Patients were assigned into active stimulus group according to random number table
62031037|NCT05499429|SHAM_COMPARATOR|sham stimulus control group|Patients were assigned into sham stimulus control group according to random number table
62031038|NCT05752123|EXPERIMENTAL|ET-01|BCL11A Enhancer modified Autologous Hematopoietic Stem Cells
62031039|NCT06574867||Surgical Patients Monitored with viQtor|This group includes adult patients admitted to the surgical ward at Catharina Hospital Eindhoven. Participants in this group will be monitored continuously using the viQtor wearable device to track vital signs such as heart rate, respiratory rate, and blood oxygen saturation during their hospital stay. The focus is on evaluating the implementation, usability, and effectiveness of the viQtor solution in a real-world clinical setting.
62031040|NCT03564912|EXPERIMENTAL|2 week group|
62031041|NCT03564912|ACTIVE_COMPARATOR|3 week group|
62031042|NCT06087601|ACTIVE_COMPARATOR|Sham blocks|US-guided Bilateral genicular nerve block with 0,9% NaCl
62031043|NCT06087601|ACTIVE_COMPARATOR|Genicular nerve neurolysis|US-guided Bilateral genicular nerve neurolysis with 0,5ml 95% ethanol
62031044|NCT03001648||PGS|Patients with RIF scheduled for PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridation (aCGH) underwent one or more stimulation cycles. If euploid blastocysts were available, patients underwent frozen embryo transfer/s.
62031045|NCT03001648||Standard IVF|Patients with RIF scheduled for standard IVF (In Vitro Fertilization) underwent a single stimulation cycle with the fresh embryo transfer and the subsequent frozen embryo transfers if there were surplus frozen embryos and the fresh embryo transfer was unsuccessful.
62031046|NCT06060691|EXPERIMENTAL|Kaempferol group|Kaempferol gel received the vaginal gel containing antioxidant extract every day for seven days. Then, the treatment continued for two months, twice weekly
62591865|NCT06623539|EXPERIMENTAL|Fenofibrate group|
62031047|NCT06060691|PLACEBO_COMPARATOR|Placebo group|Plain formulation received the vaginal gel containing antioxidant extract every day for seven days. Then, the treatment continued for two months, twice weekly
62230255|NCT05631301|EXPERIMENTAL|Move&Connect-Caregiver-Virtual|"* The treatment sessions run once a week using Zoom videoconferencing and last approximately one hour. Participants will provide electronic consent and complete the pre-intervention measures one week before the intervention begins. Data collection will also occur on week 8 (post intervention) and at 3-month follow-up.~* Caregivers will participate in a group-based psychoeducational support group with sessions consisting of focused discussions on topics including: the ripple effect, school advocacy, child well-being, family functioning, parenting, and stress \& daily challenges. The sessions will be run by a clinical neuropsychologist and social worker.~* Data collection sessions will include a series of questionnaires and surveys to acquire consent, demographic information, and assess pre-post changes in their youth's concussion symptoms, and mental health, as well as parental self-efficacy, quality of life, mental health and social support."
62422275|NCT03490331|EXPERIMENTAL|Genetically corrected cultured epidermal autograft|"The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate epidermal cells including stem cells. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where they will be corrected, expanded and prepared as final sheets to be implanted.~In the second surgery, genetically corrected cultured epidermal autograft (Hologene17) will be implanted into the selected area. The specialist surgeon will either use a local or general anaesthetic for the implant operation. The treated area will be immobilized for some days after this operation. Antibiotics and anti-inflammatory drugs will be administered (if necessary) to prevent infections and to minimise swelling."
62422276|NCT05517018||single layer uterotomy|53 women with a single-layer uterotomy while closing the uterus during Ceserian
62591866|NCT02171013|EXPERIMENTAL|Dabigatran etexilate batch A|
62807182|NCT02526277|ACTIVE_COMPARATOR|MMF07 Foot Massager device and heat therapy|Participants randomized to both the MMF07 Foot Massager device and heat therapy will be provided both the MMF07 Foot Massager device and electric heating pad. Participants will be instructed to set the MMF07 Foot Massager device at setting 3, then increase or decrease the setting to their desired level of comfort. They will also be instructed to use the electric heating pad at a medium setting at the same time for 30 minutes at bedtime.
62031048|NCT00957502|EXPERIMENTAL|One year aged staples|Subjects implanted with sterile staples aged to approximately one year.
62422277|NCT05517018||double layer uterotomy|53 women with a double layer uterotomy while closing the uterus during Ceserian
62591867|NCT02171013|EXPERIMENTAL|Dabigatran etexilate batch B|
62031049|NCT00957502|EXPERIMENTAL|18 month aged staples|Subjects implanted with sterile staples aged to approximately 18 months.
62031050|NCT03669848||Pulse CO-oximetry|Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO) Measurements are taken with a noninvasive method by placing a sensor on a patient, usually on the fingertip.
62031051|NCT01785238|EXPERIMENTAL|cases with neonatal acute renal failure in preterm|
62031052|NCT01785238|OTHER|controls without neonatal acute renal failure in preterm|
62031053|NCT00920426|EXPERIMENTAL|GSK1265744 30 mg|GSK1265744 30 mg
62031054|NCT00920426|EXPERIMENTAL|Placebo|Placebo to match GSK1265744
62031055|NCT00920426|EXPERIMENTAL|GSK1265744 5 mg|GSK1265744 5 mg
62422278|NCT05517018||purse string uterotomy|53 women with a purse string uterotomy tecnique had used while closing the uterus during Ceserian
62422279|NCT03801213|ACTIVE_COMPARATOR|Urinary catheterization|
62230256|NCT05631301|OTHER|Move&Connect-Caregiver Waitlist control|"The control group will be recruited from the waitlist for the Persistent Concussion Clinic and the Early Care Concussion Clinic at Holland Bloorview, in addition to partnered community medical offices and organizations.~For the control group, the research assistant will schedule the participants first session to obtain consent and provide youth/caregivers with week 1 questionnaires. At this time, the participants will be able to ask any questions related to the study. After eight weeks the control group will be asked to complete the post measures in order to mimic the length of the intervention. The control group will then be given the opportunity to enroll in one of the intervention arms of the Move\&Connect study. They will then follow the same approved procedures for the intervention treatment group. Youth and their caregivers will be able to participate as waitlist controls without completing the intervention, if they choose."
62422280|NCT03801213|EXPERIMENTAL|manual bladder stimulation Technique|
62422281|NCT04537936|EXPERIMENTAL|Meaning Centered Psychotherapy for Latinos (MCP-L)|
62807183|NCT02526277|NO_INTERVENTION|No treatment|Participants receiving no intervention will be asked to not alter their nighttime routine.
62807184|NCT05339360||ZNN Bactiguard Antegrade Femoral Nail|Subjects that have received or will receive the ZNN Bacitugard Antegrade Femoral Nail to treat femoral fractures or osteotomies according to the cleared/approved indications.
62230257|NCT01095263|EXPERIMENTAL|Sham then Stimulation|
62422282|NCT04537936|ACTIVE_COMPARATOR|Control|
62422283|NCT00602979|OTHER|Macintosh laryngoscope|Macintosh laryngoscope (control group/direct laryngoscopy) - current standard
62591868|NCT06088004|EXPERIMENTAL|ABO2011|Monotherapy
62591869|NCT06088004|EXPERIMENTAL|ABO2011 and Toripalimab|Combination therapy
62591870|NCT01378169||SIRS patients|Every patient, without exclusion criteria, presenting with SIRS during an hospitalization in ICU.
62807185|NCT01451723|EXPERIMENTAL|Polyphenon E 400mg twice a day|Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.
62807186|NCT01451723|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules.
62230258|NCT01095263|EXPERIMENTAL|Stimulation then Sham|
62230259|NCT00593957|EXPERIMENTAL|DM1( 0.25 mg/kg /day)|Dextromethorphan 0.25 mg/kg per day
62230260|NCT00593957|EXPERIMENTAL|DM2 (2.5 mg/kg/day)|Dextromethorphan 2.5 mg/kg/day
62230261|NCT00593957|EXPERIMENTAL|DM3 (5mg/kg/day)|Dextromethorphan 5mg/kg/day
62230262|NCT02911493|EXPERIMENTAL|Sedentary Group-Experimental|The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.
62422284|NCT00602979|OTHER|Airtraq Optical Laryngoscope|Airtraq® Optical Laryngoscope (an experimental group/indirect laryngoscopy)
62422285|NCT00602979|OTHER|Storz DCI Video Laryngoscope|Storz DCI Video Laryngoscope® (an experimental group/indirect laryngoscopy)
62422286|NCT00602979|OTHER|GlideScope Video Laryngoscope|GlideScope® Video Laryngoscope (an experimental group/indirect laryngoscopy)
62422287|NCT00602979|OTHER|McGRATH Video Laryngoscope|McGRATH® Video Laryngoscope (an experimental group/indirect laryngoscopy)
62422288|NCT00937053|EXPERIMENTAL|Hemoglobin below 120 g/dL|
62422289|NCT00937053|ACTIVE_COMPARATOR|Hemoglobin below 70 g/dL|
62422290|NCT00872365|OTHER|1|Regular aerobic physical exercise + placebo
62591871|NCT04515706|EXPERIMENTAL|Iguratimod|Iguratimod 25 twice a day (bid) on Week 1-48.
62591872|NCT04515706|PLACEBO_COMPARATOR|Placebo|Placebo twice a day (bid) on Week 1-24, and Iguratimod 25 twice a day (bid) on Week 25-48.
62591873|NCT06159491|EXPERIMENTAL|Pacritinib in combination with Azacitidine|Participants will take pacritinib 200 mg BID for each 28 day cycle, azacitidine 75mg/m2 will be administered IV or SQ QD D1-7 of each 28 day cycle
62422291|NCT00872365|OTHER|2|Activities of daily living + Micronutrients
62422292|NCT00872365|OTHER|3|Regular aerobic exercise + micronutrients
62591874|NCT03990571|EXPERIMENTAL|Treatment (axitinib, avelumab)|Patients receive axitinib PO BID on days 1-28 and avelumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62591875|NCT02511054|EXPERIMENTAL|1a|Arm 1a (n=2), the pilot phase, is designed to examinethat the dosing of PYR on 2, 3 days post DVI with Sanaria PfSPZ Challenge while under CQ prophylaxis does not result in subpatent parasitemia (positive qRT-PCR result defined as two consecutive samples \> 20 parasites/uL or a single positive qRTPCR (Bullet) 100) or a single episode of patent parasitemia (positive blood smear defined as two unambiguous parasites in a thicksmear) in (Bullet)1/2 subjects. Subjects will considered enrolled into the study upon receipt of the loading dose of CQ (2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
62807187|NCT02475538|EXPERIMENTAL|Electroacupuncture|"Subjects in this group will be treated with electroacupuncture along with a gradual tapering schedule.~Benzodiazepines will be tapered off over four weeks. The expected reduction rate of benzodiazepines should be 25% in the first two weeks and 12.5% in 3-4 days in week 3 and week 4. If the participants cannot tolerate the effects after tapering according to our suggested plan, the dose can be kept unchanged or they can reduce the dose at a slower pace.~Subjects will receive electroacupuncture 2 times per week for 4 consecutive weeks. Electroacupuncture involves acupuncture needling at traditionally used acupoints according to Chinese medicine theory."
62422293|NCT00872365|PLACEBO_COMPARATOR|4|Activities of daily living + placebo
62422294|NCT04061057|EXPERIMENTAL|IV lidocaine|Perioperative IV lidocaine infusion
62422295|NCT04061057|PLACEBO_COMPARATOR|Normal saline|Perioperative IV normal saline infusion
62422296|NCT00354731|ACTIVE_COMPARATOR|corticosteroid|Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
62422297|NCT00354731|EXPERIMENTAL|Pentoxifylline + corticosteroid|Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M + oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
62031056|NCT02534909|EXPERIMENTAL|LFG316 then LNP023|"During treatment periods 1 to 3, the regimen included LFG316 at a dosage of 20 mg/kg administered as an intravenous (i.v.) infusion biweekly.~In treatment period 4, the patients were given:~* LFG316 at a dosage of 20 mg/kg as an i.v. infusion every two weeks for four weeks, amounting to two infusions in total.~* LNP023 at a dose of 200 mg administered orally twice daily (b.i.d.) for approximately 20 weeks, with four 50 mg capsules taken at each administration."
62031057|NCT03775239|OTHER|Treatment-as-usual|Those who are randomly selected to treatment-as-usual will receive a minimum of 6 sessions at Sexological Clinic.
62031058|NCT03775239|OTHER|Treatment-as-usual + MSIR|Those who are randomly selected to receive Mindfulness in Sex Therapy and Intimate Relationships (MSIR) will first receive 6 weeks of mindfulness followed by treatment-as-usual. The intervention will take place at Sexological Clinic.
62031059|NCT06670950|EXPERIMENTAL|Part 1: Relative bioavailability and food effect|Randomised, open label, single-dose, three period, three-sequence crossover study to evaluate the relative bioavailability (rBA) of a new oral formulation of SYT-510 under fasting conditions and the effect of food in healthy participants.
62031060|NCT06670950|EXPERIMENTAL|Part 2: Multiple Ascending Dose|Randomised, double-blind, placebo-controlled multiple ascending dose (MAD) study in healthy participants to assess the safety, tolerability and pharmacokinetics (PK) of SYT-510 after repeated administrations.
62230263|NCT02911493|ACTIVE_COMPARATOR|Physical Activity Group|The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.
62230264|NCT02707731|EXPERIMENTAL|Hydrokinesiotherapy in preterm|Salivary cortisol samples, pain applying the Neonatal Infant Pain Scale Scale, heart rate, respiratory rate and oxygen saturation were collected before and after hydrokinesiotherapy
62230265|NCT05802641||single fraction of SBRT（30Gy/1f）|Participants with early lung cancer receive single fraction of SBRT（30Gy/1f).
62230266|NCT05802641||Multiple fractions of SBRT（36Gy/3f）|Participants with early lung cancer receive multiple fractions of SBRT（36Gy/3f).
62230267|NCT06215677|EXPERIMENTAL|Neoadjuvant immunotherapy|
62807188|NCT02475538|PLACEBO_COMPARATOR|Placebo acupuncture|"Subjects in this group will be treated with placebo acupuncture along with a gradual tapering schedule.~Benzodiazepines will be tapered off over four weeks. The expected reduction rate of benzodiazepines should be 25% in the first two weeks and 12.5% in 3-4 days in week 3 and week 4. If the participants cannot tolerate the effects after tapering according to our suggested plan, the dose can be kept unchanged or they can reduce the dose at a slower pace.~The subjects will be receive placebo acupuncture 2 times per week for 4 consecutive weeks. Placebo acupuncture is a treatment that simulates the procedure of acupuncture treatment but may not have the effects of acupuncture."
62807189|NCT04363203|ACTIVE_COMPARATOR|Hydroxychloroquine|Hydroxychloroquine: 2x200mg mg PO in the AM and 2x200mg PO in the PM on Day 1, followed by 200mg capsule in the AM and 200 mg in the PM on Days 2-5
62807190|NCT04363203|ACTIVE_COMPARATOR|Azithromycin|Azithromycin: 2x250mg by mouth (PO) in the AM followed by 250mg PO every day on days 2-5
62031061|NCT06364189|EXPERIMENTAL|Exercise and music stimulation|"Participants are given an aerobic and strength training program with faded supervision across 6 months.~For aerobic exercise (AE), participants will be instructed to walk at moderate intensity with duration increasing up to an ultimate goal of 150 min/week. Participants will be trained to walk in synchrony with the beats of their personalized playlists.~The strength training (ST) incorporates single-leg exercises for balance training and training with resistance bands and body weight. During the ST, participants will be asked to synchronize their concentric and eccentric muscle contractions in time with the tempo of BMS playlists at a specific beats-per-minute rhythm."
62031062|NCT06364189|ACTIVE_COMPARATOR|Exercise only|"Participants are given an aerobic and strength training program with faded supervision across 6 months.~The ST incorporates single-leg exercises for balance training and training with resistance bands and body weight.~For aerobic exercise (AE), participants will be instructed to walk at moderate intensity with duration increasing up to an ultimate goal of 150 min/week."
62031063|NCT06636461|EXPERIMENTAL|microfragmented adipose tissue|microfragmented adipose tissue loaded on allograft on ridge preservation
62230268|NCT01314820|ACTIVE_COMPARATOR|normal saline injection|20 cc normal saline injection into the knee joint
62807191|NCT04363203|PLACEBO_COMPARATOR|Placebo|The pills packs for the 3 arms are identical.
62031064|NCT06636461|ACTIVE_COMPARATOR|allograft|allograft only on ridge preservation
62031065|NCT05373394||Case|patients with a history of surgical removal of diffuse low grade glioma located in the supplementary motor area
62230269|NCT01314820|SHAM_COMPARATOR|sham injection|knee injection without saline
62230270|NCT04524884|EXPERIMENTAL|Cohort A|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle. After neoadjuvant Toripalimab and Surufatinib treatment, the patients will receive operation treatment if the tumor is evaluated as resectable cases by clinical examination.
62807192|NCT03168113||AD and Peanut Food Allergy|"Participants with active Atopic Dermatitis (AD) and food allergy to peanut.\* Twenty participants ages 4 to 17 years of age will be enrolled in this group.~\*Peanut skin prick test wheal ≥ 8 mm."
62031066|NCT05373394||Control|patients with a history of surgical removal of diffuse low-grade glioma located in another brain area
62230271|NCT04524884|EXPERIMENTAL|Cohort B|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle. After neoadjuvant Toripalimab and Surufatinib treatment, the patients will receive further drug reatment, if the tumor is evaluated as unresectable cases and patients have potential benefits by clinical examination.
62230272|NCT04524884|EXPERIMENTAL|Cohort C|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle. After neoadjuvant Toripalimab and Surufatinib treatment, the patients will be removed from the study, if the tumor is evaluated as unresectable cases and patients have no potential benefits by clinical examination.
62230273|NCT03869723||Conventional surgery|Classical surgery for mandibular reconstruction with fibula free flap
62031067|NCT02732925|SHAM_COMPARATOR|Arm 1 - Sham Procedure|"Sham Procedure \& Conservative Treatment~Subjects will be blinded and randomised to Arm 1 and will undergo a general anaesthetic and undergo a sham procedure. They will also be treated under conservative management alone.~Below is a list of the conservative management they will be managed by their Doctor:~1. Bisphosphonates~2. Pain relief~3. Systemic chemotherapy for Myeloma disease~4. Bed rest~5. Radiotherapy~6. Physiotherapy~This is a non interventional as conservative treatment (standard of care for multiple myeloma patients) is used."
62230274|NCT03869723||Virtual planning|Fibula free flap in mandibular reconstruction using preoperative virtual planning, cutting guides and osteosynthesis plates. Preoperative modeling was conducted by obtaining scans of patient maxillofacial skeleton and angioscans of the lower extremities. The planning phase was then carried out by the surgeon and the engineer (from MATERIALISE, Leuven, Belgium) so as to define the clinical and technical parameters of the reconstruction. This stage consisted of discussing and determining osteotomy lines, donor side, anastomosis site, and overall reconstruction contour. Resection was decided by the surgeon. 3D modeling and the manufacture of cutting guides and customized osteosynthesis plates were then undertaken
62422298|NCT06540326|EXPERIMENTAL|irinotecan liposome (II), fluorouracil in combination with bevacizumab|patients accept irinotecan liposome (II), fluorouracil in combination with bevacizumab
62807193|NCT03168113||AD and No Food Allergy|"Participants with active Atopic Dermatitis (AD) and no food allergy.\* Twenty participants ages 4 to 17 years of age will be enrolled in this group.~\*Negative skin prick test (wheal \< 3 mm) to peanut, milk, egg, wheat, soy, shellfish mix, tree nuts, and sesame seed."
62807194|NCT03168113||Non-Atopic Health Control|"Participants that are non-atopic, healthy controls\*. Twenty participants ages 4 to 17 years of age will be enrolled in this group.~\*Negative for Atopic Dermatitis (AD), asthma, or allergic rhinitis; negative for food allergy; and negative by skin prick test to peanut, milk, egg, wheat, soy, shellfish mix, tree nuts, and sesame seed, and negative to environmental allergens - cat, dog, dust mite, cockroach, and local trees/grasses/weeds/molds."
62807195|NCT00981097||Specimen Collection|Subjects with a diagnosis of HIV and an untreated aggressive B-cell lymphoma.
62807196|NCT05581017||No PBD|Patients without preoperative biliary drainage before pancreaticoduodenectomy
62807197|NCT05581017||PBD < 2 months|Patients who had undergone preoperative biliary drainage and the pancreaticoduodenectomy was in 2 months after the drainage.
62807198|NCT05581017||PBD ≥ 2 months|Patients who had undergone preoperative biliary drainage and the pancreaticoduodenectomy was at 2 months or later after the drainage.
62807199|NCT03973216|EXPERIMENTAL|A primary care group-based therapeutic yoga program|A primary care care group-based therapeutic yoga program that consists of 9 sessions.
62807200|NCT01831167|EXPERIMENTAL|dynamic light|dynamic light
62807201|NCT01831167|NO_INTERVENTION|reference|normal light
62807202|NCT02872116|EXPERIMENTAL|Nivolumab + Ipilimumab|"Nivolumab + Ipilimumab for 4 doses, followed by Nivolumab monotherapy~Enrollment is closed for this arm"
62807203|NCT02872116|ACTIVE_COMPARATOR|XELOX (Oxaliplatin + Capecitabine)|
62807204|NCT02872116|ACTIVE_COMPARATOR|FOLFOX (Oxaliplatin + Leucovorin + Fluorouracil)|
62807205|NCT02872116|EXPERIMENTAL|Nivolumab + XELOX|
62807206|NCT02872116|EXPERIMENTAL|Nivolumab + FOLFOX|
62807207|NCT02107066|ACTIVE_COMPARATOR|attention control|Women randomized to attention control will receive the same attention as women randomized to exercise intervention, i.e., weekly phone calls for 6 months. Each call is about 15 min. Women in the attention control will receive information on ovarian cancer health education topics.
62230275|NCT05888051||Young Adult|
62230276|NCT05888051||Adult|
62230277|NCT03369561||normal cardiac patient|"Full history and clinical examination ECG on the left and right side Echocardiography and measurement of both left and right ventricular functions Laboratory investigation including cardiac enzymes, CK, CK MB, and cardiac troponin I.~Serum urea and creatinine and the calculated e GFR"
62422299|NCT06540326|EXPERIMENTAL|irinotecan liposome (II), fluorouracil in combination with cetuximab|patients（especially gene wild type） accept irinotecan liposome (II), fluorouracil in combination with cetuximab
62422300|NCT01779349|EXPERIMENTAL|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
62422301|NCT00701558|EXPERIMENTAL|Erlotinib + Gemcitabine|Participants received erlotinib 150 mg/day, orally (po) on a continuous schedule in combination with gemcitabine at 1000 mg/m\^2 administered intravenously (iv) on days 1, 8, 15 of each 4 week cycle for 6 cycles as per standard medical care, or until disease progression or participant's withdrawal due to any reason or death.
62807208|NCT02107066|EXPERIMENTAL|exercise|Women randomized to exercise will receive telephone-counseling weekly for 6 months to increase their exercise
62807209|NCT05299476|EXPERIMENTAL|CAPOX combined with bevacizumab and Tislelizumab|
62807210|NCT04169165||compliant patients|Patients with compliance to suggestions on metabolic evaluation and dietary/medical advices
62807211|NCT04169165||non-compliant patient|Patients without compliance to suggestions on metabolic evaluation and dietary/medical advices
62807212|NCT03634085|EXPERIMENTAL|Cohort A|"Ascending doses of BDM-2 in Bottle (50 mg - 3600 mg); oral suspension or placebo will be orally administered and will be investigated, alternately dosed in Cohort A of 8 healthy male subjects under fasted conditions. For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo.~The last session for the subjects in Cohort A will be under fed conditions where the same treatment allocation as in the session of the selected dose (administered under fasted conditions) will be used."
62807213|NCT03634085|EXPERIMENTAL|Cohort B|Ascending doses of BDM-2 in Bottle (50 mg - 3600 mg); oral suspension or placebo will be orally administered and will be investigated, alternately dosed in Cohort B of 8 healthy male subjects under fasted conditions. For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo.
62422302|NCT06217835|EXPERIMENTAL|0,5 cm jig|A template with the dimensions indicated is introduced to the user and he/she walks for 1 minute.
62230278|NCT05084443|PLACEBO_COMPARATOR|Placebo/Control|Placebo drink-- Orally (200 ml/day)
62230279|NCT05084443|EXPERIMENTAL|Roselle Based drink (Test)|Roselle-Based Drink--- Orally (200 ml/day)
62031068|NCT02732925|ACTIVE_COMPARATOR|Arm 2 - Balloon Kyphoplasty|"Balloon Kyphoplasty \& Conservative Treatment - Interventional Arm~Subjects will be blinded and randomised to Arm 2 (balloon kyphoplasty) and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.~Below is a list of the conservative management they will be managed by their Doctor:~1. Bisphosphonates~2. Pain relief~3. Systemic chemotherapy for Myeloma disease~4. Bed rest~5. Radiotherapy~6. Physiotherapy~This is a interventional arm (balloon kyphoplasty procedure) and the patient will receive conservative treatment (standard of multiple myeloma patients) is used."
62031069|NCT06180824|NO_INTERVENTION|normal saline|Insulin will be diluted with normal saline crystalloid fluid in 50mls syringe and tubing (same product manufacturer). Blood glucose level will be taken from arterial line at presentation or prior to start insulin and checked using glucometer. Then, at 2 hour and 6 hours after initiation of treatment.
62031070|NCT06180824|ACTIVE_COMPARATOR|gelafundin|Insulin will be diluted with gelafundin colloid fluid in 50mls syringe and tubing (same product manufacturer). Blood glucose level will be taken from arterial line at presentation or prior to start insulin and checked using glucometer. Then, at 2 hour and 6 hours after initiation of treatment.
62031071|NCT01944501|ACTIVE_COMPARATOR|Transcranial Magnetic Stimulation|Patients receiving real transcranial magnetic stimulation
62031072|NCT01944501|PLACEBO_COMPARATOR|Sham TMS|Patients receiving sham transcranial magnetic stimulation
62591876|NCT02511054|EXPERIMENTAL|2|Arm 2 (n=12) will receive the selected regimen of pyrimethamine, on 2, 3 days (unless another Arm other than Arm 1a is determined from the pilot phase) post Sanaria PfSPZ Challenge via DVI while under CQprophylaxis. These subjects will be considered enrolledinto the study upon receipt of the loading dose of CQ(2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
62230280|NCT00575029|EXPERIMENTAL|megace treatment|Study subjects will be given 600mg of MA for oral ingestion per day for duration of 8 weeks. They will be monitored every week clinically for the development of adrenal insufficiency by review of symptoms, physical exam, body weight, pulse, and blood pressure. Subjects also will undergo biochemical evaluation of adrenal status every two weeks by measurement of serum electrolytes, serum cortisol, serum adrenocorticotropic hormone(ACTH) levels, and the adrenal response to a low dose ACTH (1µgm) stimulation test(see methods).
62591877|NCT02511054|EXPERIMENTAL|3|Arm 3 (n=6) will receive Sanaria PfSPZ Challenge DVI while under CQ prophylaxis without PYR treatment. These subjects will be considered enrolled into the study upon receipt of the loading dose of CQ (2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
62230281|NCT04433585|EXPERIMENTAL|LY3471851 High Dose|LY3471851 administered subcutaneously (SC).
62230282|NCT04433585|EXPERIMENTAL|LY3471851 Mid Dose|LY3471851 administered SC.
62591878|NCT02511054|EXPERIMENTAL|4|Arm 4 (n=5) will only receive one dose of Sanaria PfSPZ Challenge at CHMI as a positive control for thestudy. Subjects in Arm 4 will be considered enrolledon the day of Sanaria PfSPZ Challenge via DVI.
62031073|NCT01944501|ACTIVE_COMPARATOR|Transcranial Direct Current Stimulation|Patients receiving real transcranial direct current stimulation
62422303|NCT06217835|EXPERIMENTAL|1 cm jig|A template with the dimensions indicated is introduced to the user and he/she walks for 1 minute.
62422304|NCT06217835|EXPERIMENTAL|1,5 cm jig|A template with the dimensions indicated is introduced to the user and he/she walks for 1 minute.
62591879|NCT04829032||Hartmann's procedure|Evaluate the role of Hartmann's procedure in emergency setting for left-sided acute surgical colonic disease (perforated diverticulitis with purulent or fecal peritonitis; colon cancer perforation-obstruction; ischemic colitis; abdominal trauma).
62807214|NCT01799707|ACTIVE_COMPARATOR|vision restoration training|Vision restoration training (VRT): visual stimuli repetitively presented to stimulate areas of residual vision. The training consists of luminance increment stimuli similar to perimetry and the task isa simple detection task (pressing a key whenever a target stimulus was detected).
62031074|NCT01944501|PLACEBO_COMPARATOR|Sham TDCS|Patients receiving sham transcranial direct current stimulation
62422305|NCT05426473|EXPERIMENTAL|Patients with a completed form|
62591880|NCT04829032||Colonic resection with primary anastomosis|Evaluate the role of colonic resection with primary anastomosis in emergency setting for left-sided acute surgical colonic disease (perforated diverticulitis with purulent or fecal peritonitis; colon cancer perforation-obstruction; ischemic colitis; abdominal trauma).
62591881|NCT05871151|EXPERIMENTAL|active taVNS + exercise|Participants who are randomized into the active taVNS + exercise group will receive 15 minutes of active taVNS prior to exercise sessions.
62230283|NCT04433585|EXPERIMENTAL|LY3471851 Low Dose|LY3471851 administered SC
62230284|NCT04433585|PLACEBO_COMPARATOR|Placebo|Placebo administered SC.
62230285|NCT03027154|EXPERIMENTAL|TB subjects in 5-18 years old|24 cases TB subjects in 5-18 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
62243168|NCT03312699|EXPERIMENTAL|Group B Typhoid VI|Group B: Up to 30 healthy volunteers 65 plud years old, will be given Typhoid Vi Polysaccharide Vaccine (Typhoid VI), Typhim Vi® vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
62422306|NCT06542419|EXPERIMENTAL|Brain Cooling Treatment|"Brain cooling consists of a 30-minute seated period, in a dimly lit, quiet room, while listening to calming natural sounds, during which they will wear an Arctic Cooling Cap V1.30, set at a temperature of 33.0 degrees Fahrenheit. Participants will be asked to remain awake, refrain from observing a screen, and relax to the best of their ability.~This brain cooling treatment will occur on 7 consecutive days."
62031075|NCT01380327|EXPERIMENTAL|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Glycerinated German cockroach (Blatella germanica) allergen extract administered sublingually with a maximally tolerated dose of 420 microliters daily
62422307|NCT06542419|NO_INTERVENTION|Control|The control arm consists of a 30-minute seated period, in a dimly lit, quiet room, while listening to calming natural sounds. Participants will be asked to remain awake, refrain from observing a screen, and relax to the best of their ability.
62591882|NCT05871151|SHAM_COMPARATOR|sham taVNS + exercise|Participants who are randomized into the sham taVNS + exercise group will receive 0 mA of current for 15 minutes prior to exercise sessions.
62422308|NCT05406622|EXPERIMENTAL|MOTIV Sirolimus-Eluting Bioresorbable Scaffold|Participants who receive the MOTIV device will be included in this arm
62422309|NCT05406622|ACTIVE_COMPARATOR|Percutaneous Transluminal Angioplasty (PTA)|Participants who receive PTA treatment will be included in this arm
62422310|NCT00390949|EXPERIMENTAL|Intervention arm|Peer education with female sex workers and potential male clients. Strengthened syndromic management of STIs with community-based promotion activities
62591883|NCT03545594|EXPERIMENTAL|Patient-centered in home rehabilitation|Eight contacts of about 2 hours duration each delivered over a 4-month period (Six in home visits and two telephone contacts before the Corona pandemic and adjusted to eight contacts and up to six of them video based when necessary during the Corona pandemic) in three phases:
62591884|NCT03545594|ACTIVE_COMPARATOR|Control|Usual follow-up assessment and health care and rehabilitation services provided in the municipality
62807215|NCT01799707|PLACEBO_COMPARATOR|Discrimination training|Discrimination training. Here, the stimulus is a line segment (bar) which is always presented within the central ±5° visual field in one of four possible random orientations: horizontal, vertical, oblique to the right or oblique to the left. If the patient has visual field defects in this central area, 80% of the stimuli are presented in the intact part of the training region. The task is to identify the orientation of the line segment and press, as fast as possible, one of 4 assigned buttons on the keyboard.
62807216|NCT04992117||Unplanned-extubation in the ICU|Patients with unplanned extubation in the ICU
62807217|NCT05238389|EXPERIMENTAL|Robotic group|In the robotic group, patients will undergo a 30-session upper limb robotic rehabilitation using the device MOTORE.
62807218|NCT02968264||TOF participants|Tetralogy of fallot patients at any age
62422311|NCT00390949|NO_INTERVENTION|Control|Standard of care
62807219|NCT04198025||Patients who underwent colorectal resection|"Patients in this observational study will have undergone CT scan as routine work up prior to resection of elective colorectal cancer.~Psoas muscle density will be measured (in Hounsfield units from CT images) at lumbar vertebral level L3."
62807220|NCT03418155|EXPERIMENTAL|Treatment of TongBi Capsule|
62807221|NCT03418155|PLACEBO_COMPARATOR|Treatment of TongBi Placebo|
62807222|NCT03844399||Patients|Cancer patients who are scheduled to undergo an ablation or biopsy of a liver or kidney tumour
62807223|NCT03881839||patient in emergency department|
62807224|NCT03360266|ACTIVE_COMPARATOR|Profluorid group|5% Sodium Fluoride varnish (Profluorid varnish) applied over white spot lesions on maxillary anterior teeth
62807225|NCT03360266|EXPERIMENTAL|Enamel Pro|Sodium Fluoride with ACP varnish (Enamel Pro varnish) applied over white spot lesions on maxillary anterior teeth
62807226|NCT03360266|EXPERIMENTAL|MI varnish|Sodium Fluoride with CPP-ACP varnish (MI varnish) applied over white spot lesions on maxillary anterior teeth
62807227|NCT04044768|EXPERIMENTAL|Autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) SPEAR™ T cells|
62031076|NCT01380327|PLACEBO_COMPARATOR|Placebo|Placebo administered sublingually not to exceed the maximally tolerated dose of either 1.) 420 microliters daily (placebo - low dose randomization) or 2.) 840 microliters twice daily (placebo - high dose randomization)
62422312|NCT05432245|EXPERIMENTAL|Treatment group|
62422313|NCT02056574|EXPERIMENTAL|NA-1|20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and an 11 amino acid domain that enables the peptide to cross the blood-brain barrier. Single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion.
62422314|NCT02056574|PLACEBO_COMPARATOR|Placebo|Single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion.
62422315|NCT06702332|ACTIVE_COMPARATOR|Active Treatment: MSD-001|Planned doses of MSD-001; N = 42
62422316|NCT06702332|PLACEBO_COMPARATOR|Placebo Comparator|Non-active study drug N = 10
62591885|NCT01608243|EXPERIMENTAL|SLIT tablets of HDM allergen extracts|
62591886|NCT01608243|PLACEBO_COMPARATOR|Placebo|
62591887|NCT01571999|EXPERIMENTAL|Severe renally impaired subjects|Approximately 9 subjects will complete each treatment arm
62591888|NCT01571999|EXPERIMENTAL|Matched healthy volunteers|Matched to the severe renal impairment subjects based on gender, ethnicity, body mass index (±15%) and age (±5 years). Approximately 9 subjects will complete each treatment arm
62807228|NCT02579668|EXPERIMENTAL|Language therapy in BSL|Working with Deaf practitioners to provide language activities in British Sign Language aimed at developing children's language skills.
62807229|NCT06083649|EXPERIMENTAL|Experimental group A (AI Group: EG-A)|The AI group scanned their own mouths at home once a week for 6 months, with each scan taking approximately 5 min. After scanning, they uploaded the results to the AI system for evaluation. The AI system then selected and sent a message to each patient depending on their intraoral conditions.
62807230|NCT06083649|EXPERIMENTAL|Experimental group B (AI and health counseling group: EG-B)|The AI and health counseling group scanned their own mouths at home once a week for 6 months, with each scan taking approximately 5 min. After scanning, they uploaded the results to the AI system for evaluation. The EG-B received both AI-assisted DM and real-person oral health counseling and advice from a counselor, who assessed their oral hygiene conditions on the basis of their scanning results and then provided individualized counseling, such as pointing out unclean teeth and offering suggestions on cleaning tools.
62807231|NCT06083649|NO_INTERVENTION|No Intervention: Control group (CG)|the control group(CG) only have standard oral hygiene education
62807232|NCT06036277||Experimental group|Women who wish to give birth without epidural anesthesia and have benefited of water immersion during labor
62807233|NCT06036277||Control group|Women who wish to give birth without epidural anesthesia and have not benefited of water immersion during labor
62807234|NCT00702858|ACTIVE_COMPARATOR|1|Blue Citrus either months 1-3 or 4-6
62230286|NCT03027154|EXPERIMENTAL|non-TB subjects in 5-18 years old|24 cases non-TB subjects in 5-18 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
62230287|NCT03027154|EXPERIMENTAL|TB subjects under 5 years old|24 cases TB subjects under 5 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
62230288|NCT03027154|EXPERIMENTAL|non-TB subjects under 5 years old|24 cases non-TB subjects under 5 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
62230289|NCT05637385|EXPERIMENTAL|central vision loss|will receive behavioral intervention
62230290|NCT05637385|ACTIVE_COMPARATOR|normal vision|using simulated central scotomas, will receive behavioral intervention
62422317|NCT00435825|EXPERIMENTAL|peginterferon alfa-2a 90 μg_24 Weeks|Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.
62422318|NCT00435825|EXPERIMENTAL|peginterferon alfa-2a 180 μg_24 Weeks|Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.
62591889|NCT03829618|ACTIVE_COMPARATOR|Topical Lidocaine|16 ml of 1% lidocaine sprayed in 4 ml aliquots to vocal cords, midtrachea, left main stem bronchus and right main stem bronchus.
62591890|NCT03829618|ACTIVE_COMPARATOR|Nebuliser Solution|2% lidocaine dosed at 2mg/kg with max dose of 160mg nebulized via jet nebulizer in operating room over ten minutes.
62591891|NCT03829618|ACTIVE_COMPARATOR|Nebuliser Suspension|2% lidocaine dosed at 2mg/kg with max dose of 160mg nebulized via vibrating mesh nebulizer in operating room over ten minutes.
62230291|NCT00621387|EXPERIMENTAL|1|ofloxacin and roxithromycin
62807235|NCT00702858|PLACEBO_COMPARATOR|2|Placebo
62807236|NCT02602535|EXPERIMENTAL|M.O.R.E.|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
62807237|NCT02602535|ACTIVE_COMPARATOR|Support Group|Participants will attend a support group weekly for eight weeks.
62807238|NCT05147181||Participants With HAE|Participants with type 1 or type 2 HAE when treated with lanadelumab in real life in accordance with Summary of Product Characteristics (SmPC) and NDP requirements will be observed in this prospective observational study for 36 months
62230292|NCT00621387|PLACEBO_COMPARATOR|2|placebo
62230293|NCT04289766|ACTIVE_COMPARATOR|Conventional Treatment|Conventional Treatment includes exercises limbs
62230294|NCT04289766|EXPERIMENTAL|Focal Muscle Vibration (120Hz)|"* Each session will span 40 minutes plus 10 of Focal Muscle vibration for each muscle at a frequency of 120 Hz.~* Conventional Treatment"
62230295|NCT04289766|EXPERIMENTAL|Focal Muscle Vibration (60Hz)|"* Each session will span 40 minutes plus 10 of Focal Muscle vibration for each muscle at a frequency of 60 Hz.~* Conventional Treatment"
62230296|NCT04921137|EXPERIMENTAL|Omission of endocrine therapy|Omission of endocrine therapy
62230297|NCT04921137|ACTIVE_COMPARATOR|Administration of endocrine therapy for at least 5 years|Administration of endocrine therapy for at least 5 years
62230298|NCT01812551|ACTIVE_COMPARATOR|Alendronate|"128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).~65 subjects were randomized to this arm. Oral alendronate dose: 5 mg/day, if body weight ≤25 kg; 10 mg/day, if body weight \>25 kg."
62230299|NCT01812551|PLACEBO_COMPARATOR|Placebo|"128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).~63 subjects were randomized to this arm. Oral placebo (inactive pills)."
62422319|NCT00435825|EXPERIMENTAL|peginterferon alfa-2a 90 μg_48 Weeks|Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.
62422320|NCT00435825|EXPERIMENTAL|peginterferon alfa-2a 180 μg_48 Weeks|Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.
62591892|NCT00231114|EXPERIMENTAL|Alair|Treatment of airways with the Alair System
62591893|NCT00231114|SHAM_COMPARATOR|Sham|Sham treatment of airways
62591894|NCT04079413|EXPERIMENTAL|GP40071|Subcutaneous (SC), before meals intake, up to Week 26
62591895|NCT04079413|ACTIVE_COMPARATOR|NovoRapid® Penfill®|Subcutaneous (SC), before meals intake, up to Week 26
62591896|NCT05025384|EXPERIMENTAL|Intervention|Acupressure stickers will be applied to one ear in accordance with the NADA protocol acupuncture technique.
62591897|NCT05025384|NO_INTERVENTION|No Intervention|No intervention
62591898|NCT03648671||PD with PAIN|12 patients will undergo add-on drugs therapy with safinamide metansolfonato.
62591899|NCT03648671||PD without PAIN|12 patients will undergo add-on drugs therapy with safinamide metansolfonato.
62591900|NCT03648671||PD with PAIN rasagilina|12 patients will undergo add-on drugs therapy with rasagilina mesilato.
62591901|NCT03648671||PD without PAIN rasagilina|12 patients will undergo add-on drugs therapy with rasagilina mesilato.
62807239|NCT06021639|EXPERIMENTAL|Low fiber diet group|250 ml Sennozit A+B calcium (half dose is taken orally at 17.00 on the day before the procedure and the other half at 19.00 will be consumed. Enema 210 cc (Monobasic sodium phosphate 28.5 g. Dibasic sodium phosphate 10.5 g.) The procedure is rectal at 07.00 in the morning. will be used as Routine feeding of the patient up to the last 24 hours before the procedure. He/she will consume low fiber food in the last 24 hours.
62031077|NCT01380327|EXPERIMENTAL|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Glycerinated German cockroach (Blatella germanica) allergen extract administered sublingually with a maximally tolerated dose of 840 microliters taken twice daily
62031078|NCT02081092||Pulmonary Alveolar Proteinosis (PAP)|Patients diagnosis with Pulmonary Alveolar Proteinosis.
62031079|NCT03600337|EXPERIMENTAL|Experimental Condition|Working to Optimize Wellness in Teens with PCOS
62031080|NCT03600337|NO_INTERVENTION|Control Condition|Participants in this arm will receive treatment as usual and will be given the intervention after 1 month assessments are completed for the intervention group
62031081|NCT06308939|EXPERIMENTAL|Eribulin Combined With Sintilimab|Eribulin: 1.4mg/m\^2 day1、8，repeated every 3 week. Sintilimab: 500mg once every three weeks.
62230300|NCT06076603||Intravenous combined with nebulized polymyxin B|The intravenous combined nebulization patient group was divided into two subgroups based on the different doses received -25mg q12h and 50mg q12h. Patients in the intravenous combination nebulized polymyxin B group received a total medication dose of 1.25 to 1.5mg/kg, of which 25-50mg was used for nebulization and the remaining portion was used for intravenous administration. The specific method of nebulization is to receive nebulized bronchodilator 30 minutes before nebulization, add 25-50mg of polymyxin B to 5ml of physiological saline for dilution, use a vibrating mesh nebulizer to connect to the patient's ventilator pipeline suction tube, do not change the original ventilator parameter settings, and continue nebulization for 30 minutes. After 30 minutes, regardless of whether there is any residue of the nebulized drug, it will be discarded according to general nursing methods.
62230301|NCT06076603||Intravenous polymyxin group B|This group of patients received intravenous injection of polymyxin B alone, with intravenous doses of 1.25-1.5mg/kg of polymyxin B administered every 12 hours.
62230302|NCT05955313|EXPERIMENTAL|Naltrexone|NALTREXONE HYDROCHLORIDE 4,5 mg, coated oral tablets, 1xd. for 4 months
62230303|NCT05955313|PLACEBO_COMPARATOR|Placebo|Placebo, coated oral tablets, 1xd.
62230304|NCT02985320|EXPERIMENTAL|Phase I Adult Group - High dosage|"* Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~* Intervention: Single-dose regimen of high dosage investigational sIPV"
62230305|NCT02985320|EXPERIMENTAL|Phase I Adult Group - Medium dosage|"* Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~* Intervention: Single-dose regimen of medium dosage investigational sIPV"
62422321|NCT01832545|ACTIVE_COMPARATOR|Educational Program|The communitarian PESO program is based on appropriate clinical guidelines and on validated behavior change principles. Implemented by an intervention team with expertise gained from current scientific research in weight control determinants, this program as well PICO, is free of charge for all interested adults who wish to manage their weight and health. It operates since 2005 with the aims to prevent obesity or reduce excess weight, as well as, some of the risks associated with obesity in adults through a change to steady healthy habits, attitudes and behaviors. PESO has 3 months duration and it is structured in 12 sessions of one and a half hour, once a week.
62591902|NCT06027918|ACTIVE_COMPARATOR|Group V (1726 meter altitude)|"In the application of infraclavicular brachial plexus blocks (coracoid approach); 1.5mg/kg dose of bupivacaine and 1mg/kg lidocaine mixture will be applied around the axillary artery in the 6 o'clock position under US guidance.~The block will be applied only once, approximately 15-20 minutes before surgery."
62230306|NCT02985320|EXPERIMENTAL|Phase I Child Group - High dosage|"* Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~* Intervention: Single-dose regimen of high dosage investigational sIPV"
62591903|NCT06027918|ACTIVE_COMPARATOR|Group D (675 meter altitude)|"In the application of infraclavicular brachial plexus blocks (coracoid approach); 1.5mg/kg dose of bupivacaine and 1mg/kg lidocaine mixture will be applied around the axillary artery in the 6 o'clock position under US guidance.~The block will be applied only once, approximately 15-20 minutes before surgery."
62591904|NCT06027918|ACTIVE_COMPARATOR|Group H( 100 meter altitude)|"In the application of infraclavicular brachial plexus blocks (coracoid approach); 1.5mg/kg dose of bupivacaine and 1mg/kg lidocaine mixture will be applied around the axillary artery in the 6 o'clock position under US guidance.~The block will be applied only once, approximately 15-20 minutes before surgery."
62591905|NCT04092946|EXPERIMENTAL|Patients with musculoskeletal disorders|Tailored digital programs for individuals working for organizations that enter into a commercial agreement with SWORD Health, which acts as a service provider.
62591906|NCT02017795|EXPERIMENTAL|SMS-Web eAAP group|electronic asthma action plan (eAAP) group
62591907|NCT02017795|ACTIVE_COMPARATOR|regular-care group|written asthma action plan (WAAP) group
62031082|NCT06030609|EXPERIMENTAL|Ringer lactate arm|The patient will receive RLS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
62031083|NCT06030609|ACTIVE_COMPARATOR|Normal saline arm|The patient will receive NSS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
62031084|NCT06482372|EXPERIMENTAL|rTMS + mirror therapy + traditional OT|Patient would receive treatment three time per week, including individualized rTMS, and following mirror therapy and traditional occupational therapy.
62031085|NCT06482372|ACTIVE_COMPARATOR|rTMS + traditional OT|Patient would receive treatment three time per week, including individualized rTMS and following traditional occupational therapy.
62031086|NCT06482372|PLACEBO_COMPARATOR|sham rTMS + traditional OT|Patient would receive treatment three time per week, including sham rTMS and following traditional occupational therapy.
62031087|NCT04482647|EXPERIMENTAL|Supportive Care (video, breathing techniques, meditation)|Patients view an instructional video on breathing techniques and meditation. Patients then perform breathing techniques over 3 minutes and meditation over 2 minutes BID for 28 days.
62031088|NCT01821469|EXPERIMENTAL|psychoeducation|psychoeducation (12 weeks)
62031089|NCT03911492|OTHER|SCP Pressure Management|Active management of Spinal Cord Perfusion Pressure (SCPP) at or above 65 mmHg.
62031090|NCT03620942|EXPERIMENTAL|ADIVA system|Vasopressor delivery automated system administering phenylephrine and ephedrine using a three-step algorithm vasopressor delivery technique
62031091|NCT03620942|ACTIVE_COMPARATOR|DIVA system|Vasopressor delivery automated system administering phenylephrine and ephedrine using a two-step algorithm vasopressor delivery technique
62031092|NCT00414700|EXPERIMENTAL|ChondroCelect|
62031093|NCT00414700|ACTIVE_COMPARATOR|Microfracture|
62230307|NCT02985320|EXPERIMENTAL|Phase I Child Group - Medium dosage|"* Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~* Intervention: Single-dose regimen of medium dosage investigational sIPV"
62807240|NCT06021639|NO_INTERVENTION|Clear diet group|250 ml Sennozit A+B calcium (half dose is taken orally at 17.00 on the day before the procedure and the other half at 19.00 will be consumed. Enema 210 cc (Monobasic sodium phosphate 28.5 g. Dibasic sodium phosphate 10.5 g.) The procedure is rectal at 07.00 in the morning. will be used as Routine feeding of the patient up to the last 24 hours before the procedure. The last 24 hours will consume clear diet.
62807241|NCT03148535|EXPERIMENTAL|lithium carbonate|recieve lithium carbonate
62807242|NCT03148535|EXPERIMENTAL|lithium carbonate combined with SSRI antidepressant treatment|recieve lithium carbonate combined with SSRI antidepressant treatment
62807243|NCT02486575|OTHER|self-learning|Residents training alone with pre-recorded instructions. No tutor intervention, only self-learning training Intervention Type: Behavioral (video-based and instruction based learning)
62807244|NCT02486575|OTHER|Mentoring|"Residents training with a mentor, giving tailored instruction to each of them and correction to wrong behaviours.~Intervention Type: Behavioral (tutored learning)"
62807245|NCT02906423||Allina health patients|
62230308|NCT02985320|EXPERIMENTAL|Phase I Infant Group - High dosage|"* Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~* Intervention: Three-dose regimen of high dosage investigational sIPV"
62591908|NCT06145698|EXPERIMENTAL|Experimental: theta-gamma tACS|The study is investigating the use of transcranial alternating current stimulation (tACS). For the experimental arm, the stimulation is delivered at 2 milliamperes (mA) with the stimulation electrode over the left prefrontal cortex (F3) and left orbitofrontal cortex (Fp1) using the cross-frequency stimulation waveform theta-gamma.
62807246|NCT01217944|EXPERIMENTAL|Ranibizumab driven by disease activity|Participants received active ranibizumab on day 1. Thereafter they received ranibizumab treatment based on disease activity criteria
62807247|NCT01217944|EXPERIMENTAL|Ranibizumab driven by stabilization criteria|Participants received ranibizumab on day 1 and month 1. Thereafter they received ranibizumab based on stabilization criteria for visual acuity
62807248|NCT01217944|ACTIVE_COMPARATOR|Verteporfin PDT|Participants received active vPDT on day 1. From month 3 onwards participants could receive ranibizumab, vPDT or a combination of the two if needed.
62807249|NCT03573934|EXPERIMENTAL|GLP-2|Glucagon-Like Peptide-2 (GLP-2) injection
62807250|NCT03573934|EXPERIMENTAL|GIP|Glucose-dependent Insulinotropic polypeptide (GIP) injection
62807251|NCT03573934|EXPERIMENTAL|GLP-2+GIP|GLP-2+GIP injection
62807252|NCT03573934|PLACEBO_COMPARATOR|Placebo|Placebo injection
62807253|NCT01285817|EXPERIMENTAL|traetment|
62422322|NCT01832545|EXPERIMENTAL|Aquatic Exetcise|Aquatic Exercise program is organized in 24 sessions distributed over 12 consecutive weeks, with a frequency of twice a week. The duration of each session will be 60 minutes, being that 10 minutes are for patient reception, blood pressure control, pain register or others and the effective time inside the water is 45 minutes. The indoor pool works with an air temperature around 27±1ºC and water temperature is controlled for 30.5±5ºC. Workout is organized in order to have a progressive overload every week or every two sessions, when occurs an introduction of a new stimulus. Water is the main instrument to create resistance and only in the last weeks, according with participants progression and if the self-reported pain controlled, drag equipment will be added.
62807254|NCT04925349||affected subjects|"* adult patients with adrenomyeloneuropathy/adrenoleukodystrophy~* children with adrenoleukodystrophy~* children with metachromatic leukodystrophy"
62591909|NCT06145698|SHAM_COMPARATOR|Active-sham tACS|For the active sham stimulation, the stimulation is delivered for 12 seconds with the theta-gamma cross-frequency stimulation waveform and then returns to baseline. The stimulus parameter of the sham stimulation is designed to mimic the adaptive sensations experienced by the subject when receiving the real stimulation treatment settings, but no effective brain modulation will be produced, which assists with blinding the participant's assignment.
62807255|NCT04925349||control subjects|-healthy children
62807256|NCT00364676|EXPERIMENTAL|1|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
62807257|NCT00364676|EXPERIMENTAL|2|Patients are dosed on Day 1 of a 21-day cycle.
62807258|NCT02868554|NO_INTERVENTION|Standard Invisalign Therapy|Patients receiving standard Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 14 days of compliant aligner wear.
62807259|NCT02868554|EXPERIMENTAL|Accelerated Invisalign|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
62807260|NCT02868554|EXPERIMENTAL|Accelerated Invisalign and Vibration|In addition to the accelerated Invisalign protocol described in Arm #2, patients will undergo intraoral vibration therapy using an AcceleDent Aura device for a duration of 20 minutes per day.
62807261|NCT03752047||Suspicion of Sepsis|Patients who are admitted and are diagnosed with sepsis will be recruited for this investigation.
62807262|NCT03298802|ACTIVE_COMPARATOR|Hydrochlorothiazide 50mg Tablet|Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
62807263|NCT03298802|PLACEBO_COMPARATOR|Placebo Tablet|Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for fourteen days postpartum
62230309|NCT02985320|EXPERIMENTAL|Phase I Infant Group - Medium dosage|"* Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~* Intervention: Three-dose regimen of medium dosage investigational sIPV"
62807264|NCT01173601|EXPERIMENTAL|12 milligrams (mg) LY2216684 + SSRI|"LY2216684: 12 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the LY2216684 12-mg treatment arm (AT Phase).~Participants who completed the AT Phase or discontinued early entered a 2-week Discontinuation (DC) Phase. Participants were randomly assigned to either abrupt DC or tapered DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
62230310|NCT02985320|EXPERIMENTAL|Phase I Infant Group - Low dosage|"* Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~* Intervention: Three-dose regimen of low dosage investigational sIPV"
62230311|NCT02985320|EXPERIMENTAL|PhaseⅡExperimental Group - High dosage|"* Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~* Intervention: Three-dose regimen of high dosage investigational sIPV"
62422323|NCT05860712|ACTIVE_COMPARATOR|Sodium hypochlorite Irrigation|standardized pulpectomy procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, and a sharp spoon excavator will remove pulpal tissues to the orifice level , the working lengths of root canals were estimated by apex locator and Cleaning and shaping of the root canals was done by rotary files .The pre - irrigation sample were collected after debridement of the radicular pulp tissues by a sterile paper point ,then Second microbial sample : The canals were irrigated with Sodium hypochlorite Irrigation (group A) .All the microbiological culturing procedures were carried out in the Microbiology and Immunology Department , the plates were examined and the colonies were directly counted using colony forming unit .
62591910|NCT01641497|ACTIVE_COMPARATOR|3D conformational radiotherapy|25 \* 1.8 Gy in 5 weeks (=45 Gy). 3D conformational radiation
62807265|NCT01173601|EXPERIMENTAL|18 milligrams (mg) LY2216684 + SSRI|"LY2216684: 12 milligrams (mg), administered orally, once daily (QD) for 1 week, followed by 18 mg, administered orally, once daily for 7 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the LY2216684 18-mg treatment arm (AT Phase).~Participants who completed the AT Phase or discontinued early entered a 2-week Discontinuation (DC) Phase. Participants were randomly assigned to either abrupt DC or tapered DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
62807266|NCT01173601|PLACEBO_COMPARATOR|Placebo + SSRI|"Placebo: Tablet equivalent to LY2216684, administered orally, once daily (QD) for 11 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the placebo treatment arm (AT Phase).~Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase. Participants who had received placebo were assigned to the abrupt DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
62807267|NCT01631435|OTHER|bowel prep regimen|Each study subject will undergo a bowel preparation followed by a PillCam procedure.
62807268|NCT02195908|EXPERIMENTAL|Single point PC6|"choose single point: Neiguan(PC6).Neiguan(PC6): On the anterior aspect of the forearm,between the tendons of the palmaris longus and the flexor carpi radialis, 2 B-cun proximal to the palmar wrist crease.Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
62807269|NCT02195908|EXPERIMENTAL|Single point CV12|"choose another single point Zhongwan（CV12）. Zhongwan(CV12): On the upper abdomen, 4 B-cun superior to the centre of the umbilicus, on the anterior median line. Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
62230312|NCT02985320|EXPERIMENTAL|PhaseⅡExperimental Group - Medium dosage|"* Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~* Intervention: Three-dose regimen of medium dosage investigational sIPV"
62230313|NCT02985320|EXPERIMENTAL|PhaseⅡExperimental Group - Low dosage|"* Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~* Intervention: Three-dose regimen of low dosage investigational sIPV"
62230314|NCT02985320|ACTIVE_COMPARATOR|PhaseⅡControl Group -commercialized sIPV|"* Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~* Intervention:Three-dose regimen of commercialized sIPV"
62591911|NCT01641497|EXPERIMENTAL|Intensity-Modulated Radiation Therapy|25 \* 1.8 Gy in 5 weeks (=45 Gy). IMRT
62591912|NCT05899023|EXPERIMENTAL|Telehealth Bridge Visits|Patients in the experimental arm will receive post-emergency department telehealth bridge visits to connect ED patients with newly diagnosed diabetes to outpatient primary care.
62591913|NCT05899023|ACTIVE_COMPARATOR|Control|Patients in the control arm will receive standard of care.
62230315|NCT02985320|ACTIVE_COMPARATOR|PhaseⅡ Control Group -commercialized IPV|"* Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~* Intervention: Three-dose regimen of commercialized IPV"
62230316|NCT04417946|EXPERIMENTAL|PrEP Messages|The peer leaders and the study staff will post PrEP related health messages
62031094|NCT05767944|EXPERIMENTAL|Wide Awake Local Anesthesia (WALANT)|Study arm: (WALANT) patient received local anaesthesia (25ml of 2%lidocaine with 0.5 ml of adrenaline (1mg/mL) and 5 ml of 8.4% of sodium bicarbonate. the final 50 ml mixture contained 10 mg/ml Lidocaine and adrenaline 1:100,000 concentration) infiltration along rays at site of surgery (15 ml or more per ray (150 mg lidocaine) by 27G needle, 10 ml (or more) in the palm, then 2 ml in the proximal and middle phalanges and 1 ml in the distal phalanx (if required )) for hand flexor tendons repair.
62031095|NCT05767944|ACTIVE_COMPARATOR|Supra Clavicular- Brachial Plexus Block (SC-BPB)|Control arm:(SC-BPB): ultrasound-guided injection of local aesthetics (15 mL of 2% lidocaine and 15 mL of 0.5% bupivacaine were injected incrementally over 3-5 min) at supra-clavicular level where brachial plexus trunks are located this will provide anesthesia for the whole upper limb distal to shoulder joint.
62031096|NCT01650259||Oral antidiabetic drug (OAD)|
62031097|NCT01650259||Trazenta|
62031098|NCT05101538||patients and controls|AN patients and controls are recruited, studied using imaging and followed for 5 years
62591914|NCT05248230|EXPERIMENTAL|4D-710 Phase 1: Dose Exploration|Participants who are ineligible for or intolerant of modulator therapy will receive one of various dose levels of 4D-710 to identify recommended phase 2 dose(s) for further evaluation.
62807270|NCT02195908|EXPERIMENTAL|Matching points PC6+CV12|"Choose both Neiguan point(PC6) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
62031099|NCT06668935||Randomization to FSL 3 or Standard of Care|Subjects with type 2 diabetes who are newly beginning GLP-1 or dual GLP-1/GIP drug therapy will be randomized to use either the FSL3 or their existing Standard of Care (SOC) to manage their diabetes.
62031100|NCT01483001|EXPERIMENTAL|Sensitivity Assay|Patients treated with a treatment chosen by sensitivity assay in vitro
62031101|NCT02625623|EXPERIMENTAL|Physician choice chemotherapy+Best Supportive Care (BSC)|Participants received BSC plus physician's choice chemotherapy. Chemotherapy comprises of one of the following: paclitaxel at a dose of 80 milligram per meter square (mg/m\^2) on Days 1, 8, and 15 of a 4-week treatment cycle until confirmed progressive disease or unacceptable toxicity OR irinotecan at a dose of 150 mg/m\^2 on Days 1 and 15 of a 4-week treatment cycle until confirmed progressive disease or unacceptable toxicity. Participants who are not deemed eligible to receive paclitaxel or irinotecan at the dose and schedule specified above receive BSC alone once every 3 weeks. BSC is defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and is based on investigator's discretion.
62031102|NCT02625623|ACTIVE_COMPARATOR|Avelumab+BSC|Participants received avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with BSC. BSC is defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and is based on investigator's discretion.
62031103|NCT04028700|EXPERIMENTAL|G6PD Deficient Red Blood Cell Transfusion, then Non-G6PD deficient Red Blood Cell Transfusion|Transfusion of a red blood cell unit that has been identified by local laboratory procedures to be deficient in G6PD enzyme activity followed after 4 months by transfusion of a red blood cell unit that has been identified by local laboratory procedures to not be deficient in G6PD enzyme activity.
62031104|NCT04028700|ACTIVE_COMPARATOR|Non-G6PD deficient Red Blood Cell Transfusion, then G6PD Deficient Red Blood Cell Transfusion,|Transfusion of a red blood cell unit that has been identified by local laboratory procedures to not be deficient in G6PD enzyme activity followed after 4 months by transfusion of a red blood cell unit that has been identified by local laboratory procedures to be deficient in G6PD enzyme activity
62031105|NCT04440735|EXPERIMENTAL|DSP107 monotherapy in advanced solid tumors|DSP107 will be administered by intravenous infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle for up to 12 treatment cycles. Starting dose will be 0.01 mg/kg and maximum dose will not exceed 10 mg/kg.
62031106|NCT04440735|EXPERIMENTAL|DSP107 in combination with atezolizumab in advanced solid tumors|DSP107 will be administered by IV infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. Subjects will receive atezolizumab 1200 mg by intravenous infusion over 30 mins (first infusion over 1 hour) on Day 1 of every treatment cycle. DSP107 infusion will commence 1 hour following completion of atezolizumab infusion. The study will include up to 12 treatment cycles.
62230317|NCT04417946|ACTIVE_COMPARATOR|Health messages|The peer leaders and study staff will post general health messages that are not related to sexual health.
62230318|NCT01197859|ACTIVE_COMPARATOR|Contamac 74% silicone hydrogel contact lens|Definitive Contact Lens
62591915|NCT05248230|EXPERIMENTAL|4D-710 Phase 2: Dose Expansion|Participants will receive a single inhalational administration of 4D-710 at the dose level(s) selected for dose expansion.
62591916|NCT05248230|EXPERIMENTAL|4D-710 Dose Exploration (Sub-Study)|Participants who are on currently available CFTR modulator therapy will receive a dose of 4D-710 at various dose levels.
62591917|NCT01864369|ACTIVE_COMPARATOR|Control: eInfo + Usual Care|Usual Care + eInfo on general guidelines for heart healthy living
62591918|NCT01864369|EXPERIMENTAL|Behavioral: eCounseling + Usual Care|Behavioral:eCounseling + Usual Care: interactive web pages utilized to provide e-counseling messages and e-tools.
62807271|NCT02195908|ACTIVE_COMPARATOR|only antiemetic|The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.
62807272|NCT02828371|EXPERIMENTAL|Erigo|Single daily sessions of verticalization, using a tilt table with an integrated robotic stepping device (Erigo. Hocoma AG, Switzerland) located in the ICU room. Sessions were performed five times per week (Monday-Friday) for three consecutive weeks (a total of 15 sessions per patient). On the same days the patients received conventional physiotherapy for 30 minutes a day. Before the verticalization period the experimental group received conventional in-bed physiotherapy for 60 minutes a day.
62591919|NCT03989206|EXPERIMENTAL|Nemolizumab|Nemolizumab administered via subcutaneous injection
62422324|NCT05860712|SHAM_COMPARATOR|Cinnamon extract Irrigation|standardized pulpectomy procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, and a sharp spoon excavator will remove pulpal tissues to the orifice level , the working lengths of root canals were estimated by apex locator and Cleaning and shaping of the root canals was done by rotary files .The pre - irrigation sample were collected after debridement of the radicular pulp tissues by a sterile paper point ,then Second microbial sample : The canals were irrigated with cinnamon Irrigation (group B) . All the microbiological culturing procedures were carried out in the Microbiology and Immunology Department , the plates were examined and the colonies were directly counted using colony forming unit .
62422325|NCT06246513|EXPERIMENTAL|SRP-9003|Participants will receive a single intravenous (IV) infusion of SRP-9003.
62422326|NCT02308865|NO_INTERVENTION|Control arm|Patient supported by the onco respiratory service for the treatment of their disease by chemotherapy and for the treatment of complications.
62422327|NCT02308865|EXPERIMENTAL|intervention arm|Multi disciplinary palliative care monthly consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a chaplain in addition to standard onco-pneumologic care.
62422328|NCT06396221|EXPERIMENTAL|Estetrol 15 mg/Drospirenone 3 mg (24/4)|
62422329|NCT06396221|ACTIVE_COMPARATOR|Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)|
62422330|NCT02388607||assessing attention span|"* Electrophysiological measurements (evocated potentials and spectral densities)~* Clinical scales and subjective assessments of difficulty of the tasks performed, and commitment to the task"
62422331|NCT05504369|ACTIVE_COMPARATOR|Magnetic tape arm|Tape application bilaterally in the lumbar spine
62807273|NCT02828371|ACTIVE_COMPARATOR|Conventional|treated with conventional in-bed physiotherapy for 60 minutes a day, from Monday to Friday, throughout the ICU stay.
62807274|NCT03253042|EXPERIMENTAL|WBV exercise program|8-week exercise program associated with the vibratory platform. Each exercise session will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will be connected at the beginning of each series, set at a vibration frequency of 40 Hertz (Hz) and peak-to-peak amplitude of 4 millimeters (mm) resulting in a peak acceleration of 128 ms2 (12.8 g). This should provide the equivalent of 3600 vertical vibrations, totaling 14400 vibrations per training session.
62807275|NCT03253042|SHAM_COMPARATOR|Sham WBV exercise program|8-week exercise program in which each session will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
62807276|NCT03282461|EXPERIMENTAL|ABY-029|Between 3-9 patients will be administered ABY-029 as a single intravenous injection approximately 1-3 hours prior to surgery.
62807277|NCT05241379|EXPERIMENTAL|Amber UI Therapy|Participants will undergo surgical implantation of the Amber UI System incorporating 2 electrode leads connected to a single IPG
62807278|NCT01009658|ACTIVE_COMPARATOR|MSG first|
62422332|NCT05504369|SHAM_COMPARATOR|Placebo tape arm|Tape application bilaterally in the lumbar spine
62807279|NCT01009658|PLACEBO_COMPARATOR|NaCl first|
62807280|NCT04977440||standard protein|
62807281|NCT04977440||high protein|
62807282|NCT06020157|EXPERIMENTAL|Simple Suture Group|
62422333|NCT00190684|EXPERIMENTAL|Atomoxetine|Atomoxetine-naive patients will have an acute titration to a stable dose, atomoxetine experienced patients whose therapy has been interrupted with be rapidly titrated to their previously established stable dose, and atomoxetine patients on a known stable dose may continue treatment at that dose.
62591920|NCT03781258|OTHER|Anit-thrombotic monotherapy|Patients with HeartMate 3 LVAS transitioning from Warfarin and Acetylsalicylic Acid (ASA) therapy to receive anti-thrombotic monotherapy (ASA).
62591921|NCT05342051|EXPERIMENTAL|balneotherapy group|balneotherapy plus usual care
62230319|NCT01197859|PLACEBO_COMPARATOR|Cooper Vision Biofinity|Biofinity Contact Lens
62230320|NCT03616925|EXPERIMENTAL|Platelet rich fibrin matrix|surgical open flap debridement with Application of Platelet rich fibrin matrix using Platelet Rich Fibrin Matrix kit in 15 intrabony defect sites
62591922|NCT05342051|NO_INTERVENTION|control group|usual care
62807283|NCT06020157|EXPERIMENTAL|Continuous Suture Group|
62807284|NCT03389022|ACTIVE_COMPARATOR|Treatment1|0,15 mg/kg (LBM) of intravenous pre-incisional single bolus injection of ketamine given for bariatric patients in the operating room.
62807285|NCT03389022|ACTIVE_COMPARATOR|Treatment2|0,3 mg/kg (LBM) of intravenous pre-incisional single bolus injection of ketamine given for bariatric patients in the operating room.
62807286|NCT03389022|ACTIVE_COMPARATOR|Treatment3|0,15 mg/kg (LBM) of intravenous pre-incisional single bolus injection, followed by continuous infusion of 1mg/kg ketamine given for bariatric patients in the operating room.
62807287|NCT03389022|PLACEBO_COMPARATOR|Control|The same amount of intravenous single pre-incisional injection of saline for bariatric patients in the operating room.
62807288|NCT03389022|ACTIVE_COMPARATOR|Treatment4|0,3 mg/kg (LBM) of intravenous pre-incisional single bolus injection, followed by continuous infusion of 1mg/kg ketamine given for bariatric patients in the operating room.
62807289|NCT00887302||Restricted food intake without rerouting food flow cohort|Obese non-diabetic patients and diabetic patients undergoing gastric band surgery will be studied before they have surgery, 1 week after the band is adjusted to restrict food intake and again after they have lost the weight equal to that which gastric bypass patients loose 3 months after surgery (to match data we already have in the current study). All patients will be studied with an intravenous glucose tolerance test to measure insulin sensitivity and IV glucose-induced insulin secretion and a meal challenge to measure the secretion of metabolites and peptides.
62807290|NCT00887302||Response to meal when a portion of the stomach is excluded from food flow cohort|Obese-diabetic patient undergoing gastric sleeve surgery will be studied before they have surgery, 1 week after surgery and again 3-6 months after surgery (to match data we already have in the current study). The patient will be studied with an intravenous glucose tolerance test to measure insulin sensitivity and insulin secretion and a meal challenge to measure the secretion of metabolites and peptides.
62807291|NCT00887302||Response to meal when a portion of the GI tract is excluded from food flow cohort|"In approximately 6 patients/year our surgeons have to insert a gastrostomy tube into the bypassed stomach of gastric bypass patients. This provides a unique opportunity to see the changes in metabolites and peptides in blood in response to a meal delivered to the bypassed stomach, duodenum and proximal jejunum. Since we can not anticipate which patients will require this procedure, we cannot do tests before surgery, but we will do four tests post-operatively: (1) an IV glucose tolerance test, (2) an oral meal challenge (with Hi-cal), and (3) a meal challenge (identical to that given orally/Hi-Cal) delivered through the gastrostomy tube.~Gastrostomy subjects will also have a 4) test, a 75 gram dextrose meal challenge."
62230321|NCT03616925|ACTIVE_COMPARATOR|surgical open flap debridement|only surgical open flap debridement was done without application of Platelet rich fibrin matrix in 15 intrabony defect sites
62807292|NCT02478008|EXPERIMENTAL|CardiAQ TMVI System (Transapical DS)|
62807293|NCT04344223|EXPERIMENTAL|Experimental balance shoes|Tests and familiarization phases with experimental balance shoes (Axis Comfort Development®)
62230322|NCT05400980|EXPERIMENTAL|Urocross implant group|The investigational products in this trial are the Urocross Expander Implant as delivered by the Urocross Expander System and the Urocross Retrieval Sheath used to retrieve the implant after 6 months following its implant.
62230323|NCT05400980|SHAM_COMPARATOR|Sham-control group|The sham-control in this trial is cystoscopy only.
62031107|NCT04440735|EXPERIMENTAL|DSP107 in combination with atezolizumab in non-small cell lung cancer|DSP107 10mg/kg will be administered by IV infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. Subjects will receive atezolizumab 1200 mg by intravenous infusion over 30 mins (first infusion over 1 hour) on Day 1 of every treatment cycle. DSP107 infusion will commence 1 hour following completion of atezolizumab infusion. The study will include up to 12 treatment cycles.
62230324|NCT04658082|OTHER|Non invasive glucose monitor|Single arm. All subjects will have glucose levels measured both by non invasive glucometer and by core lab
62230325|NCT06020807||Healthy|Healthy subjects and urology patients without prior history or evidence of bladder cancer
62230326|NCT00790465|ACTIVE_COMPARATOR|1|dark chocolate consumption during manometry and 2 weeks treatment with dark chocolate
62230327|NCT00790465|OTHER|2|placebo comparator: 7 grams of placebo-chocolate at day 1 during manometry, and than crossover to treatment with dark chocolate for 2 weeks.
62230328|NCT04327076|EXPERIMENTAL|Robot system intervention|"1. Evaluate the patient and sign the informed consent~2. The patient was given general anesthesia~3. Use magnetically guided tracheal intubation and airway cleaning robot system"
62230329|NCT01445067|ACTIVE_COMPARATOR|Arm 1: BMS-927711 (300 mg)|
62230330|NCT01445067|ACTIVE_COMPARATOR|Arm 2: BMS-927711 (600 mg)|
62230331|NCT06447077||Predetermined embryo transfer on day 5|The control group will include patients who have their oocyte pick-up on a monday (embryo transfer on saturday, day 5), wednesday (embryo transfer on monday, day 5), thursday (embryo transfer on tuesday, day 5), friday (embryo transfer on wednesday, day 5) and saturday (embryo transfer on thursday, day 5).
62230332|NCT06447077||Predetermined embryo transfer on day 6|The study group will include patients who have their oocyte pick-up on a tuesday (embryo transfer on monday, day 6).
62230333|NCT04823221||Rezūm system|The basic principle of the Rezūm System is to deliver a controlled amount of sterile water vapor directly into the hyperplastic tissue in the transition zone of the prostate using a transurethral approach .The stored thermal energy in the vapor is transferred directly onto the cell membranes as the vapor condenses and releases the heat of condensation, causing cell death. Inaddition, this thermal energy transfer collapses the vasculature within the treatment zone, resulting in a bloodless procedure. During procedure the water vapor is created by a heating element in the Rezūm Delivery Device,Saline flush during vapor delivery protects and preserves the urethra.
62230334|NCT05369273|EXPERIMENTAL|adipose graft + Platelet Rich Plasma|
62230335|NCT05369273|OTHER|adipose graft|
62230336|NCT00436033|PLACEBO_COMPARATOR|Placebo|
62230337|NCT00436033|EXPERIMENTAL|Minalcipran|
62230338|NCT04457167|EXPERIMENTAL|Robotic surgery|Robotic surgery for breast mastectomy with conservation of areolo-nipple plate and immediate or delayed reconstruction by latissimus dorsi flap,
62807294|NCT04344223|ACTIVE_COMPARATOR|Personal shoes|"Same tasks than the condition Experimental balance shoes but realized with personal shoes (own personal shoes of subjects)"
62807295|NCT05361616|ACTIVE_COMPARATOR|PBM Ortho Active device|PBM Ortho Active group will be given an active device.
62807296|NCT05361616|SHAM_COMPARATOR|PBM Ortho Sham|PBM Ortho Sham device group will be given a non-active device that will not emits light.
62807297|NCT03022877|PLACEBO_COMPARATOR|Placebo|Placebo is given as a Bolus (instead of Bolus application of Levosimendan) over 10 min i.v., starting 10 min before recanalization.
62230339|NCT04457167|ACTIVE_COMPARATOR|Non robotic surgery|Non-robotic surgery for breast mastectomy with conservation of areolo-nipple plate and immediate or delayed reconstruction by latissimus dorsi flap,
62230340|NCT01179425|ACTIVE_COMPARATOR|non-marijuana dependent controls|
62031108|NCT04440735|EXPERIMENTAL|DSP107 monotherapy in colorectal cancer|DSP107 10mg/kg will be administered by intravenous infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle for up to 12 treatment cycles..
62031109|NCT04440735|EXPERIMENTAL|DSP107 in combination with atezolizumab in colorectal cancer|DSP107 10mg/kg will be administered by IV infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. Subjects will receive atezolizumab 1200 mg by intravenous infusion over 30 mins (first infusion over 1 hour) on Day 1 of every treatment cycle. DSP107 infusion will commence 1 hour following completion of atezolizumab infusion. The study will include up to 12 treatment cycles.
62807298|NCT03022877|ACTIVE_COMPARATOR|Bolus Levosimendan|Levosimendan is given as Bolus (12 µg/kg over 10 min i.v.), starting 10 min before recanalization.
62031110|NCT01195012|OTHER|wait-list control arm|Participants wait-listed to start the behavioral obesity treatment program (Helping HAND) after time two data collection (7 months after baseline).
62031111|NCT01195012|EXPERIMENTAL|Intervention arm|see intervention description
62031112|NCT01858168|EXPERIMENTAL|One|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle for patients with Ewing sarcoma
62230341|NCT01179425|EXPERIMENTAL|Marijuana-dependent subjects|
62230342|NCT05488574|EXPERIMENTAL|Deep breathing with Yoga positioning|subjects participating in breathing and moving meditation program. 12 minutes daily of deep breathing and yoga positioning first 30 days, then continuation of breathing and positioning and self-directed, mentored, behavior modification activities the second 30 days.
62230343|NCT05488574|NO_INTERVENTION|Control|No changes in lifestyle or activities over the 60 day period.
62591923|NCT05306314||TREATAPROST 0 mL( BID- 10mL*2) PO|Treataprost 10 mL ( 5 mL 2\*1- PO ) 42 days Generic Name : Treatarost Advance Dosage Form: Suspension, vials of 250 mL Dosage : 250 mL Frequency : 2\*1 (BID) Duration: 42 days (6 weeks) Administration:Oral administration before meals 30 minutes as 20 mL(10mL\*2)
62807299|NCT03022877|ACTIVE_COMPARATOR|Bolus and infusion Levosimendan|Levosimendan is given as Bolus (12 µg/kg over 10 min i.v.), starting 10 min before recanalization and additionally as continuous infusion (0.1-0.2 µg/kg/min i. v. for 24 hours).
62807300|NCT05865626|EXPERIMENTAL|VOT without cash incentive at the begining|Participants in this group start VOT without financial motivation. In the second part of their follow-up, VOT is combined with financial motivation.
62807301|NCT05865626|EXPERIMENTAL|VOT with cash incentive at the begining|The participants in this group start the VOT with the financial motivation. In the second part of their follow-up, VOT is no longer associated with financial motivation
62807302|NCT05865626|NO_INTERVENTION|Standard care|The participants in this group self-administer the anti-tuberculosis treatment as is done routinely.
62031113|NCT01858168|EXPERIMENTAL|Two|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle Irinotecan, given by IV once per day on days 1-7 of each cycle
62031114|NCT01858168|EXPERIMENTAL|Three|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle for patients with Rhabdomyosarcoma
62031115|NCT04717804|ACTIVE_COMPARATOR|AIP (Average Intensity Projection) CT (Computed Tomagraphy)|An image taken over a longer time of the lungs (average intensity projection of 4DCT) will be compared with breathing during treatment.
62031116|NCT04717804|PLACEBO_COMPARATOR|FB (Free-Breathing) CT|A snapshot of breathing (free-breathing traditional CT) will be used to compare with breathing during treatment.
62031117|NCT04952324||Pregnant women with GDM|Pregnant women with GDM
62031118|NCT04952324||Pregnant women without GDM|Pregnant women without GDM
62031119|NCT05323526||Study Group|100 patients who will undergo cataract surgery
62031120|NCT01416792|EXPERIMENTAL|Multiple-pass hemofiltration|
62230344|NCT06310057|EXPERIMENTAL|Tofacitinib 10mg|All patient that fulfill the inclusion ans exclusion criteria will start at 10mg tofacitinib.
62230345|NCT06310057|EXPERIMENTAL|Tofacitinib 15 mg|At 3rd month, patients that do not fulfill the ASDAS major improvement criteria will get 15mg tofacitinib.
62230346|NCT05379582|NO_INTERVENTION|control group|Implement nutrition therapy according to existing feeding procedures
62230347|NCT05379582|EXPERIMENTAL|intervention group|Implement nutrition therapy according a procedure assisted by gastrointestinal ultrasound
62230348|NCT02585479|EXPERIMENTAL|systemic chemotherapy|Pirarubicin 30mg/m2 intravenously on Day 1 and Oxaliplatin 100 mg/m2 intravenously on Day 2 every 3 weeks until disease progression or limiting toxicity.
62422334|NCT02534207|EXPERIMENTAL|Basmisanil in Japanese Healthy Volunteers|Japanese healthy volunteers will receive a single oral dose of RO5186582 within 15 minutes after completing a standard meal.
62422335|NCT00858039||Her-2 positive ESBC|
62807303|NCT04107662||Traumatic Brain Injury|
62807304|NCT04684264|EXPERIMENTAL|Pharmacist-directed collaborative practice|Participants will be referred to a pharmacist-directed collaborative practice for heart failure prevention.
62807305|NCT04684264|NO_INTERVENTION|Usual care|Participants will receive usual care with their primary care physician.
62807306|NCT01418638||30 Patients with MDD.|30 Patients aged 18-65, who were diagnosed with MDD according to the DSM-IV criteria.
62807307|NCT06112574|ACTIVE_COMPARATOR|Single-task|Visuomotor training
62807308|NCT06112574|EXPERIMENTAL|Dual-task|Visuomotor + cognitive components training
62807309|NCT01027715|EXPERIMENTAL|EEG seizure treatment group|EEG data available to physicians. Treatment based on EEG seizures. Treatment will be dictated by the detailed treatment protocol. Standard antiepileptic medications will be used.
62807310|NCT01027715|NO_INTERVENTION|Clinical Seizure treatment Group|Seizure treatment in this group will be based on standard care - treating clinical seizures only. While EEG data will be collected in this group, the data will not be available to the treating physicians. A one-hour EEG report will be available to the treating team. Continuous EEG monitoring and treatment will only be allowed if the initial EEG shows status.
62807311|NCT05327179|EXPERIMENTAL|Group 1|Action Observation Treatment
62807312|NCT05327179|EXPERIMENTAL|Group 2|Virtual Rehabilitation
62031121|NCT02808962|OTHER|Cooled Radiofrequency Ablation|"This is a single arm, prospective observational study. All subjects enrolled are patients that meet the inclusion criteria, as deemed by a physician.~Typical standard of care for these patients is an initial visit followed by two diagnostic blocks ((0.5ml) of 1% Lidocaine per level). Subjects are asked to complete the pain diary and if they experience a 75% or more decrease in the NRS, they are scheduled for Cooled RFA of the lateral branches of S1, S2, and S3 dorsal rami nerves and of the dorsal ramus of L5 nerve."
62031122|NCT00000457|PLACEBO_COMPARATOR|Placebo|Subjects who achieved smoking abstinence and give a bupropion-placebo (sugar) pill for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
62031123|NCT00000457|ACTIVE_COMPARATOR|Bupropion|Subjects who achieved smoking abstinence and give bupropion (300 mg/day) for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
62031124|NCT06525623|EXPERIMENTAL|VAGA Group|This group will receive an algorithm-based recommendation based on the 2024 Acute Disease Quality Initiative (ADQI)/International Club of Ascites (ICA) joint consensus meeting on AKI in cirrhosis, which recommends a personalized approach to AKI in cirrhosis in order to avoid volume overload. This includes balanced crystalloids as first-line resuscitative fluids unless there is a patient-specific indication for an alternative colloid (e.g. blood for gastrointestinal bleeding, IV albumin for spontaneous bacterial peritonitis or suspicion of hepatorenal syndrome), or no further resuscitation.
62230349|NCT02585479|ACTIVE_COMPARATOR|Transcatheter Arterial Chemoembolization|Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using Gelfoam every 4 weeks until disease progression or limiting toxicity.
62230350|NCT00743275|EXPERIMENTAL|Study Group|Participants received one dose of Fluzone® vaccine on Day 0.
62230351|NCT00102609|EXPERIMENTAL|Trabectedin and doxorubicin|Doxorubicin (50 to 75 mg/m2) administered intravenously on Day 1 followed by trabectedin (0.9 to 1.3 mg/m2) administered intravenously on Day 1 every 3 weeks for up to 6 cycles. Dexamethasone 20 mg administered intravenously will be given within 1 hour before the start of doxorubicin. Patients may receive filgrastim for unmanageable neutropenia.
62230352|NCT02083874|EXPERIMENTAL|CBD|Open label CBD
62230353|NCT01556295||Experimental|
62230354|NCT01556295||Control|
62807313|NCT01256268|EXPERIMENTAL|Endometrial Cancer|Phase 1A + Cohort 1B - Recurrent or Metastatic Endometrial Cancer. Patients with recurrent or metastatic endometrial cancer with up to 1 prior chemotherapy. Ridaforolimus at the Phase 1A MTD and schedule will be administered with paclitaxel at the Phase 1A MTD (175 mg/m2) IV and carboplatin at the phase 1 MTD (AUC 5 to 6) in mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Treatment will continue until disease progression or adverse events prohibit further therapy.
62807314|NCT01256268|EXPERIMENTAL|Ovarian Cancer|Phase 1 A + Cohort 1B - Recurrent or Metastatic Ovarian Cancer. Patients with platinum-sensitive, recurrent ovarian cancer with up to 2 prior chemotherapy regimens. Ridaforolimus at the phase 1A MTD and schedule will be administered with paclitaxel at the phase 1 MTD (175 mg/m2) IV and carboplatin at the phase 1 MTD (AUC 5 to 6) in mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Treatment will continue until disease progression or adverse events prohibit further therapy.
62807315|NCT01388517|ACTIVE_COMPARATOR|Calcitriol|Repigmentation treatment for the relief of hypopigmented pityriasis alba lesions
62807316|NCT01388517|ACTIVE_COMPARATOR|Tacrolimus|Treatment for the relief of hypopigmented pityriasis alba lesions
62031125|NCT06525623|PLACEBO_COMPARATOR|Standard of Care|This group will receive a recommendation based on the 2021 American Association for the Study of Liver Diseases (AASLD) and 2018 European Association for the Study of the Liver (EASL) clinical practice guidelines, which recommends a 1 g/kg/d IV albumin (maximum 100 g/day) IV albumin over 2 days as an initial resuscitation approach for patients with AKI and cirrhosis.
62031126|NCT01517802|EXPERIMENTAL|Abiraterone acetate|Patients will continue the same treatment regimen they were receiving during their participation in the previous abiraterone acetate clinical study.
62031127|NCT04213196|EXPERIMENTAL|HSK21542 0.2 μg/kg（15 min)|Healthy volunteers 0.2 μg/kg HSK21542
62031128|NCT04213196|EXPERIMENTAL|HSK21542 0.5 μg/kg|Healthy volunteers 0.5 μg/kg HSK21542 or Placebo
62031129|NCT04213196|EXPERIMENTAL|HSK21542 1 μg/kg （15min)|Healthy volunteers 1 μg/kg HSK21542 or Placebo
62230355|NCT01139021|EXPERIMENTAL|B246_12_M12|Subjects assessed one year post administration of rMenB+OMV NZ and MMRV at 12th month after primary vaccination at 2nd ,4th and 6th months of age.
62230356|NCT01139021|EXPERIMENTAL|B246_12M13|Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 13th month after primary vaccination at 2nd ,4th and 6th months of age.
62230357|NCT01139021|EXPERIMENTAL|B13_15_27|Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at 13th and 15th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27 months of age.
62230358|NCT01139021|EXPERIMENTAL|B12_14_26|Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 26 months of age.
62230359|NCT01139021|EXPERIMENTAL|B_24_26|Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.
62230360|NCT01139021|EXPERIMENTAL|B12M13|Subject was randomized in group B13_15_27 but treated as group B12_M13.
62230361|NCT01896154|EXPERIMENTAL|NPS from yeast|Powder containing the active ingredients (500mg NPS from yeast) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks. 2 weeks before vaccination and 3 weeks after vaccination.
62230362|NCT01896154|EXPERIMENTAL|NPS from shiitake|Powder containing the active ingredient (500mg NPS from shitake) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
62230363|NCT01896154|EXPERIMENTAL|NPS from oat|Powder containing the active ingredient (10g NPS from oat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
62230364|NCT01896154|EXPERIMENTAL|NPS from wheat|Powder containing the active ingredient (10g NPS from wheat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
62230365|NCT01896154|EXPERIMENTAL|NPS from Lactobacillus mucosae|Powder containing the active ingredient (2,3g NPS from L. mucosae) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
62230366|NCT01896154|PLACEBO_COMPARATOR|Maltodextrin|12.0 g Maltodextrin and flavour with identical/similar appearance and taste (when mixed in drink), consumed once daily as described for the active products (NPS.
62230367|NCT00945308|ACTIVE_COMPARATOR|Eptifibatide (intracoronary)|
62230368|NCT00945308|ACTIVE_COMPARATOR|Eptifibatide (intravenous)|
62230369|NCT01296373||HIV-1-infected, off ART|HIV-1-infected, antiretroviral naive or off antiretroviral therapy for at least 12 months with CD4+ T-cell counts less than or equal to 350 cells/µL who are about to commence combination antiretroviral therapy
62031130|NCT04213196|EXPERIMENTAL|HSK21542 1 μg/kg （2min)|Healthy volunteers 1 μg/kg HSK21542 or Placebo
62031131|NCT04213196|EXPERIMENTAL|HSK21542 0.75 μg/kg|Healthy volunteers 0.75 μg/kg HSK21542 or Placebo
62807317|NCT01388517|PLACEBO_COMPARATOR|Petrolatum|Petrolatum treatment for the relief of hypopigmented pityriasis alba lesions
62031132|NCT04213196|EXPERIMENTAL|HSK21542 1.5 μg/kg|Healthy volunteers 1.5 μg/kg HSK21542 or Placebo
62031133|NCT04213196|EXPERIMENTAL|HSK21542 2.25 μg/kg|Healthy volunteers 2.25 μg/kg HSK21542 or Placebo
62031134|NCT04213196|EXPERIMENTAL|HSK21542 3.375 μg/kg|Healthy volunteers 3.375 μg/kg HSK21542 or Placebo
62031135|NCT04213196|EXPERIMENTAL|HSK21542 0.2 μg/kg（2min)|Healthy volunteers 0.2 μg/kg HSK21542 or Placebo
62230370|NCT03258164|EXPERIMENTAL|ASC|
62807318|NCT04955171|ACTIVE_COMPARATOR|BEOVU|Intravitreal injection of BEOVU 3 loading injections( monthly) then under treat and extent regimen
62230371|NCT03258164|ACTIVE_COMPARATOR|Control|
62230372|NCT00838929|EXPERIMENTAL|Vorinostat (200 mg) and radiation|Cohort 1: Patients receive 200 mg of Vorinostat and radiation
62230373|NCT00838929|EXPERIMENTAL|Vorinostat (300 mg) and radiation|Cohort 2: Patients receive 300 mg of vorinostat and radiation
62230374|NCT00838929|EXPERIMENTAL|Vorinostat (400 mg) and radiation|Cohort 3: Patients receive 400 mg of vorinostat and radiation
62230375|NCT00372385|PLACEBO_COMPARATOR|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 48 weeks.
62230376|NCT00372385|EXPERIMENTAL|Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet orally thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 24 weeks.
62230377|NCT00372385|EXPERIMENTAL|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 12 weeks.
62230378|NCT00372385|EXPERIMENTAL|Telaprevir 12 Week+Peg-IFN-alfa-2a 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 12 weeks.
62230379|NCT06444685|EXPERIMENTAL|Table Tennis|Participants will follow supervised Table Tennis sessions lasting 60 minutes during 6 weeks, for a total of 12 sessions.
62230380|NCT06444685|EXPERIMENTAL|Tabletop Games|Participants will follow supervised Tabletop Game sessions lasting 60 minutes during 6 weeks, for a total of 12 sessions.
62422336|NCT00430638|EXPERIMENTAL|Treatment|Olmesartan medoxomil, plus hydrochlorothiazide, if necessary
62807319|NCT04955171|ACTIVE_COMPARATOR|Eylea|Intravitreal injection of Eylea 3 loading injections( monthly) then under treat and extent regimen
62807320|NCT03908333|EXPERIMENTAL|AA NABPLAGEM|ascorbic acid paclitaxel protein-bound cisplatin gemcitabine
62031136|NCT04756518||COVID 19 group|The COVID 19 group will consist of peripheral blood smear slides from patients who are in the hospital who had qPCR results positive for COVID-19.
62031137|NCT04756518||CONTROL group|A control group will consist of i) peripheral blood smear slides from patients with no viral infection and ii) from those with a non-SARS-CoV-2 viral infection. Control group peripheral blood slides will be randomly selected from the laboratory slides archive within the facility. The laboratory slides used will be inclusive of slides archived prior to the emergence of COVID-19 infection in the United Kingdom.
62031138|NCT04637204||Subgroup 1|Patients with index treatment: cabozantinib treatment post vascular endothelial growth factor (VEGF)-targeted therapy in any line, except axitinib.
62031139|NCT04637204||Subgroup 2|Patients with index treatment: axitinib treatment post VEGF-targeted therapy in any line, except cabozantinib.
62031140|NCT04637204||Subgroup 3|Patients with index treatment: cabozantinib treatment post axitinib by line of therapy (2L, 3L, 3L+)
62031141|NCT04637204||Subgroup 4|Patients with index treatment: axitinib treatment post cabozantinib by line of therapy (2L, 3L, 3L+)
62031142|NCT02046980|EXPERIMENTAL|Gufoni|Gufoni maneuver for apogeotropic horizontal BPPV at the first day
62031143|NCT02046980|EXPERIMENTAL|Vibration|Vibration maneuver for apogeotropic horizontal BPPV at the first day
62031144|NCT02046980|SHAM_COMPARATOR|Sham|Sham maneuver for apogeotropic horizontal BPPV at the first day
62230381|NCT02200692||plasma transfusion|Patients receiving plasma transfusion.
62230382|NCT00988520|EXPERIMENTAL|0.6 mg/kg intubation dose under sevoflurane|
62230383|NCT00988520|EXPERIMENTAL|0.9 mg/kg intubation dose under sevoflurane|
62230384|NCT00988520|EXPERIMENTAL|continuous dose following 0.6 mg/kg intubation dose + propofol|
62230385|NCT00988520|EXPERIMENTAL|continuous dose following 0.9 mg/kg intubation dose + propofol|
62230386|NCT00138671|ACTIVE_COMPARATOR|Subcutaneous Insulin|
62230387|NCT00138671|EXPERIMENTAL|Inhaled Insulin|
62422337|NCT00430638|PLACEBO_COMPARATOR|Placebo|Placebo tablets were taken once daily for 12 weeks
62807321|NCT04403412|EXPERIMENTAL|Left atrial appendage closure group|
62807322|NCT04403412|EXPERIMENTAL|Radiofrequency ablation group|
62807323|NCT04403412|EXPERIMENTAL|LAAC combined with radiofrequency ablation group|
62807324|NCT06187259|ACTIVE_COMPARATOR|carbide bur group|"carbide burs are extremely hard and can withstand high temperatures. Because of their hardness, carbide burs can maintain a sharp cutting edge and can be used many times without becoming dull. They are best operated at high speeds with light pressure.~Carbide dental bur was designed to, efficiently, remove non-decalcified enamel and dentin, yet, it does not facilitate the differentiation between carious and normal dentin, during cavity preparation."
62031145|NCT02049073|EXPERIMENTAL|Zonisamide|Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
62031146|NCT02049073|EXPERIMENTAL|Methylprednisolone|Methylprednisolone 32 mg or 64 mg pill administered orally once
62031147|NCT02049073|NO_INTERVENTION|Control|no medication
62031148|NCT00989651|EXPERIMENTAL|Regimen I (paclitaxel, carboplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes (beginning in course 2) on day 1. Patients also receive veliparib PO BID on days 1-21. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment with bevacizumab repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
62031149|NCT00989651|EXPERIMENTAL|Regimen II (paclitaxel, carboplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Patients also receive carboplatin, bevacizumab, and veliparib as in Regimen I. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment with bevacizumab repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
62031150|NCT00989651|EXPERIMENTAL|Regimen III (paclitaxel, cisplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 3 hours on day 1 and IP on day 8, and cisplatin IP on day 1 or 2. Patients also receive bevacizumab and veliparib as in Regimen I. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
62031151|NCT06668064|EXPERIMENTAL|EYP-1901 2686 µg|EYP-1901
62230388|NCT04131400||Patients with Inherited Retinal Dystrophy|known patients with a diagnosis of inherited retinal dystrophy (IRD) will be recruited to identify the type of IRD diagnosis. The comprehensive ophthalmic examinations and retinal imaging will be performed. Additionally, blood sample of all participants and their family members will be kept in our bio- bank for genetic testing.
62230389|NCT04130386|EXPERIMENTAL|Motivational Interviewing|Participants assigned to this arm will complete three MI sessions over 10 weeks.
62422338|NCT05629273||Children treated with continuous renal replacement therapy in the intensive care unit.|"Children treated with CRRT in the ICU due to AKI stage ≥1 (according to KDIGO) and/or ≥2 organ failures. The aim is to evaluate their long term renal function and establish the frequency of chronic kidney disease. Nephrology follow up will be done by a pediatric nephrologist for children living in the Stockholm area or have ongoing care at Karolinska University Hospital.~Due to high mortality in this group of patients and the fact that many patients are referred to Karolinska University Hospital from other regions in Sweden, a substantial number of patients will be lost to follow-up. The investigators will therefore conduct a register-based study of all children who received CRRT due to AKI and/or MOF at Karolinska University Hospital from 2008-2021. Data regarding mortality, cause of death and diagnosis of chronic renal disease will be collected from the Swedish National Patient Register and National Cause of Death Register."
62031152|NCT06668064|ACTIVE_COMPARATOR|Aflibercept|
62031153|NCT05804565|ACTIVE_COMPARATOR|Bone Saw|"In the intervention arm, the metatarsal bone will be transected using an oscillating microsaw. This is an accepted surgical method."
62031154|NCT05804565|OTHER|Bone Cutter|"In the control arm, the metatarsal bone will be transected using a manual bone cutters. This is also an accepted surgical method"
62031155|NCT05481879|EXPERIMENTAL|Placebo-Controlled MAD Period: DYNE-101|Participants will be randomized to receive ascending doses of DYNE-101, once every 4 weeks (Q4W) or once every 8 weeks (Q8W) for up to 24 weeks.
62031156|NCT05481879|PLACEBO_COMPARATOR|Placebo-Controlled MAD Period: Placebo|Participants will be randomized to receive DYNE-101 matching placebo, Q4W or Q8W for up to 24 weeks.
62422339|NCT00478634|EXPERIMENTAL|A1: RAD001 + cetuximab + irinotecan|RAD001 30mg weekly oral, 400mg/m2, loading i.v. (250mg/m2 for subsequent weekly dose i.v.), 350mg/m2 every 3 weeks i.v.
62807325|NCT06187259|EXPERIMENTAL|polymer bur II group|Polymer bur tools resemble conventional burs in appearance, but they are made of unique polymer material rather than metal. The cutting edges are not spiral, like those of a shovel. The polymer material was designed to be softer than healthy dentin (Knoop hardness 70-90) but harder than carious, softening dentin (Knoop hardness 50-70) (Knoop hardness 0-30). Therefore, it has a knoop hardness of 50 kg/mm2, and its cutting elements effectively remove soft dentin but cannot remove healthy dentin.
62807326|NCT00925834|PLACEBO_COMPARATOR|Sodium chloride|"Control arm A: Hidden intracoronary infusion of 5ml sodium chloride"
62807327|NCT00925834|EXPERIMENTAL|Sodium chloride and verbal suggestions|"Experimental arm A: Open intracoronary infusion of 5ml sodium chloride plus the suggestion of a vasodilatory effect on coronary vessels"
62807328|NCT00925834|ACTIVE_COMPARATOR|Nitroglycerin|"Control arm B: Hidden intracoronary infusion of 0.01mg nitroglycerin in 5 ml sodium chloride"
62807329|NCT00925834|EXPERIMENTAL|Nitroglycerin and verbal suggestions|"Control arm B: Open intracoronary infusion of 0.01 mg nitroglycerin in 5 ml sodium chloride plus the suggestion of a vasodilatory effect on cardiac vessels"
62807330|NCT01790594|ACTIVE_COMPARATOR|Immunosuppression without Belatacept|"* Induction: 5 day course of methylprednisolone or equivalent;~* Induction: Anti-thymocyte Globulin (Rabbit);~* Maintenance Immunosuppression: Tacrolimus (or generic). The site investigator will identify a starting tacrolimus dose at his or her discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. Tacrolimus dosing will be initiated on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed, then adjusted to target trough levels of 8-12 ng/ml during the first 24 weeks post-transplant, then adjusted to target trough levels of 5-8 ng/ml thereafter.~* Maintenance Immunosuppression: Mycophenolate mofetil (or Myfortic (mycophenolate sodium), or generic)."
62807331|NCT01790594|EXPERIMENTAL|Immunosuppression Including Belatacept|"* Induction: 5 day course of methylprednisolone or equivalent;~* Induction: Anti-thymocyte Globulin (Rabbit);~* Maintenance Immunosuppression: Belatacept~* Maintenance Immunosuppression: Tacrolimus (or generic)- The site investigator will identify a starting tacrolimus dose at his or her discretion, in order to achieve the target trough levels no later than 5 days post-transplantation. Tacrolimus dosing will be initiated on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed. The dosage will be adjusted to achieve the following therapeutic trough levels: 5-8 ng/ml during the first 24 weeks post-transplant and then 3-5 ng/ml until day 280 (week 40). Subjects may be withdrawn if they meet all the criteria defined below.~* Maintenance Immunosuppression: Mycophenolate mofetil (or Myfortic (mycophenolate sodium), or generic)."
62807332|NCT01364714||ICU survivors|Male ICU survivors 12 month after discharge
62807333|NCT01364714||Controls|Age and gender matched controls
62807334|NCT00716235||DCD|Children with a diagnosis of DCD
62422340|NCT00478634|EXPERIMENTAL|B1 dose: RAD001 + cetuximab + irinotecan|RAD001 30mg weekly oral, 400mg/m2 loading i.v (250mg/m2 for subsequent weekly dose i.v.), 250mg/m2 every 3 weeks i.v.
62422341|NCT03411122|EXPERIMENTAL|Single-sequence 3-period|Period 1: napabucasin 240 mg BID on days 1-2 Period 2: cytochrome P450 probe drugs during days 1-4 Period 3: napabucasin 240 mg BID on days 1-11, cytochrome P450 probe drugs during days 6-9
62807335|NCT00716235||Autism|Children with a diagnosis of Autism disorder
62807336|NCT00716235||ADHD|Children with a diagnosis of ADHD
62807337|NCT00716235||Control|Control group - children with no neurological or psychiatric problems
62807338|NCT03360123|ACTIVE_COMPARATOR|Midazolam Hydrochloride 2Mg/mL Syrup|"The participants in this arm will receive midazolam+nitrous oxide at the 1st dental appointment.~Dosage: Midazolam: Midazolam HCl Syrup 0.5mg/kg (Max: 15mg) taken 10-15 minutes prior to dental treatment."
62230390|NCT04130386|ACTIVE_COMPARATOR|E-education|The e-education group receives three educational modules lasting approximately 10 minutes each over a period of 10 weeks.
62807339|NCT03360123|ACTIVE_COMPARATOR|Triazolam 0.125 MG|The participants in this arm will receive triazolam+nitrous oxide at the 1st dental appointment. Dosage: Triazolam: 0.125mg tablet taken 30 minutes prior to dental treatment.
62807340|NCT05036174|EXPERIMENTAL|Diphenhydramine|Topical 5% diphenhydramine ointment applied at knee joint at a dose of 2 g three times a day for 7 days
62422342|NCT03282617|EXPERIMENTAL|locally recurrent or metastatic nasopharyngeal cancer|This cohort consists of patients with metastatic or locally recurrent NPC who have received systemic concurrent chemotherapy and have a favourable response of stable disease, partial or complete response. As up to 30% of these patients will suffer from relapse within 5 months of completion of chemotherapy, following definitive treatment, y, and treatment with CD137L-DC-EBV-VAX may activate T cell response against the tumor and prolong time to progression.
62422343|NCT03282617|EXPERIMENTAL|stage 4 locally advanced nasopharyngeal cancer|This cohort consists of patients with stage 4 locally advanced patients (N2 and N3 disease, and/or T4 disease) who are treated definitely with chemoradiation with curative intent, but who have a high risk of distant relapse. Treatment with CD137L-DC-EBV-VAX may activate antitumor T cell responses and prolong time to relapse.
62422344|NCT00812305|EXPERIMENTAL|Low dose in healthy patients|
62807341|NCT05036174|PLACEBO_COMPARATOR|Placebo|Vehicle (placebo) ointment applied at knee joint at a dose of 2 g three times a day for 7 days
62031157|NCT05481879|EXPERIMENTAL|Treatment Period: DYNE-101|"Participants who receive DYNE-101 in Placebo-Controlled Period will continue to receive DYNE-101, Q4W or Q8W for up to 24 weeks.~Participants who receive placebo in Placebo-Controlled Period will receive DYNE-101, Q4W or Q8W for up to 24 weeks."
62422345|NCT00812305|EXPERIMENTAL|Low dose in hepatically impaired patients|
62422346|NCT04991311|EXPERIMENTAL|once-weekly glepaglutide|All participants will receive 10 mg of glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.)
62422347|NCT04739852|ACTIVE_COMPARATOR|Healthy Participants|Healthy participants
62422348|NCT04739852|ACTIVE_COMPARATOR|Metabolic Syndrome|Participants with diagnosed metabolic syndrome
62422349|NCT04739852|ACTIVE_COMPARATOR|Rheumatoid Arthritis|Participants with diagnosed rheumatoid arthritis
62807342|NCT01378559||Penis prosthesis cohort|
62807343|NCT05238077|OTHER|VL-UVA1 vs NB-UVB|Participants will be treated with both VL-UVA and NB-UVB on different areas
62807344|NCT05376384||Case|Patients, over 18 years old, undergoing laparoscopic cyst enucleation surgery with an occasional, unanticipated finding of cyst rupture and intraoperative spillage
62807345|NCT05376384||Control|Patients, over 18 years old, undergoing laparoscopic cystic enucleation surgery with the extraction of the intact operative specimen.
62807346|NCT00660192|PLACEBO_COMPARATOR|Placebo|Subjects are randomized to receive Placebo which is inactive saline (sterile salt water solution). The Subjects are injected with a comparable amount of placebo solution (2cc-3cc) as received by those randomized to receive active study drug. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.
62422350|NCT00854607||Invasive Aspergillosis|Observational
62422351|NCT02582359|EXPERIMENTAL|MLN9708|"Phase I dose escalation study of MLN9708 with induction chemotherapy~* MLN9708 -oral on predetermined days per cycle~* Cytarabine, continuous infusion for predetermined duration and dosage~* Daunorubicin short IV infusion or rapid injection for predetermined~Phase I dose escalation study of MLN9708 with consolidation chemotherapy after establishment of MTD with induction"
62422352|NCT06044740|EXPERIMENTAL|Sevoflurane+Pain|Single-arm study. All subjects receive sevoflurane and painful electric nerve stimulation, as described in the interventions.
62422353|NCT04437082||Normal|no pre-existing conditions
62422354|NCT04437082||Glaucoma|diagnosis of glaucoma
62807347|NCT00660192|ACTIVE_COMPARATOR|Botox|Subjects are randomized to receive Active study drug Botox (onobotulinumtoxinA). The Botox is prepare by diluting 100units of toxin /1cc Saline. The Subjects are injected with 200-300units of units of Botox which is 2cc-3cc of solution. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.
62031158|NCT05481879|EXPERIMENTAL|Long-Term Extension Period: DYNE-101|Participants will receive DYNE-101, Q4W or Q8W for up to 96 weeks.
62230391|NCT01131871|ACTIVE_COMPARATOR|Standard Behavioral Weight Loss Intervention|
62230392|NCT01131871|EXPERIMENTAL|Enhanced Weight Loss Intervention|
62230393|NCT03375216|ACTIVE_COMPARATOR|taper|participants undergoing a taper as directed by their pain physician. Interventions include sensory testing ( heat, cold, and pressure) and PROMIS surveys.
62230394|NCT03375216|PLACEBO_COMPARATOR|non taper systemic <90|participants on systemic opioids \< 90 MEDD (morphine equivalent daily dose) and no taper
62230395|NCT03375216|PLACEBO_COMPARATOR|non taper systemic >90|participants on systemic opioids \> 90 MEDD and no taper
62422355|NCT04437082||Retina|diagnosis of retina pathology
62422356|NCT04437082||Cornea|diagnosis of corneal condition
62807348|NCT00556075|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62807349|NCT00556075|EXPERIMENTAL|25 mg|Proellex 25 mg once daily
62807350|NCT00556075|EXPERIMENTAL|50 mg|Proellex 50 mg once daily
62807351|NCT05664321||Normal weight|Body mass index (BMI) between 18.50 and 24.99 kilograms per square meter
62807352|NCT05664321||Obese|Body mass index (BMI) of more than 30 kilograms per square meter
62807353|NCT05754216|OTHER|Surgical Procedure|Consented patients who meet eligibility will have a surgical procedure for management of head and neck cancer, with dissection and exposure of the relevant anatomic structures as part of regular clinical care.
62807354|NCT06185465|EXPERIMENTAL|Prontosan Wound Irrigation Solution rinse|The test group is selected according to the randomization number of enrollment. For experimental group, Prontosan Wound Irrigation Solution is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, Prontosan wound irrigation solution is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
62807355|NCT06185465|ACTIVE_COMPARATOR|Normal Saline rinse|For control group, Normal saline is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, Normal saline is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
62807356|NCT03965975|OTHER|All participants (single arm)|All study participants once enrolled into the study were asked to collect their midstream urine in the designated urine cups. The urine sample was then sent the Lab and tested sequentially; first by the golden standard techniques used by the Lab (first intervention) and by the S-There device (comparative device - second intervention).
62807357|NCT04507022|EXPERIMENTAL|HRT Plus Aromatase Inhibitor|"Hormone replacement treatment (HRT) will be used in all cases. Exogenous estradiol will be started on day 2 or 3 of the cycle. In all participants, 2 mg oral estradiol valerate, will be administered three times daily. Ultrasound evaluation of endometrium will be performed 10 to 12 days after starting E2. Trilaminar endometrium of 9 mm will be the targeted cutoff . If not yet ready, E2 supplementation will be continued with serial US assessment until the desired cutoff is achieved. Thereafter, participants will be randomized to two groups:~Group A (HRT plus AI): will be given aromatase inhibitor for 5 days only (2.5 mg twice daily), along with the oral 6 mg E2. Then, daily intramuscular (IM) P in oil (100 mg IM P) will be started in addition to the daily dose of oral 6 mg E2.~In both groups, embryos will be warmed on the 6th day of P supplementation. Before undergoing FET, endometrial thickness will be re-evaluated. IM P and 6mg E2 will be continued thereafter."
62819521|NCT06206317||Study Group|Comprising children diagnosed with Type 1 Diabetes Mellitus (T1DM). This group constitutes the focal point of the study, assessing the motor and sensory functions of the hand. These children undergo various tests and measurements aimed at evaluating the motor skills, sensory perception, and functionality of the hand. The study solely involves evaluation and will not include any treatment or intervention.
62031159|NCT03682718|EXPERIMENTAL|vaginal misoprostol and intracervical Foley catheter|participants will receive misoprostol by the same dose and method. Transcervical Foley catheter (size 16F, with 30ml balloon capacity) will be passed. The catheter will deﬂated, removed and cervix re-assessed if no spontaneous expulsion occurred at 12 hours post- insertion. A new catheter will be passed for another 12 hours, if the Bishop score is less than 8 this will be considered as failure of induction.
62230396|NCT03375216|PLACEBO_COMPARATOR|non taper intrathecal|Participants on intrathecal therapy and no taper
62591924|NCT05306314||Antibiotic Treatment (1*1) PO + NSAID (PRN) PO ya da SUPP|"Levolon 500 mg ( 1\*1 -PO) 28 daANTIBIOTIC TREATMENT Levolon 500 mg ( 1\*1 - PO) 28 days (4 weeks) Dosage Form:Film-coated tablet Dosage : 500 mg Frequency : 1\*1 Duration: 28 days (4 weeks) Administration:It should be taken orally, without chewing, with a sufficient amount of water. The tablets can be taken during or between meals.~NSAID Diclomec 75 mg ( PRN- PO )- 28 days (4 weeks) Dosage Form:Tablet Dosage : 75 mg Frequency : PRN Duration: 28 days (4 weeks as per needed) Administration:It should be taken orally, without chewing, with a sufficient amount of water. The tablets can be taken during or between meals."
62591925|NCT06117501|OTHER|First Revision Cubital Tunnel with application of Axoguard HA+ Nerve Protector|Single group assignment. Patients will receive the Axoguard HA+ Nerve Protector™ in their first revision cubital tunnel surgery.
62230397|NCT03375216|SHAM_COMPARATOR|non opioids|Participants on non-opioid therapy will undergo behavioral tests and PROMIS surveys
62230398|NCT02513745|ACTIVE_COMPARATOR|Conventional|Surgeon's standard of care prior to getting VERION. Spherical power will be selected using the surgeon's preferred formula (Haigis, Holladay 2, Holladay, or other) and biometry method (IOL Master, Lenstar). Astigmatism correction will be planned using the surgeon's preferred keratometry method and calculator/nomogram to determine toric power and corneal incisions (i.e. Alcon toric calculator, Holladay toric calculator, Abbott Medical Optics (AMO) LRI calculator, etc). At time of surgery, axis of placement will be marked using blue ink marks. Corneal incisions will be made manually.
62230399|NCT02513745|ACTIVE_COMPARATOR|Refractive Cataract Suite (Verion + ORA)|Digital Surgical Planning and Positioning Tools + ORA System with VerifEye or VerifEye +. Spherical power of the IOL will be selected using the Verion Planner with the surgeon's preferred formula with an optimized A-constant (Haigis, Holladay 2, Holladay, or other). Both toric lenses and corneal incisions will be calculated with the Verion Planner using the Verion Reference Unit keratometry and white to white measurements, and Lenstar biometry. The VERION Digital Markers L and M will be used for axis of placement and confirmed using ORA System with VerifEye or VerifEye +.
62591926|NCT05599087|EXPERIMENTAL|Acellular system|Regenerative Endodontic Procedure (REP) the acellular system derived from umbilical cord-derived mesenchymal stem cells encapsulated in a platelet-poor plasma-derived biomaterial.
62591927|NCT06071143|EXPERIMENTAL|KDSTEM Inj.|"1. Low dose : Urine derived stem cells 1.0x10\^8 cells~2. High dose : Urine derived stem cells 3.0x10\^8 cells"
62230400|NCT03244735|EXPERIMENTAL|Modified Atkins Diet (MAD)|CCH patients that follows at least 3 months of MAD
62591928|NCT04079192|EXPERIMENTAL|Biolimus A9™ Drug Coated Balloon|Patients who meet the eligibility criteria and who are randomised to this arm, will receive treatment with the Biolimus A9™ Drug Coated Balloon
62591929|NCT04079192|ACTIVE_COMPARATOR|Sequent ® Please Paclitaxel coated balloon|Patients who meet the eligibility criteria and who are randomised to this arm, will receive treatment with the Sequent ® Please Paclitaxel coated balloon
62230401|NCT05184088|EXPERIMENTAL|Patients with suspected cardiac amyloidosis|After enrolment, patients will be subjected to diagnostic procedures according to standard of care to resolve diagnostic uncertainties and to clarify possible cardiac involvement. The results of the clinical work-up will be used a standard of truth, i.e. patients with initially suspected cardiac amyloidosis that where subsequently clinically diagnosed with cardiac AL Amyloidosis, cardiac ATTR Amyloidosis, other cardiac Amyloidosis or non cardiac amyloidosis.
62230402|NCT03226236|EXPERIMENTAL|study treatment|boost radiotherapy (XRT) plus intradermal autologous dendritic cell vaccine loaded with autologous tumor homogenate (Autologous DC vaccine) plus High-Dose IL-2
62230403|NCT06304974|EXPERIMENTAL|Experimental Group|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62230404|NCT06304974|EXPERIMENTAL|Control group|Participants receive Irinotecan or paclitaxel or docetaxel in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62230405|NCT03103763||Aged 90 and older|Subjects 90 years and older with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
62807358|NCT04507022|ACTIVE_COMPARATOR|HRT Only|"Hormone replacement treatment (HRT) will be used in all cases. Exogenous estradiol will be started on day 2 or 3 of the cycle. In all participants, 2 mg oral estradiol valerate, will be administered three times daily. Ultrasound evaluation of endometrium will be performed 10 to 12 days after starting E2. Trilaminar endometrium of 9 mm will be the targeted cutoff . If not yet ready, E2 supplementation will be continued with serial US assessment until the desired cutoff is achieved. Thereafter, participants will be randomized to two groups Group B (HRT only): will be administered daily intramuscular (IM) P in oil (100 mg IM P) in addition to the daily dose of oral 6 mg E2.~In both groups, embryos will be warmed on the 6th day of P supplementation. Before undergoing FET, endometrial thickness will be re-evaluated. IM P and 6mg E2 will be continued thereafter."
62230406|NCT03103763||Aged 80-89|Subjects aged 80-89 with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
62230407|NCT03103763||Aged 70-79|Subjects aged 70-79 with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
62230408|NCT04647916|EXPERIMENTAL|Treatment (sacituzumab govitecan)|Patients receive sacituzumab govitecan IV over 1-3 hours on days 1 and 8. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62230409|NCT02726685|EXPERIMENTAL|RT (respiratory training) group|Besides traditional rehabilitation therapy, subjects also receive 12-week respiratory training.
62422357|NCT06151158|ACTIVE_COMPARATOR|Safety Planning Intervention|The SPI is a brief, evidence- based intervention that provides people with an individualized set of steps that can be used progressively to both reduce risk and maintain safety when suicide ideation (SI) emerges. Safety plans are developed collaboratively between providers, at risk youth, and family members when possible. Core SPI components include recognizing warning signs of an imminent suicidal crisis (e.g., changes in mood, thoughts or behaviors); using internal coping skills to reduce distress; using people or places in the individual's support network as a means of distraction from SI; reaching out to family or friends to help manage the crisis; contacting health professionals or emergency services; and reducing access to lethal means. SPI+ includes a brief follow-up component post- discharge that includes contacting the patient for a mood and risk check-in; reviewing and revising the safety plan; and facilitating connection with community mental health services.
62422358|NCT06151158|ACTIVE_COMPARATOR|Ultra-Brief Crisis IPT-A|Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI) is a scalable, flexible, and extensively examined mental health treatment developed to reduce depressive symptoms and improve interpersonal functioning, and has been adapted for use in adolescents (IPT-A SCI) and shown to be effective in treating depression and reducing associated suicide risk. Interpersonal problems are often at the core of suicidal thinking and behavior in youths including minority youths.
62422359|NCT05652101||Patients suffering from hereditary hyperekplexia, above 2 years of age|"40 patients suffering from hereditary hyperekplexia will be included. The investigators study patients suffering from hereditary hyperekplexia. The diagnostic is clinical, based on the following symptoms, appearing shortly after birth: stiffness, exaggerating response startles to unexpected stimuli, generalized stiffness after the startles.~Children above 2 years old and adults are included, so the neurodevelopment can be evaluated."
62230410|NCT02726685|SHAM_COMPARATOR|Control group|Besides traditional rehabilitation therapy, subjects receive 12-week sham training unrelated to respiratory function.
62230411|NCT03697577||ER+/HER2- metastatic breast cancer|Subjects have metastatic ER+/HER2- breast cancer, and their doctor is offering treatment with CDK 4/6 inhibitors as standard of care treatment.We hypothesize that cyclin-dependent kinase (CDK) 4/6 inhibitors decrease fat mass among women with ER+/HER2- metastatic breast cancer without significant effect in the skeletal mass. Body composition will be obtained from CT scans (CT or PETCT) as part of their standard of care, and body fat mass will be obtained from DEXA scan(as part of proposed study)
62230412|NCT00871780|EXPERIMENTAL|Natalizumab|natalizumab 300 mg IV every 4 weeks for 48 weeks
62230413|NCT00003193|EXPERIMENTAL|Paclitaxel, amifostine, RT|Dose-escalation arm for paclitaxel with amifostine and RT.
62230414|NCT05468346|EXPERIMENTAL|[14C]-HEC585|\[14C\]-HEC585,solid powder，200 mg/100 µCi,single dose，oral
62230415|NCT03111693||obese patients|obese patients of our clinical nutrition service, hospitalized for nutrional assessement, are included.
62230416|NCT02540057|ACTIVE_COMPARATOR|Flexor carpi radialis|These patients will have their trapeziectomy with ligament reconstruction and tendon interposition using the flexor carpi radialis tendon.
62230417|NCT02540057|ACTIVE_COMPARATOR|Abductor pollicis longus|These patients will have their trapeziectomy with ligament reconstruction and tendon interposition using the abductor pollicis longus tendon.
62230418|NCT02072447|EXPERIMENTAL|Microdose|
62591930|NCT01910987|EXPERIMENTAL|optimized retreatment, prolonged therapy|Patients will start therapy with retreatment with 6 cycles of bortezomib and dexamethasone (two 21-day cycles followed by four 35-day cycles) followed by a second randomization in a 1:1 ratio to 1 of 2 prolonged therapy schedules with bortezomib alone (Group A1: once weekly for the first 4 weeks in 35-day cycles; or Group A2: once every other week)
62591931|NCT01910987|OTHER|standard retreatment|Current Standard of Care: Patients will start retreatment with eight 21-day bortezomib and dexamethasone cycles, followed by posttreatment follow-up every 6 weeks.
62591932|NCT03572816|NO_INTERVENTION|Current standard|"* mobilization without weight bearing for 6 weeks starting with the day of either decision-making for non-operative therapy or open reduction and internal fixation, if needed a cast or another kind of orthosis as a Static Walker are applied, then 4 weeks 15-20 kg, 2 weeks 35-45 kg, after that transition to full-weight bearing (always only if possible)~* X-ray after 6 and 12 weeks; depending on the results, the schedule for weight bearing may be adjusted to the need in case of delayed healing or complications related to implants"
62591933|NCT03572816|EXPERIMENTAL|Intervention|"* mobilization with the custom-made heel-unloading orthosis ('Settner shoe') without pads for 6 weeks, then 2 weeks one pad, 2 weeks 2 pads, 2 weeks 3 pads, after that full-weight bearing without any support (always only if possible)~* X-ray after 6 and 12 weeks; depending on the results, the schedule for weight bearing may be adjusted to the need in case of delayed healing or complications related to implants"
62591934|NCT00581347|OTHER|Outreach|Receives outreach services
62591935|NCT00581347|NO_INTERVENTION|Standard of Care|Receives standard medical care provided by primary care practice.
62591936|NCT05204173|EXPERIMENTAL|Intraperitoneal|Sintilimab 200mg intravenous (IV) infusion on day 1, PTX 50 mg/m2 IV and PTX 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days every 3 weeks.
62591937|NCT01899742|EXPERIMENTAL|Umeclidinium/Vilanterol|Long-acting muscarinic antagonist (LAMA)/Long-acting Beta agonist (LABA)
62230419|NCT00924261|EXPERIMENTAL|Hip Stretching|Kneeling Hip flexor stretch - 3 minutes a day, daily, for 10 weeks
62230420|NCT00924261|EXPERIMENTAL|Shoulder Stretch|Shoulder Stretch - 3 minutes daily for 10 weeks
62230421|NCT02179099|EXPERIMENTAL|BTX mixed with TC-3 Gel|Patients will be treated with a single intravesical instillation of 40 ml TC-3 gel mixed with 300U BTX
62230422|NCT00978666||Healthy controls|Healthy comparison adolescent females
62230423|NCT00978666||Anorexia Nervosa|Adolescent females currently ill with Anorexia Nervosa, restricting type
62230424|NCT02568865||Major Depressive Disorder|
62230425|NCT02568865||Healthy Volunteers|
62230426|NCT04308772|NO_INTERVENTION|Usual Care|Those randomised to the usual care arm will receive a leaflet which contains a standard programme of exercises Participants will be asked to complete their exercise programme as prescribed (at least once per day).
62230427|NCT04308772|EXPERIMENTAL|Web-based physiotherapy|Participants will receive a six week exercise programme, based on those in the usual care exercise sheet delivered via the web-based physio website (www.giraffehealth.com).
62230428|NCT06089889|EXPERIMENTAL|Group 1|Group 1 will receive ice application as intervention 3 minutes before venous puncture.
62422360|NCT05073302|EXPERIMENTAL|Treatment Group|Implantation of the Device-Less sentinel units. Ultrasound Monitoring. Islet Transplantation. Explantation of Device-Less Sentinels. Standard of Care. Concomitant Care. Post Transplant Testing and Visits. Participant Retention (nine month follow up assessment).
62230429|NCT06089889|EXPERIMENTAL|Group 2|Group 2 will be control group, without ice application.
62230430|NCT03646500|EXPERIMENTAL|Retrobulbar block|Retrobulbar block administered prior to Transcleral Diode Procedure
62230431|NCT03646500|ACTIVE_COMPARATOR|Remifentanil|Conscious IV sedation administered prior to Transcleral Diode Procedure.
62230432|NCT04335812|EXPERIMENTAL|R-ICBT|The intervention offered is a guided relaxation-based CBT offered via the Internet. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned. The modules provided will focus on applied relaxation only.
62422361|NCT03760965|EXPERIMENTAL|Sotagliflozin dose 1|Sotagliflozin dose 1, given as two (2) dose 2 tablets, once daily, before the first meal of the day
62591938|NCT01899742|ACTIVE_COMPARATOR|Tiotropium|Long-acting muscarinic antagonist (LAMA)
62807359|NCT03041571||Medical Honors Students|The Medical Honors Program students will fill out the Patient Provider Orientation Scale (PPOS). MHP students will then interview a patient with a chronic or life limiting illness.
62807360|NCT03041571||Patients with chronic illnesses|The patients will fill out the PPOS scale. The patient will then have an Interview performed by MHP student
62031160|NCT03682718|ACTIVE_COMPARATOR|vaginal misoprostol|"Misoprostol group; participants will receive 50 μg intravaginal in the posterior vaginal fornix, 25 μg will be given every 4 hours for another two doses, if a satisfactory Bishop score of 8 not reached, patient will take an overnight rest and she will continue induction by the same doses on the next day-provided that there is no ROMs- (this is according to Ain Shams University Protocol) The maximum dose of Misoprostol is 200 μg.~Oxytocin infusion will not started until 6 hours after the last dose or if there is no adequate contractions obtained."
62031161|NCT05663515||Initiators of exenatide|Patients with T2DM, aged 18 years or older, who initiated treatment with exenatide during the study period, 2006 to 2023
62031162|NCT05663515||Initiators of non-GLP-1 RA based glucose lowering drugs|Patients with T2DM, aged 18 years or older, who initiated treatment with non-GLP-1 RA based glucose lowering drugs during the study period, 2006 to 2023
62031163|NCT04551170|EXPERIMENTAL|Theophylline|Theophylline capsules by mouth once daily or Theophylline elixir by mouth q6h (dose determined by serum drug levels)
62031164|NCT04551170|PLACEBO_COMPARATOR|Placebo|Placebo capsule by mouth once daily or Placebo elixir by mouth q6h
62031165|NCT02222779||Patients with Parkinson´s Disease|
62031166|NCT02222779||Patient´s with Alzheimer´s Disease|
62031167|NCT02222779||Patients with Multiple Sclerosis|
62031168|NCT02222779||Patients with any other neurodegenerative diseases|
62422362|NCT03760965|EXPERIMENTAL|Sotagliflozin dose 2|Sotagliflozin dose 2, given as 1 sotagliflozin dose 2 tablet and 1 sotagliflozin-matching placebo tablet (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
62031169|NCT03801239||patients with Overactive Bladder (OAB)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
62422363|NCT03760965|PLACEBO_COMPARATOR|Placebo|Two sotagliflozin-matching placebo tablets (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
62422364|NCT00540007|EXPERIMENTAL|Cohort 1 - Lenalidomide daily on days 1-21|"* The first group of participants will be assigned to Cohort 1 and if no unacceptable toxicities occur in Cohort 1 then the second group of participants will be assigned to Cohort 2~* Lenalidomide 25 mg per day PO daily on days 1-21 of a 28 day cycle."
62807361|NCT00439257||Group 1|
62422365|NCT00540007|EXPERIMENTAL|Cohort 2 - Lenalidomide daily on days 1-28|"* The first group of participants will be assigned to Cohort 1 and if no unacceptable toxicities occur in Cohort 1 then the second group of participants will be assigned to Cohort 2~* Lenalidomide 25 mg per day PO daily on days 1-28 of a 28 day cycle."
62807362|NCT01129622|EXPERIMENTAL|Letrozole, Breast enhancement, Safety|Single arm of healthy postmenopausal women who received baseline diagnostic MRI will receive letrozole of 12.5 mg/day orally for three successive days. A second post treatment breast MRI is done right after receiving the three days of letrozole treatment and within one month after the first MRI .
62031170|NCT03801239||patients with Mixed Urinary incontinence (MUI)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
62031171|NCT03801239||patients with Stress Urinary Incontinence (SUI)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
62031172|NCT02820779|EXPERIMENTAL|WILLIS|Patients undergo WILLIS intracranial covered stent interventional treatment
62230433|NCT04335812|ACTIVE_COMPARATOR|F-ICBT|The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned. The modules are a mixture of applied relaxation, Cognitive Behavioral Therapy and advice addressing common problems
62422366|NCT06569693|EXPERIMENTAL|MSOS Intervention Group|Participants (patient-sleep-partner caregiver dyads) in this group will receive the My Sleep Our Sleep (MSOS) intervention. Total participation is up to 13 weeks.
62230434|NCT03022032|EXPERIMENTAL|Comparing Steps Collected by Accelerometer (HOPE)|"* 10 patients will be enrolled in stage 1 to refine the HOPE App intervention~* All participants will receive :~  * HOPE App~ * The Fitbit Zip~ * The Fitbit Charge 2 The amount of step collected by each device will be compared. This will allow the team to identify which wearable accelerometer to use in stage 2"
62230435|NCT03022032|OTHER|Usual care (HOPE)|"Stage 2 will consist of arm 2-5 and will enroll 100 randomized patients.~* Usual care~* The app will also collect passive data from the smartphone"
62230436|NCT03022032|EXPERIMENTAL|Wearable accelerometer (HOPE)|"* Participants will be asked to wear the Fitbit~* The Hope App will measure daily steps~* The app will also collect passive data from the smartphone"
62230437|NCT03022032|EXPERIMENTAL|Refined smartphone app (HOPE)|"* Participants will be prompted to answer questions about their quality of life and physical health daily~* The HOPE App will present tailored advice to improve symptoms if one or more low-risk toxicities are reported. If the symptoms are determined to be high-risk, the App will prompt the patient to call their clinician.~* The app will also collect passive data from the smartphone"
62230438|NCT03022032|EXPERIMENTAL|Refined smartphone app and accelerometer (HOPE)|"* Participants will be prompted to answer questions about their quality of life and physical health daily~* The HOPE App will present tailored advice to improve symptoms if one or more low-risk toxicities are reported. If the symptoms are determined to be high-risk, the App will prompt the patient to call their clinician.~Participants will be asked to wear the Fitbit~-The Hope App will measure daily steps The app will also collect passive data from the smartphone"
62807363|NCT01410890|EXPERIMENTAL|Alglucosidase alfa|Participants received intravenous (IV) infusion of Alglucosidase alfa 20 milligrams per kilogram (mg/kg) body weight on Day 1. Infusion was administered at an initial rate of approximately 1 milligram per kilogram per hour (mg/kg/hr) with allowed rate increased of 2 mg/kg/hr every 30 minutes, if there were no signs of infusion-associated reactions (IARs), until a maximum rate of approximately 7 mg/kg/hr was reached.
62807364|NCT00837915|EXPERIMENTAL|1|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets of Ranbaxy
62807365|NCT00837915|ACTIVE_COMPARATOR|2|(Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets
62807366|NCT00790426|EXPERIMENTAL|FGFR3 wild type|
62807367|NCT00790426|EXPERIMENTAL|FGFR3 mutant|
62807368|NCT05987358|EXPERIMENTAL|TQB3454 tablets|TQB3454 tablets orally administered, 21 days as a treatment cycle.
62807369|NCT05987358|PLACEBO_COMPARATOR|Placebo|Placebo tablets orally administered, 21 days as a treatment cycle.
62230439|NCT03022032|EXPERIMENTAL|SMART Study Arm|"* Two smartphone apps and a wearable accelerometer (Fitbit) in 30 patients with gynecologic cancers receiving chemotherapy at two NCI Community Oncology sites.~* The SMART intervention refers to the combination of both smartphone apps (SMART app and Beiwe app) and the accelerometer (Fitbit).~* The SMART app is the technology that is actively collecting symptom reporting information from patients (e.g. patients are receiving surveys, recording their symptoms daily, and receiving tailored symptom management materials on their phone in response).~* The Beiwe app is the technology involved in the passive data collection of participants' symptoms (GPS and accelerometer data) without their involvement."
62230440|NCT04753970|EXPERIMENTAL|Cilostazol|Cilostazol 100mg BID
62807370|NCT02787395|EXPERIMENTAL|Milch|modified Milch technique for self reduction
62230441|NCT04753970|NO_INTERVENTION|No intervention|
62230442|NCT00686725|ACTIVE_COMPARATOR|Temozolomide + Radiation|"Standard therapy regimen:~Treatment will start 4 weeks after surgery. Temozolomide will be administered concomitantly with radiotherapy, at 75 mg/m\^2/day orally for 42 days. Four weeks after completing concomitant radiotherapy, temozolomide will be administered for an additional six cycles. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m\^2/day, and may be increased to 200 mg/m\^2/day for Cycle 2 and subsequent cycles depending on nonhematological toxicity observed and neutrophil and platelet count values. Capsules containing 20 mg or 100 mg of temozolomide will be used.~Radiotherapy will be administered in combination with temozolomide. Radiotherapy will be administered for a total daily dose of 60 Gy in 30 fractions, 5 days a week for 6 weeks."
62230443|NCT00686725|EXPERIMENTAL|Temozolomide alone, then Temozolomide + Radiation|"Early postsurgery temozolomide chemotherapy plus standard regimen:~Treatment with temozolomide alone will start 2 weeks after surgery at 75 mg/m\^2/day orally for 14 days. Then, starting on Day 29 after surgery, temozolomide will be administered according to standard treatment as described for the temozolomide + radiation arm (standard therapy regimen).~Radiotherapy will be administered in combination with temozolomide. Radiotherapy will be administered for a total daily dose of 60 Gy in 30 fractions, 5 days a week for 6 weeks."
62807371|NCT02787395|EXPERIMENTAL|Boss Holtzach|Boss Holtzach technique for self reduction
62807372|NCT02787395|EXPERIMENTAL|Stimson|Stimson technique for self reduction
62807373|NCT06001346|EXPERIMENTAL|ActiveCBT|Participants will complete a standardized 30-minute exercise session on a stationary bike prior to therapy. Participants will view one of 8 standardized 30-minute nature documentary videos while exercising.
62807374|NCT06001346|ACTIVE_COMPARATOR|CalmCBT|Participants will view one of 8 standardized 30-minute nature documentary videos while resting quietly prior to therapy.
62807375|NCT02754973|EXPERIMENTAL|Experimental group|During hospitalization for cancer treatment, besides receiving usual care, participants in the experimental group will first receive a health education talk Participants will then be taught and encouraged to practice with some stretching and relaxing exercises during their hospitalization. After hospitalization, participants will receive an integrated experiential training program with coaching by nursing students through home visits.
62230444|NCT03496584|ACTIVE_COMPARATOR|Pomegranate Juice|Postprandial high fat meal will be administered with pomegranate juice with the first dose of the intervention, Pomegranate Juice , followed by 12 weeks of pomegranate juice consumption.
62230445|NCT03496584|PLACEBO_COMPARATOR|Placebo Juice|Postprandial high fat meal will be administered with pomegranate juice with the first dose of the intervention, Placebo Juice , followed by 12 weeks of pomegranate juice consumption.
62422367|NCT06569693|EXPERIMENTAL|BBTI Intervention Group|Participants (patient-sleep-partner caregiver dyads) in this group will receive the Brief Behavioral Treatment for Insomnia (BBTI). Total participation is up to 13 weeks.
62591939|NCT01966068|EXPERIMENTAL|MyAsthma Web Portal|The portal, MyAsthma, will provide asthma education, collect patient-reported outcomes, evaluate medication use and side effects, and track parents' concerns and goals. Parents will log into the web portal each month (for a total of 3 portal visits in 6 months), and the information entered by parents will be shared through the electronic health record with the child's primary care provider.
62230446|NCT02444481|EXPERIMENTAL|Polygynax, antibiotic, vaginal treatment|Polygynax combinaison of nystatine, polymyxin, neomycin, Local treatment of vaginal infection during 12 days. One vaginal capsule every evening.
62230447|NCT04001985|ACTIVE_COMPARATOR|Immediate NG tube removal|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function the NG tube will be removed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger.
62230448|NCT04001985|ACTIVE_COMPARATOR|NG tube clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function, a 4 hour clamp trial will be performed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger. The NG tube will be taken off of suction and clamped. The NG tube is then reconnected to suction at the end of the four hour clamp trial and removed if less 125 mL drains or kept in place if greater than 125 mL drains. The same initial criteria are used again to determine if a clamp trial will be performed after 24 hours.
62422368|NCT00628745||Observational|
62422369|NCT01179191|EXPERIMENTAL|morphine sulfate and naltrexone hydrochloride (EMBEDA)|
62422370|NCT06015217|EXPERIMENTAL|Treatment Group|"All subjects have mild to moderate diaper dermatitis and are given Cetaphil Healing Ointment to use with every diaper change."
62422371|NCT04631185|ACTIVE_COMPARATOR|SPD (Arm A)|Single pre-operative dose of intravenous antibiotics with intraoperative redosing (SPD): Intravenous cefazolin, a cephalosporin antibiotic, will be prescribed to all patients before surgery. All patients will receive one dose of antibiotic within 60 minutes prior to incision, and any intraoperative doses of antibiotics according to current recommendations based on the antibiotic's dosing and on operative time.
62422372|NCT04631185|EXPERIMENTAL|WPO (Arm B)|The patients assigned to this arm will receive same pre-op and intraoperative antibiotics similar to SPD (Arm A). In addition, patients in this group will receive one week of post-operative antibiotics (WPO). The post-operative antibiotic will be a first generation Cephalosporin of their surgeon's choice.
62422373|NCT05736952|EXPERIMENTAL|Oral Topotecan Combined With Anlotinib|
62422374|NCT04815356|EXPERIMENTAL|Experimental therapy: Dose Escalation|Escalating doses of autologous anti-CD22-CAR T-cells in subjects to determine the MTD
62422375|NCT04815356|EXPERIMENTAL|Experimental therapy: Dose Expansion|Autologous anti-CD22-CAR T-cells at the MTD
62422376|NCT04537130|EXPERIMENTAL|Experimental|The investigational medical product, the IN01 vaccine, will be administered in two phases to those patients in the experimental arm: the induction phase and the maintenance phase. During the induction phase IN01 vaccine will be administered on day 1 and will be repeated on Day 14, Day 28, Day 42 and day 56. During the maintenance phase, the vaccination will be administered every 2 months with the same dosage and administration mode as during induction.
62422377|NCT04537130|NO_INTERVENTION|Control|The patients enrolled in the control arm of the study will receive standard of care.
62422378|NCT05844644|EXPERIMENTAL|GOLO for Life® Plan (G4LP) and Release Supplement|Participants will be instructed to use the resources provided and follow the G4LP for the duration of the study period. Participants will also take one capsule of Release three times a day, to be taken at the beginning of or during each meal, starting on Day 1. If a dose is missed before or during a meal, participants are instructed to take the dose as soon as they remember after the meal. Participants will be advised not to exceed three capsules daily.
62422379|NCT04196270|EXPERIMENTAL|Ropivacaine|This double-blind dose-finding trial is based on a biased coin up-and-down sequential design, where the volume of local anesthetic administered to each patient depends on the response from the previous one. The TQL block is performed preoperatively, and the first patient recruited receives 20 mL of ropivacaine 0.75%. In case of block failure, the next patient will receive a higher volume (defined as the previous volume with an increment of 2 mL). Given a successful block for the first patient, the next patient will be randomized to either a lower volume (defined as the previous volume with a reduction of 2 mL) or the same volume as the previous patient. The respective probabilities being b=0.11 for a reduced volume and 1-b=0.89 for the same volume. Block success is defined as patient reported numeric rated scale (NRS) pain (NRS value ≤ 3 (0-10/10)), 30 minutes after arrival in the post anesthesia care unit (PACU).
62422380|NCT04059276||Patients with stroke|
62422381|NCT04059276||Healthy subjects|
62230449|NCT03448120|NO_INTERVENTION|Control Group|The volunteers who will remain in prolonged rest (10 minutes for homeostasis plus 30 minutes of no intervention).
62422382|NCT06421623|EXPERIMENTAL|Workshops aiming to preserve elderly's autonomy through foot health|Study participants will benefit from a plantar massage session (5-10 min foot massage) and one posture and walking workshop per week, supervised by a trained health professional. Minimalist shoes have been purchased by the centers and used during the workshops. They will also be available to participants outside the workshops for the duration of the study.
62591940|NCT02666378||CMR/ECHO|"Prior to starting chemotherapy treatment, the participant will undergo the following procedures:~* Cardiac Magnetic Resonance Imaging (CMR)~* Echocardiogram (ECHO) in patients with no clinically indicated scans~* Each imaging procedure will be repeated at predetermined times during the protocol~* Simple blood collection for plasma biomarker analysis"
62591941|NCT05283980|EXPERIMENTAL|Bupivacaine Group|Receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block
62591942|NCT05283980|PLACEBO_COMPARATOR|Control group|Receive up to 25 ml of normal 0.9% sodium chloride for the Pecs block
62230450|NCT03448120|EXPERIMENTAL|Acupuncture Group|The volunteers will receive six needles in six acupoints in the non-dominant upper limb for 30 minutes.
62591943|NCT05633992|EXPERIMENTAL|V116|Participants receive a single intramuscular (IM) injection of V116 on Day 1.
62591944|NCT05633992|ACTIVE_COMPARATOR|PPSV23|Participants receive a single IM injection of PPSV23 on Day 1.
62422383|NCT06141954|ACTIVE_COMPARATOR|Ultrasound|Effect of ultrasound therapy on sacroiliac joint pain in woman postpartum
62591945|NCT06620536|EXPERIMENTAL|Restoring hand function in patients with tetraplegia by intraneural stimulation of peripheral nerves|
62422384|NCT06141954|ACTIVE_COMPARATOR|Low level laser|Effect of low level laser therapy on sacroiliac joint pain in woman postpartum
62422385|NCT00425516|NO_INTERVENTION|standard (A)|3 FEC100 followed 3 Taxotere
62422386|NCT00425516|EXPERIMENTAL|Modulated (B)|possibility treatments receive: 2 FEC100 followed by 4 Taxotere 4 FEC100 followed by 2 Taxotere 6 FEC 100
62422387|NCT05369299|EXPERIMENTAL|Two-piece zirconia implants|Immediate dental implant placement will be performed by using the new two-piece zirconia implant Straumann® Pure Ceramic Two Piece Implant
62422388|NCT05369299|ACTIVE_COMPARATOR|Two-piece titanium implants|Immediate dental implant placement will be performed by using the conventional two-piece titanium implant Neoss® ProActive Tapered Implant
62422389|NCT06341192|EXPERIMENTAL|Double bundle ACL combined anterolateral ligament reconstruction|ACL reconstruction with triple folded semitendinosus and non folded gracilis and fibertape
62422390|NCT06341192|EXPERIMENTAL|Single bundle ACL combined anterolateral ligament reconstruction|Single bundle ACL combined anterolateral ligament reconstruction
62422391|NCT01642927||Intra-Aortic Balloon Pump (IABP) Group|Advanced Heart Failure and/or pre-LVAD surgical patient with IABP
62422392|NCT01642927||IABP/LVAD Group|Post-LVAD surgical patients with IABP
62422393|NCT01642927||Post-LVAD Group|LVAD patients 3 months or greater post-implantation undergoing echocardiography
62591946|NCT06665243|EXPERIMENTAL|Technology-enhanced horticultural activities|
62807376|NCT02754973|PLACEBO_COMPARATOR|Placebo Control group|Since participants in both groups are hospitalized in the same unit, to avoid contamination, participants in the placebo control group will receive the same intervention as those participants in the experimental group during their hospitalization. When discharged home, participants will receive an amount of time and attention (home visits by research assistants) that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures.
62807377|NCT03836625|NO_INTERVENTION|Control|The control arm will receive standard CareConekta, which will track their mobility with no additional features.
62807378|NCT03836625|EXPERIMENTAL|Intervention|The intervention arm will receive standard CareConekta, plus text notifications of nearby ART facilities when they have traveled \>50 km from the study site for \>7 days. At enrollment, participants in the intervention arm also will be able to opt-in to phone call(s) and/or WhatsApp message(s) from study staff to when they have met this travel threshold. The study staff calls and messages will ask about medication supply and will provide assistance with nearby facilities, if requested.
62807379|NCT04948853|NO_INTERVENTION|Treatment as usual|Treatment as usual, with respect to employment, for individuals on probation typically entails the probation officer informing the probationer that probationer is responsible for obtaining employment or could entail a referral from a probation officer to an employment or job assistance service, such as vocational rehabilitation. The probationer is responsible for follow up with that service.
62422394|NCT01642927||LVAD Event Group|LVAD patients who have developed LVAD thrombosis or GI hemorrhage related to LVAD
62230451|NCT03448120|EXPERIMENTAL|Dry needling Group|The volunteers will receive application of six needles arranged in the non-dominant biceps brachialis for 30 minutes.
62230452|NCT02744326|EXPERIMENTAL|Text message reminder group|A subset of patients discharged from the ED with an outpatient referral will be randomized to receive text message reminders to attend or schedule a follow-up outpatient referral.
62422395|NCT01642927||Arrhythmia group|LVAD patient with an irregular heartbeat.
62422396|NCT01642927||Valvular disease group|LVAD patient with valvular heart disease
62230453|NCT02744326|NO_INTERVENTION|Usual Care group|A subset of patients discharged from the ED with an outpatient referral will be randomized to receive the usual standard of care.
62230454|NCT04213430||Training dataset|Retinal images collected from hospitals and multiple screening sites all over China
62422397|NCT01642927||Normal control group|Healthy participant without any known heart disease (Control group).
62422398|NCT06700590|EXPERIMENTAL|massed/intensive treatment|
62422399|NCT06700590|ACTIVE_COMPARATOR|spaced/weekly treatment|
62422400|NCT05112679|ACTIVE_COMPARATOR|Proprio Foot|microprocessor-controlled prosthesis that regulates the angle of ankle dorsiflexion during the swing phase
62422401|NCT05112679|ACTIVE_COMPARATOR|Empower Ankle|a powered prosthesis that provides active propulsion in late stance to mimic the positive work performed by the ankle plantar-flexors in push-off. The Empower has been shown to improve affected leg kinematics (increased ankle range of motion and reduced knee flexion) on smooth flat ground, ramp ascent, and gravel
62422402|NCT04659837|ACTIVE_COMPARATOR|Inhibitory Control Training|Active Inhibitory Control Training vs. Sham Inhibitory Control Training
62422403|NCT04659837|OTHER|Gameification|Gameified elements added vs. No gameified elements added
62422404|NCT03525327||Line Dance Class participants|The group will be participating in line dance classes as intervention.
62591947|NCT03116555|EXPERIMENTAL|Irinotecan plus apatinib|"Irinotecan: 180mg/m2, ivgtt,given on the first day; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day).~Repeat the therapeutic schedule every 3 weeks till progressive disease or intolerable toxicities."
62591948|NCT06666777|EXPERIMENTAL|Experimental arm involving parents|Subjects assigned to this arm will receive the intervention focused on intersubjective prelinguistic and socio-communicative skills. A parent is required to participate in all sessions.
62591949|NCT06666777|ACTIVE_COMPARATOR|Standard speech therapy|Participants in this group will receive standard speech therapy. Parental involvement will only occur if strictly necessary.
62591950|NCT01062035||ACP (advanced colon polyp) Group|Between the ages of 50 and 60 years old and have an ACP (advanced colon polyp)
62591951|NCT01062035||Control Group|Individuals between the ages of 50 and 60 years old who have had a negative screening colonoscopy.
62807380|NCT04948853|EXPERIMENTAL|Intervention - Individual Placement Support-Supported Employment|Subjects in this condition will receive services from a 1.5 FTE IPS-SE team that will work to provide one-on-one person-centered services to help obtain employment, including but not limited to career profiling, resume assistance, job placement, training and other activities.
62230455|NCT04213430||Validation dataset|Retinal images separated from training dataset
62230456|NCT04213430||Testing dataset|Retinal images prospectively collected from the hospitals and ocular disease screening sites totally different from training dataset
62230457|NCT02924142|EXPERIMENTAL|Intervention|Mandibular removable partial denture with OT Cap attachment
62230458|NCT02924142|NO_INTERVENTION|Comparator|Mandibular removable partial denture with gingival approaching clasp assembly
62230459|NCT01147237|EXPERIMENTAL|Single arm study|
62230460|NCT06071026|EXPERIMENTAL|1 ml/kg/h|Net ultra filtration setting: 1 ml/kg/h
62230461|NCT06071026|EXPERIMENTAL|2 ml/kg/h|Net ultra filtration setting: 2 ml/kg/h
62230462|NCT06071026|EXPERIMENTAL|3 ml/kg/h|Net ultra filtration setting: 3 ml/kg/h
62230463|NCT00690040|ACTIVE_COMPARATOR|1|Ripening of the unfavorable cervix is done with Single balloon catheter (Foley catheter)
62230464|NCT00690040|ACTIVE_COMPARATOR|2|Ripening of the unfavorable cervix is done with double balloon catheter (Atad catheter)
62230465|NCT01092000||Faculty/Staff|
62230466|NCT01092000||Graduate Students|
62230467|NCT01092000||Undergraduate Students|
62230468|NCT02186223|EXPERIMENTAL|The Angel® Catheter|All eligible subjects will receive an Angel® Catheter.
62230469|NCT01607554|EXPERIMENTAL|Irinotecan|The starting dose of irinotecan for the study is 180 mg/m2, given intravenously every 14 days. Each 14 day period will constitute one cycle of treatment.
62230470|NCT02286778|ACTIVE_COMPARATOR|Acetogenins|Dietary Supplement: Acetogenins BID for 12 months
62230471|NCT02286778|PLACEBO_COMPARATOR|Placebo|Dietary Supplement: No Acetogenins BID for 12 months
62807381|NCT05313789||Intensive Care Patients (Cardiovascular)|Intensive care unit patients, mechanically ventilated and lacking communication. Will examine whether the positive inotropic/vasoconstrictor agents will have any effect on Analgesia Nociception Index.
62230472|NCT02286778|NO_INTERVENTION|Control|Control subjects will not receive the Acetogenins or the placebo. They will be evaluated every other month to monitor disease progress.
62230473|NCT06245720||AKI group|AKI is then defined as an increase in serum creatinine (SCr) of at least 26.4 μmol/L over 48 hours, or an increase in SCr greater than 1.5 times baseline over 7 days, or a urine output of less than 0.5 mL/kg per hour for more than 6 hours, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.
62230474|NCT06245720||Non-AKI group|According to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, patients do not develop acute kidney injury.
62230475|NCT01406340|EXPERIMENTAL|Normal subjects and subjects with Stage 3/4 renal function|Subjects will receive 5mg GSK1278863 for 14 days.
62230476|NCT01406340|EXPERIMENTAL|Subjects with Stage 5 renal function|Subjects will receive 5mg GSK1278863 for 15 days.
62230477|NCT00697879|EXPERIMENTAL|1|Oral, once daily administration of CHR-3996 to determine safety and tolerability
62230478|NCT05831813|EXPERIMENTAL|Goal-Based Cognitive Behavioural Intervention|"Participants start with a 1 to 7 weeks baseline period. The duration is based on the enrolment date and therefore not random. Afterward, all participants enter the intervention, which promotes social behavioural activation aligned with personal values and teaches skills that make negative emotions and thoughts less bothersome and reduce feelings of loneliness. The intervention comprises seven weekly sessions and a follow-up, conducted in a group format to facilitate interpersonal practice and is presented as a course for enhanced acceptability.~Please note: The original design involved an RCT with a Goal-Based Cognitive Behavioral Intervention as the experimental arm and a waitlist arm. Participants in the waitlist arm would enter the intervention after a waitlist period. Due to limited enrollments, the design was modified to a single arm resembling the waitlist arm of the initial RCT design."
62230479|NCT01216384|EXPERIMENTAL|BI 671800 active|SRD part: 3 dose groups each consisting of 12 subjects (9 active, 3 placebo), subjects receive single dose. MRD part: 3 dose groups each consisting of 12 subjects (9 active, 3 placebo), subjects receive single dose followed by multiple doses with a PK sampling interval in between.
62230480|NCT01216384|PLACEBO_COMPARATOR|Placebo|3 subjects will receive placebo in each of the 3 doses in the SRD part and 3 doses in the MRD part
62230481|NCT01295034|PLACEBO_COMPARATOR|conventional vitamin D treatment|Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
62230482|NCT01295034|EXPERIMENTAL|tiered/titrated vitamin D dosing|Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
62422405|NCT05960708|EXPERIMENTAL|YH35324|"\[Part 1\] A total of 18 subjects will be randomized in a 1:1:1 ratio to the YH35324 A mg/kg, YH35324 B mg/kg, or omalizumab group.~\[Part 2\] A total of 9 subjects will be randomized in a 2:1 ratio to the YH35324 B mg/kg or placebo group.~\[Part 3\] A total of 9 subjects will be randomized in a 2:1 ratio to the YH35324 B mg/kg or placebo group."
62591952|NCT04021121|EXPERIMENTAL|High Dose RIF with LZD|Arm 1 participants will receive high dose oral RIF (35mg/kg/day) and LZD 1200 mg daily for the first 4 weeks of therapy, along with standard doses of Isoniazid (INH), Pyrazinamide (PZA), and Ethambutol (EMB). After 4 weeks, LZD will be discontinued and high dose RIF will return to standard dose for the remainder of treatment.
62591953|NCT04021121|EXPERIMENTAL|Standard dose RIF with LZD|Arm 2 participants will receive standard dose RIF, INH, PZA, and EMB along with LZD 1200 mg daily. After 4 weeks, LZD will be discontinued.
62591954|NCT04021121|EXPERIMENTAL|High Dose RIF|Arm 3 participants will receive high dose oral RIF (35mg/kg/day) for the first 4 weeks of therapy, along with standard doses of INH, PZA, and EMB. After 4 weeks, high dose RIF will return to standard dose for the remainder of treatment.
62591955|NCT04021121|ACTIVE_COMPARATOR|Standard Dose RIF|Arm 4 participants will receive standard doses of RIF, INH, PZA, and EMB.
62230483|NCT01548157|EXPERIMENTAL|HCP1007|HCP1007
62591956|NCT02078375|PLACEBO_COMPARATOR|Carbohydrate supplement|Participants will be enrolled in a twice weekly resistance exercise program. They will receive a carbohydrate supplement to take twice daily (once after exercise).
62591957|NCT02078375|EXPERIMENTAL|Protein Supplementation|Participants will be enrolled in a twice weekly resistance exercise program. They will receive a twice daily protein supplement (once after exercise).
62230484|NCT01548157|ACTIVE_COMPARATOR|omarco and crestor|Rosuvastatin plus Omega-3
62422406|NCT05960708|ACTIVE_COMPARATOR|Omalizumab|\[Part 1\] A total of 18 subjects will be randomized in a 1:1:1 ratio to the YH35324 A mg/kg, YH35324 B mg/kg, or omalizumab group.
62591958|NCT06648382|EXPERIMENTAL|Self-directed psychotherapy program|The intervention consists of receiving 11 videos that are 10-15 minutes in length along with a workbook containing homework exercises. Participants are instructed to watch the videos over the course of two menstrual cycles: the first 6 during the first cycle and the last 5 during the second cycle. Each module focuses on a different skill inspired by cognitive behavioral therapy and dialectical behavior therapy.
62591959|NCT05383365|EXPERIMENTAL|Suboccipital Myofascial Release|The therapist places the supinated forearm on the bed and positions the tips of the middle three fingers inferior to the occiput bone and the head is supported by the thenar eminences
62591960|NCT05383365|EXPERIMENTAL|Deep Neck Flexor Exercise|After placing the airbag of PBU under the occiput bone in the supine position and inflating it to a base pressure of 11 mmHg, the participant will increase the pressure to 12 mmHg by nodding action.
62591961|NCT06668350|EXPERIMENTAL|Concept flavored cigarillo|Participants will smoke a concept flavored cigarillo in the lab
62591962|NCT06668350|EXPERIMENTAL|Characterizing flavored cigarillo|Participants will smoke a characterizing flavored cigarillo
62591963|NCT06668350|EXPERIMENTAL|Tobacco flavored cigarillo|Participants will smoke a tobacco flavored cigarillo
62591964|NCT05901233|EXPERIMENTAL|RS-LRT|
62591965|NCT05901233|EXPERIMENTAL|RS-VISTA|
62230485|NCT06370260|EXPERIMENTAL|UNISEPT® ORAL GEL|A gel containing hydrogen carbamide/peroxide as active ingredient
62422407|NCT05960708|PLACEBO_COMPARATOR|Placebo|"\[Part 2\] A total of 9 subjects will be randomized in a 2:1 ratio to the YH35324 B mg/kg or placebo group.~\[Part 3\] A total of 9 subjects will be randomized in a 2:1 ratio to the YH35324 B mg/kg or placebo group."
62591966|NCT03702010|ACTIVE_COMPARATOR|CME branch|In this study, the conventional spinal cord stimulation method (control Branch-CME branch)
62591967|NCT03702010|EXPERIMENTAL|EME branch|In this study, the experimental spinal cord stimulation method are used in the same patient with the EVOLVE programming guide (EME branch)
62591968|NCT02486640||Betaferon|
62230486|NCT06370260|PLACEBO_COMPARATOR|PLACEBO|A gel that looks and tastes like UNISEPT® ORAL GEL without active ingredients
62422408|NCT01314222|OTHER|Arm 1: BMS-954561 40mg or 80mg|"BMS-954561 40mg or 80mg TID to Placebo OR Placebo to 40mg or 80mg TID~Active to Placebo or Placebo to Active (cross-over)"
62422409|NCT01314222|OTHER|Arm 2: BMS-954561 150mg or 300mg|"BMS-954561 150mg or 300mg TID to Placebo OR Placebo to 150mg or 300mg TID~Active to Placebo or Placebo to Active (cross-over)"
62422410|NCT01314222|OTHER|Arm 3: Pregabalin 100mg|"Pregabalin 100mg TID to Placebo OR Placebo to 100mg TID~Active to Placebo or Placebo to Active (cross-over)"
62422411|NCT01935882|ACTIVE_COMPARATOR|Artemether-Lumefantrine|Artemether-Lumefantrine combination
62591969|NCT02983149|OTHER|Double lumen tube|One lung ventilation will be achieved using a double lumen tube
62591970|NCT02983149|OTHER|Fuji blocker|One lung ventilation will be achieved using the Fuji blocker
62591971|NCT02983149|OTHER|EZ blocker|One lung ventilation will be achieved using the EZ blocker
62591972|NCT03963050|EXPERIMENTAL|CF|30 participants (randomized in 3 groups) with CF will perform a program of intervention for 1 hour a day, 3 days per week, for 1 year.
62591973|NCT03963050|EXPERIMENTAL|PF|30 participants (randomized in 3 groups) with PF will perform a program of intervention for 1 hour a day, 3 days per week, for 1 year.
62591974|NCT01163669||kidney transplant recipients|
62591975|NCT05710991|ACTIVE_COMPARATOR|Sleep Hygiene Workshop|The Sleep Hygiene workshop contains psychoeducation on sleep hygiene and has been modified to target the transitions and concerns faced by perinatal individuals. Sleep hygiene is commonly utilized as a treatment for insomnia in general practice, with the information provided through verbal advice and a sleep hygiene info sheet. As such, the sleep hygiene protocol used in this study reflects standard care commonly offered to perinatal individuals outside of our specialized clinic.
62230487|NCT02890394|EXPERIMENTAL|2 minutes Group|The group was perform the technique inhibition suboccipital two minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
62591976|NCT05710991|EXPERIMENTAL|Cognitive Behavioural Therapy for Insomnia Workshop|The Cognitive Behavioural Therapy (CBT) for Insomnia workshop contains empirically supported strategies for insomnia that have been modified to target the transitions and concerns faced by perinatal individuals. CBT is the first-line treatment for insomnia and promising research on CBT for insomnia specifically during pregnancy and postpartum is emerging.
62591977|NCT04740034|EXPERIMENTAL|Dose Escalation|Sequential dose escalation cohorts are planned until maximum tolerated dose (MTD) is reached or recommended phase 2 dose (RP2D) is identified.
62591978|NCT04740034|EXPERIMENTAL|Dose Expansion|An expansion cohort in subjects with mCRPC will be enrolled after RP2D is established.
62591979|NCT01662453||SUDEP Group|The SUDEP group refers to epileptic patients that had a sudden unexplained death; excludes trauma, drowning, status epilepticus, or other known cause, but there is often evidence of an associated seizure.
62591980|NCT01662453||Control Group|We will recruit living patients with epilepsy for the control group. In particular, epileptic patients with Dravet Syndrome of Idic 15.
62230488|NCT02890394|EXPERIMENTAL|4 minutes Group|The group was perform the technique inhibition suboccipital four minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
62230489|NCT02890394|EXPERIMENTAL|8 minutes Group|The group was perform the technique inhibition suboccipital eight minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
62591981|NCT00027183||1|Healthy Volunteers
62591982|NCT00027183||2|Cystic Fibrosis subjects
62591983|NCT06064838|EXPERIMENTAL|Flavonoids|Capsules with 500mg of cacao flavonoids, twice a day for 90 days
62591984|NCT06064838|PLACEBO_COMPARATOR|Placebo|Capsules with 500mg of excipients, twice a day for 90 days
62591985|NCT02338219|ACTIVE_COMPARATOR|vaginal delivery|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
62230490|NCT02890394|NO_INTERVENTION|not intervention Group|The not intervention group will be asked to lie supine on the table for ten minutes, collecting data by measuring with algometer and test repositioning of the head before and after laying.
62230491|NCT02317081|EXPERIMENTAL|Axetis Inert Coronary Stents|Axetis Inert Coronary Stents for de novo coronary lesion
62230492|NCT03486457|EXPERIMENTAL|Treatment Sequence A|Tofacitinib 5 mg BID for 6 months
62230493|NCT03486457|PLACEBO_COMPARATOR|Treatment Sequence B|Placebo for 3 months then tofacitinib 5 mg BID for 3 months
62230494|NCT04568720||Shanghai General Hospital|
62230495|NCT02550717||Acetylsalicylic Acid|New users of low-dose Acetylsalicylic Acid (ASA)
62230496|NCT02550717||Other medications|Users of other medications such as clopidogrel, oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs)
62230497|NCT02207348|EXPERIMENTAL|Liraglutide 0.6 mg s.c. with FlexPen®|
62230498|NCT02207348|EXPERIMENTAL|Liraglutide 0.6 mg s.c. with the PDS290 pen-injector|
62230499|NCT04822623||MS|
62230500|NCT04822623||NMOSD|
62230501|NCT04822623||Control|
62591986|NCT02338219|ACTIVE_COMPARATOR|elective cesarean section|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
62591987|NCT02338219|ACTIVE_COMPARATOR|urgent cesarean section|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
62591988|NCT00974467|EXPERIMENTAL|After The Injury website|
62591989|NCT00974467|OTHER|Usual care|Treatment as usual
62591990|NCT02938793|EXPERIMENTAL|Single Arm|Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) intravenously for 13 doses and Tremelimumab 300mg intravenously as a single dose on cycle 1 day 1 only.
62591991|NCT06105970||Community sample|Using social media to randomly inviting participants across all regions of China.
62591992|NCT03583060|EXPERIMENTAL|MABT|Receive 8 weekly sessions of Mindful Awareness in Body-oriented Therapy (MABT).
62591993|NCT03583060|NO_INTERVENTION|Control|
62591994|NCT02655016|EXPERIMENTAL|Participants receiving Niraparib|
62422412|NCT01935882|EXPERIMENTAL|Artemether-Lumefantrine-Primaquine 0.25|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine
62591995|NCT02655016|PLACEBO_COMPARATOR|Participants receiving Placebo|
62591996|NCT05447819|EXPERIMENTAL|DELTA Xtend Reverse Shoulder System Lateralized Glenosphere Line Extension|"By using a lateralized glensphere complications can be reduced and patients can achieve an improved outcome.~Currently, little is known about the results of the lateralized design. The initial results have been promising, but migration and eventually loosening of the prosthesis can lead to poor results and, in some cases, revision"
62422413|NCT01935882|EXPERIMENTAL|Artemether-Lumefantrine-Primaquine 0.4|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine
62807382|NCT05313789||Intensive Care Patients (Internal diseases)|Intensive care unit patients, both mechanically ventilated and lacking communication and mechanically ventilated and conscious. Will examine whether the positive inotropic/vasoconstrictor agents will have any effect on Analgesia Nociception Index.
62807383|NCT05313789||Intensive Care Patients (Obese)|Intensive care unit patients. Will examine whether the positive inotropic/vasoconstrictor agents will have any effect on Analgesia Nociception Index.
62031173|NCT01925079|EXPERIMENTAL|Intensive Educational Group|The Intensive Educational Group will receive 5 visits, including 2 visits via phone contacts. The expected dates for each visit will be stamped on the follow-up brochure for convenience. Patient education in this group includes routine education at discharge; 4 educational brochures, a calendar with health tips, and follow-up brochure with medical expert letter sent to patients at the day for discharge (baseline); and educational short messages through message platform once a week. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded.
62807384|NCT01389882|EXPERIMENTAL|ventilator assist|
62031174|NCT01925079|SHAM_COMPARATOR|Control Group|The Control Group will receive 3 visits and receive care as per usual practice by the treating doctor and a follow-up brochure without medical expert letter. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded. Blood lipid panel (4 items), hepato-renal functions, and creatine kinase will be examined; while, Morisky 8-item questionnaire will be used to evaluate medication compliance at outpatient visits. In addition, the occurrence of major cardiovascular events and AE/SAE will be collected during the study.
62031175|NCT05725538|EXPERIMENTAL|COVIDReApp Group|The intervention group will complete a program of exercise guided by a m-health system (COVIDReApp) for 24 weeks.
62031176|NCT05725538|ACTIVE_COMPARATOR|Control Group|The comparator group will complete a program of exercise in a traditional way (exercises will be provided in paper format) for 24 weeks.
62422414|NCT01529749|ACTIVE_COMPARATOR|EFV/FTC/TDF|
62422415|NCT01529749|EXPERIMENTAL|EFV/FTC/TDF + Losartan|
62031177|NCT04554875||Cohort 1|Derivation Cohort of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
62422416|NCT01529749|EXPERIMENTAL|FTC/TDF + MK-0518|
62591997|NCT05447819|ACTIVE_COMPARATOR|Standard DELTA Xtend Reverse Shoulder System|A design with a standard glenosphere is currently regarded as the standard treatment
62591998|NCT03211780|EXPERIMENTAL|Ultrasound|
62591999|NCT04818762||Preterm neonates with infection|Preterm neonates (30+0 - 36+6 weeks of gestation) with clinical and laboratory signs of early onset infection (within 72 hours after birth).
62807385|NCT00860730|EXPERIMENTAL|Perceval S|
62807386|NCT05313113|EXPERIMENTAL|Experimental group|In the first stage, pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
62807387|NCT05313113|NO_INTERVENTION|Control Group|The pregnant women continued to their routine prenatal care. No intervention was applied to the pregnant women in addition to their routine prenatal care.The pregnant women were called about whether continuing their routine care or having any problems during the research.
62807388|NCT00301795|EXPERIMENTAL|Treatment (oblimersen sodium and rituximab)|"Induction therapy (month 1): Patients receive oblimersen IV continuously on days 1-7 and 15-21 and rituximab IV on days 3, 10, 17, and 24 in month 1.~Extended induction therapy (months 3, 5, 7, and 9): Patients receive oblimersen IV continuously on days 22-28 and rituximab IV on day 24 in months 3, 5, 7, and 9.~Treatment continues for 9 months in the absence of disease progression or unacceptable toxicity."
62807389|NCT01329302|ACTIVE_COMPARATOR|Group A: Direct aspiration|
62807390|NCT01329302|ACTIVE_COMPARATOR|Follicular Flushing|
62807391|NCT05242029|EXPERIMENTAL|Psilocybin|"Participants will be administered 40mg of psilocybin in a clinical setting. Psilocybin is administered orally as a capsule and taken with water.~At 3 months, half will be randomized to receive a blinded dose of psilocybin 40mg and half a blinded dose of placebo."
62031178|NCT04554875||Cohort 2|One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
62031179|NCT04554875||Cohort 3|One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
62807392|NCT05242029|PLACEBO_COMPARATOR|Placebo|"Participants will be administered placebo in a clinical setting. Placebo is administered orally as a capsule taken with water.~At 3 months, participants will receive a blinded dose of psilocybin 40mg."
62031180|NCT04554875||Cohort 4|One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
62031181|NCT03961165|EXPERIMENTAL|Treatment arm|1mL 20 mg/mL butylscopolamine bromide i.v.
62422417|NCT01529749|EXPERIMENTAL|FTC/TDF+MK-0518+Losartan|
62422418|NCT00116129|PLACEBO_COMPARATOR|Placebo|Placebo
62592000|NCT04818762||Preterm neonates without infection|Preterm neonates (30+0 - 36+6 weeks of gestation) without clinical and laboratory signs of early onset infection (within 72 hours after birth).
62592001|NCT04818762||Term neonates with infection|Preterm neonates (30+0 - 36+6 weeks of gestation) with clinical and laboratory signs of early onset infection (within 72 hours after birth).
62031182|NCT03961165|PLACEBO_COMPARATOR|Placebo|1mL 9mg/mL NaCl
62230502|NCT04246320|EXPERIMENTAL|Intervention|Patients monitored and receiving a standard anesthesia plan in addition of a goal directed therapy (GDT) hemodynamic management (MAP \> 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).
62230503|NCT04269330|SHAM_COMPARATOR|1-Normal size mesh in open inguinal herni|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
62807393|NCT06391099|EXPERIMENTAL|Arm I (Ketogenic diet)|Patients undergo a ketogenic dietary intervention with personalized coaching from a dietician about the KD, which includes extensive educational and ongoing support on the KD and continuous ketone monitoring by talking to a dietician directly, with the ability to text a dietician at any time and expect a response within 12 hours over 24weeks. Patients also undergo daily blood glucose and ketone monitoring, undergo CT, undergo blood sample collection and may undergo stool sample collection on the study.
62807394|NCT06391099|ACTIVE_COMPARATOR|Arm II (usual caare)|Patients follow a standard of care diet on the study.
62230504|NCT04269330|ACTIVE_COMPARATOR|2- small size mesh in open inguinal herni|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
62230505|NCT03487926||Group 1 (IBD primary diagnosis)|Participants have active IBD
62422419|NCT04534387|EXPERIMENTAL|Experimental Group|This group will receive the Spanish-Language Hearing Loss Toolkit materials.
62592002|NCT04818762||Term neonates without infection|Preterm neonates (30+0 - 36+6 weeks of gestation) without clinical and laboratory signs of early onset infection (within 72 hours after birth).
62807395|NCT06461988|EXPERIMENTAL|Talquetamab|Study participants will receive talquetamab (JNJ-64407564) for one cycle and a combination of talquetamab and lenalidomide for cycles 2-13 after autologous stem cell transplant (ASCT).
62807396|NCT05878834|EXPERIMENTAL|Beta-glucan supplement group|Beta-glucan supplement capsule composes of beta-glucan 250 mg, broccoli 75 mg, quercetin 50 mg.
62031183|NCT00159211|ACTIVE_COMPARATOR|1|UMULINE NPH at bed time
62031184|NCT00159211|EXPERIMENTAL|2|pioglitazone 30 mg
62230506|NCT03487926||Group 2( IBD + comorbid MDE)|1 \[18F\]FEPPA PET scan in those with IBD symptoms in the past 2 years as well present with MDE
62422420|NCT04534387|ACTIVE_COMPARATOR|Active Control Group|This group will receive standard of care Spanish language information from the American Speech-Language-Hearing Association (ASHA) Audiology Series
62422421|NCT05410509|EXPERIMENTAL|RCC Participants|Receive Trans-arterial embolization (TAE)
62422422|NCT01359072|EXPERIMENTAL|Immediate Intervention Treatment|
62422423|NCT01359072|EXPERIMENTAL|Wait list|
62422424|NCT00303134|EXPERIMENTAL|Islet Cell Transplantation|
62422425|NCT06539286|ACTIVE_COMPARATOR|Control|Desensitizing Agent Gluma
62422426|NCT06539286|ACTIVE_COMPARATOR|1. Laser Group|Er:YAG laser
62422427|NCT06539286|ACTIVE_COMPARATOR|2. Laser Group|Nd:YAG laser
62422428|NCT06539286|ACTIVE_COMPARATOR|3. Laser Group|970 nm diode laser
62807397|NCT05878834|PLACEBO_COMPARATOR|Placebo group|Placebo capsule is empty capsule.
62807398|NCT00322881|EXPERIMENTAL|Carboplatin/Paclitaxel|Patients received chemotherapy on day 1 of a 21 day cycle for 6 cycles. Paclitaxel was given via peripheral or central IV catheter at the dose of 175 mg/m2 over 3 hours. IV carboplatin followed using a dose of Area Under the Curve (AUC) equal to 5 with creatinine clearance based on Jelliffe formula.
62807399|NCT05973734|EXPERIMENTAL|Recipient T Regulatory Cell|T regulatory cells prior to islet transplantation, induction therapy with ATG and Belatacept and maintenance immunosuppression with Tacrolimus Extended-release tablets (Envarsus XR) and Mycophenolate Mofetil (MMF).
62807400|NCT05973734|EXPERIMENTAL|Donor Derived Vertebral Bone Marrow|Deceased donor vertebral bone marrow (VBM) cells, induction therapy with ATG and Belatacept and maintenance immunosuppression with Tacrolimus Extended-release tablets (Envarsus XR) and Mycophenolate Mofetil (MMF).
62031185|NCT05917405|EXPERIMENTAL|Experimental: CloB2 arm|"* 30 mg/m2/day IV clofarabine for 5 days (day-6 to day-2)~* 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)~* ATG (Thymoglobuline®) 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1) Corticosteroids may be used in profilaxis"
62230507|NCT03487926||Group 3-Controls|"Matched for Level of Depressive Symptoms and Otherwise Healthy~-Subjects in an otherwise healthy state with major depressive episodes, obsessive compulsive disorder, or generalized anxiety disorder will provide psychiatric diagnosis matched controls to those with IBD. Data for group three will be largely obtained from previous recent studies (it is anticipated that 95% of this data is already available)."
62230508|NCT06251453||SGLT2 inhibitors users|Adults undergoing cardiothoracic surgery who had been using SGLT2 inhibitors for a minimum of 1 week before surgery, regardless of diabetes status
62422429|NCT05174078|EXPERIMENTAL|Medically-Tailored Meals (MTM)|Medically-tailored meals delivered to participants' homes for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
62592003|NCT01893060|EXPERIMENTAL|Povidone-Iodine|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
62031186|NCT05917405|ACTIVE_COMPARATOR|Comparator: FB2A2 arm|"* 30 mg/m2/day IV fludarabine for 5 days (day-6 to day-2)~* 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)~* ATG (Thymoglobuline®) 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1)"
62592004|NCT01893060|EXPERIMENTAL|Chlorhexidine|Umbilical stump care. ChloraPrep® Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
62230509|NCT06251453||SGLT2 inhibitors non-users|Adults not receiving SGLT2 inhibitors undergoing cardiothoracic surgery
62592005|NCT01893060|EXPERIMENTAL|Pluronic Cream|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin), applied twice a day to cord stump while umbilical line(s) are in place
62592006|NCT01893060|SHAM_COMPARATOR|Control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
62230510|NCT04700722||Parkinson's disease|Looking for 105 patients with a clinically established diagnosis of Parkinson's disease between 40-99 years of age.
62230511|NCT04700722||Multiple System Atrophy|Looking for 40 patients with a clinically established diagnosis of Multiple System Atrophy between 40-99 years of age.
62230512|NCT04700722||Dementia with Lewy bodies|Looking for 95 patients with a clinically established diagnosis of Dementia with Lewy bodies between 40-99 years of age.
62230513|NCT04700722||Pure Autonomic Failure|Looking for 60 patients with a clinically established diagnosis of Pure Autonomic Failure between 40-99 years of age.
62592007|NCT01382524||Stabilization system A|A commercialized stabilization dressing using a winged PIV catheter.
62807401|NCT04053257|NO_INTERVENTION|Before intervention|HH opportunities, compliant moments and HAIs recorded before the intervention
62230514|NCT04700722||Healthy Controls|No history of clinical or symptoms suggestive of Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies or Pure Autonomic Failure between 40-99 years of age.
62230515|NCT03538249|EXPERIMENTAL|Aerobic training|Patients follow an alternating aerobic training using a treadmill at an intensity of 60% of maximum heart rate, 3 mn and 3 mn working off an alternative way.To ensure progressive overload appropriate, we adjust moderate intensity aerobic exercise every two weeks with an overall 5% increase in heart rate.
62807402|NCT04053257|ACTIVE_COMPARATOR|After intervention|HH opportunities, compliant moments and HAIs recorded after the intervention
62807403|NCT00778778|EXPERIMENTAL|1|Cefprozil 500mg tablets of ranbaxy
62807404|NCT00778778|ACTIVE_COMPARATOR|2|CEFZIL ® 500 mg cefprozil tablets of BMS, USA
62807405|NCT00778778|ACTIVE_COMPARATOR|3|CEFZIL ® 500 mg tablets, BMS Canada
62031187|NCT05699759|EXPERIMENTAL|Patients with Diabetic Macular Edema|Patients with Diabetic Macular Edema
62230516|NCT03538249|EXPERIMENTAL|Inspiratory muscle training|The inspiratory muscle training involves a high intensity endurance training to 60% of PI, max. We recalculate the individual SPImax and PImax in each training session. Patients use the driving tool inspiratory muscle.
62031188|NCT06636279|EXPERIMENTAL|Gas bubble group|Inject the sterile air into the anterior chamber after the conventional cataract surgery to reduce the corneal endothelial damage
62592008|NCT01382524||Stabilization System B|A commercialized stabilization device using a non-winged PIV catheter
62592009|NCT04392128|EXPERIMENTAL|Treatment arm|Patients enrolled in the experimental arm will receive hydroxychloroquine (200mgx3 tablets per day during 10 days) and azithromycine (500 mg at day 1 (2 capsules taken at the same time) then 250mg per day (1 capsule per day) during 4 days).
62592010|NCT04392128|PLACEBO_COMPARATOR|Control arm|Patients enrolled in the control arm will receive a placebo of hydroxychloroquine (3 tablets per day during 10 days) and a placebo of azithromycine (2 capsules taken at the same time at day 1, then 1 capsule per day during 4 days)
62807406|NCT03369821||Study 1: Existing EET1D (Case)|"* Aged 0 to 70 years~* Clinical diagnosis of diabetes \<24 months (+ evidence of WHO diabetes criteria)~* Negative genetic test for mutations causing non-autoimmune neonatal diabetes if diagnosed \<12 months~* Type 1 diabetes genetic risk score \>50th centile of T1D reference group, or monogenic cause of T1D (e.g. STAT3 or FOXP3 mutation)."
62807407|NCT03369821||Study 1: T1D (Control)|"* Age 0-70 years (matched to above)~* Clinical diagnosis of T1D (diagnosed age 1-20 years)~* Insulin treated from diagnosis."
62031189|NCT06636279|NO_INTERVENTION|The control group|Conventional cataract surgery
62031190|NCT00450086|EXPERIMENTAL|A|
62230517|NCT03538249|EXPERIMENTAL|Resistance training|The resistance should be measured on 1 RM (Repetition Maximum) for each muscle group. The exercises are performed in three sets of ten repetitions of exercises at 60% of 1RM intensity recalculated every two weeks training.
62230518|NCT03538249|NO_INTERVENTION|Control|The control group patients were allocated to a non-training time period, during which they were told to continue their life as before enrollment.
62230519|NCT03538249|EXPERIMENTAL|Aerobic and Inspiratory training|Note that the Aerobic and Inspiratory group participant undergone same protocols of inspiratory and aerobic training stated above, with almost a 5 minutes rest in between.
62230520|NCT03538249|EXPERIMENTAL|Combined|Note that the Aerobic, Inspiratory and resistance group participant undergone same protocols of inspiratory and aerobic training stated above, with almost a 5 minutes rest in between.
62230521|NCT02842606|EXPERIMENTAL|Fiber-enriched pasta|The participants consume whole wheat pasta with added fiber (fiber 12 g fiber/100 g).
62230522|NCT02842606|ACTIVE_COMPARATOR|Control pasta|The participants consume pasta made from durum wheat semolina (fiber 2.7g/100g).
62807408|NCT03369821||Study 2: Newly diagnosed EET1D (Case)|"* Aged 0 to 24 months at recruitment~* Clinical diagnosis of diabetes \<24 months (+ evidence of WHO diabetes criteria)~* Negative genetic test for mutations causing non-autoimmune neonatal diabetes~* Type 1 diabetes genetic risk score \>50th centile of T1D reference group, or monogenic cause of T1D (e.g. STAT3 or FOXP3 mutation)"
62807409|NCT03369821||Monogenic / NDM (Control)|"* Diagnosis of diabetes \<24 months~* Age 0 to 24 months at recruitment~* Diagnosis of Monogenic / NDM (confirmed by Exeter Molecular Genetics Laboratory)."
62230523|NCT05353348|EXPERIMENTAL|Iron treatment intervention arm|The combination therapy group will receive three treatments consisting of 200 mg/100 ml of iron sucrose IV infusion, 150 IU/Kg of erythropoietin subcutaneously and 2 mg/100 ml of vitamin C IV infusion in the week prior to surgery
62592011|NCT00811902|EXPERIMENTAL|Nerispirdine 50mg|Nerispirdine 50mg once daily for 14 weeks
62592012|NCT00811902|EXPERIMENTAL|Nerispirdine 100mg|Nerispirdine 100mg once daily for 14 weeks
62807410|NCT03369821||Without diabetes (Control)|"* Aged 0-6 years~* Attending specified participating hospital sites for elective surgery, including but not limited to: inguinal hernia repair, umbilical/midline hernia repair, orchidopexy, gastrostomy insertion/change, hypospadias repair, cleft palate repair, excision of accessory digit, laryngoscopy, adenoidectomy, tonsillectomy, MRI under general anaesthesia, eye surgery.~Should recruitment be slower than anticipated, we would recruit children with congenital non-immune thyroid disease when they attend paediatric clinic for blood draw."
62230524|NCT05353348|PLACEBO_COMPARATOR|control arm|The standard treatment group will receive 200 ml of saline equal to the intervention group, and 1 ml of saline injected subcutaneously
62230525|NCT04068623||Triple negative breast cancer|
62230526|NCT02742259||Beta Cutoff|Assay
62230527|NCT02742259||Pivotal|Assay
62230528|NCT05020431|EXPERIMENTAL|One arm|One arm nonrandomized clinical trial
62230529|NCT00031551|EXPERIMENTAL|Main Study: Etanercept Mouthwash|Etanercept 2.5 mg in 20cc mouthwash is swished and spit by the participant every 6 hours. The experimental mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant (BMT) Day +14, whichever occurs first.
62230530|NCT00031551|PLACEBO_COMPARATOR|Main Study: Placebo Mouthwash|Placebo 20cc mouthwash is swished and spit by the participant every 6 hours. The placebo mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant day (BMT) Day +14, whichever occurs first.
62230531|NCT00031551|NO_INTERVENTION|Pilot Study|Participants were enrolled in the pilot study to collect descriptive data about pain perception and laboratory techniques.
62592013|NCT00811902|EXPERIMENTAL|Nerispirdine 200mg|Nerispirdine 200mg once daily for 14 weeks
62807411|NCT01390896||Patients prescribed fondaparinux|Patients undergoing general surgery of the lower limb at high risk for venous thromboembolism
62230532|NCT03875677|EXPERIMENTAL|HD-tDCS group|Constant current (1mA) will be applied for 20min and the anode will be placed over the defined target area
62230533|NCT03875677|EXPERIMENTAL|Conventional tDCS group|Constant current (1mA) will be applied for 20min and the anode will be placed over the standard C3/C4 position
62807412|NCT06037915|ACTIVE_COMPARATOR|low flow oxygen|
62807413|NCT06037915|ACTIVE_COMPARATOR|high flow oxygen|
62031191|NCT00450086|EXPERIMENTAL|B|
62807414|NCT02549547|EXPERIMENTAL|Lifestyle Intervention|Physical Activity focused, interdisciplinary, Group Medical Visits (GMVs)
62031192|NCT00450086|PLACEBO_COMPARATOR|C|
62230534|NCT03875677|SHAM_COMPARATOR|Sham HD-tDCS group|The stimulator will be shut down after 30s of stimulation. The patients will feel the initial itching sensation at the beginning in order to evaluate the placebo effect.
62230535|NCT05937087||TOC community advisory research team|Participants were given a pre-and post community engagement survey.
62230536|NCT06353438|EXPERIMENTAL|Intervention|All subjects will participate in a 2x/week for 6 weeks exercise program using Frei FACTUM® novus II line exercise equipment, which uses hydraulic resistance. Each session will take 30-45 minutes to complete. The equipment uses concentric movements only but works both agonist and antagonist muscles with each piece of equipment (IE: push and pull). Participants results will be compared pre and post intervention.
62031193|NCT03861598|EXPERIMENTAL|Cohort 1|Carvedilol orally with standard chemotherapy starting at 6.25 mg and increasing to 12.5 mg if tolerated after 1-2 weeks for a total of 4 cycles of treatment.
62031194|NCT03755505||Healthy Smoker|Healthy smoker with normal spirometry value
62230537|NCT00475033|EXPERIMENTAL|1|
62230538|NCT00475033|ACTIVE_COMPARATOR|2|
62230539|NCT01749904|EXPERIMENTAL|BOL-303259-X|BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
62592014|NCT00811902|PLACEBO_COMPARATOR|Placebo|Placebo for Nerispirdine once daily for 14 weeks
62807415|NCT05513352|NO_INTERVENTION|Experiment 1 - Normal hearing - AAT|Each participant assigned to the normal hearing group will undergo one experimental session during which EEG is recorded while participants perform an auditory attention task (AAT).
62807416|NCT05513352|NO_INTERVENTION|Experiment 1 - Hearing impaired - AAT|Each participant assigned to the normal hearing impaired group will undergo one experimental session during which EEG is recorded while participants perform an auditory attention task (AAT).
62807417|NCT05513352|NO_INTERVENTION|Experiment 2 - normal hearing _ SAT|Each participant assigned to the normal hearing group will undergo one experimental session in which EEG is used to measure neural speech tracking while participants undergo the selective speech attention task (SAT).
62031195|NCT03755505||COPD|Patients with smoking history at least 10 pack-year Patients with persistent airflow limitation that was not fully reversible (e.g. post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) \<0.7)
62230540|NCT01749904|ACTIVE_COMPARATOR|Timolol|Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).
62807418|NCT05513352|NO_INTERVENTION|Experiment 2 - hearing impaired - SAT|Each participant assigned to the hearing impaired group will undergo one experimental session in which EEG is used to measure neural speech tracking while participants undergo the selective speech attention task (SAT).
62807419|NCT05513352|NO_INTERVENTION|Experiment 2 - tinnitus - SAT|Each participant assigned to the tinnitus group will undergo one experimental session in which EEG is used to measure neural speech tracking while participants undergo the selective speech attention task (SAT).
62230541|NCT04214600|EXPERIMENTAL|Cognitive Behavioral Therapy|This group will receive four CBT sessions twice a month for two months
62230542|NCT04214600|NO_INTERVENTION|Control|This group will be scheduled the same number of visits as a follow up for diabetes
62230543|NCT01090622|PLACEBO_COMPARATOR|Matching Placebo|
62592015|NCT06260423|EXPERIMENTAL|Experienced dentist using lateral compaction with bioceramic sealer group.|The canals in this group obturation were obturated by an Experienced dentist using lateral compaction with bioceramic sealer.
62592016|NCT06260423|EXPERIMENTAL|Unexperienced dentist using lateral compaction with bioceramic sealer group.|The canals in this group obturation were obturated by an Unexperienced dentist using lateral compaction with bioceramic sealer.
62031196|NCT02283866|EXPERIMENTAL|Administering desflurane according to the patient's BIS value|The anesthesiologist administers the volatile anesthetic desflurane to set the patient's BIS value at 50 during balanced anesthesia, and titrate the remifentanil dose to set the patient's systolic arterial blood pressure between 100-140mmHg.
62031197|NCT02283866|EXPERIMENTAL|Administering desflurane at 1 MAC|The anesthesiologist administers the volatile anesthetic desflurane at 1 MAC during balanced anesthesia, and titrate the remifentanil dose to set the patient's systolic arterial blood pressure between 100-140mmHg.
62031198|NCT06257758|EXPERIMENTAL|Dose Escalation|Dose escalation: Multiple dose levels of VIO-01 will be administered via intravenous infusion over a 60-minute period once weekly.
62230544|NCT01090622|EXPERIMENTAL|XPF-001|
62230545|NCT00992433|EXPERIMENTAL|Group 2, 30 mcg|CD4\<200, n=60; CD4 greater than or equal to 200, n=60. 30 mcg H1N1 vaccine on Day 0 and Day 21.
62230546|NCT00992433|EXPERIMENTAL|Group 1, 15 mcg|CD4\<200, n=60; CD4 greater than or equal to 200, n=60. 15 micrograms (mcg) H1N1 vaccine on Day 0 and Day 21.
62230547|NCT04026087||patient with kidney transplant|Blood sample will be took from subjects during this research
62230548|NCT05923268|EXPERIMENTAL|The tested injected doses of [99mTc]Tc-G3-(G3S)3C 3000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 3000 μg.~Subjects withdrawn from the study for any reason will be replaced."
62230549|NCT06215430|EXPERIMENTAL|Period 1: Probe Drug Cocktail|Caffeine, omeprazole, and warfarin administered as a single dose of probe drug cocktail along with vitamin K (tablets) in the morning on Day 1 followed by a fast of at least 10 hours pre dose and 2 hours post dose.
62592017|NCT06260423|EXPERIMENTAL|Experienced dentist using Single cone with bioceramic sealer group.|The canals in this group obturation were obturated by an Experienced dentist using Single cone with bioceramic sealer.
62592018|NCT06260423|EXPERIMENTAL|Unexperienced dentist using Single cone with bioceramic sealer group.|The canals in this group obturation were obturated by an Unexperienced dentist using Single cone with bioceramic sealer.
62230550|NCT06215430|EXPERIMENTAL|Period 2: LOXO-305 + Probe Drug Cocktail|"LOXO-305 will be administered orally once daily for 14 consecutive days in the morning. On Day 15, LOXO-305 will be coadministered with caffeine, omeprazole and warfarin administered orally as a single dose of probe drug cocktail, along with vitamin K.~There will be a washout period of 5 days between administration of the probe drug cocktail on Day 1 (Period 1) and the first dose of LOXO-305 on Day 6 (Period 2)."
62230551|NCT04947423|EXPERIMENTAL|DPI-386 Nasal Gel|Each 0.12 gram of the gel contains 0.2 mg of scopolamine HBr
62230552|NCT04947423|PLACEBO_COMPARATOR|Placebo|Placebo Nasal Gel (0.12 g)
62230553|NCT00609882|ACTIVE_COMPARATOR|HHFNC|Infants randomized to the Humidified High Flow Nasal Cannula (HHFNC) treatment group post extubation
62230554|NCT00609882|ACTIVE_COMPARATOR|nCPAP|Infants randomized to the nasal Continuous Positive Airway Pressure (nCPAP) treatment group
62230555|NCT03313921|EXPERIMENTAL|Online Manifest Refraction|All participants will undergo three assessments of refractive error, in random order. All will perform an unsupervised manifest refraction with the use of a computer screen and their smartphone. Next, a regular manifest refraction assessment performed by an optometrist will function as active comparator. An automated refraction assessment will be performed to relate the quality and repeatability of the online refraction to another unsupervised method of refraction assessment.
62230556|NCT05393284|EXPERIMENTAL|OPL-0401 Dose 1|Participants are randomized to OPL-0401 Dose 1 twice daily for 24 weeks
62230557|NCT05393284|PLACEBO_COMPARATOR|Placebo|Participants are randomized to matching Placebo twice daily for 24 weeks
62592019|NCT02619110|OTHER|backward walking treadmill training|The intervention group not only received four weeks of conventional physical therapy but also accepted additional four weeks of backward walking treadmill training at the same time
62592020|NCT02619110|OTHER|conventional physical therapy|The conventional physical therapy training focused on strengthening, postural control, functional mobility and forward gait training program but excluded backward walking training
62230558|NCT05696431|PLACEBO_COMPARATOR|Universal adhesive|After preparation of three posterior cavities in each patient. The cavities will be randomly divided into three groups according to the type of the adhesive used. This group will receive a universal adhesive as control group.
62230559|NCT05696431|ACTIVE_COMPARATOR|Fluoride-releasing universal adhesive|After preparation of three posterior cavities in each patient. The cavities will be randomly divided into three groups according to the type of the adhesive used. This group will receive a Fluoride-releasing universal adhesive.
62230560|NCT05696431|ACTIVE_COMPARATOR|Universal adhesive with bioactive properties|After preparation of three posterior cavities in each patient. The cavities will be randomly divided into three groups according to the type of the adhesive used.This group will receive a universal adhesive with bioactive properties.
62230561|NCT03177278|EXPERIMENTAL|Arm 1|
62230562|NCT01451125|EXPERIMENTAL|Treated|
62230563|NCT05750537|EXPERIMENTAL|EMPACT-Us|An innovative suite of tobacco cessation services designed in partnership with patients, providers, and other community stakeholders during a pilot study.
62230564|NCT05750537|NO_INTERVENTION|Newly-enhanced usual care (EUC)|Newly-enhanced usual care (EUC)
62230565|NCT04667897|EXPERIMENTAL|601 1.25mg|
62230566|NCT04667897|EXPERIMENTAL|Ranibizuman 0.5 mg|
62592021|NCT04398485|EXPERIMENTAL|ION251|In Part 1, the dose escalation phase, increased amounts of ION251 will be administered at multiple time points by intravenous (IV) infusion during 28-day cycles. In Part 2, the determined RP2D of ION251 will be administered at multiple time points by IV infusion.
62422430|NCT05174078|EXPERIMENTAL|Produce Box and Recipes|Weekly produce box delivered to participants' homes and access to recipes via the internet for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
62422431|NCT05174078|NO_INTERVENTION|Standard of Care|Matched controls from the same base population as participants in the intervention arms. Controls will identified from the electronic medical record (EMR).
62422432|NCT02488473|EXPERIMENTAL|Ropivacaine + Dexmedetomidine|Adductor Canal Block 20 ml Ropivacaine 5mg/ml + 1 ml Dexmedetomidine 100ug/ml
62422433|NCT02488473|PLACEBO_COMPARATOR|Ropivacaine + Placebo|Adductor Canal Block 20 ml Ropivacaine 5mg/ml + 1 ml Saline
62422434|NCT06613542|ACTIVE_COMPARATOR|4g of taurine daily|"Intervention group (4g of taurine/day):~2g of taurine (4 capsules, 500mg each) in the morning and 2g of taurine (4 capsules, 500mg each) in the evening for 6 months"
62422435|NCT06613542|PLACEBO_COMPARATOR|Placebo|
62422436|NCT02252497|ACTIVE_COMPARATOR|Tranexamic acid|"* 1g Intra Venous just before surgery~* Then infusion of 1g of Exacyl over eight hours."
62422437|NCT02252497|PLACEBO_COMPARATOR|Physiologic serum|"* 1g Intra Venous, just before surgery~* Then infusion of 1g of physiologic serum over eight hours."
62031199|NCT06257758|EXPERIMENTAL|Dose Expansion HRRm or HRD+ Solid Tumors|Participants with advanced HRRm or HRD+ solid tumors will be administered recommended Phase 2 dose of VIO-01 via intravenous infusion over a 60-minute period once weekly.
62230567|NCT04470466|ACTIVE_COMPARATOR|short pulse and Q-switched ND-YAG laser with topical carbon|
62230568|NCT04470466|ACTIVE_COMPARATOR|Fractional CO2 Laser|
62230569|NCT01652599|EXPERIMENTAL|Eltrombopag and dexamethasone|
62031200|NCT06257758|EXPERIMENTAL|Dose Expansion HRRm or HRD+ Ovarian Cancer|Participants with advanced HRRm or HRD+ ovarian cancer will be administered recommended Phase 2 dose of VIO-01via intravenous infusion over a 60-minute period once weekly.
62031201|NCT03336619|ACTIVE_COMPARATOR|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
62230570|NCT00948051|EXPERIMENTAL|Fructo-oligosaccharides|
62230571|NCT00948051|PLACEBO_COMPARATOR|Placebo|
62230572|NCT02590809|EXPERIMENTAL|Treatment group|20 patients
62230573|NCT02590809|PLACEBO_COMPARATOR|Placebo group|20 patients
62230574|NCT02377804|EXPERIMENTAL|Experimental intervention|The experimental intervention will consist of 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity. In addition, during this intervention patients will also receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pectoralis mayor
62230575|NCT02377804|ACTIVE_COMPARATOR|Control intervention|The control intervention will consist of 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity.
62230576|NCT00784953||1|Asthma patients who were partly controlled or uncontrolled, need to step up, or adjust dose of the controller medications to ICS/LABA
62230577|NCT04208776|EXPERIMENTAL|Midodrine+Propranolol|
62230578|NCT04208776|ACTIVE_COMPARATOR|Propranolol|
62230579|NCT00729768|EXPERIMENTAL|1|
62230580|NCT00729768|ACTIVE_COMPARATOR|2|
62243169|NCT04194853|EXPERIMENTAL|EMG Biofeedback assisted Quadriceps exercises.|Hot Pack will be applied before session for general relaxation for 10 minutes. Knee isometric exercises will be performed via an EMG Biofeedback device; patients in the EMG BF group will receive visual and auditory feedback.Knee isometrics will be performed with 5 seconds hold. Then, the muscle will be relaxed for 10 seconds and the cycle repeated for a total of 15 minutes. (20 reps, 3 sets) Session will be performed thrice a week for six weeks.
62422438|NCT04476017|EXPERIMENTAL|Part A: SAGE-718 3 mg|Participants received SAGE-718 3 milligrams (mg) tablets, once daily with food in the morning for 14 days.
62422439|NCT04476017|EXPERIMENTAL|Part B: SAGE-718 3 mg|Participants received SAGE-718 3 mg tablets, once daily with food in the morning for 28 days.
62422440|NCT01288417|EXPERIMENTAL|boceprevir + raltegravir|9 days of boceprevir 800mg TID; day 10 two doses of boceprevir 800mg and one dose of raltegravir 400mg
62422441|NCT01288417|ACTIVE_COMPARATOR|raltegravir alone|single dose of raltegravir 400mg
62422442|NCT02404779|EXPERIMENTAL|CISATRACURIUM|To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo.
62422443|NCT02404779|PLACEBO_COMPARATOR|PLACEBO|To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo.
62422444|NCT05321121|EXPERIMENTAL|Precedex arm|The intervention arm will receive an infusion of dexmedetomidine (precedex) at 0.4-0.6 mcg/kg/h (Based off ideal body weight).
62422445|NCT05321121|PLACEBO_COMPARATOR|Control arm|The control arm will receive an infusion of normal saline. Medication distribution and management will be handled by the Investigational Drug Service (IDS) at UCI medical center.
62422446|NCT00669136|OTHER|1|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
62592022|NCT03095560|EXPERIMENTAL|Semi-immersive virtual training with shadow (S-IVTS)|All the participants underwent a neurocognitive-rehabilitative training consisting of 24 sessions of BTsN. Each treatment session lasted 45 minutes, and was repeated three times a week for 8 weeks. in the BTsN device used in the S-IVTS group the projector is located behind the patient, thus the shadow of the patient is projected on the screen.
62592023|NCT03095560|EXPERIMENTAL|Semi-immersive virtual training without shadow (S-IVT)|All the participants underwent a neurocognitive-rehabilitative training consisting of 24 sessions of BTsN. Each treatment session lasted 45 minutes, and was repeated three times a week for 8 weeks. in the BTsN device used in the S-IVT group the projector is located in front of the patient and the shadow is not visible.
62807420|NCT05513352|EXPERIMENTAL|Experiment 3 - normal hearing (tACS) - AAT|"The subjects assigned to the normal hearing group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
62031202|NCT03336619|PLACEBO_COMPARATOR|Placebo|Two Placebo tablets orally twice daily (b.i.d.) for 5 days
62230581|NCT02043678|EXPERIMENTAL|Radium-223 dichloride + Abi/Pred|Participants received 6 intravenous (IV) administrations of radium-223 dichloride 50 kiloBecquerel per kilogram (kBq/kg) (55 kBq/kg after implementation of National Institute of Standards and Technology \[NIST\] update) body weight at intervals of 4 weeks, along with oral abiraterone acetate tablets 1000 milligrams (mg) every day plus prednisone/prednisolone 5 mg twice daily (abi/pred) for 6 cycles, followed by abi/pred until an on-study symptomatic skeletal event (SSE) occurred (or other withdrawal criteria were met)
62230582|NCT02043678|PLACEBO_COMPARATOR|Placebo + Abi/Pred|Participants received 6 IV administrations of placebo matched to radium-223 dichloride at intervals of 4 weeks, along with abi/pred for 6 cycles, followed by abi/pred until an on-study SSE occurred (or other withdrawal criteria were met)
62230583|NCT01808482|EXPERIMENTAL|Part A: GSK2618960|Subjects will receive ascending single dose in 3:1 ratio of active:placebo respectively in each dosing session.
62422447|NCT01400373|NO_INTERVENTION|Control|Patients in the control group standard advanced cardiac life support care. Patients that achieve return of spontaneous circulation will be treated with hypothermia according to current guidelines upon arrival at the intensive care unit.
62422448|NCT01400373|EXPERIMENTAL|Intervention|Intra-arrest trans-nasal cooling with RhinoChill will be initiated during advanced cardiac life support. In patients achieving return of spontaneous circulation, trans-nasal cooling will continue until systemic cooling is started at the intensive care unit.
62422449|NCT02706041|ACTIVE_COMPARATOR|Definitive closure laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
62422450|NCT02706041|OTHER|Damage control laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
62422451|NCT02825472|ACTIVE_COMPARATOR|Exercise training program|Six-months sports participation, three times per week for 30 minutes in the target heart rate zone
62422452|NCT02825472|NO_INTERVENTION|No exercise training program|no exercise training program, usual care
62422453|NCT02470442|EXPERIMENTAL|Sevoflurane/Desflurane|After induction of general anesthesia with sevoflurane, anesthesia was maintained with desflurane.
62422454|NCT02470442|EXPERIMENTAL|Sevoflurane|the anesthetic induction and maintenance with sevoflurane.
62230584|NCT01808482|PLACEBO_COMPARATOR|Part A: Placebo|Subjects will receive ascending single dose in 3:1 ratio of active:placebo respectively in each dosing session
62230585|NCT01808482|EXPERIMENTAL|Part B: GSK2618960|Subjects will receive ascending repeat dose (dose decided from Part A) in 3:1 ratio of active:placebo respectively in each cohort.
62230586|NCT01808482|PLACEBO_COMPARATOR|Part B: Placebo|Subjects will receive ascending repeat dose (dose decided from Part A) in 3:1 ratio of active:placebo respectively in each cohort.
62230587|NCT01808482|EXPERIMENTAL|Part C: GSK2618960|Subjects will receive active treatments for 2 to 4 repeated doses (dose decided from Part A\& B)
62230588|NCT04173637|EXPERIMENTAL|AK101 45mg every 8 weeks|AK101 45mg on Week 0 and 4 administered subcutaneously followed by AK101 45mg administered subcutaneously every 8 weeks
62230589|NCT04173637|EXPERIMENTAL|AK101 45mg - every 12 weeks|AK101 45mg on Week 0 and 4 administered subcutaneously followed by AK101 45mg administered subcutaneously every 12 weeks
62230590|NCT04173637|EXPERIMENTAL|AK101 90mg - every 8 weeks|AK101 90mg on Week 0 and 4 administered subcutaneously followed by AK101 90mg administered subcutaneously every 8 weeks
62230591|NCT04173637|EXPERIMENTAL|AK101 90mg -every 12 weeks|AK101 90mg on Week 0 and 4 administered subcutaneously followed by AK101 90mg administered subcutaneously every 12 weeks
62230592|NCT04173637|EXPERIMENTAL|AK101 135mg -every 8 weeks|AK101 135mg on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously every 8 weeks
62230593|NCT04173637|EXPERIMENTAL|AK101 135mg -every 12 weeks|AK101 135mg on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously every 12 weeks
62230594|NCT04173637|PLACEBO_COMPARATOR|Placebo to AK101|Placebo on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously at Week 12, 16 and then every 12 weeks
62230595|NCT03609853|PLACEBO_COMPARATOR|Placebo|Placebo (5mL distilled water)
62230596|NCT03609853|EXPERIMENTAL|Vaporized low THC|15mg of pure THC
62230597|NCT03609853|EXPERIMENTAL|Vaporized high THC|30mg of pure THC
62230598|NCT03609853|EXPERIMENTAL|Vaporized low d-limonene|1mg of d-limonene
62422455|NCT01544816|PLACEBO_COMPARATOR|Control Food Product|Control food product
62422456|NCT01544816|EXPERIMENTAL|Experimental Food Product 1|Experimental food product 1
62422457|NCT01544816|EXPERIMENTAL|Experimental Food Product 2|Experimental food product 2
62422458|NCT02490527|PLACEBO_COMPARATOR|Statin only|The subject will consume simvastatin (40mg) and placebo once daily for 3 months.
62422459|NCT02490527|EXPERIMENTAL|Statin and epicatechin|The subject will consume simvastatin (40mg) and pure epicatechin capsules (50mg) once daily for 3 months.
62422460|NCT04127682||Physicians|Physicians dealing with cases of pediatrics' acute URIs at PHC units either urban or rural, insurance hospitals or Assiut university hospitals.
62230599|NCT03609853|EXPERIMENTAL|Vaporized high d-limonene|5mg of d-limonene
62230600|NCT03609853|EXPERIMENTAL|Low THC and low d-limonene|15mg of THC paired with 1mg of d-limonene
62230601|NCT03609853|EXPERIMENTAL|High THC and low d-limonene|30mg of THC paired with 1mg of d-limonene
62230602|NCT03609853|EXPERIMENTAL|Low THC and high d-limonene|15mg of THC paired with 5mg of d-limonene
62230603|NCT03609853|EXPERIMENTAL|High THC and high d-limonene|30mg of THC paired with 5mg of d-limonene
62230604|NCT03609853|EXPERIMENTAL|High THC and 15mg d-limonene|30mg of THC paired with 15mg of d-limonene
62230605|NCT00502827|OTHER|Recommended Standard of Care|Recommended Standard of Care (RSOC) = Physician Advice + Written Materials
62422461|NCT00000318|EXPERIMENTAL|1|Maintenance treatment with daily medication
62230606|NCT00502827|OTHER|RSOC + Cell Phone Intervention|Recommended Standard of Care (RSOC) + Cell Phone Intervention
62230607|NCT05691556||Children CP|Children with cerebral palsy with motor impairment of the upper limb(s), seen in consultation and included in a HABIT-ILE therapeutic program and/or botulinum toxin injections
62230608|NCT05112107|NO_INTERVENTION|Control|
62230609|NCT05112107|EXPERIMENTAL|Intervention|
62807421|NCT05513352|SHAM_COMPARATOR|Experiment 3 - normal hearing (sham) - AAT|"The subjects assigned to the normal hearing group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
62031203|NCT00383448|EXPERIMENTAL|Treated Patients|Patients receiving chemotherapy (Hydroxyurea, Alemtuzumab, Clofarabine, Melphalan), Hematopoietic Stem Cell Transplantation and radiation therapy (Total body Irradiation) mycophenylate mofetil and cyclosporine A.
62031204|NCT04969081|ACTIVE_COMPARATOR|treatment as usual|usual substance use treatment
62230610|NCT05715866|EXPERIMENTAL|non-invasive neurostimulation experimental group (NEG)|The non-invasive neuromodulation experimental group, made up of 10 participants, are treated 20 sessions with the NXSignal non-invasive neuromodulation device (NESA)
62230611|NCT05715866|EXPERIMENTAL|Experimental group Therapeutic Exercise (TEG)|The experimental group of therapeutic exercise, made up of 10 participants, receives 3 weekly sessions of one hour duration for 16 weeks, and 1 weekly session until week 20, of an adapted program of cardiovascular exercises in a small group format, supervised by a physical therapist.
62230612|NCT05715866|SHAM_COMPARATOR|Control group (CG)|The control group, made up of 10 participants, the caregivers receive recommendations about sleep habits through an information brochure.
62230613|NCT03608540|EXPERIMENTAL|Intervention|Suturing system with suture apposition then bulging formation then cutting the lesion
62230614|NCT01516177||Renal Transplant Recipients|Subjects who received a kidney transplant within the past 1 to 5 years
62230615|NCT01871311|EXPERIMENTAL|Nilotinib + Cetuximab|All patients with receive Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly
62230616|NCT04926220||Patients undergoing general anesthesia and benefiting from intraoperative hemodynamic optimization|Patients undergoing general anesthesia and benefiting from intraoperative hemodynamic optimization, including routine monitoring of blood pressure and measurement of cardiac output by trans-esophageal Doppler.
62230617|NCT02001610|ACTIVE_COMPARATOR|Hard shell gelatin capsules|"* Comparison delivery vehicle in the form of gelatin capsule~* One capsule (containing at least 1 x 10\^9 colony forming units) every morning for 12 days"
62230618|NCT02001610|EXPERIMENTAL|Acidophilus pearls|"* Encapsulated using patented process~* One capsule (containing at least 1 x 10\^9 colony forming units) every morning for 12 days"
62230619|NCT03090230|EXPERIMENTAL|Relay Pro Thoracic Stent-Graft System|The Relay Pro arm includes subjects who receive the device to treat traumatic injury of the descending thoracic aorta with the RelayPro Thoracic Stent-Graft System
62230620|NCT01450254|EXPERIMENTAL|Experimental|These patients will carry out a therapy program with the study intervention device.
62031205|NCT04969081|EXPERIMENTAL|treatment as usual plus referral to work focused program|usual substance use treatment plus referral to a competitive or non-competitive work-focused program
62031206|NCT01408368|ACTIVE_COMPARATOR|Bilateral subtotal thyroidectomy|
62230621|NCT01450254|ACTIVE_COMPARATOR|Control|The patients in this group will not carry out a therapy program with the study intervention device.
62230622|NCT01208493|EXPERIMENTAL|high protein preterm infant formula|preterm infant formula with high protein levels
62230623|NCT01208493|ACTIVE_COMPARATOR|control preterm formula|
62230624|NCT02694939|EXPERIMENTAL|STAND|Receives STAND intervention delivered in community mental health setting.
62230625|NCT02694939|ACTIVE_COMPARATOR|Usual Care|Receives usual care from community therapists.
62230626|NCT02522455|OTHER|Preterm infants with RDS|
62230627|NCT05868343|ACTIVE_COMPARATOR|Center-based cardiac rehabilitation program|
62230628|NCT05868343|EXPERIMENTAL|Hybrid cardiac rehabilitation program|
62230629|NCT02774031|EXPERIMENTAL|Aisys with Et control|the ventilation modus will be pressure control ventilation with volume guarantee (PCV-VG). Settings: tidal volume (TV) 7-9 ml/kg BW, respiratory rate (RR) 12 -14/min, and 8-10 cmH2O positive end expiratory pressure (PEEP). Target for end expired desflurane concentration (F A des) is set to 4.2%, and target for end expired oxygen (F AO2) is set to 35%.
62422462|NCT00000318|EXPERIMENTAL|2|Maintenance treatment with thrice-weekly medication
62422463|NCT01738490|OTHER|Wide diameter implant|Bone anchored hearing implant For the wide diameter arm (test group), the Ponto wide implant (diameter 4,5mm, length 4mm) and abutment 6mm developed by Oticon Medical AB (Gothenburg, Sweden) will be installed.
62230630|NCT02774031|ACTIVE_COMPARATOR|Aisys conventional ventilation|50% oxygen and 50% air in 1 liter FGF will be administered. To be started with a FGF of 5l/min and vaporizer setting at 6 Vol% for 5 min. Then the FGF will be reduced to 1 l/min. 25 min later the vaporizer setting will be reduced to 5.5 Vol % for the rest of the study period. Ventilation modus for this group will be the same as for 'Aisys with PCV-VG'
62230631|NCT02774031|EXPERIMENTAL|Flow-i with ACG|the following parameters will be preset: FIO2= 40%; end expired gas concentration (FA des) to 4.2%; speed 6; and ventilation modus = pressure regulated volume control (PRVC) with tidal volume (TV) 7-9 ml/kg BW, respiratory rate (RR)12-14/min, and 8-10 cmH2O positive end expiratory pressure (PEEP).
62807422|NCT05513352|EXPERIMENTAL|Experiment 3 - hearing impaired (tACS) - AAT|"The subjects assigned to the hearing impaired group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
62807423|NCT05513352|SHAM_COMPARATOR|Experiment 3 - hearing impaired (sham) - AAT|"The subjects assigned to the hearing impaired group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
62807424|NCT05513352|EXPERIMENTAL|Experiment 3 - tinnitus (tACS) - AAT|"The subjects assigned to the tinnitus group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
62807425|NCT05513352|SHAM_COMPARATOR|Experiment 3 - tinnitus (sham) - AAT|"The subjects assigned to the tinnitus group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
62807426|NCT05513352|EXPERIMENTAL|Experiment 4 - normal hearing (tACS) - SAT|"The subjects assigned to the normal hearing group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
62807427|NCT05513352|SHAM_COMPARATOR|Experiment 4 - normal hearing (sham) - SAT|"The subjects assigned to the normal hearing group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
62807428|NCT05513352|EXPERIMENTAL|Experiment 4 - hearing impaired (tACS) - SAT|"The subjects assigned to the hearing impaired group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
62031207|NCT01408368|EXPERIMENTAL|Total thyroidectomy|
62031208|NCT00847262|EXPERIMENTAL|Telmisartan Group|Telmisartan intervention group
62031209|NCT00847262|ACTIVE_COMPARATOR|Amlodipine Group|Amlodipine intervention group
62031210|NCT04052672|ACTIVE_COMPARATOR|Randomized Intervention|The intervention will consist of an exercise intervention, a combination of supervised exercise classes and in home exercises and open label nutritional supplement.
62031211|NCT04052672|NO_INTERVENTION|Randomized - Control|The control will consist of a single group educational session which will include the discussion of general advice on health, exercise and nutrition as well as open label nutritional supplement
62031212|NCT01587664|EXPERIMENTAL|NewBreez ILP|Implantation of a NewBreez ILP
62230632|NCT02774031|ACTIVE_COMPARATOR|Flow-I conventional ventilation|50% oxygen and 50% air in 1 liter FGF will be administered. To be started with a FGF of 5l/min and vaporizer setting at 6 Vol% for 5 min. Then the FGF will be reduced to 1 l/min. 25 min later the vaporizer setting will be reduced to 5.5 Vol % for the rest of the study period. Ventilation modus for this group will be the same as for 'Flow-i with ACG'
62230633|NCT02957721|OTHER|Behavioral self-management|Eligible patients who are registered on the practice EHR linked portal will be invited to join the study. Following informed consent, enrollment and randomization, participants in the treatment group will receive the type 2 diabetes behavioral self-management education intervention; comprised of 9 modules derived from Medline Plus.
62031213|NCT06255223|EXPERIMENTAL|Experimental group|For eligible subjects, multimodal radiotherapy will be added to the treatment besides original immunotherapy or combinations of immunotherapy and TKIs after adjustment.
62031214|NCT01556438|EXPERIMENTAL|100 mg Tabalumab+Bortezomib (BTZ)IV+Dexamethasone (Dex)|Cohort 1. 100 mg tabalumab (LY2127399) intravenously (IV) on day 1 of each cycle, each cyle is 21 days. Bortezomib (BTZ), 1.3 milligram per square meter (mg/m\^2), IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dexamethasone (Dex), 20 mg/day, on day of and day after BTZ.
62031215|NCT01556438|EXPERIMENTAL|300 mg Tabalumab+BTZ IV+Dex|Cohort 2. 300 mg tabalumab (LY2127399) IV on day 1 of each cycle, each cycle is 21 days. BTZ, 1.3 mg/m\^2, IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ.
62031216|NCT01556438|EXPERIMENTAL|300 mg Tabalumab+BTZ SC+Dex|Cohort 2-SC. 300 mg tabalumab (LY2127399)IV on day 1 of each cycle, each cycle is 21 days. BTZ, 1.3 mg/m\^2, subcutaneously (SC) on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ. Cohort 2-SC was added per protocol amendment in February 2013.
62031217|NCT00017381|EXPERIMENTAL|Treatment|"PART I: Patients receive rituximab IV on days 1, 8, 15, and 22 and cyclophosphamide IV over 1 hour on day 25. G-CSF is administered SC daily beginning on day 26 and continuing until autologous PBSC are harvested.~PART II: Beginning 4-6 weeks after completion of the fourth rituximab infusion, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1 followed by dosimetry imaging on days 1, 2, 4, and 7. Patients then receive IDEC-Y2B8 IV over 10 minutes once between days 8-15.~PART III: All patients undergo PBSCT beginning after residual bone marrow radioactivity resolves. G-CSF is administered SC beginning 1 day after PBSCT and continuing until blood counts recover."
62031218|NCT04333667|EXPERIMENTAL|Intervention group|The intervention group will get an 8-week mindfulness-based internet intervention.
62230634|NCT02957721|NO_INTERVENTION|Usual Care|Usual care includes whatever care and services the patient's clinical provides as well as generic type 2 diabetes education built into the patient's EHR linked portal.
62230635|NCT04712331|EXPERIMENTAL|The Study group A|they received graduated abdominal strengthening exercises for 30 min., 3 times per week for 6 weeks preoperatively.
62031219|NCT04333667|NO_INTERVENTION|Control group|The waiting list will get no intervention while the intervention group is getting the intervention. The waiting list has the possibility to get an intervention after the intervention group finishes it.
62031220|NCT00781625|ACTIVE_COMPARATOR|Probiotic vaginal capsules|Probiotic vaginal capsule, placebo oral capsule
62592024|NCT01168908|EXPERIMENTAL|Revatio (sildenafil)|This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
62592025|NCT01168908|OTHER|Placebo|This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
62592026|NCT04274504||patients|metatstatic breast
62592027|NCT05176418|ACTIVE_COMPARATOR|delivery rate for nicotine dose 1mg/70kg|delivery rate 50,35, 16.6 and 12.5 ug per second
62031221|NCT00781625|PLACEBO_COMPARATOR|placebo|placebo oral capsule, placebo vaginal capsule
62031222|NCT00781625|ACTIVE_COMPARATOR|Probiotic oral capsules|Probiotic oral capsules, placebo vaginal capsules
62031223|NCT00781300|ACTIVE_COMPARATOR|Loteprednol|
62031224|NCT00781300|ACTIVE_COMPARATOR|Dexamethasone|
62031225|NCT02156713|EXPERIMENTAL|CIMT Camp|Members of this study will participate in the group CIMT camp.
62230636|NCT04712331|EXPERIMENTAL|The Study group B|they received Russian stimulation on abdominal muscles for 30 min., 3 times per week for 6 weeks preoperatively.
62230637|NCT04712331|EXPERIMENTAL|The Study group C|they received combination between graduated abdominal strengthening exercises and Russian stimulation on abdominal muscles for 30 min., 3 times per week for 6 weeks preoperatively.
62230638|NCT04712331|NO_INTERVENTION|The Control group D|they were instructed to presume in normal activities of daily living preoperatively, without abdominal exercises or Russian stimulation.
62230639|NCT05142137|EXPERIMENTAL|Novel alpha glucan_dose1|Total of 180 g of the novel alpha glucan per day, consumed in 4 individual doses (i.e. 4x45 g, with each dose dissolved in 300 ml of water)
62422464|NCT01738490|OTHER|Control group|Bone anchored hearing implant For the control group, the previous generation Ponto implant (diameter 3,75mm, length 4mm) and 6mm abutment (Oticon Medical AB, Gothenburg, Sweden) will be installed.
62422465|NCT04008082||Lenvatinib|Lenvatinib capsules 12 milligram (mg) for participants with body weight greater than or equal to (\>=) 60 kilograms (kg) or 8 mg for participants with body weight less than (\<) 60 kg, orally, once daily as per routine clinical practice.
62592028|NCT05176418|ACTIVE_COMPARATOR|Delivery rate for nicotine dose 0.2mg/70kg|delivery rate 10,5, 3.3 and 2.5
62031226|NCT04978493|EXPERIMENTAL|BI 706321 + ustekinumab|
62031227|NCT04978493|PLACEBO_COMPARATOR|Placebo + ustekinumab|
62592029|NCT03403296||CLASSIC cohort|Patients with stage II-III GC who underwent D2 resection were randomized (1:1) after surgery to receive adjuvant capecitabine and oxaliplatin (eight three-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or observation alone. Assessment whether patients were disease free were done by abdominal CT or MRI and chest radiograph at regular intervals as planned by protocol.
62031228|NCT06476405|EXPERIMENTAL|Group 1 Non-Menthol: Study Product A, Ploom Non-Menthol Flavor|Heated Tobacco Product (HTP) denoted as Ploom PX1.5TN HTP; Tobacco HTS (Heated Tobacco Stick); R8. Test product sourced from Japan Tobacco Inc.
62031229|NCT06476405|ACTIVE_COMPARATOR|Group 1 Non-Menthol: Study Product B, UBCC Non-Menthol Flavor|Subject's Non-menthol UBCC (usual brand combustible cigarette). Reference product supplied by subject.
62230640|NCT05142137|EXPERIMENTAL|Novel alpha glucan_dose2|Total of 80 g of the novel alpha glucan + 100 g glucose syrup per day, consumed in 4 individual doses (i.e. 4x45 g, with each dose dissolved in 300 ml of water)
62230641|NCT05142137|ACTIVE_COMPARATOR|glucose syrup|Total of 180 g glucose syrup per day, consumed in 4 individual doses (i.e. 4x45 g, with each dose dissolved in 300 ml of water).
62230642|NCT03226275|EXPERIMENTAL|Fasting: First Bisoprolol-Amlodipine FDC, Then Both Separately|Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 1 in treatment period 1 followed by a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 15 in treatment period 2 under fasting conditions. The two periods were separated by a washout period of 14 days.
62230643|NCT03226275|EXPERIMENTAL|Fasting: First Bisoprolol and Amlodipine Separately, Then FDC|Participants received a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 1 in treatment period 1 followed by a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 15 in treatment period 2 under fasting conditions. The two periods were separated by a washout period of 14 days.
62230644|NCT03226275|EXPERIMENTAL|Fed: First Bisoprolol-Amlodipine FDC, Then Both Separately|Participants received a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 1 in treatment period 1 followed by a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 15 in treatment period 2 under fed conditions. The two periods were separated by a washout period of 14 days.
62230645|NCT03226275|EXPERIMENTAL|Fed: First Bisoprolol and Amlodipine Separately, Then FDC|Participants received a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 1 in treatment period 1 followed by a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 15 in treatment period 2 under fed conditions. The two periods were separated by a washout period of 14 days.
62230646|NCT01838122||Study Arm|This group/cohort will have subjects having infertility due to PCOS (as per Rotterdam criteria)
62230647|NCT01838122||Control arm|This group/cohort will have subjects without PCOS but with any other diagnosis of infertility or any other complain.
62422466|NCT06309615||Standard of Care|Patients with a diagnosis of early-stage invasive breast cancer, post-surgery, in the process of developing a treatment plan. After a period of 2-4 weeks, patient and provider will receive the PreciseDx breast test results with follow up questionnaires to assess change in care path.
62422467|NCT06309615||Standard of Care plus PreciseDx Breast test|Patients with a diagnosis of early-stage invasive breast cancer, post-surgery, in the process of developing a treatment plan. In addition to standard of care the patient and their provider will also receive the results from the PreciseDx breast test. Questionnaires will be utilized to assess impact on decision making and planned care path.
62230648|NCT00344474|EXPERIMENTAL|learning to cope with your impulsivity|cognitive behavioural intervention teaching high impulsive youth how to manage their impulsive thinking and behaviours
62592030|NCT02606006|ACTIVE_COMPARATOR|Non-AAT Group|Inpatients in this group will receive 3-5 brief afternoon physical therapy sessions over 3-5 successive days. None of the sessions will include use of a canine for AAT. This group will include the intervention of Standard of Care Physical Therapy
62592031|NCT02606006|EXPERIMENTAL|AAT Group|Inpatients in this group will receive 3-5 brief afternoon physical therapy sessions over 3-5 successive days. The session on the middle day will include use of a canine for AAT. This group will receive a behavioral intervention of Canine Animal-Assisted Therapy.
62592032|NCT02647970|EXPERIMENTAL|Group A|Dietary intervention
62592033|NCT02647970|ACTIVE_COMPARATOR|Group B|Dietary intervention
62592034|NCT06662461|ACTIVE_COMPARATOR|Ultrasound guided bilateral Greater Occipital nerve Block|
62230649|NCT00344474|EXPERIMENTAL|learning to cope with your sensation seeking|cognitive-behavioural intervention teaching high sensation seeking youth how to manage their need for stimulation and excitement
62230650|NCT00344474|EXPERIMENTAL|learning to cope with your anxiety sensitivity|cognitive behavioural intervention targeting catastrophic thinking in high anxiety sensitive youth
62230651|NCT00344474|EXPERIMENTAL|learning to manage your negative thinking|cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
62230652|NCT01476774|ACTIVE_COMPARATOR|Buprenorphine Transdermal System|
62230653|NCT01476774|ACTIVE_COMPARATOR|Tramadol CR|
62230654|NCT01115296|ACTIVE_COMPARATOR|'L. reuteri DSM 17938 and ATCC PTA 6475|L. reuteri will be delivered at a dose of 1x108 CFU of each strain of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day.
62031230|NCT06476405|EXPERIMENTAL|Group 2 Menthol: Study Product C: Ploom Menthol Flavor|Heated Tobacco Product (HTP) denoted as Ploom PX1.5TN HTP; Menthol HTS (Heated Tobacco Stick); MX3. Test product sourced from Japan Tobacco Inc.
62230655|NCT01115296|PLACEBO_COMPARATOR|Placebo|Placebo
62230656|NCT06189586|ACTIVE_COMPARATOR|Nebulized inhalation group|2 mg budesonide suspension for inhalation, nebulized inhalation for minutes,administered 4 times a day for 5 consecutive days.
62422468|NCT01550068|EXPERIMENTAL|Experimental Arm|Echocardiographic screening
62230657|NCT06189586|ACTIVE_COMPARATOR|Intravenous hormone group|40mg sodium methylprednisolone succinate for injection(dissolved in 0.9% saline or5% glucose injection 50ml), intravenous infusion for 30 minutes, once a day for 5 consecutive days.
62230658|NCT00400985|OTHER|Implantable Device diagnostics|All enrolled subjects were implanted with a device. Audible Device diagnostics turned on or off
62807429|NCT05513352|SHAM_COMPARATOR|Experiment 4 - hearing impaired (sham) - SAT|"The subjects assigned to the hearing impaired group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
62230659|NCT00419666|EXPERIMENTAL|Calcitriol 3mcg/g|Participants receive calcitriol 3 micrograms per gram (mcg/g) ointment applied topically twice daily for 56 days.
62230660|NCT03253926|EXPERIMENTAL|Lorcaserin + Marijuana|
62230661|NCT03253926|PLACEBO_COMPARATOR|Placebo + Marijuana|
62230662|NCT06248970|EXPERIMENTAL|the observation group|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy.Based on this, the patients in the observation group were given enteral nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University).
62230663|NCT06248970|ACTIVE_COMPARATOR|the control group|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy. The patients in the control group were provided nutrition support with Nasogastric tube feeding , while the feeding process strictly followed the relevant guideline
62230664|NCT03360838||CogCheck application|Performance in the application
62230665|NCT04137900|EXPERIMENTAL|TAB004 0.3 mg/kg repeat dose every 21 days up to 2 years|
62230666|NCT04137900|EXPERIMENTAL|TAB004 1 mg/kg repeat dose every 21days up to 2 years|
62230667|NCT04137900|EXPERIMENTAL|TAB004 3 mg/kg repeat dose every 21 days up to 2 years|
62230668|NCT04137900|EXPERIMENTAL|TAB004 10 mg/kg repeat dose every 21 days up to 2 years|
62592035|NCT06662461|ACTIVE_COMPARATOR|Ultrasound guided bilateral Stellate Ganglion Block|
62230669|NCT04137900|EXPERIMENTAL|TAB004 200mg repeat dose every 21 days up to 2 years|
62230670|NCT04137900|EXPERIMENTAL|TAB004 20mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
62230671|NCT04137900|EXPERIMENTAL|TAB004 70mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
62230672|NCT04137900|EXPERIMENTAL|TAB004 200mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
62230673|NCT04137900|EXPERIMENTAL|TAB004 500mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
62422469|NCT01550068|NO_INTERVENTION|Control Arm|No echocardiographic screening
62592036|NCT02992977|EXPERIMENTAL|AutoSynVax™ vaccine|AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant
62807430|NCT05513352|EXPERIMENTAL|Experiment 4 - tinnitus (tACS) - SAT|"The subjects assigned to the tinnitus group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
62807431|NCT05513352|SHAM_COMPARATOR|Experiment 4 - tinnitus (sham) - SAT|"The subjects assigned to the tinnitus group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
62422470|NCT01393626|PLACEBO_COMPARATOR|Placebo BID|
62422471|NCT01393626|EXPERIMENTAL|5mg BID|
62422472|NCT01393626|EXPERIMENTAL|10mg BID|
62807432|NCT05513352|EXPERIMENTAL|Experiment 5 - normal hearing (NF right) - AAT|Each participant of the normal hearing group will undergo the neurofeedback training in which the participants learn to increase alpha power in the right relative to the left parietal cortex. Before and after the NF training, participants will perform the AAT and concurrent EEG will be recorded.
62807433|NCT05513352|ACTIVE_COMPARATOR|Experiment 5 - normal hearing (NF left) - AAT|Each participant of the normal hearing group will undergo the neurofeedback training in which the participants learn to increase alpha power in the left relative to the right parietal cortex. Before and after the NF training, participants will perform the AAT and concurrent EEG will be recorded.
62807434|NCT01582815|EXPERIMENTAL|JNJ-40411813|
62422473|NCT05288374|EXPERIMENTAL|Celecoxib|Celecoxib 100 mg orally will be administered in the day of surgery at 6 in the morning and will be continued regularly at 6 in the morning and 6 in the afternoon for 3 days.
62422474|NCT05288374|PLACEBO_COMPARATOR|Placebo|A placebo pill provided by a hospital pharmacy will be administered in the day of surgery at 6 in the morning and 6 in the afternoon for 3 days.
62422475|NCT03923309||Intended rectal preservation|When rectal preservation (non-operative management or local excision) was agreed by their surgeon.
62422476|NCT03923309||Unintended rectal preservation|When rectal preservation (non-operative management or local excision) was disagreed by their surgeon.
62592037|NCT05874427|EXPERIMENTAL|Multimedia informed consent|Multimedia informed consent with videos to explain transforaminal epidural steroid injection
62592038|NCT05874427|ACTIVE_COMPARATOR|Standard informed consent|A standard consent form to describe the procedure previously used.
62807435|NCT01582815|PLACEBO_COMPARATOR|Placebo|
62807436|NCT02444429|EXPERIMENTAL|Sub-study A experimental arm|"This experimental arm corresponds to patients with borderline infiltrates at 3 months, who will be randomized to receive a treatment for rejection (intensification of the corticotherapy with corticosteroid boluses = Corticosteroid boluses Methylprednisolone )"
62230674|NCT01054846|EXPERIMENTAL|Helmet and helmet education|Each participant preschool child received a free bicycle Bell helmet, manufactured by Bell Sports Inc., Rantoul IL, USA. In addition, classroom bicycle helmet education was provided to all participant children and their caregivers, consisting of a video on rules of biking and the importance of proper helmet use and a classroom melon drop demonstration with and without a helmet to participants and their caregivers.
62230675|NCT01054846|ACTIVE_COMPARATOR|Helmet education|Each child did not receive a bicycle Bell helmet but the child and his/her caregiver was given bicycle helmet education package as above.
62807437|NCT02444429|ACTIVE_COMPARATOR|Sub-study A control arm|"This control arm corresponds to patients with borderline infiltrates at 3 months, who will be randomized to not change their immunosuppressive treatment (No therapeutic modification)"
62807438|NCT02444429|EXPERIMENTAL|Sub-study B experimental arm|This experimental arm corresponds to patients without significant infiltrates 3 months, who will be randomized to stop maintenance corticotherapy (Stop maintenance corticotherapy )
62807439|NCT02444429|ACTIVE_COMPARATOR|Sub-study B control arm|This control arm corresponds to patients without significant infiltrates 3 months, who will be randomized to not change their immunosuppressive treatment (No therapeutic modification)
62230676|NCT03081754||IUGR|Fifty women with intrauterine growth restricted fetuses were included in the study. Gestational age was based on the precisely dated last menstrual period and ultra-sonographic examination of crown-rump length in the first trimester. Intrauterine growth restriction was diagnosed when fetal abdominal circumference was more than two standard deviations below the mean for gestational age and also confirmed by the serial assessment of the fetal growth parameters (Chitty and Altman, 1999). Detailed obstetric history was available for each patient. Caesarean sections were performed on clinical grounds
62807440|NCT00923858||Control - participants from cycles 1 & 2|no intervention. Control group is composed of participants from Cohort I (recruited during our first grant cycle) and from Cohort II (recruited during our second grant cycle). Continued observation is planned for those controls, partial tears and full tears who enrolled in study at age 65 years or younger and have less than 11 years of follow up.
62807441|NCT00923858||Cuff Tear Cohort III|These participants are being recruited from our clinical population and have been scheduled to undergo a standard of care rotator cuff repair and post op therapy. One shoulder has been indicated for rotator cuff repair and the contralateral shoulder is asymptomatic. Both shoulders will be monitored.
62230677|NCT03081754||control group|Twenty five uneventful pregnancies with appropriate for gestational age fetuses are selected as control. Obstetric history Doppler results and placenta were examined for any remarkable pathology. Caesarean sections were performed on clinical grounds. The indications for Caesarean section of the controls, which were tried to be at equivalent gestational ages with the study group, were presentation abnormalities or previous Caesarean section
62230678|NCT00911482||Diabetes/weight loss|12 individuals with type 2 diabetes and hypertriglyceridemia
62230679|NCT00911482||Nondiabetic/hypertriglyceridemic|10 insulin resistant nondiabetic individuals with dyslipidemia
62422477|NCT04308109|NO_INTERVENTION|Control|No intervention, the same as the current state of education. Caregivers will still complete the teaching and post-discharge surveys (QDTS and PDCDS) and be followed for a year after discharge.
62422478|NCT04308109|EXPERIMENTAL|Active study|In addition to the current state of education, the active study group will undergo highly realistic simulation. This involves the use of a highly realistic tracheostomy mannequin and audiovisual devices which will be used to replicate emergent clinical situations. If home invasive ventilation is anticipated, a home ventilator will be used. Caregivers will complete the teaching and post-discharge surveys (QDTS and PDCDS) and be followed for a year after discharge.
62592039|NCT04482075|OTHER|SEGMENTAL STABILISATION TRAINING (SST)|Segmental Stabilisation Training is an established treatment technique for chronic low back pain
62230680|NCT00911482||Normotensive/nondiabetic|10 insulin resistant, normotensive, nondiabetic individuals
62230681|NCT00911482||Insulin resistant/dyslipidemic|14 insulin resistant nondiabetic individuals with dyslipidemia
62592040|NCT06609473|EXPERIMENTAL|CHEF Program|"Enrolled participants and caregivers will complete:~* Baseline visit and survey~* Meeting with a certified benefits counselor by phone or video teleconference~* Kitchen equipment delivery~* Weekly meal kit deliveries~* Monthly grocery support via gift card~* Second meeting with a certified benefits counselor~* 3-month survey~* Final survey and interview with study staff"
62230682|NCT04007185||Control group|30 patients undergoing biopsy for brain tumour. They have the effect of the tumour but not the impact of surgery. Changes in QoL will inform the RCI measures planned
62422479|NCT04308109|ACTIVE_COMPARATOR|Active control|In addition to the current state of education, the active control will undergo low-fidelity simulation that approximates the highly realistic clinical scenarios except with the use of a low-fidelity doll equipped with a tracheostomy and without the audiovisual inputs. If home invasive ventilation is anticipated, a home ventilator will be used. Caregivers still complete the teaching and post-discharge surveys (QDTS and PDCDS) and be followed for a year after discharge.
62592041|NCT04313179|EXPERIMENTAL|Music group|"Deep Sleep music track from Bedtime Mozart: Classical Lullabies for Babies, played through smart phone speakers, at maximum sound up to 45 dB, starting 20 minutes before the heel prick procedure, continuing through the procedure and for 5 minutes after the procedure. Also given 0.5 ml of 24% Sucrose given 2 minutes prior to heel prick procedure for baseline pain relief."
62592042|NCT04313179|PLACEBO_COMPARATOR|Placebo group|0.5 ml of 24% Sucrose given 2 minutes prior to heel prick procedure. No music played.
62592043|NCT05315206|EXPERIMENTAL|Citicoline Treated Group, TC Group|In a group of patients with open angle glaucoma (OAG), Citicoline in oral solution (10 ml / day) will be administered for 12 months (Citicoline Treated Group, TC Group)
62422480|NCT01103401|ACTIVE_COMPARATOR|Tobramycin/Dexamethasone|
62422481|NCT01103401|ACTIVE_COMPARATOR|Tobramycin/Dexamethasone plus Ketorolac tromethamine|
62422482|NCT03473119||Control|Healthy individuals
62807442|NCT04955717|EXPERIMENTAL|Testing and treatment|Participants will receive CT and NG testing and treatment (if necessary) at their first antenatal care visit and a visit during their third trimester. Women will also receive support for partner notification. All women will receive postnatal testing and treatment. Those who test positive at the postnatal visit will be offered infant testing.
62230683|NCT04007185||Surgery Group|The main test group. This group have been determined by their treating surgeon to undergo a resection of the tumour so will be different from the control arm by undergoing a safe, maximal resection of their tumour
62592044|NCT05315206|PLACEBO_COMPARATOR|Placebo Treated Group, TP Group|in another group of patients with open angle glaucoma (OAG) will be administered Placebo (Containing all excipients of Citicoline in oral solution) (10 ml / day) for 12 months (Placebo Treated Group, TP Group)
62592045|NCT05716256|EXPERIMENTAL|Ulinastatin|The experimental groups （Rocuronium-Ulinastatin group and Cisatracurium-Ulinastatin group）received ulinastatin 5000U/kg followed by rocuronium 0.6 mg/kg or cisatracurium 0.1 mg/kg
62230684|NCT06391502|NO_INTERVENTION|Routine exercise group|The routine exercise care group, that is, the control group, will complete the routine exercise care of patients with acute ischemic stroke after venous hemolytic surgery in accordance with the hospital regulations: From 24 hours after surgery, patients with mild and moderate stroke can be turned over in bed (once every 2 hours), ankle pump exercise (three times a day), and transitional bedside rehabilitation exercise (such as walking around the bed, etc.) after no discomfort.
62230685|NCT06391502|EXPERIMENTAL|Multicomponent exercise group|Select the corresponding intervention according to the SPPB score:0-3 scores (Plan A) :1. Walking 2.Relax your hand 3.Lift a bottle 4.Leg extensions with an ankle weight 5.Getting up from a chair with help 6.Holding onto the person who helps you 7.Arm stretching 4-6 scores(Plan B):1. Walking 2.Lift a bottle 3.Squeeze a ball 4.pretend to sit 5.Walking on tip toes and heels 6.Arm stretching in a chair 7.Stretch your arms up with your hands clasped;7-9 scores(Plan C):1.Walking 2.Roll-up a small towel 3.Take two plastic bottles filled with 500ml of water 4.Getting up from a chair 5.Walking over obstacles 6.Walking in a figure of eight 7.Leg stretching sit in a chair 8.Arm stretching;10-12 scores( Plan D):1.Walking 2.Twist a towel 3.Lift a bottle 4.Getting up from a chair 5.Going up and down stairs 6.Walking in a figure of eight 7.Walking while touching a balloon 8.Arm stretching;See details at http://vivifrail.com/
62230686|NCT01648335|ACTIVE_COMPARATOR|immobilization of the shoulder in internal rotation|
62230687|NCT01648335|EXPERIMENTAL|Immobilization of the shoulder in external rotation|
62422483|NCT03473119||Asthma|Asthma acute exacerbations
62422484|NCT03473119||Asthma with CAP|Asthma acute exacerbations with community-acquired pneumonia
62422485|NCT03473119||COPD|Acute exacerbations of chronic obstructive pulmonary disease
62230688|NCT00679627|EXPERIMENTAL|Galantamine|Galantamine 8mg/ day oral capsule increased to 16mg/day then to 24 mg per day
62230689|NCT00679627|PLACEBO_COMPARATOR|Placebo|Matching placeco
62230690|NCT03872570|ACTIVE_COMPARATOR|phenylephrine|starts at 15 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg
62230691|NCT03872570|ACTIVE_COMPARATOR|norepinephrine|starts at 1.5 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg
62230692|NCT00858884|NO_INTERVENTION|No intevention|No intervention
62230693|NCT04975438|EXPERIMENTAL|Group 1: GSK1070806|Participants received a single dose of 2 mg/kg GSK1070806 as intravenous infusion on Day 1.
62230694|NCT04975438|PLACEBO_COMPARATOR|Group 1: Placebo|Participants received Placebo as intravenous infusion on Day 1.
62230695|NCT04975438|EXPERIMENTAL|Group 2: Dupilumab-IR with GSK1070806|Participants received a single dose of 2 mg/kg GSK1070806 as intravenous infusion on Day 1.
62230696|NCT04975438|PLACEBO_COMPARATOR|Group 2: Dupilumab IR with Placebo|Participants received Placebo as intravenous infusion on Day 1.
62422486|NCT03473119||COPD with CAP|Acute exacerbations of chronic obstructive pulmonary disease with community-acquired pneumonia
62422487|NCT03473119||CAP|Community-acquired pneumonia
62422488|NCT03489031||Diabetes Mellitus, Type 1|patients with type 1 diabetes
62422489|NCT03489031||Diabetes Mellitus, Type 2|patients with type 2 diabetes
62592046|NCT05716256|SHAM_COMPARATOR|Conventional treatment group|The control groups（Rocuronium-Saline group and Cisatracurium-Saline group） received normal saline 0.1ml/kg followed by rocuronium 0.6 mg/kg or cisatracurium 0.1 mg/kg
62592047|NCT04494945|OTHER|Screening (genetic testing)|Patients undergo collection of saliva samples for genetic testing. If genetic test is positive, patients receive genetic counseling.
62592048|NCT04401761||CAD/PAD-patients|Adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) who are treated with a combination of rivaroxaban and acetylsalicylic acid.
62422490|NCT01565122||Cohort|
62422491|NCT00549120|EXPERIMENTAL|Propranolol alone|Propranolol 80 mg (5 doses at 6 hourly intervals)
62422492|NCT00549120|EXPERIMENTAL|Propranolol + salbutamol|Propranolol 80 mg (5 doses at 6 hourly intervals) + salbutamol 600 μg (4 doses at 6 hourly intervals)
62422493|NCT00549120|EXPERIMENTAL|Salbutamol alone|Salbutamol 600 μg (4 doses at 6 hourly) + placebo (5 doses at 6 hourly intervals)
62422494|NCT00549120|PLACEBO_COMPARATOR|Placebo|Placebo (5 doses at 6 hourly)
62422495|NCT00549120|EXPERIMENTAL|Propranolol + ipratropium + salbutamol|Propranolol 80 mg (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose)
62422496|NCT00549120|EXPERIMENTAL|Placebo + ipratropium + salbutamol|Placebo (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose)
62592049|NCT02873962|EXPERIMENTAL|Cohort 1: Nivolumab with Bevacizumab|Patients will receive treatment every 14 days with Nivolumab and Bevacizumab administered on day 1 of each cycle.
62592050|NCT02873962|EXPERIMENTAL|Cohort 2: Nivolumab with Bevacizumab and Rucaparib|Patients will receive treatment every 14 days with Nivolumab, Bevacizumab administered on day 1 of each cycle and Rucaparib will be taken orally twice daily on days 1-14 .
62031231|NCT06476405|ACTIVE_COMPARATOR|Group 2 Menthol: Study Product D: UBCC Menthol Flavor|Subject's menthol UBCC (Usual Brand Combustible Cigarette). Reference product supplied by subject.
62031232|NCT04514848|EXPERIMENTAL|Individuals accessing screening for syphilis and HIV|Individuals at risk for syphilis and HIV (e.g. gay and bisexual men, indigenous communities experiencing a resurgence of syphilis, persons who inject drugs, etc) will undergo testing with both POCT and standard laboratory testing. Individuals testing positive for syphilis or HIV on the POCT will be informed that this is a preliminary positive and standard testing will be done. Individuals testing positive for syphilis on POCT may be offered treatment at the time of testing.
62230697|NCT02306486|PLACEBO_COMPARATOR|z250 resin composite|(n=31) Treated with distilled water (placebo) and restored with a methacrylate resin-based-composite (Z250, 3M ESPE, shade: A3)
62230698|NCT02306486|ACTIVE_COMPARATOR|z250 resin composite + oxalic acid|(n=31) treated with 0.5% oxalic acid (Desenssiv, SSWhite)(intervention)// and restored with a methacrylate resin-based-composite (Z250, 3M ESPE, shade: A3)
62230699|NCT02306486|PLACEBO_COMPARATOR|p 90 resin composite|(n=31) Treated with distilled water (placebo) and restored with a silorane resin-based-composite.
62422497|NCT03151967|ACTIVE_COMPARATOR|Applicator with LACTIN-V Treatment|Vaginal applicator containing Lactobacillus crispatus CTV-05
62422498|NCT03151967|PLACEBO_COMPARATOR|Applicator with Placebo|Inactive vaginal applicator without any drug
62422499|NCT01162135|EXPERIMENTAL|Open Label Pilot Study|
62422500|NCT05135286|EXPERIMENTAL|BRIMOCHOL™ PF|A single drop in each eye at a visit.
62230700|NCT02306486|ACTIVE_COMPARATOR|p 90 resin composite + oxalic acid|(n=31) treated with 0,5% oxalic acid (Desenssiv SSWhite)(Intervention)/ and restored with a silorane resin-based-composite (Filtek Silorane p90, £M ESPE, shade:)
62230701|NCT02180022|PLACEBO_COMPARATOR|Placebo|Patients treated with placebo for 12 weeks
62422501|NCT05135286|ACTIVE_COMPARATOR|Carbachol PF|A single drop in each eye at a visit.
62422502|NCT05135286|PLACEBO_COMPARATOR|Vehicle|A single drop in each eye at a visit.
62422503|NCT05527834|EXPERIMENTAL|Cohort 1|Cohort 1 will assess the impact of a high fat meal.
62031233|NCT06552741||Control|Subjects without substance use disorders
62031234|NCT06552741||Patient|Patient with substance use disorders
62031235|NCT00921492|EXPERIMENTAL|Low-frequency electro-acupuncture|
62031236|NCT00921492|ACTIVE_COMPARATOR|Meeting a therapist - attention|
62031237|NCT00263666|EXPERIMENTAL|Rotarix Group|Subjects received 3 doses of Rotarix vaccine co-administered with routine Tritanrix HepB Hib and Polio Sabin vaccines.
62031238|NCT00263666|PLACEBO_COMPARATOR|Placebo Group|Subjects received 3 doses of placebo co-administered with routine Tritanrix HepB Hib and Polio Sabin vaccines.
62031239|NCT05427669|EXPERIMENTAL|mFOLFOXIRI|Patients will receive mFOLFOXIRI chemotherapy once every two weeks for at the most 12 cycles as adjuvant therapy
62031240|NCT05427669|ACTIVE_COMPARATOR|mFOLFOX6|Patients will receive mFOLFOX6 chemotherapy once every two weeks for at the most 12 cycles as adjuvant therapy
62230702|NCT02180022|EXPERIMENTAL|Onion peel extract|Patients treated with onion peel extract for 14 days
62230703|NCT01992042|EXPERIMENTAL|Fluvastatin/Pimonidazole|Patients will take 40mg BID of fluvastatin. The day before surgery patients will take a single dose of pimonidazole that will be calculate based on body surface area.
62230704|NCT01912456|EXPERIMENTAL|Higher-volume placebo, then low-volume C1-esterase inhibitor|A higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.
62422504|NCT05527834|EXPERIMENTAL|Cohort 2|Cohort 2 will be conducted to assess the impact of an alternative lower fat meal if administration with high fat meal has a food effect on drug exposure.
62422505|NCT05527834|EXPERIMENTAL|Cohort 3|Cohort 3 will evaluate realistic fasting intervals and/or additional meal types if administration with food has a food effect on drug exposure.
62422506|NCT06298500||Histoacryl Lapfix|Histoacryl Lapfix - Cannula for laparoscopic mesh fixation in patients undergoing hernia repair surgery
62422507|NCT03069131|EXPERIMENTAL|Active rifaximin|
62422508|NCT03069131|PLACEBO_COMPARATOR|Rifaximin placebo|
62422509|NCT05402865||Denosumab group|patients who had received denosumab
62230705|NCT01912456|EXPERIMENTAL|Low-volume C1-esterase inhibitor, then higher-volume placebo|A low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.
62230706|NCT01912456|EXPERIMENTAL|Low-volume placebo, then higher-volume C1-esterase inhibitor|A low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks then a higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.
62230707|NCT01912456|EXPERIMENTAL|Higher-volume C1-esterase inhibitor, then low-volume placebo|A higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.
62230708|NCT02577757|OTHER|healthy volunteers|achieving functional MRI
62230709|NCT02577757|EXPERIMENTAL|Eligible patients with awakened surgery|achieving functional MRI
62230710|NCT02255266||A|
62230711|NCT00133146|EXPERIMENTAL|Grass MATA MPL|"300 SU/0.5 mL Grass MATA MPL (Visit 2);~800 SU/0.5 mL Grass MATA MPL (Visit 4);~2000 SU/0.5 mL Grass MATA MPL (Visit 6)"
62230712|NCT00133146|ACTIVE_COMPARATOR|Grass MATA|"300 SU/0.5 mL Grass MATA (Visit 2);~800 SU/0.5 mL Grass MATA (Visit 4);~2000 SU/0.5 mL Grass MATA (Visit 6);"
62230713|NCT02373254|ACTIVE_COMPARATOR|Ibuprofen 400 mg|Ibuprofen 400 mg po q 8 hours as needed (PRN) for pain. Subjects will receive Norco, 5/525 mg po q 6 hours PRN if pain relief with Ibuprofen is not sufficient.
62230714|NCT02373254|ACTIVE_COMPARATOR|Ibuprofen 800 mg|Ibuprofen 800 mg po q 8 hours PRN pain. Subjects will receive Norco, 5/525 mg po q 6 hours PRN if pain relief with Ibuprofen is not sufficient.
62230715|NCT02373254|ACTIVE_COMPARATOR|Norco|Norco (acetaminophen/hydrocodone) 10/325 mg po q 6 hours PRN pain. If pain is not relieved, physician should be contacted.
62230716|NCT00604812|EXPERIMENTAL|Panel A Rizatriptan|"Subjects allocated to Panel A and randomized to receive a single dose of rizatriptan 5 mg orally disintegrating tablet (ODT) on Day 1.~Subjects weighing 20-39 kg were allocated to Panel A."
62230717|NCT00604812|PLACEBO_COMPARATOR|Panel A Placebo|"Subjects allocated to Panel A and randomized to receive a single dose of rizatriptan 5 mg orally disintegrating tablet (ODT) placebo on Day 1.~Subjects weighing 20-39 kg were allocated to Panel A."
62230718|NCT00604812|EXPERIMENTAL|Panel B Rizatriptan|"Subjects allocated to Panel B and randomized to receive a single dose of rizatriptan 10 mg orally disintegrating tablet (ODT) on Day 1.~Subjects weighing 40 kg and above were allocated to Panel B."
62230719|NCT00604812|PLACEBO_COMPARATOR|Panel B Placebo|"Subjects allocated to Panel B and randomized to receive a single dose of rizatriptan 10 mg orally disintegrating tablet (ODT) placebo on Day 1.~Subjects weighing 40 kg and above were allocated to Panel B."
62230720|NCT00604812|EXPERIMENTAL|Panel C Rizatriptan|"Subjects allocated to Panel C and randomized to receive a single dose of rizatriptan ODT on Day 1. Subjects in Panel C weighing 20-39 kg received a 5 mg dose and subjects weighing 40 kg and above received a 10 mg dose.~Panel C was added to the study by amendment to increase the number of male subjects in the 12-17 year old age group."
62230721|NCT00604812|PLACEBO_COMPARATOR|Panel C Placebo|"Subjects allocated to Panel C and randomized to receive a single dose of rizatriptan ODT placebo on Day 1. Subjects in Panel C weighing 20-39 kg received a 5 mg placebo dose and subjects weighing 40 kg and above received a 10 mg placebo dose.~Panel C was added to the study by amendment to increase the number of male subjects in the 12-17 year old age group."
62230722|NCT02080312|EXPERIMENTAL|intratympanic injection|Magnevist (gadopentetate dimeglumine, Bayer Health Care) will be diluted eightfold with sterile saline (1:7 v/v) in a 1 ml syringe and injected intra-tympanically with a 23-25g needle up to 0.4 ml or less if contrast reflux is noted under direct visualization. Anesthesia with topical phenol is available for this procedure.
62230723|NCT04413123|EXPERIMENTAL|Cabozantinib|"Eligible patients will be enrolled and receive treatment with~* Cycle 1-4 (cycles of 21 days)~  * Cabozantinib predetermined protocol dosage po daily~ * Nivolumab predetermined protocol dosage via IV every 3 weeks~ * Ipilimumab predetermined protocol dosage via IV every 3 weeks~* After the first four cycles of therapy,~  * Cabozantinib determined protocol dosage po daily~ * Nivolumab predetermined protocol dosage via IV every 3 weeks (cycles of 28 days)"
62230724|NCT03752099|EXPERIMENTAL|VERU-111 4.5mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
62230725|NCT03752099|EXPERIMENTAL|VERU-111 9mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
62230726|NCT03752099|EXPERIMENTAL|VERU-111 18mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
62230727|NCT03752099|EXPERIMENTAL|VERU-111 27mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
62230728|NCT03752099|EXPERIMENTAL|VERU-111 36mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
62230729|NCT03752099|EXPERIMENTAL|VERU-111 45mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
62230730|NCT00572390|PLACEBO_COMPARATOR|1|No oestrogen treatment
62230731|NCT00572390|EXPERIMENTAL|2|Oestrogen treatment
62230732|NCT00875654|NO_INTERVENTION|1|Control group without intervention nor placebo
62230733|NCT00875654|EXPERIMENTAL|2|First dose of stem cells
62230734|NCT00875654|EXPERIMENTAL|3|Second dose of stem cells
62230735|NCT05969054|EXPERIMENTAL|Group A: lacosamide|Subjects who were randomly divided into group A took lacosamide for 6 months during treatment (initial dose was 50mg bid, maintained for one week and then increased to 100mg bid and maintained at this dose)
62230736|NCT05969054|EXPERIMENTAL|Group B: levetiracetam|Subjects randomly divided into group B took levetiracetam for 6 months during treatment (initial dose was 250mg bid, maintained for one week and then increased to 500mg bid and maintained at this dose).
62230737|NCT04290442|ACTIVE_COMPARATOR|Adductor canal block (ACB)|
62230738|NCT04290442|EXPERIMENTAL|Adductor canal block plus SPANK block|
62230739|NCT05902234||Pediatric pain patients and their parents|patients and their parents
62230740|NCT01749605|ACTIVE_COMPARATOR|nitrofurantoin 100 mg|
62230741|NCT01749605|ACTIVE_COMPARATOR|Ciprofloxacin 250 mg|
62230742|NCT03260231|ACTIVE_COMPARATOR|Intervention group|Dietary Supplement: Milled Seed Mix Intervention arm includes milled mix of flax, sesame and pumpkin seeds (18/6/6 g) in sour milk taken as dietary replacement meal during the day, and between lunch and dinner. Seeds are provided with the same producer at the Belgrade market.
62230743|NCT03260231|NO_INTERVENTION|Control group|No supplement Control arm includes nutritional counseling with a similar dietary regime as for the intervention arm, but without milled seed mix. patients were instructed to avoid plant seeds during the study.
62230744|NCT00969878|PLACEBO_COMPARATOR|Placebo injection|TA-CD placebo will be administered intra muscular. A total of 5 injections will be given over 12 weeks (i.e., at Day 1 and at the beginning of Weeks 3, 5, 9 and 13).
62230745|NCT00969878|EXPERIMENTAL|TA-CD Vaccination|TA-CD 400 μg will be administered intramuscular. A total of 5 injections will be given over 12 weeks (i.e., at Day 1 and at the beginning of Weeks 3, 5, 9 and 13).
62230746|NCT02361151|ACTIVE_COMPARATOR|TECH (standard program)|"Receive 3-month healthy eating and physical activity intervention delivered via email newsletters and mobile apps plus self-monitoring with paper records; based on standard behavior change recommendations and materials (e.g., Diabetes Prevention Program)~Intervention: remotely-delivered evidence-based intervention to support healthy eating and physical activity; use of supporting app-based games and activities and self-monitoring."
62230747|NCT02361151|EXPERIMENTAL|TECH+ (enhanced program)|"Receive 3-month family-based healthy eating and physical activity intervention delivered via email newsletters and mobile apps plus self-monitoring with special study website~Intervention: remotely-delivered evidence-based intervention to support healthy eating and physical activity; use of supporting app-based games and activities; enhanced self-monitoring and family activities via special study website"
62230748|NCT05602948|EXPERIMENTAL|'Run, Jump & Fun' intervention|"The Run, jump \& fun intervention consists of four 30 minutes sessions per week for one school year. Activities are mostly conducted as whole class activities. Head of schools and teachers/school pedagogues are involved in an initial intervention establishing process, guided by Active School personnel. The aim is to create a local plan for the intervention tailored to the particular school. Examples are movement band, structured activities during recess with older students (13-15 years olds), etc. Activities are created to be fun, motivating and with moderate to high intensity PA."
62230749|NCT05602948|EXPERIMENTAL|'Move & Learn' intervention|"This intervention is implemented as PA for 30 min in two Mathematics and two Danish lessons each week for one school year. Activities are conducted at whole-class level.~The physical activities in Move \& Learn are closely linked to the Mathematic curriculum and the Danish curriculum. The way the body is integrated in the learning task can vary. Examples are bodily or motor-skill demanding activities or less vigorous activities, e.g. standing up miming, using hand gestures or facial expressions. An important aspect of the interventions is that movements should be task relevant. The intervention is developed based on the embodied learning theory."
62230750|NCT05602948|NO_INTERVENTION|Control|Control schools will continue their usual practice.
62230751|NCT06375421|OTHER|Intervention, then Active Comparator|Participants complete the Intervention (MEMI spaced retrieval) week, followed by the Active Comparator (blocked retrieval) week.
62230752|NCT06375421|OTHER|Active Comparator, then Intervention|Participants complete the Active Comparator (blocked retrieval) week, followed by the Intervention (MEMI spaced retrieval) week.
62230753|NCT05804266|ACTIVE_COMPARATOR|Conventional coagulation of vessels|during study procedure accomplished under CO2-insufflation with the HK using SWIFT COAG E3, 89 W for POEM and SWIFT COAG E4, 124 W for ESD
62230754|NCT05804266|EXPERIMENTAL|Underwater coagulation of vessels|during study procedure carried out in the underwater setting with the HK using SWIFT COAG E3, 89 W for POEM and SWIFT COAG E4, 124 W for ESD
62230755|NCT00473135|EXPERIMENTAL|1|Two subcutaneous vaccinations with rDEN1delta30 into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on Day 120.
62230756|NCT00473135|EXPERIMENTAL|2|Two subcutaneous vaccinations with rDEN1delta30 into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on Day 180.
62230757|NCT00473135|PLACEBO_COMPARATOR|3|Two subcutaneous vaccinations with placebo into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on either Day 120 or 180, depending on arm assignment.
62230758|NCT04143074|OTHER|intervention|multidisciplinary intervention arm - behavioral intervention by physician, dietician, psychologist and physical activity trainer
62422510|NCT05402865||Non-denosumab group|patients who had received anti-GCTB drug therapy other than denosumab, or who did not receive any anti-GCTB medication
62230759|NCT01127139||Czech patients with essential hypertension|Czech hypertensive patients (women and men) with systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg who can be treated with fixed-combination Tarka®.
62230760|NCT04581889||Children|Children from1 to 18 years, enrolled in kindergartens, primary, or secondary school located in city of Tübingen, Germany.
62230761|NCT04581889||Adult comparator|Adults of unknown status of previous SARSCoV-2 infection.
62230762|NCT04581889||Adult validation|Adults who report a history of SARS-CoV-2 infections between 1. February 2020 and the time point of sampling.
62422511|NCT03539848|EXPERIMENTAL|Subjects with mTBI|Individuals who come to the emergency department or urgent/acute care facility with an mTBI will undergo testing with the I-PAS Goggles.
62422512|NCT03539848|ACTIVE_COMPARATOR|Subjects with minor injuries|Individuals who come to the emergency department or urgent/acute care facility with minor injuries (such as ankle sprains or knee sprains) will undergo testing with the I-PAS Goggles.
62422513|NCT04265456|EXPERIMENTAL|1300 mg Acetaminophen and 100 mg IV Pregabalin|The dose for the first cohort will be 1300 mg APAP and 100 mg PGB. For subsequent cohorts, the dose of APAP will remain constant at 1300 mg while the dose of PGB will be varied (will start with 100 mg TID and then based on tolerability will be either increased or decreased by 25 mg based on Safety Monitoring Committee decision).
62422514|NCT04265456|NO_INTERVENTION|Placebo|Saline solution
62422515|NCT04265456|EXPERIMENTAL|1300 mg Acetaminophen and 100 mg +/- 25 IV Pregabalin|Decisions to escalate or decrease the dose for Cohorts 2 through 6 will be dependent upon blinded review of emerging safety and tolerability data by the Safety Monitoring Committee (SMC). However, PK data is not part of the SMC review, but may be reviewed by a SMC designee at a later time.
62422516|NCT04675528|EXPERIMENTAL|Fasting treatment|
62422517|NCT04675528|EXPERIMENTAL|Fed treatment|
62422518|NCT02328404|ACTIVE_COMPARATOR|vitamin D3 (Biodal 50,000 IU)|50,000 IU Vitamin D3 tablet given orally once weekly for 3 months
62422519|NCT02328404|PLACEBO_COMPARATOR|placebo|Placebo tablet given orally once weekly for 3 months
62422520|NCT05760482|EXPERIMENTAL|Bruxism Group|
62422521|NCT05760482|EXPERIMENTAL|Control Group|
62422522|NCT01305135|EXPERIMENTAL|azacitidine 75mg/m²/d + idarubicin 5mg/m²/d|"phase I : palier 1 have 10 patients and palier 2 have to 10 patients.~palier 1: Ida 5mg/m²/d (D8) + AZACITIDINE 75mg/m²/d (D1-D7)"
62592051|NCT02873962|EXPERIMENTAL|Cohort 3: Nivolumab with Bevacizumab and Rucaparib|Patients will receive treatment every 14 days with Nivolumab, Bevacizumab administered on day 1 of each cycle and Rucaparib will be taken orally twice daily on days 1-14 .
62422523|NCT01305135|EXPERIMENTAL|Azacitidine 75mg/m²/d + idarubicin 10mg/m²/d|palier 2: Ida 10mg/m²/d (D8)+ Azacitidine 75mg/m²/d (D1-D7)
62422524|NCT03365973||Spinal metastases of breast cancer|Patients with potentially unstable spinal metastases of breast cancer
62422525|NCT02406742|EXPERIMENTAL|CC-122 Single Agent|An intrasubject dose escalation design was selected to determine the safety of single agent CC-122 (Arm A) in order to reach an optimal, clinically active dose and to mitigate the risk of early tumor flare reactions, based on earlier experience with lenalidomide monotherapy in CLL.
62422526|NCT02406742|EXPERIMENTAL|CC-122 in combination with ibrutinib|Ascending fixed dose cohorts evaluated in a 3 + 3 dose-finding design will be used to determine the safety and tolerability of the combination of CC-122 and ibrutinib to determine the NTD, MTD, and Recommended Phase 2 Dose (RP2D). An intrasubject dose escalation cohort may also be evaluated at the discretion of the Safety Review Committee. The RP2D of the combination may be evaluated in ibrutinib-naïve and high-risk CLL patients in the dose expansion phase to continue to evalute safety and efficacy.
62592052|NCT03886519|ACTIVE_COMPARATOR|BRAP (Bevel/rotate/advance procedure)|The BRAP procedure is a full-thickness beveled full-thickness incision
62592053|NCT03886519|ACTIVE_COMPARATOR|Trabut 3 mm|The Trabut procedure is a partial-thickness incision through the tarsal conjunctiva and tarsus parallel to the eyelid margin and 3 mm above the lash line.
62592054|NCT06666140|EXPERIMENTAL|Group HDC|40 children with diaphragmatic hernia with or without prosthesis (HDC)
62592055|NCT06666140|OTHER|Control Group|40 children free of any diaphragmatic pathology
62230763|NCT02009995|ACTIVE_COMPARATOR|Aerobic Training (AT) only|All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.
62230764|NCT02009995|EXPERIMENTAL|AT plus Primarily Home-Based Resistance Band Training|"Both of the bands + AT groups will engage in RBT 3 times per week, progressing to 3 sets of 8-12 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.~Participants in this group will attend supervised group sessions weekly in weeks 1-4, every 2 weeks in weeks 5-8, and every 4 weeks thereafter to ensure proper form and appropriate progression. Participants in this group will be responsible to complete all remaining sessions (a total of 3 per week, including supervised sessions) at home on their own time."
62230765|NCT00565474|ACTIVE_COMPARATOR|1|fluvastatin 40mg b.i.d.
62230766|NCT00565474|PLACEBO_COMPARATOR|2|Placebo b.i.d.
62230767|NCT05125263|EXPERIMENTAL|group 1|This group receives KinesioTaping along with conventional treatment
62230768|NCT05125263|EXPERIMENTAL|group 2|This group receives mulligan taping along with conventional treatment
62230769|NCT05255367|EXPERIMENTAL|Intake of (poly)phenol rich foods|Daily consumption of 100 ml of a commercial juice of berries and pomegranate, 20 g dark chocolate and 1 green tea, to test if the supplementation of the diet with (poly)phenol rich foods, during 2 months, reduce the cardiometabolic risk in post-post-menopausal women.
62422527|NCT02406742|EXPERIMENTAL|CC-122 in combination with obinutuzumab|Ascending fixed dose cohorts evaluated in a 3 + 3 dose-finding design will be used to determine the safety and tolerability of the combination of CC-122 and obinutuzumab to determine the , MTD, and Recommended Phase 2 Dose (RP2D). An intrasubject dose escalation cohort may also be evaluated at the discretion of the Safety Review Committee.. The RP2D of the combination may be evaluated in CLL patients who failed a B-cell receptor pathway inhibitor or venetoclax in the dose expansion phase to continue to evalute safety and efficacy.
62592056|NCT02523924|EXPERIMENTAL|18F-DCFPyL PET/CT|Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT
62031241|NCT01293448|EXPERIMENTAL|Intervention|CryoBalloon ablation of esophageal tissue in patients scheduled for esophagectomy for reasons unrelated to the objective of the study.
62230770|NCT05596838||Patient operated at Somain institute with the placement of intracorneal rings|patient operated in the last 10 years on one or both eyes
62230771|NCT03754413|EXPERIMENTAL|Investigational medical device|Neuramis® Volume Lidocaine
62230772|NCT03754413|OTHER|Comparator device|No-treatment
62230773|NCT01315951|EXPERIMENTAL|Petroleum Jelly|Every patient will be applying petroleum jelly to the affected areas per protocol.
62230774|NCT06237686|EXPERIMENTAL|one-armed study|
62422528|NCT05988593|PLACEBO_COMPARATOR|placebo drink|
62422529|NCT05988593|EXPERIMENTAL|MelaGene+|
62422530|NCT03147521|EXPERIMENTAL|Accidental falls care bundle|Care Bundle Implementation Arm
62031242|NCT02289300|EXPERIMENTAL|DCB-BO1202|
62031243|NCT02289300|EXPERIMENTAL|DCB-BO1202+Placebo|
62031244|NCT02289300|PLACEBO_COMPARATOR|Placebo|
62031245|NCT02571569|EXPERIMENTAL|Without inhibitors|Dose escalation steps for participants without inhibitors - intravenous infusion and subcutaneous injection
62230775|NCT02472769|ACTIVE_COMPARATOR|IBP-9414|IBP-9414 Oral Daily
62230776|NCT02472769|PLACEBO_COMPARATOR|Placebo|Sterile water
62230777|NCT02654873||Benign|Benign pathology specimens with macroscopically
62230778|NCT02654873||Suspicious|Suspicious group includes the conditions such as increasing of the gallbladder wall thickness, having calcifications or polyps in the gallbladder.
62230779|NCT02654873||Malign|Malign group includes the conditions such as detecting mass or irregularities in the gallbladder wall.
62230780|NCT00516243|EXPERIMENTAL|Arm I (defined green tea catechin extract)|Patients receive defined green tea catechin extract PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
62422531|NCT03147521|ACTIVE_COMPARATOR|Accidental falls standard care|Standard Care Implementation Arm (Universal strategy application for the environmental and patient)
62592057|NCT00796952|ACTIVE_COMPARATOR|Usual Care|"Patient management by the attending Radiation oncologist as usual."
62592058|NCT00796952|EXPERIMENTAL|Pharyngocise|Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their chemo-radiation treatment (up to a maximum of 6 weeks)
62230781|NCT00516243|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
62230782|NCT04017286||depressive disorder group|At 21 weeks of pregnancy, women diagnosed with depressive disorder by the Hamilton depression scale and Beck depression rating scale and their offspring were enrolled.
62592059|NCT00796952|SHAM_COMPARATOR|Valchuff|"Standardised sham swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of chemo-radiation treatment."
62422532|NCT03888092|EXPERIMENTAL|Z650 , Single-arm|Z650 will be administered daily, at dose of 350 mg orally
62422533|NCT03986918||Ovation and Ovation Tribute|All patients having undergone a total hip arthroplasty that received the Ovation® or Ovation Tribute® (Ortho Development, Draper, Utah) Hip system will be sent the survey.
62422534|NCT02147262|ACTIVE_COMPARATOR|ACA-doxy 14 days|patients with chronic atrophic acrodermatitis treated with doxycycline for 14 days
62422535|NCT02147262|ACTIVE_COMPARATOR|ACA-doxy 28 days|patients with chronic atrophic acrodermatitis treated with doxycycline for 28 days
62422536|NCT03432026||Non-smoker COPD patients|stable non-smoker COPD patients diagnosed by a previous spiromtery to have FEV1/FVC less than 70
62422537|NCT06232759|EXPERIMENTAL|Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab|Patients with unresectable hepatocellular carcinoma were received transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab
62422538|NCT05380882|EXPERIMENTAL|TQB2930 injection|Drug:Weekly intravenous infusion of TQB2930 injection,21 days as a treatment cycle. (2.5mg/kg, 5mg/kg, 10mg/kg) Drug:Every two weeks intravenous infusion of TQB2930 injection , 28 days as a treatment cycle.(20mg/kg) Drug:Every three weeks intravenous infusion of TQB2930 injection, 21 days as a treatment cycle. (30mg/kg)
62422539|NCT05513430||controlled hypertension|Controlled hypertension was defined as systolic blood pressure (SBP) ≤139 mmHg and/or diastolic blood pressure (DBP)≤89 mmHg for non-diabetic patients, and as SBP ≤139 mmHg and/or DBP ≤84 mmHg for diabetic patients, based on the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) guidelines. observational study
62592060|NCT01746420|PLACEBO_COMPARATOR|Placebo Control|Dose A - sodium acetate buffer (0 mg rhPDGF-BB)
62592061|NCT01746420|EXPERIMENTAL|0.45 mg rhPDGF-BB|Dose B - sodium acetate buffer + 0.45 mg rhPDGF-BB
62592062|NCT01746420|EXPERIMENTAL|0.75 mg rhPDGF-BB|Dose C - sodium acetate buffer + 0.75 mg rhPDGF-BB
62592063|NCT01746420|EXPERIMENTAL|1.5 mg rhPDGF-BB|Dose D - sodium acetate buffer + 1.5 mg rhPDGF-BB
62592064|NCT01746420|EXPERIMENTAL|3.0 mg rhPDGF-BB|Dose E - sodium acetate buffer + 3.0 mg rhPDGF-BB
62031246|NCT02571569|EXPERIMENTAL|With inhibitors|Dose escalation steps for participants with inhibitors - intravenous infusion and subcutaneous injection
62031247|NCT02571569|EXPERIMENTAL|Without inhibitors_multiple dose|Multiple dose cohort for participants without inhibitors - a single subcutaneous injection once a week for 6 weeks
62031248|NCT01212367|EXPERIMENTAL|Dose Level 1|
62031249|NCT01212367|EXPERIMENTAL|Dose Level 2|This is a dose de escalation.
62031250|NCT05607693|EXPERIMENTAL|SHR3680|
62031251|NCT05924152|ACTIVE_COMPARATOR|Treatment A|Treatment A: A single oral dose of adagrasib 400 mg (2 × 200-mg tablets) on Day 1;
62230783|NCT04017286||Nutrient-deficient group|Nutrients (Vitamin A,D,E) were tested at 21 weeks of pregnancy, and pregnant women with one or more nutrient deficiencies or insufficiency and their offspring were enrolled.
62230784|NCT04017286||depressive disorder and nutrient deficiency group|At 21 weeks of pregnancy, pregnant women with depressive disorder and nutrient deficiency or insufficiency and their offspring were enrolled.
62230785|NCT04017286||Neither group|At 21 weeks of pregnancy, pregnant women without depressive disorder and nutrient deficiency or insufficiency and their offspring were enrolled.
62230786|NCT03151096|EXPERIMENTAL|treatment arm|5mg Riboflavin pills
62230787|NCT03151096|PLACEBO_COMPARATOR|Placebo arm|Placebo pills
62422540|NCT05513430||uncontrolled hypertensive patients.|Individuals who had blood pressure levels above these values were defined as uncontrolled hypertensive patients.
62422541|NCT00414986|EXPERIMENTAL|1|Practice in this arm will receive the Chronic Care Improvement intervention
62592065|NCT01665885|ACTIVE_COMPARATOR|Endovascular cooling|Endovascular cooling using the cooling device ZOLL Thermogard XP with ZOLL Quattro cooling catheter
62592066|NCT01665885|ACTIVE_COMPARATOR|Surface cooling|Surface cooling using the cooling device BARD/Medivance Arctic Sun 5000 with BARD/Medivance Arctic Gel Pads
62592067|NCT01665885|NO_INTERVENTION|Control group|Best medical treatment following international stroke guidelines
62592068|NCT03408470|EXPERIMENTAL|TD-1473 Oral Capsule & [14C]-TD-1473 IV bolus|Cohort 1 - One oral dose and IV bolus administered 1 hr after oral dose of TD-1473
62592069|NCT03408470|EXPERIMENTAL|[14C]-TD-1473 Oral Capsule|Cohort 2 - One oral dose
62592070|NCT02441127|EXPERIMENTAL|Diode laser group|In the test sites, an aluminum, gallium, and arsenide diode laser (wavelength 810 nm and power of 1W) was applied in continuous mode.
62031252|NCT05924152|ACTIVE_COMPARATOR|Treatment B|"Treatment B: A single oral dose of eltrombopag 75 mg~(1 × 75-mg tablet) plus adagrasib 400 mg (2 × 200-mg tablets) on Day 8."
62031253|NCT02979262|EXPERIMENTAL|Fathers for Change|Fathers for Change treatment begins with individual-focused sessions followed by co-parenting focused sessions and ending with restorative parenting sessions. The areas of focus for each of the three phases of Fathers for Change are: 1) abstinence from SA and violence; 2) co-parenting; 3) parenting/father-child relationship. Treatment begins with motivational enhancement by focusing the role of men as fathers to their young children, child development and the impact of violence and SA on parenting, and the father's own childhood experiences of SA and violence to highlight the multigenerational nature of these problems. The program then focuses on skills training in the following areas: reducing automatic hostile cognitions and increasing emotion regulation skills, 2) communication and problem solving around co-parenting, and 3) restorative parenting.
62230788|NCT03569657|OTHER|A positive psychology workshop|The group intervention implements a manualized treatment protocol outlining the content of each of the four 90 minute sessions. The sessions will include topics such as mindfulness, self-compassion, gratitude and forgiveness, grief and growth, utilizing one's strengths, and resilience; with each session including homework exercises to be practiced between sessions. To assess the outcome measures, participants complete a baseline survey, a survey after the second session (2 weeks), a survey after the final session (4 weeks), and a follow-up survey 3 months after the workshop has ended (4 months).
62230789|NCT00081770|EXPERIMENTAL|PegIntron 1.5 ug/kg/wk plus REBETOL|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up
62230790|NCT00081770|EXPERIMENTAL|PegIntron 1.0 ug/kg/wk plus REBETOL|PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up
62230791|NCT00081770|ACTIVE_COMPARATOR|PEGASYS 180 ug/wk Plus COPEGUS|PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up
62230792|NCT02938533|NO_INTERVENTION|Standard of Care|Standard HIV primary care services available at HIV care and treatment clinics in Tanzania.
62422542|NCT00414986|EXPERIMENTAL|2|Practices in this arm will receive the standard CQI intervention. An in-practice CQI coordinator will assist the practices in implement a chronic disease registry.
62230793|NCT02938533|EXPERIMENTAL|Behavioral Intervention Using Social Norms and Priming|Patients in this arm may have been exposed to the behavioral intervention, which included the following components: 1) visual feedback about clinic-level retention in care through an interactive poster; 2) a self-relevant priming image that appeared on all components; and 3) a take-home item (i.e., pillbox or calendar) with the priming image.
62230794|NCT04182594|EXPERIMENTAL|Degarelix|GnRH Antagonist
62031254|NCT02979262|ACTIVE_COMPARATOR|Parent Education (PE)|PE is an individual intervention.PE was developed to represent parent education and support that is typically available to parents with substance use problems who are at high risk for neglecting their children. Fathers enrolled in PE will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs (e.g., health care, child care, housing and education). The PE counselor will provide a choice of pamphlets on age-related parenting topics each week from a series of pamphlets designed for work with substance abusing parents. Sample pamphlet topics include routines and rituals, ages and milestones, alternatives to spanking, and nutrition and fitness.
62031255|NCT00605800||1|normal healthy volunteers
62031256|NCT00605800||2|Patients undergoing major liver resections
62031257|NCT04328844|EXPERIMENTAL|Group 1: Cutaneous Melanoma|IOA-244 in combination with avelumab
62031258|NCT04328844|EXPERIMENTAL|Group 2: Uveal Melanoma|IOA-244 as monotherapy
62230795|NCT04182594|ACTIVE_COMPARATOR|GnRH-agonist|GnRH Agonist
62230796|NCT02583139|EXPERIMENTAL|Music Narrative Group|Prescribed medical/chemotherapy treatment plus standard care + Designed Music Narratives
62230797|NCT02583139|NO_INTERVENTION|Control Group|Prescribed medical/chemotherapy treatment plus standard care
62230798|NCT04329832|EXPERIMENTAL|Hydroxychloroquine|
62230799|NCT04329832|ACTIVE_COMPARATOR|Azithromycin|
62422543|NCT00414986|ACTIVE_COMPARATOR|3|Practice in this arm will have access to all chronic care tools, but will not have an in-practice change agent.
62422544|NCT00554177|EXPERIMENTAL|1|Medicane (mifepristone)
62422545|NCT00554177|PLACEBO_COMPARATOR|2|Placebo
62592071|NCT02441127|ACTIVE_COMPARATOR|Scalpel control group|The surgical technique used in the control group was a FGG harvested by two horizontal and two vertical incisions by scalpel defining the area to be harvested .
62592072|NCT01594190|ACTIVE_COMPARATOR|Low Dose Training|15 minutes/day on a weight-bearing treadmill
62592073|NCT01594190|ACTIVE_COMPARATOR|High Dose Training|2x 30 minutes/day on a weight-bearing treadmill
62422546|NCT05090085|ACTIVE_COMPARATOR|3M Adper Single Bond2|O.I. will clean the labial surface of the tooth with polishing paste and brush Roughening of the surface may be needed by the diamond point The tooth will be isolated by a rubber dam. Apply etchant for 30 s for enamel and 15 s for dentin. Rinse thoroughly with water for 15 s. blot-drying with paper tissue was carefully performed leaving the dentin surface slightly moist. Active application of consecutive coats of the adhesive for 15 s. Gently air for 5 s. Light cure for 10 s. Composite build ups (Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA) were performed in increments and individually light-cured for 20 s. Light curing of all resin materials was performed using (3M Elipar Curing Light) delivering 1100 mW/cm2.
62230800|NCT01551160|EXPERIMENTAL|Medical Emergency Team|A communication and team-working initiative
62243170|NCT04194853|ACTIVE_COMPARATOR|Quadriceps exercises without EMG Biofeedback|Hot Pack will be applied before session for general relaxation 10 minutes. In the control group, the active electrode will not be connected, so subjects will not receive any feedback from the device. Knee isometrics perform with 5 seconds hold. Then, the muscle will be relaxed for 10 seconds and the cycle repeated for a total of 15 minutes. (20 reps, 3 sets)Session will be performed thrice a week for six weeks.
62031259|NCT04328844|EXPERIMENTAL|Group 3: Myelofibrosis|IOA-244 in combination with ruxolitinib
62422547|NCT05090085|EXPERIMENTAL|DMSO application before 3M Adper Single Bond2, etch and rinse adhesive|The same steps of the comparator group with an additional step, after dentin etching and humidity control, dentin pretreatments were performed consisting of active application of 10% DMSO/H2O (OT Primer, OT Dent) solutions on etched-dentin for 1 minute followed by 20 seconds of air drying then apply adhesive.
62422548|NCT01233128||polypoidal choroidal vasculopathy|patients who were treated for polypoidal choroidal vasculopathy with intravitreal injections of 0.5 mg of ranibizumab monthly for 3 months
62422549|NCT02428231|ACTIVE_COMPARATOR|Standard Treatment (One-Week Titration)|120 mg DMF twice daily for 1 week, then 240 mg (as 2 120-mg capsules) DMF twice daily for 11 weeks
62422550|NCT02428231|EXPERIMENTAL|Slow Up-Titration (Six-Week Titration)|120 mg DMF once daily (morning dose) and placebo once daily (evening dose) for 2 weeks, then 120 mg DMF twice daily for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF in the morning and 120 mg in the evening for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF twice daily for 6 weeks
62422551|NCT06406231|ACTIVE_COMPARATOR|Group 1: Patients treated with transcutaneous electrical nerve stimulation (TENS)|
62422552|NCT06406231|ACTIVE_COMPARATOR|Group 2: Patients treated with magnetotherapy (PEMF)|
62807443|NCT04955717|NO_INTERVENTION|Standard of care|Participants will receive the standard of care for STI management, which is treatment based on signs and symptoms. Women will also receive support for partner notification. All women will receive postnatal testing and treatment. Those who test positive at the postnatal visit will be offered infant testing.
62422553|NCT00057785|EXPERIMENTAL|IMRT +/- chemotherapy|Intensity modulated radiation therapy (IMRT) for all patients and chemotherapy (cisplatin and fluorouracil) for patients with stage ≥ T2b and/or N+
62422554|NCT03654365|ACTIVE_COMPARATOR|Control|Pts in the control arm receive usual care. Usual care includes a EHR based reminder of single HCV testing for patients who are in the birth cohort. (routine alerting)
62422555|NCT03654365|EXPERIMENTAL|Intervention|Pts in the intervention arm receive bulk messaging and bulk ordering of the HCV ab test.
62422556|NCT01270607|EXPERIMENTAL|Acupuncture|
62422557|NCT04931134|EXPERIMENTAL|Active stimulation|"Active or sham TNS treatment will be performed at the patients' home for approximately 8 hours per night 7 days a week for 8 consecutive weeks.~Trigeminal nerve stimulation will occur by placement of electrodes (1.25 silver electrodes Bio-Flex BF4, Biotens/Vermed, Buffalo, NY, USA) bilaterally on the V1 branches of the trigeminal nerve (CNV) located on the forehead. Current will be generated from the EMS 7500 stimulator (TENS Products, Inc., Granby, CO) (Class II medical device) and will be set to a level that is clearly perceptible by each patient (i.e. tingling sensation) but not uncomfortable or painful. Current level will be determined for each patient at baseline and will likely be between 4-6 mA. Active stimulation will occur at 120 Hz with a 250 µs pulse width and with a duty cycle of 30 seconds on to 30 seconds off."
62422558|NCT04931134|SHAM_COMPARATOR|Sham stimulation|"Active or sham TNS treatment will be performed at the patients' home for approximately 8 hours per night 7 days a week for 8 consecutive weeks.~Sham stimulation will occur by placement of electrodes (1.25 silver electrodes Bio-Flex BF4, Biotens/Vermed, Buffalo, NY, USA) bilaterally on the V1 branches of the trigeminal nerve (CNV) located on the forehead. Current will be generated from the EMS 7500 stimulator (TENS Products, Inc., Granby, CO) (Class II medical device) and will be set to a level that is clearly perceptible by each patient (i.e. tingling sensation) but not uncomfortable or painful. Current level will be determined for each patient at baseline and will likely be between 4-6 mA. Sham stimulation will use the same parameters of active stimulation, but after 60 seconds the stimulator will turn off."
62592074|NCT06649240|EXPERIMENTAL|Intensive group|Target LDL-cholesterol \<70 mg/dL
62592075|NCT06649240|ACTIVE_COMPARATOR|Standard group|Target LDL-cholesterol 90-110 mg/dL
62592076|NCT03092765|EXPERIMENTAL|low-dose, high-frequency E6011; high-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively higher frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
62807444|NCT04825301||training cohort|data collection
62807445|NCT04825301||validation cohort|data collection
62807446|NCT03137992|EXPERIMENTAL|Test Product (tiotropium bromide inhalation powder)|Once daily administration of test product (tiotropium bromide inhalation powder), 18 mcg for open-label extension (device robustness).
62807447|NCT03137992|ACTIVE_COMPARATOR|Reference Product (Spiriva®)|Single dose of reference product (Spiriva®) 18 mcg
62230801|NCT04105309|EXPERIMENTAL|Implementation Intention (IMP)|"Following review of a psychoeducational packet regarding making changes for weight loss, all participants were assigned five dietary goals (e.g. avoiding high-fat foods, eating five servings of fruits and vegetables a day) and a goal to weight daily. Participants in the IMP condition formed an implementation intention for each of the goals at the baseline session. Two examples of implementation intentions were provided for each goal as a model. Participants thought about how they would best be able to achieve the outlined goals in their life on a daily basis (goal-aligned behavior), as well as when, where, and how they would initiate these new behaviors (retrieval cue). Participants then created and wrote down a unique implementation intention for each of the goals using the sentence structure If/When I _______, then I will ______. No repetitions or combinations of implementation intentions were allowed for standardization across participants."
62807448|NCT03137992|PLACEBO_COMPARATOR|Placebo|Single dose of placebo inhalation powder
62031260|NCT04328844|EXPERIMENTAL|Group 4: Mesothelioma|IOA-244 in combination with pemetrexed/cisplatin/avelumab
62230802|NCT04105309|EXPERIMENTAL|Enhanced Implementation Intention (IMP+)|Participants completed all tasks of the IMP group and additionally, individuals in the IMP+ condition received fluency training and text message reminders. Fluency training occurred weekly using an online survey tool. On fluency training days, participants received a survey link via email, which consisted of six multiple-choice questions for participant's unique implementation intentions. Participants had to correctly identify their matching goal-aligned behavior among three distractor behaviors as quickly as possible and were given corrective feedback if they chose incorrectly. Text messages containing all six implementation intentions as well as goal reminders that were obtained by asking participants to write down their reasons for wanting to lose weight were sent on four days each week of the intervention (16 days total). At baseline, participants chose how text messages were bundled and when they were sent. Text schedules stayed constant across the study.
62807449|NCT05936489|OTHER|LNZ101|Aceclidine 1.75% / Brimonidine combination (non-preserved) ophthalmic solution
62031261|NCT04328844|EXPERIMENTAL|Group 5: NSCLC 1st line|IOA-244 in combination with pemetrexed/cisplatin/avelumab
62031262|NCT04328844|EXPERIMENTAL|Group 6: NSCLC 2nd/3rd line|IOA-244 in combination with avelumab
62031263|NCT04328844|EXPERIMENTAL|Group 7: NHL-FL and NHL-PTCL|IOA-244 as monotherapy
62031264|NCT06373094|EXPERIMENTAL|Group 1|Single dose of 34 mg Donepezil Dihydroxynaphthalate for Injection.
62230803|NCT04105309|ACTIVE_COMPARATOR|Goal Intentions (GOL)|Participants in the GOL condition were assigned the five dietary goals and the daily weighing goal. No additional intervention was given.
62422559|NCT02543164|OTHER|REFERENCE: white bread|Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
62422560|NCT02543164|OTHER|TEST: b-glucan enriched bread|Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
62422561|NCT00705796|EXPERIMENTAL|Group 1|Group 1 will be treated with MPP10, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
62422562|NCT00705796|ACTIVE_COMPARATOR|Group 2|Group 2 will be treated with AndroGel® 50 mg, once daily in the morning after washing/showering.
62422563|NCT05073263|ACTIVE_COMPARATOR|Partial weight -bearing for the first six weeks after surgery|Partial weightbearing will be defined as 40% of the patient's body weight.
62422564|NCT05073263|EXPERIMENTAL|Full weight -bearing for the first six weeks after surgery|If the patient is randomized to the full weightbearing group, the patient will be instructed about acceptable exercises and activities.
62031265|NCT06373094|EXPERIMENTAL|Group 2|Single dose of 68 mg Donepezil Dihydroxynaphthalate for Injection.
62422565|NCT02729545|EXPERIMENTAL|Tung's acupuncture|The Tung's acupuncture group received acupuncture treatments twice per week for 12 weeks. The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).
62592077|NCT03092765|EXPERIMENTAL|low-dose, high-frequency E6011; low-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively higher frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
62807450|NCT05936489|OTHER|LNZ100|Aceclidine 1.75% (non-preserved) ophthalmic solution
62807451|NCT02055326|EXPERIMENTAL|Yoga|One-hour sessions of twice weekly yoga for 8 weeks.
62807452|NCT02055326|ACTIVE_COMPARATOR|Health & Wellness|8 week program of health \& wellness classes, materials and handouts. Topics included healthy eating, cancer prevention and cardiovascular disease prevention.
62807453|NCT06352580||Parents|It was aimed for the parents of pediatric patients to fill out the survey consisting of 26 questions. The questions were about the Covid-19 Pandemic, Covid-19 vaccines and their approach to their children's dental treatment during the Covid-19 Pandemic.
62031266|NCT06373094|EXPERIMENTAL|Group 3|Single dose of 136 mg Donepezil Dihydroxynaphthalate for Injection.
62031267|NCT06373094|EXPERIMENTAL|Group 4|Single dose of 204 mg Donepezil Dihydroxynaphthalate for Injection.
62031268|NCT06373094|EXPERIMENTAL|Group 5|Single dose of 306 mg Donepezil Dihydroxynaphthalate for Injection.
62031269|NCT06373094|EXPERIMENTAL|Group 6|Single dose of 408 mg Donepezil Dihydroxynaphthalate for Injection.
62807454|NCT02721875|EXPERIMENTAL|Volasertib monotherapy|
62807455|NCT02721875|EXPERIMENTAL|Volasertib + azacitidine combination|
62807456|NCT03826108||Cases|Patient who underwent a primary hip (total or partial) or knee arthroplasty and developed a PJI that was culture-confirmed for SA during the first year after the procedure.
62807457|NCT03826108||Controls|Patient who underwent a primary hip or knee arthroplasty and did not develop any type of PJI during the first year after the procedure.
62422566|NCT02729545|ACTIVE_COMPARATOR|CPA/EE|Cyproterone acetate/ethinylestradiol (CPA/EE) was taken orally one tablet per day from the 8th day of menstrual cycle or any day for patients with amenorrhea. The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
62422567|NCT00140101|EXPERIMENTAL|1|ZoMaxx™ Drug-Eluting Stent System
62807458|NCT01105910|EXPERIMENTAL|Systane Ultra|Systane Ultra Lubricant Eye Drops
62807459|NCT01105910|ACTIVE_COMPARATOR|Sensitive Eyes|Sensitive Eyes Eye Drops (Bausch \& Lomb)
62807460|NCT03749759|EXPERIMENTAL|Biofeedback measurement|A Biofeedback measurement will be done during cataract surgery of both eyes
62807461|NCT04018053|EXPERIMENTAL|18F-fluciclovine|"* 18F-fluciclovine will be administered via slow push over 10 seconds through a peripheral intravenous line~* Immediately after the injection of the radiopharmaceutical, dynamic PET/CT images of the pelvis will be obtained for 15 minutes~* Subsequently, PET/CT images will be obtained from the pelvis to the base of skull."
62807462|NCT02051452|EXPERIMENTAL|Methylphenidate|Methylphenidate
62422568|NCT00140101|ACTIVE_COMPARATOR|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
62422569|NCT02102022|EXPERIMENTAL|ADI-PEG 20 plus modified FOLFOX6|"Dose: 36 mg/m2 given weekly~Route of Administration: Intramuscular (IM)~In combination with modified FOLFOX6, every 2 weeks, intravenous (IV) / IV bolus"
62807463|NCT02051452|PLACEBO_COMPARATOR|placebo|Saline
62031270|NCT04251000|EXPERIMENTAL|Joovv Pilot Experimenta Arm|Individuals will receive 90 day access to the Joovv infrared mini light device.
62422570|NCT04536467|OTHER|Goserelin arm|3.6 mg subcutaneous injection in the abdominal wall every 4 weeks (28 ± 3 days) plus standard chemotherapy at start of regimen for 3 months
62422571|NCT04536467|OTHER|control Arm|Standard chemotherapy
62807464|NCT02870777|EXPERIMENTAL|MRD-directed therapy|
62422572|NCT06518720|EXPERIMENTAL|Psilocybin (25 mg)|One capsule of psilocybin 25 mg will be taken orally with a glass of water.
62807465|NCT02375659||Focus group|Each focus group (4 total) will be approximately 90 minutes in duration. A trained facilitator will pose 8 scripted questions to the focus group participants and manage the conversation, ensuring all participants have an opportunity to respond and steering the conversation to remain on task. A note-taker will also be present at the focus group to document via handwritten notes the flow and content of the focus group conversation. All focus groups will be audio taped and transcribed.
62807466|NCT03892616|EXPERIMENTAL|A - B - C|
62807467|NCT03892616|EXPERIMENTAL|D - A - B|
62807468|NCT03892616|EXPERIMENTAL|E - B - A|
62807469|NCT03892616|EXPERIMENTAL|C - A - D|
62807470|NCT03892616|EXPERIMENTAL|A - E - C|
62807471|NCT03892616|EXPERIMENTAL|E - D - A|
62807472|NCT03892616|EXPERIMENTAL|B - C - D|
62422573|NCT03895307|EXPERIMENTAL|kinesio taping|two 15 cm I type kinesio tape applied longitudinally
62807473|NCT03892616|EXPERIMENTAL|C - E - B|
62807474|NCT03892616|EXPERIMENTAL|B - D - E|
62807475|NCT03892616|EXPERIMENTAL|D - C - E|
62807476|NCT03892616|EXPERIMENTAL|C - B - A|
62807477|NCT03892616|EXPERIMENTAL|A - E - D|
62807478|NCT00099372||Abdominal Sacral Colpopexy with no Burch colposuspension|Participants had an Abdominal Sacral Colpopexy without Burch colposuspension for treatment of pelvic organ prolapse
62807479|NCT00099372||Abdominal Sacral Colpopexy with Burch Colposuspension|Participants had an Abdominal Sacral Colpopexy with Burch colposuspension for treatment of pelvic organ prolapse
62807480|NCT02349633|EXPERIMENTAL|Cohort 1|Cohort 1 will be initiated (current dose 200 mg)
62807481|NCT02349633|EXPERIMENTAL|Cohort 2A|Cohort 2A will evaluate PF-06747775 200 mg by mouth (PO) daily (QD) in combination with palbociclib continuous PO QD dosing in 21-day cycles. The starting dose (DL1) for palbociclib will be 100 mg PO daily. Dose finding will follow mTPI method with adjustments using DLT rate.
62807482|NCT02349633|EXPERIMENTAL|Cohort 2B|Cohort 2B will be initiated once the RP2D of the PF-06747775 and palbociclib combination is determined.
62807483|NCT02349633|EXPERIMENTAL|Cohort 3|Cohort 3 combination is PF-06747775 200 mg PO QD and avelumab 10 mg/kg IV Q2W in 28-day (4-week) cycles. Dose finding will follow the mTPI design. Once RP2D of PF-06747775 in combination with avelumab is determined, the Dose Expansion Phase will be opened.
62031271|NCT01874223||IPF-diagnosed patients|A group of up to 40 patients with a diagnosis of mild to severe IPF per American Thoracic Society (ATS) guidelines, either with no cough at baseline to severe cough at baseline, will be followed for at least a one-time assessment and every six months for up to 18 months to establish validity, responsiveness, and reliability of cough, dyspnea, and QOL instruments in patients with IPF.
62031272|NCT05222191|ACTIVE_COMPARATOR|Spironolactone + Placebo|Subjects with stage 3B/4 chronic kidney disease and poorly controlled hypertension will be randomized into two groups: one receiving spironolactone and placebo and one receiving spironolactone and chlorthalidone. At randomization, subjects will begin at 25 mg spironolactone and 6.25 mg placebo/chlorthalidone daily.
62422574|NCT03895307|PLACEBO_COMPARATOR|sham kinesio taping|two 15 cm I type kinesio tape applied longitudinally but without stretching
62422575|NCT03895307|EXPERIMENTAL|local anesthetic|18-20 cc %0.5 lidocaine subcutaneous injection
62807484|NCT04736914|EXPERIMENTAL|Zanubrutinib+R-CHOP/R-DHAOx|"Induction:~Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~ASCT conditioning~Maintenance:~* Zanubrutinib, 160mg PO BID, continuously for 2 year~* Zanubrutinib maintenance will start after regeneration of peripheral blood count after the end of the last cycle of induction therapy or ASCT~Requirements for start of maintenance:~* ANC ≥ 1,000 cells/mm³ (1.0 X 109/L);~* Platelets ≥ 50,000 cells/mm³ (50 X 109/L);"
62230804|NCT02976454|EXPERIMENTAL|Guided Self-Help Obesity Treatment|Guided Self-Help obesity treatment will include 14 meetings over 6 months to mimic the structure of the proposed Medicare funding for obesity treatment for adults. These meetings will include a single one-hour meeting and 13 twenty-minute meetings that occur in the clinic. During this time, the health coach will assess patient/parent readiness to engage in behavior change, assess barriers and facilitators to behavior change, engage in behavior change and problem solving, and provide feedback and accountability.
62230805|NCT02976454|ACTIVE_COMPARATOR|Family-based behavioral obesity treatment|The active control group will receive usual care, i.e. PCP provides obesity management using decision support tools in the electronic health record and refers to a tertiary care program at the academic center. This program is the traditional family-based behavioral weight control program which consists of 20 one-hour, group-based sessions over 6 months.
62422576|NCT03895307|PLACEBO_COMPARATOR|local serum physiologic|18-20 cc % 0.09 NaCl subcutaneous injection
62422577|NCT05675072|EXPERIMENTAL|FB2001 group|FB2001 will be administered by nebulized inhalation, plus Standard Of Care(SOC)
62422578|NCT05675072|PLACEBO_COMPARATOR|Placebo group|Placebo will be administered by nebulized inhalation, plus Standard Of Care(SOC)
62031273|NCT05222191|EXPERIMENTAL|Spironolactone + Chlorthalidone|Subjects with stage 3B/4 chronic kidney disease and poorly controlled hypertension will be randomized into two groups: one receiving spironolactone and placebo and one receiving spironolactone and chlorthalidone. At randomization, subjects will begin at 25 mg spironolactone and 6.25 mg placebo/chlorthalidone daily.
62031274|NCT06185660||Chronic Kidney Disease patients not on dialysis|Chronic Kidney Disease patients not on dialysis
62422579|NCT05386238|EXPERIMENTAL|Tailored treatment|6-months of group-based behavioral weight loss treatment tailored to men working in blue-collar occupations.
62422580|NCT05386238|ACTIVE_COMPARATOR|Standard of care treatment|6-months of group-based behavioral weight loss treatment following the Diabetes Prevention Program Group Lifestyle balance.
62031275|NCT06185660||Chronic Disease Patients on dialysis|Chronic Disease Patients on dialysis
62422581|NCT00765999|EXPERIMENTAL|Linaclotide|Linaclotide 290 μg/day capsules, administered orally once daily for up to 78 weeks in participants with either CC or IBS-C. Dose reduction to 145 μg/day was permitted at the discretion of the Investigator if a participant experienced AEs intolerable enough to prompt consideration of study withdrawal. After a temporary suspension of dosing, participants may have received either 145 μg/day or 290 μg/day of linaclotide, at the discretion of the Investigator. Subsequent dose adjustments (increases or decreases between 290 μg/day and 145 μg/day) were permitted also at the Investigator's discretion.
62031276|NCT06185660||Heart Failure patients|Heart Failure patients receiving Renin angiotensin aldosterone inhibitors/Mineralocorticoid receptor antagonists (Raas i/Mras)
62592078|NCT03092765|EXPERIMENTAL|high-dose, low-frequency E6011; high-dose, low-frequency E6011|Participants will receive high-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
62592079|NCT03092765|EXPERIMENTAL|high-dose, low-frequency E6011; low-dose, low-frequency E6011|Participants will receive high-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
62031277|NCT00783991||IVR-PC|This group will have instruments administered through interactive voice response (IVR) and personal computer (PC).
62031278|NCT00783991||PP-PC|This group will have instruments administered through paper and pencil (PP) and PC.
62031279|NCT00783991||PDA-PC|This group will have instruments administered by personal digital assistant (PDA) and PC.
62230806|NCT04388241|EXPERIMENTAL|Behavioral Intervention|Children and adolescents with SCD between the ages of 8 and 17 years old (n=20) will be recruited to complete a four-week behavioral intervention designed to reduce pain-related impairment in SCD.
62230807|NCT06115551|NO_INTERVENTION|Control|Subjects in the control group will be asked to keep their normal diet during the study period.
62031280|NCT00783991||PC-PC|This group will have all instruments administered through PC.
62031281|NCT03443960|EXPERIMENTAL|Treatment A (TNX-102 SL)|2 x TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 2.8 mg once daily for 20 consecutive days
62031282|NCT03443960|ACTIVE_COMPARATOR|Treatment B (AMRIX)|1 x AMRIX ER capsule 30 mg once daily for 20 consecutive days
62422582|NCT05315986|EXPERIMENTAL|Group 1: Sleep intervention (ESE) & Saffron (food supplement)|"Saffron: Dietary supplement consists of a gummy sweet (Saffr'Inside; 30mg). Ingest one gummy per day for a duration of 4 weeks total.~Enhanced Sleep Education (ESE): Receive a psycho-education based multi-component sleep intervention consisting of: Sleep education, Sleep hygiene, mindfulness and sleep behavioural recommendations adapted from the validated Brief Behaviour Treatment for Insomnia (BBTi) intervention.The intervention is presented to participants via a pre-recorded presentation, lasting approximately 15 minutes. Participants will also receive some personalized feedback from their objective sleep measurements, collected from their EEG data to help them better understand their sleep patterns."
62230808|NCT06115551|EXPERIMENTAL|FMD1-ProLon|Subjects in FMD1 groups will be provided and asked to consume a 5-day low calorie fasting-mimicking diet (ProLonTM).
62230809|NCT06115551|EXPERIMENTAL|FMD2-ProMete|Subjects in FMD2 groups will be provided and asked to consume a 5-day low calorie fasting-mimicking diet (ProMeteTM).
62592080|NCT03092765|EXPERIMENTAL|low-dose, low-frequency E6011; high-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
62592081|NCT03092765|EXPERIMENTAL|low-dose, low-frequency E6011; low-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
62592082|NCT03092765|EXPERIMENTAL|Placebo; high-dose, low-frequency E6011|Participants will receive placebo up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
62592083|NCT03092765|EXPERIMENTAL|Placebo; low-dose, low-frequency E6011|Participants will receive placebo up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
62592084|NCT05122910|EXPERIMENTAL|SMART-MR Program|Participants will participate in the Stress Management and Resilience Training - Moral Resilience (SMART-MR) program.
62807485|NCT01862289|EXPERIMENTAL|Severe uncontrolled asthma|Asthmatics patients with uncontrolled symptoms despite a daily treatment by high doses of inhaled steroids and LABA. Diagnostic of chronic hyperventilation syndrome.
62807486|NCT03707353|EXPERIMENTAL|Group 1|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by ChAd63 ME-TRAP vaccination intravenously.
62592085|NCT06347055|EXPERIMENTAL|cTBS to Ventrolateral Prefrontal Cortex|Continuous theta-burst stimulation (cTBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. cTBS will be applied to the ventrolateral prefrontal cortex.
62807487|NCT03707353|EXPERIMENTAL|Group 2|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by MVA ME-TRAP vaccination intravenously.
62807488|NCT03707353|EXPERIMENTAL|Group 3|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, followed by ChAd63 ME-TRAP vaccination intravenously.
62807489|NCT03707353|EXPERIMENTAL|Group 4|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, followed by MVA ME-TRAP vaccination intravenously. 4 weeks after the last vaccine dose, all vaccinated volunteers will undergo malaria challenge by mosquito bite.
62592086|NCT06347055|EXPERIMENTAL|cTBS to Dorsomedial Prefrontal Cortex|Continuous theta-burst stimulation (cTBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. cTBS will be applied to the dorsomedial prefrontal cortex.
62031283|NCT05170373|ACTIVE_COMPARATOR|ESP group|
62031284|NCT05170373|NO_INTERVENTION|control group|
62031285|NCT05006781|EXPERIMENTAL|tDCS+Dose A|Drug: DAOIB at dose A The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS
62031286|NCT05006781|EXPERIMENTAL|tDCS+Dose B|Drug: DAOIB at dose B The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS
62031287|NCT05006781|EXPERIMENTAL|tDCS+Dose C|Drug: DAOIB at dose C The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS
62031288|NCT05006781|PLACEBO_COMPARATOR|tDCS+placebo|Drug: Placebo Placebo Device: tDCS tDCS
62031289|NCT02786082|EXPERIMENTAL|Group I|"For Pharmacokinetics Studies of Azilsartan with Single-dose oral administration, 12 subjects in group I, half are male and half are female, will take Azilsartan tablet 20mg orally on fasting.~For Pharmacokinetics Studies of Azilsartan with Multiple-dose oral administration, 12 subjects in group I will take 20mg Azilsartan orally once daily for 7 day (day 3\~day 9) after completing the last time blood sample collection (in day 2, 48h) of the first time administration (day 1)"
62031290|NCT02786082|EXPERIMENTAL|Group II|"For Pharmacokinetics Studies of Azilsartan with Single-dose oral administration, 12 subjects in group II, half are male and half are female, will take Azilsartan tablet 40mg orally on fasting.~For The effects of diet for pharmacokinetic study: The 12 healthy subjects, in group II (in single-dose administration study), after 7-day washout period after the first administration (at day 1, 40mg) will receive Azilsartan tablet 40mg after high-fat diet at day 8"
62031291|NCT01310439||ADHD adolescents and adults|30 adolescents and adults diagnosed with Combined-subtype AD/HD
62031292|NCT00093054|ACTIVE_COMPARATOR|1|Cranberry juice
62031293|NCT00093054|PLACEBO_COMPARATOR|2|Placebo juice
62031294|NCT04947800|EXPERIMENTAL|Arm A: 12 week intervention, 8 week control|Electro acupuncture (EA) intervention will be administered for 12 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 8 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
62031295|NCT04947800|EXPERIMENTAL|Arm B: 8 week intervention, 12 week control|Electro acupuncture (EA) intervention will be administered for 8 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 12 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
62592087|NCT06347055|EXPERIMENTAL|cTBS to Vertex|Continuous theta-burst stimulation (cTBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. cTBS will be applied to the vertex.
62031296|NCT04947800|EXPERIMENTAL|Arm C: 4 week intervention, 16 week control|Electro acupuncture (EA) intervention will be administered for 4 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 16 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
62031297|NCT01076569||Ancillary-Correlative (molecular analysis)|Banked bone marrow samples from diagnosis and remission are used to develop a detailed molecular map of pediatric high-risk acute myeloid leukemia. Analysis includes genome SNP genotyping, expression, and methylation profiling.
62031298|NCT02302079|EXPERIMENTAL|ASP8232 + sham intravitreal (IVT) injections|ASP8232 will be given orally once daily and sham injections 3 times with 1 month intervals
62230810|NCT02490553||Dunkirk area|Representative sample of Dunkirk and the surrounding urban area (of \~200 000inhabitants).Dunkirk area is characterize by high emission of industrial air pollutant
62422583|NCT05315986|EXPERIMENTAL|Group 2: Sleep intervention (ESE) & No Saffron (placebo food supplement)|"Placebo (no Saffron): Placebo food supplement identical looking (gummy sweet) to experimental food supplement. Ingestion of one gummy per day for a duration of 4 weeks total.~Enhanced Sleep Education (ESE): Receive a psycho-education based multi-component sleep intervention consisting of: Sleep education, Sleep hygiene, mindfulness and sleep behavioural recommendations adapted from the validated Brief Behaviour Treatment for Insomnia (BBTi) intervention.The intervention is presented to participants via a pre-recorded presentation, lasting approximately 15 minutes. Participants will also receive some personalized feedback from their objective sleep measurements, collected from their EEG data to help them better understand their sleep patterns."
62422584|NCT05315986|EXPERIMENTAL|Group 3: No sleep intervention (Control ESE) & Saffron (food supplement)|"Saffron: Dietary supplement consists of a gummy sweet (Saffr'Inside; 30mg). Ingest one gummy per day for a duration of 4 weeks total.~No Psycho-education (ESE) intervention. Control."
62422585|NCT05315986|PLACEBO_COMPARATOR|Group 4: No sleep intervention (Control ESE) & No Saffron (placebo food supplement)|"Placebo (no Saffron): Placebo food supplement identical looking (gummy sweet) to experimental food supplement. Ingestion of one gummy per day for a duration of 4 weeks total.~No Psycho-education (ESE) intervention. Control."
62031299|NCT02302079|EXPERIMENTAL|ASP8232 + ranibizumab intravitreal (IVT) injections|ASP8232 will be given orally once daily and ranibizumab injections 3 times with 1 month intervals
62031300|NCT02302079|ACTIVE_COMPARATOR|Placebo + ranibizumab intravitreal (IVT) injections|Placebo will be given orally once daily and ranibizumab injections 3 times with 1 month intervals
62031301|NCT04997174||ERAS|Patients undergoing laparoscopic colorectal surgery with ERAS
62422586|NCT06462235|EXPERIMENTAL|Part A, Cohorts 1-4|Single dose pharmacokinetics.
62422587|NCT06462235|EXPERIMENTAL|Part B, Cohorts 1-4|Multi-dose pharmacokinetics and treatment
62422588|NCT00300573|EXPERIMENTAL|Dexelvucitabine (DFC)|200 mg once daily
62422589|NCT00300573|ACTIVE_COMPARATOR|lamivudine (3TC)|300 mg once daily
62422590|NCT03150134|EXPERIMENTAL|early reduction|Usually in the absence of GvHD, immunosuppressive drugs(Cyclosporine) were gradually reduced by 6 weeks and discontinued in three months after transplant in the advanced patients while immunosuppressive agents were gradually reduced by 2 months and discontinued in four months after transplant in the advanced patients in haploidentical SCT even if complete donor chimerism (CDC) achieved. If donor chimerism had not achieved CDC with no significant acute GVHD at four weeks after HSCT, immunosuppressive agents were gradually reduced. If GvHD was present during the time of immunosuppressive agents reduction, CsA was added again and tapering was done over longer periods.
62422591|NCT03150134|PLACEBO_COMPARATOR|routine reduction|Arm/Group Descriptions.Immunosuppressive drugs(cyclosporine) were routine reduced by 3 months and discontinued in the 5 months without GvHD in the CR group. We used the result of chimerism as the reference.
62422592|NCT01888159|ACTIVE_COMPARATOR|Tubal Sterilization with bipolar|Salpingectomy vs Tubal Sterilisation
62422593|NCT01888159|ACTIVE_COMPARATOR|Bilateral Salpingectomy|Salpingectomy vs Tubal Sterilisation
62422594|NCT00837031|EXPERIMENTAL|Intervention|"The study began with a lead-in portion to confirm the tolerability of lenalidomide (25mg PO days 1-21) in combination with gemcitabine (1000mg/m2 IV days 1, 8, and 15).~After completion of the lead-in phase, all subsequent patients received lenalidomide 25mg PO on days 1-21 and gemcitabine 1000mg/m2 IV days 1, 8, and 15 of 28-day treatment cycles. Patients were instructed to take lenalidomide at approximately the same time each morning. Patients were permitted to continue treatment until disease progression or intolerable toxicity occurred."
62230811|NCT02490553||Lille area|Representative sample of Lille and the surrounding urban area (of \~1 million inhabitants, the fourth urban area in France)
62031302|NCT04997174||Non ERAS|Patients undergoing laparoscopic colorectal surgery without ERAS
62031303|NCT04997174||Open|Patients undergoing open colorectal surgery
62031304|NCT03441425|NO_INTERVENTION|Control|The control group participants will complete a cardiac arrest simulation scenario on the first day in which the mannequin returns to spontaneous circulation at the end of the scenario. They will then complete a retention simulation session three months later.
62031305|NCT03441425|EXPERIMENTAL|Unexpected death|The experimental group participants will complete a cardiac arrest simulation scenario on the first day in which the mannequin unexpectedly dies at the end of the scenario. They will then complete a retention simulation session three months later.
62422595|NCT05094986|EXPERIMENTAL|Intervention group: IMA Intervention|"General practitioners (GP) applied the IMA intervention to all patients receiving a new prescription for pharmacological treatments of cardiovascular disease or diabetes.~Following the IMA intervention, nurses and community pharmacists offered information support in line with the information provided by the GP. Professionals had the intervention support tools available (leaflets, website and dispensing alert in community pharmacies)."
62422596|NCT05094986|ACTIVE_COMPARATOR|Control group|Healthcare professionals from the control group prescribed medication and provided information as usual.
62592088|NCT02611570||Non-smokers at risk for lung cancer|"1. Non-smoking subjects with lung cancer family history~2. Non-smoking subjects with a given lung cancer risk other than lung cancer family history"
62592089|NCT04417192|EXPERIMENTAL|Olaparib or Olaparib Plus Pembrolizumab|Cohort 1 : Olaparib will be administered for 6 weeks before surgery. Cohort 2 : Olaparib and Pembrolizumab will be administered simultaneously for 2 cycles(6 weeks) before surgery.
62807490|NCT03707353|NO_INTERVENTION|Group 5|6 Volunteers will receive no vaccinations but will undergo malaria challenge infection by mosquito bite at the same time as groups 1-4.
62807491|NCT03707353|NO_INTERVENTION|Group 6|6 Volunteers will be used as infectivity controls if any volunteers from Groups 1-4 are rechallenged 5 - 7 months after the initial CHMI.
62031306|NCT02384954|EXPERIMENTAL|Phase 1 Cohort 1: N-803 - IV 1 ug/kg|
62031307|NCT02384954|EXPERIMENTAL|Phase 1 Cohort 2: N-803 - IV 3 ug/kg|
62422597|NCT06037031|EXPERIMENTAL|Cohort 1: Severe Renal Impairment|Participants with severe renal impairment will receive a single oral dose of PF-07923568
62807492|NCT03707353|EXPERIMENTAL|Group A|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by MVA ME-TRAP vaccination intravenously.
62807493|NCT06116734|EXPERIMENTAL|Biosimilar pegfilgrastim|Day +5 of cell infusion: Biosimilar pegfilgrastim or Lapelga™ (one dose)
62031308|NCT02384954|EXPERIMENTAL|Phase 1 Cohort 3: N-803 - IV 6 ug/kg|
62031309|NCT02384954|EXPERIMENTAL|Phase 1 Cohort 4: N-803 - SQ 6 ug/kg|
62031310|NCT02384954|EXPERIMENTAL|Phase 1 Cohort 5: N-803 - SQ 10 ug/kg|
62031311|NCT02384954|EXPERIMENTAL|Phase 1 Cohort 6: N-803 - SQ 15 ug/kg|
62031312|NCT02384954|EXPERIMENTAL|Phase 1 Cohort 7: N-803 - SQ 20 ug/kg|
62031313|NCT02384954|EXPERIMENTAL|Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg|
62031314|NCT02384954|EXPERIMENTAL|Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg|
62031315|NCT00629187|EXPERIMENTAL|1|
62031316|NCT05562440|EXPERIMENTAL|Focus Group Discussion on breast cancer risk prediction report|Woman population with no breast cancer who received the dummy report result
62031317|NCT06670703||the obesity group|Obese patients attending the First Affiliated Hospital of Chongqing Medical University, the Affiliated Hospital of Yunnan University, and the Second People's Hospital of Qujing City.
62422598|NCT06037031|EXPERIMENTAL|Cohort 2: Normal Renal Function|Participants with normal renal function will receive a single oral dose of PF-07923568
62592090|NCT05935748|EXPERIMENTAL|Lead-in Doublet combination|Lead-in Doublet assesses safety of oral dosing NKT2152 at increasing dosage levels in combination with palbociclib to determine a recommended dose for expansion (RDE).
62031318|NCT02114242||Parkinson's disease patients|Patients suffering from Parkinson desease
62230812|NCT02485535|EXPERIMENTAL|Treatment (selinexor)|Beginning on day 60-100 after allo-SCT without evidence of GVHD above grade 1 and disease relapse with stable hematopoietic recovery, patients receive selinexor PO on day 1 of each week or on days 1 and 3 of weeks 1-3. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62230813|NCT02904486|EXPERIMENTAL|change behavior|Modified Health Belief Model Based Intervention and study health topic in classroom to change behavior for Reduce Body Mass Index for Age in Overweight Junior High School Students.
62230814|NCT02904486|EXPERIMENTAL|lifestyle behavior|study health topic in classroom to change behavior for Reduce Body Mass Index for Age in Overweight Junior High School Students.
62230815|NCT03952429|ACTIVE_COMPARATOR|Active Cognitive Bias App|Participants will receive the Anti-Alcohol App with the Active Cognitive Bias modification, as well as participant diaries assessing alcohol consumption and several questionnaires.
62230816|NCT03952429|PLACEBO_COMPARATOR|Inactive Cognitive Bias Modification|Participants will receive the Anti-Alcohol App with the Inactive Cognitive Bias Modification, as well as participant diaries assessing alcohol consumption and several questionnaires.
62230817|NCT03221517|EXPERIMENTAL|Cohort 1|Shift workers receive a standardized meal with a glucose challenge test
62230818|NCT03221517|EXPERIMENTAL|Cohort 2|Matched healthy controls receive a standardized meal with a glucose challenge test
62230819|NCT05822167|EXPERIMENTAL|High Protein Meal with cold temperature|
62230820|NCT05822167|EXPERIMENTAL|High Protein Meal with warm temperature|
62230821|NCT05822167|EXPERIMENTAL|High Protein Meal with Hot temperature|
62230822|NCT05822167|EXPERIMENTAL|High Carbohydrate Meal with cold temperature|
62230823|NCT05822167|EXPERIMENTAL|High Carbohydrate Meal with warm temperature|
62230824|NCT05822167|EXPERIMENTAL|High Carbohydrate Meal with hot temperature|
62230825|NCT05822167|EXPERIMENTAL|High Fat Meal with cold temperature|
62230826|NCT05822167|EXPERIMENTAL|High Fat Meal with warm temperature|
62592091|NCT05935748|EXPERIMENTAL|Lead-in Triplet combination|Lead-in Triplet assesses the safety of two doses of NKT2152 identified in the Doublet arm (RDE and RDE-1) by orally dosing ccRCC patients with NKT2152 in combination with palbociclib and sasanlimab
62230827|NCT05822167|EXPERIMENTAL|High Fat Meal with hot temperature|
62230828|NCT01717690|ACTIVE_COMPARATOR|CHG antiseptic body cleanser|"One randomly selected intervention unit in Complex Continuing Care program where all patients (MRSA-positive and MRSA-negative) will be bathed daily with an antiseptic body cleanser (CHG).~Only MRSA-negative patients at enrollment will be included in the study analysis, and only their outcomes (MRSA status and time to conversion) will be analyzed.~Antiseptic body cleanser - 2% Chlorhexidine Gluconate in a non-alcohol and non-alkaline base, delivered to skin surface through the bath cloths impregnated with this antiseptic solution."
62230829|NCT01717690|NO_INTERVENTION|Non-antiseptic body cleanser|"Two control units in Complex Continuing Care program where all patients (MRSA-positive and MRSA-negative) will be bathed daily with a non-antiseptic body cleanser (Comfort Bath ®).~Only MRSA-negative patients at enrollment will be included in the study analysis, and only their outcomes (MRSA status and time to conversion) will be analyzed."
62230830|NCT01658826|EXPERIMENTAL|AIC316, Then Valacyclovir|Participants first received AIC316 100 mg once daily for 28 days. After a washout period of 28 days, they then received Valacyclovir 500 mg once daily for 28 days.
62422599|NCT06037031|EXPERIMENTAL|Cohort 3 (Optional): Moderate Renal Impairment|Participants with moderate renal impairment will receive a single oral dose of PF-07923568
62230831|NCT01658826|ACTIVE_COMPARATOR|Valacyclovir, Then AIC316|Participants first received Valacyclovir 500 mg once daily for 28 days. After a washout period of 28 days, they then received AIC316 100 mg once daily for 28 days.
62230832|NCT00914160|EXPERIMENTAL|1|Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)
62422600|NCT06377969|OTHER|Treatment|Patient will go through trial of spinal cord stimulator. If trial results in \>50% reduction in pain, they will receive implantable spinal cord stimulator
62592092|NCT05935748|EXPERIMENTAL|Expansion Doublet combination|Subjects randomized to Arm 1 will receive the Doublet combination (NKT2152 in combination with palbociclib) to provide an assessment of anti-tumor activity and to determine the RP2D.
62592093|NCT05935748|EXPERIMENTAL|Expansion Triplet combination|Subjects randomized to Arm 2 will receive the Triplet therapy (NKT2152 in combination with palbociclib and sasanlimab) to provide an assessment of anti-tumor activity and to determine the RP2D.
62031319|NCT02114242||multiple system atrophy patients|"Patients suffering from probable multiple system atrophy according to clinical consensus criteria and age \> 30"
62230833|NCT00914160|EXPERIMENTAL|2|Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)
62230834|NCT00914160|ACTIVE_COMPARATOR|3|Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
62031320|NCT02114242||progressive supranuclear palsy|Patients suffering from progressive supranuclear palsy and age \> 40
62031321|NCT05878639|EXPERIMENTAL|Patients take Lactulose for bowel preparation|Patients take Lactulose for bowel preparation.
62031322|NCT05878639|ACTIVE_COMPARATOR|Patients take 3L-polyethylene glycol for bowel preparation|"Patients take 3L-polyethylene glycol for bowel preparation~."
62230835|NCT03252275|EXPERIMENTAL|Intervention|Standard HBB and ECEB training with peer learning
62230836|NCT03252275|NO_INTERVENTION|Control|Standard HBB and ECEB training only
62230837|NCT05742737||Robust|Unlike previous frailty index, mFI-5 uses a small number of variables readily available in a patient's history, including functional status (partial or complete dependence), history of diabetes, COPD, congestive heart failure, and hypertension requiring medication. 1 point is assigned to each variable. Functional status refers to needing some or all of the assistance of others in daily activities, including bathing, eating, dressing, going to the toilet, moving, traveling, and more. The mFI-5 score was calculated by increasing the number of variables per patient Patients were divided into 3 groups based on their mFI-5: frail group (mFI-5, 2-5) , prefrail group (mFI-5, 1) and robust group (mFI-5, 0). The range of the mFI-5 is from 0 to 5 with increments of 1, and increasing the mFI-5 implies increasing frailty.
62422601|NCT02687763|EXPERIMENTAL|Open Label|Open Label. Two 0.5-mL doses of ProQuad® will be given by intramuscular injection at least 30 days but no more than 365 days apart..
62230838|NCT05742737||Prefrail|Unlike previous frailty index, mFI-5 uses a small number of variables readily available in a patient's history, including functional status (partial or complete dependence), history of diabetes, COPD, congestive heart failure, and hypertension requiring medication. 1 point is assigned to each variable. Functional status refers to needing some or all of the assistance of others in daily activities, including bathing, eating, dressing, going to the toilet, moving, traveling, and more. The mFI-5 score was calculated by increasing the number of variables per patient Patients were divided into 3 groups based on their mFI-5: frail group (mFI-5, 2-5) , prefrail group (mFI-5, 1) and robust group (mFI-5, 0). The range of the mFI-5 is from 0 to 5 with increments of 1, and increasing the mFI-5 implies increasing frailty.
62243171|NCT05895604|EXPERIMENTAL|Treatment-NFP|NFP is a prenatal and infancy home visiting program for vulnerable first-time mothers and their families. Registered nurses begin visiting their clients as early in the pregnancy as possible, guiding the mothers-to-be on different aspects of the parental role and offer practical and emotional support. The nurses continue visiting regularly until the child is two years old (up to 64 visits in total).
62422602|NCT01445431|EXPERIMENTAL|Virgin Coconut Oil|
62592094|NCT03830957|ACTIVE_COMPARATOR|Ivabradine|
62592095|NCT03830957|ACTIVE_COMPARATOR|metoprolol|
62031323|NCT05934344|EXPERIMENTAL|Observational learning from the therapist|Patients with MCI (Mild Cognitive Impairment) will undergo intervention using therapist-led imitation exercises. They will engage in a 5-week exercise program based on observation and action. Data will be collected at the beginning and end of the program.
62031324|NCT05934344|EXPERIMENTAL|peer learning|Patients with MCI (Mild Cognitive Impairment) will undergo intervention using exercises by imitation from individuals residing in the facility but without cognitive impairment. They will participate in a 5-week exercise program based on observation and action. Data will be collected at the beginning and end of the program.
62031325|NCT05934344|NO_INTERVENTION|control group|Patients with cognitive impairment who will receive the standard treatment provided by the facility.
62592096|NCT00653770|EXPERIMENTAL|1|FP85A at day 0
62592097|NCT00653770|EXPERIMENTAL|2|MVA85A at day 0 and FP85A at day 28
62031326|NCT06258174|EXPERIMENTAL|Pirtobrutinib (Test)|Test formulation of pirtobrutinib administered orally.
62031327|NCT06258174|EXPERIMENTAL|Pirtobrutinib (Reference)|Reference formulation of pirtobrutinib administered orally.
62031328|NCT05680025|NO_INTERVENTION|Control|Participants in the control group will be invited to attend two workshops, where they will be given and have explained a guide to physical activity and one for diet for patients with hypertension. In addition to pharmacological treatment, this is the information given as part of conventional treatment patients with hypertension receive from health care personnel.
62031329|NCT05680025|EXPERIMENTAL|Physical exercise intervention|Promoting physical exercise. The intervention group will have access to training videos through social networks and infographics.
62592098|NCT00653770|EXPERIMENTAL|3|FP85A at day 0 and MVA85A at day 28
62592099|NCT06094257||Nipple sparing mastectomy (NSM) and implant reconstruction|Nipple sparing mastectomy (NSM) and implant reconstruction
62592100|NCT06094257||Nipple sparing mastectomy (NSM) and autologous reconstruction|Nipple sparing mastectomy (NSM) and autologous reconstruction
62592101|NCT06094257||Gender mastectomy with free nipple grafting|Gender mastectomy with free nipple grafting
62592102|NCT06094257||Control patients matched by surgical procedure, age, BMI and mastectomy weight.|Control patients matched by surgical procedure, age, BMI and mastectomy weight.
62592103|NCT00244335||1|PTSD Subjects
62592104|NCT00244335||2|Trauma Controls: subjects who have experienced a trauma but never developed PTSD
62592105|NCT03546036|EXPERIMENTAL|Weighted metal chain blanket|As experimental intervention, a weighted metal chain blanket of 8 kg was used during the night. Using a flexible dose protocol, participants who found the 8 kg blanket too heavy were allowed to change to a 6 kg weighted blanket (see below)
62807494|NCT06116734|ACTIVE_COMPARATOR|Biosimilar filgrastim|Day +5 of cell infusion: Biosimilar filgrastim or Grastofil® (one dose for 5 days)
62807495|NCT01947036||Healthy Subjects|Healthy adult controls (no auto-immune disease)
62807496|NCT01947036||Subjects with Crohn's Disease|Diagnosed with or suspected of having Crohn's disease (CD)
62230839|NCT05742737||frail|Unlike previous frailty index, mFI-5 uses a small number of variables readily available in a patient's history, including functional status (partial or complete dependence), history of diabetes, COPD, congestive heart failure, and hypertension requiring medication. 1 point is assigned to each variable. Functional status refers to needing some or all of the assistance of others in daily activities, including bathing, eating, dressing, going to the toilet, moving, traveling, and more. The mFI-5 score was calculated by increasing the number of variables per patient Patients were divided into 3 groups based on their mFI-5: frail group (mFI-5, 2-5) , prefrail group (mFI-5, 1) and robust group (mFI-5, 0). The range of the mFI-5 is from 0 to 5 with increments of 1, and increasing the mFI-5 implies increasing frailty.
62807497|NCT01947036||Subjects with Rheumatoid Arthritis|Diagnosed with or suspected of having rheumatoid arthritis (RA)
62230840|NCT00607022|ACTIVE_COMPARATOR|immediate load|immediate load of dental implant based on the bone quality determined by the insertion torque value
62230841|NCT00607022|ACTIVE_COMPARATOR|Loading at 6 weeks|delayed load (6 weeks post surgery) of dental implants based on bone quality determined by the insertion torque value
62230842|NCT00607022|ACTIVE_COMPARATOR|Loading at 12 weeks|traditional loading of dental implants (12 weeks post surgery) based on bone quality determined by the insertin torque value.
62807498|NCT01947036||Subjects with Type 1 diabetes|Diagnosed with or suspected of having type 1 diabetes mellitus (T1D, T1DM)
62230843|NCT04101604||Patients with VKH, BD, DR, AMD, or PCV|Collection of blood samples and clinical information from patients with VKH, BD, DR, AMD, or PCV
62230844|NCT04101604||Healthy subjects|Collection of blood samples and clinical information
62422603|NCT01445431|ACTIVE_COMPARATOR|Mineral Oil|
62422604|NCT06125873|ACTIVE_COMPARATOR|Metformin|Metformin 500mg taken orally twice daily
62230845|NCT05925556|EXPERIMENTAL|Communal Coping Intervention|"The intervention consists of a single session brief communal coping intervention followed by 7 days of intervention prompts delivered via text message to help couples generalize what they have learned into their daily life. There are 9 components to the intervention:~1. establishment of rapport~2. shared stressor recollection~3. communal coping education~4. application of appraisal to diabetes~5. we-statements to reframe diabetes as shared~6. facilitated discussion between couple members to identify each person's needs with active listening~7. collaborative implementation intentions~8. EMI text messaging for 7 days following intervention"
62807499|NCT01947036||Subjects with Multiple Sclerosis (MS)|Diagnosed with or suspected of having MS
62807500|NCT01947036||Subjects with Psoriasis|Diagnosed with or suspected of having psoriasis (Ps)
62031330|NCT02043210|ACTIVE_COMPARATOR|Standard Treatment as Usual|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on substance abuse.
62031331|NCT02043210|EXPERIMENTAL|CBT4CBT plus Standard treatment as usual|A computerized program that teaches skills for stopping substance use by increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc. plus standard treatment as usual.
62230846|NCT05925556|NO_INTERVENTION|Diabetes Education Attention Control|These participants will receive diabetes education via a 15-20 minute videotape (as well the intervention group)
62230847|NCT00913653|EXPERIMENTAL|Stable heart failure patients|
62230848|NCT00606567|ACTIVE_COMPARATOR|1-treatment|remote monitoring with carelink every 3 months
62230849|NCT00606567|NO_INTERVENTION|2- control|device interrogations in clinic every 3 months
62230850|NCT05997927|EXPERIMENTAL|VC005 Tablets Low Dose groups|
62230851|NCT05997927|EXPERIMENTAL|VC005 Tablets Medium Dose groups|
62230852|NCT05997927|EXPERIMENTAL|VC005 Tablets High Dose groups|
62422605|NCT06125873|EXPERIMENTAL|"Moringa+Metformin"|Metformin 500mg taken orally twice daily with Moringa Oliefera (MO) capsule 1g once daily before breakfast
62422606|NCT04673266|EXPERIMENTAL|romiplostim|Romiplostim will be administered from the beginning of the next chemotherapy cycle with a starting dose of 3 mcg/kg subcutaneously. Dose will be titrated based on nadir of the platelet counts during the prior cycle. The maximum dose of romiplostim will be 6 mcg/kg.
62422607|NCT00323635|EXPERIMENTAL|Tolterodine|Tolterodine 4 mg q.d. X 8 weeks
62422608|NCT00323635|PLACEBO_COMPARATOR|Placebo|A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine
62422609|NCT00839007|EXPERIMENTAL|A|Dose 1 of CD-NP
62422610|NCT00839007|EXPERIMENTAL|B|Dose 2 of CD-NP
62422611|NCT00839007|EXPERIMENTAL|C|Dose 3 of CD-NP
62422612|NCT00839007|EXPERIMENTAL|D|Dose 4 of CD-NP
62422613|NCT00839007|EXPERIMENTAL|E|Dose 5 of CD-NP
62807501|NCT01917383|EXPERIMENTAL|Trabodenoson Plus Latanoprost|Experimental ophthalmic eye drop plus a prostaglandin analogue eye drop
62807502|NCT01917383|ACTIVE_COMPARATOR|Timolol Plus Latanoprost|A Beta-blocker eye drop plus a prostaglandin analogue eye drop
62807503|NCT02138890|EXPERIMENTAL|APS injection|Autologous Protein Solution
62807504|NCT02138890|PLACEBO_COMPARATOR|Control|Saline
62807505|NCT01091675|EXPERIMENTAL|etoricoxib|All the patients who fulfil the eligibility criteria will start a 4-week open label treatment period to evaluate the response to treatment with etoricoxib 90 mg.
62807506|NCT06238440|OTHER|Control|In the control group (CG), a conventional physiotherapy program will be implemented for 2 weeks. A 10-session treatment will be completed using thermal and electrical agents specified in the program prescribed by the physiotherapist.
62807507|NCT06238440|EXPERIMENTAL|Splint|In the Splint (SP) group, in addition to the 10-session conventional physiotherapy program, individuals will be instructed to use the splint prescribed by the physician for 2 weeks.
62031332|NCT03487250||TenJet System|Percutaneous ultrasound guided medial and lateral tenotomy using the TenJet HydroSurgery System
62031333|NCT01818323|EXPERIMENTAL|Intra-tumoral T4 immunotherapy|Treatment arms comprise escalating doses of T4 immunotherapy, administered alone or in combination with lymph-depleting chemotherapy
62031334|NCT06373757|EXPERIMENTAL|Group I (nano-HAP/Chitosan hydrogel):|The periodontal pockets more than or equal 3-5mm were isolated. Chitosan and nano-HAP hydrogel were prepared in the same steps that were mentioned in the methodology and then the prepared gel was applied to the test site of patients with the deepest probing pocket measurement once per week for 3 weeks. Periodontal dressing (Coe-pack) was to secure the hydrogel in place.
62031335|NCT06373757|NO_INTERVENTION|Group II|Patients were treated with supra and sub-gingival debridement only.
62031336|NCT02468024|ACTIVE_COMPARATOR|Arm 1 lung surgery|Sublobar Resection (SR)
62422614|NCT00839007|EXPERIMENTAL|F|Dose 6 of CD-NP
62422615|NCT00839007|PLACEBO_COMPARATOR|G|Placebo
62422616|NCT05037552|ACTIVE_COMPARATOR|BIPOLAR FORCEPS|The bipolar forceps allow electrocoagulation and are part of the standard laparoscopy box, delivered by the sterilization service to the gynecology operating room.
62422617|NCT05037552|EXPERIMENTAL|FLOSEAL|"FLOSEAL® is a hemostatic agent based on gelatin of bovine origin added to thrombin of human origin. It is a recommended medical device in surgical procedures as an adjunct to hemostasis when control of bleeding, arterial jet seepage, ligation or any other conventional method proves impractical or ineffective.~During this study, it will be used in 1st intention."
62031337|NCT02468024|EXPERIMENTAL|Arm 2 radiation therapy|Stereotactic Ablative Radiotherapy (SAbR)
62031338|NCT04537962|PLACEBO_COMPARATOR|Colgate Periogard and Peroxyl®|Patients hospitalized in the ICU with orotracheal intubation or negative pressure room - will undergo antisepsia of the oral mucosa with 1.5% hydrogen peroxide solution, following by a 0.12% non-alcoholic chlorhexidine solution
62031339|NCT04537962|PLACEBO_COMPARATOR|Colgate Periogard®|Patients hospitalized in the ICU with orotracheal intubation or negative pressure room - will undergo antisepsia of the oral mucosa with 0.12% non-alcoholic chlorhexidine solution;
62422618|NCT02386722|EXPERIMENTAL|Intervention group|Patients assigned to the intervention group will receive a Smartinhaler/POEMS, which will contain an audio reminder function. If the alarm function is on, a ring tone will be generated, after the time predesigned for inhalation. If the use of rescue medication doubles or if the inhaled medication is not inhaled as prescribed for more than two consecutive days, the investigator will call them to see if they need help and to find out the reason for non-adherence.
62422619|NCT02386722|NO_INTERVENTION|Control group|Patients in the control group will receive a Smartinhaler/POEMS, which only records their adherence. The alarm function of the devices will be switched off, and these participants will not be reminded to take their inhalers. This group will not receive any calls, if they do not comply with the prescribed medication schedule or if they use their rescue medication too frequently.
62422620|NCT02206724|EXPERIMENTAL|STEREOTACTIC BODY RADIOTHERAPY|STEREOTACTIC BODY RADIOTHERAPY to the prostate gland
62422621|NCT00913016||letrozole (Femara)|
62422622|NCT00566618|EXPERIMENTAL|Dasatinib + Zoledronic Acid|"Dasatinib Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Zoledronic Acid Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort. Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
62031340|NCT04537962|PLACEBO_COMPARATOR|Colgate Peroxyl®|Patients hospitalized in negative pressure rooms - will undergo antisepsia of the oral mucosa with 1.5% hydrogen peroxide solution
62230853|NCT05997927|PLACEBO_COMPARATOR|VC005 Tablets Placebo groups|
62230854|NCT01498653|EXPERIMENTAL|FF/VI 200/25mcg once daily|ICS/LABA
62031341|NCT04537962|PLACEBO_COMPARATOR|Colgate Total 12®|Patients hospitalized in negative pressure rooms - will undergo antisepsia of the oral mucosa with 0.075% cetylpyridinium chloride associated with 0.28% zinc lactate
62230855|NCT01498653|ACTIVE_COMPARATOR|Fluticasone propionate 500mcg twice daily|ICS
62031342|NCT04537962|ACTIVE_COMPARATOR|Toothpaste with sodium monofluorophosphate|Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing only 1.1% fluoride, water, glycerin, cellulose, sodium lauryl sulfate, and sodium bicarbonate
62031343|NCT04537962|ACTIVE_COMPARATOR|Toothpaste with sodium fluoride and zinc|Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing 0.32% fluoride, 0.96% zinc, arginine, poloxamer, glycerin, water, hydrated silica, sodium lauryl sulfate, and sodium saccharin
62031344|NCT04537962|ACTIVE_COMPARATOR|Toothpaste with tin fluoride|Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing 0.454% stannous fluoride, water, sorbitol, hydrated silica, glycerin, tetrasodium pyrophosphate, microcrystalline cellulose, and xanthan gum
62031345|NCT01785329|EXPERIMENTAL|alirocumab SAR236553 (REGN727) - Dose A|"alirocumab SAR236553 (REGN727) - Dose A - Injection in healthy subjects through subcutaneous administration in the abdomen.~alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)"
62031346|NCT01785329|EXPERIMENTAL|alirocumab SAR236553 (REGN727) - Dose B|alirocumab SAR236553 (REGN727) - Dose B - Injection in healthy subjects through subcutaneous administration in the upper arm.
62031347|NCT01785329|EXPERIMENTAL|alirocumab SAR236553 (REGN727) - Dose C|alirocumab SAR236553 (REGN727) - Dose C - Injection in healthy subjects through subcutaneous administration in the thigh.
62031348|NCT04424381|ACTIVE_COMPARATOR|Rivaroxaban 20 MG Oral Tablet [Xarelto]|rivaroxaban oral tablet \[Xarelto\] at a single oral dose of 20 mg
62031349|NCT04424381|EXPERIMENTAL|Rivaroxaban 20 MG Oral Tablet|rivaroxaban oral tablet at a single oral dose of 20 mg
62031350|NCT06151197|EXPERIMENTAL|EN3835|
62031351|NCT06151197|PLACEBO_COMPARATOR|Placebo|
62230856|NCT05273853|OTHER|Patients with high risk of hypernasality|In 1958, Gibb indicated an incidence of hypernasality (escape of air from nose as in patients with cleft palate) postadenoidectomy in approximately 1of 2000 cases. Closure pattern of velopharyngeal valve in children is veloadenoidal rather than velopharyngeal closure. Adenoid tissue is vital to velopharyngeal closure in children and its removal necessitates a change in the closure pattern of velopharyngeal valving. These changes are easily overcome if there is no anatomic abnormality
62230857|NCT01174654|NO_INTERVENTION|Referral to community resources|
62230858|NCT01174654|EXPERIMENTAL|Contingency Management|
62031352|NCT01935817|ACTIVE_COMPARATOR|Silybin + vitamin E + phospholipids complex|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill per day for 12 months
62230859|NCT00069238|EXPERIMENTAL|Alemtuzumab Dose Escalation|Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles. Three cohorts of 3 to 6 patients will be treated. Cohort 1 will receive 30mg of Alemtuzumab, cohort 2 will receive 60mg of Alemtuzumab, and cohort 3 will receive 90mg of Alemtuzumab. If 1 of 3 participants entered at a given dose level experiences dose limiting toxicity (DLT), up to 3 additional participants will be entered at that dose level. If 2 of 6 participants experience DLT at a particular dose level, the maximum tolerated dose (MTD) has been exceeded. The preceding dose level will be the MTD, provided 6 participants have been entered at this level and no more than 1 has experienced DLT.
62422623|NCT02483260|OTHER|10-day course of treatment|10-day course of treatment with follow-up 14 ± 2 days after first dose
62031353|NCT01935817|PLACEBO_COMPARATOR|sugar pill|one placebo pill per day for 12 months
62031354|NCT06462326|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin PO (400 mg)q24h D1-D10
62031355|NCT06462326|EXPERIMENTAL|Omadacycline|Omadacycline PO (450 mg) q24h D1-D2 PO (300 mg) q24h D3-D10
62031356|NCT06507267||Pain and Clinical Reflections in Pelvic Congestion Syndrome|
62031357|NCT04160819|EXPERIMENTAL|individualized nutritional intervention programs (iNIPs)|Participants in the NI group received an iNIP according to energy and protein intake requirements in addition to dietary advice based on face-to-face interviews with their family members during hospitalization. After discharge, phone calls are adopted for prescribing iNIPs. Anthropometry (i.e., body mass index, limb circumference, and subcutaneous fat thickness), blood parameters (i.e., albumin and total lymphocyte count), hospital stay, Mini-Nutritional Assessment-Short Form (MNA-SF) score, target daily calorie intake, total calorie intake adherence rate, and three-major-nutrient intake were assessed during hospitalization and 3 and 6 months after discharge. Both groups received regular follow-up through phone calls. Furthermore, the rate of readmission resulting from pneumonia was recorded after discharge.
62031358|NCT04160819|NO_INTERVENTION|standard care (SC) group|SC group was only provided standard nutritional supplements according to the Kaohsiung Chang Gung Memorial Hospital Nutrition Department, and patients' family members were not provided dietary advice.
62230860|NCT02127918||ESES treated with clobazam|The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
62230861|NCT00203476|ACTIVE_COMPARATOR|Statin with Niacin|Niacin dose range of 500-1500mg (average 888mg)
62230862|NCT00203476|ACTIVE_COMPARATOR|Statin with Colestipol|Colestipol dose range 5-15gm (average 9.5gm)
62230863|NCT00203476|ACTIVE_COMPARATOR|Statin with Ezitimibe|Ezitimibe 10mg (average 10mg)
62031359|NCT06669026|EXPERIMENTAL|vitamin D3-loaded Poly lactic-co-glycolic acid nanoparticles gel adjunct to mechanical debridement|vitamin D3-loaded Poly lactic-co-glycolic acid nanoparticles gel adjunct to mechanical debridement, and Interleukin 8/alkaline phosphatase Elisa analysis Frequency: once a week for 8 consecutive weeks Dosage, up to periodontal pocket fil
62422624|NCT01222182||Eligible plan beneficiaries on atorvastatin|A group of 225 eligible patients would no longer have atorvastatin covered by their prescription plan and would need to be changed to another equivalent anti-hyperlipidemic agent.
62807508|NCT06238440|EXPERIMENTAL|Rigid taping|In the Rigid taping (RB) group, along with the 10-session conventional physiotherapy program, a rigid strapping application will be performed by an experienced researcher at the end of each physiotherapy session, five days a week.
62807509|NCT06238440|EXPERIMENTAL|Kinesiotape|In the Kinesiotape (KT) group, in addition to the 10-session conventional physiotherapy program, kinesiotape application will be carried out by a certified researcher. To ensure homogeneity, individuals in both strapping groups will be asked to remove the tape before coming to treatment and reapply it at the end of the session.
62807510|NCT03107260|OTHER|Occurrence of postoperative cognitive dysfunction|
62230864|NCT02920333|EXPERIMENTAL|tDCS+ rehab training|tDCS will be applied 10 days, followed by conventional rehab training. Anodal stimulation will be conducted at the intensity of 2 mA and last for 20 minutes over the affected primary motor cortex of cortical representation of the tibialis anterior muscle.
62592106|NCT03546036|SHAM_COMPARATOR|Control plastic chain blanket|As sham comparator, light chain blankets were used, were plastic chains of the same shape and size as the metal chains in the weighted blanket were sewn in. The control blanket has a weight of 1535 grams. When checking the weight of standard blankets for sale in one of the largest stores in Stockholm, weight was ranging from 550 to 2389 grams (average 1332).
62807511|NCT05452889|EXPERIMENTAL|18F-FGLN PET Imaging|10.0 mCi of 18F-FGln will be injected intravenously as a slow bolus (20 sec)
62807512|NCT02326038|EXPERIMENTAL|Ritalin|Methylphenidate, capsule, 20 mg, single oral administration
62807513|NCT02326038|PLACEBO_COMPARATOR|Placebo|Placebo, capsule, single oral administration
62807514|NCT02677298|EXPERIMENTAL|Botulinum toxin A|Botulinum Toxin A (Clostridium botulinum toxin type A) will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into the glabellar area.
62807515|NCT02677298|PLACEBO_COMPARATOR|Placebo|Placebo will be administered in double blind fashion in cycle 1. divided in five 0.1 mL i.m. injections into the glabellar area.
62807516|NCT02677298|EXPERIMENTAL|Botulinum toxin A Open Label Extension Arm|"Open Label Extension Arm where all Subjects from Arm 1 and 2 can receive Experimental Treatment in up to 3 treatment cycles.~20 Units will be administered (divided in five 0.1 mL i.m. injections) into the glabellar area."
62031360|NCT06669026|ACTIVE_COMPARATOR|vitamin D3 gel (regular non-nanoparticle form) as an adjunct to mechanical debridement.|vitamin D3 gel (regular non-nanoparticle form) as an adjunct to mechanical debridement, and Interleukin 8/alkaline phosphatase Elisa analysis Frequency: once a week for 8 consecutive weeks Dosage, up to periodontal pocket fil
62031361|NCT06669026|PLACEBO_COMPARATOR|Poly lactic-co-glycolic acid nanoparticles placebo gel adjunct to mechanical debridement.|Poly lactic-co-glycolic acid nanoparticles placebo gel adjunct to mechanical debridement, and Interleukin 8/alkaline phosphatase Elisa analysis Frequency: once a week for 8 consecutive weeks Dosage, up to periodontal pocket fil
62031362|NCT06669026|SHAM_COMPARATOR|only mechanical debridement only|only mechanical debridement only.
62031363|NCT06669026|NO_INTERVENTION|Healthy patients|healthy patients, only added for Interleukin 8 and alkaline phosphatase Elisa analysis
62807517|NCT06411717|EXPERIMENTAL|Trial Group A|12-month defocusing lens (microstructured lens A)
62807518|NCT06411717|EXPERIMENTAL|Trial Group B|12-month defocusing lens (microstructured lens B)
62807519|NCT06411717|ACTIVE_COMPARATOR|Control group|12 months wearing aspherical lens
62031364|NCT03335033|ACTIVE_COMPARATOR|Carotid Plaques with >70% Stenosis|Subjects being seen in the Mayo Clinic Gonda Vascular Center who have a plaque causing a \> 70% stenosis will be approached for recruitment to receive an ultrasound examination including duplex imaging, shear wave elastography and contrast-enhanced ultrasound.
62422625|NCT02933827|EXPERIMENTAL|Low dose:|ELIXCYTE 8 mL (ADSC 6.4\*10\^7 cells in total)
62807520|NCT05123534|EXPERIMENTAL|Cohort 1|5 mg/kg IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy Level 1
62807521|NCT05123534|EXPERIMENTAL|Cohort 2|5 mg/kg IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy Level 2
62592107|NCT05192590|NO_INTERVENTION|Control|These providers will complete two rounds of three simulated patient cases (CPVs). Control arm physicians will continue to have access to standard of care diagnostic tools, but not the CDMT test results.
62031365|NCT03335033|ACTIVE_COMPARATOR|Carotid Plaques with 50-69% Stenosis|Cardiovascular high-risk patients with moderate (50-69% diameter) stenosis carotid plaques from the Mayo Clinic Gonda Vascular Center will be approached for recruitment to receive an ultrasound examination including duplex imaging, shear wave elastography and contrast-enhanced ultrasound.
62230865|NCT02920333|EXPERIMENTAL|rTMS+ rehab training|rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
62031366|NCT02289131|EXPERIMENTAL|Frequency of Once a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours)
62031367|NCT02289131|EXPERIMENTAL|Frequency of Twice a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 1:00 pm (+/- 1.5 hours)
62031368|NCT02289131|EXPERIMENTAL|Frequency of Three Times a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 1:00 pm (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 6:00 pm (+/- 1.5 hours)
62230866|NCT02920333|SHAM_COMPARATOR|sham tDCS+ rehab training|The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
62031369|NCT02777151|EXPERIMENTAL|Cohort 1|REGN3470-3471-3479 dosing level 1 or placebo
62230867|NCT03075007||Group A|All participants will undergo an amyloid PET scan with Florbetaben F 18 contrast as well as a transcranial Doppler ultrasound.
62592108|NCT05192590|EXPERIMENTAL|Educational Materials and CDMT Test Results (Intervention 1)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the CDMT test results whether they select it or not. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
62807522|NCT05123534|EXPERIMENTAL|Cohort 3|10 mg/kg IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy Level 3
62807523|NCT05123534|EXPERIMENTAL|Cohort 4 - DIPG Cohort at RP2D|The RP2D of SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy
62807524|NCT05123534|EXPERIMENTAL|Cohort 5 - DMG Cohort at RP2D|The RP2D of SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy
62807525|NCT01344915|ACTIVE_COMPARATOR|Knee brace|
62807526|NCT01344915|ACTIVE_COMPARATOR|Locked knee brace|
62031370|NCT02777151|EXPERIMENTAL|Cohort 2|REGN3470-3471-3479 dosing level 2 or placebo
62031371|NCT02777151|EXPERIMENTAL|Cohort 3|REGN3470-3471-3479 dosing level 3 or placebo
62031372|NCT02777151|EXPERIMENTAL|Cohort 4|REGN3470-3471-3479 dosing level 4 or placebo
62230868|NCT06384638|ACTIVE_COMPARATOR|interventional|coconut oil as topical application as adjunctive to scaling and root debridement
62230869|NCT06384638|ACTIVE_COMPARATOR|control|scaling and root debridement
62230870|NCT03741569|OTHER|parturients (gestational age ≥37 weeks).|
62230871|NCT03120767|EXPERIMENTAL|Condition 1|enrolled in the Risk and Resilience course during Fall 2017 and directly encouraged to participate in the Founders Living and Learning Community wellness activities for the Fall of 2017 (Coordinated Wellness Programming)
62031373|NCT05695365|EXPERIMENTAL|Resistance Exercise Training|Participants will complete a 16-week, twice/week program to increase strength.
62031374|NCT04396067|ACTIVE_COMPARATOR|Aerosolized 13 cis retinoic acid|COVID 19 infected patients will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
62031375|NCT04396067|ACTIVE_COMPARATOR|All trans retinoic acid|COVID 19 infected patients will receive one dose daily of Aerosolized All trans retinoic acid in gradual doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled All trans retinoic acid therapy for 14 days
62230872|NCT03120767|ACTIVE_COMPARATOR|Condition 2|enrolled in the Risk and Resilience course in Spring 2018, and not directly encouraged to participate in the WIN Living and Learning Community wellness activities
62230873|NCT03120767|NO_INTERVENTION|Condition 3|a control group that receives none of the interventions during the first year. This group will instead receive an online pamphlet that contains a number of wellness tips and advice for first-year students. Condition 3 participants have access to the WIN Living and Learning Community wellness activities in Fall of 2017 and Spring of 2018, but are not directly encouraged to participate.
62807527|NCT02159066|EXPERIMENTAL|LGX818 + MEK162|
62230874|NCT02275494||shortening group|Shortening group where the operated leg was more than 5mm shorter compared with the contralateral side
62807528|NCT02159066|EXPERIMENTAL|LGX818 + MEK162 + LEE011|
62807529|NCT02159066|EXPERIMENTAL|LGX818 + MEK162 + BGJ398|
62230875|NCT02275494||Restoration group|the restoration control group where the operated leg was within 5mm shortening and 9mm lengthening compared with the contralateral side
62807530|NCT02159066|EXPERIMENTAL|LGX818 + MEK162 + BKM120|
62807531|NCT02159066|EXPERIMENTAL|LGX818 + MEK162 + INC280|
62807532|NCT06356402|EXPERIMENTAL|OHEM- Lecture|In this arm, OHEM will be delivered by the lecture to the participants.
62807533|NCT06356402|EXPERIMENTAL|OHEM-Exhibition|In this arm, OHEM will be delivered by the exhibition to the participants.
62807534|NCT06356402|EXPERIMENTAL|OHEM-Demonstration|In this arm, OHEM will be delivered by the demonstration to the participants.
62807535|NCT06356402|NO_INTERVENTION|Control|There will be no educational intervention given to the control group. However, this group will receive oral hygiene kits and a booklet without instruction to teach their children.
62807536|NCT05279352|EXPERIMENTAL|Treatment Arm|FBR-002 at 4.3 EU/kg on D1 and D3 or FBR-002 at 5.7 EU/kg on D1 and D3
62807537|NCT05279352|PLACEBO_COMPARATOR|Placebo Arm|Two administrations of placebo at D1 and D3
62807538|NCT01259141|EXPERIMENTAL|Moxifloxacin|
62807539|NCT01259141|EXPERIMENTAL|Cephalosporins and azithromycin|
62807540|NCT00359463|ACTIVE_COMPARATOR|Healthy subjects|Subjects will receive a single 50 mg oral dose of eltrombopag.
62031376|NCT04396067|PLACEBO_COMPARATOR|Placebo Comparator|4 Placebo tablets twice daily by mouth for 2 weeks
62230876|NCT02275494||Lengthening group|The lengthening group where the operated leg became more than 9mm longer compared with the contralateral side.
62230877|NCT03163485|EXPERIMENTAL|Dialytrode|Multimodal neuro-monitoring by dialytrode (investigational medical device)
62230878|NCT03163485|OTHER|Standard treatment|Either EVD and/or micro-dialysis according to standard treatment
62592109|NCT05192590|EXPERIMENTAL|Educational Materials and CDMT Test Results when Selected (Intervention 2)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the CDMT test results only if they select it. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
62807541|NCT00359463|EXPERIMENTAL|Subjects with hepatic impairment|Subjects with mild, moderate or severe hepatic impairment will receive a single 50 mg oral dose of eltrombopag.
62807542|NCT05361824|EXPERIMENTAL|Ketorolac|Ketorolac 30mg 8 hourly for 48 hours post-operatively
62807543|NCT05361824|ACTIVE_COMPARATOR|Paracetamol|Paracetamol 1gm 6 hourly for 48 hours post-operatively
62031377|NCT02853968||Castleman's Patients|Castleman's patients with HHV8 negative multicentric MCD
62031378|NCT02853968||Related Disease Controls|Controls with inflammatory diseases similar to idiopathic multicentric Castleman's: i.e. HHV8+ MCD, HLH, Hodgkin disease
62230879|NCT04262973|EXPERIMENTAL|experimental group|The experimental group will not only receive six-hour dementia care course, but also a half-day interprofessional education workshop, maintain a six-month interprofessional practice model, and join interprofessional practice experience-sharing conferences.
62230880|NCT04262973|ACTIVE_COMPARATOR|control group|The control group will only receive six-hour dementia care course.
62422626|NCT02933827|EXPERIMENTAL|Middle dose|ELIXCYTE 24 mL (ADSC 19.2\*10\^7 cells in total)
62031379|NCT02853968||Healthy Donor Controls|Healthy subjects used for controls. These healthy subjects have no history of autoimmune disorders.
62031380|NCT01559298|ACTIVE_COMPARATOR|Aspirin + clopidogrel|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin (80 mg/d) + clopidogrel (75 mg/d) following the TAVI procedure.
62592110|NCT06018896|EXPERIMENTAL|Ascorbate|For patients with baseline serum Vitamin C concentration \< 65 μmol/L, intravenous Vitamin C 10 g × 7 days, intravenous Vitamin C 4 g × 7 days, intravenous Vitamin C 2 g × 7 days, followed by continuously 900 mg/day, three times a day, orally. For patients with baseline serum Vitamin C concentration ≥ 65 μmol/L, continuously 900 mg/day, three times a day, orally.
62807544|NCT03753685|EXPERIMENTAL|X-396(Ensartinib) Capsule|
62807545|NCT06148207|EXPERIMENTAL|Low-dose group|Subjects in this group were injected intravenously with 5 ± 1 mCi \[18F\]BF3-BPA
62422627|NCT02933827|EXPERIMENTAL|High dose|ELIXCYTE 40 mL (ADSC 32.0\*10\^7 cells in total)
62422628|NCT05635773|ACTIVE_COMPARATOR|eFONA No Alexa|Arm randomised to performing the procedure without Alexa cognitive aid first
62422629|NCT05635773|EXPERIMENTAL|eFONA Alexa|Arm randomised to performing the procedure using Alexa cognitive aid first
62807546|NCT06148207|EXPERIMENTAL|High-dose group|Subjects in this group were injected intravenously with 9 ± 1 mCi \[18F\]BF3-BPA
62807547|NCT04055675||Asymptomatic Male Volunteers|These are subjects over the age of 18 who have no acute symptoms, volunteered to provide a urine sample, and are male.
62807548|NCT04055675||Asymptomatic Female Volunteers|These are subjects over the age of 18 who have no acute symptoms, volunteered to provide a urine sample, and are female.
62031381|NCT01559298|ACTIVE_COMPARATOR|Aspirin|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin (80 mg/d)
62031382|NCT06670209|EXPERIMENTAL|Treatment arm|
62230881|NCT02416817|EXPERIMENTAL|Blood Products only.|This arm will receive 1:1:1 Red blood cells : Fresh Frozen Plasma : Platelets upon a major trauma triggers. 1:1:1 Ratio for packs of blood products. The patient will be re-evaluated every hour again for the major bleeding triggers and another 1:1:1 intervention may or may not occur.
62230882|NCT02416817|EXPERIMENTAL|Point of care guided|This arm will receive Red blood cells, Human Fibrinogen and Prothrombinic complex concentrates (PCC) based on thromboelastometry. The dosis of each drug will be determined by the analyses of the thromboelastometry curves.
62422630|NCT01336309||Focus Group|We conducted three focus groups per site, at three sites, with around eight people each. These data were used to guide refinement and selection of the items we developed for Phase III data collection. We will administer the Yoga Research Tool.
62031383|NCT06276192|EXPERIMENTAL|Digital Physiotherapy (diSAID)|The digital physiotherapy group receives the digital Shoulder Aid (diSAID) strategy available via a web application. For three months, this group will complete a home-based rehabilitation programme containing education and evidence based exercises for patients with subacromial pain tutored by videos, images and instructions.The treatment is standardized but can be customized by a responsible physiotherapist during the whole treatment period. The Physiotherapist also deliver progression in the education and in the exercises during the whole treatment period and can support the patient via a messenger function in the web application.
62230883|NCT01718782|ACTIVE_COMPARATOR|laryngeal mask Ambu AuraOnce|laryngeal mask Ambu AuraOnce
62230884|NCT01718782|ACTIVE_COMPARATOR|laryngeal mask LMA Supreme|laryngeal mask LMA Supreme
62592111|NCT02393807|EXPERIMENTAL|Open label single dose crossover study of PF-06260414|This will be a Phase 1, open label, randomized, single dose, 3 period, 3 way crossover study to evaluate the relative bioavailability of solid dose formulation of PF 06260414 under fasted conditions compared to the nanosuspension under fasted conditions
62592112|NCT00956592|ACTIVE_COMPARATOR|CMAC Video laryngoscope|Subjects will have their intubation attempted first with the CMAC video laryngoscope
62807549|NCT02525471|EXPERIMENTAL|RNS60|"Following screening visit to determine eligibility, enrolled subjects will undergo the baseline visit within 6 weeks where the first intravenous (IV) infusion of study medication, RNS60, will be administered. Study medication for inhalation use will be dispensed at this time, and again at weeks 7 and 15. Subjects will continue once a week follow ups to receive RNS60 by IV infusion, continuing inhalation use the remaining 6 days per week, for 23 weeks total. Additionally, eligible subjects will undergo PET imaging at baseline and again between weeks 18 and 23.~In addition, upon nearing completion of the core study, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug, following the optional extension phase schedule of activities."
62031384|NCT06276192|ACTIVE_COMPARATOR|Traditional Physiotherapy|The traditional physiotherapy group receives current practice provided by physiotherapist in primary care with no predefined directives. The treating physiotherapist are instructed to treat their patient as they usually do.
62031385|NCT05450965|EXPERIMENTAL|Single Treatment Arm|Onvansertib
62592113|NCT00956592|ACTIVE_COMPARATOR|Macintosh blade|Patients will have their first intubation attempted utilizing the conventional Macintosh design laryngoscope blade
62592114|NCT01931995|ACTIVE_COMPARATOR|TMS to positively correlated DLPFC|High frequency TMS to a target region of dorsolateral prefrontal cortex which is positively correlated with the subgenual cingulate cortex
62592115|NCT01931995|ACTIVE_COMPARATOR|TMS to negatively correlated DLPFC|High frequency TMS to a target region of dorsolateral prefrontal cortex which is positively correlated with the subgenual cingulate cortex
62230885|NCT02457312|ACTIVE_COMPARATOR|Letrozole group|Letrozole 10 mg daily for 7 days before suction evacuation
62230886|NCT02457312|PLACEBO_COMPARATOR|Placebo group|Placebo tablets (look identical to letrozole tablets) daily for 7 days before suction evacuation
62230887|NCT02867293|ACTIVE_COMPARATOR|Preop-drainage|ascites drained over the pre-operative week through multiple ultrasound guided paracentesis
62230888|NCT02867293|ACTIVE_COMPARATOR|Op-drainage|ascetic fluid drained through an abdominal incision after anesthesia
62230889|NCT06247644|EXPERIMENTAL|Arm 1 - On-body Injector (OBI) - only|Adhesion of device with adhesive on left or right upper arm
62230890|NCT06247644|EXPERIMENTAL|Arm 2 - OBI + additional adhesive ring|Adhesion of device with adhesive on left or right upper arm + additional adhesive ring to be placed additional on the skin.
62230891|NCT04568746|OTHER|patients with qSOFA ≥ 2|adult patients with a qSOFA score ≥ 2 at the screening in the emergency department, will be referred to the emergency vital room
62230892|NCT04568746|OTHER|patients with qSOFA <2|adult patients with a qSOFA score \< 2 at the screening in the emergency department, will be referred to the box
62592116|NCT02064504|EXPERIMENTAL|Sequence 1|Participants will receive the study treatment in the following order: ABFCED in each period (one per period). Where A=GSK961081 administered from DISKUS, B=GSK961081 Single strip (SS) administered from DPI, C=GSK961081 Dual Strip (DS) administered from DPI with a filled (lactose) second strip (DS configuration), D=GSK961081/fluticasone furoate (GSK961081/FF) administered from DPI (GSK961081 higher dose), E=FF DS administered from DPI with a filled (lactose) second strip (dual strip configuration), F=GSK961081/FF administered from DPI (GSK961081 lower dose).
62592117|NCT02064504|EXPERIMENTAL|Sequence 2|Participants will receive the study treatment in the following order: BCADFE in each period (one per period)
62592118|NCT02064504|EXPERIMENTAL|Sequence 3|Participants will receive the study treatment in the following order: CDBEAF in each period (one per period)
62592119|NCT02064504|EXPERIMENTAL|Sequence 4|Participants will receive the study treatment in the following order: DECFBA in each period (one per period)
62592120|NCT02064504|EXPERIMENTAL|Sequence 5|Participants will receive the study treatment in the following order: EFDACB in each period (one per period)
62031386|NCT04616157|EXPERIMENTAL|ICBT-I|The ICBT-I treatment program is a web-based intervention consisting of six chapters/sessions that adolescents go through during six consecutive weeks.The program starts with psychoeducation regarding sleep disorders and the rationale for a cognitive behavioral intervention. The main focus for the treatment is behavioral interventions, mainly sleep restriction and stimulus control. The intervention also addresses problem solving, maintenance of treatment gains, relapse prevention and relaxation techniques. Caregivers will not actively participate in the treatment. During the treatment phase participants will be in contact with a therapist through standardized forms in the program.
62243172|NCT05895604|NO_INTERVENTION|Control|Control group members have access to the standard of care and whatever other programs and services are available in the community.
62807550|NCT03410628|EXPERIMENTAL|gammaCore Active Device|open label
62807551|NCT02232035|PLACEBO_COMPARATOR|normal saline, active phase of labor|A single dose intravenous injection of normal saline (2ml) at the beginning of active phase of labor in the group.
62807552|NCT02232035|EXPERIMENTAL|diazepam, active phase of labor|A single dose intravenous injection of diazepam (10mg, 2ml) at the beginning of active phase of labor in the group.
62807553|NCT04622111|EXPERIMENTAL|CPL207280|"PART A: 8 cohorts are to receive single dose of IMP.Each participant is to take single dose of IMP. There is to be dose escalation between cohorts.~PART B: 4 cohorts are to receive multiple dose of IMP. Each participant is to take IMP once daily for 14 days. There is to be dose escalation between cohorts."
62807554|NCT04622111|PLACEBO_COMPARATOR|Placebo|PART B: 2 Participants from each of 4 cohorts (total of 8 participants) are to receive masking placebo tablet once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
62807555|NCT04622111|EXPERIMENTAL|CPL207280 120 mg + Metformin 750 mg|1 cohort (total of 12 participants) are to receive single dose of IMP in fed and fasted state, IMP with metformin and metformin alone to assess the effect of food and metformin on bioavailability of CPL207280. There is to be one week wash-out between four treatments periods for this cohort.
62807556|NCT02016196|EXPERIMENTAL|rifaximin|6 rifaximin caps of 200 mg per day morning and night, during 15 days before TIPS, and after TIPS during 6 months.
62422631|NCT01336309||Cognitive Interviews|We conducted cognitive interviews at three different sites, with about ten in each group. These data were used to guide refinement and selection of the items we developed for Phase III data collection. We collected this data via a large, online survey and administered the Yoga Research Tool.
62422632|NCT01336309||Survey Prototype Administration|We administered a prototype of the study measure to a large group of yoga students, with about 450 total participants. These data were used to further inform the refinement and selection of items to be used in the final measure.
62592121|NCT02064504|EXPERIMENTAL|Sequence 6|Participants will receive the study treatment in the following order: FAEBDC in each period (one per period)
62592122|NCT04842617|EXPERIMENTAL|Treatment group A|
62592123|NCT04842617|PLACEBO_COMPARATOR|Treatment group B|
62807557|NCT02016196|PLACEBO_COMPARATOR|placebo|6 caps placebo morning and night, 15 days before and 6 months after TIPS
62807558|NCT01856699||Study Group|Patients with cortical superficial siderosis and possible or probable cerebral amyloid angiopathy meeting the modified Boston criteria.
62807559|NCT01856699||Control Group|Patients with possible or probable cerebral amyloid angiopathy meeting the classic Boston criteria but without any cortical superficial siderosis.
62807560|NCT04647201||Control|Non-sepsis and non-GI adults
62592124|NCT03986788|OTHER|Weightlessness|Weightlessness measurements during flight
62592125|NCT06620679|EXPERIMENTAL|LPS then Saline|A crossover arm where the participant first receives the intervention (LPS), undergoes a wash-out period, then receives the placebo (saline).
62807561|NCT04647201||Sepsis patients without GI|Patients who meet the criteria of sepsis3.0 with AGI grade I or less
62807562|NCT04647201||Sepsis patients with GI|Patients who meet the criteria of sepsis3.0 with AGI grade II or above
62230893|NCT05647239|EXPERIMENTAL|Intervention|Since the patients included in the study were discharged early (mean hospitalization duration was 3 days), the first, third and fifth SC heparin injection (0.6 ml) administrations were performed by the researcher for three days. The application was made to the arm area due to the fact that Shotblocker was difficult to place in the abdominal area, and the outer side of the arm was preferred for subcutaneous injection administrations in the clinic where the study was conducted. Shotblocker was placed on the injection site determined on the outer side of the upper arm of the patient and the injection was administered by gently pressing the tool with the fingertips during the injection. Shotblocker was removed after removal of the injector. Injections were completed in 20 seconds and the injection site was supported with cotton for 30 seconds.
62592126|NCT06620679|EXPERIMENTAL|Saline then LPS|A crossover arm where the participant first receives the placebo (saline), undergoes a wash-out period, then receives the intervention (LPS).
62230894|NCT05647239|NO_INTERVENTION|Control|"Verbal and written informed consents of the patients included in the control group were obtained after they were informed by the researcher. Before the application, questions in patient information form were asked to each patient and how to use the VAS pain and injection satisfaction scale was explained. During injection, SC Clexan (0.6 ml) was injected on the site without using Shotblocker. Injections were completed in 20 seconds and the site was supported for 30 seconds. In the first minute after each SC injection administration, the patients were asked about pain level felt during the injection and injection satisfaction status.~In this study, the researcher administered all SC injections by throughout the study by considering the reliability of the study results."
62230895|NCT01038063|EXPERIMENTAL|Artemether-lumefantrine|Children in this study arm will be treated with artemether-lumefantrine during a three year follow-up period each time a child develops uncomplicated malaria.
62230896|NCT01038063|ACTIVE_COMPARATOR|Dihydroartemisinin-piperaquine|Children in this study arm will be treated with dihydroartemisinin-piperaquine during a three year follow-up period each time a child develops uncomplicated malaria.
62230897|NCT06418828||Return to work group|Asked whether the patient returned to work, if the patient returned to work, included in this group.
62422633|NCT01336309||Reliability and Validity Testing|We are conducting yoga classes at community partner facilities near each site, with about ten participants in each class. Participants at each class will complete the study measure and related questionnaires, in order to test the reliability and validity of the study measure.
62422634|NCT04767022|EXPERIMENTAL|Genoss® DCB|Paclitaxel Coated PTCA Balloon Catheter
62807563|NCT03788057|OTHER|stable asthma|"In patients with previously stable course of the asthma, every 3 months the symptoms are evaluated and the dose of ICS is customized - in accordance with the GINA guidelines. This decision is based solely on clinical data (control of symptoms) and is the same as in patients not participating in the study.~In patients participating in the study, inflammatory parameters are also measured (sputum eosinophilia, eNO, EBT, bronchial reactivity), but results are not known to clinician taking decision about possible ICS dose reduction."
62807564|NCT05150184||Healthy adults, various ethnicities|Non-interventional
62807565|NCT00883363|EXPERIMENTAL|Precondition|Induction of precondition at start of operation on a arm
62230898|NCT06418828||Non-return to work group|Ask whether the patient returned to work, if the patient did not return to work, included in this group.
62807566|NCT00883363|NO_INTERVENTION|Control|No precondition
62230899|NCT02757859|ACTIVE_COMPARATOR|Arm I (EIPL-S)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after removal of tumor, patients receive EIPL-S lavage 10 times over 15 minutes.
62422635|NCT04767022|ACTIVE_COMPARATOR|SeQuent® Please NEO|Paclitaxel Coated PTCA Balloon Catheter
62422636|NCT01284816|OTHER|severely obese patients|35 patients addressed for severe obesity in the Endocrinology department of Marseille North Hospital before (V1) and 6 months (V2) after bariatric surgery
62422637|NCT01291069|EXPERIMENTAL|Tadalafil Citrate|The study subjects will be given Tadalfil citrate, encapsulated, 0.8-1 mg/kg/day in 1 dose orally. Max dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
62807567|NCT04649112|EXPERIMENTAL|Dose Level 1|"In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL).~Route of Administration: Intravenous injection/infusion."
62807568|NCT04649112|EXPERIMENTAL|Dose Level 2|"In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL).~Route of Administration: Intravenous injection/infusion."
62422638|NCT01291069|PLACEBO_COMPARATOR|Sugar pill|If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a sugar pill. All patients will receive either study drug or placebo for a total of 20 days.
62807569|NCT04649112|EXPERIMENTAL|Dose Level 3|"In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL).~Route of Administration: Intravenous injection/infusion."
62807570|NCT03473236|EXPERIMENTAL|Cohort 1A|Dose 1 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
62807571|NCT03473236|EXPERIMENTAL|Cohort 2A|Dose 2 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
62031387|NCT05985187|EXPERIMENTAL|TQB2440 injection + Trastuzumab + docetaxel|"Neoadjuvant phase (cycle 1-4):~TQB2440 injection + Trastuzumab + Docetaxel, intravenous infusion on the first day of each cycle, each cycle is 21 days.~Adjuvant chemotherapy phase (cycle 5-7):~Fluorouracil (600 mg/m2)+Epirubicin (90 mg/m2)+Cyclophosphamide (600mg/m2), intravenous injection once a day, on the first day of each cycle, each cycle is 21 days.~Double targeted maintenance phase (cycle 8-20):~TQB2440 injection+Trastuzumab, intravenous infusion on the first day of each cycle, each cycle is 21 days."
62031388|NCT05985187|ACTIVE_COMPARATOR|Perjeta® + Trastuzumab + docetaxel|"Neoadjuvant phase (cycle 1-4):~Perjeta® (Pertuzumab injection) + Trastuzumab + Docetaxel, intravenous infusion on the first day of each cycle, each cycle is 21 days.~Adjuvant chemotherapy phase (cycle 5-7):~Fluorouracil (600 mg/m2)+Epirubicin (90 mg/m2)+Cyclophosphamide (600mg/m2), intravenous injection once a day, on the first day of each cycle, each cycle is 21 days.~Double targeted maintenance phase (cycle 8-20):~TQB2440 injection+Trastuzumab, intravenous infusion on the first day of each cycle, each cycle is 21 days."
62230900|NCT02757859|ACTIVE_COMPARATOR|Arm II (EIPL-D)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after removal of tumor, patients receive EIPL-D lavage 10 times over 15 minutes.
62031389|NCT03589898|EXPERIMENTAL|Gabapentin|Single dose of gabapentin 900 mg will be given and neuroimaging markers will be measured before and after administration of gabapentin
62031390|NCT01510847|OTHER|Oral Testosterone Therapy|90 day oral testosterone therapy
62031391|NCT05041673|ACTIVE_COMPARATOR|Group 1|metformin +/- insulin +/- sulfonylurea
62230901|NCT02757859|SHAM_COMPARATOR|ARM III (NO LAVAGE)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy with no extensive lavage after removal of tumor.
62230902|NCT03436108||PCOS group|patients who have PCOS
62230903|NCT03436108||control group|patients who donnot have PCOS
62230904|NCT01344512|EXPERIMENTAL|Patients treated with Ceftazidime|
62230905|NCT01344512|EXPERIMENTAL|Patients treated with Ciprofloxacin|
62230906|NCT01344512|EXPERIMENTAL|Patients treated with Voriconazole|
62230907|NCT04998370||Study cohort|The study population consists of patients admitted to an academic tertiary care center due to an aneurysmal subarachnoid hemorrhage. The primary objective of the study focuses on patients included with external ventricular drain (EVD), while secondary objectives consider patients with both EVD and lumbar drain (LD) as well as patients without any drainage system.
62230908|NCT02873507|EXPERIMENTAL|MRI of donor liver|MRI evaluation of graft steatosis in donor liver prior to transplantation
62230909|NCT00227890|EXPERIMENTAL|1|Motivational Interviewing followed by Cognitive Behavior Therapy (MI/CBT)
62230910|NCT00227890|EXPERIMENTAL|2|Relaxation Training followed by Treatment as Usual (RT/TU)
62230911|NCT05330637||Migratory old people with asthma from northern China in Sanya|Migratory old people with asthma from northern China to Sanya have being exposure to two different climate and environment from northern China to Sanya for months.
62422639|NCT02754505|OTHER|Early rehabilitation group|Directly after transfer to a general ward the early rehabilitation group started with an early rehabilitation program, as ordered by an experienced physiatrist. The applied intervention (early rehabilitation) is a combination out of different therapeutic modalities (for further information please see interventions).
62592127|NCT05665972|EXPERIMENTAL|Mandala coloring group|Mandala painting will be applied to women suffering from premenstrual syndrome.
62807572|NCT03473236|EXPERIMENTAL|Cohort 3A|Dose 3 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
62807573|NCT03473236|EXPERIMENTAL|Cohort 4A|Dose 4 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
62807574|NCT03473236|EXPERIMENTAL|Cohort 5A|Dose 5 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
62807575|NCT03473236|EXPERIMENTAL|Cohort 1B|Dose 1 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
62031392|NCT05041673|EXPERIMENTAL|Group 2|Metformin plus vildagliptin +/- insulin +/- sulfonylurea
62031393|NCT05041673|EXPERIMENTAL|Group 3|Metformin plus liraglutide +/- insulin+/- sulfonylurea
62230912|NCT05330637||Migratory old people with allergic rhinitis from northern China in Sanya|Migratory old people with allergic rhinitis from northern China to Sanya have being exposure to two different climate and environment from northern China to Sanya for months.
62230913|NCT05330637||Migratory old people with Chronic Obstructive Pulmonary Disease (COPD) from northern China in Sanya|Migratory old people with Chronic Obstructive Pulmonary Disease (COPD) from northern China to Sanya have being exposure to two different climate and environment from northern China to Sanya for months.
62230914|NCT05330637||Migratory old people with atopic dermatitis from northern China in Sanya|Migratory old people with atopic dermatitis from northern China to Sanya have being exposure to two different climate and environment from northern China to Sanya for months.
62230915|NCT05330637||Children with asthma in Sanya|Children with asthma have being exposure to tropical climate and environment in Sanya for years.
62807576|NCT03473236|EXPERIMENTAL|Cohort 2B|Dose 2 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
62031394|NCT05041673|EXPERIMENTAL|Group 4|Metformin plus empagliflozin +/- insulin +/- sulfonylurea
62807577|NCT03473236|EXPERIMENTAL|Cohort 3B|Dose 3 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
62807578|NCT00115505||Ancillary-Correlative (QOL, employment, informal care cost)|Patients complete the QOL Assessments comprising the Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form; Employment and Informal Care Cost Assessments; and Peripheral Neuropathy of the FACT-NTX subscale at baseline, 29-42 and 57-70 days, and at 9 and 18 months. Patients meeting the cut-off score for peripheral neuropathy on the FACT-NTX subscale at 18 months complete the Symptoms in Relation to Patient Functioning Survey, FACT-NTX subscale, the EORTC QLQ-C30, EORTC QLQ-BR23, and the Medications Used for Treating Peripheral Neuropathy at 24, 36, 48, and 60 months.
62807579|NCT03239834||OncAlert RAPID test in oral cavity biopsy patients.|Patients at an intermediate and high level of clinical risk for HNSCC and scheduled for initial and immediate incisional diagnostic biopsy of their Oral Cavity.
62807580|NCT03239834||OncAlert RAPID test in oropharyngeal biopsy patients.|Patients at an intermediate to high level of clinical risk for HNSCC and scheduled for initial and immediate incisional diagnostic biopsy of their Oropharnyx
62807581|NCT03239834||OncAlert RAPID test in clinical decision to biopsy.|Patients at a lower level of clinical risk for HNSCC and not scheduled for an immediate biopsy. Patients will be offered medical management and have an initial RAPID test. All patients will return within 1-3 months for follow-up test and a possible biopsy if clinically indicated.
62807582|NCT02963454|EXPERIMENTAL|levosimendan 0.2 μg/kg/min|"Treatment with levosimendan 0.2 μg/kg/min 24h (without bolus).~Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle."
62807583|NCT02963454|ACTIVE_COMPARATOR|dobutamine 5 μg/kg/min|"Treatment with dobutamine 5 μg/kg/min. Dobutamine were administered during all the 72 hours study period.~Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle."
62807584|NCT03865446|EXPERIMENTAL|Cohort 1 (Dacomitinib)|severe hepatic impairment group
62031395|NCT01914796|PLACEBO_COMPARATOR|Single ascending doses|
62422640|NCT02754505|OTHER|Usual care group|The usual care group received single physical therapy sessions as ordered by the primary care team after transfer from the ICU to the general ward. The applied intervention (usual care) is a combination out of different therapeutic modalities (for further information please see interventions).
62422641|NCT04155957|ACTIVE_COMPARATOR|Conventional Rehabilitation Group|Participants follow the usual fast-track protocol used at Hospital Clínic de Barcelona for Total Knee Arthroplasty and perform a daily 5-exercise plan autonomously.
62807585|NCT03865446|EXPERIMENTAL|Cohort 2 (Dacomitinib)|normal hepatic function
62807586|NCT02268149|EXPERIMENTAL|BIIL 284 BS + Prednisone|BIIL 284 BS 9 days; prednisone 2 single doses
62807587|NCT02268149|PLACEBO_COMPARATOR|Placebo|
62807588|NCT06515587|EXPERIMENTAL|Study group|All enrolled subjects will accurately complete one Lewis genotype test and at least one CA19-9 test
62807589|NCT05706779|EXPERIMENTAL|Encorafenib + Cetuximab|
62807590|NCT01222845|EXPERIMENTAL|Pinhead oat porridge|
62031396|NCT01914796|PLACEBO_COMPARATOR|Measurement of eye blink rate|
62031397|NCT06529952|EXPERIMENTAL|Hysteroscopic resection|26 patients subjected to hysteroscopic surgery in the form of resection of lower edge, resection of upper edge and endocoagulation to fulgurate the visible dilated blood vessels or endometrial-like glands inside the base of the niche by using a roller ball resectoscope with monopolar electrical current and glycine as distension media.
62031398|NCT06529952|EXPERIMENTAL|hysteroscopic endocoagulation|include 26 patients subjected to hysteroscopic endocoagulation to the base of the niche by roller ball using monopolar electrical current and glycine as distension media.
62031399|NCT06529952|EXPERIMENTAL|hormonal treatment|26 patients received hormonal treatment in the form of 3rd generation combined oral contraceptive pills in a cyclic manner for 6 months.
62031400|NCT01535404|ACTIVE_COMPARATOR|Right ventricular apex pacing|
62031401|NCT01535404|EXPERIMENTAL|Left ventricular apex pacing|
62230916|NCT05330637||Children with allergic rhinitis in Sanya|Children with allergic rhinitis have being exposure to tropical climate and environment in Sanya for years.
62230917|NCT05330637||Children with atopic dermatitis in Sanya|Children with atopic dermatitis have being exposure to tropical climate and environment in Sanya for years.
62230918|NCT05330637||Children with eczema in Sanya|Children with eczema have being exposure to tropical climate and environment in Sanya for years.
62230919|NCT05330637||Children with urticaria in Sanya|Children with urticaria have being exposure to tropical climate and environment in Sanya for years.
62230920|NCT05330637||Migratory old people with eczema from northern China in Sanya|Migratory old people with eczema from northern China to Sanya have being exposure to two different climate and environment from northern China to Sanya for months.
62230921|NCT05330637||Migratory old people with urticaria from northern China in Sanya|Migratory old people with urticaria from northern China to Sanya have being exposure to two different climate and environment from northern China to Sanya for months.
62230922|NCT02977117|EXPERIMENTAL|Dialysate magnesium 1.0 mmol/L|Increase dialysate magnesium from 0.5 mmol/L to 1.0 mmol/L.
62230923|NCT02977117|ACTIVE_COMPARATOR|Dialysate magnesium 0.5 mmol/L|Maintain dialysate magnesium at 0.5 mmol/L.
62230924|NCT03125525||Active treatment patients|Patients using Cefaly device on routine daily basis
62230925|NCT04168333|ACTIVE_COMPARATOR|T101 Group|"The study will consist of 2 cohorts:~Single Dose (SD) Cohort:~9 chronic hepatitis B patients will be enrolled and be divided into 3 groups, with 3 patients in each group.~Multiple Dose (MD) Cohort:~18 chronic hepatitis B patients will be enrolled and be divided into 2 groups, with 9 patients in each group."
62230926|NCT04168333|PLACEBO_COMPARATOR|Placebo Group|"The study will consist of 2 cohorts:~Single Dose (SD) Cohort:~3 chronic hepatitis B patients will be enrolled in this group.~Multiple Dose (MD) Cohort:~6 chronic hepatitis B patients will be enrolled in this group."
62807591|NCT01222845|EXPERIMENTAL|Rolled oat porridge|
62422642|NCT04155957|EXPERIMENTAL|ReHub Group|Participants follow the usual fast-track protocol used at Hospital Clínic de Barcelona for Total Knee Arthroplasty but use the telerehabilitation platform ReHub to do the exercises in their rehabilitation plan at home and to have their progress monitored.
62422643|NCT04144231|NO_INTERVENTION|Treatment-as-usual (TAU)|Treatment-as-usual (TAU) delivered by psychiatrists and psychiatric nurses in HUS Psychiatry Outpatient Clinic for Psychosis. Participants who randomized to TAU -group, may receive medication for insomnia, but they will not received CBT-I. Treatment-as-usual is included in all intervention groups.
62422644|NCT04144231|EXPERIMENTAL|Internet-Based Cognitive Behavioral Therapy for Insomnia|"TAU and Internet-Based Cognitive Behavioral Therapy for Insomnia (iCBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I): There will be seven manualized sessions, conducted at intervals of either every one or two weeks.~HUS iCBT-I, is based on the same theoretical model of insomnia as described in Morin 2003 and Edinger 2015- and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. iCBT-I consists of psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep.~During the therapy, the therapist monitors progress at least once a week, sends messages to the participant, and answers any treatment-related questions. The aim of the feedback is to comment on exercises, clarify intervention and motivate the patient to persist the in carrying out the treatment and the requested behavioral changes."
62422645|NCT04144231|EXPERIMENTAL|Cognitive Behavioral Group Therapy for Insomnia|TAU and Cognitive Behavioral Group Therapy for Insomnia (GCBT-I): There will be six 90-minute manualized sessions, conducted at intervals of either one or two weeks. One booster session will be conducted one month after the treatment. Each group will have 4-8 people. The content of the CBT-I group is based on CBT for insomnia (as described above) and a previously published insomnia treatment manual for psychotic patients (Waters 2017).To ensuring the rights, safety and wellbeing of participants during the COVID-19 (Coronavirus) pandemic, we produce GCBT-I via internet.
62422646|NCT01700088||Oxygen cannular|After lung resection surgery,every patient will received supplementary oxygen 5 L/minutes via oxygen cannular for 120 minutes
62592128|NCT05665972|NO_INTERVENTION|Control group|Participants in this group will consist of people who do not routinely do any practice on their own to reduce premenstrual syndrome symptoms.
62592129|NCT03374592|ACTIVE_COMPARATOR|Conventional Radiotherapy|8Gy in 1 fraction or 20Gy in 5 fractions
62592130|NCT03374592|EXPERIMENTAL|Volumetric Intensity-Modulated Arc Therapy|8Gy in 1 fraction or 20Gy in 5 fractions
62592131|NCT01504607||Congenital cataract surgery with IOL implantation|Congenital cataract surgery was performed with or without anterior vitrectomy, followed by in the bag IOL implantation
62592132|NCT01520558|EXPERIMENTAL|CNDO-109-AANK Cells Dose 1|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the lowest of these three doses (dose 1) is 3×10\^5 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
62592133|NCT01520558|EXPERIMENTAL|CNDO-109-AANK Cells Dose 2|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the middle dose of these three doses (dose 2) is 1×10\^6 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
62807592|NCT03522298|EXPERIMENTAL|Dose Escalation and Expansion Cohorts|"This is an open-label study.~Patients in Stage 1 will be enrolled and sequentially assigned to a dose cohort.~The initial cohort will receive an oral dose of 60 mg paxalisib QD (4 x 15 mg capsules). Patients of future dose cohorts will receive paxalisib at increasing levels with 15 mg steps until a dose-limiting toxicity occurs (DLT) occurs. The dose level where \<1/3 of the patients exhibit a DLT will be determined the Maximum Tolerated Dose (MTD).~In stage 1, dose escalation will occur for QD dosing.~In stage 2, the expansion phase, patients will receive doses of oral paxalisib at the MTD in stage 1, until disease progression or an unacceptable toxicity, whichever occurs first.~Patients will be randomized in a 1:1 ratio to fed or fasted schedules."
62807593|NCT01132807|EXPERIMENTAL|Treatment (chemotherapy and F-18 PET/CT)|See Detailed Description
62807594|NCT05218369||Critically ill COVID-19 patients|Patients in ICU due to critical COVID-19 infection, who receive early (within the first 24 hours, but no later than 48 hours after intubation) IL-6 antagonist therapy at the consultant's discretion.
62807595|NCT01780857||PPP patients|Patients with palmoplantar pustulosis who have had blood and tissue samples taken.
62807596|NCT01780857||Healthy controls|Patients without palmoplantar pustulosis or any inflammatory skin condition who have had blood and tissue samples taken.
62807597|NCT03921827|EXPERIMENTAL|EECP therapy|Half of the study sample will be allocated to EECP therapy (35 sessions) of 1-hour each. Acetazolamide challenged HMPAO-SPECT will be performed before randomization and repeated 2-months after the completion of EECP therapy. MRI of the brain would be performed after completion of EECP therapy to document any silent stroke.
62807598|NCT03921827|NO_INTERVENTION|Best Medical Therapy|This group will receive the best medical therapy according to our institutional practice and as per the recommendations of American Stroke Association.
62807599|NCT03147846|EXPERIMENTAL|delayed cord clamping|"Keep the baby at the level or below the placenta for 45-60 seconds before clamping the cord.~Keep the room temperature at 23-25˚C and wrap the baby if possible"
62807600|NCT03147846|ACTIVE_COMPARATOR|cord milking|Do 4-5 strips from proximal (maternal) end of the cord (as proximal as possible) towards the baby abdomen with thumb and forefinger Wait for 2 seconds between each stripping Keep the baby at the level of placenta
62031402|NCT02370212|EXPERIMENTAL|Creatine|"Creatine will be ingested after interval training and at supper time on training days and in the morning and afternoon on non-training days (0.05 g/kg body mass of creatine with 0.05 g/kg flavoured dextrose per dose).~Both experimental and placebo groups will perform the same high intensity interval training protocols (3x/week for 4 weeks)."
62031403|NCT02370212|PLACEBO_COMPARATOR|Placebo|"The placebo will be ingested after interval training and at supper time on training days and in the morning and afternoon on non-training days (0.1 g/kg flavoured dextrose per dose, isocaloric to the creatine).~Both experimental and placebo groups will perform the same high intensity interval training protocols (3x/week for 4 weeks)."
62031404|NCT04830449|EXPERIMENTAL|HCP1904-2|
62230927|NCT05363423||Procedure/Surgery: lateral pedicled nasoseptal flaps applied in Draf III procedure|"The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre. Tumors were totally resected under endoscope and lateral pedicled nasoseptal flaps were applied for covering the exposed bone around frontal neo-ostium. Type 1 flaps consisted of mucosa over the lateral nasal wall, and type 2 flaps consisted of the aforementioned mucosa and corresponding septal mucosa."
62031405|NCT04830449|ACTIVE_COMPARATOR|RLD2001-2|
62807601|NCT03910504|ACTIVE_COMPARATOR|Rocuronium 0,3 mg/kg|"One hour before the operation the patient will receive the midazolam from 1 to 5 mg intravenous. After the adequate preoxigenation and denitrogenation, the induction phase will be performed with the propofol 2 mg/kg intravenous bolus (for the sedation). At the same time continues infusion of remifentanyl (up to 1 mcg/kg/min) will guarantee the adequate anaesthesia.~Patients, who have been randomized to this group, will be obtained single reduced dose of rocuronium (0,3 mg/kg) once intravenous bolus. The dose of rocuronium will be prepared by an external investigator, to leave the anesthesiologist blinded of the group treatment. The drug will be diluited in a syringe with 20 ml of solution."
62230928|NCT05363423||Procedure/Surgery: no flaps applied in Draf III procedure|"The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre. Tumors were totally resected under endoscope and no flaps were applied."
62422647|NCT01971229|SHAM_COMPARATOR|Carbohydrate|Patients in this arm will drink a 425 mL 100% clear apple juice (carbohydrate 50 g, 700 mOsmol). 1.5 g of acetaminophen will be dissolved in the beverage for determination of gastric emptying.
62230929|NCT03408054|NO_INTERVENTION|Control group|No oxytocin desensitization (pretreatment), no nitroglycerin
62230930|NCT03408054|ACTIVE_COMPARATOR|Oxytocin desensitized - no nitroglycerin|Pretreated with oxytocin, no nitroglycerin exposure
62230931|NCT03408054|ACTIVE_COMPARATOR|Oxytocin desensitized - plus nitroglycerin|Pretreated with oxytocin followed by nitroglycerin exposure
62031406|NCT06666400|ACTIVE_COMPARATOR|Attention Control|The attention control arm (N=300) will receive standard doula care and the same number of telephone or video-delivered sessions and will last the same amount of time on general postpartum health topics not related to CV health or depression. Attention control participants will not receive doula-initiated outreach during the first 7 days.
62031407|NCT06666400|EXPERIMENTAL|LHMoms Intervention Arm|The LHM arm (N=300) will receive a CBT+ Cardiovascular Health (CVH) Intervention to reduce CV risk. LHM employs a cognitive behavioral training (CBT) + cardiovascular health (CVH) intervention delivered by doulas and integrating a healthy lifestyle intervention to reduce CV risk. The LHM intervention integrates the following key elements: (1) doula-led emergency detection in the first 7 days post-discharge; (2) home BP monitoring (HBPM); and (3) 11-sessions of the doula-delivered intervention to prevent PPD and reduce CV risk from 1 week to 6 months post-discharge, supported by (4) education through the Patient-Activated Learning System (PALS), a novel education platform used to engage low-literacy, racially marginalized individuals. LHM is based on the Thinking Healthy Programme (THP), an intervention originally designed to treat PPD in low and middle-income countries using community health workers.
62230932|NCT03408054|ACTIVE_COMPARATOR|Non oxytocin desensitized - plus nitroglycerin|No oxytocin pretreatment, followed by nitroglycerin exposure
62230933|NCT05822453|EXPERIMENTAL|Gemcitabine plus S1 and tislelizumab|Participants will receive gemcitabine plus S1 and tislelizumab until disease progression or unacceptable toxicity
62422648|NCT01971229|ACTIVE_COMPARATOR|Whey Protein|Patients in this arm will drink a 330 mL Boost fruit flavoured clear beverage (whey protein 12.2 g, carbohydrate 50 g, 700 mOsmol).1.5 g of acetaminophen will be dissolved in the beverage for determination of gastric emptying.
62422649|NCT03585868|PLACEBO_COMPARATOR|Placebo|Beverage without flavonoids
62031408|NCT02868060|EXPERIMENTAL|1 mcg/kg AMG531|The administration of Romiplostim will be performed on Day 1 and 8
62031409|NCT02868060|EXPERIMENTAL|3 mcg/kg AMG531|The administration of Romiplostim will be performed on Day 1 and 8
62031410|NCT06369298|ACTIVE_COMPARATOR|JK07 low dose|JK07 administered by intravenous (IV) infusion
62422650|NCT03585868|SHAM_COMPARATOR|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
62422651|NCT03585868|EXPERIMENTAL|Flavonoids|Beverage with a flavonoid rich mixture
62422652|NCT03054935||Subject-CD|Subjects with Crohn's Disease in active or quiescent phase, classified according to Crohn's Disease Activity Index (CDAI \>150 active; CDAI \< 150 quiescent)
62807602|NCT03910504|EXPERIMENTAL|No rocuronium|"One hour before the operation the patient will receive the midazolam from 1 to 5 mg intravenous. After the adequate preoxigenation and denitrogenation, the induction phase will be performed with the propofol 2 mg/kg intravenous bolus (for the sedation). At the same time continues infusion of remifentanyl (up to 1 mcg/kg/min) will guarantee the adequate anaesthesia.~Patients, who have been randomized to this group, will not receive rocuronium, but normal saline will be administered by the anesthesiologist in charge of the patients. The dose of normal saline (20 ml in one syringe) will be prepared by an external investigator, to leave the anesthesiologist blinded of the group treatment."
62807603|NCT03416140|EXPERIMENTAL|Therapeutic exercise|
62807604|NCT03416140|NO_INTERVENTION|Control|
62230934|NCT05402748|EXPERIMENTAL|exosome cases|The patients whose fistula is treated by exosome (40 patients).
62422653|NCT05446480|EXPERIMENTAL|Desloratadine|Desloratadine (Aerius) 10mg compounded to oral pill
62807605|NCT04712955|ACTIVE_COMPARATOR|Bloodflow restricted exercise|Healthy subjects undergoing low intensity blood flow restricted resistance exercise (BFRRE) conducted as 4 sets of bilateral knee extensions at 30% of 1RM until voluntary fatigue. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
62807606|NCT04712955|NO_INTERVENTION|Non-exercise control|No intervention.
62422654|NCT05446480|EXPERIMENTAL|Inert Placebo|Placebo 10mg compounded to oral pill
62422655|NCT05446480|EXPERIMENTAL|No Intervention|No intervention: neither drug nor placebo
62422656|NCT05163431|EXPERIMENTAL|Painful Hallux Valgus|
62422657|NCT04886869|EXPERIMENTAL|Coffee|Oral consumption of 3 cups of coffee containing 240 mg caffeine
62422658|NCT04886869|EXPERIMENTAL|Energy drink|Oral consumption of 750 mL of a commercial energy drink containing 240 mg caffeine
62422659|NCT04886869|PLACEBO_COMPARATOR|Placebo|Oral consumption of 750 mL water
62422660|NCT02149862|EXPERIMENTAL|cancer|patients with an indication of partial or total bladder resection will have urine infrared analysis
62230935|NCT05402748|PLACEBO_COMPARATOR|Controls|The patients whose fistula is treated with conventional treatment plan (40 patients).
62230936|NCT01138579|EXPERIMENTAL|1|
62230937|NCT02031315||Resident of health areas of interest|Residents of 4 health areas will be monitored for sudden unexpected death within 72 months of follow up. Circumstances and past medical conditions will be checked.
62422661|NCT02149862|PLACEBO_COMPARATOR|control group|"Lithiasic patients should be operated a urinary calculation, without catheter double J, will have urine infrared analysis"
62422662|NCT01030250||Under 65 years|Breast cancer patients receiving adjuvant chemotherapy. Those under 65 years of age will be prospectively evaluated for outcome.
62422663|NCT01030250||Over 65 years|Breast cancer patients receiving adjuvant chemotherapy. Those over 65 years of age will be prospectively evaluated for outcome.
62422664|NCT06442059||copd|Patients over the age of 45 who have been diagnosed with COPD and whose clinical condition is stable
62230938|NCT06485440||BTA|10 patients with giant hernias of the anterior abdominal wall (W3 in the classification of the European Hernia Society) prepared with BTA injections prior to surgery
62230939|NCT05792969||Stroke patients with USN and their caregivers|
62230940|NCT05792969||Stroke patients without USN and their caregivers|
62422665|NCT02706600|OTHER|Written Self Management|The HealthQuest written self management plan was produced in 2013. It is a one page document which contains a written self management plan which can be individualised for the patient. It consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate.
62422666|NCT02706600|ACTIVE_COMPARATOR|Online Self Management|"myCOPD is a system that can be accessed by patients using any device that can connect to the internet and can operate in any internet browser. It contains: Educational information, Inhaler technique videos explaining the correct technique required to use different inhaler devices licensed for use in people with COPD.~Medication and symptom diaries. Appointment diary, pulmonary rehabilitation videos to promote and support exercises that can be done in the home.~Oxygen Alert Card - Users can create their own oxygen alert card online A 5 Day local weather and pollution reports - Feed for reports come from the met office and DEFRA.~A Self management plan, which consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate. The action plan is populated automatically with the information input by the patients."
62422667|NCT06349434|EXPERIMENTAL|MyoPro|Receiving MyoMo training in-clinic for 6 weeks, and continuing MyoMo training in-clinic and at home for another 6 weeks.
62807607|NCT01488045|ACTIVE_COMPARATOR|Fentanyl and Midazolam|Fentanyl and Midazolam sedation for colonoscopy discomfort
62807608|NCT01488045|ACTIVE_COMPARATOR|Propofol|Propofol sedation for colonoscopy discomfort
62807609|NCT02093507|EXPERIMENTAL|parents manipulation|parents manipulation
62230941|NCT05632445|OTHER|Apixaban|Apixaban 5mg bid oral.Duration: 3 months Aspirin 80 / 100 mg bid oral. Duration: 9 months
62230942|NCT05632445|OTHER|DAPT|Aspirin 80/100 mg + Clopidogrel 75 mg bid oral. Duration: 3 months Aspirin 80 / 100 mg bid oral. Durtaion: 9 months
62807610|NCT02093507|NO_INTERVENTION|no manipulation|no manipulation
62807611|NCT05086497|NO_INTERVENTION|Conventional Array Mapping Layout|Participants in this study arm will still receive Optune array layout mapping based on standard MR imaging sequences.
62807612|NCT05086497|EXPERIMENTAL|Advanced MR Imaging Array Mapping Layout|Participants in this study arm will receive Optune array layout mapping created from advanced MR imaging sequences obtained through trial enrollment.
62807613|NCT00859547|EXPERIMENTAL|Recombinant thrombin (rThrombin), 1000 IU/mL|
62031411|NCT06369298|ACTIVE_COMPARATOR|JK07 high dose|JK07 administered by intravenous (IV) infusion
62230943|NCT02558309||Intracranial Pressure Reduction|"Subjects scheduled to undergo gradual, step-wise reduction of Intracranial Pressure (ICP) will be screened.~* The Glasgow Coma Scale will be administered to ascertain the cognitive ability of the participant.~* A slit lamp examination and indirect ophthalmoscopy will be performed.~Experimental:~* The subject's eye will be held open with an eye speculum during the exam.~* Another eye exam, which includes a slit lamp examination and indirect ophthalmoscopy, will be performed.~* Intraocular Pressure will be measured.~* An Optic Coherence Tomography (OCT) will be performed.~* At each step along the process of ICP reduction, the eye exam, IOP \& OCT will be performed.~Optional:~* The Ophthalmology study team will raise the IOP using an Ophthlmodynanometer. It will be raised to 20 mmHg and 40 mmHg while OCT scans are obtained.~* OCT scans will be taken at pre-manipulation, 20mmHg, 40mmHg, and post-manipulation at each step of the ICP lowering procedure."
62230944|NCT00681330|EXPERIMENTAL|A|
62230945|NCT00351143|EXPERIMENTAL|Interventional group: Period 2|Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training in Period 2
62230946|NCT00351143|ACTIVE_COMPARATOR|Control group: Period 2|Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg in treatment Period 2
62230947|NCT00351143|EXPERIMENTAL|Subjects receiving salmeterol/fluticasone propionate: Period 1|All subjects treated with salmeterol/fluticasone propionate 50/250 µg b.i.d without any other intervention will be included in Period 1
62422668|NCT06349434|ACTIVE_COMPARATOR|Control|Receiving conventional therapy in-clinic and using their prescribed static brace (or others) for 6 weeks, and continuing the conventional therapy in-clinic and home using their prescribed static brace (or others) at home for 6 weeks.
62422669|NCT01318200|ACTIVE_COMPARATOR|Transarterial Chemoembolization|
62422670|NCT01318200|ACTIVE_COMPARATOR|CyberKnife SBRT|
62807614|NCT03093896|PLACEBO_COMPARATOR|snack mix|snack mix, 3 ounces: dried coconut, meat jerky, butter, cereal party mix
62807615|NCT03093896|ACTIVE_COMPARATOR|almonds, 1.5 ounces|almonds, 1.5 ounces/day
62422671|NCT06495125|EXPERIMENTAL|Treatment (defactinib, avutometinib, nivolumab)|Patients receive defactinib PO BID on days 1-21, avutometinib PO twice weekly on Monday and Thursday, Tuesday and Friday or Wednesday and Saturday for 21 days and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy, blood sample collection, CT or PET on study.
62422672|NCT04143997||PPCM with Diastolic Dysfunction & Normal Systolic Function|The patient population examined will include patients diagnosed with peripartum cardiomyopathy who have diastolic dysfunction and normal systolic function.
62592134|NCT01520558|EXPERIMENTAL|CNDO-109-AANK Cells Dose 3|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the highest dose of these three doses (dose 3) is 3×10\^6 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
62592135|NCT02651155|EXPERIMENTAL|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
62807616|NCT03093896|ACTIVE_COMPARATOR|almonds, 3 ounces|almonds, 3 ounces/day
62807617|NCT01557426|OTHER|Ultrasound|Single interventional group - patients agree to an ultrasound of their skin or soft tissue infection and an ultrasound to an uninfected portion of skin.
62807618|NCT02604381|EXPERIMENTAL|Glucosamine Sulfate Potassium Chloride/Ginkgo Biloba Extract|2 capsules daily, immediately following a meal. 1 capsule in the morning, and 1 capsule in the evening, at approximately the same time each day.
62807619|NCT02604381|PLACEBO_COMPARATOR|Placebo|2 capsules daily, immediately following a meal. 1 capsule in the morning, and 1 capsule in the evening, at approximately the same time each day.
62807620|NCT00647296|PLACEBO_COMPARATOR|Part 1: Placebo or Dexpramipexole|During Part 1, subjects received twice daily doses of dexpramipexole (50 mg/day, 150 mg/day, or 300 mg/day) or matching placebo for approximately 12 weeks.
62807621|NCT00647296|EXPERIMENTAL|Part 2: Placebo washout|At the beginning of Part 2, subjects received twice daily doses of placebo for approximately 4 weeks.
62807622|NCT00647296|EXPERIMENTAL|Part 2: Dexpramipexole|Following the Part 2 placebo washout, subjects received dexpramipexole (50 mg/day or 300 mg/day), subjects received twice daily doses of placebo for up to 18 months.
62807623|NCT00822614|ACTIVE_COMPARATOR|Active Comparator|Current BTP Medication
62807624|NCT00822614|EXPERIMENTAL|Fentanyl TAIFUN|Titration for dose confirmation followed by observation period
62031412|NCT06369298|PLACEBO_COMPARATOR|Placebo|Placebo administered by intravenous (IV) infusion
62230948|NCT05617352||2F Group|Patients with Two-field Lymphadenectomy
62230949|NCT05617352||3F Group|Patients with Three-field Lymphadenectomy
62807625|NCT02728180|EXPERIMENTAL|Xingnaojing and standard care|Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.
62807626|NCT02728180|ACTIVE_COMPARATOR|Standard care only|Subjects will receive guidelines-based standard care only.
62031413|NCT05880992|OTHER|Progress Check|This arm will include pre- and post-prehabilitation questionnaires as well as twice weekly progress checks by the research assistant to check on participant progress, answer questions and provide accountability and motivation.
62031414|NCT05880992|OTHER|No Progress Check|This arm will include only pre- and post-prehabilitation questionnaires.
62031415|NCT00450827|EXPERIMENTAL|Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab|Patients will be administered a therapeutic doses of intravenous (IV) 131I-3F8 given in a single dose per the dose escalation regimen on day 0 of study. This will be followed by blood draws for pharmacokinetic and dosimetry studies and by gamma camera scan, where feasible. Bevacizumab will be administered at a fixed dose of 15mg/kg on days 1 and 15. Thyroid protection is commenced 10 days prior to administration of 131I-3F8 and continued for 28 days after the therapeutic dose of 131I-3F8. ASCR will be carried out if ANC \< 500/ul on day 28 (blood radioactivity will be confirmed to be \<1 uCi/ml prior to ASCR). ASCR will be carried out sooner in the case of life-threatening infection in the setting of neutropenia (ANC\<500). G-CSF can be used to maintain ANC\>500/ul but should not be used for 24 hours immediately before and after ASCR. Blood product support will be provided with platelet and red cell transfusions as required.
62031416|NCT04347681|EXPERIMENTAL|Treatment Group|We are aiming to include 40 patients (recipients) who have COVID 19 but have not recovered yet as per the inclusion criteria.
62031417|NCT04347681|NO_INTERVENTION|control group|Patients who only consent for sharing their clinical and laboratory data will serve as a control group to compare the efficacy of the convulsant plasma. Age and sex matched historical control could be used if need.
62031418|NCT02136277||Colorectal patients|Subjects undergoing colorectal surgery
62031419|NCT04740515|EXPERIMENTAL|Involvement of pharmacists in improving medication|Pharmacists involved care group. Tools used to improve medication adherence, (1)Patient medication guide (2)tailored Short Messaging Service (SMS) (3)Pharmaceutical follow-up
62031420|NCT04740515|NO_INTERVENTION|usual care only|Patients were provided with usual care.
62031421|NCT03713593|EXPERIMENTAL|lenvatinib plus pembrolizumab|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
62031422|NCT03713593|ACTIVE_COMPARATOR|lenvatinib plus placebo|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) orally QD plus saline placebo by IV infusion on Day 1 Q3W. Saline placebo will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
62031423|NCT02959437|EXPERIMENTAL|Treatment Group A: Azacitidine + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.
62031424|NCT02959437|EXPERIMENTAL|Treatment Group B: INCB057643 + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.
62230950|NCT00446628|EXPERIMENTAL|intervention|Five elementary school received intervention consistin of training in hand and respiratory hygiene, and access to hand sanitizer
62230951|NCT00446628|NO_INTERVENTION|control|Five elementary school received no training or hand sanitizer.
62230952|NCT02181712|EXPERIMENTAL|Mesenchymal Stem cells|Subjects who have never received Mesenchymal Stem Cells
62230953|NCT02181712|EXPERIMENTAL|Booster Mesenchymal Stem Cells|Subjects who have previously received Mesenchymal Stem Cells
62230954|NCT00597441|EXPERIMENTAL|I|Thymic tissue from third party donor
62592136|NCT02651155|PLACEBO_COMPARATOR|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
62592137|NCT05169437|EXPERIMENTAL|Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations|
62592138|NCT03014128||Inspection and Packaging|self-descriptive
62592139|NCT03014128||Grinding, Polishing and Matting|self-descriptive
62031425|NCT02959437|EXPERIMENTAL|Treatment Group C: INCB059872 + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.
62031426|NCT01240174|OTHER|Intervention Arm|Single arm in the study of doctors receiving feedback about their antibiotic prescribing rate for acute bronchitis.
62422673|NCT04690322|ACTIVE_COMPARATOR|Extended half-life factor VIII-based replacement therapy|"Subjects who are either already on prophylactic standard half-life FVIII products or have not started prophylactic treatment will be randomized to start prophylactic extended half-life FVIII products or non-factor product (emicizumab). Both therapies are considered the current standard of care.~The study has 4 planned visits at baseline, 1 month, 6 months, and 12 months. They will coincide with the standard of care visits."
62422674|NCT04690322|ACTIVE_COMPARATOR|Non-Factor VIII-based replacement therapy|"Subjects who are either already on prophylactic standard half-life FVIII products or have not started prophylactic treatment will be randomized to start prophylactic extended half-life FVIII products or non-factor product (emicizumab). Both therapies are considered the current standard of care.~The study has 4 planned visits at baseline, 1 month, 6 months, and 12 months. They will coincide with the standard of care visits."
62422675|NCT06521788|EXPERIMENTAL|AI assisted B-ultrasound breast cancer screening|Participants aged 35-70 years will be screened for breast cancer with AI assisted B-ultrasound
62592140|NCT03014128||All other employees at Aesculap (not in first 2 groups)|including administration and offices as well as all other mechanical workplaces
62592141|NCT03758222|EXPERIMENTAL|Arm-1: Device implantation for 1 month|Treatment group receives intervention with the XFLO Expander System implantation for 1 month, and then retrieved.
62592142|NCT03758222|EXPERIMENTAL|Arm-2: Device implantation for 6 months|Treatment group receives intervention with the XFLO Expander System implantation for 6 months, and then retrieved.
62031427|NCT03405987||ECV < median|
62592143|NCT03758222|EXPERIMENTAL|Arm-3: Device implantation for 12 months|Treatment group receives intervention with the XFLO Expander System implantation for 12 months, and then retrieved.
62592144|NCT06246968|EXPERIMENTAL|Pembrolizumab + Cryoablation|Participants will have a diagnosis of metastatic triple negative breast cancer or locally advanced inoperable triple negative breast cancer. Participants will be randomized 2 (cryoablation arm): 1 (no cryoablation arm).
62592145|NCT06246968|ACTIVE_COMPARATOR|Pembrolizumab|Participants will have a diagnosis of metastatic triple negative breast cancer or locally advanced inoperable triple negative breast cancer. Participants will be randomized 2 (cryoablation arm): 1 (no cryoablation arm).
62031428|NCT03405987||ECV ≥ median|
62031429|NCT06669845|OTHER|Ultrasonography pelvic|Ultrasound measurements before and after bladder emptying
62031430|NCT01452269|EXPERIMENTAL|Immediate intervention group|This arm will receive the intervention immediately following baseline data collection.
62592146|NCT06188455|EXPERIMENTAL|Fuzuloparib With Apatinib Mesylate Tablets|
62807627|NCT05103007|ACTIVE_COMPARATOR|Drug-eluting bead transarterial chemoembolization（DEB-TACE)|Percutaneous drug-eluting bead transarterial chemoembolization, followed by conventional transarterial chemoembolization（cTACE) every 2 months. A total of 3 times of chemoembolization will be performed.
62807628|NCT05103007|EXPERIMENTAL|PVL/PVE+DEB-TACE|PVL and PVE will be performed randomly assigned according to 1:1 according to the random number table.
62807629|NCT01600885|ACTIVE_COMPARATOR|Guanfacine then Placebo|During the first study session, the participant will receive guanfacine before undergoing a ketamine-infusion fMRI. During the second study session, at least two weeks later, the participant will receive a placebo before undergoing a ketamine-infusion fMRI.
62807630|NCT01600885|ACTIVE_COMPARATOR|Placebo then Guanfacine|During the first study session, the participant will receive a placebo before undergoing a ketamine-infusion fMRI. During the second study session, at least two weeks later, the participant will receive guanfacine before undergoing a ketamine-infusion fMRI.
62807631|NCT03955835|OTHER|ACUTE|Patients with acute ischemic stroke and proven large vessel occlusion (e.g. intracranial internal carotid artery or middle cerebral artery) with unsuccessful recanalization after endovascular treatment with mechanical thrombectomy and suspected underlying stenosis of the occluded intracranial artery amenable to stenting based on judgment by the treating neurointerventionalist.
62807632|NCT01057953|NO_INTERVENTION|Patient|Blood sample for patient included
62807633|NCT04418778||BEAR intervention group|BEAR Therapeutic group for women who have experienced interpersonal trauma
62807634|NCT04418778||Control Condition|Treatment as usual group, women participating in individual or group therapy but not taking the BEAR group
62807635|NCT05514769|EXPERIMENTAL|Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty (GAP)|The reconstruction including esophagogastric anastomosis and pyloroplasty for patients who underwent proximal gastrectomy . The anastomosis locate in the anterior of gastric stump.
62807636|NCT05514769|ACTIVE_COMPARATOR|Control|The reconstruction including esophagogastric anastomosis and pyloroplasty for patients who underwent proximal gastrectomy . The anastomosis locate in the posterior or side of gastric stump.
62807637|NCT04706962|EXPERIMENTAL|TH1902|TH1902 peptide-drug conjugate
62422676|NCT06521788|ACTIVE_COMPARATOR|routine screening|Participants aged 35-70 years will be screened for breast cancer with routine B-ultrasound by experienced primary care physicians.
62422677|NCT01372254|ACTIVE_COMPARATOR|Standard smoking cessation|Participants will receive a standard smoking cessation treatment in individual format. Treatment will be delivered in five, 90-minute individual sessions, and with two booster sessions assessed scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
62807638|NCT04123522||anterior cervical spine surgery|The patients will be enrolled for elective anterior cervical spine surgery.
62807639|NCT04123522||posterior cervical spine surgery|The patients will be enrolled for elective postieor cervical spine surgery
62422678|NCT01372254|EXPERIMENTAL|BA for substance abusing smokers|The Behavioral Activation for Drug Abusing Smokers (BA-DAS) treatment protocol will incorporate elements of the ST along with behavioral activation strategies, modified for smoking. Treatment will consist of five, 90-minute individual sessions, and with two booster sessions scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
62807640|NCT04757493|ACTIVE_COMPARATOR|Prucalopride group (A)|"Prucalopride 2 mg tablet, once daily in morning before breakfast will use as intervention in arm A."
62807641|NCT04757493|PLACEBO_COMPARATOR|Placebo group (B)|"Placebo will be given at the same time and same dose in arm B . Both active drug and placebo have packed in the same type of strip."
62592147|NCT00247078|EXPERIMENTAL|1|Patients with moderate or severe pain due to Black Widow envenomation
62592148|NCT00247078|PLACEBO_COMPARATOR|2|Patients with moderate to severe pain due to Black Widow envenomation
62031431|NCT01452269|EXPERIMENTAL|Delayed intervention group|This arm will receive the intervention one year following the immediate intervention group.
62031432|NCT03601832|EXPERIMENTAL|4-D navigated stereotactic radiosurgical ablation|The patients enroled to this arm of the study will undergo 4-D navigated stereotactic radiosurgical ablation.
62592149|NCT05694884|PLACEBO_COMPARATOR|Placebo|Placebo loading dose equivalents at Baseline and Week 1, then placebo dose equivalents every week (QW) from Week 2 to Week 15
62592150|NCT05694884|EXPERIMENTAL|ASLAN004|Week 0, 1: LD of 600 mg; Week 2 through Week 15 QW: 400 mg dose
62592151|NCT02622412|EXPERIMENTAL|Intervention Group|Patients randomised to the intervention group will get immediate access to the Multi-professional breathlessness service (MBS).
62592152|NCT02622412|OTHER|Control Group|Patients randomised to the control group will get delayed MBS intervention. They will receive standard care and get access to the service after a waiting time of eight weeks.
62807642|NCT01475591|NO_INTERVENTION|Multimodal rehabilitation|The arm intervention is just multimodal rehabilitation.
62807643|NCT02063204|EXPERIMENTAL|HV selumetinib Stage 1|Healthy volunteer (HV)group to receive selumetinib 50mg (2x25mg) orally
62807644|NCT02063204|EXPERIMENTAL|ESRD selumetinib Stage 1|End stage renal disease (ESRD)patients to recieve selumetinib 50mg (2x25mg) orally
62422679|NCT02476760||Treated with incretins|Current use of incretin-based drugs ((DPP-4 inhibitors \[sitagliptin, vildagliptin, and saxagliptin\] or GLP-1 analogs \[exenatide, liraglutide\]) alone or in combination with other anti-diabetic drugs (if the prescription overlaps with the index or event day with a 30-day grace period).
62422680|NCT02476760||Treated with insulin|Any use of insulins between base cohort entry and the index or event day (alone or in combination with other antidiabetic drugs) and no current use of incretin-based drugs.
62807645|NCT02063204|EXPERIMENTAL|Selumetinib stage 2|If deemed necessary patients with mild and/or moderate and/or severe renal impairment will recieve selumetinib 50mg(2x25mg) orally
62422681|NCT02476760||Treated with ≥2 oral hypoglycemic agents|Current use of 2 or more non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alphaglucosidase inhibitors, meglitinides) (if the prescriptions overlap with the index or event day with a 30-day grace period), and no current use of incretin-based drugs or insulins.
62422682|NCT02476760||Treated with a single oral agent|Current use of any single non-insulin anti-diabetic medication (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescription overlaps with the index or event day with a 30-day grace period) and no current use of more than 2 OHAs, incretin-based drugs, or insulins from base cohort entry.
62592153|NCT01878084|OTHER|all study participants|"This study represents a split-mouth study where the right or left/ upper or lower premolar could be assigned to either the control group (socket left empty) or test group (socket filled with bioactive glass (sol-gel)~The extraction sockets will be allocated either to the control : Extraction socket will be left empty~or~Test: Extraction socket will be augmented using bioactive glass (sol-gel)"
62592154|NCT03736408||1. Group without Pain - TMJ disorders symptoms|1. The symptoms concerning joints were: the type of sound symptoms (clicking or popping), their frequency and the phase of the movement of lowering and lifting the jaw during which they occurred, occurrence of the tension type headache or back pain. Hypertension of the mastication muscles is frequently connected with a parafunction activity like grinding or clenching the teeth, which cause abnormal pressure on the joints
62807646|NCT05806463|EXPERIMENTAL|Mother's Time Intervention|Working with local research partners, the research team will train HEWs in the intervention clusters in the Amhara region of Ethiopia to deliver four intervention sessions in a group setting of approximately six to eight women (average: 7). These sessions will take place over a period of approximately one month. Participants in the intervention group will receive four sessions of Mother's Time, delivered by an HEW.
62807647|NCT05806463|NO_INTERVENTION|Standard of care|Participants in the control group will receive the standard of care that postpartum mothers in Ethiopia receive. Standard of care for postpartum mothers related to family planning and mental health in Ethiopia includes multiple touch points that correspond with postpartum care as well as routine immunization.
62807648|NCT02919228|EXPERIMENTAL|Visible light exposure cognitive Red|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to red LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
62807649|NCT02919228|EXPERIMENTAL|Visible light exposure cognitive Orange|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to orange LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
62422683|NCT02476760||Not currently exposed group|All patients not currently exposed to: incretin-based drugs, ≥2 OHAs, a single OHA and no use of insulins since base cohort entry.
62422684|NCT02433535|EXPERIMENTAL|Simvastatin|Simvastatin 40 mg daily will be given for 12 weeks.
62422685|NCT02433535|PLACEBO_COMPARATOR|Placebo|A placebo capsule will be given daily for 12 weeks.
62422686|NCT00881595|OTHER|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Temozolomide five days per week during radiotherapy for 5 weeks. Proton radiation five days per week for 5 weeks Standard surgery will take place 4-6 weeks after completion of chemoradiation.
62230955|NCT02241954||Expansion Thoracoplasty|The rib prosthesis is lengthened periodically to correct the concavity of the deformity, expanding the volume of the hypoplastic thorax and improving associated spinal deformity. This device has been FDA approved by a Humanitarian Device Exemption and is described as a Vertical Expandable Prosthetic Titanium Rib (VEPTR). An updated version of the VEPTR, the VEPTR II, may be used instead depending on the physician's preference and the patient's anatomy. The VEPTR II device has greater size range and modularity of implants than the original VEPTR.
62230956|NCT03560089|ACTIVE_COMPARATOR|Rehabilitation with active serious game|25 patients will perform motor rehabilitation programme using the serious game
62230957|NCT03560089|PLACEBO_COMPARATOR|No active serious game|25 patients will not perform motor rehabilitation programme using the serious game
62230958|NCT00616369||1|"I:~For those patients who have had blood samples drawn as a result of participating in current protocol, Identification of Genetic Markers for Primary Pulmonary Hypertension study (X980515002), we would like to use their previously obtained blood and continue to draw samples (12mL; less than 3 tablespoons) ONLY if they change disease therapies.~For those patients who participated in Pulmonary Arterial Hypertension (PAH) Database study (X030403017), these participants will also sign a consent form to participant in this new trial. We would like to use the previously obtained data from the X030403017 in part with this study.~As for the X980515002 expired patients, we would like to use the previously obtained data ONLY in part for this study that was collected as a result of the X980515002 study."
62230959|NCT00616369||2|"II:~Group 2: After signing a consent form, these participants will have a 12mL (less than 3 teaspoons) blood sample drawn at baseline, at 3-4 month, at 6-8 month, at 12 month, and at 24 month visits. With each disease therapy change, the blood draws (12mL samples) will begin again at baseline and continue through the 3-4, 6-8, 12, and 24 month visits."
62230960|NCT01813708|EXPERIMENTAL|Intensive Life-Style Counseling|16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
62230961|NCT01813708|ACTIVE_COMPARATOR|Collaborative Educational|16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
62592155|NCT03736408||2. Group with Pain and symptoms TMJ disorder|The pain form of the disease is manifested by spontaneous pain in the preaural region, accompanied by pain or tenderness of the mastication muscle. Pain that appears during palpation examination of temporomandibular joints is frequently not related to inflammation of the soft tissue around the temporomandibular joints, as it is claimed by several authors of the paper. The cause of this problem is a long-term overload of soft tissue causally associated with excessive muscle tension, that sometimes even persists for years
62592156|NCT04726748||Urolift cohort|80 patients with prostatic urethral lift surgery will be included
62230962|NCT04578613|EXPERIMENTAL|ICP-022|ICP-022 will be orally administered until disease progression or unacceptable toxicity.
62230963|NCT04578613|ACTIVE_COMPARATOR|Chlorambucil combined with Rituximab|Chlorambucil orally administered and Rituximab via IV infusion for 6 cycles.
62230964|NCT05052866|EXPERIMENTAL|Robot Intervetnion|Participants in this Arm will interact with Ryan Companionbot.
62230965|NCT06144177|ACTIVE_COMPARATOR|Darkened room and star projector with parental presence|Subjects assigned to this arm, when in the operating room prior to the start of induction, the room will be darkened, and a star projector that lights up the ceiling and walls will be turned on. They will also have a parent in the room with them during induction of anesthesia.
62230966|NCT06144177|ACTIVE_COMPARATOR|Preoperative midazolam 0.5 mg/kg po and parental presence|Subjects assigned to this arm will be given midazolam by mouth preoperatively, and will have a parent in the room with them during induction of anesthesia.
62230967|NCT06144177|ACTIVE_COMPARATOR|Parental presence alone|Subjects assigned to this arm will have a parent in the room with them during induction of anesthesia.
62230968|NCT03275753||Normal Population|VA of 20/25 or better in the study eye with no prior diagnosis of any retinal or ocular diseases
62230969|NCT03275753||Early Dry AMD Population|VA of 20/40 or better in the study eye with clinical diagnosis of early dry AMD
62230970|NCT03275753||Intermediate Dry AMD Population|VA of 20/40 or better in the study eye with clinical diagnosis of intermediate dry AMD
62592157|NCT04726748||Transurethral Resection of the Prostate/laser cohort|80 patients with a transurethral resection of the prostate or laser surgery (enucleation or vaporisation) will be included.
62230971|NCT03275753||Advanced Dry AMD Population|Clinical diagnosis of advanced dry AMD in the study eye
62230972|NCT02931825|EXPERIMENTAL|Reminder letter|A letter is sent for remind the importance of compliance with colonoscopy AND to encourage people to to consult their general practitioner or gastroenterologist (if they haven't done their follow-up in time).
62230973|NCT02931825|NO_INTERVENTION|Control|No intervention (what is done currently)
62230974|NCT06058169|EXPERIMENTAL|Whole Body Training (12 week)|
62230975|NCT04692935||Asian lung adenocarcinoma|Asian LUADs patients who had broad-panel next-generation sequencing (NGS) performed on their primary tumor between January 2018 and December 2019 at the department of thoracic surgery of Peking University People's Hospital
62230976|NCT04692935||Caucasian lung adenocarcinoma|Caucasian LUADs patients who had targeted NGS (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets \[MSK-IMPACT\]) will be identified in the AACR GENIE database, which consists of 6673 primary lung adenocarcinoma samples with clinical annotations
62230977|NCT01803568|EXPERIMENTAL|Exercise in normoglycaemic individuals|
62230978|NCT01803568|EXPERIMENTAL|Exercise in hyperglycaemic individuals|
62230979|NCT04596696|OTHER|Single arm Rotavac|Single arm Open Label study without comparator
62230980|NCT05647850||Baseline characteristics of all patients|
62230981|NCT05647850||General characteristics of the patients.|
62230982|NCT05024994|EXPERIMENTAL|E7820|Each patient will receive daily administration of E7820. The starting dose for every patient will be 100 mg daily but the dose can subsequently be reduced if excessive toxicity is encountered.
62230983|NCT00104312||1|Participants with symptomatic knee osteoarthritis
62230984|NCT00104312||2|Participants without symptomatic knee osteoarthritis, age-matched as controls
62230985|NCT05097027|EXPERIMENTAL|Blood flow restriction recovery (Experimental I)|Active recovery program with blood flow restriction using a periodization methodology in soccer. (Post-match +1 training).
62230986|NCT05097027|EXPERIMENTAL|Non-Blood flow restriction recovery (Experimental II)|Active recovery program without blood flow restriction using a periodization methodology in soccer. (Post-match +1 training).
62230987|NCT04440982|EXPERIMENTAL|Device Intervention: LUM Imaging System used during surgery|The LUM Imaging Device will be used to look inside the lumpectomy cavity to see if the dye indicates any areas that may contain residual tumor. If the imaging identifies that there may be cancer cells remaining in the lumpectomy cavity, the surgeon will remove an additional piece of tissue. This process will be continued until a negative reading from the device is obtained or a maximum of 2 shaves of additional tissue has been removed. Patients in this arm will receive the study drug, LUM015
62592158|NCT04726748||National healthcare insurance system database (SNDS) cohort|1200 patients with any transurethral surgery (TURP/laser) will be included and randomly matched to patients of the Urolift cohort with ratio 5:1.
62592159|NCT05987904||Group 1: Cardiologic Group|This group includes patients who are scheduled for echocardiography.
62592160|NCT05987904||Group 2: Surgery Group|This group includes patients that are scheduled for non-cardiac surgery.
62031433|NCT04237662|EXPERIMENTAL|Test Group|"Root Instrumentation + Enamel Matrix Derivative Application~Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one- stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.~In this group, at the end of the instrumentation enamel matrix derivatives is placed in all sites with a periodontal pocket depth deeper than 5mm."
62230988|NCT04440982|NO_INTERVENTION|Standard of Care Arm|The LUM Imaging Device will not be used to guide additional tissue removal. Patients in this arm will receive the study drug, LUM015.
62230989|NCT04597528||Elective induction group|Nulliparous singleton gestations undergoing elective induction between 39weeks and 0days -39weeks and 6 days based on clinical information and evaluation of the earliest ultrasound as described in Gestational Age
62230990|NCT05998356|EXPERIMENTAL|Intervention group (BET procedure)|Subjects randomly assigned to the intervention group will benefit from BET procedure
62230991|NCT05998356|PLACEBO_COMPARATOR|Control group|Subjects from control group will undergo insertion of catheter for probing and flushing the Eustachian tube, the catheter won't be dilated
62230992|NCT04316208|EXPERIMENTAL|Supratentorial tumor surgery|Patients undergoing elective supratentorial tumor surgery under general anesthesia will be ventilated with positive end-expiratory pressures of 0, 5 and 10 cmH2O after craniotomy.
62230993|NCT05430893||Athletic pubalgia|Patients with chronic athletic pubalgia for whom medical and/or surgical treatments have failed and who were treated with an intra-muscular injection of botulinum toxin A injection under ultrasound guidance
62230994|NCT02982915|EXPERIMENTAL|Pilot Phase- Cohort A|Single dose of 20 million Longeveron Mesenchymal Stem Cells (LMSCs) will be delivered followed by vaccination with Fluzone High-Dose at 1 week post-infusion.
62230995|NCT02982915|EXPERIMENTAL|Pilot Phase Cohort B & C|Single dose of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) followed by vaccination with Fluzone High-Dose at either 1 week (Cohort B) or 4 weeks (Cohort C) post infusion.
62230996|NCT02982915|EXPERIMENTAL|Double-Blind,Randomized,Placebo Phase|2 cohorts to receive a single infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort A: 30 subjects) or placebo (Cohort B:30 subjects) followed by vaccination with Fluzone High-Dose.
62230997|NCT01556893|OTHER|LASIK Flap Arm|This is a single arm study.
62230998|NCT00210977||Erythropoietin receptor agonist|Participants with borderline serum anti erythropoietin (EPO) antibody (Ab) titers and who are treated with any erythropoietin receptor agonist (ERA) for any indication, having anti-EPO Ab identified by radioimmunoprecipitation (RIP), who are responding to ERA therapy, will be included in the study.
62230999|NCT04206579|EXPERIMENTAL|10% Dextrose|Oral 10% Dextrose
62231000|NCT04206579|EXPERIMENTAL|Natrium Dextrose|Oral Natrium Dextrose
62231001|NCT02564926|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10mg + Metformin 1000mg
62231002|NCT02564926|ACTIVE_COMPARATOR|Glimepiride|Glimepiriide 1-2mg + Metformin 1000mg
62231003|NCT00340977||Case-Control Parent-Triad|Norwegian infants born with cleft lip or palate over a 5 year period
62231004|NCT01941797|EXPERIMENTAL|Peri-implant mucosa|
62231005|NCT01941797|ACTIVE_COMPARATOR|periodontal mucosa|
62231006|NCT06422780|ACTIVE_COMPARATOR|Maternal Role Preparation Training Group|Pregnant women in the second trimester (14-27th week) will be included in the trainings.
62231007|NCT06422780|ACTIVE_COMPARATOR|Awareness Centred Occupational Therapy Group|Pregnant women in the second trimester (14-27th week) will be included in the trainings.
62231008|NCT06422780|NO_INTERVENTION|Control Group|Pregnant women in the second trimester (14-27th week) will be included in the trainings.
62231009|NCT04364854|EXPERIMENTAL|SET (Speech Entrainment Therapy) 3 weeks|
62231010|NCT04364854|EXPERIMENTAL|SET (Speech Entrainment Therapy) 4.5 weeks|
62231011|NCT04364854|EXPERIMENTAL|SET (Speech Entrainment Therapy) 6 weeks|
62231012|NCT04364854|OTHER|No Therapy 6 weeks|
62231013|NCT05119309||patient group|Renal biopsy diagnosis of MGRS or disease linked to multiple myeloma and B cell lymphoma
62592161|NCT05062980|EXPERIMENTAL|Investigational|In Phase 1, the dose expansion portion of Phase 2 and the investigational arm of the randomized portion of Phase 2, patients will receive their assigned dose of quaratusugene ozeplasmid (via intravenous infusion) in combination with a fixed 200 mg dose of pembrolizumab (via intravenous infusion) once in every 21-day treatment cycle until disease progression or unacceptable toxicity.
62592162|NCT05062980|ACTIVE_COMPARATOR|Control|In the control arm of the randomized portion of Phase 2, patients will receive either 75 mg/m2 docetaxel (via intravenous infusion) with or without 10 mg/kg ramucirumab (via intravenous infusion) -OR- investigator's choice of treatment. The treatment regimen for patients randomized to the control arm, must begin at Cycle 1 Day 1 and continue every 21 days until disease progression or unacceptable toxicity.
62807650|NCT02919228|EXPERIMENTAL|Visible light exposure cognitive Yellow|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to yellow LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
62031434|NCT04237662|ACTIVE_COMPARATOR|Control Group|"Root Instrumentation~Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one- stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour."
62231014|NCT05119309||control patient group|Renal biopsy diagnosis of nephropathy linked to onco-haematological pathology with full clinical expression (Multiple Myeloma, B-cell Lymphoma)
62231015|NCT03169322|ACTIVE_COMPARATOR|Test Group|patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing (SRP)
62231016|NCT03169322|ACTIVE_COMPARATOR|Control Group|Nose breathers having chronic periodontitis will receive scaling and root planing (SRP)
62231017|NCT00771563|ACTIVE_COMPARATOR|Arm A|Chemotherapy without LMWH
62231018|NCT00771563|EXPERIMENTAL|Arm B|Chemotherapy with LMWH
62231019|NCT03588728|EXPERIMENTAL|CR + tDCS|Cognitive Remediation (CR) and Transcranial Direct Current Stimulation (tDCS)
62231020|NCT03588728|SHAM_COMPARATOR|CR + sham tDCS|Cognitive Remediation (CR) and Sham Transcranial Direct Current Stimulation (tDCS)
62031435|NCT00688636|ACTIVE_COMPARATOR|1|
62031436|NCT00688636|PLACEBO_COMPARATOR|2|
62031437|NCT04479813|EXPERIMENTAL|No conditioning + placebo|Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests.
62031438|NCT04479813|EXPERIMENTAL|No conditioning + moxonidine|Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests.
62231021|NCT03588728|SHAM_COMPARATOR|control CR + tDCS|Control Cognitive Remediation (CR) and Transcranial Direct Current Stimulation (tDCS)
62231022|NCT03588728|NO_INTERVENTION|control CR + sham tDCS|Control Cognitive Remediation (CR) and Sham Transcranial Direct Current Stimulation (tDCS)
62231023|NCT02313233|EXPERIMENTAL|Umooze|Tablet oral dosage. Astragalus radix Extracts 480 mg+ Soy extracts 20 mg
62231024|NCT02313233|PLACEBO_COMPARATOR|Placebo|Cornstarch.
62231025|NCT01348360||NOBORI stent|
62231026|NCT02580695|EXPERIMENTAL|Umbilical-cord mesenchymal stromal cells|"Umbilical-cord mesenchymal stromal cells (UC-MSCs)~Allogeneic UC-MSCs 20 x 10e6 diluted on 3 mL of saline solution + 5% of Plasma AB~Arm 2a: single infusion group. UC-MSCs at 0 month~Arm 2b: double infusion group. UC-MSCs at 0 and 6 months"
62231027|NCT02580695|ACTIVE_COMPARATOR|Hyaluronic Acid (HA)|Drug: Hyaluronic Acid 3 mL of HA intra-articular injection at baseline and 6 months
62231028|NCT05121987|ACTIVE_COMPARATOR|Erector spinae plane block|
62231029|NCT05121987|ACTIVE_COMPARATOR|Continuous wound infusion|
62231030|NCT00511472|EXPERIMENTAL|MK-0941|
62231031|NCT00511472|PLACEBO_COMPARATOR|Placebo|
62231032|NCT03045601|EXPERIMENTAL|CT-FFR|Analyse With New CT-FFR Method
62231033|NCT03045601|ACTIVE_COMPARATOR|Stress echocardiography|Analyse With invasive FFR and stress echocardiography
62231034|NCT03553368|EXPERIMENTAL|Step 1: Healthy volunteers|"Experimental intervention:~MRI data will be acquired with the use of HF-NIV (HF-NIV-MR).~Control intervention:~MRI data will be acquired without the use of HF-NIV, as a reference (MR)."
62231035|NCT03553368|EXPERIMENTAL|Step 2: Patients (arm A)|"Experimental intervention:~MRI data will be acquired with the use of HF-NIV (HF-NIV-MR).~Control intervention:~MRI data will also be acquired without the use of HF-NIV, as a reference (MR). The clinically prescribed CT will be the gold standard."
62422687|NCT00881595|ACTIVE_COMPARATOR|Chemoradiotherapy Temozolomide|Chemoradiotherapy Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
62031439|NCT04479813|EXPERIMENTAL|Remote pre-conditioning + placebo|Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests.
62031440|NCT04479813|EXPERIMENTAL|Remote pre-conditioning + moxonidine|Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests.
62031441|NCT02491008|EXPERIMENTAL|Drug: Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
62031442|NCT02491008|PLACEBO_COMPARATOR|Drug: Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
62031443|NCT00182754|EXPERIMENTAL|Arm I|Patients receive octreotide subcutaneously (SC) once on day 1.
62031444|NCT00182754|PLACEBO_COMPARATOR|Arm II|Patients receive placebo SC once on day 1.
62031445|NCT02486328|OTHER|Group MM|2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3
62031446|NCT02486328|OTHER|Group RP|100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3
62031447|NCT02882568|OTHER|investigational|Blood test for Inflammatory and immunological analysis during acute sepsis phase and one month later
62031448|NCT04525391|EXPERIMENTAL|Durvalumab+AZD2811 to SCLC patients|"Dosage and Schedule: AZD2811 500mg and durvalumab 1500mg via IV administered on Day 1 for every 3weeks (fixed dosing for subjects \> 30 kg body weight for durvalumab). One cycle is consisted of 3 weeks.~The drug products must be dosed consecutively using different infusion lines. The sequence of infusions is as follows: durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. A waiting time interval of at least 30 minutes between the end of durvalumab infusion and start of AZD2811 infusion should be adhered to."
62031449|NCT01990469|EXPERIMENTAL|Gemigliptin|Gemigliptin 50mg qd
62031450|NCT01990469|PLACEBO_COMPARATOR|Placebo|Gemigliptin placebo
62031451|NCT03771482|ACTIVE_COMPARATOR|Opioid module first then fluid|The providers in this arm will first receive daily information and questions related to opioid use for eight weeks and then daily information and questions related to intravenous fluid prescribing for five weeks.
62031452|NCT03771482|ACTIVE_COMPARATOR|Fluid module first then opioid|The providers in this arm will first receive daily information and questions related to intravenous fluid prescribing for five weeks and then daily information and questions related to opioid use for eight weeks.
62031453|NCT06634485||control group|This group include healthy volunteers who aged ≥ 40 years .
62422688|NCT00881595|ACTIVE_COMPARATOR|Proton Therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
62422689|NCT00549107|EXPERIMENTAL|1|
62422690|NCT00549107|ACTIVE_COMPARATOR|2|
62031454|NCT06634485||study group|This include stable COPD Patients who will be diagnosed by GOLD 2024 and last excerbation ≥ 6weeks .
62031455|NCT01049425|ACTIVE_COMPARATOR|Epirubicin and Cyclophosphamid followed by Docetaxel|4 cycles of EC on day one every three weeks followed by 4 cycles of Docetaxel on day one every three weeks
62031456|NCT01049425|EXPERIMENTAL|Combination of Docetaxel and Cyclophosphamid|intravenous infusion on day one every three weeks
62031457|NCT06585969|EXPERIMENTAL|Trastuzumab-deruxtecan|Trastuzumab deruxtecan until progression or intolerable toxicity: 5.4 mg/kg intravenous on day 1 of a 21 days cycle.
62422691|NCT00388115|EXPERIMENTAL|RFA prior to surgery|
62422692|NCT02100241|EXPERIMENTAL|Active stretching with currents|Active stretching performed while currents are applied on hamstring muscles.
62422693|NCT02100241|EXPERIMENTAL|Active stretching|Active stretching are performed.
62422694|NCT02100241|NO_INTERVENTION|Control group|Routine clinical practice
62422695|NCT02106793|EXPERIMENTAL|Mitomicin C|Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
62031458|NCT06585969|ACTIVE_COMPARATOR|Immunohistochemistry guided treatment (standard)|"- CDK4/6 inhibitor with an endocrine therapy until progression og intolerable toxicity~* CDK4/6 inhibitor: Physician's choice of ribociclib (600mg daily for 21 days in a 4 week schedule) or abemaciclib (125mg twice daily).~* Endocrine therapy: letrozole (2.5mg daily), anastrozole (1mg daily), exemestane (25mg daily), tamoxifen (20mg daily) or fulvestrant (intramuscular 500mg every 4 weeks)"
62031459|NCT05884060||group 1|patients with evidence of haemolysis without obvious cause
62231036|NCT03553368|EXPERIMENTAL|Step 2: Patients (arm B)|"Experimental intervention:~PET/CT data will be acquired with the use of HF-NIV (HF-NIV-PET). MRI data will be acquired with the use of HF-NIV (HF-NIV-MR). PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV (PET/CT breath hold).~Control intervention:~Data from the clinically indicated PET/CT acquisition will be used as reference.~MRI data will also be acquired without the use of HF-NIV, as a reference (MR). Histological data will be used when available."
62592163|NCT03896737|EXPERIMENTAL|Dara-VCd|"treatment period includes administration of four 28-day cycles of induction with Dara- VCd; then patients will undergo transplant and finally they will receive two 28-day cycles of Dara-VCd consolidation treatment.~The response will be assessed after each cycle. Patients in the first randomization will be stratified according to FISH (standard/missing vs high risk,defined as del17, t 4;14, t 14;16) and ISS (I vs II and III).~TREATMENT SCHEMA - INDUCTION Daratumumab: 16 mg/Kg given by IV infusion on days 1, 8, 15, 22, on cycles 1-2 and on days 1, 15 on cycles 3-4.~Bortezomib: 1.3 mg/m2 given SC injection on days 1, 8,15, 22; Cyclophosphamide: 300 mg/ m2 given orally or IV infusion on days 1, 8, 15, 22; Dexamethasone: 40 mg given orally or by IV infusion on days 1, 8, 15,22 Repeat for four 4-week induction cycles."
62807651|NCT02919228|EXPERIMENTAL|Visible light exposure cognitive Green|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to green LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
62807652|NCT02919228|EXPERIMENTAL|Visible light exposure cognitive Cyan|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to cyan LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
62422696|NCT02106793|PLACEBO_COMPARATOR|Placebo|Identical placebo solution
62422697|NCT01256827||ranibizumab in MARINA/ANCHOR|Exudative AMD patients previously enrolled in the ranibizumab treatment arms of the MARINA or ANCHOR studies with subsequent enrollment into the HORIZON extension study.
62422698|NCT06240572||Adults who attended the emergency department|
62031460|NCT05884060||group 2|patients with evidence of bone marrow dysfunction (AA, MDS, unexplained cytopenia)
62031461|NCT05884060||group 3|patients with thrombosis
62031462|NCT05884060||group 4|patient group that needs to be eliminated from final high risk cohort: patients with cirrhosis, patients wit septic embolisms \& embolisation
62231037|NCT03553368|EXPERIMENTAL|Step 1 bis: Healthy volunteers|"Experimental intervention:~MRI data will be acquired with the use of CPAP (CPAP-MR).~Control intervention:~MRI data will be acquired without the use of CPAP, as a reference (MR)."
62231038|NCT01399333|ACTIVE_COMPARATOR|Group 1|full liquid diet utilizing meal replacements with PDCAAS of 1.0
62231039|NCT01399333|ACTIVE_COMPARATOR|Group 2|full liquid diet utilizing protein supplements with PDCAAS of 0.5-0.99
62231040|NCT01399333|ACTIVE_COMPARATOR|Group 3|full liquid diet utilizing protein supplement with a PDCAAS less than 0.5
62231041|NCT05269810|EXPERIMENTAL|Group 1|SA001 Low dose
62231042|NCT05269810|EXPERIMENTAL|Group 2|SA001 Mid dose
62231043|NCT05269810|EXPERIMENTAL|Group 3|SA001 High dose
62231044|NCT05269810|PLACEBO_COMPARATOR|Placebo|Placebo
62422699|NCT04523831|ACTIVE_COMPARATOR|Ivermectin and Doxycycline|Ivermactin 6 mg 2 tab stat, cap Doxycycline 100 mg 1 cap BD 5 days
62231045|NCT04126772||Active MS patients|10 MS patients with an active lesion of 0,5 cm diameter
62231046|NCT04126772||Healthy controls|20 healthy controls
62231047|NCT04126772||SPMS patients|10 SPMS patients
62231048|NCT03728556|EXPERIMENTAL|CS1001monoclonal antibody|
62231049|NCT03728556|PLACEBO_COMPARATOR|CS1001 Placebo|
62231050|NCT06526351|EXPERIMENTAL|Test group (Early implant placement + immediate provisionalization)|Patients in test group receive an implant 6 to 8 weeks following tooth extraction with immediate provisional restoration
62231051|NCT06526351|ACTIVE_COMPARATOR|Control group (Early implant placement + delayed loading)|Patients in control group receive an implant 6 to 8 weeks following tooth extraction with submerged healing and conventional loading
62231052|NCT02228655|OTHER|FMX-8|FMX-8 for injection, 15mg/kg, twice weekly, 29 days
62231053|NCT01096303||COPD tobacco and/or marihuana users|COPD patients with history of tobacco and/or marihuana smoking.
62231054|NCT02512757||Group 1|Patients with lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and diagnosed with primary lung cancer who have not yet initiated treatment of any kind for their lung cancer will contribute a fasting blood sample.
62231055|NCT02512757||Group 2|Patients whose most recent screening imaging is within 60 days who have lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and determined to not be cancerous OR that have demonstrated no nodule growth for \>2 years by repeat CT imaging will contribute a fasting blood sample.
62231056|NCT02512757||Group 3|Patients who have undergone low-dose computed tomography (LDCT) or standard computed tomography (CT) or X-ray testing to screen for lung cancer with no nodules suspicious for lung cancer within 1 year prior to signing informed consent will contribute a fasting blood sample.
62231057|NCT05291000|EXPERIMENTAL|RoT-ReWiH|First, pre-tests were applied to the patients in the training and reminder by watch group at first home visit.Second home visits were conducted participants 12th weeks after the first home visit.One of the researchers presented the education program to individuals with hypertensive.The education program included issues related to hypertension, measurament of pressure blood, lifestyle changes and adherence to treatment. The program using face-to-face communication technique and lasted about 45 minutes.For the patients in this group, the alarm time was set according to the time when blood pressure medication was taken, the cord was adjusted according to the arm, and then information was given about the use of the watch. At the end of the interview, the blood pressure of the experimental groups was measured and the measurement value was recorded on the blood pressure follow-up card.
62231058|NCT05291000|EXPERIMENTAL|Training group|First, pre-tests were applied to the patients in the training group at first home visit.The education program included issues related to hypertension, measurament of pressure blood, lifestyle changes and adherence to treatment. The program using face-to-face communication technique and lasted about 45 minutes. In addition, other drugs used by individuals at home (such as painkillers, antibiotics) were also evaluated during the home visit, and a red label was made on the antihypertensive drug box to distinguish antihypertensive drugs from other drugs. At the end of the interview, the blood pressure of the experimental groups was measured and the measurement value was recorded on the blood pressure follow-up card.
62231059|NCT05291000|NO_INTERVENTION|Control group|Pre-tests was applied to the patients in the control group.No intervention was be applied to the patients in this group and second home visit 12th weeks after the first home visit and were readministered the post-tests.
62231060|NCT03090815||Patient receiving TKI|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive TKI
62422700|NCT04523831|PLACEBO_COMPARATOR|Placebo|Standard treatment
62422701|NCT04383080|EXPERIMENTAL|Low-level laser therapy|Low-level laser irradiation on specific acupuncture points
62807653|NCT02919228|EXPERIMENTAL|Visible light exposure cognitive Blue|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to blue LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
62422702|NCT04383080|ACTIVE_COMPARATOR|Acupuncture therapy|Dry needle inserting specific acupuncture points
62422703|NCT03786809|EXPERIMENTAL|Experimental|Women will use Cimifuga Racemosa for 28 days and will be submitted to measurement of the diameter of the brachial artery before and after treatment
62819522|NCT06206317||Control Group|Consisting of children without any health issues. This group comprises healthy individuals and serves as a comparative reference against the study group. Similar tests and measurements are applied to assess the motor and sensory functions of the hand in healthy individuals for comparison with the study group. The study solely involves evaluation and will not include any treatment or intervention.
62231061|NCT03090815||Patient receiving ALK-TKI|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive ALK-TKI
62807654|NCT02919228|EXPERIMENTAL|Visible light exposure cognitive Violet|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to violet LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
62231062|NCT03090815||Patient receiving chemotherapy|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive chemotherapy
62231063|NCT03622554|NO_INTERVENTION|Control arm|Curist taking a spa treatment of 3 weeks in the usual conditions for each Center
62231064|NCT03622554|EXPERIMENTAL|Intervention|"Addition to the usual cure: -12 adapted physical activity (APA) sessions of 60 minutes to improve the balance , muscular strength, endurance and suppleness without creating additional fatigue for the curists~- personalized therapeutic patient education (ETP) with an individual assessment at the beginning of the treatment (1h), 3 group sessions (1h30) and an end-of-cure interview (1h) and an educational follow-up by phone at 3, 6 and 12 months"
62231065|NCT01293929||Non- obese group|
62231066|NCT01293929||Obese group|
62231067|NCT03656523||Acute Coronary Syndrome|Patients with Aute coronary syndrome trated with Percutaneous Coronary Intervention plus Stent implantation and Atrial Fibrillation
62231068|NCT04732533|EXPERIMENTAL|tDCS|Active transcranial direct current stimulation (tDCS) will be administered with the goal of facilitating the excitability of the left dorsolateral prefrontal cortex (dlPFC). Electrode placement and current parameters for each electrode have been optimized using a standard brain with the goal of generating an average electric field of 0.25 V/m67 within the left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
62231069|NCT01210066|ACTIVE_COMPARATOR|Pain Challenge|Cold pressor test
62231070|NCT01210066|ACTIVE_COMPARATOR|Pain + Opioid Challenge|IV fentanyl 1mcg/kg followed by cold pressor test
62231071|NCT01210066|ACTIVE_COMPARATOR|Opioid Challenge|Administration of fentanyl 1mcg/kg of subject weight
62422704|NCT03786809|PLACEBO_COMPARATOR|Placebo|Women will use Placebo for 28 days and will be submitted to measurement of the diameter of the brachial artery before and after treatment
62422705|NCT00365469|EXPERIMENTAL|Probiotic|Commercially available cow's milk based infant formula with Bifidobacterium longum \[BL999} and Lactobacillus rhamnosus \[LPR\]
62422706|NCT00365469|PLACEBO_COMPARATOR|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
62422707|NCT06169020|EXPERIMENTAL|Experimental group|All subjects will participate in this arm. They will conduct a series of fitness tests in order to assess energy expenditure, from rest to maximal, body composition and health related fitness. They will also use the wearable during free living condition to estimate free living energy expenditure.
62422708|NCT00656019|NO_INTERVENTION|Normal Vitamin D Levels|No additional Vitamin D administered
62422709|NCT00656019|EXPERIMENTAL|Low-normal Vitamin D Levels|2000 IU dose of Vitamin D per day administered orally
62422710|NCT00656019|EXPERIMENTAL|Low Vitamin D Levels|4000 IU dose of Vitamin D per day administered orally
62422711|NCT00656019|EXPERIMENTAL|Very-low Vitamin D Levels|6000 IU dose of Vitamin D per day administered orally
62422712|NCT04227652|EXPERIMENTAL|Aggressive treatment strategy|The antipyretic strategy was initiated immediately upon increase of the temperature above 38.3°C. The antipyretic strategy consisted of administration of ibuprofen (per-orally or into the nasogastric tube, or rectal administration in the form of a suppository) in therapeutical dose, alway supplemented with physical cooling in cases when the temperature exceeded 39.5°C. The body temperature was measured in the urinary bladder.
62807655|NCT02919228|EXPERIMENTAL|Visible light exposure cognitive White|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to white LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
62592164|NCT03896737|ACTIVE_COMPARATOR|VTd|"treatment period includes administration of four 28-day cycles of induction with VTd; then patients will undergo transplant and finally they will receive two 28-day cycles of VTd consolidation treatment.~TREATMENT SCHEMA INDUCTION~ARM VTd:~Bortezomib: 1.3 mg/m2 given by SC injection on days 1, 4, 8, 11 of 28-day cycle; Thalidomide: 100 mg given orally on days 1-28. Dexamethasone: 20 mg given orally or by IV injection on days 1, 2, 3, 4, 8, 9, 10 and 11 of every 28-day cycle.~Repeat for four 4-week induction cycles."
62592165|NCT01171703|EXPERIMENTAL|bypass|femoral-popliteal bypass
62592166|NCT01171703|EXPERIMENTAL|stent|
62592167|NCT01820572|EXPERIMENTAL|Belatacept|Belatacept 5 mg/kg intravenous 30 minute infusion on Days 1, 15, 29, 43, 57 then every 28 days for 24 months
62592168|NCT01820572|ACTIVE_COMPARATOR|CNI|"Tacrolimus 4-11 ng/mL tablet orally according to package insert for 24 months~Cyclosporine 50-250 ng/mL tablet orally according to package insert for 24 months"
62592169|NCT06665750|EXPERIMENTAL|Intervention group|
62592170|NCT06665750|NO_INTERVENTION|Control group|The control group will perform only routine warm-up exercises.
62592171|NCT01070095|EXPERIMENTAL|Electronic Asthma Action Plan System|Electronic Asthma Action Plan System (eAAPS)
62592172|NCT06588426||Participants with congenital heart disease|
62592173|NCT03078296||Members of the AAGL|Physicians and other providers who are members of the AAGL.
62592174|NCT04590508|EXPERIMENTAL|Xanthohumol|Participants will take capsules containing 24 mg of xanthohumol in a rice protein vehicle by mouth once daily with the first daily meal.
62592175|NCT04590508|PLACEBO_COMPARATOR|Placebo|Participants will receive capsules filled with a rice protein vehicle by mouth once daily with the first daily meal.
62592176|NCT00562302|EXPERIMENTAL|Bio-Seal Group|Bio-Seal Plug Implanted
62807656|NCT02383563|ACTIVE_COMPARATOR|Metformin Treatment Arm|500 mg metformin Extended Release tablets - one tablet daily increased at 4 weeks to 2 tablets (1000 mg) daily.
62592177|NCT00562302|NO_INTERVENTION|Control Group|Control group with no intervention
62807657|NCT02383563|NO_INTERVENTION|Observational Arm|Observation only
62592178|NCT02636998||Normal weight|BMI \<85th percentile
62592179|NCT02636998||Obese|BMI \> 95th percentile
62807658|NCT06110663|EXPERIMENTAL|HS-10241+Almonertinib|Experimental group (Experimental): HS-10241 combined with Almonertinib NSCLC with MET amplification after failure of EGFR-TKI treatment randomized to HS-10241 combined with Almonertinib
62592180|NCT05556161|EXPERIMENTAL|Intervention Group|The 12-month general practitioners and diabetes specialists co-management will be received by intervention group participants.
62592181|NCT05556161|NO_INTERVENTION|Control group|Routine primary health care will be received by control group participants during the course of the Study.
62735428|NCT05023785|EXPERIMENTAL|Cardio-Oncology Rehabilitation (CORE)|"Participants in the CORE group will have~1. A personalized, supervised exercise program ((in-person at intuition and virtual/ homebased exercises)~2. CV risk factor management,~3. behavioural support for the first 6 months. The behavioural support will continue for CORE participants from months 7-24. Behavioural support includes professionally guided and peer-enhanced exercise behavioural support based on behaviour change stage theories.~CORE participants will be provided a wrist-worn heart and physical activity monitor to use throughout the 24-month observation period."
62735429|NCT05023785|NO_INTERVENTION|Standard of Care (CON)|Participants in the CON group will receive standard medical care and physical activity will be monitored by a wrist-worn activity tracker for 2 years.
62735430|NCT03363191|EXPERIMENTAL|Subjects received Fluticasone Furoate/Vilanterol|Subjects will receive fluticasone furoate/vilanterol 100/25 mcg inhalation powder via ELLIPTA dry powder inhaler (DPI) once daily for the 12 week treatment period. Subjects will receive salbutamol/albuterol as rescue medication on an as-needed basis.
62807659|NCT06110663|ACTIVE_COMPARATOR|Pemetrexed + Cisplatin /Carboplatin|Control group (Active Comparator): Pemetrexed combined with Platinum NSCLC with MET amplification after failure of EGFR-TKI treatment randomized to standard chemotherapy treatment of platinum-based chemotherapy
62422713|NCT04227652|EXPERIMENTAL|Conservative treatment strategy|The antipyretic strategy was initiated only after the body temperature exceeded 39.5°C. The antipyretic strategy consisted of administration of ibuprofen (per-orally or into the nasogastric tube, or rectal administration in the form of a suppository) in therapeutical dose, alway supplemented with physical cooling in cases when the temperature exceeded 39.5°C. The body temperature was measured in the urinary bladder.
62422714|NCT05220865|ACTIVE_COMPARATOR|Hall Technique|A preformed metal crown will be cemented on the carious primary molar tooth without any tooth preparation and local anesthesia.
62422715|NCT05220865|EXPERIMENTAL|Modified Hall Technique|In the Modified Hall technique only infected soft dentin tissue will be removed with hand instruments and a preformed metal crown will be placed with Hall technique.
62592182|NCT01814293|ACTIVE_COMPARATOR|Handheld humidifier|Study design is a nonblinded randomized controlled comparison study of pediatric patients presenting to the UCSF Emergency Department (ED) with upper respiratory infection (URI) symptoms for which the ED physician has recommended supportive care only (ie. non-prescription symptom relief). Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) \& control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
62231072|NCT02446886|ACTIVE_COMPARATOR|One Time Treatment|"MS patients enrolled in this study will be randomized into:~Intervention for Group A: 80 units/day ACTH (H.P. Acthar®)for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.)"
62231073|NCT02446886|EXPERIMENTAL|Monthly Treatments|Intervention for Group B: 80 units/day ACTH (H.P. Acthar®) for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.), followed by monthly 80 units/day ACTH for 3 days for 12 months of treatment.
62231074|NCT02838433|EXPERIMENTAL|Biological samples|"Blood samples will be collected :~* at baseline,~* 6 months after the first-line therapy or at disease progression (if occurs first).~In particular case of patient with immunotherapy or targeted therapy, 3 blood samples will be collected :~* at baseline~* 3 months after the initiation of immunotherapy or targeted therapy~* at disease progression Tumor tissues will be collected if available."
62422716|NCT00858234|EXPERIMENTAL|Vorinostat + Bortezomib|Participants undergo up to 3 successive 21-day treatment cycles. During Cycle 1, participants receive vorinostat (400 mg once daily \[QD\] on Days 1 through 14) + bortezomib (1.3 mg/m\^2 intravenous \[IV\] on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 2 participants receive vorinostat (400 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m\^2 IV on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 3 participants receive vorinostat (300 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m\^2 IV on Days 1, 4, 8, and 11).
62422717|NCT01980316|EXPERIMENTAL|Argatroban group|Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
62592183|NCT01814293|NO_INTERVENTION|Control group|Subjects will manage cold symptoms with any desired supportive over the counter treatment, and complete surveys related to symptom scores and modalities used.
62592184|NCT01797549||History of having sustained TBI|Males and females between 18 and 60 years who have a diagnosis of TBI
62422718|NCT01980316|EXPERIMENTAL|non-argatroban treated group|Patients in control group will receive Unfractionated heparin treatment
62422719|NCT04117217||Central venous lines|Patients having a central venous catheter placed at Banner University Medical Center, University of Arizona
62422720|NCT04117217||Cardiac catheterization|Patients undergoing a cardiac catheterization procedure done at Banner University Medical Center, University of Arizona
62807660|NCT02714192|EXPERIMENTAL|BCTT|Participants received an standardized exercise stress test within 7 days of concussive injury. Stress test is stopped when participant experiences any exacerbation of symptoms. Heart rate at time of symptom exacerbation is referred to as the threshold heart rate (THR). Stress test is known as the Buffalo Concussion Treadmill Test.
62807661|NCT02714192|NO_INTERVENTION|No BCTT|All participants in the no intervention arm did not get assessed using the BCTT until they had fully recovered or when they had their second clinic visit fourteen days after their first visit.
62231075|NCT02849288|EXPERIMENTAL|Intervention|Use of the Investigational Bigfoot Type 1 Diabetes Management System (T1DMS)
62422721|NCT01649245|EXPERIMENTAL|Reiferon retard plus ribavirin|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is \>75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses
62422722|NCT02241200|EXPERIMENTAL|IV Administration|The iv solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
62422723|NCT02241200|EXPERIMENTAL|SC Administration|The sc solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
62422724|NCT06120452|EXPERIMENTAL|Test arm: Acne Serum|Participants will use the serum after cleansing and toning every morning for 8 weeks (56 days).
62422725|NCT03679312|EXPERIMENTAL|COPD Group|COPD to receive either placebo or inhaled nitric oxide (40ppm)
62592185|NCT01797549||Control group|Control group with no history of TBI or concussion. Gender and age matched non-TBI volunteers
62807662|NCT03844555|EXPERIMENTAL|End Stage Renal Disease|Single oral dose of elafibranor 120mg
62807663|NCT03844555|EXPERIMENTAL|Healthy|Single oral dose of elafibranor 120mg
62807664|NCT02760615|OTHER|Part 1: UC and CD Participants|Participants with UC or CD and not concurrently treated with vedolizumab or other biologics will receive caffeine 200 milligram (mg), tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan, 30 mg (2\*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
62807665|NCT02760615|OTHER|Part 1: Healthy Participants|Healthy participants will receive caffeine 200 mg, tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan 30 mg (2\*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
62231076|NCT02674789|EXPERIMENTAL|Exercise day|Behavioral intervention: 90min bike ergometer test at 70% of VO2max. Blood samples are collected at set time points (08:30, 11:00, 12:30, 13:30, 15:00, 16:00 and 18:30). Blood samples are analyzed on the pHOx analyzer for their ionized magnesium concentration. And on the Dimension Vista 1500 from Siemens for their total magnesium concentration.
62231077|NCT02674789|NO_INTERVENTION|Non exercise day (Rest day)|No exercise protocol. Estimating daily variation of magnesium concentration. Blood samples are collected at set time points (08:30, 11:00, 12:30, 13:30, 15:00, 16:00 and 18:30). Blood samples are analyzed on the pHOx analyzer for their ionized magnesium concentration. And on the Dimension Vista 1500 from Siemens for their total magnesium concentration.
62231078|NCT01578759|EXPERIMENTAL|Salpingectomy group|Participants in this group will have their fallopian tubes removed.
62231079|NCT01578759|NO_INTERVENTION|No Salpingectomy Group|Participants in this group will not have their fallopian tubes removed.
62592186|NCT05182359|OTHER|CVD-T2D Informed Medical Management (Informed)|The SomaSignal Metabolic Factors test results will be provided in the Open Label Extension; results will not be provided to provider and participant until study conclusion.
62592187|NCT05182359|OTHER|Standard of Care (Uninformed)|The SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) and Metabolic Factors test results will be provided in the Open Label Extension; results will not be provided to provider and participant until study conclusion.
62231080|NCT00624143|ACTIVE_COMPARATOR|1|Oral Voriconazole
62231081|NCT00624143|ACTIVE_COMPARATOR|2|IV Amphotericin B
62231082|NCT02582723|ACTIVE_COMPARATOR|High protein/high fat hard cheese|Served for breakfast together with bread, juice and coffee, tea or water
62231083|NCT02582723|ACTIVE_COMPARATOR|High protein/low fat hard cheese|Served for breakfast together with bread, juice and coffee, tea or water
62231084|NCT02582723|EXPERIMENTAL|Low protein/high fat creme cheese|Served for breakfast together with bread, juice and coffee, tea or water
62422726|NCT03679312|EXPERIMENTAL|Control Group|Control group to receive either placebo or inhaled nitric oxide (40ppm)
62422727|NCT04767217|ACTIVE_COMPARATOR|artemether-lumefantrine (ALN)|
62422728|NCT04767217|ACTIVE_COMPARATOR|dihydroartemisinin-piperaquine (DHA-PPQ)|
62422729|NCT00995930|PLACEBO_COMPARATOR|Placebo|subcutaneous (SQ) monthly
62422730|NCT00995930|EXPERIMENTAL|ACZ885|150 mg SQ monthly
62231085|NCT04744285|ACTIVE_COMPARATOR|Condition 1 (normal cigarettes)|Participants receive regular package cigarettes for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection.
62231086|NCT04744285|EXPERIMENTAL|Condition II (cigarettes with neutral message)|"Participants receive cigarettes with neutral message Nothing about this product's color or name means that it will protect a smoker from the health risks of smoking on package for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection."
62422731|NCT04235764||1/ Cohort 1|Bladder Cancer Patients
62422732|NCT04281654|EXPERIMENTAL|Ballroom Dance|The Dance group participants will take part in ballroom dance lessons twice/week for 45-minutes/session for 10 weeks
62422733|NCT04281654|EXPERIMENTAL|Ukulele|The Music group participants will take part in ukulele lessons twice/week for 45-minutes/session for 10 weeks
62422734|NCT04281654|ACTIVE_COMPARATOR|Control|The Control group participants will meet 2 times per week for 45-minutes/session for 10 weeks to participate in a social conversational group for 10 weeks
62422735|NCT02253407|EXPERIMENTAL|Disposable syringe jet injector|Subjects in this arm will be given a single subcutaneous 0.5 mL dose of Serum Institute of India Ltd.'s MMR vaccine (Brand name: Tresivac) via Disposable Syringe Jet Injector (Brand Name:Stratis) of Pharmajet Inc.
62422736|NCT02253407|ACTIVE_COMPARATOR|Needle-Syringe|Subjects in this arm will be given a single subcutaneous 0.5 mL dose of Serum Institute of India Ltd.'s MMR vaccine (Brand name: Tresivac) via conventional needle and Syringe
62422737|NCT03174925|EXPERIMENTAL|Tissue Stiffness by Elastography|Potentially cancerous thyroid nodules were assessed by elastrography, then a fine needle biopsy specimen or the surgically-excised nodule was assessed pathologically to determine cancer status.
62422738|NCT04953208|ACTIVE_COMPARATOR|Active treatment|active tDCS (using the Neuroelectrics Starstim tCS 5G kit) and cognitive and emotional control video game
62422739|NCT04953208|SHAM_COMPARATOR|Sham treatment|sham tDCS (using the Neuroelectrics Starstim tCS 5G kit) and non-active videogame
62422740|NCT06344988|EXPERIMENTAL|Intervention Group|"A 40-minute online education presentation will be given on the role of postural and dynamic muscles, the importance of physical activity, the gradual adaptation of the body to workload and physical stressors, rest, and injury management. They will also be asked to wear a smart band. Additionally, the exercise program developed by Chan et al., will be practised online via Google Meet once a week for 8 weeks, each session lasting 40-45 minutes."
62422741|NCT06344988|OTHER|Control Group|A 40-minute online education presentation will be given on the role of postural and dynamic muscles, the importance of physical activity, the gradual adaptation of the body to workload and physical stressors, rest, and injury management. They will also be asked to wear a smart band.
62422742|NCT03980860|ACTIVE_COMPARATOR|HIIT (High Intensity Interval Training)|Subjects are undergoing high intensity interval training
62422743|NCT03980860|ACTIVE_COMPARATOR|Low intensity training long duration|Subjects are undergoing a lower intensity training program for a long duration
62422744|NCT03980860|NO_INTERVENTION|Control|No exercise program intervention (usual care)
62422745|NCT02885259|EXPERIMENTAL|HyQvia|human immunoglobulin and one vial of recombinant human hyaluronidase (rHuPH20
62422746|NCT03682627|ACTIVE_COMPARATOR|preventive fenestration|Fenestration is performed at the time of kidney transplantation
62807666|NCT02760615|EXPERIMENTAL|Part 2: Vedolizumab|Participants who are on established vedolizumab intravenous (IV) maintenance treatment of 300 mg for treatment of UC or CD and in clinical remission will receive vedolizumab 300 mg IV infusion, once, caffeine 200 mg, tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan 30 mg (2\*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
62422747|NCT03682627|EXPERIMENTAL|preventive fenestration and clipping|Fenestration and clipping of the edges are performed at the time of kidney transplantation
62422748|NCT03705403|ACTIVE_COMPARATOR|Control|Standard of Care (SOC) according to the local and national guidelines: (wait and see or surgery and/or chemotherapy and/or standard (symptomatic) radiation therapy and/or SABR (oligometastatic disease)
62231087|NCT04744285|EXPERIMENTAL|Condition III (cigarettes with compensation message)|"Participants receive cigarettes with compensation message This product has a ventilated filter. Filter vents increase how deeply a smoker inhales without them knowing, which can increase the health risks of smoking on package for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection"
62231088|NCT04744285|EXPERIMENTAL|Condition IV cigarettes with blocking message|"Participants receive cigarettes with blocking message This product has a ventilated filter. Be sure not to block the vent holes with your fingers or lips, which can increase the health risks of smoking for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection"
62231089|NCT05150496|EXPERIMENTAL|Two doses CoronaVac® + one dose medium-dose CoronaVac®|200 participants who were vaccinated with CoronaVac® will be given one dose booster immunization using medium-dose CoronaVac®3-8 months after their second dose
62231090|NCT05150496|EXPERIMENTAL|Two doses CoronaVac® + one dose high-dose CoronaVac®|200 participants who were vaccinated with CoronaVac® will be given one dose booster immunization using high-dose CoronaVac® 3-8 months after their second dose
62231091|NCT05150496|EXPERIMENTAL|Two doses Comirnaty + one dose medium-dose CoronaVac®|120 participants were vaccinated with Comirnaty will be given one dose booster immunization using medium-dose CoronaVac® 6-8 months after their second dose
62592188|NCT05415605|EXPERIMENTAL|healthy Volunteers|Healthy male or female volunteers between 18 and 50 years old
62422749|NCT03705403|EXPERIMENTAL|Experimental treatment|Standard of Care (SOC SABR (oligometastatic disease) or radiation therapy (diffuse disease) + L19-IL2 up to 6 cycles (Darleukin)
62422750|NCT04831931|EXPERIMENTAL|Supervised Exercise Group|"Telerehabilitation will be applied in this group, which will last 4 weeks, and include the following processes~* Exercises that will be performed every Monday will be taught and applied face-to-face under the supervision of the therapist with online videoconferencing method. Then, videos of weekly exercises that will be prepared by the therapist will be transmitted online to patients.~* Patients will be asked to perform these exercises 4 days a week in the same week, on Wednesdays, Fridays and Sundays.~* Also, a video call will be made on Fridays to evaluate whether the movements are done effectively and correctly, and questions of patients (if any) will be answered.~* Patients will be informed by the physiotherapist that they should send messages on Wednesdays and Sundays to show that they are doing the exercises.~* The exercise program of new week will be taught every Monday for 4 weeks, the prepared video will be sent, and the program will be advanced and completed."
62422751|NCT04831931|ACTIVE_COMPARATOR|Exercise Group|Exercise recommendations will be made to this group. Videos and photographs of weekly exercises prepared by the therapist will be sent online to the patient every Monday for 4 weeks, patients will be advised to repeat these exercises 4 days a week.
62422752|NCT04831931|NO_INTERVENTION|Control Group|No exercise application will be done in this group.Evaluation tests will be applied for 4 weeks only online.
62422753|NCT00963599|EXPERIMENTAL|1|montelukast/loratadine
62422754|NCT00963599|EXPERIMENTAL|2|loratadine
62422755|NCT00963599|EXPERIMENTAL|3|montelukast
62422756|NCT00963599|PLACEBO_COMPARATOR|4|placebo
62592189|NCT03428672|EXPERIMENTAL|osteoporotic fractures|patients with osteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
62592190|NCT03428672|SHAM_COMPARATOR|nonosteoporotic fractures|patients with nonosteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
62592191|NCT01092039|EXPERIMENTAL|XIGO pill|Oral Xigo tablet
62592192|NCT01092039|PLACEBO_COMPARATOR|Placebo|Oral placebo tablet
62422757|NCT00716586|EXPERIMENTAL|Trusopt (2% dorzolamide)|Intent to treat population. All participants assigned to Trusopt (2% dorzolamide)
62422758|NCT04859647|OTHER|Therapy Intervention|Method of Levels Therapy Intervention - Clients will choose how many sessions to attend during the 6 months therapy window. Clients will also choose how often to attend sessions and the duration of each session.
62422759|NCT05799365||2 to 4 Years|The children with cerebral palsy between the age of 2 and 4. GMFCS-FR Turkish adaptation was applied the childrens mother, father and clinical physiotherapist.
62422760|NCT05799365||4 to 6 Years|The children with cerebral palsy between the age of 4 and 6. GMFCS-FR Turkish adaptation was applied the childrens mother, father and clinical physiotherapist.
62422761|NCT05799365||6 to 12 Years|The children with cerebral palsy between the age of 6 and 12. GMFCS-FR Turkish adaptation was applied the childrens mother, father and clinical physiotherapist.
62422762|NCT05799365||12 to 18 Years|The children with cerebral palsy between the age of 12 and 18. GMFCS-FR Turkish adaptation was applied the childrens mother, father and clinical physiotherapist.
62422763|NCT05799365||12 to 18 Years Young with Good Cognitive Levels|The children with cerebral palsy with good cognitive levels between the age of 12 and 18. GMFCS-FR Turkish adaptation was applied the childrens mother, father and clinical physiotherapist.
62422764|NCT00755937||Subjects receiving Remicade|Crohn's disease subjects receiving Remicade® per Product Monograph.
62422765|NCT06129799||paradoxical LF-LG AS|
62592193|NCT03790228|EXPERIMENTAL|Anlotinib Combined With Pemetrexed And Carboplatin|Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)
62592194|NCT00852215|ACTIVE_COMPARATOR|1|Taxus stent group
62031463|NCT01697293|EXPERIMENTAL|Treatment (chemotherapy, surgery)|"COURSES A 1-12 (PHASE I \& II): Patients receive triciribine phosphate IV over 60 minutes on days 1, 8, and 15, 29, 36, 43, 57, 64, and 71 and paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 79. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.~COURSES B 1-4 (PHASE II): Patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~SURGERY (PHASE II): Eligible patients undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy."
62231092|NCT05150496|EXPERIMENTAL|Two doses Comirnaty + one dose high-dose CoronaVac®|120 participants were vaccinated with Comirnaty will be given one dose booster immunization using one dose high-dose CoronaVac® 6-8 months after their second dose
62231093|NCT00589082|ACTIVE_COMPARATOR|1|standard 3+7
62231094|NCT00589082|EXPERIMENTAL|2|DNX 3+7
62231095|NCT04217928|ACTIVE_COMPARATOR|Arthroscopic Debridement|Patients who are randomized into this arm will receive arthroscopic debridement
62231096|NCT04217928|ACTIVE_COMPARATOR|Arthroscopic Hemi-Trapeziectomy with Mini TightRope|Patients who are randomized into this arm will receive arthroscopic hemi-trapeziectomy with mini tightrope
62231097|NCT02778932||Intubation|General anesthesia including intubation and muscle relaxation
62231098|NCT02778932||Laryngeal Mask|General anesthesia including laryngeal mask without muscle relaxation
62231099|NCT01462838|EXPERIMENTAL|Immunization|P16_37-63 peptide plus Montanide ISA-51 VG
62231100|NCT06078839|PLACEBO_COMPARATOR|Placebo control group|
62231101|NCT06078839|EXPERIMENTAL|Nafamostat mesilate treatment group (experimental group)|
62592195|NCT00852215|ACTIVE_COMPARATOR|2|Vision stent group
62592196|NCT00676312|EXPERIMENTAL|1|Cross-over treatment with increasing doses of PTH134, placebo and active comparator.
62231102|NCT02179723|EXPERIMENTAL|Leukosan Adhesive|Leukosan Adhesive applied to one wound (left or right)
62231103|NCT02179723|ACTIVE_COMPARATOR|Transcutaneous suture|Transcutaneous suture applied to second wound (left or right)
62231104|NCT01350336|EXPERIMENTAL|Alair|Alair system
62231105|NCT00634660|ACTIVE_COMPARATOR|0.001 mg/kg|One subcutaneous injection of 0.001 mg/kg of rAvPAL-PEG.
62231106|NCT00634660|ACTIVE_COMPARATOR|0.003 mg/kg|One subcutaneous injection of 0.003 mg/kg of rAvPAL-PEG.
62231107|NCT00634660|ACTIVE_COMPARATOR|0.01 mg/kg|One subcutaneous injection of 0.01 mg/kg of rAvPAL-PEG.
62231108|NCT00634660|ACTIVE_COMPARATOR|0.03 mg/kg|One subcutaneous injection of 0.03 mg/kg of rAvPAL-PEG.
62231109|NCT00634660|ACTIVE_COMPARATOR|0.1 mg/kg|One subcutaneous injection of 0.1 mg/kg of rAvPAL-PEG.
62231110|NCT00634660|ACTIVE_COMPARATOR|0.3 mg/kg|One subcutaneous injection of 0.3 mg/kg of rAvPAL-PEG.
62231111|NCT00634660|ACTIVE_COMPARATOR|1.0 mg/kg|One subcutaneous injection of 1.0 mg/kg of rAvPAL-PEG.
62231112|NCT02237651||topical anesthesia multi-use device|anesthesia with multi-use device (Laryngeal atomizer, Karl Storz, Tuttlingen, Germany
62422766|NCT06129799||conventional LF-LG AS|
62592197|NCT03483961|EXPERIMENTAL|Group 1: 20 mcg/unadjuvanted (Day 1 & 29)|20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)
62807667|NCT06171958||ICM|Patients receiving ICM at CT
62231113|NCT02237651||topical anesthesia Intranasal Mucosal Atomization|single-use product (LMA® MAD Nasal™ Intranasal Mucosal Atomization Device, Teleflex medical, Kernen Germany) for topical anesthesia
62231114|NCT06323018|SHAM_COMPARATOR|Control group|SHAM procedure is done one hour before cemented hip arthroplasty and comprises of 4 cycles of 5min sham procedure. Everything apart from the pressure in the cuff is similar to the RIPC procedure.
62231115|NCT06323018|ACTIVE_COMPARATOR|Remote Ischemic preconditioning group|RIPC procedure is done one hour before cemented hip arthroplasty and comprises of 4 ischemia (using brachial cuff with suprasystolic blood pressure for 5 min) and reperfusion (5 min) cycles.
62592198|NCT03483961|EXPERIMENTAL|Group 2: 6 mcg/adjuvanted (Day 1 & 29)|6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
62807668|NCT06171958||No ICM|Patients not receiving ICM at CT
62231116|NCT06311604|EXPERIMENTAL|ISOFLURANE SEDATION|"Inclusions will have 4 phases according to gradual increased doses of isoflurane (0.3 MAC; 0.5 MAC and 0.7 MAC) Upgrading dose of isoflurane in each phase will be validated by an independent data and safety monitoring committee (DSMC).~Inclusion of 12-15 additional patients will be included at the 0.7 MAC dose, to have 18 patients exposed to 0.7 MAC isoflurane."
62807669|NCT01706172|ACTIVE_COMPARATOR|Dextrose 20 % Injection|Injecting 20 % Dextrose and 0.2 % lidocaine intra-articularly into the TM Joint
62231117|NCT06236282||ArtiSential® Use|Laparoscopic low anterior resection, with use of both straight devices and articulated devices
62231118|NCT06236282||ArtiSential® Non-Use|Laparoscopic low anterior resection, with use of straight devices only
62231119|NCT04743167|ACTIVE_COMPARATOR|Surgery|Patients undergoing surgery for endometriosis, after surgery, will receive indications for seeking for a natural pregnancy up to 12 months from the time of randomization
62231120|NCT04743167|ACTIVE_COMPARATOR|In Vitro Fertilization|Patients included in the IVF arm will undergo three complete cycles of IVF (i.e. three oocytes retrievals regardless of the number of embryo transfers)
62231121|NCT02263937|ACTIVE_COMPARATOR|Bilateral Nucleus Basalis Meynert DBS|6 week period of active NBM DBS
62231122|NCT02263937|SHAM_COMPARATOR|Sham Nucleus Basalis Meynert DBS|6 week period of Sham DBS
62231123|NCT03282812||cases|
62231124|NCT03282812||controls|
62231125|NCT01444456||Cohort 1: Darbepoetin alfa|Participants receiving systemic chemotherapy for solid tumors who also received darbepoetin alfa (Aranesp®) to treat symptomatic anemia according to routine institutional practice.
62807670|NCT01706172|ACTIVE_COMPARATOR|Sterile Water Injection|Injection of Sterile water in 0.2 % lidocaine intra-articularly into the TM joint
62231126|NCT01444456||Cohort 2: Any ESA|Participants receiving systemic chemotherapy for solid tumors who also received darbepoetin alfa (Aranesp®) or another erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia according to routine institutional practice.
62422767|NCT06190873|EXPERIMENTAL|group to be trained over the phone|This group will be trained by phone for 6 weeks after discharge.
62592199|NCT03483961|EXPERIMENTAL|Group 3: 10 mcg/adjuvanted (Day 1 & 29)|10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
62807671|NCT02611973|EXPERIMENTAL|HU without aspirin|
62807672|NCT02611973|ACTIVE_COMPARATOR|HU + aspirin maintenance|
62807673|NCT02611973|OTHER|HU + AAG|Observational arm
62807674|NCT01830374||Women with bulimia nervosa|This is not a treatment study. All participants will go through the same steps.
62807675|NCT01863381|EXPERIMENTAL|Hydrocephalus/Pseudotumor|Patients between the ages of 18-65 years with suspected hydrocephalus or idiopathic intracranial hypertension (IIH), also known as pseudotumor cerebri, who are recommended by their doctor based on standard clinical criteria to undergo intracranial pressure monitoring. The interventions include tympanic membrane displacement (TMD) and DPOAE.
62807676|NCT02497924|EXPERIMENTAL|GBT440|GBT440 / \[C14\] GBT440
62807677|NCT01677689|PLACEBO_COMPARATOR|Control Group|Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal
62807678|NCT01677689|EXPERIMENTAL|Study Group|Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
62807679|NCT01650558|ACTIVE_COMPARATOR|Standard of Care Prophylaxis (TS)|Standard of care prophylaxis with daily trimethoprim sulfamethoxazole (TS).
62807680|NCT01650558|EXPERIMENTAL|Chloroquine (CQ) prophylaxis|Discontinuation of standard of care TS prophylaxis and starting weekly chloroquine prophylaxis
62231127|NCT02501538|EXPERIMENTAL|Transcutaneous O2 device|Continuous diffusion of oxygen (CDO) (topical oxygen) therapy, which will be administered using a portable device.
62231128|NCT04876742|EXPERIMENTAL|0.5 liters of alcoholic beer|
62231129|NCT04876742|PLACEBO_COMPARATOR|0.5 liters of water|
62231130|NCT04876742|NO_INTERVENTION|non-interventional cohort control group|
62231131|NCT00002565|EXPERIMENTAL|Arm I|"Sequential 4-, 5-, and 3-Drug Combination Chemotherapy. IdSHAP: IDA/CDDP/ARA-C/MePRDL; followed by BIdCOS: BLEO/IDA/CTX/VCR/MePRDL; followed by MINE: Mesna/IFF/DHAD/VP-16.~Alternating triple therapy (ATT) of IdSHAP (idarubicin, cisplatin, cytarabine, methylprednisolone), BIdCOS (idarubicin, vincristine, bleomycin, cyclophosphamide, methylprednisolone), and MINE (mesna, ifosfamide, mitoxantrone, etoposide)."
62231132|NCT00002565|EXPERIMENTAL|Arm II|4-Drug Combination Chemotherapy. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone): CTX/DOX/VCR/PRED.
62422768|NCT06190873|NO_INTERVENTION|Group without telephone training|This group will be given training during their stay in the hospital. There will be no training over the phone after discharge.
62422769|NCT01881217|EXPERIMENTAL|BAY1179470 (Dose escalation)|BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
62031464|NCT06038123|EXPERIMENTAL|Subjects with market released 3.0T conditional CIED systems receive 3.0T MRI scans|Signal arm, To confirm safety and effectiveness of the SureScan CIED System in the clinical MRI environment
62031465|NCT00777725||1|Chronic stable left sided HF patients
62031466|NCT00777725||2|Predominant right sided HF patients secondary to valvular heart disease, pulmonary artery hypertension (PAH), chronic obstructive pulmonary disease (COPD), or thrombotic disease and etc
62031467|NCT00777725||3|Acute decompensated left sided heart failure patients who have volume overload and have been admitted for diuresis
62422770|NCT01881217|EXPERIMENTAL|BAY1179470 (additional)|Additional cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
62422771|NCT01881217|EXPERIMENTAL|BAY1179470 (expansion)|Expansion cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
62422772|NCT05241626||group 1|70 eyes of 35 patients of thyroid inactive disease
62031468|NCT00777725||4|Control subjects with no evidence of heart disease.
62422773|NCT05241626||Group 2|70 eyes of 35 patients of thyroid active disease
62422774|NCT05241626||Group 3|Healthy controls
62422775|NCT03224741|PLACEBO_COMPARATOR|Information|
62422776|NCT03224741|ACTIVE_COMPARATOR|Active Choice|
62422777|NCT03224741|EXPERIMENTAL|Monetary incentive|
62422778|NCT00768105|EXPERIMENTAL|1|
62422779|NCT00768105|PLACEBO_COMPARATOR|2|
62422780|NCT01327378||Dialysis, normal glucose tolerance|Chronic dialysis treatment, N=10 OGTT,120 min \< 7.8 mmol/L
62031469|NCT02958969|EXPERIMENTAL|Apixaban|apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
62031470|NCT05903144|EXPERIMENTAL|Study group|they received manual diaphragm release with conventional breathing exercises and prone positioning in addition to their prescribed medications.
62031471|NCT05903144|ACTIVE_COMPARATOR|Control group|they received conventional breathing exercises and prone positioning alone in addition to their prescribed medications.
62031472|NCT03708679||Group F|Patients with menstrual cycle between 8-12 days were called Group F (Follicular phase)
62031473|NCT03708679||Group L|Patients with menstrual cycle between 20-24 were called Group L (Luteal phase)
62422781|NCT01327378||Dialysis, impaired glucose tolerance|Chronic dialysis treatment, N=10 OGTT,120 min 7.7\<11.1 mmol/L
62422782|NCT01327378||Control, normal glucose tolerance|Healthy Control subjects, N=10 OGTT,120 min \<7.8 mmol/L
62422783|NCT03601806|EXPERIMENTAL|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62422784|NCT00892424|EXPERIMENTAL|Sorafenib + RT|
62422785|NCT01297569|EXPERIMENTAL|Ranibizumab|
62422786|NCT01166997|EXPERIMENTAL|Ultrasound accelerated thrombolysis|Patients in this arm will receive anti-coagulation (intravenous unfractionated heparin) plus the EkoSonic Endovascular System will be used to deliver a low dose \<20mg rt-PA (Actilyse) directly into the occlusive pulmonary thrombus.
62422787|NCT01166997|ACTIVE_COMPARATOR|Intravenous unfractionated heparin|Patients in this arm will receive the standard of care: intravenous unfractionated heparin used as anti-coagulation treatment.
62422788|NCT03912350|EXPERIMENTAL|Test group|Participants with moderate hepatic impairment.
62031474|NCT04051229|EXPERIMENTAL|Exercise Training Group|All 20 participants will be assigned to this arm. These individuals will participate in 6 weeks of a moderate supervised aerobic exercise training program.
62031475|NCT06669507|OTHER|Treatment as usual|All patients referred to the Sleep Clinic and that is considered eligible and has a signed consent will be included in the study.
62031476|NCT02468765||Depressive MS patients|Neuropsychological and emotional evaluation with monitoring
62031477|NCT02468765||Non depressive MS patients|Neuropsychological and emotional evaluation with monitoring
62031478|NCT02468765||Control|Neuropsychological and emotional evaluation with monitoring
62031479|NCT03317977|EXPERIMENTAL|Reach for Control|Reach For Control is a multi-component, home-based family therapy that targets the multiple causes of poor adolescent asthma management across individual, family and community systems.
62031480|NCT03317977|ACTIVE_COMPARATOR|Michigan MATCH|Program endorsed by the State of Michigan for treatment of poorly controlled asthma.
62031481|NCT03690505|OTHER|Assessment|Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place
62031482|NCT00288158|EXPERIMENTAL|Allopurinol|
62031483|NCT00288158|EXPERIMENTAL|Probenecid|
62031484|NCT00288158|ACTIVE_COMPARATOR|Placebo|
62031485|NCT01994330|EXPERIMENTAL|Desmopressin|"0,3 mcg per kilogram of desmopressin in 100 ml of saline, labeled as study drug and administered in 30 minutes a half hour before surgical incision"
62422789|NCT03912350|ACTIVE_COMPARATOR|Reference group|Healthy pariticipants with normal hepatic function.
62422790|NCT03649906|EXPERIMENTAL|Optimized Localization Group|Subjects have small pulmonary nodules. In order to facilitate the search for nodules during surgery, it is necessary to indwelling markers pre-operative.
62422791|NCT02366039||EMR|patients undergoing clinically indicated endoscopic mucosal resection as standard of care will be asked to participate for this observational study
62422792|NCT06562296|EXPERIMENTAL|AIC for DFUs|Participants with a diabetic foot ulcer (DFU) will receive treatment with an Amnion-Intermediate-Chorion sheet product, a dehydrated multilayer human placental tissue derived from donated human tissue, and weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
62422793|NCT06562296|EXPERIMENTAL|AIC for VLUs|Participants with a venous leg ulcer (VLU) will receive treatment with an Amnion-Intermediate-Chorion sheet, a dehydrated multilayer human placental product derived from donated human tissue, and weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
62422794|NCT06562296|EXPERIMENTAL|ACA for DFUs|Participants with a diabetic foot ulcer (DFU) will receive treatment with an Amnion-Chorion-Amnion sheet allograft product, a dehydrated trilayer human placental tissue derived from donated human tissue, and weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
62422795|NCT06562296|EXPERIMENTAL|ACA for VLUs|Participants with a venous leg ulcer (VLU) will receive treatment with an Amnion-Chorion-Amnion allograft sheet, a dehydrated trilayer human placental product derived from donated human tissue, and weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
62422796|NCT06562296|ACTIVE_COMPARATOR|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
62031486|NCT01994330|PLACEBO_COMPARATOR|placebo|"100 of saline labeled as study drug administered in 30 minutes a half hour before surgical incision"
62422797|NCT01042002|EXPERIMENTAL|High intensity exercise|
62422798|NCT01042002|NO_INTERVENTION|Control|
62422799|NCT02590978|EXPERIMENTAL|Early cholecystectomy|Cholecystectomy within the first 72 hours of admission.
62422800|NCT02590978|OTHER|Control (Delayed cholecystectomy)|Standard care arm. Cholecystectomy is delayed until normalization of laboratory values, abdominal pain resolves and oral intake is restored.
62422801|NCT00350194|PLACEBO_COMPARATOR|1|Omega-3 fatty acid vs. placebo comparator
62422802|NCT05225116|EXPERIMENTAL|Sintilimab+Lenvatinib+Radiotherapy|
62592200|NCT03483961|EXPERIMENTAL|Group 4: 20mcg/adjuvanted (Day 1 & 29);40mcg/adjuvant (Day 547)|20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)
62592201|NCT03483961|EXPERIMENTAL|Group 5: 6 mcg/adjuvanted (Day 15 & 29)|Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
62031487|NCT01064739|EXPERIMENTAL|Study Diet +/- fava beans|Participants underwent testing while on a methylxanthine-free diet providing 150 mEq sodium and 75 mEq potassium per day. The study involved a longitudinal design where the participants served as their own controls. Subjects consumed the standard fixed sodium diet on study day one. On study day two, participants ate 100 g of puréed fava beans and pods with study diet at breakfast (0800hr) and lunch (1200hr).
62031488|NCT05872633|EXPERIMENTAL|Online self-management intervention (and care-as-usual)|At the start of the treatment, a face-to-face introductory meeting takes place between the participant and a psychologist, for acquaintance and to formulate goals for the treatment. Subsequently, a tailored self-management intervention, based on cognitive-behavioral therapeutic methods will be offered via an online program. Treatment will be conducted by a therapist who is specifically trained in the tailored cognitive-behavioral protocol. After finishing the online program, patients will be approached by their treating psychologist for two booster sessions via telephone. In these booster sessions it will be evaluated how the patient further attained his/her pre-set goals for the intervention. Strategies to strengthen the achieved results will be discussed. The booster sessions will take place 1 month and 2,5 months after finishing the online program.
62231133|NCT04934488|EXPERIMENTAL|Immediate Treatment|The experimental (immediate workshop) group will receive the online workshop at baseline (T1). The experimental group will also receive care as usual from their healthcare providers.
62422803|NCT04089163|EXPERIMENTAL|Sequential Dose Cohorts|Doses of Toca 511 will be evaluated in sequential cohorts. Toca 511 will be administered as a single intravesical instillation. Following Toca 511 administration, Toca FC will be administered orally at a dose of 220 mg/kg/day for 7 days every 6 weeks.
62231134|NCT04934488|OTHER|Waitlist Control|The waitlist control group will receive care from usual healthcare providers and will receive the intervention at the conclusion of the study period (T2, 12 weeks after enrollment).
62231135|NCT03298685||CF patient and parents cohort in 3 CF center|All adolescents for whom the transition to the adult center is scheduled within six months and their parent will be interviewed before and after transition.
62231136|NCT05208866|EXPERIMENTAL|Lixivaptan|Lixivaptan capsules 100-200mg twice daily
62231137|NCT03458065||S-ICD|
62231138|NCT03458065||T-ICD|
62231139|NCT03760705||Coronary Artery Disease|"1. Clinical data collected by Singapore Cardiac Data Bank (SCDB)~2. Clinical, administrative, pharmacy, financial data collected by each participating hospital~3. Administrative data collected by the Ministry of Health"
62422804|NCT01835808||Fractional Flow Reserve|Coronary artery disease patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation).
62422805|NCT00850382|EXPERIMENTAL|Dasatinib|"Induction cycle(s):~Patients will receive in cycle 1 induction therapy with daunorubicin 60 mg/m2/day administered on days 1 through 3 and cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7). Patients will receive dasatinib 100 mg QD on days 8-21. Patients not achieving CR or CRi at the end of cycle 1 will be evaluable to receive a second induction cycle identical in schedule and dosage to the first induction cycle.~Consolidation Cycles 1, 2, 3, 4:~Patients achieving CR or CRi at the end of cycle 1 will receive consolidation therapy for 4 cy-cles. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (\>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours. Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
62422806|NCT06078995||Tenecteplase|acute ischemic stroke patients who receive intravenous thrombolysis with tenecteplase
62422807|NCT06078995||alteplase|acute ischemic stroke patients who receive intravenous thrombolysis with alteplase
62422808|NCT00802776|ACTIVE_COMPARATOR|FLAK|Femtosecond laser assisted keratoplasty
62422809|NCT00802776|ACTIVE_COMPARATOR|PKP|Penetrating Keratoplasty
62422810|NCT02732886|EXPERIMENTAL|Betafoam®|Brand name: Betafoam® Generic term: Wound dressing with 3% povidone iodine
62422811|NCT02732886|ACTIVE_COMPARATOR|Medifoam®|Brand name: Medifoam® Generic term: Wound dressing
62422812|NCT06552572|EXPERIMENTAL|Glofitamab|"Glofitamab every 21 days for 12 cycles or until progression.~1. First cycle~   * Obinutuzumab (GPT) 1000mg (D1)~  * Glofitamab step up dosing 2.5mg (D8) → 10mg (D15)~2. After the first cycle (completed priming): 30mg IV every 3 weeks."
62231140|NCT03760705||Heart Failure|"1. Clinical data collected by Singapore Cardiac Data Bank (SCDB)~2. Clinical, administrative, pharmacy, financial data collected by each participating hospital~3. Administrative data collected by the Ministry of Health"
62231141|NCT03760705||Atrial Fibrillation|"1. Clinical data collected by Singapore Cardiac Data Bank (SCDB)~2. Clinical, administrative, pharmacy, financial data collected by each participating hospital~3. Administrative data collected by the Ministry of Health"
62231142|NCT02137720|EXPERIMENTAL|Telephonic Diabetes Self-Management Support|This group receives all the Educational Print Materials received by the comparison condition plus telephone calls from a health educator to provide tailored diabetes self-management training and support. Participants with significant emotional distress at baseline also receive additional calls focused on distress management.
62422813|NCT00948181||Surgeon|To detect the degree of intraoperative stress, venous blod will be drawn from one surgeon during 8 pheochromocytoma resections.
62422814|NCT00948181||Anesthesiologist|To detect the degree of intraoperative stress, venous blood will be drawn from one anesthesiologist during 8 pheochromocytoma resections.
62422815|NCT00948181||Patients with pheochromocytoma|Venous blood will be drawn from 8 patients with pheochromocytoma during tumor resection.
62592202|NCT03483961|EXPERIMENTAL|Group 6: 10 mcg/adjuvanted (Day 15 & 29)|Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
62592203|NCT03483961|EXPERIMENTAL|Group 7: 20 mcg/adjuvanted (Day 15 & 29)|Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)
62592204|NCT03483961|EXPERIMENTAL|Group 8: 40 mcg/adjuvanted (Day 29)|Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)
62807681|NCT01650558|NO_INTERVENTION|Discontinuation of standard of care|Control arm - Discontinuation of standard of care trimethoprim sulfamethoxazole.
62231143|NCT02137720|ACTIVE_COMPARATOR|Educational Print Materials|Participants randomized to this arm will receive print materials on diabetes, glycemic control, self-management, and distress/depression.
62231144|NCT01247571|EXPERIMENTAL|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62231145|NCT05999968|EXPERIMENTAL|Abemaciclib + Darolutamide|Abemaciclib plus (+) darolutamide. Participants who have not undergone bilateral orchiectomy are required to continue background androgen deprivation therapy (ADT) with a luteinizing hormone-releasing hormone (LHRH) agonist/antagonist throughout the study.
62231146|NCT03207685|OTHER|All Subjects|This is a single arm study With a device intervention of Additional Seizure Monitoring
62231147|NCT03186196|EXPERIMENTAL|Group 1|Diet with 191 mcg/day of Folate
62231148|NCT03186196|ACTIVE_COMPARATOR|Group 2|Diet containing 90 mcg / day of Folate
62231149|NCT02920931|EXPERIMENTAL|A|"1. st period: Tenofovir disoproxil fumarate~2. nd period: Tenofovir Disoproxil"
62231150|NCT02920931|ACTIVE_COMPARATOR|B|"1. st period: Tenofovir disoproxil~2. nd period: Tenofovir Disoproxil fumarate"
62807682|NCT05315349|EXPERIMENTAL|Patient requiring cardiac surgery for myocardial revascularization|
62807683|NCT04513756|EXPERIMENTAL|Active Treatment Group|Community Reinforcement Approach (CRA) as an intervention consisting of nine sessions (each session consists of 45-minutes). Treatment is primarily based upon the guidelines by Robert Meyers and William Miller (2001). The techniques included in the sessions are functional analysis, sobriety sampling, behavioral skills, and relapse prevention techniques.
62807684|NCT04513756|NO_INTERVENTION|Treatment As Usual Group|CRA comprising of nine sessions will not be provided to this group. However, patients who will be already receiving treatment from any psychiatric or some other rehabilitation facility will be advised to continue their routine treatment.
62807685|NCT02372877|EXPERIMENTAL|Amicus Red Cell Exchange in SCD patients|Open arm. Patients with sickle cell disease (SCD) treated using one Amicus Red Cell Exchange procedure.
62807686|NCT01329263|EXPERIMENTAL|Nonmenthol|Participants switch from menthol to non-menthol cigarettes.
62807687|NCT01329263|NO_INTERVENTION|Menthol|Participants smoke own brand of menthol cigarettes.
62807688|NCT03470688||Originator|Originator anti-TNF agents. Dosage as per physician's decision based on approved indication.
62807689|NCT03470688||Biosimilar|Biosimilar anti-TNF agents. Dosage as per physician's decision based on approved indication.
62807690|NCT05445895|EXPERIMENTAL|Renexin CR 200/160mg|Renexin CR 200/160mg will be added to Aspirin 100mg
62231151|NCT02254525|EXPERIMENTAL|800 mg intravenous ibuprofen|Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours, infused over 15 minutes.
62231152|NCT02254525|PLACEBO_COMPARATOR|200 ml of saline solution|Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours, infused over 15 min.
62231153|NCT06128993|EXPERIMENTAL|Transcoronary cooling and dilution|Intervention with transcoronary cooling and dilution
62231154|NCT06128993|PLACEBO_COMPARATOR|Standard of care|Routine clinical care
62231155|NCT01400555|EXPERIMENTAL|001|Cohort 1 Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
62231156|NCT01400555|EXPERIMENTAL|002|Cohort 2 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
62422816|NCT04196088|ACTIVE_COMPARATOR|Ultivision AI Software enhanced screening colonoscopy|Ultivision Artificial Intelligence enhanced screening colonoscopies will be performed.
62592205|NCT03483961|EXPERIMENTAL|Group 9: 20 mcg/adjuvanted (Day 1 & 29)|20 mcg CHIKV VLP/adjuvanted (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 29). This group will also have plasmapheresis performed on Day 57 and Leukapheresis on Day 182
62592206|NCT03483961|EXPERIMENTAL|Group 10: 40 mcg/adjuvanted (Day 1)|40 mcg CHIKV VLP/adjuvanted (Day 1). This group will also have plasmapheresis performed on Day 22.
62807691|NCT05445895|ACTIVE_COMPARATOR|Clopidogrel 75mg|Plavix 75mg will be added to Aspirin 100mg
62807692|NCT04895449|EXPERIMENTAL|≥ 1 x 10E7 IU (low dose) in seronegative subjects|≥ 1 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 \& 28) in seronegative subjects
62807693|NCT04895449|EXPERIMENTAL|≥ 5 x 10E7 IU (middle dose) in seronegative subjects|≥ 5 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 \& 28) in seronegative subjects
62807694|NCT04895449|EXPERIMENTAL|≥ 1 x 10E8 IU (high dose)in seronegative subjects|≥ 1 x 10E8 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 \& 28) in seronegative subjects
62807695|NCT04895449|EXPERIMENTAL|≥ 1 x 10E7 IU (low dose)|≥ 1 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: Single MVA-SARS-2-ST vaccination in mRNA vaccinated subjects
62807696|NCT04895449|EXPERIMENTAL|≥ 5 x 10E7 IU (middle dose)|≥ 5 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: Single MVA-SARS-2-ST vaccination in mRNA vaccinated subjects
62231157|NCT01400555|EXPERIMENTAL|003|Cohort 3 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
62231158|NCT01400555|EXPERIMENTAL|004|Cohort 4 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
62231159|NCT03782025||Patients with increased PK-INR|Critically ill patients with spontaneously increased prothrombin complex (PK-INR) who are given phytomenadione intravenously at the discretion of the treating physician
62231160|NCT05137353|EXPERIMENTAL|Music Training (RitMoZ Training)|12 sessions spread in the course of 1.5 months: each session has a duration of 90 minutes; each week will have 2 sessions
62231161|NCT05137353|ACTIVE_COMPARATOR|Spelling Training|12 sessions spread in the course of 1.5 months: each session has a duration of 90 minutes; each week will have 2 sessions
62231162|NCT06350578|EXPERIMENTAL|Hall Crown Technique|HT is a conservative restorative technique used for primary molars with single- or multi-surface carious lesions. This technique involves cementing a SSC directly over the affected primary molar without any caries removal or tooth reduction.
62422817|NCT04196088|PLACEBO_COMPARATOR|No AI enhancement screening colonoscopy|Screening colonoscopies without Artificial Intelligence enhancement will be performed.
62807697|NCT04895449|EXPERIMENTAL|≥ 1 x 10E8 IU (high dose)|≥ 1 x 10E8 IU MVA-SARS-2-ST Intervention: Biological: Single MVA-SARS-2-ST vaccination in mRNA vaccinated subjects
62807698|NCT04310111|EXPERIMENTAL|EUS-RFA|Patients were placed in the lateral position under deep sedation with supplementary oxygen and electrocardiograph monitoring. The target tumor was identified by EUS, then the biopsy needle stylet was removed and replace with the RFA probe. RF energy was applied for 90-120 seconds at 5 Watts. Wait 1 minute before repositioning the Habib™ EUS RFA needle and repeat procedure as many times as needed to ensure complete ablation of the tumor. EUS-guided celiac plexus neurolysis (EUS-CPN) was performed on patients with intractable upper abdominal pain.
62807699|NCT00446979|EXPERIMENTAL|1|UC 781 0.1% carbomer gel
62807700|NCT00446979|EXPERIMENTAL|2|UC 781 0.25% carbomer gel
62422818|NCT00247130|ACTIVE_COMPARATOR|Omeprazole|Omeprazole (20 mg), intravenous, 2x /day
62807701|NCT00446979|PLACEBO_COMPARATOR|3|Placebo vaginal gel
62422819|NCT00247130|ACTIVE_COMPARATOR|Ranitidine|Ranitidine (100 mg), intravenous drip infusion, 2x /day.
62422820|NCT04501341|EXPERIMENTAL|BM-MNC experimental|Autologue bone marrow mononuclear cell
62231163|NCT06350578|ACTIVE_COMPARATOR|Conventional SSC Technique|CT is the traditional restorative technique often used for primary molars with multi-surface carious lesions. This technique involves caries removal and occlusal-proximal tooth surface reduction before crown cementation.
62231164|NCT03433248|EXPERIMENTAL|EMPA/LINA 10/5 mg QD (n=22)|8w EMPA followed by 8w EMPA/LINA 10/5 mg QD (n=22)
62231165|NCT03433248|EXPERIMENTAL|LINA/EMPA 5/10 mg QD (N=22)|8w LINA followed by LINA/EMPA 5/10 mg QD (N=22)
62422821|NCT04501341|EXPERIMENTAL|UC-MSC|Umbilical cord mesenchymal stem cell
62231166|NCT03433248|ACTIVE_COMPARATOR|Gliclazide 30 mg QD/BID (N=22)|8w Gliclazide 30 mg QD, followed by 8w Gliclazide BID (N=22)
62231167|NCT06117098|EXPERIMENTAL|Mobile application|This group will receive individual guidance via the mobile application (12 weeks)
62231168|NCT06117098|ACTIVE_COMPARATOR|Group-based lifestyle intervention at the Healthy Lifestyle Centres|This group will receive a group-based lifestyle intervention program at a Healthy Lifestyle Centre (12 weeks)
62422822|NCT00533585|EXPERIMENTAL|BAY 43-9006 + Bevacizumab|BAY 43-9006 (Sorafenib) + Bevacizumab + Paclitaxel + Carboplatin
62422823|NCT02034227|EXPERIMENTAL|SG2000 - 15 µg/m2/day|Cohort 1 - will commence at 15 µg/m2/day intravenous doses of SG2000 until Maximum Tolerated Dose is determined.
62819523|NCT06599996|EXPERIMENTAL|Evaluation of learnability and utility of artificial intelligence algorithm|Participants will be learning to use the artificial intelligence algorithms and testing them for ease of use and efficiency
62819524|NCT00057200|OTHER|Arm 1|
62031489|NCT05872633|OTHER|Care-as-usual|Care-as-usual encompasses a consultation with the rheumatologist and a 1,5-hour consultation with a clinical nurse or occupational therapist of the Leiden University Medical Center. During this consultation, patients receive information on the nature of osteoarthritis, the prognosis, and available treatment modalities, and education on chronic pain, joint protection, healthy life style, and assistive devices.
62231169|NCT06117098|EXPERIMENTAL|Group-based lifestyle intervention at a Healthy Lifestyle Centre and recieving a mobile application|This group will receive a group-based lifestyle intervention program at a Healthy Lifestyle Centre plus the mobile application (12 weeks)
62031490|NCT01371344|EXPERIMENTAL|Part A: Heart Transplant (Tacrolimus granules)|In Part A of the study, participants who are heart transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
62031491|NCT01371344|EXPERIMENTAL|Part A: Liver Transplant (Tacrolimus granules)|In Part A of the study, participants who are liver transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
62031492|NCT01371344|EXPERIMENTAL|Part A: Kidney Transplant (Tacrolimus granules)|In Part A of the study, participants who are kidney transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
62231170|NCT01284660|ACTIVE_COMPARATOR|I. DHA|Oral ingestion 5 tablets DHA + EPA (daily ingestion DHA 2040 mg and EPA 2710 mg)- (Omega 3 - 950,the Solgar Pharmaceutical Co., Israel).
62231171|NCT01284660|PLACEBO_COMPARATOR|II. Placebo|Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
62031493|NCT01371344|EXPERIMENTAL|Part B: All Participants (Tacrolimus capsules)|In Part B of the study, participants who are heart, kidney or liver transplant recipients and who are converted from tacrolimus granules-based immunosuppression regimen, receive tacrolimus capsules twice daily for 1 month and thereafter receive commercially available tacrolimus capsules.
62031494|NCT01276964||1. Women in the fertile age|Healthy women in the fertile age (between 20-45 years) with apparently normal periods
62231172|NCT05615090|EXPERIMENTAL|I (Prepectoral)|Participants received the Self-help app-based CBT-E for eating disorder for 8 weeks
62231173|NCT05615090|OTHER|II (Subpectoral)|Waiting list Wait-list control(participants will use the smartphone app after the intervention phase) The waitlist group will receive treatment as usual, Patients from the waitlist group will be offered access to App after a 8-weeks period.
62231174|NCT03404830|EXPERIMENTAL|HIIT group|This group receives physical training based on HIIT
62231175|NCT03404830|EXPERIMENTAL|MICT group|This group receives physical training based on MICT
62231176|NCT03404830|NO_INTERVENTION|No intervention group|This group does not receive any treatment.
62231177|NCT05826574|EXPERIMENTAL|Part 1: Period 1: Brensocatib|Period 1: Participants will receive a single oral dose of brensocatib on Day 1 in Part 1 of the study.
62231178|NCT05826574|EXPERIMENTAL|Part 1: Period 2: Brensocatib + Rifampin|Period 2: Participants will receive rifampin 600 mg once daily (QD), orally, on Days 8 to 23 along with a single oral dose of brensocatib prior to the rifampin administration on Day 17 in Part 1 of the study.
62231179|NCT05826574|EXPERIMENTAL|Part 2: Period 1: Brensocatib|Period 1: Participants will receive a single oral dose of brensocatib on Day 1 in Part 2 of the study.
62231180|NCT05826574|EXPERIMENTAL|Part 2: Period 2: Brensocatib + Esomeprazole|Period 2: Participants will receive esomeprazole 40 mg QD, orally, on Days 8 to 12 along with a single oral dose of brensocatib prior to the esomeprazole administration on Day 12 in Part 2 of the study.
62231181|NCT04697303||Middle and low rectal cancer|
62422824|NCT02034227|EXPERIMENTAL|SG2000 - 30 µg/m2/day|Cohort 2 - will commence at 30 µg/m2/day intravenous doses of SG2000 until Maximum Tolerated Dose is determined.
62031495|NCT02603653|EXPERIMENTAL|Patients|Virtual radial task in 3D
62231182|NCT02617056||Observational group|Subjects with dementia
62231183|NCT05031403|EXPERIMENTAL|Stroke (Telerehabilitation)|Exercise therapy with telerehabilitation system
62031496|NCT02603653|EXPERIMENTAL|Controls|Virtual radial task in 3D
62031497|NCT05984953||Statin|85 patients treated with statin
62031498|NCT05984953||Evolocumab|110 patients treated with evolocumab in addition to statin or evolocumab alone
62031499|NCT04130646|ACTIVE_COMPARATOR|Active taVNS, Active TMS|
62031500|NCT04130646|SHAM_COMPARATOR|Sham taVNS, Active TMS|
62031501|NCT04130646|SHAM_COMPARATOR|Active taVNS, Sham TMS|
62031502|NCT04130646|SHAM_COMPARATOR|Sham taVNS, Sham TMS|
62031503|NCT06291272|EXPERIMENTAL|Psyllium|375 ml containing 15g inulin made up in 375 ml water with 15 g psyllium husk
62231184|NCT05031403|OTHER|Stroke (Home Exercise)|Exercise therapy with brochure
62231185|NCT05031403|EXPERIMENTAL|Multiple Sclerosis (Telerehabilitation)|Exercise therapy with telerehabilitation system
62231186|NCT05031403|OTHER|Multiple Sclerosis (Home Exercise)|Exercise therapy with brochure
62231187|NCT05031403|EXPERIMENTAL|Parkinson Disease (Telerehabilitation)|Exercise therapy with telerehabilitation system
62231188|NCT05031403|OTHER|Parkinson Disease (Home Exercise)|Exercise therapy with brochure
62231189|NCT02843971|EXPERIMENTAL|Healthy volunteers|
62231190|NCT02902003|NO_INTERVENTION|Control|Not eligible for program services
62031504|NCT06291272|EXPERIMENTAL|Methylcelulose|375 ml containing 15g inulin made up in 375 ml water with 15g modified methylcellulose
62031505|NCT06291272|PLACEBO_COMPARATOR|Maltodextrin|375 ml containing 15g inulin made up in 375 ml water with maltodextrin powder (placebo)
62031506|NCT06670040|SHAM_COMPARATOR|Sham controlled|Sham aTBS targeting the left dorsolateral prefrontal cortex, 5 sessions per day for 5 days. If participants in the sham group do not show a significant treatment response by the 12-week follow-up - defined as a 50% reduction from baseline on the HDRS- they will then become eligible for and offered active, open-label treatment.
62031507|NCT06670040|ACTIVE_COMPARATOR|Active TBS Treatment|Active aTBS targeting the left dorsolateral prefrontal cortex, 5 sessions per day for 5 days.
62231191|NCT02902003|ACTIVE_COMPARATOR|Empowering Families|"These couples will be eligible to participate in the Empowering Families program."
62231192|NCT01207726|EXPERIMENTAL|Arm I (azacitidine, entinostat)|Patients receive azacitidine SC on days 1-5 and 8-10 and entinostat PO QD on days 3 and 10. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62031508|NCT02142049|EXPERIMENTAL|Part 1: Dose Level 1|Ibrutinib 560 mg PO + DA-EPOCH-R
62231193|NCT01207726|NO_INTERVENTION|Arm II (standard of care)|Patients receive standard of care.
62231194|NCT03800641|EXPERIMENTAL|oral administration|oral administration of dexmedetomidine 4μg/kg
62031509|NCT02142049|EXPERIMENTAL|Part 1: Dose Level 2|Ibrutinib 560 mg (PO) +lenalidomide 15 mg (PO) + DA-EPOCH-R
62231195|NCT03800641|ACTIVE_COMPARATOR|intravenous administration|intravenous administration of dexmedetomidine 0.8μg/kg
62231196|NCT03800641|EXPERIMENTAL|nasal administration|nasal administration of dexmedetomidine 1μg/kg
62231197|NCT02260882|EXPERIMENTAL|Revaccination Group|0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who received an initial vaccination at least 5 years prior
62231198|NCT02260882|EXPERIMENTAL|Primary Vaccination Group|0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who have never received PNEUMOVAX™ 23 vaccination
62231199|NCT02778711|EXPERIMENTAL|Cosentyx|secukinumab (anti-IL-17)
62231200|NCT00081874|EXPERIMENTAL|RAD001|"Phase I: Participants initially treated with 5 mg RAD001 by mouth daily for 28 days.~Phase II: The MTD (either 5mg or 10mg) administered daily until intolerance or failure or lack of response after 4 cycles of therapy. For assessment purposes, each cycle will comprise a 28-day period."
62422825|NCT02284152|EXPERIMENTAL|Typical versus Infant-Led feeding|This is a within-subject study; all infants and mothers will be exposed to both conditions (typical feeding versus infant-led feeding conditions). Order of presentation will be counterbalanced across infant/mother dyads.
62422826|NCT05469503|EXPERIMENTAL|TOTUM-854|Experimental active diet supplement TOTUM-854 3.71-g dose. Seven capsules per day to consume orally in two intakes
62031510|NCT02142049|EXPERIMENTAL|Part 1: Dose Level 3|Ibrutinib 560 mg (PO) +lenalidomide 20 mg (PO) + DA-EPOCH-R
62031511|NCT02142049|EXPERIMENTAL|Part 1: Dose Level 4|Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
62422827|NCT05469503|PLACEBO_COMPARATOR|Placebo|Placebo comparator Seven capsules per day to consume orally in two intakes
62031512|NCT02142049|EXPERIMENTAL|Part 2: RP2D|Recommended Phase 2 Dose(RP2D): Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
62031513|NCT06477900|EXPERIMENTAL|SMS receiption|150 participants will follow the FindRiscPei-CPTM program (current care) and will also receive 72 SMS messages over 6 months encouraging them to take part in sports and offering nutritional advice.
62231201|NCT01391585|EXPERIMENTAL|text message recipients|Patients will be recruited to receive text messages
62231202|NCT02373553|NO_INTERVENTION|Group 1( G1): CONTROL GROUP|not be submitted to intervention, only receive informations about health education.
62422828|NCT02275182|EXPERIMENTAL|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
62422829|NCT02275182|PLACEBO_COMPARATOR|Controlled|0.5μg/kg Saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
62422830|NCT01854801|EXPERIMENTAL|Experimental|Patients who declare themselves to be intolerant to electromagnetic fields benefit from medical care in occupational and environmental diseases centers and from a measurement of individual electromagnetic exposures and symptoms episodes. Each patient is his own control.
62422831|NCT03033589|ACTIVE_COMPARATOR|Adductor Canal Nerve Block|One hour prior to procedure, subject to receive 20 mL of 0.5% ropivacaine injected into the sheath of the saphenous nerve at the adductor hiatus. Ultrasound guidance utilized for appropriate localization of the targeted nerve sheath for local infiltration. No nerve stimulators to be utilized during or after the procedure.
62031514|NCT06477900|NO_INTERVENTION|No SMS|150 participants will only follow the FindRiscPei-CPTM program (current care) and will not receive SMS.
62031515|NCT03369600|EXPERIMENTAL|Healthy Controls|Women Supersonic Imagine Aixplorer SWE Ultrasound Imaging on two separate occasions.
62231203|NCT02373553|EXPERIMENTAL|Group 2(G2) : HEALTH EDUCATION|The family will receive a booklet of guidance of exercises to be performed at home.
62231204|NCT02373553|EXPERIMENTAL|Group 3(G3): EXERCISES IN OUTPATIENTS UNIT|The postural reeducation through lengthening of the anterior muscles and strengthening of the posterior muscles of the trunk.
62231205|NCT06022562||With gender-affirming hormone therapy|With gender-affirming hormone therapy
62231206|NCT06022562||Without gender-affirming hormone therapy|Without gender-affirming hormone therapy
62231207|NCT04834206|OTHER|DNF-N|"1. Induction chemotherapy:~   three cycles of intravenous docetaxel 60 mg/m² on day 1, intravenous nedaplatin 60 mg/m² on day 1, and continuous intravenous fluorouracil 600 mg/m² per day from day 1 to day 5, every 3 weeks~2. Concurrent chemoradiotherapy:~   three cycles of 100 mg/m² nedaplatin every 3 weeks, concurrently with intensity-modulated radiotherapy~3. Radiotherapy: radical intense modulated radiation therapy"
62231208|NCT04357860|EXPERIMENTAL|Sarilumab 200 mg|Subjects treated with the best available treatment up to 14 days plus Sarilumab 200 mg single dose.
62231209|NCT04357860|EXPERIMENTAL|Sarilumab 400 mg|Subjects treated with the best available treatment up to 14 days plus Sarilumab 400 mg single dose.
62231210|NCT04357860|ACTIVE_COMPARATOR|Control|Subjects treated with the best available treatment up to 14 days.
62592207|NCT02683057||IPAQ HIgh|Excessive physical activity:IPAQ quantifying the activity physical according vigorous intensity activities at least 3 days per week adding a minimum total physical activity of at least 1500MET-minutes / week or 7 or more days any combination of walking, moderate intensity or vigorous intensity activities a total minimum of physical activity of at least 3,000 MET-minutes / week
62592208|NCT02683057||IPAQ Moderate|Ideal Physical activity: IPAQ quantifying the activity physical according 3 days or more of vigorous intensity physical activity at least 20 minutes per day or 5 or more days of moderate intensity and / or walk at least 30 minutes per day or 5 or more days of any combination of walking, moderate-intensity activity and activity vigorous intensity for a total minimum of physical activity of at least 600 MET-minutes / week.
62592209|NCT02683057||IPAQ Low|IPAQ quantifying the activity physical according Insufficient physical activity: Individuals who can not put on the criteria of the above categories.
62592210|NCT02683278|EXPERIMENTAL|Cognitive-Behavioral Therapy|Group-based cognitive-behavioral manualized treatment
62592211|NCT02683278|EXPERIMENTAL|Mindfulness-acceptance Therapy|Group-based mindfulness-acceptance manualized treatment
62592212|NCT02683278|ACTIVE_COMPARATOR|Education|Group-based manualized pain education
62592213|NCT03144271|EXPERIMENTAL|NNC 0113-0217|Dose-escalation trial
62592214|NCT03144271|PLACEBO_COMPARATOR|Placebo|Dose-escalation trial
62592215|NCT00637000|EXPERIMENTAL|Buprenorphine soluble film|"Day 1: Buprenorphine soluble film administered at a dose of 4 mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.~Days 2-5: Buprenorphine soluble film administered at a dose of 16 mg to 24 mg once per day, plus placebo. Dosing occurred at 0900 hours."
62592216|NCT00637000|EXPERIMENTAL|Buprenorphine/naloxone soluble film|"Day 1: Buprenorphine/naloxone soluble film administered at a dose of 4mg/1mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.~Days 2 to 5: Buprenorphine/naloxone soluble film administered at a dose of 16mg/4 mg to 24 mg/6 mg once per day, plus placebo. Dosing occurred at 0900 hours."
62592217|NCT02630329|EXPERIMENTAL|vNOTES adnexectomy|Vaginal Natural Orifice Transluminal Endoscopic Surgery
62231211|NCT06389253||Control Group|Control group are patients that will insert the calcaneo-stop screw (age between 10 and 14 years old).
62231212|NCT06389253||Study Group|Study group are patient that remove the calcaneo-stop screw (age from 14 years old)
62231213|NCT03201705|EXPERIMENTAL|Refractory neuropathic leg and low back pain|Patients with refractory neuropathic leg and low back pain as result of FBSS will be enrolled in the study and receive electrocatheter implant. Then, they will be observed for a two-weeks trial period in which the efficacy of the stimulation and the compliance of the patient is evaluated. During this trial a Tonic wave stimulation is administered by the external generator. After the trial, the definitive generator will be implanted. Tonic stimulation will be selected as wave form for four weeks. After this period, the stimulation will be switched into the combined waveform for 30 days. At the end of the study period, the final waveform setting of the SCS will be in accord with the patient's stimulation preference.
62231214|NCT02793479||BE|Patients presenting Barrett's Esophagus as a complication of a gastroesophageal reflux disease.
62422832|NCT03033589|ACTIVE_COMPARATOR|Femoral Nerve block|One hour prior to procedure, subject to receive 30 mL of 0.5% ropivacaine injected into the nerve sheath of the femoral nerve at the level of the femoral triangle. Ultrasound guidance utilized for appropriate localization of the targeted nerve sheath for local infiltration. No nerve stimulators to be utilized during or after the procedure.
62422833|NCT04274088||Tecnis;|Patients who received the Tecnis multifocal IOL.
62231215|NCT04129853|EXPERIMENTAL|Crossover|Performing a sit to stand with the Cyberlegs Xleg and comparing with their current prosthesis.
62422834|NCT04274088||Diffractiva|Patients who received the Diffractiva multifocal IOL.
62422835|NCT01610167|ACTIVE_COMPARATOR|NUPRO(r) Classic Prophy Paste|
62422836|NCT01610167|EXPERIMENTAL|NUPRO Sensodyne Prophy Paste w/ Novamin(r) w/ fluoride.|
62592218|NCT02630329|ACTIVE_COMPARATOR|LSC adnexectomy|Laparoscopic adnexectomy
62592219|NCT04164251|EXPERIMENTAL|Inpatient screening mammography for non-adherent and high risk|All non-adherent women were offered inpatient screening mammography during hospitalization
62592220|NCT05301179|EXPERIMENTAL|RDA Lacto-Vegetarian/Vegan|Subjects will receive diets containing the RDA for protein from Lacto-vegetarian and Vegan sources in different periods during the protocol.
62592221|NCT05301179|EXPERIMENTAL|Higher than RDA Lacto-Vegetarian/Vegan|Subjects will receive diets containing more than the RDA for protein from Lacto-vegetarian and Vegan sources in different periods during the protocol.
62031516|NCT03369600|EXPERIMENTAL|FIB-Sx|Women receiving Supersonic Imagine Aixplorer SWE Ultrasound Imaging prior to elective hysterectomy for treatment of symptomatic uterine fibroids.
62231216|NCT04129853|EXPERIMENTAL|Case study|Comparing the cyberlegs xleg with other devices.
62422837|NCT01610167|EXPERIMENTAL|NUPRO Sensodyne Prophy Paste w/ Novamin|
62592222|NCT06162013|ACTIVE_COMPARATOR|Intervention|Following our basket trial design, there will be three parallel intervention cohorts (one per disease/cohort)
62592223|NCT06162013|PLACEBO_COMPARATOR|Placebo|Following our basket trial design, there will be three parallel placebo cohorts (one per disease/cohort)
62592224|NCT06619067|ACTIVE_COMPARATOR|Treated group|Dietary supplement: PROBAFLOR 20 Billion CFU/dose, serving size = 1 capsule/day
62592225|NCT06619067|PLACEBO_COMPARATOR|Placebo group|Placebo Placebo product, serving size = 1 capsule/day
62592226|NCT03391544|EXPERIMENTAL|V4c toric ICL implantation Group|V4c toric ICL implantation Group
62592227|NCT03216590|NO_INTERVENTION|Standard draping|Shoulder arthroscopy will be performed using standard draping with the shoulder exposed.
62592228|NCT03216590|EXPERIMENTAL|Compressive draping|After standard preparation similar to the no-intervention group, the shoulder will be draped with compressive draping using adhesive incise drape (Ioban™2 Antimicrobial Incise Drape, 3M Inc.,USA)
62592229|NCT02588716|ACTIVE_COMPARATOR|Terlipressin|Terlipressin will be given at the beginning of surgery as an initial bolus dose of (1 mg over 30 mins) followed by a continuous infusion of 2μg/kg/h to be continued throughout the surgery then gradually withdrawn over 4 hours
62592230|NCT02588716|PLACEBO_COMPARATOR|Control|same volumes of normal saline with the same rate of infusion, throughout the operation then gradually withdrawn over 4 hours.
62592231|NCT01975571|EXPERIMENTAL|Adult|"Population 1: 15 Adults who have a severe sensorineural hearing loss with a pure-tone average (PTA) between 60-90 dB HL between 125-1500 Hz and profound loss at higher frequencies.~Intervention: These patients will receive a Hybrid L24 cochlear implant."
62231217|NCT05244889|EXPERIMENTAL|Digital CBT-I|After assignment to dCBT-I, participants will complete a baseline assessment of their sleep, migraines and other outcomes and complete a 30-day sleep and headache diary, and wear an actigraphy device for 7 days to record their sleep and light exposure. They will then be given access to the 6-session dCBT-I programme. At month 1, participants will wear an actigraph device for 1 week.. At month 3 participants will complete a 30-day post-treatment assessment including a sleep and headache diary and the same battery of questionnaires as during the baseline assessment. A subset of participants (and providers) will be invited to participate in an interview about uptake of dCBT-I. At month 6, all participants will complete follow-up questionnaires (similar to baseline and post-treatment questionnaires) and one last 30-day assessment of sleep and headaches and wear a 7-day actigraphy device.
62231218|NCT05244889|ACTIVE_COMPARATOR|Sleep Hygiene Education (SHE)|After assignment to SHE, participants will complete a baseline assessment of their sleep, migraines and other outcomes and complete a 30-day sleep and headache diary, and wear an actigraphy device for 7 days to record their sleep and light exposure. They will then be given access to the 6-session SHE programme. At month 1, participants will wear an actigraph device for 1 week.. At month 3 participants will complete a 30-day post-treatment assessment including a sleep and headache diary and the same battery of questionnaires as during the baseline assessment. A subset of participants (and providers) will be invited to participate in an interview about uptake of SHE. At month 6, all participants will complete follow-up questionnaires (similar to baseline and post-treatment questionnaires) and one last 30-day assessment of sleep and headaches and wear a 7-day actigraphy device.
62231219|NCT00624923|EXPERIMENTAL|1- Active Pharmacologic|Salsalate
62592232|NCT01975571|EXPERIMENTAL|Children and adolescents (L24)|"Children (ages 5-12 years) and adolescents (ages 13-15 years) who have a sensorineural hearing loss with a pure-tone average (PTA) between 70-90 dB HL between 125-1500 Hz, a hearing threshold \>90 dB HL at 1500 Hz and profound loss at higher frequencies.~Intervention: These patients will receive a Hybrid L24 cochlear implant."
62592233|NCT01975571|EXPERIMENTAL|Children and adolescents S12|"Children (ages 5-12 years) and adolescents (ages 13-15 years) who have a sensorineural hearing loss with a pure-tone average (PTA) between 70-90 dB HL between 125-1500 Hz, a hearing threshold hearing threshold between 70-90 dB HL at 1500 Hz and profound loss at higher frequencies.~Intervention: These patients will receive a Hybrid S12 cochlear implant."
62592234|NCT02171338|OTHER|Antibiotic treatment based on PCT-level|"Information regarding the PCT-levels in the intervention group is available to the treating doctor and the test subjects are randomized for treatment based on the level of PCT (PCT algorithm).~With a PCT ≥0.25 µg/l and ≥0.10 µg/l for pneumonia and AECOPD respectively antibiotic treatment is advised to be started."
62231220|NCT00624923|PLACEBO_COMPARATOR|2- Placebo|Placebo
62231221|NCT00434473|PLACEBO_COMPARATOR|Placebo|
62231222|NCT00434473|EXPERIMENTAL|A-001|
62231223|NCT00642382|ACTIVE_COMPARATOR|Active|Agilus (Hyaluronic Acid)
62231224|NCT00642382|PLACEBO_COMPARATOR|Control|Normal Saline
62231225|NCT02020629|EXPERIMENTAL|Lixisenatide|Lixisenatide 20µg daily
62231226|NCT01144767|EXPERIMENTAL|Computer-generated advisor|Participants receive sessions with a computer-generated adviser who will provide tailored advice and encouragement to engage in physical activity.
62231227|NCT01144767|ACTIVE_COMPARATOR|Comparison control condition|Participants will receive live, group sessions on health topics unrelated to physical activity.
62422838|NCT05947149||Cohort A Survivors|about 80 patients with at least a 5 year follow up with head and neck, skull base and brain tumors and no evidence of progressive disease.
62422839|NCT05947149||Cohort B|100 patients with histological and/or radiological diagnosis of head and neck tumors enrolled at baseline
62422840|NCT04237259|EXPERIMENTAL|Parent-administered TCM massage group|Parents of subjects in the parent-administered TCM massage group (n=30) will attend 2 training sessions (5 hours in total) to learn and practice the parent-administered TCM massage for ADHD before treatment starts. The parents will be told to practice the TCM massage on their child every 2 days for 2 months.
62231228|NCT00265447|ACTIVE_COMPARATOR|Strength training|3 months of strength training
62422841|NCT04237259|ACTIVE_COMPARATOR|Parent-child interaction group|Parents in the parent-child interaction group (comparison group, n=30) will attend a 3-hour training course on line and spend extra time on interacting with their child at home.
62422842|NCT01725737|PLACEBO_COMPARATOR|Placebo|
62231229|NCT00265447|ACTIVE_COMPARATOR|Aerobic conditioning|3 months of aerobic conditioning
62231230|NCT00265447|OTHER|Delayed exercise|delayed exercise control group
62422843|NCT01725737|ACTIVE_COMPARATOR|GlyTI-M|GlyTI-M: 0.03gm/kg/day
62422844|NCT06116448|EXPERIMENTAL|high-fidelity simulation|These students participated in a breastfeeding management scenario with a high-fidelity simulation mannikin named Noella S554.100 (n=11).
62422845|NCT06116448|EXPERIMENTAL|hybrid simulation|These students participated in the same breastfeeding management scenario with a standardized patient (n=11).
62231231|NCT00921960|NO_INTERVENTION|Usual Care|Usual Care will involve ongoing management from the general practitioner, nurse-led assessment of cardiovascular risk at the general practice and referral to specialist services as deemed necessary.
62231232|NCT00921960|OTHER|Intervention|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate
62231233|NCT01543724|EXPERIMENTAL|Lithium|
62231234|NCT05332405|EXPERIMENTAL|Study Group|Participants will have planned surgical procedure to repair the median or ulnar nerve compression. During the procedure, the doctor will administer a small injection of indocyanine green (ICG) and laser angiography using the SPY Elite device will be used to evaluate blood flow and extent of nerve decompression at the surgical site. Participation will also involve filling out two questionnaires on pain and function level and an examination of hand strength and range of motion.
62422846|NCT06116448|EXPERIMENTAL|telesimulation|These students participated in the same breastfeeding management scenario with a standardized patient via Microsoft Teams video conferencing. (n=11)
62422847|NCT06116448|NO_INTERVENTION|control|The students in this group were the control group, and no intervention was made.
62422848|NCT05049460|ACTIVE_COMPARATOR|Active intervention|Four sessions of theta burst stimulation, amounting to 7200 pulses at 120% resting motor threshold. Targeting will be done using neuronavigation and processed resting state brain scan.
62422849|NCT05049460|PLACEBO_COMPARATOR|Sham TMS|Four sessions of sham TMS. Targeting will be done using neuronavigation and processed resting state brain scan.
62422850|NCT00159081|EXPERIMENTAL|1|Maintenance antipsychotic treatment with risperidone
62422851|NCT00159081|ACTIVE_COMPARATOR|2|Maintenance antipsychotic treatment with haloperidol in low-dose
62422852|NCT05052827|ACTIVE_COMPARATOR|Children|Participants underwent 3 metabolic trials in a randomized crossover fashion, where they were provided with an isonitrogenous quantities of either milk protein concentrate, soy protein isolate, and rice protein isolate following a standardized bout of variable intensity exercise.
62422853|NCT05052827|ACTIVE_COMPARATOR|Adolescent Females|Participants underwent 3 metabolic trials in a randomized crossover fashion, where they were provided with an isonitrogenous quantities of either milk protein concentrate, soy protein isolate, and rice protein isolate following a standardized bout of variable intensity exercise.
62422854|NCT05052827|ACTIVE_COMPARATOR|Adolescent Males|Participants underwent 3 metabolic trials in a randomized crossover fashion, where they were provided with an isonitrogenous quantities of either milk protein concentrate, soy protein isolate, and rice protein isolate following a standardized bout of variable intensity exercise.
62422855|NCT01832688||Baseline cohort|The baseline survey will be implemented among pregnant women in randomly selected villages using a continuous enrollment schedule over the period of 18 months
62807702|NCT03630796|ACTIVE_COMPARATOR|Sevoflurane|"Anesthetic induction with sevoflurane by mask 3-8% and fresh gas flow 2-8 l/min (FiO2 50-100%) followed by ketamine 1-2 mg/kg, midazolam 0,1-0,5 mg/kg, fentanyl 2-4 mcg/kg and pancuronium 0,1 mg/kg.~After orotracheal intubation, anesthesia is maintained with fentanyl 10 - 30 mcg/kg according to clinical needs and sevoflurane 1-3% (end-tidal concentration) before and after cardiopulmonary bypass. Specifically during cardiopulmonary bypass extra fentanyl 1-5 mcg/kg and pancuronium 0,1 mg/kg will be administered and the sevoflurane sustained 1-3% in a specific sevoflurane vaporizer included in the CPB machine.~Pressure-controlled ventilation will be applied to both groups objectifying normocarbia and normoxia.~Ringer's lactate (RL) will be used as crystalloid solution for fluid therapy."
62231235|NCT02170935|EXPERIMENTAL|BIBR 1048 capsule|
62231236|NCT05843188|EXPERIMENTAL|High DTP-signature|Take HCQ, 400 mg by mouth, twice daily. Receive FOLFIRI+bevacizumab (irinotecan 180 mg/m2, leucovorin 400 mg/m2, 5-FU 2400 mg/m2 over 46 - 48 hours, bevacizumab 5 mg/kg), intravenously, every 2 weeks
62231237|NCT05843188|ACTIVE_COMPARATOR|Low DTP-signature|Receive FOLFIRI+bevacizumab (irinotecan 180 mg/m2, leucovorin 400 mg/m2, 5-FU 2400 mg/m2 over 46 - 48 hours, bevacizumab 5 mg/kg), intravenously, every 2 weeks
62231238|NCT03583177||healthy volunteers|
62231239|NCT03583177||cancer patients|
62231240|NCT03583177||undergoing chronic hemodialysis patients|
62231241|NCT03451162|EXPERIMENTAL|Dose Escalation Cohort: DHES0815A|Participants will receive DHES0815A in escalating doses in the dose-escalation cohort of the study. Participants will receive additional infusions of DHES0815A on Day 1 of subsequent cycles provided that they meet the protocol specified criteria for acceptable toxicity and ongoing clinical benefit.
62231242|NCT03451162|EXPERIMENTAL|Dose Expansion Cohort: DHES0815A|Participants will be treated at or below the Maximum Tolerated Dose (MTD) of DHES0815A (based on the review of the totality of the data) to obtain additional safety, tolerability, PK, and anti-tumor activity data.
62231243|NCT01483664||initial survivorship planning consultation|The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt/TGH). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site.
62231244|NCT01483664||initial wellness rehabilitation consultation|The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt/TGH). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site.
62592235|NCT02171338|NO_INTERVENTION|Control|"Test subjects randomized for standard treatment (control group) are treated in accordance with the existing treatment guidelines of Holbaek Hospital.~PCT-level will be measured but the treating doctor has no access to the result."
62422856|NCT01832688||Optimization cohort|The programmatic impact of optimized prenatal care services on women's health and behavior will be assessed among pregnant women in randomly selected villages (Programmatic prenatal care optimization)
62592236|NCT02091986|ACTIVE_COMPARATOR|Symbicort pMDI 80/2.25 µg|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
62231245|NCT01668108||carcinoma, Paclitaxel onkovis (Paclitaxel)|treatment in mono- or combination therapy with Paclitaxel of breast-, non-small cell lung- and ovarial cancer.
62422857|NCT01933412|EXPERIMENTAL|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
62422858|NCT01933412|ACTIVE_COMPARATOR|Engerix B Hepatitis B Vaccine|Engerix B Hepatitis B Vaccine
62422859|NCT00934778|EXPERIMENTAL|Bronchoscopy|
62422860|NCT01563393|OTHER|STAMP using|Relevant to the third part of the study. 30 Children between 1 and 17 years of age from internal medicine department will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale.
62592237|NCT02091986|ACTIVE_COMPARATOR|Symbicort pMDI 80/4.5µg|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
62592238|NCT02091986|ACTIVE_COMPARATOR|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
62231246|NCT00302627|EXPERIMENTAL|Pamidronate, Vitamin D, and Calcium|"60mg or 90mg given at baseline, 6,12,18, and 24 months~vitamin D 800 units/day~calcium carbonate 1500 milligrams/day"
62231247|NCT04878731|EXPERIMENTAL|single arm|PF-06741086 300mg subcutaneous(SC)
62231248|NCT02768051|EXPERIMENTAL|AF Ablation Intervention|Subjects who are scheduled to undergo ablation procedure due to atrial flutter.
62231249|NCT05868174|EXPERIMENTAL|89Zr-TLX250, 177Lu-TLX250 and Peposertib|"Diagnostic test: A single IV administration of 37 Megabecquerel (+/- 10%) 89Zr-DFO-girentuximab, containing a mass dose of 10 mg of girentuximab, followed by a diagnostic scan~Treatment test: A single IV administration that could be 1887 - 2516 or 3145 Megabecquerel (+/- 10%) 177Lu-DOTA-girentuximab,containing a mass dose of 10 mg of girentuximab, on Day 1 of each 84-day cycle and p.o. administration of that could be 100-150 or 200 mg Peposertib BID on days 4-21 of each 84-day cycle."
62231250|NCT04242589|ACTIVE_COMPARATOR|Radiotherapy|Radiotherapy dose: 20 Gy/5 fractions/1 week or 8 Gy/1 fraction (at the discretion of the Radiation Oncologist)
62231251|NCT04242589|EXPERIMENTAL|Vertebroplasty + Radiotherapy|"Vertebroplasty followed by radiotherapy within 2-3 weeks~Radiotherapy dose: 20 Gy/5 fractions/1 week or 8 Gy/1 fraction (at the discretion of the Radiation Oncologist)"
62231252|NCT01640054|EXPERIMENTAL|Dosing regimen|Open label Oral treatment 100mg once daily
62231253|NCT02882828|EXPERIMENTAL|DBS (dried blood spots) collection|In this study, we make a switch from Prograf® to Envarsus®. Patients will be trained to collect their blood from a finger prick on filter paper. DBS will be done at home, collected on filter paper and mailed by the patients to a centralized laboratory (Department of Pharmacology, Toxicology and Pharmacovigilance at Limoges University Hospital), where tacrolimus concentration will be determined by HPLC-MS/MS
62231254|NCT04902833||Cohort I|"Approximately 75 anemic (Hgb \<11.0 g/dL) MDS Participants without overt clinical evidence of hemolysis.~- Single Blood Draw"
62231255|NCT04902833||Cohort 2|"25 Participants with clonal myeloid disorders of any type with evidence of non-immune, otherwise unexplained hemolytic anemia~-Single Blood Draw"
62231256|NCT03999320|EXPERIMENTAL|Sophrology group|8 sophrology sessions, approximately 60 minutes each, spread over 12 months
62231257|NCT03999320|OTHER|Control group|usual care
62231258|NCT02234245|NO_INTERVENTION|Hospital monitoring of pacemakers|Patients have to go to the hospital to be monitorized
62422861|NCT01563393|OTHER|No STAMP using|Relevant to the third part of the study. Other 30 children that are not screened by dietitian and either not by STAMP
62422862|NCT00976313||1|male patients
62422863|NCT00976313||2|female patients
62422864|NCT02546037||SOLACEA 21H|single haemodiafiltration treatment using a SOLACEA 21H dialyzer (Nipro Corp, Osaka, Japan)
62422865|NCT02546037||FX100|single haemodiafiltration treatment using a FX100 dialyzer (Fresenius MC, Bad Homburg, Germany)
62422866|NCT00897429||Ancillary-Correlative (laboratory biomarker analysis)|Previously collected tissue samples are analyzed for K-ras mutations; COX-2, phospho-AKT, and VEGF overexpression; microvessel density; association of genomic instability with microsatellite instability and p53 mutations; and methylation status of MLH1, MGMT, and WRN and to identify prognostic biomarkers by LINE-1 hypomethylation, PIK3CA mutation, BRAF mutation, FASN expression, and VDR expression via immunohistochemistry, PCR, RT-PCR, and microarray.
62422867|NCT04390074||COVID-19|Patients with COVID-19 who have received or are receiving Intensive Care in Sweden. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
62422868|NCT04390074||Control|Age- and sex-matched controls are drawn from all residents of Sweden by Statistics Sweden.
62422869|NCT06542796|EXPERIMENTAL|Comprehensive treatment group|Immunotherapy combined with targeted therapy
62422870|NCT06542796|ACTIVE_COMPARATOR|non-comprehensive treatment group|Standard treatment plan
62422871|NCT03864367||Device|This group will use the MWeST lift device along with regular physical therapy. The lift device is the Prism Medical FGA-700 Bariatric Floor Lift including a sling to assist in walking.
62422872|NCT03864367||Control|This group will only receive regular physical therapy.
62422873|NCT00828581|EXPERIMENTAL|Lorcaserin|
62422874|NCT02231671|EXPERIMENTAL|Part 1: Absolute Bioavilability|Part 1 of this study is an absolute bioavailability study where the IV (intravenous) microtracer dose of ALS-008112 is administered 15-30 minutes after the oral dose to determine the bioavailability of the oral dose compared to the IV dose. The maximum microtracer IV dose administered in Part 1 of this study will not exceed a single dose of 100 μg \[14C\]-ALS-008112 containing NMT (not more than) 37.0 kBq (1000 nCi) 14C. Based upon previous clinical observations, it is anticipated that the single oral dose and IV microdose to be utilised in Part 1 will provide acceptable PK data and will be safe and well tolerated.
62592239|NCT02051140|EXPERIMENTAL|Strawberry|Participants randomized into this arm of the study consume freeze-dried strawberry.
62231259|NCT02234245|EXPERIMENTAL|Remote monitoring of pacemakers|"Telemedicine System:~Patients have not to go to the hospital to be monitorized"
62231260|NCT04011618|PLACEBO_COMPARATOR|Placebo|16 patients to receive 1 homologated placebo capsule (calcined magnesia 500 mg) every 12 hours along 12 weeks
62231261|NCT04011618|EXPERIMENTAL|Ellagic acid|16 patients to receive 1 homologated intervention capsule (ellagic acid 500 mg) every 12 hours along 12 weeks
62231262|NCT01561209|ACTIVE_COMPARATOR|Amitryptiline|Amitryptiline 5 mg before bedtime
62231263|NCT01561209|PLACEBO_COMPARATOR|Placebo|Placebo pill
62231264|NCT03917680|EXPERIMENTAL|Type III angioedema|White angioedema. Positive for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
62231265|NCT03917680|EXPERIMENTAL|Idiopathic angioedema|White angioedema. Negative for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
62231266|NCT03917680|EXPERIMENTAL|Type I or II angioedema|White angioedema. Negative for Factor XII mutation. C1-inhibitors anomaly. Not caused by IEC.
62422875|NCT02231671|EXPERIMENTAL|Part 2: Mass Balance|Part 2 of this study is an absorption, metabolism and excretion study, for which a single 375 mg \[14C\]-ALS-008176 (containing NMT 6.85 MBq (megabecquerel) (185 μCi) 14C) dose has been selected for evaluation based upon data from prior studies. Based upon previous clinical observations, it is anticipated that the dose to be utilised in Part 2 will provide acceptable PK data, will be safe and well tolerated and is within the therapeutic range.
62422876|NCT02015338||Typically Developing Children|Children with typical development (e.g. no presence of neurological disorders or diagnoses)
62031517|NCT03369600|EXPERIMENTAL|FIB-Mx|Women receiving Supersonic Imagine Aixplorer SWE Ultrasound Imaging prior to and at two points during elective medical therapy for treatment of symptomatic uterine fibroids.
62231267|NCT03917680|EXPERIMENTAL|Post IEC (conversion enzyme inhibitors) angioedema|White angioedema. Negative for Factor XII mutation. No C1-inhibitors anomaly. Caused by IEC.
62592240|NCT02051140|PLACEBO_COMPARATOR|Placebo|Participants randomized into this arm of the study consume a strawberry placebo.
62592241|NCT01630863|EXPERIMENTAL|50% group|power of PDT is applied to the patients at 50% of the full energy based on TAP study.
62231268|NCT03917680|EXPERIMENTAL|Histaminic angioedema|Red angioedema.Negative for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
62231269|NCT03917680|OTHER|Control|Healthy individuals, no angioedema.
62231270|NCT02583035|OTHER|Nurse telephone contact|3 days of consultation, telephone follow-up of the patient by the nurse coordinator of the Geriatric Oncology Unit to validate
62422877|NCT02015338||Children with Hemiparesis|Children diagnosed with Hemiparesis
62592242|NCT01630863|EXPERIMENTAL|40% group|Decreasing power of PDT is applied to the patients at 40% of the full energy based on TAP study.
62592243|NCT01630863|EXPERIMENTAL|30% group|Decreasing power of PDT is applied to the patients at 30% of the full energy based on TAP study.
62231271|NCT06409780|EXPERIMENTAL|Diagnosis of Pulmonary Tuberculosis in index case|CUS, CXR and CAD analysis will be performed in all patients with new diagnosis of pulmonary tuberculosis according to microbiological criteria
62422878|NCT05640375|NO_INTERVENTION|Follow-up|Intussuception diagnosed, Informed consent was obtained by explaining treatment options to their families, no tenderness on abdominal examination, the duration of complaints is less than 24 hours, no findings of complication, Just IV hydration and ultrasonography is repeated 4 hours later (clinical and physical examination findings are monitored)
62422879|NCT05640375|EXPERIMENTAL|Single dose Steroid treatment|Intussuception diagnosed, Informed consent was obtained by explaining treatment options to their families, no tenderness on abdominal examination, the duration of complaints is less than 24 hours, no findings of complication, Methylprednisolone 1 mg/ kg single dose was given and ultrasonography is repeated 4 hours later (clinical and physical examination findings are monitored)
62422880|NCT04215653|EXPERIMENTAL|Anaprazole Sodium + Rabeprazole Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
62031518|NCT04199091|EXPERIMENTAL|Craniosacral self-help techniques (CST)|The experimental group consists of 24 teaching units (TUs) à 45 minutes over 12 weeks. The course starts with an introductory day (8 TUs), followed by 6 practice evenings every two weeks (2 TUs each) and a final afternoon (4 TUs). The patients will also receive a script with theoretical CST basics and descriptions of the techniques, which should facilitate the correct practice at home.
62231272|NCT06409780|EXPERIMENTAL|Screening of Pulmonary Tuberculosis in household contacts|CUS, CXR and CAD analysis will be performed in all participants who are household contacts of an index case
62231273|NCT06346860|ACTIVE_COMPARATOR|Modified Thoracoabdominal Nerve BlockThrough Perichondral Approach and PCA|Modified Thoracoabdominal Nerve BlockThrough Perichondral Approach and Intravenous Patient Controlled Analgesia
62231274|NCT06346860|PLACEBO_COMPARATOR|Intrathecal Morphine and Intravenous Patient Controlled Analgesia|Intrathecal Morphine 200 mcg and Intravenous Patient Controlled Analgesia (1 mg/ml morphine, 1 cc bolus, 7 min. locked
62231275|NCT03975166|EXPERIMENTAL|Test Product|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
62231276|NCT03975166|ACTIVE_COMPARATOR|Reference Product|ADVAIR DISKUS® 100/50
62422881|NCT04215653|ACTIVE_COMPARATOR|Rabeprazole +Anaprazole Sodium Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
62592244|NCT01211457|EXPERIMENTAL|Sapacitabine/decitabine (Part 1 - completed)|decitabine will be administered in alternating cycles with sapacitabine
62592245|NCT01211457|EXPERIMENTAL|sapacitabine/venetoclax (Part 2 - recruiting)|sapacitabine will be administered concomitantly with venetoclax
62592246|NCT06243367|PLACEBO_COMPARATOR|Fast (Control) group|Patients were instructed to be fasting for 6 hours before surgery and received only placebo drink (200 ml clear water) two hours before surgery
62231277|NCT03113903|EXPERIMENTAL|scheduled surgery|
62231278|NCT03113903|OTHER|healthy volunteers|
62231279|NCT00321113|ACTIVE_COMPARATOR|1|oral
62231280|NCT00321113|EXPERIMENTAL|2|oral
62231281|NCT00234546|EXPERIMENTAL|1|Dysport
62231282|NCT00234546|PLACEBO_COMPARATOR|2|Placebo
62231283|NCT06419829||Pediatric group|Pediatric group - children aged 0-3 years old, participating in physiotherapeutic visits carried out as part of the assessment of the child's psychomotor development
62592247|NCT06243367|EXPERIMENTAL|Carbohydrate group|Patients were given a meal of cup of yogurt (100 ml) with 2 spoonful of honey (42 gm) at midnight before surgery and 200 ml of a clear carbohydrate drink on the day of surgery, 2 h before anesthesia induction. This drink consisted of 200 ml water in which two spoonful of honey were dissolved.
62592248|NCT02807012|EXPERIMENTAL|Nursing educational intervention|The intervention will consist in three home visits (14, 21, 30 days after discharge) by nurses to family caregivers. The nurses will give verbal information and printed materials related to the care of older adults por stroke.
62592249|NCT02807012|NO_INTERVENTION|Usual care|The family caregivers won't receive the home visits and could have or not the usual care guidelines provide by health services that have access.
62592250|NCT03088046|OTHER|Micronized Progesterone|Administration of 200 mg of vaginal Micronized Progesterone (100 mg every 12 hours) for a 7-day course
62592251|NCT02357095|EXPERIMENTAL|hysteroscopic monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under hysteroscopic monitoring.The brand of hysteroscope machine is STORZ.
62031519|NCT04199091|ACTIVE_COMPARATOR|Progressive muscle relaxation (PMR)|The active control group consists of 24 teaching units (TUs) à 45 minutes over 12 weeks. Every week patients will meet for 2 TUs. The patients will also receive a script with theoretical basics and descriptions of the PMR techniques, hich should facilitate the correct practice at home.
62231284|NCT06419829||Pediatric older group|Pediatric older group - Children aged 3-6 years recruited as part of pre-school education
62231285|NCT06419829||School group|School group - Children aged 7-15 recruited as part of compulsory schooling at primary school level
62422882|NCT00792675|EXPERIMENTAL|Exercise|Exercise consists of 30 minutes of treadmill exercise at approximately 85% of heart rate max and 2 sets of 6 resistance weight lifting exercises resulting in volitional fatigue at 12 to 15 repetitions.
62592252|NCT02357095|EXPERIMENTAL|ultrasonography monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under ultrasonography monitoring.The brand of ultrasonograph is mindray(Z6).
62592253|NCT02357095|EXPERIMENTAL|no monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under no monitoring
62031520|NCT00916565||Experimental milk-based infant formula|
62592254|NCT05126667||Breast-conserving surgery|Patients who underwent breast-conserving surgery plus whole-breast irradiation
62592255|NCT05126667||Mastectomy|Patients who underwent mastectomy
62592256|NCT03258840|PLACEBO_COMPARATOR|EPA placebo|EPA- placebo softgel (Containing 2 g edible paraffin oil), 2 times/day, for 8 weeks
62031521|NCT00916565||Control milk-based infant formula|
62031522|NCT00916565||Breastfed Reference Group|
62592257|NCT03258840|ACTIVE_COMPARATOR|EPA supplement|EPA supplement softgel (containing 2 g EPA per day), 2 times/day, for 8 weeks.
62592258|NCT04811274||Patients|Minor patients with alveolar proteinosis by mutations of the MARS gene.
62231286|NCT06419829||Youth group|Respondents aged 15-25 recruited as part of secondary education, taking into account age (secondary school, university, graduate school) and gender division
62231287|NCT06419829||Adult group|Adult group - Respondents aged 25-55
62231288|NCT06419829||Senior group|Senior group - Tests at the age of over 55, in the case of women, the condition for inclusion in this group is the postmenopausal period
62231289|NCT02800577|OTHER|All participants|Study has a single, non-interventional arm where the General Practitioner Emotional Test Battery (GP-ETB) will be administered.
62231290|NCT04294563|EXPERIMENTAL|Immediate Intervention Group|Participants will complete baseline measures and begin daily supplementation of peanut protein powder (72g/day) 7 days prior to total knee arthroplasty until 6 weeks after surgery.
62231291|NCT04294563|ACTIVE_COMPARATOR|Wait-llist Control Group|Participants will complete baseline measures 7 days prior to total knee arthroplasty and will receive a 7 week supply after completion of 12 week post-surgery visit.
62592259|NCT04811274||Controls|Minors patients without alveolar proteinosis.
62031523|NCT03058679|EXPERIMENTAL|Specific Carbohydrate Diet|For the first six 6 weeks of the trial, participants received a weekly delivery of prepared meals compliant with the SCD (breakfast, lunch, dinner, and two 2 snacks per day). Meals were prepared by Healthy Chef Creations (Orlando, FL) based on menus developed by the food vendor in consultation with study dietitians. Participants assigned to the SCD received a three3-day starter diet as recommended in Breaking the Vicious Cycle. Meals were designed to be heated in an oven or microwave. No other preparation was required.
62231292|NCT03549312|EXPERIMENTAL|Switch to Genvoya Followed By HCV Therapy Then Start Biktarvy|Oral Genvoya 150/150/200/10 mg \& Epclusa 400/100 mg once daily. Once completed HCV therapy, switch anti-retroviral treatment to Oral Biktarvy 50/200/25 mg.
62231293|NCT02289612|PLACEBO_COMPARATOR|Tapioca Starch - Low-Fibre|Tapoica starch pudding without added fibre
62231294|NCT02289612|PLACEBO_COMPARATOR|High Maltose Corn Syrup - Low-Fibre|High maltose corn syrup pudding without added fibre
62231295|NCT02289612|PLACEBO_COMPARATOR|Trutol Glucose Beverage (#1)|Trutol Glucose Beverage containing 50 g of glucose without added fibre. Consumed at first treatment study visit.
62422883|NCT04960774||Control group|Patients with non-severe periodontitis or healthy people who were treated in our department in the same period were included as the control group.
62422884|NCT04960774||Severe periodontitis group|Severe periodontitis patients who meet the inclusion and exclusion criteria in the Department of Stomatology, the second affiliated Hospital of Medical College of Zhejiang University
62422885|NCT00607906|EXPERIMENTAL|Subjects receiving treatment in cohort A1|Eligible subjects will receive oral immediate release capsules of SB-756050 with doses of 5 milligrams, 15 milligrams, 50 milligrams, or 100 milligrams.
62592260|NCT05622877|PLACEBO_COMPARATOR|Placebo Group|Basic treatment according to the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack and placebo granules (6g/ bag, one bag each time, twice a day after meals);
62592261|NCT05622877|EXPERIMENTAL|Qushi Formula Group|Basic treatment according to the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack and Qushi Formula granules (6g/ bag, one bag each time, twice a day after meals);
62592262|NCT05622877|EXPERIMENTAL|Zhu's Wenban Formula Group|Basic treatment according to the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack and Zhu's Wenban Formula granules (6g/ bag, one bag each time, twice a day after meals);
62031524|NCT03058679|ACTIVE_COMPARATOR|Mediterranean Style Diet|For the first six 6 weeks of the trial, participants received a weekly delivery of prepared meals compliant with the MD (breakfast, lunch, dinner, and two 2 snacks per day). Meals were prepared by Healthy Chef Creations (Orlando, FL) based on menus developed by the food vendor in consultation with study dietitians. Meals were designed to be heated in an oven or microwave. No other preparation was required.
62231296|NCT02289612|PLACEBO_COMPARATOR|Trutol Glucose Beverage (#2)|Trutol Glucose Beverage containing 50 g of glucose without added fibre. Consumed at final treatment study visit.
62231297|NCT02289612|ACTIVE_COMPARATOR|Yellow Mustard Gum Fibre - Tapioca Starch|Yellow mustard gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
62231298|NCT02289612|ACTIVE_COMPARATOR|Yellow Mustard Gum Fibre - High Maltose Corn Syrup|Yellow mustard gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
62592263|NCT05265728|EXPERIMENTAL|Natalizumab 300 mg|Participants will receive natalizumab 300 mg SC Q4W for 48 weeks.
62592264|NCT02034981|EXPERIMENTAL|CRIZOTINIB|All eligible patients entering the study will receive oral crizotinib as monotherapy
62422886|NCT00607906|EXPERIMENTAL|Subjects receiving treatment in cohort A2|Eligible subjects will receive oral immediate release capsules of SB-756050 with doses of 100 milligrams, 200 milligrams, 300 milligrams, or 400 milligrams.
62422887|NCT00607906|EXPERIMENTAL|Subjects receiving treatment in cohort A3|Eligible subjects will receive oral immediate release capsules of SB-756050 with a dose of 150 milligrams. Subjects will also receive oral modified release capsules of SB-756050 with doses of 150 milligrams, 300 milligrams, or 400 milligrams.
62422888|NCT00607906|EXPERIMENTAL|Subjects receiving treatment in cohort A4|Eligible subjects will receive SB-756050 in this additional cohort.
62422889|NCT00607906|EXPERIMENTAL|Subjects receiving treatment in cohort B1|Eligible subjects will receive oral modified release capsules of SB-756050 with doses of 50 milligrams, 150 milligrams or 400 milligrams. Subjects will also receive immediate release oral capsules of SB-756050 with a dose of 150 milligrams.
62422890|NCT04698278||Surgical Treatment Group|This is a prospective, single center, bilateral, non-randomized, open-label, observational clinical study. All patients will have had prior myopic Lasik and will receive a PanOptix Trifocal IOL in both eyes at the time of cataract surgery. These patients will then be followed for up to 6-months to assess their refractive predictability, quality of vision, spectacle independence, and overall patient satisfaction.
62422891|NCT01741428|ACTIVE_COMPARATOR|Intervention (INT1)|The participants will join a 5-days course at the Feiring Heart Clinic.
62592265|NCT04490044|ACTIVE_COMPARATOR|1|Participants in Arm 1 will be posted the Under \& Over study pack (1) and asked to complete the Under \& Over tool daily for up to 30 minutes per day, 5 days per week for 3 months. They will be instructed to follow the instruction booklet and complete each pattern in the specific order described in the booklet.
62592266|NCT04490044|ACTIVE_COMPARATOR|2|Participants in Arm 2 will be posted the Under \& Over study pack (2) and asked to complete the Under \& Over tool daily for as long or short as they choose or are able to. They will be asked to complete 5 days per week for 3 months. They will be instructed to follow the instruction booklet in any order they wish, choosing which pattern they would like to complete. They will also be encouraged to create their own patterns. These participants will have access to a section of the study website where they will be able to upload photographs of their patterns and see other participants' patterns over the 3-month period.
62592267|NCT04490044|PLACEBO_COMPARATOR|3|Participants in Arm 3 will be posted the Under \& Over study pack (3). For the first three months of the study they will be asked to complete the c9HPT 5 days a week. After three months, they will be able to complete the Under \& Over tool daily for as long or short as they choose. Similar to Arm 2, They will be asked to do this 5 days per week for 3 months. They will be instructed to follow the instruction booklet in any order they wish, choosing which pattern they would like to
62592268|NCT01717482|ACTIVE_COMPARATOR|Metformin|Metformin 850mg twice a day
62592269|NCT01717482|PLACEBO_COMPARATOR|Observation|Standard of Care Observation
62031525|NCT06481917|EXPERIMENTAL|Advance care plan|Scheduling of 2 home visits by an expert nurse in the month following the return home and proposal to carry out an advance care plan.
62231299|NCT02289612|ACTIVE_COMPARATOR|Soluble Flaxseed Gum Fibre - Tapioca Starch|Soluble flaxseed gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
62231300|NCT02289612|ACTIVE_COMPARATOR|Soluble Flaxseed Gum Fibre - High Maltose Corn Syrup|Soluble flaxseed gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
62231301|NCT02289612|ACTIVE_COMPARATOR|Fenugreek Gum Fibre - Tapioca Starch|Fenugreek gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
62592270|NCT04427475|OTHER|pabolizumab|Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
62592271|NCT04427475|OTHER|nafulizumab|Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
62592272|NCT06059430||patient already on treatment|Patients already on biologic or synthetic TRT will be followed for 10 years
62592273|NCT06059430||Naive patients|Patients who are naive to biological or synthetic treatments
62735431|NCT03363191|ACTIVE_COMPARATOR|Subjects received Fluticasone Furoate|Subjects will receive fluticasone furoate 100 mcg inhalation powder via ELLIPTA DPI once daily for the 12 week treatment period. Subjects will receive salbutamol/albuterol as rescue medication on an as-needed basis.
62031526|NCT06481917|NO_INTERVENTION|Usual care|Usual care with the possibility of proposing ACP according to the department's habits
62231302|NCT02289612|ACTIVE_COMPARATOR|Fenugreek Gum Fibre - High Maltose Corn Syrup|Fenugreek gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
62231303|NCT02463643|EXPERIMENTAL|Z-215 10 mg/day|Drug: Z-215 10mg Drug: Z-215 Placebo Drug: Rabeprazole Sodium Placebo
62231304|NCT02463643|EXPERIMENTAL|Z-215 20 mg/day|Drug: Z-215 20mg Drug: Z-215 Placebo Drug: Rabeprazole Sodium Placebo
62422892|NCT01741428|NO_INTERVENTION|Control (KTR1)|The participants in the Control Group will receive care as usual at their local Doctors Office
62735432|NCT00600275|EXPERIMENTAL|BGT226|
62592274|NCT06622928||End-Stage Renal Disease Patients on Hemodialysis|"Patients with end-stage renal disease (ESRD) undergoing regular hemodialysis, recruited based on specific inclusion and exclusion criteria. Inclusion criteria include patients aged 18 or older, receiving a standard renal replacement therapy of three dialysis sessions per week, with a dialysis history of at least 3 months and dialysis adequacy (Kt/V \>1.2). Exclusion criteria include patients with a history of kidney transplantation, recent myocardial infarction or stroke, severe heart failure, chronic atrial fibrillation, obesity (BMI \>40 kg/m²), and malignancy.~Patients will undergo echocardiographic evaluations before and after dialysis, with a focus on left ventricular function and ventriculo-arterial coupling (VAC) using speckle-tracking echocardiography and pressure-volume loop analysis."
62231305|NCT02463643|EXPERIMENTAL|Z-215 40 mg/day|Drug: Z-215 20mg Drug: Z-215 20mg Drug: Rabeprazole Sodium Placebo
62422893|NCT01741428|ACTIVE_COMPARATOR|Subgroup Intervention (INT2)|Subgroup of 200 participants from the (INT1)where multiple, known CVD risk factors are studied: Physical Activity, Physical Condition (O2-consumption), Quality of life, Biochemical markers (fasting Glucose, Insulin, Apo Lipoprotein A (ApoA), Apo Lipoprotein B (ApoB), micro-C reactive protein (CRP), Total-, LDL- and HDL-cholesterol, Triglycerides and HbA1C.
62592275|NCT01895881|EXPERIMENTAL|Estradiol Daily|1 mg Estradiol daily for 180 days.
62592276|NCT01895881|PLACEBO_COMPARATOR|Placebo|Placebo for 180 days.
62592277|NCT04684628|EXPERIMENTAL|Biochemical Reoccurrence|"Patients with biochemical reoccurrence (post-prostatectomy or post radical radiotherapy) or patients with biochemical relapse with rising PSA in spite of taking hormone treatment (this situation is characterized as non-metastatic castration resistant prostate cancer M0CRPC) and compare it to bone scan and CT in 2 groups:~PSA \>= 0.2 ng/mL and \<= 0.5 ng/mL or PSA \> 0.5 ng/ml"
62592278|NCT04684628|EXPERIMENTAL|High Risk Prostate Cancer|Patients with high risk prostate cancer who have not received any definitive treatment. These high-risk patients are defined using the D'Amico Classification System: Those with a PSA of more than 20, or a Gleason score equal to or greater than 8, or have a clinical stage greater than T2c.
62031527|NCT03977220|EXPERIMENTAL|Nab-paclitaxel combined with S-1|Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
62031528|NCT05229692|EXPERIMENTAL|NEUBIE|"Experimental group will receive rehabilitation training with the NEUBIE for 6 weeks post-operative. Training will occur at Neufit 2x a week from week 1-5, and will be administered by NeuFit clinic staff. Exercises and ability to complete exercises will be recorded by NeuFit staff in standardized clinic evaluation forms.~Participants will undergo will undergo both active muscle tests and body analysis tests.~Measurements will be taken at The Piazza Center by clinic staff prior to surgery at 2,4,6,8, and 12 weeks post-operative. Measurements will be used to demonstrate milestones of functional recovery, comparable between subjects by weeks achieved."
62231306|NCT02463643|ACTIVE_COMPARATOR|Rabeprazole Sodium 10 mg/day|Drug: Z-215 Placebo Drug: Z-215 Placebo Drug: Rabeprazole Sodium
62422894|NCT01741428|NO_INTERVENTION|Subgroup control (KTR2)|Subgroup of 200 participants from the (KTR1)where multiple, known CVD risk factors are studied: Physical Activity, Physical Condition (O2-consumption), Quality of life, Biochemical markers (fasting Glucose, Insulin, Apo Lipoprotein A (ApoA), Apo Lipoprotein B (ApoB), micro-C reactive protein (CRP), Total-, LDL- and HDL-cholesterol, Triglycerides and HbA1C.
62592279|NCT06079177||Male patients with age ≥ 60 years undergoing TURP surgery|"All patients will receive spinal anesthesia Under complete aseptic technique at level of L 4-L5 or L3-L4 using 12.5-15 mg of 0.5 % hyperbaric bupivacaine and 25 ug fentanyl.~Lung ultrasound score:~A curvilinear (5-2 MHz) probe will be used. The sliding multiple B-lines will be evaluated in eight antero-lateral lung examination zones.~Inferior vena cava (IVC) measurement using ultrasound:~A curvilinear (5-2 MHz) probe with B-mode scan will be used. Caval-Aorta index will be calculated by taking the ratio of the two respective diameters measured.~Other vital parameter as ,heart rate (HR), Mean arterial pressure (MAP), oxygen saturation (SpO2), arterial blood gases (ABG), serum Na and K levels will be measured and recorded at same time as the following:~(T0) ,(T1) ,(T2),(T3) ,(T30, T60, T90) intraoperative ,(T PACU),(T critical)"
62592280|NCT05703880||Finerenone (Kerendia, BAY948862)|Adults with CKD and T2D from the USA who initiate finerenone.
62231307|NCT04019548|EXPERIMENTAL|Prophylactic PEG|Prophylactic PEG tube will be placed before the start of the study treatment (CRT). The enteral nutrition will start following the assessment by the clinical dietitian in order to complete the current oral consumption according to the estimated energy needs (on the basis of 30 to 35 kcal / kg adapted and 1.2 to 1.5 g / prot./ kg.BW) with an increase as needed during the treatment.
62422895|NCT04863326|EXPERIMENTAL|Making Proud Choices|This evaluation tests the effect of the MPC School Edition, the version of the MPC 5th Edition designed for implementation in school. This edition includes 9.5 hours of content implemented in 14 40-minute modules. Schools assigned to the MPC condition received MPC in a targeted class.
62592281|NCT04158102|EXPERIMENTAL|20 mg single dose cohort|Subjects would receive a 20 mg single dose of EXPAREL®
62592282|NCT03681990|EXPERIMENTAL|3M CHG/IPA Prep / Center|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70% solution applied topically to intact skin; sample collected from center test site on skin in application area.
62735433|NCT04986826||Healthy master athletes|
62807703|NCT03630796|OTHER|Intravenous anesthetics (TIVA)|"Anesthetic induction with ketamine 1-3 mg/kg, midazolam 0,1-0,5 mg/kg, fentanyl 2-4 mcg/kg and pancuronium 0,1 mg/kg after preoxygenation with FiO2 between 50-100% and fresh gas flow 4-8 l/min.~After orotracheal intubation, anesthesia is maintained with fentanyl 10 - 30 mcg/kg according to clinical needs and continuous infusion of midazolam and ketamine 0,2-0,8 mg/kg/h and 1-2 mg/kg/h respectively before and after cardiopulmonary bypass. Specifically during cardiopulmonary bypass extra fentanyl 1-5 mcg/kg, midazolam 0,1-0,5 mg/kg and pancuronium 0,1 mg/kg will be administered.~Pressure-controlled ventilation will be applied to both groups objectifying normocarbia and normoxia.~Ringer's lactate (RL) will be used as crystalloid solution for fluid therapy."
62807704|NCT04752267|EXPERIMENTAL|Diagnostic (18F-FMAU, PET/CT, mpMRI)|Patients receive 18F-FMAU intravenously (IV) and undergo a PET/CT scan over 60 minutes. Patients then undergo standard of care mpMRI over approximately 45 minutes.
62031529|NCT05229692|NO_INTERVENTION|Control|"Control group will receive current post-operative standard of care for abdominoplasty, which includes using an abdominal binder, rest and minimal activity for 6 weeks.~Participants will undergo both active muscle tests and body analysis tests. Measurements will be taken at The Piazza Center by clinic staff prior to surgery at 2,4,6,8, and 12 weeks post-operative. Measurements will be used to demonstrate milestones of functional recovery, comparable between subjects by weeks achieved."
62807705|NCT02040649|EXPERIMENTAL|Non-sedation|Non-sedation supplemented with pain management during mechanical ventilation.
62807706|NCT02040649|ACTIVE_COMPARATOR|Sedation|Current gold standard: Sedation with a daily wake-up trial.
62807707|NCT00516113|ACTIVE_COMPARATOR|1|Paroxetine 20mg during the luteal phase of the menstrual cycle
62807708|NCT00516113|PLACEBO_COMPARATOR|2|Placebo during the luteal phase of the menstrual cycle
62807709|NCT05925777|EXPERIMENTAL|experimental group|"The protocol provides for the administration of 10 polymodal high energy laser therapy sessions, to be carried out every other day. The THEAL device (Mectronic, Bergamo) allows to deliver 4 wavelengths (650 nm, 810 nm, 980 nm and 1064 nm), with continuous and pulsed mode, with power up to 20 W.~Patients will perform stretching exercise like those of the control group."
62807710|NCT05925777|NO_INTERVENTION|Control group|"Patients will perform four daily stretching exercises (three sets of 30 seconds), for 6 weeks.~1. Hamstring and ankle plantar flexor stretch (straight leg raise in supine position)~2. self-stretching of the surae muscles: the patient bends forward in a standing position with the affected foot farthest from the wall, keeping the heel on the floor; 3. the soleus muscle is exercised with the knee flexed and the gastrocnemius muscle with the knee extended~4. Plantar fascia self-stretch: In a seated position, the patient crosses the affected foot over the contralateral thigh and passively extends the metatarsophalangeal joints .~In the first session, the volunteers will be trained on how to perform the exercises correctly and will be monitored once a week."
62807711|NCT04477408|OTHER|plantar exercise group|"plantar sensitive exercises~Plantar sensitive exercises:~30 minutes / 3 days per week / 8 weeks Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min)"
62031530|NCT03046212|EXPERIMENTAL|Electrical stimulation|This group received application of transcutaneous electrical nerve stimulation (TENS) associated with conventional physical therapy (exercises).
62031531|NCT03046212|ACTIVE_COMPARATOR|Physical therapy|This group received only conventional physical therapy (exercises).
62031532|NCT06356064|EXPERIMENTAL|rESWT( Radial Extracorporeal shock wave therapy)|rESWT(2.4 bar, 12 hz, 2000 beats), to painful calcaneal area, three sessions, once a week, for total of three weeks
62031533|NCT06356064|EXPERIMENTAL|fESWT(Focused Extracorporeal shock wave therapy))|fESWT (0.14 bar, 14 hz, 1000 beats), to painful calcaneal area, three sessions, once a week, for total of three weeks
62231308|NCT04019548|EXPERIMENTAL|Reactive PEG|Reactive PEG tube will be placed and enteral nutrition initiated, during the study treatment period in case of decrease of oral intake less than 2/3 of estimated energy requirements (based on 30-35 kcal / adapted kg .BW and 1.2 - 1.5 g/prot./adapted kg. BW) for a period of or anticipated to be, greater than 7 days or weight loss ≥ 5% from pre-treatment baseline).
62231309|NCT01484730||Vascular Occlusion|Multi-Spectral and Laser Speckle Imaging
62231310|NCT00755703|EXPERIMENTAL|Group 1|There will be 12 subjects in Group 1 that will receive 10e8 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
62422896|NCT04863326|ACTIVE_COMPARATOR|Business as usual|The control group continued with their regular programming in the targeted class, which was often a health or Reserve Officer Training Corps (ROTC) class.
62592283|NCT03681990|EXPERIMENTAL|3M CHG/IPA Prep / Mid-peripheral|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70% solution applied topically to intact skin; sample collected from mid-peripheral test site on skin in application area.
62807712|NCT00914186|PLACEBO_COMPARATOR|Vehicle|
62231311|NCT00755703|EXPERIMENTAL|Group 2|There will be 12 subjects in Group 2 that will receive 10e9 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
62592284|NCT03681990|EXPERIMENTAL|3M CHG/IPA Prep / Peripheral|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70% solution applied topically to intact skin; sample collected from peripheral test site on skin in application area.
62807713|NCT00914186|EXPERIMENTAL|TS-022 0.005% lotion|
62231312|NCT00755703|EXPERIMENTAL|Group 3|There will be 12 subjects in Group 3 that will receive 10e10 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
62422897|NCT06476743|ACTIVE_COMPARATOR|Sensory Integration Therapy|Sensory integration therapy in older adults focuses on optimizing sensory processing to enhance overall function and well-being. It aims to improve sensory perception, coordination, and integration, which are essential for maintaining balance and mobility
62422898|NCT06476743|ACTIVE_COMPARATOR|Balance Board Training|Balance board training in older adults is a targeted approach aimed at enhancing stability and reducing fall risk. Utilizing specialized boards, it challenges balance control and proprioception, crucial for maintaining equilibrium. Through regular practice, older adults can improve muscle strength, coordination, and confidence in weight-bearing activities
62592285|NCT02892422|EXPERIMENTAL|Flexible-dose of Lu AF35700|
62735434|NCT04986826||Genotype positive phenotype negative transthyretin amyloidosis|
62807714|NCT00914186|EXPERIMENTAL|TS-022 0.010% lotion|
62031534|NCT01900990|EXPERIMENTAL|Noninvasive ventilation weaning|Patients in this group were weaned by noninvasive ventilation
62031535|NCT01900990|NO_INTERVENTION|Conventional weaning|Patients in this group were weaned by conventional stratiges.
62592286|NCT02375594|EXPERIMENTAL|Exercise in park equipment|Participants in the intervention arm will attend a 3-month long program of 2 weekly one-hour exercise sessions in the exercise park equipment, guided by a physical therapist. The sessions will comprise a combination of aerobic, strength, balance and flexibility exercises. Up to 20 participants exercising simultaneously in the equipment under the guidance of an experienced LAPPSET physical therapist.
62592287|NCT02375594|NO_INTERVENTION|Control|Participants in the control arm will receive usual advice on healthy habits. During the study, they will be offered to attend the talks on healthy living for elderly periodically organised by their primary care centre (CAP Vallcarca - Sant Gervasi). At the end of the study, they will be invited to an exercise session at the exercise park equipment, conducted by the study physical therapist.
62031536|NCT04019938||Diabetic adults|
62031537|NCT03150056|EXPERIMENTAL|GSK525762 + Abiraterone (+ Prednisone) (Arm A)|
62031538|NCT03150056|EXPERIMENTAL|GSK525762 + Enzalutamide (Arm B)|
62031539|NCT00868439|ACTIVE_COMPARATOR|patiromer|
62592288|NCT03992989|EXPERIMENTAL|Phonak Bolero M90-M|The Phonak Bolero M90-M is a Behind-the-Ear Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss
62592289|NCT03992989|ACTIVE_COMPARATOR|Roger Select|The Roger Select is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
62592290|NCT05625945||Symptomatic statin users|Statin users with self-reported muscle symptoms
62592291|NCT05625945||Asymptomatic statin users|Statin users without muscle symptoms
62592292|NCT06208735|EXPERIMENTAL|CLIC-2201|A single Intravenous infusion of CLIC-2201 will be given.
62592293|NCT02648893|EXPERIMENTAL|MBFC-Exp|The MBFC-Exp (Multiple biofortified food crops - Experimental) arm will consume meals based on biofortified food crops.
62592294|NCT02648893|ACTIVE_COMPARATOR|MBFC-C|The MBFC-C (Multiple biofortified food crops - Control) arm will consume the same meals based on non-biofortified (commercially available) food crops.
62592295|NCT04315233|EXPERIMENTAL|Treatment: all patients|Ribociclib and belinostat will be given at escalating doses and on multiple administration schedules throughout the dose escalation component of the study. The MTD identified in the dose escalation component will be used to define the dose and administration schedule used in the dose expansion.
62592296|NCT06438523|EXPERIMENTAL|Advanced Platelet rich fibrin,A-prf,A-PRF scaffold|"A-PRF will be prepared according to Choukroun's technique by drawing whole blood from the median cubital vein into a 10 ml plain plastic test tubes (non-citrated) without the addition of an anticoagulant reagent .~To prevent the blood from coagulating, it will be centrifuged immediately using a table top centrifuge at 1500 rpm for 14 minute."
62592297|NCT06438523|EXPERIMENTAL|A-prf mixed with nano chitosan|"A-PRF will be prepared according to Choukroun's technique by drawing whole blood from the median cubital vein into a 10 ml plain plastic test tubes (non-citrated) without the addition of an anticoagulant reagent .~To prevent the blood from coagulating, it will be centrifuged immediately using a table top centrifuge at 1500 rpm for 14 minute then mixed with nanochitosan"
62592298|NCT06438523|EXPERIMENTAL|chitosan|he access cavity will be prepared up to the level of pulp chamber floor using sterile round diamond bur size 1 in high-speed hand piece with coolant.Once the pulp has been reached, a sharp sterile excavator should be used to remove the pulp tissue to the level of the radicular/root canal orifices then chitosan will be applied
62592299|NCT04830384|EXPERIMENTAL|Fully Active|LLLT \& Music Therapy
62592300|NCT04830384|ACTIVE_COMPARATOR|LLLT Only|LLLT Therapy
62807715|NCT00914186|EXPERIMENTAL|TS-022 0.020% lotion|
62231313|NCT00755703|PLACEBO_COMPARATOR|Experimental: Group 4|There will be 12 subjects in Group 4 that will receive a placebo consisting of buffer administered via intranasal spray on day 0 and day 28 (+/- 4d).
62592301|NCT04830384|PLACEBO_COMPARATOR|Music Only|Music Therapy
62592302|NCT04830384|SHAM_COMPARATOR|Placebo|No Therapy
62592303|NCT00829972||1|children undergoing adenotonsillectomy
62031540|NCT00868439|PLACEBO_COMPARATOR|placebo|
62031541|NCT01576926||surgery|patients with obstructive sleep apnea
62031542|NCT06027229|EXPERIMENTAL|Participants who have had Solid Organ Transplants|Male and females aged 18 to 85 who are solid organ transplant recipients and receive the study intervention.
62031543|NCT06027229|EXPERIMENTAL|Participants with IBD|Male and females aged 18 to 85 who have IBD and receive the study intervention.
62031544|NCT05155826|NO_INTERVENTION|standard care (control group)|Patient benefit the standard care during the placement of Cook's balloon (standard care).
62031545|NCT05155826|EXPERIMENTAL|standard care and virtual reality (experimental group)|Patient benefit the standard care during placement of Cook's balloon (standard care) with the use of a virtual reality.
62422899|NCT02260752||Medical|Patients who receive medical therapy only for treatment of their uterine fibroids
62422900|NCT02260752||Procedure|Patients who have a hysterectomy, myomectomy, uterine arterial embolization, endometrial ablation, radiofrequency ablation, or magnetic resonance guided focused ultrasound to treat their UF.
62592304|NCT00829972||2|children undergoing elective procedures other than adenotonsillectomy
62592305|NCT02648854|OTHER|Group 1|\<Group 1\> Period 1: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (Fasting condition) 7 days for wash out Period 2: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (High fat meal fed condition)
62735435|NCT04986826||Phenotype positive transthyretin amyloidosis|
62231314|NCT04130529|EXPERIMENTAL|Adjusted group CBT-i for Bipolar disorder|"The experimental group receives group-CBT-i adjusted for Bipolar disorder. This is a version of CBT for insomnia (CBT-i) developed during the pilot phase of this Project. Traditional CBT-i is adjusted for use in the population with Bipolar Disorder. This behavioral intervention adresses not only traditional aspects of insomnia, but also sleep phase problems and other aspects of sleep specifically relevant to the Bipolar population.~Treatment is given as 8 weekly group sessions."
62231315|NCT04130529|ACTIVE_COMPARATOR|Sleep lectures|The control group is offered a series of 3 lectures on sleep during the same time-period.
62592306|NCT02648854|OTHER|Group 2|\<Group 2\> Period 1: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (High fat meal fed condition) 7 days for wash out Period 2: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (Fasting condition)
62592307|NCT00796705|EXPERIMENTAL|Adalimumab / Adalimumab Placebo|1 sub-cutaneous (SQ) injection of adalimumab or 1 SQ injection of placebo will be given in a blinded and alternating fashion for a total of 12 weeks
62807716|NCT05214326||Participants with moderate to severe atopic dermatitis|Participants initiating dupilumab therapy within 30 days of enrollment, according to the treating physician's decision independently of study participation.
62807717|NCT06285487|EXPERIMENTAL|Interpersonal Psychotherapy adapted for Type 2 Diabetes|Participants in the IPT-T2D will receive 1 hour weekly IPT from a licensed psychologist in a group setting for 6 weeks.
62807718|NCT06285487|EXPERIMENTAL|Health Education adapted for Type 2 Diabetes|Participants in the Health Education-T2D will receive 1 hour weekly Health Education lessons from a licensed psychologist in a group setting for 6 weeks.
62807719|NCT01232868|OTHER|Age 25-40|Trivalent Influenza vaccine given to age 25-40
62807720|NCT01232868|OTHER|Age ≥65|Trivalent Influenza vaccine given to age≥65
62807721|NCT04312308||Non-Small Cell Lung Cancer Treated with Atezolizumab|Patients with Non-Small Cell Lung Cancer Treated with Atezolizumab
62231316|NCT02018835|OTHER|patients of an insufficiency organic severe surgical mitrale|
62231317|NCT02018835|OTHER|insufficiency organic mitrale moderated in severe asymptomatic|
62592308|NCT00796705|EXPERIMENTAL|Etanercept|Participants will receive 1 SQ injection of etanercept each week for 12 weeks
62592309|NCT04424082|OTHER|dead space removal|external dead space will be removed and Vcap parameters (VCO2, PaCO2 and alveolar dead space) recorded before and after.
62807722|NCT01503008|EXPERIMENTAL|Sustained Behavior Change system support|
62807723|NCT01503008|ACTIVE_COMPARATOR|Control|
62807724|NCT01379417|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin
62807725|NCT01379417|ACTIVE_COMPARATOR|Probiotic B lactis/B longum|Bifidobacterium lactis + Bifidobacterium longum
62807726|NCT01379417|ACTIVE_COMPARATOR|Probiotic B longum|Bifidobacterium longum
62592310|NCT04430764|EXPERIMENTAL|smoker|
62807727|NCT01379417|ACTIVE_COMPARATOR|Probiotic B lactis|Bifidobacterium lactis
62807728|NCT02324517||Hemophilia|Patients with Hemophilia A OR B
62231318|NCT02018835|OTHER|patients of an aortic bicuspidie|
62231319|NCT02018835|OTHER|patients of a syndrome of Marfan|
62231320|NCT02018835|OTHER|Healthy volunteers|
62592311|NCT04430764|ACTIVE_COMPARATOR|non-smoker|
62807729|NCT02324517||inhibitor patients|Hemophilia or FXI def with inhibitors
62807730|NCT02324517||anticoagulants|patients under therapy with various anticoagulant drugs
62592312|NCT02157649|EXPERIMENTAL|ER Tablet under Fasted Conditions|Administration of a single dose of two ER Tablets, combination of Codeine/Guaifenesin 30gm/600mg, to subjects under fasted conditions.
62592313|NCT02157649|ACTIVE_COMPARATOR|IR Tablet under Fasted conditions|IR Tablet combination tablet of Codeine/Guaifenesin 20mg/400mg administered under fasted conditions as a single tablet every 4 hours during a 12 hour study \[three doses\]
62592314|NCT02157649|EXPERIMENTAL|ER Tablet under Fed Conditions|Administration of a single dose of two ER Tablets, combination of Codeine/Guaifenesin 30gm/600mg, following a standard high-fat breakfast.
62592315|NCT02319174|EXPERIMENTAL|Sphygmo|All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device.
62807731|NCT02324517||thrombocytopenia|patients with ITP, chronic thrombocytopenia, chemotherapy induced thrombocytopenia
62807732|NCT02324517||platelet function disorders|Glanzmann, Bernard Soulier, antiplatelet therapy
62807733|NCT02324517||Fibrinogen disordsers|hyperfibrinogenemia, hypofibrinogenemia, dysfibrinogenemia
62231321|NCT01570036|EXPERIMENTAL|Herceptin + NeuVax vaccine|Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year; the first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive vaccinations of NeuVax vaccine administered intradermally every 3 weeks for 6 total vaccinations, 30-120 minutes after completion of Herceptin infusion. The NeuVax vaccine series will begin immediately after completion of the third Herceptin infusion, but may be delayed to the fourth or fifth Herceptin infusion with prior approval from the PI. Patients will be blinded regarding assigned arm. After completion of primary vaccine series, patients will receive 4 NeuVax vaccine booster inoculations to be administered every 6 months x 4 for total treatment duration of 30 months.
62807734|NCT02324517||acquired hemophilia|patients with autoimmune Ab's to FVIII
62807735|NCT02324517||RBD|FXIII DEF, FV+FVIII DEF, FVII DEF, FV DEF
62807736|NCT02324517||THROMBOLYTICS|Patients treated by thrombolytic agents
62807737|NCT02324517||Hypercoag|thrombophilias, thrombosis- inc under therapy, acquired high thrombotic risk (eg: cancer)
62807738|NCT00404651|EXPERIMENTAL|Group 1|Participants receive vaccine Batch A
62807739|NCT00404651|EXPERIMENTAL|Group 2|Participants receive vaccine Batch B
62807740|NCT00404651|EXPERIMENTAL|Group 3|Participants receive vaccine Batch C
62807741|NCT00404651|ACTIVE_COMPARATOR|Group 4|Participants receive Infanrix hexa™
62807742|NCT04041583||Arm 1|Patients undergoing posterior cervical arthrodesis procedures for spondylosis supplemented with CIS involving three or more segmental levels in the subaxial cervicothoracic spine (between C2-upper thoracic)
62807743|NCT03144739|ACTIVE_COMPARATOR|Control|Children enrolled during the control phase will receive care under the Current collaborative care protocol. Participating general practitioners are currently trained to recognize child mental health problems and refer them to partner community mental health centers for treatment.
62807744|NCT03144739|EXPERIMENTAL|Intervention|Children enrolled during the intervention phase will receive Training in management of children's mental health problems. This will involve treatment by their general practitioner in collaboration with a partner community mental health center; children meeting certain criteria for severity, or whose parents prefer center treatment, will be immediately referred.
62422901|NCT02985567||Intraocular pressure evaluation|Intraocular pressure evaluation using Icare tonometer 25 minutes after sedation, and then every 10 minutes until sedation is complete
62422902|NCT02985567||Safety of sedation|"Documentation of:~1. The need for repeat dosing of chloral hydrate.~2. The level of alertness of the patient at the end of sedation and the total time between induction and readiness for discharge~3. Interventions required for the patient including administration of oxygen, and need for intubation."
62807745|NCT05998122|EXPERIMENTAL|Experimental|"Radiation: Long-course chemoradiotherapy is delivered in 50 Gy/25 fractions with concurrent Capecitabine (825mg/m2, P.O. Bid, 5d/w).~Drug: CapeOX (Capecitabine 1000mg/m2, P.O. Bid, d1-d14, q3w; Oxaliplatin 130mg/m2, i.v., d1, q3w), and Sintilimab (200mg, i.v. , d1).~Surgical Approach: TME surgery, The surgical approach can be open, laparoscopic or robotic depending on the patient."
62807746|NCT02146417|ACTIVE_COMPARATOR|Normal pressure pneumoperitoneum & deep neuromuscular block|Normal pressure pneumoperitoneum
62807747|NCT02146417|EXPERIMENTAL|Low pressure pneumoperitoneum & deep neuromuscular block|Low pressure pneumoperitoneum
62807748|NCT04875013|EXPERIMENTAL|Vestibular rehabilitation with dynamic posturography|12 sessions, twice per week, of rehabilitation exercises last about 20 minutes, using CDP and interactive visual feedback
62807749|NCT02172963|EXPERIMENTAL|Decidual Stromal Cell therapy for Hemorrhagic Cystitis|
62807750|NCT01944007|EXPERIMENTAL|CLP 15 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
62807751|NCT01944007|EXPERIMENTAL|CLP 25 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
62807752|NCT01944007|EXPERIMENTAL|CLP 7.5 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
62807753|NCT01944007|EXPERIMENTAL|CLP 15 g fasted|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d 1 hour prior to 4 standardized meals/snack
62807754|NCT03215017|EXPERIMENTAL|Transanal irrigation|Manual transanal irrigation to control bowel function.
62031546|NCT04525404||Troponin Substudy|Participants with new COVID-19 infection will undergo high-sensitivity Troponin testing; participants with elevated Troponin will undergo MRI, bloodwork, and olfaction testing at Baseline, then repeat MRI, bloodwork and all functional testing at the Recovered (ie 12weeks post diagnosis) phase. Participants with normal Troponin will undergo only olfaction testing and bloodwork at baseline, then MRI, bloodwork and all functional testing at the Recovered phase.
62807755|NCT03215017|ACTIVE_COMPARATOR|Medication|Medication to control bowel function.
62807756|NCT04903561|EXPERIMENTAL|Intervention|In the experimental arms, the woman will be asked to collect a vaginal sample with the Evalyn® Brush or a urine sample with the Colli-PeeTM. Women shall receive this self-sampling device directly from the GP or shall pick it up at a close by pharmacist with a prescription of the GP. In four GP practices (1, 2, 5, 6) the patient has to collect the SS preferentially in the GP practice (at home if the GP practice is not well equipped) whereas in the other four GP practices (3, 4, 7, 8), the patient has to collect the SS at home and send it to the laboratory by using a prepaid envelope.
62807757|NCT04903561|NO_INTERVENTION|control|Women in the control group will receive an oral recommendation given by the GP with a reminder of the current screening policy to have a cervical sample taken by a physician chosen by the woman. This clinician-taken cervical sample will be sent to a laboratory for processing with the usual screening test. Today the usual screening test still is cytology, but this will change in the future (date to be defined) to an HPV test.
62807758|NCT02575755|EXPERIMENTAL|Efficacy Study: Azithromycin plus piperaquine|At baseline, participants receive three daily doses (0, 24 and 48 hours) of i) 1 g azithromycin as 2 x film-coated 500 mg tablets ii) 960 mg piperaquine tetraphosphate tablets as 3 x 320 mg tablets
62807759|NCT02575755|ACTIVE_COMPARATOR|Efficacy Study Control: National Standard Treatment|At baseline, participants receive a single dose of sulfadoxine-pyrimethamine comprising 1,500 mg of sulfadoxine and 75 mg pyrimethamine in tablet form
62807760|NCT02575755|EXPERIMENTAL|Pharmacokinetic Study: Azithromycin plus piperaquine|At baseline, participants receive three daily doses (0, 24 and 48 hours) of i) 1 g azithromycin as 2 x film-coated 500 mg tablets ii) 960 mg piperaquine tetraphosphate tablets as 3 x 320 mg tablets
62807761|NCT04842708|NO_INTERVENTION|Healthy Volunteers that are not to be vaccinated against COVID19|Healthy Volunteers that are not eligible to be vaccinated against COVID19
62807762|NCT04842708|EXPERIMENTAL|Healthy Volunteers that are assigned to be vaccinated against COVID19|Healthy Volunteers that are eligible to be vaccinated against COVID19
62807763|NCT01179321|NO_INTERVENTION|Control|
62422903|NCT02034994|EXPERIMENTAL|Intervention group|Reduction of sugar sweetened beverages. cookies, sedentary activities and increasing physical activity
62422904|NCT02034994|NO_INTERVENTION|Control group|No intervention
62422905|NCT06301477|ACTIVE_COMPARATOR|Resistant Starch|Once daily oral consumption of either 7.5g/m2 or 5.0g/m2 (body surface area) of a resistant starch for 48 weeks that is individually optimized at 24 weeks.
62422906|NCT06301477|PLACEBO_COMPARATOR|Placebo|Once daily oral consumption of a readily digestible food-grade cornstarch that resembles the study product in appearance, smell and taste for 48 weeks
62422907|NCT05959707|EXPERIMENTAL|VRC01.23LS 5 mg/kg|VRC01.23LS 5 mg/kg to be administered via intravenous (IV) infusion at Month 0
62422908|NCT05959707|EXPERIMENTAL|VRC01.23LS 20 mg/kg|VRC01.23LS 20 mg/kg to be administered via IV infusion at Month 0
62422909|NCT05959707|EXPERIMENTAL|VRC01.23LS 40 mg/kg|VRC01.23LS 40 mg/kg to be administered via IV infusion at Month 0
62807764|NCT01179321|EXPERIMENTAL|Early nutrition intervention|
62807765|NCT00965081|EXPERIMENTAL|Duloxetine|
62807766|NCT00965081|PLACEBO_COMPARATOR|Placebo|
62807767|NCT05925946|EXPERIMENTAL|Intervention Group|"1. Phase1 (Partial diet replacement) (850 Kcal/day) (12-20 weeks)):~2. Phase 2 (Gradual increase in calories) (20-28 weeks) (1100 Kcal/day):~3. Phase 3 (Weight loss maintenance) (29-104 weeks) (up to 1200Kcal/day) :"
62807768|NCT05925946|NO_INTERVENTION|Control Group|Subjects will be given routine care for diabetes and obesity management with no change in medication. The meal plan for the control group will consist of 1400 Kcal/day achieved through small frequently distributed meals constituting around 15% of protein, 60% of carbohydrates and 25% of fat; with a menu resembling standard Indian dietary patterns and meal combinations.
62807769|NCT05841368||Adult ICU patients|Adult patients in ICU setting
62807770|NCT05841368||Pediatric ICU patients|Pediatric patients in ICU setting
62807771|NCT05470387|EXPERIMENTAL|LB1148|
62807772|NCT05470387|PLACEBO_COMPARATOR|Placebo|
62807773|NCT02204930|EXPERIMENTAL|Haemostat|PeproStat
62807774|NCT00602212|ACTIVE_COMPARATOR|VR + Mobile Phone without Biofeedback|In this experimental condition patients received an eight-session VR-based treatment including relaxation and exposure
62422910|NCT05959707|EXPERIMENTAL|VRC01.23LS 5 mg/kg + PGT121.414.LS 5 mg/kg + PGDM1400LS 5 mg/kg|VRC01.23LS 5 mg/kg + PGT121.414.LS 5 mg/kg + PGDM1400LS 5 mg/kg to be administered via IV infusion sequentially in this order at Month 0 and Month 6
62422911|NCT05959707|EXPERIMENTAL|VRC01.23LS 20 mg/kg + PGT121.414.LS 5 mg/kg + PGDM1400LS 5 mg/kg|VRC01.23LS 20 mg/kg + PGT121.414.LS 5 mg/kg + PGDM1400LS 5 mg/kg to be administered via IV infusion sequentially in this order at Month 0 and Month 6
62422912|NCT05959707|EXPERIMENTAL|VRC01.23LS 20 mg/kg + PGT121.414.LS 20 mg/kg+ PGDM1400LS 20 mg/kg|VRC01.23LS 20 mg/kg + PGT121.414.LS 20 mg/kg+ PGDM1400LS 20 mg/kg to be administered via IV infusion sequentially in this order at Month 0 and Month 6
62422913|NCT05959707|EXPERIMENTAL|VRC01.23LS 40 mg/kg + PGT121.414.LS 5 mg/kg + PGDM1400LS 5 mg/kg|VRC01.23LS 40 mg/kg + PGT121.414.LS 5 mg/kg + PGDM1400LS 5 mg/kg to be administered via IV infusion sequentially in this order at Month 0 and Month 6
62422914|NCT05959707|EXPERIMENTAL|VRC01.23LS 40 mg/kg + PGT121.414.LS 40 mg/kg + PGDM1400LS 40mg/kg|VRC01.23LS 40 mg/kg + PGT121.414.LS 40 mg/kg + PGDM1400LS 40mg/kg to be administered via IV infusion sequentially in this order at Month 0 and Month 6
62422915|NCT04252690|EXPERIMENTAL|Mobiderm|MOBIDERM® autofit : auto-adjustable compression stocking
62422916|NCT00999245|OTHER|High Demand / Low Infusion|PCA dosing plan
62422917|NCT00999245|OTHER|Low Demand / High Infusion|PCA plan for Low Demand / High Infusion
62422918|NCT06156579|EXPERIMENTAL|Treatment|Salvage therapy with Venetoclax and intensified Decitabine
62807775|NCT00602212|EXPERIMENTAL|VR + Mobile Phone with biofeedback|The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
62807776|NCT02313220|EXPERIMENTAL|Dapagliflozin and exenatide|Dapagliflozin 10 mg film-coated tablet once daily and exenatide 2 mg once weekly injection combined treatment for 24 weeks
62807777|NCT02313220|PLACEBO_COMPARATOR|Placebo|Placebo film-coated tablet once daily and placebo once weekly injection combined treatment for 24 weeks
62807778|NCT01893801|EXPERIMENTAL|nab-paclitaxel+Cisplatin+gemcitabine|This is a phase Ib/II open-label, pilot study evaluating the preliminary efficacy and safety of nab-paclitaxel 125mb/m2, cisplatin 25mg/m2, and gemcitabine 1000mg/m2, all administered intravenously (IV) on Days 1 and 8 every 21 days until development of toxicity that is unacceptable in the opinion of the patient or the Investigator or upon disease progression.
62807779|NCT04283305|EXPERIMENTAL|Virtual reality approach avoidance training|Participants will receive six sessions (three sessions per week for two weeks; session duration = 30 mins) of approach-avoidance training in the virtual reality. Alcoholic beverages are pushed away with a controller and soft-drinks will be pulled towards oneself. Training will begin approximately three weeks before discharge from the inpatient clinics to measure the add-on effect and to ensure that the add-on treatment does not extend the treatment period.
62807780|NCT04283305|ACTIVE_COMPARATOR|Computer-based approach avoidance training|Participants will receive six sessions (three sessions per week for two weeks; session duration = 30 mins) of approach-avoidance training on the computer. Alcoholic beverages are pushed away with a joystick and soft-drinks will be pulled towards oneself. Training will begin approximately three weeks before discharge from the inpatient clinics to measure the add-on effect and to ensure that the add-on treatment does not extend the treatment period.
62807781|NCT04283305|NO_INTERVENTION|Treatment as usual|Participants will receive treatment as usual on the wards. For ethical reasons, participants in this condition will get the offer to undertake the already scientifically validated computer-based approach avoidance training after their completion of the study.
62592316|NCT05551546|ACTIVE_COMPARATOR|Functional Medicine Health Coaching for Elimination Diet|"Participants randomized into the Functional Medicine Health Coaching for Elimination Diet arm will receive five remote health coaching sessions over 10 weeks in support of their progress through an elimination diet. All study arms will receive written elimination diet support materials."
62592317|NCT05551546|OTHER|Self-guided Elimination Diet|"Participants randomized into the Self-guided Elimination Diet group will engage with the elimination diet without health coaching. All study arms will receive written elimination diet support materials."
62807782|NCT06419985|EXPERIMENTAL|80mg Ketamine HCl PR|One 40mg tablet of Ketamine HCl PR twice a day
62031547|NCT04525404||Late Cross-Sectional Substudy|Participants with a COVID-19 diagnosis at least 3 months prior to enrollment will undergo MRI, bloodwork and all functional testing at the Recovered phase only.
62031548|NCT05788549|EXPERIMENTAL|Progressive Relaxation Group|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting. The first application was done face to face with the researcher. Individuals were asked to perform subsequent applications at home.Educational booklet describing the progressive relaxation exercises with pictures was given to individuals, and a video prepared by the researcher was uploaded to their mobile phones. Individuals were asked to practice progressive relaxation exercises every day, at least once a day, in a quiet and peaceful environment for 30-minute sessions. The researcher sent reminder SMS messages to individuals twice a week for eight weeks to encourage regular practice of the progressive relaxation exercises. Four and eight weeks after the first meeting, forms were transferred to an online environment and sent to individuals via WhatsApp Messenger as a link to be completed
62231322|NCT01570036|ACTIVE_COMPARATOR|Herceptin + GM-CSF only|Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year. The first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive inoculations of GM-CSF only (250mcg) administered intradermally every 3 weeks for 6 total inoculations, 30-120 minutes after completion of Herceptin infusion. The GM-CSF only inoculation series will begin immediately after completion of the third Herceptin infusion. Patients will be blinded as to whether they are receiving NeuVax vaccine or GM-CSF only. After completion of six-inoculation primary vaccine series, patients will then receive a total of four GM-CSF only booster inoculations to be administered at 12, 18, 24, and 30 months from the date of the first Herceptin infusion.
62231323|NCT02718937|EXPERIMENTAL|BTA-C585|BTA-C585 100 mg oral capsule
62231324|NCT02718937|PLACEBO_COMPARATOR|Placebo|Matching placebo capsule
62231325|NCT05046366||Lung cancer group|Participants with lung cancer/pulmonary nodules
62231326|NCT05046366||Pulmonary tuberculosis group|Participants with pulmonary tuberculosis
62231327|NCT05046366||COIVD-19 group|Participants with COIVD-19
62231328|NCT04002609||Group A, Active comparator|Patients in this group did not receive any rountine oxygen supplementation during the procedure. Rescue supplemental oxygen through nasal cannual was provided if clinically significant desaturation could be observed during bronchoscopy. This significant desaturation was defined as systemic oxygen saturation ≤90% on pulsoxymetry or a relative change of ≥ 4% lasting for 1 minute. N=31 patients
62231329|NCT04002609||Group B, Active comparator|Supplemental oxygen was provided for the patients through nasal cannula by a flow rate of 2 l/minutes throughout the procedure. N= 31 patients
62231330|NCT04002609||Group C, Active comparator|Supplemental oxygen administration through nasal cannula by a flow rate of 4 l/minutes throughout the procedure. N= 30 patients
62231331|NCT05889065|ACTIVE_COMPARATOR|Conventional PT Group|"Conventional group will receive routine physical therapy including~10~ultrasound(1.5w/cm2~,3 MHz continuous type, duration 10 minutes),hot packs (on affected region of shoulder for 10 minutes),shoulder ROM, stretching exercises, and joint mobilization five times per week for two weeks with 40 minutes duration of each session. Maitland mobilization will be given in supine position.~· After giving glenohumeral joint distraction, caudal, dorsal, and ventral glides will be given at a rate of 2-3 oscillation/second for 1 to 2 minutes to patients. Grade I or II rhythmic oscillations will be applied in free range."
62231332|NCT05889065|EXPERIMENTAL|Scapular PNF + Conventional PT Group|This group will receive scapular PNF techniques along with routine physical therapy (same as above). In this group 20 repetitions of diagonal scapular pattern (anterior elevation and posterior depression, posterior elevation and anterior depression) with 20 seconds rest period will be given to subjects. PNF techniques of rhythmic initiation and repeated contractions will be used in all patterns, applied for 40 minutes.
62422919|NCT02524665|EXPERIMENTAL|MAXCLARITY II|MAXCLARITY II Foam Cleanser (2.5% BPO) plus Foam Treatment (2.5% BPO) and (0.5% Salicylic Acid) Toner Foam. Available over the counter. Each subject applies both arms (MAXCLARITY II and MURAD) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
62807783|NCT06419985|EXPERIMENTAL|160mg Ketamine HCl PR|Two 40mg tablets of Ketamine HCl PR twice a day
62807784|NCT06419985|EXPERIMENTAL|240mg Ketamine HCl PR|Three 40mg tablets of Ketamine HCl PR twice a day
62807785|NCT01719796|EXPERIMENTAL|Bilateral TAP catheter|Ultrasonography guided bilateral TAP catheter insertion.
62422920|NCT02524665|ACTIVE_COMPARATOR|MURAD|MURADClarifying Cleanser (1.5% SA) plus Exfoliating Acne Treatment Gel (1% SA) and Skin Perfecting Lotion. Available over the counter. Each subject applies both arms (MAXCLARITY II and MURAD) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
62807786|NCT01719796|NO_INTERVENTION|No TAP catheter|
62807787|NCT01799096|EXPERIMENTAL|Sucrose|Receives sucrose
62807788|NCT01799096|PLACEBO_COMPARATOR|Aspartame|Receives Aspartame sweetened drinks
62807789|NCT03707795|EXPERIMENTAL|Arm 1 - Amyotrophic Lateral Sclerosis|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
62807790|NCT03707795|ACTIVE_COMPARATOR|Arm 2 - Familial Amyotrophic Lateral Sclerosis|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
62231333|NCT04616703||BMI < 25 kg/m2|Those with NFAT and BMI \< 25 kg/m2.
62231334|NCT04616703||BMI 25-30 kg/m2|Those with NFAT and BMI 25-30 kg/m2.
62231335|NCT04616703||BMI > 30 kg/m2|Those with NFAT and BMI \> 30 kg/m2.
62231336|NCT01637623|ACTIVE_COMPARATOR|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.
62592318|NCT06504953|EXPERIMENTAL|Group 1 Women on estrogen-progestin contraception|"For women on estrogen-progestin contraception:~* Correct use of the estrogen-progestin pill in accordance with AMM Or wearing a vaginal ring according to AMM protocol Or wearing a contraceptive skin patch according to AMM protocol~* Regular cycles of 26 to 33 days"
62807791|NCT04960449||patients with partial-thickness rotator cuff tendon tears|Partial rotator cuff tears can be divided into three categories, bursa side tears, tendon tears and joint side tears. Studies have found that rotator cuff tendon tears account for 55% of partial tears, compared to the other two types of partial tears, there has been very little research on partial-thickness rotator cuff tendon tears, which has no consensus on diagnosis and treatment.
62807792|NCT04959734||Bronchiolitis|Infants less than 2 years who the clinician has diagnosed Bronchiolitis
62592319|NCT06504953|EXPERIMENTAL|Group 2 Women on progestogen contraception|"For women on progestin-only contraception:~o Continuous use of the micro-progestogen or progestogen pill Or subcutaneous hormonal implant, Or a progesterone intrauterine device Or dienogest-type contraception"
62807793|NCT04959734||LRTI|Infants less than 2 years who the clinician has diagnosed a viral or bacterial lower respiratory tract infection
62592320|NCT06504953|EXPERIMENTAL|Group 3 Women without hormonal contraception|"For women without hormonal contraception :~* No method of contraception Or copper intrauterine device~* Regular cycles of 26 to 33 days"
62592321|NCT03891043|PLACEBO_COMPARATOR|Group A, Placebo group|Placebo consisted in a pill of 100 micrograms of starch, to be taken twice a day.
62592322|NCT03891043|EXPERIMENTAL|Group B, Selenium group|Selenium consisted in a pill of 100 micrograms, to be taken twice a day.
62231337|NCT01637623|ACTIVE_COMPARATOR|Allopurinol|Allopurinol 300 mg daily for 6 weeks
62231338|NCT01637623|PLACEBO_COMPARATOR|Placebo|Placebo capsule daily for 6 weeks
62592323|NCT06494410|ACTIVE_COMPARATOR|High Fraction of Inspired Oxygen(Group A)|About 40 patients received FiO2 1.0 during recruitment maneuvers
62592324|NCT06494410|ACTIVE_COMPARATOR|Low Fraction of Inspired Oxygen(Group B)|About 40 patients received FiO2 0.4 during recruitment maneuvers
62231339|NCT02855424|NO_INTERVENTION|control|traditional rehabilitation merely, no ergocycling training
62231340|NCT02855424|EXPERIMENTAL|the low-intensity exercise group|traditional rehabilitation plus the low-intensity ergocycling exercise training
62231341|NCT02855424|EXPERIMENTAL|the moderate-intensity exercise group|traditional rehabilitation plus the moderate-intensity ergocycling exercise training
62592325|NCT06281210|EXPERIMENTAL|Omission of surgical treatment|Omission of surgical treatment in patients with complete pathological response after neoadjuvant chemotherapy and negative VABB biopsy
62592326|NCT03395470|EXPERIMENTAL|Group A1|Dose 1 or placebo
62231342|NCT00828841|ACTIVE_COMPARATOR|Paclitaxel, Carboplatin, Cetuximab (Arm A)|Patients with squamous or non-squamous histologies will receive carboplatin and paclitaxel for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion.
62592327|NCT03395470|EXPERIMENTAL|Group A2|Dose 2 or placebo
62592328|NCT03395470|EXPERIMENTAL|Group A3|Dose 3 or placebo
62592329|NCT03395470|EXPERIMENTAL|Group A4|Dose 4 or placebo
62592330|NCT03395470|EXPERIMENTAL|Group A5|Dose 5 or placebo
62592331|NCT03395470|EXPERIMENTAL|Group B|Dose + Rosuvastatin
62592332|NCT01893281|EXPERIMENTAL|Topical Testosterone Solution|Topical Testosterone Solution 30 milligrams up to 120 milligrams per day (mg/day) administered topically to axillae titrated based on testosterone levels.
62807794|NCT04959734||Wheeze|Infants less than 2 years who the clinician has diagnosed the first presentation of a viral wheeze
62807795|NCT00687401|EXPERIMENTAL|Infliximab 5 mg/kg|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6, and 14.
62807796|NCT00583635||1|Low Risk Pregnancy, Placebo
62807797|NCT00583635||2|Low Risk Pregnancy, Active Food Supplement
62807798|NCT00583635||3|High Risk Pregnancy, Placebo
62807799|NCT00583635||4|High Risk Pregnancy, Active Food Supplement
62031549|NCT05788549|PLACEBO_COMPARATOR|Relaxative Music Group|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting. Individuals were asked to perform subsequent applications at home.Individuals were provided with a relaxing music file prepared by the researcher and were asked to listen to it at least once a day for 30 minutes in a quiet and calm environment. The researcher also sent reminder SMS messages twice a week for eight weeks to remind individuals. Four and eight weeks after the first meeting, forms were transferred to an online environment and sent to individuals via WhatsApp Messenger as a link to be completed to listen to the relaxing music regularly. At 4 and 8 weeks after the first meeting, the researcher transferred the forms to an online environment via Google Forms and asked individuals to fill them out by accessing the link sent to them via WhatsApp Messenger
62231343|NCT00828841|ACTIVE_COMPARATOR|Platinum, Gemcitabine, Cetuximab (Arm B)|Patients with squamous or non-squamous histologies will receive gemcitabine with either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion.
62231344|NCT00828841|ACTIVE_COMPARATOR|Platinum, Pemetrexed, Cetuximab (Arm C)|Patients with squamous histology will receive pemetrexed and either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion. Patients with non-squamous histology are not eligible for this arm.
62231345|NCT02749656|EXPERIMENTAL|0.25% Desoximetasone cream (Topoxy®)|"0.25% Desoximetasone cream (Topoxy®): apply on scalp psoriasis lesion twice a day for 8 weeks.~(Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)"
62231346|NCT02749656|ACTIVE_COMPARATOR|0.25% Desoximetasone cream (Topicorte®)|"0.25% Desoximetasone cream (Topicorte®): apply on scalp psoriasis lesion twice a day for 8 weeks.~(Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)"
62231347|NCT02749656|PLACEBO_COMPARATOR|Placebo|Placebo: apply on scalp psoriasis lesion twice a day for 8 weeks. (Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)
62231348|NCT02804776|EXPERIMENTAL|Gefitinib|Gefitinib 250mg oral daily will be given for 4 weeks prior to surgery
62231349|NCT05895565|EXPERIMENTAL|PMG1015|
62031550|NCT05788549|NO_INTERVENTION|Control Group|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting.The members of this group have not undergone any intervention and continued their routine maintenance, treatment, and follow-up.At 4 and 8 weeks after the first meeting, the researcher transferred the forms to an online environment via Google Forms and asked individuals to fill them out by accessing the link sent to them via WhatsApp Messenger
62231350|NCT05895565|PLACEBO_COMPARATOR|Placebo Comparator|
62231351|NCT01778023|EXPERIMENTAL|hGH:12months treatment|
62231352|NCT01778023|ACTIVE_COMPARATOR|hGH: 6 month un-treatment + 6 month treatment|
62231353|NCT02184650||Premature infants|Premature infants with a GA \< 32 weeks
62231354|NCT02071667||Subjects who require sinus surgery|
62231355|NCT01487031|EXPERIMENTAL|Music Therapy|Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room.
62231356|NCT01487031|ACTIVE_COMPARATOR|No music therapy|Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
62231357|NCT00459160|EXPERIMENTAL|Low MAP Group|Hypotensive Group with a target minimum MAP of 50 mmHg
62031551|NCT05508282|EXPERIMENTAL|Intervention|"These parents will have a new mobile app (Reading Bees) installed onto their smartphone during a baseline clinic visit between 0 and 2-months old. They will also receive a specially designed children's book modeling the SHARE/STEP approach to reading with infants.~At 6-months, these parents will also receive guidance regarding limiting digital media use (screen time) using content in the app and a specially designed children's book.~They will also receive usual guidance during clinic visits via the Reach Out and Read program"
62231358|NCT00459160|NO_INTERVENTION|High MAP group|Non experimental group: These patients will have a target minimum MAP of 65 mm Hg
62231359|NCT05798533|EXPERIMENTAL|Treatment of Neo-T and anti-PD1|Dose escalation will use a 3+3 design and will enroll cohorts of 3-6 patients with MEL or NSCLC at escalating doses of 1.2×10\^9 cells and 3.6×10\^9 cells.
62231360|NCT02552641|EXPERIMENTAL|Test 1|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, in fasting conditions, twice daily
62231361|NCT02552641|EXPERIMENTAL|Test 2|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, after meals, twice daily
62231362|NCT02552641|EXPERIMENTAL|Test 3|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, twice daily in schedules variables with an interval of at least 8 hours between the doses
62231363|NCT00824811|EXPERIMENTAL|Group 1: Cyclosporine eye drops|Cyclosporine Eye Drops (Restasis) 1 drop twice/day for 84 days to both eyes + Fluorometholone Eye Drops (FML Forte) on declining dose schedule.
62592333|NCT05357144|EXPERIMENTAL|Drug shops, also known as Accredited Drug Dispensing Outlets (ADDOs), owners or staff|All drug shopkeepers in intervention areas (within Shinyanga or Mwanza) will be invited to participate in Malkia Klabu, a loyalty card program. Consenting drug shops in intervention areas should be willing and able to keep records of referrals and sexual and reproductive health (SRH) product distribution given to AGYW through the use of Maisha Meds during the one month run-in period.
62592334|NCT05357144|PLACEBO_COMPARATOR|Shopkeepers in control arm for comparison area|Drug shopkeepers, staff and/or owners as part of the control arm will receive standard HIV training, guidance on referring AGYW to proximal HIV care, and HIVST for free distribution to AGYW.
62592335|NCT04827628|EXPERIMENTAL|Obese with Oryza sativa extract|The group with a body mass index of more than 25 kg/m2 that receive the Oryza Sativa Extract
62807800|NCT02922725|ACTIVE_COMPARATOR|Depressed patients receiving study drug|Participants diagnosed with MDD
62807801|NCT02922725|PLACEBO_COMPARATOR|Depressed patients receiving placebo|Participants diagnosed with MDD
62807802|NCT02922725|NO_INTERVENTION|Healthy Control|
62231364|NCT00824811|EXPERIMENTAL|Group 2: Lubricant Eye Drops|Lubricant Eye Drops (Refresh Endura) 1 drop twice/day for 84 days to both eyes + Fluorometholone Eye Drops (FML Forte) on declining dose schedule.
62231365|NCT01958970|EXPERIMENTAL|PINTA 745|
62231366|NCT01958970|PLACEBO_COMPARATOR|Placebo|
62231367|NCT05019378|EXPERIMENTAL|autologous SVF treatment|Three milliliter of cell suspension injection containing 1.0E8 SVF cells into the knee joint
62231368|NCT05019378|NO_INTERVENTION|Placebo group|No treatment
62231369|NCT00359151|EXPERIMENTAL|Celecoxib|Celecoxib
62231370|NCT00359151|PLACEBO_COMPARATOR|Placebo|Placebo
62231371|NCT05000502|EXPERIMENTAL|Home-based aerobic exercise training|home-based aerobic exercise condition will receive a fitness bracelet (with heart rate measurement capability) and weekly exercise counseling from an exercise trainer (i.e., exercise physiologist) by videoconference. The weekly counseling will be guided by the fitness bracelet data (both participant and exercise trainer will share the same log in information). The aerobic exercise progression will gradually increase duration and intensity of aerobic exercise with the goal of improving cardiorespiratory fitness.
62231372|NCT05000502|ACTIVE_COMPARATOR|Home-based standard attention flexibility/toning control|Home-based standard attention flexibility/toning control will receive light resistance bands, stretching/toning log book, and weekly videoconference counseling from an exercise trainer.
62231373|NCT00724308|EXPERIMENTAL|Arm 1|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
62592336|NCT04827628|ACTIVE_COMPARATOR|Obese with control|The group with a body mass index of more than 25 kg/m2 that receive the citric acid and sorbitol mixture
62592337|NCT04827628|ACTIVE_COMPARATOR|Normal Body Mass Index|The group with a body mass index of less than 25 kg/m2 that receive the citric acid and sorbitol mixture
62807803|NCT02785185|EXPERIMENTAL|IDP-122 Lotion|Lotion
62807804|NCT02785185|ACTIVE_COMPARATOR|Ultravate Cream|Cream
62807805|NCT02785185|ACTIVE_COMPARATOR|IDP-122 Vehicle Lotion|Lotion
62807806|NCT02785185|ACTIVE_COMPARATOR|IDP-122 Vehicle Cream|Cream
62807807|NCT05870514|EXPERIMENTAL|Fospropofol disodium for injection|Patients in the experimental group received fospropofol disodium for injection at an initial infusion rate of 10 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.
62807808|NCT05870514|ACTIVE_COMPARATOR|Propofol|Patients in the active comparator group received propofol at an initial infusion rate of 3 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.
62031552|NCT05508282|NO_INTERVENTION|Control|These parents will receive usual reading and screen time guidance during pediatric clinic visits, including via the Reach Out and Read program.
62422921|NCT03620773|OTHER|Clinical Investigation|"Participants will include youth who are scheduled for, and will undergo, vertical sleeve gastrectomy (VSG) surgery at the Bariatric Surgery Clinic at Children's Hospital of Colorado.~To understand how bariatric surgery affects renal function, all participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI."
62422922|NCT04835415|ACTIVE_COMPARATOR|group T|Group (T) (n=26): will receive ultrasound guided thoracic epidural analgesia: 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000).
62592338|NCT05285566|EXPERIMENTAL|Exparel® Injection Group|On the day of clinically indicated nasal surgery the surgical wound on the chest, where the rib cartilage is removed, will be injected with Exparel®
62031553|NCT00481429||1|Rosiglitazone
62031554|NCT00481429||2|Diet control +/- metformin
62031555|NCT06370767|EXPERIMENTAL|Bike-Share|Participants in this arm will participate in an 8-week bikeshare training program, using Indego, the bike sharing service in Philadelphia. The first sessions will be aimed at increasing knowledge of the bike share program and the procedures for utilizing it successfully. Then participants will meet with a peer support specialist, who will help facilitate individualized route planning and independent ride support. Peer support specialists will use motivational interviewing during these individual sessions in order to help participants identify personally meaningful motivations for participation and to enhance their sense of self-efficacy.
62031556|NCT06370767|EXPERIMENTAL|Public Transportation|An established travel-training program developed for individuals with disabilities, including those with SMI, serves as the curriculum for the public transportation intervention arm. Participants will use SEPTA, the public transportation provider in Philadelphia and surrounding areas. We will offer an 8-week intervention which will include instruction on foundational skills needed to travel on public transportation and 1-on-1 direct training in using public transportation. Participants will meet twice weekly for direct instruction and role-playing sessions to cover the core components and the latter weeks of intervention will be focused on individual travel training instruction provided by the peer support interventionists, with participants and peer support interventionists meeting for two travel trips each week.
62031557|NCT06370767|NO_INTERVENTION|Waitlist Control|Half of the participants in either arm (bike-share or public transportation) will be randomly assigned to either begin the intervention immediately, or be placed on a waitlist, serving as a control arm. The waitlist will be 8 weeks long, the same timeline as the intervention. After the eighth week, participants assigned to the waitlist will then begin the intervention for the next 8 weeks. Participants assigned to starting the intervention immediately will then be placed on the waitlist for the second-8 weeks of the total study enrollment.
62422923|NCT04835415|ACTIVE_COMPARATOR|group R|Group (R) (n=26): will receive bilateral ultrasound guided retrolaminar block analgesia: 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000).
62422924|NCT05298215|EXPERIMENTAL|5 mg/kg UB-221|Total of 2 doses on Day 0 (week 1) and 84 (Week 12), respectively, by intravenous (IV) infusion.
62422925|NCT05298215|EXPERIMENTAL|10 mg/kg UB-221|Total of 2 doses on Day 0 (week 1) and 84 (Week 12), respectively, by intravenous (IV) infusion.
62422926|NCT05298215|PLACEBO_COMPARATOR|Placebo|sterile saline solution (0.9% NaCl) for intravenous (IV) infusion
62422927|NCT02797626|OTHER|Primary RPNLD|
62422928|NCT05216328|ACTIVE_COMPARATOR|Macrogol/electrolytes|"Macrogol/electrolytes is started at a dose of 1 sachet once a day orally, based on the current guideline 'Diagnosis and treatment of pain in patients with cancer' (www.pallialine.nl). The dose of macrogol/electrolytes may be increased to 2 sachets a day during the study period.~The effect of laxatives will be judged after 14 days."
62422929|NCT05216328|ACTIVE_COMPARATOR|Magnesium hydroxide|Magnesium hydroxide is started at a dose of 724 mg three times a day orally, based on the current guideline 'Diagnosis and treatment of pain in patients with cancer' (www.pallialine.nl). The dose of magnesium hydroxide may be increased to 1448 mg three times a day during the study period. The effect of laxatives will be judged after 14 days.
62422930|NCT02656615|EXPERIMENTAL|Abiraterone|Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
62231374|NCT00724308|EXPERIMENTAL|Arm 2|"The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state smoking cessation Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status."
62231375|NCT01383772|EXPERIMENTAL|Visual fields|One arm study. All patients will receive laser treatment following visual field testing.
62422931|NCT01695837|EXPERIMENTAL|Group A-dietary counseling month 0-6|"Group A Visit #1 - Weight, height, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the primary care physician (PCP) reviewed the results of the fasting lipid panel and diet test with the patient; the PCP provide the patient with written educational materials and access to the counseling website. Weekly automatic emails sent to patient reminding to visit the counseling website~Visit #2 - Same as visit #1. Weekly automatic emails sent to patient reminding to visit the counseling website.~Visit #3 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the new fasting lipid panel and diet test with the patient."
62031558|NCT06043050||Neonates with severe thrombocytopenia|Neonates with a gestational age below 34 weeks and at least one platelet count below 50x10\^9/L, who were admitted to a NICU between January 1st, 2017 and January 1st, 2022.
62422932|NCT01695837|OTHER|Group B- Dietary counseling month 3-6|"Group B Visit #1: Weight, height, blood pressure and pulse were measured at the beginning of the visit. Follow up visit and lab order were scheduled for 3 months. No blood test or diet test results were reviewed with the patient.~Visit #2 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the two fasting lipid panels ; the PCP provide the patient with written educational materials and access to the counseling website. Weekly automatic emails sent to patient reminding to visit the counseling website~Visit #3 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the new fasting lipid panel and diet test with the patient."
62592339|NCT05285566|ACTIVE_COMPARATOR|Xylocaine® Injection Group|On the day of clinically indicated nasal surgery the surgical wound on the chest, where the rib cartilage is removed, will be injected with Xylocaine® as part of standard of care.
62031559|NCT05099848|EXPERIMENTAL|CAHAIC group|Hepatic Arterial Infusion Chemotherapy combined with Camrelizumab and Apatinib
62592340|NCT00057304|EXPERIMENTAL|RO 205-2349 2 mg QD|RO 205-2349 2 mg was taken once daily (QD) for 16 weeks during the double-blind treatment period.
62031560|NCT01552213|ACTIVE_COMPARATOR|Treatment for glucose intolerance|Regular visit with dietician, exercise, self blood glucose monitoring, Insulin therapy if determined necessary.
62031561|NCT01552213|ACTIVE_COMPARATOR|Minimum intervention control group|Single visit with dietician or health educator followed by routine care per provider.
62031562|NCT03913585|EXPERIMENTAL|Lifestyle intervention|The intervention group comprises \~4800 patients born 1959-1988, living in the municipalities of Haderslev or Middelfart, and affiliated to one of the participating GPs. No control group is included.
62031563|NCT02630264|EXPERIMENTAL|Combination therapy|"E10A+chemotherapy group (360 subjects):~1. E10A (Endostatins) of 1.0×1012VP on day 1 and 6~2. Paclitaxel Injection 160mg/m2 on day 3~3. Cisplatin Injection 25mg/m2 on day 3, 4, and 5. Repeat every 21 days."
62031564|NCT02630264|EXPERIMENTAL|Chemotherapy|"Chemotherapy-alone group (180 subjects):~1. Paclitaxel Injection 160mg/m2 on day 1~2. Cisplatin Injection 25mg/m2 on day 1, 2, and 3. Repeat every 21 days"
62031565|NCT02931734|ACTIVE_COMPARATOR|Resin modified glass ionomer (RMGI)|Resin modified glass ionomer; an application every 48 hours; 4 sessions.
62031566|NCT02931734|ACTIVE_COMPARATOR|Potassium Nitrate 2% (KF)|Potassium Nitrate and Sodium fluoride 2%; an application every 48 hours; 4 sessions.
62031567|NCT02931734|ACTIVE_COMPARATOR|Low level laser therapy - GaAlAs (LLLT)|Low level laser therapy - GaAlAs; an application every 48 hours; 4 sessions.
62031568|NCT02931734|ACTIVE_COMPARATOR|RMGI and KF|Resin modified glass ionomer and potassium nitrate and sodium fluoride 2%; an application of the two associated products, every 48 hours; 4 sessions.
19589537|NCT06566963|EXPERIMENTAL|Part 1: Panel A|Participants in Panel A receive single doses of placebo or MK-1708 Dose 1 (Period 1) and Dose 3 (Period 2).
62231376|NCT02154009||Healthy Volunteers|Volunteers will be studied for Fellows to practice and gain normative values for pupillometric function.
19589538|NCT06566963|EXPERIMENTAL|Part 1: Panel B|Participants in Panel B receive single doses of placebo or MK-1708 Dose 2 (Period 1) and Dose 4 (Period 2).
19589539|NCT06566963|EXPERIMENTAL|Part 1: Panel C|Participants in Panel C receive a single dose of placebo or MK-1708 Dose 1 in Period 1.
19589540|NCT06566963|EXPERIMENTAL|Part 1: Panel D|Participants in Panel D receive single doses of placebo or MK-1708 Dose 1 (Period 1) and Dose 3 (Period 2).
62231377|NCT02154009||Patients|Referred patients with known or suspected abnormalities of one or more components of the autonomic nervous system
62231378|NCT06135077|EXPERIMENTAL|T-PRF|
62231379|NCT06135077|ACTIVE_COMPARATOR|T-PRF/xenograft|
62231380|NCT02982733|ACTIVE_COMPARATOR|ABS|Ankaferd blood stopper
62231381|NCT02982733|PLACEBO_COMPARATOR|CS|Conventional sterile gauze
62231382|NCT02982733|ACTIVE_COMPARATOR|TR BAND|Dedicated hemostatic device
62231383|NCT03082222||Group 1|Participants with epilepsy, partial onset seizures with or without secondary generalization with one concomitant antiepileptic drug (AED) at baseline
62231384|NCT03082222||Group 2|Participants with epilepsy, partial onset seizures with or without secondary generalization with two or more concomitant AEDs at baseline
62231385|NCT03082222||Group 3|Participants with epilepsy, partial onset seizures with or without secondary generalization with eslicarbazepine acetate (ESL) as anticonvulsant monotherapy
19589541|NCT06566963|EXPERIMENTAL|Part 1: Panel E|Participants in Panel E receive single doses of placebo or MK-1708 Dose 2 (Period 1) and Dose 4 (Period 2).
62031569|NCT02931734|ACTIVE_COMPARATOR|RMGI and LLLT|Resin modified glass ionomer and Low level laser therapy - GaAlAs; an application of the two associated products, every 48 hours; 4 sessions.
62231386|NCT06473545||Socket Preservation|Socket preservation is completed at the time of extraction. After removal of the tooth, the gum is elevated away from the bone, the socket is thoroughly cleansed, the socket is packed with the SBG and the wound closed. A healing time between 3 to 9 months is .
62422933|NCT02357173|ACTIVE_COMPARATOR|cigarette group|This group (1/3 of the sample) will not receive electronic cigarettes to sample and will continue smoking their regular cigarettes as much or as little as they would like.
62422934|NCT02357173|EXPERIMENTAL|electronic cigarette|This group (2/3 of the sample) will be given electronic cigarettes for a 3-week period, to use as much or as little as they would like.
62422935|NCT03343145|EXPERIMENTAL|Test Drug Group|Leucostim 5µg/kg/day
62422936|NCT03343145|ACTIVE_COMPARATOR|Reference Drug Group|Neupogen 5µg/kg/day
62422937|NCT06539780|EXPERIMENTAL|Imagery Rescripting|"Baseline consists of a random assigned period of 1-3 weeks with measurements and no intervention.~Intervention consists of a maximum of 6 sessions of imagery rescripting, provided twice-weekly.~Post treatment follow up consists of 3 weeks with only measurements and no intervention."
62422938|NCT01325896|OTHER|All patients are receiving PEG-Intron|
62422939|NCT05130086|EXPERIMENTAL|Islatravir|60 mg Islatravir taken orally in tablet form once monthly for up to 24 weeks
62231387|NCT06473545||Immediate implant placement|Implant placement immediately after tooth extraction, the bone grafting material is packed between the implant and the bone wall.
62422940|NCT03564509|EXPERIMENTAL|FE 999302 (1 μg) and follitropin delta|
62422941|NCT03564509|EXPERIMENTAL|FE 999302 (2 μg) and follitropin delta|
62422942|NCT03564509|EXPERIMENTAL|FE 999302 (4 μg) and follitropin delta|
62422943|NCT03564509|EXPERIMENTAL|FE 999302 (8 μg) and follitropin delta|
62422944|NCT03564509|EXPERIMENTAL|FE 999302 (12 μg) and follitropin delta|
62422945|NCT03564509|PLACEBO_COMPARATOR|Placebo and follitropin delta|
62422946|NCT01817335|EXPERIMENTAL|Supportive care (psycho-educational program)|Patients participate in a psycho-educational program focused on medical/symptom management and communication with a medical team, coping skills, self image, and relationships and communication for 1.5 hours once weekly for 6 weeks.
62592341|NCT00057304|EXPERIMENTAL|RO 205-2349 5 mg QD|RO 205-2349 5 mg was taken once daily (QD) for 16 weeks during the double-blind treatment period.
62031570|NCT02931734|ACTIVE_COMPARATOR|KF and LLLT|Potassium Nitrate and Sodium fluoride 2% and Low level laser therapy - GaAlAs; an application of the two associated products, every 48 hours; 4 sessions.
62031571|NCT02931734|ACTIVE_COMPARATOR|RMGI, KF, LLLT|Resin modified glass ionomer, potassium nitrate and sodium fluoride 2% and Low level laser therapy - GaAlAs ; an application of the three associated products, every 48 hours; 4 sessions.
62031572|NCT00734227|ACTIVE_COMPARATOR|A|"Randomization: By the blind card method to TIPS or emergency portacaval shunt. Diagnostic Workup: Completed within 6hr. Rapidity of Therapy: Within 24 hr. Failure of Therapy: Bleeding requiring \>6u PRBC in first 7 days, or 8 units PRBC during 12 months.~Rescue Crossover Therapy: When primary therapy has failed. Followup: Lifelong data collection on line, analysis by biostatistician Florin Vaida, PhD. External Advisory, Data Monitoring and Safety Committee by 3 senior academicians.~Procedure: Emergency portacaval shunt."
62031573|NCT00734227|ACTIVE_COMPARATOR|B|Procedure: Emergency TIPS.
62231388|NCT06473545||Guided bone regeneration|When ridge augmentation is indicated, guided bone regeneration with the SBG and a barrier membrane are utilized at the time of tooth extraction or at an edentulous bone ridge. Either simultaneous implant placement or delayed implant placement are performed at the time of GBR surgery or after a 4 to 9 months healing time respectively.
62231389|NCT06473545||Sinus elevation|Schneiderian membrane elevation to increase the residual crestal bone height in the posterior maxilla, bone grafting material is placed into the newly created space, including elevation through the lateral approach.
62592342|NCT04613661||Researcher 1|The first researcher assessing elbow, wrist, and ankle spasticity, respectively
62592343|NCT04613661||Researcher 2|The second researcher assessing elbow, wrist, and ankle spasticity, respectively
62592344|NCT05769400||Patients wiht Hepatitis C Virus Infection|Patients with hepatitis c virus infection.
62592345|NCT04097262|EXPERIMENTAL|Own-Price Elasticity|"The price of fruit will vary (own-price elasticity) while the price of all other foods in the mock grocery store will remain constant."
62592346|NCT04097262|EXPERIMENTAL|Cross-Price Elasticity|"The price of fruit will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
62031574|NCT04935502|EXPERIMENTAL|Home based exercises with postural and ergonomic training|Home based exercises which consist of stretching, strengthening exercises along with postural and ergonomic training will be given to participants for a period of one month by a physiotherapist for 60 minutes via distance education
62031575|NCT04935502|EXPERIMENTAL|Home based exercises|Home based exercises which consist of stretching and strengthening exercises will be given to participants for a period of one month by a physiotherapist for 60 minutes via distance education.
62031576|NCT01704417|EXPERIMENTAL|IDeg followed by IGlar|
62231390|NCT01522313||Patients|Data of patients anesthetized in the years 2006 to 2012 (Hospital stay: January 2006 - June 2012) will be analysed in the study.
62231391|NCT04536987|EXPERIMENTAL|low-dosage robot therapy|12 sessions of robotic therapy over 4-5 weeks
62231392|NCT04536987|EXPERIMENTAL|hi-dosage robot therapy|24 sessions of robotic therapy over 8-10 weeks
62231393|NCT05525611|EXPERIMENTAL|Cabergoline|
62422947|NCT04959279|EXPERIMENTAL|ED-TREAT|EHR-embedded clinical decision support (CDS) tool designed to overcome the challenges to risk assessment and suggest pre-emptive use of behavioral techniques in the emergency setting.
62592347|NCT02057029|OTHER|BCI Assay Results|The Breast Cancer Index (BCI) is a novel gene expression-based prognostic predictor for ER positive cancers and is provided through a CLIA certified commercial laboratory. It is an RT-PCR assay that can be performed on formalin fixed paraffin embedded sections of archived tissues. Participants will work in concert with a physician to determine future treatment options based on BCI results.
62592348|NCT06234098|EXPERIMENTAL|AT-1965 Liposome Injection|
62592349|NCT04259203|EXPERIMENTAL|Erickson hypnosis|5 sessions of Erickson hypnosis (1 session per week), associated with autohypnosis at home in-between sessions.
62592350|NCT04259203|NO_INTERVENTION|Usual care|Usual management of pain symptoms
62031577|NCT01704417|EXPERIMENTAL|IGlar followed by IDeg|
62031578|NCT01558622|PLACEBO_COMPARATOR|dexketoprofen trometamol|Dexketoprofen trometamol is a water-soluble salt of the dextrorotatory enantiomer of the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen.
19589542|NCT06566963|EXPERIMENTAL|Part 2: Panel F|Participants in Panel F receive multiple doses of placebo or MK-1708.
62031579|NCT01558622|PLACEBO_COMPARATOR|tramadol hydrochloride|Tramadol Hydrochloride is a well-known centrally acting opioid pain killer.
62031580|NCT01558622|PLACEBO_COMPARATOR|pethidine hydrochloride|Pethidine is a synthetic opioid analgesic which produces a pattern of effects similar to morphine the standard against which opioid analgesics are compared.
62592351|NCT06666374|EXPERIMENTAL|OHL Program|This program used OHL as its core structure and incorporated elements of experiential learning and self-efficacy to enhance patient engagement and understanding.
62592352|NCT06666374|ACTIVE_COMPARATOR|Traditional program|Patients acquired traditional oral health instruction from another dental professional, which primarily focused on providing information without the OHL components, self-efficacy strategies, or the interactive elements of the intervention program.
62031581|NCT01558622|PLACEBO_COMPARATOR|dexketoprofen trometamol + tramadol hydrochloride|
62031582|NCT01558622|PLACEBO_COMPARATOR|dexketoprofen trometamol + pethidine hydrochloride|
62592353|NCT00936325||Healthy volunteers|healthy volunteers to act as controls.
62031583|NCT01558622|PLACEBO_COMPARATOR|vitamin c|
62031584|NCT06170827|EXPERIMENTAL|AIO-001 (Formulation A)|400 milligram (mg) of 100 milligrams per milliliter (mg/ml) AIO-001 Subcutaneous (SC) injection will be administered.
62031585|NCT06170827|EXPERIMENTAL|AIO-001 (Formulation B)|400 mg of 182 mg/ml AIO-001 SC injection will be administered.
62031586|NCT04938895|EXPERIMENTAL|Black Woman Investigator|Survey respondents are exposed to a Black woman investigator.
62031587|NCT04938895|EXPERIMENTAL|Black Man Investigator|Survey respondents are exposed to a Black man investigator.
62031588|NCT04938895|EXPERIMENTAL|White Woman Investigator|Survey respondents are exposed to a white woman investigator.
62031589|NCT04938895|EXPERIMENTAL|White Man Investigator|Survey respondents are exposed to a white man investigator.
62031590|NCT01262066|EXPERIMENTAL|LifeSkills workshop intervention|Participants attended 10 1-hr weekly sessions. The content of the groups followed the LifeSkills Workshop manual and Video(Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
62231394|NCT05525611|PLACEBO_COMPARATOR|Control|
19589543|NCT06566963|EXPERIMENTAL|Part 2: Panel G|Participants in Panel G receive multiple doses of placebo or MK-1708.
19589544|NCT06566963|EXPERIMENTAL|Part 2: Panel H|Participants in Panel H receive multiple doses of placebo or MK-1708.
62422948|NCT04959279|NO_INTERVENTION|Usual Care|
62031591|NCT01262066|NO_INTERVENTION|Enhanced usual care|The Usual Care group received a self-help brochure on BP control developed by the National Heart, Lung, and Blood Institute (NHLBI). In addition, with the participants' permission, their BP readings were sent to their listed physicians, along with the 1-page JNC-7 express summary for the management of high BP.
62422949|NCT00916292|EXPERIMENTAL|Low dose|Four subjects will receive low dose FGF-1
62422950|NCT00916292|EXPERIMENTAL|High Dose|Four subjects will receive high dose FGF-1
62422951|NCT05503914|EXPERIMENTAL|low-dose radiotherapy group|Neoadjuvant chemotherapy combined with low-dose radiotherapy sequential concurrent chemoradiotherapy
62422952|NCT05503914|NO_INTERVENTION|control group|Neoadjuvant chemotherapy sequential concurrent chemoradiotherapy
62422953|NCT01052038|PLACEBO_COMPARATOR|Group 1 Placebo|Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.
62592354|NCT00936325||Patients with SCLS|patients who have been diagnosed, or are suspected of having systemic capillary leak syndrome.
62592355|NCT00936325||Relatives|relatives of patients who have systemic capillary leak syndrome.
62031592|NCT00421252|ACTIVE_COMPARATOR|Clopidogrel 600 mg pre-treatment|Patients will receive 600 mg Clopidogrel load \>2 hours pre-angiography with possibility for ad hoc PCI based on angiographic results
62807809|NCT02451059|EXPERIMENTAL|Intervention-WE CARE|"1. The WE CARE survey is used to identify unmet material needs; it will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age.~2. Providers will be trained to review the WE CARE survey at health supervision visits and generate our WE CARE community resource handouts (referrals) through the EMR.~3. A peer patient navigator will offer personalized guidance to families with accessing community resources. The patient navigator will be available for at least a 1/2 day per week at each intervention health center to meet with families and offer guidance. Providers can communicate the patient navigator to refer families via the electronic medical record and families will also have the opportunity to contact the peer navigator at any time via the hotline number listed on the referral information sheets."
62807810|NCT02451059|NO_INTERVENTION|Control-Standard of Care|Participants in the delayed-intervention control group will receive standard pediatric care. However, since the health centers share a common EMR, and for ethical reasons, investigators will also embed the health IT referral mechanism into the EMR at the control sites. Control providers will be made aware of this prior to the start of the study. Although this may potentially reduce the effect size, the investigator's prior study found that the impact on referral rates of provider access to resource information was minimal. Families at control health centers will not receive the WE CARE surveys at health supervision visits and will not have access to the peer patient navigators
62807811|NCT01411826|ACTIVE_COMPARATOR|Information|
62807812|NCT01411826|EXPERIMENTAL|Information + Narratives + Support group|
62807813|NCT00941941|EXPERIMENTAL|Non-mesh Hernia Repair|Reinforcement with a strip of external oblique aponeurosis
62807814|NCT00941941|ACTIVE_COMPARATOR|Mesh Hernia Repair|Polypropylene mesh placement
62807815|NCT03140514|EXPERIMENTAL|Intervention|Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant. Sustained elevated levels will trigger performance of a renal allograft biopsy. Any rejection will be treated. Rejection treatment according to clinical standard-of-care
62231395|NCT02169453|EXPERIMENTAL|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
62231396|NCT02169453|EXPERIMENTAL|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
62807816|NCT03140514|NO_INTERVENTION|Control|Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant, but the values are concealed.
62807817|NCT01689142|EXPERIMENTAL|New formulation of insulin glargine|once daily in the evening on-top of oral antihyperglycemic drug (OADs)
62807818|NCT01689142|ACTIVE_COMPARATOR|Lantus (insulin glargine)|once daily in the evening on-top of OADs
62807819|NCT00433641|PLACEBO_COMPARATOR|1|placebo tablet
62031593|NCT00421252|ACTIVE_COMPARATOR|No clopidogrel 600 mg pretreatment|Patients will receive 600 mg Clopidogrel load after PCI, if performed
62031594|NCT00421252|ACTIVE_COMPARATOR|5Fr arterial access sheath|Patients will have angiography performed using 5Fr sheath. If PCI required, sheath will be upsized.
62031595|NCT00421252|ACTIVE_COMPARATOR|6Fr arterial access sheath|Patients will have angiography performed using 6Fr sheath
62031596|NCT06150027|NO_INTERVENTION|Standard|Conventional strategy: patients will be managed regardless of their PALLIA-10 score. The need for additional care, including palliative care, will be assessed by the team in charge of the patient, as per routine practice.
62031597|NCT06150027|EXPERIMENTAL|Experimental|Experimental strategy: patients will be systematically referred to a palliative care team.
62422954|NCT01052038|ACTIVE_COMPARATOR|Group 2: Dexamethasone 0.05mg/kg|Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery
62807820|NCT00433641|EXPERIMENTAL|2|sibutramine
62807821|NCT00433641|EXPERIMENTAL|3|sibutramine
62807822|NCT05670522|EXPERIMENTAL|Transcranial direct current stimulation group|Children assigned to the transcranial direct current stimulation group received active transcranial direct current at their primary motor cortex (Active dose 11, ser. No 13070350, Active Tek Inc., USA). Stimulation was conducted at an intensity of 1 mA for 20 min per session, 5 times/week for 2 successive weeks (total of 10 sessions). 1 mA was shown to be appropriate in children's investigations. The anode (+) was positioned on the midline sagittal plane of the skull, corresponding to the motor area of lower limbs, and the cathode (-) was positioned over the inion. In addition to their assigned intervention, the children received the standard-of-care gait training. During the two-week intervention phase, gait training was administered immediately after each intervention session. Training was delivered in one hour increments 5 times/week for those first two weeks, then 3 times/week for the next 10 weeks.
62807823|NCT05670522|EXPERIMENTAL|Virtual reality group|Children assigned to the virtual reality group received virtual balance training using Nintendo Wii and Wii Balance Board, with a custom training program developed from activities on the Wii Fit Plus game. Training was conducted for 30 minutes, 5 sessions/week for 2 successive weeks (total of 10 sessions). Two sessions with Wii Fit Plus were conducted before the treatment protocol to help the children familiarize with the VR setup. In addition to their assigned intervention, the children received the standard-of-care gait training. During the two-week intervention phase, gait training was administered immediately after each intervention session. Training was delivered in one hour increments 5 times/week for those first two weeks, then 3 times/week for the next 10 weeks.
62807824|NCT02933788|EXPERIMENTAL|Cilostazol group|Cilostazol Cilostazol 200mg tablet by mouth, once daily for 14 days
62807825|NCT02933788|ACTIVE_COMPARATOR|Aspirin group|Acetylsalicylic acid Acetylsalicylic acid 100mg tablet by mouth, once daily for 14 days
62231397|NCT02169453|EXPERIMENTAL|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
62231398|NCT02169453|EXPERIMENTAL|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~Subjects were to attend four treatment periods and were to receive a different dose of BIA 9-1067 (25 mg, 50 mg and 100 mg) or placebo during each of these treatment periods."
62231399|NCT04259073|PLACEBO_COMPARATOR|Group C|two capsules filled with sugar
62231400|NCT04259073|ACTIVE_COMPARATOR|Group P150|two capsules; one of them containing sugar (like the placebo one), the other is the active drug (pregabalin 150 mg)
62807826|NCT01686334|EXPERIMENTAL|DC vaccine|Vaccination with autologous WT1 mRNA-electroporated DCs plus follow-up care. Patients receiving low-intensity chemotherapy are allowed to continue this treatment in combination with DC vaccination.
62807827|NCT01686334|NO_INTERVENTION|Control arm|Follow-up care. Patients receiving low-intensity chemotherapy are allowed to continue this treatment during the follow-up care
62031598|NCT03708198|OTHER|Intercostal Nerve Block|The study participants will be given a standard 266 mg single dose injection of liposomal bupivacaine by the surgeon at the start of the surgery.
62231401|NCT04259073|ACTIVE_COMPARATOR|Group P300|two capsules of pregabalin (150 mg)
62231402|NCT04775589|EXPERIMENTAL|Stepped Exercise for Knee Osteoarthritis|Patients start with a home-based exercise program, supported by an internet-based tool (Step 1). Patients are then assessed for degree of improvement in symptoms, and then can step up sequentially to telephone or video-based physical activity coaching (Step 2) and physical therapy (Step 3) if they do not make clinically relevant improvements in prior steps.
62231403|NCT05679856|EXPERIMENTAL|Single vocal cord hypofractionated radiotherapy|Hypofractionated radiotherapy 58.08Gy/16 fractions to affected vocal cord plus margins to account for motion and setup errors using IMRT/VMAT technique
62231404|NCT05679856|ACTIVE_COMPARATOR|Whole laryngeal radiotherapy|Radiotherapy 63Gy/28 fractions to whole larynx from lower border of hyoid bone to lower border of cricoid cartilage using IMRT/VMAT technique
62031599|NCT06413108|PLACEBO_COMPARATOR|1A: control|0.2 mL normal saline
62231405|NCT00706433|ACTIVE_COMPARATOR|ALA 1000 seconds|Aminolevulinic acid HCL (ALA) applied to the entire facial area 45 minutes prior to BLUE light treatment for 1000 seconds (16 minutes and 40 seconds)
62231406|NCT00706433|ACTIVE_COMPARATOR|ALA 500 seconds|Aminolevulinic acid HCL (ALA) applied to the entire facial area 45 minutes prior to BLUE light treatment for 500 seconds (8 minutes and 20 seconds)
62231407|NCT00706433|PLACEBO_COMPARATOR|Vehicle 1000 seconds|Vehicle (VEH) applied to the entire facial area 45 minutes prior to BLUE light treatment for 1000 seconds (16 minutes and 40 seconds)
62231408|NCT00706433|PLACEBO_COMPARATOR|Vehicle 500 seconds|Vehicle (VEH) applied to the entire facial area 45 minutes prior to BLUE light treatment for 500 seconds (8 minutes 20 seconds)
62422955|NCT01052038|ACTIVE_COMPARATOR|Group 3:Dexamethasone 0.1mg/kg|Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.
62422956|NCT04815408|EXPERIMENTAL|NIC|"1. Neoadjuvant treatment BGB-A317 200mg q3 weeks (total 3 dosing) Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 q3 weeks (total 3 dosing)~2. Interval debulking surgery and HIPEC~3. Adjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5, Bevacizumab 7.5mg/kg q3 weeks (total 3 dosing)"
62422957|NCT04815408|ACTIVE_COMPARATOR|NC|"1. Neoadjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 q3 weeks (total 3 dosing)~2. Interval debulking surgery and HIPEC~3. Adjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5, Bevacizumab 7.5mg/kg q3 weeks (total 3 dosing)"
62422958|NCT01257529|EXPERIMENTAL|Pregabalin controlled release, 330 mg, low-fat|
62422959|NCT01257529|EXPERIMENTAL|Pregabalin controlled release, 330 mg, medium-fat|
62422960|NCT01257529|EXPERIMENTAL|Pregabalin controlled release, 330 mg, high-fat|
62422961|NCT01257529|OTHER|Pregabalin immediate release, 300 mg|Reference Treatment
62422962|NCT05059717|EXPERIMENTAL|Diagnostic (standard of care MRI, MR DENSE MRI)|Patients undergo standard of care MRI and then undergo an MRI of the liver using MR DENSE imaging sequences over 60-90 minutes. Healthy volunteers undergo MRI of the liver using DENSE imaging sequences.
62422963|NCT00875537|ACTIVE_COMPARATOR|Capsaicin oral gel 0.01%|
62735436|NCT06421714|EXPERIMENTAL|Venglustat and Itraconazole|The first period will include a single dose administration of venglustat followed by a second period including a multiple dose administration of itraconazole for 12 days and a second single dose administration of venglustat on the 6th day of itraconazole administration
62807828|NCT02619760|ACTIVE_COMPARATOR|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists , followed by 59-month clopidogrel monotherapy
62807829|NCT02619760|ACTIVE_COMPARATOR|12-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists with 11-month DAPT composed of aspirin and clopidogrel, followed by 48-month aspirin monotherapy
62807830|NCT05404243|EXPERIMENTAL|phenolization group|Curettage of the sacral cyst is performed using a disposable otorhinolaryngologists curette. The perimeter of the cyst is covered with petroleum jelly to protect the skin, and an Abbocath catheter 18 G is introduced into the cystic cavity. Undiluted 88% phenol is instilled into the cavity, ensuring that the cystic cavity is filled. It is maintained for 5 min until complete coagulation of the cyst is achieved.
62807831|NCT05404243|ACTIVE_COMPARATOR|conventional surgery|entire exeresis is performed by means of an electric scalpel
62031600|NCT06413108|EXPERIMENTAL|1B: 10 mg TB31F|0.2 mL (10 mg) TB31F
62031601|NCT06413108|PLACEBO_COMPARATOR|2A: control|2 mL normal saline
62031602|NCT06413108|EXPERIMENTAL|2B:100 mg TB31F|2 mL (100 mg) TB31F
62231409|NCT00622453||Registry of Arrhythmias|Screening of individuals with myotonic muscular dystrophy to evaluate the utility of non-invasive electrocardiographic screening methods and history in predicting serious arrhythmic events.
62422964|NCT00875537|ACTIVE_COMPARATOR|Capsaicin oral gel 0.025%|
62422965|NCT03901222|ACTIVE_COMPARATOR|Bi-Anodal tDCS|Subjects will receive 20 min of bi-anodal tDCS
62231410|NCT00701077|EXPERIMENTAL|1|3,4-Di-amino-Pyridine : a single 20 mg dosing
62807832|NCT04440267|EXPERIMENTAL|single arm|Patients will receive acute lymphoblastic leukemia (ALL) -based chemotherapy and are permitted to receive allogeneic hematopoietic stem cell transplantation (HSCT) in CR. Otherwise, they will finish the consolidation chemotherapy. Patients with t(9;22) will receive chemotherapy combined with tyrosine kinase inhibitors.
62807833|NCT03683173|EXPERIMENTAL|Multilevel Intervention|Participants will receive the multilevel intervention consisting of community events, walking group formation, and short messaging service.
62807834|NCT03683173|NO_INTERVENTION|Control|Does not receive the multilevel intervention.
62807835|NCT02494232||minor blunt thoracic trauma patient|demographic data, physical examination findings
62807836|NCT03467347|EXPERIMENTAL|VR used continuously for approximately 90 days|One silicone elastomer vaginal ring (VR) containing the active 200 mg dapivirine (DPV) and 320 mg levonorgestrel (LNG), used continuously for approximately 90 days.
62231411|NCT00701077|PLACEBO_COMPARATOR|2|
62231412|NCT06202235||CKD Patients|Participants with diagnosed Chronic Kidney Disease will undergo the same MRI protocol as the Healthy Volunteers, including T1-weighted, T2-weighted imaging, and Magnetic Resonance Elastography (MRE). In addition to the imaging, these participants will have their blood creatinine, cystatin C, and blood pressure measured within 3 days before and after the MRE. A renal biopsy will be performed as part of their clinical assessment to evaluate the extent of kidney fibrosis.
62422966|NCT03901222|SHAM_COMPARATOR|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
62807837|NCT03467347|EXPERIMENTAL|VR used cyclically for approximately 90 days|One silicone elastomer vaginal ring (VR) containing the active 200 mg dapivirine (DPV) and 320 mg levonorgestrel (LNG), used cyclically for approximately 90 days. Use the VR for 28 days, remove for 2 days.
62031603|NCT06413108|PLACEBO_COMPARATOR|3A: control|4 mL normal saline
62807838|NCT01785888||Locally advanced/metastatic NSCLC pts.|Patients(pts.) with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy)
62807839|NCT04103359|EXPERIMENTAL|MDS patients|MDS patients receiving blood transfusion
62807840|NCT02028377|EXPERIMENTAL|Imaging|PET/MRI
62807841|NCT04713280|ACTIVE_COMPARATOR|Maxillary posterior dento-alveolar intrusion|Mini-screw supported maxillary posterior dento-alveolar intrusion
62807842|NCT04713280|EXPERIMENTAL|Bi-maxillary posterior dento-alveolar intrusion|Mini-screw supported bi-maxillary posterior dento-alveolar intrusion
62807843|NCT01320475|EXPERIMENTAL|iv Ketamine|Epidural infusion of levobupivacaine and saline (placebo for sufentanil)and iv infusion of ketamine Up to the third postoperative day (6 PM)
62807844|NCT01320475|ACTIVE_COMPARATOR|Sufentanil|Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
62031604|NCT06413108|EXPERIMENTAL|3B: 200 mg TB31F|4 mL (200 mg) TB31F
62031605|NCT06413108|PLACEBO_COMPARATOR|4A: control|0.2 mL normal saline
62031606|NCT06413108|EXPERIMENTAL|4B: 10 mg TB31F|0.2 mL (10 mg) TB31F
62422967|NCT02298595|EXPERIMENTAL|1: Low risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then observation.
62422968|NCT02298595|EXPERIMENTAL|2: Intermediate risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then Intensity Modulated Radiation Therapy (IMRT).
62422969|NCT02298595|EXPERIMENTAL|3: High risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then Intensity Modulated Radiation Therapy (IMRT) + cisplatin.
62422970|NCT06537206|EXPERIMENTAL|Application Footbath|"The experimental group will then receive the first foot bath with water at 38-40°C for approximately 10 minutes. After this, the second set of physiological parameters will be measured at the 40th minute. The child will rest for 10 minutes, followed by measurement and recording of the third set of parameters at the 50th minute.~A second foot bath at 38-40°C will be applied for another 10 minutes. After this, the fourth set of physiological parameters will be measured, and the FLACC pain score (2nd measurement) will be recorded by the same nurse observer and parent at the 60th minute. The procedure will then be terminated."
62422971|NCT06537206|NO_INTERVENTION|Control Group|"Approximately 10 minutes after the application of the antipyretic, the adaptation of the family and the child to the clinic will be awaited. Children and families who meet the sample selection criteria and verbally and in writing agree to participate in the study will be included.~A data collection form will be applied to all members of the sample group, and the information will be recorded by the researcher on the form. (20th minute) The parents of the children and the observer nurse will be explained how to use the FLACC pain assessment scale. For inter-observer agreement, the nurse administering the antipyretic and the accompanying parent will simultaneously evaluate using the scale. Throughout the process, the parents of both groups will be with the child."
62422972|NCT00306852|ACTIVE_COMPARATOR|Trabeculectomy|Trabeculectomy with mitomycin C
62592356|NCT00624195|EXPERIMENTAL|CNS-targeted|"CNS-T will comprise two components: 1) initial selection of agents to optimize CNS penetration of the overall regimen; and 2) modification of the regimen if an interim pharmacokinetic (PK) assessment determines that plasma ARV exposure is not appropriate (overdosing, under dosing).~Possible regimens include combinations of these FDA approved antiretroviral agents: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
62031607|NCT06413108|PLACEBO_COMPARATOR|5A: control|2.0 mL normal saline
62031608|NCT06413108|EXPERIMENTAL|5B: 100 mg TB31F|2.0 mL (100 mg) TB31F
62031609|NCT06413108|PLACEBO_COMPARATOR|6A: control|0.6 or 2.0 mL normal saline
62031610|NCT06413108|EXPERIMENTAL|6B: 30 mg TB31F|0.6 mL (30 mg) TB31F
62031611|NCT06413108|EXPERIMENTAL|6C: 100 mg TB31F|2.0 mL (100 mg) TB31F
62031612|NCT04681638|EXPERIMENTAL|Plasma|Pathogen-Reduced Plasma resuscitation
62422973|NCT00306852|ACTIVE_COMPARATOR|Implant|Baerveldt Implant
62422974|NCT01669278|NO_INTERVENTION|Traditional flexible nasopharyngolaryngoscopy|No sheath procedure
62422975|NCT01669278|ACTIVE_COMPARATOR|Sheath flexible nasopharyngolaryngoscopy|Flexible nasopharyngolaryngoscopy using endosheath
62422976|NCT00944008|EXPERIMENTAL|Depocyte|
62422977|NCT05812924|EXPERIMENTAL|Platelet-rich plasma (PRP) Group|Participants will undergo two sessions of platelet-rich plasma (PRP) injections to the vulva/vagina one month apart.
62422978|NCT03454672|EXPERIMENTAL|Tixel|Tixel Treatment.
62422979|NCT03454672|ACTIVE_COMPARATOR|Laser|Laser Treatment.
62422980|NCT01586832||ED Nurses|"Nurses in the emergency department (ED) providing patient care using supplies found in the stocking towers"
62422981|NCT00379925|EXPERIMENTAL|Behavioral|Participants will take part in the Physical Activity and Dietary Health Promotion Program.
62031613|NCT04681638|ACTIVE_COMPARATOR|Crystalloid|Standardized crystalloid resuscitation
62031614|NCT01682460|EXPERIMENTAL|Refresh Tears Lubricant Eye Drops (Allergan)|Artificial tears eye drops QID for 1 month
62031615|NCT01486160||nursing home residents|participants in this group are nursing home residents
62031616|NCT01486160||Nursing home employees|Participants in this group are health care workers, employees at the nursing home
62031617|NCT02950246|EXPERIMENTAL|2% alcoholic chlorhexidine group|"Skin preparation Use of 10 ml of 2% alcoholic Chlorhexidine drug for disinfection in place of povidone iodine without scrubing device Wait at least 30 secondes for drying Perineural catheterization implementation Ultrasonography use"
62031618|NCT02950246|ACTIVE_COMPARATOR|povidon iodine group|"Skin preparation Use of 10 ml of povidone iodine drug for disinfection with scrubing device Wait at least 30 seondes for drying Perineural catheterization implementation Ultrasonography use"
62031619|NCT01940042|EXPERIMENTAL|maneuver group|In the intervention group, CO2 was removed by means of Trendelenburg position (30 degrees) and a pulmonary recruitment maneuver consisting of five manual inflations of the lung.
62031620|NCT01940042|NO_INTERVENTION|clasical group|no additional action will be taken after the operation
62031621|NCT06430450||Healty|Individuals who have no clinical signs of inflammation in the periodontal tissues and the number of areas showing bleeding on probing does not exceed 20%.
62031622|NCT06430450||Grade A|Individuals with a probing pocket depth of 5 mm or more in at least 2 teeth in each quadrant of the jaw, attachment loss, and radiological bone loss percentage/age ratio in the tooth with the most bone loss \<0.25
62031623|NCT06430450||Grade B|Individuals with a probing pocket depth of 5 mm or more in at least 2 teeth in each quadrant jaw, attachment loss, and a radiological bone loss percentage/age ratio of 0.25-1.0 in the tooth with the most bone loss.
62031624|NCT06430450||Grade C|Individuals with a probing pocket depth of 5 mm or more in at least 2 teeth in each quadrant of the jaw, attachment loss, and a radiological bone loss percentage/age ratio \>1.0 in the tooth with the most bone loss.
62031625|NCT03624504|EXPERIMENTAL|Micra Implant Group|Subjects with implant attempt with the Micra Transcatheter Pacing System (TPS)
62031626|NCT03404128||Questionnaires|Questionnaire for patient Questionnaire for neurologist
62031627|NCT03786679|ACTIVE_COMPARATOR|Orthosis group|An orthosis with the broken arm in neutral position fixed for four weeks. After these four weeks the patient is instructed to start rehabilitation.
62031628|NCT03786679|ACTIVE_COMPARATOR|Early rehabilitation group|The patient is instructed to start early rehabilitation about one week after the trauma.
62231413|NCT06202235||Healthy Volunteers|Age-matched healthy individuals with no known kidney disease will be recruited. They will undergo the same MRI protocols as the CKD patient group, including T1-weighted, T2-weighted imaging, and MRE, to establish baseline viscoelasticity parameters for comparison with the CKD patients.
62807845|NCT05968677|EXPERIMENTAL|FSMP|Nutritional counseling plus one sachet of the study product (6.5 g) per day, away from meals, starting the day after the first chemotherapy cycle until three weeks after the last chemotherapy cycle (for a total of 12 weeks)
62422982|NCT00379925|NO_INTERVENTION|Delayed intervention|Participants are assigned to a delayed intervention group and serve as a no-intervention control group.
62422983|NCT04745325|EXPERIMENTAL|Smartphone app - full access|"A smartphone app containing 5 modules: 1) personalized feedback on alcohol use (containing normative feedback by age and sex for those located in the Canada), 2) self-monitoring and goal setting tool, 3) tool to choose a designated driver, 4) blood alcohol content (BAC) calculator, and 5) educational information on alcohol use and its consequences (i.e. fact sheets)."
62422984|NCT04745325|ACTIVE_COMPARATOR|Smartphone App - education only|"A version of the Smartphone app containing only the module with the educational information on alcohol use and its consequences (i.e. fact sheets)."
62031629|NCT06670885||Group A|Patients with diagnosis of infection confirmed by culture results
62031630|NCT06670885||Group B|Patients with diagnosis of prosthetic joint infection according to criteria of the MusculoSkeletal Infection Society (MSIS) but with negative culture
62031631|NCT06670885||Group C|Patients with no evidence of prosthetic joint infection according to criteria of MusculoSkeletal Infection Society (MSIS) (negative controls)
62031632|NCT05613660|EXPERIMENTAL|VEGCOL™️ (Veg Collagen Peptide)|"Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water~VEGCOL helps in providing the necessary nutrition needed for the body to produce collagen. Vegan collagen gives a lighter feel on consumption compared to any other collagen and increases the elasticity of the skin and makes skin supple. VEGCOL has more amino acids than animal derived Collagen which makes it very ideal to consume not only in Vegetarian populated countries like in India but around the world. Pepsin, a digestive enzyme, is added to help structure the building blocks into collagen molecules with the exact structure of human collagen."
62031633|NCT05613660|EXPERIMENTAL|PROCOL (Bovine Collagen Peptide)|"Bovine collagen is a naturally occurring protein present in the connective tissue, bones, cartilage, and hides of cows.~Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water."
62031634|NCT05613660|EXPERIMENTAL|"AQUACOL (Fish | Marine Collagen Peptide)"|"Marine Collagen is made from Fish Skin which delays the signs of aging such as wrinkles, Joint issues and weakness.~Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water."
62807846|NCT05968677|OTHER|Control|Nutritional counseling
62807847|NCT04052490|EXPERIMENTAL|flat occlusal reduction with feather edge finish|
62231414|NCT00261768|EXPERIMENTAL|1|Noise reduction on
62231415|NCT00718354|ACTIVE_COMPARATOR|B|Standard Chemotherapy (upto 6 cycles)
62231416|NCT00718354|EXPERIMENTAL|A|Enoxaparin: 1 mg/kg once daily in addition to standard chemotherapy up to 6 months
62231417|NCT00988871||Liver transplantation (LT) recipients|LT recipients who had both PICC and CICC at the same time according to the LT protocol of our hospital
62231418|NCT02405026||HIV infected patients|HIV infected patients with asthma
62422985|NCT04253756|NO_INTERVENTION|18-gauge autogard catheter|Standard of care
62807848|NCT04052490|EXPERIMENTAL|flat occlusal reduction with shoulder finish line|
62807849|NCT04052490|NO_INTERVENTION|planar occlusal reduction with shoulder finish line|
62807850|NCT02033434|EXPERIMENTAL|Intranasal Ketamine|All patients
62807851|NCT03324373|EXPERIMENTAL|Lenvatinib and Everolimus prior to cytoreductive nephrectomy|Eligible patients will start treatment with lenvatinib 18 mg PO daily (administered as one 10 mg capsule and two 4 mg capsules) and everolimus 5 mg PO daily for 4 weeks constituting one cycle. Two cycles of treatment will be administered and after 2 weeks wash out period, the patients will go for nephrectomy.
62807852|NCT03285802|EXPERIMENTAL|Letrozole and Everolimus|Letrozole 2.5mg daily q 30 days Everolimus 10mg daily q 28 days
62231419|NCT02405026||HIV uninfected patients|HIV uninfected patients with asthma
62031635|NCT05613660|EXPERIMENTAL|CALCOL (Chicken Collagen Peptide)|"Chicken collagen is used to treat joint pain associated with many types of arthritis and surgery, as well as back pain, neck pain, and pain following injury. Chicken collagen works by causing participants' body to produce substances that fight inflammation and pain. It also contains chondroitin and glucosamine, two compounds that help rebuild cartilage. That's why chicken collagen can provide some amazing benefits for participants' gut, immune system, skin, and more.~Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water."
62031636|NCT06078332||Remote assessment first|Participants will perform the first neuropsychological assessment remotely via video conferencing. After 15 days, the participants will repeat the same neuropsychological tests (second assessment) face to face. Finally, participants and caregivers will complete online the satisfaction questionnaire about remote administration.
62031637|NCT06078332||Face-to-face assessment first|Participants will perform the first neuropsychological assessment in presence in the hospital. After 15 days, the participants will repeat the same neuropsychological tests (second assessment) remotely via video conferencing. Finally, participants and caregivers will complete online the satisfaction questionnaire about remote administration .
62231420|NCT02405026||HIV infected non-asthmatic patients|HIV infected patients without asthma
62231421|NCT00597298|ACTIVE_COMPARATOR|1|inspiratory muscle training program using a pressure threshold device
62422986|NCT04253756|EXPERIMENTAL|20-gauge BD Nexiva Diffusics|Intervention
62231422|NCT00597298|SHAM_COMPARATOR|2|
62231423|NCT04923152|EXPERIMENTAL|moderate dose statin|Patients 1 month post PCI, allocated to 5 mg rosuvastatin per day
62231424|NCT04923152|ACTIVE_COMPARATOR|high dose statin|patients 1 month post PCI, allocated to 40 mg rosuvastatin
62231425|NCT02422056|PLACEBO_COMPARATOR|Placebo|Saline infusion: Group receiving saline as placebo during the surgical procedure
62231426|NCT02422056|EXPERIMENTAL|Intervention|Tranexamic acid infusion: Group that received a Tranexamic acid bolus of 10mg / kg, followed by continuous infusion of 1 mg / kg / hr until the end of the procedure.
62231427|NCT05690100|EXPERIMENTAL|Ozone Gel|Ozone is a potent oxidant with marked antimicrobial activity and the potential to act as a metabolic and host immune modulator.The routes of ozone administration are topical and regional for both gaseous and aqueous forms .Ozone gel is contains ozonated extra virgin olive oil and Arnica montana extract, containing essential fatty acids Ozone gel was claimed to have analgesic (Tasxdemir et al,2016) and anti-inflammatory effect its high content of essential fatty acids and the effect of ozone, natural extra virgin olive oil (I. Lezcano,et al.2000). Ozone gel has a beneficial role in wound healing, Its wound healing properties may be due to enhancing blood circulation and immune response.(M.colombo et,al 2019), Generic name : GeliO3 Dosage form : Gel Frequency/Duration : Once on this interval : 0,3,7,14
62231428|NCT05690100|EXPERIMENTAL|Hyaluronic Acid 0.2%|"HA was Known for hygroscopicity that allows it to maintain conformational stiffness and to retain water.(Yıldırım et al., 2017b) .Another major feature is viscoelasticity that provides stability and elasticity to tissues and delays penetration of viruses and bacteria (Finn, Schow and Schneiderman, 1992) .~In periodontology, HA has been advocated as monotherapy(Hammad et al., 2011) or as an adjunct to non-surgical and/or surgical (Fawzy El-Sayed et al., 2012) periodontal treatment to reduce inflammation and promote wound healing.~HA gel was used in two different concentrations 0.2% and 0.8% versus negative control in the management of post-operative pain after FGG surgery and it was found effective with more superior results for the 0.2% concentration (Yıldırım et al., 2017b).~Generic name : GingiGel Dosage form : Gel Frequency/Duration : Once on this interval : 0,3,7,14"
62422987|NCT05831267|EXPERIMENTAL|Study group 1|
62422988|NCT05831267|EXPERIMENTAL|Study group 2|
62422989|NCT05831267|OTHER|Control group|
62422990|NCT06036537||rheumatoid arthritis|
62422991|NCT06039878|EXPERIMENTAL|Mother-Infant Dyad|The researchers will enroll 120 infants and their mothers (120 dyads, 240 total participants). The researchers anticipate, based on prior experience and the slightly more restrictive inclusion and exclusion criteria in this study compared to our prior work, needing to screen about 600 mother-infant dyads to achieve the target sample size of 120. The researchers anticipate that the sample will be 63% non-Hispanic white, 13% non-Hispanic black, 4% non-Hispanic Asian, 12% non-Hispanic multiracial, and 8% Hispanic (any race). The researchers expect that 50% of the infants will be male and 50% female, and all of the biological mothers will be female sex. Infants will be 0.5-1.5 months at enrollment and the researchers estimate that mothers will be between 18.0 and 50.0 at enrollment (upper age limit is estimated due to menopause ).
62592357|NCT00624195|ACTIVE_COMPARATOR|non-CNS-targeted|"Subjects in the non-CNS-T (Comparison) arm will be randomized to receive a regimen (see list of FDA approved antiretrovirals listed below) designed to suppress plasma Viral Load, but not expected to have targeted CNS penetration.~Combinations of FDA approved antiretroviral agents: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
62592358|NCT05193916|EXPERIMENTAL|Chiglitazar low dose|3 tablets of drug and 1 tablet of placebo p.o. per day
62592359|NCT05193916|EXPERIMENTAL|Chiglitazar high dose|4 tablets p.o. per day
62592360|NCT05193916|PLACEBO_COMPARATOR|control group|4 placebo tablets p.o. per day
62231429|NCT02839642|ACTIVE_COMPARATOR|Rivastigmine|"Subject will receive a treatment of Rivastigmine twice daily during 24 weeks of treatment.~Study drug will be administered orally. Sufficient test drug will be dispensed to subjects or their caregivers at each study visit to allow twice daily dosing until the next scheduled study visit"
62231430|NCT02839642|PLACEBO_COMPARATOR|Placebo|Subject will receive a placebo twice daily during 24 weeks of treatment. Study drug will be administered orally. Sufficient test drug will be dispensed to subjects or their caregivers at each study visit to allow twice daily dosing until the next scheduled study visit
62231431|NCT05201014||1 year follow-up|patients who were treated in the year before and are now returning for their 1-year follow-up.
62231432|NCT05201014||Prior to anthracycline-based therapy|patients presenting before the start of anthracycline-based therapy, then to be followed thereafter for 1 year and thereby contributing to the pool of patients with 1-year post-anthracycline assessment.
62231433|NCT04502628|EXPERIMENTAL|HBOT group|Patients with hemorrhagic cystitis (HC) after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the HC diagnosis was determined. Then HBOT will be scheduled every day until symptoms of HC vanished.
62231434|NCT02086266|EXPERIMENTAL|PILATES|Weekly Pilates sessions, guided by a specialized physiotherapist. The duration of the treatment was 10 weeks, and each session lasted 45 to 50 minutes. All subjects received instruction to perform specific daily home exercises.
62231435|NCT02086266|ACTIVE_COMPARATOR|PFMT and AES|For also 10 weeks, the participants went trough anal electrical stimulation associated with Pelvic Floor Muscle Training, supervised by a specialized physiotherapist. All subjects received orientation to perform the same pelvic floor exercises at home.
62231436|NCT01074619|EXPERIMENTAL|1|Memantine
62231437|NCT01074619|PLACEBO_COMPARATOR|2|Placebo
62231438|NCT02660307|EXPERIMENTAL|PROGRESS group|this group received the intervention based in meditation in the first 8 weeks. They were instructed to practice at least 5 times a week for up to half an hour a day. During the second 8 week period this group were left to manage their practice on their own.
62231439|NCT02660307|OTHER|control group|this group received no intervention in the first 8 weeks. During the second 8 week period, this group received the same intervention based in meditation that received PROGRESS group.
62231440|NCT01832441|OTHER|Transfer of autologous MNC intrathecally|single arm Intra thecal transplantation of autologous MNC
62231441|NCT03005860|ACTIVE_COMPARATOR|Fluoromethyl hexafluoroisopropyl ether|In Sevoflurane group, anaesthesia will be induced with Thiopental 5 - 7mg/kg, fentanyl citrate 2mcg/kg and atracurium besylate 0.5mg /kg to facilitate LMA placement. Anaesthesia will be maintained with sevoflurane 2-2.2 % to maintain a target MAC value between 0.8 \& 1.0.
62231442|NCT03005860|EXPERIMENTAL|2,6 diisopropylphenol|In Propofol group, anesthesia will be will be induced with Propofol TCI \[target controlled infusion pump - Injectomat® TIVA Agilia (Fresenius Kabi)\] using Schneider model to achieve target site concentration of 4-6mcg/ml, fentanyl citrate 2mcg/kg and atracurium besylate 0.5mg /kg to facilitate LMA placement. Anaesthesia will be maintained with TCI propofol at 3 - 6 mcg/ml as effect site concentration to maintain BIS 40-60.
62231443|NCT03690648||Saliva collection|"* Clinical examination;~* Quality of life survey;~* Saliva collection for genetical analysis"
62231444|NCT03690648||Saliva and Blood collection|"* Clinical examination;~* Quality of life survey;~* Saliva and blood collection for genetical analysis"
62231445|NCT03740997|EXPERIMENTAL|Body Weight Group <=40 kg: OPTISON|"Participants with body weight greater than or equal to (\>=) 20 to less than or equal to (\<=) 28 kilograms (kg) received OPTISON 0.1 milliliter (mL; dose level 1) or 0.2 mL (dose level 2); and participants with body weight greater than (\>) 28 to \<=40 kg received OPTISON 0.2 mL (dose level 1) or 0.3 mL (dose level 2) intravenous (IV) injection, 10 minutes apart on Day 1. The maximum allowed cumulative dose for body weight \>=20 to \<=28 kg and \>28 to \<=40 kg was 1.0 mL and 1.5 mL per dose level, respectively.~The treated subjects received both dose levels. Per protocol, up to 3 injections per dose level were allowed for acquiring different imaging views. A maximum of 2 injections was recorded in the treated population."
62592361|NCT03527810|EXPERIMENTAL|Sleeve Gastrectomy With Interrogation of Hiatus|In those randomized to interrogation, the hiatus will be opened posteriorly during surgical procedure intervention with preservation of the phreno-esophageal ligament where possible, as per standard described techniques. Dissection into the mediastinum will be stopped if no hernia is seen or when appropriate intra-abdominal length of 2 cm of esophagus is created. Once opened, the Hiatal Surface Area will be measured, calculated and recorded and when possible, a photo taken of the area. Repair of the crura will then be performed around the sizing tube used to create the sleeve with enough space to allow a 5 mm instrument to be easily inserted. Permanent sutures will be placed posterior to the esophagus.
62031638|NCT03887468|ACTIVE_COMPARATOR|"EvoCit"|"Standardized hemodialysis treatments 3x4hours/week. Intervention: EvoCit procedure using a heparin-grafted AN69ST dialyzer in combination with a citric acid enriched dialysate without any systemic anticoagulation."
62031639|NCT03887468|ACTIVE_COMPARATOR|"EvoHep"|"Control: EvoHep procedure using a heparin-grafted AN69ST dialyzer in combination with a conventional bicarbonate-based dialysate and standardized systemic anticoagulation using unfractionated heparin."
62031640|NCT00317772|EXPERIMENTAL|Topotecan + Gefitinib|"Phase I: Topotecan: 2.0, 3.0, or 4.0 mg/m\^2 by vein Days 1, 8 and 15 of 28 day cycle.~Gefitinib: 250 mg by mouth daily.~Phase II: Topotecan starting dose: MTD from Phase I by vein Days 1, 8, and 15 of 28 day cycle.~Gefitinib: 250 by mouth daily for 28 Days."
62031641|NCT01535716|EXPERIMENTAL|ECOM group|50 Patients scheduled for elective coronary surgery with cardiopulmonary bypass
62031642|NCT01535716|ACTIVE_COMPARATOR|standard management group|50 Patients scheduled for elective coronary surgery with cardiopulmonary bypass
62031643|NCT02198027|EXPERIMENTAL|Bupivacaine infiltration|10 ml of 0.25 % Bupivacaine
62031644|NCT02198027|PLACEBO_COMPARATOR|Normal saline infiltration|10 ml of normal saline
62031645|NCT04367753||Fulfilled contract|The contract before the epiphysiodesis has been fulfilled with the wanted limb length at the final analysis
62031646|NCT04367753||Failed contract|The contract before the epiphysiodesis hasn't been fulfilled with the wanted limb length at the final analysis
62031647|NCT05966441|EXPERIMENTAL|Experimental group|Patients will receive their Paclitaxel-based chemotherapy along with Curcumin at a dose of oral 2g daily till the end of chemotherapy.
62031648|NCT05966441|PLACEBO_COMPARATOR|Control group|Patients will receive their Paclitaxel-based chemotherapy only
62031649|NCT01426191||xinzhijun|1.5-3.0g,iv,bid or tid for 5-12 days
62031650|NCT01672801|PLACEBO_COMPARATOR|Placebo|All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Placebo comparator subjects will receive 8 total doses of liquid placebo orally 4 times a day for 8 total doses in pre-filled liquid placebo containing syringes
62422992|NCT04926740|EXPERIMENTAL|Ringer's lactate|The intervention is administration of IV Ringer's lactate. Rate of study fluid will be at the treating physician's (both ED and inpatient, if consulted for admission) discretion. Apart from fluid administered, there will be no other changes to the patient's clinical care, and patients will receive standard DKA treatment which may include insulin, electrolyte replacement, and/or supportive management. Pharmacy-prepared kits of 8 x 1L bags of study fluid (in Self et al., a maximum of 7090mL was given8) will be kept in a secure space within the ED. Once packaged, IV bags are useable for 30 days before expiration. If a kit is opened but not used completely, individual 1L bags may be returned to the pharmacy to save on costs.
62031651|NCT01672801|ACTIVE_COMPARATOR|Nimodipine|All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Active comparator subjects will receive Nimodipine 30mg liquid orally 4 times a day for 8 total doses in pre-filled syringes
62031652|NCT05133596|EXPERIMENTAL|Study population|Adult subjects up to 55 years of age with persistent olfaction disorder after a symptomatic episode of COVID-19.
62031653|NCT04039672|EXPERIMENTAL|Biopsy|Skin biopsy before BRAFi/MEKi treatment
62031654|NCT03312556|PLACEBO_COMPARATOR|Placebo pill or patch or sham CPAP|Placebo pill or patch or sham CPAP
62031655|NCT03312556|ACTIVE_COMPARATOR|CPAP (continuous positive airway pressure)|Continuous positive airway pressure during the night
62031656|NCT00872144|ACTIVE_COMPARATOR|Sativex|
62031657|NCT03641482|ACTIVE_COMPARATOR|NBF|Propolis Extract, Ascorbic Acid, Tocopherol Acetate, Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethyleneglycol 150, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate and Deionized Water
62031658|NCT03641482|PLACEBO_COMPARATOR|Placebo|Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethyleneglycol 150, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate and Deionized Water
62031659|NCT05795725|EXPERIMENTAL|Colonoscopy|Fecal samples will be obtained from patients who are enrolled for colonoscopy procedures for the suspicion of colon cancer.
62031660|NCT05184725|NO_INTERVENTION|Control Group|Patients will follow the usual care procedures and after each procedure they answer questionnaires related to pain and stress levels (VAS), Anxiety and depression levels (HADS), health-related quality of life (HRQoL), mental wellbeing (SWEMWBS), self-efficacy (GSE) and Patient Activation status (PAM-13).
62231446|NCT03740997|EXPERIMENTAL|Body Weight Group >40 kg: OPTISON|"Participants with body weight \>40 kg received OPTISON 0.2 (dose level 1) or 0.4 mL (dose level 2) IV injection, 10 minutes apart on Day 1. The maximum allowed cumulative dose was 1.8 mL per dose level.~The treated subjects received both dose levels. Per protocol, up to 3 injections per dose level were allowed for acquiring different imaging views. A maximum of 2 injections was recorded in the treated population."
62231447|NCT00710281|OTHER|2D/3D Phase contrast MR|
62031661|NCT05184725|EXPERIMENTAL|SaMD CARINAE|Intervention group will be exposed to the use of SaMD CARINAE for 2 months approximately, a patientcentred digital health support program. The intervention trial will include a total of 4 visits: 1. Baseline (2-4 weeks before surgery); 2. Hospital admission (1-3 days before surgery); 3. Hospital discharge (1 week after the surgery approx.); 4. Post-operative day 14 (2 weeks after the surgery approx). After each visit and intervention trial with SaMD CARINAE the experimental group answer the same questionnaires of the control group, above mentioned Participants allocated to the intervention group will also be asked to complete questionnaires about usability, satisfaction and subjective experience.
62031662|NCT05549037|EXPERIMENTAL|Arm A: Morning group|All the patients in this arm will be treated with immunochemotherapy before 15:00.
62031663|NCT05549037|EXPERIMENTAL|Arm B: Afternoon group|All the patients in this arm will be treated with immunochemotherapy after 15:00.
62031664|NCT02325765||category of RACHS-2 for cardiac surgery|ASD \& VSD repair; VSD repair; Tetralogy repair; Tetralogy repair
62031665|NCT02325765||category of RACHS-3 for cardiac surgery|DORV repair with or without RV obstruction; AVSD (complete or transitional) repair with or without valve replacement; Coarctation \& VSD repair
62031666|NCT04779801|EXPERIMENTAL|ABFT|Adolescents and one or both parents will complete 16 weeks of Attachment-Based Family Therapy treatment.
62231448|NCT01266733|EXPERIMENTAL|Interdisciplinary treatment|
62231449|NCT01266733|NO_INTERVENTION|Usual treatment|
62231450|NCT02502097|EXPERIMENTAL|Gefapixant>Placebo Pre-Amendment 3|Gefapixant 50 mg twice daily (BID) for 10 days, then 150 mg BID for 4 days in Period 1, followed by a 14-21 day washout period, then placebo BID for 14 days in Period 2
62422993|NCT04926740|ACTIVE_COMPARATOR|Normal saline|The comparator is administration of IV normal saline. Rate of study fluid will be at the treating physician's (both ED and inpatient, if consulted for admission) discretion. Apart from fluid administered, there will be no other changes to the patient's clinical care, and patients will receive standard DKA treatment which may include insulin, electrolyte replacement, and/or supportive management. Pharmacy-prepared kits of 8 x 1L bags of study fluid (in Self et al., a maximum of 7090mL was given8) will be kept in a secure space within the ED. Once packaged, IV bags are useable for 30 days before expiration. If a kit is opened but not used completely, individual 1L bags may be returned to the pharmacy to save on costs.
62031667|NCT01206738|EXPERIMENTAL|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
62031668|NCT01206738|EXPERIMENTAL|Alternative intervention|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
62031669|NCT01206738|ACTIVE_COMPARATOR|General information|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
62031670|NCT04844164|EXPERIMENTAL|Cushing's Disease|
62031671|NCT04844164|EXPERIMENTAL|Acromegaly|
62031672|NCT04844164|EXPERIMENTAL|Diabetes Mellitus Type 1|
62031673|NCT04844164|EXPERIMENTAL|Primary Hyperparathyroidism|
62031674|NCT04844164|EXPERIMENTAL|Control group|
62031675|NCT03223363|EXPERIMENTAL|Development Group|Development Group is used to establish the prediction model.2D and 3D ultrasonography are performed in this group. Through statistical analysis we obtain a new model.
62031676|NCT03223363|OTHER|Validation group|Validation Group is used to confirm the efficacy of the prediction model.2D and 3D ultrasonography are performed in this group.Absolute and percentage error are calculated and compared with a common formula to confirm the accuracy of this new model.
62031677|NCT01060982|EXPERIMENTAL|HIFU treatment|
62031678|NCT00293735|ACTIVE_COMPARATOR|1. Labetolol|
62031679|NCT00293735|ACTIVE_COMPARATOR|2. Magnesium Sulfate|
62031680|NCT06537453|EXPERIMENTAL|Virtual Care|Participants will receive virtual care through Virtual Home Hospital programs in Alberta for their hospital to home transition of care.
62031681|NCT06537453|NO_INTERVENTION|Usual Care|Participants will be discharged as per usual care practices from hospital to their home.
62031682|NCT06102941|EXPERIMENTAL|Cognitive Training for Obsessive-Compulsive Disorder|This is an open-label, one-arm study. Children who meet DSM-V diagnostic criteria for OCD and have clinically significant obsessive-compulsive symptoms (CY-BOCS score\>16) will complete 4-weeks of at-home cognitive training.
62031683|NCT01846130|NO_INTERVENTION|Control|Control bed rest group
62031684|NCT01846130|EXPERIMENTAL|Leucine|Leucine will be administered in mixed meal 3 times a day at 0.06g/kg lean body mass/meal
62231451|NCT02502097|EXPERIMENTAL|Placebo>Gefapixant Pre-Amendment 3|Placebo BID for 14 days in Period 1, followed by a 14-21 day washout period, then gefapixant 50 mg BID for 10 days, then 150 mg for 4 days in Period 2
62231452|NCT02502097|EXPERIMENTAL|Gefapixant>Placebo Post-Amendment 3|Gefapixant 50 mg twice daily (BID) for 14 days in Period 1, followed by a 14-21 day washout period, then placebo BID for 14 days in Period 2
62231453|NCT02502097|EXPERIMENTAL|Placebo>Gefapixant Post-Amendment 3|Placebo BID for 14 days in Period 1, followed by a 14-21 day washout period, then gefapixant 50 mg BID for 14 days in Period 2
62231454|NCT01386060|EXPERIMENTAL|Mindfulness Meditation Training|Participants receive the 6-week meditation training intervention between the 1st and 2nd study visits.
62231455|NCT01386060|NO_INTERVENTION|Waitlist Control|Participants receive no intervention between the 1st and 2nd study visits. They receive the training between the 2nd and 3rd study visits only.
62422994|NCT03172104||Very preterm group|"Preterm infants \<30 weeks' GA at birth admitted to one of the neonatal nurseries at the Royal Women's Hospital in Melbourne, Australia.~Inclusion criteria: Infants admitted to the Royal Women's Hospital, Melbourne, Australia, neonatal nurseries, born \<30 weeks' GA. Exclusion criteria: (i) infants with congenital abnormalities known to affect neurodevelopment and (ii) infants with non-English speaking parents."
62807853|NCT05180695|EXPERIMENTAL|extension part : Soft-tissue sarcomas with MDM2 amplification|"The aim of each extension cohort is to provide preliminary evidence of anti-tumor activity while refining toxicity data, and to gain insight progressive disease activity and exploratory biological analyses. A maximum of 14 patients patients will be enrolled in this cohort  Soft-tissue sarcomas with MDM2 amplification . Both study drugs (pazopanib and HDM201) will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
62592362|NCT03527810|ACTIVE_COMPARATOR|Sleeve Gastrectomy Without Interrogation of Hiatus|In those randomized without interrogation, the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature. The procedure involves a longitudinal resection of the stomach starting from the antrum at the point 5-6 cm from the pylorus and finishing at the fundus close to the cardia.\[1\] The remaining gastric sleeve is calibrated with a bougie. Most surgeons prefer to use a bougie between 36-40 Fr with the procedure and the ideal approximate remaining size of the stomach after the procedure is about 150 mL.
62592363|NCT01842295|NO_INTERVENTION|Bariatric surgery|Obese men with associated co-morbidities selected for bariatric surgery by multidisciplinary team
62807854|NCT05180695|EXPERIMENTAL|extension part : Soft-tissue sarcomas with no MDM2 amplification|"A maximum of 14 patients patients will be enrolled in this cohort  Soft-tissue sarcomas with no MDM2 amplification. Both study drugs (pazopanib and HDM201) will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
62807855|NCT03416088|EXPERIMENTAL|Beverage consumption|Drink 300ml red wine (alcohol concentration:12.5%), 300ml coffee (caffeine concentration 72 mg), or 300ml water.
62807856|NCT03416088|EXPERIMENTAL|Daily reading|Reading paper books, playing video games with mobile phones, or non-reading.
62231456|NCT02853253|EXPERIMENTAL|SMOF|parenteral nutrition using SMOFlipid® (FreseniusKabi France, Sèvres, France)
62231457|NCT02853253|ACTIVE_COMPARATOR|Medialipide®|parenteral nutrition using Medialipide® 20% (B Braun Medical, Boulogne, France)
62231458|NCT00370409|EXPERIMENTAL|1|Cryotherapy
62807857|NCT03416088|EXPERIMENTAL|Body motion|Exercise and body postural changes.
62031685|NCT01846130|EXPERIMENTAL|Exercise|Daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate.
62031686|NCT01846130|EXPERIMENTAL|Leucine + Exercise|Leucine (0.06 g/kg lean body mass/meal, 3 meal/day) and exercise daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate.
62031687|NCT01846130|EXPERIMENTAL|Whey protein|22 g of whey isolate 3x a day (with meals)
62031688|NCT01846130|EXPERIMENTAL|Whey protein + exercise|22 g whey isolate 3x day (with meals) and daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate
62031689|NCT01846130|NO_INTERVENTION|Skewed|Protein intake is distributed similar to typical American diet with low protein intake at breakfast, intermediate at lunch and high at dinner.
62031690|NCT04247620|EXPERIMENTAL|DiaBetter Together Intervention|Young Adult participants with type 1 diabetes (ages 17-25) who are approaching transfer from pediatric to adult care will be randomized to either the DiaBetter Together Intervention group or the Usual Care group. After randomization to the intervention group, young adults will be assigned a Peer Mentor. Following an intervention manual, the Peer Mentor will teach behavioral strategies and offer support to the young adult. In both conditions, participation in this study will not impact participants' ability to contact the pediatric TCH diabetes care team or any other medical services to receive medical care.
62807858|NCT00068159||1|Untreated-NYHA Class I HH subjects without conventional therapy for HH
62807859|NCT00068159||2|Treated- NYHA Class I HH subjects with conventional phlebotomy and/or iron chelation therapy
62807860|NCT00068159||3|Age-gender matched healthy HH control volunteers
62807861|NCT02620969||Patients on haemodialysis|During a midweek session of a patient on haemodialysis, blood and dialysate sampling is performed at different time points.
62031691|NCT04247620|OTHER|Peer Mentors|Peer Mentors will deliver the DiaBetter Together intervention and will also be enrolled as study participants to permit assessment of their own outcomes from delivering this peer support intervention to younger people with diabetes. Peer Mentors will be experienced young adults with T1D who have transferred to adult diabetes care.
62231459|NCT00370409|PLACEBO_COMPARATOR|2|
62231460|NCT00760903||> 18 years moderate head trauma|Group I: (Pilot group): 5-10 patients \> 18 years old, gender and race indifferent with moderate head trauma.
62231461|NCT00760903||> 18, gender and race indifferent|Group II: 30 patients \> 18 years old, gender, and race indifferent with moderate head trauma
62231462|NCT00760903||Pediatric|Group III: 30 patients \< 18 years old, gender and race indifferent with moderate head trauma (pediatric patient group)
62231463|NCT00760903||Pre-evaluated|Group IV: 10-20 patients age, gender and race indifferent with moderate head trauma that have been examined with conventional MRI of the brain, MRS and DTI as clinically requested. The images of these patients will be evaluated retrospectively for data- point collection.
62422995|NCT03172104||Term control group|Inclusion criteria: Infants admitted to the Royal Women's Hospital Melbourne, Australia, born \>36 completed weeks' GA and weighing \>2500 g. Exclusion criteria: (i) infants with congenital abnormalities known to affect neurodevelopment (ii) infants requiring admission to neonatal intensive or special care nursery and (iii) infants with non-English speaking parents.
62422996|NCT04264988||Patients who had pelvic hemorrhage|Patients who had pelvic hemorrhage during complex abdomino-pelvic surgery
62422997|NCT01479556|PLACEBO_COMPARATOR|Placebo|Study subjects wil be randomized to the Placebo arm following a stratification procedure based on AIS scale (A-E), neurological level of injury (cervical or thoracic), and presence of at-level neuropathic pain before or after 3 months from the time of spinal cord injury.
62422998|NCT01479556|ACTIVE_COMPARATOR|Pregabalin|Study subjects wil be randomized to the Pregabalin arm following a stratification procedure based on AIS scale (A-E), neurological level of injury (cervical or thoracic), and presence of at-level neuropathic pain before or after 3 months from the time of spinal cord injury.
62422999|NCT06114017|EXPERIMENTAL|1: Social Media Abstention|People in this arm will be encouraged to disable social media and not use social media for one week.
62423000|NCT06114017|NO_INTERVENTION|2: Control|People in this group will continue their normal behavior in regard to social media use.
62423001|NCT00904189|NO_INTERVENTION|Standard of care radiation therapy|Standard of care given for treatment of cancer. Subjects receiving incidental radiation dose to fingernails.
62423002|NCT02955394|PLACEBO_COMPARATOR|Fulvestrant Without Enzalutamide|500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
62423003|NCT02955394|EXPERIMENTAL|Fulvestrant With Enzalutamide|500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC), plus160mg of Enzalutamide will be given daily.
62423004|NCT06155825|PLACEBO_COMPARATOR|Group 4 (placebo)|this group will be A control group receive no intervention.
62423005|NCT06155825|EXPERIMENTAL|group 1 (interventional group)|Intervention groups which will receive nonnutritive suckling.
62423006|NCT06155825|EXPERIMENTAL|group 2 (interventional group )|Group 2 will receive oral glucose 25%
62423007|NCT06155825|EXPERIMENTAL|Group 3 (interventional group)|Group 3 will undergo facilitated tuckling
62423008|NCT03717974|EXPERIMENTAL|telemedecine's follow-up|Telemedecine follow-up after an intervention at home of the mobile team
62423009|NCT03717974|ACTIVE_COMPARATOR|mobile team's follow-up|Mobile team follow-up after an intervention at home of the mobile team
62423010|NCT05886283|ACTIVE_COMPARATOR|ultrasound phaco groupe|this group had US PHACO using the phaco-chop technique (Stellaris PC: Bausch + Lomb®)
62423011|NCT05886283|ACTIVE_COMPARATOR|nanolaser phaco group|this group underwent an NL PHACO (Cetus A.R.C. Laser system®)
62807862|NCT01919944|EXPERIMENTAL|VLY-686 20 mg|Single dose, 20 mg VLY-686, administered as two 10 mg VLY-686 oral capsules
62807863|NCT01919944|EXPERIMENTAL|VLY-686 50 mg|Single dose, 50 mg VLY-686, administered as one 50 mg VLY-686 oral capsule and one placebo capsule mimicking the VLY-686 50 mg capsule
62807864|NCT01919944|EXPERIMENTAL|VLY-686 100 mg|Single dose, 100 mg VLY-686, administered as two 50 mg VLY-686 oral capsules
62807865|NCT01919944|PLACEBO_COMPARATOR|Placebo|Single dose, placebo, administered as either two 10 mg oral capsules or two 50 mg oral capsules
62231464|NCT00760903||Control Group|Group V (control group): 20 volunteers without prior history of traumatic brain injury or neurological problems.
62231465|NCT00388557|EXPERIMENTAL|1|
62231466|NCT04012229||Patients treated by chemotherapy for an early breast cancer|Patients (Women or Men) older than 18 years old, histologically confirmed invasive early breast cancer, treated by neo-adjuvant and/or adjuvant chemotherapy with the first cure of chemotherapy received between January 1st, 2003 and December 31th, 2013 were included.
62423012|NCT04219800|EXPERIMENTAL|mHealth|"1. Activity tracker armband (Garmin Vivofit); warns of prolonged sitting and counts daily steps.~2. SMS text messages; reminds of activity breaks.~3. Mobile video instruction for standing pause gymnastics."
62423013|NCT04219800|OTHER|Control|Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.
62423014|NCT00530439|EXPERIMENTAL|Lifestyle intervention|physical activity, dietetic counselling
62423015|NCT00530439|NO_INTERVENTION|Control|
62423016|NCT00869141|EXPERIMENTAL|Research arm (postop IOP>10)|Receive glaucoma medications if the eye pressure more than 10 mmHg after AHmed valve implantation
62423017|NCT00869141|ACTIVE_COMPARATOR|Standard of care arm (postop IOP>17)|Receive glaucoma medication if eye pressure more than 17 mmHg after Ahmed valve implantation
62423018|NCT06296459|ACTIVE_COMPARATOR|Low volume CBCT|Radiographic low volume cone beam computed tomography used to plan implant placement
62423019|NCT06296459|PLACEBO_COMPARATOR|Standard periapical radiographs|Standard radiography used to plan implant placement
62423020|NCT02681627|ACTIVE_COMPARATOR|endometrial scratch|Patient will be randomised to the intervention arm which is the luteal phase endometrial scratch
62423021|NCT02681627|SHAM_COMPARATOR|touching cervix|Patient will have a speculum examination and cleaning of the cervix with cotton tip with saline but no scratch
62423022|NCT06200688|EXPERIMENTAL|Peanut Ball Group|In this group, pregnant women changed positions with a peanut ball during labor.
62423023|NCT06200688|NO_INTERVENTION|Control Group|No intervention was applied in this group.
62592364|NCT06128252|EXPERIMENTAL|Taurine + Serplulimab + investigator's choice chemotherapy|Taurine + Serplulimab + XELOX or Taurine + Serplulimab + FLOT
62592365|NCT06128252|ACTIVE_COMPARATOR|Serplulimab + investigator's choice chemotherapy|Serplulimab + XELOX or Serplulimab + FLOT
62807866|NCT03790111|EXPERIMENTAL|Xermelo 250mg plus first line therapy for a week, then Xermelo 500mg|Xermelo 250 milligram (mg) plus first line therapy for a week, then Xermelo 500mg plus first line therapy for the duration of the study
62807867|NCT01216202||Preoperative RT|Men with rectal cancer treated with preoperative radiotherapy (RT) and surgery.
62807868|NCT01216202||No preoperative RT|Men with rectal cancer or prostate cancer treated with surgery alone (no RT).
62031692|NCT04247620|NO_INTERVENTION|Usual Care|Participants randomized to the comparison condition will receive usual diabetes care only, without additional intervention through the study. They will participate in all study activities related to data collection, but will not receive the Peer Mentor intervention. In both conditions, participation in this study will not impact participants' ability to contact the pediatric TCH diabetes care team or any other medical services to receive medical care.
62031693|NCT04247620|NO_INTERVENTION|Research Supplement|Following completion of 12-month data collection, a subset of participants from the Usual Care group will have the opportunity to complete an optional and additional week (7 days) of follow-up data collection to characterize general and diabetes-specific sleep patterns.
62031694|NCT05247151|ACTIVE_COMPARATOR|Oxytocin|The patients received either a spray of the synthetic oxytocin (24 I.U. Syntocinon®) with mindfulness-bases grow therapy (MBGT) as a positive social context in each condition. Due to an effect latency of 30-80 mins after intranasal administration of oxytocin on social behavior, the dose was administered 30 min before the 50-min session.
62031695|NCT05247151|PLACEBO_COMPARATOR|Placebo|The patients received either a spray of the synthetic placebo (24 I.U.) with mindfulness-bases grow therapy (MBGT) as a positive social context in each condition. Due to an effect latency of 30-80 mins after intranasal administration of oxytocin on social behavior, the dose was administered 30 min before the 50-min session.
62031696|NCT04916470|EXPERIMENTAL|Semaglutide 2.4 mg once weekly (OW)|Participants will receive semaglutide injections for 52 weeks.
62031697|NCT04916470|PLACEBO_COMPARATOR|Semaglutide placebo OW|Participants will receive semaglutide placebo injections for 52 weeks.
62031698|NCT05499923|ACTIVE_COMPARATOR|Wing method of debonding|In this method after removal of the orthodontic wire, each bracket would be gripped mesiodistally by a conventional bracket debonding plier at the level of wings and a squeezing force would be applied.
62031699|NCT05499923|ACTIVE_COMPARATOR|Base method of debonding|In this method after removal of the orthodontic wire, each bracket would be gripped mesiodistally by a conventional bracket debonding plier at the level of the bracket base and a squeezing force would be applied.
62031700|NCT03070613|EXPERIMENTAL|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda will be sprayed onto the colonic surface during colonoscopy or TEM surgery.
62031701|NCT01924650|EXPERIMENTAL|PH-797804 PARTICLE SIZE 9-11UM|
62423024|NCT05966259|OTHER|Intervention Group- Intensive Multilevel Intervention|Intervention Group: intensive multilevel intervention, with a minimum of 26 contact hours, for a period of 5 months. The children will be re-evaluated in the eighth month (three months after intervention) and in the eleventh month (six months after intervention). The monthly activities were composed of four weekly contacts: Individual Attendance, Food and Nutrition Education (at home), Group Food and Nutrition Education in the basic health unit and Telephone monitoring. There will be five monthly themes: food, physical activity, sedentary behavior, sleep, and mental health.
62423025|NCT05966259|OTHER|Control Group|The children in the Control Group were followed in a similar way, observing the activities so that they did not exceed 26 hours of contact, during the 5 months.
62423026|NCT00893230|EXPERIMENTAL|Lactobacillus sakei KCTC 10755BP|
62423027|NCT00893230|PLACEBO_COMPARATOR|microcrystalline cellulose|
62423028|NCT04819282||One group|Physical performance was evaluated with the Senior Fitness Test in one group of geriatric individuals.
62423029|NCT02977494|EXPERIMENTAL|Daratumumab Bortezomib|
62423030|NCT04048720|EXPERIMENTAL|Family Nurture Intervention (FNI)|FNI sessions will be held once a week in the afternoon for eight weeks. Participants will take part in FNI group therapy with their child alongside other mother-child pairs. One to two staff members will lead FNI sessions.
62423031|NCT02177773|EXPERIMENTAL|Ga-68 DOTA-TOC PET/CT|Patients receive Gallium Ga 68-DOTA-TOC IV over 1-2 minutes. Within 55-70 minutes, patients then undergo either a PET/CT scan lasting 30-40 minutes or a PET/MRI scan lasting 50 minutes.
62592366|NCT03693105|ACTIVE_COMPARATOR|SAINT stimulation|Active SAINT stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC)
62592367|NCT03693105|SHAM_COMPARATOR|Sham stimulation|Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC)
62592368|NCT03596281|EXPERIMENTAL|Cohort A|
62592369|NCT03596281|EXPERIMENTAL|Cohort B|
62592370|NCT04804670|EXPERIMENTAL|Sonic-Floss toothbrush and small brush head|sonic toothbrush used for 2 minutes and water flosser used for 1 minute
62592371|NCT04804670|EXPERIMENTAL|Sonic-Floss toothbrush and full size brush head|sonic toothbrush used for 2 minutes and water flosser used for 1 minute
62807869|NCT03630835|EXPERIMENTAL|99mTc-Annexin-V-128 uptake on scintigraphy|
62231467|NCT05869630|EXPERIMENTAL|Exercise Group|A total of 30 knee OA patients and 30 age/sex-matched healthy volunteers were included in the exercise and control groups. Exercises were performed twice a week under supervision and once a week as home program for eight weeks. Before and after exercise treatment, peripheral venous blood samples were taken from both groups. miRNA-146a, miRNA-155, miRNA-221-3p and miRNA-145 gene expressions were studied with the Real-time PCR method. miRNA-146a, miRNA-155, and miRNA-221-3p, miRNA-145 gene expressions were studied with the Real-time PCR method. The pain was evaluated with the Numeric Rating Scale (NRS), functional status with Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), depression level with the Beck Depression Inventory (BDI), and quality of life with Short Form-36 (SF-36).
62231468|NCT05997498|EXPERIMENTAL|dilation group|mechanical cervical dilatation will be done.
62231469|NCT05997498|NO_INTERVENTION|control|in which no mechanical cervical dilatation will be done.
62231470|NCT01259843||Acute Aortic Syndrome|Patients admitted to cardiology, radiology or surgery for a clinical picture suggestive of acute aortic syndrome whose diagnosis was subsequently confirmed in due course of hospitalization by further investigations.
62231471|NCT02004548|EXPERIMENTAL|Metatinib Tromethamine|"Dose escalation is in accordance with the traditional 3 +3 design, and dose groups are subsequently set as: 25, 50, 100, 200, 300, 450, 600, 800 mg/d."
62231472|NCT04248985||Pre-Intervention|Baseline measurement of timing and behavior in OOH cardiac arrest patients presenting with ongoing CPR.
62231473|NCT04248985||Post-Intervention|Timing and behavior in OOH cardiac arrest patents presenting with ongoing CPR
62807870|NCT01612975|PLACEBO_COMPARATOR|Placebo|This study arm will encompass the administration of a placebo (physically identical to Naproxen) orally to participants. Naproxen is a painkiller with intrinsic anti-inflammatory properties, while the placebo has no pharmacological properties associated with it. Participants will also be taking Pantoprazole to negate the gastrointestinal consequences of Naproxen (or the placebo). Participants will not know which arm of the study they belong to. In addition, they will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety.
62231474|NCT02170792|EXPERIMENTAL|BIBR 1048 MS with ranitidine|Low, medium or high dose in combination with ranitidine
62231475|NCT02170792|EXPERIMENTAL|BIBR 1048 MS without ranitidine|Low, medium or high dose
62231476|NCT02340767|NO_INTERVENTION|No Device Clinicians|The clinicians will not receive any additional training.
62231477|NCT02340767|EXPERIMENTAL|Spectra Device Clinicians|The clinicians in the Spectra Device Arm will be trained to the device according to the manufacturers' usual care for training. The training will consist of viewing the manufacturer's instructions for the device. Training will also consist of clinicians familiarizing themselves with the device through unsupervised clinical use with patients.
62423032|NCT05351073|EXPERIMENTAL|Normobaric Oxygen Inhalation Group|Participants in the intervention group will receive oxygen inhalation through a mask at a rate of 10 L/min at 1 absolute atmosphere pressure (1 ATA = 101.325 kPa) after randomization until adimisson to the hospital. Participants will subsequently receive standard diagnosis and treatment service according to the guidelines during hospitalization.
62423033|NCT05351073|NO_INTERVENTION|Control Group|Participants in the control group will not receive oxygen inhalation therapy during ambulance transportation. Participants will subsequently receive standard diagnosis and treatment service according to the guidelines during hospitalization.
62423034|NCT00386100|PLACEBO_COMPARATOR|Metformin|MET began at a total daily dose of 500 mg and could be increased up to a maximum dose of MET 2000 mg. The dose level was to be increased unless a tolerability issue existed at the current dose level.
62592372|NCT04804670|ACTIVE_COMPARATOR|Manual brushing and flossing|American Dental Association standard manual toothbrush used for 2 minutes and dental floss all teeth
62423035|NCT00386100|ACTIVE_COMPARATOR|Avandamet (Rosiglitazone maleate/metformin hydrochloride)|AVM began at a total daily dose of 4 mg/500 mg and could be increased up to a maximum dose of AVM 8 mg/2000 mg
62423036|NCT05227807|ACTIVE_COMPARATOR|Control group|the control group received routine care.
62423037|NCT05227807|EXPERIMENTAL|Intervention group|Intervention develop from the theoretical framework of social cognition theory
62592373|NCT02723903|OTHER|with CAD and somatic symptom|Patients with the coronary artery disease and with the somatization symptom, the investigators treat the patients according to the guideline for coronary artery disease and anti-somatic agents (Deanxit, Prozac according to the somatization type)
62592374|NCT02723903|OTHER|without CAD, with somatic symptom|Only somatic symptom is presented, anti-somatic agents is prescribed (Deanxit, Prozac according to the somatization type)
62592375|NCT02723903|NO_INTERVENTION|without CAD, without somatic symptom|Have neither coronary artery disease nor somatic symptom, continue follow-up.
62031702|NCT01924650|EXPERIMENTAL|PH-797804 PARTICLE SIZE 9-11UM WITH SLS|
62031703|NCT01924650|EXPERIMENTAL|PH-797804 PARTICLE SIZE <= 20UM|
62031704|NCT01924650|EXPERIMENTAL|PH-797804 PARTICLE SIZE <= 20UM WITH SLS|
62031705|NCT01924650|EXPERIMENTAL|PH-797804 PARTICLE SIZE <= 5UM|
62031706|NCT01924650|EXPERIMENTAL|PH-797804 PARTICLE SIZE <= 5UM WITH SLS|
62031707|NCT06495736|NO_INTERVENTION|Histology Paraffin dyeing|
62031708|NCT06495736|EXPERIMENTAL|ROSE technique|
62423038|NCT02959554|EXPERIMENTAL|Nivolumab (A)|Nivolumab: 240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
62423039|NCT02959554|ACTIVE_COMPARATOR|TKI (B)|Sunitinib: According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study) or Pazopanib: According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study)
62423040|NCT06528067|EXPERIMENTAL|Mindful Motivation Group|Participants will be assigned to a eating intervention that combines general mindfulness (via headspace) with motivational interviewing for mindful eating They will be asked to attend an online counseling session along with three 10-minute booster phone calls. They will be asked to engage with a digital-based mindful eating program once per week over the course of 8 weeks. In addition, participants will have access to optional educational materials on mindful eating and an optional online private support forum after the intervention period is finished.
62423041|NCT06528067|ACTIVE_COMPARATOR|Active Control Condition|Participants in the meditation intervention group will be assigned to a digitally-based meditation intervention (via Headspace) and asked to use this for at least 10 minutes a day over the course of 8 weeks.
62423042|NCT05155020|EXPERIMENTAL|AK120 regimen 1|
62423043|NCT05155020|EXPERIMENTAL|AK120 regimen 2|
62423044|NCT05155020|EXPERIMENTAL|AK120 regimen 3|
62423045|NCT05155020|PLACEBO_COMPARATOR|Placebo|
62423046|NCT06401642|EXPERIMENTAL|Zavegepant Treatment|Participants will receive zavegepant to treat up to 8 migraine attacks over 24 weeks.
62423047|NCT04759716|EXPERIMENTAL|Health Literacy-based Weight Control Intervention arm|intervention arm will receive weight control program
62423048|NCT04759716|NO_INTERVENTION|control arm|routine care
62423049|NCT03349437|EXPERIMENTAL|Vitabreath Device|The Philips Respironics investigational device VitaBreath is a handheld, battery powered, intermittent positive airway pressure device that is non-invasive, and provides positive airway pressure (PAP) of 18 cm water (H2O) during inspiration and 8 cm H2O on expiration, thus creating 10 cm H2O of pressure support. Pressure support is defined as the difference between inhalation pressure and exhalation pressure. The study device is intended as an adjunct therapy to relieve shortness of breath in COPD patients who experience exertion-related dyspnea to allow them to be more active. The air is delivered to the patient via a mouthpiece on the device.
62423050|NCT03349437|ACTIVE_COMPARATOR|Pursed Lip Breathing|Pursed lip breathing is a commonly used technique by COPD patients. That involves exhaling through tightly pressed lips and inhaling through the nose with the mouth closed.
62423051|NCT03160365|OTHER|ACQUISITION OF IMAGES|4 MRIs were performed at Day 0, day 1, day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
62423052|NCT03203005|EXPERIMENTAL|IMA970A plus CV8102 and Cyclophosphamide|Investigational treatment with IMA970A, CV8102, Cyclophosphamide
62423053|NCT06449209|EXPERIMENTAL|Cohort 1 Arm 1 - BNT327 DL1 + carboplatin + etoposide|Participants with ES-SCLC without prior systemic anticancer therapy received in the ES setting
62423054|NCT06449209|EXPERIMENTAL|Cohort 1 Arm 2 - BNT327 DL2 + carboplatin + etoposide|Participants with ES-SCLC without prior systemic anticancer therapy received in the ES setting
62031709|NCT06495736|NO_INTERVENTION|Cytological HE staining|
62031710|NCT06495736|NO_INTERVENTION|Cytological Pap staining|
62031711|NCT01842854||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
62031712|NCT02509533|EXPERIMENTAL|V.A.C.® Therapy|In this arm, investigators will use the V.A.C.® Therapy after a transplants of leg ulcers.
62031713|NCT02509533|ACTIVE_COMPARATOR|usual dressing method (compresses)|In this arm, investigators will use the usual dressing method after a transplants of leg ulcers.
62031714|NCT03975283|EXPERIMENTAL|Exparel (Liposomal Bupivicaine)|20 ml vial of liposomal bupivacaine containing 266 mg (maximum dose), will be diluted with 20 ml of 0.25% bupivacaine (containing 50 mg of bupivacaine) and 20 ml saline (60 ml total). That total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
62031715|NCT03975283|ACTIVE_COMPARATOR|0.25% Bupivicaine HCL|Two 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes and levels via laparoscopy. Medication will be given just below the last rib and extend to below the lowest incision.
62031716|NCT01592643|EXPERIMENTAL|Eye shield|Participants receive eye shield during PRK surgery
62031717|NCT00395876|PLACEBO_COMPARATOR|Placebo + Tenecteplase + Tenecteplase (PTT)|
62031718|NCT00395876|EXPERIMENTAL|Tenecteplase + Tenecteplase + Placebo (TTP)|
62423055|NCT06449209|EXPERIMENTAL|Cohort 2 Arm 1 - BNT327 DL1 + paclitaxel|Participants with SCLC who have disease progression/relapse
62423056|NCT06449209|EXPERIMENTAL|Cohort 2 Arm 2 - BNT327 DL2 + paclitaxel|Participants with SCLC who have disease progression/relapse
62423057|NCT06449209|EXPERIMENTAL|Cohort 3 Arm 1 - BNT327 DL1 + topotecan|Participants with SCLC who have disease progression/relapse
62807871|NCT01612975|EXPERIMENTAL|Naproxen|Intervention arm involves administering 500mg Naproxen twice a day to participants and 40mg of Pantoprazole once a day in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
62231478|NCT02340767|EXPERIMENTAL|DIAGNOdent Device Practitioners|The clinicians in the DIAGNOdent Device Arm will be trained to the device according to the manufacturers' usual care for training. The training will consist of viewing the manufacturer's instructions for the device. Training will also consist of clinicians familiarizing themselves with the device through unsupervised clinical use with patients.
62031719|NCT04423068|EXPERIMENTAL|Overall Study|
62423058|NCT06449209|EXPERIMENTAL|Cohort 3 Arm 2 - BNT327 DL2 + topotecan|Participants with SCLC who have disease progression/relapse
62423059|NCT01906034|EXPERIMENTAL|Exercise with supervision|The expert panel selected balance and strength / power exercises which can be performed with one's own bodyweight or with the help of small, low-cost exercise equipment (i.e., small weights, resistance bands, unstable surfaces). In this study, intensity during training will be regulated using the Borg Rating of Perceived Exertion scale (i.e., 6-20 points, maximal exertion at 20 points). According to the individual fitness level, exercises should be performed with a perceived exertion between 12 and 16 points (somewhat hard - hard) during balance and strength / power training. Exercise intensity will be progressed individually using the Borg Rating of Perceived Exertion scale and varying the balance and strength / power exercises in order to sufficiently stimulate the neuromuscular system. Strength / power exercises will be progressed from single to multiple joint, isometric to dynamic muscle contraction, short to long lever arm and slow to fast exercises.
62031720|NCT06219239|EXPERIMENTAL|KL003 cell injection Drug Product|Traditional myeloablative conditioning regimen consists of Busulfan, which may increase the risk of irreversible pulmonary fibrosis, VOD, and infertility due to potential serious toxicity. In this study, we intend to use genetic hematopoietic stem cells (lentivirus transduction) transfusion with no conditioning regimen, which could avoid toxicity due to chemotherapy drugs.
62031721|NCT02395120|ACTIVE_COMPARATOR|Standard letter|Modified standard letter will be sent to caregivers.
62031722|NCT02395120|EXPERIMENTAL|Intervention letter|The CSM-based referral letter alone will be sent to caregivers
62031723|NCT02395120|EXPERIMENTAL|Reduced intervention letter|"The reduced (removing text corresponding to timeline) CSM-based referral letter alone will be sent to caregivers."
62031724|NCT02395120|EXPERIMENTAL|Intervention letter+DIG|The CSM-based referral letter with the dental information guide will be sent to caregivers.
62031725|NCT02395120|EXPERIMENTAL|Reduced intervention letter+reduced DIG|The reduced CSM-based referral letter with the reduced dental information guide will be sent to caregivers.
62231479|NCT01029652|EXPERIMENTAL|Canakinumab 150 mg|"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive re-dose of study drug on demand upon occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after previous dose. Patients completing 12 weeks core study were allowed to continue treatment in another 12-week extension for any new gout flare on demand with same treatment as assigned in core study.~After completing the first extension, patients were offered to enter second extension study, whereby all patients were treated open-label on demand with canakinumab 150 mg sc upon new flare for 1 year for a total duration of 18 months following randomization in core study. Patients completing first 12 weeks extension study were allowed to continue to be treated in another single-arm, open-label 48 weeks extension when all patients from both treatment arms received canakinumab on demand"
62433559|NCT03769181|EXPERIMENTAL|Cohort A1: cHL: Isatuximab + Cemiplimab|Classic Hodgkin's lymphoma (cHL), anti-programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitor naïve participants received isatuximab 10 milligrams per kilogram (mg/kg), intravenous (IV) infusion once a week (QW) in Cycle 1 and then every 2 weeks (Q2W) from Cycle 2 to Cycle 6 (each cycle of 28 days), and then every 3 weeks (Q3W) from Cycle 7 to Cycle 30 (each cycle of 21 days) along with cemiplimab 250 milligrams (mg) Q2W, IV infusion from Cycle 1 to 6 and then 350 mg Q3W from Cycle 7 to Cycle 30, with optional radiotherapy until, unacceptable adverse events (AEs) or participant's decision to stop the treatment, or at least 96 weeks (at least 48 weeks from initial signal of complete response \[CR\], whichever was longer) of delivery of investigational medicinal product(s) without documented progressive disease (PD), or study cut-off date, whichever occurs first (maximum duration: up to 103 weeks).
62031726|NCT03910153|PLACEBO_COMPARATOR|Placebo - (Age 30-50 years)|
62031727|NCT03910153|EXPERIMENTAL|MSPrebiotic - (Age 30-50 years)|
62031728|NCT03910153|PLACEBO_COMPARATOR|Placebo - (Aged 70 years and above)|
62031729|NCT03910153|EXPERIMENTAL|MSPrebiotic - (Aged 70 years and above)|
62031730|NCT04288570|ACTIVE_COMPARATOR|Bone socket formation with a punch|suture anchor socket creation with punch
62592376|NCT02723903|OTHER|with CAD, without somatic symptom|Patient with the coronary artery disease, without the somatization symptom, the investigators treat the patients according to coronary artery disease treatment guideline including coronary artery stent implantation,medication according to the severity of stenosis of the coronary arteries.
62592377|NCT01892111|EXPERIMENTAL|structured exercise program (SET)|SET one month before and during ARTs. IVF/ICSI procedure.
62592378|NCT01892111|NO_INTERVENTION|no intervention|IVF/ICSI procedure.
62592379|NCT01259310||Women with epilepsy|Women with epilepsy, age 18-40 years, who express a desire to conceive and have stopped or plan to stop taking birth control.
62592380|NCT01259310||Women without epilepsy|Healthy women, age 18-40 years, who express a desire to conceive and have stopped or plan to stop taking birth control.
62592381|NCT06506318||Patients with ESBL(-) liver abscess|
62592382|NCT06506318||Patients with ESBL(+) liver abscess|
62592383|NCT06470035|EXPERIMENTAL|Active VeNS|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
62423060|NCT01906034|EXPERIMENTAL|Home-based without supervision|The expert panel selected balance and strength / power exercises which can be performed with one's own bodyweight or with the help of small, low-cost exercise equipment (i.e., small weights, resistance bands, unstable surfaces). In this study, intensity during training will be regulated using the Borg Rating of Perceived Exertion scale (i.e., 6-20 points, maximal exertion at 20 points). According to the individual fitness level, exercises should be performed with a perceived exertion between 12 and 16 points (somewhat hard - hard) during balance and strength / power training. Exercise intensity will be progressed individually using the Borg Rating of Perceived Exertion scale and varying the balance and strength / power exercises in order to sufficiently stimulate the neuromuscular system. Strength / power exercises will be progressed from single to multiple joint, isometric to dynamic muscle contraction, short to long lever arm and slow to fast exercises.
62423061|NCT01906034|NO_INTERVENTION|control group|The control group is a traditional waiting group and will receive a supervised training program after the completion of this study
62423062|NCT01297634|OTHER|Botulinum Toxin Type-A 1U|
62423063|NCT01297634|OTHER|Botulinum Toxin Type-A 2U|
62423064|NCT01297634|OTHER|Botulinum Toxin Type-A 3U|
62423065|NCT00246441|EXPERIMENTAL|Paroxetine|Active medication containing the drug Paroxetine
62423066|NCT00246441|PLACEBO_COMPARATOR|Placebo|A Placebo medication that appears just like the active medication but does not contain placebo
62423067|NCT02818179|OTHER|Patients undergoing radiation|In this study, patients undergoing radiation treatment will undergo thermography imaging during radiation treatment course. Patients will be evaluated with thermography imaging every week during the brachytherapy treatment for 5 procedures
62423068|NCT00637052|EXPERIMENTAL|ARRY-520|
62423069|NCT05517863|EXPERIMENTAL|laser sequential mode|All patients received 2 sessions of laser therapy / week with different wavelengths in sequential mode in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care
62423070|NCT05517863|EXPERIMENTAL|laser seperate mode|All patients received 2 sessions of laser therapy / week with different wavelengths in seperate mode in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care
62423071|NCT05517863|ACTIVE_COMPARATOR|traditional wound care|"(II) Traditional wound care inform of~1. Wound care treatment~   * Debridement to remove necrotic tissue~  * Irrigation of the wound by normal saline~  * Change dressing daily to protect wound from infection~2. Foot care~   * Wash feet daily, dry carefully especially between toe~  * Avoid extreme temperatures~  * Inspection daily of foot blisters~3. Foot wear~   * Avoid walking bare foot~  * Properly fitted shoes~  * Avoid wearing open-toed shoes"
62423072|NCT06257186|EXPERIMENTAL|Art Therapy|Women in the experimental group will be offered a series of three to five art therapy sessions, depending on the participants' needs/preferences. The art therapy sessions will be given anytime after consent has been obtained till approximately 36 weeks of gestation. The art therapy sessions are in addition to routine antenatal care.
62423073|NCT06257186|NO_INTERVENTION|Routine Antenatal Care|Women in the control group will receive routine antenatal care.
62423074|NCT01831518|EXPERIMENTAL|CRT Eligible|ACC/AHA/HRS/ESC guidelines for device-based therapy
62592384|NCT06470035|SHAM_COMPARATOR|Sham VeNS|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
62592385|NCT02752165|EXPERIMENTAL|TEAM-ED Intervention Group|Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting
62592386|NCT02752165|ACTIVE_COMPARATOR|Enhanced Usual Care|Report of symptoms to primary care physician
62592387|NCT00283855|NO_INTERVENTION|Control Group|No intervention
62592388|NCT00283855|ACTIVE_COMPARATOR|Online Self-Management|RAHelp.org
62592389|NCT02019147||Term Hypoxic Ischaemic Encephalopathy|Term Hypoxic Ischaemic Encephalopathy (HIE)
62592390|NCT02019147||Healthy Term Neonates|Controls
62592391|NCT03179553||HIE|Babies admitted to the neonatal unit with suspected mild, moderate or severe hypoxic ischaemic encephalopathy .
62592392|NCT03179553||Healthy|Babies who are inpatients in the postnatal ward, born following uncomplicated pregnancy and delivery.
62807872|NCT04835844||Mapping with CARTO|CARTO (Biosense Webster) in conjunction with CONFIDENSE mapping module and PENTARRAY catheter
62807873|NCT04835844||Mapping with RHYTHMIA|RHYTHMIA (Boston Scientific) in conjunction with the 64-electrodes ORION mini-basket catheter.
62807874|NCT01091064|EXPERIMENTAL|Early depart|Patients who will be liberated at triage with mild acute viral bronchiolitis
62807875|NCT01091064|NO_INTERVENTION|Medical visit group|Patients with acute viral bronchiolitis who will wait to be seen by the physician
62807876|NCT03170726|ACTIVE_COMPARATOR|arveles|Ibuprofen 800 mg in normal saline 150 cc and dexketoprofen (50 mg) before operation will be given in 30 minutes
62031731|NCT04288570|ACTIVE_COMPARATOR|Bone socket formation with a drill|suture anchor socket creation with drill
62031732|NCT03174223||Deep neuromuscular block|patients received a continuous rocuronium dose to maintain a depth of neuromuscular block of 1-2 twitches post tetanic count
62031733|NCT03174223||moderate neuromuscular block|patients received neuromuscular block aimed at \> 0 twitches train of four
62423075|NCT04604496|EXPERIMENTAL|PF-06882961 participants without Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 milligrams (mg) on Day 1
62423076|NCT04604496|EXPERIMENTAL|PF-06882961 participants with mild Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
62423077|NCT04604496|EXPERIMENTAL|PF-06882961 participants with moderate Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
62423078|NCT04604496|EXPERIMENTAL|PF-06882961 participants with severe Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
62592393|NCT03932175|EXPERIMENTAL|Intervention group|The multicomponent intervention will comprise three aspects on-top of usual care: i) Motivational interview to assess patient's adherence profile and to raise the compromise with the behaviour change towards NIV, physical activity and nutritional habits; ii) Bi-directional interaction between the study participants and clinical staff delivered by the MyPathway app, where specific clinical problems regarding NIV will be addressed as they arise; and iii) Motivational messages and educational material delivered via the MyPathway app regarding changes in physical activity and/or nutritional habits. As part of the behavioural intervention, goal setting for NIV adherence and life-style changes will be introduced to the MyPathway app in order for the participants to follow the advice.
62592394|NCT03932175|NO_INTERVENTION|Control group|Patients will receive usual care according to guidelines on management of chronically ventilated patients, without any mHealth tool or behavioural intervention
62592395|NCT05322135|EXPERIMENTAL|PET scan|PET scans: an 11C-Glutamine PET scan and an 18F-FSPG PET scan. A small tube (called an IV) will be placed in a vein in your arm through which you will receive the radioactive material for the PET scan(s).
62592396|NCT04736927|EXPERIMENTAL|GLPG3667 + Midazolam|
62592397|NCT06550011|EXPERIMENTAL|Dose level 1|Low Dose
62592398|NCT06550011|EXPERIMENTAL|Dose level 2|Medium Dose
62592399|NCT06550011|EXPERIMENTAL|Dose level 3|High Dose
62031734|NCT05854472|EXPERIMENTAL|Use of smartphone application|A smartphone application content will be developed to facilitate the use of immunosuppressive drugs by individuals with liver transplantation and to provide guidance to patients. The effect of smartphone application usage on immunosuppressive drug compliance, anxiety and quality of life in liver transplant patients will be evaluated.
62592400|NCT05036668|EXPERIMENTAL|ABO809|Participants will receive ABO809 at a single oral dose of 1x10\^4 oocysts. Other doses such as 1x10\^6 oocysts may be considered to optimize the model
62031735|NCT05854472|NO_INTERVENTION|not use a smart phone application|In this group, patients who have liver transplantation and do not use a smart phone application for liver transplantation patients after discharge will be included.
62031736|NCT01182220||Ultrasound L5/S1 catheter placement|Pt will have back scanned with Ultrasound and L5/S1 interspace localized for epidural placement.
62031737|NCT01182220||Control Group|Patients will have catheter placed after clinically evaluating the back as is done routinely resulting in mid lumbar catheter placement in general.
62423079|NCT04210700|ACTIVE_COMPARATOR|Fascia iliaca compartment block|Participants will receive fascia iliaca compartment block before spinal anesthesia and operation
62423080|NCT04210700|EXPERIMENTAL|Pericapsular nerve group block group|Participants will receive pericapsular nerve group block before spinal anesthesia and operation
62423081|NCT06249269||RASTA AF Cohort|Patients who meet the inclusion criteria for RASTA-AF, and do not meet any of the exclusion criteria but decline or are not approached for participation in the RCT will be asked to participate.
62423082|NCT01370434|NO_INTERVENTION|VAD combination|"* vincristine 0.4mg iv on D1-4~* doxorubicin 9mg/m2 iv on D1-4~* dexamethasone 40mg/d po on D1-4,9-12,17-20~* Many physicians use vincristine, doxorubicin, and dexamethasone (VAD) for three to four months as induction therapy (Alexandrian et al, 1990). VAD produces partial response (PR) in about 50% patients, with complete response (CR) observed in 5%-10% patients (Kyle et al, 2004)."
62423083|NCT01206946|EXPERIMENTAL|Antenatal steroids|
62423084|NCT01206946|PLACEBO_COMPARATOR|Normal saline|
62423085|NCT05335473|EXPERIMENTAL|Eribulin plus Tucidinostat|phase 1b： 3+3 trial design will be used for Tucidinostat dose escalation cohorts phase 2: Eribulin+Tucidinostat
62423086|NCT04294641|EXPERIMENTAL|Intervention|Determine response rate via continuous daily dose by mouth to determine efficacy
62592401|NCT01354665||Group 1|
62031738|NCT04723875|EXPERIMENTAL|Adjuvant chemotherapy group|"Participant will receive 3 cycles of adjuvant chemotherapy if having any of the following factors；participant will receive 6 cycles of adjuvant chemotherapy if having ≥2 of the following factors.~Risk factors: (1) Deep cervical invasion（≥ 2/3）；（2）Differentiation grade 2-3；（3）Lymphatic vascular space infiltration；（4）Adenocarcinoma or adenosquamous carcinoma；（5）Tumor size ≥ 2cm"
62031739|NCT04723875|NO_INTERVENTION|Control group|The participants receive no intervention.
62031740|NCT05660746|ACTIVE_COMPARATOR|Conventional dosing|Induction Phase: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance Phase : 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.
62031741|NCT05660746|EXPERIMENTAL|Precision dosing|Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool.
62031742|NCT06670820|ACTIVE_COMPARATOR|Active iTBS for Patients With MCI or AD|The patient will receive one daily rTMS session for 10 days of iTBS, delivered through an H-coil applied to the left dorsolateral prefrontal cortex. The TBS frequency parameters consist of 3-pulse 50-Hz bursts every 200 ms at 5 Hz, and the intensity will be set at 80% of the active motor threshold (AMT). A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times.
62031743|NCT06670820|SHAM_COMPARATOR|Sham iTBS for Patients With MCI or AD|Sham stimulation will be delivered 10 sessions.
62031744|NCT03034148|OTHER|Coronary artery disease|blood sampling for biomarkers assessment in a population undergoing coronary angiogram
62031745|NCT01579708|EXPERIMENTAL|Program SI! educational intervention|
62231480|NCT01029652|ACTIVE_COMPARATOR|Triamcinolone acetonide 40 mg|"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.~Patients under this arm who agreed to continue to 2nd extension period of 12 months, were switched to canakinumab 150 mg sc for any new gout flare during this period Triamcinolone acetonide was not to be administered in the 48-week session."
62031746|NCT01579708|NO_INTERVENTION|Control|
62031747|NCT04295564|EXPERIMENTAL|eCPAP|Participants will remain on CPAP for 2 additional weeks once CPAP stability criteria is met.
62031748|NCT04295564|NO_INTERVENTION|dCPAP|Participants will discontinue CPAP as per usual care once CPAP stability criteria is met.
62031749|NCT02827877|EXPERIMENTAL|Treatment (trastuzumab, copper Cu 64-DOTA-trastuzumab PET)|Patients receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV on day 0. Patients undergo PET scans at 18-24 and 42-48 hours, on day 1 and day 2. Within 4 days after completion of PET scans, patients receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks and pertuzumab IV over 30-60 minutes. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after 6 cycles of trastuzumab and pertuzumab.
62031750|NCT05290558|PLACEBO_COMPARATOR|Placebo|Patients in this arm will be given a placebo pill that resembles the actual Bu Shen Yi Jing Pill.
62031751|NCT05290558|ACTIVE_COMPARATOR|Bu Shen Yi Jing Pill|Patients in this arm will be given the BSYJ Pill.
62231481|NCT00573885|EXPERIMENTAL|Arm I|Patients receive oral defined green tea catechin extract twice daily for 6 months.
62031752|NCT03704376|ACTIVE_COMPARATOR|Femoral Nerve Blockade|Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation.
62592402|NCT03721692|EXPERIMENTAL|RIC group|The patients will accept cardio-cerebrovascular disease secondary prevention treatment and use RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
62592403|NCT03721692|NO_INTERVENTION|non-RIC group|The patients will only accept cardio-cerebrovascular disease secondary prevention treatment.
62031753|NCT03704376|ACTIVE_COMPARATOR|Adductor Canal Blockade|Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ).
62031754|NCT06669832||Cancer surviviors|Cancer Survivors who are on a scheduled therapeutic break or having completed cancer treatments,
62031755|NCT05484674|EXPERIMENTAL|One axilla will be treated with deroofing surgery and laser|One axilla will be randomly selected for treatment with deroofing surgery and laser while the other axilla will serve as a control with no treatment for each participant
62031756|NCT05294068||All subjects with cognitive impairments|
62031757|NCT05294068||All subjects with neuromotor impairments|
62031758|NCT05294068||All subjects with sensory impairments|
62031759|NCT03497325|EXPERIMENTAL|PRP|55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision
62031760|NCT03497325|PLACEBO_COMPARATOR|placebo|55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
62031761|NCT03463902|EXPERIMENTAL|left IFG anodal|2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
62231482|NCT00573885|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo twice daily for 6 months.
62592404|NCT03330262|EXPERIMENTAL|BALCAP prosthesis, then Control|Participants performed exercises daily at home wearing the BALCAP prosthesis for 6 weeks. After 6 weeks, participants performed the control condition (the same exercises without the BALCAP). Tests were performed before and after each 6-week period. Exercises included: (1) standing on a firm surface with feet apart, eyes open and closed; (2) standing on a firm surface with feet together, eyes open and closed; (3) standing on thick footing (e.g., multiple pairs of socks) with feet apart, eyes open and closed; (4) standing on thick footing with feet together, eyes open and closed; (5) standing in a modified Romberg position on a firm surface, eyes open and closed; (6) standing in a Romberg position on a firm surface, eyes open and closed; (7) walking on a firm surface eyes open; (8) walking with thick footing, eyes open; (9) walking with head turns and tilts, eyes open; and (10) walking around a room, with turns and movements other than straight forward walking, eyes open.
62807877|NCT03170726|ACTIVE_COMPARATOR|intrafen|intrafen 800 mg in normal saline 150 cc before operation will be given in 30 minutes
62807878|NCT03170726|PLACEBO_COMPARATOR|plasebos|150 cc normal saline will be given in 30 minutes during preoperative period
62807879|NCT02085759||Normal BMI|Subjects with a BMI range of 18.5 to 24.9 which is defined by the CDC as within normal range.
62031762|NCT03463902|ACTIVE_COMPARATOR|left IFG cathodal|2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
62231483|NCT05880550|EXPERIMENTAL|study group|
62231484|NCT05880550|ACTIVE_COMPARATOR|control group|
62231485|NCT03252171|EXPERIMENTAL|Experimental: CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen by infusion.
62231486|NCT03252171|NO_INTERVENTION|No Intervention|
62807880|NCT02085759||Overweight BMI|Subjects with a BMI of 25.0 to 29.9 are defined by the CDC as being overweight.
62807881|NCT02085759||Obese BMI|Subjects with a BMI of 30.0 and above are defined by the CDC as being obese.
62807882|NCT03783507|EXPERIMENTAL|Order 1|Meal 1, Meal 2, Meal 3, Meal 4
62807883|NCT03783507|EXPERIMENTAL|Order 2|Meal 2, Meal 3, Meal 4, Meal 1
62807884|NCT03783507|EXPERIMENTAL|Order 3|Meal 3, Meal 4, Meal 1, Meal 2
62807885|NCT03783507|EXPERIMENTAL|Order 4|Meal 4, Meal 1, Meal 2, Meal 3
62807886|NCT00248495|EXPERIMENTAL|Neoadjuvant chemotherapy|Patients receive pemetrexed disodium IV over 10 minutes followed by cisplatin IV over approximately 1 hour on day 1. Treatment repeats every 21 days for 3 courses
62807887|NCT06052228||Assessment Group|Evaluation forms will be applied to the participant who meets the inclusion criteria by face-to-face interview method. The sociodemographic information of the participants and the time taken to answer the questions in the questionnaires will vary according to each participants but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1-week intervals.
62807888|NCT04781335|ACTIVE_COMPARATOR|Dexycu|
62807889|NCT04781335|ACTIVE_COMPARATOR|Standard Care Post operative drops|
62807890|NCT04692623|EXPERIMENTAL|Moxfloxacin Group|In this arm 30 healthy volunteers were selected and they were given Moxifloxacin drug.
62807891|NCT04692623|EXPERIMENTAL|Gemifloxacin Group|In this arm 30 healthy volunteers were selected and they were given Gemifloxacin
62807892|NCT03998540||Patients with myopathy suspected of titinopathy|Patients with myopathy in which one or more potentially pathogenic TTN variants have been previously identified (index cases and related cases affected). Muscle biopsy performed previously
62592405|NCT03330262|EXPERIMENTAL|Control, then BALCAP prosthesis|Participants performed exercises daily at home for 6 weeks without wearing the BALCAP prosthesis (control), followed by another 6 weeks of the same exercises with the BALCAP prosthesis (intervention). Tests were performed before and after each 6 week period. Exercises included: (1) standing on a firm surface with feet apart, eyes open and closed; (2) standing on a firm surface with feet together, eyes open and closed; (3) standing on thick footing (e.g., multiple pairs of socks) with feet apart, eyes open and closed; (4) standing on thick footing with feet together, eyes open and closed; (5) standing in a modified Romberg position on a firm surface, eyes open and closed; (6) standing in a Romberg position on a firm surface, eyes open and closed; (7) walking on a firm surface eyes open; (8) walking with thick footing, eyes open; (9) walking with head turns and tilts, eyes open; and (10) walking around a room, with turns and movements other than straight forward walking, eyes open.
62592406|NCT06021938|ACTIVE_COMPARATOR|Patients starting with RVI|"Patients will begin by wear a virtual reality headset (GAMIDA®) and headphones (Bose®). A tablet (Samsung®) equipped with Healthy Mind software will allow patients to live a 360° visual and auditory 3D experience via Bluetooth connection. After that patients will be handed a smartphone with the Spotify® application to listen to music. Patients will wear headphones."
62592407|NCT06021938|ACTIVE_COMPARATOR|Patients starting with music therapy|"Patients will begin by handed a smartphone with the Spotify® application to listen to music. Patients will wear headphones. After that patients will wear a virtual reality headset (GAMIDA®) and headphones (Bose®). A tablet (Samsung®) equipped with Healthy Mind software will allow patients to live a 360° visual and auditory 3D experience via Bluetooth connection."
62031763|NCT03463902|ACTIVE_COMPARATOR|left IPL anodal|2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
62031764|NCT03463902|ACTIVE_COMPARATOR|left IPL cathodal|2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
62031765|NCT03463902|PLACEBO_COMPARATOR|Placebo|anodal electrode over left IFG, cathodal electrode over right IFG, stimulation only during 30 sec ramp at beginning and end of 10 min
62807893|NCT01419795|EXPERIMENTAL|Arm I (lenalidomide, rituximab)|Patients who have relapsed/progressed within 180 days post-transplant (Cohort 1), beyond day 180 post-transplant (Cohort 2), or within 6 months but were not started within 3 months of relapse, receive lenalidomide PO QD on days 1-28 (patients with CLL/SLL/PLL) or days 1-21 (patients with NHL). Patients in Cohorts 1 and 2 also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and then every two months for courses 3, 5, 7, 9, and 11.
62231487|NCT05724823|EXPERIMENTAL|10-week group|Will receive a 10-week seated exercise program, occurring 3 times per week. Sessions will be 60 minutes in duration.
62031766|NCT04728295|EXPERIMENTAL|Exablate Pallidothalamic Tractotomy|Exablate treatment for Advanced Idiopathic Parkinson's Disease
62031767|NCT02637297|EXPERIMENTAL|Group I (immediate intervention group)|Participants undergo hypnotherapy session over 20-30 minutes using a standardized script for pain reduction that contains post-hypnotic suggestions for permanence of hypnotherapy benefits. The hypnotherapy session is recorded and the participant listens to the recording daily for 4 weeks.
62031768|NCT02637297|ACTIVE_COMPARATOR|Group II (wait-list control group)|At week 5, participants undergo hypnotherapy session over 20-30 minutes using a standardized script for pain reduction that contains post-hypnotic suggestions for permanence of hypnotherapy benefits. The hypnotherapy session is recorded and the participant listens to the recording daily for 4 weeks.
62031769|NCT03310151|EXPERIMENTAL|Intervention|Group follows usual care plus imagined movements in a home exercise plan. The exercises will be taught to the subject by reading through an exercise booklet with them, this ensures the advice is standardised. The imagined movement programme will consist of imagined wrist movement in all planes. The frequency of approximately 10-15 minutes, four times a day has been selected as a practical compromise of previous investigations, (Moseley, 2004 and Frenkel et al., 2014), and mirrors routine advice.
62031770|NCT03310151|NO_INTERVENTION|control|Follows usual care
62231488|NCT05724823|NO_INTERVENTION|Delayed 2-week group (Boot Camp)|The Boot Camp group will complete a 2-week seated exercise program following the 10-week active trial period.
62231489|NCT01708993|ACTIVE_COMPARATOR|Arm A: Pemetrexed and Reolysin (and safety run-in)|
62231490|NCT01708993|ACTIVE_COMPARATOR|Arm B: Pemetrexed|
62807894|NCT01419795|ACTIVE_COMPARATOR|Arm II (lenalidomide)|Patients who have relapsed/progressed at any time point post-transplant and who have contraindications, prior severe hypersensitivity reaction to rituximab infusion, to receive rituximab or have CD20 negative disease (Cohort 3) receive lenalidomide as in Arm I.
62231491|NCT01708993|ACTIVE_COMPARATOR|Arm C: Docetaxel and Reolysin (and safety run-in)|
62231492|NCT01708993|ACTIVE_COMPARATOR|Arm D: Docetaxel|
62807895|NCT03571230|EXPERIMENTAL|Antimicrobial susceptibility testing guided therapy|"Patients in this group will receive a 10-day triple therapy for the Helicobacter pylori eradication. The regimen contains one proton pump inhibitor and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 10d 2.two sensitive antibiotics: amoxicillin 1000mg bid for 10d, clarithromycin 500mg bid for 10d, metronidazole 500mg tid for 10d, tinidazole 500mg tid for 10d, levofloxacin 500mg qd for 10d, furazolidone 100mg bid for 10d, tetracycline 750mg bid for 10d."
62807896|NCT03571230|EXPERIMENTAL|Empirical tailored therapy|"Patients in this group will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and clarithromycin 500mg bid for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
62807897|NCT03571230|OTHER|Salvage therapy for negative culture|"When the culture results are negative, patients will receive 14-day empirical tailored therapy based on personal medication history.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and clarithromycin 500mg bid for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
62031771|NCT04989348|PLACEBO_COMPARATOR|Antagonist group|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
62031772|NCT04989348|ACTIVE_COMPARATOR|PPOS group|"Women will receive oral medroxyprogesterone 10 mg daily or Duphaston 10mg bd from Day 3 till the day of ovulation trigger.~Gonadotrophin (human menopausal gonadotrophin or recombinant FSH) injections will be started. Ovarian response will be monitored by transvaginal scanning with or without serum hormonal level. Human chorionic gonadotrophin (hCG 1,000 IU) and GnRH agonist (decepepty 0.2mg) will be given for triggering of final maturation when at least 3 follicles reach \>17mm in diameter. Blood will be checked for serum estradiol and progesterone levels. Transvaginal USS-guided oocyte retrieval will be performed 36 hours after the trigger."
62031773|NCT00690703|EXPERIMENTAL|1|Treatment
62031774|NCT00991354|EXPERIMENTAL|Group 1|Participants will receive 3 mg of PENNVAX-B vaccine or placebo at Months 0, 1, and 3.
62807898|NCT03571230|OTHER|Salvage therapy for failed eradication|"If patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics for rescue therapy: tetracycline 750mg bid and furazolidone 100mg bid for 14d."
62423087|NCT06249217|EXPERIMENTAL|Experimental|At Week 0, participants will provide a comprehensive assessment of sleep environment and sleep hygiene practices and participants will be given a Fitbit watch to wear for the duration of the study. At Week 2, participants will receive information about the benefits of good sleep, feedback about their sleep environment and sleep hygiene practices based on the assessment data to implement at home, and sleep environment modification items based on participant-identified areas of need (e.g., a fan, sound machine, bedding). At Week 4, families in the intervention group will provide post-intervention assessment data and feedback on the intervention.
62031775|NCT00991354|EXPERIMENTAL|Group 2|Participants will receive 3 mg of PENNVAX-B vaccine and 1 mg of IL-12 vaccine or placebo at Months 0, 1, and 3.
62031776|NCT00991354|EXPERIMENTAL|Group 3|Participants will receive 3 mg of PENNVAX-B vaccine and 1 mg of IL-12 vaccine or placebo at Months 0, 1, and 3.
62031777|NCT04866316||GSH Participants|"Qualitative - Semi-structured focus group discussions with care recipients~Quantitative - Pre-test post-test design using survey-based data collection~Quantitative - Retrospective cohort design with propensity score matched comparators"
62031778|NCT04866316||Policy owners, implementers & care partners, health and social care professionals|"Qualitative - Semi-structured in-depth interview with key policy and programme decision-makers~Qualitative - Semi-structured focus group discussions with health and social care professionals~Qualitative - Participant observations~Quantitative - Longitudinal monitoring of process indicators"
62231493|NCT02425930||C3 Depletion|Patients with persistent low-level of complement C3 within the perioperative period would be assigned into this main observational group. After a careful multidisciplinary treatment (MDT) discussion, a radical operation with gastrectomy plus D2 lymphadenectomy would be performed, followed by an adjuvant chemotherapy if required. Generally, SOX chemo regimen (S-1+Oxaliplatin) would be first considered for the candidates.
62031779|NCT01507870|ACTIVE_COMPARATOR|prophylactic onlay mesh|
62231494|NCT02425930||Non-C3 depletion|Patients with normal plasma values of complement C3 within the perioperative period would be assigned into this control group. Those patients would undergo the same decision making process to determine the final treatment plan.
62231495|NCT06327750|ACTIVE_COMPARATOR|Hemodialysis (DNa=PNa)|High-flux hemodialysis with expected diffusive zero sodium balance (DNa=PNa)
62231496|NCT06327750|ACTIVE_COMPARATOR|Hemodialysis (DNa<PNa)|High-flux hemodialysis with expected diffusive sodium efflux (DNa\<PNa, difference: 3 mmol/L)
62231497|NCT06327750|ACTIVE_COMPARATOR|Hemodialysis after isolated ultrafiltration (DNa=PNa)|High-flux hemodialysis after isolated ultrafiltration with expected zero sodium balance (DNa=PNa)
62231498|NCT06327750|ACTIVE_COMPARATOR|High volume hemodiafiltration (DNa=PNa)|High volume hemodiafiltration with expected diffusive zero sodium balance (DNa=PNa)
62031780|NCT01507870|NO_INTERVENTION|continuous running suture|continuous running suture of the linea alba
62031781|NCT04390438|EXPERIMENTAL|High-Intensity short time percutaneous electrolysis|Application of a 0,66uA galvanic current in the active TrP through a needle during 10 seconds. During the 20 seconds left necessary to blind the patient and the examiner, the needle was inside but with no electrical current
62031782|NCT04390438|EXPERIMENTAL|Low-Intensity long time percutaneous electrolysis|Application of a 0,22uA galvanic current in the active TrP through a needle during 30 seconds
62031783|NCT04390438|ACTIVE_COMPARATOR|Dry needling|One acupuncture needle was placed in the active TrP to produce a local twitch response during 30 seconds
62031784|NCT06038565|EXPERIMENTAL|"Randomization to CPAP with higher change of impedance as measured by EIT. Arm A-1"|"After comparing change of impedance as measured by electrical impedance tomography while supported on RAM cannula ventilator CPAP versus occlusive interface bubble CPAP, the participants in this arm are placed on the CPAP that had a greater change of impedance (or less pressure rate product as measured by the esophageal balloon manometry if the change of impedance between the two CPAP modalities are clinically similar).~In this Arm A-1, these subjects had higher change in impedance while supported on RAM cannula ventilator CPAP"
62031785|NCT06038565|EXPERIMENTAL|"Randomization to CPAP with higher change of impedance as measured by EIT. Arm A-2"|"After comparing change of impedance as measured by electrical impedance tomography while supported on RAM cannula ventilator CPAP versus occlusive interface bubble CPAP, the participants in this arm are placed on the CPAP that had a greater change of impedance (or less pressure rate product as measured by the esophageal balloon manometry if the change of impedance between the two CPAP modalities are clinically similar).~In this Arm A-2, these subjects had higher change in impedance while supported on occlusive mask bubble CPAP"
62031786|NCT06038565|ACTIVE_COMPARATOR|"Randomization to standard of care - a 'one size fits all' approach. Arm B-1"|"Currently, the approach to which CPAP modality is chosen for these newborns is defaulted to the preferred CPAP of the Neonatal Intensive Care Unit (NICU) where the newborn is hospitalized.~In this Arm B-1, these subjects are randomized 1:1 to RAM cannula ventilator CPAP"
62031787|NCT06038565|ACTIVE_COMPARATOR|"Randomization to standard of care - a 'one size fits all' approach. Arm B-2"|"Currently, the approach to which CPAP modality is chosen for these newborns is defaulted to the preferred CPAP of the NICU where the newborn is hospitalized.~In this Arm B-2, these subjects are randomized 1:1 to occlusive mask bubble CPAP"
62031788|NCT06647095||Healthy controls|
62031789|NCT06647095||MASH|
62031790|NCT06647095||Steatosis|
62423088|NCT06249217|NO_INTERVENTION|Waitlist control|The waitlist control group will not receive the sleep intervention at Week 2 but families in the waitlist-control group can elect to receive the intervention if they choose to after Week 4.
62031791|NCT05149274|ACTIVE_COMPARATOR|Part1|DWP14012 Tablet A : single/multiple dose, 1 group, 2 period study
62031792|NCT05149274|ACTIVE_COMPARATOR|Part2|DWP14012 Tablet A 4T vs DWP14012 Tablet B 1T
62031793|NCT06669429|EXPERIMENTAL|Cohort 1: Part A1-RS-C1001 tablet dose 1|
62231499|NCT06327750|ACTIVE_COMPARATOR|High volume hemodiafiltration (DNa<PNa)|High volume hemodiafiltration with expected diffusive sodium efflux (DNa\<PNa, difference: 3 mmol/L)
62231500|NCT00256451|EXPERIMENTAL|ALC and NAL|alcohol and active naltrexone
62231501|NCT00256451|ACTIVE_COMPARATOR|Sham ALC and NAL|"sham alcohol and active naltrexone"
62231502|NCT00256451|PLACEBO_COMPARATOR|placebo pill and ALC|placebo naltrexone and alcohol
62231503|NCT00256451|PLACEBO_COMPARATOR|placebo pill and Sham ALC|placebo naltrexone and placebo (non-alcoholic) alcohol
62231504|NCT04656925|EXPERIMENTAL|Contingency management A-B-A|All participants will be assigned a single arm where we will utilize an A-B-A, or return to baseline design where all participants will experience the intervention in between two baseline observation periods.
62423089|NCT06030479|EXPERIMENTAL|Topical Adrenaline Group|Topical adrenaline group
62423090|NCT06030479|PLACEBO_COMPARATOR|Warm saline Group|Warm saline Group
62423091|NCT04514146||Water-only Fasting Group|Overweight and obese, non-diabetic participants undergoing elective water-only fasting treatment
62423092|NCT03564535|EXPERIMENTAL|SELF FIXATING GROUP|Monofilament polyester mesh with polylactic acid (PLA) microgrips of size 11\*15 will be used. It is an isoelastic large-pore knitted fabric with a density of 73g/m2 at implantation and 38g/m2 after microgrips absorption which will be at 18 months. The resorbable micro grips provide immediate adherence to surrounding muscle and adipose tissue during the initial days post hernia surgery, serving as an alternate method of fixation to traditional sutures, tacks, staples, or fibrin sealants. No additional tacks, staples, sutures, or fibrin sealant will be used.
62423093|NCT03564535|ACTIVE_COMPARATOR|TACKER FIXATION GROUP|Patients will be undergoing mesh ﬁxation with non-absorbable tacks. The tacks would be used such that they avoid bony prominences and vascular and neural structures. One or two tacks will be put at the Cooper's ligament and another applied laterally superior to the iliopubic tract in the anterior abdominal wall. In any patient, the maximum number of tacks applied will not exceed three.
62031794|NCT06669429|EXPERIMENTAL|Cohort 2: Part A1-RS-C1001 tablet dose 2/placebo tablet|
62031795|NCT06669429|EXPERIMENTAL|Cohort 3: Part A1-RS-C1001 tablet dose 3/placebo tablet|
62031796|NCT06669429|EXPERIMENTAL|Cohort 4: Part A1-RS-C1001 tablet dose 4/placebo tablet|
62031797|NCT06669429|EXPERIMENTAL|Cohort 5: Part A1-RS-C1001 tablet dose 5/placebo tablet|
62031798|NCT06669429|EXPERIMENTAL|Cohort 6: Part A1-RS-C1001 tablet dose 6/placebo tablet|
62031799|NCT06669429|EXPERIMENTAL|Cohort 7: Part A1-RS-C1001 tablet dose 6/placebo tablet|
62031800|NCT06669429|EXPERIMENTAL|Cohort 8: Part A1-RS-C1001 tablet dose 8/placebo tablet|
62031801|NCT06669429|EXPERIMENTAL|Cohort 9: Part A1-RS-C1001 tablet dose 9/placebo tablet|
62031802|NCT06669429|EXPERIMENTAL|Cohort 10: Part A1-RS-C1001 tablet dose 10/placebo tablet|
62031803|NCT04363801|EXPERIMENTAL|Part A First Line Treatment|Part A patients will receive IV DKN-01 (300 mg) on Days 1 and 15, IV tislelizumab (200 mg) on Day 1, IV oxaliplatin (130 mg/m2) on Day 1, and oral capecitabine (1000 mg/m2 twice daily \[BID\]) on Days 1-15 of each 21-day cycle. Part A is restricted to patients who have not had prior systemic therapy for locally advanced or metastatic disease. Patients may have received prior neoadjuvant or adjuvant therapy as long as it was completed without disease recurrence for at least 6 months.
62031804|NCT04363801|EXPERIMENTAL|Part B1 Second Line Treatment|"Part B patients will receive IV DKN-01 (300 mg) on Days 1 and 15 and IV tislelizumab (200 mg) on Day 1 of each 21-day cycle.~Patients enrolled in Part B are required to have DKK1-high (H-score ≥ 35) G/GEJ adenocarcinoma (pre-screen biopsy) and must have had only 1 prior systemic therapy for locally advanced/metastatic disease (platinum + fluoropyrimidine-based therapy; ±HER2 therapy if applicable). Patients may have received prior neoadjuvant or adjuvant therapy."
62231505|NCT03616041||Colon capsule endoscopy|Participant who meet the eligible criteria undergo an evaluation for severe hematochezia with a second-generation colon capsule endoscopy system in addition to standard diagnostic tests including tagged RBC scan, and/or computerized tomographic angiography (CTA), and/or conventional angiography.
62231506|NCT05755360||Participants with T2D|Participants will be treated with commercially available oral semaglutide according to routine clinical practice at the discretion of the treating physician.
62231507|NCT06450678||Adult patients with mechanical ventilation|Adult patients admitted to intensive care with mechanical ventilation for more than 48 hours
62031805|NCT04363801|EXPERIMENTAL|Part B2 Second Line Treatment|"Part B patients will receive IV DKN-01 (600 mg) on Days 1 and 15 and IV tislelizumab (200 mg) on Day 1 of each 21-day cycle.~Patients enrolled in Part B are required to have DKK1-high (H-score ≥ 35) G/GEJ adenocarcinoma (pre-screen biopsy) and must have had only 1 prior systemic therapy for locally advanced/metastatic disease (platinum + fluoropyrimidine-based therapy; ±HER2 therapy if applicable). Patients may have received prior neoadjuvant or adjuvant therapy."
62231508|NCT04740554||Duchenne Muscular Dystrophy group with Deflazacort|Individuals Duchenne Muscular Dystrophy, with age 11 to 18 years which make use of deflazacort.
62231509|NCT04740554||Duchenne Muscular Dystrophy group with Prednisone/Predisolone|Individuals Duchenne Muscular Dystrophy, with age 11 to 18 years which make use of Prednisone/Predinisolone.
62231510|NCT04740554||Duchenne Muscular Dystrophy group without Corticosteroids therapy|Individuals Duchenne Muscular Dystrophy, with age 11 to 18 years which don't use of corticosteroids.
62423094|NCT05235737|ACTIVE_COMPARATOR|Treatment arm 1|n=12 evaluable patients - neoadjuvant Pembrolizumab (2 doses, 200mg each) plus adjuvant Pembrolizumab (16 cycles q3w, 200mg each) on top of standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 of body surface area (BSA) daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 for 5 days in each 28-day cycle)
62031806|NCT04363801|ACTIVE_COMPARATOR|Part C Control First Line Treatment|Part C control patients will receive only tislelizumab in combination with chemotherapy regimen (CAPOX or mFOLFOX6). Part C is restricted to patients who have not had prior systemic therapy for locally advanced or metastatic disease. Patients may have received prior neoadjuvant or adjuvant therapy as long as it was completed without disease recurrence for at least 6 months.
62031807|NCT04363801|EXPERIMENTAL|Part C Experimental First Line Treatment|Part C experimental patients will receive DKN-01 in combination with tislelizumab and chemotherapy regimen (CAPOX or mFOLFOX6). Part C is restricted to patients who have not had prior systemic therapy for locally advanced or metastatic disease. Patients may have received prior neoadjuvant or adjuvant therapy as long as it was completed without disease recurrence for at least 6 months.
62031808|NCT02041195|ACTIVE_COMPARATOR|Setmelanotide Once Daily|Once daily in the morning, equivalent placebo in evening.
62231511|NCT04740554||Control Group Typically Developing|Individuals with typical development age 11 to 18 years which don't use of corticosteroids.
62231512|NCT00862355|EXPERIMENTAL|1|SPARC147609
62423095|NCT05235737|ACTIVE_COMPARATOR|Treatment arm 2|n=12 evaluable patients - neoadjuvant Pembrolizumab (2 doses, 200mg each) on top of standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 BSA daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 for 5 days in each 28-day cycle)
62592408|NCT00908791|EXPERIMENTAL|CLA|open-label, single-institution proof of principle study of oral CLA in patients with newly diagnosed adenocarcinoma of the breast.
62231513|NCT00862355|ACTIVE_COMPARATOR|2|Reference147609
62231514|NCT06110325|EXPERIMENTAL|Cawthorne and Cooksey exercise program|The exercise program will span one month and will center on the Cawthorne and Cooksey exercises targeting the vestibular system. Each session will be conducted individually and last for twenty minutes. The program will take place three times a week, with the initial session held in person and the subsequent two via video assistance from their homes
62231515|NCT06110325|ACTIVE_COMPARATOR|Control group|Information/Education on Fall Prevention and Promoting an Active, Healthy Lifestyle through Informational Leaflets.
62231516|NCT03203720|NO_INTERVENTION|Standard Care (SC)|Standard Care (SC) in a specialty mood disorders clinic for youth with mood disorders.
62231517|NCT03203720|EXPERIMENTAL|SC + Brief Motivational Intervention|Standard Care (SC) in a specialty mood disorders clinic plus a Brief Motivational Intervention (BMI) targeting medication adherence.
62231518|NCT00711893||ICD and CRT-D|Patients indicated for an implantable defibrillator or cardiac resynchronization defibrillator
62231519|NCT01041352|ACTIVE_COMPARATOR|Endotracheal group|airway management: endotracheal tube
62231520|NCT01041352|ACTIVE_COMPARATOR|laryngeal mask group|airway management: laryngeal mask
62231521|NCT03929315||Non-spaced learning|Learning/testing sessions will take place within 30 minutes of one another
62231522|NCT03929315||Spaced learning|Learning/testing sessions will take place 1 week after one another
62807899|NCT03658005||Study cohort|"Adult (\>18 years, \<90 years) patients admitted and treated for acute myocardial infarction, and whose treatment includes ticagrelor in association with aspirin.~Blood samples will be taken at 3 timepoints between two doses of ticagrelor (taken at 12 hours interval)."
62231523|NCT06023082|EXPERIMENTAL|Colon Broom Premium supplement|"Participants will add 1 scoop (0.23 oz/ 6.47 g) to 12-14 fl oz of water, mix well and drink immediately. Participants will take the supplement 30 -60 minutes before their meal and will then drink an additional glass of water. Participants will be instructed not to take the supplement less than 2 hours before bedtime. The test product may be consumed before breakfast, lunch, or dinner.~First week: Start with 1 serving per day Rest of the study period: Increase to 2 servings per day at 2 different times during the day."
62231524|NCT03417336|EXPERIMENTAL|brachytherapy + External radiotherapy|Prostate booster, HDR brachytherapy with 15Gy in 1 fraction + external radiotherapy 25Gy in 5 fractions
62231525|NCT03417336|ACTIVE_COMPARATOR|External radiotherapy|Exclusive external radiotherapy. 25Gy in 5 fractions + a 40Gy prostate boost in stereotaxic conditions.
62231526|NCT02414737|EXPERIMENTAL|corifollitrophin alfa|corifollitrophin alfa used as COH stimulant in IVF
62231527|NCT01211522|EXPERIMENTAL|Haloperidol|Haloperidol
62807900|NCT03383861||SSRI long-term user|Adults, 655 with an SSRI prescription ≥180 days and identified in the National Health and Nutrition Examination Survey (NHANES) data.
62231528|NCT01211522|EXPERIMENTAL|Ziprasidone|Ziprasidone
62231529|NCT01211522|PLACEBO_COMPARATOR|Placebo|Placebo
62231530|NCT04065178||Level of Activity|Level of activity for all patients admitting to the inpatient neurological rehabilitation unit.
62231531|NCT02024763|EXPERIMENTAL|Educational Intervention|Intervention was applied to classroom teachers by the RRIDA Project team. Training lasted six weeks, 12 hours devoted to physical activity and 18 hours to nutritional content. Modules of educational activities were taught in order to be replicated at PE classes to 1st and 2nd grades' children of three exposed schools. Physical activity module was based on a theoretical approach of physical activity benefits and risks for health, children's physical fitness and activity patterns, physical education and change behavior models. In each meeting the PE professionals, performed PE classes with the classroom teachers as students, focusing in strategies to keep them in movement for the most of PE class time to stimulate students' joint participation instead of individual participation or games.
62231532|NCT02024763|NO_INTERVENTION|No Intervention|No educational intervention was taken place in the control schools while the project was running. Afterwards, control schools received training.
62231533|NCT02852473|EXPERIMENTAL|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure (CPAP) will be administered using FDA-approved equipment.
62231534|NCT01173198|ACTIVE_COMPARATOR|WAVEFRONT GUIDED LASIK|
62231535|NCT01173198|ACTIVE_COMPARATOR|WAVEFRONT OPTIMIZED|
62231536|NCT05854550|EXPERIMENTAL|Apreo Implant Group|This group will undergo up to 2 procedures and will receive up to 3 implants during in each lung.
62231537|NCT04355910|EXPERIMENTAL|Intermittent fasting mimic-diet (IFD)|Restrict 75% energy on two non-consecutive days each week.
62231538|NCT04355910|ACTIVE_COMPARATOR|Continuous calorie restriction (CCR)|A daily 25% energy-restricted Mediterranean-type diet
62231539|NCT04355910|NO_INTERVENTION|Control|No advice to restrict energy
62231540|NCT05477459|EXPERIMENTAL|Verum|Lysergic diethylamide tartrate (equivalent to 25 microgram LSD base), one dose every 3 days for 3 weeks (totalling 7 vials)
62423096|NCT05235737|NO_INTERVENTION|Treatment arm 3|n=12 evaluable patients - standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 BSA daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 for 5 days in each 28-day cycle)
62807901|NCT03383861||Non-user|Adults, 12,372 non-users, were identified in the National Health and Nutrition Examination Survey (NHANES) data.
62231541|NCT05477459|PLACEBO_COMPARATOR|Placebo|Placebo vial looking like verum vial, one vial every 3 days for 3 weeks (totalling 7 vials)
62231542|NCT03015818|EXPERIMENTAL|18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT|
62231543|NCT06062732|EXPERIMENTAL|Intervention|Face It programme, including pre-programme one-to-one and group sessions, 5-day intensive programme, and post-programme one-to-one and group sessions
62231544|NCT06062732|ACTIVE_COMPARATOR|Control|Services as usual
62231545|NCT02686060|EXPERIMENTAL|in-line filters|0.2 micron positively charged PALL Corporation filters for parenteral nutrition (Posidyne® NEO Intravenous Filter Set) and 1.2 micro IV in-line filters used for lipid administration (Lipipor™ NEO Filters for Neonatal Parenteral Nutrition)
62231546|NCT02686060|NO_INTERVENTION|without in-line filters.|
62231547|NCT05225350|NO_INTERVENTION|Controls|In the first arm the patients received care consistent with regional guidelines. Treatment as usual.
62231548|NCT05225350|EXPERIMENTAL|Dietary Intervention|In the second arm the patients received care consistent with regional guidelines in combination with the intensive dietary intervention for three months
62231549|NCT02946970|PLACEBO_COMPARATOR|Control|Intragastric infusion
62807902|NCT03564288|EXPERIMENTAL|Dose Escalation Cohort|To identify the recommended phase 2 dose (RP2D) of SKI-G-801 in patients with relapsed or refractory AML (Acute Myeloid Leukemia)
62231550|NCT02946970|EXPERIMENTAL|Quinine hydrochloride|Intragastric infusion
62231551|NCT01810120|EXPERIMENTAL|TCR alfa beta depleted graft, infusion|The leukapheresis product will undergo TCR alfa beta negative selection following the standardized protocol.
62031809|NCT02041195|ACTIVE_COMPARATOR|Setmelanotide Split Dose|Split dose, one half in the morning and one half in the evening.
62231552|NCT01932554|EXPERIMENTAL|Abciximab|"Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission.~Patients will receive standard supportive care, including intravenous hydration, supplemental oxygen, incentive spirometry, ibuprofen, and parenteral narcotic pain medications (morphine, hydromorphone or fentanyl)"
62231553|NCT01932554|PLACEBO_COMPARATOR|Placebo|"Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission.~Patients will receive standard supportive care, including intravenous hydration, supplemental oxygen, incentive spirometry, ibuprofen, and parenteral narcotic pain medications (morphine, hydromorphone or fentanyl)"
62231554|NCT04654065|EXPERIMENTAL|IN-C004|IN-C004
62231555|NCT01115790|EXPERIMENTAL|Prexasertib|
62231556|NCT02411500|EXPERIMENTAL|Formulation A|
62231557|NCT02411500|EXPERIMENTAL|Formulation B|
62231558|NCT02411500|EXPERIMENTAL|Formulation C|
62231559|NCT02411500|EXPERIMENTAL|Formulation D|
62231560|NCT02411500|EXPERIMENTAL|Formulation E|
62423097|NCT00118222|ACTIVE_COMPARATOR|Low light dose during surgery|Arm I: During surgery, patients receive low light dose photodynamic therapy.
62423098|NCT00118222|ACTIVE_COMPARATOR|High light dose during surgery|Arm II: During surgery, patients receive high light dose photodynamic therapy.
62031810|NCT02041195|PLACEBO_COMPARATOR|Placebo|Placebo in the morning, placebo in the evening.
62231561|NCT02411500|EXPERIMENTAL|Formulation F|
62231562|NCT04705636|EXPERIMENTAL|Connected device|Connected device for three months period to support children care
62231563|NCT01690611|EXPERIMENTAL|Walking & Visual Feedback|Individuals in this arm will walk on a treadmill while viewing real time visual feedback regarding their body motions and use the visual feedback to correct their body motions.
62231564|NCT01690611|ACTIVE_COMPARATOR|Walking & No Visual Feedback|Individuals in this arm will walk on a treadmill without viewing real time visual feedback regarding their body motion.
62231565|NCT02916680|EXPERIMENTAL|Pancreatic islet transplantation|Pancreatic islet transplantation in the anterior chamber of the human eye
62031811|NCT03455972|EXPERIMENTAL|anti-CD19 and anti-BCMA CAR|Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the anti-CD19 CAR T cells (on d0) and anti-BCMA CAR T cells as split-dose (40% on d1 and 60% on d2)
62031812|NCT03936686|ACTIVE_COMPARATOR|Children in grades 4 or 5|This group was comprised of participants that were in grades 4 or 5 in school.
62231566|NCT03448133|EXPERIMENTAL|rTMS treatment group|The participants will be devided into rTMS treatment and sham treatment by means of randomized methods.The protocol of treatment is to use rTMS with high frequency 10/20Hz 120%RMT 20 times for one month. The device is Magtism rTMS made in London, UK
62231567|NCT03448133|SHAM_COMPARATOR|sham treatment group|The control group is to receive sham treatment. The device is the same as the one used in the real treatment group.
62031813|NCT03936686|ACTIVE_COMPARATOR|Adolescents in grades 10 or 11|This group was comprised of participants that were in grades 10 or 11 in school.
62231568|NCT03610165|PLACEBO_COMPARATOR|Arterial line - Control|Arterial line waveform and pressure
62231569|NCT03610165|EXPERIMENTAL|Acumen HPI-enabled EV1000 screen|Arterial line waveform and pressure + HPI alert from EV1000 monitor
62592409|NCT02538289|OTHER|Patients admitted before talks|Patients admitted to Cardiology or Respiratory Medicine Departments before the interventional teaching talks.
62031814|NCT03936686|ACTIVE_COMPARATOR|College Age Participants|This group was comprised of participants that were sophomores or juniors in college/university that were non-health career majors.
62031815|NCT03936686|ACTIVE_COMPARATOR|Cardiac Rehab Adults|This group was comprised of participants that were adults over the age of 40 that had completed a phase II cardiac rehabilitation program.
62031816|NCT03936686|ACTIVE_COMPARATOR|General Adults|This group was comprised of participants that were adults over the age of 40 that had never attended an outpatient cardiac rehabilitation program before.
62031817|NCT01349569|EXPERIMENTAL|Myeloma Vaccine, Prevnar, & Lenalidomide|Lenalidomide will be continued on the same dose as was being administered prior to the study. The allogeneic myeloma vaccine and Prevnar-13 vaccine will be given on four days over the course of the study.
62031818|NCT03131518|OTHER|E-bicycle|Access to an e-bicycle will be provided.
62031819|NCT03131518|OTHER|Longtail bicycle|Access to a longtail bicycle will be provided.
62231570|NCT02539537|ACTIVE_COMPARATOR|Arm A: Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 30 minutes on D1 of each week for the 4 weeks of the first cycle (1 cycle = 4 weeks). For the following five cycles, gemcitabine infusion on D1, D8, and D15 of each cycle, followed by 1 week without injection (i.e. in total 4 cycles over 24 weeks; with 19 administrations of Gemcitabine).
62423099|NCT00294632|EXPERIMENTAL|Lenalidomide + Rituximab|Lenalidomide Starting Dose 10 mg oral daily on Days 1-21 + Rituximab 375 mg/m\^2 intravenous weekly for 4 weeks
62423100|NCT02454322||Magnesium|Hypertensive Disorder of Pregnancy (gestational hypertension or preeclampsia) Treated with Magnesium Sulfate
62423101|NCT02454322||No Magnesium|Hypertensive Disorder of Pregnancy (gestational hypertension or preeclampsia) Not Treated with Magnesium Sulfate
62231571|NCT02539537|EXPERIMENTAL|Arm B: Folfirinox|"Administered once every 14 days for 24 weeks (12 cycles). A cycle equals 14 days with injection on D1 of each cycle. Treatment starts with oxaliplatin (85 mg/m²) administration; IV infusion over 2 hours, followed by the simultaneous administration (using a Y-tubing) of folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours and irinotecan 180 mg/m² IV infusion over 90 minutes. The irinotecan will begin 30 minutes after the start of the folinic acid infusion.~5-Fluoro-uracil (5-FU) IV 2,400 mg/m²/h will be administered over 46 hours after the end of the folinic acid infusion, i.e. 1200 mg/m²/day for the duration of 2 days.~Treatment will be continued for 24 weeks (12 cycles)."
62423102|NCT04493554|EXPERIMENTAL|Vasopressin|Vasopressin (20 IU) intranasally
62231572|NCT04191044||NAFLD with mild steatosis and grade <3 fibrosis in patients|NAFLD with mild steatosis and grade \<3 fibrosis in patients with grade 1 or 2 obesity and insulin resistance (HOMA index\> 2.6) or diabetes mellitus.
62231573|NCT04191044||NAFLD with severe steatosis and grade <3 fibrosis in patients|NAFLD with severe steatosis and grade \<3 fibrosis in patients with grade 1 or 2 obesity and insulin resistance (HOMA index\> 2.6) or diabetes mellitus.
62423103|NCT04493554|PLACEBO_COMPARATOR|Placebo|Placebo intranasally
62423104|NCT04084028|EXPERIMENTAL|Active Cooking +meal kits and recipes|"Participants will attend a weekly 2-hour cooking class to learn how to prepare meals. Participants cook and sample the meal at the end of class and the chef will walk them through a sensory exercise. At the end of each class, participants will be provided with the recipe for the next class and asked to create a timeline for the various steps of preparation. Participants will bring this timeline to class and discuss as a group before preparing the meal.~Following 6 weeks of cooking classes, participants will receive 6 weeks of home-delivered meal kits. Following 6 weeks of meal kits, participants will received 6 weeks of recipes. Both the meal kits and recipes will accommodate major dietary needs (vegan, gluten-free, etc.)"
62592410|NCT02538289|OTHER|Patients admitted after talks|Patients admitted to Cardiology or Respiratory Medicine Departments after the interventional teaching talks.
62592411|NCT00429936|ACTIVE_COMPARATOR|100 mg fenretinide softgel capsules|Three (3) 100-mg fenretinide softgel capsules
62592412|NCT00429936|ACTIVE_COMPARATOR|Fenretinide and placebo softgel capsules|One (1) 100-mg fenretinide softgel capsule and two (2) placebo softgel capsules
62031820|NCT03131518|OTHER|Traditional bicycle|Access to a traditional bicycle will be provided.
62031821|NCT03137511|EXPERIMENTAL|Intervention group|"General practitioners will be invited to screen for melanoma as part of their regular consultations.~* The MG collects relevant clinical information~* The MG takes 2 photographs of the lesion with his smartphone.~* The MG sends to the dermatologist by e-mail the 2 photographs of the lesion accompanied by relevant clinical information~* The MG calls the secretariat of the dermatologist to record the admissibility of the mail, to give the identity and the coordinates of the patient whose photos have just been sent and to obtain an appointment.~* The dermatologist proposes an appointment to the patient."
62031822|NCT03137511|NO_INTERVENTION|Control group|"General practitioners will be invited to screen for melanoma as part of their regular consultations.~General practitioners and dermatologists continue their practice in the usual way."
62592413|NCT00429936|PLACEBO_COMPARATOR|Placebo softgel capsules|Three (3) placebo softgel capsules
62592414|NCT03577977||Patients treated with Betaferon|Patients with very early onset of MS, who received at least one injection of interferon beta-1b as prescribed by the treating physician, before the age of 18.
62592415|NCT00441376|EXPERIMENTAL|ThermoDox + RFA|ThermoDox administered as single dose intravenously over 30 minutes in combination with radiofrequency ablation. Dose is determined by dose cohort patient enters study.
62592416|NCT01190410|EXPERIMENTAL|Certolizumab pegol: high-dose group|400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg
62592417|NCT01190410|EXPERIMENTAL|Certolizumab pegol: low-dose group (weight adjusted)|200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to \< 40 kg
62807903|NCT03059316|ACTIVE_COMPARATOR|nitroglycerin group|this group will receive nitroglycerin infusion for controlled hypotension.0.5-5ug/kg/min to keep MAP 55-65mmhg then Massimo device will be attached to the patients when MAP reached the desired level
62807904|NCT03059316|ACTIVE_COMPARATOR|labetalol group|this group will receive labetalol infusion fo controlled hypotension 0.4-3mg/kg/hr to keep MAP 55-65mmhg.then Massimo device will be attached to the patients when MAP reached the desired level
62807905|NCT02458716|EXPERIMENTAL|Surgery followed by hormone therapy (ADT)|Patients undergo Robotic Assisted Radical Prostatectomy (RARP) or conventional open retropubic radical prostectomy (RRP). Immediately following surgery, patients receive the standard systemic androgen deprivation therapy.
62807906|NCT00591682|EXPERIMENTAL|1|MSX-122
62807907|NCT03775460|PLACEBO_COMPARATOR|control|Participants will receive placebo+ prednisolone. Participants will start receiving 4 dummy tablets per week, than participants weighing less than 60 kg will receive 6 dummy tablets from week 8. The placebo will be prescribe weekly. Participants weighing 60 kg or more will receive 8 dummy tablets from week 8. Participants will receive dummy tablets for 52 weeks. Along with prednisolone. The start dose of prednisolone will be 40 mg per day decreasing dosage for 20 weeks.
62807908|NCT03775460|EXPERIMENTAL|intervention|Participants will receive Methotrexate(MTX)+prednisolone. All participants in intervention arm will receive an initial dose of MTX 10 mg. The MTX will be increased to 15 mg the following week. Participants weighing less than 60 kg will continue to receive 15 mg of MTX weekly thereafter. Individuals weighing 60 kg or more will receive MTX 20 mg from week 8. At week 48 the MTX will be reduced to 10 mg for two weeks followed by 5 mg for two weeks and then stopped. In total participants will receive 52 weeks of MTX along side prednisolone, which will be the same as the control arm.
62807909|NCT05603117|EXPERIMENTAL|Intervention|Participants received a behavioral intervention, CISBAR, via zoom sessions.
62807910|NCT01102114|PLACEBO_COMPARATOR|Placebo Vaccine|
62807911|NCT01102114|EXPERIMENTAL|NicVAX Vaccine|
62807912|NCT02521506|EXPERIMENTAL|Verio Pattern Alert® activated|In this cohort, the patients will monitoring the glucose levels with capillar glucometer and they have activated the software Verio Pattern Alert® that could predict the glucose trends.
62807913|NCT02521506|ACTIVE_COMPARATOR|Verio Pattern Alert® deactivated|In this cohort, the patients will monitoring the glucose levels with capillar glucometer.
62807914|NCT01905098|EXPERIMENTAL|Observation-First Arm|"A group that first attends 4 observation visits without sauna, and then attends sauna sessions 5 times a week for 3.5 hours per visit for 3 weeks.~Participants in this Arm will undergo both listed interventions: Observation and Sauna Protocols."
62807915|NCT01905098|ACTIVE_COMPARATOR|Sauna-First Arm|"A group that first attends sauna sessions 5 times a week for 3.5 hours per visit for 3 weeks and then attends 4 observation visits without sauna.~Participants in this Arm will undergo both listed interventions: Observation and Sauna Protocols."
62807916|NCT02981147|EXPERIMENTAL|Intervention|Phytus (Cisti, thyme and Ivy leaves) given to patients on day 1 and day 4. On 4th day, night and day cough score along with adverse event will be assessed. Sponsor will bear the treatment cost during the study time period.
62031823|NCT03565445|EXPERIMENTAL|ASP1948 70 mg Monotherapy Dose Escalation|Participants have received ASP1948 70 mg intravenously, on day 1 of every 2-week (Q2W) cycle for a period of up to 24 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received treatment for an additional 24 cycles or until a discontinuation criteria is met.
62807917|NCT04471519|EXPERIMENTAL|BBV152A - Phase I|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine \[BBV152A\], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14
62807918|NCT04471519|EXPERIMENTAL|BBV152B - Phase I|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine \[BBV152B\], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14
62807919|NCT04471519|EXPERIMENTAL|BBV152C - Phase I|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine \[BBV152C\], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14
62807920|NCT04471519|ACTIVE_COMPARATOR|Placebo - Phase I|0.5 mL of Placebo will be administered intramuscularly twice at Day 0 and Day 14.
62807921|NCT04471519|EXPERIMENTAL|BBV152A - Phase II|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine \[BBV152A\], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 28.
62807922|NCT04471519|EXPERIMENTAL|BBV152B - Phase II|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine \[BBV152B\], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 28
62231574|NCT04191044||NAFLD with advanced fibrosis|NAFLD with advanced fibrosis (i.e. grade 3 or 4 fibrosis) without previous portal hypertension-related complications
62231575|NCT04191044||Decompensated NAFLD cirrhosis|Decompensated NAFLD cirrhosis (i.e. development of ascites, variceal hemorrhage, and/or hepatic encephalopathy) up to Child B (9 points)
62807923|NCT01301807|EXPERIMENTAL|Treatment (carfilzomib, panobinostat)|Participants receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 and panobinostat PO QD on days 1, 3, 5, 8, 10, and 12 of each course. Courses repeat every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. After 8 courses, participants may continue carfilzomib IV on days 1, 2, 15, and 16, and panobinostat PO on days 1, 3, 5, 8, 10, and 12 of each course. If the disease becomes worse, participants can receive carfilzomib on the original dosing schedule (days 1, 2, 8, 9, 15, and 16 of each course).
62231576|NCT05478551|EXPERIMENTAL|Botulinum toxin|"Biopsy site receiving botulinum toxin~Following the biopsy closures, one of two biopsy sites (left or right) will be selected to receive 30u (0.3cc) of botulinum toxin injected into the suture line at a depth of PPD bleb.~The treatment for each wound site will be randomized (left versus right) and blinded but consistent throughout dosing."
62231577|NCT05478551|PLACEBO_COMPARATOR|Placebo|"Placebo Comparator: Biopsy site receiving placebo~Following the biopsy closures, the other biopsy site will receive 30u (0.3cc) of bacteriostatic normal saline injected into the suture line at a depth of PPD bleb."
62231578|NCT02736604|EXPERIMENTAL|Air anesthesia|air will be used as carrier agent for maintenance of anesthesia
62231579|NCT02736604|ACTIVE_COMPARATOR|Nitrous Oxide anesthesia|nitrous oxide will be used as carrier agent for maintenance of anesthesia
62231580|NCT02791373|ACTIVE_COMPARATOR|Mobilisation Chemotherapy: Vinorelbine|Vinorelbine is given at a standard dose of 35mg/m2 i.v. at day 1 as an infusion over 10 minutes, on an ambulatory basis.
62231581|NCT02791373|EXPERIMENTAL|Mobilisation Chemotherapy: Gemcitabine|Gemcitabine is given at the standard dose of 1250 mg/m2 i.v. in 500ml NaCl 0.9% (sodium chloride) as an infusion over 30 minutes, on an ambulatory basis.
62592418|NCT03727048|ACTIVE_COMPARATOR|Control|To the control group post ankle fracture surgery, per subject 30 tablets of 5/325 oxycodone-acetaminophen with instructions to take 1 or 2 tabs every 4 to 6 hours as needed for pain
62592419|NCT03727048|EXPERIMENTAL|Intervention|To the treatment group post ankle fracture surgery, per subject 30mg of IV ketorolac intraoperatively; 20 tablets of 10mg ketorolac with instructions to take every 6 hours, and 30 tablets of 5/325 oxycodone-acetaminophen with instructions to take 1 or 2 tabs every 4 to 6 hours as needed for pain
62592420|NCT04871061|ACTIVE_COMPARATOR|PENG Block|For patients with hip fracture and having hip surgery this study evaluates the analgesic effects of Pericapsular Nerve Group (PENG) block for positioning before spinal anesthesia.
62807924|NCT02681198|EXPERIMENTAL|Lofexidine and paroxetine|Lofexidine in the presence of paroxetine
62231582|NCT03885830||Bosutinib|Subjects who have been prescribed or administered bosutinib (Bosulif) for treatment of chronic-phase CML for less than 12 months.
62231583|NCT03885830||Dasatinib|Subjects who have been prescribed or administered dasatinib (Sprycel) for treatment of chronic-phase CML for less than 12 months.
62231584|NCT03885830||Imatinib|Subjects who have been prescribed or administered imatinib (Gleevec) for treatment of chronic-phase CML for less than 12 months.
62231585|NCT03885830||Nilotinib|Subjects who have been prescribed or administered nilotinib (Tasigna) for treatment of chronic-phase CML for less than 12 months.
62231586|NCT06434454|EXPERIMENTAL|EXPERİMENTAL: EFT GROUP|The young individuals in the intervention group will be informed about the study, including its purpose and methodology, and their consent will be obtained. Emotional Freedom Techniques (EFT) will be applied to groups of 20 individuals to improve sleep quality, and all scales will be administered beforehand. EFT will be applied twice, with a 15-day interval between sessions, and the same scale questionnaires will be administered again after the second EFT session. Subsequently, the analysis will be conducted.
62592421|NCT04871061|ACTIVE_COMPARATOR|Control|in this group, standardised opioid doses (drug: Fentanyl) will be used for analgesia for positioning pain
62592422|NCT01409525||cardiac surgery patients|
62592423|NCT05901012|EXPERIMENTAL|60mg of N,N-Dimethyltryptamine|One inhaled dose of 60mg of vaporized DMT.
62592424|NCT05901012|PLACEBO_COMPARATOR|Placebo-like|One inhaled dose of 1mg of vaporized DMT.
62592425|NCT03404726|EXPERIMENTAL|Dose Escalation|Dose escalation with sequential cohorts enrolling patients with AML, MDS, or CMML. Patients will be treated in 28-day cycles with once daily oral administration of BAY2402234
62592426|NCT03404726|EXPERIMENTAL|Dose Expansion: AML|After completion of dose escalation, an expansion cohort comprised of patients with AML will start. These patients will be treated in 28 day cycles with once daily oral administration of BAY2402234 at the maximum tolerated dose or pharmacologically active dose.
62807925|NCT02027012|EXPERIMENTAL|Renal denervation with Vessix system|
62807926|NCT05510063|EXPERIMENTAL|Switched between Humira and SB5|All subjects will receive an initial dose of Humira 80 mg at Week 0, followed by Humira 40 mg every other week starting one week after the initial dose up to Week 11. From Week 13, the subjects will switch between Humira and SB5 up to Week 23.
62807927|NCT05510063|ACTIVE_COMPARATOR|Continued on Humira|All subjects will receive an initial dose of Humira 80 mg at Week 0, followed by Humira 40 mg every other week starting one week after the initial dose up to Week 23.
62592427|NCT03404726|EXPERIMENTAL|Dose Expansion: MDS|After completion of dose escalation, an expansion cohort comprised of patients with MDS will start. These patients will be treated in 28 day cycles with once daily oral administration of BAY2402234 at the maximum tolerated dose or pharmacologically active dose.
62592428|NCT00355576|EXPERIMENTAL|Minocycline + Creatine|Minocycline 100 mg BID and Creatine 10 g BID
62592429|NCT00355576|EXPERIMENTAL|Celecoxib + Creatine|Celecoxib 400 mg BID and Creatine 10 g BID
62592430|NCT02158468|ACTIVE_COMPARATOR|Combined intrahospital pre- and postconditioning|After admission to hospital 3 cycles of preconditioning with 5-min inflation and 5-min deflation of a blood-pressure cuff. After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion).
62807928|NCT01174407||cd35|
62807929|NCT02753166|EXPERIMENTAL|Dexamethasone|
62592431|NCT02158468|ACTIVE_COMPARATOR|Postconditioning|4 cycles of postconditioning (30s ischemia, 30s reperfusion) after primary PCI/stenting
62807930|NCT02753166|NO_INTERVENTION|Control|
62231587|NCT06434454|NO_INTERVENTION|CONTROL GROUP|The young individuals in the control group will be informed about the study, including its purpose and methodology, and their consent will be obtained. The control group will receive sleep education, consisting of two educational presentations provided 15 days apart. The questionnaires of the scales used for analysis will be administered to assess their sleep problems. The content of the education will be prepared based on the literature and will be reviewed by at least three experts.
62231588|NCT05438368|EXPERIMENTAL|bi-4SCAR-GD2/CD70 T Cell Therapy for GD2 and/or CD70 positive tumor|
62231589|NCT05735795|OTHER|Carbon Black Tattoo arm|In patients with breast cancer diagnosed with positive axillary lymph node involvement by fine needle aspiration cytology, 0.1-0.5 ml Carbon Black Tattoo dye will be applied simultaneously to the lymph node capsule and surrounding tissue, while clips are placed on the axilla before starting neoadjuvant chemotherapy. After the neoadjuvant treatment is completed, the patient who is taken into surgery will be injected with periareolar blue dye as in the standard practice, and blue stained node, clipped node and carbon stained node will be searched as sentinal lymph node. The removed lymph nodes will be evaluated histopathologically in terms of metastasis with a frozen study during the operation, and if metastasis is detected, axillary lymph node dissection will be performed
62592432|NCT02158468|NO_INTERVENTION|Control group|Standard infarction treatment without conditioning intervention
62592433|NCT01804790|ACTIVE_COMPARATOR|Arm A : Radiotherapy + capecitabine|Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session ; 25 fractions) + capecitabine 800 mg/m² twice daily 5 days/7, excluding weekends), then 6-8 weeks after chemoradiation, surgery with total mesorectal excision (TME), followed by adjuvant chemotherapy for 6 months, either mFolfox6 or capecitabine, depending on the center's choice.
62592434|NCT01804790|EXPERIMENTAL|Arm B : Chemotherapy then radiochemotherapy|"Drug: Chemotherapy mFolfirinox~Investigational arm: Neoadjuvant CT mFolfirinox, 6 cycles (ca. 3 months; each cycle = 2 weeks):~oxaliplatin: 85 mg/m² in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m² simultaneously in 2 hours at D1 during the irinotecan infusion 5-fluorouracil (5-FU): 2400 mg/m² continuous infusion during 48 hours (1200 mg/m² at D1 and D2), every 14 days during 2 months (4 cycles).~Then followed by 5 weeks of chemoradiotherapy 50 Gy (2 Gy/session, 5 sessions per week) + capecitabine 800 mg/m² twice daily 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, followed by 3 months of adjuvant chemotherapy, either mFolfox6 or capecitabine depending on the center's choice."
62807931|NCT01591356|EXPERIMENTAL|Treatment (EphA2-targeting DOPC-encapsulated siRNA)|Patients receive EphA2-targeting DOPC-encapsulated siRNA IV over 120 minutes on days 1 and 4. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62231590|NCT03668353|EXPERIMENTAL|treatment 1|Recombinant SeV-hFGF2/dF Injection 2×10 8CIU
62231591|NCT03668353|EXPERIMENTAL|treatment 2|Recombinant SeV-hFGF2/dF Injection 1×10 9CIU
62231592|NCT03668353|EXPERIMENTAL|treatment 3|Recombinant SeV-hFGF2/dF Injection 5×10 9CIU
62231593|NCT03668353|EXPERIMENTAL|treatment 4|Recombinant SeV-hFGF2/dF Injection 1×10 10CIU
62592435|NCT04212312||Single course of Betamethasone|Women with twin pregnancy who received 1 course of betamethasone between 24 - 34 weeks' gestation.
62592436|NCT04212312||Repeat course of Betamethasone|Women with twin pregnancy who received 2 courses (Repeat course) of betamethasone between 24 - 34 weeks' gestation.
62592437|NCT05924815|EXPERIMENTAL|Part A (Dose Finding Cohort 1): Aficamten 50 mg|Participants in this arm will receive a single oral dose of 50 mg aficamten.
62592438|NCT05924815|EXPERIMENTAL|Part A (Dose Finding Cohort 2): Aficamten 75 mg|Participants in this arm will receive a single oral dose up to 75 mg aficamten.
62807932|NCT05970575|EXPERIMENTAL|Experimental Arm: NE3107|All participants will take 200mg BID (12 hours apart) of NE3107 for 6 months.
62807933|NCT05182723|ACTIVE_COMPARATOR|oXiris|Monotoring of extracorporeal Method for Removing Mediators of Systemic Inflammation of oXiris will be performed for 24 hours
62807934|NCT05182723|EXPERIMENTAL|oXiris in combination with Jafron HA330|"Extracorporeal Method for Removing Mediators of Systemic Inflammation oXiris in combination with Jafron HA330 will be performed for 4 hours.~If SOFA is more or equally 4 , CRP is more than 100 ng/ml;, the IL6 value is increased by 5 or more times after 12 hours of procedure Jafron HA330 will be reconnected and performed for 4 hours.~Monitoring of whole procedure will be performed for 24 hours."
62807935|NCT00628017|EXPERIMENTAL|1|omega-3 PUFAs(180mg eicosapentaenoic acid\[EPA\] + 120mg docosahexaenoic acid\[DHA\]/capsule), 3 capsules twice daily, total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA
62807936|NCT00628017|PLACEBO_COMPARATOR|2|three identical placebo capsules twice daily which contained olive oil esters.
62807937|NCT06464354||LIMA - pedicle|
62231594|NCT01016977|ACTIVE_COMPARATOR|Duac & taz|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
62231595|NCT01016977|ACTIVE_COMPARATOR|Acanya & taz|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
62807938|NCT06464354||LIMA - skeletonised|
62807939|NCT06464354||Control group - LIMA not harvested|
62592439|NCT05924815|EXPERIMENTAL|Part A (Dose Finding Cohort 3): Aficamten 100 mg|Participants in this arm will receive a single oral dose up to 100 mg aficamten.
62592440|NCT05924815|EXPERIMENTAL|Part B (TQT Study): Aficamten|Participants will receive a single oral dose of aficamten. The dose will be determined based on review of Part A PK parameters, echocardiogram parameters, safety, and tolerability for aficamten.
62592441|NCT05924815|PLACEBO_COMPARATOR|Part B (TQT Study): Aficamten-matching Placebo|Participants in this arm will receive a single oral dose of aficamten-matching placebo.
62231596|NCT01507818|ACTIVE_COMPARATOR|Ivivi Torino II|Active treatment with Non-thermal Pulsed Radio Frequency device
62231597|NCT01507818|SHAM_COMPARATOR|Inactive Sham|Sham treatment
62231598|NCT05419362|EXPERIMENTAL|GEN-001 with avelumab|42 patients in total with metastatic GC/Gastroesophageal Junction Adenocarcinoma who have progressed after 2 prior systemic treatments and confirmed PD-L1 positive expression will be enrolled in this study.
62231599|NCT04746443||STUDENTS|COLLEGE STUDENTS WITH POSITIVE COVID-19 TEST
62592442|NCT05924815|ACTIVE_COMPARATOR|Part B (TQT Study): Moxifloxacin 400 mg|Participants will receive a single oral dose of 400 mg moxifloxacin
62807940|NCT01429675|ACTIVE_COMPARATOR|Bonviva|
62807941|NCT01429675|EXPERIMENTAL|DP-R206|
62592443|NCT04282317|OTHER|Healthy Volunteer|This arm will enroll healthy volunteers as controls
62592444|NCT04282317|OTHER|Gastroparesis Subjects|This arm will enroll a) patients with gastroparesis from type 1 diabetes and b) patients with gastroparesis from vagus nerve trauma
62592445|NCT03912649|EXPERIMENTAL|RemovAid arm|"RemovAid arm -~All subjects have their implant removed by the RemovAid device"
62592446|NCT03892577||Patients with advanced hepatobiliary tumors|"2000 patients with advanced hepatobiliary tumors will be enrolled and the enroll patients should be treat with any type of the following three treatment program:~1. Monotherapy or combination therapy with the targeted drug related to genetic variation of the subject;~2. Treatment with pan-target anti-angiogenic drugs, such as sorafenib, regorafenib, lenvatinib, apatinib, etc;~3. Immunotherapy or immunotherapy combined with targeted therapy or (and) chemotherapy."
62807942|NCT00564681|ACTIVE_COMPARATOR|botulinum toxin Type A|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
62807943|NCT00564681|ACTIVE_COMPARATOR|botulinum toxin Type A Formulation 2|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
62231600|NCT02370810|EXPERIMENTAL|experimental group|CBT-based internet-intervention for tinnitus The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
62231601|NCT02370810|OTHER|weekly check-in group with delayed treatment|will complete weekly measures and commence the treatment once the experimental group completes the intervention
62231602|NCT03248154|NO_INTERVENTION|Immunocompetent with 2-14% TBSA|Immunocompetent with 2-14% TBSA thermal burn subjects. Does biofilm infection result in conversion of partial-thickness burn wounds to full-thickness?
62592447|NCT05230342|EXPERIMENTAL|Nutritional strategy based on functional foods|Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein and genistein.
62592448|NCT05230342|PLACEBO_COMPARATOR|Placebo Ingredient Group|The placebo group will receive a comparable set of food items that contain an equivalent number of calories per portion but without the added functional ingredients
62592449|NCT04884425|ACTIVE_COMPARATOR|PEMF Device Group|This arm will consist of participant's who have been randomly assigned to use the PEMF device daily for 30 mins for an overall 3 months
62592450|NCT04884425|NO_INTERVENTION|Waiting List Control Group|These participants will be randomly selected to be on the waiting list group. All waiting list participants will be offered the use of the PEMF device after the study has completed
62807944|NCT00564681|OTHER|Placebo (Normal Saline) / botulinum toxin Type A|Intramuscular injections of the assigned study medication into the affected muscles (placebo for treatment cycle 1 and botulinum toxin Type A for subsequent treatments). Maximum dose of 360 units. Subjects may receive up to three treatments.
62807945|NCT00564681|OTHER|Placebo (Normal Saline) / botulinum toxin Type A Formulation 2|Intramuscular injections of the assigned study medication into the affected muscles (placebo for treatment cycle 1 and botulinum toxin Type A Formulation 2 for subsequent treatments). Maximum dose of 360 units. Subjects may receive up to three treatments.
62807946|NCT03271424|NO_INTERVENTION|Focus Group Discussions|Focus group discussions (FGD) with young women (n=2 FGDs) and young men (n=2 FGDs) in the study area to determine the best way to offer self-testing to study participants.
62807947|NCT03271424|ACTIVE_COMPARATOR|In Clinic Observation-Both|10 young women and 10 young men were assigned and conducted BOTH of the HIV self-tests. Participants tried two different self-testing kits, one that is oral fluid based (saliva), Oraquick HIV Self Test, and one that is blood based via a finger prick, Atomo HIV Self Test. Oraquick HIV Self Test and Atomo HIV Self Test - Both
62807948|NCT03271424|ACTIVE_COMPARATOR|In Clinic Observation-Subject Choice|20 young women and 20 young men were assigned and conducted EITHER of the HIV self-tests. Investigators asked them to choose which test they would prefer to use, one that is oral fluid based (saliva), Oraquick HIV Self Test, or one that requires the use blood via a finger prick, Atomo HIV Self Test. Oraquick HIV Self Test - Choice; Atomo HIV Self Test - choice
62231603|NCT03248154|EXPERIMENTAL|Immunocompromised with >=20% TBSA|Immunocompromised patients with large thermal burn \>=20% TBSA. Higher bacterial burden with biofilm infection will result in higher rates of graft loss. Does application of a wireless electroceutical dressing (Procellera) lower biofilm burden compared to burn subjects receiving standard of care therapy?
62231604|NCT03248154|NO_INTERVENTION|Peripheral blood - all subjects|All subjects enrolled in arms 1 and 2. Do children have a more robust innate immune response to prevent biofilm infection?
62423105|NCT04084028|ACTIVE_COMPARATOR|Active cooking only|Participants will attend a weekly 2-hour cooking class to learn how to prepare meals. Participants cook and sample the meal at the end of class and the chef will walk them through a sensory exercise. At the end of each class, participants will be provided with the recipe for the next class and asked to create a timeline for the various steps of preparation. Participants will bring this timeline to class and discuss as a group before preparing the meal. Unlike the previous arm, no further instruction will be given once cooking classes end.
62592451|NCT02729038|EXPERIMENTAL|Part 1: Subjects with normal renal function (Group A)|Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
62031824|NCT03565445|EXPERIMENTAL|ASP1948 200 mg Monotherapy Dose Escalation|Participants have received ASP1948 200 mg intravenously, on day 1 of Q2W cycle for a period of up to 24 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received treatment for an additional 24 cycles or until a discontinuation criteria is met.
62031825|NCT03565445|EXPERIMENTAL|ASP1948 700 mg Monotherapy Dose Escalation|Participants have received ASP1948 700 mg intravenously, on day 1 of every 2 week cycle for a period of up to 24 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received treatment for an additional 24 cycles or until a discontinuation criteria is met.
62031826|NCT03565445|EXPERIMENTAL|ASP1948 1200 mg Monotherapy Dose Expansion|Participants have received ASP1948 1200 mg intravenously, on day 1 of every 2 week cycle for a period of up to 24 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received treatment for an additional 24 cycles or until a discontinuation criteria is met.
62031827|NCT03565445|EXPERIMENTAL|ASP1948 2000 mg Monotherapy Dose Escalation|Participants have received ASP1948 2000 mg intravenously, on day 1 of every 2 week cycle for a period of up to 24 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received treatment for an additional 24 cycles or until a discontinuation criteria is met.
62031828|NCT03565445|EXPERIMENTAL|ASP1948 3000 mg Monotherapy Dose Escalation|Participants have received ASP1948 3000 mg intravenously, on day 1 of every 3-week (Q3W) cycle for a period of up to 16 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received treatment for an additional 16 cycles or until a discontinuation criteria is met.
62231605|NCT03098420|PLACEBO_COMPARATOR|Control Group|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of ropivacaine) and 1mL of normal saline bilaterally (control) with standard intrathecal bupivacaine and morphine.
62231606|NCT03098420|ACTIVE_COMPARATOR|2mg Dexamethasone|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline split between 2 sides with standard intrathecal bupivacaine and morphine.
62423106|NCT04084028|ACTIVE_COMPARATOR|Meal Kits only|Participants will receive weekly meal kit deliveries for 6 weeks. Following 6 weeks of meal kit deliveries, students will receive emails at the beginning of each week providing them with 5 healthy recipes.
62423107|NCT04084028|NO_INTERVENTION|Control|Participants will receive no interventions.
62423108|NCT00779844|EXPERIMENTAL|1|obese patients
62423109|NCT00779844|ACTIVE_COMPARATOR|2|lean patients
62423110|NCT05628766||Women diagnosed with primary infertility (n:41)|Women which followed up with infertility of unknown cause.
62423111|NCT05628766||Control group ( n:41)|Healthy women who are not infertile
62423112|NCT01915394||Hospitalized Respiratory Syncytial Virus Infected Newborns|All admitted newborns to the neonatal intensive care unit (NICU) will be enrolled in the study
62423113|NCT02312531|EXPERIMENTAL|HBIG group|Mothers in HBIG group received 'Hepatitis B immunoglobulin' (HBIG 200 IU, S20023028, Hualan Biological Engineering Inc.) injection at gestational weeks 20, 24, 28, 32, 34, 36, 38, 39, and 40.
62592452|NCT02729038|EXPERIMENTAL|Part 1: subjects with moderate renal impairment (Group B)|Subjects with moderate renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
62031829|NCT03565445|EXPERIMENTAL|ASP1948 2000 mg Monotherapy Dose Expansion|Participants have received ASP1948 2000 mg intravenously, on day 1 of Q2W cycle for a period of up to 24 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received treatment for an additional 24 cycles or until a discontinuation criteria is met.
62031830|NCT03565445|EXPERIMENTAL|ASP1948 1200 mg + Nivolumab 240 mg CT Dose Escalation|Participants have received ASP1948 1200 mg intravenously in combination with nivolumab 240 mg administered as a 30 minute intravenous infusion, on day 1 of Q2W cycle for a period of up to 24 cycles or until a discontinuation criterion is met. Qualifying participants have entered a re-treatment period and have received combination treatment for an additional 24 cycles or until a discontinuation criteria is met.
62031831|NCT03565445|EXPERIMENTAL|ASP1948 2000 mg+ Nivolumab 240 mg CT Dose Escalation|Participants have received ASP1948 2000 mg intravenously in combination with nivolumab 240 mg administered as a 30 minute intravenous infusion, on day 1 of Q2W cycle for a period of up to 24 cycles or until a discontinuation criterion is met. Qualifying participants have entered a re-treatment period and have received combination treatment for an additional 24 cycles or until a discontinuation criteria is met.
62031832|NCT03565445|EXPERIMENTAL|ASP1948 2000 mg + Nivolumab 240 mg CT Dose Expansion|Participants have received ASP1948 2000 mg intravenously in combination with nivolumab 240 mg administered as a 30 minute intravenous infusion, on day 1 of every 2 week cycle for a period of up to 24 cycles or until a discontinuation criterion is met. Qualifying participants have entered a re-treatment period and have received combination treatment for an additional 24 cycles or until a discontinuation criteria is met.
62031833|NCT03565445|EXPERIMENTAL|ASP1948 2000 mg + Pembrolizumab 400 mg CT Dose Escalation|Participants have received ASP1948 2000 mg intravenously on day 1 of Q2W cycle in combination with pembrolizumab 400 mg administered as a 30 minute intravenous infusion, on day 1, once every 6 weeks (Q6W) for a period of up to 24 cycles or until a discontinuation criterion is met. Qualifying participants have entered a re-treatment period and have received combination treatment for an additional 24 cycles or until a discontinuation criteria is met. Participants who completed 24 cycles of treatment and have entered the follow-up period with PR or SD are allowed to continue on pembrolizumab alone for a period of up to an additional 10 doses of pembrolizumab. If the participant is eligible for a re-treatment period during follow up, administration of pembrolizumab alone is discontinued and combination therapy with ASP1948 is resumed per the protocol.
62231607|NCT03098420|ACTIVE_COMPARATOR|4mg Dexamethasone|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 20mL of 0.5% ropivacaine) and 1 mL (4mg) of dexamethasone between 2 sides with standard intrathecal bupivacaine and morphine.
62231608|NCT06003946|EXPERIMENTAL|Intervention group (BreLax)|BreLax: midwife-led antenatal education class
62231609|NCT06003946|ACTIVE_COMPARATOR|Control group (Standard care)|Midwife-led antenatal education class
62231610|NCT02424513|EXPERIMENTAL|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of \[89Zr\]Df-IAB2M in a mass dose of 10 mg.
62231611|NCT02123433|EXPERIMENTAL|13-valent vaccine|
62423114|NCT02312531|NO_INTERVENTION|Control group|Mothers in control group had no HBIG injection during pregnancy.
62592453|NCT02729038|EXPERIMENTAL|Part 1: subjects with severe renal impairment (Group C)|Subjects with severe renal impairment and subjects with ESRD not on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
62592454|NCT02729038|EXPERIMENTAL|Part 2: subjects with normal renal function (Group D)|Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
62592455|NCT02729038|EXPERIMENTAL|Part 2: subjects with mild renal impairment (Group E)|Subjects with mild renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
62231612|NCT06385756|EXPERIMENTAL|amobarbital-propofol group|Participants were given amobarbital sodium 1 mg/kg 1 min before induction and propofol 1.5mg /kg following.
62231613|NCT06385756|PLACEBO_COMPARATOR|propofol group|The propofol group was given the same volume of normal saline 1 min before induction, followed by propofol 2.5mg /kg.
62807949|NCT03744728|ACTIVE_COMPARATOR|Accelerate Pheno|Fast ID and AST of positive blood culture bottles using the Accelerate PhenoTest™ BC kit with the Accelerate Pheno™ System
62807950|NCT03744728|ACTIVE_COMPARATOR|Standard of Care|Standard culture and AST of positive blood culture bottles plus the Verigene® BC-GP/GN
62807951|NCT06327698|EXPERIMENTAL|Combination+ Anlotinib|Cadonilimab (AK104) (10 mg/kg, Q3W, administered on the frst day of each cycle, Q3W, until there is no clinical beneft) + anlotinib (8 mg, QD, 2 weeks off for 1 week)
62031834|NCT03565445|EXPERIMENTAL|ASP1948 3000 mg + Pembrolizumab 200 mg CT Dose Escalation|Participants have received ASP1948 3000 mg intravenously in combination with pembrolizumab 200 mg administered as a 30 minute intravenous infusion, on day 1 of Q3W cycle for a period of up to 16 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received combination treatment for an additional 16 cycles or until a discontinuation criteria is met. Participants who completed 16 cycles of treatment and have entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant is eligible for a re-treatment period during follow up, administration of pembrolizumab alone is discontinued and combination therapy with ASP1948 is resumed per the protocol.
62031835|NCT03565445|EXPERIMENTAL|ASP1948 3000 mg + Pembrolizumab 200 mg CT Dose Expansion|Participants have received ASP1948 3000 mg intravenously in combination with pembrolizumab 200 mg administered as a 30 minute intravenous infusion, on day 1 of Q3W cycle for a period of up to 16 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received combination treatment for an additional 16 cycles or until a discontinuation criteria is met. Participants who completed 16 cycles of treatment and have entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant is eligible for a re-treatment period during follow up, administration of pembrolizumab alone is discontinued and combination therapy with ASP1948 is resumed per the protocol.
62031836|NCT03796988|EXPERIMENTAL|Intervention arm|The donor area will be anesthetized with injected local anesthesia, harvested with the ART device, and bandaged with an occlusive dressing. The skin harvested will be placed on the recipient wound area. The area will be bandaged will a non-stick silicone dressing (covered by appropriate primary and secondary dressings) and left intact for 1-7 days.
62031837|NCT05975281||Hand osteoarthritis|Those diagnosed with hand osteoarthritis according to the American College of Rheumatology (ACR) criteria
62031838|NCT05975281||Rheumatoid arthritis|Those diagnosed with rheumatoid arthritis according to the American College of Rheumatology (ACR) criteria
62031839|NCT01478568|EXPERIMENTAL|mirabegron / desipramine|
62231614|NCT02142660||Sprayshield|Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie
62231615|NCT01749020|EXPERIMENTAL|Polyphenol-rich Dark chocolate|Dark chocolate with 500 mg of polyphenols
62231616|NCT01749020|PLACEBO_COMPARATOR|Placebo Dark chocolate|This chocolate contains little or no polyphenols
62231617|NCT02919657|ACTIVE_COMPARATOR|Genepro Gen2 Protein|"1 tablespoon Serving of Genepro Gen2 Protein daily will be used in each subject.~Intervention: Weekly blood draws will determine the effect on blood protein levels."
62231618|NCT02919657|ACTIVE_COMPARATOR|Whey Protein Isolate|"30g Serving of Whey Isolate Protein will be used daily in each subject.~Intervention: Weekly blood draws will determine the effect on blood protein levels."
62807952|NCT03402334|EXPERIMENTAL|CVD risk factor counseling|"This arm will receive intervention 'Patient counseling for HCV associated CVD risk factors' in addition to standard of care Hepatitis C counseling.~Cardiovascular risk factor counseling will include:~1. Increased risk for atherosclerosis with chronic HCV infection~2. Increased risk of heart attack and stroke~3. Treatment of HCV infection and reduction of viral load reducing risk of stroke and heart attack"
62031840|NCT02351557||Reference|Baseline cardiac index more than or equal to 2.1 liters per minute per square meter
62807953|NCT03402334|NO_INTERVENTION|Standard of care counseling|"This arm will receive standard of care Hepatitis C counseling:~1. HCV infection poses an increased risk for hepatocellular carcinoma~2. Hepatitis C is a curable disease~3. Hepatitis C is transmitted through blood to blood contact, primarily through sharing needles~4. HCV+ individuals should be vaccinated for Hepatitis A (HAV) and Hepatitis B (HBV)~5. HCV+ individuals should reduce alcohol intake and shellfish consumption"
62807954|NCT05543954|EXPERIMENTAL|68Ga-FAPI-RGD and 18F-FDG PET/ CT scan|Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-FAPI-RGD and 18F-FDG, respectively.
62807955|NCT05543954|EXPERIMENTAL|68Ga-FAPI-RGD and 68Ga-FAPI PET/ CT scan|Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-FAPI-RGD and 68Ga-FAPI, respectively.
62031841|NCT02351557||Low cardiac output|Baseline cardiac index less than 2.1 liters per minute per square meter
62031842|NCT03108924|EXPERIMENTAL|Moderate RI|Participants with moderate renal insufficiency (RI) are treated with a single 50 mg dose of gefapixant
62031843|NCT03108924|EXPERIMENTAL|Severe RI|Participants with severe RI are treated with a single 50 mg dose of gefapixant
62231619|NCT04379141||hypotension|Patients with hypotension after induction of anesthesia
62031844|NCT03108924|OTHER|Healthy Matched Controls|Healthy, participants matched for age and body weight are treated with a single 50 mg dose of gefapixant
62031845|NCT03108924|EXPERIMENTAL|ESRD Requiring HD|Participants with end stage renal disease (ESRD) requiring hemodialysis (HD), are treated in Period 1 with a single 50 mg dose of gefapixant immediately after the scheduled HD, followed in Period 2 with a single 50 mg dose of gefapixant two hours prior to HD. Between the Periods 1 and 2 MK-7264 dose administrations there was approximately a 7-day washout period with 3 dialysis sessions.
62231620|NCT04379141||non-hypotension|Patients without hypotension after induction of anesthesia
62231621|NCT00822172|ACTIVE_COMPARATOR|Cilostazol + L-Carnitine|1 tablet cilostazol 100 mg PO BID and 3 capsules L-carnitine 334 mg PO BID
62231622|NCT00822172|PLACEBO_COMPARATOR|Cilostazol + Placebo|1 tablet cilostazol 100 mg PO BID and 3 capsules placebo PO BID
62231623|NCT02483182|EXPERIMENTAL|ZEP-3 ointment 1.0%|Topical administration
62231624|NCT02483182|ACTIVE_COMPARATOR|Acyclovir cream 5%|Topical administration
62031846|NCT06634602||residents, specialist physicians and academicians working in a medical faculty in İstanbul, Turkey|A survey was administered to collect sociodemographic and professional characteristics, followed by a face-to-face application of the Utrecht Work Engagement Scale (UWES-17).
62031847|NCT06465849|EXPERIMENTAL|Experimental group 1|35 non-carious cervical lesions (NCCL) will receive composite resin restorations in the etch-and-rinse strategy.
62031848|NCT06465849|EXPERIMENTAL|Experimental group 2|35 non-carious cervical lesions (NCCL) will receive composite resin restorations in the etch-and-rinse strategy.
62031849|NCT06465849|ACTIVE_COMPARATOR|Control group 1|35 non-carious cervical lesions (NCCL) will receive composite resin restorations in the etch-and-rinse strategy.
62031850|NCT06465849|ACTIVE_COMPARATOR|Control group 2|35 non-carious cervical lesions (NCCL) will receive composite resin restorations in the etch-and-rinse strategy.
62031851|NCT05094323|ACTIVE_COMPARATOR|Group I|Patients will receive ultrasound-guided deep serratus anterior plane block.
62031852|NCT05094323|ACTIVE_COMPARATOR|Group II|Patients will receive local wound infiltration (LWI).
62031853|NCT05094323|PLACEBO_COMPARATOR|Group III|Patients will receive ultrasound-guided thoracic paravertebral block.
62031854|NCT05134454|EXPERIMENTAL|Extended ECG investigation|Participants will undergo 0-48 hours of continuous ECG recording and at least two long-term continuous ambulatory ECG recordings with a duration of 14 days each.
62031855|NCT05134454|NO_INTERVENTION|Standard of care|Participants will undergo 24-48 hours of continuous ECG recording.
62031856|NCT03578874|EXPERIMENTAL|SECOX|Sorafenib 400 mg twice daily from Day 1 to 14, Capecitabine 850 mg/m2 twice daily from Day 1 to 7, Oxaliplatin 85 mg/m2 on Day 1
62031857|NCT01097967|ACTIVE_COMPARATOR|CPAP in sleepy patients with SDB|SDB defined as AHI \>=20 Sleepy defined as Epworth Sleepiness Score \>=10
62031858|NCT01097967|NO_INTERVENTION|no CPAP in non sleepy patients with SDB|SDB defined as AHI \>=20 Sleepy defined as Epworth Sleepiness Score \>=10
62031859|NCT01097967|ACTIVE_COMPARATOR|CPAP in non sleepy patients with SDB|SDB defined as AHI \>=20 Sleepy defined as Epworth Sleepiness Score \>=10
62231625|NCT02972866|EXPERIMENTAL|Noex 32mcg|"Noex/Budesonide 32mcg, 2 atomizations in each nostril by the morning and during the night, total of 256 mcg per day.~Tretament of 28 days."
62231626|NCT02972866|EXPERIMENTAL|Budecort Aqua 32 mcg|"Budecort Aqua/Budesonide 32mcg, 2 atomizations in each nostril by the morning and during the night, total of 256 mcg per day.~Tretament of 28 days."
62231627|NCT04190329||10 non-frail (robust) study patients|Patients fulfill 0 criteria according to modified Fried frailty score.
62231628|NCT04190329||10 pre-frail study patients|Patients fulfill 1-2 criteria criteria according to modified Fried frailty score.
62231629|NCT04190329||10 frail study patients|Patients fulfill 3, 4 or 5 criteria according to modified Fried frailty score.
62031860|NCT05827068|EXPERIMENTAL|mRNA-1011.1|Participants will receive mRNA-1011.1 by intramuscular (IM) injection on Day 1.
62031861|NCT05827068|EXPERIMENTAL|mRNA-1011.2|Participants will receive mRNA-1011.2 by IM injection on Day 1.
62031862|NCT05827068|EXPERIMENTAL|mRNA-1012.1 Dose Level A|Participants will receive mRNA-1012.1 at dose level A by IM injection on Day 1.
62031863|NCT05827068|EXPERIMENTAL|mRNA-1012.1 Dose Level B|Participants will receive mRNA-1012.1 at dose level B by IM injection on Day 1.
62031864|NCT05827068|ACTIVE_COMPARATOR|mRNA-1010|Participants will receive mRNA-1010 by IM injection on Day 1.
62031865|NCT05827068|ACTIVE_COMPARATOR|mRNA-1010.2|Participants will receive mRNA-1010.2 by IM injection on Day 1.
62031866|NCT05827068|ACTIVE_COMPARATOR|mRNA-1010.3|Participants will receive mRNA-1010.3 by IM injection on Day 1.
62031867|NCT01047839|EXPERIMENTAL|>=2 months to <3 years|IC51 0.25 ml, 2 i.m. vaccinations at Day 0 and 28
62031868|NCT01047839|EXPERIMENTAL|>=3 to <12 years|IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28
62031869|NCT01047839|EXPERIMENTAL|>=12 to <18 years|IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28
62031870|NCT01808157|EXPERIMENTAL|0.05% w/w CT327 ointment|Active
62031871|NCT01808157|EXPERIMENTAL|0.5% w/w CT327 ointment|Active
62031872|NCT01808157|PLACEBO_COMPARATOR|vehicle|Placebo
62031873|NCT04429490|EXPERIMENTAL|"Group Cases"|patients with pancreatic adenocarcinoma
62031874|NCT04429490|OTHER|"Group Controls"|patients without pancreatic adenocarcinoma
62031875|NCT06670196|EXPERIMENTAL|SKB264+Osimertinib|Participants will receive SKB264 on Day 1 and Day 15 of each 4-week cycle, Osimertinib once-daily for each 4-week cycle.
62031876|NCT06670196|ACTIVE_COMPARATOR|Osimertinib|Participants will receive Osimertinib once-daily for each 4-week cycle.
62031877|NCT06349369|EXPERIMENTAL|Treatment group|the cathode will be located over a point midway between T3 and P3 (left temporo-parietal junction, assumed to correspond to a region including BA 22, 39, 40, 41, and 42, depending on the patient) and the anode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex, assumed to correspond to a region including Brodmann's areas \[BA\] 8, 9, 10, and 46, depending on the patient).The transcranial brain stimulation will be given 2 sessions per day for 10 days, in which 20 minutes of stimulation with an inter-session interval of 3 hours.
62031878|NCT06349369|SHAM_COMPARATOR|Sham control group|To Maximize the stimulatory effects 1mA current will be applied for the first 30 seconds, to provide the initial sensation of real stimulation and then the current will be stopped, thus minimizing the stimulatory effects.
62031879|NCT05967520|EXPERIMENTAL|JMKX000189 - higher dose|Randomized 16 patients will be received JMKX000189 at a higher dose in oral continuously from Week 0 to Week 12 in addition to SOC.
62031880|NCT05967520|EXPERIMENTAL|JMKX000189 - lower dose|Randomized 16 patients will be received JMKX000189 at a lower dose in oral continuously from Week 0 to Week 12 in addition to SOC.
62031881|NCT05967520|PLACEBO_COMPARATOR|Placebo|Randomized 16 patients will be received Placebo in oral continuously from Week 0 to Week 12 in addition to SOC.
62031882|NCT06667921||Ultrasonographic group|Ultrasound will be used to measure the hyomental distance in neutral position (HMDRn), hyomental distance in extended position (HMDRe), (HMDR) and (DSE).
62031883|NCT06133894|EXPERIMENTAL|Experimental group|The experimental group was educated and instructed and agaged in a 12-week exercise program - 15 minutes 6 times per week of complex daily routines delivered via on-line platform.
62031884|NCT06133894|NO_INTERVENTION|Contol group|The control group continued in regular daily activities and was offered the same intervention as the experimental group after the research trial.
62231630|NCT04187053|EXPERIMENTAL|Conventional mechanical therapy with aPDT adjunct|Traditional non-surgical mechanical debridement along with antimicrobial photodynamic therapy will be done at implant sites by applying a photosensitizing dye methylene blue (0.1mg/ml) with a disposable syringe from the bottom of pocket in a coronal direction. The dye will be applied topically confined to the epithelialized space surrounding the implant fixture and will not be internalized. After 5 minutes in situ, the surrounding gingival tissues will be irradiated at six sites around the implant using a diode laser with a wavelength of 660nm, providing an energy density of 10 J/site, 100mW power, time equal to 100 seconds. After irradiation, the site will be thoroughly rinsed with saline.
62231631|NCT04187053|SHAM_COMPARATOR|Conventional mechanical therapy with sham aPDT treatment|"Control group will have conventional mechanical instrumentation of implant site with Sham aPDT treatment with saline and non-light emitting laser"
62231632|NCT00692978|EXPERIMENTAL|Asthma|Asthma patients
62031885|NCT02727894||Screening Group|CRC diagnosed by screening was defined as cancer diagnosed by primary screening colonoscopy, or colonoscopy after a positive immunochemical based faecal occult blood test i(FOBT) in patients without symptoms invited to examination according to the national screening programme policy
62031886|NCT02727894||Non-screening Group|Symptomatic CRC was defined as cancer diagnosed in symptomatic patients.
62592456|NCT02729038|EXPERIMENTAL|Part 2: subjects with ESRD on hemodialysis (Group F)|Subjects with ESRD on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion starting approximately 2 hours before the initiation of the last hemodialysis session of the week (Period 1) and gepotidacin 750 mg administered as a 2 hour IV infusion starting within 2 hours after completion of the last hemodialysis session of the week (Period 2).
62031887|NCT02485210|ACTIVE_COMPARATOR|Covencional treatment|"Convencional endodontic treatment for deciduous teeth, with Surgical chemical preparation with series of Kerr files appropriate for each case, using initial file and an additional two files of larger size, with irrigation and aspiration with 1% sodium hypochlorite (Milton's solution) and endo PTC (Fórmula \& Ação) with each change of file.~Filling of root canals with calcium hydroxide (Ultra-cal, Ultradent, Brazil); base of thin gutta-percha and filling with glass ionomer cement; restorative treatment performed in subsequent session."
62231633|NCT00692978|ACTIVE_COMPARATOR|Healthy volunters|Healthy participants
62592457|NCT06619015|ACTIVE_COMPARATOR|Semaglutide and placebo|All subjects will receive weekly semaglutide inj. for 26 weeks. After 24 weeks of treatment, this group will be randomized to receive placebo, in addition to semaglutide for the last two weeks of the study.
62592458|NCT06619015|EXPERIMENTAL|Semaglutide and pramlintide|All subjects will receive weekly semaglutide inj. for 26 weeks. After 24 weeks of treatment, this group will be randomized to receive pramlintide, in addition to semaglutide for the last two weeks of the study.
62031888|NCT02485210|EXPERIMENTAL|Photodynamic therapy|Endodontic Treatment with photodynamic terapy Irrigation of the root canal system Insertion of sterile paper cone immersed in Chimiolux® methylene blue for three minutes; administration of wireless Therapy XT EC laser device (DMC - São Carlos, Brazil) after removal of cone; energy density: 4 J/cm², power: 100 mw; wavelength: 660 nm; exposure time: 40 seconds Filling of root canals with calcium hydroxide (Ultra-cal, Ultradent, Brazil); base of thin gutta-percha and filling with glass ionomer cement; restorative treatment performed in subsequent session
62031889|NCT03033823|EXPERIMENTAL|Intervention|Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).
62592459|NCT00319592|EXPERIMENTAL|ChimeriVax™-JE|Subjects received 2 injections of placebo (normal saline), 1 each on Days 0 and 7, and 1 injection of ChimeriVax™-JE on Day 28.
62807956|NCT05543954|EXPERIMENTAL|68Ga-FAPI-RGD and 68Ga-RGD PET/ CT scan|Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-FAPI-RGD and 68Ga-RGD, respectively.
62807957|NCT02986217|NO_INTERVENTION|Control Group|Participants randomized to the Control Group will submit a video of surgical performance of vaginal cuff closure during a hysterectomy. Subjects in the control group will receive traditional feedback methods as determined by each participant's training program. Subjects in the control group will repeat the process of video submission of the same procedure using the same surgical approach every 2 weeks for 2 cycles. At 6 weeks, participants will submit a final video performing vaginal cuff closure during hysterectomy.
62807958|NCT02986217|EXPERIMENTAL|Experimental Group|Participants randomized to the Experimental Group will submit a video of surgical performance of vaginal cuff closure during a hysterectomy. Subjects in the experimental group will then receive feedback within 5 business days of video submission and repeat the process of video submission of the same procedure using the same surgical approach every 2 weeks for 2 cycles. At 6 weeks, participants will submit a final video performing vaginal cuff closure during hysterectomy.
62807959|NCT04214223||PANE -> PAC|First, the patient carry out her Pre-Anesthesic Numerical Evaluation and then she benefits from her Pre-Anesthesic Consultation.
62031890|NCT03033823|PLACEBO_COMPARATOR|Control|Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
62592460|NCT00319592|ACTIVE_COMPARATOR|JE-VAX®|Subjects received 1 injection of JE-VAX® each on Days 0, 7, and 28.
62592461|NCT00747474|EXPERIMENTAL|Lipotecan|Intravenous Lipotecan (TLC388 HCl for Injection)
62592462|NCT05956158|EXPERIMENTAL|Behavioral Treatment|
62592463|NCT05956158|PLACEBO_COMPARATOR|Sleep Education Treatment|
62807960|NCT04214223||PAC -> PANE|First, the patient benefits from her Pre-Anesthesic Consultation and then, she carry out her Pre-Anesthesic Numerical Evaluation
62807961|NCT05389098|EXPERIMENTAL|Experimental|eat-hands type food mode
62807962|NCT05389098|ACTIVE_COMPARATOR|Control|Usual food administration
62807963|NCT04585698||headache patients|
62807964|NCT04585698||healthy subjects|
62031891|NCT02669823||Children <15y|no intervention
62031892|NCT02669823||Adults >=15y|no intervention
62031893|NCT01752504|EXPERIMENTAL|Intervention group|Community members who become engaged in the coalitions and in the broader mobilization effort. A subset of community members..
62031894|NCT01478867||Celiac patients|
62592464|NCT02233101|ACTIVE_COMPARATOR|Oral Tranexamic Acid|Patients will receive either oral or intravenous Tranexamic Acid
62592465|NCT02233101|ACTIVE_COMPARATOR|Intravenous Tranexamic Acid|Patients will receive either oral or intravenous Tranexamic Acid
62807965|NCT00528957|EXPERIMENTAL|Tenofovir DF|
62592466|NCT05670288||Spinal Cord Injury|Patients who have had an acute spinal cord injury in the past 72 hours
62592467|NCT03934723|ACTIVE_COMPARATOR|Control|This arm will consist of healthy overweight and obese individuals who are physically inactive and do not have clinically diagnosed depression or depression symptoms.
62592468|NCT03934723|EXPERIMENTAL|Antidpressants|This arm will consist of healthy overweight and obese adults who are physically inactive and who are diagnosed with clinical depression and have been taking antidepressant medications for at least 1 year.
62807966|NCT00528957|ACTIVE_COMPARATOR|stavudine or zidovudine|
62807967|NCT05800600|EXPERIMENTAL|Venofer treatment|Venofer (iron-sucrose) 200mg (5 days) every week administered as an IV infusion
62807968|NCT02076607||Conservative Treatment|Eleven patients underwent conservative treatment with Brace.
62807969|NCT02076607||Surgical Treatment|Fourteen patients who underwent surgical treatment (arthrodesis).
62807970|NCT01366001|EXPERIMENTAL|ALKS 33-BUP|
62807971|NCT01366001|EXPERIMENTAL|ALKS 33|
62031895|NCT00808808||Arm A (Control)|A control arm of usual care offering TIV with baseline advertisement
62231634|NCT04866498||Analgosedation in ICU patients after head and neck tumor resection in general anesthesia|Head and neck tumor resections were performed in general anesthesia. Midazolam and etomidate or propofol were used in introduction and then anesthesia was maintenance with sevoflurane. Patients received intravenous continuous infusion of oxycodone as an analgesic component and sedatives (propofol/dexmedetomidine/midazolam) during analgosedation in ICU.
62592469|NCT06043778|EXPERIMENTAL|COPSI plus mindLAMP|Participants allocated to this arm will be enrolled in COPSI and also have access to the mindLAMP mobile application. mindLAMP's materials will be available on demand for participants use.
62592470|NCT06043778|ACTIVE_COMPARATOR|COPSI|Participants allocated to this arm will be enrolled in COPSI alone. COPSI is delivered in three phases: 1) intensive engagement (0-3 months), including six to eight home visits by Community Health Officers; 2) stabilization phase (4-7 months) with sessions delivered once every 15 days; 3) and maintenance phase (8-12) with sessions delivered once a month.
62592471|NCT04287725|EXPERIMENTAL|exercise + active Photobiomodulation therapy (PBMT)|"Exercise protocol: The program will consist of individual sessions of progressive and submaximal exercises with aerobic training on a treadmill and spine strengthening exercise.~Photobiomodulation therapy: will be performed using the active super pulsed laser (904nm)."
62592472|NCT04287725|PLACEBO_COMPARATOR|exercise + placebo Photobiomodulation therapy (PBMT)|"Exercise protocol: The program will consist of individual sessions of progressive and submaximal exercises with aerobic training on a treadmill and spine strengthening exercise.~Photobiomodulation therapy: will be performed using the placebo super pulsed laser (904nm)."
62592473|NCT00422695||HIV +|Groups divided according to CD4 counts
62592474|NCT00422695||Healthy Controls|HIV -ve subjects
62592475|NCT01275508|EXPERIMENTAL|FITC-Adalimumab|
62592476|NCT04510506|EXPERIMENTAL|Randomized substudy: Artificial Pancreas Therapy|Participants will use a study assigned Tandem t:slim X2 with Control-IQ Technology.for two years.
62592477|NCT04510506|NO_INTERVENTION|Randomized substudy: Usual Care + CGM|Participant will use their usual diabetes care along with a study CGM.
62592478|NCT04510506|NO_INTERVENTION|Triple Label Surveillance substudy (observational arm)|Participants will remain on own baseline diabetes management (e.g. automated insulin delivery system, non-AID pump, MDI)
62592479|NCT03631615|EXPERIMENTAL|Neoadjuvant therpy|neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)
62592480|NCT01772745|ACTIVE_COMPARATOR|Group 1|SILS cholecystectomy
62592481|NCT01772745|ACTIVE_COMPARATOR|Group 2|TPCL cholecystectomy
62592482|NCT03928262|EXPERIMENTAL|Benralizumab - Subcutaneous administration of Dose 1|Benralizumab single dose administration subcutaneously
62592483|NCT03928262|EXPERIMENTAL|Benralizumab - Subcutaneous administration of Dose 2|Benralizumab single dose administration subcutaneously
62592484|NCT03928262|EXPERIMENTAL|Benralizumab - Subcutaneous administration of Dose 3|Benralizumab single dose administration subcutaneously
62031896|NCT00808808||Arm B (Choice)|An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
62231635|NCT02888704|EXPERIMENTAL|intervention: Biological: ADSTEM Inj.|"1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study.~2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study."
62592485|NCT04973371|EXPERIMENTAL|Home-based GeneXpert TB test|Screening household contacts + home-based GeneXpert® MTB/RIF TB testing for those with TB symptoms + immediate referral for clinic-based treatment initiation.
62592486|NCT04973371|NO_INTERVENTION|Standard home-based TB symptom screening with immediate referral|Screening household contacts + immediate referral for clinic-based TB testing
62592487|NCT06358443|EXPERIMENTAL|Jarlsberg cheese + vitamin D and Calcium tablets|All the patients will receive optimal daily efficacy dose of Jarlsberg cheese pluss vitamin D ampulles and calcium tablets in one year
62592488|NCT02075528|EXPERIMENTAL|Paliperidone Extended Release (ER)|The participants were assigned to receive a fixed dosage of 9 mg/d of paliperidone ER for the first 2 weeks. The paliperidone ER dosage was adjusted flexibly after 2 weeks according to the clinical judgment of the physicians in charge.
62592489|NCT04016922||Group A|Patients with mild anemia (Hb concentration: 9.0-10.9 g\\dl).
62592490|NCT04016922||Group B|Patients with moderate anemia (Hb concentration: 7.0-8.9 g\\dl).
62592491|NCT04016922||Group C|Patients with severe anemia (Hb concentration: \>7.0 g\\dl).
62592492|NCT02688062|EXPERIMENTAL|NeuroRegen Scaffold with BMMCs transplantation|
62592493|NCT02688062|EXPERIMENTAL|Surgical intradural decompression and adhesiolysis|
62592494|NCT00851916|OTHER|CyberKnife Radiosurgery|Single arm study using CyberKnife radiosurgery to treat recurrent prostate cancer patients that have already received external beam radiotherapy.
62592495|NCT03843541|EXPERIMENTAL|Active test treatment-NAC|NAC 600mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
62592496|NCT03843541|ACTIVE_COMPARATOR|Active control treatment-Ambroxol hydrochloride|Ambroxol hydrochloride 30 mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
62031897|NCT00808808||Arm C (Choice Plus)|An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
62031898|NCT03518177|EXPERIMENTAL|Hospital-based PR group|The patient will receive an 8-week supervised Pulmonary Rehabilitation Exercise Program at hospital
62031899|NCT03518177|EXPERIMENTAL|Home-based PR group|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program at home
62592497|NCT03843541|PLACEBO_COMPARATOR|Placebo|Placebo will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
62031900|NCT06059716|ACTIVE_COMPARATOR|Standard of Care|Participants will be provided with continuous Telehealth dietitian follow-up
62031901|NCT06059716|EXPERIMENTAL|Standard of Care Plus Technology|In addition to standard of care, participants will be provided with gluten detection technology so as to assist in navigating the gluten-free diet.
62031902|NCT04096079||OHCA patients|Patients who suffered an out-of-hospital cardiac arrest between 2015 and 2018 in Province of Pavia (Italy), Ticino Region (Switzerland), Wien area (Austria) and Nicosia area (Cyprus) who underwent a coronary angiography.
62031903|NCT03360253|EXPERIMENTAL|HMilkProb|L. reuteri DSM 17938 in drops will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together to give the product the correct rheological properties
62231636|NCT01122251|EXPERIMENTAL|Lercanidpine + Valsartan|L10/V80, L20/V80, L10/V160, L20/V160
62592498|NCT04057131||Firazyr|Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.
62807972|NCT01366001|PLACEBO_COMPARATOR|Placebo|
62807973|NCT01207635||Breast Cancer Patients|
62031904|NCT03360253|PLACEBO_COMPARATOR|HMilkPlacebo|The placebo consists of an identical formulation except that the L. reuteri is not present
62807974|NCT05107544|EXPERIMENTAL|High Intensity Interval Training|The entire group is going to be undergo the intervention
62031905|NCT03360253|EXPERIMENTAL|IFormProb|L. reuteri DSM 17938 in drops will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together to give the product the correct rheological properties
62031906|NCT03360253|PLACEBO_COMPARATOR|IFormPlacebo|The placebo consists of an identical formulation except that the L. reuteri is not present
62031907|NCT00574080|EXPERIMENTAL|Arm A|DPACE Induction, Melphalan/DPACE Transplant 1, BEAM Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases
62031908|NCT00574080|EXPERIMENTAL|Arm B|DPACE Induction, Melphalan/DPACE + VTD Transplant 1, BEAM + VTD Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases
62031909|NCT01367873|PLACEBO_COMPARATOR|Placebo|Multiple, single-dose, ascending dosing groups (cohorts) will be evaluated.
62231637|NCT01122251|ACTIVE_COMPARATOR|Lercanidipine or Valsartan|L10, L20, V80, V160
62231638|NCT01122251|PLACEBO_COMPARATOR|Placebo|Placebo comparators of Lercanidipine and Valsartan
62231639|NCT05866926|EXPERIMENTAL|Open Label|Drug: FAB122 Daily dose 100 mg
62592499|NCT01978990||Diabetes Management System , blood glucose|
62592500|NCT00985998|EXPERIMENTAL|Nimotuzumab|
62592501|NCT06618352|EXPERIMENTAL|Daylong exposure to extreme heat|Young adults exposed to daylong indoor overheating associated with an extreme heat event involving a 10-hour daytime exposure at 36°C (45% relative humidity) followed by a 14-hour nighttime exposure at 31°C (45% relative humidity) over three successive days with only a daytime exposure on the final day.
62592502|NCT03463707|EXPERIMENTAL|Treatment with BP101|
62807975|NCT04772014||e-cigarette users|daily e-cigarette use (additional smoking of traditional tobacco cigarettes is not an exclusion criterion)
62807976|NCT04772014||nicotine-naïve|lifetime consumption of less than 20 cigarettes or e-cigarettes
62031910|NCT01367873|EXPERIMENTAL|VIA-3196|Multiple, single-dose, ascending dosing groups (cohorts) will be evaluated.
62423115|NCT05072093|EXPERIMENTAL|All men in cohort: MSM|Prospective cohort of MSM who are followed either in-person at the PRISM Health Research Clinic and/or virtually with remote study visits. Participants will have the option to switch prevention options at any point during the study by indicating their interest during monthly surveys or contacting study staff directly.
62592503|NCT03463707|PLACEBO_COMPARATOR|Treatment with placebo|
62807977|NCT05919407|EXPERIMENTAL|Pyridostigmine|The dose of pyridostigmine will be based on the patient's prior experience with pyridostigmine under the assumption that the patient already gained sufficient experience during their disease course to know which dose is effective for them as patients are advised by their treating neurologist to continually adjust their dose based on their symptoms and side effects.
62592504|NCT05851313|EXPERIMENTAL|Vitamin D supplementation for 16 weeks|The intervention group received 600IU of vitamin D supplements every day, one hour after breakfast for 14-16 weeks.
62592505|NCT05851313|PLACEBO_COMPARATOR|Placebo|The control group took a placebo prepared with the same shape and size of supplements.
62807978|NCT05919407|PLACEBO_COMPARATOR|Placebo (pyridostigmine)|"Same as Experimental, however capsules contain placebo."
62423116|NCT02517099|ACTIVE_COMPARATOR|Pathological phenotype|Regular inhaled steroids- Beclometasone dipropionate 200mcg bd for 4 months OR antibiotic therapy- Co- amoxiclav (0.3ml/kg bd) or Azithromycin (10mg/kg od) for 4 weeks
62592506|NCT06618456|EXPERIMENTAL|Experimental group|Participants undergo an VR-supported trance induction. Participants will see an underwater world adapted to the sound (i.e. text) of the trance. The following exposure will be nearly the same for both groups (see differences in study design).
62592507|NCT06618456|ACTIVE_COMPARATOR|Control group|Participants see the same underwater world in VR but receive no trance induction. The following exposure will be nearly the same for both groups (see differences in study design).
62807979|NCT05919407|EXPERIMENTAL|Amifampridine (base) with modified release|Patients will receive amifampridine 2 dd 15 mg and amifampridine 2 dd 30 mg as add-on to the pre-study dose of pyridostigmine.
62807980|NCT05919407|PLACEBO_COMPARATOR|Placebo (amifampridine)|"Same as Experimental, however capsules contain placebo."
62807981|NCT02050477|EXPERIMENTAL|Laparoscopic Vertical Gastroplasty|
62031911|NCT06143618|EXPERIMENTAL|escape room games|The escape room game will include a patient scenario of four female patients who are victims of violence and apply to different clinics. Necessary equipment and materials will be provided and stations will be established where four female patients who are victims of violence will be evaluated. In order for them to solve puzzles and puzzles related to the subject at the stations; Colorful puzzle set, lettered chest lock, ballot box, colorful stickers, digital countdown clock, and materials to be used by students will be provided by the researchers. In the game, each student will contact the patient at only one station and evaluate signs and symptoms of violence. The group, which completes the tasks and activities and collects the puzzle pieces that will lead to the code of the lock, will complete the puzzle and enter the number codes on it into the key of the locked box on the table (4 numerical codes received), open the box and get the message 'you can escape'.
62031912|NCT06143618|EXPERIMENTAL|role playing|In the role play application, there will be scenarios of four female patients who are victims of violence and apply to different clinics. Before the role play activities, students will be asked to form groups of 4-5 people, and each week, a group will be asked to choose one of the four scenarios given by lot and improvise the case-based role play activity within 40 minutes.
62231640|NCT06181565||Patients who will have isolated aortocoronary bypass grafting surgery|"Patients who will have isolated aortocoronary bypass grafting surgery will be included.~The Medistim machine will be use before and after pericardial closure. Datas will be collected and analysis."
62231641|NCT03815032|EXPERIMENTAL|Optowire Deux FFR assessment (1)|"A total of 45 consecutive patients will be recruited:~group 1 (n=30): To assess the differences in FFR measurements (drift) made by the OptoWire Deux FFRTM guidewire by comparison of simultaneous data of two different OptoWire DeuxTM guidewires"
62423117|NCT02517099|ACTIVE_COMPARATOR|Clinical guidelines|The children will be treated as directed by their Consultant Paediatrician. The treatment may include- regular inhaled steroids- beclometasone dipropionate 200mcg bd for 4 months OR antibiotic therapy- Co-amoxiclav (0.3ml/kg bd) or Azithromycin (10mg/kg od) for 4 weeks
62423118|NCT01087801|ACTIVE_COMPARATOR|ChiRhoStim|Human Secretin for Injection
62423119|NCT01087801|PLACEBO_COMPARATOR|Placebo|Saline for Injection
62423120|NCT00666718|ACTIVE_COMPARATOR|Glargine|Glargine plus Insulin Lispro (2-3 injections)
62423121|NCT00666718|EXPERIMENTAL|ILPS|Insulin Lispro Protamine Suspension (ILPS) plus Insulin Lispro (2-3 injections)
62423122|NCT05199207|EXPERIMENTAL|Sarcopenic patient|Patient with sarcopenic criteria (SARC-F Score, muscle strengh value, appendicular lean mass value)
62423123|NCT05199207|ACTIVE_COMPARATOR|Non sarcopenic patient|Patient without sarcopenic criteria (SARC-F Score, muscle strengh value, appendicular lean mass value)
62423124|NCT06516393|EXPERIMENTAL|Radial extracorporeal shock wave therapy (r-ESWT) application group|Patients with unilateral PF, that were randomly assigned into two groups receiving four sessions of either r-ESWT or r-ESWT+KT treatment once per week. All patients performed home exercises.
62231642|NCT03815032|EXPERIMENTAL|Optowire Deux FFR assessment (2)|group 2 (n=15): To assess the differences in FFR measurements (drift) obtained from an OptoWire DeuxTM FFR guidewire and compare it to the FFR measurement by a VERRATATM guidewire
62423125|NCT06516393|ACTIVE_COMPARATOR|r-ESWT + Kinesio taping (KT) application group|Patients with unilateral PF, that were randomly assigned into two groups receiving four sessions of either r-ESWT or r-ESWT+KT treatment once per week. All patients performed home exercises.
62423126|NCT06346600||Long-term Follow-Up of Participants exposed to SKG0106 Dose level 1|No investigational product will be administered in this study.
62423127|NCT06346600||Long-term Follow-Up of Participants exposed to SKG0106 Dose level 2|No investigational product will be administered in this study.
62423128|NCT06346600||Long-term Follow-Up of Participants exposed to SKG0106 Dose level 3|No investigational product will be administered in this study.
62807982|NCT01969708|ACTIVE_COMPARATOR|aflibercept|2.0 mg aflibercept every 4 weeks
62807983|NCT01969708|ACTIVE_COMPARATOR|bevacizumab|1.25 mg bevacizumab every 4 weeks
62231643|NCT06323577|EXPERIMENTAL|Restricted kinematic alignment|
62423129|NCT01051973|EXPERIMENTAL|Cognitive behavior therapy|
62231644|NCT06323577|ACTIVE_COMPARATOR|Mechanical alignment|
62423130|NCT01051973|ACTIVE_COMPARATOR|Stress management|
62423131|NCT01856231|EXPERIMENTAL|8 week group|Lifestyle physical activity self-efficacy
62423132|NCT03405909||Patients at risk for HCC|"Patients with any of the following conditions:~liver cirrhosis of any origin chronic hepatitis B infection chronic hepatitis C infection with advanced fibrosis non-alcoholic steatohepatitis (NASH) hemochromatosis~Interventions: B-mode ultrasound, contrast enhanced ultrasound (CEUS); MRI / histology"
62231645|NCT00402363|EXPERIMENTAL|omega-3-acid ethyl esters|
62423133|NCT06191185|EXPERIMENTAL|Best Practices Bundle (BPB), No Patient Instructions and Navigation (PIN)|"BPB: patient tracking and lists, audit and feedback, standardized documentation, standardization of care team communication.~No PIN: Patients will receive usual communication from their care team."
62423134|NCT06191185|EXPERIMENTAL|BPB, PIN|"BPB: patient tracking and lists, audit and feedback, standardized documentation, standardization of care team communication.~PIN: enhanced patient instructions and navigation (PIN)."
62423135|NCT06191185|EXPERIMENTAL|No BPB, PIN|"No BPB: Clinic's usual practice after a patient receives an abnormal FIT result.~PIN: enhanced patient instructions and navigation (PIN)."
62423136|NCT06191185|EXPERIMENTAL|No BPB, No PIN|"No BPB: Clinic's usual practice after a patient receives an abnormal FIT result.~No PIN: Patients will receive usual communication from their care team."
62423137|NCT02139085|ACTIVE_COMPARATOR|GSV Electrocoagulation|GSV Electrocoagulation Source: Electrosurgical Generator(FX-Valley Lab; USA) Energy: 60 Watts x 10 seconds
62423138|NCT02139085|ACTIVE_COMPARATOR|GSV Radiofrequency|GSV Radiofrequency Source: Closure FAST(Covidien, USA) Energy: 60 Joules / cm
62423139|NCT05558852|EXPERIMENTAL|Meshless Approach|Laparoscopic Sacrocolpopexy in central or anterior compartment prolapse.
62423140|NCT05672173|EXPERIMENTAL|Treatment (nivolumab, ibrutinib, chemotherapy, liso-cel)|Patients receive ibrutinib PO, nivolumab IV, fludarabine IV, cyclophosphamide IV, and liso-cel IV on study. Patients also undergo apheresis, PET/CT, biospecimen collection, and bone marrow biopsy on study. Patients may receive low-moderate intensity chemotherapy in combination with the study induction therapy per treating physician discretion with approval of study principal investigator.
62231646|NCT00402363|PLACEBO_COMPARATOR|Placebo|
62231647|NCT03155256|EXPERIMENTAL|Coils + Cyanoacrylate Group|Patients with Gastric Varices GOV II or IGV I and with active bleeding, history of previous bleeding due to GV (secondary prophylaxis) or high-risk GV according to Baveno VI consensus for primary prophylaxis will be treated using EUS-guided injection of coils with cyanoacrylate
62423141|NCT02360059|EXPERIMENTAL|Metformin Group|"Participants take 1,000 mg Metformin by mouth twice daily for 12 weeks during Paclitaxel treatment.~Adaptation phase begins 12 days prior to the start of the Paclitaxel therapy. During this phase, study medication dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by the desired dose of 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit."
62423142|NCT02360059|PLACEBO_COMPARATOR|Placebo Group|"Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit."
62807984|NCT06333249|EXPERIMENTAL|Low Dose Group|Male subjects at least 8 y/o treated with a lower dose (Dose 2 in RPGR-001 Horizon Phase 1/2 study) of rAAV2tYF-GRK1-RPGR study drug.
62423143|NCT05348707||Pre Covid 19 cohort|"Infants hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2019 to 16th March 2020."
62807985|NCT06333249|EXPERIMENTAL|High Dose Group|Male subjects at least 8 y/o treated with a higher dose (Dose 5 in RPGR-001 Horizon Phase 1/2 study) of rAAV2tYF-GRK1-RPGR study drug.
62807986|NCT00786227||Legacy HAQ-DI first, PROMIS 20-item short form first|To eliminate effects due to order of administration, patients with RA will be randomized to complete either the Legacy measure HAQ-DI first in the assessment battery or the PROMIS 20-item short forms first.
62423144|NCT05348707||Per Covid 19 cohort year 1|"Infant hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2020 to 16th March 2021. The need to recruit patients for an additional per-covid year (from 17th March 2021 to 16th March 2022) will be evaluated after the data from the first 2 years of recruitment are available."
62807987|NCT01263626||Cough as Primary Complaint|"1. Male and female volunteers 18 years of age and older~2. Cough as chief complaint~3. Referred to the GI clinic to evaluate if reflux is the cause of their chief complaint~4. pH testing for standard of care purposes"
62807988|NCT01263626||Healthy Volunteers|"1. Male and female volunteers 18 years of age and older~2. No history of chronic or acute cough and throat clearing~3. Ability to read a 5th grade script written in English for approximately 20 minutes"
62807989|NCT05239481|EXPERIMENTAL|intervention|Before the examination, the nurse chose the appropriate colonoscopy position size sheet according to the patient's age and body size and spread it on the examination bed; instructed the patient to lie in the designated area according to the body size.Description: ① take off your shoes; ② follow the bed chart; ③ fade your pants to your knees.
62807990|NCT05239481|PLACEBO_COMPARATOR|control|Traditional disposable cleaning sheets were used during control colonoscopy.Before the examination, the nursing staff took a unified and simple language to guide the patient, the following: ① please remove the shoes; ② please sit on the end of the bed mattress; ③ please lie to the left side; ④ please put the head close to the pillow; ⑤ please fade the pants to the knee; ⑥ please put the knee close to the abdomen.
62807991|NCT05638165|EXPERIMENTAL|Cohort QD, NCP112 Gel 0.05%|Single dose of NCP112 Gel 0.05% or Single dose of Placebo
62807992|NCT05638165|EXPERIMENTAL|Cohort BID, NCP112 Gel 0.05%|Multiple dose of NCP112 Gel 0.05% or Multiple dose of Placebo
62807993|NCT00101686|EXPERIMENTAL|Modified Bolus 5-FU/LV with Irinotecan|
62807994|NCT00101686|EXPERIMENTAL|FOLFIRI + bevacizumab|
62231648|NCT03155256|EXPERIMENTAL|Coils Group|Patients with Gastric Varices GOV II or IGV I and with active bleeding, history of previous bleeding due to GV (secondary prophylaxis) or high-risk GV according to Baveno VI consensus for primary prophylaxis will be treated using EUS-guided injection of coils
62231649|NCT01725542|EXPERIMENTAL|Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a|"* Lead-in Phase: day 0 to week 4 PegInterferon alpha-2a + Ribavirin~* Quadruple therapy: week 4 to week 28 Asunaprevir + Daclatasvir + PegInterferon alpha-2a + Ribavirin"
62231650|NCT02521220|EXPERIMENTAL|L-citrulline|Oral food-supplemental amino-acid L-citrulline. 2 times 3g per day.
62807995|NCT00101686|EXPERIMENTAL|miFL + bevacizumab|
62807996|NCT00101686|EXPERIMENTAL|Infusional 5-FU/LV with Irinotecan|
62807997|NCT00101686|OTHER|Oral Capecitabine with Irinotecan|
62031913|NCT06143618|NO_INTERVENTION|control|No application will be given to the control group other than theoretical lectures. The theoretical course covers the definition of violence, types of violence, symptoms and findings seen in women exposed to violence, and evaluation of violence. The theoretical course will be delivered in the form of verbal explanation supported by power point presentation. Before the intervention, one week after the intervention and one month later, all students will be administered the Violence Against Women Knowledge Test, the Attitudes towards Violence Scale and the Scale for Nurses and Midwives to Recognize the Signs of Violence Against Women.
62031914|NCT05013450|EXPERIMENTAL|Dupilumab + anti-PD-1/PD-L1 (SOC)|Patients will continue SOC immunotherapy with PD-1/PD-L1 blockade following progression of disease, and three q3w cycles of dupilumab will be administered
62031915|NCT05013450|EXPERIMENTAL|Anakinra + Dupilumab + anti-PD-1/PD-L1 (SOC)|Patients will continue SOC immunotherapy with PD-1/PD-L1 blockade following progression of disease, and three q3w cycles of dupilumab and anakinra will be administered
62031916|NCT01615731|ACTIVE_COMPARATOR|Two sets of dilators|Two sets of osmotic dilators inserted 1 and 2 days pre-op
62031917|NCT01615731|EXPERIMENTAL|Mifepristone plus one set of dilators|One set of dilators plus mifepristone
62423145|NCT05348707||Per Covid 19 cohort, year 2|"Infants hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2021 to 16th March 2022. The need to recruit patients for this additional cohort will be evaluated after the data from the first 2 years of recruitment are available and analyzed."
62592508|NCT06209970|EXPERIMENTAL|35kDa hyaluronan fragment HA35 injection|A total of 2000 units of bovine testis hyaluronidase PH20 (hyaluronidase for injection H31022111, P.R.C) and 100 mg high molecular weight HA (sodium hyaluronate for injection, H20174089, P.R.C) were mixed at room temperature for 20 minutes, then was locally injected into patient's abdominal deep fat layer by a registered nurse or a physician in order to quickly alleviate pain associated with radiotherapy for treatment colorectal and rectal cancer.
62592509|NCT04115592|EXPERIMENTAL|Liquid oil type 1|Cocoa butter (CB)
62807998|NCT02429635|EXPERIMENTAL|My exercise|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshp.~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan."
62031918|NCT01515670||Fast-track THA/TKA|Any patient receiving THA/TKA in the participating wards
62031919|NCT03364205|EXPERIMENTAL|intervention|solution-focused interview techniques
62423146|NCT00919802|ACTIVE_COMPARATOR|Oxytocin|Oxytocin, 40 IU intranasally, once
62423147|NCT00919802|PLACEBO_COMPARATOR|Saline as a nasal spray|Saline, 4ml intranasally, once
62423148|NCT02689726|EXPERIMENTAL|GTL001 + Aldara, 5% imiquimod cream|2 doses, 6 weeks apart, GTL001 will be adjuvanted with Aldara, 5% imiquimod cream, applied to the injection site 15 minutes and 24 hours after each vaccination
62031920|NCT03364205|NO_INTERVENTION|control|This group did not apply solution-focused interview techniques.
62031921|NCT02988973|EXPERIMENTAL|rHuEPO or DA to ASP1517|Participants will receive roxadustat according to the prior randomization treatment, with starting doses of 70mg thrice weekly (TIW) to participants on \<4500 IU/week of rHuEPO or \<20 microgram (μg)/week of darbepoetin alfa (DA) and 100mg TIW to participants on ≥4500 IU/week rHuEPO or ≥ 20 μg/week DA. Participants roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300 mg.
62031922|NCT02988973|EXPERIMENTAL|rHuEPO or DA to DA|Participants will receive DA according to the prior randomization treatment, with starting doses of 15 μg/2weeks to participants on ≤ 1500 IU/week of rHuEPO or \<11.25 microgram (μg)/week of DA, 30μg/2weeks to participants on \>1500 to \<6000 IU/week of rHuEPO or ≥ 11.25 to \< 22.5 μg/week of DA, 60μg/2weeks to participants on ≥ 6000 IU/week of rHuEPO or ≥ 22.5 to \< 37.5 μg/week of DA, 90μg/2weeks to participants on ≥ 37.5 to \< 52.5 μg/week of DA, 120μg/2weeks to participants on ≥ 52.5 to \< 75 μg/week of DA, 180μg/2weeks to participants on ≥ 75 μg/week of DA. Participant's roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 15, 30, 60, 90, 120, and 180 μg.
62592510|NCT04115592|EXPERIMENTAL|Solid oil type 1|Cocoa butter oleogel (CBOG)
62592511|NCT04115592|EXPERIMENTAL|Liquid oil type 2|Sal seed oil (SL)
62592512|NCT04115592|EXPERIMENTAL|Solid oil type 2|Sal seed oleogel (SLOG)
62592513|NCT06624306|ACTIVE_COMPARATOR|prone PNL|Prone PNL
62231651|NCT02521220|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin as placebo. 2 times 3g per day
62231652|NCT05158582|EXPERIMENTAL|SPECIFIC MODIFIED EXERCISE PROGRAM GROUP|The modified exercise group will perform 12 exercises.
62592514|NCT06624306|ACTIVE_COMPARATOR|prone-flexed PNL|prone-flexed PNL
62807999|NCT02429635|EXPERIMENTAL|Control group - delayed intervention|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team workshops and training groups The control groups will consist of teams that will receive the team-based health promotion measures about 9 months after the Team-based health promotion measures group."
62808000|NCT04315155|EXPERIMENTAL|Double Regimen|belinostat in combination with nivolumab
62031923|NCT02988973|EXPERIMENTAL|Epoetin beta pegol to ASP1517|Participants will receive roxadustat according to the prior registration treatment, with starting doses of 70mg thrice weekly (TIW) to participants on ≤100 μg/week of Epoetin beta pegol and 100mg TIW to participants on \>100 μg/week of Epoetin beta pegol. Participant's roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300 mg.
62031924|NCT04531046|EXPERIMENTAL|axicabtagene ciloleucel|Single infusion administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg
62231653|NCT05158582|ACTIVE_COMPARATOR|CONVENTIONAL EXERCISES PROGRAM GROUP|The conventional exercises program will perform conventional exercises.
62231654|NCT02182570|EXPERIMENTAL|WAL 801 CL|
62231655|NCT04123392|EXPERIMENTAL|Decitabine + BUCY|For TP53+ myeloid tumors undergoing allo-HSCT, Decitabine +BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10, Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
62231656|NCT04123392|ACTIVE_COMPARATOR|BUCY|For TP53+ myeloid tumors undergoing allo-HSCT, BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
62592515|NCT03486444|EXPERIMENTAL|Patient population|When a patient receives an ultrasound examination as part of standard of care or within another clinical research trial, such an examination may serve for an intra-individual comparator examination between conventional and new, ultra-portable ultrasound imaging. Patients will be identified in the clinical setting when appropriate and will be appropriately approached for consent for a combination of ultrasound with the physical exam, for medical student education, IV access, and novel application. Patients will be enrolled and accounted for in the appropriate sub-population.
62592516|NCT03486444|EXPERIMENTAL|Healthy volunteer population|The volunteer population will allow us to practice the use of this equipment and understand the limitations and applicability. The results will be the images acquired as well as surveys from the volunteers and those performing the scans, who will be enrolled in the staff population of this study.
62808001|NCT04315155|EXPERIMENTAL|Triplet Regimen|belinostat in combination with nivolumab and ipilimumab
62808002|NCT05986370|EXPERIMENTAL|lumbar spinal manipulative therapy|Participants will receive spinal manipulative therapy (SMT) exclusively at dysfunctional lumbar segments. Participants will receive 36 SMT sessions over 12 weeks, 3 times per week, each session lasting ≈15 min. Spinal manipulation will be performed using the diversified technique. For each treatment, the SMT provider will perform two spinal manipulations, one on each side of the most painful lumbar vertebra. During spinal manipulations, participants will lay on their side and they will be instructed to inhale and exhale fully before each thrust.
62031925|NCT06387901||Breast Cancer Patients on Paclitaxel|Intervention: Paclitaxel Chemotherapy Generic Name: Paclitaxel Dosage Form: Intravenous infusion Dosage: 80 mg/m² Frequency: Once weekly Duration: 12 weeks
62231657|NCT01424150|EXPERIMENTAL|Liberal|At the commencement of surgery a bolus of Hartmann's balanced salt crystalloid 10 ml/kg followed by 8 ml/kg/h will be administered until the end of surgery. A maintenance infusion will then continue at 1.5 ml/kg/h, for at least 24 hours, but this can be reduced postoperatively if there is evidence of fluid overload and no hypotension, and increased if there is evidence of hypovolaemia or hypotension. Alternative fluid types (crystalloid, dextrose, colloid) and electrolyte supplements will be allowed postoperatively in order to account for local preferences and patient biochemistry, for which we will collect data.
62592517|NCT03486444|EXPERIMENTAL|Student and staff population|To understand the impact of ultraportable ultrasound, survey tools will be used to understand the workflow and clinical care applications and integration of these devices. All staff and student members will be appropriately consented; however, we anticipate that this portion of the study will be minimal risk.
62592518|NCT05844176||Symptomatic intracranial arterial stenosis|
62592519|NCT05844176||Asymptomatic intracranial arterial stenosis|
62231658|NCT01424150|EXPERIMENTAL|Restrictive|Will provide less than 2.0 L water and 120 mmol sodium per day. Induction of anaesthesia will limit IV bolus fluid to ≤5 ml/kg; no other IV fluids will be used at the commencement of surgery (unless indicated by goal-directed device \[see below\]). Hartmann's balanced salt crystalloid 5 ml/kg/h will be administered until the end of surgery, and bolus colloid/blood used intraoperatively to replace blood loss (ml for ml); then an infusion at 1 ml/kg/h until expedited cessation of IV fluid therapy within 24 hours. The rate of postoperative fluid replacement can be reduced if there is evidence of fluid overload and no hypotension, and can be increased if there is hypotension AND evidence of hypovolaemia.
62808003|NCT05986370|EXPERIMENTAL|full spine spinal manipulative therapy|Participants will receive spinal manipulative therapy (SMT) at dysfunctional spinal segments in the lumbar AND other spine regions. Participants will receive 36 spinal manipulative therapy (SMT) sessions over 12 weeks, 3 times per week, each session lasting ≈15 min. Spinal manipulation will be performed using the diversified technique. For each treatment, the SMT provider will perform a minimum of two spinal manipulations, one on each side of the most painful lumbar vertebra. Spinal manipulation will also be delivered at other dysfunctional spinal segments, based on clinical examination. During spinal manipulations, participants will lay prone, supine or on their side and they will be instructed to inhale and exhale fully before each thrust.
62808004|NCT05986370|SHAM_COMPARATOR|sham spinal manipulative therapy|"Participants will receive 36 sham SMT sessions (3x/week for 12 weeks, each session ≈15 min). This will target dysfunctional segments in the lumbar and other spine regions. Three maneuvers will be used:~* Ventral decubitus: 1 to 5 light and brief manual contacts (≈ 20 N and 5 s) will be applied and quickly released over the spinous process of dysfunctional vertebrae identified during clinical examination.~* Dorsal decubitus: sections of the treatment table will be slightly raised or lowered (≈ 5 cm) and their lower limbs' position changed once or twice e.g., knees bent, hips internally or externally rotated. Each position maintained during ≈ 30 s.~* Lateral decubitus: 1 to 5 impulses at the lowest setting of the Activator V instrument (Activator Methods Int. Ltd., Phoenix, Arizona, USA) will be applied on their gluteus and quadratus lumborum muscles. The position of the instrument will change after each impulse."
62808005|NCT05986370|NO_INTERVENTION|no intervention|This fourth arm will comprise healthy volunteers (age/sex-matched to the participants in the test intervention - lumbar group) who will not receive any intervention. The main purpose of this fourth group is to provide reference values to interpret some results obtained in participants with chronic primary low back pain.
62808006|NCT05691881|EXPERIMENTAL|68Ga-NY105|
62808007|NCT05261386|PLACEBO_COMPARATOR|Placebo Comparator: CBT-008|Vehicle
62808008|NCT05261386|EXPERIMENTAL|Experimental: CBT-008 lower concentration|lower concentration dose
62808009|NCT05261386|EXPERIMENTAL|Experimental: CBT-008 higher concentration|higher concentration dose
62808010|NCT04139226|EXPERIMENTAL|Administration of CC-11050|Part 1: Single Ascending Dose Part 2: drug-drug interaction/ food effect (DDI/FE)
62808011|NCT01904409|PLACEBO_COMPARATOR|Placebo|Placebo tablets once daily.
62808012|NCT01904409|EXPERIMENTAL|Rifaximin SSD 40 mg IR tablet|Rifaximin soluble solid dispersion (SSD) 40 mg immediate release (IR) tablet once daily.
62808013|NCT01904409|EXPERIMENTAL|Rifaximin SSD 80 mg IR tablet|Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet once daily.
62808014|NCT01904409|EXPERIMENTAL|Rifaximin SSD 40 mg SER tablet|Rifaximin soluble solid dispersion (SSD) 40 mg sustained extended release (SER) tablet once daily.
62808015|NCT01904409|EXPERIMENTAL|Rifaximin SSD 80 mg SER tablet|Rifaximin soluble solid dispersion (SSD) 80 mg sustained extended release(SER) tablet once daily.
62808016|NCT01904409|EXPERIMENTAL|Rifaximin SSD 80mgIR/80mgSER tablet|Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet + rifaximin SSD 80 mg sustained extended release (SER) tablet once daily.
62808017|NCT06389630|EXPERIMENTAL|video-assisted training group|
62808018|NCT06389630|EXPERIMENTAL|low fidelity simulation model group|
62031926|NCT02698072|EXPERIMENTAL|Exercise and dry needling|"24 therapeutic exercise sessions (twice a week) of a land-based therapeutic exercise program consisting of aerobic exercise (20-25 min warm-up), lower limbs muscle strengthening (20-25 min) and lower limbs muscles stretching (10-15 min).~6 dry needling sessions (once a week) at all the pain points of the involved symptomatic lower limb/s using Hong's fast-in and fast-out technique with multiple rapid needle insertion."
62031927|NCT02698072|ACTIVE_COMPARATOR|Exercise and sham dry needling|"24 therapeutic exercise sessions (twice a week) of a land-based therapeutic exercise program consisting of aerobic exercise (20-25 min warm-up), lower limbs muscle strengthening (20-25 min) and lower limbs muscles stretching (10-15 min).~6 sham dry needling sessions (once a week) at all the pain points of the involved symptomatic lower limb/s using a park sham device consists of a base with a hole in the centre and sticky tape on the bottom. From the top of the base extends a double tube, continuing the central hole in the base."
62031928|NCT00843167|EXPERIMENTAL|Sulforaphane Supplement|Patients receive oral broccoli sprout extract supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.
62031929|NCT00843167|PLACEBO_COMPARATOR|Placebo|Patients receive oral placebo supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.
62231659|NCT06060093|PLACEBO_COMPARATOR|Normoxia - placebo|Both training and sleep in normoxia, supplemented with placebo
62231660|NCT06060093|EXPERIMENTAL|Hypoxia - placebo|Training in normoxia and sleep in hypoxia, supplemented with placebo
62423149|NCT06325176|EXPERIMENTAL|Cryotherapy group|During the 1st visit, the patients will be assessed for pain and episiotomy wound. The cryotherapy group will include 12 postnatal women. This group will use a bag of ice packs applied to the perineal region. The ice pack will be sealed in a plastic bag and wrapped with one layer of thin cotton tissue so that the skin of the participant will not be in direct contact with ice, which could cause discomfort. During the intervention, the women will be asked to remove their underpants and hygienic pads and remain in the dorsal recumbent position during cryotherapy that lasts 20 minutes. This procedure will be done twice a day for seven consecutive days
62592520|NCT05897086|NO_INTERVENTION|Control (No Intervention)|For the control groups, epineural repair will be undertaken in the standard end-to-end fashion using interrupted nylon suture after irrigation of the wound with normal saline as deemed necessary by the operating surgeon.
62031930|NCT02414893||Non obese|
62031931|NCT02414893||Morbidly obese|
62031932|NCT02414893||Sleeve gastrectomy|
62031933|NCT01349075||TheraSphere|
62231661|NCT06060093|EXPERIMENTAL|Hypoxia - ketones|Training in normoxia and sleep in hypoxia, supplemented with ketones
62231662|NCT03133520|NO_INTERVENTION|Standard oxygen group|This patient groups will receive only routine oxygen therapy. Routine oxygen therapy involves administering low-to-medium oxygen flows through a nasal cannula or mask to achieve SpO2≥95%.
62031934|NCT02814318||IV Vancomycin|GBS positive laboring women who are allergic to penicillin and clindamycin and are treated using IV vancomycin.
62031935|NCT02814318||IV Penicillin|GBS positive laboring women who are not allergic to penicillin and are treated using IV penicillin.
62031936|NCT02815553|EXPERIMENTAL|Cardiac tumors|
62231663|NCT03133520|EXPERIMENTAL|High flow oxygen therapy group|This patients group will receive high flow oxygen therapy. High flow nasal oxygen therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, it allows the delivery of higher flow rates \[of up to 60 L/min\] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
62231664|NCT06450431||Control group|Patients attempting surgical consultation for thyroid nodule, with no history of PHPT.
62231665|NCT06450431||PHPT before surgery group|Patients attempting surgical consultation for PHPT.
62231666|NCT06450431||PHPT 6 months after surgery group|Patients operated for PHPT interrogated 6 months after surgery
62231667|NCT06450431||PHPT 12 months after surgery group|Patients operated for PHPT interrogated 12 months after surgery
62423150|NCT06325176|ACTIVE_COMPARATOR|Infrared light therapy|The infrared group will include 12 postnatal women they will be encouraged to place an infrared lamp at a distance of 45 cm from the perineum and the heat produced with 230 volts for twenty minutes. But the mother is checked after the first five minutes to make sure that she is not being burned. The researcher will demonstrate for each woman how to use an infrared lamp, and it will be followed by re-demonstrations and discussions. These procedures will be carried out in the morning and evening for seven consecutive days. The researcher gives the infrared lamp device to each woman and then restores it after completion of the study
62423151|NCT02908698|EXPERIMENTAL|Prednisone Treatment|"Prednisone will be administered orally for 15 days at the following doses:~0.75 mg/kg of body weight for 5 days 0.5 mg/kg of body weight for 5 days 0.25 mg/kg of body weight for 5 days"
62423152|NCT02908698|PLACEBO_COMPARATOR|Placebo Control|Placebo will be administered orally for 15 days in a capsule identical to the experimental treatment.
62423153|NCT01280565|EXPERIMENTAL|Masitinib|Participants receive masitinib (7.5 mg/kg/day), given orally twice daily.
62423154|NCT01280565|ACTIVE_COMPARATOR|Dacarbazine|Participants receive dacarbazine, given via IV bolus at 1,000 mg/m2 once every 3 weeks. Following a protocol amendment, the dacarbarzine treatment group has been closed
62423155|NCT00379366|ACTIVE_COMPARATOR|1|14 Gy ionizing radiations
62423156|NCT00379366|NO_INTERVENTION|2|
62231668|NCT06450431||PHPT 36 months after surgery group|Patients operated for PHPT interrogated 36 months after surgery
62231669|NCT00133887|EXPERIMENTAL|1|patients receiving Rapamycin
62231670|NCT00133887|ACTIVE_COMPARATOR|2|patients receiving anticalcineurin treatment
62031937|NCT03780764|ACTIVE_COMPARATOR|Conventional fixed appliance|"A pre-adjusted edgewise fixed appliance (3M Gemini Unitek, 0.022 Roth prescription brackets) on one side of lower arch."
62031938|NCT03780764|EXPERIMENTAL|Self ligating fixed appliance|"Self-ligating brackets (Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets) on the other side."
62231671|NCT01703663|EXPERIMENTAL|EPAP|Provent Sleep Apnea Therapy.
62423157|NCT04565015|EXPERIMENTAL|GC5107|Immune Globulin Intravenous (Human), 10% Liquid
62423158|NCT05219773|OTHER|Clinic vs Home spirometry|The collection of medical history and demographic data Spirometry testing in both the clinic and home setting. The measurement of height and weight. The evaluation of the perception of home spirometry via a survey.
62423159|NCT02239601|EXPERIMENTAL|Physical Therapy|4 Physical therapy treatment sessions provided prior to chemotherapy and a home program to continue throughout the trial.
62423160|NCT02414074|OTHER|Youth Behavioral Intervention|Teen Intervene Program
62231672|NCT01703663|NO_INTERVENTION|control|
62231673|NCT01804062||no treatment|no treatment, prospective observational
62423161|NCT02414074|OTHER|Parent Education|Everyday Parenting Program
62423162|NCT01408056|EXPERIMENTAL|Timolol 0.5% Gel Forming Solution (GFS)|Half of enrolled subjects will receive topical Timolol
62423163|NCT01408056|ACTIVE_COMPARATOR|Mupirocin 2% ointment|Half of enrolled subjects will receive Mupirocin
62423164|NCT06072755||Critically ill adults|Inpatient adults who require internal jugular venous central line and radial arterial line
62423165|NCT06365229||UBE Group|Patients with LSS undergoing UBE
62592521|NCT05897086|EXPERIMENTAL|Experimental|For the experimental group, after obtaining hemostasis, prior to neurorrhaphy, the operative field will be irrigated with calcium-free Plasmalyte A® (Baxter: Deerfield, IL) throughout the neurorrhaphy. At this point, the nerves will be repaired using standard suture neurorrhaphy techniques. Subsequently, approximately 1 or 2 drops of 5mg/ml (0.5%) methylene blue in sterile water solution are applied to the trimmed nerve endings. Then, approximately 2 ccs of a 190 mM solution of 50% PEG 3.35 kD in sterile water will be irrigated onto the neurorrhaphy site and the surgeon will wait one minute prior to continuing. Following this, the repaired nerve will be irrigated with calcium-containing Lactated Ringers (Hospira; Lake Forest, IL).
62031939|NCT06628921||Episodic migraine|Patients affected by migraine with an episodic pattern (\< 15 monthly migraine days) with or without aura according to ICHD-III criteria with ongoing migraine attack.
62031940|NCT06628921||Chronic migraine|Group/Cohort Description: atients affected by chronic migraine (\> 15 monthly headache days with at least 8 days with migraine features) according to ICHD-III criteria with ongoing migraine attack.
62231674|NCT04660266|OTHER|all cohort|
62231675|NCT05183854|EXPERIMENTAL|Arm I (PCV20, PPSV23)|Patients receive pneumococcal 20-valent conjugate vaccine IM on day 1. PnumoVax23 will be given as an intramuscular injection on Visit 2 (approximately Day 75)
62231676|NCT05183854|EXPERIMENTAL|Arm II (PCV20, PPPSV23)|Patients who have received or are receiving venetoclax therapy, receive pneumococcal 20-valent conjugate vaccine IM at study visit 1 and pneumococcal polyvalent vaccine IM at study visit 2 in the absence of disease progression or unacceptable toxicity.
62231677|NCT01305525||Spinal Cord Stimulation|
62231678|NCT00588484||1|Men, age 35 to 65, being seen at the Mayo Clinic Department of Cardiovascular Health clinic, or has an appointment for a carotid duplex ultrasound exam.
62423166|NCT06365229||UE Group|Patients with LSS undergoing UE
62423167|NCT06165510|EXPERIMENTAL|Convergent AF Ablation with Left Atrial Appendage Exclusion|"Two Staged Convergent AF Ablation Procedure~Stage 1 - Minimally Invasive Surgical Epicardial Ablation Procedure with concomitant LAA exclusion (LARIAT procedure)~Stage 2 - Percutaneous Endocardial Catheter Ablation"
62423168|NCT06165510|ACTIVE_COMPARATOR|Standard Endocardial Catheter Ablation|Standard Endocardial Catheter Ablation
62423169|NCT04299737||First patient in the case pair|This patient will receive the treatment bundle. S. aureus transmission surveillance will be conducted.
62423170|NCT04299737||Second patient in the case pair|This patient will receive usual care. S. aureus transmission surveillance will be conducted.
62423171|NCT01005680|EXPERIMENTAL|Pemetrexed plus Cisplatin|
62423172|NCT01005680|ACTIVE_COMPARATOR|Gemcitabine plus Cisplatin|
62031941|NCT06153173|EXPERIMENTAL|Mirdametinib|Mirdametinib will be dosed by mouth twice a day at a dose of 2 mg/m2 BID with a max of 4 mg BID (8 mg per day max).
62231679|NCT00588484||2|Women, age 35 to 65, being seen at the Mayo Clinic Department of Cardiovascular Health clinic, or has an appointment for a carotid duplex ultrasound exam.
62231680|NCT02550665|EXPERIMENTAL|donepezil 15mg titration|donepezil 15mg during the first 4 weeks before escalation to 23mg
62231681|NCT02550665|EXPERIMENTAL|donepezil 10mg & 23 mg alternating|alternating donepezil 10mg and 23mg during the first 4 weeks before escalation to 23mg
62231682|NCT02550665|ACTIVE_COMPARATOR|no titration of donepezil|no titration and direct escalation to 23mg donepezil
62231683|NCT02146651|EXPERIMENTAL|BioChaperone insulin lispro 0.2U/Kg|BioChaperone insulin lispro 0.2U/Kg
62231684|NCT02146651|EXPERIMENTAL|BioChaperone insulin lispro 0.1U/Kg|BioChaperone insulin lispro 0.1U/Kg
62231685|NCT02146651|EXPERIMENTAL|BioChaperone insulin lispro 0.4U/Kg|BioChaperone insulin lispro 0.4U/Kg
62231686|NCT02146651|ACTIVE_COMPARATOR|Humalog® 0.2U/Kg|Humalog® 0.2U/Kg
62031942|NCT03796624|EXPERIMENTAL|Investigational Device Micropure 1.2.3.|"Implantation of monofocal intraocular lens (IOL) Micropure 1.2.3. in one of the eyes of the study subject"
62231687|NCT01978860|EXPERIMENTAL|NovaCross, CTO|assess the safety and technical feasibility, deployment and withdrawal characteristics of the NovaCross™ micro-catheter during an interventional coronary angioplasty procedure and evaluating the CTO penetration rate.
62231688|NCT03732313|ACTIVE_COMPARATOR|Central toenail resection|Under local ring anaesthesua using xylocaine injection in base of big toe ,Surgical resection of the central part of toenail with underlying germinal matrix.the defect is sutures by prolene.
62231689|NCT03732313|ACTIVE_COMPARATOR|wedge toenail resection|Under local ring anaesthesiausing xylocaine injection around the base of big toe. Resect lateral wedge of toenail with removal of ingrown toenail and periungual skin. The wound is then sutured.
62231690|NCT02910661||Patients|Focus groups (n=6-8/group) will be conducted at 4 sites selected to maximize racial diversity and to ensure availability of adequate numbers in each age group (Montreal (incl. the McGill University Health Centre (MUHC), Centre Hospitalier Universitaire-Ste. Justine \& CHUM ), Pittsburgh, Seattle, and St. Louis). Separate focus groups will be conducted with patients clustered by patient age to maximize homogeneity in developmental stage. Purposive sampling will be employed to ensure that each focus group includes patients with combinations of characteristics that are likely to account for variation in perspectives, including the major racial and ethnic groups, both sexes, time since transplant, and level of adherence.
62231691|NCT02910661||Parents|Focus groups (n=6-8/group) will be conducted at Pittsburgh \& Seattle. Focus groups will be conducted with parents clustered by patient age (12-14 y. \& 15- 17 y.)
62231692|NCT02910661||Healthcare professionals|One focus group of healthcare professionals (HCP) representing the variety of multidisciplinary transplant team members at each center will be convened. We will aim for 4-8 HCP per group; however, the number will be dictated by the composition and size of the transplant team at each site. We expect variability in the organization of care across the 7 sites, which represent 2 countries and small to large program sizes; including all sites will capture this variability.
62231693|NCT01662115|ACTIVE_COMPARATOR|Nicotine gum|100 subjects who will actually get the intervention medication
62231694|NCT01662115|SHAM_COMPARATOR|regular chewing gum|100 subjects who will be part of a control group
62231695|NCT01662115|NO_INTERVENTION|No gum|100 subjects who will not get neither the intervention nor the placebo gum.
62231696|NCT02456077|EXPERIMENTAL|Intervention Practices|Intervention offices will adopt a multi-modal vaccine program to increase their patients' vaccine rates.
62423173|NCT04938063||Cerebral palsy children|Sample size estimation was carried out to determine the recruited number of the diplegic CP children from the outpatient clinic at the Faculty of Physical Therapy, Cairo University, Physical Therapy Department at the National Institute of Neuromotor Disorder, Abu El-Reesh Hospital, and private physiotherapy clinics. The age of patients will range from 18 months to 5 years old. Both sexes will participate in this study
62423174|NCT06181448||Hospitalized patients with acute exacerbations of chronic liver disease|"1. Patient data will be collected through a mobile application, providing real-time prognostic scores for patients.~2. Standary therapy for chronic liver disease with ALI and/or AD"
62592522|NCT02859428||Patients with hereditary spastic paraplegia (HSP)|Patients with hereditary spastic paraplegia types 3A, 4 and 31.
62592523|NCT03030989|ACTIVE_COMPARATOR|Chlorhexidine Gluconate 2% Wipe|
62031943|NCT03796624|ACTIVE_COMPARATOR|Comparator PODEYE|"Implantation of monofocal intraocular lens (IOL) PODEYE in the contralateral eye of the study subject"
62031944|NCT02975167|EXPERIMENTAL|Inpatient|"Subjects randomized to this group will receive the same intervention as the outpatient group -- cervical ripening with Foley catheter -- but remain within the hospital. Subjects will be asked to complete a survey assessing their fears, opinions, anxiety, satisfaction and hours of sleep before and after the catheter is placed and removed, respectively.~The intervention: randomization to inpatient cervical ripening"
62031945|NCT02975167|EXPERIMENTAL|Outpatient|"Subjects randomized to this group will receive the same intervention as the inpatient group -- cervical ripening with Foley catheter -- but will be discharged home. Subjects will be asked to return to the hospital when the catheter falls out or if 24 hours has elapsed. They will be given detailed instructions and provided a 24 hour phone number to call should they have any concerns. Subjects will be asked to complete a survey assessing their fears, opinions, anxiety, satisfaction and hours of sleep before and after the catheter is placed and removed, respectively.~The intervention: randomization to outpatient cervical ripening"
62031946|NCT05461625|SHAM_COMPARATOR|ACL|Anterior cruciate ligament reconstruction without additional procedure
62031947|NCT05461625|ACTIVE_COMPARATOR|ACL + ALL anatomic|Anterior cruciate ligament reconstruction and anatomic anterolateral ligament reconstruction
62231697|NCT02456077|NO_INTERVENTION|Control Practices|Control offices will offer usual health care related to immunizations throughout the duration of the study.
62592524|NCT03030989|PLACEBO_COMPARATOR|Placebo wipe|
62808019|NCT04369378|EXPERIMENTAL|Meditation app group|Participants will also be given access to the mindfulness app (Insight Timer), and instructed to use it for 10 min daily for 30 days. Two days before the end of the 30 day intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. Two months after the conclusion of the 30 day intervention period (90 days after study began), participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
62808020|NCT04369378|NO_INTERVENTION|Control group|Participants will be in the no intervention period for 30 days. Two days before the end of the 30 day no intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. After this 30 day no intervention period, participants are invited to use the Insight Timer app if they so choose. Two months after the conclusion of the 30 day no intervention period (90 days after study began), participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
62592525|NCT05528107|ACTIVE_COMPARATOR|Laparoscopic Intraperitoneal Onlay Mesh plus ventral hernia repair|Laparoscopic Intraperitoneal Onlay Mesh plus repair will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement and suturing hernia defect.
62592526|NCT05528107|ACTIVE_COMPARATOR|Extended-view totally extraperitoneal ventral hernia repair|Extended-view totally extraperitoneal ventral hernia repair will be used to perform minimally invasive ventral hernia repair with retrorectus mesh placement
62592527|NCT02006797|EXPERIMENTAL|intervention|patients with reconciliation procedure at discharge and included in the exchange process
62808021|NCT01853826|EXPERIMENTAL|afatinib|Patients will receive afatinib once daily
62592528|NCT02006797|NO_INTERVENTION|control|usual care
62423175|NCT06566794|PLACEBO_COMPARATOR|Placebo|"Placebo tablets (2 x Placebo) and 150 ml water at 8.00 a.m. on the study day.~Study drug doses (caffeine 50 mg, bupropion 20 mg, repaglinide 0,05 mg, flurbiprofen 10 mg, omeprazole 10 mg, dextromethorphan 10 mg, midazolam 1,0 mg, simvastatin 10 mg) and 250 ml water at 9:00 a.m."
62592529|NCT06354998|EXPERIMENTAL|Investigational mRNA-1273.815|Participants will receive Investigational mRNA-1273.815 by intramuscular injection.
62592530|NCT06354998|ACTIVE_COMPARATOR|Licensed Spikevax Vaccine|Participants will receive a licensed Spikevax vaccine by intramuscular injection.
62031948|NCT05461625|ACTIVE_COMPARATOR|ACL + ALL tenodesis|Anterior cruciate ligament reconstruction and anterolateral ligament tenodesis
62592531|NCT02593526|NO_INTERVENTION|No Diuretic and 37°C dialysate|Standard of care, no diuretic
62592532|NCT02593526|EXPERIMENTAL|No Diuretic and 35.5°C dialysate|Cool dialysate only, no diuretic
62592533|NCT02593526|EXPERIMENTAL|Diuretic and 37°C dialysate|Isothermic dialysate (37°C) and bumetanide (diuretic)
62592534|NCT02593526|EXPERIMENTAL|Diuretic and 35.5°C dialysate|Cool dialysate (35.5°C) and bumetanide (diuretic)
62592535|NCT06665282|EXPERIMENTAL|Pulsed high intensity level laser therapy group|This group includes 38 patients who will receive pulsed high intensity level laser therapy 3 sessions per week over 8 successive weeks in addition to routine physical therapy in the form of hot therapy, stretching and strengthening exercises
62031949|NCT05745077|EXPERIMENTAL|Telemedicine Consultation|Patient will schedule a Telemedicine Consultation in place of traditional in-person visit.
62031950|NCT05745077|ACTIVE_COMPARATOR|Traditional In-Person Care|Patient will schedule a traditional in-person visit as per usual care.
62031951|NCT01357967|EXPERIMENTAL|Seroquel XR adjunctive|"The quetiapine XR adjunct group will be titrated up to 300mg. Initial dosing will begin at 50mg on Day 1 and 2, increased to 150mg on Day 3 and 4. Further adjustments will be able to be made upwards or downwards within the recommended dose range of 50mg to 300mg depending upon the clinical response and tolerance of the patient. Seroquel XR will be administered daily in the evening.~The dosage of SSRIs will be maintained as low (es-citalopram 5mg, paxil CR 6.25mg, fluoxetine 10mg, and sertraline 25mg)."
62231698|NCT02737917|EXPERIMENTAL|Diffuse apneic oxygenation|This group of patients will receive the standard of care treatment of rapid sequence intubation (pre-oxygenation, induction and intubation) plus the application of oxygen.
62808022|NCT00118183|EXPERIMENTAL|Arm I|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and cetuximab IV over 1-2 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 4 courses receive cetuximab alone as above in the absence of disease progression or unacceptable toxicity.
62031952|NCT01357967|ACTIVE_COMPARATOR|SSRI monotherapy|active comparator
62231699|NCT02737917|OTHER|Usual care|This group of patients will receive the standard of care treatment of rapid sequence intubation (pre-oxygenation, induction and intubation)
62231700|NCT05368987|EXPERIMENTAL|PTSD group|Participants will undergo a 3-day experimental paradigm. Before the experiment, participants will undergo a resting-state fMRI scan to determine the specific anatomical location of the TMS target for that particular individual (day 1). The resting-state scan will be about 10 minutes. Functional MRI scans will occur on days 1, 2, 3, and TMS on day 2. A blood draw will occur on experimental day 1 or, if needed due to scheduling, on any of the other experimental visits.
62231701|NCT05368987|ACTIVE_COMPARATOR|Healthy Control group|Participants will undergo a 3-day experimental paradigm. Before the experiment, participants will undergo a resting-state fMRI scan to determine the specific anatomical location of the TMS target for that particular individual (day 1). The resting-state scan will be about 10 minutes. Functional MRI scans will occur on days 1, 2, 3, and TMS on day 2. A blood draw will occur on experimental day 1 or, if needed due to scheduling, on any of the other experimental visits
62231702|NCT02294916|EXPERIMENTAL|Child ETI withoutchest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
62231703|NCT02294916|EXPERIMENTAL|Child ETI with chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
62808023|NCT00118183|EXPERIMENTAL|Arm II|Patients receive docetaxel as in arm I and bortezomib IV over 3-5 seconds on days 1, 8, and 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 4 courses receive bortezomib alone as above in the absence of disease progression or unacceptable toxicity.
62031953|NCT02483169|EXPERIMENTAL|Cilostazol+ Probucol|100mg cilostazol bid plus probucol plus placebo of aspirin
62031954|NCT02483169|ACTIVE_COMPARATOR|Aspirin + Probucol|aspirin plus placebo cilostazol plus probucol
62031955|NCT02483169|EXPERIMENTAL|Cilostazol|cilostazol plus placebo of aspirin
62031956|NCT02483169|ACTIVE_COMPARATOR|Aspirin|aspirin plus placebo of cilostazol
62031957|NCT06556927|EXPERIMENTAL|Laughter yoga group|Laughter yoga will be performed in 8 sessions, 2 days a week for 4 weeks. The duration of each session will be 40 minutes. Laughter yoga sessions will be held on a day suitable for all participants and with the participation of at least 8 people. The session will start with warm-up exercises and continue with laughter exercises. People in the group will do these exercises with the guidance of the researcher.
62231704|NCT02084641|EXPERIMENTAL|Insulin resistant|Both groups will be given the same intervention and then outcomes compared between groups
62231705|NCT02084641|EXPERIMENTAL|Insulin Sensitive|Both groups will be given the same intervention and then outcomes compared between groups
62231706|NCT02866110|EXPERIMENTAL|Treatment group|25 patients with BPD. In a diagnostic session, diagnostics of psychiatric disorders are conducted. For BPD diagnosis, the International Personality Disorder Examination (IPDE) is used and symptom severity is assessed with the Borderline Symptom List. The Treatment group will receive fMRI amygdala neurofeedback training (3 sessions within 2 weeks). Patients in regular psychotherapeutic treatment (treatment-as-usual) will not be excluded.
62231707|NCT03064035|EXPERIMENTAL|Fixed dose 4FPCC|"Incorporating a fixed dose of 1500 IU.~If the patient receiving the 1500 IU fixed dose remains in a bleeding state and the INR remains above goal, an additional 500 IU may be administered at the physician's discretion to minimize bleeding and attempt to achieve hemostasis."
62423176|NCT06566794|ACTIVE_COMPARATOR|Carvedilol|"Carvedilol tablets (2 x Carvedilol STADA 25 mg) and 150 ml water at 8.00 a.m. on the study day.~Study drug doses (caffeine 50 mg, bupropion 20 mg, repaglinide 0,05 mg, flurbiprofen 10 mg, omeprazole 10 mg, dextromethorphan 10 mg, midazolam 1,0 mg, simvastatin 10 mg) and 250 ml water at 9:00 a.m."
62592536|NCT06665282|ACTIVE_COMPARATOR|Shame pulsed high intensity laser level therapy|This group includes 38 patients who will receive shame pulsed high intensity laser level therapy 3 sessions per week over 8 successive weeks in addition to routine physical therapy in the form of hot therapy, stretching and strengthening exercises
62592537|NCT05667831|EXPERIMENTAL|Alginate silver dressing|The experimental group received alginate calcium and silver ion dressing
62808024|NCT05228665|EXPERIMENTAL|Prospective cohort|Participants will be shown a paced breathing programme and instructed to implement this for 10 minutes twice daily for 4 weeks. During the 10-minute breathing exercises, the participant will need to wear the Polar H10 chest strap and can remove this when finished. The breathing will ideally be a breathing pattern of a 4-second nasal inhale, and 6-second nasal exhale using the 'resonance' programme in the 'biofeedback' section of EliteHRV app. They will be advised to monitor the graph of HRV on EliteHRV which allows real-time assessment of HRV and to aim to breathe in and out deeply to raise the HRV graph reading as much as possible each time. They will be advised to perform the breathing programme lying down with minimal distractions on waking in the morning and just before bed in the evening, preferably in the same location each time.
62592538|NCT05667831|NO_INTERVENTION|traditional dressing|Study subjects received traditional dressing changes such as wet dressing or SSD
62592539|NCT06665919|EXPERIMENTAL|Normal Metabolizers of Clopidogrel|157 study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers.
62592540|NCT06665919|EXPERIMENTAL|Passive Metabolizers of Clopidogrel|43 study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping, identified as LoF \*2, \*3 alleles carriers.
62592541|NCT06665919|ACTIVE_COMPARATOR|Unspecified Metabolizers of Clopidogrel|83 participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomization, without CYP2C19 genotyping and clopidogrel metabolism phenotype have not been specified.
62808025|NCT03007550|EXPERIMENTAL|Laparoscopic total gastrectomy|The surgeon will perform LTG with D1+/D2-10 lymphadenectomy for patients enrolled in this group.
62592542|NCT00395941|ACTIVE_COMPARATOR|Control|Acitretin
62592543|NCT00395941|EXPERIMENTAL|Experimental|Pioglitazone
62592544|NCT05601622|EXPERIMENTAL|Study group|Fluid loading, Stroke volume index measurement via transthoracic echocardiography, measurement of pleth variability index and Rainbow pleth variability index, change of tidal volume under mechanical ventilation
62592545|NCT02327403|EXPERIMENTAL|Proteinuric Kidney Transplant Recipients|Belatacept conversion
62592546|NCT05963607|EXPERIMENTAL|Heavy blanket|Wear heavy blanket overnight for 6 weeks
62592547|NCT05963607|ACTIVE_COMPARATOR|Light blanket|Wear light blanket overnight for 6 weeks
62592548|NCT01167881|EXPERIMENTAL|BI 10773 dose plus metformin|Patients receive one BI10773 tablet and one placebo Glimepiride capsule once daily
62808026|NCT03007550|OTHER|Open total gastrectomy|The surgeon will perform OTG with D1+/D2-10 lymphadenectomy for patients enrolled in this group.
62423177|NCT06566794|ACTIVE_COMPARATOR|Diclofenac|"Diclofenac tablet (1 x Voltaren Rapid 50 mg) three times a day around 8.00 a.m., 3.00 p.m. and 9.00 p.m. for three days.~Diclofenac tablet (1 x Voltaren Rapid 50 mg) and 150 ml water at 8.00 a.m., 3.00 p.m. and 9.00 p.m. on the study day (3rd day of diclofenac treatment).~Study drug doses (caffeine 50 mg, bupropion 20 mg, repaglinide 0,05 mg, flurbiprofen 10 mg, omeprazole 10 mg, dextromethorphan 10 mg, midazolam 1,0 mg, simvastatin 10 mg) and 250 ml water at 9:00 a.m."
62231708|NCT03064035|ACTIVE_COMPARATOR|Variable dose 4FPCC|"The FDA-approved variable dosing algorithm is as follows:~initial INR 2-3.9: 25 IU/kg (maximum dose 2500 IU), initial INR 4-6: 35 IU/kg (maximum dose 3500 IU), and initial INR \>6: 50 IU/kg (maximum dose 5000 IU). The patient weight will be obtained using a scale and documented by the treating registered nurse"
62423178|NCT04638725||HER2 positive breast cancer treated only with trastuzumab|
62231709|NCT04089969|EXPERIMENTAL|Evaluation of Standard of care followed by CTA/FFRct|Patient received clinical recommendation based on the Standard of Care i.e 2 D echocardiogram, plus ECG, plus, pharmacological stress test followed by re-evaluation of clinical recommendation with addition of CTA/FFRct
62423179|NCT04638725||HER2 positive breast cancer treated with pertuzumab|
62231710|NCT05397860|EXPERIMENTAL|Patients with clinically diagnosed hepatocellular carcinoma (HCC) (equal or less than 4 cm )|Patients with chronic hepatitis B or liver cirrhosis have hepatocellular carcinoma (HCC) (equal or less than 4 cm) which is diagnosed on contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI).
62231711|NCT05296720|OTHER|Patients|Patients with schizophrenia
62231712|NCT05296720|OTHER|Controls|Controls matched with patients on age, sex and education level
62231713|NCT04834856|EXPERIMENTAL|ensovibep dose 1|
62423180|NCT04638725||HER2 positive breast cancer treated with neratinib|
62423181|NCT04638725||HER2 positive breast cancer treated with Trastuzumab emtansine (TDM1)|
62423182|NCT04638725||HER2 positive breast cancer treated with TDM1 and neratinib|
62423183|NCT04150588||Good reaction to Efrin test|
62423184|NCT04150588||Unsatisfied reaction to Efrin test|
62423185|NCT01289990|EXPERIMENTAL|BI 10773 low (drug naive)|BI 10773 tablets once daily
62231714|NCT04834856|EXPERIMENTAL|ensovibep dose 2|
62231715|NCT04938024|EXPERIMENTAL|People with hyperuricemia (HU) or gout without urate-lowering therapy (ULT)|Participants with HU or gout who are not treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
62423186|NCT01289990|EXPERIMENTAL|BI 10773 high (drug naive)|BI 10773 tablets once daily
62423187|NCT01289990|PLACEBO_COMPARATOR|Placebo (drug naive)|Placebo tablets matching BI 10773 / Sitagliptin once daily
62423188|NCT01289990|ACTIVE_COMPARATOR|Sitagliptin 100mg (drug naive)|Sitagliptin once daily
62423189|NCT01289990|EXPERIMENTAL|BI 10773 low (pioglitazone)|BI 10773 tablets once daily
62423190|NCT01289990|EXPERIMENTAL|BI 10773 high (pioglitazone)|BI 10773 tablets once daily
62231716|NCT04938024|EXPERIMENTAL|People with hyperuricemia (HU) or gout with urate-lowering therapy (ULT)|Participants with HU or gout who are treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
62231717|NCT04938024|ACTIVE_COMPARATOR|People without hyperuricemia (HU) or gout without urate-lowering therapy (ULT)|Participants without HU or gout who are not treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
62592549|NCT01167881|ACTIVE_COMPARATOR|Glimepiride 1-4 mg plus metformin|Patients receive one glimepiride capsule and one placebo tablet Bi 10773 once daily.
62592550|NCT03486678|EXPERIMENTAL|SHR1210+GEMOX|This is a single arm trial. Participants will receive SHR1210 + GEMOX treatment.
62231718|NCT06044402|PLACEBO_COMPARATOR|group L|Ventilation was subsequently changed to individualized positive end-expiratory pressure and recruitment maneuvers during trendelenburg pneumoperitoneum, and the tidal volume was set to 6 ml/kg.
62423191|NCT01289990|PLACEBO_COMPARATOR|Placebo (pioglitazone)|Placebo tablets matching BI 10773 once daily
62423192|NCT01289990|EXPERIMENTAL|BI 10773 low (metformin)|BI 10773 tablets once daily
62423193|NCT01289990|EXPERIMENTAL|BI 10773 high (metformin)|BI 10773 tablets once daily
62423194|NCT01289990|PLACEBO_COMPARATOR|Placebo (metformin)|Placebo tablets matching BI 10773 once daily
62423195|NCT01289990|EXPERIMENTAL|BI 10773 low (metformin+sulfonylurea)|BI 10773 tablets once daily
62592551|NCT03342027|EXPERIMENTAL|Bupropion + Positively Smoke Free|Positively smoke free-- an 8 session tailored behavioral treatment for smoking cessation bupropion--used for smoking cessation
62592552|NCT03342027|EXPERIMENTAL|Bupropion + Standard of Care|Standard of Care--brief advice to quit provided in a standardized format bupropion--used for smoking cessation
62592553|NCT03342027|EXPERIMENTAL|Placebo + Positively Smoke Free|Placebo--matched to bupropion Positively smoke free-- an 8 session tailored behavioral treatment for smoking cessation
62592554|NCT03342027|PLACEBO_COMPARATOR|Placebo + Standard of Care.|Placebo--matched to bupropion Standard of Care--brief advice to quit provided in a standardized format
62592555|NCT04025437|EXPERIMENTAL|Hepatectomy alone|Patients in this group will receive hepatectomy alone.
62592556|NCT04025437|ACTIVE_COMPARATOR|Neoadjuvant radiotherapy plus hepatectomy|Radiotherapy for type I PVTT will be perfomed before hepatectomy. Hepatic resection will be performed in about 4 weeks after radiotherapy.
62423196|NCT01289990|EXPERIMENTAL|BI 10773 high (metformin+sulfonylurea)|BI 10773 tablets once daily
62423197|NCT01289990|PLACEBO_COMPARATOR|Placebo (metformin+sulfonylurea)|Placebo tablets matching BI 10773
62423198|NCT05835999|EXPERIMENTAL|Daily Everolimus (0.5 mg/day) and Weekly Placebo|Once daily (0.5 mg) everolimus and once weekly placebo taken orally for 24 weeks
62423199|NCT05835999|EXPERIMENTAL|Daily Placebo and Weekly Everolimus (5mg/week)|Once daily placebo and once weekly (5 mg) everolimus taken orally for 24 weeks
62423200|NCT05835999|PLACEBO_COMPARATOR|Daily Placebo and Weekly Placebo|Once daily placebo and once weekly placebo taken orally for 24 weeks
62808027|NCT02159586||GES subjects|male and female patients at least 18 years of age, with gastroparesis, who will or have already undergone the implantation of a GES device
62808028|NCT01043172|EXPERIMENTAL|Gemcitabine|Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
62808029|NCT02796677|EXPERIMENTAL|AB/FF 400/12 μg BID|Participants were administered AB/FF 400/12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
62808030|NCT02796677|EXPERIMENTAL|AB 400 μg BID|Participants were administered AB 400 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
62231719|NCT06044402|EXPERIMENTAL|group I|Ventilation was subsequently changed to individualized positive end-expiratory pressure and recruitment maneuvers during trendelenburg pneumoperitoneum, and the tidal volume was set to 8 ml/kg.
62231720|NCT05525884||MAFLD and Non-MAFLD|
62423201|NCT05835999|NO_INTERVENTION|Young Adult Reference Group|Baseline testing only
62423202|NCT03668925|EXPERIMENTAL|"Group Case"|patient diagnosed with hidrosadenitis suppurativa
62423203|NCT03668925|ACTIVE_COMPARATOR|"Group control"|patient without hidrosadenitis suppurativa
62423204|NCT05232838|EXPERIMENTAL|Treatment Arm|The Treatment Arm receives the eShunt Implant.
62423205|NCT00471185|EXPERIMENTAL|A|Subjects will receive progressively increasing doses of 10, 20 and 40 mg of oral acyline, on 3 occasions, each separated by 1 week
62423206|NCT01154400|EXPERIMENTAL|Casein protein hydrolysates|15 g casein protein hydrolysates and 15 g maltodextrin
62423207|NCT01154400|EXPERIMENTAL|Whey protein hydrolysates|15 g whey protein hydrolysates and 15 g maltodextrin
62423208|NCT01154400|EXPERIMENTAL|Casein protein hydrolysates + LEU|15 g casein protein hydrolysates + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
62423209|NCT01154400|EXPERIMENTAL|Whey protein hydrolysates + LEU|15 g whey protein hydrolysates + 1.5 g LEU (40% of EAA content) + 15 g maltodextrin
62592557|NCT04158674|EXPERIMENTAL|Levosimendan|
62592558|NCT04158674|SHAM_COMPARATOR|Placebo|
62808031|NCT02796677|EXPERIMENTAL|FF 12 μg BID|Participants were administered FF 12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
62031958|NCT06556927|NO_INTERVENTION|Control group|"Participants in this group will consist of people who do not routinely do any practice on their own to reduce anxiety and increase life quality. The researcher will ask the participants via phone 4 times a week for 1 month whether they have taken any action to reduce their anxiety and increase life quality symptoms.~Participants who use any of the pharmacological or non-pharmacological practices to reduce anxiety and increase life quality symptoms will be excluded from the study."
62031959|NCT01643694|EXPERIMENTAL|Electronic intervention|Completion of 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks
62031960|NCT01643694|NO_INTERVENTION|control group|Completion of baseline and 3 mo survey
62031961|NCT05707637||VA group|Consecutive patients with VA originating from the base of the heart undergoing unipolar ablation
62423210|NCT03409497|ACTIVE_COMPARATOR|Concord Grape Juice|Concord Grape Juice
62423211|NCT03409497|SHAM_COMPARATOR|Low flavonoid low essence beverage|Low flavonoid low essence beverage
62423212|NCT03409497|SHAM_COMPARATOR|Low flavonoid beverage|Low flavonoid beverage
62423213|NCT06536699|ACTIVE_COMPARATOR|Radiotherapy - conventional|Conventional Radiotherapy of 66 Gy in 30 fractions in definitive setting and 60 Gy in 30 fractions in adjuvant setting Total Duration- 6 weeks
62423214|NCT06536699|EXPERIMENTAL|Radiotherapy - hypofractionated|Hypofractionated Radiotherapy of 55 Gy in 20 fractions in definitive setting and 52.5 Gy in 20 fractions in adjuvant setting. Total duration - 4 Weeks
62423215|NCT01035593|ACTIVE_COMPARATOR|Standard of Care (PP + IVIG)|Plasmapheresis and IVIG 100mg/kg every other day x 5 treatments
62423216|NCT01035593|EXPERIMENTAL|PP + IVIG + rhC1INH|Plasmapheresis + 100mg/kg IVIG every other day x 5 treatments plus rhC1Inh 100u/kg IV daily x 7 consecutive days (once daily on PP days, twice daily on non-PP days).
62423217|NCT00529802|EXPERIMENTAL|Everolimus (RAD001) 10mg daily|All patients were to receive 10mg everolimus (RAD001) daily.
62423218|NCT01029080||Sepsis|All patients with sepsis defined by actually sepsis guidelines
62423219|NCT02375646|EXPERIMENTAL|Continued Warfarin|continuous Warfarin therapy (aiming for therapeutic INR: 2-3) will be given throughout the study
62423220|NCT02375646|ACTIVE_COMPARATOR|LMW Heparin|Enoxaparin 1mg/kg SC bid (adjusted to renal function) will be given 5 days before the colonoscopy while withholding therapy with Warfarin. The day after procedure Warfarin therapy will be added, and Enoxaparin stopped when therapeutic INR will be reached
62423221|NCT03179956|EXPERIMENTAL|Ribociclib|
62423222|NCT02674074|EXPERIMENTAL|measurement of corneal temperature by infrared thermography|
62423223|NCT00891501|EXPERIMENTAL|Single|Clinical case series
62423224|NCT04074473|PLACEBO_COMPARATOR|Propranolol alone|TPropranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)
62423225|NCT04074473|ACTIVE_COMPARATOR|Esophageal variceal ligation alone|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy. After eradication, follow-up endoscopy every 3 months and variceal ligation again if recurrence.
62423226|NCT04074473|EXPERIMENTAL|Esophageal variceal ligation(DC inderal after EV eradication)|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
62423227|NCT04074473|NO_INTERVENTION|Propranolol(Keep BB after EV eradication)|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
62423228|NCT05273398|EXPERIMENTAL|Treatment|Single arm of treatment
62423229|NCT01839227|EXPERIMENTAL|regional cerebral oxygen saturation|
62423230|NCT02146235|EXPERIMENTAL|Treatment Group - Music Therapy|The experimental group participates in once weekly group music therapy session for 6 weeks using playing of simple wind instruments, singing, and music visualization. The Music therapy session lasts 45 min. and encourages patients to use breathing techniques to achieve a relaxation response. Extructured techniques involving singing, music improvisation supports breath pattens and provides supporting coping styles. The use of wind instruments involves a focus of breathing efficiently and elongating the exhalation to prolong musical tones and transferring breath control. Music Visualization involving deep breathing techniques provides optimal mind-body connection, influences breathing rhythms through more indirect means while reducing stress, accessing altered states and encourages healing imagery.
62423231|NCT02146235|NO_INTERVENTION|Standard Pulmonary Rehabilitation|"Pulmonary rehabilitation is a program to people with chronic lung diseases like COPD, emphysema, and chronic bronchitis lead full, satisfying lives and restore them to their highest functional capacity. Pulmonary rehab is aimed to improve quality of life by:~Decreasing respiratory symptoms and complications Encouraging self-management and control over daily functioning Improving physical conditioning and exercise performance Improving emotional well-being Reducing hospitalizations~Pulmonary rehab programs include:~Medical management Exercise Breathing retraining Education Emotional support Nutrition counseling"
62423232|NCT03067506||Participants With Major Depressive Disorder (MDD)|Participants with MDD were provided with an Apple watch on which brief cognitive and mood tests were evaluated daily up to 6 weeks.
62423233|NCT01483612|EXPERIMENTAL|Lifestyle counseling|
62423234|NCT01483612|NO_INTERVENTION|control|
62423235|NCT04789811|EXPERIMENTAL|Exercise Group|It describes the exercise protocol that the patients will do.
62423236|NCT04789811|EXPERIMENTAL|Exercise plus Dry Needling Group|It describes the exercise protocol to be performed by the patients and the methodology of dry needling to be applied.
62031962|NCT06485310|EXPERIMENTAL|TELECONSULTATION|Teleconsultation with a nurse for psychological support, after the diagnosis has been announced, before hospitalization for the first treatment (chemotherapy, surgery, radiotherapy) in addition to the standard practice.
62423237|NCT01826968|EXPERIMENTAL|Recruitment Group|The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. In this group PEEP was set to 8 cmH2O, after the recruitment maneuver, and was left until the end of the operation.
62423238|NCT01826968|NO_INTERVENTION|Control Group|We did not used alveolar recruitment maneuver
62423239|NCT04508621|EXPERIMENTAL|TNX-102 SL Tablet, 5.6 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
62031963|NCT06485310|NO_INTERVENTION|NO TELECONSULTATION|The control group will be cared for according to standard practice (without teleconsultation)
62031964|NCT02496013|EXPERIMENTAL|68Ga-NEB injection and PET/CT scan|"Patients for blood pool imaging:~The patients were intravenously injected with 68Ga-NEB and underwent PET/CT scan 30\~45min after the injection.~Patients for lymph node imaging:~The patients were locally injected 10\~20MBq 68Ga-NEB and followed by dynamic regional PET acquisitions."
62423240|NCT04508621|PLACEBO_COMPARATOR|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
62423241|NCT05309707||Patients with aortic arch pathologies treated by branch stent graft systems|Patients with aortic arch pathologies treated by branch stent graft systems (Nexus stent-graft system®, Relay Branch® or Zenith arch branch graft®), with proximal landing at zone 0.
62423242|NCT02120859|EXPERIMENTAL|FFR - guided DEB angioplasty|DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (\> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis \< 40% and FFR \> 0.8.
62423243|NCT02120859|OTHER|DEB angioplasty with provisional bare metal stenting|In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
62423244|NCT05986214|EXPERIMENTAL|VC-OPTIONS|Participants will be enrolled in the Annie texting VC-OPTIONS protocol
62423245|NCT01926301||Hemodialysis|Patients with severe sepsis or septic shock with acute renal failure and requirement of continuous veno-venous hemodialysis
62423246|NCT01926301||No hemodialysis|Patients with severe sepsis or septic shock without acute renal failure and no requirement of continuous veno-venous hemodialysis
62423247|NCT03740178|EXPERIMENTAL|Donepezil + MK-4334|Oral MK-4334 60/120 mg QD and open-label, oral donepezil 10 mg QD.
62423248|NCT03740178|PLACEBO_COMPARATOR|Donepezil + Placebo|Placebo to MK-4334 QD and open-label, oral donepezil 10 mg QD.
62423249|NCT04231994|EXPERIMENTAL|TPE|additive singular therapeutic plasma Exchange (TPE) using fresh frozen Plasma (FFP) as replacement fluid
62808032|NCT02796677|EXPERIMENTAL|TIO 18 μg QD|Participants were administered TIO 18 μg via Handihaler® inhale once daily for 24 weeks of treatment.
62031965|NCT05266118||Former ICU patients|Participants is former ICU patients, immediately after transferred from ICU to a hospital ward. At least one of these criteria is needed for the participation in the study: ICU stays \> 24 hours; ventilatory support; transferals to other ICU \< 24 hours; continuous infusion of vasoactive substances. In addition, to be included, the patients must be more than 18 years of age; understand and be able to write and read Norwegian; be able to communicate verbally; not have a manifest cognitive deficit; and not being readmitted to ICU \< 72 hours
62808033|NCT05114824|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy
62031966|NCT01064037|EXPERIMENTAL|Arm 1|
62031967|NCT01064037|EXPERIMENTAL|Arm 2|
62031968|NCT01064037|EXPERIMENTAL|Arm 3|
62231721|NCT05525884||Steatosis and Non-Steatosis|
62231722|NCT05525884||Fibrosis and Non-Fibrosis|
62423250|NCT04231994|NO_INTERVENTION|SMT|Standard medical Treatment (SMT) for septic shock following the present surviving sepsis guidelines
62423251|NCT02203188|EXPERIMENTAL|Lid debridgement scaling|Perform lid debridgement scaling
62592559|NCT02715505|EXPERIMENTAL|HSC835|HSC835 is an expanded umbilical cord blood product used during single umbilical cord blood transplantation
62423252|NCT02203188|NO_INTERVENTION|Control|No Treatment
62423253|NCT06023303|EXPERIMENTAL|Group A- Split face|Group A will receive split face treatments with the Potenza and Morpheus. Randomization will not be used for enrolling subjects to a group but will be used for Group A to determine which side of the face will receive which device.
62423254|NCT06023303|EXPERIMENTAL|Group B- none split face|Group B will receive treatments on the face, abdomen, and/or back with Potenza and/or Morpheus.
62031969|NCT01064037|PLACEBO_COMPARATOR|Arm 4|
62231723|NCT05988255|EXPERIMENTAL|Static progressive stretch|
62231724|NCT05988255|ACTIVE_COMPARATOR|Cyclic manual stretch|
62231725|NCT05988255|NO_INTERVENTION|No treatment|
62231726|NCT03688607||POKE|All babies in NICU at Intermountain Healthcare hospitals
62231727|NCT04261023|EXPERIMENTAL|Abatacept|Treatment arm - 125mg sub-cutaneous injection at week 0 and once weekly thereafter for a maximum of 48 weeks
62231728|NCT04261023|NO_INTERVENTION|Control arm - CCP Next Generation|Observational study cohort - usual care
62423255|NCT03637920||transmen|Biological women, who identify as men and are seeking gender reassignment.
62423256|NCT04596462|EXPERIMENTAL|68Ga-FAPI PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
62423257|NCT01866995|EXPERIMENTAL|Raylis|"This arm (10 men with symptoms of prostatostasis) will get Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months"
62423258|NCT01866995|ACTIVE_COMPARATOR|standard prostatostasis therapy|This arm (20 men with symptoms of prostatostasis) will get the standard (pathogenetic) therapy of prostatostasis
62592560|NCT06554847|EXPERIMENTAL|611 interval 1+Topical Corticosteroid|Participants will receive 611 according to established dosing interval 1. TCS will be initiated at Baseline in all patients and may be tapered or stopped, as needed, based on treatment response.
62592561|NCT06554847|EXPERIMENTAL|611 interval 2+Topical Corticosteroid|Participants will receive 611 according to established dosing interval 2. TCS will be initiated at Baseline in all patients and may be tapered or stopped, as needed, based on treatment response.
62592562|NCT06554847|PLACEBO_COMPARATOR|Placebo+Topical Corticosteroid|Participants will receive Placebo according to according to established dosing intervals. TCS will be initiated at Baseline in all patients and may be tapered or stopped, as needed, based on treatment response.
62423259|NCT01866995|EXPERIMENTAL|Raylis plus standard prostatostasis therapy|"This arm (20 men with symptoms of prostatostasis) will get Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months together with standard prostatostasis therapy"
62031970|NCT02302729|EXPERIMENTAL|Micronutrients No responsive feeding|Micronutrient powder and no responsive feeding
62031971|NCT02302729|PLACEBO_COMPARATOR|Placebo and Responsive Feeding|Placebo (vitamin B2) and Responsive Feeding
62031972|NCT02302729|EXPERIMENTAL|Micronutrients and Responsive caregiving|Micronutrients and Responsive feeding intervention
62031973|NCT02302729|PLACEBO_COMPARATOR|Placebo and No responsive caregiving|Placebo and No responsive caregiving
62423260|NCT04870931||TEM-Group|All patients that underwent TEM
62423261|NCT04870931||TEM-ESD-Group|All patients that underwent TEM-ESD
62423262|NCT03598673||Hypertensives to receiving Nevibolol|Patients to receive Nevibolol
62423263|NCT00057252||1|Patients with medical imaging records
62423264|NCT03757741||AF-SG 01|Study subjects with atrial fibrillation recurrence after ablation: Blood sampling (assessment of complete blood count, biochemistry, inflammatory biomarkers), 2D transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance, and complex left and right atrium analysis, Pulmonary vein isolation radiofrequency ablation
62592563|NCT04423952||Patients with chronic otitis media|Patients aged 7 to 15 years with chronic otitis media.
62592564|NCT04423952||Controls|Minors aged 7 to 15 years, with no and no history of chronic otitis.
62031974|NCT03627481|EXPERIMENTAL|AERD patients|Patients managed with Endoscopic sinus surgery for treatment of AERD.
62031975|NCT05093231|EXPERIMENTAL|Pembrolizumab and olaparib|"Pembrolizumab will be given as a fixed dose of 200mg standard dose on Day 1 (+/-3 days) of every 3 weeks cycle , administered intravenously as a \~30 minute infusion, as per standard clinical practice.~Olaparib dose is 300mg given orally, twice daily, from Day 1 to Day 21 continuously of each 3-week cycle. Dosing will start on day 1 of each cycle."
62031976|NCT01155544|ACTIVE_COMPARATOR|Aripiprazole|
62031977|NCT01155544|PLACEBO_COMPARATOR|Placebo|
62031978|NCT03147248|ACTIVE_COMPARATOR|Cohort 1: CT-P13 IV 3 mg/kg|CT-P13 Intravenous (IV) (Infliximab), 3 mg/kg by IV infusion every 8 weeks (Part 1)
62031979|NCT03147248|EXPERIMENTAL|Cohort 2: CT-P13 SC 90 mg|CT-P13 Subcutaneous (SC) (Infliximab), 90 mg by SC injection every other week (Part 1)
62031980|NCT03147248|EXPERIMENTAL|Cohort 3: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every other week (Part 1)
62031981|NCT03147248|EXPERIMENTAL|Cohort 4: CT-P13 SC 180 mg|CT-P13 SC (Infliximab), 180 mg by SC injection every other week (Part 1)
62031982|NCT03147248|EXPERIMENTAL|Arm 1: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every other week with placebo intravenous infusion at Weeks 6, 14 and 22 (Part 2)
62031983|NCT03147248|ACTIVE_COMPARATOR|Arm 2: CT-P13 IV 3 mg/kg|CT-P13 IV (Infliximab), 3 mg/kg by IV infusion every 8 weeks with placebo subcutaneous injection at Week 6 and every 2 weeks thereafter up to Week 28 (Part 2)
62031984|NCT06015854|EXPERIMENTAL|HPV16+ CIN3|Patients with histological proven HPV16-positive cervical intraepithelial neoplasia grade 3.
62031985|NCT06209710|EXPERIMENTAL|Intervention Arm: BPA + PADN + Standard Drug Therapy|Participants in this arm will undergo the combination of Balloon Pulmonary Angioplasty (BPA) and Pulmonary Artery Denervation (PADN) procedures.
62031986|NCT06209710|SHAM_COMPARATOR|Control Arm: BPA + Sham PADN + Standard Drug Therapy|Participants in this arm will receive the combination of Balloon Pulmonary Angioplasty (BPA) and standard drug therapy as the control group. Similar to the intervention arm, a denervation catheter will be placed in the same anatomical position, but no further denervation intervention will be performed.
62031987|NCT04036175|OTHER|Group 1|Standard oxygen - High-Flow Nasal Oxygen - Non-invasive ventilation - Standard Oxygen (20 minutes for each condition)
62592565|NCT06621758||MCI|Individuals diagnosed with mild cognitive impairment (MCI)
62031988|NCT04036175|OTHER|Group 2|Standard oxygen - Non-invasive ventilation - High-Flow Nasal Oxygen - Standard Oxygen (20 minutes for each condition)
62031989|NCT04286373|EXPERIMENTAL|Group A: active stimulation then placebo stimulation|"VNS active stimulation: Use of device (Tens Eco Plus SCHWA MEDICO™) for 8 weeks, then VNS placebo for 8 weeks.~The two stimulation periods will be separated by a 4 +/- 1 weeks wash-out period.~The VNS placebo stimulation period being the control one."
62031990|NCT04286373|EXPERIMENTAL|Group B: placebo stimulation then active stimulation|"VNS placebo for 8 weeks, then VNS active stimulation Use of device (Tens Eco Plus SCHWA MEDICO™) for 8 weeks.~The two stimulation periods will be separated by a 4 +/- 1 weeks wash-out period.~The VNS placebo stimulation period being the control one."
62031991|NCT05018611|EXPERIMENTAL|LifeSkills Mobile|Access to LifeSkills Mobile app. Participants will complete 4 modules with 20 activities across 6 months. Participants can log in at their convenience but will not be able to access the next module until the previous module is completed.
62031992|NCT05018611|NO_INTERVENTION|Standard of Care|HIV home testing every 6 months, information regarding sexual and other behaviors that potentiate one's risk for HIV infection, receipt of a fact sheet about PrEP and PEP and referrals to the local PrEP clinics, and sexually transmitted infection testing via an on-line location findings app.
62031993|NCT02532660|EXPERIMENTAL|Escitalopram + LABCAT TCJUSS|Escitalopram 10mg + LABCAT TCJUSS 1000 mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night);
62031994|NCT02532660|PLACEBO_COMPARATOR|Escitalopram + LABCAT TCJUSS placebo|Escitalopram 10mg + LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
62031995|NCT02532660|EXPERIMENTAL|Escitalopram Placebo + LABCAT TCJUSS|Escitalopram Placebo + LABCAT TCJUSS 1000 mg daily (2 capsules in the morning + 2 capsules at night).
62231729|NCT02905994|EXPERIMENTAL|Volasertib with chemotherapy|"Patients enrolled on this trial will receive induction chemotherapy with 7+3~* Cytarabine continuous infusion days 1-7~* Idarubicin IV bolus on days 1, 2, and 3.~* Patients will receive Volasertib as an intravenous infusion over approximately 1 hour, according to dosing level, on day 8~* Patients will receive Standard Anti Fungal and Standard Antibiotic during induction~* A bone marrow biopsy will be performed according to standard practice on day 14"
62231730|NCT05321888|ACTIVE_COMPARATOR|Mechanical Ventilation|Mechanical Ventilation
62231731|NCT05321888|EXPERIMENTAL|Mechanical Ventilation with Postural drainage|Mechanical Ventilation with Postural drainage
62231732|NCT02049151|EXPERIMENTAL|Tecemotide|
62423265|NCT03757741||AF-SG 02|Study subjects without atrial fibrillation recurrence after ablation: Blood sampling (assessment of complete blood count, biochemistry, inflammatory biomarkers), 2D transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance, and complex left and right atrium analysis, Pulmonary vein isolation radiofrequency ablation
62423266|NCT00974610||Breast|
62423267|NCT00974610||Lung|
62423268|NCT00974610||Melanoma|
62423269|NCT00974610||Pancreatic|
62423270|NCT00974610||Colorectal|
62423271|NCT02059031|EXPERIMENTAL|Part A|In Part A, subjects will be randomized to receive two new formulations of GSK1265744 30 mg (New formulation 1 -micronized \[B\], New formulation 2un-micronized \[C\]) and the sodium salt reference formulation 30 mg (Reference formulation \[A\]) in one of six sequences; ABC, BCA, CAB, BAC, ACB, CBA in three treatment periods under fasting condition.
62423272|NCT02059031|EXPERIMENTAL|Part B|Fifteen eligible subjects completing the Part A of the study will enter in to Part B where they will receive either formulation B or C. The selected drug (B or C) will be administered under fed (moderate fat meal) condition in the fourth treatment period.
62423273|NCT01508572|EXPERIMENTAL|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
62423274|NCT03169699||Cough Arm|Children age 16 years old and below with cough at presentation - Patients presenting with active or chronic or residual cough
62423275|NCT03169699||Well Arm|Children age 16 years old and below and Well with no presentation of cough
62423276|NCT04324307|EXPERIMENTAL|PD-L1/CTLA4 BsAb|For 2nd line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W
62423277|NCT04324307|EXPERIMENTAL|PD-L1/CTLA4 BsAb + GP|For 1st line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W in combination with Gemcitabine 1000 mg/m2 and Nab-paclitaxel 125 mg/m2 , 28days/cycle
62423278|NCT04324307|EXPERIMENTAL|PD-L1/CTLA4 BsAb + FOLFIRINOX|For 1st line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W in combination with Oxaliplatin 68 or 85 mg/m2, Irinotecan 135 or 150 or 180 mg/m2, Calcium Folate 400 mg/m2, Fluorouracil 2400mg/m2, 14 days/cycle
62423279|NCT00323271|EXPERIMENTAL|Arm 1|Behavioral: Cognitive-behavior therapy
62423280|NCT00323271|ACTIVE_COMPARATOR|Arm 2|Interventional: Educational intervention
62592566|NCT06621758||SCD|Individuals diagnosed with subjective cognitive decline (SCD)
62808034|NCT05114824|NO_INTERVENTION|Control Group|Control group
62231733|NCT02049151|PLACEBO_COMPARATOR|Placebo|
62231734|NCT04362605|EXPERIMENTAL|intervenional group|ENPT
62231735|NCT02564354|EXPERIMENTAL|ΔF508 Homozygous|QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
62808035|NCT03349723|EXPERIMENTAL|BI 1265162|BI 1265162
62231736|NCT02564354|EXPERIMENTAL|ΔF508 Compound Heterozygous|QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
62231737|NCT01703351|EXPERIMENTAL|Drug: 0.5% ropivacaine|
62231738|NCT01703351|ACTIVE_COMPARATOR|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg|
62231739|NCT00938470|EXPERIMENTAL|Arm I (combination chemotherapy, radiation therapy, surgery)|Patients receive docetaxel IV over 1 hour and oxaliplatin IV over 2 hours on day 1. Patients also receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. After completion of the second course, patients receive fluorouracil IV continuously on days 1-5 and oxaliplatin IV over 2 hours on days 1, 15, and 29. Patients also undergo radiotherapy 5 days a week for 5.5 weeks in the absence of disease progression or unacceptable toxicity. Approximately 4-12 weeks after completion of radiotherapy, patients undergo surgery.
62231740|NCT00938470|ACTIVE_COMPARATOR|Arm II (oxaliplatin, fluorouracil, radiation, and surgery)|Patients receive fluorouracil IV continuously on days 1-5 and oxaliplatin IV over 2 hours on days 1, 15, and 29. Patients also undergo radiotherapy and then surgery as in Arm I.
62231741|NCT00381303|EXPERIMENTAL|001|darunavir 600mg bid for 48 wks,ritonavir 100mg bid for 48 wks
62592567|NCT01760967|ACTIVE_COMPARATOR|Dexmedetomidine|administer dexmedetomidine (0.1-0.7ug/kg/h) from the beginning of ICU treatment
62231742|NCT04295980||Geschwind's area BAVMs|
62808036|NCT03349723|PLACEBO_COMPARATOR|Placebo|Placebo
62808037|NCT03454295|EXPERIMENTAL|Part I|Focus group (Part 1) of four to ten GBM ICs bereaved at least one year to help determine our recruitment strategy. Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received. Should consensus among participants be reached (e.g., if the majority report that being approached at time of their loved one's cancer recurrence would have been the optimal time for enrollment), we will target our enrollment timeline to this point (and this timeline will be reflected in amended inclusion criteria). If no consensus is reached, the study staff will enroll ICs at all points in the caregiving trajectory and revisit the appropriateness of various points of contact during the Part 2 individual interviews.
62231743|NCT04295980||Healthy controls|
62231744|NCT06148974|EXPERIMENTAL|Polar lipid 1|15 g Plant polar lip 1 consumed with a white wheat bread including 50 g available carbohydrates
62231745|NCT06148974|EXPERIMENTAL|Polar lipid 2|15 g Plant polar lipids 2 consumed with a white wheat bread including 50 g available carbohydrates
62231746|NCT06148974|ACTIVE_COMPARATOR|non-polar lipids|15 g commonly consumed non-polar lipids consumed with a white wheat bread including 50 g available carbohydrates
62231747|NCT06148974|PLACEBO_COMPARATOR|no lipids|A white wheat bread including 50 g available carbohydrates
62231748|NCT04811209||single group, open labelled observational study with no blinding.|All study patients will be managed per routine clinical practice and institutional standard for the performed surgery.
62231749|NCT02647866|EXPERIMENTAL|KHK4083 Cohort 1|Subjects received one 1.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
62592568|NCT01760967|ACTIVE_COMPARATOR|non-Dexmedetomidine|administer sedatives except Dexmedetomidine
62808038|NCT03454295|EXPERIMENTAL|Part II|In Part 2, we will recruit 60 ICs of patients with GBM who will be randomized to receive either MCP-C or EUC. MCP-C will be delivered individually over 7 1-hour-long sessions within 7 - 14 weeks.
62231750|NCT02647866|EXPERIMENTAL|KHK4083 Cohort 2|Subjects received one 3.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
62231751|NCT02647866|EXPERIMENTAL|KHK4083 Cohort 3|Subjects received one 10.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
62231752|NCT02647866|EXPERIMENTAL|KHK4083 Cohort 4|Subjects received one maximum tolerated dose (10.0 mg/kg) IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
62231753|NCT02647866|PLACEBO_COMPARATOR|Placebo|Subjects received one IV infusion treatment of Placebo every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48. Subjects who participated in Open-Label Therapy received KHK4083 instead of placebo.
62231754|NCT06416553|ACTIVE_COMPARATOR|PD patients with real tDCS and speech therapy|Patients will receive real tDCS during 4 weeks, 5 sessions per week. Altogether 20 sessions, each 20 minutes long. Stimulation is combined with Lee-Silverman voice treatment, 4 sessions per week. Altogether 16 sessions, each 1 hour long.
62231755|NCT06416553|SHAM_COMPARATOR|PD patients with sham tDCS and speech therapy|Patients will receive sham tDCS during 4 weeks, 5 sessions per week. Altogether 20 sessions, each 20 minutes long. Stimulation is combined with Lee-Silverman voice treatment, 4 sessions per week. Altogether 16 sessions, each 1 hour long.
62231756|NCT05390983|EXPERIMENTAL|carotid endarterectomy|carotid endarterectomy with stent removal
62231757|NCT05390983|ACTIVE_COMPARATOR|repeated angioplasty and stenting|percutaneous transluminal angioplasty with or without stenting
62231758|NCT02939248|ACTIVE_COMPARATOR|Crushed ticagrelor followed by morphine|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously
62231759|NCT02939248|ACTIVE_COMPARATOR|Crushed ticagrelor, morphine,naloxone|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
62231760|NCT01972711|EXPERIMENTAL|SEP-363856|Single-dose SEP-363856 50 mg
62231761|NCT01972711|ACTIVE_COMPARATOR|Amisulpride|Single-dose Amisulpride 400 mg.
62231762|NCT01972711|PLACEBO_COMPARATOR|Placebo|Matched placebo
62423281|NCT03128073|EXPERIMENTAL|Single group|The intervention is with the Carry Life system ultrafiltration (CLS UF) device, which administers a Glucose-salt solution intermittently to a volume of the intraperitoneal fluid in the device.
62231763|NCT01276431|OTHER|Buprenorphine transdermal patch|For two age groups: 50-60 years and \>= 75 years of age
62231764|NCT02386709|EXPERIMENTAL|Experimental Arm|"1. Diagnostic~2. PET1 : before the neoadjuvant treatment~3. start neoadjuvant treatment~4. PET2: two weeks after the start of the first course of chemotherapy~5. surgery"
62231765|NCT01264822||Treatment Arm 1 Rabeprazole Sodium|
62231766|NCT04291599|EXPERIMENTAL|Experimental Arm - Ketorolac (Opioid-Sparing)|Patients assigned to this arm of the study will follow the standardized step-up approach to pain management per the hospital Evidenced Based Guideline (EBG). If analgesia is not obtained with first-line medications such as acetaminophen, the patient will be given the NSAID ketorolac intravenously every 6 hours at the standard weight-based dose throughout hospitalization. If the patient experiences continued pain, they (or their guardian/ caregiver) may request a rescue medication in the form of low-dose morphine (or an alternative opioid if allergic to morphine) at 0.025 mg/kg/dose every 4 hours.
62231767|NCT04291599|ACTIVE_COMPARATOR|Control Arm - Conventional Treatment/Standard of Hospital Care|Patients assigned to this arm of the study will be treated per institutional policy and procedural care as dictated by established hospital order sets and at the discretion of the provider. This may involve the step-up approach per the hospital EBG utilizing acetaminophen or ibuprofen as first-line agents; however, it remains at the discretion of the treating provider. The current standard of care for children presenting to the ED is based on prescribing order sets within the electronic medical record (EMR). Physicians in the BCH emergency department choose in an intermittently-prescribed manner, standard doses of analgesia including acetaminophen (Tylenol) or ibuprofen per the hospital EBG, as well as opioids (morphine, hydromorphone).
62423282|NCT02026882|OTHER|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway with gastric tube. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
62423283|NCT02065882|EXPERIMENTAL|BT524|Single intravenous infusion of a fixed dose of 70 mg BT524 per kilogram body weight (BW)
62423284|NCT00282425|EXPERIMENTAL|Allogeneic Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation will be performed on eligible patients
62423285|NCT04033627|EXPERIMENTAL|In Vitro T cell depletion|Use the CliniMACS TCRα/β and CD45 Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.
62231768|NCT02790580|ACTIVE_COMPARATOR|Dose-dense doxorubicin/cyclophosphamide|Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles, Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles, Subcutaneous pegfilgrastim 6mg, 24-36 hours after doxorubicin/cyclophosphamide
62808039|NCT04516720||Primary Nervous System Tumors arm|"The information letter will be delivered by the investigator physician to the patients to inform them on the study, its implementation and their complete freedom to participate or not.~Clinical Data and Questionnaires:~1. For the retrospective part~   * Patient identification based on data from the Medical Information Department (DIM) of the ICM;~  * Verification of the eligibility criteria;~  * Inclusion of patients in a coded form in BDD-NO;~  * Implementation of the database with the data already collected (as an coded EXCEL file) in specific studies (some patients are included in several of these studies): study of diffuse low grade gliomas, study on anaplastic gliomas, study on the place of Bevacizumab in high-grade gliomas, clinical database created~  * Collection of clinical data from each patient's medical record~2. For the prospective part~   * Inclusion of patients in a coded form in BDD-NO;~  * Collection of clinical data from each patient's medical record."
62808040|NCT01892670|EXPERIMENTAL|Filtered whole blood|"Leukocyte-reduced whole blood, 2 hours holding-time after collection. Gravitational filtration.~Device: Terumo IMUFLEX WB(Whole blood)-SP(saving platelets) collection bag system"
62031996|NCT05411458|EXPERIMENTAL|Experimental group|"Experimental group consists of 15 Type-2 DM patients who applied for routine outpatient follow-up in the internal medicine clinic, whose diabetes tests and treatments were arranged by an internist, who had COVID-19 at least 3 months ago.~12-week treatment program; A - 6 weeks of aerobic exercise (AE) (outdoor walking program) 6 week program B - Jacobson Progressive Relaxation Exercises (JIGE) (done by patients at home). The 6-week B program (JIGE) was applied in addition to the aerobic exercise (AE) program.~An exercise program is 30-45 minutes, and the applications are done every other day and 3 days a week.The treatment programs started with the evaluation of the cases by the physiotherapist and are followed up using the Telerehabilitation method. At the beginning of each week, the patients were called and checked, and their exercise treatments were completed at the end of 12 weeks."
62423286|NCT06202807|EXPERIMENTAL|the observation group|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
62592569|NCT04091100|ACTIVE_COMPARATOR|electroacupuncture|The individuals in the electroacupuncture group were administered the therapy by a certified acupuncturist. Two Shenlong acupuncture needles were inserted in each of the trapezius and levator scapulae muscles at intervals of 0-3 mm and clips were attached to their ends. Afterwards, an electrical current of 2 mA and 60 Hz was administered using the Enraf Nonius Sonoplus 492 (OPTOMED) device for 20 minutes.
62808041|NCT01892670|EXPERIMENTAL|Unfiltered whole blood|"Non-leukocyte-reduced whole blood, 2 hours holding-time after collection.~Device: Terumo IMUFLEX WB-SP collection bag system"
62031997|NCT05411458|OTHER|Control Group|"Control group consists of 15 Type-2 DM patients without COVID-19, who applied to the internal medicine outpatient clinic for routine outpatient follow-up, whose diabetes examinations and treatments were arranged by an internist.~12-week treatment program; A - 6 weeks of aerobic exercise (AE) (outdoor walking program) 6 week program B - Jacobson Progressive Relaxation Exercises (JIGE) (done by patients at home). The 6-week B program (JIGE) was applied in addition to the aerobic exercise (AE) program.~An exercise program is 30-45 minutes, and the applications are done every other day and 3 days a week.The treatment programs started with the evaluation of the cases by the physiotherapist and are followed up using the Telerehabilitation method. At the beginning of each week, the patients were called and checked, and their exercise treatments were completed at the end of 12 weeks."
62031998|NCT05108233||Observational (survey)|"COHORT 1-TP1: Patients complete surveys over 20 minutes on post-op day 3 and on day of discharge (or within 1 week).~COHORT 1-TP2: Patients complete surveys over 15 minutes at all regularly scheduled follow-up appointments (approximately 1 month, 3 months, 6 months, 12 months).~COHORT 2: Patients complete surveys over 15 minutes once."
62231769|NCT02790580|EXPERIMENTAL|Dose-dense doxorubicin/cyclophosphamide + sunitinib|Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles, Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles, Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide, Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0), Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)
62231770|NCT01306487||Macular hole patients|The patients who underwent vitreous surgery for idiopathic macular hole.
62808042|NCT01892670|EXPERIMENTAL|Warm-filtered whole blood|"Leukocyte-reduced whole blood, no holding-time after collection. Gravitational filtration.~Device: Terumo IMUFLEX WB-SP collection bag system"
62808043|NCT01892670|EXPERIMENTAL|Forced warm-filtration of whole bood|"Leukocyte-reduced whole blood, no holding-time after collection. Forced filtration.~Device: Terumo IMUFLEX WB-SP collection bag system"
62808044|NCT01892670|EXPERIMENTAL|RCC produced from cold-stored whole blood|"RCC production from 7 days old, cold-stored, leukocyte-reduced whole blood. Units stored for another 35 days. (42 days of storage in total).~Devices: Terumo IMUFLEX WB-SP/WB-RP collection bag systems."
62808045|NCT01892670|EXPERIMENTAL|RCC produced from cold-stored non-filtered whole blood|"RCC production from 7 days old, cold-stored, non-leukocyte-reduced whole blood. Units stored for another 35 days. (42 days of storage in total).~Devices: Terumo IMUFLEX WB-SP/WB-RP(removing platelets) collection bag systems."
62808046|NCT05117541||Observational (interview, biospecimen collection)|Patients participate in interviews over 20-40 minutes and undergo collection of hair samples at baseline and 18-24 months. Patients' medical records are also reviewed.
62808047|NCT05826483|EXPERIMENTAL|Almonertinib|Almonertinib, 110 mg, po, QD; 28 days every cycle
62808048|NCT03659318|EXPERIMENTAL|Robot|TKA is done with robotic-assisted manner. Final implantation of implants is done by surgeons, same as the conventional way. Robotic-assisted TKA for this arm.
62808049|NCT03659318|ACTIVE_COMPARATOR|Conventional|TKA is done with conventional instruments. Conventional TKA for this arm.
62808050|NCT04739826||flumatinib|flumatinib 600mg QD, fasting administration
62231771|NCT05384353||Healthy controls|Synaptic density PET-MR and neuropsychological testing
62031999|NCT06034860|EXPERIMENTAL|Part A- Dose Escalation Monotherapy|"Part A- Dose escalation of MT-8421 monotherapy in patients with selected advanced solid tumors.~The assigned dose level of MT-8421 will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e. on day 1, day 8, day 15, and day 22 of each 28-day cycle)."
62032000|NCT06034860|EXPERIMENTAL|Part A- Dose Escalation Combination Therapy|"Part A- Dose escalation of MT-8421 in combination with nivolumab in patients with selected advanced solid tumors.~The assigned dose level of MT-8421 will be given as an intravenous (IV) infusion over about 30 minutes prior to the infusion of 480 mg nivolumab. MT-8421 will be given on the same day every week (i.e. on day 1, day 8, day 15, and day 22 of each 28-day cycle). Nivolumab will be given on the first day of each cycle beginning at cycle 2."
62808051|NCT04739826||nilotinib|nilotinib 300mg BID, fasting administration
62231772|NCT05384353||Patients with Alzheimer's disease|Synaptic density PET-MR and additional neuropsychological testing (if necessary)
62231773|NCT05384353||Patients with Frontotemporal degeneration|Synaptic density PET-MR and additional neuropsychological testing (if necessary)
62231774|NCT05384353||Patients with Dementia with Lewy Bodies|Synaptic density PET-MR and additional neuropsychological testing (if necessary)
62231775|NCT05384353||Patients with late-life psychiatric disorders|Synaptic density PET-MR and additional neuropsychological testing (if necessary)
62808052|NCT02996201|EXPERIMENTAL|Electronic reporting of PRO-CTCAE items|Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
62231776|NCT06328426|ACTIVE_COMPARATOR|Vtamin D and omega-3.|First arm will be treated with vitamin D and omega-3.
62231777|NCT06328426|ACTIVE_COMPARATOR|vitamin D and metformin|: Second arm will be treated with vitamin D and metformin.
62231778|NCT06328426|PLACEBO_COMPARATOR|Placebo|Third arm will be treated with placebo.
62032001|NCT06034860|EXPERIMENTAL|Part B Dose Expansion Monotherapy|"Part B- Dose expansion of MT-8421 monotherapy in patients with selected advanced solid tumors.~Part B monotherapy will include two expansion groups: Group B1 (NSCLC) and group B2 (HCC).~The assigned dose level of MT-8421 determined in Part A will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e. on day 1, day 8, day 15, and day 22 of each 28-day cycle)."
62032002|NCT06034860|EXPERIMENTAL|Part B Dose Expansion Combination|"Part B- Dose escalation of MT-8421 in combination with nivolumab in patients with selected advanced solid tumors.~Part B combination therapy will include two expansion groups: Group B3 (Melanoma) and Group B4 (RCC).~The assigned dose level of MT-8421 determined in Part A will be given as an intravenous (IV) infusion over about 30 minutes prior to the infusion of 480 mg nivolumab. MT-8421 will be given on the same day every week (i.e. on day 1, day 8, day 15, and day 22 of each 28-day cycle). Nivolumab will be given on the first day of each cycle beginning at cycle 2."
62808053|NCT02996201|NO_INTERVENTION|Standard practice|
62231779|NCT02648750|EXPERIMENTAL|Rehabilitation Assistant|Bridges stroke self-management programme. Delivered by rehabilitation assistants. Participants will receive a minimum of 4 sessions over a 4-6 week period.
62231780|NCT02648750|ACTIVE_COMPARATOR|Therapist|"Bridges stroke self-management programme. Delivered by registered stroke therapists (Occupational therapists or physiotherapists).~Participants will receive a minimum of 4 sessions over a 4-6 week period."
62231781|NCT00830648|EXPERIMENTAL|1|
62231782|NCT03861377|ACTIVE_COMPARATOR|Remifentanil R2|Low dose Remifentanil induction dose (R2)
62231783|NCT03861377|ACTIVE_COMPARATOR|Remifentanil R4|Medium dose Remifentanil induction dose (R4)
62231784|NCT03861377|ACTIVE_COMPARATOR|Remifentanil R8|Medium dose Remifentanil induction dose (R8)
62231785|NCT04916522|EXPERIMENTAL|Colchicine|Colchicine 0.5 mg once daily
62231786|NCT04916522|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62231787|NCT00334555|ACTIVE_COMPARATOR|usual care|patient told to refer her partner for treatment
62231788|NCT00334555|ACTIVE_COMPARATOR|partner delivered|patient given medication to deliver to her partners
62231789|NCT00334555|ACTIVE_COMPARATOR|field intervention|field intervention to find partners
62231790|NCT05021523|EXPERIMENTAL|HEAT group|Participants are doing passive and active heat exposures
62231791|NCT05021523|SHAM_COMPARATOR|CON group|Participants are doing sham altitude exposures
62231792|NCT02681133||patients with knee pain|
62231793|NCT05082129|EXPERIMENTAL|Intervention|The intervention will consist of young patients with constipation presenting at secondary and tertiary care with intractable constipation. They will undergo the MRI gastrointestinal transit test (TransiCap). Their results will be shared with the patients after both MRI scans are preformed and results calculated. Their treatment selection will therefore be informed by the TransiCap results.
62231794|NCT05082129|EXPERIMENTAL|Control|The control arm will consist of young patients with constipation presenting at secondary and tertiary care with intractable constipation. They will undergo the MRI gastrointestinal transit test (TransiCap). The patients will undergo 2 MRI scans but their results will be shared with the patients after 12 months has elapsed. They will receive standard care treatment not informed by the TransiCap results.
62231795|NCT00571831|NO_INTERVENTION|letter|a blue-filtering IOL an UV-filtering IOL
62231796|NCT02638935|OTHER|BI-RADS 3|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
62231797|NCT02638935|OTHER|BI-RADS 4a|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
62231798|NCT02638935|OTHER|BI-RADS 4b|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
62231799|NCT02638935|OTHER|BI-RADS 4c|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
62231800|NCT00144651|EXPERIMENTAL|1|
62231801|NCT04822012||Female|Female patients going through an egg retrival procedure and were identified as post COVID-19 vaccine/ post COVIS-19 infection or not post vaccine/post disease and screened negative for COVID-19 in the week prior to the procedure.
62808054|NCT04985526|EXPERIMENTAL|Polymorphic light eruption patients|PLE patients subjected to MED testing and photoprovocation
62808055|NCT04985526|OTHER|Healthy subjects|Normal healthy subjects
62808056|NCT02633670|EXPERIMENTAL|Hemopatch|The hemopatch is a promising new sealing synthetic hemostatic agent with a noval dual mechanism of action. The hemopatch is a polyethylene glycol coated (PEG coated) collagen patch. The PEG coating helps in rapid adhesion to the tissue surface while the collagen layer causes platelet activation and adhesion.
62808057|NCT02633670|ACTIVE_COMPARATOR|Standard technique|Standard hemostatic agents (floseal, tisseal).
62231802|NCT04822012||Male|male patients going through an in vitro fertilization cycle and were identified as post COVID-19 vaccine/ post COVIS-19 infection or not post vaccine/post disease and screened negative for COVID-19 in the week prior to the procedure.
62592570|NCT04091100|ACTIVE_COMPARATOR|myofascial release|Firstly, longitudinal stretching was done with forearm to the muscles in the person's neck in order to relax. Afterwards, the researcher placed one hand under the person's head and placed their fingertips on the muscles under the occipital bone in the neck area. The researcher applied lateral flexion to the neck with one hand while placing the other hand on the trapezius and levator scapulae muscles and then stretched the muscles with friction massage. After this step, the participant's neck was guided back into a neutral position and the pinching technique was applied to the muscles. During the administration of therapies, the trigger points on muscles were identified and friction was applied to these sites until a loosening could be felt. The myofascial release sessions concluded with the administration of the friction massage technique once again to the muscles.
62592571|NCT03705650|EXPERIMENTAL|Medicare Primary Care Provider (PCP) Patients|This is a non-randomized study of non-significant risk (NSR) that will be conducted at Northwestern's Central Dupage Hospital. Medicare patients \> 65 years who are scheduled for a routine physical exam with their PCP that meet inclusion and exclusion criteria will be asked to participate in this study. Consenting patients will be scheduled for 2 back to back ultrasound scans including 5 standard 2D echocardiogram views each. The first scan will be performed by a non-ultrasound specialist using EchoGPS experimental guidance technology and the second control exam will be performed by a trained sonographer using a cleared conventional ultrasound platform.
62808058|NCT06021925||Blood donors tested for anti-HLA Antibody|Blood donors tested for anti-HLA Antibody between 2010 and 2020 as part of TRALI prevention program.
62808059|NCT00278577|EXPERIMENTAL|Autologous Hematopoietic Stem Cell Transplant|
62808060|NCT03072446|EXPERIMENTAL|Gel-Beads arm|This group will undergo embolization of symptomatic uterine fibroids with Gel-Beads embolic agent
62808061|NCT00849940|EXPERIMENTAL|CAS NIRS FORE-SIGHT oximeter|Pediatric patients presenting for cardiac catheterization.
62032003|NCT02462746|NO_INTERVENTION|No supplement|This group subjects will not receive the supplement
62231803|NCT00905138|EXPERIMENTAL|1|single ascending doses
62231804|NCT00905138|PLACEBO_COMPARATOR|2|single dose placebo
62231805|NCT00905138|EXPERIMENTAL|3|multiple dose, 5 days, oral solution
62231806|NCT00905138|PLACEBO_COMPARATOR|4|multiple dose, 5 days, oral solution
62231807|NCT03774251|ACTIVE_COMPARATOR|Greater Trochanter Pain Syndrome - PRP Arm|Individuals with Greater Trochanter Pain Syndrome with MRI evidence of gluteus medius or gluteus minimus tendinopathy, assigned to undergo platelet rich plasma injection
62231808|NCT03774251|ACTIVE_COMPARATOR|Greater Trochanter Pain Syndrome - ESWT Arm|Individuals with Greater Trochanter Pain Syndrome with MRI evidence of gluteus medius or gluteus minimus tendinopathy, assigned to extracorporeal shock wave therapy
62231809|NCT02361138|EXPERIMENTAL|Cohort SHR3824/Placebo 1.25 mg|SHR3824 1.25 mg/day or placebo for 10 days.
62808062|NCT03444610|OTHER|Arm (blood transfusion escalation rate)|The intervention for the arm (blood transfusion escalation rate) will be about giving blood transfusion with escalating rate as described in intervention part to Any condition that expected to receive more than one blood transfusion, like thalassemia major or intermedia, sickle cell anemia, aplastic anemia, malignant diseases.
62808063|NCT02843230||Avastin Combine with MRI, DSC and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin treatment (baseline scan).~* Subsequently, patients will receive their follow-up MRI exams every 8 weeks as standard of care.~* Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
62808064|NCT02843230||Avastin and Temozolomide Combine with DSC, MRI and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin and Temozolomide treatment (baseline scan).~* Subsequently, patients will receive their follow-up MRI exams every 8 weeks as standard of care.~* Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
62808065|NCT02843230||Avastin and Lomustine Combine with MRI, DSC, and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin and Lomustine treatment (baseline scan).~* Subsequently, patients will receive their follow-up MRI exams every 6 weeks as standard of care.~* Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
62808066|NCT04388761|EXPERIMENTAL|Intra parenchymal injection|5 subjects will receive AMSCs via direct injection into the kidney parenchyma only
62032004|NCT02462746|ACTIVE_COMPARATOR|1.5 gram of l-cysteine|Intervention: single dose of 1.5 g L-Cysteine.
62032005|NCT02462746|ACTIVE_COMPARATOR|3 grams of l-cysteine|Intervention: single dose of 3.0 g L-Cysteine.
62032006|NCT06293729|EXPERIMENTAL|NGGT006|3 doses of NGGT006 will be administered according to the principle of dose escalation
62032007|NCT01840540|EXPERIMENTAL|infusion of autologous mesenchymal stem cells|Patients will undergo a subcutaneous fat biopsy for expansion of mesenchymal stromal (stem) cells (MSC) in the Human Cell Therapy Laboratory. Patients will be admitted to the inpatient Clinical Research Unit of the Mayo Clinic Center for 3 days prior to treatment, for pre-infusion tests. Renal angiography will be performed to deliver a single intra-arterial dose of MSC's into one affected kidney. Patients will be observed for 24 hours for acute adverse events. Patients will have remote visits at 1 week, 4 weeks,8 weeks, and 6 months. At 3 months, patients will return for repeat evaluation of kidney function, blood flow and structural alterations within the clinical research unit at St. Mary's Hospital, Rochester, Minnesota. Thereafter, health assessment and blood draws will be repeated at 12 and 24 months with urinary cytology and MRI.
62231810|NCT02361138|EXPERIMENTAL|Cohort SHR3824/Placebo 2.5 mg|SHR3824 2.5 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
62231811|NCT02361138|EXPERIMENTAL|Cohort SHR3824/Placebo 5 mg|SHR3824 5 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
62231812|NCT02361138|EXPERIMENTAL|Cohort SHR3824/Placebo 10 mg|SHR3824 10 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
62231813|NCT02361138|EXPERIMENTAL|Cohort SHR3824/Placebo 25 mg|SHR3824 25 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
62231814|NCT02361138|EXPERIMENTAL|Cohort SHR3824/Placebo 100mg|SHR3824 100 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
62231815|NCT00782522|EXPERIMENTAL|1|Eccentric training program
62231816|NCT00782522|ACTIVE_COMPARATOR|2|Traditional training program
62231817|NCT02882087|EXPERIMENTAL|Placebo Comparator|Placebo SC plus MTX. Patients received placebo SC weekly administered subcutaneously for 24 times.All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
62231818|NCT02882087|EXPERIMENTAL|Experimental: RC18 160 mg plus MTX|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times. All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.
62423287|NCT06202807|ACTIVE_COMPARATOR|the control group|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the control group was given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements."
62423288|NCT06272812|EXPERIMENTAL|MTBVAC|MTBVAC
62423289|NCT06272812|PLACEBO_COMPARATOR|Placebo|Placebo
62592572|NCT04937933|ACTIVE_COMPARATOR|Coolant spray group|Coolant spray (Cryos ®Spray, Phyto Performance, Italy) was applied as suggested by the manufacturer (at a distance of 20 cm from the injured area for 5-10 s). Saline solution was sprayed for the same duration and at the same distance from the injured area as well. The first spray application was performed after the initial assessment, and the second spray application was performed at the end of the 30th minute (immediately after the pain level/score measurement). All patients were given intravenous (IV) dexketoprofen (50 mg in 50 ml standard saline solution) in 5 minutes simultaneously with the first spray application. The physicians applied the designated treatment protocol for each treatment group. As a rescue analgesic treatment, patients were scheduled to be given IV fentanyl at a dose of 1 mcg/kg.
62032008|NCT06027268|EXPERIMENTAL|Trilaciclib, Pembrolizumab, Gemcitabine, and Carboplatin|Trilaciclib is an agent that helps protect the bone marrow from the side effects of chemotherapy. It is given as an intravenous (IV) infusion over 30 minutes prior to gemcitabine and carboplatin. Gemcitabine is given IV over 30 minutes. Carboplatin is given over 30 minutes. Trilaciclib, gemcitabine and carboplatin are given on Days 1 and 8 every 21 days. Pembrolizumab is given IV over 30 minutes on Day 1 every 21 days.
62231819|NCT05622851|ACTIVE_COMPARATOR|Restylane Contour|"Form: transparent gel of Hyaluronic Acid with the addition of lidocaine hydrochloride.~Mode of administration: injection Dosage: at investigator's discretion for optimal outcome. Frequency and duration: injection at baseline and optional touch-up at week 4."
62231820|NCT05622851|ACTIVE_COMPARATOR|Juvederm Voluma|"Form: sterile, biodegradable, non-pyrogenic, viscoelastic, clear, colorless, homogenous gel implant of Hyaluronic Acid crosslinked with BDDE, formulated with lidocaine.~Mode of administration: injection Dosage: at investigator's discretion for optimal outcome. Frequency and duration: injection at baseline and optional touch-up at week 4."
62231821|NCT02562495|EXPERIMENTAL|CT scan and Ultrasonography|Up to three measurements (CT scan and Ultrasonography), will be made concurrently between the day of admission (D1) in intensive care unit and the tenth day ( D10 ) .
62231822|NCT00852046|EXPERIMENTAL|1. Low dose dexmedetomidine|Dexmedetomidine 0.2 mcg/kg/hr added to fentanyl \& propofol.
62231823|NCT00852046|EXPERIMENTAL|2. High dose dexmedetomidine|Dexmedetomidine 0.6 mcg/kg/hr added to fentanyl \& propofol.
62423290|NCT02855788|EXPERIMENTAL|POLF regimen|Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly
62423291|NCT00734617|EXPERIMENTAL|Less Dependent Smokers|
62735437|NCT03571750|EXPERIMENTAL|Building Stronger Allies Condition|"BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness."
62231824|NCT00852046|PLACEBO_COMPARATOR|3. Placebo|Placebo added to fentanyl \& propofol.
62231825|NCT03658668|EXPERIMENTAL|active tDCS+PA|
62231826|NCT03658668|SHAM_COMPARATOR|sham tDCS+PA|
62231827|NCT02802098|EXPERIMENTAL|Bevacizumab + Durvalumab|Treatment with DURVALUMAB 10 mg/kg Q2W IV infusion plus Bevacizumab 10 mg/ Kg Q2W, IV infusion for a maximum duration of treatment of 12 months. Study treatment should be discontinued prior to 12 months if there is confirmed PD (unless the investigator considers the subject to continue to receive benefit from treatment), initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or if other reasons to discontinue study treatment occur.
62231828|NCT00440700|EXPERIMENTAL|Patient-directed music|Patients select preferred music for listening through headphones whenever they like for as long as they like whenever feeling anxious, desire some rest and quiet time, or for listening enjoyment while mechanically ventilated in the ICU.
62423292|NCT00734617|EXPERIMENTAL|More Dependent Smokers|
62423293|NCT02639195||Treatment, retrospective|Retrospective analysis on patients treated with manual physical therapy in quality of life outcomes as measured by pre and post treatment questionnaires. Chart review.
62032009|NCT06656299|ACTIVE_COMPARATOR|Grup E (External Oblique Intercostal Plane Block)|At the end of the surgical procedure,a high-frequency linear probe will be sterilely covered,and an 80mm block needle will be used for the procedure.Under sterile conditions,the ultrasound probe will be placed in a parasagittal position in the area between the anterior axillary line and the midclavicular line at the level of the 10th rib, and then slid cranially along the longitudinal axis to the level of the 6th and 7th ribs. After visualizing the external oblique muscle, the block needle will be inserted using an in-plane technique,and 5ml of saline will be administered to confirm the location at the external oblique intercostal plane between the external oblique muscle and the 6th rib. Once the location is confirmed, 20cc of 0.25%bupivacaine will be infiltrated into the EOIP. The same procedure will be applied to the opposite side (totally 40 ml).
62032010|NCT06656299|OTHER|Grup T ( Trocar entry site infiltration)|After the trocar removed during the surgical procedure, the surgeon will administer 5 ml of 0.25% bupivacaine infiltration to each trocar entry site.
62032011|NCT03987308|EXPERIMENTAL|Beinaglutide|Five-week Beinaglutide pump treatment group
62592573|NCT04937933|PLACEBO_COMPARATOR|Placebo group|A standard saline solution in a bottle covered with opaque white paper and refrigerated at 4°C was prepared. Saline solution was sprayed for the same duration and at the same distance from the injured area as well like coolant spray application. The first spray application was performed after the initial assessment, and the second spray application was performed at the end of the 30th minute (immediately after the pain level/score measurement). All patients were given intravenous (IV) dexketoprofen (50 mg in 50 ml standard saline solution) in 5 minutes simultaneously with the first spray application. The physicians applied the designated treatment protocol for each treatment group. As a rescue analgesic treatment, patients were scheduled to be given IV fentanyl at a dose of 1 mcg/kg.
62592574|NCT00281632|EXPERIMENTAL|Pazopanib|800 mg GW786034 administered orally on a daily basis.
62592575|NCT00971464|EXPERIMENTAL|Eccentric viewing|"Eccentric viewing is the use of a retinal locus other than the anatomical fovea for fixation in cases when there is central vision loss. This other area (or areas) is called the preferred retinal locus (PRL). In eccentric viewing the patient is aware that they are looking to the side or using their side vision. Most patients with a dense central scotoma will develop eccentric viewing naturally over time. It is thought, however, that, in many cases the naturally developed PRL is not in the ideal position. The four components of eccentric viewing that will be taught are: 1) The optimal direction for eccentric viewing 2) Using large objects to teach eccentric viewing 3) Repetitive practicing of the technique and 4) Maintaining the eye in the eccentric viewing position."
62592576|NCT00971464|ACTIVE_COMPARATOR|CCTV arm|A CCTV is an electro-optical device mainly used for reading, but which can also be used for writing or viewing pictures. It is comprised of a video camera which faces downwards towards the reading material and which inputs the image to a digital monitor. Magnification is variable over a large range. By means of a zoom lens and the brightness, contrast, and image polarity (black letters on white or white on black) can be controlled to provide the best combination of viewing conditions for an individual user. The significant advantages of CCTV over optical magnifiers are that it provides high levels of magnification with a greater field of view (compared to the equivalent optical device), allows reading at a more normal viewing distance of about 40 - 50 cms and allows binocular viewing.
62592577|NCT02005692|EXPERIMENTAL|DynaSense sensor|
62592578|NCT06097689|EXPERIMENTAL|Investigational arm|Induction of different glycaemia states via intravenous regular insulin and intravenous glucose administration and measurements of transcutaneous spectral data with the investigational device and reference blood glucose values.
62592579|NCT03005652|EXPERIMENTAL|Mindfulness intervention|consists of eight weekly group-based sessions of 2 hours duration and an individual pre-class interview, in which the participants will be socialised to the treatment. The intervention will combine intensive training in mindfulness and compassion meditation and gentle yoga practices with psycho-educational components targeted at helping individuals to deal more effectively with emotional difficulties and stressors commonly encountered in old age. These will include addressing concerns about cognitive functioning and health, and will have a particular emphasis on cultivating wholesome attitudes towards self and others.
62592580|NCT03005652|ACTIVE_COMPARATOR|Health education intervention|"follow the same format and structure as the mindfulness-based intervention, and will be matched to the mindfulness-based intervention in administration, dosage, and duration.~The treatment is based on a published manual, with every session of the program covering different subjects, including self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with family, friends, and healthcare professionals, eating, weight management, and planning for the future. Participants will be provided with information about these subjects and engage in group exercises and discussions about these subjects. They will be given a workbook and asked to actively engage in activities described in by the workbook to improve health and well-being on 6 out of 7 days each week, matching home assignments in the mindfulness-based intervention."
62808067|NCT04388761|EXPERIMENTAL|Intra-arterial infusion|5 subjects will receive AMSCs via intra-arterial infusion only
62808068|NCT04388761|EXPERIMENTAL|Intra parenchymal injection & Intra-arterial infusion|5 subjects will receive AMSCs via direct injection into the kidney parenchyma and intra-arterial infusion
62808069|NCT00792012|EXPERIMENTAL|Glioblastoma Multiforme Patients|Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining with Temozolomide (TMZ) Chemotherapy
62808070|NCT01665196|EXPERIMENTAL|18F-FDG PET/CT scanning|18F-FDG PET/CT scanning will be performed in patients with IgG4RD to determine the pictorial characteristics and measure the standardized uptake values (SUVs) of the lesions and their response to treatment.
62808071|NCT03899714|ACTIVE_COMPARATOR|Ankle evertors|Ice packs will be applied to the selected muscles according to the random selection that will be performed previously. The ice bags will be filled with crushed ice, weighing approximately one half of a kilogram. They will be wrapped in a thin cotton towel, and applied on the skin along the anatomical location of the tested muscles. For the ankle evertors, the ice bag will be applied to the lateral side of the ankle encompassing the lateral malleolus.The cryotherapy session will be lasted for exactly 20 minutes . Sessions will be separated by a 30-minute rest interval
62231829|NCT00440700|ACTIVE_COMPARATOR|Headphones|Noise-canceling headphones only (no music) are applied by the patient to block out noise/sound in the ICU whenever desired.
62231830|NCT00440700|OTHER|Standard of Care|Patients receive usual care for the ICU and are encouraged to self-initiate rest periods twice daily.
62032012|NCT03987308|EXPERIMENTAL|Insulin aspart|Five-week short-term CSII (insulin aspart) treatment group
62032013|NCT02605954|EXPERIMENTAL|E/C/F/TAF|Participants will switch to E/C/F/TAF FDC and receive treatment for 48 weeks.
62032014|NCT02605954|ACTIVE_COMPARATOR|ABC/3TC+3rd Agent|"Participants will maintain prior regimen of ABC/3TC plus a third antiretroviral agent for 24 weeks followed by a delayed switch to E/C/F/TAF FDC.~Note: the prior regimen is determined by the participant's clinician (prior to entry into the study) and will consist of one of the third antiretroviral agents listed."
62032015|NCT02765529|EXPERIMENTAL|20-30 years|Blood sampling
62032016|NCT02765529|EXPERIMENTAL|45-55 years|Blood sampling
62592581|NCT03146689|EXPERIMENTAL|Topical NSAID and topical capsaicin|"Within each participant:~Topical NSAID (A) or capsaicin (B) are taken for a treatment period of four weeks. This is followed by another four week treatment period with the other treatment. These two treatment periods comprise one treatment cycle. The order of treatments within a treatment cycle is determined randomly (AB or BA).~This treatment cycle is repeated so that all participants undergo a maximum of three topical NSAID treatment periods and three topical capsaicin treatment periods (i.e., three treatment cycles). This is reduced to two cycles if they are found to meet the criteria for response at the interim analysis (after cycle two)."
62592582|NCT06337916|ACTIVE_COMPARATOR|Cervical Stabilization Exercise Group|"1. The patients age is between the ages of 18-55~2. Being literate and with good cognitive function,~3. Having neck pain longer than 3 months~4. Not taking painkillers and nsaid in the last 1 week"
62592583|NCT06337916|ACTIVE_COMPARATOR|Cervical Standard Exercise Group|"1. The patients age is between the ages of 18-55~2. Being literate and with good cognitive function,~3. Having neck pain longer than 3 months~4. Not taking painkillers and nsaid in the last 1 week"
62592584|NCT00657033|EXPERIMENTAL|Arm 1|
62592585|NCT00657033|EXPERIMENTAL|Arm 2|
62592586|NCT00254800|EXPERIMENTAL|Sequence 1|Oral contraceptive 1 hour prior to exenatide/oral contraceptive 30 minutes after exenatide/oral contraceptive alone
62592587|NCT00254800|EXPERIMENTAL|Sequence 2|Oral contraceptive 30 minutes after exenatide/oral contraceptive alone/oral contraceptive 1 hour prior to exenatide
62592588|NCT00254800|EXPERIMENTAL|Sequence 3|Oral contraceptive alone/oral contraceptive 1 hour prior to exenatide/oral contraceptive 30 minutes after exenatide
62592589|NCT03871790||Participants with colorectal cancer|Participants with colorectal cancer ongoing surgery older than 18 years old.
62592590|NCT03871790||Participants with pancreatic cancer|Participants with pancreatic cancer ongoing surgery older than 18 years old.
62592591|NCT06664840|EXPERIMENTAL|MyRareDiet|MyRareDiet (MRD) entries: Participants will enter their dietary intake into the MyRareDiet app on a series of three random nonconsecutive days. Participants will receive reminders from both OHSU bionutritionist (via email, phone, or text) and from the MRD system to record their dietary intake on the MRD app for particular randomized days.
62592592|NCT06664840|ACTIVE_COMPARATOR|24 hour recall|24-hour diet recalls: A series of three randomized nonconsecutive days of 24-hour food recall interviews by telephone will be completed by trained OHSU Bionutrition personnel to determine nutrient intake. Dietary intake will be evaluated with on Nutrition Data System for Research (NDSR) and Metabolic Pro nutrient databases.
62032017|NCT02765529|EXPERIMENTAL|70-80 years|Blood sampling
62032018|NCT02765529|EXPERIMENTAL|Control|Blood sampling for standardization of technical procedures
62032019|NCT06101693||Patients with NTproBNP<125ng/L and clinical suspicion of heart failure in primary care|Expected recruitment of 400 patients (50-60% expected prevalence of obesity, according to population study)
62231831|NCT04604548|EXPERIMENTAL|Open Label treatment|Oral administration of 100 mg KH176 twice daily
62032020|NCT06101693||Patients with NTproBNP125-399ng/L and clinical suspicion of heart failure in primary care|Expected recruitment of 400 patients (50% expected prevalence of obesity, according to population study)
62032021|NCT06101693||Patients with NTproBNP≥400ng/L and clinical suspicion of heart failure in primary care|Expected recruitment of 400 patients (50% expected prevalence of obesity, according to population study)
62032022|NCT00001651|EXPERIMENTAL|HIV-infected subjects|HIV-infected adults
62423294|NCT02639195||Untreated control|Prospective data collection via questionnaire of subjects with a history of small bowel obstruction in an observational manner. No treatment is performed.
62231832|NCT03124095|EXPERIMENTAL|Combined Exercise Group|The subjects of the combined training group will undergo the intervention three times a week for eight weeks. The combined group will carry out both resistance and aerobic exercises in the same session. The resistance training will be comprised by ten exercises which will alternate body segments with maximum repetitions in the first set and the lower limit of the repetitions interval in the next sets. Along the training, the number of series will be increased whereas the number of repetitions will be decreased. The intensity of the aerobic exercises will be based on the percentage of the heart rate of the anaerobic threshold on the first weeks and on the speed of the anaerobic and aerobic threshold on the last weeks
62231833|NCT03124095|NO_INTERVENTION|Control Group|The control group will be advised not to change their health habits. After the intervention they will be invited to participate in a physical exercise program.
62231834|NCT04785235||ACS|Group ACS: Acute Coronary Syndrome
62231835|NCT04785235||Periodontitis|Group P :Periodontitis
62592593|NCT05728606|EXPERIMENTAL|Robot-assisted D2 distal gastrectomy|Robot-assisted D2 distal gastrectomy after 3-Cycle SOX neoadjuvant chemotherapy
62808072|NCT03899714|ACTIVE_COMPARATOR|Hip adductors|Ice packs will be applied to the selected muscles according to the random selection that will be performed previously. The ice bags will be filled with crushed ice, weighing approximately one half of a kilogram. They will be wrapped in a thin cotton towel, and applied on the skin along the anatomical location of the tested muscles. For the hip adductors, the ice bag will be applied to the medial side of the thigh, covering the entire area from the groin, to just above the knee joint. The cryotherapy session will be lasted for exactly 20 minutes . Sessions will be separated by a 30-minute rest interval
62808073|NCT00018148|EXPERIMENTAL|1|Transdermal nicotine plus nortriptyline
62808074|NCT00018148|ACTIVE_COMPARATOR|2|Transdermal nicotine plus placebo
62808075|NCT00528112|EXPERIMENTAL|LCS12|Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro
62808076|NCT00528112|EXPERIMENTAL|LCS16|Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro
62808077|NCT02735239|EXPERIMENTAL|Cohort A1: Metastatic/locally advanced OC, Durva + Chemotherapy (Chemo)|Durvalumab (750 mg IV every two weeks \[Q2W\]) was to be given for up to 11 doses. Oxaliplatin (130 mg/m\^2 IV)/capecitabine (1250 mg/m\^2/day given orally) chemotherapy was started on the day of the third dose of durvalumab and continued for 6 doses.
62808078|NCT02735239|EXPERIMENTAL|Cohort A2: Metastatic/locally advanced OC, Durva, Treme + Chemo|Durvalumab (750 mg IV Q2W) was to be given for up to 11 doses. One dose of tremelimumab (37.5 mg IV) was given on the same day as the first dose of durvalumab. Oxaliplatin (130 mg/m\^2 IV)/capecitabine (1250 mg/m\^2/day given orally) chemotherapy was started on the day of the third dose of durvalumab and continued for 6 doses.
62808079|NCT02735239|EXPERIMENTAL|Cohort B: Metastatic/locally advanced OC, Durva, Treme + Chemo|Durvalumab (750 mg IV Q2W) was to be given for up to 11 doses. One dose of tremelimumab (75 mg IV) was given on the same day as the first dose of durvalumab. Oxaliplatin (130 mg/m\^2 IV)/capecitabine (1250 mg/m\^2/day given orally) chemotherapy was started on the day of the third dose of durvalumab and continued for 6 doses.
62231836|NCT01687530|EXPERIMENTAL|AMCA bone membrane|AMCA Bone is manufactured from Polyethylene Glycol 400 and Ammonio Methacrylate copolymer type A (Eudragit RL 100) materials.
62592594|NCT03197324|ACTIVE_COMPARATOR|Digoxin Alone first, then Digoxin With Bexagliflozin|
62592595|NCT03197324|ACTIVE_COMPARATOR|Digoxin with Bexagliflozin, then Digoxin alone|
62592596|NCT01032239|ACTIVE_COMPARATOR|ITB therapy|Intrathecal Baclofen therapy (Intrathecal baclofen + implantable pump)
62592597|NCT01032239|NO_INTERVENTION|Best Medical Treatment (BMT)|Use one or a combination oral antispastic medication.
62032023|NCT00001651|EXPERIMENTAL|HIV-negative subjects|HIV-negative adults
62032024|NCT05579860|EXPERIMENTAL|Olezarsen Dose Level 1|Participants will receive two doses of Dose Level 1 each, using one of the following two sequences: (i) AI on Day 1 of Treatment Period 1, followed by vial on Day 1 of Treatment Period 2; or (ii) vial on Day 1 of Treatment Period 1, followed by AI on Day 1 of Treatment Period 2. A washout period of 28-42 days will be maintained between the 2 treatment periods.
62032025|NCT05579860|EXPERIMENTAL|Olezarsen Dose Level 2|Participants will receive two doses of Dose Level 2 each, using one of the following two sequences: (i) AI on Day 1 of Treatment Period 1, followed by vial on Day 1 of Treatment Period 2; or (ii) vial on Day 1 of Treatment Period 1, followed by AI on Day 1 of Treatment Period 2 A washout period of at least 28 days will be maintained between the 2 treatment periods.
62592598|NCT05024240|EXPERIMENTAL|Patient group|20 patients with cerebellum disorders, who suffer from stability disorders and with specific 3 Hz tremor
62808080|NCT02735239|EXPERIMENTAL|Cohort C: Operable OC; Durva + Chemo|Durvalumab (750 mg IV Q2W) was to be given for up to 5 doses. Two cycles of neoadjuvant oxaliplatin (130 mg/m\^2 IV)/capecitabine (1250 mg/m\^2/day given orally) chemotherapy were to be administered before surgery. Subjects were to undergo surgery 6 to 8 weeks after completing chemotherapy or according to institutional policies for surgery; and would be eligible to resume durvalumab dosing (to a maximum of 12 infusions) once recovered from surgery, provided that this was within 3 months of surgery.
62808081|NCT02735239|EXPERIMENTAL|Cohort C-FLOT: Operable OC, Durva + FLOT Chemotherapy|Durvalumab (750 mg IV Q2W) was to be given for up to 6 doses. Two cycles of neoadjuvant 5-fluorouracil (5-FU) (2600 mg/m\^2 24-hr IV), leucovorin (200 mg/m\^2 IV), oxaliplatin (85 mg/m\^2 IV), and docetaxel (50 mg/m\^2 IV) chemotherapy (FLOT) were to be administered before surgery starting on the day of the third dose of durvalumab. Subjects were to undergo surgery 6 to 8 weeks after completing chemotherapy or according to institutional policies for surgery; and would be eligible to resume durvalumab dosing (to a maximum of 12 infusions), FLOT or durvalumab plus FLOT at the discretion of the Investigator once recovered from surgery, provided that this was within 3 months of surgery.
62808082|NCT02735239|EXPERIMENTAL|Cohort D/D2: Operable OC, Durva + Neoadjuvant Chemo(radio)therapy|"Durvalumab (750 mg IV Q2W) was to be given for 2 doses. This was followed by five weekly doses of neoadjuvant paclitaxel (50 mg/m\^2 IV) / carboplatin (AUC 2) IV chemotherapy + radiotherapy (41.4 Gy radiotherapy given over 23 fractions) before surgery. Subjects could receive an additional dose of durvalumab after completion of chemoradiation.~In Cohort D2, subjects continued durvalumab for 3 additional doses while receiving chemoradiation. Subjects were to undergo surgery 6 to 8 weeks after completing chemo(radio)therapy or according to institutional policies for surgery; and would be eligible to resume durvalumab dosing (to a maximum of 12 infusions) once recovered from surgery, provided that this was within 3 months of surgery."
62808083|NCT01643668|EXPERIMENTAL|BuClo RIC + SCT|Busulfan and Clofarabine (BuClo) reduced intensity conditioning (RIC) followed by allogeneic stem cell Transplantation (SCT)
62808084|NCT00738998|EXPERIMENTAL|Questionnaire and Telephone Assessments|Breast cancer patients assigned to one or two groups: Group 1) enrolled at beginning of anastrozole treatment; or Group 2) if beginning third year of anastrozole treatment.
62808085|NCT02153268|EXPERIMENTAL|single arm, Liposuction, BonoFill Transplantation|"* Liposuction - will be performed on Visit 2 for all eligible subjects~* BonoFill Transplantation - will be performed on Visit 6 for all eligible subjects"
62032026|NCT04863066|EXPERIMENTAL|CAR-T-cell therapy|Four patients with plasma HIV RNA \<50 copies/ml and CD4+T cell count more than 350 cells/μl receiving at least one-year antiviral treatment are injected intravenously with 1×10\^5 CAR-T cells/kg body weight. If the dosage of 1×10\^5 CAR-T cells/kg body weight is well tolerated, 5×10\^5 CAR-T cells/kg body weight will be infused for another 4 subjects who meet the inclusion and exclusion criteria.
62592599|NCT05024240|ACTIVE_COMPARATOR|Control group|20 healthy age-matching probands without any neurological disorders and stability issues
62032027|NCT06189417|EXPERIMENTAL|Intervention Group|A total of 280 study participants are allocated to intervention group
62032028|NCT06189417|NO_INTERVENTION|control group|A total of 280 study participants are allocated to control group
62032029|NCT03736434|EXPERIMENTAL|Mindfulness plus DASH group|Receives Mindfulness and DASH Diet education once a week for 8 weeks (2.5-hour sessions)
62032030|NCT03736434|ACTIVE_COMPARATOR|Education Group|The sham intervention includes general education on non-health related topics such as fire-safety and learning how to dispose of medication properly, once a week for 8 weeks (2.5-hour sessions)
62423295|NCT05886673|EXPERIMENTAL|Study treatment|The experimental cream formulation has the same components as the control plus 2% pterostilbene, 1% silibinin and 2% nicotinamide riboside.
62423296|NCT05886673|OTHER|Control treatment|The control cream formulation is designed to help maintaining skin hydration and texture. It contains common ingredients largely used in cosmetics: stearic acid, cetyl alcohol, liquid vaselin, isopropyl myristate, triethanolamine, methyl paraben, propyl paraben, propylene glycol, ethoxydiglycol, and water.
62423297|NCT04592198|EXPERIMENTAL|A (Buccal 0.25 Mg)|Palonosetron HCl Buccal Film 0.25 Mg and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3
62808086|NCT01350999|EXPERIMENTAL|TAK-085 2 g|TAK-085 2 g, orally, once daily for up to 52 weeks.
62808087|NCT01350999|EXPERIMENTAL|TAK-085 4 g|TAK-085 2 g, orally, twice daily for up to 52 weeks.
62808088|NCT01350999|ACTIVE_COMPARATOR|EPA-E 1.8 g|Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.
62808089|NCT01228279|ACTIVE_COMPARATOR|DIANEAL|One group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with the same type of solution for another 12 weeks.
62808090|NCT01228279|ACTIVE_COMPARATOR|EXTRANEAL|The other group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with DIANEAL solution during the day and the non-glucose-based solution, EXTRANEAL, during the night
62808091|NCT03829085|ACTIVE_COMPARATOR|Early oral refeeding|"The patients will be started the oral refeeding from the first day of admission in the hospital.~Patients will receive a low fat solid diet with more and less 1500 calories, 35 g fat day"
62808092|NCT03829085|NO_INTERVENTION|FASTING|The oral diet will be reintroduced in a traditional stepwise manner until the symptoms, signs, inflammatory parameters of AP have resolved
62808093|NCT05967598|ACTIVE_COMPARATOR|taVNS100 in advanced PD patients|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 100Hz to advanced PD patients. Participants will complete an 8 minute block design fMRI block.
62808094|NCT05967598|ACTIVE_COMPARATOR|taVNS25 in advanced PD patients|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 25Hz to advanced PD patients. Participants will complete an 8 minute block design fMRI block.
62808095|NCT05967598|PLACEBO_COMPARATOR|xVNS in advanced PD patients|The electrode will be placed in the left cyma conchae however no electrical current will be applied to advanced PD patients. Participants will complete an 8 minute block design fMRI block.
62808096|NCT05967598|ACTIVE_COMPARATOR|taVNS100 in early PD patients|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 100Hz to early PD patients. Participants will complete an 8 minute block design fMRI block.
62808097|NCT05967598|ACTIVE_COMPARATOR|taVNS25 in early PD patients|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 25Hz to early PD patients. Participants will complete an 8 minute block design fMRI block.
62808098|NCT05967598|PLACEBO_COMPARATOR|xVNS in early PD patients|The electrode will be placed in the left cyma conchae however no electrical current will be applied to early PD patients. Participants will complete an 8 minute block design fMRI block.
62808099|NCT05572008|EXPERIMENTAL|paediatric Crohn's disease|CD young population (ages 12-17 years) - N=20
62032031|NCT03736434|NO_INTERVENTION|Control Group|Continue care as usual without intervention.
62423298|NCT04592198|EXPERIMENTAL|B (Buccal 0.5 Mg)|Palonosetron HCl Buccal Film 0.5 Mg and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3
62423299|NCT04592198|ACTIVE_COMPARATOR|C (IV Injection 0.25 Mg)|IV palonosetron 0.25 Mg (ALOXI®) and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3
62423300|NCT03428009||Dystonia group|Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.
62423301|NCT03428009||Control Group|Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.
62423302|NCT02493985|ACTIVE_COMPARATOR|Atmosphere 1 - Ambient air|First, the subjects will have 1 baseline day in the upright body position. This will be followed by 28 hours of head down tilt body position and ambient air at sea level, followed by 2 hour exposure of 3% carbon dioxide inhalation.
62423303|NCT02493985|EXPERIMENTAL|Atmosphere 2 - 0.5% CO2|First, the subjects will have 1 baseline day in the upright body position. This will be followed by 28 hours of head down tilt body position and air with 0.5% carbon dioxide, followed by 2 hour exposure of 3% carbon dioxide inhalation.
62423304|NCT00975884|EXPERIMENTAL|GSK2340272A (D21) GROUP|Healthy male or female adults, above 18 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21 (D21).
62423305|NCT00975884|EXPERIMENTAL|GSK2340272A (M6) GROUP|Healthy male or female adults, above 18 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Month 6 (M6).
62808100|NCT05572008|ACTIVE_COMPARATOR|Healthy volunteers|Age-, BMI- and gender-matched healthy volunteers (HV) - N=20
62808101|NCT04678583|EXPERIMENTAL|A - Anatomical resection|removal of the entire, tumor-bearing liver segment(s)
62808102|NCT04678583|ACTIVE_COMPARATOR|B - Non-anatomical resection|metastasectomy with a margin of healthy liver tissue irrespective of segmental borders
62808103|NCT02738008|EXPERIMENTAL|ARC-520 Injection|Multiple administrations of ARC-520 starting at a dose level of 2 mg/kg, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
62808104|NCT00637078|ACTIVE_COMPARATOR|1|Drug: Fix dose combination therapy
62808105|NCT00637078|NO_INTERVENTION|2|Guidelines based management
62423306|NCT02604238|EXPERIMENTAL|Group A|"Administered a safe dose of Alteplase. All patients are treated with low molecular weight heparin ( LMWH ) according to the Guidelines ESC2014 heparin in addition it is administered a safe dose of Alteplase."
62423307|NCT02604238|NO_INTERVENTION|Group B|All patients are treated with low molecular weight heparin ( LMWH ) according to the Guidelines ESC2014 heparin. It not added any treatment.
62808106|NCT02608944|EXPERIMENTAL|MRI perfusion vs. PET Imaging perfusion|Adenosine Regadenoson O-15 labeled radioactive water MRI PET Imaging
62808107|NCT00647179||1|Patients recently diagnosed with acromegaly
62808108|NCT03759834|EXPERIMENTAL|Testing Arm|"There will only be one arm. The patient and investigator will initially be blinded to the on-off status of the electrode. The patient will thus serve as an internal control for testing. Once device integrity and possible benefit is confirmed, the patients will undergo non-tactile electrical stimulation to the bone of the inner ear (cochlear promontory) for short term relief of tinnitus via Cochlear promontory stimulation."
62808109|NCT02451085|EXPERIMENTAL|remote rehabilitation group|'training with video therapy' a domestic exercise plan through remote rehabilitation system based on short film. (http://videotherapy.co/vt/home.php), the plan will include installation of exercises adapted according to the physical condition of the patient. The content of each exercise is dynamic and variable. The difference between each exercise and the other depends on the feedback that the patient fills at the end of each exercise and sends to the therapist. Before each exercise, it is shown with explanations about the importance of performing it the way of performing. Furthermore, during the training, the patient listens to vocal explanation about the quality and importance of performing the exercise, and a vocal counting is heard and then a positive feedback is given.
62032032|NCT06426641||polyethylene containing Vitamin E|polyethylene containing Vitamin E
62423308|NCT06537245|EXPERIMENTAL|5 minutes massage group|"The anatomical location chosen for applying the massage was the anterior part of the thigh (muscular quadriceps femoris), due to the effort required by the stress protocol.~The participant was placed in the supine position and the massage was performed on the dominant limb (DOM) and the non-dominant limb (ÑDOM). The techniques used were: superficial and deep sliding, which is presented in two intensities, moderate or intense, with gradual increase. Intensity grading was controlled through participant self-reports. The massage was performed in the direction of the muscle fibers, from distal to proximal and following the lymphatic flow.~The massage had the following rhythm: 1 second of sliding and 1 second to return the hand to the initial position, totaling 2 seconds of sliding. The rhythm of the massage was controlled by an electronic metronome that was used only by the therapists during the technique."
62592600|NCT03200756|EXPERIMENTAL|Sedentary Group|The experimental group undergoes a behavioral intervention to reduce sedentary behavior which includes a patient centered approach with monitoring and goal setting.
62032033|NCT06426641||conventional polyethylene (no highly cross-linking)|conventional polyethylene (no highly cross-linking)
62032034|NCT06426641||conventional polyethylene (with highly cross-linking)|conventional polyethylene (with highly cross-linking)
62032035|NCT05601973|EXPERIMENTAL|Treatment Arm|Amivantamab (fixed dose of 1750 mg (or 2100 mg, i.v. every 3 weeks, until disease progression, or intolerable toxicity) PLUS Lazertinib (240 mg, orally, once daily, until disease progression or intolerable toxicities) PLUS Bevacizumab (Zirabev® is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity).
62032036|NCT02393794|EXPERIMENTAL|Romidepsin (8mg/m2) + Cisplatin (75mg/m2)|Romidepsin 8mg/m2 IV on days 2 \& 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
62423309|NCT06537245|EXPERIMENTAL|10 minutes massage group|"The anatomical location chosen for applying the massage was the anterior part of the thigh (muscular quadriceps femoris), due to the effort required by the stress protocol.~The participant was placed in the supine position and the massage was performed on the dominant limb (DOM) and the non-dominant limb (ÑDOM). The techniques used were: superficial and deep sliding, which is presented in two intensities, moderate or intense, with gradual increase. Intensity grading was controlled through participant self-reports. The massage was performed in the direction of the muscle fibers, from distal to proximal and following the lymphatic flow.~The massage had the following rhythm: 1 second of sliding and 1 second to return the hand to the initial position, totaling 2 seconds of sliding. The rhythm of the massage was controlled by an electronic metronome that was used only by the therapists during the technique."
62592601|NCT03200756|ACTIVE_COMPARATOR|Exercise Group|The Active Comparative group undergoes a standard clinical approach to increase exercise which is patient centered with monitoring and goal setting.
62808110|NCT02451085|OTHER|conventional exercise group|will receive instruction for self-training as accepted today through exercise sheet. The exercises will be suited to the ones provided to the patients in the intervention group. Moreover, a follow-up sheet will be given to the patients to fill in order to receive a feedback at the end of experiment. The training duration will be identical in both groups and will last for 30-45 minutes, three times a week.
62592602|NCT05958264||Children of younger school age|10 children of younger school age aged 6-10,9 years with T1D.
62032037|NCT02393794|EXPERIMENTAL|Romidepsin (10mg/m2) + Cisplatin (75mg/m2)|Romidepsin 10mg/m2 IV on days 2 \& 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
62592603|NCT05958264||Children in puberty|10 children in puberty aged 11-14,9 years with T1D
62592604|NCT05958264||Postpubertal adolescents|10 postpubertal adolescents aged 15-18,9 years with T1D
62592605|NCT06409390|EXPERIMENTAL|Sequential therapy|"In this study sequential therapies will be administered.~Strike 1: Cytoxan/Taxotere/GM-CSF Strike 2: Sacituzumab govitecan or trastuzumab deruxtecan Strike 3: Capecitabine Strike 4: Fulvestrant + CDK 4/6 inhibitor (ribociclib or abemaciclib)"
62808111|NCT01525836|EXPERIMENTAL|combination treatment group|120 enrolled patients are randomly picked up to take Rituximab in combination with Rh-TPO at the indicated dose.
62808112|NCT01525836|ACTIVE_COMPARATOR|single treatment group|120 enrolled patients are randomly picked up to take Rituximab at the indicated dose.
62808113|NCT03662958|EXPERIMENTAL|Lutrate|a novel leuprolide acetate 3.75mg depot
62808114|NCT03662958|ACTIVE_COMPARATOR|Enantone|market reference leuprolide acetate 3.75 mg depot
62808115|NCT00844844|EXPERIMENTAL|Eculizumab|
62032038|NCT02393794|EXPERIMENTAL|Romidepsin (12mg/m2) + Cisplatin (75mg/m2)|Romidepsin 12mg/m2 IV on days 2 \& 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
62808116|NCT04816448|EXPERIMENTAL|Studygroup|cervical mobilization (Headache SNAG) with baseline treatment (Hot pack for 10 minutes, TENS 10 minutes, Neck isometrics and stretching).
62808117|NCT04816448|ACTIVE_COMPARATOR|Control Group|Sub-occipital myofascial release with baseline treatment (Hot pack for 10 minutes, TENS for 10 minutes, Neck isometrics and stretching
62808118|NCT00115440|EXPERIMENTAL|A|Active treatment arm.
62808119|NCT03146611||COPD patients|A diagnosis of COPD was made by a clinical history, examination and spirometer (forced expiratory volume in 1st second/forced vital capacity (FEV1/FVC)ratio of \<0.7). The severity of COPD was graded according to the Global Initiative for Chronic Obstructive Lung Disease guidelines. \[9\] (Stage I, mild COPD: FEV1≥80.0% predicted; Stage II, moderate COPD: FEV1 80-50.0%; Stage III, severe COPD: FEV1 50- 30.0%; Stage IV, very severe COPD: FEV1\< 30.0%). The exacerbation of COPD was defined as the patient being diagnosed with COPD with two or more of the following three symptoms of exacerbations: new or worsening cough, worsened dyspnea, and worsened sputum volume and/or change in its color.
62032039|NCT02393794|EXPERIMENTAL|Romidepsin Dose Expansion|Romidepsin maximum tolerated dose (MTD) from Phase I IV on days 2 \& 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle Nivolumab 360mg on day 1 of each 21 day cycle
62032040|NCT02322957|EXPERIMENTAL|Treatment Regimen A|FV-100 400mg OD as a single dose fasted (\>/= 8 hours)
62032041|NCT02322957|EXPERIMENTAL|Treatment Regimen B|FV-100 400 mg OD as a single dose with ritonavir 200mg OD as a single fasted dose (\>/= 8 hours)
62032042|NCT01754831|OTHER|Fluoride varnish|Topical fluoride
62032043|NCT06100042||Asthma patients|Adult patients with a diagnosis of moderate to severe asthma treated with BDP/FF/G medium strength or high strength as per clinical practice.
62032044|NCT05312775|ACTIVE_COMPARATOR|Single-layer uterine closure|Women will undergo a CD following a standard way with respect to the mode of hysterotomy, non-closure of the peritoneum. The control group will receive a single-layer closure using unlocked continuous running multifilament sutures and the endometrial layer will be included
62032045|NCT05312775|ACTIVE_COMPARATOR|Double-layer uterine closure|Women will undergo a CD following a standard way with respect to the mode of hysterotomy, non-closure of the peritoneum. In the intervention group, double-layer closure of the uterus will be performed using unlocked multifilament continuous running sutures for both layers and the endometrial layer will be included in the first layer. The second layer is a continuous running suture that imbricates the first layer
62423310|NCT04651218|NO_INTERVENTION|control|sedentary control group watches TV between being assessed for outcome measures
62423311|NCT04651218|EXPERIMENTAL|exercise|exercise treatment performs exercise between being assessed for outcome measures
62592606|NCT02078453|ACTIVE_COMPARATOR|Visual inspection|Dental treatment performed according to the caries diagnosis obtained with visual inspection performed alone
62808120|NCT03146611||control|healthy sex and age matched group
62423312|NCT03625752|ACTIVE_COMPARATOR|Active Comparator: Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
62423313|NCT03625752|SHAM_COMPARATOR|Sham|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
62423314|NCT01855100||Rivaroxaban|
62423315|NCT00102388|EXPERIMENTAL|vildagliptin|
62423316|NCT00102388|ACTIVE_COMPARATOR|Gliclazide|
62423317|NCT05932927||Chronic liver disease with hepatopulmonary syndrome|Liver disease (usually cirrhosis with portal hypertension) ；Positive CE-TTE（Contrast enhanced contrast ultrasound）；Abnormal arterial oxygenation: Alveolar-arterial oxygen gradient (AaO2) ≥ 15 mm Hg (\>20 mm Hg if age \> 64)
62423318|NCT05932927||Chronic liver disease without hepatopulmonary syndrome|Liver disease (usually cirrhosis with portal hypertension) ； Negative CE-TTE
62808121|NCT03091725|EXPERIMENTAL|RYGB group|Subjects in this group are scheduled to undergo Roux-en-Y gastric bypass surgery and will be assessed after 16-18% weight-loss
62808122|NCT03091725|ACTIVE_COMPARATOR|VLCD Group|Subjects in this group will participate in a very low-calorie diet intervention to obtain a 16-18% weight loss.
62808123|NCT04673214|EXPERIMENTAL|Triple therapy|Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C, Azithromycin 500 mg tablets will take 1 tablet single dose the first day and then half tablet (250 mg) orally every 24 for 4 days, Ivermectin tablets of 200mcg which will be calculated according to your weight and dose, will be every 24 hours for 2 days and Rivaroxaban tablets of 10 mg will take 1 every 24 hours for 10 days
62808124|NCT04673214|ACTIVE_COMPARATOR|Double therapy|Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C, Azithromycin 500 mg tablets will take 1 tablet single dose the first day and then half a tablet orally every 24 for 4 days and Rivaroxaban 10 mg tablets will take 1 every 24 hours for 10 days.
62808125|NCT05305352|NO_INTERVENTION|No intervention|The no intervention arm will not receive counselling but will follow their routine diet suggested during their routine antenatal visits.
62808126|NCT05305352|EXPERIMENTAL|Intervention|The intervention arm will be counselled about very low carbohydrate diet (\<10%carbohydrate)
62808127|NCT05653414|EXPERIMENTAL|"short early psychological care group"|Women with short early psychological care associated with encouragement of early support consultation with generalist practitioner or midwife
62808128|NCT05653414|ACTIVE_COMPARATOR|"control group"|Women with encouragement of early support consultation with generalist practitioner or midwife
62808129|NCT02230735|EXPERIMENTAL|Bipivacaine 0.5% with epinephrine|Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
62808130|NCT02230735|PLACEBO_COMPARATOR|Normal Saline|Total of 14 ml of normal saline, 7ml into the right uterosacral ligament and 7ml into the left uterosacral ligament
62808131|NCT00961311|EXPERIMENTAL|Trial Arm|All patients with systematic ischemic heart disease with stenotic lesions that are amenable to percutaneous treatment.
62808132|NCT03597815||DME positive, OSA positive|Visit 1: Baseline DME Treatment. Includes first EYELEA(aflibercept) injection. (DME positive patients will receive a minimum of 6 injections with the first five occurring at 1-month intervals and the sixth occurring two months after the fifth. Further injections will be provided at the discretion of the ophthalmologist in according to the treat and extend protocol of Eylea to ensure the DME is resolved by the end of the study.) Each injection is 2 mg (0.05 mL). Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 1 month follow up post-CPAP initiation Visit 4: 6-month visit post DME initial treatment Visit 5: 2-3 month follow up - titration study (at sleep lab) Visit 6: 12-month visit post DME initial treatment in the OSA- group and at least 3 months post CPAP initiation in the OSA+ group Visit 7: 12-month sleep apnea follow up
62808133|NCT03597815||DME positive, OSA negative|Visit 1: Baseline DME Treatment Includes first EYELEA(aflibercept) injection. (DME positive patients will receive a minimum of 6 injections with the first five occurring at 1-month intervals and the sixth occurring two months after the fifth. Further injections will be provided at the discretion of the ophthalmologist in according to the treat and extend protocol of Eylea to ensure the DME is resolved by the end of the study.) Each injections is 2 mg (0.05 mL). Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 6-month visit post DME initial treatment Visit 4: 12-month visit post DME initial treatment in the OSA- group and at least 3 months post CPAP initiation in the OSA+ group
62231837|NCT01844245|EXPERIMENTAL|Endobiliary RFA group|"1. Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive endobiliary radiofrequency ablation (Endobiliary RFA) followed by plastic stent(s) placement.~2. Three months later, subjects will receive the second RFA therapy followed by biliary stents (plastic or SEMS) placement.~3. During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA"
62231838|NCT01844245|NO_INTERVENTION|Control group|"1. Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive plastic biliary stent(s) placement only.~2. Three months later, subjects will receive the second endoscopic intervention for stents (plastic or SEMS) exchange.~3. During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA"
62423319|NCT00393978|PLACEBO_COMPARATOR|Quetiapine and Placebo|Quetiapine and Placebo
62423320|NCT00393978|ACTIVE_COMPARATOR|Quetiapine and Topiramate|Quetiapine and Topiramate
62423321|NCT00003119|EXPERIMENTAL|Treatment 1 - Asymptomatic - no immediate chemotherapy|
62423322|NCT00003119|EXPERIMENTAL|Symptomatic - immediate chemotherapy|
62423323|NCT01204073|EXPERIMENTAL|TAK-441|
62423324|NCT05828745|EXPERIMENTAL|CB06-036 Cohort 1|CB06-036 1.5 mg once weekly
62423325|NCT05828745|PLACEBO_COMPARATOR|Placebo Cohort 1|Placebo 1.5 mg once weeky
62423326|NCT05828745|EXPERIMENTAL|CB06-036 Cohort 2|CB06-036 3.0 mg once weekly
62423327|NCT05828745|PLACEBO_COMPARATOR|Placebo Cohort 2|Placebo 3.0 mg once weekly
62423328|NCT05828745|EXPERIMENTAL|CB06-036 Cohort 3|CB06-036 1.5 mg twice-a-week, for 4 weeks
62423329|NCT05828745|PLACEBO_COMPARATOR|Placebo Cohort 3|Placebo 3.0 mg twice-a-week, for 4 weeks
62423330|NCT05828745|EXPERIMENTAL|CB06-036 Cohort 4|CB06-036 3.0 mg once weekly for 4 weeks
62231839|NCT04651907|EXPERIMENTAL|acupuncture group|The needle set for the sham acupuncture group and the real acupuncture group will use the CASOON Acupuncture Needle (Wuxi Jiajian Medical Instrument Company, limited), which needle size is 0.3mm×30mm. The needle placed for the real acupuncture group will be the same needle size as 0.3mm×30mm. The depth of needling varied based on the patient's body sizes. After insertion, the needles were manually manipulated to obtain the De Qi sensation, which was defined as the acupuncturist feeling a tugging or grasping sensation from the needle manipulation and the patient feeling soreness, fullness, heaviness, or local distension at local needling sites.
62808134|NCT03597815||DME negative (NPDR positive), OSA positive|no injections needed. Visit 1: Baseline NPDR diagnosis Sleep lab visits Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 1 month follow up post-CPAP initiation Visit 4: 2-3 month follow up - titration study Visit 5: 12-month sleep apnea follow up
62808135|NCT03597815||DME negative (NPDR positive), OSA negative|no injections needed. Visit 1: Baseline NPDR diagnosis Visit 2: Diagnosis of OSA - Overnight sleep study
62808136|NCT02050061|EXPERIMENTAL|compression stocking|compression stocking (SIGVARISTM), daily for 3 months
62808137|NCT02050061|NO_INTERVENTION|standard medical therapy|Usual care
62808138|NCT03398304|EXPERIMENTAL|Graded Exercise|Volunteers will participate in 3 study visits. The study visits will consist either of 20 minutes of walking, 20 minutes of running or 20 minutes of sitting. At the beginning of each study visit, prior to any exercise, a 4.5mL blood sample will be collected. The participant will then complete either 20 minutes of walking, running or sitting and will then have a 4.5mL blood draw taken from a new site.
62808139|NCT03398304|EXPERIMENTAL|Marathon Participation|On the day of the marathon prior to start, the participant will be seated for 10 minutes prior to measuring their baseline heart rate. A 4.5 mL blood sample will be collected prior to initiation of exercise. Immediately after completion of the marathon, a 4.5 mL blood draw will be completed. Additional 4.5 mL blood draws will be taken at 1 and 2 days post-marathon to measure to length of time required to return to baseline coagulation, fibrinolysis, and inflammation following the prolonged, intense exercise.
62808140|NCT05089006||robot-assisted surgery group|Patients undergoing robot-assisted surgery for small renal tumor
62231840|NCT04651907|PLACEBO_COMPARATOR|sham-controlled group|The sham acupuncture group will be performed by superficial needling with less than 4mm depth. The needling location is about 0.5 cm away from the acupoints. Both the real acupuncture group and the sham acupuncture group received the same treatment protocol.
62592607|NCT02078453|EXPERIMENTAL|Radiographic examination|Dental treatment performed according to the caries diagnosis obtained with visual inspection and additional radiographic method.
62592608|NCT02251145|EXPERIMENTAL|tipranavir/ritonavir low dose|
62592609|NCT02251145|EXPERIMENTAL|tipranavir/ritonavir high dose|
62592610|NCT02824601|EXPERIMENTAL|One-visit treatment PDT|Intervention: Chemo-mechanical preparation (CMP) was performed by using the single-file reciprocating technique + 2.5% NaOCL and a final rinse with 17% EDTA. Next, the root canals were irrigated with 10 mL of saline solution, with calcium hydroxide medication being neutralized with 0.5% citric acid. Afterwards, the photosensitizer agent (methylene blue 10 mg/mL) was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP in the one-visit treatment
62808141|NCT05089006||open surgery group|Patients undergoing open surgery for small renal tumor
62808142|NCT01074775|EXPERIMENTAL|Challenge group|Recipients of three challenge infections with oral M bovis
62808143|NCT05805423|EXPERIMENTAL|Bilateral superficial cervical plexus blocks + local wound infiltration|the bilateral superficial cervical plexus block will be performed with 10mL of 0.25% Bupivacaine injected bilaterally (total 20mL) at Erb's point in the lateral neck, which is located at the mid-point between the mastoid process and the posterior border of the clavicular head of the sternocleidomastoid muscle. The injection is just below the lateral border of the sternocleidomastoid muscle, which produces surface level anesthesia of the neck, targeting superficial nerves of the cervical plexus. Then 10mL of 0.25% Bupivacaine will be injected at the planned neck incision (local wound infiltration) on the anterior neck. These will be done intra-operative and only once
62808144|NCT05805423|PLACEBO_COMPARATOR|placebo + local wound infiltration|10mL of 0.25% bupivacaine injected at the planned neck incision (local wound infiltration), with 10mL of normal saline injected at bilateral Erb's point (total 20mL) (placebo at site of BSCPB). These will be done intra-operative and only once.
62808145|NCT00105911|OTHER|Arm 1|
62032046|NCT03069482|EXPERIMENTAL|Learn to Quit|A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms.
62032047|NCT03069482|ACTIVE_COMPARATOR|NCI QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.
62808146|NCT02167308|ACTIVE_COMPARATOR|Laser acupuncture group|Subjects will receive 24 activated laser acupuncture treatments. The laser will be applied for 10 seconds to each of the selected acupuncture points.
62808147|NCT02167308|SHAM_COMPARATOR|Control group|Subjects in the control group will undergo sham laser acupuncture treatment with no laser power output. Acupuncture points, application duration, and total number of treatments will be identical to the Laser acupuncture group.
62808148|NCT00002643|EXPERIMENTAL|Arm I|See detailed description.
62808149|NCT01357174||All Participants|Infants who were vaccinated with ROTATEQ™
62032048|NCT05583591|ACTIVE_COMPARATOR|Combined cataract surgery with Hydrus microstent|
62032049|NCT05583591|ACTIVE_COMPARATOR|Combined cataract surgery with iStent Inject W|
62808150|NCT04261686|OTHER|COVERA Vascular Covered Stent|COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit of hemodialysis subjects dialyzing with an AV fistula.
62808151|NCT05866666||Cardiac Function Monitoring|Subjects scheduled for cardiac catheterization will undergo measurement with the Cardiac Performance System non-invasive device for a brief period before the catheterization procedure.
62808152|NCT00103168|EXPERIMENTAL|Imatinib mesylate|400 mg/day for 2 years
62808153|NCT00103168|NO_INTERVENTION|Control|
62231841|NCT04651907|NO_INTERVENTION|waitlist-controlled group|As an waitlist control group, no acupuncture will be performed.
62231842|NCT02918123|EXPERIMENTAL|Treatment|"1. FURESTEM-CD Inj. 5.0x10\^7 cells~2. FURESTEM-CD Inj. 1.0x10\^7 cells~3. FURESTEM-CD Inj. 2.0x10\^8 cells"
62231843|NCT01003990|EXPERIMENTAL|Atazanavir|
62808154|NCT01602224|EXPERIMENTAL|100 mg Tabalumab+Dexamethasone (Dex)+Bortezomib (BTZ)|"Tabalumab 100 milligram (mg) administered once intravenously (IV) over 30 minutes on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.~Bortezomib 1.3 milligram per square meter (mg/m\^2) administered once subcutaneously (SQ) on Days 1, 4, 8 and 11 every 21 days for a minimum 8 cycles.~All treatment may continue past 8 cycles."
62808155|NCT01602224|EXPERIMENTAL|300 mg Tabalumab+Dexamethasone+Bortezomib|"Tabalumab 300 mg administered once IV over 30 minutes on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for a minimum 8 cycles.~Bortezomib 1.3 mg/m\^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.~All treatment may continue past 8 cycles."
62808156|NCT01602224|PLACEBO_COMPARATOR|Placebo Comparator: Placebo + Dexamethasone + Bortezomib|"Placebo administered once IV on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for a minimum 8 cycles.~Bortezomib 1.3 mg/m\^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.~All treatment may continue past 8 cycles."
62032050|NCT02742168|EXPERIMENTAL|Breast Cancer,99mTc-3PRGD2,SPECT/CT|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and efficacy evaluation of breast cancer
62231844|NCT01003990|EXPERIMENTAL|Atazanavir/Ritonavir|
62231845|NCT01003990|ACTIVE_COMPARATOR|Lopinavir/Ritonavir|Ritonavir-boosted Lopinavir (LPV/RTV 400/100 mg) administered twice a day (BID) with Tenofovir/ Emtricitabine (TDF/FTC).
62231846|NCT04929743|EXPERIMENTAL|5.5 mm implants|
62231847|NCT04929743|ACTIVE_COMPARATOR|>6.5 mm implants|
62423331|NCT05828745|PLACEBO_COMPARATOR|Placebo Cohort 4|Placebo 3.0 mg once weekly for 4 weeks
62231848|NCT00835120|EXPERIMENTAL|Pioglitazone|Pioglitazone has been approved by the U.S. Food and Drug Administration (FDA) to help people who are diagnosed with diabetes
62808157|NCT06215534|OTHER|arm 1|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62231849|NCT03371030|EXPERIMENTAL|Pronator quadratus reparation|Surgical Intervention: Radius fracture teated with plate and pronator quadratus muscle repair.
62231850|NCT03371030|ACTIVE_COMPARATOR|No pronator quadratus reparation|Surgical Intervention: Radius fracture with plate without pronator quadratus muscle repair.
62231851|NCT04677868|EXPERIMENTAL|MTX and corticosteroid|Methylprednisolone 1 mg/kg/day MTX (10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II;
62231852|NCT02829788||Digestive peritoneal carcinomatosis staging|All patients underwent laparoscopic followed by laparotomic surgical staging.
62231853|NCT02370043|EXPERIMENTAL|KQ-791|Escalating doses of KQ-791, starting at 15 milligrams
62231854|NCT02370043|EXPERIMENTAL|KQ-791 (after meal)|Single dose of KQ-791 in capsule form, after a meal
62231855|NCT02370043|PLACEBO_COMPARATOR|Placebo|Single dose of placebo matching KQ-791 dose
62231856|NCT05889481||Retrospective cohort|Patients diagnosed with uveal melanoma undergoing histological and cytogenetic analysis. The cases will be identified from patients referred to the Ocular Oncology Unit and they finished the follow-up
62231857|NCT05889481||Prospective cohort|Patients diagnosed with uveal melanoma undergoing histological and cytogenetic analysis. The cases will be identified from patients referred to the Ocular Oncology and they still have to complete the follow-up
62423332|NCT00893867|EXPERIMENTAL|DP-b99|
62808158|NCT06215534|OTHER|arm 2|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62808159|NCT06215534|OTHER|arm 3|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62808160|NCT06215534|OTHER|arm 4|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62808161|NCT06215534|OTHER|arm 5|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62808162|NCT06215534|OTHER|arm 6|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62032051|NCT04158947|EXPERIMENTAL|T-DM1 + Afatinib|"Trastuzumab emtansine (T-DM1) : 3.6 mg/kg IV Day 1 every 21 days.~Afatinib: the highest dose of Afatinib with T-DM1 found in Phase I, po every day"
62032052|NCT04158947|ACTIVE_COMPARATOR|T-DM1|Trastuzumab emtansine (T-DM1) :3.6 mg/kg IV Day 1 every 21 days.
62231858|NCT05895838|EXPERIMENTAL|Dexamethasone intervention, active|"As soon as possible after hospital admittance 20 mg of dexamethasonephosphate (Dexavit, Vital Pharma Nordic ApS, Denmark) will be given intravenously (i.v.) over 15 minutes - followed by 20 mg dexamethasonephosphate (or placebo) i.v. administered daily at 0600 (or at least 8 hours after initial dose) for two days, for a total of 3 doses.~For this arm the dexamethasonephosphate solution is provided in the DANOHCA trial kit in the form of Dexavit at a concentration of 4mg/mL stored in glass vials of 5mL; three vials are provided in total."
62231859|NCT05895838|PLACEBO_COMPARATOR|Dexamethasone intervention, placebo|"As soon as possible after hospital admittance placebo (isotonic saline) will be given intravenously (i.v.) over 15 minutes - followed by placebo solution administered i.v. daily at 0600 (or at least 8 hours after initial dose) for two days, for a total of 3 doses.~For this arm the placebo solution is provided in the DANOHCA trial kit in the form of isotonic sodium chloride stored in glass vials of 5mL; three vials are provided in total."
62423333|NCT00893867|PLACEBO_COMPARATOR|Mannitol|
62423334|NCT02440074|EXPERIMENTAL|MSV autologous transplantation|
62808163|NCT06215534|OTHER|arm 7|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62808164|NCT06215534|OTHER|arm 8|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62808165|NCT06215534|OTHER|arm 9|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62808166|NCT06215534|OTHER|arm 10|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62808167|NCT06215534|OTHER|arm 11|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62808168|NCT06215534|OTHER|arm 12|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62808169|NCT06215534|OTHER|arm 13|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62808170|NCT06215534|OTHER|arm 14|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62032053|NCT03291574|EXPERIMENTAL|Electroacupuncture group|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu
62032054|NCT03291574|PLACEBO_COMPARATOR|Sham electroacupuncture group|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu
62032055|NCT05250596|EXPERIMENTAL|Colchicine and Atorvastatin|Colchicine 1 mg (0.5 mg for patients ≤ 70 Kg) on-admission followed by 0.5 mg/day until discharge plus Atorvastatin 80 mg on admission followed by 80 mg/day until discharge.
62032056|NCT05250596|ACTIVE_COMPARATOR|Atorvastatin|Atorvastatin 80 mg on admission followed by 80 mg/day until discharge.
62032057|NCT06181162|EXPERIMENTAL|Adolescents growing up in vulnerable life situations in four diverse urban environments.|
62032058|NCT01842139|EXPERIMENTAL|Arm A (vaccine with Montanide)|Patients receive WT1 126-134 peptide vaccine emulsified in Montanide ISA 51 VG SC on day 0 and then once every 2 weeks.
62032059|NCT01842139|EXPERIMENTAL|Arm B (vaccine with poly-ICLC)|Patients receive WT1 126-134 peptide vaccine in poly-ICLC SC on day 0 and then once every 2 weeks.
62032060|NCT01842139|EXPERIMENTAL|Arm C (vaccine therapy, monoclonal antibody)|Patients assigned to Arm C receive basiliximab IV over 30 minutes on day -7 and WT1 126-134 peptide vaccine as in Arm A or Arm B, whichever had a superior cellular immune response.
62032061|NCT05989308|NO_INTERVENTION|Usual Care|Care as usual
62032062|NCT05989308|EXPERIMENTAL|Preferred Modality|Text or email message to guardian with proxy information. If the guardian has no personal MyChart access, before sending proxy information to set up access to their child's MyChart, the investigators will message the guardian up to two times with information enabling them to access their personal MyChart.
62032063|NCT05989308|EXPERIMENTAL|Patient Portal|Patient portal message (MyChart) to guardian with proxy information. If the guardian has no personal MyChart access, before sending proxy information to set up access to their child's MyChart, the investigators will message the guardian up to two times with information enabling them to access their personal MyChart.
62032064|NCT06532214||PHLF/NPHLF|PHLF:Post-hepatectomy liver failure,PHLF is commonly diagnosed and classified according to the criteria of the International Study Group for Liver Surgery (ISGLS), utilizing markers of liver function measured on or after postoperative day 5 (POD5). NPHLF:Patients who did not experience liver failure following hepatectomy.
62032065|NCT06532214||Liver Cirrhosis/No Liver Cirrhosis|Whether the patient has cirrhosis
62032066|NCT03948776||Healthy volunteers|Adults without HF or prior heart transplantation
62032067|NCT03948776||Participants in our existing LVAD body composition study|Currently-enrolled LVAD body composition participants, who chose to participate in this study on the same day as a DXA scan already scheduled for study #12026
62032068|NCT03948776||Patients with heart failure, an LVAD or heart transplantation|Any patients with a current diagnosis of HF, with or without an LVAD, or prior HF now status post heart transplantation
62032069|NCT03948776||Inpatients with heart failure, LVAD, heart transplantation|Patients with a current diagnosis of HF, with or without an LVAD, or prior HF now status post heart transplantation, currently admitted as inpatients at Tufts Medical Center. The 6/20/2019 protocol update includes these patients who will participate without a DXA scan (which can only be performed as an outpatient).
62032070|NCT05440110|ACTIVE_COMPARATOR|active and active|The patients will be subjected to TBS for 5 daily interventions per week for four consecutive weeks.
62032071|NCT05440110|SHAM_COMPARATOR|sham and active|The patients will be subjected to TBS for 5 daily interventions per week for the first two weeks, followed by an open-label trial for the next two weeks.
62032072|NCT04250649|ACTIVE_COMPARATOR|Intervention|Betadine solution disinfection of the subcutaneous tissue during primary shoulder surgery
62032073|NCT04250649|NO_INTERVENTION|Controle|Control group with surgery without disinfection of the subcutaneous tissue but dissection with an electric cautery during primary shoulder surgery
62032074|NCT04323852|EXPERIMENTAL|vitamin D|35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units
62032075|NCT04323852|PLACEBO_COMPARATOR|control group|35 patients that will receive placebo for 3 days and each day for 3 doses
62032076|NCT06138977|EXPERIMENTAL|Prosthesis|Participants in this arm of the study will perform various tasks while wearing the powered prosthesis
62808171|NCT06215534|OTHER|arm 15|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62808172|NCT06215534|OTHER|arm 16|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62808173|NCT06215534|OTHER|arm 17|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62808174|NCT06215534|OTHER|arm 18|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62808175|NCT02511379|EXPERIMENTAL|Systane Balance|Propylene Glycol 0.6% eye drops, 1 drop QID (with the last dose of each day at bedtime) in each eye for 90 days
62808176|NCT06296017|EXPERIMENTAL|Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy (ESWT for short) application will be performed on A1 pulley at 15 Hz, 1000 shock wave impulses, and 2.0 bar level, for a total of 5 sessions, one week apart.
62808177|NCT06296017|EXPERIMENTAL|Trigger Finger Splint|A trigger finger splint that immobilizes the MCF joint will be recommended for the splint treatment group. The patient will be asked to use this splint throughout the day for 8 weeks.
62808178|NCT06296017|EXPERIMENTAL|Extracorporeal Shock Wave Therapy+Trigger Finger Splint|Splint treatment will be applied together with ESWT. ESWT application will be performed on A1 pulley at 15 Hz, 1000 shock wave impulses, and 2.0 bar level, in a total of 5 sessions, one week apart. A trigger finger splint that immobilizes the MCF joint will be recommended for the splint treatment group. The patient will be asked to use this splint throughout the day for 8 weeks.
62423335|NCT05138328|EXPERIMENTAL|Treatment of basal cell carcinoma with Nd:YAG laser|All enrolled patients will be treated with the Nd:YAG laser for this study as part of the intentional intervention for this study.
62423336|NCT04106401|EXPERIMENTAL|hypoxia & confinement|Participants exposed to high-altitude hypoxia and confinement during a one-year stay at Concordia station, Antarctica (3200 m)
62808179|NCT02422706|ACTIVE_COMPARATOR|group I|"Metronidazole(MTZ) 500mg twice daily ,Omeprazole 20 mg twice daily as (Proton Pump Inhibitor (PPI)\& Clarithromycin 500 mg twice daily .for 14 days .~40 patients"
62808180|NCT02422706|EXPERIMENTAL|Group II|"Nitazoxanide(NTZ)500 mg twice daily ,PPI 20 mg twice daily \& Clarithromycin 500 mg twice daily for 14 days.~40 patients."
62808181|NCT02422706|EXPERIMENTAL|Group III|"Levofloxacin 250 mg once daily,Omeprazole 40mg once daily(PPI),Nitazoxanide (NTZ) 500mg twice daily \& Doxicycline 100 mg once daily (LOND).~40 patients"
62808182|NCT00596414|PLACEBO_COMPARATOR|1|
62808183|NCT00596414|EXPERIMENTAL|2|midazolam
62808184|NCT00596414|EXPERIMENTAL|3|midazolam + pethidine
62808185|NCT06474624|EXPERIMENTAL|Moderate Intensity Continuous Training|"* A total of 24 -30 (8-10 weeks) sessions of an exercise-based Cardio Rehabilitation program 3 days a week.~* Cycling for 20-30 minutes at 50-70% of Wmax between warm-up and cool-down periods."
62808186|NCT06474624|EXPERIMENTAL|High-intensity interval training|"* A total of 24 -30 (8-10 weeks) sessions of an exercise-based Cardiac Rehabilitation program 3 days a week.~* Cycling a total of 4 cycles consisting of 4 minutes at 85-100% of Wmax followed by 3 minutes of active recovery periods at 50-70% of Wmax between warm-up and cool-down periods."
62032077|NCT06401148|EXPERIMENTAL|Exercise-based cardiac rehabilitation|Participants will complete an 8-week-long cardiac rehabilitation programme consisting of supervised exercise sessions run by a clinical exercise physiologist and psychoeducation sessions.
62032078|NCT06401148|NO_INTERVENTION|Treatment as Usual|Participants randomised to usual care will not receive any intervention but continue with usual medical treatment for their AF as determined by their healthcare team.
62032079|NCT04899349|EXPERIMENTAL|Alpelisib + Fulvestrant + Dapagliflozin + Metformin XR|Alpelisib 300mg administered orally once daily starting at Cycle 1 Day 8 in combination with fulvestrant 500mg intramuscular at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle. Participants also received a combination treatment of dapagliflozin+metformin XR (as a single tablet or as two separate tablets, at the discretion of the investigator) at a starting dose of 5 mg dapagliflozin + 500 mg metformin XR orally once daily which could be titrated to a maximum dose of 10 mg dapagliflozin + 2000 mg metformin XR once daily.
62032080|NCT04899349|ACTIVE_COMPARATOR|Alpelisib + Fulvestrant + Metformin XR|Alpelisib 300mg administered orally once daily starting at cycle 1 Day 8 in combination with fulvestrant 500mg intramuscular at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle. Participants also received metformin XR 500mg orally once daily which could be titrated to a maximum dose of 2000 mg once daily.
62032081|NCT00167544|EXPERIMENTAL|1|1. Tapering dose of hydrocortisone every 12 h over 7 day period
62032082|NCT00167544|PLACEBO_COMPARATOR|2|2. Identical-appearing saline placebo
62032083|NCT06368245||primary/revision long-segment posterior TL instrumented fusion with dual-rod constructs|The index surgery for this study is the primary or revision of long-segment posterior TL instrumented fusion using dual-rod construct.
62808187|NCT01329978|EXPERIMENTAL|SOF+PEG+RBV 12 weeks|Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks.
62808188|NCT01329978|EXPERIMENTAL|SOF+PEG+RBV 24 weeks|Participants were randomized to receive sofosbuvir+PEG+RBV for 24 weeks.
62808189|NCT01329978|EXPERIMENTAL|SOF+PEG+RBV 12 week/Rerandomization Group|Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks, then were rerandomized to receive sofosbuvir only or sofosbuvir+RBV for 12 additional weeks.
62808190|NCT00539981|EXPERIMENTAL|FluBlok (Lots A, B, C)|Participants received a single 0.5 milliliters (mL) dose of FluBlok vaccine from any of the Lots A, B, or C, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.
62032084|NCT06368245||primary/revision long-segment posterior TL instrumented fusion with supplementary rod constructs|The index surgery for this study is the primary or revision of long-segment posterior TL instrumented fusion using either a supplementary rod construct.
62808191|NCT00539981|PLACEBO_COMPARATOR|Placebo|Participants received a single dose of placebo matched to FluBlok, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.
62808192|NCT05235126|OTHER|Treatment arm|All subjects receive treatment at V1 and option to receive touch-up at V2.
62808193|NCT00792844|EXPERIMENTAL|Bio-K capsule|1 capsule of lactobacillus acidophilus and lactobacillus casei (50 billion live bacteria) daily for duration of antibiotic therapy and 7 days after or until discharge, whichever comes first
62808194|NCT00792844|ACTIVE_COMPARATOR|Bio-K liquid|98 g of lactobacillus acidophilus and lactobacillus casei (50 billion live bacteria) daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever comes first
62808195|NCT00792844|NO_INTERVENTION|no Bio-K|No lactobacillus product - standard infection control procedures (i.e. handwashing, etc.)
62808196|NCT04752163|EXPERIMENTAL|Cohort A and B (DS-1594b)|Patients with MLLr or NPM1m receive DS-1594b PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62808197|NCT04752163|EXPERIMENTAL|Cohort C (DS-1594b, venetoclax, azacitidine)|Patients receive DS-1594b PO BID on days 1-28, venetoclax PO QD on days 1-28, and azacitidine IV or SC on days 1-7. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62808198|NCT04752163|EXPERIMENTAL|Cohort D (DS-1594b, mini-HCVD)|Patients receive DS-1594b PO BID on days 1-28. For additional information, see trial description.
62032085|NCT06635317|ACTIVE_COMPARATOR|Long term aspirin group|Long term aspirin group received enoxaparin, 40 mg/day subcutaneously for 3 days, and aspirin, 100 mg/day orally for 25 days
62423337|NCT04106401|ACTIVE_COMPARATOR|confinement|Participants exposed to confinement during a one-year stay at Dumont d'Urville station, Antarctica (sea level)
62808199|NCT04752163|EXPERIMENTAL|Drug-Drug Interaction (DS-1594b, posaconazole, voriconazole)|Patients receive DS-1594b PO BID on days 1-8 and 19-28, and posaconazole PO BID on day 9 and QD on days 10-18 or voriconazole PO BID on days 9-18 in the absence of disease progression or unacceptable toxicity.
62808200|NCT04752163|EXPERIMENTAL|Food-Effect (DS-1594b)|Patients receive DS-1594b PO BID on days 1-8 within 30 minutes after eating a standard meal and PO BID on days 9-15 under fasting conditions in the absence of disease progression or unacceptable toxicity.
62808201|NCT04752163|EXPERIMENTAL|Phase I (DS-1594b)|Patients receive DS-1594b PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.
62808202|NCT01054105||Step I: BMPR-2 gene analysis|BMPR-2 gene analysis on 100 IPAH or heritable PAH Patients
62808203|NCT01054105||Step-II: Iloprost and Exercise Echo|Illoprost inhalation for 3 months \& Check-up before and after treatment; WHO functional classification Assessment of exercise capacity (6M walk test) Cardiopulmonary exercise echocardiography NT-proBNP
62808204|NCT05072626||high MCT formula nutritional support|Infants aged 0-3 months who underwent Kasai operation for congenital biliary atresia and were able to receive enteral nutrition through oral or tube feeding were administered a high MCT formula powder + breast milk (with the high MCT formula powder accounting for ≥50%) after the Kasai operation. If breast milk was insufficient, regular formula was used as a substitute. The recommended energy intake was set at 100-130% of DRIs.
62423338|NCT01746849|EXPERIMENTAL|palifermin with Lupron|All patients undergo total body irradiation (TBI) on days -9 to -6 \& receive thiotepa intravenously (IV) over 2-4 hours on days -5 to -4, cyclophosphamide IV over 30-60 minutes on days -3 to -2, \& anti-thymocyte globulin infused over 12 hours on days -3 to -2 Pts undergo T-cell depleted allogeneic hematopoietic stem cell transplant on day 0. Pts will receive a three month depot dose of Lupron 3-6 weeks prior to the start date of the pre-transplant conditioning regimen. Pts will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 \& no more than 48 hours prior to the start of cytoreduction. Pts will receive three additional daily doses of palifermin the first approximately 6 hours after the stem cell infusion on day 0, followed by two daily doses given at 24 hour intervals on d+1 \& d+2. Pts will receive a further 3-month depot injection of Lupron approximately 3 months (+/- one week) post the first dose.
62423339|NCT01746849|EXPERIMENTAL|palifermin with Degarelix|Participants on the degarelix arm will receive a loading dose of degarelix 240 mcg subcutaneous 4-14 days before the start of pre-transplant conditioning. All participants will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 and no more than 48 hours prior to the start of cytoreduction.
62592611|NCT02824601|EXPERIMENTAL|Two-visit treatment PDT|Intervention: Chemo-mechanical preparation (CMP) was performed by using the single-file reciprocating technique + 2.5% NaOCL and a final rinse with 17% EDTA. In the following, 14-day inter-appointment medication with Ca(OH)2 + SSL was placed in the root canal. After 14 days with intracanal medication, the tooth was isolated for surgery and disinfection, including removal of provisional restoration. Next, the root canals were irrigated with 10 mL of saline solution, with calcium hydroxide medication being neutralized with 0.5% citric acid. Afterwards, the photosensitizer agent (methylene blue 10 mg/mL) was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP in the one-visit treatment
62592612|NCT00691769||I|CCSA subjects will be recruited from patients who have been diagnosed through biopsy with CCSA and treated with standard of care for up to eight months in the Department of Dermatology clinic of Wake Forest University School of Medicine.
62592613|NCT00691769||II|patients with lichen planopilaris (LP) and patients with discoid lupus erythematosus (DLE) will be collected from patients who have been diagnosed through biopsy in the clinic.
62032086|NCT06635317|ACTIVE_COMPARATOR|Enoxaparin group|enoxaparin group received enoxaparin, 40 mg/day subcutaneously for 28 days, with the dose reduced to 20 mg for patients weighing less than 50 kg or with an estimated glomerular filtration rate less than 30 mL/min/1.73 m².
62032087|NCT06372730|EXPERIMENTAL|Patients with PE who have been treated with anticoagulant therapy for 3 to 6 uninterrupted months|Patients who experienced an objectively proven PE who have been treated initially with anticoagulant therapy for 3 to 6 uninterrupted months (180 - 210 days) and for whom anticoagulation will not be prolonged.
62032088|NCT05205265|EXPERIMENTAL|Rivet Shunt Therapy|
62592614|NCT00691769||III|Healthy study subjects will be patients from the Wake Forest University School of Medicine Department of Dermatology population undergoing excisions for cosmetic purposes or excision of free margins around tumors that would have otherwise been discarded.
62592615|NCT03274141||T2T Patients|RA patients managed with a treat-to-target (T2T) strategy
62592616|NCT03274141||RC Patients|RA patients managed with routine care(RC)
62808205|NCT06412510|EXPERIMENTAL|Intervention - Arm 1|"Exercise Intervention: Participants will be referred to Langston Hughes Community Center and work with exercise physiologists who will utilize our SmartGym ecosystem in providing exercise assessments, prescriptions, and training.~Nitrition Intervention: Participants in the intervention group will be provided with 1-2 bottles of high protein oral nutritional supplements daily (ONS) to ensure that protein needs are met daily. There will be two options of ONS to choose from: one option a high calorie, high protein supplement, and the other option a low fat/low sugar, high protein supplement.~Supportive care/Mind-body intervention: Participants will have access to Taussig Cancer Institute Patient Support services that are offered for free."
62808206|NCT06412510|NO_INTERVENTION|Control - Arm 2|"Exercise: Standard of care. Level of activity will be reported and monitored at each visit through study coordinator assessment and patient interview.~Nutrition: Participants will be referred to dietitian and will be seen for a baseline evaluation, as needed throughout treatment and post treatment. A full nutrition assessment will be performed, and malnutrition diagnosis will be documented. When no malnutrition is identified participants will be provided general nutrition counseling related to their cancer type, cancer treatment, and recommendations for symptom management as needed. Those participants identified to be malnourished to any degree will receive personalized medical nutrition therapy including nutrition interventions to improve caloric intake.~Supportive care/Mind-body intervention: Per standard of care, participants will be offered support services from Taussig Cancer Institute program."
62808207|NCT02978417|ACTIVE_COMPARATOR|Vivitrol|All drug court clients in the pilot RCT will receive standard psychosocial treatment for opioid dependence from FHR as part of their drug court program participation. Participants randomized to Vivitrol® will receive standard treatment along with monthly Vivitrol® injections administered by study staff at outpatient visits. Vivitrol® is naltrexone for extended-release injectable suspension. It is an injectable suspension containing 380 mg of naltrexone in a microsphere formulation and 4 mL diluent. The recommended dose of Vivitrol® is 380 mg delivered intramuscularly every 4 weeks or once a month. The injection should be administered by a healthcare provider as an intramuscular (IM) gluteal injection, alternating buttocks for each subsequent injection (see Links section of PRS for more information about Vivitrol).
62808208|NCT02978417|ACTIVE_COMPARATOR|Oral naltrexone|Subjects randomized to oral naltrexone in addition to standard psychosocial treatment for opioid dependence from FHR as part of their drug court program participation. Oral naltrexone is the daily tablet formulation naltrexone that carries the same risks and benefits as the long-acting injectable formulation (Vivitrol®), except it does not have any of the risks related to injection (discomfort, potential for infection). Oral naltrexone is administered and provided by FHR to interested and eligible clients as part of the range of their usual care services.
62808209|NCT05084040|NO_INTERVENTION|A|Porth-a-Cath maintenance with 60-day interval
62808210|NCT05084040|EXPERIMENTAL|B|Porth-a-Cath maintenance with 90-day interval
62808211|NCT03838185|EXPERIMENTAL|Study Drug|Healthy young male subjects will receive a single ascending oral dose of J147 following an overnight fast of at least 8 hours. Healthy elderly subjects will receive doses that have been found to be safe in healthy young subjects.
62808212|NCT03838185|PLACEBO_COMPARATOR|Placebo|Subjects will receive a single oral dose of placebo with 240 mL non-carbonated water in the morning following an overnight fast of at least 8 hours.
62808213|NCT02926872||Entire Study Population|Male or female patients who are between 2 and 16 years of age (inclusive) will be eligible for the study if they meet all components of Criterion A and/or Criterion B below, provided that these abnormalities are of unknown or unconfirmed etiology and the patient has not previously had a normal LAL enzyme activity result, has not received treatment with sebelipase alfa (Kanuma), and has no evidence of neurological dysfunction within the past year. (Note: Female patients who are of childbearing potential or are pregnant may participate in this study.)
62808214|NCT06430996|EXPERIMENTAL|caffeine gum|The participants chewing caffeine gum 10 minutes before exercise
62808215|NCT06430996|PLACEBO_COMPARATOR|placebo gum|The participants chewing placebo gum 10 minutes before exercise
62423340|NCT06542185|EXPERIMENTAL|online education|- Nurses' self-efficacy levels regarding safe blood transfusion practices will be measured with the Safe Blood and Blood Products Transfusion Self-Efficacy Scale (SBT-SES). SBT-SES pre-tests will be applied to the control and intervention groups, and online training on safe blood transfusion prepared by the researcher will be provided to the intervention group. After the training given to the intervention group, SBT-SES post-tests will be applied to both the intervention and control groups.
62423341|NCT06542185|NO_INTERVENTION|control|No training will be given, only the Blood Products Transfusion Self-Efficacy Scale (SBT-SES) pre-test and post-test will be conducted.
62423342|NCT02860273|EXPERIMENTAL|High Flow Nasal Cannula Oxygen|"1. Incremental Load Treadmill Test (ILTT) using HFNCO at 21%~2. Constant Treadmill Load Test (CTLT) using HFNCO at 21%"
62423343|NCT02860273|OTHER|Control Group|"1. Incremental Load Treadmill Test (ILTT) at Room Air~2. Constant Treadmill Load Test (CTLT) at Room Air"
62808216|NCT01255423|EXPERIMENTAL|Diclofenac sodium topical gel 1%|
62808217|NCT01255423|PLACEBO_COMPARATOR|Placebo|
62808218|NCT03549221|EXPERIMENTAL|MAC with adrenaline|the multimodal anesthetic cocktail (MAC) consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). They were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
62592617|NCT04796506|ACTIVE_COMPARATOR|Exercise Group|PD participants randomized to progressive resistance training PRT) will have 12 weeks of supervised PRT 3 times per week. After the 1st 12 weeks, responders to PRT (increase in slow wave sleep) will continue PRT for an additional 12 weeks, non-responders to PRT will transition to endurance training (ET).
62592618|NCT04796506|PLACEBO_COMPARATOR|Delayed Exercise Group|PD participants randomized to the delayed exercise control group will not exercise for the 1st 12 weeks of the study. After the 1st 12 weeks, participants in the delayed exercise group will transition to PRT for the 2nd 12 weeks.
62423344|NCT03250507|ACTIVE_COMPARATOR|Bupivacaine|Patients will receive a TAP block with 60 mL 0.25% bupivacaine. this group will not receive Liposomal bupivacaine
62808219|NCT03549221|NO_INTERVENTION|MAC without adrenaline|the multimodal anesthetic cocktail (MAC) consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). They were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
62808220|NCT00841334|EXPERIMENTAL|1|ACTION
62592619|NCT03308591|EXPERIMENTAL|NACT|The patients will receive 2 courses of platinum based chemotherapy before surgery, 2-3 weeks after each course, doctors will appraise the effect of the chemotherapy. Patients who are sensitive to the treatment will undergo radical hysterectomy and pelvic lymph node dissection 3 weeks after chemotherapy. And 2-3weeks after the surgery, patients will receive adjuvant chemotherapy according to the pathological risk factors.
62592620|NCT03308591|ACTIVE_COMPARATOR|PST|The patients in this group will undergo radical hysterectomy and pelvic lymph node dissection directly, and 2-6 weeks after the surgery, they will receive adjuvant chemotherapy according to the pathological risk factors.
62423345|NCT03250507|ACTIVE_COMPARATOR|Liposomal bupivacaine|"Patients will receive a TAP block with 20 mL liposomal bupivacaine and 40 mL saline.~this group will not receive bupivacaine. they receive only liposomal bupivacaine."
62423346|NCT03250507|EXPERIMENTAL|Liposomal bupivacaine and bupivacaine|"Patients will receive a TAP block with 20 mL liposomal bupivacaine and 40 mL 0.25% bupivacaine.~this group will receive the mixture of Liposomal bupivacaine and bupivacaine."
62423347|NCT04093973||MAC subjects|Outpatients with moderate to severe mitral annular calcification on echocardiogram who are able to perform supine bicycle exercise.
62592621|NCT06621979|EXPERIMENTAL|Gastroesophageal reflux disease|Disabling post-bypass gastroesophageal reflux, resistant to medical treatment and requiring surgery
62592622|NCT03386396|EXPERIMENTAL|High protein/low carbohydrate|A breakfast shake will be made with high protein/low carbohydrate mixture.
62592623|NCT03386396|EXPERIMENTAL|High carbohydrate/low protein|A breakfast shake will be made with high carbohydrate/low protein mixture.
62592624|NCT01734538|EXPERIMENTAL|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories, Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
62592625|NCT01734538|PLACEBO_COMPARATOR|Placebo Capsule|Oral ingestion of 5 capsules of a placebo oil pill (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
62423348|NCT04093973||Controls|Sex matched individuals who are within 5 years of age of the paired MAC subject and who have the same left ventricular wall thickness as measured by echocardiography.
62423349|NCT01547273|EXPERIMENTAL|bone graft inside socket only|bone graft inside socket only
62423350|NCT01547273|EXPERIMENTAL|bone graft inside and outside socket|bone graft inside and outside socket
62423351|NCT01547273|EXPERIMENTAL|no bone graft|no bone graft
62423352|NCT05020626||Controls|
62423353|NCT05020626||Mild cognitive impairment|
62592626|NCT04703374|EXPERIMENTAL|A|Period 1: Test drug(CKD-382 formulation I) Period 2: Test drug(CKD-382 formulation II) Period 3: Reference drug(D026)
62592627|NCT04703374|EXPERIMENTAL|B|Period 1: Test drug(CKD-382 formulation II) Period 2: Reference drug(D026) Period 3: Test drug(CKD-382 formulation I)
62592628|NCT04703374|EXPERIMENTAL|C|Period 1: Reference drug(D026) Period 2: Test drug(CKD-382 formulation I) Period 3: Test drug(CKD-382 formulation II)
62592629|NCT04703374|EXPERIMENTAL|D|Period 1: Test drug(CKD-382 formulation I) Period 2: Reference drug(D026) Period 3: Test drug(CKD-382 formulation II)
62423354|NCT05020626||AD dementia|
62423355|NCT00393770|EXPERIMENTAL|L-acetylcarnitine|
62423356|NCT05841706|EXPERIMENTAL|Arm I (Transfusion for Hgb less than 7 g/dL)|Patients undergo red blood cell transfusion if Hgb is less than 7 g/dL while on study. Patients undergo CT scan, x ray imaging, and blood sample collection throughout the study.
62592630|NCT04703374|EXPERIMENTAL|E|Period 1: Test drug(CKD-382 formulation II) Period 2: Test drug(CKD-382 formulation I) Period 3: Reference drug(D026)
62592631|NCT04703374|EXPERIMENTAL|F|Period 1: Reference drug(D026) Period 2: Test drug(CKD-382 formulation II) Period 3: Test drug(CKD-382 formulation I)
62592632|NCT00514644|EXPERIMENTAL|Panorama to Ultrasound|100 asymptotic patients that have findings of calcifications in the area of the carotid arteries when examined with panorama. These persons are examined with carotid ultrasound.
62592633|NCT00514644|EXPERIMENTAL|Ultrasound to Panorama|100 patients with a known carotid stenosis seen on ultrasound will be examined with panorama before any intervention is made. These patients must undergo surgery to be finally included.
62808221|NCT00841334|ACTIVE_COMPARATOR|2|Usual care
62808222|NCT02309944|ACTIVE_COMPARATOR|Standard Wound Closure|Standard surgical closure of the fascia and skin.
62808223|NCT02309944|EXPERIMENTAL|Negative Pressure Wound Therapy|Standard surgical closure as used by the standard of care group plus placement of the Prevena™ Incision Management System over the closed incision.
62808224|NCT02461667|PLACEBO_COMPARATOR|placebo|SRP plus placebo SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
62808225|NCT02461667|ACTIVE_COMPARATOR|Metformin|SRP plus Metformin SRP was done for all the subjects. metformin was delivered in the pocket subgingivally
62808226|NCT02461667|ACTIVE_COMPARATOR|Alendronate|SRP plus Alendronate SRP was done for all the subjects. Alendronate was delivered in the pocket subgingivally
62808227|NCT01303211||serogroup A meningococcal disease|Cases of serogroup A meningococcal disease
62808228|NCT01303211||Community controls|Healthy members of the community controls matched with cases for age, sex and place of residence
62808229|NCT01303211||Hospital controls|Patients admitted to the hospital with an acute illness other than meningitis or septicemia
62808230|NCT04971460||Mother and Baby Unit|Fathers and partners of women admitted to a Mother and Baby Unit
62808231|NCT04971460||Peri-natal Community Mental Health Services|Fathers and partners of women accessing community perinatal mental health services
62808232|NCT04971460||Control group|Fathers and partners of women who are not accessing mental health services in the perinatal period
62032089|NCT01560390|OTHER|Rémifentanil + Kétamine|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
62032090|NCT01560390|OTHER|Rémifentanil + Placebo|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
62032091|NCT04111445|EXPERIMENTAL|ADG116|
62032092|NCT06119633|EXPERIMENTAL|Immediate tissue expander and fat grafting after mastectomy|Patients underwent simple mastectomy, skin-sparing or nipple-sparing mastectomy and implant-based, two-stage breast reconstruction: contextual mastectomy and expander positioning were performed during first stage (stage I) while substitution of the expander with definitive implant occurred during second stage (stage II). Fat grafting with regenerative intent was performed during stage I or between stage I and II. Adipose tissue was harvested from the abdomen, flanks, trochanter regions, inner thigh and medial aspect of knees. Fat was injected in the subfascial plane of the pectoralis major muscle with blunt cannula in order to avoid thrombo-embolic risks. At least six months after stage I patients underwent expander substitution with definitive implant and contralateral mammoplasty when required. In case of complications that required removal of the implant, autologous reconstruction was performed.
62032093|NCT04110808|ACTIVE_COMPARATOR|Nitroglycerine|Patients will receive hypotensive anesthesia with nitroglycerine infusion via syringe pump by adding 5mg (5ml) of Nitroglycerin to 45ml of normal saline making it to final concentration of 100μg/ml at the rate of 0.5- 10 μg/kg/min according to the patients desired target blood pressure.
62032094|NCT04110808|OTHER|Phentolamine|Patients will receive hypotensive anesthesia with phentolamine infusion via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.
62032095|NCT02352311|EXPERIMENTAL|Arm 1 AVODART, CIALIS, DKF-313|In Period 1, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose. In Period 2, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose.
62032096|NCT02352311|EXPERIMENTAL|Arm 2 DKF-313, AVODART, CIALIS|In Period 1, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose. In Period 2, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose.
62808233|NCT03636555|ACTIVE_COMPARATOR|Oxytocin|Syntocinon Spray (intranasal oxytocin spray). Each dose is 10 intranasal insufflations totaling 1.0 mL of Syntocinon Spray containing 40 IU of oxytocin. Subjects self-administer doses twice daily (before breakfast and before dinner) for 12 consecutive weeks.
62423357|NCT05841706|EXPERIMENTAL|Arm II (Transfusion for Hgb less than 9 g/dL)|Patients undergo red blood cell transfusion if Hgb is less than 9 g/dL while on study. Patients undergo CT scan, x ray imaging, and blood sample collection throughout the study.
62423358|NCT05409222||Cohort 1A: preventive salpingo-oophorectomy with hormone replacement therapy|Healthy carriers who decide undergo preventive surgery and opt to have hormone replacement therapy
62808234|NCT03636555|PLACEBO_COMPARATOR|Placebo|Each dose is 10 intranasal insufflations totaling 1.0 mL of a solution containing all ingredients in Syntocinon Spray except oxytocin. Subjects self-administer doses twice daily (before breakfast and before dinner) for 12 consecutive weeks.
62808235|NCT06514872||Turkish older|The data obtained from individuals aged 60 and above were used in this study.
62808236|NCT01889823|EXPERIMENTAL|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
62808237|NCT01889823|EXPERIMENTAL|Hyperoxia|Subjects will be breathing 100% of oxygen
62808238|NCT02246049|EXPERIMENTAL|FOLFOXIRI plus bevacizumab|"Induction therapy is followed by the maintenance therapy.~\[Induction treatment:FOLFOXIRI plus bevacizumab\] Administered for a maximum of 12 cycles. BV: 5mg/kg (d.i.v.) L-OHP: 85 mg/sq.m (d.i.v.) CPT-11:165mg/sq.m (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~\[Maintenance treatment:5-FU / I-LV plus bevacizumab\] BV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks."
62808239|NCT00254917|EXPERIMENTAL|1|Concommitant recombinant hepatitis B vaccine at 0, 6 and 14 weeks of age
62808240|NCT00254917|EXPERIMENTAL|2|Concommitant recombinant hepatitis B vaccine at 6, 10, and 14 weeks of age.
62808241|NCT06293521|EXPERIMENTAL|MTA Pulpotomy|Intervention group
62808242|NCT06293521|ACTIVE_COMPARATOR|Chlorohexidine Pulpectomy|Control group
62808243|NCT02697266||Post-call anesthesiologists|Attending anesthesiologists, and Anesthesiology residents
62808244|NCT02697266||Regular-shift anesthesiologists|Attending anesthesiologists, and Anesthesiology residents
62032097|NCT01763931|EXPERIMENTAL|Digoxin|Digoxin administration for 2 weeks prior to surgery.
62231860|NCT05895838|EXPERIMENTAL|Backrest elevation intervention, elevation to 35 degrees|As soon as possible after hospital admittance the patients will have their headrest positioned at 35 degrees straight elevation of backrest in Semi-Fowler's position (elevated lower limp position). This position will be maintained during the initial 72 hours or until extubated. Adherence to assigned stratum will be checked every 8 hours and cuff pressure will be assessed and corrected if needed at the same time during the intervention period. The backrest position intervention may be temporarily canceled by the treating physician if needed for procedures or mobilization but will return to the assigned position if invasive ventilator treatment with orotracheal intubation is continued. The intervention will be terminated if the patient is extubated, or a tracheostomy is performed, during the intervention period of 72 hours.
62231861|NCT05895838|ACTIVE_COMPARATOR|Backrest elevation intervention, elevation to 5 degrees|As soon as possible after hospital admittance the patients will have their headrest positioned at 5 degrees straight elevation of backrest in Semi-Fowler's position. This position will be maintained during the initial 72 hours or until extubated. Adherence to assigned stratum will be checked every 8 hours and cuff pressure will be assessed and corrected if needed at the same time during the intervention period. The backrest position intervention may be temporarily canceled by the treating physician if needed for procedures or mobilization but will return to the assigned position if invasive ventilator treatment with orotracheal intubation is continued. The intervention will be terminated if the patient is extubated, or a tracheostomy is performed, during the intervention period of 72 hours.
62231862|NCT05895838|EXPERIMENTAL|Early wake-up intervention, wake-up ≤6 hours after ICU admission|"Patients will be subjected to a wakeup call and potential extubation after ≤6 hours after admission to the ICU. Definition for ready for extubation will be: GCS≥12, RASS 0- -1, able to raise arm or voluntary hand shake on command, spontaneous breathing trial and low ventilator settings (pressure support≤14, PEEP≤8 (10 if obese), and FiO2≤40%). A wakeup call may be aborted for the following reasons: seizures, respiratory distress, shock, or other cause with specification. Sedation prior to the scheduled wakeup calls is permitted in this early wakeup call group as needed for clinical care, while it is mandatory for the late wakeup call group. For both groups sedation as needed for clinical care will be permitted after the scheduled wakeup calls.~For this arm, information on the assigned time for wakeup call is provided in the DANOHCA trial kit. The assigned time for wakeup will be noted in the electronic patient file."
62231863|NCT05895838|ACTIVE_COMPARATOR|Early wake-up intervention, wake-up 28-36 hours after ICU admission|"Patients will be subjected to a wakeup call and potential extubation after 28-36 hours after admission to the ICU. Definition for ready for extubation will be: GCS≥12, RASS 0- -1, able to raise arm or voluntary hand shake on command, spontaneous breathing trial and low ventilator settings (pressure support≤14, PEEP≤8 (10 if obese), and FiO2≤40%). A wakeup call may be aborted for the following reasons: seizures, respiratory distress, shock, or other cause with specification. Sedation prior to the scheduled wakeup calls is mandatory for this late wakeup call group. For both groups sedation as needed for clinical care will be permitted after the scheduled wakeup calls.~For this arm, information on the assigned time for wakeup call is provided in the DANOHCA trial kit. The assigned time for wakeup will be noted in the electronic patient file."
62423359|NCT05409222||Cohort 1B: preventive salpingo-oophorectomy without hormone replacement therapy|Healthy carriers who decide undergo preventive surgery and reject hormone replacement therapy
62423360|NCT05409222||Cohort 2: without preventive salpingo-oophorectomy|Healthy carriers who decide not to proceed to preventive surgery
62423361|NCT00720473|OTHER|A: Other|Open Label Study
62032098|NCT01763931|NO_INTERVENTION|No drug administration prior to surgery|Group of participants who will not receive digoxin; however, tissue will be collected at time of definitive breast surgery.
62423362|NCT00720473|NO_INTERVENTION|B: Healthy Controls|
62423363|NCT04822428|EXPERIMENTAL|study group(A)|Group (A): included Twenty patients who received osteopathic manipulative techniques, 1 session per week for 3 weeks.
62423364|NCT04822428|NO_INTERVENTION|Control group(B)|Group (B): included twenty patients who received analgesic drugs only.
62592634|NCT03538977|ACTIVE_COMPARATOR|Conventional physiotherapy (GP)|The sample will be evaluated once a day in the morning until they complete at least 11 intervention sessions of conventional physiotherapy in five moments: immediately before therapy, immediately after, 15, 30 and 60 minutes after the intervention.While they are in need of intensive care and hospitalized in the NICU, infants will receive conventional physiotherapy care three times a day. After discharge to the intermediate care unit (ICU), patients will receive care only once a day. Evaluations and interventions will be carried out five days a week (Monday to Friday), according to the logistics of the unit.
62592635|NCT03538977|EXPERIMENTAL|GP + hydrotherapy (GH)|The sample will be evaluated once a day in the morning until they complete at least 11 intervention sessions of hydrotherapy in five moments: immediately before therapy, immediately after, 15, 30 and 60 minutes after the intervention. While they are in need of intensive care and hospitalized in the NICU, infants allocated to GH, hydrotherapy will be performed once a day, associated with two sessions of conventional physiotherapy. After discharge to the intermediate care unit (ICU), patients will receive care only once a day, both conventional physiotherapy and hydrotherapy. Evaluations and interventions will be carried out five days a week (Monday to Friday), according to the logistics of the unit.
62592636|NCT01148303|EXPERIMENTAL|Etoricoxib First|This arm will receive etoricoxib for six days, followed by placebo for eight days.
62592637|NCT01148303|EXPERIMENTAL|Etoricoxib Second|This arm will get placebo for eight days before beginning their fast, followed by etoricoxib for six days.
62032099|NCT05345015|EXPERIMENTAL|Acute effects|The experimental group will receive one single session of 20-min electrical energy transfer session (Capacitive mode, 0.5 Mhz radiofrequency, intensity 40%). The TENS group will receive one 20-minute session of transcutaneous electrical stimulation (TENS, asynchronous rectangular pulse, f\< 50Hz). The control (CON) group will not receive any intervention. Outcome measures will be measured prior to, immediately after, 24 and 48 hours after.
62032100|NCT05345015|EXPERIMENTAL|Chronic effects|The experimental group will receive 10 sessions of 20-min electrical energy transfer session (Capacitive mode, 0.5 Mhz radiofrequency, intensity 40%). The TENS group will receive 10 20-minute sessions of transcutaneous electrical stimulation (TENS, asynchronous rectangular pulse, f\< 50Hz). The control (CON) group will not receive any intervention. Outcome measures will be measured prior to, immediately after, 3 and 6 months after.
62032101|NCT06193876|ACTIVE_COMPARATOR|Petitgrain group|In this group petitgrain oil will be used
62032102|NCT06193876|ACTIVE_COMPARATOR|Ylang-ylang group|In this group ylang-ylang oil will be used
62032103|NCT06193876|PLACEBO_COMPARATOR|Placebo group|In this group water will be used
62032104|NCT00915642||Normal volunteers|Volunteers, body mass index 17 to 25
62032105|NCT00915642||Obese volunteers|Volunteers body mass index higher than 30
62423365|NCT02139579|EXPERIMENTAL|Avastin|bevacizumab 7.5mg/kg+paclitaxel 200mg/m2＋carboplatin area under curve(AUC)=6, every 3 weeks，maximum 4 cycles
62423366|NCT02173301|EXPERIMENTAL|XP23829 400 mg QD (once daily)|After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg QD for 12 weeks including titration period
62032106|NCT04706832|OTHER|ThorS-MagNT Treatment|Low-frequency, low-intensity repetitive magnetic stimulation bilaterally at T7-8 intravertebral space twice a day for 5 days with a total 1200 magnetic stimulations per treatment session at 1 Hz.
62423367|NCT02173301|EXPERIMENTAL|XP23829 800 mg QD|After 4-week screening period, eligible subjects will be randomized to XP23829 800 mg QD for 12 weeks including titration period
62423368|NCT02173301|EXPERIMENTAL|XP23829 400 mg BID (twice daily)|After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg BID for 12 weeks including titration period
62592638|NCT04471233|EXPERIMENTAL|Multimodal analgesia regimen including pregabalin|For the pregabalin group, patient will be provided with an oral preoperative pregabalin dose of 150mg on the day of surgery. Patient will continue pregabalin 75mg two times a day, for two weeks postoperatively. For both the intervention and control groups, the operative technique and additional perioperative analgesic modalities will follow a standard protocol
62808245|NCT04687657|EXPERIMENTAL|cord blood transfusion|The arm that will receive the target treatment.
62032107|NCT02576067|EXPERIMENTAL|Low dose methotrexate|average dose of 15-20 mg po/weekly
62808246|NCT03084796|EXPERIMENTAL|Treatment A|CHF 5259 pMDI 6.25 μg, 1 inhalation twice daily (bid); (total daily dose \[TDD\] of CHF 5259 12.5 μg)
62808247|NCT03084796|EXPERIMENTAL|Treatment B|CHF 5259 pMDI 12.5 μg, 1 inhalation bid; (TDD of CHF 5259: 25 μg)
62032108|NCT02576067|PLACEBO_COMPARATOR|Placebo|matching placebo
62032109|NCT06434038|EXPERIMENTAL|Low dose intranasal insulin|One dose of 40 international units of regular insulin administered intranasally.
62423369|NCT02173301|PLACEBO_COMPARATOR|Placebo|After 4-week screening period, eligible subjects will be randomized to Placebo for 12 weeks
62423370|NCT00758706|EXPERIMENTAL|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
62032110|NCT06434038|EXPERIMENTAL|High dose Intranasal Insulin|One dose of 80 international units of regular insulin administered intranasally.
62032111|NCT06434038|PLACEBO_COMPARATOR|Placebo Control|One dose of 0.9% saline administered intranasally.
62423371|NCT00758706|PLACEBO_COMPARATOR|Placebo|Dosing to match AZD1236
62423372|NCT06418360|EXPERIMENTAL|conventional physical therapy (CPT)|Group 1 (HP, TENS, knee isometric and theraband exercise) to painful side knee area, two weeks, five times a week, 10 sessions.
62808248|NCT03084796|EXPERIMENTAL|Treatment C|CHF 5259 pMDI 12.5 μg, 2 inhalations bid; (TDD of CHF 5259: 50 μg)
62808249|NCT03084796|EXPERIMENTAL|Treatment D|CHF 5259 pMDI 25 μg, 2 inhalations bid; (TDD of CHF 5259: 100 μg)
62808250|NCT03084796|PLACEBO_COMPARATOR|Treatment E|Placebo, 2 inhalations of CHF 5259 pMDI-matched Placebo bid;
62032112|NCT00303524|EXPERIMENTAL|1|Zoladex 3-month depot
62032113|NCT00303524|EXPERIMENTAL|2|Zoladex 1-month depot
62032114|NCT04704063|ACTIVE_COMPARATOR|Active|Tocovid Suprabio 200mg
62032115|NCT04704063|PLACEBO_COMPARATOR|Placebo|Placebo
62032116|NCT02816580|EXPERIMENTAL|elderly subjects|
62032117|NCT04327414|EXPERIMENTAL|Intervention group|Implementation of standing desks in classroom. To ensure that adolescents will spend sufficient time at the standing desks, 1/3 to half of the classroom will be provided with standing desks. The school will be asked to actually replace some traditional desks with these standing desks, instead of just adding standing desks to the classroom set-up to ensure as much as possible that the desks are being continuously used throughout the intervention period.
62032118|NCT04327414|NO_INTERVENTION|Control group|No implementation of standing desks in classroom.
62032119|NCT02734212|EXPERIMENTAL|Ending Self-Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
62423373|NCT06418360|EXPERIMENTAL|conventional physical therapy (CPT) and TECAR therapy|Group 2 (HP, TENS, knee isometric and theraband exercise) 10 sessions, two weeks, five times a week and in addition TECAR therapy, to painful side knee quadriceps and peripatellar area, three times a week for two weeks, for a total of 6 sessions.
62423374|NCT05723861|EXPERIMENTAL|VR group|Participants will receive Virtual Reality intervention in addition to routine care during colonoscopy.
62423375|NCT05723861|NO_INTERVENTION|Control group|Receive routine treatment.
62423376|NCT03284866|EXPERIMENTAL|Arm I, recombinant HPV 9-valent vaccine|Patients receive Recombinant Human Papillomavirus Nonavalent Vaccine (Gardasil 9) IM at baseline, 4, and 26 weeks in the absence of disease progression or unacceptable toxicity, with sample collection for Laboratory Biomarker Analysis.
62423377|NCT03284866|PLACEBO_COMPARATOR|Arm II, saline|Patients receive saline placebo vaccine IM at baseline, 4, and 26 weeks, with sample collection for Laboratory Biomarker Analysis.
62808251|NCT03084796|ACTIVE_COMPARATOR|Treatment F|Tiotropium (TIO) 18 μg, SPIRIVA® HandiHaler®, 2 inhalations once daily (od) of the content of 1 capsule; (TDD of TIO: 18 μg)
62231864|NCT05895838|EXPERIMENTAL|Olanzapine intervention, active|"As soon as possible after arriving at the ICU olanzapine 10mg (dissolved tablet) is administered by feeding tube. Thereafter 10 mg olanzapine is administered by feeding tube (or orally in awake patients) the following two evenings at 1800 (with a minimum of 12 hours between the initial doses) for a total of 3 doses. Due to the potential QT-prolonging effect, and concern for arrythmia, patients will be excluded prior to randomization if Long QT Syndrome (LQTS) is suspected, and telemetry of heart rhythm is mandatory for 96 hours or until life sustaining therapies are withdrawn. In case of delirium patients are treated according to standard care most often including dexmedetomidine, haloperidol or midazolam.~For this arm the olanzapine tablets are provided in the DANOHCA trial kit in the form of olanzapin 10mg tablets (Accord Healthcare B.V., The Netherlands); three tablets are provided in total. Prior to administration by feeding tube the tablets are dissolved in water."
62231865|NCT05895838|PLACEBO_COMPARATOR|Olanzapine intervention, placebo|"As soon as possible after arriving at the ICU a placebo tablet (dissolved) is administered by feeding tube. Thereafter placebo will be administered by feeding tube (or orally in awake patients) the following two evenings at 1800 (with a minimum of 12 hours between the initial doses) for a total of 3 doses. Due to the potential QT-prolonging effect of olanzapine, and accompanying concern for arrythmia, patients will be excluded prior to randomization if LQTS is suspected, and telemetry of heart rhythm is mandatory for 96 hours or until life sustaining therapies are withdrawn. In case of delirium patients are treated according to standard care most often including dexmedetomidine, haloperidol or midazolam.~For this arm the placebo tablets are provided in the DANOHCA trial kit in the form of placebo tablets manufactured by the Pharmacy of the Capital Region; three tablets are provided in total. Prior to administration by feeding tube the tablets are dissolved in water."
62231866|NCT03614910||Locally Advanced Pancreatic Cancer|"Patients with locally advanced unresectable pancreatic cancer. Unresectable tumors as defined by:~* occlusion, thrombosis or several centimeters of encasement of the superior mesenteric vein or portal vein~* tumor abutment greater than 180 degrees of the superior mesenteric artery or thrombosis of the artery~* abutment or encasement of the celiac axis~* involvement of lymph nodes outside the area of resection"
62231867|NCT01838252|EXPERIMENTAL|Hyaluronic acid|Patients in this arm will receive hyaluronic acid fillers to the lower lid.
62231868|NCT01838252|SHAM_COMPARATOR|Saline|
62231869|NCT06225934||congenital muscular torticollis|Babies diagnosed with congenital muscular torticollis (CMT) who agree to participate in the study and meet the inclusion criteria will be included in the study without using any sample selection method, since it is a single-arm study. The parents of each baby will first be informed about the content of the study and will read and sign the consent form stating that they participate in the study voluntarily.
62231870|NCT03717831||Healthy|Healthy subjects will be enrolled as age and activity matched controls for muscle power assessment at one time-point to establish normative values.
62231871|NCT03717831||ICU|Observational, subjects enrolled initially in the ICU and followed for six months after hospital discharge. ICU subdivided based on diagnosis
62231872|NCT02196454|NO_INTERVENTION|Vaccine Information Statement|Study participants will receive the HPV Vaccine Information Statement (VIS) which is part of routine care.
62808252|NCT01916135|EXPERIMENTAL|[18F]-SKI- 249380 and PET/CT scanning|Patients will receive an injection of up to 7.5 (0.5-7.5) mCi of \[18F\]-SKI- 249380, followed by serial PET/CT scanning and blood draws, over a period of 3.5 hours, on a single day. PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. Each patient will be offered the opportunity to repeat the 18F-SKI-249380 injection and subsequent set of post-injection PET-CT scans, once, on a separate date. Each patient may or may not be receiving treatment with dasatinib therapy at the time of 18F-SKI-249380 PET, for their first PET study, as well as repeat PET study, at the discretion of their oncologist according to best clinical judgment.
62808253|NCT00964496|ACTIVE_COMPARATOR|Thalidomide Group|
62808254|NCT00964496|OTHER|Iron-controlled Group|
62808255|NCT06059365|ACTIVE_COMPARATOR|hospitalization group|Patients in the hospitalization group, once the surgical intervention was finished, were transferred to the postoperative recovery unit and later they were discharged to the usual hospital ward. Patients received adequate intravenous fluid resuscitation based on their individual hemodynamic parameter and fluid balance, and they received analgesia according to personal requirement. In the hospital ward, the usual patient management protocols were followed until a complete recovery and consequently discharged according to the usual criteria
62592639|NCT04471233|ACTIVE_COMPARATOR|Multimodal analgesia regimen not including pregabalin|For the non-pregabalin group, patient will be undergo total knee arthroplasty with the same operative technique and additional perioperative analgesic modalities will follow a standard protocol
62808256|NCT06059365|EXPERIMENTAL|outpatient group|Patients in the outpatient group , once operated, were transferred to the surgery unit without admission and were later discharged home if they met the ALDRETE criteria in less than 23 hours after the intervention (following the surgery criteria without admission stages). If the patient was operated during the night shift, following the advice of major outpatient surgery where overnight stays are allowed, the patient was admitted to the post-anesthetic recovery unit and discharged the next day, always in less than 23 hours. In case of being discharged after 23 hours or not meeting ALDRETE criteria, it was considered a failure of the outpatient treatment.
62808257|NCT00659061|ACTIVE_COMPARATOR|Intervention|Multiple micronutrient fortificant (Sprinkles) and nutrition education given by LHWs.
62808258|NCT00659061|NO_INTERVENTION|Control|Routine public health massages by Lady Health Workers (LHWs) during their community visits.
62808259|NCT01120366|ACTIVE_COMPARATOR|SWITCH|Tocilizumab monotherapy
62808260|NCT01120366|ACTIVE_COMPARATOR|ADD-ON|Tocilizumab plus methotrexate combination
62808261|NCT04265196|EXPERIMENTAL|cognitive behavioral group therapy|A Cognitive Behavioral Therapy intervention is based on a unique protocol built in the light of previous research in the field and includes a 10-week treatment focused on coping with pain and stress.
62808262|NCT04265196|EXPERIMENTAL|Mindfulness-based group therapy|A mindfulness-based group therapy intervention was built inspired by a mindfulness protocol that is effective in treating pain, and includes adjustments to the physical distress of fibromyalgia patients as well as an emphasis on coping with stress and pain.
62808263|NCT04265196|NO_INTERVENTION|control group|A control group will wait for 3 months, during which the subjects will complete the questionnaires and only after the end of the period will they participate in the treatment so that it will serve as a control group without intervention.
62808264|NCT04731389|EXPERIMENTAL|internet CBT|Intervention with remote and self-applicable cognitive behavioral therapy, during 4 weeks.
62808265|NCT04731389|ACTIVE_COMPARATOR|Quality of life promotion|Control intervention, during 4 weeks.
62808266|NCT00707785|EXPERIMENTAL|1|Sepsis - vitamin A
62808267|NCT00707785|PLACEBO_COMPARATOR|2|Sepsis - placebo
62032120|NCT02734212|OTHER|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
62423378|NCT05751928|EXPERIMENTAL|Subjects with pCR and pnCR (Group 1A)|"Subjects will receive 2 cycles of BCD-217 neoadjuvant therapy, followed by index lymph node removal.~Subjects with pathological complete (pCR) and near complete response (pnCR) (Group 1A): excision of the primary lesion (if not previously performed) without regional lymphadenectomy, followed by up to 12 months of anti-PD1 agent in the adjuvant setting."
62423379|NCT05751928|EXPERIMENTAL|Subjects with a pPR or pNR to neoadjuvant therapy (Group 1B)|"Subjects will receive 2 cycles of BCD-217 neoadjuvant therapy, followed by index lymph node removal.~Subjects with a pathological partial response (pPR) or non-responders (pNR) to neoadjuvant therapy (Group 1B): excision of the primary lesion (if not performed earlier), regional lymphadenectomy, then up to 12 months of adjuvant therapy with anti-PD1 agent."
62423380|NCT05751928|ACTIVE_COMPARATOR|Control Group (Group 2)|Subjects start treatment with excision of the primary lesion (if not previously performed), regional lymphadenectomy followed by adjuvant therapy with anti-PD1 agent (up to 12 months). This approach is considered the standard therapy for patients in the target population.
62032121|NCT01134900|EXPERIMENTAL|Dashboard|Patients appear on dashboard and are eligible for pharmacy intervention in addition to existing clinical decision support interventions.
62032122|NCT01134900|NO_INTERVENTION|Control|Patients do not appear on dashboard for pharmacy intervention, but only receive existing clinical decision support interventions.
62423381|NCT06134765|EXPERIMENTAL|Bemalenograstim alfa for the prevention of reduced ANC in patients with colorectal/pancreatic cancer|Patients with colorectal cancer and pancreatic cancer（N=32）receive FOLFOXIRI or mFOLFIRINOX with or without targeted therapy. Subcutaneous injection of Bemalenograstim alfa 20mg/ time 24-48h after each cycle of chemotherapy.
62423382|NCT06134765|EXPERIMENTAL|Bemalenograstim alfa for the prevention of reduced ANC in patients with colorectal cancer|Patients with colorectal cancer(N=57)receiving FOLFIRI with or without targeted therapy.Subcutaneous injection of Bemalenograstim alfa, 20mg/ time, 24-48h after each cycle of chemotherapy.
62423383|NCT02179931|EXPERIMENTAL|Flupentixol/melitracen film-coated tablet|test treatment - 0.5 mg/10 mg; oral as a single dose
62423384|NCT02179931|OTHER|Flupentixol/melitracen coated tablet (Deanxit®)|reference treatment - 0.5 mg/10 mg, oral as a single dose
62808268|NCT00707785|EXPERIMENTAL|3|NEC - vitamin A
62808269|NCT00707785|PLACEBO_COMPARATOR|4|NEC - Placebo
62808270|NCT04559854|EXPERIMENTAL|Mindful After Cancer|Participants will be asked to attend 8 weekly sessions via videoconference, and to complete home activities and mindfulness practice between sessions.
62032123|NCT02587351|ACTIVE_COMPARATOR|Metoprolol succinate|Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).
62032124|NCT02587351|PLACEBO_COMPARATOR|Placebo|Matched placebo
62032125|NCT03853629||CF|"* Age 1-17~* Diagnosis of Cystic Fibrosis~* Living in or around London"
62032126|NCT03853629||Controls|"* Age 1-17~* Healthy~* Living in or around London"
62032127|NCT02477618|ACTIVE_COMPARATOR|SAGE-547|Intravenous
62808271|NCT02647307|EXPERIMENTAL|DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg).
62808272|NCT00725777|EXPERIMENTAL|A|
62808273|NCT03166514|EXPERIMENTAL|Commercially Available Food Bar|62 g. Fitjoy Bar
62032128|NCT02477618|PLACEBO_COMPARATOR|Placebo|Intravenous
62032129|NCT02742844|EXPERIMENTAL|APZ2 application|Topical, single application of APZ2; 500000 cells per square cm;
62231873|NCT02196454|EXPERIMENTAL|Video & Vaccine Information Statement|Participants will view an educational video about the HPV vaccine with a male or female narrator. Participants will also receive the HPV Vaccine Information Statement (VIS) which is part of routine care.
62231874|NCT06475443|EXPERIMENTAL|Arms and Interventions|HER2-positive: pyrotinib plus capecitabine
62592640|NCT05673837||Type 1 Diabetes|111 persons with Type 1 Diabetes since childhood
62592641|NCT05673837||Controls|37 persons without diabetes
62592642|NCT06004856|EXPERIMENTAL|Orelabrutinib|
62592643|NCT06004856|PLACEBO_COMPARATOR|Placebo|
62592644|NCT00965978|EXPERIMENTAL|Low dose group|Receives low dose of ONO-5920/YM529 with and without food
62808274|NCT03166514|PLACEBO_COMPARATOR|Placebo|25 g. Dextrose
62592645|NCT00965978|EXPERIMENTAL|High dose group|Receives high dose of ONO-5920/YM529 with and without food
62592646|NCT04324346|EXPERIMENTAL|PICC-Line|Women allocated to PICC-line when receiving chemotherapy
62592647|NCT04324346|EXPERIMENTAL|Subcutaneous Venous Access Port (SVAP)|Women allocated to SVAP when receiving chemotherapy
62032130|NCT03881735|EXPERIMENTAL|Cohort A (enasidenib, hematopoietic cell transplantation)|Patients receive enasidenib PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo a HCT 7-14 days after treatment. Within 30-100 days following the transplant, patients receive enasidenib QD. Treatment repeats every 28 days for 24 cycles in the absence of disease progression or unacceptable toxicity.
62231875|NCT01020448|EXPERIMENTAL|Triptorelin (Decapeptyl®) 22.5 mg|
62231876|NCT03798093|ACTIVE_COMPARATOR|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk the entire length of umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC as we have demonstrated in our previous trials.
62231877|NCT03798093|ACTIVE_COMPARATOR|Early Cord Clamping|This will occur by clamping the umbilical cord as soon as possible. Since both ECC and UCM will occur after a brief assessment, it is important to note that the cord clamping time will be longer than in previously conducted preterm trials (average 20 seconds) which performed the intervention on all subjects regardless of whether or not they were vigorous. In all cases, the cord clamping time will be documented to ensure consistency.
62231878|NCT02778243|EXPERIMENTAL|Bladder cancer|▪ Patients justifying prostatectomy together with the bladder (radical cystectomy for bladder cancer).
62231879|NCT02778243|OTHER|benign prostate hyperplasia|▪ Patients with benign prostate hyperplasia who justified a prostatectomy.
62231880|NCT06455150||Cases|Female badminton athletes
62231881|NCT06455150||Controls|Sedentary women
62808275|NCT05817656|EXPERIMENTAL|Intervention group|After polypectomy with a suitable method, either cold snare polypectomy, hot snare polypectomy, endoscopic mucosal resection, or endoscopic submucosal dissection, we will monitor if immediate polypectomy bleeding occurs. If immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine, heater probe coagulation, and/or hemoclipping. If there is no immediate bleeding, we will apply prophylactic clipping in high-risk patients with polyp size ≥ 1cm. After then, we will spray 3g of sucralfate powder through colonoscopy precisely on the polypectomy wound in the intervention group.
62231882|NCT02871310|EXPERIMENTAL|IQP-AS-118|To be taken once daily dosing of 1 tablet in the morning with 250 mL of water. The tablets should not be chewed, but swallowed whole.
62231883|NCT02871310|PLACEBO_COMPARATOR|Placebo|To be taken once daily dosing of 1 tablet in the morning with 250 mL of water. The tablets should not be chewed, but swallowed whole.
62231884|NCT03489174|EXPERIMENTAL|Monthly Pregnancy Screening|Patients at the Hamilton Clinic present to the clinic most often on a weekly basis to provide a urine sample for urine drug screening and to meet with their MRP. This same urine sample will be tested for pregnancy in the intervention group once per month. Resulting positive test results will be reported to the patient through their attending physician on the day of testing.
62231885|NCT03489174|ACTIVE_COMPARATOR|Usual Care|Participants in the control group will not receive study-initiated urine pregnancy testing but will receive usual care, which may include pregnancy testing based on patient request or clinical judgement.
62592648|NCT01245543|EXPERIMENTAL|AC480IV|Dose range finding study
62592649|NCT01245543|EXPERIMENTAL|Docetaxel|Dose range finding study in subjects with solid tumors
62592650|NCT01564888|PLACEBO_COMPARATOR|Patent hemostasis|Patent hemostasis is the technique for radial artery hemostasis after transradial catheterization, with proactive attempt to maintain radial artery hemostasis and radial artery patency.
62592651|NCT01564888|ACTIVE_COMPARATOR|Ulnar artery compression|Ulnar artery compression will involve radial artery hemostasis using patent hemostasis technique and compression of ulnar artery to the point of occluding flow, in an attempt to augment radial artery flow.
62592652|NCT01873456|EXPERIMENTAL|Multifactorial nutritional intervention|dietician, resistance type exercise, dysphagia assessment and treatment
62592653|NCT01873456|NO_INTERVENTION|usual care|usual care
62592654|NCT04578834|EXPERIMENTAL|LNP023 200mg b.i.d|
62592655|NCT04578834|PLACEBO_COMPARATOR|Placebo to LNP023 200mg b.i.d|
62592656|NCT06621849|EXPERIMENTAL|Group {E}|patients in this group will receive Erector spinae plane block on the ipsilateral side of the surgery then 3.5 ml of bupivacaine 0.5% and 0.25 ml of normal saline intrathecal
62592657|NCT06621849|ACTIVE_COMPARATOR|Group {M}|patients in this group will receive 5 ml of subcutaneous lidocaine 1% then 3.5 ml of bupivacaine 0.5% and 0.1 mg of morphine in 0.25 ml of normal saline intrathecal.
62231886|NCT04760054|EXPERIMENTAL|HUBOD martial arts practice|Participants will be trained in the Hubod exercise over 5 separate training sessions. Sessions will last approximately 30 minutes, involving a warm up, review of material from the previous session and the learning of the next movement in the HUBOD sequence. Heartrate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate cardiovascular exercise as in the active comparator.
62032131|NCT03881735|ACTIVE_COMPARATOR|Cohort B (enasidenib)|Patients receive enasidenib PO QD. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62032132|NCT05278273|EXPERIMENTAL|At home cognitive training|We recruited 20 adults (10 female, mean age = 68.3 years, SD = 6.75) as the at-home training group. We assessed cognitive health status for participants using a self-report questionnaire and the Mini-Mental State Examination (MMSE), and all participants were deemed cognitively healthy (MMSE \> 26). At-home participants loaned the necessary equipment (e.g., 3D-glasses, computer equipment) from the research facilities and engaged in 10 training sessions over five weeks (2x per week). Participant recruitment, retention, adherence and experience were used as markers of feasibility.
62032133|NCT00470951|ACTIVE_COMPARATOR|open rectal resection|conventional open resection
62032134|NCT00470951|ACTIVE_COMPARATOR|laparoscopic rectal resection|laparoscopic rectal resection
62032135|NCT05759273||Triptorelin 6 Month Formulation|Participants treated with the 6-month triptorelin formulation
62032136|NCT04901429|EXPERIMENTAL|Truncal Vagotomy|Truncal vagotomy will be performed during other routine procedure.
62032137|NCT04901429|NO_INTERVENTION|No Truncal Vagotomy|No truncal vagotomy will be performed during other routine procedure.
62032138|NCT03386370|OTHER|"Treatment by Indigo mechanical thrombectomy system"|Acute or Chronic clot: if chronic (\> 14 days) no intervention given via Indigo
62032139|NCT04272281|EXPERIMENTAL|Share making tool decision|Patient recruited from general practitioner in this group will use a share making tool decision to adapt antibiotherapy
62231887|NCT04760054|ACTIVE_COMPARATOR|Active Comparator - Stationary Bicycle|Participants will be given 5 separate sessions, each approximating 30 minutes in duration, of mild to moderate intensity cardiovascular training on a stationary bicycle. Heartrate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate exercise as in the Experimental group.
62231888|NCT04760054|PLACEBO_COMPARATOR|Attentional Control Group|Participants will be given 5 separate sessions, each approximating 30 minutes in duration, of watching videos on martial arts training methods and techniques. These sessions will be completely sedentary.
62231889|NCT05401279|EXPERIMENTAL|Gemcitabine, Cisplatin and Tislelizumab|Patients will receive transurethral resection or partial cystectomy to remove all visible tumors with no residual disease left. 2-4 weeks after the surgery, patients will receive 8 cycles of tislelizumab combined with 4-6 cycles of gemcitabine and cisplatin.
62231890|NCT06178926|ACTIVE_COMPARATOR|Propofol|Use propofol for sedation during anesthesia.
62231891|NCT06178926|EXPERIMENTAL|Ciprofol|Use ciprofol for sedation during anesthesia
62231892|NCT01947192|EXPERIMENTAL|Chlorhexidine|Dentin pre-treatment with a experimental solution (chlorhexidine), after the dentin acid etching
62231893|NCT01947192|PLACEBO_COMPARATOR|Water|Application of water (placebo) after dentin acid etching.
62231894|NCT04685226|EXPERIMENTAL|ICP-723|ICP-723
62231895|NCT01605266||Nephrotic Syndrome|The cohort includes all children diagnosed with nephrotic syndrome between ages 1-18. Children and their caregiver must be willing to provide informed consent, complete questionnaires, and provide biospecimens of the child. Those with secondary causes of nephrotic syndrome and/or systemic disease are excluded.
62231896|NCT00874341|NO_INTERVENTION|1|
62032140|NCT04272281|ACTIVE_COMPARATOR|Standard recommandation|Patients recruited from general practitioner will receive the standard medical care
62032141|NCT06273072|ACTIVE_COMPARATOR|Metformin hydrochloride extended-release tablets|Metformin hydrochloride extended-release tablets 2000 mg once daily
62032142|NCT06273072|PLACEBO_COMPARATOR|Visually identical placebo tablets|Placebo tablet once daily
62032143|NCT06669299|EXPERIMENTAL|Group 1|AAD therapy
62032144|NCT06669299|EXPERIMENTAL|Group 2|Re-Do ablation procedure
62032145|NCT05189730|EXPERIMENTAL|Total neoadjuvant therapy|The patients would receive neoadjuvant chemoradiotherapy treatment firstly. And then evaluated efficacy according to RECIST 1.1. If patients with cCR would receive surgery treatment after 4-6 weeks. After surgery, patients with pCR would always perform surveillance and patients with non-pCR would receive immunotherapy alone treatment. If patients evaluated as PD, they would receive new treatment regimen after MDT discussed. Other patients with PR and SD would receive 2 cycles of neoadjuvant immunochemotherapy. And then, Efficacy of immunochemotherapy would be evaluated according to RECIST 1.1. For patients suitable for surgery, surgery should be performed after 4-6 weeks of immunotherapy. After surgery, the patients with R0 resection would divided into two groups, if patients with pCR would always perform surveillance and patients with non-pCR would receive immunotherapy treatment. Other patients without R0 resection would receive new treatment regimen after MDT discussed.
62032146|NCT05860699|EXPERIMENTAL|Placebo|add-on placebo (Echo Pharmaceutical, BV) for 10 days during their inpatient stay
62032147|NCT05860699|EXPERIMENTAL|Half-dose CBD|add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 10 days during their inpatient stay
62032148|NCT05860699|EXPERIMENTAL|Full dose CBD|add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 10 days during their inpatient stay
62231897|NCT00874341|ACTIVE_COMPARATOR|2|4 portions fruit and vegetables daily for 12 weeks
62231898|NCT00874341|ACTIVE_COMPARATOR|3|7 portions of fruit and vegetables daily for 12 weeks
62592658|NCT00673751|PLACEBO_COMPARATOR|2|subcutaneous isotonic saline
62592659|NCT00673751|ACTIVE_COMPARATOR|1|subcutaneous GLP-2
62592660|NCT05098119|EXPERIMENTAL|Sintilimab+ Carboplatin + Nab-paclitaxel|"Neoadjuvant therapy (the total cycles of the treatment is 3) ：~Cycle1（Cycle length: 21 days）： Sintilimab (IV), dose= 200mg, day=1; Carboplatin (IV), dose=300mg/m2, day=1; Nab-paclitaxel (IV), dose=260mg/m2, day=1.~Cycle2、3（Cycle length: 21 days）： Sintilimab (IV), dose= 200mg, day=1.~Adjuvant therapy（will be dictated by surgical pathology and occurs after standard of care surgery）：~Sintilimab will be given intravenously once every 3 weeks for up to 1 year if participant is considered high-risk based on surgical pathology（high risk features：positive margins or extracapsular extension).~These doses of Sintilimab will be given after surgery and after all acute toxicities of post-operative standard of care chemotherapy and radiation have resolved to grade 1 or less."
62592661|NCT04818606|EXPERIMENTAL|Intervention (MORE) Group|Participants randomized to the intervention group will undergo an eight-week mindfulness training program as instructed by MORE for the Treatment of Chronic Pain manual. This eight-week intervention will consist of weekly synchronous video conferencing sessions during which participants will be asked to follow along with a guided meditation read by the study lead and to engage in reflection and discussion exercises with other study participants. Participants will also be asked to complete weekly activities and daily mindfulness practices outside of weekly synchronous meetings. Pre-recorded guided meditations created by study personnel using scripts from the MORE manual will be provided to participants to facilitate their daily practice.
62032149|NCT03372226|EXPERIMENTAL|Online self-help program|"The intervention group receives the login data for the online program directly following the baseline assessment. The program consists of 10 modules with many interactional exercises and homework-sheets.~Themes that are addressed in the online-program are for example self-esteem, sleep hygiene, problem solving strategies, mindfulness-based relaxation and attention exercises as well as gambling-specific topics such as money/debt management and impulse control. In addition, the user learns to modify negative and gambling-specific thought distortions, to integrate positive activities into his/her daily routine, strategies to deal with the urge to play as well as ways to regulate debts and to prevent relapse."
62231899|NCT04431817||Left transtibial|Left below knee amputation- 25
62231900|NCT04431817||Right transtibial|Right below knee amputation- 25
62231901|NCT04431817||Left transfemoral|Left above knee amputation- 25
62231902|NCT04431817||Right transfemoral|Right above knee amputation- 25
62231903|NCT04431817||Provider|Provider- 15
62231904|NCT05773989|EXPERIMENTAL|Genotype guided P2Y12 monotherapy|Patients will be tested for the CYP2C19 genotype. Patients without a loss-of-function (LOF) allele will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.
62231905|NCT05773989|ACTIVE_COMPARATOR|Standard DAPT|Patients will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.
62231906|NCT01142596|EXPERIMENTAL|Asenapine 5 mg BID|Participants continue in the same arm they were on in core trial P06124 (except placebo arm starts 5 mg BID at Week 2) and will be re-randomized after Week 6 to asenapine 5 mg BID or asenapine 10 mg BID, administered open-label for 46 weeks. Open label dose can be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
62423385|NCT01955031|EXPERIMENTAL|Telemonitoring|Patient with type 2 diabetes randomized in telemonitoring group have a telemonitoring device with educational Tools at their home
62592662|NCT04818606|NO_INTERVENTION|Control Group|This group will undergo treatment as usual (TAU) over the course of the eight-week time period of parallel group comparison. This may or may not involve regularly scheduled, standard visits with other medical personnel, including primary care, specialized medical services, or complementary and integrative health practitioners (e.g., acupuncture). Participants will be asked to refrain from altering therapeutic approaches to pain management during this time unless medically necessary and will be asked to report any changes made to their treatment plan on a daily basis.
62808276|NCT05817656|NO_INTERVENTION|Control group|After polypectomy with a suitable method, either cold snare polypectomy, hot snare polypectomy, endoscopic mucosal resection, or endoscopic submucosal dissection, we will monitor if immediate polypectomy bleeding occurs. If immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine, heater probe coagulation, and/or hemoclipping. If there is no immediate bleeding, we will apply prophylactic clipping in high-risk patients with polyp size ≥ 1cm.
62423386|NCT01955031|SHAM_COMPARATOR|Usual care|patient randomized in this group have a usual care
62808277|NCT05709860|NO_INTERVENTION|Usual Care|Usual care includes: 1) no specific materials to promote PrEP knowledge or uptake among women in primary care, and 2) variable physician counseling on PrEP among women with increased vulnerability to HIV.
62808278|NCT05709860|ACTIVE_COMPARATOR|The EMC2 PrEP Strategy|The EMC2 PrEP Strategy will utilize health information and consumer technologies to automatically deposit an interactive PrEP educational material into the patient portal of women with clinically indicated increased vulnerability to HIV. The material will: 1) promote PrEP knowledge, and 2) prompt discrete scheduling of a dedicated PrEP visit among those interested.
62808279|NCT02102295|ACTIVE_COMPARATOR|Experimental toothpaste|L-ascorbic acid 2-phosphate magnesium salt / fluoride
62808280|NCT02102295|PLACEBO_COMPARATOR|Control toothpaste|fluoride
62231907|NCT01142596|EXPERIMENTAL|Asenapine 10 mg BID|Participants continue in the same arm they were on in core trial P06124 (except placebo arm starts 5 mg bid at Week 2) and will be re-randomized after Week 6 to asenapine 5 mg BID or asenapine 10 mg BID, administered open-label for 46 weeks. Open label dose can be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
62231908|NCT05977114|EXPERIMENTAL|4Rs Group|
62231909|NCT05977114|ACTIVE_COMPARATOR|4As Group|
62231910|NCT02319525|EXPERIMENTAL|Computerized patient decision-aid|A computerized decision-aid showing benefits and harms of medications in words patients prefer
62231911|NCT02319525|ACTIVE_COMPARATOR|Usual care (lupus pamphlet)|A handout/pamphlet from a non-profit organization on lupus and lupus medications (American College of Rheumatology \[ACR\])
62231912|NCT01259726|PLACEBO_COMPARATOR|Placebo|
62231913|NCT01259726|EXPERIMENTAL|VP20621 Low Dose and Placebo|
62423387|NCT04172779|EXPERIMENTAL|Erlotinib treatment|
62423388|NCT06112184|EXPERIMENTAL|All participants|All participants will use the SK-M11/3A1 digital health program for 12 weeks.
62423389|NCT05117073||spontaneous bacterial peritonitis|cirrhotic patients diagnosed with SBP
62423390|NCT05117073||spontaneous fungal peritonitis|irrhotic patients diagnosed with SFP
62032150|NCT03372226|NO_INTERVENTION|Wait-list control group|The participants of the wait-list control condition do not receive any new intervention during the intervention period of 8 weeks, but may continue any treatment that has already been started before, including medication. Participants in the wait-list control condition receive full access to the program after completion of the post-assessment.
62032151|NCT00854451|ACTIVE_COMPARATOR|1 omeprazole plus amoxicillin|omeprazole 20mg bid 2wk + amoxicillin 500mg qid 2wk
62032152|NCT00854451|ACTIVE_COMPARATOR|2 omeprazole plus amoxicillin|omeprazole 20mg bid 2wk + amoxicillin 250mg qid 2wk
62423391|NCT06567249|EXPERIMENTAL|Intracoronary hypothermia|Selective intracoronary hypothermia starts by advancing the coronary guidewire beyond the occlusion of the culprit coronary vessel with subsequent over-the-wire balloon inflation at 5 atm at the site of the occlusion. Then, the guidewire is removed, and the infusion pump is connected to the over-the-wire balloon. Normal saline infusion starts with an infusion rate of 5 ml per minute and a duration of 5 minutes. The temperature of the saline is 4 °C. After that, the over-the-wire balloon is deflated, and infusion continues for 15 minutes at the same temperature and infusion rate of 5 mL per minute, followed by the standard percutaneous coronary intervention.
62423392|NCT06567249|OTHER|Conventional percutaneous coronary intervention|The group will receive standard percutaneous coronary intervention.
62032153|NCT00854451|ACTIVE_COMPARATOR|3 omeprazole plus amoxicillin|omeprazole 20mg qd 2wk + amoxicillin 500mg qid 2wk
62231914|NCT01259726|EXPERIMENTAL|VP20621 High Dose and Placebo|
62231915|NCT01259726|EXPERIMENTAL|VP20621 High Dose|
62423393|NCT02106611||Hodgkin Lymphoma Survivor|This is a prospective cross-sectional study of 200 HL survivors whose treatment included mediastinal RT at initial diagnosis or relapse, and are at least 5 years from last HL treatment.
62032154|NCT00854451|ACTIVE_COMPARATOR|4 omeprazole plus amoxicillin|omeprazole 20mg qd 2wk + amoxicillin 250mg qid 2wk
62231916|NCT01946841|EXPERIMENTAL|RealDiet®Renal enteral nutrition|
62231917|NCT05503654|EXPERIMENTAL|intervention group|Intervention Arm is an arm in which nutrition education will be given to caregivers of infants and young children less than two years aged using the Health Belief Model and Theory of Planned Behavior.
62231918|NCT05503654|NO_INTERVENTION|Control group|Control Arm is an arm to which the intervention will not be implemented.
62231919|NCT04692415|ACTIVE_COMPARATOR|degludec arm|25 patients were discontinued their previous therapy and given metformin alone (2 g/day) for seven days. After seven days they were randomized to first receive IDeg-100 In phase one they received IDeg-100 and metformin for 12 weeks. Phase one was followed by a second wash-up period in which patients received metformin alone again for seven days. In phase two, which also lasted for 12 weeks, patients were switched from IDeg-100 to IGlar-300 (and metformin was continued). The initial dose of both insulins was 0.2 IU/kg.
62423394|NCT04428060|EXPERIMENTAL|PERSEUS CPR|Patients will be resuscitated according to the PERSEUS protocol
62808281|NCT02971423|EXPERIMENTAL|Part A; Cohort 1: 0.25 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a single ascending dose (SAD) of intravenous (IV) ETX2514. Participants in Cohort 1, aged 18 to 55 years, will receive 0.25 grams (g) IV ETX2514/placebo infused over 3 hours.
62423395|NCT04428060|ACTIVE_COMPARATOR|CONTROL|Patients will be resuscitated according to current Advanced Life Support guidelines
62423396|NCT06312501||RPM heart failure patients|Patients that use RPM for the follow-ups of their condition.
62808282|NCT02971423|EXPERIMENTAL|Part A; Cohort 2: 0.5 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 2, aged 18 to 55 years, will receive 0.5 g IV ETX2514/placebo infused over 3 hours.
62231920|NCT04692415|ACTIVE_COMPARATOR|glargine arm|25 patients were discontinued their previous therapy and given metformin alone (2 g/day) for seven days. After seven days they were randomized to first receive IGlar-300 In phase one they received IGlar-300 and metformin for 12 weeks. Phase one was followed by a second wash-up period in which patients received metformin alone again for seven days. In phase two, which also lasted for 12 weeks, patients were switched from IGlar-300 to IDeg-100 (and metformin was continued). The initial dose of both insulins was 0.2 IU/kg.
62808283|NCT02971423|EXPERIMENTAL|Part A; Cohort 3: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 3, aged 18 to 55 years, will receive 1.0 g IV ETX2514/placebo infused over 3 hours.
62808284|NCT02971423|EXPERIMENTAL|Part A; Cohort 4: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 4, aged 18 to 55 years, will receive 1.0 g IV ETX2514/placebo infused over 2 hours.
62808285|NCT02971423|EXPERIMENTAL|Part A; Cohort 5: 2.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 5, aged 18 to 55 years, will receive 2.0 g IV ETX2514/placebo infused over 3 hours.
62808286|NCT02971423|EXPERIMENTAL|Part A; Cohort 6: 4.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 5, aged 18 to 55 years, will receive 4.0 g IV ETX2514/placebo infused over 3 hours.
62032155|NCT02362490|EXPERIMENTAL|peginterferon alpha 2a|in this group, patients who were on treatment of Nucleoside (Acid) Analogues and had achieved HBsAg level ≤250 IU/ml will switch to treatment of peginterferon alpha 2a for 72 week.
62808287|NCT02971423|EXPERIMENTAL|Part A; Cohort 7: 8.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 7, aged 18 to 55 years, will receive 8.0 g IV ETX2514/placebo infused over 3 hours.
62032156|NCT02362490|NO_INTERVENTION|control group|in this group, patients who were on treatment of Nucleoside(Acid) Analogues and had achieved HBsAg level ≤250 IU/ml will be continue to treatment of Nucleoside(Acid) Analogues for 72 week.
62032157|NCT06025526|EXPERIMENTAL|Intervention|
62032158|NCT06025526|OTHER|Control|
62032159|NCT05084196|EXPERIMENTAL|Melatonin Arm|Melatonin 5 mg capsule by mouth at bedtime for the duration of hospitalization or discontinuation of broad spectrum antibiotics, whichever comes first.
62032160|NCT05084196|PLACEBO_COMPARATOR|Placebo Arm|Placebo capsule by mouth at bedtime for the duration of hospitalization or discontinuation of broad spectrum antibiotics, whichever comes first.
62032161|NCT04519918|NO_INTERVENTION|Standard ICSI procedure|a single spermatozoon was injected into the ooplasm.
62032162|NCT04519918|EXPERIMENTAL|Chemical oocyte activation|After CaCl2 was injected, the oocytes were transferred into the calcium ionophore A23187 activation solution for two times of post-ICSI AOA.
62032163|NCT04519918|EXPERIMENTAL|Mechanical oocyte activation|Mechanical stimulation was done before standard ICSI procedure, then the oocytes were transferred into the calcium ionophore A23187 activation solution for two times of post-ICSI AOA.
62032164|NCT01235468|EXPERIMENTAL|CB expnasion|ex-vivo expansion of cord blood for transplantation
62231921|NCT05975151|EXPERIMENTAL|Pseudomonas aeruginosa Group|
62808288|NCT02971423|EXPERIMENTAL|Part A; Cohort 8: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 8, aged 65 years or older, will receive 1.0 g IV ETX2514/placebo infused over 3 hours.
62808289|NCT02971423|EXPERIMENTAL|Part B; Cohort 9: 0.25 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of multiple ascending doses (MAD) of IV ETX2514. Participants in Cohort 9, aged 18 to 55 years, will receive 0.25 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
62808290|NCT02971423|EXPERIMENTAL|Part B; Cohort 10: 0.5 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 10, aged 18 to 55 years, will receive 0.5 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
62032165|NCT06111716|ACTIVE_COMPARATOR|Information-Based Childbirth Education Group|"Information-Based Birth Preparation Education Content; Physical and mental preparation for birth, the birth process, non-pharmacological methods that reduce birth pain and facilitate birth, postpartum period characteristics, physiological and psychological effects on the mother after birth.It includes topics such as changes, adaptation to the maternal role, newborn care. Education is information-based, not based on a philosophy or model."
62032166|NCT06111716|EXPERIMENTAL|Mindfulness-Based Childbirth Education Group|Mindfulness-Based Childbirth Education includes topics related to birth as well as mindfulness, mindfulness attitudes and practices, mindfulness in daily life, mindfulness during pregnancy and postpartum period, mindfulness breastfeeding and meditation practices. The training duration is 8 weeks (2 hours each week).
62032167|NCT02676869|EXPERIMENTAL|IMP321 dose escalation|IMP321 administered fortnightly in addition to SOC pembrolizumab.
62231922|NCT00334724|ACTIVE_COMPARATOR|1|Home blood pressure group
62231923|NCT00334724|ACTIVE_COMPARATOR|2|Office blood pressure group
62423397|NCT06312501||Real-life heart failure patients recieving conventional care|Patients that do not use any medical devices and/or solutions such as RPM for the follow-ups of their condition.
62592663|NCT06665594|EXPERIMENTAL|Facial Filler Injection|TXA plus HA injection in half of face, saline plus HA injection on other half of face
62592664|NCT01240980|EXPERIMENTAL|BMS-903452 (0.1 mg) or Placebo - A1|(Healthy Subjects)
62592665|NCT01240980|EXPERIMENTAL|BMS-903452 (0.6 mg) or Placebo - A2|(Healthy Subjects)
62592666|NCT01240980|EXPERIMENTAL|BMS-903452 (3.0 mg) or Placebo - A3|(Healthy Subjects)
62592667|NCT01240980|EXPERIMENTAL|BMS-903452 (10 mg) or Placebo - A4|(Healthy Subjects)
62032168|NCT06669650|ACTIVE_COMPARATOR|Standard post-operative pain management (control)|Patients in the control groups will follow the current hospital standard of care and receive oxycodone 5mg every 4 hours as needed for moderate pain and oxycodone 10mg every four hours as needed for severe pain.
62032169|NCT06669650|EXPERIMENTAL|Pharmacogenomics (PGx) guided treatment (hydromorphone)|Patients who are poor CYP2D6 metabolizers or rapid CYP2D6 metabolizers with moderate or severe pain, will be prescribed either oral hydromorphone 2mg every 4 hours as needed or oral hydromorphone 4mg every 4 hours as needed, respectively.
62032170|NCT02239783||Total Hip Arthroplasty|Single group previously implanted with the following combination of components: PROFEMUR® TL modular femoral stem, MicroPort Orthopedics acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.
62032171|NCT04663152|EXPERIMENTAL|INSTACARE arm|Participants in this arm will receive the INSTACARE intervention for three months.
62032172|NCT01564966||Living kidney donors|Those who donate kidneys
62032173|NCT04628689|ACTIVE_COMPARATOR|Group 0.25% bupivacaine|30 ml 0.25% bupivacaine
62032174|NCT04628689|ACTIVE_COMPARATOR|Group 0.375% bupivacaine|0.375% bupivacaine
62032175|NCT04016597||Lung diffusing capacity measurements|Participants perform single-breath lung diffusing capacity measurements in random order during one study visit.
62032176|NCT04082949|PLACEBO_COMPARATOR|Subgroups:control and initial pocket depths:5-6mm|Control group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths:5-6mm
62032177|NCT04082949|PLACEBO_COMPARATOR|Subgroups:control and initial pocket depths≥7mm|Control group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths higher than 7mm
62032178|NCT04082949|EXPERIMENTAL|Subgroups:AFG and initial pocket depths:5-6mm|AFG group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths:5-6mm
62231924|NCT04870853||Observational (medical record review)|Patients' medical records are reviewed retrospectively.
62231925|NCT05605587|EXPERIMENTAL|Leflunomide 20mg|
62433560|NCT03769181|EXPERIMENTAL|Cohort A2: cHL: Isatuximab + Cemiplimab|cHL, anti-PD-1/PD-L1 inhibitor progressor participants received isatuximab 10 mg/kg, IV infusion, QW in Cycle 1 and then Q2W from Cycle 2 to Cycle 6 (each cycle of 28 days) and Q3W from Cycle 7 to Cycle 30 (each cycle of 21 days) along with cemiplimab 250 mg Q2W, IV infusion from Cycle 1 to 6 and then 350 mg Q3W from Cycle 7 to Cycle 30, with optional radiotherapy until, unacceptable AEs or participant's decision to stop the treatment, or at least 96 weeks (at least 48 weeks from initial signal of CR, whichever was longer) of delivery of investigational medicinal product(s) without documented PD, or study cut-off date, whichever occurs first (maximum duration: up to 103 weeks).
62032179|NCT04082949|EXPERIMENTAL|Subgroups:AFG and initial pocket depths≥7mm|AFG group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths higher than 7mm
62032180|NCT01235208|EXPERIMENTAL|Eurodiet treatment|
62032181|NCT01614548||all patients|We selected 9 cities (Zhengzhou, Luoyang, Kaifeng, Anyang, Xinyang, Zhoukou, Shangqiu, Nanyang, Zhumadian) by probability proportional to size sampling from geographical regions in central China. All cases with complete follow-up data of histological-proven prostate cancer treated in 2003 and 2008 at 14 department of urology in the 9 cities were retrospectively collected. Only patients with newly diagnosed prostate cancer were included in the study. Those with a history of prostate cancer who were treated for another disease were excluded from study.
62032182|NCT05084872|EXPERIMENTAL|Treatment|Patients will be treated by hydroxychloroquine at a dose of 6 to 6.5mg/kg/day
62032183|NCT06281548|EXPERIMENTAL|Intervention arm|Participants in the intervention arm will receive 56 text messages over 4-weeks.
62032184|NCT00996996|EXPERIMENTAL|open-label, single arm|Tositumomab and Iodine I 131 Tositumomab
62032185|NCT02804854|EXPERIMENTAL|Patients in ICU|Delivery of Neutrophil Activation Probe (NAP) (80mcgs) to ventilated patients up to three times.
62032186|NCT04556708|ACTIVE_COMPARATOR|saline control group|"Periodontal clinical parameters and gingival crevicular fluid (GCF) samples were evaluated at baseline and 8 weeks after periodontal treatment in patients with periodontal disease.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with saline was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination."
62231926|NCT02170389|EXPERIMENTAL|Treatment (AGS-003 immunotherapy, nephrectomy)|Patients receive 3 injections of renal cell carcinoma/cluster of CD40L RNA-transfected autologous dendritic cell vaccine AGS-003 ID once every 7 days during weeks 6-8 in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy on week 10.
62808291|NCT02971423|EXPERIMENTAL|Part B; Cohort 11: 1.0 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 11, aged 18 to 55 years, will receive 1.0 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
62032187|NCT04556708|ACTIVE_COMPARATOR|ozone group|"Periodontal clinical parameters and gingival crevicular fluid (GCF) samples were evaluated at baseline and 8 weeks after periodontal treatment in patients with periodontal disease.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with ozoned water was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination."
62032188|NCT04556708|ACTIVE_COMPARATOR|chlorhexidine group|"Periodontal clinical parameters and gingival crevicular fluid (GCF) samples were evaluated at baseline and 8 weeks after periodontal treatment in patients with periodontal disease.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with 0.12% chlorhexidine digluconate was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination."
62032189|NCT06343766||Experimental group|Caries-susceptible group
62032190|NCT06343766||Control group|Caries-resistant group
62032191|NCT01626768||Enrolled patients|
62032192|NCT03762395|EXPERIMENTAL|CXA-10|Administered orally, continuously, and daily for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Drug will be dispensed at Visit 4.
62032193|NCT03762395|PLACEBO_COMPARATOR|Matching Placebo|Administered orally, daily, and continuously for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Placebo will be dispensed at Visit 4.
62032194|NCT02199236|EXPERIMENTAL|endorectal brachytherapy, concurrent chemo and questionnaires|This is a phase I, dose-escalation study to evaluate the safety of endorectal brachytherapy with concurrent capecitabine or 5-fluoruracil (5-FU) in the management of locally recurrent/residual rectal or anal cancer in patients who have received pelvic external beam radiation therapy (EBRT) +/- chemotherapy. We will use magnetic resonance imaging (MRI) with dynamic contrast enhancement (DCE) and diffusion weighted imaging (DWI) series to contribute to the assessment of tumor response.
62032195|NCT02440958|EXPERIMENTAL|modified FOLFIRINOX|
62032196|NCT02409173|EXPERIMENTAL|Noninvasive Ventilation and Surgery|Noninvasive positive airway pressure flow generator device by full face or nasal mask and bariatric surgery.
62032197|NCT02409173|NO_INTERVENTION|Control Group|
62032198|NCT01507220|ACTIVE_COMPARATOR|Morphine sulfate|morphine sulfate (or Sponsor-approved equivalent)
62032199|NCT01507220|EXPERIMENTAL|EXPAREL|EXPAREL (bupivacaine liposome extended-release injectable suspension)
62032200|NCT04484467|EXPERIMENTAL|Food supplement Standart Zdorovya GASTRO|"In the intervention group (Group 1), the supplement Standart Zdorovya GASTRO (1 capsule, 730 mg, once a day) was added to the standard treatment regimen for 30 days."
62032201|NCT04484467|PLACEBO_COMPARATOR|Placebo|In the control group (Group 2), placebo (1 capsule, 730 mg, once a day) was added to the standard treatment regimen for 30 days.
62032202|NCT00793468|PLACEBO_COMPARATOR|Placebo Arm|Subjects in placebo arm will be taking placebo once daily for 12 weeks from week 5 to 16.
62032203|NCT00793468|EXPERIMENTAL|GSK598809 Arm|Subjects in GSK598809 arm will be taking GSK598809 once daily for 12 weeks from weeks 5 to 16.
62032204|NCT01715987||Tenofovir Disoproxil Fumarate|Patients who are taking Tenofovir Disoproxil Fumarate.
62032205|NCT01715987||Entecavir|Patients who are taking Entecavir.
62231927|NCT04502966|EXPERIMENTAL|Grazax® +Dupixent®|"Participants randomized to this assignment will receive the following during the initial 2-year period of the trial:~* Once daily tablet of Grazax® sublingual immunotherapy and~* Dupixent® administered every other week (e.g., biweekly) by subcutaneous injection"
62808292|NCT02971423|EXPERIMENTAL|Part B; Cohort 12: 2.0 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 12, aged 18 to 55 years, will receive 2.0 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
62032206|NCT05706805||Coronary Artery Disease (CAD)|
62032207|NCT06634810|EXPERIMENTAL|Selt-Management Support (SaMBA-COPD)|"Participants receiving SaMBA-COPD intervention by community health workers (CHW).~Participants will receive comprehensive screening and targeted management of barriers to COPD control, incorporating home-based pulmonary rehabilitation, oral steroid and antibiotic prescribing for pre-emptive treatment of COPD exacerbations."
62808293|NCT02971423|EXPERIMENTAL|Part C; Cohort 13: ETX2514/placebo with sulbactam|Part C of the study will explore the safety and tolerability of IV ETX2514 when administered as a single dose in combination with sulbactam (1.0 g) and/or imipenem/cilastatin (0.5 g) to healthy participants. On Day 1, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours. On Day 3, participants will receive a single dose of 1.0 g IV sulbactam infused over 3 hours. On Day 5, participants will receive a single dose of 1.0 g IV ETX2514/placebo plus 1.0 g sulbactam infused over 3 hours at the same time. The actual Day 1 and Day 5 ETX2514 dose and infusion time will be determined based on PK and safety data from Part A.
62423398|NCT04962711|EXPERIMENTAL|Heart failure intervention ( Cardio-Oncology Disease Management Plan (CO-DMP)|"1. Optimization of pharmacotherapy: Cardioprotection with angiotensin-converting enzyme inhibitor (ACEi, Ramipril) and beta blocker (Metoprolol).Participants will be initially treated with ramipril at a dose of 1.25 or 2.5mg (according to baseline systemic arterial pressure), once or twice a day, and gradually up-titrated to 10mg/day, or to the maximal-tolerated dose. In patients receiving at least 2.5mg/day of ramipril, metoprolol will be started at an initial dose of 50 (25mg twice a day) and progressively up-titrated to the maximal dose of 100mg/day. Patients will be reviewed every 2 weeks during the up titration phase.~2. Exercise intervention: Individualized training program provided by an exercise physiologist."
62423399|NCT04962711|ACTIVE_COMPARATOR|Usual care|Provided by participants' usual healthcare professional(s), guided by a brochure regarding optimal risk factor management addressing hypertension, lipids, alcohol intake and tobacco use.
62808294|NCT02971423|EXPERIMENTAL|Part C; Cohort 14: ETX2514/placebo with SUL and/or IM/CIL|Part C of the study will explore the safety and tolerability of IV ETX2514 when administered as a single dose in combination with sulbactam (SUL: 1.0 g) and/or imipenem/cilastatin (IM/CIL: 0.5 g) to healthy participants. On Day 1, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours. On Day 3, participants will receive a single dose of 0.5 g IV imipenem/cilastatin infused over 30 minutes. On Day 5, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours plus 0.5 g imipenem/cilastatin infused over 30 minutes initiated at the same time as ETX2514/placebo. On Day 8, participants will receive a single dose of 1.0 g IV ETX2514/placebo plus 1.0 g sulbactam infused over 3 hours at the same time plus 0.5 g imipenem/cilastatin infused over 30 minutes initiated at the same time as ETX2514/placebo. The actual Day 1, Day 5, and Day 8 ETX2514 dose and infusion time will be determined based on PK and safety data from Part A.
62808295|NCT02971423|EXPERIMENTAL|Part D; Cohort 15: ETX2514/placebo with SUL and/or IM/CIL|Part D of the study will explore the safety and tolerability of multiple doses of combined IV ETX2514/sulbactam (1.0 g)/imipenem/cilastatin (0.5 g) to healthy participants. Participants in Cohort 15 will receive 1.0 g IV ETX2514/placebo and 1.0 g IV sulbactam both infused over 3 hours and 0.5 g IV imipenem/cilastatin infused over 30 minutes every 6 hours (4 times a day) for 10 days and will receive 1 dose on Day 11. The actual ETX2514 dose and infusion time will be determined based on PK and safety data from Part C.
62808296|NCT03942289|EXPERIMENTAL|Healthy controls|
62808297|NCT03942289|EXPERIMENTAL|Parkinson disease|
62231928|NCT04502966|EXPERIMENTAL|Grazax® + Dupixent® Placebo|"Participants randomized to this assignment will receive the following during the initial 2-year period of the trial:~* Once daily tablet of Grazax® sublingual immunotherapy and~* Placebo for Dupixent® administered every other week (e.g., biweekly) by subcutaneous injection"
62231929|NCT04502966|PLACEBO_COMPARATOR|Grazax® Placebo +Dupixent® Placebo|"Participants randomized to this assignment will receive the following during the initial 2-year period of the trial:~* Once daily tablet of placebo for Grazax® sublingual immunotherapy and~* Placebo for Dupixent® administered every other week (e.g., biweekly) by subcutaneous injection"
62231930|NCT00866723|EXPERIMENTAL|bevacizumab|Bevacizumab was administered at 15 mg/kg intravenously every 3 weeks. Treatment continued until disease progression or unacceptable toxicity.
62808298|NCT03979898|EXPERIMENTAL|Astrostem|Autologous Adipose Tissue Derived Mesenchymal Stem Cells
62808299|NCT04511481||platinum-resistant group|
62808300|NCT04511481||platinum-sensitive group|
62808301|NCT04070365||FLEX Vessel Prep followed by angioplasty|
62808302|NCT02558517|NO_INTERVENTION|Prednisone maintenance|Patients will be kept under Prednisone 5 milligrams/day. Other treatments will be maintained (in particular HYDROXYCHLOROQUINE, METHOTEXATE etc..)
62808303|NCT02558517|EXPERIMENTAL|Prednisone discontinuation|Prednisone will be stopped and remplaced by HYDROCORTISONE for one month (20 mg/day). Other treatments will be maintained (in particular HYDROXYCHLOROQUINE, METHOTEXATE etc..)
62231931|NCT02088307|NO_INTERVENTION|Control|Subjects in the control arm will not receive an intervention.
62231932|NCT02088307|EXPERIMENTAL|CardioLife|The main ingredients in the CardioLife supplements are as follows: garlic, co-enzyme Q10, arjuna, hawthorn, guggul, red yeast rice, policosanol, nattokinase, tumeric/curcumin, ashwangandha, L-carnitine, grape seed extract and vitamin B12.
62231933|NCT02650245|EXPERIMENTAL|Moderate protein and 10gm lactulose|40% of daily recommended intake of protein based on weight
62231934|NCT04162340|EXPERIMENTAL|CD4 CAR T cells|Dose escalation phase: CD4 CAR T cells transduced with a lentiviral vector to express CD4 chimeric receptor domain on T cells with an escalation approach, 2e6 to 5e6 CAR-T cells/kg
62231935|NCT02158520|EXPERIMENTAL|Arm A (bevacizumab and nab-paclitaxel)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may cross-over to Arm B within 2-4 weeks.
62231936|NCT02158520|EXPERIMENTAL|Arm B (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may cross-over to Arm A within 2-4 weeks.
62231937|NCT05760053|EXPERIMENTAL|EP/EC+PD-1|Toripalimab 240mg D1 of each 21-day cycle IV drip; Etoposide 100mg/m2 D1-3 of each 21-day cycle IV drip; Cisplatin 25mg/m2 D1-3 of each 21-day cycle IV drip; Carboplatin AUC 5 D1 of each 21-day cycle IV drip;
62423400|NCT04499430||1|"Group 1: 29 weeks and six days of gestation and earlier~Group 1a: complementary feeding began chronologically in the sixth month~Group 1b: Complementary feeding corrected at sixth month"
62423401|NCT04499430||2|"Group 2: Those whose gestational age is between 30 weeks and 33 weeks and sixth days~Group 2a: complementary feeding began chronologically in the sixth month~Group 2b: complementary feeding started in the sixth month, corrected"
62423402|NCT04499430||3|"Group 3: Those whose gestational age is between 34 weeks and 37 weeks and sixth day~Group 3a: complementary feeding began chronologically in the sixth month~Group 3b: complementary feeding started in the sixth month, corrected"
62592668|NCT01240980|EXPERIMENTAL|BMS-903452 (30 mg) or Placebo - A5|(Healthy Subjects)
62808304|NCT02849977||Cohort 1|If the subject has a history of hyperphagia, early onset obesity and/or clinical characteristics known to be related to mutations in the MC4R pathway and related to obesity (1.4 times 95th percentile in children).
62231938|NCT05709795|EXPERIMENTAL|Confluent areas|Ablation first of confluent areas of low wave speed and high voltage in the CTI
62808305|NCT02849977||Cohort 2|If the subject has exponentially high BMI (≥50 to 59), without hyperphagia and early onset obesity, whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.5 - 1.6 times 95th percentile in children).
62808306|NCT02849977||Cohort 3|If the subject has exponentially high BMI (≥60), without hyperphagia and early onset obesity, whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.6 times 95th percentile in children).
62231939|NCT05709795|EXPERIMENTAL|Wave Speed|Ablation first of areas of low wave speed in the CTI
62231940|NCT05709795|ACTIVE_COMPARATOR|Voltage|Ablation first of areas of high voltage in the CTI
62231941|NCT05709795|ACTIVE_COMPARATOR|CTI line|Direct CTI line performance (gold standard)
62231942|NCT02928107|EXPERIMENTAL|At-Home Telephone Screening (Tele-HS)|Subjects receive printed educational materials about hearing loss and access to at-home Tele-HS
62231943|NCT02928107|EXPERIMENTAL|PCP Encouragement, At-Home Tele-HS|Subjects receives encouragement from primary care provider (PCP) or hearing screening, printed materials and access to at-home Tele-HS.
62423403|NCT06111560||Patients with tumor progression or recurrence|Patients enrolled in our retrospective study with tumor progression or recurrence
62423404|NCT06111560||Patients without tumor progression or recurrence|Patients enrolled in our retrospective study without tumor progression or recurrence
62423405|NCT02703974|EXPERIMENTAL|Early handwashing station + nudge|This arm will include 5 randomly selected schools that will have had handwashing stations built after the baseline observation (Phase I), and nudges built after Phase II data collection.
62592669|NCT01240980|EXPERIMENTAL|BMS-903452 (60 mg) or Placebo - A6|(Healthy Subjects)
62592670|NCT01240980|EXPERIMENTAL|BMS-903452 (120 mg) or Placebo - A7|(Healthy Subjects)
62592671|NCT01240980|EXPERIMENTAL|BMS-903452 (0.6 mg) or Placebo - B1|(Subjects with type 2 Diabetes Mellitus)
62592672|NCT01240980|EXPERIMENTAL|BMS-903452 (10 mg) or Placebo - B2|(Subjects with type 2 Diabetes Mellitus)
62592673|NCT01240980|EXPERIMENTAL|BMS-903452 (120 mg) or Placebo - B3|(Subjects with type 2 Diabetes Mellitus)
62592674|NCT01240980|EXPERIMENTAL|BMS-903452 (10 mg) or Placebo - A11|(Healthy Subjects)
62592675|NCT01240980|EXPERIMENTAL|BMS-903452 (60 mg) or Placebo - A12|(Healthy Subjects)
62231944|NCT02928107|EXPERIMENTAL|PCP Encouragement, In-Office Tele-HS|Subjects receives PCP encouragement for hearing screening, printed materials and access to Tele-HS while in clinic.
62231945|NCT02928107|NO_INTERVENTION|CHEER Cohort (non-randomized)|Participants will complete a one page questionnaire related to Red Flag conditions during a routine Otolaryngology appointment for suspected hearing loss. The audiologist will be complete a questionnaire about the participants audiological assessment including Red Flag conditions. The Otolaryngology provider will complete a questionnaire about the participants otoscopic exam findings, Red Flag conditions, and indicate if any other conditions exist that me be considered a medical contraindication to hearing aid fitting.
62231946|NCT01061957||Raltegravir patients|HIV patients who initiated raltegravir due to virological failure
62231947|NCT01061957||Haart naive patients|HIV patients initiating HAART for the first time
62231948|NCT04386707|EXPERIMENTAL|Experimental Vaccine-lot 1|sIPV manufactured by Sinovac Biotech Co., Ltd at commercial scale.
62231949|NCT04386707|EXPERIMENTAL|Experimental Vaccine-lot 2|sIPV manufactured by Sinovac Biotech Co., Ltd at commercial scale.
62231950|NCT04386707|EXPERIMENTAL|Experimental Vaccine-lot 3|sIPV manufactured by Sinovac Biotech Co., Ltd at commercial scale.
62231951|NCT04386707|ACTIVE_COMPARATOR|Control Vaccine|Wild strain IPV (wIPV）manufactured by Sanofi Pasteur S.A.
62231952|NCT02373410|EXPERIMENTAL|Umbilicus|The height of the operating table which set at the needle insertion point, is the level of umbilicus of the anesthesiologist in a standing posture.
62231953|NCT02373410|ACTIVE_COMPARATOR|Lowest rib margin|The height of the operating table which set at the needle insertion point, is the level of lowest rib margin of the anesthesiologist in a standing posture.
62423406|NCT02703974|EXPERIMENTAL|Late handwashing station + nudge|This arm will include 5 randomly selected schools that will have had handwashing stations and nudges built at the same time, after Phase II data collection.
62423407|NCT02703974|ACTIVE_COMPARATOR|Early handwashing station + education|This arm will include 5 randomly selected schools that will have had handwashing stations built after the baseline observation (Phase I), and will receive a Hand hygiene education-based program, after Phase II data collection is complete.
62423408|NCT02703974|ACTIVE_COMPARATOR|Late handwashing station + education|This arm will include 5 randomly selected schools that will have had handwashing stations built after Phase II data collection is complete, when the Hand hygiene education-based program will commence.
62423409|NCT01788137|ACTIVE_COMPARATOR|CHOP|CHOP regimen Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles.
62423410|NCT01788137|ACTIVE_COMPARATOR|c-ATT regimen|c-ATT regimen Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
62592676|NCT06621745|EXPERIMENTAL|Gratitude Intervention Group|The intervention group used the Gratitude Intervention App (GIA), and the Predicting Risk and Outcomes of Social InTerActions (PROSIT) app, which is a mobile sensing app.
62592677|NCT06621745|NO_INTERVENTION|Control Non-gratitude Intervention Group|Participants in the control group downloaded and used only the PROSIT app, they did not use the Gratitude Intervention App (GIA).
62808307|NCT02849977||Cohort 4|If the subject has had or is undergoing bariatric surgery, who represents a refractory population of severely obese individuals whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.4 times 95th percentile in children and adolescents aged 12 and older).
62808308|NCT01663870||Breast Cancer Survivors|Patients in the LBJ General Hospital Cancer Survivorship Clinic.
62231954|NCT02373410|ACTIVE_COMPARATOR|Xiphoid|The height of the operating table which set at the needle insertion point, is the level of xiphoid of the anesthesiologist in a standing posture.
62231955|NCT02373410|ACTIVE_COMPARATOR|Nipple|The height of the operating table which set at the needle insertion point, is the level of nipple of the anesthesiologist in a standing posture.
62231956|NCT03237182|EXPERIMENTAL|Individualized treatment for drug resistant tuberculosis|Patients with drug resistance will have whole genome sequencing performed on the respective positive MGIT sample. An individualized TB treatment regimen will be provided to patients based on the whole genome sequencing results
62808309|NCT01663870||Clinic Stakeholders|Survivorship clinic stakeholders include clinic nurses, physicians, case managers, oncology patient navigators currently working with those in active treatment, information technology support professionals from the Harris County Hospital District (HCHD).
62808310|NCT05860088|EXPERIMENTAL|Beef Diet|Participants will be randomized to consume the beef diet for 8 weeks. After a 2-week period, participants will cross-over to consume the vegetarian diet for 8 weeks.
62231957|NCT03237182|ACTIVE_COMPARATOR|Standard treatment regimen for drug resistant tuberculosis|As per South African Department of Health Standard of Care for the treatment of drug resistant tuberculosis
62231958|NCT05003726|EXPERIMENTAL|Non-pharmacological group including KM|Non-pharmacological treatment including Korean medicine will be implemented to the participants for total 8 weeks. This is a pragmatic clinical trial, and the specific intervention will be determined according to the physician's choice. intervention data will be recorded in the case report form.
62231959|NCT05003726|ACTIVE_COMPARATOR|Pharmacological group|Pharmacological treatment will be implemented to the participants for total 8 weeks. This is a pragmatic clinical trial, and the specific intervention will be determined according to the physician's choice. intervention data will be recorded in the case report form.
62592678|NCT04427163||Genomic, transcriptomic, proteomic, metabolomic profiles|Determination of genomic, transcriptomic, proteomic, metabolomic profiles in subjects.
62592679|NCT03481374|ACTIVE_COMPARATOR|subjects with Type 1 Diabetes mellitus|Type 1 diabetes patients without cardiovascular disease undergo autonomic function testing
62808311|NCT05860088|EXPERIMENTAL|Vegetarian Diet|Participants will be randomized to consume the vegetarian diet for 8 weeks. After a 2-week period, participants will cross-over to consume the beef diet for 8 weeks.
62808312|NCT03986996|ACTIVE_COMPARATOR|Group 1 -Amoxycillin Doxycyclin and metronidazole|triple therapy with amoxicillin, metronidazole and tetracycline twice daily, for 2 weeks.
62808313|NCT03986996|EXPERIMENTAL|Group 2 -Amoxycillin and Doxycyclin|double therapy with Amoxycillin and Doxycyclin twice daily, for 2 weeks.
62592680|NCT03481374|PLACEBO_COMPARATOR|Healthy controls|healthy people without known disease undergo autonomic function testing
62032208|NCT06634810|PLACEBO_COMPARATOR|Attention-Matched Support|Participants will receive support by CHWs providing education using the COPD 1-2-3 booklet. Participants will receive similar visit frequencies but will not undergo barrier screening or targeted interventions.
62032209|NCT02445612||Experimental: MA09-hRPE|Sub-retinal transplantation of MA09-hRPE cells
62032210|NCT00567125||I|Patients with cholelithiasis operated on using standard laparoscopy method
62032211|NCT00567125||II|Patients with cholelithiasis operated on using low-pressure CO2 pneumoperitoneum laparoscopy
62032212|NCT04522401||People aged 65 and over|"People aged 65 and over who have had a gerontological evaluation Bien vieillir at the St-Etienne University Hospital Day Hospital."
62032213|NCT05519254|EXPERIMENTAL|Lactoferrin Arm|16-week course of lactoferrin
62032214|NCT05519254|EXPERIMENTAL|Lysozyme Arm|16-week course of lysozyme
62032215|NCT05519254|EXPERIMENTAL|Combination Arm (Lactoferrin + Lysozyme)|16-week course of lactoferrin and lysozyme
62032216|NCT05519254|PLACEBO_COMPARATOR|Placebo Arm|16-week course of taste/appearance-matched placebo
62808314|NCT05665439|EXPERIMENTAL|local treatment|
62808315|NCT05665439|NO_INTERVENTION|observation|
62032217|NCT05033288||Observational (questionnaires, medical record review)|Patients complete quality of life questionnaires over 20 minutes at baseline (before any therapy), 2-4 and 5-9 months after completion of therapy, and then annually for up to 5 years. Patients' medical records are also reviewed.
62032218|NCT00400010|EXPERIMENTAL|Expert System Intervention|Computerized Expert System Intervention based on the Transtheoretical Model of Change: 1. Normative feedback and feedback on motivational variables during the first week of hospital stay 2. Ipsative feedback on drinking behavior and motivation to change after three months
62032219|NCT00400010|NO_INTERVENTION|Control group|Controls received a brochure on health behavior
62032220|NCT05595304|EXPERIMENTAL|Oral Functionalization|Prosthesis repairment: prosthetic reline and occlusal stabilization through repair of missing pieces and recovery of occlusal contacts and follow up with conventional prosthesis treatment
62032221|NCT05595304|ACTIVE_COMPARATOR|control|conventional prosthetic treatment (new prosthesis)
62032222|NCT01509573|EXPERIMENTAL|FSI-R (Intervention group)|The intervention group will participate in the mental health assessments and FSI-R, and will participate in post-intervention assessments and follow-up assessments.
62032223|NCT01509573|NO_INTERVENTION|TAU (Treatment as Usual)|The TAU control group will not receive any intervention, but will participate in treatment as usual as provided by Partners In Health. They will complete assessments at all three time points.
62032224|NCT02235493||Retrospective Case Only|
62032225|NCT03570177||all subject|the all population (described in eligibility criteria)
62032226|NCT00179465|ACTIVE_COMPARATOR|Antipsychotic plus study drug|Half of the subjects will receive the study medications in addition to their ongoing antipsychotic regimen.
62032227|NCT00179465|PLACEBO_COMPARATOR|Antipsychotics plus placebo|Half of the subjects will receive placebo in addition to their antipsychotic regimen.
62231960|NCT03272425|EXPERIMENTAL|Sequence ABBA|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
62592681|NCT04932031||Study group|Adult females with newly diagnosed early-stage (stages I III) non-metastatic breast cancer receiving neoadjuvant or adjuvant chemotherapy that includes paclitaxel or docetaxel
62592682|NCT02557932|ACTIVE_COMPARATOR|Standard triple therapy|7 day-PPI based standard triple therapy
62592683|NCT02557932|ACTIVE_COMPARATOR|Bismuth quadruple therapy|10 day-bismuth quadruple therapy
62592684|NCT02704572|EXPERIMENTAL|6months to 2years after shingles|Patients will be vaccinated with Zostavax from 6 months to 2 years after zoster illness.
62592685|NCT02704572|ACTIVE_COMPARATOR|2years to 5years after shingles|Patients will be vaccinated with Zostavax from 2 years to 5 years after zoster illness.
62808316|NCT03149055|EXPERIMENTAL|Isavuconazole prophylaxis|Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose. The minimum duration of prophylaxis with isavuconazole will be through D +60. Beyond day +60 discontinuation is at the discretion of the treating physician.
62808317|NCT00669890|EXPERIMENTAL|study 515|
62808318|NCT01840007|EXPERIMENTAL|Metformin|"The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.~Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken."
62032228|NCT02223234|ACTIVE_COMPARATOR|Control|Control- monthly mailed information on children's health
62423411|NCT03225066|EXPERIMENTAL|Poly-L-Lactic Acid - Sculptra|Each area will be treated with a dose contained in a vial of Sculptra®. For conducting the study, six vials of the product will be available per subject, and one vial will be used in each session with up to maximum a total volume of 16mL per treated area. It will be 3 session with interval of 1 month in total.
62423412|NCT02421770|EXPERIMENTAL|Experimental Chamaemelum Nobile|"Experimental Chamaemelum Nobile 2% gel During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel twice daily with occlusion on the affected are"
62423413|NCT02421770|PLACEBO_COMPARATOR|Placebo|During the 6-week double-blind phase, all patients will be randomly assigned to receive vehicle ( placebo)twice daily with occlusion on the affected are
62592686|NCT06600152|EXPERIMENTAL|Microporous Annealed Particle (MAP) Wound Matrix|The Microporous Annealed Particle (MAP) Wound Matrix device will be topically applied to the wound immediately following Mohs micrographic surgery (MMS).
62592687|NCT06600152|ACTIVE_COMPARATOR|Hydrocolloid dressing (DuoDerm)|A hydrocolloid (DuoDerm) will be topically applied to the wound immediately following Mohs micrographic surgery.
62592688|NCT06667427|EXPERIMENTAL|Control|Participants will be identified and recruited during their visit to the Center of Reconstructive Surgery.
62592689|NCT06667427|EXPERIMENTAL|Surgery|
62808319|NCT01222013|EXPERIMENTAL|Imatinib Mesylate|
62808320|NCT05296265|EXPERIMENTAL|Active VR treatment|Subjects assigned to the Active VR treatment will begin by selecting an avatar, with features such as gender and skin color that can be chosen according to preference. During treatment, they will participate in a variety of games and activities developed and used by our teams including Kick, Dog Food, Quest for Fire, Chess, Checkers, Sudoku, and surfing the internet. Subjects will have substantial flexibility to select games according to their interests but will be required to spend at least 30 minutes in each session in games that require forceful, large amplitude, movements of the amputated lower limb (e.g., Quest for Fire, Kick). Time spent and level of engagement as measured by movements of the avatar or, in the case of chess, checkers, solitaire, Sudoku, and internet surfing, the number of clicks produced with each leg will be recorded for each activity using custom software
62808321|NCT05296265|EXPERIMENTAL|Distractor VR treatment|"Subjects assigned to the Distractor VR treatment will participate in REAL i-Series immersive VR experience (REAL system), which has been demonstrated to reduce pain in several studies but lacks the hypothesized active ingredients of our Active VR treatment (visual and auditory feedback of movement of an extrapolated amputated limb). Subjects will navigate through pleasant and relaxing VR environments; they will not see any rendering of their body and make no movements with their legs"
62032229|NCT02223234|EXPERIMENTAL|Email and 4 Home Visits|Weekly emails and 4 home visits with a health educator
62032230|NCT02223234|EXPERIMENTAL|Email and 2 Home Visits|Weekly emails and 2 home visits
62032231|NCT05668754|EXPERIMENTAL|Experimental: SDX|SDX capsules at the optimized daily dose, once in the evening daily (qd pm) or twice per day (bid), for 2 weeks (DBWP)
62423414|NCT03503474||CDI cases|
62423415|NCT03503474||CDI negative controls|
62423416|NCT02672774|OTHER|Gastric cancer|Consecutive patients with gastric cancer will be examined using magnification endoscopy with narrow band imaging and probe based confocal laser endomicroscopy.
62423417|NCT02672774|OTHER|Colorectal cancer|Consecutive patients with colorectal cancer will be examined using magnification endoscopy with narrow band imaging and probe based confocal laser endomicroscopy.
62423418|NCT05093192|EXPERIMENTAL|Cohort 1: Pre-treatment CLL|This group comprises patients who are diagnosed with CLL, but are asymptomatic and not receiving anti-CLL treatments (e.g. watch-and-wait disease).
62592690|NCT06520982|OTHER|Women|Women will be 18-55 years of age
62592691|NCT06096207|EXPERIMENTAL|Discontinuation Phase Group 1|Patients will be randomized into two groups for crossover treatment analysis of different parameter settings for six weeks.
62592692|NCT06096207|EXPERIMENTAL|Discontinuation Phase Group 2|Patients will be randomized into two groups for crossover treatment analysis of different parameter settings for six weeks.
62592693|NCT02691013|PLACEBO_COMPARATOR|Placebo|Patients will receive a Placebo tablet every evening.
62592694|NCT02691013|ACTIVE_COMPARATOR|Ramelteon|Patients will receive Ramelteon 8mg every evening.
62592695|NCT05835011|EXPERIMENTAL|Oral Decitabine/Cedazuridine + Magrolimab|Participants will receive 35 milligrams (mg) decitabine/100 mg cedazuridine as a fixed dose combination (FDC) tablet, orally, once daily (QD) on Days 1-5 of each 28-day cycle in combination with magrolimab, intravenous (IV) infusion of 1 milligrams per kilogram (mg/kg) on Days 1 and 4, 15 mg/kg on Day 8, 30 mg/kg on Days 11, 15, 22, 29, 36, 43, and 50, followed by a maintenance dose of 30 mg/kg on Day 57 and every 14 days thereafter until toxicity, progressive disease, withdrawal, death or end of study (approximately 44 months).
62592696|NCT03956680|EXPERIMENTAL|Part 1A Group 1: BMS-986301 Monotherapy Intramuscular (IM)|
62592697|NCT03956680|EXPERIMENTAL|Part 1A Group 2: BMS-986301 Monotherapy Intratumoral (I-TUMOR) Sub-study|
62592698|NCT03956680|EXPERIMENTAL|Part 1A Group 3: BMS-986301 Monotherapy Intravenous (IV) Sub-study|
62592699|NCT03956680|EXPERIMENTAL|Part 1B Group 4: Systemic BMS-986301 + Nivolumab + Ipilimumab|
62592700|NCT03956680|EXPERIMENTAL|Part 1B Group 5: I-TUMOR BMS-986301 + Nivolumab + Ipilimumab|
62808322|NCT01911715|EXPERIMENTAL|Single Oral MDV3100 dose|
62231961|NCT03272425|EXPERIMENTAL|Sequence BABA|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
62592701|NCT03132064||post total knee arthroplasty|The measurements will made for patients before and after total knee arthroplasty to explore the improvements and possible correlation with preoperative pain psychology and hypersensitivity
62423419|NCT05093192|EXPERIMENTAL|Cohort 2: During treatment CLL|This group comprises patients who are diagnosed with CLL, have symptomatic disease, and are undergoing anti-CLL treatments (e.g. chemo-immunotherapy).
62423420|NCT05093192|EXPERIMENTAL|Cohort 3: Post-treatment CLL|This group comprises patients who were diagnosed with CLL, but are considered to be in either complete or partial remission following anti-CLL treatment for at least 6-months.
62592702|NCT03995589|EXPERIMENTAL|Walking Group|
62592703|NCT03995589|ACTIVE_COMPARATOR|Control|
62032232|NCT05668754|PLACEBO_COMPARATOR|Active Comparator|Placebo capsules once in the evening daily (qd pm) or twice per day (bid), for 2 weeks (DBWP)
62231962|NCT03272425|EXPERIMENTAL|Sequence ABAB|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
62231963|NCT03272425|EXPERIMENTAL|Sequence BAAB|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
62423421|NCT03196739|EXPERIMENTAL|Virtual rehabilitation|Upper limb rehabilitation using virtual reality with a head-mounted display (HTC Vive; HTC Co., New Taipei City, Taiwan)
62423422|NCT02428634|EXPERIMENTAL|Program SI! for Elementary 6 levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. The intervention is implemented during all the elementary levels (PSIE13+PSIE46).
62808323|NCT04396535|EXPERIMENTAL|Arm I (docetaxel, bintrafusp alfa)|Patients receive docetaxel IV over 1 hour and bintrafusp alfa IV over 60 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bintrafusp alfa IV over 60 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
62808324|NCT04396535|ACTIVE_COMPARATOR|Arm II (docetaxel)|Patients receive docetaxel IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may crossover to Arm I and receive bintrafusp alfa alone.
62231964|NCT02091050|OTHER|HDR Brachytherapy 24Gy (4 x 6Gy)|Vaginal vault brachytherapy, associated or not with external beam radiotherapy.
62032233|NCT03006523|ACTIVE_COMPARATOR|Intrauterine Insemination with 200 µl|The sperm sample will be concentrated by centrifugation to a volume of 200 µl
62032234|NCT03006523|EXPERIMENTAL|Intrauterine Insemination with 500 µl|The sperm sample will be concentrated by centrifugation to a volume of 500 µl.
62032235|NCT00885404|OTHER|Intravenous fluids|
62231965|NCT01222260|EXPERIMENTAL|Treatment Arm|Subjects with AL will receive Bendamustine and Dexamethasone
62231966|NCT04664231||Children with JIA|Children with JIA coming to clinic
62231967|NCT04664231||Healthy Children|Healthy Children in the school
62423423|NCT02428634|NO_INTERVENTION|Normal curriculum|The schools on the control group keep their normal curriculum and don't join any school program about health until the end of the study.
62592704|NCT03206047|EXPERIMENTAL|Cohort I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62592705|NCT03206047|EXPERIMENTAL|Cohort II (guadecitabine, atezolizumab)|Patients receive guadecitabine SC on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on days 8 and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62592706|NCT03206047|EXPERIMENTAL|Cohort III (guadecitabine, atezolizumab, CDX-1401 vaccine)|Patients receive guadecitabine and atezolizumab as in Cohort II. Patients also receive CDX-1401 vaccine IV on day 15 and poly ICLC SC on days 15-16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62592707|NCT06621394|EXPERIMENTAL|Mediterranean Diet|
62592708|NCT06621394|EXPERIMENTAL|Mindful Eating|
62592709|NCT06621394|EXPERIMENTAL|Mediterranean Diet and Mindful Eating|
62592710|NCT06621394|SHAM_COMPARATOR|Befriending|
62808325|NCT03826940|EXPERIMENTAL|NF1 - experimental|
62808326|NCT03826940|PLACEBO_COMPARATOR|NF1 - control|
62808327|NCT03826940|EXPERIMENTAL|ASD - experimental|
62808328|NCT03826940|PLACEBO_COMPARATOR|ASD - control|
62808329|NCT00588926|EXPERIMENTAL|A|The patients get a period of sedation with remifentanil, before, during and after which, the changes in the electrical activity of the Basal Ganglia is recorded.
62032236|NCT03732209|EXPERIMENTAL|Episodic future thinking|Participants will generate positive future events and related text cues that will be accessed via an electronic app to engage in episodic future thinking.
62032237|NCT03732209|SHAM_COMPARATOR|Control thinking|Participants will generate non-future-oriented information and related text cues that will be accessed via an electronic app to engage in control thinking..
62231968|NCT01690364|EXPERIMENTAL|Cisatracurium Group|MEP monitoring with continuous infusion of cisatracurium during general anesthesia
62231969|NCT01690364|ACTIVE_COMPARATOR|Vecuronium Group|MEP monitoring with continuous infusion of vecuronium during general anesthesia
62592711|NCT06323746|EXPERIMENTAL|Denneroll Group|"The participants will be instructed to lie flat on their back on the ground with their legs extended and arms by their sides and gently folded across their stomach. The subject will place the Denneroll on the ground and the examiner positions the apex of the Denneroll.~The apex of the Denneroll orthotic will be placed in one of three regions based on lateral cervical radiographic displacements."
62592712|NCT06323746|OTHER|Wait List|This group will receive the same posture correction program after all data will be collected.
62592713|NCT01608087|EXPERIMENTAL|BI 695502|Subject to receive one intravenous (i.v.) infusion of BI 695502
62032238|NCT01280487|EXPERIMENTAL|Oral ZSTK474|Daily oral dosing for 21 days per cycle
62032239|NCT02672111|EXPERIMENTAL|CAM2038 q1w or q4w exposure to SL BPN/NX|"CAM2038 (buprenorphine FluidCrystal®)~Subjects previously exposed to SL BPN/NX who received CAM2038 q1w or q4w"
62032240|NCT02672111|EXPERIMENTAL|CAM2038 q1w or q4w new to BPN treatment|CAM2038 (buprenorphine FluidCrystal®) New to BPN Treatment who received CAM2038r q1w or q4w
62231970|NCT04827745|EXPERIMENTAL|Subjects with R/R CD19-positive MPAL|"Cohort A: Evaluate the efficacy of blinatumomab to achieve the best morphologic response after the first two cycles of therapy in subjects with morphologic R/R CD19-positive MPAL~* The treatment of blinatumomab consists of induction, consolidation and maintenance therapy~* Subject will receive study drug blinatumomab by continuous IV infusion (CIV)~* Each treatment cycle consists of 28 days of blinatumomab CIV followed by a 14±3 days treatment-free interval for induction, 28±3 days treatment-free interval for consolidation, and 56±3 days treatment-free interval for maintenance~* The initial dose of blinatumomab is 9 mcg/day for 7 days. The target dose for rest of treatment is 28 mcg/day"
62032241|NCT06667115|ACTIVE_COMPARATOR|PNF and PNF with virtual reality and PNF with concurrent feedback|Participants began with the PNF D2 shoulder exercise for 1 minute. Then participants did PNF D2 exercise with virtual reality gaming as second intervention for 1 minute and then they did PNF D2 exercise with concurrent feedback as third intervention for 1 minute. Between each intervention, participants were given a 2-minute break. Baseline was always PNF exercise, however second and third interventions for the arm 1 and arm 2 were different.
62231971|NCT04827745|EXPERIMENTAL|Subjects with CD19-positive MPAL in CR/CRh/CRi/CRp and detectable MRD|"Cohort B: Evaluate the efficacy of blinatumomab to achieve MRD-negativity in subjects with CD19-positive MPAL in CR, or CRh, or CRi or CRp after receiving at least one chemotherapy block of standard ALL or AML treatment with MRD-positivity at a level of ≥ 0.1% using an assay with a minimum sensitivity of 0.01%~* The treatment of blinatumomab consists of induction, consolidation and maintenance therapy~* Subject will receive study drug blinatumomab by continuous IV infusion (CIV)~* Each treatment cycle consists of 28 days of blinatumomab CIV followed by a 14±3 days treatment-free interval for induction, 28±3 days treatment-free interval for consolidation, and 56±3 days treatment-free interval for maintenance.~* The dose of blinatumomab is 28 mcg/day"
62808330|NCT00475670|ACTIVE_COMPARATOR|Trastuzumab Monotherapy|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose on Day 1, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death.
62808331|NCT00475670|EXPERIMENTAL|Trastuzumab, Taxane|Participant received an initial loading dose of 4 mg/kg trastuzumab i.v. on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death; and concomitant taxane, which is either 100 milligrams per square meter (mg/m2) docetaxel i.v. every 3 weeks, or 75 mg/m2 weekly or 175 mg/m2 every 3 weeks paclitaxel for at least 18 weeks, or more at the discretion of the investigator.
62808332|NCT06045312|EXPERIMENTAL|peer education|peer-trained group
62808333|NCT06045312|EXPERIMENTAL|adult education|adult-trained group
62808334|NCT06045312|NO_INTERVENTION|control|no education
62808335|NCT05413668|EXPERIMENTAL|RVP-001 group|4 Cohorts of 6 subjects each will receive RVP-001 at doses of 2, 4, 7 and 12 mg Mn/kg.
62808336|NCT05413668|PLACEBO_COMPARATOR|Placebo group|4 Cohorts of 2 subjects each will receive placebo (saline).
62808337|NCT05568446|EXPERIMENTAL|Social VR group|Social VR (SocVR) intervention is developed to enhance the social interaction skills of children. The participants will wear a head-mounted display (HMD) for the SocVR intervention. Each session of the SocVR intervention lasts for a maximum of 20 minutes to ensure the participants focus on the intervention and prevent causing any physical effect (Yamaguchi, 1999). The intervention contains three real-life virtual scenarios, including (1) classroom and playground, (2) MTR station and compartment, and (3) street and building. One scenario will be adopted in each session. The sequences of the scenarios used in each session will be the same for all participants. During the SocVR intervention, one RA will also appear as one avatar in the scenario to guide the participants to complete a series of tasks. Each intervention session will be conducted in a classroom independently for each participant.
62592714|NCT01608087|ACTIVE_COMPARATOR|bevacizumab A|Subject to receive one i.v. infusion of bevacizumab
62231972|NCT03809741|EXPERIMENTAL|Preventing L&D Infections|Low-cost bundled L\&D infection prevention interventions will be implemented, including education, visual reminders, feedback, and alcoholic hand rub supply. Infection control practices and child delivery outcomes will be assessed after implementation of these interventions.
62032242|NCT06667115|ACTIVE_COMPARATOR|PNF and PNF with concurrent feedback and PNF with virtual reality gaming|Participants began with the PNF D2 shoulder exercise for 1 minute. Then participants did PNF D2 exercise with concurrent feedback as second intervention for 1 minute and then they did PNF D2 exercise with virtual reality gaming as third intervention for 1 minute. Between each intervention, participants were given a 2-minute break. Baseline was always PNF exercise, however second and third interventions for the arm 1 and arm 2 were different.
62032243|NCT00712842||1|Patients with non or mild non-proliferative diabetic retinopathy
62231973|NCT01716117|EXPERIMENTAL|Surpass Flow Diverter|The objective of this study is to determine the safety and effectiveness of the Surpass Flow Diverter (Surpass System) in the endovascular treatment of large or giant wide-necked intracranial aneurysms in the internal carotid artery up to the terminus.
62808338|NCT05568446|ACTIVE_COMPARATOR|Traditional social skills group|An experienced special educational needs (SEN) teacher will teach the participants social interaction skills through tradidactic instructions and role-play activities. Four modules will be covered in the 4-week training: (1) how to introduce yourself and basic social skills; (2) how to listen to others; (3) how to share with others; (4) learn to know how people feel and how to empathise. These modules have been applied in many studies (Braswell \& Bloomquist, 1991; Huang et al., 2015). The content of this training will be as similar as possible to the SocVR training. The training lasts 20 minutes which depends on the emotion of the participants. Each training session will be conducted in a classroom independently for each participant.
62808339|NCT05568446|NO_INTERVENTION|Waitlist control group|With reference to Beck et al. (2010), the participants in this group will receive no training and they can participate in the social VR training after the intervention period. To ensure the consistency of the experiment, the participants are not allowed to initiate or change their pharmacological treatment during the 8-week intervention period.
62808340|NCT04258423|ACTIVE_COMPARATOR|Control Arm|Tacrolimus as maintenance immunosuppression
62808341|NCT04258423|EXPERIMENTAL|Study Arm|Everolimus as maintenance immunosuppression
62808342|NCT03793348|EXPERIMENTAL|Micro-exisional skin removal|Micro-coring of skin on the facial and neck areas will be conducted in one treatment and followed for 90 days post treatment.
62231974|NCT04547153|EXPERIMENTAL|LD-FUD (Zhen Long)|5-fluorouracil 200mg/square metre/day continuously venous infusion on days 1-21; Docetaxel 25mg/square metre, on days 1, 8 and 15; This regimen repeats every 4 weeks.
62592715|NCT01608087|ACTIVE_COMPARATOR|bevacizumab B|Subject to receive one i.v. infusion of bevacizumab
62808343|NCT00733785|EXPERIMENTAL|2mg tablet|2 mg tablet fasted
62808344|NCT00733785|EXPERIMENTAL|4 mg tablet|4 mg tablet fasted
62808345|NCT00733785|EXPERIMENTAL|8mg tablet|8 mg tablet fasted
62808346|NCT00733785|EXPERIMENTAL|2 x 4 mg tablets|2 x 4mg tablets fasting
62808347|NCT00733785|EXPERIMENTAL|2 x 2mg tablets|2 x 2mg tablets fasting
62808348|NCT00733785|EXPERIMENTAL|8 mg tablet fed|8 mg tablet fed
62808349|NCT00733785|EXPERIMENTAL|Repeat dose|8 mg once a day for 6 days
62032244|NCT00712842||2|Healthy control subjects
62231975|NCT03718078|EXPERIMENTAL|Confocal Laser Endomicroscopy|lt includes patients will undergo probe-based Confocal Laser Endomicroscopy during laparoscopic hepatic masses resection.
62231976|NCT04354844||Cyanotic and acyanotic group|questinnaire
62231977|NCT00360256||Control|
62032245|NCT03588208|EXPERIMENTAL|Intervention Group|
62032246|NCT03588208|ACTIVE_COMPARATOR|Control Group|
62592716|NCT01767506|EXPERIMENTAL|Intervention|Communities will receive usual care, including annual mass drug administration with azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more. In addition, surveillance and treatment with azithromycin of newcomer and traveler families within 2 weeks of arrival to or return to the community.
62592717|NCT01767506|ACTIVE_COMPARATOR|Usual Care|Communities will receive usual care, including annual mass drug administration with azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
62592718|NCT03960866|EXPERIMENTAL|Nyxol Ophthalmic Solution 1%|1 drop in each eye daily (QD) at or before bedtime (8pm to 10pm) for 14 days
62808350|NCT02519439|EXPERIMENTAL|ganaxolone|Up to a maximum of 1800 mg/day
62808351|NCT04320004|NO_INTERVENTION|Baseline|"Participating clinics will enter a baseline period where no interventions are used, but survey collection of baseline information about patient storage and disposal is collected. The baseline period varies depending on the cohort timing for each clinic but will last a minimum of one month for each clinic. In order to generate a survey list, the investigators will institute a silent best practice alert (BPA) in these clinics. This Silent BPA is not seen by providers, but a silent report is generated for reporting purposes, and for the study team to generate the baseline survey list."
62032247|NCT03910127|EXPERIMENTAL|TQB2450 + Anlotinib (10 mg)|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 10 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
62231978|NCT00360256||Case group|
62231979|NCT05588687|NO_INTERVENTION|Control group|Children in the control group will be received standard care. Control group children will not receive any distraction techniques.
62231980|NCT05588687|EXPERIMENTAL|Virtual reality group|The children in the VR groups will watch the video by wearing virtual glasses during the blood draw. By wearing the VR headsets in the VR-Rollercoaster Group, will watch Ice Age.
62231981|NCT05588687|EXPERIMENTAL|Tablet group|The children in the tablet groups will watch the video during the blood draw with tablet. They will watch Ice Age.
62808352|NCT04320004|ACTIVE_COMPARATOR|Education Intervention|If a patient meets study criteria, an alert will fire in the EHR to remind the provider to discuss proper storage and disposal of the opioid medication with the subject. Following the subject's visit, participants will be mailed an education packet consisting of a cover letter and a flyer detailing the importance of medication disposal of unused opioids and instructing how to properly dispose. Between 30-45 days following the new opioid prescription, the survey call center will contact subjects by telephone to interview them regarding opioid prescription disposition and actions taken to disposal of any leftover medications, household information, their satisfaction with interventions, including provider-based education, and mailed educational material.
62231982|NCT02369770|EXPERIMENTAL|Study group|Subjects in the Study group will receive stretching and active movement training with robotic guidance and intelligent control
62231983|NCT02369770|EXPERIMENTAL|Control group|Subjects in the Control group will receive stretching and active movement training without robotic guidance.
62231984|NCT04579133|EXPERIMENTAL|durvalumab plus olaparib|Durvalumab 1500 mg IV week 0, 3, 6 plus Olaparib tablets will be given orally on a continuous dosing schedule 300 mg BID OR 200 mg BID (if glomerular filtration rate \[GFR\] 31 to 50 mL/min) to complete 9 weeks of treatment.
62032248|NCT03910127|EXPERIMENTAL|TQB2450 + Anlotinib (12 mg)|TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
62231985|NCT04579133|EXPERIMENTAL|durvalumab alone|Durvalumab 1500 mg IV week 0, 3, 6 to complete 9 weeks of treatment
62423424|NCT02428634|EXPERIMENTAL|Program SI! for Elementary first levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. To evaluate the effects of different exposures to the program, the intervention is implemented in the first three levels (PSIE13).
62231986|NCT05209750|EXPERIMENTAL|FAPI PET/CT|"Colon cancer patients: one FAPI PET/CT scan early after standard diagnostic imaging and prior to planned surgery.~Rectal cancer patients: two FAPI PET/CT scans, one for initial staging (pre neoadjuvant therapy) and one for restaging (post neoadjuvant therapy)."
62423425|NCT02428634|EXPERIMENTAL|Program SI! for Elementary last levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. To evaluate the effects of different exposures to the program, the intervention is implemented in the last three levels (PSIE46).
62423426|NCT01093716|EXPERIMENTAL|rTMS|Compare the change in craving parameters following high frequency rTMS stimulation of right and left DLPFC in patients with alcohol dependence
62423427|NCT03577119|EXPERIMENTAL|Full-fat yogurt|Participants will receive a 21-day controlled diet that includes three daily servings of whole (3.25% fat) yogurt (38% of energy from fat, 44% of energy from carbohydrates, and 18% of energy from protein).
62592719|NCT03960866|PLACEBO_COMPARATOR|Nyxol Ophthalmic Solution Vehicle|1 drop in each eye daily (QD) at or before bedtime (8pm to 10pm) for 14 days
62592720|NCT05189301||CHF|CHF for chronic heart failure
62592721|NCT05189301||COPD|COPD for chronic obstructive pulmonary disease
62808353|NCT04320004|ACTIVE_COMPARATOR|Education Intervention with Reminder|This arm will follow the Education Intervention arm (BPA, provider education, mailed education and follow up survey) Approximately 50% of patients in the Education Intervention arm will be randomized to receive an interactive voice response (IVR) telephone call approximately 14 calendar days following receipt of his/her new opioid prescription. The IVR is intended to remind patients/caregivers to properly dispose of any unused medication and gather information from the patient on any disposal actions the patient has taken.
62819525|NCT06409169|EXPERIMENTAL|DBS TaT|At DBS TaT sites, peers administer dried blood spot tests to all those interested in HCV screening or treatment. When HCV is diagnosed, peers coordinate a telemedicine visit with a PATHS provider and peer. At the time of the telemedicine visit, a questionnaire, Decompensated Cirrhosis in Hepatitis C Evaluation Questionnaire (DCHEQ), is used to determine risk level of liver fibrosis (liver scaring that is sometimes caused by hepatitis C). Those at low risk for liver fibrosis can start HCV treatment before completing the usual tests for liver fibrosis. Those at high risk for liver fibrosis will be directed to receive a confirmatory blood draw at a local laboratory prior to treatment initiation. Participants will complete transient elastography after treatment initiation.
62032249|NCT03910127|PLACEBO_COMPARATOR|TQB2450 + Placebo|TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle plus Placebo for Anlotinib capsules given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
62231987|NCT04567290|EXPERIMENTAL|Chewed ticagrelor|"Ticagrelor pills. The 180 mg loading dose will be administered as soon as possible by investigation staff after a baseline VerifyNow measurement and after signed informed consent. Patients will be asked to chew, but not to swallow, during at least 40 seconds in presence of investigation staff.~Drug: ticagrelor (Brilinta) 90 mg tablets, 2 tablets chewed"
62231988|NCT04567290|ACTIVE_COMPARATOR|Swallowed ticagrelor|"Ticagrelor integral tablet. The 180 mg loading dose will be administered as soon as possible by investigation staff after a baseline VerifyNow measurement is drawn. Patients will swallow the loading dose followed by 25-40 ml of water.~Drug: ticagrelor (Brilinta) 90 mg tableta, 2 tablets swallowed"
62423428|NCT03577119|EXPERIMENTAL|Non-fat yogurt (Control)|Participants will receive a 21-day controlled diet that includes three daily servings of fat-free yogurt (28% of energy from fat, 54% of energy from carbohydrates, and 18% of energy from protein).
62423429|NCT01379079|EXPERIMENTAL|aspirin at bedtime|
62423430|NCT01379079|ACTIVE_COMPARATOR|aspirin on awakening|
62808354|NCT04320004|ACTIVE_COMPARATOR|Education + Disposal Bag Intervention|If a patient meets study criteria, an alert will fire in the EHR to remind the provider to discuss proper storage and disposal of the opioid medication with the subject. Following the subject's visit, participants will be mailed an education packet consisting of a cover letter and a flyer detailing the importance of medication disposal of unused opioids and instructing how to properly dispose plus a postage paid medication disposal mail bag and instructions for use. Between 30-45 days following the new opioid prescription, the survey unit will contact subjects by telephone to interview them regarding opioid prescription disposition and actions taken to disposal of any leftover medications, household information, their satisfaction with interventions, including provider-based education, mailed educational material and mail-back bags.
62808355|NCT04320004|ACTIVE_COMPARATOR|Education + Disposal Bag Intervention with Reminder|This arm will follow the Education+ Disposal Bag Intervention arm (BPA, provider education, mailed education+ disposal bag and follow up survey) Approximately 50% of patients in the Education + Disposal Bag Intervention arm will be randomized to receive an interactive voice response (IVR) telephone call approximately 14 calendar days following receipt of his/her new opioid prescription. The IVR is intended to remind patients/caregivers to properly dispose of any unused medication and gather information from the patient on any disposal actions the patient has taken.
62808356|NCT01577017|EXPERIMENTAL|Letrozole|Group L will be assigned with Letrozole 5 mg on night on day 5 to day 9 of the cycle
62423431|NCT06537271|EXPERIMENTAL|experimental group|Participation in the study is entirely voluntary. After the purpose of the study is explained to the experimental group by the researcher and written and verbal permission is obtained from those who voluntarily agree to participate in the study, the pre-test data will be collected by the researcher.
62808357|NCT02730481|EXPERIMENTAL|ORAXOL|"Oraxol (paclitaxel + HM30181AK-US) Oraxol paclitaxel - supplied as 30-mg capsules~Oraxol HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
62808358|NCT00660725|OTHER|Vandetanib/GEMOX|All subjects receive the same combination study drug and follow the same study schedule. As a phase 1 study, only the doses will vary between subjects.
62423432|NCT06537271|EXPERIMENTAL|Control Group|After the purpose of the study is explained to the control group by the researcher and written and verbal permission is obtained from those who voluntarily agree to participate in the study, the pre-test data will be collected by the researcher.At the end of 8 weeks, the researcher will fill out the questionnaire forms for the experimental group and collect post-test data.
62423433|NCT03944018|EXPERIMENTAL|Intervention with rehabilitation coordinator|Intervention with rehabilitation coordinator (RECO)
62423434|NCT03944018|NO_INTERVENTION|Control|TAU
62592722|NCT05189301||control|control for normal controls
62592723|NCT04071548|EXPERIMENTAL|HIIT Exercise|All individuals recruited in exercise portion will be on an active exercise intervention
62231989|NCT02803892|PLACEBO_COMPARATOR|Group 1: Placebo|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received placebo x 2 placebo (Group 1) After 4 weeks of treatment, patients will discontinue relevant placebo treatment, but continue the second placebo for a further 8 weeks
62592724|NCT04314531|EXPERIMENTAL|Arm A|
62592725|NCT04314531|PLACEBO_COMPARATOR|Arm B|
62231990|NCT02803892|EXPERIMENTAL|Group 2: Rapamycin plus Placebo|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received rapamycin plus placebo. After 4 weeks of treatment, patients will discontinue rapamycin, but continue the second placebo for a further 8 weeks
62231991|NCT02803892|EXPERIMENTAL|Group 3: Rapamycin plus Vildagliptin|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received rapamycin plus vildagliptin. After 4 weeks of treatment, patients will discontinue rapamycin , but continue Vildagliptin o for a further 8 weeks
62231992|NCT02730364|EXPERIMENTAL|Theraflu night powder|Participants will receive a single dose (1 sachet) of Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
62423435|NCT04266119|EXPERIMENTAL|Intervention|"The HOPE intervention can be accessed through web. It consists of two sessions per week, with a total of four sessions. In this study, participants will be sent weekly weblinks for access to each session. Each session take about ten minutes to complete. Each session consist of pre-post multiple-choice and/or open-end question, video(s) and mental health information. The first session is about depression. The second session is about positive psychology and consists of relevant exercises such as gratitude, affect-based and strength-based exercises. The third session describes anxiety disorder. The last session describes relaxation techniques and self-management of unhelpful thoughts.~Each session consists of quizzes, video(s), and graphical / written information"
62231993|NCT02730364|NO_INTERVENTION|No Treatment|Participants in this arm will not receive any medication
62423436|NCT04266119|ACTIVE_COMPARATOR|Control|The group will receive a control website intervention that consists of several graphical inspirational quotes. Examples of the quotes are, 'Today is full of possible' and 'You can do anything'.
62592726|NCT06621368|NO_INTERVENTION|control group = participants maintained their usual activities normally|Participants maintained their ususal activities normally
62592727|NCT06621368|EXPERIMENTAL|exercise group = participants performed two years of strength training|Participants will performed two years of strength training
62592728|NCT05796284|EXPERIMENTAL|Breast pressure relief intervention at the end of pregnancy|"The Breast Compression Intervention at the End of Pregnancy group is expected to start after the 36th week of pregnancy and continue until three months after delivery. In addition to routine care, breast relaxation methods of different intensities during pregnancy and postpartum will be provided in stages."
62231994|NCT04534556|EXPERIMENTAL|Immediate Start Vagus Nerve Stimulation group|The Immediate Start VNS group will receive rehabilitation and active stimulation for 18 in-office sessions over the course of approximately six weeks during Phase 1. For Phase 2, all subjects will be provided with the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately six weeks. Additionally, participants may be provided with a system of rehabilitative devices to utilize at home.
62592729|NCT05796284|ACTIVE_COMPARATOR|Routine care group|Cases in the routine care group receive routine prenatal care and guidance during weekly outpatient checkups, and routine postpartum care and guidance after delivery, including breastfeeding posture and skills, hand expression, and breast milk storage methods, etc.
62592730|NCT06246123||All Participants|Korean participants who are prescribed with Jyseleca (Filgotinib Maleate) tablet 100 mg and 200 mg per approved prescribing information of Filgotinib Maleate in the post marketing setting will be enrolled and observed for up to 24 weeks or until discontinuation of treatment due to AEs or any other reason, whichever occurs first.
62423437|NCT05033028|NO_INTERVENTION|Treatment-as-Usual|Participants will receive the same treatment as if they had not joined the study
62423438|NCT05033028|EXPERIMENTAL|Smartphone with dose changes after using|Participants will have an app installed on their phone and have to complete a brief questionnaire and some days play a 2-4 minute game.
62592731|NCT06368895|EXPERIMENTAL|Fecal microbiota transplantation through colonoscopy and oral capsules|Patients with cirrhosis and hepatic encephalopathy refractory to conventional treatment will undergo a two-stage fecal microbiota transplantation: initial colonoscopic delivery followed by daily oral capsules administration one month later. Patients will continue also conventional therapy with rifaximin and lactulose
62592732|NCT06368895|EXPERIMENTAL|Fecal microbiota transplantation through oral capsules|Patients with cirrhosis and hepatic encephalopathy refractory to conventional treatment will undergo fecal microbiota transplantation through daily oral capsules administration. Patients will continue also conventional therapy with rifaximin and lactulose.
62592733|NCT06368895|NO_INTERVENTION|Controls|Patients with cirrhosis and hepatic encephalopathy refractory to conventional treatment will continue only conventional therapy with rifaximin and lactulose
62032250|NCT06012760|EXPERIMENTAL|Combined Iron Protocols group（CIP group）|Preoperative randomization was conducted, followed by a three-day regimen in the week preceding surgery, involving the administration of intravenous iron sucrose at a dosage of 200 mg per day, vitamin C at a dosage of 2 g per day, and subcutaneous administration of Human Erythropoietin Injection at a dosage of 150 IU per kilogram.
62808359|NCT01269112|PLACEBO_COMPARATOR|heparin|CVVHDF performed using unfractionated heparin as anticoagulant and Prismasol as reinjection and dialysate fluids
62423439|NCT05033028|EXPERIMENTAL|Smartphone with dose changes before using|Participants will have an app installed on their phone and have to complete a brief questionnaire and some days to play a 2-4 minute game.
62231995|NCT04534556|PLACEBO_COMPARATOR|Delayed Start Vagus Nerve Stimulation group|The Delayed Start VNS group will receive equivalent rehabilitation with placebo stimulation for 18 in-office sessions over the course of approximately six weeks during Phase 1. For Phase 2, all subjects will be provided with the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately six weeks. Additionally, participants may be provided with a system of rehabilitative devices to utilize at home.
62231996|NCT02698969|EXPERIMENTAL|Sugammadex|patients enrolled who will receive sugammadex 2 mg\*kg-1 at the end of surgery
62231997|NCT02698969|ACTIVE_COMPARATOR|Nestigmine, Atropine|patients enrolled who will receive neostigmine 50 mcg\*kg-1 and atropine 15 mcg\*kg-1 at the end of surgery
62032251|NCT06012760|ACTIVE_COMPARATOR|Standard Medical Care group（SMC group）|Standard Medical Care (SMC) for the treatment of IDA. SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA).
62032252|NCT01618838|OTHER|CyberKnife Radiosurgery, Colonoscopy|CyberKnife radiosurgery for prostate cancer; bowel toxicity will be evaluated at 2 years by colonoscopy (lower endoscopy).
62032253|NCT03214497|ACTIVE_COMPARATOR|Protector group|All patients collocated randomly to the Protector Group Primary and secondary outcome Parameters are studied
62032254|NCT03214497|PLACEBO_COMPARATOR|Supreme group|All patients collocated randomly to the Supreme Group, Primary and secondary outcome Parameters are studied
62231998|NCT04727853|EXPERIMENTAL|irinotecan liposome injection|Patients will receive irinotecan liposome injection at 70 mg/m\^2 intravenously, over 90 min on Days 1 of every 14-day cycle.
62231999|NCT03791671|EXPERIMENTAL|individual balance training|"After the initial assessments, the three week intervention time begins, which is completed with the reassessments.~The patients receive 2x weekly individual balance training for 25 minutes each. This runs in addition to the normal, prescribed rehabilitation program. The rehabilitation program includes at least 3 therapies daily. These may be group therapies, speech therapy, occupational therapy, neuropsychology and physiotherapy adapted to the needs of the patient. In physiotherapy and occupational therapy no balance training will be performed during the intervention period."
62423440|NCT05033028|EXPERIMENTAL|Focus group with Study Physicans|Study physicians asked to participate in a focus group session or 1:1 interviews if unable to attend the focus group during year one of the study and once annually towards the end of years 2, 3, 4, and 5 of the study
62423441|NCT05033028|EXPERIMENTAL|Focus group with Clinicians|Clinicians asked to participate in a 1:1 interview and a separate focus group at roughly the same time. Prior to the first structured interview with our study team, you will participate in a 1-hour training and familiarization session with the SOAR system using synthetic or training data.
62433561|NCT03769181|EXPERIMENTAL|Cohort B: DLBCL: Isatuximab + Cemiplimab|Diffuse large B-cell lymphoma (DLBCL), anti PD-1/PD-L1 naïve participants received isatuximab 10 mg/kg, IV infusion, QW in Cycle 1 and then Q2W from Cycle 2 to Cycle 6 (each cycle of 28 days) and Q3W from Cycle 7 to Cycle 30 (each cycle of 21 days) along with cemiplimab 250 mg Q2W, IV infusion from Cycle 1 to 6 and then 350 mg Q3W from Cycle 7 to Cycle 30 until, unacceptable AEs or participant's decision to stop the treatment, or at least 96 weeks (at least 48 weeks from initial signal of CR, whichever was longer) of delivery of investigational medicinal product(s) without documented PD, or study cut-off date, whichever occurs first (maximum duration: up to 103 weeks).
62032255|NCT06060457|EXPERIMENTAL|Fluzone HD + mRNA-1345|Participants will receive Fluzone HD + mRNA-1345 by intramuscular (IM) injection on Day 1 followed by placebo by IM injection on Day 22.
62032256|NCT06060457|EXPERIMENTAL|Fluzone HD Followed by mRNA-1345|Participants will receive Fluzone HD + placebo by IM injection on Day 1 followed by mRNA-1345 by IM injection on Day 22.
62032257|NCT02101892|ACTIVE_COMPARATOR|Amitriptyline|Amitriptyline, 25 mg per os, daily, evening, for 8 weeks; starting dose is 12.5 mg for 2 days
62032258|NCT02101892|PLACEBO_COMPARATOR|placebo|sugar pills
62232000|NCT03791671|ACTIVE_COMPARATOR|group balance training|"The patients receive 2x weekly group balance training for 25 minutes each. This runs in addition to the normal, prescribed rehab program. The rehabilitation program includes at least 3 therapies daily. These may be group therapies, speech therapy, occupational therapy, neuropsychology and physiotherapy adapted to the needs of the patient. In physiotherapy and occupational therapy no balance training will be performed during the intervention period.~In group therapy are 3 to 6 patients with different neurological diagnoses. As it is usual in rehabilitation everyday life."
62232001|NCT01661478||Emergency Department personnel|survey
62423442|NCT02300818|ACTIVE_COMPARATOR|Pulsed Electromagnetic Field Therapy|"Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.~PEMF has also proved to be beneficial in vision acuity of patients with low vision. In 50 per cent of the cases, values improved. Patients with vision acuity of 0.2 diopters showed improvement from 46 before treatment to 75 after treatment.~Different studies on varied diseases have proved that Pulsed Electromagnetic Field Therapy (PEMF) treatment is a safe, non-invasive and effective option for curing ocular conditions."
62423443|NCT02300818|ACTIVE_COMPARATOR|Seawater eyedrops|instantly soothes and clears the eye irritation caused by pollution, pollen, smoke, etc. It is a very practical system for eye daily hygiene · enables efficient therapeutic help in basic eye conditions such as: · · internal and external stye blepharitis and keratoconjunctivitis · · Conjuntiviti Episcleritis and scleritis
62592734|NCT04158895||Patients enrolled in differentiated service delivery models|
62592735|NCT04158895||Patients not enrolled in DSD models|
62592736|NCT03400176|EXPERIMENTAL|Dose Escalation|Increasing doses of VAY736 in combination with a fixed dose of ibrutinib.
62808360|NCT01269112|ACTIVE_COMPARATOR|citrate regional anticoagulation|CVVHDF performed using Prismocitrate 18/0 solution (Trisodium citrate 18 mmol/L
62032259|NCT06041724|EXPERIMENTAL|Envafolimab combined with recombinant human endostatin and first-line chemotherapy|
62032260|NCT00232804|OTHER|1|
62032261|NCT06670079|EXPERIMENTAL|Prolonged exposure therapy + incentives for therapy session attendance|
62232002|NCT01661478||Department of Psychiatry personnel|survey
62232003|NCT05147961|EXPERIMENTAL|mHealth|A mHealth automated behavioral intervention via E-mail, web, and mobile phone will be developed and tested in the intervention trial trial (phase 4 of the project)
62232004|NCT05147961|ACTIVE_COMPARATOR|Standard care|Traditional recommendations (lifestyle modification) (phase 4 of the project)
62592737|NCT03400176|EXPERIMENTAL|Dose expansion|Evaluation of the MTD/RD of the combination of VAY736 and ibrutinib that was identified in dose escalation.
62808361|NCT00921271||At risk for compartment syndrome.|"Patients admitted to Selly Oak Hospital, Birmingham, Uk, meeting one or more of the following inclusion criteria:~1. Patients with one or more of the following injuries:~   * tibial fracture.~  * crush injury/soft tissue injury to lower limb without fracture.~  * pelvic fracture.~  * major vascular injury below the aortic bifurcation.~  * 2 or more long bone fractures.~2. Any patient sustaining a traumatic injury with a base deficit ≥ 6 mEq/L within 12 hours of Hospital admission.~3. Any patient receiving ≥ 6 units packed red blood cells within 12 hours of hospital admission."
62808362|NCT05474352|EXPERIMENTAL|ALLON System|The ALLON system water garment, is like a large apron that covers your body. There are tubes that run throughout the water garment, which allow warm liquid to flow so that the garment keeps the participant warm. The ALLON system water garment will be filled with warm water.
62808363|NCT03083925||Bare metal stent (BMS) TIPS|retrospective patients receiving BMS-TIPS for treatment of complications of portal hypertension.
62808364|NCT03083925||Regular Viatorr (RV) TIPS|retrospective patients receiving RV-TIPS for treatment of complications of portal hypertension.
62032262|NCT04282135||Infected|patients with detected Influenza RNA in nasopharyngeal swabs
62232005|NCT02391857|EXPERIMENTAL|EGDgroup|Intervention (gastric decompression by naso(oro)-gastric tube insertion) was performed
62232006|NCT03634514|EXPERIMENTAL|Application of Biomatrop|A single dose of Recombinant Human Somatropin - Biomatrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
62232007|NCT03634514|ACTIVE_COMPARATOR|Application of Hormotrop|A single dose of Recombinant Human Somatropin - Hormotrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
62808365|NCT03083925||Viatorr Control Expansion (VCX)TIPS|prospective patients receiving VCX-TIPS for treatment of complications of portal hypertension.
62808366|NCT01154868|OTHER|Healos|
62032263|NCT04282135||not infected|patients without detected Influenza RNA in nasopharyngeal swabs
62032264|NCT04282135||SARS CoV2|patients with SARS-Cov-2 infection
62032265|NCT04706468|EXPERIMENTAL|40 mg TG-1000|Participants received 40 mg of TG-1000 and 40 mg of placebo orally on Day 1 and 40 mg of placebo on Day 3.
62032266|NCT04706468|EXPERIMENTAL|80 mg TG-1000|Participants received 80 mg of TG-1000 orally on Day 1 and 40 mg of placebo on Day 3.
62032267|NCT04706468|EXPERIMENTAL|40 mg TG-1000+40 mg TG-1000|Participants received 40 mg of TG-1000 and 40 mg of placebo orally on Day 1 and 40 mg of TG-1000 on Day 3.
62032268|NCT04706468|PLACEBO_COMPARATOR|Placebo|Participants received 80 mg of placebo orally on Day 1 and 40 mg of placebo on Day 3.
62032269|NCT01292603|EXPERIMENTAL|1|
62032270|NCT01292603|EXPERIMENTAL|2|
62032271|NCT01292603|EXPERIMENTAL|3|
62808367|NCT04546035|EXPERIMENTAL|500 pulses|In this group, patients received one single rESWT session consisting of 500 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
62232008|NCT05685589|EXPERIMENTAL|Mindfulness-based Intervention|The intervention will include weekly 90-minute group meetings held online through Zoom. Adolescents and parents will meet in separate groups and will learn about mindfulness-based strategies that can be used to manage and reduce stress, anxiety, and depression. They will also learn evidence-based strategies to complete daily guided mindfulness meditations using Ten Percent Happier, a commercially-available mobile app. Participants will be encouraged to meditate using the mobile app for at least 10 minutes each day during and after the 8-week intervention.
62232009|NCT05685589|NO_INTERVENTION|Delayed Treatment Control|Participants will be instructed to engage in treatment as usual during their 8-week wait period. After their wait period, participants will be enrolled in the mindfulness-based intervention.
62232010|NCT02369445|EXPERIMENTAL|Moisture Pager (MP) Intervention Group|"This group receives the innovative toilet training intervention comprised of a wireless moisture pager (i.e., an app based on an iPod that communicates via electronic signal with a disposable moisture sensor located in the child's underwear)."
62232011|NCT02369445|ACTIVE_COMPARATOR|Standard Behavioral Intervention Group|This group receives standard-of-care intervention as presented in the Autism Treatment Network's Toilet Training Tool Kit (https://www.autismspeaks.org/site-wide/atn-tool-kits).
62232012|NCT03881553|EXPERIMENTAL|Premature Infants (NICU)|Premature infants receiving care in the Neonatal Intensive Care Unit (NICU) will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
62232013|NCT03881553|EXPERIMENTAL|Opioid-Exposed Newborns (NICU)|Opioid-exposed newborns receiving care in the Neonatal Intensive Care Unit (NICU) will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
62232014|NCT03881553|EXPERIMENTAL|Hospitalized Infants (PICU)|Infants receiving treatment in the Pediatric Intensive Care or Inpatient Unit will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
62232015|NCT00044538|EXPERIMENTAL|Arm 1|
62232016|NCT01769235|EXPERIMENTAL|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)
62232017|NCT01769235|ACTIVE_COMPARATOR|Acanya® Gel, 1.2%/2.5%|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)
62232018|NCT01769235|PLACEBO_COMPARATOR|Vehicle of test product|Vehicle of test product (Taro Pharmaceuticals Inc.)
62232019|NCT01520298|PLACEBO_COMPARATOR|Placebo|For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container.
62423444|NCT06221683|EXPERIMENTAL|SDC group|Patients with CBF fusion gene (RUNX1: : RUNX1T1 and CBFB: : MYH11) or KMT2A: : MLLT3(AF9) , KMT2A: : MLLT10(AF10) , KMT2A: : MLLT4(AF6) fusion gene or KIT mutation will receive SDC regimen, including one course of HAE (Homoharringtonine, cytarabine, etoposide) in induction I. These patients will continue on the SDC (HAE) regimen in the second course if the MRD is \< 1% after induction I, otherwise venetoclax will be added to the SDC group sequentially on Day 2 after the end of HAE. FLT3-ITD will be given sorafenib or gilteritinib as early as possible, and patients with KIT mutations will be recommended to add avapritinib as appropriate. These targeted drugs will not be combined with venetoclax.
62423445|NCT06221683|EXPERIMENTAL|LDC group|Patients with the exception of the CBF fusion gene (RUNX1: : RUNX1T1 and CBFB: : MYH11) or those with the KMT2A: : MLLT3(AF9) , KMT2A: : MLLT10(AF10) , KMT2A: : MLLT4(AF6) fusion gene or KIT mutation will receive the LDC (MAG/IDAG+ venetoclax) regimen in induction I. Patients with MRD ≥1% or KIT mutations, assessed after induction I, will receive the HAE plus venetoclax (or targeted drugs) regimen, otherwise, they will receive MAG/IDAG + venetoclax. FLT3-ITD will be given sorafenib or gilteritinib as early as possible, and patients with KIT mutations will be recommended to add avapritinib as appropriate. These targeted drugs will not be combined with venetoclax.
62808368|NCT04546035|EXPERIMENTAL|1,000 pulses|In this group, patients received one single rESWT session consisting of 1,000 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
62808369|NCT04546035|EXPERIMENTAL|1,500 pulses|In this group, patients received one single rESWT session consisting of 1,500 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
62808370|NCT04546035|EXPERIMENTAL|2,000 pulses|In this group, patients received one single rESWT session consisting of 2,000 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
62808371|NCT00681044|EXPERIMENTAL|SCT with melphalan conditioning|Mobilization with Filgrastim Stem Cell Transplant Melphalan Conditioning Stem Cell infusion
62808372|NCT00558246|EXPERIMENTAL|I|On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.
62808373|NCT00558246|ACTIVE_COMPARATOR|II|On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.
62808374|NCT02624271|EXPERIMENTAL|GastroPanel|GastroPanel test on blood samples
62808375|NCT01439516|EXPERIMENTAL|Information|Participants randomized to this arm of the study will received the PREPARED educational book and video.
62808376|NCT01439516|EXPERIMENTAL|Information and Financial Assistance|Participants randomized to this arm of the study will receive the PREPARED educational book and video plus financial assistance for family members to cover costs associated with an evaluation for becoming a live kidney donor.
62808377|NCT01439516|NO_INTERVENTION|Usual Care|Participants randomized to this arm of the study will receive usual care from their physician.
62808378|NCT02778646||MINAP Audit|Individuals within this group are those that have been admitted into a United Kingdom (UK) based hospital following a major cardiac event. The FH status of individuals within this group is unknown.
62808379|NCT02778646||BCIS Audit|Individuals within this group are those who have undergone percutaneous coronary intervention in the United Kingdom (UK). The FH status of individuals within this group is unknown.
62808380|NCT02222935|EXPERIMENTAL|Balance exercise training|Balance exercise training - thrice week, 2 weeks, 10 repetition Maximum/ set, 2 sets
62808381|NCT02222935|ACTIVE_COMPARATOR|Routine Back exercise Program|Routine Back exercise Program - 10 Repetition Maximum / set, 2 sets, three times weekly, 2 weeks
62032272|NCT01349634|NO_INTERVENTION|Comparison group|This arm will use the salt that is on the open market, which is primarily non-iodized salt. Iodized salt may enter in these communities through the normal trade route. No active interference with salt trade will occur in these communities.
62032273|NCT01349634|EXPERIMENTAL|Early delivery of iodized salt|Iodized salt that is produced nationally for the open market (which meets only about 10% of national needs) will be directed to these communities through the normal trade system or by direct delivery to the communities.
62423446|NCT02998515|EXPERIMENTAL|ESWT order: 1.liquid oxygen, 2. concentrator|Patients will start with the endurance shuttle walk test (ESWT) by using supplemental Oxygen from a portable liquid Oxygen device (Companion) and continue on the day after with ESWT by using supplemental Oxygen from a portable concentrator.
62423447|NCT02998515|EXPERIMENTAL|ESWT order: 1. concentrator, 2. liquid oxygen|Patients will start with the endurance shuttle walk test (ESWT) by using supplemental Oxygen from a concentrator and continue on the day after with ESWT by using supplemental Oxygen from a portable liquid Oxygen device.
62423448|NCT00423488|EXPERIMENTAL|Ezetimibe 10 mg + Simvastatin Placebo + Simvastatin 20 mg|Participants were instructed to take one 10-mg ezetimibe tablet and one simvastatin placebo tablet orally in the evening every day for six weeks in addition to their daily, oral, open-label, 20-mg simvastatin tablet.
62808382|NCT05532826|EXPERIMENTAL|EBV-CTL infusion patients|Given donor EBV-CTL infusion after allo HSCT
62808383|NCT03121859|ACTIVE_COMPARATOR|Neck stabilization exercise|The patients who had only neck stabilization exercise
62808384|NCT03121859|ACTIVE_COMPARATOR|TENS+ neck stabilization exercise|The patients who had both TENS and neck stabilization exercise
62808385|NCT03121859|ACTIVE_COMPARATOR|IFC+ neck stabilization exercise|The patients who had both interferential current therapy and neck stabilization exercise
62808386|NCT02888106|ACTIVE_COMPARATOR|Arm A|PEG IFN alfa-2a 180 µg for 48 weeks
62808387|NCT02888106|EXPERIMENTAL|Arm B|Myrcludex B 2 mg + PEG IFN alfa-2a 180 µg for 48 weeks
62808388|NCT02888106|EXPERIMENTAL|Arm C|Myrcludex B 5 mg + PEG IFN alfa-2a 180 µg for 48 weeks
62808389|NCT02888106|EXPERIMENTAL|Arm D|Myrcludex B 2 mg for 48 weeks
62032274|NCT06139874|EXPERIMENTAL|THRIVE Coached|Thrive is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention. It will be delivered by school social workers/counselors. Following training in THRIVE, school therapists in this condition will receive ongoing weekly group supervision over the life of the study.
62232020|NCT01520298|ACTIVE_COMPARATOR|Acetaminophen treatment|For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer.
62808390|NCT02888106|EXPERIMENTAL|Arm E|Myrcludex B 10 mg (10 mg once a day) + PEG-IFN alfa-2a 180 μg during 48 weeks
62808391|NCT02888106|EXPERIMENTAL|Arm F|Myrcludex B 10 mg (5 mg twice a day) + Tenofovir during 48 weeks
62808392|NCT01099371|EXPERIMENTAL|exercise|
62808393|NCT02362321|EXPERIMENTAL|Dexamethasone|Participants allocated to the treatment group received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
62808394|NCT02362321|PLACEBO_COMPARATOR|Control|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
62808395|NCT01964508||Thyroid nodule|Patients with thyroid nodules undergoing FNA.
62808396|NCT05378685|ACTIVE_COMPARATOR|Oral|Infants in this group are endotracheally intubated through their mouth.
62232021|NCT05427903|EXPERIMENTAL|Cryotherapy|
62232022|NCT05427903|EXPERIMENTAL|IANB plus buccal infiltration local anesthesia|
62232023|NCT05427903|ACTIVE_COMPARATOR|IANB|
62232024|NCT00104676|ACTIVE_COMPARATOR|Arm I|Patients receive 4 courses of bleomycin, etoposide, and cisplatin (BEP).
62232025|NCT00104676|EXPERIMENTAL|Arm II|Patients receive 1 course of bleomycin, etoposide, and cisplatin (BEP). Patients then receive dose-dense sequential combination chemotherapy comprising cisplatin, etoposide, bleomycin, paclitaxel, oxaliplatin, and ifosfamide.
62232026|NCT01438268||Reconstructive breast cancer patients|Patients having unilateral, bilateral immediate or delayed TRAM flaps who are discharged 18 hours postoperatively
62232027|NCT04317703|EXPERIMENTAL|Test: Gemigliptin/Metformin|Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg)
62232028|NCT04317703|ACTIVE_COMPARATOR|Reference: Gemigliptin and Metformin|Coadministration of Zemiglo Tablet 50 mg (Gemigliptin 50 mg) and Glucophage XR 1000 mg (Metformin Hydrochloride Prolonged Release 1000 mg)
62232029|NCT02569957|ACTIVE_COMPARATOR|Arm I (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 (+/- 1 day window for each treatment day). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62232030|NCT02569957|EXPERIMENTAL|Arm II (topotecan hydrochloride, acetylcysteine)|Patients receive topotecan hydrochloride as in Arm I. Patients also receive acetylcysteine IV over 60 minutes on days 1, 8, 15, and 22 (+/- 1 day window for each treatment day) and acetylcysteine PO BID on days 2-7, 9-14, 16-21, and 23-28, unless administration window was utilized. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62808397|NCT05378685|ACTIVE_COMPARATOR|Nasal|Infants in this group are endotracheally intubated through their nose.
62808398|NCT02752594|EXPERIMENTAL|probiotic|2 mg of probiotic powder mixed in 10 ml of distilled water
62808399|NCT02752594|PLACEBO_COMPARATOR|placebo|10 ml of distilled water
62808400|NCT00956735|EXPERIMENTAL|Pistachio Diet|Incorporates 3.0 oz (2 servings) of pistachios into a daily diet
62808401|NCT00956735|NO_INTERVENTION|Non-Pistachio|Does not incorporate pistachios into a daily diet
62423449|NCT00423488|ACTIVE_COMPARATOR|Ezetimibe Placebo + Simvastatin 40 mg|Participants were instructed to take one ezetimibe placebo tablet and one simvastatin 20-mg tablet orally in the evening every day for six weeks in addition to their daily, oral, open-label, 20-mg simvastatin tablet.
62232031|NCT00903656|EXPERIMENTAL|Caelyx/Lapatinib|
62232032|NCT04473430|EXPERIMENTAL|Real-time Dexcom CGM, then Point-Of-Care Blood Glucose Group (Intervention-Control Group)|Patients with type 2 DM treated with insulin and receiving hemodialysis will use a real-time/personal CGM for 4 weeks (Intervention-Control Group), then 2 weeks of wash-out period, and cross over to use POC BG for 4 weeks.
62232033|NCT04473430|EXPERIMENTAL|Point-Of-Care Blood Glucose (Control) then Real-time Dexcom CGM Group (Control-Intervention Group)|Patients with type 2 DM treated with insulin and receiving hemodialysis will use POC BG for 4 weeks, then 2 weeks of wash-out period, and cross over to use a real-time/personal CGM for 4 weeks (Control-Intervention Group).
62232034|NCT03960307||Septic patients|ICU patients with resuscitated sepsis, based on the sepsis-3 criteria. (n=30)
62232035|NCT03960307||Healthy controls|Apparently healthy controls (n=10)
62232036|NCT05134051|EXPERIMENTAL|Single arm|single arm intervention with IVL in calcified de novo coronary stenoses with indication of plaque modification technique during PCI
62808402|NCT02621112|EXPERIMENTAL|Intradermal HBVv with imiquimod|Intradermal hepatitis B vaccination with topical imiquimod pretreatment. Subjects to receive intradermal 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical imiquimod ointment pretreatment 5 minutes before injection at 0, 1, 3, 6 months
62808403|NCT02621112|ACTIVE_COMPARATOR|Intradermal HBVv with aqueous cream|Intradermal hepatitis B vaccination with topical aqueous cream. Subjects to receive intradermal 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical aqueous cream pretreatment 5 minutes before injection at 0, 1, 3, 6 months
62808404|NCT02621112|ACTIVE_COMPARATOR|Intramuscular HBVv with aqueous cream|Intramuscular hepatitis B vaccination with topical aqueous cream. Subjects to receive intramuscular 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical aqueous cream pretreatment 5 minutes before injection at 0, 1, 3, 6 months
62808405|NCT02004730|EXPERIMENTAL|long single vessel disease|ABSORB implantation for long single vessel disease
62808406|NCT02004730|EXPERIMENTAL|multivessel disease ABSORB only|multivessel disease treated with ABSORB implantation only
62808407|NCT02004730|EXPERIMENTAL|"multivessel disease hybrid"|multivessel disease treated with ABSORB implantation and other devices such as drug eluting stents
62808408|NCT03642873|EXPERIMENTAL|Treatment A|Guaifenesin (Humibid®) single extended release 1200 mg tablet administered with 240 mL of room temperature water under fasted conditions.
62232037|NCT05402397|ACTIVE_COMPARATOR|Enalapril|"Children with proteinuric nephropathies will receive enalapril prior or after a losartan period, according to randomization sequence.~Enalapril will be given at a dose between 0.1 to 0.4 mg/kg/day (according to the dose that they usually receive), once a day."
62423450|NCT05718882|EXPERIMENTAL|Lenvatinib plus VIC-1911 combination therapy|Subjects with lenvatinib unresponsive or lenvatinib resistant hepatocellular HCC will receive Lenvatinib plus VIC-1911 combination therapy.
62808409|NCT03642873|EXPERIMENTAL|Treatment B|Hydrocodone Bitartrate of 10 mg in 3 oral doses of a single 3.33 mg tablet in three intervals administered with 240 mL of room temperature water in the fasted state.
62232038|NCT05402397|EXPERIMENTAL|Losartan|"Children with proteinuric nephropathies will receive losartan prior or after a enalapril period, according to randomization sequence.~Losartan will be given at a dose 5 times the dose of enalapril that they usually receive, (with a maximum dose of 1.4 mg/kg/day), once a day."
62232039|NCT05166980|EXPERIMENTAL|FePP-Q5S|Salt fortified with iron in the form of ferric pyrophosphate (at 1.3 mg of iron per gram of salt) plus ethylenediaminetetraacetic acid (EDTA) as an enhancer of absorption, zinc in the form of zinc oxide (at 1.4 mg of zinc per gram of salt), vitamin B12 (at 0.6 ug of vitamin B12 per gram of salt), folic acid (at 52 ug per gram of salt) and iodine (at 30 mg of iodine per gram of salt). Mean intake of discretionary salt among women of reproductive age in the study area is 4.6 grams per day. Therefore, the FePP-Q5S will deliver an average of 6.0 mg of iron, 6.4 mg of zinc, 2.8 ug of vitamin B12, 241 ug of folic acid, and 138 mg of iodine to each participating woman per day.
62423451|NCT02204774||Dilatated or aneurysmatic Aorta|Complete cohort, which will be followed over 3 years
62423452|NCT06236152|ACTIVE_COMPARATOR|Deltacortil|Deltacortil 10mg was given in oral formulation once daily for 4 to 6 weeks
62423453|NCT06236152|PLACEBO_COMPARATOR|Placebo|Iron 150mg was given in oral formulation once daily for 4 to 6 weeks
62423454|NCT04713228|EXPERIMENTAL|Pregnant with Pre-eclampsia|There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit will be 6-7 months post partum where there is a collection of a clinical questionnaire, demographics, vitals, chart review, echocardiogram and vascular compliance will be re-measured.
62808410|NCT03642873|EXPERIMENTAL|Treatment C|Hydrocodone Bitartrate 10 mg in 3 oral doses of a single 3.33 mg tablet in three intervals and guaifenesin (Humibid®) 1200 mg ER administered with 240 mL of room temperature water in the fasted state.
62808411|NCT01404039|EXPERIMENTAL|Motor Learning (ML) sighted|"In this arm, subject will perform motor Learning with visual feedback - ML sighted.~There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session."
62232040|NCT05166980|EXPERIMENTAL|eFF-Q5S|Salt fortified with iron in the form of encapsulated ferrous fumarate (at 1.3 mg of iron per gram of salt), zinc in the form of zinc oxide (at 1.4 mg of zinc per gram of salt), vitamin B12 (at 0.6 ug of vitamin B12 per gram of salt), folic acid (at 52 ug per gram of salt) and iodine (at 30 mg of iodine per gram of salt). Mean intake of discretionary salt among women of reproductive age in the study area is 4.6 grams per day. Therefore, the eFF-Q5S will deliver an average of 6.0 mg of iron, 6.4 mg of zinc, 2.8 ug of vitamin B12, 241 ug of folic acid, and 138 mg of iodine to each participating woman per day.
62232041|NCT05166980|ACTIVE_COMPARATOR|Iodized Salt|Iodized salt containing 30 mg of iodine per gram of salt. Mean intake of discretionary salt among women of reproductive age in the study area is 4.6 grams per day. Therefore, the iodized salt will deliver an average of 138 mg of iodine to each participating woman per day.
62232042|NCT02493543||Spinal cord injury|Patients (n=90) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed twice: after recruitment and 3 months later.
62232043|NCT02493543||Controls|Control subjects (n=20) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed only once.
62232044|NCT02088346||Teleconsultation|Intravenous thrombolysis guided by telemedicine consultation system based on portable hardwares
62032275|NCT06139874|EXPERIMENTAL|THRIVE Low Coached|Thrive is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention. It will be delivered by school social workers/counselors. Following training in THRIVE, school therapists in this condition will receive weekly group supervision only during thier first THRIVE case.
62232045|NCT02088346||Historical control|Usual stroke care without the guidance from hub hospital
62232046|NCT05782686|EXPERIMENTAL|Shaving|Subsequent to lumpectomy, a circumferential enlargement of all lumpectomy margins, including lateral, medial, superior, inferior, anterior, and posterior, approximately 5-10mm thick, will be resected.
62232047|NCT05782686|ACTIVE_COMPARATOR|No Shaving|Standard lumpectomy
62232048|NCT00762970|EXPERIMENTAL|Test Lens 1|Investigational soft contact lenses worn daily.
62232049|NCT00762970|EXPERIMENTAL|Test Lens 2|Investigational soft contact lenses worn daily.
62232050|NCT00762970|ACTIVE_COMPARATOR|Control lens|Spectacle lenses worn daily.
62232051|NCT03018054|EXPERIMENTAL|E6007 30 mg|Participants will receive E6007 30 milligrams (mg) once daily after breakfast.
62232052|NCT03018054|EXPERIMENTAL|E6007 60 mg|Participants will receive E6007 60 mg once daily after breakfast.
62808412|NCT01404039|EXPERIMENTAL|Motor Learning (ML) blind|"In this arm, subject will perform motor Learning without visual feedback - ML blind.~There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session."
62232053|NCT03018054|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo once daily after breakfast.
62232054|NCT00558337|ACTIVE_COMPARATOR|A|
62232055|NCT00558337|ACTIVE_COMPARATOR|B|
62808413|NCT01404039|PLACEBO_COMPARATOR|Motor Learning (ML) control group|In this arm, subject will perform simple hand movements - control group. There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session.
62808414|NCT01404039|EXPERIMENTAL|Somatosensory Learning (SL sighted)|"In this arm, subject will perform sensory Learning with visual feedback - SL sighted.~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
62032276|NCT06139874|ACTIVE_COMPARATOR|Parenting Wisely|Online asynchronous parenting training that parents will complete independently.
62032277|NCT06669910||mild TMD|
62032278|NCT06669910||moderate TMD|
62032279|NCT06669910||advanced TMD|
62032280|NCT02127164|EXPERIMENTAL|"Veraflo device, Dakin's solution"|
62032281|NCT02768896|NO_INTERVENTION|Baseline|Patients will walk naturally with EEG measuring brain waves
62032282|NCT02768896|EXPERIMENTAL|Visual stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
62032283|NCT02768896|EXPERIMENTAL|Auditory stimuli|Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
62592738|NCT05033730|NO_INTERVENTION|Standard care: Control (Group A)|Patients who are scheduled for elective surgical upper airway surgery will be given General Anesthesia by an anesthesiologist who is the principal investigator and the surgical procedures will be done by the same ENT surgeon. IV Induction of Anesthesia with Propofol Target controlled infusion (TCI), Remifentanil Target controlled infusion (TCI) and Rocuronium (0.5mg/Kg) for muscle relaxation. The airway will be secured with cuffed endotracheal tube after direct laryngoscopy. After intubation by a Suitable size Endotracheal tube, they will be mechanically ventilated using Volume Controlled Ventilation (VCV) with 40% Oxygen and minute ventilation adjusted to keep ETCO2 of 40 mmHg or less, and a PEEP of 5 cmH2O.
62032284|NCT02768896|EXPERIMENTAL|Visual and auditory stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
62032285|NCT03500874|EXPERIMENTAL|HAI group|Patients will receive systemic chemotherapy on days 1 and 15 using either of the following regimens: mFOLFOX6 (Oxaliplatin 85 mg/m2; Leucovorin 200mg/m2; followed by an infusion of 5-fluorouracil 2.4 g/m2 administered over 46 hours) or mFOLFIRI (Irinotecan 180mg/m2; Leucovorin 200mg/m2; followed by an infusion of 5-fluorouracil 2.4 g/m2 administered over 46 hours) For HAI, FUDR was administered as a continuous infusion of 0.12 mg/kg/day over 14 days via the HAI pump, along with dexamethasone 20 mg, and normal saline was used to fill up the 300ml pump reservoir.
62032286|NCT03500874|ACTIVE_COMPARATOR|Non-HAI group|Patients will receive systemic chemotherapy on days 1 and 15 using either of the following regimens: mFOLFOX6 (oxalipatin 85 mg/m2 infusion for 3 h, Leucovorin 200 mg/m2 for 3 h and 5-FU 2,400 mg/m2 continuous infusion for 46 h) or mFOLFIRI (Irinotecan 180mg/m2; Leucovorin 200mg/m2; 5-FU 2,400 mg/m2 continuous infusion for 46 h).
62808415|NCT01404039|EXPERIMENTAL|Somatosensory Learning (SL blind)|"In this arm, subject will perform sensory Learning without visual feedback - SL blind.~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
62032287|NCT03580265|EXPERIMENTAL|Six-sessions of laser acupuncture|Laser acupuncture was given three times a week for 2 weeks.
62032288|NCT03580265|SHAM_COMPARATOR|Six-sessions of sham laser acupuncture|Sham laser acupuncture was given three times a week for 2 weeks.
62032289|NCT01288482|EXPERIMENTAL|Asthma Subjects|
62032290|NCT02097472|EXPERIMENTAL|Adult Cohort 1, PATH-wSP, 600 mcg|A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.
62032291|NCT02097472|PLACEBO_COMPARATOR|Adult Cohort 1, Saline|A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
62032292|NCT02097472|EXPERIMENTAL|Adult Cohort 2, PATH-wSP, 1000 mcg|A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.
62032293|NCT02097472|PLACEBO_COMPARATOR|Adult Cohort 2, Saline|A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
62032294|NCT02097472|EXPERIMENTAL|Toddler Cohort 1 PATH-wSP 300 mcg+Active control|A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
62032295|NCT02097472|EXPERIMENTAL|Toddler Cohort 1 PATH-wSP 300 mcg+Saline|A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
62032296|NCT02097472|ACTIVE_COMPARATOR|Toddler Cohort 1: Active Control Only|A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
62032297|NCT02097472|EXPERIMENTAL|Toddler Cohort 2 PATH-wSP 600 mcg+Active control|A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
62032298|NCT02097472|EXPERIMENTAL|Toddler Cohort 2 PATH-wSP 600 mcg+saline|A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
62032299|NCT02097472|ACTIVE_COMPARATOR|Toddler Cohort 2: Active Control Only|A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
62032300|NCT01680328|OTHER|Different injection speed and volume combinations|The study consists of 80 treatment arms in a cross-over design with 19 treatments and 19 periods. The 80 treatment arms will represent different orders of the 19 treatments and each treatment arm will be used for one subject. A subject not completing all treatments will be replaced by another subject using the same treatment arm.
62032301|NCT03151434|ACTIVE_COMPARATOR|Group #1|US Guided Single Shot Paravertebral Block
62232056|NCT03118674|EXPERIMENTAL|Harvoni|1 tablet per day, oral, taken with or without food. 8 weeks for patients without cirrhosis, not previously treated with HCV GT1 and HCV rNA \< 6 million IU/mL; 12 weeks for patients without cirrhosis; 24 weeks for patients with compensated cirrhosis
62232057|NCT01078311||HCC patients on Sorafenib|
62032302|NCT03151434|ACTIVE_COMPARATOR|Group #2|US Guided Paravertebral Catheter
62423455|NCT04713228|EXPERIMENTAL|Pregnant with gestational hypertension|There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit will be 6-7 months post partum where there is a collection of a clinical questionnaire, demographics, vitals, chart review, echocardiogram and vascular compliance will be re-measured.
62423456|NCT04713228|ACTIVE_COMPARATOR|Pregnant without Hypertension - Control|There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit is not applicable to the control group.
62032303|NCT03151434|ACTIVE_COMPARATOR|Group #3|Thoracic Epidural
62423457|NCT04101084|EXPERIMENTAL|Rocking chair therapy|Rocking sessions in a safe rocking chair for 2 hours daily for six weeks
62808416|NCT01404039|EXPERIMENTAL|Somatosensory Activation (S activation)|"In this arm, subject will receive simple sensory stimulation over their left index finger - Sactivation.~There will be an anticipated total of 10 subjects in this experimental arm.This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
62808417|NCT01404039|PLACEBO_COMPARATOR|Somatosensory Learning (SL) control group|"In this arm,the subjects will not receive any somatosensory input (SL control group).~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
62808418|NCT01404039|EXPERIMENTAL|Observational Task (OT) - real|In this arm, the subjects will perform an observational task - observation of hand movements. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
62808419|NCT01404039|PLACEBO_COMPARATOR|Observational Task (OT) - control group|In this arm, the subjects will perform a controlled observational task - observation of geometric shapes. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
62808420|NCT01404039|EXPERIMENTAL|Mental Imagery (MI) - real|In this arm, the subjects will perform mental imagery - mental imagery of finger movements. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
62808421|NCT01404039|PLACEBO_COMPARATOR|Mental Imagery (MI) - control group|In this arm, the subjects will perform a controlled task - simple mental calculation. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
62808422|NCT01404039|EXPERIMENTAL|transcranial direct current stimulation - tDCS real|tDCS will be applied over the motor cortex for 20minutes at an intensity of 2mA. 15 subjects will be enrolled. The subjects will undergo two interventions, real and sham in a counterbalanced randomized order. There will be at least 3 days between each experimental session.
62032304|NCT02285816|EXPERIMENTAL|Arm A (MG1MA3 virus alone)|The starting dose of MG1MA3 will be 1 x 10\^10 pfu administered by IV on day 1 and day 4.MG1MA3 dose will be escalated as per protocol.
62032305|NCT02285816|EXPERIMENTAL|Arm B- AdMA3 (vaccine prime) alone|Six patients will receive prime AdMA3 vaccine at a dose of 1x10\^10 pfu administered IM on day (-14). No dose escalation is planned.
62032306|NCT02285816|EXPERIMENTAL|Arm C- AdMA3 plus MG1MA3 (prime + boost)|Prime AdMA3 vaccine will be administered as a single dose of 1x10\^10 pfu IM at day (-14) followed by dose escalation of MG1MA3 boost, IV administered on days 1 \& 4 at a starting dose of 1 log below the recommended phase II dose (RP2D), as determined in Arm A of this study. MG1MA3 dose will be escalated as defined in protocol.
62032307|NCT06053567|EXPERIMENTAL|High-Intensity Aerobic Exercise|Participants assigned to this arm will be instructed to complete 75 minutes per week of aerobic training at 60-85% of the their heart rate reserve.
62032308|NCT06053567|ACTIVE_COMPARATOR|Low-Intensity Aerobic Exercise|Participants assigned to this arm will be instructed to complete 75 minutes per week of aerobic training at 20-40% of the their heart rate reserve.
62232058|NCT02957864|EXPERIMENTAL|Switch to tenofovir alafenamide|Switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide
62232059|NCT02957864|ACTIVE_COMPARATOR|Switch to abacavir|Switch from tenofovir disoproxil fumarate (TDF) to abacavir
62232060|NCT01519466|OTHER|Intervention|Subjects will use a FreeStyle InsuLinx blood glucose meter during the study
62232061|NCT01519466|OTHER|Control|Subjects will use a FreeStyle Freedom Lite blood glucose meter during the study.
62032309|NCT02676479|EXPERIMENTAL|Uterine Lavage Group|"The study will involve up to 30 pairs of male and female sexually intimate partners who are carriers for a genetic disease (e.g Sickle Cell Disease or Thalassemia) and at high risk of transmitting the gene.~The female partner will be superovulated to mature multiple oocytes which can be fertilized, inseminated with her partner's sperm through intra-uterine insemination (IUI). Four to six days after IUI, the female partner will undergo a non-surgical uterine lavage procedure (Previvo Uterine Lavage System™, CA, U.S.A.) to recover preimplantation embryos."
62032310|NCT04241861|EXPERIMENTAL|High-flow oxygen therapy|Nasal high flow oxygen therapy will be delivered with the Optiflow system. Initial set flow will be ≥ 50 /min and flows will be decreased in case of intolerance and/or according to patients' requirements: flows≥30 L/min will be mandatory in all enrolled patients. Humidification chamber (MR860, Fisher and Paykel healthcare, New Zealand) will be set at 37 °C or 34 °C according to patient's comfort33. FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.
62032311|NCT04241861|EXPERIMENTAL|Helmet PSV|"Dedicated helmets for noninvasive ventilation will be used and size will be chosen according to neck circumference or according to manufacturer recommendations.~Each patient will be connected to a compressed-gas based ventilator through a bitube circuit with no humidification.~The ventilator will be set in PSV, with the following suggested settings 34-38:~1. initial pressure support≥8-10 cmH2O and adequate to permit of a peak in the inspiratory flow of 100 l/min;~2. positive end-expiratory pressure=10-12 cmH2O and increased to achieve the oxygenation target according to the choice of the attending physician.~3. FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.~4. Inspiratory flow trigger = 1 l/min or according to the practice of each institution;~5. fastest pressurization time;~6. expiratory trigger: 10-50% of the maximum inspiratory flow;~7. maximum inspiratory time 1.2 second."
62032312|NCT04241861|EXPERIMENTAL|Helmet CPAP|"Dedicated helmets for noninvasive ventilation will be uses and size will be chosen according to neck circumference or according to manufacturer recommendations.~Treatment will be delivered through a high-flow generator. The following settings will be applied:~1. Continuous air flow=50-60 L/min.~2. Expiratory positive end-expiratory pressure valve set to achieve a PEEP==10-12 cmH2O and eventually increased to achieve the oxygenation target according to the choice of the attending physician.~3. FiO2 will be titrated to obtain an SpO2≥92% and ≤98%. Pressure inside the helmet will be monitored with a manometer in order to maintain the set PEEP."
62232062|NCT02489123|EXPERIMENTAL|Treatment (enzalutamide)|Patients receive enzalutamide PO QD. Courses 1-3 repeat every 4 weeks (28 days) and subsequent courses repeat every 12 weeks (84 days) in the absence of disease progression or unacceptable toxicity.
62423458|NCT04030884|EXPERIMENTAL|Intervention Lap.Chol.|Honey and water mixture was ingested up to two hours preoperatively by the participants who were going to have a laparoscopic cholecystectomy.
62423459|NCT04030884|NO_INTERVENTION|Control Lap.Chol.|The participants received standard care for their laparoscopic cholecystectomy.
62808423|NCT01404039|PLACEBO_COMPARATOR|transcranial direct current stimulation - tDCS sham|"tDCS will be applied over the motor cortex for 20minutes at an intensity of 2mA. The stimulation will be stopped after 30seconds.~15 subjects will be enrolled. The subjects will undergo two interventions, real and sham in a counterbalanced randomized order. There will be at least 3 days between each experimental session."
62423460|NCT04030884|EXPERIMENTAL|Intervention Thyroidectomy|Honey and water mixture was ingested up to two hours preoperatively by the participants who were going to have a thyroidectomy.
62808424|NCT04389359|EXPERIMENTAL|HCQ group (dialysis)|"Dialysis patients will receive Hydroxychloroquine sulfate 200 mg capsules or tablets (oral administration), as 600mg weekly in divided doses, given as 200mg after each dialysis session.~Non-dialysis patients will receive Hydroxychloroquine sulfate, 400mg twice daily for two days, then 400mg weekly.~Maximum treatment duration will be 26 weeks (6 months)."
62808425|NCT04389359|NO_INTERVENTION|Control|Patients will continue with their usual medicines and clinical care without additional HCQ.
62423461|NCT04030884|NO_INTERVENTION|Control Thyroidectomy|The participants received standard care for their thyroidectomy.
62808426|NCT01668459|EXPERIMENTAL|Cabazitaxel|6 cycles (3 weekly) of 25 mg/m\^2 IV infusion
62423462|NCT05301452|PLACEBO_COMPARATOR|Control Group|This group will receive an application of placebo ILIB and an orofacial myofunctional therapy (MFT) exercise protocol.
62808427|NCT01668459|OTHER|Best Supportive Care|Best supportive care including single agent chemotherapy as determined by the patient's study doctor
62808428|NCT04986202|EXPERIMENTAL|Part A 2.5 mg|AZD4831 2.5 mg
62808429|NCT04986202|EXPERIMENTAL|Part A 5 mg|AZD4831 5 mg
62808430|NCT04986202|PLACEBO_COMPARATOR|Part A Placebo|Placebo
62808431|NCT04986202|EXPERIMENTAL|Part B Dose based on Part A|AZD4831 Dose based on Part A
62808432|NCT04986202|PLACEBO_COMPARATOR|Part B Placebo|Placebo
62808433|NCT01139814|EXPERIMENTAL|Catheter Robot|device
62808434|NCT05824364|EXPERIMENTAL|Case|two-four weeks of on-site cardiac rehabilitation (CR) followed by 12 weeks of telerehabilitation
62032313|NCT01369862|PLACEBO_COMPARATOR|SPGNH buffer|SPGNH buffer administration by liquid nasal spray
62032314|NCT01369862|EXPERIMENTAL|GHB16L2|Dose level \~7.0 log10 fTCID50/strain/person
62032315|NCT03019211|EXPERIMENTAL|Hydrotherapy|Exercise performed in an aquatic environment. The participants will perform static/dynamic exercises (balance and resistance training) in an aquatic environment. Training volume and intensity we will increase systematically over 12 weeks.
62032316|NCT03019211|ACTIVE_COMPARATOR|Control|The participants will perform exercises (balance and resistance training) like hydrotherapy group but out of the aquatic environment, during a 12 weeks training period (3sessions/week). Training volume and intensity we will increase systematically over 12 weeks.
62032317|NCT02680054|ACTIVE_COMPARATOR|Arm 1 (usual treatment)|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given at the same time as the insulin for the carbohydrate content BEFORE the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
62032318|NCT02680054|ACTIVE_COMPARATOR|Arm 2|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given one hour after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
62032319|NCT02680054|ACTIVE_COMPARATOR|Arm 3|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given two hours after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
62032320|NCT01815268|EXPERIMENTAL|HD Vaccine (Residents) + Free Vaccine (Staff)|NH facilities randomized to receive high-dose trivalent influenza vaccine (Fluzone High-Dose) for the residents and provided free SD vaccine (Fluzone) for the staff.
62032321|NCT01815268|EXPERIMENTAL|HD Vaccine (Residents) + Usual Care (Staff)|NH facilities randomized to receive high-dose trivalent influenza vaccine (Fluzone High-Dose) for the residents and not provided free vaccine for the staff.
62032322|NCT01815268|ACTIVE_COMPARATOR|SD Vaccine (Residents) + Free Vaccine (Staff)|NH facilities randomized to receive standard dose influenza vaccine (Fluzone) for the residents and provided free standard dose vaccine (Fluzone) for the staff.
62032323|NCT01815268|ACTIVE_COMPARATOR|SD Vaccine (Residents) + Usual Care (Staff)|NH facilities randomized to receive standard dose influenza vaccine (Fluzone) for the residents and not provided free vaccine for the staff.
62423463|NCT05301452|ACTIVE_COMPARATOR|ILIB Group|This group will receive an application of ILIB and an orofacial myofunctional therapy (MFT) exercise protocol.
62423464|NCT04388527|EXPERIMENTAL|Treatment|Penn COVID-19 convalescent plasma
62808435|NCT05824364|ACTIVE_COMPARATOR|Control|4 weeks of on-site standard CR
62032324|NCT05997238|PLACEBO_COMPARATOR|Placebo|LIA preparation was administered without triamcinolone. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
62032325|NCT05997238|EXPERIMENTAL|Low dose triamcinolone|Add 20mg triamcinolone to the LIA preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
62032326|NCT05997238|EXPERIMENTAL|Moderate dose triamcinolone|add 40mg triamcinolone to the LIA preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
62032327|NCT05997238|EXPERIMENTAL|High dose triamcinolone|add 80mg triamcinolone to the LIA preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
62032328|NCT00704457||A|One arm study. Urine collection.
62032329|NCT04897958||Degarelix|Reference group
62032330|NCT04897958||Leuprolide|Exposure group
62032331|NCT05737810||People with Type 2 Diabetes|Participants are recruited via email through online panel companies
62423465|NCT05365347|NO_INTERVENTION|Treatment as Usual|
62032332|NCT03640260|EXPERIMENTAL|experimental|The experiment arm will get educational leaflets to pursed-lip with diaphragmatic breathing training and oximetry level evaluation.
62232063|NCT03821389|EXPERIMENTAL|NIOD Frequencer of 40Hz|40 Hz of NIOD will be applied and then 60Hz will be used 3 hours later. 60 Hz of NIOD will be applied and then 40Hz will be used 3 hours later for the rest of the patients. The investigators will analyze the difference in average effects between 40Hz and 60Hz.
62423466|NCT05365347|EXPERIMENTAL|Cognitive enhancement therapy (CET)|Cognitive enhancement therapy with an aim to reduce alcohol consumption
62423467|NCT01304017|EXPERIMENTAL|Virtual Reality Therapy|The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing.
62808436|NCT02492178|EXPERIMENTAL|IR artesunate + IV artesunate|Patients receive 1 dose of intrarectal artesunate (10 mg/ kg b.w.) on admission and 1 dose of intravenous artesunate (2.4 mg/kg body weight) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.
62808437|NCT02492178|EXPERIMENTAL|IV artesunate + IR artesunate|Patients receive 1 dose of intravenous artesunate (2.4 mg/kg b.w) on admission and 1 dose of intrarectal artesunate (10 mg/ kg b.w.) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.
62232064|NCT03821389|ACTIVE_COMPARATOR|NIOD Frequencer of 60Hz|
62423468|NCT01304017|ACTIVE_COMPARATOR|Traditional Therapy|The traditional therapy will include exercises for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
62032333|NCT03640260|NO_INTERVENTION|controlled|
62032334|NCT02111057||Perioperative RA|Patients with Rheumatoid Arthritis undergoing a primary or secondary total hip replacement, between the ages of 18 and 90.
62032335|NCT05427279|PLACEBO_COMPARATOR|Placebo|This arm will be given a placebo (20g maltodextrin with 50mg vitamin C)
62232065|NCT04842656|EXPERIMENTAL|Active release technique alongwith conventional treatment|Patients in Group A will receive active release technique. ART will be applied with patient in prone lying, knee flexed at 90. The therapist will place his elbow tip on taut band of piriformis and direct pressure is applied, patient is then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This will be repeated 5-7 times(22).
62032336|NCT05427279|EXPERIMENTAL|Hydrolized Collagen|This arm will be given Hydrolized Collagen (20g with 50mg vitamin C)
62032337|NCT05427279|EXPERIMENTAL|PrimaColl|This arm will be given PrimaColl, a vegan collagen supplementation (20g with 50mg vitamin C)
62032338|NCT05427279|EXPERIMENTAL|Whey Protein|This arm will be given whey protein (20g with 50mg vitamin C)
62232066|NCT04842656|EXPERIMENTAL|Post isometric relaxation alongwith conventional treatment|Patients in group B will receive post isometric relaxation technique. Patient lying in supine position, with the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra lateral knee (the leg on the side to be treated is crossed over the other). Therapist places one hand on the contra lateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis (PIR MET). The starting position will be the 1st sign of resistance towards end range. Therapist Force will be same as patient's force. Initial effort is approximately 20% of patient's strength. Duration of contraction is 7-10 seconds with three repetitions(32)
62232067|NCT04795882|EXPERIMENTAL|Cohort 1: BCMA CAR T cells|Treatment with Advanced Therapy Investigational Product (ATIMP): BCMA CAR T-cells
62232068|NCT04795882|EXPERIMENTAL|Cohort 2: BCMA/CD19 CAR T cells|Treatment with Advanced Therapy Investigational Product (ATIMP): BCMA/CD19 CAR T-cells
62232069|NCT00111527|ACTIVE_COMPARATOR|1|Normal RV pacing
62423469|NCT05921331|EXPERIMENTAL|The RJBC-APP group|Participants randomized to the RJBC-APP group should register on the RJBC-APP, through which they can receive treatment reminders, matters needing attention as well as science knowledge and communicate with the medical staff.
62032339|NCT05404542|EXPERIMENTAL|Severe Renal Impairment|Participants with severe renal impairment will receive a single dose of tavapadon, 0.25 milligrams (mg) tablet, on Day 1.
62032340|NCT05404542|EXPERIMENTAL|Normal Renal Function|Participants with normal renal function will receive a single dose of tavapadon, 0.25 mg tablet, on Day 1.
62032341|NCT06636409||Liver transplant patients|Liver transplant patients from all French centers between 2008 and 2013 and followed up during the period 2008-2023.
62032342|NCT03787394|EXPERIMENTAL|FAAA-enriched|food products enriched with FAAA-conjugates
62032343|NCT03787394|PLACEBO_COMPARATOR|Plain|Food products without FAAA-conjugates
62032344|NCT06530914|EXPERIMENTAL|MRG003+Pucotenlimab|"Neoadjuvant:~Patients receive MRG003 in combination with Pucotenlimab for 3 cycles before surgery.~Surgery:~Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Adjuvant:~Patients receive adjuvant Pucotenlimab for 8 cycles."
62032345|NCT06530914|EXPERIMENTAL|MRG003+Pucotenlimab+Cisplatin|"Neoadjuvant:~Patients receive MRG003 in combination with Pucotenlimab + cisplatin for 3 cycles before surgery.~Surgery:~Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Adjuvant:~Patients receive adjuvant Pucotenlimab for 8 cycles."
62032346|NCT01820728|EXPERIMENTAL|DA-3801 injection|Recominant human follicle stimulating hormone 75 IU/day is injected for 14 days
62032347|NCT01820728|ACTIVE_COMPARATOR|Gonal-F®|75 IU/day is injected for 14 days
62032348|NCT00755989|PLACEBO_COMPARATOR|1|group to receive topical gel without morphine
62032349|NCT00755989|EXPERIMENTAL|2|Morphine gel
62232070|NCT00111527|EXPERIMENTAL|2|Echo-guided optimization of pacing
62232071|NCT02951741||RTHRA group|patients undergoing revision total hip replacement
62232072|NCT04919239|EXPERIMENTAL|RUTI® arm|A dose of 25 μg of of RUTI vaccine will be given at week 1 (Cohort A-DS TB Patients) or month 1 (Cohort B-MDR TB Patients) after starting standard TB treatment.
62232073|NCT04919239|PLACEBO_COMPARATOR|Placebo arm|Placebo will be given at week 1 (Cohort A-DS TB Patients) or month 1 (Cohort B-MDR TB Patients) after starting standard TB treatment.
62032350|NCT05796570|EXPERIMENTAL|Cohort A: Standard Risk|"Participants with MDS, AML, AML/MDS, treatment related myeloid neoplasm (tAML/MDS) with either idiopathic disease or inherited bone marrow failure syndrome (iBMF) with standard risk for treatment related toxicities will be enrolled and will undergo study procedures as outlined:~* Cycles 1: Study treatment start must occur 40 - 120 days post allogenic HCT.~  * Day 2 - 6 of 28-day cycle: Predetermined dose of Decitabine.~ * Day 1 - 6 of 28-day cycle: Predetermined dose of Filgrastim.~* Cycles 2 - 6:~  * Day 2 - 6 of 28-day cycle: Predetermined dose of Decitabine.~ * Day 1 - 6 of 28-day cycle: Predetermined dose of Filgrastim.~* Follow up visit every 6 months for 24 months post allogenic HCT."
62032351|NCT05796570|EXPERIMENTAL|Cohort B: inherited bone marrow failure (iBMF) with Increased Risk for treatment related toxicities|"Participants with MDS, AML, AML/MDS, tAML/MDS with iBMF with increased risk for treatment related toxicities will be enrolled and will undergo study procedures as outlined:~* Cycles 1: Study treatment must occur 40 - 120 days post allogenic HCT.~  * Day 2 - 6 of 28-day cycle: Predetermined dose of Decitabine.~ * Day 1 - 6 of 28-day cycle: Predetermined dose of Filgrastim.~* Cycles 2 - 6:~  * Day 2 - 6 of 28-day cycle: Predetermined dose of Decitabine.~ * Day 1 - 6 of 28-day cycle: Predetermined dose of Filgrastim.~* Follow up visit every 6 months for 24 months post allogenic HCT."
62032352|NCT06635928|NO_INTERVENTION|Wait list|
62032353|NCT06635928|EXPERIMENTAL|Intervention|Bright light therapy for 2 weeks, 30min a day
62032354|NCT02175433|EXPERIMENTAL|Dose Escalation of AGS67E 0.05 mg/kg Without GF|Participants will receive 0.05 milligram per kilogram (mg/kg) AGS67E without growth factor (GF) by intravenous infusion once every three weeks.
62032355|NCT02175433|EXPERIMENTAL|Dose Escalation of AGS67E 0.1 mg/kg Without GF|Participants will receive 0.1 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
62032356|NCT02175433|EXPERIMENTAL|Dose Escalation of AGS67E 0.3 mg/kg Without GF|Participants will receive 0.3 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
62032357|NCT02175433|EXPERIMENTAL|Dose Escalation of AGS67E 0.6 mg/kg Without GF|Participants will receive 0.6 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
62032358|NCT02175433|EXPERIMENTAL|Dose Escalation of AGS67E 0.9 mg/kg Without GF|Participants will receive 0.9 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
62032359|NCT02175433|EXPERIMENTAL|Dose Escalation of AGS67E 1.2 mg/kg Without GF|Participants will receive 1.2 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
62032360|NCT02175433|EXPERIMENTAL|Dose Expansion of AGS67E 0.9 mg/kg Without GF|Participants will receive 0.9 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
62032361|NCT02175433|EXPERIMENTAL|Dose Escalation of AGS67E 1.2 mg/kg With GF|Participants will receive 1.2 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
62032362|NCT02175433|EXPERIMENTAL|Dose Escalation of AGS67E 1.5 mg/kg With GF|Participants will receive 1.5 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
62032363|NCT02175433|EXPERIMENTAL|Dose Escalation of AGS67E 1.8 mg/kg With GF|Participants will receive 1.8 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
62423470|NCT05921331|ACTIVE_COMPARATOR|The Control group|Participants randomized to the Control group have no access to the RJBC-APP and post-surgical follow-up can only be conducted in outpatient clinic.
62423471|NCT01308658|EXPERIMENTAL|001|Darunavir (DRV) 2x400-mg DRV tablet or 800-mg tablet on Day 3
62423472|NCT01308658|EXPERIMENTAL|002|ritonavir 100-mg once daily on Day 1 to Day 5
62423473|NCT02103634||Lesion Imaging|Image patients with the standard of care of a FDG PET/CT and the experimental method of the NaF PET/MRI and compare the number of images found within and between patients to determine the most effective way of looking at breast cancers metastasized to bone
62423474|NCT05526274||General population aged ≥9 to ≤16 years.|
62032364|NCT02175433|EXPERIMENTAL|Dose Expansion of AGS67E 1.5 mg/kg With GF|Participants will receive 1.5 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
62423475|NCT06004076|EXPERIMENTAL|Release Group|Release of upper track of deep front fascial line
62423476|NCT06004076|OTHER|Corrective Group|Corrective exercises for upper crossed syndrome.
62423477|NCT00871065|EXPERIMENTAL|Sildenafil Treatment of Cerebral Aneurysm Vasospasm|Trial Arm (single arm study)
62592739|NCT05033730|EXPERIMENTAL|Intervention Group: (Group B)|General Anesthesia will be induced with IV Induction of Anesthesia by an anesthesiologist with Propofol (Target controlled infusion), Remifentanil (Target controlled infusion), and Rocuronium (0.5mg/Kg) for muscle relaxation. The airway will be secured with cuffed Tritube after direct laryngoscopy. They will be mechanically ventilated using Flow Controlled Ventilation (FCV) with 40% Oxygen, Flow rate:13L/Min., Peak Airway Pressure (15 cmH2O), and a PEEP of (5 cmH2O) to keep ETCO2 of 40 mmHg or less. The anesthesia will be maintained with Intravenous Infusion of Propofol, Remifentanil (TCI) to keep BIS 40-60.
62592740|NCT02009397|EXPERIMENTAL|Ipilimumab and GM-CSF|IV ipilimumab followed by subcutaneous GM-CSF, for up to 4 cycles
62032365|NCT04493398|ACTIVE_COMPARATOR|Titanium curette and ultrasonic.|Debridement of mandibular furcations with conventional ultrasonic/curette (control).
62423478|NCT05676879|EXPERIMENTAL|Intervention Group|Ice massage was applied to the SP6 points (SP6 point is located 3-4 fingers above the posterior malleolus bone, that is, 4 fingers above the ankle) of the pregnant women in first stage of childbirth at 4-5 cm, 6-7 cm, and 8-9 cm cervical dilatations during 3 contractions. In order to prevent direct contact of ice with the skin, ice was applied as ice cubes wrapped in gauze.
62592741|NCT04293913|EXPERIMENTAL|intervention group|In the intervention group, communication was established with the illustrated communication material. The pain, anxiety scores, and hemodynamic data of the patients were recorded by the intensive care nurse in three consecutive measurements starting with the first communication (0th minute) and at 30th and 60th minutes. On the first postoperative day, the satisfaction of the communication established with them, as well as their evaluations regarding the adequacy of this communication and their comfort levels were determined during the time they received mechanical ventilation therapy.
62592742|NCT04293913|NO_INTERVENTION|control group|no intervention
62592743|NCT05036577|EXPERIMENTAL|ORMD (Orelabrutinib, Rituximab, Methotrexate and Dexamethasone)|Patients were treated for 6-8 cycles of induction therapy with 21 days per cycle, receiving rituximab (375mg/m2 on day 1), dexamethasone (10-15mg on d1-d4), MTX (d2, 3.5g/m2 or 5g/m2), and orelabrutinib (once daily, after MTX clearance, 150mg/d, or 200mg/d), followed by orelabrutinib maintenance up to one year among CR/CRu patients or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first). The primary objective was to determine the maximum tolerated dose (MTD) of the combination of orelabrutinib and MTX with R and D and investigate the safety and tolerability of this regimen using Bayesian Optimal Interval (BOIN) waterfall design to determine rule of dose escalation and movement among dose combination matrix to identify MTD contour.
62592744|NCT05657990|EXPERIMENTAL|Pre-operative Tamsulosin administration|Subjects will be provided with a prescription for Tamsulosin (generic) to be taken 7 days prior to scheduled surgery for thoracic cancer. Tamsulosin dose is set at 0.4mg/day and should be taken daily for seven days prior to their planned surgery date. Study subjects will also be given a diary to record their daily usage. Study subjects should take Tamsulosin on the day of the surgery with a sip of water.
62592745|NCT05785585|EXPERIMENTAL|Methylcobalamin group|One capsule daily with 500 µg of methylcobalamin for 12 weeks
62592746|NCT05785585|ACTIVE_COMPARATOR|Cyanocobalamin group|One capsule daily with 500 µg of Cyanocobalamin for 12 weeks
62592747|NCT05785585|PLACEBO_COMPARATOR|Control group|One capsule daily with microcrystalline cellulose for 12 weeks
62592748|NCT02884557|OTHER|PSC + IBD group|collection of gut biopsies collection of blood samples in patients with PSC and IBD
62592749|NCT02884557|OTHER|IBD alone group|collection of gut biopsies collection of blood samples in patients with IBD alone
62232074|NCT04008602|ACTIVE_COMPARATOR|Experimental: Quick Icing|Group receiving the application of cold on the ventral side of the thigh (bilaterally) for 30 seconds, using the technique of ice beakers dynamically.
62423479|NCT05676879|NO_INTERVENTION|Control Group|All the pregnant women, those in the control group, were provided with standard midwifery care.
62232075|NCT04008602|ACTIVE_COMPARATOR|Experimental: Prolonged Cold|"Group receiving the intervention of ice bag for a period of eight minutes n the ventral side of the thigh (bilaterally)."
62423480|NCT03791918|EXPERIMENTAL|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62423481|NCT03791918|ACTIVE_COMPARATOR|TACE|Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
62032366|NCT04493398|EXPERIMENTAL|Erythritol air-polishing.|Treatment of mandibular furcations with erythritol powder/air-polishing system (test)
62032367|NCT05234164|EXPERIMENTAL|EXIST 6F NiTi Stent System FLEX|Stent implantation of lesions in the SFA graded with Fanelli 1 and 2, and lesions in the P1 segment of the proximal popliteal artery.
62032368|NCT05234164|EXPERIMENTAL|EXIST 6F NiTi Stent System PULL|Stent implantation of lesions in the SFA graded with 3 and 4.
62032369|NCT04602325||Inherited Hyperammonemias|"A clinical diagnosis of 1 of 7 diagnosed urea cycle disorders:~1. N-acetylglutamate Synthetase Deficiency (NAGS)~2. Carbamyl Phosphate Synthetase Deficiency (CPSD)~3. Ornithine Transcarbamylase Deficiency (OTCD)~4. Argininosuccinate Synthetase Deficiency (ASD)~5. Argininosuccinate Lyase Deficiency (ALD)~6. Arginase Deficiency (AD)~7. Hyperammonemia-Hyperornithinemia-Homocitrullinuria (HHH)~A clinical diagnosis of 1 of 2 organic acidemias:~1. Propionic Acidemia (PA)~2. Methylmalonic Acidemia (MMA)"
62032370|NCT04602325||Acute Metabolic Disorder + Neurological Sequelae|"Acute metabolic disorder without hyperammonemia but with neurological sequelae:~1. Maple Syrup Urine Disease (MSUD)~2. Glutaric Acidemia (GA1)"
62032371|NCT04602325||Fatty Acid Oxidation Disorders|"Acute metabolic disorder without hyperammonemia and without neurological sequelae:~1. Medium Chain-Acyl CoA Dehydrogenase Deficiency~2. Very Long Chain-Acyl CoA Dehydrogenase Deficiency~3. Trifunctional Protein Deficiency~4. Long Chain Hydroxyacyl-CoA Dehydrogenase Deficiency~5. Carnitine Palmitoyltransferase I or II Deficiency~6. Carnitine/Acylcarnitine Translocase Deficiency~7. Primary Carnitine Transport Deficiency"
62032372|NCT04602325||Hypoxic-Ischemic Encephalopathy|Patients with hypoxic-ischemic encephalopathy
62032373|NCT04310826|EXPERIMENTAL|Prevention (dietary intervention)|Patients receive a dietary magnesium intervention consisting of a food reference list and phone calls or video interviews from a registered dietitian, integrative medicine physician, or a mid-level provider over 10-20 minutes once a week for up to the 6th cycle of chemotherapy (average 15 weeks).
62032374|NCT03761602||Proper selenium and iodine condition|"The subjects should have proper dietary intake of selenium and iodine, according to Chinese Dietary Reference Intakes (DRIs) (intake of selenium 65μg/d and iodine 230 μg/d).~The Serum iodine concentration are 45-92μg/L，and the urinary I/Cr 150-249μg/g Cr.~The Serum selenium concentrations are 18-40μg/L."
62032375|NCT03761602||Excessive selenium or iodine condition|"The subjects have excessive dietary intake of selenium and iodine, usually more than 2 times of DRIs. The Serum iodine concentration are more than 100μg/L，and the urinary I/Cr more than 300μg/g Cr.~The Serum selenium concentrations are more than 40μg/L."
62423482|NCT01284725|EXPERIMENTAL|immunosuppressive treatment discontinuation,|
62592750|NCT02490462|EXPERIMENTAL|Education + Conventional PhysicalTherapy|Parents of children with cerebral palsy receive instructions for active inclusion of children in everyday activities. The education program for parents will take place once a week for twelve weeks. Children with Cerebral Palsy make conventional physical therapy twice a week for a period of twelve weeks.
62592751|NCT02490462|ACTIVE_COMPARATOR|Conventional Physical Therapy|Children with Cerebral Palsy make conventional physical therapy twice a week for a period of twelve weeks.
62232076|NCT04008602|NO_INTERVENTION|Control:|Group that does not receive intervention and that will rest for ten minutes.
62232077|NCT01489410|ACTIVE_COMPARATOR|Drug-Eluting Beads with Doxorubicin|Drug-Eluting Beads (DEB) with Doxorubicin is administered via beads that release it to the liver through a groin puncture site and delivered via catheter through the vessels that feed the liver.
62423483|NCT01284725|ACTIVE_COMPARATOR|Continuation of immunosuppressive therapy|with MMF or AZA, with a background therapy with hydroxychloroquine, and possibly low-dose corticosteroids
62232078|NCT01489410|ACTIVE_COMPARATOR|Lipiodol Ethanol Mixture (LEM)|Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered via catheter through the vessels that feed the liver.
62232079|NCT04889547|EXPERIMENTAL|Dexamethasone|Patient will receive intraoperative dexamethasone during distal radius open reduction and internal fixation
62232080|NCT04889547|PLACEBO_COMPARATOR|No dexamethasone|Patient will not receive intraoperative dexamethasone during distal radius open reduction and internal fixation
62423484|NCT03964090|EXPERIMENTAL|1|Temozolomide, etoposide, doxil, dexamethasone, and rituximab without ibrutinib (TEDD-R) or TEDD-R with ibrutinib (TEDDI-R), concurrent with cytarabine and isavuconazole, based upon response to 14-day ibrutinib window
62423485|NCT03964090|EXPERIMENTAL|2|Temozolomide, etoposide, doxil, dexamethasone, and rituximab without ibrutinib (TEDD-R) or TEDD-R with ibrutinib Days 1-10 (TEDDI-R), concurrent with cytarabine and isavuconazole, based upon response to 14-day ibrutinib window
62592752|NCT05738967|EXPERIMENTAL|Transdiagnostic cognitive behavioral therapy|
62592753|NCT05738967|ACTIVE_COMPARATOR|Treatment as usual|
62592754|NCT02396420|EXPERIMENTAL|Treatment arm|Patients will receive prostate artery embolization (PAE) with Embosphere Microspheres.
62592755|NCT00581321|EXPERIMENTAL|1|water ingestion
62592756|NCT05637047|EXPERIMENTAL|pulsed radiofrequency|
62592757|NCT05637047|ACTIVE_COMPARATOR|Dry needling|
62232081|NCT03832413||Stroke|Diagnostic Test: DELPhI (TMS-EEG analysis)
62232082|NCT03832413||TBI|Diagnostic Test: DELPhI (TMS-EEG analysis)
62232083|NCT03832413||ABD|Diagnostic Test: DELPhI (TMS-EEG analysis)
62232084|NCT03832413||Fibromyalgia|Diagnostic Test: DELPhI (TMS-EEG analysis)
62232085|NCT03832413||PDD|Diagnostic Test: DELPhI (TMS-EEG analysis)
62232086|NCT03832413||ADHD|Diagnostic Test: DELPhI (TMS-EEG analysis)
62232087|NCT03832413||MCI|Diagnostic Test: DELPhI (TMS-EEG analysis)
62232088|NCT03832413||Dementia|Diagnostic Test: DELPhI (TMS-EEG analysis)
62232089|NCT03832413||Healthy|Diagnostic Test: DELPhI (TMS-EEG analysis)
62232090|NCT03832413||Cognitive impairment|Diagnostic Test: DELPhI (TMS-EEG analysis)
62232091|NCT02686905|EXPERIMENTAL|Topical vitamin patch|Dietary Supplement: PatchMD Vitamin D3/Calcium Patch Dietary Supplement: PatchMD Multivitamin Patch Dietary Supplement: PatchMD B12 Energy Plus Patch
62423486|NCT02773888|EXPERIMENTAL|HS-1000 recording|ICP readings will be recorded in parallel from both the invasive ICP monitor, and HeadSense's non-invasive ICP monitor. Each recording session will be done until an aggregate of at least 30 minutes worth of quality data is collected, depending on the patient's clinical condition. For each patient, two recording sessions will be completed for 30-60 minutes each for 120 minutes total.
62808438|NCT06061952|EXPERIMENTAL|Customized Adherence Enhancement for Schizophrenia (CAE-S)|CAE is an adjunctive (to standard medication treatment) behavioral intervention delivered virtually (real-time one on one video-conferencing) in 6 individual sessions. All participants will receive content from the 4 currently existing CAE modules delivered over a 6-session series spaced out over approximately 6-10 weeks. The material from the 4 modules will be broken down into predetermined sub-sections and delivered in 6 sessions. The modules themselves are delivered in sections (thematic units within the module) and do not correspond to a specific session. The 4 CAE modules are Psychoeducation, Communication with Providers, Medication Routines, and Substance Use.
62232092|NCT02686905|EXPERIMENTAL|Oral vitamins|Dietary Supplement: Chewable Multivitamin with Iron Dietary Supplement: Chewable Calcium Dietary Supplement: Quick Dissolve B12
62232093|NCT03049176||HIV+male/HIV-female|discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or semen washing
62232094|NCT03049176||HIV+female/HIV-male|discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or artificial vaginal insemination
62232095|NCT02745743|EXPERIMENTAL|Arm 1|Biomarker-enriched advanced hematological neoplasms
62232096|NCT02745743|EXPERIMENTAL|Arm 2|Other selected advanced hematological neoplasms
62232097|NCT04643288|EXPERIMENTAL|OFD control group|open flap debridement for periodontal intrabony defects
62232098|NCT04643288|EXPERIMENTAL|n-HA bone graft intervention group|Nanocrystalline Hydroxyapatite (n-HA) bone graft substitute was added to periodontal intrabony defects
62232099|NCT02274194|ACTIVE_COMPARATOR|Nasal CPAP during titration|Group nasal mask: use of CPAP for one night whit wash out of two weeks
62232100|NCT02274194|EXPERIMENTAL|Oronasal CPAP during titration|Group oronasal mask: use of CPAP for one night with wash out of two weeks.
62232101|NCT01510496||Patients who had inguinal herniorraphy.|
62232102|NCT01510496||Patients who had hysterectomy.|
62232103|NCT01510496||Patients who had thoracotomy.|
62232104|NCT05257031|EXPERIMENTAL|SmofKabiven extra Nitrogen|"The investigational product will be administered in a volume that provides the target caloric intake of 15 kcal/kg BW on Study Day 1 and 20 kcal/kg BW/day on Study Days 2 to 5.~If calories are provided from other sources (e.g., enteral/oral nutrition/oral nutritional supplements or non-nutritional sources including glucose solution for drug dilution or propofol), the dose of the investigational product will be reduced accordingly to avoid calorie overload above the respective daily caloric targets."
62232105|NCT03200600|EXPERIMENTAL|Dexamethasone and flurbiprofen axetil|"1. Dexamethasone 10 mg is administered before anesthesia induction.~2. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
62232106|NCT03200600|EXPERIMENTAL|Dexamethasone and lipid microsphere|"1. Dexamethasone 10 mg is administered before anesthesia induction.~2. Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
62232107|NCT03200600|EXPERIMENTAL|Normal saline and flurbiprofen axetil|"1. Normal saline 2 ml is administered before anesthesia induction.~2. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
62232108|NCT03200600|EXPERIMENTAL|Normal saline and lipid microsphere|"1. Normal saline 2 ml is administered before anesthesia induction.~2. Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
62232109|NCT01453530|ACTIVE_COMPARATOR|Sugammadex|A single dose of sugammadex 2 mg/kg iv. Dose calculation will be based on the patient's actual body weight. No dose adjustments are allowed
62232110|NCT01453530|ACTIVE_COMPARATOR|Neostigmine/glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv. Dose calculation will be based on the patient's actual body weight. No dose adjustments are allowed.
62232111|NCT01453530|PLACEBO_COMPARATOR|No reversal agent|No treatment
62808439|NCT06061952|OTHER|Enhanced Treatment as Usual (eTAU)|To optimize control intervention rigor, the eTAU participants will view a pre-taped series of 6 videos (based on NAMI or DBSA general wellness guidelines) 1:1 with a therapist who has similar credentials and competency as the CAE mental health clinician. The therapist will view the video with the participant and field questions the patient may have.
62232112|NCT05621031|EXPERIMENTAL|PDExperimental|This group will receive usual care (physical therapy) and whole body vibration sessions.
62232113|NCT05621031|ACTIVE_COMPARATOR|PDControl|This group will receive usual care (physical therapy) and placebo whole body vibration session.
62232114|NCT05417633|ACTIVE_COMPARATOR|Group 1|monovision 0.25 - 0.74 D
62232115|NCT05417633|ACTIVE_COMPARATOR|Group 2|monovision 0.75 -1.24 D
62232116|NCT05417633|ACTIVE_COMPARATOR|Group 3|monovision 1.24 - 1.75
62232117|NCT02934321|ACTIVE_COMPARATOR|Aspartame Sweetened Beverage|Volunteers will consume a low-calorie, aspartame sweetened beverage (185 mg aspartame in water) after fasting for 10 hours and abstaining from alcohol, caffeine, and strenuous exercise for 24 hours prior to the visit.
62232118|NCT02934321|EXPERIMENTAL|Erythritol Sweetened Beverage|Volunteers will consume an isosweet, compared to aspartame, high osmolar, low-calorie erythritol sweetened beverage (50.8 g erythritol in water, 1.66 Molar) after fasting for 10 hours and abstaining from alcohol, caffeine, and strenuous exercise for 24 hours prior to the visit.
62808440|NCT03771755|ACTIVE_COMPARATOR|Ibuprofen group|800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
62032376|NCT03761602||Insufficient selenium or iodine condition|"The subjects have insufficient dietary intake of either selenium or iodine, compared with DRIs. The Serum iodine concentration are less than 45μg/L，and the urinary I/Cr less than150μg/g Cr.~The Serum selenium concentrations are less than 18μg/L."
62232119|NCT03495128|EXPERIMENTAL|Bed rest|Three days of bed rest at -6 degrees of head-down tilt
62808441|NCT03771755|PLACEBO_COMPARATOR|Acetaminophen group|1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
62808442|NCT03984110|EXPERIMENTAL|Combination of Ozurdex and Eylea|Eyes receiving intravitreal injection of Ozurdex every 3 months (as needed per protocol) and intravitreal injection of Eylea every month (as needed per protocol)
62808443|NCT03984110|ACTIVE_COMPARATOR|Eylea Monotherapy|Eyes receiving intravitreal injection of Eylea every month (as needed per protocol)
62808444|NCT02903160|EXPERIMENTAL|Intensive, Non-Cross Reactive Therapy|Prostate Cancer Rapidly cycling, Intensive, Non-Cross Reactive Therapy (PRINT) Rapidly cycling, consecutive treatment modules: 1. Abiraterone acetate; 2. Cabazitaxel + Carboplatin; 3. Enzalutamide + Radium-223
62808445|NCT00793858|ACTIVE_COMPARATOR|1|placebo in left nostril, isotonic ciclesonide in right
62808446|NCT00793858|ACTIVE_COMPARATOR|2|hypotonic ciclesonide in left nostril, placebo in right
62808447|NCT00793858|ACTIVE_COMPARATOR|3|hypotonic ciclesonide in right and left nostrils
62808448|NCT00793858|ACTIVE_COMPARATOR|4|isotonic ciclesonide in both right and left nostrils
62032377|NCT02466022|EXPERIMENTAL|Dexmedetomidine|Patients will receive one 0.5ug/kg bolus of Dexmedetomidine over 10 minutes for sedation prior to spinal anesthetic (12.75mg of heavy Bupivicaine and 10ug of Fentanyl) and 0-4mg of Midazolam for rescue sedation
62232120|NCT03495128|EXPERIMENTAL|Reconditioning|Three days of one-legged knee extension contractions to recondition one leg
62232121|NCT04494581||Pregnant and postpartum women|Pregnant and postpartum women over 18, meeting inclusion and exclusion criteria.
62232122|NCT04494581||healthcare workers|Health professionals over 18, working in maternity wards included.
62232123|NCT02612753|EXPERIMENTAL|Aphasics Patients|Patients which have difficulties to speak. Improvement of language for aphasics patients.
62232124|NCT02612753|SHAM_COMPARATOR|Aphasics Patients control|Patients which have difficulties to speak will receive Sham tDCS +SLT for aphasics patients control
62232125|NCT06023277|EXPERIMENTAL|ConvitVax|"ConvitVax is a vaccine made of three components: autologous tumor cells homogenate obtained from 0.3 g of tumor tissue, 0.0625 mg of BCG D1331, and 0.02% of formalin.~There is no dose escalation in this study. Four doses of 0.5 mL of ConvitVax will be applied via id injection with a 2-week interval between each dose."
62232126|NCT01610011|EXPERIMENTAL|Glycine administration|Glycine will be administered once orally to all subjects to determine brain and plasma pharmacodynamics.
62232127|NCT01800422|EXPERIMENTAL|Arm I (telapristone acetate)|Patients receive telapristone acetate orally once daily for 2-10 weeks and then undergo surgical resection.
62232128|NCT01800422|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo orally once daily for 2-10 weeks and then undergo surgical resection.
62423487|NCT04495192||Patients affected by severe Acquired Brain Injury|All patients admitted in the participant IRU with a history of sABI and fulfilling our inclusion and exclusion criteria will be recruited.
62423488|NCT02198755|ACTIVE_COMPARATOR|High Resolution Ultrasound|High Resolution Ultrasonography (HRUS) with a Hitachi-Aloka Noblus Scanner
62808449|NCT00793858|PLACEBO_COMPARATOR|6|placebo in both right and left nostrils
62808450|NCT00793858|ACTIVE_COMPARATOR|5|isotonic ciclesonide in left nostril and hypotonic ciclesonide in right
62232129|NCT03339128|EXPERIMENTAL|Eluxadoline 25mg|Eluxadoline 25mg, oral administration, twice daily
62232130|NCT03339128|EXPERIMENTAL|Eluxadoline 50mg|Eluxadoline 50mg, oral administration, twice daily
62232131|NCT03339128|EXPERIMENTAL|Eluxadoline 100mg|Eluxadoline 100mg, oral administration, twice daily
62232132|NCT03339128|EXPERIMENTAL|Placebo|Dose-matched placebo, oral administration, twice daily
62232133|NCT03509233|ACTIVE_COMPARATOR|Q-SRP|Quadrant scaling and root planing
62423489|NCT02198755|ACTIVE_COMPARATOR|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI)
62592758|NCT06649318||Group 1|Control group (n=40) Patients with normal thyroid function tests
62592759|NCT06649318||Group 2|Hypothyroid patients group (n=40) . Hypothyroid and treated with Levothyroxine
62592760|NCT04450784||Secondary Acute Myeloid Leukemias (AML) of the child|
62592761|NCT06364501|EXPERIMENTAL|Dose escalation|KH801 will be sequentially escalated at the dose of 0.01 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1.0 mg/kg , 3.0 mg/kg, 6.0 mg/kg , 10.0 mg/kg, administered via intravenous infusion every 2 weeks in 28-day treatment cycles.
62592762|NCT06018025||NPDH (New Persistent Daily Headache)|Patients with new persistent daily headache (NDPH) ages 12-18 years will be recruited and consented by the study coordinator. Patients will be recruited from patients already established with the Duke Pediatric Neurology clinic with a diagnosis of NDPH, or after their initial visit to establish the diagnosis of NDPH through the Duke, pediatric neurology clinics, personal communication and networking, and through the Duke adult headache clinic.
62592763|NCT06018025||Healthy (Normal) Controls|"Children with normal development, aged 12-18 years, will be identified via the electronic health records of well-child visits in Duke Children's Hospital, community advertising and through networking with colleagues and friends.~Exclusion: 1) History of concussion or head injury 2) Psychiatric disorders 3) History of migraines or other headache disorder treated in the past 4) Known structural brain lesions (tumor, hydrocephalus, congenital anomalies)"
62032378|NCT02466022|PLACEBO_COMPARATOR|Normal Saline|Patients will receive 0.1cc/kg Normal Saline bolus delivered over 10 minutes for control arm prior to spinal anesthetic (12.75mg of heavy Bupivicaine and 10ug of Fentanyl) and 0-4mg of Midazolam for rescue sedation
62032379|NCT00622167|OTHER|1|All patients will receive integrated backscatter IVUS and dual source CT.
62232134|NCT03509233|EXPERIMENTAL|FMS|Full mouth scaling and root planing
62423490|NCT05021588|EXPERIMENTAL|Group A:dexamethasone|
62423491|NCT05021588|EXPERIMENTAL|Group B: prednisolone or methyl prednisolone according to D-dimer levels.|
62032380|NCT03079752|ACTIVE_COMPARATOR|Developmental Screening|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age.
62032381|NCT03079752|ACTIVE_COMPARATOR|Screening plus Transportation|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two).
62032382|NCT03079752|ACTIVE_COMPARATOR|Screening, Transport, Prenatal Visits|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy.
62592764|NCT06018025||Chronic Migraine|"Patients between 12-18 yrs of age:~A) Headache (migraine-like or tension-type-like) on ≥15 days/month for \>3 months, and fulfilling criteria B and C, B) Occurring in a patient who has had at least five attacks fulfilling criteria B-D for 1.1 Migraine without aura and/or criteria B and C for 1.2 Migraine with aura C) On ≥8 days/month for \>3 months, fulfilling any of the following (1) criteria C and D for 1.1 Migraine without aura 2) criteria B and C for 1.2 Migraine with aura 3) believed by the patient to be migraine at onset and relieved by a triptan or ergot derivative D) Not better accounted for by another ICHD-3 diagnosis"
62592765|NCT04481230|EXPERIMENTAL|99mTc-NTP 15-5 (level 1)|99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg
62032383|NCT03079752|EXPERIMENTAL|Screen, Transport, Prenatal/Inf Visits|Participants received regular sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy and through child age two.
62032384|NCT01197222|ACTIVE_COMPARATOR|EndoClear used|The EndoClear device is used during a laparoscopic abdominal surgery.
62032385|NCT01197222|NO_INTERVENTION|Control|EndoClear Lens Cleaning Device not used during a laparoscopic abdominal surgery.
62032386|NCT02566031|EXPERIMENTAL|Indacaterol and glycopyrronium (QVA149)|QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 12 weeks
62232135|NCT03509233|EXPERIMENTAL|FMD|Full mouth disinfection
62232136|NCT03509233|EXPERIMENTAL|FMDP|Full mouth disinfection with periopolishing
62423492|NCT05021588|EXPERIMENTAL|Group C: prednisolone or methylprednisolone and anticoagulants according to the flexible protocol.|
62423493|NCT02719782|EXPERIMENTAL|HBV/TCR T cell Infusion|"This is a single-arm study.~Patients will receive a total of 2 cycles, in which first 28-day treatment cycle consists of escalating doses of TCR-T on Day 1, Day 8, Day 15 and Day 22, followed by every 2-week dosing on Day 1, Day 15, Day 29 and Day 43 of second (final) cycle. A one month treatment break will be given between the cycles."
62423494|NCT04141137|EXPERIMENTAL|TricValve® System Single-Arm|Two self-expanding biological valves for implantation into the inferior and superior vena cava.
62592766|NCT04481230|EXPERIMENTAL|99mTc-NTP 15-5 (level 2)|99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg
62592767|NCT04481230|EXPERIMENTAL|99mTc-NTP 15-5 (level 3)|99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
62592768|NCT05996835|EXPERIMENTAL|TIN816 Dose A|Administered as a one time intravenous dose
62592769|NCT05996835|EXPERIMENTAL|TIN816 Dose B|Administered as a one time intravenous dose
62592770|NCT05996835|EXPERIMENTAL|TIN816 Dose C|Administered as a one time intravenous dose
62592771|NCT05996835|PLACEBO_COMPARATOR|Placebo|0.9% sterile saline administered as a one time intravenous dose
62592772|NCT03339193||Patients having LAAC|Patients who meet current clinical criteria for left atrial appendage closure (LAAC), ie have atrial fibrillation, a CHA2DS2-VASc score of 3 or more and a contraindication to long-term oral anticoagulation therapy and who have been approved by the OUH NHS Foundation Trust LAAC Multidisciplinary Team (MDT) as suitable for left atrial appendage occlusion in accordance with National Health Service (NHS) guidelines.
62592773|NCT02041143|EXPERIMENTAL|Milk protein|Study product will provide 25 g of protein to subjects. One single supplement will be taken.
62592774|NCT02041143|PLACEBO_COMPARATOR|Placebo|Placebo (no protein)
62592775|NCT04182269||Study Group|Multiple Sclerosis Patients
62592776|NCT04182269||Control Group|Healthy Subjects
62592777|NCT06602466|EXPERIMENTAL|Test Toothpaste|Participants will brush their teeth with full ribbon of test toothpaste on head of toothbrush for one timed minute twice a day (morning and evening) for 4 weeks.
62808451|NCT01813396|EXPERIMENTAL|joint mobilization/massage|"joint mobilization: End-range joint mobilization~massage: massage twice a week on the identified muscle(s) of the involved shoulder about 6 minutes for each muscle for 3 months. The techniques of massage include petrissage for 3 minutes and rolling for 3 minutes of soft tissues"
62032387|NCT02566031|ACTIVE_COMPARATOR|Tiotropium|Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 12 weeks
62032388|NCT04458610|EXPERIMENTAL|Treatment (zanubrutinib, rituximab)|See Detailed Description.
62808452|NCT01813396|EXPERIMENTAL|joint mobilization/shoulder physical activity guide|joint mobilization: End-range joint mobilization shoulder physical activity guide: shoulder physical activity guide is based on the appropriate cut off activity level identified in the predication rule
62808453|NCT03776695|EXPERIMENTAL|2 mg/kg|Subject will be administered with 2 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
62808454|NCT03776695|PLACEBO_COMPARATOR|2 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
62032389|NCT03455426|EXPERIMENTAL|letrozole group|letrozole 5mg/day starting from day 3 of menstrual cycle for 5 days
62032390|NCT03455426|NO_INTERVENTION|natural cycle group|
62032391|NCT02911948|EXPERIMENTAL|Insulin degludec/liraglutide|
62808455|NCT03776695|EXPERIMENTAL|5 mg/kg|Subject will be administered with 5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
62032392|NCT02911948|ACTIVE_COMPARATOR|Insulin degludec|
62423495|NCT01123980|EXPERIMENTAL|BIAsp 30|0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride
62808456|NCT03776695|PLACEBO_COMPARATOR|5 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
62032393|NCT02176135|EXPERIMENTAL|Dose escalation|Auranofin 3 to 6 mg/day oral administration for 12 weeks
62032394|NCT02345148|EXPERIMENTAL|Cohort 1|Elder participants will receive esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter \[mcl\] of intranasal spray) by intranasal route using nasal spray pump at 0, 5 and 10 minutes on Day 1.
62032395|NCT02345148|EXPERIMENTAL|Cohort 2|Younger adults will receive esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter \[mcl\] of intranasal spray) by intranasal route using nasal spray pump at 0, 5 and 10 minutes on Day 1.
62032396|NCT01116570|EXPERIMENTAL|Physical training|The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. As a result, lower limb muscles will be mainly solicited. These muscles are heterogeneous in terms of deficiency, but this latter is compatible with cycling. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. Over a 2 to 4 weeks initial period, the program will be conducted in the laboratory or at home under the supervision of a coach. Then a systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
62423496|NCT01123980|ACTIVE_COMPARATOR|Insulin glargine|0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride
62423497|NCT01551394|EXPERIMENTAL|Meropenem|"Infants will received the Meropenem 20 mg/kg every 8 hours (every 12 hours in the youngest age group: \< 32 weeks GA and \< 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes.~Treatment duration is 11 ± 3 days."
62423498|NCT01551394|ACTIVE_COMPARATOR|Standard of care|"The two accepted therapeutic options are:~* ampicillin + gentamicin (SOC regimen 1) and~* cefotaxime + gentamicin (SOC regimen 2)."
62423499|NCT03998215|EXPERIMENTAL|Diphtheria booster vaccination|One booster dose of the trivalent vaccine against diphtheria, tetanus and acellular pertussis
62423500|NCT02095626|EXPERIMENTAL|AP301|Treatment group
62423501|NCT02095626|PLACEBO_COMPARATOR|Saline solution|
62423502|NCT03090919|PLACEBO_COMPARATOR|Saline|Subjects randomized to the Saline arm will receive 250cc of physiological saline.
62423503|NCT03090919|EXPERIMENTAL|Platelet transfusion|Subjects randomized to platelet transfusion will receive a unit of platelets (\~250cc in volume).
62423504|NCT01833221|EXPERIMENTAL|Neurotized facial muscle patients|injection of 1% lidocaine, 2mL for facial nerve block
62423505|NCT04427514|EXPERIMENTAL|CAPD group|Standard CAPD therapy wtih telemedicine system
62423506|NCT00876811|EXPERIMENTAL|one-cup|
62423507|NCT00876811|EXPERIMENTAL|two-cups|
62423508|NCT00876811|EXPERIMENTAL|four-cups|
62423509|NCT01098383|PLACEBO_COMPARATOR|Placebo for AChEI and Choline|
62423510|NCT01098383|EXPERIMENTAL|AChEI and Choline|Acetyl-choline Esterase Inhibitor and Choline supplements
62423511|NCT03932435|EXPERIMENTAL|TWLO_C → TWLO|"TWLO_C: Dong-a Bepotastine Besilate Tab (Bepotastine Besilate 10mg), TWLO: Twolion Tab (Bepotastine Besilate 10mg)"
62423512|NCT03932435|EXPERIMENTAL|TWLO → TWLO_C|"TWLO_C: Dong-a Bepotastine Besilate Tab (Bepotastine Besilate 10mg), TWLO: Twolion Tab (Bepotastine Besilate 10mg)"
62423513|NCT01340703|OTHER|optic disc pit maculopathy|
62808457|NCT03776695|EXPERIMENTAL|10 mg/kg|Subject will be administered with 10 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
62423514|NCT04567719||Changes in Taste Perception After Exposure to Chemotherapy|A total of 20 participants with histologically-proven MIBC planning to receive pre-surgery chemotherapy followed by radical cystectomy will be recruited.
62592778|NCT06602466|ACTIVE_COMPARATOR|Reference Toothpaste (Negative Control)|Participants will brush their teeth with full ribbon of reference toothpaste (Colgate Cavity Protection) on head of toothbrush for one timed minute twice a day (morning and evening) for 4 weeks.
62808458|NCT03776695|PLACEBO_COMPARATOR|10 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
62808459|NCT03776695|EXPERIMENTAL|20 mg/kg|Subject will be administered with 20 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
62808460|NCT03776695|PLACEBO_COMPARATOR|20 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
62808461|NCT01538069|NO_INTERVENTION|Control group|
62808462|NCT01538069|EXPERIMENTAL|Exercise group|
62808463|NCT01538069|EXPERIMENTAL|CPAP group|
62808464|NCT01538069|EXPERIMENTAL|Exercise and CPAP group|
62808465|NCT03186300|OTHER|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
62808466|NCT03295396|EXPERIMENTAL|Arm A|ONC201 in relapsed H3 K27M glioma
62808467|NCT03295396|EXPERIMENTAL|Arm B|"ONC201 in relapsed H3 K27M glioma, excluding:~* Primary malignant lesion located in the pons or spinal cord.~* Atypical non-astrocytic histologies such as ependymoma, ganglioma and pleomorphic xanthoastrocytoma, or pilocytic astrocytoma and subependymal giant cell astrocytoma (SEGA).~* Prior bevacizumab treatment of \>4 doses of \>7.5 mg/Kg~* Tumors with known 1p/19q co-deletion."
62808468|NCT01548547|EXPERIMENTAL|LP mastery learning group|
62808469|NCT01548547|ACTIVE_COMPARATOR|IV mastery learning group|
62808470|NCT02418572|EXPERIMENTAL|Transdermal testosterone gel|"Patients will receive once daily application of 0.55 gr TTG (Testosterone gel 1%; Laboratories Besins International,Paris,France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~Pituitary down-regulation will be induced by daily injections of 0.1mg triptorelin started on day 21 of the next cycle following enrollment in the study, up to and including the day of hCG administration.~After 2 weeks of down-regulation, daily SC injections of HP-hMG (Menopur®) (300 IU/day) will be administered up to the day of hCG administration.~Ovulation triggering will be induced with 250μg rhCG (Ovidrelle®) followed by oocyte pick-up \~36 hours later and ICSI. A maximum of 2 embryos, following each center's national criteria of single embryo transfer, will be transferred 3 days later.~Luteal phase support with be performed with progesterone tablets ( Utrogestan®) (200mg x3, intravaginally)."
62808471|NCT02418572|PLACEBO_COMPARATOR|Placebo transdermal gel|"Patients will receive once daily application of 0.55 gr identical placebo gel starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~Pituitary down-regulation will be induced by daily injections of 0.1mg triptorelin started on day 21 of the next cycle following enrollment in the study, up to and including the day of hCG administration.~After 2 weeks of down-regulation, daily SC injections of HP-hMG (Menopur®) (300 IU/day) will be administered up to the day of hCG administration.~Ovulation triggering will be induced with 250μg rhCG (Ovidrelle®) followed by oocyte pick-up \~36 hours later and ICSI. A maximum of 2 embryos, following each center's national criteria of single embryo transfer, will be transferred 3 days later.~Luteal phase support with be performed with progesterone tablets ( Utrogestan®) (200mg x3, intravaginally)."
62808472|NCT03520881|EXPERIMENTAL|Pediatric ASTHMA-Educator arm|This arm corresponds to the pediatric version of the ASTHMA-Educator mobile application.
62808473|NCT00644358|EXPERIMENTAL|Vilazodone|Vilazodone titrated up to 40 mg/day for 1 year.
62808474|NCT06256978||Critical care patients|
62808475|NCT01571102|ACTIVE_COMPARATOR|physiotherapy|Promote mobility, strength and stability and exercises to reduce pain and swelling depending on the phase of tissue repair and evolution of the patient.
62808476|NCT01571102|NO_INTERVENTION|Rest|
62423515|NCT02345863|EXPERIMENTAL|Bendamustine + GA101 + Ibrutinib|"Bendamustine 70mg/m² i´v~GA101: 1000 mg iv~Ibrutinib: 420 mg po daily"
62423516|NCT04313686|EXPERIMENTAL|Mindfulness-based therapy|The mindfulness training program included mindfulness meditation practices, self-enquiries, mindful movement as well as understanding of stress physiology and cognitive awareness in the Breathworks/ Paradigm system of mindfulness-based approaches. Participants were enrolled in 5-10-person groups that met weekly for 2-3-hour long sessions for six weeks at the patient's usual follow-up clinic.
62808477|NCT01571102|ACTIVE_COMPARATOR|Home exercises|Promote mobility, strength and stability and exercises to reduce pain and swelling depending on the phase of tissue repair and evolution of the patient.
62808478|NCT06394037||Observation|Active surveillance
62808479|NCT03833492|EXPERIMENTAL|Underwater EMR|"The patients who are randomized to the  Underwater EMR arm polypectomy with water will be performed under full water emersion without the use of submucosal injection."
62423517|NCT04313686|ACTIVE_COMPARATOR|No-Intervention|The control group would attend their routine follow-up visits at the neurology outpatient clinic.
62423518|NCT03663959||Vaginal Sacrospinous Fixation group|Women who had vaginal sacrospinous fixation procedure with Dr.Aksakal's Desta suture carrier in our clinic between January 2014 and June 2018.
62032397|NCT01116570|OTHER|control|None intervention
62808480|NCT03833492|NO_INTERVENTION|Traditional EMR|"The patients who are randomized to the  Traditional EMR arm polypectomy will be performed with selective saline injection to the layer of tissue underneath the polyp in order to create a safety cushion for resection."
62808481|NCT06143358|EXPERIMENTAL|treatment group|Qingkepingchuan Granules+Conventional basic therapy
62032398|NCT01694862|EXPERIMENTAL|Integrated FP /PNC service delivery|Clinic or district identified as 'intervention' in which FP and PNC services are (theoretically) being provided together with HIV services (counselling, testing, treatment etc.) and in which the procedural intervention has been applied.
62232137|NCT05664386|ACTIVE_COMPARATOR|propofol group|According to grouping，patients were premeditated with injection of Propofol 2-2.5mg / kg IV . If BIS is ≤ 60, Tracheal intubation was facilitated with cisatracurium 0.2mg/kg a IV and sufentanil 0.3 μ g / kg IV. if BIS is \>60, propofol 1mg/kg was titrated intravenously, with an interval of more than 1min until the BIS is ≤ 60，and intubation was performed after cisatracurium and sufentanil injected .General anesthesia was maintained with Propofol and remifentanil.Then propofol was maintained in group P at 4-12 mg/kg/h and remifentanil was maintained at 0.1-0.3 ug/kg/min .BIS was kept at 40 \~ 60 during the surgery, and infusion drugs were stopped at the end of the operation. The patients were Transfered to Postanesthesia care unit(PACU) after the operation.
62808482|NCT06143358|OTHER|control subjects|Conventional basic therapy
62808483|NCT04551040|EXPERIMENTAL|Primary Cohort|Titrating doses of terazosin starting at 1mg daily and increasing to 5mg daily on a weekly basis for five weeks.
62808484|NCT02971917|EXPERIMENTAL|Clinical study of TRUVIEW ART|Chest x-ray image acquisition Creation of TRUVIEW ART applied image Comparison of TRUVIEW ART image with original image
62808485|NCT01882673|EXPERIMENTAL|Brief Computer Motivational Interviewing for Smoking Cessation|Brief computer motivational interviewing intervention to motivate tobacco quitline use
62808486|NCT01882673|ACTIVE_COMPARATOR|Nutrition Control|Computer delivered nutrition education
62808487|NCT03400618|EXPERIMENTAL|Moderate carbohydrate diet|A healthy diet containing 30 E % carbohydrates
62032399|NCT01694862|NO_INTERVENTION|Non-integrated FP/PNC service delivery|Clinic or district where FP and PNC services are not (theoretically) being provided together with HIV services, and in which no procedural intervention has been applied.
62032400|NCT04029922|EXPERIMENTAL|Part A- Dose Escalation|"Part A- Dose Escalation in patients with previously treated advanced HER2-positive solid tumors.~The assigned dose level of MT-5111 will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e., on day 1, day 8 and day 15 of each cycle)."
62423519|NCT03663959||Laparoscopic Pectopexy Group|Women who had Laparoscopic Pectopexy procedure in our clinic between January 2014 and June 2018
62808488|NCT03400618|EXPERIMENTAL|Higher carbohydrate diet|A healthy diet containing 50 E % carbohydrates
62808489|NCT05599308|ACTIVE_COMPARATOR|Atrial fibrillation (AFib)|Patient with known history of AFib who are in AFib at the time of study screening.
62808490|NCT05599308|ACTIVE_COMPARATOR|Non-Afib|Patient with no known diagnosis of AFib
62808491|NCT03167385|EXPERIMENTAL|Experitmental|Continuous oral intake of Apatinib Mesylate (500mg), once a day, until progression of disease or severe adverse effect.
62808492|NCT00657540|EXPERIMENTAL|Analatro|Antivenin Latrodectus (Black Widow) Equine Immune F(ab)2
62032401|NCT04029922|EXPERIMENTAL|Part B- Dose Expansion|"Part B - Dose Expansion in previously treated HER2-positive breast, GEA and other HER2-positive solid cancers~Part B will include 3 expansion groups: Group B1 (Breast Cancer) will begin enrolling while Part A is being conducted following the completion of Cohort 7 and Subsequent cohort of subjects in group B1 may enroll into higher doses that are tolerated in Part A. Group B2 (GEA) and Group B3 (Other HER-2 positive solid cancer groups) will begin enrollment after the MTD or RP2D is determined in Part A.~The assigned dose level of MT-5111 will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e., on day 1, day 8 and day 15 of each cycle)."
62808493|NCT00657540|PLACEBO_COMPARATOR|Normal Saline Placebo|Normal Saline
62808494|NCT02756481||NVAF Treatment patterns|"Treatment patterns will be collected during the follow-up period. Data will be directly extracted from medical charts of the arrhythmia unit.~Anticoagulation use will be reported as drug class: Vitamin K antagonist, antiplatelet, nonsteroidal anti-inflammatory drugs. The following data on anticoagulation use will be collected:~* Type of treatment, start \& stop dates, dosage, administration schedule, method of administration, reason for discontinuation if applicable~* Type of therapy utilized (monotherapy/combination therapy)~* Total number of therapy changes or switches through the course of treatment~  * Monitoring visit (visits per month) for International normalized ratio (INR) control by Time in Therapeutic Range(cTTR)~ * Routine care (visits per month) by anticoagulation regimen"
62808495|NCT06423365|NO_INTERVENTION|Usual care|Participants randomized to usual care will continue to receive usual care at Kaiser Permanente Colorado as they would under normal, non-study conditions.
62819526|NCT06409169|ACTIVE_COMPARATOR|Usual Care|At usual care sites, participants either self-report a known history of untreated HCV or undergo peer-performed point-of-care HCV antibody testing or DBS for HCV testing. Peers take those with positive results to local laboratories for a confirmatory blood draw prior to treatment initiation, the results of which are received and managed by PATHS providers. When active HCV is diagnosed, PATHS staff coordinate on-demand telemedicine visits with peers and participants, during which PATHS clinicians recommend treatment. Participants will complete transient elastography after treatment initiation.
62819527|NCT06433999|EXPERIMENTAL|Brepocitinib|
62592779|NCT04040452|EXPERIMENTAL|Treatment|"1. Description: Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte). To eliminate excess exposure and the associated side effects, all patients enrolled in the study will not be given any additional NSAIDs (except aspirin, which is standard of care in many post-operative cardiac surgery patients) during the study period.~2. Dosage and Route of Administration:~   1. Continuous ketorolac 0.08mg/kg/hr, with a maximum of 5mg/hr for patients weighing greater than or equal to 60kg, administered intravenously by nursing staff. Study drug will infuse continuously for 48 hours.~  2. Intermittent Plasmalyte 0.033mL/kg (max 2mL) infusion every 6 hours for 48 hours."
62423520|NCT01874730|OTHER|Standard of Care (SOC)|Intraoperative fluid management includes Volulyte® (6% hydroxyethyl starch {HES} 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg. Intraoperative anesthesia and postoperative analgesia will follow the established practice of the individual institution.
62592780|NCT04040452|PLACEBO_COMPARATOR|Standard of care|"1. Description: Patients randomized to the standard of care arm of the study will receive a generically marked syringe of Plasmalyte to be infused at the same rate as the treatment medication, and will only receive intermittent dosing of ketorolac (current standard of care). As in the treatment group, no additional NSAIDs (except aspirin) are to be given during the 48 hour study period.~2. Dosage and Route of Administration~   1. Continuous Plasmalyte infusion to match the aforementioned ketorolac dosing~  2. Intermittent ketorolac 0.5mg/kg IV infusion every 6 hours (max 30mg per dose)"
62592781|NCT04901351|EXPERIMENTAL|Patients chronically infected with HPV|The study will be offered to patients with chronic HPV infection as part of an annual consultation scheduled in the gynecology care package.
62592782|NCT01539551||1|sepsis and septic shock patients
62808496|NCT06423365|EXPERIMENTAL|Usual Care + Virtual Statin Management (VSM)|Participants randomized to usual care + virtual statin management (VSM) will continue to receive usual care at Kaiser Permanente Colorado as they would under normal, non-study conditions, and they will also be given a link to engage with the VSM website. The VSM website is an educational tool which has four principal components: 1) learning how to distinguish if and when muscle symptoms are caused by the statin; 2) learning the essentials about heart disease, focusing on causes, risk factors, and the crucial role of cholesterol management in prevention; exploring various cholesterol lowering options, including when it makes sense to retry a statin and what options exist beyond statins; and 4) learning to engage in productive discussions with healthcare providers and set effective treatment goals together.
62808497|NCT01383603|EXPERIMENTAL|Cat-PAD|
62808498|NCT05454774|EXPERIMENTAL|Arm of BBM 002|1×10\^13 vg/kg, Single-dose treatment.
62808499|NCT00756249|EXPERIMENTAL|Lu AA24493 (CEPO): 0.005 mcg/kg|
62423521|NCT01874730|ACTIVE_COMPARATOR|Enhanced Recovery Strategy (ERS) group|GDFT regimen using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg. Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
62423522|NCT05282823||Treatment Subjects|Subjects will be clinically indicated for pulmonary vein isolation ablation procedure (in compliance with instructions for use (IFU)/Tenpubunsyo as legally approved conditions) for the treatment of paroxysmal AF.
62592783|NCT06660745|EXPERIMENTAL|Intervention Group|Intervention Group includes 25 children and their caregivers. interventional content with educational-practical and care-support model is in the form of an audio-visual file or an educational text (5-10 minutes) within a period of three months and through the content link (Send Big website) to the email address or number. It will be sent to teenager or caregiver of children with Cystic fibrosis, and after observation, remote follow-up will be done twice a week on the Skype platform, and the researcher will answer All of the questions that relate to contents. The content included topics related to various aspects of the disease and its management, Adjusting and moderating the physical activity program, medication regimen, Nutrition, and mental health.
62592784|NCT06660745|NO_INTERVENTION|Control group|in control group, No intervention will take place and the patients will receive their routine treatment plan.
62592785|NCT06667037|EXPERIMENTAL|Ortho-k and 0.01% atropine sequential treatment|Participants will be treated with ortho-k lenses during the first year, and swiched to recieve 0.01% atropine twice a day in the second year.
62592786|NCT06667037|ACTIVE_COMPARATOR|Ortho-k continuous treatment|Participants will be treated with ortho-k lenses throughout, during the 2-year study period.
62592787|NCT05290909|EXPERIMENTAL|The protocol of blended and problem-based learning|The experimental group will accept the protocol of blended and problem-based learning in the professional ethics course, 2 hours /per week, for 18 weeks
62592788|NCT05290909|ACTIVE_COMPARATOR|The traditional problem-oriented teaching model|The control group will accept the traditional problem-oriented teaching model in the professional ethics course, 2 hours /per week, for 18 weeks
62592789|NCT06647589|EXPERIMENTAL|Acceptance and Commitment Therapy|Participants will receive eight consecutive weeks of acceptance and commitment therapy
62808500|NCT00756249|EXPERIMENTAL|Lu AA24493 (CEPO): 0.05 mcg/kg|
62808501|NCT00756249|EXPERIMENTAL|Lu AA24493 (CEPO): 0.5 mcg/kg|
62808502|NCT00756249|EXPERIMENTAL|Lu AA24493 (CEPO): 5.0 mcg/kg|
62808503|NCT00756249|EXPERIMENTAL|Lu AA24493 (CEPO): 50.0 mcg/kg|
62232138|NCT05664386|EXPERIMENTAL|ciprofol group|Group C was given ciprofol 0.4 \~ 0.5mg/kg, if bispectral index(BIS) value ≤60 during anesthesia induction, cisatracurium 0.2mg/kg and sufentanil 0.5μg/kg were injected intravenously, endotracheal intubation was performed after the improvement of muscle relaxation. If the BIS value was greater than 60, ciprofol 0.2mg/kg each time, and the interval of administration was greater than 1min, until BIS≤60. Cisatracurium and sufentanil were injected intravenously, followed by endotrachealintubation.Ciprofol was maintained in Group C at 0.8-2.5 mg/kg/h and remifentanil was maintained at 0.1-0.3 ug/kg/min . Intermittent addition of cisatracurium,Sufentanil was added as required, and total dosage of Sufentanil was 0.7ug \~ 1ug/kg. BIS was kept at 40 \~ 60 during the surgery, and infusion drugs were stopped at the end of the operation. The patients were Transfered to Postanesthesia care unit(PACU) after the operation.
62232139|NCT02622958|EXPERIMENTAL|PH94B Nasal Spray|Water based solution of 16 ppm PH94B. Each nasal spray delivers .8 micrograms PH94B in 50 microliters
62232140|NCT02622958|PLACEBO_COMPARATOR|Placebo Nasal Spray|Water based solution, each nasal spray delivers 50 microliters of droplets.
62232141|NCT06531161|EXPERIMENTAL|Experimental: Suxiao Jiuxin Pill group|Participants who are randomly assigned to Suxiao Jiuxin Pill group will receive Suxiao Jiuxin Pills (6 pills per time, 3 times a day, taken sublingually) for 4 days at sea level and another 3 days at high altitude.
62232142|NCT06531161|PLACEBO_COMPARATOR|Placebo: Placebo group|Participants who are randomly assigned to Placebo group will receive placebo (6 pills per time, 3 times a day, taken sublingually) for 4 days at sea level and another 3 days at high altitude.
62808504|NCT00756249|PLACEBO_COMPARATOR|Placebo|
62232143|NCT06473129|EXPERIMENTAL|Food for Life Culinary Workshop|winning Food for Life (FFL) classes are 2 hours and include: 1 hour of education and 1 full hour of a culinary demonstration. All participants receive printed program guidebooks with resources and recipes. Each language specific cohort will have (15 in-person dyads) for a total of 30 participant-care partner dyads (N=60). 2 care partner roundtable sessions at week 3 and week 6 are also included.
62232144|NCT03603028|EXPERIMENTAL|Exergaming|
62423523|NCT03963700||Cancer patients with Paraneoplastic neurological syndromes|"Cancer patients with Paraneoplastic neurological syndromes presenting various autoimmune anomalies:~* Anti-Hu also known as anti-Neuron specific cell Nuclear Antibodies (anti-ANNA1) (350 patients), uncommon form of brain inflammation associated with an underlying cancer~* anti-Yo (130 patients), antibody associated with paraneoplastic cerebellar degeneration~* anti-Ma2 (50 patients), antibody associated with paraneoplastic encephalitis~* anti-N-methyl-d-aspartate (NMDA) Receptor (350 patients), autoimmune disorder in which antibodies attack N-methyl-D-aspartate-type glutamate receptors~* anti-gamma-aminobutyric acid-B (GABAb) receptor (35 patients), autoimmune disorder in which antibodies attack gamma-aminobutyric acid-B receptors~* anti-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor (15 patients), autoimmune disorder in which antibodies attack alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors~* without antibodies (50 patients)."
62032402|NCT06237972|EXPERIMENTAL|FES group|This group will conduct the experimental protocol using neuromuscular electrical stimulation during the training.
62423524|NCT03205007|EXPERIMENTAL|Health promotion nutrition program|Health promotion nutrition program
62423525|NCT04499690||Global CALM Training Program Clinicians|Clinicians engaging in the CALM Training Program.
62808505|NCT06473922||General anasthesia|Patients who are about to undergo surgery to extract wisdom teeth or no more than 3 implants in the jaw under general anesthesia in a hospital operating room.
62808506|NCT06473922||Regional anesthesia|Patients who are about to undergo surgery to extract wisdom teeth or no more than 3 implants in the jaw under regional anesthesia in the dental clinic
62808507|NCT00587717|ACTIVE_COMPARATOR|1|Two 80 mg pills simvastatin taken 24 hours prior to surgery
62808508|NCT00587717|PLACEBO_COMPARATOR|2|Two 80 mg pills placebo are taken 24 hours prior to surgery
62232145|NCT03898947||Tamoxifen users|Women undergoing therapy with Tamoxifen after surgery for breast cancer.
62232146|NCT03898947||Aromatase inhibitors|Women undergoing therapy with Aromatase Inhibitors after surgery for breast cancer.
62232147|NCT03898947||No treatment|Women who did not undergo any hormonal therapy after surgery for breast cancer.
62808509|NCT02655848|ACTIVE_COMPARATOR|@ Cuff repair with LHB tenodesis|In case of pathologic changes of the long Head Biceps tendon, a tenodesis is performed in adjunct to performing an arthroscopic rotator cuff repair.
62232148|NCT04326504||Patients starting DTG-based regimens|ART-naïve patients, starting cART regimens based on DTG
62232149|NCT04326504||Switch cohort|Patients on stable ART regimens switching to DTG (any reason)
62232150|NCT04326504||Therapy failure|ART-experienced patients switching to DTG-containing regimens due to virological failure
62592790|NCT05390151|ACTIVE_COMPARATOR|Laser assisted fistula closure|Group to be actively treated with laser assisted fistula surgery
62592791|NCT05390151|ACTIVE_COMPARATOR|Rectal advancement flap|Group to be actively treated with a rectal advancement flap.
62808510|NCT02655848|ACTIVE_COMPARATOR|@ cuff repair with LHB tenotomy|In case of pathologic changes of the long Head Biceps tendon, a tenotomy is performed in adjunct to performing an arthroscopic rotator cuff repair.
62808511|NCT03743441|ACTIVE_COMPARATOR|Exercise + Cryotherapy + LLLT|
62808512|NCT03743441|SHAM_COMPARATOR|Exercise + Cryotherapy + Sham LLLT|
62808513|NCT00980187|ACTIVE_COMPARATOR|Hydrochlorothiazide|
62423526|NCT02148731||Comprehensive Geriatric Assessment (CGA)|Functional status, Comorbidities, Objective physical performance, Nutrition, Cognition, Depression, Social support
62592792|NCT00405522|EXPERIMENTAL|Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg|
62808514|NCT00980187|EXPERIMENTAL|Indapamide SR|
62808515|NCT03414775|ACTIVE_COMPARATOR|Pediasure|Patients assigned to this arm will receive Pediasure
62592793|NCT00405522|EXPERIMENTAL|Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg|
62592794|NCT00154778|EXPERIMENTAL|A|
62032403|NCT06237972|ACTIVE_COMPARATOR|No-FES group|This group will conduct the experimental protocol without using neuromuscular electrical stimulation during the training.
62032404|NCT05585723||students at the university|
62808516|NCT03414775|ACTIVE_COMPARATOR|Nourish|Patients assigned to this arm will receive Nourish
62808517|NCT06181526|EXPERIMENTAL|Intrathecal administration combined with intravenous administration of Aleeto(0.5μg/kg) or placebo|"Four patients will be randomly assigned to the treatment group and the placebo group. 3 patients will receive intrathecal administration combined with intravenous administration of 0.5 μg/kg Aleeto and sodium chloride, while another patient will receive the same dose of placebo.~Day 1-12: Intrathecal administration of Aleeto will be conducted on Days 1, 4, 8, and 11, and intravenous administration of Aleeto on Days 2, 3, 5, 6, 9, 10, 12, and 13.~Day 31-36: Intrathecal administration of Aleeto will be conducted on Days 31 and 34, and intravenous administration of Aleeto on Days 32, 33, 35, and 36.~D61-66: Intrathecal administration of Aleeto will be conducted on Days 61 and 64, and intravenous administration of Aleeto on Days 62, 63, 65, and 66."
62808518|NCT06181526|EXPERIMENTAL|Intrathecal administration combined with intravenous administration of Aleeto (1μg/kg) or placebo|"Seven patients will be randomly assigned to the treatment group and the placebo group. 6 patients will receive intrathecal administration combined with intravenous administration of 1μg/kg Aleeto and sodium chloride, while another patient will receive the same dose of placebo.~Day1-12: Intrathecal injection of Aleeto would be given on Day 1, 4, 8, and 11, and intravenous injection of Aleeto on Day 2, 3, 5, 6, 9, 10, 12, and 13.~Day31-36: Intrathecal injection of Aleeto would be given on Day 31 and 34, and intravenous injection of Aleeto on Day 32, 33, 35, and 36.~D61-66: Intrathecal injection of Aleeto would be given on Day 61 and 64, and intravenous injection of Aleeto on Day 62, 63, 65, and 66."
62808519|NCT06181526|EXPERIMENTAL|intrathecal injection and intravenous injection of Aleeto (2μg/kg) or placebo|"Seven patients will be randomly assigned to the treatment group and the placebo group. 6 patients will receive intrathecal administration combined with intravenous administration of 2μg/kg Aleeto and sodium chloride, while another patient will receive the same dose of placebo.~Day1-12: Intrathecal injection of Aleeto would be given on Day 1, 4, 8, and 11, and intravenous injection of Aleeto on Day 2, 3, 5, 6, 9, 10, 12, and 13.~Day31-36: Intrathecal injection of Aleeto would be given on Day 31 and 34, and intravenous injection of Aleeto on Day 32, 33, 35, and 36.~D61-66: Intrathecal injection of Aleeto would be given on Day 61 and 64, and intravenous injection of Aleeto on Day 62, 63, 65, and 66."
62032405|NCT05585723||teenagers|
62032406|NCT05585723||parents of teenagers|
62032407|NCT02910648|EXPERIMENTAL|Approach/Inhibit group|"Participants in the experimental group and control sham sound cues group will complete the Modified Go/No-Go Task.~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
62032408|NCT02910648|SHAM_COMPARATOR|Sham sound cues group|"Participants in the experimental group and control sham sound cues group will complete the Modified Go/No-Go Task.~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
62423527|NCT00089310|EXPERIMENTAL|Sentinal node mapping|
62592795|NCT05645419|EXPERIMENTAL|personalized chronoprevention|the main group (n=30), where patients with T2D, in addition to their traditional prescriptions, will receive the intervention method of personalized chronoprevention
62592796|NCT05645419|NO_INTERVENTION|traditional prescriptions|the control group (n=30), where patients with T2D will only be under observation in addition to their traditional prescriptions
62592797|NCT03999736|EXPERIMENTAL|Treatment|"14 sessions x 30 minutes of 2mA transcranial direct current stimulation to the dorsolateral prefrontal cortex.~10 x sessions over the course of the initial two weeks (e.g. 5 x per week with flexibility).~4 x sessions over the course of a two week maintenance treatment."
62592798|NCT01345981|EXPERIMENTAL|lidocaine 20 mg|intravenous lidocaine
62592799|NCT01345981|EXPERIMENTAL|lidocaine 40 mg|intravenous lidocaine 40 mg
62592800|NCT01345981|PLACEBO_COMPARATOR|normal saline|2 ml
62592801|NCT05888389|ACTIVE_COMPARATOR|General anesthesia (GA)|The GA group will receive general anesthesia.
62592802|NCT05888389|EXPERIMENTAL|Cranial nerve block anesthesia combined with sedative anesthesia (CNB-D)|The CNB-D group will receive cranial nerve block anesthesia combined with sedative anesthesia
62592803|NCT03775863||Latin American multicenter Cohort|Transplanted patients with HCC in LATAM from 2005-2011
62592804|NCT03775863||French mutlicenter Cohort|Transplanted patients with HCC in France from 2003-2005
62592805|NCT03775863||Italian multicenter Cohort|Transplanted patients with HCC in Italy from 2005-2011
62032409|NCT02910648|SHAM_COMPARATOR|Sham go/no-go group|"Participants in the control sham go/no-go group will complete a modified Go/No-Go Task with sham approach and inhibit items.~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
62423528|NCT02572973|ACTIVE_COMPARATOR|Active Treatment|The Acoustic Neuromodulation (ANM) active treatment intervention is a non-invasive form of therapy in which certain sounds at certain intervals are delivered to a subject through headphones five times over the course of two weeks. The sounds are delivered for 12 minutes at each session. The level of sound during Sound Stimuli (SS) presentation is relatively low (20-40 decibels), and the volume level can be adjusted downward if the subject requests it. The active intervention sounds used in the trial couple sequential frequencies to the base frequency in a nonlinear (exponential) manner following a special algorithm developed by Dr. Izvarina. This algorithm varies both the rate of change and duration of the overlaying modulation that is presented to the brain.
62592806|NCT02372929||Endoscopic Ultrasound Staging|Prospective study of esophageal cancer patients referred for endoscopic ultrasound
62592807|NCT02898727|OTHER|Local Therapy|"The local therapy offered will be determined by the participant's doctor in consultation with the site multidisciplinary team and will be dependent on the size and location of the brain metastases.~Neurosurgery: The surgery may be performed up to 6 weeks before participant being registered on the trial or up to 4 weeks after registration.~Sometimes stereotactic radiosurgery is required to be delivered to the cavity left after the metastasis has been removed (Cavity Boost).~Stereotactic Radiosurgery: Treatment is to commence within 4 weeks of study registration. The size, number and location of the brain metastasis will determine the dose and fractionation schedule of radiotherapy."
62592808|NCT06359171|NO_INTERVENTION|Control|Standard care
62808520|NCT06181526|EXPERIMENTAL|intravenous injection of Aleeto (2μg/kg)|"Six patients will receive intravenous administration of 2 μg/kg Aleeto and sodium chloride.~Day1-12: Patients would be given intravenous injection of Aleeto(2μg/kg) +100ml sodium chloride for 12 days (Day 1 to 6, 8 to 13) once a day.~Day31-36: Patients would be given intravenous injection of Aleeto(2μg/kg) +100ml sodium chloride for 6 days (Day 31 to 36) once a day.~D61-66: Patients would be given intravenous injection of Aleeto(2μg/kg) +100ml sodium chloride for 6 days (Day 61 to 66) once a day."
62232151|NCT04326504||Non-DTG group|Patients who started a non-DTG containing regimen
62232152|NCT03832634|OTHER|Fetal Genome Profiling|Trophoblast cells will be collected from the cervix approximately 5-6 weeks once pregnancy is achieved.
62232153|NCT05053425|EXPERIMENTAL|Venetoclax group|"Induction therapy: venetoclax d1 100mg, d2 200mg, d3-28 400mg, po; azacytidine 75mg/m2, d1-7, sc.~Consolidation therapy: Regimen A or B was chosen according to the wishes of the patients. In addition, venetoclax was used for 14 days for positive minimal residual disease(MRD) and 7 days for MRD negative.~regimen A: the first two cycles: venetoclax 400mg, d1-7/14, po; cladribine 5mg/m2, d1-3, ivgtt; cytarabine 10mg/m2, q12h, d1-10, sc; the last two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 0.5-1.0g/m2, d1-3, ivgtt; regimen B: the first two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 100mg/m2, d1-5/7, ivgtt; idarubicin 8mg/m2, d1-2/3, ivgtt; the last two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 0.5-1.0g/m2, d1-3, ivgtt; If the patient's ECOG performance status ≥2,the reduction of regimen IA(cytarabine+idarubicin)was 5+2.~Maintenance therapy: azacytidine 75mg/m2, d1-7, sc."
62232154|NCT05968547||Glaucoma patients questionnaire|Questionnaire to understand patients driving needs and understanding of driving vision standards
62232155|NCT05968547||Visual acuity standards|DVLA vision standard estimated in the clinic is compared with standandard car number plate outside the clinic. We estimate the vision in the clinic using standard visual acuity chart and electronic number plate vision and compare with number plate vision estimated outside the clinic by the patient. Instruction to estimate number plate vision will be provided to the patient.
62232156|NCT02095951|EXPERIMENTAL|Pre-emptive Ethanol Lock Therapy Group|Participants receive ethanol lock before blood cultures grow germ
62232157|NCT02095951|ACTIVE_COMPARATOR|Standard Ethanol Lock Therapy Group|Participants receive ethanol lock if and only after blood cultures grow germ
62232158|NCT00882427|EXPERIMENTAL|eMPC|improved model predictive control algorithm (eMPC) for glycaemic control in ICU patients
62232159|NCT02358382|NO_INTERVENTION|Alpha Stat|Standard CPB blood gas management conditions
62808521|NCT03527849|EXPERIMENTAL|In-Person MBSR Course|
62032410|NCT05290350||OSA Cohort|Patients With post COVID-19 condition and OSA
62032411|NCT05290350||Control Cohort|Patients With post COVID-19 condition without OSA
62232160|NCT02358382|EXPERIMENTAL|pH Stat|pH stat blood gas management conditions.
62592809|NCT06359171|EXPERIMENTAL|Experimental group|Standard care and participants use the ARTH-e application for 6 months
62808522|NCT03527849|EXPERIMENTAL|Online MBSR Course|
62808523|NCT03527849|ACTIVE_COMPARATOR|In-Person HEP|
62808524|NCT00672555|EXPERIMENTAL|Pilonidal Sinus T. With Limberg F.|All patients treated by excision and covering of the defect by a Limberg-flap, who gave their informed consent to participate in the study, as there is only one study group.
62032412|NCT02191982|EXPERIMENTAL|Intervention|This arm will begin the Walk With Ease program after the completion of chemotherapy.
62808525|NCT02306746|EXPERIMENTAL|TARGET protocol EN 1.5 kcal/mL|Enteral (EN) feed 1.5 kcal/mL. The goal rate for administration of TARGET protocol EN is 1ml/kg/hr. To calculate the goal rate, weight is based on ideal body weight.
62592810|NCT00416130|EXPERIMENTAL|Vorinostat|A phase I portion that will determine the safety of 400mg Vorinostat once a day, continuously in the Asian population. A pre-determined dose reduction schema will be followed in the event of significant dose-limiting toxicities at this dose. Phase II will recruit additional patients at the determined dose with the goal of evaluating drug efficacy.
62592811|NCT05451784|EXPERIMENTAL|PD1+ TILs (NUMARZU-001) product infusion|The treatment administration is divided in NMA-LD chemotherapy(auxiliary medication), TILs product (IMP) and IL-2 (auxiliary medication).
62592812|NCT06174038|OTHER|Hearing Intervention|Participants will receive 4 sessions across 8 weeks with a later booster session and hearing aid fitting. Each session will take \~75 minutes.
62808526|NCT02306746|ACTIVE_COMPARATOR|TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL The goal rate for administration of TARGET protocol EN is 1ml/kg/hr. To calculate the goal rate, weight is based on ideal body weight.
62808527|NCT01431612|ACTIVE_COMPARATOR|Esmolol|50 µg/kg/min of the ß-1-receptor-blocker esmolol (Qilu Pharmaceutical Co, Shandong, China) wss infused intravenously over 3 hours
62808528|NCT01431612|ACTIVE_COMPARATOR|Phenylephrine|Intravenous infusion of 0.01 µg/kg/min of phenylephrine (alpha1-adrenergic agonist) over 3 hours.
62032413|NCT02191982|ACTIVE_COMPARATOR|Wait List Control|The arm will begin the Walk With Ease program three months after completion of chemotherapy.
62032414|NCT01972841|EXPERIMENTAL|1: Solifenacin 5 mg + Mirabegron 25 mg|Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.
62423529|NCT02572973|PLACEBO_COMPARATOR|Non-Active Placebo|The Acoustic Neuromodulation (ANM) treatment intervention is a non-invasive form of therapy in which certain sounds at certain intervals are delivered to a subject through headphones five times over the course of two weeks. The sounds are delivered for 12 minutes at each session. The placebo sounds used in this trial mimic the active sounds, but instead of using nonlinear modulation, they are coupled to the base frequency in a linear manner. Both the sequence used as well as the rate of change and duration of this overlaying modulation are the same as that used for the active sounds. The only difference is use of a linear algorithm for the placebo sounds and a nonlinear (exponential) algorithm for the active sounds.
62423530|NCT05521087|EXPERIMENTAL|Arm A: <2 Years Old|Participants aged less than (\<) 2 years old in dose escalation portion of the study will receive JNJ-75276617 orally on a 28-day cycle. Starting dose of JNJ-75276617 is based on the adult dose from the ongoing study NCT04811560 with additional dose reductions based on age. Further dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by study evaluation team (SET) until the recommended Phase 2 Doses (RP2Ds) has been identified. Participants in dose expansion portion of the study will receive JNJ-75276617 orally at one of the RP2D(s) determined in dose escalation portion of the study, in 3 cohorts divided on the basis of disease diagnosis. Participants with acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (ALL) will receive conventional chemotherapy backbone regimen (dexamethasone, vincristine, pegaspargase, fludarabine, cytarabine and intrathecal chemotherapy) in combination with JNJ-75276617.
62423531|NCT05521087|EXPERIMENTAL|Arm B: >=2 Years Old|Participants aged greater than or equal to (\>=) 2 years old in dose escalation portion of the study will receive JNJ-75276617 orally on a 28-day cycle. Starting dose of JNJ-75276617 is based on the adult dose from the ongoing study NCT04811560 with additional dose reductions based on age. Further dose levels will be escalated based on the DLT evaluation by SET until the RP2Ds has been identified. Participants in dose expansion portion of the study will receive JNJ-75276617 orally at one of the RP2D(s) determined in dose escalation portion, in 3 cohorts divided on the basis of disease diagnosis. Participants with AML and B-cell ALL will receive conventional chemotherapy backbone regimen (dexamethasone, vincristine, pegaspargase, fludarabine, cytarabine and intrathecal chemotherapy) in combination with JNJ-75276617.
62423532|NCT03121469|EXPERIMENTAL|Per-Operative Radiotherapy|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
62423533|NCT00996632|EXPERIMENTAL|A|Patients were operated using an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
62423534|NCT00996632|ACTIVE_COMPARATOR|B|Patients were operated using a conventional diarthermy knife
62423535|NCT05983029||Study Group|Each patient will be requested to adopt a standardised upright position. First, two of the investigators will use a spirit level ruler and ink pen to agree upon and visibly mark the horizontal intercristal line on the back of the patient. Second, investigator B will leave the room, and investigator A will make a vertical mark with an ultraviolet pen denoting the intersection of the inferior aspect of the intergluteal cleft and the horizontal intercristal line. Third, investigator A will then leave the room, and investigator B will return to the room to make a vertical mark with an ink pen representing the intersection of the neuraxial midline, as established with the transverse spinous process view on ultrasound, and the horizontal intercristal line. After these two vertical marks have been made at the level of the intercristal line, the horizontal distance between them will be measured in mm by these same two investigators
62423536|NCT02582801|EXPERIMENTAL|breast cancer|Perform 18F-Alfatide Ⅱ PET/CT in breast cancer patients
62423537|NCT02582801|ACTIVE_COMPARATOR|benign breast lesions|Perform 18F-Alfatide Ⅱ PET/CT in patients with benign breast lesions
62423538|NCT03945760|EXPERIMENTAL|Subjects Taking Baricitinib 2 mg|Subjects will be taking Baricitinib 2mg
62423539|NCT03945760|PLACEBO_COMPARATOR|Subjects Taking Placebo|Subjects will be taking placebo
62808529|NCT01431612|PLACEBO_COMPARATOR|Lactated Ringer´s solution|10 ml/h lactated Ringer's solution without active drug was infused intravenously over 3 hours.
62808530|NCT02718521|EXPERIMENTAL|Hydration Therapy Combined With Isosorbide Dinitrate|Intravenous Infusion of Isosorbide Dinitrate 2mg/h combined with normal saline 1 ml/kg·h 6 hours before angiography and 12 hours after angiography
62032415|NCT01972841|EXPERIMENTAL|2: Solifenacin 5 mg + Mirabegron 50 mg|Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.
62808531|NCT02718521|ACTIVE_COMPARATOR|Conventional hydration group|normal saline 0.5 ml/kg·h 6 hours before angiography and 12 hours after angiography
62032416|NCT01972841|PLACEBO_COMPARATOR|3: Placebo|Participants who received matching placebo once a day for 12 weeks.
62423540|NCT03333382|ACTIVE_COMPARATOR|Plastic Biliary Stent|Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary plastic biliary stent placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
62423541|NCT03333382|ACTIVE_COMPARATOR|FCSEMS|Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary fully covered self-expanding metal stent (FCSEMS) placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
62032417|NCT01972841|ACTIVE_COMPARATOR|4: Solifenacin 5 mg|Participants who received solifenacin 5 mg once a day for 12 weeks.
62032418|NCT01972841|ACTIVE_COMPARATOR|5:Mirabegron 25 mg|Participants who received mirabegron 25 mg once a day for 12 weeks.
62032419|NCT01972841|ACTIVE_COMPARATOR|6: Mirabegron 50 mg|Participants who received mirabegron 50 mg once a day for 12 weeks.
62032420|NCT06242626||Low T3|
62032421|NCT06242626||Low T3T4|
62032422|NCT02201927|EXPERIMENTAL|patient with right parietal lobe lesion|Patient with right parietal lobe lesion
62032423|NCT02201927|EXPERIMENTAL|patient stroke|patient with cerebral vascular accident
62032424|NCT02201927|EXPERIMENTAL|healthy volunteers|healthy volunteers
62032425|NCT05467553|EXPERIMENTAL|TAF and P1101 combination therapy with UDCA|Ursodeoxycholic Acid (UDCA) 15 mg/kg orally (PO) QD plus TAF 25 mg orally (PO) QD for 60 weeks, with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.
62032426|NCT05467553|ACTIVE_COMPARATOR|TAF and P1101 combination therapy without UDCA|TAF 25 mg orally (PO) QD for 60 weeks with P1101 450 µg sub-cutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.
62423542|NCT01900392|NO_INTERVENTION|Control Arm|No other financial incentive other than for the 3-, 6-, 9-, \& 12-month weigh-ins and surveys. Participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). Two weigh-ins will be required during Phase II, one at 9 months and the other at 12 months.
62808532|NCT02271464|EXPERIMENTAL|Maintenance:BEVACIZUMAB|Induction: FOLFOXIRI; Manteinance: Bevacizumab
62808533|NCT02271464|EXPERIMENTAL|Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE|Induction: FOLFOXIRI; Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE(Metronomic Chemotherapy)
62808534|NCT05261555|EXPERIMENTAL|Using the NoObesity app|"A mobile digital app (NoObesity) that enables families to set goals, track progress, play games, and access additional information and healthcare professionals to access training and monitor patients' progress."
62808535|NCT03752138|EXPERIMENTAL|Group 1 Part 1 TK216: Days 1-7|Patients receive TK216 IV continuously on days 1-7 every 21 days.
62808536|NCT03752138|EXPERIMENTAL|Group 2 Part 1 TK216: Days 1-7 and 15-28|Patients receive TK216 IV on days 1-7 and 15-21 every 28 days.
62808537|NCT03752138|EXPERIMENTAL|Part 2 TK216 + Decitabine 10mg/m2|Patients receive recommended dose of TK216 from Part 1 plus Decitabine.
62808538|NCT03752138|EXPERIMENTAL|Part 2 TK216 + Decitabine 20 mg/m2|Patients receive recommended dose of TK216 from Part 1 plus Decitabine.
62232161|NCT06298253|EXPERIMENTAL|Behavioral economics-enhanced SWAP implementation strategy|Pantries assigned to the intervention group will receive behavioral nudges for implementing the SWAP nutrition program. These include: 1) invoice labeling with the food labeled as red, yellow, or green; 2) receipt of the SWAP toolkit at no cost; 3) pantry learning communities; 4)incentives to purchase SWAP implementation materials (e.g., shelves); 5) food bank recognition for SWAP implementation.
62232162|NCT06298253|ACTIVE_COMPARATOR|Basic SWAP implementation strategy|Pantries assigned to the control arm will receive email communication from the food bank dietitian providing them with information about SWAP, online links to SWAP implementation guides, and encouragement to purchase SWAP Toolkits on their own.
62232163|NCT00948142|ACTIVE_COMPARATOR|Linezolid|600 mg BID
62232164|NCT00948142|EXPERIMENTAL|CEM-102 Regimen A|
62808539|NCT03752138|EXPERIMENTAL|Expansion Phase: TK216 + Decitabine|All patients in the expansion cohort will receive the RP2D of TK216 and Decitabine.
62808540|NCT01339689|EXPERIMENTAL|Ganaxolone|active
62232165|NCT00948142|EXPERIMENTAL|CEM-102 Regimen B|
62592813|NCT06174038|OTHER|Health Education Intervention|Participants will receive a modified health education program on healthy aging. It will match the number and length of sessions as the hearing intervention, including compliance/phone checks. Participants will be on a waitlist to obtain hearing aids without fee at the end of their 12-month participation.
62592814|NCT05246189||Patient with PXE working aged|Patient diagnosed with PXE on working age and followed up by the French Reference Center.
62808541|NCT01339689|PLACEBO_COMPARATOR|Placebo|non-active
62808542|NCT04260685|ACTIVE_COMPARATOR|lidocaine|the Patient will receive IV bolus of 1.5mg/kg lidocaine 1% over ten minutes followed by continuous infusion of 1.5mg/kg/h
62808543|NCT04260685|ACTIVE_COMPARATOR|esmolol|the Patient will receive IV bolus of esmolol 0.5 mg/kg over ten minutes followed by continuous infusion of 100-300 ug/kg/min
62808544|NCT03539406|EXPERIMENTAL|NK-cells without preparative regimen|NK-cells without preparative regimen
62808545|NCT03539406|EXPERIMENTAL|NK-cells with preparative regimen|NK-cells with preparative regimen
62808546|NCT06410430|EXPERIMENTAL|Ba-Duan-Jin group|The participants will be trained and guided online by an experienced Ba-Duan-Jin instructor with reference to the standard operating procedure (SOP) for a 12-week course of 1 hour twice a week.
62808547|NCT06410430|NO_INTERVENTION|Healthy control group|
62232166|NCT04774770|EXPERIMENTAL|HED-Start Intervention arm|Participants assigned to the intervention arm will undergo 4 sessions of the HED-Start program. Each session is 2 hours long and will be conducted fortnightly.
62232167|NCT04774770|NO_INTERVENTION|Standard care arm|Participants assigned to the standard care arm will proceed with routine standard care.
62808548|NCT02211794||1 cohort|subject requires primary total knee arthroplasty with the Journey II BCS Total Knee System, including patella resurfacing due to degenerative joint disease (primary osteoarthritis, post-traumatic arthritis, avascular necrosis, rheumatoid arthritis)
62808549|NCT04265014|ACTIVE_COMPARATOR|Goal-directed fluid treatment|"Fluid management will be performed according to SVV and CI monitoring. When patients have SVV\>10%, 250 cc crystalloid will be administered and when SVV fell below 10% during 30-minute monitoring standard (5 mL/kg/hr) crystalloid infusion continues. If SVV continues above 10%, a second fluid bolus of 250 cc colloid (minifluid challenge) will be administered.~If the desired SVV level can not be reached, the Hct values will be examined. Blood replacement will be performed when Hct\<30% in patients with coronary artery disease (CAD) and when Hct\<25% for other patient groups. If the desired SVV level can not be reached in spite of blood replacement products, if CI will be below 2.5 L/min/m2 vasopressor will begun. If SVV will be at normal values with CI below 2.5 L/min/m2, inotrop will begun."
62819528|NCT02516696|EXPERIMENTAL|BiRD treatment regimen|Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles.
62232168|NCT04578769|ACTIVE_COMPARATOR|conventional myotomy|conventional myotomy for achalasia type I, II and III
62232169|NCT04578769|EXPERIMENTAL|short myotomy|modified myotomy (short myotomy) for achalasia type I and II
62819529|NCT02516696|ACTIVE_COMPARATOR|Rd treatment regimen|Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles.
62819530|NCT01151917||Bilio-pancreatic diversion|Each subject is own control
62808550|NCT04265014|ACTIVE_COMPARATOR|liberal fluid treatment|"Fluid management will be performed according to MAP, HR and urine output.~If peroperative urine amounts will be \<0.5 mL/kg/hr during two-hour monitoring, with MAP\<65 mmHg, HR\>100/min for at least 30 minutes and CVP falls 20% compared to basal values, the same anesthesiologist will begin additional fluid replacement of 5 mL/kg/hr based on clinical experience.~Blood product replacement will be provided at Hct\<30% for those with coronary artery disease and at Hct\<25% for other patients."
62032427|NCT02806180|EXPERIMENTAL|Single-Operator|For the 'Single Operator Ultrasound Guided IV placement' arm the RN operator will use the ultrasound probe to identify the target vein, and continue to hold and adjust the probe while placing the IV.
62232170|NCT04578769|EXPERIMENTAL|full-thickness myotomy|modified myotomy (full-thickness myotomy) for achalasia type I and II
62232171|NCT04578769|EXPERIMENTAL|tailored myotomy|modified myotomy (tailored myotomy) for achalasia type III
62232172|NCT06154486||semaglutide group|patients without risk factors for gastroparesis, fasting for at least 8 hours, BMI less than 30 and currently using semaglutide
62232173|NCT06154486||control group|patients without risk factors for gastroparesis, fasting for at least 8 hours, BMI less than 30 and who have never used semaglutide or another GLP-1 analogue
62423543|NCT01900392|EXPERIMENTAL|Direct payment|"In addition to the incentives for the 3-, 6-, 9-, \& 12-month weigh-ins, participants who meet their daily goal will be eligible to receive an incentive for each day their goal is met during the first 6 months of the study. All daily incentive earnings will be paid out after verifying participants' weights during an in person weigh in at a Weight Watchers location at months 3 and 6. Winnings will be proportional to weight loss. For example, if a participant's goal was to lose 6 pounds by month 3, but he/she only lost 3 pounds, that participant would only receive 50% of their total eligible winnings.~Similar to the control arm, participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weigh-ins at 9- and 12-months will also be required."
62423544|NCT01900392|EXPERIMENTAL|Lottery|"In addition to the incentives for the 3-, 6-, 9-, \& 12-month weigh-ins, participants who meet their daily goal will be eligible for the daily lottery during the first 6 months of the study. The expected daily winning for the lottery is the same as for the direct payment arm. All daily incentive earnings will be paid out after verifying participants' weights during an in person weigh in at a Weight Watchers location at months 3 and 6. Winnings will be proportional to weight loss. For example, if a participant's goal was to lose 6 pounds by month 3, but he/she only lost 3 pounds, that participant would only receive 50% of their total eligible winnings.~Similar to the control arm, participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weigh-ins at 9- and 12-months will also be required."
62423545|NCT03816956|EXPERIMENTAL|Study treatment|Investigational/ Interventional Product group: AR-301 (tosatoxumab) 20 mg/kg administered once intravenously on the day of randomization.
62423546|NCT03816956|PLACEBO_COMPARATOR|Placebo treatment|Control group: Placebo administered intravenously on the day of randomization.
62808551|NCT04743830|EXPERIMENTAL|Treatment Group|Neurodevelopmental Treatment (Bobath) + Scapular Training Group
62032428|NCT02806180|EXPERIMENTAL|Dual-Operator|For the 'Dual Operator Ultrasound Guided IV placement' arm the RN operator will use the US to identify the target vein, at which time the study coordinator will hold the ultrasound probe in position. The RN operator will then place the IV.
62032429|NCT02980159||Before triage liaison physician|All patients admitted before the introduction of the function of triage liaison physician.
62032430|NCT02980159||After triage liaison physician|All patients admitted after the introduction of the function of triage liaison physician.
62423547|NCT04320992||tested group|
62032431|NCT05944419|ACTIVE_COMPARATOR|V3 Implant MIS Iberica|Implant with triangular neck macro design
62423548|NCT04320992||controlled group|
62423549|NCT02937662|EXPERIMENTAL|IAC regimen|Patients receive IAC regimen including idarubicin, cytarabine and cyclophosphamide.
62423550|NCT02937662|ACTIVE_COMPARATOR|Control Group|Patients receive physician-directed regimens without cyclophosphamide including FLA±G regimen, AAG regimen, decitabine with AA regimen. Physicians can choose one of these regimens based on their experience and patients' condition.
62032432|NCT05944419|ACTIVE_COMPARATOR|C1 Implant MIS Iberica|Implant with circular neck macro design
62232174|NCT01180998|OTHER|Spherical contact lens users|Habitual spherical contact lens (non-toric lens) users tried one of two toric lenses in a daily wear modality.
62232175|NCT01180998|OTHER|Contact lens drop-outs|Habitual spectacle users (for vision correction) who have failed contact lens fit and wear, tried one of two toric lenses in a daily wear modality.
62423551|NCT03775382|PLACEBO_COMPARATOR|Placebo|Normal saline will be infused by the research nurse into an antecubital vein using an IV infusion pump.
62808552|NCT04743830|ACTIVE_COMPARATOR|Control Group|Neurodevelopmental Treatment (Bobath) Group
62032433|NCT04139395|EXPERIMENTAL|Diagnostic 68Ga-Citrate PET/MRI Imaging|Participants will receive separate scans, first a SPECT scan following administration of the 67Ga Citrate tracer (standard of care), then a PET/MRI scan following administration of the 68Ga-Citrate tracer (investigational); some participants will also receive IV gadolinium-based contrast injection. Scans will be performed 45-60 minutes following injection of the tracer.
62232176|NCT01180998|OTHER|Habitual Correction with Spectacles (Neophytes)|Habitual spectacle lens wearers (for vision correction) who have never used or been fitted with contact lenses tried one of two toric lenses in a daily wear modality.
62232177|NCT03555474|EXPERIMENTAL|Theta burst stimulation & Physiotherapy|"Patients were given theta burst stimulation (intermittent TBS (iTBS) to the affected hemisphere and continuous TBS (cTBS) to the unaffected hemisphere) along with physiotherapy. TBS was delivered for 3 times in a week for 4 weeks.The stimulation was given with an intensity of 60% of RMT. The iTBS protocol of 10 bursts of high-frequency stimulation (3 pulses at 50 Hz) was applied at 5 Hz every 10 second for a total of 600 pulses.~Continuous TBS (inhibitory) was delivered to the unaffected hemisphere at the hot-spot with an intensity of 60% of RMT, 3 pulses at 50 Hz, repeated every 200 ms for a total of 600 pluses."
62232178|NCT03555474|EXPERIMENTAL|Functional stimulation & Physiotherapy|"Patients in the functional electrical stimulation (FES) group received the electrical stimulation with electrodes positioned according to pattern 3 \[Grasp/Flexion/Extension, PATT (pattern movement)\] of the FES (F) mode of the instrument. The electrodes were connected to a stimulator controller unit that delivers alternating current at a frequency of 35 Hz and a pulse width of 200 µs, intensity 10\~50 mA.~The FES group stimulation session was given for 30 minutes for each day 3 times in a week (alternate days) for 4 weeks and it was concurrently synchronized with the physiotherapy."
62232179|NCT03555474|ACTIVE_COMPARATOR|Physiotherapy|"The following different physiotherapy regimens were followed for all the patients in the study.~Passive/Active Range of Motion (ROM); Weight bearing and supportive reaction; Reaching activities; Grasping, holding and release; Upper extremity activities of daily living (ADL). Physiotherapy intervention was given to all the patients 5 days per week for 1 month. In addition, all patients continued to receive in-home physiotherapy 1 to 2 times per week by a home physiotherapist who was guided by the research physiotherapist."
62423552|NCT03775382|ACTIVE_COMPARATOR|Ascorbic Acid|"Ascorbic acid will be measured into sterile syringes by the research nurse and infused into an antecubital vein using a IV infusion pump beginning with a priming bolus of 0.06 g Ascorbic Acid per kg fat-free mass dissolved in 100 ml of saline or lactated ringers followed by a drip-infusion of 0.02 g Ascorbic Acid per kg fat-free mass dissolved in 30 ml of saline."
62423553|NCT02711579|EXPERIMENTAL|Celecoxib for electroencephalography|Electroencephalography will be performed before and after celecoxib administration
62423554|NCT02711579|PLACEBO_COMPARATOR|Placebo for electroencephalography|Electroencephalography will be performed before and after placebo administration
62808553|NCT05398367|EXPERIMENTAL|Oat Mama Lactation Supplement|Participants will receive a 20 day supply of oat mama lactation supplement for consumption per the manufacturer instructions
62808554|NCT05398367|EXPERIMENTAL|Moringa Supplement|Participants will receive a 20 day supply of moringa supplement for consumption per the manufacturer instructions
62423555|NCT02711579|EXPERIMENTAL|Celecoxib for motor evoked potential|Motor evoked potential will be measured before and after celecoxib administration
62423556|NCT02711579|PLACEBO_COMPARATOR|Placebo for motor evoked potential|Motor evoked potential will be measured before and after placebo administration
62232180|NCT05793918|EXPERIMENTAL|Percutaneous Electrolysis and neuromodulation.|The intervention for this group consisted of Therapeutic Percutaneous Electrolysis and neuromodulation. Patient received once week for four weeks associated with eccentric exercises device at home.
62423557|NCT02641171||Entire Cohort|This is an observational/validation study and there is no intervention involved. Exhaled air samples, blood samples, and fecal samples will be obtained.
62423558|NCT01398982|PLACEBO_COMPARATOR|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
62808555|NCT05398367|EXPERIMENTAL|Shatavari Supplement|Participants will receive a 20 day supply of shatavari supplement for consumption per the manufacturer instructions
62808556|NCT05398367|PLACEBO_COMPARATOR|Placebo|Participants will receive a 20 day supply of placebo pills containing a mixture of flour and brown sugar. Participants will consume 2 placebo pills once per day for 20 days.
62808557|NCT06012682|EXPERIMENTAL|metformin|patients randomized to received metformin
62808558|NCT06012682|PLACEBO_COMPARATOR|placebo|patients randomized to received placebo
62808559|NCT06012682|NO_INTERVENTION|group without intervention|
62808560|NCT00938184|EXPERIMENTAL|Treatment sequence A/B/C|Eligible subjects will be randomized in sequence A/B/C and will receive A: single tablet of paroxetine 12.5 milligrams, B: single tablet of paroxetine 25 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
62819531|NCT01808755|EXPERIMENTAL|D Mannose|1 gr. every 8 hours for 2 weeks, subsequently 1 gr. every 12 hours for 22 weeks
62232181|NCT05793918|ACTIVE_COMPARATOR|Control group|"The multimodal physical therapy program includes 10 sessions of:~Ultrasound pulsatil therapy (US) for 10 minutes , transcutaneous electric nerve stimulation (TENS) for 20 minutes ans associated with eccentric exercises device at home."
62232182|NCT01240668||Hyponatremia Patients|Euvolemic or hypervolemic hyponatremia with serum sodium ≤130 mmol/L
62232183|NCT01522105|EXPERIMENTAL|1|i.v. daptomycin given 24 hours after first ceftriaxone dose at age appropriate dosage
62232184|NCT01562457|EXPERIMENTAL|Low dose|
62232185|NCT01562457|EXPERIMENTAL|Medium dose|
62232186|NCT01562457|EXPERIMENTAL|High dose|
62232187|NCT02473666||All Health Conditions.|All Health Conditions. Area of Focus: Transfusions of blood products.
62592815|NCT05983120|EXPERIMENTAL|Training group|In the first five weeks, the experimental group was given training consisting of five modules, accompanied by power point presentations and applied social cognitive learning theory, then SMS reminders were sent every fortnight for seven weeks, and the study was completed at the end of the twelfth week. The control group received standard training from a diabetes nurse. Scale evaluations, metabolic and anthropometric measurements were made at the beginning and end of the study in the experimental and control groups. In addition, the scale evaluation was repeated in the fifth week for the experimental group. Data were evaluated using appropriate statistical methods.
62592816|NCT05983120|NO_INTERVENTION|Control Group|The control group received standard training from a diabetes nurse.
62808561|NCT00938184|EXPERIMENTAL|Treatment sequence A/C/B|Eligible subjects will be randomized in sequence A/C/B and will receive A: single tablet of paroxetine 12.5 milligrams, C: two tablets of paroxetine 25 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
62032434|NCT03716713|EXPERIMENTAL|CeraShield Endotracheal Tube|Subjects who are expected to require mechanical ventilation for 24 hours or longer will be intubated with the CeraShield ETT.
62032435|NCT04250272|EXPERIMENTAL|Serratus Anterior Plane Block|Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and latissimus dorsi near 5th rib.
62032436|NCT04250272|ACTIVE_COMPARATOR|Intercostal Nerve Block|Intercostal Nerve Block was performed just before closing the surgical incision while looking directly at the affected intercostal space. 10ml of 0.375% ropivacaine was delivered evenly at anterior and posterior intercostal spaces from the port site.
62032437|NCT02732366|EXPERIMENTAL|Group-based exercise and peer coaching|This treatment arm will include physical therapist-led group-based exercise, goal-setting, peer coaching training, individualized home program, and activity monitoring.
62032438|NCT02732366|ACTIVE_COMPARATOR|Usual PT and attention control grp class|This arm consists of the continuation of one-on-one PT along with participation in an attention control - healthy living class.
62032439|NCT04576169|EXPERIMENTAL|Central or Radial Tear: Arthroscopic debridement|Arthroscopic debridement
62232188|NCT01535950|EXPERIMENTAL|LFG316|
62232189|NCT01535950|SHAM_COMPARATOR|Sham|
62232190|NCT02222051|EXPERIMENTAL|Tai Chi|Simplified 24 Yang Style 12 weeks, 1x/week, 60-90 minutes
62819532|NCT01808755|ACTIVE_COMPARATOR|trimethoprim/sulfamethoxazole|intervention was a 5-days course of trimethoprim/sulfamethoxazole cp 160 mg/800 mg twice a day. Then one week of antibiotic every 4 weeks for the following 23 weeks
62032440|NCT04576169|PLACEBO_COMPARATOR|Central or Radial Tear: Sham surgery|Diagnostic arthroscopy only (placebo surgery).
62032441|NCT04576169|EXPERIMENTAL|Ulnar Tear: Arthroscopic or open repair|Arthroscopic or open repair
62592817|NCT04866628|EXPERIMENTAL|Helichrysum italicum|1 g of milled plant material (Helichrysum italicum) immersed in hot water (200 mL, 100 °C) for 10minutes
62032442|NCT04576169|ACTIVE_COMPARATOR|Ulnar Tear: Physiotherapy|Diagnostic arthroscopy and physiotherapy
62032443|NCT02372409|EXPERIMENTAL|Arm A (MRI-guided laser ablation)|"* MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.~* Participants will undergo DCE and DSC-MRI imaging at the following time points:~  * no more than 3 weeks prior to MLA (OPTIONAL)~ * within approximately 4 days after MLA~ * 2-4 weeks after MLA~ * Every 12 weeks (+/- 7 days) for the first year or until disease progression"
62232191|NCT02222051|ACTIVE_COMPARATOR|Neck exercise|conventional neck exercises 12 weeks, 1x/week, 60 min stretching and strengthening, neck education
62232192|NCT02222051|NO_INTERVENTION|Usual care|Usual care, no specific study intervention this group is offered Tai Chi or neck exercises at the end of the study
62232193|NCT06485609|NO_INTERVENTION|radical right hemicolectomy|
62232194|NCT06485609|EXPERIMENTAL|radical right hemicolectomy combined with indocyanine green fluorescence imaging lymphatic tracer di|
62232195|NCT03025386|OTHER|Adult cochlear implant users|Evaluation of a concordance between the mismatch negativity amplitude mesured by electroencephalography and the capacity of logatoms discrimination by using a logatoms test
62232196|NCT04497142|EXPERIMENTAL|Perampanel|"* Participants will take a predetermined first dose of perampanel on the day before their tumor surgery~* During surgery, an approximately 4x6cm recording grid will be placed on the surface of the brain over the tumor, and brain activity around the tumor will be recorded for 10 minutes during surgery (Electrocorticography).~* After surgery participants will take perampanel at a predetermined dose once a day for as long as they do not have serious side effects and their disease does not get worse, up to a maximum of 12 months. Participants will be provided a drug and seizure diary to document drug and seizure information and have monthly study visits either in clinic or by phone."
62032444|NCT02372409|EXPERIMENTAL|Arm B (MRI-guided laser ablation, doxorubicin, etoposide)|"* MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.~* Within 7 days of MLA (range 2-14 days) doxorubicin will be given intravenously on an outpatient basis weekly for 6 weeks at a dose of 25 mg/m\^2 over 5-30 minutes~* Following the completion of doxorubin, etoposide 50 mg/m\^2/day will be given orally for 21 days of each 28-day cycle (treatment can continue up to 24 cycles)~* Participants will undergo DCE and DSC-MRI imaging at the following time points:~  * no more than 3 weeks prior to MLA (OPTIONAL)~ * within approximately 4 days after MLA~ * 2-4 weeks after MLA~ * every 8 weeks (+/- 7 days) until 2 years have elapsed or disease progression, whichever comes first"
62032445|NCT03375944|NO_INTERVENTION|control group|Cardiac supervision
62032446|NCT03375944|OTHER|study group|Cardiac supervision and rehabilitation
62032447|NCT03580876|OTHER|switch to anti-TNF alone|"Switch to the second anti-TNF drug alone (infliximab or adalimumab)~Loss of response under Infliximab: 10 mg/kg IV every 8 weeks Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC OR Loss of response under Adalimumab: 40mg EW SC Randomization to: Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks."
62032448|NCT03580876|OTHER|switch to anti-TNF with addition of azathioprine|"Switch to anti-TNF (infliximab or adalimumab) with addition of azathioprine~Loss of response under Infliximab: 10 mg/kg IV every 8 weeks Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC with azathioprine 2.5 mg/kg/day OR~Loss of response under Adalimumab: 40mg EW SC Randomization to:~Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks with azathioprine 2.5 mg/kg/day."
62032449|NCT03772301||Group 1|At least 200 Jewish Holocaust survivors of the first generation living in Germany and Israel - an equal number in each country
62032450|NCT03772301||Group 2|The second generation, whose parents lived in Europe during the Second World War, now live in Germany (originating from Western and Eastern Europe) - at least 200 participants.
62592818|NCT04866628|ACTIVE_COMPARATOR|Helichrysum arenarium|1 g of milled plant material (Helichrysum arenarium) immersed in hot water (200 mL, 100 °C) for 10minutes
62592819|NCT04009668|EXPERIMENTAL|adalimumab|Adalimumab dose every other week (study weeks 0, 2, 4, 6, and 8), subcutaneously
62808562|NCT00938184|EXPERIMENTAL|Treatment sequence B/A/C|Eligible subjects will be randomized in sequence B/A/C and will receive B: single tablet of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
62808563|NCT00938184|EXPERIMENTAL|Treatment sequence B/C/A|Eligible subjects will be randomized in sequence B/C/A and will receive B: single tablet of paroxetine 25 milligrams, C: two tablets of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
62808564|NCT00938184|EXPERIMENTAL|Treatment sequence C/A/B|Eligible subjects will be randomized in sequence C/A/B and will receive C: two tablets of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
62808565|NCT00938184|EXPERIMENTAL|Treatment sequence C/B/A|Eligible subjects will be randomized in sequence C/B/A and will receive C: two tablets of paroxetine 25 milligrams, B: single tablet of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
62423559|NCT01398982|EXPERIMENTAL|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
62423560|NCT03467828|EXPERIMENTAL|Study Group|Infants diagnosed with BPD.
62423561|NCT03467828|NO_INTERVENTION|Control Group|Infants born in similar gestational week and birth weight but not diagnosed with BPD.
62423562|NCT01458132||Subjects who experienced seizure|Subjects who were previously randomized in the Phase 2b studies SGN113399 or SGN113404 and experienced seizure
62592820|NCT03909919|EXPERIMENTAL|Heart Failure|Heart Failure patients Subjects diagnosed with heart faikure, who will receive the best treatment of clinical practice, will be recruited. They must be more than 70 years old.
62592821|NCT03909919|ACTIVE_COMPARATOR|Healthy Subjects|Healthy Subjects/ Match control Healthy subjects of the same age as people with heart failure.
62592822|NCT01337713|EXPERIMENTAL|Swedish Massage|
62592823|NCT01337713|SHAM_COMPARATOR|Light Touch|
62592824|NCT06221488||Health workers|Health workers with baseline negative interferon gamma release assays
62592825|NCT03777332|EXPERIMENTAL|(Cohort 1) Pegcetacoplan, 15 mg/100 μL, monthly for up to 60 months|
62592826|NCT03777332|EXPERIMENTAL|(Cohort 2) Pegcetacoplan, 15 mg/100 μL, monthly for up to 36 months|
62592827|NCT03777332|EXPERIMENTAL|(Cohort 2) Pegcetacoplan, 15 mg/100 μL, every other month for up to 36 months|
62592828|NCT00342563|EXPERIMENTAL|Mecamylamine- Smoker|
62592829|NCT00342563|PLACEBO_COMPARATOR|Placebo-Smoker|
62592830|NCT00342563|EXPERIMENTAL|Mecamylamine- Non-Smoker|
62592831|NCT00342563|PLACEBO_COMPARATOR|Placebo-Non-Smoker|
62592832|NCT01949012|NO_INTERVENTION|Control|Standard monitoring
62592833|NCT01949012|EXPERIMENTAL|Capnography|Standard monitoring and capnography
62592834|NCT04828265|EXPERIMENTAL|Aldafermin 0.3mg|Subcutaneous injection of a single dose of aldafermin 0.3mg in healthy adult male Japanese or non-Japanese subjects
62592835|NCT04828265|EXPERIMENTAL|Aldafermin 1mg|Subcutaneous injection of a single dose of aldafermin 1mg in healthy adult male Japanese or non-Japanese subjects
62592836|NCT04828265|EXPERIMENTAL|Aldafermin 3mg|Subcutaneous injection of a single dose of aldafermin 3mg in healthy adult male Japanese or non-Japanese subjects
62592837|NCT03452384|EXPERIMENTAL|acupucture|For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface.
62592838|NCT03452384|SHAM_COMPARATOR|control|For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998). The needles will be affixed with plastic O-rings and adhesive tapes. The needles with blunt tips will be quickly put onto the same acupoints used in real acupuncture without inserting into the skin.
62592839|NCT03064685||Group I - Cases|Patients older than 18 years of age with a history of liver transplantation since January 2002 for any cause and who have undergone medical follow-up at HIBA and had at least one event of pyogenic liver abscess after transplantation.
62592840|NCT03064685||Group II - Controls|Patients older than 18 years with a history of liver transplantation since January 2002 for any cause and who have performed their medical follow-up at HIBA without developing any event of pyogenic liver abscess after transplantation
62592841|NCT02721810|NO_INTERVENTION|Control|Prompts standard to rounds or electronic medical records.
62592842|NCT02721810|EXPERIMENTAL|Prompting Intervention|Prompting consideration of 3-month functional outcome.
62032451|NCT03772301||Group 3|Third generation of Jewish Holocaust survivors who participated in the first phase, currently living in Germany and Israel - at least 200 participants including at least 100 subjects in each country. These are adults only. The research program does not include children and adolescents
62032452|NCT00446316|EXPERIMENTAL|Gleevec plus antacids|Gleevec® will be administered at a dose of 400 mg, and the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide). Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1.
62232197|NCT04497142|ACTIVE_COMPARATOR|Standard of Care|"* Participants will receive standard of care medication before surgery.~* During surgery, an approximately 4x6cm recording grid will be placed on the surface of the brain over the tumor, and brain activity around the tumor will be recorded for 10 minutes during surgery (Electrocorticography).~* After surgery participants will take standard of care medications as predetermined by their doctor. Participants will be provided a drug and seizure diary to document drug and seizure information and have monthly study visits either in clinic or by phone.~* Participants will be followed up to 12 months after completing surgery."
62232198|NCT00320541|ACTIVE_COMPARATOR|paclitaxel plus bevacizumab (PB)|paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days
62232199|NCT00320541|EXPERIMENTAL|paclitaxel plus bevacizumab plus gemcitabine (PB+G)|paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by gemcitabine 1500 mg/m2 IV on days 1 and 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days
62232200|NCT03278106|EXPERIMENTAL|Treatment (TAS-102)|Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 orally PO BID on days 1-5 and 8-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62808566|NCT01467141|EXPERIMENTAL|IAsp|
62032453|NCT00446316|EXPERIMENTAL|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
62232201|NCT03711851|EXPERIMENTAL|Web-based|Self-help Acceptance and commitment therapy (Web-based)
62232202|NCT03711851|EXPERIMENTAL|Bibliotherapy|Self-help Acceptance and commitment therapy (bibliotherapy)
62232203|NCT03711851|ACTIVE_COMPARATOR|Education pamphlets on pain|Self-help Education on Chronic pain (pamphlet style pdf documents)
62232204|NCT01340196|EXPERIMENTAL|sequence 1|tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through day 22 (morning dose on day 22 only)
62232205|NCT03947437|EXPERIMENTAL|Low dose|2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in healthy participants.
62232206|NCT03947437|EXPERIMENTAL|High dose|10 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in healthy participants.
62592843|NCT01628653|EXPERIMENTAL|U-SMART|U-SMART (Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training)
62592844|NCT02151734|EXPERIMENTAL|KALOMIN™ Tab.|KALOMIN™ Tab./Placebo to Umckamin syrup
62592845|NCT02151734|ACTIVE_COMPARATOR|Umckamin syrup|Umckamin syrup/Placebo to KALOMIN™ Tab.
62592846|NCT03589638|ACTIVE_COMPARATOR|direct laryngoscope|Endotracheal intubation was applied by anesthesiologist with direct laryngoscope.
62423563|NCT01458132||Subjects who did not experience seizure|Subjects who were previously randomized in the Phase 2b studies SGN113399 or SGN113404 and did not experience seizure
62592847|NCT03589638|ACTIVE_COMPARATOR|C-MAC videolaryngoscope|Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
62592848|NCT03589638|ACTIVE_COMPARATOR|McGrath videolaryngoscope|Endotracheal intubation was applied by anesthesiologist with McGrath videolaryngoscope.
62592849|NCT05320783|ACTIVE_COMPARATOR|music intervention|Headphone was placed on the each patient. The classical music was started to the patients with individual comfortable volume.
62808567|NCT01467141|ACTIVE_COMPARATOR|HI|
62808568|NCT01945021|EXPERIMENTAL|Crizotinib|Single-arm trial whereby all consented, enrolled, eligible patients receive crizotinib
62808569|NCT00628121|EXPERIMENTAL|Cetrorelix 1 mg|
62808570|NCT00628121|EXPERIMENTAL|Cetrorelix 2 mg|
62808571|NCT00628121|EXPERIMENTAL|Cetrorelix 3 mg|
62808572|NCT05990387|PLACEBO_COMPARATOR|Placebo|Given once, followed by observation for up to 4 hours in a progressively cold water challenge
62808573|NCT05990387|EXPERIMENTAL|100 mg Mirabegron|Given once, followed by observation for up to 4 hours in a progressively cold water challenge
62808574|NCT02916966||ALS Patients in Case-Control|ALS patients enrolled by Cleveland Clinic Foundation (CCF)
62032454|NCT01601574|EXPERIMENTAL|Modified Weight Watchers program|
62032455|NCT01601574|ACTIVE_COMPARATOR|Standard Diabetes Counseling group|
62032456|NCT03330665|NO_INTERVENTION|Control|No meditation
62232207|NCT03947437|EXPERIMENTAL|TBD dose in patients|TBD μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in paucibacillary leprosy patients. Dose will be determined by safety and immunogenicity data from healthy participants.
62232208|NCT03947437|PLACEBO_COMPARATOR|Placebo|Sterile normal saline for injection will be administered by IM injection on Days 0, 28, and 56 in healthy participants and paucibacillary leprosy patients.
62232209|NCT00683748||Kidney transplant|
62232210|NCT00683748||Liver transplant|
62232211|NCT00534573|ACTIVE_COMPARATOR|Moclobemide,|treatment during 2 weeks
62232212|NCT00534573|ACTIVE_COMPARATOR|Amisulpride|Comparison
62232213|NCT02895451|EXPERIMENTAL|Extended behavioral intervention|Specific goal-setting, self-monitoring and feed-back
62232214|NCT02895451|NO_INTERVENTION|Usual care|Hospital-based or home-based aerobic exercise 3 times a week with a duration of 30-60 minutes and an intensity of 40-80 % of Vo2max and resistance exercise 2 times a week of 1-3 sets of 10-15 repetitions. The exercise period is 16 weeks.
62232215|NCT05694754|EXPERIMENTAL|1 session|Participants will receive 1 session from monday to friday,during 4 weeks, with 600 total pulses per session
62423564|NCT01652573|EXPERIMENTAL|Nasal calictonin|Subjects will received nasal calcitonin once daily
62232216|NCT05694754|EXPERIMENTAL|3 sessions|Participants will receive 3 sessions from monday to friday,during 4 weeks, with 1800 total pulses per session with a 10 minutes rest interval
62232217|NCT02851082|EXPERIMENTAL|Haemophilia A patients|Patients will perform endurance training program on 6 consecutive weeks
62423565|NCT01652573|PLACEBO_COMPARATOR|Saline Nasal spray|Patients will receive saline nasal spray once daily
62423566|NCT04769908|EXPERIMENTAL|Systemic Chemotherapy, Lenvatinib Plus Sintilimab|
62423567|NCT04509752||Dysphagia clinicians|Clinicians from swallowing centers (from all over the world)
62423568|NCT04333199|NO_INTERVENTION|Control|Patients do not receive an email
62423569|NCT04333199|EXPERIMENTAL|Timely nudge - view results|"Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a View My Lab Results button, which encourages them to click as a pre-commitment step that then brings them to the myGeisinger sign-up page."
62423570|NCT04333199|EXPERIMENTAL|Timely nudge - get started|"Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a Get Started With myGeisinger button that is transparent about the next step in the process, before the patient can view test results."
62592850|NCT05320783|PLACEBO_COMPARATOR|control|Headphone was placed on the each patients, but the music player was not started.
62592851|NCT01178879|EXPERIMENTAL|Telehealth consultation|Telehealth nurse consultation plus treatment as usual
62808575|NCT02916966||Non-neurodegenerative patients in case control|Non-neurodegenerative patients enrolled by CCF
62808576|NCT02916966||Non-neurodegeneration population in population control|Non-neurodegenerative general population enrolled by ABS mailing system from DHMC
62232218|NCT03174548|EXPERIMENTAL|Fed Tablet period (Test, T)|Sotagliflozin oral in fed conditions
62232219|NCT03174548|EXPERIMENTAL|Fasted Tablet period (Reference, R)|Sotagliflozin oral in fasting conditions
62808577|NCT02916966||ALS Patients in State of OH|ALS registry of all cases in Ohio
62032457|NCT03330665|EXPERIMENTAL|Intervention|Meditate using headspace app 3 times a week
62032458|NCT03160027|EXPERIMENTAL|Immediate PBM treatment|This arm will receive photobiomodulation (PBM), delivered with the Vielight Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes (the device automatically shuts itself off after 20 minutes) for 12 weeks.
62232220|NCT03174548|EXPERIMENTAL|Oral Solution period (S)|Sotagliflozin oral solution in fasting conditions
62232221|NCT01477333|EXPERIMENTAL|UT-15C SR BID|Initiated at 0.125 mg twice daily (BID), titrated as clinically indicated.
62232222|NCT04483986|ACTIVE_COMPARATOR|Study group|This arm is going to include the patients who are performed rectus reapproximation.
62232223|NCT04483986|NO_INTERVENTION|Control group|This arm is going to include the patients who are not performed rectus reapproximation.
62232224|NCT03631160|EXPERIMENTAL|TAES treatment|"Patients in the treatment group receive Transcutaneous Acupoint Electrical Stimulation (TAES) at Zhongji ( CV3),Guanyuan ( CV4), bilaterally Sanyinjiao ( SP6) and bilaterally Ciliao ( BL32) points by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected and maintained until the end of treatment."
62423571|NCT00437437|EXPERIMENTAL|1|
62423572|NCT06266507|EXPERIMENTAL|Research Group|Mothers who will receive a 10-week occupational therapy-based parent coaching intervention will be included in this group.
62423573|NCT06266507|OTHER|Control Group|The control group will not receive an active intervention, but will be provided with an informative brochure on dealing with nutritional problems.
62423574|NCT00943384|EXPERIMENTAL|chronOS Strip|This is a single arm, outcome study for treatment of patients with degenerative disc disease (DDD), with or without stenosis, with interbody fusion, posterolateral pedicle screw system, and the study device (chronOS Strip).
62232225|NCT03631160|SHAM_COMPARATOR|Sham TAES treatment|"Participants in the control group receive shallow TAES at SP6, BL32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the acuponit is shamed without manual stimulation and Deqi and the stimulation apparatus is inefficiency without actual current output."
62592852|NCT01178879|NO_INTERVENTION|Conventional|Treatment as usual
62592853|NCT05696925|EXPERIMENTAL|motor imagery, observation of the action, and execution of the action (GE1)|in the sitting position, the participant will watch the recorded video to observe the action, for two minutes. Soon after, they will close their eyes, and receive the description of the action, through recorded audio of the same action, to imagine it, for two minutes. In the sitting or standing position, depending on the action to be performed, the participant must execute the same action imagined previously, for two minutes. Each session will have five different actions that will be repeated twice, totaling 60 minutes of intervention.
62808578|NCT03326596|EXPERIMENTAL|ProphylacticTranexamic Acid|Once consented, patients to receive 1000mg/10ml normal saline infusion of TXA with the delivery of the infant's anterior shoulder.
62592854|NCT05696925|EXPERIMENTAL|motor imagery and execution of the action (GE2)|in the sitting position, the participant will close his eyes and will receive the description of the action, through recorded audio, to imagine it, for two minutes. Then, in the sitting or standing position, depending on the action to be performed, the participant must execute the same action imagined previously, for two minutes. Each session will have five different actions that will be repeated twice, totaling 40 minutes of intervention.
62232226|NCT03650257|EXPERIMENTAL|gp96 group|"Patients receive standard treatment with radiation and temozolomide after surgery.~Then 6 times of autologous gp96 vaccination are administered via subcutaneous injection in 25μg doses at the 2nd week after the end of postoperative radiotherapy.~( gp96 is administered once a week for the first 4 weeks, the 5th injection is administered 2 weeks after the 4th injection, and the 6th injection is administered 3 weeks after the 5th injection. )~The first adjunctive temozolomide startes on the day of the fifth gp96 injection.~(150-200 mg/m2/day for 5 days, then stop for 23 days, one cycle is 28 days for a total of 6 cycles)"
62232227|NCT03650257|ACTIVE_COMPARATOR|control group|Patients receive standard treatment with radiation and temozolomide after surgery. Then only adjuvant treatment with temozolomide is administered.
62423575|NCT03593772|ACTIVE_COMPARATOR|Treatment arm - Veteran|Treatment Arm: MR is an user-driven, dyadic, self-care management program developed with National Institute of Mental Health (NIMH) funding (R43/44) for use by Veterans and their selected partners, individually or together, to reduce pain and distress and support physical, mental, and relationship health. MR was designed for Veterans who face obstacles accessing formal mental health services. It can also be used to complement formal services. MR is a patient-centered intervention, allowing users to determine the pace at which to proceed in each program component. MR Content. The program provides video and audio instruction in a set of 11 evidence-based wellness.
62423576|NCT03593772|NO_INTERVENTION|Control arm - Veteran|Usual Care Waitlist Control Arm: For ethical reasons, this study will use a waitlist control arm to ultimately provide all participants exposure to the MR intervention. Dyads in the control arm will participate in all assessments like those in the treatment group, however, they will be asked to agree to not access the public web site during their participation. Wait-list control participants will be instructed to seek advice about treatment from their providers. Other than this initial advice, there will be no attempt by study personnel to influence condition management unless an issue (i.e., suicidal ideation) arises. The control condition will account for potential temporal effects that occur from passage of time (brief), and expectation effects associated with anticipation of MR participation. The control group will receive access to MR after they complete data collection.
62808579|NCT02919644|EXPERIMENTAL|vaccine + Interleukin -2 (IL2)|autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1), followed by IL-2 given by subcutaneous injection daily for five days (days 3-7)
62808580|NCT00555412|EXPERIMENTAL|A - 10 mg loxapine q 4 h x 3 (30 mg total)|
62808581|NCT00555412|EXPERIMENTAL|B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|
62423577|NCT03593772|EXPERIMENTAL|Treatment arm - Partner|Treatment Arm: MR is an user-driven, dyadic, self-care management program developed with NIMH funding (R43/44) for use by Veterans and their selected partners, individually or together, to reduce pain and distress and support physical, mental, and relationship health. MR was designed for Veterans who face obstacles accessing formal mental health services. It can also be used to complement formal services. MR is a patient-centered intervention, allowing users to determine the pace at which to proceed in each program component. MR Content. The program provides video and audio instruction in a set of 11 evidence-based wellness.
62808582|NCT00555412|EXPERIMENTAL|C - 5 mg loxapine q 4 h x 3 (15 mg total)|
62808583|NCT00555412|PLACEBO_COMPARATOR|D - inhaled placebo q 4 h x 3|
62808584|NCT05790889|PLACEBO_COMPARATOR|Group 1 (Control group)|n= 60. Age= 5-17 months Rabies Vaccine administered on Days 0, 28 and 152.
62808585|NCT05790889|EXPERIMENTAL|Group 2|n=120 Age= 5-17 months First vaccination of RH5.1 10μg with 50μg Matrix-M will be administered on day 0, followed by a second dose administered on Day 28, followed by a third and final dose at Day 152.
62808586|NCT05790889|PLACEBO_COMPARATOR|Group 3 (Control Group)|n= 60. Age= 5-17 months Rabies Vaccine administered on Days 0, 28 and 56.
62808587|NCT05790889|EXPERIMENTAL|Group 4|n=120 Age= 5-17 months First vaccination of RH5.1 10μg with 50μg Matrix-M will be administered on day 0, followed by a second dose administered on Day 28, followed by a third and final dose at Day 56.
62808588|NCT05790889|EXPERIMENTAL|Group 5|n=120 Age= 5-17 months First vaccination of RH5.2-VLP 5μg with 50μg Matrix-M will be administered on day 0, followed by a second dose administered on Day 28, followed by a third and final dose at Day 56.
62808589|NCT06133335|OTHER|cystic fibrosis subjects|Adult patients with cystic fibrosis consulting the Resource and Competence Center for Cystic Fibrosis at the C.H.U. from Reims
62808590|NCT01480661|ACTIVE_COMPARATOR|Roflumilast|
62808591|NCT01480661|PLACEBO_COMPARATOR|Placebo|
62808592|NCT00959608|ACTIVE_COMPARATOR|Basic|Basic program participants receive 10-15 minute PCP weight management counseling at approximately four month intervals for up to 24 months and weight management materials.
62808593|NCT00959608|EXPERIMENTAL|Basic Plus|Half of study participants are randomly assigned to Basic Plus program, where in addition to receiving the same intervention as the Basic program participants, the Basic Plus participants also receive counseling from a lifestyle coach at the primary care provider's office (monthly in year 1 and bimonthly in year 2).
62808594|NCT01590979|ACTIVE_COMPARATOR|Ranolazine|The antianginal properties of the drug are due to inhibition of the late inward sodium current, demonstrated in animal experiments and human studies that it can prevent atrial and ventricular arrhythmias.
62808595|NCT01590979|PLACEBO_COMPARATOR|Placebo|Company generated placebo, will be similar in size and color to Ranolazine; and administered two times a day (12 hour intervals)
62808596|NCT03091465||Metastatic Renal Cell Carcinoma patients|This is a nation-wide retrospective observational study with patients treated with first-line pazopanib for mRCC in daily clinical practice since April 2011 (date of approval of pazopanib in Spain), January 2016.
62032459|NCT03160027|NO_INTERVENTION|Delayed PBM treatment|This arm will maintain usual activities for 12 weeks. After the week 12 psychometric and MRI assessment, this arm will receive PBM, delivered with the Vielight Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes (the device automatically shuts itself off after 20 minutes) for 12 weeks.
62032460|NCT01782989|EXPERIMENTAL|ORACEA®|40mg doxycycline
62032461|NCT01782989|PLACEBO_COMPARATOR|Placebo|
62232228|NCT04578574|EXPERIMENTAL|BI-TDCS Stimulation Group|Participants in this group will receive the BI and TDCS interventions for 10 sessions over two weeks.
62232229|NCT04578574|SHAM_COMPARATOR|BI-TDCS (Sham) Stimulation Group|Participants in this group will receive the BI and TDCS (Sham) interventions for 10 sessions over two weeks.
62232230|NCT04555538||Atrial Fibrillation Group|
62232231|NCT04555538||Non-Atrial Fibrillation Group|
62232232|NCT01498289|EXPERIMENTAL|Arm I|FOLFOX regimen: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62232233|NCT01498289|EXPERIMENTAL|Arm II|Patients receive irinotecan hydrochloride IV over 90 minutes and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62232234|NCT02261597||Insomnia Disorder|Testing reactivity of stress-related systems to repeated exposure to the cold pressor test (hand immersion into ice-cold water) among participants with a clinical diagnosis of insomnia disorder.
62232235|NCT02261597||Healthy Control|Testing reactivity of stress-related systems to repeated exposure to the cold pressor test (hand immersion into ice-cold water) among healthy participants without a diagnosis of insomnia disorder.
62232236|NCT00526032||Spectroscopic Oblique-Incidence Reflectometry (OIR)|
62232237|NCT01652950|EXPERIMENTAL|Vitality Wellness program Direct Payment|In addition to the base program and supplementary communication, members of the Direct Payment group received a gift voucher, corresponding to their level of engagement. Members received payouts at the end of each month of registration, for 5 different levels of engagement. The payout for the lowest level of engagement corresponded to about 25% of the monthly subscription for the wellness program. The payout for the highest level of engagement was 3 times more than the monthly subscription for the wellness program. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
62232238|NCT01652950|EXPERIMENTAL|Vitality Wellness Program Lottery Incentive|Members of the Lottery Incentive group were entered into a cash-prize draw at the end of each month following registration, if they achieved physical activity targets. The chance of winning was set at one in fifty with an expected value identical to the direct payment group. Four lottery payouts corresponding to the member's levels of engagement were made at the end of each month following registration. Enrollment took place over a period of 5 months, and the intervention took place over a period of 12 months following registration.
62232239|NCT01652950|EXPERIMENTAL|Vitality Wellness Program Charity Incentive|Members of the Charity Incentive Group were offered a selection of charities to which earned rewards could be donated. Nominated charities received the payouts at the end of each month of registration, for 5 different levels of engagement of the individual members. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
62032462|NCT06624969|EXPERIMENTAL|Virtual reality|Intervention with virtual reality
62592855|NCT05696925|EXPERIMENTAL|action observation and action execution (GE3)|in the sitting position, the participant will watch the recorded video to perform the action observation, which will last two minutes. Then, in the sitting or standing position, depending on the action to be performed, the participant must execute the same action observed previously, for two minutes. Each session will have five different actions that will be repeated twice, totaling 40 minutes of intervention.
62032463|NCT06624969|NO_INTERVENTION|Standard of care|No virtual reality intervention
62032464|NCT01019876|ACTIVE_COMPARATOR|Regimen A - Standard Conditioning Regimen|"Standard conditioning regimen for all diseases except those diseases or conditions noted in Regimen B, C and D:~* Fludarabine (180 mg/m2 total dose)~* Busulfan (16 mg/kg less than or equal to 4 yrs and 12.8 mg/ kg \>4 yrs total dose)~* Alemtuzumab (2mg/m2 x 1day, 6mg/m2 x 2 days, 20mg/m2 x 2days)"
62032465|NCT01019876|EXPERIMENTAL|Regimen B|"Includes patients with a diagnosis of: Osteopetrosis and Severe Aplastic Anemia with a history of \>10 blood transfusions, or Blackfan-Diamond's anemia, or Chronic Granulomatous Disease, or Wiskott Aldrich Syndrome:~* Cyclophosphamide (200 mg/kg total dose)~* Fludabarine (180 mg/m2 total dose)~* Rabbit Anti-thymocyte Globulin (8mg/kg total dose)"
62032466|NCT01019876|EXPERIMENTAL|Regimen C|"Includes patients with any one of the following speciﬁc diagnosis: Fanconi Anemia, Dyskeratosis Congenita or Schwachman Diamond Syndrome~* Cyclophosphamide (40 mg/kg total dose)~* Fludarabine (140 mg/m2 total dose)~* Anti-Thymocyte Globulin (horse) (150mg/kg total dose)/TBI 450 cGy"
62592856|NCT05696925|EXPERIMENTAL|motor imagery, execution of the action, and exoskeleton (GE4)|in the sitting position, the participant will perform the exoskeleton protocol for 40 minutes. Then, the participant will close his eyes and will receive the description of the action, through recorded audio, to imagine it, for two minutes. In the sitting or standing position, depending on the action to be performed, the participant must execute the same action imagined previously, for two minutes. Each session will have five different actions that will be repeated twice, totaling 80 minutes of intervention.
62808597|NCT05106127|EXPERIMENTAL|EG-007 1000mg + Len + Pem|3 to 6 patients will receive EG-007 1000 mg once weekly starting on the day of injection of Pembrolizimab starting the next 21-day cycle of treatment.
62232240|NCT01652950|EXPERIMENTAL|Vitality Wellness Program Choice Incentive|Members of the Choice Incentive Group were asked to choose one of the three aforementioned incentive options on enrollment to the study. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
62232241|NCT01652950|OTHER|Vitality Wellness Program Standard of Care|The Vitality Wellness program is the incentive-based wellness initiative of Discovery Health Medical Aid Scheme, a national private health insurer in South Africa. The standard program includes membership to three national gym chains, which is subsidized to 80% of the normal monthly subscription cost. Members have the opportunity to earn points by attending gyms, which contribute, together with points earned from engagement in other wellness and preventive activities, to tier status (Blue, Bronze, Silver, Gold and Diamond). Tier status allows members to receive increasing discounts on a range of goods and services from commercial partners. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
62232242|NCT01652950|ACTIVE_COMPARATOR|Vitality Wellness Program Enhanced Communication|"In this group, members were offered the base program and, in addition, were sent bi-weekly communications by alternating email and text messaging which included information on the importance of physical activity, tips on accumulating fitness points on the base program, a status update of points earned and information on benefits and rewards offered on the program. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration."
62592857|NCT05696925|EXPERIMENTAL|observation of the action, execution of the action, and exoskeleton (GE5)|"in the sitting position, the participant will perform the exoskeleton protocol for 40 minutes.~Then, the participant will watch the recorded video to observe the action, for two minutes. Then, in the sitting or standing position, depending on the action to be performed, the participant must execute the same action observed previously, for two minutes. Each session will have five different actions that will be repeated twice, totaling 80 minutes of intervention."
62232243|NCT04782843||Cohort|"he retrospective cohort studied includes all the patients included in a previous study carried out in our center, the objective of which was to study the diagnostic performance of the HEP score in surgical intensive care.~The cohort studied is made up of all patients admitted for surgical resuscitation between October 2011 and October 2013 and validating the following criteria:~* Inclusion criteria: any adult patient (age ≥ 18 years), admitted to surgical intensive care, treated with heparin (UFH or LMWH), and suspected of TIH by a clinician in the department according to the criteria of the SFAR 2002.~* Non-inclusion criteria: minor patients, pregnant women and adults incapable."
62232244|NCT01285271|EXPERIMENTAL|Xenon|Xenon will be administered for balanced general anesthesia for CABG surgery before and after the extracorporal circulation.
62232245|NCT01285271|ACTIVE_COMPARATOR|Sevoflurane|Sevoflurane will be administered for balanced general anesthesia for CABG surgery before and after the extracorporal circulation.
62592858|NCT04369131|EXPERIMENTAL|Intervention|All participants will receive intervention in four conditions: (a) no FES, (b) calves only FES, (c) quads and abdominals only FES, and (d) calves, quads, and abdominals FES. Session-by-session alternation among conditions will occur in a unique, predetermined, randomized order for each participant.
62592859|NCT06178731|EXPERIMENTAL|Virtual reality + rTMS|Each treatment session involves: 12-15 min VR viewing, 15 min descriptive and imaginal recounting followed immediately by 3 min rTMS delivery with iTBS to the left DLPFC.
62592860|NCT06178731|SHAM_COMPARATOR|Virtual reality sham + rTMS|Each treatment session involves: 12-15 min VR viewing, 15 min descriptive and imaginal recounting followed immediately by 3 min rTMS delivery with iTBS to the left DLPFC.
62592861|NCT02796352|EXPERIMENTAL|High dose bolus interleukin-2 (HD IL2)|
62808598|NCT05106127|EXPERIMENTAL|EG-007 1000mg Loading + Len + Pem|6 to 10 patients will receive EG-007 loading dose of 5000 mg given as 1000 mg daily over 5 consecutive days starting 4 days before the first dose of Pembrolizumab under this protocol.
62808599|NCT05106127|EXPERIMENTAL|EG-007 1000mg D-4 Loading + Len + Pem|6 to 12 patients initiating new regimens of Len+Pem will receive EG-007 loading dose of 5000 mg given as 1000 mg daily over 5 consecutive days starting 4 days before the first dose of Pembrolizumab.
62808600|NCT02520817||Antioxidant supplementation and zinc plus Lactulose(Group A)|Patients With MHE were assigned to receive zinc and antioxidant plus lactulose (group A)
62808601|NCT02520817||Lactulose only (Group B)|Patients with MHE were assigned to receive lactulose oly (group B)
62808602|NCT04894721|EXPERIMENTAL|Experimental Group|The EG receives ivermectin 0,6mg/kg of weight orally on days 1 (one) and 7 (seven) plus standard biosecurity care
62808603|NCT04894721|PLACEBO_COMPARATOR|Control Group|The CG receives a placebo on days 1 (one) and 7 (seven) plus standard biosecurity care
62808604|NCT00702702|EXPERIMENTAL|A 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
62808605|NCT00702702|EXPERIMENTAL|B 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
62808606|NCT00702702|PLACEBO_COMPARATOR|C Placebo|Placebo, 2 capsules daily for 3 months
62808607|NCT02732600|NO_INTERVENTION|Standard Implementation|Standard Implementation sites will receive written guidance and limited consultation by the investigators' team.
62808608|NCT02732600|EXPERIMENTAL|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation.
62808609|NCT04173806|EXPERIMENTAL|Facebook group|"Participants will be included in an online classroom through a closed group of Facebook to receive an asynchronous course of telemedicine."
62808610|NCT04173806|ACTIVE_COMPARATOR|Control group|In this group the participants are exposed to the same course of telemedicine but on the Moodle educational platform.
62232246|NCT01273077||Evaluation of Rotarix Program|All infants in Nova Scotia DHA 9 and PEI born after October1, 2010 until September 30, 2012 will be eligible for Rotarix immunization as part of the publicly funded immunization program. New Brunswick will serve as the non-intervention control location.
62808611|NCT02533414|EXPERIMENTAL|UAS (+)|RIRS with UAS: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
62808612|NCT02533414|ACTIVE_COMPARATOR|UAS (-)|RIRS without UAS: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
62808613|NCT01119053|SHAM_COMPARATOR|Arm I|In this branch of study, study participants obtain the VNS therapy after a defined space of time of 12 weeks.
62232247|NCT01273077||Retrospective Surveillance|All laboratory- confirmed cases of rotavirus gastroenteritis and all cause diarrhea admitted to the trial hospitals from 2008-2010 will be entered in the database.
62232248|NCT01273077||Prospective Surveillance|Will begin on December 1, 2010. Data will be collected to identify hospitalizations for all cause diarrhea and rotavirus gastroenteritis at all 3 sites through the first two consecutive rotavirus seasons following vaccination.
62808614|NCT01119053|EXPERIMENTAL|Arm II|Within this space of time, study participants obtain the VNS therapy at once.
62232249|NCT01273077||Safety Intussusception|Each trial hospital will identify cases of severe diarrhea and intussusception in Rotarix vaccine recipients through the first two consecutive rotavirus seasons following vaccination.
62592862|NCT05174949|EXPERIMENTAL|Sham, Anodal, Cathodal|Treatment order 1: Sham, Anodal, Cathodal
62808615|NCT00531284|EXPERIMENTAL|Phase 1B Solid Tumors: Carfilzomib 20 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62808616|NCT00531284|EXPERIMENTAL|Phase 1B Solid Tumors: Carfilzomib 20/27 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 27 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62232250|NCT01273077||ED Rotavirus Snap Shot Study|During rotavirus peak season, a prospective study of a sample of children under the age of 2 years presenting with diarrhea with or without vomiting to the ER of participating trial centers will be conducted in year one. In year 2 and 3 of the project:, systematic stool sampling will be carried out for cases of gastroenteritis in children \< 5 years of age presenting to the ED departments.
62592863|NCT05174949|EXPERIMENTAL|Anodal, Cathodal, Sham|Treatment order 2: Anodal, Cathodal, Sham
62592864|NCT05174949|EXPERIMENTAL|Cathodal, Sham, Anodal|Treatment order 3: Cathodal, Sham, Anodal
62592865|NCT05174949|EXPERIMENTAL|Sham, Cathodal, Anodal|Treatment order 4: Sham, Cathodal, Anodal
62592866|NCT05174949|EXPERIMENTAL|Cathodal, Anodal, Sham|Treatment order 5: Cathodal, Anodal, Sham
62808617|NCT00531284|EXPERIMENTAL|Phase 1B Solid Tumors: Carfilzomib 20/36 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62232251|NCT01273077||KAB Questionnaire for HCP and Parents|Data will be collected by a validated survey given to Parents, Healthcare providers and Program organizers throughout the 2 year program.
62592867|NCT05174949|EXPERIMENTAL|Anodal, Sham, Cathodal|Treatment order 6: Anodal, Sham, Cathodal
62592868|NCT01665820||Auscultate with mechanical stethoscope|Cardiologist \& Medical Resident auscultate using mechanical stethoscope
62592869|NCT01665820||Auscultate with electronic stethoscope|Cardiologist \& Medical Resident auscultate using electronic stethoscope
62592870|NCT05451550|EXPERIMENTAL|General anesthesia group|Patients were maintained with propofol/remifentanil in general anesthesia
62592871|NCT05451550|EXPERIMENTAL|General anesthesia combined with brachial plexus block group|An additional ultrasound-guided brachial plexus block were performed
62808618|NCT00531284|EXPERIMENTAL|Phase 2 Solid Tumors: Carfilzomib 20/36 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62808619|NCT00531284|EXPERIMENTAL|Phase 1B Solid Tumors: Carfilzomib 36 mg/m²|Participants received carfilzomib 36 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62032467|NCT01019876|EXPERIMENTAL|Regimen D|"Includes patients with the following speciﬁc diagnosis of: Severe Combined Immune Deﬁciency Syndrome with no evidence of host NK function (will receive Regimen A) and matched related donor~* Cyclophosphamide (30 mg/kg total dose)~* Fludarabine (90 mg/m2 total dose)~* Rabbit anti-thymocyte globulin (Thymoglobulin)(TMG)\*\*(8 mg/kg total dose)~TMG only in family haploidentical and unrelated donors"
62808620|NCT00531284|EXPERIMENTAL|Phase 1B Solid Tumors: Carfilzomib 45 mg/m²|Participants received carfilzomib 45 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62232252|NCT02271997|ACTIVE_COMPARATOR|Ferrous fumarate|40 patients receive ferrous fumarate 3 times a day 200mg
62819533|NCT03021200|EXPERIMENTAL|Indocyanine green in Conventional Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (SPY-Elite) for conventional oncological surgeries
62032468|NCT01176539||Sleep Clinic|
62032469|NCT04372771|NO_INTERVENTION|Control|No diet or exercise intervention
62032470|NCT04372771|EXPERIMENTAL|Curves Program|The Curves group will follow the high protein/low fat diet (30% carbohydrate, 45% protein, 25% fat) for 7-days at 1,200 kcals/day and then 1,500 kcals/day for the remaining 21-days of the 30-day diet period. The participants will then consume a normal maintenance diet (2,200 kcals/d; 45% carbohydrate, 30% protein, 25% fat) for 30-days. During the maintenance period, participants will diet for 2-days at 1,200 kcals/day if they gain 3 pounds of weight.
62032471|NCT04372771|EXPERIMENTAL|Weight Watchers Momentum Program|"This program is based on the Weight Watchers four pillar approach (food, exercise, behavior and support). The Momentum Program uses POINTS values to help keep track of what you eat. A POINTS budget will be personalized for you at the weekly meetings."
62232253|NCT02271997|ACTIVE_COMPARATOR|Ferrous gluconate|40 patients receive ferrous gluconate 2 times a day 695 mg
62032472|NCT04367675|EXPERIMENTAL|INO-5401|Participants receive INO-5401 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
62232254|NCT02271997|ACTIVE_COMPARATOR|Iron(III)carboxymaltose|40 patients receive a single intravenous shot of ferinject
62232255|NCT00734383|EXPERIMENTAL|1|Propofol Cardioprotection
62232256|NCT00734383|EXPERIMENTAL|2|Volatile Anesthesia Preconditioning
62232257|NCT01980550|EXPERIMENTAL|sublingual nicotine，placebo|sublingual nicotine：one or two tablets per hour, up to a maximum of 20 tablets per day Subjects were advised to use the full treatment dose for 4 weeks
62423578|NCT03593772|NO_INTERVENTION|Control arm - Partner|Usual Care Waitlist Control Arm: For ethical reasons, this study will use a waitlist control arm to ultimately provide all participants exposure to the MR intervention. Dyads in the control arm will participate in all assessments like those in the treatment group, however, they will be asked to agree to not access the public web site during their participation. Wait-list control participants will be instructed to seek advice about treatment from their providers. Other than this initial advice, there will be no attempt by study personnel to influence condition management unless an issue (i.e., suicidal ideation) arises. The control condition will account for potential temporal effects that occur from passage of time (brief), and expectation effects associated with anticipation of MR participation. The control group will receive access to MR after they complete data collection.
62423579|NCT01238731||Valve replacement|Patients undergoing valve replacement for severe valve disease will be screened for study entry
62423580|NCT04278365|EXPERIMENTAL|AMP-A|Participants will complete 11, 90-minute sessions of positive affect training. The positive affect training will be conducted in an individual setting. Positive affect training directly targets reward and positive valence processing and has been shown by previous research to enhance positive affect (and decrease negative affect).
62423581|NCT03849170|EXPERIMENTAL|Psychological Intervention|Six session intervention, each session 20-25 minutes in length. Stress inoculation technique-based intervention. Participants will be taught stress coping skills and relaxation skills such as self-efficacy statements, imagery, relaxation breathing, relaxation scripts, thought stoppage, cognitive reframing, positive self-talk, goal setting, event planning, and preparing for competition
62423582|NCT03849170|PLACEBO_COMPARATOR|Health Intervention|Six session intervention, each session 20-25 minutes in length. Participants will be taught relevant health and nutrition guidelines and practice using a food diary app (MyFitnessPal). Nutrition and health content will include such topics as reading Canadian food labels, vitamins and supplements, effects of alcohol on performance and recovery, vegetarian vs. omnivore diets, and hydration \& performance.
62423583|NCT03843268|ACTIVE_COMPARATOR|AMPS Gondola|Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS)
62423584|NCT03843268|PLACEBO_COMPARATOR|Sham Gondola|The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger.
62423585|NCT04238780|ACTIVE_COMPARATOR|ESP( Erector Spinae Plane Block)|"After induction parturient in the ESPB underwent bilateral ESPB at the level of T7 using a linear ultrasound (US) transducer.~Intravenous fentanyl patient control device 24-hour fentanyl consumption will be recorded."
62592872|NCT05451550|EXPERIMENTAL|general anesthesia combined with suprascapular nerve block group|An additional ultrasound-guided suprascapular nerve block were performed
62592873|NCT06127524|EXPERIMENTAL|Nursing Home Residents in intervention|All Nursing Home residents in the facility during the 8 month intervention period
62808621|NCT00531284|EXPERIMENTAL|Phase 1B Solid Tumors: Carfilzomib 20/45 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62808622|NCT00531284|EXPERIMENTAL|Phase 1B Solid Tumors: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62808623|NCT00531284|EXPERIMENTAL|Phase 1B Solid Tumors: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62032473|NCT04367675|EXPERIMENTAL|INO-5401 and INO-9012|Participants receive INO-5401 and INO-09012 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
62232258|NCT01078675|EXPERIMENTAL|1|
62232259|NCT00507676||Group 1|One hundred and sixty healthy infants between 1 and 24 months of age will be evaluated. Subjects will be recruited so that there are 40 subjects within each of four subgroups: 1) Negative ETS exposure and Negative Fm Asthma, 2) Positive ETS exposure and Negative Fm Asthma, 3) Negative ETS exposure and Positive Fm Asthma and 4) Positive ETS exposure and Positive Fm Asthma. Equal numbers of males and females will be recruited. The ethnic composition will be approximately 80% Caucasian and 20% African-American in each of the four groups, which represents the distribution within the cities where infants will be evaluated. Subjects will be excluded if they were born prematurely (\<37 weeks gestation), have a history of congenital cardio-respiratory disease, or have history of lower respiratory illness.
62592874|NCT06127524|NO_INTERVENTION|Nursing Home Residents in baseline|All Nursing Home residents in the facility during the 12 month baseline period
62592875|NCT02589327|EXPERIMENTAL|Exercise Intervention|Hight intensity resistance training group
62032474|NCT00476476|EXPERIMENTAL|Erlotinib|Patients rcvd oral erlotinib 150 mg/day. Cohort 1 pts would have at least 28 days and no more than 42 days of therapy in advance of definitive therapy (surgery or chemoradiation). Cohort 2 pts continued on therapy (28 days per cycle) until disease progression, unacceptable toxicity or withdrawal of consent. Two potential dose reductions were prescribed to 100 and 50 mg/day.
62232260|NCT00507676||Group 2|Eighty infants between 1 and 24 months of age scheduled for CT scans of the abdomen or chest will be evaluated. Subjects will be excluded if they are born prematurely (\<37 weeks gestation), have history of congenital cardio-respiratory disease, or have history of recurrent wheezing.
62232261|NCT00507676||Group 3|Eighty infants with recurrent wheezing between 1 and 24 months of age will be evaluated when they are not acutely symptomatic for at least 3 weeks. Subjects will be recruited so that there are 20 subjects within each of four subgroups: 1) Negative ETS exposure and Negative Fm Asthma, 2) Positive ETS exposure and Negative Fm Asthma, 3) Negative ETS exposure and Positive Fm Asthma and 4) Positive ETS exposure and Positive Fm Asthma. Equal numbers of males and females will be recruited. Subjects will be excluded if they were born prematurely (\<37 weeks gestation) or have history of congenital cardio -respiratory disease.
62232262|NCT00001521|EXPERIMENTAL|Investigational 1|boys/flutamide, letrozole, and reduced hydrocortisone dose or conventional treatment (with hydrocortisone and fludrocortisone ) until the age of 14
62423586|NCT04238780|ACTIVE_COMPARATOR|control group|"No regional anesthesia technique will be applied to the control group.~Intravenous fentanyl patient control device 24-hour fentanyl consumption will be recorded."
62423587|NCT04977635||600-cohort|"Patients with long-term (\> 5 years) type 1 diabetes aged 16 years and older~As this is an observational study there is no intervention."
62232263|NCT00001521|EXPERIMENTAL|Investigational 2|girls/flutamide, letrozole, and reduced hydrocortisone dose, the Letrozole will discontinue at 13 y.o. and continue flutamide until 2 years after menarche or when final height is reached, whichever occurs first
62232264|NCT00409773|OTHER|1|Arm 1: drug + comparator + Placebo
62423588|NCT03528837||Diagnosed as acute kidney injury|Sure diagnosed as acute kidney injury
62808624|NCT00531284|EXPERIMENTAL|Phase 1b Multiple Myeloma: Carfilzomib 20/36 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62808625|NCT00531284|EXPERIMENTAL|Phase 1b Multiple Myeloma: Carfilzomib 20/45 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62232265|NCT00409773|OTHER|2|Arm 2: drug + comparator + Placebo
62423589|NCT02134769|NO_INTERVENTION|Control|No use of Bionecteur; handling according to institutional guideline
62232266|NCT00409773|OTHER|3|Arm 3: drug + comparator + Placebo
62423590|NCT02134769|ACTIVE_COMPARATOR|Bionecteur|Use of Bionecteur; handling according to institutional guideline
62423591|NCT01255579|ACTIVE_COMPARATOR|SF|Extrafine Fluticasone/Salmeterol
62423592|NCT01255579|ACTIVE_COMPARATOR|FB|Extrafine Formoterol and beclometasone HFA
62808626|NCT00531284|EXPERIMENTAL|Phase 1b Multiple Myeloma: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62808627|NCT00531284|EXPERIMENTAL|Phase 1b Multiple Myeloma: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62423593|NCT02702271|EXPERIMENTAL|WATCHMAN FLX - M|WATCHMAN FLX Main Cohort
62423594|NCT02702271|EXPERIMENTAL|WATCHMAN FLX - R|WATCHMAN FLX Roll-In Cohort
62032475|NCT00477191|EXPERIMENTAL|Etanercept|Etanercept
62232267|NCT00409773|OTHER|4|Arm 4: drug + comparator + Placebo
62232268|NCT00409773|OTHER|5|Arm 5: drug + comparator + Placebo
62232269|NCT02152657|EXPERIMENTAL|Mesenchymal stem cell transplantation|
62232270|NCT02751567|EXPERIMENTAL|Arm 1|All subjects are patched with the same product
62232271|NCT05115604|EXPERIMENTAL|Intrervention group|One and a half hour sessions (6 sessions) of cognitive behavioural therapy and psychoeducation. The sessions will consist of: sleep hygiene, cognitive therapy, bedtime restriction, stimulus control and relaxation.
62232272|NCT05115604|NO_INTERVENTION|Control group|routine clinical follow-up
62423595|NCT05165017|ACTIVE_COMPARATOR|Intervention Arm 1|AlloRx Stem Cells IV infusion treatment
62423596|NCT05165017|PLACEBO_COMPARATOR|Intervention Arm 2|IV infusion of normal saline
62423597|NCT04106856|EXPERIMENTAL|Treatment (losartan, hypofractionated radiation therapy)|Beginning on day 1, patients receive losartan potassium PO QD. Beginning day 14, patients also undergo hypofractionated radiation therapy over 15 fractions 5 days a week for up to 3 weeks. Patients continue to receive losartan potassium PO QD during radiation therapy and for 28 days after completion of radiation therapy. Patients may begin additional anti-cancer therapy per investigator discretion after the last dose of HRT. Losartan can be given concurrently with additional therapy and Losartan dosing can continue until 28 days after last dose of HRT, regardless of when additional therapy is started.
62423598|NCT02567266|EXPERIMENTAL|Unified Protocol for Adolescents (UP-A)|Participants will be treated with the Unified Protocol for the Treatment of Emotional Disorders in Adolescence. Their clinicians will also receive feedback using the Youth Outcomes Questionnaire feedback system.
62592876|NCT02589327|NO_INTERVENTION|Control|No-exercise control group
62032476|NCT06595108|EXPERIMENTAL|Patients with advanced hepatocellular carcinoma|Patients indicated for the first-line atezolizumab-bevacizumab combination therapy are the primary subjects, and those voluntarily agree to the clinical trial after explanation of the study, are enrolled in the study.
62032477|NCT01343407|EXPERIMENTAL|MK-1029 60 mg|Part 2 - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design
62032478|NCT01343407|EXPERIMENTAL|MK-1029 500 mg|Part 2 - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design
62032479|NCT01343407|PLACEBO_COMPARATOR|Placebo|Part II - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design
62032480|NCT06273917|EXPERIMENTAL|PRIDE Patients|Community-dwelling adults (age 18+) in the ED with prior outpatient visits within the NM system and a history of dementia or mild cognitive impairment recorded in the NM EHR will be eligible for inclusion. We will include 290 patients across 3 sites to have medication reconciliation conducted by the clinical pharmacist. Patients who were previously prescribed CNS PIMs will have deprescribing recommendations communicated by the clinical pharmacist to the outpatient prescriber.
62032481|NCT04090424|EXPERIMENTAL|NovoSorb BTM|Application of NovoSorb BTM to study lesions
62032482|NCT04090424|ACTIVE_COMPARATOR|Standard of Care|Application of the institution's standard of care to study lesions.
62032483|NCT04100772|EXPERIMENTAL|vaccine 1A|Subjects received one dose of PCV13i at 18 to 49 years old
62032484|NCT04100772|EXPERIMENTAL|vaccine 2A|Subjects received one dose of PCV13i at 50 years old and above
62032485|NCT04100772|EXPERIMENTAL|vaccine 3A|Subjects received one dose of PCV13i at 6 to 17 years old
62032486|NCT04100772|EXPERIMENTAL|vaccine 4A|Subjects received one dose of PCV13i at 2 to 5 years old
62032487|NCT04100772|EXPERIMENTAL|vaccine 5A|Subjects received two doses of PCV13i at 7 months to 2 years old
62032488|NCT04100772|EXPERIMENTAL|vaccine 6A|Subjects received three doses of PCV13i at 3,4,5 months of age
62032489|NCT04100772|EXPERIMENTAL|vaccine 7A|Subjects received three doses of PCV13i at 2,4,6 months of age
62032490|NCT04100772|ACTIVE_COMPARATOR|vaccine 7B|Subjects received three doses of PCV13 at 2,4,6 months of age
62032491|NCT04957966|EXPERIMENTAL|Music listening vs. No music listening|Random assignment (50:50) of every participant to one of the following two conditions: Music listening after a stressful/discriminatory event (i.e., intervention condition) or no music listening after a stressful/discriminatory event (i.e., control condition).
62032492|NCT03370887|EXPERIMENTAL|Low dose AZD8601 (3 mg)|8 patients will be randomised to receive 3 mg AZD8601
62423599|NCT02567266|EXPERIMENTAL|Treatment as Usual Plus (TAU+)|Participants will be treated by clinicians who receive feedback using the Youth Outcomes Questionnaire, but who otherwise use Treatment as Usual
62423600|NCT02567266|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Participants will receive Treatment as Usual provided at the study clinics.
62423601|NCT02190383|EXPERIMENTAL|Habit Reversal Training|At first patients get informed about Tics in general. Then the individual Tics are specified and the tic-reaction is looked at further. The Tic-Symptoms are observed and the premonitory urge is specified. For all individual tics a specific reversal movement is developed. Relaxation methods are introduced.
62423602|NCT02396069|EXPERIMENTAL|JPI-289|Each cohort, volunteers will be infused JPI-289 for 60 min. (6 volunteers per each cohort, total 3 cohort)
62423603|NCT02396069|PLACEBO_COMPARATOR|Placebo|Each cohort, volunteer will be infused placebo for 60 min. (2 volunteers per each cohort, total 3 cohort)
62423604|NCT01819701|PLACEBO_COMPARATOR|Placebo|starch
62423605|NCT01819701|EXPERIMENTAL|LC and Coenzyme Q10|L-carnitine: 1000 mg/d and 2000 mg/d Coenzyme Q10: 150 mg/d and 300 mg/d
62423606|NCT04779411||Food Frequency Questionnaire Validation Group|"The validation procedure will span over four weeks, consisting of administering the Lutein and Zeaxanthin Food Frequency Questionnaire (FFQ L/Z) and 24-hour diet recalls at multiple timepoints. Timepoints for the eight 24-hour diet recalls will be determined by random number generator for each of the participants at baseline (https://www.random.org/), of which two will take place on weekend days, and the remainder on week days.~* The weekly L/Z FFQ will be completed at the conclusion of each of the four weeks.~* The monthly L/Z FFQ will be completed at baseline and at the conclusion of week four."
62423607|NCT04779411||Electronic Device Use Questionnaire Validation Group|The validation procedure will occur over eight weeks consisting of administering eight 24-hour diary of electronic device use (24-hour ED use diary) and the Electronic Device Use Questionnaire (EDUQ) at three time points. The time points for the eight 24-hour ED use diaries will be determined by random number generator for each of the participants at baseline (https://www.random.org/), of which two will take place on weekend days, and the remainder on weekdays. The EDUQ will be completed at baseline and at the conclusion of weeks four and eight.
62592877|NCT01535508|EXPERIMENTAL|Liquid Vitamin D|
62032493|NCT03370887|EXPERIMENTAL|High dose AZD8601 (30 mg)|8 patients will be randomised to receive 30 mg AZD8601
62032494|NCT03370887|PLACEBO_COMPARATOR|Placebo|8 patients will be randomised to receive placebo injections
62032495|NCT06397469|EXPERIMENTAL|MediTrain 30m/day for 6wks|Participants will engage with a digital meditation app for the time listed above.
62032496|NCT06397469|EXPERIMENTAL|MediTrain 15m/day for 6wks|Participants will engage with a digital meditation app for the time listed above.
62032497|NCT06397469|EXPERIMENTAL|MediTrain 30m/day for 3wks|Participants will engage with a digital meditation app for the time listed above.
62032498|NCT06397469|EXPERIMENTAL|MediTrain 15m/day for 3wks|Participants will engage with a digital meditation app for the time listed above.
62032499|NCT06397469|ACTIVE_COMPARATOR|Active Control Group|An active control application will be used for this arm. The total training experience here will be for 6 weeks (5 days/week), with each training session lasting \~30 minutes (not including self-paced breaks). Here an app that is matched in terms of expectancy of benefits compared to our training groups will be determined by questioning 100 naïve individuals to predict their expected improvement on each cognitive domain across a multitude of possible applications.
62032500|NCT04553757||Observational (survey)|Patients complete a seizure assessment survey over 5 minutes at each clinic visit.
62032501|NCT01828242|EXPERIMENTAL|Empowerment model to Diabetes|Empowerment model to improve dietary intake
62423608|NCT06319521|EXPERIMENTAL|Rehabilitation therapy+Stellate ganglion block|The study lasts 10d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. Based on this, the patients in the experimental group are provided with Stellate Ganglion Block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day.
62808628|NCT00531284|EXPERIMENTAL|Phase 1b Lymphoma: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62808629|NCT00531284|EXPERIMENTAL|Phase 1b Lymphoma: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62808630|NCT00531284|EXPERIMENTAL|Phase 1b MM: Carfilzomib 20/45 mg/m² + Dexamethasone|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62032502|NCT01828242|ACTIVE_COMPARATOR|Control group following conventional approach|Control group following conventional approach
62032503|NCT02580097||Stroke|Ischemic stroke patients with sympton onset in 24 hours and no contradiction to MRI scan
62032504|NCT01048528|EXPERIMENTAL|Stress Management|Stress Management and Relaxation Training workshops
62032505|NCT01048528|NO_INTERVENTION|Wait-list|Wait-list comparison group
62032506|NCT00733317|ACTIVE_COMPARATOR|1-Budesonide nebulized suspension|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times and will not give after 3 doses
62032507|NCT00733317|PLACEBO_COMPARATOR|2- 0.9% saline|Children will receive 2 ml of saline every 20 minutes for 3 times and will not give after 3 doses
62032508|NCT05472428|EXPERIMENTAL|Autologous BMMNC transplantation|- Autologous bone marrow mononuclear cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
62032509|NCT03118960|ACTIVE_COMPARATOR|Freedom Bed|Bed turns and positions subjects automatically for the healing and prevention of pressure injury
62032510|NCT03118960|ACTIVE_COMPARATOR|Group II Low Air Loss/Alternating Pressure Mattress|Bed provides subjects with alternating pressure with low air loss mattress for the healing and prevention of pressure injury
62032511|NCT06344312|EXPERIMENTAL|Experimental group|Randomly take 2 bags of Yangxue Qingnao Granules orally during intravenous thrombolysis with ateplase, and then take 1 bag of Yangxue Qingnao Granules three times a day for a total of 2 weeks
62032512|NCT06344312|PLACEBO_COMPARATOR|Control Group|When receiving intravenous thrombolysis with ateplase, two bags of Yangxue Qingnao Granule Simulator were randomly taken orally. Afterwards, one bag of Yangxue Qingnao Granule Simulator was taken three times a day for a total of two weeks.
62032513|NCT04499794||FISH diagnosed EML4-ALK fusion positive NSCLC group|
62032514|NCT04499794||FISH diagnosed EML4-ALK fusion negative NSCLC group|
62032515|NCT01519713|EXPERIMENTAL|Adults Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
62032516|NCT01519713|EXPERIMENTAL|Adolescents Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
62032517|NCT01519713|EXPERIMENTAL|Children Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
62032518|NCT05319431|EXPERIMENTAL|AK104+Lenvatinib+TACE|Participants will receive AK104 IV every 3 weeks (Q3W) and Lenvatinib 12mg weight≥60kg or 8mg weight\<60kg,PO QD The first Transarterial chemoembolization will be performed at the beginning of study.
62032519|NCT06634446|EXPERIMENTAL|Experimental group|the experimental group will use a mobile application for cognitive training for 3 months.
62032520|NCT06634446|ACTIVE_COMPARATOR|comparative control group|Patients in the control group will use video games with no prominent cognitive involvement
62232273|NCT04507061|EXPERIMENTAL|runcaciguat|Participant randomized to this arm will be up-titrated. A 30-day safety follow up will be performed after end of treatment or after early discontinuation from the study.
62232274|NCT04507061|PLACEBO_COMPARATOR|Placebo|Participant randomized to this arm will be sham-titrated. A 30-day safety follow up will be performed after end of treatment or after early discontinuation from the study.
62423609|NCT06319521|PLACEBO_COMPARATOR|Rehabilitation therapy+placebo block|The study lasts 10d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy.
62232275|NCT03770637|EXPERIMENTAL|Glucagon RTU (glucagon injection)|Glucagon Ready-to-Use (RTU); 60 μL injection (0.3 mg glucagon)
62592878|NCT01906021|EXPERIMENTAL|1|Intra-patient comparison of temperature map obtained during CT/CBCT with standard ablation temperature measurements
62423610|NCT01837485|EXPERIMENTAL|Lactol|
62592879|NCT05219292||Adult patients followed for a recent lung transplant.|Patients will be recruited during the pre-transplant assessment by the physiotherapist, the pneumologist and/or the transplant nurse coordinator. The patient has the hospital stay of the pre-transplantation to give his answer. The protocol starts on arrival in the rehabilitation department.
62232276|NCT03770637|PLACEBO_COMPARATOR|Placebo|Non-active vehicle for Glucagon RTU; 60 μL injection
62232277|NCT01006928||Mothers|Mother of infants in NICU
62232278|NCT00108147|EXPERIMENTAL|1|Circuit Training
62232279|NCT00108147|ACTIVE_COMPARATOR|2|Cardiac Rehabilitation
62232280|NCT00108147|ACTIVE_COMPARATOR|3|Flexibility and toning
62232281|NCT06528886|EXPERIMENTAL|regional anesthesia|hysterectomy will be done by V-NOTES under regional anesthesia .
62592880|NCT00453531|EXPERIMENTAL|Healthy Volunteers|
62232282|NCT02782403|EXPERIMENTAL|Treatment (alternating therapy)|Patients with chronic phase CML receive either bosutinib PO QD or axitinib PO BID alone for 3 months. Patients then switch to the other drug for 3 months and alternate between the two every 3 months in the absence of disease progression or unacceptable toxicity.
62232283|NCT02782403|EXPERIMENTAL|Treatment (combined therapy)|Patients with accelerated or blastic phase CML receive bosutinib PO QD and axitinib PO BID for 3 months. Courses repeat every 3 months in the absence of disease progression or unacceptable toxicity.
62232284|NCT05751863|EXPERIMENTAL|Analgesia First Sedation|Subjects will be randomized to receive analgesia-first sedation by intermittent doses of Fentanyl (25 mcg), instead of continuous IV infusions. If the intermittent IVP x4 fails to achieve the target pain score, an infusion starts at 50 mcg/hr and titration by 25 mcg q15 minutes. If sedation score is not achieved, propofol infusion starts at 5 mcg/kg/min to achieve goal RASS of 0 to -2. Subjects will be assessed for a ventilator weaning trial daily.
62423611|NCT01837485|PLACEBO_COMPARATOR|Placebo|
62423612|NCT02470078|EXPERIMENTAL|Pharyngeal electrical stimulation|Pharyngeal electrical stimulation once daily for 10 minutes on three consecutive days.
62423613|NCT02470078|SHAM_COMPARATOR|Sham stimulation|Sham stimulation once daily for 10 minutes on three consecutive days.
62423614|NCT01880541|EXPERIMENTAL|hypnosedation|hypnosedation
62423615|NCT01880541|OTHER|general anesthesia|general anesthesia
62423616|NCT03865992|EXPERIMENTAL|Arm I (nanoemulsion curcumin)|Patients receives nanoemulsion curcumin orally (PO) twice daily (BID) for up to 3 months in the absence of disease progression or unacceptable toxicity.
62423617|NCT03865992|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID for up to 3 months in the absence of disease progression or unacceptable toxicity.
62592881|NCT01579045|EXPERIMENTAL|Sequence 1|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, nelfilcon A, etafilcon A, senofilcon A, Filcon II 3"
62592882|NCT01579045|EXPERIMENTAL|Sequence 2|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, nelfilcon A, etafilcon A, Filcon II 3, senofilcon A"
62592883|NCT01579045|EXPERIMENTAL|Sequence 3|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, etafilcon A, nelfilcon A, senofilcon A, Filcon II 3"
62592884|NCT01579045|EXPERIMENTAL|Sequence 4|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, etafilcon A, nelfilcon A, Filcon II 3, senofilcon A"
62592885|NCT01579045|EXPERIMENTAL|Sequence 5|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, Filcon II 3, etafilcon A, senofilcon A, Filcon II 3"
62592886|NCT01579045|EXPERIMENTAL|Sequence 6|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, Filcon II 3, etafilcon A, Filcon II 3, senofilcon A"
62592887|NCT01579045|EXPERIMENTAL|Sequence 7|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, etafilcon A, Filcon II 3, senofilcon A, Filcon II 3"
62592888|NCT01579045|EXPERIMENTAL|Sequence 8|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, etafilcon A, Filcon II 3, Filcon II 3, senofilcon A"
62592889|NCT01579045|EXPERIMENTAL|Sequence 9|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, Filcon II 3, nelfilcon A, senofilcon A, Filcon II 3"
62592890|NCT01579045|EXPERIMENTAL|Sequence 10|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, Filcon II 3, nelfilcon A, Filcon II 3, senofilcon A"
62808631|NCT00531284|EXPERIMENTAL|Phase 1b MM: Carfilzomib 20/56 mg/m² + Dexamethasone|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
62032521|NCT01358968|EXPERIMENTAL|LY2603618|"Single 50 milligrams (mg) oral dose of desipramine on day 1 of study period 1. Single 275 mg intravenous infusion over one hour of LY2603618 followed by single 50 mg oral dose of desipramine on day 1 of study period 2. Participants may then receive additional doses of LY2603618 in combination as follows: 1000 milligrams per square meter (mg/m²) intravenous administration over 30 minutes of gemcitabine on days 1, 8 and 15 and 230 mg intravenous dose of LY2603618 on days 2, 9 and 16 of 28-day cycles OR 500 mg/m² intravenous administration over 10 minutes of pemetrexed on day 1 and 275 mg intravenous dose of LY2603618 on day 2 of 21-day cycles.~Participants will be allowed to continue to receive the combination therapy until fulfilling one of the criteria for discontinuation, such as unacceptable toxicity or disease progression."
62032522|NCT06670118||Patients with Normal Lung Ultrasound (LUS) Findings|This cohort includes patients aged 65 and older admitted with acute respiratory symptoms who undergo lung ultrasound (LUS) upon hospital admission. LUS findings in this cohort show normal lung conditions with no significant pleural or parenchymal abnormalities (e.g., no comet-tail artifacts, consolidations, or effusions). The primary interest is to assess the absence of LUS abnormalities and their correlation with clinical outcomes, including delirium, oxygen therapy, and mortality.
62032523|NCT06670118||Patients with Abnormal Lung Ultrasound (LUS) Findings|This cohort includes patients aged 65 and older admitted with acute respiratory symptoms who undergo lung ultrasound (LUS) upon hospital admission. LUS findings in this cohort show significant abnormalities such as pleural effusions, consolidations, or diffuse comet-tail artifacts (B-lines). The primary interest is to assess the presence of LUS abnormalities and their correlation with clinical outcomes, including delirium, duration of hospitalization, need for oxygen therapy, non-invasive ventilation, and mortality.
62032524|NCT01302119|EXPERIMENTAL|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%
62032525|NCT01302119|PLACEBO_COMPARATOR|Solution Vehicle|Solution Vehicle
62032526|NCT05239039|EXPERIMENTAL|Spesolimab single dose treatment|Patients with Generalized Pustular Psoriasis (GPP) presenting a flare received a single intravenous dose of 900 milligrams of spesolimab.
62032527|NCT05239039|EXPERIMENTAL|Spesolimab double dose treatment|Patients with Generalized Pustular Psoriasis (GPP) presenting a flare received a single intravenous dose of 900 milligrams of spesolimab. One week after the initial dose, patients received a second intravenous single dose of 900 mg of spesolimab due to persistence of flare symptoms.
62032528|NCT02507895|EXPERIMENTAL|MI-BCI training|subjects will undergo 12 sessions over 4 weeks of MI-BCI training
62032529|NCT05974527|EXPERIMENTAL|Intervention - BXCL501|
62232285|NCT05751863|ACTIVE_COMPARATOR|Protocol Directed Sedation and Daily Sedation Interruption|Subjects will receive Fentanyl for analgesia and midazolam for sedation management. The RASS score is used to guide sedation to a goal of 0 to -2 and daily sedation by IV Midazolam at 1 mg/hr and titrated by 1 mg/hr q60 mins. Midazolam boluses are allowed by 1 mg IVP q5 mins x2 before increasing the infusion rate. Propofol and dexmedetomidine are permitted under existing institutional sedation protocol. Fentanyl IV starts at 50 mcg/hr and is titrated by 25 mcg/hr q15 mins to achieve target pain score. Fentanyl bolus of 25 mcg IVP q5 min x2 doses is given before increasing the infusion rate. Daily sedation interruption (DSI) is performed daily and ventilator weaning trial if they pass.
62232286|NCT03969147|ACTIVE_COMPARATOR|MRI Comparison|MRI images will be obtained of the airways of healthy volunteers both with the ManMaxAirway oropharyngeal airway adjunct and with no airway adjunct in place in order to observe any changes to the airway anatomy caused by placement of the airway adjunct. The order of the scans (with and without airway adjunct) will be determined by randomization software in advance.
62808632|NCT01244685|ACTIVE_COMPARATOR|probe|Patients in the 'goal-directed fluid' Lactated Ringers solution according to ideal body weight for the first 24 hours. The fluids will be changed after the first 24 hours and continued until the patient is tolerating a regular diet. The Deltex CardioQ esophageal probe will be evaluated every 15 minutes in the Post Anesthesia Care Unit (PACU) by the Anesthesia service. Stroke Volume (SV), Flow Time Corrected (FTc), and Peak Velocity (PV) will be measured. A short FTc (\<330 ms) indicative of hypovolemia will receive a 3cc/kg fluid challenge with Lactated Ringers crystalloid solution over 5 minutes. A SV increase of \>10% will receive a further 3cc/kg fluid challenge. A SV increase of \<10% will not receive further fluid challenge.
62819534|NCT03021200|EXPERIMENTAL|Indocyanine green in minimally invasive Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (Pinpoint) for minimally invasive oncological surgeries
62423618|NCT04217031||Decision variability assessment group|Patients with angiographically confirmed 3-vessel or left main disease will be enrolled. Patients data and heart team decision will be collected to analyze the variability between different heart team decisions.
62423619|NCT03962660|EXPERIMENTAL|HaRTS-TRENDS|See description below.
62423620|NCT03962660|ACTIVE_COMPARATOR|Standard Care (SC)|See description below.
62423621|NCT03384420|EXPERIMENTAL|Intervention CD34+ cells enriched with MNV-BLD|Intervention CD34+ cells enriched with MNV-BLD
62032530|NCT03680599|EXPERIMENTAL|Connection to Health for Smokers|Participants in this arm will participate in the Connection to Health for Smokers Arm of the study, wherein an electronic survey will be administered and participants will be guided through an evidence-based action planning sequence, taking into account each patient's unique social environment, health related behaviors, and behavioral health status, with multimodal follow up.
62423622|NCT04352036||patient|
62423623|NCT02185235|EXPERIMENTAL|Biofeedback & Electrical Stimulation|Twice a week, 20 minutes for each time. One course includes 18 times treatment.
62423624|NCT02185235|ACTIVE_COMPARATOR|Biofeedback & Pelvic Floor Training|Pelvic floor training every 20 minutes for each time, twice a week. and total for 18 times.
62808633|NCT01244685|NO_INTERVENTION|Standard Fluid|Patients in the 'standard fluid' group will receive Lactated Ringers solution for 24 hours post-operatively at 1 times maintenance rate according to ideal body weight. Then the fluids will be changed to physiologic maintenance with D5½NS at the same rate. Fluids will be decreased by ½ once the patient is tolerating a clear liquid diet, and then discontinued once the patient is tolerating a regular diet.
62808634|NCT04510714|EXPERIMENTAL|Microwave ablation arm|Single arm patients with lung sarcoma metastasis that will be treated with microwave ablation
62808635|NCT01160276|ACTIVE_COMPARATOR|Cyclosporine|The first group is composed of 14 renal graft recipients under cyclosporine
62808636|NCT01160276|ACTIVE_COMPARATOR|Tacrolimus|The second group is composed of 14 renal graft recipients under tacrolimus
62808637|NCT00923923|EXPERIMENTAL|levels of stress|
62808638|NCT05837338|EXPERIMENTAL|Sequence A|Single topical application of BXP154 6ml (right leg), treatment period 1; single topical application of Placebo 6ml (left leg), treatment period 2
62232287|NCT03969147|EXPERIMENTAL|Tolerability Comparison|Healthy volunteers will self-place either the ManMaxAirway oropharyngeal airway adjunct or the Guedel Oropharyngeal airway adjunct, which will be left in place for an interval of one minute, while supervised by research staff. After completing a questionnaire and resting for a timed interval, they will then self-place the other airway adjunct, which will be left in place for the same length of time as the first, before completing another questionnaire. The order in which the devices are placed by each subject will be determined in advance via computer randomization.
62032531|NCT03680599|ACTIVE_COMPARATOR|Enhanced Standard of Care|Participants in this arm will participate in Enhanced Standard Care, wherein participants will receive a brief electronic survey and receive standard smoking cessation program that does not include formal action planning and multimodal follow up.
62032532|NCT01504594|EXPERIMENTAL|Patients|Children which meet eligibility criteria and after being assessed, are stimulated with G-CSF, undergo bone marrow extraction and then have them applied directly to the coronary arteries through cardiac catheterization.
62423625|NCT03743675|EXPERIMENTAL|Diet-Induced Weight Loss|Subjects in this arm will undergo 6-months of dietary counseling targeting 5-10% weight loss by the end of the intervention period.
62423626|NCT03743675|EXPERIMENTAL|Exercise Training|Subjects in this arm will undergo 6-months of supervised aerobic exercise training (3 days per week, moderate-to-vigorous intensity).
62423627|NCT03743675|EXPERIMENTAL|Diet Plus Exercise|Subjects in this arm will undergo 6-months of dietary counseling targeting 5-10% weight loss by the end of the intervention period. They will simultaneously undergo 6-months of supervised aerobic exercise training (3 days per week, moderate-to-vigorous intensity).
62423628|NCT03743675|NO_INTERVENTION|Control|Subjects in this group will be asked to maintain their habitual physical activity, and will received counseling regarding a healthy, weight-maintenance diet.
62423629|NCT02426125|EXPERIMENTAL|Ramucirumab + Docetaxel|Ramucirumab (10 milligram/kilogram \[mg/kg\]) intravenously (IV) plus docetaxel (75 milligram/square meter \[mg/m²\]) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62808639|NCT05837338|EXPERIMENTAL|Sequence B|Single topical application of Placebo 6ml (right leg), treatment period 1; single topical application of BXP154 6ml (left leg), treatment period 2
62808640|NCT05837338|EXPERIMENTAL|Sequence C|Single topical application of BXP154 6ml (left leg), treatment period 1; single topical application of Placebo 6ml (right leg), treatment period 2
62808641|NCT05837338|EXPERIMENTAL|Sequence D|Single topical application of Placebo 6ml (left leg), treatment period 1; single topical application of BXP154 6ml (right leg), treatment period 2
62808642|NCT00881517|EXPERIMENTAL|Cytotect|
62808643|NCT00881517|PLACEBO_COMPARATOR|placebo|
62808644|NCT04610359|EXPERIMENTAL|Stem cell group|Interstitial cystitis patients who receive submucosal injection of hESC-MSCs
62808645|NCT02316028|EXPERIMENTAL|decitabine|"administration of decitabine by hepatic arterial infusion~* Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.~* Proposed dose levels:~  1. 10 mg/m2 per course~ 2. 15 mg/m2 per course~ 3. 20 mg/m2 per course"
62808646|NCT00113841|EXPERIMENTAL|Curcumin|Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.).
62808647|NCT00113841|EXPERIMENTAL|Curcumin + Bioperine|Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.) and Bioperine 5 mg orally twice daily.
62808648|NCT02542865|EXPERIMENTAL|Test Group|Fortified malt based food (27 grams) made up in 150 mL lukewarm water administered twice daily
62808649|NCT02542865|NO_INTERVENTION|Control Group|No treatment was administered
62808650|NCT02922530|EXPERIMENTAL|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring up to a maximum of 80 treatment sessions, up to 7 sessions per week, 15-60 minutes per session
62808651|NCT02922530|ACTIVE_COMPARATOR|Active Comparator|Commercially available computerized training requiring up to a maximum of 80 treatment sessions, up to 7 sessions per week, 15-60 minutes per session.
62232288|NCT03969147|ACTIVE_COMPARATOR|Forced Oscillation|Volunteers from the tolerability comparison arm will also be invited as a subset of subjects to participate in a measurement of resistance to forced oscillation. The volunteers will be subject to forced oscillations in a pulmonary function lab with the ManMaxAirway oropharyngeal airway adjunct in place and with no airway adjunct in order to observe changes in resistance to oscillatory airflow
62232289|NCT01602562|EXPERIMENTAL|VACV (256U87; valaciclovir hydrochloride)|Adult patients (16-65 years): A VACV tablet (containing 500mg of valaciclovir) is orally given twice daily. Pediatric patients (1-16 years): VACV granules are orally given at a dose of 25 mg/kg b.w. twice daily. The maximum dose per treatment is limited to 500 mg. Pediatric patients weighing 40 kg or over may be orally given a VACV tablet (containing 500 mg of valaciclovir) twice daily.
62232290|NCT02652013|EXPERIMENTAL|40 patients with multiple sclerosis|The study sample will consist of 40 patients with multiple sclerosis. MS patients and control subjects will be recruited on the Rennes (Centre Hospitalier Universitaire and Pôle de Médecine Physique et de Réadaptation Saint-Hélier) and Angers sites (Centre Hospitalier Universitaire) participating in COGNISEP project
62232291|NCT02652013|OTHER|40 healthy subjects|All the performance of the 40 MS patients will be compared to 40 control subjects matched in age, gender and sociocultural level. Subjects with a history of neurological and psychiatric condition or substance abuse will be excluded from the study. Control subjects will receive an honorary as a token for their time.
62232292|NCT01882751||ConforMIS|Patients with ConforMIS implants
62423630|NCT02426125|PLACEBO_COMPARATOR|Placebo + Docetaxel|Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62423631|NCT05699577||metastatic breast cancer|
62423632|NCT05699577||non metastatic breast cancer|
62423633|NCT04339361|EXPERIMENTAL|lidocaine spray|four puffs (50ml, 10 mg/puff) of lidocaine spray will be applied to the cervical canal and cervix before tenaculum placement plus vaginal placebo will be given 3 hours before IUD insertion
62423634|NCT04339361|ACTIVE_COMPARATOR|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray will be applied to the cervical canal and cervix before tenaculum placement
62423635|NCT04339361|PLACEBO_COMPARATOR|placebo|vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray will be applied to the cervical canal and cervix before tenaculum placement
62423636|NCT05406596|EXPERIMENTAL|LiquID GCE Use|
62423637|NCT04618315|ACTIVE_COMPARATOR|Audiology-Based Best Practice|Hearing aids will be fit using current best practices used by audiologists to fit hearing aids.
62423638|NCT04618315|EXPERIMENTAL|Consumer Decides|Hearing aids will be self fit by patients using an interactive application on a tablet computer. Patients will choose their preferred hearing aid settings after comparing four settings with varying loudness levels.
62808652|NCT06288555||Diabetic patient|This study focused on a group of 274 patients with type 2 diabetes who were receiving services at Nong Khantee Subdistrict Health Promoting Hospital in Phra Phutthabat District, Saraburi Province. Participants underwent both the Ipswich touch test and the 10-g monofilament test.
62808653|NCT02693808|ACTIVE_COMPARATOR|Autologous fat injection|Patients have undergone lateral orbital wall decompression on both sides. Temporal hollowing after surgery will be treated with injection on one side with autologous fat and the other side with long-lasting hyaluronic acid.
62423639|NCT04618315|EXPERIMENTAL|Efficient Fitting|Hearing aids will be self fit by patients using an interactive application on a tablet computer. Patients will choose their preferred hearing aid settings after comparing four settings with varying base and treble settings.
62592891|NCT01579045|EXPERIMENTAL|Sequence 11|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, nelfilcon A, Filcon II 3, senofilcon A, Filcon II 3"
62232293|NCT01882751||Standard Total Knee Implant|Patients implanted with standard total knee implant
62232294|NCT04476225||Individuals with Hirschsprung Disease|Individuals with Hirschsprung disease
62232295|NCT04476225||Unaffected Relatives|Unaffected relatives of individuals with Hirschsprung disease
62232296|NCT02882724|EXPERIMENTAL|Exercise training|
62423640|NCT06060639|EXPERIMENTAL|transfused patients|patients receiving red blood cell transfusion
62423641|NCT05598645|EXPERIMENTAL|Thulium Fibre Laser (TFL)|Patients randomized to this arm will undergo treatment using the TFL.
62423642|NCT05598645|EXPERIMENTAL|MOSES Holmium Laser|Patients randomized to this arm will undergo treatment using the MOSES Holmium laser.
62423643|NCT02606682|EXPERIMENTAL|NPT200-11 - Cohort 1, Dose 1|Single ascending dose of orally administered capsule(s) NPT200-11: 15 mg OR Single dose of orally administered placebo capsule(s) to match dose
62423644|NCT02606682|EXPERIMENTAL|NPT200-11 - Cohort 2, Dose 2|Single ascending dose of orally administered capsule(s) NPT200-11: 30 mg OR Single dose of orally administered placebo capsule(s) to match dose
62423645|NCT02606682|EXPERIMENTAL|NPT200-11 - Cohort 3, Dose 3|Single ascending dose of orally administered capsule(s) NPT200-11: 60 mg OR Single dose of orally administered placebo capsule(s) to match dose
62808654|NCT02693808|ACTIVE_COMPARATOR|Hyaluronic acid injection|Patients have undergone lateral orbital wall decompression on both sides. Temporal hollowing after surgery will be treated with injection on one side with autologous fat and the other side with long-lasting hyaluronic acid.
62232297|NCT02882724|EXPERIMENTAL|Control|Control group did not do any exercise training.
62232298|NCT00395460|EXPERIMENTAL|Gadobutrol 0.1 mmol/kg Body Weight (BW) (Gadavist, BAY86-4875)|Participant received 0.1 mmol/kg BW Gadobutrol (= 0.1 mL/kg BW by intravenous injection at a rate of 1.0 mL/sec)
62808655|NCT04936607|EXPERIMENTAL|Personnalized hydration strategy|In the experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration of the procedure (\<13 mmHg: 5 ml/kg/h; 13-18 mmHg: 3 ml/kg/h; \>18 mmHg: 1.5 ml/kg/h), or for one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration rate (eGFR)) ratio, according to the following scheme: 1.5 ml/kg/h if contrast volume/eGFR ratio \<2.0; 3 ml/kg/h for contrast volume/eGFR ratio 2.0-2.9; 5 ml/kg/h for contrast volume/eGFR ratio ≥3.0.
62232299|NCT00395460|ACTIVE_COMPARATOR|GD 0.1 mmol/kg BW (Magnevist, BAY86-4882)|Participant received 0.1 mmol/kg BW Gadopentetate Dimeglumine (GD) (= 0.2 mL/kg BW by intravenous injection at a rate of 2.0 mL/sec
62232300|NCT05323006|ACTIVE_COMPARATOR|scapular stabilization exercises|the effect of the scapular stabilization exercises on clavicular movement
62232301|NCT05323006|NO_INTERVENTION|no intervention|no intervention
62232302|NCT04152460|ACTIVE_COMPARATOR|Thermo-Viscous preheated bulk fill resin composite|Viscalor Despenser (Preheating dispenser for composite Viscalor Bulk Caps)
62232303|NCT04152460|PLACEBO_COMPARATOR|Conventional Bulk Fill resin Composite|GrandioSo X-tra (Voco,Cuxhaven
62232304|NCT05863858|ACTIVE_COMPARATOR|Levofloxacin-based sequential Therapy|"1. Tablets Levofloxacin 500mg BID for the first five days~2. Tablet Amoxicillin 1 gm BID for first five days~3. Capsules Omeprazole 20 mg BID for first five days followed by~1. Tablet Levofloxacin 500 mg BID for five days 2. Tablet Tinidazole 500mg BID for five days 3. Capsule Omeprazole 20 mg BID for five days~Infection eradication will be observed and confirmed by stool antigen test correlated with the signs and symptoms"
62232305|NCT05863858|ACTIVE_COMPARATOR|Moxifloxacin-based Triple Therapy|"1. Tablet Moxifloxacin 400 mg OD for ten days~2. Tablet Amoxicillin 1 gm BID for ten days~3. Capsule Omeprazole 20 mg BID for ten days~Infection eradication will be observed and confirmed with a stool antigen test along with patient compliance and tolerability observance."
62232306|NCT00389233|EXPERIMENTAL|1|2L gut cleansing solution
62232307|NCT00389233|ACTIVE_COMPARATOR|2|4L preparation
62232308|NCT03739541|EXPERIMENTAL|[14C]-Benznidazole|A single dose of 100 mg \[14C\]-BNZ, orally administered on Day 1 following an overnight fast.
62232309|NCT01894061|EXPERIMENTAL|Bevacizumab and NovoTTF-100A|Bevacizumab will be administered intravenously on days 1 and 15 of each 28 day cycle.The dose of bevacizumab will be 10 mg/kg of actual body weight.
62232310|NCT04085315|EXPERIMENTAL|Dose Escalation (Closed to Enrollment)|Patients will continue to receive osimertinib 80 mg PO daily as part of standard of care therapy during screening and study treatments. Alisertib will be administered to eligible patients in combination with osimertinib at doses ranging from 20 mg to 50 mg PO twice daily on days 1-3, 8-10, and 15-17 of a 28-day cycle. The starting alisertib dose will be 30 mg twice daily (dose level 1). All patients at a given dose level must complete the DLT period before any additional cohorts can be opened.
62232311|NCT04085315|EXPERIMENTAL|Dose Expansion: Cohort A|Stage IV EGFR-mutant NSCLC currently receiving and progressing on osimertinib who have received no more than one additional line of systemic cancer therapy other than osimertinib (e.g., chemotherapy +/- immunotherapy, amivantamab +/- Lazertinib) for metastatic disease. Patients may receive alisertib therapy until lack of clinical benefit or intolerable toxicity.
62232312|NCT04085315|EXPERIMENTAL|Dose Expansion: Cohort B|Stage IV EGFR-mutant NSCLC patients who are currently receiving first line osimertinib treatment and have received at least 3 months, but no more than 6 months, of osimertinib with a best response of PR or SD. Patients may receive alisertib therapy until lack of clinical benefit or intolerable toxicity.
62232313|NCT04085315|EXPERIMENTAL|Dose Expansion: Cohort C|Stage IV EGFR-mutant NSCLC patients with no known tumor non-synonymous TP53 genomic alteration who are currently receiving first line osimertinib treatment and have received at least 3 months, but no more than 6 months, of osimertinib with a best response of PR or SD. Patients may receive alisertib therapy until lack of clinical benefit or intolerable toxicity.
62232314|NCT03133325|OTHER|All subjects|Treatment with both GP0045 and Restylane Lyft Lidocaine
62232315|NCT02981654|EXPERIMENTAL|Femilift treatment|"The Alma Lasers Pixel carbon dioxide laser system delivers fractionated laser energy through a special lens that divides the energy into a 9 x 9 (81) matrix of 1 cm square area. The fractional laser rays cause thermal damage that reaches the vaginal sub - epithelium to stimulate the growth of new collagen.~Intervention: FemiLift vaginal handpiece is inserted into the vagina, to deliver CO2 laser energy. The vaginal epithelium is covered by rotation of vaginal handpiece in 360 degrees, releasing laser energy at 6-8 points, and than withdrawn 1 cm each time to perform the same process, to cover the the total vaginal length."
62423646|NCT02606682|EXPERIMENTAL|NPT200-11 - Cohort 4, Dose 4|Single ascending dose of orally administered capsule(s) NPT200-11: 120 mg OR Single dose of orally administered placebo capsule(s) to match dose
62423647|NCT02606682|EXPERIMENTAL|NPT200-11 - Cohort 5 ,Dose 5|Single ascending dose of orally administered capsule(s) NPT200-11: 240 mg OR Single dose of orally administered placebo capsule(s) to match dose
62423648|NCT02606682|EXPERIMENTAL|NPT200-11 -Cohort 6, Dose 6|Single ascending dose of orally administered capsule(s) NPT200-11: 360 mg OR Single dose of orally administered placebo capsule(s) to match dose
62232316|NCT02779478||Positive NTM Culture|Subjects that meet inclusion criteria and have culture positivity for NTM: at least two separate expectorated induced sputum samples or from one bronchoalveolar lavage (BAL) or lung biopsy
62808656|NCT04936607|ACTIVE_COMPARATOR|Standard of care|In the control group, infusion rate will be of 1.5 ml/kg/h during the procedure, and for the 4 following hours.
62032533|NCT05338788||Patient Group|"Thirty-two 32 patients with cervical disk herniation related chronic neck pain participated in this cross-sectional controlled study. Patients who aged 18-64 years, had neck pain for at least 12 weeks, no tumor, trauma, fracture pathology in the spinal region and no history of spine surgery were included.~The Neck Disability Index (NDI) was used to assess neck pain related disability. The Biodex Balance System (BBS; Biodex Medical Systems, Shirley, New York, USA) was used to assess postural control. The evaluated parameters of this system are presented below: modified clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task. Dual-task interference (DTI) was assessed."
62232317|NCT02779478||Negative NTM Culture|Subjects that meet inclusion criteria and have less than two separate expectorated induced sputum samples culture negative or culture negative bronchoalveolar lavage (BAL) or lung biopsy.
62808657|NCT01815723|EXPERIMENTAL|FP187|500 mg FP187 daily (250 mg twice daily)
62423649|NCT02606682|EXPERIMENTAL|NPT200-11 - Cohort 7, Dose 7|Single ascending dose of orally administered capsule(s) NPT200-11: 480 mg OR Single dose of orally administered placebo capsule(s) to match dose
62423650|NCT03676673||ASD group|120 patients with clinical diagnosis of ASD according to the DSM-5 diagnostic criteria
62423651|NCT03676673||Unaffected siblings of ASD|40 unaffected siblings of ASD probands
62423652|NCT03676673||TD group|40 healthy age/gender-matched TD controls according to age and neighborhood distribution of the ASD group after interviewed by the Chinese K-SADS-E-DSM-5
62423653|NCT06053437||Hyp'Op Cohort|The 'HYP'OP' cohort comprises patients who underwent endoscopic endonasal surgery (EES) for pituitary adenoma during a 10-year period spanning from January 2012 to June 2022 at the Nancy University Hospital. Post-operative hospitalization in our endocrinology department is part of the standard care protocol, which also includes a systematic reevaluation 4 -6 months following the surgical intervention.
62808658|NCT01815723|ACTIVE_COMPARATOR|Dimethyl fumarate|720 mg Fumaderm® daily (240 mg three times daily)
62423654|NCT02149199|EXPERIMENTAL|"Symbicort as needed+placebo Pulmicort bid"|Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
62808659|NCT01815723|PLACEBO_COMPARATOR|Placebo|Matching FP187 and Fumaderm® placebo
62808660|NCT05118191|ACTIVE_COMPARATOR|OOLER|Participants will use the OOLER device.
62808661|NCT05118191|ACTIVE_COMPARATOR|EmbrWave|Participants will use the Embr Wave 2 device.
62808662|NCT02418871|EXPERIMENTAL|FluidVision|FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery
62808663|NCT03439501|OTHER|avelumab|"* 1 Cycle: 10mg/kg Avelumab administered via IV every 2 weeks (1st, 15th)~  * Interval of 1 cycle: 28 days ③ Administration schedule: Repeated until disease progression or unacceptable toxicity and dose adjustments may be permitted based on the toxicity that occurs every cycle."
62808664|NCT05239052|EXPERIMENTAL|computer intervention group|stroke subjects with wheelchair users completed computer screen tasks with affected arm or bilateral arm movement
62808665|NCT05239052|ACTIVE_COMPARATOR|conventional long-term care services group|stroke subjects with wheelchair users receive conventional long-term care services
62808666|NCT06251063|EXPERIMENTAL|Web-based psychoeducational Resource|Eligible families will be provided with website access instructions. Parents and children will be instructed to review the materials separately. The intervention will provide each person with individualized action items to be discussed as a family. It is anticipated that reviewing all of the psychoeducational materials will take the parent/child approximately one hour, resulting in a total intervention burden of two hours for the family. Participants will be encouraged to return to the website as often as needed to review content. For the purposes of this project, they will be instructed to review all intervention materials within one month of receiving the website access instructions.
62423655|NCT02149199|ACTIVE_COMPARATOR|"terbutaline as needed+placebo Pulmicort bid"|terbutaline Turbuhaler 0.4 mg 'as needed' + placebo Pulmicort 200 μg Turbuhaler bid
62423656|NCT02149199|ACTIVE_COMPARATOR|"Pulmicort bid + terbutaline as needed"|Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
62232318|NCT04079803|PLACEBO_COMPARATOR|Placebo Cohort|Subjects administered placebo oral tablets twice daily (BID)
62808667|NCT03596905|EXPERIMENTAL|0.5 mg plecanatide|Plecanatide 0.5 mg Taken orally once daily for 4 weeks Group A: 6 to 11 years old
62232319|NCT04079803|EXPERIMENTAL|Simufilam (PTI-125) 100 mg tablets Cohort|Subjects administered simufilam (PTI-125) 100 mg oral tablets twice daily (BID)
62232320|NCT04079803|EXPERIMENTAL|Simufilam (PTI-125) 50 mg tablets Cohort|Subjects administered simufilam (PTI-125) 50 mg oral tablets twice daily (BID)
62232321|NCT00713726|ACTIVE_COMPARATOR|F|Patients that received continued infusion of fentanyl at a steady dose for the first 48 hours and, then, doses were gradually decreases until stop
62423657|NCT05576285||Accelerating head growth in infancy|Infants \<=18 months of age referred to head ultrasound because of accelerating head growth
62808668|NCT03596905|EXPERIMENTAL|1.0 mg plecanatide|Plecanatide 1.0 mg Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to \< 18 years old
62808669|NCT03596905|EXPERIMENTAL|2.0 mg plecanatide|Plecanatide 2.0 mg Taken orally daily for 4 weeks Group B: 12 to \< 18 years old
62808670|NCT03596905|EXPERIMENTAL|3.0 mg plecanatide|Plecanatide 3.0 mg Taken orally daily for 4 weeks Group B: 12 to \< 18 years old
62808671|NCT03596905|PLACEBO_COMPARATOR|Matching placebo|Matching placebo Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to \< 18 years old
62808672|NCT02153632|EXPERIMENTAL|240mg amantadine HCl ER tablets|amantadine HCl ER, 240 mg tablets, once daily, 22 weeks
62032534|NCT05338788||Control Group|"Twenty-three 23 age and sex-matched asymptomatic controls participated in this cross-sectional controlled study.~The Biodex Balance System (BBS; Biodex Medical Systems, Shirley, New York, USA) was used to assess postural control.The evaluated parameters of this system are presented below: modified clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task. Dual-task interference (DTI)was assessed."
62032535|NCT03586648|EXPERIMENTAL|Test/Control|Hyperopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Test/Control. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
62032536|NCT03586648|EXPERIMENTAL|Control/Test|Hyperopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Control/Test. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
62032537|NCT01566045|ACTIVE_COMPARATOR|Core Needle TRUS biopsy (Transrectal ultrasound)|Patient receiving core needle TRUS biopsy (Standard of care biopsy)
62032538|NCT01566045|EXPERIMENTAL|Core Needle MRI/US fusion guided biopsy|Patients receiving Standard of Care core needle TRUS biopsy will then receive the MRI / Ultrasound fusion core needle guided biopsy
62032539|NCT01772433|PLACEBO_COMPARATOR|Phonophoresis Gel|The Phonophoresis gel will be used as placebo
62423658|NCT05576285||Children at ICU with neurological symptoms that require brain MRI or CT|Children \< 15 years of age who are cared for at ICU becaus of neurological symptoms that require brain MRI or CT scans
62423659|NCT05576285||Children entering the emergency department with the need of acute brain CT|Children \< 2 years of age that enter the emergency department because of brainthreatening conditions that require acute brain CT scans
62423660|NCT01946087|EXPERIMENTAL|RIPC group|
62423661|NCT01946087|PLACEBO_COMPARATOR|Control group|
62423662|NCT04876859|ACTIVE_COMPARATOR|Conventional Radiofrequency Group|Will be submitted to an anesthetic block of the sensory branches of femoral and obturator nerves to the hip, with 1 ml of 1% lidocaine with 1ml of steroid (Betamethasone Dipropionate 5 mg/ml + Betamethasone Sodium Phosphate 2 mg/ml) for each branch, followed by denervation with CRF (22¬gauge 5¬mm active tip cannula, 10cm in length) with the tip temperature set at 90° C in a single cycle of 90 min.
62423663|NCT04876859|SHAM_COMPARATOR|Anesthetic plus steroid group|The sham group will be submitted to the same anesthetic block as described in the intervention group, followed by a simulation of CRF use.
62808673|NCT02153632|EXPERIMENTAL|320mg amantadine HCl ER tablets|amantadine HCl ER, 320 mg tablets, once daily, 22 weeks
62808674|NCT02153632|PLACEBO_COMPARATOR|Placebo Tablets for Amantadine|Placebo, tablets, once daily, 26 weeks.
62808675|NCT00239239|EXPERIMENTAL|test treatment period|
62032540|NCT01772433|EXPERIMENTAL|Olive Oil|Olive oil will be used as a replacement to phonophoresis gel in this arm
62232322|NCT00713726|EXPERIMENTAL|T|Patients that received continued infusion of tramadol at a steady dose for the first 48 hours and, then, doses were gradually decreases until stop
62423664|NCT02946619|NO_INTERVENTION|Control Condition|Participants in the control group were asked to write for three weeks about facts regarding their cancer and its treatment for three sessions.
62592892|NCT01579045|EXPERIMENTAL|Sequence 12|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, nelfilcon A, Filcon II 3, Filcon II 3, senofilcon A"
62808676|NCT05001334|EXPERIMENTAL|Kangaroo care|The mothers of the experimental group who accept to participate in the research are given training on how to make kangaroo care and what to pay attention to.
62808677|NCT05001334|NO_INTERVENTION|Control group|The mothers of the control group who accept to participate in the research are NOT given any extra training other than routine breastfeeding and care of a newborn.
62808678|NCT02551835||Tromso Impaired Glucose Tolerance (IGT) study|RCT on 20000 IU vitamin D3/week versus placebo for 1 year among persons with impaired glucose tolerance and/or impaired fasting glucose.
62808679|NCT02551835||Tromso OBESITY study|RCT on 20000 or 40000 IU vitamin D3/week plus 500 mg calcium/day versus placebo plus 500 mg calcium/day for 1 year among persons with a high body mass index.
62808680|NCT02551835||Tromso Bone Mineral Density (BMD) study|RCT on 40000 IU vitamin D3/week plus 800 IU/day and 1000 mg calcium/day versus placebo plus 800 IU/day and 1000 mg calcium/day for 1 year among women with a low bone mineral density.
62032541|NCT04365634||Diabetes|Diabetes mellitus was diagnosed according to the standards of American Diabetes Association which were briefly described as FPG ≥ 7.0 mmol/L (Fasting is defined as no caloric intake for at least 8 h) or 2-h plasma glucose ≥ 11.1 mmol/L during Oral glucose tolerance test (OGTT), or with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose (RPG) ≥ 11.1 mmol/L. And in this group, we have 129 COVID-19 patients with diabetes.
62808681|NCT02551835||Tromso CLAMP study|RCT on 40000 IU vitamin D3/week versus placebo for 6 months among persons with 25(OH)D values \<42 nmol/L.
62232323|NCT03141008||Ketogenic diet exposed group|"Fibroscan changes with different diets:~Patients in a weight loss program using a ketogenic diet. Will compare differences in Fibroscan and metabolic changes."
62232324|NCT03141008||NAFLD diet exposed group|"Fibroscan changes with different diets:~Patients in a NAFLD clinic using low calorie, low fat diet. Will compare differences in Fibroscan and metabolic changes."
62232325|NCT02308020|EXPERIMENTAL|Part A Abemaciclib: HR+, HER2+ Breast Cancer|Abemaciclib 200 milligram (mg) was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive (HR+), HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62808682|NCT02551835||Tromso DEPRESSION study|RCT on 40000 IU vitamin D3/week versus placebo for 6 months among persons with 25(OH)D values \<55 nmol/L.
62232326|NCT02308020|EXPERIMENTAL|Part B Abemaciclib: HR+, HER2- Breast Cancer|"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants in combination with endocrine therapy (ET).~Participants may continue to receive treatment until discontinuation criteria are met."
62232327|NCT02308020|EXPERIMENTAL|Part C Abemaciclib: Surgical Resection|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+, HER2+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated receiving concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours for 5-14 days prior to surgical resection. Dosing may resume following wound healing on a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62232328|NCT02308020|EXPERIMENTAL|Part D Abemaciclib: Non-Small Cell Lung Cancer (NSCLC)|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62808683|NCT02551835||Styrian Vitamin D Hypertension Trial|RCT on 2800 IU vitamin D3/day versus placebo for 8 weeks among persons a history of arterial hypertension and 25(OH)D values \<75 nmol/L.
62808684|NCT02551835||Paravit study|RCT on 7000 IU vitamin D3/day versus placebo for 6 months among persons with a high body mass index and 25(OH)D values \<50 nmol/L.
62808685|NCT02551835||Oosterwerff study|RCT on 1200 IU vitamin D3/day plus 500 mg calcium/day versus placebo plus 500 mg calcium/day for 16 weeks among non-western immigrants with pre-diabetes and 25(OH)D values \<50 nmol/L.
62808686|NCT02551835||Chel study|RCT on 600 IU vitamin D3/day (or daily equivalent) versus placebo for 4 months among nursing home residents \>70 years of age.
62808687|NCT02551835||Wicherts study|RCT on 800 IU vitamin D3/day versus 100,000 IU/3 months versus sunlight advice for 6 months among non-western immigrants with 25(OH)D values \<25 nmol/L.
62232329|NCT02308020|EXPERIMENTAL|Part E Abemaciclib: Melanoma|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62808688|NCT02551835||University College Cork (UCC) 1 study|RCT on 200, 400, or 600 IU vitamin D3/day versus placebo for 22 weeks among persons \> 63 years of age.
62808689|NCT02551835||UCC 2 study|RCT on 200, 400, or 600 IU vitamin D3/day versus placebo for 22 weeks among persons 20-40 years of age.
62232330|NCT02308020|EXPERIMENTAL|Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+ (either HER2+ or HER2-) breast cancer, NSCLC, or melanoma and leptomeningeal metastases received concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62808690|NCT01860664|EXPERIMENTAL|hydrocortisone ophthalmic ointment 0.5%|Topical ophthalmic corticosteroid ointment, is produced in a concentration of 0.5% of hydrocortisone Acetate in a vehicle composed of mineral oil and white petrolatum
62808691|NCT01860664|PLACEBO_COMPARATOR|Placebo|mineral oil and white petrolatum
62232331|NCT03591302|EXPERIMENTAL|Immune tolerance, Kidney transplantation|Intervention: HLA matched living donor recipients of a functioning kidney transplant graft at one year will receive hematopoietic cell transplantation and Total lymphoid irradiation. The intervention is intended to induce immune tolerance such as to allow withdrawal of the immunosuppressive drugs. Immune tolerance is achieved through the development of donor/recipient mixed chimerism following combined kidney and hematopoietic stem cell transplantation from the living donor.
62423665|NCT02946619|EXPERIMENTAL|Self-regulation condition|For the self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; in session two, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
62423666|NCT02946619|EXPERIMENTAL|Enhanced self-regulation condition|For the enhanced self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; during session two, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
62808692|NCT04657471|EXPERIMENTAL|revised HOMe-CoV|Revised HOME-CoV
62808693|NCT06528366|EXPERIMENTAL|Experimental Group HD-tDCS (Hospital fase)|Experimental group HD-tDCS will be started at hospital fase when the patients will be randomly enrolled into tis group. They will receive 3mA current for 20 minutes with anodal stimulation through HD-tDCS (4x1) to the left dorsolateral prefrontal cortex, with 5 sessions on 5 consecutive days and before the surgical procedure.
62808694|NCT06528366|SHAM_COMPARATOR|Sham Group (Hospital Fase)|Sham Group (Hospital Fase) will be started at hospital fase when the patients will be randomly enrolled into tis group. They will receive simulated HD-tDCS anodic current (4x1) to the left dorsolateral prefrontal cortex with 3mA that accelerates for 30 seconds and decelerates for another 30 seconds, 5 sessions on 5 consecutive days and before the surgical procedure.
62032542|NCT04365634||Non-diabetes|Patients who do not meet the American Diabetes Association's standard diagnosis of diabetes are defined as non-diabetes. And in this group, we have 177 COVID-19 patients without diabetes.
62032543|NCT04365634||Survivors|COVID-19 patients who survived on the 28th day in hospital belong to survivors group. In the survivors group, we included 201 patients with complete data.
62032544|NCT04365634||Non-survivors|COVID-19 patients who did not survive on the 28th day in hospital belong to non-survivors group. In the non-survivors group, we included 54 patients with complete data.
62232332|NCT02016456|EXPERIMENTAL|Theta-Burst Stimulation|Theta-Burst protocol for transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
62232333|NCT02016456|ACTIVE_COMPARATOR|High Frequency stimulation|High frequency Transcranial Magnetic Stimulation using the standard protocol for depression, on left dorsolateral prefrontal cortex.
62423667|NCT03593239|EXPERIMENTAL|Tobacco flavored JUUL 1.7% ENDS|Tobacco flavored JUUL 1.7% ENDS (10 puffs)
62423668|NCT03593239|EXPERIMENTAL|Tobacco flavored JUUL 5% ENDS|Tobacco flavored JUUL 5% ENDS (10 puffs)
62423669|NCT03593239|EXPERIMENTAL|Mint flavored JUUL 1.7% ENDS|Mint flavored JUUL 1.7% ENDS (10 puffs);
62808695|NCT06528366|ACTIVE_COMPARATOR|Experimental Group Chlorella pyrenoidosa (Outpatient phase)|The groups are inverted due to the crossover design, so the previous sham group becomes the active group for Chlorella p consumption after the washout . So, this group must consume 10 tablets per day of Chlorella p for 30 days. (5g/day) and must return within 30 days for evaluation.
62808696|NCT06528366|NO_INTERVENTION|Control Group (Outpatient phase)|This group was inverted using the crossover method, so the active group for HD-tDCS in the previous phase and after the washout is inverted and becomes the control group in this phase. So, they will not receive intervention and must return within 30 days for evaluation.
62032545|NCT01676168||hypertrophic scar|1x1cm2 hypertrophic scar of post-burn patients are taked by visiting staff when they accept scar-reconstructive surgery.
62032546|NCT01676168||normal skin|When the patient accept skin grafting surgery, visiting staff will take 1x1cm2 normal skin.
62032547|NCT02474927|EXPERIMENTAL|Carfilzomib Treatment Arm|Carfilzomib will be administered at a dose of 20 mg/m2 on two consecutive days, each week for three weeks (Days 1 2, 8, 9, 15, and 16) to constitute one therapeutic cycle. Carfilzomib may be administered for 1-2 complete cycles in the study.
62032548|NCT05574127|EXPERIMENTAL|Older Adult Cancer Survivors (OACS) - Behavioral Activation (BA)|Older adult cancer survivors (OACS) will receive a Behavioral Activation intervention
62423670|NCT03593239|EXPERIMENTAL|Mint flavored JUUL 5% ENDS|Mint flavored JUUL 5% ENDS (10 puffs)
62808697|NCT05049590|EXPERIMENTAL|Intervention Group|Perform blood conservation in the operating room (OR).
62808698|NCT05049590|NO_INTERVENTION|Control Group|Blood conservation will not be performed in the OR.
62808699|NCT04033562|ACTIVE_COMPARATOR|Lidoderm patch|Participants will receive a topical 3.6% Lidocaine/1.25% Menthol patch at the time of their Cesarean section. Patches will be replaced every 12 hours for a total of 60 hours.
62808700|NCT04033562|ACTIVE_COMPARATOR|Infusion pump|Participants will undergo placement of Ambu ACTion drug delivery system at the time of Cesarean delivery. 0.125% of bupivacaine will be infused at a rate of 8cc/hr for a total of 48-60hrs post-operatively.
62032549|NCT05574127|EXPERIMENTAL|Older Adult Cancer Survivors (OACS) - Supportive Psychotherapy (SP)|Older adult cancer survivors (OACS) will receive a Supportive Psychotherapy intervention
62032550|NCT03913611|OTHER|Traditional Rehabilitation|In this arm, patients will undergo the standard rehabilitation protocol, with sling use for 6 weeks.
62032551|NCT03913611|EXPERIMENTAL|Accelerated Rehabilitation|In this arm, patients will undergo the accelerated rehabilitation protocol, with no sling use outside the immediate postoperative period.
62032552|NCT05046795|EXPERIMENTAL|Revefenacin inhalation solution 175 mcg QD.|Revefenacin inhalation solution 175 mcg QD.
62423671|NCT03593239|EXPERIMENTAL|Fruit Medley flavored JUUL 1.7% ENDS|Fruit Medley flavored JUUL 1.7% ENDS (10 puffs)
62423672|NCT03593239|EXPERIMENTAL|Fruit Medley flavored JUUL 5% ENDS|Fruit Medley flavored JUUL 5% ENDS (10 puffs)
62423673|NCT03593239|EXPERIMENTAL|Crème brulee flavored JUUL 1.7% ENDS|Crème brulee flavored JUUL 1.7% ENDS (10 puffs)
62423674|NCT03593239|EXPERIMENTAL|Crème brulee flavored JUUL 5% ENDS|Crème brulee flavored JUUL 5% ENDS (10 puffs)
62423675|NCT03593239|EXPERIMENTAL|JUUL 1.7% ENDS 10 puffs vs. ad lib puffs|Tobacco flavoured JUUL 1.7% ENDS products 10 puffs versus ad libitum puffs
62423676|NCT03593239|EXPERIMENTAL|JUUL 5% ENDS 10 puffs vs. ad lib puffs|Tobacco flavoured JUUL 5% ENDS products 10 puffs versus ad libitum puffs
62423677|NCT00047554||TRAVATAN|Travoprost, 0.004% ophthalmic solution, 1 drop to the study eye once daily in the evening for up to 5 years
62808701|NCT05930119|EXPERIMENTAL|fast overnight|Subjects in treatment A will administered HMPL-453 at fast overnight condition.
62423678|NCT02858076|ACTIVE_COMPARATOR|Intravitreous 2 mg aflibercept injections|Initial injection must be given on the day of randomization. Follow-up injections will be performed as often as every 4 weeks unless criteria for deferral are met.
62808702|NCT05930119|EXPERIMENTAL|high-fat meal|Subjects in treatment B will administered HMPL-453 at high-fat meal condition.
62808703|NCT05930119|EXPERIMENTAL|low-fat meal|Subjects in treatment C will administered HMPL-453 at low-fat meal condition.
62232334|NCT01224795|EXPERIMENTAL|Peramivir|Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to \< 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
62808704|NCT05930119|EXPERIMENTAL|rabeprazole|Subjects in treatment D will administered rabeprazole combined with HMPL-453 at low-fat meal condition hour prior to receiving a standardized low-fat meal.
62808705|NCT04220216|EXPERIMENTAL|H4H fitness program|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~* Patients will attend the 16-week program of boxing conditioning.~* This 16-week program will include supervised exercises designed to improve strength, flexibility, balance,and cardiopulmonary fitness.~* There will be 4, 1-hour sessions each week per participant"
62808706|NCT05794035|ACTIVE_COMPARATOR|Surgery alone|After inclusion of patient aged ≥ 70 years with performance status OMS 0-3 who had completed surgery (R0) for SCC and BCC with at least one unfavorable prognostic factor, patient will have surgery alone with no hypo fractionation treatment
62423679|NCT02858076|ACTIVE_COMPARATOR|Prompt vitrectomy plus panretinal photocoagulation|For the prompt vitrectomy + panretinal photocoagulation group, the vitrectomy must be scheduled to be performed within 2 weeks of randomization. Vitrectomy will be performed according to the investigator's usual routine, including pre-operative care, surgical procedure, and post-operative care, although anti-VEGF may not be given post-operatively unless there is recurrent hemorrhage.
62232335|NCT01224795|PLACEBO_COMPARATOR|Placebo|Placebo Peramivir, administered intravenously.
62232336|NCT05176535|EXPERIMENTAL|FertyBiotic Balance|Participants received FertyBiotic Balance one capsule a day
62808707|NCT05794035|EXPERIMENTAL|Surgery + Moderate hypo fractionation (HF)|Surgery + Moderate hypo fractionation (HF) 45Gy in 15 fractions, 3 fractions per week over 5 weeks to the operative bed.
62808708|NCT05794035|EXPERIMENTAL|Surgery + Extreme hypo fractionation (HF)|Surgery + Extreme hypo fractionation (HF): 30Gy in 5 fractions of 6Gy, 1 fraction per week, over 5 weeks to the operative bed.
62808709|NCT00683878|EXPERIMENTAL|Arm 1|
62232337|NCT04372407|EXPERIMENTAL|Treatment Crossover Arm|All patients will receive a single dose of surufatinib on day 1 in period 1, and a both itraconazole and single dose of surufatinib in period 2
62808710|NCT00683878|EXPERIMENTAL|Arm 2|
62808711|NCT00683878|PLACEBO_COMPARATOR|Arm 3|
62808712|NCT00461006|EXPERIMENTAL|Aleglitazar|
62808713|NCT00461006|ACTIVE_COMPARATOR|Actos|
62232338|NCT04532138|ACTIVE_COMPARATOR|C-MAC Video laryngoscope awake intubation|In this group, patients with severe predicted difficult airways scheduled for elective surgery receive awake endoscopic intubation using Videolaryngoscope (C-MAC) with Hyperangulated blade (D-blade) Spontaneous breathing will be preserved in both groups of patients enrolled and the same protocol of sedation plus upper airways topical anesthesia will be applied.
62808714|NCT05324111|EXPERIMENTAL|12 Lead ECG|Application of hand held electrocardio gram
62232339|NCT04532138|EXPERIMENTAL|VS-CMAC Rigid Fiberoptic Stylet awake intubation|"In this group, patients with severe predicted difficult airways scheduled for elective surgery receive awake endoscopic intubation using VS-CMAC Rigid Fiberoptic Stylet.~Spontaneous breathing will be preserved in both groups of patients enrolled and the same protocol of sedation plus upper airways topical anesthesia will be applied."
62808715|NCT05354817|OTHER|mFolfirinox|
62808716|NCT05400655|EXPERIMENTAL|Part 1: Children age 5-10: 5 mg/kg of L9LS|Enrolled individuals will receive 5 mg/kg of L9LS via SC injection.
62808717|NCT05400655|PLACEBO_COMPARATOR|Part 1: Children age 5-10: Placebo|1/4 of children age 5-10 will receive placebo of Normal Saline for comparison.
62032553|NCT05046795|PLACEBO_COMPARATOR|Placebo inhalation solution QD.|Placebo inhalation solution QD.
62032554|NCT02336334|EXPERIMENTAL|With macular hole|"Inclusion of patients with macular holes and randomized allocation to sensor-types and information-types~Interventions:~Positioning measurement Patient feedback Usefulness of a sketch Closure rate of macular holes"
62032555|NCT02336334|EXPERIMENTAL|Without macular hole|"Inclusion of patients without macular holes and randomized allocation to sensor-types and information-types~Interventions:~Positioning measurement Patient feedback Usefulness of a sketch"
62232340|NCT06080893||Ferric Carboxymaltose - Administrated Group|"Patients eligible for inclusion who received preop FCM intravenous therapy~FCM will be administered intravenously at preop 24th hour according to weight and preop hgb level"
62232341|NCT06080893||Ferric Carboxymaltose - Not Administrated Group|Patients eligible for inclusion who are not received preop FCM intravenous therapy
62423680|NCT01787188|EXPERIMENTAL|Meloxicam Test Capsules low dose QD|Meloxicam Test Capsules low dose QD
62423681|NCT01787188|EXPERIMENTAL|Meloxicam Test Capsules high dose QD|Meloxicam Test Capsules high dose QD
62808718|NCT05400655|EXPERIMENTAL|Part 1: Children age 5-59 months: 5 mg/kg of L9LS|
62423682|NCT01787188|PLACEBO_COMPARATOR|Placebo Capsule QD|Placebo Capsule QD
62423683|NCT06191380|ACTIVE_COMPARATOR|Cycling Alone|Cycling alone, with no virtual reality.
62808719|NCT05400655|EXPERIMENTAL|Part 1: Children age 5-10 years: 10 mg/kg of L9LS|
62808720|NCT05400655|EXPERIMENTAL|Part 1: Children age 5-10 years: 20 mg/kg of L9LS|
62808721|NCT05400655|EXPERIMENTAL|Part 1: Children age 5-59 months: 10 mg/kg of L9LS|
62808722|NCT05400655|EXPERIMENTAL|Part 1: Children age 5-59 months: 20 mg/kg of L9LS|
62808723|NCT05400655|PLACEBO_COMPARATOR|Part 1: Children age 5-59 months: Placebo|1/4 of subjects age 5-59 months will receive placebo of Normal Saline for comparison.
62808724|NCT05400655|EXPERIMENTAL|Part 2: Children age 5-17 months: 1 dose L9LS at 10-19 mg/kg|Subjects age 5-17 months will receive 1 dose of L9LS via SC injection.
62808725|NCT05400655|EXPERIMENTAL|Part 2: Children age 5-17 months: 2 doses L9LS at 10-19 mg/kg|Subjects age 5-17 months will receive 1 dose of L9LS and a second dose at 6 months via SC injection.
62808726|NCT05400655|PLACEBO_COMPARATOR|Part 2: Children age 5-17 months: Placebo|1/3 of subjects age 5-17 months will receive placebo of normal saline for comparison.
62808727|NCT05400655|EXPERIMENTAL|Part 2: Children age 18-59 months: 1 dose L9LS at 10-19 mg/kg|Subjects age 18-59 months will receive 1 dose L9LS via SC injection.
62808728|NCT05400655|EXPERIMENTAL|Part 2: Children age 18-59 months: 2 doses L9LS at 10-19 mg/kg|Subjects age 18-59 months will receive 1 dose L9LS, followed by a second dose at 6 months via SC injection.
62232342|NCT05748054|ACTIVE_COMPARATOR|Study group|Children who receive a single application of 38% SDF
62232343|NCT05748054|NO_INTERVENTION|Control group|Children do not receive any intervention
62232344|NCT02171325|EXPERIMENTAL|irinotecan|irinotecan； 60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
62808729|NCT05400655|PLACEBO_COMPARATOR|Part 2: Children age 18-59 months: Placebo|1/3 of subjects age 18-59 months will receive placebo of normal saline for comparison.
62808730|NCT04634084|EXPERIMENTAL|Experimental group|
62808731|NCT04634084|ACTIVE_COMPARATOR|Control Group|
62232345|NCT02070796|EXPERIMENTAL|Treatment A - B|Single application of the test transdermal patch (Treatment A, Rotigotine PR2.2.1) for 24 hours, followed by a Wash-Out Period of 7 days and a single application of the reference transdermal patch (Treatment B, Rotigotine PR2.1.1) for 24 hours.
62232346|NCT02070796|ACTIVE_COMPARATOR|Treatment B - A|Single application of the reference transdermal patch (Treatment B, Rotigotine PR2.1.1) for 24 hours, followed by a Wash-Out Period of 7 days and a single application of the test transdermal patch (Treatment A, Rotigotine PR2.2.1) for 24 hours.
62232347|NCT06101849|EXPERIMENTAL|Cancer Pain Management Group|Participants in the study will attend a 6-week online pain management program (I-Can-Manage-Pain after cancer) that will cover the topics of understanding cancer pain, exercises to manage pain and psychological strategies to cope with pain. Questionnaires will be administered before and after the program
62808732|NCT02513563|EXPERIMENTAL|Carboplatin/Paclitaxel/AZD1775|Treatment: Combination of AZD1775 plus carboplatin and paclitaxel. Participants will be treated with this combination of drugs twice daily on days 1 and 2 and once on day 3 for a total of 5 doses during each 21 day cycle of treatment.
62808733|NCT01299844|NO_INTERVENTION|Standard Care|
62808734|NCT01299844|EXPERIMENTAL|Diabetes Peer Counseling|
62808735|NCT03341416|EXPERIMENTAL|Device - deep brain stimulation ON|"Intervention type: device (deep brain stimulation of the dentate nucleus in cerebellum). The intervention is a device called deep brain stimulation bilaterally placed in the sub thalamic nucleus.~The stimulation will remained turned ON during 3 months - phase 1 - blinded and continuous during the open-label phase"
62423684|NCT06191380|EXPERIMENTAL|Cycling with Visually Stimulating VR|Cycling with virtual reality where I only have to look at the environment while I cycle.
62232348|NCT05612165|EXPERIMENTAL|tDCS group|
62232349|NCT05612165|SHAM_COMPARATOR|Control group|
62232350|NCT02843204|EXPERIMENTAL|Pembrolizumab and NK immunotherapy|In this group, the patients will receive regular Pembrolizumab first to control tumor burden; then NK immunotherapy will be given. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62232351|NCT02843204|ACTIVE_COMPARATOR|Pembrolizumab|In this group, the patients will receive regular Pembrolizumab to control tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62423685|NCT06191380|EXPERIMENTAL|Cycling with Cognitively Stimulating VR|Cycling with virtual reality where I have to complete a thinking task while cycling in the virtual environment.
62423686|NCT05273606|EXPERIMENTAL|Experimental Group|one group for contact lens
62423687|NCT03804931|EXPERIMENTAL|Fecal microbiota transplantation|Fecal microbiota transplantation
62423688|NCT03804931|SHAM_COMPARATOR|placebo fecal microbiota transplantation|Infusion of Saline
62808736|NCT03341416|SHAM_COMPARATOR|Device - deep brain stimulation Sham|"Sham stimulation: device (deep brain stimulation of the dentate nucleus in cerebellum). Intervention type: device (deep brain stimulation of the dentate nucleus in cerebellum). The intervention is a device called deep brain stimulation bilaterally placed in the sub thalamic nucleus.~During the sham stimulation the intervention will remained turned OFF during 3 months"
62808737|NCT05529498|EXPERIMENTAL|Experimental|High intensity interval gait training
62808738|NCT05529498|ACTIVE_COMPARATOR|Control|Moderate intesnity continuous gait training
62808739|NCT06239584|OTHER|Patients undergoing diagnostic bronchoscopies for suspected lung cancer|Preparation of organoids starting from lung tumor tissue collected during biopsies performed via diagnostic bronchoscopy according to standard clinical practice
62808740|NCT04228588|EXPERIMENTAL|Mepolizumab|Mepolizumab 100mg, SC, every 4 weeks
62808741|NCT03796507|EXPERIMENTAL|Temozolomide Arm|This study will only include one treatment group who will receive oral temozolomide at 75 mg per square meter of body surface area daily for 21 days before progressing to standard chemoradiation treatment.
62808742|NCT03935126||All patients|
62808743|NCT05651282|EXPERIMENTAL|Progesterone Challenge Test|10-day course of medroxyprogesterone acetate (Provera) 10 mg per os (po) daily.
62032556|NCT04339231|ACTIVE_COMPARATOR|Ropivacaine group|The block of the sphenopalatine ganglion will be performed bilaterally through a cotton bud soaked with the anesthetic solution ropivacaine, at a concentration of 1%, advancing it through the nasal cavities towards the posterior nasopharynx wall. A slight resistance in the progression of the cottonoid indicates its contact with the mucosa of the posterior pharyngeal wall. The cottonoid will remain in this position for 20 minutes, so that there is absorption of the anesthetic solution through the mucosa up to the sphenopalatine ganglion, which, in general, is found anatomically around 3 millimeters in depth from the surface. After the established time, the cotton buds are removed.
62032557|NCT04339231|PLACEBO_COMPARATOR|Saline 0,9% group|The block of the sphenopalatine ganglion will be performed bilaterally through a cotton bud soaked with saline solution, in a concentration of 0.9%, advancing it through the nasal cavities towards the posterior wall of the nasopharynx. A slight resistance in the progression of the cottonoid indicates its contact with the mucosa of the posterior pharyngeal wall. The cottonoid will remain in this position for 20 minutes, so that the solution is absorbed by the mucosa up to the sphenopalatine ganglion, which, in general, is anatomically three millimeters deep from the surface. After the established time, the cotton buds are removed.
62032558|NCT02730494|ACTIVE_COMPARATOR|Lcr Regenerans® vaginal capsule|Name: Lcr Regenerans® containing at least 10e7 CFU per intravaginal capsule. 1 vaginal capsule per day
62232352|NCT02133053||Ectoin Group|Ectoin Allergy Nasal Spray (Medical Device, drug-like)
62232353|NCT02133053||Beclomethasone Group|Beclomethasone nasal spray
62592893|NCT04204668|ACTIVE_COMPARATOR|Targeted Muscle Reinnervation (TMR)|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. These nerves are then cleaned up to be rerouted and connected to smaller nerves that control individual muscles. The connection to nerves that run into muscles is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 2 - 4 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
62735438|NCT03571750|PLACEBO_COMPARATOR|Health Education Training Condition|In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
62032559|NCT02730494|EXPERIMENTAL|Lcr Regenerans® vaginal tablet every 3 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 3 days
62032560|NCT02730494|EXPERIMENTAL|Lcr Regenerans® vaginal tablet every 4 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 4 days
62032561|NCT02730494|EXPERIMENTAL|Lcr Regenerans® vaginal tablet every 5 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 5 days
62032562|NCT02775526|ACTIVE_COMPARATOR|TOT|TOT
62032563|NCT02775526|ACTIVE_COMPARATOR|TVT|TVT
62032564|NCT02775526|ACTIVE_COMPARATOR|Burch colposuspension|Burch colposuspension
62032565|NCT02571504|EXPERIMENTAL|Immediate cognitive training group|Plasticity-based Adaptive Cognitive Remediation (PACR) is an 8 week training to improve executive functions (e.g., working memory, flexibility, cognitive control) as well as attention. Participants in the immediate cognitive training group will receive the PACR intervention shortly after enrollment.
62232354|NCT00629434|EXPERIMENTAL|1|This arm will receive diabetes education via telemedicine
62232355|NCT00629434|ACTIVE_COMPARATOR|2|diabetes education in-person
62232356|NCT01164124|EXPERIMENTAL|Probiotic supplementation|500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter \& Gamble.Inc)
62232357|NCT01164124|PLACEBO_COMPARATOR|Routine feedings|
62232358|NCT02918760|EXPERIMENTAL|Gabapentin|This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
62232359|NCT02918760|PLACEBO_COMPARATOR|Placebo|Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
62232360|NCT02647320|EXPERIMENTAL|DS-8500a 25mg|One DS-8500a 25 mg tablet, 2 placebo tablets, and one placebo capsule in a once-daily oral dose
62232361|NCT02647320|EXPERIMENTAL|DS-8500a 50 mg|Two DS-8500a 25 mg tablets, 1 placebo tablet, and one placebo capsule in a once-daily oral dose
62232362|NCT02647320|EXPERIMENTAL|DS-8500a 75 mg|Three DS-8500a 25 mg tablets and one placebo capsule in a once-daily oral dose
62232363|NCT02647320|PLACEBO_COMPARATOR|Placebo|Three placebo tablets and one placebo capsule in a once-daily oral dose
62232364|NCT02647320|ACTIVE_COMPARATOR|Sitagliptin 100 mg|Three placebo tablets and one sitagliptin 100 mg over-capsule in a once-daily oral dose
62232365|NCT04003220||MyeloDysplastic Syndrome|platelets \<150 G/l and diagnosis of myelodysplasia according to the WHO classification (abnormal bone marrow features).
62232366|NCT04003220||Idiopathic Chronic Thrombocytopenia of Unknown Significance|Acquired thrombocytopenia lasting\>6 months, without feature of dysimmunity (antiplatelet Ab, or anti nuclear Ab, anti ENA Ab, ANCA, anti-CCP Ab, cryoglobulinemia), normal bone marrow examination, absence of other thrombocytopenia in the family. All ICTUS patients included in the study will thus have a bone marrow aspiration.
62232367|NCT04003220||Immune Thrombocytopenic Purpura|Diagnosis of Immune Thrombocytopenic Purpura (ITP) is made according to the international ITP consensus (diagnostic criteria of Rodeghiero){Provan, 2010 #18}, knowing that a presumptive diagnosis of ITP is made when the history, physical examination, complete blood count, and examination of the peripheral blood smears do not suggest other etiologies for the thrombocytopenia
62232368|NCT04003220||healthy volunteers undergoing cardiac surgery|patients with normal blood counts undergoing cardiovascular surgery for valve replacement, or healthy bone-marrow donors
62232369|NCT04225221|EXPERIMENTAL|Sequence A: estradiol followed by progesterone|"Participants are randomly assigned to treatment Sequence A: after achieving hormone suppression using Lupron, participants begin the addback period and take study medications for 8 weeks. During the 8 week period, participants will take placebo or estradiol or progesterone. Participants will not know when or for how long they are on active medication (i.e., estradiol or progesterone) or inactive (i.e., placebo) medication. When active medication is administered, participants randomized to treatment sequence A will receive estradiol addback first, followed by progesterone.~Estradiol and progesterone are never given simultaneously. Participants are on active medication for a total of 4 weeks."
62232370|NCT04225221|EXPERIMENTAL|Sequence B: progesterone followed by estradiol|"Participants are randomly assigned to treatment Sequence B: after achieving hormone suppression using Lupron, participants begin the addback period and take study medications for 8 weeks. During the 8 week period, participants will take placebo or estradiol or progesterone. Participants will not know when or for how long they are on active medication (i.e., estradiol or progesterone) or inactive (i.e., placebo) medication. When active medication is administered, participants randomized to treatment sequence B will receive progesterone first followed by estradiol.~Estradiol and progesterone are never given simultaneously. Participants are on active medication for a total of 4 weeks."
62232371|NCT03645954|ACTIVE_COMPARATOR|Femoral Nerve Block|The femoral nerve block will be performed under the ultrasound guidance by a single injection of local anesthetic around all the femoral nerve branches inside the proximal part of the femoral triangle.
62423689|NCT03804931|OTHER|Traditional treatments|Drug:5-Aminosalicylic acid(5-ASA) and/or Prednisone
62423690|NCT00960310|EXPERIMENTAL|1|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
62423691|NCT00960310|ACTIVE_COMPARATOR|2|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
62808744|NCT01307826|EXPERIMENTAL|tensegrity massage|In this group of patients massage sessions based on the tensegrity method were applied.
62808745|NCT01307826|ACTIVE_COMPARATOR|classical massage|In this group of patients 10 classical massage sessions were applied
62423692|NCT03060148|ACTIVE_COMPARATOR|Spinal cord stimulation|Medtronic neurostimulation system for spinal cord stimulation
62423693|NCT03060148|NO_INTERVENTION|Control|No implantation of Medtronic neurostimulation system
62735439|NCT02733549||patient|Patients with sudden onset dizziness (SOD) analysed LFTs
62735440|NCT02733549||control|The control group with 98 healthy volunteer analysed LFTs
62423694|NCT06536725||PCa Patients With Visceral Metastasis|Prostate cancer patients with visceral metastasis.
62423695|NCT06462209|EXPERIMENTAL|ladder training|ladder training will be given to group 1
62423696|NCT06462209|ACTIVE_COMPARATOR|plyometric training|plyometric training will be given to group 2
62423697|NCT03001518||Surgery|No intervention. Patients who undergo surgical resection of their pancreatic cancer.
62423698|NCT05187663|ACTIVE_COMPARATOR|Study group|In the test group, implant surface decontamination was performed with photodynamic therapy.
62735441|NCT02943070|EXPERIMENTAL|Rezum Treatment|Patients received the Rezum transurethral needle ablation procedure to treat benign prostatic hyperplasia.
62735442|NCT01422941|EXPERIMENTAL|CAVU Attune Device|
62735443|NCT03870373||Test Subject|neonatal patients undergoing complex cardiac surgical procedures
62735444|NCT06133855|EXPERIMENTAL|Pulsed electromagnetic field|the patients will receive pulsed electromagnetic field plus traditional physical therapy program three times a week for four weeks
62735445|NCT06133855|ACTIVE_COMPARATOR|traditional physical therapy program|the patients will receive traditional physical therapy program three times a week for four week
62735446|NCT05801848||Chronic lower back pain patients|Patients with chronic lower back pain where the source could not be identified on MRI scans
62735447|NCT05801848||Age matched healthy controls|Healthy individuals without any previously known pain or intervention on lower back
62735448|NCT02346227|ACTIVE_COMPARATOR|AV2|Drug: application of topical spray on the cervix one time (2 puffs) topical application of 100µl AV2 antiviral spray( natural essential oil components in equal volumes diluted 50% in olive oil)
62735449|NCT02346227|PLACEBO_COMPARATOR|Placebo|Drug: application of topical spray on the cervix one time (2 puffs) topical spray of 100 µl on the cervix.
62735450|NCT01413243|EXPERIMENTAL|Drug: Trichuris suis ova|Experimental: Trichuris suis ova (TSO) 2500 eggs every 2 weeks for 12 months
62808746|NCT03426670|ACTIVE_COMPARATOR|OraQuick HIV Self-Test|Sex workers in the intervention arm will be instructed to self-test before starting each monthly course of PrEP. HIV Self-testing will be performed during the months between scheduled quarterly visits.
62232372|NCT03645954|ACTIVE_COMPARATOR|Femoral Triangle & Adductor Canal Blocks|"These two blocks will be performed together.~Firstly, the femoral triangle block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the medial border of the sartorius muscle intersects the medial border of the adductor longus muscle. Local anesthetic will be injected laterally to the femoral artery.~Secondly, the adductor canal block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the femoral vessels (artery and vein) dive deeper from the sartorius muscle. Local anesthetic will be injected under the femoral artery."
62232373|NCT00247377|ACTIVE_COMPARATOR|Laparoscopic Gastric Bypass|Subject undergoes Laparoscopic Gastric Bypass
62232374|NCT00247377|ACTIVE_COMPARATOR|LAP-BAND|Subject undergoes LAP-BAND procedure
62423699|NCT05187663|ACTIVE_COMPARATOR|Control group|In the control group, implant surface decontamination was performed with 1% chlorhexidine gel.
62423700|NCT01364259|PLACEBO_COMPARATOR|Placebo|Placebo and SRS
62735451|NCT01413243|PLACEBO_COMPARATOR|Placebo|Drug: Placebo, fluid every 2 weeks
62735452|NCT02818764||Delirium|"Subjects undergoing elective total joint arthroplasty determined to have delirium by post operative 3D-CAM.~Data collected on intraoperative cerebral blood flow and oxygen extraction fraction.~CSF collected for biomarkers. Blood colelcted for biomarkers."
62808747|NCT03426670|NO_INTERVENTION|In-clinic testing|All study participants will receive quarterly in-clinic HIV testing as standard-of-care.
62808748|NCT04473209|ACTIVE_COMPARATOR|diabetic group|diabetic patients with chronic periodontitis
62808749|NCT04473209|ACTIVE_COMPARATOR|non-diabetic group|non diabetic patients with chronic periodontitis
62808750|NCT03929185||Tumor affected|Patients affected by colorectal cancer who underwent to surgical resection in Sant'Anna Hospital in Cona (Ferrara)
62808751|NCT03929185||Control|Healthy people aged 20-35 years old without risk factors for colorectal cancers who voluntarily participated to the study
62808752|NCT03226717||Hepatitis C patients|Antiviral agents (sofosbuvir,daclatasvir,ribavirin) will be given to hepatitis C patients with arthropathy.
62808753|NCT04051359|ACTIVE_COMPARATOR|Standard carbohydrate (200 g) group|Assignment to treatment groups will be performed on the enrollment to the study by evaluating the dietary carbohydrate intake personal patient preferences from 3 days prospective 24 hours' food dairy. After, the randomization will be performed and GDM patients will be assigned to the standard carbohydrate (200 g) group.
62808754|NCT04051359|EXPERIMENTAL|Low carbohydrate (130 g) group|Assignment to treatment groups will be performed on the enrollment to the study by evaluating the dietary carbohydrate intake personal patient preferences from 3 days prospective 24 hours' food dairy. After, the randomization will be performed and GDM patients will be assigned to the low carbohydrate (130 g) group.
62808755|NCT01122641|PLACEBO_COMPARATOR|Placebo|
62808756|NCT01122641|EXPERIMENTAL|Vildagliptin|Vildagliptin 50mg bid
62808757|NCT03831477|EXPERIMENTAL|80 pin applicator|
62232375|NCT04099017|EXPERIMENTAL|Mulligan mobilization group|"This study ARM will received Mulligan joint mobilization and concomitant therapies in this group.~The following are the brief detail of therapy~1. Mulligan joint mobilization in Non-weight bearing (NWB):~2. Knee strengthening~3. Kinesiotaping"
62232376|NCT04099017|EXPERIMENTAL|Trunk stabilization group|"This study ARM will received Trunk stabilization exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~1. Trunk stabilization i. modified supermen extension exercise ii. Back bridge: iii. Unilateral back bridge:~   Iv. lateral step up:~2. Knee strengthening i. Isometric quadriceps exercise: ii. Straight leg raising (SLR) exercise:~3. Kinesiotaping:"
62232377|NCT04099017|OTHER|Knee strengthening group|"This study ARM will received Knee strengthening exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~1. Knee strengthening i. Isometric quadriceps exercise ii. Straight leg raising (SLR) exercise:~2. Kinesio-taping:"
62232378|NCT00892723|EXPERIMENTAL|Low Dose|
62232379|NCT00892723|EXPERIMENTAL|High Dose|
62232380|NCT00892723|PLACEBO_COMPARATOR|Placebo|
62423701|NCT01364259|EXPERIMENTAL|Amifostine|Amifostine and CyberKnife stereotactic radiosurgery
62423702|NCT05117866|EXPERIMENTAL|Prasugrel Monotherapy|The patients will be loaded with standard dual antiplatelet therapy according to local practice (usually aspirin 81 to 330 mg and clopidogrel 300 mg or prasugrel 20 mg or ticagrelor 180 mg, unless patient is on long-term therapy) prior to the PCI procedure. After PCI, if the results are considered to be satisfactory by the operator based on clinical (e.g. clinical status, ECG, etc.), angiographic and/or findings from intracoronary imaging, only then patients will be enrolled in the study and loaded with prasugrel 20 mg if the patients have not loaded prasugrel prior to PCI or have not taken a maintenance dose of prasugrel before the index PCI. Patients continued with prasugrel only (3.75 mg once a day) for three months in CCS patients and for 12 months in NSTE-ACS patients. Aspirin, clopidogrel, and ticagrelor will be discontinued just after the index procedure.
62808758|NCT03831477|ACTIVE_COMPARATOR|160 pin applicator|
62808759|NCT04260893|EXPERIMENTAL|Tixel Treatment|3 Tixel treatment sessions, 2 weeks apart follow by 3 Follow up sessions
62808760|NCT02314936|EXPERIMENTAL|Litesse powder containing 12 g polydextrose|12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
62808761|NCT02314936|EXPERIMENTAL|Litesse powder containing 8 g polydextrose|8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
62808762|NCT02314936|EXPERIMENTAL|Litesse powder containing 4 g polydextrose|4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
62423703|NCT01909817||Routine coronary angiogram patients|
62423704|NCT05437510|EXPERIMENTAL|Nirsevimab|1 intramuscular injection at Day 01
62808763|NCT02314936|PLACEBO_COMPARATOR|Placebo|Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
62232381|NCT06204354||samples of cervical cancer|fresh samples collected from patients diagnosed with cervical cancer
62232382|NCT06204354||samples of endometrial cancer|fresh samples collected from patients diagnosed with endometrial cancer
62232383|NCT06204354||samples of ovarian cancer|fresh samples collected from patients diagnosed with ovarian cancer
62232384|NCT06204354||samples of vulva cancer|fresh samples collected from patients diagnosed with vulva cancer
62232385|NCT06204354||samples of vaginal cancer|fresh samples collected from patients diagnosed with vaginal cancer
62232386|NCT06204354||samples of rare gynecological cancer|fresh samples collected from patients diagnosed with rare gynecological cancer
62232387|NCT02147353|ACTIVE_COMPARATOR|Sinecatechins 15% Ointment & Cryotherapy|Cryotherapy and then Sinecatechins 15% Ointment 1 week later.
62232388|NCT02147353|PLACEBO_COMPARATOR|Cryotherapy Alone|Cryotherapy will be standardized in all subjects and for all treated lesions: EGW lesions will be treated with 2 sprays, 5 seconds each, with a 5 second interval. All subjects will be treated with the same cryo-spray regimen.
62232389|NCT01864837||Functional dyspepsia|They should meet the Rome III criteria for functional dyspepsia.
62232390|NCT02146456|NO_INTERVENTION|Colloid|During the operation, Lactate Ringer's solution is used as the maintenance fluid, and colloid is infused for the compensation of the intraoperative blood loss.
62232391|NCT02146456|EXPERIMENTAL|Tranexamic acid|"During the operation, Lactate Ringer's solution is used as the maintenance fluid, and colloid is infused for the compensation of the intraoperative blood loss.~In addition, 1 g of tranexamic acid in 100 ml normal saline is administered intravenously over 30 min after finishing the procedure of hip implant insertion."
62232392|NCT02777385|EXPERIMENTAL|Arm 1|Cisplatin, Radiation, and Pembrolizumab started 3 weeks after completion of cisplating and radiation.
62808764|NCT00152503|EXPERIMENTAL|Seletracetam|Escalating doses twice daily were to be administered.
62232393|NCT02777385|EXPERIMENTAL|Arm 2|Cisplatin and Radiation and Pembrolizumab given 1 week prior to the start of cisp/radiation and given every 3 weeks
62808765|NCT04338672||Pandemic Period|Patients who presented to the emergency department at our medical institute Sheba Medical Center between January 1 - March 31 in 2020.
62232394|NCT00718640|EXPERIMENTAL|Bortezomib and Dexamethasone|Bortezomib 1.3 milligram (mg) per meter\^2 (m\^2) bolus (a large amount) intravenous (into the vein) injection will be administered once daily on Days 1, 4, 8 and 11 of each 21-day cycle with addition of Dexamethasone 20 mg per day administered orally, once daily on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-day cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
62808766|NCT04338672||Pre Pandemic Period|Patients who presented to the emergency department at our medical institute Sheba Medical Center between January 1 - March 31 in the following years: 2017, 2018, 2019,
62232395|NCT02061098|EXPERIMENTAL|Pomegranate extract|"Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.~Group A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks."
62232396|NCT02061098|PLACEBO_COMPARATOR|Placebo|"Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.~Group A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks."
62423705|NCT05437510|NO_INTERVENTION|No preventive intervention for RSV|No intervention
62423706|NCT02049554|NO_INTERVENTION|Usual Care|
62423707|NCT02049554|EXPERIMENTAL|Preconception Care Screener Group|Women's Health Screener and Clinician discussion
62735453|NCT02818764||Non-delirium|"Subjects undergoing elective total joint arthroplasty determined not to have delirium by post oeprative 3D-CAM.~Data collected on intraoperative cerebral blood flow and oxygen extraction fraction.~CSF collected for biomarkers. Blood colelcted for biomarkers."
62735454|NCT02831504||Myotonic Dystrophy type 1 (DM1) patients|Natural History Study
62808767|NCT04279886|OTHER|Three-dimensional scan arm|
62808768|NCT02609308|ACTIVE_COMPARATOR|Short leg cast|The patients in this group will be immobilize with a short leg cast for 14 days, and later they will be able to do physical rehabilitation and will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.
62808769|NCT02609308|EXPERIMENTAL|Platelet-rich plasma|In this group, the patients will be receive a single dose of autologous platelet-rich plasma, and will be immobilized with a short leg cast. Posteriorly, they will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.
62808770|NCT00498940|ACTIVE_COMPARATOR|Biventricular Pacing|After weaning from bypass, patients received temporary biventricular pacing for 24 hours. Values obtained from optimization testing determined pacemaker settings (AVD, VVD, heart rate).
62808771|NCT00498940|ACTIVE_COMPARATOR|Standard of Care|No continuous pacing occurred about surgery. Patients underwent optimization testing.
62808772|NCT04122365|EXPERIMENTAL|Interventional group|Chest Wall Mobilization Program
62808773|NCT04122365|OTHER|Control Group|Routine limbs exercises and education
62808774|NCT05887869|EXPERIMENTAL|Telehealth solution|Telehealth solution offered
62232397|NCT03027492|ACTIVE_COMPARATOR|1. NCWS retrospective patients|The clinical charts of NCWS female patients attending the outpatient centers of the Department of Internal Medicine at the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca will be reviewed with a retrospective method. They had all been diagnosed with NCWS between January 2001 and June 2011 and included in a previously published study. These charts included specific sections for associated gynaecological disorders. Incomplete clinical charts will be excluded. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
62232398|NCT03027492|ACTIVE_COMPARATOR|2. CD retrospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of CD female patients had been randomly chosen by a computer-generated method from female patients diagnosed during the same period (2001-2011) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group was asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
62232399|NCT03027492|ACTIVE_COMPARATOR|3. IBS retrospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of IBS female patients had been randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2001-2011) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group was asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
62592894|NCT04204668|ACTIVE_COMPARATOR|Regenerative peripheral nerve interface (RPNI)|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. The nerves are then cleaned up to enhance the possibility of healthy healing. Then the surgeon takes a small sample from a muscle (usually one close by to the nerves that are being operated on but sometimes through a second incision in the arm or leg, depending on the exact medical situation) and form something called a muscle graft. The muscle graft is used to wrap the cleaned ends of the nerves mentioned above. This is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 1 - 3 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
62592895|NCT04204668|ACTIVE_COMPARATOR|Vascularized, denervated muscle target (VDMT )|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. The nerves are then cleaned up to enhance the possibility of healthy healing. The surgeon will then identify a local muscle along with a small artery and vein that supply blood to part of the muscle. A small sample of muscle, still attached to the artery and vein, is then created. The nearby nerves are then nestled into this segment of muscle that is still connected to the artery and vein. This is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 2 - 4 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
62592896|NCT06606444|EXPERIMENTAL|Surfactant administered via laryngeal mask airway|Enrolled infants will receive surfactant delivered via a neonatal size laryngeal mask airway.
62735455|NCT00633178|EXPERIMENTAL|Group Interpersonal Therapy (IPT)|Participants will receive group interpersonal therapy.
62423708|NCT05361811|EXPERIMENTAL|1/Internal Pilot|Participants will begin their 1-week baseline EMA data collection period and then take part in intervention procedures immediately after enrollment to assess feasibility and acceptability.
62423709|NCT05361811|ACTIVE_COMPARATOR|2/Immediate Intervention|Participants will begin their 1-week baseline EMA data collection period immediately after randomization and will begin receiving the 8-week intervention at the end of this week/beginning of the next week (depending on participant schedule).
62808775|NCT05887869|NO_INTERVENTION|Usual care|Control
62423710|NCT05361811|ACTIVE_COMPARATOR|3/Waitlist Control|After an initial 1-week baseline period for EMA data collection and 8 weeks of maintaining their usual routine (wait list period), participants will begin receiving the 8-week intervention.
62423711|NCT02756078|ACTIVE_COMPARATOR|Group 1 (TEST / CONTROL wear sequence)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the TEST / CONTROL wearing sequence will wear each of the study lenses for 4 weeks according to the manufacturer's guidelines. Subjects will be dispensed the other (second) lens type at the second dispense visit.
62423712|NCT02756078|ACTIVE_COMPARATOR|Group 2 (CONTROL / TEST wear sequence)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the CONTROL / TEST wearing sequence will wear each of the study lenses for 4 weeks according to the manufacturer's guidelines. Subjects will be dispensed the other (second) lens type at the second dispense visit.
62423713|NCT05319977|EXPERIMENTAL|Mobile incentive-based intervention|Contingent incentives on abstinence from alcohol; Text-based health promotion support
62423714|NCT03422081||growth hormone deficiency|
62423715|NCT03422081||small for gestational age|
62423716|NCT03422081||matched controls|
62423717|NCT03806478|EXPERIMENTAL|0.5 µg|Intranasal (IN) nanoparticles - 0.5 micrograms. The study is planned to include 1 dose of APH 1105 / 0.5 µg, administered twice a week for 12 weeks, for a total of 24 doses.
62735456|NCT00633178|ACTIVE_COMPARATOR|Treatment as Usual (ETAU)|Participants will receive psychiatric treatment as usual.
62808776|NCT04013607|EXPERIMENTAL|Fiber drink|A drink high in fructo- and galacto-oligosaccharides.
62808777|NCT02364908|OTHER|Patients with Systemic Lupus|
62808778|NCT01147666|EXPERIMENTAL|Cohort A-1 (Roxadustat 1.0 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.0 milligrams (mg)/kg, administered orally 3 times weekly (TIW) in the morning of the day after dialysis (interdialytic days) for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 grams \[g\]/deciliter \[dL\]) will be based upon regular monitoring of Hb.
62808779|NCT01147666|EXPERIMENTAL|Cohort A-2 (Roxadustat 1.5 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.5 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
62808780|NCT01147666|EXPERIMENTAL|Cohort A-3 (Roxadustat 2.0 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
62808781|NCT01147666|EXPERIMENTAL|Cohort A-4 (Roxadustat 1.8 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.8 mg/kg, administered orally TIW for 6 weeks. Participants who have not completed 6-week treatment at the time of Amendment 2, will continue treatment for up to 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
62808782|NCT01147666|EXPERIMENTAL|Cohort A-5 (Roxadustat 1.8 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 85-115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.8 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
62808783|NCT01147666|EXPERIMENTAL|Cohort A-6 (Roxadustat 1.3 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.3 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
62808784|NCT01147666|EXPERIMENTAL|Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)|Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.3 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (\>60 to 90 kg), and heavy weight (\>90 to 140 kg) participants will receive roxadustat 70 mg, 100 mg, and 150 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
62808785|NCT01147666|EXPERIMENTAL|Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)|Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.5 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (\>60 to 90 kg), and heavy weight (\>90 to 140 kg) participants will receive roxadustat 70 mg, 120 mg, and 200 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
62808786|NCT01147666|EXPERIMENTAL|Cohort A-9 (Roxadustat 2.0 mg/kg)|Normoresponsive participants (with baseline epoetin alfa dosage 85-150 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
62808787|NCT01147666|EXPERIMENTAL|Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)|Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.5 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (\>60 to 90 kg), and heavy weight (\>90 to 140 kg) participants will receive roxadustat 70 mg, 120 mg, and 200 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
62808788|NCT01147666|ACTIVE_COMPARATOR|Cohorts A (Epoetin Alfa)|Normoresponsive participants will receive IV epoetin alfa treatments on Day 1, at their prestudy dose and according to their prestudy dosing schedule (TIW). Epoetin alfa dosing will occur on dialysis days in each Cohort A. Dose adjustment will be per local standard of care (exclusive of IV iron) for routine maintenance of stable Hb levels on dialysis participants.
62592897|NCT05146739|EXPERIMENTAL|Treatment (uproleselan, fludarabine, cytarabine)|Patients receive uproleselan IV QD over 20 minutes on day 1 and IV over 20 minutes BID on days 2-8, fludarabine IV QD over 30 minutes on days 2-6, and high dose cytarabine IV QD over 1-3 hours on days 2-6. Patients also receive cytarabine IT on day 0 then weekly starting on day 7-28 or ITT on day 0 then weekly starting on day 7-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients (with down syndrome only) receive leucovorin PO or IV BID on days 1, 8, 15, 22, and 29.
62032566|NCT02571504|EXPERIMENTAL|Waitlist control group|Participants in the waitlist control group will receive a brochure with 8 simple tips for better brain health around the time of enrollment. They will begin the Plasticity-based Adaptive Cognitive Remediation (PACR) intervention within 8 weeks of the initial enrollment.
62592898|NCT06647602||Liothyronine cohort|Patients in the UMCG will receive L-T3 according to local protocol.
62032567|NCT02265900|ACTIVE_COMPARATOR|Exercise 1|One type of exercise
62032568|NCT02265900|PLACEBO_COMPARATOR|Exercise 2|A different type of exercise
62032569|NCT02207920|EXPERIMENTAL|Group 1|"At study entry and Month 1, participants will receive placebo for DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.~At Months 3 and 6, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid."
62592899|NCT06647602||Levothyroxine cohort|Patients in the Radboud UMC will receive L-T4 according to local protocol.
62232400|NCT03027492|ACTIVE_COMPARATOR|4. NCWS prospective patients|The investigators prospectively will survey adult female patients with functional gastroenterological symptoms according to the Rome III criteria, and a suspected diagnosis of NCWS. The patients will be recruited between January 2017 and January 2018 at the same 2 centers. Most of the patients will be referred owing to gastrointestinal and extraintestinal symptoms, the onset of which, they reported, could be related to wheat ingestion. In addition, patients will be asked about the presence and characteristics of gynaecological disorders using an ad hoc questionnaire. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
62232401|NCT03027492|ACTIVE_COMPARATOR|5. CD prospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of CD female patients will be randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2017-2018) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group will be asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
62232402|NCT03027492|ACTIVE_COMPARATOR|6. IBS prospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of IBS female patients will be randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2017-2018) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group will be asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
62232403|NCT06475872|EXPERIMENTAL|Crecheck Tab|On the day of the visit, take 2 tablets of the test drug orally with 150 mL of water around 8 am.
62808789|NCT01147666|EXPERIMENTAL|Cohort B-1 (Roxadustat 1.5 mg/kg TIW)|Hyporesponsive participants (with baseline epoetin alfa dosage 125-400 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.5 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
62808790|NCT01147666|EXPERIMENTAL|Cohort B-2 (Roxadustat 2.0 mg/kg TIW)|Hyporesponsive participants (with baseline epoetin alfa dosage \>115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 6 weeks. Participants who have not completed 6-week treatment at the time of Amendment 2, will continue treatment for up to 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
62232404|NCT06475872|ACTIVE_COMPARATOR|Comparator|On the day of the visit, take 1 tablet of the comparator drug orally with 150 mL of water around 8 am.
62232405|NCT02823535|EXPERIMENTAL|Iwin: Individual Well-Being Navigator|Iwin intervention during 6-month intervention period plus study assessments at baseline, 6, and 9 months.
62232406|NCT02823535|NO_INTERVENTION|Control group|Study assessments at baseline, 6 months, and 9 months, plus two short surveys unrelated to the study behaviors at 4 and 5 months.
62232407|NCT01267877|ACTIVE_COMPARATOR|Guideline unfavorable article|
62232408|NCT01267877|ACTIVE_COMPARATOR|Guideline favorable article|
62232409|NCT04341766||Patient hospitalised with COVID-19 infection|Patients admitted to hospital with proven COVID-19 infection with respiratory signs warranting a chest CT scan
62232410|NCT01346436|ACTIVE_COMPARATOR|Robotic|Use of daVinci surgical system (Intuitive Surgical Inc, Sunnyvale, CA) for the treatment of complex pelvic floor dysfunction
62808791|NCT01147666|ACTIVE_COMPARATOR|Cohort B (Epoetin Alfa)|Hyporesponsive participants will receive IV epoetin alfa treatments on Day 1, at their prestudy dose and according to their prestudy dosing schedule (TIW). Epoetin alfa dosing will occur on dialysis days in each Cohort B. Dose adjustment will be per local standard of care (exclusive of IV iron) for routine maintenance of stable Hb levels on dialysis participants.
62232411|NCT01346436|ACTIVE_COMPARATOR|Laparoscopy|Use of standard laparoscopy for the treatment of complex pelvic floor dysfunction
62232412|NCT01925287|ACTIVE_COMPARATOR|Native curcumin powder|500 mg curcumin as native powder
62423718|NCT03806478|EXPERIMENTAL|1.0 µg|Intranasal (IN) nanoparticles - 1.0 micrograms. The study is planned to include 1 dose of APH 1105 / 1.0 µg, administered twice a week for 12 weeks, for a total of 24 doses.
62423719|NCT03806478|EXPERIMENTAL|2.0 µg|Intranasal (IN) nanoparticles - 2.0 micrograms. The study is planned to include 1 dose of APH 1105 / 2.0 µg, administered twice a week for 12 weeks, for a total of 24 doses.
62808792|NCT01147666|PLACEBO_COMPARATOR|Cohort B (Placebo)|Hyporesponsive participants will receive placebo matched to roxadustat, administered orally TIW for 19 weeks.
62808793|NCT00101231|EXPERIMENTAL|Treatment (flavopiridol)|Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression.
62808794|NCT00883779|EXPERIMENTAL|1|
62808795|NCT00883779|PLACEBO_COMPARATOR|2|
62232413|NCT01925287|EXPERIMENTAL|Micronized curcumin powder|500 mg curcumin as micronized powder
62232414|NCT01925287|EXPERIMENTAL|Curcumin micelles|500 mg curcumin incorporated into liquid micelles
62232415|NCT05206019|EXPERIMENTAL|cohort 1: Albuvirtide|Single dose of 320 mg by intervenous drop infusion for 45 min
62232416|NCT05206019|EXPERIMENTAL|cohort 2: Albuvirtide|Single dose of 320 mg by intervenous injection for 0.5 min
62232417|NCT05206019|EXPERIMENTAL|cohort 3: Albuvirtide|Single dose of 320 mg by intervenous injection for 3 min
62232418|NCT01593306|EXPERIMENTAL|cisplatin and paclitaxel with concurrent radiotherapy|weekly cisplatin at 30mg/m2 and paclitaxel at 50mg/m2 are given with concurrent radiotherapy at 2Gy per fraction at 5 fractions per week for 5 weeks followed by either low dose rate (LDR) Intracavitary (I/C) Brachytherapy or supplement Chemoradiotherapy (CRT); if not fit for I/C Brachytherapy
62232419|NCT01593306|ACTIVE_COMPARATOR|cisplatin with concurrent radiotherapy|weekly cisplatin @ 40mg/m2 is given along with concurrent radiotherapy at 2Gy per fraction with 5 fractions per week for 5 weeks followed by LDR I/C brachytherapy or supplement CRT; if not fit for I/C Brachytherapy
62592900|NCT02683655|EXPERIMENTAL|Apatinib 500mg qd p.o.|Apatinib Mesylate Tablets 500 mg qd p.o. after the failure of chemotherapy or radiotherapy
62808796|NCT02003235|EXPERIMENTAL|Single Arm|Daily watching videos using Reviview™, a dichoptic video display device
62808797|NCT01100866|ACTIVE_COMPARATOR|Group 1|POMELLA™ 2 x 500mg capsule once daily
62808798|NCT01100866|PLACEBO_COMPARATOR|Group 2|POMELLA™ placebo
62808799|NCT05861596|EXPERIMENTAL|Group A|Conscript 10 individuals, every individual will receive 20 mins of repetitive transcranial magnetic stimulation and 30 min NMES combined with conventional swallowing therapy, 5 times per week, lasting for 2 weeks.
62808800|NCT05861596|SHAM_COMPARATOR|Group B|Conscript 10 individuals, every individual will receive sham repetitive transcranial magnetic stimulation and 30 min NMES combined with conventional swallowing therapy, 5 times per week, lasting for 2 weeks.
62808801|NCT04980534|EXPERIMENTAL|Viusid Plus Asbrip Adjuvant|25 Patients who received standard therapy Remdesivir IV 200 mg for the first day and then 100 mg daily for the next 4 days AND Viusid (sachets with powder for dilution, oral administration) 1 sachet bid and Asbrip (liquid form, oral administration) 10 ml bid for the total duration of hospitalization. Time Frame: 21 days.
62808802|NCT04980534|EXPERIMENTAL|Viusid Plus Asbrip Monotherapy|25 Patients who did not receive standard antiviral therapy with the inclusion of food supplements Viusid (4.5 gr every 12 hours, oral administration) and Asbrip (10 mL every 12 hours, oral administration). Time Frame: 21 days.
62808803|NCT04980534|ACTIVE_COMPARATOR|Control|30 patients who received standard therapy (Remdesivir IV 200 mg for the first day and then 100 mg daily for the next 4 days), without the inclusion of food supplements Viusid and Asbrip.
62808804|NCT02920892|EXPERIMENTAL|Double-Blind AFQ056 with language intervention|"After a 4-month single-blind placebo lead-in period, subjects with FXS were randomized to receive AFQ056 suspension by mouth twice per day in an 8 month double-blind treatment period.~During the double-blind treatment period, subjects in the AFQ056 treatment group began with a dose of 25 mg AFQ056 twice per day and titrated to their maximum tolerated dose over the course of 7 weeks. After 7 weeks the dose was fixed, and at the 2 month visit, the intensive language intervention was initiated. Subjects continued the language intervention while remaining on a stable dose of AFQ056 (ranging from 12.5 mg BID to 100 mg BID), for the next 6 months.~Safety and efficacy assessments were performed throughout."
62808805|NCT02920892|PLACEBO_COMPARATOR|Double-Blind Placebo with language intervention|"After a 4-month single-blind placebo lead-in period, subjects with FXS were randomized to receive a placebo suspension by mouth twice per day in an 8 month double-blind treatment period.~During the double-blind treatment period, dose titration to maximum tolerated dose of matching placebo occurred over 7 weeks. After 7 weeks, the dose was fixed, and at the 2 month visit, the intensive language intervention was initiated. Subjects continued the language intervention while remaining on placebo for the next 6 months.~Safety and efficacy assessments were performed throughout."
62808806|NCT02920892|EXPERIMENTAL|Open-Label AFQ056 with language intervention|"After 8 months of treatment in the placebo-controlled phase, all subjects had assessments completed and were given the opportunity to enter the open-label extension (OLE) in which all subjects received AFQ056. The OLE began with 2 months of flexible dose titration to each subject's maximum tolerated dose followed by a period of stable treatment. Subjects also continued the language intervention through the extension phase.~The duration of the stable treatment depended on when the subject was enrolled into the study. Those enrolled prior to June 15-30, 2019 received a 6-month period of stable treatment. Those enrolled after June 15, 2019 had their period of stable treatment shortened on a sliding scale, such that their treatment including weaning, if necessary, ended before August 31, 2021 (study drug expiration)."
62032570|NCT02207920|EXPERIMENTAL|Group 2|"At study entry and Month 1, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.~At Months 3 and 6, participants will receive placebo for DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid."
62592901|NCT02683655|EXPERIMENTAL|Apatinib 750mg qd p.o.|Apatinib Mesylate Tablets 750 mg qd p.o. after the failure of chemotherapy or radiotherapy
62592902|NCT01630408|EXPERIMENTAL|Paricalcitol|Paricalcitol oral capsules (1 mcg per day for 48 weeks)
62808807|NCT02313701|NO_INTERVENTION|Vaginal hysterectomy counseling|Standard verbal counseling to consent for vaginal hysterectomy in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
62819535|NCT03021200|EXPERIMENTAL|Indocyanine green in robot-assisted Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (Firefly) for robot-assisted oncological surgeries
62032571|NCT02207920|EXPERIMENTAL|Group 3|"At study entry and Month 1, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.~At Months 3 and 6, participants will receive DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid."
62808808|NCT02313701|EXPERIMENTAL|Vaginal hysterectomy visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for vaginal hysterectomy. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
62808809|NCT02313701|NO_INTERVENTION|Robotic sacrocolpopexy counseling|Standard verbal counseling to consent for robotic sacrocolpopexy in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
62808810|NCT02313701|EXPERIMENTAL|Robotic sacrocolpopexy visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for robotic sacrocolpopexy. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
62808811|NCT02313701|NO_INTERVENTION|Sub-urethral sling counseling|Standard verbal counseling to consent for sub-urethral sling in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
62808812|NCT02313701|EXPERIMENTAL|Sub-urethral sling visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for sub-urethral sling. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
62808813|NCT00768417||Participants|Participants completed all 3-arms of this cross-over design study.
62808814|NCT03798717|NO_INTERVENTION|Control|Participants will lie in a semi recumbent position in minimal clothing for the entirety of the visit. Initially, participants will be cannulated and blood samples drawn.every 30 min of each experimental visit. Following cannulation an 180 min OGTT (75g) will commence in a thermoneutral room (\~ 23C). During the OGTT, HR will be measured continuously, whilst blood pressure, deep body temperature (rectal probe) and resting metabolic rate will be assessed every 30 min.
62808815|NCT03798717|EXPERIMENTAL|Pre OGTT|Condition 2 will employ identical procedures to condition 1, except thirty minutes into the OGTT, the participant will be immersed into an immersion tank (\~39oC) for 60 min. Water temperature will be manipulated as required to achieve and maintain a target Trec at 38.5 oC using water between 37.5 and 39oC, and then participants will be removed horizontally back into the thermoneutral room for the reminder of the OGTT. Participants will be towel dried and given a towelled robe to wear.
62808816|NCT03798717|EXPERIMENTAL|Post OGTT|Condition 3 will employ identical procedures to condition 2, with the exception that the heating via immersion will start as soon as the participant is instrumented (and following a 15 min rest period) and the OGTT will commence 30 min after the 60 min immersion time for a further 180 min.
62819536|NCT06593535|PLACEBO_COMPARATOR|Placebo|containing edible yellow No. 4, edible yellow No. 5, sucrose, silica, talc, oxidized starch, gelatin, magnesium stearate, and palm wax.
62232420|NCT03017274||NCWS patients|Fifty consecutive adult patients with an IBS-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients was recruited between January 2015 and November 2016 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
62232421|NCT03017274||CD control patients|To compare the abdominal ultrasonographic features of NCWS patients, a control group of CD patients was randomly chosen by a computer-generated method from subjects diagnosed during the same period and age- and sex-matched with the NCWS patients. All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
62819537|NCT06593535|EXPERIMENTAL|Astaxanthin (AST)|Each capsule containing 4 mg of AST
62232422|NCT05902923||intervention|All patients in the study will undergo same procedure. The implanted devices can be one of more of the study devices.
62032572|NCT02207920|EXPERIMENTAL|Group 4|At study entry and Months 1, 3, and 6, participants will receive DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.
62232423|NCT03681197|ACTIVE_COMPARATOR|Metformin Group|Will receive metformin plus clomiphene citrate
62423720|NCT03806478|PLACEBO_COMPARATOR|Placebo|Intranasal (IN) Placebo nanoparticles. The study is planned to include 1 dose of placebo drug administered twice a week for 12 weeks, for a total of 24 doses.
62423721|NCT03857139|EXPERIMENTAL|NRT smoking Cessation Intervention|All participants will be provided with the Nicotine Patch as an intervention
62423722|NCT03102788|ACTIVE_COMPARATOR|Control|Patients in the control group will receive their first consultation in specialist health care by a rheumatologist. Rheumatologist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, and, for some patients, Intra-articular injection of long-acting Corticosteroid. The rheumatologist may also refer participants to occupational therapy if needed.
62592903|NCT05495152|EXPERIMENTAL|Adjuvant Arm|Patients in arm A receive 17 cycles of Sintilimab within 4 to 12 weeks after esophagectomy for ESCC. Sintilimab was administered intravenously at a dose of 200 mg over 30 minutes every 3 weeks.
62592904|NCT05495152|NO_INTERVENTION|Observation Arm|Patients in observation arm receive routine follow-up after surgery.
62592905|NCT06017752|EXPERIMENTAL|STAC Teacher Module|
62808817|NCT01186666|EXPERIMENTAL|Non ST-elevation acute coronary syndrome|"Coronary intervention using IVUS-VH \& FDG PET-MDCT:~All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers."
62808818|NCT01186666|EXPERIMENTAL|Stable coronary artery disease|"Coronary intervention using IVUS-VH \& FDG PET-MDCT:~All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers."
62808819|NCT05559177|EXPERIMENTAL|Treatment of recurrent or metastatic bladder cancer|Lack of conventional effective treatment, failure or recurrence of treatment with conventional methods (surgery, chemotherapy, radiotherapy, immune checkpoint inhibitors, targeted therapy, etc.), or refusal of conventional treatment
62808820|NCT02172430|EXPERIMENTAL|Tiotropium|
62808821|NCT02172430|ACTIVE_COMPARATOR|Oxitropium bromide|
62232424|NCT03681197|PLACEBO_COMPARATOR|Placebo|Will receive placebo plus clomiphene citrate.
62232425|NCT03270423|ACTIVE_COMPARATOR|Intervention SG|Therapy during 6 months with PathMate2 design. 6 therapy visits + PathMate2 over 6 months
62819538|NCT06602336|EXPERIMENTAL|Investigational Lactate Device|Continuous interstitial fluid lactate monitoring using the Abbott Investigational Lactate Device
62592906|NCT06489327|ACTIVE_COMPARATOR|1st group: melatonin 0.2 mg/kg group|patients will receive oral melatonin at a dose of 0.2 mg/kg
62592907|NCT06489327|ACTIVE_COMPARATOR|2nd group: M04 groupmelatonin 0.4 mg/kg group|patients will receive oral melatonin at a dose of 0.4 mg/kg
62232426|NCT03270423|NO_INTERVENTION|Control SG|Therapy during 6 months with usual care. 10 therapy visits over 6 months
62232427|NCT03270423|ACTIVE_COMPARATOR|Intervention VD|Adapted sport session 1h/week + PathMate-S during 6 months
62232428|NCT03270423|NO_INTERVENTION|Control VD|Adapted sport session 1h/week during 6 months
62592908|NCT06489327|PLACEBO_COMPARATOR|3rd group: placebo group|patients will receive oral placebo premedication
62032573|NCT06066060|EXPERIMENTAL|JMKX000623/Metformin/ JMKX000623+Metformin|D1-D8, JMKX000623; D14-D19, Metformin; D20-D27, JMKX000623+Metformin
62592909|NCT04921527|EXPERIMENTAL|Chiauranib plus weekly paclitaxel|Patients receive the combined treatment of chiauranib plus paclitaxel, 21 days for a cycle, 6 cycles at most,Chiauranib is given orally, 50mg once daily. Paclitaxel is given in intravenous infusion on Day 1, 8 and 15. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
62592910|NCT04921527|PLACEBO_COMPARATOR|placebo plus weekly paclitaxel|Patients receive the combined treatment of placebo plus paclitaxel, 21 days for a cycle, 6 cycles at most,placebo is given orally, 50mg once daily. Paclitaxel is given in intravenous infusion on Day 1, 8 and 15. After 6 cycles combined treatment, patients enter the single agent therapy of placebo.
62592911|NCT06112158|EXPERIMENTAL|Education Intervention|"The BSE training program for the early diagnosis of breast cancer will be offered to students in two ways: face-to-face and via web support.~While the training program prepared by the researchers was applied to the intervention group, it was planned that no application would be applied to the nonınterventıon group.~In this study, the training period was determined in two ways:~First; In face-to-face training, each training is planned as four sessions of 45 minutes. Each session is planned with a different purpose and application.~Latter; The system will continue to be open during the training provided through web support and face-to-face training, but the system will be closed to access immediately after the face-to-face training is completed."
62592912|NCT06112158|NO_INTERVENTION|nonıntervention Group|Until the research is finalized, no intervention will be made. After the research is finalized, the system will be opened to the nonınterventıon group and the university in general to contribute to their knowledge and awareness.
62232429|NCT04534504|EXPERIMENTAL|SG-uncut JJB|For SG-uncut JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
62423723|NCT03102788|EXPERIMENTAL|Intervention|Patients in the intervention group will receive their first consultation in specialist health care by an occupational therapy specialist. Occupational therapist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, teaching of hand exercises and ergonomic working methods, and, for some patients, provision assistive devices and orthoses/splints. The occupational therapist will refer patients to a short rheumatologist consultation if confirmation of diagnosis or intra-articular injections of long-acting Corticosteroid are needed.
62423724|NCT00116376|EXPERIMENTAL|AEE788 + non EIACD|
62592913|NCT06617520|EXPERIMENTAL|Tobacco flavor cigarillo|A participant will use a tobacco flavored cigarillo at home for 7-days, as they wish, and then smoke it once in the laboratory
62592914|NCT06617520|EXPERIMENTAL|Concept flavor cigarillo|A participant will use a concept flavored cigarillo at home for 7-days, as they wish, and then smoke it once in the laboratory
62232430|NCT04534504|ACTIVE_COMPARATOR|SG-JJB|For SG-JJB procedure, after SG was finished, the jejunum was transected 20-cm distal to Treiz ligament. After that, another 200-cm jejunum was measured and side-to-side jejunojejunal anastomosis was made. The anastomotic and mesenteric defects were closed by hand suture.
62592915|NCT06617520|EXPERIMENTAL|Characterizing flavor|A participant will use a characterizing flavored cigarillo at home for 7-days, as they wish, and then smoke it once in the laboratory
62592916|NCT06084819|EXPERIMENTAL|Venetoclax Combined With CACAG Regimen|Venetoclax combined with CACAG regimen for relapsed/refractory AML. Recipients were randomized and those entering the experimental group received azacytidine,cytarabine,aclacinomycin,chidamide,venetoclax and granulocyte colony-stimulating factor. Azacytidine was used as 75 mg/m2/day from day 1 to day 7.Cytarabine was used as 75-100 mg/m2 bid from day 1 to day 5. Aclacinomycin was used as 20 mg/day on days 1,3,5. Chidamide was used as 30 mg/day on days 1,4,8,11. Venetoclax was used as 400 mg/day from day 1 to day 14.Granulocyte colony-stimulating factor was used as 300 ug/day from day 0 until agranulocytosi recovery.
62032574|NCT04522518||DD group|160 pairs of children with disabilities 6-12 years of age and their caregivers (n=320)
62032575|NCT04522518||TD group|160 pairs of typically developing children 6-12 years of age and their caregivers (n=320)
62032576|NCT06669559|OTHER|Person aged 70 and over with a neurocognitive disorder and hospitalized in geriatrics|
62232431|NCT02877979|EXPERIMENTAL|DS003 vaginal tablet|participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.
62232432|NCT02877979|PLACEBO_COMPARATOR|placebo|participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.
62232433|NCT06096896||single-group with MWA|334 patients with confirmed or suspected eHCC as indicated by EOB-MRI were to be included in this study in a population with high or extremely high-risk of hepatocellular carcinoma in chronic liver disease. Then Microwave ablation (MWA) was performed under EOB-MRI guidance in patients with confirmed or suspected eHCC.
62232434|NCT03646656|EXPERIMENTAL|peer partner|Veterans with at least one CVD risk factor who are interesting in increasing heart healthy behaviors through peer support
62423725|NCT00116376|EXPERIMENTAL|AEE788 + EIACD|
62423726|NCT05630001|EXPERIMENTAL|Iptacopan treatment in adult PNH patients|Subjects will receive iptacopan at a dose of 200 mg b.i.d. orally
62423727|NCT03538522|EXPERIMENTAL|Low-dose N-831(Traneurocin)- 10 mg QD|Oral administration of 10 mg of NA-831 (Traneurocin) per day for 24 weeks
62423728|NCT03538522|EXPERIMENTAL|Medium-dose NA-831(Traneurocin)- 20 mg QD|Oral administration of 20 mg of NA-831(Traneurocin) per day for 24 weeks
62423729|NCT03538522|EXPERIMENTAL|High-dose NA-831(Traneurocin)- 40 mg QD|Oral administration of 40 mg of NA-831(Traneurocin) per day for 24 weeks
62232435|NCT03646656|OTHER|peer coach|Veterans with at least one CVD risk factor who have made and sustained changes in diet or exercise in the past 3-6 months prior to enrollment. While the investigators will collect data on peer coach participants, their participation is primarily as part of intervention to examine the feasibility and benefit of adding peer coaching to a peer partner intervention.
62232436|NCT03107650||High risk patients|Patients with high risk of suboptimal mesorectum quality and/or positive circumferential margin after the application of the preoperative prediction model developed
62232437|NCT03107650||Low risk patients|Patients with low risk of suboptimal mesorectum quality and/or positive circumferential margin after the application of the preoperative prediction model developed
62592917|NCT06084819|ACTIVE_COMPARATOR|Best-Available Therapy(BAT) Regimen|BAT regimen for relapsed/refractory AML.Recipients were randomized and those entering this group received FLAG/CLAG/MAE/DCAG/HAA/HAD regimen.
62032577|NCT02856464|EXPERIMENTAL|Experimental|
62032578|NCT02856464|OTHER|Control|
62423730|NCT03538522|PLACEBO_COMPARATOR|Placebo|Oral administration of placebo per day for 24 weeks
62423731|NCT04717232|EXPERIMENTAL|The blended learning approach to mentoring education for dental health care professionals|The blended learning approach to mentoring education for dental health care professionals will last five weeks, including four face-to-face seminars, interprofessional group work and self-reflection assignments lasting for two days. The educational content will include mentoring as a process, mentoring as a relationship, challenges of mentoring, and personal mentoring.
62423732|NCT04717232|EXPERIMENTAL|The interprofessional online mentoring education|The intervention group will attend mentoring competence education. The Interprofessional online mentoring educations includes videos of specialist lectures, e-learning materials, along with assignments concerning reflection skills and participant-based evaluation. The education content included the processes and interactions of mentoring, goal-oriented mentoring, along with student-based feedback and student-centered evaluation. The mentoring education can be completed in an online learning environment and participants can complete the education at their own pace within six weeks.
62592918|NCT05365646|EXPERIMENTAL|Fall risk assessment|Participants will wear study hearing aids that are equipped with embedded sensors and artificial intelligence. This will help track their movement and signal if the participant falls or is at fall risk.
62032579|NCT04417959|OTHER|Phaco-DSAEK|Subjects randomized to this arm will consist of patients with both Fuchs' endothelial dystrophy and cataract. These will be treated with phacoemulsification and Descemet's stripping automated endothelial keratoplasty.
62032580|NCT04417959|OTHER|Phaco-DMEK|Subjects randomized to this arm will consist of patients with both Fuchs' endothelial dystrophy and cataract. These will be treated with phacoemulsification and Descemet's membrane endothelial keratoplasty.
62032581|NCT05475054||Open liver resection|Non-obese or obese patients that underwent an open liver resection for all indications
62423733|NCT04717232|ACTIVE_COMPARATOR|The Control group|The control group are dentists´ and dental hygienists´ who are working at health care centers on the Finnish Dental Association site, participate in student mentoring and have not received any education before.
62735457|NCT00633178|NO_INTERVENTION|No Treatment|Participants are healthy and will receive no treatment.
62032582|NCT05475054||Minimally invasive liver resection|Non-obese or obese patients that underwent a minimally invasive liver resection for all indications
62032583|NCT00670774|EXPERIMENTAL|Eculizumab|Patients received eculizumab intravenously according to details provided in the intervention description.
62032584|NCT02034747|EXPERIMENTAL|Corticosteroid with the 50% reduced dose|oral
62032585|NCT02034747|ACTIVE_COMPARATOR|Corticosteroid with the maintained dose|oral
62232438|NCT03123809|ACTIVE_COMPARATOR|Gastric Electrical Stimulation (GES) ON|"Gastric Electrical Stimulation (GES) system involves surgical implantation of a pulse generator in the abdominal wall and 2 electrodes into the muscularis propria of the stomach.~After surgery this group of GP patients will have their GES programed and system will be turned ON for 3 months during a double-blind phase of the study. This step will be followed with additional 3 months of active stimulation (GES System will be turned ON) as it is described in the protocol.Therefore all subjects in this arm will receive overall 6 months of intervention, which will be provided by the active stimulation of GES System (GES turned ON for 6 months)."
62232439|NCT03123809|PLACEBO_COMPARATOR|Gastric Electrical Stimulation (GES) OFF|"Gastric Electrical Stimulation (GES) system involves surgical implantation of a pulse generator in the abdominal wall and 2 electrodes into the muscularis propria of the stomach.~After surgery this group of GP patients will have their GES programed and system will be turned OFF for 3 months.This step will be followed with additional 3 months of active stimulation (GES System will be turned ON) as it is described in the protocol. Therefore all subjects in this arm will receive first 3 months of non GES intervention (GES System OFF), and 3 following months of active intervention which will be provided by the stimulation of GES System (GES turned ON for 3 months)."
62592919|NCT05365646|EXPERIMENTAL|Speech intelligibility|Participants will wear study hearing aids that are equipped with embedded sensors and artificial intelligence. This will help track their movement and signal if the participant falls or is at fall risk.
62232440|NCT02482870|ACTIVE_COMPARATOR|Macintosh|Patients scheduled for general anesthesia during the study period, who had been intubated with Macintosh laryngoscope first and then with KingVision videolaryngoscope.
62592920|NCT01000532||Pacemaker therapy|
62592921|NCT00740909|NO_INTERVENTION|MAC|Minimal Attention Control
62592922|NCT00740909|EXPERIMENTAL|CBT|Cognitive Behavioral Therapy
62592923|NCT03155178|EXPERIMENTAL|3M CHG/IPA Prep|Apply topically for 30 seconds (abdominal site) or 2 minutes (inguinal site), and allow to dry for 3 minutes.
62232441|NCT02482870|ACTIVE_COMPARATOR|KingVision|Patients scheduled for general anesthesia during the study period, who had been intubated with King Vision videolaryngoscope first and then with Macintosh laryngoscope.
62232442|NCT01924728|ACTIVE_COMPARATOR|Magnetic stimulation|Active magnetic stimulation delivered to the pelvic floor muscles
62232443|NCT01924728|SHAM_COMPARATOR|Sham magnetic stimulation|Sham magnetic stimulation delivered to the pelvic floor muscles
62423734|NCT06460246|EXPERIMENTAL|Pulse Oximeter|The subjects will have a 22-gauge catheter inserted in the radial artery to measure the oxygen saturation of arterial blood and also wear pulse oximeters.
62423735|NCT01027026|EXPERIMENTAL|Group 1 Fast Track Group|The patients are discharged the same day after coronary angiography to the refering Hospital
62423736|NCT01027026|ACTIVE_COMPARATOR|Group 2: Ordinary care|Ordinary Cardiology care in the Intervention hospital
62423737|NCT00542958|EXPERIMENTAL|NK012|"This is a Phase I dose-escalation study of the intravenous administration of NK012 in patients with refractory solid tumors. Patients will receive NK012 as an intravenous infusion over 30 minutes on Day 1 followed by a 20-day observation period for a total of 21 days (3 weeks) per cycle. Two patient populations will be evaluated separately: patients with UGT1A1\*28 genotype homozygous wild type (wt/wt) and heterozygous (wt/\*28) variants as one group, and patients with UGT1A1\*28 homozygous variant (\*28/\*28) as another group. Dose-escalation in each patient population will proceed according to the predefined dose level.~For UGT1A1\*28 (wt/wt and wt/\*28) patients, at least 3 evaluable patients will be treated at each dose level.~UGT1A1 homozygous (\*28/\*28) patients will be treated at 50% of the current dose level.~Patients will receive up to 6 cycles of NK012, unless they experience unacceptable toxicity or disease progression, requiring withdrawal from the study."
62423738|NCT00417859|ACTIVE_COMPARATOR|TKA mobile|TKA mobile
62423739|NCT00417859|NO_INTERVENTION|TKA|TKA fix
62592924|NCT03155178|ACTIVE_COMPARATOR|ChloraPrep|Apply topically for 30 seconds (abdominal site) or 2 minutes (inguinal site), and allow to dry for 3 minutes.
62592925|NCT02718690|EXPERIMENTAL|Transcutaneous nerve stimulation|"Transcutaneous application of TENS current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
62592926|NCT02718690|SHAM_COMPARATOR|Sham stimulation|Electrodes are placed over the back for a 40 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel
62592927|NCT01895608|EXPERIMENTAL|Balance rehabilitation + dual-tasking|Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant can safely perform the primary balance or gait task.
62232444|NCT02913235|EXPERIMENTAL|Oral hygiene discontinuation group|The intervention of the present study is discontinuation of regular oral hygiene procedures for a period of 10 days. Discontinuation of oral hygiene will allow undisturbed biofilm formation (supragingival dental plaque) along the gingival margin of the teeth. After 10 days all individuals will resume regular oral hygiene. Clinical registrations and collection of microbiological samples (supragingival and saliva) will be performed at baseline and 4, 7 and 10 days after discontinuation of regular oral hygiene, and will be repeated 14 days after regular oral hygiene has been resumed.
62423740|NCT01294605|EXPERIMENTAL|Group A|
62423741|NCT01294605|EXPERIMENTAL|Group B|
62423742|NCT01294605|ACTIVE_COMPARATOR|Group C|
62592928|NCT01895608|ACTIVE_COMPARATOR|Standard balance rehabilitation|Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
62592929|NCT01895608|EXPERIMENTAL|Cognitive training (speed of processing)|Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
62592930|NCT01895608|ACTIVE_COMPARATOR|Cognitive training (general cognition)|General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
62592931|NCT05115227|EXPERIMENTAL|Multidisciplinary|A pragmatic team-based management approach is individualized for each patient.
62592932|NCT04081025||Adults|Age Groups 35, 50, 65, 75 and 85
62592933|NCT05639816|EXPERIMENTAL|saline irrigation group|The patients received saline irrigation of common bile duct after complete ERCP stone removal confirmed by occluded cholangiogram
62592934|NCT05639816|NO_INTERVENTION|control|The patients whom complete ERCP stone removal confirmed by occluded cholangiogram were follow up according to standard treatment
62032586|NCT01446458|EXPERIMENTAL|5-Fluorouracil, Oxaliplatin, Irinotecan|5-Fluorouracil, Oxaliplatin, Irinotecan are administered as a modified FOLFIRINOX regimen every 15 days. Subjects receive bi-weekly cycles of therapy on the 1st week, the 3rd week, the 5th week and finally the 7th week for a total of 4 cycles. Assessments include history and physical, laboratory tests on a weekly basis throughout the treatment period prior to and including week 8 assessment for stereotactic body radiotherapy (SBRT).
62032587|NCT03512665|EXPERIMENTAL|Full dose supplement group|Patients assigned to this group will receive a daily dose of 7 mL of the study supplement (a mixture of pine, macadamia and pomegranate oils). The appearance and organoleptic properties will be similar to those of the interventions in the other two groups
62032588|NCT03512665|EXPERIMENTAL|Low dose Supplement group|Patients assigned to this group will receive a daily dose of 7 mL of a mixture containing 50% study supplement and 50% sunflower oil. The appearance and organoleptic properties will be similar to those of the interventions in the other two group
62032589|NCT03512665|OTHER|Control Oil Group|Patients assigned to this group will receive a daily 7 mL dose of an oil (sunflower oil) with appearance and organoleptic properties similar to those of the supplement provided in the intervention groups
62032590|NCT05879887|EXPERIMENTAL|Basic palliative care coaching + financial coaching + outpatient visit + 1 monthly follow-up call|4 telehealth sessions on principles of problem solving, self-care, symptom management, and advanced care planning, 1 telehealth session on strategies to address healthcare-related financial toxicity, one-time Comprehensive Specialty Outpatient Palliative Care Clinic guided by the National Consensus Project for Quality Palliative Care Guidelines, and a single monthly follow-up call
62032591|NCT05879887|EXPERIMENTAL|Basic palliative care coaching + financial coaching + outpatient visit + 4 monthly follow-up calls|4 telehealth sessions on principles of problem solving, self-care, symptom management, and advanced care planning, 1 telehealth session on strategies to address healthcare-related financial toxicity, one-time Comprehensive Specialty Outpatient Palliative Care Clinic guided by the National Consensus Project for Quality Palliative Care Guidelines, and monthly follow-up calls for 4 months
62232445|NCT04496063|EXPERIMENTAL|Group 1 Ustekinumab|Intravenous induction (6mg/kg) followed by Ustekinumab subcutaneous 90mg every 8 weeks
62232446|NCT04496063|PLACEBO_COMPARATOR|Group 2 Placebo|Placebo intravenous followed by Placebo subcutaneous every 8 weeks
62232447|NCT02116985|EXPERIMENTAL|Dual-Loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
62423743|NCT04800367|EXPERIMENTAL|Romosozumab followed by denosumab|Romosozumab 210 mg subcutaneous injection, once a month for 12 months followed by denosumab 60 mg subcutaneous injection, once every six months for 12 months.
62423744|NCT06102967||Non-delirious group|No postoperative delirium occurred
62423745|NCT06102967||Delirious group|Postoperative delirium occurs
62423746|NCT06122571|EXPERIMENTAL|Test arm: ConcenTrace|"Participants will follow this weekly dosing schedule:~Week 1: Day 1-3: take 5 drops of ConcenTrace with 8oz of water or flavored water. Day 4-7: take 5 drops of ConcenTrace 2x per day with 8 oz of water or flavored water.~Week 2: Take 10 drops of ConcenTrace 2x per day with 8 oz of water or flavored water.~Week 3: Take 15 drops of ConcenTrace 2x per day with 8 oz of water or flavored water.~Week 4: Take 20 drops of ConcenTrace 2x per day with 8 oz of water or flavored water.~Weeks 5 - 12: Take 40 drops of ConcenTrace 1x per day with 8 oz of water or flavored water."
62423747|NCT01566474|EXPERIMENTAL|Melatonin + omeprazole|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
62423748|NCT01566474|ACTIVE_COMPARATOR|omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
62423749|NCT00468312|EXPERIMENTAL|Mometasone Furoate Nasal Spray (MFNS)|200 mcg daily
62423750|NCT00468312|PLACEBO_COMPARATOR|Placebo|Two sprays in each nostril in the morning
62423751|NCT06382220|ACTIVE_COMPARATOR|Group (A) Bupivacaine group|who received 7.5 mg (low dose) hyperbaric bupivacaine 0.5%
62423752|NCT06382220|ACTIVE_COMPARATOR|Group (B) Prilocaine group|patients received 40 mg (low dose) intrathecal hyperbaric prilocaine
62423753|NCT02941822|EXPERIMENTAL|Arm 1|"Each patient will self-administer the study drug, ambroxol (60 mg per tablet) at 5 intra-dose escalations (DE) over the duration of 6 months that will be taken three times a day, see below:~1. Day 1-7, 60 mg~2. Day 8-14, 120 mg~3. Day 15-21, 180 mg~4. Day 22-28, 300 mg~5. Day 29-186, 420 mg"
62423754|NCT00677586|EXPERIMENTAL|1|simultaneous resection of liver metastasis and the rectal primary tumor
62592935|NCT00468754|EXPERIMENTAL|A|
62592936|NCT00468754|EXPERIMENTAL|B|
62592937|NCT04586738|OTHER|Non-resorbable uveoscleral implant associated with absorbable collagen matrix|non-perforating deep sclerectomy surgery with non-resorbable uveoscleral implant associated with absorbable collagen matrix
62592938|NCT04586738|OTHER|Isolated absorbable collagen matrix implant|non-perforating deep sclerectomy surgery with isolated absorbable collagen matrix implant
62232448|NCT02116985|PLACEBO_COMPARATOR|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
62232449|NCT04742322|PLACEBO_COMPARATOR|Placebo|1x capsule/day - maltodextrin, period of 10 to 14 days
62232450|NCT04742322|EXPERIMENTAL|B Lactis|1x capsule/day - 9x10x10 UFC, period of 10 to 14 days
62423755|NCT00677586|ACTIVE_COMPARATOR|2|staged resection of the liver metastasis and the rectal primary tumor
62592939|NCT02942381|ACTIVE_COMPARATOR|Hydroxychloroquine Sulfate|200mg Bid (eGFR\>60 ml/min/1.73m2), 100mg Tid (eGFR45-59 ml/min/1.73m2), 100mg Bid (eGFR 30-44 ml/min/1.73m2) and supportive treatment
62592940|NCT02942381|PLACEBO_COMPARATOR|Placebo|Placebo and supportive treatment
62592941|NCT05629611|EXPERIMENTAL|Study 1 Vi-Sealer|This group of women undergoing hysterectomy is randomized to the energy device, Vi-sealer.
62232451|NCT02050230|ACTIVE_COMPARATOR|Fresh blood transfusion|One unit of blood stored for less than 14 days
62232452|NCT02050230|EXPERIMENTAL|Standard issue blood transfusion|One unit of blood stored under standard conditions
62232453|NCT04580485|EXPERIMENTAL|Treatment Group A (TGA) - INCB106385|"In part 1 dose escalation, the dose levels will be escalated following a BOIN design.~In part 2 dose expansion, participants will be assigned to different groups based on their tumor types and treated at the RDE."
62232454|NCT04580485|EXPERIMENTAL|Treatment Group B (TGB) - INCB106385+INCMGA00012|"In part 1 dose escalation, the dose levels will be escalated following a BOIN design.~In part 2 dose expansion, participants will be assigned to different groups based on their tumor types and treated at the RDE."
62592942|NCT05629611|ACTIVE_COMPARATOR|Study 1 Ligasure|This group of women undergoing hysterectomy is randomized to the energy device, Ligasure.
62592943|NCT05629611|EXPERIMENTAL|Study 2 Vi-sealer|This group of women undergoing hysterectomy is randomized to the energy device, Vi-sealer.
62592944|NCT05629611|ACTIVE_COMPARATOR|Study 2 Other AHD|This group of women undergoing hysterectomy is randomized to energy devices other than Ligasure.
62592945|NCT01967706|ACTIVE_COMPARATOR|mTHS then mCC|"Each subject will follow the below study design:~* Day 0 = Wash-out (1 day)~* Day 1 = 1st intervention (single product use of mTHS)~* Day 2 = wash-out~* Day 3 = 2nd intervention (single product use of mCC)."
62592946|NCT01967706|ACTIVE_COMPARATOR|mCC then mTHS|"Each subject will follow the below study design:~* Day 0 = Wash-out (1 day)~* Day 1 = 1st intervention (single product use of mCC)~* Day 2 = wash-out~* Day 3 = 2nd intervention (single product use of mTHS)."
62232455|NCT05767671|OTHER|Study Population Group|People in the ICU on mechanical ventilation due to a diagnosis of ARDS or any other diagnosis that requires mechanical ventilation (following surgery, sepsis without lung involvement, seizures)
62232456|NCT05371782||Derivation cohort|The derivation cohort will comprise about 235,000 patients with dementia, who were admitted to a hospital in Ontario from April 1st, 2009 to December 31st, 2017.
62232457|NCT05371782||Validation cohort|The validation cohort will comprise about 63,000 dementia patients, who were admitted to a hospital in Ontario from January 1st, 2018 to March 31st, 2019.
62232458|NCT02426879|OTHER|surgery|esophagectomy with three-field lymphnode dissection
62232459|NCT01998009|OTHER|Fecal occult blood tests|Each patient will perform one guaiac and two immunochemical fecal occult blood tests at home.
62232460|NCT03759860|EXPERIMENTAL|Selective Retina Therapy and ranibizumab combination therapy|"Perform R:GEN laser (SRT) on the 6,000 microns diameter region including macular edema, while excluding the 500 microns diameter region from the fovea, with the appropriate treatment energy determined.~Ranibizumab (Lucentis®; Novartis AG, Basel, Switzerland) injection into the vitreous cavity at 3.5-4.0 mm posterior to the corneal limbus, towards the center of the eye, avoiding horizontal meridians. Then, 0.05 mL of the injection solution is slowly injected.~In study group and the control group, ranibizumab is administered 5 times in total from the baseline to month 4."
62423756|NCT00877214|EXPERIMENTAL|Rituximab|Follicular Lymphomas: Rituximab 375 mg/m² for additional 2 years after 2 years of standard maintainance All other lymphomas: Rituximab 375 mg/m² for 2 years as maintainance. From 2014 only Morbus Waldenstroem: Rituximab 1.400 mg absolute s. c. injection
62423757|NCT00877214|ACTIVE_COMPARATOR|Standard|Rituximab / Observation
62423758|NCT06542783||experts|with over 20 years of experience in ANA-IIF reading
62592947|NCT01967706|ACTIVE_COMPARATOR|mTHS then NRT|"Each subject will follow the below study design:~* Day 0 = Wash-out (1 day)~* Day 1 = 1st intervention (single product use of mTHS)~* Day 2 = wash-out~* Day 3 = 2nd intervention (single administration of NRT)"
62592948|NCT01967706|ACTIVE_COMPARATOR|NRT then mTHS|"Each subject will follow the below study design:~* Day 0 = Wash-out (1 day)~* Day 1 = 1st intervention (single administration of NRT)~* Day 2 = wash-out~* Day 3 = 2nd intervention (single product use of mTHS)."
62592949|NCT04949750|EXPERIMENTAL|Paper based cognitive training|Patients with Alzheimer's disease in the early stage receive 12 weeks paper based cognitive training and standard care (medication)
62592950|NCT04949750|NO_INTERVENTION|Control group|Patients with Alzheimer's disease in the early stage only receive standard care (medication)
62592951|NCT01216956|EXPERIMENTAL|Extended release nicotinic acid|
62592952|NCT01216956|PLACEBO_COMPARATOR|Placebo|
62232461|NCT03759860|SHAM_COMPARATOR|Sham Selective Retina Therapy and ranibizumab monotherapy|"For the participants assigned to the control group, sham procedures are performed in Sham Mode. All procedures except for the absence of laser light emission at the laser irradiation stage are the same with the study group.~Sham SRT is performed three times in total, one time for each visit for month 1, 3, and 5. At the time of month 1 and 3, Sham SRT should be performed before administration of ranibizumab."
62232462|NCT05263479|EXPERIMENTAL|HS-20089 (Phase Ia：Dose escalation )|HS-20089 for IV infusion of various dose strengths administered in 21 day dosing cycles.
62232463|NCT05263479|EXPERIMENTAL|HS-20089 (Phase Ib: Dose expansion)|The recommended dose from the dose-escalation stage and other potential doses will be further explored.
62808822|NCT03956186||Hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure drop below 80 mmHg or have symptoms of hypotension such as dizziness, nausea and vomiting during the procedure.
62808823|NCT03956186||Non-hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure does not drop below 80 mmHg or have any symptoms of hypotension during the procedure.
62808824|NCT03186209|EXPERIMENTAL|Benralizumab|Benralizumab administered subcutaneously
62808825|NCT03186209|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously
62808826|NCT04871841||Sputnik V Vaccinees|Participants (healthy adults aged \>=18) will receive rAd26-S prime at day 0 and rAd5-S boost at day 21.
62808827|NCT03605667|EXPERIMENTAL|BHV-4157|troriluzole, 280 mg (2 x 140 mg) capsules, QD
62808828|NCT03605667|PLACEBO_COMPARATOR|Placebo|matching 280 mg (2 x 140 mg) placebo capsules, QD
62808829|NCT04970277|EXPERIMENTAL|drinking water group|Patients in this group drink colorless water after capsule ingestion.
62232464|NCT05614895|EXPERIMENTAL|Cohort 1|Bacteremia participants without pneumonia and who are not mechanically ventilated at screening will be enrolled in this cohort. Participants will receive RO7223280 on Day 1.
62423759|NCT06542783||junior cytopathologists|less than 5 years of academic medical experience
62032592|NCT05879887|EXPERIMENTAL|Basic palliative care coaching + outpatient visit + 1 monthly follow-up call|4 telehealth sessions on principles of problem solving, self-care, symptom management, and advanced care planning, one-time Comprehensive Specialty Outpatient Palliative Care Clinic guided by the National Consensus Project for Quality Palliative Care Guidelines, and a single monthly follow-up call
62232465|NCT05614895|EXPERIMENTAL|Cohort 2|Participants with hospital-acquired bacterial pneumonia (HABP) and who are not mechanically ventilated at screening will be enrolled in this cohort. Participants will receive RO7223280 on Day 1.
62232466|NCT05614895|EXPERIMENTAL|Cohort 3|Participants with mechanical ventilation at screening will be enrolled in this cohort. Participants will receive RO7223280 on Day 1.
62232467|NCT05614895|EXPERIMENTAL|Cohort 4|Participants with mechanical ventilation who have a bronchoalveolar lavage (BAL) planned as a part of routine practice will be enrolled in this cohort. Participants will receive RO7223280 on Day 1.
62232468|NCT00688831|EXPERIMENTAL|A|AZD1305 solution for iv infusion
62592953|NCT01981538||Adult informal caregivers|Subjects will be eligible for this protocol if they are adult informal caregivers that are family members or friends of a patient enrolled in a cancer treatment study at the NIH Clinical Center
62808830|NCT04970277|OTHER|control group|Patients in this group don't drink colorless water after capsule ingestion.
62232469|NCT00688831|PLACEBO_COMPARATOR|B|NaCl solution for iv infusion
62423760|NCT06107959||Male|50 male subjects undergoing orthopedic surgery.
62423761|NCT06107959||Female|50 female subjects undergoing orthopedic surgery
62423762|NCT03414307|EXPERIMENTAL|Intracerebral hemorrhage|Patients with ICH meeting inclusion/exclusion criteria undergo ROSA stereotactic robot-assisted intracerebral catheter placement to evacuate intracerebral or intracranial hemorrhage
62423763|NCT02781688|EXPERIMENTAL|Physical Activity Intervention|Participants will participate in a multi-component physical activity intervention for 12 weeks.
62808831|NCT06276322|EXPERIMENTAL|Low Back Pain Group|Low back pain group will be evaluated the kinematics of all spine segments in 3 planes while performing the tasks that patients with chronic low back pain often describe as painful in their daily lives,
62808832|NCT06276322|ACTIVE_COMPARATOR|Healthy Group|Healthy Group's results will be compared them with low back pain group
62592954|NCT00484562|ACTIVE_COMPARATOR|Standard oxygen delivery system|Standard oxygen tank with pulse dose regulator
62592955|NCT00484562|ACTIVE_COMPARATOR|Homefill oxygen delivery system|Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.
62808833|NCT06325059|EXPERIMENTAL|Patients with kidney diseases undergoing renal biopsy|Patients with kidney diseases undergoing renal biopsy for diagnostic purposes
62808834|NCT03780049|EXPERIMENTAL|HAIC plus H101|Patients receive oxaliplatin, 5-fluorouracil and leucovorin and recombinant human type-5 adenovirus 0.5ml via hepatic artery
62808835|NCT03780049|ACTIVE_COMPARATOR|HAIC|Patients receive oxaliplatin, 5-fluorouracil and leucovorin and normal saline via hepatic artery
62808836|NCT05525377|EXPERIMENTAL|Intervention|Subjects in the intervention group receive access to an online training and educational phenotype-specific programme on how to support their relative with non-memory-led dementia. The online course consists on 6 modules to complete in 7 weeks. A course facilitator is available throughout the duration of the intervention to support participants.
62232470|NCT04821518||The study group (post-stroke)|The study group consisted of 26 patients in whom ischaemic brain stroke occurred within 14 days before the admission to the Clinical Department, and were hospitalised at the Department of Neurological Rehabilitation of the Clinical Department of Rehabilitation in the Wiktor Dega Orthopaedic and Rehabilitation Clinical Hospital in Poznań
62232471|NCT04821518||The control group|The control group was composed of 26 healthy individuals recruited from the hospital staff who did not experience stroke.
62232472|NCT00185679|EXPERIMENTAL|Haploidentical Allogeneic Transplant Using CliniMACS System|The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.
62808837|NCT05525377|NO_INTERVENTION|Treatment as usual (TAU)|"The treatment as usual group does not receive access to the educational programme."
62808838|NCT01984866||Breast tumors sensitive to neoadjuvant|"Treated patients as usual clinical practice with unicentered tumors in stages II or III and good response determined by MR after 6 cycles of treatment (less than 2 cm apparent residual injury) will be consecutively subjected to radiofrequency biopsy and the surgery previously established for each case (Tumorectomy or mastectomy). Before surgery, the sentinel node will be biopsied in order to define the surgical treatment on the axilla (none in case of negative sentinel node, axillary lymphadenectomy if positive).~The tumor samples obtained by percutaneous radiofrequency and mastectomy-Tumorectomy biopsy will be studied thoroughly to define the correlation between the two."
62808839|NCT03034486|EXPERIMENTAL|A single sequence, 3-period|
62808840|NCT04085419|ACTIVE_COMPARATOR|denosumab|denosumab 60 mg subcutaneously every 6 months
62808841|NCT04085419|ACTIVE_COMPARATOR|zoledronic acid|zoledronic acid 5 mg intravenously once a year
62808842|NCT05574478||Patients and Caregivers|Participants will include patients diagnosed with metastatic breast cancer and caregivers for patients diagnosed with metastatic breast cancer. Participants will be recruited from the UNC Medical Center breast oncology group as well as other practices identified by the Principal Investigator based on existing professional networks (referring physicians, other UNC oncology entities, collaborative groups).
62808843|NCT05042674|OTHER|Placebo, Ergothioneine 25mg, Ergothioneine 25mg for 1 week daily|Participants will consume placebo on first study day, consume 25mg of ergothioneine on second study day, then consume 25mg of ergothioneine daily for 1 week
62808844|NCT05383209|EXPERIMENTAL|EYP-1901 2060 ug|EYP-1901 2060 ug; single injection
62808845|NCT05383209|EXPERIMENTAL|EYP-1901 3090 ug|EYP-1901 3090 ug; single injection
62808846|NCT05383209|SHAM_COMPARATOR|Sham IVT|Sham IVT; single injection
62808847|NCT01062750|OTHER|adipose tissue derived stromal cells|
62232473|NCT02052089|ACTIVE_COMPARATOR|Physiotherapy|patients were educated to do stretching and eccentric strengthening exercise of wrist extensor muscles
62032593|NCT05879887|EXPERIMENTAL|Basic palliative care coaching + outpatient visit + 4 monthly follow-up calls|4 telehealth sessions on principles of problem solving, self-care, symptom management, and advanced care planning, one-time Comprehensive Specialty Outpatient Palliative Care Clinic guided by the National Consensus Project for Quality Palliative Care Guidelines, and monthly follow-up calls for 4 months
62232474|NCT02052089|EXPERIMENTAL|extracorporeal shockwave therapy|patients were treated with 3 sessions of high-energy shock wave therapy ESWT (Evotron, Switech medical, Kreuzlingen, CH) in 2 weeks interval. Total energy flux density ranged from 0.1 to 0.14 mJ/mm2 (1500 impulses). Shockwave was targeted over lateral epicondyle where maximum tenderness was located.
62423764|NCT06148337|EXPERIMENTAL|uESM (Ovolux brand)|This arm will receive a treatment protocol consisting of enough capsules to provide a daily dose of one 300 mg capsule of uESM.
62423765|NCT06148337|PLACEBO_COMPARATOR|Placebo|This arm will receive a treatment protocol consisting of enough capsules to provide a daily dose of one capsule containing psyllium husk fiber.
62423766|NCT00675701|PLACEBO_COMPARATOR|A|Placebo by mouth
62808848|NCT03921658||Cohort 1 - Cross-sectional (within 2 years of diagnosis)|Individuals diagnosed and treated for ovarian cancer in past two years, will complete 1 study measure
62808849|NCT03921658||Cohort 2- Prospective (from diagnosis)|Individuals newly diagnosed with ovarian cancer, will complete 3 study measures (baseline/diagnosis, completion of chemotherapy, one year post-diagnosis)
62232475|NCT02052089|EXPERIMENTAL|Prolotherapy|injection of 20% dextrose (3cc mixed with 0.3cc of lidocaine) to ECRB tendon was done under ultrasound guidance
62232476|NCT02052089|EXPERIMENTAL|Platelet-rich plasma|3 cc of PRP (Harvest SmartPReP 2 APC 30 Process Kit, Harvest Technologies, Plymouth, MA) was injected into ECRB tendon under ultrasound guidance
62232477|NCT04239716|EXPERIMENTAL|regional anesthesia|combination of erector spinae plane block (ESPB) and interscalene block(IB).the ESPB will be performed using linear ultrasound transducer (Philips® cx 50 extreme edition, USA) and we will inject 20 ml solution(10 ml 0.5% bupivacaine, 5 ml 2% lidocaine, and 5 ml normal saline). the IB will be performed using the same ultrasound machine and injecting the same solution
62232478|NCT02857998|EXPERIMENTAL|HMPL-523|Oral administration, at dose of 200, 400, 600 and 800 mg once daily;at dose of 200,300, 400mg twice daily at Dose-escalation stage; At Dose-expansion stage, if patients dosing at 600mgQD.
62423767|NCT00675701|EXPERIMENTAL|B|lixivaptan
62423768|NCT00675701|ACTIVE_COMPARATOR|C|moxifloxacin
62423769|NCT03943121|EXPERIMENTAL|Steroid-eluting stent implant|The ESS procedure had to be successfully completed without complication on both sides. Steroid-eluting stent were implanted in one side of ethmoid sinus and frontal sinus randomly.
62808850|NCT00818610|EXPERIMENTAL|Monotherapy|
62808851|NCT00818610|ACTIVE_COMPARATOR|Bi-therapy|
62808852|NCT02413307|EXPERIMENTAL|Intervention Group|Self-practice compassion focused therapy intervention following written or audio scripts. This includes instructions, an explanation of compassion and aims of the intervention. It includes several exercises designed to increase self-compassion including breathing exercises and compassionate imagery exercises focused on self and others
62808853|NCT02413307|NO_INTERVENTION|Waiting List Control|Participants on the waiting list for trauma specific therapy. These will be participants who have consented to engaging in the research project but their intervention phase has a delayed start.
62808854|NCT01847352|OTHER|Iron-deficient|Healthy volunteers meeting iron-deficient entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
62232479|NCT05029960|EXPERIMENTAL|Experimental|Brivaracetam at a dose of 50 mg twice daily for 6 months
62232480|NCT05735821|NO_INTERVENTION|control group|The control group will be pre-tested with data collection tools and a post-test will be applied 1 month later. No intervention will be made.
62232481|NCT05735821|EXPERIMENTAL|video group|A pre-test will be applied to the video group. Afterwards, a video containing the breastfeeding education prepared by the researcher will be watched. A post-test will be administered after the training. After 1 month, contact will be made and the test will be done again.
62232482|NCT05735821|EXPERIMENTAL|simulator group|A pre-test will be applied to the simulator group. Afterwards, a training will be given by the researcher with a breastfeeding simulator. A final test will be given after the training. After 1 month, the contact will be made and the test will be done again.
62232483|NCT02011815||Breast cancer|Diagnosed breast cancer patients who are getting chemotherapy for the first time.
62232484|NCT04687228|ACTIVE_COMPARATOR|Media Advocacy (MA)|Participants assigned to this condition take place in a time and attention-matched active control where they discuss the role of media in promoting the body ideal.
62232485|NCT04687228|EXPERIMENTAL|Body Project: More than Muscles (MTM)|Participants assigned to this condition take part in a two-session intervention based on dissonance theory which encourages them to challenge the body ideal.
62232486|NCT04066790|EXPERIMENTAL|Pyrotinib in combination with nab-paclitaxel|Prior to surgery: pyrotinib and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.
62232487|NCT04066790|ACTIVE_COMPARATOR|Trastuzumab in combination with nab-paclitaxel|Prior to surgery: trastuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.
62232488|NCT01211743|ACTIVE_COMPARATOR|Lap Group|Patients in this group are operated for uncomplicated cholelithiasis with standard 4 port laparoscopic cholecystectomy
62232489|NCT01211743|ACTIVE_COMPARATOR|SILS group|Patients in this group are operated for uncomplicated cholelithiasis with Single Incision Laparoscopic Cholecystectomy
62232490|NCT03345134|EXPERIMENTAL|MK-3475 and BCG|Single treatment group of high risk superficial upper urinary tract transitional cell carcinoma; combination treatment with MK-3475 and BCG
62232491|NCT04875741|ACTIVE_COMPARATOR|Neural mobilization|Patient in this study group will get 30 minutes session, twice weekly for 6 weeks. Neural mobilization technique will be applied to the subjects in addition to conventional treatment.
62232492|NCT04875741|EXPERIMENTAL|Muscle energy technique|Patient in this study group will get 30 minutes session, twice weekly for 6 weeks. Muscle energy technique will be applied to the subjects in addition to conventional treatment.
62423770|NCT03943121|SHAM_COMPARATOR|Without Steroid-eluting stent implant|The ESS procedure had to be successfully completed without complication on both sides. The side without the stent is defined as the control side.
62423771|NCT00287352|PLACEBO_COMPARATOR|Double-Blind Treatment|Olanzapine continuing with placebo
62592956|NCT00484562|ACTIVE_COMPARATOR|Helios oxygen delivery system|Liquid oxygen portable system pre-filled from a larger liquid oxygen tank
62808855|NCT01847352|OTHER|Iron-replete|Healthy volunteers meeting iron-replete entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
62232493|NCT01461239|ACTIVE_COMPARATOR|cast post and core|
62232494|NCT01461239|EXPERIMENTAL|fiber post - self-adhesive cement|
62232495|NCT01461239|EXPERIMENTAL|fiber post - conventional cement|
62232496|NCT04823715||TACE- hypofractionated radiation therapy|Patients will receive one course of transarterial chemoembolization followed 1 to 4 weeks later by hypofractionated radiation therapy up to a total dose of 45 to 60 Gy, 3 Gy per fraction, 5 fractions per week, for an overall treatment time of 3 to 4 weeks.
62423772|NCT00287352|ACTIVE_COMPARATOR|Olanzapine, Amantadine|Standard combine with Amantadine
62423773|NCT06541912|ACTIVE_COMPARATOR|conventional dental implant group|conventional dental implant placement will act as control group.
62423774|NCT06541912|EXPERIMENTAL|UV dental implant group|UV activated implant placement will act as test group which has better osseointegration properties.
62423775|NCT03716999||Palliative Care Patients|Palliative care Patients meeting criteria will receive Starlight Therapy
62232497|NCT04823715||Surgical resection|Surgical resection by open-laparotomy or laparoscopy of hepatocellular carcinoma
62232498|NCT03559478|ACTIVE_COMPARATOR|Treatment Group 1|Sharp dissection with scalpel plus electrocautery to vessels
62232499|NCT03559478|ACTIVE_COMPARATOR|Treatment Group 2|Electrocautery for all dissection
62232500|NCT04547673||NPC group|Patients pathologically diagnosed as NPC by agreement of 2 experienced pathologists who were blinded to the corresponding endoscopic assessment.
62232501|NCT04547673||Non-NPC group|Patients pathologically diagnosed as non-NPC (including inflammatory hyperplasia, Atypical hyperplasia, Papilloma etc.) by agreement of 2 experienced pathologists who were blinded to the corresponding endoscopic assessment.
62232502|NCT04531215|ACTIVE_COMPARATOR|ultrasound guided Retrolaminar Block|ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
62232503|NCT04531215|ACTIVE_COMPARATOR|ultrasound guided erector spinae|ultrasound guided Erector Spinae Plane Block (ESPB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
62232504|NCT05373589|EXPERIMENTAL|group C|
62232505|NCT05373589|EXPERIMENTAL|group PS|
62423776|NCT00764816|ACTIVE_COMPARATOR|1 grain (soy) protein diet:|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
62423777|NCT00764816|ACTIVE_COMPARATOR|2 casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
62423778|NCT04801030|EXPERIMENTAL|Culturally-appropriate social marketing campaign|Participants will receive a multi-layered, social marketing campaign which is deemed culturally appropriate. This will occur over a 6 month -time period. Rates will be observed at 0, 6, and 12 months.
62592957|NCT00484562|ACTIVE_COMPARATOR|FreeStyle oxygen system|portable battery-powered oxygen concentrator delivery system
62592958|NCT01265979||GIST treated with regorafenib/placebo|patients with advanced, metastatic gastro-intestinal stromal tumors treated with regorafenib or placebo
62808856|NCT06452537|EXPERIMENTAL|Tocilizumab with oral prednisone|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, with oral prednisone
62808857|NCT06452537|EXPERIMENTAL|Prednisone|
62808858|NCT02538744|PLACEBO_COMPARATOR|placebo|placebo po 1x/day from day -12 through 4
62808859|NCT02538744|ACTIVE_COMPARATOR|doxazosin 8 mg|day -12 through -9: Doxazosin 1 mg po 1x/day day -8 through -5: Doxazosin 2 mg po 1x/day day -4 through -1: Doxazosin 4 mg po 1x/day day 1 through 4: Doxazosin 8 mg po 1x/day
62808860|NCT04192188||ART-Group|Patients undergoing supportive periodontal therapy and independently antiresorptive therapy.
62808861|NCT04192188||Control Group|Patients undergoing supportive periodontal therapy without the need for antiresorptive therapy.
62808862|NCT02119871|EXPERIMENTAL|Bilateral Open Pleurae|Bilateral open pleurae and usage of right pulmonary vein drainage
62423779|NCT04801030|NO_INTERVENTION|Control Arm 1|Participants will receive no intervention, only to serve as a control site. Rates will be observed at 0, 6, and 12 months.
62423780|NCT04801030|NO_INTERVENTION|Control Arm 2|Participants will receive no intervention, only to serve as a control site. Rates will be observed at 0, 6, and 12 months.
62423781|NCT02556931|EXPERIMENTAL|PBSCT D90|Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 90 or Day 180 depending on GVHD status.
62423782|NCT02556931|EXPERIMENTAL|PBSCT D60|Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 60 or Day 180 depending on GVHD status.
62423783|NCT05481554||Common variable immunodeficiency with enteropathy|20 patients with a common variable immunodeficiency associated to enteropathy will be recruited in the study and will be compared with patients with a common variable immunodeficiency associated to enteropathy and porto-sinusoidal vascular disease
62423784|NCT05481554||Common variable immunodeficiency with enteropathy and porto-sinusoidal vascular disease|20 patients with common variable immunodeficiency associated to enteropathy and porto-sinusoidal vascular disease will be recruited in the study and will be compared with patients with a common variable immunodeficiency associated to enteropathy
62423785|NCT05785416|EXPERIMENTAL|PNF- CR Group|The participants in the group were given PNF contract- relax stretching using the standard protocol. One trial had two isometric contractions each followed by five seconds muscle stretch and there was a total of four trials. Total of 12 sessions in 4 weeks (3sessions/week).
62423786|NCT05785416|EXPERIMENTAL|Static Stretching Group|"The participants in the group were given sustained stretching for a period of 80s at a stretch.~Total of 12 sessions in 4 weeks (3sessions/week)."
62423787|NCT05785416|NO_INTERVENTION|Control Group|No intervention was given in this group
62423788|NCT01397656|ACTIVE_COMPARATOR|CPR 30:2|30 chest compressions to 2 ventilations followed by cross-over to CPR with Continuous Compressions
62423789|NCT01397656|ACTIVE_COMPARATOR|CPR with Continuous Compressions|Continuous Chest Compressions without ventilation followed by CPR 30:2 (30 chest compressions to 2 ventilations)
62423790|NCT02170142||No treatment|All subjects studied are normal healthy neonates without a condition. MRI will be used to assess normal brain development.
62808863|NCT02119871|ACTIVE_COMPARATOR|Right pleura open|Opening of right pleura and usage of left ventricular apical drainage.
62808864|NCT02826746|EXPERIMENTAL|Magnesium group|intravenous administration of Magnesium Sulfate
62423791|NCT05785221|PLACEBO_COMPARATOR|Healthy Comparators|They will receive general lifestyle and nutritional education.
62423792|NCT05785221|EXPERIMENTAL|Overweight/Obese Group|They will receive personalized nutritional and lifestyle weight reduction intervention including dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians.
62423793|NCT00203931|ACTIVE_COMPARATOR|Cetuximab|Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes.
62423794|NCT00203931|EXPERIMENTAL|Cetuximab and Pemetrexed|Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes. Starting on day 15 and then subsequently on day 1 of each 21 day cycle, Pemetrexed 500 mg/m2.
62423795|NCT03989037|EXPERIMENTAL|SIBP-01 & Docetaxel & Carboplatin|SIBP-01→ Docetaxel→ Carboplatin: injection, every 3 weeks for 18 weeks; SIBP-01: first dose 8mg/kg, then 6mg/kg; Docetaxel: dose 75mg/m2; Carboplatin: dose AUC6
62423796|NCT03989037|ACTIVE_COMPARATOR|Herceptin & Docetaxel & Carboplatin|Herceptin→ Docetaxel→ Carboplatin: injection, every 3 weeks for 18 weeks; Herceptin: first dose 8mg/kg, then 6mg/kg; Docetaxel: dose 75mg/m2; Carboplatin: dose AUC6
62592959|NCT05737576|EXPERIMENTAL|Cohort 1|HR011408 injection + NovoRapid®
62808865|NCT02826746|PLACEBO_COMPARATOR|Control group|intravenous administration of normal saline
62808866|NCT04515004|EXPERIMENTAL|Intervention|All qualified participants meeting entry criteria that are enrolled will receive 2-3 weeks of oral LP treatment.
62808867|NCT06244004|EXPERIMENTAL|Arm 1A (FDG-PET, MDRT, SOC cytotoxic chemotherapy & ADT)|Patients undergo an FDG-PET scan after 6 months of SOC cytotoxic chemotherapy + ADT. Patients with PET-avid disease continue their SOC ADT and undergo MDRT to up to 5 disease sites in the absence of unacceptable toxicity. Patients also undergo CT and bone scans throughout the trial.
62808868|NCT06244004|ACTIVE_COMPARATOR|Arm 1B (FDG-PET, SOC cytotoxic chemotherapy & ADT)|Patients undergo an FDG-PET scan after 6 months of SOC cytotoxic chemotherapy + ADT. Patients with PET-avid disease continue their SOC ADT on study. Patients also undergo CT and bone scans throughout the trial.
62808869|NCT06244004|ACTIVE_COMPARATOR|Arm 1C (FDG-PET, SOC cytotoxic chemotherapy & ADT)|Patients undergo an FDG-PET scan after 6 months of SOC cytotoxic chemotherapy + ADT. Patients without PET-avid disease continue their SOC ADT on study. Patients also undergo CT and bone scans throughout the trial.
62592960|NCT05737576|EXPERIMENTAL|Cohort 2|NovoRapid® + HR011408 injection
62808870|NCT06244004|EXPERIMENTAL|Arm 2A (FDG-PET, MDRT, SOC ADT)|Patients undergo an FDG-PET scan after 6 months of SOC ADT. Patients with PET-avid disease continue their SOC ADT and undergo MDRT to up to 5 disease sites in the absence of unacceptable toxicity. Patients undergo an additional FDG-PET scan at 6 months. Patients also undergo CT and bone scans throughout the trial.
62808871|NCT06244004|ACTIVE_COMPARATOR|Arm 2B (FDG-PET, SOC ADT)|Patients undergo an FDG-PET scan after 6 months of SOC ADT. Patients with PET-avid disease continue their SOC ADT on study and undergo an additional FDG-PET scan at 6 months. Patients also undergo CT and bone scans throughout the trial.
62808872|NCT06244004|ACTIVE_COMPARATOR|Arm 2C (FDG-PET, SOC ADT)|Patients undergo an FDG-PET scan after 6 months of SOC ADT. Patients without PET-avid disease continue their SOC ADT on study and undergo an additional FDG-PET scan at 6 months. Patients also undergo CT and bone scans throughout the trial.
62808873|NCT03679975|EXPERIMENTAL|Subjects with ALS|Subjects with a diagnosis of probable or definite ALS in accordance with the Revised El-Escorial Criteria were administered a single dose of the Riluzole Oral Soluble Film (ROSF) 50 mg.
62808874|NCT02343042|EXPERIMENTAL|1: Selinexor, Low-dose Dexamethasone and Pomalidomide (SPd)|"Each cycle is of 28 days~Cohort 1.1: Selinexor (SEL) 60/80/100 mg orally (PO) once weekly (QW); Dexamethasone (DEX) 40 mg PO once weekly; Pomalidomide (POM) 2/3/4 mg PO Days 1-21.~Cohort 1.2: SEL 40/60/80 mg PO twice weekly (BIW); DEX 20 mg PO twice weekly; POM 3/4 mg PO Days 1-21.~Cohort 1.3: Selinexor, Dexamethasone and Pomalidomide will be dosed at RP2D-1.~Cohort 1.4: SEL 40 mg PO QW; DEX 40 mg PO QW; POM 4mg PO once daily (QD) Days 1-21."
62808875|NCT02343042|EXPERIMENTAL|2: Selinexor, Low-dose Dexamethasone and Bortezomib (SVd)|"Each cycle is of 35 days~Cohort 2.1: SEL 60/80/100 mg PO once weekly; DEX 40 mg PO once weekly; Bortezomib (BOR) 1.3 milligram per meter square (mg/m\^2) subcutaneous (SC) once weekly.~Cohort 2.2: SEL 40/60/80 mg PO twice weekly; DEX 20 mg PO twice weekly; BOR 1.3 mg/m\^2 subcutaneous (SC) once weekly.~Cohort 2.3: Selinexor, Dexamethasone and Bortezomib will be dosed at RP2D-2."
62808876|NCT02343042|EXPERIMENTAL|3: Selinexor, Low-dose DEX, and Lenalidomide (SRd) in RRMM|"Each cycle is of 28 days~Cohort 3.1: SEL 40/60/80/100 mg PO once weekly; DEX 40 mg PO once weekly; Lenalidomide (LEN) 15/25 mg PO Days 1-21.~Cohort 3.2: SEL 40/60/80 mg PO twice weekly; DEX 20 mg PO twice weekly; LEN 15/25 mg PO Days 1-21.~Cohort 3.3: Selinexor, Dexamethasone and Lenalidomide will be dosed at RP2D-3."
62232506|NCT03171831|EXPERIMENTAL|Haploidentical HSCT|"Procedure: Haploidentical hematopoietic stem cell transplantation from a related donor (partially matched sibling, father or mother).~Conditioning: Busulfan （4 mg/kg/day,4 days） + Cyclophosphamide （50 mg/kg/day,4 days）+ Fludarabine （50 mg/m2/day,3 days）~GVHD Prophylaxis：Mycophenolate mofetil（0.25g/day）+ Tacrolimus（0.03mg/kg/day）+ Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）+ Thymoglobulin（2.5 mg/kg/day,4 days）+Basiliximab（10mg on day 0 and +4）"
62232507|NCT03463967|ACTIVE_COMPARATOR|Lycopene supplemented|Energy-restricted diet supplemented with lycopene-enriched tomato juice
62232508|NCT03463967|SHAM_COMPARATOR|Calories Restricted|Energy-restricted diet
62423797|NCT06309121|PLACEBO_COMPARATOR|Active control|Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 3 months. Participants will receive a daily dose of placebo for these 3 months, then given the option to receive a daily dose of probiotic ABB C3 for 3 more months.
62423798|NCT06309121|EXPERIMENTAL|Treatment|Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 3 months. Participants will receive a daily dose of postbiotic blend (ABB C3) for these 3 months, then given the option to receive a daily dose of probiotic ABB C3 for 3 more months.
62423799|NCT01578343|EXPERIMENTAL|Vorinostat-FND|Vorinostat-fludarabine, mitoxantrone, dexamethasone Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)
62423800|NCT02632227||Hypovolemia|patients with hypovolemic signs including hypotension, decreased central venous pressure (less than 5mmHg), and decreased urine output
62423801|NCT01692431|EXPERIMENTAL|DHA|High fat meal containing DHA rich oil.
62423802|NCT01692431|EXPERIMENTAL|EPA|High fat meal containing EPA.
62423803|NCT01692431|PLACEBO_COMPARATOR|Control|High fat meal with no/negligable omega-3 fatty acid content.
62423804|NCT01374906|EXPERIMENTAL|10 mg LAR dose|Randomization was stratified based on Screening mUFC to ensure balanced distribution of disease severity in the two dose arms.
62423805|NCT01374906|EXPERIMENTAL|30 mg LAR dose|Randomization was stratified based on Screening mUFC to ensure balanced distribution of disease severity in the two dose arms.
62423806|NCT02997969|ACTIVE_COMPARATOR|Group 1: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in the left deltoid at months 0, 1, 3, and 6. They will receive placebo in the right deltoid at months 0 and 1, and the Protein/MF59 vaccine at months 3 and 6. All injections are via needle and syringe.
62423807|NCT02997969|ACTIVE_COMPARATOR|Group 2: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in the left deltoid at months 0, 1, and 6. They will receive placebo in both deltoids at month 3, and the Protein/MF59 vaccine at months 0, 1, and 6. All injections are via needle and syringe.
62423808|NCT02997969|PLACEBO_COMPARATOR|Group 3: Placebo|Participants will receive placebo in both deltoids at months 0, 1, 3, and 6. All injections are via needle and syringe.
62423809|NCT02997969|ACTIVE_COMPARATOR|Group 4: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine via Biojector in the left deltoid at months 0, 1, 3, and 6. They will receive placebo in the right deltoid at months 0 and 1, and the Protein/MF59 vaccine at months 3 and 6, via needle and syringe.
62423810|NCT02997969|ACTIVE_COMPARATOR|Group 5: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine at months 0, 1, and 6, and placebo at month 3, in the left deltoid via Biojector. They will receive placebo at month 3, and the Protein/MF59 vaccine at months 0, 1, and 6, in the right deltoid via needle and syringe.
62592961|NCT05737576|EXPERIMENTAL|Cohort 3|HR011408 injection + NovoRapid®
62592962|NCT05737576|EXPERIMENTAL|Cohort 4|NovoRapid® + HR011408 injection
62032594|NCT05879887|EXPERIMENTAL|Advanced palliative care coaching + financial coaching + outpatient visit + 1 monthly follow-up call|8 telehealth sessions on principles of self-care, symptom management, and advanced care planning: This component level will expand the depth and topic range of content offered in the 4 sessions into eight 20-30 minute sessions, 1 telehealth session on strategies to address healthcare-related financial toxicity, one-time Comprehensive Specialty Outpatient Palliative Care Clinic guided by the National Consensus Project for Quality Palliative Care Guidelines, and a single monthly follow-up call
62032595|NCT05879887|EXPERIMENTAL|Advanced palliative care coaching + financial coaching + outpatient visit + 4 monthly followup calls|8 telehealth sessions on principles of self-care, symptom management, and advanced care planning: This component level will expand the depth and topic range of content offered in the 4 sessions into eight 20-30 minute sessions,1 telehealth session on strategies to address healthcare-related financial toxicity, one-time Comprehensive Specialty Outpatient Palliative Care Clinic guided by the National Consensus Project for Quality Palliative Care Guidelines, and monthly follow-up calls for 4 months
62032596|NCT05879887|EXPERIMENTAL|Advanced palliative care coaching + outpatient visit + 1 monthly follow-up call|8 telehealth sessions on principles of self-care, symptom management, and advanced care planning: This component level will expand the depth and topic range of content offered in the 4 sessions into eight 20-30 minute sessions, one-time Comprehensive Specialty Outpatient Palliative Care Clinic guided by the National Consensus Project for Quality Palliative Care Guidelines, and a single monthly follow-up call
62032597|NCT05879887|EXPERIMENTAL|Advanced palliative care coaching + outpatient visit + 4 monthly follow-up calls|8 telehealth sessions on principles of self-care, symptom management, and advanced care planning: This component level will expand the depth and topic range of content offered in the 4 sessions into eight 20-30 minute sessions, one-time Comprehensive Specialty Outpatient Palliative Care Clinic guided by the National Consensus Project for Quality Palliative Care Guidelines, and monthly follow-up calls for 4 months
62032598|NCT05879887|EXPERIMENTAL|Basic palliative care coaching + financial coaching + 1 monthly follow-up call|4 telehealth sessions on principles of problem solving, self-care, symptom management, and advanced care planning, 1 telehealth session on strategies to address healthcare-related financial toxicity, and a single monthly follow-up call
62032599|NCT05879887|EXPERIMENTAL|Basic palliative care coaching + financial coaching + 4 monthly follow-up calls|4 telehealth sessions on principles of problem solving, self-care, symptom management, and advanced care planning, 1 telehealth session on strategies to address healthcare-related financial toxicity, and monthly follow-up calls for 4 months
62032600|NCT05879887|EXPERIMENTAL|Basic palliative care coaching + 1 monthly follow-up call|4 telehealth sessions on principles of problem solving, self-care, symptom management, and advanced care planning, and a single monthly follow-up call
62032601|NCT05879887|EXPERIMENTAL|Basic palliative care coaching + 4 monthly follow-up calls|4 telehealth sessions on principles of problem solving, self-care, symptom management, and advanced care planning, and monthly follow-up calls for 4 months
62032602|NCT05879887|EXPERIMENTAL|Advanced palliative care coaching + financial coaching + 1 monthly follow-up call|8 telehealth sessions on principles of self-care, symptom management, and advanced care planning: This component level will expand the depth and topic range of content offered in the 4 sessions into eight 20-30 minute sessions, 1 telehealth session on strategies to address healthcare-related financial toxicity, and a single monthly follow-up call
62032603|NCT05879887|EXPERIMENTAL|Advanced palliative care coaching + financial coaching + 4 monthly follow-up calls|8 telehealth sessions on principles of self-care, symptom management, and advanced care planning: This component level will expand the depth and topic range of content offered in the 4 sessions into eight 20-30 minute sessions, 1 telehealth session on strategies to address healthcare-related financial toxicity, and monthly follow-up calls for 4 months
62032604|NCT05879887|EXPERIMENTAL|Advanced palliative care coaching + 1 monthly follow-up call|8 telehealth sessions on principles of self-care, symptom management, and advanced care planning: This component level will expand the depth and topic range of content offered in the 4 sessions into eight 20-30 minute sessions, and a single monthly follow-up call
62232509|NCT05974774|ACTIVE_COMPARATOR|Arm A - continuous treatment|Arm A (cMAB): ADT (LHRH agonist or antagonist) + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide) continuously until start of a new anti-cancer therapy.
62232510|NCT05974774|EXPERIMENTAL|Arm B - intermittent treatment|Arm B (iMAB): no further treatment, including ADT and ARPI; decision to restart ADT (LHRH agonist or antagonist) and the initial ARPI (abiraterone, enzalutamide, apalutamide or darolutamide) is left at Investigator discretion.
62423811|NCT02997969|PLACEBO_COMPARATOR|Group 6: Placebo|Participants will receive placebo in the left deltoid via Biojector, and in the right deltoid via needle and syringe, at months 0, 1, 3, and 6.
62423812|NCT00589693|EXPERIMENTAL|Doripenem|Doripenem from Days 1 to 7 and imipenem-cilastatin placebo from Days 1 to 10
62423813|NCT00589693|ACTIVE_COMPARATOR|Imipenem-Cilastatin|Imipenem-Cilastatin Days 1 to 10 and doripenem placebo from Days 1 to 7
62032605|NCT05879887|EXPERIMENTAL|Advanced palliative care coaching + 4 monthly follow-up calls|8 telehealth sessions on principles of self-care, symptom management, and advanced care planning: This component level will expand the depth and topic range of content offered in the 4 sessions into eight 20-30 minute sessions and monthly follow-up calls for 4 months
62032606|NCT04484285|ACTIVE_COMPARATOR|Younger Cohort|Healthy individuals aged 18 - 55
62032607|NCT04484285|ACTIVE_COMPARATOR|Older Cohort|Healthy individuals aged 56 - 85
62232511|NCT02489903|EXPERIMENTAL|Small Cell Lung Cancer (Arm 1)|RRx-001 weekly for 3 weeks followed by up to 4 cycles of carboplatin or cisplatin plus etoposide and then RRx-001 and carboplatin or cisplatin (for patients with stable disease (SD) or better at discontinuation of platinum).
62232512|NCT02489903|ACTIVE_COMPARATOR|Small Cell Lung Cancer (Arm 2)|Carboplatin or cisplatin plus etoposide or irinotecan or vinorelbine until progression or intolerable toxicity
62232513|NCT02489903|EXPERIMENTAL|Non Small Cell Lung Cancer|RRx-001 weekly for 3 weeks followed by up to 6 cycles of cisplatin or carboplatin plus paclitaxel or nab-paclitaxel or pemetrexed and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).
62592963|NCT05737576|EXPERIMENTAL|Cohort 5|
62592964|NCT05737576|EXPERIMENTAL|Cohort 6|
62592965|NCT01246349|EXPERIMENTAL|Motivational Interviewing Group|For the Motivational Interviewing (MI) treatment group, a clinical psychology doctoral student trained in Motivational Interviewing administered six individual motivational interviewing treatment sessions, each 30 minutes in length.
62592966|NCT01246349|ACTIVE_COMPARATOR|Control Group|The comparison group received six social skills training sessions instead of Motivational Interviewing (MI).
62808877|NCT02343042|EXPERIMENTAL|4:Selinexor, Low-dose dexamethasone, Pomalidomide, Velcade (SPVd)|"PK Run-in Period: Selinexor and Clarithromycin:~* For the first 9 patients enrolled into this dose escalation arm~* 14 day run-in period after which patients will proceed to Dose-Escalation Phase C1D1~Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.~PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.~Dose-escalation Phase:~* All patients enrolled into this Arm~* Each cycle is of 28 days.~Cohort 4.1:~SEL 40/60 mg PO once weekly; DEX 40 mg PO once weekly; POM 4 mg PO Days 1-21; BOR 1.3 mg/m\^2 subcutaneous (SC) once weekly.~Cohort 4.3: Selinexor, Dexamethasone, Pomalidomide, Velcade (Bortezomib) will be dosed at RP2D-4."
62032608|NCT01693120|EXPERIMENTAL|Ablation|Phased RF ablation
62232514|NCT02489903|EXPERIMENTAL|Neuroendocrine tumors|RRx-001 weekly until progression followed by up to 6 cycles of carboplatin or cisplatin plus etoposide and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).
62592967|NCT04441840|ACTIVE_COMPARATOR|Active Probiotic Culture|Active culture of Bacillus Coagulans Dose: 1 x 10\^9 colony forming units (CFU)
62592968|NCT04441840|ACTIVE_COMPARATOR|Inactive Probiotic Culture|"Inactive culture of Bacillus Coagulans (GBI-30, 6086) - Marked as StaImune Dose: 1 x 10\^9 colony forming units (CFU)"
62032609|NCT04564183||Full Cohort|Entire study population
62032610|NCT04094311|EXPERIMENTAL|Group A: pALL|Pediatric/young adult patients with r/r pALL who meet the indication in the Health Authority-approved CTL019 package insert in the respective country/region whose final manufactured product is OOS for commercial release, but it is considered that the benefit-risk profile may remain favorable and the usual expected benefits of infusing such a product outweigh the potential risks for the patient.
62232515|NCT02489903|EXPERIMENTAL|Ovarian epithelial cancer (Arm 1)|RRx-001 weekly for 2 weeks followed by 2 cycles of Carboplatin chemotherapy and then RRx-001/Carboplatin maintenance (for patients with stable disease or better at discontinuation of platinum).
62232516|NCT02489903|ACTIVE_COMPARATOR|Ovarian epithelial cancer (Arm 2)|Carboplatin, Etoposide, Doxil, Gemcitabine or Vinorelbine or Taxane until progression or intolerable toxicity
62232517|NCT05738031||Group A|"Aim 1 (Part A). To utilize natural language processing (NLP) to identify all ED patients with incidentally detected lung nodules found on chest radiographs or chest or abdominal CT scans, and to develop a standardized referral and notification process~Aim 1.1) Utilization of NLP to screen radiologic reports and identify nodules meeting criteria for follow-up per Fleischner Society Guidelines~Aim 1.2) Creation of an electronic medical record-based notification system to alert patients and providers of the identification of an IPN that requires follow-up, tracked by a dedicated patient navigator~Aim 1.3) Establishment of a multidisciplinary lung nodule management team, hereafter referred to as the lung nodule clinic, to ensure guideline-directed management of nodules with emphasis on high risk nodules as identified in subsequent aims"
62423814|NCT04872127|EXPERIMENTAL|CAS with proximal protection|using proximal embolism protection device during CAS
62592969|NCT06086561|EXPERIMENTAL|Feasibility Assessment Cohort|Non-invasive device data acquisition; study is not interventional
62592970|NCT05590637|ACTIVE_COMPARATOR|quetiapine|Elderly patients with dementia-related psychosis will be treated with quetiapine, an atypical antipsychotic indicated for the treeatment of: schizophrenia, bipolar I manic episodes and bipolar depressive episodes.
62592971|NCT05590637|ACTIVE_COMPARATOR|pimavanserin|Elderly patients with dementia-related psychosis will be treated with pimavanserin, an atypical antipsychotic indicated for treatment of hallucinations and delusions associated with Parkinson's disease.
62592972|NCT06615518|EXPERIMENTAL|TELD|Transforaminal endoscopic lumbar discectomy
62592973|NCT06615518|EXPERIMENTAL|IELD|Interlaminar endoscopic lumbar discectomy
62592974|NCT06615518|ACTIVE_COMPARATOR|MD|microdiscectomy
62592975|NCT03499899|EXPERIMENTAL|LAG525 + PDR001|Participants received LAG525 and PDR001 administered as infusion once every 3 weeks
62592976|NCT03499899|EXPERIMENTAL|LAG525 + PDR001 + carboplatin|Participants received LAG525, PDR001 and carboplatin administered as infusion once every 3 weeks.
62423815|NCT04872127|ACTIVE_COMPARATOR|CAS with distal protection|using distal protection device during CAS
62423816|NCT03690726|EXPERIMENTAL|Active rTMS|SCI patients fulfilling criteria for participation giving informed written and verbal consent, who are enrolled and randomised to active treatment arm receive consecutive treatment sessions with rTMS directed at cranium and cortex regions as described in protocol.
62423817|NCT03690726|SHAM_COMPARATOR|Sham rTMS|SCI patients fulfilling criteria for participation giving informed written and verbal consent, who are enrolled and randomised to sham/control arm receive consecutive treatment sessions with coil from rTMS that fires at other spot (pillow/mattress) as described in protocol.
62592977|NCT03499899|EXPERIMENTAL|LAG525 + carboplatin|Participants received LAG525 and carboplatin administered as infusion once every 3 weeks
62592978|NCT04174183|EXPERIMENTAL|Prevena (right side) - Dry dressing (left side)|
62808878|NCT02343042|EXPERIMENTAL|5: Selinexor, Low-dose dexamethasone, and Daratumumab (SDd)|"Each cycle is of 28 days~Cohort 5.1:~SEL 80/100 mg PO once weekly; DEX 40 mg once weekly (IV or PO); DARA: 16 mg/kg IV infusion Cycle 1-2: Once weekly, Cycle 3-6: Every other week, Cycle 6 and greater: Once a month.~Cohort 5.2:~SEL: 60 mg PO twice weekly; DEX: 40 mg weekly (IV or PO); DARA: 16 milligram per kilogram (mg/kg) IV infusion Cycle 1-2: Once. weekly, Cycle 3-6: Every other week, Cycle 6 and greater: Once a month.~Cohort 5.3: Selinexor, Dexamethasone and Daratumumab will be dosed at RP2D-5."
62592979|NCT04174183|EXPERIMENTAL|Prevena (left side) - Dry dressing (right side)|
62592980|NCT06085443|EXPERIMENTAL|Auricular spray|Subjects using the medical device under investigation: 2 sprays in each ear, every 3 days at home.
62032611|NCT04094311|EXPERIMENTAL|Group B: r/r LBCL|Adult patients with r/r LBCL including DLBCL not otherwise specified, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, that is consistent with the Health Authority-approved indication in the package insert for CTL019 in the respective country/region whose final manufactured product is OOS for commercial release, but it is considered that the benefit-risk profile may remain favorable and the usual expected benefits of infusing such a product outweigh the potential risks for the patient.
62032612|NCT04094311|EXPERIMENTAL|Group C: r/r NHL|Adult patients with r/r NHL in consistent with the Health Authority approved indication in the package insert for CTL019 in Japan whose final manufactured product is OOS for commercial release, but it is considered that the benefit-risk profile may remain favorable and the usual expected benefits of infusing such a product outweigh the potential risks for the patient.
62423818|NCT01817569||Byetta|
62423819|NCT06542497|ACTIVE_COMPARATOR|0.75% phentolamine ophthalmic solution|Drug: phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist
62423820|NCT06542497|PLACEBO_COMPARATOR|phentolamine ophthalmic solution vehicle|Drug: Placebo
62592981|NCT06085443|NO_INTERVENTION|Control|Subjects not using any spray (can use ear drops in case of discomfort or pain)
62592982|NCT03580109|ACTIVE_COMPARATOR|Immediate spa treatment|Spa treatment linked with education therapeutic during 18 days just after randomization : common to all of spa resorts
62592983|NCT03580109|SHAM_COMPARATOR|Late spa treatment|Spa treatment linked with education therapeutic during 18 days 6 months visit after randomization
62592984|NCT02554058|EXPERIMENTAL|Cycling and Mechanical stimulation|Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
62819539|NCT05571137||Cohort 1: Resistant, Refractory, or Intolerant (RRI) to Anti-CMV treatment|Participants who had a HSCT after January 1, 2016, and developed post-transplant CMV infection were subsequently characterized as RRI to currently available anti-CMV treatment for at least 12 months before being enrolled, will be observed in this retrospective study for 24 months.
62592985|NCT05353244|ACTIVE_COMPARATOR|Active PrTMS|Participants will receive PrTMS five days a week for six weeks.
62592986|NCT05353244|SHAM_COMPARATOR|Sham|Participants will receive sham treatment five days a week for six weeks.
62592987|NCT02416128|ACTIVE_COMPARATOR|Iritis prevention after LPI: prednisolone|To use prednisolone acetate after and peripheral laser iridotomy to determine efficacy and side effects compared to arm 2.
62592988|NCT02416128|EXPERIMENTAL|Iritis prevention after LPI: euphrasia|To use euphrasia after and peripheral laser iridotomy to determine efficacy and side effects compared to arm 1.
62032613|NCT00511576|ACTIVE_COMPARATOR|Part 1|In Part 1, cohorts of three to six subjects will receive doses of MGCD0103 administered orally three times per week (TIW) in combination with 60 mg/m2 IV docetaxel administered as a 1-hour infusion on Day 1 of each 3-week (21-day) cycle. The starting dose of MGCD0103 in Part 1 will be 50 mg (approximately 25 mg/m2).
62592989|NCT01190267|EXPERIMENTAL|Asenapine|All enrolled participants receive open-label asenapine 2.5 mg twice daily (BID) on Day 1-3, which is increased to 5.0 mg BID on Day 4 (dose can be increased earlier at the investigator's discretion). Asenapine dosing is flexible for the remainder of the 26-week open-label drug administration period, and can be adjusted to either 2.5 mg or 5.0 mg BID at the investigator's discretion, based on tolerability and/or symptomatology.
62592990|NCT02529124|PLACEBO_COMPARATOR|CONTROL|a group of subjects receiving a placebo nutrient supplement (per kg of body mass: 0.25g maltodextrin; energy \~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks
62592991|NCT02529124|ACTIVE_COMPARATOR|PROTEIN|a group of subjects receiving a nutrient supplement (per kg of body mass: 0.33g milk protein + 0.25ug vitamin D + 10mg calcium; energy \~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks
62808879|NCT02343042|EXPERIMENTAL|6: Selinexor, Low-dose dexamethasone, and Carfilzomib (SKd)|"PK Run-in Period: Selinexor and Clarithromycin:~* For the first 9 patients enrolled into this dose escalation arm~* 14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1~Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.~PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.~Dose-Escalation Phase:~* All patients enrolled into this Arm~* Each cycle is of 28 days~Cohort 6.1:~SEL 40/60/80/100 mg PO once weekly on days 1, 8, 15, and 22; DEX 40 mg IV or PO once weekly; Carfilzomib (CAR) 56 or 70 mg/m\^2 IV infusion once weekly on days 1, 8, and 15.~Cohort 6.2:~SEL 60/80/100 mg PO once weekly on days 1, 8, and 15; DEX 40 mg IV or PO once weekly; CAR 56 or 70 mg/m\^2 IV infusion once weekly on days 1, 8, and 15.~Cohort 6.3: Selinexor, Dexamethasone and Carfilzomib will be dosed at RP2D-6."
62808880|NCT02343042|EXPERIMENTAL|7: Selinexor, Low-dose DEX and Lenalidomide (SRd) in NDMM|"Each cycle is of 28 days~Cohort 7.1:~SEL 40/60/80 mg PO once weekly; DEX 40 mg PO once weekly; LEN 25 mg PO Days 1-21.~Cohort 7.3: Selinexor, Dexamethasone and Lenalidomide will be dosed at RP2D-7."
62808881|NCT02343042|EXPERIMENTAL|8: Selinexor, Low-dose dexamethasone, and Ixazomib (SNd)|"PK Run-in Period: Selinexor \& Clarithromycin:~* For the first 9 patients enrolled into this dose escalation arm~* 14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1~Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.~PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.~Dose-Escalation Phase:~* All patients enrolled into this Arm~* Each cycle is of 28 days~Cohort 8.1:~SEL 40/60/80/100 mg PO once weekly; DEX 20 mg PO twice weekly; IXA 3/4 mg PO once weekly.~Cohort 8.3: Selinexor, Dexamethasone and Ixazomib will be dosed at RP2D-8."
62808882|NCT02343042|EXPERIMENTAL|9: Selinexor, Low-dose DEX, Pomalidomide and Elotuzumab (SPEd)|"PK Run-in Period: Selinexor and Clarithromycin:~* For the first 9 patients enrolled into this dose escalation arm~* 14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1~Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.~PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.~Dose-Escalation Phase:~* All patients enrolled into this Arm~* Each cycle is of 28 days~Cohort 9.1:~SEL 20/40/60 mg PO once weekly; DEX 28/20 mg PO twice weekly; POM 4 mg PO QD Days 1-21; Elotuzumab (ELO) 10/20 mg/kg IV will be given once weekly on Days 1,8, 15 and 22 of Cycles 1-2. Starting on Cycle 3 and continuing for future cycles, elotuzumab will be dosed at 20 mg/kg on Day 1 of each cycle only.~Cohort 9.3: Selinexor, Dexamethasone, Pomalidomide and Elotuzumab will be dosed at RP2D-9."
62808883|NCT02343042|EXPERIMENTAL|10. Selinexor, Dexamethasone, and Belantamab Mafodotin (SBd)|"Each cycle is of 21 days~Cohort 10.1:~SEL 40/60/80 mg PO once weekly on Days 1, 8, and 15; DEX 40 mg PO QW on Days 1, 8, and 15; Belantamab Mafodotin (BEL) 2.5 mg/kg IV infusion every 3 weeks (Q3W) Day 1 of each cycle.~Cohort 10.3:~Selinexor, Dexamethasone, and Belantamab Mafodotin will be dosed at RP2D-10."
62819540|NCT05571137||Cohort 2: Pre-emptive CMV Treatment|Participants who had a HSCT after January 1, 2019, were preemptively treated for CMV for at least 12 months before being enrolled, will be observed in this retrospective study for 24 months.
62232518|NCT05738031||Group B|"Aim 2 (Part B). To clinically risk stratify patients with IPNs utilizing artificial intelligence (AI) processing of known clinical risks factors for pulmonary malignancy, such as age, smoking history, and history of malignancy, along with radiographic risk classifiers including nodule location, size, and imaging features.~Aim 2.1) Development of an integrated classifier based on automated scanning and data retrieval from the electronic medical record (EMR) to stratify patients with IPNs as low, intermediate or high risk for malignancy, with factor analysis to assess contributions of individual factors to the model~Aim 2.2) Prospective evaluation of the integrated classifier and comparison of automated integrated classifier to established manual risk calculators"
62592992|NCT02529124|ACTIVE_COMPARATOR|PROTEIN+PHYSICAL ACTIVITY|a group of subjects receiving a nutrient supplement (per kg of body mass: 0.33g milk protein + 0.25ug vitamin D + 10mg calcium; energy \~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks plus a prescribed regimen of physical activity
62032614|NCT00511576|ACTIVE_COMPARATOR|Part 2|Part 2 will begin once the MTD for MGCD0103 in combination with 60 mg/m2 IV docetaxel has been determined and further evaluated in the expansion phase. In Part 2, cohorts of three to six subjects will receive escalating doses of MGCD0103 administered orally TIW in combination with 75 mg/m2 docetaxel administered as a 1-hour IV infusion on Day 1 of each cycle. The starting dose of MGCD0103 administered in combination with 75 mg/m2 IV docetaxel will be the MTD from Part 1 minus 25 mg.
62032615|NCT06669819||vegan pregnant women and vegan parents|
62032616|NCT06669819||medical experts|paediatricians, gynaecologists, general practitioners, pharmacists, dieticians
62032617|NCT01661374||Mechanically Ventilated|
62032618|NCT01661374||Chronic obstructive pulmonary disease (COPD).|
62808884|NCT02343042|EXPERIMENTAL|11. Selinexor, Dexamethasone, Pomalidomide, and Daratumumab (SDPd)|"Each Cycle is of 28 days~Cohort 11.1 SEL 40/60 mg PO once weekly on Days 1, 8, and 15; DEX total 40 mg weekly (IV or PO) single or divided doses on Days 1, 8, 15, and 22; POM 4 mg PO QW Days 1-21; DARA 16 mg/kg IV or SC QW on Days 1, 8, 15 and 22 of Cycles 1-2 and on Days 1 and 15 of Cycles 3-6, Day 1 of every Cycle greater than (\>6).~Cohort 11.3 Selinexor, Dexamethasone, Pomalidomide, and Daratumumab will be dosed at RP2D-11."
62808885|NCT02343042|EXPERIMENTAL|12. Selinexor + dexamethasone + mezigdomide (SMd)|The dose of selinexor will be formally escalated from 40 mg QW to 60 mg QW in combination with mezigdomide 0.6 mg daily. Mezigdomide dosing may be de-escalated as per 3+3 criteria to 0.3 mg or escalated to 1.0 mg. The dose level that passes DLT evaluation will be considered the MTD for the cohort.
62808886|NCT04896996|EXPERIMENTAL|Whole eggs (WE)|consume 10 additional eggs per week
62808887|NCT04896996|EXPERIMENTAL|Egg substitute (ES)|consume the yolk-free egg substitute equivalent to 10 eggs per week
62808888|NCT04896996|NO_INTERVENTION|Control group|Regular school meals
62808889|NCT00960375|EXPERIMENTAL|BTSCS|BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
62808890|NCT00960375|ACTIVE_COMPARATOR|StSST|The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide test at the start of each group meeting. StSST groups provide education about smoking and support for quitting.
62032619|NCT01168492|EXPERIMENTAL|ketamine|group with triple sedation (ketamine, midazolam, meperidine)
62423821|NCT02706522|EXPERIMENTAL|Allocated to Carbohydrated group|"1. Patients was administered in hospital~2. Randomization~3. Patient was allocated to Carbohydrated group~4. Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal."
62423822|NCT02706522|PLACEBO_COMPARATOR|Allocated to Placebo group|"1. Patients was administered in hospital~2. Randomization~3. Patient was allocated to Placebo group~4. Patients received 400 mL of water 12 hours before anesthesia and 400 mL 2 hours before anesthesia."
62423823|NCT00434148|EXPERIMENTAL|Pasireotide 600 ug|At randomization, participants received 600 ug subcutaneously (sc) twice daily (bid). Participants continued at this dose until month 6 if their month 3 mean urinary free cortisol (mUFC) was \<= 2 x the upper limit of normal (ULN) and the mUFC was below or equal to their baseline mUFC. Participants not meeting the mUFC criteria at month 3 were unblinded and required to increase their dose to 900ug bid on an open label basis. Participants had the option to continue in the extension phase as long as they did not meet any discontinuation criteria or until pasireotide was available commercially in their country.
62808891|NCT04608981|EXPERIMENTAL|Prednisolone premedication|Single, oral dose of 30 mg prednisolone pre-medication 30 min before starting endodontic treatment.
62808892|NCT04608981|EXPERIMENTAL|Diclofenac potassium premedication|Single, oral dose of 50 mg diclofenac potassium pre-medication 1 hour before starting endodontic treatment.
62423824|NCT00434148|EXPERIMENTAL|Pasireotide 900 ug|At randomization, participants received 900 ug subcutaneously (sc) twice daily (bid). Participants continued at this dose until month 6 if their month 3 mean urinary free cortisol (mUFC) was \<= 2 x the upper limit of normal (ULN) and the mUFC was below or equal to their baseline mUFC. Participants not meeting the mUFC criteria at month 3 were unblinded and required to increase their dose to 1200 ug bid on an open label basis. Participants had the option to continue in the extension phase as long as they did not meet any discontinuation criteria or until pasireotide was available commercially in their country.
62423825|NCT00817258|OTHER|1|All patients will receive radical radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
62808893|NCT04608981|PLACEBO_COMPARATOR|Placebo|Placebo tablet 1 hour before starting endodontic treatment.
62808894|NCT00799201|EXPERIMENTAL|Control|Sennosides liquid 5mL (8.8mg) every 6 hours plus docusate sodium liquid 10mL (100mg) every 12 hours
62808895|NCT05958940|ACTIVE_COMPARATOR|Light@Home|Standard Care - BLT in the home environment
62808896|NCT05958940|EXPERIMENTAL|LightCafé|BLT will be administered in a specialized cafe, under the supervision of clinical staff, promoting lifestyle changes and social interaction.
62808897|NCT05958940|EXPERIMENTAL|LightCafé+|Treatment will be identical to the second arm but now complemented with the use of blue-light blocking glasses in the evening and the adoption of personalized BLT timing based on sleep-wake patterns
62808898|NCT02398916|EXPERIMENTAL|Music|"* Listening to relaxing music for the entire period starting from waiting period in the surgical waiting area until the end of the LEEP procedure~* Undergoing LEEP according to the usual protocol"
62808899|NCT02398916|NO_INTERVENTION|Control|- Undergoing LEEP according to the usual protocol without listening to music
62808900|NCT03222635|EXPERIMENTAL|Endoscopic follow-up|Patients treated with endoscopic resection (ER) for a submucosal or high-risk mucosal esophageal adenocarcinoma without lymphnode- or distant metastases (N0M0) will undergo endoscopic follow-up.
62032620|NCT01168492|PLACEBO_COMPARATOR|placebo|group with conventional sedation and placebo ( midazolam, meperidine and placebo)
62423826|NCT00800722|EXPERIMENTAL|Treatment of Port Wine Stain|Rapamycin Treatment of Port Wine Stain
62032621|NCT06568705|EXPERIMENTAL|26Gy/5f online adaptive radiotherapy|The CTV receives a dose of 26Gy in 5 fractions by online adaptive radiotherapy.
62032622|NCT06568705|ACTIVE_COMPARATOR|43.5Gy/15f online adaptive radiotherapy|The CTV receives a dose of 43.5Gy in 15 fractions by online adaptive radiotherapy.
62032623|NCT05809037|ACTIVE_COMPARATOR|Active Stimulation for right hemiparesis patients|Active non-invasive transauricular vagus nerve stimulation over left ear in post-stroke right hemiparesis
62232519|NCT05738031||Group C|"Aim 3 (Part C). To investigate biologic risk classifiers that may aid in the risk stratification of pulmonary nodules~Aim 3.1) Evaluation of a blood-based gene expression assay for risk stratification of pulmonary nodules using biobanked specimens~Aim 3.2) Prospective collection of plasma from patients enrolled in lung nodule clinic and evaluation of gene expression to assess malignancy risk"
62808901|NCT05846126|EXPERIMENTAL|Telematic group|This program combines cognitive training, physical exercise, and mindfulness tasks delivered remotely to participants. The cognitive training includes 24 interactive sessions over 12 weeks aimed at training attention, memory, and executive function. The physical exercise program is personalized and includes balance work, stretching, and muscle strengthening exercises, with two sessions per week for 12 weeks. The mindfulness component adapts the Mindfulness-Based Stress Reduction program, including body scanning, seated meditation, and gentle Hatha yoga, with one supervised session per week via video call over 12 weeks. The program is designed for autonomous use by participants.
62808902|NCT05846126|EXPERIMENTAL|Immersive Virtual Reality group|"The sessions will consist of carrying out a face-to-face multimodal stimulation program with the application of MK360 immersive technology for the cognitive, emotional, behavioral, physical, functional - social areas. The multimodal intervention includes 24 interactive sessions two sessions per week, over 12 weeks. They will follow the following scheme:~1. Welcome and awareness of the here and now.~2. Physical activation.~3. Cognitive stimulation.~4. Relaxation techniques and Mindfulness.~5. Feedback and end of session.~During the intervention period, patients will be provided with a downloadable App with a username and password, so they can access it. From the App, they will view the tests to answer according to tempos and therapeutic direction."
62808903|NCT05846126|ACTIVE_COMPARATOR|Active control program|In paper or pdf format, patients in the active control group will receive guidelines for physical and cognitive stimulation to do autonomously at home. Patients in the active control group will receive guidelines for cognitive and physical stimulation and meditation exercises in paper or pdf format, to be done independently at home. They will be encouraged to do physical exercises, meditation, and cognitive activities two times a week.
62808904|NCT06079788|EXPERIMENTAL|Adrenocorticotrophic Hormone Group|"ACTH 2 IU/kg/ day, qd,（the maximum dose ≤ 50 IU）, 28 days of continuous use for 5 days， for 24 weeks.~Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd"
62232520|NCT03726814|EXPERIMENTAL|EPC treatment group|
62032624|NCT05809037|SHAM_COMPARATOR|Sham Stimulation for right hemiparesis patients|Sham non-invasive transauricular vagus nerve stimulation over left ear in post-stroke right hemiparesis
62232521|NCT02667717|EXPERIMENTAL|Experimental group : Mirror Therapy|Experimental group will perform mirror therapies during 16 weeks, added to the usual care. Therapy mirror sessions will take place at hospital units but also at home.
62032625|NCT05809037|ACTIVE_COMPARATOR|Active Stimulation for left hemiparesis patients|Active non-invasive transauricular vagus nerve stimulation over left ear in post-stroke left hemiparesis
62232522|NCT02667717|ACTIVE_COMPARATOR|Control group : Usual care|The control group will benefit from the usual care during 16 weeks. No mirror therapies will be performed to this group.
62232523|NCT00793000|EXPERIMENTAL|Cohort 1|
62032626|NCT05809037|SHAM_COMPARATOR|Sham Stimulation for left hemiparesis patients|Sham non-invasive transauricular vagus nerve stimulation over left ear in post-stroke left hemiparesis
62032627|NCT02358603|EXPERIMENTAL|Case group|At the beginning of the study, each subject of the case group will complete echo examination and related lab test for BNP. During the study, each subject will have a six minutes' walk test and 24 hour ambulatory monitoring while having an ActiGraph device placed on his/her wrist and a Holter device with ECG electrodes placed on his/her chest. The treadmill test is optional to patients per physicians' instruction and/or patients' own judgment. It would be performed at the end of the study if chosen.
62232524|NCT00793000|EXPERIMENTAL|Cohort 2|
62232525|NCT00793000|EXPERIMENTAL|Cohort 3|
62232526|NCT00793000|EXPERIMENTAL|Cohort 4|
62232527|NCT00793000|EXPERIMENTAL|Cohort 5|
62232528|NCT00793000|EXPERIMENTAL|Cohort 6|
62232529|NCT00793000|EXPERIMENTAL|Cohort 7|
62232530|NCT00793000|EXPERIMENTAL|Cohort 8|Japanese volunteers, low dose previously tested (based on PK)
62232531|NCT00793000|EXPERIMENTAL|Cohort 9|Japanese volunteers, intermediate dose previously tested (based on PK)
62232532|NCT00793000|EXPERIMENTAL|Cohort 10|Japanese volunteers, high dose previously tested (based on safety)
62232533|NCT04040400|EXPERIMENTAL|Treatment Arm|intraoperative radiotherapy (IORT) arm
62232534|NCT01545570|ACTIVE_COMPARATOR|GSK2376497|single dose escalation or multiple-dose titration
62232535|NCT01545570|PLACEBO_COMPARATOR|0.9% sodium chloride|placebo injection
62232536|NCT06243419|EXPERIMENTAL|vein viewer|The vein imaging device was used before the vascular access attempt
62232537|NCT06243419|EXPERIMENTAL|virtual reality|wearing virtual reality glasses
62232538|NCT06243419|EXPERIMENTAL|vein viewer and virtual reality|The vein imaging device was used before the vascular access attempt and wearing virtual reality glasses
62232539|NCT06243419|NO_INTERVENTION|Control group|standard care
62232540|NCT03993912|EXPERIMENTAL|Arm 1: Experimental group|"Daratumumab SC 1800 mg~* once every week for 8 weeks~* then once every other week for 16 weeks~* thereafter once every 4 weeks, until progression Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression Dexamethasone PO (20mg): days 1, 8, 15, 22 of a 28-day cycle, for the first 2 cycles, then discontinued"
62232541|NCT03993912|SHAM_COMPARATOR|Arm 2: Control group|Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
62232542|NCT00994500|EXPERIMENTAL|Treatment (vorinostat, bortezomib)|Patients receive oral vorinostat once daily on days 1-5 and 8-12 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62592993|NCT04738097|EXPERIMENTAL|intervention|Intervention group will be treat with ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 21 days.
62592994|NCT04738097|ACTIVE_COMPARATOR|control|control group will be treat with ASA 325 mg stat and clopidogrel 300 mg stat, then ASA 80 mg and clopidogrel 75 mg daily for 21 days.
62232543|NCT05902182|EXPERIMENTAL|ConvaFoam Dressings|All participants skin areas will be assessed and allocated a dressing based upon the investigator's clinical judgement. They will receive either ConvaFoam Border, Silicone or Non-Adhesive for up to 2 weeks as an addition to their standard pressure injury prevention protocol.
62232544|NCT02609854|EXPERIMENTAL|Sham Sustained Acoustic Medicine Device|Sham Sustained Acoustic Medicine device - the device is to be used 4 hours/day, ≥4 days per week for 8 weeks.
62423827|NCT04432818|EXPERIMENTAL|Pack Health's digital life coaching (DLC)|Access to the DLC platform during a 16-week period encompassing pre-HCT conditioning chemotherapy, post-HCT recovery, and 100-day follow-up
62808905|NCT06079788|ACTIVE_COMPARATOR|Steroid Group|Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg （qod） or 0.125mg/kg （qd） every 4 weeks.
62032628|NCT02358603|PLACEBO_COMPARATOR|Control group|Each subject of the control group will do the same test and examination with the subjects in the case group.
62232545|NCT02609854|EXPERIMENTAL|3 MHz Sustained Acoustic Medicine Device|3 MHz Sustained Acoustic Medicine device - the device is to be used 4 hours/day, ≥4 days per week for 8 weeks.
62423828|NCT03076528|EXPERIMENTAL|Intervention with game-based exercise|Subjects will be receiving sensor-based interactive ankle \& foot exercise program (game-based exercise) during hemo-dialysis, approximately 30 minutes, twice per week and for 4 weeks.
62592995|NCT02837939|EXPERIMENTAL|Active|Drug: Human derived Transfer factor applied by subcutaneous injection in specified time points.
62032629|NCT05659602|EXPERIMENTAL|HH-120 group|HH-120 Nasal Spray
62032630|NCT00781976|PLACEBO_COMPARATOR|1|
62032631|NCT00781976|ACTIVE_COMPARATOR|2|
62032632|NCT01029223|EXPERIMENTAL|ivabradine|
62592996|NCT02837939|PLACEBO_COMPARATOR|Control|Aqua pro injectione 4 mL ampules for subcutaneous administration in the same time points as in the active arm
62592997|NCT05774093||COVID-19 Antibody Group 1|Participants will be divided into positive group and negative group according to the baseline of COVID-19 antibody titer.Group 1 is for those COVID-19 antibody are positive.
62592998|NCT05774093||COVID-19 Antibody Group 2|Participants will be divided into positive group and negative group according to the baseline of COVID-19 antibody titer.Group 1 is for those COVID-19 antibody are negative.
62808906|NCT04213547|EXPERIMENTAL|Intervention|This will be a single-arm study utilizing a loss-framed incentive intervention to induce increased sleep duration.
62423829|NCT03076528|ACTIVE_COMPARATOR|Non-technology foot and ankle exercise program|Subjects will be receiving non-technology foot and ankle exercise program during hemodialysis, approximately 30 minutes, twice per week and for 4 weeks.
62423830|NCT06199973|EXPERIMENTAL|SHR-A1811|
62423831|NCT06199973|EXPERIMENTAL|physician choiced treatment|include: TAS-102, or Regorafenib, or Fruquintinib
62232546|NCT01019512|ACTIVE_COMPARATOR|Arm I|Patients undergo complex decongestive therapy comprising daily compression garment (sleeve and glove) use, daily manual lymphatic drainage (self-administerd), and nighttime bandaging with low stretch Comprilan bandages.
62232547|NCT01019512|EXPERIMENTAL|Arm II|Patients undergo daily compression with garments (sleeve and glove), nighttime bandaging with low stretch Comprilan bandages, and daily Flexitouch treatment over 1 hour every evening.
62232548|NCT01019512|EXPERIMENTAL|Arm III|Patients undergo daily compression with garments (sleeve and glove) and daily Flexitouch treatment over 1 hour every evening.
62232549|NCT02601196|OTHER|Ulipristal acetate treatment|Women who receive UPA treatment before another IVF cycle.
62232550|NCT01740323|PLACEBO_COMPARATOR|Placebo|Placebo
62232551|NCT01740323|EXPERIMENTAL|Curcumin|500 mg BID
62232552|NCT02877160|EXPERIMENTAL|Reference Formulation Fasted|150 mg of AL-794 study drug in suspension dosed in a fasted condition
62232553|NCT02877160|EXPERIMENTAL|Test Formulation Fasted|150 mg of AL-794 tablet formulation (3 x 50 mg tabs) dosed in a fasted condition
62808907|NCT05718973|EXPERIMENTAL|Intervention Arm|"At Time 1, the Intervention Arm will view a short, animated storytelling video designed to promote psychological capital and, immediately thereafter, complete the CPC-12R, the GQ-6 as well as a single-item validated happiness scale.~Two weeks later, the participants will complete the CPC-12R, the GQ-6 and the single-item validated happiness scale."
62808908|NCT05718973|NO_INTERVENTION|Scale-Exposed Control Arm|"The Scale-Exposed Control Arm will watch no video content at Time 1, but will complete the CPC-12R, the GQ-6 as well as a single-item validated happiness scale.~Two weeks later, the participants will complete the CPC-12R, the GQ-6 and the single-item validated happiness scale."
62423832|NCT05786521|EXPERIMENTAL|Semaglutide and lifestyle intervention|Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks.
62423833|NCT05786521|ACTIVE_COMPARATOR|Lifestyle intervention|Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program
62423834|NCT04184479|ACTIVE_COMPARATOR|A-LEVAmetoden by Bertz et al|Individual dietary advices for weight loss, based on the participants' food record of 4 consecutive days aimed to achieve an energy intake reduction of 500 kcal/d with a nutrient composition according to the Nordic Nutrition Recommendations. Follow up visits after 3 months, 1 year and 2 years after baseline. Follow up by electronic platform every other week until 3 months after baseline and each month after 3 months until 1 year after baseline.
62808909|NCT05718973|PLACEBO_COMPARATOR|Attention Placebo Control Arm|"The Attention Placebo Control Arm will view an attention placebo control video, unrelated to the outcomes measured in this trial, before completing the CPC-12R, the GQ-6 and the single-item validated happiness scale.~Two weeks later, the participants will complete the CPC-12R, the GQ-6 and the single-item validated happiness scale."
62808910|NCT05718973|NO_INTERVENTION|Un-exposed Control Arm|"The Un-exposed Control Arm will neither watch video content, nor complete the CPC-12R, the GQ-6 and the single-item validated happiness scale at Time 1.~Two weeks later, the participants will complete the CPC-12R, the GQ-6 and the single-item validated happiness scale."
62232554|NCT02877160|EXPERIMENTAL|Test Formulation Fed|150 mg of AL-794 tablet formulation (3 x 50 mg tabs) dosed in a fed condition
62232555|NCT05404308|EXPERIMENTAL|Weekly follow-up by a medical radiography technician and weekly follow-up by the radiotherapist|
62232556|NCT05404308|ACTIVE_COMPARATOR|Standard weekly follow-up by the radiotherapist only|
62232557|NCT05573087|ACTIVE_COMPARATOR|Aquatic Based Exercise|maximal jump squats in a pool
62232558|NCT05573087|ACTIVE_COMPARATOR|Land Based Exercise|cycle ergometer
62232559|NCT02513888|EXPERIMENTAL|Vitamin D + diet and lifestyle|subjects will be given vitamin D supplement will be given along with diet nd lifestyle modification
62819541|NCT06705010|ACTIVE_COMPARATOR|Application of novel MRSI pulse sequences to healthy persons|Optimized MR-pulse sequences are applied to three healthy person groups after glucose solution ingestion to obtain healthy control 3D metabolic reference data.
62232560|NCT02513888|PLACEBO_COMPARATOR|placebo + diet and lifestyle|Subjects will be given placebo with diet and lifestyle
62232561|NCT01249430|EXPERIMENTAL|Treatment (azacitidine, mitoxantrone, etoposide, cytarabine)|Patients receive azacitidine IV over 30 minutes on days 1-8 and mitoxantrone hydrochloride IV over 10 minutes, etoposide phosphate IV over 30-60 minutes, and cytarabine IV over 6 hours on days 3-8. Treatment continues for 1 course in the absence of disease progression or unacceptable toxicity.
62232562|NCT04266665|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
62232563|NCT04266665|PLACEBO_COMPARATOR|Normal saline|Normal saline (NaCl 0.9%) administration will start 10 minutes after anesthesia induction and maintained throughout the surgical procedure.
62032633|NCT01029223|EXPERIMENTAL|metoprolol|
62808911|NCT06436235||Kidney stone formers|"The study team plans to enroll 20 non-diabetic participants with a history of at least one calcium-based kidney stone. Activities are the same for both cohorts, as follows:~* Before clinic visit, participants will halt specific supplements and diuretics for a week.~* At home, they complete a dietary questionnaire and collect 24-hour urine.~* On the 7th day, they visit University of Chicago CRC. There, investigators will take measurements (height, weight) and DEXA scan, alongside kidney stone history review.~* Throughout the day, participants provide urine and blood samples, undergo blood pressure checks, and fast until sample collection.~* Samples undergo testing for kidney stone, inflammation, and diabetes risk factors and are stored for future research."
62808912|NCT06436235||Control cohort|"The study team plans to enroll 20 healthy control participants with no history of kidney stones or family history of kidney stones. Activities are the same for both cohorts, as follows:~* Before clinic visit, participants will halt specific supplements and diuretics for a week.~* At home, they complete a dietary questionnaire and collect 24-hour urine.~* On the 7th day, they visit University of Chicago CRC. There, investigators will take measurements (height, weight) and DEXA scan, alongside kidney stone history review.~* Throughout the day, participants provide urine and blood samples, undergo blood pressure checks, and fast until sample collection.~* Samples undergo testing for kidney stone, inflammation, and diabetes risk factors and are stored for future research."
62808913|NCT02527681|EXPERIMENTAL|Ceftobiprole|Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for intravenous administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.
62808914|NCT05765682|ACTIVE_COMPARATOR|Mepivacaine Spinal|Mepivacaine (60 mg: 3ml of 2%) or will be injected into the intrathecal space.
62808915|NCT05765682|ACTIVE_COMPARATOR|Bupivacaine Spinal|Isobaric bupivacaine (10mg: 2ml or 0.5%) will be injected into the intrathecal space.
62808916|NCT00973726|OTHER|Glucose|Subjects are given an oral glucose tolerance test.
62808917|NCT03303326|EXPERIMENTAL|Immediate Interview|A 60-minute interview about women's health conducted immediately after baseline questionnaires.
62232564|NCT02027623|EXPERIMENTAL|Motor skill training|The motor skill training condition involves supervised, massed practice of novel, challenging functional activities that are difficult or painful for the participant to perform due to his low back pain.
62808918|NCT03303326|NO_INTERVENTION|Delayed Interview|The interview is conducted after the follow-up questionnaires are completed, rather than after baseline.
62808919|NCT04809831|ACTIVE_COMPARATOR|Trial Group - Biorepair Peribioma Toothpaste + Mousse|Domiciliary oral hygiene with Biorepair Peribioma Toothpaste in association with Peribioma Mousse twice a day until T2 session.
62808920|NCT04809831|ACTIVE_COMPARATOR|Control Group - Curasept Toothpaste (chlorhexidine 0,2%)|Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%) twice a day until T2 session.
62032634|NCT01029223|PLACEBO_COMPARATOR|placebo|
62232565|NCT02027623|ACTIVE_COMPARATOR|Strength and flexibility exercise|The strength and flexibility exercise condition involves performance of 1) strengthening exercises that target all trunk muscles, and 2) flexibility exercises that target all trunk and lower extremity motions.
62232566|NCT03546933||Chest pain patients presenting to the ED|All patients that present to the emergency department with chest pain and potentially other symptoms consistent with ACS and meet all eligibility criteria will undergo VitalScan Magnetocardiograph.
62232567|NCT01769066|EXPERIMENTAL|Sequential Gefitinib With Pemetrexed/Platinum|Pemetrexed IV 500 mg/m2 ，DAY2 DDP IV 75mg/m2 ，DAY1 OR CAP IV AUC 5,DAY1 Gefitinib PO. 250mg DAY3-16
62232568|NCT01769066|ACTIVE_COMPARATOR|Pemetrexed/Platinum|Pemetrexed IV 500 mg/m2 ，DAY2 DDP IV 75mg/m2 ，DAY1 OR CAP IV AUC 5,DAY1
62423835|NCT04184479|PLACEBO_COMPARATOR|B-Ordinary treatment|Dietary advices for weight loss aimed to achieve calorie restriction. Follow up visits after 3 months, 1 year and 2 years after baseline. Additional visits, up to 4 times in the first year after baseline.
62423836|NCT03820999|EXPERIMENTAL|Teaching arm|The Primary Health Care physicians getting oral and written information on tick-bites and Lyme disease with focus on Lyme neuroborreliosis.
62423837|NCT03820999|NO_INTERVENTION|Passive arm|The Primary Health Care physicians that does not get contacted with an offer to receive oral and written information.
62808921|NCT05720650||Case subjects diagnosed with gestational hypertension or preeclampsia|This is a restrospective observational study and there is no intervention.
62808922|NCT05720650||Control subjects diagnosed without any hypertensive disorders|This is a restrospective observational study and there is no intervention.
62808923|NCT04406298|EXPERIMENTAL|Small Quantity Paracentesis|Intermittent small quantity (upto 3L per day) paracentesis through an indwelling catheter for up to 5 days.
62808924|NCT04406298|ACTIVE_COMPARATOR|Large Volume Paracentesis|Large Volume Paracentesis \> 5 litres
62032635|NCT04302350|EXPERIMENTAL|Group75|According to preoperative 3D-CTBA evaluation of bronchial and vascular structure of pulmonary nodules and pulmonary segments, the target segmental bronchus, arteries and intra-segment veins were accurately identified and dissected by ligation or stapler cutting. After that, the anesthesiologist began to make preparations for the lung inflation. The portable nitrous oxide concentration detector (TD600-SH-B-N2O) was installed to detect N2O concentration (vol%), and then adjusted the anesthesia machine to the manual control mode. The flow of the selected gas mixture was set to 8L/min (Group75 set to N2O:O2=6:2). When the N2O concentration detector reached the predetermined gas concentration, and then the collapsed lung was re-expanded completely with controlled airway pressure under 20 cmH2O (1cm H2O=0.098 kPa) by the anesthesiologist. This procedure took approximately 1 min, and then FiO2=1.0 was performed after the initiation of the OLV.
62808925|NCT01386164|EXPERIMENTAL|Gardasil®|
62808926|NCT01386164|EXPERIMENTAL|Cervarix®|
62808927|NCT04138303|EXPERIMENTAL|Exercise Only Group (EX)|Participants will only receive the exercise protocol without nutrition education or counseling and instructed to continue to consume their regular diet.
62808928|NCT04138303|EXPERIMENTAL|Exercise with CR-LC Group|Participants will receive the exercise protocol and CR-LC Diet regimen.
62808929|NCT04138303|EXPERIMENTAL|Exercise with Ancestral Diet (AD) Group|Participants will receive the exercise protocol and AD regimen.
62808930|NCT04499755|EXPERIMENTAL|Nucleo CMP forte|Nucleo CMP forte twice daily for 6 weeks with supportive treatment.
62232569|NCT01222507||Brain Speed Test|60 subjects who complete 60 Second Brain Game and Brain Speed Test
62232570|NCT02065141|OTHER|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day: stable isotope infusions with blood draws, sip feed"
62232571|NCT02065141|OTHER|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical information about them that will help determine study eligibility or can be used for later coding.~study day: stable isotope infusions with blood draws, sip feed"
62232572|NCT02065141|OTHER|Chronic Heart Failure|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical information about them that will help determine study eligibility or can be used for later coding.~study day: stable isotope infusions with blood draws, sip feed"
62232573|NCT00221247|ACTIVE_COMPARATOR|Group 1|Intensely administered (5 times per week for 12wk) physical therapy, occupational therapy, and hydrotherapy with acupuncture
62232574|NCT00221247|NO_INTERVENTION|Group 2|Intensely administered (5 times per week for 12wk) physical therapy, occupational therapy, and hydrotherapy without acupuncture
62232575|NCT02715154|ACTIVE_COMPARATOR|Dexmedetomidine 0.5 µg/kg/h|Solution containing 5 µg/mL of dexmedetomidine was continuously infused by 0.5 μg/kg in 10 min, followed with 0.1 ml/kg/hr continuous infusion until the closure of the abdominal.
62808931|NCT04499755|NO_INTERVENTION|Supportive treatment|Supportive treatment only.
62808932|NCT00321789|EXPERIMENTAL|Spouse-assisted intervention|Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse developed a plan to support patient goal achievement.
62423838|NCT02043561|SHAM_COMPARATOR|no urge|rectal balloon deflated
62423839|NCT02043561|EXPERIMENTAL|moderate urge|moderate urge induced by rectal balloon
62423840|NCT02043561|EXPERIMENTAL|high urge|high urge induced by rectal balloon
62423841|NCT01211496|ACTIVE_COMPARATOR|High-speed power training|Volunteers randomized into High-speed power training (HSPT) will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength for leg press (LP) and seated knee extension (KE) exercises.
62808933|NCT00321789|NO_INTERVENTION|Usual care|Couples assigned to this arm received educational materials at baseline and usual care thereafter, with no contact from the study interventionist.
62032636|NCT04302350|EXPERIMENTAL|Group50|According to preoperative 3D-CTBA evaluation of bronchial and vascular structure of pulmonary nodules and pulmonary segments, the target segmental bronchus, arteries and intra-segment veins were accurately identified and dissected by ligation or stapler cutting. After that, the anesthesiologist began to make preparations for the lung inflation. The portable nitrous oxide concentration detector (TD600-SH-B-N2O) was installed to detect N2O concentration (vol%), and then adjusted the anesthesia machine to the manual control mode. The flow of the selected gas mixture was set to 8L/min (Group50 set to N2O:O2=4:4). When the N2O concentration detector reached the predetermined gas concentration, and then the collapsed lung was re-expanded completely with controlled airway pressure under 20 cmH2O (1cm H2O=0.098 kPa) by the anesthesiologist. This procedure took approximately 1 min, and then FiO2=1.0 was performed after the initiation of the OLV.
62032637|NCT04302350|ACTIVE_COMPARATOR|Group0|According to preoperative 3D-CTBA evaluation of bronchial and vascular structure of pulmonary nodules and pulmonary segments, the target segmental bronchus, arteries and intra-segment veins were accurately identified and dissected by ligation or stapler cutting. After that, the anesthesiologist began to make preparations for the lung inflation. The portable nitrous oxide concentration detector (TD600-SH-B-N2O) was installed to detect N2O concentration (vol%), and then adjusted the anesthesia machine to the manual control mode. The flow of the selected gas mixture was set to 8L/min (Group0 set to O2=8). When the N2O concentration detector reached the predetermined gas concentration, and then the collapsed lung was re-expanded completely with controlled airway pressure under 20 cmH2O (1cm H2O=0.098 kPa) by the anesthesiologist. This procedure took approximately 1 min, and then FiO2=1.0 was performed after the initiation of the OLV.
62808934|NCT02245477||Obstetric Ultrasoud|Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
62808935|NCT02245477||Serum Vascular Endothelial Growth Factor|Serum VEGF concentration will be determined by Enzyme Linked immunosorbant assay using Quantitative Human VEGF Immunoassay kit (cat. No. DVEOO) manufactured by R \& D Systems, Inc , (Minneapolis, MN, USA).
62808936|NCT05472935|EXPERIMENTAL|MBSR Intervention|Participants will engage with MBSR instructional videos. The videos are 30 minutes in length, and designed to be watched once a day, Monday-through-Friday, over an eight-week period. Additionally, a coaching video of three minutes in length will be available to participants on Mondays. Participants will watch the videos and engage with the content and activities as prompted by the videos. Activities include guided meditations, guided mindfulness activities, such as body scans where participants notice the sensations they feel in various parts of their body, and relaxation exercises. Participants will also be asked to complete light exercises to their comfort level, which involves getting comfortable, light self-guided stretching, and relaxation exercises that are no more physical exertion than they otherwise might experience while moving around completing their normal tasks/activities of daily living outside of this program.
62808937|NCT06086509|NO_INTERVENTION|control group|Questionnaires and scales were filled out by the researcher five minutes before the CT scan. Routine CT scans were performed on the control group without listening to music by wearing a Bluetooth headset. The scales were repeated five minutes after the CT scan.
62808938|NCT06086509|EXPERIMENTAL|music group|"Questionnaires and scales were filled out by the researcher five minutes before the CT scan. Just before the CT scan began, the children in the music group were started to listen to Lullaby K 350 music by inserting a Bluetooth headset into their ears. If the process took longer, the music was played again. Additionally, the Bluetooth headset was properly disinfected before each use to prevent the spread of infectious diseases among patients."
62032638|NCT01673932|EXPERIMENTAL|Group A - UCBMC Early Treatment Group|Group A subjects will receive transplant of UCBMC isolated from HLA-matched umbilical cord blood at Day 0.
62032639|NCT01673932|EXPERIMENTAL|Group B - UCBMC Delayed Treatment Group|Group B subject will partipate in 6 months observation and then receive the UCBMC transplant at month 6.
62232576|NCT02715154|PLACEBO_COMPARATOR|Placebo|The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal.
62808939|NCT00517764|NO_INTERVENTION|Healthy control|Healthy matched control, no intervention
62808940|NCT00517764|ACTIVE_COMPARATOR|Escitalopram|Depressed subjects receiving escitalopram
62808941|NCT00517764|NO_INTERVENTION|subjects with major depression|Depressed subjects not receiving study treatment, but taking part in study measures.
62808942|NCT01838317|EXPERIMENTAL|Pioglitazone & Chemotherapy in Patients without Diabetes|
62808943|NCT01838317|EXPERIMENTAL|Pioglitazone & Chemotherapy in Patients with Diabetes|
62808944|NCT05710055|ACTIVE_COMPARATOR|Study product A (Wonderlab wonder4shape)|"2g/bottle, containing the following probiotics total dosage 2.0\*10\^10 CFU:~* CECT7527, CECT7528, CECT7529, B420, HN019~* FOS~* Polydextrose~* IMO"
62808945|NCT05710055|ACTIVE_COMPARATOR|Study product B (Wonderlab wonder4shape)|"2g/bottle, containing the following probiotics total dosage 2.0\*10\^10 CFU:~* B420, HN019, NCFM~* FOS~* Polydextrose~* IMO"
62808946|NCT05710055|ACTIVE_COMPARATOR|Study product C (Wonderlab wonder4shape)|"2g/bottle, containing the following probiotics total dosage 2.0\*10\^10 CFU:~* CECT7527, CECT7528, CECT7529, B420, HN019~* XOS~* Polydextrose~* IMO"
62808947|NCT05710055|PLACEBO_COMPARATOR|Study product D|"2g/bottle:~* MD~* Cucumber powder"
62808948|NCT04420013||exposed group|for CRC patients with non-resectable hepatic metastases: surgery for CRC combined with RFA.
62808949|NCT04420013||no-exposed group|for CRC patients with resectable metastases: surgery only without RFA.
62808950|NCT00419393|EXPERIMENTAL|Keppra XR (Levetiracetam XR)|1000 - 3000 mg/day Keppra XR (Levetiracetam XR), flexible dosing, throughout the duration of the study (planned: approximately 6 months-3 years)
62232577|NCT02673957||Blood pressure cuff protocol|All participants receive a baseline control blood test, and all participants receive the blood pressure cuff inflation protocol and blood sampling following the cuff protocol.
62808951|NCT01338441|EXPERIMENTAL|Erythromycin|
62232578|NCT03565731|EXPERIMENTAL|ACT-PA Intervention|The primary goal of the intervention is to increase values-based autonomous motivation to increase bout-related MVPA using a single workshop. Participants will engage in basic and advanced values clarification exercise to help clarify (1) the relative importance of major values domains (e.g. social, vocational, recreational), and (2) the potential role of PA in empowering functioning in these domains. Participants will generate their own activity goals and additional values-based goals. In addition, acceptance strategies will be taught to reduce cognitive and emotional barriers to meeting values-based goals. Participants will be asked to report progress on goals each week via an automated email survey from a secure project website. Upon completing the survey, participants will receive standardized responses via email. Monthly phone calls will be brief, semi-structured, and designed to review key principles and trouble-shoot specific barriers identified by the participant.
62808952|NCT01338441|PLACEBO_COMPARATOR|Placebo|
62808953|NCT05118646|EXPERIMENTAL|Microcirculation-oriented resuscitation group|The microcirculation-oriented resuscitation group will evaluate the organ perfusion level and adjust the hemodynamic therapy according to the sublingual microcirculation parameters (PPV \> 68%).
62032640|NCT05780203|EXPERIMENTAL|One session exposure treatment + active Cognitive Bias Modification training|The exposure treatment will be administered at the tower of the German Mining museum. The day after the exposure session, patients will complete the CBM training in the lab of the Mental Health and Research Center of Ruhr University Bochum.
62032641|NCT05780203|SHAM_COMPARATOR|One session exposure treatment + sham Cognitive Bias Modification training|The exposure treatment will be administered at the tower of the German Mining museum. The day after the exposure session, patients will complete the sham CBM training in the lab of the Mental Health and Research Center of Ruhr University Bochum.
62032642|NCT05186623||Patients with confirmed ulcerative colitis|Patients with confirmed ulcerative colitis, who are going to receive vedolizumab therapy (n=100: development cohort n=70 and validation cohort n=30), ustekinumab therapy (n=100: development cohort n=70 and validation cohort n=30), or tofacitinib therapy (n=100: development cohort n=70 and validation cohort n=30), will be enrolled.
62032643|NCT05831319||Above the knee (ATK) group|Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau)
62032644|NCT05831319||Below the knee (BTK) group|Target lesions involve arteries below the tibial plateau
62032645|NCT00492284|EXPERIMENTAL|1/4 Fluence Triple Therapy|Very low fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy \[within 2 hours\] administered on Day 0, and then as required every 2 months thereafter
62032646|NCT00492284|EXPERIMENTAL|1/2 Fluence Triple Therapy|Reduced-fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy \[within 2 hours\] administered on Day 0, and then as required every 2 months thereafter
62032647|NCT00492284|EXPERIMENTAL|1/2 Fluence Double Therapy|Reduced-fluence Visudyne followed by Lucentis double therapy \[within 2 hours\] administered on Day 0, and then as required every 2 months thereafter
62032648|NCT00492284|EXPERIMENTAL|Ranibizumab|Lucentis monotherapy administered on Day 0, Month 1 and Month 2, and then as required monthly thereafter
62032649|NCT05638867|EXPERIMENTAL|Experimental Group|Triple Antithrombotic Therapy: Aspirin (12 months) + Clopidogrel (12 months) + Rivaroxaban (3 months)
62232579|NCT05521802|EXPERIMENTAL|C-CAR088|Autologous C-CAR088 administered by intravenous (IV) infusion
62232580|NCT03595839|ACTIVE_COMPARATOR|Fistulotomy with Marsupialization|Lay open and Marsupialization of the fistula track
62232581|NCT03595839|ACTIVE_COMPARATOR|Fistulotomy without Marsupialization|lay open of the fistula track
62232582|NCT03372356||Neuroendocrine tumors|Patients with neuroendocrine tumors will be given access to an application that monitors distress, anxiety, depression, self-perceived burden, and resilience at regular intervals for 3 months lasting for 24 months.
62808954|NCT05118646|OTHER|Control group|The standard treatment group will adjust the shock management scheme through systemic hemodynamic parameters.
62032650|NCT05638867|OTHER|Control Group|Dual Antiplatelet Therapy: Aspirin (12 months) + Clopidogrel (12 months)
62032651|NCT01275625|EXPERIMENTAL|Treatment|Single arm study of combivir and maraviroc for 48 weeks
62032652|NCT03346876||Study group|patients with pectus excavatum
62032653|NCT03346876||Control group|healthy subjects without pectus excavatum
62423842|NCT01211496|ACTIVE_COMPARATOR|Slow-speed strength training|Volunteers randomized into Slow-speed strength training (SSST) will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength for LP and KE exercises.
62423843|NCT01211496|NO_INTERVENTION|placebo exercise (control group)|Volunteers randomized into the control group (CON) will undergo a placebo exercise intervention consisting of lower extremity range of motion and flexibility exercises performed 2 times per week with the assistance of the research staff.
62592999|NCT06668610|EXPERIMENTAL|SHAM-REAL tDCS Group|Participants randomly assigned to this group will receive a first cycle of SHAM multifocal tDCS (8 sessions, twice a week) and a second cycle of REAL multifocal tDCS (8 sessions, twice a week). During both cycles participant will receive cognitive stimulation treatment after brain simulation.
62232583|NCT02762253|OTHER|Riboflavin drops - epithelium on or off|Riboflavin is applied with Epithelium on or with it off. 6 months follow up to find out magnitude of Decrease in Kmax
62232584|NCT05610176|EXPERIMENTAL|Amvia Sky pacemaker or CRT-P implantation|Patients implanted with an Amvia Sky pacemaker or CRT-P device
62423844|NCT01350531|EXPERIMENTAL|Skills training|
62593000|NCT06668610|EXPERIMENTAL|REAL-SHAM tDCS Group|Participants randomly assigned to this group will receive a first cycle of REAL multifocal tDCS (8 sessions, twice a week) and a second cycle of SHAM multifocal tDCS (8 sessions, twice a week). During the two cycles participant will receive cognitive stimulation treatment after brain simulation.
62593001|NCT00660933|ACTIVE_COMPARATOR|Group A|Group A: Administration of intravenous iron sucrose.
62593002|NCT00660933|PLACEBO_COMPARATOR|Group B|Group B: Administration of intravenous NaCl 0,9%.
62593003|NCT05015998||Non-dialysis dependent patients with CKD stage 3-5|A cohort of patients will be created from the Stockholm CREAtinine Measurement (SCREAM) cohort based on the eligibility criteria.
62032654|NCT02062632|EXPERIMENTAL|Group I (doxepin hydrochloride)|Patients receive doxepin hydrochloride oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1. Patients then crossover to Arm II on day 3.
62032655|NCT02062632|PLACEBO_COMPARATOR|Group II (placebo)|Patients receive placebo oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1. Patients then crossover to Arm I on day 3.
62232585|NCT03541096|EXPERIMENTAL|Winter Swimmers|4 Months of supervised winter swimming.
62232586|NCT03541096|PLACEBO_COMPARATOR|Control group|No winter swimming activities.
62232587|NCT04028882||Non viremic HIV patients under treatment|Patients with various immune activation profiles
62232588|NCT02092220|EXPERIMENTAL|Bionic Pancreas|Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.
62232589|NCT02092220|ACTIVE_COMPARATOR|Usual Care|Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.
62232590|NCT00221169|OTHER|surgical candidates|surgical candidates who underwent PET CT evaluation
62423845|NCT01350531|EXPERIMENTAL|Contingency Management|
62423846|NCT04542330|ACTIVE_COMPARATOR|BCG-Denmark|"Participants that are randomized to the active comparator arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the left upper deltoid muscle.~Each 0.1 ml dose of vaccine contains between 200,000 to 800,000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331."
62423847|NCT04542330|PLACEBO_COMPARATOR|Control|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
62423848|NCT01489696|EXPERIMENTAL|Treatment Arm 1|tamsulosin singles doses; mirabegron multiple dose
62423849|NCT01489696|EXPERIMENTAL|Treatment Arm 2|mirabegron single doses; tamsulosin multiple dose
62423850|NCT06537908||Anti-PD-1/PD-L1 antibodies and Anti-VEGF combination|
62423851|NCT01825616|EXPERIMENTAL|Vitamin D2 mushroom powder|4000 IU/day vitamin D2 mushroom powder
62593004|NCT04025411|EXPERIMENTAL|Experimental group|Patient with stroke ischemic or hemorrhagic will be included. They will have visual motor simulation with the Intensive Visual Simulation 3 (IVS3) device and electroencephalography (EEG).
62593005|NCT04025411|ACTIVE_COMPARATOR|Control group|Patient with stroke ischemic or hemorrhagic will be included. They will have simulation with the traditional Mirror Therapy (TM) and electroencephalography (EEG).
62593006|NCT01497964|EXPERIMENTAL|Cabazitaxel|Cabazitaxel, several dosages
62593007|NCT06621160||Control group|The control group consists of healthy women.
62593008|NCT06621160||CC Group|The CC group consists of women with chronic constipation.
62593009|NCT06277882|EXPERIMENTAL|Intensive 3 dose|Receiving the intensive 3-dose regimen of the Havrix hepatitis A vaccine, administered at months 0, 1, and 6.
62232591|NCT04674670|EXPERIMENTAL|Healthy controls|In this arm, healthy controls will be administered placebo or a dopamine receptor agonist or a dopamine receptor antagonist on separate days to investigate the role of dopamine and fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
62232592|NCT04674670|EXPERIMENTAL|Fibromyalgia patients|In this arm, fibromyalgia patients will receive placebo or a dopamine receptor agonist to investigate the effects of normalizing dopamine transiently on fronto-striatal connectivity and BOLD response in relation to emotional-motivational pain processing.
62232593|NCT05131620|EXPERIMENTAL|Venture in the Virtual Reality Group|Informed consent form will be signed by the patients who will be included in this group as a result of randomization, and a personal information form and STAI will be filled. After CAG, 10 minutes before the catheter extraction, the patients will be selected from videos such as park and nature walks, beach and seaside walks, underwater, museum tour, and virtual reality glasses will be put on and will be worn during the procedure. In the literature, VR glasses were put on 5-10 minutes before the procedure, continued throughout the procedure, and used for a total of 30-60 minutes. Catheter extraction takes approximately 15-20 minutes and it is planned to continue the virtual reality glasses viewing period for 30 minutes. VAS will be applied during the catheter extraction process, and VAS, SAI and PCS will be applied to all patients after catheter extraction. Vital signs of patients will be recorded before, during and after catheter extraction.
62232594|NCT05131620|EXPERIMENTAL|Venture in the Acupressure Group|Initiative in the Acupressure Group Informed consent form will be signed by the patients who will be included in this group as a result of randomization, and a personal information form and STAI will be filled. Acupressure will be applied 10 minutes before catheter extraction after CAG. Catheter extraction takes approximately 15-20 minutes. VAS will be applied during the catheter extraction process, and then VAS, SAI and PCS will be applied to all patients. Vital signs of patients will be recorded before, during and after catheter extraction.
62423852|NCT01825616|PLACEBO_COMPARATOR|Placebo|Mushroom powder without vitamin D2 (not exposed to UV radiation)
62423853|NCT05384327|OTHER|Interview|Content experts who will be interviewed in order to collect their opinion on theoretical knowledge.
62423854|NCT05384327|OTHER|Novices|Medical students who will complete the test
62423855|NCT05384327|OTHER|Intermediates|Junior residents (surgery, pneumology, emergency medicine) who will complete the test.
62423856|NCT05384327|OTHER|Experienced|Faculty members (surgery, pneumology, emergency medicine) who will complete the test.
62423857|NCT02034500|EXPERIMENTAL|S. sonnei 1790GAHB - 0.1 mcg - ID|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 0.1 mcg intradermally (ID)
62423858|NCT02034500|EXPERIMENTAL|S. sonnei 1790GAHB - 1 mcg - ID|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 1 mcg intradermally (ID)
62593010|NCT06277882|ACTIVE_COMPARATOR|Standard 2 dose|Receiving the standard 2-dose regimen of the Havrix hepatitis A vaccine, administered at months 0, and 6.
62593011|NCT05425459|EXPERIMENTAL|Treatment|Participants randomized to the treatment arm will undergo a fluoroscopic and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and InterAtrial Shunt Device (IASD) System II implant procedure.
62808955|NCT01506271|EXPERIMENTAL|Relebactam 250 mg with imipenem/cilastatin|Participants randomized to receive relebactam 250 mg will be administered 250 mg doses of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
62423859|NCT02034500|EXPERIMENTAL|S. sonnei 1790GAHB - 10 mcg - ID|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 10 mcg intradermally (ID)
62423860|NCT02034500|EXPERIMENTAL|S. sonnei 1790GAHB - 5 mcg - IN|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 5 mcg intranasally (IN)
62423861|NCT02034500|EXPERIMENTAL|S. sonnei 1790GAHB - 20 mcg - IN|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 20 mcg intranasally (IN)
62423862|NCT02034500|EXPERIMENTAL|S. sonnei 1790GAHB - 80 mcg - IN|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 80 mcg intranasally (IN)
62423863|NCT02034500|EXPERIMENTAL|S. sonnei 1790GAHB - 5 mcg - IM|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 5 mcg intramuscularly (IM)
62423864|NCT02034500|PLACEBO_COMPARATOR|Placebo - ID|2 subjects enrolled in each COHORT A, B and C receiving 3 injections of Placebo intradermally (ID). These were pooled in one Placebo group in the analyses
62423865|NCT02034500|PLACEBO_COMPARATOR|Placebo - IN|2 subjects enrolled in each COHORT A, B and C receiving 3 injections of Placebo intranasally (IN). These were pooled in one Placebo group in the analyses
62423866|NCT02034500|PLACEBO_COMPARATOR|Placebo - IM|2 subjects enrolled in COHORT C receiving 3 injections of Placebo intramuscularly (IM)
62423867|NCT03478345|EXPERIMENTAL|THRIVE Study|
62423868|NCT03446716|EXPERIMENTAL|EXTENSION|During the extension condition, caregivers were instructed to put their child to bed 90 minutes earlier than their habitual bedtime for five consecutive nights. Caregivers were provided a list of tips to aid in implementing the earlier bedtime.
62232595|NCT05131620|NO_INTERVENTION|Control Group|Informed consent form will be signed by the patients who will be included in this group as a result of randomization, and a personal information form and STAI will be filled. Routine application will be made. VAS will be applied during the catheter extraction process, and then VAS, SAI and PCS will be applied to all patients. Vital signs of patients will be recorded before, during and after catheter extraction.
62232596|NCT05924685|ACTIVE_COMPARATOR|Continue immunosuppressive therapy with MMF/MPA|Kidney transplant recipients with maintenance therapy, receiving the monovalent Omicron XBB.1.5 COVID-19 mRNA vaccine (Comirnaty, I.M.). Optional to receive the Recombinant Zoster Vaccine (Shingrix, I.M.).
62232597|NCT05924685|ACTIVE_COMPARATOR|Replace immunosuppressive therapy with MMF/MPA by everolimus|Kidney transplant recipients replacing MMF/MPA by everolimus for at least six weeks, receiving the monovalent Omicron XBB.1.5 COVID-19 mRNA vaccine (Comirnaty, I.M.). Optional to receive the Recombinant Zoster Vaccine (Shingrix, I.M.).
62232598|NCT00232141|EXPERIMENTAL|1|
62232599|NCT00232141|PLACEBO_COMPARATOR|2|
62232600|NCT00846547|EXPERIMENTAL|Arbaclofen|
62232601|NCT02442323|EXPERIMENTAL|Walking Intervention|Intervention patients will receive a 12-week home-based walking program, which includes a personalized instruction booklet and pedometer. The walking program consists of 3 phases and will be individualized for each patient based on their physical condition and baseline assessment. Patients are instructed to walk 3 to 5 times each week at home or other safe environment. Patients will be instructed on a gradual increase in walking time over the course of the intervention.
62232602|NCT02442323|NO_INTERVENTION|Usual Care|Usual care patients will receive standard of care. They will not receive any instruction on walking or other physical activity other than what is normally provided by their physician or clinical staff.
62232603|NCT06200831|ACTIVE_COMPARATOR|Staged resection|Resection of the primary colorectal carcinoma and liver metastases in two separate surgeries.
62232604|NCT06200831|EXPERIMENTAL|Simultaneous resection|Resection of both the primary colorectal carcinoma and the liver metastases in one surgical procedure.
62232605|NCT04098965|EXPERIMENTAL|Experimental|Physical Therapy Techniques
62232606|NCT04098965|OTHER|Control|physician treatment
62232607|NCT01874860|EXPERIMENTAL|Extensive treatment group|"Doxycycline capsule, 100 mg, taken twice daily; sunscreen SPF 30 or higher applied to exposed skin areas at least 30 minutes before going outdoors each morning; moisturizer applied to the face, hands, feet, neck, back, and chest each morning after sunscreen; Hydrocortisone 1% topical cream applied to the face, hands, feet, neck, back, and chest each evening.~For patients with grade 1 rash, hydrocortisone 1% cream and clindamycin 1% gel (tetracycline antibiotic) are recommended for daily use.~For patients with grade 2 rash, hydrocortisone cream and doxycycline 100mg twice daily or minocycline (tetracycline antibiotic) 100mg once daily is recommended.~For patients with grade 3 rash, systemic steroid therapy (a Medrol dose-pack) will be added to the grade 2 treatment."
62232608|NCT01874860|EXPERIMENTAL|Standard care group|Patient will not receive preventive treatment but will be allowed to use sunscreen and moisturizer if desired.
62232609|NCT05488223|EXPERIMENTAL|PUFA ω-3 (1.8g/day)|"ω-3 PUFAs (Triple Strength Fish Oil®) were purchased in advance, each capsule contained 540 mg of eicosapentaenoic acid (20:5 n-3) and 360 mg of docosahexaenoic acid (22:6 n-3), for a 0.9g total. Children and parents were told that they should take 2 capsules of ω-3 PUFAs daily, that is, they took 1.8g/day.~Parents and children were informed that the duration of the study would be 5 months, in the first three months, the children should take the capsules of the assigned treatment; in the fourth and fifth months they should continue their surveillance with the researchers. At the beginning, they were given 2 bottles of 30 capsules each, identified as formula A or B, according to the assigned group, and they were given a calendar sheet indicating that they should cross out a box if they had consumed the breakfast capsule and cross out another box if the consumed during the meal; Likewise, they were asked to write down any adverse effect, if any, on the same sheet."
62232610|NCT05488223|ACTIVE_COMPARATOR|PUFAs ω-3 0.9 g/day + MUFAs (avocado oil) 0.9 g/day.|A commercial brand of avocado oil (MUFA) was purchased in advance by putting 0.9g in each capsule. The appearance of the ω-3 PUFA capsules and the avocado oil capsules were the same. Then we worked with the company that prepared the blinding of the treatments, packaging bottles of 30 capsules each, labeling them as bottles A and B. The design contemplated giving each child two bottles, one marked to take it for breakfast and another marked to take it with food. The child was instructed to take 1 capsule per day of PUFA ω-3 (0.9g/d) and 1 capsule of avocado oil (0.9g/d)
62232611|NCT05488223|PLACEBO_COMPARATOR|MUFAs (avocado oil) 1.8 g/day.|The child was instructed to take 2 capsules per day, 1.8g of avocado oil per day.
62593012|NCT05425459|SHAM_COMPARATOR|Control|Participants randomized to the control arm will undergo fluoroscopy and intracardiac echocardiography from the femoral vein or transesophageal echocardiography, for examination of the atrial septum and left atrial appendage.
62232612|NCT00714597|EXPERIMENTAL|Semuloparin|Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment \[SRI\]) once daily for 10-14 days
62232613|NCT00714597|ACTIVE_COMPARATOR|Enoxaparin|Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment \[SRI\]) once daily for 10-14 days
62232614|NCT05380492|EXPERIMENTAL|Low Dose|VOY-101 Low Dose (single dose, IVT)
62232615|NCT05380492|EXPERIMENTAL|Mid Dose|VOY-101 Mid Dose (single dose, IVT)
62232616|NCT05380492|EXPERIMENTAL|High Dose|VOY-101 High Dose (single dose, IVT)
62232617|NCT00093808|EXPERIMENTAL|capecitabine + vinorelbine + trastuzumab|"Patients receive oral capecitabine twice daily on days 1-14, vinorelbine IV over 6-10 minutes on days 1 and 8, and trastuzumab (Herceptin\^®) IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years."
62423869|NCT03446716|NO_INTERVENTION|CONTROL|Children followed their normal bedtime routine for five consecutive nights.
62423870|NCT00467038|OTHER|Dialectical Behavior Therapy|Dialectical Behavior Therapy
62423871|NCT00467038|NO_INTERVENTION|Healthy Controls|Healthy controls
62423872|NCT06562530|ACTIVE_COMPARATOR|The control group|15 patients: receiving 36 sessions of selected physical therapy program for 1 hour 3 times per week for 3 months.
62819542|NCT06705010|EXPERIMENTAL|Application of novel MRSI pulse sequences to four patient groups|Optimized MR-pulse sequences are applied to four groups of 10 patients after glucose solution ingestion followed by patient level comparison of patient 3D metabolic data to healthy control data by z-score mapping.
62808956|NCT01506271|EXPERIMENTAL|Relebactam 125 mg with imipenem/cilastatin|Participants randomized to receive relebactam 125 mg will be administered 125 mg doses of relebactam IV, in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
62232618|NCT00916825|EXPERIMENTAL|3-week family oriented rehabprogramme|waiting control group
62232619|NCT03401541|EXPERIMENTAL|Fat-Mal, calcifediol then calciferol|Participants with diagnosed fat malabsorption syndrome will initially receive one capsule of calcifediol for the first round of blood draws and then receive one capsule of calciferol for the second round.
62232620|NCT03401541|EXPERIMENTAL|Fat-Mal, calciferol then calcifediol|Participants with diagnosed fat malabsorption syndrome will initially receive one capsule of calciferol for the first round of blood draws and then receive one capsule of calcifediol for the second round.
62232621|NCT03401541|EXPERIMENTAL|Non Fat-Mal, calcifediol then calciferol|Participants that do not have a diagnosed fat malabsorption syndrome will initially receive one capsule of calcifediol for the first round of blood draws and thenreceive one capsule of calciferol for the second round.
62232622|NCT03401541|EXPERIMENTAL|Non Fat-Mal, calciferol then calcifediol|Participants that do not have a diagnosed fat malabsorption syndrome will initially receive one capsule of calciferol for the first round of blood draws and then receive one capsule of calcifediol for the second round.
62423873|NCT06562530|EXPERIMENTAL|The study group1|15 patients: receiving 36 sessions of High tone power therapy program for 30 minutes and selected physical therapy program for 30 minutes 3 times per week for 3 months (total session: 1 hour).
62423874|NCT06562530|EXPERIMENTAL|The study group 2|15 patients: receiving 36 sessions of TENS program for 30 minutes and selected physical therapy program for 30 minutes 3 times per week for 3 months (total session: 1 hour).
62423875|NCT01682512|EXPERIMENTAL|Part I BI 695500 group|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
62423876|NCT01682512|ACTIVE_COMPARATOR|Part I Rituxan®|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
62808957|NCT01506271|PLACEBO_COMPARATOR|Placebo to relebactam with imipenem/cilastatin|Participants randomized to receive placebo for relebactam will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
62808958|NCT02084485|EXPERIMENTAL|Arm A|
62808959|NCT02084485|PLACEBO_COMPARATOR|Arm B|
62808960|NCT00214045|ACTIVE_COMPARATOR|Flexible Cystoscopy|Flexible Cystoscopy
62232623|NCT02262143|EXPERIMENTAL|Experimental|Rosuvastatin 10 mg, Fenofibrate 160 mg
62232624|NCT02262143|ACTIVE_COMPARATOR|Comparator|Rosuvastatin 10 mg
62808961|NCT00214045|ACTIVE_COMPARATOR|Rigid Cystoscopy|Rigid Cystoscopy
62808962|NCT04706949|EXPERIMENTAL|Pyrotinib combined with pemetrexed plus carboplatin|
62808963|NCT03308344|EXPERIMENTAL|Spouse Trainers (MT-ST)|Participants will engage in a short-form mindfulness training delivered by their peers who underwent an extensive training practicum.
62808964|NCT03308344|NO_INTERVENTION|Wait-list control|Participants will be tested before and after a no-training interval and may receive training at a later time.
62808965|NCT03308344|EXPERIMENTAL|Mindfulness Expert (MT-ME)|Participants will engage in a short-form mindfulness training delivered by an expert mindfulness trainer.
62808966|NCT03390465|OTHER|Arm1(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
62808967|NCT03390465|OTHER|Arm2(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
62808968|NCT03390465|OTHER|Arm3(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
62232625|NCT02972125|EXPERIMENTAL|Treatment A - B|Single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 100 mg tablet), followed by a Wash-Out Period of at least 7 days and a single administration of the test drug (Treatment B, a single dose of LCM 100 mg given as dry syrup).
62232626|NCT02972125|EXPERIMENTAL|Treatment B - A|Single administration of the test drug (Treatment B, a single dose of LCM 100 mg given as dry syrup), followed by a Wash-Out Period of at least 7 days and a single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 100 mg tablet).
62232627|NCT00681746|EXPERIMENTAL|1|
62423877|NCT01682512|ACTIVE_COMPARATOR|Part I MabThera®|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
62423878|NCT01682512|EXPERIMENTAL|Part II BI 695500 group|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
62423879|NCT01682512|ACTIVE_COMPARATOR|Part II rituximab group|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
62423880|NCT06032819||hemorrhage|The result of the Intracranial hyper-density on CT images is determined by dual-energy CT or follow-up images: hyper-density can be seen on the virtual non-contrasted image of dual-energy CT, or high density persist longer than 48 hours.
62423881|NCT06032819||simple contrast extravasation|There is no Intracranial hyper-density on the virtual non-contrast images of dual-energy CT, or the follow-up CT show that the hyper-density is absorbed within 48 hours.
62808969|NCT03390465|OTHER|Arm4(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
62808970|NCT03390465|OTHER|Arm5(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
62808971|NCT03390465|OTHER|Arm6(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
62808972|NCT00657046|ACTIVE_COMPARATOR|1|Droxidopa at 400 mg (2 capsules each containing 200 mg droxidopa plus one capsule with Placebo)
62808973|NCT00657046|ACTIVE_COMPARATOR|2|Droxidopa at 600 mg (3 capsules each containing 200 mg droxidopa)
62808974|NCT00657046|PLACEBO_COMPARATOR|3|Placebo (3 capsules with mannitol substituted for droxidopa)
62232628|NCT05310487|EXPERIMENTAL|162|The dose-escalation stage will be conducted sequentially at 5 dose levels, which are 100 mg in the pre-test, and 200 mg, 400 mg, 800 mg and 1200 mg in the formal test. Two healthy adult subjects will be enrolled at 100 mg dose level and all given 162. At the start of each level with the exception of 100 mg level which there are only two subjects, two sentinel subjects will be randomized 1:1 to 162 or placebo. The remaining subjects will be randomized 5:1 to receive a single ascending dose of 162 or placebo.
62232629|NCT05310487|PLACEBO_COMPARATOR|placebo|At the start of each level with the exception of 100 mg level which there are only two subjects, two sentinel subjects will be randomized 1:1 to 162 or placebo. The remaining subjects will be randomized 5:1 to receive a single ascending dose of 162 or placebo.
62232630|NCT06525961|EXPERIMENTAL|Participants with iTEAR100 Neurostimulator|The participants will use iTEAR100 Neurostimulator for the stimulation of the anterior ethmoidal nerve - which is located at the point between bony and fleshy tissue alongside the nose. Participants should apply stimulation to each side of the nose for 30 seconds, twice a day. It is recommended to apply once in the morning and once in the evening.
62232631|NCT04136665|EXPERIMENTAL|Physical Activity Adapted program|
62232632|NCT01091753|PLACEBO_COMPARATOR|morning administration group|
62232633|NCT01091753|EXPERIMENTAL|nocturnal administration group|
62232634|NCT05417867||Observational (survey, biospecimen collection)|Patients undergo collection of stool samples over 10 minutes and complete questionnaires over 60 minutes at baseline and 3-5 days following initiation of standard of care chemotherapy.
62232635|NCT01607112|EXPERIMENTAL|Fluarix/Influsplit 18-60 Years Group|Subjects 18-60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
62232636|NCT01607112|EXPERIMENTAL|Fluarix/Influsplit > 60 Years Group|Subjects above 60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
62232637|NCT01100034||1|pediatric patients with plaque psoriasis on etanercept
62232638|NCT00816686|EXPERIMENTAL|1. AGS-16M18 Dose 1|
62808975|NCT03442816|EXPERIMENTAL|MHRC camera|Subjects will undergo a retina imaging session with the MHRC camera.
62232639|NCT00816686|EXPERIMENTAL|2. AGS-16M18 Dose 2|
62232640|NCT00816686|EXPERIMENTAL|3. AGS-16M18 Dose 3|
62232641|NCT00816686|EXPERIMENTAL|4. AGS-16M18 Dose 4|
62232642|NCT00816686|EXPERIMENTAL|5. AGS-16M18 Dose 5|
62232643|NCT06137222|EXPERIMENTAL|SOC plus TXB MicroTip Ultrasound|Sharp debridement of the outer margins of the index DFU using standard technique (curettage or sharp blade debridement) plus a single additional percutaneous debridement of bone and surrounding tissue via the TXB MicroTip for the first treatment session only plus wound care offloading. The index foot ulcer will be dressed with collagen alginate, gauze and roll gauze. Each subject will return for weekly wound assessment, serial sharp debridement if needed and repeat dressing changes. This care will occur for a duration of 12 weeks or until wound closure is confirmed.
62232644|NCT06137222|PLACEBO_COMPARATOR|SOC|Subcutaneous sharp debridement of the index DFU using standard technique (curettage or sharp blade debridement) plus wound care offloading. The index foot ulcer will be dressed with collagen alginate, gauze and roll gauze. Each subject will return for weekly wound assessment, serial sharp debridement if needed and repeat dressing changes. This care will occur for a duration of 12 weeks or until wound closure is confirmed. Defined as standard of care (SOC).
62808976|NCT01869738|EXPERIMENTAL|MGuard Prime|MGuard Prime stent
62808977|NCT01869738|ACTIVE_COMPARATOR|Control|(BMS/DES) Includes FDA approved bare metal or drug eluting stents, including ENDEAVOR, TAXUS Liberte, XIENCE Prime, PROMUS Element, ION, RESOLUTE, Driver, Vision, VeriFlex and Integrity.
62808978|NCT03025425|EXPERIMENTAL|MPV-arm|Subjects use mouth piece ventilation (MPV) according to their will for 24 hours to alleviate dyspnea.
62808979|NCT02507765|EXPERIMENTAL|Treatment (SBRT, TACE)|Patients undergo SBRT on day 1 and TACE on day 2.
62808980|NCT00610402||blood sample tear drop sample|blood sample tear drop sample
62808981|NCT04854343||Case|200 patients with a suspicion of prostate cancer
62808982|NCT04854343||Control A|(a) 50 patients with benign prostate hyperplasia (BPH)
62808983|NCT04854343||Control B|(b) 30 male subjects older than 50 years with neither prostate disease nor any other neoplasia
62808984|NCT02881788||Traumatic Brain injury|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have sustained a traumatic brain injury. We are hoping to find patterns that may indicate a TBI in the data we collect.
62808985|NCT02881788||Non-Traumatic Brain injury|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have sustained a non-trauma related brain injury. We are hoping to find patterns that we may compare this data to subjects who have sustained a TBI as well as healthy controls.
62808986|NCT02881788||Control|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have not recently sustained any brain injury. We are hoping to find patterns that we may compare this data to subjects who have sustained a TBI as well as subjects who have had a non-trauma related brain injury.
62808987|NCT02190136|ACTIVE_COMPARATOR|Protein whole foods|Ingestion of 20-25 grams per serving consumed 4-6 times per day; 1 within an hour of waking in the morning and the other 2.5-3 hours apart during the day.
62808988|NCT02190136|EXPERIMENTAL|Protein Resistance Exercise Training|Ingestion of 4-6 protein-rich meals per day and 3 times per week of resistance functional training.
62808989|NCT02190136|EXPERIMENTAL|Protein Stretching/Yoga Training|Ingestion of Protein-rich diet 4-6 meals/day and stretching/yoga training 3 times per week
62808990|NCT01152658|PLACEBO_COMPARATOR|Nacl Injection|"1. Blood samples (4 test tubes) will be extracted from control groups and 8 test tubes for the trial group. The blood of the trial group will be centrifuged and the platelet fraction extracted and counted (only 4 test tubes).~2. NACL0.9% solution will be then injected to the control group in sterile conditions under ultrasound control~double blind procedure~."
62232645|NCT00802009|EXPERIMENTAL|1|Dexamethasone 8mg added to routine local anesthetic during brachial plexus blockade.
62232646|NCT00802009|ACTIVE_COMPARATOR|2|Routine anesthetic solution (30 cc 1.5% mepivicaine) used during brachial plexus blockade.
62232647|NCT00051363|ACTIVE_COMPARATOR|Active CPAP|Active Continuous Positive Airway Pressure (CPAP)
62423882|NCT03354923|EXPERIMENTAL|immediate intervention group|Immediate PEERS intervention
62808991|NCT01152658|EXPERIMENTAL|PRGF|1. Blood samples (4 test tubes) will be extracted from control groups and 8 test tubes for the trial group. The blood of the trial group will be centrifuged and the platelet fraction extracted and counted (only 4 test tubes).2. The enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control.
62808992|NCT00963963|ACTIVE_COMPARATOR|health promotion materials|Parents receive health promotion booklets
62232648|NCT00051363|PLACEBO_COMPARATOR|Sham CPAP|Sham Continuous Positive Airway Pressure (CPAP)
62232649|NCT02390830|EXPERIMENTAL|Intervention|Participants in the intervention group received at least 25-45' of balance treatment. The balance treatments were aimed at improving participants' control of the position and movement of the center of mass and body segments during static, dynamic and transitional tasks.
62232650|NCT02390830|ACTIVE_COMPARATOR|Control|Participants in the control group were treated to reduce limitations at body function and activity levels, while treatment for balance disorders was restricted to a maximum of 10' per session. Treatment mainly focused on increasing range of joints motion, reducing of muscle contractures and strength training.
62423883|NCT03354923|OTHER|delayed intervention|delayed PEERS intervention to begin after experimental group
62423884|NCT04058600|EXPERIMENTAL|Virtual Reality|The patients will be exposed to a virtual reality software that simulates the environment of the hospital, from admission to the operating room and the recovery room.
62423885|NCT04058600|NO_INTERVENTION|Control|Patients in this group are not exposed preoperatively to the virtual reality software and are given the standard therapy and cares for their disease.
62423886|NCT01593709||Cohort 1|Healthy adults; age 18 or older
62423887|NCT00243282|NO_INTERVENTION|1|Control (Support Group)
62423888|NCT00243282|OTHER|2|Intervention (Mindfulness Based Breathing Therapy)
62808993|NCT00963963|ACTIVE_COMPARATOR|attention-controlled parent print materials|Booklets on adolescent sexuality and health
62808994|NCT00963963|EXPERIMENTAL|audio-CD parent education|audio-CDs on parenting practices
62808995|NCT04061122||EX + / ECTS +|Patients suffering COPD exacerbation in last 7 days; active tobacco smokers
62232651|NCT02318823|OTHER|Beer (alcoholic) followed by placebo (non-alcoholic)|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has two treatment conditions in the same subject.
62232652|NCT02318823|OTHER|Placebo (non-acoholic beer) followed by Beer (alcoholic)|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has two treatment conditions in the same subject.
62232653|NCT04987723|OTHER|AF + HFrEF cohort|"Left Ventricular Ejection Fraction (LVEF) \< 50% by echocardiogram during routine screening or within 12 months prior to enrolment day. The echo must have been performed \>3 weeks after optimisation of HF and rate control therapies, otherwise repeat imaging will be performed after this has been achieved~With~NYHA functional status II-III at the enrolment visit."
62232654|NCT04987723|OTHER|AF + symptoms cohort|"Left Ventricular Ejection Fraction (LVEF) \> 50% by echocardiogram during routine screening or within 12 months prior to enrolment day~With~modified European Heart Rhythm Association symptom classification 2b-4."
62232655|NCT01893892|EXPERIMENTAL|Arm I (levocarnitine start)|Patients receive levocarnitine PO BID during weeks 1-4. Washout is weeks 5-8. Patients then cross-over to placebo for weeks 9-12.
62232656|NCT01893892|PLACEBO_COMPARATOR|Arm II (placebo start)|Patients receive placebo PO BID during weeks 1-4. Washout is weeks 5-8. Patients then cross-over to levocarnitine for weeks 9-12.
62423889|NCT02913261|EXPERIMENTAL|Ruxolitinib|These patients were administered Ruxolitinib orally twice per day (b.i.d) at a dose of 10 mg bid, as two 5-mg tablets. Ruxolitinib was taken without regards to food.
62423890|NCT02913261|ACTIVE_COMPARATOR|Best Available Therapy (BAT)|These patients were administered BAT per the Investigator's best judgement based on a specific list of BAT.
62423891|NCT05309174|NO_INTERVENTION|General anesthesia group|Patients received general anesthesia.
62423892|NCT05309174|EXPERIMENTAL|General anesthesia combined laryngeal nerve block|Group L received ultrasound-guided internal branch of the upper laryngeal nerve block (USG-guided iSLN block) bilaterally with 5 ml of 0.375% ropivacaine, along with general anesthesia.
62423893|NCT02791711|OTHER|High Flow Nasal Cannula|Use of High Flow Nasal Cannula
62423894|NCT06541899|EXPERIMENTAL|Group 1 - 360° M applicator, abdominal|Group 1: 360° M applicator - Abdominal region
62423895|NCT06541899|EXPERIMENTAL|Group 2 - 360° G applicator, abdominal|Group 2: 360° G applicator - Abdominal region
62423896|NCT06541899|EXPERIMENTAL|Group 3 - flanks|Group 3: Plate applicator - Flank region
62423897|NCT02460133|OTHER|HCV Genotype 1, with and without cirrhosis|
62232657|NCT04849936||evaluation of fecal biomarkers|comparison of the biomarker levels between different gastrointestinal diseases
62232658|NCT01954381|OTHER|control|
62232659|NCT01954381|EXPERIMENTAL|patient|
62423898|NCT05318807|EXPERIMENTAL|Personalised prehabilitation|A personalised plan of diet, exercise and emotional support for patients having chemotherapy, radiotherapy and/or immunotherapy treatment for lung cancer.
62423899|NCT02615197|ACTIVE_COMPARATOR|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT) as described in the 2 DBT treatment manuals (Linehan, 1993; 2014).
62423900|NCT02615197|EXPERIMENTAL|Dialectical Behavior Therapy + DBT Prolonged Exposure protocol|Standard Dialectical Behavior Therapy (DBT) as described in the 2 DBT treatment manuals (Linehan, 1993; 2014) plus an adapted version of Prolonged Exposure therapy for PTSD.
62232660|NCT05959694|EXPERIMENTAL|TQB3909 tablets|Oral administration, 400mg or 600 mg, once a day, and 28 days is a treatment cycle. Continue medication until the disease progresses or intolerant toxicity appears.
62232661|NCT02940938|EXPERIMENTAL|Children under general anesthesia|During general anesthesia without surgical stimuli, pulse oximeter sensor is applied with gradually increased contact force, from 0 to maximal 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds at each contact force. Delta POP will be calculated and compared.
62423901|NCT01883531|PLACEBO_COMPARATOR|Inhaled Placebo|Eight-week treatment period with inhaled placebo b.d.
62808996|NCT04061122||EX - / ECTS +|Patients without COPD exacerbation in last 6 months; active tobacco smokers
62423902|NCT01883531|ACTIVE_COMPARATOR|Inhaled Mannitol|Eight-week treatment period Inhaled Mannitol 400 mg b.d.
62808997|NCT04061122||EX + / ECTS -|Patients suffering COPD exacerbation in last 7 days; quited tobacco smoking at least 12 months earlier
62232662|NCT01658150|EXPERIMENTAL|isradipine|open label
62232663|NCT03177551||Developement Cohort|Development the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
62232664|NCT03177551||Validation Cohort|Validation the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
62232665|NCT01274585|SHAM_COMPARATOR|No active treatment|
62232666|NCT01274585|EXPERIMENTAL|stimulation/treatment|
62232667|NCT04563338|EXPERIMENTAL|Arm A (Liver Cancer)|"Atezolizumab: 1200 mg, intravenously (IV), every 3 weeks~Bevacizumab: 15 mg/kg, intravenously (IV), every 3 weeks"
62232668|NCT04563338|EXPERIMENTAL|Arm B (Lung Cancer)|"Atezolizumab: 1200 mg, intravenously (IV), every 3 weeks~Bevacizumab: 15 mg/kg, intravenously (IV), every 3 weeks"
62232669|NCT04563338|EXPERIMENTAL|Arm C (Lung Cancer)|Atezolizumab: 1200 mg, intravenously (IV), every 3 weeks
62232670|NCT01205256|EXPERIMENTAL|Methadone|0.25mg/kg IV of racemic methadone at the induction of anesthesia.
62423903|NCT06539637|ACTIVE_COMPARATOR|OMIDRIA|OMIDRIA is a combination product containing 10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac in a single-patient-use vial. Once the 4mL of OMIDRIA is diluted in 500 mL of ophthalmic irrigation solution, the resulting solution is intended to be used as needed during cataract surgery or intraocular lens replacement.
62423904|NCT06539637|ACTIVE_COMPARATOR|Topical Ketorolac|Topical ketorolac tromethamine 0.5% is a nonsteroidal anti-inflammatory drug. It is FDA-approved for the treatment of inflammation following cataract surgery and relief of ocular itching due to seasonal allergic conjunctivitis.
62232671|NCT02960347|EXPERIMENTAL|Active tDCS|open label active tDCS treatment
62232672|NCT06402422||rMDD patients|Participants are required to visit the lab twice. In the first visit, participants will first perform a verbal fluency task during which the brain activity will be recorded by fNIRS. Then participants complete a cognitive test called Raven's Advanced Progressive matrices (\~ 40 min). In the second visit, participants will receive concurrent iTBS/fNIRS.
62232673|NCT06402422||MDD patients|Participants are required to visit the lab twice. In the first visit, participants will first perform a verbal fluency task during which the brain activity will be recorded by fNIRS. Then participants complete a cognitive test called Raven's Advanced Progressive matrices (\~ 40 min). In the second visit, participants will receive concurrent iTBS/fNIRS.
62232674|NCT06402422||Health Controls|Participants are required to visit the lab twice. In the first visit, participants will first perform a verbal fluency task during which the brain activity will be recorded by fNIRS. Then participants complete a cognitive test called Raven's Advanced Progressive matrices (\~ 40 min). In the second visit, participants will receive concurrent iTBS/fNIRS.
62232675|NCT06402422||High Risk-HCs|Participants are required to visit the lab twice. In the first visit, participants will first perform a verbal fluency task during which the brain activity will be recorded by fNIRS. Then participants complete a cognitive test called Raven's Advanced Progressive matrices (\~ 40 min). In the second visit, participants will receive concurrent iTBS/fNIRS.
62232676|NCT01281150|EXPERIMENTAL|Treatment (veliparib, paclitaxel, carboplatin)|"DOSE-ESCALATION: Patients receive veliparib PO twice daily BID on days 1-5, 8-12, and 15-19 and paclitaxel IV over 1 hour and carboplatin IV over 30 minutes in course 1 and 3 hours in subsequent courses on days 3, 10, and 17. After 4 courses, patients receive paclitaxel and carboplatin on days 3 and 10 only. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (Completed as of 12/2012)~EXPANSION COHORT: Patients receive veliparib PO BID on days 1-21 and paclitaxel IV over 1 hour and carboplatin IV over 3 hours on days 3 and 10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
62232677|NCT01143038|EXPERIMENTAL|Romiplostim|Participants received romiplostim administered weekly by subcutaneous injection during the 12-month treatment period. The starting dose was 1 μg/kg with weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L.
62232678|NCT04371861||Treatment of lower extremity lesion via transradial access.|Interventions performed are standard of care for treatment of a peripheral lesion.
62232679|NCT01272804|EXPERIMENTAL|PF-04937319|
62232680|NCT01272804|PLACEBO_COMPARATOR|Placebo|
62232681|NCT04589754|EXPERIMENTAL|Sintilimab plus chemotherapy|Adriamycin and ifosfamide combined with sintilimab in the treatment of advanced or unresectable soft tissue sarcoma
62232682|NCT04589754|PLACEBO_COMPARATOR|Adriamycin-based chemotherapy|Adriamycin-based chemotherapy in the treatment of advanced or unresectable soft tissue sarcoma
62232683|NCT00298090||StO2 values|StO2 monitoring
62423905|NCT06030271|EXPERIMENTAL|TrueCross microcatheter|The TrueCross Single-use Microcatheter will be used in percutaneous coronary intervention(PCI) of the enrolled subjects.
62032656|NCT00639717|EXPERIMENTAL|Etanercept and ECP|"Etanercept and ECP (Extracorporeal Photopheresis) in addition to standard GVHD prevention:~Etanercept will be given twice weekly by subcutaneous injection starting on the day of HSCT (Hematopoietic stem cell transplantation) conditioning until 8 weeks post transplant. ECP treatments will begin at once weekly starting at 4 weeks post transplant and continue at less frequent intervals until 6 months post transplant.~GVHD prophylaxis will consist of a standard two drug regimen: mycophenolate for 4 weeks and tacrolimus (titrated to a therapeutic level) for 8 weeks, then weaned over 4 months with discontinuation by 6 months post-transplant."
62232684|NCT03891576|EXPERIMENTAL|Niraparib 200 mg|Niraparib will be administered every day as oral at a fixed dose of 200 mg
62232685|NCT03891576|ACTIVE_COMPARATOR|Niraparib 300 mg|Niraparib will be administered every day as oral at a fixed dose of 300 mg
62232686|NCT03891576|OTHER|Niraparib 200mg/300mg|Niraparib will be administered every day as oral at a fixed dose of 200 mg or 300 mg
62032657|NCT05880095|EXPERIMENTAL|Unrestricted Mediterranean diet (MedD)|The aim of this group is to serve as control group. Participants will be advised to adhere to a traditional Mediterranean diet
62232687|NCT03048799|ACTIVE_COMPARATOR|Radiofrequency on and Kinesiotherapy|The radiofrequency application protocol with CAPENERGY device, which has two electrodes: an active one, which will be introduced into the anal region, using a condom and gel to The emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The temperature used in the treatment will be 41 ° C, which this parameter will be placed in the equipment, maintained for 2 minutes. Five RF sessions will be performed, with a seven-day interval between them. For the application, participants will be placed in lateral decubitus position. The session will be quick, with an average duration of 20 minutes.Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given.
62232688|NCT03048799|PLACEBO_COMPARATOR|Radiofrequency off and Kinesiotherapy|"The patient will be in lateral decubitus, the anal probe of the radiofrequency apparatus will be introduced, with the gel previously heated. The radio frequency will be off.~Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given. In addition, at this point will be advised on the performance of The Knack, which is a pre-contraction of the PA during the performance of some abdominal effort such as coughing, sneezing or laughing."
62032658|NCT05880095|EXPERIMENTAL|Energy-reduced Mediterranean diet (MedD_RC)|The aim of this group is to allow the comparison between a traditional caloric restriction approach and a time-restricted eating program without caloric restriction.
62032659|NCT05880095|EXPERIMENTAL|Mediterranean diet with time-restricted eating (MedD_TRE)|This is the intervention group designed to asses the main hypothesis.
62232689|NCT03216057|EXPERIMENTAL|Omega-3 fatty acid 3 grams per day|Each capsule contains 400 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 2000 mg of eicosapentaenoic acid and 1000 mg of docosahexaenoic acid per day (3 grams of Omega 3 per day) by mouth for 12 weeks. The trademark is Omega Rx Dr.Sears Zone labs Inc.
62232690|NCT03216057|PLACEBO_COMPARATOR|Placebo|Each capsule contains 600 mg of soybean oil. We allocated five capusles per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 3000 mg of soybean oil per day (3 gr soya oil per day) by mouth for 12 weeks.
62232691|NCT03939455|EXPERIMENTAL|Experimental|Participants will complete a brief tablet-based intervention, which includes watching a 5 minute educational video on the importance of HIV testing, and respond via tablet computer to the offer of an HIV test.
62232692|NCT03939455|NO_INTERVENTION|Treatment as usual|Participants will be offered an HIV test by hospital staff, and will respond face-to-face.
62232693|NCT02330783|EXPERIMENTAL|Bevacizumab plus Sorafenib|Bevacizumab 5mg/kg Q2w Sorafenib 400mg Bid
62032660|NCT02943603|EXPERIMENTAL|mFOLFX6 + Pembrolizumab|Subjects will receive mFOLFOX6 every 2 weeks (on Days 1, 15, 29, 43) and Pembrolizumab every 3 weeks (on Days 1, 22, 43).
62032661|NCT04542343|EXPERIMENTAL|Risk Reduction of COVID-19 Among African American Parishioners|"This arm will implement one group pretest-posttest design to improve COVID associated health outcomes of AA older parishioners in collaboration with trained young church-based health educators."
62032662|NCT03212105|ACTIVE_COMPARATOR|60 Second Video|The mindfulness intervention is a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
62032663|NCT03212105|OTHER|Educational Pamphlet|The educational pamphlet contains information about pain and stress, which patients will be able to read within 60 seconds.
62032664|NCT00857324|EXPERIMENTAL|ZMP|Combination with Vorinostat, Melphalan and Prednisone
62032665|NCT06120764|EXPERIMENTAL|Guided imagery group|Participants will receive guided imagery intervention.
62032666|NCT06120764|NO_INTERVENTION|Control|Participants will receive routine care.
62032667|NCT02065531|EXPERIMENTAL|Myofascial Soft Tissue Release|Protocol: Transverse Plane-Level Clavicular Release. Diaphragmatic Transverse Plane Release. Square the Lumbar Fascia Release. Gluteal Fascia Release. Hint Of Pubic Region Release. Fascia Psoas Release. Lumbo-sacral Decompression. Pelvic Floor Release.
62232694|NCT02330783|ACTIVE_COMPARATOR|Sorafenib|Sorafenib 400mg Bid
62232695|NCT05847725|EXPERIMENTAL|Elastic bandaging|Patients who have undergone TKA for primary knee OA
62232696|NCT05847725|EXPERIMENTAL|Short stretch bandaging|Patients who have undergone TKA for primary knee OA
62232697|NCT05847725|EXPERIMENTAL|Kinesio taping|Patients who have undergone TKA for primary knee OA
62423906|NCT01866137||no treatment|no treatment
62423907|NCT05706454|EXPERIMENTAL|Ramatroban 75 mg tablet|
62423908|NCT05706454|PLACEBO_COMPARATOR|Placebo|
62423909|NCT01139892||Surgical management|Surgical clipping will be performed within 6 weeks of randomization, according to standards of practice, and under general anaesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, bypasses, and other flow-redirecting treatments that do not directly clip the aneurysm will not be included.
62232698|NCT02216643|EXPERIMENTAL|thrombectomy|mechanical thrombectomy with stentriever Solitaire FR® and/or thromboaspiration with Penumbra System® in patients with large vessel occlusion in cerebral anterior circulation vessels
62423910|NCT01139892||Endovascular management|Endovascular treatment will be performed within 6 weeks of randomization, according to standards of practice, and under general anaesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling or stents, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
62423911|NCT01376180||Subjects prescribed lamotrigine tablet|Subjects with epilepsy prescribed lamotrigine tablet during study period
62032668|NCT02065531|ACTIVE_COMPARATOR|Mobilization with impulse technique|Subject in lateral decubitus with extension and lower limb traction contact the couch with contralateral lower limb was performed triple flexion and left trunk rotation. This technique reduces the slack (tension joints) of the ventral pelvis, head and into the contralateral side of the sacrum support (base) with the forearm.
62232699|NCT02216643|NO_INTERVENTION|best medical treatment|best medical treatment in patients with acute ischemic stroke with anterior circulation large vessel occlusion
62232700|NCT06248346||dexmedetomidine|dexmedetomidine group: abbreviated for dexmedetomidine group, refers to the group with intraoperative administration of dexmedetomidine adjunct to propofol
62232701|NCT06248346||non-dexmedetomidine|non-dexmedetomidine group: abbreviated for non-dexmedetomidine group, refers to the group without intraoperative administration of dexmedetomidine adjunct to propofol
62232702|NCT04896112|EXPERIMENTAL|Patient with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 15 mg|Single dose of LNK01002 15 mg; followed by a 3-day observation period then 15mg BID in 28-day treatment cycles
62232703|NCT04896112|EXPERIMENTAL|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 30 mg|LNK01002 30 mg twice daily (BID), followed by a 3-day observation period then 30 mg BID in 28-day treatment cycles
62423912|NCT04430101|ACTIVE_COMPARATOR|Negative WB radiographs and stress fluoroscopy|"Cohort 1~Negative weight bearing radiographs:~Interval between medial cuneiform and base of the second metatarsal (C1-M2) are less than 2mm increased compared to the uninjured side.~Negative stress fluoroscopy: the midfoot is tested stable"
62232704|NCT04896112|EXPERIMENTAL|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 60 mg|LNK01002 60 mg BID, followed by a 3-day observation period then 60 mg BID in 28-day treatment cycles
62232705|NCT04896112|EXPERIMENTAL|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 100 mg|LNK01002 100 mg BID, followed by a 3-day observation period then 100 mg BID in 28-day treatment cycles
62808998|NCT04061122||EX - / ECTS -|Patients without COPD exacerbation in last 6 months; quited tobacco smoking at least 12 months earlier
62032669|NCT04169737|ACTIVE_COMPARATOR|Arm I (acalabrutinib, venetoclax, obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28. Beginning cycle 3, patients receive venetoclax PO BID on days 1-28. Patients who are BM MRD4-positive or in PR also receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 15 and day 1 of cycles 16-20. Treatment repeats every 28 days (or 42 days for cycle 14) for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
62032670|NCT04169737|EXPERIMENTAL|Arm II (acalabrutinib, venetoclax, early obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28 beginning cycle 2 and venetoclax PO BID on days 1-28 beginning cycle 3. Patients also receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and day 1 of cycles 2-6. Patients who are BM MRD4-positive or in PR receive obinutuzumab IV over 4-6 hours on day 1 cycles 15-20. Treatment repeats every 28 days (or 42 days for cycle 14) for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
62232706|NCT04896112|EXPERIMENTAL|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 150 mg|LNK01002 150 mg BID, followed by a 3-day observation period then 150 mg BID in 28-day treatment cycles
62232707|NCT04896112|EXPERIMENTAL|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 200 mg|LNK01002 200 mg BID, followed by a 3-day observation period then 200 mg BID in 28-day treatment cycles
62232708|NCT04896112|EXPERIMENTAL|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 260 mg|LNK01002 260 mg BID, followed by a 3-day observation period then 260 mg BID in 28-day treatment cycles
62232709|NCT04896112|EXPERIMENTAL|Patients with Acute Myeloid Leukemia With Mutant FLT3|LNK01002 at the RP2D dose in 28-day treatment cycles
62232710|NCT04896112|EXPERIMENTAL|Patients with Malignant Myeloid Hematologic Neoplasms Without Mutant FLT3|LNK01002 at the RP2D dose in 28-day treatment cycles
62232711|NCT04896112|EXPERIMENTAL|Patients with Primary or Secondary Myelofibrosis,PV|LNK01002 at the RP2D dose in 28-day treatment cycles
62232712|NCT04643860||General population|Subjects, at low and high risk of SARS-Cov-2, who undergo the nasopharyngeal swab procedure for the diagnosis of SARS-CoV-2 infection will be consecutively recruited at the Clinic Laboratory of IRCCS Neuromed in Pozzilli and Diagnostica Medica Spa in Avellino, Italy.
62232713|NCT00679653|ACTIVE_COMPARATOR|1|verapamil/trandolapril
62593013|NCT04375722|EXPERIMENTAL|tACS 10 Hz low frequency|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS with 10-Hz stimulation for 20-minutes with 1 milliampere (mA) peak-to-peak intensity. Stimulation will be maintained no longer than 20 minutes.
62032671|NCT03710915|EXPERIMENTAL|HG146 capsule treat multiple myeloma|"Experimental: 5/10/15/20 mg HG146 capsule 5 mg starting dose taken orally on Day 1, 3, 5, 7, 9, 11, 13 of each cycle, and off drug for 8 days (3 weeks).~Intervention: Drug: HG146 capsule"
62032672|NCT05281380|OTHER|Intervention with vitamin supplement|Intervention with vitamin supplement Multi-E and Multi-G
62032673|NCT03397264|EXPERIMENTAL|Ph 1b: 2.0 mg aflibercept with 0.3 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 0.3 mg OPT-302 intravitreal injection (0.05 mL)
62032674|NCT03397264|EXPERIMENTAL|Ph 1b: 2.0 mg aflibercept with 1.0 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 1.0 mg OPT-302 intravitreal injection (0.05 mL)
62232714|NCT00679653|ACTIVE_COMPARATOR|2|metoprolol/HCT
62232715|NCT00679653|ACTIVE_COMPARATOR|3|felodipine/ramipril
62232716|NCT04174144||TLIF group|Participants with degenerative spondylolysthesis who underwent a single-level TLIF procedure.
62232717|NCT02880033|ACTIVE_COMPARATOR|Parkinson's disease|ex vivo analysis of lymphocytes from 30 patients with Parkinson's disease with deferiprone and placebo treatment
62232718|NCT02880033|ACTIVE_COMPARATOR|Amyotrophic lateral sclerosis|ex vivo analysis of lymphocytes from 30 patients with Amyotrophic lateral sclerosis with deferiprone and placebo treatment
62232719|NCT02880033|PLACEBO_COMPARATOR|healthy age and sex matched controls|ex vivo analysis of lymphocytes from 30 healthy age and sex matched controls with deferiprone and placebo treatment
62232720|NCT05303350||e_FLS|Patients detected by an automated patient detection tool with a web-based platform
62808999|NCT01292941|ACTIVE_COMPARATOR|Active comparator/Yellow catheter|SpeediCath coated catheter
62809000|NCT01292941|EXPERIMENTAL|NonCE marked intermittent catheter/red|
62809001|NCT01292941|EXPERIMENTAL|NonCE marked intermittent catheter/green|
62809002|NCT01292941|EXPERIMENTAL|NonCE marked intermittent catheter/Blue|
62809003|NCT00614575||BI-Sifrol® Tablets (Pramipexole)|BI-Sifrol® Tablets, pramipexole dose: 0.125 mg, 0.5 mg, No reference therapy
62809004|NCT04847843|EXPERIMENTAL|Mindfulness Orientated Recovery Enhancement (MORE) Intervention|8-week MORE intervention adapted for preventing weight regain
62232721|NCT05303350||FLS|Control group / Conventional group : Patients followed in a conventional fracture liaison department
62232722|NCT05291767|EXPERIMENTAL|Diet: high fat meal|Participants will consume either a high fat or a high carbohydrate meal.
62232723|NCT05291767|EXPERIMENTAL|Exercise: medium intensity exercise|After consuming the meal, participants will either exercise at moderate intensity for 30 minutes or rest.
62232724|NCT01444209|EXPERIMENTAL|Radiation Therapy|Interstitial Radioactive Iodine Implants
62232725|NCT02700945|ACTIVE_COMPARATOR|Reveal LINQ™ Insertable Cardiac Monitor|Subjects randomized to the Reveal LINQ™ Insertable Cardiac Monitor arm will be continuously monitored via the inserted Reveal LINQ™ device.
62232726|NCT02700945|NO_INTERVENTION|Control Arm|Subjects randomized to the control arm will be followed per site specific standard of care.
62232727|NCT01136811|EXPERIMENTAL|Computer assisted surgery|
62423913|NCT04430101|ACTIVE_COMPARATOR|Negative WB radiographs / positive stress fluoroscopy|"Cohort 2~Negative weight bearing radiographs:~Interval between medial cuneiform and base of the second metatarsal (C1-M2) are less than 2mm increased compared to the uninjured side.~Positive stress fluoroscopy: manual testing reveals midfoot instability"
62809005|NCT04847843|ACTIVE_COMPARATOR|Control Intervention|8-week control intervention based on the Diabetes Prevention Program's Prevent T2 for Life program.
62232728|NCT01474499|EXPERIMENTAL|Docusate sodium and sorbitol rectal solution|
62232729|NCT01474499|ACTIVE_COMPARATOR|Glycerine|
62809006|NCT02639494|EXPERIMENTAL|Self-Centering Guide Catheter|Subjects who provided written informed consent and an attempt is made to insert the Self-Centering Guide Catheter into the subject's femoral artery.
62232730|NCT05128734|EXPERIMENTAL|Temozolomide Arm|Temozolomide: 50 mg/m2 daily in cycles of 21 days
62232731|NCT05128734|EXPERIMENTAL|Temozolomide+Olaparib Arm|Temozolomide 75 mg/m2 day 1 to day 7 with Olaparib 200 mg BID, oral, day 1 to day 7 in cycles of 21 days
62232732|NCT03993860|EXPERIMENTAL|Intervention arm|Infants will be given fish powder called Chisense (Potamothrissa acutirostris) for a period of 6 months from the time they are 6 months up to the time they are 12 months.
62232733|NCT03993860|PLACEBO_COMPARATOR|Control arm|Infants will be given fish powder called sorghum powder for a period of 6 months from the time they are 6 months up to the time they are 12 months.
62232734|NCT01037244|PLACEBO_COMPARATOR|Placebo|
62232735|NCT01037244|EXPERIMENTAL|Udenafil 50 mg|
62423914|NCT04430101|OTHER|Surgical cohort (Cohort 3)|Patients with positive weightbearing radiographs will be operated on with minimally invasive technique and followed up as an independent cohort.
62423915|NCT05496101|OTHER|Breast Cancer undergoing BCS|Intraoperative CLI + FAR LightPath imaging compared with Standard-of-care histopathology (gold standard)
62423916|NCT03643406|EXPERIMENTAL|Mental Fatigue Condition|
62423917|NCT03643406|PLACEBO_COMPARATOR|Control Condition|
62423918|NCT00788684|EXPERIMENTAL|ABT-263 + rituximab|
62809007|NCT06306833|EXPERIMENTAL|sEMG Biofeedback Intervention|Participants in the intervention group will receive biofeedback surface EMG (sEMG) therapy as an alternative therapy to reduce chronic low back pain
62232736|NCT01037244|EXPERIMENTAL|Udenafil 100 mg|
62232737|NCT01037244|EXPERIMENTAL|Udenafil 150 mg|
62232738|NCT00402597|EXPERIMENTAL|001|Rivaroxaban 1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
62232739|NCT00402597|EXPERIMENTAL|002|Rivaroxaban/Placebo 1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
62232740|NCT00402597|PLACEBO_COMPARATOR|003|Placebo 1 placebo tablet twice daily for 6 months.
62232741|NCT01378923|EXPERIMENTAL|Values-based mindfulness group|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
62232742|NCT01378923|OTHER|Treatment as usual|has access to standard jail interventions and programs
62232743|NCT04086433||Arm A - Echelon Stapler|"Excised gastric tissue specimens will be resected with the Echelon Stapler (Ethicon, size: 60mm, Echelon) and evaluated for burst pressure and staple malformation"
62232744|NCT04086433||Arm B - Titan Stapler|"Excised gastric tissue specimens will be resected with the Titan SGS Stapler (Standard Bariatrics, Titan) and evaluated for burst pressure and staple malformation"
62232745|NCT01592864|EXPERIMENTAL|Arm 1|Dentifrice containing stannous fluoride
62809008|NCT06306833|NO_INTERVENTION|Control|Participants in the control group will receive usual care
62032675|NCT03397264|EXPERIMENTAL|Ph 1b: 2.0 mg aflibercept with 2.0 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 2.0 mg OPT-302 intravitreal injection (0.05 mL)
62032676|NCT03397264|EXPERIMENTAL|Ph 2a: 2.0 mg aflibercept with 2.0 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 2.0 mg OPT-302 intravitreal injection (0.05 mL)
62032677|NCT03397264|SHAM_COMPARATOR|Ph 2a: 2.0 mg aflibercept with sham|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by sham intravitreal injection
62423919|NCT02365818|EXPERIMENTAL|CG0070|Single arm intervention with CG0070 to be given at a dose of 1e12 vp weekly for six weeks. Patients who achieve a partial response or a complete response at 6 months post first intravesical intervention will be maintained with the same induction cycle of weekly times six. Patients will be followed every 3 months through Month 24.
62423920|NCT03851731|EXPERIMENTAL|Naltrexone|Subject received a single intranasal dose of 2 mg naltrexone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
62423921|NCT03851731|EXPERIMENTAL|Naloxone|Subject received a single intranasal dose of 4 mg naloxone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
62423922|NCT03851731|EXPERIMENTAL|Naltrexol|Subject received a single intranasal dose of a combination of 2 mg naltrexone and 4 mg naloxone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
62423923|NCT01241266||1|Target subject population are the consecutive patients hospitalized due to peptic ulcer bleeding. Subjects should be: ≥18 years; admitted to the hospital with an overt upper GI bleed (hematemesis/coffee ground vomiting, melena, hematochezia and other clin
62809009|NCT04497649|EXPERIMENTAL|Sofosbuvir and Daklatasuvir|Sofosbuvir and Daklatasuvir with standard of care treatment
62809010|NCT04497649|NO_INTERVENTION|Standard of care treatment|Standard of care treatment
62032678|NCT02125526|ACTIVE_COMPARATOR|IABP group|After primary percutaneous coronary intervention, IABP will be implanted for 12-24 hours to alleviate persisting ischemia
62032679|NCT02125526|NO_INTERVENTION|Control group|After primary percutaneous coronary intervention, this group undergoes standard treatment according to the guidelines
62032680|NCT03122418|EXPERIMENTAL|Exercise Study Group|All subjects in this study will receive a personal fitness device and be asked to participate in some routine exercise. Each participant will be compared to their own initial CFQ-R score (to measure quality of life) before and after use of the personal fitness device.
62032681|NCT03453398|EXPERIMENTAL|Group 1|Shifts over 24-hours, shift cycle of 5 days (morning, afternoon, night, night off, rest).
62032682|NCT03453398|EXPERIMENTAL|Group 2|Shifts over 24-hours, shift cycle of 10 days (morning, morning, afternoon, afternoon, rest, night, night, night off, rest, rest).
62032683|NCT03453398|ACTIVE_COMPARATOR|Group 3|Only diurnal shifts, shift cycle of 5 days (morning, afternoon, morning, afternoon, morning, rest, rest).
62032684|NCT04383496|EXPERIMENTAL|Physical Activity|In-person, virtual conferencing, and telephone sessions, wearable device for daily feedback and motivation
62032685|NCT05557942|EXPERIMENTAL|Placebo Crossover AV-101 10 mg|Participants who previously received placebo in AV-101-002 received AV-101 (imatinib) 10 milligrams (mg) administered twice daily (BID) via dry powder inhalation.
62032686|NCT05557942|EXPERIMENTAL|Placebo Crossover AV-101 35 mg|Participants who previously received placebo in AV-101-002 received AV-101 (imatinib) 35 mg administered BID via dry powder inhalation.
62032687|NCT05557942|EXPERIMENTAL|Placebo Crossover AV-101 70 mg|Participants who previously received placebo in AV-101-002 received AV-101 (imatinib) 70 mg administered BID via dry powder inhalation.
62032688|NCT05557942|EXPERIMENTAL|Continuing AV-101 10 mg|Participants who previously received AV-101 10 mg in AV-101-002 received AV-101 (imatinib) 10 mg administered BID via dry powder inhalation.
62032689|NCT05557942|EXPERIMENTAL|Continuing AV-101 35 mg|Participants who previously received AV-101 35 mg in AV-101-002 received AV-101 (imatinib) 35 mg administered BID via dry powder inhalation.
62032690|NCT05557942|EXPERIMENTAL|Continuing AV-101 70 mg|Participants who previously received AV-101 70 mg in AV-101-002 received AV-101 (imatinib) 70 mg administered BID via dry powder inhalation.
62032691|NCT01815164|ACTIVE_COMPARATOR|Hypnotherapy|Hypnotherapy
62032692|NCT01815164|ACTIVE_COMPARATOR|Educational intervention|Educational intervention
62032693|NCT02148250|EXPERIMENTAL|100 Syringe Units, then 200|Participants randomized to first receive 100 syringe units of U-500 regular insulin, then 200 units
62423924|NCT04619069|ACTIVE_COMPARATOR|Arm 1: Standard of Care|Intermittent Hormone treatment (minimum of 8 months)
62423925|NCT04619069|EXPERIMENTAL|Arm 2: SBRT to mets|"Intermittent Hormone treatment (minimum of 8 months)~+ SBRT to all sites of metastatic disease"
62423926|NCT00377715|EXPERIMENTAL|Dimebon|Dimebon 20 mg three times a day x 26 weeks
62423927|NCT00377715|PLACEBO_COMPARATOR|Placebo|Placebo 20 mg three times a day x 26 weeks
62819543|NCT05532150|EXPERIMENTAL|Operative group|The operative group will undergo an arthroscopic Bankart repair, which is type of surgery used to repair a dislocated shoulder.
62232746|NCT01592864|ACTIVE_COMPARATOR|Arm 2|Marketed dentifrice containing Sodium Monofluorophosphate
62232747|NCT04530331|EXPERIMENTAL|Intervention group|Providing nutrition education.
62423928|NCT06390423||Fluid responder|Stability of vasopressor dose with maximum of 500 cc of crystalloids
62423929|NCT06390423||Fluid non responder|Escalating dose of vasopressors despite 1 L of crystalloid fluid challenge
62232748|NCT04530331|NO_INTERVENTION|Control group|Without any intervention.
62423930|NCT01254994|ACTIVE_COMPARATOR|Control group|The patients were prescribed the tradition comprehensive medical treatment without entecavir.
62423931|NCT01254994|EXPERIMENTAL|ETV group|All the patients were prescribed the tradition comprehensive medical treatment with entecavir. Entecavir was supplied by the Sino-US Shanghai Squibb Pharmaceutical Co., Ltd. Patients took 0.5 mg entecavir following oral fasting one time per day.
62423932|NCT03526185|EXPERIMENTAL|Cohort 1|"* Subjects will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide (60 mg/kg/day IV) on days -7 and -6 and fludarabine (25 mg/m2/day) on days -5 through -1.~* Prophylactic antibiotics will be administered as medically indicated until recovery of ANC to \> 500 and recovery of ALC to \> 400~* On day 0 subjects will receive the infusion of autologous TIL and one hour later (but can be delayed up to 24 hours) will begin low-dose aldesleukin (IL-2) (72,000 IU/kg IV every 12 hours for up to 10 doses)."
62423933|NCT03526185|EXPERIMENTAL|Cohort 2|"* Subjects will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide (60 mg/kg/day IV) on days -7 and -6 and fludarabine (25 mg/m2/day) on days -5 through -1.~* Prophylactic antibiotics will be administered as medically indicated until recovery of ANC to \> 500 and recovery of ALC to \> 400~* On day 0 subjects will receive the infusion of autologous TIL and one hour later (but can be delayed up to 24 hours) will begin low-dose aldesleukin (IL-2) (72,000 IU/kg IV every 12 hours for up to 10 doses).~* Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment."
62423934|NCT03023098|EXPERIMENTAL|Drug-eluting balloon|
62032694|NCT02148250|EXPERIMENTAL|200 Syringe Units, then 100|Participants randomized to first receive 200 syringe units of U-500 regular insulin, then 100 units
62032695|NCT05440526|ACTIVE_COMPARATOR|Herbst Group|• Group I: Include ten young adult orthodontic patients who are treated by using fixed orthodontic appliances followed by the type IV Herbst appliance (mini plate anchored appliance). The age of patients will be (18-20y).
62032696|NCT05440526|ACTIVE_COMPARATOR|TFBC Group|• Group II: Include ten young adult orthodontic patients who are treated by using fixed orthodontic appliances followed by the Twin Force Bite Corrector appliance (dentally anchored appliance). The age of patients will be (18-20y).
62032697|NCT01327326|ACTIVE_COMPARATOR|TMD patients|"Intervention:~* Drug: Naltrexone~* Drug: placebo"
62032698|NCT01327326|ACTIVE_COMPARATOR|Healthy controls|"Intervention:~* Drug: Naltrexone~* Drug: placebo"
62032699|NCT00887497|EXPERIMENTAL|Catheterization|Patients receive angioembolization prior to surgery
62032700|NCT06670937|EXPERIMENTAL|study group|This is the single arm of this study. Patients with non-CF bronchiectasis will provide 1) an induced sputum sample after inhaling 15 ml of 0.9% NaCl solution and 2) a blood sample.
62232749|NCT03217305|OTHER|NAVA vs Pressure Support|Control (pressure support) - NAVA - Control (Pressure Support) Intervention is NAVA
62232750|NCT01684267|EXPERIMENTAL|Healthy|Healthy individuals
62232751|NCT01684267|EXPERIMENTAL|Post-stroke|Chronic stroke survivors
62819544|NCT05532150|ACTIVE_COMPARATOR|Non-operative group|The non-operative group will undergo physical therapy following a specific rehabilitation schedule.
62819545|NCT06446882|OTHER|Arm A: Treatment by physician´s choice without the diagnostic test results|Treatment by physician´s choice, blinded to the diagnostic HER2DX test results
62819546|NCT06446882|EXPERIMENTAL|Arm B: Personalized treatment according to molecular diagnosis with HER2DX|Personalized treatment according to molecular diagnosis with non-blinded HER2DX results
62232752|NCT05222607||Facial treatment with incobotulinumtoxinA in treatment naïve participants|
62232753|NCT03765411||Open Proctectomy Patients|Patients who underwent Proctectomy through an open approach
62232754|NCT03765411||Laparoscopic Proctectomy Patients|Patients who underwent Proctectomy through a Laparoscopic approach
62232755|NCT03765411||Robotic Proctectomy Patients|Patients who underwent Proctectomy through a Robotic approach
62232756|NCT01414777|EXPERIMENTAL|ondansetron|ondansetron 8 mg IV will be administered prior to placement of the spinal anesthesia
62232757|NCT01414777|PLACEBO_COMPARATOR|Placebo|Ondansetron 8 mg IV or Placebo will be administered prior to placement of the spinal anesthestic
62232758|NCT04829929|EXPERIMENTAL|One arm|Patients with Non-Valvular Atrial Fibrillation and High Bleeding Risk
62232759|NCT02404207|ACTIVE_COMPARATOR|Soybean oil|
62232760|NCT02404207|EXPERIMENTAL|High-oleic soybean oil|
62232761|NCT02404207|EXPERIMENTAL|High-oleic soybean oil + fully hydrogenated soybean oil|
62232762|NCT02404207|ACTIVE_COMPARATOR|Palm olein + palm stearin|
62232763|NCT03011502|EXPERIMENTAL|Experimental arm|
62819547|NCT04644224|EXPERIMENTAL|Group I (coaching session, navigation session, support group)|Parents/caregivers whose churches are randomized to Group I, attend monthly health coaching sessions over 1 hour each for 12 months, 9 resource navigation sessions over 12 months, and monthly support groups for 12 months.
62819548|NCT04644224|EXPERIMENTAL|Group II (coaching session, navigation session, support group)|Families whose churches are randomized to Group II, attend monthly health coaching sessions over 1 hour each for 12 months, 9 resource navigation sessions over 12 months, and monthly support groups for 12 months.
62819549|NCT04644224|ACTIVE_COMPARATOR|Group III (educational handbook)|Families whose churches are randomized to Group III, receive an educational handbook on cancer prevention.
62819550|NCT05264857|EXPERIMENTAL|Thyroid nodule information|
62232764|NCT06099847|EXPERIMENTAL|Chronic Pelvic Pain Patients with TENS|19 patients with chronic pelvic pain have been received sacral TENS intervention.
62232765|NCT06099847|SHAM_COMPARATOR|Chronic Pelvic Pain Patients with Sham Stimulation|19 patients with chronic pelvic pain have been received sham stimulation intervention.
62423935|NCT03023098|ACTIVE_COMPARATOR|Conventional PTA|
62032701|NCT05136573|EXPERIMENTAL|Combined Exercises on Symptoms of CIPN, Fatigue, and Quality of Life in Colon Cancer Patients|The control group received routine care and maintenance of general daily activities; the experimental group received routine care and maintenance of general daily activities, and also received combined exercises
62032702|NCT03353935||NERVE SPARING|Patients who underwent surgery for deep endometriosis were submitted to surgical procedures aiming at sparing the pelvic ortho- and parasympathetic nerves. The subjects were then followed with interviews using validated questionnaires, to assess the possible changes in post-operative urinary sexual and fecal function.
62232766|NCT00213291|EXPERIMENTAL|1|
62423936|NCT03180346|ACTIVE_COMPARATOR|Single-Use Negative Pressure Wound Therapy|
62809011|NCT04001712|EXPERIMENTAL|early caffeine citrate group|preterm neonates who require respiratory support either nasal canula, continuous positive airway pressure (CPAP) or mechanical ventilation.were given caffeine citrate upon start of the respiratory support Caffeine citrate was given at a loading dose of 10 mg/kg and with a daily maintenance dose of 5 mg/kg until the patient was off respiratory support
62423937|NCT03180346|ACTIVE_COMPARATOR|Standard of Care|
62423938|NCT06537856|EXPERIMENTAL|Intervention|Prior to the intervention, both the control and intervention groups were interviewed face-to-face and completed the Cardiovascular Disease Risk Awareness Rating Scale (CDRAAS), the Cardiovascular Disease Risk Factor Knowledge Level Scale (CARRF-KL) and the EQ-5D Quality of Life Scale. The intervention group then received health belief model-based cardiovascular disease risk factor prevention training. This training, conducted by the researcher, was carried out in 3 sessions, including interactive question-answer sessions. After the training, a total of 39 reminder text messages were sent to the intervention group via WhatsApp 2-3 times a week for 12 weeks.
62232767|NCT02630888|ACTIVE_COMPARATOR|Memantine|Patients randomized to this group will receive a dose of 15 mg / day of memantine during the first week (V0); all have the dose of memantine increased on the second week (V1) at the dose of 30 mg / day (in two divided doses of 15 mg).
62809012|NCT04001712|ACTIVE_COMPARATOR|late caffeine citrate group|preterm neonates who require respiratory support either nasal canula, continuous positive airway pressure (CPAP) or mechanical ventilation.were given caffeine citrate 6 hours before weaning of respiratory support
62232768|NCT02630888|PLACEBO_COMPARATOR|Placebo|Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine.
62809013|NCT05754034|EXPERIMENTAL|High flow oxygen|Heated and humidified oxygen delivered via high flow oxygen device through nasal cannula, up to 60 liters per minute of flow.
62809014|NCT05754034|ACTIVE_COMPARATOR|Standard flow oxygen|Oxygen delivered via standard oxygen devices at standard flows up to 15 liters per minute: nasal cannula, face mask, or nonrebreather mask.
62809015|NCT01081691|EXPERIMENTAL|001|CNTO 5825 0.1 mg/kg single dose Intravenously (IV) or matching placebo
62232769|NCT02910154|EXPERIMENTAL|Weight loss, training, medication|"The intervention program consists of a comprehensive 24-week treatment period of: 1) Body weight loss without significant loss of muscle mass, through low energy diet combined with 2) Exercise training based on interval training and resistance exercise and 3) Optimal medical treatment for hypertension and hypercholesterolemia (with statin and ACE-inhibition). Further, participants in this allocation group receive nutrition counselling.~The diet products are sponsored by Cambridge Weight Plan. No persons with interest in Cambridge Weight Plan will take part in the intervention phase, analyzing phase, data processing, or publication of data in this study."
62809016|NCT01081691|EXPERIMENTAL|002|CNTO 5825 0.3 mg/kg single dose IV or matching placebo
62809017|NCT01081691|EXPERIMENTAL|003|CNTO 5825 1 mg/kg single dose IV or matching placebo
62809018|NCT01081691|EXPERIMENTAL|004|CNTO 5825 3 mg/kg single dose IV or matching placebo
62809019|NCT01081691|EXPERIMENTAL|005|CNTO 5825 10 mg/kg single dose IV or matching placebo
62809020|NCT01081691|EXPERIMENTAL|006|CNTO 5825 For atopic patient:10 mg/kg single IV dose or matching placebo
62809021|NCT01081691|EXPERIMENTAL|007|CNTO 5825 For atopic patient: 3 mg/kg single dose SC or matching placebo
62809022|NCT05087771|ACTIVE_COMPARATOR|Oral naltrexone|patients will receive a 30 day supply of oral naltrexone 50 mg daily at hospital discharge. This medication was FDA approved in 1984 for the treatment of alcohol use disorder
62809023|NCT05087771|EXPERIMENTAL|injectable naltrexone|patient will receive 360 mg injection of naltrexone prior to hospital discharge
62809024|NCT04404426|EXPERIMENTAL|L-citrulline|Administration of citrulline enterally for 7 days
62809025|NCT04404426|PLACEBO_COMPARATOR|Placebo|Administration of placeboenterally for 7 days
62809026|NCT01066975||young and fit|5 healthy subjects, age lower than 30 yrs and high physical fitness
62032703|NCT01334801||Aortic Stenosis|Restricted aortic valve motion and a peak Doppler aortic velocity \> 2.5 m/sec blood draw
62423939|NCT06537856|NO_INTERVENTION|No intervention|No intervention was given to the control group. After the education given to the intervention group and the reminder text messages sent for 12 weeks, the intervention and control groups were asked to fill out the Cardiovascular Disease Risk Awareness Rating Scale (CDRAAS), Cardiovascular Disease Risk Factor Knowledge Level Scale (CARRF-KL) and EQ-5D Quality of Life Scale again in the same week. After the post-tests were taken, the control group also received training.
62423940|NCT00188279|EXPERIMENTAL|MnDCT|
62423941|NCT02905318|EXPERIMENTAL|Palbociclib|125mg orally days 1-21 every 28 day cycle
62809027|NCT00942903|EXPERIMENTAL|Compliant HME users|Laryngectomized patients who are currently compliant (24/7) users of a Provox HME
62809028|NCT01884077|ACTIVE_COMPARATOR|Reverse Shoulder Arthroplasty|Shoulder Joint Replacement Reverse Arthroplasty Implant to surgically replace arthritic shoulder
62809029|NCT01884077|ACTIVE_COMPARATOR|Total Shoulder Arthroplasty|Shoulder Joint Replacement Total Arthroplasty Implant used to surgically replace osteoarthritic shoulder joint
62809030|NCT00871767|EXPERIMENTAL|1|40 or 100mg AZD5672, Reference formulation
62809031|NCT00871767|EXPERIMENTAL|2|40 or 100mg AZD5672, Test formulation
62809032|NCT06005935||Participants with Lewy body dementia|50 women and 50 men with a clinical diagnosis of Lewy body dementia (Parkinson's disease dementia or dementia with Lewy bodies) will be included. If assistance is needed to complete the survey, care partners can help, however, they cannot answer the questions on the participant's behalf without the participant's contribution.
62809033|NCT06005935||Controls|50 women and 50 men with normal cognition and without Parkinson's disease will be included. Normal cognition will be determined using a screening questionnaire in the beginning of the survey to determine eligibility.
62809034|NCT04303455||Study group|"The study will evaluate a cohort of participants meeting the following inclusion criteria:~1. Admission to ICU after elective and emergency cardiac surgery following cardiopulmonary bypass~2. Age 18 years and above~3. Arterial, central venous and pulmonary arterial catheters have been inserted as part of routine care~Data collection, serum renin among routine blood collection on admission, 6 and 24 hours after admission to ICU"
62809035|NCT00648336|EXPERIMENTAL|1|Mercaptopurine 50 mg
62809036|NCT00648336|ACTIVE_COMPARATOR|2|Purinethol® Tablets 50 mg
62032704|NCT01334801||Aortic regurgitation|Echocardiographic and Doppler evaluation revealing aortic regurgitation with data adequate to calculate regurgitant volume
62032705|NCT01334801||Aortic valve replacement|Mechanical or biological aortic valve replacement
62032706|NCT01334801||Mitral regurgitation|Echocardiographic and Doppler evaluation revealing mitral regurgitation with data adequate to calculate regurgitant volume
62032707|NCT01334801||Mitral valve replacement|Mechanical or biological mitral valve replacement
62032708|NCT01334801||Hypertrophic cardiomyopathy|Patients with known hypertrophic cardiomyopathy who are referred for clinically indicated echocardiography
62032709|NCT01334801||Severe TR with pacemaker / ICD lead|Patients referred for clinically indicated echocardiography who have severe tricuspid regurgitation associated with a pacemaker or defibrillator lead documented by echocardiography
62032710|NCT01334801||Prosthetic valve dysfunction|Patients with prior heart valve replacement or repair referred for clinically indicated echocardiography who demonstrate stenosis, regurgitation, dehiscence.
62809037|NCT06274463|EXPERIMENTAL|Brain disease|
62809038|NCT04886323|EXPERIMENTAL|cold atmospheric plasma treatment group|Patients are treated with a plasma device. Each treatment time was 3min per area based on the lesion size.The frequency of treatment is once a day. The duration of the treatment period is 2weeks.
62809039|NCT04886323|ACTIVE_COMPARATOR|Itraconazole capsules treatment group|Patients are treated with Itraconazole capsules, 200mg a day.The duration of the treatment period is 2weeks.
62809040|NCT02040623|ACTIVE_COMPARATOR|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
62809041|NCT02040623|ACTIVE_COMPARATOR|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
62809042|NCT02040623|PLACEBO_COMPARATOR|Placebo|Placebo Ophthalmic Solution 2 drops per eye twice a day
62809043|NCT02368665|EXPERIMENTAL|AML 5mg|- Amlodipine 5mg, once a day for 8 weeks
62423942|NCT05805956|EXPERIMENTAL|IMM2902|"Phase 1 is the dose escalation part, patients with HER2 expressing solid tumors will be enrolled in groups of different dose levels, to explore MTD, RP2D, safety, and preliminary efficacy of IMM2902.~Phase 2 is the cohort expansion part, patients with HER2 overexpressing advanced solid tumors will be enrolled in three cohorts, to explore the safety and efficacy of IMM2902."
62809044|NCT02368665|EXPERIMENTAL|AML 5mg / CC 16mg|- Amlodipine 5mg and Candesartan cilexetil 16mg, once a day for 8 weeks
62809045|NCT02368665|EXPERIMENTAL|AML 10mg / CC 16mg|- After 8 weeks of treatment period, Amlodipine 10mg and Candesartan ceilexetil 16mg, once a day for 8 weeks
62809046|NCT05143840|EXPERIMENTAL|Asciminib|"Asciminib 80mg taken orally once a day starting cycle 1 day 1 for up to 24 months during the single agent asciminib phase.~Patients who have not achieved MR4.5 after 24 months will be given a low dose tyrosine kinase inhibitor (low-TKI). There will be three options of low-TKIs to be given at the investigator's discretion."
62809047|NCT05129748|EXPERIMENTAL|Standard Cisplatin-based Chemotherapy + Sodium Thiosulfate + Mannitol|Participants will receive the standard of care (cisplatin-based chemotherapy) plus the experimental treatment of Sodium Thiosulfate and Mannitol. Both drugs will be administered IV 4 - 8 hours following chemotherapy treatment, as part of post-chemotherapy hydration.
62809048|NCT05129748|NO_INTERVENTION|Standard Cisplatin-based Chemotherapy|Participants will receive the standard of care (cisplatin-based chemotherapy) only.
62809049|NCT03936114|EXPERIMENTAL|SMART|
62809050|NCT01295359|EXPERIMENTAL|Trained Group|This group will receive the usual care of the hospital and a ground walking training program associated with respiratory exercises.
62809051|NCT01295359|NO_INTERVENTION|Usual Care Group|This group will only receive the usual care of the hospital, including physical therapy
62423943|NCT02320838|EXPERIMENTAL|5 KHz|"Transcutaneous application of 5 KHz current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
62809052|NCT03309878|EXPERIMENTAL|Arm I (pembrolizumab, mogamulizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 and mogamulizumab IV over 60 minutes on days 1, 8, and 15 of cycle 1, then day 1 of subsequent courses. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62809053|NCT03309878|EXPERIMENTAL|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62809054|NCT02319941|EXPERIMENTAL|Low dose ticagrelor|60mg bid
62593014|NCT04375722|EXPERIMENTAL|tACS 40 Hz high frequency|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS with 40-Hz stimulation for 20-minutes with 1 milliampere (mA) peak-to-peak intensity. Stimulation will be maintained no longer than 20 minutes.
62809055|NCT02319941|ACTIVE_COMPARATOR|standard dose ticagrelor|90mg bid
62809056|NCT02319941|ACTIVE_COMPARATOR|standard dose clopidogrel|75mg qd
62809057|NCT06298084|EXPERIMENTAL|Part 1a (safety run-in module 0)|Patients with HER2-low ABC who have progressed on T-DXd. Patients in part 1a will receive intravenous infusion of HER3-DXd monotherapy (5.6 mg/kg every 21 days)
62809058|NCT06298084|EXPERIMENTAL|Part 1b (dose finding module 1 + dose expansion module 0)|In the dose expansion part, patients will receive the RP2D defined in the dose finding part of different combinations (module 1) and HER3-DXd single agent 5.6 mg/kg IV D1 every 21 days in module 0.
62809059|NCT06298084|EXPERIMENTAL|Part 2 (dose expansion module 1 + module 0)|In the dose expansion part, patients will receive the RP2D defined in the dose finding part of different combinations (module 1) and HER3-DXd single agent 5.6 mg/kg IV D1 every 21 days in module 0.
62809060|NCT02203877|PLACEBO_COMPARATOR|Maltodextrin|1 capsule/day for 16 weeks
62809061|NCT02203877|EXPERIMENTAL|Lactobacillus fermentum CECT5716|L.fermentum 3,00E+09cfu/day. 1 capsule/day for 16 weeks
62809062|NCT00468299|ACTIVE_COMPARATOR|Misoprostol and placebo|Women in this arm receive placebo and misoprostol 800 mcg buccally
62809063|NCT00468299|EXPERIMENTAL|Mifepristone and misoprostol|Womwn in this group receive mifepristone 200 mg orally and misoprostol 800 mcg buccally
62809064|NCT04351217|EXPERIMENTAL|Music|Music was Indian Classical Flute music, 23 minutes long. It was played on a speaker at equal volume to ensure uniformity.
62809065|NCT04351217|EXPERIMENTAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation was recorded for uniformity of delivery, and was 22 minutes in length. It was played on a speaker at equal volume to ensure uniformity.
62809066|NCT00333775|EXPERIMENTAL|Docetaxel 100 mg/m^2 plus placebo|Participants received docetaxel 100 mg/m\^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
62232770|NCT02910154|NO_INTERVENTION|Control|The control group receives 24 weeks of usual care according to guidelines of Danish Cardiology Society. Treatment of angina pectoris in absence of coronary artery disease is normally provided by the patient's general practitioner and does not comprise intensive lifestyle intervention or medical treatment. If control group participants in this study need medical therapy for hypertension or hypercholesterolemia, this will be effectuated by the researcher, MD. Then, control participants will be monitored with blood pressure and LDL blood samples and receive medicine adjustments according to National Prevention Guidelines during the full study period.
62232771|NCT03289377|EXPERIMENTAL|RDAD training to APNs|Half-day workshop to provide APNs with all skills necessary to conduct RDAD in their clinical settings. A subset of the trained APNs will implement RDAD as part of their ongoing care of persons with ADRD.
62032711|NCT01334801||Normal controls|Patients with no heart murmur or history of valve replacement, stenosis, regurgitation, or hypertrophic cardiomyopathy
62232772|NCT02800239|EXPERIMENTAL|Active, adolescent females|Subjects will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
62809067|NCT00333775|EXPERIMENTAL|Docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg|Participants received docetaxel 100 mg/m\^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
62232773|NCT02225496|EXPERIMENTAL|Transoral Robotic Surgery (TORS)|Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm. Functional assessment performed at pre-treatment, within 1-4 weeks post-op from TORS (before adjuvant therapy), and after completion of treatment at the following time points: 6 months (±2 months), 12 months (±2 months), and 24 months (±6 months). Functional measures include video-fluoroscopic examination of swallowing (modified barium swallow \[MBS\] study) with administration of the Performance Status Scale-Head and Neck (PSS-HN) and MD Anderson Dysphagia Inventory (MDADI) questionnaire.
62232774|NCT00744185|PLACEBO_COMPARATOR|2|30-days placebo treatment
62593015|NCT04375722|SHAM_COMPARATOR|tACS sham|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion for 10 to 30 seconds and then ramped down. In this way, the participants experience the same initial sensations (mild tingling) as the active tACS groups.
62593016|NCT04248140|EXPERIMENTAL|WiFi - Sham|first Intervention WiFi, second intervention sham
62593017|NCT04248140|EXPERIMENTAL|Sham - WiFi|first intervention sham, second intervention WiFi
62809068|NCT00333775|EXPERIMENTAL|Docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg|Participants received docetaxel 100 mg/m\^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
62809069|NCT05425056|EXPERIMENTAL|Treatment Arm|Subjects randomized to the treatment arm will undergo AV fistula surgery and will receive the Sirolimus eluting Collagen Implant (SeCI).
62032712|NCT01334801||Left ventricular assist device patients|Patients with previously implanted LVAD
62032713|NCT01334801||Renal dialysis patients|Patients on hemodialysis, peritoneal dialysis, or chronic kidney disease with dialysis fistula to be created.
62032714|NCT04024618|ACTIVE_COMPARATOR|Parenteral Nutrition|Patients who have been randomized to receive PN will be started on day 5 post AHSCT. This will be if patient intake is \< 80% of usual oral intake at that time. The central venous catheter required for PN administration will be already in place for AHSCT treatment, prior to admission and pre-transplant evaluation. Nutritional support will continue until oral intake is \>50% or until the patient is ready for discharge if intake remains \< 50% of recommendations.
62232775|NCT00744185|EXPERIMENTAL|1|30-days propranolol treatment
62232776|NCT05239351|EXPERIMENTAL|Jalucomplex 1|Sixteen patients will be administered Jalucomplex® 1 for the treatment of minor-sized facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects)
62232777|NCT05239351|EXPERIMENTAL|Jalucomplex 2|Sixteen patients will be administered Jalucomplex® 2 for the treatment of medium-sized facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects)
62232778|NCT05239351|EXPERIMENTAL|Jalucomplex 3|Sixteen patients will be administered Jalucomplex® 3 for the treatment of major-sized facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects)
62232779|NCT05535465|EXPERIMENTAL|Intervention arm|Heath system strengthening with additional trained mobile health care worker to help community health workers
62232780|NCT05535465|NO_INTERVENTION|Standard of care|National strategy to control malaria
62232781|NCT02907138|EXPERIMENTAL|Medical Yoga|Medical Yoga Group therapy for eight weeks, 60 minutes per week, with the guidance of a physical therapist.
62232782|NCT02907138|ACTIVE_COMPARATOR|Treatment as Usual (physical therapy)|Treatment as Usual provided by physical therapist
62593018|NCT06422663||Moderate-to-Severe Asthma|enroll 500 subjects
62593019|NCT01443338|ACTIVE_COMPARATOR|Triptergium Wilfordii|a kind of traditional chinese medicine
62593020|NCT01443338|ACTIVE_COMPARATOR|Acitretin|
62593021|NCT04483375|EXPERIMENTAL|anti-SARS-CoV-2 monoclonal antibody(SCTA01)|SCTA01: single dose on Day0
62809070|NCT05425056|NO_INTERVENTION|Control Arm|Subjects randomized to the control arm will undergo AV fistula surgery alone and will not receive an implant.
62809071|NCT00763113|EXPERIMENTAL|1|Vanguard PS Knee
62809072|NCT00763113|ACTIVE_COMPARATOR|2|Vanguard CR Knee
62809073|NCT02530021||Heart rate monitor|"Hospitalized patients with chest pain and suspected ischemic heart disease who are candidates for non invasive exercise stress test by their treating physician.~The patients will perform a one hour heart rate variability monitoring prior to the stress test."
62032715|NCT04024618|EXPERIMENTAL|Enteral Nutrition|Patients who have been randomized to receive EN will have a Nasogastric tube (NGT) inserted on day 5 post AHSCT, prior to start of Enteral feeds. This would be a polyurethane tube, 8-10 French, which will be inserted by physician or Nurse Practitioner with position confirmed by radiological examination. This will be if patient intake is \< 80% of usual oral intake at that time. Nutritional support will continue until oral intake is \>50% or until the patient is ready for discharge if intake remains \< 50% of recommendations.
62032716|NCT00228020|EXPERIMENTAL|Basiliximab|Patients will be on a regimen of Basiliximab, MMF, cyclosporine and steroids
62593022|NCT04483375|PLACEBO_COMPARATOR|Placebo|Placebo: single dose on Day0
62593023|NCT02926729|EXPERIMENTAL|Experimental|Standard lumpectomy followed by nonlinear microscopy imaging of excised surgical margins. If invasive cancer or DCIS at or close to the margin is detected, additional excision may be performed.
62593024|NCT02926729|ACTIVE_COMPARATOR|Control|Standard lumpectomy without nonlinear microscopy imaging.
62593025|NCT04131309|EXPERIMENTAL|Daratumumab|"Daratumumab monotherapy 16 mg/kg intravenous infusion (iv) or 1800 mg subcutaneous injection (sc) weekly for Cycles 1-2, every 2 weeks for Cycles 3-6 and every 4 weeks thereafter.~Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive, in addition to daratumumab, bortezomib (for a maximum of 6 cycles) and low dose dexamethasone."
62032717|NCT00228020|ACTIVE_COMPARATOR|Basiliximab-free|Patients will be on a regimen of MMF, cyclosporine and steroids.
62593026|NCT02263248|EXPERIMENTAL|venlafaxine XR plus buprenorphine|Drug Intervention: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks.
62593027|NCT02263248|PLACEBO_COMPARATOR|venlafaxine XR plus placebo|Drug Intervention: venlafaxine XR plus placebo Dosage varies . Subject remains on antidepressant throughout the 32 weeks study. Will be randomized to buprenorphine or placebo for up to 16 weeks
62593028|NCT05830981|NO_INTERVENTION|Phase 1|n=600
62032718|NCT06196268|EXPERIMENTAL|core strengthening exercise|Patients in Group A will receive core strengthening exercises along with the warm up exercises (lumbar stretches). CSE will constitute of abdominal hollowing, Side Bridge, supine extension bridge, straight leg rise from prone, alternate arm and leg raise from quadruped, and prone bridge. Total treatment will be of 60 mins with thrice a week for 6 weeks.
62032719|NCT06196268|EXPERIMENTAL|Pilates exercise|Patients in Group B will receive Pilates exercises along with warm up exercises which includes hundreds, one leg stretch, shoulder bridge, hip twist, scissors, side kicks. Total treatment will be of 60 mins with thrice a week for 6 weeks.
62032720|NCT06378346|PLACEBO_COMPARATOR|Observational Arm 1|10 participants will be randomized to observational arm
62032721|NCT06378346|EXPERIMENTAL|Glycyrrhizin Arm 2|25 participants will be randomized to receive 75mg daily for 6 weeks (+/- 2 weeks)
62032722|NCT06378346|EXPERIMENTAL|Glycyrrhizin Arm 3|25 participants will be randomized to receive 150mg daily for 6 weeks (+/- 2 weeks)
62032723|NCT03282448|EXPERIMENTAL|Family therapy|Adolescent mothers and their family members will receive a total of 10 weekly, 30-minute, video-based family therapy sessions.
62032724|NCT03282448|NO_INTERVENTION|Historical comparison group|The Edinburgh Postnatal Depression Scale scores of adolescent mothers in the intervention group will be compared to those of adolescent mothers, who were previously enrolled in the home visiting programs, at the same time points.
62032725|NCT01427868|EXPERIMENTAL|LB80380 maleat salt|
62032726|NCT01427868|ACTIVE_COMPARATOR|LB80380 free base|
62032727|NCT03727633|EXPERIMENTAL|Treatment arm|hepatic intra-arterial injection of an emulsion of Idarubicine and Lipiodol
62032728|NCT06415656|EXPERIMENTAL|Patients with hematologic malignancies|Patients who are scheduled to receive CAR-T or BiTE through the Duke Adult Blood and Bone Marrow Transplant (ABMT) and Hematologic Malignancies Program.
62032729|NCT02995772|ACTIVE_COMPARATOR|Neoadjuvant hormonal therapy|Neoadjuvant hormonal therapy: Aromatase inhibitors (Arimidex, Femara, Aromasin), Tamoxifen, SOB and AI, SOB and Tamoxifen
62593029|NCT05830981|ACTIVE_COMPARATOR|Phase 2|n=504
62809074|NCT04383509|EXPERIMENTAL|Cognitive control training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
62809075|NCT04383509|ACTIVE_COMPARATOR|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
62232783|NCT04905147|ACTIVE_COMPARATOR|The mosapride group|The mosapride group received 15 mg of mosapride by mouth or feeding via NG with 50 ml of water three times a day, starting on the morning of postoperative day 1, until hospital discharge or for a maximum of 10 postoperative days if the patient remained hospitalized.
62232784|NCT04905147|PLACEBO_COMPARATOR|The control group|The control group received 15 mg of placebo drug with 50 ml of water three times a day, starting on the morning of postoperative day 1, until hospital discharge or for a maximum of 10 postoperative days if the patient remained hospitalized.
62232785|NCT02397811|EXPERIMENTAL|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
62232786|NCT02397811|EXPERIMENTAL|Liposomal Astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 2.66 grams per dose
62232787|NCT02397811|EXPERIMENTAL|Standard Softgel|Standard softgel containing 4 mg per softgel. 3 softgels per dose
62232788|NCT02397811|EXPERIMENTAL|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
62232789|NCT02397811|EXPERIMENTAL|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
62232790|NCT02397811|EXPERIMENTAL|Standard Softgel with Astaxanthin Gel|Statndard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 softgels per dose
62232791|NCT01244451|EXPERIMENTAL|Bendofa|Bendamustine + Ofatumumab
62232792|NCT05240352|EXPERIMENTAL|active tDCS|
62232793|NCT05240352|SHAM_COMPARATOR|sham tDCS|
62593030|NCT03475121|EXPERIMENTAL|Low Risk Patients|Patients with IRSS stage I, pT1, pT2 and pT3 stage will not receive adjuvant therapy
62593031|NCT03475121|EXPERIMENTAL|Higher Risk Patients|Patients with IRSS stage I, pT3b, pT3c, pT3d will receive 6 cycles of adjuvant chemotherapy plus 6 doses of intrathecal topotecan
62809076|NCT02608658|EXPERIMENTAL|Interventional Arm|The experimental arm of this study will involve all patients in this study. Subjects will be evaluated in a clinical setting and undergo a brief healthcare questionnaire, blood work, and a breath test. Subjects will then take a medical food (EnteraGam) twice daily for 8 weeks total, after which they will be seen in clinic at 4 weeks for follow up and then at 8 weeks to repeat the healthcare questionnaire, breath tests, and blood draw.
62232794|NCT01453426|EXPERIMENTAL|Chinese Subjects - Dose 1 BG00012|
62232795|NCT01453426|EXPERIMENTAL|Chinese Subjects - Dose 2 BG00012|
62232796|NCT01453426|EXPERIMENTAL|Japanese Subjects - Dose 1 BG00012|
62232797|NCT01453426|EXPERIMENTAL|Japanese Subjects - Dose 2 BG00012|
62232798|NCT01453426|EXPERIMENTAL|Caucasian Subjects - Dose 1 BG00012|
62232799|NCT01453426|EXPERIMENTAL|Caucasian Subjects - Dose 2 BG00012|
62232800|NCT01440374|EXPERIMENTAL|Part 1, Open Label|100 mg daily (50 mg for subjects of East Asian heritage), intrasubject dose escalations to a maximum dose 300 mg (150 mg for subjects of East Asian heritage) are allowed.
62232801|NCT01440374|EXPERIMENTAL|Part 2, eltrombopag arm|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
62232802|NCT01440374|EXPERIMENTAL|Part 2, placebo arm|100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
62593032|NCT03475121|EXPERIMENTAL|Stage II Patients|Patients with Stage II (pT4) will receive 6 cycles of adjuvant chemotherapy plus 6 doses of intrathecal topotecan and orbital radiotherapy
62593033|NCT03475121|EXPERIMENTAL|Patients with buphthalmus|Patients with buphthalmus (cT3c, cT3e) will receive 2 cycles of neo-adjuvant chemotherapy plus 6 doses of intrathecal topotecan followed by secondary enucleation and 6 cycles of adjuvant chemotherapy.
62232803|NCT01440374|EXPERIMENTAL|part 3 extension|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
62232804|NCT01171105|EXPERIMENTAL|1|AZD5213 (dose escalating)
62232805|NCT01171105|PLACEBO_COMPARATOR|2|Placebo
62232806|NCT03057808|EXPERIMENTAL|Gestational weight gain intervention (GWG-only)|The GWG intervention will begin upon randomization to the GWG-only or the GWG+PPWL arm, and continue until the birth of the participant's child.
62232807|NCT03057808|EXPERIMENTAL|Postpartum weight loss intervention (PPWL-only)|The PPWL intervention will begin at 6-weeks postpartum (when most women will be approved for weight loss and exercise by their obstetrician) for those participants randomized to the PPWL only or the GWG+PPWL arms, and will continue until 6-months postpartum.
62232808|NCT03057808|EXPERIMENTAL|Combined|During the gestational phase participants will receive the same intervention as the GWG only group. During the postpartum phase participants will receive the the same intervention as the PPWL group.
62232809|NCT05809817||Intervention (Periodontal treatment)|Patients with T2DM under follow-up in the PSCV will receive the usual periodontal therapy performed at the CEMO Villa Sur in the commune of Pedro Aguirre Cerda and at the CESFAM Puerto Varas in the context of PSCV. The care protocols and national evidence establish that the standard treatment of periodontitis consists of 4 or more sessions of scaling and root planing per sextant, depending on the severity of the disease.
62232810|NCT05809817||Control (Matched, non-active intervention)|Patients with T2DM under follow-up in the PSCV, with non-active control (withouth periodontal treatment) that will be matched in a ratio of 1:1 through Propensity Score Matching according to baseline HbA1c levels and demographic baseline data (age, sex).
62232811|NCT00759291|ACTIVE_COMPARATOR|Acipimox|Acipimox treatment QID for 7 days
62232812|NCT00759291|PLACEBO_COMPARATOR|Placebo|Placebo treatment QID for 7 days
62232813|NCT01679574|EXPERIMENTAL|letrozole|Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
62232814|NCT01679574|ACTIVE_COMPARATOR|Metformin and clomiphene|".Drug: metformin (Cidophage®; CID,Cairo, Egypt) metformin 1500 daily for 3 months~* Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation"
62593034|NCT01258062|EXPERIMENTAL|of GelVac™ nasal powder H5N1 influenza vaccine.|
62593035|NCT01258062|PLACEBO_COMPARATOR|Placebo|
62232815|NCT06240091|EXPERIMENTAL|DISC-MA|All participants will be asked to download and use the DISC-MA study application. They will have access to the app throughout the 4 week study.
62232816|NCT00592085|ACTIVE_COMPARATOR|Relapse Prevention Counseling|Motivational Relapse Counseling: 6 counseling calls over two weeks accompanied by questionnaires
62593036|NCT03461419|EXPERIMENTAL|Microcannula Harvest Adipose Stroma|Acquisition of AD-tSVF via closed syringe microcannula
62232817|NCT00592085|ACTIVE_COMPARATOR|Relapse Prevention + Alcohol Counseling|Motivational Relapse Prevention Plus Alcohol Risk Reduction Counseling: 6 counseling calls over two weeks for both smoking cessation and at-risk alcohol use accompanied by questionnaires
62232818|NCT03227796|EXPERIMENTAL|Cohort 1 Healthy Volunteers Active|LEVI-04 0.003 mg/kg single intravenous dose Healthy Volunteers
62232819|NCT03227796|EXPERIMENTAL|Cohort 2 Healthy Volunteers Active|LEVI-04 Dose Level 2 (planned 0.01 mg/kg) single intravenous dose Healthy Volunteers
62232820|NCT03227796|EXPERIMENTAL|Cohort 3 Healthy Volunteers Active|LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Healthy Volunteers
62232821|NCT03227796|EXPERIMENTAL|Cohort 4 Osteoarthritis Patients Active|LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Osteoarthritis Patients
62232822|NCT03227796|EXPERIMENTAL|Cohort 5 Osteoarthritis Patients Active|LEVI-04 Dose Level 4 (planned 0.1 mg/kg) single intravenous dose Osteoarthritis Patients
62593037|NCT03461419|EXPERIMENTAL|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via enzymatic isolation/concentration closed system to create cellular stromal vascular fraction (cSVF)
62593038|NCT03461419|EXPERIMENTAL|Sterile Normal Saline IV|Re-suspension of cSVF pellet in Sterile Normal Saline Intravenous Delivery
62423944|NCT02320838|EXPERIMENTAL|TENS|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are frequency 110 Hz and pulse width 200 microseconds"
62809077|NCT05574023|EXPERIMENTAL|Predictive Alarm (PA)|Patients use the CGM sensor with Predictive Alarm on set at 70 mg/dl in 20 minutes for hypoglycemia and at 250 mg/dl in 20 minutes for hyperglycemia.
62593039|NCT06328881|EXPERIMENTAL|Intermittent Oro-esophageal Tube+Comprehensive rehabilitation training|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding"
62809078|NCT05574023|ACTIVE_COMPARATOR|Alarm on Threshold (AoT)|Patients use the CGM sensor with alarms on a threshold of 70 mg/dl for hypoglycemia and 250 mg/dl for hyperglycemia.
62809079|NCT00786292|OTHER|Noisy PSV|Assisted mechanical ventilation with noisy PSV
62809080|NCT00786292|OTHER|PSV|Assisted mechanical ventilation with PSV
62809081|NCT04944459|EXPERIMENTAL|Muse-S|multi-sensor neurofeedback-assisted mindfulness training device (Muse-S)
62809082|NCT03839368|EXPERIMENTAL|K plate|fixation of angle fracture using K plate versus two miniplates
62809083|NCT03839368|ACTIVE_COMPARATOR|Conventional two miniplates|fixation of angle fracture using K plate versus two miniplates
62809084|NCT05608603||3 months postcovid patients|"Included 100 patients, aged 18-80 years old, at 3 months after infection COVID-19.~Intervention: cardiorespiratory stress test to determine the patient's oxygen consumption; electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark; the analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria)."
62809085|NCT05608603||9 months postcovid patients|"Included the same 100 patients, aged 18-80 years old, at 9 months after infection COVID-19.~Intervention: cardiorespiratory stress test to determine the patient's oxygen consumption; electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark; the analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria)."
62809086|NCT01796925|EXPERIMENTAL|aura6000 THN Therapy|The aura6000 THN system will be implanted and activated for nightly therapy during sleep.
62809087|NCT01464086|NO_INTERVENTION|Standard arm|standard follow-up
62809088|NCT01464086|EXPERIMENTAL|Intensive follow-up|Standard follow-up plus whole body MRI at inclusion, one and two years
62809089|NCT05478421|NO_INTERVENTION|Control group|Patients in control group will be treated by cyst enucleation.
62809090|NCT05478421|EXPERIMENTAL|Collagen sponge group|Cystic lesions in collagen sponge group will be filled by collagen sponge.
62809091|NCT05478421|EXPERIMENTAL|GBR group|Cystic lesions in GBR group will be filled by deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and covered by absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG).
62809092|NCT05478421|EXPERIMENTAL|CS/GBR group|Cystic lesions in GBR group will be filled by collagen sponge and deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and covered by absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG).
62809093|NCT01446627||metal staples|
62232823|NCT03227796|EXPERIMENTAL|Cohort 6 Osteoarthritis Patients Active|LEVI-04 Dose Level 5 (planned 0.3 mg/kg) single intravenous dose Osteoarthritis Patients
62809094|NCT01446627||Insorb vicryl staples|
62809095|NCT05326451|EXPERIMENTAL|active tDCS|
62809096|NCT01803425||Synflorix™ cohort|Only those subjects to whom Synflorix™ will be administered as per normal clinical practice, according to the locally approved PI, will be included in the study.
62809097|NCT01013129||Probands|
62809098|NCT01958996|EXPERIMENTAL|idarubicin|
62232824|NCT03227796|EXPERIMENTAL|Cohort 7 Osteoarthritis Patients Active|LEVI-04 Dose Level 6 (planned 1.0 mg/kg) single intravenous dose Osteoarthritis Patients
62809099|NCT03095079|EXPERIMENTAL|EDP|Dacarbazine,DTIC： 250 mg/m2/d，IV, d1-5 Cisplatin PDD：75 mg/m2，IV Endostar ENDO：15 mg/m2/d，CIV,d1\~14
62809100|NCT02422498|EXPERIMENTAL|Concurrent Cisplatin & Radiation Therapy|
62809101|NCT03701139|EXPERIMENTAL|posterior capsulotomy|Primary posterior capsulotomy will be performed to remove the primary posterior capsule opacification after posterior capsule polishing during phacoemulsification.
62809102|NCT03701139|ACTIVE_COMPARATOR|Nd:YAG laser capsulotomy|Nd:YAG laser capsulotomy will be performed 1 month postoperative to remove the primary posterior capsule opacification.
62809103|NCT00713635||1|Fetuses and neonates with congenital heart disease consisting of hypoplastic left heart syndrome (HLHS)
62423945|NCT02320838|SHAM_COMPARATOR|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
62423946|NCT03510013|EXPERIMENTAL|1-1-8 wash-in|Wash-in using O2:N2O or O2:air 1:1 L/min with sevoflurane 8%
62809104|NCT00713635||2|Fetuses and neonates with congenital heart disease consisting of transposition of the great arteries (TGA)
62809105|NCT00713635||3|Fetuses and neonates with congenital heart disease consisting of tetralogy of fallot
62809106|NCT00713635||4|Fetuses and neonates with lung masses but without congenital heart disease will serve as a control group
62809107|NCT01723423||Expander/Implant|Patients receiving expander/implant breast reconstruction procedures.
62032730|NCT02995772|ACTIVE_COMPARATOR|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy: FAC 6 cycles
62232825|NCT03227796|EXPERIMENTAL|Cohort 8 Healthy Volunteers Active|LEVI-04 Dose Level 7 (planned 3.0 mg/kg) single intravenous dose Healthy Volunteers
62593040|NCT06328881|ACTIVE_COMPARATOR|Comprehensive rehabilitation training+Nasogastric tube|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines."
62593041|NCT03381300|OTHER|Single cohort|
62032731|NCT01044004|EXPERIMENTAL|Post treatment remission armodafinil|Armodafinil 150 mg/day for 13 weeks
62032732|NCT01044004|PLACEBO_COMPARATOR|Post treatment remission placebo|Placebo 150mg/day for 13 weeks
62032733|NCT01044004|EXPERIMENTAL|Chemotherapy armodafinil|Armodafinil 150 mg/day for 13 weeks
62032734|NCT01044004|PLACEBO_COMPARATOR|Chemotherapy placebo|Placebo 150mg/day for 13 weeks
62232826|NCT03227796|PLACEBO_COMPARATOR|Cohort 1 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
62232827|NCT03227796|PLACEBO_COMPARATOR|Cohort 2 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
62232828|NCT03227796|PLACEBO_COMPARATOR|Cohort 3 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
62232829|NCT03227796|PLACEBO_COMPARATOR|Cohort 4 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
62232830|NCT03227796|PLACEBO_COMPARATOR|Cohort 5 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
62232831|NCT03227796|PLACEBO_COMPARATOR|Cohort 6 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
62232832|NCT03227796|PLACEBO_COMPARATOR|Cohort 7 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
62232833|NCT03227796|PLACEBO_COMPARATOR|Cohort 8 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
62809108|NCT01723423||Lat Dorsi|Patients receiving latissimus dorsi breast reconstructions with or without implant.
62809109|NCT01723423||PTRAM|Patients receiving pedicle transverse rectus abdominis musculocutaneous (PTRAM)breast reconstruction.
62032735|NCT02232893|EXPERIMENTAL|Daikenchuto (TU-100)|Daikenchuto (TU-100) 5g TID (15g/day)
62032736|NCT02232893|PLACEBO_COMPARATOR|Placebo|Placebo TID
62032737|NCT04537923|EXPERIMENTAL|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
62809110|NCT01723423||FTRAM|Patients receiving free transverse rectus abdominis musculocutaneous (FTRAM.)
62232834|NCT02682641|EXPERIMENTAL|IBRUTINIB + RITUXIMAB|"Subjects will receive the ibrutinib in combination with rituximab according to the following schedule:~* Ibrutinib 560 mg daily po until disease progression or unacceptable toxicity. In case of sustained negative MRD (at least for 6 months) after 2 years of continuous therapy, ibrutinib will be discontinued.~* Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1). Rituximab 375 mg/m2 iv, day one of every cycle 3, 5, 7 and 9."
62593042|NCT04010526|EXPERIMENTAL|treatment|CD patients with complex refractory perianal fistula refractory to conventional medical and surgical therapy referred to the gastroenterology departments of the 3 centers in charge of treatment local co-administration of autologous ADIpose will be performed
62032738|NCT04537923|EXPERIMENTAL|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
62232835|NCT05727254|EXPERIMENTAL|Agility Training|16 weeks, two times per week, 1 hour of multi-component exercise training, exercise guidelines and exercise diary.
62032739|NCT04537923|EXPERIMENTAL|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
62032740|NCT04537923|ACTIVE_COMPARATOR|Insulin Lispro|Insulin lispro 100 units per milliliter (U100) administered SC three times a day.
62232836|NCT05727254|ACTIVE_COMPARATOR|Control|Exercise guidelines and exercise diary.
62032741|NCT05921968|ACTIVE_COMPARATOR|Intravenous Iron Sucrose group|"50 pregnant women will receive 200 mg elemental iron in 100 ml 0.9 NaCl intravenous over 20 -30 minutes daily up to the total dose~-The dose of the total iron sucrose to be administrated was calculated from the following formula: Total dose required = weight (kg) x (target Hb in g\\dL - actual Hb in g\\dL) x 2.4 + 500 mg rounded up to the nearest multiple of 100 mg"
62032742|NCT05921968|ACTIVE_COMPARATOR|Lactoferrin group|50 pregnant women will receive lactoferrin 100 twice daily orally .
62232837|NCT01313650|EXPERIMENTAL|GSK573719/GW642444|62.5/25mcg
62593043|NCT04010526|PLACEBO_COMPARATOR|placebo|CD patients with complex refractory perianal fistula refractory to conventional medical and surgical therapy referred to the gastroenterology departments of the 3 centers in charge of treatment local co-administration of placebo will be performed
62593044|NCT00178932|ACTIVE_COMPARATOR|1 Outcome in schizophrenia with certain antipsychotic|clozapine
62593045|NCT00178932|ACTIVE_COMPARATOR|2 Outcome in schizophrenia with other Antipsychotics|Other Antipsychotics
62809111|NCT01723423||DIEP|Patients receiving deep inferior epigastric perforator (DIEP) breast reconstructions.
62232838|NCT01313650|EXPERIMENTAL|GSK573719|62.5mcg
62232839|NCT01313650|EXPERIMENTAL|GW642444|25mcg
62232840|NCT01313650|PLACEBO_COMPARATOR|Placebo|Placebo
62423947|NCT06365931|EXPERIMENTAL|G1 (percutaneous neuromodulation)|Patients will receive a needle circuit approaching the deep peroneal nerve in an ultrasound-guided manner. They will receive a symmetrical biphasic current of 20-30Hz and 250 μs at tolerable intensity.
62032743|NCT06158750|EXPERIMENTAL|Test group|Patients can be included in the study if they meet all of the inclusion and none of the exclusion criteria and have provided written informed consent, intent to use Flow modulation device to treat intracranial aneurysm.
62032744|NCT01865370|EXPERIMENTAL|Kochujang Pills|
62032745|NCT01865370|PLACEBO_COMPARATOR|Placebo|
62032746|NCT00193934||1|Cervical Cancer Patients
62032747|NCT03989947|EXPERIMENTAL|Active BMN 111|Once daily subcutaneous injections of recommended dose of BMN 111 based on weight-band dosing.
62232841|NCT03438851|EXPERIMENTAL|Full-time Cognitive Rehabilitation Program|Participants in full-time program will be asked to complete 4 experimental sessions with the NeuroCatch Platform™ over the course of 3 months (i.e. one session/ month).
62232842|NCT03438851|EXPERIMENTAL|Part-time Cognitive Rehabilitation Program|Participants in the part-time program will be asked to complete 3 experimental sessions with the NeuroCatch Platform™ over 3 months (i.e. one session/1.5 months).
62232843|NCT03032471||DCI group|"Patients that experience DCI, defined as~1. Cerebral infarction identified on imaging or proven at autopsy, after exclusion of procedure-related infarctions; and~2. Clinical deterioration caused by DCI, after exclusion of other potential causes of clinical deterioration will be assigned to the DCI group."
62423948|NCT06365931|EXPERIMENTAL|G2 (transcutaneous neuromodulation)|Patients will have a superficial electrode circuit placed over the belly of the tibialis anterior muscle. They will receive a symmetrical biphasic current of 20-30Hz and 250 μs at tolerable intensity.
62809112|NCT01723423||SIEA|Patients receiving superficial inferior epigastric artery (SIEA)breast reconstruction.
62809113|NCT01723423||S-GAP|Patients receiving superior gluteal artery perforator breast reconstruction.
62032748|NCT04323618|OTHER|Free breathing or Breathe Well|Free breathing or Breathe Well
62032749|NCT05772546|EXPERIMENTAL|Group A - Avatromopag|"30 participants will be randomized into a 1:1 fashion and will be stratified based on the number of cytotoxic agents in the patient's chemotherapy regimen. Participants will complete study procedures as outlined:~Lead-In Period (Day 1 - 15)~* Pre-determined dose of Avatrombopag 1x daily.~* Participants failing to achieve a platelet count ≥100,000/µL within 2 weeks will be considered a treatment failure (and will proceed to the end-of-study visit).~On-Cycle Period (Day 15 - up to Week 6)~• Pre-determined dose of Avatrombopag 1x daily.~Follow-up Period~* End of Treatment on-site visit.~* Follow-up visit 30-42 days after End of Treatment visit."
62809114|NCT01723423||I-GAP|Patients receiving inferior gluteal artery perforator breast reconstruction.
62809115|NCT02472860|EXPERIMENTAL|Cognitive Training|Targeted Cognitive Training (TCT)
62032750|NCT05772546|ACTIVE_COMPARATOR|Group B - Matching Placebo|"30 participants will be randomized into a 1:1 fashion and will be stratified based on the number of cytotoxic agents in the patient's chemotherapy regimen. Participants will complete study procedures as outlined:~Lead-In Period (Day 1 - 15)~* Pre-determined dose of matching placebo 1x daily.~* Participants failing to achieve a platelet count ≥100,000/µL within 2 weeks will be considered a treatment failure (and will proceed to the end-of-study visit).~On-Cycle Period (Day 15 - up to Week 6)~• Pre-determined dose of matching placebo 1x daily.~Follow-up Period~* End of Treatment on-site visit.~* Follow-up visit 30-42 days after End of Treatment visit."
62032751|NCT01541228|ACTIVE_COMPARATOR|Group I|Patients with actinic keratosis (AK) on the left and right sides of face/scalp region treated with photodynamic therapy using 20% 5-aminolevulinic acid.
62032752|NCT01541228|ACTIVE_COMPARATOR|Group II|Patients with actinic keratosis (AK) on the left and right sides of the face/scalp region treated with photodynamic therapy using 20% 5-aminolevulinic acid.
62032753|NCT04898101|EXPERIMENTAL|Cohort 1|Participants will receive a single 100 mg oral capsule dose of acalabrutinib and at 58 minutes postdose, participants will receive a single microtracer (\<10 μg; \<=1 μCi) \[14C\]ACP-196 as a 5 mL IV push over 2 minutes.
62032754|NCT04898101|EXPERIMENTAL|Cohort 2|Participants will receive a single 100 mL oral solution of acalabrutinib, 1 mg/mL oral solution containing a microtracer dose (\<10 μg; \<=1 μCi) of \[14C\]ACP-196.
62232844|NCT03032471||non-DCI group|Patients not experiencing DCI as defined above.
62232845|NCT01059136|EXPERIMENTAL|1:Spironolactone|Aldosterone blockade on top of standard therapy
62232846|NCT01059136|NO_INTERVENTION|2:Standard therapy|Standard therapy
62232847|NCT04279938|OTHER|Safety Run in & Main Efficacy Part|"Part 1 (safety run-in) aims to evaluate the maximum tolerated dose (MTD) of tinostamustinein combination with pembrolizumab (200mg Q3W) and rituximab (375mg/m2 Q3W). The dose of tinostamustineestablished to be safe and tolerable in this combination will be used in part 2 of the trial (main efficacy part).~The aim of part 2 is to detect signals of anti-tumour activity and to further assess the safety of this combination treatment in r/r DLBCL. The study has a strong focus on correlative research in order to identify mechanisms of response and resistance to pembrolizumab and the pembrolizumab/R-tinostamustinecombination."
62232848|NCT00004660|EXPERIMENTAL|Radiotherapy|
62232849|NCT00004660|SHAM_COMPARATOR|Sham treatment|
62423949|NCT06365931|PLACEBO_COMPARATOR|G3 (placebo-percutaneous group)|Patients will receive the neuromodulation circuit with needles at 0 intensity, approaching the deep peroneal nerve in an ultrasound-guided manner
62423950|NCT06365931|PLACEBO_COMPARATOR|G4 (placebo-transcutaneous group)|Patients will have the electrodes placed over the tibialis anterior muscle at intensity 0.
62809116|NCT02472860|PLACEBO_COMPARATOR|Control Condition|Youth appropriate online games
62809117|NCT01026012|EXPERIMENTAL|Combined Protocol|patient with submaximal symptom limited maximal exercise testing will also be administered regadenoson pharmacological stress test.
62809118|NCT01859234|EXPERIMENTAL|89Zr-bevacizumab PET scan|all patients included in the study will have a 89Zr-bevacizumab PET scan
62809119|NCT01507922|EXPERIMENTAL|Fenoverine|Fenoverine 100mg three times a day will be administered for 8 weeks.
62809120|NCT01507922|ACTIVE_COMPARATOR|Trimebutine|Trimebutine maleate 150mg three times a day will be administered for 8 weeks.
62809121|NCT02854085|EXPERIMENTAL|Art Therapy|Art Therapy, 24 sessions
62032755|NCT04974164||Clinic cases group|Those with a positive RT-PCR test will be the test-positive cases or clinic cases (approximate N=700)
62032756|NCT04974164||Clinic controls group|Those with a negative RT-PCR test will be the test-negative cases or clinic controls (N=700)
62809122|NCT02854085|EXPERIMENTAL|Music Reminiscence Activity|Music Reminiscence Activity, 24 sessions
62809123|NCT02854085|NO_INTERVENTION|Control|Participants will not participate in either of the interventions and will continue life as usual.
62809124|NCT01283555|EXPERIMENTAL|User-Filled Applicator|
62809125|NCT01283555|OTHER|Prefilled applicator|
62809126|NCT05563610|EXPERIMENTAL|Oral Challenge|Patients will be screened for high vs. low risk of penicillin allergy. Low risk patients will be randomized to oral amoxicillin 500 mg challenge.
62032757|NCT00342316|EXPERIMENTAL|Stem cell transplant (RICT)|Receiving intervention consisting of Reduced Intensity Conditioning Stem Cell Transplantation
62032758|NCT00342316|NO_INTERVENTION|Control arm|Treatment according to standard of care, i.e. not undergoing RICT
62032759|NCT01586143|EXPERIMENTAL|transbuccal paracetamol 125 mg|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
62032760|NCT01586143|PLACEBO_COMPARATOR|placebo|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
62032761|NCT06580574|EXPERIMENTAL|dMMR/MSI-H gastric cancer|"PD1/PDL1 antibody monotherapy will be given per local treatment standards.~If (near-) clinical complete response is not achieved after 24 weeks of PD1/PDL1 antibody monotherapy, then combination of intensive immunotherapy plus anti-VEGF treatment will be used.~If (near-) clinical complete response is not achieved after 24 weeks of intensive immunotherapy plus anti-VEGF treatment, radical surgery will be recommended."
62032762|NCT06580574|EXPERIMENTAL|dMMR/MSI-H colon cancer|"PD1/PDL1 antibody monotherapy will be given per local treatment standards.~If (near-) clinical complete response is not achieved after 24 weeks of PD1/PDL1 antibody monotherapy, then combination of intensive immunotherapy plus anti-VEGF treatment will be used.~If (near-) clinical complete response is not achieved after 24 weeks of intensive immunotherapy plus anti-VEGF treatment, radical surgery will be recommended."
62032763|NCT01986257|EXPERIMENTAL|Emotion Regulation Group Therapy (ERGT).|
62032764|NCT00596440||1|Relatives of Cancer Patients
62032765|NCT00596440||2|Relatives of Orthopedic Patients
62032766|NCT00725296||Remicade (Infliximab)|Participants with active and progressive PsA who have responded inadequately to disease-modifying anti-rheumatic drugs will receive induction infusions of Remicade at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians. Whole observation period cannot exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in the Summary of Product Characteristics (SPC) is taken into consideration.
62809127|NCT05563610|NO_INTERVENTION|No Oral Challenge|Patients will be screened for high vs. low risk of penicillin allergy. Low risk patients will be randomized to no oral amoxicillin 500 mg challenge..
62809128|NCT02251626|EXPERIMENTAL|Coenzyme Q10 (ubiquinol)|Coenzyme Q10 (ubiquinol) group will be given 1,800 mg coenzyme Q10 (ubiquinol) per day
62809129|NCT02251626|PLACEBO_COMPARATOR|Placebo for CoQ10 (ubiquinol)|Placebo group will be given placebo only
62809130|NCT02925897|EXPERIMENTAL|Intervention|participants will receive their usual treatment from nurses who have had some training in behaviour change and motivational interviewing.
62032767|NCT00047879|OTHER|Glioblastoma multiforme stratum|Glioblastoma multiforme is one of the most common and aggressive types of brain tumor.
62032768|NCT00047879|OTHER|Anaplastic Glioma Stratum|Anaplastic glioma is a type of brain tumor that develops from star-shaped glial cells that support nerve cells. Anaplastic oligodendroglioma is a malignant type of brain tumor sensitive to treatment with chemotherapy and radiotherapy.
62423951|NCT05762120|NO_INTERVENTION|Control|Usual Care
62423952|NCT05762120|OTHER|Intervention|Weight Management Programme
62809131|NCT02925897|NO_INTERVENTION|Control|The participants will receive their usual treatment from nurses who have had no additional training in behaviour change and motivational interviewing.
62809132|NCT03308227||Experimental Group|septic shock patients;
62809133|NCT03308227||Conrol Group|non-septic shock patients;
62809134|NCT00265564|ACTIVE_COMPARATOR|Seeking Safety|Seeking Safety is a manualized, empirically supported, cognitive behavioral therapy that treats substance use disorders and comorbid PTSD. Participants assigned to the Seeking Safety arm attend two one hour sessions of group therapy for 12 weeks.
62809135|NCT00265564|ACTIVE_COMPARATOR|Usual Care|Usual Care Condition. Patients randomized to usual care will receive standard outpatient SUD treatment.
62809136|NCT03211468|EXPERIMENTAL|Intervention Program|Clinical intervention designed to prevent eating disorders and promote healthy eating habits and body image among female adolescent athletes. The intervention program will include 10 45-min interactive sessions led by the researcher. Each session will include a brief theoretical background, experiential activities (artistic or cognitive / emotional) and group discussions.
62809137|NCT03211468|NO_INTERVENTION|Control Group|No participation in intervention program.
62232850|NCT03358966||Early to moderate CKD (stage 1-3)|40 patients with CKD stage 1-3. All subjects performed a comprehensive metabolic analysis including measurement of Resting Energy Expenditure using indirect calorimetry, bioimpedance, doubly-labelled water technique and body size measures. Physical activity was assessed using a Stanford 7 day recall questionnaire.
62232851|NCT03358966||Advanced CKD (stage 4-5)|40 patients with CKD stage 4-5. All subjects performed a comprehensive metabolic analysis including measurement of Resting Energy Expenditure using indirect calorimetry, bioimpedance, doubly-labelled water technique and body size measures. Physical activity was assessed using a Stanford 7 day recall questionnaire.
62032769|NCT02216123|EXPERIMENTAL|Tafenoquine+ Chloroquine|All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg \[2×CQ 300 mg\] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily \[OD\] orally; OR, 620 mg \[4×CQ 155 mg\] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily \[OD\] orally). Tafenoquine 300mg (2×TQ 150 mg) will be given as a single oral dose on Day 1 or Day 2. Primaquine matching placebo will be given OD orally beginning on Day 1 or Day 2 and continue for 14 days total dosing. All subjects will be followed-up till 180 days.
62032770|NCT02216123|EXPERIMENTAL|Primaquine+ Chloroquine|All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg \[2×CQ 300 mg\] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily \[OD\] orally; OR, 620 mg \[4×CQ 155 mg\] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily \[OD\] orally). Primaquine 15mg will be given OD orally beginning on Day 1 or Day 2 and continue for 14 total dosing. Tafenoquine matching placebo will be given as a single oral dose on Day 1 or Day 2. All subjects will be followed-up till 180 days.
62032771|NCT03584698|EXPERIMENTAL|study group|Misoprostol + Evening primrose oil group
62032772|NCT03584698|ACTIVE_COMPARATOR|control group|Misoprostol only group
62032773|NCT04854291|EXPERIMENTAL|Donor FMT|FMT from a healthy donor
62032774|NCT04854291|PLACEBO_COMPARATOR|Placebo|NaCl + glycerol mixture (carrier solution of FMT arm)
62032775|NCT04757623|NO_INTERVENTION|Group B : conventional primary closure|allileostomies are reversed with conventional method
62032776|NCT04757623|EXPERIMENTAL|Group A: Purse string closure|the ileostomy reversal circular incision used with stitches of continuous and non-absorbable. The wound of skin was closed by using (Proline No. 1) that leaving 0.5 cm defect on middle in the skin.
62032777|NCT05131295|EXPERIMENTAL|Dapsone|Besides the standard of care, those assigned to the dapsone group received orally 100mg (2.5 ml) of dapsone suspension daily, from the admission day until the 15th-day post-ictus.
62232852|NCT00465556|EXPERIMENTAL|1|Dove Intervention
62232853|NCT00465556|ACTIVE_COMPARATOR|2|Intimate Partner Violence (IPV) Protocol
62232854|NCT05024227|EXPERIMENTAL|Experimental: nursing education interventions|nursing education interventions (including e-health platform assistance)
62232855|NCT05024227|NO_INTERVENTION|No Intervention: Routine care|Only the original form of nursing education leaflets are given
62232856|NCT01412463|EXPERIMENTAL|Protégé EverFlex+|Stenting with Protégé EverFlex+
62232857|NCT05210218|EXPERIMENTAL|mildly hypocaloric diet + CC 300 mg +WS 150 mg tid|The study product, in a capsule formulation, was made by the extract of Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively) (Nutrintech Ltd., London, UK) to be taken three times a day. All patients received a mildly hypocaloric diet (i.e., -20% of the usual caloric intake as assessed by a 24-hour dietary recall).
62232858|NCT05210218|PLACEBO_COMPARATOR|mildly hypocaloric diet + placebo tid|Each patient took the placebo (i.e., the same amount of cellulose). All patients received a mildly hypocaloric diet (i.e., -20% of the usual caloric intake as assessed by a 24-hour dietary recall).
62232859|NCT04734327|EXPERIMENTAL|Orthokine periradicular injection|Ultrasound guided injections
62232860|NCT04734327|ACTIVE_COMPARATOR|Orthokine epidural injection|Ultrasound guided injections
62809138|NCT06237582|EXPERIMENTAL|patients|"patients planned for complete cytoreductive surgery~Only one arm in the study: all patients operated for complete cytoreductive surgery and who signed informed consent form"
62809139|NCT01031719|EXPERIMENTAL|Group A: High Risk Population|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
62809140|NCT01031719|EXPERIMENTAL|Group B: High Risk Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
62809141|NCT01031719|EXPERIMENTAL|Group C: Healthy Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
62809142|NCT01031719|EXPERIMENTAL|Group D: Healthy Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
62809143|NCT06066216|EXPERIMENTAL|Cadonilimab+carboplatin/cisplatin+paclitaxel|Cadonilimab (10 mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+ carboplatin(AUC=4-5, d1, Q3W, 6cycles) or cisplatin(75 mg/m2, d1, Q3W, 6cycles), +Paclitaxel(175 mg/m2, d1, Q3W, 6cycles), every 3 weeks (21 days) is a treatment cycle
62809144|NCT05947188|EXPERIMENTAL|Sample for Circulating Tumoral Cells|Sampling of Circulating Tumoral Cells will be done
62819551|NCT03009058|EXPERIMENTAL|IMM-101 + Gem panc ca|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
62593046|NCT01450826|ACTIVE_COMPARATOR|aprepitant+ondansetron|On day 1, patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide). Additionally, On days 1-5, patients receive a single dose of Ondansetron 30 minutes before the receiving their prescribed dose of 5-day oral temozolomide.
62593047|NCT01450826|ACTIVE_COMPARATOR|ondansetron|On days 1-5, patients receive a single dose of Ondansetron 30 minutes before the receiving their prescribed dose of 5-day oral temozolomide.
62809145|NCT05252897|ACTIVE_COMPARATOR|Endoscopic step-up approach|"After endoscopic drainage of WON, patients will be reassessed 72 hours after the procedure. If there is no clinical improvement 72 hours after drain placement, a CECT is performed to check the adequacy of the drainage. Irrigation of the WON via a nasocystic drain or endoscopic irrigation (step 1) is performed in case of inadequate drainage. If a nasocystic drain is inserted, 500ml of normal saline, twice a day will be used to irrigate the WON. If endoscopic irrigation is performed, only irrigation with normal saline without necrosectomy is allowed.~Patients are again evaluated 72 hours after step 1. In case of improvement, treatment is conservative; otherwise step 2 will be initiated, which is endoscopic necrosectomy. Further endoscopic necrosectomy will be performed until there is clinical improvement."
62032778|NCT05131295|PLACEBO_COMPARATOR|Placebo|Besides the standard of care, those assigned to the placebo group received orally 2.5 ml of aluminum hydroxide gel daily, from the admission day until the 15th-day post-ictus.
62032779|NCT00297752|ACTIVE_COMPARATOR|'ceriumnitrate silversulfadiazine (flammacerium)|facial burns treatment with Cerium nitrate silver sulfadiazine
62032780|NCT00297752|ACTIVE_COMPARATOR|flammazine|facial burns treatment with silver sulfadiazine
62032781|NCT01964170|EXPERIMENTAL|ASP3550 PART 1 and PART 2|Part 1 for 1 year treatment and Part 2 for an extended period of treatment
62032782|NCT01964170|ACTIVE_COMPARATOR|Goserelin|part 1 for 1 year treatment
62032783|NCT02935335||Menopur® HP-hMG|Treatment according to routine clinical practice.
62032784|NCT03846700|EXPERIMENTAL|aquablation|patients with prostatic volume included between 30 and 120 ml will be treated with water jet (aquablation). patients with prostatic volume \> 65 ml will be compared with holep arm and patients with prostatic volume included between 30 and 65 ml will be compared with pvp arm.
62032785|NCT03846700|ACTIVE_COMPARATOR|holep|patients with prostatic volume \> 65 ml will be treated with holmium laser technique (Holep)
62032786|NCT03846700|ACTIVE_COMPARATOR|pvp|patients with prostatic volume included between 30 and 65 ml will be treated with photoselective vaporization of prostate (pvp).
62032787|NCT06245083|ACTIVE_COMPARATOR|PQQ supplement|Pyrroloquinoline quinone (PQQ) 20 mg/day
62032788|NCT06245083|PLACEBO_COMPARATOR|Placebo|Placebo supplement with soybean oil 20 mg/day
62032789|NCT04425564|ACTIVE_COMPARATOR|Classic (A)|patients recieving classic XELOX (oxaliplatin 130mg/m2 and capecitabine 1000mg/m2 bid)
62032790|NCT04425564|EXPERIMENTAL|metronomic (B)|patients recieving low dose capecitabine (2000mg daily divided in two doses for 8 weeks) and oxaliplatin (30mg/m2 weekly for eight weeks) followed by 2 weeks rest.
62032791|NCT06415955||Lower Limb Amputation|Patients with lower limb amputations, unilateral or bilateral, walking with or without technical aids, at any level (trans-femoral or trans-tibial) and hospitalised in the locomotor rehabilitation department of the Nîmes University Hospital.
62032792|NCT05918926|EXPERIMENTAL|Exercise|Remote 12-week exercise intervention
62032793|NCT05918926|NO_INTERVENTION|Control/Routine Care|No exercise intervention, continue with routine care
62032794|NCT04636255|EXPERIMENTAL|Exercise training group|Patients in the experimental group, under clinic follow up will perform combined exercise training for 16 weeks
62032795|NCT04636255|SHAM_COMPARATOR|Control Group|Patients will be only clinically followed up. They will not perform exercise training.
62032796|NCT06511232|EXPERIMENTAL|Intraosseous Injection of Morphine|The intervention group will receive an intraosseous (IO) injection of 10mg of morphine mixed with up to 100mg of saline into the tibial tubercle during a standard ACL reconstruction.
62032797|NCT06511232|NO_INTERVENTION|Standard of Care Morphine Administration|The control group will receive the standard of care treatment, which is no IO injection during a standard ACL reconstruction.
62032798|NCT04014660|ACTIVE_COMPARATOR|Probiotic group|The participants in this group are provided with a dietary supplement (capsules) containing freeze dried bacteria (active lactobacilli culture) mixed with corn starch, for daily intake (1 capsule per day).
62032799|NCT04014660|PLACEBO_COMPARATOR|Placebo group|The participants in this group are provided with a dietary supplement (capsules) containing corn starch only, for daily intake (1 capsule per day).
62032800|NCT03684629|EXPERIMENTAL|the response of KPI and corresponding suggestion|The hospitals will receive their own monthly KPI and the monthly highest KPI of all hospitals included in the study. Based on the compare of the monthly KPI of all hospitals, Quality control platform will give corresponding suggestions to all hospitals for the improve of next month. The multifaceted quality improvement interventions include: 1) implementation of standardized templates of medical record, evidence-based clinical pathway, and written care protocols; 2) feedback system of performance measures; 3) expert online consultation.
62032801|NCT03684629|NO_INTERVENTION|a control arm|The control group indicated that the hospitals will not be provided with the multifaceted quality improvement interventions. They just provide patients with routine care.
62032802|NCT05321420|PLACEBO_COMPARATOR|Placebo|Placebo oral administration
62032803|NCT05321420|ACTIVE_COMPARATOR|pirfenidone 801 mg TID|pirfenidone 801 mg TID oral administration
62032804|NCT05321420|EXPERIMENTAL|LYT-100 550 mg TID|LYT-100 (Deupirfenidone) 550 mg TID oral administration
62032805|NCT05321420|EXPERIMENTAL|LYT-100 825 mg TID|LYT-100 (Deupirfenidone) 825 mg TID oral administration
62032806|NCT05388253|EXPERIMENTAL|Static Stretching Among Plantar Fasciitis Patients|Using Static Stretching exercises
62032807|NCT05388253|EXPERIMENTAL|Deep Kneading Massage Among Plantar Fasciitis Patients|Using Deep Kneading Massage technique
62032808|NCT01220011|EXPERIMENTAL|NO INTERVENTION|
62032809|NCT01220011|ACTIVE_COMPARATOR|fetoscopic laser|
62032810|NCT06670248||Severe burn patients|Adult severely burned patients (TBSA ≥ 20%) undergoing debridement surgery.
62232861|NCT00860613|EXPERIMENTAL|1|women in this group received usual medical treatment and counseling from a nutritionist and diabetes educator. They received a specific diet using carbohydrate counting (40-45% of carbohydrates)and a moderate energy restriction. Weight gain, adequacy of diet, results of the self glucose monitoring, and ketonuria were evaluated every two weeks. They also received education on diabetes, diet and glucose monitoring.
62232862|NCT00860613|EXPERIMENTAL|2|Women in this group received usual medical treatment and counseling from a nutritionist and diabetes educator. The diet they received was based on carbohydrate counting (40-45% of carbohydrates), but recommended only low-moderate glycemic index foods. Weight gain, adequacy of diet, results of the self glucose monitoring, and ketonuria were evaluated every two weeks. They also received education on diabetes, diet and glucose monitoring.
62423953|NCT06114810|ACTIVE_COMPARATOR|Arm A : 3 doses of nOPV2 and bOPV with IPV|Participants in arm A will receive the following polio vaccines: nOPV2 +bOPV (2 drops = 0.1 ml) @ 6, 10, 14 weeks and IPV (0.5 mL) @ 14 weeks
62232863|NCT00860613|NO_INTERVENTION|3|women in this group received the current hospital treatment. They did not receive any intervention except for the self glucose monitoring that they did every two weeks. Weight gain and the results of the self glucose monitoring, were evaluated every two weeks.
62423954|NCT06114810|ACTIVE_COMPARATOR|Arm B : 2 doses of nOPV2 and bOPV with IPV|Participants in arm B will receive the following polio vaccines: nOPV2+bOPV , (2 drops = 0.1 ml) @ 6, 10 weeks and IPV (0.5 mL) @ 14 weeks
62423955|NCT06114810|ACTIVE_COMPARATOR|Arm C: Single dose of bOPV, nOPV2, IPV|Participants in arm C will receive the following polio vaccines: bOPV ( 2 drops) @ 6 week , nOPV2 (2 drops) at 10 weeks and IPV ( 0.5mL) @ 14 weeks
62423956|NCT06114810|ACTIVE_COMPARATOR|Arm D: Single dose nOPV2, IPV|Participants in arm D will receive the following polio vaccines: nOPV2 (2 drops = 0.1 ml) at 6 and 10 weeks and IPV ( 0.5mL) @ 14 weeks
62423957|NCT00319020|EXPERIMENTAL|Bosentan|Bosentan was administered at 4 mg/kg twice daily (b.i.d.) until the end of the study. It could be down-titrated to 2 mg/kg b.i.d. if not well tolerated.
62809146|NCT05252897|ACTIVE_COMPARATOR|Direct endoscopic necrosectomy approach|Patients in the DEN group will undergo an immediate endoscopic necrosectomy after LAMS placement and balloon dilatation. A 10Fr 5cm double pigtail plastic stent will be inserted within the LAMS after necrosectomy. Patients will be assessed in 72 hours after the procedure. If there is no clinical improvement, a CECT is performed to check the adequacy of the drainage. DEN will be repeated in case of inadequate drainage. Patients will be reassessed every 72 hours and DEN repeated until there is clinical improvement. Subsequently, necrosectomy is performed weekly until a reassessment CECT at 3 weeks.
62809147|NCT05136508|EXPERIMENTAL|TIVA|In the TIVA group, anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
62809148|NCT05136508|ACTIVE_COMPARATOR|Inhalation|In the volatile group, anesthesia was induced with an intravenous bolus of propofol 1.0-1.5 mg/kg and TCI of remifentanil (effect-site concentration \[Ce\] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
62809149|NCT01106599|EXPERIMENTAL|A|
62809150|NCT06301230|ACTIVE_COMPARATOR|Hospital-based surgical training group|This group represents the surgical residents who trained with PLET at the hospital.
62809151|NCT06301230|EXPERIMENTAL|Home-based surgical training group|This group represents the surgical residents who trained with PLET at home.
62809152|NCT04643275|EXPERIMENTAL|Non-invasive lipolysis of the upper arms|The treatment administration phase consists of four (4) treatment visits, delivered 5- 10 - days apart. Each therapy session will last 30 minutes. Follow-ups visits at 1 month and 3 months after the final treatment will be held.
62809153|NCT03502837||Healthy controls|age-matched right-handed healthy volunteers
62809154|NCT03502837||the mininally conscious state|Patients present reproducible signs of awareness such as purposeful eye movements or response to verbal order
62809155|NCT03502837||the vegetative state|Patients preserved autonomous functioning (e.g., preserved sleep-wake cycles),but without awareness of oneself or of the environment
62809156|NCT01033240|EXPERIMENTAL|Safety Cohort 1 CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (2 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth twice daily) over 4 weeks observation, and may continue treatment until progression.
62809157|NCT01033240|EXPERIMENTAL|Safety Cohort 2 CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (4 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth twice daily) over 4 weeks observation, and may continue treatment until progression.
62809158|NCT01033240|ACTIVE_COMPARATOR|Safety Cohort 3 CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (6 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth twice daily) over 4 weeks observation, and may continue treatment until progression.
62809159|NCT01033240|EXPERIMENTAL|Treatment Group 1 CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib. Treatment Group 1: CS-1008 (6 mg/kg \[or as determined\] loading, 2 mg/kg/week maintenance) + sorafenib twice daily (N=50)
62809160|NCT01033240|EXPERIMENTAL|Treatment Group 2 with CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib. Treatment Group 2: CS-1008 (6 mg/kg \[or as determined\] loading, 6 mg/kg/week \[or maximum tolerated dose {MTD}\] maintenance) + sorafenib twice daily (N=50)
62809161|NCT01033240|EXPERIMENTAL|Treatment Group 3 with Sorafenib Alone|Sorafenib. Treatment Group 3: sorafenib twice daily (N=50)
62819552|NCT03009058|EXPERIMENTAL|IMM-101+Gem/nab-paclitaxel panc ca|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
62423958|NCT03800186||Trauma femoral fracture|Patients to be aged ≥20 years and hospitalized for the treatment of femoral fracture following injury. Patients were grouping into five subgroups as patients with fracture of proximal type A, proximal type B, proximal type C, femoral shaft, and distal femur.
62423959|NCT04986566|EXPERIMENTAL|Arm I (telemonitoring)|Patients wear a Vivofit 4 daily for 30 days after hospital discharge for steps monitoring, and complete questionnaires over 5-7 minutes about symptoms and quality of life using the Aetonixx app up to 7 days before surgery, before being discharged from the hospital after surgery, and on days 2, 7, 14, 30 after discharge. Patients also complete pulse oximetry, temperature, blood pressure, heart rate, and weight assessment using at-home monitoring devices before surgery, then on days 2, 7, 14, 30 after discharge. Patients assessments are monitored by the surgical team in real-time to identify outcome trends, including onset, worsening/improving measures, and sporadic versus consistent measures.
62423960|NCT04986566|ACTIVE_COMPARATOR|Arm II (enhanced usual care)|Patients wear a Vivofit 4 for daily steps monitoring, and complete questionnaires over 5-7 minutes about symptoms and quality of life using the Aetonixx app up to 7 days before surgery, before being discharged from the hospital after surgery, and on days 2, 7, 14, 30 after discharge. Patients also complete pulse oximetry, temperature, blood pressure, heart rate, and weight assessment using at-home monitoring devices before surgery, then on days 2, 7, 14, 30 after discharge. Patients use standard procedures for reporting problems.
62032811|NCT03969654|ACTIVE_COMPARATOR|Robotic Assisted TKA|Robotic Assisted TKA
62032812|NCT03969654|ACTIVE_COMPARATOR|Conventional TKA|Conventional TKA
62232864|NCT03764956|EXPERIMENTAL|Low Glycemic Index therapy|Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only
62423961|NCT03791515|ACTIVE_COMPARATOR|Calcitonin Gene-Related Peptide (CGRP)|"30 patients with PPTH will be allocated to receive intravenous infusion of 1.5 µg/min calcitonin-gene related peptide over 20 minutes~Other Name: CGRP"
62423962|NCT03791515|PLACEBO_COMPARATOR|Placebo|"30 patients with PPTH wil be allocated to receive 40 mL Placebo (isotonic saline) over 20 minutes.~Other Name: Isotonic Saline"
62423963|NCT04112615||Patients and/or carers|Patients and/or their nominated carers come in to give feedback on the device and the system as a whole, from usability to design.
62423964|NCT04112615||Healthcare professionals|Healthcare professionals come in to give feedback on the device and the system, from what results they would like to see and their concerns about patients using it.
62819553|NCT03009058|EXPERIMENTAL|IMM-101+Gem+capecitabine panc ca|"IMM-101 will be given in combination with gemcitabine + capecitabine combination therapy.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
62032813|NCT02130193|EXPERIMENTAL|Part A|Subjects will receive 50 mg danirixin twice daily (BID) orally for 14 days. If the exposure to danirixin is lower than expected, after 14 days of dosing, then the dose may be increased to 75 mg BID for Part B.
62032814|NCT02130193|EXPERIMENTAL|Part B|Subjects will be randomized to receive either danirixin BID or placebo BID treatment along with standard care of treatment for 52 weeks. Subjects completing Part A and meeting the eligibility criteria for Part B could also be randomized in Part B.
62032815|NCT06139523||Group 1: Healthy adult volunteers|Healthy adult volunteers recruited from the patient population, students or employees of Duke University or Duke Eye Center (n=10)
62032816|NCT06139523||Pediatric participants|Pediatric patients with eye disease recruited from the patient population of Duke Eye Center (n=20)
62032817|NCT01681589|SHAM_COMPARATOR|Control Group|The control group will receive sham-tDCS and computerized cognitive training also twice a week for 20 minutes for 6 weeks (12 training sessions).
62593048|NCT01777828||Transcatheter Aortic Valve Implantation|FRANCE TAVI registry aims to identify all patients with a change of valves implanted catheter meets the selection criteria of the technical accepting the scheduled evaluations in the context of this disease and who have agreed to participate in the study .
62809162|NCT02900794|OTHER|Contrast Arm (Microdebridement)|Typical pre-operative intervention including injectable local anesthetic into the inferior and middle turbinates followed by topical anesthetic on soaked cottonoids or pledgets placed in the nasal cavity floor, medial to the middle turbinate, behind the uncinate process will be performed. Using endoscopy, the nasal passage is located. Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.
62032818|NCT01681589|EXPERIMENTAL|Transcranial Direct Current Stimulator (TDCS)|The experimental group will receive active tDCS for 20 minutes and computerized cognitive training twice a week for 30 minutes for 6 weeks.
62032819|NCT01681589|OTHER|Healthy Control Group|Fifteen (15) healthy control subjects will participate.
62032820|NCT05354050|EXPERIMENTAL|DARE-BV1|
62423965|NCT04103411|EXPERIMENTAL|High Intensity Interval Training (HIIT)|For the twelve weeks of intervention, participants will have three training sessions per week. Each session will be done on a cycle ergometer and will last approximately 40 minutes. Participants will be supervised by certified kinesiologists and their training programs will be revised every four weeks.
62032821|NCT06283550|EXPERIMENTAL|Abrocitinib 200 mg|Abrocitinib at dose 200 mg will be orally administered once daily for 32 weeks.
62032822|NCT06283550|EXPERIMENTAL|Abrocitinib 100 mg|Abrocitinib at dose 100 mg will be orally administered once daily for 32 weeks.
62232865|NCT03764956|ACTIVE_COMPARATOR|Modified Atkins Diet|Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio
62423966|NCT04103411|ACTIVE_COMPARATOR|HydroChloroThiazide|For this group, participants have to take a diuretic (12,5 mg of Hydrochlorothiazide) daily prescribed by the doctor of this study, for twelve weeks. Participants should also maintain the same lifestyle habits that they had before the study.
62423967|NCT04977817||Control Group|By using the Baby Steps Program, neonates less than or equal to 1500 grams and less than 32 weeks GA will be identified. The control group will contain those that did not receive probiotics.
62423968|NCT04977817||Treatment Group|By using the Baby Steps Program, neonates less than or equal to 1500 grams and less than 32 weeks GA will be identified. The treatment group will contain those neonates that did receive the probiotic nutritional supplement.
62423969|NCT02821117|EXPERIMENTAL|Intervention|FreeStyle Libre Flash Glucose Monitoring System
62423970|NCT00927979|EXPERIMENTAL|Ropivacaine|
62423971|NCT00927979|PLACEBO_COMPARATOR|Water for injection|
62423972|NCT05467865|EXPERIMENTAL|Experimental, nutrition education program|
62819554|NCT03009058|EXPERIMENTAL|IMM-101 + FOLFIRINOX panc ca|"IMM-101 will be given in combination with standard FOLFIRINOX (FOLinic acid, Fluorouracil, IRINotecan and OXaliplatin) treatment.~The treatment regimen with IMM 101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
62032823|NCT06283550|PLACEBO_COMPARATOR|Placebo then abrocitinib|Placebo will be orally administered once daily for 16 weeks (Part A) then abrocitinib 200 mg will be orally administered once daily for 16 weeks (Part B).
62032824|NCT06507293|ACTIVE_COMPARATOR|ESP Group|Patients who will receive erector spinae plane block
62032825|NCT06507293|ACTIVE_COMPARATOR|PVB Group|Patients who will receive paravertebral block
62032826|NCT06068413|EXPERIMENTAL|AI-assisted diagnosis|Doctors diagnose the focal liver lesion with the help of AI.
62032827|NCT06068413|NO_INTERVENTION|common diagnosis|Doctors diagnose the focal liver lesion without the help of AI.
62232866|NCT02876666|EXPERIMENTAL|Coach Intervention|
62232867|NCT02876666|NO_INTERVENTION|Usual Care|
62232868|NCT00334347|ACTIVE_COMPARATOR|Depakote ER|
62232869|NCT00334347|ACTIVE_COMPARATOR|Depakote DR|
62423973|NCT05467865|NO_INTERVENTION|control group|
62423974|NCT04753918|EXPERIMENTAL|Novel light delivery methods for photodynamic therapy|High refraction-index contrast medium: Lipiodol injected in the bronchial tree can enhance the treatment extension of the photodynamic therapy
62423975|NCT04160676|ACTIVE_COMPARATOR|Group I|"The patients in this group will be managed only according to the surviving sepsis campaign 2016 and the surviving sepsis campaign bundle 2018 update.~The patients will receive 50 ml normal saline I.V within 30 mins / 6 h, 10 ml normal saline I.V / 6 h, 5 ml normal saline I.V / 12 h."
62593049|NCT01865669|NO_INTERVENTION|Control|A control sample from each patient (no oxytocin applied) will be measured concurrently with samples treated with varying concentrations of oxytocin.
62593050|NCT01865669|EXPERIMENTAL|Oxytocin|Samples from each patient will be bathed in a solution containing varying concentrations of oxytocin.
62593051|NCT06137638|EXPERIMENTAL|ENA-001 Treatment Arm|ENA-001 consisting of continuous infusion of a loading dose of 2.0 mg/kg/hr for 20 minutes followed by a maintenance dose of 1.1 mg/kg/hr.
62032828|NCT06670573||25 were healthy children|25 were diagnosed with Allergic Rhinitis
62032829|NCT01892072||HCC patients|Hepatocellular carcinoma patients treated by surgical treatment
62593052|NCT06137638|PLACEBO_COMPARATOR|Placebo Treatment Arm|Matching placebo for ENA-001 will consist of the solution that is used as diluent for ENA-001. Placebo will be administered similarly consisting of continuous infusion of a loading dose of 2.0 mg/kg/hr for 20 minutes followed by a maintenance dose of 1.1 mg/kg/hr.
62593053|NCT02967289|EXPERIMENTAL|Arm A|mFOLFIRINOX Folfox Protocol + Irinotecan
62593054|NCT02967289|ACTIVE_COMPARATOR|Arm B|mFOLFOX 6 Folfox Protocol
62809163|NCT02900794|OTHER|Treatment Arm (Gold Laser)|Typical pre-operative intervention including injectable local anesthetic into the inferior and middle turbinates followed by topical anesthetic on soaked cottonoids or pledgets placed in the nasal cavity floor, medial to the middle turbinate, behind the uncinate process will be performed. Using endoscopy, the nasal passage is located. Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary. If the Investigator determines that the sinus is not sufficiently dilated or cannot be accessed, the need for and the type of additional treatment will be at the discretion of the Investigator.
62032830|NCT04359927||SARS-CoV2/Covid-19 (cases)|Patients with detectable real-time reverse transcriptase-polymerase chain reaction for SARS-CoV2/Covid-19.
62032831|NCT04359927||No SARS-CoV2/Covid-19 (controls)|Patients with undetectable real-time reverse transcriptase-polymerase chain reaction for SARS-CoV2/Covid-19.
62232870|NCT05217654|ACTIVE_COMPARATOR|Dapagliflozin|14 day orally treatment with dapagliflozin
62593055|NCT03590535||Patients with Possible ACS|Adult patients presenting to the Emergency Department with symptoms that maybe be caused by acute coronary syndrome, who are clinically considered to be at enough risk for ACS to send a cardiac enzyme as part of the diagnostic evaluation.
62593056|NCT03689543|EXPERIMENTAL|Arm 1|LY500307 at 25mg per day
62593057|NCT03689543|ACTIVE_COMPARATOR|Arm 2|LY500307 at 75mg per day
62593058|NCT03689543|PLACEBO_COMPARATOR|Arm 3|Matched placebo
62809164|NCT02750189||Mild Group|FEV₁/FVC \<70% and FEV₁≥80% direct/indirect cost
62809165|NCT02750189||Moderate Group|FEV₁/FVC \<70% and 50%≤FEV₁≤80% direct/indirect cost
62809166|NCT02750189||Severe Group|FEV₁/FVC \<70% and 30%≤FEV₁≤50% direct/indirect cost
62809167|NCT02750189||Very Severe Group|FEV₁/FVC \<70% and FEV₁\<30% direct/indirect cost
62809168|NCT06150521||The hysteroscopic myomectomy group|Patients underwent cold knife hysteroscopic myomectomy
62809169|NCT01310465|EXPERIMENTAL|Experimental group|Three days postoperatively, patients in this group are given one infusion of zoledronic acid intravenously.
62809170|NCT01310465|PLACEBO_COMPARATOR|Placebo Comparator|Three days postoperatively, patients in this group are given one infusion of sodium chloride intravenously.
62809171|NCT00866177|EXPERIMENTAL|Arm I|Patients receive oral MEK inhibitor AZD6244 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62809172|NCT03043534|EXPERIMENTAL|Gel and Brush|The Experimental group of subjects will be given the study product Pre-Shave Gel and Brush. The gel and brush will be used prior to their normal shave routine. Subjects will shave at least 3 times weekly.
62809173|NCT03043534|NO_INTERVENTION|Control|Subjects will use their normal razors and shave products during the six week study. Subjects must shave at least 3 times weekly. No change in normal shaving is done in this group
62809174|NCT04024917|EXPERIMENTAL|Coherence cardiac|
62809175|NCT04024917|ACTIVE_COMPARATOR|Standard care|
62809176|NCT05075330|EXPERIMENTAL|Intervention|Participants who live in the Orange Mound community of Memphis. Billboards targeting stigma reduction were posted in the community for one month.
62809177|NCT05075330|NO_INTERVENTION|Control|Participants who live in the Frayser community of Memphis. No billboards (intervention) were placed here.
62032832|NCT03119454||Patients receiving diprospan|Patients who are receiving diprospan in standard therapy of their existing disease, or multiple times, but following the introduction of diprospan is planned no earlier than 28 days after the first administration.
62032833|NCT03119454||Control subjects|Patients or healthy volunteers who had not received systemic or local corticosteroids in the last 12 weeks before the screening visit.
62032834|NCT04184063|EXPERIMENTAL|active treatment with NBMI|
62032835|NCT04184063|PLACEBO_COMPARATOR|Placebo|
62232871|NCT05217654|PLACEBO_COMPARATOR|Dapagliflozin-placebo|14 day orally treatment with dapagliflozin - placebo
62232872|NCT02168842|ACTIVE_COMPARATOR|Isradipine|Oral capsule of up to 5 mg of isradipine taken twice daily for 36 months.
62593059|NCT02380261|EXPERIMENTAL|Systane|Systane® Lid Wipes, 1 per eyelid, used once and discarded after each use, for 21 days
62593060|NCT01193465|EXPERIMENTAL|humidity|
62593061|NCT01605123||Lean children|n=100 (anticipated), n=70 currently Age: 6-25 years BMI-SDS: -1.88 to +1.23 , currently -0.25±0.77; Height-SDS: \> - 2 SDS, currently 0.03±1.07;
62593062|NCT01605123||Obese children|n=106 Age: 6-25 years BMI-SDS: \>1.23 , currently 2.41±0.52; Height-SDS: \> - 2 SDS, currently 0.80±1.18;
62593063|NCT01605123||Obese Exercise Group|Obese children will engage in increased physical activity (one to two lessons per week) at 40-60 and 60-80% of maximal exercise capacity (n=50 each anticipated). Within the frame of the study we will assess the effect of the exercise on cardiovascular outcomes.
62593064|NCT01605123||Classical Lifestyle Intervention|Obese children will receive a classical lifestyle intervention, including dietary, activity and psychosocial counselling (n=50 anticipated). Within the frame of the study we will assess the effect of the exercise on cardiovascular outcomes.
62593065|NCT00744588||alcohol dependence|Alcohol-dependent subjects currently being treated in an inpatient treatment facility.
62593066|NCT02683252|EXPERIMENTAL|Normal patients|Patients with normal bone appearance on conventional MR images
62032836|NCT03234426|EXPERIMENTAL|Experimental Group|manual perturbations were given in forward, Backward,right and left sideways, 10 perturbations were given,6 days in week,in fallowing positions- sitting,kneeling, standing positions
62032837|NCT03234426|PLACEBO_COMPARATOR|Control group|Conventional Physiotherapy were given 6 days in a week, for 30 mins for 4 weeks, includes stretching, strengthening of contralateral limbs
62032838|NCT03814889|ACTIVE_COMPARATOR|Acute Stimulation: Vibration pattern 1-3 and sham control|All participants try on several wearable prototypes in our laboratory that provide vibration or sham stimulation to the arm. Sensors or electrodes taped onto the arm and hand will sense muscle activity and record any changes during periods of vibration and periods with vibration turned off.
62032839|NCT03814889|ACTIVE_COMPARATOR|Longitudinal Stimulation: Vibration pattern 4|1) If the patient gets Botox injections in their hand and arm, their arm function will be measured for three months during this standard care. 2) Next, all patients will be given a wearable device to take home. The patient will wear the device while feeling vibrations for 3 hours during the day while awake for two months. During this time and 1 month after this intervention, arm function will be tested.
62032840|NCT03882476|EXPERIMENTAL|Experimental|The experimental arm will involve patients monitored by InSight.
62032841|NCT03882476|NO_INTERVENTION|Control|The control arm will have no intervention and will involve patients with the usual standard of care.
62232873|NCT02168842|PLACEBO_COMPARATOR|Placebo (for Isradipine)|Oral capsule taken twice daily for 36 months.
62232874|NCT00503659|ACTIVE_COMPARATOR|A|Methacholine challenge, five-breath dosimeter protocol
62232875|NCT00503659|ACTIVE_COMPARATOR|B|Methacholine challenge five incremental dosages protocol
62232876|NCT01800214||Alzheimer's disease (AD)|
62232877|NCT01800214||Vascular Cognitive Disorders (VCD)|
62232878|NCT01800214||Lewy Body Disease (LBD)|
62232879|NCT01800214||Frontotemporal Dementia (FTD)|Behavioral-variant Frontotemporal Dementia (bvFTD) Language-variant Frontoemporal Dementia including Semantic dementia (SD) and Progressive non-fluent aphasia (PNFA) Corticobasal degeneration (CBD) Progressive supranuclear palsy (PSP)
62232880|NCT01800214||Mild Cognitive Impairment (MCI)|
62232881|NCT01800214||Cognitively Normal (CN)|
62423976|NCT04160676|EXPERIMENTAL|Group II|The patients will receive the conventional therapy of sepsis and combined therapy of hydrocortisone (Solucortif® 100 mg , vial, dried powder Pfizer, Egypt) 50 mg diluted in 5 ml normal saline IV / 6 h, ascorbic acid (VITAMIN C-®, Amp, ROTEXMEDICA, Germany, 500mg/5ml) 1.5 gm diluted in 50 ml normal saline IV within 30 min /6 h , and thiamine (Vitamin B1-injektopas®, Ampoule, Germany, 100 mg / 2 ml) 200 mg diluted in 10 ml normal saline IV /12 h This combined therapy will be given for 4 days or to the time of discharge if the admission period is less than 4 days
62423977|NCT04147052|EXPERIMENTAL|iSLEEPms|Participants randomized to iSLEEPms complete a 4-week online program with telephone support, based on CBT-I.
62423978|NCT04147052|NO_INTERVENTION|Treatment As Usual|Participants randomized to TAU continue their usual care and are encouraged to avoid starting any new sleep treatment unless deemed necessary by a health care provider.
62809178|NCT03057496|EXPERIMENTAL|Intervention|Participants will use the collision warning device as much as possible for about one month during everyday activities, when walking indoors and outdoors.
62809179|NCT02267239|ACTIVE_COMPARATOR|Essential Oils, immersion|Professional oral cleaning Plaster cast IDODS Immersion the disk with the biofilm in the essential oils antiseptic solution
62032842|NCT05432193|EXPERIMENTAL|Dose escalation|Up to 30 patients with FAP-avid solid tumors.
62032843|NCT06118372|EXPERIMENTAL|Treatment with recombinant vWF|ECMO patients with major bleeding who are enrolled in the trial will receive treatment with recombinant von Willebrand Factor a single time. The dose will be 50 IU/kg and the drug will be given intravenously.
62032844|NCT03930472|EXPERIMENTAL|Voucher intervention F&V|Receiving $20 in vouchers at each of up to 4 markets ($80 total) that are good for F\&V only
62032845|NCT03930472|EXPERIMENTAL|Voucher intervention SNAP|Receiving $20 vouchers at each of up to 4 markets that are good for any foods that SNAP/EBT benefits can be used for
62032846|NCT03930472|NO_INTERVENTION|Waitlist control|Delayed intervention/waitlist control (who, at the final data gathering, will receive 5 x $20 in vouchers good at the WFfT 2019 and 2020 markets).
62032847|NCT03876652|EXPERIMENTAL|DDD-CLS|Patients with a pacemaker programmed in DDD-CLS mode
62032848|NCT03876652|ACTIVE_COMPARATOR|DDD-R|Patients with a pacemaker programmed in DDD-R mode
62032849|NCT05188846|EXPERIMENTAL|SDF|
62032850|NCT05188846|ACTIVE_COMPARATOR|SDF + ART ( SMART technique )|
62232882|NCT01800214||Small Vessel Disease -Neurodegenerative (SVD)|
62232883|NCT01800214||Subjective Cognitive Complaints (SCC)|
62232884|NCT02963181|EXPERIMENTAL|Effects of Yohimbine|Investigation into the integrity of post-ganglionic sympathetic nerves in patients with idiopathic neurogenic orthostatic hypotension
62232885|NCT02963181|EXPERIMENTAL|Effects of melatonin on blood pressure|Investigation into the effects of melatonin at two separate dosages (2 and 5mg) on nocturnal blood pressure in NOH patients with intact versus denervated post-ganglionic sympathetic nerves
62232886|NCT01222065||Glaucoma/Normal|Two groups will be studies: patients with glaucomatous visual field loss and age and gender matched normal patients without visual field loss
62232887|NCT01847118|EXPERIMENTAL|Sevacizumab|2mg/kg、5mg/kg、7.5mg/kg、10mg/kg、12.5mg/kg、or 15mg/kg. d1, d29, d43, d57
62232888|NCT04363684||Longitudinal Arm|Annual clinic visits throughout the length of the study.
62232889|NCT04363684||Biofluid-Focused Arm|Single clinic visit.
62232890|NCT04251260|EXPERIMENTAL|Positioning in flexion|Intervention: Positioning of body in flexion and aligment towards midline with Snuggle up (Philips, USA)
62232891|NCT04251260|NO_INTERVENTION|Control group|No intervention
62232892|NCT03674125|EXPERIMENTAL|Group 1|GLS-6150 at 2.0 mg DNA/dose (3 dose prime plus boost)
62423979|NCT04957914|ACTIVE_COMPARATOR|Insulin Glargine (Period 1)|Insulin glargine administered subcutaneously (SC).
62423980|NCT04957914|EXPERIMENTAL|LY3209590 (Period 2)|LY3209590 administered SC.
62593067|NCT02683252|EXPERIMENTAL|Carpal osteonecrosis|Patients presenting signal anomalies compatible with osteonecrosis of the carpal bones on conventional MR images (hypointensity on T1 weighted sequences, no contrast enhancement).
62593068|NCT02683252|EXPERIMENTAL|Femoral head osteonecrosis|Patients presenting signal anomalies compatible with osteonecrosis of the femoral head on conventional MR images (fat containing signal anomalies with geographic contours in the femoral epiphysis).
62809180|NCT02267239|ACTIVE_COMPARATOR|Chlorhexidine, immersion|Professional oral cleaning Plaster cast IDODS Immersion the disk with the biofilm in the chlorhexidine antiseptic solution
62809181|NCT02267239|OTHER|baseline|Professional oral cleaning Plaster cast IDODS Disk in basal conditions.
62809182|NCT02267239|ACTIVE_COMPARATOR|Essential Oils, mouthwash|Professional oral cleaning Plaster cast IDODS Active mouthwash with the essential oils antiseptic solution
62809183|NCT02267239|ACTIVE_COMPARATOR|Chlorhexidine, mouthwash|Professional oral cleaning Plaster cast IDODS Active mouthwash with the chlorhexidine antiseptic solution
62809184|NCT03284463|ACTIVE_COMPARATOR|Glibenclamide|Glibenclamide Tablets
62809185|NCT03284463|PLACEBO_COMPARATOR|Placebo|Placebo for Glibenclamide
62809186|NCT02942212|EXPERIMENTAL|Project HALT II: In-Depth Interviews|"Participants complete a computerized questionnaire to assess demographics and smoking history.~Participants take part in individual in-depth interviews discussing smoking history, attempts to quit, and suggestions for smoking cessation program."
62809187|NCT02942212|ACTIVE_COMPARATOR|Project HALT II: Standard Treatment (ST)|"Participants complete a computerized questionnaire to assess demographics and smoking history at baseline.~Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.~Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Participants receive brief advice to quit smoking. Participants receive phone counseling for support in quitting smoking (5 sessions over the course of 6 weeks) with a counselor at the Texas Quitline.~Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up."
62809188|NCT02942212|EXPERIMENTAL|Project HALT II: Tailored Treatment (HALT)|"Participants complete a computerized questionnaire to assess demographics and smoking history at baseline.~Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.~Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Participants receive brief advice to quit smoking. Participants scheduled to attend 5 individual, in-person smoking cessation treatment counseling sessions.~Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up."
62809189|NCT05256602||survey respondant|
62809190|NCT01131988|EXPERIMENTAL|Tacrolimus|Tacrolimus Capsules, 5 mg of Dr.Reddy's Laboratories Limited
62809191|NCT01131988|ACTIVE_COMPARATOR|Prograf Capsules|Prograf Capsules of Astellas Pharma US, Inc.,
62809192|NCT01416818|EXPERIMENTAL|group 1|
62809193|NCT01416818|ACTIVE_COMPARATOR|group 2|
62809194|NCT01416818|PLACEBO_COMPARATOR|group 3|
62809195|NCT03284177|EXPERIMENTAL|C13-CAC|
62809196|NCT03432507||disc herniation|patients suffering from disc herniation
62809197|NCT03432507||spinal stenosis|patients suffering from spinal stenosis
62809198|NCT00350025|OTHER|Cetuximab alone|Cetuximab 250mg/m2 IV weekly during each 28 day cycle. Arm A closed to accrual June 11, 2009 for lack of efficacy
62809199|NCT00350025|OTHER|Cetuximab with Paclitaxel|Paclitaxel 80 mg/m2 IV weekly for every 28 day cycle. Cetuximab 250mg/m2 IV weekly for every 28 day cycle.
62809200|NCT03090477|EXPERIMENTAL|Pharmaceutical care and adherence aids|
62032851|NCT06110923|EXPERIMENTAL|A1 (Test group)|CKD-846 A, Single dose
62232893|NCT03674125|EXPERIMENTAL|Group 2|GLS-6150 at 1.0 mg DNA/dose (3 dose prime plus boost)
62423981|NCT06381375||Tuberculous Patients|
62593069|NCT02683252|EXPERIMENTAL|Pseudarthrosis|Patients presenting a non consolidated macroscopic bone fracture for over 6 months (clinical history and imaging findings).
62593070|NCT02683252|EXPERIMENTAL|Compartment syndrome|Patients with a confirmed compartment syndrome on intra-compartment pressure assessement
62593071|NCT05245916|EXPERIMENTAL|IBI397 single-agent dose escalation|
62593072|NCT05245916|EXPERIMENTAL|IBI397+ Rituximab|
62593073|NCT05245916|EXPERIMENTAL|IBI397 + Sintilimab|
62232894|NCT03674125|EXPERIMENTAL|Group 3|GLS-6150 at 2.0 mg DNA/dose(3 dose prime plus boost)
62232895|NCT03674125|EXPERIMENTAL|Group 4|GLS-6150 at 2.0 mg DNA/dose(2 dose prime plus boost)
62232896|NCT00473941|EXPERIMENTAL|1|Writing in a journal 15 minutes a day
62593074|NCT06648265|EXPERIMENTAL|TXA Group|Tumescent solution with TXA
62593075|NCT06648265|PLACEBO_COMPARATOR|Control Group|Tumescent Solution without TXA
62809201|NCT03090477|NO_INTERVENTION|Control (dispensing of TKI & instruction about administration)|
62809202|NCT06074848|EXPERIMENTAL|Pain/fatigue tDCS real|"tDCS will be applied for 30 minutes (2 mA; 0.057 mA/cm²) during motor training. The anode will be positioned in the area referring to the left motor cortex (C3). The cathode will be positioned in the contralateral supraorbital region.~Motor Training: the participant will be positioned on the mat where the initial 5 minutes will be warmed up with the target heart rate maintained at 50-60% of the maximum heart rate. The treadmill speed must be adjusted to keep the HR within the pre-established target range. At 5 minutes, Borg scale values, treadmill speed and HR should be recorded. The central 20 minutes will be considered the main part. For this, the target HR must be maintained between 64-76% of the maximum HR. Every 5 minutes (minutes 10, 15, 20 and 25) the values of the Borg scale, treadmill speed and HR must be recorded. In the final 5 minutes, the target HR must be kept below 60% of the maximum HR. Totaling 30 minutes of training on the treadmill."
62232897|NCT00473941|PLACEBO_COMPARATOR|2|Control Writing in a journal 15 minutes a day
62232898|NCT03681951|EXPERIMENTAL|Part 1: Dose Escalation - GSK3145095 monotherapy|In Part 1, advanced or metastatic PDAC will be enrolled. Part 1 will be using escalating doses of GSK3145095 (total daily dose of 100 mg, 200 mg, 400 mg, 800 mg, and 1600 mg) orally as monotherapy for up to 2 years. For each dose level, subjects will receive a single dose of half the total daily dose on Day 1; and as BID (total daily dose divided in two equal doses) starting from Day 2.
62232899|NCT03681951|EXPERIMENTAL|Part 2: Dose Escalation - GSK3145095 + pembrolizumab|In Part 2, subjects with selected solid tumors, including but not limited to, PDAC, NSCLC, TNBC and/or melanoma will be enrolled. Part 2 will be using GSK3145095 combination escalation to start at least one dose level below the highest dose of GSK3145095 shown to be safe in Part 1, orally BID for up to 2 years along with pembrolizumab 200 mg intravenous (IV) every 3 weeks (Q3W) for up to 2 years.
62232900|NCT03681951|EXPERIMENTAL|Part 3: Dose Expansion - GSK3145095 + pembrolizumab|In Part 3, subjects with selected solid tumors will be enrolled. Part 3 will be using GSK3145095 at one or two dose levels shown to be tolerable in Part 2 orally BID for up to 2 years along with pembrolizumab 200 mg IV Q3W for up to 2 years.
62232901|NCT03681951|EXPERIMENTAL|Part 4: Dose Expansion - GSK3145095 + anticancer agent|In Part 4, subjects with selected solid tumors will be enrolled. Part 4 will be using GSK3145095 at one or two dose levels shown to be tolerable in Part 2 orally BID for up to 2 years along with combination of additional anticancer agents.
62232902|NCT01928498|EXPERIMENTAL|Paclitaxel Eluting Balloon|Paclitaxel Eluting Balloon Angioplasty
62232903|NCT01928498|ACTIVE_COMPARATOR|Conventional uncoated balloon|Percutaneous Transluminal Angioplasty (PTA)
62232904|NCT00052182|EXPERIMENTAL|1|Immunization on Day 0 and Weeks 4, 8, and 16
62232905|NCT04993612||No pulmonary Hypertension|
62232906|NCT04993612||pulmonary Hypertension Group 1|
62593076|NCT04477590|NO_INTERVENTION|NO EXERCISE TRAINING|25-32 individuals with metabolic syndrome that will remain sedentary during the 4 months of treatment taking their habitual medication (i.e., blood pressure, glucose, cholesterol, and triglycerides lowering drugs) and meals at the habitual time (CONTROL GROUP).
62593077|NCT04477590|EXPERIMENTAL|EXERCISE TRAINING FED|2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingesting a liquid test meal (500 calls, 50% fat) 30 min before exercise (EXERCISE TRAINING FED).
62809203|NCT06074848|SHAM_COMPARATOR|Pain/fatigue tDCS sham|"tDCS will be applied for 30 seconds (2 mA; 0.057 mA/cm²) during motor training. The anode will be positioned in the area referring to the left motor cortex (C3). The cathode will be positioned in the contralateral supraorbital region.~Motor Training: the participant will be positioned on the mat where the initial 5 minutes will be warmed up with the target heart rate maintained at 50-60% of the maximum heart rate. The treadmill speed must be adjusted to keep the HR within the pre-established target range. At 5 minutes, Borg scale values, treadmill speed and HR should be recorded. The central 20 minutes will be considered the main part. For this, the target HR must be maintained between 64-76% of the maximum HR. Every 5 minutes (minutes 10, 15, 20 and 25) the values of the Borg scale, treadmill speed and HR must be recorded. In the final 5 minutes, the target HR must be kept below 60% of the maximum HR. Totaling 30 minutes of training on the treadmill."
62032852|NCT06110923|EXPERIMENTAL|R (Reference group)|D091, Multi dose
62032853|NCT06110923|EXPERIMENTAL|A2 (Test group)|CKD-846 A, Single dose
62593078|NCT04477590|EXPERIMENTAL|EXERCISE TRAINING FASTED|2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingestion of a placebo meal (0 kcals) 30 min before exercise (EXERCISE TRAINING FAST).
62593079|NCT06664320|NO_INTERVENTION|Control group|patients undergoing cardiac surgery supposed not to get aucte normovolemic hemodilution (ANH) before CPB
62819555|NCT03009058|EXPERIMENTAL|IMM-101+FOLFOX colorectal cancer (CRC)|"IMM-101 will be given in combination with standard FOLFOX (FOLinic acid, Fluorouracil and OXaliplatin) treatment.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
62032854|NCT06110923|EXPERIMENTAL|B2 (Test group)|CKD-846 B, Single dose
62032855|NCT06110923|EXPERIMENTAL|A3 or B3 (Test group)|CKD-846 A or B, Single dose
62032856|NCT05997043|EXPERIMENTAL|Experimental group|Experimental group
62232907|NCT04993612||pulmonary Hypertension Group 2|
62232908|NCT04993612||pulmonary Hypertension Group 3|
62232909|NCT04993612||pulmonary Hypertension Group 4|
62232910|NCT04993612||pulmonary Hypertension Group 5|
62232911|NCT04902469|EXPERIMENTAL|Pleasant Odor|Participants in this condition will sniff the olfactory cue they rate as both pleasant (\>5 on the 1-9 scale) and the most intense following cigarette cue exposure. If this odor is the same as their self-reported preferred e-cigarette flavor, we will choose the next most intense odor out of the odors rated as pleasant.
62032857|NCT05997043|PLACEBO_COMPARATOR|Control group|Control group
62232912|NCT04902469|OTHER|Odor Blank|Participants in this condition will sniff a neutral olfactory cue (odor blank) following cigarette cue exposure.
62232913|NCT05552209||Orthosis group 1|Use of Elbow Mid 500 device during sport practice
62232914|NCT05552209||Control group 1|Control group of the Elbow Mid 500 group - no medical device used during sport practice
62232915|NCT05552209||Orthosis group 2|Use of Elbow Strap device during sport practice
62232916|NCT05552209||Control group 2|Control group of the Elbow Strap group - no medical device used during sport practice
62232917|NCT04922489||Patients with Astra Tech EV|Patients who has receive Astra Tech dental implant system placement.
62232918|NCT01058408|EXPERIMENTAL|Rad001 with cisplatin|
62232919|NCT02474160||Ancillary-correlative (tissue and blood procurement)|Tumor tissue and blood samples are procured during procedures that are required for the patients' clinical management and stored via xenograft (transplant to another species) models or in vitro cell culture for future analysis.
62232920|NCT01894373|EXPERIMENTAL|CIK, psoriasis|
62232921|NCT01995877||Subjects scheduled for IVC filter placement|A filter may be needed to be placed in the IVC (inferior vena cava) to prevent blood clots from traveling from legs to lungs. Patients who have had a pelvic fracture, or have blood clots in the leg(s) may need an IVC. Filter placement may be ordered when a patient is scheduled for major surgery and extensive bed rest.
62032858|NCT01093729|EXPERIMENTAL|Cohort1|HM11260C 0.5mcg/kg or Placebo
62032859|NCT01093729|EXPERIMENTAL|Cohort2|HM11260C 2mcg/kg or Placebo
62032860|NCT01093729|EXPERIMENTAL|Cohort3|HM11260C 4mcg/kg or Placebo
62032861|NCT01093729|EXPERIMENTAL|Cohort4|HM11260C 8mcg/kg or Placebo
62032862|NCT01093729|EXPERIMENTAL|Cohort5|HM11260C 14mcg/kg or Placebo
62232922|NCT00701220|ACTIVE_COMPARATOR|Ischemic Cardiomyopathy|Patients with Ischemic Cardiomyopathy receiving Lipitor (Atorvastatin calcium).
62232923|NCT00701220|ACTIVE_COMPARATOR|Non Ischemic Cardiomyopathy|NonIschemic Cardiomyopathy receiving Lipitor (Atorvastatin calcium) treatment
62433562|NCT03769181|EXPERIMENTAL|Cohort C: PTCL: Isatuximab + Cemiplimab|Peripheral T-cell lymphoma (PTCL), anti PD-1/PD-L1 naïve participants received isatuximab 10 mg/kg, IV infusion, QW in Cycle 1 and then Q2W from Cycle 2 to Cycle 6 (each cycle of 28 days) and Q3W from Cycle 7 to Cycle 30 (each cycle of 21 days) along with cemiplimab 250 mg Q2W, IV infusion from Cycle 1 to 6 and then 350 mg Q3W from Cycle 7 to Cycle 30 until, unacceptable AEs or participant's decision to stop the treatment, or at least 96 weeks (at least 48 weeks from initial signal of CR, whichever was longer) of delivery of investigational medicinal product(s) without documented PD, or study cut-off date, whichever occurs first (maximum duration: up to 103 weeks).
62593080|NCT06664320|ACTIVE_COMPARATOR|Acute normovolemic hemodilution group|patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB
62593081|NCT06665880||DRE patients|Patients with drug-resistant epilepsy.
62593082|NCT06665880||Traumatic Brain Injury|Individuals with traumatic brain injury.
62809204|NCT06074848|EXPERIMENTAL|Cognitive deficit and depressed mood tDCS real|"tDCS will be applied for 30 minutes (2 mA; 0.057 mA/cm²) during cognitive training. For volunteers with symptoms of depressed mood and/or cognitive impairment, the anode will be positioned in the area of the left dorsolateral prefrontal cortex (F3) and cognitive training will be performed. The cathode will be positioned in the contralateral supraorbital region.~Cognitive Training: For cognitive training, performed during tDCS, a n-Back task will be performed online in the PsyToolkit (https://www.psytoolkit.org/). A previous study demonstrated the benefit of tDCS when combined with this cognitive training on working memory learning curves."
62032863|NCT06377241||Cohort 1|No cognitive impairment, and no family history of Alzheimer's disease
62032864|NCT06377241||Cohort 2|No cognitive impairment, with a family history of Alzheimer's disease
62032865|NCT06377241||Cohort 3|Mild cognitive impairment due to Alzheimer's disease
62032866|NCT02363946|EXPERIMENTAL|Part A: 0.38 mg/kg|Single dose administration of ARC-AAT intravenous (IV) injection, 0.38 mg/kg in healthy volunteers
62032867|NCT02363946|EXPERIMENTAL|Part A: 1.0 mg/kg|Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers
62032868|NCT02363946|EXPERIMENTAL|Part A: 2.0 mg/kg|Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers
62032869|NCT02363946|EXPERIMENTAL|Part A: 3.0 mg/kg|Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers
62232924|NCT00701220|NO_INTERVENTION|Healthy Subjects|Healthy subjects with no history of high cholesterol, heart disease, or heart attacks
62232925|NCT00676065||1|Women who take oral contraceptives containing drospirenone
62232926|NCT00676065||2|Women who take oral contraceptives containing levonorgestrel
62593083|NCT06506643|EXPERIMENTAL|KLS-1 dose escalation Phase I - Cohort 1: 2.0 mg/kg|3-6 patients will receive KLS-1 at 2.0 mg/kg.
62593084|NCT06506643|EXPERIMENTAL|KLS-1 dose escalation Phase I - Cohort 2: 3.0 mg/kg|3-6 patients will receive KLS-1 at 3.0 mg/kg.
62593085|NCT06506643|EXPERIMENTAL|KLS-1 dose escalation Phase I - Cohort 3: 3.9 mg/kg|3-6 patients will receive KLS-1 at 3.9 mg/kg.
62593086|NCT06506643|EXPERIMENTAL|KLS-1 dose escalation Phase I - Cohort 4: 4.75 mg/kg|3-6 patients will receive KLS-1 at 4.75 mg/kg.
62819556|NCT03009058|EXPERIMENTAL|IMM-101+FOLFIRI+CETUXIMAB colorectal cancer (CRC)|"IMM-101 will be given in combination with standard FOLFIRI (FOLinic acid, Fluorouracil and IRInotecan) + cetuximab combination treatment.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
62032870|NCT02363946|EXPERIMENTAL|Part A: 4.0 mg/kg|Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers
62032871|NCT02363946|EXPERIMENTAL|Part A: 5.0 mg/kg|Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers
62032872|NCT02363946|EXPERIMENTAL|Part A: 6.0 mg/kg|Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers
62232927|NCT00676065||3|Women who take oral contraceptives containing other progestogens
62232928|NCT02053038|EXPERIMENTAL|iFR|Treatment guided by iFR
62232929|NCT02053038|ACTIVE_COMPARATOR|FFR|Treatment guided by FFR
62232930|NCT00705523|ACTIVE_COMPARATOR|1|
62423982|NCT04766593|EXPERIMENTAL|Oncological functional reeducation program|"It will consist of the following actions:~1. Prescription of multimodal physical exercise: This therapeutic measure will be carried out both in the individuals of the experimental group and in those of the control group. It will be held daily in two short sessions of 15-20 minutes, one in the morning and one in the afternoon. The sessions were structured according to the recommendations of the American College of Sports Medicine (ACSM) 18, with an initial warm-up (2-3 minutes), a main part (8-12 minutes) and a final cool-down and relaxation (5 minutes).~2. Retraining in activities of daily living: Gradation and simplification of activities and training in energy saving techniques (EAT).~Finally, an exhaustive daily record of the activity carried out by the patient will be carried out, from which it will be modified, adapting it to the clinical situation of the patient."
62032873|NCT02363946|EXPERIMENTAL|Part A: 7.0 mg/kg|Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers
62032874|NCT02363946|EXPERIMENTAL|Part A: 8.0 mg/kg|Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers
62032875|NCT02363946|PLACEBO_COMPARATOR|Part A: Placebo|Single dose administration of 0.9% normal saline IV injection in healthy volunteers
62032876|NCT02363946|EXPERIMENTAL|Part B: 2.0 mg/kg|Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD
62032877|NCT02363946|EXPERIMENTAL|Part B: 4.0 mg/kg|Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD
62032878|NCT02363946|EXPERIMENTAL|Part B: 6.0 mg/kg|Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in participants with AATD
62232931|NCT00705523|PLACEBO_COMPARATOR|2|
62232932|NCT04607525|EXPERIMENTAL|Group D|Group D: Patients received 0.5 µg/kg/h of Dexmedetomidine. Dexmedetomidine dosage was diluted in 50 ml syringe of normal saline
62232933|NCT04607525|PLACEBO_COMPARATOR|Group C|Patients received equal volume and rate of normal saline as Group D.
62232934|NCT00913666|NO_INTERVENTION|Group 1|Healthy Volunteers
62232935|NCT00913666|EXPERIMENTAL|Group 2|MS patients previously naïve to interferon therapy
62232936|NCT00913666|EXPERIMENTAL|Group 3|MS patients on Interferon beta-1a treatment with no history of breakthrough disease (clinically stable)
62232937|NCT00913666|EXPERIMENTAL|Group 4|MS patients on interferon beta-1a treatment with a history of breakthrough disease.
62232938|NCT00223678|ACTIVE_COMPARATOR|1|pt will switch from calcineurin inhibitor (CYA, prograf) to Rapamycin
62232939|NCT00223678|NO_INTERVENTION|2|Patient will remain on calcineruin inhibitor
62593087|NCT06506643|EXPERIMENTAL|KLS-1 dose escalation Phase I - Cohort 5: 6.5 mg/kg|3-6 patients will receive KLS-1 at 6.5 mg/kg.
62593088|NCT06506643|EXPERIMENTAL|KLS-1 dose expansion Phase II cohort|The Phase II dose (P2D) defined in Phase I will be administered in a dose expansion cohort during 5 weeks of continuous bi-weekly administration of KLS-1, demonstrating that this dose was well-tolerated and safe.
62593089|NCT05462132|EXPERIMENTAL|Cohort 1|"HV subjects receive doses 3 × 10\^11 live cells of SYNB1353 and 30 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of 30 mg/kg will be evaluated."
62819557|NCT03009058|EXPERIMENTAL|IMM-101+Gem cholangio|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
62819558|NCT03009058|EXPERIMENTAL|IMM-101+Gem lung ca|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter
62819559|NCT03009058|EXPERIMENTAL|IMM-101+Gem + nab-paclitaxel lung ca|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.~The treatment regimen with IMM 101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
62819560|NCT03009058|EXPERIMENTAL|IMM-101+ anti-programmed death-1 (PD1) lung ca|"IMM-101 will be given in combination with standard treatment with either pembrolizumab or nivolumab.~In order to ensure that there are no increased immune-related adverse events (AEs), the first 3 patients entering the anti-PD1 (pembrolizumab or nivolumab) cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen."
62423983|NCT04766593|ACTIVE_COMPARATOR|Prescription of multimodal physical exercise|This therapeutic measure will be carried out both in the individuals of the experimental group and in those of the control group. It will be held daily in two short sessions of 15-20 minutes, one in the morning and one in the afternoon. The guideline will be to maintain a multimodal exercise to perform exercises of different characteristics, including aerobic exercises, balance exercises and low-load strength exercises for muscle groups, both in the upper quadrant and the lower quadrant. The sessions were structured according to the recommendations of the American College of Sports Medicine (ACSM) 18, with an initial warm-up (2-3 minutes), a main part (8-12 minutes) and a final cool-down and relaxation (5 minutes).
62423984|NCT04390035|NO_INTERVENTION|Control|Participants in the control arm will follow the standard-of-care treatment exercises for the 6 months following ACL reconstruction surgery.
62423985|NCT04390035|EXPERIMENTAL|Test (BFRT)|Participants in the test arm will follow the identical physical therapy exercises as the control arm but will perform the exercises with BFRT during the first 16 weeks post-surgery. After reaching the 16-week mark, participants will complete the identical standard-of-care rehabilitation between weeks 16-24.
62032879|NCT02363946|EXPERIMENTAL|Part B: 7.0 mg/kg|Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in participants with AATD
62032880|NCT02363946|PLACEBO_COMPARATOR|Part B: Placebo|Single dose administration of 0.9% normal saline IV injection in participants with AATD
62032881|NCT04582630||Omega 3 fatty acid|Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
62032882|NCT04582630||Control (standart)|Standart medical nutrition therapy
62032883|NCT03104634|EXPERIMENTAL|Active arm|Aclidinium bromide/formoterol fumarate dihydrate 400 mcg/12 mcg Twice daily (once in the morning, once in the evening) 7-days
62032884|NCT03104634|PLACEBO_COMPARATOR|Placebo arm|Placebo Twice daily (once in the morning, once in the evening) 7-days
62032885|NCT06204627|ACTIVE_COMPARATOR|Active bipolar TDCS associated with laterality recognition stimuli|Participants will have carbon electrodes positioned, with contact through a 5x7cm sponge moistened in saline solution, with the anode on M1 and the cathode in the supra-orbital region. Individuals with active bipolar TDCS will receive a 2mA stimulus for twenty minutes. Meanwhile, they will use the Regognise hand application to discriminate right/left side of hand images.
62032886|NCT06204627|ACTIVE_COMPARATOR|Active bipolar TDCS associated with landscape recognition stimuli|"Participants will have carbon electrodes positioned, with contact through a 5x7cm sponge moistened in saline solution, with the anode on M1 and the cathode in the supra-orbital region. Individuals with active bipolar TDCS will receive a 2mA stimulus for twenty minutes.~At the same time, they will be guided to recognize landscapes that do not refer to the recognition of laterality."
62032887|NCT06204627|ACTIVE_COMPARATOR|Sham TDCS associated with laterality recognition stimuli|Participants will have carbon electrodes positioned, with contact through a 5x7cm sponge moistened in saline solution, with the anode on M1 and the cathode in the supra-orbital region. Stimulation will remain inactive for the 20 minutes. Meanwhile, they will use the Regognise hand app to discriminate right/left hand images.
62032888|NCT06204627|PLACEBO_COMPARATOR|Sham TDCS associated with landscape recognition stimuli|Participants will have carbon electrodes positioned, with contact through a 5x7cm sponge moistened in saline solution, with the anode on M1 and the cathode in the supra-orbital region. Stimulation will remain inactive for the 20 minutes. At the same time, they will be guided to recognize landscapes that do not refer to the recognition of laterality.
62032889|NCT01015391|EXPERIMENTAL|T2|
62032890|NCT01015391|ACTIVE_COMPARATOR|AZA|
62032891|NCT02437591|EXPERIMENTAL|fidaxomicin|tablet twice daily
62032892|NCT01983293|EXPERIMENTAL|QLV based implant strategy|QLV represents the pacing site with the largest amount of dyssynchrony as measured by the left ventricular electrical delay. The QLV based implant strategy finds the left ventricle vein branch and left ventricular lead cathode with the longest QLV measurement and places the lead at this location and programs the device using this lead cathode.
62032893|NCT01983293|PLACEBO_COMPARATOR|Standard of care implant strategy|The placement of LV lead will be carried out according to the physician's standard of care implant approach.
62032894|NCT02836418|EXPERIMENTAL|ATYR1940|Participants will receive ATYR1940 up to 3.0 milligrams per kilograms (mg/kg) intravenous (IV) infusion once weekly until approval of ATYR1940, discontinuation of its development, the study was closed by the Sponsor, or a criterion for study drug discontinuation (up to 34 weeks).
62032895|NCT06190301|EXPERIMENTAL|Intralesional Rituximab Injection|
62032896|NCT06190301|ACTIVE_COMPARATOR|Involved Site Radiation Therapy|
62032897|NCT04207099||ARM 1|Patients receive standard of care treatment for their diabetic foot ulcer
62423986|NCT02966574|EXPERIMENTAL|metastatic breast cancer|
62032898|NCT04207099||ARM 2|Patients receive MolecuLight i:X guided treatment for their diabetic foot ulcer
62032899|NCT03585244||Individuals with Prader-Willi Syndrome|Individuals with Prader-Willi Syndrome aged 12 and over will be recruited to gather data on weekly weight over six months
62032900|NCT02412137|EXPERIMENTAL|Counseled Patients|The counseled cohort will have their brace wear compliance documented on the Brace Progress Report after the Orthotist downloads the time/temperature data onto a laptop from the sensor reader (A piece of computer hardware which the sensor clips into and is attached to the laptop via the USB port). The Orthotist will then reset the temperature logger discs and reinstall them into the padding in the inside front of the brace in order to monitor the next period of brace wear. This group will then be counseled for about 10 minutes or less regarding their brace-wear using the Brace Progress report as a checklist.
62032901|NCT02412137|PLACEBO_COMPARATOR|Non-counseled patients|The non-counseled cohort will have their brace wear compliance documented on the Brace Progress Report after the Orthotist downloads the time/temperature data onto a laptop from the sensor reader (A piece of computer hardware which the sensor clips into and is attached to the laptop via the USB port). The Orthotist will then reset the temperature logger discs and reinstall them into the padding in the inside front of the brace in order to monitor the next period of brace wear. This group will not be counseled, and will only receive standard clinical care.
62032902|NCT06670300|EXPERIMENTAL|cardonilimab for advanced melanoma|Subjects will receive cardonilimab 10mg/kg once every three weeks; The maximum duration of administration is 2 years until disease progression or death, toxicity becomes intolerable, subject voluntarily requests withdrawal, or investigator determines that subject needs to withdraw from the study.
62032903|NCT06670300|EXPERIMENTAL|cardonilimab for advanced kidney cancer|Subjects will receive cardonilimab 10mg/kg once every three weeks; The maximum duration of administration is 2 years until disease progression or death, toxicity becomes intolerable, subject voluntarily requests withdrawal, or investigator determines that subject needs to withdraw from the study.
62032904|NCT06670781|SHAM_COMPARATOR|Control - standard of care: Self-Directed Valsalva maneuver|The Valsalva maneuver is performed by the patient taking a normal (or deep) inspiration, followed by forceful expiration against a closed airway for up to 15 to 20 sec and then release of the expiratory effort on entry of saline into the right atrium.
62032905|NCT06670781|ACTIVE_COMPARATOR|Intervention arm: Goal-Directed Valsalva maneuver|For the Goal directed Valsalva maneuver, the same method patients are instructed to blow into a plastic pipe connected to the manometer device, in order to reach a pressure of 40 mmHg for at least 5 seconds. Then patients are instructed to exhale quickly.
62032906|NCT06309693|ACTIVE_COMPARATOR|Quadratus Lumborum Block|The QL block will be performed by the regional anesthesia team according to their standard protocol with a uniform quantity and concentration of analgesic agent (ropivacaine 60cc). Intraoperatively, patients will undergo subcutaneous injections of lidocaine (2cc per port site) at each port site. Preoperatively, patients will only receive acetaminophen and no preoperative narcotics or neuro-modulators will be administered. Intraabdominal pressure intraoperative will be standardized among surgeons (plan for 15mm Hg for port placement, then 12 mm Hg once docked). At the conclusion of each surgery, eligible patients will receive a dose of IV ketorolac. Postoperatively, patients will be prescribed a standard regimen of NSAIDs, acetaminophen and opioids. Patients will be asked to rate their pain according to the numeric pain rating scale immediately postoperatively in the PACU and patient opioid requirements while in the PACU will be reviewed in the chart.
62032907|NCT06309693|ACTIVE_COMPARATOR|Enhanced Recovery After Surgery (ERAS) Protocol|The ERAS protocol is a multimodal approach to pain control while minimizing opioid medications. Subjects randomized to the ERAS arm will undergo the standard ERAS protocol of early postoperative ambulation, no bowel preparation, and the use of multimodal pain medications including acetaminophen and non-steroid anti-inflammatory drugs (NSAIDs). Intraabdominal pressure intraoperative will be standardized among surgeons (plan for 15mm Hg for port placement, then 12 mm Hg once docked). At the conclusion of each surgery, eligible patients will receive a dose of IV ketorolac. Postoperatively, patients will be prescribed a standard regimen of NSAIDs, acetaminophen and opioids. Patients will be asked to rate their pain according to the numeric pain rating scale immediately postoperatively in the PACU and patient opioid requirements while in the PACU will be reviewed in the chart.
62032908|NCT03268876||Epithelial ovarial cancer|Patients primary treated with primary surgery for advanced epithelial ovarian cancer (\> stage IIa) at the participating institutions will be asked to participate.
62032909|NCT02208180|EXPERIMENTAL|Return of genomic results on cardiovascular disease risk|Participants will receive genomic cardiovascular disease risk information.
62423987|NCT01959230|EXPERIMENTAL|Brimonidine Tartrate|Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.
62423988|NCT01959230|PLACEBO_COMPARATOR|Brimonidine Tartrate Vehicle|Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.
62423989|NCT03506425|EXPERIMENTAL|Group 1|Standard care for 1 month, then standard care and Triheptanoin for 5 months.
62423990|NCT03506425|EXPERIMENTAL|Group 2|Standard care and Triheptanoin for 6 months.
62423991|NCT03506425|NO_INTERVENTION|Group 3|Healthy controls for biomarkers
62032910|NCT02208180|ACTIVE_COMPARATOR|Return of lifestyle results on cardiovascular disease risk|Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study.
62423992|NCT00315328|ACTIVE_COMPARATOR|Patching|Patching 2 hours per day plus near activities for one hour while patching (with increase to 4 hours per day for moderate amblyopes and \>4 hours per day for severe amblyopes at 5 weeks if acuity not improved at least 5 letters)
62809205|NCT06074848|SHAM_COMPARATOR|Cognitive deficit and depressed mood tDCS sham|"tDCS will be applied for 30 seconds (2 mA; 0.057 mA/cm²) during cognitive training. For volunteers with symptoms of depressed mood and/or cognitive impairment, the anode will be positioned in the area of the left dorsolateral prefrontal cortex (F3) and cognitive training will be performed. The cathode will be positioned in the contralateral supraorbital region.~Cognitive Training: For cognitive training, performed during tDCS, a n-Back task will be performed online in the PsyToolkit (https://www.psytoolkit.org/). A previous study demonstrated the benefit of tDCS when combined with this cognitive training on working memory learning curves."
62032911|NCT04396613|ACTIVE_COMPARATOR|Running Subcuticular Suture|
62032912|NCT04396613|ACTIVE_COMPARATOR|Interrupted Vertical Mattress Suture|
62032913|NCT04396613|ACTIVE_COMPARATOR|Staple Closure Techniques|
62032914|NCT00687037|EXPERIMENTAL|I|Cetylpyridinium chloride during 21 days.
62032915|NCT05598333|EXPERIMENTAL|AB-1002|"Randomized in 1:1:1 into one of three groups.~Group 1: 3.25E13vg (n=30-50)"
62032916|NCT05598333|EXPERIMENTAL|Treatment Group 2 AB-1002|"Randomized in 1:1:1 into one of three groups.~Group 2: 6.5E13vg (n=30-50)"
62423993|NCT00315328|ACTIVE_COMPARATOR|Atropine|Atropine 1% once each weekend day in the sound eye plus near activities for at least one hour every day (with increase to daily atropine at 5 weeks if acuity not improved by at least 5 letters)
62032917|NCT05598333|PLACEBO_COMPARATOR|Treatment Group 3|"Randomized in 1:1:1 into one of three groups.~Group 3: Placebo (n=30-50)"
62032918|NCT02123654|EXPERIMENTAL|Arm 1: DCV 3DAA + Placebo for DCV/Placebo for ASV|DCV 3DAA tablet orally twice daily for 12 weeks + Placebo for DCV tablet orally once daily and Placebo for ASV capsule orally twice daily for 24 weeks (Double blind)
62032919|NCT02123654|ACTIVE_COMPARATOR|Arm 2: DCV/ASV + Placebo for DCV 3DAA|Daclatasvir 60 mg tablet orally once daily and Asunaprevir 100 mg capsule orally twice daily for 24 weeks + Placebo for DCV 3DAA tablet orally twice daily for 12 weeks (Double blind)
62032920|NCT02123654|EXPERIMENTAL|DCV 3DAA|DCV 3DAA (open label) Tablet orally twice daily for 12 weeks
62032921|NCT03569280|EXPERIMENTAL|KPG-121|Safety and Antitumor Activity of KPG-121 capsules at different dose level for 21 days
62423994|NCT06640244|EXPERIMENTAL|Cosmetic product G18|Cosmetic face care product to be used twice daily on the whole face for 12 weeks.
62423995|NCT06640244|EXPERIMENTAL|Cosmetic product N70|Cosmetic face care product to be used twice daily on the whole face for 12 weeks.
62232940|NCT02080221|EXPERIMENTAL|FOLFOXA|"1 cycle = 14 days Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
62809206|NCT04472663||Cohort 1|Retrospective Long-term Chart Review
62809207|NCT04472663||Cohort 2|Prospective-Retrospective Chart Review and Humanistic Burden
62809208|NCT04470518|ACTIVE_COMPARATOR|Intervention: Diagnostic algorithm|diagnostic algorithm including a standardised clinical assessment, a Point-of-care C-reactive protein test, and safety netting advice
62809209|NCT04470518|NO_INTERVENTION|Usual care|"In the control arm, patients will receive 'usual care' left at the discretion of the treating physician.~Apart from the general training session for all participating physicians they have attended prior to recruitment and randomization, physicians in the control arm will not receive additional tools.~They are expected (but not forced) to follow the Belgian guidelines (as described in BAPCOC National guidelines and the RIZIV consensus meeting Rational use of antibiotics in children)."
62809210|NCT01616628|NO_INTERVENTION|Wait listed control|Participants grocery shop without the intervention for extended baseline and have delayed entrance into the intervention period.
62809211|NCT01616628|EXPERIMENTAL|Rewards for purchases & topic education|Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables.
62809212|NCT05896228|EXPERIMENTAL|Iber-KDd Combination Therapy|Prior to Iber-KDd combination therapy, participants will receive Acetaminophen, Diphenhydramine and Montelukast therapy per protocol. Participants will receive up to eight (8) 28-day cycles of combination Iberdomide (I), Carfilzomib (K), Daratumumab (D), and Dexamethasone (d) (Iber-KDd) therapy. Participants will receive Iber-KDd combination therapy for approximately 8 months. In the absence of disease progression, participants will continue on to Iber monotherapy. Participants with disease progression will discontinue study therapy but will continue to be followed for up to three (3) years after conclusion of Iber-KDd combination therapy.
62593090|NCT05462132|EXPERIMENTAL|Cohort 2|"HV subjects receive doses 3 × 10\^11 live cells of SYNB1353 and up to 100 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of up to 100 mg/kg will be evaluated."
62423996|NCT06640244|EXPERIMENTAL|Cosmetic product D79|Cosmetic face care product to be used twice daily on the whole face for 12 weeks.
62809213|NCT05896228|EXPERIMENTAL|Iber Monotherapy|After completion of Iber-KDd combination therapy, and In the absence of disease progression, participants will then receive up to twelve (12) 28-day cycles of Iberdomide (Iber) monotherapy. Participants will receive Iber monotherapy for up to 12 months or until disease progression. Participants will be followed for up to three (3) years after conclusion of Iber monotherapy. Total study participation is up to five (5) years.
62809214|NCT03883256|ACTIVE_COMPARATOR|high flow nasal cannula|Subjects perform a constant-load exercise test with high flow nasal cannula oxygen device.
62809215|NCT03883256|ACTIVE_COMPARATOR|nasal cannula|Subjects perform a constant-load exercise test with nasal cannula oxygen device.
62809216|NCT04778735|OTHER|Pediatric Patients with Liver Transplantation|
62809217|NCT05249023|EXPERIMENTAL|Irritable Bowel Syndrome (IBS) participants|100 mM sodium butyrate solution containing indigo carmine as a dye agent will be administered to subjects in this arm.
62423997|NCT06640244|EXPERIMENTAL|Cosmetic product E84|Cosmetic face care product to be used twice daily on the whole face for 12 weeks.
62232941|NCT01670123|EXPERIMENTAL|Mobile Phone Condition|This arm will involve daily self-monitoring with an electronic mobile device with responses to survey questions about mood status. Mood status reports are linked with personalized coping strategies.
62232942|NCT01670123|PLACEBO_COMPARATOR|Paper-and-pencil condition|This arm will complete a paper-and-pencil mood chart on a daily basis
62423998|NCT06640244|EXPERIMENTAL|Cosmetic product C68|Cosmetic face care product to be used twice daily on the whole face for 12 weeks.
62423999|NCT00450177|EXPERIMENTAL|Iron Group|Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
62424000|NCT00450177|PLACEBO_COMPARATOR|Placebo Group|Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
62424001|NCT05442359|EXPERIMENTAL|Nano-biofusion gel gingival gel (NBF)|Coverage of the free gingival graft area in the palate with stent
62424002|NCT05442359|ACTIVE_COMPARATOR|stent|Coverage of the free gingival graft area in the palate
62424003|NCT02770053|EXPERIMENTAL|Intervention|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Foraminal enlargement will be achieved with #35 K-files in foraminal enlargement group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit.
62809218|NCT05249023|EXPERIMENTAL|Healthy participants|100 mM sodium butyrate solution containing indigo carmine as a dye agent will be administered to subjects in this arm.
62819561|NCT03009058|EXPERIMENTAL|IMM-101+Gem melanoma|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
62424004|NCT02770053|ACTIVE_COMPARATOR|Control|In the control group, no foraminal enlargement will be performed.
62032922|NCT00489970|EXPERIMENTAL|Boostrix Group|Subjects received in the primary study (NCT00346073) a single dose of Boostrix vaccine \[Tdap\](GSK776423) intramuscularly in the deltoid region of the non-dominant upper arm and in this study at Year 9 received a second dose of Boostrix vaccine \[Tdap\](GSK776423).
62424005|NCT02192541|EXPERIMENTAL|Ganetespib and Ziv-Aflibercept|Ganetespib was administered intravenously, over 1 hour, weekly, on days 1, 8, and 15 of each 28-day cycle. Ziv-aflibercept was administered intravenously, over 1 hour, every 2 weeks, on days 1 and 15 of each 28-day cycle. Ganetespib was started at a dose level of 100 mg/m\^2 + ziv-aflibercept at 3 mg/kg or 4 mg/kg.
62424006|NCT01950338|EXPERIMENTAL|Dry needling group|The experimental group will receive a single session of DDN with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the gastrocnemius and tibialis anterior muscles.
62424007|NCT01950338|NO_INTERVENTION|Control group|The control group will not receive any intervention.
62424008|NCT01094509|EXPERIMENTAL|Tai Chi|Tai Chi exercises
62424009|NCT01094509|EXPERIMENTAL|Guided autobiography|Autobiographical writing during class sessions and at home
62424010|NCT01094509|EXPERIMENTAL|Qigong|Qigong exercises (exploratory, not part of the original protocol, added to gain experience with this intervention)
62424011|NCT01094509|ACTIVE_COMPARATOR|Successful aging|Seminars on the theme of successful aging
62424012|NCT01094509|EXPERIMENTAL|Combination|Combination of Tai Chi exercises and autobiographical writing
62424013|NCT01094509|PLACEBO_COMPARATOR|Comparison|No assigned experimental activity (exploratory, not part of the original protocol, added to gain experience with a placebo comparator)
62424014|NCT01095029|EXPERIMENTAL|Off/Off|Pacemaker status: Bilateral Off for four weeks before first PET scann.
62424015|NCT01095029|EXPERIMENTAL|On/On|Pacemaker status: Bilateral On. PET scan one hour after activation and after four weeks continuous stimulation.
62424016|NCT01095029|EXPERIMENTAL|On/Off|Pacemaker status: Unilateral On. PET scan one hour after activation and after four weeks continuous stimulation.
62032923|NCT00489970|ACTIVE_COMPARATOR|Adacel Group|Subjects received in the primary study (NCT00346073) a single dose of Adacel vaccine intramuscularly in the deltoid region of the non-dominant upper arm and in this study at Year 9 received a dose of Boostrix vaccine \[Tdap\](GSK776423).
62424017|NCT00979238|OTHER|Group 1|"All participants who meet the eligibility requirements.~Intervention: Gene Transfer and drug (scAAV2/8-LP1-hFIXco)."
62424018|NCT05538169|EXPERIMENTAL|Laser therapy group|There will be 2 weekly applications of a low-level laser diode (Pioon Laser) for a 4-week active treatment period. Thus, a total of 8 therapeutic sessions will be conducted
62424019|NCT02322242|ACTIVE_COMPARATOR|Perineural Dexamethasone|ISB performed with local anesthetic (ropivacaine 0.5%) and perinerual dexamethasone (4mg)
62424020|NCT02322242|OTHER|Systemic Dexamethasone|ISB with local anesthetic alone (ropivacaine 0.5%) alone and intravenous dexamethasone (4mg)
62424021|NCT01189071|ACTIVE_COMPARATOR|Darifenacin|3 days of preoperative darifenacin anticholinergic medication
62424022|NCT01189071|NO_INTERVENTION|no pill|The control group will have the standard of care which is no preoperative anticholinegic medication.
62424023|NCT05430568||bypass graft, sternotomy|patients who have received coronary artery bypass graft surgery with conventional sternotomy procedure
62424024|NCT05430568||bypass graft, robot|patients who have received coronary artery bypass graft surgery with robot-assisted procedure
62032924|NCT00489970|ACTIVE_COMPARATOR|Control group|Subjects received the first dose of Boostrix vaccine \[Tdap\](GSK776423) in this study at Year 9.
62424025|NCT05430568||valvular heart disease, sternotomy|patients who have received valvular replacement surgery with conventional sternotomy procedure
62424026|NCT05430568||valvular heart disease, robot|patients who have received valvular replacement surgery with robot-assisted procedure
62424027|NCT03229239|EXPERIMENTAL|corneal stroma implantation|implant the corneal stroma to the diseased cornea of keratoconus patients
62593091|NCT05462132|EXPERIMENTAL|Cohort 3|"HV subjects receive doses 6 × 10\^11 live cells of SYNB1353 and 30 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of 30 mg/kg will be evaluated."
62593092|NCT05462132|EXPERIMENTAL|Cohort 4|"HV subjects receive doses 6 × 10\^11 live cells of SYNB1353 and up to 100 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of up to 100 mg/kg will be evaluated."
62424028|NCT00782275|EXPERIMENTAL|bevacizumab and temsirolimus|"bevacizumab: given intravenously at a dose of 10mg/kg every 2 weeks (days 1 and 15)~temsirolimus: given intravenously at a dose of 25mg weekly on days 1, 8, 15, and 22~1 cycle=28-days~There were no dose reductions for bevacizumab allowed. If bevacizumab was held, the same dose would be used if treatment were resumed. If temsirolimus was held, the same or a reduced dose (15mg IV weekly) could be used upon resumption of therapy. Treatment was continued until the development of unacceptable toxicity or progression."
62424029|NCT00149552|ACTIVE_COMPARATOR|Zinc gluconate|Zinc supplementation
62424030|NCT00149552|PLACEBO_COMPARATOR|Placebo|Placebo
62424031|NCT05375682|EXPERIMENTAL|Integrated care program|ICP intervention consists of several core intervention components.
62424032|NCT04593680|EXPERIMENTAL|20 HIV-negative TGM will take daily TDF/FTC-based PrEP|"MHT will be initiated on week 0 and will be last administered on week 12. PrEP will be initiated on week 6 and continued without interruption.~MHT: Intramuscular testosterone enanthate 200 mg bi-weekly, which is the treatment of choice for MHT in the Pribta Clinic, will be provided to all participants.~PrEP: Fixed-dose combination of emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF) will be provided for arm 1 and 2, respectively.~Pharmacokinetic measurement of study drug Two full pharmacokinetic (PK) measurements will be performed. Samples collected will include: plasma for testosterone, emtricitabine (FTC) and tenofovir (TFV), with an additional tenofovir alafenamide (TAF)."
62809219|NCT04189367|EXPERIMENTAL|Western medicine + TCM|"1. Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the informed consent.~2. Blood test and physiological assessment, and do the TCM model.~3. Primary type BMS patients receive clonazepam 0.5 mg PO every day before sleep or twice a day for 12 weeks~4. Secondary BMS patients receive nutritional supplements according to the patient's hematic deficiency status for 12 weeks.~5. TCM therapy: one bag of Qingre Liangkou Ningxin Fang, three times a day for 12 weeks."
62424033|NCT04593680|EXPERIMENTAL|20 HIV-negative TGM will take daily F/TAF-based PrEP|"MHT will be initiated on week 0 and will be last administered on week 12. PrEP will be initiated on week 6 and continued without interruption.~MHT: Intramuscular testosterone enanthate 200 mg bi-weekly, which is the treatment of choice for MHT in the Pribta Clinic, will be provided to all participants.~PrEP: Fixed-dose combination of emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF) will be provided for arm 1 and 2, respectively.~Pharmacokinetic measurement of study drug Two full pharmacokinetic (PK) measurements will be performed. Samples collected will include: arm 2, measurement; and peripheral blood mononuclear cells (PBMC) for emtricitabine-triphosphate (FTC-TP) and tenofovir-diphosphate (TFV-DP) intracellular quantification."
62593093|NCT05462132|EXPERIMENTAL|Cohort 5|"HV subjects receive doses 1 × 10\^12 live cells of SYNB1353 and 30 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of 30 mg/kg will be evaluated."
62809220|NCT04189367|ACTIVE_COMPARATOR|Western medicine|"1. Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the informed consent.~2. Blood test and physiological assessment, and do the TCM model.~3. Primary type BMS patients receive clonazepam 0.5 mg PO every day before sleep or twice a day for 12 weeks~4. Secondary BMS patients receive nutritional supplements according to the patient's hematic deficiency status for 12 weeks."
62809221|NCT03153774|EXPERIMENTAL|Heart failure patients|The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
62809222|NCT03153774|EXPERIMENTAL|TAVI patients|The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
62809223|NCT05754294||Coronary arteries bypass grafting with conventional cardiopulmonary bypass (cCPB)|(n=20) patients, were allocated for Conventional Cardiopulmonary Bypass (cCPB)
62232943|NCT05210296|EXPERIMENTAL|Trunk strengthening exercises|"After 5 minutes of warm-up exercises, 20 minutes of trunk strengthening exercises and 10 minutes of balance exercises will be applied to the participants, and the session will end with 5 minutes of cooling-off exercises.~In trunk strengthening exercises, trunk resistance exercises will be applied with an elastic exercise band."
62809224|NCT05754294||Coronary arteries bypass grafting with Minimally invasive extracorporeal circulation (MiECC)|(n=20) patients, were allocated for Minimal invasive Extracorporeal Circulation (MiECC) type III.
62032925|NCT05427799|EXPERIMENTAL|Honey|"Treatment with honey will extend for four months and the actual treatment phases will be preceded by a 2-week run-in period, in which the participants will be asked to refrain from honey consumption.~During the six months intervention, a daily dose of 0.5 g/kg body weight of honey will be consumed by each participant. Participants will be provided with Mixed flora honey that will be obtained from local producers. The daily dose of treatments will be divided into two doses to simulate a natural pattern of consumption.~All participants will be required to limit the consumption of caffeinated beverages to two beverages a day during the study periods.~A nutritionist will calculate the energy requirement and provide dietary instructions and a nutritionally adequate, hypocaloric, balanced sample diet plan with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein will be individualized for each participant monthly."
62032926|NCT05427799|PLACEBO_COMPARATOR|Other carbohydrate alternatives|"Treatment with simple sugar alternatives (other carbohydrates, such as jell-o) will extend for four months and the actual treatment phases will be preceded by a 2-week run-in period, in which the participants will be asked to refrain from honey consumption, and during the study periods.~A daily dose of 0.5 g/kg body weight of jell-O will be consumed by each participant and will be divided into two doses to simulate a natural pattern of consumption. Jell-O was selected as a source of sucrose with negligible phenolic capacity, which will serve as a control.~All participants will be required to limit the consumption of caffeinated beverages to two beverages a day during the study periods.~A nutritionist will calculate the energy requirement and provide dietary instructions and a nutritionally adequate, hypocaloric, balanced sample diet plan with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein will be individualized for each participant monthly."
62032927|NCT05602376|EXPERIMENTAL|U=U testing messaging scripts|Aim 1: Human-centred designed, behavioural nudge theory informed U=U messaging intervention to improve HIV testing uptake by men
62032928|NCT05602376|EXPERIMENTAL|U=U adherence messaging scripts|Aim 2: Human-centred designed, behavioural nudge theory informed U=U messaging intervention to improve ART adherence, HIV viral suppression and retention in care
62032929|NCT05602376|NO_INTERVENTION|Standard of Care (SoC) messaging|"Aim 1: SoC messaging scripts will be used to both invite men for CB-HTS and to refer those that test HIV-positive for DoH clinic-based ART initiation~Aim 2: SoC messaging as part of ART initiation counselling, and as part of their HIV care and treatment program"
62032930|NCT04609254|EXPERIMENTAL|First Group|1000 mg of paracetamol ( parol 1000mg vial-atabay chemistry-İstanbul) intravenous (IV) was given 71 patients,
62232944|NCT05210296|EXPERIMENTAL|Lower extremity strengthening exercises|"After 5 minutes of warm-up exercises, lower extremity strengthening exercises and 10 minutes of balance exercises will be applied to the participants, and the session will end with 5 minutes of cool-down exercises.~In lower extremity strengthening exercises, lower extremity resistance exercises will be applied with elastic exercise band."
62032931|NCT04609254|EXPERIMENTAL|Second Group|dexketoprofen 50 mg arveles 50 mg ampoule -Menarini- Istanbul) intravenous (IV) was given 70 patients,
62232945|NCT05210296|NO_INTERVENTION|Control|Participants will not be included in any exercise program. At the end of the study, the elderly will be informed about the effects of exercises and appropriate exercise program training will be given.
62232946|NCT04201509||ADHD group|Participants in the clinical group were recruited to the project when they were assessed for and diagnosed with ADHD at the Neuropsychiatric Unit of the CAP Clinic in Lund in 2011-2012. The ADHD group was treated as usual in the clinic and re-assessed during 2014-2015.
62424034|NCT02802137|ACTIVE_COMPARATOR|Tafluprost drops|Treatment with preservative-free talfuprost drops administered once in the evening. Evaluation of 24-hour efficacy and ocular surface health after 3 months of therapy.
62424035|NCT02802137|ACTIVE_COMPARATOR|Tafluprost and dorzolamide/timolol drops|Concomitant therapy with preservative-free talfuprost drops administered once in the evening and dorzolamide/timolol fixed combination drops given twice daily. Evaluation of 24-hour efficacy and ocular surface health after 3 months of therapy.
62424036|NCT04179474|EXPERIMENTAL|Part 1 (Intervention A then B then D)|Intervention A: Single oral dose of ubrogepant 100 mg tablet on Day 1 under fasted conditions; followed by Intervention B: Single subcutaneous (SC) injection of erenumab 140 mg on Day 8; followed by Intervention D: Ubrogepant 100 mg tablet orally once daily on Days 12, 13, 14 and 15 under fasted conditions.
62424037|NCT04179474|EXPERIMENTAL|Part 2 (Intervention A then C then D)|Intervention A: Single oral dose of ubrogepant 100 mg tablet on Day 1 under fasted conditions; followed by Intervention C: Two SC injections of galcanezumab 120 mg on Day 8; followed by Intervention D: Ubrogepant 100 mg tablet orally once daily on Days 12, 13, 14 and 15 under fasted conditions.
62809225|NCT05754294||Minimally invasive mitral valve repair (MIMVR) with CPB time (< 60 min.)|(n=20) patients, were allocated for Minimally invasive mitral valve repair (MIMVR) with CPB time (\< 60 min.)
62809226|NCT05754294||Minimally invasive mitral valve repair (MIMVR) with CPB time (>100 min.)|n=20) patients, were allocated for Minimally invasive mitral valve repair (MIMVR) with CPB time (\> 100 min.)
62032932|NCT04609254|EXPERIMENTAL|Third group|400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
62809227|NCT03905096|EXPERIMENTAL|Part 1|
62032933|NCT06127667|EXPERIMENTAL|Experimental group|Healthy participants in 3 age groups
62032934|NCT06216457||Group 1: LVO|Subjects with Methinks NCCT algorithm detecting ICA, M1, and M2 occlusions.
62032935|NCT06216457||Group 2: ICH|Subjects with Methinks NCCT algorithm detecting ICHs.
62232947|NCT04201509||Non-clinical group|Participants in the non-clinical group were recruited recruited 2012 from schools in the same district and among children of the same average age as the ADHD-group 2012. The non-clinical group did not have any intervention during the follow-up time. Th non-clinical group was re-assessed during 2015.
62809228|NCT03905096|EXPERIMENTAL|Part 2|
62232948|NCT05141123||Preloaded Fenestrated Stent-graft Designs for Endovascular Aortic Procedures|Patients presenting with an acute (up to two weeks from the onset) and subacute (between 3 and 12 weeks from the onset) type B dissection with a proximal suitable non-dissected landing zone in the aortic arch or descending thoracic aorta (supra-aortic trunks debranching may be employed to obtain an adequate proximal landing zone)
62232949|NCT03639233|OTHER|Arm 1|Intervention access
62232950|NCT00582868||Hemorrhage|Patients having experienced subarachnoid hemorrhage and have in place a ventriculostomy
62424038|NCT01674959|EXPERIMENTAL|concurrent chemoradiation|"• Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative current chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks)."
62032936|NCT06216457||Group 3: Controls|Subjects with final diagnosis confirmed not to be Stroke (i.e. stroke mimic) or any type of stroke not determined to be: LVO (ICA, M1 or M2) or ICH.
62232951|NCT02722720|EXPERIMENTAL|Carotid stenting, Transradial approach|Internal carotid artery stenting using transradial arterial approach
62809229|NCT03600272|EXPERIMENTAL|Combined spinal-epidural analgesia|The combined spinal epidural analgesia technique was used to maintain analgesia for parturients in the combined spinal-epidural analgesia group. First, the investigator injected a dose of 5 ug sufentanil into cerebrospinal fluid. If no adverse effects were observed 10 minutes after the first dose, the parturient then received mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate through a patient-controlled epidural analgesia (PCA) pump, which provided patients themixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
62819562|NCT03009058|EXPERIMENTAL|IMM-101+ anti-programmed death-1 (PD1) melanoma|IMM-101 will be given in combination with standard treatment with either pembrolizumab or nivolumab. The first 3 patients entering the anti-PD1 (pembrolizumab or nivolumab) cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen thereafter.
62032937|NCT02173977|ACTIVE_COMPARATOR|ARM A- Agonist/Antagonist protocol|The Ultrashort GnRH Agonist/antagonist method entails pre-treatment with oral contraceptive pills before the combination of GnRH ultrashort agonist and antagonist protocol
62032938|NCT02173977|ACTIVE_COMPARATOR|ARM B- Antagonist protocol|The standard IVF method entails Flexible Multidose GnRH Antagonist protocol during COH
62232952|NCT02722720|ACTIVE_COMPARATOR|Carotid stenting, Transfemoral approach|Internal carotid artery stenting using transfemoral arterial approach
62232953|NCT05323799||Group 1/Seed set 1 - recently diagnosed 'COVID-19 cases|(Group1) and their social network with up to 2 waves of /Key people, will be followed up for 1 month initially with specific monitoring tools before they will transition into ongoing follow up and monitoring as recruitment group 2
62232954|NCT05323799||Group 2/Seed set 2 - people from the general community that are not currently infected with COVID19|'Group 2' that are practicing physical distancing and represent specific key risk groups, and their social network with up to 2 waves of Key people
62232955|NCT03463148||1|Men/Women who meet the inclusion/exclusion criteria of this protocol.
62232956|NCT02839837|EXPERIMENTAL|Depressed and non-depressed controls|All participants will participate in three different conditions: Low intensity aerobic exercise and paired associative stimulation, high intensity aerobic exercise and paired associative stimulation, no exercise control and paired associative stimulation. The order of conditions will be randomized.
62232957|NCT05395910|EXPERIMENTAL|PIPAC Paclitaxel|"3 patients will be allocated to PIPAC arm at Paclitaxel 15mg/m2. If there is 1 dose limiting toxicity (DLT), an additional 3 patients will be allocated to PIPAC arm at 15mg/m2. If there is 2 - 3 DLT, study had exceeded its Maximum Tolerable Dose (MTD) and we will proceed to stop recruitment.~Should there be no DLT, recruitment at PIPAC 30mg/m2 and ePIPAC 15mg/m2 will occurs concurrently in an alternating fashion. PIPAC/ePIPAC dose escalation will continue until a MTD has been reached. Should there be no DLT at PIPAC 30mg/m2 and ePIPAC 15mg/m2, recruitment at PIPAC 45mg/m2 and ePIPAC 30mg/m2 will occurs concurrently in an alternating fashion. Finally, should there be no DLT, recruitment at ePIPAC 45mg/m2 will occurs."
62232958|NCT05395910|EXPERIMENTAL|ePIPAC Paclitaxel|Should there be no DLT under PIPAC arm at Paclitaxel 15mg/m2, recruitment at ePIPAC 15mg/m2 and PIPAC 30mg/m2 will occurs concurrently in an alternating fashion. PIPAC/ePIPAC dose escalation will continue until a MTD has been reached. Should there be no DLT at PIPAC 30mg/m2 and ePIPAC 15mg/m2, recruitment at PIPAC 45mg/m2 and ePIPAC 30mg/m2 will occurs concurrently in an alternating fashion. Finally, should there be no DLT, recruitment at ePIPAC 45mg/m2 will occurs.
62232959|NCT04652167||Patients suspected of community-acquired pneumonia|All patients admitted to the emergency department with suspected community- acquired pneumonia by the attending physician
62232960|NCT04519112|EXPERIMENTAL|Remote magnetic navigation group|PVC ablation with RMN
62424039|NCT03256708|EXPERIMENTAL|Prolardii|Prolardii GR Caps includes 4 strains of living lyophilized lactic bacteria (Lactobacillus rhamnosus GG, Bifidobacterium lactis B94, Lactobacillus casei 5773 and Lactobacillus acidophilus LA3), a yeast (Saccharomyces boulardii), a fructo-oligosaccharide (Actilight) and a dry extract of Inula helenium.
62424040|NCT03256708|PLACEBO_COMPARATOR|Placebo|Inactive ingredients
62424041|NCT01586117|EXPERIMENTAL|Amifostine|intrarectal Amifostine assign to the Amifostine arm
62032939|NCT02699333||Microscopic colitis cases|Patients found to have microscopic colitis based on colonic biopsies.
62032940|NCT02699333||Controls|Patients who meet eligibility requirements but do not have microscopic colitis on biopsy.
62032941|NCT05403580|EXPERIMENTAL|Arm I (olanzapine)|Patients receive olanzapine PO every night on days 1-28.
62232961|NCT04519112|ACTIVE_COMPARATOR|Mannual control navigation group|PVC ablation with mannual navigation
62232962|NCT02966392|EXPERIMENTAL|Continuous Pressure Control (CPC)|Continuous endotracheal cuff pressure control using Tracoe cuff pressure controller during their intubated stay on ICU.
62232963|NCT02966392|NO_INTERVENTION|Standard Care|Intermittent cuff pressure control through manual measurement performed 3 times per day (standard care)
62232964|NCT04200131|EXPERIMENTAL|Moray micro-forceps|
62232965|NCT02374021|ACTIVE_COMPARATOR|Triple therapy (MTX+SSZ+HCQ)|Sulfasalazine (SSZ) 1 g bid and hydroxychloroquine (HCQ) 200 mg twice daily, not to exceed 6.5mg/kg HCQ (in addition to concomitant methotrexate \[MTX\]).
62424042|NCT02421107|OTHER|all patients|all patients
62032942|NCT05403580|ACTIVE_COMPARATOR|Arm II (placebo, olanzapine)|Patients receive placebo PO every night on days 1-2 and olanzapine PO every night on days 3-28.
62032943|NCT03252587|EXPERIMENTAL|BMS-986165 Dose 1 oral administration|
62424043|NCT01040676|NO_INTERVENTION|Control Group|"Patients in this (the control group) will be eligible to receive the intervention (see Intervention Group) after 12 weeks (essentially when the trial is over)."
62424044|NCT01040676|EXPERIMENTAL|Intervention Group|Patients in the intervention group will receive automated telephone calls at regular intervals twice a week. The system will be programmed to call them at these intervals until contact. The ATNS system will solicit information from them in a culture specific manner, inquiring as to what foods they are eating each meal, each day, and each month. The ATNS system will then make proactive suggestions regarding low glycemic index foods, giving encouragement and feedback as appropriate.
62424045|NCT05949931|EXPERIMENTAL|Concurrent penpulimab and AVD|Participants will receive Penpulimab and AVD injection at the same time for a total of 6 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
62032944|NCT03252587|EXPERIMENTAL|BMS-986165 Dose 2 oral administration|
62032945|NCT03252587|EXPERIMENTAL|BMS-986165 Dose 3 oral administration|
62424046|NCT05949931|EXPERIMENTAL|Sequential penpulimab and AVD|Participants will receive penpulimab for 3 cycles; follewed by 6 cycles of AVD; finally, penpulimab for 3 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
62809230|NCT03600272|OTHER|Epidural analgesia|The epidural analgesia technique was used to maintain analgesia for parturients in the epidural analgesia group, which involved placing a thin catheter through a needle inserted into the epidural space. First, the investigator injected a test dose of 5ml 1% lidocaine through it. If not adverse effects were observed 10 minutes after the test dose, the parturient then received a bolus injection of an initial dose of 8-10 ml mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate. We then connected the catheter with a patient-controlled epidural analgesia (PCA) pump, which provided patients the same mixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
62809231|NCT00976131|PLACEBO_COMPARATOR|Arm A Placebo|"Patients will begin taking their study pills (CoQ10) on the morning of Cycle 2 Day 3 (11-15 days prior to Cycle 3), and will continue taking the study pills through the morning of their Cycle 3 infusion (Day 1 Cycle 3). Patients will then be crossed-over to the alternative condition. On the morning of Cycle 3 Day 3, patients will begin taking their study pills (CoQ10 placebo) and will continue taking the study pills through the morning of their Cycle 4 infusion (Day 1 Cycle 4).~Infusion will be standard of care chemotherapy with doxorubicin and cyclophosphamide."
62032946|NCT03252587|PLACEBO_COMPARATOR|Placebo oral administration|
62032947|NCT02048943|EXPERIMENTAL|Treatment (dovitinib, gemcitabine, nab-paclitaxel)|Patients receive dovitinib lactate PO QD 5 days per week, paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62032948|NCT00607334|EXPERIMENTAL|GP|Children with Developmental Language Impairments were enrolled in this group.
62032949|NCT00607334|EXPERIMENTAL|GC|Children with normal language development were enrolled in this group.
62032950|NCT05194774||GT overgrowth group|pediatric patients with greater trochanter overgrowth
62032951|NCT01837381|OTHER|Transarterial Ethanol Ablation (TEA)|Two treatment sessions at 2 months apart were given and started within 4 weeks after randomization.
62032952|NCT05987683|EXPERIMENTAL|Thread-Embedding Acupuncture|Thread-Embedding Acupuncture using a 29-gauge TEA needle with a 50-mm PDO (polydioxanone) thread
62032953|NCT05987683|SHAM_COMPARATOR|Sham Thread-Embedding Acupuncture|Sham Thread-Embedding Acupuncture using a 29-gauge TEA needle but thread-removed, just needle alone
62032954|NCT02657226||Intensive Monitoring of Renal Function|Urine output measurements recorded at least every 2 hours within the first 48 hours of ICU admission and serum creatinine measurements recorded daily for 3 days following ICU admission.
62032955|NCT02657226||Less-Intensive Monitoring of Renal Function|Urine output measurements with gaps of more than 3 hours recorded during the first 48 hours of ICU admission and fewer than 3 days of serum creatinine measurements after ICU admission.
62032956|NCT02671435|EXPERIMENTAL|Dose-escalation Cohort 1: Monalizumab 22.5 mg Q2W + Durvalumab 1500 mg Q4W|Participants will receive intravenous (IV) infusions of durvalumab 1500 mg every 4 weeks (Q4W) in combination with monalizumab 22.5 mg every 2 weeks (Q2W) up to 3 years until unacceptable toxicity, documentation of confirmed disease progression (PD), or documentation of subject withdrawal for another reason.
62032957|NCT02671435|EXPERIMENTAL|Dose-escalation Cohort 2: Monalizumab 75 mg Q2W + Durvalumab 1500 mg Q4W|Participants will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 75 mg Q2W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
62032958|NCT02671435|EXPERIMENTAL|Dose-escalation Cohort 3: Monalizumab 225 mg Q2W + Durvalumab 1500 mg Q4W|Participants will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 225 mg Q2W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
62424047|NCT00230620||Individuals with HHT and their families|No intervention - blood or saliva sample only
62424048|NCT05445037|EXPERIMENTAL|Continuos Monitoring|Continuos monitoring will be done with clearsight continuously assessing blood pressure, cardiac output and heart rate; NIRS electrode to access cerebral O2 saturation, peripheral O2 saturation, BIS value and axillary temperature.
62424049|NCT05445037|EXPERIMENTAL|Standard monitoring|Standard monitoring will be done with non-invasive
62424050|NCT06084273|EXPERIMENTAL|Bobath Exercises|Bobath Exercises
62032959|NCT02671435|EXPERIMENTAL|Dose-escalation Cohort 4: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W|Participants will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
62424051|NCT06084273|EXPERIMENTAL|Breathing Exercises,Breathing Exercises, Bobath Exercises|Breathing Exercises,Breathing Exercises, Bobath Exercises
62593094|NCT05462132|EXPERIMENTAL|Cohort 6|"HV subjects receive doses 1 × 10\^12 live cells of SYNB1353 and up to 100 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of up to 100 mg/kg will be evaluated."
62593095|NCT05462132|EXPERIMENTAL|Cohort 7|"HV subjects receive doses less than or equal to 2 × 10\^12 live cells of SYNB1353 and 30 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of 30 mg/kg will be evaluated."
62032960|NCT02671435|EXPERIMENTAL|Dose-escalation Cohort 5: Monalizumab 750 mg Q4W + Durvalumab 1500 mg Q4W|Participants will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q4W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
62032961|NCT02671435|EXPERIMENTAL|Dose-expansion Cohort: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W (MSS-CRC)|Participants with microsatellite-stable colorectal cancer (MSS-CRC) will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
62032962|NCT02671435|EXPERIMENTAL|Dose-expansion Cohort: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W (ovarian)|Participants with ovarian cancer will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
62032963|NCT02671435|EXPERIMENTAL|Dose-expansion Cohort: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W (Endometrial MSS)|Participants with endometrial MSS will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
62032964|NCT02671435|EXPERIMENTAL|Dose-expansion Cohort: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W (NSCLC)|Participants with non-small cell lung cancer (NSCLC) will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
62232966|NCT02374021|ACTIVE_COMPARATOR|TNF inhibitor (etanercept or adalimumab)|etanercept 50 mg subcutaneously weekly or adalimumab 40 mg subcutaneously every other week (in addition to concomitant methotrexate, plus hydroxychloroquine, for subjects who were taking this at screening). Biologic treatment will be assigned randomly.
62809232|NCT00976131|EXPERIMENTAL|Arm B CoQ10|"Patients will begin taking their study pills (CoQ10 placebo) on the morning of Cycle 2 Day 3 (11-15 days prior to Cycle 3), and will continue taking the study pills through the morning of their Cycle 3 infusion (Day 1 Cycle 3). Patients will then be crossed-over to the alternative condition. On the morning of Cycle 3 Day 3, patients will begin taking their study pills (CoQ10) and will continue taking the study pills through the morning of their Cycle 4 infusion (Day 1 Cycle 4).~Infusion will be standard of care chemotherapy with doxorubicin and cyclophosphamide."
62232967|NCT04513704|EXPERIMENTAL|Oral Semaglutide A|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-specified timing for 2 hours of the pre-dose fast, followed by a 30 minutes post-dose fast.
62809233|NCT01161186|EXPERIMENTAL|Nab-paclitaxel,Gemcitabine, and Capecitabine|
62809234|NCT05480683|EXPERIMENTAL|Targeted CT of pelvis with specific penile anatomical positioning for Peyronie Disease|Subject presenting with Peyronie disease signs or symptoms to Mayo Clinic Florida Department of Urology will undergo a targeted noncontrast CT of the pelvis with specific penile anatomical positioning
62232968|NCT04513704|EXPERIMENTAL|Oral Semaglutide B|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-specified timing for 4 hours of the pre-dose fast, followed by a 30 minutes post-dose fast.
62433563|NCT04582448|EXPERIMENTAL|Insulin icodec treatment sequence with injection region abdomen|Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.
62433564|NCT04582448|EXPERIMENTAL|Insulin icodec treatment sequence with injection region upper arm|Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.
62433565|NCT04582448|EXPERIMENTAL|Insulin icodec treatment sequence with injection region thigh|Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.
62809235|NCT04014335|EXPERIMENTAL|IONIS-FB-LRx|
62433566|NCT03061760||1. OAB (-) BOO (-)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with no overactive bladder (OAB) symptoms and without bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
62433567|NCT03061760||2. OAB (-) BOO (+)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with no overactive bladder (OAB) symptoms and with bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
62232969|NCT04513704|EXPERIMENTAL|Oral Semaglutide C|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-specified timing for 6 hours of the pre-dose fast, followed by a 30 minutes post-dose fast.
62809236|NCT04467073|EXPERIMENTAL|Stepped-Care Online Reciprocal Imitation Training (Online RIT)|"Participants completed four telehealth modules over a period of 5 weeks (\~1 per week, 1 week to practice). Two variables were selected as tailoring variables for this stepped-care model. Fidelity (RIT-PFF) and self-efficacy (EIPSES) at 5 weeks were used to determine which participants were in need of a step up in care, in the form of remote parent coaching.~Parents who demonstrated ≥80% on the RIT-PFF, and who reported gains on the EIPSES continued to have access to Online RIT and practiced on their own for the next 5 weeks, but did not receive any remote coaching. Parents who demonstrated \<80% fidelity on the RIT-PFF and/or who didn't report increases in the EIPSES were directed into coaching. Coaching involved videoconferences once per week (wks. 6-10) with a parent coach (PI), and followed the occupational performance coaching model. Sessions included review of successes and challenges, parent practice with feedback, problem solving, and planning."
62232970|NCT04513704|EXPERIMENTAL|Oral Semaglutide D|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-dose fasting time of 2 hours followed by a post-dose overnight fast.
62232971|NCT04513704|ACTIVE_COMPARATOR|Oral Semaglutide E|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days). Participants will be instructed to take the trial product in the morning after an overnight fast and wait 30 minutes before taking any food, water or other oral medication in accordance with the approved dosing schedule for oral semaglutide.
62809237|NCT04467073|NO_INTERVENTION|Wait List Control|Participants provided with information about available community resources after randomization. These participants were given the opportunity to engage in the stepped-care format of Online RIT after the post-intervention data collection time point; however their data was included exclusively in control group analyses.
62424052|NCT03942952||CNS demyelinating diagnosis|"Diagnosis of CNS demyelinating disorder: Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, anti-MOG antibody, Optic Neuritis.~* 3T and 7T MRI~* Neuropsychological testing~* Optical Coherence Tomography~* Questionnaires: Quality of Life and Behavior scales~* Non invasive clinical assessment : Walking, hand and eye coordination tests Repeat same research activities one to year and a half year later"
62424053|NCT03942952||Healthy Control|"* 3T and 7T MRI~* Neuropsychological testing~* Optical Coherence Tomography~* Questionnaires: Quality of Life and Behavior scales~* Non invasive clinical assessment : Walking, hand and eye coordination tests Repeat same research activities one year to a year and a half later"
62232972|NCT05078320|EXPERIMENTAL|Internet-delivered cognitive-behaviour therapy for adolescents with body dysmorphic disorder|Cognitive-behaviour therapy, Exposure and response prevention (ERP)
62232973|NCT00802425|EXPERIMENTAL|2|AM-111 low dose
62424054|NCT03175445||mandible CBCT scans in males|74 males CBCT scan by planmeca promax 3D Mid machine using 90 kVp, 10 mA, 14 seconds and 200×60 mm FOV with a 0.2 mm voxel size.
62232974|NCT00802425|PLACEBO_COMPARATOR|1|
62232975|NCT00802425|EXPERIMENTAL|3|AM-111 high dose
62809238|NCT01277744|EXPERIMENTAL|HIPEC + Cisplatin|HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions. Cisplatin 100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the Cisplatin.
62809239|NCT00561652|ACTIVE_COMPARATOR|Education + exercise|Education was provided in four, 1-hour sessions to improve patients' understanding of their back problem, reduce unwarranted concern about serious outcomes, \& empower them to maintain normal activities \& reduce risk of future back problems. Patients were taught that recovery depends on moving \& restoring normal function \& fitness. Patients were shown stretching \& strengthening exercises to perform daily at home to enhance mobility \& increase trunk endurance while minimizing spinal load. At follow-up, therapists reviewed exercise form \& adherence. Participants allocated to no chiropractic care also were scheduled for 10 weekly 10-15 minute sessions to equalize provider attention vs. the group also receiving chiropractic care \& not to provide education, exercise instruction, or therapy.
62809240|NCT00561652|EXPERIMENTAL|Education + exercise + chiropractic|In addition to education \& exercise, all participants in this arm will be assigned chiropractic treatment. A minimum of 4 \& up to 12 treatments will be provided over 6 weeks, based on patient response (i.e. treatments stopped if symptoms resolve). Each treatment visit will last 10-20 minutes. After 6 weeks, if the treating chiropractor determined that the patient's LBP was continuing to improve but hadn't reached therapy goals defined at baseline, the patient could receive up to 12 additional treatments over the next 6 weeks. Chiropractic treatment was delivered following standardized protocols. Treatment consisted of manual therapies, including SMT and mobilization techniques, with the assistance of light soft tissue techniques as indicated to facilitate the SMT.
62032965|NCT02671435|EXPERIMENTAL|Exploration Cohort A1: Monalizumab 750 mg Q2W+Durvalumab 1500 mg Q4W+mFOLFOX6 Q2W+Bevacizumab Q2W|Participants with first-line (1L) MSS-CRC will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W plus mFOLFOX (oxaliplatin 85 mg/m\^2 IV infusion, folinic acid 400 mg/m\^2 infusion, fluorouracil 400 mg/m\^2 IV bolus, followed by 2400 mg/m\^2 continuous IV infusion over 46 to 48 hours on Day 1) Q2W plus IV infusion of bevacizumab 5 mg/kg Q2W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
62032966|NCT02671435|EXPERIMENTAL|Exploration CohortA2: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W + mFOLFOX6 Q2W + Cetuximab Q2W|Participants with 1L MSS-CRC will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W, plus mFOLFOX6 (oxaliplatin 85 mg/m\^2, folinic acid 400 mg/m\^2, fluorouracil 400 mg/m\^2 IV bolus, followed by 2400 mg/m\^2 continuous IV infusion over 46 to 48 hours on Day 1) Q2W plus IV infusion of cetuximab (loading dose of 400 mg/m\^2 on Day 1, followed by maintenance dose of 250 mg/m\^2 IV infusion every week starting on Day 8, then changed to 500 mg/m\^2 IV infusion Q2W) up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
62232976|NCT04662762|EXPERIMENTAL|nursing intervention group|An educational interview by trained nurses was performed at three months in patients allocated to the intervention group. The visit was carried out at the hospital. Family and caregivers were also asked to attend this visit for instruction. For patients unable to move, the nursing team went to their home to perform the intervention, or it was conducted by phone. The duration of this interview was approximately 40 minutes and was focused on some measures and recommendations to improve or maintain adherence. Then, there is a reminder call at 6 months.
62232977|NCT04662762|NO_INTERVENTION|Usual care group|The patient is followed up and regular visits
62232978|NCT02343731|EXPERIMENTAL|Dog Introduction|Participants will receive a dog from the Humane Society of Southern Arizona's (HSSA) foster care program to live with them for three months.
62232979|NCT01351753|ACTIVE_COMPARATOR|Metformin|
62232980|NCT01351753|EXPERIMENTAL|Metformin + Orlistat|
62232981|NCT01351753|EXPERIMENTAL|Metformin + Topiramate|
62232982|NCT01351753|EXPERIMENTAL|Topiramate|
62232983|NCT01351753|EXPERIMENTAL|Metformin + Topiramate + Orlistat|
62809241|NCT01460966|ACTIVE_COMPARATOR|Filtrap™+ Thrombus aspiration catheter|
62809242|NCT01460966|ACTIVE_COMPARATOR|Thrombus aspiration catheter|
62809243|NCT04068701|EXPERIMENTAL|MaNMT Biofeedback|A group that will receive a neuromuscular training intervention that incorporates biofeedback training
62809244|NCT04068701|SHAM_COMPARATOR|Sham|a group that will receive the same neuromuscular training intervention with sham feedback training.
62809245|NCT01021735|ACTIVE_COMPARATOR|Anti-TNF therapy|Etanercept or adalimumab by s/c injection
62232984|NCT01351753|PLACEBO_COMPARATOR|Placebo|
62232985|NCT05997888|EXPERIMENTAL|At-Home Strength Training Group|Participants in this arm will undergo an in-person meeting before the start of the study to meet each other, go over movements to minimize risk of injury, and to discuss intervention logistics. Then, for six weeks, participants will be sent five workouts at the start of each week (Monday). Participants will choose 2 or 3 to complete on their own. Additionally, participants will have a weekly Zoom meeting in which 30 minutes will be dedicated to exercising, and 30 minutes will be for group counseling.
62232986|NCT05997888|NO_INTERVENTION|Wait-List Control Group|This will be a wait-list control group. Participants at the end of the study will have the option to complete the full, partial, or none of the intervention.
62809246|NCT01021735|EXPERIMENTAL|Rituximab therapy|Rituximab given by IV infusion
62424055|NCT03175445||mandible CBCT scans in female|74 females CBCT scan by planmeca promax 3D Mid machine using 90 kVp, 10 mA, 14 seconds and 200×60 mm FOV with a 0.2 mm voxel size
62424056|NCT05968755|EXPERIMENTAL|Intervention group|
62232987|NCT06155448|EXPERIMENTAL|PMC intervention|The PMC intervention is designed to deliver a core regimen of six paediatric doses of sulphadoxine pyrimethamine linked to the EPI delivery platform in children 10 weeks to 15 months of age through trained health facility staff, plus additional 'pragmatic' monthly doses offered outside of the EPI schedule to children up to 18 months of age. Additional social mobilisation and social behaviour change (SBC) activities will be conducted throughout the implementation period to increase demand and uptake of vaccination and PMC services in the study population. at EPI scheduled touchpoints, plus additional monthly doses at non-scheduled monthly intervals up to age 18 months. The primary source of delivery will be government-run primary care health facilities in intervention arm wards. Coordination of implementation of the study within intervention and control arm wards will take place at the LGA level (unit of implementation).
62032967|NCT02671435|EXPERIMENTAL|Exploration Cohort C1A: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W + Cetuximab Q2W|Participants with recurrent or metastatic third-line (3L) RAS mutant MSS-CRC will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W plus IV infusion of cetuximab 500 mg/m\^2 on Day 1 then 500 mg/m\^2 IV infusion Q2W starting on Day 15 up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
62232988|NCT06155448|NO_INTERVENTION|Control|The control sites will have normal immunization as business as usual. However, the same sentinel site surveillance happening in the intervention arm will also be carried out in this arm. Pharmacovigilance will be passive in the control arm.
62232989|NCT04238065|EXPERIMENTAL|VR treatment|"The arm will use the virtual reality headset reproduces dynamic video content with perceptual learning and binocular perception (including stereopsis) that is visually perceived a little bit faster, brighter, and higher contrast to the amblyopia eyes .~The each VR therapy length is 30 minutes with 5 minute break after 15 minutes' therapy sequence, 3 times per week, total 13 weeks.~All amblyopia eyes are best optical correction or combining patching non-amblyopia eyes if there're more than 2 lines difference best corrected vision acuity."
62232990|NCT04238065|PLACEBO_COMPARATOR|control|"This arm of amblyopia eyes are all best optical correction or combining patching non-amblyopia eyes if there're more than 2 lines difference best corrected vision acuity.~No VR therapy."
62232991|NCT05516550|EXPERIMENTAL|Treamid 25 mg|1 tablet of Treamid 25 mg + 1 tablet of Placebo in the morning and 2 tablets of Placebo in the evening daily during 4 weeks of treatment period.
62232992|NCT05516550|EXPERIMENTAL|Treamid 50 mg twice a day|1 tablet of Treamid 25 mg + 1 tablet of Placebo in the morning and 1 tablet of Treamid 25 mg + 1 tablet of Placebo in the evening daily during 4 weeks of treatment period.
62424057|NCT05968755|PLACEBO_COMPARATOR|Control group|
62032968|NCT02671435|EXPERIMENTAL|Exploration Cohort C1B: Monalizumab 750 mg Q2W + Cetuximab Q2W|Participants with recurrent or metastatic 3L RAS mutant MSS-CRC will receive IV infusion of monalizumab 750 mg Q2W plus IV infusion of cetuximab 500 mg/m\^2 on Day 1 then 500 mg/m\^2 IV infusion Q2W starting on Day 15 up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
62032969|NCT02671435|EXPERIMENTAL|Exploration Cohort C2A: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W + Cetuximab Q2W|Participants with recurrent or metastatic 3L RAS/BRAF wild type MSS-CRC will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W plus IV infusion of cetuximab 500 mg/m\^2 on Day 1 then 500 mg/m\^2 IV infusion Q2W starting on Day 15 up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
62032970|NCT02671435|EXPERIMENTAL|Exploration Cohort C2B: Monalizumab 750 mg Q2W + Cetuximab Q2W|Participants with recurrent or metastatic 3L RAS/BRAF wild type MSS-CRC will receive IV infusion of monalizumab 750 mg Q2W plus IV infusion of cetuximab 500 mg/m\^2 on Day 1 then 500 mg/m\^2 IV infusion Q2W starting on Day 15 up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
62232993|NCT05516550|EXPERIMENTAL|Treamid 50 mg once a day|2 tablets of Treamid 25 mg in the morning and 2 tablets of Placebo in the evening daily during 4 weeks of treatment period.
62424058|NCT03667170|EXPERIMENTAL|Subjects with MSI-H/dMMR|patients receive 600 mg of the KN035 Subcutaneously every 3 weeks
62809247|NCT04176198|EXPERIMENTAL|Arm 1: nuvisertib (TP-3654)|
62032971|NCT02526264|EXPERIMENTAL|Krankenhaus Nordwest Concept|specific preoperative education program realised by a specialized stoma-therapist containing individualized information on material maintenance, hygiene, nutrition, complications, activities of daily life and occupation
62032972|NCT02526264|EXPERIMENTAL|Standard concept|standard preoperative education program administered by a surgeon containing information on surgery, outcome, risks and alternatives
62032973|NCT01909310|ACTIVE_COMPARATOR|with head support|patients are ventilated with their heads positioned on a support
62424059|NCT03445247|SHAM_COMPARATOR|Control|No intervention, no placebo, but do the same blood tests and examinations as experiment group at the same time points
62424060|NCT03445247|EXPERIMENTAL|Extracorporeal low-intensity shockwave group|with 12 times extracorporeal low intensity shockwave therapy and do the blood test and assessments at baseline, 3, 6, 12 m after initiation of therapy.
62809248|NCT04176198|EXPERIMENTAL|Arm 2: nuvisertib (TP-3654) added on to ruxolitinib|
62809249|NCT04176198|EXPERIMENTAL|Arm 3: nuvisertib (TP-3654) in combination with momelotinib|
62809250|NCT05260671|EXPERIMENTAL|Penpulimab+cetuximab|Erbitux 500 mg/m2 without immunotherapy for 14 days prior to the first cycle. Cetuximab Injection 500 mg/m2 and Penpulimab Injection 200 mg are intravenously infused on Day 1 (D1) of Cycle 1, with 14 days as one cycle. Penpulimab for up to 96 weeks (48 cycles)
62232994|NCT05516550|PLACEBO_COMPARATOR|Placebo|2 tablets of Placebo in the morning and 2 tablets of Placebo in the evening daily during 4 weeks of treatment period.
62232995|NCT04761302|EXPERIMENTAL|Group 1: Intravenous Ketorolac and oral acetaminophen|Group 1 will be composed of patients receiving the following standard pain control protocol: ketorolac 30 mg intravenous (IV) every 6 hours for patients younger than 70 years versus ketorolac 15 mg IV every 6 hours for patients older than 70 years, first dose will be administered 30 minutes preoperatively. An additional 1000mg of oral acetaminophen will be administered every 6 hours simultaneously regardless of the age group. Patients who determine pain to be unbearable and wish to opt out of the non-opioid group will receive may do so.
62809251|NCT06235866||Follow-up cohort of patients with severe COVID-19|The scores of various scales, pulmonary function and imaging changes of patients with severe COVID-19 were collected at 3 months, 6 months and 12 months after rehabilitation and discharge.
62809252|NCT04541407|EXPERIMENTAL|Exon 19 deletions or L858R point mutations in exon 21|Will include patients with exon 19 deletions or L858R point mutations in exon 21 of the epidermal growth factor receptor (EGFR) gene. Temozolomide plus Osimertinib will be the study drug combination administered. Osimertinib will be given at a fixed dose of 80 mg daily for dose level 1, with a potential to increase to 160 mg daily for dose level 2. Temozolomide will be started at a dose of 150 mg/m2 on days 1-5 of a 28 day cycle for cycle 1 and if tolerated will be increased to 200 mg/m2 on days 1-5 of a 28 day cycle for cycles 2+. There will be a -1 dose level.
62809253|NCT04541407|EXPERIMENTAL|Patients with anaplastic lymphoma kinase (ALK) fusions|Will include patients with anaplastic lymphoma kinase (ALK) fusions. Temozolomide plus Lorlatinib will be the study drug combination administered. Lorlatinib will be given at a fixed dose of 100 mg daily. Temozolomide will be started at a dose of 150 mg/m2 on days 1-5 of a 28 day cycle for cycle 1 and if tolerated will be increased to 200 mg/m2 on days 1-5 of a 28 day cycle for cycles 2+. There will be a -1 dose level depending on tolerability.
62809254|NCT03588663|EXPERIMENTAL|Bionic Leg|Participants will wear the Bionic Leg during a series of different activities including a timed-up-and-go, balance tests, 6-min walk test and sit-to-stand exercises.
62809255|NCT03588663|ACTIVE_COMPARATOR|Control|Participants will complete a series of different activities including a timed-up-and-go, balance tests, 6-min walk test and sit-to-stand exercises without wearing the bionic leg (control condition).
62032974|NCT01909310|SHAM_COMPARATOR|without head support|patients are ventilated without head support
62032975|NCT06447857||STEMI underwent CMR|This retrospective study included patients diagnosed with STEMI at the Affiliated Hospital of Xuzhou Medical University.
62032976|NCT06352710||Lumbar decompression, including single- or multiple-level procedures|
62232996|NCT04761302|ACTIVE_COMPARATOR|Group 2: Intravenous Morphine and oral oxycodone|Group 2 will be composed of patients receiving the following pain control protocol: morphine 0.1 mg per kg intravenous every 6 hours with an additional oral oxycodone combined with acetaminophen 2 tabs every 6 hours.
62232997|NCT02720536|EXPERIMENTAL|Deferasirox|Treatment will be administered daily for up to 24 months. For each patient the daily dose is calculated based on the patient's actual body weight.
62424061|NCT03499249|EXPERIMENTAL|N-Acetylcysteine Treatment|Will receive continuous intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
62424062|NCT05212831|NO_INTERVENTION|Standard of Care (SOC)|SOC is defined as the patient symptoms or complications based treatment.
62424063|NCT05212831|EXPERIMENTAL|Portable Oxygen Concentrator|"Inogen One® G4 Portable Oxygen Concentrator (POC) is used on a prescriptive basis by subjects requiring supplemental oxygen. It supplies a high concentration of oxygen and is used with a nasal cannula which channels oxygen from the concentrator to the subject.~Inogen One® G4 is designed to provide a flow of high purity oxygen. Inogen One® G4 may be used in home, institution, vehicle and various mobile environments."
62424064|NCT02513173||Low back pain group|No intervention
62424065|NCT02513173||Control|No intervention
62424066|NCT02344459|EXPERIMENTAL|80mL double balloon catheter (Cook catheter®)|
62424067|NCT02344459|ACTIVE_COMPARATOR|30mL single Foley balloon catheter|
62593096|NCT05462132|EXPERIMENTAL|Cohort 8|"HV subjects receive doses less than or equal to 2 × 10\^12 live cells of SYNB1353 and up to 100 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of up to 100 mg/kg will be evaluated."
62232998|NCT02645695|ACTIVE_COMPARATOR|routine pulmonary rehabilitation|routine pulmonary rehabilitation consisted of position giving technique
62232999|NCT02645695|ACTIVE_COMPARATOR|chest wall vibration technique|chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours.
62233000|NCT02046824|EXPERIMENTAL|Xtra®, Sorin cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the Xtra Sorin cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
62809256|NCT00049023|EXPERIMENTAL|90Y-DOTA-tyr3-OCTREOTIDE|Dose escalation will proceed so that the single-cycle and three-cycle maximum tolerated doses of 90Y-DOTA-tyr3-Octreotide can be determined. The initial dose of 90Y-DOTA-tyr3-Octreotide to be administered is 30 mCi/m2 in each of three cycles. Dose escalation will proceed in 10 mCi/m2 intervals and will be permitted for the next cohort of subjects pending completion of Cycle 3 by 2 members of the previous cohort with no DLTs. A DLT is defined as a Grade 3 renal toxicity, Grade 4 bone marrow toxicity, or any other Grade 3 toxicity whether or not related to study drug and regardless of duration. Lymphopenia will not be used to define a DLT.
62233001|NCT02046824|EXPERIMENTAL|C.A.T.S.®, Fresenius cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the C.A.T.S. cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
62233002|NCT02046824|EXPERIMENTAL|CardioPAT®, Haemonetics, cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the CardioPAT cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
62233003|NCT02046824|OTHER|no use of cell saver|When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
62233004|NCT00343135|EXPERIMENTAL|ARM 1|
62233005|NCT03675178|EXPERIMENTAL|treatment group|Anerning particle +ceftriaxone sodium
62233006|NCT03675178|PLACEBO_COMPARATOR|control group|Anerning particle placebo+ceftriaxone sodium
62233007|NCT01712022||Dry Eye|clinical diagnosis of dry eye
62233008|NCT01712022||Contact Lens|routine wear of contact lens
62233009|NCT01712022||Normal|Not having history of dry eye or contact lens wear or corneal pathology or surgery
62233010|NCT01413100|EXPERIMENTAL|Treatment (HDIT autologous PBSCT)|"STEM CELL MOBILIZATION AND PREPARATION: Patients receive filgrastim SC on mobilization days 1-4 followed by apheresis until a target dose of CD34+ cells \>= 2.5 x 10\^6/kg are collected. Patients difficult to mobilize with filgrastim alone receive cyclophosphamide IV or \*plerixafor SC on mobilization days 1-2 and filgrastim SC on mobilization days 5-7.~HDIT CONDITIONING: Patients receive high-dose cyclophosphamide IV over 1-2 hours on days -5 to -2 and anti-thymocyte globulin IV on days -5, -3, -1, 1, 3, and 5.~TRANSPLANTATION: Patients undergo autologous PBSCT on day 0.~MAINTENANCE THERAPY: Beginning 2-3 months after transplant, patients receive mycophenolate mofetil PO BID for 2 years."
62233011|NCT05080998||Single arm - Patients undergoing surveillance for UC recurrence|Subjects previously diagnosed with UC and are undergoing a schedule of surveillance cystoscopies and treatment for the possible recurrence of UC will be recruited. Only intermediate and high-risk group, according to AUA /SUO risk categorisation for non-muscle invasive UC, will be eligible for this study. All subjects will undergo CxBladder urine diagnostic testing.
62233012|NCT01562951|PLACEBO_COMPARATOR|PLACEBO|Treatment with placebo
62809257|NCT04905550|EXPERIMENTAL|Craniocerebral radiotherapy combined with Almonertinib 110mg p.o qd|"Almonertinib mesylate tablet, 110mg, qd; until the disease progresses or unacceptable toxicity.~The craniocerebral radiotherapy was acceptable from 1 week before to 6 weeks after treatment with Almonertinib.~Dose adjustment and delay of Almonertinib are allowed. Delay of Almonertinib is allowed for up to 9 weeks, calculated from the time of last administration, otherwise, treatment is terminated."
62233013|NCT01562951|ACTIVE_COMPARATOR|ADALIMUMAB|Treatment with Adalimumab
62233014|NCT05712733||Case group|"Patients suffering from acute calculous cholecystitis undergoing subacute laparoscopic cholecystectomy.~Samples of bile and gallbladder wall specimens will be taken during surgery and will be sent for microbiological and pathological investigation"
62424068|NCT04006691|EXPERIMENTAL|UGN-101 instillations|The Mitomycin C (MMC) concentration of UGN-101 to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, the maximum dose is 15ml. 3-6 once weekly intravesical instillations for the ablation treatment.
62424069|NCT02067585|EXPERIMENTAL|LAGB|Standardized Lipid meals will be served to Laparoscopic adjustable gastric banding patients.
62424070|NCT02067585|EXPERIMENTAL|LRYGB|Standardized Lipid meals will be served to the Laparoscopic Rou-en-Y gastric bypass patients.
62424071|NCT02067585|EXPERIMENTAL|Non-surgical|Standardized Lipid meals will be served to the non-surgical obese patients
62424072|NCT01921036|EXPERIMENTAL|combined exercise|90 minutes combined endurance and resistance exercise once a week plus 90 minutes traditional cardiac rehabilitation once a week over six months
62809258|NCT06135961|ACTIVE_COMPARATOR|eCTG monitoring|"eCTG monitoring with the Nemo Fetal Monitoring System (Nemo Healthcare B.V., Veldhoven, the Netherlands).~The NFMS consists of a wireless and beltless electrode patch on the maternal abdomen. It monitors fetal heart rate by fetal electrocardiography, maternal heart rate by maternal electrocardiography and the electrical activity of the uterine muscle by electrohysterography.~The advantage of the NFMS is that it is a safe method that can be used in all situations that are contraindicated for invasive monitoring. Furthermore, it can be used when the membranes are not ruptured and the patch does not have to be repetitively repositioned during labor. Because the NFMS is wireless, it gives women more freedom of movement during labor."
62809259|NCT06135961|NO_INTERVENTION|Conventional CTG monitoring|"Philips Avalon FM 30 (Philips Healthcare, Eindhoven, the Netherlands).~The fetal heart rate is measured non-invasively by doppler ultrasound or invasively by fetal scalp electrode. The uterine activity and maternal heart rate is measured by tocodynamometry."
62809260|NCT02690181|EXPERIMENTAL|GBS NoAdj/GBS NoAdj|Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
62809261|NCT02690181|EXPERIMENTAL|GBS Alum/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
62809262|NCT02690181|EXPERIMENTAL|GBS MF59 Full/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
62809263|NCT02690181|EXPERIMENTAL|GBS MF59 Half/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
62032977|NCT06352710||Lumbar transpedicular instrumentation and fusion, including extension to thorax/pelvis|
62032978|NCT06352710||Supratentorial craniotomy for tumor, vascular or other pathology|
62032979|NCT06352710||Infratentorial craniotomy for tumor, vascular or other pathology|
62233015|NCT05712733||Control group|"Patients suffering from painattacks due to gallstones, who have not symptoms of cholecystitis. The patients will undergo elective laparoscopic cholecystectomy.~Samples of bile and gallbladder wall specimens will be taken during surgery and will be sent for microbiological and pathological investigation"
62233016|NCT01942720|OTHER|Capsule endoscopy|
62233017|NCT06176339|ACTIVE_COMPARATOR|Pentoxyphyllin group|Patients will undergo a treatment plan determined by the multidisciplinary team. This involves four cycles of intravenous (IV) doxorubicin at a dose of 60 mg/m2 along with IV cyclophosphamide at 600 mg/m2 per cycle. Following this, taxane will be administered. Additionally, patients are prescribed 400 mg pentoxifylline tablets to be taken three times daily.
62233018|NCT06176339|PLACEBO_COMPARATOR|Control group|Patients will undergo a treatment plan determined by the multidisciplinary team. This involves four cycles of intravenous (IV) doxorubicin at a dose of 60 mg/m2 along with IV cyclophosphamide at 600 mg/m2 per cycle. Following this, taxane will be administered. Additionally, patients will take placebo tablets three times daily.
62233019|NCT04939922||Migraine|Patients with migraine (including vestibular migraine), including all types of migraine as defined by ICHD-3
62233020|NCT04939922||Other Primary Headache Disorders|Patients with other primary headache disorders (excluding migraine), including all types of other primary headache disorders (such as Tension-Type Headache, Cluster Headache) as defined by ICHD-3.
62233021|NCT04939922||Vertigo|Patients with other vertigo disorders (excluding vestibular migraine).
62233022|NCT04939922||Secondary Headache Disorders|Patients with secondary headache disorders as defined by ICHD-3.
62233023|NCT04939922||Normal control|Normal people do not have headache and vertigo.
62233024|NCT03167931|EXPERIMENTAL|18-49 years group|Participants undergo 2 sessions of MRI + transcranial Magnetic Stimulation or transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
62233025|NCT03167931|EXPERIMENTAL|50-85 years group|Participants undergo 2 sessions of MRI + transcranial Magnetic Stimulation or transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
62424073|NCT01921036|ACTIVE_COMPARATOR|traditional cardiac rehabilitation|The group-based program is offered for 90 minutes twice a week and is a combination of gymnastics, coordination and flexibility exercises, and includes educational components targeting diet and nutrition, stress and relaxation, methods for coping with CVD and behavioral and lifestyle change.
62424074|NCT00995488|EXPERIMENTAL|ABI-007|ABI-007 combined with Carboplatin, and Gemcitabine
62424075|NCT06540612|EXPERIMENTAL|Aerobic Exercise Intervention|In this group, participants do moderate-intensity aerobic exercise three days a week.
62809264|NCT02690181|EXPERIMENTAL|Placebo/GBS NoAdj|Subjects who had received placebo in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
62032980|NCT00576069||asthma, quality of life, lung function|All Asthmatics will be treated with 1 of 3 long acting beta 2 agonist + corticosteroid using low or medium dose of inhaled (Advair) fluticasone or equivalent corticosteroid 200-500mcg/day plus salmeterol 100 mcg/day or (Symbicort) budesonide 320-640 mcg +formoterol 18 mcg/day or (Dulera) mometasone 400-800mcg + formoterol 20 mcg/day. In addition tiotropium 18ucg/day will be used. Additionally, albuterol 0.083%/ipratropium 0.02% solution or MDI HFA for acute exacerbation.Will measure lung function and asthma quality of life questionaire
62032981|NCT01716312|PLACEBO_COMPARATOR|1|Subjects who were randomized to the placebo arm originally will receive 600 mg omalizumab by subcutaneous injection
62032982|NCT01716312|ACTIVE_COMPARATOR|2|Subjects in the omalizumab arm will receive 300 mg omalizumab by subcutaneous injection in a doubleblinded fashion
62032983|NCT01463748|EXPERIMENTAL|Placebo|starch
62032984|NCT01463748|EXPERIMENTAL|Graptopetalum paraguayense E. Walther|Graptopetalum paraguayense E. Walther
62032985|NCT02201069|EXPERIMENTAL|health coaching|12 weeks of health coaching using weekly contact in the first month and biweekly contacts in months 2-3.
62809265|NCT02690181|EXPERIMENTAL|Naive/GBS NoAdj|Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
62032986|NCT03809481|EXPERIMENTAL|Danaparoid Sodium|Subjects will receive danaparoid via IV infusion for at least 7 days then transition to a VKA. IV loading bolus injection of 2250 U, followed by 400 U/h for 4 hours, then 300 U/h for 4 hours, then a maintenance infusion of 150-200 U/h.
62032987|NCT03809481|ACTIVE_COMPARATOR|Argatroban|Subjects will receive argatroban 2 microgram/kg/min as a continuous infusion, titrated to an aPTT that is 1.5 to 3.0 x initial baseline value, but not exceeding 100 seconds.
62433568|NCT03061760||3. OAB (+) BOO (+)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with overactive bladder (OAB) symptoms and with bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
62809266|NCT05139043|ACTIVE_COMPARATOR|Arm I (standard dose dexamethasone)|Patients receive standard dose dexamethasone PO q 12 h for 3 days. On the day of surgery, patients receive standard dose dexamethasone IV before and after the surgery. Patients receive standard dose dexamethasone IV q 12 h on days 1-3 post surgery and tapered dexamethasone PO q 12 h on days 4-14 in the absence of disease progression or unacceptable toxicity. Additional doses of dexamethasone are given if needed.
62809267|NCT05139043|EXPERIMENTAL|Arm II (lower dose dexamethasone)|Patients receive lower dose dexamethasone PO q 12 h for 3 days. On the day of surgery, patients receive lower dose dexamethasone IV before and after the surgery. Patients receive lower dose dexamethasone IV q 12 h on days 1-3 post surgery and tapered dexamethasone PO q 12 h on days 4-14 in the absence of disease progression or unacceptable toxicity. Additional doses of dexamethasone are given if needed.
62809268|NCT02220257||Newly diagnosed type 1 diabetes|
62809269|NCT03590652|EXPERIMENTAL|ixazomib, daratumumab, pomalidomide and dexamethasone|Daratumumab will be administered at 16mg/kg IV weekly x 8 weeks, biweekly x 8 weeks, then monthly. Pomalidomide 4mg will be administered orally daily for days 1-21. Patients ≤ age 75 will receive a 40mg dose of dexamethasone, and those over the age of 75 may receive a 20mg dose of dexamethasone orally on days 1, 8, 15, and 22 (weekly). Ixazomib will be administered 4mg orally on days 1, 8 and 15.
62032988|NCT05013333|OTHER|AED 3 with Uni-padz|
62032989|NCT03588533|EXPERIMENTAL|Herzuma-capecitabine/cisplatin(XP)|"* Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)~* Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle\~ ) every 3 weeks~* Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks~* Cisplatin 60\~100mg/m2 i.v. D1 every 3 weeks"
62032990|NCT00278434|EXPERIMENTAL|Zoledronate|"100 cc of saline with 4 mg of zoledronate intravenous (IV), over 20 minutes, for 3 doses one week apart~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.~After completion of study treatment, patients are followed at week 10 by telephone."
62032991|NCT00278434|PLACEBO_COMPARATOR|Saline|"100 cc of saline IV, over 20 minutes, for 3 doses one week apart~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.~After completion of study treatment, patients are followed at week 10 by telephone."
62032992|NCT04443023|ACTIVE_COMPARATOR|Sapien|Patients randomized to treatment
62032993|NCT04443023|ACTIVE_COMPARATOR|Myval|Patients randomized to treatment
62032994|NCT03139487|ACTIVE_COMPARATOR|Low molecular weight heparin|Dalteparin, 200 IU/kg subcutaneously once daily for 4 weeks followed by 150 IU/kg once daily for 20 weeks
62233026|NCT04793802||Patients benefiting from HIGH-FLOW OXYGENATION + NONINVASIVE VENTILATION|Patients benefiting from high-flow oxygenation will have their physiotherapy session with non-invasive ventilation.
62032995|NCT03139487|EXPERIMENTAL|Direct oral anticoagulant|"Rivaroxaban, 15 mg orally twice daily for 3 weeks followed by 20mg once daily for 21 weeks~Apixaban, 10 mg orally twice daily for 7days followed by 5mg twice daily for 21 weeks"
62032996|NCT01776918||Metabolic Disease- Phenylketonuria|
62032997|NCT01776918||Mitochondrial disorder|
62233027|NCT04793802||Patients benefiting from HIGH-FLOW OXYGENATION|Patients benefiting from high-flow oxygenation will have their physiotherapy session without non-invasive ventilation.
62424076|NCT06540612|ACTIVE_COMPARATOR|Physical activity counseling|Realistic and achievable goals are set based on the individual's needs and goals. An individualized exercise program is created. This program may include aerobic exercise, strength training, flexibility exercises, and other activities. The individual is educated about proper techniques, safe practices, and benefits of the exercises. The individual's progress is monitored and evaluated regularly, and adjustments to the program are made as needed. Ongoing support and encouragement is provided to help the individual stay motivated and achieve their goals.
62032998|NCT04242199|EXPERIMENTAL|Cohort 1|Participants with select solid tumors who are immunotherapy treatment-naive
62032999|NCT04242199|EXPERIMENTAL|Cohort 2|Participants with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) tumors who are immunotherapy treatment-naïve.
62033000|NCT04242199|EXPERIMENTAL|Cohort 3|Participants with progression of any solid tumor treated with an approved anti-PD-1 monoclonal antibody therapy
62033001|NCT05394870|EXPERIMENTAL|study group|
62033002|NCT05394870|ACTIVE_COMPARATOR|control group|
62033003|NCT01936064|ACTIVE_COMPARATOR|Jobelyn + Cyclophosphamide-Epirubicin6|Cyclophosphamide- Epirubicin 6 course regimen to be used with Jobelyn
62233028|NCT04637308|EXPERIMENTAL|Succinylated gelatin|The patients received intravenous infusion of succinylated gelatin one day before and on the day of chemotherapy, 500ml each time, once per day.
62033004|NCT01936064|ACTIVE_COMPARATOR|Placebo + Cyclophosphamide- Epirubicin 6|Routine drugs for treatment of Breast Cancer used with Placebo
62233029|NCT04637308|NO_INTERVENTION|Control|Observation.
62233030|NCT04579627||Hospital Doctors|Hospital doctors working at Royal Cornwall Hospital during the COVID-19 pandemic
62233031|NCT01688674|PLACEBO_COMPARATOR|Bolus arm|two hourly dextrose boluses administered via an intravenous cannula
62233032|NCT01688674|EXPERIMENTAL|infusion|10% dextrose infusion by burettes
62233033|NCT02575820||RBC_old|shelf life of red blood cells of 15 or higher days
62424077|NCT06540612|NO_INTERVENTION|control group|The control group continued their current daily activities and did not perform any new exercise program.
62424078|NCT03537222||MyPOS|
62424079|NCT02595541|ACTIVE_COMPARATOR|milrinone group|milrinone
62424080|NCT02595541|ACTIVE_COMPARATOR|sildenafil and milrinone group|milrinone and sildenafil
62424081|NCT06125964|EXPERIMENTAL|Intensity|Participants receive intensity-based goals for two weeks. No enhancements are added to the standard mHealth intervention.
62033005|NCT01274091|EXPERIMENTAL|P/S-ratio 1.0|"Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:~polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0."
62033006|NCT01274091|EXPERIMENTAL|P/S-ration 0.3|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:. Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
62033007|NCT00272168|EXPERIMENTAL|Arm 1: MPROVE|The Maryland Program for Vocational Effectiveness (MPROVE)
62033008|NCT00272168|ACTIVE_COMPARATOR|Arm 2: Control|Supportive Treatment for SMI (control)
62033009|NCT01919008|EXPERIMENTAL|Group 1 (FK949E low dose tablet-first group)|"Days 1 and 2: One FK949E low dose tablet~Days 3 to 6: Three FK949E low dose tablets~Days 7 to 10: One FK949E high dose tablet"
62033010|NCT01919008|EXPERIMENTAL|Group 2 (FK949E high dose tablet-first group)|"Days 1 and 2: One FK949E low dose tablet~Days 3 to 6: One FK949E high dose tablet~Days 7 to 10: Three FK949E low dose tablets"
62033011|NCT02271126|EXPERIMENTAL|TEG|TEG-driven anticoagulation group: Anticoagulation will be monitored by TEG. Target will be a range of R parameter at Kaolin activated-TEG (R K-TEG) is 16 - 24 seconds; frequency of TEG assays may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol. When TEG value falls well below the desired range an heparin bolus will be administered, when is too high infusion will be stopped for either 30 or 60 minutes.
62033012|NCT02271126|ACTIVE_COMPARATOR|APTT|APTT-driven anticoagulation group: anticoagulation will be monitored by aPTT. aPTT ratio target is 1.5 - 2.0 as for actual clinical practice; frequency of aPTT measurements may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol. When aPTT value falls well below the desired range an heparin bolus will be administered. When too high, infusion will be stopped for either 30 or 60 minutes.
62033013|NCT05525494|ACTIVE_COMPARATOR|Text Fixed R/R Messages with Direct Appointment Schedule Link + Text Pre-Appointment Reminders|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period.
62233034|NCT02575820||RBC_new|shelf life of red blood cells 14 or lower days
62233035|NCT02924974|SHAM_COMPARATOR|Control|subcutaneous lidocaïne and intravenous loading dose of morphine
62233036|NCT02924974|EXPERIMENTAL|Intervention|Spinal injection of 4 or 5 ml of bupivacaine/morphine 2,5 mg/ml/60mcg/ml. The reduction to 4 ml is for patients over 75 years of age
62593097|NCT06305741|EXPERIMENTAL|Latino caregivers and the Latino older adults with cancer (OACs)|The intervention, MAC, is a seven-session (45- 60 minutes per session) psychotherapy intervention delivered via videoconference and/or telephone by licensed social workers. All sessions will be audio-recorded. MAC content, structure, and length are consistent with core components of cognitive behavioral therapy (CBT) (Freeman, 2004).
62593098|NCT05801939|EXPERIMENTAL|Cevostamab|
62593099|NCT05099614|EXPERIMENTAL|Healthy adults|Healthy adults will receive 1.2 mg of naloxone hydrochloride injection solution, administered once via a wearable auto-injector, West Pharma SmartDose Generation I system. The respiratory sensing system under study is used to detect slowed breathing for the purpose of triggering the administration of the naloxone.
62593100|NCT04756570|ACTIVE_COMPARATOR|Control|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose Mini-Mental State Examination (MMSE) scores equal or above the 25 will be included in this study. Modified Ashworth Scale (MAS), Barthel Index, The Modified Rankin Scale, Berg Balance Scale , \&-min walk test, and Stroke-Specific Quality of Life Scale (SSQOL) assessments will be applied just before the rehabilitation program, after the application and at the end of 6 weeks
62593101|NCT04756570|ACTIVE_COMPARATOR|Robotic 1|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Modified Ashworth Scale (MAS), Barthel Index, The Modified Rankin Scale, Berg Balance Scale , \&-min walk test, and Stroke-Specific Quality of Life Scale assessments will be applied just before the rehabilitation program, after the application and at the end of 6 weeks
62593102|NCT04756570|ACTIVE_COMPARATOR|Robotic 2|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Modified Ashworth Scale (MAS), Barthel Index, The Modified Rankin Scale, Berg Balance Scale , \&-min walk test, and Stroke-Specific Quality of Life Scale assessments will be applied just before the rehabilitation program, after the application and at the end of 6 weeks
62593103|NCT01346189|ACTIVE_COMPARATOR|Physician Incentives|"(with adherence feedback)~Quarterly payments to physician combined based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL with daily patient statin adherence information made available."
62593104|NCT01346189|ACTIVE_COMPARATOR|Patient Incentives|"(with adherence feedback)~Quarterly payments to patient based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL."
62593105|NCT01346189|ACTIVE_COMPARATOR|Physician and Patient Combined Incentives|"(with adherence feedback)~Quarterly payments shared evenly by physician and patient based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL. Physicians will receive daily information about patients' statin adherence."
62593106|NCT01346189|NO_INTERVENTION|Usual Care|
62233037|NCT06435130|EXPERIMENTAL|Dietary intervention with chokeberry juice and fibre|Study participants consumed 100 mL of chokeberry juice daily for 8 weeks. After 8 weeks, participants consumed 100 ml of chokeberry juice and 10 g of chokeberry fiber daily for 4 weeks.
62233038|NCT05243030|EXPERIMENTAL|MES-PrEP and MTM|Participants in this arm will receive standard PrEP counseling, followed by mHealth interventions to improve PrEP uptake and support PrEP adherence.
62233039|NCT05243030|ACTIVE_COMPARATOR|Standard PrEP Counseling|Participants in this arm will receive the standard PrEP counseling.
62593107|NCT05570006|EXPERIMENTAL|ABBV-668|Participants will receive ABBV-668 twice daily approximately at same time each day for 52 weeks.
62593108|NCT00135798|EXPERIMENTAL|LADR Treatment, Genotypes 1,4,6|Subjects randomized to low accelerating dose regimen (LADR) treatment
62809270|NCT04059510||Screening for GBS|Women will be recruited for screening for GBS in the UK and Uganda (250 at each site). At screening women will be consented for a vaginal and rectal swab to assess for GBS carriage and will also undergo an asymptomatic STI screen according to local usual practice. Anyone who meets the full inclusion criteria following screening will be invited to take part in the sampling study until the recruitment targets are reached. If any woman tests positive for any of the infections, she will be referred to a local centre for treatment and may still be included after completed treatment for the infection.
62233040|NCT03072277|ACTIVE_COMPARATOR|Docosa Hexaenoic Acid (DHA)|Omega 3 Fatty Acid
62233041|NCT03072277|PLACEBO_COMPARATOR|Placebo|Corn/Soy Oil
62233042|NCT04620226|NO_INTERVENTION|Conventional Serum Testing|Participants will be screened by conventional HCV antibody (anti-HCV) serology and if screen positive, a second sample will be collected and tested for HCV RNA using a standard commercial assay.
62424082|NCT06125964|ACTIVE_COMPARATOR|Affect + TYPE/CONTEXT|Participants receive affect-based goals for two weeks. In addition to the standard mHealth intervention, participants engage in the TYPE/CONTEXT enhancement to augment the treatment effects of the affect-based goals condition.
62233043|NCT04620226|EXPERIMENTAL|Rapid Point-of-Care Testing|Participants will be screened using the OraQuick® Rapid Anti-HCV Point-of-Care Test (OraSure) and if screen positive, an additional whole blood sample will be collected and tested for HCV RNA using Xpert® HCV RNA (Cepheid) point-of-care testing and confirmed using a standard commercial assay.
62233044|NCT04080791|EXPERIMENTAL|Experimental Group- Virtual Reality (VR) Treatment|The participants in the experimental group will complete the educational/training session on how to use the VR equipment and programs (30 minutes). The following day, participants will begin the VR intervention attending a daily 30-minute sessions for 8 days or until a discharge date has been set, whichever comes first.
62033014|NCT05525494|ACTIVE_COMPARATOR|Text Fixed R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
62233045|NCT04080791|ACTIVE_COMPARATOR|Standard of care group|The control group participants will receive the traditional daily 30-minute intensive therapy regimen provided during acute inpatient rehabilitation stroke treatment protocol. Prior to discharge, control group participants will meet with a licensed clinical therapist to complete the cognitive and physical assessments for the posttest evaluation.
62233046|NCT05079256|EXPERIMENTAL|Laser therapy|595 nm Pulsed dye laser (PDL) therapy for psoriasis
62233047|NCT02529813|EXPERIMENTAL|Arm I (CD19 positive chimeric antigen receptor T-cells)|"LYMPHODEPLETING CHEMOTHERAPY: Patients may receive standard chemotherapy comprised of fludarabine phosphate IV over 1 hour and cyclophosphamide IV over 3 hours on days -5 to -3 or cyclophosphamide IV every 12 hours on days -5 to -3 at the discretion of the treating physician.~Within 30 days post completion of lymphodepletion, patients receive CD19 positive chimeric antigen receptor T-cells IV over 15-30 minutes on day 0, or split into two portions on days 0 and 1."
62233048|NCT05895409||PF|Patients with interstitial lung disease (ILD) of known or unknown etiology other than IPF who has radiological evidence of pulmonary fibrosis(PF).
62233049|NCT00426153|ACTIVE_COMPARATOR|Octreotide|Participants received Octreotide LAR® Depot injections (up to 40 mg) intramuscularly every 28 days (+/- 5 days) for one year
62424083|NCT06125964|ACTIVE_COMPARATOR|Affect + SAVOR|Participants receive affect-based goals for two weeks. In addition to the standard mHealth intervention, participants engage in the SAVOR enhancement to augment the treatment effects of the affect-based goals condition.
62809271|NCT04059510||Sampling method optimisation|"If a woman is deemed to meet all inclusion criteria and no exclusion criteria following screening and is willing to take part in the sampling method optimisation study, she will be consented again for the further study including consent (optional) for participation in a focus group at the end of the study. 100 eligible women will be recruited on to this part of the study (50 colonised with GBS at baseline and 50 uncolonised with GBS at baseline) at each site (UK and Uganda).~The sampling study will last for 12 weeks and samples collected include:~* A self-taken low vaginal swab~* A self-taken rectal swab~* Menstrual cup fluid~* Serum sample~* Urine pregnancy tests"
62424084|NCT06125964|ACTIVE_COMPARATOR|Affect + TYPE/CONTEXT + SAVOR|Participants receive affect-based goals for two weeks. In addition to the standard mHealth intervention, participants engage in the TYPE/CONTEXT and SAVOR enhancements to augment the treatment effects of the affect-based goals condition.
62424085|NCT04972760|EXPERIMENTAL|baricitinib arm|Patients receive baricitinib plus prednisone taper plus one immunosuppressive drug (either methotrexate or azathioprine) for a duration of 24 weeks. Corticosteroids are tapered following a predefined protocol.
62424086|NCT04972760|PLACEBO_COMPARATOR|placebo arm|Patients receive placebo plus prednisone taper plus one immunosuppressive drug (either methotrexate or azathioprine) for a duration of 24 weeks. Corticosteroids are tapered following a predefined protocol.
62593109|NCT00135798|NO_INTERVENTION|Standard care|Subjects randomized to Standard Care group, Genotypes 1,4,6
62233050|NCT00426153|PLACEBO_COMPARATOR|Placebo|Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
62233051|NCT04823520|ACTIVE_COMPARATOR|Group 15% concentration|30 patients MDA will be done to one half of the face then TCA 15% will be applied to the whole face.
62233052|NCT04823520|ACTIVE_COMPARATOR|Group 20 % concentration|30 patients will receive MDA to one side of the face , TCA 20% will then be applied to the whole face.
62424087|NCT02528318|EXPERIMENTAL|50 mg/kg|"Lucinactant for inhalation 50 mg total phospholipids (TPL)/kg with nCPAP~1 repeat dose allowed if repeat dosing criteria are met."
62424088|NCT02528318|EXPERIMENTAL|75 mg/kg|"Lucinactant for inhalation 75 mg TPL/kg with nCPAP~1 repeat dose allowed if repeat dosing criteria are met."
62424089|NCT02528318|EXPERIMENTAL|100 mg/kg|"Lucinactant for inhalation 100 mg TPL/kg with nCPAP~1 repeat dose allowed if repeat dosing criteria are met."
62424090|NCT02528318|EXPERIMENTAL|150 mg/kg|"Lucinactant for inhalation 150 mg TPL/kg with nCPAP~1 repeat dose will be allowed if repeat dosing criteria are met."
62424091|NCT02528318|ACTIVE_COMPARATOR|nCPAP alone|nCPAP therapy alone
62424092|NCT03515837|EXPERIMENTAL|Pembro+Pemetrexed+Chemo|Participants receive pembrolizumab (pembro) 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles PLUS pemetrexed 500 mg/m\^2 via IV infusion Q3W with no restrictions on the number of cycles PLUS platinum chemotherapy (chemo) (either carboplatin Area Under the Curve \[AUC\] 5 via IV infusion Q3W for 4 cycles \[Cycles 1-4\] or cisplatin 75 mg/m\^2 via IV infusion Q3W for 4 cycles \[Cycles 1-4\]).
62593110|NCT00135798|EXPERIMENTAL|LADR treatment, Genotypes 2,3|Subjects randomized to low accelerating dose regimen (LADR) treatment.
62593111|NCT05592847|NO_INTERVENTION|Usual Practice|Patients with chronic conditions slated for surgery contacted once by pre-operative nurse to discuss surgery
62233053|NCT05078216||Cancer patients|"The exercise program consisted of a 12-week supervised intervention, with twice per week sessions of 90 minutes, and was developed in a friendly and close environment, which promoted social interaction between participants. Apart from the twice-weekly supervised sessions, as early as the fifth week, one or two individualized home-based sessions were established for each patient in order to achieve his/her specific objectives with the help of any required supporting material such as documents and video references with exercise examples.~All sessions had the same structure: 10 min of warm-up at 60-70% maximal heart rate (MHR), followed by 60-70 minutes of specific training and 10 minutes of stretching exercises. At least, 20% of the total session time was based on cardiovascular work over 70% of the maximum heart rate (MHR)"
62033015|NCT05525494|ACTIVE_COMPARATOR|Portal Pre-Commitment Prompt, Tailored R/R Messages w/ Direct Scheduling + Pre-Appointment Reminders|Participants in this arm will receive a pre-commitment prompt message by portal in September. Tailored R/R messages will be sent monthly by portal based on time and place selected by patients (up to 3). R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
62033016|NCT05525494|ACTIVE_COMPARATOR|Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive a pre-commitment prompt message by portal in September. Tailored R/R messages will be sent monthly based on time and place selected by patients (up to 3). R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
62033017|NCT05525494|ACTIVE_COMPARATOR|Portal Fixed R/R Messages with Direct Appointment Schedule Link + Portal Pre-Appointment Reminder|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
62033018|NCT05525494|ACTIVE_COMPARATOR|Portal Fixed R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
62233054|NCT04951401||Normal & abnormal lipid parameters value|parameters value among normal and abnormal lipid profile
62233055|NCT05110274|EXPERIMENTAL|Sequential measurements of metabolic flexibility|Study participants will undergo three assessments of metabolic flexibility. Two measurements of metabolic flexibility will be conducted during two separate overnight stay in a metabolic chamber approximately 5-7 days apart. The third measurement of metabolic flexibility will be assessed during a hyperinsulinemic-euglycemic clamp procedure conducted 7-28 days following the completion of the second overnight stay in the metabolic chamber.
62233056|NCT03620409||Sepsis|Patients with and without diagnosis septic cardiomyopathy Patients with and without suspected or confirmed SARS-CoV-2 infection
62424093|NCT03515837|ACTIVE_COMPARATOR|Placebo+Pemetrexed+Chemo|Participants receive normal saline solution via IV infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles PLUS pemetrexed 500 mg/m\^2 via IV infusion Q3W with no restrictions on the number of cycles PLUS platinum chemotherapy (chemo)(either carboplatin AUC 5 via IV infusion Q3W for 4 cycles \[Cycles 1-4\] or cisplatin 75 mg/m\^2 via IV infusion Q3W for 4 cycles \[Cycles 1-4\]).
62424094|NCT00488839|OTHER|IPX056 20 mg - OLE|A single dose of IPX056 20 mg, Placebo IPX056 40 mg and Placebo Baclofen Tablet (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
62424095|NCT00488839|OTHER|IPX056 40 mg - OLE|A single dose of IPX056 40 mg, Placebo IPX056 20 mg and Placebo Baclofen Tablet (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
62424096|NCT00488839|OTHER|Baclofen 20 mg - OLE|A single dose of Encapsulated Baclofen 20 mg, Placebo IPX056 20 mg and Placebo IPX056 40 mg (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
62424097|NCT00488839|OTHER|Placebo - OLE|A single dose of Placebo Baclofen Tablet, Placebo IPX056 20 mg and Placebo IPX056 40 mg (Part 1), 9 week Open label extension of IPX056 (flexible dose design,IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
62424098|NCT03319693||Mucosal melanoma|Incident Mucosal melanoma in the Champagne-Ardenne region 2004-2014
62424099|NCT03858660||Elderly|Healthy elderly No intervention.
62424100|NCT06309472|EXPERIMENTAL|Mirtazapine|Mirtazapine 30-45mg at night for 12 weeks
62233057|NCT03620409||Cardiomyopathy without infection|Patients without operation and patients with scheduled LVAD-Implantation
62233058|NCT03620409||Healthy subjects|Healthy controls
62233059|NCT06101433|PLACEBO_COMPARATOR|The placebo group|Subjects in the placebo group, were advised to take two placebo tablets per day for 12 weeks along with life style modification such as physical activity of 30 minutes for 3 days per week with medium intensity and food intake consults provided by clinical guidelines of NIH and the North American Association for the Study of Obesity. The placebo tablets contained starch and they were similar to the soy isoflavone tablets in smell, taste, and appearance. The placebo tablets were made by Gol Daru Pharmaceutical Company, Isfahan, Iran.
62233060|NCT06101433|ACTIVE_COMPARATOR|The soy isoflavone group|In the soy isoflavone group, patients took 100 mg soy isoflavone in the form of two tablets per day for 12 weeks along with lifestyle modification. Each soy isoflavone 50 mg tablet contained 1.49 mg of genistein, 31.86 mg of genistin, 1.75 mg of daidzein, 13.21 mg of daidzin, 0.55 mg of glycitein and 1.14 mg of glycitin. The soy isoflavone tablets were made by Gol Daru Pharmaceutical Company, Isfahan, Iran.
62233061|NCT01395316|EXPERIMENTAL|Alemtuzumab|Single arm, single cohort study, all subjects will be dosed with alemtuzumab.
62233062|NCT03376945||trail cohort|n-3 FAs
62233063|NCT03376945||control cohort|Structolipid
62033019|NCT05525494|NO_INTERVENTION|No R/R Message or Pre-Appointment Reminder|Participants do not receive any flu vaccine R/R message or Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment during the specified flu season.
62424101|NCT06309472|PLACEBO_COMPARATOR|Placebo|Matched placebo 1-2 capsules at night for 12 weeks
62424102|NCT03558789||MT|patients complaining about metallic taste before, during or after treatment of head and neck cancer.
62424103|NCT03558789||No-MT|patients not complaining about metallic taste before, during or after treatment of head and neck cancer.
62033020|NCT04233268||Critically ill children|Children with severe infection requiring mechanical ventilation
62424104|NCT02588352|EXPERIMENTAL|Healthy volunteers|Open label administration of salt tablets for one week
62809272|NCT04059510||Focus groups|"In the UK investigators will recruit up to 20 women from the sampling study to take part in focus groups about their experiences with self-sampling methods and the acceptability of controlled human infection models. Consent to participate in focus group discussions will be included as part of the consent to take part in the sampling study but will be optional.~Women may opt out of the focus groups at any time but remain in the sampling study if they choose.~In Uganda, the investigator will recruit more widely to our focus groups, including representation from midwives and the participant's partners and community leaders.The investigator will explore potential issues around maternal vaccination, and traditional and contemporary views on taking vaginal swabs and blood samples."
62809273|NCT00786383|EXPERIMENTAL|IMC-1121B|IMC-1121B injectable solution at a concentration of 5 mg/mL in single-use vials containing 100 mg/20 mL or 250 mg/50 mL of product, administered intravenously at an initial dose of 6 mg/kg.A minimum of three patients will be enrolled into each cohort. When all patients complete a cohort, dose escalation to the next cohort will occur.
62809274|NCT03554382|EXPERIMENTAL|intervention|Daily use of interactive mobile phone-based system to support self-management of hypertension: a) relevant items on drug side effects related to patient's drug regimen; and b) blood pressure.
62233064|NCT00995020|EXPERIMENTAL|SWETZ|The intervention administered in this arm is the straight wire excision of the transformation zone, a electrosurgical method to perform a cone biopsy using a 1 cm straight wire of 0.20 mm wire. The activated wire is used in much the same way as a cold knife or laser beam fashioning the surgical specimen to achieve two centimeters cm at cervical canal..
62233065|NCT00995020|ACTIVE_COMPARATOR|LLETZ cone|The intervention administered in this arm is the large loop excision of transformation zone as a cone biopsy, performed using a large loop electrode of 2 cm depth, applied to the cervix to achieving two centimeters at cervical canal .
62809275|NCT03554382|NO_INTERVENTION|Control|"No study intervention will be made in the control group; they will receive treatment as usual."
62233066|NCT04743154|OTHER|In-hospital complete revascularization group.|Patients will undergo to a complete revascularization of non-culprit lesions at least 24 hours after STEMI and before hospital discharge.
62233067|NCT04743154|OTHER|After-discharge complete revascularization group.|Patients will undergo to a complete revascularization of non-culprit lesions after hospital discharge within 4-6 weeks after STEMI.
62424105|NCT01488071|EXPERIMENTAL|Vortioxetine 10 mg or 20 mg|
62424106|NCT01488071|ACTIVE_COMPARATOR|Agomelatine 25 mg or 50 mg|
62424107|NCT00550420|EXPERIMENTAL|Arm 1|Rosiglitazone XR
62424108|NCT01447316||Bariatric surgery|Patients undergoing bariatric surgery for weight loss.
62424109|NCT03711942|ACTIVE_COMPARATOR|Periodontally Healthy IOB|Intra orifice barrier (IOB) was placed in periodontally healthy molar.
62809276|NCT02093884|EXPERIMENTAL|Text Messaging Intervention|Patients in the text messaging group will receive educational and motivational text messages.
62809277|NCT02093884|ACTIVE_COMPARATOR|Standard Referral|Patients in the standard referral arm will receive paper based information about the Family Planning Clinic.
62593112|NCT05592847|EXPERIMENTAL|Nurse Navigator|Patients with chronic conditions slated for surgery contacted once by pre-operative nurse to discuss surgery, then contacted at intervals by nurse navigator study team members
62593113|NCT00095745|NO_INTERVENTION|Antidepressant + Aripiprazole|
62593114|NCT01083888|EXPERIMENTAL|1 group|Participants received a single oral dose of ASP1517 on Days 1 and 8
62593115|NCT05098665|ACTIVE_COMPARATOR|Arm A - RCT telemonitoring|160 ATTR-CM patients assigned to receive telemonitoring intervention
62424110|NCT03711942|EXPERIMENTAL|Periodontally Healthy Base|2mm thick base was applied in periodontally health teeth.
62424111|NCT03711942|EXPERIMENTAL|Periodontally healthy control|coronal access was restored with composite resin without any base.
62033021|NCT04233268||Non critically ill cohort|Children with severe infection admitted to hospital but not requiring mechanical ventilation
62033022|NCT04233268||Profiling of the respiratory microbiome|Mechanically ventilated children of any cause admitted to PICU
62233068|NCT04964414|ACTIVE_COMPARATOR|Smell Retraining Only|Participants will undergo smell retraining for 8 weeks. Each week, participants will choose 4 scents. They will smell each item for 15 seconds very close to the nose once a day.
62233069|NCT04964414|EXPERIMENTAL|Smell Retraining + Budesonide|Participants will undergo smell retraining as described above. They will also complete budesonide irrigations once a day by pouring 0.5mg/2ml of budesonide into a irrigation bottle with saline and irrigating the nose.
62424112|NCT03711942|ACTIVE_COMPARATOR|Periodontally diseased IOB|Intra orifice barrier (IOB) was placed in periodontally healthy molar
62424113|NCT03711942|ACTIVE_COMPARATOR|Periodontally diseased Base|2mm thick Base of GIC was applied under composite restoration
62424114|NCT03711942|ACTIVE_COMPARATOR|Periodontally diseased control|coronal access was restored with composite resin without any base
62424115|NCT05412069|EXPERIMENTAL|Fecobionics study|Fecobionics
62424116|NCT01755780||Left interscalene block|Left interscalene block on hypotension and bradycardia during beach chair positioning
62424117|NCT01755780||Right interscalene block|Right interscalene block on hypotension and bradycardia during beach chair positioning
62424118|NCT01000142|NO_INTERVENTION|Treatment as Usual Control Group|
62809278|NCT03332459|EXPERIMENTAL|Lumicitabine|Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing lumicitabine for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage.
62809279|NCT03332459|PLACEBO_COMPARATOR|Placebo|Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing placebo for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of placebo, frequency and type of respiratory infections and medical resource usage.
62809280|NCT03912012|OTHER|Children and adolescent with a history of type 1 diabetes|Children and adolescent from 10 to 18 years old, with a history of type 1 diabetes for at least 10 years. Glomerular hyper filtration and endothelial dysfunction will be evaluate.
62233070|NCT04261335|EXPERIMENTAL|CL2020 cells|Intravenous injection of CL2020 cells
62424119|NCT01000142|SHAM_COMPARATOR|Light Touch Group|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
62424120|NCT01000142|EXPERIMENTAL|Standard OMT Group|
62424121|NCT03312725||Patients with ruptured or unruptured intracranial aneurysms.|
62033023|NCT02167074|ACTIVE_COMPARATOR|25G FNA needle|Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
62424122|NCT02952794||ESD|endoscopic submucosal dissection (ESD)for early cancer
62424123|NCT02952794||EMBL|endoscopic mucosal band ligation (EMBL) for early cancer
62424124|NCT00657917|EXPERIMENTAL|Paromomycin +Gentamicin topical cream|WR279,396 topically twice a day for 20 days
62424125|NCT06315608|EXPERIMENTAL|MRG-001 (0.01 mL/kg)|MRG-001 will be subcutaneously administered at 0.01 mL/kg 3 times per week every other day for two weeks per month (Day 0, 2, 4, 7, 9, 11). This cycle will be repeated 3 months in total.
62424126|NCT05154994|EXPERIMENTAL|Treatment (durvalumab, belinostat)|"Phased Doublet Therapy~Eligible patients enrolled will be administered durvalumab 1120 mg every 3 weeks C1 through C7 followed by durvalumab 1500 mg every four weeks C8 through C15 (T300+D). Belinostat administration will begin with Cycle 2 for 6 cycles. From cycle 8 on, durvalumab will be administered in 28-day cycles to complete up to a total of 15 cycles of treatment or until treatment discontinuation criteria is met. Belinostat will be administered at the assigned dose level on days one through five of every applicable cycle. Belinostat administration on five consecutive days is preferred. Administration within seven days of Day 1 is allowed as needed to accommodate holidays and infusion schedules.~Durvalumab will be infused over 60 minutes (±10 minutes). For Cycles 2-7, belinostat will be infused over 30 minutes (-5 minutes/+15 minutes) and will be administered after durvalumab. Separate infusion bags and filters must be used for each infusion."
62424127|NCT00484120|EXPERIMENTAL|1|3% Diclofenac NE cream
62424128|NCT00484120|PLACEBO_COMPARATOR|2|
62424129|NCT04382690||India|People residing in India
62424130|NCT04382690||United Kingdom|People residing in the United Kingdom
62424131|NCT04382690||China|People residing in China
62033024|NCT02167074|ACTIVE_COMPARATOR|20G ProCore FNB needle|Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
62033025|NCT06653439|ACTIVE_COMPARATOR|Group S-QLB|A bilateral S-QLB (40 ml, %0.25 bupivacaine, totally) + IV morphine patient-controlled analgesia (PCA)
62033026|NCT06653439|ACTIVE_COMPARATOR|Group Control|IV morphine PCA
62033027|NCT06635213|ACTIVE_COMPARATOR|Group 1 (desensitisation)|Group 1 will receive desensitisation.
62033028|NCT06635213|ACTIVE_COMPARATOR|Group 2 (desensitisation and pain neuroscience education)|Group 2 will receive desensitisation and pain neuroscience education.
62424132|NCT04382690||Australia|People residing in Australia
62424133|NCT04382690||South Africa|People residing in South Africa
62424134|NCT04382690||Indonesia|People residing in Indonesia
62424135|NCT04382690||Saudi Arabia|People residing in Saudi Arabia
62433569|NCT03061760||4.OAB (+) BOO (-)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with overactive bladder (OAB) symptoms and without bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
62433570|NCT03061760||5.Control group|Healthy volunteer individuals aged 20-40. 'Initial evaluation' made only once.
62809281|NCT01746368|EXPERIMENTAL|Nurse-Supported Advance Care Planning Intervention|The Nurse-Supported Advance Care Planning Intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices.
62233071|NCT04015856|EXPERIMENTAL|Full TP intervention including emphasized social norms change|Participants in this study arm will receive the full TP intervention, including emphasized social norms change, for 18 months.
62809282|NCT01746368|ACTIVE_COMPARATOR|Care-as-Usual|The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices. Subjects in this arm who desired information about risks, benefits, and alternatives of specific choices before randomization were scheduled for the Care-as-Usual session after they received that information from the Primary Care Provider.
62809283|NCT04802330||Female genital mutilation|Assessment of FGM prevalence in Beni Suef localities and its impact on studied women.
62809284|NCT00936234|ACTIVE_COMPARATOR|Vildagliptin|starting with vildagliptin for 30 days followed by placebo for 30 days
62809285|NCT00936234|PLACEBO_COMPARATOR|Placebo|starting with placebo for 30 days followed by vildagliptin for 30 days
62033029|NCT06490484|EXPERIMENTAL|HSK16149 20mg BID|Drug: HSK16149 20mg BID HSK16149 20mg, orally twice a day; treatment period: 4 weeks fixed dose.
62033030|NCT06490484|EXPERIMENTAL|Pregabalin 150 BID|Drug: Pregabalin 150mg BID Pregabalin 150mg, orally twice a day; treatment period: 1 week titration and 3 weeks fixed dose.
62033031|NCT00700401||Peginterferon Alfa-2a + Ribavirin|
62033032|NCT00113568|EXPERIMENTAL|XP12B (tranexamic acid tablets)|
62033033|NCT02774057|EXPERIMENTAL|Initial therapy with Captafer®|This arm will consist of 10 patients who will begin Captafer® therapy twice daily for 6 weeks, then undergo a 2 week washout period before crossing over to Iron Sulfate therapy twice daily for an additional 6 weeks.
62033034|NCT02774057|EXPERIMENTAL|Initial therapy with Iron Sulfate|This arm will consist of 10 patients who will begin Iron Sulfate therapy twice daily for 6 weeks, then undergo a 2 week washout period before crossing over to Captafer® therapy twice daily for an additional 6 weeks.
62033035|NCT05426551|EXPERIMENTAL|Bolus-spi|The volunteers will consume the test-meal as a bolus in one time at t = 0, with 13C-spirulina as the reference protein
62033036|NCT05426551|EXPERIMENTAL|Plateau-spi|The volunteers will consume the test-meal in a plateau feeding protocol, with 13C-spirulina as the reference protein
62809286|NCT04608617||Pre-Viz|Pre-Viz LVO implementation patient data utilized as a control data set
62033037|NCT05426551|EXPERIMENTAL|Plateau-AA|"The volunteers will consume the test-meal in a plateau feeding protocol, with 13C-free AA mixture as the reference protein"
62233072|NCT04015856|ACTIVE_COMPARATOR|Light TP intervention without emphasized social norms change|Participants in this study arm will receive the light TP intervention, without emphasized social norms change, for 18 months
62233073|NCT04015856|NO_INTERVENTION|Control|The control group will not have any study interventions.
62233074|NCT01775254||Chemotherapy Group|Colon cancer survivors who undergo open or laparoscopic resection of their colon cancers followed by adjuvant chemotherapy.
62809287|NCT04608617||Post-Viz|Patient data collected post-Viz LVO implementation
62809288|NCT02600481|EXPERIMENTAL|low-pressure pneumoperitoneum group|Subjects assigned to the low-pressure pneumoperitoneum group will receive 7-10 mm Hg carbon dioxide pneumoperitoneum, and the expected duration is longer than 3 hours to complete robot-assisted surgeries in the Trendelenburg position;
62809289|NCT02600481|ACTIVE_COMPARATOR|standard-pressure pneumoperitoneum group|Subjects assigned to the standard-pressure pneumoperitoneum group will receive 12-16 mm Hg carbon dioxide pneumoperitoneum, which is expected lasted longer than 3 hours to complete robot-assisted surgeries in the Trendelenburg position;
62033038|NCT01275573|OTHER|healthy volunteers|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
62033039|NCT01275573|OTHER|painful Parkinson's disease patients|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
62033040|NCT01275573|OTHER|painless Parkinson's disease patients|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
62233075|NCT01775254||No Chemotherapy Group|Colon cancer survivors who undergo open or laparoscopic resection of their colon cancer and who do not receive chemotherapy.
62233076|NCT06220903|EXPERIMENTAL|Treatment Group|Complex DecongestivePhysiotherapy program was planned for the affected extremity of the cases. The treatment was performed 5 days a week, for 4 weeks, for a total of 20 sessions and each session was 60 minutes. The treatment included Manual Lymph Drainage, skin care, multi-layer bandaging, exercise and compression stockings.
62433571|NCT04854980||Experimental:|Blood Sample Taken
62433572|NCT00931853|EXPERIMENTAL|SENNA + CASSIA (Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
62033041|NCT06669390|EXPERIMENTAL|NG11-2 Treatment|Patients will undergo daily treatment with NG11-2 immediately prior to radiotherapy for 5 days/week (Mon-Fri) for up to 7 weeks.
62033042|NCT05637606|EXPERIMENTAL|MAP 80|Intervention group: intraoperative mean blood pressure target \> 80 mmHg. Treatment of hypotension (defined as a mean blood pressure of below 80 mmHg) using intravenous bolus or continuous infusion of vasopressors, or fluids using a dedicated algorithm considering the pulse pressure or stroke volume variation and the mini fluid challenge to optimize mean blood pressure values.
62033043|NCT05637606|OTHER|MAP 65|Control group: intraoperative mean blood pressure target \> 65 mmHg. Treatment of hypotension (defined as a mean blood pressure of below 65 mmHg) using intravenous bolus or continuous infusion of vasopressors, or fluids using a dedicated algorithm considering the pulse pressure or stroke volume variation and the mini fluid challenge to optimize mean blood pressure values.
62233077|NCT06372028|EXPERIMENTAL|Active tVNS combined with the training|The active stimulation will be applied through an active electrode placed on the cymba conchae (the auricular branches of the vagus nerve) of the left ear. The intensity will be set based on the individual perceptual threshold, below the perception of pain. The intensity of the stimulation will be gradually increased in order to reach the intensity of stimulation with a ramping-up phase of 30 secs. The tVNS will be applied for the first 75 minutes of the training, every day of the treatment. Before, 20 minutes and 75 minutes after the start of the stimulation SpO2 and HR will be checked. At the end of the stimulation session participants will be asked to report the sensations and possible side effects occurring during tVNS and to rate their feeling on several visual analogue scales and Likert scales. The intensive bimanual training will be administered by following the procedure described in the Detailed Description session, as for the Sham tVNS combined with the training arm.
62424136|NCT06537284|EXPERIMENTAL|Imagery Rescripting with memory reconsolidation disruption (ImRs-DSR)|"Before treatment each participant took part in two imagery sessions during which a cognitive-behavioral therapist (CBT) asked him/her to recall three events of being criticized for failures (2 past and 1 future events). The treatment scenario involved memory anticipation (similarly framed for all scenarios) that required recalling three images one after another: the image of self, the surroundings, and the person of the critic involved in the scene.~After 10 minute break (reconsolidation disruption window) the imagery of the critic was followed by the rescripting part, in which: 1) the therapist enters the scene and prevents the criticism 2) the therapist addresses a critic and points out the child's needs 3) the therapist addresses the child and acknowledges its needs 4) the therapist suggests to the child to perform an activity that would meet its needs."
62033044|NCT01398488|ACTIVE_COMPARATOR|Conventional Patient education|Conventional Patient education by health care professionals.
62424137|NCT06537284|ACTIVE_COMPARATOR|Imagery Rescripting regular (ImRs)|"Before treatment each participant took part in two imagery sessions during which a cognitive-behavioral therapist (CBT) asked him/her to recall three events of being criticized for failures (2 past and 1 future events). The treatment scenario involved memory anticipation (similarly framed for all scenarios) that required recalling three images one after another: the image of self, the surroundings, and the person of the critic involved in the scene.~Immediately after the imagery of the critic the rescripting part was presented, in which: 1) the therapist enters the scene and prevents the criticism 2) the therapist addresses a critic and points out the child's needs 3) the therapist addresses the child and acknowledges its needs 4) the therapist suggests to the child to perform an activity that would meet its needs."
62424138|NCT04742816|OTHER|Iohexol injection|The research pharmacist will prepare the iohexol injection in a 1cc tuberculin syringe, consisting of 0.5cc sterile water for injection (SWFI) and 0.5cc iohexol (Omnipaque 300). The study coordinator/personnel (licensed RN) will inject the iohexol dose into the subcutaneous tissue on the opposite arm used for blood sampling; the time will be recorded. The participant will be monitored for adverse events 30 minutes post iohexol administration at the AVRC. If the participant has not had any adverse event within 30 minutes, they will be asked to leave the AVRC and return within 2 hours and 55 minutes post Iohexol injection for lab collection.
62424139|NCT00355680|EXPERIMENTAL|1|Aurolab Green Laser
62424140|NCT00355680|ACTIVE_COMPARATOR|2|Available Green Laser
62424141|NCT04622618|ACTIVE_COMPARATOR|G 300|The patients will receive 300 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
62424142|NCT04622618|ACTIVE_COMPARATOR|G 600|The patients will receive 600 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
62424143|NCT04622618|ACTIVE_COMPARATOR|G 900|The patients will receive 900 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
62424144|NCT01315301|ACTIVE_COMPARATOR|Arm-A|Immediate Treatment Group
62424145|NCT01315301|ACTIVE_COMPARATOR|Arm-B|Deferred Treatment Group-1
62424146|NCT01315301|ACTIVE_COMPARATOR|Arm-C|Deferred Treatment Group-2
62424147|NCT03654092|EXPERIMENTAL|Exercise intervention|Home-based, minimal equipment exercise training program.
62424148|NCT03654092|NO_INTERVENTION|Control|Usual care (study participation does not have any impact on regular treatment decisions, including participation in other exercise training programs).
62593116|NCT05098665|NO_INTERVENTION|Arm B - RCT usual care|Control group of 160 ATTR-CM patients assigned to receive usual care
62593117|NCT01687569|PLACEBO_COMPARATOR|Control Cracker|Base cracker snack
62593118|NCT01687569|EXPERIMENTAL|Experimental Cracker Snack 1|Cracker snack containing test ingredient 1
62593119|NCT01687569|EXPERIMENTAL|Experimental Cracker Snack 2|Cracker snack containing test ingredient 2
62593120|NCT01970475|EXPERIMENTAL|ABP 501|Participants received ABP 501 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.
62593121|NCT01970475|ACTIVE_COMPARATOR|Adalimumab|Participants received adalimumab 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.
62033045|NCT01398488|EXPERIMENTAL|Patient education via Tablet computer|Patient education after lung transplantation via Tablet computers. An electronic patient questionnaire via tablet computer will be collected in addition.
62033046|NCT01882322|EXPERIMENTAL|Advagraf conversion group|Oral
62233078|NCT06372028|SHAM_COMPARATOR|Sham tVNS combined with the training|The sham stimulation will be applied through an active electrode placed on lobe of the left ear that is free of cutaneous vagal innervations. The stimulation intensity will be set based on the individual perceptual threshold, below the perception of pain. The intensity of the stimulation will be gradually increased in order to reach the intensity of stimulation with a ramping-up phase of 30 secs. The tVNS will be applied for the first 75 minutes of the training, every day of the treatment. Before, 20 minutes and 75 minutes after the start of the stimulation SpO2 and HR will be checked. At the end of the stimulation session participants will be asked to report the sensations and possible side effects occurring during tVNS and to rate their feeling on several visual analogue scales and Likert scales. The intensive bimanual training will be administered by following the procedure described in the Detailed Description session, as for the Active tVNS combined with the training arm.
62233079|NCT05923957||Intervention|High frequency electrical stimulation was done for thirty minutes per day for five days a week for four consecutive weeks. The stimulator provides a biphasic current of 100 Hz frequency. The pulse duration was 200 msec with an (on-off). Stimulus mode (20sec stimulation, 20 sec pause). The maximal stimulation amplitude was 40 - 60 mA
62593122|NCT04877431||De Nova Participants|De nova participants who had received teduglutide after marketing authorization will be enrolled in this study and monitored by their physicians according to local clinical practice then followed for 24-weeks unless treatment discontinuation or lost to follow-up.
62593123|NCT04877431||Legacy Participants|Legacy participants who received teduglutide treatment prior to marketing authorization under expanded access type of program will be enrolled in this study and monitored by their physicians according to local clinical practice then followed for 24-weeks unless treatment discontinuation or lost to follow-up.
62593124|NCT00399412||LQTS|Long QT syndrome
62233080|NCT01749449|EXPERIMENTAL|High protein 3 meals/day|35% protein intake eaten as 3 meals per day
62233081|NCT01749449|EXPERIMENTAL|High carbohydrate consumed 3 meals/day|High carbohydrate 3 meals/day
62233082|NCT01749449|EXPERIMENTAL|High protein consumed 6 meals/day|35% protein 6 meals/day
62593125|NCT00399412||HF|Heart Failure
62233083|NCT05055986||CBCT Dicom files of patients|CBCT Dicom files of patients will be used for measurements of mandibular bone volume by open-source software.
62233084|NCT03514212|EXPERIMENTAL|ProActiveS|As this was a feasibility study, all participants received the intervention.
62233085|NCT05576818|NO_INTERVENTION|Control group|this group will include 33 patients who will receive their standard dopamine replacement therapy for 3 months
62593126|NCT00399412||CRT|Cardiac Resynchronization Therapy
62593127|NCT00399412||Wide QRS|QRS \> 120 milliseconds
62233086|NCT05576818|ACTIVE_COMPARATOR|Synbiotic group|this group will involve 33 patients who will receive Synbiotic preparation containing Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers 2 sachets daily together with their standard dopamine replacement therapy for 3 months
62593128|NCT00351741|EXPERIMENTAL|High Frequency|Provide standard ventilatory support for burn patients utilizing high frequency percussive ventilation
62593129|NCT00351741|ACTIVE_COMPARATOR|Conventional|Standard ventilator support for non burned patients utilizing lung protective low tidal volume ventilation
62593130|NCT06022614|ACTIVE_COMPARATOR|Patients receiving Block with Bupivacaine only|consists of patients receiving erector spinae plane block with Bupivacaine only
62233087|NCT05199974|ACTIVE_COMPARATOR|Group A: Linea alba was closed with conventional continuous technique .|Group A: 25 patients included . Linea alba will be closed with conventional continuous technique .
62593131|NCT06022614|ACTIVE_COMPARATOR|Patients receiving Block using Bupivacaine with Dexmedetomidine|consists of patients receiving erector spinae plane block using bupivacaine with Dexmedetomidine
62033047|NCT01882322|ACTIVE_COMPARATOR|Prograf maintenance group|Oral
62033048|NCT02057146|EXPERIMENTAL|Mother-baby endoscopy|Spyglass mother-baby endoscopy in conjunction with ERCP
62593132|NCT06499168||groups: LABC patients who will receive neoadjuvant chemotherapy before surgery.|
62593133|NCT00471718|EXPERIMENTAL|Phase I/II: Chemotherapy ABT-751|"Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21.~Phase II: Patients receive ABT-751 twice daily"
62593134|NCT04605549|EXPERIMENTAL|CIN-107 for dosing at 2, 4, or 8 mg (QD)|"Patients will be provided with an initial dose of CIN-107 and start once daily (QD) dosing of CIN-107 tablets at 2 mg. At Visit 4, CIN-107 dose may be up-titrated to 4 mg QD if the patient has tolerated dosing of CIN-107 at 2 mg and the blood pressure (BP) records indicate minimal hypotension risk.~At Visit 5, CIN-107 dose may be up-titrated to 8 mg QD if the patient has tolerated dosing of CIN-107 at 4 mg."
62593135|NCT03065088|EXPERIMENTAL|aLiFE|The aLiFE programme is developed for young older adults, where balance activities, strengthening activities, and specific recommendations for increasing physical activity, are embedded within everyday activities, so that the activities can be performed multiple times throughout the day. The programme is presented by an instructor by use of a paper based manual during a 6 month intervention period in participants homes.
62809290|NCT04154436|EXPERIMENTAL|Sodium Bicarbonate (NaHCO3) Plus Solution|15 cc of Sodium Bicarbonate (NaHCO3) plus Solution will be sprayed on left or right side of the patient's face based on randomisation
62233088|NCT05199974|ACTIVE_COMPARATOR|Group B: Linea alba was closed with Modified Smead Jones technique with Far-near near-far technique.|Group B:25 patients included. Linea alba will be closed with Modified Smead jones technique with Far-near near-far technique.
62233089|NCT03328533|ACTIVE_COMPARATOR|Phenylephrine|Will receive spinal anesthesia using Bupivacaine. Then, phenylephrine infusion by a starting rate of 0.75 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure. The infusion will stop in case of reactive hypertension. The infusion will start again when blood pressure returns to normal reading. Infusion will be increased by 20% if hypotension occurred.
62233090|NCT03328533|EXPERIMENTAL|Norepinephrine|Will receive spinal anesthesia using Bupivacaine. Then, norepinephrine bitartrate infusion by a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min). The rate will be then adjusted according to the patient blood pressure. The infusion will stop in case of reactive hypertension. The infusion will start again when blood pressure returns to normal reading. Infusion will be increased by 20% if hypotension occurred.
62233091|NCT02727166|EXPERIMENTAL|Inulin 8 g/d|Mixture of oligo- and polysaccharides composed of fructose units connected by β (2→1) links with a total number of fructose and glucose units ranging between 2 and 70.
62233092|NCT02727166|PLACEBO_COMPARATOR|maltodextrine 8 g/d|
62233093|NCT01771328|ACTIVE_COMPARATOR|hydrocortisone|Treatment B ( Solu-Cortef) the initial standard dose of 10mg/m2/24hrs. Hydrocortisone infusate will be given as Solu-Cortef Act-o-Vial 50mg/ml, produced by Pfizer. Treatment will take 4 months.
62233094|NCT01771328|ACTIVE_COMPARATOR|cortisone acetate|Treatment A (Cortisone tbl.) is current treatment, i.e. glucocorticoid and mineralocorticoid replacement according to best clinical judgement. This treatment period will take 6 months.
62233095|NCT04421521|EXPERIMENTAL|Acupuncture Group|
62593136|NCT03065088|EXPERIMENTAL|eLiFE|The aLiFE programme is transferred to a mobile health system, called the eLiFE. The intervention is delivered on smartphones and smartwatches including inertial sensors well suited to monitor physical activity and movement quality in daily life. An instructor teaches the participants how to use the mobile health system during home visits and phone calls during the 6 month intervention period. A virtual instructor teaches the participants the eLiFE programme. Pictures and videos of the aLiFE activities are delivered by use of the system. Behavioural change strategies are also included in the system.
62593137|NCT03065088|ACTIVE_COMPARATOR|control|The control group follows the World Health Organization's recommendations of physical activity.
62593138|NCT00214149|EXPERIMENTAL|1|breast brachytherapy to a dose of 34 Gy
62593139|NCT03546426|EXPERIMENTAL|study treatment|Pembrolizumab in combination with Autologous dendritic cells and Interleukin-2
62809291|NCT04154436|PLACEBO_COMPARATOR|Water (H2O)|15 cc of Water (H2O) will be sprayed on the left or right side of the patient's face based on randomisation
62233096|NCT04421521|NO_INTERVENTION|Standard Therapy Group|
62233097|NCT04559880|EXPERIMENTAL|Tranexamic Acid|"Intra-procedural tranexamic acid (TXA) - 1 gram, IV~Post-procedural tranexamic acid (TXA) - 1 gram, oral, three times per day for 5 days"
62424149|NCT01841398|ACTIVE_COMPARATOR|Multimedia Lifestyle Improvement|Includes goal setting, self monitoring and participants will receive regular health messaging using electronic media regarding smoking, dietary habits \& physical activity
62809292|NCT05625321|ACTIVE_COMPARATOR|Educational Group Weight Loss Classes|Participants will participate in a 12-month weight loss program, taught by lay health educators, and designed to promote and encourage healthy weight loss, dietary changes, and increased physical activity. Participants will attend 90-minute sessions weekly for 6 months, bi-weekly for 3 months, and monthly for 3 months.
62809293|NCT05625321|EXPERIMENTAL|Educational Group Weight Loss Classes PLUS Home Gardening Intervention|Participants will receive the educational group weight loss classes PLUS a home gardening intervention. The gardening intervention will be led by local Master Gardeners (MGs) who will help guide participants in setting-up and maintaining their garden.
62809294|NCT02520726|EXPERIMENTAL|Sertraline|Patients age 18-65: sertraline 50mg PO qday for one week, then 100mg PO qday for one week, then 150mg PO qday for one week, then 200mg PO qday for one week, with flexible titration. Patient age \>65: sertraline 25mg PO qday for one week, then 50mg PO qday for one week, then 75mg PO qday for one week, then 100mg PO qday for one week, with flexible titration
62809295|NCT02520726|PLACEBO_COMPARATOR|Placebo|Placebo 1 capsule PO qday for one week, then 2 capsules PO qday for one week, then 3 capsules PO qday for one week, then 4 capsules PO qday for one week.
62809296|NCT00530413|EXPERIMENTAL|1|Phenobarbital - dose based by weight range
62809297|NCT00530413|PLACEBO_COMPARATOR|2|Placebo group
62809298|NCT02166099||SpyGlass Choledochoscopy procedure|Any patient who has undergone SpyGlass Choledochoscopy procedures for diagnosis and/or treatment of a pancreatico-biliary disorder
62233098|NCT05584969|EXPERIMENTAL|Moms-only treatment arm|In this treatment arm, 10 Care Groups comprised of only mothers (10 - 20 participants per group) engaged in the peer-led intervention that consisted of infant feeding guidelines \[16\], cooking demonstrations, and backyard farming demonstrations conducted over 10 months. The peer-led trainings lasted 60 - 90 minutes and were conducted every two weeks and supervised by a selected VHT.
62233099|NCT05584969|EXPERIMENTAL|Moms and Dads treatment arm|This treatment arm received a similar peer-led intervention to the Moms-only treatment arm, however, this arm comprised both moms and dads (a couple)
62233100|NCT05584969|NO_INTERVENTION|Control arm|This was the comparison arm of the study. No intervention was provided to the participants of this arm. However, all study arm participants accessed the standard of care which was the routine health services delivered through the government health centers.
62233101|NCT04754477|EXPERIMENTAL|Active Osseointegrated Steady-State Implant System (OSI)|
62233102|NCT02811185|OTHER|PET/CT Scan|Subjects will receive a single dose of \[F-18\]-FDG Injection at Visit 1, followed by PET/CT scanning according to departmental practice.
62233103|NCT02811185|OTHER|PET Scan|Subjects will receive a single dose of \[F-18\]-FDG Injection at Visit 1, followed by PET scanning according to departmental practice.
62233104|NCT04523766|ACTIVE_COMPARATOR|Mindfulness of Breath|
62424150|NCT01841398|PLACEBO_COMPARATOR|Usual Care|Includes usual advice and no regular health messaging.
62424151|NCT02022410||CAS after primary and revision TKA|CAS and RAPT
62424152|NCT01380860|EXPERIMENTAL|Mesh|The patients allocated to this arm of the study will have mesh (Covidien France: mono filament polyester bidimensional knit) implanted in association with their colostomy.
62424153|NCT01380860|ACTIVE_COMPARATOR|No mesh|The patients allocated to this arm of the protocol will not receive mesh implantation with their colostomy.
62424154|NCT06567470|EXPERIMENTAL|CIT-013 low dose|6 SC injections with low dose CIT-013
62033049|NCT02239679|EXPERIMENTAL|ALA X3|Cryotherapy followed by 3 aminolevulinic acid + blue light (BLU-U) treatments
62424155|NCT06567470|EXPERIMENTAL|CIT-013 high dose|6 SC injections with CIT-013
62424156|NCT06567470|PLACEBO_COMPARATOR|Placebo|6 SC injections with placebo
62424157|NCT00118573|EXPERIMENTAL|EVAR|AAA repair with endografting
62424158|NCT00118573|ACTIVE_COMPARATOR|Surveillance|Not AAA repair; surveillance
62424159|NCT06567158|EXPERIMENTAL|Group 1: 1st Traditional diet, 2nd Moderate carbohydrate diet|The group that starts with the traditional diet in the first 4-week diet period. After wash-out, this group will start with the moderate carbohydrate diet in the second 4-week diet period.
62424160|NCT06567158|EXPERIMENTAL|Group 2: 1st Moderate carbohydrate diet, 2nd Traditional diet|The group that starts with the traditional diet in the first 4-week diet period. After wash-out, this group will start with the moderate carbohydrate diet in the second 4-week diet period.
62424161|NCT00002774|EXPERIMENTAL|Tirapazamine + cisplatin + 5-FU|2 cycles of induction chemotherapy (tirapazamine, cisplatin, and 5-fluorouracil \[5-FU\]) followed by simultaneous chemoradiotherapy (tirapazamine, cisplatin, and 5-FU)
62424162|NCT00002774|ACTIVE_COMPARATOR|Cisplatin + 5-FU|2 cycles of induction chemotherapy (cisplatin + 5-fluorouracil \[5-FU\]) followed by simultaneous chemoradiotherapy (cisplatin + 5-FU)
62424163|NCT01844869|EXPERIMENTAL|omacetaxine mepesuccinate|"Period A: 7-day pharmacokinetic assessment period in which all patients will be administered a single subcutaneous radiolabeled dose of 1.25-mg/m2 omacetaxine.~Period B: omacetaxine will be administered as an sc injection at a dosage of 1.25 mg/m2 twice daily for 7 days (patients with solid tumors) or 14 days (patients with hematologic malignancies) of every 28-day cycle for up to 6 cycles."
62033050|NCT02239679|PLACEBO_COMPARATOR|VEH|Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving cryotherapy and 2 or 3 subsequent Topical Solution Vehicle + BLU-U treatments. Subjects receiving VEH will be considered a single treatment group.
62233105|NCT04523766|EXPERIMENTAL|Mindful Interoceptive Mapping|
62233106|NCT01692691|EXPERIMENTAL|Dacarbazine, carmustine, neulasta|Dacarbazine IV - Day 1; Carmustine IV - Day 2; Neulasta SC - Day 3
62233107|NCT02773875|NO_INTERVENTION|Sensor Augmented Pump (control)|Use sensor augmented pump (SAP) for 3 weeks.
62033051|NCT02239679|EXPERIMENTAL|ALA X2|Cryotherapy followed by 2 aminolevulinic acid + BLU-U treatments
62233108|NCT02773875|EXPERIMENTAL|Artificial Pancreas (intervention)|Artificial pancreas system (Algorithm + CGM + pump)--use the AP system for 3 weeks which consists of: (1) Fault detection and Zone MPC algorithm housed on the DiAs platform + (2) Roche insulin pump + (3) Dexcom CGM
62233109|NCT04911556|PLACEBO_COMPARATOR|the placebo group|A placebo made of starch
62233110|NCT04911556|EXPERIMENTAL|Bifidobacterium longum group 1|Bifidobacterium longum 274
62233111|NCT04911556|EXPERIMENTAL|Bifidobacterium longum group 2|Bifidobacterium longum 4-1
62233112|NCT04911556|EXPERIMENTAL|Bifidobacterium longum group 3|Bifidobacterium longum gs
62233113|NCT03330353||Neurodegenerative Diseases|Individuals with neurodegenerative diseases
62233114|NCT03398226||Control group|
62424164|NCT03222895||TIGER study cohort|This is the entire patient cohort. Alle patients with resectable esophageal cancer undergoing a transthoracic esophagectomy with at least a 2-field lymphadenectomy
62424165|NCT04295044|EXPERIMENTAL|High protein diet|received high protein diet, prescribed by dietitian
62424166|NCT04295044|ACTIVE_COMPARATOR|Normal protein diet|received normal protein diet, prescribed by dietitian
62424167|NCT01180907||patients with cancer|
62809299|NCT03531489|EXPERIMENTAL|Part 1: Feasibility|Patients will perform 6-minute walk test with AIR-AD to allow for observation and real-time feedback.
62809300|NCT03531489|EXPERIMENTAL|Part 2: Crossover|Crossover design where investigator will compare wearing of AIR-AD during exercise to compare distance walked with and without it.
62809301|NCT02006316||varicoceles|men with clinical varicoceles underwent microsurgical varicocelectomy due to causes other than infertility such as testicular pain, discomfort or scrotal mass
62809302|NCT02568735|EXPERIMENTAL|Etoricoxib|Etoricoxib 60mg if body weight≤ 60kg, 90mg if body weight 61-90kg and 120mg if body weight\> 90kg by mouth
62809303|NCT02568735|ACTIVE_COMPARATOR|Dexketoprofen|Dexketoprofen 0,5 mg/kg up to 50 mg intravenously
62809304|NCT03885635|ACTIVE_COMPARATOR|Hemiarch repair|Standard hemiarch repair with open distal anastomosis in the proximal arch without replacement of the head vessels.
62809305|NCT03885635|ACTIVE_COMPARATOR|Extended arch repair|Ascending aortic and arch replacement with or without head vessel re-implantation and single TEVAR device placement within 1 week.
62809306|NCT05219357|ACTIVE_COMPARATOR|Usual Care Group (UCG)|The usual care control group received care only on hospital wards during episodes
62033052|NCT06633263|EXPERIMENTAL|CBT-I followed by BATD|"1. Five group CBT-I sessions of two hours, one per week.~2. Two-week break - baseline~3. Five individual BATD sessions of one hour, one per week. Because of the diverse content of ruminations and avoidances in depression (Blairy et al., 2020), AC therapy will be administered in an individual format, while CBT-I will take place in a group setting."
62033053|NCT06633263|EXPERIMENTAL|BATD followed by CBT-I|"1. Five individual BATD sessions of one hour, one per week. Because of the diverse content of ruminations and avoidances in depression (Blairy et al., 2020), AC therapy will be administered in an individual format, while CBT-I will take place in a group setting.~2. Two-week break - baseline~3. Five group CBT-I sessions of two hours, one per week."
62033054|NCT03057795|EXPERIMENTAL|Treatment (brentuximab vedotin, nivolumab)|Beginning 30-60 days post-ASCT, patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
62033055|NCT06284876|EXPERIMENTAL|Ilaprazole 10 mg|Take Ilaprazole 10 mg 1 tablet + Placebo of Lansoprazole 15 mg 1 capsule by mouth, with water, once daily.
62033056|NCT06284876|ACTIVE_COMPARATOR|Lansoprazole 15 mg|Take Lansoprazole 15 mg 1 capsule + Placebo of Ilaprazole 10 mg 1 tablet by mouth, with water, once daily.
62033057|NCT04520984|EXPERIMENTAL|Arm 1|Intervention
62233115|NCT03398226||Distal Gastrectomy (DG) group|38 patients planing distal gastrectomy due to gastric cancer
62424168|NCT01180907||patients with autoimmune diseases|
62424169|NCT01180907||healthy subjects|
62809307|NCT05219357|OTHER|Ayu Care Group (ACG)|Multidisciplinary Ayurveda based treatment team aimed to manage acute crises of patients in the community settings or at their home if feasible.
62809308|NCT01140841||Fipamezole ODT|
62809309|NCT01140841||Placebo|
62809310|NCT05672329|EXPERIMENTAL|Group 1: Low-flow apnoeic oxygenation|Group 1) 0.2 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0;
62809311|NCT05672329|EXPERIMENTAL|Group 2: High-flow apnoeic oxygenation|Group 2) 2 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0;
62233116|NCT03398226||Total Gastrectomy (TG) group|38 patients planing total gastrectomy due to gastric cancer
62233117|NCT05572333|EXPERIMENTAL|EP395|EP395 in repeated doses. Oral, once-daily administration of 3 EP395 capsules for 12 weeks.
62809312|NCT05672329|ACTIVE_COMPARATOR|Group 3: Control group apnoeic oxygenation|Group 3) 4 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0;
62809313|NCT05672329|EXPERIMENTAL|Group 4: High-flow apnoeic oxygenation|Group 4): 2 l/kg/min with OptiFlow FiO2 1.0 using OptiFlow-Switch system by Fisher\&Paykel
62033058|NCT04520984|OTHER|Arm 2|Standard Care
62033059|NCT01898338|EXPERIMENTAL|Fosfomycin and Daptomycin|fosfomycin 2gr/6h + 10mg/kg/24h iv during 14 or 28 days
62033060|NCT01898338|ACTIVE_COMPARATOR|Daptomycin|daptomycin 10mg/kg/cada 24h iv during 14 or 28 days
62033061|NCT01043666|EXPERIMENTAL|YM178 group|oral
62033062|NCT01043666|PLACEBO_COMPARATOR|placebo group|oral
62033063|NCT01043666|EXPERIMENTAL|tolterodine ER group|oral
62033064|NCT03986853|EXPERIMENTAL|Blood sample|Blood sampling Under general anesthesia
62033065|NCT01252394||Hemodialysis patients|
62233118|NCT05572333|PLACEBO_COMPARATOR|Placebo|Matched placebo capsule. Oral, once-daily administration of 3 placebo capsules for 12 weeks.
62233119|NCT04531553|ACTIVE_COMPARATOR|Thoracic epidural analgesia|Patients will preoperatively receive thoracic epidural at the level T5 \& T6 with bolus 20 ml of levobupivacaine 0.25% then levobupivacaine 0.1% infused at a rate of 0.1 mL/Kg/h until chest tube removal ( 5-6 days).
62233120|NCT04531553|ACTIVE_COMPARATOR|ESPB with levobupivacaine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% on the deep aspect of erector spinae muscle then catheter inserted.A 20 ml bolus of levobupivacaine 0.1% is injected every 6 hours until chest tube removal.
62424170|NCT05622552|ACTIVE_COMPARATOR|active group|"tDCS stimulation, which was performed once a day sessions of active anodal tDCS to the right dorsolateral prefrontal cortex and cathode to the left OFC (2 mA, 20 minutes, 10 sessions over 2 weeks).~In the active group, current stimulations were gradually ramped up to 2 mA (in 30 seconds) intensity for 20 minutes, once a day, for 10 days."
62809314|NCT04380506|EXPERIMENTAL|Drain removal|Patients that fulfill criteria for surgical drains removal
62809315|NCT00918385|ACTIVE_COMPARATOR|1|High Androgen Receptor (AR) activity
62809316|NCT00918385|ACTIVE_COMPARATOR|2|Low Androgen Receptor (AR) activity
62809317|NCT01476059|OTHER|telephone follow-up|Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
62809318|NCT01476059|OTHER|No telephone follow-up|Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
62424171|NCT05622552|SHAM_COMPARATOR|sham group|"tDCS stimulation, which was performed once a day sessions of sham anodal tDCS to the right dorsolateral prefrontal cortex and cathode to the left OFC (2 mA, 20 minutes, 10 sessions over 2 weeks).~For sham stimulation, the procedure was identical, except that the current was gradually ramped up to 2mA and rapidly down to zero (in 30 seconds), thus leading to the same initial sensations of tDCS."
62809319|NCT03189186|EXPERIMENTAL|Pembrolizumab|Advanced (stage II and above with multiple tumors or vena cava) and metastatic Renal Cell Carcinoma will be first treated with cryoablation on a large primary tumor and then given 200 mg pembrolizumab every 3-week for 3 cycles, followed by cytoreductive or partial/radical nephrectomy. After the surgery, patients will resume pembrolizumab for additional 5 cycles or up to a total of 2 years if a partial response is observed at the discretion of the treating medical oncologist or urologist until a complete tumor remission, disease progression, unacceptable toxicity, subject refusal, or subject death due to any cause.
62809320|NCT03243851|EXPERIMENTAL|Temozolomide+metformin|"Temozolomide :~1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks~Metformin :~1. 1st cycle (4 weeks)~   * 1 week(1st\~7th day) = 1,000mg/day~  * 1 week(8th\~14th day) = 1,500mg/day~  * 2 weeks(15th \~28th day) = 2,000mg/day~2. 2nd to 6th cycle (20 weeks) = 2,000mg/day"
62233121|NCT04531553|ACTIVE_COMPARATOR|ESPB with levobupivacaine and dexmedetomidine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% plus 0.5mic/Kg dexmedetomidine on the deep aspect of erector spinae muscle then catheter inserted. 20 ml bolus of levobupivacaine 0.1% with dexmedetomidine 0.5 μg/Kg was injected every 6 hours until chest tube removal.
62233122|NCT06494202|ACTIVE_COMPARATOR|Conventional rehabilitation program|Conventional rehabilitation intervention with multidisciplinary team (medical services, physiotherapy, occupational therapy, physical education, psychology, nutrition, social service, speech therapy, and nurse) delivered during four to six weeks of intensive in-patient program
62424172|NCT03779113|EXPERIMENTAL|Treatment|All patients to received study drug (HMPL-523)
62424173|NCT01624155|EXPERIMENTAL|Women taking teratogens|Women taking teratogens
62424174|NCT01431235|NO_INTERVENTION|standard addiction treatment|10 sessions of standard addiction treatment. No ADHD treatment.
62424175|NCT01431235|EXPERIMENTAL|addiction treatment and ADHD treatment|10 sessions cognitive behavioral therapy on addiction treatment combined with 5 sessions on ADHD treatment.
62424176|NCT03399435|EXPERIMENTAL|Part A|8 cohorts are planned to be treated.
62424177|NCT03399435|EXPERIMENTAL|Part B|Part B will start at the earliest after 4 cohorts of Part A have been treated. Up to 8 cohorts are planned to be treated.
62424178|NCT03399435|EXPERIMENTAL|Part C|Part C will comprise 4 treatment groups. The neosaxitoxin dose will be the same in all 4 treatment groups.
62424179|NCT03951181|EXPERIMENTAL|LEAP-MS Intervention|This is a single arm study.
62424180|NCT04816500|EXPERIMENTAL|RIC group|Device: Remote ischemic conditioning RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 year after enrollment.
62424181|NCT04816500|OTHER|Regular treatment|
62424182|NCT06260384||All patients attending outpatient cardiology clinics or referred for EP study|Participants will be recruited from outpatient cardiology clinics and inpatient cardiology wards at twenty cardiac centers in 17 countries spread across all African regions. They all belong to the Africa Heart Rhythm Association (AFHRA) network, and participants are included if they have a preexcitation (WPW) pattern on an ECG. A written consent will be obtained, and an ethical clearance from each center will be obtained from their institution. The exclusion criteria were a lack of consent.
62424183|NCT04254731|OTHER|Cross over study before and after drug switch|Stabilized on racemic methadone dose, switched to R-methadone of half racemic methadone dose. Cross over study, own control
62424184|NCT03789058|ACTIVE_COMPARATOR|Surgical with conventional NSAID 3 times/day|Control group will have surgical intervention to remove wisdom tooth and receive conventional NSAID treatment three times per day
62424185|NCT03789058|EXPERIMENTAL|Surgical with conventional NSAID 2 times/days|The experimental group will have surgival intervention to remove wisdom tooth and receive NSAID treatment only two times per day: once after breakfast and once after lunch, but not at night.
62424186|NCT04456985|ACTIVE_COMPARATOR|Intervention group|Before the operation, the patient took 20ml of brown sugar aqueous solution containing folic acid and VitB12 for 3 days (folic acid concentration is 0.4mg / d for 2 year old children + 1.2μg / d of VitB12, dissolved in 20ml brown sugar water once a day). Postoperatively, PAED scores were performed at the time of awakening, extubation and every 10min within 30min after extubation. 10 points is defined as delirium during the recovery period). Long-term neurobehavioral changes were evaluated using the Gesell scale, followed up every six months until the age of three
62424187|NCT04456985|PLACEBO_COMPARATOR|Placebo group|The patients in the placebo group took 20 ml of brown sugar aqueous solution with the same concentration as the intervention group 3 days before the operation. Postoperatively, PAED scores were performed at the time of recovery, extubation, and every 10 minutes within 30 minutes after extubation. The PAED scores of all children were measured by the same person. (The total score is 0-20, and the score ≥10 is defined as delirium during the recovery period). Long-term neurobehavioral changes were evaluated using the Gesell scale, followed up every six months until the age of three
62424188|NCT00338494|EXPERIMENTAL|1|
62424189|NCT04114409||1|OSAS and type D personality
62424190|NCT04114409||2|OSAS without type D personality
62424191|NCT05748522|OTHER|Shoulder Mobility|It is one of the seven functional movements studied in FMS. This test requires the participant to simultaneously hold one hand behind the back (internal rotation) and the other hand behind the head (external rotation) with the fisted hands, and bring the hands as close to each other as possible in the back area. The distance measurement in cm is taken with a tape measure between 3 fingers of both hands. This type of reach test has been described as a tool for measuring glenohumeral joint (GH) mobility through functional shoulder movements.
62433573|NCT04541888|EXPERIMENTAL|Experimental Group|322 subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
62233123|NCT06494202|EXPERIMENTAL|Innovative rehabilitation program|Conventional rehabilitation intervention with multidisciplinary team (medical services, physiotherapy, occupational therapy, physical education, psychology, nutrition, social service, speech therapy, and nurse) delivered during four to six weeks of intensive in-patient program combined with innovative medical therapies (laser therapy, radial extracorporeal shockwaves therapy, focused extracorporeal shockwaves therapy, segmentary desensibilization with lidocaine, functional electrical stimulation - FES).
62233124|NCT02253303|EXPERIMENTAL|Midline incision|The extraction-site incision in laparoscopic colectomy is middline
62233125|NCT02253303|ACTIVE_COMPARATOR|off-midline incision|The extraction-site incision in laparoscopic colectomy is off-middline
62424192|NCT05748522|EXPERIMENTAL|Diaphragmatic Breathing|The participant lies on his back. He places his hands horizontally on the lowest part of the ribs. While inhaling, he is asked to inflate his stomach towards the bottom of his hands. It is taught that during breathing, the abdomen should swell rather than the rib cage, and the ribs should open outwards. Breath is taken through the nose, blown slowly through the mouth.
62809321|NCT03243851|PLACEBO_COMPARATOR|Temozolomide+placebo|"Temozolomide :~1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks~Placebo:~1. 1st cycle (4 weeks)~   * 1 week(1st\~7th day) = 1,000mg/day~  * 1 week(8th\~14th day) = 1,500mg/day~  * 2 weeks(15th\~28th day) = 2,000mg/day~2. 2nd to 6th cycle (20 weeks) = 2,000mg/day"
62424193|NCT05365022|NO_INTERVENTION|Conventional Non-Robotic Assisted Knee Prosthetic Surgery|
62424194|NCT05365022|ACTIVE_COMPARATOR|ROSA® System Robotic Assisted Knee Prosthetic Surgery|
62809322|NCT01343394|EXPERIMENTAL|Biologic; Autologous Cell Injection|
62233126|NCT05925166|EXPERIMENTAL|rhTNFR-Fc|Subjects will be administered rhTNFR-Fc 50 mg subcutaneously
62424195|NCT05645055||Patients with stricturing Crohn's diseases|Patients with stricturing Crohn's diseases
62424196|NCT04930198|OTHER|Social Incentive|"For the social incentive, the mHealth application will track the participant's individual adherence score (% of doses taken), track the top scorers (leaderboard), and provide a figure highlighting the proportion of their peers with poor (\<80%), medium (80-94%), or high (\>94%) adherence scores. The display of the individual's adherence score relative to peer scores is considered a descriptive norm and is meant to portray what most people are doing, as young people often inaccurately estimate behaviors for their peer groups. Participants will also receive an injunctive norm, or an indication of what they ought to be doing. This will come in the form of an emoji or congratulatory vs. motivating text for those with high or low adherence scores, respectively. When coupled with descriptive norms, injunctive norms have counteracted regression to the mean for individuals who demonstrate desirable behaviors relative to their peers."
62424197|NCT04930198|OTHER|Social Plus Financial Incentive|"For the financial incentive, the top 5 scorers in the PEER+ arm will be eligible win a lottery prize each month of the 24 week pilot of 1000 Nigerian Naira (NGN) of data that can be directly loaded onto the winner's phone. Behavioral economics theory tells us that individuals are more averse to losses than rewarded by gains, so that even incentives/prizes should be framed in terms of losses. Accordingly, participants in the financial incentive arm will receive weekly motivating messages such as take your dose today or you lose the chance of winning the lottery."
62424198|NCT01461369|EXPERIMENTAL|Diclofenac Capsules 35 mg bid|
62233127|NCT05925166|ACTIVE_COMPARATOR|Triamcinolone acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly
62233128|NCT02489513|OTHER|Single group assignment|\[14C\]-AG-120
62233129|NCT02824263|NO_INTERVENTION|CPAP (Usual care)|Continuation of established CPAP therapy. CPAP will be worn during a metabolic sleep study in the research laboratory.
62233130|NCT02824263|EXPERIMENTAL|CPAP withdrawal;|Cessation of established CPAP therapy for 3 nights. CPAP will NOT be worn during this period, and a metabolic sleep study off CPAP is performed in the research laboratory on the third night.
62233131|NCT05441917|EXPERIMENTAL|Sanae with LED|"Phototherapy is related to light emission as a form of treatment for tissue and skin conditions. Its action depends on the absorption of light by chromophores, organelles present in the dermis and epidermis that give rise to cellular responses according to the different chemical reactions caused by light. The term LED means light emitted by a diode, thus, when the diode is subjected to an electrical current, light emission occurs (photon). Its applicability occurs in various disorders such as acne, alopecia, localized adiposity, stretch marks, cellulite, pre and postoperative, dark circles, etc. And they can also enhance treatments by promoting drainage, hydration, whitening, and rejuvenation, among other benefits."
62424199|NCT01461369|EXPERIMENTAL|Diclofenac Capsules 35 mg tid|
62424200|NCT01461369|PLACEBO_COMPARATOR|Placebo Capsule|
62424201|NCT03894917||Group 1|Participants 65 years or older
62424202|NCT03894917||Group 2|Participants less than 65 years
62424203|NCT02505165|EXPERIMENTAL|Parent Uncertainty Intervention|A pediatric cancer-specific, clinic based, six-module interdisciplinary uncertainty intervention. Modules one through three target uncertainty prevention. Modules four through six target uncertainty responses for situations in which uncertainty cannot be prevented or avoided.
62424204|NCT02505165|OTHER|Education/Support Only|"Sessions in this condition aim to provide education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Information presented will be based upon, Young People with Cancer: A Handbook for Parents, a parent resource developed by the National Cancer Institute. Parents will also be provided with relevant educational brochures from COG. Each session will also include a structured set of questions that will facilitate discussion. All ESO interventionists will be trained in non-directive approaches including reflective listening. Content provided in the ESO sessions will offer valuable information to parents without providing the specific skills of the IMPACT."
62809323|NCT03274284|EXPERIMENTAL|chemoradiotherapy|Chemoradiation in the form of cisplatin plus conformal radiotherapy 55GY/20 fractions which is biologically effective to 64GY/32 fractions fr
62033066|NCT01128413|EXPERIMENTAL|Fluid Optimization (FO)|"Cheetah NICOM® (non-invasive cardiac output monitoring) Passive Leg Raise Testing (PLRT) that demonstrates a \>/= 15% change in stroke volume index (SVI) or cardiac index (CI) will receive a 500ml normal saline bolus. NICOM® PLRT with SVI or CI \<15% will receive a saline lock. If bolused, NICOM® PLRT will be performed within 10 minutes after the bolus with the decision to re-bolus or saline lock according to repeated NICOM® PLRT measurements. If saline locked, NICOM® PLRT will be performed every 30 minutes with the decision to re-bolus or saline lock according to repeated NICOM® PLRT measurements.~Additionally, USCOM®, IVC Ultrasound collapsibility, CURVES Questionnaire, and repeat lactate measurements will be performed."
62424205|NCT02264301|ACTIVE_COMPARATOR|Puerarin injection 400 mg|Patients under the treatment of Puerarin injection 400 mg,daily,for 24 weeks
62424206|NCT02264301|EXPERIMENTAL|Qingkailing injection 40 ml|Patients under the treatment of Qingkailing injection 40 ml,daily,for 24 weeks
62424207|NCT06108674|EXPERIMENTAL|Telepharmacy|Pharmaceutical care via telepharmacy
62424208|NCT06108674|ACTIVE_COMPARATOR|In-person|In-person pharmaceutical care
62424209|NCT05043727|EXPERIMENTAL|Exer gaming treatment plan|Exer gaming treatment plan
62424210|NCT05043727|ACTIVE_COMPARATOR|conventional treatment plan|conventional treatment plan
62424211|NCT04793932|ACTIVE_COMPARATOR|PAXG Arm A|cisplatin 30 mg/m2 every 2 weeks, nab-paclitaxel 150 mg/m2 every 2 weeks, gemcitabine 800 mg/m2 every 2 weeks, capecitabine 1250 mg/m2/day (for 28 consecutive days) in 28-day cycles administered for 4 cycles (4 months).
62424212|NCT04793932|ACTIVE_COMPARATOR|mFOLFIRINOX Arm B|irinotecan 150 mg/m2 day 1, oxaliplatin 85 mg/m2 day 1, folinic acid at a fixed dose of 400 mg/m2, fluorouracil continuous IV infusion 2.4 g/m2 over 46 hours in 14-day cycles administered for 8 cycles (4 months).
62424213|NCT04793932|ACTIVE_COMPARATOR|short-course chemotherapy|Allocated by second randomization after 4 months of chemotherapy to receive immediate surgery followed by 2 further months of the same chemotherapy
62424214|NCT04793932|ACTIVE_COMPARATOR|long-course chemotherapy|Allocated by second randomization after 4 months of chemotherapy to receive 2 further months of the same chemotherapy followed by surgery
62809324|NCT00447226|EXPERIMENTAL|Lapatinib Oral Tablets|
62424215|NCT03863652||Snuffboxer|Patients undergoing percutaneous coronary intervention via snuffbox approach
62424216|NCT01238211|EXPERIMENTAL|Treatment (daunorubicin hydrochloride, cytarabine, dasatinib)|"INDUCTION THERAPY (course 1): Patients receive daunorubicin hydrochloride IV on days 1-3, cytarabine IV continuously over 168 hours on days 1-7, and dasatinib PO QD on days 8-21. Patients with responsive disease on day 21 undergo consolidation therapy, and patients with non-responsive disease on day 21 (bone marrow cellularity \>= 20% and leukemia blasts \>= 5%) receive a second course of induction therapy.~INDUCTION THERAPY (course 2): Patients receive daunorubicin hydrochloride IV on days 1-3, cytarabine IV continuously over 120 hours on days 1-5, and dasatinib PO QD on days 6-19. Patients achieving complete response receive consolidation therapy.~CONSOLIDATION THERAPY: Patients receive high-dose cytarabine IV over 3 hours on days 1, 3, and 5, and dasatinib PO QD on days 6-26 or 7-27. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients in complete remission receive continuation therapy."
62424217|NCT06418880|ACTIVE_COMPARATOR|Control|"The control group will follow the hospital's usual practice for subcutaneous insulin for glucose control. It will be managed by the admitting team with the assistance of an inpatient endocrine team.~Participants will wear a real-time CGM for 10 days or until hospital discharge (if \<10 days)"
62424218|NCT06418880|EXPERIMENTAL|Intervention|"Participants in the intervention arm will be assigned to the Omnipod 5 AID system with integrated Dexcom CGM. These devices will communicate with a patient-specific smartphone secured within the patient room and remotely monitored by the nursing station.~Nursing staff on medical-surgical units will provide insulin therapy using the investigational device for participants randomized to the intervention arm, including delivering insulin boluses, monitoring CGM values and trends, validating CGM accuracy against POC glucose, and performing routine device exchanges (Pod or CGM) when indicated AID therapy will continue for 10 days or until hospital discharge (if \<10 days)"
62424219|NCT01777607|EXPERIMENTAL|Intervention|
62424220|NCT03749525|PLACEBO_COMPARATOR|placebo group|5% GS solution
62424221|NCT03749525|ACTIVE_COMPARATOR|control group|shenfu injection
62424222|NCT03672396|EXPERIMENTAL|Home-based Exercise|The sole intervention group will complete a combination of aerobic and strength training \~3 times per week for 12 weeks with each session lasting 1 hour.
62424223|NCT01083758|OTHER|LEO 80185 (Taclonex® Scalp topical suspension/ Xamiol® gel)|
62424224|NCT06539325|EXPERIMENTAL|Intervention period|Patient management will be guided by a systematic microbiological diagnostic strategy
62424225|NCT06539325|NO_INTERVENTION|Control period|Patient management will be done according to the usual practices of centers and emergency physicians
62424226|NCT03648398|OTHER|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
62424227|NCT05062031|EXPERIMENTAL|DIMS®|Defocus Incorporated Multiple Segments® lenses
62424228|NCT05062031|ACTIVE_COMPARATOR|Low-concentration atropine + monofocal lenses|
62433574|NCT04541888|PLACEBO_COMPARATOR|Control group|322 subjects will be treated with Placebo : 0 g: 0mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
62433575|NCT02182258|PLACEBO_COMPARATOR|Placebo|
62433576|NCT02182258|ACTIVE_COMPARATOR|BIBF 1120 intravenous|
62809325|NCT00447226|PLACEBO_COMPARATOR|Placebo Control|
62809326|NCT00195936|EXPERIMENTAL|Overall Study|Calcimimetics as an Adjuvant Treatment for Familial Hypophosphatemic Rickets
62809327|NCT01479101||MammaPrint, BluePrint, neo-adj CT or HT|All patients receive the MammaPrint and BluePrint gene expression profile. Treatment at the discretion of the physician while adhering to NCCN guidelines.
62809328|NCT01476423||A|
62233132|NCT05441917|PLACEBO_COMPARATOR|Sanae with Radiofrecuency|"Radiofrequency (RF) is considered a non-invasive therapy that enables thermal modification in the connective tissue of the skin, through dermal heating and vasodilation. Upon reaching the tissue, the current encounters resistance, and heat is produced by converting it into thermal energy. In this way, the deep dermis undergoes controlled volumetric heating, while the epidermis is preserved through cooling systems.~Thermal damage triggers an inflammatory cascade and stimulates neocollagenesis, causing the dermis to thicken. Vasodilation, on the other hand, leads to hyperemia and lymphatic drainage in the fat tissue. The expected physiological effects are increased circulatory and nutrient supply, improving tissue hydration and oxygenation, greater metabolic and enzymatic activity, accelerating the elimination of catabolites, lipolysis, and the contraction of connective tissue."
62233133|NCT00692302|EXPERIMENTAL|SAFETY I|Phase I participants who will receive SAFETY
62233134|NCT00692302|EXPERIMENTAL|SAFETY II|Phase II participants who will receive SAFETY
62809329|NCT00702468|EXPERIMENTAL|Sativex|Sativex
62809330|NCT00702468|PLACEBO_COMPARATOR|Placebo|Placebo
62424229|NCT03596060|ACTIVE_COMPARATOR|General anesthesia|Hip fracture patients older or equal to 65 years of age, who receive clopidogrel, will be randomly assigned to undertake surgery under general anesthesia in the first 48 hours. Anesthetics to be used are propofol, fentanyl and rocuronium. Maintenance will be achieved with remifentanyl and propofol (TIVA) and the depth of anesthesia will be monitored by BIS. Morphine will be administered bolus IV immediately postoperatively.
62809331|NCT03814707|ACTIVE_COMPARATOR|Topical application 0.2%Hyaluronic Acid|Topical application of 0.2% hyaluronic acid gel will be placed immediately in palatal donor site after free gingival graft harvesting and covered by periodontal pack
62233135|NCT00692302|ACTIVE_COMPARATOR|Control|Phase II participants who will receive enhanced usual care
62424230|NCT03596060|ACTIVE_COMPARATOR|Regional anesthesia|Hip fracture patients older or equal to 65 years of age, who receive clopidogrel, will will be randomly assigned undertake surgery under regional anesthesia (spinal) at least 5 days after the discontinuation of clopidogrel. Anesthetics to be used are chirochaine 0.5% and fentanyl.
62424231|NCT01462552||Metastatic breast cancer pre-label group|Patients with metastatic breast cancer who initiated lapatanib between January 1, 2007 and December 31, 2007. Follow-up time for this group will continue until June 30, 2008 to allow these patients to have at least six months of follow-up time prior to the label change.
62424232|NCT01462552||Metastatic breast cancer post-label group|Patients with metastatic breast cancer who initiated lapatanib between July 9, 2008 and December 31, 2009. Follow-up time for this group will continue until June 30, 2010 to allow these patients to have at least six month of follow-up.
62424233|NCT00351078|EXPERIMENTAL|PTC124 PO|4-, 4-, and 8-mg/kg TID first 14 days of cycle 10-, 10-, and 20-mg/kg TID second 14 days of cycle 28 day study
62424234|NCT02881970|EXPERIMENTAL|Neonatal hypoxic-ischaemic encephalopathy|
62424235|NCT01577966|EXPERIMENTAL|Sulfasalazine|
62424236|NCT00388674||A|
62424237|NCT00388674||B|
62424238|NCT04922788|EXPERIMENTAL|25 mcg Dose|Intramuscular injection, two doses given 28 days apart
62424239|NCT04922788|PLACEBO_COMPARATOR|Placebo|Intramuscular injection, two doses given 28 days apart
62424240|NCT00810615|SHAM_COMPARATOR|Sham treatment|Subject will breathe air at less than 1.3 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at less that 1.3 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
62424241|NCT00810615|EXPERIMENTAL|Hyperbaric oxygen 2.4 ATA|Subject will breathe 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
62424242|NCT05495360|EXPERIMENTAL|Arm 1|twice daily serving of the study product
62424243|NCT01063439|EXPERIMENTAL|BuEAM: Experimental|BuEAM: Experimental Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day Intervention: Drug: Busulfan, etoposide, cytarabine, and melphalan
62424244|NCT02149537|EXPERIMENTAL|hydroxyurea|500mg of hydroxyurea/day during 6 months
62424245|NCT02149537|NO_INTERVENTION|No treatment|No hydroxyurea treatment during 6 months
62424246|NCT03922815|EXPERIMENTAL|haemodynamic parametres-guided deep sedation|propofol will be tirtrated in a single dose of 0,5 mg/kg of body weight to disappearance of cilliary reflex; in the case of heart rate and/or arterial blood pressure increase by 20% a rescue dose of fentanyl 0,5 mcg per kilogram of body weight will be administered
62424247|NCT03922815|EXPERIMENTAL|SE-guided propofol-fentanyl deep sedation|propofol will be tirtrated in a single dose of 0,5 mg/kg of body weight to a target SE \< 80 alongside with a rescue dose 0,5 mcg per kilogram of body weight of fentanyl in the case of heart rate and/or arterial blood pressure increase by 20%
62424248|NCT03922815|EXPERIMENTAL|AoA-guided propofol-fentanyl deep sedation|propofol will be tirtrated in a single dose of 0,5 mg/kg of body weight to a target SE \< 80 alongside with a rescue dose 0,5 mcg per kilogram of body weightof fentanyl in the case of increase of SPI value \> delta 15
62424249|NCT06516302|EXPERIMENTAL|GR1802 group|GR1802 300mg is administrated every 2 weeks (first dose doubled) for a total of 26 doses, of which an additional 2 ml of placebo is given at week 24.
62424250|NCT06516302|PLACEBO_COMPARATOR|placebo group|Placebo is administered every 2 weeks for the first 16 weeks. GR1802 is given every 2 weeks from week 24 to W50.
62433577|NCT02182258|EXPERIMENTAL|BIBF 1120 capsule|
62433578|NCT05078281||Cases|Patients with severe eosinophilic asthma receiving benralizumab.
62433579|NCT05919459|EXPERIMENTAL|Parents with ACT intervention|5-week online synchronous ACT intervention plus asynchronous online AIS education
62433580|NCT05919459|OTHER|Parents without ACT intervention|5-week interactive online AIS education
62809332|NCT03814707|EXPERIMENTAL|Platelet Rich Fibrin|Palatal donor site will receive a platelet rich fibrin and then will be sutured by criss cross suture then covered by periodontal pack.
62809333|NCT05075746||enVista Toric 0.9D intra ocular lens|
62809334|NCT05075746||enVista non-Toric (spherical) intra ocular lens|
62809335|NCT03622008|EXPERIMENTAL|FEP-TAZ 4 g|FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
62809336|NCT03622008|PLACEBO_COMPARATOR|Placebo|placebo IV
62809337|NCT05366023|NO_INTERVENTION|No contact|0 hours of activities during intervention period of study
62233136|NCT01121835|EXPERIMENTAL|Insulin glargine|"Administered once a day in the evening, at the same time every day. The starting daily dose is 0.2 U/Kg of body weight or 12 U, at the investigator's decision.~Insulin glulisine is administered for patients of the insulin glargine group requiring insulin glulisine at week 12 (visit 11).~Insulin glulisine is administered prior (10-15 min) to the main meal of the day, which is the meal with highest Post-Prandial Plasma Glucose (PPPG) on the 3 profiles performed before week 12.~Starting dose is of 4 units per day."
62809338|NCT05366023|EXPERIMENTAL|TDD1|10 hours of top-down driven cognitive training games
62233137|NCT01121835|EXPERIMENTAL|Premixed insulin|administered once a day (in the evening at dinner) or twice a day (in the morning before breakfast and in the evening at dinner). Starting daily dose will be 6 U at breakfast and 6 U at dinner, if administered twice a day or 12 U at dinner if administered once a day
62233138|NCT02105350|EXPERIMENTAL|MEK 162, gemcitabine, and oxaliplatin|MEK 162 (30 mg or 45 mg by mouth), twice a day, every day. Gemcitabine (1000 mg/m2 by vein), followed by oxaliplatin (85 mg/m2 by vein) every 2 weeks.
62233139|NCT03000361|EXPERIMENTAL|Motorized Spiral Colonoscopy|Motorized Spiral Colonoscopy (MSC) with the novel motorized spiral endoscope represents a new technology which offers all of the advantageous options of spiral-assisted endoscopy with a faster and less invasive approach
62233140|NCT01275001||Intervention children|Children who are receiving a Suzuki-like violin instruction through their participation in an Early Childhood/Headstart preschool program
62233141|NCT01275001||Control Group|Preschool-age children who are not receiving Suzuki-like violin instruction
62233142|NCT05105789|EXPERIMENTAL|BinaxNOW Test + Lollipop PCR|"If a symptomatic participant's initial at-school BinaxNOW test was positive, then their study participation is complete after providing the lollipop swab for PCR testing.~If a symptomatic participant's initial at-school BinaxNOW test was negative, then they will be asked to complete an at-home BinaxNOW test approximately 24 hours later.~For the at-home BinaxNOW testing, the participant will schedule a follow-up virtual visit with the study coordinator. If they are unable to complete a virtual visit, they will schedule an in-person home visit. They will also be sent home with a BinaxNOW testing kit."
62233143|NCT04293315|NO_INTERVENTION|Control|This is the usual care arm. Healthcare workers will provide people with the Fecal Occult Blood Test (FOBT) and information about risk to develop CRC and the importance of early detection.
62233144|NCT04293315|EXPERIMENTAL|Intervention|The same as the Control Arm plus the primary care team of the PCCs will be trained and participate in 8 improvement cycles.
62233145|NCT01779687|ACTIVE_COMPARATOR|raltegravir alone|Raltegravir 400 mg BID for 7 days
62809339|NCT05366023|EXPERIMENTAL|TDD2|10 hours of top-down driven cognitive training games
62033067|NCT01128413|ACTIVE_COMPARATOR|Routine Care (RC)|Patients randomized to receive routine ED care will receive IV fluid administration per the treating clinicians discretion. The Cheetah NICOM®PLRT, USCOM®, IVC Ultrasound collapsibility, and CURVES Questionnaire will be performed and repeat lactate measurements will only be revealed to the routine care arm if they are used as part of the provider's routine care.
62233146|NCT01779687|ACTIVE_COMPARATOR|Atorvastatin alone|Atorvastatin 20 mg QD for 7 days
62233147|NCT01779687|EXPERIMENTAL|Raltegravir + atorvastatin|Raltegravir 400 mg BID + Atorvastatin 20 mg QD for 7 days
62233148|NCT03207555|EXPERIMENTAL|Ibrutinib|Participants take Ibrutinib by mouth 1 time every day for up to 2 years (24 cycles).
62809340|NCT05366023|EXPERIMENTAL|TDD1 + TDD2|20 hours of top-down driven cognitive training games
62809341|NCT05366023|EXPERIMENTAL|BUD1|10 hours of bottom-up driven cognitive training games
62809342|NCT05366023|EXPERIMENTAL|BUD2|10 hours of bottom-up driven cognitive training games
62809343|NCT05366023|EXPERIMENTAL|BUD1 + BUD2|20 hours of bottom-up driven cognitive training games
62809344|NCT05366023|EXPERIMENTAL|BUD2 + TDD2|10 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
62809345|NCT05366023|EXPERIMENTAL|BUD1 + TDD1|10 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
62809346|NCT05366023|EXPERIMENTAL|BUD2 + TDD1|10 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
62809347|NCT05366023|EXPERIMENTAL|BUD2 + TDD1 + TDD2|10 hours of bottom-up driven cognitive training games plus 20 hours of top-down driven cognitive training games
62033068|NCT03437005|EXPERIMENTAL|Desonide 0.05%|Low potency steroid topical medication applied to specific locations on the face and extremities, twice daily for two weeks
62033069|NCT03437005|EXPERIMENTAL|Ketoconazole 2%|Antifungal topical medication applied to specific locations on the face and extremities, twice daily for two weeks
62033070|NCT00534196||Group under operation of brachytherapy|Patients with histologically confirmed adenocarcinoma of the prostate and who are planning to undergo brachytherapy with PI (permanent iodine) or combination of PI with other tratement.
62033071|NCT05308173||Surgical Aortic Valve Replacement|Surgically replaced aortic valve. Patients with planned concomitant bypass grafting other valvular interventions, arrhythmia ablation, or left atrial appendage occlusion were excluded. Any tissue or mechanical valve implantation in an aortic position with sternotomy or minimal access was included.
62424251|NCT03745573|EXPERIMENTAL|Empateach Intervention|All teachers in intervention schools will be invited to participate. Participants in the intervention condition will receive Empateach, a 10-week group intervention. Groups meet 14 times for 1-1.5 hour length sessions, which are led by peers. The aim of the Empateach intervention is to improve 'student and teacher well-being; self-regulation; teacher classroom management and teacher's use of positive discipline techniques. The intervention uses cognitive behavioural therapy techniques to change negative thought and behaviour patterns related to corporal punishment. The teachers receive information on alternatives to corporal punishment, planning exercises and reinforcement SMS, and because the intervention is in a group setting, social support to change their behaviours. They discuss their experiences and challenges in group sessions.
62033072|NCT05308173||Transcutaneous Aortic Valve Implantation|Transfemoral aortic valve implantation. Patients with a planned concomitant percutaneous coronary intervention were excluded
62593140|NCT03819595|EXPERIMENTAL|Supervised arm|Supervised exercise. The intervention will be a free 12-week, small-group (\~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.
62593141|NCT03819595|ACTIVE_COMPARATOR|Control arm|"Supervised exercise.The intervention will be a Personalized program (PVS), of proven effectiveness for the promotion of physical activity, diet and smoking cessation.~After 3 months, it become supervised arm"
62233149|NCT01783587|EXPERIMENTAL|High Risk Group|Dose escalation of afatinib + docetaxel + radiation therapy
62233150|NCT01783587|EXPERIMENTAL|Intermediate Risk Group|Dose escalation of afatinib + radiation therapy
62233151|NCT02083666|EXPERIMENTAL|SOBI002|Single and repeated administration of different doses of test product
62233152|NCT02083666|PLACEBO_COMPARATOR|placebo|Single and repeated administration of placebo comparator
62233153|NCT05779397|EXPERIMENTAL|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive Masimo RAD-GT
62433581|NCT02305420|EXPERIMENTAL|EmbryoGen/BlastGen|"EmbryoGen and BlasGen media containing GM-CSF 2ng/ml will be used in the experimental arm~The intervention is to use EmbryoGen/BlastGen"
62593142|NCT03376308||Group 1|"Venous diameter measurements were made via the USG in the hand dorsum. Transverse venous diameter ≤2mm was defined group 1.~Anesthesia induction drugs were all treated in the same order and dose. Pain score, withdrawal movement score and hemodynamic response was recorded."
62593143|NCT03376308||Group 2|"Venous diameter measurements were made via the USG in the hand dorsum.Transverse venous diameter \>2mm was defined group 2.Anesthesia induction drugs were all treated in the same order and dose.~Pain score, withdrawal movement score and hemodynamic response was recorded."
62809348|NCT05366023|EXPERIMENTAL|BUD1 + TDD2|10 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
62033073|NCT03797768|EXPERIMENTAL|Intervention|
62809349|NCT05366023|EXPERIMENTAL|BUD1 + TDD1 + TDD2|10 hours of bottom-up driven cognitive training games plus 20 hours of top-down driven cognitive training games
62233154|NCT03916848|EXPERIMENTAL|Combined Micro-Macro SEEG Electrodes|Implanting SEEG electrodes with combined micro-macro electrodes capable of recording clinical data and experimental micro electrode single unit data
62233155|NCT01466426||DVT confirmed|
62233156|NCT01466426||DVT ruled out|
62233157|NCT01466426||PE confirmed|
62233158|NCT01466426||PE ruled out|
62233159|NCT04317950|OTHER|Vojta group|All participants were properly instructed and signed an informed consent previous to the interventions. They were comfortably laid down on their back with eyes open, wearing the EEG cap and electromyography electrodes during the intervention. They were asked to remain relaxed and still during the whole process. After a first minute of resting, the experimental group received a continuous reflex locomotion stimulus during the next 8 minutes.
62033074|NCT03797768|NO_INTERVENTION|Control|
62033075|NCT05845229|EXPERIMENTAL|High-N-acylethanolamines meal|Milk (150 mL), white bread (46 g), jam (10 g), cocoa powder (15 g), whole-grain cereals (30 g).
62033076|NCT05845229|ACTIVE_COMPARATOR|Low-N-acylethanolamines meal|Milk (150 mL), whole-grain bread (80 g), jam (10 g), butter (5 g), instant coffee (2 g), dried apples (30 g).
62033077|NCT01702753|ACTIVE_COMPARATOR|Bifidobacterium animalis subsp. lactis|
62033078|NCT01702753|PLACEBO_COMPARATOR|Placebo|
62033079|NCT02235948|EXPERIMENTAL|folic acid|folic acid supplementation placebo controlled
62033080|NCT03193164|EXPERIMENTAL|group 1|Neuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.
62233160|NCT04317950|SHAM_COMPARATOR|Control group|On the contrary, the control group received a continuous sham stimulus during the next 8 minutes.
62593144|NCT05546216|EXPERIMENTAL|Experimental group|"Patients in the intervention group CAG exit Written informed consent was obtained from the patients for the study. Pretest data of the patients were collected at 0 hour using the Patient Information Form, Visual Analog Scale, State Anxiety Scale and Immobility Comfort Scale. After informing the patient with hemodynamics, at the 0th hour, a 36x33x10 cm gel-containing silicone pad was placed in the lumbar cavity of the patient to fill the patient's anatomical lumbar cavity, and CAG output was supported. The patient was in the supine position 30 degrees elevated when measured with the visual aid. Patients lie in the same position for 4 hours. Back pain of the patients was evaluated again with the Visual Analog Scale at the 2nd hour. At the 4th hour, the posttest data of the patients were collected with the Visual Analogue Scale, the State Anxiety Scale and the Immobility Comfort Scale."
62233161|NCT05381779|EXPERIMENTAL|Inspiratory Muscle Training Group|Patients in the training group will be performed inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure.
62233162|NCT05381779|EXPERIMENTAL|High Intensity Interval Training Group|Training group will receive high-intensity interval aerobic exercise training on treadmill accompanied by physiotherapist for 8 weeks.
62233163|NCT05381779|SHAM_COMPARATOR|Control Group|Breathing exercises will be given to control group as a home program for 8 weeks.
62233164|NCT00654472||A|Mitral valve area above 1.5 cm2
62424252|NCT03745573|NO_INTERVENTION|Wait-list control|Teachers in wait-list control schools will receive no specific interventions related to violence prevention during the study, but will receive the intervention after the study is over if it is shown to be effective (pending donor funding).
62424253|NCT01954082|EXPERIMENTAL|myo-Inositol 5% Injection|Within 12-72 hours of birth, infants will receive 80 mg myo-inositol 5% Injection per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.
62424254|NCT01954082|PLACEBO_COMPARATOR|5% glucose(dextrose)|Within 12-72 hours of birth, infants will receive 80 mg 5% glucose(dextrose) USP for intravenous infusion per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.
62424255|NCT01242332|NO_INTERVENTION|placebo|po 2 hrs before surgery
62809350|NCT05366023|EXPERIMENTAL|BUD1 + BUD2 + TDD2|20 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
62809351|NCT05366023|EXPERIMENTAL|BUD1 + BUD2 + TDD1|20 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
62809352|NCT05366023|EXPERIMENTAL|BUD1 + BUD2 + TDD1 + TDD2|20 hours of bottom-up driven cognitive training games plus 20 hours of top-down driven cognitive training games
62809353|NCT05366023|ACTIVE_COMPARATOR|CSA10|10 hours of cognitive stimulating activities
62233165|NCT00654472||B|Mitral valve area 1.5 cm2 and below 1.5 cm2
62233166|NCT00537485|EXPERIMENTAL|1|
62233167|NCT00537485|PLACEBO_COMPARATOR|2|
62233168|NCT03442049|EXPERIMENTAL|Study group|Spinal stabilization exercises in addition to home exercise program
62233169|NCT03442049|ACTIVE_COMPARATOR|Control Group|Home exercise program
62424256|NCT01242332|EXPERIMENTAL|Pregabalin|75 mg po 2 hrs before surgery
62424257|NCT06537635|EXPERIMENTAL|30-minute session of exercise using a seated compact elliptical trainer|
62424258|NCT04442178|EXPERIMENTAL|CYT107 Treatment|Intramuscular (IM) administration of CYT107 twice a week for 3 weeks
62033081|NCT03193164|SHAM_COMPARATOR|group 2|Decubitus Position with the limbs raised to 20º without NMES and after NMES.
62233170|NCT00825617|EXPERIMENTAL|HRT|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
62233171|NCT04314141||Transgender patients|Transgender patients who carry out sex reassignment surgery.
62809354|NCT05366023|ACTIVE_COMPARATOR|CSA20|20 hours of cognitive stimulating activities
62809355|NCT05366023|ACTIVE_COMPARATOR|CSA30|30 hours of cognitive stimulating activities
62809356|NCT05366023|ACTIVE_COMPARATOR|CSA40|40 hours of cognitive stimulating activities
62809357|NCT03422835|ACTIVE_COMPARATOR|R-TME|Robotic total mesentery excision surgery for rectal cancer.
62809358|NCT03422835|EXPERIMENTAL|R-TaTME|Robotic transanal total mesentery excision surgery for rectal cancer.
62809359|NCT05924061||Pregnant women with preeclampsia between 20-28 weeks (study group)|Maternal serum cathepsin B and pentraxin 3 levels in 20-28 weeks pregnant women with preeclampsia
62809360|NCT05924061||Healthy pregnant women between 20-28 weeks ( control group)|Maternal serum cathepsin B and pentraxin 3 levels in 20-28 weeks healthy pregnant women ( control group)
62809361|NCT01342913|EXPERIMENTAL|Fluticasone Furoate/Vilanterol|Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA)
62809362|NCT01342913|ACTIVE_COMPARATOR|Fluticasone Propionate/Salmeterol|Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA
62809363|NCT05903508|ACTIVE_COMPARATOR|Functional task training Group.|In this group patients will performed functional task training program was performed including non-walking (i-iii) and walking activities: (i) standing from a seated position; (ii) reaching for an object overhead, which required ankle plantar flexion from the standing position, and returning to the initial position with the heel leaning on the floor; (iii) stepping on and off a bench; (iv) walking up and down stairs; and (v) walking on flat surfaces and ramps. for 8 weeks, 50 minutes per day, 3 times per week. The individual session lasted approximately 10 minutes including the rest intervals.
62809364|NCT05903508|ACTIVE_COMPARATOR|functional therapy program|In this group patients will performed functional therapy program as goal directed training to optimize the child to practice goal including stand when turning around between chair, cycles 5m on stationary bicyle on smooth surface, kicking a ball during 8 weeks, the children practiced a goal in 50 mintute per day and 3 times a week.
62424259|NCT04442178|PLACEBO_COMPARATOR|Placebo|Intramuscular (IM) administration of Saline twice a week for 3 weeks
62424260|NCT03248778|EXPERIMENTAL|disclosure-support counseling|
62424261|NCT03248778|NO_INTERVENTION|Treatment as Usual|
62424262|NCT01227096||Electro-acupuncture, Control|
62809365|NCT05607667|EXPERIMENTAL|Experimental: Treatment|Device: J-Valve® valve delivery system， Transvascularized biological aortic valve system
62809366|NCT04042220||GK + IT|Gamma Knife and immunotherapy
62809367|NCT04042220||GK + IT + GC|Gamma Knife, immunotherapy and glucocorticoids
62809368|NCT04042220||GK only|Gamma Knife without immunotherapy
62809369|NCT06527014|ACTIVE_COMPARATOR|Pulse Radiofrequency-Group 1|Procedures were performed with patient seated leaving their affected shoulder exposed. First, the spina scapula was identified and scapular notch and transverse scapular ligament identified. The needle was inserted out plane. A standard radiofrequency device (NeuroTherm NT1100, Neurotherm Inc.,USA) was used with 22-gauge 10-cm, 5 mm RF cannulas (Abbott Medical , USA) for SN blocks.The cannula was placed through the transverse scapular ligament area and sensory fibre stimulation was started between 0.3 and 1 V. The patient was asked for feedback on symptoms such as numbness, paresthesia and/or pain. If the patient did not report any sensory symptoms within the specified sensory stimulation range, the cannula was repositioned. Motor stimulation was applied up to 2 V and it was checked whether there was any muscle contraction or not. If any contraction was figured out as a result of motor stimulation.Eventually, the SN was ablated at 42°C for 4 minutes in pRF mode.
62809370|NCT06527014|NO_INTERVENTION|Conventional Physical Therapy-Group 2|Patients in the Group 2 received physical therapy modalities including hot packs, transcutaneous electrical nerve stimulation (TENS) and deep heater ultrasound to the shoulder. The hot packs were preserved at 71°C, then application of hot packs were done at a temperature of 40-43°C with TENS (4 cannulated electrodes) adjusted at 60-100 Hz for 20 minutes. Therapeutic deep heater ultrasound was applied to warm up subcutaneous tissues for 10 minutes at 1.5 watts/cm2. Until follow-up process was over, no medications other than paracetamol were allowed.
62424263|NCT01227096||Preconditioning, No preconditioning|
62033082|NCT03081845|EXPERIMENTAL|Sequence A1-A2|Oral consumption of milk A1 in study phase 1. Oral consumption of milk A2 in study phase 2.
62424264|NCT04307225||CABG|Patients whom has undergone CABG surgery for NSTEMI, stable or unstable angina, with no previous history of Atrial Fibrillation
62433582|NCT02305420|ACTIVE_COMPARATOR|Control|Standard Cook sequential media
62424265|NCT04307225||PCI|Patients whom has undergone PCI for NSTEMI, stable or unstable angina, with no previous history of Atrial Fibrillation
62809371|NCT02212808|EXPERIMENTAL|Antimicrobial restriction|All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario.
62809372|NCT02212808|EXPERIMENTAL|Post-antimicrobial prescription review|All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacists will review a list of patients receiving the targeted antibiotics on a daily basis to identify patients who have received one or more targeted antibiotics for 72 hours (± 24 hours). The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations.
62033083|NCT03081845|EXPERIMENTAL|Sequence A2-A1|Oral consumption of milk A2 in study phase 1. Oral consumption of milk A1 in study phase 2.
62033084|NCT02246517|EXPERIMENTAL|N2O&Oxygen|70% N2O \& 30% Oxygen by Aspiration for 5 min
62033085|NCT02246517|PLACEBO_COMPARATOR|Oxygen|100% Oxygen by Aspiration for 5 min
62233172|NCT04314141||Cismale patients|Cismale patients who carry out surgery to correct a congenital or acquired lack of penis.
62233173|NCT02151422|EXPERIMENTAL|Breathing exercises|Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
62233174|NCT00696761|ACTIVE_COMPARATOR|group1|Bladder outlet obstruction index(BOOI)≥ 20, Bladder contractility index(BCI)≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.
62233175|NCT00696761|ACTIVE_COMPARATOR|group2|BOOI≥ 20, BCI\<100 Alfuzosin was administered daily (10 mg) for 12 month.
62233176|NCT00696761|ACTIVE_COMPARATOR|group 3|BOOI\<20, BCI≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.
62424266|NCT01496079||Inactivated influenza vaccine in pregnancy|Healthy pregnant women who elect to receive inactivated influenza vaccine in early pregnancy (\< 20 weeks gestation) and their infants
62809373|NCT06160232|EXPERIMENTAL|high dose psilocybin|31 participants will receive a single administration of 30mg psilocybin provided within the context of a brief standardized psychotherapeutic intervention.
62033086|NCT03491644|ACTIVE_COMPARATOR|Liberal oxygen|"Liberal oxygen administration (to mimic current practice) for the first 24 hours without interruption.~In the trauma bay and during intrahospital transportation this implies administration of a FiO2 of 1.0 for intubated patients and an oxygen flow on a non-rebreather with reservoir of 15 l/min for non-intubated patients. In the operating room, patients will receive a FiO2 of ≥ 0.8 to obtain a saturation of ≥ 98%. Patients admitted to the ICU/PACU/floor will receive and FiO2 of ≥ 0.8 or more to obtain a saturation of ≥ 98% when intubated and for non-intubated patients a non-rebreather with reservoir will be set to 15 l/min."
62233177|NCT00696761|ACTIVE_COMPARATOR|group 4|BOOI\<20, BCI\<100 Alfuzosin was administered daily (10 mg) for 12 month.
62233178|NCT05941767|ACTIVE_COMPARATOR|Dexmedetomidine nebulization|The patient will receive nebulized dexmedetomidine via face mask nebulizer (1mcg/kg) 20 minutes before induction.
62233179|NCT05941767|ACTIVE_COMPARATOR|Lidocaine Nebulization|The patient will receive nebulized lidocaine 4% (3 mg /kg) added to 2 ml normal saline 0.9% 10 minutes before induction of general anesthesia.
62233180|NCT05941767|ACTIVE_COMPARATOR|Dexmedetomidine IV|The patient will receive an intravenous infusion of dexmedetomidine (1 ml= 4 mcg) via a syringe pump and will be started at a dose of 1 mcg/kg 20 minutes before induction of general anesthesia.
62233181|NCT05941767|ACTIVE_COMPARATOR|Lidocaine IV|The patient will receive 1.5mg/kg intravenous lidocaine 2% completed to 10 ml with normal saline 0.9% intravenous 90 seconds before induction of general anesthesia.
62233182|NCT06434376|EXPERIMENTAL|Experimental group|Conventional adjuvant therapy combined with personalized immune regulation diagnosis and treatment technology
62424267|NCT01496079||No inactivated influenza vaccine during pregnancy|Healthy pregnant women who decline inactivated influenza vaccine in pregnancy and their infants
62433583|NCT04519489|EXPERIMENTAL|PAP therapy with telemonitoring|This arm will consist of 86 subjects.
62033087|NCT03491644|EXPERIMENTAL|Titrated oxygen|"Titrated oxygen administration for the first 24 hours without interruption. Lowest dosage of oxygen possible in order to achieve a saturation of at least 94%, either using mechanical ventilation (intubated patients), a nasal cannula, a non-rebreather or nothing.~A saturation above 94% shall not be aimed for using supplemental oxygen, and thus only patients without oxygen requirement shall have saturations above 94%.~The intervention will only be interrupted in case the saturation becomes unmeasurable - if this happens, the treating physician shall treat the patient as he/she judges best fit. As soon as the saturation is measurable again, the intervention will resume. The treating physician must document and explain the situation."
62433584|NCT04519489|OTHER|Control group|This arm will consist of 43 subjects.
62424268|NCT06290258|EXPERIMENTAL|Fecal microbiota transplantation|Children with autism spectrum disorder will receive fecal microbiota transplantation after evaluation. After the first intervention, the second transplantation will be arranged 6 months later.
62809374|NCT06160232|PLACEBO_COMPARATOR|low dose psilocybin (active placebo)|31 participants will receive a single administration of a very low dose of psilocybin (active placebo) provided within the context of a brief standardized psychotherapeutic intervention.
62033088|NCT01871038||Rotavirus Positive Cases|Children \<6 years of age born on or after 8/10/2008 enrolled in active surveillance for AGE who tested positive for rotavirus.
62033089|NCT01871038||Rotavirus Negative Controls|Children \<6 years of age born on or after 8/10/2008 enrolled in active surveillance for AGE who tested negative for rotavirus
62033090|NCT03378167|EXPERIMENTAL|MICROBIOTA|Patients randomized to the INTERVENTION arm will receive a baseline fecal microbiota transplant (FMT) colonoscopic infusion at Week 0, followed by twice-weekly oral microbiota capsule (OMC) therapy for 6 weeks (including Week 0). (n = 30)
62033091|NCT03378167|PLACEBO_COMPARATOR|PLACEBO|Patients randomized to the CONTROL arm will receive a baseline normal saline (NS) colonoscopic infusion at Week 0, followed by twice-weekly dextrose-containing oral placebo capsule (OPC) therapy for 6 weeks (including Week 0). (n = 15)
62033092|NCT05088928|EXPERIMENTAL|Interventional Arm|Ecru (Apixaban )Tablets
62033093|NCT05088928|ACTIVE_COMPARATOR|Comparator/control|Rivascot (Rivaroxaban)
62033094|NCT04694274||group 1|patients with temporomandibular disorders
62033095|NCT04694274||group 2|healthy control
62033096|NCT01063400||Activity monitoring|
62033097|NCT05551949|OTHER|Vaginal estrogen therapy|Participants receive Vaginal estrogen therapy.
62033098|NCT05157191||mRNA COVID-19 vaccine|Children and adolescents (ages ≥ 5 to \< 16) who receive mRNA COVID-19 vaccine per standard of care
62033099|NCT05973526|EXPERIMENTAL|Percutaneous|In one of the infraumbilical hemibody, for percutaneous electrolipolysis, 2 pairs of needles will be introduced (0 ,25mm x 40mm) paired at a distance of 5 cm at 45º reaching the dermis-hypodermis tissue. The needles will be positioned at a distance of 2 cm laterally to the umbilicus and 5 cm below this marking, covering an area of about 10 cm laterally. This technique will have their electrodes connected to the Neurodyn 10-channel device belonging to the brand Ibramed®, in the electrolipolysis program.
62033100|NCT05973526|EXPERIMENTAL|Transcutaneous|In one of the infraumbilical hemibody, for transcutaneous electrolipolysis, 1 pair of silicone electrodes with conductive gel will be fixed with adhesive tape. The surface electrodes will be positioned at a distance of 2 cm laterally to the umbilicus and 5 cm below this marking, This technique will have their electrodes connected to the Neurodyn 10-channel device belonging to the brand Ibramed®, in the electrolipolysis program.
62033101|NCT02930239|EXPERIMENTAL|Gait rehabilitation|Will perform 2 weeks of gait rehabilitation using the anti gravity treadmill. Intervention will start 2 weeks post-surgery. This rehabilitation will be performed simultaneously as the patient receives the standardized rehabilitation at Linkoping University Hospital.
62033102|NCT02930239|ACTIVE_COMPARATOR|Control group|Will only receive the standardized rehabilitation at Linkoping University Hospital.
62033103|NCT01087853|ACTIVE_COMPARATOR|Phase A1: Plasmalyte|Plasmalyte
62033104|NCT01087853|ACTIVE_COMPARATOR|Phase A2: 0.9% Saline|0.9% Saline
62033105|NCT01087853|ACTIVE_COMPARATOR|Phase B1: PlasmaVolume|PlasmaVolume
62033106|NCT01087853|ACTIVE_COMPARATOR|Phase B2: Voluven|Voluven
62033107|NCT05538624|EXPERIMENTAL|Part 1 escalating AVB-001 between 0.6 and 3.6 ug hIL-2/kg/day; and Part 2 AVB-001 at the MTD/RP2D|"Part 1: one of four ascending doses of AVB-001 planned for IP, single dose administration at each dose level cohort of the Dose Escalation Phase.~Part 2: a single dose of AVB-001 at the MTD/RP2D level (determined in Part 1) to be further evaluated in the Dose Expansion Phase."
62033108|NCT04099810|OTHER|Patients undergoing Cardiac MRI|Patients scheduled to undergo cardiac magnetic resonance for clinical reason will be asked if they are willing to undergo additional non invasive testing (three-dimensional echocardiography) which will take about 15-20 minutes
62033109|NCT05003089|EXPERIMENTAL|BAY1834845 arm|BAY1834845 will be administered twice daily for 7 consecutive days (Days 1 - 7).
62033110|NCT05003089|EXPERIMENTAL|BAY1830839 arm|BAY1830839 will be administered twice daily for 7 consecutive days (Days 1 - 7).
62033111|NCT05003089|ACTIVE_COMPARATOR|Prednisolone arm|Prednisolone will be administered twice daily for 7 consecutive days (Days 1 - 7).
62033112|NCT05003089|PLACEBO_COMPARATOR|Placebo arm|Placebo will be administered twice daily for 7 consecutive days (Days 1 - 7).
62033113|NCT03776981|NO_INTERVENTION|Baseline Gait Comparisons of Groups|Determine if kinetic (time to first peak ground reaction force \[T1\] and second peak ground reaction force \[F2\], both in the sagittal plane) and kinematic (peak stance knee flexion angle \[KFA\] and external knee adduction moment \[KAM\]) gait variables, and speed, differ between patients with KOA and age and gender matched controls during self-selected paced ambulation, and determine which ones have predictive relationships with Knee Injury and Osteoarthritis Outcome Score (KOOS) scores in the patients with KOA.
62033114|NCT03776981|EXPERIMENTAL|Gait with core activation|Determine if volitional core activation alters gait kinetics (T1 and F2), kinematics (KFA and KAM), and speed in patients with and without KOA during self-selected paced ambulation when compared to ambulating without volitional core activation, and whether the subjective pain complaints are significantly changed in the group with KOA. Determine whether there are baseline differences in core activation between those with and without KOA.
62033115|NCT03776981|EXPERIMENTAL|Knee OA Gait After core stabilization|Determine if a six-week core stabilization program alters KOOS score, and the kinetics (T1 and F2), kinematics (KFA and KAM), and speed of gait in patients with KOA during self-selected paced ambulation as compared to their pre-intervention baselines. Determine if there is a predictive relationship between the number of completed intervention sessions performed and these observed changes.
62033116|NCT01937676||Adults admitted to ER|All adult patients admitted to emergency department during the study period.
62033117|NCT04290026|ACTIVE_COMPARATOR|metoclopramide versus granisetron|Ultrasound assessment of the effect of metoclopramide versus granisetron on gastric volume in patients undergoing caesarean section: A randomized, double-blind, placebo-controlled study
62033118|NCT01632605|EXPERIMENTAL|Sirolimus|Daily single oral dose of 1-3mg sirolimus with an initial loading dose of 6mg.
62424269|NCT02235337|EXPERIMENTAL|Riboflavin|
62809375|NCT00797004||endoscopic sinus procedure candidates|
62424270|NCT05719844|EXPERIMENTAL|Neuropsychological tests|The neuropsychological tests are computerized (TAP battery) or paper-and-pencil tests. They assess processing speed, short-term memory and auditory-verbal working memory capacity, episodic memory and selective attention.
62424271|NCT04236635|EXPERIMENTAL|Group 1: CCH Single Injection Technique|"Participants were administered 0.07 milligrams (mg) CCH subcutaneously using a single injection technique.~Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -43 and -22. Area 2 was administered CCH on Day -14."
62809376|NCT03409614|OTHER|Chemo|Part 1: Chemotherapy
62809377|NCT03409614|EXPERIMENTAL|REGN2810+Chemo Part 1|Part 1: REGN2810+chemo
62809378|NCT03409614|EXPERIMENTAL|REGN2810+AbbrevChemo+ipi|Part 1: REGN2810+abbrev chemo+ipi
62809379|NCT03409614|EXPERIMENTAL|Placebo+Chemo|Part 2: Placebo plus chemo
62809380|NCT03409614|EXPERIMENTAL|REGN2810+Chemo Part 2|Part 2: REGN2810+chemo
62809381|NCT03324776|OTHER|Addition of mealtime Afrezza Inhalation Powder|Patients will be instructed to follow a Weekly Treat-to-Target BG Testing Regimen and make Afrezza dose changes according to an Afrezza Titration Algorithm
62809382|NCT03777943||Cytoreductive surgery (CRS)|In patients presenting with colorectal peritoneal carcinomatosis, peritoneal tissue will be sampled during surgery at 4 different locations.
62809383|NCT06162988|EXPERIMENTAL|Patients who underwent 68Ga-NOTA-H006 and 18F-FDG PET/CT|68Ga-NOTA-H006, single dose
62809384|NCT04607486||CVA and spasticity|Adults with first-ever chronic CVA and leg spasticity
62809385|NCT04607486||CVA without spasticity|Control group
62809386|NCT04607486||healthy subjects|Control group
62809387|NCT00689390|OTHER|Participants from Boceprevir Studies|Participants who previously participated in treatment studies in which boceprevir was administered were subsequently enrolled in Part 1 of the current follow-up study P05063 (NCT00689390). Participants may have received boceprevir or control peginterferon plus ribavirin (PR) in the previous treatment study. No treatment was administered in the current follow-up study.
62809388|NCT00689390|OTHER|Participants from Narlaprevir Studies|Participants who previously participated in treatment studies in which narlaprevir was administered were subsequently enrolled in Part 2 of the current follow-up study P05063 (NCT00689390). Participants may have received narlaprevir or control PR in the previous treatment study. No treatment was administered in the current follow-up study.
62809389|NCT04127721|EXPERIMENTAL|Prevention (itacitinib, busulfan, fludarabine, ASCT)|"CONDITIONING CHEMOTHERAPY: Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, and fludarabine IV over 1 hour on days -6 to -3 in the absence of disease progression or unacceptable toxicity.~ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo ASCT on day 0.~GVHD PROPHYLAXIS: Patients receive itacitinib PO QD on days -21 to 80. Patients with no evidence of GVHD at day 80 receive a tapered dose of itacitinib until day 90. Patients also receive tacrolimus IV then PO BID for 3 months when able, and methotrexate IV over 30 minutes on days 1, 3, and 6 (day 11 also for patients with a matched unrelated donor)."
62233183|NCT00688181||Subjects treated with the Prefyx PPS System|All patients presenting to the institution for treatment of female Stress Urinary Incontinence (SUI), excluding those patients meeting any of the contraindications as noted in the Directions For Use.
62233184|NCT05432778|EXPERIMENTAL|Study Group|All patients in the Study Group will receive virostatic prophylaxis with letermovir 480 mg qd (We will be utilizing Letermovir oral formulation of 240 mg or 480 mg as available).
62233185|NCT05432778|NO_INTERVENTION|Control Group|Patients in Controls will receive standard-of-care virostatic prophylaxis with valgancyclovir 450 mg bid.
62233186|NCT00926211|EXPERIMENTAL|Computer-Assisted|Hair harvest using the computer-assisted system
62233187|NCT00926211|ACTIVE_COMPARATOR|Manual Harvest|Hair harvesting via manual technique
62233188|NCT03800459|EXPERIMENTAL|Experimental: Intervention group|Experimental: Intervention group
62233189|NCT03800459|NO_INTERVENTION|Control:no intervation group|Control:no intervation group
62424272|NCT04236635|EXPERIMENTAL|Group 2: CCH Single Injection Technique|Participants were administered 0.07 mg CCH subcutaneously using a single injection technique. Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -24 and -3. Area 2 was administered CCH on Day -3.
62424273|NCT04236635|EXPERIMENTAL|Group 3: CCH Single Injection Technique|Participants were administered 0.07 mg CCH subcutaneously using a single injection technique. Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -22 and -1. Area 2 was administered CCH on Day -1.
62433585|NCT02128867|EXPERIMENTAL|Assisted Autogenic Drainage (AAD)|airway clearance technique for infants :Assisted Autogenic Drainage
62433586|NCT02128867|EXPERIMENTAL|bouncing and AAD|airway clearance technique for infants : bouncing combined with AAD
62809390|NCT02694744|EXPERIMENTAL|Group 1 - Dosing Without Food|Patiromer dosing without food
62809391|NCT02694744|ACTIVE_COMPARATOR|Group 2 - Dosing With Food|Patiromer dosing with food
62809392|NCT06091696|EXPERIMENTAL|study group|Inspiratory muscle training will be conducted using a pressure threshold loading device (Threshold Inspiratory Muscle Training, Respironics, Pittsburg, PA, USA). Using a spring-loaded one-way valve, this device provides air flow-independent resistance to inspiration at a detectable intensity. Patients will start training with a maximum inspiratory pressure (MIP) of 40%. The training intensity will be adjusted every week based on the MIP measurement.
62233190|NCT01520896|EXPERIMENTAL|Part 1 - A|Single dose NKTR-118 25 mg on Day 1 only
62233191|NCT01520896|ACTIVE_COMPARATOR|Part 1 - B|Ketoconazole 400 mg once daily on Days 4 to 8
62233192|NCT01520896|ACTIVE_COMPARATOR|Part 1- C|Ketoconazole 400 mg plus NKTR-118 25 mg on Day 7
62233193|NCT03832296|EXPERIMENTAL|Weight-Loss Maintenance|Weight Loss Maintenance Intervention
62233194|NCT03832296|ACTIVE_COMPARATOR|Health Education (Attention Control)|Health Education Intervention
62233195|NCT00881608|PLACEBO_COMPARATOR|Placebo|Initiation-Placebo Cycle-Five (5) placebo capsules will be dispensed to subjects to self-administer for five days starting on cycle day 18.
62809393|NCT06091696|ACTIVE_COMPARATOR|control group|5 minutes of warming up and a similar time for cooling down in addition to light aerobic activity will be performed by the patients in both groups. Aerobic exercise training will be done through selected activities for 30 minutes /3 times per week for 8 weeks.
62424274|NCT04236635|EXPERIMENTAL|Group 4: CCH Multiple Injection Technique|"Participants were administered 0.0653 mg CCH subcutaneously using a multiple injection technique.~Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -43 and -22. Area 2 was administered CCH on Day -14."
62424275|NCT04236635|EXPERIMENTAL|Group 5: CCH Multiple Injection Technique|"Participants were administered 0.0653 mg CCH subcutaneously using a multiple injection technique.~Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -24 and -3. Area 2 was administered CCH on Day -3."
62809394|NCT03925623||Commercial closure system|Participants (42-54 months of age) will be assigned to try to open one of three treatments. One cohort will receive a 38/400 bottle equipped with a standard two piece push and turn cap and asked to open this during 2 five minute trials.
62809395|NCT03925623||Physically based design strategy|Participants (42-54 months of age) will be assigned to try to open one of three treatments. One cohort will receive a 38/400 bottle equipped a novel closure that was designed using anthropometric data such that it disallows children from engaging the system and enables adults. Children will be asked to open this during 2 five minute trials.
62424276|NCT04236635|EXPERIMENTAL|Group 6: CCH Multiple Injection Technique|"Participants were administered 0.0653 mg CCH subcutaneously using a multiple injection technique.~Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -22 and -1. Area 2 was administered CCH on Day -1."
62424277|NCT05498831||Pain relief protocol according to the recommendations of the French Emergency Medicine Society|The first phase consists in collecting, over a one-month period, data concerning the analgesic management of patients based on the recommendations of the 2010 French Emergency Medicine Society, before the effective implementation of the new pain management protocol, which should be implemented between 2 to 4 months later. Adverse events and patient's satisfaction will also be collected.
62424278|NCT05498831||Pain relief protocol with intranasal sufentanil as a starter|The second phase consists in collecting, over a one-month period, data concerning the analgesic management of patients after the implementation of the new protocol based on the use of intranasal sufentanil as a starter for pain of moderate and severe intensity. Adverse events and patient's satisfaction will also be collected during the second phase.
62424279|NCT03056001|EXPERIMENTAL|Pembrolizumab + doxorubicin|Participants will receive pembrolizumab IV infusion and doxorubicin IV injection on Day 1 of every 21 (+/- 3) days
62809396|NCT03925623||Cognitively based design strategy|Participants (42-54 months of age) will be assigned to try to open one of three treatments. One cohort will receive a 38/400 bottle equipped with the design feature that was introduced as part of the physical intervention (above); however, this treatment is sized such that children should be able to engage it (if they understand how). In having these three treatments, we began to evaluate the paradigm which enables the design to work. (Do they fail to understand how?- Cognitive treatment fail- and or Can they not effectively manipulate the closure? --- Physical failure).
62809397|NCT00455299|ACTIVE_COMPARATOR|a|a: suture anchoring + tackers and approximation of defect
62809398|NCT00455299|ACTIVE_COMPARATOR|b|b: suture anchoring + tackers without approximation of defect
62809399|NCT00455299|ACTIVE_COMPARATOR|c|c: only tacker fixation and approximation of defect
62809400|NCT00455299|ACTIVE_COMPARATOR|d|d: only tacker fixation without approximation of defect
62809401|NCT05901987|EXPERIMENTAL|Low dosing group|1.2x10\^14 vg/person of GC101 delivered one-time intrathecally (n=3)
62809402|NCT05901987|EXPERIMENTAL|Medium dosing group|2.4x10\^14 vg/person of GC101 delivered one-time intrathecally (n=3)
62809403|NCT05901987|EXPERIMENTAL|High dosing group|4.8x10\^14 vg/person of GC101 delivered one-time intrathecally (n=3)
62809404|NCT02462044|EXPERIMENTAL|240|Group 240 will receive CM with 240 mg Iodine/ml IDR 2.0 gI/s
62809405|NCT02462044|EXPERIMENTAL|300|Group 300 will receive CM with 300 mg Iodine/ml IDR 2.0 gI/s
62809406|NCT02462044|EXPERIMENTAL|370|Group 370 will receive CM with 370 mg Iodine/ml IDR 2.0 gI/s
62033119|NCT03819660|EXPERIMENTAL|amifampridine phosphate|The dose of amifampridine was based on optimal neuromuscular benefit determined from the Run-in Period from SMA-001 or could be modified as the discretion of the Investigator. The maximum single dose was 20 mg. The dose range for patients 6 to 16 years of age was 15 to 60 mg, and for those 17 years and older the range was from 30 to 80 mg daily.
62809407|NCT05738135|EXPERIMENTAL|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 50 ml normal saline over 30 minutes.
62809408|NCT05738135|PLACEBO_COMPARATOR|Control group|Patients will receive 50 ml normal saline over 30 minutes.
62033120|NCT06618326|EXPERIMENTAL|acupuncture|Group (A): will receive acupuncture in addition to non-pharmacological treatment advice from health care authorities such as the British Nutrition Foundation includes increasing fluid intake, physical activity and increasing dietary fiber consumption to a recommended daily intake of 30 g.
62033121|NCT06618326|EXPERIMENTAL|biofeedback training|Group (B): will receive biofeedback training in addition to non-pharmacological treatment advice from health care authorities such as the British Nutrition Foundation includes increasing fluid intake, physical activity and increasing dietary fiber consumption to a recommended daily intake of 30 g.
62033122|NCT05568992|EXPERIMENTAL|AI assisted group|AI assisted endoscopist' optical detection of advanced adenomas among 100 images of polyps
62033123|NCT05568992|NO_INTERVENTION|non-AI assisted group|Endoscopist' optical detection of advanced adenomas among 100 images of polyps using their experience of colonoscopy
62033124|NCT01705054||Outpatient Coronary Artery Disease Patient|CAD patients being seen in a participating cardiology office for a scheduled clinic visit who agree to take the survey.
62033125|NCT01848873|EXPERIMENTAL|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid (FA),once daily for 8 weeks.
62033126|NCT01848873|EXPERIMENTAL|amlodipine-FA tablet ,high dose group|5mg amlodipine combined with 0.8 mg of folic acid (FA), once daily for 8 weeks.
62033127|NCT01848873|ACTIVE_COMPARATOR|amolodipine|5 mg amlodipine, once daily for 8 weeks.
62033128|NCT04509947|EXPERIMENTAL|Ad26.COV2.S: High Dose|Participants (healthy adults aged greater than or equal to (\>=) 20 to less than or equal to (\<=) 55 years \[cohort 1\] and \>= 65 years \[cohort 2\]) will receive intramuscular (IM) injection of Ad26.COV2.S at high dose, as 2-dose schedule on Day 1 and Day 57.
62809409|NCT04555395||gonadal|
62809410|NCT04555395||extra-gonadal|
62593145|NCT05546216|NO_INTERVENTION|control group|"After the patients in the control group were placed in the supine position on the CAG exit, they were monitored, their vital signs were evaluated, and the necessary information of the patient was collected with the Patient Information Form, Visual Analog Scale, State Anxiety Scale and Immobilization comfort scale at the 0th hour of CAG exit. The patient was in a routine supine position without back support for 4 hours and received standard nursing care. After the . position was given, back pain was evaluated again at the 2nd hour and 4th hour using the Visual Analogue Scale. Anxiety and comfort levels were evaluated with the State Anxiety Scale and Immobilization Comfort Scale at the 0th minute before the position and at the 4th hour after the position ."
62233196|NCT00881608|EXPERIMENTAL|3 mg Proellex|First Cycle (3 mg)- Five (5) 3 mg capsules of Proellex will be dispensed to subjects to self-administer for five days starting on cycle day 18.
62233197|NCT00881608|EXPERIMENTAL|6 mg Proellex|Second Cycle (6 mg)-Subjects, who have not experienced menses, will have their dose of Proellex escalated, and be dispensed ten (10) 3 mg capsules of Proellex to self-administer 2, 3 mg capsules each day for five days starting on cycle day 18.
62233198|NCT00881608|EXPERIMENTAL|12 mg Proellex|Third Cycle (12 mg)-Subjects, who have not experienced menses, will have their dose of Proellex escalated, and be dispensed twenty (20) 3 mg capsules of Proellex to self-administer 4, 3 mg capsules for five days starting on cycle day 18.
62233199|NCT00881608|EXPERIMENTAL|25 mg Proellex|Fourth Cycle (25 mg)-Subjects, who have not experienced menses, will be dispensed five (5) 25 mg capsules of Proellex to self-administer for five days starting on cycle day 18.
62233200|NCT04300101||DLBCL patients|All patients with diagnosis of DLBCL
62233201|NCT01630122||patients newly diagnosed non small cell lung cancer|patients with presumed newly diagnosed non small cell lung cancer, where radiographic studies and clinical description favor a probable diagnosis of non small cell lung cancer
62233202|NCT04577196||Briefing supported by the trauma dashboard|During the entire chain of transmission (from the initial phone call to the end of the briefing to the trauma team) the trauma leader will be provided with a trauma dashboard to synthesize and disseminate the available information about the arriving patient.
62233203|NCT04577196||Briefing without the trauma dashboard|The transmission chain will not be supported by any specific tool.
62424280|NCT02806635|NO_INTERVENTION|Waitlist|Participants are assessed start, during, and end wait list; however, no active intervention is given.
62424281|NCT02806635|EXPERIMENTAL|OurRelationship|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner. The first conversation between partners centers on discussing possible core relationship issues and jointly deciding on the problem(s) to focus on during the program. During the second conversation, both partners' previous written responses are displayed on the screen and conversation is encouraged. During the final conversation, couples share their strategies to decrease stress, improve patterns of communication, and engage in problem-solving exercises specific to their core issue(s).
62433587|NCT02128867|EXPERIMENTAL|bouncing|bouncing . intervention to relax the infant
62433588|NCT02805374|EXPERIMENTAL|ASP1517 fasting then fed|Subjects will receive a single oral dose of ASP1517 under fasting conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fed conditions in period 2.
62593146|NCT00759460|EXPERIMENTAL|1|
62593147|NCT00759460|ACTIVE_COMPARATOR|2|
62809411|NCT04555395||chemotherapy|
62809412|NCT04555395||without chemotherapy|
62809413|NCT03002961|EXPERIMENTAL|Cohort 1|Subjects to receive low dose of RBP-6000 subcutaneously as a single injection
62033129|NCT04509947|EXPERIMENTAL|Ad26.COV2.S: Low Dose|Participants (healthy adults aged \>= 20 to \<= 55 years \[cohort 1\] and \>= 65 years \[cohort 2\]) will receive IM injection of Ad26.COV2.S at low dose, as 2-dose schedule on Day 1 and Day 57.
62233204|NCT01840787|EXPERIMENTAL|Contralateral lens comfort comparisons|Subjects will be randomized into receiving balafilcon A (8.3), or balafilcon A (8.6), or senofilcon A in one eye, and balafilcon A (8.3), or balafilcon A (8.6), or senofilcon A in the other eye.
62233205|NCT05033418|EXPERIMENTAL|IPRP + CBT-I|Interdisciplinary Pain Rehabilitation Program + Cognitive Behavioral Therapy for Insomnia (IPRP + CBT-I)
62233206|NCT05033418|ACTIVE_COMPARATOR|IPRP-UC|Interdisciplinary Pain Rehabilitation Program Usual Care (IPRP-UC)
62233207|NCT02605421|EXPERIMENTAL|Patients Treated for Neuroblastoma|Consolidation course #1 consists of thiotepa and cyclophosphamide followed by a PBSC rescue. Consolidation course #2 consists of melphalan, etoposide and carboplatin followed by a second PBSC rescue. Post infusion, patients will receive Granulocyte-Colony Stimulating Factor beginning on Day 0 of each consolidation course.
62233208|NCT00645541|EXPERIMENTAL|Axillary Reverse Mapping (ARM)|
62233209|NCT01792193||Parkinson's disease|Patients with Parkinson's disease
62809414|NCT03002961|EXPERIMENTAL|Cohort 2|Subjects to receive medium dose of RBP-6000 subcutaneously as a single injection
62233210|NCT01792193||Control|Healthy controls
62233211|NCT03421093||Surgeries and adjuvant therapies|Surgeries or surgeries plus adjuvant therapies
62233212|NCT02244996|EXPERIMENTAL|Lycium Barbarum|Daily Lycium Barbarum dosage: 10g of granules for 12 months
62233213|NCT02244996|PLACEBO_COMPARATOR|Placebo|Placebo
62233214|NCT04792957||Pyoderma Gangrenosum|Skin biopsies obtained from patients with pyoderma gangrenosum will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods.
62233215|NCT04792957||Hidradenitis Suppurativa|Skin biopsies obtained from patients with hidradenitis suppurativa, will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods
62233216|NCT04792957||Psoriasis|Skin biopsies obtained from patients with psoriasis, will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods
62233217|NCT04792957||Healthy Subjects|Skin biopsies obtained from patients with healthy subjects, will be used to control group.
62233218|NCT01115972|EXPERIMENTAL|single-add first group|single administration first, then concomitant administration
62233219|NCT01115972|EXPERIMENTAL|combi-add first group|concomitant administration first, then single administration
62233220|NCT02582125|EXPERIMENTAL|ONO-4538|ONO-4538 water-soluble injection, 100 mg/vial, 3 times once every 2 weeks in each 6-week cycle
62233221|NCT00553423|EXPERIMENTAL|1|Lactulose 30 ml q6h for 48 hrs
62233222|NCT00553423|PLACEBO_COMPARATOR|2|Placebo 30 ml q6 hrly for 48hrs
62233223|NCT00637923|EXPERIMENTAL|1|One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
62233224|NCT00637923|PLACEBO_COMPARATOR|2|One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
62424282|NCT02806635|EXPERIMENTAL|PREP Online|The PREP Online program is based on the in-person Prevention and Relationship Enhancement Program. The PREP Online program consists of seven sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour.
62809415|NCT03002961|EXPERIMENTAL|Cohort 3|Subjects to receive high dose of RBP-6000 subcutaneously as a single injection
62809416|NCT03002961|EXPERIMENTAL|Cohort 4|Subjects would receive medium dose RBP-6000 as a single injection after up to 12 mg daily dosing of sublingual (SL) suboxone tablets for 7 days
62233225|NCT05384262|ACTIVE_COMPARATOR|Cohort 1: Part A1 - AZD0780 dose 1/placebo tablet|A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.
62233226|NCT05384262|ACTIVE_COMPARATOR|Cohort 2: Part A1 - AZD0780 dose 2/placebo tablet|A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.
62233227|NCT05384262|ACTIVE_COMPARATOR|Cohort 3: Part A1 - AZD0780 dose 3/placebo tablet|A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.
62233228|NCT05384262|ACTIVE_COMPARATOR|Cohort 4: Part A1 - AZD0780 dose 4/placebo tablet|A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.
62233229|NCT05384262|ACTIVE_COMPARATOR|Cohort 5: Part A1 - AZD0780 dose 5/placebo tablet|A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.
62233230|NCT05384262|ACTIVE_COMPARATOR|Cohort 6: Part B - AZD0780 dose 6/placebo tablet|A total of 20 subjects will be assigned as 3:1::AZD0780:Placebo to receive multiple ascending doses.
62424283|NCT00995540|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection tid for 12 weeks
62233231|NCT05384262|ACTIVE_COMPARATOR|Cohort 7: Part B - AZD0780 dose 7/placebo tablet|A total of 20 subjects will be assigned as 3:1::AZD0780:Placebo to receive multiple ascending doses.
62233232|NCT05384262|ACTIVE_COMPARATOR|Cohort 8: Part B - AZD0780 dose 8/placebo tablet|A total of 20 subjects will be assigned as 3:1::AZD0780:Placebo to receive multiple ascending doses.
62233233|NCT05384262|ACTIVE_COMPARATOR|Cohort 9: Part B - AZD0780 dose 9/placebo tablet|A total of 6 subjects will receive single and multiple ascending doses of AZD0780 and 2 will receive placebo.
62424284|NCT00995540|ACTIVE_COMPARATOR|100 mg INGAP Peptide tid|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
62424285|NCT00995540|ACTIVE_COMPARATOR|200 mg INGAP Peptide tid|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
62593148|NCT06440408|EXPERIMENTAL|Ferumoxytol enhanced cMRI|A one time dose of Ferumoxytol will be administered prior to the cMRI in order to enhance the images. A dose of 4 mg/kg (max dose 510 mg) administered at a concentration of 8 mg/mL (in saline) will be used for this study. If the volume being administered is less than 6 mL, this is diluted with 3 mL of normal saline prior to administration. The drug is given over 15 minutes intravenously through a central or peripheral line. The drug is given at least 15 minutes prior to cardiac imaging.
62593149|NCT02659514|EXPERIMENTAL|Cohort 1: Poziotinib 24 mg|Participants received poziotinib 24 milligrams (mg), administered as three 8 mg tablets, orally, once daily (QD) on an intermittent dosing schedule of 14 days on treatment followed by 7 days off treatment, in a 21-day cycle until disease progression, death, intolerable adverse events (AEs) or for up to a maximum of 24 months, whichever occurs first.
62809417|NCT03561675|ACTIVE_COMPARATOR|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
62424286|NCT06329076|EXPERIMENTAL|Losartan group|Drug:Losartan
62424287|NCT06329076|PLACEBO_COMPARATOR|Placebo group|Drug: Placebo
62424288|NCT02513693|EXPERIMENTAL|Standard Neuromuscular Blockade|"Drug: rocuronium + neostigmine~Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Train-of-Four (TOF) count = 1-2, TOF-count measurement every 1 min. Neuromuscular blockade reversal at the end of anesthesia: neostigmine 0.03 mg/kg iv + atropine 0.5-1.0 mg iv Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1.5-2.5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv Extubation when patient is conscious and attained the recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
62433589|NCT02805374|EXPERIMENTAL|ASP1517 fed then fasting|Subjects will receive a single oral dose of ASP1517 under fed conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fasting conditions in period 2.
62593150|NCT02659514|EXPERIMENTAL|Cohort 2: Poziotinib 16 mg|Participants received poziotinib 16 mg, administered as two 8 mg tablets, orally, QD, on a continuous dosing schedule in a 21-day cycle until disease progression, death, intolerable AEs or for up to a maximum of 24 months, whichever occurs first.
62233234|NCT05384262|ACTIVE_COMPARATOR|Cohort 10: Part B - AZD0780 dose 10/placebo tablet|A total of 6 subjects will receive single and multiple ascending doses of AZD0780 and 2 will receive placebo.
62233235|NCT05384262|ACTIVE_COMPARATOR|Cohort 11: Part A2 - AZD0780 dose 11/placebo tablet|A total of 5 subjects will receive single ascending doses of AZD0780 and placebo.
62809418|NCT03561675|PLACEBO_COMPARATOR|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.
62593151|NCT00818467|EXPERIMENTAL|Tanning spray|To characterize the 25(OH)D response to 4 weeks of thrice weekly 40 mJ of UV-B light in a group of normal subjects with skin types I and II while using multiple applications of 3% DHA for five weeks.
62233236|NCT05384262|ACTIVE_COMPARATOR|Cohort 12: Part B - AZD0780 dose 1/rosuvastatin dose 12|A total of 20 subjects will receive single dose of AZD0780 and rosuvastatin.
62233237|NCT05384262|ACTIVE_COMPARATOR|Cohort 13: Part B - placebo tablet/rosuvastatin dose 12|A total of 20 subjects will receive single dose of placebo and rosuvastatin.
62233238|NCT05384262|ACTIVE_COMPARATOR|Cohort 14: Part B - AZD0780 with placebo tablet/AZD0780 with rosuvastatin dose 12|A total of 20 subjects will receive AZD0780 in combination with rosuvastatin or 5 subjects will receive placebo in combination with rosuvastatin.
62233239|NCT02388646|ACTIVE_COMPARATOR|Exercise Only|Home exercise program.
62233240|NCT02388646|ACTIVE_COMPARATOR|Brace Only|Reaction Web brace.
62424289|NCT02513693|EXPERIMENTAL|Deep Neuromuscular Blockade|"Drug: rocuronium + sugammadex~Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Post-tetanic Count (PTC) = 1-2; PTC measurement every 4 min. Neuromuscular blockade reversal at the end of anesthesia: sugammadex 2 mg/kg iv (when PTC is 18-20 and TOF-count 0) or sugammadex 4 mg/kg iv (when PTC under 18).~Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1,5-2,5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv.~Extubation when patient is conscious and attained recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
62233241|NCT02388646|ACTIVE_COMPARATOR|Bracing + Exercises|Reaction Web brace and home exercises.
62233242|NCT05363462|EXPERIMENTAL|Ankle fracture surgical treated plus 1 g of topical vancomycin|A standard surgical treatment of patients with ankle fracture must be carried out. Classified according to Danis Webber classification system. Plus application of 1 g of vancomycin in powder in the surgical site
62233243|NCT05363462|ACTIVE_COMPARATOR|Ankle fracture surgical treated|A standard surgical treatment of patients with ankle fracture must be carried out. Classified according to Danis Webber classification system
62233244|NCT06401460|EXPERIMENTAL|Experimental group|Yannianjiuzhuan method combined with reverse breathing training.
62233245|NCT06401460|EXPERIMENTAL|Control group|"The control group received standard care in accordance with the Constipation Nursing Protocol for Cardiology Patients, which included basic care, disease education, dietary and exercise guidance, bowel movement and psychological counseling ."
62424290|NCT01169844|EXPERIMENTAL|AIN457/AIN457 3 mg/kg.|Participants who were treated with secukinumab 2x10 mg/kg during the core study were treated with secukinumab at 3mg/kg infused intravenously every 4 weeks during the extension study, over a total period of 52 weeks.
62433590|NCT03804801|EXPERIMENTAL|Intervention Arm (or Group)|This arm will receive the intervention (Hibiscus Sabdariffa extract supplement)
62593152|NCT00818467|ACTIVE_COMPARATOR|UVB|To characterize the 25(OH)D response to 4 weeks of thrice weekly 40 mJ of UV-B light in a control group of normal subjects with skin types I and II who are not using 3% DHA applications.
62593153|NCT03070769||Control|Subjects without Obstructive sleep apnea (Apnea-hypopnea index-AHI\<5). Venous blood collection for biomarkers measurements.
62593154|NCT03070769||Obstructive sleep apnea (OSA) patients|Patients with Obstructive sleep apnea (AHI\> or =5). Venous blood collection for biomarkers measurements.
62809419|NCT00531765|ACTIVE_COMPARATOR|1|hydration with normal saline
62809420|NCT00531765|EXPERIMENTAL|2|hydration with sodium bicarbonate
62809421|NCT05569434|EXPERIMENTAL|68Ga-P16-093 and MRI scan|Within 1 week, each patient underwent MRI scan and PET/CT scan after intravenous administration of 68Ga-P16-093, respectively.
62809422|NCT05721495|EXPERIMENTAL|Freeze all strategy embryo transfer|Three days after fecundation, the best embryo is criopreserved. It is transferred in a posterior cicle
62809423|NCT05721495|ACTIVE_COMPARATOR|Fresh embryo transfer strategy|Two or three days after fecundation, the best embryo is transferred.
62809424|NCT02866058||Cesarean|Mothers delivered by cesarean section
62809425|NCT02866058||Vaginal|Mothers delivered by vaginal delivery
62809426|NCT01308736|ACTIVE_COMPARATOR|varenicline|
62809427|NCT01308736|PLACEBO_COMPARATOR|placebo pill|
62809428|NCT05342961|EXPERIMENTAL|spinous balloon dilatation catheter(Plastic-Blade)|Patients with CAD will be treated with spinous balloon dilatation catheter(Plastic-Blade).
62809429|NCT05342961|EXPERIMENTAL|spinous balloon dilatation catheter(lacrosse NSE)|Patients with CAD will be treated with spinous balloon dilatation catheter(lacrosse NSE)
62809430|NCT05405010|PLACEBO_COMPARATOR|Control|Participants remain seated for 1 hour
62809431|NCT05405010|EXPERIMENTAL|1 min|Participants remain seated for 1 hour except for 1 minute of stair climbing and descending
62809432|NCT05405010|EXPERIMENTAL|3 min|Participants remain seated for 1 hour except for 3 minute of stair climbing and descending
62809433|NCT02680522|ACTIVE_COMPARATOR|Control Group|composed of healthy volunteers who underwent training with virtual reality. Exercises with game through virtual reality
62809434|NCT02680522|EXPERIMENTAL|Parkinson's Group|composed of patients with Parkinson's disease and who underwent training with virtual reality. exercises with game through virtual reality
62809435|NCT01402440|EXPERIMENTAL|AEB071|
62809436|NCT04277949|EXPERIMENTAL|Erbium laser|All participants will receive Erbium laser treatment on their right post-auricular region
62809437|NCT04277949|EXPERIMENTAL|DNA repair enzyme|All participants will apply topical DNA repair enzymes on their left post-auricular region
62593155|NCT03638284|EXPERIMENTAL|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS):All enrolled study participants will receive 10 sessions (5 per week X 2 weeks) of tDCS in an open label study. Inhibitory stimulation will be delivered to the frontal lobes.
62593156|NCT01470651|EXPERIMENTAL|Armodafinil|Active medication
62593157|NCT01470651|PLACEBO_COMPARATOR|Sugar pill|Inactive pill, matched to look like active medication
62593158|NCT04928170||HALLOA|306 individuals with knee pain in the age between 30 and 65 years, without cruciate ligament injury
62593159|NCT05128630|EXPERIMENTAL|Single-arm|Chemotherapy plus durvalumab, hypofractionated RT plus durvalumab, durvalumab maintenance
62593160|NCT02925182|EXPERIMENTAL|test|Recurrent Aphthous Stomatitis were irradiated with Er,Cr:YSGG laser (Waterlase MD, Biolase, Irvine, CA, USA) on hard tissue mode with a mg6 sapphire tip (600 µm diameter, 6 mm length) using non-contact mode at an energy level of 0.25W and a repetition rate of 20 kHz and pulse duration of 140 µs, 0% water and 10% air at 5 J/cm2 energy density. The treatment time was 20 s per surface by scanning the Recurrent Aphthous Stomatitis area.
62809438|NCT02907034|EXPERIMENTAL|Group 1|First,Virtual reality approach (VR), then classical narrative approach (CN)
62809439|NCT02907034|ACTIVE_COMPARATOR|Group 2|First, classical narrative approach (CN), then virtual reality approach
62033130|NCT04509947|PLACEBO_COMPARATOR|Placebo|Participants (healthy adults aged \>= 20 to \<= 55 years \[cohort 1\] and \>= 65 years \[cohort 2\]) will receive IM injection of placebo on Day 1 and Day 57.
62233246|NCT01941134|EXPERIMENTAL|Gastric bypass COC|"This is a before-and-after comparison. Women will enroll prior to planned gastric bypass surgery and complete one cycle of oral contraceptive use and evaluation. There will then be no more study procedures/interventions until 3-4 months after surgery. At that time, women will complete the second cycle of OC use and evaluation. Study participation is then complete.~Intervention: Ethinyl estradiol-levonorgestrel(EE 20mcg/LNG 150mcg)"
62233247|NCT06058260||Children With Thalassemia (Cases)|Hematological Disease which are a heterogeneous group of single gene disorders, inherited in an autosomal recessive manner ( Thalassemia Syndrome )
62233248|NCT06058260||Healthy Children ( Controls )|Healthy Children free from any chronic illness
62233249|NCT02742337||Test|Newly diagnosed female patients with rheumatoid arthritis who have not previously used a disease modifying anti-rheumatic drug.
62233250|NCT02742337||Control|Female patients not having a diagnosis of rheumatoid arthritis and who have not previously used a disease modifying anti-rheumatic drug.
62593161|NCT02925182|PLACEBO_COMPARATOR|Control|In the placebo group, the same Er,Cr:YSGG laser without laser emission was used.
62593162|NCT05482373|PLACEBO_COMPARATOR|Placebo|Patients will receive hard gelatin capsules containing placebo (only the excipients).
62809440|NCT03599206|EXPERIMENTAL|Ozone|
62593163|NCT05482373|EXPERIMENTAL|Oleuropein|Patients will receive the same hard gelatin capsules but containing 200 mg of an olive leaf extract.
62593164|NCT02297178||Cystoscopy Alone|Patients who received cystoscopy only for treatment of OAB and voiding dysfunction.
62809441|NCT03599206|PLACEBO_COMPARATOR|Filtered Air|
62809442|NCT00664547|NO_INTERVENTION|C|
62809443|NCT00664547|ACTIVE_COMPARATOR|DWL|Diet Weight Loss
62809444|NCT00664547|ACTIVE_COMPARATOR|EWL|Exercise Weight Loss
62809445|NCT00664547|ACTIVE_COMPARATOR|EWS|Exercise without weight loss
62033131|NCT04928950|EXPERIMENTAL|Adults undergoing TEMLA|Adults undergoing TEMLA (Transcervical Extended Mediastinal Lymphadenectomy) take Oral Activated Charcoal (OAC) dissolved in apple juice a night before the surgery
62033132|NCT05974969|EXPERIMENTAL|BCD-264|INN: daratumumab, single IV infusion at a dose of 8 mg/kg.
62033133|NCT05974969|ACTIVE_COMPARATOR|Darzalex|INN: daratumumab, single IV infusion at a dose of 8 mg/kg.
62033134|NCT04169139|ACTIVE_COMPARATOR|MIST - minimally invasive surgical therapy|"Beginning with the papilla preservation technique (Takei et al), further improved by Cortellini et al (1995) and combined with minimally invasive approaches (Harrel et al 1995), MIST, using minimally invasive surgical approaches and micro-surgery instruments, has evolved into a decision tree guideline for treating periodontitis based on periodontal pocket morphology and papilla width/ interdental space (Cortellini P, Tonetti MS (2007) J Clin Periodontol;34(1):87-93)."
62233251|NCT02802709|EXPERIMENTAL|SB-061|SB-061
62809446|NCT03913858|OTHER|high-flow anesthesia|Before beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Group 1 had 4 liter/minute (50% O2, 50% air) flow administered. Mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered.
62233252|NCT02802709|PLACEBO_COMPARATOR|Placebo|Placebo
62233253|NCT01013922||No treatment|Patients with a smoking history of 15 pack years or more.
62233254|NCT03849950|EXPERIMENTAL|SMARTCare|"1. Training in self-management support (SMS) strategies for ambulatory nursing staff~2. A web-based self-management education (I-Can-Manage Cancer) for patients~3. Telephone-based, nurse-led health coaching~4. Optional end of study patient interview (sub-study)"
62233255|NCT03849950|ACTIVE_COMPARATOR|Control|1. Training in self-management support (SMS) strategies for ambulatory nursing staff
62233256|NCT01937325|ACTIVE_COMPARATOR|Ivacaftor|150mg orally twice daily
62233257|NCT01937325|PLACEBO_COMPARATOR|Placebo|Matching placebo
62593165|NCT02297178||Cystoscopy & Urethral Dilatation|Patients who received urethral dilatation and cystoscopy for treatment of OAB and voiding dysfunction.
62593166|NCT06622343||Necrotizing Skin Infections Group|This cohort includes patients who developed necrotizing skin infections following venomous snakebites. These patients were treated at three hospitals in Guangdong Province between January 2020 and April 2024. The study aims to identify key risk factors, including Snakebite Severity Score (SSS), blood glucose levels, and D-dimer levels, that are associated with the development of necrotizing skin infections in these patients.
62809447|NCT03913858|OTHER|low-flow anesthesia|Before beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Group 2 had 1 liter/minute (50% O2, 50% air) flow administered. Mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered.
62809448|NCT00317473|EXPERIMENTAL|FMP1/AS02A Malaria vaccine 10ug|Subject vaccinated with 10 ug of FMP1/AS02A on days 0, 29 and 57
62809449|NCT00317473|EXPERIMENTAL|FMP1/AS02A Malaria vaccine 25 ug|Subject vaccinated with 25 ug of FMP1/AS02A on days 14, 42, and 70
62033135|NCT04169139|EXPERIMENTAL|REPaiR - laser periodontal therapy|The REPaiR regimen is a step-by-step protocol for using the Waterlase Express Er,Cr:YSGG laser for periodontitis. The protocol steps and associated laser delivery is controlled by a computer interface that dictates laser tip, energy and associated air and water mixes. Like MIST, REPaiR uses a set, decision tree approach for periodontal therapy, with prescribed steps and laser settings to quantify and standardize treatment. Potential clinical benefit, as with MIST, are not only effective periodontal therapy with reduced recession compared with traditional surgical approaches, but also reduced patient morbidity (Arnabat-Domínguez et al (2010). Lasers Med Sci;25(3):459-64).
62033136|NCT02444455|EXPERIMENTAL|UCMSC group|Human umbilical cord MSCs are administrated to patients by intravenous infusion
62033137|NCT06269926|EXPERIMENTAL|Education-CBT|The Education-CBT group will receive pain education (a pain education booklet in addition to usual medical care) followed by Cognitive Behavioral Therapy for Chronic Pain (CBT-CP; the primary intervention-a 12-week group therapy course).
62233258|NCT01971203|EXPERIMENTAL|seroquel xr|quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day 16 weeks of treatment including CBT
62424291|NCT01169844|PLACEBO_COMPARATOR|Placebo/AIN457 3 mg/kg.|Participants who were treated with placebo during the core study were treated with secukinumab at 3mg/kg infused intravenously every 4 weeks during the extension study, over a total period of 52 weeks.
62809450|NCT00317473|EXPERIMENTAL|FMP1/AS02A Malaria vaccine 50 ug|Subject vaccinated with 50 ug of FMP1/AS02A on days 28, 56 and 84
62033138|NCT06269926|EXPERIMENTAL|CBT-Education|The CBT-Education group will receive Cognitive Behavioral Therapy for Chronic Pain (CBT-CP; the primary intervention-a 12-week group therapy course) followed by pain education (a pain education booklet in addition to usual medical care).
62424292|NCT01680289|EXPERIMENTAL|Three adhesive coats|Consecutive application of three one-bottle adhesive coats
62424293|NCT01680289|ACTIVE_COMPARATOR|Two adhesive coats|Consecutive application of two one-bottle adhesive coats
62424294|NCT04475068||Moderate to severe ARDS patients due to COVID-19 infection|Mechanically ventilated patients with moderate to severe ARDS due to COVID-19 infection admitted to the COVID Intensive Care Unit of Rebagliati Hospital.
62424295|NCT04189406||Girls with Turner syndrome|"Girls with a pre- or perinatal diagnosis TS who are born in a medical centre in the Netherlands during the duration of the study.~The subjects will have an extra venapuncture of 3.5 mL blood at 3 and 9 months."
62233259|NCT01971203|PLACEBO_COMPARATOR|placebo plus CBT|treatment group receiving placebo pill plus CBT
62233260|NCT04181151||Stroke patients|
62233261|NCT04181151||Healthy Subjects|
62424296|NCT02533505|ACTIVE_COMPARATOR|Symbicort pressurized Metered Dose Inhaler (pMDI)|Symbicort pressurized Metered Dose Inhaler (pMDI)
62424297|NCT02533505|PLACEBO_COMPARATOR|Placebo of reference drug|Placebo of reference drug
62424298|NCT04153097||pembrolizumab-treated advanced NSCLC|Patients with advanced non-small cell lung cancer treated with pembrolizumab
62424299|NCT03991065|EXPERIMENTAL|with endoscopy|high digestive endoscopy
62424300|NCT03991065|NO_INTERVENTION|without endoscopy|no endoscopy
62424301|NCT04462133|ACTIVE_COMPARATOR|Empirical therapy for H. pylori infection|The empirical group receives triple therapy of 7 or 14 days for H. pylori eradication
62424302|NCT04462133|EXPERIMENTAL|Tailored therapy for H. pylori infection|The tailored therapy group receives eradication regimens based on their DPO-PCR results. Triple therapy of 7 or 14 days for clarithromycin sensitive patients based on DPO-PCR and bismuth quadruple therapy of 7 or 14 days for clarithromycin resistant patients based on DPO-PCR.
62809451|NCT00317473|ACTIVE_COMPARATOR|Imovax Rabies Vaccine|Subject vaccinated with Imovax Rabies Vaccine on corresponding FMP1/AS021 vaccination days
62424303|NCT01066273|EXPERIMENTAL|P-Stim device|Receiving the device that is activated
62424304|NCT00101894|EXPERIMENTAL|Part 2 AMG 706 (MTD) + FOLFOX-4|Maximum Tolerated Dose of AMG 706 established in Part 1b + FOLFOX-4
62424305|NCT00101894|EXPERIMENTAL|125 mg QD AMG 706 + FOLFOX-4|125 mg QD AMG 706 + FOLFOX-4
62424306|NCT00101894|EXPERIMENTAL|50 mg QD AMG706 + panitumumab + FOLFIRI|50 mg QD AMG706 + panitumumab + FOLFIRI
62424307|NCT00101894|EXPERIMENTAL|Part 2 AMG 706 (MTD) + FOLFIRI|Maximum Tolerated Dose of AMG 706 established in Part 1b + FOLFIRI
62424308|NCT00101894|EXPERIMENTAL|100 mg QD AMG 706 + FOLFIRI|100 mg AMG 706 + FOLFIRI
62424309|NCT00101894|EXPERIMENTAL|75 mg QD AMG 706 + panitumumab + FOLFOX-4|75 mg QD AMG 706 + panitumumab + FOLFOX-4
62424310|NCT00101894|EXPERIMENTAL|75 mg BID AMG 706 + panitumumab + FOLFIRI|75 mg BID AMG 706 + panitumumab + FOLFIRI
62424311|NCT00101894|EXPERIMENTAL|125 mg QD AMG 706 + panitumumab + FOLFIRI|125 mg QD AMG 706 + panitumumab + FOLFIRI
62424312|NCT00101894|EXPERIMENTAL|125 mg QD AMG 706 + FOLFIRI|125 mg QD AMG 706 + FOLFIRI
62424313|NCT00101894|EXPERIMENTAL|100 mg QD AMG 706 + panitumumab + FOLFIRI|100 mg QD AMG 706 + panitumumab + FOLFIRI
62424314|NCT00101894|EXPERIMENTAL|75 mg QD AMG 706 + FOLFOX-4|75 mg QD AMG 706 + FOLFOX-4
62424315|NCT00101894|EXPERIMENTAL|100 mg QD AMG 706 + FOLFOX-4|100 mg QD AMG 706 + FOLFOX-4
62424316|NCT00101894|EXPERIMENTAL|50 mg QD AMG 706 + panitumumab + FOLFOX-4|50 mg QD AMG 706 + panitumumab + FOLFOX-4
62593167|NCT06622343||Non-Infection Group|This cohort includes patients who did not develop necrotizing skin infections after venomous snakebites. These patients were treated at the same three hospitals between January 2020 and April 2024. The cohort serves as a control group to compare against the infection group, helping to determine risk factors associated with necrotizing skin infections in snakebite patients.
62593168|NCT00638443|OTHER|Pregabalin then Diphenhydramine|Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days; no drug for 7 days; diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
62233262|NCT06200064|EXPERIMENTAL|Self-stretching exercise group|Static neck muscle self-stretching exercises were performed for 30 min. after the TENS procedure. Every muscle in the neck region (head rotator cuff, neck stair muscles, upper part of the trapezius muscle, scapula levator muscle, semiscapular neck muscle, upper oblique head muscle, girdle head and neck muscles, and deep anterior neck flexor muscles) were stretched 3 times for 30 seconds per muscle group. While performing exercises, the subjects applied resistance with their hands. All exercises were performed without causing pain.
62233263|NCT06200064|EXPERIMENTAL|Post-isometric relaxation exercise group|"The investigators used one of the autogenic inhibition techniques - post-isometric relaxation (PIR), known as the muscle contraction-relaxation technique, during which, the subject is lying on his back, he is asked to press his head in the specified direction (50% of the subject's maximum pressure force). to the resistance provided by the therapist. During the press, resistance was provided for 10 seconds and followed by a passive stretch of the muscle in the opposite direction of movement. A total of 5 repetitions are performed for each muscle with a 5-second break. All movements are performed without causing pain of more than moderate intensity."
62233264|NCT04255069|PLACEBO_COMPARATOR|Placebo|Placebo, oral, daily
62233265|NCT04255069|EXPERIMENTAL|Dose 1|JKB-122, Dose 1, oral, daily
62233266|NCT04255069|EXPERIMENTAL|Dose 2|JKB-122, Dose 2, oral, daily
62233267|NCT05467397|EXPERIMENTAL|Patients will undergo [11C]acetate PET/CT|Patients will undergo a single \[11c\]acetate PET scan OR Patients will undergo an \[11c\]acetate PET scan, initiate treatment with rapamycin or rapalogs and receive a second \[11c\]acetate PET scan 3 or 4 months after starting the treatment.
62233268|NCT02598817||Standard Infant Formula|Standard Infant Formula containing High Sn-2
62233269|NCT00849043||Provent|Provent Professional Sleep Apnea Therapy device
62233270|NCT00893646|EXPERIMENTAL|weight loss counseling|individual monthly counseling on diet, physical activity and sleep
62233271|NCT00893646|NO_INTERVENTION|control|no lifestyle advice, yearly assessments
62424317|NCT00101894|EXPERIMENTAL|75 mg QD AMG706 + panitumumab + FOLFIRI|75 mg QD AMG706 + panitumumab + FOLFIRI
62593169|NCT00638443|OTHER|Diphenhydramine then Pregabalin|diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days; no drug for 7 days; pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
62593170|NCT05531526|ACTIVE_COMPARATOR|Group A - Active Comparator|Active, AR1001 30 mg QD will be administered daily for 52 weeks during the Treatment Phase of the study. In the Extension Phase, all eligible participants who choose to participate will receive AR1001 30 mg QD for 52 weeks.
62809452|NCT05753410|EXPERIMENTAL|Mindful Courage|Mindful Courage is a digital intervention including mindfulness and cognitive behavioral elements for individuals with anorexia nervosa or bulimia nervosa. Mindful Courage will consist of 8-weeks of self-guided modules which will be completed over the course of 8 weeks. Elements included in the intervention include psychoeducation, self-monitoring, regular eating, body image, values clarification, and mindful awareness and acceptance. Participants learn a range mindfulness skills and practice a range of mindfulness meditations. Participants will also receive phone coaching. Homework consists of meditation practices.
62233272|NCT04527120|OTHER|Model A first and then B|Model A and B would be randomly allotted to commercial model and IDUP. Intervention limb would involve performing on sequentially on the commercial and IDUP, following which a feed back of the candidates would be recorded about their performance on the same with respect to sonological appearance, tactile feedback, artefacts and ease of performing the procedure. Set time points (time to needle tip visualisation, time to puncture) and no of attempts before successful cannulation would be recorded by an assessor on a pre set proforma.
62233273|NCT04527120|OTHER|Model B first and then A|Model A and B would be randomly allotted to commercial model and IDUP. Intervention limb would involve performing on sequentially on the commercial and IDUP, following which a feed back of the candidates would be recorded about their performance on the same with respect to sonological appearance, tactile feedback, artefacts and ease of performing the procedure. Set time points (time to needle tip visualisation, time to puncture) and no of attempts before successful cannulation would be recorded by an assessor on a pre set proforma.
62233274|NCT03245970|ACTIVE_COMPARATOR|Treatment Arm|"Treatment arm patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.~Intervention: Labetalol Hydrocholoride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily"
62233275|NCT03245970|NO_INTERVENTION|Non Treatment|Non treatment Arm patients who are randomized to the non-treatment arm will not receive antihypertensive medications.
62233276|NCT02079610|EXPERIMENTAL|real-time fMRI neurofeedback: Amygdala|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
62424318|NCT05754437|EXPERIMENTAL|Low Level Light Therapy Group|Patients enrolled in the treatment group will undergo Low Level Light therapy using Meibomask (Espansione Marketing S.p.A., Bologna, Italy) for 15 minutes one week (±2 days) before surgery (T0) and one week (±2 days) after surgery (T1).
62424319|NCT05754437|NO_INTERVENTION|Control group|Patients enrolled in the control group will not receive Low Level Light therapy at any time.
62424320|NCT06500052|EXPERIMENTAL|BL-M17D1|Participants receive BL-M17D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62424321|NCT05139901|ACTIVE_COMPARATOR|4% saline|4% Saline inhalations twice daily
62233277|NCT02079610|ACTIVE_COMPARATOR|real-time fMRI neurofeedback: HIPS|HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
62233278|NCT00832637|EXPERIMENTAL|Gemcitabine, Cisplatin, Erlotinib|A combination of Cisplatin at 40 mg/m2 + Gemcitabine at 1000 mg/m2, every 28 days + Erlotinib 100 mg daily, orally. Cycles will be repeated every four weeks.
62233279|NCT02752321|EXPERIMENTAL|eDischarge + Standard Discharge (SDeD)|"Patients in this arm will be enrolled in the eDischarge technology prior to hospital discharge. Upon hospital discharge, these patients will receive a personalized eDischarge, containing text and multimedia information, in addition to receiving the standard discharge process.~Follow-up interviews and surveys will be conducted at 7-14 days post discharge, and at 30-45 days post discharge."
62233280|NCT02752321|NO_INTERVENTION|Standard Discharge (SD)|"Patients in this arm will receive the standard discharge process upon hospital discharge.~Follow-up interviews and surveys will be conducted at 7-14 days post discharge, and at 30-45 days post discharge."
62233281|NCT03041922||Healthy group|Every participant passes one ultrasound exam for soft tissues in buttocks in order to measure the elasticity of soft tissues in sitting and lying down positions. This kind of exam may help to predict a development in pressure ulcers
62233282|NCT01155375|EXPERIMENTAL|Ferumoxytol|"Participants will receive 1 of the following 2 ferumoxytol dose regimens:~* Four IV injections of ferumoxytol 3.5 mg Fe/kg (maximum of 255 mg/dose) administered on nonconsecutive days within a 14-day period as follows: Day 1 (dose 1), Days 3\* through 10 (dose 2), Days 5 through 12 (dose 3), and Days 7 through 14 (dose 4). \*Participants participating in PK sampling received the second dose on Day 4 after the 72-hour PK sample was collected.~* Two IV injections of ferumoxytol 7.0 mg Fe/kg (maximum of 510 mg/dose), the first administered on Day 1 and the second on Days 3 through 9."
62233283|NCT01155375|ACTIVE_COMPARATOR|Oral Iron|Participants will receive oral iron 2.5 mg Fe/kg twice daily (maximum of 100 mg/dose) on Days 1 through 35.
62233284|NCT04906447|NO_INTERVENTION|Control arm|Participants randomized to the control arm will receive usual care
62233285|NCT04906447|EXPERIMENTAL|Acupuncture|Acupuncture treatments twice a week for five weeks
62233286|NCT04906447|EXPERIMENTAL|Guided Relaxation|Daily use of a guided relaxation app for 6 weeks
62233287|NCT00294554|ACTIVE_COMPARATOR|Active Memantine|Memantine tablets, formulated in appearance to match the placebo comparator, were initiated at 5 mg daily and advanced by 5mg /week to 20 mg/week by week 4 with dosing at 10 mg bid over the remaining 20 weeks of the trial. Over the 6 month duration of the trial, dosage could be titrated downward in increments of 5 mg to a minimum dose of 5mg/day in the event of intolerance.
62233288|NCT00294554|PLACEBO_COMPARATOR|Placebo Oral Tablet|Placebo tablets were formulated to match active 5mg memantine tablets. Dosing same as the active comparator with initiation at 5 mg daily and advancing by 5mg /week to 20 mg/week by week 4 with dosing at 10 mg bid over the remaining 20 weeks of the trial. Over the 6 month duration of the trial, dosage could be titrated downward in increments of 5 mg to a minimum dose of 5mg/day in the event of intolerance.
62233289|NCT02497625|EXPERIMENTAL|Positive Therapeutic Alliance|Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.
62424322|NCT05139901|EXPERIMENTAL|Pulmosyme|DNAse alpha inhalations twice daily
62424323|NCT05709626|ACTIVE_COMPARATOR|No aspirin (Prasugrel monotherapy)|To start prasugrel monotherapy before primary percutaneous coronary intervention (PCI).
62424324|NCT05709626|ACTIVE_COMPARATOR|12-month DAPT|To start dual antiplatelet therapy with prasugrel and aspirin for 12 months before primary percutaneous coronary intervention (PCI).
62424325|NCT00415311|OTHER|0 mg/kg|
62424326|NCT00415311|OTHER|0.5 mg/kg|
62424327|NCT00415311|OTHER|1.0 mg/kg|
62424328|NCT03709407|EXPERIMENTAL|cervical stimuli|Godoy´s maneuver with traction-sliding in supraclavicular fossa
62424329|NCT03709407|EXPERIMENTAL|terminus|Vodder´s maneuver with medial and anterior traction in supraclavicular fossa
62424330|NCT03709407|SHAM_COMPARATOR|placebo|maneuver with sliding ON clavicular
62424331|NCT03709407|NO_INTERVENTION|Control group|only lying down
62424332|NCT03137758|EXPERIMENTAL|Level 1 (50 mg) PCUR-101|Starting Dose, 3+3 Cohort Design
62033139|NCT05371184|EXPERIMENTAL|cases|• 30 patients will receive glutamine in a dose of 0.3 gm /kg/dose twice daily orally (up to a maximum of 15 g/dose) for 24 weeks as an add on to the SOC
62424333|NCT03137758|EXPERIMENTAL|Level 2 (100 mg) PCUR-101|
62424334|NCT03137758|EXPERIMENTAL|Level 3 (150 mg) PCUR-101|
62424335|NCT03137758|EXPERIMENTAL|Level 4 (200 mg) PCUR-101|
62424336|NCT03137758|EXPERIMENTAL|Level 5 (250 mg) PCUR-101|
62424337|NCT03137758|EXPERIMENTAL|Level 6 (300 mg) PCUR-101|
62424338|NCT03455647|EXPERIMENTAL|ASF Promotion plus Girinka|Participants have received a cow from the government of Rwanda through the Girinka program and will receive an animal source food promotion intervention from the study.
62424339|NCT03455647|NO_INTERVENTION|Girinka only|Participants have received a cow from the government of Rwanda through the Girinka program and will not receive any intervention from the study.
62433591|NCT03804801|NO_INTERVENTION|Control Arm (or Group)|This arm will receive no intervention whatsoever, not even placebo
62233290|NCT02497625|ACTIVE_COMPARATOR|Usual Care|Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.
62809453|NCT03257761|EXPERIMENTAL|Treatment (guadecitabine, durvalumab)|Patients receive guadecitabine SC QD on days 1-5 and durvalumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62809454|NCT05265975|EXPERIMENTAL|ATG-010|Enrolled patients will be treated with dosage groups. Dosage group 1:40mg/time, dosage group 2:60mg/time, dosage group 3:80mg/time; The treatment period was 28 days. The drug was administered on day 1,8 and 15 of each cycle
62809455|NCT05983419|EXPERIMENTAL|intervantion|Complete resection of Barrett's esophagus harboring neoplasia with endoscopic submucosal dissection.
62809456|NCT01356160|ACTIVE_COMPARATOR|Arm 1|RGT with GS-5885 30 mg QD + GS-9451 200 mg QD + PEG/RBV
62809457|NCT01356160|PLACEBO_COMPARATOR|Arm 2|RGT with GS-5885 30 mg QD + GS-9451 placebo QD + PEG/RBV
62809458|NCT02559011||All study participants|Patients who need a TAVI with symptomatic severe aortic valve stenosis
62809459|NCT02629029|OTHER|Surgical - therapeutic free flap|patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will be imaged using two systems: (i) pre-operative CTA with IV contrast; (ii) intra-operative fluorescence endoscopy with ICG.
62809460|NCT00871910|EXPERIMENTAL|2 Hour SCH 727965 infusion|Participants treated with 2 hour SCH 727965 IV infusion
62233291|NCT02497625|OTHER|Control group|Patients will not receive intervention in the first mo nth of enrollment. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.
62233292|NCT00003600|EXPERIMENTAL|epoetin alfa|Patients receiving chemotherapy are randomized to receive epoetin alfa subcutaneously once a week for a maximum of 16 weeks Quality of life is assessed at randomization and monthly throughout study. Patients are followed every 6 months for 1 year.
62233293|NCT00003600|PLACEBO_COMPARATOR|placebo|Patients receiving chemotherapy are randomized to receive placebo subcutaneously once a week for a maximum of 16 weeks. Quality of life is assessed at randomization and monthly throughout study. Patients are followed every 6 months for 1 year.
62233294|NCT03394430|PLACEBO_COMPARATOR|Group A|
62233295|NCT03394430|EXPERIMENTAL|Group B|
62233296|NCT03394430|EXPERIMENTAL|Group C|
62233297|NCT03305354|EXPERIMENTAL|CBTI app intervention|Cognitive Behavioral Therapy for Insomnia delivered for 6 weeks via the CBT-I Coach app with use guided by a self-management guide
62233298|NCT03305354|ACTIVE_COMPARATOR|CBTI app+Physical Activity Intervention|Cognitive Behavioral Therapy for Insomnia delivered for 6 weeks via the CBT-I Coach app with use guided by a self-management guide plus self-management guidance on increased step counts
62233299|NCT03267940|EXPERIMENTAL|Run-in Portion: PEGCISGEM|Participants will receive 3.0 micrograms per kilogram (mcg/kg) PEGPH20 on Days 1, 8, and 15 in combination with 25 milligrams per meter square (mg/m\^2) of CIS plus 1000 mg/m\^2 of GEM administered on Days 2 and 9 of each 21-day cycle by intravenous (IV) infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
62233300|NCT03267940|EXPERIMENTAL|Run-in Portion: PEGCISGEMATEZO|After 6 participants from the PEGCISGEM arm are treated for at least 1 cycle without significant toxicities, new participants will be enrolled in this arm to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m\^2 of CIS and 1000 mg/m\^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
62233301|NCT03267940|EXPERIMENTAL|Expansion Portion: PEGCISGEM|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the Run-in portion safe and tolerable, new participants will be enrolled to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 25 mg/m\^2 CIS and 1000 mg/m\^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
62809461|NCT00871910|EXPERIMENTAL|8 Hour SCH 727965 infusion|Participants treated with 8 hour SCH 727965 IV infusion.
62809462|NCT00871910|EXPERIMENTAL|24 Hour SCH 727965 infusion|Participants treated with 24 hour SCH 727965 IV infusion.
62033140|NCT05371184|ACTIVE_COMPARATOR|control|30 patients will be assigned as a control group to receive standard of care therapy without glutamine intake.
62233302|NCT03267940|EXPERIMENTAL|Expansion Portion: PEGCISGEMATEZO Twice Weekly|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the Run-in portion safe and tolerable, new participants will be enrolled to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m\^2 of CIS and 1000 mg/m\^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
62424340|NCT03455647|NO_INTERVENTION|Girinka eligible|Participants are eligible to receive a cow through the government of Rwanda Girinka program, but have not yet received a cow. They will not receive any intervention from the study.
62809463|NCT00871910|EXPERIMENTAL|2 Hour SCH 727965 infusions plus aprepitant in Cycle 1|Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 1 only.
62809464|NCT00871910|EXPERIMENTAL|2 Hour SCH 727965 infusion plus aprepitant in Cycle 2|Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 2 only.
62809465|NCT01478971|EXPERIMENTAL|peginesatide injection|In the first 6 months participants received standard of care treatment with epoetin (the Standard of Care Period \[SCP\]), followed by a 1-week erythropoiesis-stimulating agent (ESA)-Free Period, followed by peginesatide injection for 6 months (the Peginesatide Treatment Period \[PTP\]).
62033141|NCT01298128|EXPERIMENTAL|NuvaRing|NuvaRing for IVF pre-treatment
62033142|NCT01298128|ACTIVE_COMPARATOR|Combined oral contraceptive pill|OCP for IVF pre-treatment
62424341|NCT05539599||Cohort|Patients will undergo a spontaneous breathing trial. Any extubation will be decided by an independent operator.
62809466|NCT00855959|EXPERIMENTAL|1|Four weeks treatment with either Pulmicort Turbuhaler at a dose of 400 μg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily
62809467|NCT00855959|EXPERIMENTAL|2|Pulmicort Turbuhaler at a dose of 200 μg twice daily and Pulmicort Respules at a dose of 0.5 mg twice daily or 1.0 mg once daily (low dose)
62809468|NCT04349072|EXPERIMENTAL|Drug: Mavacamten|"Mavacamten Capsules~Other names:~MYK-461"
62809469|NCT04349072|PLACEBO_COMPARATOR|Drug: Placebo|Matching Placebo Capsules
62809470|NCT05243875|EXPERIMENTAL|Navigation|COVID education for people with lupus and tailored guidance in vaccination and testing for COVID and making appointments.
62809471|NCT05243875|ACTIVE_COMPARATOR|Education|COVID education for people with lupus.
62809472|NCT05208905|EXPERIMENTAL|Esprit BTK|Participants who receives Esprit BTK device will be included in this arm
62233303|NCT03267940|EXPERIMENTAL|Expansion Portion: PEGCISGEMATEZO Once Weekly/Twice Weekly|After the implementation of Protocol Amendment #3 and as communicated to the Investigators via a letter dated 22 March 2019, participants will receive 3.0 mcg/kg PEGPH20 on Days 1, 4, 8, 11, 15 and 18 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 Cycle 1) plus 25 mg/m\^2 of CIS and 1000 mg/m\^2 GEM on Days 2 and 9 of Cycle 1 (cycle length = 21 days) by IV infusion. Participants will receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m\^2 of CIS and 1000 mg/m\^2 GEM on Days 2 and 9 of each 21-day cycle from Cycle 2 and beyond by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
62809473|NCT06090604|EXPERIMENTAL|Control of lateral COM motion during and after walking practiced in the MAE|"For Aim 1a, participant's preferred and fast treadmill walking speeds will be determined followed by 2-min of baseline walking. Each participant will perform eight 2-min trials of treadmill walking 1) Null Environment: no forces, 2) MAE Low Gain: 25 Nsm-1, 3) MAE Medium Gain: 35 Nsm-1, 4) MAE High Gain: 45 Nsm-1, that will be repeated at both treadmill walking speeds. The trial order will be randomized.~For Aim 1b, we will assess participant's maximum ability to control their lateral COM motion with no forces applied, using three 21-meter walking trials with visual projections on the treadmill to provide feedback used to challenge their lateral COM motion control. Five 2-min trials in a Null environment will be followed by COM control assessment. Participants will rest and repeat the above sequence in a MAE. The order of the external environments will be randomized across participants.~Participants may participate in more than one aim (1a, 1b and 2)."
62809474|NCT04458155||Chest pain patients|"Patients are eligible for participation if they are admitted to:~* The cardiac emergency department (ED) because of chest pain for ruling out acute coronary syndrome by troponin analysis~* The Coronary Care Unit (CCU) with a NSTEMI or post-percutaneous coronary intervention (PCI) STEMI.~Troponin analysis will be performed according to standard protocol. From every included patient two capillary blood samples and an extra venous blood sample will be drawn during regularly ordered blood work to evaluate HS cTnI levels obtained with the POC instrument."
62233304|NCT03267940|ACTIVE_COMPARATOR|Expansion Portion: CISGEM|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the run-in portion safe and tolerable, new participants will be enrolled to receive 25 mg/m\^2 CIS and 1000 mg/m\^2 GEM on Days 1 and 8 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
62233305|NCT05429333|NO_INTERVENTION|Control group|After randomization control group was recommended to continue their regular diet with increased fluid (2 lt/day) and fiber intake (30 g/day) and received 5 mg of sodium picosulfate daily for 10 weeks.
62424342|NCT04808765|EXPERIMENTAL|VAC group|A randomized group of patients receiving negative pressure wound therapy dressing (Avelle-ConvaTec) on closed incision
62424343|NCT04808765|ACTIVE_COMPARATOR|ST group|A randomized group of patients receiving standard dressing (sterile gauze and medical tape) on closed incision
62424344|NCT00843063|ACTIVE_COMPARATOR|pantoprazole|pantoprazole 20 mg om and matching placebo nocte
62593171|NCT05531526|PLACEBO_COMPARATOR|Group B - Placebo Comparator|Placebo QD will be administered daily for 52 weeks during the Treatment Phase of the study. In the Extension Phase, all eligible participants who choose to participate will receive AR1001 30 mg QD for 52 weeks.
62809475|NCT03315741|EXPERIMENTAL|Patient centered approach|Drug titration of maximum dose over 3-8 weeks
62809476|NCT00453154|EXPERIMENTAL|Arm I (Combination Chemotherapy + Sunitinib Maintenance)|"Participants will receive the following combination chemotherapy for 4-6 cycles (21 days):~Cisplatin 80 mg/m\^2 by IV over 1 hour on day 1 every cycle OR Carboplatin AUC = 5\* by IV Etoposide 100 mg/m\^2 by IV over 1 hour on days 1, 2, and 3 every cycle~Maintenance: Following 4-6 cycles of combination chemotherapy, start sunitinib at 150 mg on day 1, then 37.5 daily until disease progression."
62424345|NCT00843063|ACTIVE_COMPARATOR|famotidine|Famotidine 40 mg om and nocte
62424346|NCT05409807|EXPERIMENTAL|Classic Ultrasound Guided|Ultrasound guided interscalene nerve block
62424347|NCT05409807|EXPERIMENTAL|Smart Glasses Assisted|Ultrasound guided smart glasses assisted interscalene nerve block
62233306|NCT05429333|EXPERIMENTAL|Treatment group|In the study group, after fecal samples were taken, patients were recommended to continue their regular diet with increased fluid (2 lt/day) and fiber intake (30 g/day) for 4 weeks until the microbiome analysis resulted. During subsequent 6 weeks, they received the personalized microbiome modulatory diet.
62424348|NCT03576469|EXPERIMENTAL|C1-esterase inhibitor [recombinant] (C1-INH-R)|"Single-site, open-label arm to evaluate the benefit of C1-INH-R in subjects on IVIG therapy who experience ADRs. The study will have 2 periods:~* 6 - 8 weeks - subjects will receive 2 infusions of IVIG~* 9 - 12 weeks - subjects will receive 3 infusions of C1-INH-R prior to IVIG infusion"
62424349|NCT05055778|EXPERIMENTAL|SmokfreeTXT|Research version of the publicly available SmokefreeTXT program
62424350|NCT05596552|ACTIVE_COMPARATOR|Bupivacaine-Dexmedetomidine group|
62424351|NCT05596552|ACTIVE_COMPARATOR|Bupivacaine-Fentanyl group|
62424352|NCT04015479|EXPERIMENTAL|Immediate Intervention Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder (72g/day) will be provided for daily consumption during the study period
62593172|NCT04274244|EXPERIMENTAL|Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML|"1. The study participants will first undergo SCALE AND ROOT PLANING. This procedure is the same as that used in the active comparator group and the control group.~2. Eight weeks following the initial therapy, reevaluation of the intrabony defects in the interproximal sites with a clinical probing depth \>5 mm will be performed by radiographs as well as by using William's graduated periodontal probe to confirm the indication for periodontal surgery. Pairs of premolar and molar teeth in the maxilla or the mandible will be randomized to receive the test treatment (REGENERATIVE PERIODONTAL SURGERY with adjunctive hyaluronic acid gel application) or to serve as active comparators (regenerative periodontal surgery with adjunctive enamel matrix derivative application)."
62593173|NCT04274244|ACTIVE_COMPARATOR|Enamel Matrix Proteins|"1. SCALE AND ROOT PLANING~2. REGENERATIVE PERIODONTAL SURGERY: Application of enamel matrix derivative."
62593174|NCT04274244|NO_INTERVENTION|Scale and root planning|Control group: Just SCALE AND ROOT PLANING is performed
62593175|NCT05186246|EXPERIMENTAL|Experimental Combination Cream Group|Subjects were randomized to have combination cream to be applied on one side of the face twice daily post fractional CO2 laser. The subjects were evaluated on day 3 and day 7 post fractional CO2 laser. Combination cream consisted of Spent Grain Wax, Argan Oil, Shea Butter and Saccharide Isomerate cream
62593176|NCT05186246|PLACEBO_COMPARATOR|Placebo comparator|Subjects were randomized to have placebo cream to be applied on the other side of the face twice daily post fractional CO2 laser. Placebo cream were packaged in identical-looking containers with combination cream. The subjects were evaluated on day 3 and day 7 post fractional CO2 laser.
62593177|NCT06575179|PLACEBO_COMPARATOR|Control group|The control group received volume-matched 0.9% saline infusions at identical rates.
62593178|NCT06575179|EXPERIMENTAL|Low-dose dexmedetomidine group|The low-dose dexmedetomidine group received a 75 μg/h loading dose over 15 minutes, followed by 60 μg/h maintenance infusion intravenously.
62233307|NCT02308826|EXPERIMENTAL|Turtle Program|The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
62424353|NCT04015479|ACTIVE_COMPARATOR|Wait-list Control Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder will be provided after the study period
62424354|NCT03540407|EXPERIMENTAL|Oncoxin-Viusid®|will receive the Oncoxin-Viusid® (oral solution) concomitant to the onco-specific treatment.
62424355|NCT03540407|PLACEBO_COMPARATOR|Placebo|will receive a Placebo concomitant to the onco-specific treatment
62233308|NCT02308826|ACTIVE_COMPARATOR|Cool Little Kids|A 6-week parent psychoeducation group administered over an 8-week period.
62233309|NCT04308525||ERAS Group|Prospectively included patients after introduction of an ERAS programme
62233310|NCT04308525||Control group|We retrospectively evaluated our procedures for the period 2014-2016
62233311|NCT05062083|EXPERIMENTAL|Participants with multiple sclerosis|Participants had two brain positron emission tomography (PET) scan visits. In one visit, participants had a baseline \[11C\]PS13 scan followed by a second \[11C\]PS13 scan after blockade with ketoprofen 75 mg orally. In another visit, participants had baseline \[11C\]MC1 scan followed by a second scan with \[11C\]MC1 after blockade by a dose of celecoxib 600 mg orally. Participants receive injection of up to 20 millicurie (mCi) of \[11C\]PS13 or \[11C\]MC1 during each scan.
62233312|NCT04221386|EXPERIMENTAL|MIT group|Subjects will receive the developed Melodic Intonation Therapy.
62593179|NCT06575179|EXPERIMENTAL|High-dose dexmedetomidine group|The high-dose dexmedetomidine group received a 150 μg/h loading dose over 15 minutes, followed by 120 μg/h maintenance infusion intravenously.
62593180|NCT04410016|EXPERIMENTAL|Staff Wellbeing Centre|Wellbeing Centres are rooms where staff employed at the hospital trust can go for a break, rest, relaxation, quiet time out, advice support or signposting. They are manned by Wellbeing Buddies who are support workers who offer advice and signposting services. The Centres are accessible to all staff at the Trust.
62233313|NCT04221386|NO_INTERVENTION|Control group|Subjects will not receive any intervention.
62233314|NCT03411460|EXPERIMENTAL|Interstitial glucose|Glucose level tested by continuous monitoring device
62233315|NCT03411460|ACTIVE_COMPARATOR|Blood glucose|Glucose level tested on glucose monitor using standard finger prick
62593181|NCT04711928||Trained athletes|Active individuals with at least 4 training hours per week.
62809477|NCT00453154|ACTIVE_COMPARATOR|Arm II (Combination Chemotherapy + Placebo Maintenance)|"Participants will receive the following combination chemotherapy for 4-6 cycles (21 days):~Cisplatin 80 mg/m\^2 by IV over 1 hour on day 1 every cycle OR Carboplatin AUC = 5\* by IV Etoposide 100 mg/m2 by IV over 1 hour on days 1, 2, and 3 every cycle~Maintenance: Following 4-6 cycles of combination chemotherapy, start placebo at 150 mg on day 1, then 37.5 daily until disease progression."
62809478|NCT00624949||1|women with Turner syndrome
62233316|NCT04612387|EXPERIMENTAL|Mind-body Intervention arm|Online yoga, meditation and nutrition tips.
62233317|NCT04942093|EXPERIMENTAL|With diet|A low-calorie, high-protein diet will be prescribed to the patient for a period of 4 weeks. The diet will be done the 4 weeks before the bariatric surgery
62233318|NCT04942093|OTHER|Without diet|A low-calorie, high-protein diet will not be prescribed to the patient for a period of 4 weeks.
62233319|NCT02742623||Rivaroxaban|Female and male patients with active cancer and treated with rivaroxaban after a diagnosis of DVT/ and/or PE
62809479|NCT00624949||2.|Control women
62233320|NCT03956823|EXPERIMENTAL|Telmisartan|generic name：telmisartan；dosage form：80 mg；dosage：80 mg；frequency：once a day；duration：June , 2019-June , 2021
62233321|NCT03956823|ACTIVE_COMPARATOR|Amlodipine|generic name： amlodipine；dosage form：5mg；dosage：5mg；frequency：once a day；duration：June , 2019-June , 2021
62809480|NCT03636074||Hearth-valve surgery|
62809481|NCT03636074||Hearth bypass surgery|
62233322|NCT04409886|EXPERIMENTAL|HBOT (Hyperbaric Oxygen Therapy)|Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)
62233323|NCT03077360|EXPERIMENTAL|Weight loss only|
62233324|NCT03077360|EXPERIMENTAL|Exercise Only|
62233325|NCT03077360|NO_INTERVENTION|Delayed Intervention Control|
62233326|NCT03240757|ACTIVE_COMPARATOR|Breakfast without exercise|Each subject of the same arm underwent 2 interventions: breakfast with/without exercise
62233327|NCT03240757|EXPERIMENTAL|Breakfast with exercise|Each subject of the same arm underwent 2 interventions: breakfast with/without exercise
62233328|NCT04532372|EXPERIMENTAL|Phase I (leflunomide, SOC)|Patients receive leflunomide PO QD on days 1-14. Patients may receive SOC drugs in addition to leflunomide.
62233329|NCT04532372|EXPERIMENTAL|Phase II Arm I (leflunomide, SOC)|Patients receive leflunomide PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive SOC.
62424356|NCT04949984|EXPERIMENTAL|Bright light therapy|The devices used for the intervention were bright white light lamps providing an intensity of 10,000 lux. Four users participated in each session, placing two users per lamp, seated in a comfortable chair with armrests 70 cm from the lamp. The sessions were 30 minutes/day in the time slot between 10:30 and 12:00 in the morning, 5 days a week (Monday to Friday) for 4 weeks (total 20 sessions). Two groups of participants per day were established, the first shift being from 10:30 to 11:00, and the second from 11:15 to 11:45 a.m., which means the stimulation of 8 people per day (month). During the sessions, while exposed to light, participants were watching documentaries on neutral topics (nature, Spanish and Galician culture, etc.).
62424357|NCT04949984|NO_INTERVENTION|Control group|Participants were evaluated before and after the experimental group finishes the intervention program (pre- vs. postintervention) to facilitate an examination of the changes in the outcome measures.
62424358|NCT01079078|EXPERIMENTAL|Test|Acetaminophen extended release gelcaps 650 mg of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
62424359|NCT01079078|ACTIVE_COMPARATOR|Reference|Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)of McNeil Consumer \& Specialty Pharmaceuticals, Division of MCNEIL-PPC, Inc. Fort Washington, PA 19034 USA
62424360|NCT04167280|ACTIVE_COMPARATOR|Ipratropium bromide|20mcg bronchodilator inhaler
62424361|NCT04167280|PLACEBO_COMPARATOR|placebo|matching bronchodilator inhaler
62433592|NCT04819347|EXPERIMENTAL|Early treatment of infection|"HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) within 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA \<50 copies/mL for at least 12 months.~Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks."
62593182|NCT03505593|EXPERIMENTAL|EFT placement using ENVUE System|Placement of the ENvizion Medical™ Enteral Feeding Tube (EFT) in the stomach or small intestine of adult patients who require feedings via the oro/ nasoenteric route, using the ENVUE™ System.
62593183|NCT02716831|EXPERIMENTAL|Counseling & Acceptance-based Therapy|Nutritional Counseling \& Acceptance-based Therapy (N-CAAT) incorporates acceptance-based behavioral strategies and nutritional counseling designed to encourage willingness to tolerate distress and the ability to pursue chosen values in an adaptive manner despite distressing internal experiences. In addition to these skills, a principal focus of the treatment will be on identifying, practicing, and achieving behavioral goals, such as normalization of eating, reduction of maladaptive dietary restraint and restriction, and elimination of compensatory behaviors.
62433593|NCT04819347|EXPERIMENTAL|Chronic period of infection treatment|"Chronically HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) after 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA \<50 copies/mL for at least 12 months.~Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks."
62809482|NCT06368102|EXPERIMENTAL|1day-group|Participants will receive 1g of IV ampicillin before surgery and 1 time after surgery on the day of surgery (total 2g)
62233330|NCT04532372|PLACEBO_COMPARATOR|Phase II Arm II (placebo, SOC)|Patients receive placebo PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive SOC.
62233331|NCT03442985|EXPERIMENTAL|Palovarotene 2.5 mg daily regimen|
62233332|NCT03442985|EXPERIMENTAL|Palovarotene 5.0 mg daily regimen|
62233333|NCT03442985|PLACEBO_COMPARATOR|Placebo regimen|
62233334|NCT05090215|ACTIVE_COMPARATOR|Exercise intervention group|2 resistance training session per week using a home-based resistance training pack and 75 minutes of vigorous or 150 minutes of moderate aerobic exercise per week (as per UK government guidelines) for 12 weeks. They will have 4 assessment points, pre-op, prior to the start of the exercise programme postoperatively, at 6 weeks post commencement of exercise and at 12 weeks to conclude the study. The assessment will include bloods, cardiopulmonary exercise testing, muscle ultrasound to ascertain muscle structure, functional composite scores and quality of life questionnaires.
62233335|NCT05090215|PLACEBO_COMPARATOR|Control group|This group will receive standard postoperative care. They will also have 4 assessment points, pre-op, prior to the start of their standard postoperative care, 6 and finally 12 weeks later to conclude the study. The assessment will include bloods, cardiopulmonary exercise testing, muscle ultrasound to ascertain muscle structure, functional composite scores and quality of life questionnaires.
62233336|NCT02401360|EXPERIMENTAL|Experimental Group|Oral care regimen
62233337|NCT02401360|PLACEBO_COMPARATOR|Control Group|Toothbrush and toothpaste
62233338|NCT04861025||Users Group|Patients admitted to any Hospitalization Unit belonging to Geriatrics Department
62233339|NCT04861025||Health Professionals Group|All health professionals working at some Hospitalization Unit belonging to CSAPG Institution
62233340|NCT02740972|EXPERIMENTAL|NS-065/NCNP-01 40mg/kg|Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 40mg/kg dose once a week for 24 weeks
62809483|NCT06368102|EXPERIMENTAL|2day-group|Participants will receive 1g of IV ampicillin before surgery and 2 times after surgery up to the next day (total 3g)
62809484|NCT03812380|EXPERIMENTAL|EffCaMgCit|19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate; designed to be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. Each sachet of EffCaMgCit will contain 400 units of vitamin D.
62233341|NCT02740972|EXPERIMENTAL|NS-065/NCNP-01 80mg/kg|Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 80mg/kg once a week for 24 weeks
62593184|NCT02716831|ACTIVE_COMPARATOR|Cognitive Therapy for Eating Disorders|Participants in the Cognitive Behavioral Therapy for Eating Disorders (CBT) condition will receive 20-sessions of standard CBT for eating disorders based on the treatment approach developed by Dr. Christopher Fairburn and published in his book Cognitive Behavioral Therapy and Eating Disorders.
62233342|NCT02740972|PLACEBO_COMPARATOR|Placebo|Two patients in each of the dose groups will be administered placebo as an intravenous infusion once a week for 4 weeks followed by 20 weeks of open label treatment
62233343|NCT06312280||Pediatric children and adolescents with obesity or overweight|"The study will include all children and adolescents who visit the SCDU of Pediatrics, Surgery of Endocrinology and Auxology of the Major Charity Hospital of Novara for first visit or checkup for excess weight between 1 January 2024 and 30 May 2024 of both sexes that meet the following criteria of inclusion:~Criteria for inclusion:~Age between 6 and 17 years; BMI compatible with obesity or overweight according to IOTF criteria (6) Signature of informed consent by parents/legal guardians.~Criteria for exclusion:~Age below 6 years or over 18 Previous diagnosis of diabetes mellitus type 2 already placed in dietary or pharmacological therapy Subjects already included in dieto-therapeutic regimen Obesity secondary to diseases: genetic (Prader Willi syndrome, Down syndrome); metabolic and endocrine (Cushing syndrome, hypothyroidism)"
62233344|NCT03136328|EXPERIMENTAL|68Ga-DOTATOC PET/CT|Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study.
62233345|NCT02688283|EXPERIMENTAL|Test-cluster|56g of optimized savory cluster made through a proprietary process with slowly digestible carbohydrates and fiber
62433594|NCT04777773|OTHER|control group|classical physical therapy+ classical physical therapy
62433595|NCT04777773|OTHER|study group|classical physical therapy+ dual-task training
62433596|NCT01021137||TBI & Blast|OEF/OIF Veterans complaining of dizziness and/or imbalance with history of blast exposure and a diagnosis of mild TBI
62593185|NCT05104216|EXPERIMENTAL|Experimental Group|Subjects receive a third dose of inactivated COVID-19 vaccine
62593186|NCT04664478||Subjects with abnormal elastogenesis|Participants with genetic variant in the connective tissue target genes
62593187|NCT06621680|ACTIVE_COMPARATOR|Multivitamins group|This group will receive multivitamins capsule once daily, for 12 weeks.
62593188|NCT06621680|EXPERIMENTAL|Connective tissue massage group|This group will receive multivitamins in addition to connective tissue massage on (Sacral, lumbar, last thoracic vertebrae-T12, and subcostal regions), 2 sessions/week, 20 minutes/ session for 12 weeks
62593189|NCT01077609||Allergic rhinitis (AR) & Flixonase|Patients initiating treatment for allergic rhinitis on intranasal fluticasone propionate
62593190|NCT01077609||AR & prescription for intranasal steroid other than Flixonase|Random sample of patients initiating treatment for allergic rhinitis with an intranasal steroid other than Flixonase
62593191|NCT06523023|EXPERIMENTAL|Treatment group (an integrated online program)|Our intervnetion is an integrated online program using psychoeducation and expressive writing. It is a 10-week program that consists of a 5-week psychoeducation module and a 5-week expressive writing module.
62593192|NCT06523023|OTHER|Waitlist control group|After the treatment group has received and completed the integrated online program, the waitlist control group will receive the same program that is identical in content, procedures, and activities to the one received by the treatment group
62233346|NCT02688283|PLACEBO_COMPARATOR|Control-cluster|56g of control cluster made from general baking process with typical ingredients commonly used in commercially available energy snacks or bars
62433597|NCT01021137||Blast Only|OEF/OIF Veterans complaining of dizziness and/or imbalance with history of blast exposure without TBI
62433598|NCT01021137||TBI Only|OEF/OIF Veterans complaining of dizziness and/or imbalance with a history of mild TBI and no blast exposure
62593193|NCT00757458|ACTIVE_COMPARATOR|1|TCI with EDTA
62593194|NCT00757458|ACTIVE_COMPARATOR|2|Re-filling of propofol syringe (Diprivan®-Astra Zeneca) with propofol containing EDTA
62233347|NCT02688283|PLACEBO_COMPARATOR|White-bread|45g of white bread containing equivalent amount of available carbohydrate in 56g of optimized savory cluster
62593195|NCT00757458|ACTIVE_COMPARATOR|3|Re-filling of propofol syringe (Diprivan®-Astra Zeneca) with propofol without EDTA
62424362|NCT04356092|EXPERIMENTAL|Perfusion|Consecutive patients scheduled to undergo infrapopliteal angioplasty or stenting, or both, as part of their standard treatment for Rutherford-Becker class 5 and 6 chronic limb-threatening ischemia, were included in the study. All procedures were performed using local anesthesia. An antegrade access was used in all patients followed by the deployment of a 5 or 6 Fr arterial sheaths. A semi-lateral foot projection was preferred and the pre-revascularization DSA of the foot was performed via a 5 Fr angiographic catheter placed at the distal third of the popliteal artery. Following revascularization of one or more tibial arteries, the catheter was placed at the same popliteal segment and post-procedural DSA of the foot was performed following the exact pre-revascularization injection protocol at the same semi-lateral projection. The 2D-perfusion imaging and analysis of the DICOM files was performed after revascularization.
62424363|NCT03336645|EXPERIMENTAL|SHP615|Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram \[mg/kg\] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
62424364|NCT04261517|EXPERIMENTAL|Hydroxychloroquine and conventional treatments|After randomization, subjects take hydroxychloroquine 400mg per day for 5 days, also take conventional treatments.
62424365|NCT04261517|NO_INTERVENTION|Conventional treatments|After randomization, subjects take conventional treatments without hydroxychloroquine.
62424366|NCT04193033|EXPERIMENTAL|FLOW intervention|Sites receive the FLOW program, including internal and external facilitation, use of the FLOW online report to identify patients, patient and provider education materials, a medical record template, and regular data tracking and feedback about the process.
62433599|NCT01021137||Healthy Controls|Age and gender matched control participants with no complaints of dizziness and/or imbalance or history of TBI or blast exposure
62593196|NCT00757458|ACTIVE_COMPARATOR|4|Target controlled infusion of propofol without EDTA
62593197|NCT01292694|EXPERIMENTAL|Losartan|Angiotensin II AT1 receptor antagonist which blocks the actions of angiotensin II
62593198|NCT01292694|EXPERIMENTAL|Captopril|ACE inhibitor which blocks the formation of angiotensin II
62593199|NCT01292694|PLACEBO_COMPARATOR|Placebo Tablet|A placebo tablet will be provided by the Vanderbilt Investigational Drug Service for these studies.
62593200|NCT06668285|SHAM_COMPARATOR|Control|The group in which the routine functioning of the clinic is applied and caregivers are not admitted to the recovery room
62233348|NCT02271425|EXPERIMENTAL|Evacetrapib Tablet + Evacetrapib Intravenous|A single oral dose of 130 milligrams (mg) evacetrapib tablet + a single intravenous (IV) dose of 175 micrograms (μg)\[¹³C₈\] evacetrapib administered over a 4 hour infusion.
62233349|NCT00171704|EXPERIMENTAL|Letrozole|2.5 mg once daily (q.d.)orally for 5 years
62233350|NCT00171704|EXPERIMENTAL|Tam-Let|20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.
62593201|NCT06668285|EXPERIMENTAL|family group|The group in which caregivers are admitted to the recovery room
62593202|NCT04033341|EXPERIMENTAL|LY3214996 + [14C]-LY3214996|A single dose of LY3214996 and \[14C\]-LY3214996 administered orally.
62593203|NCT04917458|EXPERIMENTAL|Cholecalciferol|-Vitamin D 25 (OH) 4000 IU capsules, tablet @ 1000 IU One capsule for once a day for 30 days of study period.
62593204|NCT04917458|PLACEBO_COMPARATOR|Control Group|Placebo will be administrated orally, One capsule once a day for 30 days of study period
62593205|NCT05757427|EXPERIMENTAL|All patients will have an MBI scan with Wavelia #2 in addition to standard reference imaging.|Patients with an investigator assessed discrete breast abnormality of size \>1cm and who attend the symptomatic breast unit for assessment as per standard of care protocol will be considered for participation in this clinical investigation.
62593206|NCT05400070|EXPERIMENTAL|neoadjuvant therapy|Sintilimab (200mg fixed dose) iv, d1, q3w，anlotinib 10mg, po, qd1-14, q3w combine with Chemotherapy
62593207|NCT04097795||Prehabilitation|Patients aged 70 years and above or with an American Society of Anesthesiologists (ASA) score of III, who are scheduled for colorectal cancer surgery in one of the participating hospitals which offer prehabilitation.
62593208|NCT04097795||No prehabilitation|Patients aged 70 years and above or with an American Society of Anesthesiologists (ASA) score of III, who are scheduled for colorectal cancer surgery in one of the participating hospitals which do not offer prehabilitation.
62233351|NCT02820337||non comparative|Bariatric surgery patients infected with HIV, overweight with controlled viral load and HIV lipohypertrophy particularly truncal
62233352|NCT01236651|EXPERIMENTAL|meperidine and duration of 1st stage of labor|meperidine 100mg i.v in 1st stage of labor and calculate the duration of the 1st stage of labor
62233353|NCT01236651|EXPERIMENTAL|drotaverine and duration of 1st stage of labor|drotaverine 40mg i.v in 1st stage of labor and calculate the duration of the 1st stage of labor
62593209|NCT03194750|EXPERIMENTAL|Share Data|
62593210|NCT03194750|ACTIVE_COMPARATOR|Do Not Share Data|
62593211|NCT06358846|NO_INTERVENTION|standard care advice|The control group will simply get standard advice from clinicians at the clinic during consultations.
62233354|NCT02902627|EXPERIMENTAL|Metastatic cancer|
62233355|NCT04358900||Mood disorder group|Participants must meet criteria for one of the following disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 criteria (52): major depressive disorder (MDD), persistent depressive disorder (PDD), bipolar disorder (BD) type I/type II, cyclothymia. Multiple mood disorders are employed, in line with the Research Domain Criteria (RDoC; (53)) framework and the relative imprecision of current symptom diagnostic clusters for tracking treatment responses and course of disease. To ensure adequate representation across diagnostic categories (including controls), the investigators will cap enrollment of major mood disorders (MDD, BD type I/II) to 50%, PDD and cyclothymia to 25% and recruit a healthy comparison group to comprise the remaining 25% of the sample.
62424367|NCT04193033|NO_INTERVENTION|Waitlist until Time 2|Arm 2: In this stepped wedge design, sites will be randomized to receive the FLOW intervention at Time 1, or to be in a waitlist until Time 2.
62233356|NCT04358900||Control group|Participants who do not meet the Diagnostic and Statistical Manual of Mental Disorders-5 criteria for (52): major depressive disorder (MDD), persistent depressive disorder (PDD), bipolar disorder (BD) type I/type II, or cyclothymia.
62233357|NCT06503562|OTHER|Traditional Physiotherapy Program|
62233358|NCT06503562|EXPERIMENTAL|Traditional Physiotherapy Program and central nervous system focused treatment program|
62233359|NCT00551460|EXPERIMENTAL|Treatment|"Induction:~ATRA 45mg/m2 PO D1-CR Gemtuzumab Ozogamicin 9 mg/m2 IV D1 Arsenic Trioxide 0.15 mg/kg/d IV 5days/wk D10-CR~Consolidation 1 and 2:~Arsenic Trioxide 0.15 mg/kg/d IV 5days/wk x 5 weeks, repeat after 2 weeks rest~Consolidation 2 and 3:~ATRA 45 mg/m2 PO D1-7 Daunomycin 50 mg/m2/d IV D1-3~Consolidation 5 and 6:~GO 9mg/m2 IV D1~Maintenance:~ATRA 45 mg/m2/d PO D1-7 every 14 days 6-MP 60 mg/m2/d PO daily for 1 year Methotrexate 20 mg/m2 PO once/wk for 1 year"
62233360|NCT00353379|EXPERIMENTAL|guanfacine|Participants will take guanfacine.
62233361|NCT00353379|PLACEBO_COMPARATOR|placebo|Participants will take placebo.
62233362|NCT01136772|EXPERIMENTAL|Paliperidone palmitate|Intramuscular injections of paliperidone palmitate 39-234 mg every month
62233363|NCT01136772|ACTIVE_COMPARATOR|Haloperidol decanoate|Intramuscular injections of haloperidol decanoate 25-200 mg every month
62233364|NCT04893954|OTHER|Obese patients|
62233365|NCT04615247|EXPERIMENTAL|Yoga Program|The study yoga intervention is designed to provide instruction and practice in selected yoga postures and techniques chosen by an expert panel for their potential to improve pelvic pain in women.
62233366|NCT04615247|ACTIVE_COMPARATOR|Physical Conditioning Program|A low-impact, muscle stretching and strengthening program.
62233367|NCT04127149|EXPERIMENTAL|Group with ultrasound|The first group consists of nine general practitioners having received a brief training on the use of ultrasound scanners in general practice. The general practitioner includes all adult patients who are consulting for one of the 8 medical conditions studied and perform an ultrasound scan. Two weeks later, he/she calls each patient to collect the necessary data.
62424368|NCT04193033|NO_INTERVENTION|Waitlist until Time 3|Arm 3: In this stepped wedge design, sites will be randomized to receive the FLOW intervention at Time 1, or to be in a waitlist until Time 3.
62593212|NCT06358846|EXPERIMENTAL|standard care advice+ structured training through pictures containing learning pamphlet|Interventional group will receive standard advice from clinician along with the structured training from qualified diabetes' educator through pictures containing learning pamphlet
62424369|NCT02688101|EXPERIMENTAL|DpC|DpC capsules, administered orally
62233368|NCT04127149|NO_INTERVENTION|Group without ultrasound|The second group consists of nine general practitioners. Each physician includes all adult patients who are consulting for one of the 8 medical conditions studied and performs a standard consultation. Two weeks later, he/she calls each patient to collect the necessary data.
62233369|NCT04367987||Patients undergoing colorectal surgery|
62233370|NCT06406556|EXPERIMENTAL|Patients diagnosed with early ENKTL.|Patients received 4 cycles of pegaspargase including CCRT ( involved field radiotherapy 50GY, concurrent 2 cycles of pegaspargase treatment ).
62233371|NCT01919710|EXPERIMENTAL|rHSA/GCSF for injection|rHSA/GCSF Start from 300mcg
62233372|NCT00822588|EXPERIMENTAL|1|
62233373|NCT00822588|NO_INTERVENTION|2|
62233374|NCT00639912|ACTIVE_COMPARATOR|A: low volume saline|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 1 ml/kg/hour for 12 hours after the procedure, starting in the Cath Lab.
62233375|NCT00639912|ACTIVE_COMPARATOR|B: high volume saline|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath lab.
62233376|NCT00639912|ACTIVE_COMPARATOR|C: low volume sodium bicarbonate|Solution of 154 mEq/L of sodium bicarbonate. Rate of infusion: 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath Lab.
62424370|NCT04477317|EXPERIMENTAL|Experimental|4% Articaine Hydrochloride with 1:100,000 Adrenaline (Alexadricaine, Alexandria Co., Egypt).
62424371|NCT04477317|ACTIVE_COMPARATOR|Control|2% Mepivacaine Hydrochloride with 1:20,000 Levonordefrin (Mepicaine-L, Alexandria Co., Egypt)
62424372|NCT03087773|ACTIVE_COMPARATOR|Empagliflozin|The subjects will receive Empagliflozin 10mg.
62424373|NCT03087773|PLACEBO_COMPARATOR|Placebo Oral Tablet|The subjects will receive placebo.
62424374|NCT01393548|EXPERIMENTAL|brompheniramine + phenylephrine|Fixed dose combination of brompheniramine + phenylephrine
62593213|NCT01326468|EXPERIMENTAL|Cohort A - Temsirolimus with Cisplatin|Temsirolimus with cisplatin, Erbitux and radiation therapy
62593214|NCT01326468|EXPERIMENTAL|Cohort B - Temsirolimus|Temsirolimus with Erbitux and radiation therapy
62593215|NCT04699110|EXPERIMENTAL|Treatment group|Patients receiving intracoronary adrenaline
62593216|NCT04699110|ACTIVE_COMPARATOR|Control group|Patients receiving intracoronary adenosine
62593217|NCT05659979|EXPERIMENTAL|Comprehensive Geriatric Assessment|This group will receive a comprehensive geriatric assessment evaluation during the study, using the multidimensional prognostic index
62593218|NCT05659979|NO_INTERVENTION|Controls|This group will receive standard/usual care
62233377|NCT00639912|ACTIVE_COMPARATOR|D: high volume sodium bicarbonate|Solution of 154 mEq/L of sodium bicarbonate. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath Lab.
62233378|NCT01074671|OTHER|No control arm|There is no control arm as part of the study design.
62233379|NCT01177787|ACTIVE_COMPARATOR|zeltiq|Cryolipolysis had been done for 1 hour on ipsilateral thigh fat through Zeltiq machine.
62233380|NCT01177787|SHAM_COMPARATOR|electrical stimulation|Lipolysis had been done for 30 minutes on controlateral thigh fat through amplitude modulated frequency.
62233381|NCT04777526|ACTIVE_COMPARATOR|Control group|"Thumb orthosis at night. Daily exercises program during 4 weeks grouped in 3 sets of 10 repetitions in absence of pain. Exercises will consisted of active~- resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle."
62233382|NCT04777526|EXPERIMENTAL|Experimental group|The experimental group will also carried out a proprioceptive exercise program divided in three phases of 2 weeks per phase.
62233383|NCT00649090|ACTIVE_COMPARATOR|Exemestane group|
62233384|NCT03225495|ACTIVE_COMPARATOR|Standard Implant|
62233385|NCT03225495|EXPERIMENTAL|Ultra-narrow Implant|
62233386|NCT06411483|ACTIVE_COMPARATOR|Active Band|Participants in this group will receive an active band which provides electrostimulation at PC6
62233387|NCT06411483|PLACEBO_COMPARATOR|Placebo|Participants in this group will receive an inactive band which does not provide any electrostimulation when turned on.
62233388|NCT02732054|ACTIVE_COMPARATOR|HIV-Group 1|Receiving three intramuscular injections of 20 µg of recombinant hepatitis B vaccine \[(CIGB) La Habana, Cuba\] at months 0, 1, and 6
62424375|NCT01393548|ACTIVE_COMPARATOR|brompheniramine + pseudoephedrine|Fixed dose combination of brompheniramine + pseudoephedrine
62424376|NCT06099041|OTHER|ND-YAG Laser for iris depigmentation|ND-YAG Laser for iris depigmentation
62424377|NCT05371418|EXPERIMENTAL|guided regeneration (GTR) followed by orthodontic intrusion|Ten over erupted teeth were selected with an angular bone loss with presence of their opposing for spilt mouth study aged from 20- 35 years old, were treated by GTR followed by Orthodontic intrusion
62593219|NCT05627310||Training Cohort|Nasopharyngeal endoscopic images collected from 8 hospitals all over China
62593220|NCT05627310||Validation Cohort|Nasopharyngeal endoscopic images collected from 8 hospitals all over China
62593221|NCT05627310||Testing Cohort|Nasopharyngeal endoscopic images prospectively collected from 8 hospitals all over China
62593222|NCT03909750|EXPERIMENTAL|Lipoaspiration Microcannula ARM 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
62593223|NCT03909750|EXPERIMENTAL|Isolation-Concentration Adipose cSVF ARM 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
62593224|NCT03909750|EXPERIMENTAL|Normal Saline IV ARM 3|Sterile Normal Saline IV with cSVF
62593225|NCT00749684||Adults with malignant melanoma at high risk of relapse|"Adults with malignant melanoma of the following stages:~* II and III (\>/= 1.5 mm Breslow thickness without distant metastases~* melanoma with lymph node metastases"
62593226|NCT02338297|EXPERIMENTAL|TACE+EGM|Occlude APS with EGM and perform TACE sequentially
62593227|NCT02338297|ACTIVE_COMPARATOR|TACE+PVA|Occlude APS with PVA and perform TACE sequentially
62233389|NCT02732054|EXPERIMENTAL|HIV-Group 2|Receiving four intramuscular injections of 20 µg of recombinant hepatitis B vaccine \[(CIGB) La Habana, Cuba\] at months 0, 1, 2, and 6
62233390|NCT01243697|EXPERIMENTAL|desogestrel|Tablets of 75 µg, once daily during 112 days
62593228|NCT03784144|EXPERIMENTAL|Cognitive Strategy|Performing a mathematical subtracting task (starting at 300, by sevens)
62593229|NCT03784144|ACTIVE_COMPARATOR|Control|The patients will perform both tests without any cognitive condition
62233391|NCT04598204|EXPERIMENTAL|Treatment Arm|To treat the enrolled patients with oral rapamycin at an initial dosage of 0.8mg/m2, once daily for children under 3 years old and twice daily (every 12 hours) for those above 3 years, and adjust the dosage to target a trough concentration of rapamycin in plasma as 10-15ng/ml （OR 15-20ng/ml if the efficacy of treatment is not satisfactory）. One course lasts for 12weeks and no more than 4 course is given.
62233392|NCT05031208|EXPERIMENTAL|Vagus nerve stimulation|Invasive vagus nerve stimulation
62233393|NCT05031208|EXPERIMENTAL|Transcutaneous vagus nerve stimulation|Cymba concha stimulation
62233394|NCT05031208|SHAM_COMPARATOR|Sham vagus nerve stimulation|No vagus nerve stimulation
62424378|NCT05371418|EXPERIMENTAL|Orthodontic intrusion followed by GTR|Ten over erupted teeth were selected with an angular bone loss with presence of their opposing for spilt mouth study aged from 20- 35 years old, were treated by orthodontic intrusion followed by GTR
62593230|NCT05970276|EXPERIMENTAL|Deep Sleep Enhancement with TES|Transcranial Electrical Stimulation, 0.5 Hz sine wave, 0.5 mA, between frontal (frontopolar and inferior lateral frontal) and posterior (mastoid and occipital) electrodes.
62593231|NCT00746824|EXPERIMENTAL|1|"AM dose: 0.85 mg~PM dose: placebo"
62593232|NCT00746824|EXPERIMENTAL|2|"AM dose: 0.85 mg~PM dose: 0.85 mg"
62593233|NCT00746824|EXPERIMENTAL|3|"AM dose: 2.55 mg~PM dose: placebo"
62593234|NCT00746824|EXPERIMENTAL|4|"AM dose: placebo~PM dose: 2.55 mg"
62233395|NCT00807235|EXPERIMENTAL|Regimen 1|
62233396|NCT00807235|EXPERIMENTAL|Regimen 2|
62233397|NCT04888325|EXPERIMENTAL|Oral glucose|ORal glucose consumption 1.25 grams/kg in 200 ml water at time 0 and the same amount again at 3 hours
62233398|NCT04888325|EXPERIMENTAL|Intravenous glucose|0% intravenous glucose infusion at a rate of 3.6 ml/kg/h
62233399|NCT01762722|EXPERIMENTAL|Desaturation|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
62233400|NCT00815672|NO_INTERVENTION|Treatment Arm 1|Usual Care: Standard care monitoring
62233401|NCT00815672|EXPERIMENTAL|Treatment arm 2|Home-based Exercise: Progressive walking and resistance exercise treatment.
62233402|NCT02917278|EXPERIMENTAL|Meals|High-protein renal-specific meals
62233403|NCT02917278|NO_INTERVENTION|Control|No Meals
62233404|NCT03797079|ACTIVE_COMPARATOR|Group A (ESP block)|Ultrasound-guided ESP block will be performed under strict aseptic precautions with patient in the sitting position. Catheter insertion will be performed and bupivacaine will be administered.
62424379|NCT03154931|ACTIVE_COMPARATOR|CBT-SG|This CBT-Supportive group will focus on the interaction here-and-now, realizing that the group acts as a secure place, driven by interactions among its participants and therapist and co-therapist. The main objective is to welcome and support the participation of all patients and stimulate the group's initiatives, encouraging interpersonal interactions and mutual aid. There will be no specific therapeutic intervention in relation to any PTSD related content.
62424380|NCT03154931|EXPERIMENTAL|CFT-G|This CFT-group will focus on activities using specific therapeutic strategies, to learn and training compassionate skills - psychoeducation and exercises developed for use in session and at home.They will learn What is compassion and shame? Steps to the training of compassion and how Building a compassionate image. Will use Thoughts Daily Record - self critical and self compassionate. Explanation of Formulation of Strategy Threats and Security, The Three Emotional regulation systems and PTSD formulation - based on shame and guilt. They will learn how to incorporate these skills to everyday situations. At the end, will write an Autobiography writing about this experience and share with the group.
62424381|NCT02350322|EXPERIMENTAL|Schoolmeal with fatty fish|Fatty fish diet
62424382|NCT02350322|EXPERIMENTAL|Schoolmeal without fish|Meat/cheese diet (non-seafood)
62424383|NCT02350322|EXPERIMENTAL|Supplement|Omega-3 capsules
62424384|NCT02380066|EXPERIMENTAL|Anyu Peibo 0.4g per day|Anyu Peibo Capsule, oral, 0.2g twice per day
62424385|NCT02380066|EXPERIMENTAL|Anyu Peibo 0.8g per day|Anyu Peibo Capsule, oral, 0.4g twice per day
62424386|NCT02380066|EXPERIMENTAL|Anyu Peibo 1.2g per day|Anyu Peibo Capsule, oral, 0.6g twice per day
62424387|NCT02380066|EXPERIMENTAL|Anyu Peibo 1.6g per day|Anyu Peibo Capsule, oral, 0.8g twice per day
62424388|NCT02380066|PLACEBO_COMPARATOR|Placebo|Placebo,oral, twice per day
62593235|NCT00746824|EXPERIMENTAL|5|"AM dose: 2.55 mg~PM dose: 2.55 mg"
62593236|NCT00746824|EXPERIMENTAL|6|"AM dose: placebo~PM dose: placebo"
62593237|NCT02270359|OTHER|MI without obstructive CAD|MI without obstructive CAD, with OCT and CMR imaging
62424389|NCT03448601|NO_INTERVENTION|Non-tailored control group|Participates will read the standard Alzheimer's disease and Precision Medicine brochure with standard text-based content NOT specifically tailored for AI/ANs.
62424390|NCT03448601|EXPERIMENTAL|Culturally tailored video intervention group|Participants will view a short 5-minute culturally-tailored video.
62424391|NCT03448601|EXPERIMENTAL|Culturally tailored brochure intervention group|Participants will read a culturally-tailored educational brochure on Alzheimer's disease and Precision Medicine.
62433600|NCT01021137||Excluded|Participants who did not meet inclusion criteria, did not return to complete evaluation, and/or were excluded from data analysis.
62593238|NCT05711056|EXPERIMENTAL|Sociobehavioral program Group|A novel sociobehavioral collaborative program that will improve the health of individuals in rural areas by expanding access to MOUD through an ED- based telemedicine strategy. Researchers will prospectively study a poison center OUD consultation and peer recovery coach (PRC) intervention as it is rolled out at each site, collecting participant-level data at baseline, one week post intervention and 30 days post intervention.
62593239|NCT05711056|NO_INTERVENTION|Control Group|Patients who are seen at a participating hospital prior to the initiation of the intervention will be considered controls.
62593240|NCT04243473||Prostate Biopsy, Urine sample and Blood sample|For purposes of exploratory analyses, blood (whole blood, serum, plasma) and urine samples will be collected pre-IR treatment, 1-month post-implant, 6 month follow-up and 2 years follow-up. Patients will be asked to opt-in on the consent form specifically for the 2-year biopsy, otherwise they have the choice to opt out.
62233405|NCT03797079|ACTIVE_COMPARATOR|Group B (TEA)|TEA will be performed under strict aseptic precautions with patient in the sitting position. Catheter insertion will be performed and bupivacaine will be administered.
62233406|NCT02782130|ACTIVE_COMPARATOR|Intervention Group|Subjects randomized to the Epic Allies Intervention will download and install the intervention branch of the Epic Allies app and receive a tour of the app guided by site staff. During the 26-week intervention phase, intervention arm subjects will receive daily adherence reminders set up through Epic Allies with tailored feedback for encouragement and reinforcement. Intervention arm subjects will have 24-hour access to all features of Epic Allies and will receive supportive messages from other subjects on the intervention arm.
62593241|NCT03134534|OTHER|VATS group|Surgical procedure: VATS lobectomy
62593242|NCT03134534|OTHER|RATS group|Surgical procedure: RATS lobectomy
62233407|NCT02782130|PLACEBO_COMPARATOR|Control Group|Subjects randomized to the control arm will download and install the control branch of the Epic Allies app (phone-based notifications only) and be provided with instructions on using the app. During the 26-week intervention phase, the control arm subjects will receive weekly phone-based notifications to encourage the subjects to view educational information presented in the app.
62233408|NCT01679353|PLACEBO_COMPARATOR|placebo group|normal saline 0.5ml
62424392|NCT04754919|ACTIVE_COMPARATOR|Transition intervention group|Intervention group -will be working with the specialist diabetes transition nurse. The nurse will follow a specific protocol involving visits, clinic support, community support and appointment rearranging. She will also maintain communication with the Hospital based adult and paediatric diabetes teams and the participants General Practitioner and relevant community health care professionals.
62424393|NCT04754919|PLACEBO_COMPARATOR|Post Transition group|The previous fifty eligible young people who have transitioned to adult service, will be compared with the active comparator group.
62593243|NCT03606538|EXPERIMENTAL|Moderate hepatic impairment|Eight participants with moderate hepatic impairment receive a single dose of 80 mg midomafetamine HCl.
62809485|NCT03812380|PLACEBO_COMPARATOR|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.
62809486|NCT02289664|EXPERIMENTAL|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
62424394|NCT02561000|EXPERIMENTAL|PZ-128 0.3 mg/kg|PZ-128, 0.3 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
62233409|NCT01679353|EXPERIMENTAL|magnesum group|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.5mL added to ropivacaine 0.15% 1.0 ml/kg was administered to Group R , Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.
62424395|NCT02561000|EXPERIMENTAL|PZ-128 0.5 mg/kg|PZ-128, 0.5 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
62424396|NCT02561000|PLACEBO_COMPARATOR|Placebo|Placebo, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
62424397|NCT06170840|PLACEBO_COMPARATOR|QY101 placebo ointment|40 subjects use QY101 placebo ointment twice daily for 12 weeks
62809487|NCT02289664|EXPERIMENTAL|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
62809488|NCT06527339|EXPERIMENTAL|Dry needling with vibration for 10 minutes|The patients will receive an intervention involving dry needling with vibration for 10 minutes.
62809489|NCT06527339|ACTIVE_COMPARATOR|Conventional dry needling|The patients will receive an intervention involving conventional dry needling
62233410|NCT05090553|ACTIVE_COMPARATOR|surgical treatment|Lumbar Spinal Fusion Surgery
62233411|NCT05090553|EXPERIMENTAL|Bacterial culture|"Cutibacterium acnes culture in two different atmosphere:~* Carbon dioxide (CO2) from 5% up to 10%~* CO2 10%, H2 10% and N2 80%"
62424398|NCT06170840|EXPERIMENTAL|0.3% QY101 ointment|60 subjects use QY101 placebo ointment twice daily for 12 weeks
62424399|NCT06170840|EXPERIMENTAL|1.0 % QY101 ointment|60 subjects use1.0 % QY101 ointment twice daily for 12 weeks
62424400|NCT00727896|EXPERIMENTAL|1 is experimental with SMS|Arm 1 is experimental with SMS intervention
62424401|NCT00727896|ACTIVE_COMPARATOR|2 is (active comparator) standard care|Arm 2 is the usual care arm (standard care)
62593244|NCT03606538|EXPERIMENTAL|Normal hepatic function|Eight participants, each matched on age, weight and gender to a participant with moderate hepatic impairment, receive a single dose of 80 mg midomafetamine HCl.
62593245|NCT06334653|PLACEBO_COMPARATOR|Placebo|Saline infusion
62593246|NCT06334653|EXPERIMENTAL|Tocilizumab|IL-6 receptor antibody infusion (8 mg/kg body weight, max 800 mg)
62593247|NCT04680065|EXPERIMENTAL|Active Treatment|
62593248|NCT04680065|SHAM_COMPARATOR|Placebo Surgery|
62593249|NCT02828124|EXPERIMENTAL|Dose Escalation Monotherapy|
62593250|NCT02828124|EXPERIMENTAL|Dose Expansion Monotherapy|
62593251|NCT02828124|EXPERIMENTAL|Dose Escalation Combination Therapy|
62033143|NCT05790733|ACTIVE_COMPARATOR|Standard|"When the patient is in the conventional arm, the nurse of the service will place the NGS according to the recommendations of the French Health Authorities on the management of the induced pain. The patient is seated at 90 degrees. The nurse takes its landmarks on the NGS to be able to install the NGS at the correct landmark (it takes the NGS and measures nose-ear, ear-stomach).~This arm involves the use of the 5% Xylocaine nebulizer spray and a single-use cannula.~The nurse checks its expiry date and that the quantity is sufficient to practice the 7 instillations in one nostril and the other 7 in the mouth. A waiting time is respected and the installation of the NGS can begin. She will also set up a fast for 2 hours after this local anesthesia."
62033144|NCT05790733|EXPERIMENTAL|Hypnosis|"Hypnosis is a particular psychological state marked by the functioning of the individual at a level of attention other than the ordinary state of consciousness. It can, under certain conditions, give the appearance of sleep or somnambulism without sharing all the characteristics.~As part of the treatment, hypnosis is widely used for pain control. The adverse effects reported are nil. One of its main benefits is improved patient comfort. Another benefit is the reduction of exposure to anesthetic products.~The installation of the SNG with hypnosis will be carried out according to the protocol set out in appendix 4.~In the hypnosis arm, there will be none local anesthesia."
62233412|NCT05090553|EXPERIMENTAL|Phenotypic and genotypic characterization|Mass spectrometry and (Polimerase Chain Reaction) PCR
62233413|NCT05090553|EXPERIMENTAL|Multiomics analysis|"* Genome sequencing~* Proteomics~* Metabolomics"
62233414|NCT00454389|EXPERIMENTAL|A|Epi-Rad90™ Ophthalmic System procedure + Lucentis
62233415|NCT00454389|ACTIVE_COMPARATOR|B|Lucentis only
62233416|NCT03181750|NO_INTERVENTION|Control|Patients and caregivers randomized to this arm will receive a packet of educational materials in English or Spanish. These materials are written at 5-6th grade reading level. The materials focus on advance care planning, pain and symptom management, and hospice care.
62424402|NCT00654446|EXPERIMENTAL|1|Rosuvastatin
62424403|NCT00654446|ACTIVE_COMPARATOR|2|Simvastatin
62424404|NCT04902261|EXPERIMENTAL|Tislelizumab combined with Nab-paclitaxel and Gemcitabine|
62424405|NCT04902261|ACTIVE_COMPARATOR|Nab-paclitaxel and Gemcitabine|
62593252|NCT02828124|EXPERIMENTAL|Dose Expansion Combination Therapy|
62233417|NCT03181750|EXPERIMENTAL|Patient Navigator Intervention Group|Patient and caregivers randomized to this arm will receive the same packet of educational materials. They will also receive at least 5 visits from a bicultural bilingual patient navigator. The navigator will utilize a annualized visit guide manual to lead discussions on advance care planning, pain and symptom management, and hospice care.
62233418|NCT02047292|ACTIVE_COMPARATOR|THA28|THA Corail PinnacleCoC28
62233419|NCT02047292|ACTIVE_COMPARATOR|THA36|THA Corail DeltaMotion36
62233420|NCT02047292|ACTIVE_COMPARATOR|THA40|THA Corail DeltaMotion40
62424406|NCT05766761|EXPERIMENTAL|Intervention condition, the usual prenatal care plus the alcohol intervention|The alcohol intervention consists of (1) a self-paced computer-delivered component to enhance knowledge, norms, and motivation for alcohol reduction and (2) a nurse-delivered component to reinforce the computer-delivered content and address women's questions.
62424407|NCT05766761|NO_INTERVENTION|Comparison condition, usual prenatal care only|Prenatal usual care involves clinicians assessing alcohol use and counseling women on alcohol-related risks.
62424408|NCT06138431|EXPERIMENTAL|Virtual Cognitive Behavioral Therapy (CBT) group|The Cognitive Behavioral Therapy (CBT) groups will be 6 weekly one-hour parent groups run by a Cognitive Behavioral Therapy (CBT) therapist according to a Cognitive Behavioral Therapy (CBT) manual focusing on anxiety and depression related to having a child with food allergies.
62424409|NCT06138431|NO_INTERVENTION|Waitlisted group|The comparator groups will be waitlisted groups of parents of children with food allergies.
62593253|NCT02791321|OTHER|Patients with ADS-MR|Patients presenting Autism Spectrum Disorder and mental retardation who are evaluated for their ADS severity, their adaptative and intellectual functioning, psychiatric and somatic comorbidities
62593254|NCT05115786||Cohort A|FFPE specimen collection. FFPE tumor tissue samples must be collected after surgical resection and before starting chemotherapy or other treatment.
62593255|NCT05115786||Cohort B|FFPE specimen collection. FFPE tumor tissue samples must be collected after surgical resection and before starting chemotherapy or other treatment.
62593256|NCT05115786||Cohort C|FFPE specimen collection. FFPE tumor tissue samples must be collected after surgical resection and before starting chemotherapy or other treatment.
62033145|NCT03939468||Observational Cohort|Patient with diffuse CAD disease treated with hybrid strategy (DES+DCB)
62033146|NCT01696422|EXPERIMENTAL|Step A: dengue lyophilized vaccine|Dengue 1,2,3,4 (attenuated) vaccine Two doses with a six-months interval, SC
62033147|NCT01696422|ACTIVE_COMPARATOR|Step A:dengue liquid vaccine|TetraVax-DV Vaccine - Admixture TV003 Two doses with a six-months interval, SC
62033148|NCT01696422|PLACEBO_COMPARATOR|Step A: Placebo|Placebo comparator Two doses with a six-months interval, SC
62033149|NCT01696422|EXPERIMENTAL|Step B: dengue lyophilized vaccine|Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC
62033150|NCT01696422|PLACEBO_COMPARATOR|Step B: Placebo|Placebo comparator Single dose, SC
62033151|NCT03315000|EXPERIMENTAL|Vilanterol|Vilanterol (25mcg)+ fluticasone (100mcg) inhaled through Ellipta® inhaler
62809490|NCT04264858|EXPERIMENTAL|Treatment group|Immunoglobulin of cured patients
62033152|NCT03315000|EXPERIMENTAL|Fluticasone|Fluticasone (100mcg) monotherapy inhaled through Ellipta® inhaler
62033153|NCT03315000|PLACEBO_COMPARATOR|Placebo|Lactose powder inhaled through Ellipta® inhaler
62233421|NCT01866618||Natural IVF Cycle|All patients will undergo a natural IVF cycle using trigger shots of Leuprolide Acetate(Lupron) and human chorionic gonadotropin (hCG) to ensure the patient surges.
62233422|NCT01008215|EXPERIMENTAL|Algorithm|Algorithm (available in paper version and web-based version) will be used for warfarin maintenance dosing.
62233423|NCT01008215|NO_INTERVENTION|Care as usual|Control group
62809491|NCT04264858|PLACEBO_COMPARATOR|Control group|γ-Globulin
62233424|NCT02709421||Indomethacin Group|"All the patients with high risks of PEP received administration of one single dose of 100mg rectal indomethacin after ERCP.~Patients were considered high risk of PEP if they met one of the following criteria: clinical suspicion of sphincter of Oddi dysfunction, a history of PEP, pancreatic sphincterotomy, precut sphincterotomy, ≥8 cannulation attempts, cannulation time≥10 minutes; pneumatic dilatation of an intact biliary sphincter, ≥3 inadvertent pancreatic duct cannulation, opacification of pancreatic acini, or the acquisition of a cytologic specimen from the pancreatic duct with the use of a brush or forceps."
62033154|NCT03555396|EXPERIMENTAL|Intervention|Subjects will receive an intervention is based off of current evidence-based practices and will consist of activities designed to strengthen support within the couple to improve adherence to antiretroviral therapy.
62033155|NCT03555396|ACTIVE_COMPARATOR|Standard of Care|Standard of Care is the comparison arm that consists of care currently provided at the AIDS Center. Subjects will receive a consultation with a healthcare provider every three months, prescription refills, and blood draws for viral load and CD4 testing.
62033156|NCT04811027|EXPERIMENTAL|(CPS ≥1): pembrolizumab (KEYTRUDA®) + efti|"eftilagimod alpha: 30 mg every 2 weeks for the first 4 cycles;thereafter every 3 weeks for up to 18 cycles(1 cycle = 6 weeks).~pembrolizumab (KEYTRUDA®): 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks)."
62033157|NCT04811027|ACTIVE_COMPARATOR|(CPS ≥1): pembrolizumab (KEYTRUDA®)|pembrolizumab (KEYTRUDA®): 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks).
62033158|NCT04811027|EXPERIMENTAL|(CPS <1): pembrolizumab (KEYTRUDA®) + efti|"eftilagimod alpha: 30 mg every 2 weeks for the first 4 cycles;thereafter every 3 weeks for up to 18 cycles(1 cycle = 6 weeks).~pembrolizumab (KEYTRUDA®): 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks)."
62033159|NCT03181880|ACTIVE_COMPARATOR|Aclidinium/formoterol|Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination
62033160|NCT03181880|ACTIVE_COMPARATOR|Bronchodilators|The comparator arm consists of SOC.
62233425|NCT05578144|EXPERIMENTAL|Patient decision aids group|shared decision making with using patient decision aids. (SDM group)
62233426|NCT05578144|NO_INTERVENTION|Control group|oral explanation. (Non-SDM group)
62233427|NCT02931799|EXPERIMENTAL|Nurse Follow-Up and Electronic Monitoring|
62809492|NCT02542657|EXPERIMENTAL|Treatment (PiC-D therapy)|"Patients receive pomalidomide PO QD on days 1-21; ixazomib citrate PO on days 1, 8, and 15; clarithromycin PO BID on days 15-21 of course 1 and days 1-21 of courses 2-6; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY:~Patients receive pomalidomide, ixazomib citrate, and dexamethasone as above and receive clarithromycin PO BID or QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62809493|NCT05294926|ACTIVE_COMPARATOR|deep neuromuscular blockade|
62809494|NCT05294926|ACTIVE_COMPARATOR|moderate neuromuscular blockade|
62809495|NCT04319367|ACTIVE_COMPARATOR|Arm A|ART plus dual long-acting (LS) broadly neutralising antibodies (bNAbs) infusion followed by intensively monitored Antiretroviral Treatment Interruption (ATI)
62424410|NCT01372527|EXPERIMENTAL|TopCare Intervention|"The TOP-CARE intervention will be based on a medical informatics platform that:~1. Identifies all patients eligible for any of the three cancer screening programs~2. Links patients with a specific clinician~3. Offers a visit-independent method for clinicians to review panels of their eligible patients~4. For patients due for one or more cancer screenings, clinicians will access a web-based informatics tool to:~   1. Screen their panel based upon risk~  2. Defer patients, document exclusions, and update the EHR~  3. Order a screening test with patient information material based upon the patient's risk profile and automatically initiate the process of:~      1. Informing the patient by letter of the need to schedule a test, educating the patient with respect to the benefits of cancer screening, and properly documenting the transaction in the patient's EHR, or~     2. Referral to a patient navigator for patients most likely to benefit from this more intensive approach"
62424411|NCT01372527|ACTIVE_COMPARATOR|Augmented Standard Care|In augmented standard care control practices, we will implement a system that includes: 1) a population-based perspective to identify all eligible patients overdue for screening, 2) an automated, centralized process to contact selected patients by letter, 3) a result management system that automatically tracks test scheduling and completion, 4) a web-based, easily accessible tool allowing practice personnel to contact patients not completing testing, and 5) use of patient navigators for high risk patients not responding to initial outreach. In the control arm, the process of escalating the reminder intervention from a letter, to contact by phone call, to a patient navigator, will occur in a standard algorithmic fashion without provider input.
62424412|NCT05397288|EXPERIMENTAL|Resistance-Aerobic-Education (RAE)|"Participants first receive 6 months of resistance exercise, then 6 months of aerobic exercise, and finally 6 months of education program on healthy lifestyle.~Behavioral: Resistance exercise (R) Behavioral: Aerobic exercise (A) Behavioral: Healthy lifestyle education (E)"
62424413|NCT05397288|EXPERIMENTAL|Aerobic-Resistance-Education (ARE)|"Participants first receive 6 months of aerobic exercise, then 6 months of resistance exercise, and finally 6 months of education program on healthy lifestyle.~Behavioral: Aerobic exercise (A) Behavioral: Resistance exercise (R) Behavioral: Healthy lifestyle education (E)"
62424414|NCT05397288|EXPERIMENTAL|Education-Resistance-Aerobic (ERA)|"Participants first receive 6 months of education program on healthy lifestyle, then 6 months of resistance exercise, and finally 6 months of aerobic exercise.~Behavioral: Healthy lifestyle education (E) Behavioral: Resistance exercise (R) Behavioral: Aerobic exercise (A)"
62424415|NCT04064333|EXPERIMENTAL|Slow-Stream Expiratory Muscle Strength Training|The therapy protocol consists of 12 sets of five breaths through the EMST150 device per week, in sessions of three or four sets (15 or 20 breaths). A typical schedule might be one 15 breath session four days per week, or one 20 breath session three days per week.
62424416|NCT05417126|EXPERIMENTAL|Experimental-vMCO-010|Participants receive 1.2E11gc/eye of vMCO-010
62424417|NCT05353426|EXPERIMENTAL|PG-ANB Block|The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four of the areas are next to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries
62233428|NCT02931799|ACTIVE_COMPARATOR|Minimal Intervention|
62424418|NCT05353426|NO_INTERVENTION|Control|No paragastric neural block is performed in the control group. The same standard analgesic protocol consisting of acetaminophen (1 g) and morphine (3-5 mg) is used in all patients before extubation and TAP block is performed in both groups (control and experimental)
62424419|NCT02585973|OTHER|open label, single-arm, Phase 1b|AZD1775 when added to standard of care concomitant chemotherapy (cisplatin) and radiation
62424420|NCT06538454|ACTIVE_COMPARATOR|80% of 1 repetition maximum|"The recent guideliness suggest a resistance training intensity for this population between 50 and 80% of 1 repetition maximum (1RM), i.e, this group will training in accordance with the recommendations.~These group will be training with 80% 1RM, performining 8-10 repetitions per set."
62433601|NCT02350530|EXPERIMENTAL|A (FOLFOXIRI + Bevacizumab)|FOLFOXIRI + Bevacizumab
62433602|NCT02350530|ACTIVE_COMPARATOR|B (FOLFOXIRI)|FOLFOXIRI
62433603|NCT01848652|EXPERIMENTAL|MYOCET|
62809496|NCT04319367|PLACEBO_COMPARATOR|Arm B|ART plus placebo infusion followed by an ATI (control arm). On re-starting ART, participants will receive immediate dual LS bNAbs and then a second ATI 24 weeks after bNAb infusion.
62809497|NCT05260047|ACTIVE_COMPARATOR|IMANI BREAKTHROUGH|Participants will participate in 24-week IMANI weekly groups
62809498|NCT05260047|EXPERIMENTAL|IMANI BREAKTROUGH + church-based telehealth MAT option (IMANI + CTM)|Participants will participate in the 24-week Imani weekly group. During weeks 1-4 participants will received education on MAT. Those participants randomized will receive the IMANI weekly group as well as a church based telehealth Medication Assisted Treatment option. The church based telehealth MAT will consist of participants assigned to receive MAT from addiction treatment providers via telehealth. Telehealth sessions will be provided in the church.
62809499|NCT05260047|EXPERIMENTAL|IMANI BREAKTHROUGH + Traditional MAT plus Referral and Linkage|Participants will participate in the 24-week Imani weekly group. During weeks 1-4 participants will received education on MAT. Those participants randomized will receive the IMANI weekly group as well as Traditional MAT services with Referral and Linkage to services. Participants in this arm will be provided a list of referrals and links to community MAT providers. They will choose their providers.
62233429|NCT02225353|EXPERIMENTAL|Progesterone Cervical Pessary 6.3 g|90 pregnant women with Progesterone Cervical Pessary
62033161|NCT05876065|EXPERIMENTAL|capecitabine and cyclophosphamide (XC)|capecitabine and cyclophosphamide as maintenance therapy every 3 weeks
62233430|NCT02225353|EXPERIMENTAL|Progesterone Cervical Pessary 7.7 g|90 pregnant women with Progesterone Cervical Pessary
62233431|NCT02225353|ACTIVE_COMPARATOR|Progesterone 200 mg vaginal capsules|90 pregnant women using Progesterone 200 mg vaginal capsules daily
62593257|NCT05115786||Cohort D|FFPE specimen collection. FFPE tumor tissue samples must be collected after surgical resection and before starting chemotherapy or other treatment.
62233432|NCT04300088||Patients with advanced solid cancer treated with anti-PD(L)1|Adult patients with advanced solid cancer treated with anti-PD(L)1 immunotherapy with or without anti-CTLA4 immunotherapy.
62233433|NCT03911011|ACTIVE_COMPARATOR|Fresh air|2 litres of fresh air
62233434|NCT03911011|NO_INTERVENTION|no fresh air|no supply of fresh air
62424421|NCT06538454|ACTIVE_COMPARATOR|60% of 1 repetition maximum|"The recent guideliness suggest a resistance training intensity for this population between 50 and 80% of 1 repetition maximum (1RM), i.e, this group will training in accordance with the recommendations.~These group will be training with 60% 1RM, performining 18-20 repetitions per set."
62424422|NCT04149769|OTHER|Interventional|Walking in an exoskeleton within the home and community.
62424423|NCT06224478||Hypodivergent|
62424424|NCT06224478||Normodivergent|
62424425|NCT06224478||Hyperdivergent|
62424426|NCT04767542|SHAM_COMPARATOR|Paracetamol|Patients with emergency LC will be administered intravenously 1 gr vial of paracetemol in 30 minutes during the awakening phase.
62424427|NCT04767542|ACTIVE_COMPARATOR|Transversus Abdominis Plane Block|With USG, the lateral part of the latissumus dorsi muscle attaches to the external lip of the iliac crest, just behind the middle axillary line and the end is directed slightly cranially, first through the external oblique muscle and fascia, then the internal oblique muscle and fascia, and after hydrodissection with saline for about 15-20 ml of local anesthetic agent (Bupivacaine 0.5%) will be injected bilaterally
62424428|NCT05980351|EXPERIMENTAL|Study group|This group will receive exercise program
62424429|NCT05980351|NO_INTERVENTION|Control group|This group will receive routine hospital care
62593258|NCT01707355|ACTIVE_COMPARATOR|invention with poster|intervention - poster
62233435|NCT03607539|EXPERIMENTAL|Sintilimab in combination with pemetrexed and platinum|Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W (qualer 3 weeks); duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria Sintilimab 200mg + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains
62809500|NCT06040411|EXPERIMENTAL|Study Group (experimental)|The order of application was determined by lottery. HT7, LI4 and EX-HN3 points were applied respectively. Before starting the application, the area around to be pressurized was gently rubbed with the palm of the hand for 20-30 seconds. The surrounding tissue was relieved by rubbing gently. After rubbing, pressure was applied to the point determined based on the pain threshold level of each individual with a depth of 1-1.5 cm with the thumb for 5 seconds, rested for 2 seconds and the application was continued for 2 minutes. Acupressure was applied to each point for 2 minutes and the total application time was 15 minutes on average (for 5 points).
62233436|NCT03607539|PLACEBO_COMPARATOR|Sitilimab Placebo Comparator|placebo 2 vials + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains
62233437|NCT02230553|EXPERIMENTAL|lapatinib + trametinib|lapatinib: oral tablets, once daily trametinib: oral tablets, once daily
62424430|NCT03936777|EXPERIMENTAL|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an open-label oral solution.Doses will include up to 0.8 mg/kg/day divided into 2 daily doses, up to a maximum of 30 mg/day (subjects taking concomitant STP will receive up to 0.5 mg/kg/day, up to a maximum of 20 mg/day) in a concentration of 2.5 mg/mL.
62424431|NCT04525859|EXPERIMENTAL|Safety|Six patients will be enrolled in the Phase 1 safety cohort. Patients will have an IR guided biopsy and FNA. Up to four core biopsies and FNAs at one site will be performed prior to intratumoral (IT) administration of Poly-ICLC. Pleural fluid will be collected for research analysis if available. Poly-ICLC will be injected in 2 locations within the pleura. Patients will undergo surgery 21±7 days after the biopsy and Poly-ICLC intratumoral (IT) injection. The type of surgery that will be performed is at the discretion of the thoracic surgeon and per the standard of care. This includes pleurectomy/decortication or extrapleural pneumonectomy. Patients will be evaluated per the standard of care post-operatively. On day 7±4 days a final toxicity assessment, physical exam and research blood will be collected. All post-operative care and monitoring thereafter is as per standard of care.
62593259|NCT01707355|NO_INTERVENTION|control|control - no poster
62593260|NCT02199353|EXPERIMENTAL|Stimulation of Activities Daily Living|"The experimental group received the Stimulation of Activities of Daily Living (SADL) programme which is a new treatment approach created by the authors of this study for the training of activities of daily living (ADL) through cognitive intervention. The programme is based on the reestablishment of the cognitive functions implied in the performance of basic activities of daily living.~The sequence of the sessions was always the same, varying the activities, subject, cognitive functions and BADL to work on. Each session started with an activity of temporal and space orientation, continued with the performance of the specific activity of the session and finished with a reminiscence activity.~The treatment was applied twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
62593261|NCT02199353|ACTIVE_COMPARATOR|Conventional ADLoccupational therapy|"The control group treatment was based on a conventional occupational therapy intervention for the management of ADL deficits. The compensation approach was used and environment modifications and simplification of activities were applied as the intervention method.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
62593262|NCT04811612|EXPERIMENTAL|Infants sampled for warmed and unwarmed heel stick glucose measurements|This single study arm will be samples for blood glucose measurement using both a warmed and unwarmed heel.
62809501|NCT06040411|NO_INTERVENTION|Standard of care|Standard care was given.
62233438|NCT02805608|EXPERIMENTAL|uPAR PET/CT and FDG PET/MR|One injection of 68Ga-NOTA-AE105 followed by PET/CT and on a separate day one injection of 18F-FDG followed by PET/MRI. Both scans will be evaluated for possible regional lymph node metastases.
62424432|NCT04525859|EXPERIMENTAL|Expansion Cohort|If at most one (1) patient in the Phase 1 safety cohort experiences a DLT then a total of thirteen (13) additional patients will be enrolled into the Phase 1b Expansion Cohort. Patients in the Expansion Cohort will receive the same dose and schedule of Poly-ICLC as in the Phase 1 safety cohort. Patients will be followed for safety and tolerability, as well as efficacy. If a total of 4 or more patients experience DLTs then the study will be closed due to excessive toxicity.
62424433|NCT06135519|EXPERIMENTAL|Mesenchymal stem cells|Mesenchymal Stem Cells taken from adipose tissue will be used
62593263|NCT03448627||Group 1: HSCT recipients|Pulmonary functions \[spirometry\], maximal exercise capacity \[Modified-Incremental Shuttle Walk Test (ISWT)\], inspiratory and expiratory muscle strength (MIP and MEP, respectively) \[mouth pressure device\] and peripheral muscle strength \[hand-held dynamometer\] were evaluated in allogeneic HSCT recipients (n=66).Vital signs, dyspnea and fatigue perception \[Modified Borg Scale\] were recorded as pre-post measurements of Modified-ISWT.
62593264|NCT03448627||Group 2: healthy individuals|Healthy individuals (n=50) were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
62233439|NCT01972256||Previous transsacral fusion|Subject candidates are those who had required a transsacral fusion at L4-L5-S1 where these were the only lumbar levels treated for pseudoarthrosis, spinal stenosis, spondylolisthesis, or degenerative disc disease (DDD).
62233440|NCT01972256||Previous transforaminal lumbar interbody fusion|Subject candidates are those who had required transforaminal lumbar interbody fusion at L4-L5-S1 where these were the only lumbar levels treated for pseudoarthrosis, spinal stenosis, spondylolisthesis, or degenerative disc disease (DDD).
62593265|NCT06617871|ACTIVE_COMPARATOR|Mechanical Alignment (MA)|Primary TKA with the Medacta SpheriKA, utilizing either MA methodology.
62033162|NCT05876065|ACTIVE_COMPARATOR|physician's choice|Any physician's choice as maintenance therapy (except for XC regimen).
62233441|NCT00461838||1|All women (n=56) who had undergone CO2 laser laparoscopic radical excision of deep infiltrating endometriosis with active involvement of colorectal surgeon and/or urologist were selected retrospectively from the list of all patients (n=more than 2000) operated at the Leuven University Fertility Centre (LUFc) between September 1996 and July 2004.
62233442|NCT02844881|EXPERIMENTAL|Apatinib+MASCT|Apatinib+Multiple Antigens Specific Cellular Therapy(MASCT) in patients with advanced solid tumors,excluding T cell lymphoma
62424434|NCT06135519|EXPERIMENTAL|Homogenized fat|Adipose tissue will be harvested and used
62424435|NCT03983746|EXPERIMENTAL|traditional physical therapy program (control group)|fifteen children with DS received a traditional exercises program with instructions to the children for 60 minutes aiming to improve posture control and balance
62424436|NCT01175161|EXPERIMENTAL|Immediate postpartum IUD insertion|Women assigned to have the IUD placed 10 minutes to 48 hours postpartum
62424437|NCT01175161|EXPERIMENTAL|6 week postpartum IUD insertion|Women who receive the IUD at the traditional time frame.
62424438|NCT05691699|EXPERIMENTAL|Part 1, ABBV-903|Participants will receive a single ascending dose of ABBV-903 in Part 1.
62424439|NCT05691699|EXPERIMENTAL|Part 1, Placebo|Participants will receive a single ascending dose of placebo in Part 1.
62593266|NCT06617871|ACTIVE_COMPARATOR|Kinematic Alignment (KA)|Primary TKA with the Medacta SpheriKA, utilizing either KA methodology.
62809502|NCT02892994|EXPERIMENTAL|Ultrasound|Subjects will receive 5 minutes of ultrasound treatment at 0.4 W/cm\^2 and 100% duty cycle on each masseter muscle.
62233443|NCT01541553|ACTIVE_COMPARATOR|PEP005 Gel, 0.015%|Cryotherapy followed by PEP005 Gel, 0.015%
62233444|NCT01541553|PLACEBO_COMPARATOR|Vehicle gel|Cryotherapy followed by vehicle gel
62593267|NCT05002647||exposure group|Data from electronic clinical pharmacist records of two infectious disease hospitals
62809503|NCT02892994|PLACEBO_COMPARATOR|Placebo|Subjects will receive 5 minutes of ultrasound treatment at zero power on each masseter muscle.
62809504|NCT01102335|EXPERIMENTAL|Telbivudine|
62809505|NCT01102335|ACTIVE_COMPARATOR|TACE only|
62809506|NCT05392608|EXPERIMENTAL|Arm A (one-arm study)|Alpelisib plus fulvestrant beyond progression
62809507|NCT06021314||Adolescent Idiopathic Scoliosis|
62033163|NCT01817179|EXPERIMENTAL|FES neuroprosthesis to dorsiflexors on affected side|Participants will use FES neuroprosthesis to dorsiflexors on affected leg for 3 months at home.
62424440|NCT05691699|EXPERIMENTAL|Part 2, ABBV-903|Participants will receive multiple ascending doses of ABBV-903 in Part 2.
62424441|NCT05691699|EXPERIMENTAL|Part 2, Placebo|Participants will receive multiple ascending doses of placebo in Part 2.
62593268|NCT05002647||Non-exposure group A|Data from medical records of the hospital with no clinical pharmacy.
62593269|NCT05002647||Non-exposure group B|Data from a medical record of the hospital with clinical pharmacy, but the department did not cover by the clinical pharmacy
62233445|NCT00751842|ACTIVE_COMPARATOR|A|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on days 90 and 270.
62593270|NCT00031681|EXPERIMENTAL|Treatment (combination chemotherapy)|"PART I: Patients receive irinotecan hydrochloride IV over 90 minutes on days 1, 8, 15, and 22 and 7-hydroxystaurosporine IV over 3 hours on days 2 and 23. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan hydrochloride and 7-hydroxystaurosporine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Blood samples are collected periodically during study treatment.~PART II: (treatment of triple negative recurrent breast cancer): Patients receive irinotecan hydrochloride IV and 7-hydroxystaurosporine IV as in part I at the MTD and undergo blood sample collection."
62593271|NCT02997644|EXPERIMENTAL|Video Education|Video education delivered on a tablet computer
62593272|NCT02997644|PLACEBO_COMPARATOR|Usual Care Group|Regular information about opioid usage they typically receive from their surgeon.
62593273|NCT02622373||Birth Between 23-32 Weeks Gestation|Babies born between 23-32 weeks of gestational age will have their body composition determined using PEA POD Infant Body Composition System at 34 weeks, 36 weeks and 40 weeks of corrected age.
62233446|NCT00751842|ACTIVE_COMPARATOR|B|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on days 90 and 270.
62233447|NCT00751842|PLACEBO_COMPARATOR|C|This arm will receive 4 injections of placebo, 1 each on days 1, 30, 90 and 270.
62424442|NCT05691699|EXPERIMENTAL|Part 3, Sequence 1|Participants in Part 3 will follow Sequence 1.
62424443|NCT05691699|EXPERIMENTAL|Part 3, Sequence 2|Participants in Part 3 will follow Sequence 2.
62033164|NCT03288662|EXPERIMENTAL|CT and histopathological classification|With each histopathological type of thymic epithelial tumors, we measure the maximun diameter in chest CT scan. Comparison of some characteristics of the tumor on preoperative chest CT scans and histopathological type of thymic epithelial tumors .
62809508|NCT02656277|EXPERIMENTAL|Decision tool|The decision tool includes a questionnaire and statistical model used to determine how patient preference regarding shoulder pain, physical limitations, physical therapy, recovery period, prognosis, and cost impact choice of surgical versus non-surgical intervention.
62033165|NCT01097538|ACTIVE_COMPARATOR|Body-weight supported treadmill training|Supported treadmill walking
62033166|NCT01097538|EXPERIMENTAL|Total body recumbent stepper training|Recumbent stepper exercise training
62033167|NCT05020639|EXPERIMENTAL|TQB3820 tablets|TQB3820 tablets are administrated orally on Days 1-28 of each 28-day treatment cycle. Dose escalation of TQB3820 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data.
62033168|NCT02969889|ACTIVE_COMPARATOR|intubation time|handling the device till the endotracheal tube passing through the glottis
62424444|NCT02964884|ACTIVE_COMPARATOR|NF1: Lovastatin + reading tutoring|"Participants (NF-1 patients) will receive 20mg of Lovastatin per day for the first two weeks, the dose will be escalated 40 mg for the remaining 11 weeks.~And one week of intensive, one-on-one reading tutoring intervention"
62809509|NCT02656277|ACTIVE_COMPARATOR|Information on Shoulder Dislocation|Subjects in this arm will receive the standard of care information available to patients to make this treatment decision.
62809510|NCT02962258|EXPERIMENTAL|Test|Torrent's Olmesrtan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg
62033169|NCT02969889|ACTIVE_COMPARATOR|insertion time|handling of the device till the glottic visualization
62033170|NCT02300220|ACTIVE_COMPARATOR|Ciprofloxacin|500 mg, twice daily for 1 week (oral).
62033171|NCT02300220|PLACEBO_COMPARATOR|Placebo|one capsule, twice daily for 1 week.
62033172|NCT06104410|ACTIVE_COMPARATOR|Arm A (standard fractionated dose): Groups A-B|Arm A contains of 2 groups. Group A: Total dose of 6 Gy in 4 single fractions of 1.5 Gy applied twice weekly (most commonly used regimen, considered standard arm in this trial) Group B: Total dose of 3 Gy in 2 single fractions of 1.5 Gy applied twice weekly
62033173|NCT06104410|EXPERIMENTAL|Arm B (experimental single dose): Groups C-F|Arm B contains of four groups. Group C: Total dose of 0.5 Gy in 1 single fractions of 0.5 Gy Group D: Total dose of 1 Gy in 1 single fractions of 1 Gy Group E: Total dose of 1.5 Gy in 1 single fractions of 1.5 Gy Group F: Total dose of 2 Gy in 1 single fractions of 2 Gy
62809511|NCT02962258|ACTIVE_COMPARATOR|Reference|Tribenzor of Daichi Sankyo Inc., USA
62809512|NCT04077021|EXPERIMENTAL|Part 1a: Dose Escalation QOD|CCW702 administered subcutaneously QOD, dose escalating cohorts.
62033174|NCT00179023|OTHER|Part 1|Estimation of resting energy expenditure and effect of autonomic blockade with trimethaphan infusion.
62033175|NCT00179023|OTHER|Part 2 (closed)|Estimation of autonomic function and effect of autonomic blockade with trimethaphan infusion.
62033176|NCT00179023|OTHER|Part 3|Estimation of energy metabolism and effect of sympathetic stimulation with pseudoephedrine.
62033177|NCT00179023|OTHER|Part 4a (closed)|Isoproterenol sensitivity in adipose and muscle tissue with and without systemic autonomic blockade with trimethaphan infusion.
62424445|NCT02964884|PLACEBO_COMPARATOR|NF1: Placebo + reading tutoring|Participants (NF-1 patients) will receive placebo daily And one week of intensive, one-on-one reading tutoring intervention
62424446|NCT02964884|PLACEBO_COMPARATOR|RD: Reading tutoring|Participants (RD-only participants) will receive one week of intensive, one-on-one reading tutoring intervention
62424447|NCT02964884|SHAM_COMPARATOR|RD: Other Academic (sham) tutoring|"Participants (RD-only participants) will receive one week of intensive, one-on-one tutoring intervention with an academic focus other than reading.~These participants will have the opportunity to receive reading tutoring upon finishing study participation."
62424448|NCT01329705|ACTIVE_COMPARATOR|Control|All patients will be treated with the current standard of care including onabotulinum toxin
62809513|NCT04077021|EXPERIMENTAL|Part 1b: Dose Escalation Q7D|CCW702 administered subcutaneously Q7D, dose escalating cohorts.
62809514|NCT04077021|EXPERIMENTAL|Part 2: Dose Expansion|CCW702 administered subcutaneously Q7D at RP2D.
62809515|NCT03936998|EXPERIMENTAL|vancomycin plus VE416 before PNOIT|active vancomycin plus VE416 before PNOIT
62809516|NCT03936998|EXPERIMENTAL|Vancomycin plus VE416 with PNOIT|active vancomycin plus active VE416 with active PNOIT
62033178|NCT00179023|OTHER|Part 4b (closed)|Metabolic and hemodynamic response to submaximal exercise in adipose and muscle tissue with and without systemic autonomic blockade with trimethaphan infusion.
62033179|NCT03282227|EXPERIMENTAL|M207 Microneedle System 3.8 mg|M207 Microneedle System 3.8 mg (1.9 mg/patch x 2 patches)
62033180|NCT01870141|EXPERIMENTAL|Psychological Intervention|Cognitive Behavioural Intervention
62033181|NCT01870141|NO_INTERVENTION|Current standard of care|
62033182|NCT03823118|EXPERIMENTAL|S1/Anlotinib|Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
62033183|NCT06291168|EXPERIMENTAL|Chiropractic Manipulation (CM) Group|Sacroiliac joint manipulation and manipulations to be applied to the lumbar region will be applied twice a week for 8 weeks in the side lying position.
62233448|NCT03445351|EXPERIMENTAL|Aerobic, resistance and concorrent|The group underwent exercise program with protocols of resistance training, aerobic training and concurrent training, with frequency of three times per week.
62233449|NCT01829399|EXPERIMENTAL|Injected with Bupivacaine|A subcutaneous axillary ring of 10 to 15 mL of 0.25% Bupivacaine with epinephrine 1:200,000 will be injected in the arm 15 minutes prior to tourniquet inflation.
62233450|NCT01829399|SHAM_COMPARATOR|Injected with saline|A subcutaneous axillary ring of 10 to 15 mL of normal saline will be injected in the arm 15 minutes prior to tourniquet inflation.
62233451|NCT02642731||Patients for elective TKA|patients with normal or near normal plasma creatinine who come for elective total knee arthroplasty
62233452|NCT00001984|EXPERIMENTAL|Alemtuzumab and DSG|The recipients of live donor kidneys were treated perioperatively with alemtuzumab and DSG and followed postoperatively without maintenance immunosuppression.
62233453|NCT02453360|EXPERIMENTAL|5 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
62233454|NCT02453360|EXPERIMENTAL|10 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
62233455|NCT02453360|EXPERIMENTAL|20 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
62233456|NCT02092779||Obese patients, no treatment|
62233457|NCT06370468||18000 cases|The first part of the study will use a multi-stage cluster sampling survey, aiming to complete a questionnaire survey of 18,000 cases to assess the incidence and characteristics of chronic rhinitis. Each center will need to complete 3,000 face-to-face questionnaires to ensure reliable survey results.
62233458|NCT06370468||132000 cases|The second part will involve distributing 132,000 electronic questionnaires to community health service centers through convenient sampling. This method will allow us to obtain a large volume of questionnaire data more conveniently, thereby enhancing our investigation and analysis of chronic rhinitis. Each of the six centers will need to complete 22,000 online questionnaires.
62233459|NCT05604638|EXPERIMENTAL|Tenecteplase plus Tirofiban|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over \~10 seconds). Patients will receive a continuous intravenous infusion of tirofiban at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min, if there was no parenchymal hemorrhage or extensive subarachnoid hemorrhage beyond the Sylvian fissure on the posttreatment computed tomography scan. Aspirin (100 mg/d) will be given orally at 4 hours before the end of infusion and continued for at least 3 months after intravenous thrombolysis .
62233460|NCT05604638|PLACEBO_COMPARATOR|Tenecteplase plus Placebo|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over \~10 seconds). Patients will receive a continuous intravenous infusion of placebo at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min, if there was no parenchymal hemorrhage or extensive subarachnoid hemorrhage beyond the Sylvian fissure on the posttreatment computed tomography scan. Aspirin (100 mg/d) will be given orally at 4 hours before the end of infusion and continued for at least 3 months after intravenous thrombolysis .
62233461|NCT03867058||Cochlear implant users with Nucleus and AB devices|"Temporal processing acuity will be compared using electrodes or electrode configurations that create broad versus sharp spatial excitation.~Speech recognition will be compared in the same group of subjects using electrode-dependent focused versus monopolar stimulation."
62233462|NCT00675805|ACTIVE_COMPARATOR|Group I|IVIG infusion with filter
62233463|NCT00675805|PLACEBO_COMPARATOR|Group II|IVIG infusion without filter
62809517|NCT03936998|EXPERIMENTAL|Placebo plus VE416 with PNOIT|placebo vancomycin plus active VE416 with active VE416
62233464|NCT00581490||Idiopathic premature pubarche|Children with premature pubarche without precious puberty, adrenal hyperplasia or androgen secreting tumors
62233465|NCT05912582||Observation Group|
62593274|NCT02622373||Birth Between 34-36 Weeks Gestation|Babies born at 34 weeks and 36 weeks of gestational age will have their body composition measured using PEA POD Infant Body Composition System as soon as they are off parenteral nutrition and receiving full enteral nutrition.
62809518|NCT03936998|ACTIVE_COMPARATOR|Placebo plus placebo with PNOIT|placebo vancomycin and placebo VE416 with active peanut oral immunotherapy
62809519|NCT00908453|EXPERIMENTAL|15mg/kg of loading dose|
62593275|NCT02622373||Birth at Term|Body composition will be measured using PEA POD Infant Body Composition System in this group will be obtained prior to discharge.
62593276|NCT01619137|ACTIVE_COMPARATOR|Povidone-iodine And normal salin|40 patients with complaint of ununion wound of laparatomy or episiotomy coming to Gynecologist's office or hospital enrolled to this study randomly recieve Povidone-iodine And normal salin treatment.
62593277|NCT01619137|ACTIVE_COMPARATOR|water and soap|40 patients coming to Gynecologist's offices or hospital with complaint of ununion wound of laparatomy or episiotomy in Bandarabbas enrolled to this study and randomly recieve water and soap to irrigation of the wound (it's not require to be at hospital), washing is for each 6-8 hours per day. and if not difference seen after 4 day, treatment change to Povidone-iodine And normal salin.
62593278|NCT03279549|ACTIVE_COMPARATOR|dressing change group|Routine dressing change group
62593279|NCT03279549|EXPERIMENTAL|Dermal matrix dressing group|Limited debridement \& Acellular dermal matrix dressing group.
62593280|NCT03279549|EXPERIMENTAL|Epidermal cell spraying group|Limited debridement \& Epidermal cell spraying group
62593281|NCT03279549|EXPERIMENTAL|BFGF group|Limited debridement \& Basic fibroblast growth factor group
62593282|NCT02117908|EXPERIMENTAL|CPAP +4 cm H2O|CPAP +4 cm H2O pressure using ResMedTM face mask
62593283|NCT02117908|SHAM_COMPARATOR|ShamCPAP|shamCPAP using ResMedTM CPAP face mask modified for technical sham
62593284|NCT01846429|EXPERIMENTAL|Sodium Bicarbonate Treatment|A 3+3 design for Phase I component and a two staged design for Phase II were to be used. Treatment: Sodium Bicarbonate Capsules (900 mg).
62593285|NCT02302742||Triple Negative Breast Cancer patients|No intervention
62593286|NCT02302742||Germline HBOC Mutation Carriers|No intervention
62593287|NCT01522287|ACTIVE_COMPARATOR|BT STEPS alone|"Subjects assigned to BT STEPS without coaching will receive computer assisted Cognitive Behavior Therapy. They will receive a welcome and orientation call from the project manager and up to three automated reminder e-mails if there is no activity in the BT Steps website for 5 days. E-mails will describe most recent step the participant used and what to expect in upcoming steps. The focus of reminder messages is on the patients progress through BT STEPS."
62593288|NCT01522287|ACTIVE_COMPARATOR|BT Steps with non-therapist coaching|Subjects randomized to BT STEPS with coaching will receive computer assisted Cognitive Behavior Therapy plus regularly scheduled weekly coaching, encouragement and support via phone. Calls will focus on user's progress in BT STEPS, troubleshoot problems the participant is having with the program, and set progress goals for the next coaching session. Coaches will be supervised by the CBT therapist, and may consult with the CBT clinician as needed.
62593289|NCT01522287|ACTIVE_COMPARATOR|BT STEPS with therapist coaching|Subjects randomized to BT STEPS with therapist coaching will receive computer-assisted Cognitive Behavior Therapy plus regularly scheduled weekly coaching and support from a CBT therapist via phone. Calls will focus on user's progress in BT STEPS, troubleshoot problems the participant is having with the program, and set progress goals for the next coaching session.
62593290|NCT05453279|ACTIVE_COMPARATOR|Active (experimental)|Delcetravir inhalation via dry powder inhaler device administered up to 4 single ascending doses. According to tolerability of single ascending doses, delcetravir is then given as inhalation via dry powder device in multiple ascending doses, once daily for 7 days.
62593291|NCT05453279|PLACEBO_COMPARATOR|Placebo comparator|Placebo inhaler, identical in appearance to the active comparator, administered doses up to 4 single ascending doses. According to tolerability of single ascending doses, placebo doses are then given as inhalation via dry powder device in multiple ascending doses, once daily for 7 days.
62593292|NCT04894552|EXPERIMENTAL|One arm clinical trial|Convenience sampling method in which the first twenty cases of endometrial carcinoma patients who will undergo laparoscopic hysterectomy will be included. All cases will undergo laparoscopic hysterectomy. Sentinel lymph node biopsy will be detected, dissected and isolated. Then standard lymphadenectomy will be done
62593293|NCT06524492||FlowSense|This study compares the performance of two generations of non-invasive cerebrospinal fluid (CSF) shunt flow assessment devices. Measurements of functional implanted shunts and off-shunt locations will assess the diagnostic non-inferiority of the second-generation device to the first-generation device.
62593294|NCT03722953|OTHER|Aerobic Exercise|"Control: Cerebrovascular function and peripheral vascular function will be measured.~Aerobic Exercise: Across four separate visits, participants will perform light intensity exercise, light intensity exercise plus an additional task, vigorous intensity exercise and vigorous intensity exercise to match the energy expenditure of light intensity exercise visit."
62593295|NCT03410407||AML patients|AML patients according to the French-American-British (FAB) criteria, previously enrolled in GIMEMA Studies for AML treatment. AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.
62809520|NCT00908453|EXPERIMENTAL|18mg/kg of loading dose|
62424449|NCT01329705|EXPERIMENTAL|Dynasplint|Patients in the experimental Dynasplint group will be treated with the current standard of care, including onabotulinum toxin, and use the Ankle Dorsiflexion Dynasplint
62233466|NCT05545657||Type 2 Diabetes|These patients must have a definite diagnosis of type 2 diabetes mellitus (T2DM) according to the American Diabetes Association (ADA) standards. Some of these patients have symptoms of cognitive impairment, while others have normal cognition.
62593296|NCT05279976|EXPERIMENTAL|Children receiving education-Intervention group 1 (35 children)|Children in the intervention group 1 will be told by the researchers the operation preparation room and the pre-anesthesia process with a picture booklet. It will be ensured that the child and parent are together during the training. The booklet, which is printed separately for each child, will be given to the child and the parent after an average of 15-20 minutes of narration is completed. Simultaneous visual presentation will be made with the content of the picture booklet being explained to the child. While one of the researchers will explain the pre-operative process from the picture booklet, the other will explain the pre-operative preparation process simultaneously with the picture booklet by putting on the bonnet, mask and glove, and with the balloon inflated by the child. In this way, the pictures shown in the picture booklet will be matched with the real environment.
62809521|NCT00908453|EXPERIMENTAL|22.5mg/kg of loading dose|
62809522|NCT01636765||All participants|Patients with facial erythema associated with rosacea. There was no intervention in this study.
62809523|NCT03656003|EXPERIMENTAL|Procore needle|EchoTip ProCore needle (Cook Medical Inc., Bloomington, Ind., USA)
62809524|NCT03656003|ACTIVE_COMPARATOR|Conventional needle|Conventional 22-gauge EBUS-TBNA needle (Vizishot, Olympus, Japan)
62809525|NCT00721006|EXPERIMENTAL|MESENDO|All subjects will receive active treatment in a blinded fashion in the left or right lower limb. The opposite lower limb will receive placebo.
62809526|NCT00721006|PLACEBO_COMPARATOR|placebo|All subjects will receive placebo injections in a blinded fashion in the left or right lower limb. The opposite lower limb will receive active stem cell infusion
62809527|NCT04808817|EXPERIMENTAL|patients|
62809528|NCT04687306||Females|15 females
62233467|NCT05545657||Healthy Control|These participants have normal glucose tolerance and normal cognition.
62233468|NCT06385405|EXPERIMENTAL|The Precision Group|Patients in the precision group will be treated with Individualized alpha frequency Transcranial Magnetic Stimulation (αTMS) Treatment.
62233469|NCT06385405|ACTIVE_COMPARATOR|The Conventional Group|Patients in the conventional group will be treated with 10Hz-frequency TMS over the left dorsolateral prefrontal cortex (DLPFC).
62233470|NCT05937139|EXPERIMENTAL|Training group 1|After the scales are applied to the fathers in training group 1 on the 3rd postpartum day, breastfeeding education will begin. The training will last 39 days and the scales will be re-administered on the 42nd postpartum day and at the 12th week postpartum.
62233471|NCT05937139|EXPERIMENTAL|Training group 2|Breastfeeding education will begin to the fathers in training group 2 on the 3rd postpartum day. The training will last 39 days and the scales will be re-administered on the 42nd postpartum day and at the 12th week postpartum.
62233472|NCT05937139|NO_INTERVENTION|Control group 1|The scales will be administered to the fathers in the control group 2 on the 3rd day, 42nd day, and 12th week postpartum.
62233473|NCT05937139|NO_INTERVENTION|Control group 2|The scales will be administered to the fathers in the control group 2 on the 42nd day, and 12th week postpartum.
62233474|NCT01386281||Group 1|Drug (incl. Placebo)
62233475|NCT03416998|ACTIVE_COMPARATOR|Phototherapy Active|Phototherapy active group will be administered 30 minutes prior to the soccer match as well as 48 h after the match in direct contact with the skin with light pressure at predetermined sites: nine on the knee extensor muscles, six on the knee flexor muscles and two on the gastrocnemius muscle on both lower limbs.
62233476|NCT03416998|PLACEBO_COMPARATOR|Placebo Phototherapy|"Phototherapy placebo group will be administered 30 minutes prior to the soccer match as well as 48 h after the match in direct contact with the skin with light pressure at predetermined sites: nine on the knee extensor muscles, six on the knee flexor muscles and two on the gastrocnemius muscle on both lower limbs.~For placebo treatment, the same procedures and treatment times will be employed, but the equipment will be set in placebo mode. Only the researcher in charge of programming the device will have knowledge regarding which treatment is being used. However, the programmer will not participate in the execution of the treatment, evaluations or data analysis"
62233477|NCT06502431|EXPERIMENTAL|Symptomatic CMI group|
62233478|NCT06502431|EXPERIMENTAL|Non-Symptomatic CMI group|
62233479|NCT06502431|ACTIVE_COMPARATOR|Control group|
62233480|NCT01326533|EXPERIMENTAL|hydroxychloroquine|Thirteen weeks of daily hydroxychloroquine following FSIGTT testing
62233481|NCT01326533|PLACEBO_COMPARATOR|Placebo|Thirteen weeks of daily placebo following FSIGTT testing
62233482|NCT05741151|EXPERIMENTAL|PET-Neck Parkinsonian patients|Brain and neck PET-CT with 68Ga-PSMA scan would be administered
62809529|NCT04687306||Males|15 Males
62809530|NCT01018030|EXPERIMENTAL|FFNS 110 mcg QD|
62809531|NCT01018030|EXPERIMENTAL|FFNS 110 mcg BID|
62233483|NCT05566314|EXPERIMENTAL|Intervention|Herbal and probiotic beverage
62233484|NCT05566314|PLACEBO_COMPARATOR|Placebo|Similar beverage without the probiotics and botanicals
62809532|NCT01018030|PLACEBO_COMPARATOR|Placebo Nasal Spray|
62809533|NCT00252421|ACTIVE_COMPARATOR|Nitroglycerin|Nitroglycerin ointment 15 mg/day daily for 24 month
62809534|NCT00252421|PLACEBO_COMPARATOR|Placebo|Placebo ointment daily for 24 month
62809535|NCT05411718|EXPERIMENTAL|Naproxen|Participants will take two (2) naproxen matching capsules by mouth 1 time every day, at about the same time each day
62809536|NCT05411718|ACTIVE_COMPARATOR|Aspirin|Participants will take two (2) aspirin matching capsules by mouth 1 time every day, at about the same time each day
62809537|NCT06085534|EXPERIMENTAL|LNK01001 Dose A|Participants were randomized to receive LNK01001 capsule dose A BID orally for 12 weeks in Period 1. At Week 13, participants were re-randomized to LNK01001 dose A or B capsule BID orally for 12 weeks in Period 2.
62809538|NCT06085534|EXPERIMENTAL|LNK01001 Dose B|Participants were randomized to receive LNK01001 capsule dose B BID orally for 12 weeks in Period 1. At Week 13, participants were re-randomized to LNK01001 capsule dose A or B BID orally for 12 weeks in Period 2.
62809539|NCT06085534|PLACEBO_COMPARATOR|placebo|Participants were randomized to receive a placebo capsule twice a day (BID) orally for 12 weeks in Period 1. At Week 13 participants were re-randomized to receive LNK01001 capsule dose A or B BID orally for 12 weeks in Period 2.
62809540|NCT02655185||Heart failure|
62809541|NCT03296514|NO_INTERVENTION|Wait List Control|Will receive voucher for MBSR after study is concluded
62809542|NCT03296514|OTHER|Intervention|These people will receive the MBSR
62809543|NCT02849379|EXPERIMENTAL|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62593297|NCT05279976|EXPERIMENTAL|Children who are distracted-Intervention group 2 (35 children)|"Children included in intervention group 2 will be given a kaleidoscope. Each child will be given a separate kaleidoscope. It will be ensured that the child is with the parent while the child is looking at the kaleidoscope for an average of 15-20 minutes. After the attempt is over, the kaleidoscope will be presented to the child.~Usage of Kaleidoscope: It is a game tool that reproduces the outside image when viewed from inside the kaleidoscope. This image is obtained thanks to the glasses placed inside the kaleidoscope at different angles, and the images change as the kaleidoscope is rotated. Inside the kaleidoscope, there are mirrors or glasses placed with an inclination of 60 degrees. When viewed from one side of the kaleidoscope, images are often seen that are not the same."
62809544|NCT02849379|ACTIVE_COMPARATOR|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62809545|NCT04227470|EXPERIMENTAL|Experimental: HBM9161, 340mg|HBM 9161 injection, 340mg, weekly administered by subcutaneous for a period of 4 weeks.
62809546|NCT04227470|EXPERIMENTAL|Experimental: HBM9161, 680mg|HBM 9161 injection, 680mg, weekly administered by subcutaneous for a period of 4 weeks.
62809547|NCT01931540|EXPERIMENTAL|Exercise Training - 17 offspring of OM|4 months exercise training, OM: Obese mothers
62809548|NCT01931540|NO_INTERVENTION|11 non-frail controls (9 LM)|Studied only at baseline
62809549|NCT01931540|EXPERIMENTAL|Exercise Training - 20 offspring of LM|4 months exercise training, LM:Lean/Normal Mothers
62593298|NCT05279976|NO_INTERVENTION|Control group of children (35 children)|After obtaining informed consent from the children and parents included in the control group after randomization, the pre-test (first measurement) will be applied. The final test (Second Measurement) will be applied immediately after the child wears the surgical gown.
62593299|NCT05279976|EXPERIMENTAL|Parents of children receiving education-Intervention group 1 (35 parents)|The parents of children included in intervention group 1 will also be in intervention group 1.It will be ensured that the child and parent are together during the training. The booklet, which is printed separately for each child, will be given to the child and the parent after an average of 15-20 minutes of narration is completed.
62593300|NCT05279976|EXPERIMENTAL|Parents of distracted children-Intervention group 2 (35 parents)|The parents of children included in intervention group 2 will also be in intervention group 2. Children included in intervention group 2 will be given a kaleidoscope. Each child will be given a separate kaleidoscope. It will be ensured that the child is with the parent while the child is looking at the kaleidoscope for an average of 15-20 minutes.
62809550|NCT05416138|EXPERIMENTAL|TMS over the left prefrontal cortex|Transcranial magnetic stimulation (TMS) will be administrated with a figure-8 coil over the left dorsolateral prefrontal cortex (DLPFC) at the intensity of up to 120% of the individualized resting motor threshold (rMT). Stimulation will be performed during and for the duration of the cognitive test. Up to three TMS pulses will be delivered at the beginning of every test trial (each trial duration is 2-6 seconds). The total duration of the cognitive testing and stimulation per session is approximately 40 minutes (in 4 blocks with breaks in-between).
62809551|NCT05416138|SHAM_COMPARATOR|TMS over the head vertex|Transcranial magnetic stimulation (TMS) will be administrated with a figure-8 coil over the head vertex at the intensity of up to 120% of the individualized resting motor threshold (rMT). Stimulation will be performed during and for the duration of the cognitive test. Up to three TMS pulses will be delivered at the beginning of every test trial (each trial duration is 2-6 seconds). The total duration of the cognitive testing per session is approximately 40 minutes (in 4 blocks with breaks in-between).
62809552|NCT04345341|ACTIVE_COMPARATOR|Laparoscopic assisted TAP block|Laparoscopic assisted TAP block will be done by surgeon intra-operatively
62809553|NCT04345341|NO_INTERVENTION|no TAP block|no TAP block would be done
62809554|NCT04761263|ACTIVE_COMPARATOR|Selected Physical Therapy group|will receive a selected physical therapy program for 90 minutes, 3 times/week for 3 successive months.
62809555|NCT04761263|EXPERIMENTAL|Task-oriented circuit training group|Children allocated to the study group will receive the same selected physical therapy program given to the control group for 45 minutes in addition to 45 minutes task-oriented circuit training program. The frequency of the whole program will be three times per week, for three months.
62809556|NCT02804334||Healthy Volunteers|Participants with no current or lifetime psychiatric disorders
62809557|NCT02804334||Untreated Bipolar Disorder|Participants who meet criteria for current bipolar disorder but who are not currently taking any psychotropic medications
62233485|NCT05758311||Multi-center study|The study population will be inhabitants of both sexes with different levels of physical activity who reside in the metropolitan area of cities in Colombia, Mexico, Costa Rica, and Spain. The population sample will be obtained through an internal call to students and administrative personnel of universities and Smart Fit sites with an inter-institutional collaboration agreement with Dynamical Business \& Science Society (DBSS International). The first study will be carried out in Colombia.
62809558|NCT05539885|ACTIVE_COMPARATOR|Pre-incisional PIFB|Group P (ultrasound guided parasternal; PIFP block): patients will be injected with 0.4 mL/kg 0.25 bupivacaine in the fascial plane between the pectoralis major and internal intercostal muscles on each side of the sternum after induction of anesthesia and before skin incision under ultrasound guidance.
62809559|NCT05539885|ACTIVE_COMPARATOR|Post-incisional PIFB|"Group S: After sternal closure, the surgeon will inject bupivacaine (0.5- to 2-mL aliquots depending on the weight) in the fascial plane under direct vision between the 5 anterior (2nd-6th) intercostal spaces on each side 1 to 1.5 cm lateral to the sternal edge using 25-gauge, 50 mm needle. The surgeon will inject the same dose and concentration of bupivacaine used in the ultrasound technique. This technique was prescribed before by Chaudhary et al (23).~In both techniques, the maximum dose of bupivacaine will never be exceeded (2 mg/kg). In addition, all patients were administered 2 mL of 0.25% bupivacaine at the site of the mediastinal drain location."
62033184|NCT06291168|EXPERIMENTAL|Yoga-based Exercise (YBE) Group|"Yoga treatment includes exercise, respiration, balance and coordination, and stretching and will be performed by a physiotherapist with yoga certification.~Yoga exercises will be practiced with the classical yoga program, divided into groups of 3-4 people, for 8 weeks, 2 days a week, 60 minutes a day."
62033185|NCT06291168|EXPERIMENTAL|Conventional Exercise (Control) Group (CG)|Spinal stabilization exercises for the lumbar region will be given in 3 phases following the protocol given to the chiropractic manipulation group. The exercises will be performed two days a week under the supervision of a physiotherapist. Individuals will be called to the hospital two days a week for 8 weeks and will be advised to continue the exercises during the follow-up period. At the end of the 12th week, the exercises will be repeated and progressed with the physiotherapist.
62033186|NCT02100982|OTHER|Care As Usual|Before the office visit with the PCP, patient participants in the Care As Usual arm will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
62033187|NCT02100982|EXPERIMENTAL|Customized Care|Before the office visit with the PCP, patient participants in the intervention group will interact with the computer based components of the customized care intervention while in the waiting room. The research staff will help the participant use an iPad in the waiting room and direct them to the Discussion Prioritization tool (DPT). After participants use the DPT, the program automatically generates a customized questions prompt list (QPL) which will be printed out in the office. Study staff will hand the QPL to intervention patients to bring to their office visit with the PCP. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
62233486|NCT04196608||P. aeruginosa isolates|All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed
62233487|NCT04196608||Enterobacterales isolates|All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed
62593301|NCT05279976|NO_INTERVENTION|Control group of parents (35 parents)|The parents of children included in control group will also be in control group.
62809560|NCT03224130|EXPERIMENTAL|Nurse Phone Call|Families in this arm will receive a phone call within 96 hours of discharge
62809561|NCT03224130|ACTIVE_COMPARATOR|Standard of Care|This arm will receive standard of care.
62809562|NCT00867581||1|chronic-stage patients after infarction in the territory of unilateral middle cerebral artery
62233488|NCT03294109|EXPERIMENTAL|study|liposomal bupivacain
62593302|NCT06618235|EXPERIMENTAL|THEO-260|
62593303|NCT05380544|SHAM_COMPARATOR|Sham shockwave therapy|Sham shockwave therapy in standard ulcer care.
62593304|NCT05380544|ACTIVE_COMPARATOR|Low dose shockwave therapy|100 shocks per cm2 plus standard ulcer care
62809563|NCT00867581||2|age, sex and risk factor matched volunteers without ischemic stroke
62809564|NCT01575821|EXPERIMENTAL|Eucalyptus honey ,|75 children
62593305|NCT05380544|ACTIVE_COMPARATOR|High dose shockwave therapy|500 shocks per cm2 plus standard ulcer care
62809565|NCT01575821|EXPERIMENTAL|Labiatae honey|75 children allocated
62809566|NCT01575821|EXPERIMENTAL|Silan date extract (placebo)|75 children allocated
62809567|NCT01575821|EXPERIMENTAL|Citrus honey|75 children allocated
62809568|NCT00057863|EXPERIMENTAL|Treatment (paclitaxel, oxaliplatin)|Patients receive paclitaxel IV over 3 hours and oxaliplatin IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62809569|NCT06411639|EXPERIMENTAL|Ianalumab 300 mg|Participants will receive Ianalumab 300 mg subcutaneous (s.c.) monthly
62233489|NCT03294109|NO_INTERVENTION|control|no intervention
62233490|NCT04768257||Patients with COVID-19, treated in intensive care|
62233491|NCT04768257||Patients with COVID-19, treated in hospital ward|
62233492|NCT04768257||Patients with COVID-19, treated at home|
62233493|NCT02100397|EXPERIMENTAL|Dose|A dose of S.paratyphi will be given to up to 20 participants to determine the attack rate.
62233494|NCT04237766|EXPERIMENTAL|Experimental group|All patients included in the experimental group should be on prophylactic treatment with factor 8 (FVIII) or factor 9 (FIX) concentrates. Likewise, the factor should be administered on the same day that they receive each movement display therapy treatment sessions. Each session will last approximately 40 minutes, with 7 physiotherapy sessions a week taking place over a period of 4 weeks.
62233495|NCT04237766|NO_INTERVENTION|Control group|Subjects included in the control group will not receive physical therapy through mirror therapy and motion display. They will continue with their usual routine of physical activity and exercise, and with the same pharmacological treatment regimen with factor 8 (FVIII) or factor 9 (FIX) concentrates. At the end of the study period the intervention will be applied under the same conditions as the experimental group, analyzing the overall sample at the end of the study.
62233496|NCT05446688|EXPERIMENTAL|6MW3211|6MW3211 injection, 45mg/kg, Q2W
62233497|NCT01794923|EXPERIMENTAL|Ibuprofen 5% topical gel BID|IBU BID (Treatment A)
62233498|NCT01794923|PLACEBO_COMPARATOR|Placebo topical gel BID|Placebo BID (Treatment B)
62233499|NCT01794923|EXPERIMENTAL|Ibuprofen 5% topical gel TID|IBU TID (Treatment C)
62233500|NCT01794923|PLACEBO_COMPARATOR|Placebo topical gel TID|Placebo TID (Treatment D)
62233501|NCT00712309|ACTIVE_COMPARATOR|1|Percutaneous transluminal angioplasty (PTA)
62233502|NCT00712309|ACTIVE_COMPARATOR|2|Primary stenting
62233503|NCT02359877|EXPERIMENTAL|BCD-054|Pegylated interferon beta 1a Single doses - 60 mcg, SC/IM Single doses - 120 mcg, SC/IM Single doses - 240 mcg, SC/IM Single doses - 360 mcg, SC/IM Multiple doses - 180 mcg, SC/IM
62233504|NCT02359877|ACTIVE_COMPARATOR|Rebif|interferon beta 1a 44 mcg, SC, 3 times a week for 2 weeks
62233505|NCT02359877|ACTIVE_COMPARATOR|Avonex|interferon beta 1a 30 mcg, IM, once a week for 2 weeks
62233506|NCT02623881|ACTIVE_COMPARATOR|Cervical pessary|Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
62233507|NCT02623881|ACTIVE_COMPARATOR|Vaginal Progesterone|Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
62233508|NCT00542529|PLACEBO_COMPARATOR|Cohort 1|Placebo or 2.0 mg/kg of Imprime PGG dosed in 7 different treatment regimens in combination with G-CSF for up to 4 consecutive days.
62233509|NCT00542529|PLACEBO_COMPARATOR|Cohort 2|Placebo or 4.0 mg/kg of Imprime PGG dosed in 7 different treatment regimens in combination with G-CSF for up to 4 consecutive days.
62233510|NCT05213910|EXPERIMENTAL|Patients using the product|
62233511|NCT01349725|EXPERIMENTAL|ARRY-502|
62233512|NCT01349725|PLACEBO_COMPARATOR|Placebo|
62233513|NCT05420883|ACTIVE_COMPARATOR|Acupressure|One minute after the start of the Nonstress test recording, an application will be made to the Zhi yin (BL67) acupuncture point with a depth of 0.1-0.2 cm, on the outer edge of the little toe of both feet, at the nail end point. The application will be applied to both points simultaneously for 2 minutes consecutively and then repeated 2 times with a 3-minute rest period.
62233514|NCT05420883|ACTIVE_COMPARATOR|Halogen light|One minute after the start of the Nonstress Test recording, halogen light stimulation will be given from the mother's abdomen to the fetal head for 10 seconds with a flashlight device worth 1,000,000 candles. The procedure will be repeated on the same spot 10 minutes after the first halogen light stimulation.
62233515|NCT05420883|ACTIVE_COMPARATOR|Control|No action will be taken against this group.
62233516|NCT05617651|ACTIVE_COMPARATOR|A group|"Period 1 : Ilaprazole 10mg 2Tab, one a day~Period 2 : Ilaprazole 20mg 1Tab, one a day~Period 3 : Ilaprazole 10mg 2Tab, one a day"
62233517|NCT05617651|ACTIVE_COMPARATOR|B group|"Period 1 : Ilaprazole 20mg 1Tab, one a day~Period 2 : Ilaprazole 10mg 2Tab, one a day~Period 3 : Ilaprazole 20mg 1Tab, one a day"
62809570|NCT06343246|EXPERIMENTAL|Functional IMT Group|Functional IMT Group (n:15) : will recieve functional inspiratory muscle training (exercise + 50% of MIP)
62809571|NCT06343246|ACTIVE_COMPARATOR|IMT Group|IMT Group I (n:15): will recieve inspiratory muscle training (50% of MIP )
62809572|NCT06343246|EXPERIMENTAL|Control group|Control group (n:15): will recieve breathing exercises training
62809573|NCT01403623|ACTIVE_COMPARATOR|Resuscitation with plastic bag|Plastic bag will be used during and after resuscitation to assist with temperature regulation.
62809574|NCT01403623|SHAM_COMPARATOR|Standard resuscitation- no plastic bag|Infant will be resuscitated per standard of care without being placed in a plastic bag for temperature regulation.
62809575|NCT00826644|EXPERIMENTAL|Belotecan plus Cisplatin|
62809576|NCT00826644|ACTIVE_COMPARATOR|Etoposide plus Cisplatin|
62809577|NCT04777617||WU/Barnes cohort|SPK patients in this group will be recruited from WU/Barnes Transplant center. A total of 25 from this cohort will be recruited and asked to provide a blood sample to test for donor derived cell free DNA 3 times over the course of the first year of transplant. In addition, if any biopsies or rejections occur, additional samples will be requested at the time of biopsy and for an additional two follow-ups at least one month apart.
62233518|NCT00427336|EXPERIMENTAL|Fludarabine + Cyclophosphamide + ATG|Fludarabine 30 mg/m\^2/day by vein (IV), Cyclophosphamide IV 300 mg/m\^2/day, ATG (Antithymocyte Globulin) IV 3.75 mg/kg/day
62809578|NCT04777617||UT Southwestern cohort|SPK patients in this group will be recruited from WU/Barnes Transplant center. A total of 25 from this cohort will be recruited and asked to provide a blood sample to test for donor derived cell free DNA 3 times over the course of the first year of transplant. In addition, if any biopsies or rejections occur, additional samples will be requested at the time of biopsy and for an additional two follow-ups at least one month apart.
62809579|NCT04831866||Surveillance Cohort|Surveillance Cohort: Schools participating in this cohort will be performing surveillance testing weekly on approximately 10-20% of students and 100% of staff.
62809580|NCT04831866||Exposure Cohort|Exposure Cohort: Schools participating in this cohort will be performing exposure testing on students and staff who have been identified as having close contact with school members diagnosed with SARS-CoV-2 infection.
62819563|NCT03009058|EXPERIMENTAL|IMM-101+ anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) melanoma|IMM-101 will be given in combination with standard treatment with ipilimumab. In order to ensure that there are no increased immune-related adverse events (AEs), the first 3 patients entering the ipilimumab cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen thereafter.
62033188|NCT05715294|EXPERIMENTAL|Music Application Group|After explaining the purpose of the study and the way it was applied to behçet's patients in the music group, Introductory Information Form, Behçet's Syndrome Activity Scale (BSAS), Richards-Campbell Sleep Questionnaire (RCSQ) will be applied. Patients will listen to music composed in Uşşak makam for 50 minutes before going to bed every day for 7 days. After the first interview, the patients will be reminded of the music application by phone call and 2 text messages every day by the researcher. Interviews will be recorded on the Patient's Telephone Follow-up Form while Listening to Music. On the 8th day, the BSAS and RCSQ scales will be reapplied to the patients in the intervention group.
62033189|NCT05715294|NO_INTERVENTION|Control Group|After explaining the purpose of the study and the way it was applied to behçet's patients in the control group, Introductory Information Form, Behçet's Syndrome Activity Scale (BSAS), Richards-Campbell Sleep Questionnaire (RCSQ) will be applied.No application will be made to the control group. On the 8th day, the BSAS and RCSQ scales will be reapplied to the patients.
62033190|NCT01027000|EXPERIMENTAL|Treatment (Combination of chemotherapy and transplant)|See detailed description
62033191|NCT06085170||Group I|Group I (women with PCOs on ultrasound)
62033192|NCT06085170||Group II|group II(Group II will be women rated to have a normal voice as assessed using Auditory-Perceptual Evaluation of Voice, these women have a regular menstrual cycles and no PCOS on ultrasound)
62033193|NCT00607555||Observation|Premature infants over 23 weeks of gestation and less than 1.25 kilograms at birth, who are tolerating feedings, and are clinically stable
62033194|NCT01412008|NO_INTERVENTION|botox diffusion|Each subject was given 3 injections in lateral gastrocnemius muscle:2 botox, 1 saline, each injection was 2.5mL. MRI of the lower leg was taken prior to injections and 2 months post for a comparison of diffusion properties.
62233519|NCT00388453|ACTIVE_COMPARATOR|1|Healthy volunteers with no history of GERD or EERD or Proton Pump Inhibitor (PPI) use
62233520|NCT00388453|EXPERIMENTAL|2|subject is known to have GERD based on symptoms and previous positive response to PPI
62233521|NCT00388453|EXPERIMENTAL|3|subject is known to have EERD based on symptoms and previous positive response to PPI
62233522|NCT03708822|EXPERIMENTAL|Docetaxel and Cisplatin and Nimotuzumab|All eligible patients received intravenous nimotuzumab plus docetaxel and cisplatin every 3 weeks for a maximum of 6 cycles, or until disease progression, death, intolerable toxicity.
62233523|NCT04123834|EXPERIMENTAL|implantless Arthroscopic ACL reconstruction|implantless Arthroscopic ACL reconstruction using press-fit femoral technique
62233524|NCT04123834|EXPERIMENTAL|Arthroscopic ACL reconstruction with implant|ACL reconstruction with implant (hamstring autograft fixed with bioscrew and endo-button)
62033195|NCT02368249|PLACEBO_COMPARATOR|Control Group|Patients receiving post-operative placebo (Ringer lactate solution) treatment to preserve the renal function
62233525|NCT06079684|EXPERIMENTAL|Vacuum Group|Vacuum Group with 32 patients: for 10 consecutive days, all patients performed the same program procedures: Intermittent vacuum therapy (for 30 minutes, with a Vacumed device -the lower body was positioned in the vacuum chamber, which was sealed around the participant's trunk with a cuff at the level of the umbilicus to allow application of negative pressure), general warm mud bath (20 minutes at 38 degrees Celsius), hydrokinetotherapy in saline water from Lake Techirghiol by a certified physical therapist (20 minutes at 35 degrees Celsius), massage therapy for paravertebral muscles, shoulder and pelvis girdle and kinesiotherapy with a standard program for peripheric joints for 30 minutes
62233526|NCT06079684|ACTIVE_COMPARATOR|Control Group|Control Group with 33 patients: for 10 consecutive days, all patients performed the same program procedures: general warm mud bath (20 minutes at 38 degrees Celsius), hydrokinetotherapy in saline water from Lake Techirghiol by a certified physical therapist (20 minutes at 35 degrees Celsius), massage therapy for paravertebral muscles, shoulder and pelvis girdle and kinesiotherapy with a standard program for peripheric joints for 30 minutes
62233527|NCT00876928|PLACEBO_COMPARATOR|Placebo|Subjects with low vitamin D levels and pre-diabetes
62233528|NCT00876928|EXPERIMENTAL|vitamin D|Subjects with low vitamin D levels and pre-diabetes
62233529|NCT05606835|ACTIVE_COMPARATOR|Pronation Group|Participants will be assessed using the foot posture index-6 (FPI-6), and those who exhibit pronation of the subtalar joint will be included in the study. Participants to be included in the study will be divided into two groups according to their values for pronation increase in the subtalar joint. Participants with a value between 6 and 9 according to FPI-6 will be included in pronation group.
62233530|NCT05606835|ACTIVE_COMPARATOR|Hyper pronation group|Participants with a value between 10 and 12 according to FPI-6 will be included in hyper pronation group.
62233531|NCT01271803|EXPERIMENTAL|DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 milligrams (mg) cobimetinib once daily (QD) on Days 1-14, followed by 14 days off on Days 15-28 (14/14 dosing schedule) and oral 720 mg vemurafenib twice daily (BID) on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
62233532|NCT01271803|EXPERIMENTAL|DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on Days 1-21, followed by 7 days off on Days 22-28 (21/7 dosing schedule) and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
62233533|NCT01271803|EXPERIMENTAL|DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
62593306|NCT06545773|EXPERIMENTAL|Group 1: ProTaper Next Nickel-Titanium File (PTN)|Root canals will be prepared using the ProTaper Next (PTN) instrument. Coronal flaring will be performed using ProTaper Next XA (accessory) in 300 rpm speed and 2 Ncm torque settings. (The same speed and torque settings will be used for all PTN instruments). The glide path will be prepared with ProGlider (Dentsply, Maillefer). ProTaper Next X1 (17 .04) and then X2 (25 .06) will be advanced in the apical direction using a brushing motion. If debris is observed in the apical part of X2 removed from the root canal after reaching the working length, the shaping of the root canal will be completed, and X3 (30 .07) will not be used. If no debris is observed in the apical part of X2 and the #25 K-File reaches the working length loosely, shaping will be continued with X3. Shaping with ProTaper Next X3 will be done in the same way as X1 and X2.
62233534|NCT01271803|EXPERIMENTAL|DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on Days 1-28 (28/0 dosing schedule) and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
62233535|NCT01271803|EXPERIMENTAL|DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 28/0 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
62593307|NCT06545773|EXPERIMENTAL|Group 2: TruNatomy Nickel-Titanium File (TN)|"Root canals will be prepared using the TruNatomy (TN) instrument. Coronal flaring will be performed using the Orifice Modifier (20 .08) at a speed of 400 rpm and a torque setting of 1.5 Ncm. (The same speed and torque settings will be used for all TN instruments.) The Orifice Modifier will be advanced up to 3 mm within the root canal. The guide path will be prepared with TruNatomy Glider (17 .02-variable taper).~The TruNatomy Prime (26 .04) file will be used in the canal by moving it apically back and forth 2-3 times and not exceeding 2-5 mm, using a brushing motion. Before proceeding to the TruNatomy Medium (35 .04) file, the debris accumulated in the apical part of the Prime file will be checked. If there is no debris between the apical flutes of the TruNatomy Prime file, shaping will be continued with the TruNatomy Medium file. Shaping with TruNatomy Medium will be done in the same manner as with TN Prime."
62033196|NCT02368249|EXPERIMENTAL|Terlipressin Group|Patients receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
62233536|NCT01271803|EXPERIMENTAL|DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 80 mg cobimetinib QD on 14/14 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
62033197|NCT05224050|EXPERIMENTAL|Heart Rate Variability Biofeedback-Smoking Cessation Therapy (HRVB-SCT)|All participants in this open trial will receive individualized training in resonance breathing using biofeedback to help improve self-regulation (HRVB), cognitive-behavioral smoking cessation treatment (SCT), and up to 8-weeks of the transdermal nicotine patch (NRT).
62033198|NCT06446843|ACTIVE_COMPARATOR|(control group) will receive Arthrocentesis alone|arthrocentesis with Ringer's lactate solution, of the superior joint compartment
62033199|NCT06446843|EXPERIMENTAL|(study group1) will receive (Arthrocentesis+HA)|arthrocentesis with Ringer's lactate solution, of the superior joint compartment then inject 1ml of HA following arthrocentesis.
62233537|NCT01271803|EXPERIMENTAL|DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 100 mg cobimetinib QD on 14/14 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
62593308|NCT02567734|EXPERIMENTAL|Irreversible electroporation|In this group，eligible patients were selected to receive the CT-guided percutaneous irreversible electroporation ablation.
62593309|NCT06620393|EXPERIMENTAL|Dexmedetomidine|DEX (4 mcg/100 ml supplied by Juno Pharmaceuticals) will be initiated at a starting dose of 0.6 mcg/kg/hour and increased by 0.2 mcg/kg/hour every 30 minutes up to final dose of 1.4 mcg/kg/hour.
62424450|NCT05100849|EXPERIMENTAL|Kinect-based cognitive training|Standard treatment protocol and 14 sessions (biweekly during 30 minutes) of Kinect-based cognitive training inspired by instrumental activities of daily living.
62424451|NCT05100849|EXPERIMENTAL|Tablet-based cognitive training|Standard treatment protocol and 14 sessions (biweekly during 30 minutes) of Tablet-based cognitive training inspired by instrumental activities of daily living.
62593310|NCT06620393|PLACEBO_COMPARATOR|Placebo|Matching placebo (NS 0.9% 100ml)
62593311|NCT03931772|EXPERIMENTAL|Automated Self-Hypnosis Intervention for Smoking Cessation|Participants will first try this intervention at their Baseline visit following an assessment of trait hypnotizability. After being guided through the program by their experimenter (i.e., set-up procedures in addition to the actual hypnotic exercise) participants will provide initial feedback on the program through a series of questions. The entire appointment will take approximately one hour and will take place at The Center on Stress and Health. Participants will be provided with the Amazon Alexa device to take home (necessary for using the program), or the interactive Reveri (www.reveri.com) mobile app. After the lab visit participants will continue using the intervention at home as needed throughout the 24 months of study participation (recommended every few hours or whenever they feel the urge to smoke). Furthermore, participants will be taking an online 15-minute survey at the baseline visit, and then 1, 3, 6, 12 and 24-month online follow-up surveys at home.
62593312|NCT03931772|EXPERIMENTAL|Automated Self-Hypnosis Intervention for Pain Reduction|Participants will first try this intervention at their Baseline visit following an assessment of trait hypnotizability. After being guided through the program by their experimenter (i.e., set-up procedures in addition to the actual hypnotic exercise) participants will provide initial feedback on the program through a series of questions. The entire appointment will take approximately one hour and will take place at The Center on Stress and Health, or remotely during the COVID-19 pandemic. Participants will be provided with the Amazon Alexa device to take home (necessary for using the program), or the interactive Reveri (www.reveri.com) mobile app. After the lab or remote visit participants will continue using the intervention at home as needed (recommended every few hours or whenever they experience an increase in pain). Furthermore, participants will be taking an online 15-minute survey at the baseline visit, and then 1, 3, 6, 12 and 24-month online follow-up surveys at home.
62033200|NCT06446843|EXPERIMENTAL|(study group2)(Arthrocentesis following i-PRF +HA)|"arthrocentesis with Ringer's lactate solution, of the superior joint compartment then inject~1 ml of i- PRF then1ml of HA following arthrocentesis."
62233538|NCT01271803|EXPERIMENTAL|DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 14/14 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
62233539|NCT01271803|EXPERIMENTAL|DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 80 mg cobimetinib QD on 14/14 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
62233540|NCT01271803|EXPERIMENTAL|Cobimetinib Monotherapy (100 mg or 60 mg)|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule, or oral 100 mg cobimetinib QD on 14/14 dosing schedule of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
62233541|NCT01271803|EXPERIMENTAL|CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
62424452|NCT04403191||Group A|received ondansetron 4 mg intravenous immediately once reached to I.C.U and another same dose after 6 hours
62424453|NCT04403191||Group B|received isopropyl alcohol 70% inhalation every 15 min for 4 times then repeated after 6 hours
62424454|NCT04403191||Group C|received intravenous normal saline at rate of 20 ml/kg over 30 minute and repeated by the same dose after 6 hours.
62424455|NCT04738188|EXPERIMENTAL|Drug-eluting bead transarterial chemoembolization(DEB-TACE)|
62233542|NCT01271803|EXPERIMENTAL|CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
62233543|NCT05830409|EXPERIMENTAL|Multisensorial Stimulation Group|Preterm newborns who will receive multisensory stimulation during the eye examination.
62424456|NCT04738188|ACTIVE_COMPARATOR|conventional transarterial chemoembolization(cTACE)|
62424457|NCT03923400||JI-GIST|The series comprises 77 patients, of which 29 (37.7%) were located in the jejunum or ileum (JI-GIST).
62233544|NCT05830409|NO_INTERVENTION|Control Group|Preterm newborns who will receive routine care during the eye examination
62424458|NCT03923400||G-GIST|The series comprises 77 patients, of which 48 (62.3%) were located in the stomach (G-GIST).
62233545|NCT03836989|EXPERIMENTAL|High-volt electrical stimulation|"Plan to use a monophasic waveform having 100µmsec pulse duration, at 35 Hz using tolerated voltage to generate a contraction a total of 20 minutes.~The stimulation will have 10 seconds on time, 30 seconds off time and 2 second ramp up and down. Electrical stimulation will be produced with the Orthostim 3 device (VQ Ortho Care). The cathode will be placed on the ipsilateral muscle to stimulate and the anode over the ipsilateral mastoid region.~Four facial muscles will be stimulated: 1)frontalis, 2) orbicularis oculi, 3) zygomaticus major, and 4) orbicularis oris.~The voltage is turned up by the participant until he or she can see twitches or as high as tolerated. Ten contractions in each muscle group will be performed or 5 minutes per muscle if no contraction is achieved."
62233546|NCT03836989|PLACEBO_COMPARATOR|Subsensory electrical stimulation|"Plan to use the same device and settings to provide placebo treatment by delivering minimal electricity. The settings will be the same as the intervention except the voltage will be subsensory. ie. below the minimum at which patients feels any effect of the current.~The voltage is turned down two clicks from the voltage at which the participant can first notice any electricity or at the minimal setting."
62593313|NCT03931772|EXPERIMENTAL|Automated Self-Hypnosis Intervention for Stress Reduction|Participants will first try this intervention at their Baseline visit following an assessment of trait hypnotizability. After being guided through the program by their experimenter (i.e., set-up procedures in addition to the actual hypnotic exercise) participants will provide initial feedback on the program through a series of questions. The entire appointment will take approximately one hour and will take place at The Center on Stress and Health, or remotely during the COVID-19 pandemic. Participants will be provided with the Amazon Alexa device to take home (necessary for using the program), or the interactive Reveri (www.reveri.com) mobile app. After the lab or remote visit participants will continue using the intervention at home as needed (recommended every few hours or whenever they experience an increase in stress). Furthermore, participants will be taking an online 15-minute survey at the baseline visit, and then 1, 3, 6, 12 and 24-month online follow-up surveys at home.
62424459|NCT02583607|EXPERIMENTAL|Brava and fat transfer|"The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.~Woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it."
62424460|NCT01938521|EXPERIMENTAL|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
62424461|NCT01938521|PLACEBO_COMPARATOR|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) similar powder to mimic 1000 mg of Red Grape Cells (RGC), once daily by mouth for three month
62424462|NCT02498119||Normal|Patient sample within the normal range of blood results.
62424463|NCT02498119||Abnormal|Patient sample from freshly diagnosed Type 2 Diabetes Mellitus.
62424464|NCT02999919|ACTIVE_COMPARATOR|BMI ≥ 30|BMI ≥ 30
62424465|NCT02999919|ACTIVE_COMPARATOR|BMI < 30|BMI \<30
62593314|NCT05498103|ACTIVE_COMPARATOR|Methazolamide 25 mg|Once a day \[q.d\] in the morning for 1 week, Twice a day \[b.i.d.\] in the morning and evening for 1 week
62593315|NCT05498103|ACTIVE_COMPARATOR|Methazolamide 50 mg|Once a day \[q.d\] in the morning for 1 week, Twice a day \[b.i.d.\] in the morning and evening for 1 week
62424466|NCT04064437||Individuals with type 1 diabetes|
62424467|NCT04064437||Healthy controls|
62424468|NCT01488799|ACTIVE_COMPARATOR|MI-CBT|
62424469|NCT01488799|ACTIVE_COMPARATOR|CBT alone|
62424470|NCT01518621|ACTIVE_COMPARATOR|Radiotherapy alone|Total brain irradiation, 3Gy x10
62424471|NCT01518621|EXPERIMENTAL|Radiation plus erlotinib|Total brain irradiation, 3Gy x10 plus erlotinib 150 mg q d from radiation day -1 through last day of irradiation
62424472|NCT04345887||Spironolactone|2 x 100 mg spironolactone
62424473|NCT04345887||Placebo|2 x 1 placebo
62424474|NCT03944707|EXPERIMENTAL|LOU064|LOU064 100 mg once daily orally
62424475|NCT03944707|PLACEBO_COMPARATOR|Placebo|Placebo once daily orally
62424476|NCT05202600||Incidental appendectomy (IA)|Group IA will include adult patients operated on for colon tumors who have data on age, sex, data on a previously diagnosed colon tumor, data on incidental appendectomy, and a PHD finding for a removed vermiform appendix.
62424477|NCT05202600||Acute appendectomy (AA)|Group AA will include adult patients who have been operated due to clinical suspicion of acute appendicitis and have data on age, sex, data on the diagnosis of acute appendicitis and accompanying PHD findings of the performed appendectomy.
62424478|NCT05161559|EXPERIMENTAL|Fuji Bond LC (Glass ionomer based adhesive)|Patients received in Class V cavity preparation Fuji Bond LC (Glass ionomer based adhesive) on one tooth of the mouth
62424479|NCT05161559|EXPERIMENTAL|Riva Bond LC (Glass ionomer based adhesive)|Patients received in Class V cavity preparation Riva Bond LC (Glass ionomer based adhesive) on one tooth of the mouth
62424480|NCT05161559|EXPERIMENTAL|Single Bond Universal (self-etch adhesive)|Patients received in Class V cavity preparation Single Bond Universal (self-etch adhesive) on one tooth of the mouth
62424481|NCT05161559|EXPERIMENTAL|Clearfill S3 Bond (self-etch adhesive)|Patients received in Class V cavity preparation Clearfill S3 Bond (self-etch adhesive) on one tooth of the mouth
62424482|NCT05161559|EXPERIMENTAL|OptiBond FL (three step etch & rinse adhesive)|Patients received in Class V cavity preparation OptiBond FL (three step etch \& rinse adhesive) on one tooth of the mouth
62593316|NCT06621927|ACTIVE_COMPARATOR|Group receiving nutritional intervention|The ideal food pyramid created for rheumatoid arthritis patients was applied to the patients and followed for 12 weeks.
62593317|NCT06621927|PLACEBO_COMPARATOR|control group|Patients diagnosed with rheumatoid arthritis and meeting the inclusion criteria were included in the control group and no intervention was applied. At the beginning and end of the study, a questionnaire, blood and stool samples were taken.
62593318|NCT05883436|OTHER|Single Arm Observational|Cervical Interbody Cage
62593319|NCT00940966|EXPERIMENTAL|energy restricted very-low carbohydrate|non-energy restricted ketogenic diet .
62593320|NCT00940966|ACTIVE_COMPARATOR|ADA diet|standard ADA diet
62593321|NCT00940966|ACTIVE_COMPARATOR|low glycemic index|restricted ketogenic diet
62593322|NCT05098912|ACTIVE_COMPARATOR|Manual acupuncture|"The subjects/population of this study is woman at age 30-50 who meet the inclusion criteria. Subjects group with manual acupuncture treatment will be treated with 6 session of manual acupuncture at:~From the superior of zygomatic arch through ST 2 to LI 20 bilaterally using a needle size of 0.25 x 60 mm From the inferior of zygomatic arch through SI 18 to ST 4 bilaterally using a needle size of 0.25 x 60 mm From ST 7 to ST 4 bilaterally using a needle size of 0.25 x 60 mm Along the nasolabial crease through ST 4 to the bilateral EXHN-8 using a needle size of 0.25 x 40 mm"
62593323|NCT05098912|ACTIVE_COMPARATOR|Thread embedding acupuncture|"The subjects/population of this study is woman at age 30-50 who meet the inclusion criteria. Subjects group with thread embedding acupuncture group treatment will be treated with 1 session of thread embedding acupuncture at:~From the superior of zygomatic arch through ST 2 to LI 20 bilaterally using a gauge and length of the needle of 31G x 50 mm From the inferior of zygomatic arch through SI 18 to ST 4 bilaterally using a gauge and length of the needle of 31G x 50 mm From ST 7 to ST 4 bilaterally using a gauge and length of the needle of 31G x 50 mm Along the nasolabial crease through ST 4 to the bilateral EXHN-8 using a gauge and length of the needle of 31G x 30 mm"
62593324|NCT06623435||Type 2 Step Therapy Asthma|Participants in this group must meet criteria for asthma diagnosis and type 2 asthma status (1) Exhaled nitric oxide (FeNO) \> 50 ppb at any clinical care time point (2) at least one blood eosinophil count (BEC) \> 300/uL at any clinical care time point (3) eosinophilia by induced sputum or bronchoscopy (\> 3%) if available historically, performed as part of clinical care) and be on inhaled step therapy according to the Global Initiative for Asthma 2018 Step Therapy 1-5 treatment. They can not be on chronic oral corticosteroids or biologic therapy and must have an Asthma Control test (ACT) of 20 or greater.
62593325|NCT06623435||Likely Type 2 Low Step Therapy Asthma|Participants with likely type 2 low asthma (exhaled nitric oxide-FeNO \< 25 ppb AND blood eosinophil count (BEC) \< 200/uL AND no eosinophilia by induced sputum or bronchoscopy if available historically or as obtained during clinical care. On inhaled step therapy according to the Global Initiative for Asthma 2018 Step Therapy 1-5 treatment. They cannot be on chronic oral corticosteroids or biologic therapy and can have any value for Asthma Control test (ACT)
62593326|NCT06623435||Stable Biologics Asthma|Participants included in the stable biological cohort must meet criteria for asthma diagnosis. The patients must also be on biological therapy for at least 4 months at enrollment. These participants needed to have an ACT of 20 or greater at time of enrollment, or if ACT 16-19 but they had GINA symptom control level 1-2, then they are considered partly controlled and were included in this group.
62593327|NCT06623435||De Novo Biologics Asthma|Either 2 type 2 or type 2 low characteristics Asthma participants with uncontrolled asthma on inhaled therapy (Global Initiative for Asthma 2018) Any asthma control test score (ACT) Starting a clinically prescribed biologic therapy for asthma Not on another biologic therapy for at least 4 months
62233547|NCT02931071|EXPERIMENTAL|plerixafor and filgrastim treatment|to assess the safety and efficacy of CD34+ cells mobilization with plerixafor and filgrastim
62233548|NCT04046133|EXPERIMENTAL|pembrolizumab|Patients with locally advanced (stage IIIA/B, T3/T4, any N, M0) anal cancer will receive pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT.
62593328|NCT06623435||Failed Multiple Biologics Asthma|Either 2 type 2 or type 2 low characteristics. Participants included in this group must report prior biological treatment and having stopped treatment with at least 2 prior asthma biologics. They could be on or off biologic therapy at enrollment and have any level of asthma control by asthma control test and GINA at the time of enrollment.
62593329|NCT06623435||Healthy participants|Healthy individuals with no respiratory symptoms
62593330|NCT02770404|EXPERIMENTAL|Nafithromycin|"Subjects in Cohorts 1 through 5 receive active treatments. Subjects in Cohort 6 will receive an IV dose of nafithromycin and a single oral dose of nafithromycin in each crossover period.~Subjects in each of Cohorts 1, 2, and 3 will receive a single dose of 100, 200, or 400 mg, respectively, of nafithromycin on Day 1"
62593331|NCT02770404|PLACEBO_COMPARATOR|Placebo|Subjects in Cohorts 1 through 5 will be randomly assigned in an 8:2 allocation to receive active or placebo treatments.
62033201|NCT05001100|ACTIVE_COMPARATOR|Traditional rehabilitation|32 subjects will undergo a virtual motor-reality training during the post-surgical rehabilitation period with VRSS
62033202|NCT05001100|EXPERIMENTAL|Rehabilitation with virtual reality|32 subjects with demographic characteristics similar to the subjects of the Vrrs arm will undergo the habitual rehabilitative physiotherapy.
62233549|NCT05891912|EXPERIMENTAL|Technological devices intervention|"The intervention will be in individual sessions with the following technological devices and games:~* Vertical screen: game of lights and vintage game.~* Horizontal screen: cognitive function and activities of daily living games~* Tablets: cognitive function and activities of daily living games"
62233550|NCT01438684|ACTIVE_COMPARATOR|RPh201 group|7 patients will receive the treatment
62233551|NCT01438684|PLACEBO_COMPARATOR|non RPh201 group|3 patients will receive placebo
62233552|NCT01363167|ACTIVE_COMPARATOR|400 IU Cholecalciferol - Vitamin D|
62233553|NCT01363167|PLACEBO_COMPARATOR|Placebo|Placebo contains Fractionated Coconut Oil
62593332|NCT00409968||Screening Study|Screening study to find out if Patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body are eligible to take part in 1 of 4 different research studies.
62033203|NCT04622579|EXPERIMENTAL|lenalidomide combined with rituximab|Rituximab 375 mg/m2 i.v d1 q28d； Lenalidomide 10mg Po. d1-21 q28d. After 6 cycles, patients obtained CR or PR will continue with Lenalidomide maintenance till the 24th month.
62033204|NCT00949351|PLACEBO_COMPARATOR|Aliskiren|
62424483|NCT01629134||Volbella|Subjects treated with JUVÉDERM VOLBELLA™ according to the physician's experience and Directions for Use
62424484|NCT04040907|ACTIVE_COMPARATOR|XNW3009|
62424485|NCT04040907|PLACEBO_COMPARATOR|XNW3009 placebo|
62424486|NCT05940519|EXPERIMENTAL|dynamic tape group|The dynamic tape group
62424487|NCT05940519|SHAM_COMPARATOR|sham taping group|The sham tape group
62424488|NCT02046369|EXPERIMENTAL|Luradisone|Luradisone 20- 80 mg administered once daily
62424489|NCT02046369|PLACEBO_COMPARATOR|Placebo|Placebo administered once daily
62424490|NCT05243654|EXPERIMENTAL|Metformin 1000mg extended release (XR) once daily + standard-of-care MDT|Metformin hydrochloride 500mg XR tablets once daily by mouth for 2 weeks, escalating to a target dose of 1000mg XR once daily for another 22 weeks. Each participant will receive the same number of tablets made up of metformin and placebo to maintain the blinding.
62424491|NCT05243654|PLACEBO_COMPARATOR|Placebo + MDT|Matching metformin placebo tablets once daily by mouth for 2 weeks, escalating to two tablets for another 22 weeks. Each participant will receive the same number of tablets made up of metformin and placebo to maintain the blinding.
62593333|NCT02349919|EXPERIMENTAL|Procaterol|Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
62033205|NCT05229289|EXPERIMENTAL|FMT along with SMT|"FMT + Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)"
62424492|NCT00997672|EXPERIMENTAL|Lithium CARBONATE 150 and/or 300 mg|
62033206|NCT05229289|ACTIVE_COMPARATOR|Standard Medical Treatment|"Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)"
62033207|NCT05579327|EXPERIMENTAL|Tiratricol|
62033208|NCT05579327|PLACEBO_COMPARATOR|Placebo|
62033209|NCT01518868|EXPERIMENTAL|Investigational contact lens|multifocal high add soft contact lens
62424493|NCT00997672|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62424494|NCT05564273|NO_INTERVENTION|Placebo|Participants may be provided with any combination of nutritional recommendations and they receive placebo supplements. Placebo capsules will contain inert and inactive materials. The participants are asked to take the supplements on a daily basis.
62424495|NCT05564273|ACTIVE_COMPARATOR|Viome's Precision Nutrition Program|Participants may be provided with any combination of nutritional recommendations and supplements. The participants are asked to take the supplements on a daily basis.
62593334|NCT02349919|PLACEBO_COMPARATOR|Placebo|Placebo twice daily for 4 weeks
62033210|NCT01518868|ACTIVE_COMPARATOR|PureVision contact lens|Multi-focal contact lens
62233554|NCT05507918|EXPERIMENTAL|Low fluid intake|0.5 L - 1.5 L fluid intake in the 24 hours prior to NPO status for surgery
62233555|NCT05507918|EXPERIMENTAL|Medium fluid intake|1.5 L - 3 L fluid intake in the 24 hours prior to NPO status for surgery
62424496|NCT05564273|ACTIVE_COMPARATOR|Viome's condition-based supplements|Participants may be provided with any combination of nutritional recommendations and they receive condition based supplements. The participants are asked to take the supplements on a daily basis.
62424497|NCT06241651|EXPERIMENTAL|CSP group|In this group, CSP lead is attempted to be placed, including LBBP and HBP.
62424498|NCT06241651|ACTIVE_COMPARATOR|BiVP group|In this group, traditional RA lead , RV lead and LV lead are attempted to be placed.
62424499|NCT05449158|EXPERIMENTAL|LAP Group|Control of left atrial pressure changes by adjusting pacemaker frequency
62593335|NCT03199482|ACTIVE_COMPARATOR|Drug dexamethasone|preoperative single dose of dexamethasone 0.5 mg oral tablet given to patients before starting of root canal treatment by 30 minutes.
62593336|NCT03199482|PLACEBO_COMPARATOR|Placebo|Placebo will be administrated to patients before stating of root canal treatment
62593337|NCT05123664|EXPERIMENTAL|Bacillus coagulans|2 billion CFU Bacillus coagulans Unique IS2 per capsule
62233556|NCT05507918|EXPERIMENTAL|High fluid intake|3 L - 4.5 L fluid intake in the 24 hours prior to NPO status for surgery
62424500|NCT05449158|NO_INTERVENTION|Control Group|General pacemaker rate setting
62033211|NCT06143748|EXPERIMENTAL|The study group|Patients will receive 2 cycles of 3-weekly schedule of induction chemotherapy, consisting of paclitaxel 135 mg/m2, cisplatin 75 mg/m2, and cadonilimab 10 mg/kg on day 1 prior to CRT. Then all patients will receive standard fractionation radiation therapy scheme: 50.4 Gy in 28 fractions, concurrently with 2 cycles of cadonilimab. After the completion of radiotherapy, patients will then receive 12 additional cycles of cadonilimab.
62033212|NCT03295188|EXPERIMENTAL|Intervention Group|Two 0.5 mg plasmalogen capsules per day
62033213|NCT03295188|PLACEBO_COMPARATOR|Placebo Group|Two placebo capsules containing no plasmalogen per day
62033214|NCT04762680|EXPERIMENTAL|Phase 2 Cohort -SARS-CoV-2 vaccine Formulation 1|2 injections of SARS-CoV-2 vaccine Formulation 1 at Day 1 and Day 22
62033215|NCT04762680|EXPERIMENTAL|Phase 2 Cohort - SARS-CoV-2 vaccine Formulation 2|2 injections of SARS-CoV-2 vaccine Formulation 2 at Day 1 and Day 22
62033216|NCT04762680|EXPERIMENTAL|Phase 2 Cohort - SARS-CoV-2 vaccine Formulation 3|2 injections of SARS-CoV-2 vaccine Formulation 3 Day 1 and Day 22
62033217|NCT04762680|EXPERIMENTAL|Supplemental Cohort 1 - Booster Monovalent (D614)-AS03 SARS-CoV-2 vaccine|Participants who were previously vaccinated 4 to \< 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine will receive 1 booster injection of monovalent (D614)-AS03 SARS-CoV-2 vaccine
62033218|NCT04762680|EXPERIMENTAL|Supplemental Cohort 2 - Booster Monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine|Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine or SARS-Cov-2 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
62033219|NCT04762680|EXPERIMENTAL|Supplemental Cohort 2 - Booster Bivalent (D614 + B.1.351)-AS03 SARS-CoV-2 vaccine|Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine will receive 1 booster injection of bivalent (D614+B.1.351)-AS03 SARS-CoV-2 vaccine
62033220|NCT04762680|EXPERIMENTAL|Supplemental Cohort 2 - Booster Monovalent (D614)-AS03 SARS-CoV-2 vaccine|Participants who were vaccinated 4 to \< 10 months prior with SARS-Cov-2 vaccine will receive 1 booster injection of monovalent (D614)-AS03 SARS-CoV-2 vaccine
62033221|NCT04762680|ACTIVE_COMPARATOR|Supplemental Comparator for Cohort 1 and 2 Boosters - Monovalent (D614)-AS03 SARS-CoV-2 vaccine|2 injections of monovalent (D614)-AS03 SARS-CoV-2 vaccine at Day 1 and Day 22 in previously unvaccinated, naïve participants
62033222|NCT04762680|EXPERIMENTAL|Cohort 2 - Booster Exploratory 1|Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
62033223|NCT04762680|EXPERIMENTAL|Cohort 2 - Booster Exploratory 2|Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
62033224|NCT04762680|EXPERIMENTAL|Cohort 2 - Booster Exploratory 3|Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
62033225|NCT04762680|EXPERIMENTAL|Cohort 2 - Booster Exploratory 4|Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
62033226|NCT01217073|EXPERIMENTAL|Omarigliptin 0.25 mg (Base)|Omarigliptin 0.25 mg administered once weekly for 12 weeks (Base)
62033227|NCT01217073|EXPERIMENTAL|Omarigliptin 1 mg (Base)|Omarigliptin 1 mg administered once weekly for 12 weeks (Base)
62233557|NCT04285801||COVID-19 infection|critically ill patients with COVID-19 infection
62233558|NCT02113384||Observational study|Patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.
62233559|NCT02558686|EXPERIMENTAL|Eccentric Exercise|Individuals will perform 3 sets of 10 repetitions of eccentric exercise of the infraspinatus muscle after the application of trigger point dry needling
62424501|NCT00397072|EXPERIMENTAL|ZK-EPO|administered iv for 3 h every 21 days; dose reductions to 12 or 9 mg/m2 ZK-EPO were allowed in order to manage any treatment-related toxicity.
62424502|NCT03638752|EXPERIMENTAL|Comprehensive education group|"The details of Comprehensive education are as follows:~1. introduce the purpose, method and function of breathing training and the whole process of gastroscopy;~2. instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,~3. provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,~4. inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~5. inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,~6. inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting."
62424503|NCT03638752|NO_INTERVENTION|standard education|"The details of standard education are as follows:~1. inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~2. inform patients that there would be some normal physiological reaction when gastroscopy, such as the throat discomfort and nausea/vomiting."
62033228|NCT01217073|EXPERIMENTAL|Omarigliptin 3 mg (Base)|Omarigliptin 3 mg administered once weekly for 12 weeks (Base)
62033229|NCT01217073|EXPERIMENTAL|Omarigliptin 10 mg (Base)|Omarigliptin 10 mg administered once weekly for 12 weeks (Base)
62033230|NCT01217073|EXPERIMENTAL|Omarigliptin 25 mg (Base)|Omarigliptin 25 mg administered once weekly for 12 weeks (Base)
62033231|NCT01217073|PLACEBO_COMPARATOR|Placebo (Base)|Matching placebo to omarigliptin administered once weekly for 12 weeks (Base)
62233560|NCT02558686|SHAM_COMPARATOR|Detuned Ultrasound|Individuals will received 10 minutes of detuned ultrasound on the infraspinatus muscle after the application of trigger point dry needling
62233561|NCT02558686|PLACEBO_COMPARATOR|Placebo|Individuals will not perform any action after the application of trigger point dry needling
62033232|NCT01217073|EXPERIMENTAL|Pooled omarigliptin (Extension)|Participants who received omarigliptin during the base study, received omarigliptin 25 mg once weekly and placebo to metformin once daily for 66 weeks (Extension).
62033233|NCT01217073|ACTIVE_COMPARATOR|Placebo/Metformin|Participants who received matching placebo to omarigliptin during the base period, received pioglitazone administered once daily and matching placebo to omarigliptin once weekly for 66 weeks (extension period). Note: A protocol amendment removed pioglitazone during the extension period. Participants discontinued pioglitazone and switched to blinded metformin. Participants who were previously rescued with open-label metformin during the base period continued in the extension period on open-label metformin.
62033234|NCT01183676|EXPERIMENTAL|Divalproex Sodium|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG - Mylan Pharmaceuticals Inc
62033235|NCT01183676|ACTIVE_COMPARATOR|Depakote Tablets|DEPAKOTE® Tablets, 500 MG Abbott Laboratories
62033236|NCT05558033|EXPERIMENTAL|Plyometric Training Group|Individuals in the plyometric training group will receive plyometric training. In this training, individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery). All trainings will be given on the basis of telerehabilitation via distance education tools.
62033237|NCT05558033|ACTIVE_COMPARATOR|Control Group|Athletes in this group will continue their routine training programs like the athletes in the plyometric training group.
62033238|NCT00241254|EXPERIMENTAL|1|Cyclophosphamide
62033239|NCT00241254|ACTIVE_COMPARATOR|2|Methylprednisolone
62033240|NCT01253434|EXPERIMENTAL|1|
62033241|NCT01253434|EXPERIMENTAL|2|
62033242|NCT01253434|EXPERIMENTAL|3|
62033243|NCT01253434|EXPERIMENTAL|4|
62033244|NCT01253434|EXPERIMENTAL|5|
62033245|NCT06173401|EXPERIMENTAL|Single-fraction spine SRS|Single-fraction spine SRS (22 Gy x 1)
62033246|NCT06173401|EXPERIMENTAL|Multi-fraction spine SRS|Multi-fraction spine SRS (14 Gy x 2)
62033247|NCT01143948|ACTIVE_COMPARATOR|15 patient sliding scale regular insulin|
62033248|NCT01143948|ACTIVE_COMPARATOR|15 patient BBI NPH plus regular insulin|
62033249|NCT01143948|ACTIVE_COMPARATOR|15 patients BBI Glargine plus Glulisine|
62033250|NCT00695903|EXPERIMENTAL|daptomycin 10 mg/kg|Daptomycin 10 mg/kg IV every 24 hours
62233562|NCT00790322|EXPERIMENTAL|Active|
62233563|NCT00790322|PLACEBO_COMPARATOR|Placebo|
62233564|NCT03601533|OTHER|Phenol|Patients will undergo neurolysis of genicular nerves with 1,5 mL of 7% phenol in each of the genicular nerves (superior, medial and lateral).
62233565|NCT00703144|EXPERIMENTAL|Pharmacokinetic|
62433604|NCT01623232|EXPERIMENTAL|adjuvant plus 1 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 1 �g of HA antigen
62433605|NCT01623232|EXPERIMENTAL|adjuvant plus 3 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 3 �g of HA antigen
62033251|NCT00695903|EXPERIMENTAL|vancomycin high-dose|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
62033252|NCT03206346|EXPERIMENTAL|Ingavirin|Broad spectrum antiviral drug
62033253|NCT03206346|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo capsule identical in appearance to Ingavirin capsule
62033254|NCT04301336|EXPERIMENTAL|Omega-3 experimental group|"50 patients from each participating hospital that will receive Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
62033255|NCT04301336|EXPERIMENTAL|Vit-D experimental group|"50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
62033256|NCT04301336|EXPERIMENTAL|Zinc supplements experimental group|"50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
62033257|NCT04301336|EXPERIMENTAL|Statin experimental group|"50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
62033258|NCT04301336|ACTIVE_COMPARATOR|Ordinary hospital treatment group|"50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.~in addition, Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response in addition, Morphine medication as a pain killer is administered, if Patient weight \<50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.~This group received regular blood transfusion session."
62233566|NCT04603950|EXPERIMENTAL|study group|The first 20 patients received Continue Adductor Canal Block + Infiltration between the Popliteal Artery and Capsule of the Knee
62233567|NCT04603950|SHAM_COMPARATOR|control group|The second 20 patients received Continue Adductor Canal Block alone
62809581|NCT02407223|PLACEBO_COMPARATOR|Group 1: Placebo|Participants will receive placebo subcutaneously (SC) at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 milligram (mg) SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with \< 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88. NOTE: Intervention Description should have no more than 800 characters.
62233568|NCT05245565||PPS surgery|Patients who undergo modified PPS surgery in order to preserve anal sphincter function under the premise of radical resection of ultralow rectal cancer.
62233569|NCT05245565||Conventional|Patients who undergo conventional sphincter-preserving surgeries.
62424504|NCT01251692|EXPERIMENTAL|1|A retrospective chart review of 26 eyes of 23 patients with recurrent corneal erosions treated by PTK from 1996 to 2000 was performed. All eyes had failed to respond to conventional therapy. Data regarding the preoperative and postoperative best-corrected visual acuity (BCVA), spherical equivalent (SE), symptomatic relief, incidence of recurrence, and complications arising from the laser treatment were analyzed. The mean duration of symptoms prior to PTK was 18 months (range, 8 to 36 months). The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser. Mean postoperative follow-up was 12 years (range, 10 to 14 years).
62424505|NCT05815186|EXPERIMENTAL|Advanced NSCLC Patients|Patients with KRASG12C mutant NSCLC will receive ladarixin and sotorasib in combination.
62424506|NCT00862888|PLACEBO_COMPARATOR|Cohort 1; Study Period 1, 2, 3 or 4|Cohort 1: Exploring two single doses of PF-00446687 200 mg as well as sildenafil 100mg and placebo (double dummy design)
62033259|NCT03298126|ACTIVE_COMPARATOR|TR BAND Protocol A|In this group, air removal from TR band was initiated after 2 hours of TR band application. 3 ml of air was removed periodically at an interval of 15 minutes until all the air is eliminated from the band. In case of bleeding or hematoma while deflating air, 4 ml of air was re-injected and observed for 30 minutes until next attempt was made to deflate the band. The data including the attempts made at deflating TR band, time and amount of air injected along with the response to each deflation i.e. occurrence of bleeding or hematoma was noted down in the proforma
62233570|NCT02074163|EXPERIMENTAL|Glabella|"Glabella~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62233571|NCT02074163|EXPERIMENTAL|Frontal|"Frontal~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62424507|NCT00862888|PLACEBO_COMPARATOR|Cohort 2; study periods 1, 2, 3 or 4|Cohort 2: Exploring single doses of PF-00446687 20 mg - 175 mg. Subjects to receive two of 3 possible doses of PF-00446687 as well as a single dose of sildenafil 100mg and placebo (double dummy design).
62424508|NCT05000918|EXPERIMENTAL|OPH group|Participants should eat a pack of OPH once a day for 28 days. The dosage of the OPH is 11.74 g/day.
62424509|NCT00350337|EXPERIMENTAL|Pre-transfection F17|"4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine"
62433606|NCT01623232|EXPERIMENTAL|adjuvant plus 5 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 5 �g of HA antigen
62593338|NCT05123664|PLACEBO_COMPARATOR|Placebo|Appearance-matched capsule
62233572|NCT02074163|EXPERIMENTAL|Temporal|"Temporal~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62233573|NCT02074163|EXPERIMENTAL|Occipital|"Occipital~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62233574|NCT02074163|EXPERIMENTAL|Paraspinal|"Paraspinal~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62033260|NCT03298126|ACTIVE_COMPARATOR|TR BAND PROTOCOL B|In this group deflation was initiated after 2 hours of TR band application as described by Cohen and Alfonso. \[6\] 5 ml of air was deflated at first attempt. Next attempt was carried out after 15 minutes in which further 5 ml was removed. After 15 minutes, the remaining 2 ml of air was released from the band. In case of bleeding or hematoma at any attempt, 6 ml air was re-injected and interval for 15 minutes taken to attempt further air deflation. All the attempts and its response were recorded in the proforma filled out by the assessor.
62809582|NCT02407223|EXPERIMENTAL|Group 2: Ustekinumab 45 milligram (mg)|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
62809583|NCT02407223|EXPERIMENTAL|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
62033261|NCT05999955|ACTIVE_COMPARATOR|Control|Subjects in Control group receive Neomycin Nasal Spray for 10 days.
62809584|NCT01772446|NO_INTERVENTION|CONTROL GROUP|ROUTINE CLINICAL PRACTICE
62809585|NCT01772446|EXPERIMENTAL|SMS MESSAGING|SMS MESSAGES TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED HEMOGLOBIN
62233575|NCT02074163|EXPERIMENTAL|Trapezius|"Trapezius~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62233576|NCT02074163|EXPERIMENTAL|Change in frequency of headache days|Change in frequency of headache days as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
62233577|NCT02074163|EXPERIMENTAL|Change in hrs of HA on HA days|Change in hrs of HA on HA days as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
62233578|NCT02074163|EXPERIMENTAL|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62424510|NCT00350337|EXPERIMENTAL|Post-transfection F17|"4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Lyophilized, single dose vials and sterile water for injection"
62424511|NCT00350337|EXPERIMENTAL|Post-transfection F19|"4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Lyophilized, single dose vials and sterile water for injection"
62424512|NCT00350337|PLACEBO_COMPARATOR|Placebo|A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine.
62033262|NCT05999955|EXPERIMENTAL|SPEROVID|"Subjects in Experimental group receive a nasal spray containing Bacillus subtilis DSM32444 (Sperovid) for 10 days."
62424513|NCT00362427|EXPERIMENTAL|Group A|
62033263|NCT02102308|EXPERIMENTAL|Exercise|Multicomponent exercise
62033264|NCT02102308|PLACEBO_COMPARATOR|Education classes|Education classes
62033265|NCT05960500|ACTIVE_COMPARATOR|Six implants in parallel distribution|patients received 6 implants in parallel distribution in anterior, premolar and molar region
62233579|NCT02074163|EXPERIMENTAL|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62233580|NCT02074163|EXPERIMENTAL|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62233581|NCT02074163|EXPERIMENTAL|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62424514|NCT00362427|EXPERIMENTAL|Group B|
62233582|NCT02074163|EXPERIMENTAL|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62033266|NCT05960500|ACTIVE_COMPARATOR|Six implants according to all on six concept|patients recived four axially placed anterior Implants(\*General system) in lateral and first premolar region and two distally tilted 30 degree posteriorly in molar region relative to the occlusal plane supporting screw retained maxillary single denture.
62033267|NCT02324439|EXPERIMENTAL|Omega Nutrition cold-milled flaxseeds|All subjects will receive a 20g daily dose of cold-milled flaxseeds for 24 months.
62033268|NCT04764058|OTHER|Montherapy|Thirty patients will receive IV Imipenem in doses of 15 to 25 mg/kg every 6 hours
62233583|NCT02074163|EXPERIMENTAL|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62233584|NCT02074163|EXPERIMENTAL|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62424515|NCT00362427|ACTIVE_COMPARATOR|Group C|
62424516|NCT06566495||reusable tourniquets used by indefinite time|6 tourniquets from emergency department and 11 tourniquets from operating theatre
62809586|NCT04566471||PPP and GPP|Palmoplantar pustulosis (PPP) and Generalized pustular psoriasis (GPP) are rare chronic inflammatory skin diseases, characterized by repeated episodes of sterile pustules in several months or years, associated with erythrokeratodermia generally. Both two diseases are easy to cause skin rupture, leading to bleeding and pain.
62233585|NCT02074163|EXPERIMENTAL|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62233586|NCT02074163|EXPERIMENTAL|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62809587|NCT02414815|EXPERIMENTAL|AF group|Atrial fibrillation
62809588|NCT00323141|ACTIVE_COMPARATOR|Ventralex|
62033269|NCT04764058|OTHER|Combination|Thirty patients will receive IV Colistin in dosages of 50,000-75,000 IU/kg/day in three divided doses, infused IV in 10mL normal saline over 30 minutes with IV Imipenem in doses of 15 to 25 mg/kg every 6 hours¬.21,22,24 Colistin formulation consists of 2 million IU per vial.
62033270|NCT02512575|EXPERIMENTAL|AZD9567 oral suspension|"In Part A: up to 8 cohorts with single ascending doses (starting at 2 mg up to 155 mg).~In Part B: one cohort with a single dose"
62033271|NCT02512575|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo in the first 8 cohorts will receive the same dose volume of oral suspension as subjects on AZD9567 and subjects randomized to placebo in cohort 9(prednisolone cohort) will receive the same number of capsules as subjects on prednisolone.
62033272|NCT02512575|EXPERIMENTAL|Prednisolone capsules|"Within each cohort 6 subjects will be randomized to receive prednisolone 60mg oral capsules and 2 subjects randomized to receive matching placebo in a fasted state.~Sentinel dosing will not be employed for the prednisolone cohort. The SRC will not be required to evaluate the prednisolone cohort. This cohort can be performed at any time during clinical execution of the study provided the protocol amendment was approved."
62033273|NCT01558154|EXPERIMENTAL|Chinese herb|Chinese herbs special for depression
62033274|NCT01558154|EXPERIMENTAL|acupuncture|
62033275|NCT01558154|EXPERIMENTAL|Psychotherapy|
62033276|NCT01558154|EXPERIMENTAL|physiotherapy|
62033277|NCT00784810|EXPERIMENTAL|Oxycodone/Naloxone Tablets|Oxycodone/Naloxone combination
62233587|NCT02074163|EXPERIMENTAL|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62233588|NCT02074163|EXPERIMENTAL|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62233589|NCT03728374|EXPERIMENTAL|Anlotinib|
62233590|NCT06507995|OTHER|Local Group|Group I received thoracic interlaminar epidural injections of 6 mL of 2% preservative-free prilocaine.
62809589|NCT00323141|ACTIVE_COMPARATOR|Leight Weight Vypro II prothesis|
62233591|NCT06507995|OTHER|Local+steroid Group|Group II received injections of 4 mL of 2% preservative-free prilocaine combined with 2 mL or 8 mg of dexamethasone, totaling 6 mL
62233592|NCT04350554||Retrospective pregnancies|Women recruited in CoRIS from January 2004 to November 2019 and who became pregnant during this period.
62809590|NCT01302483|EXPERIMENTAL|Kovacaine Nasal Spray|3% tetracaine HCL with 0.05% oxymetazoline HCL - Delivered via 3 sprays (100 uL) in each nostril
62809591|NCT01302483|ACTIVE_COMPARATOR|Lidocaine Injection|.5 to 1 catridge of 2% lidocaine HCL with 1:100,000 epinephrine
62809592|NCT01590264|OTHER|Bimodal rTMS|"Open-label and single-arm rTMS bimodal treatment with placement of magnet over Dorsolateral Prefrontal Cortex (DLPFC) and Temporoparietal Junction (TPJ) for 2 weeks of treatment (10 days)~Stimulation Settings:~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000"
62809593|NCT01254253|EXPERIMENTAL|Group a|no severe cardiac perfusion defects
62033278|NCT00784810|ACTIVE_COMPARATOR|Codeine/Paracetamol Tablets|Codeine/Paracetamol combination
62033279|NCT06458322||Home dialysis modality|Participants that determined peritoneal dialysis or home hemodialysis as their modality of treatment.
62033280|NCT06458322||In-center dialysis modality|Participants that determined in-center hemodialysis as their modality of treatment.
62033281|NCT02523313|ACTIVE_COMPARATOR|Nivolumab + Placebo|Nivolumab (3 mg/kg) i.v. every 2 weeks + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10
62033282|NCT02523313|EXPERIMENTAL|Nivolumab + Ipilimumab|Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) i.v. every 3 weeks for 4 doses. Both study drugs are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12: Nivolumab as maintenance and at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
62033283|NCT02523313|PLACEBO_COMPARATOR|Double Placebo Control|Placebo instead of Nivolumab and Placebo instead of Ipilimumab i.v. every 3 weeks for 4 doses. Both placebos are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab as maintenance and applied as IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
62033284|NCT01161316|ACTIVE_COMPARATOR|Control|mFOLFOX-6 + cetuximab until disease progression or early withdrawal.
62033285|NCT01161316|EXPERIMENTAL|Experimental|8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.
62033286|NCT02962713|ACTIVE_COMPARATOR|ART with Equia|Occlusal-proximal restoration in primary molars using Equia (Easy/Quick/Unique/Intelligent/Aesthetic) from GC Corp, encapsulated, pre-dosed and mechanized handling.
62233593|NCT04350554||Prospective pregnancies|Women recruited in CoRIS from January 2004 to November 2019 who will become pregnant during the year 2020 and who agree to participate in a telephone survey.
62233594|NCT02038920|EXPERIMENTAL|Induction Phase: Vedolizumab, 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.
62233595|NCT02038920|PLACEBO_COMPARATOR|Induction Phase: Placebo|Vedolizumab placebo-matching IV infusion once at Weeks 0, 2 and 6 in the induction phase.
62233596|NCT02038920|EXPERIMENTAL|Maintenance Phase: Vedolizumab 300 mg|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved Crohn's Disease Activity Index (CDAI)-70 response at Week 10 and were randomized to receive vedolizumab in maintenance phase.
62233597|NCT02038920|PLACEBO_COMPARATOR|Maintenance Phase: Placebo|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved CDAI-70 response at Week 10 and were randomized to receive placebo in maintenance phase.
62233598|NCT02038920|PLACEBO_COMPARATOR|Maintenance Phase: Placebo Continuation|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved CDAI-70 response at Week 10 received placebo in maintenance phase without randomization.
62233599|NCT02038920|EXPERIMENTAL|Open-Label: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 as a maximum duration in open-label phase.
62424517|NCT06566495||reusable tourniquets used by 14 days|6 tourniquets from emergency department and 14 tourniquets from operating theatre
62424518|NCT06566495||reusable tourniquets used by 28 days|6 tourniquets from emergency department and 10 tourniquets from operating theatre
62424519|NCT00861731|ACTIVE_COMPARATOR|1|hypolipidemic treatment
62424520|NCT00861731|SHAM_COMPARATOR|2|hypolipidemic treatment
62424521|NCT00861731|SHAM_COMPARATOR|3|hypolipidemic treatment
62424522|NCT01106352|EXPERIMENTAL|Radium-223 dichloride (Xofigo, BAY88-8223) + docetaxel|Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection. In the randomized phase IIa part of the protocol, the dose established in the dose-escalation part of the protocol (Phase I) will be used, i.e. 5 doses of 50 kBq/kg b.w. every 6 weeks in combination with the approved step-down dose of docetaxel (60 mg/m\^2) administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone.
62424523|NCT01106352|ACTIVE_COMPARATOR|Docetaxel|Docetaxel (75 mg/m2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m\^2 is allowed as per the approved docetaxel label.
62424524|NCT05658289|ACTIVE_COMPARATOR|Latarjet|The Latarjet involves the use of a auto-graft to be fixated to the anterior portion of the glenoid to recreate the size of the glenoid.
62033287|NCT02962713|EXPERIMENTAL|ART with Giomer Beautifil-Bulk Restorative|Occlusal-proximal restoration in primary molars using Giomer Beautifil-Bulk Restorative (SHOFU Inc)
62033288|NCT03377491|EXPERIMENTAL|NovoTTF-200T|Patients receive TTFields using the NovoTTF-200T System together with gemcitabine and nab-Paclitaxel
62424525|NCT05658289|EXPERIMENTAL|Anatomic Glenoid Reconstruction|An allograft will be used for the patients in this group, inserted through a new portal and fixed to the anterior rim of the glenoid to recreate the size of the glenoid.
62033289|NCT03377491|ACTIVE_COMPARATOR|Best Standard of Care|Patients receive best standard of care with gemcitabine and nab-Paclitaxel
62809594|NCT01254253|EXPERIMENTAL|Gooup b|reversible cardiac perfusion defects
62809595|NCT01254253|EXPERIMENTAL|Group c|irreversible cardiac perfusion defects
62033290|NCT06167668||combined group|
62033291|NCT06167668||traditional group|
62033292|NCT01306773|ACTIVE_COMPARATOR|H1N1 convalescent plasma and oseltamivir|Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma
62424526|NCT02962869|EXPERIMENTAL|BAY987517|All subjects are patched with the same product
62424527|NCT00647426|EXPERIMENTAL|Sorafenib + Docetaxel/Carboplatin|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
62424528|NCT04976088|EXPERIMENTAL|Group A Test|Test product: treated once a day (morning) with the medicated plaster containing 140 mg Diclofenac Sodium for seven days Diclofenac Sodium 140 mg medicated plaster
62424529|NCT04976088|ACTIVE_COMPARATOR|Group B Reference|Reference product: treated once a day (morning) with the medicated plaster containing DIEP 180 mg, Flector® for seven days Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®
62424530|NCT04976088|PLACEBO_COMPARATOR|Group C Placebo|Placebo: treated once a day (morning) with the placebo plaster for seven days
62809596|NCT01500772|EXPERIMENTAL|Alisporivir|ALV 400 mg twice daily (BID), plus PEG and RBV for 48 weeks
62809597|NCT00639197|ACTIVE_COMPARATOR|1|To Tunnel
62809598|NCT00639197|ACTIVE_COMPARATOR|2|Not to tunnel
62809599|NCT01532947|EXPERIMENTAL|post restoration|
62809600|NCT01532947|NO_INTERVENTION|no post restoration|no post placement
62809601|NCT05512754|EXPERIMENTAL|Ibuprofen|Participants receive Ibuprofen 400 mg tablet orally every 8 hours for 10 days
62809602|NCT05512754|NO_INTERVENTION|Control|Participants receive no NSAIDs
62424531|NCT03923114|OTHER|Patient group with treatment response|PET/CT imaging of patients with response to GLP-1 receptor agonist treatment
62809603|NCT04590014|EXPERIMENTAL|Conventional HVNI First, Then New HVNI Second (Randomized)|The purpose of this intervention is to evaluate the efficacy of the conventional HVNI device design (Precision Flow) to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a new HVNI device design (V2.0) to provide targeted relief of dyspnea.
62809604|NCT04590014|EXPERIMENTAL|New HVNI First, Then Conventional HVNI Second (Randomized)|The purpose of this intervention is to evaluate the efficacy of the conventional HVNI device design (Precision Flow) to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a new HVNI device design (V2.0) to provide targeted relief of dyspnea.
62233600|NCT02902705|EXPERIMENTAL|Chronic Kidney disease patients - stage V|Male adults non-diabetic and non-dialyzed CKD stage 5 patients. All the CKD patient will be recruited at the Department of Nephrology of Edouard Herriot University Hospital (Lyon, France).
62424532|NCT03923114|OTHER|Patient group without treatment response|PET/CT imaging of patients with no response to GLP-1 receptor agonist treatment
62233601|NCT02902705|OTHER|Non Chronic Kidney Disease patients|Non CKD male adults matched for age, gender and body mass index (BMI) with CKD patients. All the non - CKD patient will recruited from Department of recruited at the Department of Urology of Edouard Herriot University Hospital (Lyon, France).
62233602|NCT03285178|EXPERIMENTAL|IW-1701 (Olinciguat) 2 mg|After a single-blind treatment with placebo once daily (QD) for 14 to 17 days of the Screening period and before the first dose of double-blind study drug on Day 1, participants received 1 mg olinciguat QD Week 1 and 2 mg olinciguat QD Weeks 2-12 under the original protocol, Amendment 1, Amendment 2, and Amendment 3.
62233603|NCT03285178|EXPERIMENTAL|IW-1701 (Olinciguat) 4 mg|After a single-blind treatment with placebo QD for 14 to 17 days of the Screening period and before the first dose of double-blind study drug on Day 1, participants received 2 mg olinciguat QD Week 1 and 4 mg olinciguat QD Weeks 2-12 under the original protocol, Amendment 1, Amendment 2, and Amendment 3.
62233604|NCT03285178|EXPERIMENTAL|IW-1701 (Olinciguat) 6 mg|After a single-blind treatment with placebo QD for 14 to 17 days of the Screening period and before the first dose of double-blind study drug on Day 1, participants received 3 mg olinciguat QD Week 1 and 6 mg olinciguat QD Weeks 2-12 under the original protocol, Amendment 1, Amendment 2, and Amendment 3.
62233605|NCT03285178|EXPERIMENTAL|IW-1701 (Olinciguat) 18 mg|After a single-blind treatment with placebo QD for 14 to 17 days of the Screening period and before the first dose of double-blind study drug on Day 1, participants received 6 mg olinciguat QD Days 1-7, 12 mg olinciguat QD Weeks 1-3, and 18 mg olinciguat QD Weeks 4-12 under protocol Amendment 4 and later.
62809605|NCT01112137|EXPERIMENTAL|Hypertensive individuals: clopidogrel (600 mg, bolus)|
62809606|NCT01112137|EXPERIMENTAL|Hypertensive individuals: clopidogrel (75 mg daily)|
62424533|NCT01459679|ACTIVE_COMPARATOR|VibeX Treatment Group A|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 8 minutes
62809607|NCT01112137|ACTIVE_COMPARATOR|Normotensive individuals: clopidogrel (600 mg, bolus)|
62809608|NCT01112137|ACTIVE_COMPARATOR|Normotensive individuals: clopidogrel (75 mg, daily)|
62809609|NCT03761927|ACTIVE_COMPARATOR|Hearing Aid without NR enabled.|Hearing Aid without Noise Reduction (NR) enabled serves as reference condition.
62809610|NCT03761927|EXPERIMENTAL|Hearing Aid with NR(1)|Hearing Aid with Noise Reduction I (NR) enabled.
62809611|NCT03761927|EXPERIMENTAL|Hearing Aid with NR(2)|Hearing Aid with Noise Reduction II (NR) enabled.
62809612|NCT04589858|ACTIVE_COMPARATOR|Group A|Received a supervised exercise protocol including both strengthening and stretching exercises for specific muscle groups.
62809613|NCT04589858|EXPERIMENTAL|Group B|Received manual therapies including both myofascial mobilization and manipulation technique in addition to a supervised exercise protocol.
62809614|NCT01404169|EXPERIMENTAL|1|
62809615|NCT01404169|PLACEBO_COMPARATOR|2|
62809616|NCT01895075|EXPERIMENTAL|Inhaled budesonide|Inhaled budesonide 1mg/dose (2ml) three tid
62233606|NCT03285178|PLACEBO_COMPARATOR|Placebo|After a single-blind treatment with placebo QD for 14 to 17 days of the Screening period and before the first dose of double-blind study drug on Day 1, participants received placebo treatment QD for 12 weeks.
62033293|NCT01306773|ACTIVE_COMPARATOR|Oral Oseltamivir alone|Oseltamivir 75mg bid during ICU hospitalization
62033294|NCT06669728||Eyes with ICL surgeries|Eyes with SMILE surgeries which were performed by surgeons with experiences.
62033295|NCT03722368|EXPERIMENTAL|RCHC|Participation in the Resilience and Coping of the Healthcare Community Intervention.
62233607|NCT03086213|EXPERIMENTAL|paravertebral nerve block group|non-intubated thoracic paravertebral nerve block of regional anesthesia Thoracic paravertebral nerve block of regional anesthesia at the T4 thoracic interspace
62033296|NCT03722368|EXPERIMENTAL|RCHC+|Participation in the Resilience and Coping of the Healthcare Community Intervention, support groups and one on one counseling.
62233608|NCT03086213|ACTIVE_COMPARATOR|intercostals nerve block group|non-intubated intercostal nerve block of regional anesthesia Thoracic intercostal nerve block of regional anesthesia at the T3/4/5 thoracic interspace
62233609|NCT01538329|EXPERIMENTAL|Amantadine|Patients with amantadine
62233610|NCT01538329|PLACEBO_COMPARATOR|Placebo|Patients with amantadine placebo
62233611|NCT02858830|OTHER|Group 1: Healthy Subject|Healthy Subject (Control) will undergo assessments before and after ingesting a high fat mixed meal.
62233612|NCT02858830|OTHER|Group 2: FPL Subject|FPL Subject will undergo assessments before and after ingesting a high fat mixed meal.
62233613|NCT00683176|ACTIVE_COMPARATOR|1|
62233614|NCT00683176|PLACEBO_COMPARATOR|2|
62233615|NCT06360562|EXPERIMENTAL|Resilience Training|A 6 1-hour session group based intervention to deliver mindfulness, metallization, and self-compassion.
62424534|NCT01459679|ACTIVE_COMPARATOR|VibeX Treatment Group B|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 4 minutes
62424535|NCT01459679|ACTIVE_COMPARATOR|VibeX Treatment Group C|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 2 minutes and 40 seconds
62424536|NCT01977859|PLACEBO_COMPARATOR|Saline|Saline infusion
62233616|NCT01172509|PLACEBO_COMPARATOR|sugar pill|placebo administered under double blind conditions
62233617|NCT01172509|EXPERIMENTAL|3 mg of R-baclofen|3 mg of R-Baclofen administered double blind
62033297|NCT03722368|OTHER|Waitlist Control|This group will receive treatment as usual and will be offered services once the study is complete.
62033298|NCT04647526|EXPERIMENTAL|[Lu-177]-PNT2002 (Arm A)|\[Lu-177\]-PNT2002 (6.8 GBq (±10%) every 8 weeks for 4 cycles)
62033299|NCT04647526|ACTIVE_COMPARATOR|Control Arm (Arm B)|Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone) or enzalutamide (160 mg orally qd).
62233618|NCT01172509|EXPERIMENTAL|10 mg of R-baclofen|10 mg of R-baclofen administered double-blind
62233619|NCT01172509|EXPERIMENTAL|25 mg of R-baclofen|25 mg of R-baclofen administered double blind
62233620|NCT01172509|PLACEBO_COMPARATOR|second sugar pill|the second placebo administered double blind
62233621|NCT05873426|EXPERIMENTAL|[14C]ZSP1273|
62233622|NCT05367180|NO_INTERVENTION|Reference Arm|no preventive action
62233623|NCT05367180|EXPERIMENTAL|Vivre avec le Soleil|"Use of existing validated program vivre avec le soleil"
62233624|NCT05367180|EXPERIMENTAL|Vivre avec le Soleil + program of MISOLRE association|"Use of existing validated program vivre avec le soleil associated with prevention awareness program of MISOLRE association"
62233625|NCT05367180|EXPERIMENTAL|Vivre avec le Soleil + program of MISOLRE association + sun protections|"Use of existing validated program vivre avec le soleil associated with prevention awareness program of MISOLRE association and with the distribution of caps, sunscreens and sunglasses"
62424537|NCT01977859|ACTIVE_COMPARATOR|Nesiritide 1.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 1.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
62433607|NCT01623232|ACTIVE_COMPARATOR|licensed influenza vaccine|licensed, inactivated, standard dose influenza vaccine without adjuvant
62809617|NCT01895075|PLACEBO_COMPARATOR|Normal saline|Normal saline inhalation 2ml tid
62809618|NCT06050317|EXPERIMENTAL|Sintilimab Plus Chemotherapy and Radiotherapy|Sintilimab Plus mFFN and Radiation
62809619|NCT01344265||consecutive patients|there is only one group in our study
62809620|NCT04301375|EXPERIMENTAL|Study treatment|
62809621|NCT05007613|EXPERIMENTAL|cabozantinib plus atezolizumab|cabozantinib 40mg PO QD atezolizumab 1200mg IVD 30-60mins Q3W
62033300|NCT06355986|EXPERIMENTAL|Alert|For Alert cluster sites, an on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the provider that his or her patient is at risk for stroke due to AF, and that there is no order for anticoagulation. Clinicians who receive the computer alert will have three options: 1) access an order template of United States (US) Food and Drug Administration (FDA)-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence-based clinical practice guidelines to learn more about stroke prevention in AF, or 3) continue with order entry after providing an explanation for why anticoagulation was not prescribed.
62233626|NCT00728715|EXPERIMENTAL|A|Medium Dose of budesonide-formoterol
62233627|NCT00728715|ACTIVE_COMPARATOR|B|High dose of inhaled budesonide (1600 mcg/day)
62233628|NCT03039257|OTHER|Vitamin A|Participants receive single dose vitamin A supplementation prior to HSCT. A 3x3 dose escalation/de-escalation design will be used for this study.
62233629|NCT05877625||open ICU|open ICU: open ICU
62233630|NCT05877625||negative ICU|negative ICU: negative-pressure laminar flow ward
62233631|NCT05877625||positive ICU|positive ICU: laminar flow ward
62233632|NCT04382274|EXPERIMENTAL|Quadratus Lumborum Block|the transducer will be placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border will be visualized, leaving underneath the internal oblique muscle, like a roof over the QL muscle. The probe will be tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial then placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine will be applied
62233633|NCT04382274|EXPERIMENTAL|Dual block|the probe will be located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall will be identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique will be used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine will be injected. Then abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualised between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side.
62233634|NCT05114577|EXPERIMENTAL|Recovery Sleepers program.|
62424538|NCT01977859|ACTIVE_COMPARATOR|Nesiritide 2.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 2.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
62033301|NCT06355986|NO_INTERVENTION|No Alert|For No Alert cluster sites, no computerized alert notification will be issued to providers.
62233635|NCT05114577|PLACEBO_COMPARATOR|Email recommendations|
62233636|NCT03681704|EXPERIMENTAL|HuangQi Decoction|HuangQi Decoction 150ml by mouth ,twice a day for 24 weeks
62233637|NCT03681704|PLACEBO_COMPARATOR|HuangQi Decoction placebo|HuangQi Decoction placebo 150ml by mouth, twice a day for 24 weeks
62233638|NCT03056911||ozone|Chemonucleolysis by ozone therapy Patients visiting the pain clinic of the hospital who had cervical discogenic or radicular pain that did not resolve after the use of conventional therapy. Written informed consent was obtained from all participants.
62233639|NCT03564639||Injection drug users with HCV|People who inject drugs who were confirmed positive for HCV and initiated treatment in the parent study beginning in September 2017.
62233640|NCT05730270|EXPERIMENTAL|Stress reduction program 1|Participants will complete stress reduction lessons for two weeks
62233641|NCT05730270|EXPERIMENTAL|Stress reduction program 2|Participants will complete stress reduction lessons for two weeks
62233642|NCT05730270|NO_INTERVENTION|Waitlist|Participants will have an opportunity to complete one of the two programs of stress reduction lessons after data collection is completed
62233643|NCT03134157|EXPERIMENTAL|Simvastatin and vaginal placebo|The patients with leiomyoma receive simvastatin 40 mg orally+ vaginal placebo will be given every day for 3 months.
62424539|NCT01977859|ACTIVE_COMPARATOR|Nesiritide 4.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 4.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
62033302|NCT01118208|EXPERIMENTAL|Blister Packaging|Patients will receive all prescription medications on blister pack cards.
62033303|NCT01118208|ACTIVE_COMPARATOR|Dispense as Usual|Patients will receive all prescription medications in standard pill bottles.
62233644|NCT03134157|EXPERIMENTAL|Simvastatin and oral placebo|The patients with leiomyoma receive simvastatin 40 mg orally+ oral placebo will be given every day for 3 months.
62233645|NCT03134157|EXPERIMENTAL|Vaginal placebo+ oral placebo|The patients with leiomyoma receive Vaginal placebo+ oral placebo every day for 3 months.
62233646|NCT06093126|EXPERIMENTAL|lemborexant|"The study will be an N of 1 trial over 8 weeks were treatment with lemborexant being alternated with a placebo in an ABBABAAB format."
62233647|NCT01800266|EXPERIMENTAL|Symptom and Fidelity Monitoring (SFM)|Half of the study clinicians will be randomized to this supervision condition of TF-CBT.
62233648|NCT01800266|EXPERIMENTAL|SFM + Behavioral Rehearsal|Half of the study clinicians will be randomized to this supervision condition of TF-CBT.
62233649|NCT03182725|PLACEBO_COMPARATOR|Placebo|Patient will consume one placebo pill twice a day for one month.
62233650|NCT03182725|EXPERIMENTAL|Ivabradine|Patient will consume one dose of Ivabradine twice a day for one month.
62233651|NCT06190678|EXPERIMENTAL|Pirtobrutinib (Severe Renal Impairment)|Pirtobrutinib administered orally
62233652|NCT06190678|EXPERIMENTAL|Pirtobrutinib (Normal Renal Function)|Pirtobrutinib administered orally
62424540|NCT01977859|ACTIVE_COMPARATOR|Nesiritide 8.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 8.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
62233653|NCT05965661|OTHER|Virtual reality upper limb hand training|The PD patients randomized in the experimental group will receive virtual reality upper limb hand training.
62233654|NCT05965661|OTHER|Virtual reality control training|The PD patients randomized in the control group will receive virtual reality control training.
62233655|NCT06065865|EXPERIMENTAL|Guidance document|The intervention that is investigated in this study is a guidance document, which is used to individualize the treatment trajectory for the parent-child dyad. This guidance document includes different factors that are important in deciding on the order of different types of therapy within one treatment trajectory. The document will guide the therapist in tailoring the treatment trajectory towards the needs of the dyad. The treatment trajectory can consist of EMDR-therapy for the parent, EMDR therapy for the child and NIKA for the parent-child relationship. The guidance document will guide the therapist in deciding on the order of the different therapies.
62233656|NCT05095701|EXPERIMENTAL|Experimental Group|349 subjects who enrolled in the experimental group of clinical trial and included in the immunogenicity subgroup PPS set from August to September 2016 will be collected venous blood 3.0\~3.5ml at 5 and 8 years after primary immunization.
62809622|NCT01512199|EXPERIMENTAL|U3-1287 with trastuzumab + paclitaxel (Phase 1b)|The Phase 1b portion is an open label, dose de escalation, single arm study designed to assess the safety and tolerability of up to 3 dose levels of U3- 1287 in combination with trastuzumab plus paclitaxel and will determine the recommended Phase 2 dose (RP2D) of U3 1287. The first cohort will receive U3- 1287 18 mg/kg intravenously (IV) in combination with trastuzumab plus paclitaxel once every 3 weeks (q3w).
62033304|NCT02097108|OTHER|Raltegravir|Patients will be offered to switch their protease inhibitor containing regimen to a raltegravir (400mg twice daily, orally) based regimen while maintaining the same background therapy.
62233657|NCT05095701|PLACEBO_COMPARATOR|Control Group|354 subjects who enrolled in the control group of clinical trial and included in the immunogenicity subgroup PPS set from August to September 2016 will be collected venous blood 3.0\~3.5ml at 5 and 8 years after primary immunization.
62233658|NCT03558360||Bariatric surger|Bariatric surgery and impedance measurement
62424541|NCT05605457|EXPERIMENTAL|PRG barrier coat|It is a light cured surface-partially reacted glass (S-PRG) filler particles with a multifunctional glass core embedded in a resin matrix.
62424542|NCT05605457|ACTIVE_COMPARATOR|Resin modified glass ionomer|Resin modified glass ionomer (Fuji II LC, GC, Japan). RMGIC are glass-ionomer cements with small quantity of monomers and initiators so the acid-base reaction is supplemented by a second polymerization reaction.
62424543|NCT04599673|EXPERIMENTAL|AMNIOGEN|Intraoperative1 kit of AMNIOGEN injection into shoulder joint after RCT repair.
62424544|NCT04599673|PLACEBO_COMPARATOR|Normal saline|Intraoperative 10 ml of normal saline injection into shoulder joint after RCT repair.
62593339|NCT06619366|EXPERIMENTAL|Personalized depression risk communication|"The intervention has two integrated components: PDRC and coach-guidance. The PDRC has five sections. The PDRC will be sent to participants by email/mail within two days after the baseline and follow-up assessments.~The coach will contact the participant within a week after the PDRC is provided by telephone or video conference, depending on participants' preference. The role of the coach is to assist the participant in understanding and interpreting the PDRC, answering their questions, and helping identify self-help strategies that are feasible for the participant; they do not provide psychotherapy. The coaching session will follow the four processes of motivational interview."
62809623|NCT01512199|EXPERIMENTAL|U3-1287 with trastuzumab+paclitaxel (Ph 2)|The Phase 2 portion is a randomized, 2 arm, placebo controlled, double blind study designed to evaluate the safety and the efficacy of U3-1287 at the recommended phase 2 in combination with trastuzumab plus paclitaxel (experimental arm) relative to the control arm (trastuzumab plus paclitaxel and placebo).
62424545|NCT04931758||Patients with low back pain|
62809624|NCT01512199|PLACEBO_COMPARATOR|Placebo with trastuzumab+paclitaxel (Ph 2)|The Phase 2 portion is a randomized, 2 arm, placebo controlled, double blind study designed to evaluate the safety and the efficacy of U3-1287 at the recommended phase 2 dose in combination with trastuzumab plus paclitaxel (experimental arm) relative to the control arm (trastuzumab plus paclitaxel and placebo).
62809625|NCT05164393|EXPERIMENTAL|AVX001 1%|Application of AVX001 1% gel to treatment field once daily
62033305|NCT05309265|OTHER|Breast cancer patients with work difficulties|Breast cancer patients with work difficulties can receive any of the three types of support, or a combination of these: information, occupational therapy and social support, in order to overcome barriers and return to work/continue to work
62033306|NCT03370653|EXPERIMENTAL|Double-blind - odiparcil 1000 mg per day|2 tablets of odiparcil 250 mg per os, twice daily (BID)
62809626|NCT05164393|EXPERIMENTAL|AVX001 3%|Application of AVX001 3% gel to treatment field once daily.
62809627|NCT05164393|PLACEBO_COMPARATOR|AVX001 Vehicle|Application of AVX001 vehicle gel to treatment field once daily
62809628|NCT02259673|EXPERIMENTAL|Fun exercise|effect of fun physical exercise on sarcopenia
62033307|NCT03370653|EXPERIMENTAL|Double-blind - odiparcil 500 mg per day|1 tablet of placebo and 1 tablet of odiparcil 250 mg per os, twice daily (BID)
62424546|NCT04931758||Controls|
62424547|NCT02540473|EXPERIMENTAL|Group therapy|12 week manualized group therapy (one hour per week)
62424548|NCT02540473|OTHER|Control Group|Participants get one hour of time away from patient care/duties to do as they wish.
62424549|NCT02970175|EXPERIMENTAL|Bronchoscopy with terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
62424550|NCT02970175|PLACEBO_COMPARATOR|Bronchoscopy without terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done without terlipressin administration
62433608|NCT06169657||Inpatients Post-stroke, low level ambulators|Individuals post acute or subacute stroke that that are inpatients at the Shirley Ryan AbilityLab ages 18-75 with initial gait speed 0.0-0.39 m/s
62433609|NCT06169657||Inpatients Post-stroke, high level ambulators|Individuals post acute or subacute stroke that that are inpatients at the Shirley Ryan AbilityLab ages 18-75 with initial gait speed 0.4-0.79 m/s
62809629|NCT02259673|EXPERIMENTAL|fun exercise|effect of fun physical exercise on interest in exercise
62809630|NCT02319200|EXPERIMENTAL|Metformin|"1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)~Metformin daily during 36 months"
62809631|NCT02319200|PLACEBO_COMPARATOR|placebo tablet|2 tablets at morning and 2 tablets at afternoon 4 tablets per day
62809632|NCT01259817|EXPERIMENTAL|PEGASYS|Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously.
62809633|NCT01259817|ACTIVE_COMPARATOR|Aspirin|81 or 100 mg daily.
62809634|NCT00474955|EXPERIMENTAL|Peginterferon Alpha-2a|Eligible participants will be administered peginterferon alpha-2a \[Pegasys\] (40 kilo Dalton), 180 micrograms as a subcutaneous injection, once in a week, for 48 weeks. Participants with a calculated glomerular filtration rate of \<15 milliliter /minute will be administered a reduced dose of 135 mcg as a subcutaneous injection, once in a week, for 48 weeks.
62809635|NCT02546232|ACTIVE_COMPARATOR|Control|Paclitaxel 80 mg/m2 weekly for 12 weeks, thereafter current standard chemotherapy for 12 weeks
62809636|NCT02546232|EXPERIMENTAL|Additional therapy|"Carboplatin AUC 6 (area under curve; mg/ml/min) once every 3 weeks, for 12 weeks.~Paclitaxel 80 mg/m2 weekly for 12 weeks, thereafter current standard chemotherapy for 12 weeks"
62809637|NCT00240058|OTHER|phenylephrine infusion with and without nitric oxide clamp|Participants received phenylephrine infusion with saline followed by phenylephrine infusion with nitric oxide clamp
62809638|NCT03106571|EXPERIMENTAL|Pomaglumetad methionil Low + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 9 days with intravenous methamphetamine challenges
62809639|NCT03106571|EXPERIMENTAL|Pomaglumetad methionil Mid + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 80 mg orally twice daily x 8 days with intravenous methamphetamine challenges
62033308|NCT03370653|PLACEBO_COMPARATOR|Double-blind - placebo|2 tablets of placebo per os, twice daily (BID)
62033309|NCT03370653|EXPERIMENTAL|Open Label - odiparcil 1000 mg per day|2 tablets of odiparcil 250 mg per os, twice daily (BID)
62033310|NCT05130658|EXPERIMENTAL|C-MILL training group|The participants will be screened for the inclusion/exclusion criteria and consented during the first session. They will participate in two data collection sessions, one before the training and one after the training. The participants will undergo 10 training sessions. Individuals in the CTG will receive gait and balance training sessions with the virtual reality and auditory cues using C-MILL (such as walking on a pathway, obstacle avoidance, lateral balance etc.) to provide task specific training. C-Mill (Motekforce Link, Amsterdam, The Netherlands) is an instrumented treadmill that uses visual (on the screen as well on the treadmill) and acoustic cues for gait and balance training. The C-Mill allows for gait and balance adaptability strategy as it can provide obstacle avoidance environments, change in speed and various walking pathways in a safe and controlled environment.
62033311|NCT05130658|ACTIVE_COMPARATOR|Treadmill training group (TTG)|The participants will be screened for the inclusion/exclusion criteria and consented during the first session. They will participate in two data collection sessions, one before the training and one after the training. The participants will undergo 10 training sessions. Individuals in TTG group will walk on the treadmill (C-MILL) or stand on the treadmill (C-MILL) with no visual or auditory cues.
62424551|NCT05349188|EXPERIMENTAL|Melatonin 3 mg|"Individuals will receive a kit with medication adherence devices containing melatonin 3 mg in one of three smart electronic pill bottles labeled A, B, and C. Participants will not be aware which of the pill bottles contains the 3mg of melatonin. Participants will be randomized to take pills in 6 alternating intervention periods 2 weeks in length. During periods where participants were randomized to receive melatonin 3 mg, they will receive a nightly text notification 1 hour before bed instructing them to take a pill from the corresponding smart pill bottle. The melatonin 3 mg intervention will be administered in 2 intervention periods each 2 weeks in length (4 weeks total)."
62424552|NCT05349188|ACTIVE_COMPARATOR|Melatonin 0.5 mg|"Individuals will receive a kit with medication adherence devices containing melatonin 0.5 mg in one of three smart electronic pill bottles labeled A, B, and C. Participants will not be aware which of the pill bottles contains the 0.5 mg of melatonin. Participants will be randomized to take pills in 6 alternating intervention periods 2 weeks in length. During periods where participants were randomized to receive melatonin 0.5 mg, they will receive a nightly text notification 1 hour before bed instructing them to take a pill from the corresponding smart pill bottle. The melatonin 0.5 mg intervention will be administered in 2 intervention periods each 2 weeks in length (4 weeks total)."
62433610|NCT06169657||Inpatients with iSCI, low level ambulators|Individuals post-SCI or subacute that that are inpatients at the Shirley Ryan AbilityLab ages 18-75 with initial gait speed 0.0-0.39 m/s
62809640|NCT03106571|EXPERIMENTAL|Pomaglumetad methionil High + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 160 mg orally twice daily x 8 days with intravenous methamphetamine challenges
62809641|NCT03106571|PLACEBO_COMPARATOR|Control + Methamphetamine|1-4 placebo tabs orally twice daily x 9 days (to match pomaglumetad dosing in each cohort) with intravenous methamphetamine challenges
62809642|NCT02413918|EXPERIMENTAL|Open Label iloperidone|open label iloperidone (oral tablet, 6mg-24mg, QD, 20 weeks) as adjunct to current lithium, divalproex, or lamotrigine.
62809643|NCT06524102|EXPERIMENTAL|MACS|Oocytes corresponding to this group were inseminated by spermatozoa selected after the use of MACS.
62809644|NCT06524102|NO_INTERVENTION|Control|Oocytes corresponding to this group were inseminated with spermatozoa obtained after density gradient centrifugation.
62809645|NCT01848665|EXPERIMENTAL|Drug|Indomethacin, 1.2 mg kg 1 dose
62809646|NCT01848665|PLACEBO_COMPARATOR|Placebo|generic flour placebo capsule
62033312|NCT05130658|NO_INTERVENTION|Healthy Control|HCG will participate in up to four sessions. The participants will be screened for the inclusion/exclusion criteria and consented during the first session. They will participate in two data collection sessions and one C-MILL session.
62033313|NCT00844038||1|Sick
62433611|NCT06169657||Inpatients with iSCI, high level ambulators|Individuals post-SCI or subacute that that are inpatients at the Shirley Ryan AbilityLab ages 18-75 with initial gait speed 0.4-0.79 m/s
62809647|NCT00981149|EXPERIMENTAL|duloxetine study drug|Drug
62809648|NCT00981149|PLACEBO_COMPARATOR|Placebo|Placebo
62809649|NCT04072926|EXPERIMENTAL|PDT+/BIOROOT|Photodynamic therapy will bi conducted with diode laser (660nm, 100mW, 60 seconds) with toluidine at the end of chemomechanical preparation. Final root canal filling will be with BioRoot in combination with guttapercha points.
62033314|NCT04647149|EXPERIMENTAL|Early Time-Restricted Eating|8-hour eating window between 08:00 and 16:00
62033315|NCT04647149|EXPERIMENTAL|Delayed Time-Restricted Eating|8-hour eating window between 12:00 and 20:00
62033316|NCT04647149|EXPERIMENTAL|Control|12-hour eating window between 08:00 and 20:00
62033317|NCT05710601||Tissue sealers|Procedures performed using a 5 mm diameter, 35 cm length curved branch radiofrequency tissue sealer connected to a dedicated electric generator
62033318|NCT05710601||Bipolar forceps|Procedures performed using a 5 mm diameter, 35 cm classic rotating bipolar forceps
62033319|NCT01736813||CCR5-inhibitor at 300 mg/bid|colorectal cancer patients with liver metastases (twelve patients treated with 300 mg/bid)
62033320|NCT05142267|OTHER|Adults with chronic non-cancer low back pain|
62033321|NCT05815524|EXPERIMENTAL|Active|physical activity protocol
62033322|NCT05328401|EXPERIMENTAL|Intervention group (verum laser acupuncture group )|After blind random allocation, investigators applied verum laser acupuncture on patient with shoulder pain after stroke.
62033323|NCT05328401|SHAM_COMPARATOR|Control group (sham laser acupuncture group)|After blind random allocation, investigators applied sham laser acupuncture on patient with shoulder pain after stroke.
62033324|NCT05994235|EXPERIMENTAL|Subcutaneous Mosunetuzumab and Oral Tazemetostat|50 patients will be enrolled and treated with standard dosing of subcutaneous mosunetuzumab, and with oral tazemetostat by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation.
62033325|NCT06669949||Individuals with sphingosine phosphate lyase insufficiency syndrome|Individuals diagnosed with sphingosine phosphate lyase insufficiency syndrome based on genetic testing that confirms bi-allelic pathogenic variants in the SGPL1 gene
62033326|NCT06669949||Parents of individuals with sphingosine phosphate lyase insufficiency syndrome|Parents of individuals diagnosed with sphingosine phosphate lyase insufficiency syndrome based on genetic testing that confirms bi-allelic pathogenic variants in the SGPL1 gene
62233659|NCT03195738|EXPERIMENTAL|Intervention arm|"The Cognitive Orientation to Occupational Performance (CO-OP) Approach will be delivered over 10 30-60 minute sessions over a seven week period as follows: 2 sessions/week for 3 weeks, then 1 session per week for 4 weeks. In the CO-OP intervention participants are first assisted to identify 3-5 occupation based goals which will be the focus of the intervention sessions. Over the course of the 10 intervention sessions, participants are guided to learn and practice problem solving using a metacognitive strategy, Goal-Plan-Do-Check applied to their self-identified goals. Study therapists use 'guided discovery' an iterative technique to facilitate problem solving by the participant to develop plans to work toward their goals and to evaluate their progress. Intervention takes place in the location that is most meaningful for the participant's selected goal (e.g. home, school, playground etc.). Participants are provided with a work book to track progress."
62433612|NCT01321112|EXPERIMENTAL|Conversion arm|After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
62809650|NCT04072926|EXPERIMENTAL|PUI/BIOROOT|This arm will only get PUI (passive ultrasound irrigation) with 2,5ml of 2,5% sodium hypochlorite, then 2ml of 15% EDTA which will be activated for 60seconds (EndoUltra MicroMega, France) and finally 2,5ml of 2,5% of sodium hypochlorite will be also activated for 30 seconds. Root canal filling in combination with BioRoot and guttapercha points.
62033327|NCT06669949||age and gender-matched controls|The investigators will attempt to collect biological specimens from individuals closely matched to SPLIS patient cohort by age and gender. This group may include siblings, cousins, and unrelated healthy children and adults.
62033328|NCT03228511|EXPERIMENTAL|Formerly Arm Label|
62033329|NCT02999165||CPAP group|25 infants undergoing treatment with continuous nCPAP who are making attempts at breast feeding and receiving nasogastric feeds.
62033330|NCT02999165||HHFNC group|25 infants undergoing treatment with continuous HHFNC oxygen who are making attempts at breast feeding and receiving nasogastric feeds.
62233660|NCT02214433|EXPERIMENTAL|Part A Period 1 Debio 1450 IV Solution|Part A Debio 1450 IV solution infused over two hours on Day 1 after fasting
62233661|NCT02214433|EXPERIMENTAL|Part A Period 2 Debio 1450 Tablet|Debio 1450 Tablet oral dosing once on Day 5, after fasting
62233662|NCT02214433|EXPERIMENTAL|Part A Period 3 Debio 1450 Tablet|Debio 1450 Tablet oral dosing once on Day 9, 30 minutes after a high calorie, high fat breakfast, after fasting
62233663|NCT02214433|EXPERIMENTAL|Part A Period 4 Debio 1450 Tablet|After preparation with Pantoprazole, Pantoprazole taken with Debio 1450 Tablet oral dosing once on Day 14, after fasting
62033331|NCT02125175|EXPERIMENTAL|Hypofractionated IMRT boost Radiotherapy|
62033332|NCT04083248|EXPERIMENTAL|Feasibility group|"Intervention components:~Personalized group diabetes education.~Fitbit Charge 3 wrist activity monitor for real-time monitoring of steps, active minutes and heart rate. The Fitbit will be used by the women to set activity goals, self-assess their progress and aid in motivation to be more active.~Freestyle Libre (Abbott Labs, Alameda, CA) Personal CGM (FDA approved). The Libre CGM will be used to self-monitor glucose goals and monitor the real-time effects of activity and eating choices by the women.~Final guided interview for study acceptability and feasibility. The interviews will be audiotaped, transcribed. Thematic content analyses will be performed."
62033333|NCT05949762|EXPERIMENTAL|Venetoclax in Combination With Azacitidine and HA Regimen|"Details for:~Venetoclax 200mg d1-10 Azacitidine 100mg/d (or 50-75mg/m2/d), d2-7 Hautriacontin 2mg/m2/d, d3-7 Cytarabine 100mg/m2/d, d3-8 (infusion 24h)"
62033334|NCT04827511||cohort group|80 children with disabilities like autism, ADHD, Down syndrome, deafness, phocomelia, dyslexia, different motor problems
62033335|NCT04827511||control group|81 healthy children, not known or diagnosed with a chronic disease of any kind
62033336|NCT00679939|ACTIVE_COMPARATOR|Arm 1 Treatment A|rosiglitazone up to 8mg/day
62033337|NCT00679939|ACTIVE_COMPARATOR|Arm 2 Treatment B|metformin up to 2000mg/day
62033338|NCT01158131|EXPERIMENTAL|Lifestyle Intervention group|Participants in this group will take part in the lifestyle intervention.
62033339|NCT01158131|NO_INTERVENTION|Post-gestational diabetes mellitus (GDM) Follow-up Group|Participants in this group will not take part in the intervention.
62809651|NCT04072926|ACTIVE_COMPARATOR|PDT+/AH+|Photodynamic therapy will bi conducted with diode laser (660nm, 100mW, 60 seconds) with toluidine at the end of chemomechanical preparation. Final root canal filling will be with AH+ epoxy based cement in combination with guttapercha points.
62033340|NCT02754648|ACTIVE_COMPARATOR|Group A; laparoscopic ovarian endometrial aspiration|Laparoscopic ovarian endometrial aspiration will be done for thirty patients with ovarian endometriotic cyst. .
62033341|NCT02754648|ACTIVE_COMPARATOR|group B; laparoscopic ovarian endometrial stripping|Laparoscopic ovarian endometrial stripping will be done for thirty patients with ovarian endometriotic cyst.
62809652|NCT04072926|ACTIVE_COMPARATOR|PUI/AH+|This arm will only get PUI (passive ultrasound irrigation) in combination with AH+ epoxy based cement and guttapercha points.
62809653|NCT03476200|EXPERIMENTAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy consisting of fourteen weekly group sessions, one hour and a half each, directed by two clinical psychologist.
62809654|NCT03476200|NO_INTERVENTION|Control Group|Control Group with no intervention.
62809655|NCT03512834|EXPERIMENTAL|Paclitaxel+Avelumab|Paclitaxel combination with Avelumab for inoperable angiosarcoma
62809656|NCT05582486|EXPERIMENTAL|obstetric violence prevention education intervention|"The training program for the prevention of obstetric violence was given to the midwives and nurses in the experimental group by the researcher in the form of group training in the training hall of the relevant institution. The trainings were completed in a total of 16 sessions, two sessions a day and four sessions a week. Sessions were held between 16:00 and 18:00 on weekdays, each lasting approximately 40-45 minutes, with a 10-minute break between sessions. Thus, the training program applied to the experimental group was completed in 4 weeks.~The main purpose of the training program is to prevent obstetric violence perpetrated by midwives and nurses. The training content created for this purpose included the definition of obstetric violence, pregnant and fetus rights, factors causing obstetric violence and strategies to be used to reduce obstetric violence.~Other Names:~• group-ED"
62809657|NCT05582486|EXPERIMENTAL|Standard of care|"Midwives and nurses in this group did not perform any practice.~. group- SB"
62809658|NCT02682953|EXPERIMENTAL|Hyperbaric oxygen therapy|Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
62809659|NCT00543257||Parents|Parents of children with ADHD will be recruited from the greater Boston community. We are interested in enrollment of parents with a range of educational and technical backgrounds, and specifically will look to enroll parents who may not have much computer experience.
62809660|NCT05833958|EXPERIMENTAL|GMRx-4 IR polypill in the morning and metformin Immediate Release (IR)175mg at night|One GMRx-4 IR polypill capsule (metformin IR 175mg + dapagliflozin 2.5mg + sitagliptin 17.5mg) in the morning and one metformin IR 175mg capsule at night. Capsules are taken with, or just after, food, and swallowed whole with water. Capsules will be taken at, or as close as possible to, the same time of morning (GMRx-4 IR) and the same time of evening (metformin 175mg) each day for 16 weeks.
62809661|NCT05833958|ACTIVE_COMPARATOR|Metformin IR 500mg in the morning and at night|One metformin IR 500mg capsule in the morning and at night. Capsules are taken with, or just after, food, and swallowed whole with water. Capsules will be taken at, or as close as possible to, the same time of morning and the same time of evening each day for 16 weeks.
62809662|NCT01810484|ACTIVE_COMPARATOR|Group 1|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with Ultherapy® treatment only; Treatment Area B will be treated with Ultherapy® treatment and CO2 laser treatment; Treatment Area C will be treated with CO2 laser treatment only"
62809663|NCT01810484|ACTIVE_COMPARATOR|Group 2|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with Ultherapy® treatment and CO2 laser treatment; Treatment Area B will be treated with CO2 laser treatment only; Treatment Area C will be treated with Ultherapy® treatment only"
62809664|NCT01810484|ACTIVE_COMPARATOR|Group 3|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with CO2 laser treatment only; Treatment Area B will be treated with Ultherapy® treatment only; Treatment Area C will be treated with Ultherapy® treatment and CO2 laser treatment"
62809665|NCT00627822||Ward|Patients in the hospital ward
62809666|NCT00627822||Emergency room|Patients in the emergency waiting room
62809667|NCT00627822||Intensive care unit|Family members of patients admitted to the intensive care unit
62809668|NCT04745364|EXPERIMENTAL|Session One|Session One participants undergo the 4-week course from 2/21/2021 to 3/15/2021
62809669|NCT04745364|EXPERIMENTAL|Session Two|Session Two participants undergo the 4-week course from 3/22/2021 to 4/12/2021
62809670|NCT06129526|ACTIVE_COMPARATOR|EPAVasc 2g|
62809671|NCT06129526|ACTIVE_COMPARATOR|EPAVasc 2g x 2|
62809672|NCT06129526|PLACEBO_COMPARATOR|Corn Oil|
62809673|NCT02476786|EXPERIMENTAL|Endocrine therapy alone|"* Neoadjuvant endocrine therapy will be given at the discretion of the treating physician as directed by the package insert and could include the following: goserelin, anastrozole, letrozole, exemestane, fulvestrant, or tamoxifen~* Frequency of office visits will be decided by the treating physician but must occur no less frequently than every 3 to 6 months for tumor assessment~* After 6 months and after 12 months, patients will be assessed; patients who progress will have standard care recommended , and at any point a patient can opt to receive standard care even if she has not progressed on neoadjuvant endocrine therapy~* Information on quality of life will be collected at baseline, Year 1, and Year 2 by the FACT-B questionnaire~* Archival tissue will be collected and sent to Genomic Health for analysis using the Oncotype DX assay. The Recurrence Score predicts chemotherapy benefit and indicates the 10-year risk of recurrence (will not be used to determine treatment)"
62809674|NCT02266316|EXPERIMENTAL|Mask|Using mask that warms air at the mouth by utilising body heat
62809675|NCT02266316|NO_INTERVENTION|No mask|Not using any mask that warms air at the mouth by utilising body heat
62033342|NCT02754648|ACTIVE_COMPARATOR|Group c laparoscopic ovarian endometrial de-roofing|Laparoscopic ovarian endometrial de-roofing and bed cauterization will be done for thirty patients with ovarian endometriotic cyst.
62033343|NCT03947918|EXPERIMENTAL|Short sleep|No more than 8 hours of sleep for 4 consecutive nights.
62033344|NCT03947918|EXPERIMENTAL|Long sleep|At least 10 hours of sleep for 4 consecutive nights
62033345|NCT01381692|ACTIVE_COMPARATOR|Arm I (rituximab, bortezomib, dexamethasone)|Patients receive rituximab IV over 30-60 minutes on days 1, 8, 15, and 22 (of courses 1 and 4 only) and bortezomib IV or SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62033346|NCT01381692|EXPERIMENTAL|Arm II (temsirolimus, rituximab, bortezomib, dexamethasone)|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and rituximab, bortezomib, and dexamethasone as in arm I. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62033347|NCT05626400|EXPERIMENTAL|CD-7 CART|Patients will be treated with CD7 CAR-T cells
62033348|NCT06651515|EXPERIMENTAL|SR-02 Allogeneic pancreatic endocrine cell clusters|
62033349|NCT05991752|EXPERIMENTAL|ROMA Score|Experimental group: CA125 and HE4 assays every 4 months for 3 years to assess the ROMA score, in addition to the recommended conventional follow-up.
62033350|NCT05991752|NO_INTERVENTION|CA125 alone|Control group: CA125 assay alone every 4 months for 3 years, as part of the recommended standard follow-up.
62033351|NCT00791024|EXPERIMENTAL|single arm|
62033352|NCT02564523|EXPERIMENTAL|Group 1|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
62033353|NCT02564523|EXPERIMENTAL|Group 2|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 57) or placebo (Day 1/Day 57) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
62033354|NCT02564523|EXPERIMENTAL|Group 3|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 85) or placebo (Day 1/Day 85)
62033355|NCT03886103|EXPERIMENTAL|Healthy volunteer|Single of 14C-PXL770
62033356|NCT06213766|ACTIVE_COMPARATOR|Cognitively healthy subjects|"Participants aged between 20 and 85 years old with no cognitive impairment (Montreal Cognitive Assessment ≥ 26/30 and MacNair Cognitive Difficulties Self-Rating Scale ≥15), affiliated or entitled to a social health insurance, having been informed and having given written consent to the study.~As part of the study, cognitively healthy subjects will :~* Undergo a cognitive assessment;~* Answer several questionnaires on their demographic data, lifestyle habits, quality of sleep, cognitive reserve, concomitant treatment and comorbidities;~* Complete a cognitive spatial navigation task with eye-tracking;~* Have a blood sampling for plasma biomarker and genetic risk factor for Alzheimer's disease."
62033357|NCT06213766|EXPERIMENTAL|Patients suffering from Alzheimer's disease|"Patients aged between 50 and 85 years old, undergoing memory clinic consultation for prodromal or mild Alzheimer's disease with mild or moderate cognitive decline (Mini-Mental State Examination ≥20/30) affiliated or entitled to a social health insurance, having been informed and having given written consent to the study.~As part of the study, patients suffering from Alzheimer's disease will :~* Undergo a cognitive assessment;~* Answer several questionnaires on their demographic data, lifestyle habits, quality of sleep, cognitive reserve, concomitant treatment and comorbidities;~* Complete a cognitive spatial navigation task with eye-tracking;~* Have a blood sampling for plasma biomarker and genetic risk factor for Alzheimer's disease."
62033358|NCT06449833|EXPERIMENTAL|intervention|Patients whose blood glucose are regulated by10 mg of Henagliflozein and metformin.
62033359|NCT06449833|PLACEBO_COMPARATOR|placebo|Patients whose blood glucose are regulated by5mg of Linagliptin and metformin.
62433613|NCT05354245|EXPERIMENTAL|Fibre mixture group|Use of a fibre mixture (3 times daily, 5 grams per gift, total of 15 grams per day) during 12 weeks
62033360|NCT02172508|EXPERIMENTAL|Tiotropium|
62033361|NCT02172508|PLACEBO_COMPARATOR|Placebo|
62433614|NCT05354245|PLACEBO_COMPARATOR|Placebo group|Use of a placebo (maltodextrin, isocaloric manner, 3 times daily) during 12 weeks.
62433615|NCT01971931||Patients undergoing TKR.|
62033362|NCT06670859|ACTIVE_COMPARATOR|Intervention-Control:|Intervention-Control: includes the group of patients who will perform their first mobilization with a mobilization coverall and their second mobilization with a traditional hospital gown.
62033363|NCT06670859|SHAM_COMPARATOR|Control-Intervention:|Control-Intervention: includes the group of patients who will perform their first mobilization with a traditional hospital gown and their second mobilization with a mobilization coverall.
62233664|NCT02214433|PLACEBO_COMPARATOR|Part B Placebo All Cohorts|Placebo IV solution on days 1-5 and then Placebo Tablet or Capsule on Days 6-10, according to the cohort dosing schedule
62233665|NCT02214433|EXPERIMENTAL|Part B Debio 1450 Cohort 1|Debio 1450 IV solution, once daily on days 1-5, then Debio 1450 Tablet, once daily on days 6-10
62433616|NCT02883673|EXPERIMENTAL|Intervention|Jada System for Postpartum Hemorrhage will be administered to subjects who are diagnosed with postpartum hemorrhage.
62809676|NCT02571426|ACTIVE_COMPARATOR|Propofol|Continuous infusion during surgery. Individual dosage.
62033364|NCT03568318|PLACEBO_COMPARATOR|Placebo / Upadacitinib + Topical Corticosteroids|Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
62809677|NCT02571426|ACTIVE_COMPARATOR|sevoflurane|Inhalational anesthetic during surgery. Individual dosage
62809678|NCT02753946|EXPERIMENTAL|ZTI-01|6 g ZTI-01 (IV fosfomycin) intravenously administered every 8 hours (18g total daily dose for 7-14 calendar days)
62809679|NCT02753946|ACTIVE_COMPARATOR|piperacillin tazobactam|4.5 g piperacillin/tazobactam (4 g piperacillin/0.5 g tazobactam) intravenously administered every 8 hours (13.5g total daily dose for 7-14 calendar days)
62809680|NCT04914780|EXPERIMENTAL|Intervention group|4 weeks training with mobile application
62809681|NCT04914780|NO_INTERVENTION|Control group|No intervention will be made for 4 weeks
62809682|NCT06446921|EXPERIMENTAL|Ginger formula|100 mg of ginger formula per capsule 2 capsules per day during 8 weeks
62809683|NCT06446921|PLACEBO_COMPARATOR|Placebo formula|2 capsules per day during 8 weeks
62809684|NCT03920111|OTHER|Group 1 - Any status|Up to 3-4 healthy adults
62809685|NCT03920111|OTHER|Group 2 - FlaviPrime Naive|Up to 6-8 healthy adults who have never travelled to a flavivirus endemic area and are negative in screening tests for flavivirus immunity.
62809686|NCT03920111|OTHER|Group 3 - Flavivirus Exposed|Up to 8-10 healthy adults who have had JE vaccine and/or are previously flavivirus exposed, either through receiving yellow fever vaccine up to 5 years before the study, or from being diagnosed with a flavivirus illness (e.g. dengue or Zika).
62809687|NCT04142034|EXPERIMENTAL|iAmHealthy Behavioral Intervention|This intervention will receive the American Academy of Pediatrics (AAP) newsletter, group and individual sessions with the iAmHealthy behavioral intervention team via an electronic tablet provided by the sponsor.
62809688|NCT04142034|ACTIVE_COMPARATOR|NewsLetter intervention|This intervention arm will only receive the American Academy of Pediatrics (AAP) newsletter for six months.
62809689|NCT04142034|OTHER|Consecutive Recruitment method|Using this recruitment method, clinics will identify potential eligible study participants through their medical records among those that have been seen in the clinic within the past year and those children with upcoming appointments and approach them and their caregivers about enrolling in the study.
62033365|NCT03568318|EXPERIMENTAL|Upadacitinib 15 mg QD + Topical Corticosteroids|Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
62033366|NCT03568318|EXPERIMENTAL|Upadacitinib 30 mg QD + Topical Corticosteroids|Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
62233666|NCT02214433|EXPERIMENTAL|Part B Debio 1450 Cohort 2a|Debio 1450 IV solution, once daily on day 1
62233667|NCT02214433|EXPERIMENTAL|Part B Debio 1450 Cohort 3|Debio 1450 IV solution, twice daily on days 1-5, then Debio 1450 Capsule, twice daily on days 6-10
62233668|NCT02214433|EXPERIMENTAL|Part B Debio 1450 Cohort 4|Debio 1450 IV solution, twice daily on days 1-5, then Debio 1450 Capsule, twice daily on days 6-10
62809690|NCT04142034|OTHER|Traditional Recruitment method|Flyers, advertisements, and other materials will be used to recruit potential participants to the study.
62809691|NCT00055302|EXPERIMENTAL|1|
62809692|NCT06317558||Neoadjuvant immunotherapy|Immune checkpoint inhibitors are used for neoadjuvant treatment in this cohort.
62809693|NCT06317558||Other neoadjuvant treatment|Other drugs other than Immune checkpoint inhibitors are used for neoadjuvant treatment in this cohort.
62809694|NCT04299165|EXPERIMENTAL|Device: KAIA COPD-App (Medical Mobile Application).|The study intervention is an exercise training program that requires only a chair or water bottles, consisting of training elements with progressive levels of intensity, individually adaptable to the participant's exercise level. This training program is delivered to the participants with the help of KAIA COPD-App. Additionally, the Polar A370 watch will collect the daily symptoms and training log during each session for the Database.
62809695|NCT04299165|ACTIVE_COMPARATOR|Usual Care|"The Training of the control-group is performed by regular recommendations/ Standard of care. Standard of care in this context means to hand out the brochure  Besser Leben mit COPD  including an emergency plan, providing exercise training examples, to hand out addresses of out-patient physiotherapists and to hand out a detailed medical report including medical recommendations.Additionally, the Polar A370 watch will collect the daily symptoms and training log during each session for the Database."
62809696|NCT03446872||All Study Participants|Patients in South Korea with a diagnosis of metastatic pancreatic cancer who have been prescribed ONIVYDE
62809697|NCT02670486|NO_INTERVENTION|standard of care|Usual urodynamics with no intervention.
62809698|NCT02670486|ACTIVE_COMPARATOR|Audiovisual intervention|Audiovisual stimulus during urodynamic testing.
62809699|NCT00379665|EXPERIMENTAL|Cisplatin|1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
62809700|NCT06151548|EXPERIMENTAL|supplemented|"(n = 15), who will receive four times a day one capsule of a supplement called THYROX (Atlantic krill oil). The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA - 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.~The supplementation period will be six weeks."
62809701|NCT06151548|EXPERIMENTAL|control|receiving placebo
62809702|NCT04604535|ACTIVE_COMPARATOR|Concentrated beetroot juice|70mL of concentrated beetroot juice with 400mg nitrate
62809703|NCT04604535|PLACEBO_COMPARATOR|Placebo|70mL of concentrated beetroot juice with \<0.01mmol/L nitrate
62809704|NCT04361734||Juvenile onset Systemic Lupus Erythematosus (SLE) patients|All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 11 and 21.
62233669|NCT02214433|EXPERIMENTAL|Part B Debio 1450 Cohort 2b|Debio 1450 IV solution, once daily on days 1-5, then Debio 1450 Capsule, once daily on days 6-10
62809705|NCT04361734||Adult onset Systemic Lupus Erythematosus (SLE) patients|All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 24 and 80
62809706|NCT04361734||Matching healthy volunteers|Healthy volunteers, matched by age and gender, will be used as a control group
62809707|NCT04129593|EXPERIMENTAL|Self Awakening|Participant will intend to wake up at a specific time before going to bed.
62809708|NCT04129593|EXPERIMENTAL|Snooze|Participant will set multiple alarms before bed to wake at a specific time.
62809709|NCT01731912|EXPERIMENTAL|Treatment (degarelix acetate, EBRT)|Patients receive degarelix acetate SC on day 1. Treatment repeats every 4 weeks for up to 6 courses. Beginning at week 15, patients also undergo standard EBRT for 8.5 weeks.
62809710|NCT03255239|EXPERIMENTAL|Preperitoneal mesh repair|Ventral hernia repair using polyester preperitoneal mesh repair
62809711|NCT03255239|EXPERIMENTAL|Retromuscular mesh repair|Ventral hernia repair using polyester retromuscular mesh repair
62809712|NCT03255239|EXPERIMENTAL|Suture repair|Ventral hernia repair using suture repair
62233670|NCT02214433|EXPERIMENTAL|Part C Debio 1450|Debio 1450 (IV formulation in Period 1, capsule formulation in Periods 2, 4 and 5 (with Pantoprazole), and Debio 1450 oral solution in Period 3).
62809713|NCT00464698|EXPERIMENTAL|All Study Participants|Duloxetine 30mg: Dose level 1 (Week 1) Duloxetine 60mg: Dose level 2 (Wks 2-4) Duloxetine 120mg: Dose level 3 (Wks 3-7)
62809714|NCT02367508|EXPERIMENTAL|MODEL Care|Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) is a mindfulness meditation-based intervention to facilitate timely advance care planning (ACP) and end-of-life conversations with greater ease. Participants are taught a variety of mindfulness practices (e.g., breath awareness, sitting meditation, mindful movement through gentle yoga, and mindful communication) that can be used to enhance end-of-life coping.
62809715|NCT04803877|EXPERIMENTAL|Regorafenib and Nivolumab|
62809716|NCT02848469|ACTIVE_COMPARATOR|Omega-3 fatty acids|Subjects will receive food supplements in the form of 200ml juice drinks, containing either the active component, 1000mg of eicosapentaenoic acid and 1000mg docosahexaenoic acid, or matching placebo for a duration of six months. Neither the active nor the placebo food supplements taste of fish, so the subject will be blind to whether he/she is receiving the active intervention or placebo.
62809717|NCT02848469|PLACEBO_COMPARATOR|placebo 200ml juice drinks|200ml juice drinks
62033367|NCT03568318|EXPERIMENTAL|Long-Term Extension|Participants who reach Week 260 in Studies M16-045, M18-891, and M16-047 will have the opportunity to roll over into the blinded LTE period of M16-047 to continue receiving the same daily dose of upadacitinib for up to Week 524.
62033368|NCT01848080|EXPERIMENTAL|Tai chi program via Telerehabilitation|An individualized exercise program, based on Tai Chi, was developed by our team for previous studies aiming to improve balance in elderly, diabetic individuals and in frail, elderly individuals with balance problems. The exercise program consists of movements based on a combination of alignments and body-specific orientations, weight transfers and changes in direction inspired by Tai Chi. This group will receive this program via telerehabilitation.
62033369|NCT01848080|ACTIVE_COMPARATOR|Tai chi program via home visits|An individualized exercise program, based on Tai Chi, was developed by our team for previous studies aiming to improve balance in elderly, diabetic individuals and in frail, elderly individuals with balance problems. The exercise program consists of movements based on a combination of alignments and body-specific orientations, weight transfers and changes in direction inspired by Tai Chi. This group will receive this program via home visits.
62033370|NCT03850769|EXPERIMENTAL|nab-paclitaxel and S-1|neoadjuvant chemotherapy with Nab-paclitaxel and S-1, repeat every 21 days for 4 cycles.
62033371|NCT03877042|EXPERIMENTAL|Experimental|Patients with end-stage knee disease need Total Knee Arthroplasty in both knees.
62033372|NCT01002326|EXPERIMENTAL|Cognitive-Behavioral Therapy|
62033373|NCT01864564|NO_INTERVENTION|Routine Screening|"Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.~All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation."
62033374|NCT01864564|EXPERIMENTAL|Early Screening|"Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.~All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation."
62033375|NCT00933569|EXPERIMENTAL|Dermacyd Silver Floral (Lactic Acid)|Aplication of Dermacyd Silver Floral (Lactic Acid) during 21 consecutive days
62033376|NCT06241404|EXPERIMENTAL|therapeutic exercise group|patients who have been treated for shoulder tendinopathy by exercise therapy
62033377|NCT06241404|ACTIVE_COMPARATOR|trigger points group|patients who have been treated for shoulder tendinopathy by trigger point therapy
62033378|NCT06446804||Migraine patients|Patients with severe migraine, with at least 8 migraine days per month and at least 2 failed background treatments.
62033379|NCT03356925|NO_INTERVENTION|Centralised Xpert®Ultra testing|Patients are selected to receive the standard of care for TB diagnosis at a centralised laboratory facility
62033380|NCT03356925|ACTIVE_COMPARATOR|Xpert Ultra Point of Care testing|Patients are selected to receive the point of care for TB diagnosis at the clinic facility they are visiting
62033381|NCT06296368|NO_INTERVENTION|Usual Care|Receive usual care.
62033382|NCT06296368|EXPERIMENTAL|PRIME intervention|Receive the PRIME intervention.
62033383|NCT05646953|EXPERIMENTAL|Vasu Facial Beauty Oil|"Vasu Facial Beauty Oil blends the Traditional Beauty recipe of Kumkumadi Tailam with clinically- proven Natural Plant Actives to offer a unique product that gives a Natural Glow to face, overcoming hyper-pigmentation, age spots, wrinkles, and blemishes with Avacado, Lavender, Argan, Rapeseed.~Kumkumadi Oil is an Ayurvedic Elixir that is effective for many skincare concerns such as Hyperpigmentation, Dark spots, Age spots, Acne scars, Fine lines, Wrinkles as well as Dark circles. It is also used for Beautifying, Rejuvenating and Uplifting the skin."
62033384|NCT04144842|EXPERIMENTAL|ATOR-1017|ATOR-1017 administered by intravenous infusions every 3 weeks until confirmed progressive disease, clear clinical deterioration, unacceptable toxicity or withdrawal of consent
62233671|NCT01978262|OTHER|healthy woman|All women are to receive the quadrivalent influenza vaccine
62233672|NCT03260595|EXPERIMENTAL|Crisaborole ointment 2%|
62233673|NCT03260595|PLACEBO_COMPARATOR|Vehicle|
62033385|NCT03053050|EXPERIMENTAL|SEL 18 mg|"Randomized Phase: Selonsertib (SEL) 18 mg tablet + placebo to match SEL 6 mg tablet for 240 weeks~Open-Label (OL) Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
62033386|NCT03053050|EXPERIMENTAL|SEL 6 mg|"Randomized Phase: SEL 6 mg tablet + placebo to match SEL 18 mg tablet for 240 weeks~OL Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
62033387|NCT03053050|PLACEBO_COMPARATOR|Placebo|"Randomized Phase: Placebo to match SEL 6 mg tablet + placebo to match SEL 18 mg tablet for 240 weeks~OL Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
62033388|NCT06670222|EXPERIMENTAL|ATO|Oral Arsenic treatment
62033389|NCT03414138|EXPERIMENTAL|Mindfulness Meditation Group|"Research volunteers will participate in four sessions (20 min/session) of mindfulness training. Participants are taught that perceived sensory events are momentary and fleeting, requiring no further evaluation. They will be asked to close their eyes, relax and focus on the flow of their breathing by simply letting go of discursive thoughts."
62033390|NCT03414138|ACTIVE_COMPARATOR|Book Listening Control|Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 4 session sequence is meant to match features of the experimental meditation sessions, including attention to the recording, room setting, social support, conditioning, and time elapsed during the sessions. We do not expect that this group will demonstrate significant blood oxygenation changes as a function of the intervention.
62033391|NCT05942313||Pregnant women with Opioid Use Disorder (OUD)|This study will enroll 100 pregnant women with OUD at UPMC with its high volumes
62033392|NCT01771198|EXPERIMENTAL|SIMVASTATIN 40mg|SIMVASTATIN tablet of 40mg once a day during 30 days. Single arm with pre and post treament assessment
62033393|NCT05774964|EXPERIMENTAL|Chemotherapy alone group|Patients treated with chemotherapy using SOX regimen alone. SOX regimen every 3 weeks,oxaliplatin via intravenous drip on d1 at a dose of 130 mg/m2 × patient 's body surface area, and tegafur orally on d2-d15 at 20 mg three times daily.
62033394|NCT05774964|EXPERIMENTAL|Chemotherapy targeted group|Patients treated with cetuximab targeted therapy in combination with chemotherapy using SOX regimen.SOX regimen every 3 weeks, oxaliplatin via intravenous drip on d1 at a dose of 130 mg/m2 × patient 's body surface area, and tegafur orally on d2-d15 at 20 mg three times daily. Cetuximab combined with chemotherapy was administered simultaneously,once every three weeks, and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.
62033395|NCT05774964|EXPERIMENTAL|Quintuple method group|Patients treated with a combination of SOX regimen, cetuximab, and folic acid, vitamin A, and metronidazole three-drug regimen.SOX regimen every 3 weeks, oxaliplatin via intravenous drip on d1 at a dose of 130 mg/m2 × patient 's body surface area, and tegafur orally on d2-d15 at 20 mg three times daily. Cetuximab combined with chemotherapy was administered simultaneously,once every three weeks, and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area. Metronidazole 0.4g/time, qd;vitamin A 5,000 units/time, qd; folic acid 5 mg/time,qd. The latter three drugs were continued until the end of all chemotherapy cycles.
62593340|NCT06619366|ACTIVE_COMPARATOR|Placebo control|"Participants in the control group will receive their individualized depression risk information. Receiving individualized depression risk information is considered as control because: (1) our previous RCT showed that receiving individualized depression risk information caused no psychological harm and was effective in reducing distress and improving function; (2) Receiving depression risk information was used as control in our pilot study; (3) The pilot study suggested that the coach-guided PDRC may be more effective than receiving depression risk information alone."
62593341|NCT01330394|SHAM_COMPARATOR|sham-tDCS control|simulate control for transcranial Direct Current Stimulation
62033396|NCT01880424|PLACEBO_COMPARATOR|controlled arm|
62033397|NCT01880424|EXPERIMENTAL|treatment arm|
62033398|NCT00325468|EXPERIMENTAL|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
62033399|NCT01920230|EXPERIMENTAL|Mindfulness-ACT-intervention|Group meetings face-to-face and web-based program using principles of mindfulness and ACT.
62033400|NCT01920230|EXPERIMENTAL|Control|Control group, no intervention.
62033401|NCT06086730|EXPERIMENTAL|blow bottle positive expiratory pressure|Water was poured into a 1 L plastic container until it reached a 10 cm height. A 30 cm long tube was put into the water in the bottle, 8 cm deep. The participants were instructed to close their mouths around the tubing in the apparatus for three seconds to produce bubbles, do this for a total of 10 breaths, perform two huffs, then cough. Such exhalations were conducted in two sets of ten, with a five-minute pause in between. For each subject, a fresh, disposable tube and bottle were utilized
62033402|NCT06086730|ACTIVE_COMPARATOR|acapella|"Make sure the frequency adjustment dial has been rotated counterclockwise to the lowest frequency-resistance setting before using the Acapella for the first time. On a chair, adopt a straight stance. maintaining a straight back and relaxing your elbows on a table. Now gradually tilt your head upward to maintain the opening of your upper airways. Inhale more deeply than you frequently do. Make sure your lips are encircling the mouthpiece, then blow into the device with a strong expiration. You should ideally blow out roughly twice as quickly as usual. For around ten breaths. Make careful to expel to clear the secretions from the airways after the final try. You can even conduct 2 to 3 huffs to improve secretion elimination when necessary. It should be noted that while using the device, you must be capable of exhale for a minimum of three to four seconds."
62033403|NCT06670729|EXPERIMENTAL|Quran listening group|participants listen to Quran recitation
62593342|NCT01330394|ACTIVE_COMPARATOR|active tDCS|active transcranial Direct Current Stimulation
62033404|NCT06670729|OTHER|silent headphones|participant's headphone is silent
62033405|NCT02955511|ACTIVE_COMPARATOR|Blade MAC size 3|"Patient will be intubated using a:~Direct Laryngoscope (DL) Mac size 3 (Sun-Med GreenLine®/D™ Macintosh)"
62033406|NCT02955511|ACTIVE_COMPARATOR|Blade MAC size 3.5|"Patient will be intubated using a:~DL-blade mac size 3.5 (Sun-Med Greenline®/D™ Macintosh)"
62033407|NCT02955511|EXPERIMENTAL|Inscope Blade size 3.5|"Patient will be intubated using a:~Inscope DL-blade size 3.5"
62033408|NCT02904304|EXPERIMENTAL|Desloratadine+Phenylephrine+Ibuprofen|"It's a tablet manufactured by Aché S.A., composed of desloratadine 2,5mg, Phenylephrine hydrochloride 20mg and Ibuprofen 400mg.~Tablet will be dispensed in a cartridge containing 10 tablet to 75 participants."
62033409|NCT02904304|PLACEBO_COMPARATOR|Placebo|"It's a tablet manufactured by Aché S.A,. composed of placebo will be dispensed in a cartridge containing 10 tablet to 75 participants. The participants shall administer the placebo tablets to enable the double-blind study.~The use of placebo comparator is important in this type of pathology because with this design will be able to evaluate the response of the pure treatment, rapid relief of symptoms, or 03 hours after the first administration of study drug."
62033410|NCT03943732|NO_INTERVENTION|control|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays
62033411|NCT03943732|EXPERIMENTAL|Intervention|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
62033412|NCT00373334|EXPERIMENTAL|1|
62033413|NCT00373334|EXPERIMENTAL|2|
62033414|NCT00373334|SHAM_COMPARATOR|3|
62233674|NCT02454179|EXPERIMENTAL|Arm 1|pembrolizumab
62593343|NCT06112431|EXPERIMENTAL|Telehealth-Based Intervention Arm|Participants randomized to the Telehealth-Based Intervention Arm who require referral to ophthalmology will be teamed up with a Patient Navigator who will provide telehealth-based support with scheduling an in-office glaucoma evaluation at either Columbia University Harkness Eye Institute, Harlem Hospital, or their own eye care provider. Participants will also receive telehealth-based support from a Peer Ambassador, who are individuals from the community with glaucoma or other eye diseases who have expressed interest in sharing their experiences. Each referred participant will receive several telehealth-based calls from a Peer Ambassador over 2 years to discuss their understanding of their new ocular diagnosis and encourage adherence to in-office glaucoma evaluation.
62809718|NCT05421741|ACTIVE_COMPARATOR|Intramedullary Nail|Traditional standard of care intramedullary (IM) nail
62809719|NCT05421741|ACTIVE_COMPARATOR|Antibiotic Coated Intramedullary Nail|Intramedullary Nail coated with 2 grams of vancomycin and 560 mg gentamicin liquid.
62809720|NCT04645368||Longidaze|80 subjects Longidaze® (bovhyaluronidase azoxymer), lyophilisate for solution for injection
62809721|NCT04645368||Dynamic control|80 subjects Patients not receiving active therapy
62809722|NCT01233804|NO_INTERVENTION|Opting in|Currently, pregnant women have to sign a consent stating that they want the influenza vaccine (at the clinics where the study is being conducted). Therefore, this group is the same as usual care. However, women will then be asked if they would like to take part in parts 2 and 3 of the study.
62809723|NCT01233804|EXPERIMENTAL|Opting Out|Women will sign a consent form only if they do not want to receive the flu vaccine.
62809724|NCT04864756|EXPERIMENTAL|Before/After|Grade performance before and after introduction of simulation based learning
62809725|NCT01481922|ACTIVE_COMPARATOR|Whitacre 22 gauge|lumbar puncture performed with a Whitacre 22 gauge (BD)
62809726|NCT01481922|EXPERIMENTAL|Whitacre 24 gauge|lumbar puncture performed with a Whitacre 24 gauge (BD)
62809727|NCT01342003||Subtype 1a|subtype 1a patients treated with peginterferon plus ribavirin
62809728|NCT01342003||subtype 1b|subtype 1b patients treated with peginterferon plus ribavirin
62233675|NCT02454179|EXPERIMENTAL|Arm 2|acalabrutinib in combination with pembrolizumab
62233676|NCT04501913||Observational (remote telemonitoring)|Patients undergo remote perioperative telemonitoring with home monitoring devices activity monitor beginning 7 days before surgery and up to 30 days after hospital discharge.
62233677|NCT03168789|EXPERIMENTAL|Tension Tamer (TT)|Breathing Awareness Mediation delivered by smartphone app.
62233678|NCT03168789|ACTIVE_COMPARATOR|Lifestyle education program (SPCTL)|Healthy lifestyle education provided by text messages and links to media. Runkeeper app to log physical activity.
62233679|NCT01247233|ACTIVE_COMPARATOR|Standard or Hypofractionated radiotherapy|"Whole breast RT, 50 Gy + boost 16 Gy. Whole breast hypofractionated RT without boost, either 40 Gy or 42.5 Gy"
62233680|NCT01247233|EXPERIMENTAL|Accelerated Partial Breast Irradiation (APBI)|APBI using 3D CRT technique, in 5 days, 38.5 Gy to the tumor bed
62233681|NCT02271516|EXPERIMENTAL|188Re-BMEDA-liposome|"Stage I:~188Re-BMEDA-liposomes, 14±1.4 mCi, single dose~Stage II:~188Re-BMEDA-liposomes, dose-escalation, single dose Dose Level Dose of 188Re-BMEDA-liposome (mCi/kg)~1. 0.42±0.04 mCi/kg~2. 0.63±0.06 mCi/kg~3. 0.84±0.08 mCi/kg~4. 1.05±0.11 mCi/kg~5. 1.26±0.13 mCi/kg~6. 1.47±0.15 mCi/kg"
62233682|NCT05064189|NO_INTERVENTION|Group 1|15 patients will be included in group 1 (no additional treatment)
62233683|NCT05064189|EXPERIMENTAL|Group 2|15 patients will be in group 2 (treatment directly after cataract surgery in the surgical theatre)
62809729|NCT01941511|EXPERIMENTAL|Rivipansel/Placebo/Moxifloxacin|Rivipansel 4.8 gA IV infusion over 20 minutes Phosphate Buffered Saline (PBS) IV infusion over 20 minutes Moxifloxacin (Avelox) 400 mg single oral dose
62809730|NCT00947375|EXPERIMENTAL|Starch|In these study participants are randomly (by chance) assigned for two treatment arms of a clinical trial.
62233684|NCT05064189|EXPERIMENTAL|Group 3|15 patients will receive treatment after local anaesthesia (pre-operatively) and directly after cataract surgery (group 3)
62233685|NCT00939679|EXPERIMENTAL|Earlier gastric bypass surgery (7 weeks)|These patients will undergo gastric bypass surgery 7 weeks after starting a low calorie diet, and will continue the low calorie diet for 3 weeks following surgery.
62809731|NCT00947375|NO_INTERVENTION|Lifestyle councelling|May be required to comply with US Public Law 110-85, Section 801
62233686|NCT00939679|ACTIVE_COMPARATOR|Later gastric bypass surgery (10 weeks)|These patients will undergo gastric bypass surgery 10 weeks after starting a low calorie diet.
62233687|NCT00248846|NO_INTERVENTION|Control Group|This group received follow-up every 2-months for one year. Follow-up included questions about their heart disease progression and how well they had been able to engage in their doctor approved physical activity goal.
62233688|NCT00248846|EXPERIMENTAL|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their heart disease progression and how well they had been able to engage in their doctor approved physical activity goal, which was the same as the control arm. Additionally, subjects in this arm were encouraged to use positive affect and self-affirmation techniques to motivate an increased level of participation in their physical activity goal. These subjects also received small token gifts to remind them of their study participation.
62233689|NCT02518022|EXPERIMENTAL|Intervention|For carbohydrates in beer, subjects will get covering by Insulin (1/2 of calculated amount). As well Insulin basal rate will set to half for 12 hours
62233690|NCT02518022|NO_INTERVENTION|Standard|No Insulin Treatment of carbohydrates in beer.
62233691|NCT06268769|EXPERIMENTAL|Envarsus|Participants take prolonged-release tacrolimus tablets (Envarsus) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice.
62809732|NCT00830999|EXPERIMENTAL|Positive energy balance|Comparison between isocaloric and hypercaloric diets with no exercise performed in any trials
62809733|NCT00830999|EXPERIMENTAL|Energy balance with exercise|Comparison between an isocaloric diet without exercise and a hypercaloric diet with a sufficient amount of exercise performed to match the excess calories consumed resulting in both trials being in net energy balance.
62809734|NCT00830999|EXPERIMENTAL|Negative energy balance|Comparison between isocaloric and hypocaloric diets with no exercise performed in any trials
62809735|NCT00830999|EXPERIMENTAL|Negative energy balance with exercise|Comparison between consuming an isocaloric diet without exercise and consuming the same amount of calories as in the isocaloric trial but with exercise performed resulting in net negative energy balance in the exercise trial.
62809736|NCT06183346||Main Cohort (Single Cohort)|The main cohort consists of all patients who will undergo either emergency/urgent/delayed/elective cholecystectomy in all participating hospitals in Indonesia. Inclusion/exclusion criteria will be applied.
62809737|NCT03174184|EXPERIMENTAL|Rifampin resistant A|Participants with the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive RIFAMPIN 20mg/kg once daily (QD), MEROPENEM 2 grams (G) thrice daily (TID) intravenously, Amoxicillin/Clavulanate Potassium 500 milligrams (MG)-125 MG Oral Tablet once daily for 14 days
62809738|NCT03174184|EXPERIMENTAL|Rifampin resistant B|Participants with the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 2 grams TID (thrice daily) intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
62809739|NCT03174184|EXPERIMENTAL|Rifampin susceptible C|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive RIFAMPIN 20mg/kg once daily, MEROPENEM 2 grams TID (thrice daily) intravenously, Amx/Clv orally at a dose of 500 mg/125 mg thrice daily for 14 days
62809740|NCT03174184|EXPERIMENTAL|Rifampin susceptible D|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 2 grams TID intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
62809741|NCT03174184|EXPERIMENTAL|Rifampin susceptible E|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 1 gram TID intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
62033415|NCT05883813|ACTIVE_COMPARATOR|Group 1|suboccipital muscle release for 10 mins + 5 min general warm up exercises + 10 min hot pack + 10 min TENS + trapezius stretching with 3 sec hold and 5 reps
62033416|NCT05883813|EXPERIMENTAL|Group 2|suboccipital muscle release for 10 mins + SNAGS: 3 glides with 10 sec hold of each glide + 5 min general warm up exercises + 10 min hot pack + 10 min TENS + trapezius stretching with 10 sec hold and 5 reps
62033417|NCT01387412||Genital warts|Those with and without ano-genital warts
62033418|NCT06610617|EXPERIMENTAL|Active tDCS, then Sham tDCS|Stimulation (tDCS) will be delivered in visit 2. Sham will be delivered in visit 3.
62033419|NCT06610617|EXPERIMENTAL|Sham tDCS, then Active tDCS|Sham will be delivered in visit 2. Stimulation (tDCS) will be delivered in visit 3.
62033420|NCT02081846|EXPERIMENTAL|Home Nurse Visit|Families in this arm will receive a nurse home visit within 96 hours of discharge.
62033421|NCT02081846|ACTIVE_COMPARATOR|Control|This arm will receive standard of care.
62593344|NCT06112431|NO_INTERVENTION|Usual Care Arm|Consented participants from community health centers randomized to the Usual Care Arm will receive all the basic level of services including the telehealth-based eye health screening, optometric exam if they fail the screening, and eyeglasses at no charge. Those who require referral to ophthalmology will be scheduled for the initial in-office glaucoma evaluation and their outcomes will be tracked. No additional support from a Patient Navigator or a Peer Ambassador will be provided the Usual Care participants during the study. The Usual Care Arm represents a realistic choice currently available for participants following eye health screening.
62593345|NCT01380262||Low Dose Doxycycline|Patients with metastatic colorectal cancer, qualified to either cetuximab or panitumumab based systemic treatment (either monotherapy or with chemotherapy) receiving a 100 mg of doxycycline daily
62593346|NCT06621836|ACTIVE_COMPARATOR|Group-H|
62033422|NCT03959865||Long-acting GLP-1RA|Patients who have been treated with weekly GLP-1RA (exenatide once weekly or dulaglutide)
62033423|NCT03959865||Short-acting GLP-1RA|Patients who have been treated with daily GLP-1RA (exenatide bid or liraglutide or lixisenatide)
62593347|NCT06621836|ACTIVE_COMPARATOR|Group-L|
62033424|NCT03959865||Human GLP-1 based GLP-1RA|Patients who have been treated with GLP-1RA based on human GLP-1 (dulaglutide or liraglutide)
62033425|NCT03959865||Exendin-based GLP-1RA|Patients who have been treated with weekly GLP-1RA (exenatide or lixisenatide)
62033426|NCT03959865||Fixed ratio combination of BI/GLP-1RA|Patients who have been treated with a fixed ratio combination of GLP-1RA and basal insulin (BI), such as IdegLira (insulin degludec / liraglutide) or IglarLixi (insulin glargine / lixisenatide)
62033427|NCT03959865||Flexible combination of BI/GLP-1RA|Patients who have been treated with any GLP-1RA in combination with any basal insulin (BI)
62033428|NCT04294368|OTHER|Control|Standard fortification of breast milk
62033429|NCT04294368|EXPERIMENTAL|Experimental|Targeted fortification of breast milk
62809742|NCT03174184|EXPERIMENTAL|Rifampin susceptible F|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 3 grams QD intravenously, Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet once daily for 14 days
62033430|NCT04641143|ACTIVE_COMPARATOR|Troriluzole|Troriluzole - 2 100mg capsules once daily for the first two weeks. Troriluzole - 2 140mg capsules once daily from week two through week ten.
62033431|NCT04641143|PLACEBO_COMPARATOR|Placebo|Placebo - 2 100mg capsules once daily for the first two weeks. Placebo - 2 140mg capsules once daily from week two through week ten.
62033432|NCT05854511|EXPERIMENTAL|Daclatasvir Plus Sofosbuvir|"treatment-naïve children infected with chronic HCV will be stratified according to weight~1. Children weighing 14 \<17 Kg~2. Children weighting 17\<35 Kg"
62033433|NCT04445610||A|mild
62033434|NCT04445610||B|moderate
62033435|NCT04445610||C|severe
62233692|NCT06268769|ACTIVE_COMPARATOR|Advagraf|Participants take prolonged-release tacrolimus capsules (Advagraf) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice.
62233693|NCT04023825|EXPERIMENTAL|experimental group|Patients will receive loco regional anesthesia
62593348|NCT05470621|EXPERIMENTAL|Playground Curriculum Arm|Staff (after-school staff, recess aides, and physical education teachers) receive training to implement a playground curriculum in an after-school program; children receive a training to use the curriculum during recess
62809743|NCT05217277||patient with juvenile idiopathic arthritis and gingivitis|It is a group of patients between the ages of 5 and 16 who have recently been diagnosed with juvenile idiopathic arthritis and gingivitis, have not used medication yet.
62809744|NCT05217277||healthy patient group with gingivitis|It is a group of healthy patients with gingivitis between the ages of 5-16 who have not taken antibiotics in the last 3 months.
62809745|NCT05217277||healthy patient group without gingivitis|It is a group of healthy patients without gingivitis between the ages of 5-16 who have not taken antibiotics in the last 3 months.
62809746|NCT05217277||patient with juvenile idiopathic arthritis and without gingivitis|It is a group of patients between the ages of 5 and 16 who have recently been diagnosed with juvenile idiopathic arthritis and without gingivitis, have not used medication yet.
62593349|NCT05470621|NO_INTERVENTION|Program As Usual|Staff and students receive no training and participate in after-school programs and recess as usual
62809747|NCT03690817||Bilateral vestibulopathy|Patients with bilateral vestibulopathy, according to the Barany Criteria (2017, Strupp).
62809748|NCT03690817||Healthy controls|Subjects without vestibular or neurological diseases (DHI\<5), and with normal hearing thresholds according to their age.
62809749|NCT02831621|ACTIVE_COMPARATOR|diet (usual care)|All participants will receive a hypocaloric diet based on the individual resting metabolic rate. Resting metabolic rate (RMR) will be estimated using the WHO formula or measured using indirect calorimetry. Total energy expenditure will be calculated by multiplying RMR with a physical activity level (PAL). The used physical activity level will be 1.3. A hypocaloric diet with an energy deficit of 500 kcal/day will be prescribed. Participants will see a skilled dietician two-weekly the first month and on a monthly basis the next five months to discuss problems and solutions or coping strategies. The first consultation will have a duration of 60 minutes, the next consultations will have a duration of approximately 30 minutes. Each visit, nutritional compliance will be recorded on a 0 to 10 numeric rating scale. The usual care group will be asked to continue with their normal physical activity during the six-month intervention period.
62809750|NCT02831621|EXPERIMENTAL|diet+exercise|"For participants of this group, usual care will be supplemented with a prescribed exercise program. For this exercise program the participants will be referred to a local fitness club near home, free of charge. Aerobic training will be done at an intensity of 90-95% of the heart rate achieved at the RCP. Aerobic training will have a duration of 30 to 45 minutes, according to the training stage. Cardio training will be performed on different cardio devices and strength training will be done on isotonic strength training devices. Each training day, core stability training will be completed with four strength exercises for large muscle groups. Each exercise will be done in two sets of 15 repetitions with the goal to achieve better muscular strength endurance.~This combined training will be done individually during six months, three times/week.~In this study, an effort is made to reach a uniform manner of guidance to the physical activity program."
62809751|NCT00467077|EXPERIMENTAL|Gefitinib and PEG-IFNa Treatment|Gefitinib administered at a dose of 250 mg orally once daily for 12 weeks. PEG-IFNa at 4.0 µg/kg/wk administered subcutaneously once weekly for 6 weeks (cycle repeated once for a total of 2 cycles).
62033436|NCT02741960|EXPERIMENTAL|metformin|Eligible patients for clinical trial were randomized in a 1:1 ratio to metformin/placebo add-on. Subjects randomized to metformin will receive a target dose of 500 mg three times daily. Investigators were allowed to adjust the dose according to the patients' tolerance.
62033437|NCT02741960|PLACEBO_COMPARATOR|placebo|Eligible patients for clinical trial were randomized in a 1:1 ratio to metformin/placebo add-on. Subjects randomized to placebo will receive a target dose of 500 mg three times daily. Investigators were allowed to adjust the dose according to the patients' tolerance.
62233694|NCT04023825|NO_INTERVENTION|control group|Patients will not receive loco regional anesthesia
62809752|NCT03070288||Group 1|Red-green-blue measurements of nasal mucosa images of patients with allergic rhinitis
62809753|NCT03070288||Group 2|Red-green-blue measurements of nasal mucosa images of normal healthy individuals
62809754|NCT04668469|EXPERIMENTAL|Ivermectin plus standard care in Mild/Moderate COVID-19 (Group I)|100 patients with Mild/Moderate COVID-19 (Coronavirus disease) infection received a 4-days course of Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast plus standard of care as issued by Egyptian protocol of COVID-19 treatment.
62033438|NCT03898206|EXPERIMENTAL|Prolonged sitting|Participants will remain seated for 5 h and instructed to reduce excessive movement, only rising from the chair to void.
62233695|NCT05648526|EXPERIMENTAL|ACTH4-10PRO8-GLY9-PRO10|The compound ACTH4-10Pro8-Gly9-Pro10 is a synthetic analog molecule of a short fragment of adrenocorticotropic hormone (ACTH). It is free from hormonal effects and has neuromodulatory effects.
62233696|NCT05648526|ACTIVE_COMPARATOR|ketamine 40 mg/kg BW subcutaneously|ketamine results in impaired brain function associated with neuroapoptosis injury in the immature brain.
62233697|NCT05283486|EXPERIMENTAL|Cohort 1: MYMD1 600mg|Subjects randomly assigned to the MYMD1 600mg cohort
62233698|NCT05283486|PLACEBO_COMPARATOR|Cohort 1: Placebo 600mg|Subjects assigned to the 600mg placebo group
62809755|NCT04668469|ACTIVE_COMPARATOR|hydroxychlorquine plus standard care in Mild/Moderate COVID-19 (Group II)|100 patients with mild/moderate COVID-19 infection received hydroxychlorquine (400 every 12 hours for one day followed by 200 mg every 12 hours for 5 days) plus standard care.
62809756|NCT04668469|EXPERIMENTAL|Ivermectin plus standard care and steroids in Sever COIVD-19 (Group III)|100 patients with severe COVID-19 infection received a 4 days course of Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast plus standard care and steroids
62233699|NCT05283486|EXPERIMENTAL|Cohort 2: MYMD1 750mg|Subjects randomly assigned to the MYMD1 750 cohort
62233700|NCT05283486|PLACEBO_COMPARATOR|Cohort 2: Placebo 750mg|Subjects assigned to the 750mg placebo group
62233701|NCT05283486|EXPERIMENTAL|Cohort 3: MYMD1 900mg|Subjects randomly assigned to the MYMD1 900mg cohort
62233702|NCT05283486|PLACEBO_COMPARATOR|Cohort 3: Placebo 900mg|Subjects assigned to the 900mg placebo group
62233703|NCT05283486|ACTIVE_COMPARATOR|Cohort 4: MYMD1 1050mg|Subjects randomly assigned to the MYMD1 1050mg cohort
62233704|NCT05283486|PLACEBO_COMPARATOR|Cohort 4: Placebo group 1050mg|Subjects assigned to the 1050mg placebo group
62424553|NCT05349188|PLACEBO_COMPARATOR|Placebo Pill|"Individuals will receive a kit with medication adherence devices containing the placebo pills in one of three smart electronic pill bottles labeled A, B, and C. Participants will not be aware which of the pill bottles contains the placebo. Participants will be randomized to take pills in 6 alternating intervention periods 2 weeks in length. During periods where participants were randomized to receive the placebo, they will receive a nightly text notification 1 hour before bed instructing them to take a pill from the corresponding smart pill bottle. The placebo will be administered in 2 intervention periods each 2 weeks in length (4 weeks total)."
62424554|NCT00709735|EXPERIMENTAL|Reactivation Propranolol (RP)|"0.67 mg/kg short-acting placebo capsules then 1 mg/kg long-acting placebo capsules 90 minutes later on Day 0 (non-reactivation) followed by 0.67 mg/kg short-acting propranolol capsules then 1 mg/kg long-acting propranolol capsules 90 minutes later on Day 2 (reactivation). All participants then underwent a script preparation session in which the investigator elicited five discrete personal memories, including two traumatic combat experiences."
62433617|NCT06543225||Egyptian Gynecologists|Egyptian gynecologists were included in the study to determine their awareness about the role of physiotherapists in the treatment of PCOS.
62233705|NCT04605887|ACTIVE_COMPARATOR|treatment group|Ang 1-7 subcutaneously 500 mcg/kg /day
62233706|NCT04605887|PLACEBO_COMPARATOR|control group|NaCl 0.9% subcutaneously 2.0 cc once a day
62233707|NCT02204176|SHAM_COMPARATOR|Exercise info only|"Participants in the exercise information only group will engage in a group discussion with the principal investigator to discuss what constitutes regular physical activity and benefits of exercise and basic tips on the activity itself. Guidelines for prescribing suggested exercises will be based on recommendations from the U.S. Department of Health and Human Services (USDHHS, 2008) as well as risks associated with exercise and how they can be reduced."
62424555|NCT00709735|ACTIVE_COMPARATOR|Non-Reactivation Propranolol (NRP)|"0.67 mg/kg short-acting propranolol capsules then 1 mg/kg long-acting propranolol capsules 90 minutes later on Day 0 (non-reactivation) followed by 0.67 mg/kg short-acting placebo capsules then 1 mg/kg long-acting placebo capsules 90 minutes later on Day 2 (reactivation). All participants then underwent a script preparation session in which the investigator elicited five discrete personal memories, including two traumatic combat experiences."
62424556|NCT04246840||Study group|15 adult patients who underwent allogenic hematopoietic stem cell transplantation (HSCT) for severe combined immunodeficieny 15 to 45 years ago
62424557|NCT04246840||Control group|15 age-matched healthy individuals
62424558|NCT05812222|EXPERIMENTAL|intervention group (skin-to-skin contact group)|"Skin-to-skin contact: It is the laying of the newborn in the prone position on the mother's bare chest area with only a diaper on.~The stress levels of newborns were determined using the Neonatal Stress Scale immediately after birth, under a radiant heater, 5 minutes after SSC administration, and during IM K vit injection while SSC was administered (4 different time periods).~The suction sufficiency of newborns was evaluated by the investigator using the LATCH Breastfeeding Assessment Tool, 5 minutes after the initiation of early SSC immediately after birth, within the first hour after birth in the maternity ward, and 24 hours after birth."
62424559|NCT05812222|NO_INTERVENTION|control group|"The routine applications of the hospital were applied to the mothers and newborns in the control group.~The stress level of newborns was determined immediately after birth, under a radiant heater, and during IM K vit injection (3 different time periods) using the Neonatal Stress Scale.~The suction sufficiency of newborns within the first hour after birth and 24 hours after birth was evaluated by the researcher using the LATCH Breastfeeding Assessment Tool."
62593350|NCT04507256|EXPERIMENTAL|AZD7442|Participants will receive AZD7442 doses across five fixed-dose cohorts via intravenous (IV) infusions (three cohorts will be administered sequentially, and one cohort will receive co-administration of AZD8895 + AZD1061, mixed into a single infusion) and direct gluteal intramuscular (IM) injections (administered sequentially).
62233708|NCT02204176|EXPERIMENTAL|Exercise info + implementation intentions|"Participants in the exercise information plus implementation intentions group will engage in a group discussion with the principal investigator to discuss all of the components from the exercise information only approach, but with more emphasis on how to create implementation intentions. Discussions will revolve around possible barriers to exercise plans and how to overcome/address those barriers by making specific plans of when and where to exercise, along with designating which types of exercises they will perform and for how long (or how many repetitions)."
62424560|NCT00814619|EXPERIMENTAL|Arm I|Patients receive panitumumab IV over 30-90 minutes on days 1, 15, 29, 43, and 57 and oral capecitabine twice daily on days 8-40. Beginning on day 8, patients undergo daily fractions of 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning approximately 6 weeks after completion of panitumumab and chemoradiotherapy, patients undergo surgery.
62424561|NCT00814619|ACTIVE_COMPARATOR|Arm II|Patients receive oral capecitabine twice daily on days 1-33. Patients undergo concurrent 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning 6 weeks after completion of chemoradiotherapy, patients undergo surgery.
62433618|NCT01483222|EXPERIMENTAL|QUIKDRAW Pro|Wearing an inelastic lumbar support for 6 months
62433619|NCT01483222|EXPERIMENTAL|MUELLER 4581|Wearing an elastic lumbar support for 6 months
62593351|NCT04507256|PLACEBO_COMPARATOR|Placebo|Placebo will be administered to participants across five fixed-dose cohorts similar to the active treatment.
62593352|NCT03830788|ACTIVE_COMPARATOR|Brachytherapy|radiation by brachytherapy: brachytherapy by Iodine 125 delivering 144 Gy to the prostate
62233709|NCT02204176|EXPERIMENTAL|Exercise info + implementation intentions + industriousness|"Participants in the exercise information plus implementation intentions plus industriousness training group will engage in a group discussion with the principal investigator to discuss all of the components from the second approach as well as include findings linking industriousness and exercise behavior. Participants will be directed to think about and generate solutions to how they can become more industrious and monitor their efforts despite the difficulties they may face and relate these solutions to help them engage in more exercise behavior."
62233710|NCT03604523|ACTIVE_COMPARATOR|Dilation by Balloon|Esophageal dilation by balloon device.
62233711|NCT03604523|ACTIVE_COMPARATOR|Dilation by Semi-rigid Savary|Esophageal dilation by semi-rigid savary device.
62233712|NCT02122263||NAFLD after sleeve gastrectomy surgery|
62233713|NCT06475781|EXPERIMENTAL|150 mg mirivadelgat|150 mg mirivadelgat once daily
62233714|NCT06475781|EXPERIMENTAL|300 mg mirivadelgat|300 mg mirivadelgat once daily
62424562|NCT01745419||COPD Frequent Exacerbators|COPD patients having experienced at least two episodes of acute exacerbations in the former 12 months. (Acute exacerbations are defined as worsening symptoms requiring treatment with systemic steroids (oral or parenteral) or antibiotics, a visit to the emergency room, and/or admission to a hospital. Events separated by at least 21 days are considered as separate events of exacerbation.)
62424563|NCT01745419||COPD non- exacerbators|COPD patients who have not experienced exacerbations in the former 24 months. (Acute exacerbations are defined as worsening symptoms requiring treatment with systemic steroids (oral or parenteral) or antibiotics, a visit to the emergency room, and/or admission to a hospital. Events separated by at least 21 days are considered as separate events of exacerbation.)
62424564|NCT01387360|EXPERIMENTAL|Supracor|Study arm will consist of patients who have undergone previous cataract surgery with implantation of a monofocal IOL. The Supracor procedure will be performed on the non-dominant pseudophakic eye of these patients.
62424565|NCT01188070|SHAM_COMPARATOR|Usual Care Attention Control|Provision of printed educational material and attendance at one group session. This session will focus on nutrition education and flexibility and stretching.
62433620|NCT01483222|NO_INTERVENTION|Blank Control|Receiving no intervention
62593353|NCT03830788|EXPERIMENTAL|stereotactic body radiotherapy (SBRT)|radiation by SBRT: SBRT delivers 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. Fiducials are implanted in the prostate. The prostate can be tracked/localized/treated thanks to the Cyberknife or a conventional linac equipped with an ExacTrac or a Calypso4D system.
62809757|NCT04668469|ACTIVE_COMPARATOR|hydroxychlorquine plus standard care and steroids in Sever COVID-19 (Group IV)|100 patients with Severe COVID-19 infection received hydroxychlorquine (400 mg every 12 hours for one day followed by 200 mg every 12 hours for 9days) plus standard care and steroids
62809758|NCT04668469|EXPERIMENTAL|Ivermectin plus personal protective measures in COVID-19 prophylaxis (Group V)|100 health care and or household contacts received a prophylactic dose of ivermectin 400 micrograms/kg single oral dose before breakfast to be repeated after one week in addition to Personal Protective Measures ( (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, Masks, respiratory etiquette, and self-isolation)
62809759|NCT04668469|ACTIVE_COMPARATOR|Personal protective measures in COVID-19 prophylaxis (Group VI)|100 health care and or household contacts received only Personal Protective Measures (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, Masks, respiratory etiquette, and self-isolation)
62809760|NCT05659108||CONTROL|stimuli with traditional CPR education per half-year
62809761|NCT05659108||TREATMENT|stimuli with blended CPR education per half-year
62809762|NCT01582061|EXPERIMENTAL|Pasireotide 600 μg|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined on the mean daily dose considering the following grouping rule: 600 μg bid group includes all patients whose mean daily dose \< 1500 μg /day.
62809763|NCT01582061|EXPERIMENTAL|Pasireotide 900 μg|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined on the mean daily dose considering the following grouping rule: 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day
62809764|NCT00621374|EXPERIMENTAL|Random Order 1|Randomization Order 1= 1)CONT, 2)CBT, 3)HYP, 4) CBT-HYP
62809765|NCT00621374|EXPERIMENTAL|Random Order 2|Randomization order 2= 1)CONT, 2)HYP, 3)CBT, 4) CBT-HYP
62809766|NCT02733263|EXPERIMENTAL|Group 1|Participants will first consume in the the order of 0 g RMD, 15 g RMD, 25 g RMD for 3 weeks each
62809767|NCT02733263|EXPERIMENTAL|Group 2|Participants will first consume RMD in the the order of 0 g RMD, 25 g RMD, 15 g RMD for 3 weeks each
62809768|NCT02733263|EXPERIMENTAL|Group 3|Participants will first consume RMD in the the order of 15 g RMD, 0 g RMD, 25 g RMD for 3 weeks each
62809769|NCT02733263|EXPERIMENTAL|Group 4|Participants will first consume RMD in the the order of 15 g RMD, 25 g RMD, 0 g RMD for 3 weeks each
62809770|NCT02733263|EXPERIMENTAL|Group 5|Participants will first consume RMD in the the order of 25 g RMD, 15 g RMD, 0 g RMD for 3 weeks each
62809771|NCT02733263|EXPERIMENTAL|Group 6|Participants will first consume RMD in the the order of 25 g RMD, 0 g RMD, 15 g RMD for 3 weeks each
62819564|NCT03009058|EXPERIMENTAL|IMM-101+Gem breast cancer|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
62233715|NCT06475781|PLACEBO_COMPARATOR|placebo|placebo once daily
62233716|NCT01350453|EXPERIMENTAL|LifeCIT|Participants will be asked to aim to wear the C-MIT for 9 hours a day for 5 days/week, including 4-6 hours of structured activities per day: two 30-60 minute sessions of web-based activities and 3-4 hours practicing everyday activities.
62233717|NCT01350453|ACTIVE_COMPARATOR|Standard Care|Participants received their usual care which included home exercises
62809772|NCT02831764|EXPERIMENTAL|DTG + 3TC (50 mg+300 mg|Eligible participants will receive one 50 mg tablet of DTG plus one overencapsulated 300 mg 3TC tablet orally once daily upto 96 weeks; thereafter will receive DTG plus 3TC tablet upto Week 148 and will continue to receive this schedule until (i) DTG and 3TC are both locally approved for use as part of a dual regimen, and the single entities of DTG and 3TC are available to patients (e.g. through public health services), or (ii) the DTG/3TC FDC tablet, if required by local regulations, is available, , or (iii) the participant no longer derives clinical benefit, or (iv) the participant meets a protocol defined reason for discontinuation, or (v) development of the DTG plus 3TC dual regimen is terminated.
62809773|NCT02831764|ACTIVE_COMPARATOR|DTG + TDF/FTC FDC (50 mg+300/200 mg)|Eligible participants will receive one 50 mg tablet of DTG plus one overencapsulated TDF/ FTC FDC (300/200 mg) tablet orally once daily upto 96 weeks; thereafter will receive DTG plus TDF/FTC FDC tablets upto Week 148 (open-label randomised phase).
62809774|NCT06528197||Exposed group|
62233718|NCT01326234|ACTIVE_COMPARATOR|Personalized Feedback|The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
62233719|NCT01326234|SHAM_COMPARATOR|Treatment as Usual|Practitioners are able to provide normal care with regard to smoking; participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred.
62233720|NCT03265834|EXPERIMENTAL|Long course antibiotic therapy (28 days)|Antibiotic therapy for a duration of 28 days
62233721|NCT03265834|ACTIVE_COMPARATOR|Short course antibiotic therapy (≤10 days)|Antibiotic therapy for a duration of ≤10 days
62233722|NCT05049278|ACTIVE_COMPARATOR|Norepinephrine|Norepinephrine Bitartrate Hydrate : 4 mg/4 mL
62809775|NCT06528197||Control group|
62809776|NCT05360927|EXPERIMENTAL|Cohort 0.3mg/kg|All participants (fasted) received either 0.3 mg/kg of BDB-001 as a single dose or dose-matched placebo.
62809777|NCT05360927|EXPERIMENTAL|Cohort 1mg/kg|All participants (fasted) received either 1 mg/kg of BDB-001 as a single dose or dose-matched placebo.
62809778|NCT05360927|EXPERIMENTAL|Cohort 3mg/kg|All participants (fasted) received either 3 mg/kg of BDB-001 as a single dose or dose-matched placebo.
62809779|NCT05360927|EXPERIMENTAL|Cohort 8mg/kg|All participants (fasted) received either 8 mg/kg of BDB-001 as a single dose or dose-matched placebo.
62033439|NCT03898206|EXPERIMENTAL|Breaking up sitting with walking breaks|Participants will rise from the seated position every 30 min throughout the experimental period to walk on a motorised treadmill at a light intensity walking (as determined during the preliminary test) for 3 min. Participants will start walk on a treadmill at 30 min (so physical activity would be at 30-33 min), 60 min (physical activity will be at 60-63 min), 90 min (physical activity will be at 90-93 min), 120 min (physical activity will be 120-123 min), 150 min (physical activity will be at 150-153 min ), and 180 min (physical activity will be at 180-183 min) in the breakfast postprandial period and 30 min (physical activity will be 30-33 min), 60 min (physical activity will be at 60-63 min), and 90 min (physical activity will be at 90-93 min) in the lunch postprandial period. After performing walking activity, they will return to the seated position.
62033440|NCT06459609|OTHER|P - SP|1 week with protein supplementation (P) then one week without protein supplementation (SP)
62809780|NCT05360927|EXPERIMENTAL|Cohort 16mg/kg|All participants (fasted) received either 16 mg/kg of BDB-001 as a single dose or dose-matched placebo.
62033441|NCT06459609|OTHER|SP - P|1 week without protein supplementation (SP) then one week with protein supplementation (P)
62033442|NCT02428868|EXPERIMENTAL|Tranexamic acid - intravenous iron|"IV iron (Ferroven®) : 2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.~IV Tranexamic acid (Exacyl®): 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later."
62424566|NCT01188070|EXPERIMENTAL|Psychoeducation plus exercise|Psychoeducation intervention plus an individualized exercise program which will include monitored, individually-prescribed aerobic and resistance exercise.
62033443|NCT02428868|ACTIVE_COMPARATOR|Tranexamic acid|IV Tranexamic acid (Exacyl®): 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later.
62033444|NCT02428868|PLACEBO_COMPARATOR|Placebo|20 mL saline, in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
62033445|NCT06125392||Invasive assessment of coronary vasomotor function|All lesions undergoing assessment of coronary microvascular dysfunction and coronary spasm using coronary pressure wires.
62033446|NCT06100627|EXPERIMENTAL|2.10 g/day of AP301|
62033447|NCT06100627|EXPERIMENTAL|4.20 g/day of AP301|
62033448|NCT06100627|EXPERIMENTAL|6.30 g/day of AP301|
62809781|NCT05360927|EXPERIMENTAL|Cohort 20mg/kg|All participants (fasted) received either 20 mg/kg of BDB-001 as a single dose or dose-matched placebo.
62809782|NCT02760940|EXPERIMENTAL|Oral liposomal iron treatment|Oral liposomal iron - 28 mg per day over 8 weeks
62033449|NCT06100627|EXPERIMENTAL|8.40 g.day of AP301|
62033450|NCT04460742|EXPERIMENTAL|CAPABLE Transitions|Older adults admitted to University of Rochester Medicine Home Care with and without dementia will receive care as usual as well as CAPABLE-trained occupational therapy, registered nurse, and handyman services delivered over 3-4 months.
62593354|NCT04625465|NO_INTERVENTION|No Intervention, No Intervention (AA)|Participants do not receive text messages during Interval 2 or Interval 3.
62809783|NCT02575534|EXPERIMENTAL|observational|"All patients will undergo 12-lead ECG and transthoracic echocardiography on the day of the study. These studies will be performed on patients as their previously implanted device is reprogrammed to pace in different modes. Patients will then receive an infusion of procainamide (12 mg/kg up to a maximum of 1 g) at a rate of 20 mg/min. Repeat ECG and echocardiograms will then be performed.~The patient's device will be programmed to a specific setting before and after the procainamide infusion."
62809784|NCT00804726|EXPERIMENTAL|Akreos MI Five-O|Accommodating intraocular lens
62809785|NCT05601804||Food Insecure Women with Obesity|4 focus groups with 6-8 participants each
62809786|NCT05601804||Food Secure Women with Obesity|3 focus groups with 6-8 participants each
62033451|NCT04460742|ACTIVE_COMPARATOR|Care As Usual|Older adults admitted to University of Rochester Medicine Home Care (a Medicare-certified home health agency) with and without dementia will receive care as usual.
62809787|NCT05413746|EXPERIMENTAL|Antioxidant dressing (active product)|"Wound bed debridement, Antioxidant dressing (active product) application in the wound bed, covered with secondary dressing.~Device: Reoxcare®"
62809788|NCT04681235|EXPERIMENTAL|Training Group|Training Group recieved 10 sessions on VR (Grail Motekforce, Netherlands) during two weeks. One session lasted 40 minuties.
62809789|NCT04361435|OTHER|NIOD first|In this arm, we will apply for NIOD first which will be performed by non-physiotherapists such as respiratory therapists and bedside nurses. This arm of patients will receive standard CPT at least 3 hours after the NIOD intervention.
62809790|NCT04361435|OTHER|CPT first|In this arm, we will apply for CPT first which will be performed by physiotherapists. This arm of patients will receive NIOD procedures which will be performed by non-physiotherapists such as respiratory therapists and bedside nurses at least 3 hours after the CPT intervention.
62809791|NCT04537975|ACTIVE_COMPARATOR|C2Rx|Hemofiltration device
62809792|NCT04537975|ACTIVE_COMPARATOR|Standard of Care (SOC)|Standard of Care based on protocol inclusion/exclusion criteria
62809793|NCT00074165|EXPERIMENTAL|All subjects|
62033452|NCT02283060|EXPERIMENTAL|Stribild switch arm|Patient to be taken off Atripla and switched to Stribild (co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) -one tablet taken daily with food
62033453|NCT02283060|ACTIVE_COMPARATOR|Atripla control arm|Patient to continue taking Atripla (co-formulated efavirenz/emtricitabine/ tenofovir disoproxil fumarate) - one tablet taken daily at bedtime on an empty stomach
62033454|NCT05224791||Gastric Bypass|The RYGB connects a limb of the intestine to a much smaller stomach pouch, which prevents the bile from entering the upper part of the stomach and esophagus, thereby effectively bypassing the remaining stomach and first segment of the small intestine.
62033455|NCT05224791||Sleeve Gastrectomy|"The SG is a restrictive procedure in which a partial left gastrectomy of the fundus and body of the stomach is performed in order to create a long tubular sleeve along the lesser curvature. The weight loss and resolution of comorbidities are attributed not only to the restrictive nature of the procedure but also to restriction by the pylorus, decreased ghrelin, increased satiety, increased gastric emptying, and faster small bowel transit times with a component of malabsorption."
62033456|NCT01744028|EXPERIMENTAL|Remote patient monitoring|Remote patient monitoring system including the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) tool can use changes in daily scores over a certain threshold level to alert notification to the clinical site. The site will contact the patient in order to determine the clinical significance associated with the change in score, and to treat the patient based on clinical judgment and clinical practice.
62033457|NCT01744028|EXPERIMENTAL|Usual care|This group of patient will continue on their usual standard care as close to real life situation as possible.
62033458|NCT05855044|EXPERIMENTAL|Rosemary oil|
62033459|NCT05463328|EXPERIMENTAL|Laparoscopic assisted pancreaticoduodenctomy|If inclusion criteria are met ,these group of patients will undergo Laparoscopic assisted pancreaticoduodenctomy.
62033460|NCT05463328|ACTIVE_COMPARATOR|Open pancreaticduodenctomy|criteria are met ,these group of patients will undergo open pancreaticoduodenctomy
62033461|NCT02854774|ACTIVE_COMPARATOR|Knee muscle activation/strengthening|4 weeks of exercises focused on activation and strengthening of knee extensor muscles.
62033462|NCT02854774|ACTIVE_COMPARATOR|Hip muscle activation/strengthening|4 weeks of exercises focused on activation and strengthening of hip extensor muscles.
62033463|NCT00466518|EXPERIMENTAL|1|
62033464|NCT01759589|PLACEBO_COMPARATOR|propofol (Group P)|The patients in Group P received 1 mg/kg propofol IV (over 15 sec) during anesthesia induction
62033465|NCT01759589|ACTIVE_COMPARATOR|remifentanil and propofol (Group R)|Patients in Group R received remifentanil 1 µg/kg IV (over 60 sec) and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
62033466|NCT01759589|ACTIVE_COMPARATOR|sevoflurane (Group S)|In Group S, sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered, at which time it was stopped.
62233723|NCT05049278|ACTIVE_COMPARATOR|Phenylephrine|Phenylephrine hydrochloride : 10 mg/1 mL
62033467|NCT04288908|EXPERIMENTAL|Social exclusion|Cyberball is a ball-passing task in which the participant plays with two virtual players. In this condition, the user receives fewer passes than the other two participants (i.e., 10 out of 60).
62033468|NCT04288908|ACTIVE_COMPARATOR|Social inclusion|Cyberball is a ball-passing task in which the participant plays with two virtual players. In this condition, the user receives a comparable number of passes than the other two participants (i.e., 20 out of 60).
62033469|NCT06395064|ACTIVE_COMPARATOR|Dimenhydrinate|Dimenhydrinate 50 mg
62033470|NCT06395064|PLACEBO_COMPARATOR|Placebo|NSS 10 ml
62033471|NCT06578923||690AD|35 eyes /patients implanted with 690AD IOL
62033472|NCT06578923||690ADY|35 eyes /patients implanted with 690ADY IOL
62593355|NCT04625465|ACTIVE_COMPARATOR|No Intervention, Attention-Control Texts (AB)|Participants do not receive text messages during Interval 2. Participants receive attention control text messages during Interval 3.
62033473|NCT01808690|EXPERIMENTAL|Metformin|Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
62033474|NCT01808690|PLACEBO_COMPARATOR|Placebo|Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.
62033475|NCT00727272|EXPERIMENTAL|Quinine Sulfate Caps 324 mg - Fasting|A single dose of quinine sulfate 324 mg administered with 240 mL of room temperature water after an overnight fast of at least 10 hours.
62033476|NCT00727272|EXPERIMENTAL|Quinine Sulphate Tabs 300 mg - Fasting|A single dose of quinine sulphate 300 mg administered with 240 mL of room temperature water after an overnight fast of at least 10 hours.
62033477|NCT00727272|EXPERIMENTAL|Quinine Sulfate Caps 324 mg - Fed|A single dose of quinine sulfate 324 mg administered with 240 mL of room temperature water thirty minutes after the initiation of a standardized, high-fat breakfast.
62033478|NCT02015117|EXPERIMENTAL|Cohort A (trametinib, whole-brain radiation therapy)|Patients receive trametinib PO QD for 4 weeks. Beginning in week 2, patients undergo whole brain radiation therapy five days a week for 3 weeks. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
62233724|NCT02601651|EXPERIMENTAL|Lidocaine|Lignocaine group (Group A) will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.
62424567|NCT01188070|ACTIVE_COMPARATOR|Psychoeducation|Psychoeducational program to involve group sessions over consecutive weeks. The sessions will use the principles of adult learning, emphasizing active learning, group exercises and discussion, and coaching as well as brief talks to provide content. The curriculum will focus on the strengthening of caregiver self-efficacy through enhancement of knowledge and understanding, the acquisition, strengthening, and practice of caregiving skills, and the development of a more clinical or strategic outlook on the caregiving role.
62593356|NCT04625465|EXPERIMENTAL|No Intervention, CBT Texts (AC)|Participants do not receive text messages during Interval 2. Participants receive CBT text messages during Interval 3.
62033479|NCT02015117|EXPERIMENTAL|Cohort B (trametinib, surgery)|Patients receive trametinib PO QD on days 1-14 followed by surgical resection of the tumor.
62033480|NCT01736228|EXPERIMENTAL|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
62593357|NCT04625465|ACTIVE_COMPARATOR|Attention-Control Texts, No Intervention (BA)|Participants receive attention control text messages during Interval 2. Participants do not receive text messages during Interval 3.
62593358|NCT04625465|ACTIVE_COMPARATOR|Attention-Control Texts, Attention-Control Texts (BB)|Participants receive attention control text messages during Interval 2. Participants receive attention control text messages during Interval 3.
62593359|NCT04625465|EXPERIMENTAL|Attention-Control Texts, CBT Texts (BC)|Participants receive attention control text messages during Interval 2. Participants receive CBT text messages during Interval 3.
62593360|NCT04625465|EXPERIMENTAL|CBT Texts, No Intervention (CA)|Participants receive CBT text messages during Interval 2. Participants do not receive text messages during Interval 3.
62593361|NCT04625465|EXPERIMENTAL|CBT Texts, Attention-Control Texts (CB)|Participants receive CBT text messages during Interval 2. Participants receive attention control text messages during Interval 3.
62593362|NCT06062602|EXPERIMENTAL|TAK-676, Carboplatin, 5-FU, & Paclitaxel|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected at least four hours to up to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of TAK-676, carboplatin, 5-fluorouracil (5- FU), or paclitaxel as single agents or in combination. Each microdose is simultaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node.
62593363|NCT05189327||Patients with diagnosed Nonspecific Ulcerative Colitis and Crohn Disease|All patients with diagnosed Nonspecific Ulcerative Colitis and Crohn Disease in the Republic of Kazakhstan.
62593364|NCT04986410||Myocardial Perfusion examination|
62593365|NCT02441335||Group 1 (Preterm labor, PPROM, cervical insufficiency)|Singleton pregnancy between 20 0/7 36 6/7 weeks gestational age who is admitted with PTL or cervical insufficiency (Equal or greater than 2 cm dilated) or PPROM
62593366|NCT02441335||Group 2 (Term labor)|Admitted to the hospital with spontaneous labor (regular contractions, cervical dilation) or spontaneous rupture of membranes
62593367|NCT02441335||Group 3 (PTB-medically indicated)|Singleton pregnancy between 20 0/7 34 5/6 weeks gestational age who is admitted with a medically indicated preterm birth (IOL for abruption, non reassuring fetal heart tones, intrauterine growth restriction, preeclampsia, trauma, etc.)
62593368|NCT01660347|EXPERIMENTAL|Supportive care (allogeneic PBSCT boost)|Patients undergo allogeneic PBSCT boost from cells selected for CD34+ using the CliniMACS CD34 Reagent System.
62593369|NCT04560283|EXPERIMENTAL|Experimental group receiving HYALOGYN®|
62593370|NCT04560283|PLACEBO_COMPARATOR|Control group undergoing expectant management|
62593371|NCT05104567|EXPERIMENTAL|Cohort A (Sub-study 01): 2-3L ESCC Post PD-1/PD-L1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
62593372|NCT05104567|EXPERIMENTAL|Cohort B1 (Sub-study 02): 1-3L GC/GEJ PD1/PD-L1 naïve non-MSI-H CPS ≥1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
62593373|NCT05104567|EXPERIMENTAL|Cohort B2 (Sub-study 02): 1-3L GC/GEJ PD1/PD-L1 naïve non-MSI-H CPS < 1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
62809794|NCT00311766|PLACEBO_COMPARATOR|1|Placebo comparator gel does not contain any active drug. Topical administration of 0.0% Thymosin Beta 4 gel, once a day (qd) up to 56 days
62809795|NCT00311766|ACTIVE_COMPARATOR|2|Topical Administration of 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel once a day (qd) up to 56 days
62809796|NCT05743660||POD group|According to the occurrence of postoperative delirium, the patients were divided into POD group and non-POD group
62809797|NCT05743660||non-POD group|According to the occurrence of postoperative delirium, the patients were divided into POD group and non-POD group
62809798|NCT02587221|EXPERIMENTAL|aQIV|MF59-adjuvanted Quadrivalent Influenza Vaccine (aQIV)
62809799|NCT02587221|PLACEBO_COMPARATOR|Non-influenza Comparator Vaccine|Non-influenza comparator vaccine
62593374|NCT05104567|EXPERIMENTAL|Cohort B3 (Sub-study 02): 2-4L GC/GEJ Post PD1/PD-L1 non-MSI-H|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
62593375|NCT05104567|EXPERIMENTAL|Cohort C (Sub-study 03): 2-3L HCC Post PD-1/PD-L1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
62593376|NCT05104567|EXPERIMENTAL|Cohort D1 (Sub-study 04): 3-6L CRC non-MSI-H any RAS|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
62809800|NCT00348712|ACTIVE_COMPARATOR|A|
62809801|NCT00348712|ACTIVE_COMPARATOR|B|
62809802|NCT01258777|EXPERIMENTAL|001|200 mg golimumab or placebo Single dose of 200 mg subcutaneously
62809803|NCT01258777|EXPERIMENTAL|002|400 mg golimumab or placebo Single dose of 400 mg subcutaneously
62809804|NCT05717361|ACTIVE_COMPARATOR|ketamine-lidocaine (KL) group combination of ketamine and lidocaine in one syringe|
62809805|NCT05717361|ACTIVE_COMPARATOR|: remifentanil group syringe of remifentanil|
62809806|NCT06405360|EXPERIMENTAL|Intervention Arm|Mothers in the intervention arm will receive an animal-source food supplement of two eggs per day from the day of enrollment during the first trimester through childbirth.
62809807|NCT06405360|NO_INTERVENTION|Control Arm|Mothers in the control arm will be asked to continue consuming their typical diet
62809808|NCT05033197|EXPERIMENTAL|CBBS intervention group|The CBBS intervention group received the 16-week intervention, including 16 CBBS lessons in basketball unit (two 40-minute lessons/week, 8 weeks) and 16 CBBS lessons in soccer unit (two 40-minute lessons/week, 8 weeks) during the 2018-2019 school year.
62233725|NCT02601651|PLACEBO_COMPARATOR|Normal saline|Normal saline group (Group B) will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
62424568|NCT04811911|ACTIVE_COMPARATOR|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
62424569|NCT04811911|ACTIVE_COMPARATOR|Methotrexate group|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
62424570|NCT04811911|NO_INTERVENTION|healthy individuals as control group|
62424571|NCT00958685|EXPERIMENTAL|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
62424572|NCT00958685|EXPERIMENTAL|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
62593377|NCT05104567|EXPERIMENTAL|Cohort D2 (Sub-study 04): 3-6L CRC non-MSI-H RAS wild type|SAR444245 is administered every 3 weeks on Day 1 of each cycle (21 days per cycle) and cetuximab is administered on Day 1, Day 8 and Day 15 of each cycle until progressive disease.
62593378|NCT01865201|EXPERIMENTAL|Edaravone group|Edaravone was used at a dose of 30mg,intravenously, twice per day, for 14 days. All patients also received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
62424573|NCT00142844|EXPERIMENTAL|Naltrexone|Naltrexone
62593379|NCT01865201|EXPERIMENTAL|Control group|All patients in this group received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
62809809|NCT00948064|EXPERIMENTAL|Vorinostat with Azacitidine|ARM A: Azacitidine 75 mg/m\^2/day by vein over 15 - 30 minutes daily for 5 days (Days 1 - 5). Vorinostat 200 mg by mouth three time a day with food for 5 days (Days 1 - 5). Courses repeated every 3 to 8 weeks.
62809810|NCT00948064|EXPERIMENTAL|Azacitidine|ARM B: Azacitidine 75 mg/m\^2 /day by vein over 15 - 30 minutes daily for 5 days (Days 1 - 5). Courses repeated every 3 to 8 weeks.
62809811|NCT02571114|ACTIVE_COMPARATOR|Control 1|white bread - 25 g available carbohydrate
62033481|NCT04700293|EXPERIMENTAL|AYMES AMSTERDAM|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'AMSTERDAM' for a period of \> 7 days.
62033482|NCT03760237||Acute Leukemia|Observation only. Patients newly diagnosed with acute leukemia who are scheduled to start treatment with chemotherapy will be enrolled and followed serially with blood collection, echocardiogram, arterial applanation tonometry, and questionnaires for 1 year.
62033483|NCT06320860|EXPERIMENTAL|Kidney Stone Retrieval|All patients in this group will have the EndoTheia FlexStone basket used to assist in the retrieval of kidney stones
62033484|NCT04695223|EXPERIMENTAL|Arsenic Trioxide|Arsenic Trioxide (0.16mg/kg,d1-5,ivgtt,28days as a duration) for injection
62233726|NCT01567982|EXPERIMENTAL|smokers and nonsmokers|both smokers and nonsmokers will receive same tDCS
62233727|NCT03437278|EXPERIMENTAL|Ligelizumab 120 mg|Participants received a dose of ligelizumab 120 mg (high dose) which consisted of one injection of 1 ml of ligelizumab 120 mg/ 1 ml vial every 4 weeks from Day 1 to Week 20 (inclusive).
62233728|NCT03437278|EXPERIMENTAL|Ligelizumab 24 mg|Participants received a dose of ligelizumab 24 mg (low dose) which consisted of one injection of 0.2 ml of ligelizumab 120 mg/ 1 ml vial every 4 weeks from Day 1 to Week 20 (inclusive).
62424574|NCT00142844|EXPERIMENTAL|Disulfiram|Disulfiram
62424575|NCT00142844|EXPERIMENTAL|Naltrexone and Disulfiram|Naltrexone and Disulfiram
62424576|NCT00142844|PLACEBO_COMPARATOR|Placebo|Placebo
62424577|NCT03957317|NO_INTERVENTION|Control|Subjects in this group do not receive an eye mask or ear plugs, and receive standard of care (including pain control modalities). The subjects will receive a Richards-Campbell Sleep Questionnaire (RCSQ) survey for each night they spend in the Surgical ICU, as well as a modified Family Satisfaction in the Intensive Care Unit (FS-ICU) survey upon discharge from the ICU.
62424578|NCT03957317|EXPERIMENTAL|Intervention|Subjects in this group receive an eye mask and ear plugs in addition to standard of care for pain control. The subjects will receive a Richards-Campbell Sleep Questionnaire (RCSQ) survey for each night they spend in the Surgical ICU, as well as a modified Family Satisfaction in the Intensive Care Unit (FS-ICU) survey upon discharge from the ICU.
62809812|NCT02571114|ACTIVE_COMPARATOR|Control 2|white bread - 25 g available carbohydrate
62809813|NCT02571114|SHAM_COMPARATOR|Frozen Yogurt|unflavoured frozen yogurt - 25 g available carbohydrate
62809814|NCT02571114|EXPERIMENTAL|Saskatoon Berry Frozen Yogurt|frozen yogurt containing powder prepared from Saskatoon berries - 25 g available carbohydrate
62809815|NCT03249636||ALL patients|New cases of patients with acute lymphocytic leukemia. Evaluation of markers 15 days after induction.
62809816|NCT00713609|EXPERIMENTAL|1|Benzoyl peroxide/clindamycin gel + tazarotene cream
62809817|NCT00713609|ACTIVE_COMPARATOR|2|Benzoyl peroxide/clindamycin gel + vehicle cream
62809818|NCT00713609|ACTIVE_COMPARATOR|3|Benzoyl peroxide gel + tazarotene cream
62809819|NCT00713609|ACTIVE_COMPARATOR|4|Clindamycin gel + tazarotene cream
62809820|NCT00713609|ACTIVE_COMPARATOR|5|Vehicle gel+ tazarotene cream
62809821|NCT00713609|PLACEBO_COMPARATOR|6|Vehicle gel + vehicle cream
62033485|NCT00526123|ACTIVE_COMPARATOR|1|symmetric tip catheter
62809822|NCT03755206|OTHER|Intervention|Interrupted time series design
62809823|NCT05255146|EXPERIMENTAL|Intervention Group: Cryoanalgesia|Patients receiving cryoanalgesia peri-operatively during minimally invasive cardiothoracic surgery
62033486|NCT00526123|ACTIVE_COMPARATOR|2|conventional split-tip catheter
62424579|NCT04791865|ACTIVE_COMPARATOR|Usual Care|During the control period, patients and caregivers recruited at the clinics will receive the current practice in the clinic, where the health care provider is expected to assess the caregiver and child readiness for disclosure during clinic appointments and give some information as they think indicated.
62424580|NCT04791865|EXPERIMENTAL|Disclosure intervention|Participants who are assigned to the Sankofa intervention will take part in the process of disclosure (pre-disclosure, disclosure, and post-disclosure phases) with the adherence and disclosure specialist (ADDS).
62424581|NCT06177509|EXPERIMENTAL|Intervention group - Graded Aerobic Exercise|Participants will follow a sub-symptom aerobic exercise program (approx. 30 min) 3 - 5 times pr week for twelve weeks. Sub-symptom threshold aerobic exercise means to exercise at 80-90% of the maximum threshold heart rate achieved during the BCTT. To ensure proper exercise dose and progression, participants will be retested every three weeks. During the first three weeks, the participants will be offered one weekly guided exercise session. The other 2 - 4 weekly sessions the participants will carry out on their own, choosing activities based on experience, preferences and possibilities (e.g. walking, jogging, stationary bike, swimming). The intensity of the sub-symptom threshold aerobic exercise will be monitored using a heart rate monitor and the BORG scale. Compliance with the sub-symptom threshold aerobic exercise program will be recorded by the patients in an exercise diary, which is followed up by a weekly reminder over the phone/sms by a physiotherapist in the project.
62424582|NCT06177509|NO_INTERVENTION|Control group - Outpatient multidisciplinary follow-up (Treatment as usual - TAU)|TAU includes assessment and treatment provided by a multidisciplinary outpatient rehabilitation team. Patients will undergo a medical examination and assessment of physical, cognitive, and mental health and functioning, followed by individually adapted rehabilitation program. The interdisciplinary team consists of a specialist in physical medicine and rehabilitation, (neuro)psychologist, occupational therapist, physiotherapist, and social worker. The main focus is on improving the level of function in everyday life and gradual return to work and education.
62424583|NCT00732342|NO_INTERVENTION|1|Standard Treatment
62424584|NCT00732342|EXPERIMENTAL|2|Standard Treatment with Contingency Management for 12 weeks with a 0.5 probability of winning prizes for each negative sample submitted
62424585|NCT00732342|EXPERIMENTAL|3|Standard Treatment with Contingency Management for 24 weeks with a 0.34 probability of winning prizes for each negative sample submitted
62424586|NCT00732342|EXPERIMENTAL|4|Standard Treatment with Contingency Management for 24 weeks with a 0.5 probability of winning prizes for each negative sample submitted
62424587|NCT02858518||patients with atrial fibrillation with anticoagulant treatment|
62424588|NCT02995265|EXPERIMENTAL|Exoskeleton Program|Exoskeleton-based walking rehabilitation until discharge (or to a maximum of 8 weeks), 3 - 5 days a week for 30-60 minutes per session. Participants will be assessed upon admission to the study, discharge, as well as at 6 months post-stroke. The exoskeleton will allow standing and walking with full weight bearing from the first sessions in rehabilitation.
62424589|NCT02995265|ACTIVE_COMPARATOR|Usual Care Program|Standard physiotherapy stroke rehabilitation which includes training for regaining walking as well as other functional tasks, 3 - 5 days a week for 30-60 minutes per session until discharge (or to a maximum of 8 weeks). Participants will be assessed upon admission to the study, discharge, as well as at 6 months post-stroke.
62424590|NCT01651494|ACTIVE_COMPARATOR|DAS181-F04|DAS181-F04: 20 mg single-dose each day via inhalation for 3 days; 6 subjects
62424591|NCT01651494|PLACEBO_COMPARATOR|Placebo|Placebo: 20 mg single-dose each day via inhalation for 3 days; 3 subjects
62424592|NCT05180630|EXPERIMENTAL|Custom earmolds, then Open domes, then Vented domes|Participants first fit with Audeo 90P hearing aids and custom earmolds with dynamic venting, then fit with the same hearing aids using open domes, then fit with the same hearing aids using vented domes.
62424593|NCT05180630|EXPERIMENTAL|Open domes, then Vented domes, then Custom earmolds|Participants first fit with Audeo 90P hearing aids and open domes, then fit with the same hearing aids using vented domes, then fit with the same hearing aids using custom earmolds with dynamic venting.
62424594|NCT05180630|EXPERIMENTAL|Vented domes, then Custom earmolds, then Open domes|Participants first fit with Audeo 90P hearing aids and vented domes, then fit with the same hearing aids using custom earmolds with dynamic venting, then fit with the same hearing aids using open domes.
62424595|NCT00864409|ACTIVE_COMPARATOR|Hip 1|high volume local anesthetic infiltration
62424596|NCT00864409|PLACEBO_COMPARATOR|Hip 2|
62033487|NCT03155607|NO_INTERVENTION|Standard Care|
62033488|NCT03155607|EXPERIMENTAL|Virtual Reality Distraction|
62033489|NCT06103136||Patients operated using the Maestro platform|
62033490|NCT06103136||Control|
62033491|NCT04873570|EXPERIMENTAL|Test Group|Subjects will be given one Mofest® 400mg (Moxifloxacin HCl) Tablet (1x400mg) manufactured by SAMI Pharmaceuticals (Pvt.) after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point. Blood samples will be taken up to 72.0 hours post-dose.
62233729|NCT03437278|PLACEBO_COMPARATOR|Placebo + Ligelizumab 120 mg|Participants received Placebo which consisted of one injection of 1 ml placebo every 4 weeks from Day 1 to Week 8 (inclusive). From week 12 to week 20 (inclusive), participants received a dose of ligelizumab 120 mg (high dose) which consisted of one injection of 1 ml of ligelizumab 120 mg/ 1 ml vial.
62233730|NCT06108037|OTHER|Arm A|"Each arm will receive 3 clinical scenarios spaced over time across 3 Sends. The 6 groups (Arms A-F) will be arranged with naming conventions as such:~* First letter = A, B, or C where A = scenario 1, B = scenario 2, and C = scenario 3.~* Second letter(s) = H or AI, where H = human response and AI = AI-written response to the patient question posed.~* Third letter(s) = N, C, or H, where N = no disclosure, C = computer disclosure, and H = human disclosure. This refers to the disclosure at the bottom of the response message whereby the author is or is not disclosed.~Arm A receives AHN in Send 1, BAIC in Send 2, and CHH in Send 3"
62233731|NCT06108037|OTHER|Arm B|"Each arm will receive 3 clinical scenarios spaced over time across 3 Sends. The 6 groups (Arms A-F) will be arranged with naming conventions as such:~* First letter = A, B, or C where A = scenario 1, B = scenario 2, and C = scenario 3.~* Second letter(s) = H or AI, where H = human response and AI = AI-written response to the patient question posed.~* Third letter(s) = N, C, or H, where N = no disclosure, C = computer disclosure, and H = human disclosure. This refers to the disclosure at the bottom of the response message whereby the author is or is not disclosed.~Arm B receives BHC in Send 1, CAIH in Send 2, and AAIN in Send 3"
62033492|NCT04873570|ACTIVE_COMPARATOR|Reference Group|Subjects will be given one Avelox® 400mg (Moxifloxacin HCl) Tablet (1x400mg), manufactured by Bayer HealthCare, after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point. Blood samples will be taken up to 72.0 hours post-dose.
62233732|NCT06108037|OTHER|Arm C|"Each arm will receive 3 clinical scenarios spaced over time across 3 Sends. The 6 groups (Arms A-F) will be arranged with naming conventions as such:~* First letter = A, B, or C where A = scenario 1, B = scenario 2, and C = scenario 3.~* Second letter(s) = H or AI, where H = human response and AI = AI-written response to the patient question posed.~* Third letter(s) = N, C, or H, where N = no disclosure, C = computer disclosure, and H = human disclosure. This refers to the disclosure at the bottom of the response message whereby the author is or is not disclosed.~Arm C receives CHC in Send 1, AHH in Send 2, and BAIN in Send 3"
62233733|NCT06108037|OTHER|Arm D|"Each arm will receive 3 clinical scenarios spaced over time across 3 Sends. The 6 groups (Arms A-F) will be arranged with naming conventions as such:~* First letter = A, B, or C where A = scenario 1, B = scenario 2, and C = scenario 3.~* Second letter(s) = H or AI, where H = human response and AI = AI-written response to the patient question posed.~* Third letter(s) = N, C, or H, where N = no disclosure, C = computer disclosure, and H = human disclosure. This refers to the disclosure at the bottom of the response message whereby the author is or is not disclosed.~Arm D receives AAIH in Send 1, BHN in Send 2, and CAIC in Send 3"
62233734|NCT06108037|OTHER|Arm E|"Each arm will receive 3 clinical scenarios spaced over time across 3 Sends. The 6 groups (Arms A-F) will be arranged with naming conventions as such:~* First letter = A, B, or C where A = scenario 1, B = scenario 2, and C = scenario 3.~* Second letter(s) = H or AI, where H = human response and AI = AI-written response to the patient question posed.~* Third letter(s) = N, C, or H, where N = no disclosure, C = computer disclosure, and H = human disclosure. This refers to the disclosure at the bottom of the response message whereby the author is or is not disclosed.~Arm E receives BAIH in Send 1, CHN in Send 2, and AHC in Send 3"
62233735|NCT06108037|OTHER|Arm F|"Each arm will receive 3 clinical scenarios spaced over time across 3 Sends. The 6 groups (Arms A-F) will be arranged with naming conventions as such:~* First letter = A, B, or C where A = scenario 1, B = scenario 2, and C = scenario 3.~* Second letter(s) = H or AI, where H = human response and AI = AI-written response to the patient question posed.~* Third letter(s) = N, C, or H, where N = no disclosure, C = computer disclosure, and H = human disclosure. This refers to the disclosure at the bottom of the response message whereby the author is or is not disclosed.~Arm F receives CAIN in Send 1, AAIC in Send 2, and BHH in Send 3"
62233736|NCT03331016|OTHER|Waitlist Control Group|Waitlist Control Group will serve as control group for 6 months, receiving no intervention during that time but completing periodic surveys to assess outcomes among controls (knowledge, attitudes, behaviors). They will also later receive the intervention (training program) and be followed for 6 more months.
62233737|NCT03331016|EXPERIMENTAL|Intervention Group|Intervention Group will receive the intervention (training program) right away, then will be followed for 6 months.
62233738|NCT04103697|EXPERIMENTAL|4xCapOx|Patients will receive 4 cycles of neoadjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks). In case of partial response or stable disease (based on pelvic MRI) patients proceed to surgery. In case of disease progression patients receive 50 Gy pelvic chemoradiotherapy with capecitabine 825 mg/m2 bid per os on radiation days and then surgery. The decision to proceed with adjuvant chemotherapy postoperatively will be based on pTNM stage
62233739|NCT04103697|ACTIVE_COMPARATOR|Surgery|Patients will receive standard surgery for rectal cancer with partial or total mesorectal excision (based on exact tumor location and surgeons discretion). The decision to proceed with adjuvant chemotherapy postoperatively will be based on pTNM stage
62424597|NCT02717936|OTHER|Immunohistochemistry|Patients are investigated using immunohistochemistry with Pancytokeratin
62424598|NCT04976387|EXPERIMENTAL|Group 1: Hydrocodone/Acetaminophen and Ibuprofen|"This group will take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for pain control~If pain is not controlled after 60 minutes then can take Ibuprofen 600mg every 6 hours as needed for additional pain control."
62424599|NCT04976387|EXPERIMENTAL|Group 2: Ibuprofen and Hydrocodone/acetaminophen|"This group will take Ibuprofen 600mg every 6 hours as needed for pain control~If pain is not controlled after 60 minutes then can take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for additional pain control."
62424600|NCT04976387|EXPERIMENTAL|Group 3: Ibuprofen and Acetaminophen|"This group will take Ibuprofen 600mg every 6 hours as needed for pain control~If pain is not controlled after 60 minutes then can take Acetaminophen 650mg every 6 hours as needed for additional pain control."
62424601|NCT01839565||Patients|Patients undergoing osteosynthesis of acetabular fractures by using the Quadrilateral Surface Plate
62424602|NCT00187057|OTHER|1|Acute Lymphoblastic Leukemia (ALL) Low Risk
62424603|NCT00187057|OTHER|2|Acute Lymphoblastic Leukemia (ALL) - High Risk
62424604|NCT00187057|OTHER|3A|B-Cell Non-Hodgkins Lymphoma (Group A)
62424605|NCT00187057|OTHER|3B|B-Cell Non-Hodgkins Lymphoma (Group B)
62809824|NCT05255146|NO_INTERVENTION|Control Group: No Cyroanalgesia|Patients receiving minimally invasive cardiothoracic surgery who do not receive cryoanalgesia.
62033493|NCT03626948|EXPERIMENTAL|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
62424606|NCT00187057|OTHER|4|Hodgkins Disease
62424607|NCT02754180|ACTIVE_COMPARATOR|chemotherapy|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles.
62424608|NCT02754180|EXPERIMENTAL|chemotherapy with chemoradiation|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.
62809825|NCT01650298|NO_INTERVENTION|Control|Remote transmissions were scheduled per each institution's device monitoring protocol. Anticoagulation was initiated/discontinued based on standard of care/guidelines as prescribed by doctor
62809826|NCT01650298|EXPERIMENTAL|Tailored Anticoagulation (TAC)|"Anticoagulation was initiated or discontinued based on atrial tachycardia / atrial fibrillation (AT/AF) burden as assessed through frequent remote transmissions via Merlin.net.~Patients sent in biweekly remote transmissions, automatic alert-triggered transmissions for AT/AF burden above a set threshold, and unscheduled patient-activated transmissions as needed"
62809827|NCT04999839|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to NDI-034858 oral capsules, once daily (QD) for up to 12 weeks.
62033494|NCT03214913|OTHER|EGDT Group|Early Goal Directed Therapy ：30ml/kg in the first bolus to have a CVP（central venous pressure） 8-12 mmHg and MAP（mean artery pressure ） 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenaline，red blood cell transfusion if necessary.
62809828|NCT04999839|EXPERIMENTAL|NDI-034858 2 milligrams (mg)|Participants received 2 mg of NDI-034858 oral capsules, QD for up to 12 weeks.
62033495|NCT03214913|OTHER|Ruijin Group|"Ruijin Strategy therapy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.~target： fulfillment of two or more of four criteria:1. HR（heart rate） \<120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT（hematocrit） 25%\~35%."
62033496|NCT00749138|EXPERIMENTAL|tamoxifen|open label giving of tamoxifen
62033497|NCT01904448|EXPERIMENTAL|Auditory Brainstem Implant|single-arm study of auditory brainstem implantation in children
62033498|NCT00866151||1|"Previously enrolled subjects in the Benefits and Risks of Alternative Weight Loss Strategies - a Clinical Trial, which was run at Stanford 2003-2005. (A to Z Study)"
62033499|NCT03341910|EXPERIMENTAL|DFD-03 Lotion, 0.1%|DFD-03 Lotion, 0.1% to be applied twice daily approximately 12 hours apart, for 1 minute and rinsed off
62033500|NCT03341910|ACTIVE_COMPARATOR|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% to be applied once in the evening and left overnight for approximately 12 hours
62033501|NCT03341910|PLACEBO_COMPARATOR|Vehicle Lotion|Vehicle Lotion to be applied twice daily for 1 minute and rinsed off
62233740|NCT06130748|EXPERIMENTAL|Hybrid Hyrax|"Device: Hybrid hyrax these patents will be treated using Two mini-screws supported hybrid hyrax~Other Names:~• MARPE(miniscrews-assisted rapid palatal expander)"
62809829|NCT04999839|EXPERIMENTAL|NDI-034858 5 mg|Participants received 5 mg of NDI-034858 oral capsules, QD for up to 12 weeks.
62809830|NCT04999839|EXPERIMENTAL|NDI-034858 15 mg|Participants received 15 mg of NDI-034858 oral capsules, QD for up to 12 weeks.
62033502|NCT03341910|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle Cream to be applied once in the evening and left overnight for approximately 12 hours
62033503|NCT06409026|EXPERIMENTAL|Sotatercept Therapy|All participants will receive 36 weeks of sotatercept therapy. Sotatercept is administered as a subcutaneous injection once every 3 weeks.
62033504|NCT04240405||Elderly people without cognitive impairment|
62033505|NCT04240405||Amnestic type mild cognitive impairment patients (aMCI)|
62033506|NCT04240405||Dysexecutive type mild cognitive impairment patients (dMCI)|
62033507|NCT03754296||CATCHVIEW stent retriever|
62233741|NCT06130748|NO_INTERVENTION|Untreated control group|Ethically ,these patents will be treated at the end of the study using the same appliance used for the experimental group
62233742|NCT05785234|EXPERIMENTAL|Sufentanil-remimazolam group|The sufentanil-remimazolam group receives total intravenous anesthesia with sufentanil-remimazolam.
62233743|NCT05785234|ACTIVE_COMPARATOR|Remifentanil-remimazolam group|The remifentanil-remimazolam group receives total intravenous anesthesia with remifentanil-remimazolam.
62233744|NCT04586582||ST-segment resolution <40.15%|ST-segment resolution \<40.15%
62233745|NCT04586582||ST-segment resolution >40.15%|ST-segment resolution \>40.15%
62233746|NCT05256576|NO_INTERVENTION|Control Group 1|Historic control group from both study sites: patients who took part in the FRAILTY study at Charité University hospital Berlin, as well as patients who were treated for OC at Evangelische Kliniken Essen Mitte during the same time period. Retrospective analysis looking at some of the main outcome variables will be conducted.
62233747|NCT05256576|NO_INTERVENTION|Control Group 2|Prospective control group: patients who undergo treatment for OC at both sites. Main outcomes are determined while under standard hospital care before start of the change management and implementation of the new intervention.
62233748|NCT05256576|NO_INTERVENTION|Control Group 3|Control group for health economical analysis to determine the cost-effectiveness of the new intervention.
62233749|NCT05256576|EXPERIMENTAL|Intervention Group|Intervention Group undergoing the new multi-modal perioperative care pathway, including the implementation of ERAS pathway, in combination with a tri-modal prehabilitation program following a comprehensive frailty assessment.
62233750|NCT00928174|EXPERIMENTAL|Single Arm|Fluorine-18 fluorocholine IV in conjunction with PET/CT imaging, up to 3 doses.
62233751|NCT03093987|NO_INTERVENTION|control group|usual care
62233752|NCT03093987|EXPERIMENTAL|critical care ultrasound|Circulation management will be adjusted according to the results of critical ultrasound combined with clearance of lactic acid in patients with shock.
62233753|NCT02980237|EXPERIMENTAL|eHealth_additional support|An e-learning education program whose audiovisual content will be implemented. The course could be access in the workplace but they will be additional support.
62233754|NCT02980237|ACTIVE_COMPARATOR|eHealth|This group will receive an e-learning education program same as the intervention group . However, the participants will not receive additional support by team.
62233755|NCT00117845|EXPERIMENTAL|Denileukin Diftitox in ATL|Denileukin Diftitox in adult T-cell leukemia (ATL) Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
62809831|NCT04999839|EXPERIMENTAL|NDI-034858 30 mg|Participants received 30 mg (2\*15 mg) of NDI-034858 oral capsules, QD for up to 12 weeks.
62593380|NCT04958707|EXPERIMENTAL|Informational support group|The participants in the intervention group will be added to a chat group in the Zalo app, created and managed by one investigator, which is named The Dementia Caregiver Support group. Weekly, the investigator will post one of the topics identified in Phase 1. Before posting the information, the investigator will ask the participants what topic they would like to read and discuss the week after by voting the answer. The posted information will be based on evidence-based resources and consulted by geriatricians, the neurologist, and the psychologist who specialize in dementia. Immediately after posting the topic, one investigator will call the participants to ensure they read and understand the post. The chat group monitor will also collect the questions or comments from the carers who are encouraged to share their feelings or experiences with relevant questions. Then the monitor will post the answers after consulting with the experts.
62809832|NCT00241228|EXPERIMENTAL|High Volume|ultra filtration : High volume : 70 ml/kg/h
62233756|NCT05938231|EXPERIMENTAL|trial group|In the trial group, the patients are treated with Gastric Bypass Stent System implanted under the gastroscope as well as the dietary intervention; The trial is carried out for 9 months, of which in the trial group, the patients have 3-month treatment period and then have 6-month follow-up period after the Gastric Bypass Stent System is removed.
62233757|NCT05938231|OTHER|control group|In the control group, the patients are treated only with dietary intervention; the patients have 9-month dietary intervention in the corresponding period.
62233758|NCT00302419|EXPERIMENTAL|1|Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given
62233759|NCT00302419|ACTIVE_COMPARATOR|2|Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed
62233760|NCT00153517|ACTIVE_COMPARATOR|Oral Treatment|oral (250mg three times daily for 7 days) metronidazole
62424609|NCT05371483||Narcolepsy Type 1|Study participant will complete test(s) before and after taking a stable dose of a new/different hypersomnia medication. All hypersomnia medications will be prescribed and titrated by a clinical sleep specialist outside of this protocol.
62424610|NCT05371483||Narcolepsy Type 2|Study participant will complete test(s) before and after taking a stable dose of a new/different hypersomnia medication. All hypersomnia medications will be prescribed and titrated by a clinical sleep specialist outside of this protocol.
62424611|NCT05371483||Idiopathic Hypersomnia|Study participant will complete test(s) before and after taking a stable dose of a new/different hypersomnia medication. All hypersomnia medications will be prescribed and titrated by a clinical sleep specialist outside of this protocol.
62424612|NCT02962739|ACTIVE_COMPARATOR|33%/67% dosing|The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).
62424613|NCT02962739|ACTIVE_COMPARATOR|33%/100% dosing|The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.
62593381|NCT04958707|ACTIVE_COMPARATOR|Controlled group|The participants will receive usual care, introduced to the website Alzheimer.org to search for eligible information.
62593382|NCT05622682||Children, adolescents, and young adults who recently completed ALL treatment|This cohort of participants who recently completed leukemia therapy will be assessed for infection incidence during the year following treatment and give blood samples to be measured for antibodies to vaccine-preventable diseases. A small subset will also have their blood samples tested for B and T cell recovery.
62809833|NCT00241228|ACTIVE_COMPARATOR|Medium Volume|Ultra filtration : conventional volume : 35 ml/kg/h
62809834|NCT00866463|ACTIVE_COMPARATOR|Conventional Oral Tablet With Water|
62424614|NCT02962739|ACTIVE_COMPARATOR|67%/33% dosing|The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).
62424615|NCT02962739|ACTIVE_COMPARATOR|67%/100% dosing|67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.
62424616|NCT02962739|ACTIVE_COMPARATOR|100%/33% dosing|The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.
62809835|NCT00866463|EXPERIMENTAL|Experimental Tablet With Water|
62809836|NCT00866463|EXPERIMENTAL|Experimental Tablet Without Water|
62809837|NCT03695224||Group A|Subjects with normal topological perception
62809838|NCT03695224||Group B|Subjects with abnormal topological perception
62809839|NCT05412147|ACTIVE_COMPARATOR|Control group|The control group takes the multi-vitamins (Elevit, Bayer S.A.) with the dosage of one tablet per day on the 1st to 5th day of menstruation, then perform ovulation induction on the second menstrual cycle, and continue to take multi-vitamins until the day of oocyte retrieval.
62233761|NCT00153517|ACTIVE_COMPARATOR|Vaginal Treatment|intravaginal (5 g of 0.75% gel twice daily for 5 days) metronidazole
62233762|NCT04174456|EXPERIMENTAL|Olmesartan group|olmesartan 20mg once daily with rosuvastatin 5mg once a day for 6-month
62233763|NCT04174456|ACTIVE_COMPARATOR|Valsartan group|valsartan 40mg twice daily with rosuvastatin 5mg once a day for 6-month
62233764|NCT03507374|PLACEBO_COMPARATOR|Placebo Comparator|After review of eligibility criteria, 20 patients will be randomized to the placebo arm of the study where patient will administer one subcutaneous injection of placebo every two weeks for a total of 52 weeks. Additionally, per standard-of-care, patient will also be treated with atorvastatin 40-80 mg.
62233765|NCT03507374|ACTIVE_COMPARATOR|Active Comparator|After review of eligibility criteria, 20 patients will be randomized to receive the investigational treatment of alirocumab 150mg which will be administered subcutaneously with a single-dose pre-filled pen syringe every 2 weeks for a total of 52 weeks. Additionally, per standard-of-care, patient will also be treated with atorvastatin 40-80 mg
62593383|NCT05622682||Healthy age- and sex-matched controls|Healthy control patients matched to ALL cohort patient on age and sex will be selected for comparison of infection rates during the same calendar year as each ALL cohort participant's study period. Healthy controls will be matched to ALL participants 3:1, with up to a total of 270 controls selected.
62593384|NCT03064854|EXPERIMENTAL|Group A: squamous, gem/cis+PDR001|
62593385|NCT03064854|EXPERIMENTAL|Group B: non-squamous, pem/cis+PDR001|
62593386|NCT03064854|EXPERIMENTAL|Group C: paclitaxel/carbo+PDR001|
62593387|NCT03064854|EXPERIMENTAL|Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab|
62593388|NCT06369896||Nonicteric stricture cohort|Patients with nonicteric biliary stricture
62593389|NCT02163226|EXPERIMENTAL|Hypofractionated Radiation Therapy|Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row. Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
62593390|NCT02163226|ACTIVE_COMPARATOR|One Radiation Therapy Treatment|12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV). Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
62593391|NCT01056198|ACTIVE_COMPARATOR|Santyl|2 mm Santyl applied once daily
62809840|NCT05412147|EXPERIMENTAL|Treatment group|The treatment group begins to take Reco-18 on the 1st to 5th day of menstruation with a dosage of 4 pills per day for the whole menstrual cycle, then perform ovulation induction on the second menstrual cycle, and continue to take Reco-18 until the day of oocyte retrieval.
62809841|NCT04618146|PLACEBO_COMPARATOR|Group C|given intrathecal bupivacaine 12.5 mg.
62809842|NCT04618146|ACTIVE_COMPARATOR|Group M25|given intrathecal bupivacaine 12.5mg + morphine 25 microgram.
62033508|NCT05475951|EXPERIMENTAL|Normal Weight Pregnant Women|The women who had term pregnancy and had normal BMI.
62033509|NCT05475951|EXPERIMENTAL|Overweight Pregnant Women|The women who had term pregnancy and had BMI values between 25-30.
62033510|NCT05475951|EXPERIMENTAL|Obese Pregnant Women|The women who had term pregnancy, and had BMI values more than 30.
62593392|NCT01056198|SHAM_COMPARATOR|Control|Daily gauze and optional sharp debridement
62593393|NCT04907643|EXPERIMENTAL|Virtual Reality Program A|This arm will include software that provides immersive skills-based content for pain reduction.
62593394|NCT04907643|EXPERIMENTAL|Virtual Reality Program B|This arm will include software that provides immersive distraction based content for pain reduction.
62593395|NCT04907643|SHAM_COMPARATOR|Virtual Reality Program C|This arm will include software that provides nonimmersive distraction based content for pain reduction.
62809843|NCT04618146|ACTIVE_COMPARATOR|Group M50|given intrathecal bupivacaine 12.5mg + morphine 50 microgram.
62033511|NCT00622128|EXPERIMENTAL|1|Pilot study. Developing intervention
62033512|NCT06266767|EXPERIMENTAL|Group 1|PIEB bolus vol (ml) : 8 PIEB time interval (min) : 60 PCEA bolus vol (ml) : 5 PCEA lockout time interval (min) : 20
62033513|NCT06266767|EXPERIMENTAL|Group 2|PIEB bolus vol (ml) : 8 PIEB time interval (min) : 45 PCEA bolus vol (ml) : 5 PCEA lockout time interval (min) : 20
62033514|NCT06266767|EXPERIMENTAL|Group 3|PIEB bolus vol (ml) : 10 PIEB time interval (min) : 30 PCEA bolus vol (ml) : 5 PCEA lockout time interval (min) : 20
62033515|NCT06266767|EXPERIMENTAL|Group 4|PIEB bolus vol (ml) : 10 PIEB time interval (min) : 45 PCEA bolus vol (ml) : 5 PCEA lockout time interval (min) : 20
62033516|NCT06266767|EXPERIMENTAL|Group 5|PIEB bolus vol (ml) : 10 PIEB time interval (min) : 60 PCEA bolus vol (ml) : 5 PCEA lockout time interval (min) : 20
62033517|NCT06266767|EXPERIMENTAL|Group 6|PIEB bolus vol (ml) : 10 PIEB time interval (min) : 75 PCEA bolus vol (ml) : 5 PCEA lockout time interval (min) : 20
62033518|NCT06266767|EXPERIMENTAL|Group 7|PIEB bolus vol (ml) : 12 PIEB time interval (min) : 60 PCEA bolus vol (ml) : 5 PCEA lockout time interval (min) : 20
62593396|NCT01249924|OTHER|CPAP Group|CPAP Treatment
62593397|NCT01249924|OTHER|Control Group|Routine care
62593398|NCT03993574|OTHER|Standard Care|The standard care group will receive baseline testing #1, standard care, baseline testing #2 and follow up testing approximately 8 weeks later.
62593399|NCT03993574|EXPERIMENTAL|Experimental|Experimental group will baseline testing #1, standard care, baseline testing #2 however then participate in a 6-week self-management intervention (either generic or vision specific self-management based) and then get 8 week follow up testing.
62593400|NCT06293989|EXPERIMENTAL|diazepam 5 mg|Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug.
62593401|NCT06293989|EXPERIMENTAL|diazepam 10 mg|Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug.
62593402|NCT06293989|EXPERIMENTAL|placebo|Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug.
62593403|NCT05489263||AKI|AKI is defined by KDIGO criterion based on peri-operative serum creatinine variation.
62593404|NCT05489263||No-AKI|No-AKI is defined by KDIGO criterion based on peri-operative serum creatinine variation.
62809844|NCT04401735|EXPERIMENTAL|Polydeoxyribonucleotide|Polydeoxyribonucleotide(PDRN) 5.625mg/3ml
62809845|NCT04401735|EXPERIMENTAL|Polydeoxyribonucleotide, Placebo|Polydeoxyribonucleotide(PDRN) 5.625mg/3ml Placebo (Normal saline)
62809846|NCT04401735|PLACEBO_COMPARATOR|Placebo|Placebo (Normal saline)
62809847|NCT03655145|EXPERIMENTAL|Haploidentical donor stem cell transplantation|The stem cell source will be bone marrow for haploidentical transplantation.The bone marrow collection is carried out according to the practice of each centre with a minimal target dose of 3x108 TNC/kg.
62809848|NCT03655145|ACTIVE_COMPARATOR|HLA 10/10 MUD stem cell transplantation|The stem cell source will be peripheral blood stem cell for HLA-matched unrelated transplantation.Peripheral blood stem cell (PBSC) for HLA-matched unrelated SCT will be mobilized by G-CSF (Neupogen®) administered to the donor from Day-4 to Day-1 subcutaneously (10µg/kg/day) with the minimal target dose of 4.106 CD34+ cells/kg.
62033519|NCT06266767|EXPERIMENTAL|Group 8|PIEB bolus vol (ml) : 12 PIEB time interval (min) : 45 PCEA bolus vol (ml) : 5 PCEA lockout time interval (min) : 20
62033520|NCT03152253|EXPERIMENTAL|Text Message for Smoking Cessation|smoking cessation promotion messages and medication reminders sent via text messages for up to 30 days before quit day and 8 weeks following quit day, along with access to a social support chat room
62233766|NCT04138797|EXPERIMENTAL|Electrophysiological exploration & ECG Biosemi|
62424617|NCT02962739|ACTIVE_COMPARATOR|100%/67% dosing|67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.
62424618|NCT01629693|EXPERIMENTAL|Air Optix|Lotrafilcon B contact lenses worn bilaterally (in both eyes) for at least 4 hours a day, 5 days a week, for 4 weeks, on a daily wear basis (removed nightly for cleaning and disinfection).
62424619|NCT01629693|ACTIVE_COMPARATOR|Biofinity|Comfilcon A contact lenses worn bilaterally (in both eyes) for at least 4 hours a day, 5 days a week, for 4 weeks, on a daily wear basis (removed nightly for cleaning and disinfection).
62424620|NCT02540720|EXPERIMENTAL|group 1|Dexamethasone 0.5mg/kg.d i.v.
62424621|NCT02540720|EXPERIMENTAL|group 2|Dexamethasone \& gamma globulin Dexamethasone 0.5mg/kg.d i.v. \& gamma globulin i.v. qd\*3d, and the total dose is 2g/kg
62424622|NCT02540720|EXPERIMENTAL|group 3|Dexamethasone \& hemoperfusion Dexamethasone 0.5mg/kg.d i.v \& hemoperfusion should be given at least three times in five days
62424623|NCT05459168|OTHER|Calm Meditation Smartphone App Feedback (Aim 1)|Advisory committee members will be asked to use the current Calm meditation app platform for a full week and to keep an informal journal prior to participating in focus groups in which they will provide feedback about the app.
62424624|NCT05459168|OTHER|Cancer-Specific Meditation App Prototype Design (Aim 2)|Findings from Aim 1 will inform the development of a cancer-specific meditation app prototype to be tested in Aim 3.
62424625|NCT05459168|OTHER|Cancer-Specific Meditation App Prototype (Aim 3)|Recruited cancer patients/survivors will be asked to beta-test the cancer-specific app prototype for four weeks. The prototype will be developed in Aim 2 and informed by qualitative findings of Aim 1.
62424626|NCT04572399|EXPERIMENTAL|Endotracheal UV Light|Mechanically ventilated patients who will receive UV Light therapy
62424627|NCT05958459|EXPERIMENTAL|study group|The individuals in the study group will perform home-based eye exercises for at least 1 session (\~30 min.) every day for a total of 12 weeks, after the patient's condition is stable, starting from the 7th day after the surgery. After the initial assessment, participants will be given illustrated brochures describing the exercises and will be taught how to perform the exercises. Whether individuals comply with the exercise program will be closely monitored (by keeping a diary, online meetings and periodically calling individuals). Eye exercises include eight steps. These; Covering the eyes with the palm of the hand, blinking, lateral gaze, anterior and lateral gaze, rotational gaze, up-down gaze, nasal tip gaze, and near and far gaze.
62424628|NCT05958459|EXPERIMENTAL|control group|The control group, on the other hand, will not perform any exercise, but will only be evaluated.
62424629|NCT05563025||General|Arthroscopic Shoulder Surgery under General Anesthesia
62424630|NCT05563025||Regional|Arthroscopic Shoulder Surgery under Regional Anesthesia
62424631|NCT03368547|EXPERIMENTAL|Diagnostic (68Ga-PSMA-11, PET/CT)|Patients receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 20-50 minutes on day 1.
62424632|NCT02083588|EXPERIMENTAL|open - single arm|All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
62424633|NCT01333631|EXPERIMENTAL|Valporoic acid + chemoradiotherapy|
62424634|NCT04316949||Derivation cohort|"Derivation cohort: Italian retrospective cohort of all consecutive hospitalized patients with SARS-CoV-2 pneumonia in the participating centers, from February 20 to March 19 2020.~."
62424635|NCT04316949||Validation cohort|Validation cohort: European and non-European retrospective cohort of all consecutive hospitalized patients with SARS-CoV-2 pneumonia in the participating centers, from March 19 to April 18 2020.
62424636|NCT03091400|EXPERIMENTAL|Atomoxetine|Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
62424637|NCT03091400|PLACEBO_COMPARATOR|Placebo|Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
62424638|NCT05048771||FERTITOP|300 patients (15-25 years) from 5 different hospitals (University Hospitals of Nancy, Strasbourg, Reims, Besançon, Dijon (France)) who have finished all cancer treatments for at least 2 years.
62424639|NCT00929864|ACTIVE_COMPARATOR|Abatacept|
62424640|NCT00929864|ACTIVE_COMPARATOR|Adalimumab|
62033521|NCT03152253|PLACEBO_COMPARATOR|Non-Interventional Text Messages|General motivational text messages sent on the same schedule at TMQ arm of the study with access to a social support chat room.
62033522|NCT02159833|EXPERIMENTAL|Intervention|Intranasal challenge with food protein or vehicle control
62233767|NCT05139290|EXPERIMENTAL|Prototype Intervention|The prototype intervention will be likely family-based and focused on issues of communication, problem-solving, health system literacy, and family systems, all considered in the context of the African-American (AA) adult daughter role and cultural identity.
62424641|NCT01099280|EXPERIMENTAL|oxytocin group|2 milliunits/min and doubled every 30 minutes to a maximum of 32 milliunits/min or until four contractions in 10 minutes was achieved
62424642|NCT01099280|EXPERIMENTAL|dinoprostone and oxytocin|a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
62424643|NCT05554874|EXPERIMENTAL|Case group|participants undergoing pulsed electromagnetic fields
62424644|NCT05554874|SHAM_COMPARATOR|Control group|participants undergoing sham pulsed electromagnetic fields
62424645|NCT06280027||group1|patients (laypeople) of the university clinic. The inclusion criteria were age ≥18 and ≤70 years.
62233768|NCT06007274||Active surveillance by means of troponin measurements|
62233769|NCT06007274||No active surveillance by means of troponin measurements|
62809849|NCT01808196|EXPERIMENTAL|Losartan|Participants with eosinophilic esophagitis receive Losartan daily
62809850|NCT02818309|EXPERIMENTAL|Lesogaberan|Lesogaberan
62809851|NCT02818309|PLACEBO_COMPARATOR|Placebo|Placebo
62033523|NCT06191848|EXPERIMENTAL|Tirzepatide|"Drug: Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1receptor (GLP1R) agonist Dose: Tirzepatide will be initiated at 2.5mg once weekly, with the dose increasing by a further 2.5mg every four weeks until the target weekly dose of 15mg is achieved (or participants reach a lower maximum tolerated dose of 5mg or 10mg).~Duration: 72-weeks Mode: subcutaneous"
62033524|NCT06191848|PLACEBO_COMPARATOR|Placebo|Drug: Placebo Dose: once-weekly Duration: 72 weeks Mode: subcutaneous
62033525|NCT05655312|EXPERIMENTAL|Monotherapy-Dose Escalation|"Enrolled subjects will be treated with increasing doses of \[212Pb\]VMT01 (up to 15 mCi) to determine MTD, MFD, and RP2D. Up to 32 subjects will be enrolled.~A dosimetry sub-study utilizing \[203Pb\]VMT01 has been incorporated into Monotherapy Dose-Escalation arm."
62809852|NCT00656929|ACTIVE_COMPARATOR|1|Vitamin D3 50 mcg (2000 IU) daily
62033526|NCT05655312|EXPERIMENTAL|Combination Therapy-Dose Escalation|"Enrolled subjects will be treated with increasing radioactive doses of \[212Pb\]VMT01 (up to 15 mCi) in combination with nivolumab to determine MTD, MFD, and RP2D.~A dosimetry sub-study utilizing \[203Pb\]VMT01 has been incorporated into Combination Therapy-Dose Escalation."
62033527|NCT05655312|EXPERIMENTAL|Monotherapy - Dose Expansion|"Up to 2 monotherapy expansion cohorts of up to 25 subjects will be enrolled at previously identified RP2D to confirm the RP2D and regimen for the Phase 2 dose-expansion cohort.~A dosimetry sub-study utilizing \[203Pb\]VMT01 has been incorporated into Monotherapy-Dose Expansion."
62033528|NCT05655312|EXPERIMENTAL|Combination Therapy - Dose Expansion|"Up to 2 Combination Therapy expansion cohorts of up to 25 subjects will be enrolled at RP2Ds previously identified to confirm the RP2D and regimen for the Phase 2 dose-expansion cohort.~A dosimetry sub-study utilizing \[203Pb\]VMT01 has been incorporated into Combination Therapy-Dose Expansion.~Once the RP2D and regimen for the Phase 2 dose-expansion cohort is confirmed, up to 100 subjects will be enrolled to confirm the efficacy and safety of the RP2D and regimen."
62033529|NCT02105116|EXPERIMENTAL|Standard chemotherapy followed by allogenic therapy|INDUCTION CHEMOTHERAPY: Patients receive standard induction chemotherapy with fludarabine phosphate IV over 1 hour QD for 5 days and cytarabine IV over 4 hours for 5 days. G-CSF 5 mcg/kg will be started at day14 if day14 bone marrow does not have \>5% leukemic blasts. Treatment may continue for 1 or 2 courses at the discretion of the treating physician. If the patient enters a complete remission they are eligible for ALLOGENEIC CELLULAR THERAPY: Patients eligible for the experimental therapy undergo irradiated Donor Lymphocyte Infusion (DLI) of 3 x 10\^8 CD3+ cells/kg at 8 weeks. Patients with stable disease may repeat irradiated DLI every 8-12 weeks in the absence of disease progression or unacceptable toxicity.
62233770|NCT01206777|EXPERIMENTAL|Rituximab|
62233771|NCT05639335|OTHER|No Character Control|Participants will view images of three breakfast cereals (Frosted Flakes, Apple Jacks, Froot Loops) containing no characters.
62424646|NCT06280027||group2|restorative dentists and prosthodontists with similar levels of clinical experience (at least 3 years of academic training). The inclusion criteria were age ≥18 and ≤70 years.
62809853|NCT00656929|PLACEBO_COMPARATOR|2|Placebo tablets
62424647|NCT00634192|EXPERIMENTAL|1|
62809854|NCT04396366|PLACEBO_COMPARATOR|placebo|Placebo controlled arm
62809855|NCT04396366|ACTIVE_COMPARATOR|QBW251|Active comparator drug arm
62809856|NCT03081702|EXPERIMENTAL|Hydroxychloroquine and Itraconazole|"Hydroxychloroquine, orally (by mouth), at a dose of 100 mg, 200 mg, 400 mg, or 600 mg, twice a day, every day.~Itraconazole, orally (by mouth) at 300 mg, twice a day, every day."
62809857|NCT06107777|EXPERIMENTAL|Pharmacopucture on Acupoints Related to Psychological Stress|"The Pharmacopucture group will recieve Pharmacopucture treatment durling the hospitalization. The mandatory acupoints are (Dan-jung(CV17), Jung-wan(CV12), Gi-hae(CV6), Gwan-won(CV4), Sin-mun(HT7). If needed, they will recieve additional acupoints are (So-hae(HT3), Jung-jeo(TE3), Sam-eumgyo(SP6). A trained doctor of Korean medicine with at least 3 years of clinical experience are going to conduct the pharmacopucture.~The Pharmacopucture group will also be treated with other Korean medical treatment everyday: acupuncture, chuna and Korean herbal medicine."
62809858|NCT06107777|ACTIVE_COMPARATOR|Korean medical treatment|The control group will receive Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture(except on mandatory and additional acupoints) and Korean herbal medicine.
62809859|NCT01890343|EXPERIMENTAL|Frontotemporal Disorder|Subjects with frontotemporal disorder (FTD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F and a one-time IV bolus injection of 185 MBq of 18F-FDG.
62809860|NCT01890343|EXPERIMENTAL|Cognitively Normal|Cognitively normal (CN) subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
62809861|NCT01890343|EXPERIMENTAL|Alzheimer's Disease|Subjects with Alzheimer's disease (AD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
62809862|NCT03587376|EXPERIMENTAL|Participants with Elevated Liver Enzymes|Blood samples will be collected on Day 1 from participants previously treated with atabecestat and who had elevated liver enzymes while on atabecestat.
62593405|NCT06193603|EXPERIMENTAL|True dry cupping therapy|Participants in the true dry cupping therapy group, who have chronic non-specific low back pain, will receive a combination of dry cupping therapy and routine physiotherapy. During the dry cupping therapy sessions, two cups will be applied to the lumbar region and moved in an up-down and down-up direction.
62593406|NCT06193603|SHAM_COMPARATOR|Sham cupping therapy|Participants in the sham cupping therapy group, who have chronic non-specific low back pain, will undergo a combination of sham cupping therapy and routine physiotherapy. During the sham cupping therapy sessions, two cups with small holes will be placed stationary on the lumbar region.
62593407|NCT04374162|PLACEBO_COMPARATOR|Conventional PEEP|PEEP = 5 cmH2O
62593408|NCT04374162|EXPERIMENTAL|Driving pressure (DP) guided-PEEP|"DP is calculated as plateau pressure - PEEP. 10 min after pneumoperitoneum， PEEP is increased from 5 to 15 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively."
62593409|NCT05622071|EXPERIMENTAL|SINGLE ARM|Tislelizumab 200 mg will be administered every 3 weeks IV. Treatment will be continued until progression or limiting toxicities, for a maximum duration of 2 years and with an average duration of 4 months
62233772|NCT05639335|EXPERIMENTAL|Character|Participants will view images of three breakfast cereals (Frosted Flakes, Apple Jacks, Froot Loops) containing their respective brand characters (e.g., Tony the Tiger) and a licensed character recently featured on these cereal brands (e.g., Buzz Lightyear).
62593410|NCT01194531|NO_INTERVENTION|CONTROL arm|Subjects assigned to this arm of the study will receive no PGS testing.
62809863|NCT03587376|ACTIVE_COMPARATOR|Participants Without Elevated Liver Enzymes|Blood samples will be collected on Day 1 from participants who completed at least 3 months of dosing with atabecestat and who did not have the elevated liver enzymes (adverse event) while on atabecestat.
62233773|NCT02953171|EXPERIMENTAL|Raw sauerkraut+Probiotic capsule|75 grams of raw, lacto-fermented sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.
62233774|NCT02953171|EXPERIMENTAL|Raw sauerkraut+placebo capsule|75 grams of raw, lacto-fermented sauerkraut + 1 placebo capsule, each day for 6 weeks.
62233775|NCT02953171|EXPERIMENTAL|Pasteurized sauerkraut+Probiotic capsule|75 grams of pasteurized sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.
62424648|NCT00634192|EXPERIMENTAL|2|
62424649|NCT04742725|PLACEBO_COMPARATOR|Placebo|
62809864|NCT02490683|EXPERIMENTAL|Luna Rich X|Luna Rich X©: 500 mg/ day in 4 pills of lunasin-enriched soy protein concentrate Reliv Now: 19 grams of powder/day, that subject will mix and consume daily with water or a beverage they commonly drink
62809865|NCT02490683|EXPERIMENTAL|Reliv Now|19 grams of power/day, that subjects will mix and consume daily with water or a beverage they commonly drink
62809866|NCT02490683|PLACEBO_COMPARATOR|Placebo|Placebo pills containing starch (provided by Reliv International, Inc.)
62809867|NCT01912066|EXPERIMENTAL|Stillen|Patients taking a tab of Stillen and a tab of placebo drug and a tab of NSAID
62233776|NCT02953171|PLACEBO_COMPARATOR|Pasteurized sauerkraut+Placebo capsule|75 grams of pasteurized sauerkraut + 1 placebo capsule, each day for 6 weeks.
62233777|NCT01191931||prostate cancer|Patients with histologically proven prostate cancer (positive biopsy) and who are planned to undergo radical prostatectomy.
62233778|NCT01642173|OTHER|OCT at baseline|"Subjects enrolled in the NIH funded and IRB approved (08-008161) protocol Lp-PLA2 and Coronary Atherosclerosis in Humans with a positive diagnosis of coronary artery endothelial dysfunction will be studied using Optical Coherence Tomography during the angiogram at baseline."
62233779|NCT01642173|OTHER|OCT following 6 month Lp-PLa2 inhibition|"Subjects who are enrolled in IRB 10-000044 Lp-PLA2 and Coronary Atherosclerosis in Humans Aim III a study in which the investigators are examining the impact of long-term inhibition of Lp-PLA2, with a specific novel inhibitor or placebo, on Lp-PLA2 activity and improvement in coronary endothelial function will be studied using Optical Coherence Tomography during the 6 month return angiogram."
62809868|NCT01912066|ACTIVE_COMPARATOR|Cytotec|The subjects taking a tab of Cytotec, a tab of placebo drug, and a tab of NSAID
62424650|NCT04742725|EXPERIMENTAL|Prothione ™|
62424651|NCT05724316|EXPERIMENTAL|Vitamin D Group|All participants in this group will receive cholecalciferol (VD3 25μg) tablets, one to be taken per day.
62424652|NCT05724316|NO_INTERVENTION|Control Group|Will receive no vitamin D supplements.
62433621|NCT04934514|EXPERIMENTAL|Ia stage-Dose escalation|"Using the 3+3 model, 1 subject was included in the 6 mg/kg dose group, and then 3 to 6 patients with HER2-positive advanced solid tumors that failed standard treatment were included in the fixed 3 dose groups (10 mg/kg, 15 mg/kg, and 20 mg/kg) ."
62593411|NCT01194531|OTHER|TEST arm|Subjects assigned to this arm of the study will receive PGS testing.
62593412|NCT06149650||Full cohort|Intravascular lithotripsy of femoropopliteal and crural lesions as per standard of care
62809869|NCT02517918|EXPERIMENTAL|Sirolimus combined with CP, MT and ZA|Drug : Metronomic Cyclophosphamide, Methotrexate, Sirolimus, Zoledronic acid Assessment of the maximum tolerated dose of sirolimus Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally. Zoledronic Acid will be administrated by infusion (IV).
62809870|NCT04789707||KERATOCONUS group|"All workers with keratoconus all stages followed at the service of ophthalmology in CHU Gabriel Montpied, Clermont-Ferrand, Auvergne.~The investigators only assessed data from usual routine practice. Patients answer the auto questionnaire in last minutes of consultation."
62809871|NCT04789707||CONTROL group|"workers with good visual acuity consulting in ophthalmology service of Clermont-Ferrand.~The investigators only assessed data from usual routine practice. Patients answer the auto questionnaire in last minutes of consultation."
62809872|NCT03678272|ACTIVE_COMPARATOR|HERNIOPLASTY WITH PANAVALE MESH|Preformed polypropylene mesh.
62593413|NCT01898221|ACTIVE_COMPARATOR|Standard Catheter Ablation Patient Group|Patients will have a standard procedure ablation
62593414|NCT01898221|ACTIVE_COMPARATOR|Vein of Marshall and Standar procedure|The doctor will inject Ethanol through a balloon catheter into the VOM
62809873|NCT03678272|ACTIVE_COMPARATOR|HERNIOPLASTY WITH PARIETEX PROGRIP MESH|Mesh consisting of mono lament polyester with a resorbable polylactic acid (PLA) microgrip technology.
62809874|NCT03678272|ACTIVE_COMPARATOR|HERNIOPLASTY WITH ADHESIX MESH|Self-adhesive mesh.
62809875|NCT03678272|ACTIVE_COMPARATOR|HERNIOPLASTY WITH TIMESH MESH|Titaniumized polypropylene mesh.
62593415|NCT02002312|EXPERIMENTAL|Lu-177-DOTA-girentuximab|Patients in receive 10 mg of girentuximab coupled to DOTA and labeled with 65 mCi/m2 of Lu-177 if targeting of In-111-DOTA-girentuximab is observed in at least 1 lesion. Patients may be retreated no sooner than 12 weeks after the prior treatment with a dose of no more than 75% of the previous dose, for a total of not more than three treatments.
62593416|NCT03992170|EXPERIMENTAL|Single Arm|"Patients will receive Daratumumab (16 mg/Kg day) every week for 8 weeks intravenous (8 infusions) and then every 2 weeks for 16 weeks intravenous (8 more infusions).~If MRD positive by NGF, the patients will receive Daratumumab every 4 weeks for 80 weeks intravenous; if MRD negative by NGF, the patients can stop the treatment."
62424653|NCT05588375|EXPERIMENTAL|home-based physical activity telemonitoring program|The home telehealth physical activity training program is a telemedicine physical activity training that uses Google Meet software to communicate and supervise through webcams. The exercise process is supervised and guided by a trained critical care nurse. The experimental group participated in a telehealth physical activity training program. The telemedicine physical activity training program included a 3-month online intervention (exercise diary, exercise training education, and 24 exercise sessions for patients) and a 3-month follow-up after exercise.
62424654|NCT05588375|ACTIVE_COMPARATOR|walk 2-3 days a week|Maintain daily physical activity and lifestyle and walk for 30 minutes 2-3 days a week for three months
62593417|NCT02079467|ACTIVE_COMPARATOR|Standard rehabilitation|"Patients randomized to the control group will be managed with hip precautions immediately following surgery. They will weight bear on the operative joint as tolerated after surgery. They will be managed as per usual protocol post total hip arthroplasty. They will be transferred from the operative table with an abduction pillow between their legs and will be asked to keep this pillow between their legs while resting in bed and during sleep throughout their course in hospital. During physiotherapy treatments they will not flex the operative hip beyond 90 degrees, internally or externally rotate the operative hip more than 45 degrees, or actively adduct the operative hip past neutral."
62424655|NCT01716507|OTHER|20 gauge pars plana vitrectomy|20 gauge pars plana vitrectomy for retinal detachment repair
62593418|NCT02079467|EXPERIMENTAL|Unrestricted rehabilitation|Patients randomized to the treatment group will have no restrictions in their post-operative rehabilitation. They will weight bear on the operative joint as tolerated after surgery. They will be asked to participate in activity as their level of comfort permits and will have no positional restrictions while in bed or completing activities of daily living.
62593419|NCT04181983|EXPERIMENTAL|Personalized exercise program|A home-based personalized exercise program using a smartphone app
62593420|NCT04181983|ACTIVE_COMPARATOR|Active Control WHO guidelines|A standard exercise program based upon WHO guidelines
62593421|NCT04181983|NO_INTERVENTION|Control|No exercise program
62593422|NCT04859153||Sprinter|All sex of healthy adolescent athletes of the athletics sprint
62593423|NCT04859153||Non-sprinter|All sex of healthy adolescent athletes of other kinds of sports
62593424|NCT04501081||1|DFNA patients and their family members (affected)
62593425|NCT04501081||2|DFNA patients and their family members (unaffected)
62593426|NCT02315495|EXPERIMENTAL|5 mg saxagliptin + 100 mg acarbose|"Acute dosing:~5 mg saxagliptin is given with water, 60 min before a test meal 100 mg acarbose is given with a test meal"
62593427|NCT02315495|EXPERIMENTAL|5 mg saxagliptin|"Acute dosing:~5 mg saxagliptin is given 60 min before a test meal,"
62233780|NCT03230656|EXPERIMENTAL|Early therapy 1 month post-injury|"Early cognitive-communication therapy 1 month post-injury:~* working memory strategies~* executive function program~* divided attention program~* environmental changes~* identification of problematic cognitive-communication situations"
62233781|NCT03230656|ACTIVE_COMPARATOR|Waitlist therapy 2 months post-injury|"Waitlist early cognitive-communication therapy 2 months post injury:~- Same cognitive-communication therapy is administered"
62424656|NCT01716507|OTHER|23 gauge pars plana vitrectomy|23 gauge pars plana vitrectomy for retinal detachment repair
62424657|NCT04296799|EXPERIMENTAL|Single Ascending Dose|The study will consist of 6 cohorts (1 cohort per dose level) of 8 subjects (6 subjects receiving the study drug and 2 receiving matching placebo), for a total of 48 subjects.
62593428|NCT02315495|EXPERIMENTAL|100 mg acarbose|"Acute dosing:~100 mg acarbose is given with a test meal"
62593429|NCT02315495|NO_INTERVENTION|control|
62593430|NCT05396105|EXPERIMENTAL|Part B: Selected dose|Single dose of deucrictibant
62593431|NCT06183476|EXPERIMENTAL|Intervention|Amplify-RHYTHM will consist of two main components: 1) timed light exposure, 2) weekly remote coaching session.
62593432|NCT05502744|EXPERIMENTAL|Emergency Versus Elective Cholecystectomy in Acute Cholecystitis in the Era of Laparoscopy|A Prospective Randomized Comparative Study.
62593433|NCT06270875|EXPERIMENTAL|Coached: Basic pain education + self-care + basic communication & Self-led: spirituality|1 telephone weekly session on pain psychoeducation, lay coach-led self-care and relaxation tips, 1 session on social support and communication coaching, self-guided spirituality and meaning coping
62593434|NCT06270875|EXPERIMENTAL|Coached: Basic pain education + self-care + basic communication + spirituality|1 telephone weekly session on pain psychoeducation, lay coach-led self-care and relaxation tips, 1 session on social support and communication coaching, coach-led spirituality and meaning coping
62593435|NCT06270875|EXPERIMENTAL|Coached: Basic pain education + self-care + advanced communication & Self-led: spirituality|1 telephone weekly session on pain psychoeducation, lay coach-led self-care and relaxation tips, 2 sessions on social support and communication coaching, self-guided spirituality and meaning coping
62593436|NCT06270875|EXPERIMENTAL|Coached: Basic pain education + self-care + advanced communication + spirituality|1 telephone weekly session on pain psychoeducation, lay coach-led self-care and relaxation tips, 2 sessions on social support and communication coaching, coach-led spirituality and meaning coping
62233782|NCT01114061|EXPERIMENTAL|InsuPatch|The arm with the treatment: using the insupatch device to heat the insulin infusion site.
62233783|NCT03897881|EXPERIMENTAL|mRNA-4157 and Pembrolizumab|Participants will receive up to 9 doses of mRNA-4157 (every 21 days). Participants may continue on pembrolizumab (every 21 days) until disease recurrence, unacceptable toxicity, or they undergo up to 18 total cycles (approximately 1 year of treatment), whichever is sooner.
62233784|NCT03897881|ACTIVE_COMPARATOR|Pembrolizumab|Participants will receive pembrolizumab (every 21 days) until disease recurrence, unacceptable toxicity, or they undergo up to 18 total cycles (approximately 1 year of treatment), whichever is sooner.
62233785|NCT04727918|ACTIVE_COMPARATOR|Cold biopsy forceps (CBF)|Patients will be allocated to the CBF arm after randomization (1:1)
62424658|NCT04296799|EXPERIMENTAL|Multiple Ascending Dose|The study will consist of 3 cohorts (1 cohort per dose level) of 8 subjects. Six subjects will receive study drug and 2 subjects will receive matching placebo, daily for 14 consecutive days, for a total of 24 subjects (18 study drug; 6 placebo).
62424659|NCT05827965|EXPERIMENTAL|patients with secondary adrenal insufficiency|education and treatment adjustment
62424660|NCT06566066||Patients with mutations in SLC16A2|Text
62424661|NCT06566066||Patients with mutations in THRA|Text
62424662|NCT06568653|EXPERIMENTAL|intervention|
62233786|NCT04727918|ACTIVE_COMPARATOR|Cold snare polypectomy (CSP)|Patients will be allocated to the CSP arm after randomization (1:1)
62233787|NCT01694355|EXPERIMENTAL|Vitamin D treatment|We assume that among postmenopausal women, Vitamin D treatment will improve bone mineralization and will cause a rapid increase in BMD.
62424663|NCT06568653|ACTIVE_COMPARATOR|control|
62424664|NCT05166473|EXPERIMENTAL|Telerehabilitation group (n=21)|"This group was conducted with a physiotherapist for video conference-based vestibular rehabilitation exercises, was called the telerehabilitation group (TR). In terms of ease of Use and applicability, the WhatsApp app was preferred. Patients were individually searched for two days a week, 25-30 minutes. The exercises were performed gradually from easy to difficult, initially in a sitting position in accordance with the levels of the patients."
62424665|NCT05166473|ACTIVE_COMPARATOR|Control Group (n=21)|"After the home exercise program, which should be applied twice a day for six weeks, was shown in practice, the home exercise program was given, in which the exercises were visual and written, this group was called the control group. All participants were given a phone number to consult when there were any problems, and were phoned to decry whether they were continuing the exercises."
62424666|NCT01906580|EXPERIMENTAL|Peg-IFNα-2a monotherapy|Participants will receive 180ug peg-IFNα-2a therapy for 72 weeks, and then followed to 96 weeks.
62424667|NCT01906580|EXPERIMENTAL|Sequential therapy|Participants will receive entecavir monotherapy for 12 weeks, and 180ug peg-IFNα-2a therapy is added for the following 12 weeks. After that, entecavir will be stopped and 180ug peg-IFNα-2a monotherapy for the following 48 weeks. All participants will followed to 96 weeks.
62424668|NCT01906580|EXPERIMENTAL|Combination therapy|Participants will receive 180ug peg-IFNα-2a combined with entecavir therapy for 72 weeks, and then followed to 96 weeks.
62424669|NCT04291911||INTENSIVE CARE UNITS|
62424670|NCT01592227|ACTIVE_COMPARATOR|Marketed paracetamol|Marketed paracetamol
62593437|NCT06270875|EXPERIMENTAL|Coached: Basic pain education + basic communication & Self-led: self-care + spirituality|1 telephone weekly session on pain psychoeducation, self-guided self-care and relaxation tips, 1 session on social support and communication coaching, self-guided spirituality and meaning coping
62809876|NCT05233865|EXPERIMENTAL|Water condition|Participants blood pressure, heart rate and self-reported symptoms (such as dizziness) will be collected multiple times during sitting, standing and walking conditions when in a pool.
62233788|NCT04762953|EXPERIMENTAL|SingleArm: Systemic therapy and IP Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis|Patients will receive sequential intraperitoneal paclitaxel along with intravenous paclitaxel, 5-FU, and leucovorin on Days 1 and 8 of every 21 day cycle for 3 months.
62233789|NCT00377247|EXPERIMENTAL|Dendritic Cells w/Tumor DNA|
62233790|NCT03234790|ACTIVE_COMPARATOR|Filtered Air Exposure|Exposure for 4 hours to filtered air
62424671|NCT01592227|EXPERIMENTAL|Experimental paracetamol formulation|Experimental formulations
62424672|NCT06190899|EXPERIMENTAL|Phase 1 Arm 1|Arm 1 - 120 mg of gedatolisib (administered once weekly for 3 weeks on/1 week off) in combination with darolutamide 600 mg (two 300 mg tablets) orally administered twice daily (equivalent to a total daily dose of 1200 mg on Days 1-28 of each cycle)
62424673|NCT06190899|EXPERIMENTAL|Phase 1 Arm 2|Arm 2 - 180 mg of gedatolisib (administered once weekly for 3 weeks on/1 week off) in combination with darolutamide 600 mg (two 300 mg tablets) orally administered twice daily (equivalent to a total daily dose of 1200 mg on Days 1-28 of each cycle)
62809877|NCT05233865|ACTIVE_COMPARATOR|Land condition|Participants blood pressure, heart rate and self-reported symptoms (such as dizziness) will be collected multiple times during sitting, standing, and walking conditions when on land.
62809878|NCT02468817|ACTIVE_COMPARATOR|Treadmill Exercise|2 (two) 1-hour of vigorous exercise bouts under different thermal conditions, one at 16 degrees C and one at 26 degrees C.
62809879|NCT02468817|EXPERIMENTAL|Magnitude of Ca loss during Exercise at 26 degrees Celcius|Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise.
62809880|NCT01590589||REGISTRY participants|"Individuals~* with manifest HD~* unaffected but known to carry the HD mutation~* unaffected but at risk of carrying the HD mutation~* from HD families known not to carry the HD mutation~* from outside HD families acting as control research participants (e.g., spouses)"
62424674|NCT06190899|EXPERIMENTAL|Phase 2|The recommended Phase 2 dose (RP2D) of gedatolisib (administered once weekly for 3 weeks on/1 week off) in combination with darolutamide 600 mg (two 300 mg tablets) orally administered twice daily (equivalent to a total daily dose of 1200 mg on Days 1-28 of each cycle)
62424675|NCT01702766|ACTIVE_COMPARATOR|Bifidobacterium animalis subsp. lactis|
62424676|NCT01702766|PLACEBO_COMPARATOR|Placebo|
62233791|NCT03234790|EXPERIMENTAL|Diesel Exhaust Exposure|Volunteers exposed to different concentrations of diesel exhaust
62233792|NCT03384654|EXPERIMENTAL|Cohort 1: B-Cell Acute Lymphoblastic Leukemia (ALL)/LL|Cohort 1 will include participants with B cell ALL/LL in second or greater relapse or refractory to at least 2 prior induction regimens. Participant will receive daratumumab in combination with vincristine and prednisone.
62233793|NCT03384654|EXPERIMENTAL|Cohort 2: T-Cell ALL/LL|Cohort 2 will include participants with T-cell ALL/LL in first relapse or refractory to at least 1 prior induction/consolidation regimen. Participant will receive daratumumab in combination with vincristine, prednisone, doxorubicin and peg-asparaginase in Cycle 1 and daratumumab in combination with cyclophosphamide, cytarabine, 6- mercaptopurine and methotrexate in Cycle 2.
62593438|NCT06270875|EXPERIMENTAL|Coached: Basic pain education + basic communication + spirituality & Self-led: self-care|1 telephone weekly session on pain psychoeducation, self-guided self-care and relaxation tips, 1 session on social support and communication coaching, coach-led spirituality and meaning coping
62593439|NCT06270875|EXPERIMENTAL|Coached: Basic pain education + advanced communication & Self-led: self-care + spirituality|1 telephone weekly session on pain psychoeducation, self-guided self-care and relaxation tips, 2 sessions on social support and communication coaching, self-guided spirituality and meaning coping
62593440|NCT06270875|EXPERIMENTAL|Coached: Basic pain education + advanced communication + spirituality & Self-led: self-care|1 telephone weekly session on pain psychoeducation, self-guided self-care and relaxation tips, 2 sessions on social support and communication coaching, coach-led spirituality and meaning coping
62593441|NCT06270875|EXPERIMENTAL|Coached: advanced pain education + self-care + basic communication & Self-led: spirituality|2 telephone weekly sessions on pain psychoeducation, lay coach-led self-care and relaxation tips, 1 session on social support and communication coaching, self-guided spirituality and meaning coping
62593442|NCT06270875|EXPERIMENTAL|Coached: advanced pain education + self-care + basic communication + spirituality|2 telephone weekly sessions on pain psychoeducation, lay coach-led self-care and relaxation tips, 1 session on social support and communication coaching, coach-led spirituality and meaning coping
62593443|NCT06270875|EXPERIMENTAL|Coached: advanced pain education + self-care + advanced communication & Self-led: spirituality|2 telephone weekly sessions on pain psychoeducation, lay coach-led self-care and relaxation tips, 2 sessions on social support and communication coaching, self-guided spirituality and meaning coping
62593444|NCT06270875|EXPERIMENTAL|Coached: advanced pain education + self-care + advanced communication + spirituality|2 telephone weekly sessions on pain psychoeducation, lay coach-led self-care and relaxation tips, 2 sessions on social support and communication coaching, coach-led spirituality and meaning coping
62033530|NCT04973280||Healthcare Professionals (HCPs)|The PASS will be conducted among HCPs in a representative sample of EEA countries where REBLOZYL is commercially available. A sample of HCPs from EEA countries who manage care for patients with certain haematologic conditions and who may/do prescribe REBLOZYL will be recruited from the target population of HCPs who were sent the REBLOZYL aRMMs in these countries. The final list of countries to be included may include 1) only countries where reimbursement has been sought and gained, 2) a geographically representative sample (e.g., northern, southern, eastern, and western EU Members States to the degree possible based on the first criteria), 3) a mixture of countries with higher and lower REBLOZYL usage, and 4) other feasibility considerations such as the ability to conduct direct-to-HCP non-market research studies.
62033531|NCT01938755|EXPERIMENTAL|levobupivacaine I|group that was administered levobupivacaine plus 60mg dextrose
62033532|NCT01938755|EXPERIMENTAL|levobupivacaine II|group that was administered levobupivacaine plus 80 mg dextrose
62033533|NCT01938755|EXPERIMENTAL|levobupivacaine III|group that was administered levobupivacaine plus 100 mg dextrose
62033534|NCT04304144|EXPERIMENTAL|Part A: CAEL-101 combined with SoC CyBorD|CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. The initial cohort dose assignments of CAEL-101 will be: Cohort 1 - 500 mg/m\^2 Cohort 2 - 750 mg/m\^2 Cohort 3 - 1000 mg/m\^2. CAEL-101 will be administered weekly for the first 4 weeks, and then every other week until end of study, in combination with the SoC CyBorD chemotherapy. Patients will be treated until death, unacceptable toxicity, symptomatic deterioration, Investigator decision, patient decision or Sponsor decision to terminate the study. Patients from Part A who are in the Continued Treatment Period and who, in the Investigator's judgment, should have their SoC treatment complemented with daratumumab may do so (Part B).
62033535|NCT04304144|EXPERIMENTAL|Part B: CAEL-101 combined with SoC CyBorD and daratumumab|CAEL-101 is administered as an intravenous (IV) infusion at the RP3D dose level. CAEL-101 will be administered weekly for the first 4 weeks, and then every other week until end of study, in combination with the SoC CyBorD chemotherapy and daratumumab. After completing approximately 50 weeks of treatment, participants may switch to an alternative maintenance dosing regimen of every four weeks (q4wk), if agreed upon by the Investigator and the Sponsor Medical Monitor. Patients will be treated until death, unacceptable toxicity, symptomatic deterioration, Investigator decision, patient decision or Sponsor decision to terminate the study.
62033536|NCT00722761|ACTIVE_COMPARATOR|Drosperinone and Ethinyl estradiol|Drospirenone and Ethinyl estradiol (3mg/0.02mg)(YAZ)tablet once a day
62033537|NCT00722761|PLACEBO_COMPARATOR|Placebo tablet|Placebo tablet once a day
62033538|NCT01314651|EXPERIMENTAL|Sleep Management|Instructions in stimulus control and sleep restriction.
62033539|NCT01314651|SHAM_COMPARATOR|Lifestyle Modification|Instructions to change general lifestyle habits (maintain consistent liquid consumption, range of motion exercises, etc.)
62033540|NCT04560257|EXPERIMENTAL|Group intervene with HFNC|Review effect of HFNC as clinical trial among hospitalized patients with COVID-19 infection.
62033541|NCT03435133|ACTIVE_COMPARATOR|Prasugrel|
62033542|NCT03435133|ACTIVE_COMPARATOR|Ticagrelor|
62233794|NCT03702556|ACTIVE_COMPARATOR|Mastectomy without breast reconstruction|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
62033543|NCT03899883|EXPERIMENTAL|Pegloticase|Single administration of pegloticase (8 mg IV in 250 mL 0.9% normal saline)
62233795|NCT03702556|ACTIVE_COMPARATOR|Breast reconstruction with nerve|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
62233796|NCT03702556|ACTIVE_COMPARATOR|Breast reconstruction without nerve|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
62593445|NCT06270875|EXPERIMENTAL|Coached: advanced pain education + basic communication & Self-led: self-care+ spirituality|2 telephone weekly sessions on pain psychoeducation, self-guided self-care and relaxation tips, 1 session on social support and communication coaching, self-guided spirituality and meaning coping
62593446|NCT06270875|EXPERIMENTAL|Coached: advanced pain education + basic communication + spirituality & Self-led: self-care|2 telephone weekly sessions on pain psychoeducation, self-guided self-care and relaxation tips, 1 session on social support and communication coaching, coach-led spirituality and meaning coping
62033544|NCT02605980||Male|Community-dwelling healthy older adults over the age of 70 years. Must be ambulatory, with or without walking aids
62033545|NCT02605980||Female|Community-dwelling healthy older adults over the age of 70 years. Must be ambulatory, with or without walking aids
62033546|NCT04545541|EXPERIMENTAL|Nebulised heparin|"Participants assigned to nebulised UFH will receive nebulised UFH in addition to the standard care required as determined by the treating team. Nebulised UFH (25,000 Units in 5 mL) will be administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days."
62424677|NCT01383954|OTHER|Diclofenac gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
62593447|NCT06270875|EXPERIMENTAL|Coached: advanced pain education + advanced communication & Self-led: self-care+ spirituality|2 telephone weekly sessions on pain psychoeducation, self-guided self-care and relaxation tips, 2 sessions on social support and communication coaching, self-guided spirituality and meaning coping
62593448|NCT06270875|EXPERIMENTAL|Coached: advanced pain education + advanced communication + spirituality & Self-led: self-care|2 telephone weekly sessions on pain psychoeducation, self-guided self-care and relaxation tips, 2 sessions on social support and communication coaching, coach-led spirituality and meaning coping
62033547|NCT04545541|NO_INTERVENTION|Control group|"Participants assigned to 'standard care' will receive the standard care required as determined by the treating team and will not be treated with nebulised heparin (Australia, Ireland).~Participants assigned to placebo will receive Nebulised 0.9% Sodium Chloride (5 mL) administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days (USA)."
62233797|NCT04250987|EXPERIMENTAL|IC connected to a sensor|Single use of a IC connected to a sensor
62593449|NCT03341442|EXPERIMENTAL|No hip precautions|No hip precautions practiced after THA surgery
62593450|NCT03341442|NO_INTERVENTION|Hip precautions|Hip precautions practiced per standard of care after THA surgery
62593451|NCT06080880|EXPERIMENTAL|Ondansetron every 3 weeks combined with aprepitant and dexamethasone|
62593452|NCT06080880|EXPERIMENTAL|Ondansetron weekly combined with aprepitant and dexamethasone|
62593453|NCT01329809|EXPERIMENTAL|JX-594 Intravenous infusion|JX-594 will be administered intravenously to patients with measurable intra-hepatic disease who are not eligible for intratumoral injection of JX-594.
62593454|NCT01329809|EXPERIMENTAL|JX-594 Intratumoral Injection|JX-594 will be injected directly into the liver tumor of patients who have at least two measurable intra-hepatic tumors, one of which must be at least 1.5cm in diameter and safety injectable.
62593455|NCT05127850|EXPERIMENTAL|Consultation audio recording|"Instructions on installation and detailed use of chosen application will be provided before an upcoming oncology visit. Research staff will contact the participant and encourage a practice recording session. 15-30 minutes prior to the consultation, research staff will send an anonymous text message to the participants' mobile device with a reminder to record the visit. Three days after the consultation, research staff will send an anonymous text reminder message to the participants' mobile device to listen to the recording."
62593456|NCT00575718|ACTIVE_COMPARATOR|1|Hospital Counseling + Nicotine Replacement Therapy (HC+NRT)
62593457|NCT00575718|EXPERIMENTAL|2|Hospital Counseling + Nicotine Replacement Therapy + Pre-surgical Schedule Reduced Smoking (HC+NRT+PS/SRS)
62593458|NCT05416983||Observational (discussion)|Patient and clinician discussions are observed to support refinement of a decision aid. Clinicians may use a prototype of the decision aid in discussions with their patients and may complete a questionnaire.
62593459|NCT02337452||Observational (family outreach program)|Patients communicate with at-risk family members to share genetic test results and other relevant information, as well as to learn more about their disease via family outreach program website. At risk family members are then contacted by a study coordinator or genetic counselor for further follow up. At-risk relatives receive resources to facilitate understanding of their at-risk status and to facilitate predictive testing.
62593460|NCT02360631|EXPERIMENTAL|Chantix (varenicline)|Participants will receive 1mg pills to take twice a day for 12 weeks.
62593461|NCT02360631|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo pill to take twice a day for 12 weeks.
62593462|NCT05523193||Treatment group|"Treatment group (Formal treatment model group): Patients who agree and accept the surgical treatment recommendation (including medical and surgical treatment) enter the formal treatment model group.~Those who have received any of the following treatments (including but not limited to) as recommended by the standardized treatment process are considered to have received the standardized treatment, otherwise, they have not.~1. Surgical procedures: valve repair or replacement, left auricular ligation, left auricular clip.~2. Internal surgery: transcatheter valve replacement, radiofrequency ablation of atrial fibrillation, and left heart ear occlusion."
62233798|NCT01488487|EXPERIMENTAL|Everolimus + pasireotide|Oral Everolimus 7.5 mg administered daily for 28 days per cycle, plus pasireotide Long Acting Release (LAR) 60 mg administered by intramuscular injection once per 28 day cycle on day 1.
62233799|NCT03379922|EXPERIMENTAL|Stress balls|The first arm will be given stress balls to squeeze during their treatment and will also receive standard care (the offer of oral analgesia)
62424678|NCT02845102|EXPERIMENTAL|Pre-Post Feasibility Testing|The pre-post feasibility testing/ intervention includes the use of tablet technology and cognitive behavioral therapy (CBT) for depression and self-management education for patients with chronic illness and/or chronic pain and depression. The pre-post feasibility testing phase will include 25 subjects. The total duration of pre-post feasibility testing will be 6 weeks upon the retrieval of the RA-CBT tablet and the inclusion of follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview.
62424679|NCT05863182|EXPERIMENTAL|Intervention Group|Students and parents attending the intervention school, will participate in the family-based intervention.
62424680|NCT05863182|NO_INTERVENTION|Comparison Group|Students and parents attending the non-intervention school will not receive the intervention and serve as comparison group.
62593463|NCT05523193||Control group|Control group（Conventional treatment model group）:Patients who do not agree to enter the Formal treatment model group will automatically enter the Conventional treatment model group.
62593464|NCT03495674|EXPERIMENTAL|Group I (FITBIT, cycling)|Starting on day 15, participants wear FITBIT and complete cycling classes over 45 minutes 3 times a week for a total of 12 classes a month for up to 1 year.
62593465|NCT03495674|ACTIVE_COMPARATOR|Group II (FITBIT, information)|Starting on day 15, participants receive information about exercise guidelines and wear FITBIT to track heart rate and activities for up to 1 year.
62809881|NCT01045486|ACTIVE_COMPARATOR|Group A|Group A received active medication (ATP mixed probiotics) for 6 weeks followed by a crossover to 6 weeks of placebo after 4-weeks washout period.
62809882|NCT01045486|PLACEBO_COMPARATOR|Group B|Group B received placebo medication for 6 weeks followed by a crossover to 6 weeks of active medication (ATP mixed probiotics) after 4-weeks washout period.
62424681|NCT06265961|ACTIVE_COMPARATOR|Education group|Among the nurses who meet the inclusion criteria (N = 30), 15 nurses will be assigned to the education group after the randomization process at the beginning of the study.
62424682|NCT06265961|ACTIVE_COMPARATOR|Bibliotherapy group|Among the nurses who meet the inclusion criteria (N = 30), 15 nurses will be assigned to the bibliotherapy group after the randomization process at the beginning of the study.
62033548|NCT00081367|EXPERIMENTAL|Cognitive behavioral therapy (CBT) + standard care|Participants will receive ten weekly sessions of treatment plus standard care for suicide prevention.
62593466|NCT02479698|EXPERIMENTAL|Treatment (BK-specific cytotoxic T lymphocytes)|Patients receive allogeneic BK-specific cytotoxic T-lymphocytes IV over 30 minutes. Patients achieving partial response, stable disease, or progressive disease are eligible for 19 additional infusions of CTL occurring at least 2 weeks after the previous CTL infusion if they meet the eligibility criteria for subsequent therapy.
62809883|NCT01045460|EXPERIMENTAL|ASCT + MILs|Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4.
62809884|NCT01045460|EXPERIMENTAL|ASCT + MILs + vaccine|Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4. The allogeneic myeloma vaccine will be administered on Days 21, 60, 180, and 300.
62233800|NCT03379922|EXPERIMENTAL|Headphones|The second arm will be given headphones to listen to music during their treatment and will also receive standard care.
62809885|NCT05093816|EXPERIMENTAL|Common Elements Tooplbox|
62233801|NCT03379922|NO_INTERVENTION|Control|The control group will receive standard care (the offer of oral analgesia)
62809886|NCT05093816|NO_INTERVENTION|Wait-list control|
62809887|NCT02160756|ACTIVE_COMPARATOR|Treatment A|Single oral dose of JNJ-56021927 240 milligram (mg) softgel capsule on Day 1.
62809888|NCT02160756|EXPERIMENTAL|Treatment B|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
62809889|NCT02160756|EXPERIMENTAL|Treatment C|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
62809890|NCT02160756|EXPERIMENTAL|Treatment D|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
62033549|NCT00081367|ACTIVE_COMPARATOR|Standard care alone|Participants will receive standard care for suicide prevention.
62243400|NCT06725147|EXPERIMENTAL|Elomia - Digital Mental Health Chatbot|"Participants randomized to Elomia will be expected to use the intervention at least once per week (for around 30 minutes) but are encouraged to use as needed/wanted. Elomia is a generative AI program that can respond to text the user types in with unique responses that are designed to address therapeutic targets like stress, anxiety, procrastination, feeling overwhelmed and so on. Elomia was trained by real therapists with expertise in cognitive-behavioral therapy who responded to many different real people typing about their concerns. Thus, Elomia can suggest a number of different evidence based therapeutic strategies and can help the user process negative feelings, think through problems, plan solutions, and trouble shoot things that might get in the way of implementing those strategies."
62424683|NCT04000373|OTHER|gait training with exoskeleton device|uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
62424684|NCT00763269|EXPERIMENTAL|A|sensitive toothpaste
62593467|NCT02414178||Experimental F 18 T807|
62593468|NCT05167370|EXPERIMENTAL|Amifostine|
62809891|NCT01469221|EXPERIMENTAL|Apaziquone|Apaziquone (4 mg in 40 mL)
62809892|NCT01469221|PLACEBO_COMPARATOR|Placebo|Matching placebo (40 mL)
62809893|NCT01417546|EXPERIMENTAL|1|NHS-IL12 escalating doses on a 4 week schedule (Completed).
62809894|NCT01417546|EXPERIMENTAL|2|NHS-IL12 escalating doses on a 2 week schedule
62809895|NCT01417546|EXPERIMENTAL|3|NHS-IL12 expansion group on a 4 week schedule (Completed).
62809896|NCT02542046||Barium|Patients who received barium sulfate oral contrast for abdominopelvic CT
62233802|NCT02302404|EXPERIMENTAL|Cohort 1: GSK2982772 Single Ascending Dose (Part A) (0.1-10mg)|Eight subjects will be randomized equally (1:1:1:1) to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2982772 + 1 placebo dose). The subjects will fast overnight from Day -1 to Day 1 of the treatment period. Two of the 8 subjects will be randomized to the dosing on Day 1 as sentinel dosing. Assuming adequate safety in the judgment of the Principal Investigator (e.g., vital signs, ECGs, and adverse events) through approximately 24 hours; the remaining 6 subjects may be randomized to dosing on the following day. Subjects will receive single planned doses of GSK2982772 as 0.1, 0.5, 2.5, and 10mg. A sequential design will be used including approximately weekly dose escalations while allowing for a sufficient washout period. The proposed doses may be adjusted based on emerging safety and PK
62233803|NCT02302404|EXPERIMENTAL|Cohort 2: GSK2982772 Single Ascending Dose (Part A) (40-240mg)|Eight subjects will be randomized equally to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having 4 dose periods (3 active dose of GSK2982772 +1 placebo dose). The subjects will fast overnight from Day -1 to Day 1 of the treatment period. Two of the 8 subjects will be randomized to the dosing on Day 1 as sentinel dosing. Assuming adequate safety in the judgment of the Principal Investigator (e.g., vital signs, ECGs, and adverse events) through 24 hours; the remaining 6 subjects may be randomized to dosing on the following day. Subjects will receive single planned doses of GSK2982772 as 40, 100, 180, and 240 mg. A sequential design with weekly dose escalations and sufficient washout period will be used. The proposed doses may be adjusted based on emerging safety and PK. After the completion of the fasted treatment periods, subjects will receive a high fat meal within 30 minutes of dosing with GSK2982772 during a final treatment period.
62424685|NCT00763269|ACTIVE_COMPARATOR|B|Triclosan control toothpaste
62809897|NCT02542046||diatrizoate|Patients who received diatrizoate oral contrast for abdominopelvic CT
62809898|NCT02542046||iohexol|Patients who received iohexol oral contrast for abdominopelvic CT
62809899|NCT04875884|EXPERIMENTAL|MRI group|Subjects enrolled in this study will undergo both standard and new MRI techniques. The standard MRI is needed for your routine care and as ordered by the referring doctor. The new MRI is performed for research purposes. Participants will be imaged with both methods and the results will be compared.
62809900|NCT06316908|ACTIVE_COMPARATOR|Unilateral Approach Group|Patients in this group have received a unilateral percutaneous posterior approach for NCPB. The procedure was performed under fluoroscopic guidance
62809901|NCT06316908|ACTIVE_COMPARATOR|Bilateral Approach Group|Patients in this group have undergone a bilateral percutaneous posterior approach for NCPB, following the same procedural guidance.
62809902|NCT01271777|EXPERIMENTAL|GFT505 80mg|
62424686|NCT01274273|EXPERIMENTAL|Interleukin-2, interferon, bevacizumab|
62424687|NCT01274273|ACTIVE_COMPARATOR|Interleukin-2 and interferon-alfa|
62809903|NCT01271777|PLACEBO_COMPARATOR|Matching placebo|
62809904|NCT03755921|EXPERIMENTAL|Brief and intensive therapy|exercises for swallowing (strength and mobility of oral and pharyngeal muscles) controlling the number of series according to each participant, daily
62809905|NCT03755921|ACTIVE_COMPARATOR|Therapy Weekly|exercises for swallowing (strength and mobility of oral and pharyngeal muscles) controlling the number of series according to each participant, weekly
62809906|NCT00668148|EXPERIMENTAL|IMC-A12 (cixutumumab)|
62809907|NCT03111875|ACTIVE_COMPARATOR|Routine thermal management|Patients assigned to routine thermal management will not be pre-warmed and ambient intraoperative temperature will be maintained near 20°C per routine. Only transfused blood will be warmed. An Multi-Position Upper Body Warming Blanket forced-air cover will be positioned over an appropriate non-operative site, but will not initially be activated. Should core temperature decrease to 35.5°C, the warmer will be activated as necessary to prevent core temperature from decreasing further.
62233804|NCT02302404|EXPERIMENTAL|Cohort 3: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in the Part A data
62233805|NCT02302404|EXPERIMENTAL|Cohort 4: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in Part A or any preceding repeat dose cohorts in Part B
62424688|NCT01374880||Dyspnea cohort|Dyspnea cohort
62233806|NCT02302404|EXPERIMENTAL|Cohort 5: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in the Part A or any preceding repeat dose cohorts in Part B.
62233807|NCT02302404|EXPERIMENTAL|Cohort 6: GSK2982772 Single Ascending Dose (Part A)|This additional cohort in Part A of the study will only be conducted to allow for evaluation of additional dose levels or repeated evaluation of a dose level already studied. Doses will be selected based on the safety, tolerability, and PK data from Part A and/or previous Part B cohorts. Eight subjects will be randomized equally (1:1:1:1) to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2982772 + 1 placebo dose). The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B.
62233808|NCT02302404|EXPERIMENTAL|Cohort 7: GSK2982772 Repeat Dose (Part B)|This additional cohort in Part B of the study will only be conducted to allow for evaluation of additional dose levels or repeated evaluation of a dose level already studied Doses will be selected based on the safety, tolerability, and PK data from Part A and/or previous Part B cohorts. Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B.
62233809|NCT06015425|EXPERIMENTAL|YMS-201B+|transcranial Direct Current Stimulation (tDCS) application 5 \~7 days a week for 4 weeks (total of 20\~28 applications)
62233810|NCT00911794|EXPERIMENTAL|Written Disclosure Therapy|
62233811|NCT00911794|SHAM_COMPARATOR|Controls|
62424689|NCT01374880||Stable chronic heart failure|Stable chronic heart failure
62424690|NCT01374880||Valvular heart disease|Valvular heart disease
62424691|NCT01374880||Ventricular assist device|Ventricular assist device
62593469|NCT06561360|EXPERIMENTAL|Vemurafenib plus Obinutuzumab|Patients assigned to the study arm will receive vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered on days 1, 8 and 15 during the cycle 2 and every 4 weeks during the cycle 3 and 4 of treatment.
62809908|NCT03111875|EXPERIMENTAL|Aggressive thermal management|"Patients assigned to aggressive warming will be pre-warmed with a full-body Bair Hugger or Bair Paws cover for ≈30 minutes before induction of anesthesia. The warmer will initially be set to high which corresponds to ≈43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be aggressively warmed during surgery to a target intraoperative core temperature between 37 and 37.5°C, using an Multi-Position Upper Body and Full Access Underbody Warming Blankets forced-air covers when clinically practical. All intravenous fluids will be warmed to body temperature."
62033550|NCT04858269|EXPERIMENTAL|Combination of Chemotherapy and Immunotherapy|The intervention will be administered on an outpatient basis. The treatment regimen will consist of combination chemotherapy and immunotherapy administered as: Pembrolizumab PLUS Carboplatin PLUS Paclitaxel.
62233812|NCT02634346|EXPERIMENTAL|ALKS 3831|Administered as a coated bilayer tablet
62233813|NCT02634346|ACTIVE_COMPARATOR|Olanzapine|Administered as a coated bilayer tablet
62233814|NCT02634346|PLACEBO_COMPARATOR|Placebo|Administered as a coated bilayer tablet
62233815|NCT05854433||Myotonic dystrophy type 2|"Adults with myotonic dystrophy type 2 who meet all inclusion and exclusion criteria for the study.~To be assessed at the baseline visit: Medical history and a focused neurological examination, brain MRI, a comprehensive Clinical Assessment Battery (CAB) of cognitive and motor measures, self-reported questionnaires, strength and motor function evaluation, and blood drawn for biomarker analysis.~A subset of the participants who agree to have cerebrospinal fluid (CSF) collection for additional biomarker analysis will undergo lumbar puncture procedure."
62424692|NCT01374880||Cardiac arrest|Cardiac arrest
62424693|NCT01374880||Cardiac rehabilitation|Cardiac rehabilitation
62424694|NCT05084807|OTHER|Healthy group|A group of healthy, strictly asymptomatic individuals of both sexes and different age groups.
62424695|NCT00866528|EXPERIMENTAL|Phase I|oral pazopanib once daily (Phase I starting dose 800 mg) and paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
62424696|NCT02034617|NO_INTERVENTION|Standard care|The family receive standard care when enrolled in the Neonatal intensive care unit
62593470|NCT06561360|ACTIVE_COMPARATOR|Standard treatment of Cladribine plus Rituximab|Patients assigned to the SOC arm will receive cladribine IV on days 1-5 concurrently with rituximab IV per week for 8 times, i.e., weekly x8 from day 1.
62424697|NCT02034617|EXPERIMENTAL|Observation|The family receive standard care when enrolled in the Neonatal intensive care unit and are also included in an observational program called LiMoNid.
62593471|NCT03957603|EXPERIMENTAL|TPF-DM Combined with Medical Nutrition Therapy Intervention|Participants in the experimental group will be provided with an individualized dietary, nutrition recommendation and the additional Enteral Nutrition Suspension (TFP-DM, Diason 0.75 kcal/ml). Participants are required to schedule the first follow-up visit one week after receiving the individualized recommendations. Afterward, the regularly scheduled follow-up visit will be scheduled every two to four weeks.
62233816|NCT05854433||Controls|"Healthy individuals who meet all inclusion and exclusion criteria for healthy controls.~To be assessed at the baseline visit: Medical history and a focused neurological examination, brain MRI, a comprehensive Clinical Assessment Battery (CAB) of cognitive and motor measures, self-reported questionnaires, strength and motor function evaluation, and blood drawn for biomarker analysis.~A subset of the participants who agree to have cerebrospinal fluid (CSF) collection for additional biomarker analysis will undergo lumbar puncture procedure."
62233817|NCT06168188|EXPERIMENTAL|Neulasta|The 0.15 mL of Neulasta will be filled into 1 mL of syringe equipped with 30 gauge beveled needle for intravitreal injection.
62593472|NCT03957603|ACTIVE_COMPARATOR|Medical Nutrition Therapy Intervention|Based on the standard care, Participants will receive an individualized dietary, nutrition recommendations with the application of food exchange porting. Participants are required to schedule the first follow-up visit one week after receiving the individualized recommendations. Afterward, the regularly scheduled follow-up visit will be scheduled every two to four weeks.
62233818|NCT02750150|EXPERIMENTAL|Freezed-dried plasma|transfusion of 4 units of freezed dried plasma when available in patients at risk pf massive bleeding (transfusion of 4 red blood cells units in the first 6 hours after trauma)
62233819|NCT02750150|ACTIVE_COMPARATOR|Fresh-frozen plasma|transfusion of 4 units of fresh frozen plasma when available in patients at risk pf massive bleeding (transfusion of 4 red blood cells units in the first 6 hours after trauma)
62233820|NCT03061630|EXPERIMENTAL|gemcitabine|cisplatin 60 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15. On day 1
62593473|NCT01003704||General Anesthesia only|
62593474|NCT01003704||Peripheral nerve block|
62233821|NCT00447382|ACTIVE_COMPARATOR|NN304|Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
62233822|NCT00447382|EXPERIMENTAL|NN729|Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
62233823|NCT01589666|EXPERIMENTAL|Spray-dried S/D-treated plasma|"Resusix (Spray-Dried Solvent/Detergent-Treated Plasma) uses source plasma from U.S.-licensed facilities as the starting material. Source plasma donors are selected from the AB blood type, which is considered a universal product."
62593475|NCT01003704||spinal|
62593476|NCT06561464|ACTIVE_COMPARATOR|Group A: EzPAP® will be applied|"This group, selected randomly and allocated to non-invasive ventilation (NIV) indication, will receive EzPAP® as a single-blind randomized trial.~Non-Invasive Indications for Acute Exacerbations of COPD:~(At least two of the following parameters must be present)~* Moderate to severe dyspnea leading to the use of accessory respiratory muscles and paradoxical abdominal movements,~* Tachypnea (respiratory rate \> 25 breaths per minute),~* Arterial blood gas (ABG) results with pH \< 7.35, pCO2 \> 45 mmHg, or~* PaO2/FiO2 \< 200 mmHg"
62593477|NCT06561464|ACTIVE_COMPARATOR|Group B: NIMV will be applied.|"This group, selected randomly and allocated to non-invasive ventilation (NIMV) as a single-blind randomized trial, NIMV provides respiratory support during both expiration and inspiration with either continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP), which operates with intermittent positive pressure.~Non-Invasive Indications for Acute Exacerbations of COPD:~(At least two of the following parameters must be present)~* Moderate to severe dyspnea leading to the use of accessory respiratory muscles and paradoxical abdominal movements,~* Tachypnea (respiratory rate \> 25 breaths per minute),~* Arterial blood gas (ABG) results with pH \< 7.35, pCO2 \> 45 mmHg, or~* PaO2/FiO2 \< 200 mmHg"
62593478|NCT04001387||Spinal anesthesia|
62593479|NCT05855590|EXPERIMENTAL|tranexamic acid|A total of 20 patients were included: 9 patients in the tranexamic acid group
62593480|NCT05855590|PLACEBO_COMPARATOR|placebo|A total of 20 patients were included: 11 patients in the control group using 0.9% isotonic saline solution.
62593481|NCT05043597|EXPERIMENTAL|Thrombus aspiration|
62033551|NCT04357574||Radiation Oncology Providers|Faculty physicians, residents and advanced practice providers in the Radiation Oncology Department in Duke University Health System (DUHS)
62033552|NCT00152776|PLACEBO_COMPARATOR|Group I|ovaria comp 10 Globuli 3 times per day 24 weeks - Placebo 12 weeks
62033553|NCT00152776|PLACEBO_COMPARATOR|Group II|Placebo 12 weeks - ovaria comp 10 globuli 3 times per day 24 weeks
62233824|NCT02844049|ACTIVE_COMPARATOR|Deep Brain Stimulation|DBS surgical procedure scheduled and realized
62233825|NCT02844049|NO_INTERVENTION|Control group|medical treatment (psycho- and pharmaco-therapy) will continue to be given and optimized according to the defined BMT strategies and criteria
62424698|NCT02255734|ACTIVE_COMPARATOR|Zovirax|
62424699|NCT02255734|EXPERIMENTAL|Virless|
62424700|NCT06500039|ACTIVE_COMPARATOR|Intervention group|Participants will implement positive psychological interventions at home for four weeks. In the first two weeks, they will do the three good things in life exercise, in the third week, they will write a gratitude letter, and in the fourth week, they will write five things they are grateful for. Participants will be given a guide booklet to write on.
62424701|NCT06500039|PLACEBO_COMPARATOR|Kontrol group|Control group participants will practice writing their daily routines for four weeks. They will write a few sentences about the nutrition routine in the first week, the hygiene routine in the second week, the sleeping routine in the third week, and the shopping routine in the fourth week. Participants will be given a guide booklet for the writing exercise.
62593482|NCT05043597|NO_INTERVENTION|control group|
62593483|NCT05889364||Sample N1|"(n=140) with ratio normal: tuberculosis 50:50"
62593484|NCT05889364||Sample N2|"(n=150) with ratio normal: tuberculosis 95:5"
62593485|NCT00672386|EXPERIMENTAL|001|JNJ16269110 5 mg twice daily for 12 weeks
62593486|NCT00672386|EXPERIMENTAL|002|JNJ16269110 10 mg twice daily for 12 weeks
62593487|NCT00672386|EXPERIMENTAL|003|JNJ16269110 15 mg twice daily for 12 weeks
62033554|NCT00152776|PLACEBO_COMPARATOR|Group III|ovaria comp 10 globuli 3 times per day 12 weeks - Placebo 12 weeks - ovaria comp 10 globuli 3 times per day 12 weeks
62233826|NCT03418337|EXPERIMENTAL|dexilansoprazole group (Dexilant 60 mg)|After randomization, 60 subjects will receive oral dexlansoprazole (Dexilant 60 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks. Subjects will record their symptoms (cough, globus, NCCP, heart burn, and acid regurgitation) at daytime and nighttime everyday for 8 weeks. Symptoms suspecting drug adverse effect including nausea, diarrhea, constipation, headache, dizziness, fatigue, flatulence, etc will be recorded for 8 weeks.
62233827|NCT03418337|ACTIVE_COMPARATOR|lansoprazole group (Takepron OD 30 mg)|After randomization, 60 subjects will receive oral lansoprazole (Takepron OD 30 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks. Subjects will record their symptoms (cough, globus, NCCP, heart burn, and acid regurgitation) at daytime and nighttime everyday for 8 weeks. Symptoms suspecting drug adverse effect including nausea, diarrhea, constipation, headache, dizziness, fatigue, flatulence, etc will be recorded for 8 weeks.
62233828|NCT01849822|EXPERIMENTAL|Neural Prosthetic System|The Neural Prosthetic System consists of two Neuroport Arrays, which are described in detail in the intervention description. Both Neuroport Arrays are inserted into the posterior parietal cortex, an area of the brain used in reach and grasp planning. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subjects will participate in study sessions 3-5 times per week in which they will learn to control an end effector by thought. They will then use the end effector to perform various reach and grasp tasks.
62233829|NCT00336752|ACTIVE_COMPARATOR|1|Non operative treatment of Weber B ankle fracture. Use of cast, with no surgical intervention
62233830|NCT00336752|ACTIVE_COMPARATOR|2|Operative treatment of Weber B ankle fracture. Open reduction and internal fixation to repair a broken bones.
62233831|NCT04572412|EXPERIMENTAL|Low Dose Radiotherapy|Low Dose Radiotherapy
62233832|NCT06294522|EXPERIMENTAL|reconstruction of alveolar cleft|gingival mucoperiosteal flaps are designed along the cleft margins and elevated. These flaps are raised up and then are separated from the nasal mucosa the palatal mucoperiosteal flaps along the cleft margins are then elevated from the palate. After complete exposure of all the bony clefts, the nasal lining of the nostril floor is approximated and sutured, and the palatal flaps are then turned back and sutured to make a soft-tissue pocket. Grafting of the defect is accomplished with cortical bone only from the chin the cortical shelf is prepared to be two layers perpendicular to each other the first one is parallel to the nasal floor and second one is continuous with buccal cortex of alveolar ridge then cancellous bone will be packed under these shelves and be compressed into the cleft defects.
62233833|NCT04854629|EXPERIMENTAL|Spinomed active orthosis|Wearing the orthosis for 16 weeks
62233834|NCT04854629|NO_INTERVENTION|Control group|No intervention: non spinomed active control
62233835|NCT02640885|EXPERIMENTAL|Foley's cather tamponade|Balloon tamponade with 2-way Foley's Cather was successfully used during cesarean section due to sever postpartum haemorrhage after failure of medical treatment.
62233836|NCT01581151|ACTIVE_COMPARATOR|Monthly Ranibizumab|"• Patients will receive a ranibizumab intravitreal injection on day 0. During each other visit, patients will receive a ranibizumab intravitreal injection. The protocol will use the term monthly to represent a 30 day interval between treatments."
62424702|NCT01128153|EXPERIMENTAL|Saxagliptin 5 mg once daily|
62424703|NCT01128153|PLACEBO_COMPARATOR|Placebo once daily|
62424704|NCT03213080||TLD Procedure|All subjects who are enrolled and meet the eligibility criteria will undergo Targeted Lung Denervation (TLD). TLD is a bronchoscopically-guided, minimally-invasive procedure using the Nuvaira™ Lung Devervation System. The Nuvaira System is intended for the long-term maintenance treatment of airway obstruction associated with COPD. TLD uses radiofrequency (RF) energy to ablate the airway nerve trunks of the vagus nerves that travel parallel to and outside of the main bronchi and into the lungs. Ablation of the nerves opens the airways and makes breathing easier.
62424705|NCT06416761||Patients with acute or chronic nephropathy|"1. Patients with chronic nephropathies~2. Patients with acute nephropathy~3. Patients with nephrectomy~4. Candidate Patients to major surgery~5. Patients with decompensated heart failure undergoing either medical or surgical therapy~6. Acute critically ill patients (e.g sepsis, post-operative)~7. Patients with hypertension~8. Patients with hematologic cancer exposed to chemotherapeutic agents or undergoing allogeneic bone marrow transplantation.~9. Long-term surviving patients who received bone marrow transplantation."
62593488|NCT00672386|PLACEBO_COMPARATOR|004|Placebo twice daily for 12 weeks
62593489|NCT06210776||Cohort A|Patients with unresectable or metastatic HER2+ breast cancer who have received one or more prior anti-HER2-based regimens.
62424706|NCT00740480||Surgical|Adult population (ages 18-65) with clinically significant nasal septum deviation.
62424707|NCT02634567|NO_INTERVENTION|Treatment as Usual|This group will not any training with the Cogmed training program.
62424708|NCT02634567|EXPERIMENTAL|Training Group|This group will receive intervention with the Cogmed training program and coach over a period of 5 weeks.
62593490|NCT06210776||Cohort B|Patients with unresectable or metastatic HER2-low breast cancer patients who have received at least a prior systemic therapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
62593491|NCT00552981|ACTIVE_COMPARATOR|1|
62593492|NCT00552981|SHAM_COMPARATOR|2|
62593493|NCT03826628|EXPERIMENTAL|0.5% Rapamycin cream, topical|Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
62033555|NCT06395597||People after stroke|Czech people after stroke, aged 20 - 64 years
62593494|NCT03826628|EXPERIMENTAL|1.0% Rapamycin cream, topical|Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
62593495|NCT03826628|PLACEBO_COMPARATOR|Placebo|Placebo cream topical, applied once daily before bed on affected area for 26 weeks
62233837|NCT01581151|EXPERIMENTAL|Dexamethasone intravitreal implant|"* Patients will receive a dexamethasone intravitreal implant injection at day 0.~* During monthly visits 1,2,3, and 5, patients will receive a ranibizumab intravitreal injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥ 250 μm or the best-corrected visual acuity is 20/40 or worse. The injection procedure is described in the next section.~* During monthly visit 4, patients will receive a dexamethasone intravitreal implant injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥ 250 μm or the best-corrected visual acuity is 20/40 or worse."
62233838|NCT03400332|EXPERIMENTAL|Part 1A: BMS-986253 + nivolumab|
62233839|NCT03400332|EXPERIMENTAL|Part 1B: BMS-986253 + nivolumab|
62424709|NCT03975088|OTHER|Persistent Diabetic macular edema|Authors defined refractory DME as eyes with persistent DME despite receiving at least 6 monthly Ranibizumab injections of anti VEGF, and then switched to Aflibercept, receiving at least three monthly injections.
62424710|NCT05761015|EXPERIMENTAL|Intervention|there is only one intervention arm and no control arm; the Bayesian analysis will be conducted under hypothetical estimates of superiority vs. control.
62424711|NCT05912179||EUS guided liver biopsy|Patients having liver biopsy through endoscopic ultrasound technique
62424712|NCT05912179||Percutaneous liver biposy|Patients having liver biopsy percutaneously
62424713|NCT05912179||Transjugular liver biopsy|Patients having liver biopsy via a transjugular route
62424714|NCT03405701|ACTIVE_COMPARATOR|IVM (in vitro maturation)|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred
62424715|NCT03405701|ACTIVE_COMPARATOR|IVF (in vitro fertilization)|Undergoing controlled ovarian hyperstimulation for in vitro Fertilization (IVF) with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist triggering will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
62424716|NCT05190640|EXPERIMENTAL|Intervention arm|The dietary supplement (Asystems) is designed, and marketed commercially to be taken in servings of one gummy: one gummy a day for De-Stress Gummies and one gummy a day for Sleep Gummies.
62424717|NCT04309955|EXPERIMENTAL|modified thoracic drainage group|After surgery, both a chest tube and a pigtail catheter are inserted into the middle and posterior axillary lines of the 7th intercostal space, respectively.
62424718|NCT04309955|NO_INTERVENTION|traditional thoracic drainage group|After surgery, only a chest tube is inserted into the midaxillary line of the 7th intercostal space, traditionally.
62424719|NCT06232707|EXPERIMENTAL|Arm A: Alnuctamab|
62424720|NCT06232707|ACTIVE_COMPARATOR|Arm B: Standard of Care Regimens|
62424721|NCT02738489|EXPERIMENTAL|Injection SHR-1210 60mg Cohort|
62424722|NCT02738489|EXPERIMENTAL|Injection SHR-1210 200mg Cohort|
62424723|NCT02738489|EXPERIMENTAL|Injection SHR-1210 400mg Cohort|
62424724|NCT00842894||Insulin detemir|
62424725|NCT00842894||Biphasic insulin aspart 30|
62233840|NCT03400332|EXPERIMENTAL|Part 1C: BMS-986253 + nivolumab + ipilimumab|
62233841|NCT03400332|EXPERIMENTAL|Part 2A: BMS-986253 + nivolumab + ipilimumab|
62424726|NCT00913861|ACTIVE_COMPARATOR|standard sedation|propofol and fentanyl
62424727|NCT00913861|ACTIVE_COMPARATOR|structured attention-standard sedation|structured attention
62424728|NCT00913861|EXPERIMENTAL|hypnosis-standard sedation|hypnosis
62424729|NCT00646178|ACTIVE_COMPARATOR|A|
62424730|NCT00646178|PLACEBO_COMPARATOR|B|
62424731|NCT01272739|EXPERIMENTAL|Study Group|Subjects will take 500 mg of the investigational product 15 minutes prior to the 3 main meals of the day.
62033556|NCT06395597||Healthy population|Czech healthy people, aged 20 - 64 years
62233842|NCT03400332|PLACEBO_COMPARATOR|Part 2B: Placebo + nivolumab + ipilimumab|
62233843|NCT00480584|EXPERIMENTAL|GemCap-T Dose Escalation|GemCap-T, capecitabine in combination with gemcitabine. Dose Escalation 6 Cycles @ 28 Days.
62424732|NCT01272739|PLACEBO_COMPARATOR|Control Group|Subjects will take a placebo 15 minutes prior to the three main meals of the day.
62424733|NCT00096200|EXPERIMENTAL|Arm I (closed to accrual 10/10/2008)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression crossover to arm II
62424734|NCT00096200|EXPERIMENTAL|Arm II|Patients receive oral sorafenib twice daily on days 2-19. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62424735|NCT03799094|EXPERIMENTAL|Experimental group|75 patients received a weekly intravenous Vitamin C injection (dose: 30 g / time, once a week, treatment termination when the disease progress is confirmed) in combination with daily taking tyrosine kinase inhibitor.
62593496|NCT05241405|EXPERIMENTAL|Qiseng|200 mg/capsule of P. quinquefolius extract, i.e. 30 mg of ginsenosides, associated with 30 mg of vitamin C extracted from Camu Camu berry
62593497|NCT05241405|PLACEBO_COMPARATOR|Placebo|neutral microgranules of Qiseng® excipients without P. quinquefolius or Camu Camu extract
62593498|NCT03566043|EXPERIMENTAL|Part 1: RGX-121 Dose 1|1.3x10\^10 GC/g brain mass of RGX-121
62809909|NCT05234411||Observational group|Eligible participants will be female patients aged 13 years or older, with regular menstrual cycle, who have been undergoing a KDT for at least 3 months and thus previously diagnosed with Drug resistant epilepsy or GLUT1DS.
62233844|NCT02480257|EXPERIMENTAL|TARA Intervention group|TARA is comprised of 12 weekly classes delivered in a group format by two trained facilitators with approximately 8-15 participants. The 90 minute sessions are designed to promote skills for autonomic regulation, attention modulation, emotion regulation and cognitive control.
62233845|NCT05474599|EXPERIMENTAL|Dry cupping therapy|For pain and severity of symptoms in primary dysmenorrhea.
62233846|NCT05474599|OTHER|Conventional physical therapy|For management of pain and severity of symptoms
62233847|NCT00973362|OTHER|Adjunct (i.e. Normal Pap)|The Adjunct study will evaluate APTIMA HPV Assay clinical performance for detecting high-risk HPV types in female subjects 30+ years of age with negative (NILM) cytology results from routine Pap testing. This will be accomplished by evaluating the assay performance compared to known cervical disease status at baseline and after a 3-year follow-up period. A comparator FDA-Approved HPV DNA test is reported.
62424736|NCT03799094|EXPERIMENTAL|Control group|75 patients received tyrosine kinase inhibitor daily. (dose: Osimertinib 80 mg/d, or Tarceva 150 mg/d, or Iressa 0.25 g/d.)
62424737|NCT00741520|PLACEBO_COMPARATOR|1|Control group
62424738|NCT00741520|ACTIVE_COMPARATOR|2|CPAP
62424739|NCT04098159|EXPERIMENTAL|ESRD Patients have functioning or failing VAs (AVFs or AVGs).|
62424740|NCT02200614|EXPERIMENTAL|Darolutamide (BAY1841788)|Participants received Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equal to a total daily dose of 1200 mg.
62424741|NCT02200614|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo 2 tablets twice daily with food.
62424742|NCT03526796|EXPERIMENTAL|Hyperbaric oxygen therapy|Patients who recieve hyperbaric oxygen therapy will be maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
62424743|NCT04682561|EXPERIMENTAL|Supportive Trauma Exposure Preparation (STEP) Program|Nurses or personal support workers in Ontario will undergo the STEP Program Psychotherapy
62424744|NCT02747251|EXPERIMENTAL|Strengthen your Shoulder & Usual Care|"Instructions in a home-based intervention consisting of progressive high volume resistance training with an elastic band. Instructions provided 0, 2, 5, and 10 weeks after baseline. Usual care includes all treatment received by a patient during the time between baseline and follow-up, except that included in Strengthen your Shoulder."
62424745|NCT02747251|ACTIVE_COMPARATOR|Usual Care|"Includes all treatment received by a patient during the time between baseline and follow-up, except that included in Strengthen your Shoulder."
62593499|NCT03566043|EXPERIMENTAL|Part 1: RGX-121 Dose 2|6.5x10\^10 GC/g brain mass of RGX-121
62809910|NCT01572181|EXPERIMENTAL|Drugs|Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)
62809911|NCT05320081|EXPERIMENTAL|Camrelizumab combined with CD30 CAR-T|This study have only one arm that is Camrelizumab combined with CD30 CAR-T experimental arm.
62809912|NCT03742765|EXPERIMENTAL|Incentivizing Planning|Participants will receive three texts each week asking a question to help plan for the next workout, and will receive 500 points for each text they answer. These bonus points are on top of points participants receive for each workout (200 points per workout).
62809913|NCT03742765|EXPERIMENTAL|Incentivizing Exercise|Participants will receive three texts each week asking a question about their workout. Regardless of whether or not they respond to the texts, participants receive 500 bonus points for their first three workouts during the week. These bonus points are on top of points participants receive for each workout (200 points per workout).
62424746|NCT04580524|ACTIVE_COMPARATOR|Phasix Mesh|Phasix mesh will be used in the repair of the hernia
62424747|NCT04580524|ACTIVE_COMPARATOR|Current Care|The hernia will be repaired with either synthetic mesh or suture repair, as determined by the operating surgeon.
62424748|NCT02016755|EXPERIMENTAL|AMG0001|Hepatocyte Growth Factor (HGF) Plasmid
62593500|NCT03566043|EXPERIMENTAL|Part 1: RGX-121 Dose 2 Expanded Cohort|6.5x10\^10 GC/g brain mass of RGX-121
62593501|NCT03566043|EXPERIMENTAL|Part 1: RGX-121 Dose 3|2.0x10\^11 GC/g brain mass of RGX-121
62593502|NCT03566043|EXPERIMENTAL|Part 1: RGX-121 Dose 3 Expanded Cohort|2.9x10\^11 GC/g brain mass of RGX-121 (transgene-specific PCR assay) equivalent to, 2.0x10\^11 GC/g brain mass of RGX-121 (Poly-A-specific PCR assay)
62593503|NCT03566043|EXPERIMENTAL|Part 2: RGX-121 Pivotal Expansion|2.9x10\^11 GC/g brain mass of RGX-121 (transgene-specific PCR assay)
62593504|NCT06617247|EXPERIMENTAL|Intervention 2: Placebo|In this group, the subjects will receive placebo intervention. For blinding purposes, caregivers in this group will use the vehicle of oral CBD 300mg (150mg twice
62809914|NCT06436794||12-14 weeks|
62809915|NCT06436794||15-17 weeks|
62809916|NCT06436794||18-20 weeks|
62809917|NCT02432326|EXPERIMENTAL|Arm A|
62809918|NCT02494193|ACTIVE_COMPARATOR|Regular Treatment|Partial caries removal; Provisional restoration - control; Total caries removal; Definitive restoration.
62809919|NCT02494193|EXPERIMENTAL|Alternative Treatment|Partial caries removal; Provisional restoration - experimental; Total caries removal; Definitive restoration.
62809920|NCT06162585||Observation of Participants exposed 1.2E11gc/eye of MCO-010|This is a long-term follow-up observational study of participants who previously received 1.2E11gc/eye of MCO-010. No investigational product will be administered in this study.
62809921|NCT06162585||Observation of Participants exposed to 0.9E11gc/eye of MCO-010|This is a long-term follow-up observational study of participants who previously received 0.9E11gc/eye of MCO-010 No investigational product will be administered in this study.
62593505|NCT06617247|EXPERIMENTAL|Intervention1: Cannabidiol|The caregivers randomized for this intervention will use oral CBD 300 mg (i.e., 150mg, twice daily) for four weeks. The substance will be provided free of charge by the company Ease Labs, and will be administered in capsules to promote blinding. This posology was based on the study, in which CBD in this dosage and form of presentation proved to be safe and effective in reducing indicators of burnout in frontline health professionals from COVID-19. The safety of CBD use has also been reported in previous studies conducted with humans. Side effects from CBD use are rare, including mild and tolerable symptoms (e.g., dizziness, drowsiness, fatigue, lethargy, nausea, headache, fever, and sensory changes).
62809922|NCT02987231|SHAM_COMPARATOR|CAF + SHAM|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. Patients randomized to the SHAM Group will receive the simulation of the electrical stimulation process.
62819565|NCT03009058|EXPERIMENTAL|IMM-101+Gem/ nab-paclitaxel breast|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
62233848|NCT00973362|OTHER|ASC-US|The ASC-US study will evaluate the APTIMA HPV Assay clinical performance for detecting high-risk HPV types in subjects with ASC-US Pap test results from routine Pap testing and known cervical disease status (based on colposcopic biopsy results). A comparator FDA-Approved HPV DNA test is reported. There is no follow-up period.
62233849|NCT04508023|EXPERIMENTAL|Rivaroxaban|Participants will receive rivaroxaban 10 milligram (mg) tablet orally once daily for 35 Days along with standard of care treatment (SOC).
62233850|NCT04508023|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo tablet orally once daily for 35 Days along with SOC.
62424749|NCT06564649||Interventional Group|Participants in the intervention group will have urinary CXCL10 testing done on the Ella Platform up to every month for a 2 year follow up.
62424750|NCT06564649||Non-Interventional Group|Participants in the control group will have the standard of care urine test done via the clinical lab.
62593506|NCT03608657||Psoriatic Arthritis patients treated with Apremilast|Active PsA as per the CASPAR criteria, based on the investigator's clinical judgement with access to commercially available Otezla
62593507|NCT04635124|ACTIVE_COMPARATOR|1: Dog visit with a dog, no additional activity (D)|The nursing home resident receives 12 10-minute visits in their own room. The visitor is accompanied with a dog, and the resident can touch the dog. Apart from the visitor, an observer is present.
62593508|NCT04635124|EXPERIMENTAL|2: Dog visit with an additional activity (DA)|"The nursing home resident receives 12 10-minute visits in their own room. The visitor is accompanied with a dog, and the resident can touch the dog. During the visit, the visitor offers the resident to participate in an activity that involves interacting with the dog.~Apart from the visitor, an observer is present."
62593509|NCT04635124|ACTIVE_COMPARATOR|3: Visit without dog, with an additional activity (A)|"The nursing home resident receives 12 10-minute visits in their own room. During the visit, the visitor offers the resident to participate in an activity.~Apart from the visitor, an observer is present, but no dog is present.."
62593510|NCT01864915|EXPERIMENTAL|No Booster-low dose prucalopride booster|low dose prucalopride booster arm
62593511|NCT01864915|EXPERIMENTAL|Prucalopride Booster-high dose prucalopride booster|additional 2mg prucalopride at time of capsule ingestion
62593512|NCT01864915|EXPERIMENTAL|Picosalax Booster Arm|One sachet of Picosalax 2hrs after capsule ingestion and 1/2 sachet at 4 hrs after swallowing colon capsule.
62593513|NCT05046886|OTHER|Usual Care Control (UCC)|Baseline advice about the Mediterranean-style diet and attention control.
62593514|NCT05046886|ACTIVE_COMPARATOR|Standardized|One-size-fits-all dietary counseling to follow a Mediterranean-style diet
62593515|NCT05046886|ACTIVE_COMPARATOR|Personalized|Dietary counseling to follow a Mediterranean-style diet personalized to reduce postprandial glycemic response
62593516|NCT01677884|EXPERIMENTAL|Patients with metastatic CRC|
62593517|NCT06573281|EXPERIMENTAL|RSV_Group A|
62593518|NCT06573281|EXPERIMENTAL|RSV_Group B|
62593519|NCT06573281|EXPERIMENTAL|RSV_Group C|
62593520|NCT06573281|EXPERIMENTAL|RSV_Group D|
62593521|NCT06573281|EXPERIMENTAL|RSV_Group E|
62593522|NCT06573281|EXPERIMENTAL|RSV_Group F|
62593523|NCT06573281|PLACEBO_COMPARATOR|Placebo Group|
62593524|NCT05478304|EXPERIMENTAL|Treatment|LAAE using the AtriClip concomitant to and at the time of planned cardiac surgery
62593525|NCT05478304|NO_INTERVENTION|Control|No LAAE concomitant to and at the time of planned cardiac surgery
62033557|NCT02580604|EXPERIMENTAL|Calcium Infusion|Continuous calcium infusion during exercise
62033558|NCT02580604|PLACEBO_COMPARATOR|Saline Infusion|Continuous saline infusion during exercise
62424751|NCT02108366|PLACEBO_COMPARATOR|Placebo|Placebo + oseltamivir 75mg bid for 5 days
62424752|NCT02108366|EXPERIMENTAL|Celecoxib|Celecoxib 200mg daily + oseltamivir 75mg bid for 5 days
62424753|NCT05003167|EXPERIMENTAL|Expiratory Muscle Strength Training|All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).
62424754|NCT00898742||head and neck cancer patients|
62593526|NCT06339164||Formal lecture|residents undergoing frontal lecture one month before the scenario
62593527|NCT06339164||Digital learning|residents learning digitally the topic for at least one month before the scenario
62809923|NCT02987231|EXPERIMENTAL|CAF + ES|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. For electrical stimulation, a unit consisting of a signal generator, a power supply, and circuit board will be used. Conductive electrodes for electrical current application will be applied to the vestibular gingival surface on each side of the flap, at a distance of 3 mm from the relaxing incisions and an alternating current of 100 μA at 9 kHz, will be distributed in order to traverse the operated area. A single application of electrical stimulation will be given for 120 seconds, once a day for five days after surgery.
62233851|NCT04572087|EXPERIMENTAL|Cognitive Control Training + Verum stimulation|This arm consists of the cognitive control training (six sessions) combined with 2mA anodal tDCS over the right dlPFC (F4) during the training for 20 minutes.
62809924|NCT01791244|ACTIVE_COMPARATOR|Technical support for the RebiSmart™ device|Subjects will be administered Rebif® by the RebiSmart™ device at a dose of either 22 or 44 microgram (mcg) subcutaneously (SC) 3 times a week in accordance to the summary of product characteristics (SPC) along with technical support for RebiSmart.
62233852|NCT04572087|ACTIVE_COMPARATOR|Cognitive Control Training + Sham stimulation|This arm consists of cognitive control training (six sessions) with sham-tDCS. 2 mA Sham-tDCS (40 seconds of tDCS) is applied to the right dlPFC (F4) before the trainings starts.
62233853|NCT03641612|EXPERIMENTAL|one shape|single file rotary system
62233854|NCT03641612|ACTIVE_COMPARATOR|protaper next|multiple file rotary system
62424755|NCT01049269||1:one group|
62424756|NCT04794400|EXPERIMENTAL|Intervention|An additional oxygen mask was applied for 30 minutes, in patients with ongoing HFNC treatment.
62424757|NCT05478603|EXPERIMENTAL|Group 1: PF-07081532 Participants without hepatic impairment|Participants without hepatic impairment will receive a single 20 mg dose of PF-07081532, administered orally as 1 PF-07081532 20 mg tablet.
62809925|NCT01791244|EXPERIMENTAL|Subject support program (MinSupport Plus)|Subjects will be administered Rebif® by the RebiSmart™ device at a dose of either 22 or 44 mcg SC 3 times a week in accordance to the SPC along with subject support program MinSupport Plus which includes technical support for RebiSmart™ device, personal coaching regarding treatment and understanding of the disease, lifestyle guide and web support.
62809926|NCT01067378|ACTIVE_COMPARATOR|Expert instructor debriefing|Expert instructor debriefing
62809927|NCT01067378|EXPERIMENTAL|Peer-led debriefing|Peer-led debriefing
62233855|NCT00632398|ACTIVE_COMPARATOR|Attention control (reading)|Caregivers read to patients from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks.
62424758|NCT05478603|EXPERIMENTAL|Group 2: PF-07081532 Participants with mild hepatic impairment|Participants with mild hepatic impairment will receive a single 20 mg dose of PF-07081532, administered orally as 1 PF-07081532 20 mg tablet
62809928|NCT01071044|ACTIVE_COMPARATOR|Lisdexamfetamine Dimesylate|Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
62809929|NCT01071044|PLACEBO_COMPARATOR|Sugar pill|"Matching Placebo 30, 50 or 70 mg"
62233856|NCT00632398|EXPERIMENTAL|Touch, Caring and Cancer DVD program|Caregivers apply the instruction of the Touch, Caring and Cancer DVD program for patients for recommended 20 minutes at least 3 times per week for 4 weeks.
62424759|NCT05478603|EXPERIMENTAL|Group 3: PF-07081532 Participants with moderate hepatic impairment|Participants with moderate hepatic impairment will receive a single 20 mg dose of PF-07081532, administered orally as 1 PF-07081532 20 mg tablet.
62424760|NCT05478603|EXPERIMENTAL|Group 4: PF-07081532 Participants with severe hepatic impairment|Participants with severe hepatic impairment will receive a single20 mg dose of PF-07081532, administered orally as 1 PF-07081532 20 mg tablet.
62424761|NCT03607656|EXPERIMENTAL|TCM combines CapOX/SOX/S-1+D/FLOT|"Traditional Chinese Medicine oral taken twice a day for at least 3 months combined with chemotherapy.~The chemotherapy can choose intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21 days; or intravenous oxaliplatin 100 mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 40mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 50mg/m(2) on day 1 plus intravenous oxaliplatin 85 mg/m(2) on day 1 plus 5-FU intravenously CIV24h on day 1, every 14 days; Each participant shoud take eight (8) cycles of chemotherapy."
62809930|NCT04096014|ACTIVE_COMPARATOR|Ensure Enlive|
62033559|NCT05509413|NO_INTERVENTION|Control Arm|Wait-and-see approach.
62233857|NCT01139658||All comers|
62233858|NCT02423239|EXPERIMENTAL|Relapsed or refractory advanced tumours|Patients with selected relapsed or refractory tumour types to receive single agent dexanabinol.
62233859|NCT02423239|EXPERIMENTAL|Newly diagnosed hepatocellular carcinoma|Patients with hepatocellular carcinoma to receive dexanabinol in combination with standard chemotherapy.
62593528|NCT05272735|EXPERIMENTAL|Hepatitis B Vaccine (Recombinant)|Hepatitis B Vaccine (Recombinant) 20 mcg intramuscular injection at 0-1-6 months
62809931|NCT04096014|PLACEBO_COMPARATOR|Standard of Care|
62809932|NCT05767008|EXPERIMENTAL|Static and water immersion SPF evaluation|
62809933|NCT04441359|EXPERIMENTAL|supplemented formula|Standard formula supplemented with prebiotic inulin-type fructans
62593529|NCT06463392||Case|Histologically confirmed sbORN that meets the eligibility criteria.
62593530|NCT06463392||Control|Histologically confirmed NPC recurrence that meets the eligibility criteria.
62593531|NCT03891472|EXPERIMENTAL|Arm 1|
62809934|NCT04441359|PLACEBO_COMPARATOR|standard formula|Standard Formula not supplemented with prebiotic inulin-type fructans
62809935|NCT02149381|EXPERIMENTAL|CBASP|Cognitive Behavioral System of Psychotherapy is a manual-based group intervention for chr depression (20 weeks).
62593532|NCT05848674|EXPERIMENTAL|Intervention Group|CABIN will be delivered in a single session to each participant (one-to-one) of the intervention group by a Research Assistant who is a cardiac nurse with over 20 years of clinical experience in cardiac rehabilitation. A private space at a Coronary Care Unit (Royal Victoria Hospital or Ulster Hospital) will be used for intervention delivery before patient discharge. Intervention delivery should take approximately 20 minutes.
62593533|NCT05848674|OTHER|Control Group|A Research Fellow will deliver (one-to-one) a refined version of CABIN prior to patient discharge from a Coronary Care Unit (Royal Victoria Hospital or Ulster Hospital). A private space will be used, with delivery taking approximately 10 minutes.
62424762|NCT03607656|ACTIVE_COMPARATOR|CapOX/SOX/S-1+D/FLOT|The chemotherapy can choose intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21 days; or intravenous oxaliplatin 100 mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 40mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 50mg/m(2) on day 1 plus intravenous oxaliplatin 85 mg/m(2) on day 1 plus 5-FU intravenously CIV24h on day 1, every 14 days; Each participant shoud take eight (8) cycles of chemotherapy.
62593534|NCT06235411|EXPERIMENTAL|Experimental group|
62593535|NCT06235411|PLACEBO_COMPARATOR|Control group|
62593536|NCT01391195|EXPERIMENTAL|Laser therapy and aerobic capacity|Effects of low level laser therapy on aerobic capacity of young women submitted to endurance training
62593537|NCT05845905|ACTIVE_COMPARATOR|RIC group|Patients are treated with remote ischemic conditioning (RIC).
62593538|NCT05845905|PLACEBO_COMPARATOR|Sham RIC group|Patients are treated with sham remote ischemic conditioning (sham-RIC).
62593539|NCT05659563|EXPERIMENTAL|Arm A|Giredestrant (GDC-9545): 30mg, orally (PO), daily (QD) during 15 days
62593540|NCT05659563|ACTIVE_COMPARATOR|Arm B|Tamoxifen: 20mg, orally (PO), daily (QD) during 15 days
62593541|NCT04197869|EXPERIMENTAL|Experimental|The experimental group will take a pre-operative course of polyethylene glycol daily for seven days prior to procedure date.
62233860|NCT02423239|EXPERIMENTAL|Newly diagnosed pancreatic cancer|Patients with pancreatic cancer to receive dexanabinol in combination with standard chemotherapy
62233861|NCT02259907|EXPERIMENTAL|KUC 7483 CL|single rising doses
62033560|NCT05509413|EXPERIMENTAL|DEFLAGYN Arm|Application of DEFLAGYN vaginal gel for 3x 28days (as per instructions provided by the manufacturer)
62233862|NCT02259907|EXPERIMENTAL|KUC 7483 CL, fed|dosing after high fat meal
62424763|NCT02593084|EXPERIMENTAL|Higher Intensity Resistance Training|Participants will take part in a 12-week higher-intensity resistance training protocol.
62424764|NCT02593084|ACTIVE_COMPARATOR|Lower Intensity Resistance Training|Participants will take part in a 12-week lower-intensity resistance training protocol that will serve as the active comparator.
62424765|NCT05110430||BS-UKA|Patients who underwent bone scintigraphy scanning between 2010 and 2018 at RTWH Aachen university hospital, and had a bone scan report that indicates the presence or absence of metastatic bone disease.
62424766|NCT05110430||BS-Namur|Patients who underwent bone scintigraphy scanning between 2010 and 2018 at Namur university hospital, and had a bone scan report that indicates the presence or absence of metastatic bone disease.
62424767|NCT05110430||BS-Aalborg|Patients who underwent bone scintigraphy scanning between 2010 and 2018 at Aalborg university hospital, and had a bone scan report that indicates the presence or absence of metastatic bone disease.
62593542|NCT04197869|NO_INTERVENTION|Control|The control group will not be given any intervention preoperatively.
62593543|NCT05687188||Retrospective Cohort|Retrospective chart review and sample analysis of both pathologically confirmed Pancreatic Ductal Adenocarcinoma (PDAC) cases and non-Cancer control cases.
62424768|NCT06310473|EXPERIMENTAL|Cadonilimab Plus Chemotherapy|"Neoadjuvant Immunotherapy and Chemotherapy：Cadonilimab+Oxaliplatin+Capecitabine, every 3 weeks for 3 cycles;~Adjuvant chemotherapy： Oxaliplatin+Capecitabine, every 3 weeks for 3-5 cycles;"
62593544|NCT05687188||Prospective Cohort|Blood samples, tissue samples and data will be collected from all participants as applicable.
62593545|NCT03862794|EXPERIMENTAL|high total and high broad spectrum prescribing letter|social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
62593546|NCT03862794|ACTIVE_COMPARATOR|high total and high broad spectrum prescribing control|standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive the standard practice overall prescribing letter as a control
62033561|NCT06188065||Participants with severe exacerbation of COPD and eosinophils < 0.05 x 10^9/L|Participants to be included in the co-primary outcomes for the time to recovery from eosinopenia analysis as well as the analysis to identify independent factors associated with eosinopenia on admission in patients with a severe exacerbation of COPD. This group of participants will also be included in all secondary outcomes.
62233863|NCT02259907|PLACEBO_COMPARATOR|Placebo|
62233864|NCT05336331||laparoscopic sleeve gastrectomy (SG)|Patients operated on with a SG
62233865|NCT05336331||laparoscopic Roux-en-Y gastric bypass (RYGB)|patients operated on with aRYGB
62233866|NCT01218776||Male, Female, Kidney Disease, Elderly|Non-interventional patient registry
62233867|NCT04312321|NO_INTERVENTION|CONTROL|CONTROL group: low urgency cases with routine operation of paramedic crew with optional consultation with a doctor over the phone.
62809936|NCT02149381|ACTIVE_COMPARATOR|Befriending|Befriending is a social support intervention
62233868|NCT04312321|EXPERIMENTAL|PHONE|In the PHONE group, there will be a mandatory consultation of a doctor over the phone in all low urgency cases.
62233869|NCT04312321|EXPERIMENTAL|VIDEO|In the VIDEO group, there will be a mandatory consultation of a doctor over the audiovisual consultation in low urgency cases
62424769|NCT04330482|OTHER|Internet Links|A tablet pre-loaded with a list of internet links relating to dementia caregiving that participants will be instructed to use at least 4 times weekly for 3 months.
62809937|NCT02149381|ACTIVE_COMPARATOR|Treatment as usual|Conventional psychiatric outpatient treatment (individual counseling)
62424770|NCT04330482|EXPERIMENTAL|CARE-Well App|A tablet pre-loaded with the CARE-Well app that participants will be instructed to use at least 4 times weekly for 3 months.
62809938|NCT00697502|EXPERIMENTAL|Group 2: TSER 3R/3R|Cohorts of 3-6 patients in each genotype group will receive escalating doses of capecitabine until MTD is reached. Once MTD is determined, an additional 6-9 patients (for a total of 12 patients) will receive treatment at that dose.
62809939|NCT00697502|EXPERIMENTAL|Group 1: TSER 2R/2R or 2R/3R|Cohorts of 3-6 patients in this genotype group will receive escalating doses of capecitabine until MTD is reached. Once MTD is determined, an additional 6-9 patients (for a total of 12 patients) will receive treatment at that dose.
62809940|NCT02424773|ACTIVE_COMPARATOR|Venturi group|Venturi group : Oxygen is delivered using oxygen Venturi mask FiO2 is started at 60% (15l/min) and modified to maintain SpO2 over 94%.
62809941|NCT02424773|EXPERIMENTAL|HFNC group|HFNC group : Oxygen is delivered using HFNC. HFNC is started with FIO2 =1 and modified to maintain SpO2 over 94%, flow is settled at 40-50l/min.
62809942|NCT05966649|EXPERIMENTAL|Synbiotics|Oral synbiotic (food supplement) containing 8 probiotic Lactobacillus strains, the prebiotics inulin, fructooligosaccharides (FOS) and D-mannose.
62809943|NCT05966649|PLACEBO_COMPARATOR|Placebo|Matching placebo
62809944|NCT05534217|EXPERIMENTAL|debridement+traditional treatment|The experimental group receives debridement of the abrasion wound before receiving traditional treatment including evofloxacin eye drops + befushu QID \* for 14 days, four times a day, and the corneal contact lens was worn for 2 weeks.
62809945|NCT05534217|ACTIVE_COMPARATOR|traditional treatment|The traditional group receives evofloxacin eye drops + befushu QID \* for 14 days, four times a day, and the corneal contact lens was worn for 2 weeks.
62033562|NCT06188065||Participants with severe exacerbation of COPD and eosinophils >= 0.05 x 10^9/L|Participants will be included in the co-primary outcome to identify independent factors associated with eosinopenia on admission in patients with a severe exacerbation of COPD. This group of participants will also be included in some of the secondary outcomes.
62033563|NCT00572949||1|Patients with chest pain syndrome
62033564|NCT02500992||Transrectal sigmoidectomy|Patients undergoing transrectal NOTES sigmoidectomy
62424771|NCT00085722|EXPERIMENTAL|Dextrose|Subjects in Group 1 receive PrT with 15% and 25% dextrose solution, as it is generally practiced in the US today.
62593547|NCT03862794|EXPERIMENTAL|high total prescribing only intervention letter|social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive a letter that has specific information about the percentile they are on for overall prescribing and a bar chart representing their overall prescribing compared to the average
62593548|NCT03862794|ACTIVE_COMPARATOR|high total prescribing control letter|standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive the standard practice overall prescribing letter as a control
62593549|NCT03862794|EXPERIMENTAL|moderate total prescribing and high broad spectrum letter|social norm feedback letter with bar chart GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum will receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
62593550|NCT03862794|NO_INTERVENTION|moderate total prescribing and high broad spectrum control|GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive no letter, which is standard practice, as a control.
62593551|NCT04155541||VIZIMPRO(dacomitinib hydrate)|Patients with EGFR mutation-positive inoperable or recorrent NSCLN (non-small cell lung cancer) who have not received VIZIMPRO (dacomitinib hydrate)
62809946|NCT05994612|EXPERIMENTAL|Cognitive Therapy for Suicide Prevention + Services as Usual|10 sessions of Cognitive Therapy for Suicide Prevention (CTSP) provided over 6 months, with 9 optional booster sessions + services as usual (SAU) received by the community.
62809947|NCT05994612|ACTIVE_COMPARATOR|Services as Usual|Services as Usual involves utilizing Strengths-Based Outreach and Advocacy to link youth to community services for a period of 6 months.
62809948|NCT03958383|EXPERIMENTAL|Experimental Groups|"PHASE IA: As described above. Participants receive hu14.18-IL2 fusion protein intratumorally (IT).~PHASE IB: As described above. Participants undergo palliative RT and hu14.18-IL2 fusion protein IT as in phase IA.~PHASE IC: As described above. Participants undergo palliative RT, receive nivolumab, and hu14.18-IL2 fusion protein IT as in phase IA.~PHASE ID: As described above. Participants undergo palliative RT, receive nivolumab in combination with ipilimumab, and hu14.18-IL2 fusion protein IT as in phase IA."
62809949|NCT04532307|EXPERIMENTAL|Standard of Care SOC|Youth friendly services at Isisekelo Sempilo clinics
62809950|NCT04532307|EXPERIMENTAL|SRH enhanced Isisekelo Sempilo|Self-collected vaginal and urine samples for gonorrhea, chlamydia and trichomonas
62033565|NCT02500992||Laparoscopic-assisted sigmoidectomy|Patients undergoing laparoscopic-assisted sigmoidectomy
62033566|NCT03191318|ACTIVE_COMPARATOR|ERAS pathway|Laparoscopic sleeve gastrectomy with ERAS pathway
62033567|NCT03191318|ACTIVE_COMPARATOR|Standard pathway|Laparoscopic sleeve gastrectomy with standard pathway
62033568|NCT03319277|ACTIVE_COMPARATOR|Routine opiate prescription|This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the standard amount of post-discharge opiate medications - 28 tablets of oxycodone 5mg.
62424772|NCT00085722|PLACEBO_COMPARATOR|Normal saline|Subjects in Group 2 will receive the same treatment as Group 1, except that a 0.9% 'normal' saline solution with no known benefit will be used instead of dextrose.
62424773|NCT00085722|OTHER|Exercise|At-home physical therapy exercises as a non-injection control
62424774|NCT00984828|EXPERIMENTAL|vel 8 - ASCT|8 cycles of velcade with ASCT
62424775|NCT00984828|ACTIVE_COMPARATOR|vel4 - ASCT|4 cycles of velcade with ASCT
62424776|NCT04256057|OTHER|magnesium sulphate|After the induction of anesthesia, a loading dose of magnesium sulfate 50mg/kg in 100mL of isotonic saline as within 5 to 10 minutes followed by a maintenance dose of 10 mg/kg/hr up to the end of surgery
62033569|NCT03319277|EXPERIMENTAL|Decreased opiate prescription|This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the decreased amount of post-discharge opiate medications - 5 tablets of oxycodone 5mg with a paper prescription for an additional 10 tablets of oxycodone 5mg as a backup for uncontrolled pain.
62033570|NCT01673802|EXPERIMENTAL|CT imaging|Patients will undergo a standard of care Gadoxetate (Eovist) MRI for cholangiocarcinoma. Patients will then be immediately placed on the CT scanner. Patients will undergo a dual energy CT of the abdomen with no additional contrast.
62593552|NCT06471036|EXPERIMENTAL|Care Champion Intervention|The participants randomized to the intervention arm will have a care champion help to navigate their inpatient-to-outpatient transition and lipid care. They will be introduced to the intervention before discharge by the CRC who has enrolled them. This will include a virtual introduction to the care champion, delivery of contact information, and expectations around communication from the care champion in the coming months. It will also include clear education around the patient's LDL-C goals, lipid management plan, plans for re-testing, and outpatient follow-up.
62593553|NCT06471036|NO_INTERVENTION|Standard of Care|Standard of Care
62809951|NCT04532307|EXPERIMENTAL|Peer-support (Thetha-Nami)|Peer support and needs assessment from an area-based peer navigator
62809952|NCT04532307|EXPERIMENTAL|SOC + SRH + peer-support|Combination of all arms
62809953|NCT01991392|ACTIVE_COMPARATOR|Maintaining tube|Maintain nasogastric tube after extubation following pancreaticoduodenectomy
62809954|NCT01991392|EXPERIMENTAL|Non-tube|Remove nasogastric tube after extubation following pancreaticoduodenectomy
62809955|NCT01207700|EXPERIMENTAL|CHW based intervention post ACS|CHW trained and supervised for intervening upon post ACS patients to improve adherence to evidence based care
62809956|NCT01207700|NO_INTERVENTION|Standard Care|Patients will be followed upto 12 months without a community health worker intervention as per standard practices of the hospital
62809957|NCT03206216|EXPERIMENTAL|Group A - Painful CIPN|Participants with painful chemotherapy-induced peripheral neuropathy (CIPN) undergo Diode Laser fiber type Selective Stimulator (DLss) test over 30 minutes at 9 and 21 weeks after the first day of standard of care chemotherapy. A questionnaire is used to assess the level of pain after stimulation.
62809958|NCT03206216|ACTIVE_COMPARATOR|Group B - Painless CIPN|Participants with painless chemotherapy-induced peripheral neuropathy (CIPN) undergo Diode Laser fiber type Selective Stimulator (DLss) test over 30 minutes at 9 and 21 weeks after the first day of standard of care chemotherapy. A questionnaire is used to assess the level of pain after stimulation.
62033571|NCT05019339|EXPERIMENTAL|Healthy HomeStyles|Six-week virtual, group nutrition education series using the HomeStyles-2 experimental curriculum administered through SNAP-Ed. This curriculum addresses factors affecting school-aged children's health and nutritional status: inadequate intake of fruits and vegetables, infrequent family meals, excessive consumption of sugar-sweetened beverages, large portion sizes, and irregular breakfast consumption.
62243173|NCT05326113|EXPERIMENTAL|Physiotherapy|"Patients will undergo physiotherapy and will be regularly examined by an assigned physician.~Initial physiotherapy will last 60minutes, other therapies will last 30minutes. Physiotherapy will aim on diaphragmatic breathing and dynamic neuromuscular stabilization exercises. In the 1st month, the patient attends physiotherapy once a week In the 2nd, 3rd and 4th month, the patient attends physiotherapy once every 14 days.~Symptomatic patients will take PPIs based on the recommendation of the treating physician who will recommend a dose of PPIs. Used PPIs will be Emanera 1x40mg (standard dose), 2x40mg (higher dose) or 1x40mg on demand.~During the follow-up period, patients may, in agreement with the attending physician, reduce the dose of PPIs (from twice a day to once a day, from once a day to an on-demand regime or discontinue them altogether).~The use of PPIs will be accurately documented."
62593554|NCT00725179||1|Patients receiving oral NAC treatment
62809959|NCT03327909|EXPERIMENTAL|TAKE|Participants in TAKE units will be advised to take all antihypertensive medications as prescribed, including on the morning of dialysis.
62809960|NCT03327909|EXPERIMENTAL|HOLD|Participants in the HOLD units will advised to hold the dose of the antihypertensive medications prior to the dialysis session on the morning of the dialysis days. Participants can choose whether they wish to take the antihypertensive medication that was held at any time after the dialysis session has ended.
62809961|NCT00634439||A|All patients 18 years or older who received a first dispensing of atomoxetine during the time period of the study (January 1, 2003 through December 31, 2006) and had at least 6 months of continuous enrollment prior to first dispensing are included in the study cohort. Patients are excluded for presence of pre-existing arrhythmia and heart failure during the baseline period. The study entry date for this cohort is the date of first atomoxetine dispensing.
62809962|NCT00634439||B|All patients 18 years or older who received a first dispensing of a stimulant medication (methylphenidate or mixed salts of amphetamine) during the time period of the study with no dispensing of the same drug in the prior 6 months and had at least 6 months of continuous enrollment prior to the first dispensing are identified. Patients are excluded for presence of pre-existing arrhythmia and heart failure during the baseline period. Patients who are matched to atomoxetine initiators using this propensity score method are retained and followed as one comparator cohort. The study entry date is the date of the first dispensing of a comparator ADHD medication.
62809963|NCT00634439||C|Patients with at least 6 months of continuous enrollment in the database, and without a history of arrhythmia or heart failure during the baseline period are sampled and frequency matched on age and gender to the atomoxetine cohort in a 2:1 ratio. Study entry dates are assigned so as to be similar to the distribution of study entry dates in the atomoxetine cohort. Patients identified and matched as initiators of atomoxetine or stimulant ADHD medications are not eligible for inclusion in this cohort
62593555|NCT00725179||2|Patients receiving IV NAC treatment
62593556|NCT01748422||Experimental: Qutenza|Single treatment with Qutenza (topical capsaicin8%) transdermal patch
62809964|NCT04421079|PLACEBO_COMPARATOR|Placebo|Comparable placebos
62809965|NCT04421079|ACTIVE_COMPARATOR|Low Dose BDPP|8 oz. Concord grape juice + 450 mg Grape seed polyphenol extract + 150 mg Trans-resveratrol
62809966|NCT04421079|ACTIVE_COMPARATOR|Medium Dose BDPP|16 oz. Concord grape juice + 900 mg Grape seed polyphenol extract + 300 mg Trans-resveratrol
62809967|NCT04421079|ACTIVE_COMPARATOR|High Dose BDPP|24 oz. Concord grape juice + 1200mg Grape seed polyphenol extract + 450mg Trans-resveratrol
62809968|NCT04942587|EXPERIMENTAL|mother's voices|Standard nursing care including, eye, mouth, nose, diaper change, skin care with baby oil and nurturing was applied respectively to the study groups for approximately 20 minutes. The baby was made listen to the lullaby recorded in the voice of mother's starting with, during and after the care for 10 minutes. Heart rate, saturation, respiration rate and comfort behiavour scores of the newborn was measured 1 minutes before, during and 15 minutes after the care.
62809969|NCT04942587|EXPERIMENTAL|father's voices group|Standard nursing care including, eye, mouth, nose, diaper change, skin care with baby oil and nurturing was applied respectively to the study groups for approximately 20 minutes. The baby was made listen to the lullaby recorded in the voice of father's starting with, during and after the care for 10 minutes. Heart rate, saturation, respiration rate and comfort behiavour scores of the newborn was measured 1 minutes before, during and 15 minutes after the care.
62809970|NCT04942587|NO_INTERVENTION|control group|Standard nursing care including, eye, mouth, nose, diaper change, skin care with baby oil and nurturing was applied respectively to the study groups for approximately 20 minutes.Heart rate, saturation, respiration rate and comfort behiavour scores of the newborn was measured 1 minutes before, during and 15 minutes after the care.
62809971|NCT02322281|EXPERIMENTAL|Rociletinib Monotherapy (500 mg BID)|Daily oral rociletinib at 500 mg BID with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Treatment with rociletinib is continuous and each cycle will comprise of 21 days.
62809972|NCT02322281|EXPERIMENTAL|Rociletinib Monotherapy (625 mg BID)|Daily oral rociletinib at 625 mg BID with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Treatment with rociletinib is continuous and each cycle will comprise of 21 days.
62033572|NCT05019339|ACTIVE_COMPARATOR|Eat Healthy Be Active|Six-week virtual, group nutrition education series using the Eat Healthy Be Active attention control curriculum administered through SNAP-Ed. This curriculum addresses factors affecting overall health and nutritional status: limiting nutrients of concern (saturated fat, sodium, and added sugars), eating healthy while dining out, eating healthy on a budget, losing weight and keeping it off, understanding nutrition facts labels, and being physically active.
62424777|NCT01385501|NO_INTERVENTION|routine care|
62424778|NCT01385501|EXPERIMENTAL|Educational intervention group|
62424779|NCT01573494|EXPERIMENTAL|Metastatic melanoma patients|Sampling of blood before and after chemotherapy
62593557|NCT00692848|EXPERIMENTAL|PCT+|Investigations include CBC, blood culture, urine analysis and culture and procalcitonin. In this arm procalcitonin result is revealed to the attending physician. The decision to treat with antibiotics or to hospitalize was left to him
62033573|NCT02263404|EXPERIMENTAL|Deep Brain Stimulation|DBS Implant and stimulation Intervention: Device: Deep Brain Stimulation
62033574|NCT04305925|EXPERIMENTAL|Focal Laser Ablation|The Orion system will be used to deploy and monitor thermal energy in cancerous regions of the prostate, identified by MRI and confirmed by targeted biopsy.
62424780|NCT02963909|EXPERIMENTAL|ZPIV in Flavivirus-naïve Subjects|Two doses of 5.0mcg ZPIV or placebo on Days 1 and 29. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive a 5.0 mcg of ZPIV or placebo on Day 224
62424781|NCT02963909|EXPERIMENTAL|ZPIV in JEV (IXIARO®)|Two 0.5mL doses of IXIARO® (Valneva) Days 1 and 29 followed by two ZPIV or placebo doses will be administered on Days 112 and 140. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive it on Day 336
62424782|NCT02963909|EXPERIMENTAL|ZPIV in YFV (YF-VAX®)|One 0.5mL dose of YF-VAX® (Sanofi Pasteur) on Day 1 followed by two ZPIV or placebo doses on Days 84 and 112. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive it on Day 308
62433622|NCT04934514|EXPERIMENTAL|Ib stage-Dose extension|In the three fixed dose groups (10 mg/kg, 15 mg/kg and 20 mg/kg), when a certain dose group meets the condition of increasing the dose to the higher dose (after the DLT observation period for the last subject in the dose group), the second phase of the dose expansion study for this dose group can be carried out. Each dose group includes 6 patients with HER2-positive advanced solid tumors who have failed the standard treatment, and the interval between enrollment is determined by the investigator.
62593558|NCT00692848|NO_INTERVENTION|PCT-|Investigations include CBC, blood culture, urine analysis and culture and procalcitonin. In this arm, procalcitonin is not revealed to the attending physician. The decision to treat with antibiotics or to hospitalize was left to him.
62809973|NCT02322281|ACTIVE_COMPARATOR|Pemetrexed or gemcitabine or paclitaxel or docetaxel|"Pemetrexed~500 mg/m2 pemetrexed given intravenously on Day 1 of each 21-day cycle.~Gemcitabine~1250 mg/m2 gemcitabine given intravenously on Day 1 and 8 of each 21-day cycle.~Docetaxel~75 mg/m2 docetaxel (60 mg/m2 for patients residing in East-Asian territories) given intravenously on Day 1 of each 21-day cycle.~or 35 mg/m2 docetaxel given intravenously on a weekly basis as part of a continuous 21-day cycle; i.e. dosing will be on Days 1, 8, and 15 of each 21-day cycle.~Paclitaxel~80 mg/m2 paclitaxel given intravenously on a weekly basis as part of a continuous 21-day cycle; i.e. dosing will be on Days 1, 8, and 15 of each 21-day cycle."
62809974|NCT00875186||multiple-exercise group (ME)|participants exercised 2 times weekly for 1 hour (aerobic endurance training)
62809975|NCT00875186||Low-exercise group (LE)|participants exercises 1 time weekly for 1 hour (aerobic endurance training)
62809976|NCT02843724|ACTIVE_COMPARATOR|Control (Conventional) Arm|Treatment of Type 2 Diabetes according to the Canadian Diabetes Association guidelines. Participants' other health concerns to be addressed as per usual care by practitioners at Wise-Elephant Family Health Team.
62809977|NCT02843724|ACTIVE_COMPARATOR|Integrative (Naturopathic + Conventional) Arm|In addition to conventional care, participants will receive free naturopathic care at Brampton Naturopathic Teaching Clinic (located within the Brampton Civic Hospital). Senior student clinicians will provide care under the direct supervision of licensed naturopathic doctors. A naturopathic menu of treatment options have been designed to reflect naturopathic practice and vetted by 3 licensed naturopathic doctors and experts in the field. Participants' other health concerns will be addressed as per naturopathic doctors' discretion.
62033575|NCT06147102||Endovascular treatment|Patients with unruptured intracranial aneurysms treated endovascularly
62033576|NCT06147102||Surgical treatment|Patients with unruptured intracranial aneurysms treated surgically
62033577|NCT01194960|ACTIVE_COMPARATOR|Docetaxel Alone|Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
62033578|NCT01194960|EXPERIMENTAL|TroVax plus Docetaxel|Subjects will receive both TroVax plus 10 cycles of Docetaxel.
62033579|NCT00440050|EXPERIMENTAL|1.|DHA
62424783|NCT01117714|ACTIVE_COMPARATOR|EUS/EBUS with FNA|EUS/EBUS staging will be performed to evaluate for the presence of mediastinal adenopathy. Each lymph node will be characterized according to published criteria. Staging will follow the TNM system of the AJCC. If present and accessible, at least one lymph node from each accessible station will be aspirated with a separate fine needle using routine FNA and cytological techniques. If multiple lymph nodes are present in a single station, the largest lymph node from that location will be sampled. Patients with cytologically proven mediastinal lymph node metastases (N2 or 3), or those with mediastinal invasion of tumor (T4), will be treated according to standard clinical practice (typically chemotherapy and/or radiotherapy). All complications, morbidity, length of stay attributed to the staging procedures will be recorded at 30 days, or at the time of surgery, whichever is first. All patients will will subsequently undergo surgical resection and complete mediastinal lymph node dissection.
62424784|NCT01117714|ACTIVE_COMPARATOR|Surgical Mediastinoscopy|Within two months following CT scan, surgical mediastinoscopy will be performed to evaluate for the presence of mediastinal adenopathy. Each lymph node will be characterized according to published criteria. Staging will follow the TNM system of the AJCC. Patients with cytologically proven mediastinal lymph node metastases (N2 or 3), or those with mediastinal invasion of tumor (T4), will be treated according to standard clinical practice (typically chemotherapy and/or radiotherapy). All complications, morbidity, length of stay attributed to the diagnostic method (medical or surgical) used for staging will be recorded at 30 days, or at the time of surgery, whichever is first. All patients will will subsequently undergo surgical resection and complete mediastinal lymph node dissection.
62424785|NCT05027373|EXPERIMENTAL|SSGJ-613|
62424786|NCT05027373|PLACEBO_COMPARATOR|Placebo|
62424787|NCT04222556|EXPERIMENTAL|Thiwáhe Gluwáš'akapi|"Weeks 1-7: Weekly in-person 2.5 hour family sessions 30 minute family meal 1 hour separate youth and adult sessions~1 hour family session"
62593559|NCT05970549|EXPERIMENTAL|IRRAflow with Active Fluid Exchange arm|The analysis of the IRRAS catheter will occur prospectively if it is determined the patient meets the enrollment criteria.
62593560|NCT05970549|ACTIVE_COMPARATOR|Retrospective analysis of traditional external ventricular drains|The retrospective analysis will be performed on the last 60 traditional external ventricular drains.
62809978|NCT06234033||Children with Autism Spectrum Disorder|Children with a confirmed diagnosis of autism spectrum disorder made by a qualified psychiatrist.
62809979|NCT06234033||Children with Attention-Deficit Hyperactivity Disorder|Children with a confirmed diagnosis of attention-deficit hyperactivity disorder made by a qualified psychiatrist.
62809980|NCT06234033||Neurotypical children|Children without a known or presumed psychiatric diagnosis.
62809981|NCT02773381|EXPERIMENTAL|Semaglutide 3 mg, 7 mg, 14 mg|
62033580|NCT00440050|PLACEBO_COMPARATOR|2.|Placebo
62033581|NCT05080400|EXPERIMENTAL|Gellan gum|White rice cooked with gellan gum
62033582|NCT05080400|PLACEBO_COMPARATOR|Control|White rice cooked without gellan gum
62033583|NCT04195464|EXPERIMENTAL|DN|
62033584|NCT04195464|SHAM_COMPARATOR|Sham-DN|
62033585|NCT04195464|NO_INTERVENTION|Control|
62033586|NCT04517266|EXPERIMENTAL|experimental group|whole breast/chest wall irradiation + SVC irradiation
62033587|NCT04517266|ACTIVE_COMPARATOR|controlled group|whole breast/chest wall irradiation + IMI+SVC irradiation
62809982|NCT02773381|PLACEBO_COMPARATOR|Placebo|
62809983|NCT04562922|EXPERIMENTAL|Lifemel|"LifeMel is bee-honey obtained using Zuf Globus Ltd technology: it is produced in Israel and distributed by VitalMel in Italy. In Italy Ministry of Health has listed it as a food supplement.~Two tea spoons (5 g each) of honey were administered to subjects on each day of the chemotherapy treatment."
62809984|NCT02805686|EXPERIMENTAL|"En face OCT (C-scan)"|
62033588|NCT02766751|PLACEBO_COMPARATOR|Health Education|The seven sessions will cover: 1) nutrition (2 sessions), 2) sleep hygiene, 3) building immunity (e.g., how to avoid colds/flu), 4) injury/disease prevention (e.g., seat belts, sunscreen, when to get regular check-ups/screenings etc.), 5) benefits of exercise/cardiac health, 6) alternative medicine (massage, acupuncture). These sessions will be primarily didactic and consist of health education, followed by discussion as to how this information compares to that which the participants may have been exposed to in the past.
62424788|NCT04222556|ACTIVE_COMPARATOR|Woyute Waśte|"Respect for community and cultural values regarding research protocols precluded use of a randomized controlled design with a control group receiving no intervention, so we identified a cost-effective comparison condition program to offer value to study participants. A focus on healthy eating and exercise was of interest to community partners and not expected to directly confound the primary outcomes of the TG program (substance use and suicide risk).~Week 1 in-person 2.5 hour family session 30 minute family meal 2 hour interactive family session (3 stations) Weeks 2-7: text messages with program content and questions"
62424789|NCT03078530|PLACEBO_COMPARATOR|Placebo|Placebo (not an active drug/ Inactive component) is given to this group
62424790|NCT03078530|EXPERIMENTAL|Visbiome|Visbiome (probiotic mixture) is given to this group.
62424791|NCT03078530|EXPERIMENTAL|VSL #3|VSL #3 (probiotic mixture) is given to this group
62424792|NCT00552617|PLACEBO_COMPARATOR|Rocuronium + Placebo|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
62593561|NCT04190511|EXPERIMENTAL|Prebiotic-containing dairy intervention group|
62593562|NCT04190511|ACTIVE_COMPARATOR|Dietary intervention group|
62593563|NCT04190511|NO_INTERVENTION|Conventional care group|
62593564|NCT06488495|EXPERIMENTAL|Immediate Intervention Group|Participants receive the exercise intervention immediately after randomization
62809985|NCT03651635||Medical ICU Patients|All patients admitted to the medical intensive care unit of the University hospital of Zurich during the recruitment period
62809986|NCT04974736|EXPERIMENTAL|iEHR + Navigator|
62809987|NCT04974736|NO_INTERVENTION|Usual Care Control|Usual care delivery in pediatric primary care offices.
62809988|NCT04527640|EXPERIMENTAL|Synbiotic Arm|Patients receiving synbiotics: Lactobacillus acidophilus \& Bifidobacterium longum 5x10\^9 Colony Forming Unit (CFU) and Fructooligosaccharides (FOS) 60 mg, 2 capsules/day for 60 days
62593565|NCT06488495|OTHER|Delayed Intervention Group|Participants receive the exercise intervention immediately after enrollment.
62809989|NCT04527640|PLACEBO_COMPARATOR|Placebo Arm|Patients receiving placebo capsules containing saccharum lactis (2 capsules/day for 60 days)
62593566|NCT05197647||Patients with mild COVID-19|Patients with symptomatic COVID-19 disease not requiring hospitalization.
62593567|NCT04948203|ACTIVE_COMPARATOR|Sirolimus 0.5mg|Subject will take Sirolimus 0.5mg orally daily for 14 days.
62809990|NCT03367767||1|Former AREDS2 and AREDS2 Follow-On participants
62809991|NCT05876481|EXPERIMENTAL|Psilocybin-assisted Psychotherapy|All participants will receive 25mg psilocybin (capsule, hard, oral administration) in two 8-hour psilocybin dosing sessions, followed by Cognitive Processing Therapy.
62424793|NCT00552617|EXPERIMENTAL|Rocuronium + 0.5 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
62424794|NCT00552617|EXPERIMENTAL|Rocuronium + 1.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
62593568|NCT04948203|ACTIVE_COMPARATOR|Sirolimus 1mg|Subject will take Sirolimus 1mg orally daily for 14 days.
62593569|NCT04948203|ACTIVE_COMPARATOR|Sirolimus 2mg|Subject will take Sirolimus 2mg orally daily for 14 days.
62809992|NCT02536612|EXPERIMENTAL|Lottery|"Conditional economic incentive (CEI) lotto arm participants will get a chance to win a type of lottery or lotto ticket with a 50% chance of winning each time: (a) if they come back to the clinic and are still using a modern contraception method after 3 months (including IUD, injectable contraceptive, or implant); (b) if they come back to the clinic and are still using modern contraception after 6 months; and (c) if they come back to the clinic at 6 months and they don't have a new curable STD (such as syphilis).~They will also will receive reimbursement to cover their transport and time at baseline, at 3 months and at 6 months."
62809993|NCT02536612|ACTIVE_COMPARATOR|No Lottery|Participants in the Control (No CEI Lotto) group will receive reimbursement to cover their transport and time at baseline, at 3 months and at 6 months; they will NOT have a chance to win a lottery even if they are still using a modern contraception and are free of new curable STDs.
62809994|NCT03602677|EXPERIMENTAL|ICG fluorescence imaging|Colorectal surgery and anastomosis will be performed according to standard practice with the addition of intraoperative indocyanine green fluorescence imaging.
62033589|NCT02766751|EXPERIMENTAL|HIVPASS|Over 7 sessions, the interventionist and the participant will explore the relationship between pain, depressive symptoms, and HIV. General information about pain, HIV and depression will be discussed, as will avoidance of physical activity. Psychoeducation about these areas will be tied to the participant's stated life goals, and exposure exercises and goal lists will be developed. Later sessions will integrate continued efforts towards reaching goals and reducing avoidance. A release of information will be obtained from the participant to allow study session chart notes to be placed in the medical record at the participant's PCP office and to allow the PCP and the study interventionist to discuss treatment coordination.
62233870|NCT04265560|EXPERIMENTAL|Progressive Resistance Training|"The intervention group will receive 8 weeks of Progressive Resistance Training (PRT), twice a week, in addition to usual care. An upper limb functional goal will be identified through discussion with the researcher and the participant. PRT will be individually tailored to target two muscle groups and will be chosen in order to develop strength to progress towards the participants functional goal.~The chronic spinal cord injury exercise guideline parameters will be applied (3 sets of 8-10 repetitions, 1-2 mins rest between sets). Participants will be inducted to their PRT programme and will then independently complete the 8 week programme. During each of the following sessions, assistance for set up of equipment and/or limb position will be given by the researcher and/or the participants family, friend or carer, once they have been trained. PRT sessions will be recorded in a diary to monitor sets and repetitions completed, and intensity (visual analogue scale (VAS))."
62233871|NCT04265560|NO_INTERVENTION|Usual care only|Participants will continue with their usual care, consistent with standard National Health Service (NHS) care in this population. Usual physiotherapy care is provided, up to 2 times per day, 4 to 5 days per week, each lasting up to 90 minutes. Physiotherapists provide a combination of group exercise and one to one function-orientated physiotherapy sessions to improve balance, general muscle strength, wheelchair and/or transfer skills.
62424795|NCT00552617|EXPERIMENTAL|Rocuronium + 2.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
62424796|NCT00552617|EXPERIMENTAL|Rocuronium + 4.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
62424797|NCT00552617|PLACEBO_COMPARATOR|Vecuronium + Placebo|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
62424798|NCT00552617|EXPERIMENTAL|Vecuronium + 0.5 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
62424799|NCT00552617|EXPERIMENTAL|Vecuronium + 1.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
62593570|NCT02893982|EXPERIMENTAL|brachytherapy|image-guided navigation of catheter placement for high dose rate (HDR) brachytherapy treatment of patients with primary liver lesions
62593571|NCT03740555|EXPERIMENTAL|HNC042 single dose|HNC042,freeze-dried powder,single ascending doses Single dose,
62809995|NCT03602677|NO_INTERVENTION|Standard procedure|Standard colorectal surgery and anastomosis.
62809996|NCT02656017|EXPERIMENTAL|Metformin|"Participants will be started on 500 mg of metformin once daily, with the following scheduled dose titrations:~* Increase to 500mg twice daily at week 2~* Increase to 1000mg qAM, 500mg qPM at week 4~* Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months).~  * Increased titrations based on tolerability"
62033590|NCT00924885|EXPERIMENTAL|Thin Follicle Aspiration Needle|Transvaginal oocyte retrieval was performed under local anaesthesia and under guidance of ultrasound with the RN needle that had an outer diameter of 0.9 mm (20 gauge) and inner diameter of 0.6 mm for the last 50 mm from the tip of the needle and an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the remaining length of the needle. The puncture procedure was performed according to each clinic's standard routine. Aspiration pressure was kept at a negative pressure between 90 and 120 mmHg.
62033591|NCT00924885|ACTIVE_COMPARATOR|Standard Follicle Aspiration Needle|"Transvaginal oocyte retrieval was performed under local anaesthesia and under guidance of ultrasound with the SN needle that had an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the remaining length of the needle. or the SN with an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the whole length of the needle.~The puncture procedure was performed according to each clinic's standard routine. Aspiration pressure was kept at a negative pressure between 90 and 120 mmHg."
62593572|NCT03740555|PLACEBO_COMPARATOR|Placebo single dose|Placebo single ascending doses , Intravenous route Single dose
62593573|NCT03740555|EXPERIMENTAL|HNC042 multiple ascending doses|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route
62809997|NCT02656017|PLACEBO_COMPARATOR|Placebo|"Participants will be started on 500 mg of placebo once daily, with the following scheduled dose titrations:~* Increase to 500mg twice daily at week 2~* Increase to 1000mg qAM, 500mg qPM at week 4~* Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months).~  * Increased titrations based on tolerability"
62424800|NCT00552617|EXPERIMENTAL|Vecuronium + 2.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
62243401|NCT06725147|ACTIVE_COMPARATOR|Penn Wellness Modules|Participants randomized to the control condition will be expected to use the intervention at least once per week (for around 30 minutes) but are encouraged to use as needed/wanted. The control condition consists of a curated collection of digital wellness resources that are already available freely to Penn students, including tips on getting good sleep, learning center material on time management and procrastination, and so on. The resources will be accessed via a single website, but there is no interactive component.
62424801|NCT00552617|EXPERIMENTAL|Vecuronium + 4.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
62593574|NCT03740555|PLACEBO_COMPARATOR|Placebo, multiple ascending doses|Placebo, multiple ascending doses, Intravenous route,
62593575|NCT06085963|PLACEBO_COMPARATOR|Control group|"20 subjects will be challenged with both a dissolved placebo-tablet and 0.9% saline solution. This provocation will be performed as a one-sided blinded challenge which will demonstrate that the NAC is truly negative.~Subjects will be randomized to dissolved placebo-tablet or saline solution in a cross over design. 10 subjects will start with dissolved placebo-tablet and 10 will start with 0.9% saline solution. After 30 minutes the subjects will switch to receive a challenge with the other solution. This will ensure negative reactivity to the excipients and challenge as a method. The placebo solution will be prepared the same as way as the active ITULAZAX® stock solutio"
62593576|NCT06085963|ACTIVE_COMPARATOR|Birch group|NAC will be applied to 70 patients with birch pollen allergy. Subjects will initially receive a NAC with 0,9% saline solution to ensure negative reactivity to the challenge as method. If negative after 30 minutes NAC will continue with one puff (1x0.1 ml) dissolved ITULAZAX® (1 SQ-Bet/ml) in each nostril.
62593577|NCT05919992|EXPERIMENTAL|Metyrapone And Hydrocortisone|During one of the study periods, subjects receive hydrocortisone 19.9 mg/d subcutaneously via a pump in a pulsed fashion (eight times/day) and metyrapone per os (starting with a dose of 500 mg/d, then the dose will be increased the next days until 3000mg/d is achieved).
62593578|NCT05919992|PLACEBO_COMPARATOR|Placebo|During the other study period, subjects receive placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion and the same dose of placebo tablets p.o instead of metyrapone
62593579|NCT04178707|OTHER|Intervention|Using microdialysis the patients inner enviorment of the anal fistula will be measured - levels of lactate, glucose and pyruvate.
62593580|NCT06410001|EXPERIMENTAL|Spinal injury patients|Patients with chronic, traumatic SCI will be recruited if they meet the following criteria: greater than 22 years of age, motor complete ASIA classification A or B with a neurological level of injury between C4 and C7 (upper extremity weakness), \>1 year post-injury, exhibit signs of autonomic dysfunction on tilt table testing, and have intact segmental reflexes below the level of injury.
62593581|NCT03509428|NO_INTERVENTION|Control|Usual care plus additional monitoring
62593582|NCT03509428|EXPERIMENTAL|SRETP|Structured Responsive Exercise Training Programme (SRETP) prior to surgery
62593583|NCT03509428|EXPERIMENTAL|Psychological support|Psychological support prior to surgery
62033592|NCT06435234|EXPERIMENTAL|intervention group|
62033593|NCT06435234|NO_INTERVENTION|control group|
62424802|NCT05593783||patients with lithiasis treated with ureterolithotripsy|patients with lithiasis treated with ureterolithotripsy
62033594|NCT04179487||Pregnant Patients with Suspected PE|Pregnant Patients with Suspected pulmonary embolism undergoing low dose CT pulmonary angiogram
62424803|NCT05593783||patients with lithiasis treated with percutaneous nephrolithotomy|patients with lithiasis treated with percutaneous nephrolithotomy
62424804|NCT05593783||patients with lithiasis treated with extracorporeal shockwave lithotripsy|patients with lithiasis treated with extracorporeal shockwave lithotripsy
62424805|NCT00429091|PLACEBO_COMPARATOR|1|
62424806|NCT00429091|EXPERIMENTAL|2|
62424807|NCT00429091|ACTIVE_COMPARATOR|3|
62424808|NCT01864525|PLACEBO_COMPARATOR|Inactive capsule|Participants will receive a pill/capsule with an inactive ingredient during the placebo arm of this study.
62424809|NCT01864525|EXPERIMENTAL|Octanoic acid|Participants will receive a pill/capsule with octanoic acid (amount determined by the participant's weight) during the experimental arm of this study.
62424810|NCT03563235|EXPERIMENTAL|Xulin Jiangu granules|Xulin Jiangu granule 15g tablet by mouth every 6 hour for 6 months
62424811|NCT03563235|ACTIVE_COMPARATOR|Calcitriol capsules|Calcitriol capsules tablets 0.25 ug by mouth every 6 hour for 6 months
62424812|NCT00934622|EXPERIMENTAL|AcrySof® ReSTOR® Aspheric IOL|AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL)
62424813|NCT01456871||Healthy adult females|Females, aged 20 to 30 with no history of upper extremity injury or disorder in the non-dominant arm, no history of neurologic or bleeding disorder, and no evidence of Linburg-Comstock syndrome.
62424814|NCT01812291|EXPERIMENTAL|Stepped Care Approach for Depression|"Step 1: Diabetes-Specific CBT (5 group sessions)~Step 2: Depression-Specific CBT (6 single sessions)~Step 3: Referral to Psychotherapist and/or Psychiatrist"
62424815|NCT01812291|ACTIVE_COMPARATOR|Treatment-as-usual|Standard Diabetes Education
62424816|NCT01954784|EXPERIMENTAL|Treatment (nonmyeloablative alloHSCT, lenalidomide)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate on days -5 to -3 and undergo TBI on day -1.~TRANSPLANT: Patients undergo allogeneic hematopoietic SCT on day 0.~GVHD PROPHYLAXIS: Patients receive standard GVHD prophylaxis comprising cyclosporine PO BID beginning on day -1 with taper beginning on day 100, mycophenolate mofetil PO BID on days 1-56, and bortezomib SC weekly from day 1 to day 91.~MAINTENANCE THERAPY: Beginning on day 100, patients receive lenalidomide PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62424817|NCT01424618|ACTIVE_COMPARATOR|GnRh agonist|This arm will use a GnRH agonist to suppress pituitary-ovarian function
62424818|NCT01424618|EXPERIMENTAL|GnRH antagonist|A GnRH antagonist will be used to suppress pituitary-ovarian function
62424819|NCT04254263|EXPERIMENTAL|Pyrotinib|pyrotinib 400 mg, orally once daily for one year
62424820|NCT04254263|NO_INTERVENTION|No Pyrotinib|Observation follow-up
62424821|NCT04300907|EXPERIMENTAL|Provant Infinity Therapy|Open-label treatment with Provant Infinity Therapy
62424822|NCT04474288||Person Under Investigation (PUI)|PUI's are subjects who were admitted to the hospital with symptoms suspicious for COVID-19.
62424823|NCT04474288||Asymptomatic Person under Screening (APS)|APS's are those patients who do NOT meet the criteria to be a suspect COVID- 19 patient but are being tested because they are being admitted, are required for testing by state mandate, or are having a procedure, etc.
62593584|NCT03509428|EXPERIMENTAL|SRETP and psychological support|Structured Responsive Exercise Training Programme (SRETP) and psychological support prior to surgery
62593585|NCT06562153||Volunteer Participants with Major Depressive Disorders (MDD)|20 patients with MDD receiving 5-day accelerated transcranial magnetic stimulation therapy (TMS) from the clinic will be recruited to participate in this observational neuroimaging study. Participants will undergo two fMRI scans at baseline and post-treatment.
62593586|NCT02377479|ACTIVE_COMPARATOR|Clomiphene alone|The patient will take 100mg clomiphene orally from cycle days 3-7
62809998|NCT04504422|EXPERIMENTAL|Primary motor cortex|The anodic electrode is positioned in the primary motor cortex (Cz) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
62809999|NCT04504422|EXPERIMENTAL|Left dorsolateral prefrontal cortex|The anodic electrode is positioned in the left dorsolateral prefrontal cortex (F3) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
62033595|NCT05102890|EXPERIMENTAL|Intervention group|Patients 65 years old and older will receive a pre-consultation screening questionnaire by phone prior to their virtual or in-person visit. A summary report based on the results of the questionnaire will be placed in the patient electronic chart for use by the clinician at the time of visit.
62243402|NCT01448122|ACTIVE_COMPARATOR|Avene Compact Honey SPF 50|Study product will be scraped from compact case and weighed. Product will be applied to half the area to be exposed with visible light at a concentration of 2 mg/mL.
62424824|NCT04647279||Normal control group|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
62424825|NCT04647279||Osteopenia|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
62424826|NCT04647279||Osteoporosis|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
62424827|NCT04175678|ACTIVE_COMPARATOR|Normal/Active|No intervention
62424828|NCT04175678|PLACEBO_COMPARATOR|Obese/Inactive|Observational clinic visits
62424829|NCT04175678|EXPERIMENTAL|Diet|low fat/low caloric diet
62424830|NCT04175678|EXPERIMENTAL|Exercise Training|≥3 sessions with fitness trainer per week, for ≥30 min, at moderate to high intensity
62033596|NCT05102890|NO_INTERVENTION|Control Group|Usual care in the primary care clinic
62033597|NCT06579573|EXPERIMENTAL|Cenobamate|
62424831|NCT04175678|EXPERIMENTAL|Diet and exercise training|low fat/low caloric diet and ≥3 sessions with fitness trainer per week, for ≥30 min, at moderate to high intensity
62424832|NCT00712491|EXPERIMENTAL|1|
62424833|NCT00712491|EXPERIMENTAL|2|
62424834|NCT02700074||Minimally Verbal|Minimally verbal adolescents with Autism Spectrum Disorder
62424835|NCT02700074||Verbal Impaired|Language impaired adolescents with ASD
62424836|NCT02700074||Verbal Normal|Language normal adolescents with ASD
62424837|NCT02700074||Typically Developing|Typically developing adolescent controls
62424838|NCT01119352|EXPERIMENTAL|1|
62424839|NCT01119352|PLACEBO_COMPARATOR|2|
62593587|NCT02377479|ACTIVE_COMPARATOR|Letrozole alone|The patient will take 5mg Letrozole orally from cycle days 3-7
62233872|NCT01690312|EXPERIMENTAL|1 (Dietary Supplement - Fish Oil)|"On Day 1 \& Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.~On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol."
62233873|NCT01690312|EXPERIMENTAL|2 (Placebo)|"On Day 1 \& Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.~On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol."
62593588|NCT02377479|EXPERIMENTAL|Combination Clomiphene and Letrozole|The patient will take a dose of 5mg Letrozole every night and 100mg clomiphene every day after lunch from cycle days 3-7.
62810000|NCT04504422|EXPERIMENTAL|Ventromedial prefrontal cortex|The anodic electrode is positioned in the ventromedial prefrontal cortex (Fpz) and the cathode electrode on the left dorsolateral prefrontal cortex (F4). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
62810001|NCT04504422|SHAM_COMPARATOR|Sham stimulation|The anodic electrode is positioned in the primary motor cortex (Cz) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA during first 30 seconds, decreases to 0 mA over 30 seconds, and then stops supplying for 19 minutes.
62233874|NCT05252156|EXPERIMENTAL|Therapy Dose-A|Neuromuscular electrical stimulation; two 20-minute sessions per day.
62233875|NCT05252156|EXPERIMENTAL|Therapy Dose-B|Neuromuscular electrical stimulation; one 30-minute session per day.
62593589|NCT02455258|EXPERIMENTAL|Dance/Movement Therapy (DMT)|
62593590|NCT02455258|ACTIVE_COMPARATOR|Aerobics Exercise (AE)|
62810002|NCT01526447|EXPERIMENTAL|Craniosacral Therapy (CST)|Each participant of the experimental group receives 8 Craniosacral Therapy units once a week of 45 minutes.
62810003|NCT01526447|SHAM_COMPARATOR|Sham Craniosacral Therapy (SHAM)|Each participant of the sham group receives 8 sham therapy units once a week of 45 minutes.
62810004|NCT05681650|EXPERIMENTAL|HypoSti.CAR-HER2 T cells|Enrolled participants will be given a preconditioning regimen consisted of albumin-bound paclitaxel, cyclophosphamide and/or fludarabine before the infusion of HypoSti.CAR-HER2 T cells. Fludarabine will be administered only before the first dose infusion, and will not be administered before the secondary or multiple doses of HypoSti.CAR-HER2 T cell infusion.
62810005|NCT04772872||Group A:Naturally conceived singleton|"* Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~* Apgar score will be represented by the variance of degree of scores.~* Birth weight will be measured in grams."
62593591|NCT02455258|NO_INTERVENTION|Waiting List|This group is placed on a waiting list and asked to refrain from making any changes to their current lifestyle.
62593592|NCT05239494|EXPERIMENTAL|Dailies Total1|All participants will be asked to wear Dailies Total1 for the duration of this study.
62593593|NCT06232057|EXPERIMENTAL|Intervention Group|Virtual Reality Application Group
62593594|NCT06232057|NO_INTERVENTION|Control Group|Control group without any intervention
62810006|NCT04772872||Group B: Singleton conceived from fresh embryo transfer(IVF/ICSI)|"* Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~* Apgar score will be represented by the variance of degree of scores.~* Birth weight will be measured in grams."
62033598|NCT03913741|EXPERIMENTAL|Experimental tisotumab vedotin|Open label, single arm trial where tisotumab vedotin will be administered
62033599|NCT04104867|ACTIVE_COMPARATOR|Colonoscopy preparation by PEG-EL with Itopride|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
62233876|NCT05252156|NO_INTERVENTION|No Therapy|Under the care of the referring physician, with no therapy applied
62233877|NCT03143660|ACTIVE_COMPARATOR|Coaching|A parent support component consisting of eight weekly telephone counseling calls by centrally located nutritionists to provide parents coaching tailored to their family's unique needs to help them set goals and make targeted lifestyle changes recommended by the American Academy of Pediatrics (AAP) for Stage 1, Prevention Plus, accompanied by a parent booklet
62810007|NCT04772872||Group C: Singleton conceived from frozen embryo transfer (IVF/ICSI)|"* Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~* Apgar score will be represented by the variance of degree of scores.~* Birth weight will be measured in grams."
62810008|NCT06119126|EXPERIMENTAL|Group A|Diode laser application only
62033600|NCT04104867|PLACEBO_COMPARATOR|Colonoscopy preparation by PEG-EL with Placebo|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
62233878|NCT03143660|ACTIVE_COMPARATOR|Materials|Parents will receive the same educational materials provided in the Fitline family workbook mailed over 8 weeks to control for weekly contact and educational curriculum, but no Fitline counseling.
62233879|NCT02973074|OTHER|OLEOvital|30mg iron are being administered orally twice a day for a period of 4 Weeks it is a granulated powder which is taken orally and then solved with saliva, without taking water
62233880|NCT04395703||Maternity staff|Interviews with maternity staff working within a maternity unit including midwifery managers and infant feeding lead staff members.
62433623|NCT04934514|EXPERIMENTAL|IIa stage-Single-agent study (cohort 1)|After the completion of the dose escalation in the 20 mg/kg dose group (Phase Ia), a total of 30 patients with HER2-positive advanced biliary system tumors who have failed standard treatment will be enrolled in the 20 mg/kg dose group. Every 3 weeks is a cycle, and the drug is administered once on the first day of each cycle, and the treatment is continued until any end-point event occurs.
62033601|NCT04104867|ACTIVE_COMPARATOR|Colonoscopy preparation by PEG-EL with Domperidone|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
62033602|NCT01604330|EXPERIMENTAL|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
62233881|NCT04395703||Neonatal unit staff|Staff working within a local maternity unit.
62233882|NCT02216617|EXPERIMENTAL|Induction chemotherapy TPA|"3 Cycles of induction chemotherapy TPA : (Taxotere, Cisplatin, Afatinib)~1 cycle = 3 weeks, three cycles of treatment in total (or 9 weeks)~Docetaxel 75 mg / m2 at D1 Cisplatin 75 mg / m 2 at D1 Afatinib: x mg / day D2 to D21 by level: (Level 1: 20 mg / day; Level 2: 30 mg / day; Level 3: 40 mg / day)"
62233883|NCT05087485|EXPERIMENTAL|Basic science|This group will be exposed to a written learning content that includes both the presentation and underlying reason of dermoscopic criteria
62233884|NCT05087485|EXPERIMENTAL|visual criteria|This group will be exposed to a written learning content that includes only the presentation of dermoscopic criteria
62233885|NCT00028743|ACTIVE_COMPARATOR|Cisplatin, Topotecan, Paclitaxel plus Carboplatin|Arm 1
62233886|NCT00028743|ACTIVE_COMPARATOR|Paclitaxel plus Carboplatin|Arm 2
62233887|NCT00512200||Case|Patients aged 65 or older
62233888|NCT00512200||Control|Patients aged 20 to 40
62233889|NCT00512200||Control 2|Healthy volunteers aged 65 or older
62233890|NCT02147665|EXPERIMENTAL|Hookah smoking|Healthy habitual Hookah smokers will undergo microneurography, myocardial contrast echocardiogram or venous occlusion plethysmography before and after Hookah smoking.
62243403|NCT01448122|NO_INTERVENTION|No intervention|Half of the area to be exposed to visible light will have no study product applied.
62810009|NCT06119126|EXPERIMENTAL|Group B|SDF application only
62810010|NCT06119126|EXPERIMENTAL|Group C|Diode laser application followed by pits and fissure sealant.
62810011|NCT06119126|EXPERIMENTAL|Group D|SDF application followed by pits and fissure sealant.
62810012|NCT03342586||Central Nervous System Lymphoma|Participants will have non-Hodgkins lymphoma involving the brain (primary or secondary)
62033603|NCT01604330|PLACEBO_COMPARATOR|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
62233891|NCT04487834|ACTIVE_COMPARATOR|Simethicone Solution|Treatment with simethicone (Espumisan®, 100 mg/ml, Berlin-Chemie / Menarini Polska Sp z o.o., Warsaw, Poland) for four weeks. Simethicone was administered 3-6 times per day with each treatment comprising 6 drops of the 100 mg/ml emulsion.
62233892|NCT04487834|EXPERIMENTAL|Vivatlac Baby|Treatment with one stick pack of the multi-strain synbiotic (Vivatlac® Baby, Vivatrex GmbH, Rees, Germany) per day for four weeks. Each stick pack of Vivatlac® Baby contains a total of 10\^9 colony forming units (CFU) with equal CFU amounts of the following probiotic bacteria: L. acidophilus LA-14, L. casei R0215; L. paracasei Lpc-3; L. plantarum Lp-115; L. rhamnosus GG, L. salivarius Ls-33, B. lactis Bl-04, B. bifidum R0071, B. longum R0175 and 1.43 g of the prebiotic fructooligosaccharides.
62033604|NCT01587651|EXPERIMENTAL|Prasugrel Maintenance Dose|Prasugrel 10 mg QD MD
62033605|NCT01587651|ACTIVE_COMPARATOR|Ticagrelor Maintenance Dose|Ticagrelor 90 mg twice-daily (BID) MD
62033606|NCT01587651|EXPERIMENTAL|Prasugrel Loading Dose|Prasugrel 60mg Loading Dose (LD), followed by prasugrel 10mg once-daily (QD) Maintenance Dose (MD)
62033607|NCT03358225||Anterior Cervical Discectomy and Fusion|The patients undergoing anterior cervical discectomy and fusion surgery
62033608|NCT03358225||Cervical Artificial Disc Replacement|The patients undergoing cervical artificial disc replacement surgery
62033609|NCT03358225||Hybrid surgery|The patients undergoing hybrid surgery(1-level ADR plus 1-level ACDF) surgery
62033610|NCT06670612|EXPERIMENTAL|intervention group|". Being 18 years or older~* Having orientation to place and time~* No communication (visual, auditory) barriers~* No neuromuscular blockade with medication~* Not applying nerve block,~* Not having peripheral neuropathy or quadriplegia~* Sedation level 1, 2, 3 and 4 according to the Ramsey Sedation Scale (RSS)"
62033611|NCT06670612|NO_INTERVENTION|control group|". Being 18 years or older~* Having orientation to place and time~* No communication (visual, auditory) barriers~* No neuromuscular blockade with medication~* Not applying nerve block,~* Not having peripheral neuropathy or quadriplegia~* Sedation level 1, 2, 3 and 4 according to the Ramsey Sedation Scale (RSS)"
62593595|NCT03737708|EXPERIMENTAL|tacrolimus + biologics|Participants will receive tacrolimus daily for 12 weeks. In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
62593596|NCT03737708|ACTIVE_COMPARATOR|methotrexate + biologics|Participants will receive methotrexate weekly for 12 weeks. In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
62033612|NCT00126516|ACTIVE_COMPARATOR|1|Angiotensin II Receptor Antagonists group
62593597|NCT02751879||Non small cell lung cancer (NSCLC)|patients with Epidermal growth factor receptor (EGFR) mutation (common mutations), TKI-naïve advanced non small cell lung cancer (NSCLC), treated with Gi(l)otrif® as the first-line treatment for NSCLC within the approved label
62593598|NCT02180295|EXPERIMENTAL|V212 Lot 1|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
62593599|NCT02180295|EXPERIMENTAL|V212 Lot 2|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
62593600|NCT02180295|EXPERIMENTAL|V212 Lot 3|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
62593601|NCT06618690|EXPERIMENTAL|Grupo experimental|The participants will be recruited through the oncologists of the Hospital Universitario Torrecárdenas (Almería). The proposal will be carried out in the intervention group (group 1), while the control group (group 2) will undergo the conventional recommendations indicated for this type of patients.
62593602|NCT06618690|NO_INTERVENTION|group control|The participants will be recruited through the oncologists of the Hospital Universitario Torrecárdenas (Almería). The proposal will be carried out in the intervention group (group 1), while the control group (group 2) will undergo the conventional recommendations indicated for this type of patients.
62033613|NCT00126516|ACTIVE_COMPARATOR|2|Angiotensin-converting Enzyme Inhibitors group
62033614|NCT04753840|EXPERIMENTAL|Experimental A: Drug group+lifestyle intervention|Experimental group A used only one antihypertensive drug (ACEI / ARB, beta blocker, calcium channel blocker, diuretic, etc.) plus lifestyle intervention to control blood pressure.
62033615|NCT04753840|EXPERIMENTAL|Experimental B: RIPC group+lifestyle intervention|The experimental group B received ripc treatment of upper limbs every day plus lifestyle intervention until the end of the follow-up. The treatment time was 40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles.
62033616|NCT04753840|OTHER|Experimental c: lifestyle intervention|The control group take lifestyle intervention to control blood pressure, such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.
62233893|NCT02883283|ACTIVE_COMPARATOR|Epidural Catheter Administration|Participants will receive the 10 mL epidural loading dose in 5 mL increments via the epidural catheter following catheter placement. (Current standard practice) Epidural loading dose via epidural catheter.
62243404|NCT05227872||Decompensated HF|
62243405|NCT05227872||Compensated HF|
62593603|NCT00556686||1|Individuals with a history of canker sores.
62033617|NCT01348451|EXPERIMENTAL|surgery|A sequential design of five groups will be utilized to reduce risk to subjects. The first group (Group A) will include six subjects and the subsequent groups will include three subjects per group. Each group represents both different inclusion criteria and location of surgery.
62033618|NCT02089672||Atrial flutter patients|Atrial flutter patients undergoing catheter ablation
62033619|NCT03577600|EXPERIMENTAL|QMRT using the Cytotron®|Experimental: QMRT using the Cytotron® Intervention: 28 days of treatment with QMRT with the Cytotron®. Patients diagnosed with terminal brain tumors between 3 and 16 years of age whose parents agree to participate in the study and have signed informed consent and informed consent in patients with age or mental age over 8 years.
62033620|NCT01311999||IGRA-positive group|The subjects who have positive results of interferon-gamma release assay
62033621|NCT01311999||IGRA-negative group|The subjects who have negative results of interferon-gamma release assay
62033622|NCT00333463||Intervention group|The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
62033623|NCT00333463||Non-Intervention Group|The control group was told to take drops as prescribed and received no additional intervention.
62033624|NCT05153980|EXPERIMENTAL|Blood Flow Restriction|Incorporation of Blood Flow Restriction within the warm-up routine.
62593604|NCT00556686||2|Individuals with no history of canker sores.
62810013|NCT00510835|EXPERIMENTAL|1|Early Goal Directed Therapy (EGDT) - The study team will insert a central venous catheter (CVC) for continuous monitoring of the subjects' central venous pressure (CVP) and central venous oxygen saturation (Scv02). The study team will use this information to give fluid, blood, and heart medications in a structured fashion. The CVC is FDA approved and routinely used in hospitals.
62810014|NCT00510835|EXPERIMENTAL|2|Protocolized Standard Care (PSC)- The study team will monitor the subjects' blood pressure and blood oxygen level with routine equipment. The study team will use this information to give fluid and heart medications in a structured fashion. CVCs will only be used when standard IVs are unable to give the proper amount of fluids and medicines. Blood transfusions will be given according to currently recommended guidelines.
62033625|NCT05153980|ACTIVE_COMPARATOR|Control Group|Warm-up routine without any special intervention (no Blood Flow Restriction).
62033626|NCT06665945||Women with a Recent Diagnosis of Ovarian Cancer (n=90)|
62033627|NCT06665945||Women with a Recent Diagnosis of Ovarian Mass (n=125)|
62033628|NCT06665945||Control Women without Ovarian Cancer (n=30)|
62033629|NCT06627920||Descriptive|A single population is used to estimate blood pressure, heart rate and oxygen saturation in order to study and validate the use of the KC08 smartwatch.
62033630|NCT02367261|EXPERIMENTAL|SPI dental implant|Subjects implanted with SPI implant
62033631|NCT02277106|EXPERIMENTAL|Stage 1 (Double-blind): SAGE 547, Then Placebo|Participants received a 12-hour intravenous (IV) infusion of SAGE 547, at ascending doses of 29, 58, and 86 micrograms per kilogram of body weight per hour (μg/kg/h), 4 hours each, on Day 1 of Stage 1 \[Treatment Period 1 (TP 1)\]. After a washout period of approximately 7 days, participants received a 12-hour IV infusion of SAGE-547 matching-placebo, on Day 10 of Stage 1 \[Treatment Period 2 (TP 2)\].
62033632|NCT02277106|EXPERIMENTAL|Stage 1 (Double-blind): Placebo, Then SAGE-547|Participants received a 12-hour IV infusion of SAGE-547 matching-placebo on Day 1 of Stage 1 (TP 1). After a washout period of approximately 7 days, participants received a 12-hour IV infusion of SAGE 547 at ascending doses of 29, 58, and 86 μg/kg/h, 4 hours each, on Day 10 of Stage 1 (TP 2).
62033633|NCT02277106|EXPERIMENTAL|Stage 2 (Open Label): SAGE-547|Participants who completed Stage 1 were invited to receive a 10-hour IV infusion of SAGE 547, at ascending doses of 90 μg/kg/h for 1 hour, 120 μg/kg/h for 1 hour, and 150 μg/kg/h for 8 hours on Day 1 of Stage 2.
62033634|NCT01345006|EXPERIMENTAL|MA09-hRPE|Patients will undergo subretinal injection of MA09-hRPE
62033635|NCT05534581|ACTIVE_COMPARATOR|Arctic Front Cryoballoon (Medtronic)|Pulmonary vein isolation using the Arctic Front Cryoballoon (Medtronic)
62810015|NCT00510835|ACTIVE_COMPARATOR|3|Usual Care - The attending physicians will treat the subjects according to their standard treatment plan and without any influence from the study team. A member of the study team will simply observe and record what happens.
62810016|NCT00801736|EXPERIMENTAL|Platinum Arm|Cisplatin (IMP) / Pemetrexed (IMP)
62810017|NCT00801736|EXPERIMENTAL|Non Platinum Arm|Paclitaxel (IMP) / Pemetrexed (IMP)
62810018|NCT05851118||Non-Specific Low Back Pain patients|Participants must have pain located between the thoracolumbar hinge and the lower gluteal fold, with or without pain in either leg, present for more than 12 weeks, on a daily or almost daily basis (at least 4 days out of 7).
62810019|NCT05851118||Control group|Participant with no current or past chronic pain
62810020|NCT03546985|EXPERIMENTAL|Group A|
62810021|NCT03546985|ACTIVE_COMPARATOR|Group B|
62810022|NCT01428258|EXPERIMENTAL|GMP Diet/GMP Medical Foods|The experimental intervention is the GMP diet followed at home for 3-wk. In this randomized crossover study, half of subjects (n=15) were randomized to receive the GMP diet as the first arm, and half of the subjects (n=15) were randomized to receive the GMP diet as the second arm.
62810023|NCT01428258|ACTIVE_COMPARATOR|AA Diet/AA Medical Foods|The experimental intervention is the AA diet followed at home for 3-wk. In this randomized crossover study, half of subjects (n=15) were randomized to receive the AA diet as the first arm, and half of the subjects (n=15) were randomized to receive the AA diet as the second arm.
62233894|NCT02883283|EXPERIMENTAL|Epidural Needle Administration|Participants will receive the 10 mL epidural loading dose in 5 mL increments via the epidural needle prior to catheter placement. Epidural loading dose via epidural needle.
62233895|NCT03840239|EXPERIMENTAL|TNT arm|"Drug: Neoadjuvant chemotherapy Capeox (Capecitabine + Oxaliplatin), 6 cycles; adjuvant chemotherapy, Capecitabine, 2 cycles or physicians' decision.~External beam radiotherapy: Neoadjuvant, 50 Gy, 2 Gy/session; 25 fractions. Procedure: 'Watch and wait strategy' or surgery including local excision, intersphincter resection or total mesorectal excision or other kinds of surgeries."
62810024|NCT03274323|EXPERIMENTAL|2 iStent with travoprost or latanoprost|2 iStents will be injected into the trabecular meshwork and patients will be administered topical latanoprost or travoprost following surgery
62810025|NCT03274323|ACTIVE_COMPARATOR|trabeculectomy|Standard trabeculectomy
62810026|NCT04517461||Head and neck free flap surgery patients|Patients undergoing head and neck microvascular free flap surgery at Skåne University Hospital, Lund, Sweden.
62810027|NCT06303336|EXPERIMENTAL|NMES with Dynamic Bracing|The NMES targeting the hip adductors, the knee flexor muscles and the ankle \& foot muscles, along with dynamic bracing
62810028|NCT06303336|EXPERIMENTAL|NMES without Dynamic Bracing|Neuromuscular Electrical Stimulator targeting the lower extremity
62810029|NCT06303336|EXPERIMENTAL|Dynamic Bracing Only|Dynamic Bracing of lower extremity
62810030|NCT03296917|EXPERIMENTAL|IMP - PrEP-001|"In Viral Challenge arm cohort:~A nasal dose of 6400 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1).~In the Safety arm's first dose cohort:~A nasal dose of 6400 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1).~Then assuming no significant safety issues with the lower dose (as determined by blinded review by the DSMB team), the Safety arm's second dose cohort will consist of:~A nasal dose of 12800 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1)"
62810031|NCT03296917|PLACEBO_COMPARATOR|Placebo - G-004|"In the Viral Challenge arm and each Safety Arm cohort:~A nasal dose of placebo equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1)."
62810032|NCT03154866|EXPERIMENTAL|Lactobacillus kefiri LKF01 DSM32079|
62033636|NCT05534581|ACTIVE_COMPARATOR|Pulsed Field Ablation (FARAPULSE)|Pulmonary vein isolation using the FARAPULSE PFA system (Boston Scientific)
62033637|NCT02771951|EXPERIMENTAL|Special Intervention|Study participants randomized to receive Special Intervention receive a series of 7 group classes taught by trained clinic health educators; a series of phone calls; clinical visits with a mid-level provider; and a series of 6 booster group classes over 1 year.
62033638|NCT02771951|PLACEBO_COMPARATOR|Usual Care|Study participants randomized to receive Usual Care receive up to 2 visits with a usual care health educator over 1 year.
62233896|NCT01756612||Chronic Kidney Disease Participants|Participants for whom the treating physician has decided to initiate treatment with MIRCERA for medical reasons prior to study start, will be observed for 9 months.
62424840|NCT04369079|EXPERIMENTAL|TREATMENT GROUP|Fascial techniques were used together with the following techniques: deep massage of neck and shoulder girdle muscles; trigger point therapy; tissue scar treatment in the vicinity of the scar and directly on the scar, by stretching, breaking, pulling, as well as static and dynamic rolling; post-isometric relaxation (stretching) of shoulder and neck muscles; active release technique of the chest and shoulder; selected fascial distortion model techniques; and fascial manipulation techniques consisting of developing specific CC-center of coordination and CF-center of fusion points in the operated area and the shoulder on the same side. The exact sequence and number of procedures differed in each patient according to need as determined by prior functional examination. Before or after every of the treatment procedure treatment group patients underwent ten-minute manual lymphatic drainage in the limb on the mastectomy side.
62810033|NCT03154866|PLACEBO_COMPARATOR|Placebo|
62810034|NCT01139502|ACTIVE_COMPARATOR|Work rehab with cognitive therapy|Work rehabilitation based on the cognitive therapeutical model
62810035|NCT01139502|ACTIVE_COMPARATOR|Work rehab with cognitive training|Work rehabilitation with the addition of weekly training of concentration, memory, and executive function
62810036|NCT00788463|EXPERIMENTAL|Aerosol|
62810037|NCT00788463|ACTIVE_COMPARATOR|Spray|
62243406|NCT06637501|EXPERIMENTAL|Arm A: Combination Therapy: Sonrotoclax + Zanubrutinib|Participants will receive sonrotoclax in combination with zanubrutinib daily for a fixed duration of 15 cycles.
62243407|NCT06637501|ACTIVE_COMPARATOR|Arm B: Monotherapy: Zanubrutinib|Participants will receive zanubrutinib monotherapy daily until disease progression or unacceptable toxicity, whichever occurs first.
62233897|NCT00756470|EXPERIMENTAL|Neoadjuvant Lapatinib plus Chemotherapy|"Four cycles of Lapatinib and Paclitaxel followed by 4 cycles of Lapatinib plus 5-Fluorouracil, Cyclophosphamide, Epirubicin (FEC75). Cycle is 21 days.~Lapatinib alone at 1,000 mg orally once daily for a 2-week run-in period, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each.~1. Week 3 Paclitaxel 80 mg/m\^2 weekly for 4 cycles (12 weeks) administered on Day 1, Day 8, and Day 15) of each cycle combined with Lapatinib 750 mg orally once daily.~2. Week 15, second combination treatment consisting of Lapatinib (1,000 mg orally once daily) combined with FEC75 (5-FU 500 mg/m\^2, Epirubicin 75 mg/m\^2, and Cyclophosphamide 500 mg/m\^2 every 3 weeks for 4 cycles)."
62233898|NCT05300269|EXPERIMENTAL|Perioperative treatment|Eligible subjects will receive standard chemoradiotherapy with SHR-1701 followed by XELOX combined with SHR-1701 and surgery. Adjuvant XELOX combined with SHR-1701 will be given after surgery.
62233899|NCT04017325||TOOKAD VTP TREATMENT|Subjects randomized in the treatment arm (TOOKAD VTP treatment) in the initial period of the study.
62233900|NCT04017325||Active surveillance|Subjects randomized in the control group (active surveillance) in the initial period of the study.
62233901|NCT00674869|EXPERIMENTAL|1|pit and fissure sealant on one randomized tooth by pair of permanent molar
62233902|NCT00674869|NO_INTERVENTION|2|No intervention
62233903|NCT05633602|ACTIVE_COMPARATOR|ARM A (standard of care chemotherapy)|Patients receive chemotherapy per standard of care on study.
62233904|NCT05633602|EXPERIMENTAL|ARM B (ramucirumab, pembrolizumab)|Patients receive ramucirumab IV and pembrolizumab IV on study.
62233905|NCT01259284|EXPERIMENTAL|Atorvastatin|1 Atorvastatin capsule daily plus 3 Placebo capsules twice a day orally, 5 days pre-surgery.
62233906|NCT01259284|EXPERIMENTAL|Fish Oil Supplement|3 Fish Oil capsules twice a day plus 1 Placebo capsule daily orally 5 days pre-surgery.
62233907|NCT01259284|PLACEBO_COMPARATOR|Placebo|4 capsules orally every morning and 3 every evening for 5 days pre-surgery.
62233908|NCT00568945|EXPERIMENTAL|Arm 1|
62233909|NCT00447759|EXPERIMENTAL|Celecoxib|Celecoxib. Celebrex 200-400mg daily in divided doses
62233910|NCT00447759|ACTIVE_COMPARATOR|Diclofenac|continue usual nsNSAID
62424841|NCT04369079|OTHER|CONTROL GROUP|Treatment duration was a mean of 4 weeks. Therapy was performed daily excluding weekends and consisted of 45 minutes of individual work with an oncological physiotherapist. The control group underwent kinesiotherapeutic procedures that included various floor gymnastic exercises with gymnastic stick, balls, and/or elastic tapes, conventional massage of neck and shoulder girdle muscles and therapeutic exercises to increase ROM in the upper limb and in the chest area. Before or after every of the treatment procedure control group patients underwent ten-minute manual lymphatic drainage in the limb on the mastectomy side.
62810038|NCT02578407|EXPERIMENTAL|Accommodative/Vergence Therapy|Accommodative/Vergence Therapy. No drug involved.
62810039|NCT01848158|EXPERIMENTAL|Acupuncture|Acupuncture treatment three times per week for up to two weeks.
62033639|NCT02322671|EXPERIMENTAL|Sequence ABC|Subjects will be administered a single oral dose of treatment A, B and C in the sequence ABC, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
62424842|NCT03904043|EXPERIMENTAL|Radiation + FOLFOX|"* Pelvic radiotherapy 5GY x 5 fractions once daily~* Radiation to extra-mesorectal node 7 Gy x 5 fractions once daily~* FOLFOX should begin 2-4 weeks after completion of radiotherapy and will consist of FOLFOX x 8 cycles (16 weeks).~  * Oxaliplatin day 1 every 14 days~ * Leucovorin day 1 every 14 days. Levoleucovorin may be substituted if leucovorin is not available.~ * 5-FU bolus day 1 every 14 days~ * 5-FU infusion day 1 every 14 days over 46 hours~* Alternatively CAPOX (capecitabine and oxaliplatin) may be given for 5 cycles over 15 weeks.~* An optional simultaneous integrated boost of 30 Gy in 5 fractions to the primary tumor is permitted"
62424843|NCT01146431||Hemodynamic parameters|Hemodynamic parameters will be used as a guide for anesthesia.
62424844|NCT01146431||BIS|Bispectral Index (BIS) will be used as a guide for anesthesia.
62424845|NCT01010321||all study Population|all
62424846|NCT06461676|EXPERIMENTAL|Ventrix Bio Extracellular Matrix|Treatment intervention of a total of 8 injections into the right ventricle of the heart will occur before the patient comes off of the heart-lung bypass machine used during the Stage II Glenn Operation. The treatment will be conducted according to clinical guidelines set in place while the patient is undergoing a surgical intervention before the patient comes off the heart/lung bypass machine required for the stage II Glenn Procedure.
62033640|NCT02322671|EXPERIMENTAL|Sequence ACB|Subjects will be administered a single oral dose of treatment A, B and C in the sequence ACB, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
62424847|NCT05785026|EXPERIMENTAL|WP 1a|Menthol inhalation during resistive loaded breathing trials in healthy participants.
62424848|NCT05785026|PLACEBO_COMPARATOR|WP 1b|Strawberry scent during resistive loaded breathing trials in healthy participants.
62424849|NCT05785026|EXPERIMENTAL|WP 2a|Menthol inhalation during cycle exercise in healthy participants.
62424850|NCT05785026|PLACEBO_COMPARATOR|WP 2b|Strawberry scent during cycle exercise in healthy participants.
62424851|NCT05785026|EXPERIMENTAL|WP 3a|Menthol inhalation during resting breathing in dyspneic COPD participants.
62424852|NCT05785026|PLACEBO_COMPARATOR|WP 3b|Strawberry scent during resting breathing in dyspneic COPD participants.
62424853|NCT05785026|NO_INTERVENTION|WP 3c|Resting breathing in dyspneic COPD participants.
62233911|NCT02521311|EXPERIMENTAL|Clemastine|Participants will receive clemastine until 3 months and then will be off treatment until 9 month time point.
62233912|NCT02521311|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo until 3 months and then will be off treatment until 9 month time point.
62810040|NCT01848158|SHAM_COMPARATOR|Sham Acupuncture|Sham acupuncture three times per week for up to two weeks
62424854|NCT05785026|EXPERIMENTAL|WP 4a|Menthol inhalation during cycle exercise in COPD participants.
62424855|NCT05785026|PLACEBO_COMPARATOR|WP 4b|Strawberry scent during cycle exercise in COPD participants.
62424856|NCT01552629|EXPERIMENTAL|Group 1 QGE031|QGE031 will be administered as a subcutaneous dose q2 weeks
62424857|NCT01552629|PLACEBO_COMPARATOR|Group 2 Placebo|A QGE031 matched placebo will be administered as a subcutaneous dose q2 weeks
62424858|NCT01552629|EXPERIMENTAL|Group 3 Cyclosporine A|Cyclosporine A will be administered (as per label) for atopic dermatitis.
62810041|NCT04814303|ACTIVE_COMPARATOR|ITM|spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral and Intrathecal morphine 150 μg will be added.
62424859|NCT01050673|ACTIVE_COMPARATOR|VERSAJET|Excision with VERSAJET™ Hydrosurgery System
62424860|NCT01050673|ACTIVE_COMPARATOR|Conventional Therapy|Conventional operating room excision will consist of sharp instrumentation and electrocautery techniques, with the use of pulse lavage at the investigator's discretion. The type of sharp instrumentation, together with the brand of pulse lavage will be recorded.
62424861|NCT02777931|EXPERIMENTAL|NFC-1|Doses of NFC-1 will be administered as 100, 200, or 400 mg twice daily as capsules for oral administration.
62424862|NCT02777931|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules.
62424863|NCT03022188||Observational|Observational
62424864|NCT01608776|ACTIVE_COMPARATOR|SOC - Standard of Care|Wound cleansing and debridement as needed, moist wound healing dressing, and off-loading
62424865|NCT01608776|ACTIVE_COMPARATOR|SOC + MIST Therapy|Wound cleansing and debridement as needed, moist wound healing dressing, off-loading, and MIST treatment
62424866|NCT00420888|EXPERIMENTAL|Safety group|6-12 patients
62424867|NCT00420888|EXPERIMENTAL|1|
62810042|NCT04814303|ACTIVE_COMPARATOR|ACB|spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral and Intrathecal morphine 150 μg will be added. The block will be performed in the mid adductor canal to block both the saphenous and the nerve to vastus medialis. After skin infiltration with 1 to 2 mL of 2% lidocaine, an 80-mm, 22-gauge, the short-bevel echogenic needle is advanced in-plane with the ultrasound beam in an anterior-to-posterior direction until the tip is located within the adductor canal deep to the vastoadductor membrane. After negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection plane. The study solution will be injected within the canal adjacent to the femoral artery. Patients in this group received 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine and 4 mg dexamethasone.
62424868|NCT00420888|OTHER|2|Standard treatment with IFN-alpha without add-on of ABR-217620/naptumomab estafenatox
62424869|NCT04654156||Pathological group|Patients with pulmonary embolism on thoracic CT angiography
62424870|NCT04654156||Healthy group|Patients without pulmonary embolism on thoracic CT angiography
62424871|NCT02407756|EXPERIMENTAL|Cohort 1|Cohort 1 will receive dupilumab dosing regimen 1
62810043|NCT04814303|ACTIVE_COMPARATOR|PAI|spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral and Intrathecal morphine 150 μg will be added. PAI intra-operatively will be performed with 150 mL of 0.25% bupivacaine with 1:400,000 epinephrine, 30 mg of ketorolac, and 8 mg dexamethasone.
62424872|NCT02407756|EXPERIMENTAL|Cohort 2|Cohort 2 will receive dupilumab dosing regimen 2
62424873|NCT00707122|OTHER|1, Albumin and Crystalloids|Treatment
62424874|NCT00707122|OTHER|2, Crystalloids|Control
62424875|NCT04816162|PLACEBO_COMPARATOR|Control group|21 ml of normal saline 0.9% will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively.
62233913|NCT04124393|ACTIVE_COMPARATOR|Water Exchange (WE) Colonoscopy|In the WE group, the air pump will be turned off before starting the procedure. During the insertion phase, the colon will be irrigated with warm water (32C-35C). WE entails the infusion of water to open the lumen and simultaneous suction if the endoscope has two channels, and sequentially if the endoscope has only one channel. When the cecum is reached and after most of the water is suctioned to collapse the cecal lumen, CO2 will be opened. The colonoscope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). The colonoscope will then be reinserted into the cecum by the first endoscopist. A tandem inspection of the right colon will be performed by a blinded endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
62233914|NCT04124393|ACTIVE_COMPARATOR|CO2 Insufflation Colonoscopy|In the CO2 group, colonoscopy is performed in the usual fashion, with minimal insufflation required to aid insertion. Cleaning in the CO2 group will be performed entirely during withdrawal. Upon arriving at the cecum, CO2 insufflation will be used and the colonoscope will be withdrawn from the cecum to the hepatic flexure. All polyps identified will be resected (colon polypectomy). Then, the colonoscope will be reinserted into the cecum by the first endoscopist. A tandem inspection of the right colon will be performed by a blinded endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
62233915|NCT04134676|EXPERIMENTAL|Conditioned Medium Group|"In this group, the subjects will use Conditioned Medium topical therapy for 2 weeks The Conditioned Medium gel will be applied to the wound and closed by transparent dressing.~The evaluation and dressing replacement will be done every week for 2 weeks."
62233916|NCT04112901||People with trans-femoral amputation or knee dis-articulation|include individuals with unilateral transfemoral amputation or knee disarticulation, with ≤ K2 mobility grade OR SIGAM grade D or below; i.e. able to walk ≤ 50 meters on level ground, who have been users of either microprocessor-controlled knee or non-microprocessor-controlled knee joint for at least 6 months prior to the recruitment date.
62233917|NCT01831856|EXPERIMENTAL|F373280|
62233918|NCT01831856|PLACEBO_COMPARATOR|Placebo|
62233919|NCT02807792|EXPERIMENTAL|Perianal access device|
62233920|NCT01343485|NO_INTERVENTION|Control, standard care for HPV vaccine|Study participants in control sites will receive standard care for HPV vaccine administration and follow-up per PPFA protocol
62033641|NCT02322671|EXPERIMENTAL|Sequence BAC|Subjects will be administered a single oral dose of treatment A, B and C in the sequence BAC, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
62233921|NCT01343485|EXPERIMENTAL|Intervention, computer reminder system|Study participants in the intervention sites will receive standard care for HPV vaccine administration per PPFA protocol, reminder messages for subsequent vaccination appointments, and real-time determination of financial assistance for HPV vaccine.
62243408|NCT01726452|EXPERIMENTAL|A (Modified MAGIC) OR Arm A: FLOT|"Modified MAGIC: The modified MAGIC regimen encompasses 3 cycles of chemotherapy pre-surgery and 3 cycles post-surgery. The regimen is a combination of epirubicin, cisplatin or oxaliplatin and a choice of 5-fluorouracil or capecitabine. Each cycle lasts 21 days.~FLOT: The FLOT regimen encompasses 8 cycles of chemotherapy in total , 4 cycles of chemotherapy pre-surgery and a further 4 cycles of chemotherapy post-surgery. Each cycle of chemotherapy lasts 14 days/2 weeks."
62424876|NCT04816162|ACTIVE_COMPARATOR|ketofol group|21 ml of a mixture of (ketamine and propofol) will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively
62424877|NCT04816162|ACTIVE_COMPARATOR|dexmedetomidine group|21 ml of a mixture of (dexmedetomidine diluted with normal saline 0.9%) will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively
62424878|NCT02076230|EXPERIMENTAL|[14C] TH-302 (Label 1)|
62424879|NCT02076230|EXPERIMENTAL|[14C] TH-302 (Label 2)|
62424880|NCT04075188|EXPERIMENTAL|Combined therapy|Treatment consisting in photodynamic therapy (Verteporfin, 6 mg/m2 × Body Surface Area (BSA) = Total Drug Dose; Total Drug Dose ÷ 2.0 mg/mL = Volume of Reconstituted Verteporfin; 30 mL - Volume of Reconstituted Verteporfin = Volume of 5% dextrose in water. Light dose is 50 J/cm2 administered at an intensity of 600 mW/cm2. This dose is administered over 83 seconds) and 3 intravitreal therapy of Aflibercept (2 mg/0,05 ml)monthly, the first of which performed within 7 days from photodynamic therapy.
62424881|NCT05105360|ACTIVE_COMPARATOR|Petersen's closure group|Petersen's space closure method
62424882|NCT05105360|EXPERIMENTAL|Mefix group|Mesentery fixation method
62424883|NCT05924451|ACTIVE_COMPARATOR|Early loading|The implants will be restored with a PMMA (polymethyl methacrylate) prosthesis in normal occlusion.
62424884|NCT05924451|EXPERIMENTAL|Immediate loading|The implants will be restored with a permanent prosthesis (monolithic zirconia) placed on the implants as an immediate loading.
62424885|NCT02609178|EXPERIMENTAL|FGP design (FGP, AVR)|use functional generated path to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
62424886|NCT02609178|NO_INTERVENTION|conventional design (CON)|use conventional method to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
62810044|NCT04549285|EXPERIMENTAL|hCT-MSC infusion|Doses will be given on days 1, 2, 3, and a fourth, optional dose may be given on day 7 at the discretion of the investigator and the treating physician.
62810045|NCT02264275|EXPERIMENTAL|Aerobic Exercise Training|An 8-week Nintendo Wii at-home dancing exergame Intervention
62810046|NCT00190437|EXPERIMENTAL|1|Amoxicillin-clavulanic
62233922|NCT01625572|NO_INTERVENTION|general anesthesia and epidural catheter (control)|"General anaesthesia~* total intravenous anaesthesia with propofol 5-10 mg / kg / h,~* remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~* use of a bispectral index~* monitoring with a target range of 40-60~* at the end of the anaesthesia all patients get 0.1 mg / kg morphine intravenously epidural catheter~* plant of the epidural catheter under sterile conditions at the intervertebral space of the vertebral body 8-10 of the thoracic spine• local anaesthesia with lidocaine 1%~* puncture with a Tuohy 18 G- needle, Lost of resistance technique~* after a negative test dose with bupivacaine 0,5% isobar we inject fractional ropivacaine 10 ml 0,2%, after that continuous administration of ropivacaine 0,2% via patient-controlled-analgesia-device with a sweep rate of 6 ml/h, all Patients also receive an intravenous morphine-patient-controlled-analgesia-device"
62424887|NCT02503566|EXPERIMENTAL|All patients|Optical coherence tomography will be performed in all patients
62424888|NCT06232538||gallbladder cancer|
62424889|NCT06232538||benign gallbladder diseases|
62424890|NCT03239795|EXPERIMENTAL|Intervention group|Family physicians' patients exposed to advertisement in waiting rooms consisting in a poster and pamphlets promoting seasonal influenza vaccination (+ usual mandatory information)
62424891|NCT03239795|NO_INTERVENTION|Control group|Family physicians' patients exposed to usual laying out of waiting rooms
62424892|NCT02709122|EXPERIMENTAL|With Tension pneumothorax|evaluation of the patient with the existing tension pneumothorax during a simulated CPR - breathing
62424893|NCT02709122|EXPERIMENTAL|Without Tension pneumothorax|evaluation of the patient without the existing tension pneumothorax during a simulated CPR - breathing
62810047|NCT00499486|EXPERIMENTAL|Sirolimus|Sirolimus 5mg. po QD continously (28 days=cycle)
62810048|NCT04564664|OTHER|High-flow nasal cannula oxygen therapy|
62810049|NCT04564664|OTHER|Standard oxygen therapy|
62810050|NCT01285141|EXPERIMENTAL|Vaginal immunisation|CN54gp140 glycoprotein-hsp70 conjugate vaccine
62424894|NCT03512626|EXPERIMENTAL|Multifocal IOL (OptiVis)|"Ambulatory surgery was performed by the same, experienced surgeon, under topical anesthesia, using as a technique phacoemulsification with small incision (2.75) in clear cornea in the most curved meridian.~The randomly assigned IOL (in this arm: a hybrid (refractive-diffractive) multifocal IOL (OptiVis, Aaren Scientific) was implanted in the capsular bag. The second eye with the same type of lens of the first eye was operated within 2-4 weeks."
62810051|NCT04467749|EXPERIMENTAL|Suspension Wheel|Participants will be given a set of in-wheel suspension wheels to use in their normal daily routine for three months.
62593605|NCT05483296|EXPERIMENTAL|Crossover sequence 1: Dim, Moderate, High|All participants will go through all three light conditions in the three experiment sessions: They will receive white fluorescent overhead light (given in melanopic EDI at eye level) as the 3h afternoon light intervention. In the first experimental session, they receive an intensity of \<10 lx. In the second experimental session, they receive an intensity of \~100 lx, and in the third experimental session, they receive an intensity of \>1000 lx.
62593606|NCT05483296|EXPERIMENTAL|Crossover sequence 2: Dim, High, Moderate|All participants will go through all three light conditions in the three experiment sessions: They will receive white fluorescent overhead light (given in melanopic EDI at eye level) as the 3h afternoon light intervention. In the first experimental session, they receive an intensity of \<10 lx. In the second experimental session, they receive an intensity of \>1000 lx, and in the third experimental session, they receive an intensity of \~100 lx.
62593607|NCT05483296|EXPERIMENTAL|Crossover sequence 3: Moderate, Dim, High|All participants will go through all three light conditions in the three experiment sessions: They will receive white fluorescent overhead light (given in melanopic EDI at eye level) as the 3h afternoon light intervention. In the first experimental session, they receive an intensity of \~100 lx. In the second experimental session, they receive an intensity of \<10 lx, and in the third experimental session, they receive an intensity of \>1000 lx.
62593608|NCT05483296|EXPERIMENTAL|Crossover sequence 4: Moderate, High, Dim|All participants will go through all three light conditions in the three experiment sessions: They will receive white fluorescent overhead light (given in melanopic EDI at eye level) as the 3h afternoon light intervention. In the first experimental session, they receive an intensity of \~100 lx. In the second experimental session, they receive an intensity of \>1000 lx, and in the third experimental session, they receive an intensity of \<10 lx.
62593609|NCT05483296|EXPERIMENTAL|Crossover sequence 5: High, Moderate, Dim|All participants will go through all three light conditions in the three experiment sessions: They will receive white fluorescent overhead light (given in melanopic EDI at eye level) as the 3h afternoon light intervention. In the first experimental session, they receive an intensity of \>1000 lx. In the second experimental session, they receive an intensity of \~100 lx, and in the third experimental session, they receive an intensity of \<10 lx.
62233923|NCT01625572|EXPERIMENTAL|general anesthesia and regional anesthesia|"General anesthesia~* anesthesia with propofol 5-10 mg / kg / h, remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~* Bispektralindex monitoring with a target range of 40-60~* at the end of the anesthesia all patients get 0.1 mg / kg morphine intravenously Transversus abdominis plane blockade~* ultrasound visible needles, a special pin detection software~* under visual control the needle moves into the space between Musculus obliquus internus and M. transversus abdominis~* Under sonographic control we inject a local anesthetic depot (30 ml of ropivacaine 0.375%)~* puncture is performed under constant protective nerve stimulation with a current of 1 mA, pulse duration 0.1 ms, frequency 2 Hz All Patients receive an i.v. Morphine-patient-controlled-analgesia-device"
62593610|NCT05483296|EXPERIMENTAL|Crossover sequence 5: High, Dim, Moderate|All participants will go through all three light conditions in the three experiment sessions: They will receive white fluorescent overhead light (given in melanopic EDI at eye level) as the 3h afternoon light intervention. In the first experimental session, they receive an intensity of \>1000 lx. In the second experimental session, they receive an intensity of \<10 lx, and in the third experimental session, they receive an intensity of \~100 lx.
62593611|NCT04441957||Group A, MOCA-group|Procedure/Surgery: MOCA Mechano-Chemical Ablation plus Elastic Compression
62593612|NCT04441957||Group B, Elastic Compression only group|Treatment: Elastic Compression only
62593613|NCT05104697|OTHER|TMS at visit 1, Sham at visit 2|At visit 1, participants will receive active TMS using continuous theta burst over the preSMA. At Visit 2, participants will receive sham (fake) TMS in the same location.
62593614|NCT05104697|OTHER|Sham at visit 1, TMS at visit 2|At visit 2, participants will receive active TMS using continuous theta burst over the preSMA. At Visit 1, participants will receive sham (fake) TMS in the same location.
62810052|NCT01370980||Study population|Adults (18 years old or more) with one of the following oral oncology treatments: letrozole, exémestane, imatinib, sunitinib, nilotinib, evérolimus, déférasirox
62593615|NCT00616616|EXPERIMENTAL|1|all subjects
62810053|NCT04190459||LSG|laparoscopic sleeve gastrectomy
62810054|NCT04190459||LRYGB|laparoscopic Roux-en-Y gastric bypass
62810055|NCT03935958|EXPERIMENTAL|Curcumin Arm (Arm 1)|20 subjects will be randomized (1:1) to this arm and receive curcumin for a year. In addition, subjects will have four study visits at Day 0, and 3, 6 and 12 months post-transplant. These study visits also include blood samples and questionnaires.
62810056|NCT03935958|PLACEBO_COMPARATOR|Placebo Arm (Arm 2)|20 subjects will be randomized (1:1) to this arm and receive placebo for a year. In addition, subjects will have four study visits at Day 0, and 3, 6 and 12 months post-transplant. These study visits also include blood samples and questionnaires.
62593616|NCT06424106|ACTIVE_COMPARATOR|Glucagon Infusion|A glucagon infusion (0.2 ng/kg/min) will start at 0900 (0 min), increasing to 0.4 (1000), 0.6 (1100) and 0.8 ng/kg/min (1200) at 60-minute intervals - ending at 1300 (240 min).
62233924|NCT01625572|EXPERIMENTAL|general anaesthesia and intravenous pain therapy|"General anaesthesia~* total intravenous anesthesia with propofol 5-10 mg / kg / h, remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~* we use a of BIS monitoring with a target range of 40-60~* at the end of the aneasthesia all patients get 0.1 mg / kg morphine intravenously intravenous pain therapy with~* Morphine-patient-controlled-analgesia-device"
62233925|NCT00541723|EXPERIMENTAL|IncobutolinumtoxinA (Xeomin), 4-injection scheme|"IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:~Clostridium Botulinum neurotoxin Type A free of complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl); total volume 0.24 mL per side, i.e. 4 x 0.06 mL (4 x 3 units = 12 units); mode of administration: intramuscular injection."
62233926|NCT00541723|PLACEBO_COMPARATOR|Placebo 4-injection scheme|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; total volume 0.24 mL per side, i.e. 4 x 0.06 mL placebo solution; mode of administration: intramuscular injection.
62424895|NCT03512626|ACTIVE_COMPARATOR|Monofocal IOL|"Ambulatory surgery was performed by the same, experienced surgeon, under topical anesthesia, using as a technique phacoemulsification with small incision (2.75) in clear cornea in the most curved meridian.~The randomly assigned IOL (in this arm: a monofocal IOL (AR40e, AMO) was implanted in the capsular bag. The second eye with the same type of lens of the first eye was operated within 2-4 weeks."
62424896|NCT00769158|EXPERIMENTAL|Topiramate + Naltrexone|Combination of Topiramate and Naltrexone
62593617|NCT06424106|PLACEBO_COMPARATOR|Glucose Infusion|At 0900 (0 min) a glucose infusion will commence, and the infusion rate varied to replicate (± 5mg/dL) that individual's glucose concentrations observed during the Glucagon Infusion Day. The experiment will end at 1300 (240 min) when infusions are stopped.
62593618|NCT04349189||Group 1|50 Men and Women with sickle cell disease and VTE
62593619|NCT04349189||Group 2|50 Men and Women with sickle cell disease but no VTE
62233927|NCT00541723|EXPERIMENTAL|IncobotulinumtoxinA (Xeomin), 3-injection scheme|"IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:~Clostridium Botulinum neurotoxin Type A free of complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl); total volume 0.24 mL per side, i.e. 3 x 0.08 mL (3 x 4 units = 12 units); Mode of administration: intramuscular injection."
62424897|NCT00769158|PLACEBO_COMPARATOR|Placebo|
62424898|NCT03665480|EXPERIMENTAL|G-CSF treatment|In G-CSF treatment group, all participants are treated with G-CSF at the dose of 5ug/kg per day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28 with flow cytometry and quantity PCR if a fusion gene is available.
62424899|NCT03665480|NO_INTERVENTION|G-CSF-free|In G-CSF-free group, no participants with newly diagnosed AML are treated with G-CSF after induction therapy.
62424900|NCT03801759|EXPERIMENTAL|Vadadustat, digoxin|Arm 1: Subjects will receive a single oral dose of digoxin 0.5 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone and in combination with a single dose of digoxin 0.5 mg.
62424901|NCT03801759|EXPERIMENTAL|Vadadustat, adefovir|Arm 2: Subjects will receive a single dose of oral adefovir 10 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone and in combination with a single dose of adefovir.
62424902|NCT03801759|EXPERIMENTAL|Vadadustat, Furosemide|Arm 3: Subjects will receive a single dose of oral furosemide 40 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone, and in combination with a single dose of furosemide 40 mg.
62593620|NCT04349189||Group 3|50 Men and Women with sickle cell trait
62593621|NCT04349189||Group 4|50 ethnically matched Men and Women without sickle cell disease, sickle cell trait, or VTE
62593622|NCT02042326|EXPERIMENTAL|Sirolimus treatment|"Patients will receive sirolimus (Rapamune). The dose should be adjusted to obtain a residual plasma rate of 8 to 12 ng/ml in 4 weeks. This serum level will be maintained throughout the duration of the study in the absence of side effects. In case of intolerance that do not justify the discontinuation of treatment, the dose may be reduced by maintaining a serum level greater than 3 ng/ml.~The starting dose will be 2 mg per day, and will be adapted every week for one month.~The preferred dosage form is tablet form. To prevent common side effects in early treatment, corticosteroids based prednisolone (SOLUPRED) will be established at a dose of 0.5 mg/ kg/day for the first week of treatment."
62593623|NCT05244044|ACTIVE_COMPARATOR|Pulmonary rehabilitation group|The intervention group receives a 12 weeks pulmonary rehabilitation program supervised by a primary care physiotherapist consisting of maximum 36 sessions (3 sessions per week).
62593624|NCT05244044|NO_INTERVENTION|Control group without rehabilitation|The control group will receive usual care that doesn't include pulmonary rehabilitation or a supervised physical activity program.
62233928|NCT00541723|PLACEBO_COMPARATOR|Placebo 3-injection Scheme|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; total volume 0.24 mL per side, i.e. 3 x 0.08 mL placebo solution; mode of administration: intramuscular injection.
62233929|NCT03650478|EXPERIMENTAL|Premature infants group|NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)
62233930|NCT03650478|EXPERIMENTAL|Bronchiolitis group|NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)
62233931|NCT04395430|ACTIVE_COMPARATOR|Information Group|Subjects randomized to the Information Group will receive standard care and age appropriate reading books.
62233932|NCT04395430|EXPERIMENTAL|Intervention Group|Subjects randomized to the Intervention Group will receive standard care plus invitation to participate in the online KKH Sports Singapore programme.
62233933|NCT01087931|ACTIVE_COMPARATOR|Bupivacaine|This group will receive bupivacaine (10ml of 0.5%) administered directly into the surgical wound at the iliac crest bone harvest site.
62233934|NCT01087931|PLACEBO_COMPARATOR|Saline|This group will receive normal saline (10ml) administered directly into the surgical wound at the iliac crest bone harvest site.
62424903|NCT01672307|EXPERIMENTAL|Minoxidil lotion 2%|Minoxidil lotion 2% is applied twice daily to one eyebrow.
62424904|NCT01672307|PLACEBO_COMPARATOR|Placebo|Placebo is applied twice daily to the other eyebrow.
62424905|NCT00203957|EXPERIMENTAL|Group A|Patients who completed double-blind treatment studies 6002-US-013, 6002-US-013, 6002-US-018 immediately prior to entering this open-label trial and may have had an interuption of study drug of 14 days or less.
62424906|NCT00203957|EXPERIMENTAL|Group B|Patients who previously completed double-blind treatment studies 6002-US-013, 6002-US-018 or 6002-EU-007 or discontinued from open label study 6002-US-007 and have had an interuption of study drug greater than 14 days.
62424907|NCT00053027|EXPERIMENTAL|rituximab + cladribine|"Patients receive rituximab IV over 4-8 hours on day 1 and cladribine IV over 2 hours on days 4-8. If 2 or more patients experience unacceptable toxicity during the first course, the study is discontinued; otherwise, the study is opened for enrollment at all NCCTG sites.~Treatment repeats every 28 days for a total of 2-6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually for 2 years."
62424908|NCT05066607|EXPERIMENTAL|Single-stage|"Patient eligible to enter the study will receive 9 to 12 cycles (according to response) of intravenous Isatuximab (10 mg/kg) and oral Pomalidomide 4 mg from day 1 to day 21 and Dexamethasone 10-20 mg weekly on days 1, 8, 15 and 22.~Each cycle will be of 28 days duration. During cycle 1, Isatuximab will be administered weekly on days 1, 8, 15, and 22 then days 1 and 15 in subsequent cycles from cycle 2 to 9 or 12.~For each individual patient, the treatment period will be 12 months, unless CR at the completion of 9 cycles, disease progression or unacceptable toxicity occurs. The duration of follow-up for overall survival will be 1 year after the last patient enters overall survival follow-up."
62424909|NCT05347082|EXPERIMENTAL|Vitamin D|8000 IU of vitamin D orally, once a day, for four weeks.
62424910|NCT01693731||Aromatase Inhibitor|Postmenopausal women with breast cancer taking Arimidex, Aromasin, or Femara
62424911|NCT01693731||No Treatment|Healthy volunteer postmenopausal women not taking Aromatase Inhibitors
62424912|NCT02475967|EXPERIMENTAL|Intervention group|The intervention group patients have access to the eLearning platform in addition to conventional cardiac care.
62424913|NCT02475967|ACTIVE_COMPARATOR|Control group|The control group patients receive conventional cardiac care alone.
62593625|NCT04080518|ACTIVE_COMPARATOR|Experimental|Dapagliflozin, 10mg, oral dose, once every day
62593626|NCT04080518|PLACEBO_COMPARATOR|Control|Matching placebo for dapagliflozin, oral dose, once every day
62233935|NCT00606073|ACTIVE_COMPARATOR|I|IVF Procedure-IVF Medium
62424914|NCT00819858|EXPERIMENTAL|RUTF|RUTF supplement (Plumpynut®) of 500 kcal/day for 2 weeks
62424915|NCT00819858|NO_INTERVENTION|control|no supplement given
62424916|NCT02307188|EXPERIMENTAL|Basket Catheter|The Constellation Full Contact Mapping Catheter (multipolar catheter) to be utilized for collection of atrial electrograms.
62593627|NCT01698879|EXPERIMENTAL|Single arm, three cohorts|Idarubicin, cytarabine, Mylotarg.
62593628|NCT04582916|OTHER|One Arm|All subject receive the same tests
62593629|NCT05738551|EXPERIMENTAL|STRESS BALL|Starting 5 minutes before the access to the vascular access, the patient will be asked to squeeze the stress ball in the palm until the blood collection is completed.
62593630|NCT05738551|EXPERIMENTAL|CHEWİNG GUM|Starting 5 minutes before the vascular access, the patient will be allowed to chew gum until the blood collection is completed.
62233936|NCT00606073|ACTIVE_COMPARATOR|II|IVF Procedure - ISM1 Medium
62233937|NCT00606073|ACTIVE_COMPARATOR|III|ICSI Procedure - IVF Medium
62233938|NCT00606073|ACTIVE_COMPARATOR|IV|ICSI Procedure - ISM1 Medium
62233939|NCT01917513|EXPERIMENTAL|G-EYE™ colonoscopy|G-EYE™ colonoscopy
62593631|NCT05738551|NO_INTERVENTION|ROUTINE APPLICATION|Only within the scope of routine practice of the patient, vascular access will be provided and the blood collection process will be completed.
62810057|NCT01620060|EXPERIMENTAL|Lurasidone oral tablets|Lurasidone 20, 40, 80, 120 or 160 mg/day
62593632|NCT02877095|EXPERIMENTAL|Active|All subjects in the pilot study will receive the subcutaneous pump to administer a special formulation of furosemide to be delivered subcutaneously.
62593633|NCT00287872|EXPERIMENTAL|Bortezomib and Thalidomide|The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.
62593634|NCT06059690|OTHER|Arm I en vivo Glycolic Index measurement|All biopsies are acquired for standard of care and according to standard of care procedures. A 13-gauge biopsy needle and plastic cannula will be inserted into the region of interest identified on MRI and PET. The biopsy needle will be removed, and the Softcell® pH probe, consisting of a 1.8mm diameter high quality glass tip and 1.6m long wire, will be guided down the cannula and inserted at least 15mm into the tissue. Recordings will be made for 1 minute to stabilize the reading, then the pH probe will be removed from the region of interest and placed into a saline vial for the next biopsy target.
62593635|NCT03794076|ACTIVE_COMPARATOR|Cromoglycate|Cromoglycate nasal spray
62593636|NCT03794076|PLACEBO_COMPARATOR|Placebo|Saline nasal spray
62593637|NCT04311749||Fetal growth restriction|
62593638|NCT05759624||Hormone replacement therapy with rhGH|
62593639|NCT01532336|EXPERIMENTAL|NVC-422 Solution, 0.3%|Dosed for 10 days
62593640|NCT01532336|PLACEBO_COMPARATOR|NVC-422 Vehicle Solution|Dosed for 10 days
62593641|NCT06621342|EXPERIMENTAL|PRP Experimental|The treatment group will receive 1 ml of autologous PRP infused into the cervix via Rocket IUI catheter at 72+/- 5 hours and 48 +/- 5 hours prior to embryo transfer. Prior to the first PRP infusion, endometrial secretions will be aspirated as described in a previous study regarding endometrial secretions. An embryo transfer catheter will be introduced trans-cervically. A 2 mL syringe will be used to gradually add suction, aspirating secretions from the endometrium. The outer sheath of the embryo catheter will be positioned in the exterior, and the inner catheter retracted into the outer sheath, to avoid cervical fluid contamination in the collected endometrial secretions. Secretions will be deposited into screw top cryovials by snipping the end of the transfer catheter containing secretion off into the tube. These tubes will then be snap-frozen in liquid nitrogen. Process will be repeated prior to embryo transfer
62593642|NCT06621342|PLACEBO_COMPARATOR|PRP Control|Negative control patients will have endometrial secretions aspirated at identical intervals to the test group but will not receive PRP infusions.
62593643|NCT05431023|EXPERIMENTAL|Patients with pneumonia who receive only treatment for pneumonia|They receive only treatment for pneumonia
62593644|NCT05431023|EXPERIMENTAL|pneumonia patients receive treatment for pneumonia and lactoferrin|They receive treatment for pneumonia and lactoferrin
62233940|NCT01917513|ACTIVE_COMPARATOR|Standard Colonoscopy|Standard Colonoscopy
62233941|NCT05040477|EXPERIMENTAL|Experimental Group (1): Muscle energy techniques,Moist Hot pack and TENS.|"Experimental group included Moist Hot pack of 14/15' over cervical region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45C.Conventional TENS applied for 10 mins.~Baseline NPRS, NDI, Cervical ROMs, and posterior tangent angle.These pre and post intervention values were mentioned in questionnaire. The participants were administered with muscle energy technique (PIR) and data was collected again 2 and 4 weeks after the interventions."
62233942|NCT05040477|EXPERIMENTAL|Experimental Group (2): Facets joint mobilizations, Moist Hot pack and TENS.|"Experimental group includedMoist Hot pack of 14/15' over cervical region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Conventional TENS applied for 10 mins.~Baseline NPRS, NDI, Cervical ROMs, and posterior tangent angle. These pre and post intervention values were mentioned in questionnaire. The participants were administered with Facet joint mobilization (UPA \& SNAGS) and data was collected again 2 and 4 weeks after the interventions."
62424917|NCT04404816|EXPERIMENTAL|Group 1|premature infants born \< 33 G.A. enrolled in the first 72 hours after birth, with respiratory distress syndrome, requiring non-invasive ventilation with FiO2 \<0.4
62424918|NCT04404816|EXPERIMENTAL|Group 2|premature infants born \< 33 G.A. with respiratory insufficiency requiring mechanical ventilation, after more than 1 failed extubation attempt
62424919|NCT02828228|EXPERIMENTAL|Vitamin D 1200 IU|Supplementation with vitamin D (1200 IU) once a day for 26 weeks
62424920|NCT02828228|PLACEBO_COMPARATOR|Placebo|Placebo once a day for 26 weeks
62424921|NCT02080065||liver transplantation|patients who underwent living donor liver transplantation during between 2007 and 2013
62424922|NCT05743686|EXPERIMENTAL|Application|
62424923|NCT05415826|ACTIVE_COMPARATOR|PPV group|Eyes with proliferative diabetic retinopathy underwent PPV surgery with silicone oil filling.
62424924|NCT05415826|EXPERIMENTAL|PPV+implant group|Eyes with proliferative diabetic retinopathy underwent PPV surgery with silicone oil filling and slow-release dexamethasone implant.
62424925|NCT05078801||Endoscopic drainage|All patients with perihilar malignant biliary obstruction treated with endoscopic drainage. This drainage can be multimodal using endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasound (EUS)-guided biliary drainage.
62424926|NCT05078801||Radiologic percutaneous drainage|All patients with perihilar malignant biliary obstruction treated with percutaneous drainage
62424927|NCT04833452|ACTIVE_COMPARATOR|Wide fenstrum Endoscopic DCR|
62424928|NCT04833452|ACTIVE_COMPARATOR|Narrow Fenstrum Endoscopic DCR|
62424929|NCT00937599|EXPERIMENTAL|Brazil Nuts|The first group consumed the brazil nuts and the other group placebo (lactose pills)
62424930|NCT01403428|EXPERIMENTAL|NPPV plus standard of care|Noninvasive positive pressure ventilation (NPPV) plus standard of care in the management of children admitted to the hospital with status asthmaticus
62424931|NCT01403428|NO_INTERVENTION|Standard of care|standard of care treatment in the management of children admitted to the hospital with status asthmaticus
62424932|NCT01517568|EXPERIMENTAL|Liraglutide|
62424933|NCT00289731|EXPERIMENTAL|Twinrix Group|Healthy and non-healthy male or female subjects, aged 41 years or older, who received combined Twinrix™ (720/20) vaccine, administered intramuscularly in the left deltoid region, according to a 0, 1 and 6 month schedule.
62233943|NCT05040477|ACTIVE_COMPARATOR|Control Group:Conventional Therapy (Stretching, strengthening , Moist Hot pack and TENS)|"Control group includedMoist Hot pack of 14/15' over cervical region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Conventional TENS applied for 10 mins.~Baseline NPRS, NDI, Cervical ROMs, and posterior tangent angle. These pre and post intervention values were mentioned in questionnaire. The participants were administered with Conventional (sustained stretching and isometric strengthening) physical therapy and data was collected again 2 and 4 weeks after the interventions."
62233944|NCT03289897|EXPERIMENTAL|Study Arm-LiverMultiScan|Patients will be scanned using the LiverMultiScan. Follow-up will be determined by the results of the scan.
62233945|NCT03289897|NO_INTERVENTION|Control Arm|Standard of care as per guidelines of the local centre
62424934|NCT00289731|ACTIVE_COMPARATOR|Engerix-B+Havrix Group|Healthy and non-healthy male or female subjects, aged 41 years or older, who received separate administrations of Engerix™-B (20 μg) vaccine, administered intramuscularly in the left deltoid region, according to a 0, 1 and 6 month schedule and Havrix™ (1440 EL.U) vaccine, administered intramuscularly in the right deltoid region, according to a 0 and 6 month schedule.
62593645|NCT01380717|ACTIVE_COMPARATOR|Standard treatment|Patients with CKD 3-4, hypertension, treated for 18 months with beta-blocker and if needed ACE-inhibitor or ARB.
62593646|NCT01380717|ACTIVE_COMPARATOR|Intensive vasodilation|Patients with CKD 3-4 and hypertension, randomized to treatment with calcium channel blocker and if needed ACE-inhibitor or ARB for 18 months
62593647|NCT05803213|EXPERIMENTAL|Virtual Reality|The medical students use the virtual reality headset to watch an interactive 360 video about the clinical situation on the learning platform
62593648|NCT05803213|ACTIVE_COMPARATOR|Traditional|The mini-lecture is provided by the instructor to medical students about the clinical situation
62593649|NCT03726775|EXPERIMENTAL|RT-durvalumab|durvalumab at fixed dose of 1120 mg on Day1 of RT and every 3 weeks during the RT. Durvalumab with be continued at a fixed dose of 1500 mg every 4 weeks during 6 months following RT.
62593650|NCT05148234|EXPERIMENTAL|Phase I Eligible Higher Risk (HR) Myelodysplastic Syndromes (MDS) Participants|Escalating doses of Human Humax (HuMax)-interleukin 8 (IL-8) (BMS-986253) + deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) for higher risk (HR) myelodysplastic syndromes (MDS) participants.
62593651|NCT05148234|EXPERIMENTAL|Phase I Lower Risk (LR) Myelodysplastic Syndromes (MDS) Participants|Escalating doses of Human Humax (HuMax)-interleukin 8 (IL-8) (BMS-986253) for lower risk (LR) myelodysplastic syndromes (MDS) participants.
62810058|NCT03263546|EXPERIMENTAL|Stepped care|Internet-delivered cognitive behavioral therapy (ICBT)
62233946|NCT05760391|EXPERIMENTAL|Experimental group|Patients will be treated with anti-PD-1 Immune Checkpoint Inhibitors combined with chemotherapy used as 1st line treatment for metastatic ESCC.Radiotherapy will be conducted after four cycles of IO plus chemotherapy or started simultaneously.
62233947|NCT00092495|EXPERIMENTAL|1|100% Formulation qHPV Vaccine
62233948|NCT00092495|EXPERIMENTAL|2|60% Formulation qHPV Vaccine
62233949|NCT00092495|EXPERIMENTAL|3|40% Formulation qHPV Vaccine
62233950|NCT00092495|EXPERIMENTAL|4|20% Formulation qHPV Vaccine
62233951|NCT05717608|ACTIVE_COMPARATOR|high fructose in caucasian dutch type 2 diabetes subjects|high (100gr/day) fructose diet for 4 weeks in type 2 diabetic subjects of Caucasian ethnicity.
62233952|NCT05717608|PLACEBO_COMPARATOR|low fructose in caucasian dutch type 2 diabetes subjects|low fructose diet (\<30 gram fructose intake per day isocaloric correction with dextrose) for 4 weeks in type 2 diabetic subjects of Caucasian ethnicity.
62424935|NCT00289731|ACTIVE_COMPARATOR|HB VAX PRO+Vaqta Group|Healthy and non-healthy male or female subjects, aged 41 years or older, who received separate administrations of HB VAX PRO™ (10 μg) vaccine, administered intramuscularly in the left deltoid region, according to a 0, 1 and 6 month schedule and Vaqta™ (50 IU) vaccine, administered intramuscularly in the right deltoid region, according to a 0 and 6 month schedule.
62593652|NCT05148234|EXPERIMENTAL|Phase II Higher Risk (HR) Myelodysplastic Syndromes (MDS) Participants|Phase II dose of Human Humax (HuMax)-interleukin 8 (IL-8) (BMS-986253) + deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) for higher risk (HR) myelodysplastic syndromes (MDS) participants.
62593653|NCT05148234|EXPERIMENTAL|Phase II Lower Risk (LR) Myelodysplastic Syndromes (MDS) Participants|Phase II dose of Human Humax (HuMax)-interleukin 8 (IL-8) (BMS-986253) for lower risk (LR) myelodysplastic syndromes (MDS) participants.
62593654|NCT06339411|EXPERIMENTAL|Extended Thrombectomy with Cerebrolysin|Cerebrolysin 30milliliter/quaque die(QD) for 10\~14days intravenous drip (IVD)
62593655|NCT06339411|NO_INTERVENTION|Extended Thrombectomy without Cerebrolysin|No cerebrolysin
62810059|NCT03263546|ACTIVE_COMPARATOR|Gold standard treatment|Cognitive behavioral therapy (CBT)
62810060|NCT04449913|EXPERIMENTAL|Active group|10 days intensive meditation retreat
62810061|NCT04449913|OTHER|Control group|Waiting for a 10 days intensive meditation retreat
62810062|NCT05698849|PLACEBO_COMPARATOR|Commercially Available Sports Drink A|A commercially available flavored electrolyte solution, The Coca-Cola Company
62593656|NCT06623097|EXPERIMENTAL|Arm 1: Virtually Supervised Care Comparator|"* Complete virtually supervised exercise sessions 3x weekly with their study partner.~* Complete Mediterranean eating program coaching session 1x weekly."
62593657|NCT06623097|EXPERIMENTAL|Arm 2: Unsupervised Care|"* Receives exercise and diet intervention recommendations including 3x weekly workouts and healthy eating goals~* Weekly recorded informative videos~* 4x weekly supportive text messages~* Study website access and interventional booklet"
62233953|NCT05717608|ACTIVE_COMPARATOR|high fructose in surinamese asian type 2 diabetes|high (100gr/day) fructose diet for 4 weeks in type 2 diabetic subjects of SAS ethnicity.
62233954|NCT05717608|PLACEBO_COMPARATOR|low fructose in surinamese asian type 2 diabetes|low fructose diet (\<30 gram fructose intake per day isocaloric correction with dextrose) for 4 weeks in type 2 diabetic subjects of SAS ethnicity.
62233955|NCT02347033|ACTIVE_COMPARATOR|Sertraline|The pharmacological arm of the trial is the Selective Serotonin Reuptake Inhibitor (SSRI) Sertraline, prescribed at a daily dose of between 25 and 150mg by the patient's general practitioner (GP). If the medication is well tolerated and associated with reported clinical improvement we are asking the patients in this arm to continue taking it for 12 months.
62233956|NCT02347033|ACTIVE_COMPARATOR|Cognitive Behavioural Therapy (CBT)|The psychological therapy arm of the trial is Cognitive Behavioural Therapy (CBT) delivered by high intensity psychological therapists from local IAPT services. They will provide 14 to 16 sessions of a manualised treatment developed specifically for use in GAD and will be trained in its delivery.
62424936|NCT05303480|ACTIVE_COMPARATOR|Chlormethine gel|Chlormethine gel 0.016% in 60mg tube, topical home administration from day 0 to day 155.
62424937|NCT05303480|NO_INTERVENTION|Healthy volunteers|Healthy volunteer cohort (observational)
62424938|NCT04307030||0 ~ 18 years old children|Children During Outpatient or Hospitalization
62424939|NCT05241899|EXPERIMENTAL|Fruquintinib + RC48|Fruquintinib + RC48
62424940|NCT05405530|EXPERIMENTAL|nasal mask oxygen group|In this group, patients use the nasal mask oxygen kit for oxygenation.
62424941|NCT05405530|ACTIVE_COMPARATOR|regular nasal cannula group|In this group, patients use the regular nasal cannula for oxygenation.
62424942|NCT06515093|EXPERIMENTAL|Arm 1 PelloGraft|PelloGraft treatment for diabetic foot ulcers versus Standard of Care treatment for diabetic foot ulcers
62424943|NCT06515093|EXPERIMENTAL|Arm 2 SanoGraft|SanoGraft treatment for venous leg ulcers vs Standard of Care treatment for venous leg ulcers
62424944|NCT02026102|NO_INTERVENTION|Usual Care|Patients will receive no additional ICD specific information other than what is offered by the clinic consistent with usual care. The control group will be asked where they went for information in the follow-up interviews.
62424945|NCT02026102|EXPERIMENTAL|ICD Decision Aid Toolkit|In the intervention arm, research assistants will provide the patients with the toolkit of decision aids. At that time, participants will have the option of using all of the decision aids or just some of the decision aids. Participants who do not have access to the internet, will be offered a DVD (digital video disc) version of the video and they will be asked if they would like to arrange a visit where they can review the website with the research assistant.
62424946|NCT04127435||High-Dose-Rate 192Ir Brachytherapy|"1. All patients underwent computed tomography (CT) 3-5 days before surgery. The collimation is 2.5 mm and CT Planning System.~2. Delineation of the gross tumor volume (GTV) and adjacent organs at risk (OARs);~3. Determination of the needle tract of the implanted insertion direction, distribution, and depth. Then calculation of the dose distribution of the target volume and OARs.~4. Depending on B-TPS data, we establish a digital model for the individual template.~5. Local anesthesia or intraspinal anesthesia was induced in all patients. The three-dimensional printing noncoplanar templates (3D-PNCT) was placed on the surface of the treatment area of the patient. The 3D-PNCT was aligned accurately with the outer-contour features. Through the guide hole of the 3D-PNCT, we inserted to pre-planned depths.~6. Delineation of the GTV and design planning .~7. Connect the source tube and 192Ir high dose rate interorganizational brinotherapy~8. At the end pressed to stop bleeding."
62424947|NCT02377284|EXPERIMENTAL|Intervention (personalized chef card)|Restaurant employees received a personalized chef card, which included written information about a patron's food allergies and a photograph of the patron.
62424948|NCT02377284|NO_INTERVENTION|Control (depersonalized chef card)|Restaurant employees received a depersonalized chef card, which included written information about a patron's food allergies, without a photograph of a patron.
62593658|NCT04774237|EXPERIMENTAL|BRIMOCHOL™|A single drop in each eye at a visit.
62593659|NCT04774237|EXPERIMENTAL|BRIMOCHOL™ F|A single drop in each eye at a visit.
62593660|NCT04774237|ACTIVE_COMPARATOR|Carbachol|A single drop in each eye at a visit.
62593661|NCT01901653|EXPERIMENTAL|Rovalpituzumab tesirine|Rovalpituzumab tesirine will be administered as a single agent, at increasing dose levels as permitted based on real-time assessment of safety and tolerability, intravenously over 30 minutes. Doses will be repeated on Day 1 of each 21-day or 42-day cycle until either unacceptable toxicity or evidence of disease progression occurs.
62233957|NCT03035968|EXPERIMENTAL|Vojta arm|Patients in the interventional arm are treated with Vojta therapy from randomization until discharge.
62233958|NCT03035968|ACTIVE_COMPARATOR|conventional physiotherapy arm|Patients in this control arm are treated with conventional physiotherapy for motor improvement from randomization until discharge.
62424949|NCT06336226|ACTIVE_COMPARATOR|One stage group|The one-stage operation was performed under regional anesthesia. A 5-cm incision at the ante cubital fossa identifies the basilic vein. The incision was extended proximally, and the underlying deep fascia was opened. The basilic vein was mobilized up to its junction with the brachial vein. The median cutaneous nerve of the forearm was carefully dissected and preserved. After side branches were ligated, the basilic vein was tunnelled subcutaneously, with a Roberts' forceps maintaining its axial orientation.An end-to-side arteriovenous anastomosisto the brachial artery was performed
62424950|NCT06336226|ACTIVE_COMPARATOR|two stage group|"he first stage of the two-stage procedure was performed under local anesthesia by formation of the arteriovenous anastomosis with minimal disturbance of the basilic vein. After 4 to 6 weeks, a flow assessment of the AVF by duplex scanning was made to determine if revision of the anastomosis was necessary at the second stage. The second stage was performed under regional anesthesia. The entire length of the basilic vein was mobilized, asubcutaneous flap was created, and the vein was positioned anterolaterally. Usually, a further 2 weeks was required before the AVF can be used"
62424951|NCT04416295|ACTIVE_COMPARATOR|Standard COPD care and a digital COPD support system|Device: LifePod The intervention group is testing LifePod on a digital communication platform between patient and healthcare provide
62424952|NCT04416295|OTHER|Control group Standard COPD Care|
62424953|NCT04406883|ACTIVE_COMPARATOR|A (Simavastatin 10 mg with gelatin sponge graft)|A group: After atraumatic extraction, filled the tooth socket with Simvastatin10 mg solution impregnated gelatin sponge.
62424954|NCT04406883|ACTIVE_COMPARATOR|B(Gelatin sponge graft )|B group: Following atraumatic extraction, put in the tooth socket with gelatin sponge.
62424955|NCT02913469|EXPERIMENTAL|morphine+metoclopramide|administrated intravenous morphine 5mg and metoclopramide 10mg
62424956|NCT02913469|ACTIVE_COMPARATOR|morphine|avenous morphine 5mg and 0.9%normal saline 2ml
62424957|NCT02913469|SHAM_COMPARATOR|metoclopramide|intravenous metoclopramide 10mg and 0.9%normal saline 2ml
62424958|NCT02913469|PLACEBO_COMPARATOR|placebo|intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml
62810063|NCT05698849|EXPERIMENTAL|Commercially Available Sports Drink B|A commercially available flavored carbohydrate-electrolyte solution, PepsiCo
62033642|NCT02322671|EXPERIMENTAL|Sequence BCA|Subjects will be administered a single oral dose of treatment A, B and C in the sequence BCA, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
62033643|NCT02322671|EXPERIMENTAL|Sequence CAB|Subjects will be administered a single oral dose of treatment A, B and C in the sequence CAB, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
62233959|NCT04173065|PLACEBO_COMPARATOR|Placebo|
62233960|NCT04173065|EXPERIMENTAL|1.0 mg|
62233961|NCT04173065|EXPERIMENTAL|2.5mg|
62233962|NCT04173065|EXPERIMENTAL|5.0 mg|
62233963|NCT04173065|EXPERIMENTAL|10 mg|
62233964|NCT02170454|ACTIVE_COMPARATOR|rTMS|rTMS on pharyngeal cortical area in healthy subjects
62233965|NCT02170454|PLACEBO_COMPARATOR|Placebo|Sham rTMS on pharyngeal cortical area in healthy subjects
62233966|NCT04427501|EXPERIMENTAL|LY3819253|700 mg, 2800 mg, 7000 mg, LY3819253 administered intravenously (IV)
62233967|NCT04427501|EXPERIMENTAL|LY3819253 + LY3832479|350 mg, 700 mg, 2800 mg LY3819253 + 700 mg, 1400 mg, 2800 mg LY3832479 administered IV or subcutaneously (SQ)
62424959|NCT01653223|NO_INTERVENTION|control|untreated
62424960|NCT01653223|EXPERIMENTAL|short statin|Simvastatin (20 mg) was administered every day for the 5-7 days preoperatively, but not the day of surgery in the statin group. Then simvastatin was re-administered at the second day until 7 days postoperatively.
62424961|NCT01653223|EXPERIMENTAL|long statin|Simvastatin (20 mg) was administered every day for the 5-7 days preoperatively, but not the day of surgery in the statin group. Then simvastatin was re-administered at the second day until 6 months postoperatively.
62424962|NCT05137418|EXPERIMENTAL|3-5 years old age group|500 participants aged 3-5 years will receive two doses of COVID-19 vaccine,inactivated on day 0 and day 28.
62424963|NCT05137418|EXPERIMENTAL|6-11 years old age group|500 participants aged 6-11 years will receive two doses of COVID-19 vaccine,inactivated on day 0 and day 28.
62424964|NCT00842088|EXPERIMENTAL|Active|
62424965|NCT00842088|PLACEBO_COMPARATOR|Placebo|
62424966|NCT04007588|EXPERIMENTAL|Nivolumab+BMS-986205|"* Nivolumab will be administered intravenously Day 1 of each 28 day cycle.~* BMS-986205 will be administered orally on a daily basis"
62424967|NCT04007588|EXPERIMENTAL|Nivolumab|-Nivolumab will be administered intravenously Day 1 of each 28 day cycle.
62810064|NCT05698849|EXPERIMENTAL|Commercially Available Sports Drink A with added Amino Acids|The same as sports drink A above (a commercially available flavored electrolyte solution, The Coca-Cola Company), but with the addition of a small amount of amino acids.
62233968|NCT04427501|EXPERIMENTAL|LY3819253 + LY3832479 (Pediatric Addendum, Arm 22)|LY3819253 dose based upon weight (weight Group: ≥40 kilogram (kg) = 700 mg dose, \>20 kg to \<40 kg = 350 mg dose, \>12 kg to 20 kg = 175 mg dose and 1.5 kg to 12 kg = 15 mg/kg dose) and LY3832479 dose based upon weight (weight Group: ≥40 kg = 1400 mg dose, \>20 kg to \<40 kg = 700 mg dose, \>12 kg to 20 kg = 350 mg dose and 1.5 kg to 12 kg = 30 mg/kg dose) administered IV.
62424968|NCT04007588|EXPERIMENTAL|Nivolumab+Ipilimumab|"* Nivolumab will be administered intravenously Day 1 of each 28 day cycle.~* Ipilimumab will be administered intravenously every 6 weeks"
62424969|NCT02208388|EXPERIMENTAL|Computed tomography perfusion|Patients with Computed tomography perfusion
62424970|NCT02208388|ACTIVE_COMPARATOR|Fractional flow reserve|Patients with Fractional flow reserve
62424971|NCT02026037|EXPERIMENTAL|Experimental|Brief Treatment for Acutely Burned Patients (BTBP)
62424972|NCT04252040|EXPERIMENTAL|Active tDCS with guided imagery|Subjects will receive 2 miliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
62424973|NCT06539091|EXPERIMENTAL|Fluzoparib group|During the treatment period, subjects were given fluazoparib capsules orally, two capsules/dose (50mg/capsule) twice daily, taken orally in the morning and in the evening, as a continuous dosage. Treatment will continue until an event occurs that meets the criteria for discontinuation of treatment.
62424974|NCT06539091|EXPERIMENTAL|Apatinib Mesylate group|During the treatment period, subjects will also receive oral apatinib mesylate tablets, one tablet/dose (250 mg/tablet), once daily, continuously. Treatment will continue until an event occurs that meets the criteria for discontinuation of treatment.
62424975|NCT06540599|ACTIVE_COMPARATOR|Patients using intrauterine lidocaine for analgesia|
62424976|NCT06540599|ACTIVE_COMPARATOR|Patients using oral dexketoprofen for analgesia|
62424977|NCT06540599|ACTIVE_COMPARATOR|Patients using cervical lidocaine spray for analgesia|
62424978|NCT06540599|ACTIVE_COMPARATOR|Patients using paracervical block with prilocaine for analgesia|
62593662|NCT05900141|EXPERIMENTAL|Pelacarsen (TQJ230)|open-label pelacarsen 80 mg
62424979|NCT00921804|EXPERIMENTAL|1|AZD8529 40 mg
62424980|NCT00921804|PLACEBO_COMPARATOR|2|Placebo
62810065|NCT04076085|ACTIVE_COMPARATOR|Unsupported Upper extremity exercise|Specially designed unsupported Arm exercises will be done for the population with a rating of somewhat hard 13-14 (Original scale) will be used as a guideline for intensity
62424981|NCT00921804|OTHER|3|Risperidone 4 mg (2mg on Day 1)
62424982|NCT03079674||NICE patients|Non-disabling ischemic cerebrovascular events patients indicate patients with transient ischemic attack and minor stroke (National Institute of Health stroke scale, NIHSS≤3).
62033644|NCT02322671|EXPERIMENTAL|Sequence CBA|Subjects will be administered a single oral dose of treatment A, B and C in the sequence CBA, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
62033645|NCT01817413|ACTIVE_COMPARATOR|Apexification with MTA|"The control group will receive:~Visit 1: root canal dressing with calcium hydroxide Visit 2: apexification with mineral trioxide aggregate (MTA), followed by obturation of the root canal with gutta percha.~Treatment will be carried out over two visits, two weeks apart."
62233969|NCT04427501|EXPERIMENTAL|LY3853113 (Pediatric Addendum, Arm 23)|LY3853113 dose based upon weight (Weight Group: ≥3.3 to ≤12 kg = 3 mg/kg dose, \>12 to ≤20 kg = 43.75 mg dose, \>20 to \<40 kg = 87.5 mg dose, ≥40 kg = 175 mg dose) administered IV.
62233970|NCT04427501|PLACEBO_COMPARATOR|Placebo|Placebo administered IV
62424983|NCT01598415|EXPERIMENTAL|SAR113945|TDU11685 selected dose
62424984|NCT01598415|PLACEBO_COMPARATOR|Placebo|
62424985|NCT06358807|EXPERIMENTAL|Microfracture with PRP|"Arthroscopic microfracture:~An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion.~PRP preparation and local injection:~PRP is harvested using a PRP preparation kit via centrifugation. Fifty milliliters of autologous venous blood are drawn from the patient and processed. Platelet count is measured for quality control. On average 4 ml of (range 3-6) PRP is obtained and mixed with thrombin calcium agent in preparation for PRP gel. PRP gel is administered to the injured area using a blunt and long-tip injector, with direct visualization under arthroscope."
62424986|NCT06358807|ACTIVE_COMPARATOR|Isolated microfracture|"Arthroscopic microfracture:~An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion."
62593663|NCT02481401|NO_INTERVENTION|Control Arm|Will not receive any structured program except for the health promotion education program that the children will receive for 4 months. Complementary to the Si! Program. This is essentially healthy habits related information and activities to be performed with their kids through family newsletters. All participants (including controls) have access to the study website for health related information.
62593664|NCT02481401|EXPERIMENTAL|Intensive Individual Intervention Program|A combination of one-on-one personalized lifestyle counseling (8 months with 4 complimentary sessions for a total of 12 months) and a wearable physical activity monitor such as the Garmin Vivofit.
62593665|NCT02481401|ACTIVE_COMPARATOR|Peer-To-Peer Program Intervention|Monthly meetings for 60-90 minutes in groups of about up to 20 supporting each other in self-control of CV risk factors, for a total of 12 months.
62033646|NCT01817413|EXPERIMENTAL|Pulp revascularisation|"The experimental group will receive:~Visit 1: root canal dressing with triple antibiotic paste Visit 2: pulp revascularisation procedure Treatment will be carried out over two visits, two weeks apart."
62033647|NCT05947877|EXPERIMENTAL|Non-pharmacological nursing pain management strategies|This arm considers conventional care.
62033648|NCT05947877|EXPERIMENTAL|Breast milk|This arm considers breast milk. The preterm infants were orally fed 2 ml of expressed breast milk through a syringe 2 minutes before heel stick over the anterior surface of the tongue, allowing for preterm infant swallowing rates over a period of 1-2 minutes. Thereafter, the bedside nurse conducts the heel lancing. When the mother is present with her preterm infant in the NICU, the breast milk was expressed by the mother and provided in a syringe at least 30 minutes before the intervention (n = 11). For the rest 10 preterm infants whose mothers were not present with them in the NICU, they send their breast milk to be kept in the NICU refrigerator. This milk was first warmed in room temperature 30 minutes before it was given to the preterm infant.
62233971|NCT04675021|EXPERIMENTAL|AZD6094 (Savolitinib) D5084C00010|All volunteers will receive either a single dose or two doses of AZD6094 (Savolitinib) D5084C00010
62233972|NCT01394653|EXPERIMENTAL|orally-disintegrating (OD) tablet precedence group|
62233973|NCT01394653|EXPERIMENTAL|conventional tablet precedence group|
62233974|NCT02880202|OTHER|Massage Therapy|Massage therapy for hospice patients.
62233975|NCT05428137|ACTIVE_COMPARATOR|Probiotic|Live bacteria strain in a form of a capsule daily for 16 weeks
62233976|NCT05428137|ACTIVE_COMPARATOR|Postbiotic|Heat treated bacteria strain in a form of a capsule daily for 16 weeks
62233977|NCT05428137|PLACEBO_COMPARATOR|Placebo|Placebo in a form of a capsule administered for 16 weeks
62233978|NCT02101034|EXPERIMENTAL|Phase I: Dose Level 1|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
62424987|NCT04992481|EXPERIMENTAL|1. professional mechanical tooth cleaning (PMTC)+fluoride varnish|This arm constituted of randomly selected 30 participants. In this group professional mechanical tooth cleaning (PMTC)+fluoride varnish were performed.
62424988|NCT04992481|EXPERIMENTAL|2. PMTC+fluoride varnish+gaseous ozone therapy|This arm constituted of randomly selected 30 participants. In this group PMTC+fluoride varnish+gaseous ozone therapy were performed.
62593666|NCT01692210||Blood Draw Pre and Post Surgery|Patients within the UT MD Anderson Cancer Center who are scheduled for breast cancer surgery.
62593667|NCT00737347|NO_INTERVENTION|1|usual care. Subjects had one 90 minute visit with registered dietitian
62593668|NCT00737347|ACTIVE_COMPARATOR|2.|Standard care. Subjects had 4 sessions with registered dietitian
62593669|NCT00737347|ACTIVE_COMPARATOR|3|Intensive care. subjects had 10 visits with registered dietitian
62033649|NCT05947877|EXPERIMENTAL|Oral sucrose|This arm considers oral sucrose. The researchers gave one ml of 24% oral sucrose to the preterm infant two minutes prior to the heel stick, drop-by-drop via syringe over the anterior surface of the tongue which enable the preterm infant to swallow rates over a period of 1-2 minutes. Conducting the heel stick procedure with lancet approximately two minutes after administering the sucrose. The pharmacy at the study site supplies the syringes containing the oral sucrose solution, solutions are prepared and packaged in an identical matter, the SR will label each syringe with the preterm infants' study number and name to ensure added protection.
62233979|NCT02101034|EXPERIMENTAL|Phase I: Dose Level 2|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
62033650|NCT05947877|EXPERIMENTAL|KMC|This arm considers KMC. The preterm infants were randomized to the KMC intervention; the researchers explained to the mother that she and her preterm infants will be put in KMC position, where the diaper-clad infant was held upright, at an angle of approximately 60°, between the mothers' breasts, providing maximal skin-to-skin contact between mother and baby. A blanket was placed over the preterm infant's back, and the mother's clothes were wrapped around the neonate, the preterm infant will remain in KMC for 30 minutes before the lancing procedure, during, and at least 30 minutes after the heel lance.
62233980|NCT02101034|EXPERIMENTAL|Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
62233981|NCT02101034|EXPERIMENTAL|Phase II Arm 2: Cetuximab-Resistant HPV-Unrelated SCCHN|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
62593670|NCT01963377|EXPERIMENTAL|1. Nasal Cannulae / 2. Bronchoscope channel|Supplementation of O2 through will take place first through the aspiration channel of the bronchoscope, in second phase of the study O2-supplementation will be done through nasal cannulae.
62233982|NCT02101034|EXPERIMENTAL|Phase II Arm 3:|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
62593671|NCT01963377|EXPERIMENTAL|1. Bronchoscope channel / 2. Nasal Cannulae|Supplementation of O2 through will take place first through nasal cannulae, in second phase of the study O2-supplementation will be done through the aspiration channel of the bronchoscope.
62593672|NCT01329003||exposed workers|At least six months of occupational exposure to Caesar stone
62593673|NCT05787535|EXPERIMENTAL|HRYZ-T101 TCR-T cell therapy|Patients will undergo lymphocytapheresis, then treatment with TCR-T cell.
62810066|NCT04076085|ACTIVE_COMPARATOR|Lower extremity exercise|Specially designed Lower extremity exercises will be done for the population with a rating of somewhat hard 13-14 (Original scale) will be used as a guideline for intensity
62593674|NCT05405361|EXPERIMENTAL|Dose regimen 1|ARGX-117/Placebo IV
62810067|NCT04076085|NO_INTERVENTION|Control|Here no active intervention will be given only standard care as prescribed by the hospital will be given
62810068|NCT04957446|EXPERIMENTAL|Group 1|Subjects will receive 3 treatments of 1mL Poly-L-Lactic Acid (Sculptra Aesthetic)
62810069|NCT04957446|PLACEBO_COMPARATOR|Group 2|Subjects will receive 3 treatments of 1mL Saline solution.
62810070|NCT03576508|EXPERIMENTAL|CNTX-4975-05 Intra-Articular (IA) Injection|Receives IA injection into the most painful OA knee.
62810071|NCT03576508|ACTIVE_COMPARATOR|Topical 8% Capsaicin Patch|Receives Capsaicin Patch on posterior rib cage.
62810072|NCT04032067|ACTIVE_COMPARATOR|Control Group|"GV1001-Placebo ID injection administered every 2 weeks through Week 24~+ Proscar PO administered once a day through Week 24"
62233983|NCT01188213|EXPERIMENTAL|Purified MSM|
62810073|NCT04032067|EXPERIMENTAL|Study Group 1|"GV1001 0.56 mg ID injection administered every 2 weeks through Week 24~+ Proscar-placebo PO administered once a day through Week 24"
62810074|NCT04032067|EXPERIMENTAL|Study Group 2|"GV1001 1.12 mg ID injection administered every 2 weeks through Week 24~+ Proscar-placebo PO administered once a day through Week 24"
62233984|NCT01679795|EXPERIMENTAL|Tibolone|patientes will use tibolone 2,5mg/day during 30 days
62233985|NCT01679795|PLACEBO_COMPARATOR|Placebo use|Patients will use placebo for 30 days
62810075|NCT03401307||Responders to Fampridine Treatment|Participants, who are classified as responders to Fampridine treatment, have already been identified in the MS-centers in the Region of Southern Denmark, where they undergo outpatient treatment and clinical controls. A 2-week Fampridine treatment phase, as described in the trial outline section, has been used to identify responders to Fampridine. Participants who improve with ≥20% on the T25FW are categorized as responders.
62233986|NCT02699034|EXPERIMENTAL|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device ( Vision-MR ablation catheter )
62233987|NCT02530853|EXPERIMENTAL|Group A|Laser acupuncture
62233988|NCT02530853|SHAM_COMPARATOR|Group B|Simulation Laser acupuncture
62233989|NCT00978692|EXPERIMENTAL|Toric orthokeratology lenses|Children wearing toric ortho-k lenses at night for correcting astigmatism and myopia will be the study group
62233990|NCT00978692|OTHER|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive error will be serve as control group
62233991|NCT05718310|ACTIVE_COMPARATOR|Nitroglycerin|Nitroglycerin diluted in 250 ml of sodium chloride 0.9% will be administered once via an infusion pump intravenously, at a dose of 0.5 μg/kg/min in 20 minutes.
62233992|NCT05718310|PLACEBO_COMPARATOR|Saline|250 ml of sodium chloride 0.9% will be administered intravenously in 20 minutes via an infusion pump.
62233993|NCT05048420|EXPERIMENTAL|Ramp lesion repair|
62233994|NCT05048420|EXPERIMENTAL|Anterior cruriciate ligament reconstruction|
62233995|NCT00954525|EXPERIMENTAL|Intravenous Vitamin C|
62233996|NCT03252951|EXPERIMENTAL|Eccentric Training|
62233997|NCT03252951|EXPERIMENTAL|Concentric Training|
62233998|NCT03252951|EXPERIMENTAL|Isometric Training|
62233999|NCT03252951|ACTIVE_COMPARATOR|Biofeedback|
62234000|NCT03368911|EXPERIMENTAL|Reinforced tube group|use an reinforced endotracheal tube for endotracheal intubation during general anesthesia undergoing thyroidectomy
62234001|NCT03368911|ACTIVE_COMPARATOR|Conventional tube group|use an conventional endotracheal tube for endotracheal intubation during general anesthesia undergoing thyroidectomy
62234002|NCT00638131|EXPERIMENTAL|1|Bosentan 62.5mg bid x4 weeks; up-titrated to 125mg bid x12 weeks;
62234003|NCT00638131|PLACEBO_COMPARATOR|2|placebo given bid same as experimental arm;
62234004|NCT03325998|EXPERIMENTAL|Gait training group|"Gait training with Samsung Hip Assist v1~All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions."
62234005|NCT05156632|EXPERIMENTAL|Medium-dose group|4800 participants including 3400 participants aged 18-59 years ,1200 participants aged 60 years and above who have received 2 doses of CoronaVac® (medium-dose COVID-19 Vaccine) in an interval between 21-56 days will receive a booster dose of medium-dose COVID-19 Vaccine 5-8 months after their second dose.
62234006|NCT05156632|EXPERIMENTAL|High-dose group|4800 participants including 3400 participants aged 18-59 years,1200 participants aged 60 years and above who have received 2 doses of CoronaVac® (medium-dose COVID-19 Vaccine) in an interval between 21-56 days will receive a booster dose of high-dose COVID-19 Vaccine 5-8 months after their second dose.
62234007|NCT05156632|PLACEBO_COMPARATOR|Placebo group|4800 participants including 3400 participants aged 18-59 years,1200 participants aged 60 years and above who have received 2 doses of CoronaVac® (medium-dose COVID-19 Vaccine) in an interval between 21-56 days will receive a booster dose of placebo 5-8 months after their second dose.
62234008|NCT01633814|EXPERIMENTAL|Transdermal estradiol|Transdermal estradiol, delivery rate 100 µg day-1
62234009|NCT01633814|PLACEBO_COMPARATOR|Placebo|placebo patch.
62234010|NCT04579965|OTHER|combined contraceptive pills|treat patients with isthmocele with oral contraceptive pills
62234011|NCT04579965|OTHER|Misotac|treat patients with isthmocele with misotac.
62810076|NCT03401307||Non-Responders to Fampridine Treatment|Participants, who are classified as non-responders to Fampridine treatment, have already been identified in the MS-centers in the Region of Southern Denmark, where they undergo outpatient treatment and clinical controls. A 2-week Fampridine treatment phase, as described in the trial outline section, has been used to identify non-responders to Fampridine. Participants who do not improve with ≥20% on the T25FW are categorized as non-responders.
62810077|NCT03088891|EXPERIMENTAL|Antioxidant-rich snacks|The participants received antioxidant-rich snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included fruits and vegetable smoothies, dark chocolate, walnuts, dried fruits and berries.
62033651|NCT05947877|EXPERIMENTAL|Nesting position|This arm considers nesting position. Before heel lancing, the researchers prepared and arranged all the required nesting equipment from the NICU such as linen, small pillow, and blanket. Making the nest by folding the blanket form one corner, then placing it upright and laying the linen over the blanket. Positioning the preterm infant inside the nest in supine position, ensuring that the nest size is suitable for the preterm infant's body, neither too loose nor too tight during nesting position. Position the preterm infant first in supine position through wrapping infant with hand to midline the nest through putting small pillow under the preterm infant's shoulder to keep airway open, the nested infants were placed in nest, that helped to maintain and support them in a flexed position but still facilitated unrestricted movement of their body and limbs, supine nesting position conducting 30 minutes before heel lancing and, during, and after the procedure for 30 minutes.
62033652|NCT03298139|EXPERIMENTAL|parabolic flights|parabolic flights in normogravity (1g), hypergravity (1.8g) and microgravity (0g).
62033653|NCT01854827|EXPERIMENTAL|IVIG active treatment|Intravenous immunoglobulin (IVIG) 10% 1 gm/kg body weight/dose Day 3-5,30, 60 post HPE
62033654|NCT06347172|EXPERIMENTAL|Nudge internvention|"PCPs will receive an enhanced EHR alert (nudge) that triggers when a PCP opens an encounter for an eligible patient living with dementia (PLWD). The nudge will provide information about the risks of continued medication use as well as tips and tools to help providers discuss medication discontinuation with patients and care partners. Additionally, the providers will receive a brief message in their in-basket 10 days before the patient's appointment as a reminder.~Eligible PLWD of a randomized PCP will receive the nudge intervention which includes a brief recommendation for the PLWD (and care partner, if available) via the linked patient portal prior to upcoming visits (unless explicitly opted out by the PCP) to discuss medications with the PCP at the visit and link to a general handout about medications, unless explicitly opted out by the PCP. For PLWD without a portal account, the handout will be sent to their mailing address recorded in the EHR."
62033655|NCT02107118|ACTIVE_COMPARATOR|ARM 1: AdMSC: adipose stem cells|AdMSC: Autologous adipose tissue-derived mesenchymal stem cell. Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured.
62033656|NCT02107118|PLACEBO_COMPARATOR|ARM 2 Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
62234012|NCT00935194|EXPERIMENTAL|blank|do not take antiviral therapy
62234013|NCT00935194|EXPERIMENTAL|Oseltamivir|antiviral therapy
62033657|NCT05184231||Patient cohort|
62033658|NCT05184231||Physician cohort|
62810078|NCT03088891|PLACEBO_COMPARATOR|Control snacks|The participants received antioxidant-depleted snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included milkshake, and other milk-based drinks, biscuits (both sweet and salty), white chocolate.
62234014|NCT00935194|EXPERIMENTAL|chinese medicinary herbs|antiviral therapy
62234015|NCT00935194|EXPERIMENTAL|oseltalmivir and chinese medicinal herbs|combination antiviral therapy
62234016|NCT04014725|EXPERIMENTAL|Eligible patients for AI test|
62234017|NCT01727622||Controls|ASL-MRI and FDG-PET will be compared for ability to discriminate between Control subjects and adults with Mild Cognitive Impairment (prodromal AD). A lumbar puncture will be obtained in a proportion of the participants.
62593675|NCT05405361|EXPERIMENTAL|Dose regimen 2 or Dose regimen 3|ARGX-117/Placebo IV
62033659|NCT04390737|EXPERIMENTAL|HH2853 administered on a BID schedule in continuous 28-day treatment cycles|"HH2853 is supplied as tables with dosage strength of 25mg and 200mg. HH2853 Tablet will be administered orally on a continuous twice daily (BID) schedule, on a flat scale of mg and not individually adjusted by weight or body surface area. A treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations.~All patients will be treated with HH2853 orally on a continuous BID schedule, beginning on Cycle 1 Day 1. But patients in accelerated titration (ATD) part should be administered a single dose on the first day in order to evaluate the PK of a single dose administration. Dosing is twice daily from the second day thereafter."
62810079|NCT01772966|EXPERIMENTAL|Spinal manipulation|Participants will receive spinal manipulation delivered as segmental thrust to a specific site in the neck. They will receive three intervention sessions over 7-10 days.
62810080|NCT01772966|SHAM_COMPARATOR|Control manipulation|Participants will receive spinal manipulation delivered as non-segmental thrust to the neck. They will receive three intervention sessions over 7-10 days.
62033660|NCT05198765|EXPERIMENTAL|BMI-CDS|Clinicians and their patients assigned to intervention clinics will receive shared decision support tools for weight loss management.
62424989|NCT04992481|EXPERIMENTAL|3. PMTC+fluoride varnish+domestic octenidin mouth rinse|This arm contituted of randomly selected 30 participants. In this group PMTC+fluoride varnish+domestic octenidin mouth rinse were applied.
62810081|NCT04896528|EXPERIMENTAL|Avatrombopag|"Avartripopa is a new generation of oral TPO receptor agonist that simulates the biological effects of TPO in vitro and in vivo.~TPO stimulates megakaryocytes through binding and activation of TPO receptor, which is expressed in hematopoietic stem cells, megakaryotic cell lines and platelets.~By binding to the transmembrane region of the thrombopoietin receptor, Ava Tripopa activates the thrombopoietin receptor in humans, stimulates signal transduction and mimics the biological effects of thrombopoietin, leading to an increase in platelet count."
62033661|NCT05198765|NO_INTERVENTION|Usual Care|Clinicians and their patients assigned to control clinics will engage in the usual standard of care.
62033662|NCT00185185|EXPERIMENTAL|1|olmesartan medoxomil
62033663|NCT00185185|ACTIVE_COMPARATOR|2|atenolol
62810082|NCT04820595||Control group|Patients who have RASS \< +2 and have not delirium according CAM-ICU immediately upon emergence from anesthesia
62810083|NCT04820595||Agitated non-delirious group|Patients who have RASS = +2 or more and have not delirium according CAM-ICU immediately upon emergence from anesthesia
62234018|NCT01727622||Mild Cognitive Impairment|ASL-MRI and FDG-PET will be compared for ability to discriminate between Control subjects and adults with Mild Cognitive Impairment (prodromal AD). A lumbar puncture will be obtained in a proportion of the participants.
62424990|NCT04992481|EXPERIMENTAL|4. PMTC+fluoride varnish+domestic octenidin mouth rinse+ gaseous ozone therapy|This arm constituted of randomly selected 30 participants. In this group PMTC+fluoride varnish+domestic octenidin mouth rinse+ gaseous ozone therapy were performed.
62810084|NCT04820595||Agitated delirium group|Patients who have RASS = +2 or more and have delirium according CAM-ICU immediately upon emergence from anesthesia
62424991|NCT04992481|NO_INTERVENTION|Control group|Control group not subjected to any prophylactic program constituted of randomly selected 30 participants.
62033664|NCT02697253|EXPERIMENTAL|Successful drug|"Participants who have a % weight loss ≥35 at 2 years post RYGB/SG surgery will be administered sitagliptin and receive infusion of Exendin 9-39 prior to an intake test.~Drug: Exendin 9-39 Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~Drug: Sitagliptin 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
62033665|NCT02697253|EXPERIMENTAL|Unsuccessful drug|"Participants who have a % weight loss of ≤25 at two years post RYGB/SG surgery will be administered Sitagliptin and receive infusion of Exendin 9-39 prior to an intake test.~Drug: Exendin 9-39 Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~Drug: Sitagliptin 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
62234019|NCT04894123|EXPERIMENTAL|trifluridine/tipiracil +/- oxaliplatin|"Trifluridine/tipiracil 35 mg/m² orally twice a day from day 1 to day 5 plus oxaliplatin 85 mg/m² intravenous at day 1 every 14 days.~If oxaliplatin is stopped for neurotoxicity, allergic reaction or other reason, or it is not indicated, patients will continue trifluridine/tipiracil in monotherapy 35 mg/m² orally twice a day between days 1-5 and days 8-12; repeated every 28 days."
62234020|NCT03456271||fracture group|
62234021|NCT03456271||non-fracture group|
62234022|NCT02986334|NO_INTERVENTION|No Treatment Intervention|Observational Subjects randomized to this arm will be asked to discontinue their current pain medications for the length of the study. This arm is not blinded, as both study staff and participants will be aware that they are not receiving a study treatment.
62234023|NCT02986334|ACTIVE_COMPARATOR|Active Treatment Intervention|Naproxen \& Omeprazole Subjects randomized to this arm will be asked to discontinue their current pain medications and take one 500mg naproxen capsule and one 40mg omeprazole capsule twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
62424992|NCT05151796||Aspirin continued within 5 days before surgery|
62424993|NCT05151796||Aspirin discontinued more than 5 days before surgery|
62593676|NCT02680834|EXPERIMENTAL|Dual Action Pneumatic Compression Device|ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks.
62033666|NCT02697253|PLACEBO_COMPARATOR|Success placebo|"Participants who have a % weight loss ≥35 at 2 years post RYGB/SG surgery will be administered a placebo and receive a placebo infusion prior to an intake test.~Drug: Placebo Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~Drug: Placebo 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
62033667|NCT02697253|PLACEBO_COMPARATOR|Unsuccess placebo|"Participants who have a % weight loss of ≤25 at two years post RYGB/SG surgery will be administered a placebo and receive a placebo infusion prior to an intake test.~Drug: Placebo Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~Drug: Placebo 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
62593677|NCT02680834|ACTIVE_COMPARATOR|Multi-layer bandaging|PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks.
62033668|NCT06670183||UK Biobank|UK Biobank. There are no interventions in this observational cohort study.
62033669|NCT00245895|ACTIVE_COMPARATOR|1|Aranesp
62234024|NCT02986334|PLACEBO_COMPARATOR|Placebo Treatment Intervention|Subjects randomized to this arm will be asked to discontinue their current pain medications and take two placebo capsules twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment)
62593678|NCT02480374|EXPERIMENTAL|Single Arm|Carboplatin + Paclitaxel + IMNN-001
62593679|NCT01453478|EXPERIMENTAL|GSK1325756 Immediate Release 50 mg|Administered to volunteers in the fasted and fed states
62593680|NCT01453478|EXPERIMENTAL|GSK1325756 Bioenhanced Formulation 1 50 mg|Administered to volunteers in the fasted and/or fed states
62593681|NCT01453478|EXPERIMENTAL|GSK1325756 Bioenhanced Formulation 2 50 mg|Administered to volunteers in the fasted and/or fed states
62593682|NCT03119753|EXPERIMENTAL|Group R|Rapid Prototyping method of fabrication of complete denture: the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.
62593683|NCT03119753|ACTIVE_COMPARATOR|Group C|Conventional method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
62033670|NCT05802810|EXPERIMENTAL|[14C]JT001|
62033671|NCT05415735|EXPERIMENTAL|SMART Program|The Stress Management and Resiliency Training (SMART) Program is a multimodal mind-body and cognitive skills-based program that teaches participants a variety of different approaches for reducing their physiologic stress response. The program is delivered virtually (online) for 1.5 hours once a week for 8 weeks.
62033672|NCT05606120||CL TRAUMA implanted patients|Patients who underwent hip arthroplasty with CL TRAUMA cemented femoral stem from 2017 to 2020.
62033673|NCT04981587|EXPERIMENTAL|Intervention group|This is the group that receives strength exercise in addition to usual treatment
62033674|NCT04981587|OTHER|Control group|This is the group that only receives usual treatment
62033675|NCT04050826|EXPERIMENTAL|Dermal Pharmacokinetic study|"Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dOFM after topical application of three lidocaine/prilocaine products in 20 participants.~After baseline sampling (1 hour pre-dose) the three lidocaine/prilocaine products will be applied and removed after 3 hours. ISF and blood sampling will be continued for a duration of 12 hours post-dose. Additionally different physical parameters (e.g. TEWL) will be measured."
62033676|NCT00679120|ACTIVE_COMPARATOR|1|Cemented single pegged femur with standard tibial bearing tray
62033677|NCT00679120|ACTIVE_COMPARATOR|2|Cemented twin pegged femur with standard tibial bearing tray
62033678|NCT00679120|ACTIVE_COMPARATOR|3|Cementless tibial bearing tray and femur (porous coated and HA coated)
62593684|NCT01556568|EXPERIMENTAL|MEK162|Patients will be treated with MEK162 only and will be uptitrated or down titrated based on safety and tolerability observed.
62593685|NCT06260111|EXPERIMENTAL|Photobiomodulation group|Photobiomodulation and usual care (education, cryotherapy, and mouth hygiene).
62593686|NCT06260111|OTHER|Control group|Usual care (education, cryotherapy, and mouth hygiene).
62593687|NCT04028427|EXPERIMENTAL|Participants randomly assigned to VGI|
62593688|NCT04028427|EXPERIMENTAL|Participants randomly assigned to MBI|
62810085|NCT00056095|EXPERIMENTAL|Allograft (compatible family member)|
62810086|NCT00056095|OTHER|Allograft (compatible non-family member)|
62033679|NCT05556863|EXPERIMENTAL|Part 1: Single Ascending Dose|"Cohort 1 Single dose: 0.001 mg/kg IV~Cohorts 2 - 11 Single dose: dose level and route (IV or SC) to be determined~Japanese Cohort Single dose: dose level and route (IV or SC) to be determined"
62033680|NCT05556863|EXPERIMENTAL|Part 2: Multiple Ascending Dose|Cohort 1 - 6 Multi-dose: dose level, route (IV or SC) and frequency to be determined
62234025|NCT02925026|EXPERIMENTAL|Lactoferrin+Lysozyme|lactoferrin and lysozyme in rice flour
62234026|NCT02925026|PLACEBO_COMPARATOR|Placebo|rice flour
62234027|NCT02718313||Intraventricular conduction delay|Transthoracic echocardiography will be performed to investigate whether the patients have the cardiac disease or not. The transthoracic echocardiography will be performed after the induction of general anesthesia and before the start of surgery.
62234028|NCT00460551|EXPERIMENTAL|Zalutumumab 8 mg/kg|
62234029|NCT04835701|EXPERIMENTAL|Music Intervention group|Subjects randomized to the music group will choose 10 songs, which will be played during the procedure, from the time of positioning through completion of IUD insertion and speculum removal. Participants will otherwise undergo standard protocol for IUD insertion in an outpatient clinic setting. Total participation is predicted to last approximately 30 minutes.
62424994|NCT05384197|ACTIVE_COMPARATOR|Enhanced regimen|"They will receive two days antibiotic prophylaxis according to the predetermined protocol.~Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 2 days according to the assigned randomization group with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (2 days with the last day of AP course being one day prior to intervention)"
62424995|NCT05384197|ACTIVE_COMPARATOR|Extended regimen|"They will receive seven days antibiotic prophylaxis according to the predetermined protocol.~Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 7 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule ( 7 days with the last day of AP course being one day prior to intervention)"
62424996|NCT01041937|ACTIVE_COMPARATOR|Cemented Tibia|Assessing the clinical outcomes of the different type of fixation
62424997|NCT01041937|ACTIVE_COMPARATOR|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
62424998|NCT01898858||HYPOXIA|
62424999|NCT01898858||HYPERCAPNIA|
62425000|NCT01898858||HYPOXIA + HYPERCAPNIA|
62425001|NCT05349032|OTHER|Meriva|120 mg of curcumin in Meriva.
62425002|NCT05349032|OTHER|Longvida|120 mg of curcumin Longvida.
62425003|NCT05349032|OTHER|NovaSol|120 mg of curcumin NovaSol
62425004|NCT05349032|OTHER|CurcElite|120 mg of curcumin CurcElite
62425005|NCT05349032|OTHER|UltaCur|120 mg of curcumin Ultracur
62425006|NCT00695981|ACTIVE_COMPARATOR|Rotator cuff repair|Surgery following a 3 months period of active non-operative treatment
62425007|NCT00695981|ACTIVE_COMPARATOR|Conservative treatment|Physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
62425008|NCT00837577|EXPERIMENTAL|Sitagliptin/Sitagliptin|
62425009|NCT00837577|EXPERIMENTAL|Placebo/Sitagliptin|
62425010|NCT02516878|EXPERIMENTAL|Acupuncture group|"Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated."
62033681|NCT01576536||Healthy volunteers|Normal healthy volunteers
62425011|NCT02516878|SHAM_COMPARATOR|Control group|"For subjects assigned to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to serve as sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin instead of insertion.~The Semen Vaccariae embedded tape used in treatment group will be applied on 4 non-acupoints at the helix unilaterally, retained until the next visit and then the alternate ear will be used."
62425012|NCT05069428|EXPERIMENTAL|ramelteon|ramelteon 8 mg crushed tablet daily at 20:30
62425013|NCT05069428|PLACEBO_COMPARATOR|placebo|placebo powder equivalent grams at 20:30
62810087|NCT01865422|EXPERIMENTAL|chronic cough|
62810088|NCT03536013|EXPERIMENTAL|Treatment|91 patients will undergo a typical lumbar microdiscectomy with the addition of a full-thickness placental allograft after the microdiscectomy has been performed.
62234030|NCT04835701|NO_INTERVENTION|Control group|Participants to undergo same standard protocol for IUD insertion in an outpatient clinic setting. No music will be played during the procedure.
62234031|NCT04632433|EXPERIMENTAL|single arm|Patients will receive cemiplimab at a dosage of 350 mg every 3 weeks for two cycles prior surgery. Stage III stage must be documented at screening and re-assessed prior surgery by spiral or multidetector computed tomography (CT) scan (if clinically indicated) and Positron emission tomography (PET). Postoperatively, adjuvant immunotherapy with cemiplimab will be administered at a dosage of 350 mg every 3 weeks for one year.
62810089|NCT03536013|NO_INTERVENTION|Control|91 patients will undergo a typical lumbar microdiscectomy without the addition of a full-thickness placental allograft.
62234032|NCT05729880||Older|16 older (\>50y) will be recruited. MRI, MRS and Ultrasound will be measured in each participant in calf and thigh muscle, at the same location within a 1 hour time frame.
62234033|NCT05729880||Young|16 young (\<40y) will be recruited. MRI, MRS and Ultrasound will be measured in each participant in calf and thigh muscle, at the same location within a 1 hour time frame.
62234034|NCT03459274||VR-Biofeedback Feedback Sharers|These participants would express either interest or a lack of interest in trying biofeedback/virtual reality therapy. They will be instructed on how to use the virtual reality equipment and program. Then, they will have the option to participate in the biofeedback/virtual reality experience, if they choose to do so, before sharing their feedback.
62234035|NCT00300898|ACTIVE_COMPARATOR|Nucleoplasty|Procedure/Surgery: Nucleoplasty
62425014|NCT05037942|EXPERIMENTAL|Blood flow-restricted exercise at 40% limb occlusion pressure (BFR-40)|Participants in BFR-40 will perform a lower-body exercise protocol under BFR set to 40% of the participants' relative limb occlusion pressure.
62425015|NCT05037942|EXPERIMENTAL|Blood flow-restricted exercise at 80% limb occlusion pressure (BFR-80)|Participants in BFR-80 will perform the same lower-body BFR exercise protocol as BFR-40; however, the occlusion pressure will be set to 80% of the participants' relative limb occlusion pressure.
62810090|NCT05323136|EXPERIMENTAL|Renal impairment|moderate and severe Renal impairment subjects
62234036|NCT00300898|ACTIVE_COMPARATOR|Percutaneous decompression|Procedure/Surgery: Percutaneous decompression
62234037|NCT00300898|ACTIVE_COMPARATOR|Electrothermal disc decompression (IDET)|Procedure/Surgery: Intervertebral electrothermal disc decompression (IDET)
62234038|NCT00300898|EXPERIMENTAL|Behavioral:Conservative treatment|Conservative treatment with oral medications, physical therapy, epidural steroid injections
62425016|NCT05037942|NO_INTERVENTION|Control for BFR-40|Participants randomised to BFR-40 will perform the same exercise protocol without BFR with the contralateral leg.
62425017|NCT05037942|NO_INTERVENTION|Control for BFR-80|Participants randomised to BFR-80 will perform the same exercise protocol without BFR with the contralateral leg.
62425018|NCT03971669|EXPERIMENTAL|Vaccination with Oral Typhoid Vaccine (Vivotif)|Volunteers receive immunization with Vivotif oral typhoid vaccine. Blood, saliva, and stool specimens are collected at subsequent visits.
62425019|NCT01891786|NO_INTERVENTION|Usual Care|The participant's General practitioner (GP) practice and/or practice nurse will provide care as normal for their patient.
62033682|NCT05894876||Good responders|Participants on previous treatment with growth hormone will have one study visit for taking a non-invasive biological sample. Good responders are defined as participants with a change in height Standard Deviation Score (SDS) more than (\>) 1.0, corresponding to \>85th percentile.
62810091|NCT05323136|EXPERIMENTAL|Healthy control|Healthy control subjects with normal renal function
62810092|NCT02325596||control|Patients with only nasal septum deviation
62810093|NCT02325596||CRS sNP|Chronic Rhinosinusitis patients without nasal polyps
62810094|NCT02325596||atopic CRS wNP|Chronic Rhinosinusitis patients with allergic constitution and nasal polyps
62810095|NCT02325596||non-atopic CRS wNP|Chronic Rhinosinusitis patients with nasal polyps but not allergic constitution
62810096|NCT02372643|OTHER|Sexually healthy women|20 sexually healthy volunteer women will be enrolled from subjects consulting our outpatient clinic (subjects free from sexual dysfunction). Hormonal and ultrasound parameters and self-administered questionnaires will be evaluated.
62033683|NCT05894876||Poor responders|Participants on previous treatment with growth hormone will have one study visit for taking a non-invasive biological sample. Poor responders are defined as participants with a change in height SDS less than (\<) 0.4, corresponding to \<15th percentile.
62033684|NCT03422874|EXPERIMENTAL|Nelfinavir plus MLN9708|"Both Nelfinavir and MLN9708 will be given orally (by mouth). MLN9708 will be given as 3 mg orally twice weekly. Study drugs will be administered on 21-day treatment cycles. All cycles are 21 days.~During the first cycle of MLN9708 only will initially be administered orally at a fixed dose of 3mg twice weekly for 2 weeks, on Mondays and Thursdays during this treatment cycle. During the third week there will be no study combination drug therapy(for Cycle 1 only). During Cycles 2 and 3, MLN9708 administered twice weekly on Mondays and Thursdays for the first 2 weeks of Cycles 2 and 3. Nelfinavir (escalating cohorts \[1250mg, 1875mg, 2500mg, 3125mg\]) will be administered orally twice daily in the dose cohorts listed."
62033685|NCT01290835|EXPERIMENTAL|Stereotactic radiotherapy|Accelerated stereotactic radiotherapy as an adjuvant treatment for early stage breast cancer.
62033686|NCT05411887||Experimental/ Olostar Tablet|Eligible Subjects who received Olostar Tablet treatment for 24 weeks. Dosage: 10/5mg, 10/10mg, 20/5mg, 20/10mg, 20/20mg, 40/10mg, 40/20mg
62425020|NCT01891786|ACTIVE_COMPARATOR|Group Self-Management Intervention (SMI)|Participants will be asked to attend a total of 4 SMI sessions delivered on a weekly basis.
62810097|NCT02834481|OTHER|: ventilated children|ventilated children admitted in PICU postoperative of cardiac surgery with extracorporeal circulation with ANI/NIPE
62810098|NCT01723098|NO_INTERVENTION|Control|Sedentary pregnant women
62810099|NCT01723098|EXPERIMENTAL|Exercise group|
62810100|NCT01153386|EXPERIMENTAL|0.5 mg treprostinil diethanolamine|0.5 mg treprostinil diethanolamine
62810101|NCT01153386|EXPERIMENTAL|2.5 mg treprostinil diethanolamine|2.5 mg treprostinil diethanolamine
62033687|NCT00729833|EXPERIMENTAL|CP-751,871 + Sunitinib|Escalating cohorts of CP-751,871 + Sunitinib
62033688|NCT05579353||cancer group|
62033689|NCT05579353||control group|
62033690|NCT00606372||1|Patients with ischemic heart disease, with EuroSCORE 6 additive points and more, operated with use of the cardio-pulmonary bypass
62033691|NCT00606372||2|Patients with ischemic heart disease, with EuroSCORE 6 additive points and more, operated without use of the cardio-pulmonary bypass
62033692|NCT01353014|EXPERIMENTAL|Dietary advice with genetic information|This group will receive dietary advice for caffeine, vitamin C, sugar and sodium based on genetic information.
62033693|NCT01353014|ACTIVE_COMPARATOR|General dietary recommendations|This group will receive general dietary recommendations for caffeine, vitamin C, sugar and sodium from recognized health institutions (caffeine: Health Canada; sugar: the World Health Organization; vitamin C and sodium: the Institute of Medicine).
62033694|NCT04477252|EXPERIMENTAL|App group|Use of the Mobile App for the daily performance (Monday to Friday) of lumbopelvic stability exercises apart from the usual physiotherapy treatment for 3 months.
62033695|NCT04477252|ACTIVE_COMPARATOR|conventional physiotherapy|usual physiotherapy treatment for 3 months
62033696|NCT02515136|EXPERIMENTAL|Parkinson's disease|Parkinson's disease patients
62033697|NCT02515136|OTHER|Controls|Healthy volunteers paired with Parkinson's disease patients on sex and age group, whose data will be extracted from a CNRS existing database
62033698|NCT02438618|EXPERIMENTAL|Minimally invasive punch technique|New surgical technique for Ponto bone anchored hearing implants
62033699|NCT02438618|OTHER|Hultcrantz technique|Standard surgical technique for bone anchored hearing implants
62033700|NCT03541759|ACTIVE_COMPARATOR|Hydromorphone|Hydromorphone Hcl 4 milligram (mg) Tab 2 times after surgery as basic medication. Hydromorphone Hcl 2.6mg maximum 2 per 24h when numeric rating scale (NRS) \> 5.
62033701|NCT03541759|ACTIVE_COMPARATOR|Piritramide|Piritramide 15mg s.c. 2 times after surgery as basic medication. Piritramide 7.5mg s.c. maximum 2 per 24h when numeric rating scale (NRS) \> 5.
62234039|NCT02070133|EXPERIMENTAL|Simvastatin|Patients with COPD will receive simvastatin 40 mg once a day for 12 weeks
62234040|NCT02070133|PLACEBO_COMPARATOR|Placebo|Patients with COPD will receive placebo once a day during 12 weeks
62425021|NCT01891786|ACTIVE_COMPARATOR|SMI + Risk Results|The participant will provide a saliva sample for analysis. They will attend an appointment with their nurse to receive personalised results on their combined genetic and lifestyle risk for developing CHD in the next 10 years. They will then be asked to attend the 4 week SMI programme.
62810102|NCT01153386|EXPERIMENTAL|1 mg treprostinil diethanolamine|1 mg treprostinil diethanolamine
62810103|NCT00895635|EXPERIMENTAL|Treadmill Exercise Training|Participants will take part in a 12-week supervised treadmill exercise training program.
62810104|NCT00895635|EXPERIMENTAL|Arm Ergometry Exercise Training|Participants will take part in a 12-week supervised aerobic arm ergometry exercise training program.
62234041|NCT00884338|EXPERIMENTAL|Exercise|
62810105|NCT00895635|ACTIVE_COMPARATOR|Usual Care Control Group|Participants will receive usual care for PAD from their doctor.
62810106|NCT04247386|EXPERIMENTAL|PEG-Mizone prep|"The evening before the colonoscopy: The patients who are randomized to the  PEG-Mizone prep  arm will drink single dose of 60g Polyethylene Glycol (PEG-4000) with 0.6L Mizone+0.4L water at a rate of 250 ml every 15 min.~On the day of the colonoscopy: The patients who are randomized to the  PEG-Mizone prep  arm will drink single dose of 120g Polyethylene Glycol (PEG-4000) with 1.2L Mizone+0.8L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
62033702|NCT01672775|EXPERIMENTAL|Cohort 1 AGS-16C3F highest dose|Renal Cell Carcinoma subjects with clear and non-clear histology
62033703|NCT01672775|EXPERIMENTAL|Cohort 0 AGS-16C3F higher dose|Renal Cell Carcinoma subjects with clear and non-clear histology
62033704|NCT01672775|EXPERIMENTAL|Cohort (-1) AGS-16C3F high dose|Renal Cell Carcinoma subjects with clear and non-clear histology
62033705|NCT01672775|EXPERIMENTAL|Cohort (-2) AGS-16C3F middle dose|Renal Cell Carcinoma subjects with clear and non-clear histology
62033706|NCT01672775|EXPERIMENTAL|Cohort (-3) AGS-16C3F low dose|Renal Cell Carcinoma subjects with clear and non-clear histology
62033707|NCT01672775|EXPERIMENTAL|Cohort (-4) AGS-16C3F lowest dose|Renal Cell Carcinoma subjects with clear and non-clear histology
62033708|NCT01672775|EXPERIMENTAL|AGS-16C3F in RCC Subjects with Clear Cell Histology|Expansion Cohort
62033709|NCT01672775|EXPERIMENTAL|AGS-16C3F in RCC Subjects with Papillary Histology|Expansion Cohort
62033710|NCT00786604||1|Those with a cervical spinal cord injury
62033711|NCT00786604||2|Those with a thoracic spinal cord injury
62033712|NCT00786604||3|Healthy, control group
62033713|NCT03878810|EXPERIMENTAL|Exergaming, restless legs syndrome (+)|A video game-based physical activity training will be applied under a physiotherapist supervision for 2 days/week for 8 weeks.
62033714|NCT03878810|EXPERIMENTAL|Exergaming, restless legs syndrome (-)|A video game-based physical activity training will be applied under a physiotherapist supervision for 2 days/week for 8 weeks.
62033715|NCT03878810|NO_INTERVENTION|Control, restless legs syndrome (+)|No specific intervention.
62425022|NCT03202186|PLACEBO_COMPARATOR|Placebo|oral administration of Placebo capsule
62425023|NCT03202186|EXPERIMENTAL|Progesterone 200 mg|oral administration of progesterone 200 mg
62425024|NCT03202186|EXPERIMENTAL|Progesterone 300 mg|oral administration of progesterone 300 mg
62425025|NCT03202186|EXPERIMENTAL|Progesterone 400 mg|oral administration of progesterone 400 mg
62033716|NCT03878810|NO_INTERVENTION|Control, restless legs syndrome (-)|No specific intervention.
62425026|NCT05440084||Patients referred for CTO PCI|
62425027|NCT01739088|EXPERIMENTAL|Remote ischemic preconditioning stimulus|The remote ischemic pre-conditioning arm of the study is the experimental one. Patients in this arm will receive a remote ischemic pre-conditioning stimulus at 24-48 hours pre-operatively, and again intra-operatively before CPB.
62425028|NCT01739088|SHAM_COMPARATOR|Sham Ischemic Pre-conditioning|In the control (sham-RIPC) group the cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the the control group.
62593689|NCT06624930|EXPERIMENTAL|Physical Activity + Behavioural Counselling (PA + BC)|The PA+BC group will be given an individualized, home-based aerobic and resistance prescription based on baseline assessment and previous work. The participants will also receive behavioural counselling support sessions with a QEP every two weeks during the intervention period (12 total). The focus of these sessions will incorporate tailored behaviour change content from the M-PAC framework. At the end of the 6-month program, an individualized PA prescription will be provided based on their fitness level (adjusted throughout) to continue achieving the PA goal for the 6-month post intervention and 1-year post intervention follow-up.
62810107|NCT04247386|ACTIVE_COMPARATOR|PEG-ELS prep|"The evening before the colonoscopy: In the PEG-ELS prep group, all the patients drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at a rate of 250 ml every 15 min.~On the day of the colonoscopy: all the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 2L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
62033717|NCT03106818|ACTIVE_COMPARATOR|group A|( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
62033718|NCT03106818|ACTIVE_COMPARATOR|group B|bupivacaine 0.125% infusion in the presternum , for 48 hours
62033719|NCT03106818|ACTIVE_COMPARATOR|Group C|will be conventional , will receive postoperative fentanyl , paracetamol , and ketorolac.
62033720|NCT05991154|EXPERIMENTAL|Usual Practice + JoyPop|Participants will be monitored through the existing wait-list practices, which involve regular phone calls to check in and assess functioning, and will receive access to the JoyPop app for 4 weeks.
62033721|NCT05991154|NO_INTERVENTION|Usual Practice|Participants will be monitored through existing wait-list practices which involve regular phone calls to check in and assess functioning. After 4 weeks in the Usual Practice condition, participants will be offered access to the JoyPop app.
62033722|NCT03705091||Transplant|Incident patients receiving a kidney transplant for end stage kidney disease. Patients will undergo functional magnetic resonance imaging at 2 months, 6 months and 12 months following transplantation.
62033723|NCT01867151|EXPERIMENTAL|Gluten free diet|BMS patients following a GFD
62033724|NCT01867151|SHAM_COMPARATOR|Normal Diet|Patients with BMS maintaing a normal diet
62425029|NCT05292430||Biobank|Specimens are to be collected from subjects who are having or have had a surgical or medical procedure (such as fluid or tissue removed, a biopsy or a blood or bone marrow draw). Any subject in which the primary diagnosis of disease was made within the DHR Health System and Any subject choosing to give consent for participation will be included.
62425030|NCT00297206|EXPERIMENTAL|Cohort 1|Subjects in the age group of 2 to less than 6 years will be included
62033725|NCT00778674|EXPERIMENTAL|1|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
62033726|NCT00778674|ACTIVE_COMPARATOR|2|Lotensin® HCT tablets
62033727|NCT02390284|NO_INTERVENTION|Abnormal PERG Untreated|Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to not receive therapy or intervention.
62033728|NCT02390284|EXPERIMENTAL|Abnormal PERG Treated|"Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to receive one or more drops in each eye in order to reduce the intraocular pressure by 20%.~Drugs could be:~Latanoprost 1 drop Once a day (QD) Bimatoprost 1 drop QD Travoprost 1 drop QD Timolol 1 drop Twice a day (BID) Dorzolamide 1 drop Three times a day (TID) Brinzolamide 1 drop BID Acetazolamide and Methazolamide depends on clinicians evaluation.~If Clinicians consider necessary, he/she might combine 2 drugs in order to get the desired intraocular pressure."
62033729|NCT02390284|NO_INTERVENTION|Normal|Patients with a normal PERG test that will go through the study under observation.
62234042|NCT00884338|ACTIVE_COMPARATOR|Control group|
62810108|NCT06125366|EXPERIMENTAL|Dose escalation of BAY1747846|
62810109|NCT06125366|PLACEBO_COMPARATOR|Matching Placebo|
62810110|NCT01213394|EXPERIMENTAL|CellCept optimization|
62810111|NCT01213394|ACTIVE_COMPARATOR|Control|
62810112|NCT00734435|ACTIVE_COMPARATOR|1|Zonisamide SR 360 mg and olanzapine 10-20 mg daily
62810113|NCT00734435|PLACEBO_COMPARATOR|2|Placebo and olanzapine 10-20 mg daily
62810114|NCT03784508||Bariatric surgery|200 consecutive patients that will undergo bariatric surgery as a routinary procedure at our site
62810115|NCT03547778|EXPERIMENTAL|Misoprostol group|Patients in this arm will receive vaginal misoprostol (50 mcg), the night before the procedure (concurrent office hsyteroscopy and endometrial biopsy).
62810116|NCT03547778|PLACEBO_COMPARATOR|Placebo group|Participants in this group will receive placebo (fatty acid), which looks similar to misoprostol and has to be inserted vaginally the night before the procedure.
62810117|NCT02269124|NO_INTERVENTION|Conventional Measures Only|In arm 1, the child will utilize conventional measures for management of unilateral hearing loss, such as FM system and preferential seating in the classroom. While two basic types of FM systems exist, personal and sound field, subjects in our study will utilize a personal FM system, worn at the ear-level. This will increase the likelihood that the child will receive amplification in all classes, and will help to standardize this intervention. The HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm via Redcap. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals.
62810118|NCT02269124|EXPERIMENTAL|Conventional Measures + Hearing Aid|In arm 2, the child will use the conventional measures described above in addition to a digital behind-the-ear hearing aid with a standard ear hook and custom ear mold on the affected ear. The hearing instrument will be customized by an audiologist. The subject will be instructed to wear the hearing aid both at home and at school. In both arms, the FM system will be used in school only. As in the first arm, the HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals. No washout period will take place between the two arms. Subjects will be randomized to complete one arm first for 3 months, followed immediately by 3 months in the opposite arm.
62033730|NCT01970826|EXPERIMENTAL|Sterilized Clean Full-Mouth|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~Full-mouth dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
62033731|NCT01970826|ACTIVE_COMPARATOR|Sterilized Aseptic Full-Mouth|"The operatory room will be prepared with sterilized aseptic clean instruments. Full-mouth dental implants placement will be performed and involves meticulous hand washing, use of a sterile field, use of sterile gloves for application of a sterile dressing, and use of sterile instruments and fluid only. Involves the use of only sterile instruments and materials in dressing.~There is no contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or products.~It will be evaluated the duration of surgery."
62234043|NCT05270785|EXPERIMENTAL|Suicidal Teens Accessing Treatment - Primary Care (STAT-PC)|This group will undergo a brief, suicide prevention intervention based on motivational interviewing that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management
62234044|NCT05270785|EXPERIMENTAL|Youth-Nominated Support Team (YST-III)|This group will undergo a brief, suicide prevention intervention originally developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation that has been adapted
62593690|NCT06624930|ACTIVE_COMPARATOR|Physical Activity + Exercise Couselling (PA + EC)|The PA+EC group will be given an individualized, home-based aerobic and resistance prescription based on baseline assessment and previous work. The participants will also receive the same frequency of group-based and 1:1 counseling support sessions via Zoom as PA+BC participants. The focus of these sessions will be on exercise training principles for proper PA technique, how to monitor intensity, and progress PA safely to achieve the PA guidelines. The support sessions will be 30-45 minutes and delivered via Zoom each week in either group or 1:1 format depending on the topic.
62810119|NCT01003158|EXPERIMENTAL|Monotherapy part|AZD8931 monotherapy
62810120|NCT01003158|EXPERIMENTAL|Combination part|AZD8931 plus paclitaxel
62810121|NCT00291135|EXPERIMENTAL|1|Oral Letrozole 2.5 mg daily for six months
62810122|NCT04102397|EXPERIMENTAL|Standard plus Vojta therapy (SVT)|The physiotherapist's hands produce the activation with no need for medication or external equipment, thus guaranteeing the patient's safety.this therapy is able to change pathological patterns to painless patterns that reduce the use of energy caused by movement difficulty. The end result is to facilitate movement without strain.
62810123|NCT04102397|ACTIVE_COMPARATOR|Standard therapy (ST)|It consists of one or more of the following procedures: transcutaneous electrical nerve stimulation (TENS), ultrasound therapy, kinesiotherapy, and cryotherapy.
62033732|NCT01970826|EXPERIMENTAL|Sterilized Clean Single|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~Single dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or products.~It will be evaluated the duration of surgery."
62234045|NCT04508231||Hormonal treatment|The University Hospital in Nancy is an academic regional transgender referral center in Lorraine (France) and keeps a register of subjects available from 2004. The register at the time of the present study (February 2020) included 320 subjects who met diagnostic criteria for gender dysphoria and were seen regularly in the out-patient clinic at our department of endocrinology. Our investigation is a part of the regular care of subjects with gender dysphoria.
62425031|NCT00297206|EXPERIMENTAL|Cohort 2|Subjects in the age group of 1 to less than 2 years will be included
62425032|NCT00297206|EXPERIMENTAL|Cohort 3|Subjects in the age group of 6 months to less than 1 year will be included
62425033|NCT00297206|EXPERIMENTAL|Cohort 4|Subjects in the age group of 3 months to less than 6 months will be included
62234046|NCT04508231||Controls|Data for control subjects are retrieved from medical records of healthy non-obese females and males who underwent an initial assessment for gender dysphoria in our department, but not yet receiving hormonal treatment at the time of the present study.
62593691|NCT02951533|EXPERIMENTAL|Group I: Guselkumab|Participants will receive Guselkumab 100 milligram (mg) administered as 100 milligram per milliliter (mg/mL) solution subcutaneously (SC) by single-use prefilled syringe (PFS) at weeks 0, 4, 12 and 20.
62234047|NCT02594163|EXPERIMENTAL|Brentuximab Vedotin|Subjects randomized to the brentuximab vedotin arm will receive IV infusions of brentuximab vedotin followed by bendamustine on day 1, and rituximab followed by bendamustine on day 2 of each 21 day cycle.
62425034|NCT00297206|EXPERIMENTAL|Cohort 5|Subjects in the age group of 1 month to less than 3 months will be included
62593692|NCT02951533|ACTIVE_COMPARATOR|Group II: Fumaric Acid Esters (FAE)|Participants will receive Fumaderm initial/Fumaderm tablets by self administration at week 0. The individual FAE dose representing the optimal efficacy/tolerability ratio needs to be determined for each participant according to local prescription information. To this aim, FAE doses will be slowly increased beginning with increasing doses of Fumderm initial (containing 30 mg dimethylfumarate) over the first 3 weeks. Thereafter, participants will be switched to Fumaderm tablets (containing 120 mg dimethylfumarate) starting with 1 tablet per day. Fumaderm dose may be increased to a maximum of 3\*2 tablets per day. The decision to maintain, increase or decrease the FAE dose depends on efficacy, safety and tolerability.
62033733|NCT01970826|ACTIVE_COMPARATOR|Sterilized Aseptic Single|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~Single dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
62593693|NCT01220765|NO_INTERVENTION|Standard care|Patients randomized to the standard care group receive standard of care using pulse oximetry
62810124|NCT02360566|EXPERIMENTAL|Participatory Video Intervention Group|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
62810125|NCT04144153|EXPERIMENTAL|Opioid Free Anesthesia Group|
62810126|NCT04144153|ACTIVE_COMPARATOR|Opioid Anesthesia Group|
62810127|NCT05208502||BIS|All inclusions will receive the general anesthesia with BIS monitor, a researcher who is not participated in the clinical practice will record the emergence characters and the EEG monitor signal. As the surgery ends, this researcher will record the time started from the end of the surgery to extubation, as well as the emergence quality when the patient was evaluated.
62810128|NCT05208502||DSA|All inclusions will receive the general anesthesia with SedLine monitor, a researcher who is not participated in the clinical practice will record the emergence characters and the DSA monitor signal. As the surgery ends, this researcher will record the time started from the end of the surgery to extubation, as well as the emergence quality when the patient was evaluated.
62810129|NCT03481894|EXPERIMENTAL|Kabiven®|Kabiven is a sterile, hypertonic emulsion in a three chamber container. The separate chambers contain either amino acids with electrolytes, dextrose, or lipid injectable emulsion.
62810130|NCT03481894|ACTIVE_COMPARATOR|Compounded standard parenteral nutrition|"The control drug will be compounded for each individual patient as prescribed by the physician. Compounding will be performed according to normal hospital procedure which meets the requirements of the United States Pharmacopeial Convention (USP) \<797\> Pharmaceutical Compounding-Sterile Preparations."
62810131|NCT03268772|EXPERIMENTAL|PLD-IFO|pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO)
62810132|NCT04126694|EXPERIMENTAL|CBT with smartphone application|12 weeks of CBT with SenseSupport smartphone application
62810133|NCT04199507||Autism|Assessment of physical activity level and physical fitness
62810134|NCT04199507||Healthy|Assessment of physical activity level and physical fitness
62810135|NCT01235091|OTHER|Standard|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing
62810136|NCT01235091|EXPERIMENTAL|SI/WWE|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing along with Well-Woman Exam
62810137|NCT01235091|EXPERIMENTAL|SI/WWE/PD|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing along with Well-Woman Exam and Peer-delivered Enhanced Intervention
62810138|NCT01019187|PLACEBO_COMPARATOR|Arm I|Patients receive oral placebo twice daily for 47 days.
62810139|NCT01019187|EXPERIMENTAL|Arm II|Patients receive oral armodafinil twice daily for 47 days.
62810140|NCT01019187|EXPERIMENTAL|Arm III|Patients receive oral placebo twice daily for 47 days. Patients undergo cognitive behavioral therapy for insomnia comprising sleep restriction therapy, stimulus control instruction, sleep hygiene guidelines, and a session of cognitive therapy for 7 weeks.
62810141|NCT01019187|EXPERIMENTAL|Arm IV|Patients receive oral armodafinil twice daily for 47 days. Patients undergo cognitive behavioral therapy for insomnia as in Arm III for 7 weeks.
62810142|NCT00422851||1|Normal tympanic membrane
62810143|NCT00422851||2|tympanosclerosis
62810144|NCT00422851||3|dimeric (atrophic)
62234048|NCT02594163|ACTIVE_COMPARATOR|Rituximab,Bendamustine control|Subjects randomized to the control arm will receive IV infusions of rituximab on day 1 or day 2 and bendamustine on both days 1 and 2 of each 21 day cycle.
62033734|NCT01970826|EXPERIMENTAL|Sterilized Clean - Partial|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~One or more dental implants will be made for partial rehabilitation, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
62234049|NCT03758287|EXPERIMENTAL|CT053PTSA +Gefitinib|"Patients will receive CT053PTSA and gefitinib over a 28-day cycle until progressive disease, intolerable toxicity or subject's withdrawal from treatment.~CT053PTSA will be administered daily, at a dose of 30 mg/40mg/60mg orally .~Gefitinib will be administered daily, at a dose of 250 mg orally ."
62234050|NCT05280756|EXPERIMENTAL|Active home-based transcranial direct current stimulation (tDCS)|The active home-based tDCS delivers a constant current intensity of 2mA on the subject's scalp, with electrodes positioned bilaterally (anodal-left and cathodal-right), on the dorsolateral prefrontal cortex (DLPFC), for 30 minutes.
62234051|NCT05280756|SHAM_COMPARATOR|Sham home-based transcranial direct current stimulation (tDCS)|The sham home-based tDCS looks identical to a typical active home-based tDCS cap but delivers a 30-second ramp-up (0-2 mA) stimulation followed by a 30-second ramp-down (2-0 mA) at the beginning and end of the application.
62234052|NCT05751291|ACTIVE_COMPARATOR|Group A|Group A (PENG block) patients will receive PENG block under ultrasound-guided (USG) guidance using curvilinear low-frequency ultrasound probe (2-5 MHz) will initially be placed in a transverse plane over the Anterior inferior iliac spine ( AIIS ) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees to visualize the Iliopubic Eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle. A 22 Gauge needle will be inserted in-plane and the needle tip will be positioned in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. 20 mL of 0.25% bupivacaine will be injected in increments while observing for an adequate fluid spread in this plane.
62234053|NCT05751291|ACTIVE_COMPARATOR|Group B|"Group B (FIC) patients will receive FIC block under USG guidance using high-frequency linear transducer (6-13 MHz) will be used to identify the femoral artery at the level of the inguinal crease. Immediately lateral and deep to the femoral artery and vein the iliopsoas muscle is overlaid by a hyperechoic fascia iliaca. The femoral nerve is seen lateral to the femoral artery wedged between the iliopsoas muscle and the fascia iliaca.~Maneuvering the transducer laterally helps to visualize the Sartorius muscle covered by its own fascia alongside the fascia iliaca. A line is drawn connecting the anterior superior iliac spine to the pubic tubercle; the needle tip is positioned at lateral third of the line under the fascia iliaca. 20 mL of 0.25% bupivacaine will be injected until it spreads laterally toward the iliac spine and medially toward the femoral nerve."
62593694|NCT01220765|EXPERIMENTAL|Capnography|In the intervention group capnography is measured using a cannula under the nose connected to the capnograph. The capnographic device displays respiratory rate, end-tidal carbon dioxide (ETCO2) levels, and continuous waveforms.
62234054|NCT00695253|OTHER|Talent Endoluminal Spring Graft System|Single Arm study of the endoluminal treatment of Abdominal Aortic Aneurysms using the Talent Endoluminal Spring Graft System
62234055|NCT04305080|EXPERIMENTAL|Anodic Oxidation of implant abutment|
62234056|NCT04305080|SHAM_COMPARATOR|Untreated implant abutment|
62234057|NCT06248554|EXPERIMENTAL|PD-1 inhibitor adjuvant therapy group|Received adjuvant PD-1 inhibitor 2-4 weeks after microwave surgery for a total of 9 cycles of treatment
62234058|NCT06248554|NO_INTERVENTION|Control group|Receive regular monitoring and follow-up
62425035|NCT03994679||cleft patient requiring bone graft|Patients presenting at the division of maxillofacial surgery at the AZ Sint-Jan Brugge-Oostende av (Belgium) or the 1st department of pediatrics at the USemmelweis (Hungary) for bone graft surgery of the unilateral cleft receive a complete routine work-up, including a cone-beam CT (CBCT).
62234059|NCT04780750|ACTIVE_COMPARATOR|Arm A concurrent chemoradiotherapy with weekly docitaxel and cisplatin every 3 weeks|Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\\m2) and cisplatin (80mg\\m2 every 3 weeks)
62425036|NCT00123058|EXPERIMENTAL|Nurse administered|"Nurse Administered Intervention:~Subject received nurse administered behavioral intervention every 8 weeks via telephone for 24 months."
62425037|NCT00123058|EXPERIMENTAL|Nurse & BP monitor|Subjects received both a nurse administered behavioral intervention via telephone every 8 weeks for 24 months and a study provided home BP monitor. Subject recorded home BP 3 times per week for 24 months.
62425038|NCT00123058|NO_INTERVENTION|Usual Care|Subjects received neither home BP monitor nor nurse phone intervention.
62234060|NCT04780750|ACTIVE_COMPARATOR|Arm B :concurrent chemoradiotherapy with cisplatin every 3 weeks|Arm B (standard regimen):concurrent chemoradiotherapy with cisplatin (100mg\\m2 every 3 weeks)
62810145|NCT05873049|EXPERIMENTAL|Fluorescence-guided|"Patients who used MolecuLight to achieve high-quality de-colonization during reconstruction surgery with artificial dermis or split-thickness skin graft"
62810146|NCT05873049|NO_INTERVENTION|Control|"Patients who did not use MolecuLight to achieve high-quality de-colonization during reconstruction surgery with artificial dermis or split-thickness skin graft"
62234061|NCT04580966|EXPERIMENTAL|Inquiry Based Stress Reduction (IBSR) workshop|Participants of this group received an IBSR intervention workshop.
62234062|NCT04580966|NO_INTERVENTION|Control group|Participants of this group did not take a part in the workshop.
62234063|NCT01667861||(Wind) musicians|Members of (professional) orchestras, especially wind instrument players.
62425039|NCT00123058|EXPERIMENTAL|Home BP Monitor|Subject received study provided home BP monitor. Subject recorded home BP 3 times per week for 24 months.
62425040|NCT05355987|EXPERIMENTAL|Early oncological supportive care|Evaluation of needs in oncological supportive care by a nursing coordinator from diagnosis and recommendation to plan appointments with different specialists in supportive care regarding to patient's needs
62425041|NCT05355987|OTHER|Delayed oncological supportive care|Evaluation of needs in oncological supportive care by a nursing coordinator at 6 months after diagnosis and recommendation to plan appointments with different specialists in supportive care regarding to patient's needs
62033735|NCT01970826|ACTIVE_COMPARATOR|Sterilized Aseptic - Partial|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~One or more dental implants will be made for partial rehabilitation, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
62425042|NCT05264766|EXPERIMENTAL|Cooling helmet on|Cooling helmet on means there was circulating cold water inside the helmet, put after induction during cardiopulmonary bypass on
62425043|NCT05264766|ACTIVE_COMPARATOR|Cooling helmet off|Cooling helmet on means there was no circulating cold water inside the helmet, put after induction during cardiopulmonary bypass on
62425044|NCT05098626||Individuals Working Remotely|Individuals aged between 18-60 and working remotely, who volunteered to participate in the study, will form the study group.
62425045|NCT02623309|EXPERIMENTAL|HAPLO graft|"Conditioning regimen~* Fludarabin : 30 mg/m2/day for 4 days: from D-5 à J-2.~* Busulfan IV : 130 mg/m2/day for 2 days : drom D-4 to D-3. + 1 day of Thiotepa : 5mg/kg at D-6.~Prophylaxis regimen for GVHD~* F CSA and MMF (starting day +5)~* Additional immunosuppression: PT-HDCy (50 mg/kg/day) on days +3 and +4~Hematopoietic Stem Cell Graft PBSC graft will be preferred for a minimal targeted cell dose of 4 x 106 CD34+cells/kg GCSF (Neupogen ®) during 4 to 5 days (D-4 to D-1): SC 10 µg/kg/d."
62425046|NCT02623309|ACTIVE_COMPARATOR|MUD graft|"Conditioning regimen~* Fludarabin : 30 mg/m2/day for 5 days: from D-6 to D-2.~* Busulfan IV : 130 mg/m2/day for 2 days: from D-4 to D-3.~Prophylaxis regimen for GVHD~* CSA and MMF will be used from day -1 after UD~* Additional immunosuppression: Rabbit ATG (2.5 mg/kg/day) on days -3 and -2~Hematopoietic Stem Cell Graft PBSC graft will be preferred for a minimal targeted cell dose of 4 x 106 CD34+cells/kg"
62425047|NCT04734431||Survivors|Patients admitted in geriatrics that survived of a bacterial infection after 30 days (still admitted or discharged), and treated by antibiotics.
62425048|NCT04734431||Death|Deceased individuals admitted for a bacterial infection in geriatrics, despite receiving an antimicrobial therapy.
62425049|NCT00743119|PLACEBO_COMPARATOR|Placebo + inactive marijuana (0% THC)|Participants received placebo capsules and smoked inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
62033736|NCT04224155|EXPERIMENTAL|enVista MX60EFH trifocal intraocular lens (IOL)|
62810147|NCT01101399|ACTIVE_COMPARATOR|Ferric carboxymaltose|Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the next scheduled chemotherapy cycle after randomisation or continuous chemotherapy. In subjects with weight ≤66 kg, the first dose iron will be 500 mg; the second dose (500 mg) will be administered on the visit 4 (week 2).
62810148|NCT01101399|NO_INTERVENTION|Local standard of care.|Subjects will be treated according to the local institutional practice.
62810149|NCT03155165||Group A Retroview™ colonoscope|Patients that have a polyp already seen in a previous colonoscopy and the colonoscopy is indicated for polypectomy will be submitted to a Retroview™ colonoscope
62033737|NCT04224155|ACTIVE_COMPARATOR|enVista MX60E monofocal intraocular lens (IOL)|
62425050|NCT00743119|EXPERIMENTAL|Dronabinol 10 mg + Marijuana (0% THC)|Participants received low dose Dronabinol + inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
62425051|NCT00743119|EXPERIMENTAL|Dronabinol 20 mg + Marijuana (0% THC)|Participants received High dose Dronabinol + inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
62425052|NCT00743119|EXPERIMENTAL|Placebo + Marijuana (1.98% THC)|Participants received placebo + low THC marijuana (1.98% THC) on 1 of 5 outpatient sessions in randomized order.
62425053|NCT00743119|EXPERIMENTAL|Placebo + Marijuana (3.56% THC)|Participants received placebo + smoked high THC marijuana (3.56 % THC) on 1 of 5 outpatient sessions in randomized order.
62810150|NCT03155165||Group B Retroview™ colonoscope|The rest of colonoscopies indicated will be submitted to a Retroview™ colonoscope
62810151|NCT03985241|EXPERIMENTAL|Functional Assessment of Myocardial Ischemia by icECG|Evaluation of ST-Shifts in the icECG acquired downstream of a coronary lesion during pharmacologic inotropic stress using dobutamine (40mcg/kg/min).
62810152|NCT01333748|EXPERIMENTAL|patients group|Patients with ovarian and/or breast cancer
62810153|NCT01333748|OTHER|control population|control population without history of breast and/or ovarian cancer
62810154|NCT02701517|ACTIVE_COMPARATOR|Cyclosporine + METHOTREXATE|MTX days +1, +3, +6 and +11 followed by folinic acid rescue. All patients will receive CSA from day -7.
62810155|NCT02701517|EXPERIMENTAL|Cyclosporine + CAMPATH-1H|CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.
62810156|NCT02955056|EXPERIMENTAL|Teriparatide Intervention|Will be asked to self-administer Teriparatide treatment (self-injection) once a day for 12 weeks
62810157|NCT02955056|NO_INTERVENTION|Usual care|No intervention, patients will be treated as per local practice but will be followed up identically to the intervention group.
62810158|NCT02424396|EXPERIMENTAL|1 : IL2|Interleukin-2 (ILT-101)
62810159|NCT02424396|PLACEBO_COMPARATOR|2 : Placebo|Placebo
62810160|NCT04579146||HIV-1 patients and treated effectively for more than 12 months|X-ray examination with contrast by a 64-slice CT coronary angiography.
62810161|NCT05070936|OTHER|vestibular rehabilitation group|Vestibular rehabilitation was performed. The following exercises were done with the patients: both sitting and standing gaze stabilization exercises, neck joint range of motion exercises, 20 minutes walks outside, walking backwards both open and closed eyes, and walking on tandem both open and closed eyes. Exercise program was applied for 8 weeks. Patients were observed in the hospital every two weeks. The exercises given in the session were given as home exercises, 3 times a day, for 10 repetitions.
62810162|NCT05976555|EXPERIMENTAL|BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg)|BCMA-TGFβ CAR-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of four dose levels of BCMA-TGFβ CAR-T cells based on the dose escalation design.
62033738|NCT00522275|EXPERIMENTAL|Lacosamide|Up to 800 mg/day lacosamide (flexible dosing)
62033739|NCT04862793|EXPERIMENTAL|Feedback|Feedback system through CoPS and CoRS
62033740|NCT04862793|NO_INTERVENTION|Standard procedure|Performing the standard procedure in accordance with the departments usual conduct.
62033741|NCT05785780|EXPERIMENTAL|Targeted CRC Screening Toolkit|Based on national survey data and a community engagement participatory implemention planning group, a tailored combination of widely accepted implementation strategies will be adapted for targeting CRC screening for patients with diabetes. These strategies include but are not limited to: identification of patient and practice-level barriers, patient education, provider reminders, and audit and feedback.
62033742|NCT02362698|EXPERIMENTAL|electro-acupuncture|Receiving electro-acupuncture treatment once every other day, half an hour per treatment, 10 times as one treatment course, subjects received 2 courses of treatment.
62033743|NCT02362698|ACTIVE_COMPARATOR|psychological intervention|Receiving cognitive behavioral therapy once every four days, each time two hours. Five times intervention as one treatment course, subjects received 2 courses of treatment.
62425054|NCT01743768|EXPERIMENTAL|SB010|"The drug will be administered in phosphate-buffered saline solution, inhaled over 5 - 10 min, using inhalation device.~Administered dose: 10 mg hgd40 in 2 mL solution (5.0 mg/mL).~Initial dose on Day 1 (single-dose PK profile); once daily dose for 28 consecutive days (Days 1 to 28); last inhalation on Day 28 (steady state PK profile)."
62425055|NCT01743768|PLACEBO_COMPARATOR|Placebo|"The placebo (phosphate-buffered saline) is administered as a solution, inhaled over 5 - 10 min, using inhalation device.~Initial dose on Day 1 (single-dose PK profile); once daily dose for 28 consecutive days (Days 1 to 28); last inhalation on Day 28 (steady state PK profile)."
62425056|NCT00276965|EXPERIMENTAL|A|Participants will take lithium only.
62425057|NCT00276965|EXPERIMENTAL|B|Participants will take lithium and sertraline.
62425058|NCT00276965|EXPERIMENTAL|C|Participants will take sertraline only.
62810163|NCT05976555|EXPERIMENTAL|BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)|BCMA-TGFβ CAR-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of four dose levels of BCMA-TGFβ CAR-T cells based on the dose escalation design.
62810164|NCT05976555|EXPERIMENTAL|BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg)|BCMA-TGFβ CAR-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of four dose levels of BCMA-TGFβ CAR-T cells based on the dose escalation design.
62810165|NCT05976555|EXPERIMENTAL|BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg)|BCMA-TGFβ CAR-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of four dose levels of BCMA-TGFβ CAR-T cells based on the dose escalation design.
62810166|NCT05976555|EXPERIMENTAL|BCMA-TGFβ CAR-T cells (Maximum tolerated dose)|After the maximal tolerated dose (MTD) is determined, an additional dose-expansion cohort of up to 9 patients (3 BCMA-naïve and 6 BCMA exposed) may be enrolled at that dose.
62033744|NCT00833638|EXPERIMENTAL|Tadalafil 2.5 mg|No drug during baseline period, 2.5 mg for 14 days, then will continue at 5 mg for 14 days.
62033745|NCT00833638|EXPERIMENTAL|Tadalafil 5 mg|No drug during baseline period, 5 mg for 14 days, then will continue at 5 mg for 14 days.
62033746|NCT00833638|PLACEBO_COMPARATOR|Placebo|No drug during baseline period, placebo for 14 days, then will continue tadalafil at 5 mg for 14 days.
62033747|NCT05079620|EXPERIMENTAL|Antibiotics|"5 days of empiric antibiotics selected from a guideline-appropriate regimen. Alternate agents may be selected by the treating team if allergies or other patient factors mandate, but are still recommended for a 5 day course. Supportive care including oxygen and ventilation can be offered ad libitum.~Options include ceftriaxone, Augmentin, cefepime, vancomycin, levofloxacin."
62425059|NCT02336698|PLACEBO_COMPARATOR|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
62810167|NCT05565365|PLACEBO_COMPARATOR|Transversalis fascia plane (TFP) block|Patients will receive unilateral US-TFP block with bupivacaine 15 minutes before skin incision
62810168|NCT05565365|ACTIVE_COMPARATOR|Erector Spinae Plane (ESP) Block|Patients will receive unilateral US-ESP block with bupivacaine 15 minutes before skin incision
62425060|NCT02336698|EXPERIMENTAL|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
62425061|NCT02336698|EXPERIMENTAL|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
62425062|NCT00291330|EXPERIMENTAL|dabigatran etexilate 150 mg|twice daily
62425063|NCT00291330|ACTIVE_COMPARATOR|warfarin (INR 2-3)|prn to maintain INR (2-3)
62425064|NCT01200316|EXPERIMENTAL|Standard of Care Group|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
62425065|NCT01200316|EXPERIMENTAL|Rocking Motion Group|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
62810169|NCT05544526|EXPERIMENTAL|GD2 CAR T Cells|Treatment with the ATIMP: GD2 CAR T-cells
62810170|NCT01094795||Patients initiating abatacept|
62810171|NCT01094795||Patients receiving other biologic disease-modifying drugs|
62425066|NCT01078324||Ischemic colitis|Ischemic colitis, Diverticulosis
62425067|NCT00172094|PLACEBO_COMPARATOR|1|PLACEBO
62425068|NCT00172094|EXPERIMENTAL|2|400 mg 1776 powder
62425069|NCT00172094|EXPERIMENTAL|3|1776 (800 mg)
62425070|NCT01594580|EXPERIMENTAL|Antimicrobial impregnated scrubs|Those randomized to this arm of the study will wear scrubs impregnated with an antimicrobial.
62593695|NCT02965196|ACTIVE_COMPARATOR|Dexamethasone Therapy|Three consecutive doses of IV Dexamethasone with be administered over three days. The doses will be tapered according to the following: 1st dose, 26mg., 2nd dose, 20mg., and the third dose will be 10 mg. Each dose will be administered over 24 hours in a slow drip, in a 100cc. normal saline bag (0.9%).
62810172|NCT01094795||Patients with early rheumatoid arthritis (RA)|
62810173|NCT01094795||Patients with prevalent RA identified by hospitalization|
62810174|NCT01094795||General population|
62033748|NCT05079620|NO_INTERVENTION|Control|No initial antibiotic therapy unless clinical picture changes or worsens. Supportive care including oxygen and ventilation can be offered ad libitum.
62810175|NCT01777308|EXPERIMENTAL|Menitorix Group|"Subjects who were primed with Menitorix™ (Hib-MenC-TT) + Priorix™ (MMR) vaccines in the primary study HIB-MENC-TT-016 (NCT00326118) received one dose of Nimenrix™ (MenACWY-TT) booster vaccine at Month 72 post primary vaccination (booster visit 1).~The MenACWY-TT vaccine was administered intramuscularly (IM) in the deltoid region of the non-dominant arm."
62033749|NCT01383915||inpatients|Youth with a clinical diagnosis of a mood disorder or psychosis spectrum disorder
62425071|NCT01594580|PLACEBO_COMPARATOR|Non-impregnated scrubs|Those randomized to this arm of the study will wear scrubs not impregnated with an antimicrobial.
62425072|NCT04144387|EXPERIMENTAL|Test group|Each patient included in the study will be followed for 5 years
62425073|NCT03185299|EXPERIMENTAL|Video|Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
62425074|NCT03185299|EXPERIMENTAL|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
62425075|NCT01382901|EXPERIMENTAL|Intravenous (IV) Iron|
62425076|NCT01382901|PLACEBO_COMPARATOR|Placebo|
62425077|NCT01339884|ACTIVE_COMPARATOR|Resveratrol, 1g daily|15 participants will receive resveratrol 1g daily
62425078|NCT01339884|ACTIVE_COMPARATOR|Resveratrol, 5g daily|15 participants will receive resveratrol, 5g daily
62810176|NCT01777308|EXPERIMENTAL|Meningitec + Hiberix Group|"Subjects who were primed with Meningitec™ (MCC) + Hiberix™ (Hib) + Priorix™ (MMR) vaccine in the primary study HIB-MENC-TT-016 (NCT00326118) received one dose of Nimenrix™ (MenACWY-TT) booster vaccine at Month 72 post primary vaccination (booster visit 1).~The MenACWY-TT vaccine was administered intramuscularly (IM) in the deltoid region of the non-dominant arm."
62810177|NCT04323696|OTHER|Over-sewing|Patients under over-sewing arm are subjected to staple line reinforcement using over-sewing method
62810178|NCT04323696|OTHER|Plication|Patients under over-sewing arm are subjected to staple line reinforcement using plication method
62810179|NCT01335776|EXPERIMENTAL|Cognitive Behavior Therapy|Cognitive Behavior Therapy for insomnia consists of stimulus control therapy, sleep restriction therapy, cognitive therapy and relaxation.
62033750|NCT04878562|EXPERIMENTAL|I-COPE Intervention|5 out of the 25 participating primary care sites are randomly assigned to any of the 5 steps. The ICOPE intervention is implemented after a pre interventional period of 3-15 months. The intervention is implemented during 8 weeks. The length of the post interventional period is 11-23 months.
62033751|NCT04878562|NO_INTERVENTION|No intervention|Standard of care offered to all patients.
62033752|NCT04829370|ACTIVE_COMPARATOR|PLT|All subjects are treated with fractional carbon dioxide laser, then applied 2 mL PLT solution (dissolved in normal saline) on the right face.
62033753|NCT04829370|PLACEBO_COMPARATOR|Saline|All subjects are treated with fractional carbon dioxide laser, the left face (control group) be applied 2 mL normal saline
62425079|NCT02632383|EXPERIMENTAL|Test Group|"Intervention: Young with Diabetes - app The test group receives standard care and the mHealth app Young with Diabetes - app to support young people to self-manage their diabetes.~The young people's parents are also invited to download the app. The diabetes team (doctors, nurses and dieticians) also have the app and uses the app in their consultations with the young people."
62425080|NCT02632383|NO_INTERVENTION|Control Group|The control group receives standard care
62593696|NCT02965196|PLACEBO_COMPARATOR|Placebo Therapy|Three consecutive doses of 100cc IV normal saline (0.9%), will be administered over three days. Each dose will be administered over 24 hours in a slow drip.
62810180|NCT01335776|EXPERIMENTAL|Mindfulness-Based Stress Reduction|The program consists of three primary components: theoretical material related to relaxation, meditation, and the mind-body connection; experiential practice of meditation and yoga and home based practice; group process focused on problem solving and support.
62810181|NCT04870658||Complication|Any patients with biological or mechanical complication in dental implant treatment.
62810182|NCT04273607|EXPERIMENTAL|No anticoagulation|Participants in this arm will not receive unfractionated heparin during the course of ECMO. They will receive standard venous thromboembolism prophylaxis with subcutaneous enoxaparin or unfractionated heparin
62810183|NCT04273607|NO_INTERVENTION|Anticoagulation, ECMO standard of care|Participants in this arm will receive the standard of care anticoagulation with unfractionated heparin during the course of ECMO.
62033754|NCT05909631|PLACEBO_COMPARATOR|250 ml of a placebo|250 ml of a placebo
62033755|NCT05909631|EXPERIMENTAL|beetroot juice (BJ)|250 ml of concentrated beetroot juice
62033756|NCT05909631|EXPERIMENTAL|Mediterranean diet with beet juice (BJ+MeD)|Mediterranean diet with beet juice (BJ+MeD)
62810184|NCT06417840|PLACEBO_COMPARATOR|Placebo Control|
62033757|NCT05909631|EXPERIMENTAL|Mediterranean diet alone (MeD)|Mediterranean diet alone (MeD)
62033758|NCT04797338|ACTIVE_COMPARATOR|GnRHa treatment based luteal support|Patients will initiate intranasal treatment with Nafarelin inhaler: 200 micrograms twice daily (a total of 400 micrograms/d; Synarel, Pfizer) on the evening after oocyte retrieval which will be continued up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum hCG results, the treatment will be stopped.
62033759|NCT04797338|ACTIVE_COMPARATOR|Estrogen and progesterone supplementation|Patients will start treatment with a combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of progesterone retard 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum hCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
62033760|NCT05256173|EXPERIMENTAL|Melatonin Tablets|
62033761|NCT05256173|PLACEBO_COMPARATOR|Lactasin Tablets|
62033762|NCT05256173|EXPERIMENTAL|transcutaneous vagus nerve stimulation|
62810185|NCT06417840|EXPERIMENTAL|N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT)|
62810186|NCT00232622|ACTIVE_COMPARATOR|Standard infusion of streptokinase|Standard infusion of streptokinase
62810187|NCT00232622|EXPERIMENTAL|Accelerated infusion of streptokinase|Accelerated infusion of streptokinase
62810188|NCT04366414|ACTIVE_COMPARATOR|hook breathing removing nose-clip|"It will apply a usual training program for 4 weeks, 4hours and 30 min per week distributed equally over 3 days in the week. In each session, it was performed 8 submaximes-dynamic apnoeas with 3-minute recovery between each one. Then was performed a maximal-dynamic apnoea. To finish the session, was performed a continuous training of free style swimming at moderate effort over 30 minutes.~During that training, only this group will perform an experimental breathing protocol consisted of removing nose-clip previous to surface and then perform hook breathing during 20 seconds. This protocol was applied at the end of each of the 8 submaximes-dynamic apnoeas and after the maximal-dynamic apnoea"
62810189|NCT04366414|ACTIVE_COMPARATOR|usual breathing (UB)|It will apply a usual training program for 4 weeks, 4hours and 30 min per week distributed equally over 3 days in the week. In each session, it was performed 8 submaximes-dynamic apnoeas with 3-minute recovery between each one. Then was performed a maximal-dynamic apnoea. To finish the session, was performed a continuous training of free style swimming at moderate effort over 30 minutes.
62810190|NCT05868603|EXPERIMENTAL|Remineralization gel with CPP- ACP (GC Tooth MousseTM, Tokyo, Japan)|"CPP-ACP containing remineralization gel (Tooth Mousse GC, Tokyo, Japan) will be put into the Essix appliance with a reservoir and applied for 5-7 minutes twice a day for one month.~Before and after the applying remineralization gel, the laser fluorescence values will measure with a DIAGNOdent pen (KaVo Dental corporation, East Main street Lake Zurich, lL)."
62425081|NCT04620863|EXPERIMENTAL|tDCS group|Patients randomized to the experimental group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity delivered at anodal and cathodal levels.
62033763|NCT05256173|SHAM_COMPARATOR|sham transcutaneous vagus nerve stimulation|
62033764|NCT05222919|ACTIVE_COMPARATOR|Bare performance supplement|Dietary supplement
62425082|NCT04620863|SHAM_COMPARATOR|Sham Group|The stimulation setting was exactly the same of the experimental group but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
62425083|NCT03896919||cases|HLA-DQ mismatched recipient-donor pairs
62425084|NCT03896919||control|HLA-DQ matched recipient- donor pairs
62033765|NCT05222919|PLACEBO_COMPARATOR|Placebo|Placebo
62033766|NCT03362905|EXPERIMENTAL|Lidocaine spray Arm|This arm will receive lidocaine spray (Lidocaine topical aerosol ®, 10%, Arab drug co., Egypt) with dose four puffs (50 ml, 10 mg/puff) will be applied to the cervical canal and cervix.
62033767|NCT03362905|ACTIVE_COMPARATOR|Lidocaine cream Arm|This arm will receive topical cream (Pridocaine ®, Global Napi, Egypt) with a dose of 2g lidocaine cream will be applied to the cervix via cotton swab.
62425085|NCT03412461|EXPERIMENTAL|Thought Spot Application|Participants randomly assigned to the experimental arm will have access to the Thought Spot application. The Thought Spot application is a mobile app and website. This digital platform was designed and produced in partnership with transition aged youth in post-secondary education. The platform maps out wellness and mental health services across the Greater Toronto Area. This group will continue to have access to usual care.
62234064|NCT03861819|EXPERIMENTAL|VIIT Intervention|This is a single-arm trial. The intervention itself proceeds as follows: After approximately 5 minutes of warmup subjects will perform 10 intervals of VIIT: 30 seconds of vigorous intensity exercise followed by 60 seconds of rest. Rated Perceived Exertion (RPE) will be rated by 15-point Borg scale; should correspond to HR/10 at end of each interval. The subject will self-adjust the intensity of the exercise bouts and will be encouraged by the researcher to achieve the desired intensity. The exercise session will finish with a short cool-down period and will last no more than 25 minutes in total.
62234065|NCT00151957|EXPERIMENTAL|Methylphenidate transdermal system|MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
62593697|NCT04181047|EXPERIMENTAL|Virtual EMDR|Patients will receive 1 to 3 preparation sessions (which will include psychoeducation and preparation exercises before EMDR), followed by up to 12 EMDR sessions, delivered over encrypted Zoom videoconferencing. EMDR is an evidence based trauma therapy. These EMDR sessions will focus on the experiences, urges or negative thoughts associated with their suicidal thoughts. The sessions will be 90 minutes in length and occur twice per week. This group will also have access to usual psychiatric care, which usually includes a family doctor or psychiatrist, mental health therapist and having access to Edmonton's community mental health programs.
62593698|NCT04181047|ACTIVE_COMPARATOR|Treatment as usual|This group will also have access to usual care, which usually includes a family doctor or psychiatrist, mental health therapist and having access to Edmonton's community mental health programs.
62033768|NCT03362905|ACTIVE_COMPARATOR|Lidocaine injection Arm|This arm will receive lidocaine injection (Debocaine®, 2%, Sigma-Tec, Egypt) with a dose of 80-200 mg equivalent to 10 ml lidocaine (20 mg/ml) is injected at four and eight o'clock of the cervico-vaginal junction, and 2 ml to the area to be grasped with the tenaculum for paracervical block.
62033769|NCT00487162|EXPERIMENTAL|intensive glycemic control|In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R \[Novo Nordisk\]) in 50ml of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg / dL on two consecutive samples and will be adjusted to maintain the blood glucose level between 80 and 110 mg / dL. If the glucose level falls below 80 mg / dL, the insulin infusion will be tapered and discontinued.
62593699|NCT05450003|OTHER|xp endo finisher file|
62593700|NCT05450003|OTHER|new sonic EDDY system|
62033770|NCT00487162|ACTIVE_COMPARATOR|conventional glycemic control|In this group if the subject's blood glucose level should exceed 200 mg/dL the subject will be treated with a continuous insulin infusion to maintain blood glucose levels between 180-200mg/dL
62033771|NCT01031810|OTHER|tranylcypromine|patients will receive treatment with tranylcypromine
62033772|NCT03581305|ACTIVE_COMPARATOR|Dopaminergic arm|"25 eligible HIV-infected individuals and 50 eligible HIV-negative (HIV-) individuals for the dopaminergic arm.~Dopaminergic arm:~Group A: HIV-positive subjects with or without co- morbidities; Group B: HIV-negative subjects with co-morbidities; Group C: HIV-negative subjects without co-morbidities"
62234066|NCT05645835|EXPERIMENTAL|intervention|Participants will engage with the digital meditation app delivering the intervention 15 min a day, five days, a week for 6 weeks.
62234067|NCT05645835|ACTIVE_COMPARATOR|waitlist control|Participants will be randomized to a waitlist group for six weeks. The waitlist control group will then be able to use the meditation app for six weeks as the primary intervention group
62593701|NCT05450003|OTHER|syringe needle irrigation|
62033773|NCT03581305|ACTIVE_COMPARATOR|Serotonergic arm|"20 HIV-infected individuals and 20 HIV-negative individuals for the serotonergic arm~Serotonergic arm:~Group D: HIV-positive subjects with or without co-morbidities; Group E: HIV-negative subjects with or without co-morbidities"
62033774|NCT03796455|EXPERIMENTAL|Fish Oil|2.0 g EPA + DHA / day + placebo powder
62033775|NCT03796455|EXPERIMENTAL|Fish Oil and HMB|2.0 g EPA + DHA + 3.0 g HMB / day
62033776|NCT03796455|PLACEBO_COMPARATOR|Placebo|3 g/d soy oil: corn oil (50:50 ratio) + placebo powder
62033777|NCT05301751|EXPERIMENTAL|Cohort 1|A single intravitreal (IVT) dose of 0.5 mg AG-73305
62033778|NCT05301751|EXPERIMENTAL|Cohort 2|A single IVT dose of 1 mg AG-73305
62033779|NCT05301751|EXPERIMENTAL|Cohort 3|A single IVT dose of 2 mg AG-73305
62033780|NCT05301751|EXPERIMENTAL|Cohort 4|A single IVT dose of 4 mg AG-73305
62033781|NCT01260350|EXPERIMENTAL|Group 1: SOF+RBV 12 wk: GT 2 or 3, TN|Treatment-naive (TN) participants with genotype (GT) 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
62234068|NCT03618823|EXPERIMENTAL|Opioid pain control|Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the pain diary.
62234069|NCT03618823|ACTIVE_COMPARATOR|Non-opioid pain control|Patients in this group will be receiving therapy for pain control with acetaminophen and ibuprofen only. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the diary.
62234070|NCT06124872||Community survey 1 (planned demographic/health survey)|"Households included in a planned demographic and health survey (DSS).~All participants included in this survey will be invited to respond to snakebite questions."
62033782|NCT01260350|EXPERIMENTAL|Group 2: SOF+RBV 12 wk+PEG 4 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks plus PEG 180 µg once weekly for 4 weeks.
62234071|NCT06124872||Community survey 2 (Stand alone survey)|"25 households randomly selected for inclusion within each survey cluster.~Survey clusters will be randomly selected enumeration units within study Counties."
62234072|NCT06124872||Community survey 3 (Stand alone survey)|"25 households randomly selected for inclusion within each survey cluster.~Survey clusters will be randomly selected enumeration units within study Counties."
62425086|NCT03412461|ACTIVE_COMPARATOR|Resource pamphlet|Participants randomly assigned to the active comparator will receive a pamphlet that outlines mental health services and wellness services across the Greater Toronto Area. This group will continue to have access to usual care.
62810191|NCT05868603|EXPERIMENTAL|Remineralization gel with calcium glycerophosphate (R.O.C.S.® Medical Mineral Gel, Russia)|Remineralization gel containing calcium glycerophosphate (R.O.C.S.® Medical Minerals Gel, Russia) will be put into the Essix appliance with a reservoir for 5-7 minutes twice a day for one month. Before and after the applying remineralization gel, the laser fluorescence values will measure with a DIAGNOdent pen( KaVo Dental corporation, East Main street Lake Zurich, lL).
62810192|NCT05868603|NO_INTERVENTION|Control Group|No intervention.
62033783|NCT01260350|EXPERIMENTAL|Group 3: SOF+RBV 12 wk+PEG 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks plus PEG 180 µg once weekly for 8 weeks.
62234073|NCT06124872||Key informant interviews|Stakeholders in the process of healthcare decision making and research relevant to snakebite and snakebite envenoming
62234074|NCT05537688||Control group|"Participants will complete a graphic task included in a validated test for language impairment in adults and the elderly (DTLA).~They must not have a diagnosis of minor or major neurocognitive disorder."
62234075|NCT05537688||Alzheimer's Disease group|"Participants will complete a graphic task included in a validated test for language impairment in adults and the elderly (DTLA).~They must have mild stage Alzheimer's disease: 1/ Be diagnosed according to ICD-10 criteria for the following conditions: Alzheimer's disease and 2/ Have an MMSE score between 20 and 27, corresponding to a major TNC of mild stage or have a diagnosis of minor TNC with an MMSE score between 25 and 30, the validity period of a previously done MMSE is 3 months."
62234076|NCT05537688||PPA group|"Participants will complete a graphic task included in a validated test for language impairment in adults and the elderly (DTLA).~They must have Primary Progressive Aphasia according to the Gorno-Tempini criteria (Gorno-Tempini et al., 2011) and have an MMSE score between 20 and 27, corresponding to mild stage major CND or have a diagnosis of minor CND with an MMSE score between 25 and 30, the validity period of a previously made MMSE is 3 months."
62234077|NCT02088918|ACTIVE_COMPARATOR|Nateglinide+Metformin|coadministration of nateglinide and metformin
62234078|NCT02088918|EXPERIMENTAL|Nateglinide/Metformin|Nateglinide/Metformin tablet
62234079|NCT04778774|EXPERIMENTAL|Adductor canal block group|Adductor canal block group
62234080|NCT04778774|EXPERIMENTAL|Femoral nerve block group|Femoral nerve block group
62234081|NCT02808143|EXPERIMENTAL|Treatment (pembrolizumab, BCG solution)|"PRE-INDUCTION PHASE: Patients receive pembrolizumab intravesically once on day -14.~INDUCTION PHASE: Patients receive BCG solution intravesically once weekly for 6 weeks at weeks 0-5 and pembrolizumab intravesically every 2 weeks at weeks 0, 2, and 4.~MAINTENANCE PHASE: Beginning 2 weeks after the last dose of BCG solution, patients receive pembrolizumab intravesically every 2 weeks for 12 weeks at weeks 7, 9, 11, 13, 15, and 17 for a total of 6 doses. Patients then receive pembrolizumab intravesically every 4 weeks at weeks 21, 25, 29, 33, 37, 41, 45, and 49 for a total of 8 doses."
62234082|NCT00885651|EXPERIMENTAL|1|Metoprolol for 10 days followed by placebo for 7 days.
62234083|NCT00885651|PLACEBO_COMPARATOR|2|Placebo for 7 days followed by Metoprolol for 10 days
62425087|NCT01890694|PLACEBO_COMPARATOR|Placebo|"Subjects will receive placebo once daily.~They will undergo the following procedures in every visit: Vitals (blood pressure, heart rate, respiration, temperature, weight, height), Laboratory Tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin), ascites assessment, evaluation for edema. Quality of life assessments (SF-36, and LDQOL 1.0) will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge. Hepatic encephalopathy assessment (Number Connection Test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status) will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge."
62810193|NCT03901417|ACTIVE_COMPARATOR|Non-ablative Fractional Laser|Non-ablative fractional laser (brand name Fraxel Restore) only on one half of the face.
62033784|NCT01260350|EXPERIMENTAL|Group 4: SOF+RBV+PEG 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily+weight-based RBV (1000-1200 in a divided daily dose) plus PEG 180 µg once weekly for 12 weeks.
62033785|NCT01260350|EXPERIMENTAL|Group 5: SOF 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily for 12 weeks.
62810194|NCT03901417|ACTIVE_COMPARATOR|Non-ablative Fractional Laser Plus Microneedling|Non-ablative fractional laser (brand name Fraxel Restore) in combination with a microneedling device (SkinPen) on the other half of the face.
62033786|NCT01260350|EXPERIMENTAL|Group 6: SOF+RBV+PEG 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus PEG 180 µg once weekly for 8 weeks.
62033787|NCT01260350|EXPERIMENTAL|Group 7: SOF+RBV 12 wk: GT 1, TE|Treatment-experienced (TE) participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
62033788|NCT01260350|EXPERIMENTAL|Group 8: SOF+RBV 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
62033789|NCT01260350|EXPERIMENTAL|Group 9: SOF+RBV 12 wk: GT 2 or 3, TE|Treatment-experienced participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
62033790|NCT01260350|EXPERIMENTAL|Group 10: SOF+RBV 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 8 weeks.
62033791|NCT01260350|EXPERIMENTAL|Group 11: SOF+RBV 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus split-dose RBV (800 mg in a divided daily dose) for 12 weeks.
62433624|NCT04934514|EXPERIMENTAL|IIa stage - IAH0968 combined GP regimen study (cohort 2)|After the completion of the dose escalation in the 20 mg/kg dose group (phase Ia), a total of 30 patients with newly treated HER2-positive advanced biliary system tumors will be enrolled in the 20 mg/kg dose group combined with the GP regimen (gemcitabine + cisplatin) . Every 3 weeks is a cycle, treatment until any end-point event occurs.
62433625|NCT01545219|EXPERIMENTAL|Prebiotic|
62033792|NCT01260350|EXPERIMENTAL|Group 12: SOF+RBV+LDV 12 wk: GT 1, TE|Treatment-experienced participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus LDV 90 mg once daily for 12 weeks.
62033793|NCT01260350|EXPERIMENTAL|Group 13: SOF+RBV+LDV 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus LDV 90 mg once daily for 12 weeks.
62033794|NCT01260350|EXPERIMENTAL|Group 14: SOF+RBV+GS-9669 12 wk: GT 1, TE|Treatment-experienced participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus GS-9669 500 mg once daily for 12 weeks.
62033795|NCT01260350|EXPERIMENTAL|Group 15: SOF+RBV+GS-9669 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus GS-9669 500 mg once daily for 12 weeks.
62033796|NCT01260350|EXPERIMENTAL|Group 16: LDV/SOF FDC 12 wk: GT 1, fibrosis|Treatment-experienced participants with genotype 1 HCV infection and Stage F4 fibrosis who did not respond to prior treatment will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
62433626|NCT01545219|EXPERIMENTAL|Probiotic|
62810195|NCT03287401||Patients with general anesthesia|Patients with general anaesthesia are monitored with electroencephalography and the results will be associated with the risk for PACU delirium
62810196|NCT05948241|ACTIVE_COMPARATOR|Standard treatment|The control group will undergo 1 consultation with the multidisciplinary team, offered as standard treatment at the Heart Failure outpatient clinic of the Institute of Cardiology, with the areas: medicine, nutritionist and psychology. Monitoring with a multidisciplinary team is the gold standard for monitoring patients with HF and its multiple comorbidities. These patients are followed up on average every 3 months in this outpatient clinic.
62234084|NCT01743625|EXPERIMENTAL|COV155|COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.
62433627|NCT01545219|EXPERIMENTAL|Synbiotic|
62810197|NCT05948241|EXPERIMENTAL|Online psychological support group|The intervention group, in addition to standard treatment, will have 1 weekly session in an online psychological support group of 45 minutes each, totaling 12 sessions in three months. The intervention will be carried out by research psychologists specializing in cardiology, with online consultations via whatsapp
62810198|NCT00663364|ACTIVE_COMPARATOR|I|Physiogel AI Lotion
62810199|NCT00663364|ACTIVE_COMPARATOR|II|Physiogel Lotion twice daily
62033797|NCT01260350|EXPERIMENTAL|Group 17: LDV/SOF FDC+RBV 12 wk: GT 1, fibrosis|Treatment-experienced participants with genotype 1 HCV infection with Stage F4 fibrosis who did not respond to prior treatment will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
62033798|NCT01260350|EXPERIMENTAL|Group 18: LDV/SOF FDC 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
62425088|NCT01890694|EXPERIMENTAL|Tolvaptan|"Subjects will receive Tolvaptan once daily.~They will undergo the following procedures in every visit: Vitals (blood pressure, heart rate, respiration, temperature, weight, height), Laboratory Tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin), ascites assessment, evaluation for edema. Quality of life assessments (SF-36, and LDQOL 1.0) will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge. Hepatic encephalopathy assessment (Number Connection Test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status) will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge."
62033799|NCT01260350|EXPERIMENTAL|Group 19: LDV/SOF FDC 12 wk: GT 2 or 3, TE|Treatment-experienced participants with genotype 2 or 3 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
62033800|NCT01260350|EXPERIMENTAL|Group 20: LDV/SOF FDC+RBV 12 wk: GT 1, hemophiliac|Hemophiliac participants with genotype 1 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
62033801|NCT01260350|EXPERIMENTAL|Group 21: LDV/SOF FDC+RBV 6 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 6 weeks.
62234085|NCT01743625|PLACEBO_COMPARATOR|Placebo|Matching tablet to COV155 without containing active ingredients, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.
62234086|NCT02652273|EXPERIMENTAL|Abatacept|Abatacept 125mg administered via subcutaneous injection once a week for 24 weeks
62234087|NCT04362410|EXPERIMENTAL|Tezepelumab: Low dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
62234088|NCT04362410|EXPERIMENTAL|Tezepelumab: Medium dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
62234089|NCT04362410|EXPERIMENTAL|Tezepelumab: High dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
62234090|NCT04362410|PLACEBO_COMPARATOR|Placebo|Placebo single dose subcutaneously injection.
62234091|NCT02930356|EXPERIMENTAL|NSPT-Test group|NSPT was done after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to asses the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
62234092|NCT02930356|EXPERIMENTAL|Scaling and root planing-Control group|Scaling and root planing was done after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to asses the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
62433628|NCT01545219|PLACEBO_COMPARATOR|Placebo|
62433629|NCT03872700|EXPERIMENTAL|Intranasal fentanyl|2 mcg/kg INF, administered via intranasal route by atomizer syringe
62810200|NCT03289793|EXPERIMENTAL|Group A|"Children will be assigned to this group in a random fashion according to a ratio 2:1 with respect to group B (see below).~20 subjects will be included in this group."
62234093|NCT04787497|EXPERIMENTAL|Experimental Group|The Experimental Group will be receiving 50ml of freshly, cold-pressed, oleocanthal-rich Extra Virgin Olive Oil (EVOO) alongside their prescribed medical treatment. EVOO will be consumed on a daily basis for 12 months and all participants will undergo a neuropsychological assessment at baseline, 6 months and 12 months +/- 7 days after their first assessment or beginning of supplementation.
62810201|NCT03289793|ACTIVE_COMPARATOR|Group B|Children will be assigned in this group in a random fashion. 10 subjects will be included in this group.
62033802|NCT01260350|EXPERIMENTAL|Group 22: LDV/SOF FDC 6 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection were randomized to receive LDV 90 mg/SOF 400 mg FDC once daily for 6 weeks.
62033803|NCT05969093||Healthy individuals|Participants will undergo the Tinel's Sign at different wrist positions while EMG activity and NCV are recorded.
62033804|NCT06580132|ACTIVE_COMPARATOR|Fibre arm (Pectin)|20g of pectin was provided to healthy volunteers for 4 weeks.
62810202|NCT03289793|ACTIVE_COMPARATOR|Group C|"Will be included in this group children who meet the inclusion criteria and who, with their families, are motivated to participate in the study but cannot claim to be part of groups A or B (because of logistical constraints: living too far away to comply with the frequency of the visits required by the training).~Group C allows to follow the natural evolution of children with ADHD with no intervention."
62810203|NCT02386046||Reference Group|Late preterm infants without any pathology. Intervention: Pulse oxymeter measurements at the hospital and weekly thereafter until 46 weeks postconceptional age.
62810204|NCT02386046||Study Group|Infants born 26-35 weeks requiring caffeine. Intervention: Pulse oxymeter measurements at the hospital before and after caffeine instituted, and weekly thereafter until 46 weeks postconceptional age.
62810205|NCT02386046||Control Group|Infants born 26-35 weeks not requiring caffeine. Intervention: Pulse oxymeter measurements at the hospital and weekly thereafter until 46 weeks postconceptional age.
62810206|NCT01456286|EXPERIMENTAL|Sapropterin|5 mg/kg daily first week; 10 mg/kg daily second week of treatment
62810207|NCT01456286|PLACEBO_COMPARATOR|placebo|
62810208|NCT02389166|EXPERIMENTAL|Optiflow group|
62033805|NCT06580132|PLACEBO_COMPARATOR|Maltodextrin|10g of maltodextrin was provided to healthy volunteers for 4 weeks
62425089|NCT02284373|OTHER|Randomization Arm 1:|70 subjects with venous ulcers will receive pneumatic compression with the Flexitouch® for the duration of one month in addition to routine care of venous ulcers and lymphedema. A pre- and post-PCD treatment CIVIQ-2 quality of life questionnaire will be administered to the subjects. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded
62425090|NCT02284373|OTHER|Randomization Arm 2:|70 subjects with venous ulcers will receive routine care of venous ulcers and lymphedema. A quality of life questionnaire will be administered at enrollment and again after one month. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded.
62425091|NCT02284373|OTHER|Observational Arm 3|50 subjects with lymphedema will ALL receive PCD treatment. A pre-and post- PCD treatment CIVIQ-2 QOL questionnaire will be administered to all subjects at enrollment and again after one month of treatment.
62425092|NCT02379676|EXPERIMENTAL|Ticagrelor|Ticagrelor 90mg twice daily
62425093|NCT02379676|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 75mg once daily
62425094|NCT00572247|EXPERIMENTAL|1|Behavioral
62425095|NCT00572247|NO_INTERVENTION|2|
62810209|NCT02389166|ACTIVE_COMPARATOR|Control group|
62810210|NCT02699658|EXPERIMENTAL|levofloxacin in healthy|
62810211|NCT03057093||TIII>TI|Subjects with TIII\>TI in initial ECG
62810212|NCT03057093||Non TIII>TI|Subjects without TIII\>TI in initial ECG
62810213|NCT01418144|EXPERIMENTAL|Transversus abdominis plane (TAP) block|Transversus abdominis plane (TAP) block with ropivacaine
62033806|NCT05403541|EXPERIMENTAL|Batoclimab Induction Dose 1 (Period 1)|
62425096|NCT06390358|EXPERIMENTAL|Tefillin|Wearing of tefillin in traditional manner
62425097|NCT06390358|ACTIVE_COMPARATOR|Capsaicin|Applying cream to non-dominant arm
62425098|NCT03386669|EXPERIMENTAL|F-18 AV-45 THK-5351|F-18 AV-45 THK-5351 imaging
62810214|NCT01418144|PLACEBO_COMPARATOR|Block with saline|Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
62810215|NCT05668949|EXPERIMENTAL|Part 1 (Dose Escalation)|Participants will be assigned to a study part based on when you join this study
62810216|NCT05668949|EXPERIMENTAL|Part 2 (Dose Expansion)|Participants will be assigned to a study part based on when you join this study.
62033807|NCT05403541|EXPERIMENTAL|Batoclimab Induction Dose 2 (Period 1)|
62033808|NCT05403541|PLACEBO_COMPARATOR|Placebo Induction Dose (Period 1)|
62033809|NCT05403541|EXPERIMENTAL|Batoclimab Maintenance Dose 1 (Period 2)|
62033810|NCT05403541|EXPERIMENTAL|Batoclimab Maintenance Dose 2 (Period 2)|
62033811|NCT05403541|PLACEBO_COMPARATOR|Placebo Maintenance Dose (Period 2)|
62033812|NCT01089972||20 gauge group|
62033813|NCT01089972||22 gauge group|
62425099|NCT06538233|EXPERIMENTAL|Buffered articaine|
62425100|NCT06538233|ACTIVE_COMPARATOR|non buffered articaine|
62810217|NCT01069484|EXPERIMENTAL|Postpartum pelvic floor muscle training|Beyond a customary leaflet (received from the postnatal ward) and the thorough initial instruction on how to contract the PFM correctly, the participants are given supervised pelvic floor muscle group training led by physiotherapists once a week. In addition, the participants train every day at home, with at least 3 sets of 8-12 contractions. Training period is 4 months.
62810218|NCT01069484|NO_INTERVENTION|Control|Beyond the customary leaflet (received from the postnatal ward) and the thorough initial instruction on how to contract the PFM correctly, the control group participants received no further intervention. They were not discouraged from doing PFMT on their own.
62810219|NCT01702844|EXPERIMENTAL|nab paclitaxel|Patients will receive nab-paclitaxel once weekly for 3 weeks of every 4 week cycle
62033814|NCT02068573|ACTIVE_COMPARATOR|Ventilation|Increased ventilation in the childs bedroom to at least 2-3 air changes pr hour.
62033815|NCT02068573|PLACEBO_COMPARATOR|Placebo ventilation|Ventilation system that recirculates the air in the childs bedroom
62033816|NCT03813654|NO_INTERVENTION|Control (Group A)|During the intervention block of the Field Trial, at the end of the first night shift, the participant will be told about their randomization group. In the control group (Group A), participants will not be given any instructions about the timing or duration of their sleep, but will be instructed to follow their usual night shift sleep routine.
62033817|NCT03813654|EXPERIMENTAL|8-h Afternoon-Evening Sleep (Group B)|In the 8-h afternoon-evening sleep intervention group (Group B), participants will be instructed to go to bed between 13:00 and 14:00 (depending on their individual commute time) and to remain in bed attempting to sleep for 8 hours (until 21:00-22:00) before the next two night shifts.
62033818|NCT03813654|EXPERIMENTAL|8-h Free Sleep (Group C)|In the 8-h free sleep group (Group C), participants will be instructed to remain in bed for 8 continuous hours before the next two night shifts, but will not be given any instruction regarding which 8 hours they should sleep.
62033819|NCT02558010|EXPERIMENTAL|Methadone Group|Patients will receive a total of 0.2mg/kg IV methadone intraoperative (0.1mg / kg preincision and 0.1mg/kg prior to emergence) with a maximum dosing of 20 mg.
62033820|NCT02558010|ACTIVE_COMPARATOR|Control Group|Patient will receive normal saline placebo initially, then morphine prior to emergence.
62033821|NCT04879862|EXPERIMENTAL|Locomotion|Participants will receive 160 locomotor training sessions with epidural stimulation. These sessions may occur once a day (stand and step will alternate days) or twice a day (stand and step on the same day) as recommended by the study physician. Participants will train 5 days per week and each session will last between 1 to 1.5 hours.
62033822|NCT04879862|EXPERIMENTAL|Bladder+Locomotion|Participants will receive 80 sessions of bladder training alone followed by 80 sessions of locomotor training sessions with epidural stimulation. They will be asked to continue with your bladder training once you start locomotor training. Locomotor Training sessions may occur once a day (stand and step will alternate days) or twice a day (stand and step on the same day) as recommended by the study physician. Participants will train 5 days per week and each session will last between 1 to 1.5 hours.
62033823|NCT03671096|EXPERIMENTAL|Intrastromal TCA Inlay|Implant Intrastromal TCA using femto-second laser surgery It is expected to be carried out once only during the study duration
62234094|NCT04787497|NO_INTERVENTION|Control Group|The Control Group will be continuing their standard medical treatment without additional supplementation. The neuropsychological assessment will be conducted at baseline, 6 months and 12 months +/- 7 days after their first assessment.
62425101|NCT01212601||1|
62234095|NCT03811353||Children with cerebral palsy|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale. Tongue control will also be evaluated by Tongue Thrust Rating Scale.
62033824|NCT06373822||Control group (N=25)|"Female patients visiting the service de Gynécologie of the CUSL for the purpose of intervention in the context of a benign gynecological issue (myomectomy, endometrial resection etc).~* Age ≥ 18 years~* Pre-menopausal~* Not HIV or Hepatitis-positive~* Not having participated in another clinical study in the 12 months prior to recruitment~* Not presenting symptoms of adenomyosis and/or endometriosis"
62033825|NCT06373822||Adenomyosis group (N=25)|"Female patients visiting the service de Gynécologie of the CUSL for the purpose of surgical intervention in the context of uterine adenomyosis.~* Age ≥ 18 years~* Pre-menopausal~* Not HIV or Hepatitis-positive~* Not having participated in another clinical study in the 12 months prior to recruitment~* Not presenting symptoms of endometriosis"
62234096|NCT03811353||Healthy children|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale. Tongue control will also be evaluated by Tongue Thrust Rating Scale.
62234097|NCT03336151|EXPERIMENTAL|Front-of-pack labelling Nutri-Score|"Introduction of the Nutri-Score front-of-pack nutrition label on every food and beverage in the campus cafeteria after a control period without food labelling.~The implementation of the label is accompanied by a communication campaign towards students in the form of posters and leaflets."
62425102|NCT05268965||Patients meeting DSM-5 criteria for PTSD.|
62425103|NCT05268965||Group 2: Healthy controls who experienced a traumatic event but did not meet DSM-5 criteria for PTSD|
62425104|NCT05268965||Group 3: Healthy controls who did not experience a traumatic event|
62810220|NCT04735835|EXPERIMENTAL|Dietary Intervention|Dietary intervention using standardized test meals after which the postprandial metabolic response is measured.
62810221|NCT05749146|EXPERIMENTAL|Palliative care at home|Randomized to intervention arm
62810222|NCT05749146|ACTIVE_COMPARATOR|Augmented control|Randomized to augmented control (visits to the caregiver from a CHW without training in dementia or palliative care)
62810223|NCT05075408|EXPERIMENTAL|Nemolizumab 30 mg|
62810224|NCT05075408|EXPERIMENTAL|Nemolizumab 60 mg|
62810225|NCT05075408|PLACEBO_COMPARATOR|Placebo|
62810226|NCT00984984|EXPERIMENTAL|methylprednisolone PO|
62810227|NCT00984984|ACTIVE_COMPARATOR|methylprednisolone IV|
62810228|NCT03658421|EXPERIMENTAL|H group|H group stands for High concentration group. A single bolous of 20 ml ropivacaine 0.2% in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.2% (5 ml/h) for postoperative analgesia which started right after surgery. After surgery, all patients received multimodal analgesia of 200mg celecoxib every 12 hours. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
62819566|NCT03009058|EXPERIMENTAL|IMM-101 + Gem sarcoma|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
62033826|NCT01921569|EXPERIMENTAL|dHACM|Standard of Care Therapy plus dHACM injection at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
62033827|NCT01921569|PLACEBO_COMPARATOR|Saline Injection|Standard of Care Therapy plus normal saline injection instead of active agent at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
62033828|NCT05928598|OTHER|Standard care arm - patient participants|This group will be enrolled first.
62033829|NCT05928598|EXPERIMENTAL|Intervention arm (Epilepsy Visit Planner) - patient participants|This group will be enrolled after the standard care arm enrollment is completed.
62033830|NCT05928598|OTHER|Intervention arm (Epilepsy Visit Planner) - provider participants|Epilepsy providers will be recruited from the University of Michigan (approximately 10 providers).
62234098|NCT06441084|EXPERIMENTAL|NCR300 injection|Cohort1: Low dose NCR300 injection; Cohort2: Mid-low dose NCR300 injection; Cohort3: Mid-high dose NCR300 injection; Cohort4: High dose NCR300 injection.
62234099|NCT01709747|EXPERIMENTAL|Hydromorphone Hydrochloride|Hydromorphone hydrochloride for intrathecal administration, 12 months safety evaluation
62033831|NCT01032577||cardiomyopathy, with implant indications|30-50 volunteers age \>18, male and female with ability to give informed consent, who are expected to live more than one year, with indication for defibrillator implant and who are not pacemaker dependent.
62033832|NCT04386096|EXPERIMENTAL|Mehealth for ADHD software with medication continuity tools|
62033833|NCT04386096|ACTIVE_COMPARATOR|Mehealth for ADHD software with no medication continuity tools|
62033834|NCT03960190|EXPERIMENTAL|1K expression kit|Subjects will be using the breastpump with the with 1K expression kit.
62033835|NCT03960190|EXPERIMENTAL|2K expression kit|Subjects will be using the breastpump with the with 2K expression kit.
62425105|NCT00660049|EXPERIMENTAL|SNaP application|"This is an open label pilot study of SNaP Advanced Wound Care System"
62033836|NCT04295226||Participants in Structured post-stroke follow-up in Malmö|"Consecutive patients with acute ischemic stroke or intracerebral hemorrhage, treated in-hospital at Skåne University Hospital in Malmö and discharged straight to own home.~The intervention consists of a structured follow-up visit, managed by a stroke nurse, 3 months after stroke followed by a multidisciplinary team rounds resulting in an individual treatment plan for stroke-related health problems, and a final follow-up at 12 months"
62033837|NCT00786929|EXPERIMENTAL|drainage|
62234100|NCT02772705||Hyperthyroidism|Those with Grave's Disease(GD,Hyperthyroidism),with lower TSH, and higher FT3, FT4.
62234101|NCT02772705||Health Humans|Those humans who are healthy, without GD, without any treatment, with normal TSH, FT3, FT4.
62234102|NCT02623153|ACTIVE_COMPARATOR|capecitabine and oxaliplatin|capecitabine of 1000 mg/m2, orally administered twice a day on days 1-14 and oxaliplatin at 130 mg/m2on day 1, as intravenous 2 h infusion
62033838|NCT00786929|ACTIVE_COMPARATOR|2|Conservative treatment
62033839|NCT03185611|EXPERIMENTAL|Rifaximin and Thiopurine|Prescribed Rifaximin (600mg, twice daily) combined with Azathioprine (2.0-2.5mg/kg/day) for 3 months after surgery, and then Azathioprine monotherapy (2.0-2.5mg/kg/day) for the next 3months.
62033840|NCT03185611|ACTIVE_COMPARATOR|Thiopurine|Prescribed Azathioprine (2.0-2.5mg/kg/day) for 6 months after surgery.
62234103|NCT02623153|EXPERIMENTAL|S1, oxaliplatin and docetaxel|S1 of 40 mg/m2, orally administered twice a day on days 1-14,oxaliplatin 130 mg/m2 and docetaxel 40 mg/m2on day 1 as intravenous
62234104|NCT04818138|ACTIVE_COMPARATOR|Narrowband UVB|Narrowband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
62234105|NCT04818138|ACTIVE_COMPARATOR|Broadband UVB|Broadband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
62234106|NCT06231966|EXPERIMENTAL|Rosuvastatin/ezetimibe combination therapy|Combination therapy of high-intensity dose rosuvastatin and ezetimibe
62033841|NCT02504073||PT's working in stroke in NW-Switzerland|"54 Physiotherapists (PT's) working in north-west Switzerland (at Bruderholzspital, RehaB Basel, Klinik Tschugg, Reha Rheinfelden, RehaClinic Zurzach) are asked to analyse videos of 6 hemiplegic patients when walking. They are asked to write down their main observations, the major problem and hypotheses about how this major problem is produced.~There is no intervention."
62234107|NCT06231966|ACTIVE_COMPARATOR|Rosuvastatin monotherapy|Rosuvastatin monotherapy for treat-to-target (LDL cholesterol \< 70 mg/dL)
62234108|NCT04610437|ACTIVE_COMPARATOR|intramedullary reabsorbable fixation system PLLA.|Arthrodesis interphalangeal with intramedullary reabsorbable fixation system PLLA.
62425106|NCT02329496|EXPERIMENTAL|Lotus Valve and LOTUS Edge Valve System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System
62433630|NCT03872700|EXPERIMENTAL|Placebo|0.04ml/kg of sterile water, administered via intranasal route by atomizer syringe
62033842|NCT04981665|EXPERIMENTAL|Postoperative TACE + Tislelizumab 200mg IV Q3W|TACE will be performed after curative resection (4±1w) once and then Tislelizumab Injection will be initiated after TACE (5±2d). Tislelizumab will be administered every three weeks, until the disease recurrence, intolerable toxicity, death, withdrawal of consent or completion of 17 cycles of Tislelizumab.
62033843|NCT03989466|EXPERIMENTAL|Treatment (itacitinib, alemtuzumab)|"CYCLE 1: Patients receive itacitinib PO QD on days 1-28 and alemtuzumab IV over 2 hours on days 15, 17, 19, 21, 23, 25, and 27 in the absence of disease progression of unacceptable toxicity.~CYCLE 2 AND BEYOND: Patients receive itacitinib PO QD on day 1-28 and alemtuzumab IV over 2 hours on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients who achieve a response (CR/CRi or PR) may receive itacitinib for up to 8 additional cycles in the absence of disease progression or unacceptable toxicity."
62033844|NCT06636357|EXPERIMENTAL|50% nitrous oxide (N2O) plus 50% oxygen|Patients will be treated with N20 (50% N2O combined with 50% oxygen) for 45 minutes. Both the study subject and the rater will be blinded to the treatment assignment.
62033845|NCT06636357|PLACEBO_COMPARATOR|50% oxygen plus 50% air|Here, patients will be treated with 50% oxygen plus air for 45 minutes. Both the study subject and the rater will be blinded to the treatment assignment.
62425107|NCT05763277||Ate-Bev|Individuals diagnosed with advanced hepatocellular carcinoma and treated with atezolizumab-bevacizumab between the ages of 18-80 were included. According to the recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, patients with comorbidities were excluded.
62810229|NCT03658421|EXPERIMENTAL|L group|L group stands for low concentration group. A single bolous of 20 ml ropivacaine 0.1% in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.1% (5 ml/h) for postoperative analgesia which started right after surgery. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
62033846|NCT00389558|ACTIVE_COMPARATOR|2|Biseptine
62033847|NCT00389558|ACTIVE_COMPARATOR|1|Amukin
62033848|NCT02967185|EXPERIMENTAL|Brief Behavioral Therapy for Insomnia|Treatment will consist of 4 weekly, 1 hour sessions and will be conducted by a trained graduate assistant on an individual basis.
62033849|NCT02967185|NO_INTERVENTION|Waitlist Control|Participants in this group will receive no intervention, but will complete the same set of assessments as those in the Experimental Group. They will be given the option of receiving the behavioral treatment program at no charge.
62033850|NCT04672551|NO_INTERVENTION|Waitlist control group|The intervention group consists of 30 patients diagnosed with PTSD induced by ACS. No intervention or any other procedure will be conducted during the study period of 36 weeks. Afterwards these subjects will be offered an EMDR therapy as provided in the intervention.
62234109|NCT04610437|PLACEBO_COMPARATOR|K-wire|Arthrodesis interphalangeal with kirschner wire
62425108|NCT02735226||Acute Stroke patient|Patients who are presented to hospital within 7days from onset. The key measurement of clinical quality controlled in patients with acute stroke managment and inhouse stroke care were record automatically
62810230|NCT03658421|EXPERIMENTAL|LD group|LD group stands for low concentration group with dexmedetomidine. A single bolous of 20 ml ropivacaine 0.1% plus 2 μg/kg dexmedetomidine in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.1% (5 ml/h) for postoperative analgesia which started right after surgery. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
62810231|NCT00743002|EXPERIMENTAL|TT223 with Metformin and/or TZD|TT223 as a treatment for Type 2 diabetes is administered by injection once daily at 1 mg, 2 mg and 3 mg patients currently treated with Metformin and/or Thiazolidinedione (TZD).
62810232|NCT00743002|PLACEBO_COMPARATOR|Placebo with Metformin and/or TZD|Placebo as a comparator is administered by injection once daily at 1 mg, 2 mg and 3 mg patients currently treated with Metformin and/or Thiazolidinedione (TZD).
62810233|NCT02446184|EXPERIMENTAL|Fetal cystoscopy|Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.
62810234|NCT02446184|ACTIVE_COMPARATOR|Vesicoamniotic shunt|The fetal vesicoamniotic shunt is considered the standard prenatal therapy for severe LUTO. Amnioinfusion and vesicoamniotic shunt placement will be performed under ultrasound guidance.
62810235|NCT02446184|NO_INTERVENTION|No fetal intervention group|Those patients that refuse fetal intervention and do not elect to terminate the pregnancy will be followed as part of the no fetal intervention group.
62810236|NCT01703078|ACTIVE_COMPARATOR|Ingenol mebutate gel 0.05%|once daily for two consecutive days
62810237|NCT01703078|EXPERIMENTAL|Ingenol derivative concentration 1|once daily for two consecutive days
62425109|NCT05951231|ACTIVE_COMPARATOR|Liver transplanted patient|Patients who are transplanted with an ECD liver after pretreatment with a liver perfusion machine
62810238|NCT01703078|EXPERIMENTAL|Ingenol derivative concentration 2|once daily for two consecutive days
62810239|NCT01703078|EXPERIMENTAL|Ingenol derivative concentration 3|once daily for two consecutive days
62810240|NCT03701776|EXPERIMENTAL|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
62810241|NCT03701776|ACTIVE_COMPARATOR|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre-training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge. Individuals will be instructed to perform more difficult exercises if balance challenge scores are low.
62033851|NCT04672551|EXPERIMENTAL|Intervention group|The intervention group consists of 30 patients diagnosed with PTSD induced by ACS. Eight individual EMDR sessions lasting for 1 hours will be provided over 8 weeks by licensed EMDR therapists from the German-speaking part of Switzerland. Each EMDR session follows a standardized 8-phase protocol.
62033852|NCT00788996|EXPERIMENTAL|Lifestyle counseling|Usual care
62033853|NCT04567537|ACTIVE_COMPARATOR|Scars|The entire hypertrophic scar will receive laser treatment only.
62033854|NCT04567537|ACTIVE_COMPARATOR|Scleroderma|The entire lesion will receive laser treatment.
62810242|NCT02051764|EXPERIMENTAL|Follow-up Flortaucipir PET Scan|
62810243|NCT03760029|OTHER|Study arm|All subjects in this study will be observed for 24-30 months.
62234110|NCT06185647||All infants visiting the Emergency department from october 2023 to february 2024|Extraction from medical and nursing records data on the previous administration of nirsevimab and determin whether a bronchiolitis diagnosis was given in the pediatric emergency department This information was inserted systematically in the PED records on October 31st, 2023
62425110|NCT05951231|NO_INTERVENTION|Non-liver transplanted patient|Patients who are not offered a liver transplantation during the inclusion period
62810244|NCT06252181|EXPERIMENTAL|group number 1|group of peripheral arterial disease elderly (n=20) that take their medications and will receive 3 sessions per weeks of 8-week electromagnetic one-hour therapy and one hour elliptical exercise (exercise will be applied 3 times per the week for eight week)
62033855|NCT04916223|EXPERIMENTAL|3 x 10-minute massage|Subject receives a 10-minute massage daily for three consecutive days
62033856|NCT04916223|EXPERIMENTAL|3 x 20-minute massage|Subject receives a 20-minute massage daily for three consecutive days
62033857|NCT04916223|ACTIVE_COMPARATOR|Single 20-minute massage|Subject receives one 20-minute massage
62033858|NCT06267053||Kellgren Lawrence Grade|Patients are divided into four groups based on Kellgren lawrence stage
62033859|NCT04223180||Stroke patients|Inpatients and outpatients admitted to the investigators' rehabilitation facility with an upper limb impairment due to neurologic or orthopedic disorders.
62033860|NCT02293629|PLACEBO_COMPARATOR|A1: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
62033861|NCT02293629|PLACEBO_COMPARATOR|A2: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
62033862|NCT02293629|PLACEBO_COMPARATOR|A3: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
62033863|NCT02293629|ACTIVE_COMPARATOR|B1: BMS-986147 or Placebo matching BMS-986147|Daily oral dose as specified
62033864|NCT02293629|ACTIVE_COMPARATOR|B2: BMS-986147 or Placebo matching BMS-986147|Daily oral dose as specified
62033865|NCT04396834|EXPERIMENTAL|Lorcaserin first, then placebo|Participants first receive lorcaserin (10 mg BID) for 7 days. After a washout period of 7 days, they then receive placebo tablets (BID) for 7 days.
62033866|NCT04396834|EXPERIMENTAL|Placebo first, then lorcaserin|Participants first receive placebo (BID) for 7 days. After a washout period of 7 days, they then receive lorcaserin (10 mg BID) for 7 days.
62033867|NCT06052449|EXPERIMENTAL|Social determinants of health screening|Participants will receive a social determinants of health screening assessment and referral process in addition to the community-based lung cancer screening educational tool.
62033868|NCT06052449|ACTIVE_COMPARATOR|Community-based lung cancer screening|Participants will receive a community-based lung cancer screening educational tool.
62425111|NCT00789568|EXPERIMENTAL|Sapropterin Dihydrochloride 100mg/kg and placebo Moxifloxacin|A single dose of 100mg/kg of Sapropterin Dihydrochloride taken along with placebo Moxifloxacin.
62425112|NCT00789568|EXPERIMENTAL|Sapropterin Dihydrochloride 20mg/kg and placebo Moxifloxacin|A single dose of 20mg/kg of Sapropterin Dihydrochloride taken along with a placebo Moxifloxacin.
62425113|NCT00789568|ACTIVE_COMPARATOR|Sapropterin Dihydrochloride placebo and Moxifloxacin|No placebo tablets for Sapropterin Dihydrochloride will be administered, but instead will be apple juice only, taken along with 400mg of Moxifloxacin.
62810245|NCT06252181|ACTIVE_COMPARATOR|group number 2|patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise ( exercise will be applied 3 times per the week for eight week)
62033869|NCT00342862||1. Amevive Exposure|Pregnant women with psoriasis exposed to AMEVIVE® at any point within 8 weeks prior to conception, or at any time during pregnancy, where the outcome of the pregnancy is unknown prospectively
62033870|NCT03182868|EXPERIMENTAL|Repeatability Group|Healthy participants perform goggle testing on two consecutive days to determine if the testing results are repeatable. Testing will be between 10 am and 2 pm and testing on the two sessions will be within 30 minutes of the same time. Sessions can be on two consecutive days or separated by up to 4 days.
62033871|NCT03182868|EXPERIMENTAL|Time of Day Group|Healthy participants perform goggle testing at two different times of day to determine if time of day affects goggle testing performance. One quarter of the participants in this arm will undergo one test at 8 am on the first session and 10 am on the second session. A second quarter will undergo the tests at 10 am on first session and 8 am on the second session. A third quarter will undergo one test at 3 pm on the first session and 10 am on the second session. The fourth quarter will undergo the tests at 10 am on first session and 3 pm on the second session. In all these cases the sessions can be on consecutive days or separated by up to 4 days.
62033872|NCT03182868|EXPERIMENTAL|Learning Affect Group|Healthy participants perform goggle testing back to back on the same day to determine if performance on second test changes from first test suggesting a learning affect.
62033873|NCT03182868|EXPERIMENTAL|MSQ Group|Healthy participants perform goggle testing and upon completion of each goggle testing session will complete a Motion Sickness Questionnaire (MSQ) to determine if they show any signs of motion sickness.
62033874|NCT03182868|EXPERIMENTAL|OKN Only Group|OKN Only Group is for exploratory aims only. Healthy participants will undergo goggle testing limited to Optokinetic Nystagmus (OKN) recordings at two stimulus speeds (20 and 60 deg/s) in both the counterclockwise and clockwise directions.
62810246|NCT04757506|PLACEBO_COMPARATOR|Placebo|cellulose-filled capsule
62033875|NCT01475136|EXPERIMENTAL|LY2140023|A single oral dose of 80 milligrams (mg) LY2140023 administered on Day 1.
62810247|NCT04757506|EXPERIMENTAL|Naltrexone|single 50 mg oral dose naltrexone (capsule)
62033876|NCT05634395|EXPERIMENTAL|Intervention with activity tracker|Women allocated to the intervention arm will used an activity tracker
62033877|NCT05244473|EXPERIMENTAL|Brentuximab vedotin + ART|Brentuximab vedotin given on Day 1 and Day 15. ART will be given throughout the study.
62033878|NCT05244473|PLACEBO_COMPARATOR|Placebo + ART|Placebo given on Day 1 and Day 15. ART will be given throughout the study.
62033879|NCT01022437|EXPERIMENTAL|Geranium Oil and component PN-34|
62033880|NCT02271958|EXPERIMENTAL|Group 1|Oral administration of 2,5 mg of mifepristone daily for 6 months
62033881|NCT02271958|EXPERIMENTAL|Group 2|Oral administration of 5 mg of mifepristone daily for 6 months
62033882|NCT02271958|EXPERIMENTAL|Group 3|Oral administration of 10 mg of mifepristone daily for 6 months
62033883|NCT02271958|EXPERIMENTAL|Group 4|Oral administration of mifepristone placebo daily for 3 months
62810248|NCT04859322|EXPERIMENTAL|Healthy Participants|20 healthy participants included in the arm for 3 experimental days each. On each experimental day infusions of stable isotope glucose (0,6 micromol/kg/min), glucagon (1 hour low; 0,6 ng/kg/min, 2 hours high; 4,0 ng/kg/min), somatostatin (450 micrograms/hour) and insulin (0,1 mU/kg/min) will be administered. Between the first two experimental days the participants will follow a sedentary lifestyle combined with a high-calorie diet intervention
62810249|NCT02913703|EXPERIMENTAL|Healthy subjects - Preprandial AG (Acyl Ghrelin)|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG (Acyl Ghrelin) bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
62033884|NCT04714125||Patients with COVID-19|Patients hospitalized with COVID-19 from the General Hospital of the University of Sao Paulo, Brazil.
62033885|NCT03398005|EXPERIMENTAL|CaPre|
62033886|NCT03398005|PLACEBO_COMPARATOR|Placebo|
62033887|NCT04051372||BAL group|"Adult patients with hematology disease under allo-HSCT at any phase of treatment are enrolled according to the following criteria:~1. lung infiltration detection at computed tomography (CT) scan.~2. Patients with fever, cough, respiratory symptoms. According to the investigators, the patients fulfilling these criteria undergo BAL as soon as possible"
62810250|NCT02913703|EXPERIMENTAL|Healthy subjects - Preprandial saline|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial saline bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
62810251|NCT02913703|EXPERIMENTAL|Healthy subjects - Prandial AG|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 5 hour fast, they will receive a prandial AG bolus over 1 minute starting at the same time as the liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
62810252|NCT02913703|EXPERIMENTAL|Healthy subjects - Preprandial & prandial AG|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG bolus over 1 minute. Sixty minutes later, they will receive another AG bolus over 1 minute starting at the same time as the liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
62810253|NCT02913703|EXPERIMENTAL|Diabetic subjects - Preprandial AG|Type 2 diabetic subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
62810254|NCT02913703|EXPERIMENTAL|Diabetic subjects - Preprandial Saline|Type 2 diabetic subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial saline bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
62810255|NCT01473771|EXPERIMENTAL|Caring Letter Condition (CL)|"In the Caring Letters (CL) group, participants will be emailed letters for two years on a planned schedule. The emailed letters are simple expressions of care and include standard contact information for available health care services."
62810256|NCT01473771|NO_INTERVENTION|Usual Care (UC)|The participants in the Usual Care (UC) group will not receive the emails.
62810257|NCT05494840|EXPERIMENTAL|Haptonomy- first experimental Group|Haptonomy Group Pregnant school will made to the experimental group, and haptonomy will be applied for at least 30 minutes, once a week for 6 weeks (with the researcher).
62810258|NCT05494840|EXPERIMENTAL|Haptonomy- second experimental Group|Haptonomy Group Pregnant school will made to the experimental group, and haptonomy will be applied for at least 30 minutes, once a week for 3 weeks (with the researcher).
62810259|NCT05494840|NO_INTERVENTION|Haptonomy- Control Group|Standard of care Group The control group will not be interfered with.
62810260|NCT01410942|PLACEBO_COMPARATOR|Placebo + Sham Exercise|Placebo capsules by mouth twice daily. Participants in sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
62810261|NCT01410942|EXPERIMENTAL|Methylphenidate + Sham Exercise|Methylphenidate starting dose 5 mg by mouth twice daily. Participants in sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
62810262|NCT01410942|PLACEBO_COMPARATOR|Exercise + Placebo|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Placebo capsules by mouth twice daily.
62033888|NCT00000392|ACTIVE_COMPARATOR|Peptide T|Peptide T given intranasally at a dosage of 2mg 3 times a day for 6 months
62033889|NCT00000392|PLACEBO_COMPARATOR|Placebo|Placebo given intranasally at a dosage of 2mg 3 times a day for 6 months
62425114|NCT00789568|PLACEBO_COMPARATOR|Sapropterin Dihydrocholide placebo and Moxifloxacin placebo|No placebo tablets for Sapropterin Dihydrochloride will be administered, but instead will be apple juice only, taken along with placebo of Moxifloxacin.
62425115|NCT03840642|ACTIVE_COMPARATOR|Mirror Me|Parents randomized to the Mirror Me condition will complete the 4 Mirror Me modules over a period of 5 weeks (\~1 per week plus a week to practice). They will be provided with a visual guide for how to access the website. At 5 weeks, they will complete a remote parent-child interaction. Then they will be told their condition and to continue to use the website and practice what they have learned with their children.
62425116|NCT03840642|EXPERIMENTAL|Mirror Me Plus Remote Coaching|Parents randomized to the Mirror Me plus remote coaching condition will complete the 4 Mirror Me modules over a period of 5 weeks (\~1 per week plus a week to practice). They will be provided with a visual guide for how to access the website. At 5 weeks, they will complete a remote parent-child interaction. Then all parents in this condition will be told about the opportunity to participate in remote video teleconferences once per week for 5 weeks. Trained therapists will provide feedback to parents as they use the RIT techniques with their child at home. All sessions will follow a similar format including a discussion of accomplishments and challenges, parent practice with feedback, problem solving, and planning for the next week. Sessions will be recorded for data collection and therapist coaching fidelity. Participants will have access to Mirror Me for the duration of the research study.
62810263|NCT01410942|PLACEBO_COMPARATOR|Cognitive Therapy + Placebo|Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill. Placebo capsules by mouth twice daily.
62810264|NCT01410942|EXPERIMENTAL|Methylphenidate + Exercise|Methylphenidate starting dose 5 mg by mouth twice daily. Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
62810265|NCT01410942|EXPERIMENTAL|Methylphenidate + Cognitive Therapy|Methylphenidate starting dose 5 mg by mouth twice daily. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
62425117|NCT05902637|ACTIVE_COMPARATOR|Prostate Mapping Used|Those patients' Multiparametric Prostate Magnetic Resonance (MPMR) imaging's have been assessed by a genitourinary radiologist to guide the surgeon who performs cognitive prostate biopsy
62425118|NCT05902637|SHAM_COMPARATOR|Prostate Mapping not Used|Those patients' Multiparametric Prostate Magnetic Resonance (MPMR) imaging's have not been assessed by a genitourinary radiologist to guide the surgeon who performs cognitive prostate biopsy. Surgeon assesses the Multiparametric Prostate Magnetic Resonance (MPMR) imaging's by him/herself
62425119|NCT01124526|EXPERIMENTAL|Rituximab, Fludarabine, ciclophosphamide|"Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:~RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2)"
62425120|NCT02236364|EXPERIMENTAL|New device for OPTICAL determination of blood glucose level|
62593702|NCT06558747|EXPERIMENTAL|Device: Bioactive Cement|BioCem™ (NuSmile, Texas, USA) was evenly distributed to the inner surface of the crown with the syringe and immediately placed onto the teeth. Crowns were stabilized for 20 seconds before applying halogen/LED light (800-1200mW/cm2) (Valo Cordless, Ultradent) to the buccal and lingual/palatal surfaces for three seconds each.
62425121|NCT06564610|EXPERIMENTAL|Transversus abdominis block|Patients in this group will receive Transversus Abdominis block guided by the laparoscope at the beginning of surgery.
62593703|NCT06558747|EXPERIMENTAL|Device: Resin Cement|The inner surface of the crowns was treated with 'G-Multi Primer' using a brush and subsequently air-dried. The surfaces of the prepared teeth were treated with 37% orthophosphoric acid. The tooth surfaces were rinsed with an air-water spray to remove the acid from the surfaces. After the etching process, the 'G-Premio Bond' was applied to the teeth surfaces with a brush, rubbed for 10 seconds, and then air-dried for five seconds. Then the teeth were exposed to halogen/LED light (800-1200mW/cm2) (Valo Cordless, Ultradent) for 10 seconds. G-CEM Linkforce (GC, USA) resin cement was gently applied to crowns, and then crowns were pressed onto the prepared teeth with finger pressure.
62425122|NCT06564610|ACTIVE_COMPARATOR|Erector spinae block|Patients in this group will receive Erector Spinae block guided by the ultrasound after induction of anesthesia.
62425123|NCT02923115|EXPERIMENTAL|DS-1040b|Participants who are randomized to receive DS-1040b as a single, continuous intravenous infusion (initial loading dose 3-6 mg). All participants will also receive standard of care anticoagulation enoxaparin therapy during the study drug infusion.
62425124|NCT02923115|PLACEBO_COMPARATOR|Placebo|Participants who are randomized to receive placebo as a single, continuous intravenous infusion. All participants will also receive standard of care anticoagulation enoxaparin therapy during the study drug infusion.
62425125|NCT02637609||Likert Scale|Priority elicitation survey using a Likert scale method.
62425126|NCT02637609||Best-Worst Scaling (Case 1)|Priority elicitation survey using a best-worst scaling method.
62433631|NCT01878747|EXPERIMENTAL|P-TIPS group|Provider Tailored Intervention for Perioperative Stress (P-TIPS) aims at reducing preoperative anxiety in children via modifying adults' behavior.P-TIPS program is developed from the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors.
62234111|NCT06185647||All infants having the diagnosis of bronchiolitis|All patients visiting the PED for bronchiolitis. Comparison of those who received previously nirsevimab and those who did not.
62234112|NCT05302349|EXPERIMENTAL|Core Exercise Group|Core Exercise Group will performe core stabilization exercises and routine physiotherapy exercises.
62234113|NCT05302349|ACTIVE_COMPARATOR|Routine Therapy Group|Routine Therapy Group will performe routine physiotherapy exercises.
62234114|NCT01849484|EXPERIMENTAL|hippocampal sparing radiotherapy|Radiation according to indication with hippocampal sparing
62234115|NCT01849484|ACTIVE_COMPARATOR|Control|Radiation according to indication without hippocampal sparing
62234116|NCT04017728|ACTIVE_COMPARATOR|Conventional Percutaneous Vertebroplasty|The cement is injected after the successful puncture.
62593704|NCT06558747|EXPERIMENTAL|Device: Glass-ionomer cement|The capsule was attached to the mixer and mixed for 10 seconds. The cement was evenly distributed to the crowns paying attention that there were no air voids. Then crowns were placed by pressing them onto the prepared teeth with finger pressure.
62234117|NCT04017728|EXPERIMENTAL|Percutaneous Vertebroplasty with Rotary Cutter|The rotary cutter is applied to destroy the metastatic lesion before coment injection.
62425127|NCT06303882|EXPERIMENTAL|Computer-assisted Cognitive Function Training+routine rehabilitation treatment|In this study, each patient received a continuous 15-day treatment. During the treatment, both groups of patients received routine rehabilitation treatment. The experimental group additionally underwent computer-assisted cognitive training, which generated training content of corresponding difficulty based on the patient's cognitive impairment assessment results. The training was conducted seven days a week, once a day, for a duration of 30-45 minutes per session.
62425128|NCT06303882|ACTIVE_COMPARATOR|routine rehabilitation treatment+conventional cognitive training|In this study, each patient received a continuous 15-day treatment. During the treatment, both groups of patients received routine rehabilitation treatment.The control group was given conventional cognitive training.
62593705|NCT06558747|EXPERIMENTAL|Device: Resin-modified glass-ionomer cement|The cement was placed into the crown with the self-mixing syringe, ensuring no air voids were created. The crowns were then seated onto the teeth with finger pressure.
62234118|NCT04600232|EXPERIMENTAL|Diagnosis arm|Urine TB-LAM, sputum smear, Gene Xpert, mycobacterial culture
62234119|NCT01987141|EXPERIMENTAL|EMR intervention|Patients will have an electronic medical record popup/highlight in their chart, displaying the recommended guidelines for weight gain in pregnancy.
62234120|NCT01987141|NO_INTERVENTION|Control|The patient's medical record will be displayed as usual, with no flag or highlight for weight gain recommendations
62234121|NCT02719678|EXPERIMENTAL|Intervention group|Invitation to up to three general health checks over a 10-year period
62234122|NCT02719678|NO_INTERVENTION|Control group|Control group
62234123|NCT02265367|EXPERIMENTAL|Levomilnacipran|In the first three week period levomilnacipran is evaluated whereas in the second three week period placebo is evaluated
62234124|NCT02265367|EXPERIMENTAL|Placebo|In the first three week period placebo is evaluated whereas in the second three week period levomilnacipran is evaluated
62234125|NCT00442065|ACTIVE_COMPARATOR|Open label, single arm|A prospective, open label, single-arm (non-randomized) multi-center, international clinical device investigation to collect safety and performance data concerning the Aorfix™ Stent Graft System in the treatment of abdominal aortic aneurysm and aorto-iliac aneurysm where a significant degree of vessel angulation exists
62234126|NCT04742647|EXPERIMENTAL|Single Cerclage|Standard single cervical cerclage will be placed
62234127|NCT04742647|EXPERIMENTAL|Double Cerclage|Double cerclage placement
62234128|NCT01148966|EXPERIMENTAL|Treatment (photodynamic therapy)|Patients receive aminolevulinic acid PO 4 hours before undergoing surgery.
62234129|NCT04344600|EXPERIMENTAL|Peginterferon lambda alfa-1a|peginterferon lambda-1a (Lambda) 180 micrograms by subcutaneous injection for participants who are not infected with SARS-CoV-2
62433632|NCT01878747|NO_INTERVENTION|Control Group|Subjects in this group will not be trained with the P-TIPS method. They will receive a 2-hour seminar on the management of preoperative anxiety and postoperative pain and otherwise will provide standard care to patients.
62433633|NCT06527976|ACTIVE_COMPARATOR|dexmedetomidine|
62433634|NCT06527976|ACTIVE_COMPARATOR|dexamethasone|
62234130|NCT04344600|PLACEBO_COMPARATOR|Placebo|Placebo (saline) by subcutaneous injection for participants who are not infected with SARS-CoV-2
62234131|NCT02882113|EXPERIMENTAL|Expressor|CYP3A5 expressor; containing CYP3A5\*1 wild-type allele(\*1/\*1 type \& \*1/\*3 type) intervention: Advagraf conversion
62234132|NCT02882113|ACTIVE_COMPARATOR|Non-expressor|CYP3A5 non-expressor: without CYP3A5\*1 allele( \*3/\*3 type) intervention: Advagraf conversion
62234133|NCT01329965|EXPERIMENTAL|LPS|LPS will be injected at a dose of 0.6 ng/kg body weight through a catheter by a trained GCRC staff member involved with this study.
62234134|NCT01329965|PLACEBO_COMPARATOR|Saline|A saline solution will be injected through a catheter by a trained GCRC staff member involved with this study.
62234135|NCT06320613|ACTIVE_COMPARATOR|Experimental group acupuncture(snap-needle)|Patients in the acupuncture group received acupuncture therapy (snap-needle therapy) for 24 hours. Results of the study were collected at six assessment periods of 0-0.5 h, 0-1 h, 1-3 h, 4-6h, 6-12 h, and 12-24 h after anesthesia. Conducted by an independent researcher.
62234136|NCT06320613|ACTIVE_COMPARATOR|Experimental Ginger|Patients in the Ginger Acupuncture Point Patch group received ginger patch therapy and the ginger patch was removed within 6h. Study results were collected at six assessment periods of 0-0.5h, 0-1h, 1-3h, 4-6h, 6-12h, and 12-24h after anesthesia. Conducted by an independent researcher.
62234137|NCT06320613|ACTIVE_COMPARATOR|Experimental group Acupuncture combined with ginger|Patients in the Acupuncture combined with ginger group received acupuncture treatment (snap-needle therapy) combined with ginger compresses, which were removed within 6h and snap-needles were removed after 24 hours. Study results were collected at six assessment periods of 0-0.5h, 0-1h, 1-3h, 4-6h, 6-12h, and 12-24h after anesthesia. Conducted by an independent researcher.
62234138|NCT05105308|ACTIVE_COMPARATOR|Family Assisted Diet (FAD)|This is a 20-session intervention with a child and the child's parents that consists of helping parents set goals around their child's renourishment; consider barriers to implementing proposed plans; thinking through strategies to avoid barriers; and providing ongoing support for plan implementation.
62234139|NCT05105308|EXPERIMENTAL|Feeling and Body Investigator_ARFID Division (FBI-ARFID)|This is a 20-session intervention with a child and the child's parents that consists of 4 components: 1) psychoeducation of somatic body sensations and sensory features of foods using playful characters (e.g., Aftertaste Anthony); 2) in-session exercises that expose family members to different body and food sensations so they can learn something new about their body and food; 3) body brainstorm worksheets that help them generalize what they learn in session to outside of treatment; and 4) Decision-tree practice worksheets that help them map body sensations to meanings and actions and to track explorations with food.
62425129|NCT04591600|EXPERIMENTAL|Ivermectin-Doxycycline|Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard of care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.
62425130|NCT04591600|ACTIVE_COMPARATOR|Control|Control group: The patients in this group received only standard care which included all or some of the following, according to the clinical condition of each patient.
62234140|NCT01333163|ACTIVE_COMPARATOR|GLP-1|
62234141|NCT01333163|PLACEBO_COMPARATOR|Placebo|
62234142|NCT00991263||Group 1|Tissue blocks from CALGB-9344 and CALGB-9741 are utilized to purify RNA to be tested in the PAM50 assay (a 50-gene quantitative PCR assay, that provides an intrinsic breast cancer subtype diagnosis) and generate risk of relapse (ROR) scores. For more information, see Details section.
62234143|NCT02859532|EXPERIMENTAL|Diagnosis of deep vein thrombosis|All subjects with proximal DVT will have quantitative elastography SWIRE, thrombin generation test and rotational thromboelastometry test.
62425131|NCT02394431||Sickle cell disease patients|Sickle cell disease patients
62425132|NCT02394431||Healthy patients|This is the control group for the sickle cell disease patients: each sickle cell disease patient will be matched with a healthy patient of the same sex and of similar age.
62425133|NCT00179374|EXPERIMENTAL|1|Tailored telephone intervention plus mailed print educational materials
62234144|NCT05312788|PLACEBO_COMPARATOR|Whole wheat bread|Whole wheat bread will be used as control bread.
62593706|NCT04712019|EXPERIMENTAL|Closed Incision Negative Pressure Therapy (ciNPT) Dressing|Prevena Restor Arthro-Form Dressing with Prevena Plus Therapy Unit
62234145|NCT05312788|EXPERIMENTAL|Barley supplemented wheat bread|Barley supplemented wheat bread (50% substitution) will be used as experimental bread.
62593707|NCT04712019|ACTIVE_COMPARATOR|Standard Silver-containing Dressing|Standard silver dressing - standard of care at hospital
62810266|NCT01410942|PLACEBO_COMPARATOR|Exercise + Cognitive Therapy + Placebo|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill. Placebo capsules by mouth twice daily
62810267|NCT01410942|EXPERIMENTAL|Methylphenidate + Exercise + Cognitive Therapy|Methylphenidate starting dose 5 mg by mouth twice daily. Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
62810268|NCT03340389|EXPERIMENTAL|cataract surgery|cataract extraction and intraocular implantation
62810269|NCT02559102|EXPERIMENTAL|Dex Group|Intravenous dexmedetomidine sedation prior to single shot caudal anaesthesia and maintenance infusion of dexmedetomidine during bilateral inguinal hernia surgery.
62810270|NCT02559102|ACTIVE_COMPARATOR|GA Group|General sevoflurane anaesthesia with endotracheal intubation and single shot caudal anaesthesia for inguinal hernia surgery. This is currently the standard anaesthetic technique for bilateral inguinal hernia surgery in neonates and infants in KKH.
62234146|NCT01214187|EXPERIMENTAL|carbon monoxide inhalation|The primary intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
62234147|NCT01214187|PLACEBO_COMPARATOR|Oxygen 21%|
62810271|NCT05678179|EXPERIMENTAL|Telehealth|
62810272|NCT05678179|ACTIVE_COMPARATOR|In Person (Face-2-Face)|
62234148|NCT03501186|EXPERIMENTAL|Group 1|forward walking on leveled surface
62425134|NCT00179374|ACTIVE_COMPARATOR|2|print intervention with no telephone component
62810273|NCT06240637|ACTIVE_COMPARATOR|Telemonitoring group|Follow-up model adding telemonitoring with remote review of HMV data on a daily basis during the first 2 weeks and subsequently weekly up to 6 months. Telephone contact with the patient in case of any eventuality and timely adjustments to therapy. Patients will attend in-person follow-up visits at 2, 4, and 6 months after initiating HMV. Clinical and gasometric control, nocturnal pulse oximetry, questionnaires, and download of ventilator data. Timely adjustments to therapy.
62234149|NCT03501186|ACTIVE_COMPARATOR|Group 2|forward walking on sand.
62234150|NCT03501186|EXPERIMENTAL|Group 3|Backward walking on leveled surface
62234151|NCT03501186|ACTIVE_COMPARATOR|Group 4|Backward walking on sand.
62234152|NCT06191770|ACTIVE_COMPARATOR|Morphine Arm|NRS score used
62234153|NCT06191770|ACTIVE_COMPARATOR|Nalbuphine Arm|Both Groups
62425135|NCT02953132|EXPERIMENTAL|Single ascending dose, MT-4129 or Placebo|
62234154|NCT02027701|EXPERIMENTAL|IgPro20|20% liquid formulation (200 mg/mL) of human normal immunoglobulin for SC use administered SC weekly: 0.2 g/kg bw (low-dose IgPro20) for up to 48 weeks. Subjects who experience CIDP relapse on 0.2 g/kg IgPro20 will have an increase to 0.4 g/kg IgPro20 immediately and will continue on high-dose until they have completed a total of 48 weeks of IgPro20 treatment.
62593708|NCT02784613|EXPERIMENTAL|Ospemifene open label|60 mg ospemifene daily for 20 weeks
62593709|NCT05246059|NO_INTERVENTION|Control|12 weeks of observation, safety information provided
62593710|NCT05246059|EXPERIMENTAL|Treatment|12-weeks of daily olfactory training
62234155|NCT03211650|EXPERIMENTAL|hyaluronic acid + platelet-rich plasma|Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
62234156|NCT03211650|ACTIVE_COMPARATOR|platelet-rich plasma|Intra-articular injections of platelet-rich plasma
62425136|NCT02953132|EXPERIMENTAL|Multiple ascending dose, MT-4129 or Placebo|
62593711|NCT03983473|OTHER|Crohn's disease|Patients suffering from established Crohn 's disease without spondyloarthritis
62593712|NCT03983473|OTHER|Spondyloarthritis|Patients with established spondyloarthritis without Crohn 's disease
62234157|NCT03211650|ACTIVE_COMPARATOR|hyaluronic acid|Intra-articular injections of hyaluronic acid
62234158|NCT06389019||BLCA|patients with bladder cancer who had surgery like radical cystectomy or transurethral resection of bladder tumour (TURBT).
62234159|NCT00007917|EXPERIMENTAL|Arm I|"Patients receive gemcitabine IV over 1-2.5 hours on days 1 and 8 and flavopiridol IV continuously over 24 hours on days 2 and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of gemcitabine and flavopiridol until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
62234160|NCT04581616|ACTIVE_COMPARATOR|ICNB group|After patient was turned to lateral decubitus position, local anesthetics is injected around incision site and ICNB is performed once after surgeon geys into chest cavity.
62425137|NCT00552227|EXPERIMENTAL|1|
62425138|NCT00552227|PLACEBO_COMPARATOR|2|
62425139|NCT04349826|ACTIVE_COMPARATOR|Azithromycin+Cefixime|Azithromycin 20mg/kg/day oral dose once daily (maximum 1gm/day) AND Cefixime 20-30mg/kg/day oral dose in two divided doses (maximum 400mg bd) for 7 days.
62425140|NCT04349826|PLACEBO_COMPARATOR|Azithromycin+placebo|Azithromycin 20mg/kg/day oral dose once daily (Max 1gm/day) for 7 days AND Cefixime-matched placebo for 7 days.
62425141|NCT03967106|EXPERIMENTAL|Remote Ischaemic preconditioning|Remote IPC (RIPC) intervention daily for six weeks.
62425142|NCT03967106|SHAM_COMPARATOR|Sham|Remote sham intervention daily for six weeks.
62234161|NCT04581616|EXPERIMENTAL|ESPB group|After patient was turned to lateral decubitus position, ESPB is performed via ultrasound guided technique before sound incision.
62234162|NCT03740594|ACTIVE_COMPARATOR|KMC 60 min group|
62425143|NCT04529499|EXPERIMENTAL|favipiravir + supportive care|Frequency: Twice daily (morning and evening) Dosage Form: Tablets. Tablet Strength 200 mg. Dosage: 1,800 mg BID on Day 1 + 800 mg BID for next 9 days (maximum). On Day 1, the second dose will be administered with at least a 4-hour interval from administration of the first dose.
62425144|NCT04529499|PLACEBO_COMPARATOR|Placebo with Standard of Care|Frequency: Twice daily (morning and evening) Dosage Form: Tablets Dosage: 9 tablets for BID on Day 1 + 4 tablets BID for next 9 days (maximum). On Day 1, the second dose will be administered with at least a 4-hour interval from administration of the first dose.
62425145|NCT02374931|EXPERIMENTAL|Diagnostic (18F-FES PET/CT)|Patients undergo 18F-FES PET/CT imaging over 30 minutes.
62234163|NCT03740594|ACTIVE_COMPARATOR|KMC 120 min group|
62234164|NCT03740594|ACTIVE_COMPARATOR|control group|
62234165|NCT05394376|OTHER|Inside private quiet1, Inside public loud, Inside public quiet, Inside private quiet2|"The order of noise/environment for participants randomized to this arm will be:~Inside private quiet1, Inside public loud, Inside public quiet, Inside private quiet2"
62425146|NCT01459354||post, bimanual laryngoscopy, POGO score|one control, one study group
62425147|NCT01225237|EXPERIMENTAL|ramosetron group|
62425148|NCT01225237|PLACEBO_COMPARATOR|Placebo group|
62425149|NCT04981405||Patients hospitalised to clinics of First Pavlov State Medical University of Saint - Petersburg|450 cases - patients hospitalised with COVID-19 450 control - patients hospitalised without COVID-19 in the same period (surgical, oncological, cardiological, ophthalmologic, gastroenterological departments)
62425150|NCT04981405||Patients referred to Medical Institute named after Berezin Sergey for computed tomography|Cases - patients with pneumonia confirmed after computed tomography. Controls - patients without pneumonia after computed tomography.
62425151|NCT03355807|EXPERIMENTAL|Group MgSO4|The magnesium group (group Mg, n _ 40) received an additional infusion of MgSO4 (30 mg/kg by bolus and 10 mg/kg/h by infusion for 24 hours)
62425152|NCT03355807|NO_INTERVENTION|Group Control|the control group (group C, n _ 40) received the same amount of IV saline
62433635|NCT03447483|OTHER|Cohort of patients starting a treatment by ICI|
62433636|NCT03083054|EXPERIMENTAL|Patients|High Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia
62433637|NCT04465383|EXPERIMENTAL|Digital Sedation|Digital Sedation with rescue intravenous sedation (propofol) if needed upon patient request
62433638|NCT04465383|ACTIVE_COMPARATOR|Intravenous sedation|Control arm with conventional Intravenous sedation
62810274|NCT06240637|NO_INTERVENTION|Control group|Exclusive in-person follow-up model with control visits at 2 weeks, 1, 2, 4, and 6 months after initiating HMV. Clinical and gasometric control, nocturnal pulse oximetry, questionnaires, and download of ventilator data. Timely adjustments to therapy
62810275|NCT06510933|EXPERIMENTAL|Active Comparator: Heel Cup in muscle retraction|The pattern will be performed 3 times per day (10 repetitions, 30 seconds each repetition). A daily Active Comparator: Heel Cup Group The heel cup will be 5mm high (Eva Shore 65) en 3 month and 6 month.
62234166|NCT05394376|OTHER|Inside public loud, inside private quiet1, Inside public quiet, Inside private quiet2|"The order of noise/environment for participants randomized to this arm will be:~Inside public loud, inside private quiet1, Inside public quiet, Inside private quiet2"
62234167|NCT05394376|OTHER|Inside public loud, inside public quiet, inside private quiet1, inside private quiet 2|"The order of noise/environment for participants randomized to this arm will be:~Inside public loud, inside public quiet, inside private quiet1, inside private quiet 2"
62425153|NCT00712660|EXPERIMENTAL|A|In the active-ITAREPS group, the e-mail ALERT message feedback to the investigator will be activated. The core study intervention was 20% antipsychotic dose increase within 24 hours in response to a Pharmacological Intervention Requiring Event (PIRE) defined as either: A) the receipt of any INITIAL ALERT (IA) e-mail. A dose increase was obligatory in such cases regardless of the current clinical status of the patient; or B) the receipt of an ALERT EMERGENCY (AE) e-mail after which the investigator confirmed clinical worsening via phone contact with the patient. AE is defined as further worsening in EWSQ scores during 3 week period after announcement of IA.
62425154|NCT00712660|PLACEBO_COMPARATOR|TAU|In the treatment-as-usual study arm (control, non-active ITAREPS), the e-mail ALERT message feedback will not be activated. In this group, even in the presence of early warning sings, the investigators will be kept blinded to the EWSQ scores, will receive no ALERT message and thus no early pharmacologic intervention based on the ITAREPS program will be prompted. Treatment in the control group will consist of routine clinical and medication management with the frequency of visits common in the outpatient clinical settings. There will be no intevention based on ITAREPS.
62425155|NCT06016101||100 Patients|"* Socio-demographic data (age, gender, lifestyle, medication management aids)~* Medical data (number and type of medications)~* Variables for calculating assessment criteria:~\< Pill count: this is a simple way of estimating compliance with medication. The pharmacist will calculate the pill count. The remaining pills (not taken by the patient) are brought to the pharmacist, who then calculates them. The pill count is not used as part of routine care for Medipac beneficiaries.~\< The Morisky adherence questionnaire is an 8-item hetero-questionnaire used to measure adherence to treatment. It will be carried out by the home care nurse as part of routine care. The scores can be interpreted as follows: ≥ 8: good adherence; 6 to 7: average adherence; \< 6: poor adherence."
62433639|NCT01538030||Amniotic Fluid Volume > 5|Pregnant patients with gestations between 24-34 weeks with premature rupture of membranes that, when the decision was made to interrupt the pregnancy, had amniotic fluid volume index above 5.1
62433640|NCT01538030||Amniotic Fluid Volume < 5|Pregnant patients with gestations between 24-34 weeks with premature rupture of membranes that, when the decision was made to interrupt the pregnancy, had amniotic fluid volume index of 5 or less.
62033890|NCT06219759||ALS patients|"Patients enrolled prior to determination of diagnosis on referral to neurophysiological examination. When the diagnosis is later established they get categorized as ALS patients.~ALS patients with recent diagnosis might also be included directly."
62593713|NCT03983473|OTHER|Crohn + spondyloarthritis|Patients suffering from both spondyloarthritis and Crohn 's disease
62593714|NCT03983473|OTHER|Healthy controls|Patients without spondyloarthritis and Crohn 's disease
62810276|NCT05364671|EXPERIMENTAL|Raphamin|Tablet for oral use.
62810277|NCT05364671|PLACEBO_COMPARATOR|Placebo|Tablet for oral use.
62810278|NCT00751686||RV GE Group|
62810279|NCT05581602|EXPERIMENTAL|Hemiparetic post-stroke subjects|Stroke patients with motor sequelae in the upper limb.
62810280|NCT05581602|OTHER|Healthy subjects|Subjects without stroke.
62810281|NCT01570413|ACTIVE_COMPARATOR|Pelvic Exam|Subjects receive pelvic exam
62810282|NCT01570413|EXPERIMENTAL|No Pelvic Exam|Subjects do not receive pelvic exam
62810283|NCT06053853|EXPERIMENTAL|Investigational Product|"Diphtheria Antitoxin (DAT)~Administered intravenously.~Dosage:~* Mild diphtheria (nose, skin): 20,000 unit~* Moderate diphtheria (tonsil - limited): 40,000 - 60,000 unit~* Severe diphtheria (more than 1 tonsil, or to the pharyngeal wall, or more than 5 days of illness, or with bull neck): 80,000 - 120,000 unit"
62033891|NCT06219759||ALS mimic disease patients|Patients enrolled prior to determination of diagnosis on referral to neurophysiological examination. When diagnosis is later established and the diagnosis is NOT ALS they get categorized as ALS mimic disease patients.
62033892|NCT06219759||Healthy controls|Healthy controls.
62033893|NCT06219759||Disease controls|Patients with another motor neuron disease than ALS with slow progression.
62234168|NCT05394376|OTHER|Inside public quiet, inside public loud, inside private quiet1, inside private quiet2|"The order of noise/environment for participants randomized to this arm will be:~Inside public quiet, inside public loud, inside private quiet1, inside private quiet2"
62234169|NCT05394376|OTHER|Inside public quiet, inside private quiet1, inside public loud, inside private quiet2|"The order of noise/environment for participants randomized to this arm will be:~Inside public quiet, inside private quiet1, inside public loud, inside private quiet2"
62033894|NCT01766557|EXPERIMENTAL|Semi-controlled intervention with fish protein diet|Women with polycystic ovarian syndrome who are assigned to a 12 weeks experimental diet containing cod as the protein source.
62234170|NCT05394376|OTHER|Inside private quiet1, Inside public quiet, Inside public loud, inside private quiet2|"The order of noise/environment for participants randomized to this arm will be:~Inside private quiet1, Inside public quiet, Inside public loud, inside private quiet2"
62234171|NCT03588507|NO_INTERVENTION|Papilla preservation flap techniques|Papilla preservation flap techniques will be conducted to gain access to the intrabony defects. In the narrow interproximal spaces (≤2 mm), incision with the preservation of the buccal papilla according to the simplified papilla preservation technique will be applied. Whereas, in the wide interdental spaces (\>2 mm), the modified papilla preservation technique will be applied. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
62425156|NCT06016101||Healthcare professionals (20 doctors, 20 pharmacists and 20 nurses)|"* Socio-demographic data (age, gender, profession)~* Evaluation of the user experience using the SUS (Sytem usability scale) questionnaire. This is an easy-to-use Likert-type scale consisting of 10 questions. The aim is to assess the point of view of the person using the Medissimo nurse application, after having had the opportunity to use it. The questions offer quick answers, ranging from strongly disagree to strongly agree.~* Assessment of the monthly reports produced by the application for nurses, GPs and pharmacists. Using a Likert-type questionnaire, they will be asked to describe their satisfaction, and the beneficial or negative aspects of this application in relation to patient monitoring. The questionnaire consists of 12 questions, 10 of which offer the following 5 responses: Strongly agree; Agree; Neither disagree nor agree; Disagree; Strongly disagree, and 2 short-answer, open-ended questions."
62425157|NCT04385264|PLACEBO_COMPARATOR|Placebo|Placebo (Mannitol), oral capsules Day 0: 4 capsules PO OD Days 1-5: 2 capsules PO OD
62033895|NCT01766557|ACTIVE_COMPARATOR|Semi-controlled intervention with other animal proteins|Women with polycystic ovarian syndrome who are assigned to a 12 week experimental diet containing beef, pork, veal, eggs and milk products (BPVEM) as protein sources.
62033896|NCT01512225|EXPERIMENTAL|Domperidone for days 1 to 28|Domperidone maleate tablets 10 mg orally three times daily from days 1 to 28
62033897|NCT01512225|PLACEBO_COMPARATOR|Placebo for days 1 to 14 and domperidone for day 15-28|Identical placebo tablets 10 mg orally three times daily from days 1 to 14 followed by Domperidone maleate tablets 10 mg orally three times daily from days 15 to 28
62033898|NCT03886818|EXPERIMENTAL|PICO strategy|"* Use of PICO™ device from the ankle surgery to the post-surgery day 7.~* Use of usual care by simple dressings after post-surgery day 7 up to wound healing"
62033899|NCT03886818|ACTIVE_COMPARATOR|Standard of care|-Usual care by simple dressings after the ankle surgery until the wound healing.
62033900|NCT05046353|EXPERIMENTAL|D-serine|Subjects will receive 16 sessions of auditory remediation paired with either D-serine or Placebo in a 1:1 D-serine 120 mg/kg:placebo ratio.
62033901|NCT05046353|PLACEBO_COMPARATOR|placebo|Subjects will receive 16 sessions of auditory remediation paired with either D-serine or Placebo in a 1:1 D-serine 120 mg/kg:placebo ratio.
62033902|NCT04475913|ACTIVE_COMPARATOR|(CIG Axial)|received 4 axial implants and conventional impression
62033903|NCT04475913|EXPERIMENTAL|(DIG Axial)|received 4 axial implants and digital impression
62033904|NCT04475913|ACTIVE_COMPARATOR|CIG Tilted|received two anterior axial implants and two distal tilted implants, and conventional impression
62033905|NCT04475913|EXPERIMENTAL|(DIG Tilted)|received two anterior axial implants and two distal tilted implants, and digital impression
62033906|NCT00990158|ACTIVE_COMPARATOR|Low dose vitamin K + usual warfarin|Low dose oral vitamin K (0.150 mg orally once daily) + warfarin continuation with usual warfarin monitoring
62033907|NCT00990158|PLACEBO_COMPARATOR|Usual warfarin therapy + placebo|Patients continue usual warfarin and take one placebo per day
62033908|NCT02270450|EXPERIMENTAL|Arm I (randomized to surgery)|Patients undergo therapeutic conventional surgery (abdominal) as defined by the treating physician.
62033909|NCT02270450|EXPERIMENTAL|Arm II (randomized to non-surgical management)|Patients are offered gastrointestinal complications management/prevention (non-surgical management) as determined by the treating physician.
62425158|NCT04385264|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine 200mg (HCQ, Plaquenil), oral capsules Day 0: 800mg PO OD (4 capsules) Days 1-5: 400mg PO OD (2 capsules daily)
62425159|NCT05627349|EXPERIMENTAL|wrist splinting group|wrist splinting at night for 2 weeks
62593715|NCT04979195||Group 1|patients with stable renal function.
62033910|NCT02270450|EXPERIMENTAL|Arm III (no randomization, surgery)|Patients undergo therapeutic conventional surgery (abdominal) as defined by the treating physician as in Arm I.
62033911|NCT02270450|EXPERIMENTAL|Arm IV (no randomization, non-surgical management)|Patients are offered gastrointestinal complications management/prevention (non-surgical management) as determined by the treating physician as in Arm II.
62033912|NCT05714189|OTHER|Intervention group: adherence to Low FODMAP diet|Women could choose to adhere to the low FODMAP diet, over a period of six months. In the first three months, they received extensive guidance by a dietician in training, in addition to supportive materials such as the Monash app, recipes and grocery lists, in the hope of optimal adherence to the diet. After three months, women were asked to continue the diet independently. In addition, women were asked to complete three questionnaires, one every two months. The questionnaires contained the EHP-30, the GIQLI, and self composed questions on their demographics in the first questionnaire, and their strictness of adherence in the second and third questionnaire. The third questionnaire also contained questions on their satisfaction with the dietary guidance and the dietician in training.
62234172|NCT03588507|ACTIVE_COMPARATOR|PPF+NCHA bone graft substitute|intervention: papilla preservation flap techniques + nanocrystalline hydroxyapatite bone graft substitute Same surgical techniques and procedures will be performed. Before suturing the flap, nanocrystalline hydroxyapatite bone graft substitute(Dentaurum, Germany) will be placed within the defect up to the existing level of the alveolar crest and care will be taken not to overfill the defect. The mucoperiosteal flaps will be repositioned and secured in place using non-resorbable # 6-0-suturing material. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
62234173|NCT04147650|EXPERIMENTAL|0.05% Voclosporin Ophthalmic Solution (VOS)|0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
62234174|NCT04147650|EXPERIMENTAL|0.10% VOS|0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
62234175|NCT04147650|EXPERIMENTAL|0.20% VOS|0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
62234176|NCT04147650|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks
62234177|NCT01080677|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo to match caffeine/propranolol (single dose)
62033913|NCT05714189|OTHER|Intervention group: adherence to endometriosis diet|Women could choose to adhere to the endometriosis diet, over a period of six months. In the first three months, they received extensive guidance by a dietician in training, in addition to supportive materials such as the Monash app, recipes and grocery lists, in the hope of optimal adherence to the diet. After three months, women were asked to continue the diet independently. In addition, women were asked to complete three questionnaires, one every two months. The questionnaires contained the EHP-30, the GIQLI, and self composed questions on their demographics in the first questionnaire, and their strictness of adherence in the second and third questionnaire. The third questionnaire also contained questions on their satisfaction with the dietary guidance and the dietician in training.
62033914|NCT05714189|NO_INTERVENTION|Control group: no diet adherence|Women were asked to complete three questionnaires, once every two months. These contained the EHP-30 and GIQLI. The first questionnaire contained questions on their demographics, and whether they applied a diet before.
62234178|NCT01080677|EXPERIMENTAL|Low dose|Participants will receive caffeine/propranolol 400/40 mg combination tablet (single dose)
62425160|NCT05627349|EXPERIMENTAL|FSN group|The needle inserted at the midpoint of the anterior forearm of the affected side. Swaying movement (SM) frequency is 200 times in 2 minutes. Reperfusion approach (RA) was performed with slow repetitively grasping movement while SM. On the 1st, 2nd, and 4th days, three times of FSN treatment were arranged.
62033915|NCT00806312||1 PAH|Patients who are ≥ 18 years of age, not pregnant, and undergoing right heart catheterization for PAH diagnosis as part of their clinical care will be approached for consent and participation in this study.
62033916|NCT00806312||2. Control|Patients who present with symptoms of PAH and whose clinical right heart catheterization doesn't support this diagnosis will be enrolled as control subjects.
62234179|NCT01080677|EXPERIMENTAL|High dose|Participants will receive caffeine/propranolol 1000/40 mg combination tablet (single dose)
62234180|NCT04931186||all patients|
62234181|NCT01950026|EXPERIMENTAL|white|cryotherapy application
62234182|NCT01950026|EXPERIMENTAL|black|cryotherapy application
62234183|NCT01950026|EXPERIMENTAL|Brown|cryotherapy application
62234184|NCT01950026|EXPERIMENTAL|asian|cryotherapy application
62234185|NCT05824260||patients with complications|
62234186|NCT05824260||patients without complication|
62234187|NCT01959048|EXPERIMENTAL|fecal microbiota transplant|fecal microbiota transplantation
62234188|NCT05551585|EXPERIMENTAL|Real TPS treatment group|"1. Participants with MDD will receive TPS treatment lasting for 4 weeks (3 sessions per week).~2. A follow-up assessment will be scheduled 3 months after the last REAL treatment day.~3. MRI measurements will be conducted before the start of treatment (within one week before treatment start), as well as after the last treatment day (within one week post-treatment)"
62234189|NCT05551585|SHAM_COMPARATOR|Sham TPS treatment|"1. Participants will receive sham TPS treatment lasting for 4 weeks (3 sessions per week, as done previously.~2. After treatment end and completed assessments, the study will be unblinded and participants in the sham treatment arm will receive real TPS.~3. A follow-up assessment will be scheduled 3 months after the last REAL treatment day.~4. MRI measurements will be conducted before the start of treatment (within one week before treatment start), as well as after the last treatment day (within one week post-treatment),"
62234190|NCT01688856|EXPERIMENTAL|Arm+Hand CCFES|Uses an electrical stimulator that opens the paretic hand and extends the paretic elbow in response to and with an intensity proportional to movement of the contralateral arm and hand. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
62234191|NCT01688856|EXPERIMENTAL|Hand CCFES|Uses an electrical stimulator that opens the paretic hand in response to and with an intensity proportional to movement of the contralateral hand. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
62425161|NCT06521281|EXPERIMENTAL|qigong group|Patients in qigong group was given twice daily, every 15 minutes Chan-Chuang qigong
62593716|NCT04979195||Group 2|Patients who developed AKI.
62033917|NCT06004310|EXPERIMENTAL|Post-COVID-19 Patients|"Post-COVID-19 patients are individuals who have recovered from the acute phase of COVID-19 but continue to experience lingering symptoms and health challenges for weeks or even months after their initial infection. These individuals are often referred to as long haulers or post-acute sequelae of SARS-CoV-2 infection (PASC) patients. The symptoms experienced by post-COVID-19 patients can vary widely and may include fatigue, shortness of breath, chest pain, joint pain, cognitive difficulties, and more. Medical professionals and researchers are working to better understand and address these conditions, providing supportive care and rehabilitation to help these patients regain their health and well-being."
62033918|NCT05477745||The group that the sagittal flexion angle of the femoral component less than 4°|The patients' knees were taken on the X-ray examination after the total knee arthroplasty on the medial-lateral position. The flexion (positive degree) or extension (negative degree) angle of the femoral component according to the anterior femoral cortex was measured. The patients with the sagittal flexion angle of the femoral component less than 4° were categorized into this group.
62033919|NCT05477745||The group that the sagittal flexion angle of the femoral component over 4°|The patients' knees were taken on the X-ray examination after the total knee arthroplasty on the medial-lateral position. The flexion (positive degree) or extension (negative degree) angle of the femoral component according to the anterior femoral cortex was measured. The patients with the sagittal flexion angle of the femoral component over 4° were categorized into this group.
62033920|NCT02137369|ACTIVE_COMPARATOR|SSRI|Escitalopram, pill form, 20mg-40mg, daily, for 12 weeks or Sertraline, pill form, 50 - 150 mg, daily for 12 weeks
62033921|NCT02137369|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) CBT will include 16 1-hour sessions provided over 12 weeks.
62033922|NCT04871490|OTHER|Study Group|All eligible participants.
62033923|NCT05373251|EXPERIMENTAL|Whole genomic DNA/RNA tumour sequencing|All participants will undergo pre-radiotherapy fresh core biopsies of the tumour. DNA libraries will be created and stored for future analysis.
62033924|NCT00146835||Cohort A|The primary study cohort includes all infants from SCKP who have begun their primary course of vaccine with PEDIARIX co-administered with Prevnar and for whom at least one dose of PEDIARIX was administered prior to the infant's 9-month birthday and safety follow-up information is available.
62425162|NCT06521281|NO_INTERVENTION|control group|control group received the regular care for heart failure patients
62033925|NCT00146835||Cohort B|This Historical cohort includes age-, gender- and area-matched infants who received at least one dose of DTaP vaccine co-administered with 7Pn between 1 January 2002 and 29 April 2003.
62033926|NCT00146835||Cohort C|"This delayed Pediarix use clinics cohort includes all infants who, during the enrollment period for Cohort A, begin their primary course of vaccination with a DTaP vaccine co-administered with 7Pn. It is age-, gender-, and area-matched in a similar manner to Cohort B."
62033927|NCT01303666|ACTIVE_COMPARATOR|TI of the knee|
62425163|NCT03953911|ACTIVE_COMPARATOR|Control: Mobile Clinic Only|The middle school assigned to the control arm will receive a visit by a mobile clinic every 6 months only. The school will follow normal protocol for HPV vaccination awareness. Parents will be made aware of the mobile clinic per normal school newsletters and mailers.
62033928|NCT01303666|ACTIVE_COMPARATOR|Intra-articular CSI|
62033929|NCT06093113|EXPERIMENTAL|Intervention group|"Participants will complete a web based pre-assessment and then be given access to the app Alba for two months followed by a web based post-assessment including questions regarding their experiences of using the app, and follow-up questionnaires."
62033930|NCT06093113|ACTIVE_COMPARATOR|Control group|Participants will get access to a website containing information about grief and grief reactions.
62033931|NCT05230238|EXPERIMENTAL|pituitary stimulation|Patients will receive pituitary stimulation as oncology pain treatment.
62433641|NCT05049889|ACTIVE_COMPARATOR|History of Immersion Pulmonary Edema|"The participants will have 2 visits:~At visit 1 (Day 0), the participants will perform a terrestrial exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected.~At visit 2 (Day 7), the participants will perform a swimming exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected."
62033932|NCT01297062|EXPERIMENTAL|Exenatide|
62033933|NCT01297062|PLACEBO_COMPARATOR|Placebo|
62033934|NCT01297062|ACTIVE_COMPARATOR|Moxifloxacin|
62033935|NCT04764396|EXPERIMENTAL|Heparin priming biopsies|
62033936|NCT04764396|ACTIVE_COMPARATOR|Standard of care (saline)|
62033937|NCT01454583||Aliskiren|Patients getting Aliskiren at baseline
62033938|NCT01454583||ACE-I/ARB|Patients getting ACE-I (angiotensin-converting enzyme inhibitors) or ARB (angiotensin-receptor blockers) at baseline, but not Aliskiren
62033939|NCT01454583||No RAS-inhibition|Patients getting no drugs at baseline that inhibit the renin-angiotensin-aldosterone-system (RAAS)
62033940|NCT06300008|EXPERIMENTAL|cetylated fatty acid|Topical cetylated fatty acid, apply 2 times/day for 6 weeks after operation
62425164|NCT03953911|EXPERIMENTAL|Mobile Clinic plus Educational Sessions|The middle school assigned to the Mobile Clinic every 6-mos or month plus Educational Sessions arm will receive visitation of a mobile clinic providing free HPV vaccination among other school-related vaccines once every 6-months or once a month. Parents will be made aware of the mobile clinic per normal school newsletters and mailers. In addition, parents will be provided with free weekly educational sessions about the HPV Vaccine as a cancer-prevention effort.
62810284|NCT00414635|OTHER|Control Arm with Week 24 Crossover|Subjects randomized to the control arm will remain on daily dosing of the pre-study regimen of 600mg efavirenz and 1 coformulated tablet of 300mg tenofovir df + 200 mg emtricitabine by mouth daily, or the equivalent coformulated single tablet of 600mg efavirenz + 300mg tenofovir df + 200 mg emtricitabine by mouth daily for 24 weeks. After 24 weeks of daily therapy subjects on this arm may be eligible to cross over to the experimental arm regimen of the coformulated single tablet of 600 mg efavirenz +300 mg tenofovir df +200 mg of emtricitabine on the 5/2 intermittent dosing treatment schedule for the remainder of the study.
62810285|NCT00414635|EXPERIMENTAL|5/2 Intermitent Treatment Arm|Subjects randomized to the 5/2 intermittent dosing treatment schedule regimen will be prescribed the pre-study regimen of 600mg efavirenz and 1 coformulated tablet of 300mg tenofovir df + 200 mg emtricitabine by mouth daily, or the equivalent coformulated single tablet of 600mg efavirenz + 300mg tenofovir df + 200 mg emtricitabine by mouth daily, for 5 consecutive days per week followed by 2 days off of these medications, 600 mg efavirenz, 300 mg tenoforvir dt and 200 mg emtricitabine, for 48 weeks.
62810286|NCT04834817|EXPERIMENTAL|LED treatment|LED treatment with Celluma POD device after laser test area
62810287|NCT04834817|NO_INTERVENTION|Control|No treatment after laser test area
62810288|NCT02344108|EXPERIMENTAL|Inspire® Upper Airway Simulation System|Subjects meeting inclusion criteria, including sleep study and drug induced sleep endoscopy criteria, will undergo surgical placement of a hypoglossal nerve simulator (Inspire® Upper Airway Simulation System Model 3028 IPG). The simulator will be activated one month after surgery and subjects will undergo repeat sleep study evaluation and device titration at one, two, six and twelve months after implantation. Subjects will be followed for one year to determine safety and efficacy of the device.
62810289|NCT02211053|ACTIVE_COMPARATOR|Levothyroxine|Levothyroxine infusion 20 mg IV bolus then 10 mg/h infusion
62810290|NCT02211053|PLACEBO_COMPARATOR|Placebo|Infusion matched to intervention arm
62593717|NCT01154296|EXPERIMENTAL|Rapid HIV Testing w/ Counseling (Group 1)|Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.
62810291|NCT00466232|EXPERIMENTAL|1|Weekly Topetecan in combination with Sorafenib
62810292|NCT04580355|EXPERIMENTAL|FMUD + Placebos|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus placebo administration prescribed on the day of treatment, every 8 hours for 7 days.
62810293|NCT04580355|ACTIVE_COMPARATOR|FMUD + AM|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus 500 mg Amoxicillin and 250 mg Metronidazole (AM) prescribed on the day of treatment, every 8 hours for 7 days.
62810294|NCT04296656|ACTIVE_COMPARATOR|Intervention group|"Mothers in the intervention group were taught the infant calming technique 5 S's, a part of The Happiest Baby (THB) method. THB is based on the theory that infants have an innate calming reflex that can soothe infant fussing, excessive crying and prolong sleep. This reflex is triggered by five activities that mimic the sensory milieu of the womb. The 5 S's include swaddling, side position, sound (white noise), swing and suck.~The intervention consisted of a 20-minute face-to-face guidance session with the researcher, executed individually in the mother's hospital room. Each mother was given a leaflet to take home that explained the 5 steps in short. Safety issues, such as safest sleep position (supine), allowing hips to flex and how to avoid overheating when swaddled, were addressed. The same researcher executed each guidance session to maintain standardization."
62810295|NCT04296656|NO_INTERVENTION|Control group|Standard care on postpartum ward (breastfeeding and infant care guidance and support in recovering from childbirth and transitioning into parenthood).
62810296|NCT03623243|EXPERIMENTAL|Siponimod|"Participants will receive titrated doses of siponimod tablets, orally, once daily of 0.25 mg on Day 2, 0.5 mg on Day 3, 0.75 mg on Day 4, 1.25 mg on Day 5, and maintenance dose of siponimod 2.0 mg tablets, orally, once daily from Day 6 up to 6 months.~As of protocol amendment 3, participants entering the trial converting from fingolimod will start directly with 2 mg dose of siponimod."
62810297|NCT01985295|OTHER|cohort|"Dose level Dose of pazopanib orally, once daily, # patients -1 200 mg --~1. (starting) 400 mg 3~2. 600 mg 3~3. (maximum) 800 mg 3"
62810298|NCT02022137|EXPERIMENTAL|Red cereal bar|It includes the intervention of the red cereal bar for the designation of the group.
62033941|NCT06300008|PLACEBO_COMPARATOR|Placebo|Topical placebo, apply 2 times/day for 6 weeks after operation
62033942|NCT06670716||Patients with schemic or hemorrhagic CVA|Patients admitted to the monitored bed of the neurological ICU for ischemic or hemorrhagic CVA, with the possibility of an initial examination within 24 hours of admission (not the onset of CVA), and with an anticipated length of hospitalization longer than five days, will be included in the study.
62033943|NCT00735046||1|Intervention
62425165|NCT04207554||Pregnancy Positive|Pregnant subjects within 11 weeks since the first day of last period.
62033944|NCT00735046||2|control
62033945|NCT04669496|EXPERIMENTAL|Neoadjuvant treatment|"1. Gemox chemotherapy D1 Oxaliplatin 85mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 3 courses.~2. Lenvatinib (8mg/d) for 9 weeks of continuous use.~3. Toripalimab (240 mg, once every 3 weeks), used 3 times in a row. All patients undergoing resection use capecitabine 2500mg/m2 twice a day for 2 weeks, stopping for 1 week as a course of treatment, totaling 8 courses."
62425166|NCT04207554||Pregnancy Negative|Non-pregnant subjects.
62425167|NCT01885507||Control phase (before)|Process of care and outcomes before the educational program
62810299|NCT02022137|PLACEBO_COMPARATOR|Green cereal bar|It includes the intervention of the green cereal bar for the designation of the group.
62810300|NCT02022137|ACTIVE_COMPARATOR|White cereal bar|It includes the intervention of the white cereal bar for the designation of the group.
62810301|NCT03494868|NO_INTERVENTION|Fasting|Fasting prior to elective cesarean section delivery (standard of care)
62593718|NCT01154296|NO_INTERVENTION|Rapid HIV Testing & Information Only (Group 2)|Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.
62425168|NCT01885507||Training phase (after)|"Process of care and outcomes after the educational program which recommends:~* the use of tidal volume \< 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)~* extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough"
62593719|NCT05763394|EXPERIMENTAL|Polarized workout|
62593720|NCT05763394|EXPERIMENTAL|High intensity workout|
62593721|NCT06618391|EXPERIMENTAL|Envafolimab|Envafolimab 150 mg Q3W (maximum 2 cycles of intratumoral therapy) was injected intratumorally on days 1 and 8, combined with chemotherapy + Recombinant human endostatin Q3W for 4-6 cycles;
62593722|NCT06618391|EXPERIMENTAL|Recombinant human endostatin|Intratumoral injection of Recombinant human endostatin15mg Q3W (maximum 2 cycles of intratumoral therapy) on Days 1 and 8; combined chemotherapy + Enbrelizumab Q3W for 4-6 cycles.
62593723|NCT06618391|EXPERIMENTAL|Recombinant human adenovirus type 5|1.0 ml of recombinant human adenovirus type 5 injected intratumorally on days 1 and 8, Q3W (maximum 2 cycles of intratumoral therapy); combined chemotherapy + envolumab, Q3W, 4-6 cycles of treatment.
62593724|NCT02059668||Biomarker analyses head & neck cancer tissue, blood specimen|Validation of prognostic biomarkers for local tumor control in definitive and adjuvant treatment of head and neck cancer.
62593725|NCT06010238|ACTIVE_COMPARATOR|Visual interpretation of cardiotocography|Monitoring by visual interpretation of cardiotocography
62593726|NCT06010238|EXPERIMENTAL|Short term variation|Short term variation by computer software analysis
62593727|NCT06667323|EXPERIMENTAL|Integrated health service delivery for very young adolescent girls|The intervention will be implemented in four non-randomly selected districts (woreda) in the Oromia, Sidama, and Somali regions of Ethiopia: Gomma, Sokoru, Hawella, and Owbare. In intervention areas, the intervention (a complex, supply- and demand-side implementation model with the primary objective of increasing access to HPV vaccination and other health services for very young adolescent girls \[aged 9-14 years\]) will be developed in the study's phase 1, a rapid formative phase. It is anticipated that the intervention will include supply- and demand-side components, such as household mobilization by community health workers through Ethiopia's Health Extension Program, strengthened linkages between households and community-based health posts, and routinized HPV and adolescent health service delivery in communities at the health post level.
62593728|NCT06667323|NO_INTERVENTION|Standard of care|Four non-randomly selected districts (woreda) in the Oromia, Sidama, and Somali regions of Ethiopia have been selected as concurrent comparison areas: Dedo, Gera, Teticha, and Dembel. These areas will conduct HPV vaccination (and any other adolescent health service delivery) through the standard-of-care procedures.
62593729|NCT02993952|ACTIVE_COMPARATOR|Active stimulation|A constant current (anodic) of 2mA will be applied for 20 minutes on the Primary motor cortex.
62593730|NCT02993952|SHAM_COMPARATOR|Sham stimulation|A constant current (sham) of 2mA will be applied, but the stimulator will be turned off after 30 seconds on the Primary motor cortex.
62593731|NCT03005275|OTHER|IVM|"* FSH injection: Day 9, 10 and 11 (can be adjusted 1-3 days before or after to avoid Ultrasound and OPU on holidays). Dose: normally 100 IU/day (maybe 75 - 150 IU/day).~* Follicle and endometrium can be evaluated: on the day of final injection or one day later.~* hCG 10.000 IU: one day after the final FSH injection, at 9 p.m. Can be adjusted HCG injection day (± 1-2 days) to avoid Ultrasound and OPU on vacation.~* OPU: 1,5 day after hCG injection (normally 36-42 hours later).~* Sperm collection: on OPU day (if mature follicle presents) or 1 day after OPU day.~* Embryo transfer: 3 days after OPU.~* Luteal support: progesterone gel (90 mg once daily) intra-vaginally and estradiol (4 mg/day PO, twice daily) initiated on the day of OPU or the day thereafter."
62593732|NCT03005275|OTHER|ICSI|"Daily SC injections with rFSH (minimum starting dose is around 150 IUI) are started on On day 2 or day 3 of the menstrual cycle (Stimulation Day 1) and continue up to and including Stimulation Day 7.~From Stimulation Day 8 onwards, subjects from ICSI treatment groups will continue with a daily SC dose of rFSH up to the day before GnRH agonist day. The maximum rFSH dose to continue treatment after the first 7 days is 300 IU but the dose could be adjusted when desired.~As soon as three follicles of 17mm are observed by USS at least, a GnRH agonist (Triptorelin 0.2 mg) will be used for final oocyte maturation at the same day. About 34-36 h thereafter, OPU followed by ICSI is performed. Two days after oocyte pick-up 2 fresh embryos will be transferred."
62593733|NCT06473454|EXPERIMENTAL|the group of aerobic exercise|This group will walk 4 days a week along with high-intensity interval training. Evaluations will be made before and after.
62593734|NCT06473454|EXPERIMENTAL|the group of basic body awareness therapy|This group will do basic body awareness exercises once a week, accompanied by a physiotherapist, and on the other days they will do it themselves. Evaluations will be made before and after.
62593735|NCT06473454|NO_INTERVENTION|the group of control|This group will be evaluated only before and after the study.
62593736|NCT00654992|ACTIVE_COMPARATOR|EPO group|
62593737|NCT00654992|PLACEBO_COMPARATOR|Placebo group|
62425169|NCT00902252|EXPERIMENTAL|Usual/Natura®/Vitala™|All subjects will wear usual product for 21 days, followed by Natura® for 14 days and followed by Vitala™ for 159 days.
62593738|NCT01813253|EXPERIMENTAL|Irinotecan and nimotuzumab|Adminitration of irinotecan 150 mg/m2 IV once every 2 weeks and nimotuzumab 400 mg IV once weekly
62425170|NCT03276962|EXPERIMENTAL|R012-20 Group|Participants will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and at Month 20.
62593739|NCT01813253|ACTIVE_COMPARATOR|Irinotecan|Administration of irinotecan 150 mg/m2 IV once every 2 weeks
62593740|NCT04638946|EXPERIMENTAL|Titration to high intensity exercise|
62593741|NCT04638946|ACTIVE_COMPARATOR|Low intensity exercise|
62593742|NCT04866940|EXPERIMENTAL|Sequence validation|This research aims to provide a generic framework to test the feasibility of MRI sequences requested as part of protocols, but also to optimize MRI acquisition sequences already in place, to improve image quality and reduce artifacts that can degrade the quality of images obtained.
62593743|NCT01354743|OTHER|Dysport|Dysport injections into the glabella and orbicularis oculi muscles with dose based on muscle mass
62593744|NCT05988463|EXPERIMENTAL|Artesunate|
62810302|NCT03494868|EXPERIMENTAL|Carbohydrate Drink|Subjects will drink 2 carbohydrate drinks prior to elective cesarean section delivery
62425171|NCT03276962|EXPERIMENTAL|R012-14-mD Group|Participants will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and yearly full doses at Month 14, Month 26 and Month 38.
62810303|NCT05473988||Admission to General Ward Positive|Admission to General Ward Positive
62425172|NCT03276962|EXPERIMENTAL|Fx012-14-mFxD Group|Participants will receive a full dose of RTS,S/AS01E at Month 0 and Month 1, and RTS,S/AS01E 1/5th dose at Month 2 and yearly fractional doses at Month 14, Month 26 and Month 38.
62033946|NCT04669496|NO_INTERVENTION|Traditional group|No anti-tumor drug treatment before surgery. All patients after resection use capecitabine 2500mg/m2 twice a day for 2 weeks, stopping for 1 week as a course of treatment, a total of 8 courses.
62033947|NCT03385837||Heart Failure Patients|Cardiac Rehabilitation in Advanced Heart Failure Patients
62033948|NCT01780922|ACTIVE_COMPARATOR|Low Calorie Cranberry Juice Cocktail|Beverage containing cranberry: one dose of 15.2 ounces consumed within 15 minutes
62033949|NCT01780922|ACTIVE_COMPARATOR|Cranberry Extract Beverage|Beverage containing cranberry: one dose of 15.2 ounces consumed within 15 minutes
62425173|NCT03276962|EXPERIMENTAL|Fx017-mFxD Group|Participants will receive a full dose of RTS,S/AS01E at Month 0 and Month 1, and RTS,S/AS01E 1/5th dose at Month 7 and yearly fractional doses at Month 20 and Month 32.
62425174|NCT03276962|EXPERIMENTAL|Control Group|Participants will receive rabies vaccine at Month 0, Month 1 and Month 2.
62425175|NCT05114018|EXPERIMENTAL|Experimental group receiving pasteurized Akkermansia muciniphila|Experimental group receiving pasteurized Akkermansia muciniphila.
62033950|NCT01780922|PLACEBO_COMPARATOR|Non-Cranberry Beverage|Beverage absent cranberry: one dose of 15.2 ounces consumed within 15 minutes
62033951|NCT04486352|EXPERIMENTAL|Atezolizumab and Bevacizumab Cohort|Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with no specified gene signatures will be enrolled in this cohort. Twenty participants will be enrolled. Once twenty participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
62033952|NCT04486352|EXPERIMENTAL|Atezolizumab and Ipatasertib Cohort|Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with PIK3CA/AKT1/PTEN-altered tumors will be enrolled in this cohort. Twenty participants will be enrolled. Once twenty participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
62033953|NCT04486352|EXPERIMENTAL|Atezolizumab and Talazoparib Cohort|Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with tumors that have a ≥16%genomic loss of heterozygosity (LOH) will be assigned to this cohort. Twenty participants will be enrolled. Once twenty participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
62234192|NCT01688856|ACTIVE_COMPARATOR|Arm+Hand Cyclic NMES|Uses an electrical stimulator that delivers stimulation to open the hand and extend the elbow repeatedly with preprogrammed timing and intensity. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
62234193|NCT04038593|NO_INTERVENTION|Non interventional arm|Standard conditions of complex dressing cares, without experimental intervention. It will be a control intervention
62234194|NCT04038593|ACTIVE_COMPARATOR|Comparative arm with relaxation music from Youtube©|Standard conditions of complex dressing cares + use of non standardized music relaxation during complex dressing cares
62425176|NCT05114018|PLACEBO_COMPARATOR|Control group|Control group receiving placebo, identical to verum regarding the form, size, taste, color and intake.
62425177|NCT02225028|ACTIVE_COMPARATOR|Physical Activity Counseling|Participants who are randomized to the physical activity counseling intervention group will work with a physical activity coach over the course of 6 months to come up with a physical activity program that works for each individual. Participants will have 16 phone calls and discuss goals and values, track physical activity, troubleshoot barriers, and work on keeping exercise interesting and motivating. Participants will also learn strategies for managing stress and battling unhelpful thoughts that may get in the way of activity. By the end of the intervention, the goal is to be regularly doing 150 minutes of physical activity each week. The physical activity coach will work with participants to ensure that they are increasing activity safely in order to prevent injuries.
62810304|NCT05473988||30 Day Mortality Positive|30 Day Mortality Positive
62810305|NCT05473988||Admission to Intensive Care Unit Positive|Admission to Intensive Care Unit Positive
62810306|NCT05473988||Admission to General Ward Negative|Admission to General Ward Negative
62810307|NCT05473988||30 Day Mortality Negative|30 Day Mortality Negative
62810308|NCT05473988||Admission to Intensive Care Unit Negative|Admission to Intensive Care Unit Negative
62810309|NCT01405768|ACTIVE_COMPARATOR|Lidocaine Arm|Women in this arm will receive plain lidocaine with epinephrine injected into their cervix prior to the LEEP procedure.
62033954|NCT04486352|EXPERIMENTAL|Atezolizumab and Trastuzumab emtansine (TDM-1) Cohort|Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with tumors that with an amplification of ERBB2/HER2 will be assigned to this cohort. Twenty participants will be enrolled. Once twenty participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
62234195|NCT04038593|EXPERIMENTAL|Interventional arm with MUSIC CARE©|Standard conditions of complex dressing cares + administration of a specific music therapy program (U method) delivered through headphones from a tablet, under the direction of trained nurses.
62234196|NCT00617032|ACTIVE_COMPARATOR|1|1x10\^10 DRP/mL tgAAC94
62234197|NCT00617032|ACTIVE_COMPARATOR|2|1x10\^11 DRP/mL tgAAC94
62425178|NCT02225028|NO_INTERVENTION|Usual Care|Participants randomized to the usual care control group will receive a packet of exercise related-information at the end of the baseline assessment as well as a letter from study staff informing them of their randomization status and their test results. The letter will provide information on biological markers that are in the at-risk range, advice to seek medical advice regarding lifestyle changes such as diet and exercise and information on how to contact study staff regarding test results. We will offer to forward test results to their health care provider provided they furnish written release of information We will emphasize our interest in providing them with a follow-up assessment in 6 months.
62425179|NCT03828201|EXPERIMENTAL|Investigational: DRAMATIC-16 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 16 weeks levofloxacin 1000 mg PO QD, 16 weeks clofazimine 100 mg PO QD, 16 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 600 mg PO QD, Initial 16 weeks only
62593745|NCT06217575|ACTIVE_COMPARATOR|Visual Attention Training|Visual attention training is at the core of well-known training programs such as useful field of view (UFOV) training. The adapted nature of the computerized training approach affords individual differences in performance at the training outset while evaluating gains using specified performance criteria. Training parameters (duration of stimulus presentation for processing speed) are adjusted based on accuracy.
62033955|NCT04486352|EXPERIMENTAL|Atezolizumab and Tiragolumab Cohort|Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with tumor type MSI-H and/or tTMB \>=10 mut/mb will be assigned to this cohort. Twenty participants will be enrolled initially. Once twenty participants are enrolled, the cohort may be expanded if a positive signal is shown. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
62234198|NCT00617032|PLACEBO_COMPARATOR|3|Single dose tgAAC94 placebo
62234199|NCT05658874|EXPERIMENTAL|Multimodal care bundle|"Components of multimodal care bundle~1. MD Evaluation~2. On site pelvic floor physical therapy~3. Behavioral health consult with appropriate psychiatric referrals/treatments~4. Central sensitization/neurogenic pain:~   Amitriptyline 10-50mg Or Gabapentin (doses range from 100mg po tid to 600mg po tid)~5. Urinary symptoms IC/PBS:~   Spasm: Overactive bladder medication chosen based on patient characteristics/insurance, dose may be increased as tolerated (Oxybutynin/Trospium/Detrol vs. Mirabegron)~6. Microbiome: Methenamine~7. Vaginal estrogen~   At least once within 12 weeks of initial visit:~8. Operative cystoscopy~9. Bladder instillations x 6 weeks (lidocaine, heparin, sodium bicarb, Kenalog, gentamicin)~10. Pudendal/Levator and/or Obturator internus nerve block (120mg Kenalog and 0.25% Marcaine, total 23cc)"
62234200|NCT05658874|ACTIVE_COMPARATOR|Usual care|IC/PBS treatments as directed by Urogynecology specialist
62234201|NCT02257879||Sequence A|water - GFJ - supplement
62234202|NCT02257879||Sequence B|GFJ - supplement - water
62234203|NCT02257879||Sequence C|supplement - water - GFJ
62425180|NCT03828201|EXPERIMENTAL|Investigational: DRAMATIC-24 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 24 weeks levofloxacin 1000 mg PO QD, 24 weeks clofazimine 100 mg PO QD, 24 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 600 mg PO QD, Initial 16 weeks only
62425181|NCT03828201|EXPERIMENTAL|Investigational: DRAMATIC-32 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 32 weeks levofloxacin 1000 mg PO QD, 32 weeks clofazimine 100 mg PO QD, 32 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 600 mg PO QD, Initial 16 weeks only
62425182|NCT03828201|EXPERIMENTAL|Investigational: DRAMATIC-40 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 40 weeks levofloxacin 1000 mg PO QD, 40 weeks clofazimine 100 mg PO QD, 40 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 600 mg PO QD, Initial 16 weeks only
62425183|NCT01891188||Cardiac Cath|All pediatric patients requiring cardiac catheterization who consent
62425184|NCT06120179|EXPERIMENTAL|Patients who present with PE|The Bashir™ Endovascular Catheter (BEC) is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature. Two sizes of BECs will be used in this study
62425185|NCT02151396|EXPERIMENTAL|Cogmed Working Memory Training|Cogmed (TM) working memory training following standard, recommended administration procedures
62425186|NCT01462474|EXPERIMENTAL|Drug: Famitinib|
62425187|NCT05418257||Usual-Outpatients with Epilepsy|Patient who received treatment at Samsung Medical Center more than twice for epilepsy
62425188|NCT05418257||Tele-Outpatients with Epilepsy|Patient who received telemedicine at the time of recruitment and treatment at Samsung Medical Center more than twice for epilepsy
62234204|NCT00261001|EXPERIMENTAL|Transcutaneous|
62234205|NCT00261001|ACTIVE_COMPARATOR|Intramuscular|
62234206|NCT05138913|EXPERIMENTAL|Study group|Arthroscopic treatment with TXA injection
62234207|NCT05138913|PLACEBO_COMPARATOR|Control group|Arthroscopic treatment with normal saline injection
62234208|NCT01701596|EXPERIMENTAL|Rotational atherectomy (RA)|Immediate rotational atherectomy (RA) in the treatment with nondilatable calcified lesion complicated by coronary dissection
62234209|NCT01701596|ACTIVE_COMPARATOR|Delayed rotational atherectomy (RA)|Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
62234210|NCT02430974|NO_INTERVENTION|Chemotherapy|patients received four cycles of platinum-based doublet chemotherapy (150 mg/m2 paclitaxel plus 80 mg/m2 nedaplatin or 30mg/m2 lobaplatin on day one of a three-week cycle).
62425189|NCT02484235|EXPERIMENTAL|Group HIIT|Only Aerobic Training with HIIT
62425190|NCT02484235|EXPERIMENTAL|Group Strength|Only Strength Training
62425191|NCT02484235|EXPERIMENTAL|HIIT and Strength|Both intervention HIIT and Strength training
62425192|NCT04924114|EXPERIMENTAL|MK-6194|Participants will be enrolled in sequential cohorts treated with successively higher doses of MK-6194 via subcutaneous injection.
62593746|NCT06217575|EXPERIMENTAL|Alpha Neurofeedback training|Electroencephalogram (EEG) based neurofeedback (NFB) is a method in which brain activity is modulated via self-induced increases or decreases in the power of selected EEG frequency bands. The subject's control over his or her EEG activity is mediated with visual feedback. We will employ alpha neurofeedback training to examine how this conditioning paradigm may improve visual attention.
62593747|NCT02202993|EXPERIMENTAL|Mibefradil with Radiation|"Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.~This will be given concurrently with hypofractionated radiation therapy."
62593748|NCT05024097|EXPERIMENTAL|Radiation therapy and etrumadenant (AB928)|Enrolled patients will receive Radiation therapy of 25 Gy in 5 fractions along with etrumadenant 150mg oral drug taken once daily. this will then be followed by 9 cycles of FOLFOX in combination of etrumadenant and zimberelimab investigational drugs.
62234211|NCT02430974|EXPERIMENTAL|Chemotherapy & Icotinib|patients received four cycles of platinum-based doublet chemotherapy (150 mg/m2 paclitaxel plus 80 mg/m2 nedaplatin or 30mg/m2 lobaplatin on day one of a three-week cycle).Two weeks after chemotherapy completed, patients assigned to the consolidation therapy group began oral icotinib treatment (125 mg, thrice daily). Icotinib treatment continued for four to eight months, or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity.
62593749|NCT02918435|NO_INTERVENTION|Usual Care-Control|Participants in the usual care group will receive standard pediatric care.
62425193|NCT04924114|PLACEBO_COMPARATOR|Placebo|Participants will receive MK-6194-matching placebo via subcutaneous injection.
62425194|NCT06008639|ACTIVE_COMPARATOR|treatment group|active setting
62593750|NCT02918435|EXPERIMENTAL|On-site WE CARE implementation arm|"WE CARE will be implemented in the study site using a facilitated on-site strategy. 1. Participants will receive the WE CARE survey at health supervision visits; this survey will be used to identify unmet material needs. 2. Providers will be trained on WE CARE via an on-site team which will teach them how to review the survey and provide referrals (community resource information sheets) from a Family Resource Book located in each exam room."
62593751|NCT02918435|EXPERIMENTAL|Self-directed web-based WE CARE implementation arm|WE CARE will be implemented in the study site using a web-based implementation strategy. 1. Participants will receive the WE CARE survey at health supervision visits; this survey will be used to identify unmet material needs. 2. Providers will be trained on WE CARE via web-based tools (e.g., web-based seminar) which will teach them how to review the survey and provide referrals (community resource information sheets) from a Family Resource Book located in each exam room
62593752|NCT06344351|EXPERIMENTAL|TQB3006 tablets|TQB3006 tables is administered as a single dose or multiple dose .Take200-1200 mg per day; Take TQB3006 orally on an empty stomach once or twice a day, 21 days as a cycle.
62234212|NCT05594823|ACTIVE_COMPARATOR|Fixed - dose diuretic|Pre-determined, fixed daily dose of diuretic (furosemide)
62234213|NCT05594823|EXPERIMENTAL|Flexible diuretic regimen|Variable daily dose of diuretic (furosemide) determined based on a pre-specified weight-based scale.
62234214|NCT04517552||Experimental: [11C] CS1P1|
62234215|NCT03575754|EXPERIMENTAL|Interventional|This arm utilizes the investigational device, as specified in protocol.
62234216|NCT02873273|EXPERIMENTAL|Dexamethasone delivery system|
62425195|NCT06008639|PLACEBO_COMPARATOR|Control group|sham setting
62425196|NCT02740673|OTHER|Driving simulator|Using the driving simulator for 30 min.
62425197|NCT00068445|EXPERIMENTAL|Arm I - lamotrigine|"Patients receive oral lamotrigine once daily for 2 weeks and then twice daily for 8 weeks. Treatment continues for 10 weeks in the absence of unacceptable toxicity.~Quality of life, pain, mood states, and symptom distress are assessed at baseline and at 4, 6, 8, and 10 weeks.~Patients are followed at 3-7 days."
62810310|NCT01405768|EXPERIMENTAL|Buffered Lidocaine|Women in this arm will receive sodium bicarbonate buffered lidocaine mixed with epinephrine injected into their cervix prior to the LEEP procedure.
62234217|NCT04553042|EXPERIMENTAL|Treatment Sequence ABC|Participants will receive a single dose of seltorexant as formulation (Test 1) (Treatment A) in Treatment Period 1, followed by a single dose of seltorexant as formulation (Test 2) (Treatment B) in Treatment Period 2, followed by a single dose of seltorexant as formulation (Reference) (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
62234218|NCT04553042|EXPERIMENTAL|Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
62234219|NCT04553042|EXPERIMENTAL|Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
62234220|NCT04553042|EXPERIMENTAL|Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
62234221|NCT04553042|EXPERIMENTAL|Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
62234222|NCT04553042|EXPERIMENTAL|Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
62234223|NCT04616976||convalescent plasma therapy group|the patients received convalescent plasma therapy
62234224|NCT04616976||Control group|the patients with similar situation without convalescent plasma therapy
62593753|NCT02012842|ACTIVE_COMPARATOR|Immediate periodontal treatment|Strict supragingival plaque control and non surgical periodontal treatment immediately after the baseline examination(test group).
62810311|NCT04299373|EXPERIMENTAL|Alcohol: Oral administration|Participants in this arm will consume a measured dose of alcohol orally, with the goal of achieving a target peak breath alcohol concentration of .065% within 20 minutes.
62810312|NCT04299373|EXPERIMENTAL|Alcohol: Intravenous administration|Participants in this arm will be infused intravenously with a dose of alcohol sufficient to raise their breath alcohol concentration to .065% within 20 minutes.
62810313|NCT01311817|PLACEBO_COMPARATOR|Saline Patch|1mL saline applied to the vaccine patch
62810314|NCT01311817|EXPERIMENTAL|Bacteria plus CT|0.95mL bacterial vector plus 0.05mL cholera toxin
62810315|NCT06182878|EXPERIMENTAL|Tender loving care intervention|Weekly prenatal counseling messages sent via an online platform.
62810316|NCT05555303|OTHER|Amikacin|
62234225|NCT02947776|ACTIVE_COMPARATOR|USUAL|Usual care
62234226|NCT02947776|EXPERIMENTAL|PEER|Usual care + peer-befriending
62234227|NCT01230788|EXPERIMENTAL|rituximab|study drug given
62234228|NCT05058625|EXPERIMENTAL|Needly Group|Once the trigger point has been identified, we will use the Hong tecnique looking for a local spasm response
62234229|NCT05058625|ACTIVE_COMPARATOR|Control Group|Normal volleyball training
62593754|NCT02012842|OTHER|Delayed periodontal treatment|Strict plaque control and non surgical periodontal treatment 6 months after the baseline examination (control group).
62810317|NCT04480489|EXPERIMENTAL|Group A|In Group A, students will first perform Task 1 (walk from anesthesia lounge to the day surgery unit) using intervention 1 (using the virtual reality video) first, then Task 2 (walk from anesthesia lounge to the pre-operative clinic) using intervention 2 (using the traditional 2D video).
62810318|NCT04480489|ACTIVE_COMPARATOR|group B|In Group B, students will first perform Task 1 (follow route 1: walk from anesthesia lounge to the day surgery unit) using intervention 2 (using the traditional 2D video) first, then Task 2 (follow route 2: walk from anesthesia lounge to the pre-operative clinic) using intervention 1 (using the virtual reality video).
62810319|NCT02823769|EXPERIMENTAL|SI-R21204 resin composite|Fillings made with a new dental filling material
62810320|NCT02823769|ACTIVE_COMPARATOR|Nanohybrid resin composite|Fillings made with nanohybrid resin composite (Clearfil Majesty)
62810321|NCT00367328|ACTIVE_COMPARATOR|A|Oral Antibiotics in standard care vs. Laser treatment
62810322|NCT03741088|EXPERIMENTAL|VORTX Rx treatment|Focused ultrasound ablation of liver tumors.
62234230|NCT04709380|EXPERIMENTAL|Radiotherapy plus Toripalimab|Patients in the experimental group will be given local vein tumor thrombus/hepatic vein tumor thrombus +/- intrahepatic large lesions with hypofractionated intensity modulated radiotherapy (tumor area dose 40-60Gy/10-20f), concurrent with and followed by 240mg Q3W of toripalimab within 1 week of radiotherapy.
62810323|NCT04086017|EXPERIMENTAL|Reiki teaching|Reiki Master will perform the teaching and attunement process for Level 1 Reiki and teach the caregiver(s) how to complete a simple 10-minute Reiki session with the patient and a 10-minute self-Reiki session for the caregiver(s). The Reiki Master will explain that Reiki sessions can be given whenever the patient and caregiver feel it is appropriate, but sessions should be at minimum twice per 24-hour period for at least 10 minutes with at least two hours between sessions. Reiki sessions may be more frequent than twice per day and/or longer than 10 minutes. Self-Reiki sessions should be performed daily for at least 10 minutes but maybe more frequent and/or longer in length. Each family caregiver will receive a copy of the book. The patient and caregiver will wear a Holter monitor continuously for 48 hours beginning when the caregiver(s) are trained in Reiki to measure HRV, a valid measure for stress.
62810324|NCT04086017|NO_INTERVENTION|Usual care|Patients and caregivers will complete all measures expected of the intervention cohort including daily symptom checklist for 10 days. The patient and caregiver will wear a Holter monitor for the first 48 hours of study participation to measure heart rate variability (HRV), a valid measure for stress. The patient and/or caregiver may opt out of the Holter monitor if requested and still participate in the rest of the study.
62810325|NCT05736874|EXPERIMENTAL|Arm C - Fluticasone|Fluticasone is a self-administered inhaled drug. Participants will self-administer 200 µg (1 blister) of fluticasone once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the study drug through the mouthpiece.
62234231|NCT04709380|ACTIVE_COMPARATOR|Sorafenib|Patients in the control group will be treated with sorafenib (400mg, twice a day).
62234232|NCT05666388|EXPERIMENTAL|Rescue stenting (RESFIT)|Rescue stenting in the severe atherosclerotic stenosis after the failure of intravenous thrombolysis (RESFIT)
62425198|NCT00068445|OTHER|Arm II - placebo|"Patients receive oral placebo once daily for 2 weeks and then twice daily for 8 weeks.~Treatment continues for 10 weeks in the absence of unacceptable toxicity.~Quality of life, pain, mood states, and symptom distress are assessed at baseline and at 4, 6, 8, and 10 weeks.~Patients are followed at 3-7 days."
62425199|NCT01681979||Women with asthma during pregnancy|Women with asthma during pregnancy will be identified based on one of the following: 1) an asthma related medical code recorded anytime before the pregnancy start date and at least one prescription for an asthma medicine in the 6 months before the pregnancy start date or during pregnancy; 2) no asthma related medical code but at least 6 prescriptions for an asthma medicine in their record before the pregnancy start date, including one in the 6 months before the pregnancy start date or during pregnancy.
62425200|NCT01257828|PLACEBO_COMPARATOR|Placebo|Placebo medication and decompressive cervical spine surgery
62243174|NCT05326113|ACTIVE_COMPARATOR|Control group|"Control group will undergo standard treatment of reflux with PPIs and will be regularly examined by an assigned physician.~Symptomatic patients will take PPIs based on the recommendation of the treating physician who will recommend a dose of PPIs. Used PPIs will be Emanera 1x40mg (standard dose), 2x40mg (higher dose) or 1x40mg on demand.~All patients with esophagitis LA A/B/C will be treated with IPP-Emanera 1x40mg for at least 6 weeks at the start of the study.~During the follow-up period, patients may, in agreement with the attending physician, reduce the dose of PPIs (from twice a day to once a day, from once a day to an on-demand regime or discontinue them altogether).~The use of PPIs will be accurately documented."
62033956|NCT04486352|EXPERIMENTAL|Inavolisib and Letrozole Cohort|Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with tumors that with PIK3CA activating mutations in the absence of PTEN loss-of-function alterations or AKT1 activating mutations will be assigned to this cohort. Twenty-four participants will be enrolled. Once twenty-four participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
62425201|NCT01257828|EXPERIMENTAL|Riluzole|Riluzole in dose 50mg BID for 14 days prior to surgery and 28 days after the decompressive spine surgery
62425202|NCT00918697|ACTIVE_COMPARATOR|Mechanical debridment|In this arm, corneal epithelium was removed during PRK using conventional mechanical method.
62425203|NCT00918697|EXPERIMENTAL|Alcohol-asstisted debridement|In this arm, corneal epithelium was removed using ethanol 20% during PRK.
62425204|NCT04737811||Study group|The group consists of Parkinson's disease patients with dysphagia complaints. The participants will be given the Turkish version of the Swallow Disturbance Questionnaire (SDQ-T), which consisted of 15 questions and two scales evaluated with the fiberoptic endoscopic evaluation of swallowing. After two weeks, all participants will be given the SDQ-T for sampling.
62810326|NCT05736874|PLACEBO_COMPARATOR|Arm C - Placebo|Placebo is a self-administered inhaled agent. Participants will self-administer 1 blister of placebo once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the placebo through the mouthpiece.
62810327|NCT00754702|EXPERIMENTAL|1|Vinorelbine metronomic/Lapatinib
62033957|NCT04486352|EXPERIMENTAL|Giredestrant and Abemaciclib|Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with tumors that are RB1 intact with a local grade 1-2 estrogne receptor positive (ER+) are assigned to this cohort. Twenty-four participants will be enrolled. Once twenty-four participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
62425205|NCT02929537||Western medicine|Patients in this group only choose conventional medicine treatment based on the classes of medications recommended by 2015 GOLD for COPD.
62810328|NCT02564666|ACTIVE_COMPARATOR|Telephone counseling|regular telephone counseling per week
62810329|NCT02564666|NO_INTERVENTION|No telephone counseling|no regular telephone counseling
62810330|NCT02620501|PLACEBO_COMPARATOR|Placebo|Patients will receive 10cc of 1/2 normal saline to gargle prior to EGD
62810331|NCT02620501|EXPERIMENTAL|Experimental|Patients will receive 10cc of 2% topical lidocaine to gargle prior to EGD
62810332|NCT03431298|EXPERIMENTAL|Aerobic exercise & movement control|"The duration of intervention is 8 weeks.~* Individualized functional movement control training is 60 min/week~* Aerobic exercise is 60 min/week"
62810333|NCT03431298|ACTIVE_COMPARATOR|Aerobic exercise|"The duration of intervention is 8 weeks.~* Frequency: 2 times/ week~* Duration: 60min/ time"
62810334|NCT02552966|EXPERIMENTAL|UESAD|Upper Esophageal Sphincter Assist Device
62810335|NCT01927497|EXPERIMENTAL|Biological mesh closure|Biological mesh reconstruction of the pelvic floor after extralevator abdomino perineal resection
62810336|NCT01927497|ACTIVE_COMPARATOR|Primary perineal closure|Primary perineal closure after extralevator abdomino perineal resection
62810337|NCT01361022|ACTIVE_COMPARATOR|Brotizolam tablet|Brotizolam tablets 250mcg : at least 6 and 24 subjects will be enrolled in the pre-study and main study, respectively
62810338|NCT01361022|EXPERIMENTAL|Lendormin tablet|Lendormin tablets 250mcg: at least 6 and 24 subjects will be enrolled in the pre-study and main study, respectively
62425206|NCT02929537||Traditional Chinese Medicine|Patients in this group only choose conventional medicine treatment based on the Chinese Treatment Guidelines for COPD.
62425207|NCT02929537||Integrative Medicine|Patients in this group choose western medicine and Traditional Chinese Medicine.
62425208|NCT02941380||Ischemic heart disease|Patients admitted for coronary artery bypass grafting with the use of cardiopulmonary bypass
62593755|NCT05983003||Control|"Following the efficacy assessment method outlined in the 2020 EPOS guidelines, the treatment outcomes of chronic sinusitis are categorized as controlled or uncontrolled. Clinical reference evaluation criteria include: nasal congestion, rhinorrhea, facial pain, reduced sense of smell, sleep disturbances, the need for ongoing medication maintenance and the abnormal nasal endoscopy findings, .If there are no three or more symptoms rated five or higher, the patient's chronic sinusitis is considered controlled."
62425209|NCT06073184|EXPERIMENTAL|Control Arm|pIUD
62425210|NCT06073184|EXPERIMENTAL|Intervention Arm|tirzepatide + pIUD
62425211|NCT04182984||Patients with autoimmune ocular MG|Newly-onset OMG patients who agreed to join the follow-up cohort
62425212|NCT03422796|ACTIVE_COMPARATOR|Sumatriptan|headache is induced with Cilostazol. This headache is treated double-blinded with 6mg/ml sumatriptan
62810339|NCT03449758|EXPERIMENTAL|Sarilumab|Sarilumab 200 milligram (mg) subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 as monotherapy and/or in combination with methotrexate (MTX) or other csDMARD during the randomized 6-month (24 weeks) core treatment period. Participants completing 24 weeks period entered in a long-term extension treatment period and received sarilumab 200 mg q2w from Week 25 until the commercial availability of sarilumab in the country or maximum of up to Week 39.7.
62810340|NCT01762553|EXPERIMENTAL|intervention|The TEA intervention program will be implemented for the intervention group. The TEA intervention has three modules (healthy body \& healthy mind, family interaction, and quality of life) logically connected to each other and implemented at three levels from individual, family to the community: 1) TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; 2) TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; 3) TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
62425213|NCT03422796|PLACEBO_COMPARATOR|Placebo|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placeb
62425214|NCT00470119|NO_INTERVENTION|Control|
62033958|NCT05852951||Menstrual patterns|Regular menstrual cycles and irregular menstrual cycles; irregular menstrual cycles are defined as having variation in menstrual cycles of greater than 2 days and less than 2 months
62033959|NCT04152018|EXPERIMENTAL|Dose Escalation|Single Agent Dose Escalation
62033960|NCT04152018|EXPERIMENTAL|Dose Finding Anti-PD-1 Combination 1|Part 1B PF-06940434 plus anti-PD-1
62033961|NCT04152018|EXPERIMENTAL|Dose Expansion Arm A|PF-06940434 with anti-PD-1 in SCCHN
62425215|NCT00470119|OTHER|Caloric Restriction|Nutritionist-delivered weight loss intervention though diet modification with an aim of 10% weightloss over a year long intervention based on the DPP and LookAHEAD interventions. Participants meet with a nutritionist individually and in small groups. Participants receive general information about diet and behavior strategies such as self-monitoring, goal-setting, stimulus-control, problem-solving, and relapse-prevention training. Participants learn to set a calorie goal and a fat gram goal and how to achieve the goal calorie reduction. Meetings are held weekly during the first 6 months of the diet program but taper off over the course of the study.
62810341|NCT01762553|NO_INTERVENTION|Control|In order to tease out the impact of the proposed intervention from the impact of attention in general, we will add limited activities to the control group condition. The differences between the intervention and control conditions consist in both contents and formats. For the control group, there will only be group sessions once a week for three weeks starting after baseline assessment. The content of the sessions for the control group will focus on basic care, health education and promotion, nutrition, personal and family hygiene. The Essential Care Package (ECP), a set of education materials originally developed by the World Health Organization (WHO) and supported by the Global Fund Project, will be used and explained in these group sessions. Health workers from villages in the control group will also visit participating families once a week for the initial three weeks and once a month for 12 months.
62810342|NCT04834570||Breast Cancer Survivors|Women who have survived breast cancer for at least 1 year (12 months) and 2 years (24 months) after the end of primary treatment
62810343|NCT02462694|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as usual (TAU): Standard psychological, psychopharmacology and case management services
62033962|NCT04152018|EXPERIMENTAL|Dose Expansion Arm B|PF-06940434 with anti-PD-1 in RCC
62033963|NCT04152018|EXPERIMENTAL|Dose Expansion, Arm C|PF-06940434 with anti-PD-1 (both Q3W)
62033964|NCT02266069|OTHER|Research cluster 1: Antwerp|The first Dutch-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from October 2014.
62033965|NCT02266069|OTHER|Research cluster 2: Mons|The first French-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from November 2014.
62425216|NCT00470119|OTHER|Exercise Intervention|Participants exercise 3 days per week under the supervision of a physiologist and 2 days per week independently at home, for a total of 5 exercise sessions (at least 45 minutes of moderate-intensity exercise per session) weekly over 12 months
62033966|NCT02266069|OTHER|Research cluster 3: Brussels|The only bilingual Dutch/French-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from December 2014.
62033967|NCT02266069|OTHER|Research cluster 4: Limburg|The second Dutch-speaking research cluster in a stepped wedge cluster design. Family doctors will implement the Care Pathway for Primary Palliative Care and will recruit eligible patients from April 2015.
62033968|NCT02266069|OTHER|Research cluster 5: ?|A second French-speaking research cluster in a stepped wedge cluster design. Family doctors will implement the Care Pathway for Primary Palliative Care and will recruit eligible patients from October 2015.
62033969|NCT06147895|EXPERIMENTAL|Group 1|CVI-HBV-002 1 mL Intramuscular injection at Baseline, Week 4, Week 8 / total 3 doses
62033970|NCT06147895|EXPERIMENTAL|Group 2|CVI-HBV-002 1 mL Intramuscular injection at Baseline, Week 4, Week 24 / total 3 doses
62033971|NCT05789433|SHAM_COMPARATOR|Attention control|Static stretching
62033972|NCT05789433|EXPERIMENTAL|Aerobic exercise|Aerobic exercise at a dose of 225 minutes per week
62033973|NCT01956526|EXPERIMENTAL|CORolla™ TAA Stand Alone|Single arm study design including with patients with isolated HFpEF, in NYHA f. Cl. III-IV. These patients will receive the CORolla™ TAA device. For assessments of results, intra-patient comparisons of pre-procedure and follow-up data will be performed;
62033974|NCT01956526|EXPERIMENTAL|AVR and CORolla™ TAA Add On group|patients who require aortic valve replacement (AVR) due to aortic stenosis and have diastolic dysfunction will receive the CORolla™ TAA device.
62033975|NCT01956526|NO_INTERVENTION|AVR and CORolla ADD On - Control|patients who require only the aortic valve replacement (AVR) due to aortic stenosis and have diastolic dysfunction.
62425217|NCT00470119|OTHER|Caloric Restriction AND Exercise Intervention|Combined caloric restriction \& exercise intervention
62425218|NCT05884138|EXPERIMENTAL|Improved skeletal muscle function due to protein supplementation and exercise|resistance exercise and protein supplementation including branched chain amino acids for 12 weeks
62425219|NCT05884138|NO_INTERVENTION|control|No intervention, but the same measurements as the experimental group are conducted.
62425220|NCT02237118|ACTIVE_COMPARATOR|Mepitel One|Pain on dressing removal, by VAS
62425221|NCT02237118|ACTIVE_COMPARATOR|UrgoTul|Pain on removal by VAS
62425222|NCT00140738|EXPERIMENTAL|Group A|"Patients receive study vaccinations in 3 consecutive cycles:~* In Cycle 1 each patients will receive six vaccinations at two-week intervals followed by evaluation.~* In Cycle 2, subjects will patients six vaccinations at two-week intervals followed by evaluation.~* In Cycle 3, subjects will patients six vaccinations at three-week intervals."
62810344|NCT02462694|EXPERIMENTAL|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT): weekly individual sessions, skills training group and telephone coaching as needed
62810345|NCT04569877|EXPERIMENTAL|Molgramostim nebuliser solution|300μg molgramostim nebuliser solution
62810346|NCT04569877|PLACEBO_COMPARATOR|Placebo nebuliser solution|Placebo nebuliser solution
62810347|NCT01430871||Carcinoid syndrome|Patients: Men and women age 18 years or older with carcinoid syndrome attending the Sheffield neuro-endocrine tumour clinic
62810348|NCT01430871||Healthy Volunteers|Control group: Healthy men and women individually matched to the patients by gender, age, height and BMI
62810349|NCT02219646|EXPERIMENTAL|Vardenafil|The study protocol consists of a Screening/Enrolment Phase lasting up to 4 weeks, a Treatment Phase of 24 weeks, and Follow-up/Observation Treatment-free Phase of 24 weeks after the Treatment Phase. During treatment phase, patients enrolled in the Study Group were treated with vardenafil 10 mg twice/daily.
62810350|NCT02219646|PLACEBO_COMPARATOR|Control|The study protocol consists of a Screening/Enrolment Phase lasting up to 4 weeks, a Treatment Phase of 24 weeks, and Follow-up/Observation Treatment-free Phase of 24 weeks after the Treatment Phase. During treatment phase, patients enrolled in the Control Group were treated with tablets twice/daily identical to the Study Group, but containing placebo.
62425223|NCT00140738|EXPERIMENTAL|Group B|Patients receive study vaccinations as second-line therapy
62425224|NCT04626765|EXPERIMENTAL|volunteer|The child's parents or legal guardians voluntarily signed the informed consent form, and the child himself/herself met the enter criteria for the diagnosis of patients with acute B-lymphoblastic leukemia (B-ALL) expressing specific target antigens
62033976|NCT03775850|EXPERIMENTAL|Cohort A|Cohort A includes patients with microsatellite stable (MSS) colorectal cancer (CRC). Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.
62033977|NCT03775850|EXPERIMENTAL|Cohort B|Cohort B includes patients with Triple Negative Breast Cancer (TNBC). Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.
62425225|NCT03047473|EXPERIMENTAL|Newly diagnosed GBM|single arm, open label Addition of Avelumab to standard treatment
62425226|NCT04441801|EXPERIMENTAL|15 seconds|Stretching of the hamstring muscles will be performed by the primary researcher. A straight-leg-raising technique will be used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible, each subject's knee will be maintained in extension with the ankle at 90 degrees without medial (internal) or lateral (external) rotation of the lower extremity, and the extremity was raised until the subject reported discomfort. The subject was asked to relax the lower extremity in an effort to prevent contracting muscles from affecting the stretch and to allow for a slow stretch. stretching will continue for 15 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
62425227|NCT04441801|EXPERIMENTAL|30 seconds|the same stretching technique will continue for 30 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
62425228|NCT04441801|EXPERIMENTAL|60 seconds|the same stretching technique will continue for 60 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
62425229|NCT04441801|SHAM_COMPARATOR|control|The control group followed the same procedures except that no stretching force was applied at the end.
62425230|NCT03434626|EXPERIMENTAL|ACP Education|Eligible patients in the experimental group will receive an educational intervention from an advance care planning navigator consisting of a 4-item values tool, a Goals of Care Designation form and, if applicable, watch a cardiopulmonary resuscitation video.
62425231|NCT03434626|ACTIVE_COMPARATOR|Usual care|Patients in the usual care group will complete a Goals of Care Designation form with the family physician.
62425232|NCT04033900|EXPERIMENTAL|Prewarming|Active warming is allowed prior to surgery with forced-air warming devices
62425233|NCT04033900|NO_INTERVENTION|No prewarming|Non active warming is allowed before surgery
62810351|NCT02767817|SHAM_COMPARATOR|Stereotactic Hematoma Evacuation|
62810352|NCT02767817|EXPERIMENTAL|MSCs Transplantation|
62810353|NCT02767817|EXPERIMENTAL|Injectable Collagen Scaffold with MSCs Transplantation|
62810354|NCT01445444|EXPERIMENTAL|HRT group|This group receives habit reversal training immediately.
62810355|NCT01445444|ACTIVE_COMPARATOR|TAU group|This group receives treatment as usual for 8 weeks.
62810356|NCT03776864|EXPERIMENTAL|Treatment (pembrolizumab, umbralisib)|Patients receive pembrolizumab IV on day 1. Treatment repeats every 21 for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive umbralisib PO daily on days 1-21 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62033978|NCT03775850|EXPERIMENTAL|Cohort C|Cohort C includes patients with non-small-cell lung cancer (NSCLC), bladder cancer; gastroesophageal (GE) cancer, any microsatellite unstable, or renal cell carcinoma (RCC) who are relapsed to prior PD-1/L1 therapy. Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.
62033979|NCT03007927|EXPERIMENTAL|Bupivacaine-Dexamethasone|bupivacaine 1,5 mg/kg + dexamethasone 8 mg 2ml
62033980|NCT03007927|ACTIVE_COMPARATOR|Bupivacaine- physiological solution|bupivacaine 1,5 mg/kg + physiological solution
62033981|NCT00680212|OTHER|1|dietary carotenoids
62234233|NCT05381987|EXPERIMENTAL|Intervention (experimental) group|These will receive a total of 6 sessions with a week's interval of radial shockwaves that will be performed using a (Storz Medical) device with the following manufacturer's parameters: 0.57mJ/mm2 (intensity 1.5 bar) applied as low energy, pulses 2000, frequency 15 Hz. The D20 transmitter (Ø 20 mm) headpiece will be used. Total treatment time including standard PT stretches and exercises would be 30 minutes). The radial shockwave will be delivered by designated physiotherapist, who will evaluate the participants before the treatment. Before the treatment, the treating physical therapist would ensure aseptic techniques, they would ensure the participants skin is intact and clean coupling gel will be used during the treatment. Furthermore prior to treatment, the myofascial triggers would be specifically confirmed by twitching response induced by a localized probe using a digital algometer.
62234234|NCT05381987|PLACEBO_COMPARATOR|Control (placebo) group|These will receive an identical treatment regime except that they will receive a none-therapeutic level energy shock of 0.03 mJ/mm2, an ineffective (a non-therapeutic) level of radial shockwave therapy, and participants will be blinded to their treatment by only hearing the sound from the shockwave machine.
62234235|NCT01389765|EXPERIMENTAL|LY2216684 administered in fasted then fed state|Period 1: Single 18-mg (milligram) oral dose of LY2216684 administered in fasted state. Period 2: Single 18-mg oral dose of LY2216684 administered in fed state. Periods will be separated by a minimum of 7 days.
62234236|NCT01389765|EXPERIMENTAL|LY2216684 administered in fed then fasted state|Period 1: Single 18-mg oral dose of LY2216684 administered in fed state. Period 2: Single 18-mg oral dose of LY2216684 administered in fasted state. Periods will be separated by a minimum of 7 days.
62234237|NCT04826211|EXPERIMENTAL|Node positive BC patients undergoing PST|Patients with breast cancer of any size with positive axillary nodes and candidates to PST will undergo PET/MRI both prior to PST and after PST before surgery
62234238|NCT02702726|NO_INTERVENTION|Congee and juice only|Control breakfast providing 50g carbohydrate
62234239|NCT02702726|ACTIVE_COMPARATOR|Congee and juice with coconut gel|Control breakfast, plus 25g coconut oleogel (solid)
62234240|NCT02702726|ACTIVE_COMPARATOR|Congee and juice with coconut oil|Control breakfast, plus 25g coconut oil (liquid)
62234241|NCT02702726|ACTIVE_COMPARATOR|Congee and juice with sunflower gel|Control breakfast, plus 25g sunflower oleogel (solid)
62234242|NCT02702726|ACTIVE_COMPARATOR|Congee and juice with sunflower oil|Control breakfast, plus 25g sunflower oil (liquid)
62234243|NCT02576379||HEMS patients|Patients suspected of suffering from a vascular condition within the geographical area covered by both HEMS and GEMS, and were transported by Helicopter Emergency Medical System (HEMS) to the regional stroke unit at Copenhagen University Hospital Roskilde in a 36-month period from May 1st 2010 until April 30th 2013.
62234244|NCT02576379||GEMS patients|Patients suspected of suffering from a vascular condition within the geographical area covered by both HEMS and GEMS, and were transported by Ground Emergency Medical System (GEMS) to the regional stroke unit at Copenhagen University Hospital Roskilde in a 40-month period from January 1st 2010 until April 30th 2013.
62425234|NCT04701658|EXPERIMENTAL|Bamlanivimab|Participants received 700 milligram single intravenous infusion of Bamlanivimab.
62425235|NCT04701658|NO_INTERVENTION|Controls|"Matched controls who received standard of care.~\[The study was originally designed to include a matched control arm. However, due to low enrollment, it was amended to be a single arm study with Bamlanivimab arm only. No matched controls were utilized.\]"
62810357|NCT04839341|EXPERIMENTAL|A Phase I, open-labeled multicenter study|Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC)
62234245|NCT02954640|OTHER|Patient with PID|"For patient with clinical diagnosis of PID, an additional blood sampling will be taken.~The genetic diagnosis will be done via the method of gene-panel in the frame of the study.~A genetic confirmation will, in any case, be done via the reference method (Sanger), in order to establish a final diagnosis for these patients."
62234246|NCT02159196|ACTIVE_COMPARATOR|acetylcysteine and salbutamol|Nebulisation of 3 mL-solution of acetylcysteine (fluimucil 100mg/ml, a mucolytic) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml, a bronchodilator), administered every 6 hours (i.e., 4 times per day) within 24 hours after initiation of ventilation until tracheal extubation.
62810358|NCT02193776|EXPERIMENTAL|DS-TB: J(loading dose/t.i.w.)PaZ|Subjects with DS-TB. J(loading dose/t.i.w.)PaZ: Bedaquiline 400mg once daily Days 1-14, 200mg three times per week Days 15-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
62810359|NCT02193776|EXPERIMENTAL|DS-TB: J(200mg)PaZ|Subjects with DS-TB. J(200mg)PaZ: Bedaquiline 200mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
62810360|NCT02193776|EXPERIMENTAL|MDR-TB: J(200mg)MPaZ|Subjects with MDR-TB. J(200mg)MPaZ: Bedaquiline 200mg once daily Days 1-56; plus moxifloxacin 400mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
62425236|NCT00196573|ACTIVE_COMPARATOR|Shoulder bursectomy and acromioplasty|
62425237|NCT00858559|EXPERIMENTAL|1|Home Monitoring
62425238|NCT00858559|ACTIVE_COMPARATOR|2|Home Monitoring not used
62033982|NCT06009341|EXPERIMENTAL|Intervention Group|In this study, the intervention group will be given comprehensive training in addition to standard conservative follow-up (pain spasm pain cycle, pain does not always mean that there is a problem, tissue repair, fall prevention, lower extremity classical massage, muscle relaxation relaxation methods, respiratory control), while the control group will be followed only with conservative treatment applications (muscle strengthening, stretching). The applications will be performed with 10 repetitions each day.
62033983|NCT06009341|ACTIVE_COMPARATOR|Control Group|The control group will not be trained. Only exercise brochure including muscle strengthening and stretching will be given.
62425239|NCT00990093|EXPERIMENTAL|test intermittent catheter|CH 12 hydrophilic coated catheter
62425240|NCT00990093|EXPERIMENTAL|intermittent catheter|CH 12 hydrophilic coated catheter
62810361|NCT02193776|ACTIVE_COMPARATOR|DS-TB: HRZE|Subjects with DS-TB. HRZE tablets (Isoniazid 75mg plus rifampicin 150mg plus pyrazinamide 400mg plus ethambutol 275mg combination tablets) dosed once daily Days 1-56 per the Subject's weight as follows: 30-37kg: 2 tablets; 38-54kg: 3 tablets; 55-70kg: 4 tablets; 71kg and over: 5 tablets.
62810362|NCT00617214||All|Schizophrenic outpatients who are treated with Seroquel IR and who are additionally intended to start with an integrated care program
62033984|NCT01703364|EXPERIMENTAL|Lenalidomide/Fludarabine/Rituximab|"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
62810363|NCT03045367||Outpatients|Phacoemulsification, intraocular lens implant, vitrectomy.
62593756|NCT05983003||Uncontrol|"Following the efficacy assessment method outlined in the 2020 EPOS guidelines, the treatment outcomes of chronic sinusitis are categorized as controlled or uncontrolled. Clinical reference evaluation criteria include: nasal congestion, rhinorrhea, facial pain, reduced sense of smell, sleep disturbances, the need for ongoing medication maintenance and the abnormal nasal endoscopy findings, . The classification is based on the number and severity of these symptoms,and patients with three or more symptoms rated five or higher are considered to have uncontrolled disease"
62810364|NCT04601935|EXPERIMENTAL|LCAR-BCX cells product|Each subject will be given a single-dose infusion in each dose levelThe dose-finding phase of this study is designed primarily using the Bayesian optimal interval (BOIN) method, which is combined with accelerated titration at the beginning of the study to assess incidence of DLT (dose-limiting toxicity) and estimate MTD (maximum tolerated dose).
62033985|NCT02232113|EXPERIMENTAL|CERA|We included HD patients with stable hematocrit (between 30\~36%) under intravenous administration of CERA 100 μg once monthly for two months. Then they were shifted to receive CERA 50μg twice monthly for anther two months and finally they were shifted back to receive CERA 100 μg once monthly again for additional two months. Then we compared the hematocrit, nutrition status and inflammation markers every two months for 6 months totally. Those who had bleeding or received surgery or blood transfusion were excluded.
62033986|NCT05932134|NO_INTERVENTION|Usual care|Usual care as RCC protocol in Chang Gung Memorial hospital
62033987|NCT05932134|EXPERIMENTAL|UC + high protein diet (HP)|The HP groups will maintain unchanged total daily caloric intake and increasing protein content to 1.5g/kg/day.
62033988|NCT05932134|EXPERIMENTAL|UC + HP + core muscle rehabilitation|Protein provision was not reduced in case of renal failure. Core muscle rehabilitation is sitting on bedside with or without aids, for 30 minutes, twice per day, 5 days per week, for 3 weeks.
62033989|NCT05932134|EXPERIMENTAL|UC + HP + core muscle rehabilitation + neuromuscular electric stimulation (NMES)|NMES was applied for 30 min, twice per day, 5 days per week, for 3 weeks via surface rectangular electrodes. Electrodes were placed on back designed to activate latissimus dorsi and abdominal wall designed to activate the transversus abdominis and internal and external oblique muscles. Electrical muscle stimulation was performed by using a commercial stimulator (GEMORE, GM300E, Taipei, Taiwan) with biphasic waves at a simulation frequency of 30 Hz and pulse width of 400s, cycling 2s on and 4s off. Electrical muscle stimulation intensity was gradually increased until a visible muscle contraction was observed (median 60 mA \[range 50-65 mA\].
62033990|NCT02147548|EXPERIMENTAL|etifoxine (Anxiolytic)|etifoxine, 100 mg, a single oral intake
62033991|NCT02147548|ACTIVE_COMPARATOR|lorazepam|lorazepam, 2 mg, a single oral intake
62234247|NCT02159196|EXPERIMENTAL|acetylcysteine or salbutamol|"Nebulisation on strict clinical indications; nebulisation of 3 mL-solution of acetylcysteine (fluimucil 100mg/ml, a mucolytic) in case of occurrence of persistent thick and tenacious sputum and only after active humidification is set.~Nebulisation of 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml, a bronchodilator) in case of occurrence of bronchospasm."
62810365|NCT00768612|EXPERIMENTAL|1|Lowest dose
62033992|NCT02147548|PLACEBO_COMPARATOR|Placebo|2 capsules of Placebo, a single oral intake
62810366|NCT00768612|EXPERIMENTAL|2|Middle dose
62033993|NCT06669195|EXPERIMENTAL|Intravascular lithotripsy group|
62033994|NCT06669195|ACTIVE_COMPARATOR|high-pressure balloon group|
62033995|NCT02747134|EXPERIMENTAL|Emotion Regulation and Mindfulness skills|A 10 week intervention including emotion regulation and mindfulness skills from dialectical behavioral therapy (DBT) was delivered.
62033996|NCT02747134|ACTIVE_COMPARATOR|Psychoeducation|Psychoeducation consisted of 5 session in which basic information about depressive symptoms and how to prevent depression relapse was given.
62234248|NCT03046784||Pregnant women in third trimester|"Non-labouring pregnant women hospitalised during their third trimester of pregnancy has an haemodynamic evaluation with Nexfin technology and transthoracic cardiac ultrasonography.~Evaluation is performed in two positions : dorsal decubitus and left lateral decubitus."
62234249|NCT00555490|EXPERIMENTAL|1|
62234250|NCT04500756|ACTIVE_COMPARATOR|Metformin group|Participants will either be assigned to take metformin 500 mg tablet(s) daily or identical tablet(s) that contain no active drug, also taken every day. Over the first four weeks of the study, you will increase your dosage every week by one pill, so at the end of the first month you will be taking up to four pills per day. If you develop any symptoms or side effects from pill ingestion during this process, your dose will be decreased to the last number of pills you were able to take without developing side effects.
62810367|NCT00768612|EXPERIMENTAL|3|Highest dose
62810368|NCT00768612|ACTIVE_COMPARATOR|4|Positive Control
62810369|NCT06380153|EXPERIMENTAL|Mild renal impairment group|15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
62810370|NCT06380153|EXPERIMENTAL|Moderate renal impairment group|15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
62810371|NCT06380153|EXPERIMENTAL|Healthy subjects|15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
62810372|NCT06416566|EXPERIMENTAL|Enoxaparin|will receive subcutaneous enoxaparin
62810373|NCT04040374|EXPERIMENTAL|AI-based diagnosis|• AI-based diagnosis will be performed based on analysis of endoscopic images (Olympus Optical, Tokyo, Japan). The investigators will use the Single Shot MultiBox Detector (SSD), a deep neural network architecture (https://arxiv.org/abs/1512.02325), and an optimal diagnostic cutoff from a prior report2. The AI system reviewed endoscopy images and reported those in which gastric cancer was detected, together with the coordinates (X, Y) of the lesions.
62425241|NCT05301101|EXPERIMENTAL|Cancer patients receiving definitive radiation therapy with overlap of a previously treated field|This is a re-irradiation study in solid tumor patients receiving definitive high dose radiation therapy to treatment volumes that include overlap with previously irradiated organs at risk.
62234251|NCT04500756|PLACEBO_COMPARATOR|Placebo Group|Participants will either be assigned to take metformin 500 mg tablet(s) daily or identical tablet(s) that contain no active drug, also taken every day. Over the first four weeks of the study, you will increase your dosage every week by one pill, so at the end of the first month you will be taking up to four pills per day. If you develop any symptoms or side effects from pill ingestion during this process, your dose will be decreased to the last number of pills you were able to take without developing side effects.
62234252|NCT04990492|EXPERIMENTAL|Paper Baseline|Half of the participants will complete the GAD 7 in the traditional paper format at their first appointment. At their second appointment 1-month later, they will complete the GAD 7 on the Mirror device equipped with Amazon Alexa.
62234253|NCT04990492|EXPERIMENTAL|Alexa Baseline|The other half of the participants will complete the GAD 7 on the Mirror device equipped with Amazon in the traditional paper format at their first appointment. At their second appointment 1-month later, they will complete the GAD 7 in the traditional paper format.
62234254|NCT00754143|PLACEBO_COMPARATOR|A|Placebo
62234255|NCT00754143|EXPERIMENTAL|B|FG-3019 5 mg/kg
62234256|NCT00754143|EXPERIMENTAL|C|FG-3019 10 mg/kg
62033997|NCT03326687|EXPERIMENTAL|Treatment ABAB|Participants will receive anomia treatment in isolation and will perform a physical endurance task in isolation during A phases. They will receive anomia treatment in combination with performing a physical endurance task during B phases.
62234257|NCT04415463|EXPERIMENTAL|FC-SEMS|Placement of multisegmented fully covered self-expandable metal stent
62234258|NCT03097133|EXPERIMENTAL|Esketamine + Standard of care|Participants will receive intranasal esketamine 84 milligram (mg) on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.
62234259|NCT03097133|PLACEBO_COMPARATOR|Placebo + Standard of care|Participants will receive intranasal placebo on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.
62234260|NCT06485752|ACTIVE_COMPARATOR|Lot 1 (Group 1)|influenza A \[H1N1\]
62425242|NCT04071275|ACTIVE_COMPARATOR|Mirror therapy|Subjects will be asked to perform specific movements (using the unaffected limb while watching its mirrored reflection for 20 minutes per day, for 10 treatment days, completed during two weeks (every weekday, excluding weekends)
62425243|NCT04071275|SHAM_COMPARATOR|Mirror therapy + sham tDCS|Subject will undergo the mirror therapy treatment, as in the first study arm. In addition, at the same time, a sham tDCS treatment will be applied.
62425244|NCT04071275|EXPERIMENTAL|Mirror therapy + active tDCS|Subject will undergo the mirror therapy treatment, as in the first study arm. In addition, at the same time, an active tDCS treatment will be applied.
62234261|NCT06485752|ACTIVE_COMPARATOR|Lot 2 (Group 2)|influenza A \[H3N2\]
62425245|NCT02726672|EXPERIMENTAL|Respiratory rehabilitation|Respiratory rehabilitation: Powerbreathe training of the inspiratory muscles at home twice a day (2 sessions of 30 inspirations / day) during 10 weeks
62425246|NCT02726672|NO_INTERVENTION|control group|No respiratory rehabilitation
62425247|NCT00694031|ACTIVE_COMPARATOR|A|Hemodialysis
62425248|NCT00694031|EXPERIMENTAL|B|On-line hemodiafiltration
62425249|NCT02353299|ACTIVE_COMPARATOR|Silenor 6 mg (DXP-4H)|Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments
62425250|NCT02353299|PLACEBO_COMPARATOR|Placebo (PBO-4H)|placebo single nightime dose -4 hour post dose arousability and cognitive assessments
62425251|NCT02353299|ACTIVE_COMPARATOR|Zolpidem 10 mg (ZOL-1.5H)|zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments
62425252|NCT02353299|PLACEBO_COMPARATOR|Placebo (PBO-1.5H)|placebo single nightime dose -1.5 hour arousability and cognitive assessments
62425253|NCT01185730|EXPERIMENTAL|pulmonary hypertension|cohort of patients with pulmonary hypertension
62425254|NCT06265285|EXPERIMENTAL|Health services research (in-clinic and at-home nivolumab)|Patients receive nivolumab SC on day 1 of each cycle. Cycles repeat every 28 days in clinic for 2 cycles, then at home by a HHNP for 4 cycles, followed by either in-clinic or at-home administration for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients receive in-home visits by a home health nurse and undergo remote patient monitoring including vital sign measurements and condition-specific symptom assessments throughout study.
62425255|NCT00420355|EXPERIMENTAL|Arm A|Subjects on atazanavir/ritonavir will add lopinavir/ritonavir.
62234262|NCT06485752|ACTIVE_COMPARATOR|Lot 3 (Group 3)|influenza B-Victoria lineage strains
62234263|NCT03586687|ACTIVE_COMPARATOR|20 mg Triamcinolone with 3cc of 1% Lidocaine|20mg Triamcinolone with 3cc of 1% Lidocaine
62234264|NCT03586687|ACTIVE_COMPARATOR|40 mg Triamcinolone with 3cc of 1% Lidocaine|40mg Triamcinolone with 3cc of 1% Lidocaine
62425256|NCT00420355|EXPERIMENTAL|Arm B|Subjects on lopinavir/ritonavir will add atazanavir.
62425257|NCT01560182|EXPERIMENTAL|OTL-200 Gene Therapy|CD34+ cells transduced ex vivo with lentiviral vector encoding ARSA cDNA
62425258|NCT04573361|NO_INTERVENTION|Group Control|Patients having no access to chiropractic treatment during the trial
62234265|NCT03586687|ACTIVE_COMPARATOR|80 mg Triamcinolone with 3cc of 1% Lidocaine|80mg Triamcinolone with 3cc of 1% Lidocaine
62425259|NCT04573361|EXPERIMENTAL|Group Chiropractic Care one session|Patients having access to in-person chiropractic treatment once during the trial
62425260|NCT04573361|EXPERIMENTAL|Group Chiropractic Care multiple sessions|Patients having access to in-person chiropractic treatment more than once during the trial
62425261|NCT04040959|EXPERIMENTAL|Nicotinamide Riboside|Each nicotinamide riboside capsule contains 250 mg of nicotinamide riboside chloride mixed with microcrystalline cellulose. Dosage: 500 mg by mouth twice a day for 3 months.
62810374|NCT04040374|ACTIVE_COMPARATOR|Expert endoscopist diagnosis|The expert endoscopists are two physicians with experience of more than 20,000 endoscopies. The expert endoscopists will review the endoscopy images of each patient for 5 min. They will then report endoscopy images in which gastric cancer was detected and manually annotate the lesions in those images.
62234266|NCT02767401|ACTIVE_COMPARATOR|PCI using stenting or balloon expansion|Opening single CTO lesions using drug-eluting stents (such as Xience V and Prime, Endeavor Resolute, Taxus express and Libete, Excel, Partner, BUMA, YINYI, TIVOLI,Firebird2,FireHawk, and Coroflex) or balloon expansion plus optimal medical therapy. Intravascular ultrasound (IVUS),optimal coherence tomgraphy (OCT) or fractional flow reserve (FFR) is used if they are needed. Optimal medical therapy includes dual antiplatelet therapy and statins. And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-angina therapy should be used if the patients have symptoms.
62234267|NCT02767401|NO_INTERVENTION|Optimal medical therapy|Optimal medical therapy. It includes dual antiplatelet therapy and statins. And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
62810375|NCT04355234|EXPERIMENTAL|all patients|
62810376|NCT04355234|EXPERIMENTAL|patients who presented a SARS-CoV-2 infection confirmed by PCR|
62810377|NCT01005251|EXPERIMENTAL|60 mg|PPI+lesogaberan (AZD3355) 60 mg bid
62810378|NCT01005251|EXPERIMENTAL|120 mg|PPI+lesogaberan (AZD3355) 120 mg bid
62810379|NCT01005251|EXPERIMENTAL|180 mg|PPI+lesogaberan (AZD3355) 180 mg bid
62810380|NCT01005251|EXPERIMENTAL|240 mg|PPI+lesogaberan (AZD3355) 240 mg bid
62810381|NCT01005251|PLACEBO_COMPARATOR|Placebo|PPI+ Placebo
62810382|NCT01672385|EXPERIMENTAL|Intervention Group|Telemonitoring plus self-management support
62810383|NCT01672385|NO_INTERVENTION|Usual Care Group|Usual Care
62810384|NCT04939766|OTHER|Type 1 diabetic patients under CSII eligible for closed loop use|Diabetic patients age 13 or above under CSII with continuous glucose monitoring matching eligibility criteria for the use of a closed loop during a 6 months period. During the study, 4 physical appointments with a diabetologist and 3 phone contacts are anticipated.
62810385|NCT02919774|EXPERIMENTAL|POMA 40 mg BID|40 mg BID for 10 days
62810386|NCT02919774|EXPERIMENTAL|POMA 160 mg BID|160 mg BID for 10 days
62810387|NCT02919774|PLACEBO_COMPARATOR|Placebo|Placebo BID for 10 days
62810388|NCT01502748|EXPERIMENTAL|Endovascular Sampling|Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations in acute stroke patients undergoing endovascular recanalization who received intravenous Magnesium Sulfate as a part of the FAST-MAG study
62234268|NCT03931733|ACTIVE_COMPARATOR|Music Therapy Intervention|Receiving one thirty minute music therapy intervention.
62234269|NCT03931733|NO_INTERVENTION|Usual Care|Receiving usual care for a patient in the ICU during a 30 minute intervention.
62234270|NCT00639223|ACTIVE_COMPARATOR|Pravastatin|
62234271|NCT00639223|EXPERIMENTAL|Red yeast Rice|
62810389|NCT04078802|EXPERIMENTAL|VNOTES ARM|treatment of Vaginal prolapse with VNOTES surgery and apical suspension to the uterosacral ligaments.
62810390|NCT04078802|EXPERIMENTAL|Vaginal hysterectomy Arm|treatment of Vaginal prolapse with classic vaginal hysterectomy surgery and apical suspension to the uterosacral ligaments.
62810391|NCT06391554|EXPERIMENTAL|PRT + EDU|
62810392|NCT06391554|ACTIVE_COMPARATOR|EDU|
62810393|NCT01862146||Current Smoker underwent TCA|subjects who smokes daily
62810394|NCT01862146||Former Smokers underwent TCA|subjects who do not smoke since 7 years
62810395|NCT00666666|EXPERIMENTAL|AT101 (R-(-)-gossypol acetic acid)|Patients will receive Hormone therapy with at least one LHRH agent (Leuprolide Acetate or Goserelin) for 6 weeks and include bicalutamide. Patients will begin AT101 daily at 6 weeks for 3 weeks of every 4 weeks (4 weeks - 1 cycle) and continue for 8 cycles of combined therapy (combined AT101, and LHRH agonist). After 8 cycles patients will continue hormonal therapy.
62234272|NCT01526070||Patients with Exudative Age-Related Macular Degeneration|Patients with eAMD who received intravitreal thearpy
62234273|NCT01688414|EXPERIMENTAL|Diagnostic (fluorescence imaging, PAI)|Patients undergo fluorescence imaging and PAI during robot assisted laparoscopic surgery.
62234274|NCT00861224||Observed Subjects|Subjects that submitted bone marrow biopsy and aspirates.
62810396|NCT05919342|NO_INTERVENTION|Routine care arm|Patients in this arm will undergo routine care. They will be managed and followed up as per routine clinical care. They will be remotely monitored for HF events by follow up through electronic records and routinely collected data.
62810397|NCT05919342|EXPERIMENTAL|Investigational arm|Patients in this arm will have a blood sample performed for measurement of N-terminal prohormone of B-type natriuretic peptide (NT-proBNP). Patients with an elevated Roche NT-proBNP (≥125 pg/mL) will undergo a transthoracic echocardiogram, clinical examination for signs of HF, HF symptom assessment, an ECG). Patients will undergo echocardiography with a CE-marked, FDA-approved handheld point of care (POC) EchoNous echocardiogram device in all countries. The US2.ai algorithm (which is also CE-marked and FDA-approved) will generate an AI-automated echocardiogram report.
62234275|NCT00846391|EXPERIMENTAL|MK8245 5 mg b.i.d.|MK8245
62234276|NCT00846391|EXPERIMENTAL|MK8245 50 mg b.i.d.|MK8245
62234277|NCT00846391|PLACEBO_COMPARATOR|Placebo|Placebo
62810398|NCT04921943|EXPERIMENTAL|Hypertonic saline|Patients who randomize to the hypertonic saline arm will be prescribed a nebulizer device to nebulize hypertonic saline (7%) twice daily for 12 weeks. Hypertonic saline (3%) can be prescribed in the case of poor tolerability of the 7% solution.
62810399|NCT04921943|ACTIVE_COMPARATOR|Standard of Care|Patients who randomize to the standard of care arm will receive treatment for pulmonary MAC based on the approved ATS/IDSA guidelines. Changes to standard of care regimen may be made based on the investigator's discretion.
62810400|NCT03200444|EXPERIMENTAL|Testing of 6 adhesive strips|"Each subject tests six adhesive strips on pre-striped skin.~1. Standard adhesive 1~2. standard adhesive 2~3. Standard adhesive 3~4. P-4~5. P-15~6. P-16~The six strips are applied on abdominal skin. The order to which the adhesive strips are located on the skin is randomized. The subjects will change the adhesive strips at home and the adhesion of the adhesive strips will be measured at 5 visits."
62033998|NCT03326687|EXPERIMENTAL|Treatment BABA|Participants will receive anomia treatment in isolation and will perform a physical endurance task in isolation during A phases. They will receive anomia treatment in combination with performing a physical endurance task during B phases.
62810401|NCT03691493|EXPERIMENTAL|Radiation, palbociclib, hormone therapy|Patients undergo radiation therapy over 5-10 days and receive palbociclib PO QD on days 1-21. At the discretion of treating physician, patients also receive letrozole, anastrozole, exemestane, or tamoxifen PO QD on days 1-28, or fulvestrant IM on days 1 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62033999|NCT03526250|EXPERIMENTAL|Treatment (palbociclib)|Patients receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62810402|NCT03816735|ACTIVE_COMPARATOR|hyaluronic acid suppository therapy|"Women receive a vaginal suppository called Cikatridina manufactured by the company Angelini to treat women with GSM. Angelini Pharma Österreich GmbH's headquarters are located in Brigittenauer Lände 50-54, 1200 Wien, Austria. The suppositories contain ontain hyaluronic acid, tea tree oil, tigergras extract, and aloe vera."
62810403|NCT03816735|ACTIVE_COMPARATOR|Juliet feminine laser|The fractional microablative laser with 2940 nm wavelength has a high degree of absorption in water and selectively stimulates the synthesis of sub-mucosal collagen. The erbium-doped yttrium-aluminum-garnet (Er:YAG) laser has been successfully used in the field of plastic skin rejuvenation and reconstruction. The procedure is based on photothermic treatment of connective tissue: It has been established in animal and human studies that it affects collagen remodeling resulting in tightening of the supportive tissue.
62810404|NCT01009060|EXPERIMENTAL|GSK239512|Repeat dose.
62810405|NCT01009060|PLACEBO_COMPARATOR|Placebo|Repeat dose. Placebo to match GSK239512
62810406|NCT05647681|ACTIVE_COMPARATOR|"topic analgesic Douloff"|"Patients receive a tpic analgesic douloff in association with an oral treatment placebo"
62810407|NCT05647681|ACTIVE_COMPARATOR|oral paracetamol|Patients receive oral paracetamol in association with a topic placebo
62810408|NCT02918617|ACTIVE_COMPARATOR|Control toothpaste containing Novamin® technology|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
62810409|NCT02918617|PLACEBO_COMPARATOR|Control toothpaste containing 1500 ppm fluoride as MFP|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
62810410|NCT02918617|EXPERIMENTAL|Test toothpaste with nano-HAP (high concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
62810411|NCT02918617|EXPERIMENTAL|Test toothpaste with nano-HAP (low concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
62810412|NCT02918617|EXPERIMENTAL|Test toothpaste with nano-HAP and potassium nitrate (KNO3)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
62034000|NCT01913600|OTHER|Resolute Integrity|Resolute Integrity Stent
62034001|NCT03942250|EXPERIMENTAL|Treated|Patients who received REGE pro dressing on EB wounds lesion weekly for 10 weeks
62034002|NCT05677087|EXPERIMENTAL|Prepare project education|This group will receive an intensive 6-week remote nutrition education intervention
62034003|NCT00242112|OTHER|MRI - pathology|
62034004|NCT06104475|EXPERIMENTAL|CT scan intervention|
62034005|NCT01460329||USCOM Cardiac index|
62234278|NCT05023343|ACTIVE_COMPARATOR|Active|Unilateral transmuscular quadratus lumborum block using 30 mL 0.75% ropivacaine
62810413|NCT02918617|PLACEBO_COMPARATOR|Control toothpaste without nano-HAP|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
62810414|NCT02918617|EXPERIMENTAL|Test toothpaste with nano-HAP (medium concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
62810415|NCT02918617|EXPERIMENTAL|Test cream with nano-HAP (higher concentration)|Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
62810416|NCT02918617|PLACEBO_COMPARATOR|Control cream without nano-HAP|Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
62425262|NCT04040959|PLACEBO_COMPARATOR|Placebo|Matched placebo capsules.
62425263|NCT04326569|EXPERIMENTAL|adults with trans-sphenoidal endoscopic pituitary surgery|adult with trans-sphenoidal endoscopic pituitary surgery for tumour of the sellar region
62810417|NCT02137863|PLACEBO_COMPARATOR|Control|"Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.~During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.~100 ml/10min 0.9 % NaCl administered intravenously just before the angiography.~1 ml/kg/h 0.9 % sodium chloride administered intravenously during the procedure and was continued 1 hour after the angiography."
62810418|NCT02137863|ACTIVE_COMPARATOR|Dexmedetomidine|"Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.~During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.~Dexmedetomidine was diluted as 1 μg/ml. 1 μg/kg/10min dexmedetomidine administered intravenously just before the angiography.~1 μg/kg/h dexmedetomidine administered intravenously during the procedure and was continued 1 hour after the angiography."
62810419|NCT01229189|EXPERIMENTAL|Maternal and Neonatal Intervention Arm|Pregnant women will be individually randomized; a daily dose of vitamin D in 4000 IU will be given to Intervention group, started at 20-22 weeks of pregnancy till the time of delivery. The infants of this group will further stratify into two groups, one group will receive 400 IU of Vitamin D for 6 months as Intervention.
62810420|NCT01229189|PLACEBO_COMPARATOR|Maternal and Neonatal Control Arm|
62810421|NCT03324607|EXPERIMENTAL|single arm|glycopyrrolate/formoterol (Bevespi) 2 puffs twice a day taken for two weeks, started after completion of the study XeMRI. A follow up xeMRI occurs at the end of the two weeks of taking the Bevespi in a Pre-post study design.
62810422|NCT06062654|EXPERIMENTAL|Hospital-assisted Rehabilitation Treatment|Patients in the experimental group will undergo 10 sessions (about 2 each week) of rehabilitation treatment at the outpatient clinics of the U.O. Physical Medicine and Rehabilitation Unit of the Rizzoli Orthopedic Institute. The rehabilitation protocol consists of a series of commuting exercises and passive/active mobilization exercises of the glenohumeral joint.
62810423|NCT06062654|ACTIVE_COMPARATOR|Home-based Rehabilitation Treatment|Patients in the experimental group will have 10 sessions (about 2 each week) of rehabilitation treatment with exercises to be performed self-assisted at home. The rehabilitation protocol consists of a series of commuting exercises and passive/active mobilization exercises of the glenohumeral joint
62810424|NCT05350722|EXPERIMENTAL|Pre-operative single dose partial breast irradiation|
62810425|NCT00911118|EXPERIMENTAL|Radiation|Patients enrolled in the study will undergo image-guided, intensity-modulated radiotherapy using the same equipment, techniques, and treatment-planning procedures as currently practiced as MSKCC. MSKCC patients will have the option of continued follow-up through MSKCC's established Prostate Survivorship Clinic for an indefinite period of time, meaning patients enrolled in the protocol will be encouraged to remain at MSKCC for life-long follow-up after their treatment. The standard assessments obtained in the Survivorship Clinic will not be altered. All protocol relevant data collected at these visits through month 60 will be used for protocol analysis.
62810426|NCT03550118|EXPERIMENTAL|Aim 2 - Adjustable Socket - Researcher Controls|An adjustable socket is tested where researchers control the adjustments. This arm focuses on socket size adjustments while walking.
62810427|NCT03550118|EXPERIMENTAL|Aim 3 - Adjustable Socket - Participant Controls|An adjustable socket is tested where the study participant controls the adjustments. This arm focuses on socket size adjustments while walking.
62810428|NCT03550118|EXPERIMENTAL|Aim 4 - Adjustable Socket - Automatic Controls|An adjustable socket is tested where a control system is used to automatically control the adjustments. This arm focuses on socket size adjustments while walking.
62810429|NCT03550118|EXPERIMENTAL|Aim 6A - Release/Recovery - Researcher Controls|An adjustable socket is tested where researchers control the adjustments. This arm focuses on a socket release and recovery mechanism that allows for full or partial doffing of the socket while seated.
62810430|NCT03550118|EXPERIMENTAL|Aim 6B - Release/Recovery - Participant Controls|An adjustable socket is tested where the study participant controls the adjustments. This arm focuses on a socket release and recovery mechanism that allows for full or partial doffing of the socket while seated.
62425264|NCT02691312||Type 1 diabetes (T1D)|Pediatric patients with type 1 diabetes (T1D) will have an eye exam using the Digital Retinography System (DRS) taking non-mydriatic fundus images. If the test is positive or inconclusive, subjects will be notified and referred to an ophthalmologist for a dilated retinal exam. A chart review and questionnaire will be completed to evaluate for risk factors predisposing subjects to diabetic retinopathy.
62593757|NCT06178952|EXPERIMENTAL|Verum TPS|Participants will receive 5 Verum TPS sessions over a period of 10 days, with a singular daily session, each lasting approximately 30 minutes
62593758|NCT06178952|SHAM_COMPARATOR|Sham TPS|Participants will receive 5 Sham TPS sessions over a period of 10 days, with a singular daily session, each lasting approximately 30 minutes
62234279|NCT05023343|PLACEBO_COMPARATOR|Placebo|Unilateral transmuscular quadratus lumborum block using 30 mL isotonic saline
62234280|NCT02921204||Vitamin D status|Subjects are recruited to asses Vitamin D status with no interventions
62593759|NCT03994705|EXPERIMENTAL|Dose-Escalation|
62425265|NCT05620459|EXPERIMENTAL|Interventional arm (Ridge augmentation with simultaneous implant placement)|"Chin bone ring is harvested using surgical guide to augment~1. anterior maxillary defective recent extraction sockets OR~2. remaining roots that need extraction and are accompanied with labial bone loss Associated with simultaneous implant placement with the aid of surgical guides"
62425266|NCT02558660|EXPERIMENTAL|Double Up Food Bucks|Clinic-based educational intervention about an existing SNAP healthy food incentive program, as well as a $10 voucher to spend on produce at farmers markets
62425267|NCT01241812|EXPERIMENTAL|A.|10 weeks of partially supervised lower limb muscle strengthening targeting the following muscles groups: quadriceps, hamstrings, hip abductors.
62425268|NCT01241812|NO_INTERVENTION|B|
62234281|NCT04824521|EXPERIMENTAL|Mindfulness-Oriented Recovery Enhancement via tele-health|Participants will be assigned to 8 weeks of Mindfulness-Oriented Recovery Enhancement delivered via tele-health.
62593760|NCT05533957|EXPERIMENTAL|Oxygen therapy administration|Three different dosages of oxygen therapy will be administered to Chronic Obstructive Pulmonary Disease (COPD) with Chronic Respiratory Failure (CRF) and Long Oxygen Therapy (LTOT)
62810431|NCT03550118|EXPERIMENTAL|Aim 8 - Panel Pull During Resting|"The purpose of Aim #8 was to determine if vacuum-like action (panel pull) during resting between periods of activity facilitated limb fluid volume recovery and retention in transtibial prosthesis users. Liner attached to panels."
62234282|NCT02705144||biopsies from lung tissue affected by emphysema|analysis of the number of stem cell niches
62234283|NCT02705144||biopsies from lung tissue affected by interstitial fibrosis|analysis of the number of stem cell niches
62425269|NCT05294770|EXPERIMENTAL|Very Low Calorie Diet (VLCD)|Patients randomized to this group will receive a VLCD, which consists of a replacement diet based on a liquid enteral formula (46% carbohydrates, 19% fat and 32% protein; 654 Kcal/day): OPTISOURCE® PLUS, taken as 3 shakes a day. In addition, participants may consume 2 pieces of fruit/day (about 250 g/day) and up to 300 g/day of non-starchy vegetables according to the list of foods that will be provided to patients; this will constitute a total daily energy intake of about 800 Kcal. In addition, protein intake (0.8 to 1.3 g/kg/day of adjusted weight) will be adjusted by adding Resource® Instant Protein individually, depending on the anthropometry and the renal function of the patients (to preserve fat free mass, whose loss has been correlated with subsequent weight recovery)
62810432|NCT03550118|EXPERIMENTAL|Aim 9 - Panel Pull During Ambulation|"Extending from the Aim #8 results, we sought to determine in Aim #9 if vacuum-like action during ambulation facilitated limb fluid volume recovery and retention. Vacuum-like action was achieved by quickly pulling the panels and liner (liner attached to panels) radially outward during late stance phase and then moving them back to their original position during early swing."
62234284|NCT02705144||biopsies from normal appearance lung tissue|analysis of the number of stem cell niches
62234285|NCT02092974|EXPERIMENTAL|tDCS + SSRI|
62234286|NCT02092974|PLACEBO_COMPARATOR|tDCS + placebo|
62425270|NCT05294770|ACTIVE_COMPARATOR|Hypocaloric Mediterranean diet|Randomized participants in this group will be recommended to follow a Mediterranean Diet, based on the use of olive oil as the main source of visible fat and regular consumption of vegetables (≥2 servings/day), fruits (≥3 servings/day), legumes (≥3 servings/week) and fish (≥3 times a week), reducing the consumption of red meat or sausages (\<2 times a week) and eliminating the consumption of sugary drinks, pastries or industrial pastries. In this Mediterranean Diet, an energy restriction of 30% of the estimated energy needs (Harris-Benedict equation) will be established.
62425271|NCT00406107|ACTIVE_COMPARATOR|Pegaptanib Sodium 0.3mg (Macugen)|Intravitreous injections of Macugen 0.3mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.
62425272|NCT00406107|ACTIVE_COMPARATOR|Pegaptanib Sodium 1 mg (Macugen)|Intravitreous injections of Macugen 1.0mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.
62593761|NCT00921102|PLACEBO_COMPARATOR|Control|Patients in this group will receive both an intrathecal and intravenous injection of saline solution, as a placebo comparator.
62593762|NCT00921102|EXPERIMENTAL|Intrathecal Atropine|Patients in this group will receive intrathecal atropine as a prophylactic antiemetic agent. They will also receive intravenous saline solution to maintain blinding.
62593763|NCT00921102|ACTIVE_COMPARATOR|IV Atropine|Patients in this group will receive a small dose of atropine via the intravenous route to examine its possible antiemetic activity. They will also receive intravenous saline solution to maintain blinding.
62819567|NCT03009058|EXPERIMENTAL|IMM-101+cyclophosphamide|"IMM-101 will be given in combination with low dose cyclophosphamide (300mg/m2 in patients with solid malignancies.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
62819568|NCT06465589|EXPERIMENTAL|Randomized Anonymous|After participants are randomized to the randomization arm, they will once again be randomized to the program versions. Participants in this arm will use the anonymous program.
62234287|NCT02092974|SHAM_COMPARATOR|sham-tDCS + SSRI|
62234288|NCT02092974|PLACEBO_COMPARATOR|sham-DCS + placebo|
62234289|NCT02435966|EXPERIMENTAL|Manual therapy + Dry needling|Manual therapy + Dry needling: 2 sessions, after a 7 days interval
62234290|NCT02435966|OTHER|Manual therapy + Sham Dry needling|Manual therapy + Sham Dry needling: after a 7 days interval
62234291|NCT02435966|NO_INTERVENTION|Untreated control|Natural history of the condition
62810433|NCT03550118|EXPERIMENTAL|Aim 10 - Adjustable Socket Out of Lab Testing|"Participants took the investigational device home in one of three test modes. In the first mode, the panels were in a locked flush position, similar to their traditional prosthesis. Participants were not able to adjust the panels in this first mode. The second mode allowed participants to manually make panel adjustments, incrementally enlarging or tightening the panels radially. Lastly, the third mode implemented the automated controller developed in the previous aims. Participants were still able to make manual adjustments to the panel positions but during walks adjustments would also occur automatically. Each mode was tested for a minimum of 1 week."
62810434|NCT04203511|EXPERIMENTAL|Chemoradiation therapy + INCMGA00012|
62810435|NCT04203511|ACTIVE_COMPARATOR|Chemoradiation therapy + Placebo|
62810436|NCT02257398|EXPERIMENTAL|Sequence ABDC|Subjects will be administered treatments in Sequence ABDC where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
62810437|NCT02257398|EXPERIMENTAL|Sequence BCAD|Subjects will be administered treatments in Sequence BCAD where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
62810438|NCT02257398|EXPERIMENTAL|Sequence CDBA|Subjects will be administered treatments in Sequence CDBA where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
62810439|NCT02257398|EXPERIMENTAL|Sequence DACB|Subjects will be administered treatments in Sequence DACB where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
62425273|NCT05933226|EXPERIMENTAL|Khanya|Khanya is a peer-delivered, behavioral intervention to improve HIV medication adherence and reduce problematic SUD symptoms. Khanya is delivered as a stepped-care package in which the least resource-intensive part of the intervention (i.e., Life-Steps, a single session problem solving intervention for HIV medication adherence) will be delivered first. Only individuals randomized to the Khanya intervention who are still struggling with HIV medication adherence after the first session will be stepped up to receive the more comprehensive, resource-intensive part of the intervention (i.e., six additional sessions of the intervention). Khanya Step 2 includes evidence-based treatment components to improve ART adherence and SUD, including motivational interviewing, behavioral activation, and mindfulness-based relapse prevention strategies, which have previously been piloted in this community.
62034006|NCT05719454|EXPERIMENTAL|CNT Setup Algorithm Version 1|When performing the Setup Algorithm Version 1, each subject's blood pressure is measured with a standard cuff system while the BackBeat-CNT is activated, and system parameters are varied successively according to a specified sequence or based on the blood pressure measurements obtained during previous activations of BackBeat CNT, until the Setup Algorithm is complete. The parameter values as determined by the Setup Algorithm will constitute the programming of the Moderato IPG for the 24 hour activation following setup.
62810440|NCT03065816|EXPERIMENTAL|Sequence 1 (Z0063 to Gaviscon)|The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose
62034007|NCT05719454|EXPERIMENTAL|CNT Setup Algorithm Version 2|When performing the Setup Algorithm Version 1, each subject's blood pressure is measured with a standard cuff system while the BackBeat-CNT is activated, and system parameters are varied successively according to a specified sequence or based on the blood pressure measurements obtained during previous activations of BackBeat CNT, until the Setup Algorithm is complete. The parameter values as determined by the Setup Algorithm will constitute the programming of the Moderato IPG for the 24 hour activation following setup.
62593764|NCT04090528|EXPERIMENTAL|Arm 1: One DNA vaccine|"100 µg pTVG-HP administered intradermally (i.d.) days 1, 8 plus 200 mg Pembrolizumab, administered intravenously on day 1 of 21-day cycles (for 8 cycles)~Following cycle 8, subsequent 21-days cycles: Pembrolizumab 200 mg IV day 1 of 21-day cycles~In the event of PSA rise (25% increase over cycle 9 day 1, minimum of 2 ng/ml), and no evidence of radiographic progression, participants will receive 4 additional vaccine booster cycles: 100 µg pTVG-HP i.d. days 1, 8 + 200 mg pembrolizumab IV day 1 of 21-day cycles x 4 cycles"
62425274|NCT05933226|NO_INTERVENTION|Enhanced Standard of Care (ESOC)|Enhanced Standard of Care (ESOC) includes the local standard of care, which is referral to a free local outpatient substance use treatment program, enhanced with facilitated referrals. To enhance the standard of care, study staff will provide participants with a detailed description of the program's referral process and offer to help the participant set up an intake at the program. Additionally, the team will follow up on the referral.
62425275|NCT00068406|EXPERIMENTAL|Treatment (conventional surgery, radiation therapy, cisplatin)|"Patients undergo radiotherapy daily on days 1-5 and receive concurrent cisplatin IV over 30 minutes on day 1. Treatment repeats weekly for approximately 6.5 weeks (a total of 32 fractions of radiotherapy) in the absence of unacceptable toxicity.~Six to eight weeks after the completion of chemoradiotherapy, patients with a complete clinical response may undergo incisional biopsy of the primary tumor and bilateral inguinal/femoral nodes (if the groin nodes were initially unresectable). Patients with microscopic or gross resectable residual disease may then undergo radical resection of the residual tumor. Patients with unresectable disease after the completion of chemoradiotherapy receive additional radiotherapy with 1-2 courses of concurrent cisplatin."
62593765|NCT04090528|EXPERIMENTAL|Arm 2: Two DNA vaccines|"100 µg pTVG-AR administered intradermally (i.d.) on days 1, 8 plus 200 mg Pembrolizumab administered intravenously day 1 of 21-day cycles, for cycles 1, 2, 5, and 6 alternating with 100 µg pTVG-HP administered intradermally (i.d.) on days 1, 8 plus 200 mg Pembrolizumab administered intravenously day 1 of 21-day cycles, for cycles 3, 4, 7, and 8.~Following cycle 8, subsequent 21-days cycles: Pembrolizumab 200 mg IV day 1 of 21-day cycles~In the event of PSA rise (25% increase over cycle 9 day 1, minimum of 2 ng/ml), and no evidence of radiographic progression, participants will receive 4 additional vaccine booster cycles: 100 µg pTVG-AR i.d days 1, 8 + 200 mg pembrolizumab IV day 1 of q 21-day cycles, for cycles 1 and 2 followed by 100 µg pTVG-HP i.d. days 1, 8 + 200 mg pembrolizumab IV day 1 in 21-day cycles, for cycles 3 and 4"
62810441|NCT03065816|EXPERIMENTAL|Sequence 2 (Gaviscon to Z0063)|The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose
62810442|NCT02284204|ACTIVE_COMPARATOR|Midazolam and Ketamine|In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). This combination of drugs were administered fifteen minutes before the start of treatment sessions.
62425276|NCT03954964|NO_INTERVENTION|Control Group|Subjects participating in a total joint class for patients undergoing planned hip and knee total joint replacement.
62425277|NCT03954964|EXPERIMENTAL|Intervention Group|Subjects participating in a total joint class for patients undergoing planned hip and knee total joint replacement will receive additional education about the disposal of opioids.
62425278|NCT02962531|EXPERIMENTAL|Treatment A|A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fasted conditions
62425279|NCT02962531|EXPERIMENTAL|Treatment B|A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fed conditions
62034008|NCT05719454|OTHER|CNT therapy optimization without use of the Setup Algorithm|For this optimization procedure, each subject's blood pressure is measured with a continuous blood pressure measurement system while the BackBeat-CNT is activated, and system parameters are varied according to a specified sequence until the desired blood pressure reduction is achieved. The parameter values that provide the desired blood pressure reduction will be recorded, for possible use by the investigator following trial completion
62034009|NCT04514159|EXPERIMENTAL|ZN-c5 + abemaciclib combination therapy|Participants will take abemaciclib (150mg) orally twice a day and ZN-c5 (dose escalation) orally once or twice a day to determine the safety, tolerability, and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D).
62425280|NCT02962531|EXPERIMENTAL|Treatment C|A single 1600 mg aqueous dispersion (20 mL) oral dose of IX-01 under fasted conditions.
62593766|NCT03836261|EXPERIMENTAL|Acalabrutinib, Venetoclax|Acalabrutinib in combination with Venetoclax
62593767|NCT03836261|EXPERIMENTAL|Acalabrutinib, Venetoclax, Obinutuzumab|Acalabrutinib in combination with Venetoclax with Obinutuzumab
62819569|NCT06465589|ACTIVE_COMPARATOR|Randomized Standard|After participants are randomized to the randomization arm, they will once again be randomized to the program versions. Participants in this arm will use the standard program.
62034010|NCT00738777|ACTIVE_COMPARATOR|1|Anastrozole
62425281|NCT00736931|EXPERIMENTAL|1|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
62425282|NCT00736931|ACTIVE_COMPARATOR|2|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
62425283|NCT00736931|ACTIVE_COMPARATOR|3|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
62810443|NCT02284204|EXPERIMENTAL|Midazolam, Ketamine and Sevoflurane|In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). After fifteen minutes of this drug administration, the investigators start to provide sevoflurane, through a nasal hood, in an initial concentration of 0.1%, with 0.1% increment every 30 seconds, until a final expired concentration between 0.3 and 0.4%.
62810444|NCT04087980|EXPERIMENTAL|Poseidon System Treatment|
62234292|NCT01722149|EXPERIMENTAL|Adoptive Transfer of re-directed T cells|Adoptive Transfer of re-directed FAP specific T cells in the pleural effusion
62234293|NCT04495803|EXPERIMENTAL|Experimental|After an initial assessment to confirm eligibility, the experimental group will receive 8 weekly sessions (2 hours long) of our augmented group CBT for perinatal anxiety during a global pandemic (n=6 per group). Participants will be re-assessed at post-treatment and at a 3-month follow-up to determine the effectiveness of the treatment and whether these effects are maintained in the long-term.
62234294|NCT03894254|EXPERIMENTAL|Patients with subjective cognitive complaint or neurocognitive|: Real-life cohort patients with subjective cognitive complaint or neurocognitive disorders undergoing medical examination in memory centers, and for whom extensive evaluations will be performed for the study
62234295|NCT02721745|EXPERIMENTAL|Natural Fatigue|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
62810445|NCT02559622|EXPERIMENTAL|300 mg secukinumab|300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)
62810446|NCT02559622|EXPERIMENTAL|150 mg secukinumab|150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)
62234296|NCT02721745|EXPERIMENTAL|tDCS anodal|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
62234297|NCT02721745|EXPERIMENTAL|tDCS cathodal|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
62234298|NCT02721745|EXPERIMENTAL|tDCS sham|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
62234299|NCT02721745|EXPERIMENTAL|inhibitory TMS|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
62234300|NCT02721745|EXPERIMENTAL|Sham TMS|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
62425284|NCT00736931|PLACEBO_COMPARATOR|4|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
62425285|NCT02762968|PLACEBO_COMPARATOR|Placebo|Placebo capsules similar to the experimental treatments.
62810447|NCT02559622|OTHER|Placebo followed by 300 mg secukinumab|Placebo until week 12 followed by 300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)
62810448|NCT02559622|OTHER|Placebo followed by 150 mg secukinumab|Placebo until week 12 followed by 150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)
62810449|NCT02648204|EXPERIMENTAL|Semaglutide 0.5 mg/Week|
62810450|NCT02648204|EXPERIMENTAL|Semaglutide 1.0 mg/Week|
62810451|NCT02648204|ACTIVE_COMPARATOR|Dulaglutide 0.75 mg/Week|
62810452|NCT02648204|ACTIVE_COMPARATOR|Dulaglutide 1.5 mg/Week|
62034011|NCT00738777|EXPERIMENTAL|2|Anastrozole + Fulvestrant
62234301|NCT04086654|OTHER|International Trauma Interview (ITI)|
62234302|NCT02475486|OTHER|high fatigue|Measure of ANS by VistaO2 device in Rheumatoid arthritis (RA) patients with low disease activity according to DAS28 \<3.2 with visual analog scale of fatigue is \> 5
62234303|NCT02475486|OTHER|low fatigue|Measure of ANS by VistaO2 device in Rheumatoid arthritis (RA) patients with low disease activity according to DAS28 \<3.2 with visual analog scale of fatigue is \< or equal to 5
62234304|NCT03660553|ACTIVE_COMPARATOR|Multiple Subcutaneous Injection (MSI)|MSI group will receive four insulin injections per day that will include a long acting and a short acting insulin. Short acting insulin will be either insulin aspart or insulin lispro.
62234305|NCT03660553|EXPERIMENTAL|Basal Insulin (BI)|BI group will receive only one injection of insulin glargine in the morning.
62234306|NCT04530409|EXPERIMENTAL|Early CS|early use of dexamethasone as early as the laboratory confirmation of inflammation.
62234307|NCT04530409|NO_INTERVENTION|Late CS|Dexamethasone is to be used lately upon the deterioration of cases i.e. sPO2 \< 92%
62425286|NCT02762968|EXPERIMENTAL|HMB|HMB capsules providing 3 g of calcium HMB per day.
62425287|NCT02762968|EXPERIMENTAL|HMB + BC30|Capsules providing 3 g calcium HMB per day plus Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
62425288|NCT02400827||cryopreservation|
62425289|NCT03013517|EXPERIMENTAL|Viaskin Peanut 250µg|
62425290|NCT02258607|EXPERIMENTAL|Momelotinib (MMB) dose escalation|Participants will receive momelotinib (MMB) plus trametinib. Momelotinib (MMB) dose will increase to find the MTD.
62425291|NCT02258607|EXPERIMENTAL|Trametinib dose escalation|Participants will receive momelotinib (MMB) plus trametinib. Trametinib dose will increase to find the MTD.
62234308|NCT03608982|EXPERIMENTAL|Simulated patient|The materials in this course are standardized, and consist of lectures with a slide show, questions \& answers conversations, and practical exercises on fellow-students. The courses are being taught by professional first aid tutors from the Belgian Red Cross. During the practical exercises, a simulated patient will unexpectedly enter the room requiring treatment.
62425292|NCT02258607|EXPERIMENTAL|Momelotinib (MMB)+trametinib|Expansion Phase: participants will receive momelotinib (MMB) plus trametinib for the duration of the study.
62593768|NCT03836261|ACTIVE_COMPARATOR|Chemoimmunotherapy|"Chemoimmunotherapy~FCR: Fludarabine, Cyclophosphamide and Rituximab~BR: Bendamustine and Rituximab"
62810453|NCT02436525|ACTIVE_COMPARATOR|Group I:|"will be treated using conventional stainless steel orthodontic brackets ligated with stainless steel ligature. Oromco - USA.~."
62810454|NCT02436525|EXPERIMENTAL|Group II|: will be treated using passive self-ligating stainless steel orthodontic brackets Oromco - USA.
62810455|NCT02436525|EXPERIMENTAL|Group III:|will be treated by active self-ligating stainless steel orthodontic brackets Oromco - USA .
62810456|NCT02904798|EXPERIMENTAL|Polypodium Leucotomos Extract (PLE)|"Patient will serve as their own control and will be exposed to 4 doses of visible light on one side of their back prior to receiving PLE.~PLE 240mg will be dispensed to patient after evaluation of Pre-PLE visible light doses are evaluated to be taken by the patient for a total of 28 day followed by exposure of the opposite side of the back with the same 4 doses of visible light as above"
62810457|NCT02715739||All participants|
62810458|NCT06373016|EXPERIMENTAL|Ketone Supplement-MRI/MRS|Participants (both the Bipolar Cohort and Healthy Comparison Cohort) will be tested twice, both times in an overnight fasting condition (8 hours no food, unrestricted water). Halfway through each of the two scan sessions, participants will be asked to drink either glucose (on one day) or ketones (on the other day). This within-subjects comparison will allow investigators to observe the effects of metabolism on brain function. Participants' glucose and ketone levels will also be measured, using a finger-prick blood measurement at three different times: 1) immediately before the scan session 2) 10 minutes after drinking the glucose or supplement 3) immediately following the scan session.
62810459|NCT03660462|ACTIVE_COMPARATOR|FeSO4 fortified rice test meal|
62810460|NCT03660462|EXPERIMENTAL|FePO4 fortified rice test meal|
62810461|NCT03660462|EXPERIMENTAL|HiFePO4 1 fortified rice test meal|
62810462|NCT03660462|EXPERIMENTAL|HiFePO4 2 fortified rice test meal|
62810463|NCT06072911|EXPERIMENTAL|Intervention|Pelvic floor exercise program and general exercise programming
62810464|NCT06072911|ACTIVE_COMPARATOR|Control|Pelvic floor exercises and standard care (physical activity counseling)
62810465|NCT05802004|EXPERIMENTAL|Stim, then Sham, then daily Stim|For the 2 overnights in the sleep lab, this arm will be randomized to complete acoustic stimulation (STIM) on the first overnight and no acoustic stimulation (SHAM) on the second overnight and then daily acoustic stimulation (STIM2) during the \~2 weeks at-home.
62810466|NCT05802004|EXPERIMENTAL|Stim, then Sham, then daily Sham|For the 2 overnights in the sleep lab, this arm will be randomized to complete acoustic stimulation (STIM) on the first overnight and no acoustic stimulation (SHAM) on the second overnight and then no daily acoustic stimulation (SHAM2) during the \~2 weeks at-home.
62810467|NCT05802004|EXPERIMENTAL|Sham, then Stim, then daily Stim|For the 2 overnights in the sleep lab, this arm will be randomized to complete no acoustic stimulation (SHAM) on the first overnight and acoustic stimulation (STIM) on the second overnight and then daily acoustic stimulation (STIM2) during the \~2 weeks at-home.
62810468|NCT05802004|EXPERIMENTAL|Sham, then Stim, then daily Sham|For the 2 overnights in the sleep lab, this arm will be randomized to complete no acoustic stimulation (SHAM) on the first overnight and acoustic stimulation (STIM) on the second overnight and then no daily acoustic stimulation (SHAM2) during the \~2 weeks at-home.
62810469|NCT04554420|EXPERIMENTAL|Youth Participatory Action Research-Mental Health Curriculum|Youth will be engaged with youth participatory approaches in learning about the intersection of mental health and systemic/community level issues.
62810470|NCT05489848|EXPERIMENTAL|Arm1: Chemotherapy group|Paclitaxel plus carboplatin (TC) regimen, intravenous chemotherapy. Once every three weeks with total of 6 cycles.
62810471|NCT05489848|ACTIVE_COMPARATOR|Arm2: Radiotherapy plus chemotherapy group|"Stage IA: TC(Paclitaxel plus carboplatin) regimen for 4 course+/-VBT.~Stage IB-II ( with no residual disease): TC regimen for 2 course +EBRT (external irradiation radiotherapy) plus cisplatin concurrent chemotherapy +TC regimen for 2 course ±VBT.~Stage III-IVA ( with no residual disease) and any stage except IVB (residual disease \<2cm): TC regimen for 2 course +EBRT (external irradiation radiotherapy) plus cisplatin concurrent chemotherapy +TC regimen for 2 course ±VBT.~Radiotherapy can be started 3 weeks after the completion of the chemotherapy, and Chemotherapy can be started 2 - 3 weeks after the completion of radiotherapy."
62810472|NCT05897463||Neurotized|
62810473|NCT05897463||Non-neurotized|
62819570|NCT06465589|OTHER|Preferred Anonymous|After participants are randomized to the preference arm, they will be given access to the program version they indicate a preference for after having read two descriptive texts about both versions. Participants in this arm will use the anonymous program.
62234309|NCT03608982|ACTIVE_COMPARATOR|No simulated patient|The course materials in the control courses are also standardized. Instead of using simulated patients, however, video clips will be shown to demonstrate the first aid techniques.
62234310|NCT01262703|EXPERIMENTAL|REVA Medical ReZolve Stent|ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent
62234311|NCT01246752|EXPERIMENTAL|Human Stem Cell Transplantation|Patients receive an allogenic stem cell transplantation from an HLA-matched unrelated or related donor
62234312|NCT01246752|ACTIVE_COMPARATOR|Consolidating Chemotherapy|Patients receive a standard chemotherapy as consolidation therapy
62034012|NCT00738777|ACTIVE_COMPARATOR|3|Tamoxifen
62593769|NCT03430895|EXPERIMENTAL|combination of durvalumab and tremelimumab|Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting at Week 16 for 9 doses (total treatment duration of 12 months).
62810474|NCT04325802|EXPERIMENTAL|Cohort 1: Placebo, then Intervention|Patients will start with placebo in week 1 and cross over to Naltrexone in week 3. There will be a wash-out phase during week 2 using only moisturizer regularly and if necessary as rescue medications topical corticosteroids and/or antihistamines. The same rescue medications can be used during the following weeks of the cross-over treatment. At visit 2 and 4 patients will be asked the area where they are experiencing most intense itch and we will take there suction blisters (preferably on the trunk). Suction blisters will be taken after week 1 (1 week on treatment arm 1) and after week 3 (1 week on treatment arm 2).
62810475|NCT04325802|ACTIVE_COMPARATOR|Cohort 2: Intevention, then Placebo|Patients will start with Naltrexone in week 1 and cross over to the palcebo treatment in week 3. There will be a wash-out phase during week 2 using only moisturizer regularly and if necessary as rescue medications topical corticosteroids and/or antihistamines. The same rescue medications can be used during the following weeks of the cross-over treatment. At visit 2 and 4 patients will be asked the area where they are experiencing most intense itch and we will take there suction blisters (preferably on the trunk). Suction blisters will be taken after week 1 (1 week on treatment arm 1) and after week 3 (1 week on treatment arm 2).
62810476|NCT04325802|NO_INTERVENTION|Circadian Rhythm of Itch|Patients in this arm will receive no intervention, only data collection.
62593770|NCT03111472|EXPERIMENTAL|Self-management guide for falls in Parkinson's|A guide for people with Parkinson's and their caregivers to self-manage falls.
62810477|NCT06088862|EXPERIMENTAL|Group I - NRT Responder|Participants that were successful in quitting smoking using NRT in the first four weeks of the study will have the option of remaining on their current NRT or switching to one of the other two options for the next five weeks.
62593771|NCT02901743|ACTIVE_COMPARATOR|GroupI (Test)|20 patients with renal insufficiency chronic and chronic periodontitis underwent scaling and root planing. Clinical parameters( GI,PD,CAL) were assessed at baseline and after 3 months. 2ml blood was drawn to assess serum creatinine levels and urine analysis was done at baseline and after 3 months for urinary albumin: creatinine ratio.Pooled plaque samples were taken at baseline and after 3 months to assess the microbial activity of Treponema Denticola and Tannerella Forsythia by PCR.
62593772|NCT02901743|ACTIVE_COMPARATOR|Group II- (Control)|20 patients with chronic periodontitis who underwent scaling and root planing.Clinical parameters(GI,PD,CAL)were assessed at baseline and after 3 months. 2ml blood was drawn to assess seum creatnine levels and urine analysis was done at baseline and after 3 months for serum urinary Albumin:Creatinine ratio.Pooled plaque samples were taken at baseline and after 3 months to assess the microbial activity of Treponema denticola and Tannerella Forsythia by PCR.
62593773|NCT00905281|EXPERIMENTAL|Action Group|
62810478|NCT06088862|EXPERIMENTAL|Group IIa NRT Non-Responder - Pouch Preferrers|Participants that were unsuccessful in quitting smoking using NRT in the first four weeks and reported a preference to try a nicotine pouch. Randomized to be switched to nicotine pouch for the next five weeks.
62810479|NCT06088862|EXPERIMENTAL|Group IIb NRT Non-Responder - Pouch Preferrers Control|Participants that were unsuccessful in quitting smoking using NRT in the first four weeks and reported a preference to try a nicotine pouch. Randomized to be remain on NRT for the next five weeks.
62593774|NCT00905281|OTHER|Standard care|
62810480|NCT06088862|EXPERIMENTAL|Group IIIa NRT Non-Responder - ENDS Preferrers|Participants that were unsuccessful in quitting smoking using NRT in the first four weeks and reported a preference to try ENDS. Randomized to be switched to ENDS for the next five weeks.
62034013|NCT00738777|OTHER|4|Tamoxifen (pre-menopausal and male patients)
62034014|NCT06390241|EXPERIMENTAL|Avidin-biotin-Dota-90Y|The total planned enrollment for this study is up to approximately 52 patients for Part 1 (dose-escalation) and Part 2 (dose expansion). Up to 18 patients will be enrolled in Part 1 (depending on dose-escalation) and 40 patients in dose expansion in Part 2. The 6 patients evaluated for dosimetry in Part 1 will also be evaluated in part 2.
62034015|NCT01603576|EXPERIMENTAL|Suprachoroidal retinal prosthesis|
62034016|NCT06451172|EXPERIMENTAL|ASO Single Group|ASO eye drops are used through the local administration. Dosage form: eye drop solution. Dose:20uL. Frequency of administration: 3 times per day.
62034017|NCT04805723|EXPERIMENTAL|Patients with pulmonary nodule scheduled VATS|"Patients with pulmonary nodule scheduled VATS were included in this study. Inclusion and exclusion criteria were considered.~Pulmonary function (spirometry), functional exercise capacity (6-minute walk test (6-MWT); 6-minute stepper test (6-MST)), physical activity level (metabolic holter), respiratory (maximal inspiratory and expiratory pressures (MIP-MEP); mouth pressure device) and peripheral muscle strength (dynamometer), inspiratory muscle endurance (incremental loading test), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)), fatigue (Fatigue Severity Scale), dyspnea perception (Modified Medical Research Council dyspnea scale (MMRC)) and pain severity (Visual Analog Scale) were assessed before VATS and average two weeks after surgery."
62234313|NCT00316134||Pts scheduled to remove pleural fluid|
62425293|NCT01863095|EXPERIMENTAL|Lifestyle counseling|MJ users assigned to this condition will participate in 4 individualized intervention sessions that are based on Motivational Interviewing principles. They will receive personalized feedback on their MJ use and will be provided a smart phone app on which they report their MJ use episodes, which also is designed to promote the use of exercise/physical activity as an alternative to MJ use. Level of Physical activity will be measured using accelerometers.
62593775|NCT02011711||Mirena|Women interested in beginning use of Mirena
62810481|NCT06088862|EXPERIMENTAL|Group IIIb NRT Non-Responder - ENDS Preferrers Control|Participants that were unsuccessful in quitting smoking using NRT in the first four weeks and reported a preference to try ENDS. Randomized to be remain on NRT for the next five weeks.
62810482|NCT01367899||CONSERVE® Plus hip resurfacing|Recipients/C Plus (IDE)study
62810483|NCT01153165|EXPERIMENTAL|Citalopram|Participants will be commenced on Citalopram 20mgs daily
62034018|NCT04805723|EXPERIMENTAL|Patients with pulmonary nodule scheduled thoracotomy|"Patients with pulmonary nodule scheduled thoracotomy were included in this study. Inclusion and exclusion criteria were considered.~Pulmonary function (spirometry), functional exercise capacity (6-minute walk test (6-MWT); 6-minute stepper test (6-MST)), physical activity level (metabolic holter), respiratory (maximal inspiratory and expiratory pressures (MIP-MEP); mouth pressure device) and peripheral muscle strength (dynamometer), inspiratory muscle endurance (incremental loading test), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)), fatigue (Fatigue Severity Scale), dyspnea perception (Modified Medical Research Council dyspnea scale (MMRC)) and pain severity (Visual Analog Scale) were assessed before VATS and average two weeks after surgery."
62034019|NCT01055769|OTHER|Group 1|Subjects will accept Linezolid OS 600 MG first, after 4 days wash-out, then will accept Linezolid tablet 600 MG.
62034020|NCT01055769|OTHER|Group 2|Subjects will accept Linezolid tablet 600 MG first, after 4 days wash-out, then will accept Linezolid OS 600 MG.
62034021|NCT04020770|EXPERIMENTAL|Vibrating Ball|Vibrating ball is held in both hands. Participants complete 5 30-second bouts of 68 Hz vibration with a 1 minute rest in between each bout.
62034022|NCT06669234|EXPERIMENTAL|ALN-F1202|Randomized as described in the protocol Escalating Cohorts including Optional Cohorts
62425294|NCT01863095|ACTIVE_COMPARATOR|Personalized Feedback only|MJ users assigned to this condition will participate in 4 individualized intervention sessions that are based on Motivational Interviewing principles. They will only receive personalized feedback on their MJ use.
62034023|NCT06669234|EXPERIMENTAL|Placebo|Randomized as described in the protocol
62034024|NCT05073016|ACTIVE_COMPARATOR|Finger Taping Task + iTBS intermittent group|Finger Taping Task + iTBS Daily application group: the group receives these applications every other day for 5 sessions.
62034025|NCT05073016|ACTIVE_COMPARATOR|Finger Taping Task intermittent Group|Finger Taping Task intermittent application group: the group receives the application every other day for 5 sessions.
62034026|NCT06204731|NO_INTERVENTION|Control group|The control group will not undergo the training program.
62234314|NCT05151315|ACTIVE_COMPARATOR|Evolution Total Knee Arthroplasty system|Patients will undergo total knee arthroplasty with the Evolution Total Knee System
62234315|NCT05151315|EXPERIMENTAL|Evolution with NitrX Total Knee Arthroplasty system|Patients will undergo total knee arthroplasty with the NitrX Evolution Total Knee System which has the specialized protective coating
62234316|NCT03613987|NO_INTERVENTION|NIPPV|non synchronized non invasive positive pressure ventilation
62234317|NCT03613987|EXPERIMENTAL|NAVA-NIPPV|synchronized non invasive positive pressure ventilation with NAVA
62425295|NCT01514409|EXPERIMENTAL|5-Hydroxytryptophan|
62810484|NCT01153165|PLACEBO_COMPARATOR|Control|Control group - will receive a matched placebo
62810485|NCT04434079||Included individuals|Adult patients consecutively admitted to the ICU from June to October 2018 are eligible if expected length of stay is superior to 24 hours and no oral nutritional has been offered.
62034027|NCT06204731|EXPERIMENTAL|LHTL (live high - train low)|Training performed under normoxic conditions (223m), stay and sleep in normobaric hypoxic conditions (3000m) and thermoneutral conditions (21°C) and constant humidity (40%).
62234318|NCT01493648|EXPERIMENTAL|Vitamin D|
62234319|NCT01493648|PLACEBO_COMPARATOR|Placebo|
62234320|NCT01973946|NO_INTERVENTION|Usual Care|Patients in the usual care group called the automated monitoring system daily to report presence, severity, and distress for 11 common symptoms. The attentional control group received equivalent contact time with the automated system including identical voice and assessment questions. Patients did not hear self-care messages during the call and the data were not available for clinical action by the study nurse practitioner. Patients were told on every phone call to call their oncology providers if they had concerns about their symptoms which is usual care for symptom follow up in oncology.
62425296|NCT01514409|PLACEBO_COMPARATOR|Placebo|
62425297|NCT02951884|EXPERIMENTAL|Aspiration|Participants assigned to this arm receive aspiration of the joint alone in which a needle will be introduced into the knee joint to withdraw the blood that collects within the knee.
62810486|NCT01334060|NO_INTERVENTION|CML HLA A2-|
62810487|NCT01334060|NO_INTERVENTION|AML HLA A2-|
62810488|NCT01334060|EXPERIMENTAL|AML HLA A2+|
62810489|NCT01334060|EXPERIMENTAL|CML HLA A2+|
62593776|NCT02011711||Depot-medroxyprogesterone acetate|Women interested in beginning use of depot-medroxyprogesterone acetate
62593777|NCT02011711||Oral Contraception|Women interested in beginning use of oral contraception
62593778|NCT04042766|ACTIVE_COMPARATOR|laser treatment|
62593779|NCT04042766|SHAM_COMPARATOR|sham treatment|
62593780|NCT05610384|ACTIVE_COMPARATOR|Ketorolac group|ketorolac 30 mg
62593781|NCT05610384|ACTIVE_COMPARATOR|Ibuprofen group|ibuprofen 800 mg
62593782|NCT06617221|EXPERIMENTAL|Composite graft plug|composite graft plug was placed in the socket after extraction
62593783|NCT06617221|ACTIVE_COMPARATOR|Allograft|allograft was placed in the socket after extraction
62593784|NCT01751334|EXPERIMENTAL|Mobile Bearing|Mobile bearing total knee arthroplasty
62593785|NCT01751334|ACTIVE_COMPARATOR|Fixed Bearing|Fixed Bearing total knee arthroplasty
62593786|NCT05700812|EXPERIMENTAL|IUD insertion study in three phases|"In phase one, the IUD will be placed in standard fashion with a uterine sound to obtain baseline data.~In phase two, the IUD will be placed without the use of a uterine sound and under abdominal ultrasound guidance.~In phase three, the IUD will be placed without the use of a uterine sound and without ultrasound guidance."
62593787|NCT00991757|EXPERIMENTAL|001|carisbamate Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
62593788|NCT04194762|EXPERIMENTAL|treadmill training|Three training sessions per week for two months of treadmill. The intensity of exercise is monitored through the heart rate (HR). Patients ought to maintain a HR between 40 and 50% of the reserve HR
62593789|NCT04194762|ACTIVE_COMPARATOR|Cycling|Three training sessions per week for two months of cycling. The intensity of exercise is monitored through the heart rate (HR). Patients ought to maintain a HR between 40 and 50% of the reserve HR
62593790|NCT02379351|EXPERIMENTAL|In-Home Non-Stress Test Device|Patients with physician-ordered twice-weekly NSTs scheduled in the OB Diagnostic Center at University of Utah Hospital will be eligible for enrollment. After being taught how to use the Airstrip® Sense4Baby™ system machine, participants will use the device on a weekly basis (at home) until the time of delivery. Participants will also receive an in clinic NST once a week.
62593791|NCT02192372||metabolic syndrome|Presence of 3 or more of these components: high fasting glucose (fasting serum glucose ≥ 100 mg/dl or drug treatment for elevated blood glucose), abdominal obesity (given as waist circumference \> 102 cm in men and \> 88 cm in women), high blood pressure (≥130/≥85 mmHg or drug treatment for hypertension), hypertriglyceridemia (serum triglycerides ≥150 mg/dl), low high-density lipoprotein cholesterol (\<40 mg/dl in men and \<50 mg/dl in women).
62593792|NCT02192372||control|Age and sex adjusted control subjects
62593793|NCT03340220|EXPERIMENTAL|Drug: XEN1101 XPF-008 Formulation Oral|XEN1101 XPF-008 Formulation Part 1 - Single ascending dose: Single oral dose for each cohort Part 2 - Multiple ascending dose: 7 days of single oral dose daily for each cohort
62593794|NCT03340220|PLACEBO_COMPARATOR|Placebo - Microcrystalline cellulose oral|"Part 1- Single Ascending Dose: Single oral dose for each cohort~Part 2 - Multiple Ascending Dose: 7 days of single oral dose daily for each cohort"
62593795|NCT03340220|EXPERIMENTAL|Drug: XEN1101 XPF-008 Formulation Oral Drug: XEN1101 XPF-010 Formulation Oral|"XEN1101 XPF-008 and XPF-010 Formulation Cross Over~Part 3 will explore dose proportionality of XPF-010 and confirm dosing for subsequent cohorts, and the food effect and relative bioavailability of XPF-010 compared to XPF-008"
62593796|NCT03340220|EXPERIMENTAL|Drug: XEN1101 XPF-010 Formulation Oral|"XEN1101 XPF-010 Formulation Oral~Part 4 will explore multiple dose PK"
62593797|NCT03340220|EXPERIMENTAL|Drug: XEN1101 XPF-010 Formulation Oral Drug: Itraconazole 400mg Oral|"XEN1101 XPF-010 Formulation + Itraconazole~Part 5 will explore the drug-drug interaction of XPF-010, when given with itraconazole (400mg, single dose, oral solution, fasted)"
62425298|NCT02951884|EXPERIMENTAL|Aspiration with injection|Participants assigned to this arm receive aspiration of the knee joint and an injection of 20cc bupivacaine 0.5% with 1:200,000 epinephrine
62593798|NCT03831412|ACTIVE_COMPARATOR|CBT-I|5 sessions of treating insomnia
62593799|NCT03831412|ACTIVE_COMPARATOR|ERRT|5 sessions of treating post-trauma nightmares
62593800|NCT02748135|EXPERIMENTAL|TB-403 20mg/kg|
62593801|NCT02748135|EXPERIMENTAL|TB-403 50mg/kg|
62593802|NCT02748135|EXPERIMENTAL|TB-403 100mg/kg|
62593803|NCT02748135|EXPERIMENTAL|TB-403 175mg/kg|
62593804|NCT00650117|EXPERIMENTAL|1|Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)
62593805|NCT00650117|EXPERIMENTAL|2|Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
62593806|NCT00650117|EXPERIMENTAL|3|Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)
62593807|NCT00650117|EXPERIMENTAL|4|Duragesic 25 mcg/h + Scotch Duct Tape (3M)
62593808|NCT00650117|EXPERIMENTAL|5|Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
62593809|NCT00650117|EXPERIMENTAL|6|Duragesic 25 mcg/h + Microfoam Tape (3M)
62034028|NCT06204731|EXPERIMENTAL|LLTH (live low - train high)|"Training performed under normobaric hypoxia conditions (3000m), stay and sleep in normoxic conditions (223m) and thermoneutral conditions (21°C) and constant humidity (40%).~will stay and sleep in normoxic (223m), and train in normobaric hypoxia (3000m)"
62234321|NCT01973946|EXPERIMENTAL|Symptom Alert and Coaching|"Patients in the Symptom Alert and Coaching arm called the automated monitoring system daily to report presence, severity, and distress on 11 symptoms. The system provided automated self care coaching based on the symptoms reported and automatically generated alerts to the study NP if symptoms exceeded preset thresholds. Two thresholds were set: a simple alert when severity or distress was 4 or greater on a 10 point scale and trend alerts based on a pattern of moderate severity over several days.~The alerts went into a case management site. The study NP logged into the system daily and responded to the alerts within 24 hours by calling patients to further assess the symptoms and to intensify symptom treatment using evidence based guidelines."
62234322|NCT00730171|EXPERIMENTAL|Linaclotide|Linaclotide 290 μg/day capsules, administered orally once daily for up to 78 weeks. Dose reduction to 145 μg/day was permitted at the discretion of the Investigator.
62234323|NCT02604433|EXPERIMENTAL|Luspatercept (ACE-536) plus Best Supportive Care (BSC)|Luspatercept, subcutaneous(ly) (SC) once every 21 days
62234324|NCT02604433|PLACEBO_COMPARATOR|Placebo plus Best Supportive Care (BSC)|normal saline solution subcutaneous(ly) (SC) once every 21 days
62234325|NCT00699452|ACTIVE_COMPARATOR|1|Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)
62593810|NCT06067399||1|Diabetics
62234326|NCT00699452|PLACEBO_COMPARATOR|2|Placebo
62234327|NCT01285050|OTHER|pre post ART|HCV and HIV viral load pre and post antiretroviral therapy (ART). ART is the intervention and the comparison is the HIV and HCV viral load reductions as determined by RT-PCR after administration of interferon alfa in each instance (before and after ART)
62234328|NCT01610362|ACTIVE_COMPARATOR|5-dose IM rabies vaccines, HRIG 20 IU/kg|Rabies exposed victims, 5-dose IM rabies vaccine, HRIG 20 IU/kg
62234329|NCT01610362|EXPERIMENTAL|5-dose IM rabies vaccines, HRIG 40 IU/kg|Healthy volunteers, 5-dose IM rabies vaccine, HRIG 40 IU/kg
62234330|NCT01099423|ACTIVE_COMPARATOR|Immediate nephrectomy|Surgery followed by Sunitinib
62234331|NCT01099423|EXPERIMENTAL|Deferred nephrectomy|Sunitinib (3 cycles) followed by surgery followed by Sunitinib
62034029|NCT06204731|EXPERIMENTAL|LLTL (live low - train low)|Training performed and stay and sleep in normoxic conditions (223m) and thermoneutral conditions (21°C) and constant humidity (40%).
62034030|NCT04091139|EXPERIMENTAL|Unified protocol for adolescents (UP-A)|"The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A).~A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians."
62234332|NCT01365143|ACTIVE_COMPARATOR|Open Radical Prostatectomy|
62234333|NCT01365143|ACTIVE_COMPARATOR|Robotic radical prostatectomy|
62234334|NCT03095430||ESPI Group|General Anesthesia using Entropy and Surgical Pleth Index Monitoring
62234335|NCT03095430||Control Group|General Anesthesia without Entropy and Surgical Pleth Index (Control Group)
62234336|NCT02960113|EXPERIMENTAL|scopolamine patch|Scopolamine patch will be placed on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery.
62234337|NCT02960113|EXPERIMENTAL|acupressure point P6|Acupressure point P6 stimulation will be placed on the distal right forearm just above the crest of the wrist.
62234338|NCT02960113|EXPERIMENTAL|scopolamine patch + acupressure point P6|Will receive both scopolamine patch and acupressure point P6 stimulation, as described above.
62234339|NCT04609059|EXPERIMENTAL|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
62425299|NCT02951884|NO_INTERVENTION|Control|Participants assigned to this arm receive no injection or aspiration therapy.
62593811|NCT06067399||2|Healthy control
62593812|NCT04054973|EXPERIMENTAL|L-arginine and Kuvan|Open-label single arm study, all participants will be in this group
62593813|NCT02848365|ACTIVE_COMPARATOR|Glidescope|
62593814|NCT02848365|ACTIVE_COMPARATOR|Macintosh laryngoscope|
62593815|NCT02848365|ACTIVE_COMPARATOR|Bonfill's rigid scope|
62234340|NCT04609059|PLACEBO_COMPARATOR|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
62234341|NCT00657059|ACTIVE_COMPARATOR|Pred group|Pred Group: Prednisone treatment Patients will give methylprednisolone intravenously at a dose of 0.5 g/day for 3 days at the start of months 1, 3, and 5; then take oral prednisone (0.5 mg/kg/d) on alternate days. Prednison will be tapered 5 mg per month from the seventh month to the 12th month.
62234342|NCT00657059|ACTIVE_COMPARATOR|MMF Group|MMF Group: MMF treatment Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt \< 50kg) for the first 6-month of drug treatment phase, then 0.5 bid for the remaining 6-month.
62593816|NCT02848365|ACTIVE_COMPARATOR|Air traq|
62593817|NCT02848365|ACTIVE_COMPARATOR|C -Mac scope|
62593818|NCT02848365|ACTIVE_COMPARATOR|flexible fiberoptic scope|
62593819|NCT03976687|EXPERIMENTAL|1: EYP001a Dose A|Dose A once daily morning dose
62593820|NCT03976687|EXPERIMENTAL|2: EYP001a Dose B|Dose B once daily morning dose
62593821|NCT03976687|EXPERIMENTAL|3: EYP001a Dose C|Dose C twice daily - first dose morning dose and second dose 3 hours post first dose
62593822|NCT00596128|NO_INTERVENTION|1|Blood sugar monitoring and intervention as clinical routine, no SOP defined and implemented
62593823|NCT00596128|EXPERIMENTAL|2|Blood sugar monitoring after implementation of SOP
62234343|NCT00657059|ACTIVE_COMPARATOR|Pred plus MMF Group|"Pred plus MMF Group: Prednisone plus MMF treatment. Patients will give methylprednisolone intravenously at a dose of 0.5 g/day for 3 days at the start of months 1, 3, and 5; then take oral prednisone (0.5 mg/kg/d) on alternate days. Prednison will be tapered 5 mg per month from the seventh month to the 12th month.~Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt \< 50kg) for the first 6-month of drug treatment phase, then 0.5 bid for the remaining 6-month."
62593824|NCT04084730|EXPERIMENTAL|Participants with Breast Cancer|Participants will have unicentric pathological stage I invasive ductal breast cancer or Grade 1 or 2 DCIS measuring \<3cm in longest diameter on pathology and/or mammogram that is histologically confirmed at MSKCC.
62593825|NCT02413385|EXPERIMENTAL|HealtheSteps Program|6 month evidence-based lifestyle Rx program: receive lifestyle Rx's for exercise, physical activity (step counts) and healthy eating and set goals around Rx's (in person sessions at set time points during 6-month period); take part in self-directed healthy living activities to achieve Rx's (Months 0-6); access to a suite of health technology support options for additional support and coaching (Months 0-6).
62593826|NCT02413385|NO_INTERVENTION|Usual-care wait-list control|No active intervention (usual care).
62593827|NCT05178303|EXPERIMENTAL|Cirrhosis|Experimental benefits in resistance to cirrhosis were observed in all patients who had previously received certain components of the treatment for cirrhosis SB-1121(1) for various therapeutic purposes.
62593828|NCT05178303|EXPERIMENTAL|"Cirrhosis/Hcc stable"|Experimental benefits in resistance to cirrhosis/Hcc were observed in all patients who had previously received certain components of the treatment for cirrhosis SB-1121(2) for various therapeutic purposes.
62593829|NCT04868604|EXPERIMENTAL|67Cu-SAR-bisPSMA|"In the dosimetry phase patients will receive a single 200 MBq administration of 64Cu-SAR-bisPSMA.~In the dose escalation phase patients will receive up to 2 administrations of 200 MBq of 64Cu-SAR-bisPSMA.~In the cohort expansion phase patients will receive up to 3 administrations of 200 MBq of 64Cu-SAR-bisPSMA.~In the dose escalation phase patients will receive up to 2 administrations of 67Cu-SAR-bisPSMA (dose will be determined based on cohort allocation).~In the cohort expansion phase patients will receive 2 administrations of 67Cu-SAR-bisPSMA at the recommended dose level determined through dose escalation."
62593830|NCT05798364||Index patients|Adults MDR-E carriers.
62593831|NCT05798364||Household members|Adults or children living in the same household as the index case (i.e. sharing the same kitchen and/or bathroom and/or toilets) during the 3 months following inclusion
62593832|NCT06514040|ACTIVE_COMPARATOR|Precedex group|1- Inhaled Dexmedetomidine group (Group D, n= 24): will receive nebulization of 1 µg/kg dexmedetomidine (Precedex, Dexmedetomidine HCl 100 µg/mL, Pfizer Inc.) diluted in 4 mL 0.9% saline twice daily starting from the PDPH diagnosis time. The intervention will be continued until achieving a VAS score ≤ 3 and Lybecker classification score \< 2 or for a maximum of 48 hours when occurrence of side effects in form of hypotension, bradycardia, nausea stop the medication and give supportive treatment.
62234344|NCT00926549|EXPERIMENTAL|spectral domain-OCT|Spectral domain-OCT scanning performed.
62234345|NCT02108587|EXPERIMENTAL|optical coherence tomography for diagnosis|Patients undergo optical coherence tomography over 10-15 minutes.
62234346|NCT04911816|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine sulfate
62234347|NCT02753140|EXPERIMENTAL|RT concurrent with cetuximab|Selected 60 patients with locally advanced squamous cell carcinoma of the head and neck. They will be randomized to concurrent chemoradiotherapy versus concomitant cetuximab with radiotherapy after neoadjuvant chemotherapy.To observe the curative effect of the treatment of the cetuximab
62234348|NCT02753140|EXPERIMENTAL|RT concurrent with TP|Selected 60 patients with locally advanced squamous cell carcinoma of the head and neck. They will be randomized to concurrent chemoradiotherapy versus concomitant cetuximab with radiotherapy after neoadjuvant chemotherapy. To observe the curative effect of concurrent radiotherapy and chemotherapy
62034031|NCT04091139|ACTIVE_COMPARATOR|Treatment as usual (TAU)|TAU participants will receive usual clinical psychological service provided in the clinic (i.e. treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
62593833|NCT06514040|ACTIVE_COMPARATOR|Sumatriptan group|2- Oral sumatriptan group (Group S, n= 24): sumatriptan 25 mg every 8 hours orally when occurrence of side effects in form of paresthesia, dizziness and chest tightness stop the medication.
62034032|NCT02959996|PLACEBO_COMPARATOR|Placebo|Normal saline will be infiltrated
62034033|NCT02959996|ACTIVE_COMPARATOR|Intervention|Liposomal bupivacaine will be infiltrated
62425300|NCT00919048||Urodynamic patients|Uroflow studies of patients who underwent urodynamics as part of an incontinence work-up.
62425301|NCT03694093||Patients with Hyperhidrosis|Subjects with Primary Hyperhidrosis will be followed in this study. Because this study is observational, there will be no intervention.
62425302|NCT03183973|EXPERIMENTAL|PRF group|patients who will receive Platelet Rich Fibrin (PFR) suspension
62593834|NCT06499233|EXPERIMENTAL|TMP/SMX (with PJP high risk)|AIIRD patients who have PJP high risk and receive prophylactic Trimethoprim/ Sulfamethoxazole (TMP/SMZ) treatment; Drug intervention: Patients receive Trimethoprim/Sulfamethoxazole (TMP/SMX) 480 mg p.o. every day as PJP Prophylaxis.
62810490|NCT03320668|NO_INTERVENTION|Individual OEP|"Randomized subjects (65 to 80-year-old) receiving individual Otago Exercise Program (OEP) training in a total of nine Primary Care Centers.~An OEP leader trained nurse/physiotherapist will perform in its community consult individual education to each participant in five sessions: In the 1st, 2nd, 4th and 8th week and one reinforcement session after six months. A telephone call to each participant (following a predefined telephonic interview protocol) will be carried out in the months without training session to perform the follow-up."
62234349|NCT00679588|EXPERIMENTAL|Semuloparin|Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment \[SRI\]) once daily for 7-10 days with an initial dose given 8 hours after surgery (placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind)
62425303|NCT03183973|EXPERIMENTAL|placebo group|
62425304|NCT02111382|EXPERIMENTAL|CV4 (4th ventricle technique) technique|Will be conduced a real cranial osteopathic medicine technique.
62425305|NCT02111382|SHAM_COMPARATOR|CV4 sham|This group will received only a sham manual therapy technique.
62034034|NCT05361031|EXPERIMENTAL|Engensis (VM202)|56 (ea) 0.25mg (0.5 mL) injections in each of the left and right lower limbs on Days 0, 14, 90, and 104.
62234350|NCT00679588|ACTIVE_COMPARATOR|Enoxaparin|Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment \[SRI\]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium (placebo for Semuloparin sodium 8 hours after surgery to maintain the blind)
62425306|NCT02111382|NO_INTERVENTION|Control|The participants will be in supine position for 5 minutes without any visual or verbal contact.
62425307|NCT01979588|PLACEBO_COMPARATOR|Control|Providers do not have access to What's Going Around Tool but receive an instructional video explaining tool
62425308|NCT01979588|ACTIVE_COMPARATOR|What's Going Around Tool|Provider has access to What's Going Around Tool. Provider also shown a video explaining how to use Tool
62425309|NCT05965622|EXPERIMENTAL|Attachment Based Family Therapy + Treatment As Usual|"Attachment Based Family Therapy (ABFT) is a manualized treatment, that emerges from interpersonal theories that suggest suicide can be precipitated, exacerbated, or buffered against by the quality of family relationships. Parent(s)/caregiver(s) will be involved in the therapy.~In the experimental group, patients will receive ABFT as an add-on therapy besides treatment as usual (TAU)."
62425310|NCT05965622|PLACEBO_COMPARATOR|Treatment As Usual|Treatment as Usual (TAU) contains all regular interventions that are currently used to treat suicidality. In the TAU group, a limited number of systemic family therapy sessions will be given (maximum 4 sessions).
62034035|NCT02341417|EXPERIMENTAL|Cinacalcet|"Participants received cinacalcet daily for 24 weeks in this extension study. For participants who received standard of care (SOC) in parent study 20130356, the starting dose was 0.20 mg/kg/day. For participants who received SOC and cinacalcet in parent study 20130356 or 20110100 the starting dose was either the same as the last dose received in the parent study or 0.20 mg/kg/day if the last dose of cinacalcet in the parent study was received \> 14 days before day 1 of this study.~Dose adjustments and withholding were based on weekly assessments of ionized calcium as well as plasma intact parathyroid hormone (iPTH) and corrected serum calcium levels assessed monthly."
62034036|NCT06609005|EXPERIMENTAL|Stage 1 INV-9956 Dose escalation Dose level 1|INV-9956 Dose escalation Dose level 1 is co-administered with dexamethasone and fludrocortisone acetate
62593835|NCT06499233|NO_INTERVENTION|no TMP/SMX (with PJP high risk)|AIIRD patients who have PJP high risk and do not receive prophylactic Trimethoprim/ Sulfamethoxazole (TMP/SMZ) treatment.
62810491|NCT03320668|EXPERIMENTAL|Group OEP|65-80 year-old randomized subjects receiving group Otago Exercise Program (OEP) training in a total of nine Primary Care Centers.
62034037|NCT06609005|EXPERIMENTAL|Stage 1 INV-9956 Dose escalation Dose level 2|INV-9956 Dose escalation Dose level 2 is co-administered with dexamethasone and fludrocortisone acetate
62234351|NCT02145689|EXPERIMENTAL|onabotulinumtoxinA Dose 1|Up to 4 treatments of onabotulinumtoxinA Dose 1 injected into muscles of the study limb on fulfillment of the retreatment criteria.
62234352|NCT02145689|EXPERIMENTAL|onabotulinumtoxinA Dose 2|Up to 4 treatments of onabotulinumtoxinA Dose 2 injected into muscles of the study limb on fulfillment of the retreatment criteria.
62234353|NCT00261313|EXPERIMENTAL|Aranesp|
62234354|NCT00261313|EXPERIMENTAL|Neulasta|
62234355|NCT01638117|PLACEBO_COMPARATOR|PAC14028-Vehicle|PAC-14028 Cream Vehicle
62234356|NCT01638117|EXPERIMENTAL|PAC14028-0.1|PAC-14028 Cream 0.1%
62234357|NCT01638117|EXPERIMENTAL|PAC14028-0.3|PAC-14028 Cream 0.3%
62234358|NCT01638117|EXPERIMENTAL|PAC14028-1.0|PAC-14028 Cream 1%
62234359|NCT01638117|PLACEBO_COMPARATOR|Placebo|Saline
62234360|NCT01638117|ACTIVE_COMPARATOR|Positive control|Sodium Lauryl Sulfate, 0.5%
62234361|NCT00597467|EXPERIMENTAL|Test Contact Lenses|VISA (comfilcon A) Silicone Hydrogel Soft contact lens
62234362|NCT00597467|ACTIVE_COMPARATOR|Control Contact Lenses|Acuvue 2 Soft Contact Lens
62234363|NCT04351022|EXPERIMENTAL|CD38 positive relapsed or refractory acute myeloid leukemia|
62234364|NCT01673568|ACTIVE_COMPARATOR|abdominal binder|"The abdominal binder is worn from immediately after the operation and continuously for 7 days, night and day. The belts are standard elastic belts (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done before the operation by waist measurement according to the recommendation from the company."
62810492|NCT05030025|EXPERIMENTAL|Group 1|single-dose pharmacokinetics will be characterized in twenty-four (24) healthy, adult males and females not of childbearing potential under fasting conditions.
62034038|NCT06609005|EXPERIMENTAL|Stage 1 INV-9956 Dose escalation Dose level 3|INV-9956 Dose escalation Dose level 3 is co-administered with dexamethasone and fludrocortisone acetate
62034039|NCT06609005|EXPERIMENTAL|Stage 2 INV-9956 Dose expansion - Dose Level 1|INV-9956 Dose expansion Dose Level 1 is co-administered with dexamethasone and fludrocortisone acetate
62034040|NCT06609005|EXPERIMENTAL|Stage 2 INV-9956 Dose expansion - Dose Level 2|INV-9956 Dose expansion Dose Level 2 is co-administered with dexamethasone and fludrocortisone acetate
62234365|NCT01673568|NO_INTERVENTION|no abdominal binder|no abdominal binder
62234366|NCT02714725|PLACEBO_COMPARATOR|Control group (Group C)|During bypass, patients in this group will receive propofol infusion 50 - 70 mcg/kg/min plus normal saline infusion
62234367|NCT02714725|ACTIVE_COMPARATOR|Group Dexmedetomidine (Group DEX)|During bypass, patients in this group will receive propofol infusion 50 - 70 mcg/kg/min plus dexmedetomidine infusion 0.5 mcg/kg/hr
62810493|NCT05030025|EXPERIMENTAL|Group 2|single-dose pharmacokinetics will be characterized in twenty-four (24) healthy, adult males and females not of childbearing potential under fed conditions.
62810494|NCT04050046|ACTIVE_COMPARATOR|Real tDCS + CBCT|20 minutes of 2.0mA of tDCS for 5 consecutive days
62234368|NCT02803047|EXPERIMENTAL|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62593836|NCT06499233|EXPERIMENTAL|TMP/SMX (with PJP low-risk)|AIIRD patients who have PJP low risk and receive prophylactic Trimethoprim/ Sulfamethoxazole (TMP/SMZ) treatment; Drug intervention: Patients receive Trimethoprim/Sulfamethoxazole (TMP/SMX) 480 mg p.o. every day as PJP Prophylaxis.
62810495|NCT04050046|SHAM_COMPARATOR|Sham + CBCT|Sham stimulation closely imitates reals tDCS 30 second ramp-up / ramp-down
62034041|NCT06609005|EXPERIMENTAL|Stage 3 INV-9956 Dose escalation beyond the optimal dose - Dose level 4|INV-9956 Dose escalation Dose level 4 is co-administered with dexamethasone and fludrocortisone acetate
62234369|NCT01538953|EXPERIMENTAL|Handwashing|participants received weekly, in-home handwashing promotion and soap as needed
62234370|NCT01538953|EXPERIMENTAL|handwashing and water treatment|
62234371|NCT01538953|EXPERIMENTAL|Water treatment with sodium hypochlorite|
62234372|NCT01538953|EXPERIMENTAL|Water treatment with flocculent-disinfectant|participants received a supply of flocculent-disinfectant product and instruction to use it to treat drinking water
62234373|NCT01538953|NO_INTERVENTION|Control|
62234374|NCT05964803||Males living with HIV|Males living with HIV and followed by infectious diseases clinic will be directed to Urology department.
62234375|NCT05964803||HIV-negative controls|Males admitted to Infectious Diseases clinic and documented to be HIV-negative.
62234376|NCT04146415|EXPERIMENTAL|Cardiac amyloidosis patients|
62234377|NCT01236248|EXPERIMENTAL|Prevention Program|Girls and their mothers who are assigned to participate in a tobacco, alcohol, and other drug use prevention program aimed at young girls.
62234378|NCT01236248|NO_INTERVENTION|No Prevention Program|Girls and their mothers who are assigned to participate in questionnaires only.
62234379|NCT04588623|ACTIVE_COMPARATOR|Omnibiotic Stress Repair (OBSR)|After randomisation, patients will receive a box with one sachet containing 3g of OBSR for each day.
62234380|NCT04588623|PLACEBO_COMPARATOR|Placebo|After randomisation, patients will receive an identical box with one sachet containing 3g of Placebo for each day.
62593837|NCT06499233|NO_INTERVENTION|no TMP/SMX (with PJP low-risk)|AIIRD patients who have PJP low risk and do not receive prophylactic Trimethoprim/ Sulfamethoxazole (TMP/SMZ) treatment.
62810496|NCT05135871|EXPERIMENTAL|Cohort 1: Mavacamten 15 mg|Cohort 1: 15 mg capsules × 1 on Day 1
62810497|NCT05135871|EXPERIMENTAL|Cohort 2: Mavacamten 25 mg|Cohort 2: 10 mg capsules x 1 and 15 mg capsules x 1 on Day 1
62810498|NCT05135871|EXPERIMENTAL|Cohort 3: Mavacamten 15 mg|Cohort 3: 15 mg capsules × 1 on Day 1
62810499|NCT05135871|EXPERIMENTAL|Cohort 4: Mavacamten 15 mg|Cohort 4: 15 mg capsules × 1 on Day 1
62810500|NCT03438617|EXPERIMENTAL|Peer Support Intervention|9 CHCs will receive the peer support intervention for the full duration of the study period (12 months). Baseline assessment, 12-month and 18-month evaluation to assess the effectiveness and sustainability of the intervention.
62810501|NCT00790946|ACTIVE_COMPARATOR|Valsartan|Valsartan 80 to 160mg
62810502|NCT00790946|NO_INTERVENTION|standard therapy|
62810503|NCT05763017|EXPERIMENTAL|Relative Motion Splint|In the relative motion splint, the metacarpophalangeal joint of the affected finger(s) positioned in approximately 20°-25° more extension/flexion than metacarpophalangeal joint of the adjacent fingers.
62034042|NCT06609005|EXPERIMENTAL|Stage 3 INV-9956 Dose escalation beyond the optimal dose - Dose level 5|INV-9956 Dose escalation Dose level 5 is co-administered with dexamethasone and fludrocortisone acetate
62034043|NCT06609005|EXPERIMENTAL|Stage 3 INV-9956 Dose escalation beyond the optimal dose - Dose level 6|INV-9956 Dose escalation Dose level 6 is co-administered with dexamethasone and fludrocortisone acetate
62425311|NCT05762263|NO_INTERVENTION|Control group|Habitual diet - healthy eating guidelines provided for ethical reasons, no restrictions on the time of eating
62034044|NCT04880564|EXPERIMENTAL|A (CN1 0.5mg/kg and CN401 400mg)|"Patients were administered with CN1, 0.5mg/kg, once every three week in combination with 400mg CN401 twice a day, fasted.~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral~Three to six patients are expected to be enrolled in each arm."
62034045|NCT04880564|EXPERIMENTAL|B (CN1 1mg/kg and CN401 600mg)|"Patients were administered with CN1, 1mg/kg, once every three week in combination with 600mg CN401 twice a day, fasted.~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral~Three to six patients are expected to be enrolled in each arm"
62034046|NCT04880564|EXPERIMENTAL|C (CN1 1mg/kg and CN401 800mg)|"Patients were administered with CN1, 1mg/kg, once every three week in combination with 800mg CN401 twice a day, fasted.~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral~Three to six patients are expected to be enrolled in each arm"
62034047|NCT04880564|EXPERIMENTAL|D (CN1 3mg/kg and CN401 800mg)|"Patients were administered with CN1, 3mg/kg, once every three week in combination with 800mg CN401 twice a day, fasted.~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral~Three to six patients are expected to be enrolled in each arm"
62034048|NCT04880564|EXPERIMENTAL|E (CN1 10mg/kg and CN401 800mg)|"Patients were administered with CN1, 10mg/kg, once every three week in combination with 800mg CN401 twice a day, fasted.~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral~Three to six patients are expected to be enrolled in each arm"
62034049|NCT02073084|OTHER|Sequence A|Sequence A
62034050|NCT02073084|OTHER|Sequence B|Sequence B
62034051|NCT02073084|OTHER|Sequence C|Sequence C
62034052|NCT02073084|OTHER|Sequence D|Sequence D
62234381|NCT04694846|EXPERIMENTAL|Arm I (ETIP)|Patients receive nicotine replacement therapy via trans-dermal patch, gum, nasal spray, inhaler or lozenges for 12 weeks in the absence of unacceptable toxicity. Patients also receive bupropion PO QD BID or varenicline PO QD and BID for 24 weeks in the absence of unacceptable toxicity. Patients undergo 3 cessation counseling sessions in person, via telehealth or phone within 7 days of enrollment into study, 1 week after established quit date and 3 weeks after establishing quit date.
62234382|NCT04694846|ACTIVE_COMPARATOR|Arm II SOC|Participants randomly assigned to the standard treatment (ST) group will receive an in-office smoking cessation recommendation by the physician and referral to a quit line.
62425312|NCT05762263|EXPERIMENTAL|Flexitarian diet group|Flexitarian diet (FD) will be based on planetary diet recommendations (predominantly plants; pulses and legumes as protein sources, meat and poultry consumed occasionally). Ways to facilitate this diet will be presented in the booklet prepared for them by the PI and a dietitian.
62425313|NCT05762263|EXPERIMENTAL|Time-restricted eating group|Time restricted eating (TRE) with 6 hour eating window - start and end hour to be an individual choice (some may prefer to consume their meals within an early window, e.g. 10am-4pm, some may prefer to consume their meals later in the day, e.g. 12:00-6pm). However, participants will be asked to be fairly consistent with their choice of their timing of eating hours. During fasting only water will be permitted;
62425314|NCT05762263|EXPERIMENTAL|Flexitarian diet & time-restricted eating group|Treatment TRE and FD combined.
62425315|NCT00003692|EXPERIMENTAL|video-assisted surgery|Patients undergo video-assisted thoracic surgery (VATS) lobectomy, which requires 3 small incisions on the side of the chest. The entire anatomic pulmonary lobe is removed, as well as all peribronchial lymph nodes and anterior hilar lymph nodes. If it is not possible to remove the lobe using the VATS approach, then 1 of the incisions is converted to a standard thoracotomy. Patients are followed every 4 months for the first 2 years, and then every 6 months for the next 3 years.
62425316|NCT00646087|EXPERIMENTAL|Ketamine (6K)|6K: 6 ketamine injections (0.5 mg/kg of ketamine) every other day for 12 days
62425317|NCT00646087|ACTIVE_COMPARATOR|Ketamine/Placebo (2K4P)|2K4P = two active ketamine injections(2K) and four placebo (saline) injections over 12 days.
62425318|NCT03628222|EXPERIMENTAL|ENB-TBLB|Under ENB guidance, the Location Catheter and Guide Catheter reach the lesion. After confirmation by X-ray, biopsy tools are introduced and specimens are obtained.
62425319|NCT03628222|ACTIVE_COMPARATOR|X-ray-TBLB|Based on chest CT, the physician determines the lesion location. Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and specimens are obtained.
62593838|NCT00981045|EXPERIMENTAL|Ferric Carboxymaltose (FCM)|2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
62034053|NCT02936557|EXPERIMENTAL|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62034054|NCT05465226|EXPERIMENTAL|Oliceridine Arm|Initially, patients will receive oliceridine 1-3 mg IVP every 1-3 hours as needed for moderate or severe pain (NRS ≥ 4) with 1-3 mg every 1-3 hours for breakthrough pain. NRS will be assessed every 3-4 hours routinely. Rescue doses will be allowed per clinical discretion as oliceridine 1-3 mg every hour. Doses will be titrated according to patient response and clinical discretion. In settings where rapid analgesia is needed, such as the operating room, post-anesthesia care unit, emergency room, or hydrotherapy, oliceridine will be administered in 0.5-2 mg doses every 5 minutes as needed for moderate or severe pain, according to anesthesiologist or treating physician's discretion. For the purposes of the study oliceridine will not exceed 7 days of administration and patients will be transitioned from intravenous opioids to oral therapy and de-escalated from opioids, as soon as the team deems appropriate.
62234383|NCT00701870|EXPERIMENTAL|ezatiostat hydrochloride (Telintra®)|Chemotherapy with docetaxel and carboplatin followed by Telintra until ANC recovery
62234384|NCT00701870|NO_INTERVENTION|No Intervention|Chemotherapy with docetaxel and carboplatin alone
62234385|NCT01549054|EXPERIMENTAL|10-mg dose of E5501 2G tablet|
62234386|NCT01549054|EXPERIMENTAL|10-mg dose of E5501 cyclodextrin oral solution|
62593839|NCT00981045|ACTIVE_COMPARATOR|Iron Sucrose (Venofer)|5 doses of 200 mg for a total cumulative dose of 1000 mg
62234387|NCT01549054|EXPERIMENTAL|10-mg dose of E5501-P21% powder|
62234388|NCT01549054|EXPERIMENTAL|10-mg dose of E5501 lipid-based oral|
62425320|NCT03485131|EXPERIMENTAL|Transcranial direct-current stimulation|Intervention of 2 mAmp Transcranial direct-current stimulation treatments given twice daily for 20 min each per day for 4 weeks on consecutive weekdays. Twice-daily sessions were separated by at least 3 hours (one in the AM and the other one in the PM)
62425321|NCT03485131|SHAM_COMPARATOR|Sham tDCS|Intervention of placebo stimulation with ranscranial direct-current stimulation(sham tDCS), the stimulation parameters were displayed, but after 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse was delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period
62425322|NCT00665509|EXPERIMENTAL|1|
62425323|NCT01759225||Cardiovascular Disease Patients|
62810504|NCT05763017|ACTIVE_COMPARATOR|Metacarpophalangeal Joint Blocking Splint|In the metacarpophalangeal joint blocking splint, the metacarpophalangeal joint of the affected finger(s) positioned in 0°.
62810505|NCT03678207||Potential Undiagnosed HTN|
62810506|NCT05919576||Visual-Tactile method (VTM)|In patients who come for treatment and have a prior appointment, an intraoral examination is performed using visual and tactile examination methods. A total of 639 proximal surfaces of 22 patients are examined by investigators using the visual-tactile method.
62034055|NCT05465226|ACTIVE_COMPARATOR|Historical control|Retrospective, observational, historical control arm matched by age, TBSA, number of surgeries, and opioid and illicit drug use histories
62234389|NCT04663100|EXPERIMENTAL|Pharmacist Coordinated care Oncology Model|The Pharmacist Coordinated care Oncology Model includes patient self-reported symptoms and medication adherence, comprehensive medication review(s) and intentional communication between oncology and community pharmacists.
62425324|NCT02018042|EXPERIMENTAL|Abatacept|Patients will be treated with abatacept 125mg subcutaneous (SC) self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse.
62425325|NCT05582200||Healthy subjects|Healthy subjects
62425326|NCT05582200||Patients with Alzheimer's disease|Patients with Alzheimer's disease
62425327|NCT03232554|EXPERIMENTAL|Buxue Yimu Pills|Buxue Yimu Pill 12g pill by mouth, twice daily
62034056|NCT00058123|EXPERIMENTAL|Poly-ICLC Recurrent gliomas|"Poly-ICLC 20ug/kg 3 times a week 4 week cycles (Monday-Wednesday-Friday)~Intramuscular injection~Drug Poly-ICLC"
62034057|NCT03695172|ACTIVE_COMPARATOR|TAP block|Patients will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
62034058|NCT03695172|ACTIVE_COMPARATOR|QL block|Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
62425328|NCT03232554|EXPERIMENTAL|Buxue Yimu Pills &Ferrous Sulfate|Buxue Yimu Pill 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
62425329|NCT03232554|ACTIVE_COMPARATOR|Ferrous Sulfate|Ferrous Sulfate 0.3g tablet by mouth, three times daily
62425330|NCT01393717|EXPERIMENTAL|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses. Patients in the new cohort receive regular study dose of brentuximab vedotin for courses 1 and 2. Patients not achieving CR after 2 courses receive higher-dose brentuximab vedotin IV over 60 minutes on day 1 for 2 additional courses.
62425331|NCT06134973||Nodular group|nodules less than 2 cm in diameter
62425332|NCT06134973||Macronodular group|nodules between 2-3 cm in diameter
62425333|NCT01246986|EXPERIMENTAL|Part A Cohort 1-160 milligram (mg) LY2157299|"Per the protocol, following an interim analysis, the decision was taken to no longer randomize participants to the 160 mg LY2157299 arm. As of May 25,2012, all newly enrolled participants will receive 300 mg LY2157299.~80 mg LY2157299 given orally twice daily (BID) for 14 days followed by 14 days off (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
62425334|NCT01246986|EXPERIMENTAL|Part A Cohort 2 - 300 mg LY2157299|"150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
62425335|NCT01246986|EXPERIMENTAL|Part B - 300 mg LY2157299|"150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
62593840|NCT04916743|EXPERIMENTAL|Exercise group|The patients will participate in intradialytic exercise 3 times a week for 24 weeks.
62593841|NCT04916743|NO_INTERVENTION|Control group|The patients will receive regular care and treatment in every dialysis sessions without any intradialytic exercise.
62593842|NCT01192529|EXPERIMENTAL|Experimental Group|"In addition to their daily diet, patients of this group will receive 400 ml per day of Supressi nutritional supplement"
62234390|NCT01989767|ACTIVE_COMPARATOR|control|Rehabilitation as usual
62593843|NCT01192529|ACTIVE_COMPARATOR|Control Group|"In addition to their daily diet, patients of this group will receive 400 ml per day of T-Diet plus High Protein product"
62810507|NCT05919576||Bitewing Radiography (BTW)|Bitewing radiographs available in the hospital system of patients who come to their appointment for treatment are examined. A total 639 proximal surface of 22 patient examined by investigators using bitewing radiography.
62234391|NCT01989767|EXPERIMENTAL|education|education of rehabilitation officers in psychiatric topics plus rehabilitation as usual
62234392|NCT02519309|EXPERIMENTAL|onsite|Education (the virta program) for the onsite group will be delivered in person, with 26 classes over 12 months including group and individual sessions. Sessions will be scheduled weekly for the first 3 months, biweekly during months 4-6, and monthly thereafter. Each session will last approximately 90 minutes.
62234393|NCT02519309|EXPERIMENTAL|web-based|Education (the virta program) for the web-based educational group will be the same content as the onsite group, but delivered via the web and completed at the participant's own pace.
62234394|NCT02519309|NO_INTERVENTION|Control (usual care)|The study will make no intervention to this group. Participants in this group will be recent referrals to a local diabetes education program and care for their condition will continue to be managed by their own medical providers.
62234395|NCT03355170|EXPERIMENTAL|Lansoprazole/Domperidone|Patient will be administered lansoprazole/domperidone 30/30 mg capsules (brand name: Duolans) half an hour before breakfast for eight weeks according to randomisation scheme.
62234396|NCT03355170|ACTIVE_COMPARATOR|Lansoprazole|Patient will be administered lansoprazole 30 mg capsules (brand name: Lasotab) half an hour before breakfast for eight weeks according to randomisation scheme.
62234397|NCT01645969||Cohort|
62810508|NCT05919576||Near-infrared imaging Technology (NIRI)|A total 639 proximal surface of 22 patient examined by using the NIRI feature of an intraoral scanner. Patients who came for restorative treatment were asked whether they volunteered in our study. An informed consent form was signed, and then lower and upper jaw scans were made by investigators.
62234398|NCT02689596|ACTIVE_COMPARATOR|OT|Oxytocin
62234399|NCT02689596|PLACEBO_COMPARATOR|Placebo|Placebo
62234400|NCT02934022|OTHER|Maraviroc|
62234401|NCT05048537|OTHER|18F-FACBC PET/CT and the PSA kinetics for PCa patients with BCR.|
62425336|NCT01246986|EXPERIMENTAL|Part C Cohort 1 - 160 mg LY2157299 + 800 mg Sorafenib|"80 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
62425337|NCT01246986|EXPERIMENTAL|Part C Cohort 2 - 300 mg LY2157299 + 800 mg Sorafenib|"150 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
62425338|NCT01246986|EXPERIMENTAL|Part D Cohort 1 - 160 mg LY2157299 + 8 mg/kg Ramucirumab|"80 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kilogram (kg) intravenous (IV) on days 1 and 15 (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
62425339|NCT01246986|EXPERIMENTAL|Part D Cohort 2 - 300 mg LY2157299 + 8 mg/kg Ramucirumab|"150 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kg IV on days 1 and 15 (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
62810509|NCT05919576||Panoramic radiography (PR)|Panoramic radiographs available in the hospital system of patients who come to their appointment for treatment are examined. A total 639 proximal surface of 22 patient examined by using panoramic radiography.
62810510|NCT06349564|EXPERIMENTAL|Endoscopic Procedure with VR Headset|VR google with noise cancellation headphones will be placed on patients' heads after a time-out. Patients can select from a range of entertainment videos prior and during the procedure. The anesthesiologist will administer minimal sedation. The patient can request additional sedation if needed. VR immersion continues until the procedure concludes and patients are moved to the recovery area. Goggles are removed in the recovery area
62810511|NCT06349564|NO_INTERVENTION|Endoscopic Procedure only|The control group will be chart review of patients undergoing similar endoscopic procedure from November 30, 2023 to June 31st, 2023.
62810512|NCT05683847||Adults with epilepsy|User controlled epilepsy follow-up by means of digital patient reported outcome measures (PROM).
62810513|NCT03424564|EXPERIMENTAL|Perampanel single-dose Part: 2 mg group|Participants will receive a single 2 milligrams (mg) dose of perampanel orally under fasted conditions.
62425340|NCT02028156|EXPERIMENTAL|Partially Hydrolyzed Infant Formula|Fed ad lib.
62810514|NCT03424564|EXPERIMENTAL|Perampanel single-dose Part: 4 mg group|Participants will receive a single 4 mg dose of perampanel orally under fasted conditions.
62234402|NCT02316366|EXPERIMENTAL|Warm fluid|Patients in this arm of the study receive intravenous saline warmed to 37.5 degrees Celsius by Astoflo Plus fluid warmer
62234403|NCT02316366|NO_INTERVENTION|Room temperature Fluid|Patients receive intravenous saline at room temperature (22-24 degrees Celsius)
62234404|NCT02858869|EXPERIMENTAL|Arm A (pembrolizumab, SRS 6 Gy, CLOSED):|Patients receive 200 mg pembrolizumab IV over 30 minutes on day 1. Courses repeat Q3W for at least 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo 5 SRS fractions between days 2-15 of course 1.
62234405|NCT02858869|EXPERIMENTAL|Arm B (pembrolizumab, SRS 9 Gy)|Patients receive pembrolizumab IV as in Arm A. Patients undergo 3 SRS fractions between days 2-15 of course 1.
62234406|NCT02858869|EXPERIMENTAL|Arm C (pembrolizumab, SRS 18-21 Gy)|Patients receive pembrolizumab IV as in Arm A. Patients undergo 1 SRS fraction between days 2-3 of course 1.
62234407|NCT04050137|EXPERIMENTAL|Exercise group|Exercise programme 3 times/week.
62234408|NCT02869776|EXPERIMENTAL|Rapid finger stick|HIV and HCV testing through rapid finger stick. Behavioral questionnaires will also be administered.
62234409|NCT02869776|EXPERIMENTAL|Standard venipuncture|HIV and HCV testing through venipuncture. Behavioral questionnaires will also be administered.
62425341|NCT01664000|EXPERIMENTAL|Kevetrin|thioureidobutyronitrile intravenous once/week for 3 weeks/ cycle
62425342|NCT05280873|EXPERIMENTAL|Experimental group|Grade 3-4 checkpoint inhibitor-related pneumonitis
62425343|NCT05280873|EXPERIMENTAL|Control group|Grade 3-4 checkpoint inhibitor-related pneumonitis
62425344|NCT03577652|EXPERIMENTAL|Ticagrelor, 90mg, 12h|
62425345|NCT03577652|EXPERIMENTAL|Ticagrelor, 90mg, 24h|
62425346|NCT03577652|EXPERIMENTAL|Ticagrelor, 180mg, 24h|
62433642|NCT05049889|ACTIVE_COMPARATOR|No history of Immersion Pulmonary Edema|"The participants will have 2 visits:~At visit 1 (Day 0), the participants will perform a terrestrial exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected.~At visit 2 (Day 7), the participants will perform a swimming exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected."
62433643|NCT00939133|ACTIVE_COMPARATOR|Tretinoin microsphere 0.04% gel|
62433644|NCT00939133|PLACEBO_COMPARATOR|Vehicle gel|
62593844|NCT00032188|EXPERIMENTAL|Arm I (aldesleukin and lowest dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive lowest dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
62810515|NCT03424564|EXPERIMENTAL|Perampanel single-dose Part: 8 mg group|Participants will receive a single 8 mg dose of perampanel orally under fasted conditions.
62034059|NCT03695172|ACTIVE_COMPARATOR|ESP block|Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
62034060|NCT05233228|EXPERIMENTAL|Automated Treatment|Consists of all SC components plus a fully automated smartphone-based treatment program that involves interactive and personalized proactive messages, images, or videos.
62034061|NCT05233228|ACTIVE_COMPARATOR|Standard Care|Consists of brief advice to quit smoking delivered by research staff, self-help written materials, and a 2-week supply of nicotine replacement therapy (transdermal patches).
62810516|NCT03424564|EXPERIMENTAL|Perampanel multiple-dose Part|Participants will receive multiple oral dose of perampanel (2 milligrams per day \[mg/day\] from Day 1 to Day 7 and 4 mg/day from Day 8 to Day 21). Fasted condition is required for Days 1 and 21.
62810517|NCT06081296|EXPERIMENTAL|Control group|Alveolus closure with total flap elevation and simple suture
62810518|NCT06081296|ACTIVE_COMPARATOR|Group Free Gingival Mixed Graft|Closure of the alveolus without flap elevation, and placement of a mixed free gingival tissue graft (epithelialized in the central region and de-epithelialized (2 mm) in the vestibulolingual edges
62810519|NCT06081296|ACTIVE_COMPARATOR|Bone + Mixed Free Gum Graft Group|Socket closure without flap elevation, placement of lyophilized bone graft and socket sealing with mixed free gingival tissue graft (as previously described)
62810520|NCT06081296|ACTIVE_COMPARATOR|Bone + Titanium Seal Group|Socket closure without flap elevation, placement of lyophilized bone graft, socket sealing by installing a non-absorbable titanium membrane.
62819571|NCT06465589|OTHER|Preferred Standard|After participants are randomized to the preference arm, they will be given access to the program version they indicate a preference for after having read two descriptive texts about both versions. Participants in this arm will use the standard program.
62034062|NCT03946943|EXPERIMENTAL|anlotinib + Toripalimab|Concurrent anlotinib and Toripalimab therapy, with Blood Draw and Tumor Specimen Collection for correlative studies
62034063|NCT03137303|PLACEBO_COMPARATOR|Patient Subject Usual Care|"On the day of the outpatient visit, subjects will be advised to arrive 90 minutes prior to their clinic visit. The following will be performed.~1. Subject demographic and contact information~2. Co-morbid conditions~3. Smoking history~4. Medication history from patient and also from pharmacy used by subjects~5. A respiratory exacerbation history in the past year~6. Modified Medical Research Counsel (mMRC) dyspnea scale~7. Quality of life measures~Subjects will be advised to go to their clinics and be managed by their PCP thereafter.~At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry and undergo the same spirometry protocol as the intervention group."
62034064|NCT03137303|EXPERIMENTAL|Patient-Subject Intervention|"On the day of the outpatient visit, subjects will be advised to arrive 90 minutes prior to their clinic visit in the same building as the clinic site. The following information will be collected and procedures will be performed:~1. Subject demographic and contact information~2. Co-morbid conditions~3. Smoking history~4. Medication history from patient and also from pharmacy used by subjects~5. A respiratory exacerbation history in the past year~6. Modified Medical Research Counsel (mMRC) dyspnea scale~7. Quality of life measures~8. Pre and post-bronchodilator using Albuterol (BD) spirometry"
62034065|NCT01564550||type 2 diabetes|
62034066|NCT01564550||healthy subjects|
62234410|NCT03909217|EXPERIMENTAL|TECAS|Patients will receive transcutaneous electrical cranial-auricular acupoint stimulation (TECAS) daily.
62234411|NCT03909217|ACTIVE_COMPARATOR|Anti-depressants|Each subject shall receive oral administration Escitalopram (10-20mg/day, q.d.), as prescribed by a clinical psychiatrist with respect to patients' conditions for 8 consecutive weeks.
62234412|NCT03635307||Operated patients with volume expansion|
62593845|NCT00032188|EXPERIMENTAL|Arm II (aldesleukin and middle dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive middle dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
62593846|NCT00032188|EXPERIMENTAL|Arm III (aldesleukin and highest dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive highest dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
62593847|NCT03898479|EXPERIMENTAL|CTP-543|Patients who previously completed a qualifying CTP-543 clinical trial
62034067|NCT06669806|EXPERIMENTAL|TIPS Stent Graft device|after creating and dilating the hepatic parenchymal tract, the device is planted to cover the intrahepatic shunt and hepatic vein. A second stent graft may be placed in overlapped fashion.
62034068|NCT04790318|ACTIVE_COMPARATOR|General Anesthesia +TiQLB|patients will receive combined general anesthesia and quadratus lumborum block (trans-incisional) with 0.5 mL/kg of bupivacaine 0.2 %. with maximum volume limited to 20 ml
62034069|NCT04790318|ACTIVE_COMPARATOR|General Anesthesia+ Caudal block|patients will receive combined general anesthesia and caudal analgesia (just after wound closure) with 1.25 mL/kg of bupivacaine 0.2 % (three parts 0.25 % bupivacaine to one part saline.
62234413|NCT05699226|EXPERIMENTAL|Variable amplitude|Individualized amplitude
62234414|NCT05699226|ACTIVE_COMPARATOR|Fixed amplitude|Fixed (800 milliamperes) amplitude
62433645|NCT02535000|EXPERIMENTAL|Group C (control)|subjects who will receive one capsule of placebo before the surgery and being repeated the next day
62433646|NCT02535000|ACTIVE_COMPARATOR|Group D (duloxetine)|subjects who will receive one capsule of duloxetine 60 mg before the surgery and being repeated the next day
62234415|NCT05422287|EXPERIMENTAL|Virtual Reality Glasses (VRG) Group|The participants in this group were started to watch videos by wearing virtual reality glasses about 2 minutes before the catheterization process was started and the process was continued until the end. Then, catheterization was performed by detecting the tourniquet by the emergency department nurse. Upon completion of the catheterization procedure, VRG was removed from the procedure area by the researcher. This process took an average of 5 minutes. After the procedure was completed, the pain and satisfaction status of the patients were scored on the VAS by the same nurse.
62234416|NCT05422287|EXPERIMENTAL|Thermomechanical Stimulation Device (Buzzy ®) Group|1 minute before starting the catheterization procedure in this group, a cold and vibration application was placed in the operation area by the researcher using the apparatus of the Buzzy ® device and started. The procedure was performed after evaluating the vein and determining the appropriate right or left arm. At the end of this time, the Buzzy ® has been shifted approximately 5 cm above the processing zone. Then, catheterization was performed. Upon completion of the catheterization procedure, Buzzy ® was removed from the procedure area by the researcher. This process took an average of 4 minutes. After the procedure was completed, the pain and satisfaction status of the patients were scored on the VAS by the same nurse.
62234417|NCT05422287|NO_INTERVENTION|Control group|Peripheral intravenous catheterization was performed by the same emergency department nurse in accordance with the procedure. The process took an average of 3 minutes. There was no application to the patients in the control group except for the standard procedure. After the procedure was completed, the pain and satisfaction status of the patients were scored on the VAS by the same nurse.
62234418|NCT04038853|EXPERIMENTAL|Vitamin D|Intervention drug, containing 1,25-dihydroxy-vitamin D, comes in original packages as vials containing a total amount of 10 ml of clear solution. 5 drops accounting for 1000 IU of 1,25-dihydroxy-vitamin D will be administered orally on a daily basis.
62425347|NCT05744531|EXPERIMENTAL|education group|The healthy pregnant women and their spouses meeting the inclusion criteria were determined by randomization according to the order of application to the antenatal clinic. A guide to providing access to internet-based education, training booklet and attachment diary was given to the pregnant women and their spouses in the education group .Internet-based Parenting education based on the Information-Motivation-Behavioral Skills (IMB) Model was given to the pregnant women and their spouses in the education group , once a week between 31 and 34 weeks of gestation, for a total of 4 times. . Internet-based counseling was given to the pregnant women and their spouses in the education group as part of the motivation step of the model,
62034070|NCT00297154|NO_INTERVENTION|Control|Patients continue receive a single educational session and continue medical managment of heart failure as per their physician
62425348|NCT05744531|NO_INTERVENTION|control group|The healthy pregnant women and their spouses meeting the inclusion criteria were determined by randomization according to the order of application to the antenatal clinic. A guide to providing access to internet-based education, training booklet and attachment diary was not given to the pregnant women and their spouses in the control group. No training was given to the pregnant women and their spouses in the control group.Counseling was not provided to the pregnant women and their spouses in the control group. .
62425349|NCT04209829||Patients with haematological malignancy|Patients, aged 15 years or over, with haematological malignancy (Lymphoma, ALL, MM) integrated into a CAR-T Cells program treatment
62425350|NCT02065973|ACTIVE_COMPARATOR|Cohort 1 (Low Dose)|The group will receive the lowest dose of the vaccine
62425351|NCT02065973|ACTIVE_COMPARATOR|Cohort 2 (Mid Dose)|The Group will receive the middle dose of the vaccine
62425352|NCT02065973|ACTIVE_COMPARATOR|Cohort 3 (High Dose)|The Group will receive the highest dose of vaccine to be tested
62425353|NCT06454903|EXPERIMENTAL|Treatment|This Phase 3 (Stage 1b RCT) Arm will consist of n = 20 Veterans (anticipated enrollment) who will receive the prototype ACT to RECOVER smartphone intervention for 4 weeks.
62425354|NCT06454903|SHAM_COMPARATOR|Control|This Phase 3 (Stage 1b RCT) Arm will consist of n = 20 Veterans (anticipated enrollment) who will be assigned to receive a smartphone-based symptom-monitoring program for 4 weeks.
62425355|NCT04514328|EXPERIMENTAL|one group|patients with mild or moderate Alzheimer disease
62425356|NCT05797857|EXPERIMENTAL|Intervention arm|
62810521|NCT05962866|EXPERIMENTAL|Experiment: Have pregnant women perform the 1st and 2nd Leopold Maneuvers|Voluntary information form will be read to those who want to participate in the research, verbal and written permissions will be obtained and information will be given about fetal development and Leopold maneuvers in the pregnant follow-up room of the family health center. This transaction is 28-32. 32-38 at the next follow-up at gestational weeks. Pregnancy will be carried out with the same procedure.
62034071|NCT00297154|EXPERIMENTAL|Lifestyle modification|Patients recieve weekly sessions with dietician, replace 2 meals/day with meal replacement beverage, and initiate a walking program.
62034072|NCT02298192|EXPERIMENTAL|Once weekly titration|
62425357|NCT02029313|EXPERIMENTAL|MKT-N2|Montelukast
62425358|NCT02029313|ACTIVE_COMPARATOR|Singulair|Montelukast sodium
62425359|NCT06348004||albumin user group and albumin non-user group|
62425360|NCT06456398|NO_INTERVENTION|2D (traditional method)|"Learning advanced anatomy using the traditional method of using flat diagrams to correlate with computed tomography scans."
62425361|NCT06456398|EXPERIMENTAL|3D (Metaverse Virtual 3D Printing System)|"Learning advanced anatomy using the Metaverse Virtual 3D Printing System in virtual reality."
62425362|NCT03304990||Family History of CA|Hereditary cancer genetic screening based on risk factors
62425363|NCT03304990||Risk Factors for CA|No dx of CA
62425364|NCT03304990||Suspected or Confirmed Diagnosis of CA|Suspected or confirmed diagnosis of cancer
62425365|NCT05151172|PLACEBO_COMPARATOR|best medical care|All patients will receive the best standard of medical care according to modern acute stroke care guidelines All patients including the ones in control arm will receive the best standard of medical care according to modern acute stroke care guidelines. The model will be the Canadian best practices guidelines for acute stroke care. These are very similar to the guidelines of the American Stroke Association and the European Stroke Organization. All participants are expected to be admitted to hospital as part of routine standard of care.It is expected that all participants will undergo a routine work-up for the mechanism of their stroke and be treated appropriately and definitively.
62810522|NCT05962866|NO_INTERVENTION|Control: Assigned Interventions standard care group|No intervention will be made.
62810523|NCT00670215|EXPERIMENTAL|Arm 1|
62034073|NCT02298192|EXPERIMENTAL|Twice weekly titration|
62034074|NCT06667960|EXPERIMENTAL|Dose Escalation|Escalating repeated doses of JK06 administered intravenously. A cycle of treatment is defined as 21 days.
62034075|NCT06667960|EXPERIMENTAL|Dose Expansion|The RP2D/OBD of JK06 determined by the Escalation arm. A cycle of treatment is defined as 21 days.
62034076|NCT02679690|EXPERIMENTAL|Standard dietary sodium education|Standard dietary sodium education provided to patients with heart failure using voice over powerpoint presentation.
62034077|NCT02679690|EXPERIMENTAL|color-coded cue cards|The use of a color-coded cue cards to educate patients with heart failure on dietary sodium. The education regarding the use of the color-coded cue card was provided using a voice over powerpoint presentation.
62810524|NCT00670215|EXPERIMENTAL|Arm 2|
62034078|NCT05111236|ACTIVE_COMPARATOR|RPT Group|"Routine physical therapy comprising stretching of spastic muscles, Strengthening of weak muscles, positioning ( how to make sitting and standing postures at home) and posturing strategies. This whole regimen will be practiced fives times a week for a period of twelve weeks.~Other Names:~• Routine Physical Therapy"
62034079|NCT05111236|EXPERIMENTAL|Massage Group|"Traditional massage of thirty minutes duration ( five minutes of massage will be provided to all four limbs, front and back of trunk area) prior to routine physical therapy. Routine physical therapy comprising stretching of spastic muscles, Strengthening of weak muscles, positioning ( how to make sitting and standing postures at home) and posturing strategies.~Other Names:~• Routine physical therapy and Traditional massage"
62034080|NCT01390454|EXPERIMENTAL|Tennis elbow patients|These patients have tennis elbow, according to stated inclusion criteria.
62034081|NCT01390454|ACTIVE_COMPARATOR|Healthy volunteers|Healthy volunteers are selected and paired according to age, sex, socio-professional category and left- or right-handedness.
62425366|NCT05151172|EXPERIMENTAL|endovascular thrombectomy|All participants will receive the best standard of medical care according to modern acute stroke care guidelines. In the intervention/experimental arm, participants will be treated with endovascular thrombectomy with a Solitaire device (Medtronic) as the first line approach. The trial mandates that the first attempt is performed with a Solitaire X device (3mm, 4mm or 6mm diameter devices; Medtronic). The remaining treatment technique is left to the discretion of the treating neurointerventionalist. Secondary devices may be used if success is not achieved after use of the first device.
62034082|NCT01046305||Part 1: Interview & Questionnaires|Patients interviews and questionnaires about CML symptoms once.
62425367|NCT06416007|EXPERIMENTAL|Lattice radiation therapy (LRT)|Lattice radiation therapy (LRT) : 5 fractions
62425368|NCT01953627|EXPERIMENTAL|Surgical procedure with the system Kymerax|
62425369|NCT03903952|OTHER|Papanicolaou smear result (control group)|women who did not have intraepithelial neoplasia as a result of smear
62425370|NCT03903952|OTHER|Papanicolaou smear result (study group)|women who have atypical squamous cells of undetermined significance (ASCUS) as a result of smear
62425371|NCT06541613|EXPERIMENTAL|The EOIPB ( E) group|EOIPB will be administered by a single anesthetists following the intubation. A linear ultrasound transducer is positioned in the sagittal plane at the 6th rib level, between the anterior axillary and midclavicular lines. The ribs, lungs, pleura, intercostal muscles, external oblique muscle and subcutaneous tissue are visualized in the image. The in-plane technique with a 22G, 80 mm block needle is used to inject 30 ml of 0.25% bupivacaine into the external oblique intercostal plane on both sides.
62425372|NCT06541613|PLACEBO_COMPARATOR|The Control Group (C)|Control group of patients will receive standard multimodal analgesia. Using us guidance, the external oblique intercostal plane is identified and 30 ml normal saline instead of LA will be injected in the control group.
62425373|NCT01094873|EXPERIMENTAL|Arm A, group 1|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10\^8vp at week 14 and 1 dose Ad6NSmut 5 x 10\^8vp at week 24, after starting PEG-IFN and ribavirin therapy.~Patients: 2"
62034083|NCT01046305||Part 2: Symptoms Rating|Importance of symptoms to CML patients rated by physicians, nurses, patients, and caregivers.
62034084|NCT01046305||Part 3: MDASI-CML Questionnaires|Patients questionnaires about CML symptoms over 1 year using M. D. Anderson Symptom Inventory (MDASI) module (the MDASI-CML)
62034085|NCT01741623|EXPERIMENTAL|Bisoprolol Fumarate Tablet 10 mg|Bisoprolol Fumarate Tablet 10 mg of M/s Ipca Laboratories Limited, India
62034086|NCT01741623|ACTIVE_COMPARATOR|Zebeta®|Zebeta® (Bisoprolol Fumarate) Tablets 10 mg of Duramed Pharmaceuticals Inc., USA
62034087|NCT02640768|EXPERIMENTAL|educational training|educational training
62034088|NCT02640768|NO_INTERVENTION|no educational training|no educational training wards
62034089|NCT05110859||first work experience nurses|
62034090|NCT04543110|EXPERIMENTAL|Single Arm|Immune-Modulating Radiation with Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
62034091|NCT03842657|OTHER|calcium-free citrate-containing dialysate|Dialysis session will be performed with a non-heparin grafted membrane, a dialysate without calcium (0 mmol/L) and citrate 0.8 mmol/L, a reinjection of a calcium solution (300 mM) according to the ionic dialysance, and no heparin addition
62034092|NCT03842657|OTHER|heparin-grafted membrane|dialysis session will be performed with a heparin-grafted membrane, a dialysate with calcium (1.65 mmol/L) and citrate 0.8 mmol/L, and no heparin addition
62034093|NCT04290754|EXPERIMENTAL|CATCH-IT|Competent Adulthood Transition with Cognitive-behavioral \& Interpersonal Training (CATCH-IT) is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious.
62425374|NCT01094873|EXPERIMENTAL|Arm A, group 2|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10\^9vp at week 14 and 1 dose Ad6NSmut 5 x 10\^9vp at week 24, after starting PEG-IFN and ribavirin therapy.~Patients: 2"
62425375|NCT01094873|EXPERIMENTAL|Arm A, group 3|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 14 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24, after starting PEG-IFN and ribavirin therapy.~Patients: 6"
62433647|NCT06105619|EXPERIMENTAL|PLB1001|Subjects will receive 300mg of PLB1001 twice daily in cycles of 4 weeks duration until death or adverse event(AE) leading to discontinuation
62810525|NCT05895474|EXPERIMENTAL|Focused Ultrasound Dose #1|Focused Ultrasound will be administered using high frequency stimulation as condition 1. Stimulation will last 1-10 minutes.
62034094|NCT04290754|ACTIVE_COMPARATOR|TEAMS|Teens Achieving Mastery over Stress (TEAMS) is an 8-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive-behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
62034095|NCT03413436|EXPERIMENTAL|Lobaplatin group|i) thoracic ESCC stage II to III; ii) without any preoperation treatment for ESCC; iii) underwent R0 resection; iv) received at least one cycle ajuvant chemotherapy of Lobaplatin plus Docetaxel; v) without ajuvant radiotherapy/chemoradiotherapy; vi) without history of other type of cancer. Completed clinical, pathological and follow up data.
62810526|NCT05895474|EXPERIMENTAL|Focused Ultrasound Dose #2|Focused Ultrasound will be administered using medium frequency stimulation as condition 2. Stimulation will last 1-10 minutes.
62810527|NCT05895474|EXPERIMENTAL|Focused Ultrasound Dose #3|Focused Ultrasound will be administered using low frequency stimulation as condition 4. Stimulation will last 1-10 minutes.
62810528|NCT05895474|SHAM_COMPARATOR|Focused Ultrasound Dose #4|Focused Ultrasound will be administered using the sham condition.
62810529|NCT05895474|SHAM_COMPARATOR|Focused Ultrasound Dose #5|Focused Ultrasound will be administered using the sham condition.
62810530|NCT05895474|EXPERIMENTAL|Focused Ultrasound Dose #6|Focused Ultrasound will be administered using low frequency stimulation as condition 4. Stimulation will last 1-10 minutes.
62810531|NCT05895474|EXPERIMENTAL|Focused Ultrasound Dose #7|Focused Ultrasound will be administered using medium frequency stimulation as condition 4. Stimulation will last 1-10 minutes.
62810532|NCT05895474|EXPERIMENTAL|Focused Ultrasound Dose #8|Focused Ultrasound will be administered using high frequency stimulation as condition 4. Stimulation will last 1-10 minutes.
62034096|NCT03413436|ACTIVE_COMPARATOR|Cisplatin group|i) thoracic ESCC stage II to III; ii) without any preoperation treatment for ESCC; iii) underwent R0 resection; iv) received at least one cycle ajuvant chemotherapy of Cisplatin plus Docetaxel; v) without ajuvant radiotherapy/chemoradiotherapy; vi) without history of other type of cancer. Completed clinical, pathological and follow up data.
62034097|NCT03815721|EXPERIMENTAL|daily stimulation|30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 7 times per week.
62034098|NCT03815721|EXPERIMENTAL|stimulation every other day|30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 3 times per week.
62034099|NCT00958269|EXPERIMENTAL|dutogliptin (double-blind, placebo-controlled period)|weeks 1-26
62034100|NCT00958269|EXPERIMENTAL|dutogliptin (single-blind, active-controlled period)|weeks 27-52
62034101|NCT00958269|PLACEBO_COMPARATOR|placebo (double-blind, placebo-controlled period)|weeks 1-26
62034102|NCT00958269|PLACEBO_COMPARATOR|placebo (single-blind, active-controlled period)|weeks 27-52
62034103|NCT00958269|ACTIVE_COMPARATOR|sitagliptin (single-blind, active-controlled period)|weeks 27-52
62034104|NCT02647112|EXPERIMENTAL|Bladder EpiCheck|Urine sample will be tested with the Bladder EpiCheck in conjunction with cystoscopy and cytology
62034105|NCT02647112|NO_INTERVENTION|Practice of medicine|Practice of medicine including cystoscopy and cytology
62034106|NCT02007850|PLACEBO_COMPARATOR|ropivacaine continuous mode|0.2% ropivacaine 8 ml/hr through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
62034107|NCT02007850|ACTIVE_COMPARATOR|ropivacaine patient controlled mode|0.2% ropivacaine patient controlled mode, basal rate 4 ml/hr, bolus 4 ml, lockout 60 minutes through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
62034108|NCT04219033||with postoperative cognitive dysfunction|
62034109|NCT04219033||without postoperative dysfunction|
62810533|NCT01772628|EXPERIMENTAL|Promoting parent-child communication|This is the arm in which all interventions of Promoting parent-child communication on selected sexual and reproductive health issues among young secondary school adolescents in Kampala and Wakiso Districts were implemented. The interventions included; classroom-based component, STI/HIV prevention education, parenting component and homework assignment component.
62810534|NCT01772628|NO_INTERVENTION|Comparison|The 11 comparison schools did not receive any form of intervention. Instead the students continued with the official standard school curriculum and regular parent/guardian involvement in school activities. No homework assignments were given to the senior one students.
62810535|NCT00806182||Pediatric case-controls|These are children who underwent lumbar puncture and blood drawing for diagnostic testing for non-inflammatory neurological or non-neurological disorders, and whose samples were retrieved from the clinical lab under a linked Institutional Review Board (IRB) protocol.
62810536|NCT00806182||Pediatric OMS|These are patients treated by the P.I. based on clinical decision making, not a clinical trial (this is an observational study). The types of treatments are varied, and, on the initial evaluation, the patients may be untreated or already tried on various immunotherapies. They range from monotherapy with steroids, ACTH, or IVIg, to disease modifying agents, such as rituximab, cyclophosphamide, and other chemotherapy, typically adjunctively or as combination therapy.
62810537|NCT03467321||Pregnant group|Balance with the one leg balance test with the eyes open and closed, pulmonary functions with a spirometer, and LBP with the Visual Analogue Scale (VAS) were assessed.
62810538|NCT03467321||Non-pregnant group|Balance with the one leg balance test with the eyes open and closed, pulmonary functions with a spirometer, and LBP with the Visual Analogue Scale (VAS) were assessed.
62810539|NCT02890797|OTHER|Bronchiolitis children|Under two years old patient with bronchiolitis will have thoracic radiology
62810540|NCT01476670||Posterior fossa tumor|Patients with posterior fossa tumor scheduled for elective surgery will be enrolled in the study.
62034110|NCT01178086||Participants With CLL|Participants with CLL who are being treated with intravenous (IV) rituximab in combination with chemotherapy, will be observed for 24 months including 6-month treatment period.
62034111|NCT05005832||People participating in the walking pilgrimage|People taking part in the study will be healthy people without any existing systemic diseases and musculoskeletal injuries, and will not engage in professional physical activity. The age of the respondents will be in the range of 18-65 years and BMI in the range of 18-39. People who have valid medical examinations will be admitted to the tests, with no contraindications to physical activity.
62034112|NCT01181050|EXPERIMENTAL|4.0 mg/kg|Subjects received a single dose of 4 mg/kg NNC0142-0002
62034113|NCT01181050|PLACEBO_COMPARATOR|Placebo|Subjects received a single dose of placebo
62034114|NCT01454648||Physician-staffed|Patients treated by physician-staffed emergency medical service (EMS) unit
62034115|NCT01454648||Paramedic-staffed|Patients treated by paramedic-staffed emergency medical service (EMS) unit
62034116|NCT01300130|EXPERIMENTAL|low docosahexaenoic acid formula|
62034117|NCT01300130|EXPERIMENTAL|medium docosahexaenoic acid formula|
62034118|NCT01300130|EXPERIMENTAL|high docosahexaenoic acid formula|
62034119|NCT01300130|ACTIVE_COMPARATOR|human milk|
62034120|NCT03273946||Subjects receiving fluticasone propionate|Eligible subjects will receive FP 50 µg twice daily inhaled via a pediatric pMDI with a face mask in clinical practice.
62034121|NCT02048228|EXPERIMENTAL|genotyping guided therapy|Patients randomized to the genotyping guided therapy arm will have their CYP2C19\*2 carrier status determined at the time before antiplatelet therapy with subsequent alteration in antiplatelet therapy for \*2 carriers.CYP2C19\*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers will be given 75 mg clopidogrel daily.
62034122|NCT02048228|ACTIVE_COMPARATOR|Standard Therapy|Patients randomized to the Standard Therapy arm will not undergo genotyping. All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
62425376|NCT01094873|EXPERIMENTAL|Arm A, group 4|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 2 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 12, after starting PEG-IFN and ribavirin therapy.~Patients: 6"
62034123|NCT05498376|ACTIVE_COMPARATOR|Conventional pacemaker DDD|Implantation of a conventional dual-chamber PM
62034124|NCT05498376|ACTIVE_COMPARATOR|Leadless pacemaker Micra AV|Implantation of a leadless pacemaker system (Micra AV™)
62425377|NCT01094873|EXPERIMENTAL|Arm A, group 5|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10\^10vp at weeks 14 and 18, and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 28, after starting PEG-IFN and ribavirin therapy.~Patients: 4"
62425378|NCT01094873|EXPERIMENTAL|Arm A, group 6|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10\^10vp at weeks 2 and 6, and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 16, after starting PEG-IFN and ribavirin therapy.~Patients: 4"
62425379|NCT01094873|EXPERIMENTAL|Arm B, group 1|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10\^8vp at week 4 and 1 dose Ad6NSmut 5 x 10\^8vp at week 14.~Patients: 2"
62593848|NCT00824382|EXPERIMENTAL|BI 1744 CL 5 Âµg|2 puffs of 2.5 Âµg/actuation
62593849|NCT00824382|EXPERIMENTAL|BI 1744 CL 10 Âµg|2 puffs of 5 Âµg/actuation
62034125|NCT02510495|NO_INTERVENTION|"0 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was deflated immediately. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
62810541|NCT05298488|EXPERIMENTAL|Home office for first 4 weeks, and office for the last 4 weeks|Participants will work from home for first 4 weeks, and at the office for the last 4 weeks
62810542|NCT05298488|ACTIVE_COMPARATOR|Office for first 4 weeks, and home office for the last 4 weeks|Participants will work at the office for the first 4 weeks, and from home during the last 4 weeks
62810543|NCT05957679|EXPERIMENTAL|Diagnostic（MRE, tumor grading of stiffness and adhesion）|Patients undergo a preoperative routine MRI scan and MRE the day before their scheduled surgery. During surgery, the tumor stiffness and adhesion are assessed and recorded by the surgeon according to established evaluation criteria. It is important to note that the surgeon does not have prior knowledge of the tumor's specific stiffness and adhesion before the surgery. This information is typically obtained through intraoperative assessment and observation.
62810544|NCT03552666|EXPERIMENTAL|Vitafusion Extra Strength Vitamin D3 Gummy|A single oral dose of gummy vitamin D3 to monitor Vitamin D blood levels
62810545|NCT03552666|ACTIVE_COMPARATOR|Nature Made Vitamin D3 Tablet|A single oral dose of tablet vitamin D3 to monitor Vitamin D blood levels
62810546|NCT03800056||Group 1 APS 1|Patients with a APS type 1 whose molecular diagnosis (mutation of the AIRE gene) has been established in the diagnosis of the disease, regardless of their mycological status (history of mycosis) or the presence of antifungal treatment.
62810547|NCT03800056||Group 2 APS2|Patients with APS type 2: - with adrenal insufficiency for 50% of them. - a delay of two weeks after stopping antifungal or antibiotic treatment in patients is to be respected.
62810548|NCT02974998|EXPERIMENTAL|Young Women's Health CoOp (YWHC)/ HTC|Participants received an enhanced gender-focused HTC intervention.
62810549|NCT02974998|ACTIVE_COMPARATOR|Standard HTC|Participants received the standard HTC available in South Africa for this population.
62810550|NCT06525285|EXPERIMENTAL|Study group|Connective tissue graft wall technique
62810551|NCT06525285|ACTIVE_COMPARATOR|Control group|Connective tissue graft
62034126|NCT02510495|EXPERIMENTAL|"30 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
62034127|NCT02510495|EXPERIMENTAL|"60 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
62810552|NCT03186612|ACTIVE_COMPARATOR|OT intervention|Conventional occupational therapy (OT) treatment will consist of 20 sessions in total, during which subjects will perform activities for training manipulative and functional dexterity of the upper limb aimed at activities of daily living. These will be distributed in two OT sessions per week, each lasting 30 minutes.
62810553|NCT03186612|EXPERIMENTAL|OT+VR intervention|The intervention applied to the experimental group will consist of 20 sessions of conventional OT distributed in two sessions per week, each lasting 30 minutes. Additionally, they will receive 20 treatment sessions lasting 20 minutes, twice weekly of virtual reality (VR) via the online and free website motiongamingconsole.com, during which they will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro. All the interventions will consider the level of fatigue experimented by the patient by featuring a progressive increase of the treatment times according to the same.
62810554|NCT04233008|EXPERIMENTAL|6 hour foley|The participant will have a cook catheter inserted digitally or by direct visualization with a speculum with the uterine component of the balloon inflated to maximum 60mL. The catheter will be taped to the inner thigh with gentle traction. Participants will be started on hospital-based oxytocin protocol. The cook catheter will then be removed at 6 hours, determined by randomization. At that point health care providers will manage active labor.
62810555|NCT04233008|NO_INTERVENTION|12 hour foley|The participant will have a cook catheter inserted digitally or by direct visualization with a speculum with the uterine component of the balloon inflated to maximum 60mL. The catheter will be taped to the inner thigh with gentle traction. Participants will be started on hospital-based oxytocin protocol. The cook catheter will then be removed at 12 hours, determined by randomization. At that point health care providers will manage active labor.
62810556|NCT04472052||Appendectomy|Patients who required appendectomy for suspected acute appendicitis
62810557|NCT05706922||Polycystic ovary syndrome (PCOS)|"* Hormonal screening~* Vaginal swab~* Fecal sample~* Blood samples~* Food Frequency Questionnaire"
62810558|NCT05706922||Control group|"* Hormonal screening~* Vaginal swab~* Fecal sample~* Blood samples~* Food Frequency Questionnaire"
62810559|NCT03567772|EXPERIMENTAL|Wiifit Nintendo video game|Pulmonary rehabilitation program using video games exercise from Nintendo
62810560|NCT03567772|ACTIVE_COMPARATOR|Pulmonary rehabilitation program|Pulmonary rehabilitation program with ergometer cycle
62425380|NCT01094873|EXPERIMENTAL|Arm B, group 2|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10\^9vp at week 4 and 1 dose Ad6NSmut 5 x 10\^9vp at week 14.~Patients: 2"
62593850|NCT00824382|PLACEBO_COMPARATOR|Placebo|2 puffs
62234419|NCT04038853|PLACEBO_COMPARATOR|Placebo|A placebo identical to the study intervention drug in all its characteristics (package, visual characteristics of the fluid, smell, and taste) will be administered in the same manner.
62234420|NCT02628301|ACTIVE_COMPARATOR|Hypercaloric diet|Hypercaloric diet (1.6x REE) for 30 days
62234421|NCT02628301|PLACEBO_COMPARATOR|Normal diet|Normocaloric diet (1.0xREE)
62234422|NCT01376349|EXPERIMENTAL|Arm I low dose DHEA|Participants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone \[DHEA\]) gel once daily (QD), at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
62425381|NCT01094873|EXPERIMENTAL|Arm B, group 3|"Interventions: AdCh3NSmut; Ad6NSmut.~1 dose AdCh3NSmut 2.5 x 10\^10vp at week 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 14.~Patients: 4"
62425382|NCT03417531|ACTIVE_COMPARATOR|Protein Supplement plus Active Exercise|Participants will ingest twice daily 23.7 g of L-leucine-enriched whey protein isolate powder (equivalent to 20 g of Protein) and perform a simple home exercise strength program (3x30 minutes/week)
62425383|NCT03417531|ACTIVE_COMPARATOR|Protein-free Supplement plus Active Exercise|Participants will ingest twice daily 23.7 g of a protein-free, isocaloric powder blend and perform a simple home exercise strength program (3x30 minutes/week)
62425384|NCT03417531|ACTIVE_COMPARATOR|Protein Supplement plus Control Exercise|Participants will ingest twice daily 23.7 g of L-leucine-enriched whey protein isolate powder (equivalent to 20 g of Protein) and perform a joint flexibility home exercise program (3x30 minutes/week)
62034128|NCT02510495|EXPERIMENTAL|"180 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
62034129|NCT02510495|EXPERIMENTAL|"300 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
62425385|NCT03417531|SHAM_COMPARATOR|Protein-free Supplement plus Control Exercise|Participants will ingest twice daily 23.7 g of a protein-free, isocaloric powder blend and perform a joint flexibility home exercise program (3x30 minutes/week)
62425386|NCT03582501|EXPERIMENTAL|Healthy volunteers|All volunteers will be studied at rest and during experimental condition (lower body negative pressure)
62234423|NCT01376349|EXPERIMENTAL|Arm II high dose DHEA|Participants apply a high dose (6.5 mg) of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
62425387|NCT04209244|EXPERIMENTAL|Fish oil|Eskimo-3 Pure Fish Oil, 10 ml per day (2.6 g EPA+DHA)
62425388|NCT04209244|PLACEBO_COMPARATOR|Placebo|Rapeseed Oil, 10 ml per day
62425389|NCT06073717|EXPERIMENTAL|Exercise Intervention|This arm will receive a 5-month (20 weeks) supervised exercise program based on aerobic and resistance/strength training together with a weekly calorie or step challenge.
62810561|NCT00231777|EXPERIMENTAL|1|40 mg MK0517 IV
62810562|NCT00231777|ACTIVE_COMPARATOR|2|4 mg ondansetron IV
62425390|NCT06073717|EXPERIMENTAL|Dual Motor-Cognitive Intervention|This arm will receive a 5-month (20 weeks) supervised and simultaneous dual-task program based on aerobic, resistance, and cognitive stimulation training together with a weekly calorie or step challenge
62425391|NCT06073717|ACTIVE_COMPARATOR|Health and Wellness Intervention|This arm will receive a 5-month health and wellness program.
62810563|NCT00799682|ACTIVE_COMPARATOR|Xalatan®|
62234424|NCT01376349|PLACEBO_COMPARATOR|Arm III placebo|Participants apply a vaginal placebo gel QD, at bed time, for 12 weeks. There is an Optional Continuation Phase (for placebo arm only): Participants apply a high dose of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
62593851|NCT00824382|EXPERIMENTAL|BI 1744 CL 2 Âµg|2 puffs of 1 Âµg/actuation
62810564|NCT00799682|ACTIVE_COMPARATOR|Travatan Z®|
62819572|NCT05308537|EXPERIMENTAL|Mindful Compassion Care Program|The MCCP comprises six regular 1 hour and 30-minute sessions and 1 all-day class lasting 4 hours and 30 minutes.
62819573|NCT05308537|NO_INTERVENTION|Waiting List|
62819574|NCT05575453|ACTIVE_COMPARATOR|Kvatchii Portal|The intervention group will be given access to the Kvatchii portal and home blood pressure monitor
62819575|NCT05575453|NO_INTERVENTION|Usual Care|The control group will not have access to the portal but will be provided with home blood pressure monitor
62425392|NCT00422773|EXPERIMENTAL|Cetuximab+ FOLFOXIRI|Cetuximab and Irinotecan, Oxaliplatin, 5FU and Folinic acid
62034130|NCT02768961|EXPERIMENTAL|Active treatment|"All HCV chronic infected patients will be treated with oral anti-HCV regimens containing sofosbuvir, ledipasvir (associated or not to ribavirin) according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver (EASL). EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
62234425|NCT03998254|EXPERIMENTAL|V503|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
62234426|NCT03998254|ACTIVE_COMPARATOR|Gardasil|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
62234427|NCT00947713|EXPERIMENTAL|Low dose hCG group|
62234428|NCT00947713|ACTIVE_COMPARATOR|Clomiphen citrate plus HMG|
62234429|NCT00755651|EXPERIMENTAL|H Pipelle|Endometrial sample obtained using the H Pipelle
62234430|NCT00755651|ACTIVE_COMPARATOR|Pipelle|Endometrial sample obtained with standard Pipelle
62034131|NCT06413524|EXPERIMENTAL|Whole-body Vibration Training Group|
62034132|NCT06413524|EXPERIMENTAL|Local Vibration Training Group|
62034133|NCT06413524|SHAM_COMPARATOR|Control Group|
62034134|NCT04885023|EXPERIMENTAL|Study group|Twenty six patients who received hippotherapy combined with Schroth exercises for ten weeks
62034135|NCT04885023|OTHER|Control group|Twenty six patients who received only Schroth exercises for ten weeks
62034136|NCT05893758||PFO subjects|Patients with a confirmed diagnosis of Patent Foramen Ovale (PFO) which is associated with TIA or cryptogenic stroke, and implanted with the investigational device.
62034137|NCT06292455|EXPERIMENTAL|Elastic resistance training|elastic resistance training of upper limb
62425393|NCT03406039|EXPERIMENTAL|Integrated Online CBT and MI|Participants in this arm will be given access to the online integrated treatment.
62425394|NCT03406039|NO_INTERVENTION|Psychoeducation (Control)|The control group will be provided with psychoeducational resources about alcohol and mental illness.
62810565|NCT02240485|EXPERIMENTAL|Integrative Couple Treatment for Pathological Gambling (ICT-PG)|"Couple therapy: The experimental couple treatment is offered over 8 to 12 sessions of 90 minutes. The couple treatment called (Integrative Couple Treatment for Pathological Gambling - ICT-PG) is inspired by the Alcohol Behavior Couple Therapy from Epstein and McCrady, to which the team added diverse components to adjust to gamblers. During the sessions, the focus is on a) reducing/stopping gambling behaviors, b) helping the partner to stop behaviors facilitating gambling habits and rise the frequency of behaviors incompatible with gambling habits and c) improve marital components (communication, sharing positive moments, negotiation, mutual support)."
62034138|NCT06292455|OTHER|Conventional resistance training|players follow their routine exercise protocol
62034139|NCT04136951|EXPERIMENTAL|Experimental phase|The PREVENT recommendation about patient homecare priority will be shared in homecare referral communication with the homecare intake coordinators. Homecare intake coordinators will be instructed to prioritize high risk patients for care.
62034140|NCT06670469||nursing students|Education of nursing students
62034141|NCT03955432|EXPERIMENTAL|LINQ ICM|The LINQ ICM (Medtronic, Inc.) is a small FDA approved cardiac monitor implanted in the subcutaneous tissue of the chest wall that is designed to continuously record a single-lead ECG, monitoring the cardiac rhythm for up to three years. The device records and stores patient's rhythm on two occasions: first when programmed criteria are met and second upon patient activation. These programmable arrhythmia criteria are based on heart rate (bradycardia, tachycardia), irregularity of heart rate and duration of rate disturbance. The LINQ ICM (or future iterations) will be utilized in this study to detect arrhythmias in our study population. The LINQ ICM is approved by the FDA for use in patients where there is a suspicion of occult cardiac arrhythmias and is therefore being utilized in this study in accordance with the FDA labeling.
62034142|NCT02596815|EXPERIMENTAL|Median Nerve Neural Mobilization|15 minute Median Nerve Neural Mobilization sessions 3 times a week during 6 continuous weeks.The maximum degree of elbow extension applied in the Median Nerve neural mobilization procedure was determined through the use of a Universal Goniometer Device.
62034143|NCT02596815|ACTIVE_COMPARATOR|Waiting list control group|Patients assigned to a 6 week waiting list to receive treatment
62034144|NCT04539574|EXPERIMENTAL|Diagnostic (7T MRI)|Patients undergo 7T MRI over 60 minutes.
62034145|NCT06013644|ACTIVE_COMPARATOR|Acupuncture needle (study group A)|a weekly session for 4-6 weeks on needle for each acupoint for at least 20 minutes the included acupoints are ST6, ST7, SI 18, ST 19, GB 2
62234431|NCT04068259|EXPERIMENTAL|Cohort 1, Dose 1 of PBI-4547 or Placebo|Dose 1 of PBI-4547 or matching Placebo tablets by mouth
62234432|NCT04068259|EXPERIMENTAL|Cohort 2, Dose 2 of PBI-4547 or Placebo|Dose 2 of PBI-4547 or matching Placebo tablets by mouth
62234433|NCT04068259|EXPERIMENTAL|Cohort 3, Dose 3 of PBI-4547 or Placebo|Dose 3 of PBI-4547 or matching Placebo tablets by mouth
62234434|NCT04068259|EXPERIMENTAL|Cohort 4, Dose 4 of PBI-4547 or Placebo|Dose 4 of PBI-4547 or matching Placebo tablets by mouth
62234435|NCT04068259|EXPERIMENTAL|Cohort 5, Dose 5 of PBI-4547 or Placebo|Dose 5 of PBI-4547 or matching Placebo tablets by mouth
62425395|NCT01697449||Cohort|
62234436|NCT05561829|EXPERIMENTAL|Sleep Hygiene|Administration of sleep hygiene education (single intervention)
62234437|NCT05561829|EXPERIMENTAL|Cognitive Therapy|Administration of cognitive therapy only (single intervention)
62234438|NCT05561829|EXPERIMENTAL|Relaxation Training|Administration of relaxation training only (single intervention)
62234439|NCT05561829|EXPERIMENTAL|Relaxation Training, Cognitive Therapy, Sleep Hygiene|Administration of relaxation training, cognitive therapy, and sleep hygiene education (3 interventions)
62234440|NCT05561829|EXPERIMENTAL|Stimulus Control|Administration of stimulus control therapy only (single intervention)
62234441|NCT05561829|EXPERIMENTAL|Stimulus Control, Cognitive Therapy, Sleep Hygiene|Administration of stimulus control therapy, cognitive therapy, and sleep hygiene education (3 interventions)
62425396|NCT03016104|EXPERIMENTAL|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
62425397|NCT03016104|ACTIVE_COMPARATOR|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
62034146|NCT06013644|ACTIVE_COMPARATOR|Dry needle (study group B)|a weekly session for 4-6 weeks the trigger point is held by thumb and index fingers and the needle approaches the point perpendicular to the skin and rotated clockwise for 2-3 minutes
62810566|NCT02240485|ACTIVE_COMPARATOR|Usual individual/group treatment|Usual individual/group treatment: The control group receive individual or group treatment as already offered by the specialized centers in addiction.Their partner can receive individual intervention if desired.
62810567|NCT00112736|EXPERIMENTAL|Phase 1 (erlotinib & temsirolimus)|"PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (dose escalation). Every 28 days until disease progression or unacceptable toxicity.~pharmacological study: Correlative studies"
62810568|NCT00112736|EXPERIMENTAL|Phase 2 temsirolimus MTD & erlotinib|"Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 at MTD phse I. Every 28 days until disease progression or unacceptable toxicity.~PHASE II (preoperative component): Patients who are surgical candidates may opt to undergo surgical resection of the tumor. Beginning 5-7 days before surgery, these patients receive oral erlotinib once daily until surgery. Patients also receive temsirolimus IV over 30 minutes at the MTD and then undergo surgical resection of the tumor 3-24 hours later. Beginning 2-4 weeks after surgery, patients receive temsirolimus at the MTD and erlotinib as in phase I.~therapeutic conventional surgery: Undergo surgical resection~laboratory biomarker analysis: Correlative studies"
62810569|NCT00778934|EXPERIMENTAL|1|Intimate Health Gel
62810570|NCT03407898||C-mac D blade used for intubation|
62810571|NCT03407898||mcgrath X blade used for intubation|
62810572|NCT00967564||001|epidemiologic study QoL assessment
62034147|NCT06013644|ACTIVE_COMPARATOR|Botox injection (study group C)|each patient will receive a one time treatment of a suitable dose (estimated by the research team) according to the severity of the symptoms
62034148|NCT03505632|EXPERIMENTAL|Recruitment with low PEEP|Recruitment maneuver ( RM) will carried out during 2 minutes with increasing PEEP in stepwise manner.PEEP increase from 5 to 10 cmH2O (3 breaths),then to 15 cm H2O (3 breaths), PEEP to 20 cmH2O (10 breaths).Then decrease by 5 cmH2O every 3 breaths till back to preset PEEP 5 cmH2O .Recruitment carried out at the following times: post intubation(T1) , after insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40cmH2O .
62034149|NCT03505632|ACTIVE_COMPARATOR|High PEEP without RM|"Patients will receive from the start during anesthesia high PEEP (15 cmH2O) with maintaining the peak airway pressure below 40 cm H2O.~Monitoring times: after intubation(T1), post-insufflation(T2), after desuflation (T3) and before extubation(T4)."
62034150|NCT00536003|EXPERIMENTAL|1|
62034151|NCT00536003|PLACEBO_COMPARATOR|2|
62034152|NCT02090101|EXPERIMENTAL|ANAKINRA|LV5FU2 + bevacizumab + anakinra
62034153|NCT02859857|EXPERIMENTAL|Rising dose; safety and tolerance|Sequential cohorts of patients with advanced solid tumors and recurrent high-grade gliomas will be be treated with escalating doses of BXQ-350 until the MTD is established, or in the absence of a MAD, the highest planned DL is reached.
62034154|NCT02859857|EXPERIMENTAL|Solid tumor patients|Cohort of patients with advanced solid tumors administered BXQ-350 at the MTD determined in Part 1 or at the highest planned DL if the MAD is not reached.
62034155|NCT02859857|EXPERIMENTAL|Glioblastoma Multiforme patients|Cohort of patients with recurrent high-grade gliomas administered BXQ-350 at the MTD determined in Part 1 or at the highest planned DL if the MAD is not reached.
62034156|NCT02859857|EXPERIMENTAL|Gastrointestinal tumor patients|Cohort of patients with Gastrointestinal tumors as defined in the protocol and administered BXQ-350 at the 2.4 mg/kg dose level.
62034157|NCT02859857|EXPERIMENTAL|Ependymoma tumor patients|Cohort of patients with ependymoma administered BXQ-350 at the 2.4 mg/kg dose level.
62034158|NCT02859857|EXPERIMENTAL|Solid tumor patients other than HGG|Cohort of patients with advanced solid tumors other than HGG administered BXQ-350 at the 2.4 mg/kg dose level.
62034159|NCT04236791|EXPERIMENTAL|Intervention group|
62034160|NCT04236791|ACTIVE_COMPARATOR|Control group|
62034161|NCT03923413||patients with chronic heart failure without LVAD support|patients with chronic heart failure without LVAD support
62034162|NCT03923413||patients with end-stage heart failure with LVAD support|patients with end-stage heart failure with LVAD support
62810573|NCT02830737|ACTIVE_COMPARATOR|Traditional RFA|Using Traditional RFA for the treatment of small hepatocellular carcinoma
62034163|NCT01247129|EXPERIMENTAL|SIEA,delay procedure,widening of diameter|
62034164|NCT00726752|EXPERIMENTAL|Axitinib|
62034165|NCT03963726|EXPERIMENTAL|Stereotactic radiotherapy|In this study, the liver metastases were treated with Cyberknife stereotactic radiotherapy.Using multimodal image fusion to outline the target area.According to the volume, location, organ function and other factors, the dosage of radiotherapy was determined. The range of BED value of radiotherapy was 90-120 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 70-90 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).
62425398|NCT04009057||B/F/TAF|HIV-1 infected adults who initiate B/F/TAF therapy
62034166|NCT03963726|EXPERIMENTAL|Microwave ablation therapy|In this study, 3D printing template was used to assist microwave ablation.For those whose lesions are directly smaller than 5.0cm, the ablation time is about 10 min and 15 min, and the ablation time is more than 15min in patients larger than 5.0cm.
62034167|NCT05641168|EXPERIMENTAL|Ostomy Adhesive material|Newly designed ostomy adhesive material
62034168|NCT05641168|OTHER|comparator adhesive material|Adhesive material already on the market e.g adhesive material from SenSura Mio ostomy product
62034169|NCT06192888|EXPERIMENTAL|Participants with Mantle Cell Lymphoma|Participants will be diagnosed with relapsed, refractory (R/R) mantle cell lymphoma (MCL) with prior BTK inhibitor (BTKi) failure
62034170|NCT01565707|PLACEBO_COMPARATOR|Placebo Children|Children aged 5 to 11 years received matching placebo suspension once a day for 12 weeks.
62034171|NCT01565707|EXPERIMENTAL|Solifenacin Succinate Suspension Children|Children aged 5 to 11 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.
62034172|NCT01565707|PLACEBO_COMPARATOR|Placebo Adolescents|Adolescents aged 12 to 17 years received matching placebo suspension once a day for 12 weeks.
62425399|NCT04295109|ACTIVE_COMPARATOR|Fentanyl group(group F)|Fentanyl citrate injection, specification: 10mL: 0.5mg / piece (production unit: niching chang rendu Pharmaceutical Co., Ltd., valid period: 48 months) For group F patients,0.5mg fentanyl was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
62425400|NCT04295109|EXPERIMENTAL|Oxycodone group(group O)|Oxycodone hydrochloride injection, specification: 1mL: 10mg / branch (production unit: HAMOL LIMITED, valid period: 60 months) For group O patients,30mg oxycodone was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
62425401|NCT04295109|EXPERIMENTAL|Butorphanol group(group B)|Butorphanol tartrate injection, specification: 1 mL: 1 mg / branch (production unit: Jiangsu henryi Pharmaceutical Co., Ltd., valid period: 24 months); For group B patients,10mg butorphanol was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
62425402|NCT03850561|ACTIVE_COMPARATOR|Coenzyme Q10 200|Coenzyme Q10 200mg/day for 3 months
62425403|NCT03850561|ACTIVE_COMPARATOR|Coenzyme Q10 400|Coenzyme Q10 400mg/day for 3 months
62425404|NCT04034199|EXPERIMENTAL|Denosumab group|Patients randomized into the denosumab group will receive denosumab 60mg subcutaneously every 6 months, for a total duration of 1 year. DEXA scan would be repeated at 1 year.
62425405|NCT04034199|ACTIVE_COMPARATOR|Zoledronic acid|Patients randomized into the denosumab group will receive one dose of zoledronic acid at 5mg intravenously. DEXA scan would be repeated at 1 year.
62034173|NCT01565707|PLACEBO_COMPARATOR|Solifenacin Succinate Suspension Adolescents|Adolescents aged 12 to 17 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.
62034174|NCT06550791|EXPERIMENTAL|Anticancer Learning Circle Participant|
62034175|NCT02491671|EXPERIMENTAL|Experimental group|Experimental group: At the end of lung resection, lung sutures and 1.5 cm of lung parenchyma on each side will be covered by Hemopatch. No additional measures for preventing air leak will be indicated. In the case of massive air leak in spite of the use of Hemopatch, each surgeon will decide on the indication of additional sutures of tissue plasties. These cases will be accounted for failures on an intention to treat basis.
62425406|NCT02104401|EXPERIMENTAL|tDCS|tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
62034176|NCT02491671|OTHER|Control group|Control group: The standard preventive measures will be followed in each center, including reinforcement of sutures, pleural tents, suturing pericardial or subcutaneous fat
62034177|NCT06294301|EXPERIMENTAL|Cohort 1: LP-005 Dose 1 (Single)|
62034178|NCT06294301|EXPERIMENTAL|Cohort 2: LP-005 Dose 2 (Single)|
62034179|NCT06294301|EXPERIMENTAL|Cohort 3: LP-005 Dose 3 (Single)|
62034180|NCT06294301|EXPERIMENTAL|Cohort 4: LP-005 Dose 4 (Single)|
62034181|NCT06294301|EXPERIMENTAL|Cohort 5: LP-005 Dose 5 (Single)|
62034182|NCT06294301|EXPERIMENTAL|Cohort 6: LP-005 Dose 6 (Single)|
62425407|NCT05854277|OTHER|Endoscopists|
62425408|NCT05245617||JPS treated patients|This grup will include all patients with regular indication for JPS: system is intended in pediatric (excluding newborns) and small stature adult patients. Pediatric patients include infants (greater than 1 month to 1 years of age), children (greater than 1 to 12 years of age), adolescents (greater than 12 to 18 years of age) and appropriate adults (where according to investigator assessment, the JPS plates fit the treated bone anatomy).
62425409|NCT05467449||Hematologically normal|Based on immunophenotyping
62034183|NCT06294301|PLACEBO_COMPARATOR|Cohort 7: Placebo (Single)|
62034184|NCT06294301|EXPERIMENTAL|Cohort 8: LP-005 Dose 7 (Multiple)|
62034185|NCT06294301|EXPERIMENTAL|Cohort 9: LP-005 Dose 8 (Multiple)|
62034186|NCT06294301|EXPERIMENTAL|Cohort 10: LP-005 Dose 9 (Multiple)|
62034187|NCT06294301|PLACEBO_COMPARATOR|Cohort 11: Placebo (Multiple)|
62034188|NCT03047668|ACTIVE_COMPARATOR|low-carb with PUFA|49 weeks of hypo- to isocaloric low-carb diet (\< 40 EI% carbs), amplified with walnuts and walnut-sunflower muffins
62034189|NCT03047668|ACTIVE_COMPARATOR|low-carb without PUFA|49 weeks of hypo- to isocaloric low-carb diet (\< 40 EI% carbs), without walnuts / walnut-sunflower muffins
62593852|NCT04775901|OTHER|CT-guided lung biopsy|Participants in this arm received conventional CT-guided percutaneous transthoracic lung biopsy.
62593853|NCT04775901|EXPERIMENTAL|Template-guided lung biopsy|Three-dimensionally printed navigational template was designed based on the CT scan images acquired before the biopsy. Under the guidance of navigational template, percutaneous transthoracic lung biopsy was conducted.
62425410|NCT05467449||Hematologically abnormal|Based on immunophenotyping
62425411|NCT03753373|EXPERIMENTAL|Acupuncture and Home Exercise|Acupuncture plus the prescribed home exercise program
62593854|NCT06094413|EXPERIMENTAL|Multicomponent Training Intervention|Subjects in the intervention group attended two standardized group-based sixty-minute sessions per week in the outpatient medical center and were asked not to change their current physical activity regimen during the 8-week duration of the study.
62593855|NCT06094413|NO_INTERVENTION|Control Group|Subjects in the control group were asked to not change their current level of physical activity during the 8-week duration of the study.
62810574|NCT02830737|EXPERIMENTAL|No-touch RFA|Using No-touch RFA for the treatment of small hepatocellular carcinoma
62810575|NCT02119585||Patients undergoing OLT|insertion of nasogastric tube for measurements of chest wall mechanics
62810576|NCT04262700|EXPERIMENTAL|Intervention 01|Subjects use new LifeScan provided BGMS for 12 weeks.
62810577|NCT03880539|OTHER|BEZLO + SOC taper|Single arm of patients treated with BEZLO + SOC oral VAN pulse/taper.
62034190|NCT03047668|ACTIVE_COMPARATOR|low-fat with PUFA|49 weeks of hypo- to isocaloric low-fat diet (\< 30 EI% fat), amplified with walnuts and walnut-sunflower muffins
62034191|NCT03047668|ACTIVE_COMPARATOR|low-fat without PUFA|49 weeks of hypo- to isocaloric low-fat diet (\< 30 EI% fat), without walnuts / walnut-sunflower muffins
62034192|NCT02559674|EXPERIMENTAL|Phase Ib/II ALT-803 w/ gemcitabine and nab-paclitaxel|
62425412|NCT03753373|ACTIVE_COMPARATOR|Home Exercise Only|The prescribed home exercise program alone
62034193|NCT02099838|EXPERIMENTAL|Pioglitazone and Metformin|Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks.
62425413|NCT02094430|EXPERIMENTAL|FGTW|
62425414|NCT02917356|EXPERIMENTAL|Spiritual laying on of hands group|"* Spiritist Passe - performed by spiritual healers from the religion Spiritism (5 min, once a week, for 8 weeks)~* Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
62425415|NCT02917356|ACTIVE_COMPARATOR|Non-spiritual Laying on of Hands group|"* Non-spiritual Laying on of Hands - performed by lay persons (5 min, once a week, for 8 weeks)~* Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
62425416|NCT02917356|SHAM_COMPARATOR|Control Group (CG)|"* Sham/ Control Group (CG) - performed by lay persons. They will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands (5 min, once a week, for 8 weeks)~* Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
62810578|NCT03957148|EXPERIMENTAL|SSB Education|The SSB reduction intervention consists of 10-weeks of targeted, brief interactions with parents when they come to pick up their children for a center-based early childcare program. The sessions will be twice per week.
62810579|NCT03957148|SHAM_COMPARATOR|Food Safety Education|The sham control (food safety education) consists of 10-weeks of targeted, brief interactions with parents when they come to pick up their children for a center-based early childcare program. The sessions will be twice per week.
62810580|NCT02467179|ACTIVE_COMPARATOR|Manual Catheter Manipulation|25 subjects will be randomized to this arm. Manual catheter ablation of the cavo-tricuspid isthmus will be performed.
62810581|NCT02467179|EXPERIMENTAL|Amigo™ Robotic Catheter Manipulation|25 subjects will be randomized to this arm. Robotic catheter ablation of the cavo-tricuspid isthmus with the Amigo Catheter System will be performed.
62819576|NCT05900986|EXPERIMENTAL|LS301-IT|LS301-IT will be administered by IV injection
62425417|NCT04078087||Non obese|"Non obese (whether normal weight or overweight) = Group NO"
62425418|NCT04078087||Obese|"obese = Group O"
62425419|NCT05005676|EXPERIMENTAL|adductor pollicis AP|Measurement site: M.adductor pollicis of both arms.
62425420|NCT05005676|EXPERIMENTAL|Corrugator supercilii CS|Measurement site: M. corrugator supercilii at both sides
62425421|NCT01816126||one-operator technique|
62425422|NCT01816126||two-operator technique|
62593856|NCT06051123|EXPERIMENTAL|Experimental Group|Participants in this group will be randomized to receive a probiotic formulation for 24 weeks.
62593857|NCT06051123|PLACEBO_COMPARATOR|Control Group|Participants in this group will be randomized to receive a placebo for 24 weeks.
62593858|NCT04537910|EXPERIMENTAL|LY3819253|Participants received single subcutaneous (SC) doses of 150 milligram (mg), 350 mg or 700 mg LY3819253.
62593859|NCT04537910|PLACEBO_COMPARATOR|Placebo|Participants received a single SC dose of Placebo.
62593860|NCT02874079|EXPERIMENTAL|bullous pemphigoid|patients with bullous pemphigoid
62593861|NCT02874079|ACTIVE_COMPARATOR|no bullous pemphigoid|patients with basal cell carcinoma or squamous cell carcinoma and without inflammatory skin disease
62593862|NCT01905553|EXPERIMENTAL|SSP-004184SS (fed)|21.8 mg/kg (oral capsule form) given once on Day 1 under fed conditions
62034194|NCT02099838|PLACEBO_COMPARATOR|Placebo|Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks.
62034195|NCT02157038|EXPERIMENTAL|Procedures|RNA/DNA blood sample will be collected. Participant will complete questionnaires, MRI and strength and reflex testing.
62234442|NCT05561829|EXPERIMENTAL|Stimulus Control, Relaxation Training, Sleep Hygiene|Administration of stimulus control therapy, relaxation training, and sleep hygiene education (3 interventions)
62234443|NCT05561829|EXPERIMENTAL|Stimulus Control, Relaxation Training, Cognitive Therapy|Administration of stimulus control therapy, relaxation training, and cognitive therapy (3 interventions)
62234444|NCT05561829|EXPERIMENTAL|Sleep Optimization|Administration of sleep optimization only (single intervention)
62234445|NCT05561829|EXPERIMENTAL|Sleep Optimization, Cognitive Therapy, Sleep Hygiene|Administration of sleep optimization, cognitive therapy, and sleep hygiene education (3 interventions)
62234446|NCT05561829|EXPERIMENTAL|Sleep Optimization, Relaxation Training, Sleep Hygiene|Administration of sleep optimization, relaxation training, and sleep hygiene education (3 interventions)
62234447|NCT05561829|EXPERIMENTAL|Sleep Optimization, Relaxation Training, Cognitive Therapy|Administration of sleep optimization, relaxation training, and cognitive therapy (3 interventions)
62425423|NCT03550794|EXPERIMENTAL|Thiamine|200mg parenterally administered thiamine hydrochloride given twice daily for a 3 days (6 doses)
62425424|NCT03550794|PLACEBO_COMPARATOR|Placebo|Matching placebo (50ml 0.9%NACL) given twice daily for 3 days (6 administrations)
62810582|NCT02952365|OTHER|Eyes undergoing LASIK enhancement|Eyes undergoing LASIK enhancement will have tissue sealant applied to the eye to prevent epithelial ingrowth
62034196|NCT02766530|EXPERIMENTAL|PETMR study|All the study participants will receive PET MR examinations before neoadjuvant chemotherapy and during neoadjuvant chemotherapy (during early cycle as well as during mid-cycle of chemotherapy treatment). There will be two groups of patients after completion of neoadjuvant chemotherapy, that is, responders versus non-responders. We will compare the PET MR imaging parameters before, during neoadjuvant chemotherapy between the two groups of patients.
62034197|NCT06385938||Children with Active Rickets Group|Children under 10 years of age with a diagnosis of active rickets on radiographs of the wrists and knees will undergo ultrasound imaging and quantitative vibro-acoustic assessment.
62034198|NCT06385938||Healthy Children Control Group|Healthy children under 10 years of age not diagnosed with rickets, but match the age, gender, and weight of the children with rickets, will undergo ultrasound imaging and quantitative vibro-acoustic assessment.
62234448|NCT05561829|EXPERIMENTAL|Sleep Optimization, Stimulus Control, Sleep Hygiene|Administration of sleep optimization, stimulus control therapy, and sleep hygiene education (3 interventions)
62234449|NCT05561829|EXPERIMENTAL|Sleep Optimization, Stimulus Control, Cognitive Therapy|Administration of sleep optimization, stimulus control therapy, and cognitive therapy (3 interventions)
62234450|NCT05561829|EXPERIMENTAL|Sleep Optimization, Stimulus Control, Relaxation Training|Administration of sleep optimization, stimulus control therapy, and relaxation training (3 interventions)
62593863|NCT01905553|EXPERIMENTAL|SSP-004184SS (fasted)|21.8 mg/kg (oral capsule form) given once on Day 1 under fasted conditions
62819577|NCT00521079|EXPERIMENTAL|vBloc|Subjects implanted with a functional Maestro System device that delivers therapy (Therapy ON).
62819578|NCT00521079|SHAM_COMPARATOR|Placebo|Subjects implanted with a functional Maestro System device that does NOT deliver therapy (Therapy OFF).
62819579|NCT06108414|EXPERIMENTAL|Low-dose rivaroxaban|15mg q.d. rivaroxaban for 2 years after randomization. The dose should be reduced in the following special conditions: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old. In the low-dose group, the dose was reduced from the usual 15mg q.d. to 10mg q.d. .
62034199|NCT06134544|EXPERIMENTAL|Administration of IMO|Patients will be given IMO (20g/100ml) for 7 days.
62034200|NCT00572780||CTE with CD|Crohn's disease patients who underwent a CT enteroclysis as part of their clinical evaluation for symptomatic Crohn's disease.
62034201|NCT00303966|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62034202|NCT01839929|EXPERIMENTAL|Prograf/Advagraf|conversion from Prograf to Advagraf
62034203|NCT05496881|EXPERIMENTAL|Exercise Group 1|The intervention will focus on mobility and balance.
62034204|NCT05496881|ACTIVE_COMPARATOR|Exercise Group 2|This intervention will focus on physical fitness.
62034205|NCT05496881|SHAM_COMPARATOR|Exercise Group 3|This intervention will focus on flexibility, range of motion, and muscle tone.
62034206|NCT04748744||Patients undergoing colorectal surgery|
62034207|NCT02635633|EXPERIMENTAL|continuous thetaburst stimulation|Transcranial magnetic stimulation over the epileptogenic focus using a cTBS stimulation protocol.
62034208|NCT03061253|EXPERIMENTAL|Nicotine-inclusive e-cigarettes|Participants will receive e-cigarettes (nicotine-inclusive) combined with behavioural change support over a 3 month period.
62034209|NCT03061253|EXPERIMENTAL|Nicotine-free e-cigarettes|Participants will receive e-cigarettes (nicotine-free) combined with behavioural change support over a 3 month period.
62425425|NCT03545529|EXPERIMENTAL|Innovative supported|In addition to usual care, patients benefit from connected tools (telealarm, numeric communication diary...) and from a strong accompaniment with a referent person who help better the patient.
62425426|NCT03545529|NO_INTERVENTION|conventional supported|Patients benefit from usual care
62034210|NCT03061253|ACTIVE_COMPARATOR|Nicotine Replacement Therapy (NRT)|Participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy combined with behavioural change support over a 3 month period.
62234451|NCT05561829|EXPERIMENTAL|Sleep Optimization, Stimulus Control, Relaxation Training, Cognitive Therapy, Sleep Hygiene|Administration of sleep optimization, stimulus control therapy, relaxation training, cognitive therapy, and sleep hygiene education (5 interventions)
62234452|NCT05016908||Biofluid collection|Eligible volunteers will be asked to provide a single urine sample and undergo a single blood draw.
62234453|NCT02077595|ACTIVE_COMPARATOR|120Hz alternating current stimulation group|
62234454|NCT02077595|ACTIVE_COMPARATOR|5Hz alternating current stimulation group|
62425427|NCT03874533|EXPERIMENTAL|self-adjustment tests|"For patients with an implant Cochlear™, we will be trained during workshop, to use a tablet how to do some tests; They will do alone, by themselves the tests, just after the workshop and 8 to 30 days later.~Self audiometric test : digit triplet test, consonants discrimination test, Self-fitting of cochlear implant"
62425428|NCT06538636|NO_INTERVENTION|Usual Care|Usual care
62034211|NCT06570863|EXPERIMENTAL|Group 1: Scaling and root Planning (SRD) + Antibiotics|doxycycline 100 mg 2 stat the first day followed by od for 14 days
62034212|NCT06570863|EXPERIMENTAL|Group 2: SRD + Probiotics|Probiotic powder of Lactobacillus Reuteri. After mechanical debridement patient will be prescribed with Lactobacillus rhamnosus SP1 \[(2x107colony forming units (CFU)/ day)\] (Macrofood S.A., Santiago de Chile, Chile) for 1 month. The dose would be one sachet taken orally daily. The sachets presented to the patients would be identical. Individuals will be instructed to dissolve 1 sachet in water (150 mL) and ingest it once a day after brushing their teeth.
62234455|NCT02077595|SHAM_COMPARATOR|sham alternating current stimulation group|
62234456|NCT05617911|EXPERIMENTAL|Blood flow restriction and standard of care therapy|The experimental BFR therapy will be incorporated into the standard therapy sessions and will not elongate the treatment session, quantity of sessions or incur any additional cost. As the participant progresses over time in therapy sessions, the discretion of the PT will determine when they have graduated beyond receiving any benefit from BFRT as demonstrated by quad strength.
62234457|NCT05617911|PLACEBO_COMPARATOR|Sham and standard of care therapy|The sham comparator control group will also follow the Exercise Protocol in their physical therapy sessions with a non inflated blood flow restriction cuff attached in the same position as the experimental group. Similar to the intervention group, as participant's progress in therapy, the Physical Therapist will use their clinical decision making to advance the person through resistance and repetition increases.
62234458|NCT04179331|EXPERIMENTAL|Neurotensin|
62234459|NCT04179331|EXPERIMENTAL|Saline|
62425429|NCT06538636|EXPERIMENTAL|PCP facing tools|Suite of PCP facing tools activated
62425430|NCT06538636|EXPERIMENTAL|LCS team population management tools|site-specific dashboard and proactive outreach toolkit
62425431|NCT06538636|EXPERIMENTAL|PCP facing tools plus LCS population management dashboard|both interventions activated
62425432|NCT03745027|EXPERIMENTAL|In vitro fertilization|Paients undergoing in vitro fertilization with Gonadotropin-releasing Hormone agonist. Follicular fluid sialic acid levels will be measured.
62425433|NCT05155072|EXPERIMENTAL|Sequence A|
62425434|NCT05155072|EXPERIMENTAL|Sequence B|
62425435|NCT05155072|EXPERIMENTAL|Sequence C|
62425436|NCT05155072|EXPERIMENTAL|Sequence D|
62425437|NCT05155072|EXPERIMENTAL|Sequence E|
62425438|NCT05155072|EXPERIMENTAL|Sequence F|
62425439|NCT01741909|EXPERIMENTAL|Before, After|The intervention is educational
62034213|NCT06570863|EXPERIMENTAL|Group 3: SRD + Metronidazole Gel 25%|After mechanical debridement, 25% of metronidazole gel was administered into the periodontal pockets. The gel was applied with a parojet syringe provided with a blunt cannula.
62034214|NCT04827212|NO_INTERVENTION|Control|Control group will engage in a 16-week supervised exercise program and then be followed-up after 24 weeks
62034215|NCT04827212|EXPERIMENTAL|Treatment|Treatment group will engage in a 16-week supervised exercise program and then be followed-up after 24 weeks. In addition, the Companion will be deployed in the treatment group only.
62234460|NCT04271007|ACTIVE_COMPARATOR|Group I|Use of the drug Topison on one side of the upper limb and Mometasone Furoate 1mg /g Sanofi, Medley on the opposite side
62234461|NCT04271007|ACTIVE_COMPARATOR|Group II|Use of the drug Topison on one side of the upper limb and Mometasone Furoate 1mg /g Aché on the opposite side
62234462|NCT01836653|EXPERIMENTAL|mFOLFOX + Bmab|mFOLFOX plus bevacizumab
62234463|NCT01836653|ACTIVE_COMPARATOR|mFOLFOX + Cmab|mFOLFOX plus cetuximab
62425440|NCT03149965|ACTIVE_COMPARATOR|Body mass index 18.5-24.9|The anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
62425441|NCT03149965|EXPERIMENTAL|body mass index ≥30|The anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
62425442|NCT04635904|EXPERIMENTAL|Imaginal exposure|A behavioral intervention in imagery
62425443|NCT04635904|EXPERIMENTAL|Imagery rescripting|A different behavioral intervention in imagery
62425444|NCT04089137|NO_INTERVENTION|Control|This is an assessment only control condition.
62425445|NCT04089137|EXPERIMENTAL|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. This intervention targets alcohol use, sexual assault victimization risk, sexual assault perpetration, and bystander intervention and is tailored by gender and sexual orientation.
62425446|NCT03871569|ACTIVE_COMPARATOR|telemedecine nursing home|One buccodental teleexpertise at the completion day and a second buccodental teleexpertise at the end of study
62034216|NCT05654350||Patients with neglect anosognosia|Subacute or chronic right hemispheric stroke patients with left hemispatial neglect and neglect anosognosia.
62034217|NCT05654350||Patients without neglect anosognosia|Subacute or chronic right hemispheric stroke patients with left hemispatial neglect but no neglect anosognosia.
62034218|NCT01814371|ACTIVE_COMPARATOR|Individualized Approach|The decolonization regimen will be performed only by those household members who experienced SSTI in the prior year.
62034219|NCT01814371|ACTIVE_COMPARATOR|Household Approach|All members of the household will perform the decolonization regimen.
62034220|NCT02499874|EXPERIMENTAL|Single treatment arm|All subjects will be administered oral Efavirenz 400mg together with the rest of the oral antiretroviral combination (tenofovir 245 mg/emtricitabine 200mg or tenofovir 245mg/lamivudine 300mg or lamivudine 300mg/zidovudine 600mg) throughout the study period
62034221|NCT01930370|EXPERIMENTAL|Hemodialysis patients|Each patient will be evaluated during a total of 3.5 weeks correlating to routine dialysis treatment appointments. Each participant will start with low bicarbonate, followed by the washout phase (standard bicarbonate), then high bicarbonate, finishing with the follow up period. Dialysis prescription is standardized for each patient throughout the entire 3.5 week study period.
62034222|NCT00105638|OTHER|Arm 1|
62234464|NCT02896179|EXPERIMENTAL|Robot-assisted gait training group+VR|The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
62234465|NCT02896179|ACTIVE_COMPARATOR|Robot-assisted gait training group|The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
62234466|NCT04998734||Chronic pain|Patients with chronic non-cancer pain referred to secondary and tertiary care
62234467|NCT02901366|EXPERIMENTAL|14C-FYU-981|14C-FYU-981, (Oral single dosing)
62234468|NCT01382420|ACTIVE_COMPARATOR|Adrenalectomy group|patients who undergo adrenalectomy
62234469|NCT01382420|NO_INTERVENTION|Control group|patients who receive conservative treatment
62425447|NCT03871569|NO_INTERVENTION|control nursing home|Only one buccodental teleexpertise at the end of study
62425448|NCT06528327|EXPERIMENTAL|Pre coated surface implants|
62425449|NCT06528327|ACTIVE_COMPARATOR|Non coated surface implants|
62425450|NCT00769431|NO_INTERVENTION|Focus group|
62425451|NCT03876873|EXPERIMENTAL|Group A|Head Rotation During Face Mask Ventilation. Step 1: Neutral Position (1 minute), Step 2: Head Rotation (1 minute), Step 3: Neutral Position (1 minute)
62034223|NCT06105073||Patients whit Systemic Sclerosis asociated Interstitial Lung Disease|Consecutive patients who attend the Rheumatology and Internal Medicine services with a confirmed diagnosis of Systemic Sclerosis associated Interstitial Lung disease, from the Medical Center, La Raza IMSS.
62034224|NCT01331473|ACTIVE_COMPARATOR|Carotid Artery Stenting without Protection|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and without embolic protection device
62034225|NCT01331473|ACTIVE_COMPARATOR|Carotid Artery Stenting with Proximal Protection|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and with a proximal embolic protection device provided by the GORE Neuro Protection System
62034226|NCT01053208|EXPERIMENTAL|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets of Dr. Reddy's
62034227|NCT01053208|ACTIVE_COMPARATOR|Advil|Advil PM 200 mg/38 mg Tablets of Wyeth
62034228|NCT05167864|ACTIVE_COMPARATOR|OnabotulinumtoxinA|Botox
62034229|NCT05167864|ACTIVE_COMPARATOR|AbobotulinumtoxinA|Dysport
62034230|NCT05167864|ACTIVE_COMPARATOR|IncobotulinumtoxinA|Xeomin
62034231|NCT05167864|ACTIVE_COMPARATOR|PrabotulinumtoxinA|Jeuveau
62034232|NCT02087163|EXPERIMENTAL|Movement Enhancement Technique|Movement Enhancement Technique Clear Aligner
62034233|NCT06670794|OTHER|Psychoeducation control|"Psychoeducation control CPs will be routed to visit self-help resources on NIAAA's website (Alcohol's Effects on Health) and asked to spend the same amount of time (20-30 minutes) reviewing site content."
62425452|NCT03876873|EXPERIMENTAL|Group B|Head Rotation During Face Mask Ventilation. Step 1: Head Rotation (1 Minute), Step 2: Neutral Position (1 minute), Step 3, Head Rotation (1 Minute)
62425453|NCT06428526|EXPERIMENTAL|Transcutaneous asES|Participants will be administered transcutaneous afferent-specific electrical stimulation in the upper limb using conductive pads targeting the median and radial nerves at the wrist
62425454|NCT06428526|EXPERIMENTAL|Percutaneous asES|Participants will be administered percutaneous afferent-specific electrical stimulation in the upper limb using intramuscular leads targeting the flexor and extensor muscles of the wrist
62034234|NCT06670794|EXPERIMENTAL|Experimental web-based intervention|CPs in the experimental web-based intervention condition will complete web-based sessions including personalized feedback and information about how communication and self-care affect their own well-being and their partner's alcohol use behaviors.
62034235|NCT03755453|ACTIVE_COMPARATOR|Audéo B-Direct fitted with fitting method A|Traditional standard fitting method which do not include adjustments from the participants.
62034236|NCT03755453|EXPERIMENTAL|Audéo B-Direct fitted with fitting method B|Alternative fitting method which includes additional adjustments from the participants.
62425455|NCT05784727|OTHER|Earswitch Robustness|Participants will wear the Earswitch device and voluntarily contract their TT to complete a series of tasks shown on screen and/or explained audibly. We will also ask participants to complete questionnaires to understand participant opinions about the effectiveness, usability, and comfort of both their current device (if applicable) and the Earswitch.
62425456|NCT05200507||High frequency precussive ventilation|After positioning a silicon belt for Electrical Impedance Tomography (EIT) and a baseline record, patients will receive the treatment of High Frequency Percussive Ventilation. Further recordings will be acquired soon after the end of the treatment, 1 and 3 hours later.
62593864|NCT02958280|EXPERIMENTAL|Brief Advice Plus the Fit&Sober App|"Phase 1 (app development \& Open Pilot) will consist of: 1) development of the Fit\&Sober prototype; 2) series of usability studies with patients with AUDs; and 3) An open pilot of a 12-week trial (n=20) to test the feasibility and acceptability of the Fit\&Sober app with patients with AUDs in early recovery.~Phase 2: RCT of the Fit\&Sober app with 160 patients with AUD"
62034237|NCT03156049|ACTIVE_COMPARATOR|Sphenopalatine block|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
62034238|NCT03156049|ACTIVE_COMPARATOR|Greater occipital nerve block|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
62034239|NCT04210453|PLACEBO_COMPARATOR|Control group|Participants in this group are administered IV normal saline.
62234470|NCT06206369||Abdominal Aortic Aneurysm patients|
62234471|NCT06206369||Peripheral Arterial Disease patients|
62234472|NCT04980885|EXPERIMENTAL|AK117+Azacitidine|"Phase Ib: Subjects will receive different doses of A117 in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28 day cycle;~Phase II: Subjects will receive AK117 at the recommended Phase 2 dose in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28-day cycle."
62234473|NCT04430465|EXPERIMENTAL|High wholegrain then low wholegrain|Starting with high wholegrain intervention followed by low wholegrain intervention
62234474|NCT04430465|EXPERIMENTAL|Low wholegrain then high wholegrain|Starting with low wholegrain intervention followed by high wholegrain intervention
62234475|NCT00985166|EXPERIMENTAL|1|ProQuad + Placebo
62234476|NCT00985166|ACTIVE_COMPARATOR|2|M-M-R II + Placebo
62234477|NCT00985166|ACTIVE_COMPARATOR|3|M-M-R II + Varivax
62425457|NCT00640614|EXPERIMENTAL|Sensitives|Subjects with a clinical history and positive patch test (current or previous) to any of the seven allergens. Subjects must otherwise be healthy and fulfill entry criteria.
62425458|NCT00640614|EXPERIMENTAL|Consecutives|Subjects who are being seen for standard allergy patch testing, that are asked to participate in the study.
62810583|NCT06064630|OTHER|Telemedicine treatment group|Telemedicine group need to complete sleep-related questionnaires on the Redcap website. Participants in the telemedicine group will learn Home sleep apnea testing(HSAT) online and then complete overnight monitoring at home. Patients diagnosed with OSA after HSAT monitoring will receive standardized APAP treatment. At 1 month of APAP treatment, participants in the telemedicine group will be followed up by phone/video to check their APAP treatment compliance and prompted to complete the corresponding follow-up questionnaire on the Redcap website. After 3 months of APAP treatment, the telemedicine group will be followed up by phone/video to check their APAP treatment compliance at 3 month, and they will finish corresponding follow-up questionnaires on Redcap website. 24-hour ambulatory blood pressure monitoring, and physical measurements will be conducted in sleep center at 1 month and 3 month.
62810584|NCT06064630|OTHER|Outpatient treatment group|Outpatient group need to complete sleep-related paper questionnaires at sleep center. The sleep technicians will explain to the patients how to use the Home sleep apnea testing (HSAT) and then they will complete overnight monitoring at home. Patients diagnosed with OSA after HSAT monitoring will receive standardized APAP treatment. At 1 month of APAP treatment, participants in the outpatient group will be followed up at sleep center to check their APAP treatment compliance and prompted to complete the corresponding follow-up paper questionnaires at sleep center. After 3 months of APAP treatment, the outpatient group will be followed up to check their APAP treatment compliance at 3 month, and they will finish corresponding follow-up paper questionnaires at sleep center. 24-hour ambulatory blood pressure monitoring, and physical measurements will be conducted in sleep center at 1 month and 3 month.
62810585|NCT06421857|ACTIVE_COMPARATOR|suturing|after ovarian cystectomy for endometrioma, separate sutures were applied if there was significant bleeding
62810586|NCT06421857|ACTIVE_COMPARATOR|bipolar electrocoagulation|after ovarian cystectomy for endometrioma, the inner wall was coagulated using bipolar electrocoagulation if there was significant bleeding
62810587|NCT02495428|EXPERIMENTAL|Kinesio Tape Group|muscle Kinesio Taping in Triceps Surae, Tibialis anterior, and Quadriceps according Kenzo Kase Method
62810588|NCT02495428|NO_INTERVENTION|Control group|They will do the same measurement of lactate and exercise protocol in treadmill, but always without kinesio tape intervention
62810589|NCT01157702|EXPERIMENTAL|Vaccine|Vaccination with one dose (0.5 mL) of inactivated influenza vaccine
62810590|NCT03557970|EXPERIMENTAL|Treatment (JNJ-40346527)|Participants receive JNJ-40346527 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62810591|NCT00409071|EXPERIMENTAL|1|cocculine
62810592|NCT00409071|PLACEBO_COMPARATOR|2|placebo
62810593|NCT06518356|ACTIVE_COMPARATOR|Auricular Neurostimulation (Active 1)|"•Within the MRI scanner, each participant will be connected to a series of tAN electrodes that stimulate the following ear target~-Cymba stimulation (15Hz stimulation of cymba conchae)"
62810594|NCT06518356|ACTIVE_COMPARATOR|Auricular Neurostimulation (Active 2)|"•Within the MRI scanner, each participant will be connected to a series of tAN electrodes that stimulate the following ear target~-Mastoid stimulation (15Hz stimulation of mastoid process)"
62810595|NCT06518356|SHAM_COMPARATOR|Auricular Neurostimulation (Sham 1)|"•Within the MRI scanner, each participant will be connected to a series of tAN electrodes that stimulate the following ear target~-Sham (15Hz stimulation of the earlobe)"
62810596|NCT02185911||Cohort 1|Patients with CKD
62234478|NCT02414581|EXPERIMENTAL|Chlorhexidine 0.12% & Ethyl Alcohol 7%|Chlorhexidine 0.12% and Ethyl Alcohol 7% mouthwashes 15ml by 30 seconds, twice day for 9 days.
62234479|NCT02414581|ACTIVE_COMPARATOR|Ethyl Alcohol 7%|Ethyl Alcohol 7% without chlorhexidine mouthwashes 15ml by 30 seconds, twice day for 9 days.
62234480|NCT02414581|EXPERIMENTAL|Chlorhexidine 2% & Ethyl Alcohol 7%|Chlorhexidine 2% and Ethyl Alcohol 7% mouthwashes 15ml by 30 seconds, once day for 3 days.
62234481|NCT01308957|EXPERIMENTAL|Long chain omega-3 fatty acids|
62234482|NCT01308957|PLACEBO_COMPARATOR|Corn oil|
62234483|NCT01308957|NO_INTERVENTION|Young healthy controls|Young subjects' muscle mass and physical function will be evaluated once (i.e., during baseline testing only). The data in young subjects will be used to determine the magnitude of the aging-induced decline in muscle mass and physical function in the older subjects prior to starting the interventions.
62234484|NCT04054609|OTHER|FAZA PET/MRI scan|PET/MRI scan using radiotracer 18F-Fluoroazomycin Arabinoside
62425459|NCT05100394|EXPERIMENTAL|Experimental Group|High Power laser therapy was provided.
62425460|NCT05100394|ACTIVE_COMPARATOR|Control Group|Conventional physiotherapy was applied including moist heat packs, US, and eccentric hamstring exercises.
62425461|NCT01835470|EXPERIMENTAL|Abatacept|Abatacept 10 mg/kg (for body weight less than 75 kg), 750 mg (for body weight between 75 and 100 kg), and 1g (for body weight above 100kg) intravenous infusion on Week 0 (Day 1), Week 2 (Day 15), Week 4 (Day 29) and every 4 weeks (28 days) thereafter up to the end of the study
62425462|NCT04307537|EXPERIMENTAL|pcRUG|Peri-catheter retrograde urethrography
62425463|NCT04307537|ACTIVE_COMPARATOR|VCUG|Voiding cysto-urethrography
62425464|NCT02317094|OTHER|Control|Participants receive care as usual (various DMARDs, different from patient to patient).
62425465|NCT02317094|EXPERIMENTAL|Blood-flow restricted tranining|Participants will receive care as usual (various DMARDs, different from patient to patient) + 12 wks of low-intensity blood-flow restricted training twice per week.
62425466|NCT01412710|EXPERIMENTAL|4000 IU group|This group will be given 4000 IU of vitamin D3 once daily, orally for 6 months.
62593865|NCT02958280|ACTIVE_COMPARATOR|Brief Advice for Physical Activity|Phase 2: Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
62593866|NCT03975556|EXPERIMENTAL|Intervention|Intervention group consisting of culturally-appropriate foods and diet advice in an initial individual session followed by daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
62034240|NCT04210453|EXPERIMENTAL|Vitamin C group|Participants in this group are administered IV vitamin C diluted in normal saline.
62034241|NCT06414434|EXPERIMENTAL|BTX-A51|"Participants will be enrolled and will complete study procedures as follows:~* Baseline visit with tumor biopsy.~* Tumor biopsy at the end of Cycle 1.~* Radiologic imaging every 2 cycles.~* Cycle 1 through End of Treatment:~  --Day 1 of 28 day cycle: Predetermined dose of BTX-A51 3x weekly.~* End of Treatment visit with radiologic imaging.~* Follow-up: every 3 months for 1 year."
62425467|NCT01412710|EXPERIMENTAL|6000 IU group|This group will be given 6000 IU vitamin D3 once daily, orally for 6 months.
62425468|NCT02215239|EXPERIMENTAL|Working type A & Workplace intervention|Participants: Workers tend to be seated during work hours. Intervention: WHO Healthy Workplace Framework and Model. Duration: 16 weeks.
62425469|NCT02215239|NO_INTERVENTION|Working type A & Usual care|Participants: Workers tend to be standing during work hours. Intervention: Usual care. Duration: 16 weeks.
62593867|NCT03975556|ACTIVE_COMPARATOR|Control|Control arm of standard portion-control general nutritional and cooking advice at the initial individual session, followed by text messages for 2 months. A reinforcement phase of 2-months will follow to repeat the education and text messages.
62593868|NCT05730244|PLACEBO_COMPARATOR|Placebo|a solution consisting of alcohol base, green food colouring and glycerin
62593869|NCT05730244|ACTIVE_COMPARATOR|Treatment|Cassia alata extract
62810597|NCT04746508||Unilateral Flat Foot (UniFF)|Participants with flat foot unilaterally (Only one foot's Calcaneal pitch angle ≤ 20 degree)
62034242|NCT04250194|EXPERIMENTAL|Navigation Bronchoscopy (NB) with F-Nav|
62034243|NCT04250194|EXPERIMENTAL|CT-guided Biopsy|
62034244|NCT04654338|EXPERIMENTAL|Intervention Arm|
62034245|NCT03955653|ACTIVE_COMPARATOR|RAO projection|Patients will be randomized to right anterior oblique (RAO) projection by fluoroscopy for the access to the femoral artery
62034246|NCT03955653|ACTIVE_COMPARATOR|AP projection|Patients will be randomized to anterior-posterior projection by fluoroscopy for the access to the femoral artery
62034247|NCT02042235|EXPERIMENTAL|Parent-implemented language intervention|In the intervention group, the techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
62034248|NCT02042235|NO_INTERVENTION|Control group|The control group will benefit from the actual routine care for children with language delay before the age of 3 years. In order to provide them the best routine care, the psychologist will provide some advice to the parents to enhance their child's language (e.g.: using life situations to talk with the child and encourage him/her to talk ...).
62034249|NCT02347761|EXPERIMENTAL|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow (R) Closed System (CR) nebulizer
62425470|NCT02215239|EXPERIMENTAL|Working type B & Workplace intervention|Participants: Workers tend to be standing during work hours. Intervention: WHO Healthy Workplace Framework and Model. Duration: 16 weeks.
62425471|NCT02215239|NO_INTERVENTION|Working type B & Usual care|Participants: Workers tend to be standing during work hours. Intervention: Usual care. Duration: 16 weeks.
62425472|NCT01558869|EXPERIMENTAL|Arm 1|
62425473|NCT06568965|EXPERIMENTAL|De-stress & happy gut powder-U001|
62425474|NCT06568965|EXPERIMENTAL|De-Stress & Happy Gut powder-I001|
62425475|NCT06568965|OTHER|Placebo Powder 001|
62425476|NCT04959006|PLACEBO_COMPARATOR|Placebo group|Placebo drink - oral bolus (25ml) - colour/taste matched (prune juice/cola/tonic water, 1:1:1 ratio).
62425477|NCT04959006|EXPERIMENTAL|Antioxidant supplement|Experimental condition -oral bolus (25ml) olive extract drink(https://www.oliphenolia.it/uk/)
62425478|NCT05257174|EXPERIMENTAL|Jing Si Herbal Tea LIQUID PACKETS|one packet oral twice daily for three months
62425479|NCT05257174|PLACEBO_COMPARATOR|Placebo|one packet oral twice daily for three months
62425480|NCT04580472|PLACEBO_COMPARATOR|Placebo - leg|If randomized to placebo group, 4 placebo capsules will be administered PO 30 minutes prior to incision in the leg group.
62425481|NCT04580472|EXPERIMENTAL|Antibiotic- leg|The administration time of the oral antibiotics will be 30 minutes prior to incision in the leg group. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered
62425482|NCT04580472|PLACEBO_COMPARATOR|Placebo- nose|If randomized to placebo group, 4 placebo capsules will be administered PO 5-15 minutes prior to surgery on the nose.
62425483|NCT04580472|EXPERIMENTAL|Antibiotic- nose|The administration time of the oral antibiotics will be 5-15 minutes prior to surgery on the nose. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered PO.
62425484|NCT04580472|PLACEBO_COMPARATOR|Placebo- ear|If randomized to placebo group, 4 placebo capsules will be administered PO 5-15 minutes prior to surgery on the ear.
62425485|NCT04580472|EXPERIMENTAL|Antibiotic- ear|The administration time of the oral antibiotics will be 5-15 minutes prior to surgery on the ear. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered PO.
62425486|NCT02603159|EXPERIMENTAL|Capecitabine-5 weeks-radiotherapy|Capecitabine 5 weeks : 625mg/m2, bid d1-5; q1w, po,5 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.
62425487|NCT02603159|ACTIVE_COMPARATOR|Capecitabine-10 weeks-radiotherapy|Capecitabine 10 weeks : 625mg/m2, bid d1-5; q1w, po,10 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.
62593870|NCT00614120|EXPERIMENTAL|Lira 0.6 + Met|Liraglutide 0.6 mg + metformin + glimepiride placebo
62593871|NCT00614120|EXPERIMENTAL|Lira 1.2 + Met|Liraglutide 1.2 mg + metformin + glimepiride placebo
62593872|NCT00614120|EXPERIMENTAL|Lira 1.8 + Met|Liraglutide + metformin + glimepiride placebo
62810598|NCT04746508||Bilateral Flat Foot (BiFF)|Participants with flat foot bilaterally (Both feet's Calcaneal pitch angle ≤ 20 degree)
62810599|NCT01654848||orthotopic Liver Transplantation|consecutive inclusion of all recipients
62810600|NCT06117735|EXPERIMENTAL|PTFE covered stent|Use the experimental device, PTFE covered stent to treat protal hypertension.
62810601|NCT01962792|EXPERIMENTAL|Phase 1 - Dose Finding|Ibrutinib PO 560mg + Carfilzomib IV 20/27mg/m2 + Dexamethasone PO 20mg
62234485|NCT02837835|EXPERIMENTAL|continuous administration of ceftazidime|
62234486|NCT02837835|EXPERIMENTAL|intermittent administration of ceftazidime|
62234487|NCT03995901|EXPERIMENTAL|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood of the kidney donor that is delivered as a single dose with a non- myeloablative conditioning regimen. FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T cells.
62425488|NCT05398731||patients received ACEI|patient who use ACEI ( Duration, type of response, and the time period between the begining of and the emergence of symptoms of COVID-19)
62425489|NCT05398731||patients received ARBs|patient who use ARBs ( Duration, type of response, and the time period between the begining of and the emergence of symptoms of COVID-19)
62425490|NCT05398731||other antihypertensive drugs|patient who use other antihypertensive drugs(for example ca channel blockers and Beta blockers) ( Duration, type of response, and the time period between the begining of and the emergence of symptoms of COVID-19)
62425491|NCT05398731||non hypertensive group|Non hypertensive persons with matched age and sex
62425492|NCT02881463|EXPERIMENTAL|Home Exercise Program|8- week therapeutical exercise program performing at home for women with knee joint osteoarthritis
62810602|NCT01962792|EXPERIMENTAL|Phase 2b - Main Study|Ibrutinib PO 560mg + Carfilzomib IV 20/36mg/m2 + Dexamethasone PO 20mg
62810603|NCT01962792|EXPERIMENTAL|Phase 2b - Sub-study|Ibrutinib PO 840 mg + Carfilzomib IV 20/36 mg/m2 + Dexamethasone PO 20 mg
62810604|NCT01363375||normal foot|Subjects with normal foot structure
62810605|NCT01363375||flat foot|Subjects with flat foot structure.
62810606|NCT01363375||high arch foot|Subjects with high arch foot structure.
62810607|NCT00436150|EXPERIMENTAL|A|Participants will receive interpersonal therapy-based treatment
62810608|NCT00436150|ACTIVE_COMPARATOR|B|Participants will receive standard care
62034250|NCT02347761|EXPERIMENTAL|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow (R) Closed System (CR) nebulizer
62234488|NCT03995901|NO_INTERVENTION|Control|"Standard induction therapy followed by a maintenance regimen of tacrolimus, mycophenolate, and +/- corticosteroids after kidney transplant.~Control donors are not followed beyond randomization."
62234489|NCT05686382|ACTIVE_COMPARATOR|group TAP block|TAP block is administered at the end of the surgery, bilaterally, with lateral approach, with 24 ml of 0,5% ropivacaine for each side
62593873|NCT00614120|EXPERIMENTAL|Glim + Met|Glimepiride 4.0 mg + metformin + liraglutide placebo
62425493|NCT01538589||Insulin aspart users|
62593874|NCT05748158|OTHER|Weight loss|A 37 week behavioral intervention aimed at decreasing energy intake and increasing physical activity.
62810609|NCT02660788|ACTIVE_COMPARATOR|Control Arm|Mail
62810610|NCT02660788|EXPERIMENTAL|Family Physician Reminder Letter Arm|Mail
62810611|NCT03609437||ESUS patients|Acute ischemic stroke patients satisfying embolic stroke of undetermined source (ESUS) diagnostic criteria.
62810612|NCT03609437||Controls|Healthy volunteers (colleagues, friends, relatives and others).
62810613|NCT04862715|ACTIVE_COMPARATOR|Treatment|"Active study medication Medication name: Ferinject® Active ingredient: Ferric carboxymaltose Dosage form: 50 mg iron/ml solution for injection/infusion. Appearance: Dark brown, non-transparent aqueous solution Excipients: Sodium hydroxide, hydrochloric acid and water for injection Strength/Packaging: Each 2 ml vial contains 100 mg of iron as ferric carboxymaltose.~Each 10 ml vial contains 500 mg of iron as ferric carboxymaltose. Each 20 ml vial contains 1,000 mg of iron as ferric carboxymaltose. Manufacturer: Vifor Pharma UK Limited"
62810614|NCT04862715|PLACEBO_COMPARATOR|Placebo|Medication name: NaCl (sodium chloride 0.9%) Active ingredient: NaCl (sodium chloride 0.9%) Dosage form: 0.9% w/v NaCl as sterile solution in water for injection Excipients: Water Strength/Packaging: 100 ml container with 100 ml normal saline Manufacturer: As per local hospital supplier
62810615|NCT03969914||Critically ill ventilated patients|Patients admitted to ICU with expected mechanical ventilation \>48h
62810616|NCT03212326|EXPERIMENTAL|Definity|Perflutren echo contrast is infused to enhance intracardiac echo imaging recorded during catheter ablation of ventricular tachycardia. We will compare areas that appear to be myocardial scar on ultrasound with areas of abnormal electrical signals obtained by direct catheter mapping.
62810617|NCT04247347|EXPERIMENTAL|Resourcefulness Training|A cognitive-behavioral intervention presented within an audiovisual format using a tablet computer that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
62034251|NCT02347761|PLACEBO_COMPARATOR|Placebo BID eFlow (CS) nebulizer|Placebo twice daily (BID) eFlow (R) Closed System (CR) nebulizer
62034252|NCT01069029||Combined surgery|Patient which underwent combined surgery of MH and cataract extraction
62034253|NCT01069029||Successive surgery|Patients which underwent the two successive procedures
62034254|NCT04074642|NO_INTERVENTION|Non compressive adenoma|Optical Coherence Tomography Angiography without surgery
62034255|NCT04074642|EXPERIMENTAL|Compressive adenoma|Optical Coherence Tomography Angiography before and after neurosurgery
62034256|NCT04365660|EXPERIMENTAL|18-F-FTC 146 PET/CT|For PET scans, subjects will receive intravenous injection of 10 mCi 18-F -FTC 146 administered twice with 18-F-FTC 146, once at baseline (pre chemotherapy) and once at final study visit (post chemotherapy).
62034257|NCT04177758|PLACEBO_COMPARATOR|Control|Patients randomized to the control arm will receive placebo tablets and advised to consume their medication similar to the treatment arm.
62034258|NCT04177758|EXPERIMENTAL|Treatment|Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
62034259|NCT04987515||Fenestration decompression combined with secondary curettage (FDSC)|Design of the opening window reasonably；Making cyst plug；secondary curettage
62034260|NCT04987515||local curettage (LC)|The tumor was removed by local curettage only
62034261|NCT03776513|EXPERIMENTAL|experimental group|Thirty obese boys (12-17 years old) undergoing an MRI, a clinical and psychological examination and a series of cognitive tests
62034262|NCT03776513|OTHER|control group|Thirty healthy boys (12-17 years old) paired for pubertal stage, level of education and socio-economic level undergoing an MRI, a clinical and psychological examination and a series of cognitive tests
62034263|NCT00454558|EXPERIMENTAL|Arm 1|
62034264|NCT03681028|OTHER|Individualized therapy|Study treatment for a given patient will consist of a regimen chosen from agents implicated in critical molecular signaling pathways and/or from signature-based predictions of drug efficacy. All agents are listed in the current pharmacopoeia for human use, but will differ amongst individual subjects. The study treatment will consist of up to 4 FDA approved drugs that have known dosing. This study is not only looking at 4 drugs. It is selecting up to 4 drugs per patient but the drugs chosen can be any FDA-approved drug. Therefore, it is not possible to pre-specify the medications.
62034265|NCT04675788|EXPERIMENTAL|Postmenopausal women: Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
62034266|NCT04675788|PLACEBO_COMPARATOR|Postmenopausal women: Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
62034267|NCT04675788|EXPERIMENTAL|Men 65 years of age or older: Testosterone|Subjects will receive treatment with transdermal testosterone 1% (100 mg) every morning for 3 days
62034268|NCT04675788|PLACEBO_COMPARATOR|Men 65 years of age or older: Placebo|Subjects will receive treatment with transdermal placebo every morning for 3 days
62034269|NCT00620841||A|Patients treated with tacrolimus and experiencing a drug interaction
62425494|NCT06566105|OTHER|PROCEDURES RELATED TO THE STUDY|"* Selection of blood donors at risk of NAFLD and metabolic diseases and sample collection blood~* Evaluation of early cardiovascular damage and characterization of liver damage in patients with high probability of severe NAFLD~* Study of genomics and biomarkers~* Generation of an in vitro genetic model of NAFLD"
62810618|NCT04247347|ACTIVE_COMPARATOR|Dementia Education|An educational program designed to teach family caregivers about the characteristics, types, causes, and risk factors of dementia, as well as teach about health promotion, the stages of dementia, behavior changes, communicating with a family member with dementia, and caring for oneself. The content to be presented within an audiovisual format using a tablet computer follows recommendations and guidelines developed through research and by the Alzheimer's Association and the National Institute on Aging.
62034270|NCT06635590||Hyperkalemia|Study is planned as only 1 group of patient with hyperkalemia. Pre and post treatment data obtained from patients via ECG, ECHO and laboratory values will be recorded and evaluated in terms of literature. Patient-based findings will also be recorded and evaluated.
62034271|NCT05034705|ACTIVE_COMPARATOR|Active comparator: Conventional suction system|This is the conventional method of using the dental high volume suction to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
62034272|NCT05034705|EXPERIMENTAL|Experimental: Dental aerosol box with modified high volume evacuation system|The dental aerosol box will be equipped with an exit for the high volume suction to be attached to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
62034273|NCT02230072|EXPERIMENTAL|fetoscopic surgical repair|Single arm study. All patients will receive the fetoscopic repair.
62034274|NCT01084876|EXPERIMENTAL|CT-P6 & Paclitaxel|"CT-P6 was administered at a loading dose of 8 mg/kg body weight by intravenous (IV) infusion over 90 minutes on Day 1, Cycle 1, then at 6 mg/kg repeated at 3-weekly intervals until disease progression, death or discontinuation.~Paclitaxel was administered at a dose of 175 mg/m2 BSA as a continuous 3-hour IV infusion on the day following the first dose of study drug (CT-P6). If the first dose of study drug was well tolerated, subsequent doses of paclitaxel were given immediately after the next dose of study drug. Paclitaxel cycles were repeated every 3 weeks until disease progression, death or discontinuation."
62234490|NCT05686382|EXPERIMENTAL|group CWI|A 15 cm long, multihole catheter is placed on the preperitoneal plane before fascia closure; a starting bolus of 10 ml of 0,5% ropivacaine is administered through the catheter, then a continuous infusion of 0,2% ropivacaine at a rate of 5 ml/h is started through a pump and continued for 48 hours
62234491|NCT02566265|EXPERIMENTAL|Fluzone High Dose Vaccine then Fluzone High Dose Booster|Fluzone High dose vaccine administered at Day 0. Fluzone High dose vaccine administered as a booster after 30 days from the initial vaccine.
62234492|NCT02566265|ACTIVE_COMPARATOR|Standard of Care|Fluzone High-Dose if age greater than or equal to 65 or Standard dose influenza vaccine if age less than 65 at day 0. Placebo administered 30 days after the initial vaccine.
62234493|NCT06412328|NO_INTERVENTION|Control group|The parents in the control group did not receive any psychoeducation program
62234494|NCT06412328|EXPERIMENTAL|Intervention group|The parents in the intervention group received an 8-session psychoeducation program
62810619|NCT04247347|EXPERIMENTAL|Biofeedback Training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and to continue to influence behavior."
62810620|NCT02893319|NO_INTERVENTION|Breastfeeding|control group
62810621|NCT02893319|ACTIVE_COMPARATOR|5 oz bottle|Subject will feed infant with 5oz medela bottle
62810622|NCT02893319|ACTIVE_COMPARATOR|8 oz bottle|Subject will feed infant with 8oz medela bottle
62234495|NCT04395118|NO_INTERVENTION|Usual Care|Patients randomized to Group 1 will receive visit-based HCV screening, as offered by clinic providers as part of usual care. Providers must identify at-risk patients who are eligible for HCV screening, understand the benefits of screening in this population, and enter orders for HCV Ab testing. If the HCV antibody is abnormal, providers must order appropriate follow-up tests including HCV viral load to confirm HCV infection. Once HCV is confirmed, providers must refer the patients for fibrosis assessment and treatment evaluation. These efforts are augmented by an established best practice alert and health maintenance reminders.
62234496|NCT04395118|ACTIVE_COMPARATOR|Mailed Outreach|Patients randomized to Group 2 will receive low literacy, written materials about HCV screening in English and Spanish. The invitation will include patient-centered educational materials that discuss the risk of HCV in patients with elevated LFTs and the benefits and risks of HCV screening. The invitation will include a phone number to schedule the HCV antibody test. Once a potential subject is identified and randomized in Group 2, an outreach invitation will be mailed out. Shortly after the letter, a bilingual patient navigator will call to this potential subject. Patients will also receive centralized patient navigation to facilitate screening completion and appropriate test follow-up. He/she will help patients schedule HCV antibody testing and will assume responsibility for tracking results. Patients referred to the Hepatitis C clinic for treatment evaluation will receive reminder calls from trained and credentialed study staff 5-7 business days for scheduled appointments.
62234497|NCT01228708|ACTIVE_COMPARATOR|Intervention|Patients from half the GP practices in Ringkoebing-Skjern municipality that participates in an active implementation of a guideline for COPD
62234498|NCT01228708|NO_INTERVENTION|Control group|Patients from the half of the GP practice in Ringkoebing-Skjern that do not participate in the active implementation of a guideline for COPD. The GPs are however in postgraduate training groups with intervention groups GPs
62234499|NCT01228708|NO_INTERVENTION|External control|Patients with GP practice in neighboring county Ikast-Brande where there have been no information or contact at all from the investigators
62234500|NCT02548260|EXPERIMENTAL|Syndactyly without compression|Relative immobilization with a syndactyly (CE conformity), no compression is worn.
62234501|NCT02548260|EXPERIMENTAL|Syndactyly with compression|Relative immobilization with a syndactyly (CE conformity), compression (CE conformity) is worn over the finger
62810623|NCT05898906||Children with special needs Group|Children who have diagnosed neurodevelopment disorders including cerebral palsy, autism spectrum disorder,
62810624|NCT05898906||Control Group|Typically developing children
62810625|NCT04532671|OTHER|Poly ether ether ketone (PEEK)|Poly ether ether keton (PEEK) is acknowledged as a high-performance polymer in engineering \& medical applications due to its favorable mechanical and chemical properties.
62810626|NCT04532671|OTHER|CADCAM poly ether ether ketone (PEEK)|PEEK was predominantly processed out of CAD/CAM-supported milled out of prefabricated blanks.
62234502|NCT02548260|EXPERIMENTAL|Rigid splint without compression|Rigid immobilization with a custom made thermoplastic splint (CE conformity), no compression is worn
62234503|NCT02548260|EXPERIMENTAL|Rigid splint with compression|Rigid immobilization with a custom made thermoplastic splint (CE conformity), compression (CE conformity) is worn over the finger
62234504|NCT00451100|EXPERIMENTAL|Sugammadex|2.0 mg/kg Org 25969 (sugammadex)
62234505|NCT00451100|ACTIVE_COMPARATOR|Neostigmine|50 ug/kg neostigmine
62810627|NCT04532671|ACTIVE_COMPARATOR|indirect resin composite|In CAD/CAM resin composite blocks, properties of flexibility and ease of use similar to that of resin composite are combined with durability and surface finish properties similar to that of ceramics
62810628|NCT02761226|EXPERIMENTAL|Group A (Platform Matched Design)|10 Patients with missing tooth in upper posterior area will receive dental implant (implants with the same abutment diameter)
62810629|NCT02761226|ACTIVE_COMPARATOR|Group B (intervention - Platform Switching Design)|10 patients with missing tooth in upper posterior area will receive dental implant (implants with smaller diameter abutment)
62810630|NCT02348177|EXPERIMENTAL|TB/HIV co-infection|Superboosting lopinavir with ritonavir in 1:1 ratio during TB/HIV co-infection and treatment of HIV with lopinavir/ritonavir 4:1
62034275|NCT01084876|ACTIVE_COMPARATOR|Herceptin & Paclitaxel|"Herceptin was administered at a loading dose of 8 mg/kg body weight by IV infusion over 90 minutes on Day 1, Cycle 1, then at 6 mg/kg repeated at 3-weekly intervals until disease progression, death or discontinuation.~Paclitaxel was administered at a dose of 175 mg/m2 BSA as a continuous 3-hour IV infusion on the day following the first dose of study drug (Herceptin). If the first dose of study drug was well tolerated, subsequent doses of paclitaxel were given immediately after the next dose of study drug. Paclitaxel cycles were repeated every 3 weeks until disease progression, death or discontinuation."
62034276|NCT01988246|SHAM_COMPARATOR|Sham Injection|"Patients will be sequentially randomized to treatment with a sham injection at the time of surgery. The sham injection is accomplished by pressing an empty syringe against the eye wall without penetration. This will be administered post cataract excision by the Prinicipal Investigator. The patient will be masked as to which Arm they are assigned."
62425495|NCT03821831||Continuous Positive Airway Pressure|This group consists of consenting patients and their parents who choose Continuous Positive Airway Pressure (CPAP). The CPAP is a type of therapy that applies mild air pressure to a person's upper airway to keep their airway open so that they can breathe normally while they sleep.
62810631|NCT01069432||Patients with CLL|Patients undergoing routine blood draws as part of their ongoing follow-up care for CLL at the Norris Cotton Cancer Center of DHMC.
62034277|NCT01988246|ACTIVE_COMPARATOR|Intravitreal Aflibercept Injection|Patients will be sequentially randomized to treatment with Aflibercept 2 mg via intravitreal injection (0.05 mL or 50 microliters) at the time of surgery. This will be administered post cataract excision by the Principal Investigator. The patient will be masked as to which Arm they are assigned.
62034278|NCT02388633||Plasmapharesis|Patients undergoing apheresis for elevated LDL. Patients will undergo contrast ultrasound perfusion imaging at rest and during forearm exercise at before and immediately after apheresis.
62810632|NCT01069432||Normal Volunteers|Normal volunteers who have no history of active or prior hematologic malignancy.
62810633|NCT04743115|EXPERIMENTAL|the Dose Escalation Level|"In the first 3-patient cohort, the dose of BS HH 002.SA will be 0.2 mg/m2/day. Enrollment to the next higher dose cohort will be initiated only if none of the 3 patients exhibits a DLT in the first 28-day cycle. Dose escalation will proceed according to a modified Fibonacci scheme, eg, increments of 100%, 100%, 66%, and 33% and the dose of BS-HH-002.SA will be 0.4, 0.8, 1.3, 1.7 mg/m2/day.~The dose will be administered subcutaneously once daily on Days 1 through 6 and on Days 10 through 15 of a 28 day cycle."
62819580|NCT06108414|ACTIVE_COMPARATOR|Standard-dose rivaroxaban|20mg q.d. rivaroxaban for 2 years after randomization. The dose should be reduced in the following special conditions: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old. In the standard-dose group, the dose was reduced from the 20mg q.d. to 15mg q.d. .
62034279|NCT06575218|EXPERIMENTAL|Virtual reality training group|It will be included in the virtual reality training program to be implemented with the Wii-fit console.
62034280|NCT06575218|EXPERIMENTAL|Conventional exercise and cognitive exercise group|It will be included in the cognitive exercise program along with conventional balance exercises.
62034281|NCT06575218|NO_INTERVENTION|Control group|no intervention
62034282|NCT01816594|EXPERIMENTAL|BKM120 + Trastuzumab + paclitaxel|BKM120 (oral, pan-class I PI3K inhibitor) in combination with trastuzumab and paclitaxel.
62034283|NCT01816594|PLACEBO_COMPARATOR|BKM120 PBO + Trastuzumab + paclitaxel|BKM120 placebo in combination with trastuzumab and paclitaxel
62034284|NCT05129826|EXPERIMENTAL|older adult|Subjects who has aged ≥ 60 years old.
62034285|NCT05123508|EXPERIMENTAL|Treatment Arm|2940nm laser and BBL treatment
62034286|NCT05123508|EXPERIMENTAL|Control Arm|One side of the treatment area will act as a control. No treatment on the control side.
62034287|NCT01356017|EXPERIMENTAL|Free combination of Telmisartan and S-amlodipine|Subjects received Telmisartan 80mg and S-amlodipine 5mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
62034288|NCT01356017|ACTIVE_COMPARATOR|Telmisartan monotherapy|Subjects received Telmisartan 80mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
62234506|NCT06403189|OTHER|Population|"* LHIPFOLD patients~* Patients with neurologic disease~* healthy volunteers"
62593875|NCT05140629|PLACEBO_COMPARATOR|Placebo (OGTT)|The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water.
62034289|NCT04226430||Before cytosorb|Arterial blood samples were taken from patients before the Cytosorb therapy course.
62034290|NCT04226430||after cytosorb|Arterial blood samples were taken from patients immediately after the Cytosorb therapy course.
62034291|NCT02791724|EXPERIMENTAL|Desiconnect|Desiconnect is an Internet-administered intervention developed for persons with epilepsy and elevated depression symptoms.
62034292|NCT02791724|ACTIVE_COMPARATOR|Care-as-Usual (CAU) / wait list|In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Desiconnect three months post-baseline (i.e., wait list with respect to Desiconnect access).
62034293|NCT01540851|ACTIVE_COMPARATOR|Care Navigator Intervention Group|Subjects randomized to the Care Navigator Intervention group will receive up to 10 telephone calls from a care navigator for 5 months post-operatively
62034294|NCT01540851|ACTIVE_COMPARATOR|Usual Care Group|Subjects in the Usual Care group receive the current standard post-operative TKA care
62034295|NCT02952638||Healthy|BMI is between 20 and 25
62034296|NCT02952638||Overweight|BMI is between 25 and 30
62234507|NCT01845220|ACTIVE_COMPARATOR|Broccoli Sprout Extract|Each subject will act as his/her own control and receive both treatment and placebo on adjacent skin regions.
62234508|NCT01845220|PLACEBO_COMPARATOR|Placebo|Each subject will act as his/her own control and receive both treatment and placebo on adjacent skin regions.
62234509|NCT02972463|PLACEBO_COMPARATOR|Placebo|9 maltodextrin capsules, once daily for 12 weeks
62593876|NCT05140629|EXPERIMENTAL|Intervention (OGTT plus Baobab fruit extract)|The intervention group ingested glucose solution followed by 250 ml of baobab aqueous extract (33.33 g FW).
62234510|NCT02972463|EXPERIMENTAL|IgY Max Low-Dose (1g IgY Max)|2 Immunoglobulin Y capsules and 7 maltodextrin capsules, once daily for 12 weeks
62234511|NCT02972463|EXPERIMENTAL|IgY Max Mid-Dose (2g IgY Max)|4 Immunoglobulin Y capsules and 5 maltodextrin capsules, once daily for 12 weeks
62234512|NCT02972463|EXPERIMENTAL|IgY Max High-Dose (4.5g IgY Max)|9 Immunoglobulin Y capsules, once daily for 12 weeks
62234513|NCT02272049|EXPERIMENTAL|Hyperpolarized 129 Xenon|Administration of up to 1 liter doses of Hyperpolarized Xenon gas during MRI (less for children) to optimize acquisition of images for children and adults vs. proton MR imaging
62234514|NCT05144009|EXPERIMENTAL|Cohort A : Loncastuximab Tesirine + Rituximab (Lonca-R)|"Participants who are unfit (per sGA) will receive Lonca-R for 3 cycles. Participants who achieve a complete response (CR) will receive Lonca-R for 1 additional cycle. Participants who achieve a partial response (PR) will receive Lonca-R for 3 additional cycles.~Lonca-R will be administered as rituximab 375 mg/m\^2 on Day 1 of Cycle 1 and loncastuximab tesirine 150 µg/kg on Day 2 of Cycle 1. During Cycle 2, Lonca-R will be administered as rituximab\* 375 mg/m\^2 and loncastuximab tesirine 150 µg/kg on Day 1. For cycles 3 and beyond, Lonca-R will be administered as rituximab 375 mg/m\^2 and loncastuximab tesirine 75 µg/kg on Day 1.~\*subcutaneous rituximab 1400mg/dose may be used during Cycle 2 and beyond"
62234515|NCT05144009|EXPERIMENTAL|Cohort B : Loncastuximab Tesirine + Rituximab (Lonca-R)|"Participants who are frail (per sGA) or participants with cardiac comorbidities will receive Lonca-R for 3 cycles. Participants who achieve a CR will receive Lonca-R for 1 additional cycle. Participants who achieve a PR will receive Lonca-R for 3 additional cycles for a total of up to 6 cycles. Only participants enrolled in Cohort B, who achieve stable disease (SD) and deriving clinical benefit per the treating physician, may also receive Lonca-R for an additional 3 cycles.~Lonca-R will be administered as rituximab 375 mg/m\^2 on Day 1 of Cycle 1 and loncastuximab tesirine 150 µg/kg on Day 2 of Cycle 1. During Cycle 2, Lonca-R will be administered as rituximab\* 375 mg/m\^2 and loncastuximab tesirine 150 µg/kg on Day 1. For cycles 3 and beyond, Lonca-R will be administered as rituximab 375 mg/m\^2 and loncastuximab tesirine 75 µg/kg on Day 1.~\*subcutaneous rituximab 1400mg/dose may be used during Cycle 2 and beyond"
62234516|NCT03354806|EXPERIMENTAL|Continuous peripheral nerve blocks|Ropivacaine-continous treatment using catheters for continous sciatic nerve blocks
62425496|NCT03821831||Orthodontic Intervention|This group consists of consenting patients and their parents who choose orthodontic intervention will be seen by participating orthodontists who will determine types of orthodontic intervention; mandibular advancement devices or rapid maxillary expansion devices, or Class III mid face advancement with skeletal anchored headgear. In this group, the patients will also receive a biometric shirt to use once every two weeks, to monitor their sleep during the study.
62593877|NCT01296542|ACTIVE_COMPARATOR|VIGAMOX|Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection
62593878|NCT01296542|ACTIVE_COMPARATOR|Besivance|Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection
62593879|NCT01233960|EXPERIMENTAL|Prochymal|Infusions of Prochymal on days 42-45, 84-87, and 126-129 after first infusion in Protocol 603. Each infusion of PROCHYMAL (remestemcel-L) will contain 200 million cells.
62234517|NCT03354806|ACTIVE_COMPARATOR|Analgesic treatment|Pharmacological pain management in accordance with WHO's pain relief ladder
62234518|NCT05335954|EXPERIMENTAL|Noradrenaline|Noradrenaline diluted to 16µg/ml infused at 0.06g/kg/min by peripheral venous line from the start of peripheral venous line from the start of preoxygenation
62234519|NCT05335954|NO_INTERVENTION|Standard care|standard care
62234520|NCT06249568||patients who will have coroner arter bypass surgeon|Patients undergoing coronary artery bypass surgery will be eliminated if there are exclusion criteria. Patients who do not have exclusion criteria will be included in the study if they agree to volunteer.
62425497|NCT03821831||Control|This group consists of consenting patients and their parents who choose to remain untreated. In this group, the patients will also receive a biometric shirt to use once every two weeks, to monitor their sleep during the study.
62425498|NCT02693652|EXPERIMENTAL|CVI-HBV-002 (20ug, 3 shots)|"* HBV surface antigen 20ug/dose~* Intramuscular injection at 0, 1, 2 month"
62425499|NCT02693652|EXPERIMENTAL|CVI-HBV-002 (20ug, 6 shots)|"* HBV surface antigen 20ug/dose~* Intramuscular injection at 0, 1, 2, 3, 4, 5 month"
62425500|NCT02693652|EXPERIMENTAL|CVI-HBV-002 (40ug, 3 shots)|"* HBV surface antigen 40ug/dose~* Intramuscular injection at 0, 1, 2 month"
62593880|NCT03539770||AIS|Adolescent idiopathic scoliosis subjects undergoing posterior spinal fusion.
62593881|NCT03539770||Control|Children without scoliosis
62593882|NCT05991609||Individuals with extreme body size|Any individual with a form of skeletal dysplasia, or extremely small or large body size.
62593883|NCT03628989|EXPERIMENTAL|Cardiac Cathertization Patients|Participants will use technology based distraction during procedure.
62593884|NCT03628989|EXPERIMENTAL|Allergy Patients|Participants will use technology based distraction during procedure
62425501|NCT02693652|EXPERIMENTAL|CVI-HBV-002 (40ug, 6 shots)|"* HBV surface antigen 40ug/dose~* Intramuscular injection at 0, 1, 2, 3, 4, 5 month"
62593885|NCT03628989|NO_INTERVENTION|Procedure-Only Patients|
62593886|NCT00831974|EXPERIMENTAL|2|masitinib (AB1010) 6 mg/kg/day
62593887|NCT00831974|EXPERIMENTAL|1|masitinib (AB1010) 3 mg/kg/day
62593888|NCT05839782||Re-PLM|Patient in which a new mitral valve repair is performed to treat failed mitral valve repair
62593889|NCT05839782||Re-SVM|Patient in which a mitral valve replacement is performed to treat failed mitral valve repair
62593890|NCT04869696||Subjects with tape samples|each subject had 8 types of tape samples applied on their arms
62034297|NCT02952638||Obese|BMI is between 30 and 40
62425502|NCT06254521|EXPERIMENTAL|neoadjuvant Tislelizumab combined with chemotherapy|"Patients with locally advanced rectal cancer who met the inclusion criteria received two or four cycles of Tislelizumab combined Capecitabine and Oxaliplatin regimen chemotherapy and were evaluated by enhanced CT and MRI\\TRUS. Then, these patients will receive curative surgery for rectal cancer.~Interventions:~Drug: Oxaliplatin Drug: Capecitabine Drug: Tislelizumab Procedure: curative surgery for rectal cancer"
62810634|NCT02743585|EXPERIMENTAL|Rapid diagnostic arm|"Standard Tan Tock Seng Hospital (TTSH) practices (bacterial culture and susceptibility testing) AND FilmArray Blood Culture ID (BCID) Panel test AND Rosco Diagnostica ESBL and carbapenemase screen will be performed.~The Interventions to be administered are the rapid diagnostic tests: FilmArray Blood Culture ID (BCID) Panel test AND Rosco Diagnostica ESBL and carbapenemase screen.~Subjects will be recruited 8am-3pm daily, weekdays only. Results of the BCID and Rosco test will be communicated to the managing physicians by phone in real-time."
62810635|NCT02743585|NO_INTERVENTION|Standard of care (control)|Standard Tan Tock Seng Hospital (TTSH) practices (bacterial culture and susceptibility testing) will be used. FilmArray BCID and Rosco Diagnostica ESBL and carbapenemase screen will NOT be performed. Subjects will be recruited 8am-3pm daily, weekdays only.
62034298|NCT04663048|EXPERIMENTAL|Protocol A|PiXL treatment with pulsed UV illumination (1.0 sec on /0.8 sec off) in high oxygen in a central ring-shaped 3.5-mm zone of the cornea and total illumination time of 10 min. The area consist of three rings with a central 1.5-mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring.
62034299|NCT04663048|ACTIVE_COMPARATOR|Protocol B|PiXL treatment with pulsed (0.5 sec on / 1 sec off) UV illumination in high oxygen in a central ring-shaped 3.5-mm zone of the cornea and total illumination time of 16:40 min. The area consist of three rings with a central 1.5-mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring.
62034300|NCT03311438|OTHER|Oral health intervention program|Oral Health intervention program: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
62034301|NCT05378399|EXPERIMENTAL|Digital Pills and Beiwe|Participants will take one PrEP digital pill per day, for 60 days total, while using the ID-Cap digital pill system and Beiwe digital phenotyping app.
62034302|NCT03491865|EXPERIMENTAL|REAL media Plus|Participants in this group will be assigned to use the REAL media Plus curriculum.
62034303|NCT03491865|NO_INTERVENTION|programming as usual|Participants in this group will participate in their usual school curriculum. They will have the opportunity to use the REAL media Plus curriculum at the conclusion of the study.
62034304|NCT02999555|EXPERIMENTAL|Aspirated follicular fluid|Follicular fluid aspirated by follicle size and tested for the novel markers after eggs were identified and separated for the purpose of fertilization
62234521|NCT00863109||PEG + RBV (Standard Clinical Practice)|Participants receive peginterferon alfa-2b (PEG) and ribavirin (RBV) in combination therapy for 48 weeks according to standard clinical practice followed by 24 weeks of observation.
62425503|NCT02268019|EXPERIMENTAL|Hypospadiasis repair|
62234522|NCT00572520|ACTIVE_COMPARATOR|1|Evidence-based behavioral weight loss treatment with health education counseling
62810636|NCT04540263||Sleeve Gastrectomy|Patients who underwent Sleeve gastrectomy operation
62810637|NCT04540263||Gastric Bypass|Patients who underwent Gastric Bypass operation
62425504|NCT04744077|SHAM_COMPARATOR|Control|Participants randomized to this group will follow a public Instagram account. This account was chosen because they have a strong following (over 600,000 followers) and it is a public account that anyone can follow. The content shared on this page is motivational and community driven. There is a focus of healthy living with an emphasis on exercise. Additionally, there are no paid sponsorships or radical exercise advice, which is common on other influencer pages. The Co-PIs determined that this page accurately represents the exercise-related content that is readily available on Instagram. The research team will not have control over the content of this account, but the account holder will be notified about the study.
62034305|NCT05010148|PLACEBO_COMPARATOR|Placebo|Patients will be administered D5 water intravenously at the same infusion rate (ml/hr) as the intervention group for 48 hours after major spinal surgery.
62034306|NCT05010148|EXPERIMENTAL|Intervention-Intravenous Lidocaine Infusion|Will be administered intravenous lidocaine at 1.33mg/kg/hr (adjusted body weight) for 48 hours following major spinal surgery.
62034307|NCT03962387||Atopic Dermatitis|
62234523|NCT00572520|EXPERIMENTAL|2|Evidence-based behavioral weight loss treatment with brief behavior therapy for depression
62810638|NCT02908022|EXPERIMENTAL|Interaction|"Phase 1:~Prior to the MRI sessions, the clinician will be introduced to the patient and do a general intake of physical examination.~During the MRI sessions, the patient will receive experimental pressure pain via the Hokanson Rapid Cuff Inflator and electroacupuncture analgesia to the leg for pain relief."
62810639|NCT02908022|EXPERIMENTAL|No Interaction|"Phase 1:~The clinician and the patient will first be introduced at the MRI sessions.~During the MRI sessions, the patient will receive experimental pressure pain via the Hokanson Rapid Cuff Inflator and electroacupuncture analgesia to the leg for pain relief."
62819581|NCT06271512||All Participants|Participants with β-thalassemia treated with beti-cel in the post-marketing setting will be followed in this registry study for up to 15 years after infusion with beti-cel to collect real-world longitudinal data.
62819582|NCT05387278|EXPERIMENTAL|Experimental/treatment arm|
62819583|NCT05387278|PLACEBO_COMPARATOR|Placebo|
62034308|NCT00251745|EXPERIMENTAL|Dexlansoprazole MR 60 mg QD|
62034309|NCT00251745|EXPERIMENTAL|Dexlansoprazole MR 90 mg QD|
62034310|NCT00251745|PLACEBO_COMPARATOR|Placebo|
62034311|NCT02647398|EXPERIMENTAL|A: Supervised combined training|INTERVENTION: Two supervised 75 min-vigorous aerobic training \& strength training
62034312|NCT02647398|ACTIVE_COMPARATOR|B: Supervised strength training|ACTIVE COMPARATOR: Two supervised 45-minute sessions of strength training \& Participants will be advised to comply with international recommendations of physical activity (150 min pf MVPA)
62034313|NCT06386523|EXPERIMENTAL|Passage of olfactory tests|Passage of olfactory tests: TODA2 and Sniffin Stick Test
62034314|NCT04543123|SHAM_COMPARATOR|sham tDCS treatment group|the current rose slowly for 30 seconds, descended for 30 seconds, and then remained at zero for 29 minutes
62034315|NCT04543123|EXPERIMENTAL|active tDCS treatment group|2mA of current was delivered during the 30 minutes of treatment
62034316|NCT03461068|EXPERIMENTAL|Ketone monoester|Acute morning dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.45 ml/kg body weight)
62034317|NCT03461068|PLACEBO_COMPARATOR|Placebo|Acute morning dose of flavour-matched placebo.
62034318|NCT03094026|EXPERIMENTAL|Intervention|The arm will begin the Lumosity program at enrollment in the study.
62034319|NCT03094026|ACTIVE_COMPARATOR|Wait List Control|The arm will begin the Lumosity program 3 months after enrollment in the study.
62034320|NCT05430490||HIV+ Cannabis User|Persons diagnosed with HIV who identify as using medical or recreational marijuana
62234524|NCT03975452|EXPERIMENTAL|Primary resectable cT2-low lying-T3, N0-N1 rectal tumour|Primary resectable cT2-low lying-T3, N0-N1 adenocarcinoma of the rectum, without evidence of disease in lateral lymph nodes.
62234525|NCT02345122|OTHER|Enhanced Usual Care|This group will receive Enhanced Usual Care. The subject's Primary Care Provider will receive results of baseline, four, eight, and twelve month assessments examining the subject's symptoms of depression, anxiety, and other mental health problems, use of alcohol and illicit substances, physical pain, and quality of life . If the subjects primary care provider chooses, they can use this information to construct the subject's treatment plan.
62234526|NCT02345122|EXPERIMENTAL|Intervention: Mental Health Technician|The subject's Primary Care Provider will receive results of baseline, four, eight, and twelve month assessments examining the subject's symptoms of depression, anxiety, and other mental health problems, use of alcohol and illicit substances, physical pain, and quality of life and recommendations for treatment. Over a 3-12 months period, the Intervention group will receive a brief, telephone-based intervention by a Mental Health Technician that will focus on monitoring symptoms, treatment adherence, and providing psychoeducation.
62034321|NCT05430490||HIV+ Cannabis Non-User|Persons diagnosed with HIV who identify as not using medical or recreational marijuana
62034322|NCT05430490||HIV- Cannabis User|Persons without HIV who identify as using medical or recreational marijuana
62034323|NCT05430490||HIV- Cannabis Non-User|Persons without HIV who identify as not using medical or recreational marijuana
62034324|NCT05278000||Children aged 2-17 years with asthma|Parents of children aged 2-17 years seen at CHU Sainte-Justine asthma clinic with a diagnosis of asthma will be eligible for the study
62034325|NCT03884751|EXPERIMENTAL|CAR-GPC3 T Cells|The subjects are enrolled into 2 dose levels cohorts in sequence
62593891|NCT02092480|EXPERIMENTAL|Intervention|After baseline data collection, four schools will be randomly assigned to the intervention arm, those receiving the If I Were Jack programme. RSE teachers will deliver the intervention to all participating Year 11 pupils during four weekly lessons of the 'Learning for Life and Work' strand of the Key Stage 4 curriculum.
62810640|NCT02908022|EXPERIMENTAL|Longitudinal|"Phase 2:~Prior to first MRI session, both clinician and patient will go through a training visit.~During the first MRI session, the patient will receive experimental pressure pain to the left leg via Hokanson Rapid Cuff Inflator and electroacupuncture to the same leg for pain relief.~Following the first MRI session, the patient will attend biweekly acupuncture treatment sessions with the clinician (6 treatments total). During the first session the clinician will be introduced to the patient and do a general intake in addition to the acupuncture treatment.~The final MRI session will be identical to the first. The patient will receive experimental pressure pain via Hokanson Rapid Cuff Inflator and electroacupuncture to the same leg for pain relief."
62810641|NCT01022021|ACTIVE_COMPARATOR|rituximab|
62810642|NCT01022021|ACTIVE_COMPARATOR|bendamustine|bendamustine, 90 mg/M2
62034326|NCT01741753|EXPERIMENTAL|Treatment Arm|BKM120+Abiraterone+Prednisone
62034327|NCT03772067|EXPERIMENTAL|MBdiet|This arm consist on 3 month on Bdiet with high energy and protein breakfast (660 +/-20 kcal), medium sized lunch (580+/-20 kcal) and dinner reduced in energy (300+/-20 kcal), with distribution of calories: breakfast 44%, lunch 37% and dinner 19%. The breakfast will contain 38 g protein mostly from milk and dairy products.
62034328|NCT03772067|ACTIVE_COMPARATOR|OBdiet|This arm consist on 3 month on Bdiet with high energy and protein breakfast (660 +/-20 kcal), medium sized lunch (580+/-20 kcal) and dinner reduced in energy (300+/-20 kcal), with distribution of calories: breakfast 44%, lunch 37% and dinner 19%. The breakfast will 38 g protein without milk or dairy products mostly from other proteins, i.e. eggs, tuna, soy, oatmeal. Milk product will be avoided in this diet also in other meals along the day.
62034329|NCT04192994|ACTIVE_COMPARATOR|Group 1: Antibiotic injection|A total of 0.05 ml of vancomycin 1 mg and 0.05 ml of ceftazidime 2.25 mg will be injected with a 30-gauge needle into the vitreous cavity of the affected eyes in the randomized group, as soon as the diagnosis is confirmed.
62034330|NCT04192994|ACTIVE_COMPARATOR|Group 2: Pars Plana Vitrectomy|Randomized patients will undergo PPV. Briefly, a blepharostat will be placed followed by instillation of a drop of 5% iodine-povidone over the eye. Under a surgical microscope, three 23-gauge or 25-gauge sclerotomies will be performed. Vitreous core vitrectomy will be performed, and a fluid-gas exchange with balanced saline solution (BSS) or 5,000 grams of silicone oil as a vitreous substitute. At the end of surgery, all sclerotomies will be sutured with Vicryl 7.0 and a total of 0.05 ml of vancomycin 1 mg and 0.05 ml of ceftazidime 2.25 mg will be injected into the vitreous cavity. As soon as the diagnosis is confirmed.
62425505|NCT04744077|EXPERIMENTAL|Student|Student Co-PI will manage this Instagram account created for the study. Although the student is a Kinesiology student and works within the health field, she will not disclose this information on the account. Instead, she will present herself as a general college student. By withholding her major and career aspirations, we hope to get unbiased feedback on what participants think about the content being presented. The content presented will be identical to study arm #3.
62425506|NCT04744077|EXPERIMENTAL|Scientist|"The PI will manage this Instagram account created for the study. The PI is a certified exercise physiologist and holds a PhD in Rehabilitation Sciences. She will disclose this information on the account. This group is the study's gold standard because it will provide evidence-based content delivered by an exercise scientist."
62425507|NCT00566631|EXPERIMENTAL|Paliperidone Extended Release (ER)|
62425508|NCT00517257|EXPERIMENTAL|A|Atorvastatin 80 mg orally once daily for 24 weeks
62034331|NCT04969523|EXPERIMENTAL|es-ketamine|es-ketamine 0.5mg/kg iv
62034332|NCT04969523|PLACEBO_COMPARATOR|saline|iv saline with the same volume of es-ketamine
62425509|NCT00517257|PLACEBO_COMPARATOR|P|Placebo tablet orally once daily for 24 weeks
62425510|NCT01770678|EXPERIMENTAL|Constraint induced movement therapy (prolonged restraint)|Constraint induced movement therapy(prolonged restraint)consists of a combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb over a forty-two day period.
62810643|NCT04463472|EXPERIMENTAL|Low-dose group|
62034333|NCT02457572||Valsalva maneuver|This is an observational study and as a diagnostic intervention, subjects in the study would receive valsalva maneuver. Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration. The investigators perform this procedure to every patients and do not assign this intervention to the subjects of the study.
62034334|NCT04850300|EXPERIMENTAL|Total knee prosthesis 1|prosthesis with medial condylar stabilization
62034335|NCT04850300|ACTIVE_COMPARATOR|Total knee prosthesis 2|traditional prosthesis with central pivot stabilization
62234527|NCT03406260|EXPERIMENTAL|Lasmiditan 200 mg (milligrams)|Participants received 200 mg of Lasmiditan tablet orally in the fasted state with approximately 240 (milliliter) mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
62234528|NCT03406260|EXPERIMENTAL|Lasmiditan 100 mg|Participants received 100 mg of Lasmiditan tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
62593892|NCT02092480|NO_INTERVENTION|Control|After baseline data collection, three schools will be randomly assigned to the control arm. Participating pupils will not receive the If I Were Jack intervention and will continue with normal RSE practice.
62810644|NCT04463472|EXPERIMENTAL|High-dose group|
62810645|NCT01576341|EXPERIMENTAL|HX575 epoetin alfa (Sandoz)|Single arm
62810646|NCT01210924||Pediatric ART patients|
62425511|NCT01770678|ACTIVE_COMPARATOR|Constraint induced movement therapy(manual restraint)|Constraint induced movement therapy(manual restraint)consists of a combination of manual restraint of the unaffected upper limb and massed practice of the affected upper limb over a forty-two day period.
62034336|NCT06393049|OTHER|Hyperglycaemic clamp|"The purpose of hyperglycaemic clamping is to raise the blood glucose level to a fixed plateau and maintain the plateau for at least one hour to observe a steady-state blood glucose concentration.~The investigators intend to perform the hyperglycaemic clamping procedure one time in all 14 patients following an overnight fast and aim for a fixed blood glucose level above 8 mmol/L.~The patient will have an arterial line placed in the radial artery, a retrograde catheterization of the jugular bulb and a venous line for infusions of glucose, potassium, and isotonic saline.~To maintain potassium levels at wanted levels, an isotonic saline solution containing potassium will be infused continuously and arterial samples of potassium and glucose will be measured at minimum every 10 minutes from the start of the intervention."
62034337|NCT05374421|ACTIVE_COMPARATOR|Erchonia® THL™|The Erchonia® EVRL™ is made up of (2) 405-nanometer violet laser diodes mounted in a portable handheld device.
62034338|NCT05374421|PLACEBO_COMPARATOR|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® THL™ but does not emit any therapeutic light.
62034339|NCT05735873|EXPERIMENTAL|Low-energy diet arm|Subjects who receive low-energy premade meals for three meals each day for 12 weeks.
62234529|NCT03406260|PLACEBO_COMPARATOR|Placebo|Participants received placebo tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
62425512|NCT01284569|EXPERIMENTAL|ALX-0061|
62034340|NCT03658174|ACTIVE_COMPARATOR|Nitrate-rich beetroot juice|70mls of concentrated beetroot juice to be taken twice a day. This contains 5-6 mmol of inorganic nitrate.
62034341|NCT03658174|PLACEBO_COMPARATOR|Nitrate-free beetroot juice|70mls of concentrated nitrate-free beetroot juice to be taken twice a day. This is an identical juice from which the nitrate has been removed using a standard anion exchange resin.
62034342|NCT04810598|EXPERIMENTAL|Group 1: Participants With Normal Renal Function|Participants with normal renal function will receive single dose of venetoclax on Day 1.
62034343|NCT04810598|EXPERIMENTAL|Group 2: Participants With End Stage Renal Disease|Participants with end stage renal disease (ESRD) will receive single dose of venetoclax on Period 1 Day 1 and Period 2 Day 1 (Each period is 3 days separated by 7-day washout period).
62034344|NCT03595904|EXPERIMENTAL|E-Motivate group|Participants complete a 20-minute tablet app, called e-Motivate, and receive usual care.
62034345|NCT03595904|ACTIVE_COMPARATOR|Usual Care Group|Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy
62034346|NCT05261178||Upper extremity amputation patients using myoelectric controlled prosthesis|20 patients aged 18-65 years with upper extremity amputation and using myoelectric controlled arm prosthesis for at least 3 months
62034347|NCT01337453||Flu-like symtoms, incidence|The frequency of FLS will be estimated by number of patients and number of Botox treatments.
62034348|NCT04959370|EXPERIMENTAL|Dynamic hip screw (DHS)|
62034349|NCT04959370|ACTIVE_COMPARATOR|Cannulated compression screw (CCS)|
62234530|NCT03281837|EXPERIMENTAL|Group 1: Hymovis plus Physical Exercise Program (PEP)|Intra-articular (IA) Hyaluronan (HA) (Hymovis 24mg/3mL) combined with Physical Exercise program (PEP)
62234531|NCT03281837|OTHER|Group 2: Physical Exercise Program (PEP) alone alone|Specified designed Physical Exercise Program (PEP) not combined with any other intervention
62425513|NCT01284569|PLACEBO_COMPARATOR|Placebo|
62425514|NCT01048268|EXPERIMENTAL|Healthy volunteers|
62425515|NCT01048268|EXPERIMENTAL|Patients with Type 1 diabetes mellitus|
62034350|NCT00922454|EXPERIMENTAL|Talent Stent-Graft|
62034351|NCT00922454|EXPERIMENTAL|Cook Zenith Stent-Graft|
62234532|NCT03281837|OTHER|Group 3: Cross-Over group|Patients who were randomized to receive only Physical Exercise Program (PEP) alone and do not respond after 3 months to this intervention will have the opportunity to cross-over to receive 2 intra-articular weekly injections, each injection given 1 week apart, of Hymovis.
62425516|NCT01048268|EXPERIMENTAL|Patients with type 2 diabetes mellitus|
62425517|NCT00546832|PLACEBO_COMPARATOR|1|placebo
62425518|NCT00546832|ACTIVE_COMPARATOR|2|celecoxib 200 mg qd p.o.
62425519|NCT00546832|EXPERIMENTAL|3|TDS-943 40 mg bid topically
62425520|NCT05341115|EXPERIMENTAL|Leuprorelin Acetate Depot 3M 11.25 mg|Participants with CPP having body weight ≥20 kg will receive the recommended dose of leuprorelin acetate depot 11.25 mg subcutaneous administration (SC) every 12 weeks based on the standard of 30～180ug/kg/4weeks for the 24-week Treatment Period. It is not recommended to exceed the dose above 180 μg/kg.
62425521|NCT01445873||PAH patients receiving Sitaxentan|
62819584|NCT06018337|EXPERIMENTAL|DB-1303/BNT323|Enrolled Subjects will be randomized to receive a 8 mg/kg IV dose of DB-1303/BNT323 on Day 1 of each cycle Q3W
62593893|NCT06642155|EXPERIMENTAL|RESPONSIBLEPLAY© MTM-Based Intervention|"Participants will receive a theory-based intervention designed to promote responsible gambling behaviors using the Multi-theory Model (MTM) of health behavior change. The intervention focuses on both the initiation and sustenance of responsible gambling through six constructs:~Participatory Dialogue: Discussing the pros and cons of responsible gambling. Behavioral Confidence: Building confidence to practice responsible gambling. Changes in the Physical Environment: Modifying surroundings to limit gambling opportunities.~Emotional Transformation: Managing emotions to maintain behavior change. Practice for Change: Planning and practicing responsible gambling strategies. Changes in the Social Environment: Leveraging support from family, friends, and professionals.~This intervention aims to provide practical strategies for adopting and maintaining responsible gambling behaviors."
62810647|NCT03177863|EXPERIMENTAL|Study cohort|"Healthy women 25 - 30 years of age with CIN2 who consent to inclusion and with no former history of CIN (any grade). The intervention is expectancy with clinical visits every 6 months. Women will leave study cohort if found with total regression (no CIN) or CIN3"
62034352|NCT02526693|OTHER|Glaucoma Patients|Glaucoma patients recruited from Wills Eye Hospital Glaucoma Service will be tested with the relative afferent pupillary defect test (RAPDx) Pupillometer. The noninvasive RAPDx measures the pupils response during light stimulation.
62034353|NCT02526693|OTHER|Healthy Controls|Healthy subjects with no eye diseases recruited from Wills Eye Hospital Glaucoma Service staff, family and friends will be tested with the relative afferent pupillary defect test (RAPDx) Pupillometer. The noninvasive RAPDx measures the pupils response during light stimulation.
62034354|NCT03007667||Colorectal cancer patients|Colorectal cancer patients
62034355|NCT00989287|EXPERIMENTAL|GSK2340272A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
62034356|NCT00989287|EXPERIMENTAL|GSK2340269A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
62034357|NCT05080166|EXPERIMENTAL|Clinicians Interviews|Lymphoma and mental health clinicians will participate in 1x in-depth qualitative interview to provide feedback for the development of the UPLYFT program.
62034358|NCT05080166|EXPERIMENTAL|Lymphoma Survivors Field Test|A six person group of lymphoma survivors will participate in a six session UPLYFT program field test to provide feedback for the development of the UPLYFT program.
62034359|NCT05080166|EXPERIMENTAL|UPLYFT Pilot|"Lymphoma survivors will participate in the phase 1 finalized, six session UPLYFT program.~Participants will be randomized 1:1 to either UPLYFT or usual care."
62234533|NCT04074785|EXPERIMENTAL|Safety Run-In|Abemaciclib 150 mg po bid PLUS Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
62234534|NCT04074785|EXPERIMENTAL|Abemaciclib with Bevacizumab|Abemaciclib 100 mg po bid PLUS Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
62425522|NCT00802269|EXPERIMENTAL|Reduced Fluence Parameters|Eyes receiving retinal photocoagulation with reduced fluence parameters (time 20-50 msec, power 400-700 mW)
62810648|NCT05698641||HFNC|Patients treated with HFNC
62810649|NCT05698641||NIV|Patients treated with NIV
62034360|NCT00983073|EXPERIMENTAL|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol IR tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
62234535|NCT06362213||participants with dual sensory loss|participants with both vision and hearing loss
62234536|NCT06362213||participants with vision loss|participants with vision loss only
62234537|NCT06362213||participants with hearing loss|participants with hearing loss only
62234538|NCT06362213||participants with normal vision and hearing|participants without vision or hearing loss
62810650|NCT06314386|OTHER|Exposed|Clinics are considered exposed after intensive SAIA-TB intervention, implementation phase, and maintenance phase.
62810651|NCT06314386|NO_INTERVENTION|Unexposed|Clinics are considered unexposed prior to the initiation of SAIA-TB in their clinic
62234539|NCT04452396|EXPERIMENTAL|patients|patients undergoing CGM monitoring
62234540|NCT04476056|EXPERIMENTAL|Chronic Pancreatitis + Malnutrition|Malnourished patients with chronic pancreatitis will receive intensified nutritional therapy for 6 months.
62234541|NCT00998426|EXPERIMENTAL|All study participants|Study procedures will occur one timebetween post-op day 1 and post-op day 7. Study procedures to include blood glucose monitoring prior to and after (various time points for 2 hours after) infusion with HBIG.
62425523|NCT00802269|ACTIVE_COMPARATOR|Traditional parameters|Eyes receiving retinal photocoagulation with traditional parameters (time 100-200 msec, power 200-400 mW)
62425524|NCT02441179|EXPERIMENTAL|Acute Intermittent Hypoxia Arm|AIH protocol: it consists of 15, 90-second hypoxic episodes (FiO2=0.09) interspersed with 15, 90-second normoxic intervals (FiO2=0.21) for a total time of 45 minutes. This protocol will be repeated every day for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks. After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
62425525|NCT02441179|PLACEBO_COMPARATOR|Normoxia Arm|Sham protocol: it consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
62425526|NCT01925742|EXPERIMENTAL|Low Risk of aneuploidy|Integrated prenatal screening for Down's syndrome (with follow-up fetal karyotype if positive); Serum QUAD Assay for aneuploidy screening; Semiconductor MPSS NIPT assay using ccfDNA in maternal blood; Optical-based MPSS NIPT assay using ccfDNA in maternal blood; Harmony™ Test (Ariosa Diagnostics)
62425527|NCT01925742|EXPERIMENTAL|High risk of aneuploidy|Integrated prenatal screening for Down's syndrome (with follow-up fetal karyotype if positive); Serum QUAD Assay for aneuploidy screening; Semiconductor MPSS NIPT assay using ccfDNA in maternal blood; Optical-based MPSS NIPT assay using ccfDNA in maternal blood; Harmony™ Test (Ariosa Diagnostics) (subset)
62425528|NCT04363294|OTHER|Participants|Patients who had TAVR and underwent evaluation for ATTR with PYP scan
62425529|NCT04559217|EXPERIMENTAL|Single arm with 68Ga-DOTATATE|all participants will undergo a PET scan with 68Ga-DOTATATE
62425530|NCT02306434|ACTIVE_COMPARATOR|Therapy by iCBT|Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.
62425531|NCT02306434|OTHER|Standard care-Counselling|Counselling for childbirth fear is given by the antenatal care midwife and by specially trained midwives working in collaboration with obstetricians at approximately 3-5 face to face counselling sessions. Often a visit to the delivery unit is included in the program and a care plan for the coming birth.
62425532|NCT05050357|ACTIVE_COMPARATOR|hormonal intrauterine device arm|
62425533|NCT05050357|ACTIVE_COMPARATOR|progestin arm|
62810652|NCT00711698|ACTIVE_COMPARATOR|1|In this arm patients will be randomized to receive a bolus of narcotic followed by PCA.
62810653|NCT00711698|ACTIVE_COMPARATOR|2|In this arm patients will be randomized to the current standard of care of bolus narcotic treatment.
62034361|NCT03464227|EXPERIMENTAL|UCB0107|Subjects randomized to this arm will receive UCB0107. This arm will consist of a maximum of 7 cohorts. The dose for cohort 1 will be fixed, proposed doses for cohorts 2,3,4,5,6 and 7 may be adapted based upon recommendation by the Safety Review Group.
62425534|NCT03940586|EXPERIMENTAL|Letermovir|Letermovir administered either orally or intravenously within 28 days post-transplant, once daily through week 14 (approximately 100 days). Dosing will vary based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
62425535|NCT04304846||AMPLIFy group|Mother, premature child and teacher will complete questionnaires and interviews on attachment, maternal stress and child behavior
62425536|NCT03719261|ACTIVE_COMPARATOR|sodium hypochlorite|Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
62425537|NCT03719261|EXPERIMENTAL|chitosan nanoparticles|Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
62425538|NCT00731510|EXPERIMENTAL|1|Carbohydrate supplements (drinks and gels)
62425539|NCT00731510|PLACEBO_COMPARATOR|2|Primarily Aspartame plus natural flavourings. Powder dissolved in water to provide non-distinguishable placebo drink.
62810654|NCT01528059|ACTIVE_COMPARATOR|Billroth II|After stomach resection, the remnant stomach is connected to the jejunum.
62034362|NCT03464227|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive matching Placebo to UCB0107. This arm will consist of a maximum of 7 cohorts.
62034363|NCT02430194|EXPERIMENTAL|lonafarnib/ritonavir - I|lonafarnib 100 mg BID + ritonavir 100 mg QD
62034364|NCT02430194|EXPERIMENTAL|lonafarnib/ritonavir - II|lonafarnib 100 mg BID + ritonavir 50 mg BID
62034365|NCT02430194|EXPERIMENTAL|lonafarnib/ritonavir - III|lonafarnib 100 mg QD + ritonavir 100 mg QD
62034366|NCT02430194|EXPERIMENTAL|lonafarnib/ritonavir - IV|lonafarnib 150 mg QD + ritonavir 100 mg QD
62034367|NCT02430194|EXPERIMENTAL|lonafarnib/ritonavir/PEG IFN-a - V|lonafarnib 75 mg BID + ritonavir 100 mg BID (+ PEG IFN-a 180 ug QW on Week 12)
62034368|NCT02430194|EXPERIMENTAL|lonafarnib/ritonavir - VI|lonafarnib 25 mg BID + ritonavir 100 mg BID
62034369|NCT02430194|EXPERIMENTAL|lonafarnib/ritonavir - VII|lonafarnib 50 mg BID + ritonavir 100 mg BID
62034370|NCT02430194|EXPERIMENTAL|lonafarnib/ritonavir/PEG IFN-a - VIII|lonafarnib 50 mg BID + ritonavir 100 mg BID (+ PEG IFN-a 180 ug QW on Week 12)
62034371|NCT02430194|EXPERIMENTAL|lonafarnib/ritonavir/PEG IFN-a - IX|lonafarnib 25 mg BID + ritonavir 100 mg BID + PEG IFN-a 180 ug QW
62810655|NCT01528059|ACTIVE_COMPARATOR|Roux en Y|After stomach resection, the remnant stomach is connected to the distal jejunum while duodenum and the proximal jejunum is reconnected to jejunum.
62810656|NCT01722305|EXPERIMENTAL|Treatment (pomalidomide, dexamethasone)|Patients receive pomalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 of courses 1 and 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62810657|NCT02785848||Asthma and/or Sickle Cell Anemia|The investigators will examine patients with sickle cell disease, asthma, or both who are aged 12-70 years who take daily medications.
62810658|NCT06279858|EXPERIMENTAL|Probiotics|Each participant receives probiotic for 3 months (12 weeks). Participants act as their own controls by measuring the microbiome and other parameters before and after taking the probiotics. This was chosen because individual's microbiome is highly personalized. The unique composition of an individual's microbiome can have implications for the effectiveness of probiotics. All participants will receive probiotic mixture which contains: (i) Lactobacillus casei BL 2401 (40%), (ii) Lactobacillus salivarius BL 2201 (40%) (iii) Bifidobacterium breve BL 3406 (20%). Total amount is 5 x109 CFU in one HPMC capsule, at the end of the shelf life. These strains are registered and preserved in the French National Collection of Cultures of Microorganisms (CNCM, Collection Nationale de Cultures de Microorganismes). They are on EFSA's QPS (Qualified and Presumption of Safety) list and are considered safe for use in food and dietary products
62810659|NCT03118310|PLACEBO_COMPARATOR|Placebo|Placebo diet
62034372|NCT02430194|EXPERIMENTAL|lonafarnib/ritonavir/PEG IFN-a - X|lonafarnib 50 mg BID + ritonavir 100 mg BID + PEG IFN-a 180 ug QW
62034373|NCT01318343||Treatment Group 1|Eight (8) subjects will receive one (1) treatment with the eZ8 Large Applicator.
62425540|NCT05764902|NO_INTERVENTION|Control|Patients will receive standard of care.
62810660|NCT03118310|EXPERIMENTAL|5:2|5:2 diet
62810661|NCT03118310|EXPERIMENTAL|LCHF|LCHF diet
62810662|NCT05003375||Multiple Sclerosis (MS)|People with MS diagnosis, aged 18-55 years, Relapsing Remitting type, EDSS \< 6.0, normal vision (if necessary corrected), Dutch speaking.
62810663|NCT05003375||Healthy Controls (HC)|Healthy controls without relevant health conditions (diabetes, thyroid diseases, neurological disorders), non-pregnant, aged 18-55 years, normal vision (if necessary corrected), Dutch speaking.
62034374|NCT01318343||Treatment Group 2|Eight (8) subjects will receive two (2) treatments two (2) months apart with the eZ8 Large Applicator.
62034375|NCT01318343||Treatment Group 3|Four (4) subjects will receive one (1) treatment, six (6) months after the previous treatment with the eZ App 8 large applicator to the abdomen. This is the same applicator that is being evaluated in this study. These subjects have been treated on-site at the Laser \& Skin Surgery Center of New York by the study doctor.
62034376|NCT05829161||ASD Group|ASD participants, no intervention
62234542|NCT03977662|EXPERIMENTAL|PTG with adult pancreatic islet co-transplantation|People with Type 1 (c-peptide negative) diabetes with stable kidney or liver allografts on chronic immunosuppression who receive study intervention, which is co-transplantation of allogeneic parathyroid (PTG) with adult pancreatic islets in people with Type 1 diabetes in the intramuscular (IM) site
62425541|NCT05764902|EXPERIMENTAL|Intervention|The intervention group will be given an additional questionnaire assessing individual needs and preferences. CICU staff will provide patient-tailored interventions based on the expressed needs and preferences of those in the intervention group.
62425542|NCT02585531|EXPERIMENTAL|HS3% group|Administration of nebulized hypertonic saline for 4 days. Hypertonic Saline 3% 3 ml.
62425543|NCT02585531|ACTIVE_COMPARATOR|ED group|Administration of nebulized epinephrine and dexamethasone for 4 days. Epinephrine 1:1000 solution. Dexamethasone solution 8mg/2ml.
62425544|NCT03341715|EXPERIMENTAL|Mavoglurant (AFQ056)|The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
62810664|NCT05671692|ACTIVE_COMPARATOR|Pregnenolone|
62810665|NCT05671692|PLACEBO_COMPARATOR|Placebo|
62034377|NCT05829161||TD Group|TD participants, no intervention
62034378|NCT05916651|EXPERIMENTAL|Intervention (LOS training) + care as usual (intervention group)|Intervention group: mindfulness (LOS) training + CAU
62234543|NCT05768256|EXPERIMENTAL|Advanced cancer patients|
62234544|NCT02019589|ACTIVE_COMPARATOR|Progesterone 225 mg/day|Progesterone + Placebo
62234545|NCT02019589|ACTIVE_COMPARATOR|Progesterone, 300 mg/ day|Progesterone + Placebo
62234546|NCT02019589|PLACEBO_COMPARATOR|Placebo|Placebo
62234547|NCT00273767|EXPERIMENTAL|1|epoetin beta
62234548|NCT00273767|PLACEBO_COMPARATOR|2|placebo of NaCl
62234549|NCT01529463||Disease Management|
62234550|NCT02624323|EXPERIMENTAL|Axillary catheterization|Real-time ultrasound-guided axillary vein catheterization, in plain technique.
62234551|NCT02624323|EXPERIMENTAL|Jugular catheterization|Real-time ultrasound-guided jugular vein catheterization, out of plain technique.
62234552|NCT01415154|EXPERIMENTAL|Scheduled Treatment Arm|3 Week TMS taper, clinical assessments and one NeuroStar TMS session every 4th week of block and TMS reintroduction as needed for clinical deterioration.
62425545|NCT03341715|PLACEBO_COMPARATOR|Placebo|The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
62810666|NCT04789252||Patients with NSCLC or with colon cancer|"The subjects are men or women with aged more than 18 years suffering from colon or lung cancer; The lesions are more than 1 cm. They are also able to give informed consent.~The pathologist will sample the material and select the tissue that can be used for the experiment after having taken all that is needed for diagnostic purposes. The research sample will be placed in test tubes and kept on ice.~It will then be sent to University of Milano-Bicocca laboratory whrere It will analyze approximately 60 patients for immunofluorescence studies and 4 patients for single cell transcriptomic analyzes"
62810667|NCT04931264|EXPERIMENTAL|YuWell YE660D and mercury sphygmomanometer|Blood Pressure Measurement with the YuWell YE660D Electronic Sphygmomanometer (YuWell YE660D) and with Desk Mercury Sphygmomanometer.
62810668|NCT03517475|EXPERIMENTAL|Supervising for Home Safety modified|We will train caregivers to provide adequate levels of supervision to the 3-4 year-old children.
62810669|NCT03517475|PLACEBO_COMPARATOR|Services as Usual|Clients will receive home visiting services from Head Start
62034379|NCT05916651|ACTIVE_COMPARATOR|Care-as-usual (CAU)-only (control group)|Control group: CAU-only
62034380|NCT06636526||Part 1|People with a prostate aged 40-55 years of either (i) Black African and Black African-Caribbean, (ii) South Asian or East Asian or (iii) White European ancestry to undergo genetic testing using the i4i PRODICT™ test to identify those at higher genetic risk for prostate cancer targeted screening.
62034381|NCT06636526||Part 2|Those classified as high-risk due to either falling within the high polygenic risk score category, and/or having a rare variant in a gene in the i4i PRODICT™ test will be offered a hospital clinic appointment at the Royal Marsden Hospital to discuss prostate cancer screening.
62034382|NCT04087148||patients|patients who were diagnosed as having CAH of at least 1 y duration. and On glucocorticoid replacement therapy .
62034383|NCT04087148||controls|A comparable number of age and sex matched apparently normal children will be included as control.
62034384|NCT01695967|EXPERIMENTAL|Turbinate Cauterization|Turbinate Cauterization will be completed.
62034385|NCT01695967|NO_INTERVENTION|control|no turbinate cauterization
62034386|NCT06164626|EXPERIMENTAL|Experimental: Group 1|15 patients who will only have their first teeth or second molars extracted.
62034387|NCT06164626|EXPERIMENTAL|Experimental:Group 2|15 patients who will have only their first or second molars extracted and will receive infrared laser treatment
62034388|NCT06164626|EXPERIMENTAL|Experimental: Group 3|15 patients who will have their first or second molars extracted and will receive a graft with scaffold biomaterial
62034389|NCT06164626|EXPERIMENTAL|Experimental:Group 4|15 patients who will have their first or second molars extracted and will receive a graft with scaffold biomaterial and infrared laser treatment
62034390|NCT02891187|ACTIVE_COMPARATOR|Outpatient Clinic Visits|Outpatient clinic visits for postoperative care is currently the standard of care. Patients who undergo surgery for a pelvic floor disorder will be scheduled appointments in the outpatient clinic at 1-2 weeks, 6 weeks, and 3 months where they will be evaluated by a physician.
62034391|NCT02891187|ACTIVE_COMPARATOR|Telephone Follow-up|Patients will be called instead of returning to clinic for postoperative care at 1-2 weeks, 6 weeks, and 3 months.
62034392|NCT03725644|EXPERIMENTAL|parent-training program|Parents in the treatment group received the parent-training program based on the DIR model. The parent-training program encouraged child-initiated activities according to the functional developmental levels. The treatment intensity and duration were the same for both groups including 3-week courses and 11-week home programs. The investigators in this study are two registered pediatric occupational therapists who have at least five years of early intervention experience and had studied the DIR model.
62034393|NCT03725644|EXPERIMENTAL|traditional program|Parents in the control group received the traditional program based on the developmental approach. The traditional program provided parent-lead activities that fit child's developmental stage.
62034394|NCT02267395||(No-PRMSDs)|Group 1 : No Playing Related Musculoskeletal Injury
62034395|NCT02267395||(Yes-PRMSDs)|Group 2: Playing Related Musculoskeletal Injury
62034396|NCT02530307|EXPERIMENTAL|HT-3951 (15mg)|HT-3951 capsules administered once daily
62034397|NCT02530307|PLACEBO_COMPARATOR|Placebo|Placebo capsules administered once daily
62034398|NCT05496127|EXPERIMENTAL|Sensorimotor Exercise Group|Sensorimotor exercise group; oculomotor exercise to provide information from the visual system, laser target exercise to provide information from the proprioception system, and postural stability exercise to provide information from the vestibular system. Within the scope of oculomotor exercise, gaze stability exercise and head-body coordination exercise will be given to the participants. Laser target exercise will be given with the laser target fixed on the participant's head and 90 cm away from the target. Postural stability exercise will be given in the form of tandem exercise and standing on one leg.
62034399|NCT05496127|EXPERIMENTAL|Yoga Exercise Group|Yoga group will be given yoga exercises including 14 poses. These exercises are: bridge pose, corpse pose, bharadvaja's twist, downward facing dog, downward facing hero, extended side angle, extended triangle, mountain pose, prosperous pose, reclining big toe, standing half forward bend, thunderbolt pose, upward hand pose, warrior pose II.
62034400|NCT04455672|EXPERIMENTAL|interventional group|patient using two types of splints (3d Anterior Rrepositioning Splint then printed stabilizing splint)
62034401|NCT04455672|ACTIVE_COMPARATOR|control group|patient using two types of splints (3d printed stabilizing splint then Anterior Rrepositioning Splint)
62034402|NCT03347968|EXPERIMENTAL|MEDI0382|All participants will receive MEDI0382.
62234553|NCT01415154|EXPERIMENTAL|Monthly Observational Follow up Arm|3 Week TMS Taper, clinical assessments and office follow up every 4th week of block and NeuroStar TMS reintroduction as needed for clinical deterioration.
62234554|NCT00908232|EXPERIMENTAL|Stable Disease: VD|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8
62234555|NCT00908232|EXPERIMENTAL|Stable Disease: VDC|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and cyclophosphamide 500 mg, orally daily, days 1, 8 and 15 for cycle 5 to 8
62034403|NCT03347968|ACTIVE_COMPARATOR|Warfarin|All participants will receive Warfarin
62034404|NCT03347968|ACTIVE_COMPARATOR|Esmolol|All participants will receive Esmolol
62425546|NCT06515171||CD patients referred for PC before VCE|"No intervention will be administered. Endoscopic capsule protocol will be performed in a uniform manner on all participants in the study as part of their routine clinical evaluation regardless of the study.~The patient will report capsule expulsion and send a photo for documentation or report the result of the abdominal X-ray preformed 28-30 hours post swallowing"
62593894|NCT06642155|ACTIVE_COMPARATOR|Knowledge-Based Intervention|Participants will receive educational content about the risks of gambling and strategies for responsible gambling in the form of lectures and reading materials.
62593895|NCT03762239|ACTIVE_COMPARATOR|Purified air|Purifying the air with a Pure Airbox device (Zonair 3D). Use of air purifier (Pure Airbox, Zonair 3D) in the classroom 30 minutes before the participants enter the room and during the 2 hours of the experiment.
62593896|NCT03762239|SHAM_COMPARATOR|Normal air|Using a sham air purifier (same device without filters). Use of the same air purifier but without filters, so that it only recirculates the air without purifying it. Used for the same time period than the other arm.
62810670|NCT06082934|EXPERIMENTAL|OVD regimen of Olverembatinib plus venetoclax and dexamethasone|Olverembatinib: orally every other day at a dose of 40mg Venetoclax: in a daily ramp-up strategy (100 mg d4, 200 mg d5, 400 mg d6-17) Dexamethasone: intravenously 10mg, d1-14, 5mg, d15-28
62810671|NCT06002412||Beijing Obstetrics and Gynecology Hospital affiliated to Capital Medical University|Beijing Obstetrics and Gynecology Hospital affiliated to Capital Medical University collects clinical information and ultrasound images of sagittal, NT and choroid plexus views of the fetus which was obtained from early pregnant women who underwent NT sweeps.
62810672|NCT06002412||Peking University Third Hospital|Peking University Third Hospital collects clinical information and ultrasound images of sagittal, NT and choroid plexus views of the fetus which was obtained from early pregnant women who underwent NT sweeps.
62810673|NCT06002412||Changsha Hospital for Maternal and Child Health Care|Changsha Hospital for Maternal and Child Health Care collects clinical information and ultrasound images of sagittal, NT and choroid plexus views of the fetus which was obtained from early pregnant women who underwent NT sweeps.
62234556|NCT00908232|EXPERIMENTAL|Stable Disease: VDL|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and lenalidomide 10 mg orally daily from day 1 to day 14 for cycle 5 to 8
62234557|NCT00908232|EXPERIMENTAL|Complete to Partial Response: VD|Complete, very good partial or partial response after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8
62234558|NCT06354686|EXPERIMENTAL|Single Arm|This will be a single arm study with measurements of scalp location and TMS stimulation parameters.
62234559|NCT00975507|EXPERIMENTAL|1|ProQuad™ (V221) + Placebo Followed by ProQuad™
62234560|NCT00975507|ACTIVE_COMPARATOR|2|M-M-R™ II + VARIVAX™
62234561|NCT02528565||Patients with failed RYGB (EWL <50%)|
62234562|NCT03458286|NO_INTERVENTION|Control group|The control group will be required to attend the diabetic foot clinic for their usual care for their diabetic foot ulcer with weekly review for a maximum of eight weeks. They will also have a follow up appointment 4 weeks after completion of treatment.
62234563|NCT03458286|EXPERIMENTAL|Experimental Arm|A device- BRH-A2 wound healing device will provide Combined ultrasound and electric current stimulation (CUSECS) treatment which is the intervention for this arm. Participants in this group will receive an adjunctive combined ultrasound and electric current stimulation (CUSECS) treatment along their usual treatment for their diabetic ulcer twice weekly for 8 weeks using the BRH-A2 wound healing device. They will also have a follow up appointment 4 weeks after completion of treatment.
62433648|NCT06105619|ACTIVE_COMPARATOR|Temozolomide or Cisplatin combined with etoposide|"Investigators can choose one of two treatments~1. Dose density of temozolomide：100-150mg/m2/d,day 1 to 7 and day 15 to 22 of each 28-day cycle~2. Cisplatin combined with etoposide：Cisplatin,80-100mg/m2/3 days,28 days/cycle.etoposide, 100mg/m2/d,3 days,28 days/cycle"
62593897|NCT02262689|EXPERIMENTAL|GSK2256294 15 mg|Randomised subjects will be instructed to take three capsules of GSK2256294 15 mg, each morning for 7 days. Subjects will undergo echocardiography under normoxic and hypoxic conditions on Day 1 pre-dose and on Day 7 post-dose.
62593898|NCT02262689|PLACEBO_COMPARATOR|Placebo|Randomised subjects will be instructed to take three capsules of matching placebo, each morning for 7 days. Subjects will undergo echocardiography under normoxic and hypoxic conditions on Day 1 pre-dose and on Day 7 post-dose.
62234564|NCT05694520|NO_INTERVENTION|Stand care control group (CG)|According to the Chinese nutritional guidelines for GDM women, the energy intake of 1500-1800 kcal/d will be recommended for the included participants, who all have the pregestational BMI≥24 kg/m2. Standard care and a balanced diet will be recommended to the women in CG incorporating nuts intake of less than 2.5 oz per week.
62234565|NCT05694520|EXPERIMENTAL|Intervention group (IG)|The participants in the IG will be offered the otherwise same diet as their counterparts in the CG, except for the extra intake of pistachios of 1.5 oz thrice per week.
62234566|NCT03572322||Doctors|
62234567|NCT03572322||Patients|
62234568|NCT00141323|EXPERIMENTAL|lasofoxifene 0.5 mg/day|
62234569|NCT00141323|PLACEBO_COMPARATOR|placebo|
62234570|NCT00141323|EXPERIMENTAL|lasofoxifene 0.25 mg/day|
62234571|NCT04788498|EXPERIMENTAL|Laparoendoscpoic single site surgery LESS|35 patients undergoing laparoscopic ovarian cystectomy A SILS Port (Covidien®) with three access inlets will be inserted into the abdominal cavity using a Heaney clamp
62234572|NCT04788498|ACTIVE_COMPARATOR|Conventional multiport laparoscopy|35 patients undergoing laparoscopic ovarian cystectomy It will be performed using a three-port system using a closed technique on the umbilicus, left and right lower quadrant area.
62234573|NCT02378831||PSG and WatchPAT200 in subjects age12-17|Adolescents refered to a sleep lab for sleep lab for full night PSG
62234574|NCT03343847|EXPERIMENTAL|Romiplostim|the study in a 2:1 randomization ratio(108 subjects to romiplostim)
62234575|NCT03343847|PLACEBO_COMPARATOR|Placebo|the study in a 2:1 randomization ratio (54 subjects to placebo)
62234576|NCT06221150|EXPERIMENTAL|SAPB group|
62234577|NCT06221150|NO_INTERVENTION|control|
62234578|NCT01862640|PLACEBO_COMPARATOR|Placebo|Matching placebo once daily
62425547|NCT06515171||CD patients who failed to pass an initial protocol PC on a previous attempt.|All the patients who failed the PC test will be scheduled for another test with a different preparation protocol, a common practice also today. This will be done as a standard procedure, in the clinical setting of the endoscopic capsule clinic and not as part of the study. Again, the patient will report capsule expulsion and send a photo for documentation or report the result of the abdominal X-ray preformed 28-30 hours post swallowing. If the second test was positive as well, an abdominal x-ray will be performed within 2 weeks to rule out PC retention - standard protocol for PC retention.
62234579|NCT01862640|EXPERIMENTAL|Brexpiprazole 1 mg|Titrate up from 0.25 milligrams (mg)/day brexpiprazole to 1 mg/day brexpiprazole
62234580|NCT01862640|EXPERIMENTAL|Brexpiprazole 2 mg|Titrate up from 0.25 mg/day brexpiprazole to 2 mg/day brexpiprazole
62234581|NCT03736161|EXPERIMENTAL|Group A- Tofacitinib|Tofacitinib 5mg twice daily orally. Patients with inadequate response to Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 10 mg BD.
62234582|NCT03736161|PLACEBO_COMPARATOR|Group B- Methotrexate|Methotrexate in increasing dose starting from 15 mg weekly to a maximum dose of 25 mg weekly from the end of 1st month. Patients with inadequate response to highest dose of MTX at the end of 3 months will be put on Tofacitinib 5 mg BD.
62425548|NCT04242368|ACTIVE_COMPARATOR|Isotonic rinse, then hypertonic rinse|Participants will start with a one week washout period without rinses. Then they will complete twice daily sinus rinses isotonic saline for two weeks. Next they will have a one week washout period without rinses. Then they will cross-over and complete hypertonic saline sinus rinses for two weeks. Participants will maintain fluticasone treatment throughout the study.
62425549|NCT04242368|EXPERIMENTAL|Hypertonic rinse, then isotonic rinse|"Participants will start with a one week washout period without rinses. Then they will complete twice daily sinus rinses of hypertonic saline for two weeks. Next they will have a one week washout period without rinses. Then they will cross-over and complete isotonic saline sinus rinses for two weeks. Participants will maintain fluticasone treatment throughout the study.~Fluticasone propionate nasal spray - two sprays to each nare twice a day used for the entire study duration"
62810674|NCT06002412||Second Xiangya Hospital of Central South University|Second Xiangya Hospital of Central South University collects clinical information and ultrasound images of sagittal, NT and choroid plexus views of the fetus which was obtained from early pregnant women who underwent NT sweeps.
62810675|NCT00271635|EXPERIMENTAL|1|Ascorbic acid
62810676|NCT00271635|PLACEBO_COMPARATOR|2|Placebo
62034405|NCT03996473|EXPERIMENTAL|Phase 1: Radium-223+Pembrolizumab|Participants received radium-223 dichloride at 55 kBq/kg every 6 weeks in combination with pembrolizumab every 3 weeks.
62234583|NCT02441712|EXPERIMENTAL|Motor PENS|Motor PENS will be a strong tri-phasic stimulation pattern to the hip, quadriceps, hamstring, and adductors for strength training (50Hz impulses for 200ms every 1500 ms). The stimulus will be administered for 15-minutes followed by the impairment rehabilitation program.
62234584|NCT02441712|SHAM_COMPARATOR|Subsensory PENS|Subsensory PENS will be a sub sensory stimulus also administered by a tri-phasic stimulation pattern to the hip, quadriceps, hamstring, and adductors (50Hz impulses for 200ms every 1500ms). The stimulus will be administered for 15-minutes followed by the impairment rehabilitation program
62425550|NCT04276285|ACTIVE_COMPARATOR|Laparoscopic TAP|Subcostal TAP block will be performed after surgery under laparoscopic guidance
62810677|NCT04669223|OTHER|Seldinger chest drain 14F|Patients with seldinger chest drain 14F inserted
62810678|NCT04669223|ACTIVE_COMPARATOR|Seldinger chest drain 8F|Patients with seldinger chest drain 8F inserted
62810679|NCT00675714|EXPERIMENTAL|1|Humatrope subcutaneous(SQ) 0.05-0.2 mg/kg/day for up to 2 years post burn
62810680|NCT00675714|EXPERIMENTAL|2|Ketoconazole by mouth (PO) given twice a day throughout hospitalization for up to 2 years post burn
62810681|NCT00675714|EXPERIMENTAL|3|Oxandrolone PO given daily throughout hospitalization for up to 2 years post burn
62234585|NCT01906346|EXPERIMENTAL|Low Value Alternative Reinforcer|A low value reinforcer will be made available as an alternative to cocaine and placebo.
62234586|NCT01906346|EXPERIMENTAL|Medium Value Reinforcer|A medium value reinforcer will be made available as an alternative to cocaine and placebo.
62425551|NCT04276285|ACTIVE_COMPARATOR|US TAP|Subcostal TAP block will be performed after surgery under ultrasound guidance
62810682|NCT00675714|EXPERIMENTAL|4|Propranolol PO given daily throughout hospitalization for up to 2 years post burn
62810683|NCT00675714|EXPERIMENTAL|5|Oxandrolone and propranolol PO to be given daily for up to 2 years post burn
62810684|NCT00675714|EXPERIMENTAL|6|Humatrope SQ and Propranolol PO to be given daily for up to 2 years post burn
62810685|NCT00675714|PLACEBO_COMPARATOR|7|Placebo PO to be given for up to 2 years post burn
62034406|NCT03996473|EXPERIMENTAL|Phase 2 Cohort 1: Radium-223+Pembrolizumab|Participants was planned to receive radium-223 dichloride at the maximum tolerated dose (MTD) to be determined in the Phase 1 part every 6 weeks in combination with 200 mg pembrolizumab every 3 weeks.
62034407|NCT03996473|ACTIVE_COMPARATOR|Phase 2 Cohort 1: Pembrolizumab alone|Participants was planned to receive 200 mg pembrolizumab every 3 weeks.
62425552|NCT04276285|NO_INTERVENTION|No TAP|No TAP block will be performed
62425553|NCT04325061|NO_INTERVENTION|Control group|Patients will be treated with standard intensive care
62425554|NCT04325061|ACTIVE_COMPARATOR|Dexamethasone|Standard intensive care plus dexamethasone
62425555|NCT02460315|ACTIVE_COMPARATOR|early cholecystectomy|group (A) will be managed by early laparoscopic cholecystectomy after clearness ERCP
62425556|NCT02460315|ACTIVE_COMPARATOR|late cholecystectomy|group (B) will be managed by late LC one month after ERCP.
62425557|NCT03964220||Patients with Asthma|
62425558|NCT04442373||Patients undergoing THR with no known bone neoplasm|Pre- and postoperative blood sampling for ROTEM assessment in THR patients
62425559|NCT04442373||Patients undergoing THR with known bone neoplasm|Pre- and postoperative blood sampling for ROTEM assessment before and after THR in patients with bone neoplasm
62425560|NCT01020773|ACTIVE_COMPARATOR|SBT group|In the SBT group, the patients underwent a 1 hr SBT with inspiratory PS of 7 cmH2O with other settings remaining constant (FiO2, PEEP, trigger sensitivity). The patients who tolerated the SBT underwent immediate extubation.
62425561|NCT01020773|NO_INTERVENTION|no-SBT group|In no-SBT group, as soon as a patient met readiness criteria, he or she underwent extubation without SBT process.
62425562|NCT02129530|EXPERIMENTAL|Community Social Mobilization Program|A manualized intervention developed with Sonke Gender Justice Network using a workshop intervention manual and a community mobilization toolkit will be used.
62425563|NCT02129530|NO_INTERVENTION|Control Arm|The Control Arm does not receive the Community Mobilization Intervention
62425564|NCT02295280|ACTIVE_COMPARATOR|Metoclopramide IV & Diphenhydramine IV|Intravenous (IV) access will be obtained and administration of 10mg Metoclopramide IV and 25mg Diphenhydramine IV Group A
62034408|NCT03996473|EXPERIMENTAL|Phase 2 Cohort 2: Radium-223+Pembrolizumab|Participants was planned to receive radium-223 dichloride at the MTD to be determined in the Phase 1 part every 6 weeks in combination with 200 mg pembrolizumab every 3 weeks.
62034409|NCT03973619|ACTIVE_COMPARATOR|Labial|Patients who received a labial graft as replacement of urethral tissue
62034410|NCT03973619|ACTIVE_COMPARATOR|Jugal|Patients who received a jugal (inner cheek) graft as replacement of urethral tissue
62034411|NCT05258825|EXPERIMENTAL|Intravenous Iron Infusion Arm|If the patient is found to have iron deficiency anemia, the patient will receive IV iron preoperatively. Patients that agree to be enrolled in the study will be scheduled for the IV iron dose approximately 3-4 weeks prior to surgery. A single IV dose of 1000 mg of Monoferric will be administered. This will be administered at the Brigham and Women's Hospital infusion center and coordinated with the Hematology team.
62034412|NCT04769167|PLACEBO_COMPARATOR|Healthy Non Pregnant Women (HNPW)|HNPW are healthy women and not pregnant
62034413|NCT04769167|ACTIVE_COMPARATOR|Diabetic Non Pregnant Women (DNPW)|DNPW are diabetic and not pregnant
62425565|NCT02295280|ACTIVE_COMPARATOR|Codeine|Group B (control group) will receive standard treatment consisting of a codeine 30mg tablet.
62810686|NCT00675714|EXPERIMENTAL|8|Exercise--hospital supervised intensive exercise program
62034414|NCT04769167|PLACEBO_COMPARATOR|Healthy Pregnant Women (HPW)|HNPW are healthy women and currently pregnant
62034415|NCT04769167|ACTIVE_COMPARATOR|Diabetic Pregnant Women (DPW)|DNPW are diabetic and currently pregnant
62034416|NCT04575467|EXPERIMENTAL|CBL-514 320 mg|CBL-514 will be administered via injection into the thigh subcutaneous adipose layer.
62425566|NCT01456000|EXPERIMENTAL|EAS-AC (HeartLight)|Treatment with the EAS-AC.
62425567|NCT01456000|ACTIVE_COMPARATOR|Control Arm Ablation|Treatment with standard ablation.
62425568|NCT00959387|EXPERIMENTAL|Induction TP chemotherapy followed by CRT|paclitaxel 175mg/m2 as a 3-h infusion on Day 1, and cisplatin 80mg/m2 as a 2-h infusion on Day 1 three weekly followed by concurrent chemoradiotherapy based on cisplatin. All patient were given adequate hydration and antiemetics. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
62425569|NCT04857684|EXPERIMENTAL|Stereotactic beam radiation therapy (SBRT) +Atezolizumab + Bevacizumab|"Participants will:~* undergo a pre-treatment biopsy with fiducial marker placement~* receive Stereotactic beam radiation therapy (SBRT) on three treatment days which will be arranged on an every-other-day basis~* receive two 3-week (21 days) cycles of atezolizumab plus bevacizumab~  * receive Atezolizumab on day 1 for 2 study cycles.~ * receive Bevacizumab 1x weekly for 2 study cycles~* Surgery after SBRT and the two cycles of atezolizumab and bevacizumab, unless participants are otherwise informed by their doctor. The planned surgery will take place 6-8 weeks after the last infusions of atezolizumab and bevacizumab."
62425570|NCT05614999|ACTIVE_COMPARATOR|Training group|Participants in this group will do the pre-training test, practicing eight-sessions (each session is approximately 15minutes) and then do the post-training test.
62425571|NCT05614999|NO_INTERVENTION|Non-training group|Participants in this group will do the pre-training test, and then do the post-training test after the pre-test 4-6weeks.
62425572|NCT02362594|EXPERIMENTAL|Pembrolizumab|In Part 1, participants receive pembrolizumab 200 mg intravenously (IV) as post-surgery therapy every 3 weeks (Q3W) for up to 1 year. During Part 2, participants with documented recurrence may receive optional re-treatment with pembrolizumab Q3W for up to 2 years or disease progression.
62433649|NCT05483920|EXPERIMENTAL|One-time educational video|A one-time educational video on best practices for good sleep hygiene
62810687|NCT00675714|EXPERIMENTAL|9|Exercise--home or community based exercise program
62034417|NCT04575467|EXPERIMENTAL|CBL-514 480 mg|CBL-514 will be administered via injection into the abdomen subcutaneous adipose layer.
62034418|NCT04575467|EXPERIMENTAL|CBL-514 640 mg|CBL-514 will be administered via injection into the abdomen subcutaneous adipose layer.
62810688|NCT05255523|EXPERIMENTAL|Arm 1|Pyrotinib：400mg qd po continuous medication Capecitabine: 1000 mg/m2 bid po for 14 consecutive days with 7 days off, every 21 days as a cycle.
62810689|NCT01393834|EXPERIMENTAL|Delayed cord clamping|Delayed cord clamping for 30 seconds
62810690|NCT01393834|EXPERIMENTAL|Milking of the cord|Milking of the cord 4 times in 10 seconds
62810691|NCT01393834|NO_INTERVENTION|Immediate cord clamping|Immediate cord clamping after delivery
62810692|NCT01519323|EXPERIMENTAL|Vemurafenib|Participants received vemurafenib into two separate cohorts with different starting doses based on greater than or equal to (\>=)45 kilogram (kg) and other weighing less than (\<)45 kg. The starting dose for participants (\>=45 kg) was 720 milligram (mg) of vemurafenib by mouth twice daily (BID) and the next dose level for participants in this cohort was 960 mg by mouth BID. The starting dose level for participants weighing \<45 kg was to be 480 mg of vemurafenib by mouth BID, but no participants were enrolled into this cohort.
62810693|NCT05077826|EXPERIMENTAL|Full Current tES|TES delivered with the anode over the right temple and cathode on the left arm, at an intensity of up to 4 milliamps, delivered for up to 40 minutes.
62810694|NCT05077826|PLACEBO_COMPARATOR|Partial Current tES|TES delivered with the anode over the right temple and cathode on the left arm, at an intensity of 0.1 milliamp, delivered for up to 40 minutes.
62034419|NCT04575467|EXPERIMENTAL|CBL-514 800 mg|CBL-514 will be administered via injection into the abdomen subcutaneous adipose layer.
62034420|NCT03860857|EXPERIMENTAL|Age 60-65 ApoE e4+|Participants in this cohort are between the ages of 60-65 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
62034421|NCT03860857|EXPERIMENTAL|Age 66-70 ApoE e4-|Participants in this cohort are between the ages of 66-70 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
62034422|NCT03860857|EXPERIMENTAL|Age 66-70 ApoE e4+|Participants in this cohort are between the ages of 66-70 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
62034423|NCT03860857|EXPERIMENTAL|Age 71-75 ApoE e4-|Participants in this cohort are between the ages of 71-75 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
62034424|NCT03860857|EXPERIMENTAL|Age 71-75 ApoE e4+|Participants in this cohort are between the ages of 71-75 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
62034425|NCT03860857|EXPERIMENTAL|Age 76-80 ApoE e4-|Participants in this cohort are between the ages of 76-80 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
62034426|NCT03860857|EXPERIMENTAL|Age 76-80 ApoE e4+|Participants in this cohort are between the ages of 76-80 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
62234587|NCT01906346|EXPERIMENTAL|High Value Reinforcer|A high value reinforcer will be made available as an alternative to cocaine and placebo.
62234588|NCT02357381||TMS Treatment|TMS( transcranial magnetic stimulation) -treatment for headache
62234589|NCT04484831|EXPERIMENTAL|ABT Weight Loss Intervention|Adolescent participants will attend sessions that include nutritional education and physical activity education and build skills in the areas of values clarification, mindfulness, self-regulation skills, acceptance of uncomfortable states, goal-setting, problem solving, and self-monitoring.
62234590|NCT04484831|PLACEBO_COMPARATOR|Enhanced Care|Adolescent participants will receive handouts on elements of a healthy lifestyle and will participate in a midpoint one-on-one nutrition consultation with a registered dietitian.
62234591|NCT00107120|EXPERIMENTAL|Escitalopram|Escitalopram 10mg once daily for three weeks, 10-20mg once daily for up to the remaining 5 weeks
62234592|NCT00107120|PLACEBO_COMPARATOR|2|Placebo once daily for up to 8 weeks
62234593|NCT00724295||Arm 1|Overall study population
62425573|NCT02362594|PLACEBO_COMPARATOR|Placebo|In Part 1, participants receive placebo IV as post-surgery therapy Q3W. During Part 2, participants with documented recurrence who received placebo in Part 1 may receive optional treatment with pembrolizumab Q3W for up to 2 years or disease progression.
62425574|NCT01234428|OTHER|surgery|
62034427|NCT03860857|EXPERIMENTAL|Age 81+ ApoE e4-|Participants in this cohort are between the ages of 81-85 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
62034428|NCT03860857|EXPERIMENTAL|Age 81+ ApoE e4+|Participants in this cohort are between the ages of 81-85 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
62034429|NCT06247839|EXPERIMENTAL|Psilocybin|25mg Psilocybin
62034430|NCT03117738|EXPERIMENTAL|AstroStem|
62034431|NCT03117738|PLACEBO_COMPARATOR|Placebo-Control|
62034432|NCT05225493||Hospital|Medical specialists in hospitals and their patients aged 18 years and older in the participating hospitals who are diagnosed there with an HIV indicator condition.
62034433|NCT05225493||Primary care|General practitioners and their patients aged 18 years and older in the participating general practices who are diagnosed there with an HIV indicator condition.
62810695|NCT04051398|EXPERIMENTAL|Intervention Arm (BI)|The BI participants will initially undergo simple spirometry and a 6-minute walk test and Borg scale application upon admission to the thoracic surgery department. Immediately after the exams, they will undergo a TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes. Immediately after the TENS application, the participants will be submitted to a new spirometry, a new 6-minute walk test and again to the Borg scale.
62034434|NCT04020900||Children <18 years, admitted for a general anesthesia.|Children \<18 years, admitted for a general anesthesia.
62034435|NCT04879186||Patients undergoing peripheral endovascular angioplasty|Patients undergoing peripheral endovascular angioplasty. No intervention other than what was already completed as part of routine clinical care, as this is a retrospective cohort.
62034436|NCT00043420|EXPERIMENTAL|Phase I: 0.08 mg/kg|Escalating dose groups: 0.08 mg/kg PF-3512676 Injection
62034437|NCT00043420|EXPERIMENTAL|Phase I: 0.16 mg/kg|Escalating dose groups: 0.16 mg/kg PF-3512676 Injection
62034438|NCT00043420|EXPERIMENTAL|Phase I: 0.24 mg/kg|Escalating dose groups: 0.24 mg/kg PF-3512676 Injection
62034439|NCT00043420|EXPERIMENTAL|Phase I: 0.28 mg/kg|Escalating dose groups: 0.28 mg/kg PF-3512676 Injection
62034440|NCT00043420|EXPERIMENTAL|Phase I: 0.32 mg/kg|Escalating dose groups: 0.32 mg/kg PF-3512676 Injection
62034441|NCT00043420|EXPERIMENTAL|Phase I: 0.36 mg/kg|Escalating dose groups: 0.36 mg/kg PF-3512676 Injection
62034442|NCT00043420|EXPERIMENTAL|Phase II: 10 mg|Phase II: 10 mg flat dose (random assignment in Phase II)
62034443|NCT00043420|EXPERIMENTAL|Phase II: 25 mg|Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
62034444|NCT05709834|EXPERIMENTAL|Autogenic training|It consists of patients who will receive autogenic training and conventional treatment with the frequency of 3 times per week for 4 weeks.
62034445|NCT05709834|OTHER|Control group|Its consists of patients who will receive conventional treatment with the frequency of 3 sessions per week
62034446|NCT06015321|EXPERIMENTAL|Enzalutamide|First-Line Maintenance Enzalutamide Following Docetaxel plus Androgen-Deprivation Therapy in Patients with Previously-Untreated, Metastatic, Castration-Naïve Prostatic Adenocarcinoma
62034447|NCT00443976|EXPERIMENTAL|AT9283|
62810696|NCT04051398|PLACEBO_COMPARATOR|Control Arm (BC)|The BC participants will undergo the same steps as BI, however when applying TENS to these participants investigators will place the electrodes over the points without turning on the device in order to obtain the effect of a placebo.
62034448|NCT01374256||Combination therapy|Patients with Acinetobacter baumannii bacteremia treated with combination therapy of imipenem and sulbactam
62034449|NCT01374256||Not combination therapy|Patients with Acinetobacter baumannii bacteremia not treated with combination therapy of imipenem and sulbactam
62034450|NCT06532630|EXPERIMENTAL|Anti-CD19-CAR-T cell therapy|"Investigational product: anti-CD19-CAR-T cells.~Route of administration: Intravenous injection.~Lymphodepleting chemotherapy regimen: A combination of fludarabine and cyclophosphamide will be administered prior to anti-CD19-CAR-T cells infusion."
62034451|NCT02804594|ACTIVE_COMPARATOR|N-acetyl cysteine|1250 mg of N-acetyl cysteine three times daily
62034452|NCT02804594|PLACEBO_COMPARATOR|Placebo|placebo three times daily
62034453|NCT03133975|EXPERIMENTAL|Treatment|Single high dose IM VIT D
62034454|NCT03133975|ACTIVE_COMPARATOR|Control|Usual diet mix of carbohydrates - lipid - protein - minerals \& vitamins
62735458|NCT04031248|EXPERIMENTAL|WBV group (experimental)|"Participants in the experimental group will follow a program that will consist of a routine of 18 exercises that will be executed where the greatest neuromuscular recruitment is sought. Most exercises are dynamic and isotonic. It is structured following the scheduled phases (ACSM, 2013) of warm-up, development and return to calm or stretching. The total duration of the program is 22 minutes, keeping the general lines of high-intensity aerobic interval training, which establishes a rest period at least equal to that of work.~The treatment protocol will consist of 11 sessions applied in 4 weeks under an intervention regime of weeks 3 sessions, with a duration per session of 22 minutes, which will be supervised by a physiotherapist with more than 15 years of clinical experience."
62810697|NCT02682381|EXPERIMENTAL|0.025 mg/kg/day Teduglutide|0.025 milligrams per kilogram per day (mg/kg/day) of teduglutide for 24 weeks.
62034455|NCT05798195|ACTIVE_COMPARATOR|controlled group|conventional western medicine treatment including oxygen therapy, antibiotics, nebulization therapy, etc.
62034456|NCT05798195|EXPERIMENTAL|dexamethasone group|dexamethasone 1.5mg/day for one week and 0.75mg/day for another week basing on conventional western medicine.
62034457|NCT05798195|EXPERIMENTAL|Chinese medicine group|Strengthening spleen and tonifying lung decoction for 2 weeks basing on conventional western medicine.
62034458|NCT04112004||Liver Transplant Recipients|All elective liver transplant recipients done between study period
62034459|NCT03189017|EXPERIMENTAL|ICP-022|"There are 5 cohorts in the Part 1 phase of the trial. Three quarters of subjects will be randomized to receive ICP-022 in a double-blind fashion. Five dose levels will be evaluated; dose escalation steps may be modified based on the safety from the previous dose. Cohort 4 will return on Day 8 and receive a single dose of ICP-022 under fed conditions.~In Part 2 phase of the trial,three quarters of subjects will be randomized to receive the ICP-022 in a double-blind fashion in 3 cohorts. ICP-022 will be administered once a day for 14 consecutive days."
62034460|NCT03189017|PLACEBO_COMPARATOR|Placebos|"In part 1 phase of the trial, one quarter of subjects will be randomized to receive placebo in a double-blind fashion. Cohort 4 will return on Day 8 and receive a single dose of placebo under fed conditions.~In Part 2 phase of the trial,one quarter of subjects will be randomized to receive placebo in a double-blind fashion. Placebo will be administered once a day for 14 consecutive days."
62034461|NCT06201338||Open aortic surgery|Patient undergoing open surgery for abdominal aortic aneurysm or abdominal aortic occlusion
62034462|NCT02119351|ACTIVE_COMPARATOR|ViaValve™ Safety IV Catheter|Insertion of the ViaValve™ Safety IV Catheter
62810698|NCT02682381|EXPERIMENTAL|0.05 mg/kg/day Teduglutide|0.05 mg/kg/day of teduglutide for 24 weeks.
62810699|NCT02682381|ACTIVE_COMPARATOR|Standard of care|Observational cohort for the 24-week treatment period and 4 week follow-up. The subjects in the standard of care group will follow the same visit schedule as the randomized subjects.
62810700|NCT05062122||vibration group|Vibration applied group in addition to conventional physiotherapy
62034463|NCT02119351|ACTIVE_COMPARATOR|ProtectIV® Plus Safety IV Catheter|Insertion of the ProtectIV® Plus Safety IV Catheter
62425575|NCT00665626|EXPERIMENTAL|Arm 1|Fostamatinib disodium (R935788) 100 mg tablet, orally, twice-a-day
62034464|NCT04300738|OTHER|Patients undergoing CT scann for CCS determination|
62034465|NCT04013815|EXPERIMENTAL|group E|patients receiving the ESP block
62034466|NCT04013815|ACTIVE_COMPARATOR|group I|patients receiving the intercostal nerve block
62810701|NCT05062122||kinesiology tape group|The group in which kinesiology tape was applied in addition to conventional physiotherapy
62234594|NCT00394953|EXPERIMENTAL|MIRCERA|Eligible participants with anemia in CKD who were on hemodialysis will receive methoxy polyethylene glycol-epoetin beta (MIRCERA \[RO0503821\]) IV once every month up to 52 weeks. The starting dose of MIRCERA which will be administered during the treatment period will depend on the dose of darbepoetin alfa administered during screening period i.e., 120, 200 and 360 mcg for weekly darbepoetin alfa doses of \<40, 40-80, and \>80 mcg, respectively.
62234595|NCT00394953|ACTIVE_COMPARATOR|Darbepoetin Alfa|Eligible participants with anemia in CKD who were on hemodialysis will receive darbepoetin alfa (Aranesp) IV once every two weeks up to 26 weeks and darbepoetin alfa IV twice the dose than earlier, once every month from Week 27 up to Week 52.
62234596|NCT04173650|EXPERIMENTAL|AGLE 102|Treatment arm
62234597|NCT00567216|NO_INTERVENTION|G|Endoscopic injection of cyanoacrylate alone
62234598|NCT00567216|ACTIVE_COMPARATOR|C|Combination of GVO and nadolol
62234599|NCT06528639|EXPERIMENTAL|Individualized HIIT Group|Participants in this group will receive a type of exercise prescription of High-Intensity Interval Training (HIIT). They will undergo supervised individualized intermittent high-intensity training (HIIT) guided by CPET three times per week under the supervision of the hospital. Participants will also receive guidance on healthy dietary habits. At the end of the 12th week, CPET and inspiratory muscle strength tests will be conducted to evaluate the training effects and adjust the exercise prescription. The total duration of the training will be 24 weeks
62234600|NCT06528639|NO_INTERVENTION|Control Group|Participants in this group will receive guidance on healthy dietary habits and exercise methods. They will be informed that after 24 weeks of selection, they will have the option to choose HIIT exercise program or home training.
62234601|NCT06051916|ACTIVE_COMPARATOR|group B|Group B is the intervention group with minimalistic voiding trial. The patients in this group need to have one spontaneous voiding before discharge with the sensation of normal voiding, meaning there is no measurement of the voiding volume or residual volume.
62234602|NCT06051916|NO_INTERVENTION|Group A|Group A is the control group and presents the current procedures with strict voiding trial. The bladder is scanned before voiding to determine the bladder volume, and the voiding volume is measured. If the voiding volume is \>150 ml and the residual volume is \<200 ml, the patient can be discharged. If no acceptable residual volume is reached, the patient will be instructed in intermittent catheterization
62234603|NCT00658944||A|Patients suffering from stress or mixed urinary incontinence
62234604|NCT05572268|EXPERIMENTAL|ANSA Sachet|Ansa sachet having three APIs (Vaccinium macrocarpon, Saraca indica, Cimicifuga racemosa)
62234605|NCT05572268|ACTIVE_COMPARATOR|Cran Max Sachet|Cran Max is only having Vaccinium macrocarpon
62810702|NCT05062122||control group|Group receiving only conventional physiotherapy
62735459|NCT04031248|ACTIVE_COMPARATOR|Exercise group (control)|Control subjects will perform the same exercise program without whole-body vibration.
62234606|NCT05335720|ACTIVE_COMPARATOR|Cohort 1|"1. EASYEF® + moist gauze EASYEF® is applied directly on the wound surface then moist dressing is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage.~2. Tulle gauze + moist gauze Tulle gauze is applied directly on the wound surface then moist dressing is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage."
62234607|NCT05335720|ACTIVE_COMPARATOR|Cohort 2|"1. EASYEF® + tulle gauze + moist gauze EASYEF® is applied directly on the wound surface then tulle gauze and moist gauze is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage.~2. Tulle gauze + moist gauze Tulle gauze is applied directly on the wound surface then moist dressing is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage."
62234608|NCT01569165|EXPERIMENTAL|washing after 30 min|washing with water after 30 min following APF treatment
62735460|NCT02515968|ACTIVE_COMPARATOR|Desflurane|Anesthesia is maintained with desflurane during surgery.
62810703|NCT02529540|OTHER|Group 1|Self-refraction with adjustable glasses
62810704|NCT02529540|OTHER|Group 2|Subjective refraction by an expert refractionist after auto refraction and receiving custom standard glasses
62810705|NCT02529540|OTHER|Group 3|Subjective refraction by an expert refractionist after auto refraction and receiving ready-made glasses
62234609|NCT01569165|EXPERIMENTAL|washing after 15 min|washing with water after 15 min following APF treatment
62234610|NCT01569165|EXPERIMENTAL|immediately washing with water|immediately washing with water after APF treatment
62234611|NCT01569165|EXPERIMENTAL|cleansing teeth with cotton roll|cleansing teeth with cotton roll immediately following APF treatment
62735461|NCT02515968|EXPERIMENTAL|Propofol|Anesthesia is maintained with propofol during surgery.
62735462|NCT04492241|EXPERIMENTAL|Study Arm|Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution, TID
62810706|NCT02855203|EXPERIMENTAL|SABR + Pembrolizumab|SABR treatment (18Gy-20Gy/1#) followed by 200mg pembrolizumab IV once every 3 weeks for a total of 8 cycles
62234612|NCT01569165|NO_INTERVENTION|no fluoride therapy|control group
62234613|NCT04318951|EXPERIMENTAL|Intensive communicative-pragmatic social interaction.|Intensive Language-Action Therapy (ILAT).
62234614|NCT04318951|OTHER|Standard care.|All participants will receive standard care.
62593899|NCT06178653|EXPERIMENTAL|Pulmonary Rehabilitation Group|"The program will be carried out 5 days a week, 2 times a day for 8 weeks, one day in the clinic under the supervision of the researcher, and the other four sessions in the home under the supervision of the caregiver. Caregivers will also be taught respiratory rehabilitation techniques to apply at home.~Pulmonary Rehabilitation Training Program consists of diaphragmatic breathing, Pursed-lip breathing, and segmental breathing.~Inspiratory muscle training: In our research, IMT will be performed in a sitting position using a handheld threshold valve device (Orygen Inspiratory Valve) that offers an adjustable inspiratory resistance via a spring-loaded valve with variable pressure load adjustment from 0-70 cmH2O. Inspiratory muscle training will be applied by calculating 30% of the maximal inspiratory pressure (MIP). During weekly clinic visits, the MIP value will be recalculated and the current threshold pressure value will be determined."
62810707|NCT00002998|EXPERIMENTAL|gemcitabine + cisplatin|Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 1 hour on days 1, 8, and 15 every 28 days. Patients with complete response may receive an additional 2 courses after attainment of complete response status. Treatment continues in the absence of disease progression or unacceptable toxicities for a maximum of 8 courses. Patients are followed every 3 months for 2 years and then at 3 years after treatment.
62810708|NCT02153593|EXPERIMENTAL|Tranexamic acid|Tranexamic acid, 1g intra-articular before closing the surgery wound
62810709|NCT02153593|EXPERIMENTAL|Fibrin glue|One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery
62810710|NCT02153593|ACTIVE_COMPARATOR|Usual hemostasia|Electrocauterization
62810711|NCT06524609|EXPERIMENTAL|EGCG GROUP|EGCG administration was initiated when Grade II CIPN occurred first time. EGCG solution is applied to the patient's hands/feet with a soft-bristled brush, approximately 0.05 ml/cm2. 3 times daily, and may be covered with film gloves/cling film for approximately 20-30 minutes after application. Use continuously for at least 1 week.
62810712|NCT06524609|PLACEBO_COMPARATOR|CONTROL GROUP|75% alcohol
62810713|NCT01814774||BOTOX®|Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
62810714|NCT01814774||Xeomin®|Retrospective chart review of doses of Xeomin® (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
62810715|NCT05255471|EXPERIMENTAL|Olaparib|
62810716|NCT05255471|ACTIVE_COMPARATOR|Chemotherapy|
62810717|NCT01619735||Fragments basketed|"Active extraction is whereby the ureteroscope is passed back and forth into the kidney to remove all visible stone fragments."
62810718|NCT01619735||Fragments dusted|"Dusting is whereby the stones are broken into tiny fragments or dust with the intention that achieving such a small stone size will allow the stones to pass spontaneously."
62810719|NCT03481478||Patients with greater tuberosity fractures|If humeral surgical neck fractures can be detected through CT or MRI in such groups.
62810720|NCT03481478||Dislocation patients with greater tuberosity fractures|If humeral surgical neck fractures can be detected through CT or MRI in such groups.
62234615|NCT04483076|EXPERIMENTAL|Arm A|Patients will be pre-enrolled and receive three cycles of SOX. After randomization, patients in Arm A will receive three more cycles of SOX (six cycles of neoadjuvant chemotherapy with SOX in total) followed by D2 gastrectomy.
62234616|NCT04483076|ACTIVE_COMPARATOR|Arm B|Patients will be pre-enrolled and receive three cycles of SOX. After randomization, patients in Arm B will receive D2 gastrectomy (three cycles of neoadjuvant chemotherapy with SOX in total).
62735463|NCT04492241|PLACEBO_COMPARATOR|Control Arm|Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution, TID
62234617|NCT01390181|EXPERIMENTAL|Losartan|
62810721|NCT03399058|OTHER|Group 1 5+5+5 (Control)|The standard of care in Cambodia is known as the basic health and nutrition service package or 5+5+5. The participants in the first group will be the control group and will only be implementing the standard of care, 5+5+5 package (Group 1).
62234618|NCT01557283||Plaque psoriasis patients|Plaque psoriasis patients treated with Enbrel after the approval of the new belgian reimbursement criteria
62234619|NCT00091117|EXPERIMENTAL|Treatment|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62425576|NCT00665626|PLACEBO_COMPARATOR|Arm 2|Placebo, orally, twice-a-day
62425577|NCT05178043|EXPERIMENTAL|GT90001+Nivolumab|
62735464|NCT06511479|EXPERIMENTAL|MIND-BP|Participants who are randomly assigned to receive the MIND-BP program, a virtually delivered mindfulness training group.
62735465|NCT06511479|EXPERIMENTAL|BOOST|Participants who are randomly assigned to receive the BOOST program, a virtually delivered mindfulness training group.
62433650|NCT05483920|EXPERIMENTAL|One-time educational video plus automated text messaging|A one-time educational video on best practices for sleep hygiene plus daily automated text messages to reinforce habit.
62425578|NCT06538168|EXPERIMENTAL|intervention group|The intervention group typically consists of participants who are subjected to the Diabetes Self-Management Education (DSME) program The intervention, Diabetes Self-Management Education (DSME), involves a structured educational program including daily reminders regarding medication, and foot care, educational-led video weekly, and handouts for the management of diabetes and foot care to enhance knowledge and skills in managing diabetes and preventing complications like diabetic foot ulcers (DFUs).
62425579|NCT06538168|NO_INTERVENTION|Control group|These participants do not receive any intervention.
62425580|NCT02875067|EXPERIMENTAL|Pembrolizumab and Lenalidomide|"An intravenous infusion of 200 mg of pembrolizumab (MK3475) once every 3 weeks for a total of 4 infusions~Lenalidomide at either 15 mg, 10 mg or 20 mg (depending on which cohort patients are enrolled in) days 1-14 every 21 days"
62425581|NCT00530452|EXPERIMENTAL|A|2.0 mg (loading dose, Day 0) followed by 0.3 mg/day (Days 1-20)
62425582|NCT00530452|EXPERIMENTAL|B|4.0 mg (loading dose, Day 0) followed by 0.6 mg/day (Days 1-20)
62593900|NCT06178653|EXPERIMENTAL|Trunk Control Training Group|The program will be carried out 3 days a week, with pulmonary rehabilitation in each session, for a total of 45-60 minutes, for 8 weeks. The training of children whose evaluations are completed will begin after individually structured pulmonary rehabilitation and trunk control training programs are created. The content of pulmonary rehabilitation will consist of diaphragmatic breathing, pursed-lip breathing, segmental breathing, and IMT. Exercises and activities for trunk muscle activation, pelvic control, and proximal stabilization will be used together with trunk and gluteal muscle strengthening exercises. The intensity and level of exercises will be increased gradually. Body control work will first start on hard ground and then continue on soft ground and dynamic surfaces. All trunk control training will be applied actively or actively assisted.
62593901|NCT05537441|ACTIVE_COMPARATOR|Standard Texts|"Patients randomized to this study arm will receive a standard text reminding them about the importance of influenza vaccination. The standard texts will include a clinic call back number and patient portal self-scheduling for patients to schedule their influenza vaccines:~#FirstName#, your flu shot is ready! Call your clinic at #ExternalRefNo# or visit the LA Health Portal at http://bit.ly/BookFluShot if you want this shot held for you."
62034467|NCT03477435|EXPERIMENTAL|Opt-in clinical reminder|As the investigators have done previously, the reminder will be self-explanatory, and will walk staff through each step of referral. The reminder will include the following domains: normative advice, referral to treatment, handout
62034468|NCT03477435|EXPERIMENTAL|Opt-out tobacco treatment|The investigators will directly change the treatment status quo by implementing a clinical reminder that automatically initiates tobacco treatment referral at the time the reminder is activated.
62593902|NCT05537441|EXPERIMENTAL|Standard Texts with Transportation messaging|"Patients randomized to this study arm will receive standard texts plus transportation messaging including a phone number for patients to reserve transportation to a vaccination appointment based on MediCal health plan transportation resources:~#FirstName#, your flu shot is ready! Call your clinic at #ExternalRefNo# or visit the LA Health Portal at http://bit.ly/BookFluShot if you want this shot held for you. You can call #Health Plan Phone Number# to schedule a free ride for your flu shot through #HealthPlanName#."
62593903|NCT05221346|EXPERIMENTAL|Plant food supplement|"* Dietary supplements in capsule form~* 1 capsule per day at breakfast"
62810722|NCT03399058|OTHER|Group 2: 5+5+5 & PDH|The participants in the second group will receive contextualized Hearth messages through on-going PDH programs in addition to the basic standard of care (Group 2). The Hearth messages are contextualized messages on child feeding practices that women in the community have found helpful to successfully prevent child malnutrition. This program will be delivered through in person community meetings.
62810723|NCT03399058|OTHER|Group 3: 5+5+5 & PDH lite+mHealth|The participants in the third group will receive a similar program as group 2 with contextualized child feeding messages (PDH lite program) and receive follow-up through mobile support phone calls (Group 3).
62810724|NCT06403007|EXPERIMENTAL|A. Phonics plus morphology instruction|Teachers in all schools in this arm receive three hours of phonics plus morphology professional development training as a group and the intervention manual. They receive in-school support and coaching subsequent to this.
62034469|NCT05602363|EXPERIMENTAL|Dose Escalation|"Dose escalation (3+3 design) and determination of MTD and DLTs~CLL/SLL or B-cell NHL patients will self-administer docirbrutinib oral tablet at multiple dose levels twice daily for 24 cycles (1 cycle = 28 days)."
62034470|NCT05602363|EXPERIMENTAL|Dose Expansion|"Cohort 1: CLL/SLL patients, Cohort 2: B-cell NHL patients, Cohort 3: CLL/SLL or B-cell NHL patients with prior treatment with pirtobrutinib (Jaypirca) for an approved indication~Patients will self-administer docirbrutinib oral tablet for 24 cycles (1 cycle = 28 days). Dose levels will be determined based on the result of dose escalation part."
62034471|NCT01738048||Mastectomy|Patients treated with mastectomy without reconstruction
62034472|NCT01738048||Reconstruction|Patients treated with mastectomy followed by reconstruction
62034473|NCT03456193|EXPERIMENTAL|LA transplantation|The left atrium and pulmonary veins will be transplanted into the recipient
62034474|NCT02183818||Healthy nonsmokers|Physical assessment, EKG, blood and urine draw, chest x-ray, pulmonary function test (PFT), and bronchoscopy
62425583|NCT00530452|EXPERIMENTAL|C|8.0 mg (loading dose, Day 0) followed by 1.2 mg/day (Days 1-20)
62810725|NCT06403007|EXPERIMENTAL|B. Phonics plus set-for-variability instruction|Teachers in all schools in this arm receive three hours of phonics plus set-for-variability professional development training as a group and the intervention manual. They receive in-school support and coaching subsequent to this of equivalent duration to that in the other arm.
62810726|NCT04046328|EXPERIMENTAL|"Low Dose ECC Regimen"|ECC at the 1.7 g daily dose, administered BID (twice daily) as 2 capsules of ECC, plus 3 capsules of placebo, at least 30 minutes before breakfast and 2 capsules of ECC, plus 3 capsules of placebo at least 30 minutes before evening meal.
62810727|NCT04046328|EXPERIMENTAL|"High Dose ECC Regimen"|ECC at the 4.25 g daily dose, administered BID (twice daily) as 5 capsules of ECC at least 30 minutes before breakfast and 5 capsules of ECC at least 30 minutes before evening meal.
62810728|NCT06253988|ACTIVE_COMPARATOR|Group probiotic|received conventional periodontal treatment combined with topically applied probiotic
62425584|NCT00530452|PLACEBO_COMPARATOR|D|Placebo (identical number of capsules to active drug groups) (Days 0-20)
62425585|NCT02453100|EXPERIMENTAL|Exercise|"Women will be included in group mobility and pelvic floor exercise classes for one and a half hours twice weekly for 12 weeks and encouraged to carry out independent exercises each day when there is no group session.~A research paramedics will meet with the woman each month for six months from the initial training session to encourage her continued participation and adherence to the individual exercise program. At this meeting the research paramedic will also provide and reinforce simple education about how to manage urinary incontinence."
62034475|NCT02183818||Smokers with COPD|Physical assessment, EKG, blood and urine draw, chest x-ray, pulmonary function test (PFT), and bronchoscopy
62034476|NCT05322616|ACTIVE_COMPARATOR|JK07|Single dose of intravenous JK07 administered by intravenous infusion over 60 minutes.
62034477|NCT05322616|PLACEBO_COMPARATOR|Matching Placebo|Single dose of vehicle control administered by intravenous infusion over 60 minutes
62034478|NCT05461872||girls with adnexal mass|"All girls who presented with adnexal mass from 0-21 years old (inclusive).~Subjects will be identified from review of clinical records.~Girl aged 21 or below who attended the NTEC cluster from 1990-2021 with available medical records."
62425586|NCT02453100|PLACEBO_COMPARATOR|Education|On recruitment and each month for six months a research paramedic will meet with each woman to provide and reinforce simple education about how to manage urinary incontinence.
62810729|NCT06253988|PLACEBO_COMPARATOR|Group placebo|received conventional periodontal treatment only.
62810730|NCT02473081|EXPERIMENTAL|Minimal Psychological Intervention|Participants allocated to this group not only received the usual care as given by their family physicians, but also accepted biweekly minimal psychological intervention via telephone during six weeks.
62810731|NCT02473081|OTHER|Usual care|Participants in this group received usual care only.
62810732|NCT00763412|PLACEBO_COMPARATOR|1 Placebo|1 pill before each meal 3-4 times a day for 2 years. All subjects had abnormal glucose tolerance. Subjects were randomized to placebo or drug.
62034479|NCT00307827|EXPERIMENTAL|Arm 1|Visilizumab low dose level
62034480|NCT00307827|EXPERIMENTAL|Arm 2|Visilizumab middle dose level
62034481|NCT00307827|EXPERIMENTAL|Arm 3|Visilizumab high dose level
62034482|NCT05285813|EXPERIMENTAL|AML MRD cohort only|Each study cycle is 28 days. Vibecotamab by vein (IV) over about 2 hours On Days 1, 3, 5, 8, 15 and 22 of Cycle 1 and then on Days 1, 8, 15 and 22 of Cycles 2-4.
62034483|NCT05285813|EXPERIMENTAL|MDS post-HMA failure cohort only|Each study cycle is 28 days. Vibecotamab by vein (IV) over about 2 hours On Days 1, 3, 5, 8, 15 and 22 of Cycle 1 and then on Days 1, 8, 15 and 22 of Cycles 2-4.
62034484|NCT05020223|EXPERIMENTAL|MTA pulpotomy|Usuing MTA as capping material for cervical pulpotomy as a treatment option for deep carious primary teeth with signs and symptoms of reversible pulpitis in presence of pulp exposure
62034485|NCT05020223|EXPERIMENTAL|MTA direct pulp capping|Using MTA as capping material in case of trearment of deep carious primary teeth with signs and symptoms of reversible pulpitis with presence of pulp exposure
62034486|NCT05020223|EXPERIMENTAL|MTA indirect pulp capping|Using MTA as indirect capping material for treatment of deep carious primary teeth with signs and symptoms of reversible pulpitis
62034487|NCT05535816|EXPERIMENTAL|Ultrasound|Before completing retrograde intrarenal surgery, a complete endoscopic examination will be performed along with ultrasound by the same endourologist to determine the size of the largest residual fragment.
62034488|NCT05535816|NO_INTERVENTION|Fluoroscopy|Standard of care, control Before completing retrograde intrarenal surgery, a complete endoscopic examination will be performed along with fluoroscopy by the same endourologist to determine the size of the largest residual fragment.
62034489|NCT04988308|PLACEBO_COMPARATOR|Part 1 (Group 1): Placebo|Participants will receive placebo subcutaneously (SC) at Week 0 through Week 15. At Week 16, participants will cross over to receive bermekimab dose 1 SC every week thereafter through Week 31.
62234620|NCT01121120|EXPERIMENTAL|TXA127|300mcg/kg/day administered subcutaneously up to 28 days
62234621|NCT01121120|PLACEBO_COMPARATOR|Placebo|300mcg/kg/day administered subcutaneously up to 28 days
62234622|NCT04808622|EXPERIMENTAL|TSC 0.5 mg/kg|TSC 0.5 mg/kg given as a one-time IV bolus injection
62234623|NCT04808622|EXPERIMENTAL|TSC 1.0 mg/kg|TSC 1.0 mg/kg given as a one-time IV bolus injection
62234624|NCT04808622|EXPERIMENTAL|TSC 1.5 mg/kg|TSC 1.5 mg/kg given as a one-time IV bolus injection
62425587|NCT00410215|ACTIVE_COMPARATOR|1|sodium phosphate
62810733|NCT00763412|EXPERIMENTAL|2. repaglinide|repaglinide 0.5 mg before each meal 3-4 times a day for 2 years. All subjects had abnormal glucose tolerance.Subjects were randomized to placebo or drug.
62593904|NCT05221346|PLACEBO_COMPARATOR|Maltodextrin|"* Dietary supplements in capsule form~* 1 capsule per day at breakfast"
62593905|NCT02683044|EXPERIMENTAL|Li-ESWT 5 weeks|Consists of five sessions of Low-Intensity Extracorporeal Shock Wave Therapy , one per week, with 3000 pulses at 0,15 mg/mm2, at a frequency of 4 Hz. The distribution of the shocks will be 2000 pulses to the body of the penis and 1000 pulses at its base. Total duration: 5 weeks.
62593906|NCT02683044|ACTIVE_COMPARATOR|Li-ESWT 3 weeks|Consists of six sessions of Low-Intensity Extracorporeal Shock Wave Therapy , two per week, with 1500 pulses each one at 0.1 mJ/mm2, at a frequency of 4 Hz. The distribution of the shocks will be 900 pulses to the body of the penis and 600 pulses at its base. Total duration: 3 weeks.
62593907|NCT02845960||Experimental group|rapid recovery
62810734|NCT04578600|EXPERIMENTAL|Treatment (lenalidomide, oral azacitidine, obinutuzumab)|Patients receive azacitidine PO QD on days 1-21, obinutuzumab IV over on days 8, 15, 22, and 29, and lenalidomide PO QD on days 8-28 of cycle 1. Treatment continues for 35 days in the absence of disease progression or unacceptable toxicity. Patients then receive azacitidine PO QD on days 1-21, obinutuzumab IV over on day 1, and lenalidomide PO QD on days 1-21. Cycles repeats every 28 days in the absence of disease progression, unacceptable toxicity, or until stem cell transplant. Patients who achieve SD, PR, or CR do not proceed to stem cell transplant may continue treatment for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62034490|NCT04988308|ACTIVE_COMPARATOR|Part 1 (Group 2): Adalimumab|Participants will receive adalimumab 160 milligrams (mg) SC at Week 0, placebo SC at Week 1, followed by adalimumab 80 mg SC and placebo SC at Weeks 2 and 3. Participants will then receive adalimumab 40 mg SC and placebo SC at Week 4 and every week thereafter through Week 31.
62034491|NCT04988308|EXPERIMENTAL|Part 1 (Group 3): Bermekimab Dose 1|Participants will receive bermekimab dose 1 SC and placebo SC at Week 0, followed by bermekimab dose 1 SC at Week 1 and every week thereafter through Week 31.
62034492|NCT04988308|PLACEBO_COMPARATOR|Part 2 (Group 1): Placebo|Participants will receive placebo SC from Week 0 through Week 11. At Week 12, participants will cross over to receive bermekimab dose 1 SC weekly through Week 31.
62034493|NCT04988308|EXPERIMENTAL|Part 2 (Group 2): Bermekimab Dose 1|Participants will receive bermekimab dose 1 SC at Week 0 and every week thereafter through Week 31.
62034494|NCT04988308|EXPERIMENTAL|Part 2 (Group 3): Bermekimab Dose 1|Participants will receive bermekimab dose 1 SC at Week 0 and every week thereafter through Week 11. From Week 12, participants will receive bermekimab dose 1 SC every other week thereafter through Week 30. During weeks in which bermekimab is not administered, participants will receive placebo SC through Week 31.
62034495|NCT04988308|EXPERIMENTAL|Part 2 (Group 4): Bermekimab Dose 2|Participants will receive bermekimab dose 2 SC and placebo SC at Week 0 and every week thereafter through Week 11. From Week 12, participants will receive bermekimab dose 2 SC and placebo SC every other week thereafter through Week 30. During weeks in which bermekimab is not administered, participants will receive placebo SC through Week 31.
62034496|NCT06544733|EXPERIMENTAL|Phase 2: GS-1720 + GS-4182 (Treatment Group 1)|Participants who have been virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamide (BVY) will switch to GS-1720 (650 mg tablet) and GS-4182 (300 mg tablet) coadministered. Participants will receive a 1-day loading dose of GS-1720 (1300 mg) and GS-4182 (600 mg) on Day 1. Thereafter, participants will take weekly doses of single agent GS-1720 (650 mg) and GS-4182 (300 mg) coadministered for at least 48 weeks.
62034497|NCT06544733|ACTIVE_COMPARATOR|Phase 2: Bictegravir/emtricitabine/tenofovir alafenamide (BVY) (Treatment Group 2)|Participants who have been virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamide (BVY) will continue receiving BVY daily for at least 48 weeks.
62234625|NCT04808622|EXPERIMENTAL|TSC 2.0 mg/kg|TSC 2.0 mg/kg given as a one-time IV bolus injection
62234626|NCT04808622|EXPERIMENTAL|TSC 2.5 mg/kg|TSC 2.5 mg/kg given as a one-time IV bolus injection
62234627|NCT04808622|PLACEBO_COMPARATOR|Placebo|7 mL normal saline given as a one-time IV bolus injection
62593908|NCT02845960||Controlled group|no rapid recovery
62593909|NCT03046901|EXPERIMENTAL|Vancomycin group|It is a single arm open label study and will constitute only one group that will be taking vancomycin for recurrent PSC post liver transplantation.
62593910|NCT03355157|EXPERIMENTAL|Palbociclib + endocrine therapy|Experimental arm for testing palbociclib + endocrine therapy.
62593911|NCT03355157|ACTIVE_COMPARATOR|Chemotherapy +/- endocrine maintenance therapy|Chemotherapy +/- endocrine maintenance as comparator arm.
62593912|NCT06052423|EXPERIMENTAL|HS-20093|All subjects will receive HS-20093 at 10mg/kg
62593913|NCT05546346|EXPERIMENTAL|wearable magnet tracking system|
62593914|NCT06304883|EXPERIMENTAL|Experimental: ALZ-801|ALZ-801 265 mg BID tablet orally. Subjects will take one 265 mg tablet of ALZ-801 in the evening during the first 4 weeks of the study; thereafter, they will take one 265 mg tablet BID.
62593915|NCT04014166|EXPERIMENTAL|15 refractory ITP patients|15 enrolled refractory ITP patients will be picked up to infuse hUC-MSCs at the indicated dose.
62593916|NCT03075345|ACTIVE_COMPARATOR|Treatment as usual (weight management intervention)|6 session weight management programme (over 12 weeks).
62593917|NCT03075345|EXPERIMENTAL|Treatment as usual plus acceptance and commitment therapy|6 session weight management programme (over 12 weeks) plus a 4 session acceptance and commitment therapy (ACT) programme. The ACT part will commence straight after the conclusion of the weight management programme.
62810735|NCT04935996|EXPERIMENTAL|Pleuropulmonary echography|
62810736|NCT04801420|EXPERIMENTAL|Part A+B - Group 1|Part A: VLA15 at Month 0, 2 and 6 Part B: VLA15 at Month 18, 30 and 42
62810737|NCT04801420|EXPERIMENTAL|Part A+B - Group 2|Part A: VLA15 at Month 0 and 6, placebo at Month 2 Part B: VLA15 at Month 18, 30 and 42
62810738|NCT04801420|PLACEBO_COMPARATOR|Part A+B - Group 3|Part A: Placebo at Month 0, 2 and 6 Part B: Placebo at Month 18, 30 and 42
62425588|NCT00410215|ACTIVE_COMPARATOR|2|picosalax
62810739|NCT03617172|EXPERIMENTAL|Study Drug (Misoprostol)|
62810740|NCT03617172|PLACEBO_COMPARATOR|Placebo|
62810741|NCT01319981|EXPERIMENTAL|Hyper-CMAD + Rituximab|Odd Courses 1, 3, 5, 7: Rituximab 375 mg/m2 IV Day 1 \& 8 Courses 1 \& 3; Imatinib oral 600 mg days 1-14 Course 1 then continuously; Cyclophosphamide 300 mg/m2 IV every; 12 hours for 6 doses; Mesna 600 mg/m2/day IV Days 1-3; Doxorubicin 50 mg/m2 IV CVC Day 4; VSLI 2.25 mg/M2 IV Day 1 \& 8; Pegfilgrastim 6 mg/kg after chemotherapy + G-CSF 10 µg/kg/day; Dexamethasone 40 mg IV or P.O. daily days 1-4 and days 11-14 +/- 3 days.
62810742|NCT01319981|EXPERIMENTAL|Hyper-CMAD|Courses 2, 4, 6, 8: Rituximab 375 mg/m2 IV Day 1 \& 8 Courses 2 \& 4; Imatinib oral 600 mg; Methotrexate 200 mg/m2 IV over 2 hours followed by 8-0- mg/m2 over 22 hours on Day 1; Solu-Medrol 40 mg IV hours approximately every 12 hours +/- 2 hours for 6 doses days 1-3 +/- 3 days; Decadron 40 mg IV or orally 4 times Days 1-4; Ara-C 3 gm/m2 IV every 2 hours, 4 doses on Days 2-3; Pegfilgrastim 6 mg/kg after chemotherapy + G-CSF 10 mg/kg/day.
62810743|NCT04921202||without metabolic syndrome and BMI<24|100 volunteers aged between 35-70 years old with body mass index(BMI)\<24 without Metabolic syndrome
62810744|NCT04921202||Metabolic Syndrome with BMI>27|80 Metabolic syndrome patients with BMI\>27 were included in the study
62810745|NCT06222632|EXPERIMENTAL|MIND diet|The MIND group will consume the MIND diet for 12 weeks.
62810746|NCT06222632|EXPERIMENTAL|MIND plus FB|The MIND plus FB intervention will consist of eight sessions.
62810747|NCT06222632|OTHER|Usual Care|The routine care group will be instructed to perform daily activities as usual
62234628|NCT00876694|EXPERIMENTAL|Indacaterol 300 µg|Indacaterol 300 μg once a day (o.d.) delivered via single dose dry powder inhaler (SDDPI). Daily ICS monotherapy, if needed, was allowed to remain stable throughout study. Salbutamol was available for rescue use throughout study.
62234629|NCT00876694|ACTIVE_COMPARATOR|Salmeterol 50 µg|Salmeterol 50 μg twice a day (b.i.d.) delivered via Diskus®. Daily ICS monotherapy, if needed, was allowed to remain stable throughout study. Salbutamol was available for rescue use throughout study.
62425589|NCT00410215|ACTIVE_COMPARATOR|3|picosalax plus bisacodyl
62425590|NCT05652816|SHAM_COMPARATOR|STSG (Split-Thickness Skin Graft)|Patients treated with the standard treatment; autologous skin graft
62425591|NCT05652816|EXPERIMENTAL|Amnion Bilayer Only|Patients treated with artificial graft only
62425592|NCT05652816|EXPERIMENTAL|Amnion Bilayer seeded with co-culture|Patients treated with artificial graft seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells
62425593|NCT03087929||Treatment Arm|Patients who had previously undergone high dose therapy with stem cell support followed by consolidation with Rituximab and alpha-interferon as part of the trial Treatment of Follicular non-Hodgkin's Lymphoma with High Dose Therapy and Stem Cell Support Followed by Consolidative Immunotherapy with Rituximab and Alpha Interferon. The patients in this arm have consented to long-term follow up.
62425594|NCT01311856||Standard Arm (mail/telephone)|
62425595|NCT01311856||Internet Arm|
62425596|NCT06212232|EXPERIMENTAL|Experimental: Test Group|Use of a new piezoelectric technique in third molar surgery
62425597|NCT06212232|ACTIVE_COMPARATOR|Traditional: Control Group|Use of the traditional technique in third molar surgery
62425598|NCT02023320|EXPERIMENTAL|Low dose of blueberry dry powder|0.5 g blueberry dry powder, twice a day for 12 weeks
62425599|NCT02023320|EXPERIMENTAL|High dose of blueberry dry powder|5.0 g blueberry dry powder, twice a day for 12 weeks
62425600|NCT02194231|EXPERIMENTAL|Trabectedin|Patients will receive trabectedin treatment
62425601|NCT04395131|OTHER|Clearum HF Dialysis Subjects|All subjects enrolled in the study and treated with the Clearum HF hemodialyzer
62425602|NCT04492007|EXPERIMENTAL|PRISMS|In addition to usual care, participants assigned to this arm will have access to our Patient-Reported Outcomes-Informed Symptom Management System (PRISMS) program.
62593918|NCT03991169|EXPERIMENTAL|Oral Iron therapy|Participant will receive oral iron therapy.
62593919|NCT03991169|NO_INTERVENTION|No oral iron therapy|Participant will not receive oral iron therapy for 3 months.
62593920|NCT01383629|NO_INTERVENTION|No counselling|normal preoperative procedures prior to vitrectomy surgery
62810748|NCT05363553|EXPERIMENTAL|infant formula based on whole goat milk|
62810749|NCT05363553|ACTIVE_COMPARATOR|Infant formula based on cow milk proteins|
62810750|NCT05363553|NO_INTERVENTION|Predominantly breastmilk|
62810751|NCT06185374|EXPERIMENTAL|Text Message Intervention|Participants in the experimental arm will receive a series of instructional and motivational text messages, which will be sent starting 7-14 days before and until the day of the colonoscopy procedure.
62810752|NCT06185374|NO_INTERVENTION|No Intervention|Participants will not receive text messages.
62810753|NCT03913221|ACTIVE_COMPARATOR|Low Dose Caffeine (5 mg/kg)|Within 24 hours of delivery, participants will receive low dose administration of Caffeine citrate.
62810754|NCT03913221|ACTIVE_COMPARATOR|High Dose Caffeine (10 mg/kg)|Within 24 hours of delivery, participants will receive high dose administration of Caffeine citrate.
62810755|NCT04686461|EXPERIMENTAL|Nigella sativa seeds extract containing ointment intervention|Nigella sativa seeds extract containing ointment dose- twice daily for 12 weeks
62810756|NCT02560259|ACTIVE_COMPARATOR|Physiotherapy Group|Physiotherapy
62810757|NCT02560259|PLACEBO_COMPARATOR|Conservative group|Conservative treatment
62810758|NCT02836912|NO_INTERVENTION|Regular education|Regular education for COPD, including percussion and posture drainage.
62810759|NCT02836912|EXPERIMENTAL|Exercise|Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group.
62810760|NCT00388349|EXPERIMENTAL|Gemcitabine + Autologous HCT|Gemcitabine and high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue. Chemotherapy includes Gemcitabine + Vinorelbine + Carmustine + Etoposide + Cyclophosphamide.
62810761|NCT02268890|EXPERIMENTAL|Bortezomib|Participants will receive a 1.3 milligram per square meter per dose (mg/m\^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
62810762|NCT05971316|EXPERIMENTAL|Warm-up + Foam Roller|General Warm-up + Warm-up with Foam Roller
62810763|NCT05971316|NO_INTERVENTION|Warm-up Only|General Warm-up only
62810764|NCT06305156|OTHER|Bone mineral density CT vs DXA|Single arm study, all participants receive CT and DXA.
62810765|NCT01412996|ACTIVE_COMPARATOR|single ACCESS cholecystectomy|single ACCESS laparoscopic cholecystectomy
62810766|NCT01412996|ACTIVE_COMPARATOR|traditional|conventional laparoscopic cholecystectomy
62034498|NCT06544733|EXPERIMENTAL|Phase 2 Extension Phase: GS-1720/GS-4182 Fixed-dose Combination (FDC)|At the end of the randomized treatment, Phase 2 participants will be given the option to participate in the Extension Phase. Phase 2 Treatment Group 1 will switch to GS-1720/GS-4182 FDC weekly. Phase 2 Treatment Group 2 will receive a loading dose of GS-1720/GS-4182 FDC on Extension Phase Day 1 then, GS-1720/GS-4182 FDC weekly. Participants who choose to enter the Extension Phase will receive GS-1720/GS-4182 FDC tablets until the product becomes available or until Gilead Sciences elects to discontinue the study, whichever occurs first.
62034499|NCT06544733|EXPERIMENTAL|Phase 3: GS-1720/GS-4182 FDC + Placebo to Match (PTM) BVY (Treatment Group 1)|"Participants who have been virologically suppressed on BVY will switch from BVY to GS-1720/GS-4182 FDC tablets weekly + placebo-to-match (PTM) BVY once daily. In addition, participants will receive a 1-day loading dose regimen of GS-1720/GS-4182 FDC on Day 1.~Participants will receive treatment for at least 96 weeks."
62234630|NCT04750174|ACTIVE_COMPARATOR|Kinesiotape Group|In active group, KT was applied with stretching to the suprahyoid muscles with right method.
62234631|NCT04750174|SHAM_COMPARATOR|Sham Kinesiotape Group|In sham group, KT was applied without stretching to the suprahyoid region and not including the origins of mylohyoid and digastric muscles
62425603|NCT04492007|NO_INTERVENTION|Usual Care|Participants assigned to this arm will receive the standard of care that is provided to all patients.
62425604|NCT02243059|EXPERIMENTAL|GDF-MRI|"In this pilot study, all included patients will undergo conventional MRI with contrast enhancement (gadofosveset trisodium) and diffusion weighted MRI.~Ablavar™ solution contains 244 mg/mL (0.25 mmol/mL) gadofosveset trisodium. 0.03 mmol/kg of gadofosveset will be administered by manual injection as a single intravenous bolus injection over a period of time up to 30 seconds followed by a 25-30 ml saline flush. In practice, this comes down to the maximum of one vial for one patient (one vial contains 10 ml solution, which contains a total of 2.50 mmol of gadofosveset trisodium equivalent to 2.27 g of gadofosveset)."
62425605|NCT05715788||patients ventilated in prone position|Patients ventilated in prone position
62425606|NCT05715788||Patients ventilated in prone position with NO inhalation|Patients ventilated in prone position with NO inhalation
62425607|NCT03554642|EXPERIMENTAL|Walkbot Training|This group will receive usual inpatient care that includes at least one 60-minute session of physical therapy and an additional 30-minute session of Walkbot with Augmented Reality 5-days per week during the duration of their stay (14 days).
62810767|NCT01083849||Paricalcitol|Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.
62810768|NCT02228707|EXPERIMENTAL|BIIB061|Participants receive BIIB061
62810769|NCT02228707|PLACEBO_COMPARATOR|Placebo|Participants receive matched placebo
62810770|NCT04400630|NO_INTERVENTION|Control (TAU)|patients without any intervention + treatment as usual (TAU)
62425608|NCT03554642|ACTIVE_COMPARATOR|Physical Therapy|This group will receive usual inpatient care including at least one 60-minute session of physical therapy per day, and an additional 30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
62425609|NCT03554642|NO_INTERVENTION|Usual Care Physical Therapy|Participants in this group will receive usual inpatient care including at least one 60-minute session of physical therapy per day.
62425610|NCT06279936||Long Covid patients|Long Covid patients with (neuro)psychological complaints
62810771|NCT04400630|EXPERIMENTAL|PE intervention+TAU|Physical exercise (PE) intervention + treatment as usual (TAU)
62810772|NCT04428398||No renal involvement|Patients with ANCA-vasculitis and no ANCA-associated renal involvement in disease history
62810773|NCT04428398||Renal remission|Patient with ANCA-vasculitis in renal remission
62810774|NCT01535040|ACTIVE_COMPARATOR|Arm I - Memantine|Participants receive memantine hydrochloride PO BID) on days 1-81 in the absence of unacceptable toxicity.
62810775|NCT01535040|PLACEBO_COMPARATOR|Arm II - Placebo|Participants receive a placebo PO BID on days 1-81 in the absence of unacceptable toxicity.
62810776|NCT01329315|ACTIVE_COMPARATOR|BMI-T|Brief Motivational Intervention (BMI-T): social worker/therapist-delivered intervention (25-minute tailored structured module).
62810777|NCT01329315|ACTIVE_COMPARATOR|BMI-C|Computer-delivered intervention (BMI-C): computerized tailored 25-minute intervention.
62810778|NCT01329315|NO_INTERVENTION|DPB|Drug Prevention Booklet (DPB)- National Institute on Drug Abuse (NIDA)-developed drug prevention booklet to address preventing marijuana initiation, and marijuana use.
62810779|NCT03623113|EXPERIMENTAL|BCC intervention|The BCC program consists of three group sessions and is delivered by two trained dietitians. In addition to the BCC program, the participants receive regular medical care in the diabetes clinic
62593921|NCT01383629|EXPERIMENTAL|Preoperative counselling|Counselling to patient about what to expect during vitrectomy surgery under local anaesthesia
62593922|NCT00754208|OTHER|methylpehnidate|open-label treatment with methylphenidate
62593923|NCT03358108||Group A: interferon group|formerly interferon group (including interferon alone or interferon combined with other drugs)
62593924|NCT03358108||Group B:nucleoside analogue group|formerly nucleoside analogue treatment group. Each group was followed for five years
62593925|NCT03385304|EXPERIMENTAL|10% povidone-iodine (1% free iodine) in purified water|The povidone-iodine solution will contain 10% povidone-iodine (1% free iodine) in purified water as the only active ingredient. Operating room personnel will apply the solution to the operative site as the final preoperative skin antisepsis preparation immediately prior to commencing surgical fixation. They will apply the solution as per manufacturer's directions for use (e.g., technique of application, duration of application, drying time, drying techniques, replacement of draping, etc.).
62593926|NCT03385304|EXPERIMENTAL|4% chlorhexidine gluconate (CHG) in purified water|The CHG solution will contain 4% CHG in purified water as the only active ingredient. Operating room personnel will apply the solution to the operative site as the final preoperative skin antisepsis preparation immediately prior to commencing surgical fixation. They will apply the solution as per manufacturer's directions (e.g., technique of application, duration of application, drying time, replacement of draping, etc.).
62593927|NCT01597388|EXPERIMENTAL|AZD2014 with Fulvestrant|AZD2014 with Fulvestrant
62593928|NCT06202664|EXPERIMENTAL|Opioid Free Anesthesia Group|This will be the experimental group. Patient entering this group through computer generated random numbers will receive opioid free anesthesia in form of ultrasound guided Erector Spinae Block given bilaterally at T6 level.
62593929|NCT06202664|ACTIVE_COMPARATOR|Conventional Opioid group|Patient entering this group through computer generated random numbers will receive opioid based anesthesia.
62593930|NCT06036043||Intervention group|Patients treated with Botulinum Toxin
62034500|NCT06544733|ACTIVE_COMPARATOR|Phase 3: BVY Placebo to Match GS-1720/GS-4182 FDC + BVY (Treatment Group 2)|Participants who have been virologically suppressed on BVY will continue receiving oral BVY daily. In addition, participants will receive a 1-day loading dose of PTM GS-1720/GS-4182 on Day 1 and weekly PTM thereafter. Participants will receive treatment for at least 96 weeks.
62593931|NCT03896711|EXPERIMENTAL|Active Intervention|Intervention arm with MEMORI Corps program
62593932|NCT03896711|OTHER|Control|Augmented waitlist control.
62593933|NCT01051544|ACTIVE_COMPARATOR|von Willebrand factor-free FVIII concentrates|Patients treated with FVIII concentrates
62593934|NCT01051544|ACTIVE_COMPARATOR|FVIII/VWF concentrates|Patients treated with FVIII/VWF concentrates
62593935|NCT05732142|EXPERIMENTAL|PIVoT|Gender-transformative family planning counseling and contraception provision at the time of infant vaccination
62593936|NCT05732142|NO_INTERVENTION|Standard of care|Standard infant vaccination and family planning referrals
62593937|NCT00217776|ACTIVE_COMPARATOR|Open Airways Educational Intervention|Children in this arm will receive the Open Airways educational program which is an evidenced based asthma educational program for children, developed by the investigator.
62593938|NCT00217776|ACTIVE_COMPARATOR|Open Airways and Peer Asthma Action Intervention Education|Children in this arm will receive BOTH the Open Airways asthma education program and the Peer Asthma Action education program.
62810780|NCT03623113|EXPERIMENTAL|ABC-ACC intervention|The ABC-ACC program consists of one group session and two individual follow-up sessions and is delivered by trained dietitians with supervision by a medical doctor. In addition to the ABC-ACC program, the participants receive regular medical care in the diabetes clinic
62234632|NCT04727879|OTHER|PMR|"Patients with PMR will be offered biopsy of the synovial membrane with puncture of synovial fluid during cortisone infiltration for analgesic purposes. In case of associated peripheric arthritis, the patient will also be offered a joint fluid sample during a cortisonic infiltration for analgesic purposes, performed as part of routine care~The study-specific examination that is not part of current practice is the synovial biopsy performed during the cortisonic infiltration procedure."
62425611|NCT06279936||Covid controls (Ca)|COVID-19 survivors without persistent complaints
62425612|NCT06279936||Non-Covid controls (Cb)|healthy uninfected controls
62425613|NCT05147285|EXPERIMENTAL|Stabilization group|Only stabilization exercises in patients with cystic fibrosis
62425614|NCT05147285|EXPERIMENTAL|combined group|stabilization exercise and aerobic exercise training in patients with cystic fibrosis
62425615|NCT05147285|EXPERIMENTAL|control group|physical activity recommendations in patients with cystic fibrosis
62425616|NCT03673475||fluid responsiveness|Assessment of fluid responsiveness using pleth variebility index and jugular vein distensibility in patients undergoing major abdominal surgery
62425617|NCT04069104||ABCD training with standard feedback|Asymmetry, Border, Color, Diameter (ABCD) training message intervention with standard dermatological feedback
62425618|NCT04069104||ABCD training with motivational feedback|ABCD training message intervention with dermatological feedback and a motivational message
62593939|NCT00217776|NO_INTERVENTION|Control Arm|Children in the Control Arm will be interviewed in person at baseline, 12 month and 24 months.
62593940|NCT03319264|EXPERIMENTAL|Patients with SpA|"Patients included in this single group study will have 3 interventions to assess the severity of muscle loss :~* dynamometry exam~* walking test~* Dual-energy X-ray Absorptiometry (DXA) measurement Quality of life will be assessed with Sarcopenia \& Quality of Life (SARQOL) questionnaire. Patients will also fill a Life habits Questionnaire."
62034501|NCT06544733|EXPERIMENTAL|Phase 3 Extension Phase: GS-1720/GS-4182 Fixed-dose Combination (FDC)|After the end of blinded treatment, Phase 3 participants will be given the option to participate in the Extension Phase. Phase 3 Treatment Group 1 will switch to GS-1720/GS-4182 FDC weekly. Phase 3 Treatment Group 2 will receive a 1-day loading dose of GS-1720/GS-4182 FDC on Extension Phase Day 1, then GS-1720/GS-4182 FDC weekly. Participants who choose to enter the Extension Phase will receive GS-1720/GS-4182 FDC tablets until the product becomes available or until Gilead Sciences elects to discontinue the study, whichever occurs first.
62034502|NCT05663294|EXPERIMENTAL|Partial Breast Irradiation|"Radiation treatment will be started within 120 days after surgery. The fractionation schedule depends on the policy of the treating center, but is mandatory to use CT-based planning. Both once-daily and twice-daily schedule are allowed.~The allowed schedules for external beams radiotherapy are:~* 40 Gy in 15 fractions;~* 30 Gy in 5 fractions;~* 40 Gy or 38.5 in 10 twice-daily fractions (each daily dose must be separated by at least 6 hours).~The schedule for brachytherapy are:~* 32 Gy in 8 twice-daily fractions for HDR;~* 30.3 Gy in 7 twice-daily fractions for HDR;~* 50Gy 0.60-0.80 Gy/hour (1 pulse/hour, 24 hours/day) for PDR."
62810781|NCT03623113|ACTIVE_COMPARATOR|Standard dietary education|The routine outpatient dietary care consists of three individual consultations delivered by a trained dietitian. The individual guidance is based on the overall treatment goal(s), the defined personal dietary goals for behavioral change which will be in accordance with the patient's needs and preferences. In addition to the dietary counselling, the participants receive regular medical care in the diabetes clinic
62034503|NCT04401384|OTHER|Diclectin plus active acupuncture|Diclectin (combination of doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg) , 2-4 tablets/day) + active acupuncture (30 min /every day).
62034504|NCT04401384|OTHER|Diclectin plus sham acupuncture|Diclectin (combination of doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg), 2-4 tablets/day) + sham acupuncture (30 min /every day).
62034505|NCT04401384|OTHER|Placebo plus active acupuncture|Diclectin placebo (2-4 tablets/day) + active acupuncture (30 min / every day)
62034506|NCT04401384|OTHER|Placebo plus sham acupuncture|Diclectin placebo (2-4 tablets/day) + sham acupuncture (30 min /every day)
62425619|NCT04069104||ABCD training with no feedback|ABCD message intervention with no feedback
62425620|NCT04069104||UDS method training with standard feedback|Ugly Duckling Sign (UDS) method message intervention with dermatological feedback.
62425621|NCT04069104||UDS method training with motivational feedback|UDS message intervention with dermatological feedback and a motivational message.
62425622|NCT04069104||UDS training with no feedback|UDS message intervention with no feedback.
62425623|NCT04069104||ABCD-F training with standard feedback|ABCD-F intervention with dermatological feedback.
62425624|NCT04069104||ABCD-F training with motivational feedback|ABCD-F intervention with dermatological feedback and a motivational message.
62425625|NCT04069104||ABCD-F training with no feedback|ABCD-F intervention with no feedback.
62593941|NCT06408545|EXPERIMENTAL|ACT group|8 individual weekly sessions including ACT methods
62810782|NCT02855008|EXPERIMENTAL|STEPS|Experimental: Individuals with ID and residential staff in group homes receive 6 one-hour STEPS sessions over 12 weeks and a booster in week 18 following a standardized manual. Sessions include interactive games to build group cohesiveness, along with interactive discussion and practice. Participants are given session materials and 1-2 worksheets to practice learned skills and are asked to return the worksheets at the next session. Residential staff are given additional materials with tips on how to help residents practice social problem-solving skills between sessions. Highlights of each session using a standardized format are brought to the following session to help with engagement and provide cues for retention of materials.
62810783|NCT02855008|ACTIVE_COMPARATOR|Food for Life|Active Comparator: Individuals with ID and residential staff in group homes receive 6 one-hour Food for Life sessions over 12 weeks and a booster in week 18 following a standardized manual. Sessions include interactive games regarding food and nutrition followed, along with interactive discussion and practice. Participants are given session materials and 1-2 worksheets to practice learned skills and are asked to return the worksheets at the next session. Residential staff are given additional materials with tips on how to help residents practice Food for Life skills between sessions. Highlights of each session using a standardized format are brought to the following session to help with engagement and provide cues for retention of materials.
62593942|NCT04053140|EXPERIMENTAL|Routine intermittent slow bolus|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV 1200mg administered every 4 hours.
62593943|NCT04053140|EXPERIMENTAL|Closed-loop control of intermittent slow bolus|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.
62593944|NCT04053140|EXPERIMENTAL|Closed-loop control of continuous infusion|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.
62593945|NCT01118260|ACTIVE_COMPARATOR|TIVA|Total intravenous anaesthesia (TIVA) with propofol and remifentanil
62593946|NCT01118260|ACTIVE_COMPARATOR|Spinal|Spinal anaesthesia with bupivacaine and fentanyl
62593947|NCT05753891|EXPERIMENTAL|Carpometacarpal (CMC) Suture Tape Ligament Reconstruction|Patients in this arm will undergo trapeziectomy with suture tape suspension of the 1st metacarpal to the 2nd metacarpal via Arthrex InternalBrace device. This is the experimental group.
62593948|NCT05753891|NO_INTERVENTION|Carpometacarpal (CMC) Standard Ligament Reconstruction|Patients in this arm are considered the control group and will undergo trapeziectomy with ligament reconstruction and tendon interposition.
62593949|NCT00893165||hemodialysis patients|chronic hemodialysis patients with elevated inflammation markers
62593950|NCT02101931|EXPERIMENTAL|Urine spectral analysis|The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking Amino levulinic Acid and the samples will be analyzed by photodynamic diagnostic procedure. Amino levulinic Acid gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).The above samples is taken in a four side polished quartz cuvette of 1cmx1cmx4cm and put into the table top spectral scan. This consists of a 5 mw, blue diode laser, of 405nm wavelength. The collimated laser beam falls on the urine sample and excites fluorescence and Raman signals from the porphyrin molecules which have been metabolized from the oral administration of Amino levulinic Acid.
62593951|NCT05032092|EXPERIMENTAL|Adult patients with locally advanced and/or metastasized solid cancer|"Liquid biopsies of all 235 study patients will be analysed with FoundationOne®Liquid CDx.~Tissue biopsies from all study patients for whom a tissue biopsy is available will be analysed with FoundationOne® CDx and IHC (approximately 50% of the enrolled patients).~Biomarker Monitoring of study patients receiving matched therapy with AVENIO ctDNA Expanded Kit."
62593952|NCT06618469|EXPERIMENTAL|Elastic band-based resistance training program at high intensity (HI)|
62593953|NCT06618469|EXPERIMENTAL|Elastic band-based resistance training program at moderate-high intensity (MHI-bands)|
62593954|NCT06618469|EXPERIMENTAL|Elastic band-based resistance training program at moderate intensity (MI)|
62593955|NCT06618469|EXPERIMENTAL|Elastic tubes-based resistance training program at moderate-high intensity (MHI-tubes)|
62810784|NCT05596955|EXPERIMENTAL|Buprenorphine|Study participants receive three once-a-month injections of buprenorphine and complete weekly monitoring visits.
62593956|NCT06618469|EXPERIMENTAL|Water-based resistance training program at moderate intensity (WMI)|
62593957|NCT06618469|NO_INTERVENTION|Control group|Participants randomized into the CONTROL group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet.
62593958|NCT06619977|NO_INTERVENTION|Standard practice retrospective group|Patients undergoing living liver donor resections with general anesthesia without ANI monitoring.
62810785|NCT05596955|ACTIVE_COMPARATOR|Naltrexone|Study participants receive three once-a-month injections of naltrexone and complete weekly monitoring visits.
62593959|NCT06619977|EXPERIMENTAL|ANI guided group|Patients undergoing living liver donor resections with general anesthesia with ANI nociception monitoring.
62810786|NCT01626326||Stop smoking app|Stop smoking iPhone research app provided at no charge via the iTunes store
62810787|NCT06196385|EXPERIMENTAL|intensive Cervical Traction for cervical radiculopathy|Using intensive cervical traction through mechanical computerized device
62810788|NCT06196385|ACTIVE_COMPARATOR|intensive Cervical Traction for healthy matched group|USING TRACTION FOR HEALTHY MATCHED AGE CONTROL GROUP
62593960|NCT02768116|EXPERIMENTAL|ATP technique|This arm plan to enroll 158 subjects. Sirolimus-eluting Drug stent implantation via Active transfer of Plaque technique in the treatment of non-left-main bifurcation lesion.In the ATP technique treatment of bifurcation lesions, by the balloon pre-dilation in the target side branch, the plaque will be actively transferred from side branch to main vessel. Subsequently, the plaque will be fixed by the expansive stent in main vessel. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI or stent in SB is recommended if there is at least one of following: residual stenosis\>75%, \>type B dissection and TIMI flow\<3.
62593961|NCT02768116|ACTIVE_COMPARATOR|Provisional T stenting technique|This arm plan to enroll 158 subjects. Sirolimus-eluting Drug stent implantation via Provisional T stenting technique in the treatment of non-left-main bifurcation lesions.Provisional T stenting technique is the typic step-T stenting. In brief, two wires are advanced to distal MV and SB. Pre dilation is left at operator's discretion, however, pre dilating SB is not encouraged. Kissing balloon inflation before stenting MV is left at operator's discretion. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI is recommended if there is at least one of following: residual stenosis\>75%, \>type B dissection and TIMI flow\<3.
62593962|NCT04529252||Spinocerebellar Ataxia and Other Nucleotide Repeat Diseases|Participants with a clinical diagnosis of spinocerebellar ataxia and other nucleotide repeat diseases (not including Huntington's Disease) with or without a genetic mutation and unaffected family members (grandparents, parents, brothers, sisters, cousins, uncles and aunts) who may or may not carry a genetic mutation for the disease.
62593963|NCT04529252||Control Group|Participants with no known medical or family history of inherited neurodegenerative forms of spinocerebellar ataxia or nucleotide repeat diseases (not including Huntington's Disease) and spouses or caregivers of patients with spinocerebellar ataxia and nucleotide repeat diseases (not including Huntington's Disease) will serve as controls in the study.
62593964|NCT04739722|EXPERIMENTAL|ColoSense|All participants were evaluated with ColoSense prior to undergoing a colonoscopy.
62593965|NCT03060343|EXPERIMENTAL|Zeushield Cytotoxic T Lymphocytes|Enrolled patients will receive Zeushield Cytotoxic T Lymphocytes by infusion
62593966|NCT04652908|EXPERIMENTAL|Treatment with PMSC-ECM|One-time administration of PMSC-ECM during the course of in utero fetal myelomeningocele surgery will be administered
62593967|NCT04652908|OTHER|non-PMSC untreated contemporaneous cohort|Contemporaneous cohort of patients undergoing routine fetal or postnatal MMC repair without PMSC-ECM (non-PMSC untreated contemporaneous cohort).
62593968|NCT03329170|EXPERIMENTAL|CHD intervention|educational intervention using motivational interviewing
62593969|NCT03329170|NO_INTERVENTION|CHD control|At 24 and 36 months of age the parents of the child will fill in a questionnaire via internet, designed to assess oral health behaviour. At 36 months of age the child will be offered to participate in a clinical dental examination.
62593970|NCT03329170|NO_INTERVENTION|Healthy control|At 36 months of age the parents of the child will fill in a questionnaire via internet, designed to assess oral health behaviour. At 36 months of age the child will be offered to participate in a clinical dental examination.
62810789|NCT00724841|EXPERIMENTAL|1|40 mg/m2 GMX1777 with Temozolomide
62810790|NCT00724841|EXPERIMENTAL|2|50 mg/m2 GMX1777 with Temozolomide
62810791|NCT00724841|EXPERIMENTAL|3|62 mg/m2 GMX1777 with Temozolomide
62425626|NCT04069104||No message intervention with standard feedback|No message intervention, but with dermatological feedback.
62425627|NCT04069104||No message intervention with motivational feedback|No message intervention, but with dermatological feedback and a motivational message.
62425628|NCT04069104||No message intervention with no feedback|No message intervention and no feedback. True control.
62425629|NCT04368182|EXPERIMENTAL|Treatment group|Autologous C-TCR055 administered by intravenous (IV) infusion
62425630|NCT01783899|EXPERIMENTAL|Hemospray Group|"Hemospray device consists of a syringe containing the Hemospray powder (21 g per syringe), a delivery catheter that will be inserted into the working channel of the endoscope, and an introducer handle with a built-in carbon dioxide canister to propel the Hemospray powder out of the catheter.~In addition to Hemospray device any other required endoscopic accessories can be used during the procedure."
62425631|NCT05602935|EXPERIMENTAL|Camrelizumab+SOX|The patients in the experimental arm will receive camrelizumab concurrently with SOX(S-1 and oxaliplatin).
62810792|NCT00724841|EXPERIMENTAL|4|80 mg/m2 GMX1777 with Temozolomide
62810793|NCT00724841|EXPERIMENTAL|5|100 mg/m2 GMX1777 with Temozolomide
62425632|NCT00776269|EXPERIMENTAL|argon laser|
62425633|NCT00047437|ACTIVE_COMPARATOR|2|
62425634|NCT00047437|NO_INTERVENTION|1|
62425635|NCT02135094|EXPERIMENTAL|Active ultrasound therapy device|Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours on days when their trapezius muscle pain score is at least a 3 on a scale of 0-10 (NRS). The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity
62425636|NCT02135094|PLACEBO_COMPARATOR|Placebo ultrasound therapy device|Patients apply the Sam Ultrasonic Diathermy Device for 4 hours on days when their trapezius muscle pain score is at least a 3 on a scale of 0-10 (NRS). The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
62425637|NCT04368663|ACTIVE_COMPARATOR|TJ-134 group|The traditional Japanese medicine, Keishi-ka-shakuyaku-daio-to（TJ-134, 7.5g/day), which consists of a mixture of a compound of peony root (6 g), cinnamon bark (4 g), jujube (4 g), glycyrrhiza (2 g), rhubarb (2 g), and ginger (1 g) is administered to enrolled patients for 8 weeks.
62425638|NCT04368663|PLACEBO_COMPARATOR|Lactomin group|Lactomin (3g/day) is administered to enrolled patients for 8 weeks.
62425639|NCT04741139|EXPERIMENTAL|Scheduled post-IVIG medication|Utilization of post-IVIG medication with acetaminophen and diphenhydramine on a scheduled basis of 72 hours post-infusion.
62593971|NCT06388200|EXPERIMENTAL|RHO Arm|Subjects will receive a sub-retinal injection of OCU400-301 modifier gene therapy product with a concentration of 2.5 x 10E10 vg/eye
62810794|NCT00724841|EXPERIMENTAL|6|125 mg/m2 GMX1777 with Temozolomide
62810795|NCT01110824|EXPERIMENTAL|Enalapril and carvedilol|Enalapril 2.5 to 10 mg BID plus Carvedilol 6.25 to 25 mg BID
62810796|NCT01110824|NO_INTERVENTION|Control|Control arm without intervention
62810797|NCT05257278||MonoPlus®|Patients undergoing orthopedic surgery with soft tissue approximation
62810798|NCT04386200|EXPERIMENTAL|WEB GROUP|Traditional approach integrated with web-based technologies.
62810799|NCT04386200|OTHER|TRADITIONAL GROUP|Traditional educational approach
62810800|NCT05746507|EXPERIMENTAL|Night Respite Care|18 overnight night respite care sessions over six weeks with parental skills provided through teachable moments before and after respite care supports
62810801|NCT06425081|ACTIVE_COMPARATOR|L. reuteri AMBV339|Probiotic strain, 1B AFU (per day for 28 days in capsule format)
62234633|NCT04727879|OTHER|Control|Witnesses recruited into the orthopedic surgery department will be offered a synovial membrane biopsy during a shoulder surgery in the context of mechanical pathology.
62810802|NCT06425081|ACTIVE_COMPARATOR|Humiome B2|73 mg colon delivered riboflavin containing 10 mg pure riboflavin (per day for 28 days in capsule format)
62234634|NCT06375889||aSAH group|Patient hospitalised following the occurrence of an aneurysmal subarachnoid haemorrhage of any grade of severity.
62425640|NCT06338189|ACTIVE_COMPARATOR|The 5Ad Diet|Participants are required to follow the 5Ad diet for 7 days, followed by a washout phase for 7 days, before crossing over to the active phase of the low FODMAP diet for 7 days.
62234635|NCT06375889||IPH group|Patient hospitalised following the occurrence of a non-traumatic intra-parenchymal haematoma.
62234636|NCT00594126|OTHER|1|3+3 cohort dose escalation
62234637|NCT03967639||Group T2DM|Patients with diabetes mellitus undergoing elective cardiac surgery
62234638|NCT03967639||Group Ctrl|Control patients undergoing elective cardiac surgery without T2DM
62234639|NCT04744051|ACTIVE_COMPARATOR|50 million cell infusion|Each participant in this arm will receive a single dose of 50 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
62234640|NCT04744051|ACTIVE_COMPARATOR|150 million cell infusion|Each participant in this arm will receive a single dose of 150 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
62234641|NCT04744051|ACTIVE_COMPARATOR|300 million cell infusion|Each participant in this arm will receive a single dose of 300 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
62234642|NCT04744051|PLACEBO_COMPARATOR|Placebo|Each participant in this arm will receive a single dose of placebo. Upon completion of the study each placebo participant with be given the option to be treated with their cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Dosage for the crossover will be determined by the PI following review of data collected from the other arms of the study.
62234643|NCT04750096||Esophagectomy post enhanced recovery after surgery|Patients undergoing esophagectomy due to oesophageal cancer under Enhanced Recovery After Surgery protocol.
62425641|NCT06338189|ACTIVE_COMPARATOR|The Low FODMAP Diet|Participants are required to follow the active phase of the low FODMAP diet for 7 days, followed by a washout phase for 7 days, before crossing over to the 5Ad diet for 7 days.
62234644|NCT01833715|ACTIVE_COMPARATOR|Morphine|morphine group 0.08 mg / kg, to start surgery
62425642|NCT04229277|OTHER|in tumours|consecutive enrollment of newly referred skin tumour patients
62425643|NCT06540755||H Group|periodontally healthy individuals
62425644|NCT06540755||P Group|stage 3 grade B and C periodontitis patients
62425645|NCT02306473|EXPERIMENTAL|Asthma|Subjects with asthma will be exposed to inhaled mannitol according to FDA approved protocols.
62425646|NCT02306473|EXPERIMENTAL|Controls|Healthy control subjects will be exposed to inhaled mannitol according to FDA approved protocols.
62425647|NCT00803673|EXPERIMENTAL|Active|100mcg 719
62810803|NCT06425081|ACTIVE_COMPARATOR|Combination arm|Probiotic strain, 1B AFU + 73 mg colon delivered riboflavin containing 10 mg pure riboflavin (per day for 28 days in capsule format)
62810804|NCT06425081|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose (per day for 28 days in capsule format)
62810805|NCT03238716|EXPERIMENTAL|Electric DN, NM Re-ed, Exercise|
62425648|NCT00803673|EXPERIMENTAL|Active 2|500mcg '719
62234645|NCT01833715|EXPERIMENTAL|Methadone|methadone group 0.08 mg / kg, to start surgery
62234646|NCT01104753||Non-interventional post-authorisation safety study|
62425649|NCT00803673|EXPERIMENTAL|Active 3|1000mcg '719
62425650|NCT00803673|PLACEBO_COMPARATOR|Placebo|Placebo '719
62593972|NCT06388200|EXPERIMENTAL|Gene Agnostic Arm|Subjects will receive a sub-retinal injection of OCU400-301 modifier gene therapy product with a concentration of 2.5 x 10E10 vg/eye
62810806|NCT03238716|ACTIVE_COMPARATOR|NM Re-ed and Exercise|
62810807|NCT03396796|EXPERIMENTAL|Vagus nerve-preserving group|Every patient of vagus nerve-preserving group will receive the modified vagus nerve-preserving laparoscopic azygoportal disconnection procedure.
62810808|NCT03396796|NO_INTERVENTION|Conventional group|Every patient of conventional group will receive the conventional laparoscopic azygoportal disconnection procedure.
62810809|NCT06112665|EXPERIMENTAL|Tofactinib|Patients receive Tofacitinib and Naproxene
62810810|NCT06112665|ACTIVE_COMPARATOR|Placebo Arm|Patients receive placebo pills and Naproxene
62234647|NCT03228381|EXPERIMENTAL|BOSS Device|Patients who are undergoing open chest cardiac surgery via sternotomy will receive the BOSS device to assess acute anatomical and geometric annular and ventricular changes that occur when strategically positioned an external inflatable chambers are applied to the outside of the heart.
62810811|NCT05036304|ACTIVE_COMPARATOR|Aerobic Exercise Indoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. Participants will walk or jog on treadmills or cycle on stationary bikes in the Exercise Prescription Suite of the Centre for Hip Health and Mobility.
62810812|NCT05036304|EXPERIMENTAL|Aerobic Exercise Outdoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. participants will walk or jog pre-determined routes in trails of an urban forest (Pacific Spirit Park).
62810813|NCT01510054||steroid support|Endometrial biopsies from subjects of with or without luteal phase steroid support will be compared for miRNA expression
62810814|NCT05227456|EXPERIMENTAL|Etonogestrel implant|The participants will receive an etonogestrel 68mg implant
62810815|NCT05854108|OTHER|Cervical Traction|
62810816|NCT05854108|EXPERIMENTAL|Snag Therapy|
62810817|NCT03541122||Experimental group|Patients will undergo pelvic X-ray examinations. Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads. The investigators will determine the sensitivity and specificity of OFI, MUI and TBOI for the diagnosis of adult acetabular dysplasia, and compare the accuracy of diagnosis between these three indicators and CE angle, sharp angle, and AHI. Further analysis of risk factors for hip function will be implemented.
62810818|NCT05427981|EXPERIMENTAL|Buprenorphine|Buccal Films
62810819|NCT05427981|PLACEBO_COMPARATOR|Placebo|Buccal Films
62810820|NCT00287105|OTHER|Good risk Ph+ALL|For protocols which adopt a steroid prephase: patients who are Prednisone-good responder and achieve CR after the induction course. For protocols which do not adopt steroid prephase: patients who have M1/M2 BM at day 15 or M1 BM at day 21 and achieve CR after the induction course. Expected stratification in this group: 70-75%.
62810821|NCT00287105|OTHER|Poor risk Ph+ALL|For protocols which adopt a steroid prephase: patients who are Prednisone poor-responders. For protocol which do not adopt a steroid prephase: patients who have M3 BM at day 15 or M2/M3 BM at day 21. For all protocols: patients who do not achieve CR after the induction course. Expected stratification: 25-30%.
62810822|NCT01671163||Subjects requiring fiducial placement|Endoscopic Ultrasound (EUS) for fiducial placement
62810823|NCT05133024|ACTIVE_COMPARATOR|beetroot juice|Brand: BEET IT sport NITRATE 400 concentrated beetroot shot (James White Drinks Ltd.) Dosage regimen: 7 shots of 70 mL, once daily in the morning, on 7 consecutive days before surgery
62810824|NCT05133024|PLACEBO_COMPARATOR|nitrate-depleted beetroot juice|Brand: BEET IT sport NITRATE 400 nitrate-depleted concentrated beetroot shot (James White Drinks Ltd.) Dosage regimen: 7 shots of 70 mL, once daily in the morning, on 7 consecutive days before surgery
62234648|NCT04780308||1 medial 1 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 1 medial 1 lateral K-wire
62425651|NCT05458622|OTHER|Stable or quiescent SLE|"Patients included in this study will undergo one assessment at the time of recruitment and at the time of the end of study (time of a flare or at least 24 months after inclusion)~The following information will be collected :~* General data: date of flare.~* Disease activity: BILAG; SLEDAI-2K; PhGA (0-3); PGA (0-10); LLDAS; DORIS ; CLASI for mucocutaneous involvement; 44 joint assessment; proteinuria (UPCR); serum creatinine and eGFR for lupus nephritis.~* Organ damage: SLICC/ACR Damage Index.~* Kidney histopathology~* HRQoL: EQ-5D-5L; FACIT-F; Medical Outcomes Study 36-item Short Form health survey (SF-36); Epworth Sleepiness scale (ESS); Lupus-QoL.~* Start day and current dose for current treatments~Biological samples which will be obtained twice, at baseline and at the time of the first flare documented over 24 months, or at month 24 if no flare has been documented:~* Blood~* Urine~* Stool~* Saliva~* Tissue samples for organ-specific manifestations"
62810825|NCT04268186|EXPERIMENTAL|Direct tDCS|Transcranial direct current stimulation (tDCS) was computationally optimized to target mid-cingulate cortex directly.
62425652|NCT06515717|EXPERIMENTAL|ketone ester|Participants consume a ketone ester 3x per day for 8 days.
62593973|NCT06388200|NO_INTERVENTION|Control for RHO Arm|Will not receive any active study intervention
62810826|NCT04268186|EXPERIMENTAL|Indirect tDCS|Transcranial direct current stimulation (tDCS) was computationally optimized to target the middle frontal gyrus, a brain area connected to mid-cingulate cortex.
62810827|NCT04268186|EXPERIMENTAL|Personalized tDCS|Transcranial direct current stimulation (tDCS) will be individually optimized to simultaneously stimulate key nodes connected to mid-cingulate cortex, including anterior insula, MFG and supramarginal gyrus.
62810828|NCT04268186|SHAM_COMPARATOR|Sham tDCS|Placebo transcranial direct current stimulation (tDCS) will be applied.
62234649|NCT04780308||1 medial 2 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 1 medial 2 lateral K-wire
62234650|NCT04780308||2 medial 1 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 2 medial 1 lateral K-wire
62593974|NCT06388200|NO_INTERVENTION|Control for Gene Agnostic Arm|Will not receive any active study intervention
62593975|NCT04203992|EXPERIMENTAL|Videogame|Educational videogame, five 60-minute sessions over one month
62234651|NCT04780308||2 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 2 lateral K-wire
62593976|NCT04203992|ACTIVE_COMPARATOR|Booklet|Educational booklet, one session
62593977|NCT03016481|ACTIVE_COMPARATOR|the Community Health Worker -Personalized Support for Progress|Patients will work with a Community Health Worker (CHW) to complete a prioritization tool and meet as needed over the course of the next 6 months to navigate services and overcome barriers. In addition, patients will receive referrals to other professionals based on their prioritization and meet with the CHW at the time and place of their choice.
62593978|NCT03016481|ACTIVE_COMPARATOR|Care as Usual- Social Worker|Patients in the Care as Usual- Social Worker (CAU-SW) arm, will do intake with a social worker, who follows hospital procedures for intake and referrals, does a needs assessment, and offers safety planning in referral.
62593979|NCT04711174||movement,high Aldrete score group (MH group)|LMA removal be conducted when the child's spontaneous respiratory recovers with body movement spontaneously, and the child be transited from PACU when Aldrete score reaches 9
62593980|NCT04711174||movement,low Aldrete score group (ML group)|LMA removal be conducted when the child's spontaneous respiratory recovers with body movement spontaneously, and the child be transited from PACU when Aldrete score reaches 7
62593981|NCT04711174||sedation,high Aldrete score group (SH group)|LMA removal be conducted when the child's spontaneous respiratory recovers but with no body movement, and the child be transited from PACU when Aldrete score reaches 9
62593982|NCT04711174||sedation,low Aldrete score group (SL group)|LMA removal be conducted when the child's spontaneous respiratory recovers but with no body movement, and the child be transited from PACU when Aldrete score reaches 7
62593983|NCT02496351|ACTIVE_COMPARATOR|TENS INTERVENTION|In the immediately postoperative of limb amputation, TENS will be use in this patients during 24 hours. The intensity of the impulse will be determined in a test carried out 3 days before surgery. The other parameters will be continuous, biphasic, compensated and symmetric impulse, frequency of 80 Hz, time impulse between 250 and 290 microseconds, modulation time 5´´
62034507|NCT02862106|EXPERIMENTAL|εPA-44 900μg group-placebo|These subjects from the placebo group of protocol 71006.01 InjectεPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
62034508|NCT02862106|EXPERIMENTAL|εPA-44 900μg group-εPA-44 600μg|These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
62234652|NCT04780308||3 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 3 lateral K-wire
62234653|NCT03311334|EXPERIMENTAL|DSP-7888 Dosing Emulsion in combination with Nivolumab|
62234654|NCT03311334|EXPERIMENTAL|DSP-7888 Dosing Emulsion in combination with Pembrolizumab|
62234655|NCT01482663|NO_INTERVENTION|Chronic hand eczema patients|Written information sheets and a 14-minutes DVD about hand eczema handed out by the dermatologist
62234656|NCT01482663|EXPERIMENTAL|Behavioral: Healthy Skin Clinic|1-2 counselling sessions with a nurse, tailored according to individual risks and resources and user access to a website comprising a self-monitoring log, a patients' forum and the possibility of communication with the intervention team of nurses
62234657|NCT05274984|PLACEBO_COMPARATOR|Group Placebo|the control group will be given the same volume of saline as the experimental group
62593984|NCT02496351|PLACEBO_COMPARATOR|TENS NO INTERVENTION|In the immediately postoperative of limb amputation, TENS will be use in this patients during 24 hours, but in this case TENS just will be on. No intensity impulse should be programmed.
62234658|NCT05274984|ACTIVE_COMPARATOR|Group Lidocaine|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
62234659|NCT05185544||neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma|neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma
62234660|NCT06000020||Diagnostic laparoscopy|Diagnostic laparoscopy on suspicion of acute appendicitis with normal intraoperative findings (including mesenteric adenitis).
62425653|NCT06515717|PLACEBO_COMPARATOR|Placebo containing dextrose|Participants consume a placebo 3x per day for 8 days. The placebo is matched in calories and taste to the ketone ester.
62593985|NCT01576445|EXPERIMENTAL|Mid-vastus approach|
62034509|NCT02862106|EXPERIMENTAL|εPA-44 900μg group-εPA-44 900μg|These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
62425654|NCT01416207|EXPERIMENTAL|Avonex|4 weekly injections of Avonex (IM)
62425655|NCT00886782|EXPERIMENTAL|Cdc7-inhibitor|
62425656|NCT05433688||UBS|unidirectional barbed suture (Symmcora® mid term, UBS)
62425657|NCT05433688||CS|conventional suture (Novosyn®, CS)
62593986|NCT01576445|EXPERIMENTAL|medial parapatellar approach|
62593987|NCT02668809|EXPERIMENTAL|Experimental Group 1|consent, oral health assessment, questionnaires, Educational Program, clinical exam, microbiological sampling, monitoring adherence.
62034510|NCT02862106|NO_INTERVENTION|Follow-up group-placebo|These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only
62234661|NCT06000020||Laparoscopic appendectomy|Laparoscopic appendectomy despite normal intraoperative findings (including mesenteric adenitis) and histopathology showing a normal appendix.
62810829|NCT02336282|ACTIVE_COMPARATOR|tDCS on Day 1|"On day one, participants will be randomized to receive the transcranial Direct Current Stimulation (tDCS) intervention. On day two, participants receive sham intervention.~On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.~In the second phase of the trial, participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive assessment will be conducted pre- and post-intervention using remote assessment."
62034511|NCT02862106|NO_INTERVENTION|Follow-up group-εPA-44 600μg|These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only
62234662|NCT04841551|OTHER|Kybella Flanks|10 subjects will be treated with Kybella in the flanks
62234663|NCT00128076|ACTIVE_COMPARATOR|1|All-arthroscopic repair
62234664|NCT00128076|ACTIVE_COMPARATOR|2|Mini-open repair
62234665|NCT05212454|EXPERIMENTAL|capecitabine group|All enrolled cases should be given standard chemotherapy, radiotherapy and endocrine therapy according to the Chinese Society of Clinical Oncology (CSCO) guidelines for the treatment of breast cancer, with the specific regimen decided by the doctor according to the condition. After the completion of standard chemotherapy, capecitabine 1250mg/m2 should be given orally twice a day for 2 weeks of the 3-week treatment course, and the total duration of treatment is 8 courses, which can be given simultaneously with radiotherapy and endocrine therapy. Premenopausal patients may use ovarian suppressants as needed.
62234666|NCT04217122|EXPERIMENTAL|Strawberry intervention group|Participants consume two packages of 13 g of standard strawberry powder in the morning and afternoon/evening per day for 4 weeks
62234667|NCT04217122|PLACEBO_COMPARATOR|Placebo group|Participants consume two packages of 13 grams placebo powder in the morning and afternoon/evening for 4 weeks.
62234668|NCT01658098||4-6 weeks after delivery|all patients on their 4th-6th weeks after delivery
62234669|NCT02895438|EXPERIMENTAL|gluten|One group had a introduction of gluten followed by a wash-out period, then a placebo introduction, whereas the other group had the placebo first, then the wash-out and the gluten introduction.
62234670|NCT02895438|ACTIVE_COMPARATOR|Placebo|One group had a introduction of gluten followed by a wash-out period, then a placebo introduction, whereas the other group had the placebo first, then the wash-out and the gluten introduction.
62425658|NCT03990246|EXPERIMENTAL|Acid stable emulsion with solid droplets|Acid stable emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
62593988|NCT02668809|EXPERIMENTAL|Experimental group 2|Consent, oral health assessment, questionnaires, Educational Program, clinical exam, microbiological sampling, monitoring adherence, varnish application
62593989|NCT02668809|PLACEBO_COMPARATOR|Control Group|Consent,clinical exam, microbiological sampling, questionnaires
62593990|NCT03843632|EXPERIMENTAL|VARIVAX™|All participants will receive one dose subcutaneous (SC) VARIVAX™ on Day 1. Adult participants and adolescent participants 13 years and older will also receive a second SC dose VARIVAX™ on Day 43.
62593991|NCT03290755||MSM co-infected HIV-HCV|
62593992|NCT05413018|EXPERIMENTAL|CC-486/Oral Azacitidine Administration|
62234671|NCT04101708|EXPERIMENTAL|high dose dual group|Patients in high dose dual group will receive lansoprazole (Takepron) 30mg po qid, amoxicillin 750mg po qid for 14d
62593993|NCT05413018|PLACEBO_COMPARATOR|Placebo Administration|
62593994|NCT01684098|OTHER|Tc 99m EC20|
62593995|NCT03928808|EXPERIMENTAL|FMT for SE-AN|Inpatients at the UNC-Chapel Hill Center of Excellence for Eating Disorders (CEED) and will receive weekly fecal microbiota transplantations for four weeks. This will be in addition to standard care at CEED.
62593996|NCT01123941|EXPERIMENTAL|NVGH Vi-CRM197 conjugate vaccine|
62593997|NCT01123941|ACTIVE_COMPARATOR|Vi-polysaccharide vaccine|
62234672|NCT04101708|ACTIVE_COMPARATOR|half-dose clarithromycin-containing bismuth quadruple group|Patients in half-dose clarithromycin-containing bismuth quadruple group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and clarithromycin (Klacid) 250mg po bid for 14d
62234673|NCT00606970|EXPERIMENTAL|Intervention group|Seigen Alpha EV Treatment
62593998|NCT02231879|ACTIVE_COMPARATOR|Plerixafor first then G-CSF (PG)|Study drugs were both given subcutaneously twice daily for 14 months using unmarked prefilled glass syringes
62034512|NCT02862106|NO_INTERVENTION|Follow-up group-εPA-44 900μg|These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only
62234674|NCT00606970|PLACEBO_COMPARATOR|2|Identically packaged placebo packets taken 3x daily for 3 months maximum
62234675|NCT00603200||Group 1|Patients with cirrhosis, who have refractory ascites requiring large volume paracentesis
62234676|NCT05172141|EXPERIMENTAL|IBI314|Low/medium/high dose, intravenously, once, on Day 1
62234677|NCT05172141|PLACEBO_COMPARATOR|Placebo|Placebo, intravenously, once, on Day 1
62234678|NCT05898893|EXPERIMENTAL|Intervention group|
62234679|NCT05601609||young colorectal cancer (yCRC)|"1. histologically confirmed cases of adenocarcinoma in the colon and rectum~2. the age at the time of diagnosis should be ≤ 40 years"
62234680|NCT05601609||elderly colorectal cancer (eCRC)|"1. histologically confirmed cases of adenocarcinoma in the colon and rectum~2. the age at the time of diagnosis should be ≥ 70 years"
62234681|NCT06317896||Patient with hepatocellular carcinoma|Patient with hepatocellular carcinoma who can undergo radical resection
62234682|NCT01884753||Adult women with lower urinary tract symptoms|Adult women (not less than 20 year-old) with lower urinary tract symptoms
62593999|NCT02231879|ACTIVE_COMPARATOR|G-CSF first then Plerixafor (GP)|Study drugs were both given subcutaneously twice daily for 14 months using unmarked prefilled glass syringes
62594000|NCT03624062|OTHER|33 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 33 ug IBC dose in 0.25 mL MAS-1 emulsion
62594001|NCT03624062|OTHER|109 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 109 ug IBC dose in 0.25 mL MAS-1 emulsion
62034513|NCT06319807|EXPERIMENTAL|Digital Health Intervention|Participants will receive: 1) tailored behavior change goals, 2) self-monitoring with tailored feedback, and 3) tips to foster self-efficacy and skills training around responsive feeding - provide fully automated tailored feedback, which will include theory-driven content that aims to normalize common issues and problems, provide active solutions to feeding problems and affirm positive behavior. Participants will receive daily text messages for 12 weeks. Twice a week participants will be asked to self-monitor their adherence to goals in response to a text messaging prompt and will immediately receive tailored feedback and tips.
62034514|NCT06319807|ACTIVE_COMPARATOR|Safety Control|Participants will receive tips to foster self-efficacy and skills training around infant safety. Participants will receive daily text messages for 12 weeks. Twice a week participants will be asked to self-monitor their adherence to safety goals in response to a text messaging prompt and will immediately receive tailored feedback and tips.
62034515|NCT00562887|PLACEBO_COMPARATOR|1|
62425659|NCT03990246|EXPERIMENTAL|Acid stable emulsion with liquid droplets|Acid stable emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
62425660|NCT03990246|EXPERIMENTAL|Acid unstable emulsion with solid droplets|Acid unstable emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
62425661|NCT03990246|EXPERIMENTAL|Acid unstable emulsion with liquid droplets|Acid unstable emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
62425662|NCT00387868|OTHER|Registration|Cisplatin, Etoposide \& concurrent radiotherapy
62810830|NCT02336282|ACTIVE_COMPARATOR|tDCS on Day 2|"On day one, participants will be randomized to receive sham intervention. On day two, participants receive the transcranial Direct Current Stimulation (tDCS) intervention.~On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.~The second phase of the trial will be conducted the same as for participants in the tDCS on Day 1 arm. Participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive testing will be conducted pre- and post-intervention using remote assessment."
62034516|NCT00562887|EXPERIMENTAL|400 mg|
62034517|NCT00562887|EXPERIMENTAL|700mg|
62034518|NCT04769076|EXPERIMENTAL|Paclitaxel(Album-bound)|Subjects will receive neoadjuvant therapy with paclitaxel (albumin-bound) combined with cisplatin and PD-1 inhibitor (sintilimab) as well as radical concurrent radiotherapy and chemotherapy.
62034519|NCT03137134|ACTIVE_COMPARATOR|Treatment A|(reference) Crizotinib cMS 300 mg in fasted state
62034520|NCT03137134|EXPERIMENTAL|Treatment B|(test) Crizotinib cMS 300 mg in fed state
62034521|NCT03137134|EXPERIMENTAL|Treatment C|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg in fasted state
62034522|NCT03137134|EXPERIMENTAL|Treatment D|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg with apple sauce.
62034523|NCT03137134|EXPERIMENTAL|Treatment E|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg with orange juice
62034524|NCT06304259|ACTIVE_COMPARATOR|Control|participants will receive standard root canal treatment with final flush of normal saline at the room temperature after cleaning and shaping and before obturation.
62034525|NCT06304259|EXPERIMENTAL|Submucosal cryotherapy infiltration|participants will receive Submucosal infiltration injection of 1 mL cryo-treated saline maintained at a temperature of 2 to 5°C before the normal local anaesthetic routine.
62034526|NCT06304259|EXPERIMENTAL|Intracanal cryotherapy|participants will receive root canal treatment with final flush of cold saline maintained at a temperature of 2 to 5°C
62034527|NCT01476254||Cholecystectomy|Women scheduled for laparoscopic cholecystectomy
62034528|NCT01476254||Hysterectomy|Women scheduled for laparoscopic hysterectomy
62425663|NCT00387868|OTHER|Surgical Resection|No distant Progression post Registration Arm
62425664|NCT00387868|OTHER|Post Resection|Assessment post surgical procedure to determine if at higher risk of recurrence or if complete resection could not be achieved.
62034529|NCT01373528|EXPERIMENTAL|Budesonide|
62034530|NCT03905200||coronary artery disease|Patients who were diagnosed with coronary heart disease at admission and planned to undergo coronary angiography
62034531|NCT01614665|ACTIVE_COMPARATOR|Tacrolimus|Participants receive tacrolimus twice daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus twice daily up to end of Part B and C of the study.
62034532|NCT01614665|EXPERIMENTAL|Tacrolimus Prolonged Release|Participants receive tacrolimus prolonged release once daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus prolonged release once daily up to end of Part B and of the study.
62034533|NCT05870800|EXPERIMENTAL|Neoadjuvant Therapy Arm|Subjects will receive 4 cycles of neoadjuvant atezolizumab in combination with 4 cycles of CAPEOX before standard of care surgical resection. After surgery, patients who are still considered high risk for recurrence (per the treating medical oncologist) will be offered adjuvant therapy. Adjuvant therapy will consist of mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks).
62034534|NCT03671668|ACTIVE_COMPARATOR|Screw retained prosthesis on transmucosal abutments|
62425665|NCT05743478|EXPERIMENTAL|Forging Hopeful Futures|Forging Hopeful Futures uses a group discussion format with activities that explore race, gender, class, identity, relationships, and multiple forms of violence. Forging Hopeful Futures is a 12 session curriculum for youth ages 13-19 that uses strengths-based and healing-centered approaches to critically examine structural forces that perpetuate racial and gender injustice, develop leadership skills in promoting gender equitable relationship norms, non-violent practices, and upstander skills, and enhance economic justice through job skills and employment opportunities. Through 12 sessions (3 hours/session) over a 6 to 12 week period, Forging Hopeful Futures combines racial, gender, and economic justice content with leadership development and workforce development opportunities.
62425666|NCT05743478|ACTIVE_COMPARATOR|Wellness Check-ins|Youth in neighborhoods randomized to the control group will receive individual wellness checks. This will occur through a strengths-based telephone conversation focused on wellness resources. Youth will be provided with tailored resources based on needs identified during the call. Youth will be offered the option for additional phone check-ins to coordinate access to community resources and connection to individualized behavioral health supports if desired.
62594002|NCT03624062|OTHER|327 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 327 ug IBC dose in 0.25 mL MAS-1 emulsion
62810831|NCT01077635||HIV-1 infected children aged 6 ≤ 18 years|HIV-1 infected children aged 6 ≤ 18 years currently or having ever been exposed to FPV/RTV; this is the indicated group for the licensed dose in the paediatric population.
62810832|NCT04500366|ACTIVE_COMPARATOR|Socialization|Participants randomized to the socialization arm will receive once-weekly phone calls from medical student volunteers for a total of 12-weeks (n=35). This program pairs health professional student volunteers with older adults in the community to provide social comfort while heightened physical distancing measures are in place during the current COVID-19 pandemic. Attendance and duration of the phone calls will be logged.
62034535|NCT03671668|EXPERIMENTAL|Screw retained prosthesis on titanium bases|
62034536|NCT06374485|EXPERIMENTAL|AU409|"Single-arm study. Dose escalation will follow a rule-based 3 + 3 design using increasing doses of AU409.~120 mg QD is set as the starting dose, followed by the preset doses at 210 mg QD and 300 mg QD (Based on tolerability results, 420 mg QD or higher dose might be further explored.)"
62425667|NCT01890109|PLACEBO_COMPARATOR|Placebo|Participants received a single dose of placebo administered by subcutaneous injection.
62425668|NCT01890109|EXPERIMENTAL|Erenumab|Participants received a single dose of 70 mg erenumab administered by subcutaneous injection.
62594003|NCT03624062|OTHER|TBD ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with the optimal IBC dose selected from the first 3 groups (either 33 µg, or 109 µg, or 327 µg IBC) in 0.25 mL MAS-1 emulsion
62594004|NCT05701072||All participants|
62594005|NCT01958424||women with metabolic syndrome|women undergoing ivf treatment who have BMI\>25 and meet the criteria for metabolic syndrome
62034537|NCT06052410|OTHER|Intervention Group|The group in which the early intervention program was implemented.
62034538|NCT06052410|OTHER|Control Group|The group where the home program is applied
62034539|NCT04313231||MDS|"* Female and male patients aged 18 years and older~* MDS, MDS/MPN diagnosis based on current WHO classification. CCUS and CHIP defined by Valent (Valent, Oncotarget, 2018) and by Stauder (Stauder, Blood, 2018)"
62034540|NCT04313231||control|age-matched healthy persons
62234683|NCT02670941|EXPERIMENTAL|Ginger|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
62234684|NCT02670941|EXPERIMENTAL|Lavender|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
62234685|NCT02670941|EXPERIMENTAL|Orange|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
62810833|NCT04500366|EXPERIMENTAL|Multi-Modal Frailty Rehabilitation|Multi-modal frailty rehabilitation will involve virtual care including 1x/week socialization, 2x/week exercise (small group physiotherapy live-streamed sessions), nutrition (virtual consult), and medication support (virtual pharmacist consult) all through a videoconferencing system.
62234686|NCT02670941|PLACEBO_COMPARATOR|Jojoba|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
62234687|NCT00124852|PLACEBO_COMPARATOR|High Oleic Sunflower Oil|
62234688|NCT00124852|ACTIVE_COMPARATOR|400 mg EPA+DHA/day|low dose fish oil
62234689|NCT00124852|ACTIVE_COMPARATOR|1800 mg EPA+DHA/day|high dose fish oil
62234690|NCT04039256|EXPERIMENTAL|PVR implantation group|Patients enrolled receive PVR intervention
62234691|NCT02561533|EXPERIMENTAL|BRAF immunohistochemistry (IHC)|
62425669|NCT03478774|ACTIVE_COMPARATOR|Control|These patients will receive HFNCT with oxygen 70l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, continuous videolaryngoscopy will be performed.
62425670|NCT03478774|EXPERIMENTAL|High flow|These patients will receive HFNCT with oxygen 70l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.
62425671|NCT03478774|EXPERIMENTAL|medium flow|These patients will receive oxygen 10l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.
62425672|NCT03478774|EXPERIMENTAL|low flow|These patients will receive oxygen 2l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.
62425673|NCT03478774|EXPERIMENTAL|minimal flow|These patients will receive a standard tracheal tubes after induction of general anesthesia, with 100% Oxygen and Minimum-flow 0.25l/min. The measurement period is 15 or 30 minutes.
62425674|NCT03163069|EXPERIMENTAL|Conventional Whitening dentifrice|in-office bleaching with the conventional whitening dentifrice
62425675|NCT03163069|EXPERIMENTAL|Whitening dentifrice containing blue covarine|in-office bleaching with the whitening dentifrice containing blue covarine
62425676|NCT03163069|EXPERIMENTAL|Regular dentifrice|in-office bleaching with the regular dentifrice
62425677|NCT03677635|EXPERIMENTAL|Intervention|Guided autobiographical memory recall to enhance specificity and links to the future.
62425678|NCT03677635|NO_INTERVENTION|Control|Recall without prompts or psychoeducation video.
62594006|NCT01958424||women without metabolic syndrome|women undergoing ivf treatment who have BMI\>25 and who do not meet the criteria for metabolic syndrome
62594007|NCT03104062|OTHER|Ticagrelor|Patients will be randomized to have Ticagrelor 90mg BID
62594008|NCT03104062|OTHER|Clopidogrel|Patientes will be randomized to have Clopidogrel 75mg once a day
62735466|NCT01682317|EXPERIMENTAL|Three Meal|Participants in this condition will be instructed to limit their number of eating frequency to three meals per day.
62735467|NCT01682317|EXPERIMENTAL|Grazing|Participants in the increased eating frequency condition will be instructed to eat \> 100 kcals every 2-3 hours.
62034541|NCT06285682|EXPERIMENTAL|0.5mg∙kg-1 olive derived hydroxytyrosol from OliPhenolia®.|Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass. In this arm participants will consume and oral bolus of 0.5mg∙kg-1 olive derived hydroxytyrosol.
62810834|NCT00003575|EXPERIMENTAL|Arm I|All patients receive ifosfamide IV by continuous infusion for 2 days, etoposide IV over 2 hours daily on days 1 and 2, and filgrastim (G-CSF) subcutaneously (SC) daily on days 4-13. Courses are repeated every 21 days. Patients who have complete or partial remission after a minimum of 4 courses of chemotherapy receive maintenance therapy consisting of interleukin-12 SC twice weekly beginning on day 28 of the final chemotherapy course and continuing for 6 months or until disease progression. All patients also receive combination antiretroviral therapy during study.
62810835|NCT06162052|EXPERIMENTAL|A Standard of Care group (SOC)|Participants will receive standard of care education by the physical or occupational therapist regarding performance of the prescribed movements prior to discharge. Participants will complete the study about 6 months after discharge.
62810836|NCT06162052|EXPERIMENTAL|A Standard of Care group (SOC) combined with technology enhancement|Participants will receive standard of care education by the physical or occupational therapist regarding performance of the prescribed movements prior to discharge. Participants will undergo additional training in the use of a goniometer to measure range of motion at home and record the measurement once a week for 6 months. Participants will engage in 4 virtual sessions as well as wear a Fitbit
62234692|NCT05631977||POCUS acquisition|"Prospective noninterventional single arm study collection of cardiac POCUS examination according to prespecified acquisition protocol.~Alongside POCUS images the study will also collect demographic and clinical information from the study participants and some information from the healthcare personal performing the POCUS exam (experience in US image acquisition, physician specialty or sonographer).~Patient management will not be impacted, and usual care will follow the regular practices at the study site."
62425679|NCT05107154|EXPERIMENTAL|Dialectical Behavioural Therapy|Participants randomized to the Dialectical Behavioural Therapy (DBT) skills training intervention will receive a 90-minute DBT skills training session every week for 16 weeks total. The sessions will be facilitated by a health practitioner supervised by a clinical health psychologist with expertise in program development and DBT-adaptations for a variety of populations. Sessions for Pilot 1 will be delivered via Zoom HealthCare and in person if allowable. In-person sessions would be delivered at the Children's Hospital Research Institute of Manitoba. Pilot 2 will be adapted to address any additional needs uncovered through he qualitative assessment of Pilot 1. Traditional medicine components will be developed within the first 2 years of the grant by Indigenous researchers, patient and parent advisors, elders, and community advisory groups. These elements will be offered as an encouraged, yet optional component (additional modules) within the 16-week DBT intervention in Pilot 2.
62425680|NCT05107154|NO_INTERVENTION|Control|Participants randomized to the control arm will receive standard medical care and clinical follow-up. Controls will be offered DBT after completion of Pilot 1 and 2. Participation will be optional.
62425681|NCT00857493|EXPERIMENTAL|Group 1|
62425682|NCT00857493|EXPERIMENTAL|Group 2|
62425683|NCT06569108|EXPERIMENTAL|Part A：Experimental group|Successfully screened participants in Part A will be randomly assigned to Experimental group versus Control group at a ratio of 2:1. Participants in Experimental group will receive KN057 prophylaxis through the main trial (26 weeks) and extension period (26 weeks) for total of approximately 1 year.
62425684|NCT06569108|EXPERIMENTAL|Part A：Control group|Successfully screened participants in Part A will be randomly assigned to Experimental group versus Control group at a ratio of 2:1. Participants in Control group will continue on-demand treatment with coagulation factor through the main trial for 26 weeks, in the extension period they will switch to prophylaxis treatment and receive KN057 for 26 weeks.
62425685|NCT06569108|EXPERIMENTAL|Part B：Prophylaxis group|Successfully screened participants in Part B will be nonrandomly assigned to Prophylaxis group. Participants in Prophylaxis group will continue prophylaxis with coagulation factor for the first 26 weeks (the factor period), then they will switch to prophylaxis with KN057 for the last 26 weeks (the KN057 period).
62425686|NCT02523729|NO_INTERVENTION|control|subjects drunk no Anke Malz product.
62425687|NCT02523729|EXPERIMENTAL|intervention one|subjects drunk one can Anke Malz product.
62425688|NCT02523729|EXPERIMENTAL|intervention two|subjects drunk two cans Anke Malz product.
62425689|NCT05296369|EXPERIMENTAL|Experimental|Folic acid intervention
62425690|NCT05296369|NO_INTERVENTION|Routine|Routine treatment intervention
62425691|NCT00577954||1|Patients in a coma condition after a traumatic brain injury (250), stroke, cerebral anoxia or subarachnoid hemorrhage (150), for at least 7 days.
62433651|NCT06297499|EXPERIMENTAL|Treatment Group 1. Pre-Intrathecal|Patients will receive an IV solution of 8mg ondansetron (4ml) within 30 minutes of the standard-of-care anesthetic treatment (intrathecal morphine administration) followed by a placebo treatment of an IV solution of 4ml 0.9% saline administered at the time of umbilical cord clamping.
62810837|NCT03161535|EXPERIMENTAL|exercise group|The rehabilitation program was composed of two parts: an exercise program and a diet-teaching program. The exercise program was a 12-week home-based program that comprised moderate-intensity brisk walking for 40 min per session, with 3 sessions per week; in addition, weekly exercise counseling was provided through telephone. The diet teaching program was provided to the patients by using a diet booklet at baseline (same timing as the exercise program), and its contents were used to instruct the patients regarding dietary principles to be followed.
62810838|NCT03161535|NO_INTERVENTION|usual-care group|The control group (CG) received usual care, whereas a nurse, the manager for esophageal cancer treatment, provided routine care, conducted follow-ups, and offered information on esophageal cancer to the experimental group (EG).
62594009|NCT04025775|EXPERIMENTAL|Closed loop insulin delivery|"Unsupervised home use of day and night fully automated closed loop insulin delivery system (CamAPS HX) for 20 days~The CamAPS HX closed-loop system comprises~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump~* Glooko/Diasend cloud upload system to monitor CGM/insulin data."
62594010|NCT04025775|ACTIVE_COMPARATOR|Standard therapy|Participants in the control arm will continue to follow their current diabetes management plan for the 20 day study period.Participants will be wear a masked continuous glucose monitoring (CGM) system during the 20 day study period.
62234693|NCT04549337|EXPERIMENTAL|4X4|"An exercise training protocol with a duration of 38 minutes consisting of a 10 minutes warm up with a heart rate of 60-70% of HRmax followed by 4 intervals of 4 minutes at an intensity that will induce at least 85% of HRmax (we will start with 75% of watt max).~Each interval is separated by 3-minute active pauses, biking at 50-70% of HRmax. Following this a 3-minute cooldown (at warm up intensity) will be performed."
62234694|NCT04549337|ACTIVE_COMPARATOR|6X1|"An exercise training protocol with a duration of 38 minutes consisting of a 10 minutes warm up on 30% of watt-max followed by 6 intervals of 1 minute at 100% of the watt-max.~Each interval is interspersed by 3-minute active pauses at 30% of watt-max. Following this a 7-minute cooldown (at warm up intensity) will be performed."
62594011|NCT03375671|EXPERIMENTAL|Ketamine|Single administration of Ketalar® (ketamine hydrochloride injection, USP); 5 mg/kg, IM
62594012|NCT03375671|ACTIVE_COMPARATOR|Midazolam + haloperidol|Single administration of combination of: Midazolam injection (5 mg, IM) and haloperidol injection (5mg, IM)
62594013|NCT02316899|EXPERIMENTAL|ASP0456 (Period I)|Up to 12 weeks
62594014|NCT02316899|PLACEBO_COMPARATOR|Placebo (Period I)|Up to 12 weeks
62234695|NCT04549337|ACTIVE_COMPARATOR|10-20-30|"An exercise training protocol with a duration of 38 minutes consisting of a 10 minutes warm up at 60-70% of HRmax followed by 3 intervals of 5 minutes interspersed by 3 minutes on 50-70% of HRmax.~Each interval consists of 5 minutes of 5 repeated 30-20-10 intervals, consisting of 30 seconds at easy pace, 20 seconds at medium pace and 10 seconds at all-out. Following this a 7-minute cooldown (at warm up intensity) will be performed."
62234696|NCT02749630|EXPERIMENTAL|Healthy Volunteer|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
62594015|NCT02316899|EXPERIMENTAL|ASP0456 (Period II)|From 12 weeks to 52 weeks
62735468|NCT00249652|EXPERIMENTAL|TAP|MI-based phone intervention.
62735469|NCT00249652|OTHER|TAU|Treatment As Usual
62735470|NCT03577340||Novices|Novices: Trainee cardiologists implanting cardiac devices as per guidelines under supervision
62735471|NCT03577340||Experts|Experts: Device implanting cardiologists implanting cardiac devices as per guidelines
62735472|NCT01186887|PLACEBO_COMPARATOR|Celecoxib|
62735473|NCT01186887|PLACEBO_COMPARATOR|Placebo|
62810839|NCT03167892|EXPERIMENTAL|Intervention|Oral screen
62810840|NCT03167892|NO_INTERVENTION|Control|No intervention
62810841|NCT04633668|EXPERIMENTAL|CBT-p|cognitive behavioral therapy, Monitoring of sleep through sleep diaries, nightmare experiences, and actigraphy
62810842|NCT04633668|ACTIVE_COMPARATOR|Self-monitoring|Monitoring of sleep through sleep diaries, nightmare experiences, and actigraphy
62810843|NCT05771103|ACTIVE_COMPARATOR|Stellate ganglion block with alcohol injection|Stellate ganglion block with alcohol injection by ultrasound guidance and C7 level confirmation by fluoroscopy.
62234697|NCT02749630|EXPERIMENTAL|Ulcerative Colitis|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
62234698|NCT02749630|EXPERIMENTAL|Crohn's Disease|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
62234699|NCT00338364|EXPERIMENTAL|Treatment|50% randomized to receive distraction during painful procedure
62234700|NCT00338364|NO_INTERVENTION|Control|50% randomized to receive no distraction during painful procedure
62810844|NCT05771103|ACTIVE_COMPARATOR|thermal RF neurolysis of Stellate ganglion|Stellate ganglion RF therapy will be done under fluoroscopy, integrated by ultrasound guidance
62594016|NCT01864070|EXPERIMENTAL|TheraSphere + Everolimus|"Each cycle is 28 days. Target dose of TheraSphere is fixed at 120 Gy to entire tumor bearing portion of liver given at a single session on Cycle 1 Day 15. The dose of everolimus will be escalated in 2 sequential cohorts of 6 TheraSphere-treated patients each. Starting dose of everolimus is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg PO daily starting cycle 3 day 1.~Once DLT is defined or dose level 2 has been completed, a dose expansion cohort of 10 patients with advanced low to intermediate grade neuroendocrine tumor will be enrolled.~At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had."
62594017|NCT05234866||Phase I (Feasibility Study)|
62594018|NCT05234866||Phase II (Prospective Study)|
62810845|NCT03068871|EXPERIMENTAL|CET|CET - Coping Effectiveness Training group.
62234701|NCT00985322|EXPERIMENTAL|ACE inhibitor Ramipril|
62810846|NCT03068871|EXPERIMENTAL|ACT|ACT - Acceptance and Commitment Therapy group
62234702|NCT00985322|ACTIVE_COMPARATOR|non-RAS inhibitor antihypertensive therapy|
62234703|NCT04370457|EXPERIMENTAL|Experimental arm|Administration of the MyPal ePRO system
62234704|NCT04370457|NO_INTERVENTION|Standard care arm|No further intervention besides standard palliative care approach if needed
62810847|NCT02203734|EXPERIMENTAL|Moderate Pressure Massage|Moderate Pressure Massage Therapy
62810848|NCT02203734|SHAM_COMPARATOR|Light Pressure Massage|Light Pressure Massage Therapy
62810849|NCT02237326|ACTIVE_COMPARATOR|Visual Inspection with Lugol's Iodine|Participants underwent colposcopic exam, followed by Visual Inspection with Lugol's Iodine (VILI) by a second, blinded clinician (the order of exams was reversed to eliminate potential interference with exam results due to iodine staining). Biopsy was done after the VILI.
62234705|NCT00803270|ACTIVE_COMPARATOR|Surgical Treatment|Surgical treatment will consist of the following evidence-based stress incontinence procedures: mid-urethral slings (TVT, TOT, TVT-O), fascial slings, and Burch colposuspension.
62810850|NCT02237326|ACTIVE_COMPARATOR|Visual Inspection with Acetic Acid|Participants underwent Visual Inspection with Acetic Acid followed by colposcopy by a second clinician who was blinded to the screening test result.
62810851|NCT00537602|EXPERIMENTAL|A|Oral miglustat capsules 200 mg t.i.d. for 1 week and a single 200 mg dose on day 8
62234706|NCT00803270|ACTIVE_COMPARATOR|Non Surgical Treatment|"The non-surgical treatment will include two components:~1. Pharmacological therapy with any FDA approved overactive bladder (OAB) drug in approved doses; and~2. Behavioral therapy."
62234707|NCT03200340|PLACEBO_COMPARATOR|[Part 1] Placebo|Matching placebo
62234708|NCT03200340|EXPERIMENTAL|[Part 1] EC-18 500 mg|1 capsule of EC-18
62234709|NCT03200340|EXPERIMENTAL|[Part 1] EC-18 1000 mg|2 capsules of EC-18 500 mg
62234710|NCT03200340|EXPERIMENTAL|[Part 1] EC-18 2000 mg|4 capsules of EC-18 500 mg
62234711|NCT03200340|PLACEBO_COMPARATOR|[Part 2] Placebo|Placebo 2000mg
62234712|NCT03200340|EXPERIMENTAL|[Part 2] EC-18 2000mg|RP2D: EC-18 2000mg (Part 1 result)
62234713|NCT02672709|EXPERIMENTAL|Anticoagulation|Apixaban will be prescribed at the dose of 2.5 mg twice per day for nine days.
62234714|NCT04576741|EXPERIMENTAL|bMBI standard practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using standard practices for Mindfulness-Based Cognitive Therapy (30-minutes/day).
62234715|NCT04576741|EXPERIMENTAL|bMBI shorter more frequent practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using shorter, more frequent practice than standard Mindfulness-Based Cognitive Therapy (2x15-minutes/day).
62234716|NCT06452186|EXPERIMENTAL|dEMG group|Patients go through the training procedure with the direct EMG controlled powered prosthetic ankle.
62234717|NCT06452186|ACTIVE_COMPARATOR|Passive group|Patients go through the training procedure with their own passive prosthetic ankles
62594019|NCT05243485||Cohort 1 (reference group)|500 patients will be included as an observatory control group and as a reference group to the second cohort. The PreHEART score is calculated without further consequences for triage in the ambulance and are transferred to the ED of the nearest hospital for standard care.
62810852|NCT00537602|PLACEBO_COMPARATOR|B|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. for 1 week and a single dose on day 8
62810853|NCT00189098|PLACEBO_COMPARATOR|placebo|
62810854|NCT00189098|ACTIVE_COMPARATOR|Sulfamethoxazole-trimethoprim|
62810855|NCT01743469|EXPERIMENTAL|Hepatocellular Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
62810856|NCT01743469|EXPERIMENTAL|Ovarian Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
62234718|NCT03480256|EXPERIMENTAL|SHR6390 combined with pyrotinib|Group A:pyrotinib 400mg qd combined with SHR 6390 100mg qd Group B: pyrotinib 400mg qd combined with SHR 6390 125mg qd Group C: pyrotinib 400mg qd combined with SHR 6390 150mg qd Group D: pyrotinib 400mg qd combined with SHR 6390 175mg qd Group E: pyrotinib 320mg qd combined with SHR 6390 100mg qd
62234719|NCT02053987|EXPERIMENTAL|Stroke rehabilitation|
62234720|NCT02053987|NO_INTERVENTION|Control Group|This group will undergo rehabilitation as per the current stroke rehabilitation pathway.
62425692|NCT05813665|EXPERIMENTAL|Narlumosbart|Patients will receive narlumosbart 120 mg subcutaneously (SC) once every 4 weeks (Q4W) with a loading dose of 120 mg SC on day 8 and day 15 of the first cycle until one of the following occurred: complete tumor resection, disease progression, intolerable toxicity, decision by the patient to discontinue, or decision by the investigator that the patient could no longer benefit from the treatment.
62425693|NCT05813665|ACTIVE_COMPARATOR|Denosumab|Patients will receive denosumab 120 mg subcutaneously (SC) once every 4 weeks (Q4W) with a loading dose of 120 mg SC on day 8 and day 15 of the first cycle until one of the following occurred: complete tumor resection, disease progression without clinical benefit, decision by the patient to discontinue, or decision by the investigator that the patient could no longer benefit from the treatment.
62425694|NCT01542684|EXPERIMENTAL|Azacytidine + GM-CSF|"Azacytidine administered intravenously (IV) or subcutaneously (SQ) at starting dose of 40 mg/m\^2, daily for 4 days.~GM-CSF administered IV or subcutaneously at 250 mcg/m\^2 one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.~Each treatment cycle will last at least 4 weeks"
62810857|NCT01743469|EXPERIMENTAL|Renal Cell Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
62810858|NCT01743469|EXPERIMENTAL|Gastric Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
62810859|NCT02038816|EXPERIMENTAL|Deferasirox + Azacitidine|Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles + Deferasirox 10-30 mg/kg/d depending on transfusion needs
62810860|NCT02038816|ACTIVE_COMPARATOR|Azacitidine|Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles
62810861|NCT03810677||Patients with varicose veins, eligible for EVLA|
62810862|NCT03798106|EXPERIMENTAL|durvalumab+pazopanib|Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
62810863|NCT06381934|ACTIVE_COMPARATOR|Standard Care Group|TAH patients randomised to the Standard Care Group will be followed by a physician not involved in the study.
62810864|NCT06381934|ACTIVE_COMPARATOR|aSID/ChU Guided Therapy Group|TAH patients randomised to the aSID/ChU Guided Therapy Group will have aSID and ChU determined and, depending on the results, will be assigned to fluid administration with saline or drinking restriction.
62234721|NCT03093350|EXPERIMENTAL|TAA-Specific CTLs|Patients receiving TAA-specific CTLs as therapy for breast cancer.
62234722|NCT02149082||Infrascanner exam|Infrascanner Model 2000 exams may be conducted either before or after an associated head CT for pediatric patients presenting to the emergency department (ED) or pediatric intensive care unit (PICU) with a known or suspected traumatic head injury undergoing a head CT scan to evaluate for the presence or absence of an intracranial hematoma. The time between the head CT scan and the Infrascanner exam will be within 6 hours. The exam involves placing a sensor on the designated areas of the head with the most common locations for traumatic hematoma. Readings from the monitor evaluating each region will be evaluated and recorded. The 8-point exam can be accomplished within 5 minutes or less.
62234723|NCT03739437|EXPERIMENTAL|Mobile Contingency Management|
62234724|NCT03739437|ACTIVE_COMPARATOR|Standard Care|
62234725|NCT00329342|EXPERIMENTAL|1|
62234726|NCT00329342|NO_INTERVENTION|2|
62234727|NCT02022319|OTHER|Shear Wave Elastography|All included patients undergo a supplementary Shear Wave Elastographic scan
62234728|NCT00617188|EXPERIMENTAL|Fulvestrant|Fulvestrant 500 milligrams (mg) Day 1; 250 mg Day 1, 29 and every 28 days thereafter.
62234729|NCT05975385|EXPERIMENTAL|Acupuncture|Group Acupuncture: Points PC 6 bilaterally, LI 4 bilaterally, and Yin Tang will be needled using Seirin L Type 0.25 X 40 mm needles. MH 6 is located 2 cun (a traditional Chinese unit of length) above the wrist crease in between the tendons of palmaris longus and flexor carpi radialis. LI 4 is in the middle of first and second metacarpal bones. Yin Tang is located between the eyebrows. All needles will be removed once skin closure begins, and before emergence and extubation.
62234730|NCT05975385|NO_INTERVENTION|Control|No acupuncture treatment provided
62810865|NCT04641897|OTHER|Sequence A|Sequence A: Low RR for 12 hours - High RR for 12 hours
62810866|NCT04641897|OTHER|Sequence B|Sequence B: High RR for 12 hours - Low RR for 12 hours.
62810867|NCT00454714|ACTIVE_COMPARATOR|A|Sildenafil arm
62810868|NCT00454714|PLACEBO_COMPARATOR|B|Placebo arm
62810869|NCT02111421|EXPERIMENTAL|parturients|Parturients after the umbilical cord was clapped in cesarean section were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points.
62594020|NCT05243485||Cohort 2 (intervention group)|500 patients will be included in the interventional cohort. The calculated PreHEART score has consequences for triage in the ambulance. If the PreHEART score is ≥ 5, the patient is classified as a high-risk patient for having NSTE-ACS. These patients are immediately transferred to the ED of the nearest PCI center for further diagnostic examination and to rule out other life-threatening pathologies. When the PreHEART score is ≤ 4, the patient is classified as a low-risk patient for having NSTE-ACS and is transferred to the ED of the nearest hospital without PCI facilities (non-PCI center) for further diagnostic work-up
62594021|NCT03425578|EXPERIMENTAL|MSG + CHO|Participants will ingest 150 mg/kg body mass monosodium glutamate followed by 75 g dextrose.
62810870|NCT02111421|EXPERIMENTAL|nonpregnant women|Nonpregnant women were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points.
62594022|NCT03425578|ACTIVE_COMPARATOR|MSG + placebo B|Participants will ingest 150 mg/kg body mass monosodium glutamate followed by a non-caloric, flavoured placebo.
62810871|NCT06513494|EXPERIMENTAL|Active Students Education plus Teacher Training|Clusters will perform active training for both teachers and students.
62810872|NCT06513494|EXPERIMENTAL|Active Students Education|Clusters will perform active training for only students.
62810873|NCT06513494|EXPERIMENTAL|Basic Health Unit Active Orientation|Clusters will receive a nurse-led orientation session on vaccination for students in schools.
62810874|NCT06513494|OTHER|Usual care|No project interventions will be carried out.
62810875|NCT06582758|EXPERIMENTAL|Mindful Pain Management (randomized)|
62810876|NCT06582758|ACTIVE_COMPARATOR|Pain Psychoeducation (randomized)|
62034542|NCT06285682|EXPERIMENTAL|1.0mg∙kg-1 olive derived hydroxytyrosol from OliPhenolia®.|Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass. In this arm participants will consume and oral bolus of 1.0mg∙kg-1 olive derived hydroxytyrosol.
62594023|NCT03425578|ACTIVE_COMPARATOR|Placebo A + CHO|Participants will ingest placebo capsules followed by 75 g dextrose.
62810877|NCT06582758|EXPERIMENTAL|Choice: Mindful Pain Management|
62810878|NCT06582758|ACTIVE_COMPARATOR|Choice: Pain Psychoeducation|
62810879|NCT05201144|ACTIVE_COMPARATOR|Sildenafil citrate|Sildenafil citrate 1mg/kg every 8 hours (PO or NG) for up to 14 days
62594024|NCT01846481|EXPERIMENTAL|RBP-8000 100mg/Placebo|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by a 100mg intravenous infusion of RBP-8000~Day 6: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo"
62594025|NCT01846481|EXPERIMENTAL|Placebo/RBP-8000 100mg|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo~Day 6: 50mg intravenous infusion of cocaine followed by a 100mg intravenous infusion of RBP-8000"
62594026|NCT01846481|EXPERIMENTAL|RBP-8000 200mg/Placebo|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by a 200mg intravenous infusion of RBP-8000~Day 6: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo"
62034543|NCT06285682|EXPERIMENTAL|1.5mg∙kg-1 olive derived hydroxytyrosol from OliPhenolia®.|Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass. In this arm participants will consume and oral bolus of 1.5mg∙kg-1 olive derived hydroxytyrosol.
62034544|NCT04734210|EXPERIMENTAL|SURF-200 (0.02% betamethasone sodium phosphate in vehicle)|One drop twice daily (BID) in the study eye for 14 days.
62034545|NCT04734210|EXPERIMENTAL|SURF-200 (0.04% betamethasone sodium phosphate in vehicle)|One drop BID in the study eye for 14 days.
62034546|NCT04734210|PLACEBO_COMPARATOR|Vehicle|One drop BID in the study eye for 14 days.
62594027|NCT01846481|EXPERIMENTAL|Placebo/RBP-8000 200mg|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo~Day 6: 50mg intravenous infusion of cocaine followed by a 200mg intravenous infusion of RBP-8000"
62594028|NCT03352193||SOTI group|Wheat spaghetti
62810880|NCT05201144|PLACEBO_COMPARATOR|Placebo|Equivalent volume of Ora-sweet©/Ora-plus© every 8 hours (PO or NG) for up to 14 days
62810881|NCT00189540|ACTIVE_COMPARATOR|Active Group|4.0 mg AMG0001 via intramuscular injections on days 0, 14, and 28
62810882|NCT00189540|PLACEBO_COMPARATOR|Placebo Group|Placebo (saline) via intramuscular injections on days 0, 14, and 28
62425695|NCT02085005|EXPERIMENTAL|Aflibercept|Intravenous (IV) infusion on Day 1 every 3 weeks, followed by CAPOX (capecitabine by oral administration on Day 1 to Day 14 and oxaliplatin intravenous (IV) infusion on Day 1 every 3 weeks) for the induction treatment period (6 cycles) after which the patient may enter the maintenance period during which the treatment is Aflibercept + Capecitabine
62425696|NCT00448630||Atypical Antispychotics (or second generation antipsychotics)|Patients with schizophrenia who are currently receiving or are going to start a new treatment with atypical antipsychotics, ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, amisulpride.
62425697|NCT06562712|ACTIVE_COMPARATOR|Conventional management|Patients will be subjected to conventional management for placenta accreta spectrum.
62425698|NCT06562712|EXPERIMENTAL|Bilateral internal iliac artery balloon occlusion|Patients will be subjected to bilateral internal iliac artery balloon occlusion for placenta accreta spectrum.
62594029|NCT03352193||Historical control group|No intervention
62594030|NCT05784753|EXPERIMENTAL|HEART Camp|Participants in the HEART Camp group will be provided paid, in-person access to the medical fitness center and in-person coaching by a trained coach.
62594031|NCT05784753|EXPERIMENTAL|HEART Camp Connect|Participants in the HEART Camp Connect group will be provided paid, virtual access to the medical fitness center and virtual coaching by a trained coach via videoconference. Participants will also receive automated, asynchronous motivational electronic messaging if they are below the weekly adherence threshold.
62034547|NCT00551785||1|Women prescribed Intrinsa and estrogen therapy
62034548|NCT00551785||2|Women prescribed estrogen therapy
62425699|NCT06361316|EXPERIMENTAL|Irinotecan liposome injection+ Oxaliplatin +Tegafur|Oxaliplatin: 60mg/m2, d1, ivgtt, 2h; Repeat every 15 days; Irinotecan liposomes: 50mg/m2, d1, ivgtt, 90min; Repeat every 15 days; Tegafur: 40-60mg, BID, po, d1-d10, repeat every 15 days; 30 days as one cycle, 6 treatment cycles.
62425700|NCT03028558||HEALTHY VOLUNTEER RESEARCH SUBJECTS|"Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population.~Between the ages of 21-35 years old."
62425701|NCT03028558||HEALTHY E-CIGARETTE SMOKING SUBJECTS|Criteria is identical to the healthy never-smoker group except that they must have a history of smoking e-cigarettes \>5 days/wk for a minimum of 6 months with no prior traditional tobacco exposure.
62425702|NCT02432456|PLACEBO_COMPARATOR|Placebo Infusion|"Subjects in this arm will receive the institutional standard of care for rib fractures along with a placebo (NaCl) infusion.~All patients will undergo Intercostal Nerve Blockade with administration of scheduled medications including acetaminophen, ibuprofen, pantoprazole, and methocarbamol. All subjects will receive adjunct opioids."
62425703|NCT02432456|EXPERIMENTAL|Ketamine Infusion|"Subjects in this arm will receive the institutional standard of care for rib fractures along with a ketamine infusion.~All patients will undergo Intercostal Nerve Blockade with administration of scheduled medications including acetaminophen, ibuprofen, pantoprazole, and methocarbamol. All subjects will receive adjunct opioids."
62425704|NCT06536686||The first group- silent myocardial ischemia|
62425705|NCT06536686||The second group -STEMI undergoing primary coronary angiography.|
62034549|NCT03857659|EXPERIMENTAL|Point of care ultrasound (POC-US)|Point of care ultrasound (POC-US) to measure abdominal circumference and amniotic fluid every 4 weeks from 28-36 weeks
62034550|NCT03857659|ACTIVE_COMPARATOR|Routine antenatal care|Routine care with fundal height measurement at each antenatal appointment every 2 weeks from 28-36 weeks. As well as clinically indicated obstetric ultrasound by a Registered Diagnostic Medical Sonographer (RDMS)
62034551|NCT01781728|EXPERIMENTAL|Locally advanced pancreatic cancer or locally recurrent pancreatic ductal adenocarcinoma|Patients with pathologically confirmed, locally advanced pancreatic ductal adenocarcinoma (LAPC), unresectable at diagnosis, or local recurrence pancreatic ductal adenocarcinoma (PDAC) after prior surgical resection.
62034552|NCT06153095|EXPERIMENTAL|Phase 1 Lupus Nephritis|Administration of IMPT-514
62034553|NCT06153095|EXPERIMENTAL|Phase 2 Lupus Nephritis|Administration of IMPT-514
62034554|NCT06153095|EXPERIMENTAL|Phase 2 SLE without Lupus Nephritis|Administration of IMPT-514
62034555|NCT01846338|EXPERIMENTAL|green tea extract EGCG|experimental: green tea extract EGCG, 500mg , tid, 4 weeks
62234731|NCT04557605|ACTIVE_COMPARATOR|No face mask|Progressive step-exercise cycling test to exhaustion wearing no face mask
62594032|NCT05784753|NO_INTERVENTION|Enhanced Usual Care|Participants in the Enhanced Usual Care group will be provided paid virtual access to the medical fitness center and virtual availability of the medical fitness center staff and study personnel for participant-initiated questions.
62034556|NCT01846338|PLACEBO_COMPARATOR|cellulose|Placebo Comparator: cellulose, 500 mg tid, 4 weeks
62034557|NCT03747926|EXPERIMENTAL|BI 705564|
62034558|NCT03747926|PLACEBO_COMPARATOR|Placebo|
62034559|NCT05794269||Main Group|Each patient complete the Turkish version of the QoR-15 score (TQoR-15) at 3 times (before surgery, on Day 1, on Day 3).
62034560|NCT01260844|EXPERIMENTAL|single dose of briakinumab|single dose briakinumab cocktail of CYP substrates
62034561|NCT05751473|EXPERIMENTAL|Prolonged Exposure for Primary Care|
62034562|NCT05751473|ACTIVE_COMPARATOR|EAP Treatment as Usual (TAU)|Employee Assistance Programs standard treatment.
62034563|NCT01733056|PLACEBO_COMPARATOR|Healthy Volunteer|Healthy volunteers without skin disease that received administration of Fluzone
62034564|NCT01733056|EXPERIMENTAL|Azathioprine|Patients with skin diseases taking azathioprine that received administration of Fluzone
62034565|NCT01733056|EXPERIMENTAL|TNF alpha blocker|Patients with skin diseases taking azathioprine that received administration of Fluzone
62034566|NCT02234531|EXPERIMENTAL|EVER TEACHER|"In EVER TEACHER group a specific feedback called virtual teacher will be displayed. The virtual teacher perform the correct movement to emulate, that is supposed to stimulate the motor adaptation exploiting a supervised learning mechanism. This feedback will give an on-line information on motor performance quality, allowing a real time visual comparison between patient's own execution and teacher one. During the experiment, patients will receive 1 hour of virtual reality-based therapy and the treatment will last 1 hour a day, five days weekly for four weeks."
62234732|NCT04557605|EXPERIMENTAL|Disposable face mask|Progressive step-exercise cycling test to exhaustion wearing a 3-ply disposable face mask
62810883|NCT03573414|EXPERIMENTAL|Healthy men and women|"Intervention:~2\*breakfast containing 40 g of raspberry powder, 30 g milled flax seeds and 250 mL of soy Milk."
62810884|NCT05720286||Study group|There was only one group as the study was a non-comparative study
62810885|NCT04038346|EXPERIMENTAL|NSAID|Naproxen at weight based standard dose given bid daily until symptoms resolve
62810886|NCT04038346|ACTIVE_COMPARATOR|Acetaminophen|Acetaminophen at weight based standard dose given qid until symptoms resolve
62810887|NCT04038346|EXPERIMENTAL|NSAID first, then Acetaminophen|Naproxen at weight based standard dose given bid for one week, then acetaminophen at weight based standard dose given qid until symptoms resolve
62810888|NCT04038346|NO_INTERVENTION|Standard Care|Symptom observation only
62034567|NCT02234531|OTHER|NEVER TEACHER|In NEVER TEACHER group the subjects will be asked to perform the same exercises with the upper limb without the virtual teacher assistance. The treatment will last four weeks with daily sessions of 60 minutes, five times per week.
62034568|NCT03637946|EXPERIMENTAL|SHOFU Beautifil II LS|Experimental: SHOFU Beautifil II LS Restorative system FL-Bond II (self-etching adhesive system)/ Beautifil II (composite restorative)
62425706|NCT03823339||Patients with type 2 diabetes (T2DM)|Patients with T2DM treated with any basal insulin or glucagon-Like peptide-1 receptor agonist (GLP-1 RA) (including once weekly GLP-1 RA) with/without oral antidiabetic drug (OAD) treatment, and with inadequate glycaemic control, for whom the physician had decided to intensify their treatment with Xultophy®
62425707|NCT03347227|ACTIVE_COMPARATOR|Pulmonary Vein Isolation|Wide area circumferential catheter ablation for pulmonary vein isolation
62425708|NCT03347227|EXPERIMENTAL|Pulmonary Vein Isolation and scar ablation|Wide area circumferential catheter ablation for pulmonary vein isolation and scar ablation
62425709|NCT03547531|ACTIVE_COMPARATOR|Natural Tooth Brushing Method|Natural tooth brushing method is the method that is naturally used by the people with horizontal, rotary, or simple up and down motions and any position of the brush without any instruction of particular tooth brushing method.
62425710|NCT03547531|EXPERIMENTAL|Modified Circular Tooth Brushing Method|Modified Circular tooth brushing method is a combination of small circular motion of brushing with the position of the brush slightly reach underneath the gingival that are applied for each jaw in all facial surfaces and posterior lingual of tooth arches.
62425711|NCT06082531|NO_INTERVENTION|Preoperative|
62425712|NCT06082531|EXPERIMENTAL|postoperative (6 weeks)|The patients were injected with PRP.
62425713|NCT06082531|EXPERIMENTAL|postoperative (3 months)|The patients were injected with PRP.
62594033|NCT04988971|EXPERIMENTAL|Group C|during the current cycle of chemotherapy (need to be the same regimens as the previous cycle of chemotherapy, the same dose), patients take a compound glutamine capsules, from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
62594034|NCT04988971|PLACEBO_COMPARATOR|Group D|during the current cycle of chemotherapy (need to be the same regimens as the previous cycle of chemotherapy, the same dose), patients take a compound glutamine capsule simulated placebo, from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
62810889|NCT03741153||study group|includes patients who will be diagnosed with Pseudoexfoliation syndrome
62810890|NCT03741153||control group|age matched controls who do not have Pseudoexfoliation syndrome
62810891|NCT06132269|PLACEBO_COMPARATOR|Placebo sachet|consume 1 sachet per day for 8 weeks
62810892|NCT06132269|EXPERIMENTAL|AKK formula sachet|consume 1 sachet per day for 8 weeks
62425714|NCT06290427|ACTIVE_COMPARATOR|DaVinci system|Robot-assisted partial nephrectomy is performed using the DaVinci platform
62425715|NCT06290427|EXPERIMENTAL|Hugo RAS system|Robot-assisted partial nephrectomy is performed using the Hugo RAS platform
62810893|NCT04083976|EXPERIMENTAL|Erdafitinib|Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of erdafitinib oral tablets until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
62810894|NCT03741465|ACTIVE_COMPARATOR|The SFP technique|In the SFP neuraxial positioning technique, fifty participants were planned to sit on the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs hanging freely, forearms on the lap and hand are on the knees. The position is completed with the back curved in the fetal position. Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 5-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 24 weeks.
62234733|NCT04557605|EXPERIMENTAL|Cloth face mask|Progressive step-exercise cycling test to exhaustion wearing a cloth face mask
62425716|NCT06290427|EXPERIMENTAL|Versius system|Robot-assisted partial nephrectomy is performed using the Hugo RAS platform
62594035|NCT02926586|EXPERIMENTAL|Fludarabine|The patients in experimental arm should receive the consolidation chemotherapy regimen with fludarabine and cytarabine. The dosage of fludarabine is 30mg/m2/d for 5 days intravenously and cytarabine is 1500mg/m2/d for 5 days intravenously.
62594036|NCT02926586|ACTIVE_COMPARATOR|high-dose cytarabine|The patients in control arm should receive the consolidation chemotherapy regimen with high-dose cytarabine. The dosage of cytarabine is 2000mg/m2/12h for 3 days (1,3,5) intravenously.
62594037|NCT00558662|ACTIVE_COMPARATOR|1|Coban 2 Layer Compression System
62594038|NCT00558662|ACTIVE_COMPARATOR|2|Short-Stretch Bandage
62594039|NCT02312596|EXPERIMENTAL|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix
62594040|NCT02312596|ACTIVE_COMPARATOR|Usual and customary practice|Usual and customary practice
62810895|NCT03741465|EXPERIMENTAL|The ASP technique|In the ASP neuraxial positioning technique, the same fifty participants were planned to sit on the same part of the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs crossed, forearms of the participants are on the lap and hands are on the knees, and the position is completed with the back curved in the fetal position.Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 5-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 24 weeks.
62810896|NCT00003468|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62594041|NCT06292598||Patients with untreated NT1|
62425717|NCT02190344|EXPERIMENTAL|Functionality of 8-channel paddle coil system|
62425718|NCT03406832|EXPERIMENTAL|Nitroprusside group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Nitroprusside Sodium via guide-catheter was performed. Then repeated administration of Nitroprusside Sodium was done prior to coronary stent implantation or post dilatation.
62425719|NCT03406832|EXPERIMENTAL|Tirofiban group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Tirofiban Hydrochloride via guide-catheter was performed.
62594042|NCT06292598||Matched controls|Controls matched on sex, age (+/- 2 years) and BMI class (BMI \< 25: normal; 25 ≤ BMI ≤ 30: overweight; BMI \> 30: obesity)
62594043|NCT05454969|ACTIVE_COMPARATOR|One-4-ALL Initiative|The health app arm will pilot the intervention and key outcome measures will be compared between the Health App group and the placebo control.
62234734|NCT04962802|EXPERIMENTAL|Manhood 2.0|Manhood 2.0 is a group-level intervention, delivered in 7 sessions over 13 hours, and is based on social cognitive theory, social norm theory, theory of gender and power, and the theory of reasoned action. Sessions were delivered twice a week, for approximately 3.5 weeks. For the final session, participants received one hour of content and were administered the immediate post-intervention survey. The intervention takes a holistic, gender-transformative approach, includes reproductive health knowledge, healthy relationships, altering gender norms and stereotypes which drive reproductive health behavior, and explicit and proactive support of female partner contraceptive use. Activities are designed to engage young men in critical reflection and dialogue about gender norms, and then apply these discussions to a range of key issues including intimate relationships, gender-based violence, substance abuse, STIs, and early pregnancy.
62425720|NCT03406832|PLACEBO_COMPARATOR|Control group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of heparinized saline via guide-catheter was performed.
62594044|NCT05454969|PLACEBO_COMPARATOR|Control|Will receive standard care.
62594045|NCT04634240|EXPERIMENTAL|Complete Revascularization|Routine PCI (percutaneous coronary intervention) of all suitable coronary artery stenoses of ≥70% in vessels ≥2.5mm in diameter.
62594046|NCT04634240|NO_INTERVENTION|Medical Therapy Alone|No revascularization of coronary artery lesions.
62594047|NCT00431028|NO_INTERVENTION|colirio|prednisolone 1% eye drops + ciprofloxacin 0,3% eye drops
62594048|NCT01185743|ACTIVE_COMPARATOR|olanzapine|olanzapine
62594049|NCT01185743|ACTIVE_COMPARATOR|ziprasidone|ziprasidone
62594050|NCT01185743|PLACEBO_COMPARATOR|Sugar pill|Sugar pill
62594051|NCT06375616|EXPERIMENTAL|Nafamostat|Patients in NM arm will receive nafamostat mesylate as as anticoagulation during renal replacement therapy.
62810897|NCT06490809|EXPERIMENTAL|Routine Physiotherapy Group|No action will be taken by the researchers on this group's treatment program.
62234735|NCT04962802|PLACEBO_COMPARATOR|Post-High School Readiness|The Post-High School Readiness Program helped youth build skills around identifying colleges or programs of interest, completing applications for programs, writing resumes and increasing financial literacy. The post-high school readiness curriculum was delivered by LAYC staff members and the content was delivered twice a week, for approximately 3.5 weeks (as with the intervention). For the final session, participants did not receive content and were administered the immediate post-intervention survey.
62425721|NCT02733458|EXPERIMENTAL|GELAD/Radiation|Patients will be initially treated with two cycles GELAD chemotherapy, followed by 50-56Gy radiotherapy, and completed with another two cycles GELAD chemotherapy. GELAD chemotherapy will be repeated every 21 days. Radiotherapy will be delivered in 25-32 fractions.
62425722|NCT01838525||SIRS, SEPSIS|
62034569|NCT05812001|EXPERIMENTAL|Exergames-acceptance and commitment therapy (e-ACT) group|Exergame is playing of video games that require rigorous physical exercise and are intended as a work-out, such as those in which players race a virtual bicycle on-screen by pedalling a simulator resembling an exercise bike. It not only improve motivation, physical fitness and cognitive function, but it also induces antidepressant effect similar to physical exercise. Acceptance and commitment therapy (ACT) is a third-generation cognitive behavioral approach which uses acceptance and mindfulness processes, and commitment and behavior change processes to produce psychological flexibility. ACT was designed to increase adaptive coping through acceptance, cognitive defusion, mindfulness, and perspective-taking exercises while supporting depression patients in aligning behavior with their personal values. Hence, the combination of both exergame and ACT may provide additional benefit for treatment of depression patients beyond the degree of effectiveness of ACT alone.
62034570|NCT05812001|ACTIVE_COMPARATOR|Acceptance and commitment therapy (ACT) group|It is a third-generation cognitive behavioral approach which uses acceptance and mindfulness processes, and commitment and behavior change processes to produce psychological flexibility. Unlike CBT, which aims to change unhelpful thoughts and feelings, ACT was designed to increase adaptive coping through acceptance, cognitive defusion, mindfulness, and perspective-taking exercises while supporting depression patients in aligning behavior with their personal values. Hence, ACT consists of 8 sessions, one session per week to facilitate depression patients to development and maintenance of health behavioral improvements by targeting internal barriers, such as emotional discomfort and self-defeating thoughts, and by fostering connection and commitment to personal values associated with self-management of positive health behaviors.
62034571|NCT05812001|NO_INTERVENTION|Treatment-as-usual control (TAU) group|The participants in the control group will receive treatment-as-usual in which non-specific ingredients of the psychotherapeutic approach will be administered, such as psychological understanding to the management of an individual patient, identifying current problems, providing opportunities for disclosure, reassurance, and deep breathing exercise. They will be given equal amount of time and attention from the professional figure compared to the intervention groups, whereby they will also attach to an 8-session program (with one session per week for 8 weeks). Each weekly TAU session will be held at the same time (± 2 hours) and at the same venue (in the psychology lab).
62425723|NCT01838525||sepsis, severe sepsis, septic shock|
62425724|NCT01838525||health, SIRS, Sepsis|
62594052|NCT06375616|ACTIVE_COMPARATOR|Heparin|Patients in UFH arm will receive unfractionated heparin as as anticoagulation during renal replacement therapy.
62810898|NCT03493555|EXPERIMENTAL|Intervention Development|Peer Health Navigator for PrEP
62034572|NCT05667246|ACTIVE_COMPARATOR|Caffeinated Group|Caffeinated coffee, 1 cup, 8 oz water setting, 95 mg caffeine
62034573|NCT05667246|PLACEBO_COMPARATOR|Decaffeinated Group|Decaffeinated coffee, 1 cup, 8 oz water setting
62425725|NCT01444274||Obalon Gastric Balloon|One or two balloons administered to each patient
62425726|NCT06127004|EXPERIMENTAL|Metacognitive Training for Negative Symptoms|The original MCT intervention was adapted to negative symptoms by incorporating psychoeducation and strategies to target the cognitions suggested by the cognitive model (Beck et al., 2009) to be implicated in the development and/or maintenance of negative symptoms. Although some of the strategies have traditionally been used to target positive symptoms, it is assumed that the same reasoning styles lead to negative symptoms through the dysfunctional cognitions discussed previously (e.g., jumping to conclusions in regard to social rejection and a dysfunctional attribution style reinforcing social withdrawal). Metacognitive training for negative symptoms consists of eight sessions, delivered individually as there is evidence indicating that this approach may lead to stronger effect sizes than delivery in a group format (Liu et al., 2018). The developer of MCT (Professor Steffen Moritz) approved the modification.
62425727|NCT06127004|ACTIVE_COMPARATOR|Control group|Supportive Counselling (8 sessions) will be used as a control. Participants enrolled in this condition can then get the intervention if they request this.
62594053|NCT00452673|EXPERIMENTAL|50 mg BID dasatinib + 825 mg/m^2 BID capecitabine|Twice a day (BID) for 2 weeks of a 3-week cycle
62594054|NCT00452673|EXPERIMENTAL|70 mg BID dasatinib + 825 mg/m^2 BID capecitabine|BID for 2 weeks of a 3-week cycle
62594055|NCT00452673|EXPERIMENTAL|70 mg BID dasatinib + 1000 mg/m^2 BID capecitabine|BID for 2 weeks of a 3-week cycle
62594056|NCT00452673|EXPERIMENTAL|100 mg QD dasatinib + 1000 mg/m^2 BID capecitabine|2 weeks of a 3-week cycle
62810899|NCT01172106|PLACEBO_COMPARATOR|Encouragement on drug compliance|The intervention for the placebo comparator will be encouragement on drug compliance
62810900|NCT01172106|EXPERIMENTAL|Family psychoeducation|The experimental group will receive weekly sessions of psychoeducation for 12 weeks in addition to receiving drug compliance encouragement
62810901|NCT03416868|EXPERIMENTAL|Standard of care voice therapy with ambulatory voice biofeedback.|Patients with Vocal Hyperfunction will undergo standard of care voice therapy, Ambulatory monitoring will be completed by the patients before therapy and throughout the first 3 weeks of therapy. Specifically, ambulatory monitoring will be worn by the patient for their 4 days with the most voicing during the first 3 weeks of therapy. Biofeedback will be activated only after the 2nd voice therapy session.
62810902|NCT01718379|EXPERIMENTAL|Arm A|"Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses.~Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.~Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.~The patients will be followed every 3 months for 12 months"
62810903|NCT01718379|EXPERIMENTAL|Arm B|"Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses combined with weekly subcutaneous injections of Epoetin beta (60,000 Units/w).~Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.~Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.~The patients will be followed every 3 months for 12 months"
62810904|NCT04744675|EXPERIMENTAL|Treatment|"The intervention group will receive:~1. Suprascapular nerve block - 3 mL of 0.5% Bupivacaine and 1 mL of 40 mg/mL Kenalog~2. Median nerve block - 3.5 mL of 0.5% Bupivacaine and 0.5 mL of 40 mg/mL Kenalog~3. Ulnar nerve block - 3.5 mL of 0.5% Bupivacaine and 0.5 mL of 40 mg/mL Kenalog"
62034574|NCT02716974|EXPERIMENTAL|chemohormonal and definitive therapy|(1st) Systemic chemo-hormonal therapy with up to 6-months (\~24 weeks) of neoadjuvant androgen deprivation (Leuprolide Acetate) and up to 6 cycles of chemotherapy (Docetaxel), (2nd) definitive local tumor control with prostatectomy +/- adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions. The men will receive a total of 1 year of androgen deprivation. Androgen blockade (Bicalutamide) will be the same throughout the course of treatment.
62034575|NCT05224570||Gunshot wounds admitted in ICU|patient with Gunshot wounds admitted to ICU
62034576|NCT06305351|EXPERIMENTAL|K-757 and K-833 combination|
62034577|NCT06305351|PLACEBO_COMPARATOR|Placebo|
62034578|NCT00987974|EXPERIMENTAL|rosuvastatin 3days|8 Subjects will use rosuvastatin 20 mg/day for 3 days
62034579|NCT00987974|ACTIVE_COMPARATOR|atorvastatin 3 days|8 Subjects will use atorvastatin 80 mg/day for 3 days.pj
62034580|NCT00987974|PLACEBO_COMPARATOR|placebo 3days|8 Subjects will use placebo for 3 days.
62034581|NCT00987974|EXPERIMENTAL|rosuvastatin 7 days|8 Subjects will use rosuvastatin 20 mg/day for 7 days.
62034582|NCT00987974|ACTIVE_COMPARATOR|atorvastatin 7 days|8 Subjects will use atorvastatin 80 mg/day for 7 days.
62034583|NCT00987974|PLACEBO_COMPARATOR|placebo 7 days|8 Subjects will use placebo for 7 days.
62034584|NCT02218567|OTHER|Patients|
62034585|NCT02218567|OTHER|Caregivers|
62810905|NCT04744675|PLACEBO_COMPARATOR|Placebo|"Placebo~The placebo group will receive:~1. Suprascapular nerve injection - 4 mL of normal saline~2. Median nerve injection - 4 mL of normal saline~3. Ulnar nerve injection - 4 mL of normal saline"
62810906|NCT04038502|ACTIVE_COMPARATOR|Treatment Arm 1 - Carboplatin to Olaparib|Participants are administered carboplatin AUC 5 IV first, which is administered Cycle-1, Day-1, and then every 21 days as first line therapy. For second line (crossover), olaparib is prescribed and taken orally at home, twice daily, 300 mg in 28 day cycles.
62034586|NCT01856127|EXPERIMENTAL|Vilazodone|Vilazodone
62034587|NCT01856127|ACTIVE_COMPARATOR|Sertraline|Sertraline
62034588|NCT06448091|EXPERIMENTAL|Experimental: Immediate panel-based pharmacogenetic genotyping|Subjects assigned to the immediate pharmacogenetic genotyping group will be tested and have their results both entered into their electronic health record as well as provided to them within 2-4 weeks from randomization.
62034589|NCT06448091|NO_INTERVENTION|Delayed panel-based pharmacogenetic genotyping|Subjects assigned to delayed panel-based pharmacogenetic genotyping will not be tested until after their participation in the study has ended (6 months after enrollment).
62034590|NCT03386903|EXPERIMENTAL|Ture acupuncture group|After recruiting, patients are assigned to the ture acupuncture group by randomization,and then receive ture acupuncture treatment. patients are scanned by MRI at the baseline and 3 month post-treatment respectively.
62034591|NCT03386903|PLACEBO_COMPARATOR|Sham acupuncture group|After recruiting, patients are assigned to the sham acupuncture group by randomization,and then receive sham acupuncture stimulation. patients are scanned by MRI at the baseline and 3 month post-treatment respectively.
62034592|NCT03386903|NO_INTERVENTION|Healthy group|Healthy subjects without intervention except scanned brain image by MRI at the baseline.
62034593|NCT05853848|ACTIVE_COMPARATOR|Standard postcard|Patients in this arm will receive a postcard with words and an image, typical of outreach in prior years, encouraging them to schedule their annual mammograms.
62034594|NCT05853848|EXPERIMENTAL|Formal letter|Patients in this arm will receive a letter from the Geisinger Health Plan (on Geisinger letterhead) noting that they're overdue for a mammogram and encouraging them to schedule.
62810907|NCT04038502|ACTIVE_COMPARATOR|Treatment Arm 2 - Olaparib to Carboplatin|Participants are prescribed olaparib which is taken orally at home, twice daily, 300 mg in 28 day cycles, as first line therapy. For second line (crossover), carboplatin is administered AUC 5 IV every 21 days thereafter.
62034595|NCT05853848|EXPERIMENTAL|Auto-dialer|Patients in this arm will receive a call from an auto-dialer with a message noting that they're overdue for a mammogram and encouraging them to schedule.
62034596|NCT05853848|EXPERIMENTAL|Live call|Patients in this arm will receive a call from a Geisinger Health Plan representative noting that they're overdue for a mammogram and encouraging them to schedule (and helping them schedule if they are interested).
62810908|NCT01755234|ACTIVE_COMPARATOR|Sevoflurane|Sevoflurane administered by inhalation (laryngeal mask airway or endotracheal tube)
62810909|NCT01755234|ACTIVE_COMPARATOR|Propofol|Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
62034597|NCT04541238||Novel template report|"The last 100 consecutive and anonymized MRI investigations for primary perianal fistula reported according to standard practice by dedicated radiologists (the last 10 reports from each of 10 international centers) are reviewed blindly and independently by two experienced radiologists (based on case load, years of experience and publications on anal fistula) using a novel template incorporating 8 key descriptors.~A third independent experienced radiologist will resolve any disagreement and assess the presence of descriptors in the original report compared to the novel template."
62425728|NCT05531838|OTHER|Fu Lishan instant sense hospital dynamic glucose monitoring system|Using CGM Technology (dynamic glucose monitoring system for Fu Lishan instant sense hospital), on the basis of the original eating habits of patients, according to the guidelines and the training of MMC center, patients are guided to adjust the diet model according to the glucose map monitored by the dynamic glucose monitoring system and the log recorded, so as to implement therapeutic monitoring, control the blood glucose level within the target range as far as possible, and record the amount of various foods accordingly, After that, the eating method and amount remained basically unchanged.
62425729|NCT00438932|ACTIVE_COMPARATOR|Lanthanum Carbonate and Low Phosphorus Diet|25% of subjects will receive binders plus a phosphate restricted diet.
62425730|NCT00438932|ACTIVE_COMPARATOR|Lanthanum Carbonate and Unrestricted Phosphorus Diet|25% binders + unrestricted phosphate diet.
62425731|NCT00438932|ACTIVE_COMPARATOR|Placebo and Low Phosphorus Diet|25% placebo + phosphate restricted diet.
62425732|NCT00438932|ACTIVE_COMPARATOR|Placebo and Unrestricted Phosphorus Diet|25% placebo + unrestricted phosphate diet.
62425733|NCT03118765|EXPERIMENTAL|Test Treatment T1: GSP304 Inhalation Solution|
62425734|NCT03118765|EXPERIMENTAL|Test Treatment T2: GSP304 Inhalation Solution|
62034598|NCT05888597|EXPERIMENTAL|Menthol|In the trial, 30 minutes prior to performing submaximal CPET, participants will be administered, L-menthol patch which will be attached to the inside of a facemask that is connected to the breathing circuit.
62425735|NCT03118765|EXPERIMENTAL|Test Treatment T3: GSP304 Inhalation Solution|
62425736|NCT03118765|PLACEBO_COMPARATOR|Test Treatment T4: GSP304 Placebo Inhalation Solution|
62425737|NCT03118765|ACTIVE_COMPARATOR|Test Treatment T5: Spiriva® Respimat® inhalation spray|
62433652|NCT06297499|ACTIVE_COMPARATOR|Treatment Group 2 Cord clamping|Patients will receive a placebo treatment of an IV solution of 4ml 0.9% saline administered within 30 minutes of the standard-of-care anesthetic treatment (intrathecal morphine administration) followed by an IV solution of 8mg ondansetron (4ml) administered at the time of umbilical cord clamping.
62433653|NCT01106937||Patients with low Factor XIII|Postoperative occurence of pulmonary embolism in patients scheduled to undergo a neurosurgical procedure with laboratory-confirmed low levels of Factor XIII
62810910|NCT02994238|EXPERIMENTAL|Intervention|The intervention group will have the full Remote Health Management Sensor Platform. Research staff will review uploaded sensor data on a daily basis. If participants are enrolled into the control group, they will only receive Standard Asthma Education. The Standard Asthma Education follows the National Asthma Education and Prevention Program (NAEPP) guidelines for asthma management. This will include the following topics: 1. Explanation of symptoms; 2. Asthma triggers (description and how to avoid them); 3. Using medications (how to use prescribed asthma medications, the difference between controller medications and rescue inhalers, how to use a spacer, how to use a mask); and 4. Managing asthma control (purpose of asthma control test, asthma action plan, how to use a peak flow meter).
62034599|NCT05888597|PLACEBO_COMPARATOR|Placebo|For placebo, the patch will contain a similarly patch with strawberry scent.
62234736|NCT04047238|EXPERIMENTAL|Intervention Group|Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving Reminiscence Therapy or to a control group receiving treatment as usual. Participants in the intervention group will participate in two Reminiscence Therapy sessions per week for 3 months besides their treatment as usual. The sessions will be based on the Book of Past and Present and they will follow the same protocol in every participant institution.
62810911|NCT02994238|NO_INTERVENTION|Control|The control group will receive only standardized education.
62810912|NCT05729282|PLACEBO_COMPARATOR|Placebo|Participants will ingest a placebo solution (27 doses over 14 days) formulated to approximate the taste of diazoxide oral suspension. Blinding will occur by completely covering single-dose oral syringes with labels.
62810913|NCT05729282|EXPERIMENTAL|Diazoxide oral suspension, 1 mg per kg per dose|Participants will ingest diazoxide oral suspension at 1 mg per kg body weight per dose (27 doses over 14 days). Blinding will occur by completely covering single-dose oral syringes with labels.
62433654|NCT06136845||non anastomotic leak|Non anastomotic clinical leak'
62594057|NCT06623864|EXPERIMENTAL|single group|The intervention proposal will be developed in a module with 10 elderly people, all of them men, with moderate dependence and older, with an average age of 84 years. All of them have multiple medical pathologies with the need for continuous nursing care.
62594058|NCT06623864|EXPERIMENTAL|CONTROL GROUP|The intervention proposal will be developed in a module with 10 elderly people, all of them men, with moderate dependence and older, with an average age of 84 years. All of them have multiple medical pathologies with the need for continuous nursing care.
62810914|NCT05729282|EXPERIMENTAL|Diazoxide oral suspension, 2 mg per kg per dose|Participants will ingest diazoxide oral suspension at 2 mg per kg body weight per dose (27 doses over 14 days). Blinding will occur by completely covering single-dose oral syringes with labels.
62034600|NCT01740674|EXPERIMENTAL|Electronic data collection|The group of participants who will complete questionnaires via the internet
62034601|NCT01740674|NO_INTERVENTION|Paper data collection|The group of participants who will continue to complete paper based questionnaires, as has been the practice for this longitudinal study.
62034602|NCT04933747|EXPERIMENTAL|Group 1: Participants with severe Renal Impairment (RI)|Severe Renal Impairment (RI), as defined by an eGFR \< 30 mL/min/1.73 m2 and not requiring dialysis, at screening
62034603|NCT04933747|EXPERIMENTAL|Group 2: Participants with kidney failure who are on intermittent hemodialysis (IHD)|Kidney failure participants on intermittent hemodialysis (IHD)
62234737|NCT04047238|NO_INTERVENTION|Control Group|Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
62234738|NCT01774110|EXPERIMENTAL|early standardized task training|Persons in the experimental group will receive ESTT (early standardized task specific training) for gait treatment after stroke.
62234739|NCT01767207||screening for mental disorders|screening for mental disorders
62234740|NCT03776019|EXPERIMENTAL|Modulated|modulated music
62234741|NCT03776019|SHAM_COMPARATOR|Typical|typical music
62234742|NCT04473183||General Healthy Population|Participants in this group are part of the general healthy population of adults 18 years-of-age and older, not known to be exposed to the virus as reported by potential participants and who have not sought medical help in the previous 4 months.
62433655|NCT06136845||anastomotic clinical leak|anastomotic clinical leak'
62433656|NCT02291107|EXPERIMENTAL|Experimental group|Participants received 25 sessions of robotically driven gait orthosis training on the Lokomat. Training occurred approximately 5 days/ week for 5 weeks, and each training session on the Lokomat lasted 30 minutes. All sessions were supervised by a trained research therapist. All participants started with 40% body weight-support and an initial treadmill speed of 1.5 km/h. Body weight-support was used primarily to facilitate an increase in walking speed; therefore, progression of training across subsequent sessions was standardized by preferentially increasing speed and then unloading body weight-support. Speed was increased to a range of 2.2 to 2.5 km/h before body weight-support was decreased. There was an active attempt to enhance the level of training at each session. After every Lokomat session, participants performed also 60 minutes of physiotherapy including general exercise program and a conventional gait training
62810915|NCT00148902|EXPERIMENTAL|All treated subjects|All subjects received Lapatinib in Combination with Docetaxel (Taxotere)
62810916|NCT03139760|EXPERIMENTAL|POWERSforID|POWERSforID intervention group
62810917|NCT03139760|NO_INTERVENTION|Control|Usual clinical care
62810918|NCT01863823|OTHER|Amoxicillin and Tetracyclines|drug treatment
62810919|NCT01863823|OTHER|Mouth washing|Mouth washing
62810920|NCT01828177|EXPERIMENTAL|PDI-320|Foam, twice daily for up to 12 weeks
62810921|NCT01828177|EXPERIMENTAL|PDI-320 Monad #1|Foam, twice daily for up to 12 weeks
62810922|NCT01828177|EXPERIMENTAL|PDI-320 Monad #2|Foam, twice daily for up to 12 weeks
62810923|NCT01828177|PLACEBO_COMPARATOR|Vehicle|Foam, twice daily for up to 12 weeks
62034604|NCT04933747|EXPERIMENTAL|Group 3: Participants with normal renal function|Normal renal function, as defined by a creatinine clearance (Clcr) \> 90 mL/min estimated using the Cockcroft-Gault (C-G) equation, at screening.
62234743|NCT04473183||Medical School Residents|Participants in this group are medical school residents.
62034605|NCT02906150|EXPERIMENTAL|Thymalfasin (Thymosin alpha 1, Ta1)|Arm A: 70 patients will receive Thymosin alpha 1 in 1mL SC injection five times a week (first four months); then two times a week for eight months. SoC chemotherapy and cisplatin (or carboplatin) for twelve months.
62810924|NCT05905094|EXPERIMENTAL|Postural correction exercises|cervical retraction, shoulder shrugging, neck isometrics,
62034606|NCT02906150|ACTIVE_COMPARATOR|SoC (chemotherapy and platinum agent)|Arm B: 70 patients (control group) will receive SoC chemotherapy and cisplatin (or carboplatin) for twelve months.
62034607|NCT04405596|EXPERIMENTAL|Ambroxol|Participants randomized to the 1350 mg/day group will begin with a dose of 450 mg, increasing bi-weekly to a dose of 1350 mg/day.
62234744|NCT04473183||Individuals who are HIV positive|Participants in this group are HIV positive.
62234745|NCT05484245|EXPERIMENTAL|Surgery|Ultrasound-guided resection of brain tumors, vascular malformations and hematomas
62234746|NCT00988195|EXPERIMENTAL|PEG-BCT-100|Pegylated Recombinant Human Arginase I
62234747|NCT05472948|EXPERIMENTAL|Surufatinib and Sintilimab in Combination With Capecitabine|"Patients were given solventinib (a 3+3 design was adopted in the dose exploration phase, with two dose levels of 200mg and 250mg for dose exploration; after the recommended dose was determined in the dose exploration phase, the dose amplification phase was entered), once a day (QD) for continuous administration~* sindilizumab, 200mg, iv every 3 weeks (Q3W)~* Capecitabine, 1000mg/m2, twice a day (BID, once in the morning and once in the evening), orally after meals, stopped for 1 week after 2 weeks of treatment;~The three-drug combination therapy was continued every 3 weeks in a cycle until patients developed disease progression or met other criteria for termination of study treatment specified in the protocol."
62425738|NCT05324709|EXPERIMENTAL|Experimental|The program will be carried out one day a week for four weeks. Yin yoga practices will be applied in the program. Each session will last a total of 40 minutes. The first 20 minutes of yin yoga sessions. Participants will be given training on stress management, breathing and yin yoga. Afterwards, each session of Yin yoga exercises will be started with pranayama (breathing) exercises for 2 minutes, followed by Suryanamaskar-A (Sun Salute-A) for warming up and Yin yoga exercises will be done. The program will be completed by applying the focus on Moment in the last 5 minute. In addition, the participants will be given homework related to the subject of each week. The training booklet will be distributed to the participants before the program. Stress management sessions of the Adolescent Health Promotion-Physical Activity, Nutrition, Stress Management (COPE HEALTH- TEEN ) program will be used in the stress management training to be explained in the program.
62425739|NCT05324709|NO_INTERVENTION|No Intervention|"The control group will be given 60 minutes of in the moment and stress management training."
62425740|NCT01046721|ACTIVE_COMPARATOR|Exenatide|subcutaneous administration of Exenatide (0.02ml)
62425741|NCT01046721|PLACEBO_COMPARATOR|0.9% Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
62034608|NCT04405596|PLACEBO_COMPARATOR|Placebo|Participants receive capsules visually identical to the experimental groups but without active ingredients.
62034609|NCT01187758|EXPERIMENTAL|Educational intervention|Multifacet educational intervention that includes workshops, seminars and focus group meetings
62425742|NCT05049304|EXPERIMENTAL|OA-enriched functional olive oil|
62425743|NCT05049304|ACTIVE_COMPARATOR|Olive oil not enriched in OA|
62425744|NCT06087302|NO_INTERVENTION|control group|the control group wouldnot receive the CPRT for caregivers/parents
62425745|NCT06087302|EXPERIMENTAL|CPRT intervention group|intervention group would receive the CPRT for caregivers/parents
62735474|NCT01670279|EXPERIMENTAL|Cohort 1|14 day titration phase and two fixed dose phases. The first fixed dose phase is 14 days with a daily dose of 2mg brexpiprazole/placebo. The second fixed dose phase is 14 days with a daily dose of 3 mg brexpiprazole/placebo.
62810925|NCT05866770|OTHER|U8 then N8|Participants in this arm receive U8 followed by N8
62810926|NCT05866770|OTHER|N8 then U8|Participants in this arm receive N8 followed by U8
62034610|NCT01187758|NO_INTERVENTION|Control - no intervention|This group did not have any intervention, but their population was screened for carriage of antibiotic resistant bacteria
62034611|NCT06580886||Psoriatic arthritis|Age ≥18, Meets the classification for psoriatic arthritis (CASPAR) criteria, Able to provide an informed consent, Having peripheral disease phenotype of PsA, At least one tender and swollen join on the day of US
62034612|NCT02376218|EXPERIMENTAL|Hypertonic 50% dextrose pleurodesis|
62810927|NCT02174731|EXPERIMENTAL|Roxadustat|
62810928|NCT02174731|ACTIVE_COMPARATOR|Epoetin alfa|
62810929|NCT00097500|EXPERIMENTAL|Exenatide Arm|Exenatide and Metformin
62810930|NCT00097500|ACTIVE_COMPARATOR|Insulin Glargine Arm|Insulin Glargine and Metformin
62034613|NCT05634538|ACTIVE_COMPARATOR|Robotic-assisted PCI with Corpath GRX® System|Percutaneous coronary intervention (PCI) using the Corpath GRX System.
62034614|NCT05634538|ACTIVE_COMPARATOR|Standard PCI|Percutaneous coronary intervention (PCI) using manual techniques. This arm will be completed without robotic assistance.
62594059|NCT03020199|EXPERIMENTAL|Secukinumab 300 mg|"In the Main Study, 80 new-onset psoriasis patients in Arm A1 (68 in Arm A1a, 12 in Arm A1b) received 300 mg secukinumab injections weekly for the first month, then every 4 weeks until Week 48 (52-week treatment). Arm A1b patients also joined the Mechanistic Sub-study.~In the Mechanistic Sub-study, 12 new-onset psoriasis patients (Arm A2) and 24 chronic plaque psoriasis patients (12 each in Arms C1 and C2) received similar secukinumab treatment. Arm A2 and C2 patients continued until Week 100 (104-week treatment), while Arm C1 ended at Week 48 (52-week treatment)."
62034615|NCT00702000||1.|Those with ICU-acquired weakness
62034616|NCT05916768|EXPERIMENTAL|Intervention group|"The solution of Pelargonium sidoides extract EPs® 7630:~3x30 drops/day for 7 days and will be advised to pursue the treatment until the end of symptoms if bothered by the cough up to a maximum of 21 days."
62034617|NCT05916768|ACTIVE_COMPARATOR|Control group|Usual care. Reference therapies, which are classified as symptomatic treatments, are chosen freely by the PCP except for phytotherapy
62034618|NCT02625103|EXPERIMENTAL|Clozapine|treatment as usual: administration of clozapine between 9 and 12 pm. Blood sampling 10 -14 hours post drug administration
62735475|NCT01670279|EXPERIMENTAL|Cohort 2|14 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.
62735476|NCT01670279|EXPERIMENTAL|Cohort 3|21 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.
62735477|NCT01670279|PLACEBO_COMPARATOR|Placebo|Placebo
62810931|NCT03095651|EXPERIMENTAL|T1DM MK-5160 16 nmol/kg|Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
62810932|NCT03095651|EXPERIMENTAL|T1DM MK-5160 32 nmol/kg|Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
62810933|NCT03095651|EXPERIMENTAL|T1DM MK-5160 64 nmol/kg|Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
62034619|NCT01392560|EXPERIMENTAL|BI 10773|Oral once daily
62034620|NCT03257826|EXPERIMENTAL|surgery|Percutaneous Kirschner wire
62034621|NCT06345027|EXPERIMENTAL|Treatment Arm A|"Patients will initially be consented for procurement of blood for generation of the transduced T-cells.~Three dose levels will be evaluated and a possible dose level -1 in case of unexpected toxicity at dose level 1. Each patient will receive one T cell infusion."
62034622|NCT02912403||Postpartum Cesarean Section|We will be including postpartum women as this study idea is pertaining to recent pregnancy
62034623|NCT03756181|EXPERIMENTAL|Five-week MSC program (MSC5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator may discuss the student's experience and encourage group sharing within the course of the session. These discussions will reinforce the guiding principles of compassion: self-kindness, mindfulness, and common humanity, and will work on soothing the processes of self-criticism, self-neglect and perfectionism that are believed to withhold upon experiencing psychological distress. There will also be sessions dedicated to incorporating self-compassion in daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
62034624|NCT03756181|ACTIVE_COMPARATOR|Five-week Mindfulness-based Stress Reduction program (MBSR5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator will perform a brief check-in and may discuss the student's experience within the course of the session. These discussions will reinforce the guiding principles of meditation: awareness, non-judgment and acceptance and will work on automatic mental processes that are believed to be at the root of experiencing psychological distress. There will also be sessions dedicated to incorporating mindfulness into daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
62034625|NCT06668896|EXPERIMENTAL|DARE-PTB1 8mg IVR|Intravaginal ring containing 8mg progesterone administered once for 14 days.
62034626|NCT06668896|EXPERIMENTAL|DARE-PTB1 12mg IVR|Intravaginal ring containing 12mg progesterone administered once for 14 days.
62034627|NCT06668896|EXPERIMENTAL|DARE-PTB1 12mg IVR every 3 days|Intravaginal ring containing 12mg progesterone administered every 3 days for 15 days.
62034628|NCT06668896|ACTIVE_COMPARATOR|Endometrin 100mg|100mg progesterone vaginal insert, three times daily for 14 days.
62594060|NCT03020199|ACTIVE_COMPARATOR|Narrow-band ultraviolet B (nb-UVB)|"In the Main Study, 80 new-onset psoriasis patients in Arm B1 (68 in Arm B1a and 12 in Arm B1b) received 1 or 2 cycles of nb UVB of 12 weeks each with a maximum break of 28 weeks between cycles (patients with PASI 90 at Week 40 did not receive a second treatment cycle) (treatment duration = 52 weeks).~Patients from Arm B1b participated also in the Mechanistic Sub-study."
62594061|NCT06124755|EXPERIMENTAL|Viabahn endoprosthesis group|Femoropopliteal lesions treated with Viabahn endoprosthesis.
62034629|NCT04272268||Nasal High flow Oxygen|Following consent, the participant will undergo Oesophagectomy as per routine care. During surgery, prior to trial participation and as per standard of care at the site, a nasogastric tube will be placed into the gastric conduit and secured to the nose. This tube will be left on free drainage and aspirated every 4 hours to check for inadvertent insufflation.
62034630|NCT05027165||Observational group|"In this cohort, 40 NSCLC patients with indication for chemoradiotherapy followed by durvalumab maintenance treatment (standard of care) will be consecutively recruited.~Comprehensive characterization of all patients includes immunophenotyping of peripheral blood mono-nuclear cells, ctDNA as well as gut/saliva microbiome analyses and will be performed before, after 15 fractions of radiotherapy, at the end of concurrent chemoradiotherapy as well as 3-, 6- and 12 months after start of durvalumab.~18F-FDG-PET/CT will be performed 5-10 d before start of radiotherapy, 6 weeks, 6 months,12 and 24 months after the end of radiochemotherapy. Lung function will be asssed before start of radiotherapy, at the end and 6 weeks after chemoradiotherapy as well as 3-, 6- and 12, 18, 24months after start of durvalumab."
62594062|NCT06124755|ACTIVE_COMPARATOR|Drug-coated balloon group|Femoropopliteal lesions treated with drug-coated balloon endoprosthesis.
62594063|NCT04310709|EXPERIMENTAL|REGONIVO|"Nivolumab - 480 mg IV on Day 1, every 4 weeks~Regorafenib~- 80 mg per oral once daily for 21 consecutive days starting on Day 1, every 4 weeks."
62034631|NCT03435874|EXPERIMENTAL|Group 1 Active|n=6. Age 18-35 years. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 at D56.
62034632|NCT03435874|PLACEBO_COMPARATOR|Group 1 Comparator|n=3. Age 18-35 years. Rabies vaccine at D0 and D56.
62034633|NCT03435874|EXPERIMENTAL|Group 2a Active|n=6. Age 1-6 years. 1x10 10 vp ChAd63 RH5 at D0 and 1x10 8 pfu MVA RH5 D56.
62034634|NCT03435874|PLACEBO_COMPARATOR|Group 2a Comparator|n=3. Age 1-6 years. Rabies vaccine at D0 and D56.
62034635|NCT03435874|EXPERIMENTAL|Group 2b Active|n=12. Age 1-6 years. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 D56.
62034636|NCT03435874|PLACEBO_COMPARATOR|Group 2b Comparator|n=6. Age 1-6 years. Rabies vaccine at D0 and D56.
62243175|NCT04838769|ACTIVE_COMPARATOR|REZŪM|"Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use (IFU). The REZŪM System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with benign prostatic hyperplasia (BPH). It is indicated for men with a prostate volume ≥ 30 ml. The REZŪM System is also indicated for treatment of prostate with hyperplasia of the central zone and/or a median lobe.~1:1 randomization will occur via the electronic data capture (EDC) system."
62425746|NCT01838278|EXPERIMENTAL|Vojta physiotherapy Method|Children in the experimental group or Vojta group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
62425747|NCT06070493|EXPERIMENTAL|Control group|classical physiotherapy
62425748|NCT06070493|EXPERIMENTAL|Treatment group|classical physiotherapy and myofascial release
62594064|NCT06437821|OTHER|Petrissage|
62594065|NCT06437821|EXPERIMENTAL|Graston Technique|
62594066|NCT05156554|EXPERIMENTAL|PEG-rhG-CSF|Patients in PEG-rhG-CSF group received PEG-rhG-CSF day+1 after transplantation.
62810934|NCT03095651|ACTIVE_COMPARATOR|T1DM Glargine 0.4 U/kg|Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
62034637|NCT03435874|EXPERIMENTAL|Group 3a Active|n=6. Age 6-11 months. 1x10 10 vp ChAd63 RH5 at D0 and 1x10 8 pfu MVA RH5 D56.
62034638|NCT03435874|PLACEBO_COMPARATOR|Group 3a Comparator|n=3. Age 6-11 months. Rabies vaccine at D0 and D56.
62034639|NCT03435874|EXPERIMENTAL|Group 3b Active|n=12. Age 6-11 months. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 D56.
62425749|NCT01392170|EXPERIMENTAL|PEG-IFNá-2a|PEG-IFNá-2a (Pegasys) 45 mcg subcutaneously as single weekly dose.
62425750|NCT03959137||Primary study group|Stage IV untreated NSCLC
62425751|NCT05597163|EXPERIMENTAL|0.01% atropine|0.01% atropine eye drop
62594067|NCT05156554|ACTIVE_COMPARATOR|rhG-CSF|Patients in rhG-CSF group received rhG-CSF day+1 after transplantation.
62810935|NCT03095651|EXPERIMENTAL|T2DM MK-5160 16 nmol/kg|Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
62810936|NCT03095651|EXPERIMENTAL|T2DM MK-5160 32 nmol/kg|Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
62034640|NCT03435874|PLACEBO_COMPARATOR|Group 3b Comparator|n=6. Age 6-11 months. Rabies vaccine at D0 and D56.
62034641|NCT05686057||single vessel diseased patients|sST2 level will be withdrawn at the baseline and after successful PCI
62034642|NCT05686057||2 vessels diseased patients|sST2 level will be withdrawn at the baseline and after successful PCI
62034643|NCT05686057||multivessels diseased patients|sST2 level will be withdrawn at the baseline and after successful PCI
62234748|NCT06073626|EXPERIMENTAL|Relational Agent (RA)|Participants in the RA arm will receive a clinical letter from the institution's clinical genetics program with a link to the RA. The fully HIPAA-compliant RA will provide comparable educational information to traditional genetic counseling (GC) but in a streamlined and tailored manner including video, education and decision support, patient testimonial and answers to questions in real-time. Participants will be informed that they may speak to a genetic risk specialist free of charge. For participants who wish to proceed directly to GT, the RA will alert staff to these requests and a GT kit will be mailed to them. Results will be shared with the participant, their oncologist and tailored per the result. Participants who indicate that they are unsure or do not want GT will be encouraged by RA to discuss their risk and GT options with their oncology provider and to schedule a GC appointment with the clinic or via a link to the automated scheduling tool in the RA.
62243176|NCT04838769|ACTIVE_COMPARATOR|Dual Drug Therapy|Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.
62243177|NCT01483833|ACTIVE_COMPARATOR|Iferanserin|Iferanserin administration intra-anally twice daily for 14 days
62243178|NCT01483833|PLACEBO_COMPARATOR|Placebo|Placebo administration intra-anally twice daily for 14 days
62810937|NCT03095651|EXPERIMENTAL|T2DM MK-5160 64 nmol/kg|Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
62810938|NCT03095651|ACTIVE_COMPARATOR|T2DM Glargine 0.6 U/kg|Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
62034644|NCT05686057||non-ischemic control patients|sST2 level will be withdrawn at the baseline
62034645|NCT05119920|EXPERIMENTAL|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
62034646|NCT05119920|EXPERIMENTAL|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
62034647|NCT05119920|EXPERIMENTAL|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
62034648|NCT05119920|PLACEBO_COMPARATOR|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
62034649|NCT01750138|EXPERIMENTAL|Glutamine|Glutamine powder given preoperatively for five days
62810939|NCT00287222|EXPERIMENTAL|1 - Bevacizumab/Erlotinib|Subjects will be treated with bevacizumab and erlotinib
62034650|NCT01750138|ACTIVE_COMPARATOR|Placebo|dextrose powder for 5 days pre-operatively
62034651|NCT01775904|EXPERIMENTAL|LY2886721 Capsule (water, fasting)|Reference formulation. A single oral dose of 70 milligrams (mg) LY2886721 in a capsule given with water and without a meal in one of four periods.
62034652|NCT01775904|EXPERIMENTAL|LY2886721 ODT (no water, fasting)|A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given without water and without a meal in one of four periods.
62034653|NCT01775904|EXPERIMENTAL|LY2886721 ODT (water, fed)|A single oral dose of a 70 mg LY2886721 in an orally disintegrating tablet (ODT) given with water and after a high-fat breakfast in one of four periods.
62034654|NCT01775904|EXPERIMENTAL|LY2886721 ODT (water, fasting)|A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given with water and without a meal in one of four periods.
62034655|NCT05238935|NO_INTERVENTION|control group|this group will be treated as per the common practice postoperatively and will have the home program prescribed by the orthopedic surgeon
62034656|NCT05238935|EXPERIMENTAL|intervention (treatment) group|Patients in the intervention group will be treated with conventional physiotherapy 3 times a week for 6 weeks (18 times treatment).
62034657|NCT04721054|ACTIVE_COMPARATOR|group receiving thoracic epidural anesthesia|
62034658|NCT04721054|ACTIVE_COMPARATOR|group receiving thoracic general anesthesia|
62034659|NCT03100617|EXPERIMENTAL|REACH-VA family caregiver intervention|Behavioral intervention with several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
62034660|NCT03342638|EXPERIMENTAL|Control Arm|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant.
62425752|NCT05597163|EXPERIMENTAL|0.025% atropine|0.025% atropine eye drop
62234749|NCT06073626|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|Participants in the EUC arm will also be mailed a clinical letter signed by the Medical Director of the institution's clinical genetics program. The letter sent to EUC participants will inform them of their own and their family's potential risk for carrying a pathogenic variant (PV) related to hereditary cancer. The letter will emphasize their eligibility for GT, include a recommendation to consider scheduling a GC appointment to obtain more information, and include a link to the CINJ or LCCC high-risk clinic website. The study team will help facilitate GT when requested by the participant. Results will be shared with the participant, their oncologist and tailored per the result.
62234750|NCT01000636|EXPERIMENTAL|Metvix PDT|
62234751|NCT02723409|ACTIVE_COMPARATOR|Round Procedure|umbilicoplasty technique
62234752|NCT02723409|ACTIVE_COMPARATOR|"Scarless round procedure"|umbilicoplasty technique
62234753|NCT02723409|ACTIVE_COMPARATOR|"Inverted U procedure"|umbilicoplasty technique
62234754|NCT02723409|ACTIVE_COMPARATOR|"Inverted V procedure"|umbilicoplasty technique
62234755|NCT02723409|ACTIVE_COMPARATOR|"Y deepithelialized procedure"|umbilicoplasty technique
62234756|NCT05280587|EXPERIMENTAL|Technological Group|Technological group (TG) patients will undergo robotic treatment for the improvement balance through the robotic platform (Hunova® Movendo Technology srl, Genova, IT), 3 times per week for 45 minutes each, in addition to the conventional treatment (total 180 minutes per day). In particular, the technological rehabilitation performed employing a footboard will be mostly aimed at improving the balance both in sitting and standing position, and will be proposed static and dynamic exercises, exercises dual-task exercises, and exercises to improve trunk control.
62234757|NCT05280587|NO_INTERVENTION|Control Group|Congrol Group (CG) patients will undergo conventional rehabilitation treatment only, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive neuromuscular facilitation, etc.).
62234758|NCT00823056|PLACEBO_COMPARATOR|1|
62234759|NCT00823056|ACTIVE_COMPARATOR|2|
62234760|NCT01387230|EXPERIMENTAL|GSK573719|active drug
62234761|NCT01387230|PLACEBO_COMPARATOR|Placebo|no active drug
62234762|NCT03333837|ACTIVE_COMPARATOR|Dance Group|The Dance Group will participate in 1-hour group improvisational dance lessons 2x/week for 12 weeks. Improvisational dance classes are grounded in 4 principles that shape the tone of the class and result in a sense of social belonging: non-judgment, non-competitiveness, curiosity, and playfulness. The following training strategies are used to maintain: active imagination, variability, and pacing.
62234763|NCT03333837|ACTIVE_COMPARATOR|Non-group Dance|The Non-group dance intervention is designed to capture the same dance movement and auditory stimuli as the group class without social interaction. Recordings of the dance instructor teaching a dance class will be played. This will ensure participants hear comparable music and receive comparable verbal auditory cues to prompt dance movements that students in the group class will hear, without interacting with other people. Improvisational dance is particularly suited for this means of delivery because the primary method of instruction is verbal auditory cueing. Participants will be asked to follow the same schedule as participants in the Dance Group arm and complete 2 one-hour dance sessions each week.
62234764|NCT03333837|ACTIVE_COMPARATOR|Social Group|The social group will consist of improvisational party games to foster curiosity and playfulness, use imagery, and encourage non-judgment. Games that may be used include 'Balderdash', 'Wise and Otherwise', 'Charades', 'Pictionary', and 'Tell Me A Story' cards. These games will also use the same core strategies as the dance group. Games will be varied within an hour-long session to incorporate pacing and variability into the social group, akin to the dance group. The social group will occur 2x/week for 1 hour each time and be led by the same instructors who lead the Dance Group, to control for effects of personality of the group leader.
62234765|NCT03333837|SHAM_COMPARATOR|No Contact|A No Contact condition captures the condition of no added social contact and no added dance movement. Participants randomized to the No Contact condition will be asked to continue their current disease management and lifestyle for 12 weeks
62234766|NCT05604833|EXPERIMENTAL|experimental|they will November progressive muscle relaxation exercise
62234767|NCT05604833|NO_INTERVENTION|no ıntervention|to be followed without exercise
62234768|NCT04855266|EXPERIMENTAL|Iron Sucrose Group|Subjects will receive intravenous iron sucrose during a tilt table test
62234769|NCT04855266|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive intravenous placebo during a tilt table test
62234770|NCT02864420|ACTIVE_COMPARATOR|Inpatient hospitalization|Control / usual care arm. Patients are admitted per usual to an inpatient service. Patients' medical records will be closely monitored. Patients will wear a vitals and activity monitor whose data is used only retrospectively. On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
62425753|NCT05597163|EXPERIMENTAL|0.05% atropine|0.05% atropine eye drop
62425754|NCT05597163|OTHER|cross-over|first year: placebo second year: 0.05% atropine eye drop
62425755|NCT03246334||Cohort|Critically ill patients admitted \>12 hours to the ICU
62425756|NCT03424694|EXPERIMENTAL|2 fractions of 14.5 Gy HDR Brachytherapy|"High Dose Rate (HDR) Brachytherapy as monotherapy at a dose of 29 Gy is delivered in 2 fractions of 14.5 Gy, minimum 6 hours a part, delivered on a single implant procedure with 2 MRI assisted plannings and dosimetries.~HDR brachytherapy implant is done under anesthesia with ultrasound guidance as an out-patient procedure."
62425757|NCT03424694|EXPERIMENTAL|1 fraction of 19.5 Gy HDR brachytherapy|"HDR Brachytherapy as monotherapy at a dose 19.5 Gy is delivered in 1 fraction. Treatment is done on a single ultrasound guided implant, post implant MRI assisted planning and dosimetry.~HDR brachytherapy implant is done under anesthesia with ultrasound guidance as an out-patient procedure."
62425758|NCT04581031|OTHER|Wearable monitors - Isansys Patient Status Engine|All patients will wear the continuous vital sign monitoring sensors.
62594068|NCT03555565||Alogliptin and Metformin hydrochloride|Alogliptin 25 mg and metformin hydrochloride 500 mg, combination tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
62034661|NCT03342638|EXPERIMENTAL|IVIg Arm|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. IVIg and G-CSF will be administered post-transplant.
62594069|NCT01739218|EXPERIMENTAL|Carboplatin + Paclitaxel + Bevacizumab|Participants will receive 4 cycles of neoadjuvant therapy prior to IDS and 22 cycles of adjuvant therapy before entering long-term follow-up. Each cycle will be 3 weeks in length. Carboplatin and paclitaxel will be administered during Cycles 1 to 8. Bevacizumab will be administered during both the neoadjuvant and the adjuvant treatment periods in Cycles 1 to 26 (no treatment in Cycles 4 and 5).
62594070|NCT01739218|ACTIVE_COMPARATOR|Carboplatin + Paclitaxel|Participants will receive 4 cycles of neoadjuvant therapy prior to IDS and 22 cycles of adjuvant therapy before entering long-term follow-up. Each cycle will be 3 weeks in length. Carboplatin and paclitaxel will be administered during Cycles 1 to 8. Bevacizumab will be administered only during the adjuvant treatment period in Cycles 6 to 26.
62034662|NCT00780208|OTHER|Daytrana (methylphenidate patch)|Methylphenidate patch
62810940|NCT04362436|EXPERIMENTAL|TheraSpheres Selective Internal Radiation Therapy (SIRT)|Radiation therapy
62810941|NCT01476722|EXPERIMENTAL|OPTI-FREE PureMoist|OPTI-FREE PureMoist multipurpose disinfecting solution used with study contact lenses on a daily wear basis for 30 days
62034663|NCT04592068||Retinal multi-diseases diagnosed by DL algorithm|
62234771|NCT02864420|EXPERIMENTAL|Home hospitalization|Intervention arm. Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
62234772|NCT03189043|EXPERIMENTAL|Test|Use of antimicrobial surface
62234773|NCT03189043|NO_INTERVENTION|Control|No antimicrobial surface
62594071|NCT01098656|EXPERIMENTAL|lenalidomide|
62594072|NCT01098656|NO_INTERVENTION|Observation|
62034664|NCT04592068||Retinal multi-diseases diagnosed by expert panel|
62034665|NCT02348073|ACTIVE_COMPARATOR|PS-OMEGA 3, capsules twice daily|Vayarin®, supplementation of n-3 PUFA: each capsule contains 8.5 mg of docosahexaenoic acid (DHA), 21.5 mg of eicosapentaenoic acid (EPA) and 75 mg of phosphatidylserine.
62034666|NCT02348073|PLACEBO_COMPARATOR|PLACEBO, capsules twice daily|The placebo will be made of cellulose and a small amount of fish powder to maintain the double-blind in odor and taste. The supplementation in n-3 PUFA in the placebo group may be considered as negligible. Placebo will be administered as indistinguishable capsules, identical to the active product.
62034667|NCT01581281|ACTIVE_COMPARATOR|Amitriptyline|Drug to be administered twice daily.
62034668|NCT01581281|ACTIVE_COMPARATOR|Topiramate|Drug to be administered twice daily.
62034669|NCT01581281|PLACEBO_COMPARATOR|Placebo|To be administered twice daily.
62034670|NCT00249535|EXPERIMENTAL|1|standard treatment plus usual magnitude prize CM
62034671|NCT00249535|EXPERIMENTAL|2|standard treatment plus higher magnitude prize CM
62234774|NCT06172881|EXPERIMENTAL|Distance Visual Acuity|Visual acuity will be measured while participant's wear study lenses.
62234775|NCT02677012||Arm I (RESOLVE TM)|Patients undergo AFG reconstructive surgery comprising washing and low velocity spinning using a commercially available system that washes the lipoaspirate with lactated Ringer's solution separates non-fat material from the fat with gentle centrifugal force and suction.
62594073|NCT06619197|OTHER|global reflexology|This study involves subjects under 18 years of age, suffering from sickle cell disease, hospitalized in the short-stay hospitalization unit (UHCD) or continuous monitoring unit (USC) of the Women's Mother and Child Hospital of the Hospices Civils de Lyon.
62810942|NCT03920345|EXPERIMENTAL|Treatment: Endoscopic ET on SI joint|New techniques have been developed and tested to expand the usefulness of minimally invasive spine surgery beyond disk herniation. This includes endoscopic electrothermic ablation which can be used to target SIJ-associated CLBP. A small retrospective study demonstrated significant improvements in Visual Analog Scale and Oswestry Disability Index from pre-operative levels in patients with CLBP associated with the SIJ for up to 21 months following the procedure. However, there has not yet been a prospective study to assess the efficacy of this procedure, and therefore, this is the aim of this study.
62810943|NCT03402542||Cholecystectomy|Patients with a symptomatic vesicular lithiasis, having undergone cholecystectomy during a scheduled hospitalization in the CHU Brugmann Hospital between May 2016 and November 2017.
62034672|NCT00249535|EXPERIMENTAL|3|standard treatment plus voucher CM
62810944|NCT02528084|EXPERIMENTAL|yoga intervention|patients in the group are asked to follow an online video instructing them various yoga poses. Patients in this group are asked to do the yoga exercises 2-3 times a week, for a total of 6 weeks.
62810945|NCT02528084|EXPERIMENTAL|standard exercises intervention|patients in this group are asked to follow an online standard exercises video. Patients in this group are asked to follow specific exercises 2-3 times a day, for a total of 6 weeks.
62810946|NCT02528084|NO_INTERVENTION|control|patients in this group carry forth with their daily activities. They are not asked to follow the online yoga video or the online standard exercise video.
62810947|NCT02577172|EXPERIMENTAL|Exercise group|Aerobic- and Strength Training program
62594074|NCT05680051|EXPERIMENTAL|Experimental group|Drug-coated Balloon (Lepu Medical Technology (Beijing) Co.,Ltd.)
62594075|NCT05680051|ACTIVE_COMPARATOR|Control group|Drug Eluting Stent(Microport Medical)
62594076|NCT06442098|EXPERIMENTAL|Code First|Children in this condition will receive 7 sessions of code-focused reading intervention followed by 7 sessions of morphology-focused reading intervention.
62594077|NCT06442098|EXPERIMENTAL|Morphology First|Children in this condition will receive 7 sessions of morphology-focused reading intervention followed by 7 sessions of code-focused reading intervention.
62594078|NCT06094283|ACTIVE_COMPARATOR|YCT-529|Oral single ascending dose(s)
62034673|NCT02789280|EXPERIMENTAL|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated."
62594079|NCT06094283|PLACEBO_COMPARATOR|Placebo|Placebo for YCT-529 Capsule
62594080|NCT05346211|EXPERIMENTAL|Curcumin Single|"The Single dose group will consume 1 placebo sachet and one curcumin sachet per day.~Curcumin supplementation will be from YourZooki, the supplement in question is commercially offered to the public in a tangerine flavour. The sachets will be in 750mg hydrolysed format.~The placebo is a sachet containing the same ingredients mentioned above minus the curcumin. The sachets will be in 750mg hydrolysed format.~Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am \& 8pm)."
62594081|NCT05346211|EXPERIMENTAL|Curcumin Double|"The double dose group will consume two sachets per day of curcumin.~Curcumin supplementation will be from YourZooki, the supplement in question is commercially offered to the public in a tangerine flavour. The sachets will be in 750mg hydrolysed format.~Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am \& 8pm)."
62594082|NCT05346211|NO_INTERVENTION|Placebo|"Placebo sachets containing the same ingredients mentioned above minus the curcumin. The sachets will be in 750mg hydrolysed format.~Participants will consume two sachets per day.~Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am \& 8pm)."
62594083|NCT06304792|EXPERIMENTAL|Immediate FET in a stimulated or programmed cycle|Stimulated or programmed cycle FET is performed in the first cycle following failed fresh embryo transfer or freeze all.
62594084|NCT06304792|NO_INTERVENTION|Postponed FET in a stimulated or programmed cycle|Stimulated or programmed cycle FET is performed at least one full menstrual, or one hormonal replacement treatment (HRT) cycle in case of oligo-anovulation, after the fresh embryo transfer or freeze-all cycle
62594085|NCT01763073||Medical Students|Fourth-year students in accredited US medical schools who have applied to, but not yet been matched with, residency programs in obstetrics and gynecology.
62594086|NCT06299111|EXPERIMENTAL|REGN9933|Randomized 1:1:1
62594087|NCT06299111|EXPERIMENTAL|REGN7508|Randomized 1:1:1
62594088|NCT06299111|PLACEBO_COMPARATOR|Placebo|Randomized 1:1:1
62594089|NCT00797134||DR|Diabetic Retinopathy
62594090|NCT06608875|SHAM_COMPARATOR|Adaptation Arm|Hyper-personalized feedback-based motor rehabilitation with sham targeted auditory stimulation during sleep (HPF intervention, TASS sham intervention)
62234776|NCT02677012||Arm II (Cytori PureGraft TM)|Patients undergo AFG reconstructive surgery comprising gravity filtration using a commercially available system in which the lipoaspirate is rinsed with lactated RL and the non-fat material is filtered through mesh.
62594091|NCT06608875|EXPERIMENTAL|Consolidation arm|Hyper-personalized feedback-based motor rehabilitation with targeted auditory stimulation during sleep (HPF intervention, TASS verum intervention)
62594092|NCT02478034|EXPERIMENTAL|fludrocortisone|effects of fludrocortisone on cognition compared to placebo
62594093|NCT02478034|PLACEBO_COMPARATOR|Placebo|effects of fludrocortisone on cognition compared to placebo
62810948|NCT02577172|ACTIVE_COMPARATOR|Control group|One lifestyle counseling session
62810949|NCT00655265|EXPERIMENTAL|Colesevelam hydrochloride film-coated tablets|
62810950|NCT00655265|PLACEBO_COMPARATOR|Placebo|
62810951|NCT04714606|EXPERIMENTAL|Sibling support group|8 session, tailored support group for siblings of children who have an ASD
62810952|NCT04714606|ACTIVE_COMPARATOR|Booklet|Control condition in which siblings of children who have an ASD will receive a tailored booklet to complete at home
62594094|NCT05069545||Tresiba + Fiasp using NovoPen 6 per local label|Participants will use Tresiba® and Fiasp® in NovoPen® 6 as prescribed to participants by the study doctor
62594095|NCT04196413|EXPERIMENTAL|GD2-CAR T|"Rolling-6 dose escalation design will test GD2-CAR T cells in subjects with H3K27M-mutant DIPG.~GD2CART will be administered in escalating doses on Day 0 in hospitalized subjects with either DIPG or spinal DMG~Intravenously~* Dose Level -1: 3x10\^5 transduced T cells/kg(± 20%)~* Dose Level 1: 1x10\^6 transduced T cells/kg (± 20%)~* Dose Level 2: 3x10\^6 transduced T cells/kg (± 20%)~Intracerebroventricularly, without conditioning lymphodepletion chemotherapy~* Dose Level -1: 10x10\^6 transduced T cells (±20%)~* Dose Level 1: 30x10\^6 transduced T cells (±20%)~* Dose Level 2: 50x10\^6 transduced T cells (±20%)~* Dose Level 3: 100x10\^6 transduced T cells (±20%)~Intracerebroventricularly after administration of conditioning lymphodepletion chemotherapy regimen with cyclophosphamide and fludarabine~* Dose Level -1: 10x10\^6 transduced T cells (±20%)~* Dose Level 1: 30x10\^6 transduced T cells (±20%)~* Dose Level 2: 50x10\^6 transduced T cells (±20%)"
62594096|NCT01789411||ATHEROREMO-IVUS cohort|Drawing blood samples. Coronary intravascular ultrasound imaging. Coronary near-infrared spectroscopy.
62594097|NCT06181292|EXPERIMENTAL|PHH-1V81|One dose of 40ug of PHH-1V81, administered intramuscularly
62425759|NCT01412073|ACTIVE_COMPARATOR|oxytocin bolus|"5 IU bolus iv over 3 minutes after delivery of the baby Operative blood loss will be estimated in theatre based on the volume in the suction bottle and the weight of swabs used. We will record blood loss up until the time the woman will be discharged from the theatre recovery ward.~Hemoglobin level and haematocrit value will be done as follow:-~1. After admission of each case in the pre-operative period.~2. Immediately post- operative.~3. 24 hours post- operative."
62425760|NCT01412073|ACTIVE_COMPARATOR|oxytocin bolus & oxytocin infusion|5 IU oxytoxin bolus over 3 minutes and 30 IU oxytocin infusion in 500 ml 0.9% saline over 4 hours after delivery of the baby
62810953|NCT01968486|EXPERIMENTAL|PDT Standard Fluence, ranibizumab|verteporfin (6 mg/m2) SF (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 milliwatt(mW)/cm2 for 83 s) plus 0.5 mg intravitreal ranibizumab
62810954|NCT01968486|EXPERIMENTAL|PDT Reduced Fluence, ranibizumab|verteporfin (6 mg/m2) RF ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s) plus 0.5 mg intravitreal ranibizumab
62810955|NCT01968486|EXPERIMENTAL|ranibizumab|0.5 mg (10 mg/ml) intravitreal ranibizumab.
62425761|NCT01412073|ACTIVE_COMPARATOR|misoprostol intrauterine|misoprostol 800 micrograms intrauterine, placed manually on the bottom of the uterine cavity after delivery of the placenta and cleaning of the cavity
62425762|NCT04228289|EXPERIMENTAL|Oxytocin|40 IU intranasal oxytocin
62425763|NCT04228289|PLACEBO_COMPARATOR|Placebo|intranasal saline spray
62034674|NCT02789280|ACTIVE_COMPARATOR|Wait List|Participants will be asked to wait for a week until they receive the behavioral activation condition
62034675|NCT04371003||WNND|40 subject with West-Nile Neuroinvasive Disease will be recruited
62034676|NCT04371003||WNF|40 subject with West-Nile Fever will be recruited
62034677|NCT04371003||controls|20 control will be recruited. These controls will be aged matched to the cases.
62234777|NCT02677012||Arm III (Coleman technique)|Patients undergo AFG reconstructive surgery comprising standard centrifugation at 3200 rpm for 3 minutes with the resulting oil and aqueous layers discarded.
62810956|NCT05853016||Cohort A|Healthy adults
62810957|NCT05853016||Cohort B|Adults with stable chronic morbidities
62810958|NCT00149968|EXPERIMENTAL|Myfortic|
62810959|NCT02308956|EXPERIMENTAL|Integrated mental health in primary care|Participants in the new intervention arm will receive a task sharing model of locally-delivered mental health care integrated into primary healthcare. General health workers (health officers, nurses and community-based health extension workers) will be given brief training using the WHO's mental health Gap Action Programme and ongoing supervision in order to deliver mental health care to people with severe mental disorders.
62810960|NCT02308956|ACTIVE_COMPARATOR|Psychiatric nurse-led specialist care|Participants in the active control arm will receive an established model of centralised, specialist mental health care delivered by psychiatric nurses at an out-patient clinic within Butajira general hospital and supported by outreach from project workers.
62810961|NCT00701454||1|Healthy participants (physically and mentally).
62810962|NCT01754103|EXPERIMENTAL|Functional Connectivity MRI|Functional Connectivity will be measured by MRI, we will perform one T1WI run as well as three resting state bold based runs. Bold runs parameters: TE 30ms, TR 3000ms, flip angle 90º, gap 0mm, 124 time points, voxel size 3mm, duration 6min18s each, FOV 240x240x141.
62810963|NCT02976337|EXPERIMENTAL|High-dose naloxone|Naloxone 4 mg/ml i.v. infusion, total 3.25 mg/kg, target controlled infusion with three infusion rates (0.25 mg/kg; 0.75 mg/kg; 2.25 mg/kg) each of 25 min duration)
62810964|NCT02976337|PLACEBO_COMPARATOR|Normal saline|0.9% physiological saline, i.v. infusion, total 0.81 ml/kg, target controlled infusion with three infusion rates (0.06 ml/kg; 0.19 ml/kg; 0.56 ml/kg) each of 25 min duration.
62810965|NCT06276569|EXPERIMENTAL|experimental|sivelestat was dissolved in 0.9% sodium chloride injection and diluted with 50ml of the same solution to achieve a dose of 4.8mg/kg/day; this mixture was then placed in a sealed package and administered intravenously at a rate of 0.2 mg/kg/h for seven consecutive days.
62810966|NCT06276569|PLACEBO_COMPARATOR|placebo comparator|received an equivalent volume (50ml) of saline continuously administered intravenously at a rate of 0.2 mg/kg/hour.
62810967|NCT05372718|EXPERIMENTAL|Recombinant non-immunogenic staphylokinase|"lyophilisate for preparation a solution, 5 mg (745,000 IU) in 20 ml over 1 minute through a perforated multihole catheter intrathrombally.~30 minutes after this injection, infusion of recombinant non-immunogenic staphylokinase will be continued at a dose of 1 mg/hour, maximum 10 mg (50 ml) for 10 hours through a perforated multihole catheter intrathrombally."
62810968|NCT05372718|EXPERIMENTAL|Surgical methods of treatment|endovascular intervention, open surgery and/or bypass surgery in accordance with the current National Guidelines
62810969|NCT04643808|EXPERIMENTAL|taVNS once daily|taVNS paired with bottle feeding once daily for 2-3 weeks
62810970|NCT04643808|EXPERIMENTAL|taVNS twice daily|taVNS paired with bottle feeding twice daily for 2-3 weeks
62810971|NCT04097431|EXPERIMENTAL|Precursors as Response Chain or Class|The precursor behavior occurs as a part of a sequence, or for the same maintaining variable, leading up to the severe problem behavior.
62234778|NCT06027190|SHAM_COMPARATOR|Sham group|Intervention Name and Specification: Placebo coil (Magstim Company, Whitland, UK): looks and sounds consistent with true coil but does not produce current stimulation.
62234779|NCT06027190|EXPERIMENTAL|rTMS group|"1. 5Hz-rTMS group~2. 10Hz-rTMS group~3. 30Hz-rTMS group~Intervention Name and Specification:~1. Transcranial magnetic stimulator (M-100 Ultimate, Yingzhi Technology Co., Ltd., China)~2. 70 mm diameter figure-of-eight coil (BY90A, Yingzhi Technology Co., Ltd., China).~Each group received acute and chronic stimulation, respectively. In the acute stimulation stage, patients only needed to do rTMS once, and HREM and HRV were administered before and after rTMS; in the chronic stimulation stage, patients received 25 minutes of rTMS true stimulation each time a day for 20 times, which was completed within 30 days, and the true stimulation parameters were the same as those of acute stimulation."
62594098|NCT06181292|ACTIVE_COMPARATOR|Comirnaty Omicron XBB1.5|One dose of 30ug of Comirnaty Omicron XBB1.5, administered intramuscularly
62234780|NCT03706339|PLACEBO_COMPARATOR|normal saline arm group|they received 110 ml saline infusion or placebo (110 normal salines) by slow intravenous injection at an approximate rate of 1 mL per min plus Throughout the operation irrigation was done by120 ml saline
62234781|NCT03706339|ACTIVE_COMPARATOR|intravenous tranexamic acid group|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus100 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
62234782|NCT03706339|EXPERIMENTAL|Topical tranexamic acid group|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 100 ml normal saline applied on the placental bed after Cesarean section plus110 ml normal saline IV just before skin incision
62234783|NCT03882905|EXPERIMENTAL|Ezetimibe: Base Study|10-mg tablet, oral taken once daily concomitantly with the participant' s current statin therapy for 8 weeks.
62810972|NCT02425345|EXPERIMENTAL|Physical Activity Intervention|The Physical Activity Intervention Group will receive guidance on being physically active, including aerobics, flexibility, balance, strength, and decreased sedentary time. The primary resource is the National Institute of Aging Go4Life exercise and physical activity materials. The materials are based on the United States national guidelines for physical activity for older adults
62810973|NCT02425345|NO_INTERVENTION|Usual Activity Control|Usual activity
62810974|NCT04381858|EXPERIMENTAL|Severe pneumonia due to COVID-19|"Patients who are admitted to Hospital Centers with a positive RT-qPCR SARS-CoV-2 test or a CT scan compatible with a diagnosis of COVID-19 pneumonia, in addition to one of the following two criteria:~1. Severe respiratory failure \[respiratory rate\> 25 - \<35 x minute, oxygen saturation ≤ 90% with reservoir mask (FiO2 = 100%)\]~2. Requiring invasive mechanical ventilation."
62810975|NCT04381858|ACTIVE_COMPARATOR|Severe pnemonia due to COVID-19|"Patients who are admitted to Hospital Centers with a positive RT-qPCR SARS-CoV-2 test or a CT scan compatible with a diagnosis of COVID-19 pneumonia, in addition to one of the following two criteria:~1. Severe respiratory failure \[respiratory rate\> 25 - \<35 x minute, oxygen saturation ≤ 90% with reservoir mask (FiO2 = 100%)\]~2. Requiring invasive mechanical ventilation."
62810976|NCT05514600|ACTIVE_COMPARATOR|Fascial closure|This arm will have the parastomal fascial defect closed with a running barbed suture prior to mesh placement.
62810977|NCT05514600|NO_INTERVENTION|No fascial closure|This arm will undergo mesh placement +/- fixation without the fascial defect being closed prior.
62034678|NCT00687648|EXPERIMENTAL|Arm I|Patients receive aromatase inhibitor (anastrozole, letrozole, or exemestane) as previously prescribed. Patients also receive oral cyclophosphamide once daily on days 1-28 and oral methotrexate twice on days 15, 16, 22, and 23 of course 1. For all subsequent courses, patients receive oral cyclophosphamide once daily and oral prednisolone once daily on days 1-28 and oral methotrexate twice on days 1, 2, 8, 9, 15, 16, 22, and 23. Treatment with cyclophosphamide, methotrexate, and prednisolone repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62234784|NCT03882905|PLACEBO_COMPARATOR|Placebo: Base Study|Placebo for ezetimibe 10-mg tablet, oral taken once daily concomitantly with the participant' s current statin therapy for 8 weeks.
62234785|NCT03882905|EXPERIMENTAL|Ezetimibe: Extension|10-mg tablet, oral taken once daily concomitantly with simvastatin for 48 weeks.
62234786|NCT03882905|PLACEBO_COMPARATOR|Placebo: Extension|Placebo for ezetimibe tablet, oral taken once daily concomitantly with simvastatin for 48 weeks.
62234787|NCT05252052||Adolescents 14-24 years old|Adolescents 14-24 years old
62234788|NCT05252052||Health care providers in rural Haiti|Health care providers in rural Haiti
62234789|NCT06352047|EXPERIMENTAL|Supine position group|Supine position group Before starting the study, parents of preterm infants were informed about the study, and the infants of parents who agreed to participate in the study were divided into two groups as prone and supine positions. In the study, preterm babies positioned after extubation by the researcher. Before extubation, SpO2, respiratory rate (to be counted for one minute), blood pressure, blood gas values were checked and recorded from the bedside monitor of the babies planned for extubation. Before leaving the mechanical ventilator for preterm newborns who were decided for extubation and met the research criteria, vibration and percussion were performed to premature babies over 1500 g with a mouth mask or palm dome. Oral, nasal and oranazopharynx were aspirated for 3-5 seconds with an appropriate aspiration catheter (6-8 Fr) at a pressure not exceeding 100 mmHg.
62234790|NCT06352047|ACTIVE_COMPARATOR|Prone position group|Prone position group Before starting the study, parents of preterm infants were informed about the study, and the infants of parents who agreed to participate in the study were divided into two groups as prone and supine positions. In the study, preterm babies positioned after extubation by the researcher. Before extubation, SpO2, respiratory rate (to be counted for one minute), blood pressure, blood gas values obtained from the heel blood of the Preterm baby were checked on the bedside monitor and recorded before extubation. Before leaving the mechanical ventilator for preterm newborns who were decided for extubation and met the research criteria, vibration and percussion were performed to premature babies over 1500 g with a mouth mask or palm dome. Oral, nasal and oranazopharynx were aspirated for 3-5 seconds with an appropriate aspiration catheter (6-8 Fr) at a pressure not exceeding 100 mmHg.
62234791|NCT02038439|EXPERIMENTAL|Interventions: A + B + C|"See Interventions Description. In this arm, clinicians will be offered all 3 online interventions combined:~* Intervention A - Online Clinical Questions Recorder~* Intervention B - Online Evidence Retrieval Coach~* Intervention C - Online Audit and Feedback"
62234792|NCT02038439|EXPERIMENTAL|Interventions A + B|"See Interventions Description. In this arm, clinicians will be offered the 2 following interventions combined:~* Intervention A - Online Clinical Questions Recorder~* Intervention B - Online Evidence Retrieval Coach"
62234793|NCT02038439|EXPERIMENTAL|Interventions A + C|"See Interventions Description. In this arm, clinicians will be offered the 2 following online interventions combined:~* Intervention A - Online Clinical Questions Recorder~* Intervention C - Online Audit and Feedback"
62234794|NCT02038439|EXPERIMENTAL|Interventions B + C|"See Interventions Description. In this arm, clinicians will be offered the 2 following online interventions combined:~* Intervention B - Online Evidence Retrieval Coach~* Intervention C - Online Audit and Feedback"
62234795|NCT02038439|EXPERIMENTAL|Intervention A alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:~\* Intervention A - Online Clinical Questions Recorder"
62234796|NCT02038439|EXPERIMENTAL|Intervention B alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:~\* Intervention B - Online Evidence Retrieval Coach"
62594099|NCT02861326|OTHER|Patients|Non-surgical periodontal treatment has performed to patients. Scaling and root planing were performed with Gracey curettes until the operator feels that root surface is clean, hard and smooth.
62034679|NCT00687648|ACTIVE_COMPARATOR|Arm II|Patients receive cyclophosphamide, methotrexate, and prednisolone as in arm I.
62594100|NCT00697086|EXPERIMENTAL|1|
62594101|NCT00697086|PLACEBO_COMPARATOR|2|
62810978|NCT04131023|EXPERIMENTAL|Metabolic Tracking|Metabolism (indirect calorimetry) tracking was performed
62234797|NCT02038439|EXPERIMENTAL|Intervention C alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:~\* Intervention C - Online Audit and Feedback"
62810979|NCT04131023|NO_INTERVENTION|Standard Care|Metabolic (indirect calorimetry tracking was not performed
62234798|NCT02038439|NO_INTERVENTION|No intervention|In this arm, clinicians will be offered non of the 3 online interventions, but will just be using the usual features of the search engine available to all users.
62234799|NCT01890304|OTHER|Magnetic Resonance Imaging (MRI)|Athletes at risk for mild traumatic brain injury during the course of competitive play or practice. An MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
62810980|NCT06276062|EXPERIMENTAL|pediatric distal radial fractures.|Pediatric traumatized patients aged between 4 to 16 years old who presented by distal radial fractures and need to go under operative management.
62234800|NCT05015946|EXPERIMENTAL|Small-sided team handball training|60 minutes small-sided team handball training. Initial 20 minutes of warm-up including exercises for strength, aerobic, balance, coordination, and mobility. Hereafter 20 minutes of handball specific exercises including dribbling, running and shooting. Final 20 minutes of small-sided handball matches.
62234801|NCT01702597|EXPERIMENTAL|WBV|Patients will receive supervised physical therapy using a whole body vibration device (Galileo® Med M Plus, Novotec, Pforzheim, Germany) twice a week, 30 minutes per session, for 6 weeks.
62810981|NCT05532644||Patients receiving cholinesterase inhibitors|
62810982|NCT05532644||Patients receiving memantine|
62810983|NCT05532644||Healthy people|
62810984|NCT01007903|NO_INTERVENTION|Usual Care|
62810985|NCT01007903|EXPERIMENTAL|Tai Chi|
62810986|NCT04614727|EXPERIMENTAL|polymeric nano calcium fluoride containing varnish, NANO SEAL.|
62234802|NCT01702597|ACTIVE_COMPARATOR|Physiotherapy|Patient will receive the current gold standard treatment protocol: supervised physical therapy, twice a week, 30 minutes per session, for 6 weeks.
62234803|NCT03686280|EXPERIMENTAL|Robot in combination with traditional reeducation|
62234804|NCT03686280|ACTIVE_COMPARATOR|Standard rehabilitation|
62234805|NCT04124081|EXPERIMENTAL|Drug group|
62810987|NCT04614727|OTHER|Casein Phosphopeptide Amorphous Calcium Phosphate Containing Fluoride Varnish,MI varnish|CPP-ACP with 5%NaF
62810988|NCT03790566|EXPERIMENTAL|Erector spinae plane block|With the patient in lateral decubitus position (surgical side up), the transverse processes of T10-T12 vertebrae and erector spinae (ES) fascia are visualized 1-2 cm lateral to the vertebral spine using a linear ultrasound probe. A 22G peripheral block needle is introduced with in-plane technique under the ES muscle and local anesthetic solution (0.5 ml/kg 0.25% bupivacaine) is injected in this plane after a test injection with 0.5 ml of 0.9% NaCl solution to visualize opening of ESP.
62810989|NCT03790566|ACTIVE_COMPARATOR|Transversus abdominus plane block|With the patient in supine position, three layers of abdominal muscle are visualized using the linear ultrasound probe held with the long axis on the mid-axillary line above the iliac crest. 22G peripheral block needle is introduced in-plane into the fascia between the internal oblique and transversus abdominus muscles and local anesthetic solution (0.5 ml/kg 0.25% bupivacaine) is injected in this plane after a test injection with 0.5 ml of 0.9% NaCl solution to visualize opening of ESP.
62810990|NCT03040141|EXPERIMENTAL|VIS410 low dose|Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
62810991|NCT03040141|EXPERIMENTAL|VIS410 high dose|Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
62810992|NCT03040141|PLACEBO_COMPARATOR|Placebo|Single intravenous infusion of placebo in addition to oseltamivir
62810993|NCT00585481||1|All subjects will perform samples collection for RSV analysis. Subject's enrolled in Porto Alegre's site will perform lung function tests.
62810994|NCT04026321|EXPERIMENTAL|SQ-001 125mL/day|
62810995|NCT04026321|EXPERIMENTAL|SQ-001 250mL/day|
62810996|NCT04026321|EXPERIMENTAL|SQ-001 500mL/day|
62034680|NCT02388724|EXPERIMENTAL|Vonoprazan 20 mg|Vonoprazan 20 mg, tablet, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily for up to 8 weeks.
62034681|NCT02388724|ACTIVE_COMPARATOR|Lansoprazole 30 mg|Lansoprazole 30 mg, capsule, orally, once daily and vonoprazan placebo-matching tablet, orally, once daily for up to 8 weeks.
62034682|NCT06335433|NO_INTERVENTION|No Intervention Control|Participants will be asked to maintain their normal lifestyle patterns (i.e. diet and physical activity) and will undergo no other intervention.
62234806|NCT00656123|EXPERIMENTAL|CY and colon GVAX|
62810997|NCT04026321|EXPERIMENTAL|SQ-001 625mL/day|
62034683|NCT06335433|EXPERIMENTAL|Two Sessions/Week|Participants will complete 6-weeks of supervised isometric handgrip exercise training with a frequency of two sessions/week
62234807|NCT01868113|ACTIVE_COMPARATOR|Inhaled fluticasone propionate|Inhaled corticosteroid
62425764|NCT05467709|EXPERIMENTAL|CTP-543|Subjects will receive a single 2 mg dose of midazolam on Day 1. Starting on Day 3, 12 mg dose of CTP-543 will be administered (q12 hrs) for 14 consecutive days (up to Day 16). On Day 16, subjects will be co-administered a single 2 mg midazolam dose along with the morning dose of CTP-543. The second dose of CTP-543 will be administered as scheduled on Day 16.
62810998|NCT04026321|PLACEBO_COMPARATOR|saline(0.9% NaCl injection)|
62234808|NCT01868113|PLACEBO_COMPARATOR|Inhaler propellant|Placebo
62594102|NCT02644629|ACTIVE_COMPARATOR|Active IV|Will receive IV Ketamine, along with IN placebo.
62594103|NCT02644629|ACTIVE_COMPARATOR|Active IN|Will receive IN Ketamine, along with IV placebo.
62810999|NCT00934453|EXPERIMENTAL|LGG|Lactobacillus rhamnosus GG (LGG) capsules containing 1x10\^10 LGG per capsule will be given to volunteers with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis.
62811000|NCT00934453|PLACEBO_COMPARATOR|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis.
62811001|NCT00060645|EXPERIMENTAL|1|There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
62034684|NCT06335433|EXPERIMENTAL|Four Sessions/Week|Participants will complete 6-weeks of supervised isometric handgrip exercise training with a frequency of four sessions/week
62234809|NCT00100854|ACTIVE_COMPARATOR|Arm I|Patients receive oral erlotinib hydrochloride once daily on days 1-28. Courses repeat every 28 days.
62234810|NCT00100854|EXPERIMENTAL|Arm II|Patients receive erlotinib hydrochloride as in arm I and fulvestrant intramuscularly on days 1, 15, and 29, and then every 28 days thereafter.
62243179|NCT03144804|EXPERIMENTAL|Lamivudine|"* Lamivudine administered orally every 4 weeks~* Treatment cycles will last 28 consecutive days~* The dosage will be determine by the PI"
62594104|NCT05019196||fMRI，functional reorganization, functional connectivity, functional rating scale|low-grade glioma patients healthy controls
62811002|NCT02712346|EXPERIMENTAL|Treatment|Ambrisentan 5 mg PO daily
62811003|NCT02712346|PLACEBO_COMPARATOR|Placebo|One inactive pill PO daily
62811004|NCT02747576||Medulloblastoma Group|Medulloblastoma survivors, 30 between the ages of 12-20 years and 30 between 21-30 years.
62811005|NCT02747576||Control Group|Health comparison group frequency matched on age (30 between the ages of 12-20 years and 30 between 21-30 years), gender and race.
62034685|NCT03603665|EXPERIMENTAL|Arm A|Single intravenous (IV) infusion of 0.033 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
62234811|NCT04660630|EXPERIMENTAL|Precision group|The subjects were tested for gene, and the corresponding therapeutic drugs were selected according to the results of gene detection. Regular follow-up was conducted according to the study design to evaluate the efficacy and adverse reactions.
62234812|NCT04660630|ACTIVE_COMPARATOR|Experience group|The subjects were treated with drugs selected by doctors according to their experience. Follow up was performed at the same frequency as the precision group to evaluate the efficacy and adverse reactions.
62234813|NCT04660630|NO_INTERVENTION|Observation group|The subjects did not accept any intervention, including follow-up, especially regular evaluation of efficacy and adverse reactions.
62234814|NCT02672215|EXPERIMENTAL|tailored group|Received a web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting.
62234815|NCT02672215|ACTIVE_COMPARATOR|generic group|Received a web-based intervention containing generic information and tips to reduce and/or interrupt workplace sitting.
62234816|NCT02672215|NO_INTERVENTION|control group|A waitlist control condition and received the generic intervention after completing all measurements
62234817|NCT03040622||Watchman Left Atrial Appendage Closure|
62234818|NCT01118494||CKD patients|People who have been diagnosed with CKD，and been in the stage of 3 or 4.
62234819|NCT05399121|ACTIVE_COMPARATOR|Group A: Piano Learning then Free Improvisation|This arm (n=15) will first begin the intervention with a Piano Learning exercise followed by a Free Improvisation exercise.
62234820|NCT05399121|ACTIVE_COMPARATOR|Group B: Free Improvisation then Piano Learning|This arm (n=15) will first begin the intervention with a Free Improvisation exercise followed by a Piano Learning exercise.
62243180|NCT06423612|EXPERIMENTAL|POC Urine Test Informed ART Adherence Counselling|Conduct enhanced ART adherence counselling informed by the results of the point-of-care urine assay for TFV to increase viral suppression.
62243181|NCT06423612|NO_INTERVENTION|Standard-of-care Enhanced Adherence Counselling|Follow South Africa's standard-of-care enhanced ART adherence counselling for viral suppression.
62425765|NCT06018246|EXPERIMENTAL|Intervention Group|"1. Before operation：The patients' dietary intake was assessed by a 24-hour dietary review by a professional dietitian.According to the diet of the patients, the intervention was carried out by a professional nutritionist according to the five-step treatment mode of malnutrition.If the food intake cannot meet 60% of the daily requirement, the previous step of treatment is used, and it is adjusted at any time according to the situation of the patient.~2. After operation:Same as control group.~3. Out-of-hospital: Same as before operation.~4. Strengthening Health Education and psychological intervention:Dietitians need to strengthen health education and communicate with patients during the implementation of nutrition intervention.For patients who actively cooperate with treatment, dietitians can give encouragement.~5. Exercise Instruction:After the operation, according to the tolerance, the dietitian can instruct the patient to take a certain time walking every day."
62425766|NCT06018246|OTHER|Control Group|Routine nutrition support in department.Nutritionists will give patients routine parenteral nutrition support via peripheral or central vein 0-48 hours after surgery and then start enteral nutrition support 48-72 hours after surgery.Patients were initially given half of their enteral nutrition and the rest was supplemented with parenteral nutrition.After adaptation, the patient stopped parenteral nutrition and all nutrition came from enteral nutrition.After the patient's gastrointestinal function gradually recovered, the enteral nutrition could gradually decrease.At this time, nutritionists can let the patient eat some light liquid food, but pay attention to eating a small amount of multiple times.After adaptation, patients can gradually transition from liquid diet to semi-liquid diet.We will educate patients and their families about diet and encourage them to eat more high-quality protein-rich foods.
62425767|NCT02899442|NO_INTERVENTION|individual prevention|"The individual preventive advice will be delivered to the control group by occupational physicians during routine medical examinations (defined by law, each 6 months), in occupational medical centres. The type and time spent to explain this advice will be collected in case report form.~To ensure each night workers included in the control group received the same advice, a booklet was provided outlining the content under 5 main headings:~1. Information about health risks for night workers~2. Dietetic intake~3. Leisure physical activities~4. Sleep and alertness~5. Lifestyle behaviors (Tobacco, alcohol and psychoactive drugs consumption)~That's a current practice in France for Occupational physicians."
62425768|NCT02899442|EXPERIMENTAL|individual and collective prevention|In addition to this individual prevention, the night workers from the experimental group will benefit from implementation of preventive actions in the workplace (collective prevention in workplace ). These collective preventive measures will be dispensed by the occupational health team (occupational physicians and technician of occupational risks prevention).
62425769|NCT03849079|EXPERIMENTAL|Hyponut|
62425770|NCT03077594||Successfully ablated patients|Mucosal impedance will be performed at the time of clinically indicated endoscopy. Research biopsies will be obtained during clinically indicated endoscopy.
62425771|NCT03077594||Successfully ablated patients - VLE|Mucosal impedance will be performed at the time of clinically indicated endoscopy. Research biopsies will be obtained during clinically indicated endoscopy. Volumetric laser endomicroscopy (VLE) will be done.
62243182|NCT00179166|ACTIVE_COMPARATOR|1|supplement contains protein content of 1.4 g/kg/day
62243183|NCT00179166|ACTIVE_COMPARATOR|2|supplement contains protein content of 2.0 g/kg/day
62243184|NCT02407470|ACTIVE_COMPARATOR|Rabbit antithymoglobulin （ATG）|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 with the goals of ablating host repressive T cells.
62811006|NCT03382717|EXPERIMENTAL|Excilor Forte|One application of the MD daily (at same time point), preferably after showering/bathing, during the complete study period.
62234821|NCT05964621||Pancreatic cancer patients undergoing pancreatic cancer resection|Perioperative laboratory examinations will follow institutional guidelines. These will include, but will not be limited to full blood count, conventional coagulation tests, liver function, and kidney function tests. Moreover, for the purpose of this study, the following parameters will also be obtained; vWF, factors VIII and XI, D-dimers, fibrinogen, platelets activation (multiplate), adams-13, anti-Xa and high sensitivity troponin. All samples will be obtained via puncture from a peripheral vein. Blood samples will obtained at three time points; preoperatively before induction to GA (01), early postoperatively in PACU (02) and postoperatively before discharge (10 days, 03). Of note, at 30 days our patients will undergo an evaluation for asymptomatic DVT with a US triplex scanner. In addition, any thromboembolic episode (deep vein thrombosis, pulmonary embolism) will also be recorded.
62425772|NCT02686710|ACTIVE_COMPARATOR|VIMA|Patiens receiving volatile induction and maitenance of anesthesia
62594105|NCT06420934|ACTIVE_COMPARATOR|One surgical towel|Participants will be asked to remove all accessories from the forearm, wrist, fingers and to roll up any clothing until at least 5 cm above the humeral condyles are exposed. They will be instructed to perform conventional surgical scrubbing and to dry their hands with a conventional paper towel. The research assistant will open the opaque envelope, which will indicate that the participant needs to dry their hands with one surgical towel.
62811007|NCT03382717|ACTIVE_COMPARATOR|Loceryl 5%|One application per week of the positive control Loceryl 5% during the whole study period.
62811008|NCT00829738||Group 1|All patients enrolled
62811009|NCT02587741|EXPERIMENTAL|oral drugs|oral anti-diabetic drugs only.metformin,start from 500mg bid,if blood glucose dose not reach the standard，added to 500mg tid→1000mg bid.if metformin reach the biggest dosage，added gliclazide modified release tablets，from 30mg qd,if blood glucose dose not reach the standard,add dosage 30mg qd→60 mg qd→90mg qd→120mg qd(max).if still not reach the target，add acarbose 50mg tid
62811010|NCT02587741|EXPERIMENTAL|lantus|basal insulin combine with oral drugs,started with insulin glargine 0.2 u/kg subcutaneous injection at 10pm（at 8am if patients are night workers）,add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs.
62811011|NCT02587741|EXPERIMENTAL|Novomix30|premixed insulin combine with oral drugs,started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs .
62811012|NCT01474525|EXPERIMENTAL|Telemonitoring|
62811013|NCT01474525|ACTIVE_COMPARATOR|Usual Care|
62811014|NCT05093439||Patients presenting at Emergency Department with severe disease|Participants will be patients with (possible) sepsis, myocardial infarction, cerebrovascular accident, polytrauma or Covid 19 pneumonia who were triaged red or orange following the Manchester triage system.
62811015|NCT06199934||Vaccinated|BNT162b2 recipients
62811016|NCT06199934||Unvaccinated|BNT162b2 eligible but did not receive
62811017|NCT03305666|ACTIVE_COMPARATOR|Bupivacaine indwelling catheter|Bupivacaine indwelling OnQ pain pump catheter will be placed in the subscapular space at the time of surgery, at infusion of 12 ml/hr of 0.25% bupivacaine, and left in place for a maximum of 120 hours
62811018|NCT03305666|ACTIVE_COMPARATOR|Liposomal bupivacaine injection|A single injection of liposomal bupivacaine: mixture of 20 mL liposomal bupivacaine, 20 mL 0.25% bupivacaine, and 10 mL sterile saline (50 mL total), will be delivered in the intercostal space during VATS (with a 178 mm, 22 gauge needle, at ribs 3-8).
62811019|NCT00659802|PLACEBO_COMPARATOR|placebo|Matching dose of placebo will be given orally in capsules three times per day for 56 days.
62811020|NCT00659802|EXPERIMENTAL|HMPL-004 low dose|A total of 1200 mg of HMPL-004 per day in three divided doses will be given orally in capsules, 200 mg each, for 56 days.
62234822|NCT05433350|EXPERIMENTAL|Acoziborole|"Single dose administration~Two different formulations will be used depending on the body weight and on the step of the study:~* Tablets of 320 mg dose for paediatric patients weighing 30 to 40 kg in step 1.~* Granules in bottle for paediatric patients weighing 10 to 40 kg in step 2. Granules will be packed in bottles of 160 mg dose.~* Initially, recruitment will be limited to paediatric patients weighing 30 to 40 kg who will receive the 320 mg tablet formulation.~* Once the PK data from the first six patients have been analysed and the dosing regimen confirmed or adapted, inclusion will resume and be extended to allow enrolment of paediatric patients weighing \>10 kg with the granule formulation (including for paediatric patients weighing 30 to 40 kg)."
62234823|NCT01405937|EXPERIMENTAL|Vaniprevir 12 Week Arm|Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV
62234824|NCT01405937|EXPERIMENTAL|Vaniprevir 24 Week Arm|Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV
62811021|NCT00659802|EXPERIMENTAL|HMPL-004 high dose|A total of 1800 mg of HMPL-004 per day in three divided doses will be given orally in capsules, 200 mg each, for 56 days.
62811022|NCT02385929|EXPERIMENTAL|Swallowing therapy & resistance training|"Mouth opening and swallowing exercise intervention by occupational therapist for half an hour 3 times a week for 5-6 weeks during radiotherapy.~Progressive resistance training by physiotherapist for 1 hour twice weekly for 5-6 weeks during radiotherapy."
62234825|NCT01789125|ACTIVE_COMPARATOR|Smoking Termination and Anxiety Reduction Treatment|Cognitive-behavioral treatment program that blends smoking cessation and anxiety reduction treatment strategies
62234826|NCT01789125|ACTIVE_COMPARATOR|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
62425773|NCT02686710|ACTIVE_COMPARATOR|TIVA|Patiens receiving total intravenous anesthesia based on propofol
62811023|NCT02385929|NO_INTERVENTION|Standard Care|Patients in this arm are randomized to usual care / control group
62811024|NCT05604846|EXPERIMENTAL|Probiotic group|Probiotic group: 0,5 g per day of ProPrems®, including a combination of Bifidobacterium infantis Bb-02 (DSM 33361) 300 million, Bifidobacterium lactis (BB-12®) 350 million and Streptococcus thermophilus (TH-4®) 350 million. Mixed with 3 mills of breastmilk
62811025|NCT05604846|PLACEBO_COMPARATOR|Control group|Control group receives 3 mills of breastmilk without additives
62811026|NCT03870919|OTHER|Palbociclib + locoregional treatment|All patients will receive the standard of care treatment ie Palbociclib + letrozole for 24-26 weeks (a delay of +/- 2 weeks to initiate the locoregional treatment is authorized after the day 1 of cycle 1 of palbociclib plus letrozole). After this period, patient will have the most adapted locoregional treatment ie surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy. The palbociclib will be continued until progression
62811027|NCT01913561|EXPERIMENTAL|Master Caution Garment|"each patient will be connected simultaneously with two devices:~* ECG gel electrodes~* Master Caution Garment textile electrodes The two devices will be connected to hospital ECG telemetry."
62811028|NCT01975792||Preterm Admits|Women who are admitted for preterm labor observation and management
62811029|NCT06521710|EXPERIMENTAL|NR-RALP|Nerve Grafting Technique in patients with High Grade Prostate Cancer Undergoing Robotic Assisted Radical Prostatectomy
62034686|NCT03603665|EXPERIMENTAL|Arm B|Single IV infusion of 0.165 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
62034687|NCT03603665|EXPERIMENTAL|Arm C|Single IV infusion of 0.330 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
62811030|NCT05587816|EXPERIMENTAL|Experimental|"* Training and use of the PortionSize app by children and parents or caregivers~* Using the PortionSize app at the clinic of Pennington Biomedical Research Center and at home (free-living condition)~* Rating the satisfaction of using the PortionSize app"
62811031|NCT00866424|EXPERIMENTAL|A,2, II|
62811032|NCT01285401|EXPERIMENTAL|VigantOL® oil|VigantOL oil plus Rebif in subjects with 25-hydroxy-vitamin D plasma levels below 150 nmol/L
62811033|NCT01285401|PLACEBO_COMPARATOR|Placebo|Placebo daily plus Rebif in subjects with 25-hydroxy-vitamin D plasma levels below 150 nmol/L
62811034|NCT01285401|EXPERIMENTAL|Rebif|Rebif alone in subjects with 25-hydroxy-vitamin D plasma levels equal or higher than 150 nmol/L
62811035|NCT00989001|EXPERIMENTAL|Vernakalant|Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
62811036|NCT00989001|PLACEBO_COMPARATOR|Placebo|Placebo (saline) administered IV at same volume and rate as per dosing schedule for vernakalant
62811037|NCT04924335|ACTIVE_COMPARATOR|ESP group|ESP group patients will be performed ultrasound-guided erector spinae plane block with 20 ml 0.025% Bupivacaine, preoperatively and will receive ERAS cardiac anesthesia protocol
62811038|NCT04924335|NO_INTERVENTION|Conventional group|The conventional group will receive ERAS cardiac anesthesia protocol
62811039|NCT00997035|ACTIVE_COMPARATOR|Oral Voriconazole|
62811040|NCT00997035|PLACEBO_COMPARATOR|Placebo|
62594106|NCT06420934|EXPERIMENTAL|Two surgical towel|Participants will be asked to remove all accessories from the forearm, wrist, fingers and to roll up any clothing until at least 5 cm above the humeral condyles are exposed. They will be instructed to perform conventional surgical scrubbing and to dry their hands with a conventional paper towel. The research assistant will open the opaque envelope, which will indicate that the participant needs to dry their hands with two surgical towels, one for each hand.
62811041|NCT04397510|EXPERIMENTAL|Nebulized Heparin|Heparin 5,000 units/mL Dose: 25,000 units Frequency: every 6 hours Duration: 10 days
62811042|NCT04397510|PLACEBO_COMPARATOR|Placebo|0.9% Sodium Chloride Dose: 5 mL Frequency: every 6 hours Duration: 10 days
62811043|NCT01295385|EXPERIMENTAL|healthy volunteers|
62811044|NCT01295385|ACTIVE_COMPARATOR|patients with a diabetic cardiomyopathy|
62811045|NCT03215238||neurosurgical patients|Neurosurgical patients undergoing craniotomies for tumor. 25 subjects
62811046|NCT03215238||Neurointerventional patients|Patients undergoing neurointerventional procedures under general anesthesia. 25 subjects
62811047|NCT03142386|EXPERIMENTAL|OMT group|Osteopathic manipulative treatment
62811048|NCT03142386|ACTIVE_COMPARATOR|Control Group|Physiotherapy
62811049|NCT01766609|ACTIVE_COMPARATOR|A: Triamcinolone acetonide|Injections will be given within one half of a single vitiligo patch. The concentration of triamcinolone acetonide (TA) that will be used initially is 2.5 mg/ml. Dilution will be done using a bacteriostatic normal saline. Each half will receive injections with either TA 2.5 mg/ml or normal saline as a control. Only one investigator will know the intervention each half has received. If the patient did not show any evidence of repigmentation during the 3rd visit (i.e. after two injection sessions with TA 2.5 mg/ml) , the concentration of TA will be increased to 5 mg/ml. A total of 4 injections will be given over 4 visits. The treatment will be repeated every 3 to 5 weeks for a total of 4 treatment sessions.
62811050|NCT01766609|PLACEBO_COMPARATOR|B: Normal saline|Bacteriostatic normal saline will injected into one half of the vitiligo patch.
62811051|NCT05868486|EXPERIMENTAL|Whole Body MRI and Liquid Biopsy|Patients undergo WBM without contrast and blood sample collection for liquid biopsy
62811052|NCT03961334|EXPERIMENTAL|DOACs|Direct oral anticoagulants
62811053|NCT03961334|ACTIVE_COMPARATOR|Antiplatelets|SOC therapy with antiplatelets until study completion or until detection of AF. After detection of AF treatment with DOAC becomes SOC.
62811054|NCT05524467||Haemodialysis Patients|Only one data collection timepoint per patient is planned. Eligible and consenting patients will be asked to complete several PROs and one questionnaire, and their respective medical charts will be assessed retrospectively
62811055|NCT05632523||adult patients with renal transplant|Conversion from anticalcineurin to belatacept
62811056|NCT05529108|PLACEBO_COMPARATOR|Control biscuits group|Subjects are required to consume 90 g control biscuits as their breakfast everyday during 12-week intervention period.
62811057|NCT05529108|EXPERIMENTAL|autoclaved BSG-containing group|Subjects are required to consume 90 g autoclaved BSG-containing biscuits as their breakfast everyday during 12-week intervention period.
62811058|NCT05529108|EXPERIMENTAL|bio-transformed BSG-containing group|Subjects are required to consume 90 g fermented BSG-containing biscuits as their breakfast everyday during 12-week intervention period.
62811059|NCT04146168||VenaSeal|Complete closure of previously treated veins will be assessed via ultrasound
62425774|NCT02686710|ACTIVE_COMPARATOR|Combi|Patiens receiving total intravenous induction and volatile anesthesia
62425775|NCT04568642|ACTIVE_COMPARATOR|Conventional|Device: conventional FiO2 will be selected by the clinician according to the SpO2 target
62425776|NCT04568642|EXPERIMENTAL|Closed-loop|Device: conventional FiO2 will be selected by the closed-loop algorithm according to the SpO2 target
62425777|NCT00888030||2|CKD patients with normal p-cresol
62425778|NCT00888030||3|CKD patient with normal indoxyl sulfate
62425779|NCT00888030||4|CKD patients with high indoxyl sulfate
62425780|NCT00888030||1|CKD patients with high p cresol
62425781|NCT02898064|OTHER|Standard care + brace|Spinal brace (thoracolumbosacral orthosis or cervico-thoraco-lumbar orthosis) to be fitted to the participant in addition to receiving standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
62425782|NCT02898064|OTHER|Standard care|Participant will receive standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
62811060|NCT02973100|EXPERIMENTAL|Dulaglutide 4.5mg|4.5mg of Dulaglutide administered subcutaneously (SC)
62811061|NCT02973100|EXPERIMENTAL|Dulaglutide 3.0mg|3.0mg of Dulaglutide administered SC
62811062|NCT02973100|ACTIVE_COMPARATOR|Dulaglutide 1.5mg|1.5mg of Dulaglutide administered SC
62811063|NCT02973100|PLACEBO_COMPARATOR|Placebo|Placebo administered SC
62811064|NCT00984477|EXPERIMENTAL|1|AZD5122 oral suspension (part A and B)
62811065|NCT00984477|PLACEBO_COMPARATOR|2|Placebo oral suspension (part A)
62811066|NCT00984477|EXPERIMENTAL|3|AZD5122 oral and IV infusion (part B)
62811067|NCT03607214|EXPERIMENTAL|Positive Expectations Group|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from experiencing negative emotions and generally improves their mood. They take the nasal spay in the laboratory and on seven consecutive days. Participants watch two film sequences that are supposed to induce sadness.
62811068|NCT03607214|NO_INTERVENTION|No-treatment control group|Participants do not receive the nasal spray. Participants watch two film sequences that are supposed to induce sadness.
62811069|NCT02282852|EXPERIMENTAL|Wireless Capsule Endoscopy|Wireless capsule endoscopy is the investigation modality of choice for suspected diseases of the small bowel. A small pill-sized capsule contianing a camera is swallowed by the patient. The procedure is safe and non-invasive. Normally, the pill camera travels through the gut an exits the bowel via natural means. In a small number of cases the capsule is maintained. If the capsule is still in the stomach, mobilisation is encouraged followed by an intramuscular pro-kinetic injection if this fails.
62811070|NCT02282852|ACTIVE_COMPARATOR|Magnetically steerable capsule endoscopy|A handheld magnet (manufactured by Intromedic Ltd.) has been developed to allow some control of the pill camera (that contains a small amount of magnetic material) in the upper GI tract. We propose that this could be used, alongside positional changes, to expedite capsule transit through the stomach thus improving completion rates and avoiding the risks of unnecessary medication.
62425783|NCT02476851|OTHER|POLFA (Experimental Needle Assembly) first, then Kawasumi (Control Needle Assembly)|"Ensure that whole blood passed through the POLFA needle assembly (the investigational needle assembly or INA) has a supernatant hemoglobin within the acceptable range of \< 100mg/dL. Each subject receives the same intervention (Standard of Care blood draw) and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied."
62425784|NCT02476851|OTHER|Kawasumi (Control Needle Assembly) first, then POLFA (Experimental Needle Assembly)|"Ensure that whole blood passed through the POLFA needle assembly (the investigational needle assembly or INA) has a supernatant hemoglobin within the acceptable range of \< 100mg/dL. Each subject receives the same intervention (Standard of Care blood draw) and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied."
62425785|NCT04234373|EXPERIMENTAL|Low Carb dietary Intervention|
62811071|NCT05842317|EXPERIMENTAL|Levatinib plus Tislelizumab|Native-treated aHCC Patients were administered with Levatinib plus Tislelizumab
62811072|NCT05842317|EXPERIMENTAL|Levatinib plus Lenvatinib with Transarterial Chemoembolization(TACE)|Native-treated aHCC Patients were administered with Levatinib plus Tislelizumab with Transarterial Chemoembolization(TACE)
62425786|NCT02234258|EXPERIMENTAL|Cognitive behavioral social skills|In Cognitive behavioral social skills training (CBSST), skills-based CBT is used to teach individuals how to correct inaccurate dysfunctional thoughts that interfere with goal-directed activities, including defeatist expectancies, low self-efficacy beliefs, and anomalous beliefs. SST focuses on behaviorally-based instruction of interpersonal social skills, utilizing role-modeling, rehearsal, corrective feedback, and positive reinforcement to facilitate learning. In the modified version of CBSST used in this project: 1) we will strengthen the focus on corrective feedback from successful social interactions; 2) focus on normalization and destigmatization of attenuated psychotic symptoms; 3) add motivational interviewing techniques to promote treatment engagement; and 4) use examples and role plays. CBSST will be delivered in three 6-session modules (i.e., Cognitive Skills, Social Skills, and Problem Solving Skills), a total of 18 90-minute group sessions.
62594107|NCT06433622||Repeat TEG-PM|Will receive a repeat TEG-PM after platelet transfusion based on inclusion criteria.
62594108|NCT06433622||No Repeat TEG-PM|Not eligible to be consented; will proceed with normal course of treatment.
62811073|NCT02847962|NO_INTERVENTION|Control (No FBF)|FBF provided after the intervention period
62425787|NCT02234258|ACTIVE_COMPARATOR|Psychoeducation|The purpose of this alternative treatment is to match CBSST for the nonspecific effects of therapist contact and interest, social interaction and support. Common factors include client expectancy, providing a rationale for change, therapist factors and therapeutic alliance. The psychoeducation group will meet weekly, for a total of 18 90-minute sessions. Therapists will follow brief guidelines as to what they can and cannot do. In each session the therapists will ask how the previous week had been. Any crises will be dealt with, and advice will be offered to help with any immediate problems. No active CBT or SST techniques will be taught or used. Psychoeducational information about high risk for psychosis will be offered. There will be a focus on listening, reflecting and empathizing, and demonstrating uncritical acceptance and genuineness. Social exchanges amongst participants will be encouraged.
62425788|NCT03224117|PLACEBO_COMPARATOR|Placebo|SQ injection
62425789|NCT03224117|EXPERIMENTAL|DWJ211_0.5%|SQ injection with DWJ211 0.5%
62425790|NCT03224117|EXPERIMENTAL|DWJ211_1%|SQ injection with DWJ211 1.0%
62425791|NCT03224117|EXPERIMENTAL|DWJ211_2%|SQ injection with DWJ211 2.0%
62425792|NCT04974645|EXPERIMENTAL|W-SUDs|Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.
62425793|NCT04974645|OTHER|Digitally-delivered Psychoeducation|"Psychoeducation digitally delivers weekly fact sheets that include information on:~1. Alcohol-specific topics;~2. Drug-specific topics;~3. General addiction topics;~4. Statistics relating to alcohol and substance use."
62594109|NCT01063270|ACTIVE_COMPARATOR|Oral Antibiotics|
62594110|NCT01063270|ACTIVE_COMPARATOR|Topical Antibiotics and Laser treatment|
62594111|NCT06624176|EXPERIMENTAL|ShotBlocker Administration|The treatment group will employ the medical device of interest, ShotBlocker, bundled with the standard-of-care comfort measures of swaddling and sucrose during the administration of the Hepatitis B Immunization. A Masimo Rad-97 Oximeter probe will be applied to record a baseline and intervention physiologic response. There will be an Opt-In Video Recording option to assign a pain score (PIPP Scale) during the procedure by a blinded medical professional.
62594112|NCT06624176|ACTIVE_COMPARATOR|Standard of Care Comfort Tools|The control group will employ the standard-of-care comfort measures of swaddling and sucrose during the administration of the Hepatitis B Immunization. A Masimo Rad-97 Oximeter probe will be applied to record a baseline and intervention physiologic response. There will be an Opt-In Video Recording option to assign a pain score (PIPP Scale) during the procedure by a blinded medical professional.
62811074|NCT02847962|ACTIVE_COMPARATOR|Corn Soy Blend Plus (CSB+)|Consumed Corn Soy Blend Plus (CSB+)
62811075|NCT02847962|EXPERIMENTAL|Corn Soy Blend 14 (CSB14)|Consumed Corn Soy Blend 14 (CSB14)
62811076|NCT02847962|EXPERIMENTAL|White Sorghum Cowpea Blend Variety 1|Consumed White Sorghum Cowpea Blend Variety 1
62234827|NCT01875172|EXPERIMENTAL|Bupropion SR|Study medication (150 mg bupropion SR) daily for 14 days. Women still smoking at 2-weeks \& 4-weeks were encouraged to increase their medication to two times per day (150 mg bid). Women received smoking cessation counseling at baseline, 2, 4, 6, and 8 weeks.
62234828|NCT01875172|PLACEBO_COMPARATOR|Placebo|Study medication (placebo) daily for 14 days. Women still smoking at 2-weeks \& 4-weeks were encouraged to increase their medication to two times per day. Women received smoking cessation counseling at baseline, 2, 4, 6, and 8 weeks.
62234829|NCT04050462|ACTIVE_COMPARATOR|Nivolumab Monotherapy|
62811077|NCT02847962|EXPERIMENTAL|White Sorghum Cowpea Blend Variety 2|Consumed White Sorghum Cowpea Blend Variety 2
62811078|NCT02847962|EXPERIMENTAL|Red Sorghum Cowpea Blend|Consumed Red Sorghum Cowpea Blend
62234830|NCT04050462|EXPERIMENTAL|Nivolumab/BMS-986253 combination|
62234831|NCT04050462|EXPERIMENTAL|Nivolumab/Cabiralizumab combination|
62234832|NCT01272947|EXPERIMENTAL|Diclofenac sodium topical gel 1%|
62234833|NCT01272947|PLACEBO_COMPARATOR|placebo|
62234834|NCT00359190|EXPERIMENTAL|Lapatinib receivers|Subjects with treatment-naïve breast tumors will be administered lapatinib 1500 mg once daily, 1000 mg once daily, or 500 mg twice daily for a minimum of 9 days and maximum of 15 days prior to surgical resection..
62234835|NCT00009620|EXPERIMENTAL|Phenobarbital|
62234836|NCT00009620|PLACEBO_COMPARATOR|Placebo|
62234837|NCT03543696|EXPERIMENTAL|Single Dose Radiotherapy (SDRT)|Single Dose Radiotherapy (SDRT) at a prescription dose of 24 Gy to all detectable metastatic lesions
62234838|NCT01840605|EXPERIMENTAL|TAU-284|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day, once after breakfast and once before bed.
62425794|NCT02670512|EXPERIMENTAL|Telehome Monitoring|Patients in this arm will use the telehome monitoring device (a mobile tablet) to support them with their peritoneal dialysis (communication, treatment tracking, supply tracking, appointment reminders, educational content).
62425795|NCT02670512|NO_INTERVENTION|Standard of Care|Patients in this arm use the standard of care for peritoneal dialysis, which is simple telephone communication and using pen and paper log to track their treatments and supplies.
62425796|NCT04824144|EXPERIMENTAL|Dexmedetomidine subcutaneous continuous infusion|Participants will be given a starting low dose of 0.4 mcg/kg/hr, to be titrated up to a medium dose of 0.7 mcg/kg/hr and potentially up to a maximum dose of 1.0 mcg/kg/hr by subcutaneous infusion until the target RASS-PAL level has been achieved.
62425797|NCT04552080|ACTIVE_COMPARATOR|Test: Amoxicillin|
62425798|NCT04552080|PLACEBO_COMPARATOR|Comparator: Placebo|
62425799|NCT05021328|EXPERIMENTAL|Anlotinib combined with SBRT|"Induction therapy (D1-D21): SBRT 7Gy✖️5 QD, D1-D5 + Toripalimab 240mg iv drip D1 + Anlotinib 12mg, QD, PO, D1-D14；~Maintenance (D22\~1year): Toripalimab 240mg iv drip D1 Q3W + Anlotinib 12mg, QD, PO, D1-D14, Q3W, until progression (up to approximately 1 year)"
62594113|NCT03572530|EXPERIMENTAL|group 1|5-Azacytidine (5-AZA) group 1: Enrolled patients will undergo surgical placement of a ventricular catheter into the fourth ventricle that will be attached to a subcutaneously placed reservoir. Patients will be divided into 3 dose groups and receive 8 weeks of intraventricular 5-AZA (12 mg) into the fourth ventricle. Patients in Group 1 will receive two 5-AZA infusions every week.
62234839|NCT01840605|ACTIVE_COMPARATOR|ketotifen fumarate|Two TAU-284 5mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day, once after breakfast and once before bed.
62234840|NCT00696982|EXPERIMENTAL|A|diabetic patients who are treated with metformin wiyh HBA1C\>7% will get sitagliptin
62425800|NCT05021328|EXPERIMENTAL|Anlotinib combined with SBRT and Toripalimab|"Induction therapy (D1-D21): SBRT 7Gy✖️5 QD, D1-D5 + Anlotinib 12mg, QD, PO, D1-D14；~Maintenance (D22\~1year): Toripalimab 240mg iv drip D1 Q3W + Anlotinib 12mg, QD, PO, D1-D14, Q3W, until progression (up to approximately 1 year)"
62425801|NCT05285917|ACTIVE_COMPARATOR|Weight Based Starting Dose|25 mg/kg starting dose Hydroxyurea
62425802|NCT05285917|EXPERIMENTAL|PK-guided starting dose|Individualized, PK-guided starting dose Hydroxyurea
62425803|NCT01101581|EXPERIMENTAL|Veltuzumab and 90Y-Epratuzumab Tetraxetan|Veltuzumab and 90Y-Epratuzumab Tetraxetan target different b-cells. Veltuzumab will be administered in all 4 weekly study drug treatments. 90Y-Epratuzumab Tetraxetan will be administered only on days 8 \& 15. The dose of veltuzumab remains the same for all patients.
62425804|NCT01101581|EXPERIMENTAL|90Y-epratuzumab tetraxetan|90Y-epratuzumab tetraxetan will be administered 6 mCi/m2 on days 8 and 15.
62811079|NCT02847962|EXPERIMENTAL|White Sorghum Soy Blend|Consumed White Sorghum Soy Blend
62811080|NCT06187896|EXPERIMENTAL|Remimazolam|In this group, participants are sedated with remimazolam and remifentanil.
62811081|NCT06187896|ACTIVE_COMPARATOR|propofol|In this group, participants are sedated with propofol and remifentanil.
62819585|NCT06018337|ACTIVE_COMPARATOR|investigator's choice single agent chemotherapy|Enrolled Subjects will be randomized to receive investigator's choice single agent chemotherapy (capecitabine:1000 or 1250 mg/m2, Oral, Twice daily orally for 2 weeks followed by a 1-week rest period in 3-week cycles; paclitaxel：80 mg/m2， IV, Every week (QW) in 3-week cycles; or nab-paclitaxel: 100 mg/m2, IV, Every week (QW) for 3 weeks followed by a one-week rest period in 4-week cycles) until RECIST 1.1 defined disease progression (PD), unless there is unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.
62234841|NCT00696982|EXPERIMENTAL|B|diabetic patients who are treated with metformin with HBA1C\>7% will get glibenclamide
62234842|NCT02993484|EXPERIMENTAL|non-diabetic Sham control|Heart tissue obtained from non-diabetic patients undergoing surgery will not receive drugs or ischemia
62234843|NCT02993484|EXPERIMENTAL|non-diabetic Ischemia reperfusion|Heart tissue from non-diabetic patients undergoing surgery will not receive drugs but will receive ischemia
62234844|NCT02993484|EXPERIMENTAL|non-diabetic Ischemic preconditioning|Heart tissue from non-diabetic patients undergoing surgery will not receive drugs but will receive short periods of ischemia prior to index ischemia
62594114|NCT03572530|EXPERIMENTAL|group 2|5-Azacytidine (5-AZA) group 2: Enrolled patients will undergo surgical placement of a ventricular catheter into the fourth ventricle that will be attached to a subcutaneously placed reservoir. Patients will be divided into 3 dose groups and receive 8 weeks of intraventricular 5-AZA (12 mg) into the fourth ventricle. Patients in Group 2 will receive three 5-AZA infusions every week.
62811082|NCT02517931|ACTIVE_COMPARATOR|Sphenopalatine Ganglion Block|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. Sphenopalatine ganglion block will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
62234845|NCT02993484|EXPERIMENTAL|non-diabetic Dimethyl malonate|Heart tissue from non-diabetic patients undergoing surgery will receive a drug (Dimethyl Malonate) prior to index ischemia
62594115|NCT03572530|EXPERIMENTAL|group 3|5-Azacytidine (5-AZA) group 3: Enrolled patients will undergo surgical placement of a ventricular catheter into the fourth ventricle that will be attached to a subcutaneously placed reservoir. Patients will be divided into 3 dose groups and receive 8 weeks of intraventricular 5-AZA (12 mg) into the fourth ventricle. Patients in Group 3 will receive four 5-AZA infusions every week.
62594116|NCT05554536|OTHER|Single arm intervention|All patients will undergo a PEEP titration trial in each surgery step (before pneumoperitoneum, during pneumoperitoneum, after pneumoperitoneum). The PEEP titration trial will be done in steps of 2 cmH2O, starting from clinical PEEP 16 cmH2O and ending to PEEP 6 cmH2O. Each PEEP level will be kept for 2 minutes. The PEEP titration trial will be stopped in case of haemodynamic instability or severe desaturation (Spo2 \< 92%). Each PEEP titration trial will be recorded using Electrical impedance tomography (EIT).
62594117|NCT04623879||F508del homozygous adult CF patients|F508del homozygous adult CF patients who commenced treatment with LUM-IVA
62811083|NCT02517931|PLACEBO_COMPARATOR|Placebo|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
62234846|NCT02993484|EXPERIMENTAL|Diabetic Sham control|Heart tissue obtained from diabetic patients undergoing surgery will not receive drugs or ischemia
62811084|NCT05409989|OTHER|Flow Re-Direction Endoluminal Device X|FRED™ X™ device
62234847|NCT02993484|EXPERIMENTAL|Diabetic Ischemia reperfusion|Heart tissue from diabetic patients undergoing surgery will not receive drugs but will receive ischemia
62425805|NCT05854316|EXPERIMENTAL|Frail elders|Frail elders; Age: 65-80 years; Body Mass Index: 18.5-30 kg/m²; Frailty diagnosed according to Fried's criteria (i.e., at least three of the following items: unintended loss of weight, weakness, self-reported exhaustion, slow walking speed, low level of physical activity).
62425806|NCT02287506|EXPERIMENTAL|ODS from enrolment|Optimised Diagnostic Strategy used from enrolment to study
62425807|NCT02287506|NO_INTERVENTION|ODS at end of study|ODS fed back at the end of the participants involvement with the study
62425808|NCT02044965|NO_INTERVENTION|Antibiotic|This group will be prescribed a dose of antibiotics (Septra 2mg/kg)
62425809|NCT02044965|PLACEBO_COMPARATOR|Probiotic plus placebo|Receive probiotic plus an antibiotic placebo
62425810|NCT02044965|ACTIVE_COMPARATOR|probiotics plus antibiotic|This group will be on a dose of probiotics (2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule) plus a antibiotic (Septra)
62425811|NCT00829439|EXPERIMENTAL|Levodopa/Carbidopa|"Other Names:~Sinemet L-dopa~Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
62425812|NCT02862535|EXPERIMENTAL|Cohort 1: ADX|Participants will receive andecaliximab (ADX) 800 mg every 2 weeks on Days 1 and 15 of each 28-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
62425813|NCT02862535|EXPERIMENTAL|Cohort 2: ADX + S-1 + Cisplatin|Participants will receive ADX 800 mg every 2 weeks on Days 1 and 15 of each 28-day treatment cycle in combination with S-1 orally twice daily plus cisplatin chemotherapy (dosage and regimen will be based on participant condition, investigator discretion, institutional practice, and/or the in-country label) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
62425814|NCT02862535|EXPERIMENTAL|Cohort 3: ADX + S-1 + Oxaliplatin|Participants will receive ADX 1200 mg every 3 weeks on Day 1 of each 21-day treatment cycle in combination with chemotherapy (S-1 80 mg/day to 120 mg/day according to the body surface area orally twice daily for first 14 days of 21 day cycle plus oxaliplatin 100 mg/m\^2) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study.
62425815|NCT02862535|EXPERIMENTAL|Cohort 4: ADX + Nivolumab|Participants will receive ADX 800 mg every 2 weeks followed by chemotherapy (nivolumab 3 mg/kg) on Days 1 and 15 of each 28-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
62234848|NCT02993484|EXPERIMENTAL|Diabetic Ischemic preconditioning|Heart tissue from diabetic patients undergoing surgery will not receive drugs but will receive short periods of ischemia prior to index ischemia
62234849|NCT02993484|EXPERIMENTAL|Diabetic Dimethyl malonate|Heart tissue from diabetic patients undergoing surgery will receive a drug (Dimethyl Malonate) prior to index ischemia
62594118|NCT04541108|EXPERIMENTAL|Rilvegostomig, Volrustomig, Sabestomig, Pembrolizumab|HNSCC patients presenting with a surface accessible lesion who are scheduled for tumor and/or regional node dissection as part of their standard treatment will be injected one to three days prior to surgery using the CIVO device. The planned injection scheme includes: vehicle control and microdoses of rilvegostomig, volrustomig, sabestomig, and pembrolizumab alone.
62811085|NCT01488604|EXPERIMENTAL|PNS|2 sprays of experimental nasal spray per nostril 4 times per day for 7 days
62234850|NCT02088749|EXPERIMENTAL|small group treatment|lifestyle intervention for obesity delivered to small groups of approximately 12 participants/group
62425816|NCT03791619|ACTIVE_COMPARATOR|Higher Cylinder Toric IOL|Consented subjects that are eligible will have both eyes implanted with a TECNIS Symfony IOL. Each eye may have a different TECNIS Symfony IOL implanted, as determined by the surgeon and the TECNIS Symfony Toric IOL calculator; however, at least one eye must be implanted with either a Symfony Toric IOL Model ZXT150 (lower-cylinder group) or a Model ZXT300 or ZXT375 (higher-cylinder group) and the fellow eye must have the same or a lower toric power. The eye with the highest toric power IOL will determine the model group.
62425817|NCT03791619|ACTIVE_COMPARATOR|Lower Cylinder Toric IOL|Consented subjects that are eligible will have both eyes implanted with a TECNIS Symfony IOL. Each eye may have a different TECNIS Symfony IOL implanted, as determined by the surgeon and the TECNIS Symfony Toric IOL calculator; however, at least one eye must be implanted with either a Symfony Toric IOL Model ZXT150 (lower-cylinder group) or a Model ZXT300 or ZXT375 (higher-cylinder group) and the fellow eye must have the same or a lower toric power. The eye with the highest toric power IOL will determine the model group.
62594119|NCT00587184||1|patients who were seen clinically indicated endoscopic surveillance and biopsies of BE and confocal microscopy was performed.
62594120|NCT06200311|EXPERIMENTAL|AF ablation|These patients will undergo Pulmonary vein isolation (PVI) (only)
62811086|NCT01488604|SHAM_COMPARATOR|SNS|2 sprays of sham nasal spray per nostril 4 times per day for 7 days
62594121|NCT06200311|ACTIVE_COMPARATOR|Pharmacological rhythm management|These patients will take rate control medication. If this therapy fails, pharmacological rhythm control and AF ablation are 2nd and 3rd line options respectively within this arm,
62594122|NCT04463056|EXPERIMENTAL|Elizaria®|International nonproprietary name: eculizumab
62811087|NCT04439136|EXPERIMENTAL|Treatment (afatinib dimaleate)|Patients receive afatinib dimaleate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62811088|NCT03667482|EXPERIMENTAL|Cabozantinib in Combination With Cetuximab|Cetuximab will be administered at 500 mg/m\^2 intravenously every other week. Cabozantinib will be initiated at 40 mg PO daily, with subsequent 20 mg or 40 mg doses as tolerated per the study design.
62811089|NCT01419769|EXPERIMENTAL|AXIOS Stent and Delivery System|
62811090|NCT03196908|EXPERIMENTAL|Energy Drink Brand 1|Two 16-oz bottles of Energy Drink Brand 1
62811091|NCT03196908|EXPERIMENTAL|Energy Drink Brand 2|Two 16-oz bottles of Energy Drink Brand 2
62811092|NCT03196908|PLACEBO_COMPARATOR|Placebo|Two 16-oz bottles that each contain 390 ml of carbonated water, 20 ml of reconstituted lime juice, and 70 ml of cherry flavoring
62811093|NCT02463916|ACTIVE_COMPARATOR|Immediate exercise|This group will immediately commence an 8 week exercise programme.
62811094|NCT02463916|ACTIVE_COMPARATOR|Delayed exercise|This group will continue regular activities for 8 weeks and then commence 8 week exercise programme.
62811095|NCT01640002|ACTIVE_COMPARATOR|Propantheline|
62811096|NCT01640002|PLACEBO_COMPARATOR|Placebo|
62811097|NCT06523985|ACTIVE_COMPARATOR|Standard layperson messaging (Arm 1)|Users randomized to arm 1 will receive standard monthly recruitment push messages. These push messages will differ from the certification messages because they will contain language intended to foster engagement with OEND services (eg, to get trained and carry naloxone) alongside the link to a landing page.
62234851|NCT02088749|ACTIVE_COMPARATOR|large group treatment|lifestyle intervention for obesity delivered to a large group of approximately 30 participants
62234852|NCT04448509|OTHER|Healthy donor|Healthy donor
62234853|NCT01016964|SHAM_COMPARATOR|Sham Device|Sham device
62234854|NCT01016964|ACTIVE_COMPARATOR|LLT Device 2009 12 Beams|HairMax LaserComb 2009 model 12 beam
62234855|NCT06419751|NO_INTERVENTION|Control|Study participants were given training on dietary patterns, regular monitoring and follow-up through apps and wearable devices, and no forced exercise measures were performed.
62034688|NCT06579378|EXPERIMENTAL|VSail 3D|"The VSail 3D experimental protocol includes 12 sessions (2 times a week, for 6 consecutive weeks) with scenarios (virtual environments) dedicated to the sport of sailing.~The duration of each session is 50-60 minutes."
62034689|NCT06579378|ACTIVE_COMPARATOR|WEB-Health|The intervention regards education on healthy lifestyles to promote active ageing (topics: physical activity in old age; effective communication, stress management, technologies and health). It will consist of 3 seminars, delivered in the form of webinars, on a bi-weekly basis over 6 consecutive weeks, lasting 50-60 minutes each.
62034690|NCT00270218|EXPERIMENTAL|1|Arm 1 participants will be given an injection of VRC-HIVADV014-00-VP vaccine on Days 0 and 168.
62034691|NCT00270218|PLACEBO_COMPARATOR|2|Arm 2 participants will be given an injection of final formulation buffer (FFB) on Days 0 and 168.
62034692|NCT00270218|EXPERIMENTAL|3|Arm 3 participants will be given an injection of VRC-HIVDNA009-00-VP vaccine on Days 0 and 28. Participants will also be given an injection of VRC-HIVADV014-00-VP on Day 168.
62234856|NCT06419751|ACTIVE_COMPARATOR|Combined Exercise Group|Study participants were given training on dietary patterns, regular monitoring and follow-up through apps and wearable devices.Based on the status of the study participants and the results of the cardiopulmonary exercise test, the investigators prescribe moderate-intensity aerobic exercise combined with resistance exercise
62234857|NCT06419751|EXPERIMENTAL|Mind-body Exercise Group|Study participants were given training on dietary patterns, regular monitoring and follow-up through apps and wearable devices.A standardized Baduanjin exercise program consists of eight postures, each training time is about 30 minutes (including 10 min warm-up, 2 times of Baduanjin, and 10 min of relaxation), 5 days/week, a total of 12 weeks.
62234858|NCT04459065|EXPERIMENTAL|Low dose intermediate time|Participants will receive an i.v. infusion of 50 mg IRDye800CW-nimotuzumab. Participants will undergo lung cancer resection surgery 4-6 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
62234859|NCT04459065|EXPERIMENTAL|High dose intermediate time|Participants will receive an i.v. infusion of 100 mg IRDye800CW-nimotuzumab. Participants will undergo lung cancer resection surgery 4-6 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
62234860|NCT04459065|EXPERIMENTAL|Optimal dose early time|Participants will receive an i.v. infusion of 50 or 100 mg IRDye800CW-nimotuzumab (depending on results from cohorts 1 and 2). Participants will undergo lung cancer resection surgery 1-3 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
62234861|NCT04459065|EXPERIMENTAL|Optimal dose late time|Participants will receive an i.v. infusion of 50 or 100 mg IRDye800CW-nimotuzumab (depending on cohorts 1 and 2). Participants will undergo lung cancer resection surgery 7+ days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
62234862|NCT04025463|OTHER|Intervention|Hybrid type II effectiveness/implementation study design - pre-post design with each participant serving as his or her own control.
62234863|NCT02715531|EXPERIMENTAL|Arm A (Hepatocellular Carcinoma [HCC], All subtypes)|Participants with advanced or metastatic and/or unresectable HCC who have received no prior treatment are non-randomized and will receive atezolizumab and bevacizumab, every 3 weeks (q3w), each cycle of 21 days, as long as participants are experiencing clinical benefit in the opinion of the investigator.
62425818|NCT05506163||Training set|The whole cohort is randomly assigned to a training cohort and validation cohort.
62425819|NCT05506163||validation set|The whole cohort is randomly assigned to a training cohort and validation cohort.
62425820|NCT01148680|EXPERIMENTAL|immediate registration on islet graft list|"group 1 'immediate registration on infusion waiting list' : patients who will be immediately registrated on islet cell infusion waiting list after randomization.~Intervention : Procedure/surgery (islet graft)"
62425821|NCT01148680|ACTIVE_COMPARATOR|delayed registration on islet graft list|"group 2 'delayed registration on infusion waiting list' : patients who will be registrated 6 months later on islet cell infusion waiting list after randomization.~Intervention : Procedure/surgery (islet graft)"
62811098|NCT06523985|EXPERIMENTAL|Customized layperson messaging (Arm 2)|Arm 2 will follow the same procedures that are described for arm 1 but will use separate messaging. Specifically, the push messages and landing page will contain additional, brief messages that specifically provide factual information that counteracts misperceptions about overdose and naloxone.
62811099|NCT06523985|NO_INTERVENTION|Control arm (Arm 3)|Arm 3 functions as the control arm and will not receive any monthly recruitment messaging or encouragement.
62819586|NCT06577363||Maribavir|Maribavir 400 milligrams (mg), tablets, orally twice a day.
62034693|NCT00270218|PLACEBO_COMPARATOR|4|Arm 4 participants will be given an injection of phosphate buffered saline (PBS) on Days 0 and 28 and an injection of FFB on Day 168.
62034694|NCT02611466|EXPERIMENTAL|ASP7962|Participants receive 100 mg of ASP7962 orally twice daily for 4 weeks.
62243185|NCT02407470|EXPERIMENTAL|Rabbit ATG & AD-MSCs|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own adipose derived mesenchymal stem cells (AD-MSCs) at a dose of 3000000/kg/d on day 1 to 3.
62425822|NCT02011516|PLACEBO_COMPARATOR|Sugar pill, psychosocial intervention|twice weekly appointments with a certified clinician
62425823|NCT02011516|ACTIVE_COMPARATOR|Baclofen, psychosocial intervention|20 mg. q.i.d. twice weekly appointments with a certified clinician
62425824|NCT01188005|EXPERIMENTAL|OSAS patients|This arm includes the OSAS diagnosed cohort that has been planned to undergo four polysomnographic studies. One standard, one with oxygen supplementation, one with n-CPAP device and one post antioxidants administration
62034695|NCT02611466|ACTIVE_COMPARATOR|Naproxen|Participants receive 500 mg of naproxen orally twice daily for 4 weeks.
62811100|NCT03217747|EXPERIMENTAL|Arm A (utomilumab, avelumab)|Patients receive utomilumab IV over 60 minutes on day 1 of each cycle and avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62594123|NCT04463056|ACTIVE_COMPARATOR|Soliris®|International nonproprietary name: eculizumab
62594124|NCT05350865||HDV cohort|Chronic Hepatitis B (HBsAg+) with cirrhosis (APRI \>1.5, FIB-4 \> 3.25, Fibroscan \> 12.5, imaging), PWID with HBV, HIV/HBV, HBV/HCV, aged 18 years and older
62594125|NCT02621489|EXPERIMENTAL|Bydureon 2 mg Once Weekly|Patients randomised to Bydureon will be treated with Metformin 1g BID, and only receive 10U of Humulin kwickpen QD at bedtime, with no more up-titration of insulin during the study.
62594126|NCT02621489|ACTIVE_COMPARATOR|Humulin kwickpen|Patients randomised to the comparator group will be treated with Meformin 1g BID and Humulin kwickpen to reach a fP-glucose level of 6 mmol/l. For that reason patients will be instructed to increase the bedtime Insulin dose of 2-4U every third day until this goal is reached.
62594127|NCT06617845|EXPERIMENTAL|Stimulation set A/B group|Device will be set to use stimulation parameters from set A first (e.g. 145 Hz) and then from set B (e.g. low frequency stimulation).
62034696|NCT02611466|PLACEBO_COMPARATOR|Placebo|Participants receive placebo orally twice daily for a period of 4 weeks.
62034697|NCT04385953||Trauma patients|Subject experiencing major trauma
62819587|NCT05545930|ACTIVE_COMPARATOR|Hand Wrung|Hand wrung refers to manually wringing surgical sponges by hand.
62034698|NCT04385953||Obstetric patients|Obstetric patient with postpartum hemorrhage
62034699|NCT02459873|EXPERIMENTAL|Computer games to assess change in executive function skills|Children in Intervention group get to train using executive function games at more difficult levels.
62034700|NCT02459873|ACTIVE_COMPARATOR|Easy games as active comparators for executive function skills|Children in Non-intervention group get to play executive function games at an easy level.
62594128|NCT06617845|EXPERIMENTAL|Stimulation set B/A group|Device will be set to use stimulation parameters from set B first (e.g. low frequency stimulation) and then from set A (e.g. 145 Hz).
62034701|NCT06669936||Zinplava/FMT|Patients with recurrent C. difficile infections, who failed FMT. This cohort includes patients treated with a combination of bezlotoxumab (Zinplava) and 2nd FMT.
62594129|NCT06093646|EXPERIMENTAL|Ebola+D intervention|Ebola+D intervention will include psycho-education, Problem Solving Therapy, antidepressant medication and referral to a supervising specialist mental health worker.
62594130|NCT00778284|EXPERIMENTAL|1|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets of Ranbaxy
62034702|NCT06014463||Patients with Primary Immune Deficiency|Patients between the ages of 18-65 years who have been diagnosed with primary immunodeficiency
62034703|NCT06014463||Healthy Controls|Age and sex matched healthy controls between the ages of 18-65 years
62034704|NCT05889143||Mucotra® SR Tab|
62034705|NCT00639873|EXPERIMENTAL|AS 2mg/kg|Artesunate monotherapy 2mg/kg/day for 7 days
62034706|NCT00639873|EXPERIMENTAL|AS 4mg/kg|Artesunate monotherapy 4mg/kg/day for 7 days
62034707|NCT00639873|ACTIVE_COMPARATOR|QD Control|Quinine-doxycycline for 7 days
62594131|NCT00778284|ACTIVE_COMPARATOR|2|Augumentin chewable tablets of Glaxosmithkline
62594132|NCT02286570|ACTIVE_COMPARATOR|face-to-face intubation of Glidescope|patients were intubated using glidescope by face-to-face approach
62594133|NCT02286570|ACTIVE_COMPARATOR|face-to-face intubation with Airtraq|patients were intubated using the Airtraq by face-to-face approach
62594134|NCT02286570|ACTIVE_COMPARATOR|face-to-face intubation with fastrach|patients were intubated using the Fastrach by face-to-face approach
62034708|NCT04182490|ACTIVE_COMPARATOR|3000-mg cohort|LMN-101, six 500-mg capsules orally three times daily for 14 days (n=21)
62034709|NCT04182490|PLACEBO_COMPARATOR|Placebo cohort|Placebo, six 500-mg capsules orally three times daily for 14 days (n=21)
62034710|NCT01747772|EXPERIMENTAL|Shear Wave Sonoelastography for Fibrosis Assessment|Shear Wave sonoelastography (SWE) was performed in patients who were scheduled for a non-focal liver biopsy.
62034711|NCT04501861|ACTIVE_COMPARATOR|The use of vasopressin compared with norepinephrine|The investigator hypothesize that the use of vasopressin compared with norepinephrine induces a lower mPAP-to-MAP ratio, in cardiac surgical patients with and without pulmonary hypertension who require intraoperative vasopressor support.
62034712|NCT04501861|ACTIVE_COMPARATOR|The use of norepinephrine compared with vasopressin|The investigators will compare GLS between patients who received norepinephrine versus vasopressin intraoperatively.
62034713|NCT06670339|ACTIVE_COMPARATOR|No Cooling|Participants will complete 60 min of continuous semi-recumbent cycling at a fixed metabolic heat load (200 W/m2) in the heat (wet-bulb globe temperature of 29°C; 37.5°C and 35% relative humidity) (Control condition) without pre-cooling.
62034714|NCT06670339|EXPERIMENTAL|Pre-Cooling|Participants will undergo a cold-water immersion (\~17°C) to elicit a decrease in rectal temperature by 0.5°C from baseline values. Thereafter, once the target temperature is achieved, participants will complete 60 min of continuous moderate-intensity cycling (200 W/m2) in the heat (wet-bulb globe temperature of 29°C; 37.5°C and 35% relative humidity).
62034715|NCT02119416|EXPERIMENTAL|1mg/kg Caffeine|Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg
62594135|NCT04024306||SLE with corticosteroid therapy|
62594136|NCT01958216|OTHER|Trans-intestinal cholesterol excretion in vivo|Measuring trans-intestinal cholesterol excretion in vivo in bile diverted patients
62594137|NCT05969392|EXPERIMENTAL|Intradiscal Gelified Ethanol Arm|Patients who come with symptomatic cervical disc herniation or with cervical discogenic pain and meet the eligibility criteria.
62594138|NCT06620484||Rheumatoid arthritis patients|
62594139|NCT06620484||Healthy control group|
62234864|NCT02715531|EXPERIMENTAL|Arm B (Gastric Cancer)|Participants with previously untreated human epidermal growth factor receptor 2 (HER2)-negative adenocarcinoma of the stomach or gastroesophageal junction (GEJ) are non-randomized and will receive atezolizumab, bevacizumab, and FOLFOX (oxaliplatin, leucovorin, and 5-fluorouracil \[FU\]), every 2 weeks (q2w), each cycle of 28 days, as long as participants are experiencing clinical benefit in the opinion of the investigator. Oxaliplatin will be administered for up to 8 cycles. After 6 months, at discretion of investigator, capecitabine may be administered as maintenance therapy without oxaliplatin instead of infusional 5-FU and leucovorin, and biologic therapy may be given every 3 weeks (q3w). In the event that a patient experiences unacceptable toxicity after replacement of infusional 5-FU and leucovorin with capecitabine, the patient may be allowed to switch back to 5-FU and leucovorin following investigator discussion with the Medical Monitor.
62234865|NCT02715531|EXPERIMENTAL|Arm C (Metastatic Pancreatic Cancer)|Participants with previously untreated metastatic pancreatic cancer are non-randomized and will receive atezolizumab q2w starting on Day 1, Cycle 1 (each cycle of 28 days). Administration of nab-paclitaxel followed by gemcitabine will occur on Days 1, 8, and 15 of each cycle (3-weeks-on/1-week-off schedule). Treatment consisting of atezolizumab with gemcitabine and nab-paclitaxel may be continued as long as participants are experiencing clinical benefit in the opinion of the investigator.
62234866|NCT02715531|EXPERIMENTAL|Arm E (Randomized Metastatic Esophageal Cancer)|Participants with squamous metastatic esophageal cancer (mEC) will be randomized (1:1) into Group E1 and Group E2. All participants with metastatic adenocarcinoma of esophageal carcinoma or GEJ Siewert Classification Type I will be enrolled into Group E3. In Groups E1 and E3, participants will receive atezolizumab and FOLFOX, q2w, each cycle of 28 days, as long as participants are experiencing clinical benefit in opinion of the investigator. Oxaliplatin will be administered for up to 8 cycles. In Group E2, participants will receive atezolizumab followed by cisplatin and 5-FU q3w. Cisplatin will be administered for up to 6 cycles. Treatment with atezolizumab in combination with 5-FU may be continued as long as participants experience clinical benefit in opinion of the investigator.
62234867|NCT02715531|EXPERIMENTAL|Arm F (Randomized HCC)|Participants with advanced or metastatic and/or unresectable HCC who have received no prior systemic treatment will be randomized (1:1) into Group F1 and Group F2. Participants will receive atezolizumab alone (Group F2) or combined with bevacizumab (Group F1) on a q3w schedule, with dosing on Day 1 of each 21 day Cycle. Treatment with atezolizumab with or without bevacizumab may be continued as long as participants are experiencing clinical benefit in the opinion of the investigator. Participants who are randomly assigned to Group F2 (atezolizumab monotherapy) and experience investigator-assessed unequivocal radiographic progression as per RECIST v1.1 will also be given the option to cross over to atezolizumab and bevacizumab combination therapy, provided they meet the criteria for crossover and Medical Monitor approval is obtained.
62234868|NCT04264078|EXPERIMENTAL|anti-CD7 UCAR-T cells|After preconditioning with chemotherapy ( Fludarabine, Cytoxan and/or Melphalan), the dosage of anti-CD7 UCAR-T cells between 1 and 5 ×10\^7 cells/Kg will be evaluated
62234869|NCT06246708|EXPERIMENTAL|Intervention Group|Participants receive intervention at baseline for 5 weeks
62234870|NCT06246708|OTHER|Wait-list Control Group|Participants receive the intervention after 5 weeks
62234871|NCT00421200|EXPERIMENTAL|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
62425825|NCT01188005|NO_INTERVENTION|Control Group|This group is scheduled to undergo a plain polysomnographic study, whilst plasma cytokine levels will be measured. It will comprise of healthy, non-OSAS volunteers.
62594140|NCT06356844|ACTIVE_COMPARATOR|Treated with resolvin|Transforaminal steroid injection with ultrasound and resolvin therapy
62425826|NCT01872858|ACTIVE_COMPARATOR|Aspirin|Aspirin, 100mg, Q.D, p.o, 2yr
62594141|NCT06356844|NO_INTERVENTION|No resolvin treatment|Transforaminal steroid injection with ultrasound and no resolvin treatment
62594142|NCT04807309|PLACEBO_COMPARATOR|Placebo|Placebo comparison
62594143|NCT04807309|ACTIVE_COMPARATOR|Danazol Pill|Danazol 200mg orally twice a day
62034716|NCT02119416|EXPERIMENTAL|2mg/kg caffeine|Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg
62034717|NCT02119416|EXPERIMENTAL|Placebo|Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg
62594144|NCT05179018||SLE patients group|The study will include 50 patients suffering from SLE, all patients with SLE should fulfill 2012 SLICC criteria
62594145|NCT05179018||Healthy control group|Control group of 40 healthy volunteers with age and gender-matched with SLE patients.
62594146|NCT04178824|EXPERIMENTAL|Experimental 15% discount intervention|15% discount on fruits, vegetables and non-caloric beverages at the designated supermarkets
62811101|NCT03217747|EXPERIMENTAL|Arm B (PF-04518600, avelumab)|Patients receive anti-OX40 agonist monoclonal antibody PF-04518600 IV over 60 minutes on days 1 and 15 of each cycle and avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62034718|NCT03244527|EXPERIMENTAL|BCAA group|Participants in the BCAA group take 40g of BCAA supplement before each aerobic exercise session. The interventions include 24 aerobic training sessions. Accordingly, the participants intake 960g of BCAA during a 8-week intervention period.
62034719|NCT03244527|PLACEBO_COMPARATOR|Control group|Participants in the control group take 40g of placebo before each aerobic training session. The placebo has the same caloric as the BCAA supplement but with different constitution (eg, different percentage of protein, fat and carbohydrate)
62034720|NCT06042348||Group 1|
62034721|NCT00339924||Physicians|Currently practicing, board certified general internists, both allopathic and osteopathic, whose offices are in the United States.
62034722|NCT06090266|EXPERIMENTAL|OR502 monotherapy and combination therapy dose-escalation phase (Part A)|"Escalating repeated doses of OR502 by IV administration as monotherapy or in combination with cemiplimab in subjects with advanced solid tumors. OR502 will be administered once every 3 weeks (Q3W).~Cemiplimab will be administered as an IV infusion at a dose of 350 mg."
62234872|NCT00421200|ACTIVE_COMPARATOR|Control|Voluven (HES 130/0.4)
62234873|NCT02251288|EXPERIMENTAL|Group 1|12 patients receive Intramuscular (IM) A/H7N9 15 mcg on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of Intranasal (IN) sprayer 10\^7 FFU H7 N9 pLAIV on Day 29
62425827|NCT01872858|EXPERIMENTAL|Cilostazol|cilostazol, 100mg, B.I.D, p.o, 2yr
62425828|NCT02613416|EXPERIMENTAL|Denosumab|6 monthly subcutaneous injections of denosumab
62425829|NCT05091879|NO_INTERVENTION|Standard of Care|A multigene pharmacogenomics test will not be ordered for patients in this study arm, as is the standard of care.
62594147|NCT04178824|EXPERIMENTAL|Experimental 30% discount intervention|30% discount on fruits, vegetables and non-caloric beverages at the designated supermarkets
62594148|NCT04178824|NO_INTERVENTION|No intervention control group|0% discount on fruits, vegetables and non-caloric beverages at the designated supermarkets
62594149|NCT04266886|ACTIVE_COMPARATOR|Arm I (usual care)|Patients receive usual care including receipt of multi-modal analgesia and the injection of a local analgesic at the time of surgery on the ERAS pathway.
62594150|NCT04266886|EXPERIMENTAL|Arm II (usual care, self-hypnosis guided relaxation)|Patients receive usual care as in Arm I. Patients also receive self-hypnosis guided relaxation by listening to MP3 on the ERAS pathway.
62234874|NCT02251288|EXPERIMENTAL|Group 2|12 patients receive A/H7N9 15 mcg IM on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of IN sprayer10\^7 FFU H7 N9 pLAIV on Day 85
62234875|NCT02251288|EXPERIMENTAL|Group 3|12 patients receive S A/H7N9 15 mcg IM on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of IN sprayer 10\^7 FFU H7 N9 pLAIV on Day 169
62234876|NCT02251288|EXPERIMENTAL|Group 4|8 patients receive A/H7N9 15 mcg IM on Day 1, 8 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1
62234877|NCT02251288|EXPERIMENTAL|Group 5|12 patients receive A/H7N9 15 mcg plus MF59 adjuvant on Day 1 and Day 29
62594151|NCT03178240|EXPERIMENTAL|Intervention|45 minutes seminar on skin cancer prevention and UV-protection in general.
62594152|NCT03178240|NO_INTERVENTION|Control|The control croup takes part in the survey but does not receive an intervention.
62594153|NCT02763982||G1|High or normal left ventricular ejection fraction
62594154|NCT02763982||G2|Moderate left ventricular ejection fraction
62594155|NCT02763982||G3|Reduced left ventricular ejection fraction
62594156|NCT01565668|EXPERIMENTAL|AC220 Dose Level 1|
62594157|NCT01565668|EXPERIMENTAL|AC220 Dose Level 2|
62594158|NCT05905666|EXPERIMENTAL|self-controlled design|The research period was divided into a control stage (first to fourth week: standard of care) and the experimental stage (fifth to eighth week: health education and counseling).
62811102|NCT03217747|EXPERIMENTAL|Arm C (PF-04518600, utomilumab, avelumab)|Patients receive anti-OX40 agonist monoclonal antibody PF-04518600 IV over 60 minutes on days 1 and 15 of each cycle, utomilumab over 60 minutes on day 1, and avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62819588|NCT05545930|EXPERIMENTAL|ProCell Wrung|ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
62811103|NCT03217747|EXPERIMENTAL|Arm D (avelumab, utomilumab, radiation therapy)|Patients undergo radiation therapy on days -5 to -1. Patients receive avelumab IV over 60 minutes on days 1 and 15 of beginning day 15 of cycle 1 and utomilumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62811104|NCT03217747|EXPERIMENTAL|Arm E (avelumab, PF-04518600, radiation therapy)|DISCONTINUED AS OF AMENDMENT 9 (02/11/2020) Patients undergo radiation therapy on days -14 to -1. Patients receive avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1 and anti-OX40 agonist monoclonal antibody PF-04518600 IV over 60 minutes on days 1 and 15, and. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62811105|NCT03217747|EXPERIMENTAL|Arm F (avelumab, PF-04518600, radiation therapy)|DISCONTINUED AS OF AMENDMENT 9 (02/11/2020) Patients undergo radiation therapy on days -14 to -1. Patients receive avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1, utomilumab IV over 60 minutes on day 1, and anti-OX40 agonist monoclonal antibody PF-04518600 IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62811106|NCT01559636|ACTIVE_COMPARATOR|Diarrhea|Infants with diarrhea will have blood and stool sample taken and receive zinc and ORS. They will then receive bivalent oral polio vaccine as the intervention. Four weeks later another blood sample will be drawn to measure seroconversion.
62811107|NCT01559636|ACTIVE_COMPARATOR|Non-diarrhea|Infants without diarrhea will have blood and stool sample taken and receive multivitamins. They will then receive bivalent oral polio vaccine as the intervention. Four weeks later another blood sample will be drawn to measure seroconversion.
62811108|NCT00768989|EXPERIMENTAL|Atazanavir + Raltegravir|Atazanavir 300 mg twice daily + Raltegravir 400 mg twice daily
62811109|NCT00768989|ACTIVE_COMPARATOR|Atazanavir + Ritonavir + Tenofovir /Emtricitabine|Atazanavir, 300 mg once daily, + Ritonavir, 100 mg once daily, + Tenofovir 300 mg/Emtricitabine, 200 mg once daily
62811110|NCT01148550||Group 1|Mitochondrial Hepatopathy Disease Group
62811111|NCT01148550||Group 2|Subjects with Suspected Mitochondrial Hepatopathy who do not meet the enrollment criteria for Group 1 Subjects with Suspected Mitochondrial Hepatopathy who do not meet the enrollment criteria for Group 1
62811112|NCT04472611|EXPERIMENTAL|Standard of Care (SOC) and Colchicine+Rosuvastatin|Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
62811113|NCT04472611|NO_INTERVENTION|Standard of care (SOC)|Patients will undergo standard of care treatment during hospitalization determined by the primary care team during hospitalization
62811114|NCT02218684|EXPERIMENTAL|Telmisartan + Lacidipine - low dose|
62811115|NCT02218684|EXPERIMENTAL|Telmisartan + Lacidipine - medium dose|
62811116|NCT02218684|EXPERIMENTAL|Telmisartan + Lacidipine - high dose|
62811117|NCT02218684|PLACEBO_COMPARATOR|Placebo|
62811118|NCT00807118|EXPERIMENTAL|A (Cohort I)|
62811119|NCT00807118|EXPERIMENTAL|B (Cohort I)|
62811120|NCT00807118|EXPERIMENTAL|C (Cohort I)|
62811121|NCT00807118|EXPERIMENTAL|B (Cohort II)|
62811122|NCT00807118|EXPERIMENTAL|D (Cohort II)|
62811123|NCT00807118|EXPERIMENTAL|E (Cohort II)|
62811124|NCT01998230|EXPERIMENTAL|Early oral feeding group|In this goup patients with esophagectomy are encouraged to begin the oral intake carefully and adjust according to tolerance on post operative day 1.
62811125|NCT01998230|NO_INTERVENTION|Delayed oral feeding group|In delayed oral feeding group the patients receive isotonic saline by the nasoenteral feeding tube at 20 mL/h until the morning of post operative day1. Nutrition was then commenced at 20 mL/h. The rate was increased by 20 mL/h each day if tolerated, up to 80 mL/h.Esophagography was performed on postoperative day 7. Sip of water were allowed after confirming the absence of anastomosis leakage, and a full liquid diet was implemented on the following day and enteral infusion halted.
62811126|NCT05260268|NO_INTERVENTION|Usual Care|"Usual care refers to the normal standard clinical practices immediately post-transplant to the 18 months following. Liver Transplant Recipients at sites have lab values taken weekly for the first 8-10 weeks post-transplant, shifting to every 2-4 weeks for the next 3-4 months, then monthly to every 3 months thereafter depending on clinical needs.~All sites follow a similar schedule of tapering clinic visits ranging from weekly in the first 4 weeks to every 2-4 weeks in months 4-6, every 3-6 months in months 7 12, and every 6 months in months 12-24. All sites assign each patient to a specific transplant coordinator, first paired with a transplant surgeon (first 3-6 months), and then a transplant hepatologist for the remainder of follow-up.~All patients and caregivers receive standard medication teaching prior to hospital discharge and then ad hoc. No routine text message reminders, caregiver reminders, or adherence alerts are used in usual care."
62811127|NCT05260268|EXPERIMENTAL|TEST Intervention|"Clinical activities for Usual Care will also be provided in the TEST arm. The TEST intervention is a technology-enabled strategy to routinely monitor regimen use, adherence, and persistence via a 'low touch', easy to use, online behavioral toolkit - Way to Health . It was developed by University of Pennsylvania researchers to automate behavioral intervention. The TEST approach includes monthly adherence assessments, with tailored adherence support. The following components will be included in the intervention:~* Monthly W2H Adherence Assessment \& Clinician Alerts~* Medication Reminders~* Laboratory and Appointment Notifications~* Supplemental Self-Management Support"
62811128|NCT05081908|EXPERIMENTAL|Multisession radiosurgery|Radiosurgery
62811129|NCT05894460||Chocolate balloon|
62811130|NCT05894460||Conventional ballon|
62811131|NCT04445935|ACTIVE_COMPARATOR|Standard treatment|"In this arm the patients will be treated according to our standard anticoagulation protocol.~The patients will not be treated with Bivalirudin (the investigational drug)."
62811132|NCT04445935|EXPERIMENTAL|Bivalirudin arm|The patients will be anticoagulated according to the institutional HIT-protocol which uses Bivalirudin as anticoagulant.
62811133|NCT00842569||Normal weighted|BMI\<25
62811134|NCT00842569||Obese|BMI\>30
62811135|NCT03191617|EXPERIMENTAL|Liquid human milk fortifier|Liquid human milk fortifier which has higher protein content and also LCPUFA
62811136|NCT03191617|ACTIVE_COMPARATOR|Powder human milk fortifier|Powder human milk fortifier with less protein content and no LCPUFA
62811137|NCT04826172|EXPERIMENTAL|IMB-1018972 200mg|
62811138|NCT04826172|PLACEBO_COMPARATOR|Placebo|
62034723|NCT06090266|EXPERIMENTAL|OR502 monotherapy and combination therapy dose-expansion phase (Part B)|"OR502 administered IV at 2 different dose levels identified in Part A as monotherapy or in combination with cemiplimab in subjects with platinum-resistant ovarian cancer and cutaneous squamous cell carcinoma.~Cemiplimab will be administered as an IV infusion at a dose of 350 mg."
62034724|NCT06215274||People in the stage of preclinical Alzheimer's disease|Observe the cognitive leisure activity levels, cognitive function, and MRI characteristics in patients in the preclinical stage of Alzheimer's Disease
62034725|NCT05337891||Patients with suspected or diagnosed myasthenia gravis|Patients with suspected or diagnosed myasthenia gravis (ocular and generalized form), aged 18-80, both sexes, with performed or planned determination of anti-acetylcholine receptor antibodies and muscle-specific tyrosine kinase antibodies
62034726|NCT01300546|ACTIVE_COMPARATOR|Sumatriptan/Naproxen Sodium|In Treatment Period, subjects randomized to Sumatriptan/Naproxen Sodium will be provided with 14 tablets of Sumatriptan/Naproxen Sodium to treat migraine within 1 hour of onset on 14 or fewer days per month. Subjects will be provided with 14 tablets of Sumatriptan/Naproxen Sodium per month for rescue of persistent or recurring headache.
62234878|NCT03622853|EXPERIMENTAL|intraarticular steroid injection|intraarticular steroid hydrodilatation (shincort 40mg )
62034727|NCT01300546|ACTIVE_COMPARATOR|Naproxen Sodium|In Treatment Period, subjects randomized to Naproxen Sodium 500mg will be provided with 14 tablets of Naproxen Sodium to treat migraine within 1 hour of onset on 14 or fewer days per month. Subjects will be provided with 14 tablets of Naproxen Sodium per month for rescue of persistent or recurring headache.
62234879|NCT06326853||patients affected by hypothalamic-pituitary endocrine pathology|100 patients affected by hypothalamic-pituitary endocrine pathology who have performed or who will perform a first visit at the Endocrinology Department of the San Raffaele Hospital between 01/01/2021 and 31/12/2026.
62234880|NCT06326853||affected by obesity|100 patients affected by obesity who will perform a first visit at the Endocrinology Department of the San Raffaele Hospital between 01/01/2021 and 31/12/2026.
62034728|NCT05069350|EXPERIMENTAL|bupivacaine 0.5%|
62034729|NCT05069350|EXPERIMENTAL|oxybuprocaine|
62034730|NCT06635369|EXPERIMENTAL|Young (25-44 years) with a healthy periodontium|
62034731|NCT06635369|EXPERIMENTAL|young (25-44 years) with Periodontitis|
62034732|NCT06635369|EXPERIMENTAL|Old (≥65 years) with a healthy periodontium|
62234881|NCT01734408|EXPERIMENTAL|alum-adjuvant 160U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 160U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.
62234882|NCT01734408|PLACEBO_COMPARATOR|placebo A|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.
62234883|NCT01734408|EXPERIMENTAL|alum-adjuvant 320U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 320U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 320U/0.5ml EV71 vaccines one year before.
62234884|NCT01734408|PLACEBO_COMPARATOR|placebo B|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 320U/0.5ml EV71 vaccines one year before.
62234885|NCT01734408|EXPERIMENTAL|alum-adjuvant 640U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 640U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 640U/0.5ml EV71 vaccines one year before.
62234886|NCT01734408|PLACEBO_COMPARATOR|placebo C|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 640U/0.5ml EV71 vaccines one year before.
62234887|NCT01734408|EXPERIMENTAL|adjuvant-free 640U /0.5ml EV71 vaccine|A booster dose of adjuvant-free 640U /0.5ml EV71 vaccine in 160 children whom had received two doses of adjuvant-free 640U/0.5ml EV71 vaccines one year before.
62034733|NCT06635369|EXPERIMENTAL|Old (≥65 years) with Periodontitis|
62034734|NCT04393441|ACTIVE_COMPARATOR|Systane® Ultra Multidose|All participants administered 1 to 2 drops of REFRESH PLUS® 3 times daily in each eye for approximately 7 days during a run-in period prior to randomization on Day 1. Participants then administered 1 to 2 drops of Systane® Ultra Multidose in each eye 3 times daily for up to 90 days.
62034735|NCT04393441|EXPERIMENTAL|011516X (New Artificial Tear Formulation)|All participants administered 1 to 2 drops of REFRESH PLUS® 3 times daily in each eye for approximately 7 days during a run-in period prior to randomization on Day 1. Participants then administered 1 to 2 drops of 011516X in each eye 3 times daily for up to 90 days.
62034736|NCT04139070|EXPERIMENTAL|Treátment group|8 patients are expected to be included in this study. The patients will be treated once with bleomycin in combination with elektroporation
62034737|NCT02088268|EXPERIMENTAL|platelet-rich plasma|wound healing
62234888|NCT01734408|PLACEBO_COMPARATOR|placebo D|A 0/0.5ml placebo in 80 children whom had received two doses of adjuvant-free 640U/0.5ml EV71 vaccines one year before.
62234889|NCT04144634|EXPERIMENTAL|Intervention/Strengthening|
62234890|NCT04144634|SHAM_COMPARATOR|Control/Stretching|
62234891|NCT04897672||case|case: Children aged 6 to 17 years old reffered to the pediatric cardiology consultation with a chronic renal disease and renal insufficiency
62811139|NCT02470221||Goal-directed fluid therapy|The fluid in group Goal-directed fluid therapy will be administered based upon real-time monitoring stroke volume variation and cardiac output achieved by the Flo-Trac monitoring system.
62811140|NCT02470221||Conventional fluid therapy|The fluid in group Conventional fluid therapy will be administered based on the principle crystalloid solution: colloid solution =2-3:1. The total volume of fluid will be adjusted in accordance with blood pressure, heart rate and urine output of each patient.
62034738|NCT02423187||Arm 1|Participants with combination therapy (rabeprazole and low-dose aspirin)
62034739|NCT02014714|ACTIVE_COMPARATOR|Morphine|Intrathecal Morphine 0.1mg
62034740|NCT02014714|ACTIVE_COMPARATOR|Fentanyl|Intrathecal Fentanyl 40mcg
62034741|NCT06192485|ACTIVE_COMPARATOR|Proactive balance training group|
62034742|NCT06192485|ACTIVE_COMPARATOR|Reactive balance training group|
62034743|NCT04966468|EXPERIMENTAL|VR Group|Patients will be given the VR headset with non-interactive and interactive contents at home for four days
62034744|NCT04966468|ACTIVE_COMPARATOR|CTR group|Patients will be given a tablet at home for four days with relaxing non-interactive 2D videos with natural and artistic scenarios
62234892|NCT04897672||control|control : Children aged 6 to 17 years old reffered to the pediatric cardiology consultation who were classified in the control group after a completely normal check-up, including physical examination, electrocardiogram, and echocardiography
62234893|NCT00286078|EXPERIMENTAL|Treatment|Active occipital nerve stimulation (stimulation on)
62234894|NCT00286078|SHAM_COMPARATOR|Control|Sham occipital nerve stimulation from activation to 12 weeks post-activation. Active occipital nerve stimulation from 12 weeks post-activation on.
62234895|NCT04233593|EXPERIMENTAL|LPS Challenge|Subjects will undergo one 120-minute \[11C\]PBR28 PET scan before and one scan 3-hours after LPS administration (1.0ng/kg; IV).
62234896|NCT04233593|NO_INTERVENTION|LPS Follow-up|Subjects will undergo one 120-minute \[11C\]PBR28 PET scan 24+ hours after LPS.
62811141|NCT04978896|EXPERIMENTAL|Intervention group: Stress-coping Program|Participants will complete an 8-day self-guided programme on stress-coping delivered via a mobile-phone application with daily exercises guided by cognitive-behavioural principles.
62811142|NCT04978896|ACTIVE_COMPARATOR|Control group|Participants will complete an 8-day self-guided programme on cooperation delivered via a mobile-phone application with daily exercises that differ to the intervention group in terms of content but are comparable in terms of duration.
62811143|NCT05085886|EXPERIMENTAL|DepCare Intervention|The clinic (administrators, staff, care managers) will receive quality improvement support and education around depression screening as well as local technical assistance for mental health treatment optimization. The cluster of primary care providers in the intervention arm will receive education and decisional support for optimizing mental health treatment and access to quality improvement/implementation meetings. Eligible patients will receive a tool that facilitates enhanced screening, diagnosis recognition, treatment selection support, psychoeducation, and activation.
62811144|NCT05085886|ACTIVE_COMPARATOR|Enhanced Usual Care|The clinic (administrators, staff, care managers) will receive quality improvement support and education around depression screening as well as local technical assistance for mental health treatment optimization. The cluster of primary care providers and patients in the active comparator arm will have access to this clinic-level strategy (i.e., the same clinic level intervention as in the DepCare group), but will not receive any provider or patient-level interventions.
62811145|NCT01387828|ACTIVE_COMPARATOR|Laparoscopy|Includes all patient underwent intervention with a laparoscopic approach, even if converted to open surgery during intervention
62811146|NCT01387828|ACTIVE_COMPARATOR|Open surgery|Includes all the patients underwent intervention with a laparotomic approach; it does not include patient underwent laparoscopic approach and then converted in laparotomy.
62811147|NCT04480320|EXPERIMENTAL|Pericapsular nerve group block|
62811148|NCT04480320|PLACEBO_COMPARATOR|Saline placebo group|
62811149|NCT05244512|EXPERIMENTAL|Evidence-based leadership training|The training course will take 6 months. It is divided into seven online modules. Participants join the course based on pre-structured schedule. The progress of the training course will follow specific steps to improve participants' evidence-based leadership competencies. First, each participant identifies one leadership problem on daily practice. Second, organisational data will be collected and analysed to increase the understanding of the key problem. Third, scientific literature will be searched, identified and critically appraised to find solutions. Fourth, the views of stakeholders (patients, clinicians, family members, etc.) are considered together with ethical implications. And last, all sources of information are critically appraised, new solution will be designed and implemented into the practice, and evaluated in real world context. Each module includes specific learning material. Trained tutors are responsible for mentoring each module.
62811150|NCT05244512|ACTIVE_COMPARATOR|Conventional training|The participants will join a training course with the same structure, topics, and timing as the experimental group. However, training in this group is based on independent learning methods. The participants have access to the separate learning platform, which includes reading material to be read independently. No group discussions with peers, self-reflection, assignments, or support from tutors will be offered.
62811151|NCT06208657|EXPERIMENTAL|Arm A Paxalisib|Drug: Irinotecan Drug: Temozolomide Drug: Paxalisib Irinotecan 50mg/m2/day, intravenous, on days 1-5, 28 day cycle, 13 cycles Temozolomide 150mg/m2/day, oral, on days 1-5, 28 day cycle, 13 cycles Paxalisib 21mg/m2 oral, daily, 28 day cycle, 13 cycles
62811152|NCT04694222|OTHER|Control Group|scaling and root planning (SRP) was applied.
62234897|NCT01088256|ACTIVE_COMPARATOR|etoricoxib, peripheral hyperalgesia|14 patient with neuropathic pain and peripheral hyperalgesia get etoricoxib 90mg for 8 days
62234898|NCT01088256|ACTIVE_COMPARATOR|etoricoxib, no peripheral hyperalgesia|14 patients with neuropathic pain without peripheral hyperalgesia get etoricoxib 90mg for 8 days
62234899|NCT01088256|PLACEBO_COMPARATOR|placebo, peripheral hyperalgesia|14 patients with neuropathic pain with peripheral hyperalgesia get placebo for 8 days
62594159|NCT01904292|EXPERIMENTAL|Tocilizumab|Participants will receive SC dose of tocilizumab based on body weight; participants with \<30 kg will receive 162 milligrams (mg) of tocilizumab Q2W and those participants =\>30 kg will receive 162 mg of tocilizumab QW, for 52 weeks.
62594160|NCT06009107|EXPERIMENTAL|Participant Group|Participants with relapsed or refractory B-precursor acute lymphoblastic leukemia (r/r B-ALL) will receive conditioning chemotherapy (fludarabine 25-30 mg/m\^2 intravenously \[IV\] over 30 minutes on Day -5, Day -4, and Day -3 and cyclophosphamide 500 mg/m\^2 IV over 60 minutes on Day -5, Day -4), following a single IV infusion of chimeric antigen receptor (CAR) transduced autologous T cells(HY004).
62811153|NCT04694222|ACTIVE_COMPARATOR|LANAP Group|After scaling and polishing, three LANAP stages were performed : In the first stage, Nd:YAG laser was applied. In the second stage, full mouth SRP procedure was performed. In the third stage, Nd:YAG laser was applied again.
62811154|NCT04694222|ACTIVE_COMPARATOR|LLLT Group|after SRP Low Level Laser Therapy was performed using Nd:YAG laser.
62811155|NCT04694222|ACTIVE_COMPARATOR|LANAP+LLLT Group|after scaling both LANAP and LLLT were applied.
62811156|NCT03600909|EXPERIMENTAL|Good Risk Patients|Patients 18 years old or younger with marrow aplasia or single lineage cytopenias (Arm A) will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.6-0.8 mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
62234900|NCT01088256|PLACEBO_COMPARATOR|placebo, no peripheral hyperalgesia|14 patients with neuropathic pain without peripheral hyperalgesia get placebo for 8 days
62234901|NCT02198430||Patients|Patients with haemophilia recruited for multidisciplinary assessment of the main physical, functional and psychosocial variables.
62234902|NCT02198430||Control group|Children without hemophilia
62594161|NCT03156842|EXPERIMENTAL|Fimasartan/Amlodipine, Rosuvastatin|Co-administration of a fixed dose combination of Fimasartan/Amlodipine and Rosuvastatin
62594162|NCT03156842|ACTIVE_COMPARATOR|Fimasartan/Amlodipine|a fixed dose combination of Fimasartan/Amlodipine
62811157|NCT03600909|EXPERIMENTAL|Intermediate risk patients|Patients 18 years old or younger with MDS or AML will be will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8-1.0mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
62234903|NCT06428591|EXPERIMENTAL|Tandem Freedom|After a 1 week Control-IQ run-in, adults with type 1 diabetes will complete a supervised hotel study with the Tandem Freedom system for 3 days/nights.
62234904|NCT01553097||women with stage I or II BC with adjuvant chemotherapy|"women with Stage I or II BC who~1. have undergone surgical treatment (biopsy, lumpectomy or mastectomy) and;~2. will be receiving adjuvant chemotherapy"
62234905|NCT01553097||women with Stage I or II BC without adjuvant therapy|"Women with stage I or II BC who~1. Have undergone surgical treatment (biopsy, lumpectomy or mastectomy) \\~2. will not be receiving adjuvant chemotherapy"
62234906|NCT01553097||Healthy control|healthy education-age-matched women without cancer
62234907|NCT02039960||DAWN cases including all prescription drugs|This group will consist of all DAWN cases where prescription drugs are mentioned.
62234908|NCT02039960||All bupropion cases (including use of other drugs)|This group will consist of all DAWN cases where bupropion is mentioned and is a subset of Group 1.
62594163|NCT03156842|ACTIVE_COMPARATOR|Fimasartan, Rosuvastatin|Co-administration of Fimasartan and Rosuvastatin
62234909|NCT02039960||Burpropion Only Cases|This group will consist of all DAWN cases where burpropion is specifically the only drug mentioned within the case report, and is a subset of Group 2.
62811158|NCT03600909|EXPERIMENTAL|High risk patients|Patients 19 years old or older with marrow aplasia or MDS or AML will be will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.4mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
62234910|NCT05094466|EXPERIMENTAL|Arm I (parent intervention)|Parents receive health coaching sessions over 50-60 minutes monthly for 6 months. Parents also receive navigation sessions with a lay LHW monthly for 6 months and church-based peer support monthly for 6 months.
62234911|NCT05094466|EXPERIMENTAL|Arm II (family intervention)|Family members receive health coaching sessions over 50-60 minutes monthly for 6 months. Family members also receive navigation sessions with a LHW monthly for 6 months and church-based peer support monthly for 6 months.
62811159|NCT06353997|EXPERIMENTAL|Pembrolizumab + INBRX-106|Patients will be given pembrolizumab at a dose of 200mg IV in combination with INBRX-106 at a dose of 0.1mg/kg IV every 3 weeks.
62811160|NCT06458946|EXPERIMENTAL|First product order: order not stated to protect study blinding|Participant will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7-day wash-out period before beginning the next product in the sequence
62234912|NCT05094466|ACTIVE_COMPARATOR|Arm III (delayed comparison)|Participants receive a handbook that includes core content from the parent and family interventions, but without individual support from coaches, LHWs or the church.
62425830|NCT05091879|EXPERIMENTAL|Pharmacogenomics Testing|Patients in the experimental arm will be ordered a multigene pharmacogenomics test. This DNA test requires a blood draw, with the results expected to be reported in the medical record approximately 7 to 14 calendar days after the blood draw. These results will be made available to Geisinger healthcare professionals that have a treatment relationship with study participants.
62425831|NCT05899478|EXPERIMENTAL|Tyknot® Suture-Mediated Closure System|Arterial closure device used is Tyknot® Suture-Mediated Closure System
62425832|NCT05899478|ACTIVE_COMPARATOR|Perclose® ProGlide Suture-Mediated Closure System|Arterial closure device used is Perclose® ProGlide Suture-Mediated Closure System
62425833|NCT05626231|EXPERIMENTAL|Gender-Affirming Psychotherapy (GAP)|"The single-arm intervention study will test an online asynchronous gender-affirming training intervention called GAP Training."
62425834|NCT03840135|EXPERIMENTAL|Polyoxidonium 6 mg/ml|Polyoxidonium 6 mg/ml nasal and sublingual spray - 0,15 mg/kg daily - 7 days.
62811161|NCT06458946|EXPERIMENTAL|Second product order: order not stated to protect study blinding|Participant will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7-day wash-out period before beginning the next product in the sequence
62034745|NCT02052505|NO_INTERVENTION|Usual care|The patients will receive the usual care when admitted. This includes an examination by a physician, a medication review and the physician will prescribe medications for the patients as well as other necessary interventions.
62811162|NCT06458946|EXPERIMENTAL|Third product order: order not stated to protect study blinding|Participant will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7-day wash-out period before beginning the next product in the sequence
62234913|NCT00337519|EXPERIMENTAL|1|see detailed description
62243186|NCT02407470|EXPERIMENTAL|Rabbit ATG & AD-HSCs|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own AD-MSC transdifferentiated HSCs (AD-HSCs) at a dose of 3000000/kg/d from day 1 to 4.
62425835|NCT03840135|PLACEBO_COMPARATOR|Placebo|Placebo, nasal and sublingual spray - 7 days.
62425836|NCT05677984|EXPERIMENTAL|APP group|Directive APP for a target of 12 hours per day or more
62425837|NCT05677984|NO_INTERVENTION|Control group|No intervention on APP
62425838|NCT01696227||Nissle 1917|In vitro, Nissle 1917's ability to adversely affect the growth of uropathogens associated with urinary catheters and those with a known GI resevoir will be measured.
62425839|NCT04775368|EXPERIMENTAL|Diagnosis orientation group|For this study, there is only one arm. Each patient complete diagnosis questionnaires.
62425840|NCT05610982|EXPERIMENTAL|Yoga Program|Participants will receive a yoga program program in-person or via real-time videoconferencing (if they choose).
62425841|NCT01692418|EXPERIMENTAL|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline) over a minimum of 15 minutes
62425842|NCT01692418|PLACEBO_COMPARATOR|Placebo|Normal saline will be administered as an i.v. infusion (100ml normal saline) over a minimum of 15 minutes
62811163|NCT06458946|EXPERIMENTAL|Fourth product order: order not stated to protect study blinding|Participant will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7-day wash-out period before beginning the next product in the sequence
62425843|NCT04379973|EXPERIMENTAL|Tubal flush with Lipiodol Ultra Fluide® after Hyfosy|
62425844|NCT04379973|NO_INTERVENTION|No tubal flush after Hyfosy|
62425845|NCT02176642|ACTIVE_COMPARATOR|Oxybutynin plus PTNS|Oxybutynin extended release (blinded tablet) 5mg by mouth daily for 6 weeks, Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.
62811164|NCT06458946|EXPERIMENTAL|Fifth product order: order not stated to protect study blinding|Participant will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7-day wash-out period before beginning the next product in the sequence
62594164|NCT03316469|EXPERIMENTAL|Group A: CC & ovulation|AMH level is measured before Clomiphene citrate 100 mg daily for 5 days \& detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels.
62594165|NCT03316469|EXPERIMENTAL|Group B: CC & no ovulation|AMH level is measured before Clomiphene citrate 100 mg daily for 5 days \& detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels.
62811165|NCT06458946|EXPERIMENTAL|Sixth product order: order not stated to protect study blinding|Participant will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7-day wash-out period before beginning the next product in the sequence
62594166|NCT00669643|ACTIVE_COMPARATOR|R-MDT PB|R-MDT PB group: standard/regular treatment recommended by WHO - All patients presenting fewer than 6 skin lesions will receive the standard treatment regimen for paucibacillary patients as the intervention; Intervention - PB 6 doses of rifampicin and dapsone
62811166|NCT05111860|EXPERIMENTAL|Group 1|
62811167|NCT04210648|EXPERIMENTAL|Intervention group|Those who will use the mobile app
62811168|NCT04210648|NO_INTERVENTION|Non-intervention group|Those who will not use the mobile app
62811169|NCT04219774|EXPERIMENTAL|Endovascular arm|Subjects meet all inclusion criteria and were randomized to intervention
62811170|NCT04219774|ACTIVE_COMPARATOR|Medical arm|Subjects meet all inclusion criteria and were randomized to best medical management
62811171|NCT04219774|ACTIVE_COMPARATOR|Non-Randomized Arm|Subject meets all inclusion criteria EXCEPT abnormal CTP. Subjects are not randomized and are eligible for only best medical management
62811172|NCT03922581|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy|Participants randomized to this study arm will receive Mindfulness-Based Cognitive Therapy (MBCT) for 8 weeks.
62811173|NCT03922581|NO_INTERVENTION|Wait-list Control Group|Participants randomized to the wait-list control study arm will be administered the study assessments while not receiving active treatment. Participants will be given the opportunity to participate in the MBCT intervention following completion of the study assessments.
62811174|NCT00831961||1|Patients randomized to gatifloxacin (Zymar)
62811175|NCT00831961||2|Patients randomized to moxifloxacin (Vigamox)
62811176|NCT00831961||3|Patients randomized to ofloxacin (Ocuflox)
62594167|NCT00669643|EXPERIMENTAL|U-MDT PB|U-MDT PB group: a unified treatment for all patients - All patients presenting fewer than 6 lesions (WHO PB) will receive 6 doses of rifampicin, clofazimine and dapsone as the intervention; Intervention - PB 6 doses of rifampicin, clofazimine and dapsone
62594168|NCT00669643|EXPERIMENTAL|R-MDT MB|R-MDT MB group: standard/regular treatment recommended by WHO - All patients presenting 6 skin or more lesions will receive the standard treatment regimen for multibacillary patients as the intervention; Intervention - MB 12 doses of rifampicin, clofazimine and dapsone
62811177|NCT00831961||4|Patients randomized to azithromycin (AzaSite)
62811178|NCT05946655|EXPERIMENTAL|Antibiotic therapy|Women with infertility diagnosed with CE undergoing empirical antibiotic therapy
62594169|NCT00669643|EXPERIMENTAL|U-MDT MB|U-MDT MB group: a unified treatment for all patients - All patients presenting 6 lesions or more (WHO MB) will receive 6 doses of rifampicin, clofazimine and dapsone as the intervention; Intervention - MB 6 doses of rifampicin, clofazimine and dapsone
62811179|NCT05946655|NO_INTERVENTION|Control|Women with infertility diagnosed with CE not subjected to empirical antibiotic therapy
62811180|NCT02016781|ACTIVE_COMPARATOR|Transplant|Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT)
62811181|NCT02016781|ACTIVE_COMPARATOR|Hypomethylating Therapy / Best Supportive Care|The specific non-transplant treatment regimen will be at the discretion of the treating physician.
62811182|NCT03712943|EXPERIMENTAL|Regorafenib and Nivolumab Combination - Escalation|Dose Escalation: To find the dose of regorafenib that can be safely given with nivolumab in patients with advanced, refractory colorectal cancers.
62811183|NCT03712943|EXPERIMENTAL|Regorafenib and Nivolumab Combination - Expansion|Dose Expansion: To find the effect on tumor of the combination of regorafenib and nivolumab.
62811184|NCT04958824|EXPERIMENTAL|Immediate return of results|The intervention for this study is the delivery of genetic test results that reflect pharmacokinetic and pharmacodynamic effects of specified genetic markers. We will use the Sanford panel being promoted by the VA through a clinical project entitled PHASER. The results are returned to the patient and provider approximately 1 week from randomization.
62811185|NCT04958824|NO_INTERVENTION|Delayed return of results|In the control arm the genetic test results are not returned until 12 weeks when the main outcome is assessed.
62811186|NCT02937337|EXPERIMENTAL|Videostylet|Laryngeal mask airway insertion using video stylet guided technique
62811187|NCT02937337|ACTIVE_COMPARATOR|Blind|Laryngeal mask insertion using standard index finger-guided technique
62811188|NCT00432484|PLACEBO_COMPARATOR|1|Placebo with Lingzhi(Granoderma Lucidum) and Sen Miao San
62811189|NCT03853330|ACTIVE_COMPARATOR|Thoracic Epidural Analgesia group|25 patients will receive ultrasound-guided thoracic epidural analgesia for multiple fracture ribs at the level of T8 with 7.5-12 ml of Bupivacaine HCl Inj 0.25% as a loading dose followed by catheter insertion and infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h. For breakthrough pain bolus of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution 5-10 ml can be used.
62811190|NCT03853330|ACTIVE_COMPARATOR|Erector spinae plane block group|25 patients will receive ultrasound-guided ESP block for multiple fracture ribs at the level from T1 to T5 with 7.5-12 ml of Bupivacaine HCl Inj 0.25% as a loading dose followed by catheter insertion and infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h. For breakthrough pain bolus of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution 5-10 ml can be used.
62811191|NCT05441826|EXPERIMENTAL|VB119|VB119 100 or 200mg IV doses administered 4 times
62034746|NCT02052505|EXPERIMENTAL|Medication review|The patients will receive the usual care when admitted. This includes an examination by a physician, a medication review and the physician will prescribe medications for the patients as well as other necessary interventions. Following this (usual care) a trained nurse will perform a medication review and discuss the observations with a physician.
62234914|NCT05121363|EXPERIMENTAL|TQB2858 injection + Anlotinib Hydrochloride capsules|"TQB2858 injection: once every 3 weeks, 1800mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.~Anlotinib Hydrochloride capsules: once a day,12mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur."
62594170|NCT04141891|EXPERIMENTAL|Driving Decision Aid|Web-based Driving Decision Aid
62811192|NCT04393675|ACTIVE_COMPARATOR|LT5001|Administered twice daily (maximum 6 g per time, morning and evening respectively)
62811193|NCT04393675|PLACEBO_COMPARATOR|Placebo|Administered twice daily (maximum 6 g per time, morning and evening respectively)
62234915|NCT03581201||Oral contraception|Healthy females at childbearing age with oral contraception.
62234916|NCT03581201||No contraception|Healthy females without any contraception at all.
62234917|NCT02208154|ACTIVE_COMPARATOR|Standard care|"Standard infection prevention measurements will be implemented before the baseline period and carried out throughout the entire trial. They consist of:~* Chlorhexidine 2% body washings (CHX-BW) for all ICU patients. The face and neck of the patient will not be cleansed with Chlorhexidine to prevent irritation of the eyes and face.~* A hand hygiene improvement program (HHIP) based on the program designed by the World Health organisation (WHO).~* Standard oropharyngeal care consists of oral washing with sterile water (3-4 times daily) and tooth brush twice daily."
62234918|NCT02208154|EXPERIMENTAL|Chlorhexidine oral care (CHX-Oro)|Chlorhexidine digluconate oromucosal gel 1%, 2cm, to be administered 4 times daily, during invasive mechanical ventilation.
62425846|NCT02176642|PLACEBO_COMPARATOR|Placebo plus PTNS|Placebo (blinded tablet) taken daily for 6 weeks. Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.
62425847|NCT01327209||Patients with diabetes|
62425848|NCT02949778|ACTIVE_COMPARATOR|Ropivacaine 3.75mg/mL|QL-block using 20 mL ropivacaine 3.75mg/mL
62425849|NCT02949778|PLACEBO_COMPARATOR|Sodium chloride 9 mg/mL|QL-block using 20 mL sterile sodium chloride 9 mg/mL
62425850|NCT06218888|EXPERIMENTAL|Tislelizumab combined with fruquintinib and Chidamide|The treatment option for the chidamide + tislelizumab +fruquibtinib is 200 mg of tislelizumab IV Drip Q3W, 30 mg of chidamide PO BIW, and fruquibtinib 3mg PO Q3W until loss of clinical benefit or development of intolerable toxicity
62425851|NCT01174368|EXPERIMENTAL|Cancer macrobeads|Cancer Macrobead placement in abdominal cavity
62425852|NCT02917928|ACTIVE_COMPARATOR|Intervention|Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
62425853|NCT02917928|PLACEBO_COMPARATOR|Control|Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
62425854|NCT02955810|EXPERIMENTAL|CyBorD-DARA|
62425855|NCT04088734|EXPERIMENTAL|ABO-102|Dose of 3x10\^13 vg/kg
62425856|NCT02440100|EXPERIMENTAL|Multiple Doses PF-06648671 (Cohort1)|Healthy subjects receive 14-day repeated dose once a day at 4 mg of PF-06648671 or matching placebo
62234919|NCT02208154|EXPERIMENTAL|Selective oropharyngeal decontamination|Selective oropharyngeal decontamination (SOD) mouth paste containing colistin and tobramycin in a 2% concentration and nystatin 1 x 10\^5 units, dosage 0.5g , to be administered 4 times daily during the entire period of invasive mechanical ventilation.
62425857|NCT02440100|EXPERIMENTAL|Multiple Doses PF-06648671 (cohort 2)|Healthy subject receive 14-day repeated dose once a day at 12 mg of PF-06648671 or matching placebo
62425858|NCT02440100|EXPERIMENTAL|Multiple doses PF-06648671 (cohort 3)|Healthy subject receive 14-day repeated dose once a day at 40 mg of PF-06648671 or matching placebo and CSF LP is collected at baseline and steady state predose on day 1 and 14
62425859|NCT02440100|EXPERIMENTAL|Multiple Doses PF-06648671 (cohort 4)|Healthy subject receive 14-day repeated dose once a day at 40 mg of PF-06648671 or matching placebo
62425860|NCT02440100|EXPERIMENTAL|Multiple Doses PF-06648671 (cohort 5)|Healthy subject receive 14-day repeated dose once a day at 100 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 15, 24 hours after last dosing on day 14
62425861|NCT02440100|EXPERIMENTAL|Multiple Doses in Healthy Elderly (cohort 7)|Healthy Elderly subjects receive 14-day repeated dose once a day at MTD PF-06648671 defined in healthy adult subjects (part 1)
62425862|NCT02440100|EXPERIMENTAL|Multiple Doses PF-06648671 (cohort 8)|Healthy subjects receive 14-day repeated dose once a day at 360 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 15, 24 hours post last dose
62425863|NCT02440100|EXPERIMENTAL|Midazolam DDI (optional cohort 9)|Healthy Subjects receive single dose of 2 mg midazolam in period 1 followed by 14 days PF-06648671 once a day and coadministration of PF-06648671 and midazolam 2 mg in period 2 (Optional cohort)
62811194|NCT01909895|EXPERIMENTAL|Anger induction|The participant will be asked to undergo a validated anger induction task.
62811195|NCT01909895|EXPERIMENTAL|Depressed Mood Induction|The participant will be asked to undergo a validated depression/sadness induction task.
62594171|NCT04141891|ACTIVE_COMPARATOR|Older Drivers Website|National Institute on Aging (NIA) Older Drivers website
62594172|NCT04946942|EXPERIMENTAL|Caregiver Checklist (CHEC)|CHEC is composed of two elements: 1) a checklist to identify the needs and concerns of unpaid/family caregivers who accompany older adults (aged 65+) to their primary care visits and 2) Tip Sheet for clinicians.
62594173|NCT04946942|ACTIVE_COMPARATOR|Usual care|Attendance at primary care appointments as usual.
62811196|NCT01909895|EXPERIMENTAL|Anxiety Induction|The participant will be asked to undergo a validated anxiety induction task.
62234920|NCT02208154|EXPERIMENTAL|Selective digestive decontamination|Selective digestive decontamination (SDD), suspension via the nasogastric tube containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10\^6 i.u., dosage 10ml, to be administered together with SOD (see above) 4 times daily during entire period of mechanical ventilation.
62425864|NCT02440100|EXPERIMENTAL|Multiple Doses PF-06648671 (cohort 6)|Healthy subject receive 14-day repeated dose once a day at 200 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 25, 24 hours after last dosing on day 14
62425865|NCT01678924|EXPERIMENTAL|AGN-214868 Dose 1|AGN-214868 Dose 1 given as injections into the area of pain on Day 1.
62425866|NCT01678924|EXPERIMENTAL|AGN-214868 Dose 2|AGN-214868 Dose 2 given as injections into the area of pain on Day 1.
62425867|NCT01678924|PLACEBO_COMPARATOR|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
62425868|NCT01678924|EXPERIMENTAL|AGN-214868 Dose 3|AGN-214868 Dose 3 given as injections into the area of pain on Day 1.
62425869|NCT04449588|EXPERIMENTAL|Treatment group|
62425870|NCT04449588|EXPERIMENTAL|Control group|
62425871|NCT02624349|ACTIVE_COMPARATOR|Transplant|Intervention: Quadravalent human papillomavirus vaccine 0.5ml intramuscular injection at 0, 2, and 6 months and/or post administration antibody titers as described in methods
62425872|NCT02624349|ACTIVE_COMPARATOR|Control|Intervention: Quadravalent human papillomavirus vaccine 0.5ml intramuscular injection at 0, 2, and 6 months and/or post administration antibody titers as described in methods
62425873|NCT06515366||MAP ≤ 65 mmHg|patient having heart failure symptoms with known heart failure and presenting to emergency department with a mean arterial pressure ≤ 65 mmHg
62425874|NCT06515366||MAP 66-80 mmHg|patient having heart failure symptoms with known heart failure and presenting to emergency department with a mean arterial pressure between 66-80 mmHg
62425875|NCT06515366||MAP 81-100 mmHg|patient having heart failure symptoms with known heart failure and presenting to emergency department with a mean arterial pressure between 81-100 mmHg
62425876|NCT06515366||MAP >100 mmHg|patient having heart failure symptoms with known heart failure and presenting to emergency department with a mean arterial pressure between \>100 mmHg
62425877|NCT01818037||Microphthalmos with congenital cataract|72 eyes of 36 patients with microphthalmos who underwent bilateral congenital cataract surgery between January 2003 and June 2008.
62425878|NCT01547637|EXPERIMENTAL|Ultrasound Guided|Ultrasound guided obturator nerve block will be performed after induction of general anesthesia. The anterior and posterior divisions of the obturator nerve will be identified with ultrasound. A stimulating needle will be inserted under direct ultrasound visualization. The anterior division will be blocked first. When adductor twitches are present at less than or equal to 0.5 mA, 10 ml of 2% lidocaine will be injected. Next, the needle will be re-directed under direct ultrasound visualization towards the posterior branch of the obturator nerve. After twitches \< 0.5 mA are achieved then 10 mL of 2% lidocaine will be injected when the needle tip is visualized in proximity of the posterior branch.
62425879|NCT01547637|EXPERIMENTAL|Anatomic landmark|Obturator nerve block will be performed after induction of general anesthesia. The adductor magnus tendon approach will be used. A 4 cm insulated stimulating needle will be used to verify location of the obturator nerve by contraction of the thigh adductor group. The needle will be advanced until nerve stimulation is still present at less than or equal to 0.5 mA. When the appropriate nerve stimulation is achieved 10 ml of 2% lidocaine will be injected in divided doses with frequent aspiration. Nerve conduction studies will be repeated once a minute for the first 10 minutes after block completion.
62425880|NCT03801018||Parents who have used the donation of gametes|
62425881|NCT03801018||Children born of gametes donation|
62425882|NCT03430089|EXPERIMENTAL|Group 1: 6 to 35 months|Shz QIV 0.25 mL, 2 doses
62811197|NCT01909895|OTHER|Neutral emotion task|The participant will be asked to undergo a validated neutral task (i.e. count aloud by ones, starting with one and ending with 100, over and over, until the task period has ended).
62425883|NCT03430089|EXPERIMENTAL|Group 2: 3 to 8 years|Shz QIV 0.5 mL, 2 doses
62425884|NCT03430089|EXPERIMENTAL|Group 3: 9 to 17 years|Shz QIV 0.5 mL, single dose
62234921|NCT04508322|ACTIVE_COMPARATOR|Group 1|Early treatment HGA (9 years)
62425885|NCT03430089|EXPERIMENTAL|Group 4: 18 to 60 years|Shz QIV 0.5 mL, single dose
62425886|NCT03430089|EXPERIMENTAL|Group 5: 61 years and older|Shz QIV 0.5 mL, single dose
62811198|NCT00888693|EXPERIMENTAL|1|ABT-288 vs placebo capsules administered orally once daily for 14 days
62234922|NCT04508322|ACTIVE_COMPARATOR|Group 2|Late treatment HGA (11 years)
62234923|NCT04508322|ACTIVE_COMPARATOR|Group 3|Treatment FA
62425887|NCT06375954|ACTIVE_COMPARATOR|ERCP with SEMS|"Endoscopic retrograde cholangiopancreatography (ERCP) with deployment of a self-expandable metallic stent (SEMS). Gold standard in malignant distal biliary obstruction (MDBO) in current practice.~ERCP technique: Cannulation with papillotome (advanced cannulation techniques are allowed). Sphincterotomy. Self-expandable metallic stent (SEMS) deployment."
62594174|NCT00923182|EXPERIMENTAL|Alemtuzumab|The starting dose of alemtuzumab was 3 mg. The dose was gradually escalated on a daily basis (3 mg, 10 mg, and then 30 mg) until the patient tolerated a dose of 30 mg IV infusion over 2 hours. All subsequent doses of alemtuzumab were 30 mg IV 3 times a week (every other day).
62811199|NCT00888693|EXPERIMENTAL|2|ABT-288 vs placebo capsules administered orally once daily for 14 days
62811200|NCT00888693|EXPERIMENTAL|3|ABT-288 vs placebo capsules administered orally once daily for 14 days
62811201|NCT00888693|EXPERIMENTAL|4|ABT288 vs placebo administered orally once daily for 14 days
62811202|NCT00888693|EXPERIMENTAL|5|ABT-288 vs placebo administered orally once daily for 14 days
62811203|NCT00888693|EXPERIMENTAL|6|ABT-288 vs placebo administered orally once daily for 14 days
62234924|NCT04721093|EXPERIMENTAL|PBM(Photobiomodulation)|Subjects applied PBM(Color-DNA-WSF U, Color Seven; 610 nm±10nm wavelength; 3.0 mW/㎠±20%) therapy in the locations of the sternocleidomastoid muscle in the ICA area and the trapezius muscle in VA area. PBM was applied 5 times a week for 8 weeks, 30 minutes per session.
62234925|NCT02376075|PLACEBO_COMPARATOR|Placebo|Placebo, tablets, administered once daily as add on to pre-existing antihypertensive treatment
62811204|NCT00888693|EXPERIMENTAL|7|ABT-288 vs placebo administered orally once daily for 14 days
62034747|NCT01571505|EXPERIMENTAL|IPV vaccination|Randomized IPV vaccination to children at the age of 39 weeks.
62234926|NCT02376075|ACTIVE_COMPARATOR|Linagliptin|Linagliptin, tablets containing 5 mg, administered once daily as add on to pre-existing antihypertensive treatment
62811205|NCT00888693|EXPERIMENTAL|8|ABT-288 vs placebo administered orally once daily for 14 days
62811206|NCT00888693|EXPERIMENTAL|9|ABT-288 vs placebo administered orally once daily for 14 days
62234927|NCT01037881|EXPERIMENTAL|LEO 29102 0.03 mg/g cream|
62234928|NCT01037881|EXPERIMENTAL|LEO 29102 0.1 mg/g cream|
62234929|NCT01037881|EXPERIMENTAL|LEO 29102 0.3 mg/g cream|
62234930|NCT01037881|EXPERIMENTAL|LEO 29102 1.0 mg/g cream|
62234931|NCT01037881|EXPERIMENTAL|LEO 29102 2.5 mg/g cream|
62234932|NCT01037881|PLACEBO_COMPARATOR|LEO 29102 cream vehicle|
62234933|NCT01037881|ACTIVE_COMPARATOR|Elidel® cream (pimecrolimus) 10 mg/g|
62425888|NCT06375954|EXPERIMENTAL|EUS-CDS with LAMS-Pigtail|"Echoendoscopy-guided Choledochoduodenostomy (EUS-CDS) with deployment of a lumen-apposing metal stent (LAMS) and axis-orienting double-pigtail plastic stent throug LAMS.~EUS-CDS technique: Diagnostic EUS. Classic or free-hand with preloaded guidewire choledochoduodenostomy with LAMS. Pneumatic dilation whithin LAMS is allowed. In case of bile duct \< 15mm is mandatory the 'push' technique. Deployment of a pigtail coaxial to LAMS."
62811207|NCT06523296|EXPERIMENTAL|Adults with Alzheimer's disease|
62811208|NCT06523296|EXPERIMENTAL|Adults with Myasthenia|
62234934|NCT00769860|ACTIVE_COMPARATOR|1|Arimoclomol
62811209|NCT06523296|EXPERIMENTAL|healthy volonteer|
62034748|NCT01571505|PLACEBO_COMPARATOR|OPV vaccination|Randomized OPV vaccination to children at the age of 39 weeks.
62034749|NCT06137261|EXPERIMENTAL|Participants randomized to HF screening|"Active screening on HF and its risk factors, using anamnesis, physical examination, an ECG, blood tests and an echocardiogram.~After 1 year follow-up, both participants randomized to standard care and to screening for HF will be approached. Participants will be asked whether they have had an unplanned hospital admission for HF. Also, in all participants an echocardiogram will be acquired. Finally, participants will be asked to fill-out the HR-QoL with the EQ-5D-5L questionnaire."
62234935|NCT00769860|PLACEBO_COMPARATOR|2|
62811210|NCT06082206|EXPERIMENTAL|TPVB Group|Bupivacaine 0.25% 20 ml was injected between the costotransverse ligament and the parietal pleura.
62811211|NCT06082206|EXPERIMENTAL|PECS Group|bupivacaine 0.25% 10 ml
62811212|NCT06150950|EXPERIMENTAL|Cardiac rehabilitation|For patient randomized to cardiac rehabilitation, the ACHD clinician will place the referral after they and the patient have seen the group assignment. All participants will be referred to Heart Fit for Life community-based cardiac rehabilitation program in Palo Alto, CA. Cardiac rehabilitation will be offered as an in-person, hybrid, or completely virtual program for Stanford participants and will be entirely virtual for Vanderbilt participants. Participants will attend 3 sessions per week for 12 weeks. Participants will receive weekly email reminders via the electronic medical record to encourage participation. The study protocol pertains only to referral to cardiac rehabilitation. All other aspects of the cardiac care will be at the discretion of clinicians. All study participants will receive a Fitbit for daily activity tracking.
62811213|NCT06150950|ACTIVE_COMPARATOR|Usual care|For patients randomized to the usual care (no cardiac rehabilitation group), cardiac rehabilitation will not be initiated between randomization and for up to 16 weeks following randomization. The study protocol controls only referral to cardiac rehabilitation. All other aspects of the cardiac care, such as titration of guideline directed medical therapy will be at the discretion of clinicians. All study participants will receive a Fitbit for daily activity tracking.
62234936|NCT01384422|EXPERIMENTAL|GLPG0634 100 mg bid oral capsules|
62234937|NCT01384422|EXPERIMENTAL|GLPG0634 200 mg qd oral capsules|
62234938|NCT01384422|PLACEBO_COMPARATOR|Placebo oral capsules|
62234939|NCT02451241|SHAM_COMPARATOR|sham acupuncture|group will be submitted to placebo electroacupuncture for 20 minutes, two times a week for 5 weeks. Each session lasts about 40 min.
62234940|NCT02451241|EXPERIMENTAL|acupuncture|group will be submitted to electroacupuncture for 20 minutes, two times a week for 5 weeks. Each session lasts about 40 min.
62234941|NCT01177605|PLACEBO_COMPARATOR|Vanilla flavored milk-based beverage containing no prebiotics|Vanilla flavored milk-based beverage containing no prebiotics
62234942|NCT01177605|EXPERIMENTAL|Vanilla flavored milk-based beverage containing prebiotics|Vanilla flavored milk-based beverage containing prebiotics
62243187|NCT03913481|EXPERIMENTAL|ANH|Best available treatments plus ANH, performed withdrawing a volume of blood before the CPB. The volume will be personalized for every patient, but it'll be at least 650ml.
62243188|NCT03913481|OTHER|Standard care|No ANH
62243189|NCT05802394|EXPERIMENTAL|MRD-guided|Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will receive a later-line therapy.
62234943|NCT02742766|EXPERIMENTAL|Part 1 - GSK3008356 single dose and multiple doses|Healthy subjects will receive GSK3008356 in morning as single dose or multiple doses of 5 milligrams (mg), 10 mg, 30 mg,45 mg, 75 mg, 90 mg, 125, 180 mg, 200 mg, 250 mg total daily dose or matching placebo in eleven sequential cohorts while receiving a standard fat meal. The initial dosing for the first cohort will be staggered so that 2 subjects will be dosed as sentinel subjects. Provided there are no safety concerns, the remainder of the subjects scheduled for the cohort may be dosed. Eight subjects will be enrolled in each cohort.
62234944|NCT02742766|EXPERIMENTAL|Part 2 - GSK3008356 14 day repeat dose|Healthy subjects will receive GSK3008356 or matching placebo, as 14 daily doses in the three sequential cohorts. Subjects in cohort 1 will receive their daily dose in morning, while subjects in cohort 2 and cohort 3 will receive their daily dose in evening. In all the three cohorts, Day 1 and day 14 dosing will occur while receiving a standard fat meal in morning. Eight subjects will be enrolled in each cohort.
62234945|NCT02742766|EXPERIMENTAL|Part 3 - GSK3008356 28 day repeat dose|Obese subjects will receive GSK3008356 or matching placebo, as 28 daily doses in the three parallel cohorts. Cohort 1 will evaluate 1 dose strength of GSK3008356 (or matching placebo) administered as morning doses. Cohorts 2 and 3 will evaluate 2 dose strengths (1 per cohort) of GSK3008356 (or matching placebo) administered in the evening. Ten subjects will be enrolled in each cohort.
62234946|NCT05708963||U.K. Embryologists|U.K. embryologists of all ages, career levels, and other sociodemographic groups will be asked questions about their physical and mental health related to their occupational characteristics using the nationally validated surveys and questionnaires, and also about their working conditions in the ART/IVF laboratories using a custom occupational questionnaire and the single-item work unit grade (A-F).
62234947|NCT03891303||Transfused group (TR)|Group received allogenic blood transfusion (ABT) alongside with autologous blood from intraoperative cell saver (ICS) during elective open abdominal aortic surgery.
62234948|NCT03891303||Non-transfused (non-TR)|Group received only autologous blood from intraoperative cell saver (ICS) during elective open abdominal aortic surgery.
62234949|NCT00528892|EXPERIMENTAL|1|Switch current boosted-PI to raltegravir 400 mg BID.
62234950|NCT00528892|ACTIVE_COMPARATOR|2|Continue current regimen (ritonavir-boosted PI plus at least 2 other drugs)
62234951|NCT04854733||Referees|There will be no interventions. Motor and cognitive assessments will be conducted.
62425889|NCT03457337|EXPERIMENTAL|S-1 plus Gefitinib|"S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally, continuous administration of 14 days, rest for 7 days. BSA \<1.25 m2, 80 mg / day; BSA 1.25 m2 to \<1.5 m2, 100 mg / day; BSA 1.5 m2 or more, 120 mg / day. Until disease progression, intolerance of toxicity or withdrawal of informed consent from the subject.~Gefitinib: 250mg, 1 day, orally, fasting or with the same service. Until disease progression, intolerance of toxicity or withdrawal of informed consent from the subject."
62594175|NCT02123615|EXPERIMENTAL|Gadolinium For abdomen|"Gadolinium For abdomen Total Persistent % subdermally, For abdomen Total Persistent % subcutaneously, and For abdomen Relative Prolongation Ability Score.~Gadolinium Magnevist® (gadopentetate dimeglumine)~1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg), subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
62594176|NCT02123615|EXPERIMENTAL|Gadolinium For lower back|"1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg), subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.~Gadolinium For lower back Total Persistent % subdermally, For lower back Total Persistent % subcutaneously, and For lower back Relative Prolongation Ability Score."
62594177|NCT02123615|EXPERIMENTAL|subjects (%) of any infections|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
62811214|NCT02021565|EXPERIMENTAL|Immediate Intervention Group|"Receives the in-home training intervention immediately after completing the baseline assessment.~The intervention includes three home visits from an AT Specialist (Occupational or Physical Therapist) who observes the dyad perform three ADL transfers, provides recommendations, equipment, home modifications, training, and follow-up training as needed."
62234952|NCT04854733||Athletes|There will be no interventions. Motor and cognitive assessments will be conducted.
62811215|NCT02021565|OTHER|Delayed Intervention Control Group|Receives the in-home training intervention six weeks after completing the initial baseline assessment. This allows for a control comparison group while still providing the intervention to all participants.
62811216|NCT05189743|EXPERIMENTAL|Dermis graft|
62234953|NCT06493591||Subgroup: GP ablation|"Participants underwent thoracoscopic AF ablation with additional GP ablation as the intervention group in the AFACT study.~PVI with additional left atrial ablation lines was performed and conduction block was verified.~No additional intervention will be perforemd in this study. All study procedures will be the same for the two subgroups."
62234954|NCT06493591||Subgroup: No GP ablation|"Participants underwent thoracoscopic AF ablation as the control group in the AFACT study.~PVI with additional left atrial ablation lines was performed and conduction block was verified.~No additional intervention will be perforemd in this study. All study procedures will be the same for the two subgroups."
62234955|NCT04945590|EXPERIMENTAL|Latino/Hispanic Virtual Intervention Program|Latino/Hispanic individuals will participate in culturally tailored virtual intervention program following a community-based collaborative design.
62234956|NCT02342743|EXPERIMENTAL|Active|Daily trigeminal nerve stimulation session of 20 minutes with CEFALY
62234957|NCT01412099|EXPERIMENTAL|Feedback report plus peer counseling|
62234958|NCT01412099|EXPERIMENTAL|Feedback report|
62234959|NCT05519163||Patients with type 2 diabetes|Patients with type 2 diabetes who were hospitalized in The First Affiliated Hospital of Shandong First Medical University \& Shandong Provincial Qianfoshan Hospital between January 1, 2016 and December 31, 2021.
62425890|NCT03457337|ACTIVE_COMPARATOR|Gefitinib|Gefitinib 250 mg/day oral daily
62811217|NCT05189743|EXPERIMENTAL|STSG|
62811218|NCT06413602|EXPERIMENTAL|AIH alone|Participants will undergo 30 minutes of AIH.
62811219|NCT06413602|EXPERIMENTAL|NMES alone|Participants will undergo repetitive common peroneal nerve stimulation for up to 30 minutes.
62234960|NCT00655486|EXPERIMENTAL|Lacosamide|Lacosamide 100 to 800 mg/day, flexible dosing, administered twice daily throughout the duration of the study (up to 2 years)
62811220|NCT06413602|EXPERIMENTAL|Combined AIH and NMES|Participants will undergo 30 minutes of AIH. Immediately following, participants will undergo NMES for up to 30 minutes.
62811221|NCT06118385|EXPERIMENTAL|Part A Dose 1|Part A Dose 1 Single dose of 2 mg BEN8744
62034750|NCT06137261|NO_INTERVENTION|Participants randomized to standard care|"Participants randomized to standard care will not undergo any tests related to the study at baseline.~After 1 year follow-up, both participants randomized to standard care and to screening for HF will be approached. Participants will be asked whether they have had an unplanned hospital admission for HF. Also, in all participants an echocardiogram will be acquired. Finally, participants will be asked to fill-out the HR-QoL with the EQ-5D-5L questionnaire."
62034751|NCT00657618|EXPERIMENTAL|Treatment only|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with Sodium Stibogluconate (SSG).
62034752|NCT04232423|EXPERIMENTAL|OLN 0-5-10|Placebo tablet in chemotherapy cycle 1, olanzapine 5 mg tablet in chemotherapy cycle 2, and olanzapine 10 mg tablet in chemotherapy cycle 3
62811222|NCT06118385|EXPERIMENTAL|Part A Dose 2|Part A Dose 2 Single dose of 6 mg BEN8744
62034753|NCT04232423|EXPERIMENTAL|OLN 5-10-0|Olanzapine 5 mg tablet in chemotherapy cycle 1, olanzapine 10 mg tablet in chemotherapy cycle 2, and placebo tablet in chemotherapy cycle 3
62034754|NCT04232423|EXPERIMENTAL|OLN 10-0-5|Olanzapine10 tablet in chemotherapy cycle 1, placebo tablet in chemotherapy cycle 2, and olanzapine 5 mg tablet in chemotherapy cycle 3
62034755|NCT03030300|EXPERIMENTAL|Novolin 30R;Pioglitazone;Metformin|Drugs: Insulin (Novolin 30R) monotherapy or combined with one or two oral drugs (metformin 0.5 mg tid and pioglitazone hydrochloride 15 mg qd).
62034756|NCT05317234|EXPERIMENTAL|children with cerebral palsy|Patients between 2 and 15 years old, born after 34 weeks' gestation, with a diagnosis of cerebral palsy.
62034757|NCT01262651|EXPERIMENTAL|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligram \[mg\]/milliliter \[mL\]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
62034758|NCT01262651|PLACEBO_COMPARATOR|Placebo (GA-0034)|Placebo Comparator: Placebo (GA-0034) Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol: propylene glycol (50:50)
62034759|NCT01248338|ACTIVE_COMPARATOR|metoprolol, tablets|metoprolol succinate 50-100 mg orally daily for one year
62034760|NCT01248338|EXPERIMENTAL|nebivolol|nebivolol 5 mg capsule once daily for one year
62234961|NCT02787954||Transcatheter Chemoembolization or TACE|A technique called transcatheter chemoembolization (TACE) is used for some patients with liver cancer that cannot be treated surgically. The procedure is a way of delivering cancer treatment directly to a tumor through minimally-invasive means.
62811223|NCT06118385|EXPERIMENTAL|Part A Dose 3|Part A Dose 3 Single dose of 20 mg BEN8744
62034761|NCT05166408|OTHER|Buccinator myomucosal flap for primary cleft repair|Study group
62034762|NCT05166408|OTHER|Bardach two flap palatoplasty for primary cleft repair|Control group
62034763|NCT05972629|EXPERIMENTAL|SAR444836|Participants will receive a single dose of SAR444836 on Day 1
62034764|NCT01348867|NO_INTERVENTION|Usual Care|These 120 controls will undergo a comprehensive assessment at baseline then again at 12 months, which is similar to the intervention group. However, in between these 2 time points the 'control' patients will receive usual care and hence will not be monitored under the structured care protocol by a diabetes nurse consultant led team.
62425891|NCT04334330|EXPERIMENTAL|Treatment group|
62243190|NCT05802394|NO_INTERVENTION|Routine treatment|Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will continued their current therapy.
62811224|NCT06118385|EXPERIMENTAL|Part A Dose 4|Part A Dose 4 Single dose of 60 mg BEN8744
62811225|NCT06118385|EXPERIMENTAL|Part A Dose 5|Part A Dose 5 Single dose of 100 mg BEN8744
62811226|NCT06118385|EXPERIMENTAL|Part A Dose 6|Part A Dose 6 Single dose of 120 mg BEN8744
62234962|NCT02787954||Yittrium 90 or Y-90|Radioembolization is a minimally invasive procedure that combines embolization and radiation therapy to treat liver cancer. Tiny glass or resin beads filled with the radioactive isotope yttrium Y-90 are placed inside the blood vessels that feed a tumor. This blocks the supply of blood to the cancer cells and delivers a high dose of radiation to the tumor while sparing normal tissue.
62811227|NCT06118385|EXPERIMENTAL|Part A placebo|Part A placebo Single dose of placebo
62811228|NCT06118385|EXPERIMENTAL|Part B Dose 1 fed|Part B Dose 1 Fed Single dose of BEN8744 after high-fat meal (Dose 30mg QD)
62811229|NCT06118385|EXPERIMENTAL|Part B Dose 1 Fasted|Part B Dose 1 Fasted Single dose of BEN8744 after 10 hours fasting (Dose 30mg QD)
62811230|NCT06118385|EXPERIMENTAL|Part B Dose 2 Fed|Part B Dose 2 Fed Single dose of BEN8744 after high-fat meal (Dose 50mg QD)
62234963|NCT02787954||Microwave Ablation or MWA|Microwave ablation (MWA), destroys liver tumors using heat generated by microwave energy. A CT scan or ultrasonic guidance is used to pinpoint the exact location of the tumor. A thin antenna, which emits microwaves, is then inserted into the tumor. The probe produces intense heat that ablates (destroys) tumor tissue, often within 10 minutes.
62234964|NCT02787954||electroporation|Irreversible electroporation (IRE) is a nonthermal method of destroying the cell. A cell is subjected to a powerful electrical field using high-voltage direct current (up to 3 kV); this creates multiple holes in the cell membrane and irreversibly damages the cell's homeostasis mechanism, leading to instant cell death.
62234965|NCT02366377|EXPERIMENTAL|SHR3824 Placebo|SHR3824 Placebo , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
62234966|NCT02366377|EXPERIMENTAL|SHR3824 5 mg|SHR3824 5 mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
62234967|NCT02366377|EXPERIMENTAL|SHR3824 10 mg|SHR3824 10 mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
62234968|NCT02366377|EXPERIMENTAL|SHR3824 20 mg|SHR3824 20mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
62234969|NCT04102306||Temporomandibular disorder group (TMD)|"Patients with temporomandibular disorder coming at the Cabinet Saint Alexandre for orofacial rehabilitation.~Test 1: passation of the KVIQ questionnaire, followed by the passation of the TMIQ during a rehabilitation session supervised by the physical therapist (PT) Test 2: passation of the TMIQ during the next rehabilitation session supervised by the same PT(interval between PT session 1 and 2 is a maximum of 45 days).~Questionnaires were performed during the course of the patient rehabilitation that was instructed not to perform imagined movement during the interval."
62234970|NCT04102306||Control healthy group (CTL)|"Healthy individuals with no temporomandibular disorder (i.e., no orofacial medical consultation or rehabilitation) aged-matched and gender-matched to TMD group.~Test 1: passation of the KVIQ questionnaire, followed by the passation of the TMIQ during a session supervised by the physical therapist (PT) Test 2: passation of the TMIQ during the next session supervised by the same PT(interval between PT session 1 and 2 is a maximum of 8 days).~Questionnaires were performed with no additional rehabilitation and participants were instructed not to perform imagined movement during the interval."
62234971|NCT02215460|EXPERIMENTAL|Full-mouth scaling (FMS)|
62234972|NCT02215460|EXPERIMENTAL|FMS chlorhexidine rinse|
62234973|NCT02215460|EXPERIMENTAL|FMS azithromycin tablets|
62234974|NCT02215460|PLACEBO_COMPARATOR|FMS placebo rinse|
62234975|NCT02215460|EXPERIMENTAL|Quadrant scaling (QS)|
62234976|NCT02215460|EXPERIMENTAL|QS chlorhexidine rinse|
62234977|NCT02215460|EXPERIMENTAL|QS azithromycin tablets|
62234978|NCT02215460|PLACEBO_COMPARATOR|QS placebo tablets|
62234979|NCT02215460|PLACEBO_COMPARATOR|FMS placebo tablets|
62234980|NCT02215460|PLACEBO_COMPARATOR|QS placebo rinse|
62234981|NCT03376607|EXPERIMENTAL|Intervention group 1|Intervention group 1 will receive access to the newly-established HBCP programme.
62234982|NCT03376607|EXPERIMENTAL|Intervention group 2|Intervention group 2 will receive access to the newly-established HBCP programme, and facilitated access to a mobile health application.
62234983|NCT03376607|NO_INTERVENTION|Control group|The control group will receive routine practice.
62234984|NCT04025723|ACTIVE_COMPARATOR|Young|men aged between 18 to 30 years old
62425892|NCT02559531|EXPERIMENTAL|Intervention group|EMS providers will evaluate computerized clinical scenarios using a mobile triage device
62425893|NCT01030276|EXPERIMENTAL|Bright light|
62425894|NCT01030276|PLACEBO_COMPARATOR|"Inactive placebo-light"|
62425895|NCT05413902|EXPERIMENTAL|MMA Protocol Group|"Preoperative Medications~1. Orphenadrine 100mg PO once preop~2. Gabapentin 800mg PO once preop~3. Toradol 60mg IV once preop~4. Acetaminophen 1,000mg PO once preop~Intraoperative Paraspinal Infusion~1. Bupivacaine 30cc~2. Epinephrine 1cc~3. Xylocaine-MPF Intramuscular Inj 0.5% (30cc of Saline Solution)~Postoperative Medications~1. Orphenadrine 100mg PO BID~2. Gabapentin 300mg PO Q6~3. Toradol 30mg IV Q6hrs\*~4. Methylprednisolone 125mg Q8hrs"
62594178|NCT02123615|EXPERIMENTAL|Annual rate of any infections|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
62594179|NCT02123615|EXPERIMENTAL|subjects (%) with Antibiotic use|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
62594180|NCT02123615|EXPERIMENTAL|Annual rate with Antibiotic use|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
62594181|NCT02123615|EXPERIMENTAL|subjects (%) with Days out of work|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
62811231|NCT06118385|EXPERIMENTAL|Part B Dose 2 Fasted|Part B Dose 2 Fasted Single dose of BEN8744 after 10 hours fasting (Dose 50mg QD)
62811232|NCT06118385|EXPERIMENTAL|Part C Dose 1|Part C Dose 1 14 daily doses of BEN8744 (Dose 30mg BID)
62811233|NCT06118385|EXPERIMENTAL|Part C Dose 2|Part C Dose 2 14 daily doses of BEN8744 (Dose 50mg BID)
62425896|NCT05413902|ACTIVE_COMPARATOR|Control (opioids) Group|"Postoperative Medication~1-Morphine 4mg Q4hrs"
62425897|NCT06568250|EXPERIMENTAL|Intervention|
62425898|NCT02528422|ACTIVE_COMPARATOR|50 µg Acyl-Ghrelin|Intravenous injection on examination day.
62425899|NCT02528422|ACTIVE_COMPARATOR|100 µg Acyl-Ghrelin|Intravenous injection on examination day.
62811234|NCT06118385|EXPERIMENTAL|Part C placebo|Part C placebo 14 daily doses of placebo
62425900|NCT02528422|PLACEBO_COMPARATOR|Isotonic Sodium Chloride|Intravenous injection on examination day.
62234985|NCT04025723|ACTIVE_COMPARATOR|Middle-aged|men aged between 35 to 50 years old
62425901|NCT02036827|ACTIVE_COMPARATOR|moderate NMB + standard pressure|Investigators will administrate rocuronium until moderate neuromuscular blockade (Train of Four \>=1, Post-tetanic count\>=8) is established. And pneumoperitoneum will be maintained with standard-pressure 14 mmHg.
62811235|NCT04760756|EXPERIMENTAL|This refers to Fragility Fracture Integrated Rehabilitation Management|This refers to Fragility Fracture Integrated Rehabilitation Management and will include comprehensive rehabilitation program and assessment
62811236|NCT04756765|EXPERIMENTAL|Talazoparib Arm|Talazoparib 1 mg/day for 24 cycles (28 days per cycle), continuing until withdrawn or discontinued, eg, until RECIST 1.1 progression or unacceptable toxicity.
62811237|NCT01755364|EXPERIMENTAL|AdimFlu-V|
62811238|NCT01994642|ACTIVE_COMPARATOR|Reference|CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)
62811239|NCT01994642|PLACEBO_COMPARATOR|Placebo|Placebo Sterile Otic Suspension
62243191|NCT02764164|EXPERIMENTAL|Intervention Active tDCS|Affected subjects receiving up to 2 milliamps (mA) active tDCS, open label
62243192|NCT01807923|PLACEBO_COMPARATOR|Placebo|Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.
62243193|NCT01807923|EXPERIMENTAL|LUM 600 mg qd/IVA 250 mg q12h|LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.
62425902|NCT02036827|ACTIVE_COMPARATOR|deep NMB + standard pressure|Investigators will administrate rocuronium until deep neuromuscular blockade (Train of Four=0, Post-tetanic count\<=3) is established. And pneumoperitoneum will be maintained with standard-pressure 14 mmHg.
62425903|NCT02036827|ACTIVE_COMPARATOR|deep NMB + low pressure|Investigators will administrate rocuronium until deep neuromuscular blockade (Train of Four=0, Post-tetanic count\<=3) is established. And pneumoperitoneum will be maintained with standard-pressure 8 mmHg.
62234986|NCT05610748|EXPERIMENTAL|Sub-Periosteal Peri-implant Augmented Layer (SPAL) technique simultaneous to implant placement|In patients assigned to the SPAL group, the management of the soft tissues will be performed according to the SPAL technique as originally described by Trombelli et al. (2018). Implant site preparation will be performed using a set of calibrated guided surgery steel burs under copious sterile saline irrigation. Implants will be placed, and a healing abutment will be positioned and screwed. The space underneath the periosteal layer will be then filled with a deproteinized bovine bone mineral (DBBM) graft. A sterile viscoelastic gel (SVG) based on polynucleotides and hyaluronic acid (REGENFAST®, Mastelli Srl, Sanremo, Italia) will be combined with the bone graft. The periosteal layer will be then secured to the oral flap by mean of 6/0 resorbable internal mattress sutures. SVG wil be placed underneath the mucosal layer and the latter will be coronally advanced and stabilized a using 6/0 resorbable internal mattress and sling sutures.
62425904|NCT01382134|PLACEBO_COMPARATOR|Placebo group|Subjects will be given placebo daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15 microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.
62425905|NCT01382134|ACTIVE_COMPARATOR|Aspirin group|Subjects will be given aspirin 100mg daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.
62425906|NCT06057909||Lewy Body Disease Group|Subjects identified by their physician with a diagnosis of Lewy body disease will have a physical and neurological exam, MRI of brain, electroencephalography (EEG), and electromyography (EMG).
62425907|NCT06057909||Alzheimer Disease Group|Subjects identified by their physician with a diagnosis of Alzheimer will have a physical and neurological exam, MRI of brain, electroencephalography (EEG), and electromyography (EMG).
62243194|NCT01807923|EXPERIMENTAL|LUM 400 mg q12h/ IVA 250 mg q12h|LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.
62425908|NCT06057909||Healthy Control Group|Subjects identified as a health individual will have a physical and neurological exam, MRI of brain, electroencephalography (EEG), and electromyography (EMG).
62425909|NCT01966341|ACTIVE_COMPARATOR|Routine Management|All patients will be given a prescription for the use of antispasmodics. If patients demonstrate symptoms consistent with constipation predominant IBS they will be treated with laxatives. If symptoms are more consistent with diarrhea predominant IBS they will be treated with bulking agents (fiber) +/- antibiotics. Patient will be called every week while enrolled in the study in order to titrate doses, and answer questions.
62425910|NCT01966341|EXPERIMENTAL|CBT/ Hypnotherapy|The CBT (cognitive behavior therapy) program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
62425911|NCT03633019|EXPERIMENTAL|high-dose rhTPO|rhTPO (300-600U/kg/day), ih, until the platelets increased by 50 x 109/L compared to the baseline or above 100 x 109/L
62425912|NCT02364219|NO_INTERVENTION|Standard|"Study arm in which patients are treated according to standard operating procedures. Acting as control arm."
62425913|NCT02364219|EXPERIMENTAL|Standard + Microdialysis|Study arm in which patients are treated according to standard operating procedures but also receive Microdialysis through a small catheter which is inserted into subcutaneous upper arm fatty tissue.
62425914|NCT02364219|EXPERIMENTAL|Prewarm|Study arm in which patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.
62425915|NCT02364219|EXPERIMENTAL|Prewarm + Microdialysis|Study arm in which patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia and Microdialysis through a small catheter which is inserted into subcutaneous upper arm fatty tissue
62425916|NCT06150131|EXPERIMENTAL|Treatment group|Supervised exercise one session per week, un-supervised exercise two sessions per week, for tree months, followed by three months without organized exercise.
62243195|NCT00497601|EXPERIMENTAL|A|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 and 3
62425917|NCT06150131|OTHER|Control group|Three months without organized exercise, followed by the same exercise as the Treatment group for three months.
62425918|NCT01315054|OTHER|Control arm|Using currently practiced methadone dosage prescription methods
62425919|NCT01315054|EXPERIMENTAL|MMT provider dosage training|Intensive health care provider training on prescribing methadone dosage based on national guidelines
62425920|NCT01315054|EXPERIMENTAL|MMT provider dosage training/counseling|Intensive health care provider training on prescribing methadone dosage, plus providing on-site psychosocial counseling services and peer support to clients .
62425921|NCT01963221|OTHER|fluodeoxyglucose (18f)|
62425922|NCT01732198|EXPERIMENTAL|NU300 and Prevnar 13|NU300 at a single dose of 0.5 mL IM
62425923|NCT01732198|ACTIVE_COMPARATOR|ActHIB and Prevnar 13|ActHIB at a dose of 0.5 ml IM
62425924|NCT02532140|EXPERIMENTAL|WCK 5107|A single administration of the investigational product will be administered intravenously in 7 SAD cohorts at different dose level . The SAD cohorts will enroll 10 subjects ( 8 on active drug and 2 on placebo)
62425925|NCT02532140|EXPERIMENTAL|WCK 5107 1000 mg and Cefepime 2000 mg|In the crossover cohorts (WCK 5107 and cefepime, both alone and in combination), 9 subjects will receive all 3 treatments.
62811240|NCT01994642|EXPERIMENTAL|Test|Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension
62811241|NCT00701285|ACTIVE_COMPARATOR|1|strong statin
62811242|NCT00701285|ACTIVE_COMPARATOR|2|mild statin
62811243|NCT05165160|EXPERIMENTAL|Eligible patients|
62234987|NCT05610748|ACTIVE_COMPARATOR|Soft Tissue Augmentation (STA) simultaneous to implant placement|In patients assigned to the STA group, flap management will be performed as described by Stefanini et al. (2016). Implant site preparation will be performed according to the same procedures described for the SPAL group. SVG will be placed underneath the buccal flap and the latter will be then released from tension by means of periosteal and muscular incisions, and will be coronally advanced and adapted to the healing abutment with a 6/0 resorbable sling suture. Interrupted sutures will be used to accomplish primary intention closure in the interproximal areas.
62811244|NCT03041688|EXPERIMENTAL|Treatment (decitabine, navtemadlin, venetoclax)|"Patients receive decitabine IV over 1 hour on days 1-10, navtemadlin PO QD on days 1-7, and venetoclax PO QD on days 1-21. Treatment repeats every 28 days for up to 4 cycles in patients with evidence of persistent AML.~Starting cycle 2, patients with no morphologic evidence of AML receive decitabine IV over 1 hour on days 1-5, navtemadlin PO QD on days 1-7, and venetoclax PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients also undergo bone marrow aspiration and biopsy, and blood sample collection throughout the trial."
62811245|NCT03212898|EXPERIMENTAL|Intervention|Specific pharmacist-led anticoagulation care
62425926|NCT02532140|EXPERIMENTAL|WCK 5107 2000 mg and Cefepime 2000 mg|In the crossover cohorts (WCK 5107 and cefepime, both alone and in combination), 9 subjects will receive all 3 treatments.
62425927|NCT05678218||Presumed resectable perihilar, intrahepatic or mid-common bile duct (CBD) cholangiocarcinoma|
62811246|NCT03212898|NO_INTERVENTION|Control|The control group will receive usual care; no interventions will be administered.
62811247|NCT00435916|EXPERIMENTAL|1|
62811248|NCT00651924|NO_INTERVENTION|Phase 1|Review the materials and provide feedback regarding how understandable, engaging, and informative the materials are
62811249|NCT00651924|EXPERIMENTAL|Phase 2|Piloting the 'IVR-based Cognitive-behavior therapy' using the new materials
62811250|NCT00748995||Neurocognition Deployment Health Study (NDHS) participants|Surviving NDHS participants who returned from their initial deployment to Iraq or Afghanistan.
62034765|NCT01348867|EXPERIMENTAL|Structured Care|"120 patients will be randomised to the structured care group, and these patients will receive repeated follow-ups and contact with the structured care team in between the two comprehensive assessments at week 0 and week 52.~Patients will be seen by Diabetes Nurse Consultant at week 0, 6, 12, 24 38 during the year. At each visit, clinical and laboratory measurements will be performed; treatment compliance and self care will be assessed and medications will be adjusted to optimise metabolic and cardiovascular risk factors control.~Patients will be seen by the doctors in their clinic follow up at week 0, 24 and 52.~Technical service assistance will telephone patient at week 18, 30 and 44 to reinforce patient to take medications, attend clinical follow up."
62034766|NCT05652517|ACTIVE_COMPARATOR|Fluoroscopy-guided VOMEI|Vein of Marshall ethanol infusion guided by fluoroscopy alone
62234988|NCT03493711||Breast Fed|Exclusively breastfed for first 3 months of life
62425928|NCT02313519|PLACEBO_COMPARATOR|Placebo|Capsules of powdered glucose polymer given one capsule every 12 hours for 15 days
62425929|NCT02313519|ACTIVE_COMPARATOR|Probiotics|Capsules containing Lactobacillus acidophilus LA-5 \[1.75x10\^9 cfu\], Lactobacillus plantarum \[0.5x10\^9 cfu\], Bifidobacterium lactis BB-12 \[1.75x10\^9cfu\], and Saccharomyces boulardii \[1.5x10\^9\] per capsule. One capsule is given every 12 hours for 15 days
62425930|NCT05595174|ACTIVE_COMPARATOR|group 1|"Patient with self-ligating bracket system split mouth with and without micro-osteoperforations.~Extraction of first premolars were done. A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment."
62811251|NCT00534326|ACTIVE_COMPARATOR|1|Standard Reaming of femoral shaft fracture prior to intramedullary nailing
62811252|NCT00534326|ACTIVE_COMPARATOR|2|Reamer/Irrigator/Aspirating of femoral shaft fracture prior to intramedullary nailing
62234989|NCT03493711||Milk-based formula fed|Exclusively on Similac Advance Formula for at least 1 month prior to visit
62425931|NCT05595174|ACTIVE_COMPARATOR|group 2|"Patient with conventional bracket with split mouth with and without micro-osteoperforations.~Extraction of first premolars were done. A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment."
62425932|NCT02337426|EXPERIMENTAL|Treatment (dimethyl fumarate, temozolomide, radiation therapy)|"CONCOMITANT THERAPY: Between 21 days (3 weeks) and 42 days (6 weeks) following the last surgical procedure, patients receive temozolomide PO QD for 42-49 days and dimethyl fumarate PO BID or TID continuously. Patients also undergo radiation therapy 5 days a week over 6 weeks for a total of 30 fractions~MAINTENANCE THERAPY: Patients continue to receive dimethyl fumarate PO BID or TID continuously. Four weeks after completing concomitant temozolomide and radiation therapy, patients also receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity."
62425933|NCT06251323|EXPERIMENTAL|Wave 1 Clinics|Clinics will have data evaluated for up to 3 years. Wave 1 clinics will begin the iPATH practice transformation in Year 1.
62425934|NCT06251323|EXPERIMENTAL|Wave 2 Clinics|Clinics will have data evaluated for up to 3 years. Wave 2 clinics will begin the iPATH practice transformation in Year 2.
62811253|NCT03128515|EXPERIMENTAL|MTD Dose Escalation|Maximum tolerated dose of Hydroxyurea, 25-30 mg/kg/day
62811254|NCT03128515|ACTIVE_COMPARATOR|Fixed Dose|Fixed dose of Hydroxyurea, 20 mg/kg/day
62811255|NCT04426734|EXPERIMENTAL|Dextenza|"Sustained Released 0.4 mg Dexamethasone intracanalicular insert in both upper and lower punctum.~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"
62811256|NCT04426734|ACTIVE_COMPARATOR|Topical Pred Forte 1%|"Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of~8x/day week 1 4x/day week 2 2x/day week 3~1x/day week 4~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"
62811257|NCT02263469|EXPERIMENTAL|Replenine®-VF|
62811258|NCT03900494|ACTIVE_COMPARATOR|Children treated with VHC 1|In this group children are receiving salbutamol with valved holding chamber number 1. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria. We only compare the efficacy of the two VHC devices.
62234990|NCT01295281|EXPERIMENTAL|LoFric POBE 2.0 - PVC|First period (7 days) use of LoFric POBE 2.0 followed by second period (7 days) use of LoFric PVC
62234991|NCT01295281|EXPERIMENTAL|LoFric PVC - POBE 2.0|First period (7 days) use of LoFric PVC followed by second period (7 days) use of LoFric POBE 2.0.
62425935|NCT02221583|EXPERIMENTAL|Group 1|Astagraf XL + Mycophenolate mofetil then cross over to Prograf + Mycophenolate
62594182|NCT02123615|EXPERIMENTAL|Annual rate with Days out of work|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
62811259|NCT03900494|ACTIVE_COMPARATOR|Children treated with VHC 2|In this group children are receiving salbutamol with valved holding chamber number 2. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria. In this group children are receiving salbutamol with valved holding chamber number 1. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria.
62811260|NCT00297219|ACTIVE_COMPARATOR|2|high dialysate calcium
62811261|NCT00297219|ACTIVE_COMPARATOR|1|low dialysate calcium
62811262|NCT06435208|EXPERIMENTAL|PERIODONTITIS BRUXISM|subgingival instrumentation will be done in all participants
62425936|NCT02221583|EXPERIMENTAL|Group 2|Prograf + Mycophenolate mofetil then cross over to Astagraf XL + Mycophenolate
62811263|NCT04346095|EXPERIMENTAL|Oral Sedative|"Participants will receive oral triazolam 30 minutes prior to surgery.~Dose for BMI less than 35: 0.125 mg~Dose for BMI greater than or equal to 35: 0.25 mg~Followed by topical proparacaine and 6 cc sub-tenon's mixture of lidocaine and marcaine.~Vitals will monitored by the operating room nurses."
62425937|NCT02268188|EXPERIMENTAL|Supportive Care (Harvesting Health program)|Participants undergo a series of 10 education and training sessions over 1 hour every 2 weeks, comprising education on current research, evidence-based health guidelines, application techniques, reference materials specific to extended-stage cancer survivors, and recommendations and personal health goals for survivorship. The guidelines described in class are part of a nutrition intervention and an exercise intervention with personal and group goal setting over the course of the study.
62234992|NCT02404974|EXPERIMENTAL|Exercise|This is a single arm pilot study. All participants who answer yes to interest in exercise question on the web-based osteoarthritis preference tool will be included in the exercise intervention. After completing baseline measures, they will be put in contact with the Fitness Instructor and follow the protocol described.
62425938|NCT04641754|EXPERIMENTAL|WX-0593 Tablets|60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 21-days cycle.
62425939|NCT01096407||Paclitaxel-Induced Myalgias/Arthralgias|
62594183|NCT02123615|EXPERIMENTAL|(%) with hospitalized infections|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
62594184|NCT02123615|EXPERIMENTAL|Annual rate hospitalized infections|Annual rate hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
62811264|NCT04346095|ACTIVE_COMPARATOR|Intravenous Sedative|"This group will receive an intravenous sedative. The sedative is limited to midazolam, fentanyl, propofol.~Follow by topical proparacaine and 6 cc sub-tenon's mixture of lidocaine and marcaine.~IV and monitoring will be performed by anesthesiologist or CRNA."
62811265|NCT00461617|ACTIVE_COMPARATOR|2|Nateglinide 120 mg TID
62234993|NCT04740008|EXPERIMENTAL|Control message on low nicotine cigarettes|
62234994|NCT04740008|EXPERIMENTAL|Test message on low nicotine cigarettes|
62243196|NCT00497601|EXPERIMENTAL|B|Amphotericin B in fat emulsion (Amphomul) 10 mg/kg on day 1 and 5 mg/kg on day 3
62243197|NCT00497601|EXPERIMENTAL|C|Amphotericin B in fat emulsion (Amphomul) 12.5 mg/kg on day 1 and 2.5 mg/kg on day 3
62243198|NCT00497601|EXPERIMENTAL|D|Amphotericin B in fat emulsion (Amphomul) 15 mg/kg in a single dose administration on day 1
62425940|NCT03996382|OTHER|Suspicion of cardiac amyloidosis|Patients who display signs of cardiac amyloidosis will be referred for further diagnosis.
62234995|NCT06078280|EXPERIMENTAL|Study Group|"The study group will use the CardioPulmonary Management (CPM) device daily for 6 months (beginning at visit 1 and ending at visit 2). The ADI (Analog Devices, Inc) triaging team will monitor the CPM device data and call the patient as indicated by the data.~The ADI care team will then forward the device data and patient symptomology collected to the patient's care team where that team will device if intervention is necessary. The patient's care team will also have access to view device data at any time using the CPM website."
62234996|NCT06078280|NO_INTERVENTION|Control Group|The control group will not receive a device and will continue their normal standard of care.
62234997|NCT01917019|PLACEBO_COMPARATOR|Part A Placebo|Part A: All participants will receive placebo orally twice daily for the first 2 weeks and then be randomized to receive prolonged-release fampridine 10 mg or matching placebo tablets orally twice daily for up to 14 weeks.
62594185|NCT02123615|EXPERIMENTAL|Adverse Injection Local Reactions|Adverse Injection Local Reactions as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
62811266|NCT03441438|ACTIVE_COMPARATOR|Control|Patients without asthma or aspirin intolerance who may or may not react to alcoholic beverages
62234998|NCT01917019|EXPERIMENTAL|Part A prolonged-release fampridine|Part A: All participants will receive placebo orally twice daily for the first 2 weeks and then be randomized to receive prolonged-release fampridine 10 mg or matching placebo tablets orally twice daily for up to 14 weeks.
62243199|NCT00819286|ACTIVE_COMPARATOR|wire (control)|patients will have their sternum closed using wire (stainless steel surgical wire).
62034767|NCT05652517|EXPERIMENTAL|UNIVU-guided VOMEI|Vein of Marshall ethanol infusion guided by CARTO UNIVU and fluoroscopy
62034768|NCT05777642|EXPERIMENTAL|Oxygen Nanobubble First|"In this arm, the oxygen nanobubbles drink will be provided as the first drink. The oxygen nanobubbles mixture will be mixed with water and oxygenated and provided as a one-time 200ml drink 10 minutes before the start of the 2000m row.~The placebo will be provided as the second drink, 2-4 days after the first drink. The placebo mixture will be mixed with water and oxygenated and provided as a one-time 200ml drink 10 minutes before the start of the 2000m row."
62034769|NCT05777642|PLACEBO_COMPARATOR|Placebo First|"In this arm, the placebo drink will be provided as the first drink. The placebo mixture will be mixed with water and oxygenated and provided as a one-time 200ml drink 10 minutes before the start of the 2000m row.~The oxygen nanobubbles will be provided as the second drink, 2-4 days after the first drink. The oxygen nanobubbles mixture will be mixed with water and oxygenated and provided as a one-time 200ml drink 10 minutes before the start of the 2000m row."
62594186|NCT02123615|EXPERIMENTAL|Adverse Reactions Headache|Headache as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
62034770|NCT03138148||Severe patient-ventilator asynchrony|Patients in whom the total percentage of time spent in asynchrony is superior to the entire cohort's 75th percentile
62811267|NCT03441438|ACTIVE_COMPARATOR|Aspirin Tolerant Asthma|Patients with asthma who are tolerant to aspirin and/or other NSAIDs and note sensitivity to alcoholic beverages
62234999|NCT01917019|EXPERIMENTAL|Part B prolonged-release fampridine|Part B: Eligible participants will receive open label treatment with prolonged-release fampridine 10mg orally twice daily for up to 52 weeks.
62235000|NCT01917019|EXPERIMENTAL|Part C prolonged-release fampridine|Part C: Eligible participants will receive open label treatment with prolonged-release fampridine 10mg orally twice daily until marketed product is available.
62811268|NCT03441438|ACTIVE_COMPARATOR|Aspirin Intolerant Asthma / AERD|Patients with AERD who note sensitivity to alcoholic beverages
62811269|NCT04770532|EXPERIMENTAL|Insulin icodec|Insulin icodec + non-insulin anti-diabetic drugs. Pre-trial non-insulin anti-diabetic background medication throughout the entire trial except from sulfonylureas and glinides, which must be discontinued at randomisation. The background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period.
62425941|NCT03001856|EXPERIMENTAL|Oblique Intradermal Suture|OIS is very similar to conventional interrupted intradermal suture (IS), except that the suture in OIS is canted or angled relative to the vertical plane (Figure 1). To perform OIS, the needle is passed from deep to superficial dermis and canted 30°-60° from the normal vertical plane. The needle is then inserted into the opposite wound edge from superficial to deep dermis in a mirror-image fashion. The thread is tied with a square knot to finish the suture.
62425942|NCT03001856|EXPERIMENTAL|Intradermal Suture|Conventional interrupted intradermal suture
62034771|NCT03138148||less severe patient-ventilator asynchrony|Patients in whom the total percentage of time spent in asynchrony is inferior to the entire cohort's 75th percentile
62235001|NCT03329443|PLACEBO_COMPARATOR|placebo|
62235002|NCT03329443|ACTIVE_COMPARATOR|Spironolactone|
62235003|NCT00669799|EXPERIMENTAL|1|clyndamyacin
62235004|NCT00669799|EXPERIMENTAL|2|gentamicin
62235005|NCT00621647|EXPERIMENTAL|1|1st fixed dose
62235006|NCT00621647|EXPERIMENTAL|2|2nd fixed dose
62235007|NCT00621647|SHAM_COMPARATOR|3|Placebo
62811270|NCT04770532|ACTIVE_COMPARATOR|Insulin degludec|Insulin degludec + non-insulin anti-diabetic drugs. Pre-trial non-insulin anti-diabetic background medication throughout the entire trial except from sulfonylureas and glinides, which must be discontinued at randomisation. The background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period.
62811271|NCT05072418||Children with dyslexia|
62811272|NCT05072418||Non-dyslexic children|
62235008|NCT00984763|EXPERIMENTAL|Group 1|AMA1-C1/Alhydrogel® + CPG 7909 vaccine given twice two months apart followed by malaria parasite challenge
62811273|NCT06302582|EXPERIMENTAL|Platelet-rich plasma (PRP) combined with human umbilical cord mesenchymal stem cells (huMSCs)|Inject 3ml PRP+huMSCs (5 × 106) into the edge and bottom of the wound, with 0.5 ml at each point and a distance of approximately 1-3 cm between each point. Then, apply autologous PRP gel (PRP+thrombin mixture, 2ml) evenly on the wound, with a thickness of about 2mm.
62235009|NCT00984763|NO_INTERVENTION|Group 2|Control: malaria parasite challenge without prior vaccinations
62594187|NCT02123615|EXPERIMENTAL|Adverse Reactions Fever|Fever as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
62235010|NCT00046085|ACTIVE_COMPARATOR|Patient customary care|12 months of patient customary care
62811274|NCT06302582|OTHER|Control group|Standard therapy
62425943|NCT03608696|EXPERIMENTAL|buprenorphine|"Buprenorphine 0.075 mg ml sublingual solution~Initial daily dose 24 mcg/kg/day Initial unit dose 8 mcg/kg q8 hours Maximum daily dose 75 mcg/kg/day Maximum unit dose 25 mcg/kg q8 hours Up-titration rate 33% Maximum # of up-titrations 4 Weaning rate 15% Cessation (bottom) dose \< Initial dose Dosing interval until bottom dose (hrs) 8 Dose interval extension #1 at bottom dose (hrs) 12 Dose interval extension #2 at bottom dose (hrs) 24"
62594188|NCT02123615|EXPERIMENTAL|Adverse Reactions Nausea|Nausea as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
62594189|NCT02123615|EXPERIMENTAL|Adverse Reactions Vomiting|Vomiting as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
62594190|NCT02123615|EXPERIMENTAL|Adverse Reactions Fatigue|Fatigue as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
62034772|NCT04454866|PLACEBO_COMPARATOR|Control group|For patients in the control group, a dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron 10 mg, diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
62235011|NCT00046085|EXPERIMENTAL|Online family education|12 months of patient customary care and relative access to online education and support program
62235012|NCT05283304|EXPERIMENTAL|Injectable Buprenorphine (BUP-inj)|Following successful titration to 16 mg of daily sublingual buprenorphine, the participants will then transition to injectable buprenorphine (300 mg dose) every 4 weeks
62235013|NCT05283304|PLACEBO_COMPARATOR|Injectable Placebo (PBO-inj)|Following successful titration to 16 mg of daily sublingual buprenorphine, the participants will then transition to injectable placebo (300 mg dose) every 4 weeks.
62425944|NCT03918395|PLACEBO_COMPARATOR|Placebo|Placebo beverage
62425945|NCT03918395|ACTIVE_COMPARATOR|Protein-Polyphenol supplement|Protein-polyphenol beverage
62425946|NCT06520878|EXPERIMENTAL|NANO-PSO|640 mg of NANO-PSO (pomegranate seed oil)
62425947|NCT06520878|PLACEBO_COMPARATOR|Mineral oil|640 mg of mineral oil
62811275|NCT04604145|OTHER|Positive NP results|SARS-CoV-2 testing on self-collected saliva specimens, associated with a positive NP result, using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system
62811276|NCT04604145|OTHER|Negative NP results|SARS-CoV-2 testing on self-collected saliva specimens, associated with a negative NP result, using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system
62811277|NCT01936571||NSCLC|The cohort consists of approximately 250 patients. As a rule of thumb 5-10 events per variable are needed to avoid overfitting a model. To model 6 clinical variables + 9 biomarker variables 75-150 events are needed. Assuming a two-year survival of 40%, the calculated (constant) hazard rate is 0.46 per year. With an inclusion rate of 50 patients per year, and a follow-up time varying between 0.5 and 4 year, at the time of analysis (November/December 2013) it is expected that there will be 138 events available for analysis.
62235014|NCT03629587||Patients presented H pylori positive|Upper endoscopy, Gastric biopsy, CBC, VITAMIN B12 level, iron studys, folic acid level, bone marrow aspirate
62235015|NCT03629587||Patients with H pylori negative|Upper endoscopy, Gastric biopsy, CBC, VITAMIN B12 level, iron studys, folic acid level, bone marrow aspirate
62811278|NCT02990026|EXPERIMENTAL|Treatment|Specialty mental health probation - delivered by probation officers who receive specialized training and ongoing clinical consultation with a licensed mental health professional and who have reduced caseloads of exclusively mentally ill offenders.
62811279|NCT02990026|ACTIVE_COMPARATOR|Control|Standard probation - delivered by a standard probation officer - care as usual
62235016|NCT01071525|ACTIVE_COMPARATOR|Niacin|Hypercholesterolemic patients with high-density lipoprotein (HDL) less than 40 mg% will receive Niacin\\Laropiprant.
62235017|NCT01071525|NO_INTERVENTION|Control|Maching subjects will receive no medication, Blood tests will be drawn for laboratory tests.
62235018|NCT01303263|OTHER|Intervention Group|Residents Randomized to Receive Educational Intervention
62235019|NCT01303263|NO_INTERVENTION|Control Group|Residents randomized not to receive a teaching intervention.
62235020|NCT04189237|EXPERIMENTAL|electroacupuncture|"At the 4th week after surgery, electroacupuncture was performed, and the activity of wrist joint on the affected side was performed at same time, and at a frequency of two times per week for six weeks, for a total of twelve times.~Acupoint selection: needles were inserted to Taixi (KI3), Taichong (LR3), Zusanli(ST36), Yanglingquan (GB34), contralateral to the operated leg and deqi sensation elicited at acupoints."
62235021|NCT04189237|NO_INTERVENTION|Control group|At the 4th week after surgery, only the activity of wrist joint on the affected side was performed, and at a frequency of two times per week for six weeks, for a total of twelve times.
62235022|NCT05620251||COVID-19 infection-naive adolescents with type 1 diabetes|
62235023|NCT05620251||COVID-19 infection-naive healthy controls|
62235024|NCT00604864|EXPERIMENTAL|1|women with a deep endometriosis nodule of at least 1 cm in diameter; and severe pain (at least one severe pain score on Biberoglu Behrman scale)
62235025|NCT00604864|PLACEBO_COMPARATOR|2|women with a deep endometriosis nodule of at least 1 cm in diameter; and severe pain (at least one severe pain score on Biberoglu Behrman scale)
62235026|NCT01208688|EXPERIMENTAL|FES Therapy|FES Therapy
62235027|NCT01208688|ACTIVE_COMPARATOR|Conventional Occupational Therapy|The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
62425948|NCT02106117||neutropenic patients|Patients receiving treatment for hematological malignancies expected to result in prolonged neutropenia (neutrophil counts \<0.5 x 10 \^9/L for more than seven days).
62594191|NCT02123615|EXPERIMENTAL|Adverse Reactions Diarrhea|Diarrhea as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
62811280|NCT04419831||Healthy volunteers|community volunteers
62811281|NCT04419831||Binge Heavy drinkers|Individuals who report regular binge alcohol intake and hazardous drinking levels
62811282|NCT04419831||Cannabis Use Disorder|Individuals with cannabis use disorder
62811283|NCT04419831||Alcohol Use Disorder|Individuals with alcohol use disorder
62235028|NCT01159379|EXPERIMENTAL|ertapenem, tolerance tests|Patients with IgE-mediated allergy to beta-lactams
62235029|NCT00279773|EXPERIMENTAL|TKI258 - dose escalation|Dose-Escalation
62235030|NCT00279773|EXPERIMENTAL|TKI258 - dose expansion|Dose-Expansion
62811284|NCT04419831||Individuals with Moderate to Severe Pain|Individuals with chronic pain
62811285|NCT04419831||Opioid Use Disorder in medication assisted treatment|Individuals with opioid use disorder
62811286|NCT02745171|NO_INTERVENTION|Control group|This group will be evaluated after three months there will be a reassessment, in this case the participating subjects do not perform any kind of therapy.
62235031|NCT06383520|EXPERIMENTAL|PET imaging targeting GPC3 in hepatocellular carcinoma|Determine if targeting GPC3 PET is safe and effective method for imaging of hepatocellular carcinoma
62594192|NCT02123615|EXPERIMENTAL|Adverse Reactions Asthma|Asthma as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
62235032|NCT03774160|EXPERIMENTAL|Generacion Actual|Generacion Actual includes Community-based and a Health Systems Components. This multi-level intervention reaches out to all MSM/trans by mobilizing them to encourage friends to reduce risk behavior and increase HIV testing, and for HIV+ friends, encourage them to link, stay in care, and take medications regularly. The community based component includes a leadership group, community space, community mobilization events, and group sessions to address a variety of psychosocial issues as well as HIV literacy. The Health Systems component includes sensitization of the HIV testing and care staff to working with MSM and trans, Navigators to help MSM/trans to navigate the complex health system; and positive prevention training of providers; all evidence-based approaches.
62235033|NCT03774160|NO_INTERVENTION|Comparison|No intervention is implemented in the comparison arm.
62235034|NCT04771611|EXPERIMENTAL|Treatment Group|Subjects will receive treatment drug Fisetin
62235035|NCT04771611|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo
62235036|NCT03349892|EXPERIMENTAL|Stereotactic Ablation Treatment Arm|This is a single-arm, non-blinded study.
62235037|NCT00452088|EXPERIMENTAL|1|15 microgramme candidate vaccine group
62235038|NCT00452088|ACTIVE_COMPARATOR|2|Hepatitis B comprator group
62235039|NCT00452088|EXPERIMENTAL|3|30 microgrammes candidate vaccine group
62235040|NCT00452088|ACTIVE_COMPARATOR|4|Hepatitis B vaccine group
62235041|NCT06306885|EXPERIMENTAL|AOMI-sleep|Observation and imagination of video-clips with motor contents before sleeping
62235042|NCT06306885|ACTIVE_COMPARATOR|AOMI-control|Observation and imagination of video-clips with motor contents in the morning
62235043|NCT06306885|SHAM_COMPARATOR|Control|Observation and imagination of landscapes video-clips
62235044|NCT03532412||HF+CSA+PB|Systolic heart failure with predominant central sleep apnea and periodic breathing
62425949|NCT04288115|ACTIVE_COMPARATOR|"Levothyroxine group (sham discontinuation)"|Continue the current dose of levothyroxine. The brand of levothyroxine to be used in this study will be Synthroid tablets of 25 mcg, 50 mcg, and 75 mcg (AbbVie Inc).
62594193|NCT02123615|EXPERIMENTAL|Adverse Reactions Oropharyngeal|Oropharyngeal as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
62235045|NCT02975024||Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement and quantitative determination of VEGF after mandibular vestibuloplasty. Individuals of this pre-defined group are candidates of vestibuloplasty, where the keratinized gingiva will be enlarged by a combination of apically repositioned split thickness flap with a xenogeneic collagen matrix (Mucograft).
62235046|NCT02975024||strip gingival graft + Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement and quantitative determination of VEGF after mandibular vestibuloplasty. Individuals of this pre-defined group are candidates of vestibuloplasty, where the keratinized gingiva will be enlarged by a combination of apically repositioned split thickness flap with a strip gingival graft and a xenogeneic collagen matrix (Mucograft). The strip gingival graft is harvested from the patient's palate.
62235047|NCT02690558|EXPERIMENTAL|pembrolizumab, gemcitabine and cisplatin|There is one arm in this study. Subjects will receive Pembrolizumab 200mg IV on day 1 in combination with cisplatin 35mg/m2 and gemcitabine 1000mg/m2 on day 1 and day 8 every 3 weeks for 4 cycles over 12 weeks.
62235048|NCT02019888||Normal hearing adults|Adults between 20 and 79 years old with hearing at all audiometric frequencies between 250 and 8000 Hz at less than or equal to 25 dB HL
62235049|NCT02019888||Adults with sensory neural hearing loss|Adults between 20 and 79 years old with sensory neural hearing at one or more audiometric frequencies between 250 and 8000 Hz.
62235050|NCT02019888||Adults with middle ear disorders|Adults between 20 and 89 years old with middle ear disorders: tympanic membrane perforation, serous otitis media, cholesteatoma, otosclerosis, and unspecified middle ear disorders.
62235051|NCT02530203|OTHER|Conventional treatment|Non interventional group, patients that belong to this arm will receive the conventional treatment for CABG and they will wear the Holter for 5 days.
62235052|NCT02530203|EXPERIMENTAL|Spinal Cord Stimulation System|This group will receive the Spinal Cord Stimulation System and they will wear the Holter for 5 days.
62235053|NCT05166460|EXPERIMENTAL|Surgery utilizing the Kidney Skinn cooling device|All patients in Part A, and those randomized to the Kidney Skinn arm in Part B, will receive transplant surgery in the traditional fashion with the exception that the renal allograft will be placed in the cooling device at the initiation of the vascular anastomosis. Cold saline irrigation flowing through the device will be used to maintain renal hypothermia for the duration for the vascular anastomosis. After the vascular clamps are released, the device will be removed.
62811287|NCT02745171|EXPERIMENTAL|Experimental group|There will be an initial evaluation, after a month of physical therapy at the end of the protocol, and twice more after the protocol, both interval a month.
62235054|NCT05166460|NO_INTERVENTION|Standard transplant surgery practice|Standard transplant surgery per site practice
62811288|NCT02728115|EXPERIMENTAL|Cellavita HD Lower Dose|Participants assigned to this arm will receive 3 administrations, one every 30 days, of 1x10\^6 cells/weight range per administration of Cellavita HD (n= 3) .
62811289|NCT02728115|EXPERIMENTAL|Cellavita HD Higher dose|Participants assigned to this arm will receive 3 administrations, one every 30 days, of 2x10\^6 cells/weight range per administration of Cellavita HD (n= 3).
62034773|NCT04454866|EXPERIMENTAL|Single injection group|For patients in this group, a dose of penehyclidine (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
62034774|NCT04454866|EXPERIMENTAL|Continuous infusion group|For patients in this group, a dose of penehyclidine (0.25 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of penehyclidine (0.25 mg/5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
62034775|NCT01859481|PLACEBO_COMPARATOR|Placebo|
62034776|NCT01859481|EXPERIMENTAL|Eletriptan HBr 40 mg|
62034777|NCT01859481|EXPERIMENTAL|Eletriptan HBr 80 mg|
62034778|NCT06529107|EXPERIMENTAL|A best evidence-based protocol for intermittent catheterization|
62034779|NCT06529107|NO_INTERVENTION|Routine intermittent catheterization care|
62034780|NCT00234065|EXPERIMENTAL|1|cilostazol
62034781|NCT00234065|ACTIVE_COMPARATOR|2|Aspirin
62235055|NCT04940039|EXPERIMENTAL|Paliperidone Palmitate|Participants in Observation Phase will receive their treatment prescribed by treating physicians as part of their routine clinical practice and the standard of care (SoC) treatment for Rwanda mental healthcare settings. Participants who have not received risperidone or paliperidone or paliperidone palmitate earlier in Observation Phase will receive oral risperidone 3 milligram (mg) tablets once daily for 3 days in Run-in Phase to determine tolerability. Participants will receive flexible dose range from 50 to 150 mg equivalent (eq.) long acting formulation of paliperidone palmitate once monthly (PP1M) as an intramuscular (IM) injection in Lead-in Treatment Phase for at least 17 weeks (maximum 25 weeks) and if stable dose is achieved for PP1M, participants will enter Maintenance Treatment Phase and continue to receive flexible dose range from 175 to 525 mg eq. long acting formulation of paliperidone palmitate every 3 months (PP3M) as an IM injection for up to 24 weeks.
62235056|NCT03741933|EXPERIMENTAL|Apremilast|30 mg twice daily to be administered for a period of 6 months
62811290|NCT01557153|EXPERIMENTAL|Amlodipine|
62235057|NCT05781776|EXPERIMENTAL|Otago exercise program group|Participants performed Otago exercise program and core muscle strengthening exercises for eight weeks (thrice a week).
62235058|NCT05781776|ACTIVE_COMPARATOR|Gaze stability exercises group|Participants performed Gaze stability exercises and core muscle strengthening exercises for eight weeks (thrice a week).
62811291|NCT01557153|PLACEBO_COMPARATOR|Placebo|
62034782|NCT06129773|EXPERIMENTAL|anti biotic coated group|
62034783|NCT06129773|NO_INTERVENTION|non coated group|
62034784|NCT05152433|ACTIVE_COMPARATOR|Conventional therapy|Length of period: 2 weeks
62034785|NCT05152433|EXPERIMENTAL|Therapy assisted by a humanoid robot (E-BRAiN)|Length of period: 2 weeks Fixed dose: 10 therapy sessions with E-BRAiN
62034786|NCT04101643|EXPERIMENTAL|Evolocumab group|Eligible patients receive subcutaneous injections of evolocumab 420 mg
62034787|NCT03969719|PLACEBO_COMPARATOR|Placebo|Palacebo
62034788|NCT03969719|EXPERIMENTAL|Low Dose|150 mg
62034789|NCT03969719|EXPERIMENTAL|High Dose|300 mg
62235059|NCT01902056|ACTIVE_COMPARATOR|one layer allograft|One layer allograft as a positive control
62811292|NCT06140602|EXPERIMENTAL|Intervention shake|The pecan shake is comprised of 1% milk, chocolate powder (Nesquik), soy lecithin, whole blended pecans, and water.
62235060|NCT01902056|EXPERIMENTAL|Two layer allograft|Two layer allograft as the test group.
62425950|NCT04288115|PLACEBO_COMPARATOR|"Placebo group (real discontinuation)"|Stop the current dose of levothyroxine and take study placebo
62425951|NCT00479401|EXPERIMENTAL|Pramipexole Extended Release (PPX ER)|
62034790|NCT05275894|EXPERIMENTAL|Non-surgical electrolytic cleaning|"* Implant hygiene instructions and removal of the prosthesis~* Local anaesthesia~* Removal of the granulation tissue and mucosa and bone defect curettage with a steel curette 4R/4L (Hu-Friedy, Chicago, IL, USA)~* Removal of supra and submucosal calculus with slim ultrasonic devices (Piezon PS instrument EMS; Nyon, Swiss).~* Erythritol air powder-spray system (Air-flow ® master piezon, EMS, Nyon swiss) implant surface treatment. This will be performed by separating the soft tissue with the aim of a periodontal probe (CP 15, Hu-Friedy, Chicago, IL, USA).~* Electrolytic cleaning of the implant surface following manufacturer's instructions (GalvoSurge Dental AG, Widnau, Switzerland), with the help of a non-metal periodontal probe to separate the soft tissues and aim the implant surface in all its length.~* Antibiotic treatment (Metronidazole 500 mg, every day/ 7 day).~* If necessary, modification and polishing of the prosthesis to make it cleanable."
62425952|NCT00479401|EXPERIMENTAL|Pramipexole Immediate Release (PPX IR)|
62425953|NCT00479401|PLACEBO_COMPARATOR|Placebo|
62425954|NCT06541236|EXPERIMENTAL|Use of different bone grafting materials for alveolar ridge preservation of the socket|"All patients (n=80) were divided into 4 equal groups depending on the used preservative material. A total of 151 teeth were extracted. In the 1st group, the preservation was carried out using the Cerabone xenograft (Botiss, Germany). In the 2nd group, Plasma Rich in Growth Factors (PRGF) was used, obtained from the patient's venous blood 20-30 minutes before the tooth extraction (BTI Endoret, Spain). The third group consisted of patients who underwent preservation of the extracted tooth socket with crushed autologous dentin matrix (ADM) obtained from their own tooth using Smart Dentin Grinder (KometaBio Inc., USA). In the 4th group, a material based on hydroxyapatite Kollapan-L with lincomycin (Intermedapatit, Russia) was used as a preservation graft"
62811293|NCT06140602|NO_INTERVENTION|Control shake|the control cream shake is comprised of 1% milk, chocolate powder (Nesquik), soy lecithin, dextrin, heavy whipping cream, and water.
62034791|NCT06635525||Hemodialysis patients|Subjects with advanced chronic kidney disease requiring thrice-weekly hemodialysis
62034792|NCT06635525||Peritoneal dialysis patients|Subjects with advanced chronic kidney disease on peritoneal dialysis
62034793|NCT06635525||Healthy controls|Subjects without a prior history of chronic kidney disease
62034794|NCT06097312||Participants|Pregnant women who received PREHEVBRIO® vaccine within 28 days prior to conception or at any time during pregnancy.
62034795|NCT04682496|EXPERIMENTAL|intratendon vascularization|Intratendon vascularization will be quantified using a proprietary methodology using ImageJ 1.47v image analysis software, determining the different variables related to the Doppler signal within an intratendon region of interest.
62034796|NCT04656626|EXPERIMENTAL|COVID19 Frontline Health Care Providers recieving mindfulness intervention|This arm will receive mindfulness audios (randomized and double blinded)
62034797|NCT04656626|PLACEBO_COMPARATOR|COVID19 Frontline Health Care Providers receiving progressive muscle relaxation|This arm will receive progressive muscle relaxation audios (randomized and double blinded)
62235061|NCT01944735|EXPERIMENTAL|Active|Once daily oral capsule containing 50 or 100 mg of CTX-4430
62235062|NCT01944735|PLACEBO_COMPARATOR|Placebo|Once daily oral capsule containing mannitol, visibly identical to CTX-4430 capsules
62235063|NCT06351306|EXPERIMENTAL|Safety Lead-In|"Groups of participants will receive different doses of thioguanine and decitabine-cedazuridine to identify the highest doses that can be given safely. The highest doses that are safe will then be used in the phase II portion of the clinical trial. If no dose is found to be safe, the study will be stopped.~A phase II expansion cohort will be enrolled to further explore the combination's anti-leukemia activity and safety and will proceed at the maximum tolerated dose defined in the initial Safety Cohort."
62425955|NCT04114526|EXPERIMENTAL|Community Health Advisor 4-step Program|
62425956|NCT04473729|EXPERIMENTAL|Children with an autism spectrum disorder|The intervention as described above with children with an ASD.
62425957|NCT04473729|EXPERIMENTAL|Children with Hearing Loss|
62425958|NCT04473729|EXPERIMENTAL|Typically developing children with normal hearing acuity|
62425959|NCT04722081|EXPERIMENTAL|Control Group|children received selected physical therapy exercises
62425960|NCT04722081|EXPERIMENTAL|Study Group|children received selected physical therapy exercises plus virtual reality training
62425961|NCT06541418|EXPERIMENTAL|Experimental Group|"As a pre-test, 40 students, who were determined in accordance with the research criteria and assigned to the experimental group, were asked to fill in the Sociodemographic data collection form and SCEÖ.~Before the planned program, students were sent an e-mail and the program days and times were specified. 4 groups of 10 people were formed. Transtheoretic Model Based Behavior Change Program consisting of 7 sessions was given. At the end of the program, the Risky Behavior Evaluation Scale, which was included in the RSS-ÜF, Behavior Change Stages Short Questionnaire, SEYÖ and Soyodemographic data collection form, was applied again. Follow-up was done with the same measurement tools 3 months after the end of the program."
62811294|NCT05724732|EXPERIMENTAL|GT201 treatment group|Autologous tumor infiltrating lymphocyte injection
62811295|NCT05388786||Delphi Panel|A team of experts in open inguinal lymphadenectomy, video endoscopic inguinal lymphadenectomy (VEIL), and robotic-assisted video endoscopic inguinal lymphadenectomy (R-VEIL) in the fields of General Surgery, Gynecology Oncology, Surgical Oncology, and Urology will be invited to participate. These experts are identified according to surgical experience, research, and academic interest.
62811296|NCT05830708|EXPERIMENTAL|Probiotic group|"Probiotics + conventional drug therapy: treatment includes conventional drug therapy\* (initial 2 weeks), then probiotics powder 2g, mixed into water or milk, dissolved and oral; 1 sachet per day for 12 weeks~\*Conventional drug treatment: alcohol detoxification treatment was carried out at the early stage of admission, mainly with benzodiazepine replacement therapy, while adequate supplementation of B vitamins, strengthening symptomatic supportive treatment, and corresponding antipsychotic drugs, antidepressants or emotional stabilizers were given according to the condition. Benzodiazepines are gradually discontinued after withdrawal symptoms disappear (2 weeks)."
62811297|NCT05830708|ACTIVE_COMPARATOR|Acceptance and commitment therapy (ACT) group|"ACT + conventional drug therapy: treatment includes conventional drug therapy\* (initial 2 weeks), then 50 minutes, once a week ACT session for 8 weeks (8 sessions).~\*Conventional drug treatment: alcohol detoxification treatment was carried out at the early stage of admission, mainly with benzodiazepine replacement therapy, while adequate supplementation of B vitamins, strengthening symptomatic supportive treatment, and corresponding antipsychotic drugs, antidepressants or emotional stabilizers were given according to the condition. Benzodiazepines are gradually discontinued after withdrawal symptoms disappear (2 weeks)."
62811298|NCT05830708|PLACEBO_COMPARATOR|Placebo group|"Placebo + conventional drug therapy: treatment includes conventional drug therapy\* (initial 2 weeks), then maltodextrin of the same weight as the test drug treatment group was mixed into water or milk and orally dissolved; 1 sachet per day for 12 weeks.~\*Conventional drug treatment: alcohol detoxification treatment was carried out at the early stage of admission, mainly with benzodiazepine replacement therapy, while adequate supplementation of B vitamins, strengthening symptomatic supportive treatment, and corresponding antipsychotic drugs, antidepressants or emotional stabilizers were given according to the condition. Benzodiazepines are gradually discontinued after withdrawal symptoms disappear (2 weeks)."
62811299|NCT05544864|OTHER|homogenous|Stratification - homogenous pattern
62811300|NCT05544864|OTHER|heterogenous|Stratification - homogenous pattern
62811301|NCT05118971||elliptical (GE)|The patient is suspended supported by the hip positioner, secured by nylon straps to a galvanic iron grid fixed to the ceiling with parabolts. The height of the seat belts will be measured according to the patient's proper position in the device. The weight support belt will be adjusted to maximize load bilaterally without knee deformation during correct posture, manual assistance will be provided by physical therapists on each leg. A physical therapist's hand will be placed on the anterior surface of the leg below the patella to aid in knee extension during the elliptical gait simulation. The other hand will be placed on the ankle to aid in the movement of the feet during the alternating movement of the legs and the return of the heel placement to the starting position. The patient performs the movements at the maximum speed he can, recording the electromyographic signal of the selected muscles for 20 seconds.
62811302|NCT05118971||elliptical with biofeedback (GEB)|The same described in the elliptical group adding biofeedback.
62594194|NCT02123615|EXPERIMENTAL|Adverse Reactions Abdominal Pain|Abdominal Pain as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
62594195|NCT05311228|EXPERIMENTAL|Intervention group|Intervention group will give azithromycin for 14 days, 7 days 10 mg/body weight/24 hours, 7 days 5 mg/bw/hours
62594196|NCT05311228|NO_INTERVENTION|Control group|No intervention
62594197|NCT06029933||Fluad Recipients|Kaiser Permanente Northern California members aged ≥65 years who receive Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)
62594198|NCT06029933||Fluzone High-Dose Recipients|Kaiser Permanente Northern California members aged ≥65 years who receive High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
62594199|NCT01990196|ACTIVE_COMPARATOR|AR inhibition only|"AR inhibition only Group 1: degarelix + enzalutamide~Endocrine therapy with degarelix and enzalutamide will continue for a minimum of 6 weeks and a maximum of 8 weeks in all groups prior to the planned prostatectomy."
62034798|NCT02015676|EXPERIMENTAL|Trastuzumab, Myocet, Paclitaxel; Phase I|Participants received an initial loading dose of trastuzumab 4 milligrams per kilogram (mg/kg), intravenously (IV), over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 40 mg/ square meter (m\^2), IV, every 3 weeks, from Week 1; if no dose limiting toxicity (DLT) was observed in greater than or equal to (≥) two-thirds (2/3) of cohort for 2 treatment cycles, the dose was increased to 50 mg/m\^2, IV, and continued for 6 cycles. Participants also received paclitaxel 60 mg/ m\^2, IV, once per week, from Week 19; if no DLT was observed in ≥ 2/3 of cohort for 2 treatment cycles, the dose was increased to 70 mg/m\^2, IV, and subsequently 80 mg/m\^2, IV, and continued until disease progression.
62034799|NCT02015676|EXPERIMENTAL|Trastuzumab, Myocet, Paclitaxel; Phase II|Participants received an initial loading dose of trastuzumab 4 mg/kg, IV, over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 50 mg/m\^2, IV, every 3 weeks, from Week 1 for 6 cycles. Participants also received paclitaxel 80 mg/m\^2, IV, once per week, from Week 19 until disease progression.
62034800|NCT05198960|EXPERIMENTAL|Experimental group|Patients randomized to receive Direct Oral Anticoagulants, at the choice of the investigator Apixaban 2.5 mg both in day or Rivaroxaban 10 mg one per day, at the choice of the investigator
62235064|NCT01172405|EXPERIMENTAL|Ibuprofen + Caffeine|72 patients treated with one or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
62811303|NCT05118971||bicycle (GB)|The patient will have the help of two physiotherapists to position themselves, who will also assist in pedaling as needed. The patient will also be asked to perform the movements at the maximum speed he can, recording the electromyographic signal of the same selected muscles for 20 seconds.
62235065|NCT01172405|ACTIVE_COMPARATOR|Ibuprofen|72 patients treated with one or two tablets of ibuprofen 400 mg when presenting headache.
62235066|NCT05844787|EXPERIMENTAL|SAD Phase|"SAD Phase: including Food Interaction - Blinding and Randomization: This is a randomized, double-blind, placebo-controlled, sentinel design, dose-escalating study with 40 healthy volunteers. Subjects will be assigned to 1 of up to 5 cohorts and will be randomized within each cohort to MT101-5 or placebo, as follows:~* cohort 1: 100 mg (8 subjects total; 6 receiving MT101-5, 2 receiving placebo)~* cohort 2: 150 mg (8 subjects total; 6 receiving MT101-5, 2 receiving placebo)~* cohort 3: 300 mg (8 subjects total; 6 receiving MT101-5, 2 receiving placebo)~* cohort 4: 450 mg (8 subjects total; 6 receiving MT101-5, 2 receiving placebo)~* cohort 5: 600 mg (8 subjects total; 6 receiving MT101-5, 2 receiving placebo)"
62243200|NCT00819286|EXPERIMENTAL|SternaLock Rigid Fixation Plates|patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates.
62034801|NCT05198960|ACTIVE_COMPARATOR|Control group|Patients randomized to receive Low-Dose Aspirin Aspirin 100 mg one per day
62034802|NCT01354158|EXPERIMENTAL|Droxidopa|The dose-titration response to ascending doses of Droxidopa (placebo, 100mg, 200mg, 400mg) will be measured four separate days.
62034803|NCT02539342|EXPERIMENTAL|Caphosol Arm|Caphosol Arm: Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day from the start of chemotherapy until 7 days after the completion of chemotherapy AND until the ANC is \>500 after count recovery OR until the the symptoms or oral mucositis resolve, whichever occurs last. Patients will also complete a study diary to record symptoms of oral mucositis.
62034804|NCT02539342|ACTIVE_COMPARATOR|Control Arm|Control Arm: Subjects randomized to the Control Arm will use Biotene 4 times per day. They will also complete a study diary to record doses and any symptoms of oral mucositis. This will begin at the start of chemotherapy until for 7 days AND until ANC \>500 after nadir or oral mucositis resolves (whichever occurs later)
62034805|NCT00092131|EXPERIMENTAL|1|Montelukast - Placebo
62594200|NCT01990196|ACTIVE_COMPARATOR|AR inhibition plus MEK inhibition|"AR inhibition plus MEK inhibition Group 2: trametinib + degarelix + enzalutamide~In Group 2, treatment with trametinib will begin on Day 29 (i.e. four weeks after initiation of androgen deprivation). Thus, trametinib will be administered for no less than two weeks and no more than four weeks."
62594201|NCT01990196|ACTIVE_COMPARATOR|AR inhibition plus SRC inhibition|"AR inhibition plus SRC inhibition Group 3: dasatinib + degarelix + enzalutamide~In Group 3, treatment with dasatinib will begin on Day 29 (i.e. four weeks after initiation of androgen deprivation). Thus, dasatinib will be administered for no less than two weeks and no more than four weeks."
62594202|NCT04984863|EXPERIMENTAL|magnetically controlled capsule endoscopy|magnetically controlled capsule endoscopy to evaluate the efficacy of the treatment of gastroesophageal varices
62594203|NCT05661981||Adult and pediatric patients|Undergoing cardiac and/or vascular repair or reconstruction surgery
62594204|NCT04765657|EXPERIMENTAL|inclisiran sodium 300 mg|Subcutaneous injection
62594205|NCT04765657|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection
62594206|NCT01712165|ACTIVE_COMPARATOR|ANMUM Materna|75g milk powder in 400 ml water daily for 12 weeks.
62594207|NCT01712165|PLACEBO_COMPARATOR|Control|75g of milk powder in 400 ml water for 12 weeks.
62594208|NCT03414996|EXPERIMENTAL|High-intensity interval training|Following 5 min warm-up at 30 % of maximal aerobic power (MAP) obtained at the cardiopulmonary exercise test, patients performed 2 sets of 10 minutes of repeated phases of 15 seconds at 100 % MAP alternating with 15 seconds of passive recovery. The 2 sets were separated by 4 min of passive recovery (no pedalling). Patients performed 5-minutes of recovery period at 30 % MAP after the second set. Total time duration was 34 minutes.
62034806|NCT00092131|EXPERIMENTAL|2|Placebo - Montelukast
62811304|NCT05118971||bike with biofeedback (GBB)|The patient will have the help of two physiotherapists to position themselves, who will also assist in pedaling as needed. The patient will also be asked to perform the movements at the maximum speed he can, recording the electromyographic signal from the same selected muscles for 20 seconds, adding biofeedback.
62811305|NCT00434408|EXPERIMENTAL|1|4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth
62811306|NCT00434408|EXPERIMENTAL|2|4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth
62811307|NCT00434408|ACTIVE_COMPARATOR|3|dry cord care
62811308|NCT05961267||Patients|Patients with a diagnosis of systemic lupus erythematosus, Gougerot-Sjögren's syndrome, scleroderma, Sharp's syndrome, rheumatoid arthritis or spondyloarthritis, according to current international standards.
62811309|NCT04970745||high-risk|After performing midbrain ultrasound and tremor analysis, patients with positive results of both tests are considered very high-risk patients,
62811310|NCT04970745||risk|After performing midbrain ultrasound and tremor analysis, patients with positive results of 1 out of 2 tests are considered risk patients
62811311|NCT04970745||low-risk|After performing midbrain ultrasound and tremor analysis, patients with negative results of both tests are considered risk patients
62811312|NCT01166139|EXPERIMENTAL|Nilotinib 400 mg twice daily|
62034807|NCT00818857|ACTIVE_COMPARATOR|1|Early intervention.
62034808|NCT00818857|ACTIVE_COMPARATOR|2|Delayed intervention
62235067|NCT05844787|EXPERIMENTAL|Food Interaction Phase|Food Interaction Phase: Following the completion of the SAD phase, if study stopping criteria (SSC) is not met, then subjects in cohort 5 will cross-over to the fed part of the study following a 7 day washout period. If SSC is achieved in the SAD phase, then the previous dose will be in the Food Interaction phase.
62811313|NCT02634463|OTHER|Antipsychotic Immunoassay Development Participants|No study agent will be administered as a part of this study. Participants must be on Aripiprazole or Olanzapine, or Paliperidone or Risperidone, orally, daily or long-acting injectable versions, as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for use in the development of antipsychotic immunoassays. Participants may also be on long acting injectable versions of the medication.
62811314|NCT04300985|SHAM_COMPARATOR|Placebo group|Thirty patients in this group will receive infusion of 100 saline solution. After 15 min of beginning of this infusion they will start receiving general anesthesia administration.
62811315|NCT04300985|ACTIVE_COMPARATOR|Dexmedetomidine group|Thirty patients in this group will receive infusion of dexmedetomidine (0,5 mcg/kg/min). After 15 min of the beginning of this infusion they will start in the general anesthesia induction.
62034809|NCT04822220|EXPERIMENTAL|Experimental|Fatigue Self-management Programme
62034810|NCT04822220|NO_INTERVENTION|Controlled|The control group received routine treatment and nursing care
62034811|NCT03369444|EXPERIMENTAL|FLT180a, 6x10e^11 vg/kg solution for infusion|Participants receiving gene therapy vector at a dose of 6x10e\^11 vg/kg
62034812|NCT03369444|EXPERIMENTAL|FLT180a, 2 x 10e^12 vg/kg solution for infusion|Participants receiving gene therapy vector at a dose of 2 x 10e\^12 vg/kg
62034813|NCT03369444|EXPERIMENTAL|FLT180a, 1x10e^12 vg/kg solution for infusion|Participants receiving gene therapy vector at a dose of 1 x 10e\^12 vg/kg
62034814|NCT03369444|EXPERIMENTAL|FLT180a, 1.3x10e^12 vg/kg solution for infusion|Participants receiving gene therapy vector at a dose of 1.3 x 10e\^12 vg/kg
62034815|NCT02361320|EXPERIMENTAL|Computed Tomography Scans (CT)|Participants to receive 2 computed tomography (CT) scans that are part of their regular cancer care. One (1) scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist. Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit.
62235068|NCT05844787|EXPERIMENTAL|MAD Phase|MAD Phase; Blinding and Randomization: This is a randomized, double-blind, placebo-controlled study in approximately 8 elderly healthy volunteers. If study stopping criteria (SSC) is not met in the SAD phase, then subjects will be assigned to the cohort 5 dose. If SSC is achieved in the SAD phase, then the previous dose will be used as the cohort in the MAD phase
62235069|NCT00524719|ACTIVE_COMPARATOR|Open, internal fixation volar plate|Open reduction and internal fixation (ORIF) with volar locked plate
62235070|NCT00524719|ACTIVE_COMPARATOR|Closed reduction with external fixator|Surgical procedure - Closed reduction and non-spanning external fixation (Ex-FIX)
62811316|NCT04300985|ACTIVE_COMPARATOR|Magnesium sulfate group|Thirty patients in this group will receive infusion of magnesium sulfate (20 mg/kg/h). After 15 min of the beginning of this infusion they will start in the general anesthesia induction.
62811317|NCT01043107||Compuer radiaton group|
62811318|NCT01043107||control group|
62811319|NCT05861076|EXPERIMENTAL|Moringa Powder - Medium Dose|Group A
62811320|NCT05861076|EXPERIMENTAL|Moringa Powder - High Dose|Group B
62811321|NCT05861076|EXPERIMENTAL|Moringa Powder - Low Dose|Group C
62034816|NCT03438123|EXPERIMENTAL|CZT SPECT|CZT SPECT imaging with/without the addition of CT on the Spectrum Dynamics camera
62235071|NCT00524719|ACTIVE_COMPARATOR|Closed reduction percutaneous pinning|Surgical procedure - Closed reduction with percutaneous pinning (CRPP) and the application of a cast
62235072|NCT05135949||Operative|Internal fixation of the displaced olecranon fracture.
62811322|NCT03694561||Late-Onset Pompe disease|Individuals with a confirmed diagnosis of Late-Onset Pompe disease via NBS
62811323|NCT03844776|ACTIVE_COMPARATOR|Co-Amoxiclav postoperatively alone|• Treatment 1: 0.9% normal saline irrigation immediately after the surgery with course of Co-Amoxiclav 625 mg 0.2% chlorhexidine mouthwash following the surgery for 5 days (control group)
62811324|NCT03844776|ACTIVE_COMPARATOR|Co-Amoxiclav preoperatively with Metronidazole postoperatively|• Treatment 2: 625 mg Co-Amoxiclav and 1g Paracetamol preoperatively and 0.2% chlorhexidine mouthwash immediately before the surgery with course of Metronidazole 500 mg and 0.2% chlorhexidine mouthwash following the surgery for 5 days
62811325|NCT03844776|ACTIVE_COMPARATOR|Co-Amoxiclav preoperatively with amoxicillin postoperatively|• Treatment 3: 625 mg Co-Amoxiclav and 1g Paracetamol preoperatively and 0.2% chlorhexidine mouthwash immediately before the surgery with course of amoxicillin 500 mg and 0.2% chlorhexidine mouthwash following the surgery for 5 days
62811326|NCT01204099|ACTIVE_COMPARATOR|Docetaxel (NSCLC)|IV docetaxel administered once every three weeks as per standard of care. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
62811327|NCT01204099|EXPERIMENTAL|PX-866 (NSCLC)|Oral PX-866 administered daily at the RD in combination with IV docetaxel administered once every three weeks on a 21 day cycle. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
62034817|NCT00315250|EXPERIMENTAL|[123I]β-CIT|To assess B-CIT and SPECT imaging
62235073|NCT05135949||Non Operative|Conservative treatment as determined by the treating surgeon.
62235074|NCT06094270||Experimental: Intervention arm|All patients within the study are included in the intervention arm: The withdrawal time for the interventions for all patients is documented by the physician and the proposed AI system.
62235075|NCT00991484||control group|
62235076|NCT00991484||individuals from hernia-family|
62235077|NCT06433804||HER2 low|
62235078|NCT06433804||HER2 negative|
62235079|NCT00797498||Xerostomia Questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
62034818|NCT05589051|EXPERIMENTAL|Alpha Hope|Each tablet contains 10 mg PQQ and 40 mg (19% DV) magnesium as well as malic acid, dextrose, adipic acid, citric acid, natural flavor, and blackberry leaf extract
62425962|NCT06541418|NO_INTERVENTION|Control Group|"As a pre-test, 40 students who were determined in accordance with the research criteria and assigned to the control group were asked to fill in the Sociodemographic data collection form and SCEÖ. For the posttest and 3-month follow-up, the Risky Behavior Evaluation Scale, which was included in the RSS-ÜF, Behavior Change Stages Short Question Form, SEEÖ and Soyodemographic data collection form, was applied again.~After the Transtheoretical Model-Based Behavior Change Program given to the experimental group ended, a 1-day training program on changing risky behaviors was applied to the control group in September 2021. All students in the experimental group participated in the program."
62425963|NCT02815930||HCUs|Newly incident seniors with annual total healthcare expenditures in the top 5% of Ontarians
62034819|NCT05589051|PLACEBO_COMPARATOR|Placebo|Same formulation as experimental with 250 mg calcium carbonate replacing the magnesium and PQQ.
62034820|NCT03816904||Breast or prostate cancer|Taken blood samples on patients hospitalized in medical oncology day hospital at the University Hospital of Tours or CHC oncology day hospital, for their chemotherapy with taxanes (paclitaxel or docetaxel) for breast or prostate cancer
62034821|NCT06117449||Patients going on insulin therapy|
62811328|NCT01204099|ACTIVE_COMPARATOR|Docetaxel (SCCHN)|IV docetaxel administered once every three weeks as per standard of care. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
62034822|NCT06117449||patients going on oral antidiabetic drugs|
62235080|NCT04027322|ACTIVE_COMPARATOR|Budesonide|"Drug Name: budesonide Dose: 2000mcg (2mg) of budesonide nebulizer solution is mixed with normal saline solution to make a total volume of 8mL.~Frequency: Stat Dose Route: Nebulization"
62235081|NCT04027322|ACTIVE_COMPARATOR|Dexamethasone|"Drug Name: Dexamethasone Sodium phosphate Dose: 8mg of IV formula of dexamethasone is mixed with normal saline to make a total volume of 8ml.~Frequency: Stat Dose Route: Nebulization"
62425964|NCT02815930||Non-HCUs|Seniors with annual total healthcare expenditures below the top 5% of Ontarians
62811329|NCT01204099|EXPERIMENTAL|PX-866 (SCCHN)|Oral PX-866, administered daily at the RD in combination with IV docetaxel administered once every three weeks on a 21 day cycle. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
62811330|NCT04992572|ACTIVE_COMPARATOR|General anesthesia|"Patients under this group will be undergoing lumbar decompression surgery with general anesthesia:~General Anesthesia: Medically induced unconsciousness that suppresses reflexes and requires intubation (a tube inserted through the mouth and into the airway) to assist in breathing."
62034823|NCT00901693|EXPERIMENTAL|AL-46383A|AL-46383A Ophthalmic Solution, 1 drop in each eye, 8 times a day for 10 days
62034824|NCT00901693|PLACEBO_COMPARATOR|Vehicle|AL-46383A Ophthalmic Solution Vehicle, 1 drop in each eye, 8 times a day, for 10 days
62034825|NCT02202226|EXPERIMENTAL|Lu AF35700 oral solution (1 mg/mL)|Planned daily doses range from 5 mg/day to 30 mg/day for 3 weeks. Weekly doses up to 75 mg/week for 3 weeks.
62034826|NCT02202226|PLACEBO_COMPARATOR|Matching placebo|Oral solution
62034827|NCT04798976||CDSS (MedicBK) Analysis|
62034828|NCT04798976||Core Laboratory Analysis|
62034829|NCT03008148|ACTIVE_COMPARATOR|Radiation,Temozolomide|"1. CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).~2. Rest Phase: Rest for 4 weeks.~3. Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.~4. Maintenance Phase: No maintenance treatment until disease progression confirmed."
62425965|NCT05652894|EXPERIMENTAL|HX008|Subjects receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)
62425966|NCT05652894|ACTIVE_COMPARATOR|Investigator's Choice Chemotherapy|"1. mFOLFOX6~2. mFOLFOX6+Bevacizumab~3. mFOLFOX6+Cetuximab~4. FOLFORI~5. FOLFORI+Bevacizumab~6. FOLFORI+Cetuximab"
62034830|NCT03008148|EXPERIMENTAL|Radiation,Temozolomide,Siroquine(JP001)|"1. CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks) + Daily JP001 (2 tablets once a day for 6 weeks).~2. Rest Phase: Daily JP001(2 tablets/day) for 4 weeks.~3. Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).~4. Maintenance Phase: JP001(2 tablets once a day) until disease progression confirmed."
62034831|NCT04391023|SHAM_COMPARATOR|Sham tDCS|The tDCS device will perform a 30 second ramp up to 2 mA and then an immediate 30 second ramp down to 0 mA. Until the 19:30 minute time point, the tDCS will remain at 0 mA. At this time point, the tDCS will ramp up to 2 mA and then will immediately ramp back down to 0 mA.
62235082|NCT04027322|PLACEBO_COMPARATOR|Control|Drug Name: Normal Saline Dose: 8ml. Frequency: Stat Dose Route: Nebulization
62425967|NCT06262633|EXPERIMENTAL|Targeted Microwave Ablation (TMA)|Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation
62425968|NCT04656574|EXPERIMENTAL|Experimental Group|Experimental group received the course explaining vaginal delivery for the first timethat used simulation-based training.
62425969|NCT04656574|NO_INTERVENTION|Control Group|Control group received the course explaining vaginal delivery for the first time
62034832|NCT04391023|EXPERIMENTAL|2 mA tDCS|The participants in this group will receive tDCS at 2 mA while seated comfortably. The intensity will start at 0 mA and will be incrementally increased to the target intensity (2 mA) over the initial 30 seconds. Then, the tDCS will deliver stimulation at the target intensity until the 19:30 minute time point. At this point, the current will gradually decrease back to 0 mA.
62034833|NCT04391023|EXPERIMENTAL|4 mA tDCS|The participants in this group will receive tDCS at 4 mA while seated comfortably. The intensity will start at 0 mA and will be incrementally increased to the target intensity (4 mA) over the initial 30 seconds. Then, the tDCS will deliver stimulation at the target intensity until the 19:30 minute time point. At this point, the current will gradually decrease back to 0 mA.
62034834|NCT00533377|EXPERIMENTAL|CP-533,536 Dose Level 2|
62034835|NCT00533377|PLACEBO_COMPARATOR|Placebo|
62034836|NCT00533377|OTHER|Standard of Care|
62034837|NCT00533377|EXPERIMENTAL|CP-533,536 Dose Level 1|
62034838|NCT00533377|EXPERIMENTAL|CP-533,536 Dose Level 3|
62034839|NCT00533377|EXPERIMENTAL|CP-533.536 Dose Level 4|
62235083|NCT00911079|EXPERIMENTAL|Hyperthermia with HDR brachytherapy|Hyperthermia will be delivered within approximately 2 hours of (HDR) brachytherapy associated with the implant session
62425970|NCT03339531|EXPERIMENTAL|2D radiotherapy|Patients with prostate cancer were treated with 2D-radiotherapy
62425971|NCT04690387|EXPERIMENTAL|0.1 mg antigen, 0 mcg GM-CSF|Dendritic cells previously incubated with 0.1 mcg antigen
62425972|NCT04690387|EXPERIMENTAL|0.33 mg antigen, 0 mcg GM-CSF|Dendritic cells previously incubated with 0.33 mcg antigen
62034840|NCT02158676|EXPERIMENTAL|Prebiotic|6 g/day of prebiotic (fructooligosaccharides) for 15 days.
62034841|NCT02158676|EXPERIMENTAL|Synbiotic|6 g/day of synbiotic (fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019) for 15 days.
62034842|NCT02158676|PLACEBO_COMPARATOR|Placebo|6 g/day of placebo (maltodextrin) for 15 days.
62034843|NCT04369092|OTHER|without swallowing problem|patients without swallowing problem
62034844|NCT04369092|OTHER|mild swallowing problem|patients with mild swallowing problem
62034845|NCT04369092|OTHER|severe swallowing problem|patients with severe swallowing problem
62034846|NCT05137574|ACTIVE_COMPARATOR|Group P|Patients sedated with propofol
62034847|NCT05137574|ACTIVE_COMPARATOR|Group K|Patients sedated with ketamine
62034848|NCT05061004|EXPERIMENTAL|Treatment|Treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) with the Cephea Mitral Valve System
62034849|NCT02243943|EXPERIMENTAL|Sugammadex|Subjects in this arm will be reversed with sugammadex 2-4 mg/kg
62034850|NCT02243943|ACTIVE_COMPARATOR|neostigmine|subjects in this arm will be reversed with neostigmine 1.0-2.5 mg and atropine 0.5-1.0mg
62034851|NCT00736372|EXPERIMENTAL|Investigational Drug|Dose Escalation
62235084|NCT04294732|PLACEBO_COMPARATOR|Only spinal anesthesia|Only spinal anesthesia without peripheral nerve block
62235085|NCT04294732|ACTIVE_COMPARATOR|high concentration|8 ml saline with 8 ml bupivacaine
62235086|NCT04294732|EXPERIMENTAL|low concentration|8 ml bupivacaine with 16 ml of saline
62235087|NCT02222636|PLACEBO_COMPARATOR|Group 1,Normal saline,1 milliliter|Patients will be assigned to receive intranasal normal saline 1 milliliter
62235088|NCT02222636|EXPERIMENTAL|Group 2,dexmedetomidine 1μg.kg-1,1 milliliter|Patients will be assigned to receive intranasal dexmedetomidine( 1μg.kg-1) 1 milliliter
62425973|NCT04690387|EXPERIMENTAL|1.0 mg antigen, 0 mcg GM-CSF|Dendritic cells previously incubated with 1.0 mcg antigen
62425974|NCT04690387|EXPERIMENTAL|0.1 mg antigen, 250 mcg GM-CSF|Dendritic cells previously incubated with 0.1 mcg antigen, admixed with 250 mcg GM-CSF
62811331|NCT04992572|ACTIVE_COMPARATOR|Monitored Anesthetic Care (MAC)/Local|"Patients under this group wil be undergoing limbar decompression surgery with Monitored Anesthetic care, (MAC)/Local.~Local + MAC: Local anesthetic (lidocaine) injected into the site of the incision/dissection with additional IV medication (Propofol) to achieve a state in which the patient is generally aware, but relaxed."
62034852|NCT06131866|EXPERIMENTAL|intervention group 1 in which psychoeducation based on acceptance and commitment therapy was applied|"After explaining the purpose of the study to the individuals, after obtaining their consent, Personal Information Form, Coping Attitudes Evaluation Scale COPE-R and '' The pre-test will be applied by applying the Meaning and Purpose of Life Scale, then the 8-week Acceptance and Commitment Therapy Based Psychoeducation programme will be applied and the post-test data will be collected. In the 12th week, follow-up test will be applied and evaluation will be made."
62034853|NCT06131866|NO_INTERVENTION|Control group 1|"After explaining the purpose of the study to the individuals participating in the study, after obtaining their consent, Personal Information Form, Coping Attitudes Evaluation Scale COPE-R and '' Meaning and Purpose of Life Scale'' will be applied and pre-tests will be applied. Then, the post-test will be applied 8 weeks later without any intervention. One month after the post-test, i.e. at the 12th week, a follow-up test will be applied and an evaluation is planned."
62425975|NCT04690387|EXPERIMENTAL|0.33 mg antigen, 250 mcg GM-CSF|Dendritic cells previously incubated with 0.33 mcg antigen, admixed with 250 mcg GM-CSF
62811332|NCT04998071|ACTIVE_COMPARATOR|ROUTINE DRUG - CONCENTRATION QLB|The patients will receive bilateral posterior quadratus lumborum block using 0.25% bupivacaine 0.4 ml/kg. in each side.
62425976|NCT04690387|EXPERIMENTAL|1.0 mg antigen, 250 mcg GM-CSF|Dendritic cells previously incubated with 1.0 mcg antigen, admixed with 250 mcg GM-CSF
62425977|NCT04690387|EXPERIMENTAL|0.1 mg antigen, 500 mcg GM-CSF|Dendritic cells previously incubated with 0.1 mcg antigen, admixed with 500 mcg GM-CSF
62425978|NCT04690387|EXPERIMENTAL|0.33 mg antigen, 500 mcg GM-CSF|Dendritic cells previously incubated with 0.33 mcg antigen, admixed with 500 mcg GM-CSF
62425979|NCT04690387|EXPERIMENTAL|1.0 mg antigen, 500 mcg GM-CSF|Dendritic cells previously incubated with 1.0 mcg antigen, admixed with 500 mcg GM-CSF
62425980|NCT05473858|EXPERIMENTAL|laser group|Patients will be undergoing anesthesia revision by diode laser
62425981|NCT05473858|EXPERIMENTAL|oraverse group|Patients will be undergoing anesthesia revision by oraverse
62425982|NCT02953262|EXPERIMENTAL|Encouragement Arm 1|Participants in this encouragement condition will receive a mailed brochure with basic My HealtheVet content and a training guide with (a) insights from other Veterans on how to use My HealtheVet for diabetes self-management, (b) step-by-step guidance for how to sign up for My HealtheVet and, (c) detailed guidance on how to learn to use key features.
62811333|NCT04998071|ACTIVE_COMPARATOR|ALTERNATIVE DRUG - CONCENTRATION QLB|The patients will receive bilateral posterior quadratus lumborum block using 0.125% bupivacaine 0.4 ml/kg. in each side.
62819589|NCT06590519|OTHER|Date Seed Capsule|The intervention group will receive a capsule of date-seed powder. Each person should consume 5 grams (two capsules of date-seed powder) twice daily after meals for three months. Assessments are carried out at the beginning of the study, one month and two months after the intervention (Chan et al., 2013). Participants will be contacted twice a week to ensure that they are adhering to the rules, maintaining their physical activity and clarifying any questions about taking supplements.
62235089|NCT02222636|EXPERIMENTAL|Group 3,dexmedetomidine 2μg.kg-1,1 milliliter|Patients will be assigned to receive intranasal dexmedetomidine( 2μg.kg-1 )1 milliliter
62235090|NCT06048692|EXPERIMENTAL|Cefepime Group|Pregnant women (n=100) received IV cefepime (CEF) (maxipime®1000mg) 30 minutes before cesarean delivery (CD) and 12 hours after CD
62235091|NCT06048692|ACTIVE_COMPARATOR|Ampicillin/Sulbactam|Pregnant women (n=100) received IV Ampicillin/Sulbactam (AMS) (Unictam® 1500 mg) 30 minutes before CD and 12 hours after CD
62235092|NCT05862896||Control|Healthy, age and sex matched controls
62235093|NCT05862896||Long Covid|Patients with breathlessness (defined as self-reported modified Borg Scale score of 2 or more when walking on flat ground for 100 metres) that has continued or developed and persists more than 4 weeks after acute COVID 19 i.e., related to 'long COVID' (covid confirmed by photographic evidence of positive lateral flow/NHS application, EMIS records or hospital lab data).
62425983|NCT02953262|EXPERIMENTAL|Encouragement Arm 2|Participants in this encouragement condition will receive the same brochure and training guide as Arm 1 but will also be offered optional attendance at one of several group training sessions.
62425984|NCT02953262|EXPERIMENTAL|Encouragement Arm 3|Participants in this encouragement condition will receive the same as in Arm 2 (brochure, training guide, and group training offer) but will also be offered a one-on-one My HealtheVet training session.
62425985|NCT02953262|OTHER|Brochure Only Comparison Arm|The Comparison condition will only receive a mailed brochure with basic My HealtheVet content during the trial. (The training guide will be mailed to them after completion of the interview at the end.)
62425986|NCT01601171||Patients|"Patients with reproductive disorders with or without cleft lip/palate will be recruited for:~* completion of medical questionnaire and review of medical records~* family tree (including questions on reproductive disorders and cleft lip/palate)~* specimen collection (DNA/RNA) from: serum/plasma/saliva/urine/buccal swab/hair follicles/sperm/skin biopsy~* smell testing~* hearing test~* bone density~* brain MRI~* kidney, testicular/ovarian ultrasound"
62425987|NCT01601171||Family members|"Family members of Patients will be recruited for:~* completion of medical questionnaire~* specimen collection (DNA/RNA) from: serum/plasma/saliva/urine/buccal swab/hair follicles/sperm/skin biopsy~* smell testing"
62819590|NCT06590519|NO_INTERVENTION|Control group: No Intervention|The control group will not receive any capsule ot treatment.
62235094|NCT02967354|EXPERIMENTAL|Healthy control|Healthy control
62235095|NCT02967354|EXPERIMENTAL|Obese with oral antidiabetic drugs|BMI\>30, Type 2 diabetes treated with oral antidiabetic drugs
62235096|NCT02967354|EXPERIMENTAL|Obese, treated with oral antidiabetic drugs + insulin|BMI\>30, Type 2 diabetes treated with oral antidiabetic drugs + insulin
62235097|NCT02967354|EXPERIMENTAL|Normal weight, treated with oral antidiabetic drugs|BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs
62235098|NCT02967354|EXPERIMENTAL|Normal weight, treated with oral antidiabetic drugs + insulin|BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs + insulin
62235099|NCT03392025|ACTIVE_COMPARATOR|Flaxseed|Daily consumption of 30 grams flaxseed for 3 months
62235100|NCT03392025|ACTIVE_COMPARATOR|Flaxseed and the Mediterranean-like diet|Daily consumption of 30 grams flaxseed in adjunct to the Mediterranean-like diet for 3 months
62235101|NCT03392025|PLACEBO_COMPARATOR|Placebo|Daily consumption of Placebo for 3 months
62235102|NCT01616433|ACTIVE_COMPARATOR|Arthritis Foundation Exercise Program|
62235103|NCT01616433|EXPERIMENTAL|AFEP + 10 Keys to Healthy Aging|"Arthritis Foundation Exercise Program integrated with the 10 Keys to Healthy Aging"
62235104|NCT00842881|NO_INTERVENTION|a|healingstone
62235105|NCT00842881|NO_INTERVENTION|b|stone powder
62425988|NCT04585906|EXPERIMENTAL|Sessions with a community mental health specialist|"Those randomized into the intervention group will receive 4-8 hour-long sessions with a community mental health specialist, taking place over approximately 12 weeks. The common elements treatment approach intervention (called My Pathway to Healing) includes psychoeducation and addresses safety (when identified as a problem area). It also includes relaxation techniques, problem solving, and cognitive coping. The exact number of sessions delivered will depend on presentation and symptom level using a stepped care approach where participants receive only what they need, but the provider can provide additional sessions if needed (i.e., increased element dosage; additional optional elements for specific issues)."
62811334|NCT06404099|ACTIVE_COMPARATOR|Wake-promoting drug: Modafinil or solriamfetol|Participants in Appendix A will be randomized to study drug or control. Participants who meet the eligibility criteria for modafinil will receive either active modafinil or the modafinil-matched control. If modafinil is contraindicated for any reason, participants will be assessed for their ability to take solriamfetol. If participants are eligible for solriamfetol, they will receive either active solriamfetol or the solriamfetol-matched control. If solriamfetol is contraindicated, participants will be excluded from Appendix A. Modafinil and solriamfetol will be analyzed as a single wake-promoting drug condition versus control. The intervention duration will be 10 weeks.
62425989|NCT04585906|ACTIVE_COMPARATOR|Case management|This study employs a randomized control design in which participants in the control group will receive case management and offered the intervention upon completion of their enrollment period.
62811335|NCT06404099|PLACEBO_COMPARATOR|Modafinil-matched placebo or solriamfetol-matched placebo|Participants in Appendix A will be randomized to study drug or control. Participants who meet the eligibility criteria for modafinil will receive either active modafinil or the modafinil-matched control. If modafinil is contraindicated for any reason, participants will be assessed for their ability to take solriamfetol. If participants are eligible for solriamfetol, they will receive either active solriamfetol or the solriamfetol-matched control. If solriamfetol is contraindicated, participants will be excluded from Appendix A. Modafinil and solriamfetol will be analyzed as a single wake-promoting drug condition versus control. The intervention duration will be 10 weeks.
62425990|NCT05739227|EXPERIMENTAL|allogenic CD19-CAR-NK|Enrolled patients will receive prespecified dose of allogenic CD19-CAR-NK cells.
62811336|NCT00930696|EXPERIMENTAL|Extensive Abdominal Lavage|women with full thickness excision of deep endometriosis involving the bowel
62811337|NCT00930696|ACTIVE_COMPARATOR|Standard Rinsing|women with full thickness excision of deep endometriosis involving the bowel
62425991|NCT00725725|EXPERIMENTAL|4 mg Org 25935|Participants took a total of 3 doses of 4 mg Org 25935 prior to therapy sessions over a 2-week period.
62425992|NCT00725725|EXPERIMENTAL|12 mg Org 25935|Participants took a total of 3 doses of 12 mg Org 25935 prior to therapy sessions over a 2-week period.
62594209|NCT03414996|ACTIVE_COMPARATOR|Moderate-intensity continuous exercise training|Duration was adjusted to match total energy expenditure of the high-intensity interval training session. Following 5 min warm-up at 30 % of maximal aerobic power (MAP), patients performed continuous exercise at 60 % MAP during 24 minutes. Patients performed 5-minutes of recovery period at 30 % MAP after the second set. Total time duration was 34 minutes.
62811338|NCT03855696|EXPERIMENTAL|MG1113|"* Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody~* Each vial contains 1mL of study drug~* The doses planned in healthy subjects are 0.5 mg/kg, 1.7 mg/kg, and 3.3 mg/kg by SC injection; 3.3 mg/kg by IV injection. In hemophilia patients, 1.7 mg/kg and 3.3 mg/kg will be administered by SC injection."
62811339|NCT03855696|PLACEBO_COMPARATOR|Placebo of MG1113|"* Placebo of MG1113~* Each vial contains 1mL of study drug"
62811340|NCT01784991|ACTIVE_COMPARATOR|1mg + 1mg Hydromorphone|Patient will receive 1 mg of hydromorphone for pain at timepoint 0. After 15 minutes, patients will be asked if the still need pain medication. If yes, patients will immediately receive 1mg hydromorphone. Patients will be under continuous monitoring for respiratory depression via capnometer. At 60 minutes, pain will be re-assessed for a second time. If needed, physician will give additional pain meds per their discretion.
62819591|NCT03501082|EXPERIMENTAL|L. reuteri PB-W1, Non-Industrialized-Type Diet Start|Participants will receive the non-industrialized-type diet for 3 weeks, followed by a crossover to 3 weeks of consuming their usual diet after a 3-week washout period. Participants will be provided with a one-time dose of L. reuteri PB-W1 strain on day 4 of each diet period. The L. reuteri PB-W1 strain will be provided as a drinkable solution (approximately 2.25x10\^10 viable cells will be provided in 50 ml of water).
62425993|NCT00725725|PLACEBO_COMPARATOR|Placebo|Participants took a total of 3 doses of placebo matched to Org 25935 prior to therapy sessions over a 2-week period.
62425994|NCT02523274|PLACEBO_COMPARATOR|Placebo + exercise|Placebo capsules will be taken orally daily in combination with exercise
62594210|NCT00878566|ACTIVE_COMPARATOR|Usual Care|
62594211|NCT00878566|EXPERIMENTAL|Enhanced pharmacist care|
62594212|NCT04464720|OTHER|Intervention after One Week|This arm will have baseline data on air pollutant levels, stove use and range hood use collected for one week prior to receiving an educational intervention aimed at increasing use of the range hood. Data following the intervention will be collected for an additional week.
62425995|NCT02523274|EXPERIMENTAL|Resveratrol 500 mg/day + exercise|500 mg/day resveratrol taken orally in combination with exercise
62425996|NCT02523274|EXPERIMENTAL|Resveratrol 1000 mg/day + exercise|1000 mg/day resveratrol taken orally in combination with exercise
62235106|NCT01739153|EXPERIMENTAL|CARB diet|The CARB diet will be a low-fat diet where cheese is replaced by starchy carbohydrates and lean meat. The CARB diet will have the same protein content (15 E%) and quality as the CHEESE and MEAT diet but a lower fat content (approx. 25 E%) and a correspondingly higher carbohydrate content (approx. 60 E%).
62235107|NCT01739153|EXPERIMENTAL|CHEESE diet|The CHEESE diet will contain cheese in amounts corresponding to 120 g/day on a 10 MJ diet (approx. 1.8 MJ from cheese). A high dose of cheese is chosen to provoke effects within this short time frame. The cheese types used in this study will be Danbo (45+) and Cheddar (50+) which will be supplied in equal amounts. The CHEESE diet will have the same macronutrient composition as that of the average Danish diet (15 E% from protein, max 35 E% from fat, and max 15 E% from saturated fat).
62235108|NCT01739153|EXPERIMENTAL|MEAT diet|The MEAT diet will be a diet without dairy products. In this diet cheese is mainly replaced by high-fat mixed meat products to achieve saturated fat content and protein quality similar to that of the CHEESE diet. The MEAT diet will have the same macronutrient composition as that of the average Danish diet (15 E% from protein, max 35 E% from fat, and max 15 E% from saturated fat).
62235109|NCT03278951|NO_INTERVENTION|Control Group|The control group received the mHealth devices but no health coaching or feedback. Participants in this group completed the same pre- and post-intervention measurements.
62235110|NCT03278951|EXPERIMENTAL|Video Conferencing Health Coaching|The video conferencing group participants met via the eClinicalWorks® app using their smartphone, and met 12 times with the registered dietitian (RD) and 12 times with the exercise physiologist to discuss exercise and diet goals.
62235111|NCT03278951|EXPERIMENTAL|In Person Health Coaching|The in person group participants met 12 times with the registered dietitian (RD) and 12 times with the exercise physiologist over the course of the study to discuss both diet and exercise regimens.
62235112|NCT01892137|OTHER|Open label active|
62235113|NCT03450720|EXPERIMENTAL|GLPG2737 single dose.|Single dose of GLPG2737 oral suspension.
62425997|NCT04656171|EXPERIMENTAL|Minor patients with Fanconi anemia|MRI of hands and forearm, neuropsychological and neuromotor tests
62425998|NCT04656171|ACTIVE_COMPARATOR|Minor controls|MRI of the hand and forearm, orthopedic evaluation, neuromotor tests of the upper limbs, praxies evaluation, neurocognitive evaluation
62425999|NCT02491307|EXPERIMENTAL|Ginger.io Application Users|This cohort is comprised of individuals that 1) are English-speaking; 2) possess an Android or iOS smartphone; 3) have a diagnosis for anxiety, depression, and/or bipolar disorder; and 4) are active behavioral health patients at any of the four CHCI clinic sites (New London, New Britain, Middletown, or Meriden) where behavioral health providers are using the Ginger.io app with their patients. These patients receive the Ginger.io smartphone application for daily use.
62034854|NCT06131866|EXPERIMENTAL|Intervention group 2 in which psychoeducation based on acceptance and commitment therapy was applied|"After explaining the purpose of the study to the individuals, after obtaining their consent, Personal Information Form, Coping Attitudes Evaluation Scale COPE-R and '' The pre-test will be applied by applying the Meaning and Purpose of Life Scale, then the 8-week Acceptance and Commitment Therapy Based Psychoeducation programme will be applied and the post-test data will be collected. In the 12th week, follow-up test will be applied and evaluation will be made."
62235114|NCT03613753|EXPERIMENTAL|Arm A|Chemotherapy:irinotecan plus lobaplatin
62235115|NCT03613753|ACTIVE_COMPARATOR|Arm B|Chemotherapy:irinotecan
62235116|NCT02425709|ACTIVE_COMPARATOR|Diclofenac|women will receive oral diclofenac 50 mg 1 hour before the procedure.
62235117|NCT02425709|ACTIVE_COMPARATOR|Tramadol|Women will receive oral tramadol 50 mg 1 hour before the procedure.
62235118|NCT02425709|PLACEBO_COMPARATOR|Placebo|Women will receive a placebo 1 hour before the procedure.
62235119|NCT05337163||Lung cancer group|Two groups of sequential enrolled subjects, eligible subjects will be included in the study according to the inclusion criteria. In addition to collecting sputum specimen for the testing kit of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) , eligible subjects also need to undergo the chest CT or pathological examination.
62235120|NCT05337163||The normal group|Two groups of sequential enrolled subjects, eligible subjects will be included in the study according to the inclusion criteria. In addition to collecting sputum specimen for the testing kit of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) , eligible subjects also need to undergo the chest CT or pathological examination.
62235121|NCT03652025|EXPERIMENTAL|Study group|perimenopausal women
62235122|NCT05625594|EXPERIMENTAL|Treatment (leukapheresis, CD19-CAR T cells)|Patients may undergo catheterization, undergo leukapheresis, may receive fludarabine IV and cyclophosphamide IV, and receive CD19-CAR T cells ICV on study. Patients also undergo MRI, PET, CT, collection of blood samples, and CSF aspiration throughout the trial, and lumbar puncture as clinically indicated.
62235123|NCT01465204|NO_INTERVENTION|Control|
62235124|NCT01465204|EXPERIMENTAL|Handwashing Intervention|scaling up handwashing with soap
62235125|NCT01465204|EXPERIMENTAL|Sanitation Intervention|total sanitation and sanitation marketing
62235126|NCT01465204|EXPERIMENTAL|Combined|combined scaling up handwashing with soap and total sanitation and sanitation marketing interventions
62243201|NCT05192798|ACTIVE_COMPARATOR|Group of albumin-bound paclitaxel|Albumin-bound paclitaxel (260mg/m2, intravenous infusion, once every 3 weeks).
62426000|NCT02491307|NO_INTERVENTION|Non-application users|This cohort is comprised of individuals that 1) are English-speaking; 2) possess an Android or iOS smartphone; 3) have anxiety, depression, and/or bipolar disorder; and 4) are patient of a behavioral health clinician that is providing paper surveys to patients in clinic. They do not receive the Ginger.io smartphone application.
62426001|NCT03046147||RYGB patients with preoperative type diabetes|Recruited from a previously investigated cohort (NCT 01202526)
62811341|NCT01784991|ACTIVE_COMPARATOR|Usual Care Group|"Patient will receive pain medicine per doctor's discretion at timepoint 0. After 15 minutes, patients will be asked if they still need pain medication. If yes, physicians will not be notified and patient will continue to have pain managed as deemed necessary by physician per usual care. Patients will be under continuous monitoring for respiratory depression via capnometer. At 60 minutes, pain will be re-assessed for a second time. If needed, physician will give additional pain meds per their discretion."
62426002|NCT03046147||RYGB patients with preoperative normal glucose tolerance|Recruited from a previously investigated cohort (NCT 01202526)
62034855|NCT06131866|NO_INTERVENTION|Control group 2|"After explaining the purpose of the study to the individuals participating in the study, after obtaining their consent, Personal Information Form, Coping Attitudes Evaluation Scale COPE-R and '' Meaning and Purpose of Life Scale'' will be applied and pre-tests will be applied. Then, the post-test will be applied 8 weeks later without any intervention. One month after the post-test, i.e. at the 12th week, a follow-up test will be applied and an evaluation is planned."
62034856|NCT06131866|EXPERIMENTAL|Intervention group 3 in which psychoeducation based on acceptance and commitment therapy was applied|"After explaining the purpose of the study to the individuals, after obtaining their consent, Personal Information Form, Coping Attitudes Evaluation Scale COPE-R and '' The pre-test will be applied by applying the Meaning and Purpose of Life Scale, then the 8-week Acceptance and Commitment Therapy Based Psychoeducation programme will be applied and the post-test data will be collected. In the 12th week, follow-up test will be applied and evaluation will be made."
62034857|NCT06131866|NO_INTERVENTION|Control group 3|"After explaining the purpose of the study to the individuals participating in the study, after obtaining their consent, Personal Information Form, Coping Attitudes Evaluation Scale COPE-R and '' Meaning and Purpose of Life Scale'' will be applied and pre-tests will be applied. Then, the post-test will be applied 8 weeks later without any intervention. One month after the post-test, i.e. at the 12th week, a follow-up test will be applied and an evaluation is planned."
62034858|NCT06131866|EXPERIMENTAL|Intervention group 4 in which psychoeducation based on acceptance and commitment therapy was applied|"After explaining the purpose of the study to the individuals, after obtaining their consent, Personal Information Form, Coping Attitudes Evaluation Scale COPE-R and '' The pre-test will be applied by applying the Meaning and Purpose of Life Scale, then the 8-week Acceptance and Commitment Therapy Based Psychoeducation programme will be applied and the post-test data will be collected. In the 12th week, follow-up test will be applied and evaluation will be made."
62235127|NCT03006354|EXPERIMENTAL|nHFOV|"Ventilator-derived nHFOV will be administered using binasal prongs. Standard Device: Leoni-Plus or Leoni-2 Ventilator, Heinen Löwenstein, Germany Initial nHFOV settings are: MAP: 8cmH2O, Frequency:10 MHz, Amplitude:35 cmH2O (will be adjusted to achieve adequate chest wall vibration), I:E=1:1 and FiO2: adjusted to keep preductal sPO2 between %90-95.~Failure is defined as FiO2 requirement of \>%60, capillary blood gas obtained at the 4th hour of therapy showing pH\<7.20 or pCO2\>65 cmH2O.~When nHFOV failure occurs, nasal intermittent positive pressure ventilation (nIPPV) will be applied as a rescue therapy with the following settings: Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10 L/min, FiO2:adjusted to keep preductal sPO2 between %90-95."
62235128|NCT03006354|ACTIVE_COMPARATOR|nCPAP|"Ventilator-derived nCPAP will be administered using binasal prongs. Standard Device: Leoni-Plus or Leoni-2 Ventilator, Heinen Löwenstein, Germany Initial nCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-95.~Failure is defined as FiO2 requirement of \>%60, capillary blood gas obtained at the 4th hour of therapy showing pH\<7.20 or pCO2\>65 cmH2O.~When nCPAP failure occurs, nasal intermittent positive pressure ventilation (nIPPV) will be applied as a rescue therapy with the following settings: Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10 L/min, FiO2:adjusted to keep preductal sPO2 between %90-95."
62235129|NCT06464003||Treatment need|Individuals with objective treatment need
62235130|NCT06464003||No treatment need|Individuals with no objectively determined treatment need
62594213|NCT05414396|EXPERIMENTAL|Supportive care (EML program)|Participants attend EML program sessions weekly for 12 weeks including an educational session chronic disease risk reduction via nutrition and physical activity, a physical activity session, and a cooking/taste test demonstration.
62594214|NCT01050010|OTHER|Dedicated extremity MRI|Structural deterioration radiographic assessed by dedicated extremity MRI
62034859|NCT06131866|NO_INTERVENTION|Control group 4|"After explaining the purpose of the study to the individuals participating in the study, after obtaining their consent, Personal Information Form, Coping Attitudes Evaluation Scale COPE-R and '' Meaning and Purpose of Life Scale'' will be applied and pre-tests will be applied. Then, the post-test will be applied 8 weeks later without any intervention. One month after the post-test, i.e. at the 12th week, a follow-up test will be applied and an evaluation is planned."
62034860|NCT06385808|EXPERIMENTAL|MTBF regimen group|The relapsed or refractory acute myeloid leukemia patients will pretreated with the MTBF regimen prior to salvageable allogeneic hematopoietic stem cells.
62034861|NCT05490615|EXPERIMENTAL|Mindfulness Intervention (Group-A)|"Total length of study for participants in Group-A:15 Week~Six weekly sessions (each 60 minutes in length) of group based virtual mindfulness instruction, co-led by a mindfulness teacher and two autistic adults, following a workbook designed for autistic adults. In between sessions, participants are encouraged to complete homework and keep a record of when they practice formal and informal mindfulness practices. In addition, participants are provided with a link to autism informed mental health resources (https://www.yorku.ca/health/lab/ddmh/am-help/)"
62034862|NCT05490615|NO_INTERVENTION|Waitlist Control (Group-B)|"Total length of study for participants in Group-B: 30 Week~A waitlist control group is an ethical alternative to no-treatment control groups when studying psychological and behavioral interventions. This group will have access to intervention at the end of the study as well. All waitlist participants are provided with a link to autism informed mental health resources (https://www.yorku.ca/health/lab/ddmh/am-help/)"
62426003|NCT04959565|EXPERIMENTAL|16 online lectures in sports nutrition + 8 individual consultations for 16 weeks|"Non-smoking, non-contraceptive using, competitive female endurance athletes, 18-35 years of age, training a minimum of five times per week will be recruited through social media and endurance sports clubs (running, cycling, orienteering, triathlon, biathlon, and cross-country skiing) in Norway, Sweden, Germany, and Ireland.~Athletes with a LEAF-Q score ≥8 + EDE-Q score \< 2.5 who meets the other inclusion criteria will be invited for further participation.~The lectures are designed for female endurance athletes at risk of RED-S. The participants will get access to a new lecture every week during the intervention."
62594215|NCT06623890||Omaveloxolone Naïve Participants|Participants with FA who will initiate omaveloxolone treatment per its approved label will be followed prospectively for up to 5 years.
62034863|NCT06266338|EXPERIMENTAL|Pembrolizumab and Lenvatinib Arm|"Pembrolizumab 200 mg q 3 weeks IV Lenvatinib 20 mg PO QD Continue q3 weeks~Pembrolizumab and Lenvatinib will be given together in this trial for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing and Lenvatinib daily. Participants who complete study intervention after 2 years of pembrolizumab and lenvatinib are eligible for up to 1 year of additional pembrolizumab and lenvatinib (second course) upon experiencing disease progression."
62034864|NCT00062127|EXPERIMENTAL|Arm I (irinotecan hydrochloride and thalidomide)|Patients receive irinotecan IV over 90 minutes on days 1 and 22 and oral thalidomide once daily on days 15-28. All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62034865|NCT00062127|EXPERIMENTAL|Arm II (irinotecan hydrochloride and thalidomide)|Patients receive irinotecan as in arm I and oral thalidomide once daily on days -6 to 7. All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62034866|NCT06665763|EXPERIMENTAL|Na-Lactate infusion|
62034867|NCT06665763|PLACEBO_COMPARATOR|Saline infusion (Placebo)|
62235131|NCT06464003||Controls|Random sample of individuals
62235132|NCT04107350|EXPERIMENTAL|whole body vibration on|vibration machine on combined with conventional physical therapy
62235133|NCT04107350|SHAM_COMPARATOR|whole body vibration off|vibration machine off combined with conventional physical therapy
62594216|NCT06341907|EXPERIMENTAL|Neoantigen polypeptide vaccine|Each patient synthesized 5 to 20 neoantigen peptides and was injected with 1 to 4 injections of 1ml polypeptide-poly-ICLC mixture each time. The first round of immunization was administered subcutaneously on days 1, 4, 8, 15, and 22, and the second round of immunization was administered on days 54 and 84
62811342|NCT02676414|OTHER|Education program|"Group of patients participating in the interactive hypertension education program of the DHL© My blood pressure - OK!"
62034868|NCT01260220|ACTIVE_COMPARATOR|Circumferential|Completing a complete circle of RF lesions around the left and right pulmonary veins
62034869|NCT01260220|EXPERIMENTAL|Segmental|Isolating the left and right pulmonary veins through RF lesions with a segmental antral approach.
62235134|NCT04493190|EXPERIMENTAL|Scapular control training group|Participants in these group will be taught how to correctly movement arm overhead. And they will undergo series of movement tasks with mirror and also receive scapular-focused exercises. The difficulty of the movements protocol will increase weekly.
62235135|NCT04493190|EXPERIMENTAL|General exercise group|Participants in this group will receive a general strengthening exercise, focusing on the shoulder muscles. And the load will progressively increase weekly.
62235136|NCT04493190|NO_INTERVENTION|Healthy subject group|No intervention.
62235137|NCT01013766|OTHER|AM/PM/BID|Subjects will receive a dose of 100mg in the AM on Day 1, followed by a dose of 100mg in the PM on Day 4, and a dose of 50mg BID on Day 6.
62235138|NCT01013766|OTHER|PM/AM/BID|Subjects will receive a dose of 100mg in the PM on Day 1, followed by a dose of 100mg in the AM on Day 4, followed by 50mg BID on Day 6.
62034870|NCT06097468|EXPERIMENTAL|Phase I, Dose Finding - Starting Dose (20,000 mg)|Participants will ingest oral nisin once daily starting two weeks before planned complete OSCC resection surgery and will continue once daily administration for 6 additional months post-surgery (concurrent with adjuvant radiation/chemoradiation, for participants whose routine treatment plan includes adjuvant therapy). Nisin will be temporarily withheld at the time of OSCC resection surgery while the participant is under inpatient care. The starting dose level, with dose modification permitted for toxicity management or intolerability will be 20,000 mg (2 x 10 g bottles) per day.
62034871|NCT06097468|EXPERIMENTAL|Phase IIa, Dose Expansion (MTD/RP2D)|Participants will ingest oral nisin once daily starting two weeks before planned complete OSCC resection surgery and will continue once daily administration for 6 additional months post-surgery (concurrent with adjuvant radiation/chemoradiation, for participants whose routine treatment plan includes adjuvant therapy). Nisin will be temporarily withheld at the time of OSCC resection surgery while the participant is under inpatient care. The dose level will be determined by the outcomes in Phase 1 (RP2D), with dose modification permitted for toxicity management or intolerability.
62034872|NCT04010994|OTHER|rtACS|repetitive transorbital ACS
62034873|NCT01692392||Pectus carinatum|Patients who have undergone surgical repair of pectus carinatum.
62235139|NCT05866887|EXPERIMENTAL|Sleep ALL Night|"Participants and parents will complete study procedures as outlined:~* Baseline survey completed by participant parent(s).~* Introduction to Sleep ALL Night action plan.~* Review of psychoeducational website and completion of sleep diary.~* Survey completed by participant parent(s)."
62426004|NCT04959565|NO_INTERVENTION|Control|"Non-smoking, non-contraceptive using, competitive female endurance athletes, 18-35 years of age, training a minimum of five times per week will be recruited through social media and endurance sports clubs (running, cycling, orienteering, triathlon, biathlon, and cross-country skiing).~Athletes with a LEAF-Q score ≥8 + EDE-Q score \< 2.5 who meets the other inclusion criteria will be invited for further participation."
62426005|NCT04959565|EXPERIMENTAL|16 online lectures in sports nutrition for 16 weeks|"Non-smoking, non-contraceptive using, competitive female endurance athletes, 18-35 years of age, training a minimum of five times per week will be recruited through social media and endurance sports clubs (running, cycling, orienteering, triathlon, biathlon, and cross-country skiing) in Norway, Sweden, Germany, and Ireland.~Athletes with a LEAF-Q score ≥8 + EDE-Q score \< 2.5 who meets the other inclusion criteria will be invited for further participation.~The lectures are designed for female endurance athletes at risk of RED-S. The participants will get access to a new lecture every week during the intervention."
62426006|NCT01987258|NO_INTERVENTION|Control|No exercise (control experiment)
62426007|NCT01987258|EXPERIMENTAL|Interval Walking|A one hour interval walking exercise bout
62426008|NCT01987258|EXPERIMENTAL|Continuous walking|A one hour continuous walking exercise bout
62594217|NCT06620952||Patients operated for a disease located in posterior fossa|Patients operated for a disease located in posterior fossa for which a RS, KR or CH approach has to be performed. Patients between January 2018 and October 2023 will be considered for the study. Lacking of clinical, radiological and surgical data represe
62426009|NCT01426321|ACTIVE_COMPARATOR|Imaging guided LV lead positioning|
62034874|NCT00456638|EXPERIMENTAL|Depodur|Depodur arm
62034875|NCT00456638|ACTIVE_COMPARATOR|Traditional|traditional management
62034876|NCT05428735|ACTIVE_COMPARATOR|Portal Vein Embolization (PVE) alone - (control arm)|Portal Vein Embolization (PVE) alone
62034877|NCT05428735|EXPERIMENTAL|Combined Portal and Hepatic Vein Embolization (PVE/HVE) - (interventional arm)|Combined Portal and Hepatic Vein Embolization (PVE/HVE) - (interventional arm)
62034878|NCT02978027|ACTIVE_COMPARATOR|Brief Advice|The brief advice protocol was designed by removing MI-consistent elements from the NIAAA Clinician's Guide. The protocol involves screening and assessment using the NIAAA pre-screen and single-question screen and assessing for quantity and frequency. Patients exceeding recommended limits receive feedback, information, and advice to cut down drinking to recommended levels. All patients are provided with a tip sheet on strategies for cutting down and encouraged to follow-up with a behavioral health provider with any questions or concerns.
62235140|NCT02441166|OTHER|Mastocytosis diagnosis|For each enrolled subject, 5 mL sample of peripheral blood and 1 mL sample of BM aspirate will be collected the same day to do diagnosis mastocytosis tests (quantification of the kit mutations by qPCR, plasma tryptase level, immunophenotyping of BM mastocytes by flow cytometry, BM tryptase level, degree of dilution of the BM aspirate...) using the WHO criteria as the reference standard.
62235141|NCT04029935|EXPERIMENTAL|Physical Fatigue Condition|
62235142|NCT04029935|PLACEBO_COMPARATOR|Control Condition|
62235143|NCT05343026|EXPERIMENTAL|HA treatment group|Participants in the treatment group are required to wear the HAs for at least 3 hours per day, with 24 days per month. Additionally, they will receive regular counseling and lifestyle education from their physicians.
62235144|NCT05343026|NO_INTERVENTION|non-HA treatment group|Non-HA treatment group is a waiting list control group (WLC) in which participants will receive the intervention after the waiting period has passed. They will only receive regular counseling and lifestyle education from their physicians in this waiting period.
62594218|NCT06610201||VWD, Type 1 (residual VWF antigen and/or activity less than 40 IU per dL)|
62594219|NCT06610201||VWD, Type 1 (activity less than 50 IU per dL)|
62235145|NCT01088100||Patients with POCD - cases|Out of the 976 patients included in the ISPOCD2 study (Abildstrom H, Christiansen M et al. Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery. Anesthesiology 2004;101:855-61) the 93 patients with POCD whose blood samples are stored will be included together with 2x93 controls (without POCD), who will be matched by type of surgery, age, education, ASA-score and sex.
62235146|NCT01088100||Patients without POCD - controls|Out of the 976 patients included in the ISPOCD2 study (Abildstrom H, Christiansen M et al. Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery. Anesthesiology 2004;101:855-61) the 93 patients with POCD whose blood samples are stored will be included together with 2x93 controls (without POCD), who will be matched by type of surgery, age, education, ASA-score and sex.
62235147|NCT01562509|ACTIVE_COMPARATOR|Standard implementation strategy|Standard intervention
62235148|NCT01562509|EXPERIMENTAL|Innovative implementation strategy|Implementation tools
62243202|NCT05192798|EXPERIMENTAL|Group of albumin-bound paclitaxel combined with apatinib|Albumin-bound paclitaxel (260mg/m2, intravenous infusion, once every 3 weeks)+ apatinib mesylate tablet (500 mg, orally, once daily, every 3 weeks).
62426010|NCT01426321|NO_INTERVENTION|Standard LV lead positioning|The LV lead position is decided at the discretion of the treating physician. Cardiac CT images are available for viewing, but no echocardiography data regarding segmental myocardial strain are available.
62426011|NCT05380622||Without ICA or deferral of PCI after ICA group|Patients didn't undergo invasive coronary angiography (ICA) or with a vessel determined to defer revascularization.
62426012|NCT05380622||PCI group|Patients with a vessel that undergo percutaneous coronary intervention (PCI)
62426013|NCT00709020|EXPERIMENTAL|White Button Mushroom Extract|
62426014|NCT05224518|EXPERIMENTAL|home-based elastic band training group|The interventional group received 12 weeks of home-based elastic band training, three days a week, with progressive, medium-intensity exercise.
62426015|NCT05224518|ACTIVE_COMPARATOR|stretching exercises group|The control group received home stretching exercises three days a week for 12 weeks.
62426016|NCT02030834|EXPERIMENTAL|Cohort A|murine CART19
62811343|NCT02676414|NO_INTERVENTION|Controls|"Group of patients not participating in the interactive hypertension education program of the DHL© My blood pressure - OK! (usual care)"
62426017|NCT02030834|EXPERIMENTAL|Cohort B|T cell/histiocyte-rich Diffuse Large B Cell Lymphoma (DLBCL) treated with murine CART19
62243203|NCT05192798|EXPERIMENTAL|Group of albumin-bound paclitaxel combined with bevacizumab|Albumin-bound paclitaxel (260mg/m2, intravenous infusion, once every 3 weeks) + bevacizumab (7.5mg/kg, intravenous infusion, once every 3 weeks).
62426018|NCT02030834|EXPERIMENTAL|Cohort C|Diffuse Large B Cell Lymphoma (DLBCL) treated with humanized CART19
62426019|NCT00883142||Group 1|
62426020|NCT03178422|EXPERIMENTAL|CQSS2 System (nicotine 21 mg)|Active CQSS2 System (nicotine 21 mg) with Digital Coach. One active Drug Cartridge will be used to transdermally administer 21 mg nicotine via a 5.4% w/v solution in an aqueous EtOH mixture per day. Metered pulses of 125 µL of solution will automatically be delivered by the assembled CQSS2 (containing the Control Unit and Drug Cartridge) at Time = 0, 0.5, 1, 7, 7.5, and 13 hours.
62594220|NCT06610201||VWD, Type 2 and Type 3|
62594221|NCT03241628||Dressing Glove|"Fitting bespoke dressing gloves (viscose Class 1 medical device) and evaluating dressing glove performance in the management of blisters using patient recorded outcome measures. The aim is to obtain proof of concept data for the dressing glove as an acceptable alternative to patch work dressings held in place with bandages.~The study protocol recommends a daily change of the dressing glove but the patients also contribute their preference for frequency of dressing changes."
62594222|NCT05928884||Healthy Normals|Participants with no chronic pain over a three-year timeframe.
62594223|NCT05928884||MP without TPs|Participants with chronic low back pain who are classified as having myofascial pain and no trigger points.
62594224|NCT05928884||MP with latent TPs|Participants with chronic low back pain who are classified as having myofascial pain and latent trigger points.
62811344|NCT06422377|EXPERIMENTAL|Soticlestat|Participants with DS or LGS will receive soticlestat, mini-tablets, at the starting dose of 100 mg to 300 mg, administered orally with or without food (oral or enteral feeds), twice daily (BID) based on body weight up to 4 weeks in Titration Period. Participants will continue to receive the dose that they are on at the end of the titration period, for first 12 weeks in the Maintenance Period. The dose can be adjusted in the maintenance period as per the body weight after the initial 12 weeks. Dose will be tapered down if participants decide to discontinue the treatment. Total duration of the treatment will be up to approximately 52 weeks.
62034879|NCT02978027|ACTIVE_COMPARATOR|NIAAA Clinician's Guide|"The NIAAA brief intervention was adapted directly from the NIAAA publication Helping Patients Who Drink Too Much: A Clinician's Guide. The protocol screens using the NIAAA pre-screen and single-questions. Patients exceeding recommended limits receive feedback, information, and advice to cut down. For patients unwilling to make a change, the clinician restates their concern, encourages self reflection by asking the patient about reasons to cut down on drinking and barriers to change, and reaffirms willingness to help. For patients willing to make a change, the clinician helps the patient develop a plan to cut down within maximum limits, agree on specific steps and strategies, and provides a tip sheet on strategies for cutting down."
62034880|NCT02978027|EXPERIMENTAL|Motivational Interviewing (MI)|The MI intervention condition was also adapted from the NIAAA Clinician's Guide, with additional modification to include elements of MI. Clinicians normalize Screening and Brief Intervention (SBI) and ask the patient's permission before discussing alcohol use. The NIAAA pre-screen and single-question screen are administered. Assessment of quantity, frequency, and Alcohol Use Disorder symptoms is done using open questions. The ask-tell-ask technique is used to share feedback and exchange information regarding U.S adult drinking patterns. For patients low in readiness to make a change, clinicians build readiness using structured MI tools. For patients high in readiness to change, the ask-tell-ask technique is used to explore strategies for cutting down and develop an action plan.
62034881|NCT05615792||patients with coronavirus disease 2019 (COVID-19)|Patients diagnosed with COVID-19 in Hubei Province
62034882|NCT06482281||Childhood cancer survivors|Childhood cancer cases (0-19 years old) reported to the national cancer registers from 1971 in Sweden and Denmark, who were alive five years after the cancer diagnosis
62034883|NCT06482281||Matched comparisons|Five general population comparisons were randomly selected and matched to the childhood cancer survivors by sex and year of birth
62034884|NCT06482281||Siblings|All siblings of the childhood cancer survivors
62811345|NCT02050113|EXPERIMENTAL|Endovascular repair|Endovascular repair of Complex Aortic Aneurysm using a physician modified stent graft. custom made device or arch branch device.
62811346|NCT01415882|EXPERIMENTAL|Arm A (ixazomib citrate and dexamethasone, closed to accrual)|Patients receive ixazomib citrate PO on days 1, 8, and 15. Patients with lack of minor response by the end of the second cycle or lack of partial response by the end of the fourth cycle also receive dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62034885|NCT06482281||Childhood cancer cases|Childhood cancer cases (0-19 years old) reported to the national cancer registers from 2015 in Sweden and Denmark. They will then further divided in three groups: before the pandemic (2015-2019), during the pandemic (2020-2022), and after the pandemic (2022-)
62034886|NCT04608370|EXPERIMENTAL|Active tPBM session group|Participants in the active tPBM group will take active tPBM session, which include 12 minutes active tPBM by a 1064nm laser to the left forehead , 6 minutes resting-state fNIRS measurement, and 8 minutes digital n-back task-an ubiquitous cognitive task for working memory.
62034887|NCT04608370|ACTIVE_COMPARATOR|Sham tPBM session group|Participants in the sham tPBM group will take sham tPBM session, which include 12 minutes sham tPBM by a 1064nm laser to the left forehead , 6 minutes resting-state fNIRS measurement, and 8 minutes digital n-back task-an ubiquitous cognitive task for working memory.
62034888|NCT05428566|EXPERIMENTAL|Pulse-based diet|"The pulse diet will include two pulse-based meals; each pulse meal will be consisted of about one cup of non-oil seed pulses, different varieties of pulses (dried beans, peas, lentils, lupine, and chickpeas) will be used. Varieties of pulses will be included and the participants will be provided with recipes and preparation ideas, which would enhance the palatability of pulses, give different taste choices, and ease the follow of the prescribed diet and encourage the participants to consume it for the target duration.~The diet is isocaloric and balanced with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein."
62243204|NCT06734897|EXPERIMENTAL|Group A|Group A will begin six months of music therapy immediately after cochlear implantation.
62243205|NCT06734897|EXPERIMENTAL|Group B|Group B is the delayed group and will start music therapy six months after group A.
62243206|NCT06734897|EXPERIMENTAL|Group C|Group C won't receive any music therapy and serves as a control group.
62243207|NCT00846885|EXPERIMENTAL|1|
62243208|NCT00846885|ACTIVE_COMPARATOR|2|
62426021|NCT03178422|ACTIVE_COMPARATOR|NicoDerm® CQ® patch (21 mg)|NicoDerm® CQ® patch (21 mg) with committedquitters.com. The NicoDerm patch transdermally administers 21 mg of nicotine per day. The NicoDerm patch is applied each morning of the treatment period after waking and worn for approximately 24 hours.
62426022|NCT05221879|NO_INTERVENTION|Patients with target factor 10a levels|Patients with target factor 10a levels continued to recieve the standard Enoxaparin dose of 40 mg SC daily.
62811347|NCT01415882|EXPERIMENTAL|Arm B (ixazomib citrate and dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and dexamethasone PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62594225|NCT05928884||MP with active TPs|Participants with chronic low back pain who are classified as having myofascial pain and active trigger points.
62594226|NCT05883774|ACTIVE_COMPARATOR|rTMS|Patients are treated with repetitive transcranial magnetic stimulation (rTMS).
62594227|NCT05883774|SHAM_COMPARATOR|sham-rTMS|Patients are treated with sham repetitive transcranial magnetic stimulation (sham-rTMS).
62594228|NCT05314842|ACTIVE_COMPARATOR|control group|the group that have caries in primary molars and treat them with formocresol
62034889|NCT05428566|PLACEBO_COMPARATOR|TLC diet|"TLC group will be provided with instructions to follow the TLC guidelines and a sample diet plan will be individualized for each participant. The healthy TLC diet will be tailored for each participant according to their energy levels in order to achieve the following amount of nutrients: less than 7% of total calories of saturated fatty acids, up to 10% of total calories of polyunsaturated fat, up to 20% of total calories of monounsaturated fat, less than 200 mg a day of cholesterol, at least 5 to 10 grams a day of soluble fiber.~The diet is isocaloric and balanced with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein."
62034890|NCT04003116|EXPERIMENTAL|Supplementary oxygen|Supplementary oxygen added to conventional anticoagulant treatment.
62034891|NCT04003116|NO_INTERVENTION|Standard medical therapy|Standard management.
62034892|NCT06145542|EXPERIMENTAL|AR group: aerobic exercise before resistance exercise|
62034893|NCT06145542|ACTIVE_COMPARATOR|RA group: resistance training before aerobic training|
62034894|NCT03774628|EXPERIMENTAL|Chengdu Kanghua (one booster shot)|one dose, A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd.
62034895|NCT03774628|EXPERIMENTAL|Chengdu Kanghua (two booster shots)|two doses at 0 and 3 days, on A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd.
62034896|NCT01436058|EXPERIMENTAL|stem cell recipient|patients with ankle joint osteoarthritis
62034897|NCT05624658|ACTIVE_COMPARATOR|PCSK9 inhibitors in combination Atorvastatin at a dose of 80 mg /Rosuvastatin 40 mg/ day|Patients who showed high compliance and did not reach the target LDL-C values 1 month after the development of ACS on the 2nd visit will be randomized into two groups of 60 patients each. Group 1 - taking PCSK9 inhibitors (Alirocumab 150 mg by subcutaneous injection once every 2 weeks or Evolocumab 140 mg by subcutaneous injection once every 2 weeks - open-label prescription of drugs) while taking Atorvastatin at a dose of 80 mg./ Rosuvastatin 40 mg / day.
62034898|NCT05624658|ACTIVE_COMPARATOR|Ezetimibe at a dose of 10 mg in combination with Atorvastatin 80 mg / Rosuvastatin 40 mg/ day.|Group 2 - receiving Ezetimibe at a dose of 10 mg in combination with Atorvastatin 80 mg / Rosuvastatin 40 mg/day.
62034899|NCT01452750|EXPERIMENTAL|TAK-438 10 mg QD|
62034900|NCT01452750|EXPERIMENTAL|TAK-438 20 mg QD|
62235149|NCT05859061|EXPERIMENTAL|Cryoanalgesia|Intraoperative analgesic administration will be at the discretion of the anesthesia provider. Once adequate hemostasis is achieved and prior to sternal wire placement and chest closure, patients will undergo cryoablation of bilateral T2 - T6 intercostal nerves. The cryoprobe will be positioned under direct visualization and ablation of the intercostal nerve will be performed 2-4 cm lateral to the internal mammary artery near the mid-clavicular line. Each cryoablation at -50°C to -70°C will be applied for 120 seconds to sustain an ablation length of 2-3 cm at each intercostal nerve (bilateral T2 - T6).
62235150|NCT05859061|NO_INTERVENTION|Standard of Care (Control)|Patients in this arm will receive standard of care pain management alone.
62235151|NCT03630341|EXPERIMENTAL|study group|This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral carnitine 1g tablet, three times per day from the third day until the day of the pregnancy test.
62235152|NCT03630341|ACTIVE_COMPARATOR|control group|This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral placebo tablet, three times per day from the third day until the day of the pregnancy test.
62426023|NCT05221879|OTHER|Patients with sub-therapuetic factor 10a levels|In patients with sub-therapuetic factor 10a levels we increased the Enoxaparin dose to 60 mg SC daily.
62426024|NCT06282666|EXPERIMENTAL|Epidural|"Combined spinal and epidural anesthesia will be performed before the surgery in the patient's lateral position with the operated hip down. The Espocan set will be used (B.Braun). After identification of the epidural space on the level of L3/L4, 0.5% bupivacaine (Marcaine Heavy Spinal) with fentanyl (5 mcg/mL) will be injected through the 27 G pencil point spinal needle. Then, the epidural catheter will be placed and a test dose of 2% lidocaine (2 mL) will be administered. At the end of the surgery, the patient will receive 5 mL of a mixture containing 0.1% bupivacaine with fentanyl (2 mcg/mL). Moreover, we will administer 5 mg of oxycodone i.v.~the mixture of bupivacaine and fentanyl will be administered in a constant flow of 5 mL/h for a day."
62594229|NCT05314842|EXPERIMENTAL|experimental group|the group that have caries in primary molars and treat them with premixed bioceramic MTA
62811348|NCT01415882|EXPERIMENTAL|Arm C (higher-dose ixazomib citrate and dexamethasone)|Patients receive higher doses of ixazomib citrate PO on days 1, 8, and 15 and dexamethasone PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62034901|NCT01452750|ACTIVE_COMPARATOR|Lansoprazole 15 mg QD|
62034902|NCT04788758|EXPERIMENTAL|Health Services Research (G8 screening tool, referral)|"PHASE I: Registered Nurses receive training on how to administer the G8 screening tool utilizing an Epic flowsheet to patients using a self-directed education module and by direct assessment by a geriatrician.~PHASE II: Patients complete the G8 screening tool questionnaire over 10 minutes as part of their standard initial assessment, and their answers are entered into their EHR flowsheet. Patients who score =\< 14 on the G8 are referred for a CGA at SAOC, and these patients and their medical oncologists are made aware. Within 2 weeks of the initial screening, the results are communicated with the patient and medical oncologist at a 2-hour SAOC visit. Patients with a score of \> 15 on the G8 are made aware of their results without any referral generated."
62034903|NCT00970034||AF|Patients with degenerative mitral valve regurgitation and permanent atrial fibrillation who require mitral valve repair or replacement.
62034904|NCT00970034||SR|Patients with degenerative mitral valve regurgitation and maintaining sinus rhythm who require mitral valve repair or replacement.
62235153|NCT04302454|ACTIVE_COMPARATOR|Radiotherapy without hormonal therapy|Metastase-directed radiotherapy without the addition of hormonal therapy
62235154|NCT04302454|EXPERIMENTAL|Radiotherapy combined with hormonal therapy|Metastase-directed radiotherapy with the addition of of short-term hormonal therapy (6 months)
62594230|NCT05705492|EXPERIMENTAL|Arm I (olanzapine, optional biospecimen collection)|Patients receive a lower (2.5mg) dose of olanzapine orally (PO) nightly for 12 weeks in the absence of unacceptable toxicity. Patients may choose to enroll in an additional 12 weeks of treatment. Patients can choose to undergo computed tomography (CT) scan at baseline and monthly blood sample collections on study.
62811349|NCT01415882|EXPERIMENTAL|Arm D (ixazomib citrate, dexamethasone, and cyclophosphamide)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and cyclophosphamide PO (cycles 1-18 only) and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62811350|NCT01415882|EXPERIMENTAL|Arm E (ixazomib citrate, cyclophosphamide, daratumumab)|Patients receive ixazomib citrate PO on days 1, 8, and 15, cyclophosphamide PO (cycles 1-12 only) on days 1, 8, 15, 22, and daratumumab IV on days 1, 8, 15, 22 (cycles 1-2), days 1 and 15 (cycles 3-6), and day 1 in all subsequent cycles. Patients also receive dexamethasone IV or PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62811351|NCT05262114||Pre-cursor text|A pre-notification text message (SMS) will be sent to eligible people informing them of their imminent invitation to participate in The Who, two days later a brief text message (SMS) will be sent from the general practice to eligible people, inviting them to participate in The Who.
62811352|NCT05262114||Invitation only|A brief text message (SMS) will be sent from the general practice to eligible people, inviting them to participate in The Who.
62811353|NCT01347502||HCPs with smartphone|healthcare providers in MICU who have smart cellular phones
62811354|NCT01347502||HCP with non-smart phones|healthcare providers in MICU who have non-smart cellular phones
62034905|NCT02265042|EXPERIMENTAL|electrical stimulation|electrical Stimulation using the Stimulette device
62594231|NCT05705492|EXPERIMENTAL|Arm II|Patients receive a higher dose (5 mg) of olanzapine PO nightly for 12 weeks in the absence of unacceptable toxicity. Patients may choose to enroll in an additional 12 weeks of treatment. Patients undergo an optional baseline CT scan and collections of monthly blood samples on study.
62811355|NCT03029806|ACTIVE_COMPARATOR|Afr-Amer risk allele|African Americans carrying the LSD1 affected allele
62034906|NCT01457365||subjects|it is a cross-sectional research and there is only one group.
62034907|NCT00937924|PLACEBO_COMPARATOR|Meperidine and midazolam group|Control. Normal Saline Injections.
62034908|NCT00937924|EXPERIMENTAL|Meperidine and midazolam, plus Diphenhydramine group|Diphenhydramine injections given as adjunct sedative.
62243209|NCT06049082|EXPERIMENTAL|Cohort 1: Low dose KB408|Single dose of KB408 (low dose)
62034909|NCT00937924|EXPERIMENTAL|Meperidine and midazolam, plus Promethazne group|Promethazine given as an adjunct sedative.
62034910|NCT01435538|EXPERIMENTAL|Care pathway teams.|In this experimental arm, the interprofessional teams will develop and implement a care pathways.
62594232|NCT05705492|PLACEBO_COMPARATOR|Arm III|ARM III: Patients receive placebo PO nightly for 12 weeks in the absence of unacceptable toxicity. Patients may choose to enroll in an additional 12 weeks of treatment. Patients undergo CT scan and monthly collection of blood samples on study.
62594233|NCT04183738|ACTIVE_COMPARATOR|SOC|darunavir/ritonavir 800/100mg + 2 NRTIs po od
62811356|NCT03029806|PLACEBO_COMPARATOR|Cauc risk allele|Caucasians carrying the LSD1 affected allele
62811357|NCT03029806|PLACEBO_COMPARATOR|Afr-Amer non-risk allele|African Americans carrying the LSD1 non-risk allele
62811358|NCT03029806|PLACEBO_COMPARATOR|Cauc non-risk allele|Caucasians carrying the LSD1 non-risk allele
62426025|NCT06282666|EXPERIMENTAL|ESPB|"Spinal anesthesia will be performed in the patient's lateral position with the operated hip down. 0.5% bupivacaine (Marcaine Heavy Spinal) with fentanyl (5 mcg/mL) will be used and a 25-27 G pencil point spinal needle.~The lumbar ESPB will be performed under ultrasound control at the L3 level on the ipsilateral site of the surgery. After dissection with 0.9 NaCl, a catheter will be left in the ESP. Then, we will administer 0.25% bupivacaine with epinephrine (5mcg/mL), 0.4 mL per kg, up to 40 mL. Moreover, 5 mg of oxycodone i.v. will be administered A mixture of 0.1% bupivacaine with fentanyl (2 mcg/mL) will be given in a constant flow of 5 mL/h for a day."
62426026|NCT02063386|EXPERIMENTAL|AZD1722|Single oral dose 15 mg of \[14C\]AZD1722
62034911|NCT01435538|NO_INTERVENTION|Usual care teams.|In the no intervention arm, the interprofessional teams will deliver usual care without implementing the intervention.
62034912|NCT04067466|EXPERIMENTAL|Fiber product|Fiber product: Inulin, maltodextrin, gum guar, plum powder
62426027|NCT00994721||pancreatic cancer|resected pancreatic cancer
62426028|NCT06413589|OTHER|control group|The first group constitutes the control group that was administered the standard treatment protocol for clozapine toxicity.
62426029|NCT06413589|ACTIVE_COMPARATOR|SMOF lipid treated group|The second group received the SMOF lipid infusion in addition to the standard protocol.Drug: SMOF lipid 20% SMOF 20%; a blend of soybean oil, medium-chain triglycerides, olive oil, and fish oil, is a new lipid emulsion product that was provided as a bolus dose of 1.5ml/kg for one hour, followed by a maintenance dose of 6 ml/kg for a period of four hours to the active comparator group
62811359|NCT06153134|ACTIVE_COMPARATOR|Curcuma xanthorriza Roxb.|"Fifteen patients will apply 10% Curcuma xanthorriza Roxb. cream topically at the half of the face, once daily in night, for 2 months.~Along with study drug or positive control, patients will receive standard uniform sunscreen and face wash."
62034913|NCT04067466|PLACEBO_COMPARATOR|Control product|Maltodextrin, plum powder
62594234|NCT04183738|EXPERIMENTAL|DOL|darunavir/ritonavir 800/100mg + dolutegravir 50mg po od
62811360|NCT06153134|ACTIVE_COMPARATOR|Kojic acid|"Fifteen patients will apply 2% kojic acid cream topically at the half of the face, once daily in night, for 2 months.~Along with study drug or positive control, patients will receive standard uniform sunscreen and face wash."
62034914|NCT03297788|EXPERIMENTAL|Arm A: SRS|Patient receive stereotactic radiosurgery (SRS), dose prescription according to the size of radiated brain metastases
62034915|NCT03297788|ACTIVE_COMPARATOR|Arm B: WBRT|Patients receive whole brain radiotherapy (WBRT)
62034916|NCT04897165|EXPERIMENTAL|Resilience training with mobile HRV-BfB based on an e-learning approach (with digital lectures)|
62034917|NCT04897165|EXPERIMENTAL|Resilience training with mobile HRV-BfB based on a blended learning approach (with live lectures)|
62034918|NCT04897165|NO_INTERVENTION|Waitlist controls|
62034919|NCT05265468|EXPERIMENTAL|Jones Group (Strain Counterstrain)|Jones Group consist in 90 seconds in a ralease positioning of no pain in muscle acortation
62594235|NCT04183738|EXPERIMENTAL|D2N|dolutegravir 50mg + tenofovir + emtricitabine or lamivudine po od
62594236|NCT00877409|ACTIVE_COMPARATOR|Acnase|
62594237|NCT00877409|PLACEBO_COMPARATOR|Vehicle|
62811361|NCT01292135|EXPERIMENTAL|PCI-32765 plus fludarabine/cyclophosphamide/rituximab (FCR)|
62811362|NCT01292135|EXPERIMENTAL|PCI-32765 plus bendamustine/rituximab (BR)|
62034920|NCT05265468|ACTIVE_COMPARATOR|Lewit Group|Lewit Group consist in a maximum of four minutes of muscular contraction acompaind by stretching techniques
62034921|NCT05265468|ACTIVE_COMPARATOR|Chaitow Group|Chaitow Group consist in a maximum of four minutes of muscular contraction acompaind by stretching techniques and deep diaphragmatic respiration
62034922|NCT05265468|PLACEBO_COMPARATOR|Placebo Group|Placebo Group only have to mantain no pain positioning for 3 minutes
62034923|NCT01745432|EXPERIMENTAL|ADBLOCK +laparoscopic surgery|Adhesion Barrier System is site-specific sprayable adhesion barrier gel administered on the surgical field to reduce risk of adhesion formation.
62034924|NCT01745432|NO_INTERVENTION|laparoscopic surgery|Laparoscopic surgery only without use of adhesion barrier
62034925|NCT03695497|EXPERIMENTAL|Direct anterior approach|total hip arthroplasty with direct anterior approach
62034926|NCT03695497|EXPERIMENTAL|Direct Lateral Approach|total hip arthroplasty with direct lateral approach
62034927|NCT00057096|OTHER|Arm 1|
62034928|NCT05560672|EXPERIMENTAL|Experimental group|Cord blood mononuclear cell transplantation is performed at the same time as medical treatments such as fasting, rehydration, hemostasis, anti-infection, vasodilation, repair of intestinal mucosa, regulation of intestinal flora, etc.
62426030|NCT00781131|PLACEBO_COMPARATOR|1|
62594238|NCT04490642||Concomitant bladder and bowel Dysfunction|25 patients with concomitant bladder and bowel dysfunction.
62594239|NCT04490642||Those without concomitant bladder and bowel dysfunction|25 patients without concomitant bladder and bowel dysfunction.
62034929|NCT05560672|NO_INTERVENTION|Control group|Medical treatments such as fasting, rehydration, hemostasis, anti-infection, vasodilation, repair of intestinal mucosa, and regulation of intestinal flora are given.
62034930|NCT02151279|PLACEBO_COMPARATOR|control group|Chitosan as wine fining agent
62034931|NCT02151279|ACTIVE_COMPARATOR|Shrimp allergic patients|Chitosan as wine fining agent
62594240|NCT02622763|EXPERIMENTAL|10 millions dose|a total of 10 millions tolerogenic dendritic cells
62811363|NCT00949182|EXPERIMENTAL|Sorafenib Tosylate, Doxorubicin, Mytomicin C|Micro and Macro arteriolar blockade of hepatocellular carcinoma (HCC): Treatment with Sorafenib 400mg two weeks prior to embolization HACE which includes the use of agents such as Doxorubicin Hydrochloride and Mytomicin C, continuing same Sorafenib dose after the procedure (dose adjustment according to tolerance).
62811364|NCT02254811|EXPERIMENTAL|Delivery via capsule|Fecal microbiota transplant is delivered by oral capsules
62811365|NCT02254811|EXPERIMENTAL|Delivery via colonoscopy|Fecal microbiota transplant delivered by colonoscopy
62811366|NCT05599750|ACTIVE_COMPARATOR|Hernia repair with mesh (Control arm)|Participants will undergo incisional hernia repair with prolene mesh in the retrorectus position with at least 4cm of overlap.
62811367|NCT05599750|ACTIVE_COMPARATOR|Primary closure (Intervention arm)|Participants will undergo incisional hernia repair with suture alone using modern surgical techniques.
62811368|NCT05477615|EXPERIMENTAL|lazertinib/pemetrexed/carboplatin|"combination of lazertinib with pemetrexed/carboplatin chemotherapy~- Lazertinib 240mg once daily and chemotherapy (pemetrexed and carboplatin) is administered on the 1st day every 3 weeks."
62811369|NCT01759043|EXPERIMENTAL|guiding catheter|a single transradial guiding catheter for coronary angiography and intervention in patients with STEMI
62811370|NCT01759043|ACTIVE_COMPARATOR|Diagnostic catheter|Diagnostic catheter followed by guiding catheter selection for transradial primary PCI
62811371|NCT06329908|EXPERIMENTAL|(Neo-DCVac) combined with immune checkpoint inhibitors (ICIs)|DC cell injection ,1.5 × 10 7/time, subcutaneous multi-point injection in axilla and groin or lymph node injection guided by color Doppler ultrasound in axilla and groin, continuous injection at 0W, 1W, 3W, 5W and 7W for five times as the first immunization cycle. Tumor response was evaluated 2 weeks after the completion of the first immunotherapy cycle, and treatment was continued if the response was evaluated as effective (SD/PR/CR), and every 3 weeks until disease progression or intolerable toxicity or active withdrawal of the patient, whichever came first.ICIs are PD1/PD-L1 inhibitors and continue to be pre-enrollment ICIs of any brand
62811372|NCT04283617|EXPERIMENTAL|Diabetic with short duration|Type 2 diabetics with HbA1c \> 7.5 % with short duration of diabetes \< 5 years
62811373|NCT04283617|EXPERIMENTAL|Diabetic with long duration|Type 2 diabetics with HbA1c \> 7.5 % with short duration of diabetes \> 5 years
62811374|NCT04936906|EXPERIMENTAL|Extra Care (EC) Treatment Group|Participants in this group will receive the EC intervention pre and post standard of care (SoC) scheduled Mohs Surgery.
62034932|NCT03438162|NO_INTERVENTION|Control group|Patients in both groups received diabetes education during the hospital stay. Standardized diabetes education includes education regarding the disease, diet, physical activity, alcohol intake, smoking, education regarding diabetes medication, self monitoring of glucose, and education regarding acute and chronic complications.
62034933|NCT03438162|EXPERIMENTAL|Intervention group|Patients in both groups received diabetes education during the hospital stay. Standardized diabetes education includes education regarding the disease, diet, physical activity, alcohol intake, smoking, education regarding diabetes medication, self monitoring of glucose, and education regarding acute and chronic complications. Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
62594241|NCT02622763|EXPERIMENTAL|100 millions dose|a total of 100 millions tolerogenic dendritic cells
62594242|NCT02416193|EXPERIMENTAL|High Dose|50,000 IU cholecalciferol once weekly for three months
62811375|NCT04936906|ACTIVE_COMPARATOR|Usual Care (UC) Group|Participants in this group will receive the usual care provided to patients undergoing standard of care (SoC) scheduled Mohs Surgery.
62811376|NCT06223711|EXPERIMENTAL|Treatment|"Thoracic Radiochemotherapy concomitant 2 cycles of etoposide/platinum + durvalumab~Stereotactic radiotherapy of further tumor locations + durvalumab maintenance"
62811377|NCT03684863|NO_INTERVENTION|Standard therapy|
62811378|NCT03684863|EXPERIMENTAL|capecitabine|
62034934|NCT01787617|PLACEBO_COMPARATOR|Control Group|We will randomly assign 52 individuals to a no exercise healthy living group.
62034935|NCT01787617|EXPERIMENTAL|Aerobic Plus Resistance Training Group|We will randomly assign 52 individuals to an aerobic plus resistance training group.
62034936|NCT04593446|EXPERIMENTAL|Oral Sulfate Tablet(ORA·FANGⓇ)|Subjects who are randomized into experimental arm will receive 14 pills at 8 pm in the evening 2days before the surgery and another 14 pills on 6am in the morning 1day before the surgery
62811379|NCT04853758|ACTIVE_COMPARATOR|Sacubitril/Valsartan|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan.
62811380|NCT04853758|ACTIVE_COMPARATOR|Enalapril|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril.
62034937|NCT04593446|ACTIVE_COMPARATOR|Sodium Picosulfate Solution(PicosolutionⓇ)|Subjects who are randomized into experimental arm will receive 170ml of solution with at 8 pm in the evening 2days before the surgery and another 170ml of solution on 6am in the morning 1day before the surgery
62243210|NCT06049082|EXPERIMENTAL|Cohort 2: Mid dose KB408|Single dose of KB408 (mid dose)
62243211|NCT06049082|EXPERIMENTAL|Cohort 3a/3b: High dose KB408|Single dose of KB408 (high dose)
62426031|NCT00781131|EXPERIMENTAL|2|Pregabalin 75 mg
62426032|NCT00781131|EXPERIMENTAL|3|Pregabalin 150 mg
62594243|NCT02416193|ACTIVE_COMPARATOR|Low Dose|5,000 IU cholecalciferol once weekly for three months
62811381|NCT03402737|EXPERIMENTAL|Stereotactic body radiotherapy + IM|Single arm phase I trial with 3 Stereotactic Body Radiation Therapy dose-escalation arms.
62811382|NCT00923520|EXPERIMENTAL|1|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
62811383|NCT03762408|EXPERIMENTAL|ENKO 1|ENKO 1 administered by single intra-articular injection.
62811384|NCT03762408|ACTIVE_COMPARATOR|Durolane|Durolane administered by single intra-articular injection.
62811385|NCT06385769|EXPERIMENTAL|Transcutaneous tibial nerve stimulation (TTNS)|In this study, one channel of the stimulation device will provide active stimulation to the patient, while the second channel will not be connected. The patient won't know which channel is active. Both channels will use continuous mode with a pulse frequency of 20 Hz and a pulse width of 200 ms. The intensity for the active channel will be adjusted based on comfort level and observed hallux reaction. Treatment includes 20 sessions of 30 minutes each, administered five times a week for four weeks.
62426033|NCT04398888|EXPERIMENTAL|BXD treatment|"Participants will be diagnosed and treated by Chinese medicine practitioners (CMPs) with at least 5 years of clinical experience. CMPs will differentiate syndrome and prescript herbs in a semi-standardized protocol, which consists of a base Chinese medicine decoction, Banxia Xiexin Decoction (BXD), and the additional syndrome-specific herbs.~The modified decoction will be prepared in a conventional decocting method at the Chinese medicine pharmacy in the clinic (HKBA-HKU CMCTR) and will be packaged into bags by the auto-decocting machines. Participants will take the decoction twice per day, 5 days per week, for 3 weeks."
62426034|NCT04398888|NO_INTERVENTION|Waitlist|Participants in the waiting list control group will be observed for a three-week waiting period. Rescue medication is not restricted.
62594244|NCT04487483|EXPERIMENTAL|Sleep App|"Participants in this condition will receive full free access to the Pro version of the sleep app and asked to use the app every day for three months."
62811386|NCT06385769|SHAM_COMPARATOR|Sham Transcutaneous tibial nerve stimulation (TTNS)|In the placebo group, the same electrotherapy device and settings as the active group will be used. One channel will not be connected to the patient but will display treatment details on the screen. The other channel will be connected but deliver no stimulation. Intensity for the inactive channel is limited to 2-3 mA. Patients will be informed that exceeding this threshold is prevented. Treatment includes 20 sessions of 30 minutes each, administered twice a week for four weeks.
62811387|NCT04486534||Case group|36 patients between the ages of 18-65, who have been followed up for at least 3 months with the diagnosis of unilateral transtibial amputation and who have been using prostheses for at least 3 months
62811388|NCT04486534||Control group|36 age and body mass index (BMI)-matched healthy controls
62811389|NCT01923506|EXPERIMENTAL|Treatment (SBRT)|Patients receive 5 fractions of SBRT over 1.5 weeks.
62811390|NCT01434277|EXPERIMENTAL|Healthy Subjects|Healthy Subjects instill 1-2 drops of the experimental eye drops into each eye four times per day for two weeks.
62811391|NCT01434277|EXPERIMENTAL|Dry-Eye Subjects|Dry-Eye Subjects instill 1-2 drops of the experimental eye drops into each eye four times per day for two weeks.
62811392|NCT03293602|EXPERIMENTAL|F-MISO PET imaging|F-MISO PET imaging will be added to the preoperative staging explorations of a patient with high risk prostate cancer candidate to radical prostatectomy. Patient will be selected during multidisciplinary meeting and urology consultation of Bordeaux and Toulouse university hospitals. Functional MRI imaging should be available before surgery. If patient consent to participate in the study, F-MISO PET imaging will be planed before prostatectomy. Results of this exam will not be considered for patient therapeutic management.
62811393|NCT06446401||Triple therapy|Patients with mHSPC and high tumour burden receiving treatment with androgen deprivation treatment, new hormone therapy (abiraterone, apalutamide, enzalutamide or darolutamide) and docetaxel.
62811394|NCT06446401||Double therapy|Patients with mHSPC and high tumour burden receiving treatment with androgen deprivation treatment and new hormone therapy (abiraterone, apalutamide, enzalutamide or darolutamide).
62811395|NCT06169202||Fruquintinib in combination with irinotecan and capecitabine|"Phase I: Treatment phase: 6-8 cycles (as determined by the researcher) 1. Irinotecan: 180 mg/m2, IV, day 1, repeated every 3 weeks. (Note: If patient has UGT1A1\*28 and \*6 as pure or double heterozygous variants, irinotecan dose 150 mg/m2, IV, day 1, repeated every 3 weeks, with close clinical observation).~2, Capecitabine: 1000 mg/m2 orally twice daily, D1-14, repeated every 3 weeks. 3. Fruquintinib: 4 mg orally once daily, D1-14, repeated every 3 weeks.~Phase II: Maintenance phase:~1, Fruquintinib: 4 mg orally once daily, D1-14, repeated every 3 weeks. 2. Capecitabine: 1000 mg/m2 orally twice daily, D1-14, repeated every 3 weeks"
62811396|NCT03474614|EXPERIMENTAL|treatment group|A Treatment group of ten (n=10) patients that will receive oral propranolol at a dose of 60mg per day (one 60mg ER capsule per day) for 7- to 10-days prior to surgery plus their usual medications.
62034938|NCT02982252|EXPERIMENTAL|CoPILOT (6 weeks)|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 6 hours total training time (1 hour training sessions, 3 days per week for 2 weeks).
62034939|NCT02982252|NO_INTERVENTION|Standard of Care (6 weeks)|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair consisting of 6 hours total training time (1 hour training sessions, 3 days per week for 2 weeks).
62426035|NCT01116765|EXPERIMENTAL|experimental group|Infants in the experimental group receive an oral stimulation program consisting of stimulation of the oral structures during 10 consecutive days
62426036|NCT01116765|OTHER|control group|Infant in the control group receive no stimulation only non nutritive sucking during feeding
62034940|NCT02982252|EXPERIMENTAL|CoPILOT (12 weeks)|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 12 hours total training time (1 hour training sessions, 4 days per week for 3 weeks).
62594245|NCT04487483|NO_INTERVENTION|Control|Participants in this condition will be asked to continue their life as normal and abstain from downloading or using any sleep aid and/or sleep tracker app for three months.
62594246|NCT04281901|EXPERIMENTAL|PVRP treated participants|Participants will receive PVRP in the chronically inflamed radical cavity at the baseline evaluation (day 0) and 1 month later (1. follow-up). There will be 2 additional follow-ups with a 1-month interval.
62235155|NCT01969591|EXPERIMENTAL|fast-track surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
62594247|NCT04281901|ACTIVE_COMPARATOR|Standardly treated participants|Participants will receive standard conservative measures for the chronically inflamed radical cavity at the baseline evaluation (day 0), 1 month later (1. follow-up), 2 months later (2. follow-up) and 3 months later (3. follow-up).
62594248|NCT03614078|EXPERIMENTAL|PRCL-02 Dose 1|Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
62811397|NCT03474614|OTHER|Control Group|A control group of 10 (n=10) patients will receive only their routine medications (no propranolol) during the (-7 to -10 days) preoperative period. A control group (n=10) is required to allow for a semi-quantitative comparison with mRNA and miRNA levels in the treatment group.
62811398|NCT01273766|EXPERIMENTAL|Arm I|Patients receive oral deferasirox once daily for up to 6 months or until blood counts recover in the absence of disease progression or unacceptable toxicity.
62811399|NCT01273766|NO_INTERVENTION|control arm|blood tested on healthy patients
62811400|NCT01273766|NO_INTERVENTION|correlative|treated off study with or without oral deferasirox (patient choice) but lab draws to gather lab analysis
62811401|NCT00426166|EXPERIMENTAL|1|Low Level Laser Therapy
62811402|NCT00426166|NO_INTERVENTION|2|No Laser Therapy. Outcome Measures the same.
62811403|NCT02585401||Eylea product and application information / Cohort 1|Physicians prescribing aflibercept in Canada will be selected to reflect the distribution of retinal specialists and ophthalmologists who prescribe aflibercept.
62594249|NCT03614078|EXPERIMENTAL|PRCL-02 Dose 2|Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
62811404|NCT05262075|EXPERIMENTAL|Mindfulness and Resiliency Program|This is an online mindfulness program that integrates resiliency factors to women
62811405|NCT06217042|EXPERIMENTAL|HR070803+Oxaliplatin+5-FU/LV|HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
62811406|NCT06217042|ACTIVE_COMPARATOR|GX|gemcitabine; capecitabine
62811407|NCT03166917|EXPERIMENTAL|3D printing implant|3D printing implant in bone defect
62811408|NCT03166917|PLACEBO_COMPARATOR|Autogenous bone grafting|autogenous bone grafting in bone defect
62811409|NCT06457724|EXPERIMENTAL|L. brevis|
62811410|NCT06457724|PLACEBO_COMPARATOR|Placebo|
62811411|NCT06257550|EXPERIMENTAL|THRIVE Intervention Arm|The THRIVE intervention arm will receive produce prescription, personalized dietitian coaching, adaptive bi-directional messaging; and linkages to social services.
62811412|NCT06257550|ACTIVE_COMPARATOR|Comparator Arm|The comparator arm will receive standard produce bags; and linkages to social services.
62811413|NCT02246725||Contact with palliative care unit versus contact when needed.|
62811414|NCT00380237|EXPERIMENTAL|1|Two vaccinations with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10\^7 TCID50 delivered by nose drops. The second vaccination will be given 4 to 12 weeks after the first.
62811415|NCT01739998|EXPERIMENTAL|functional oil|Treatment consisted of consuming 5 ml of functional oil \[olive oil (4 ml) with omega 3 fatty acids from fish oil (1 ml: 90% omega 3: 75-80% DHA and 10-15% EPA) Orange flavour\] during the day by 8 weeks.
62811416|NCT01739998|PLACEBO_COMPARATOR|Placebo|Treatment consisted of consuming 5 ml of olive oil during the day by 8 weeks
62811417|NCT00473434|EXPERIMENTAL|001|Paliperidone3mg or 6mg or 9mg or 12mg once daily for 52 weeks
62811418|NCT03433937|EXPERIMENTAL|Negative pressure wound therapy|
62426037|NCT04626882|ACTIVE_COMPARATOR|Staged in-hospital CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
62594250|NCT03614078|PLACEBO_COMPARATOR|Placebo|Loading dose followed by a once daily maintenance dose at matching treatment levels, commencing on Day 2 and continuing for 12 weeks
62426038|NCT04626882|EXPERIMENTAL|Immediate CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized immediately after PCI for IRA (during primary PCI). Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
62426039|NCT02294552|EXPERIMENTAL|Matched bone marrow graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv
62426040|NCT02294552|EXPERIMENTAL|Matched peripheral blood stem cells graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
62594251|NCT03429751|EXPERIMENTAL|Liberal fluid group|received 30 ml/Kg/h crystalloid for maximum 3 hours.
62034941|NCT02982252|NO_INTERVENTION|Standard of Care (12 weeks)|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair consisting of 12 hours total training time (1 hour training sessions, 4 days per week for 3 weeks).
62426041|NCT02294552|EXPERIMENTAL|Mismatched peripheral blood stem cells or bone marrow graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
62426042|NCT02843347||Biorepository substudy participants|Participants from the main study who give consent for the genetic testing substudy.
62426043|NCT05817084|ACTIVE_COMPARATOR|12 patients with varus knee malalignment and acl deficiency under went acl reconstruction and hto|anterior cruciate ligament reconstruction and medial opening wedge high tibial osteotomy in the same session
62426044|NCT05817084|ACTIVE_COMPARATOR|12 patients with varus knee malalignment and acl deficiency underwent acl reconstruction|anterior cruciate ligament reconstruction alone.
62426045|NCT04297553|ACTIVE_COMPARATOR|CAPA-Fresh|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Receiving hCG 5000IU x 2 (10000IU) after Oocytes retrieval. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Fresh embryos transfer will be performed on day 3 using HRT protocol with a maximum of 2 embryos transferred.
62426046|NCT04297553|ACTIVE_COMPARATOR|CAPA-Freeze-only|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred
62426047|NCT02394353|ACTIVE_COMPARATOR|Sleeve Gastrectomy|Patients undergoing the sleeve gastrectomy surgery
62594252|NCT03429751|ACTIVE_COMPARATOR|Restrictive fluid group|received 10 ml /Kg/h crystalloids for maximum 3 hours.
62594253|NCT04694365|EXPERIMENTAL|Normal Hepatic Function|
62034942|NCT03819491|EXPERIMENTAL|Group A|100 mg OD
62426048|NCT02394353|ACTIVE_COMPARATOR|Gastric Bypass|Patients undergoing the gastric bypass surgery
62426049|NCT00091507|EXPERIMENTAL|1 -- GIK|GIK = glucose-insulin-potassium; In one-liter: Dextrose 30% + 80 mEq Potassium Chloride + 50 units Regular Insulin; infused at 1.5 ml/kg/hour for a total of 12 hours.
62594254|NCT04694365|EXPERIMENTAL|Mild Hepatic Impairment|
62594255|NCT04694365|EXPERIMENTAL|Moderate Hepatic Impairment|
62594256|NCT00639444|ACTIVE_COMPARATOR|Gluten free diet|the intervention in this group is keeping a gluten-free diet from 0 to 12 months
62594257|NCT00639444|NO_INTERVENTION|Gluten containing diet|infants in this group are started on gluten-containing cereals at 6 months (control group)
62811419|NCT03433937|ACTIVE_COMPARATOR|Control|Micropore tape
62811420|NCT03290846|EXPERIMENTAL|Secretin study|PET and MRI scannings will be performed twice. Subjects will be given secretin hydrochloride and placebo on separate days. In addition, subjects will undergo cold exposure PET scanning once.
62811421|NCT03466385|EXPERIMENTAL|Nasal High Flow|Patients randomized to NHF device with initial settings of flow=50-60 L·min-1, temperature=37ο Celsius and FiO2 adjusted to maintain SpO2 between 88%-92%.
62811422|NCT03466385|ACTIVE_COMPARATOR|Non-Invasive Ventilation|Patients randomized to NIV with initial settings EPAP=3cmH2O, IPAP=15cmH2O, I:E=1:2 to 1:3, inspiratory time=0.8-1.2sec and FiO2 adjusted to maintain SpO2 between 88%-92%.
62811423|NCT02399215|EXPERIMENTAL|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62811424|NCT02547181|EXPERIMENTAL|Splint|Patients will be provided instructed to use a tensor bandage as well as specific behaviours to prevent movement of the injured part of the hand.
62811425|NCT02547181|EXPERIMENTAL|Behavioral Modification|Patients are given a removable plaster/fiberglass splint with a tensor bandage underneath
62811426|NCT01879111|EXPERIMENTAL|state-of-art depression screening + patient-targeted feedback|Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
62034943|NCT03819491|EXPERIMENTAL|Group B|100 mg BID
62811427|NCT01879111|NO_INTERVENTION|state-of-art depression screening|
62034944|NCT04870216||Medical student|Medical student aged more than 18, presenting menstrual cycles, and agreeing to participate in the study.
62811428|NCT04187898|EXPERIMENTAL|Early Phase: Eflapegrastim @ 30mins post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg granulocyte colony-stimulating factor \[G-CSF\]).~Supplied in prefilled single-use syringes for subcutaneous injection.~Cycle 1: Administered on the same day as TC chemotherapy, 30 minutes from the end of TC administration.~Cycles 2-4: Administered 24 hours after TC chemotherapy administration.~Each cycle is 21 days."
62034945|NCT05789043|EXPERIMENTAL|Three-drug arm|
62034946|NCT05789043|ACTIVE_COMPARATOR|Two-drug arm|
62034947|NCT05789043|ACTIVE_COMPARATOR|single-drug arm|
62811429|NCT04187898|EXPERIMENTAL|Early Phase: Eflapegrastim @ 3 hours post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).~Supplied in prefilled single-use syringes for subcutaneous injection.~Cycle 1: Administered on the same day as TC chemotherapy, 3 hours from the end of TC administration.~Cycles 2-4: Administered 24 hours after TC chemotherapy administration.~Each cycle is 21 days."
62426050|NCT00091507|PLACEBO_COMPARATOR|2 -- Placebo|Dextrose 5%, infused at 1.5 ml/kg/hour for total of 12 hours.
62811430|NCT04187898|EXPERIMENTAL|Early Phase: Eflapegrastim @ 5 hours post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).~Supplied in prefilled single-use syringes for subcutaneous injection.~Cycle 1: Administered on the same day as TC chemotherapy, 5 hours from the end of TC administration.~Cycles 2-4: Administered 24 hours after TC chemotherapy administration.~Each cycle is 21 days."
62811431|NCT04187898|EXPERIMENTAL|Expansion Phase: Eflapegrastim @ 30 mins post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).~Supplied in prefilled single-use syringes for subcutaneous injection.~Cycles 1-4: Administered on the same day as TC chemotherapy, 30 minutes following the end of TC administration.~Each cycle is 21 days."
62235156|NCT01969591|OTHER|convontional postoperative care|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
62811432|NCT03101280|EXPERIMENTAL|Dose-Finding Phase (Part 1): Rucaparib and Atezolizumab|Approximately 6-18 participants with advanced gynecological cancers will receive different doses of rucaparib administered orally (PO) twice daily (BID) with a fixed dose of atezolizumab (1200 milligrams \[mg\] intravenously \[IV\], every 21 days) in 21-day cycles, starting with 400 mg rucaparib BID. The recommended Phase II dose (RP2D), determined by the highest dose level with an acceptable safety profile and with a minimum of 6 participants at which fewer than one-third of participants experience a DLT, was identified as 600 mg rucaparib twice a day (BID).
62235157|NCT01612741||Group 1|
62426051|NCT05001373|EXPERIMENTAL|Study Group 1|eOD-GT8 60mer mRNA Vaccine (100µg)
62034948|NCT04817553||IgG4 pancreatobiliary|IgG4 patients with pancreatobiliary involvement
62034949|NCT03581721|NO_INTERVENTION|The control group|"Control group according to usual practices: no active warming (no fluid warming). The fluid warmer device will be set up but not activated. The control group will receive IV fluid coload at room temperature through the fluid warmer set to off. The device is hidden"
62034950|NCT03581721|EXPERIMENTAL|The warming group|"IV fluid warming with the enFlow® or Fluido®Compact IV fluid warmer : Women will receive IV fluid coload warmed to 40°C through the enFlow® or Fluido®Compact device. The box will be also hidden. The fluid warmer will be turned off at the end of surgery, just before transfer to the PACU."
62034951|NCT03325712|EXPERIMENTAL|Dose group 1: BI 705564 10 mg|
62034952|NCT03325712|EXPERIMENTAL|Dose group 2: BI 705564 20 mg|
62034953|NCT03325712|EXPERIMENTAL|Dose group 3: BI 705564 40 mg|
62034954|NCT03325712|EXPERIMENTAL|Dose group 5: BI 705564 60 mg|
62034955|NCT03325712|EXPERIMENTAL|Dose group 4: BI 705564 80 mg|
62811433|NCT03101280|EXPERIMENTAL|Dose-Expansion Phase (Part 2): Rucaparib and Atezolizumab|"Two tumor-specific expansion cohorts will begin treatment with a 21-day run-in period of rucaparib monotherapy at the specified dose for rucaparib in the potential RP2D identified in Part 1 for the combination. Cohort 1 will have approximately 30 participants with advanced, platinum-sensitive ovarian cancer with tumors harboring a tBRCA mutation \[tBCRA(mut)\] or BRCA-like molecular signature \[tBRCA(wt)/LOH(high)\].~Cohort 2 will have approximately 20 participants with previously treated triple-negative breast cancer (TNBC) with a tBRCA mutation \[tBCRA(mut)\] or BRCA-like molecular signature \[tBRCA(wt)/LOH(high)\] and have not been exposed to cancer immunotherapies. Following the run in period, participants will receive the combination of rucaparib (specified dose, BID) and atezolizumab (1200 mg IV, every 21 days) in 21-day cycles."
62811434|NCT01596803|ACTIVE_COMPARATOR|vitamins minerals|VitE 400/d, vitC 500mg/d, Se 200µg/d (selenomethionine), Zn 25 mg/d gluconate Venous blood samples( analysis oxidative stress inflammatory markers) Needle biopsy of the vastus lateralis muscle (analysis oxidative stress inflammatory markers)
62811435|NCT01596803|PLACEBO_COMPARATOR|Placebo|Supplementation 17 weeks placebo venous blood samples (analysis of oxidative stress inflammatory markers) needle biopsy of the vastus lateralis muscle
62235158|NCT01354808|ACTIVE_COMPARATOR|DAPT|
62235159|NCT01354808|EXPERIMENTAL|TAPT|
62235160|NCT03279133|EXPERIMENTAL|LDV/SOF for 12 weeks.|Ledipasvir 90mg/Sofosubvir 400mg fixed-dose combination (FDC) tablet for 12 weeks.
62235161|NCT00288353|ACTIVE_COMPARATOR|1|aripiprazole (Abilify)
62235162|NCT00288353|ACTIVE_COMPARATOR|2|ziprasidone (Geodon)
62235163|NCT04571866|EXPERIMENTAL|Beta-glucan bread|Participants will receive a standardised meal consisting of beta-glucan-enriched bread (in an amount corresponding to 25 g of available dietary carbohydrates) and water (250 ml). The bread is produced by NOFIMA AS, one of the collaborating parties. The participants will be asked to spend approximately 10 minutes consuming the standardised meal.
62235164|NCT04571866|SHAM_COMPARATOR|Control bread|Participants will receive a standardised meal consisting of a wheat bread with no additives (in an amount corresponding to 25 g of available dietary carbohydrates) and water (250 ml). The bread is produced by NOFIMA AS, one of the collaborating parties. The participant will be asked to spend approximately 10 minutes consuming the standardised meal.
62235165|NCT03428737|OTHER|Nocturnal controlled pressure control ventilation|use of an inspiratory pressure of 20 cm of H2O and an respiratory frequency chosen to stop all spontaneous breathing activity during the night
62235166|NCT03428737|OTHER|Nocturnal pressure support ventilation|Use of a pressure support level identical during the night to the pressure support level at the end of the day.
62235167|NCT01278251||Endobutton|
62811436|NCT04854018|EXPERIMENTAL|Single Arm|Injection of Indocyanine Green at doses detailed on summary of product characteristics for each age range
62235168|NCT00350805||Healthy volunteers|
62235169|NCT00350805||Patients|
62235170|NCT04182503||Beijing|
62811437|NCT01182636|EXPERIMENTAL|Investigational Test Product|Adapalene Topical Gel, 0.1%
62811438|NCT01182636|ACTIVE_COMPARATOR|Reference Listed Drug|Differin® (adapalene 0.1%) Topical Gel
62811439|NCT01182636|PLACEBO_COMPARATOR|Placebo|Gel base only
62811440|NCT05095636|ACTIVE_COMPARATOR|apatinib monotherapy|Apatinib，500 mg，po., qd, q2w
62811441|NCT05095636|EXPERIMENTAL|Apatinib Combined With Camrelizumab|Apatnib，250 mg，po., qd，q2w; Camrelizumab，200mg， ivgtt，d1, q2w
62811442|NCT01762696|ACTIVE_COMPARATOR|MET only|Motivational Enhancement Therapy only
62235171|NCT04182503||Guangzhou|
62235172|NCT04182503||Jinan|
62235173|NCT04182503||Nanjing|
62235174|NCT04182503||Hangzhou|
62235175|NCT04182503||Wuhan|
62235176|NCT04182503||Zunyi|
62235177|NCT04182503||Xiangyang|
62235178|NCT04182503||Nantong|
62235179|NCT04182503||Suizhou|
62235180|NCT04182503||Huangshi|
62235181|NCT04182503||Changzhou|
62235182|NCT04182503||Suqian|
62235183|NCT04182503||Shiyan|
62235184|NCT04182503||Xiaogan|
62235185|NCT04182503||Huanggang|
62235186|NCT03299257|ACTIVE_COMPARATOR|donepezil treatment|donepezil with 10 mg will be administered for 30 days.
62235187|NCT03299257|PLACEBO_COMPARATOR|placebo treatment|placebo with 10 mg placebo will be administered for 30 days.
62235188|NCT04980937||Patients with perineal nerve damage after ski injury|Retrospectively aquired patients from insight in medical records. All patients with perineal nerve damage after ski injury in the time period of question were enrolled. Inclusion required operative management of the injury interns of microsurgical reconstruction of peroneal nerve.
62811443|NCT01762696|EXPERIMENTAL|MOMENT|The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
62235189|NCT02318992|ACTIVE_COMPARATOR|Fecal Microbiota_Fresh|Donor stool (greater than 150 grams) was collected \<4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% sodium chloride (NaCl) in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was used within 2 hours of preparation (Fresh).
62811444|NCT01383746|EXPERIMENTAL|1|Yttrium microsphere injection
62811445|NCT02763059|ACTIVE_COMPARATOR|Group 1- Received Ibuprofen (N=44)|
62811446|NCT02763059|ACTIVE_COMPARATOR|Group 2- Received Dexamethasone (N=44)|
62426052|NCT05001373|EXPERIMENTAL|Study Group 2|eOD-GT8 60mer mRNA Vaccine (100µg) and Core-g28v2 60mer mRNA Vaccine (100µg)
62034956|NCT03325712|PLACEBO_COMPARATOR|Placebo matching BI 705564|
62426053|NCT05001373|EXPERIMENTAL|Study Group 3|eOD-GT8 60mer mRNA Vaccine (100µg) and Core-g28v2 60mer mRNA Vaccine (100µg)
62426054|NCT05001373|EXPERIMENTAL|Study Group 4|Core-g28v2 60mer mRNA Vaccine (100µg)
62426055|NCT05182983||People with digestive tract diseases|
62426056|NCT05182983||Healthy people|
62426057|NCT00103259|EXPERIMENTAL|Arm I (bortezomib, irinotecan hydrochloride)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and irinotecan IV over 90 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
62811447|NCT02763059|PLACEBO_COMPARATOR|Group 3 - Received Placebo (N=44)|
62034957|NCT03325712|EXPERIMENTAL|Dose group 8: BI 705564 40 mg - SPT|SPT stands for skin prick test.
62034958|NCT03325712|PLACEBO_COMPARATOR|Placebo matching BI 705564 - SPT|SPT stands for skin prick test.
62034959|NCT03812133||Surgical patients|Patients who were electively scheduled for surgery.
62034960|NCT01650753|EXPERIMENTAL|Probiotic Powder|Probiotic: Bifidobacterium longum subsp longum AH1206
62034961|NCT01650753|PLACEBO_COMPARATOR|Placebo Powder|Equivalent amount (same volume) of maltodextrin
62426058|NCT00103259|EXPERIMENTAL|Arm II (bortezomib)|Patients receive bortezomib as in arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may cross over to arm I.
62426059|NCT00929786||2|"Cases - those patients who develop DIH while on regular treatment with anti-TB drugs.~Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs."
62426060|NCT04098068|EXPERIMENTAL|MSI (Microsatellite Unstable) Negative with Mutator Phenotype|
62594258|NCT05427760|EXPERIMENTAL|Oxygen Group|"After the baby's diaper is changed, an oxygen hose placed inside the diaper will provide free oxygen flow to the diaper area.~Oxygen will be applied for 1 hour at each diaper change at a flow rate of 5L/min and at a concentration of 21% FiO2 which is equivalent to room air."
62811448|NCT04896086|EXPERIMENTAL|Group 1A-1B|20 mcg of FluMos-v1
62034962|NCT01233791|EXPERIMENTAL|Vaginal Diazepam Suppository|Patients in this arm will be asked to use one vaginal suppository every night for 28 days
62811449|NCT04896086|EXPERIMENTAL|Group 2A-2B|60 mcg of FluMos-v1
62811450|NCT04896086|ACTIVE_COMPARATOR|Group 3A-3B|standard dose of 60 mcg of the licensed QIV Flucelvax
62811451|NCT04896086|EXPERIMENTAL|Group 4A-4B|100 mcg of FluMos-v1
62811452|NCT04896086|EXPERIMENTAL|Group 5A-5B|100 mcg of FluMos-v1 plus Adjuplex
62811453|NCT04896086|EXPERIMENTAL|Group 6A-6B|Optional: 60 mcg of FluMos-v1 plus Adjuplex
62034963|NCT01233791|PLACEBO_COMPARATOR|Vaginal Placebo Suppository|Patients will be asked to use one vaginal suppository every night for 28 days
62034964|NCT04838743||IDegLira|Real-world adult population with type 2 diabetes mellitus in Japan.
62034965|NCT05628324|EXPERIMENTAL|EMG + task training|Train with EMG-controlled games and functional task practice
62034966|NCT05628324|ACTIVE_COMPARATOR|task training|Train with functional task practice
62034967|NCT03382496||Lung Cancer patients in France|Lung Cancer patients treated by nivolumab in real life condition in France from October 2016 to October 2017
62235190|NCT02318992|ACTIVE_COMPARATOR|Fecal Microbiota_Frozen|Donor stool (greater than 150 grams) was collected \<4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was kept at -80 degrees Celsius (C) freezer labeled with identity (ID) and expiration date which was 6 months after preparation day (Frozen).
62594259|NCT05427760|NO_INTERVENTION|Control Group|"This group will only receive routine care: Diaper will be changed using disposable wet wipes and disposable baby diaper.~A barrier cream containing 40% zinc oxide will be applied to the cleaned diaper area as a thin layer to cover the skin.~Baby's diaper change will be done 8 times a day, every three hours."
62594260|NCT05097092|EXPERIMENTAL|Immobilization control|The immobilization control group will undergo arm immobilization. Immobilization will be implemented with four weeks of muscle unloading with a sling and swathe on the nondominant arm. The sling will suspend the arm at the elbow joint with the elbow in a flexed position at 90°, the swathe will then wrap around the participant to fix the arm against the body.
62811454|NCT04896086|EXPERIMENTAL|Group 7A-7B|Optional: TBD mcg of FluMos-v1
62811455|NCT04896086|EXPERIMENTAL|Group 8A-8B|Optional: TBD of FluMos-v1 plus Adjuplex
62811456|NCT02529917|EXPERIMENTAL|Hemp powder|Hemp powder supplement
62811457|NCT02529917|ACTIVE_COMPARATOR|Soy powder|Soy powder supplement
62811458|NCT04013308|EXPERIMENTAL|10 iontophoresis treatments with potassium iodide|
62811459|NCT04013308|NO_INTERVENTION|10 iontophoresis treatments with placebo|
62811460|NCT03913715|ACTIVE_COMPARATOR|Ostomy Self-Management Training|Ostomy Self-management Training group in which subject will learn using pouches and equipment, skincare, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for traveling and physical activity recommendations
62034968|NCT01453595|EXPERIMENTAL|BEZ235|"This is a single-institution, open label, single-arm Phase 1b/2 trial of BEZ235 in patients with advanced RCC. The study will be conducted in two phases:~Phase 1b: dose-escalation will be performed to determine the maximally tolerated dose (MTD) of twice daily BEZ235 to use in Phase 2 (RP2 dose).~Phase 2: subjects with clear cell who have experienced disease progression on prior first or second-line mTOR targeted therapy will be treated on the MTD of twice daily BEZ235."
62235191|NCT02318992|ACTIVE_COMPARATOR|Fecal Microbiota_Lyophilized|Donor stool (greater than 150 grams) was collected \<4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was starting lyophilization process within 30 minutes after completion of stool filtration (Lyophilized). Lyophilized microbiota products were kept at 4 degrees celsius (C) and were used within 6 months after preparation day.
62811461|NCT03913715|PLACEBO_COMPARATOR|Usual care|Usual care in peri-operative and long-term settings is not standardized for ostomy patients. Usual care does not provide any formal, reproducible training for patients or their caregivers. It typically consists of an Ostomy Care Nurse who works with patients and caregivers concerning technical issues (fitting, emptying, supplies, surrounding skin care, etc.) while the new ostomate is still an inpatient.
62811462|NCT00207155|EXPERIMENTAL|A|
62811463|NCT04113850|EXPERIMENTAL|Sitting|Subjects will undergo acoustic startle testing in the sitting position.
62811464|NCT04113850|EXPERIMENTAL|Standing|Subjects will undergo acoustic startle testing in the standing position.
62034969|NCT05309304|EXPERIMENTAL|3 g cefazolin|Healthy adult subjects weighing ≥120 kg. (g=grams)
62034970|NCT05309304|ACTIVE_COMPARATOR|2 g cefazolin|Healthy adult subjects weighing \<120 kg. (g=grams)
62811465|NCT02455921|ACTIVE_COMPARATOR|sugammadex|iv sugammadex 2 mg/Kg
62811466|NCT02455921|ACTIVE_COMPARATOR|neostigmine - atropine|"iv neostigmine 0,05 mg/Kg - atropine 0,02 mg/kg~Efficacy, safety and effect on cognitive and behavioural function"
62811467|NCT05625698|OTHER|MagTrace only|Cohort 1: Clinically node negative patients undergoing neoadjuvant chemotherapy. This cN0-group will receive MagTrace injections before start of neoadjuvant chemotherapy followed standard routine technetium-99 injections after neoadjuvant chemotherapy to facilitate surgery. Nodes containing Magtrace will be detected by finding the magnetic signals using the SentiMag probe. No other interventions during chemotherapy treatments
62235192|NCT02762812|EXPERIMENTAL|BCD-055|Patients in this group will receive BCD-055 in a dose of 5 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Wekk 38, Week 46, Week 54.
62235193|NCT02762812|ACTIVE_COMPARATOR|Remicade®|Patients in this group will receive Remicade® in a dose of 5 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Wekk 38, Week 46, Week 54.
62235194|NCT01734174||cardiac patients|Patients having elective coronary artery bypass grafting surgery, valve repair or replacement surgery, aortic repair or replacement surgery, or any combination of these surgeries will be recruited for this study to validate measurements of left ventricular volume and ejection fraction (a quantitative measure of general heart function) as assessed by 3-dimensional transesophageal echocardiography (3D TEE) as compared to 3-dimensional transthoracic echocardiography (3D TTE). Secondarily, we will also compare the 3D TEE assessment to the 2D TEE and TTE assessment, which is routinely performed simultaneously. Last, we will compare this assessment to a third method of quantification of cardiac function via a pulmonary artery catheter using thermodilution.
62235195|NCT01487356||Patients undergoing colonoscopy|Data was collected on all adult patients undergoing outpatient colonoscopy at St. Paul's Hospital from May 2008 to June 2009. Exclusion criteria were prior colon resection and repeat colonoscopy for the purpose of endoscopic therapy for known lesions.
62594261|NCT05097092|EXPERIMENTAL|Immobilization with unilateral training|The immobilization with unilateral training group will undergo arm immobilization for four with a sling and swathe on the nondominant arm. The sling will suspend the arm at the elbow joint with the elbow in a flexed position at 90°, the swathe will then wrap around the participant to fix the arm against the body. The free (non-immobilzed) arm of this group will undergo heavy strength training twice per week throughout the immobilization period. The training will consist of unilateral dumbbell shoulder press and biceps curl.
62594262|NCT02155673|EXPERIMENTAL|Low Dose GCS-100|Low dose of GCS-100
62811468|NCT05625698|OTHER|MagTrace and Magseed|Cohort 2: Clinically node positive patients undergoing neoadjuvant chemotherapy. This N+ group will receive MagTrace injection in the breast to mark sentinel nodes and Magseed will be inserted into the index metastatic node before the start of neoadjuatnt chemotherapy followed by standard routine technetium-99 injections after neoadjuvant chemotherapy to facilitate surgery. Nodes containing Magtrace / Magseed will be detected by finding the magnetic signals using the SentiMag probe. No other interventions during chemotherapy treatments
62811469|NCT05847595|SHAM_COMPARATOR|Control group A|will be treated by selected physical therapy program only for 60 minutes.
62811470|NCT05847595|EXPERIMENTAL|Study group B|will be treated by implicit motor training program for 30 minutes, in addition to the conventional physical therapy program for the lower extremity for 30 minutes ,total duration 60 minutes.
62811471|NCT05847595|EXPERIMENTAL|Study group C|will be treated by explicit motor training program for 30 minutes, in addition to the conventional physical therapy program for the lower extremity for 30 minutes, total duration 60 minutes.
62811472|NCT01766440|EXPERIMENTAL|Calcitriol 3 mcg/g ointment|Topical application every 12 hours for 14 consecutive days
62811473|NCT06219525|ACTIVE_COMPARATOR|Higher dose of enteral zinc|higher dose of zinc sulfate 10 mg/day; each 1 mL contains 10 mg of elemental zinc (osmolality 450 Osm/kg H2O).
62811474|NCT06219525|PLACEBO_COMPARATOR|Standard dose of enteral zinc|standard dose of zinc sulfate 1 mg/day; each 1 mL contains 1 mg of elemental zinc (osmolality 45 Osm/kg H2O).
62811475|NCT04420377|PLACEBO_COMPARATOR|Placebo Group|Participants will engage in a 5-week, whole-body, resistance training program 2 days per week will consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. For week 5 of the study, participants will come in for 1 intense exercise training day.
62235196|NCT00505869||1|Health \& Wellness Intervention + Questionnaire
62235197|NCT00505869||2|Mood Management Intervention + Questionnaire
62235198|NCT02189356|EXPERIMENTAL|exercise programme|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group.
62235199|NCT02189356|OTHER|contol group|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group.
62594263|NCT02155673|EXPERIMENTAL|High Dose GCS-100|GCS-100 High dose
62594264|NCT03554863|ACTIVE_COMPARATOR|Facial mask|
62594265|NCT03554863|EXPERIMENTAL|Optiflow anesthesia|
62594266|NCT03150654|EXPERIMENTAL|Laser pan-retinal photocoagulation|Conventional laser pan-retinal photocoagulations were performed by using green laser photocoagulator, every month for 3 months
62594267|NCT03467217|ACTIVE_COMPARATOR|Losartan potassium capsule|Dose will be one 50 mg capsule of losartan per day for one week and then increased to two capsules of 50 mg of losartan per day (100 mg total) for 23 weeks patients with baseline weight ≥ 70 kg to \<150 kg.
62811476|NCT04420377|EXPERIMENTAL|Experimental Group|Participants will engage in a 5-week, whole-body, resistance training program 2 days per week will consuming a treatment condition (Carnipure™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. For week 5 of the study, participants will come in for 1 intense exercise training day.
62811477|NCT02757989|EXPERIMENTAL|Patients with donor|Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling)
62811478|NCT02757989|NO_INTERVENTION|Patients without donor|Patients without a matched donor
62811479|NCT04730440||AD-TAR|AD subjects who take part to Facial Emotion Recognition rehabilitation (TAR)
62811480|NCT04730440||AD-Cognitive Stimulation|AD subjects who take part to cognitive stimulation session (12 sessions during 4 weeks)
62811481|NCT06159088|EXPERIMENTAL|Feihe Investigational Formula|"Feihe Investigational Formula~1. With the highest probiotic content~2. Containing 2' -fucosyl lactose~3. Add hydrolyzed whey protein~4. Comprehensive nutrition: OPO, lactoferrin, CPP, nucleotide, choline, inositol, taurine, L-carnitine, GOS, lutein"
62811482|NCT06159088|ACTIVE_COMPARATOR|Control Formula|Control formula contains comparable macronutrients and micronutrients, but does not contain probiotics fortified with hydrolyzed whey protein
62811483|NCT06159088|OTHER|Breastfeeding|breastmilk-feeding
62811484|NCT01468558|OTHER|All subjects|Subjects received MAP0004 on Day 1 of Visit 2, Ketoconazole on Days 3 through 6 of Visit 2, and MAP0004 again on Day 6 of Visit 2. Subjects then returned for Visit 3, 7-11 days from the end of Visit 2. At Visit 3 subjects received 1.0 mg IV DHE (Intravenous Dihydroergotamine Mesylate).
62811485|NCT04725799||MESS with and without stressful stimuli|The subjects participate in meal, exercise, sleep activities alone or in combination with stressful stimuli.
62811486|NCT03572946|EXPERIMENTAL|target biopsy group|Targeted prostate biopsy
62811487|NCT03572946|ACTIVE_COMPARATOR|standard biopsy group|Standard prostate biopsy
62811488|NCT05857735||ACS patients|Patients admitted to hospital with diagnosis of ACS.
62811489|NCT05697627|EXPERIMENTAL|Computerized cognitive training (CCT) using EndeavorRx|Exciting, youth-friendly computer game, EndeavorRx engages and trains cognitive control across component processes of attention, response inhibition, shifting and working memory.
62235200|NCT01924351|OTHER|HER2-positive Breast Cancer with Brain Metastasis|Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis
62594268|NCT03467217|PLACEBO_COMPARATOR|Placebo losartan capsule|Dose will be one 50 mg capsule of placebo losartan per day for one week and then increased to two capsules of 50 mg of placebo losartan per day (100 mg total) for 23 weeks for patients with baseline weight ≥ 70 kg to \<150 kg.
62235201|NCT01066468|EXPERIMENTAL|Gleevec/Glivec|
62594269|NCT04894149|EXPERIMENTAL|Physiotherapy|
62811490|NCT04976985|EXPERIMENTAL|Interventional Group receiving Osteopathic Manipulative Therapy (OMT)|70 patients with chronic migraine who consent to OMT will receive four standardized osteopathic manipulative treatment protocol over the course of twelve weeks at week 0,2,6,10. MIDAS and HIT-6 Questionnaires will be obtained at time of consent prior to first treatment and again at the conclusion of treatment period of twelve weeks.
62811491|NCT04976985|OTHER|Control Group with Standard of Care|70 patients with the diagnosis of migraine headache who are receiving the standard of care medications will complete a MIDAS and HIT-6 questionnaire at week 0 and week 12. A new prophylactic medication may be started at time of initial questionnaires and the patient can be on up to two prophylactic medications, with no changes during the 12 week period.
62811492|NCT01950858|EXPERIMENTAL|Biological|6 weeks of HBO treatment as well as non weight bearing
62811493|NCT01950858|ACTIVE_COMPARATOR|Control|non weight bearing
62811494|NCT04834180|SHAM_COMPARATOR|Vaccaria seeds plus diet therapy|Vaccaria seeds at the exterior side of the ear area, standard points were selected according to clinical experience in traditional Chinese medicine: Shenmen (TF4), Stomach (CO4), Hunger, Mouth (CO1), Point Zero HX1) and Sanjiao (CO17). Mustard seeds (Vaccaria ear seeds, Beijing Zhongyan Taihe Medicine, Beijing, China) were used, plus diet therapy prescribed by a licensed nutritionist.
62426061|NCT03948737|ACTIVE_COMPARATOR|Alpha-Tocopgerol|"Alpha-Tocopherol supplementation will be given orally for 4 weeks with doses adjusted by age.~5-8 years old: 200 mg daily, 9-13 years old: 400 mg daily and 14-18 years old 600 mg daily."
62811495|NCT04834180|ACTIVE_COMPARATOR|ASP needles plus diet therapy|ASP needles on the outside of the ear standard points were selected according to clinical experience in traditional Chinese medicine: ASP gold needles, strengthening the centre with point 0 (the umbilicus) in the dominant ear, Porta Fortunae in the non-dominant ear, Barbiturate in the non-dominant ear, Psychosomatique key point in the dominant ear and the point Aggression, plus diet therapy prescribed by a licensed nutritionist.
62811496|NCT04834180|NO_INTERVENTION|only diet therapy|only diet therapy prescribed by a licensed nutritionist.
62811497|NCT02350517|EXPERIMENTAL|Paclitaxel+Nedaplatin+Endostar|Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14.
62811498|NCT01393275|ACTIVE_COMPARATOR|Rehabilitation intervention group|The group is performing a strength endurance training intervention in addition with rehabilitation exercise intervention.
62034971|NCT02269670|EXPERIMENTAL|Treatment (everolimus, hormone therapy)|Patients receive everolimus PO daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant IM or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO QID; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.
62594270|NCT05879406|ACTIVE_COMPARATOR|VitaMedica® Clear Skin Formula capsules|Storage Instructions: Store in a cool, dry place. Contents: 60 Capsules Directions for Use: As a dietary supplement, take two capsules with food. Caution: Do not take if safety seal on bottle is broken. KEEP OUT OF REACH OF CHILDREN.
62235202|NCT05781217|ACTIVE_COMPARATOR|short-term ADT (6 months)|"ARM 1:~LHRH analogues for 6 months + bicalutamide 50 for 30 days"
62235203|NCT05781217|ACTIVE_COMPARATOR|long-term ADT (24 months)|LHRH analogues for 24 months + bicalutamide 50 for 30 days
62235204|NCT00405470|ACTIVE_COMPARATOR|Medial Pivot|
62594271|NCT05879406|PLACEBO_COMPARATOR|Placebo Capsules|Storage Instructions: Store in a cool, dry place. Contents: 60 Capsules Directions for Use: As a dietary supplement, take two capsules with food. Caution: Do not take if safety seal on bottle is broken. KEEP OUT OF REACH OF CHILDREN.
62811499|NCT01393275|PLACEBO_COMPARATOR|Placebo rehabilitation|The group is performing a strength endurance training intervention in addition with placebo rehabilitation exercise intervention.
62811500|NCT06196541||Individuals with Chronic Venous Insufficiency|Edema, pain, respiratory functions, physical functions and quality of life will be evaluated in individuals with chronic venous insufficiency.
62811501|NCT06196541||Asymptomatic Healthy Individuals|Edema, pain, respiratory functions, physical functions and quality of life will be evaluated in asymptomatic healthy individuals.
62811502|NCT02774460|ACTIVE_COMPARATOR|Zestril® (Lisinopril)|Inhibition of angiotensin converting enzyme (ACE inhibitor). Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)
62811503|NCT02774460|ACTIVE_COMPARATOR|Atacand® (Candesartan)|Angiotensin receptor blocker. Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)
62235205|NCT00405470|ACTIVE_COMPARATOR|Posterior Stabilized|
62235206|NCT00852592|ACTIVE_COMPARATOR|Active Comparator|7000lux broad-spectrum light
62235207|NCT00852592|PLACEBO_COMPARATOR|Inactive Comparator|50lux dim red light
62235208|NCT01367353|EXPERIMENTAL|ovarian cancer|
62235209|NCT01510522|EXPERIMENTAL|Glucophage sachets|Patients receive Glucophage sachets, the powder formulation for oral solution in sachets.
62235210|NCT01510522|ACTIVE_COMPARATOR|Glucophage tablets|Patients received Glucophage tablets.
62594272|NCT06076018|ACTIVE_COMPARATOR|intrathecal morphine|In spinal anesthesia, 12 mg hyperbaric bupivacaine and 20 mcg fentanyl, 120 mcg intrathecal morphine (ITM) will be administered intrathecally.
62811504|NCT02774460|ACTIVE_COMPARATOR|Norvasc® (Amlodipine)|Calcium channel blocker. Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)
62811505|NCT02774460|ACTIVE_COMPARATOR|Hydrochlorothiazide® (Hydrochlorothiazide)|Diuretic agent. Treatment step up: 1-2 weeks (12,5 mg tablet) Target dose: 5-7 weeks (25 mg tablet)
62235211|NCT02623374|EXPERIMENTAL|SH-CBT|This intervention will be a tailored CBT intervention adapted from the previously validated (Ayres, et al., 2012) self-help CBT intervention that comprises of a self-help booklet containing information, advice, a relaxation CD and daily diaries. This intervention lasts 4 weeks (approx. 4 hours per week) and the materials guide the individual through each chapter and exercise, including the homework set out for each chapter.
62235212|NCT02623374|NO_INTERVENTION|No Treatment-Wait Control (NTWC)|Women will be offered no intervention but will complete questionnaires at the same assessment points as the intervention/treatment arm participant group (i.e. baseline (A0), 6 weeks (A1), 20 weeks (A2) post randomisation). They will be offered the SHCBT intervention off trial following the final assessment (i.e. A2).
62235213|NCT05412381|PLACEBO_COMPARATOR|Control Arm|The control arm will receive a pre-op placebo injection of saline, and ACLR surgery with intra-op placebo injection
62426062|NCT03948737|PLACEBO_COMPARATOR|Control|Placebo is the drug with the same shape and color as the alpha-tocopherol supplementation.
62594273|NCT06076018|PLACEBO_COMPARATOR|intrathecal fentanyl|Intrathecal 12 mg hyperbaric bupivacaine and 20 mcg fentanyl in spinal anesthesia, ITM will not be applied
62235214|NCT05412381|EXPERIMENTAL|Investigational Arm|The investigational arm will receive a pre-op PRP injection, and ACLR surgery with PRP injection
62235215|NCT03520933||Embryos undergoing PGT-A / niPGT-A|Embryos from IVF patients between 20 and 44 years of age, undergoing PGT-A for any medical indication, with own oocytes or ovum donation cycles and with single embryo transfer (SET)
62235216|NCT01360060||Group N|parturients who had undergone Cesarean section under the diagnosis of non-preeclampsia
62235217|NCT01360060||Group P|parturients who had undergone Cesarean section under the diagnosis of preeclampsia
62235218|NCT01339741|ACTIVE_COMPARATOR|Vitamin D|
62235219|NCT01339741|PLACEBO_COMPARATOR|Placebo|
62235220|NCT05877183|EXPERIMENTAL|Wearable device group|Participants will be instructed to wear the wristwatch for a minimum of 3 hours per day, 5 days per week and engage in telerehabilitation, 1 hour per day 5 times per week over 4 weeks. Weekly, there will be a 45-minute therapy consultation.
62235221|NCT05877183|SHAM_COMPARATOR|Sham group|The participants will be instructed to wear the sham device for a minimum of 3 hours per day, 5 days per week. In addition, they will be instructed to engage in upper limb training with the prescribed exercises presented in the form of a pictorial handout rather than an in-app video, 1 hour per day 5 times per week over 4 weeks. Weekly, there will be a 45-minute therapy consultation.
62235222|NCT06251609|ACTIVE_COMPARATOR|Naloxone|The intervention consists of naloxone 2mg (2ml of 1mg/ml solution) administered by EMS personnel via the IV or IO route. The study intervention will be administered immediately (within 5 minutes) following the first dose of epinephrine.
62235223|NCT06251609|PLACEBO_COMPARATOR|Saline|Saline 2ml will be supplied in pre-filled syringes within numbered trial treatment packs. The trial will be double-blind; patients, investigators, and the clinical team will be blinded. Only the pharmacy providing the numbered syringes will be aware of the allocation but will not be involved with clinical care or outcome evaluation. The saline placebo will be stored in syringes identical to the naloxone syringes without identifying features.
62426063|NCT04337515|EXPERIMENTAL|Patients receiving allogeneic hematopoietic cell transplant|"The test product is a stem cell product which has been alpha-beta T- cell depleted using the CliniMACS system. Alpha-beta T-cell depleted cells are given intravenously over a period of time as dictated by the final volume of the infused product (5 ml/kg/hour).~The target dose of CD34+ cells is ≥20x10\^6/kg, but a minimum of~≥2.5x10\^6/kg is required. The target dose of T-cell receptor (TCR) alpha-beta CD3+ cells is ≤1x10\^5/kg."
62426064|NCT03651895|ACTIVE_COMPARATOR|Treatment Group|Metformin 500mg bd
62426065|NCT03651895|PLACEBO_COMPARATOR|Placebo Group|Placebo
62426066|NCT05802979|ACTIVE_COMPARATOR|group 1|consists of patients receiving Serratus anterior plane block using Bupivacaine + Ketamine.
62594274|NCT05885035|EXPERIMENTAL|Treated with hyperdilute Calcium Hydroxylapatite (CaHA)|Subjects will have 3 treatment sessions at weeks 0, 4, and 8 and a final live assessment visit at week 14. Approximately two syringes of CaHA will be injected per side of the buttocks (at sites with cellulite dimpling) during each of the three treatment sessions.
62811506|NCT02774460|ACTIVE_COMPARATOR|Repeated treatment X|"Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y.~The repeated arms will be given with the same duration and dosing as the other arms."
62811507|NCT02774460|ACTIVE_COMPARATOR|Repeated treatment Y|"Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y.~The repeated arms will be given with the same duration and dosing as the other arms."
62235224|NCT03149471||Normal endothelial function|patients diagnosed with PE and have normal endothelial function test- RHI score \>=1.67
62594275|NCT05233150|EXPERIMENTAL|PriCARE/CARIÑO plus Usual Care|Caregiver-child dyads assigned to the PriCARE/CARIÑO plus usual care group will receive the PriCARE/CARIÑO intervention within 4 months of randomization plus usual care. The intervention will last 6 weeks. Each group, administered by 1-2 trained mental health professionals, will have approximately 4-10 caregiver participants and will meet weekly for 6 weeks. Each of the 6 sessions is approximately 80 minutes. Caregivers are expected to practice the skills they learn with their children between sessions.
62811508|NCT02774460|PLACEBO_COMPARATOR|Placebo|This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
62811509|NCT00976846|EXPERIMENTAL|Baxter Xenium XPH 210|Device: Baxter Xenium XPH 210 dialyzer
62235225|NCT03149471||Endothelial dysfunction group|patients diagnosed with PE and have endothelial function- RHI\<1.67
62235226|NCT00615836|EXPERIMENTAL|Desmopressin Melt 10 μg|Participants received desmopressin melt 10 μg once a day, placed under the tongue one hour before bedtime until they were re-randomized to one of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).
62235227|NCT00615836|EXPERIMENTAL|Desmopressin Melt 25 μg|Participants received desmopressin melt 25 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
62235228|NCT00615836|EXPERIMENTAL|Desmopressin Melt 50 μg|Participants received desmopressin melt 50 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
62235229|NCT00615836|EXPERIMENTAL|Desmopressin Melt 100 μg|Participants received desmopressin melt 100 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
62235230|NCT05149365|EXPERIMENTAL|Sitagliptin Group|95 adult patients with hematologic malignancies receiving Alternative Donor HSCT, who will receive Sitagliptin combined with Standard prophylaxis regimen for GVHD of Alternative Donor HSCT.
62426067|NCT05802979|ACTIVE_COMPARATOR|group 2|consists of patients receiving Serratus anterior plane block using Bupivacaine + neostigmine.
62426068|NCT05802979|PLACEBO_COMPARATOR|group 3|consists of patients receiving Serratus anterior plane block using Bupivacaine + normal saline.
62426069|NCT01904552|EXPERIMENTAL|apical periodontitis (AP)|clinical pulp necrosis periapical index scores of 3, 4 or 5
62426070|NCT01904552|EXPERIMENTAL|normal periapex (NP)|clinical pulp vitality periapical index score of 1
62426071|NCT03305783||Patients having cholecystectomy|Healthy, normal weight patients (BMI\<27) undergoing elective cholecystectomy will have a meal test performed before and after surgery.
62426072|NCT03305783||Healthy controls|Healthy matched controls will have one meal test performed.
62235231|NCT05149365|ACTIVE_COMPARATOR|Standard Group|95 adult patients with hematologic malignancies receiving Alternative Donor HSCT, who will only receive Standard prophylaxis regimen for GVHD of Alternative Donor HSCT
62235232|NCT04439721|EXPERIMENTAL|γδT|γδT,Infusion,iv,0.5×10\^6-8×10\^7γδT /kg,once.
62235233|NCT06071273|EXPERIMENTAL|Home-based exercise|6 months home-based exercise program with continuous monitoring of the cardiovascular response of the participants during exercise via the online platform.
62235234|NCT06071273|EXPERIMENTAL|Community-based exercise|6-month community based (i.e., local community gym) exercise intervention
62235235|NCT06071273|NO_INTERVENTION|Control group|Control group, no exercise intervention.
62235236|NCT01480674||Trastuzumab|Eligible participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic or locally advanced breast cancer, who were treated with trastuzumab as a first-line therapy and were progression-free for at least 3 years after treatment initiation, were included and were followed for one year.
62235237|NCT03753633|EXPERIMENTAL|Speech therapy Group|25 patients will be treated with speech therapy, once a week, during 40 minutes for 12 weeks. Oropharyngeal exercises will be performed under the supervision of a speech therapist. Patients will perform the oropharyngeal exercises at home every day.
62235238|NCT03753633|SHAM_COMPARATOR|Control Group|25 patients will perform inspiratory and expiratory exercises recruiting diaphragmatic muscle.
62235239|NCT02141984||Patients with Polyarticular JIA or ERA|Patients with polyarticular juvenile idiopathic arthritis (JIA) or enthesitis-related arthritis (ERA)
62235240|NCT02032303|ACTIVE_COMPARATOR|Ticagrelor|Patient randomized to Ticagrelor
62235241|NCT02032303|ACTIVE_COMPARATOR|Prasugrel|Patient randomized to Prasugrel
62235242|NCT04286490|EXPERIMENTAL|Prone position|
62235243|NCT04065152|EXPERIMENTAL|oncolytic immunotherapy|Talimogene laherparepvec Dose: 10\^6 pfu/ml at week 1 then 10\^8/ml at week 4 and every 2 weeks (up to 4ml for each injection) Route: intralesional injection Duration of treatment: 6 months (12 cycles)
62235244|NCT05073237|EXPERIMENTAL|conjugated estrogens/bazedoxifene (CE/BZA)|Participants assigned to CE/BZA will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg. Recommended and only FDA approved dosage is one CE/BZA tablet daily, taken without regard to meals. Tablets should be swallowed whole. If a dose of BZA/CE is missed, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications.
62243212|NCT02947477|EXPERIMENTAL|Treatment|The EMA intervention uses twice-a-day interactive questions for emotion tracking including type of emotion, intensity of emotion, trigger to emotion and response to emotion through an Iphone app designed for the study. The study users receive individualized feedback about their daily reporting of emotions, sleep and stress.The study tracking is for 14 days.
62426073|NCT06520267||symptomatic BPH|All patients with symptomatic BPH attending the Urology Out-Patient Department (OPD) of the study site were enrolled. Informed and written consent was obtained from all participants. Demographic data were recorded, and detailed histories were taken regarding the duration and symptoms of BPH and relevant past history. IPSS scoring was conducted. A thorough clinical examination, including general physical, systemic, and digital rectal examination, was performed. During the rectal examination, the prostate was checked for nodules, softness, induration, or tenderness. Urine culture and antibiotic sensitivity tests were conducted to assess the bacteriological profile.
62426074|NCT04098471|EXPERIMENTAL|single transanal loca excision|
62426075|NCT04098471|EXPERIMENTAL|transanal local excision following radiotherapy|
62426076|NCT04098471|EXPERIMENTAL|total mesorectal excision|
62426077|NCT06540313|EXPERIMENTAL|Relieve anxiety symptoms|
62426078|NCT06540313|EXPERIMENTAL|Restore mental function|
62426079|NCT06540313|EXPERIMENTAL|Verify Stellate Ganglion Block security|
62426080|NCT06540313|EXPERIMENTAL|Explore the Stellate Ganglion Block intervention mechanism|
62426081|NCT01261416||Infants with seizures|
62235245|NCT05073237|PLACEBO_COMPARATOR|Placebo|Participants assigned to placebo will receive a daily tablet. To assure the blind is maintain, participants in the placebo group will be given the same instructions for taking the study medication. Tablets should be swallowed whole. If a dose, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about CE/BZA and its potential side effects and contraindications, again to maintain the blind.
62235246|NCT03024853|EXPERIMENTAL|BPS PAST|Participants write down about themselves in a past when they displayed their best self. Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.
62235247|NCT03024853|EXPERIMENTAL|BPS PRESENT|Participants write down about themselves in in the present, focusing on what currently makes the best version of themselves (skills, features...). Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.
62235248|NCT03024853|EXPERIMENTAL|BPS FUTURE|"Participants write down about themselves in the future after everything has gone as well as it possibly could. Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.~This is the original BPS exercise (already validated in other studies)."
62235249|NCT03024853|ACTIVE_COMPARATOR|CONTROL|Participants write down the activities they did during the last 24 hours. Then, they visualize (imagine) the content. They practice the visualization exercise for 7 consecutive days.
62235250|NCT01220232|ACTIVE_COMPARATOR|Abacavir/Lamivudine|
62235251|NCT01220232|EXPERIMENTAL|Lersivirine + Abacavir/Lamivudine|
62235252|NCT00733993|EXPERIMENTAL|1 Caffeine 150 mg|Caffeine 150 mg
62235253|NCT00733993|PLACEBO_COMPARATOR|2 Placebo|Placebo
62235254|NCT00733993|EXPERIMENTAL|3 Amphetamine|Amphetamine
62235255|NCT00733993|EXPERIMENTAL|4 Caffeine 300 mg|Caffeine 300 mg
62426082|NCT04075383|OTHER|immediate dental implant|The implant is installed immediately after tooth extraction.
62426083|NCT04075383|OTHER|immediate-delayed dental implant|The implant is installed 8 weeks after tooth extraction.
62426084|NCT01136005|EXPERIMENTAL|dexpanthenol 5% cream|dexpanthenol 5% cream
62426085|NCT01136005|ACTIVE_COMPARATOR|cetomacrogol cream|a vehicle
62426086|NCT06528990|EXPERIMENTAL|Periop-OSMT Telehealth Intervention Arm|Arm 1 includes the following key components: 1) assignment to a peer ostomate; 2) ostomy self-management skills building delivered through group telehealth sessions and led by trained ostomy nurses and peer ostomates; 3) intervention resource manual. The intervention is delivered through 2 telephone and 5 telehealth sessions over a 16 week period.
62594276|NCT05233150|NO_INTERVENTION|Usual care|Caregiver-child dyads assigned to the usual care group will receive usual care and will not be aware of being in a group of about 8-10 recently-enrolled subjects.
62594277|NCT05682378|EXPERIMENTAL|Inclisiran|Inclisiran sodium 300mg (equivalent to 284mg inclisiran\*) in 1.5mL solution
62235256|NCT04731220||Study group|Newly diagnosed as bile duct cancer
62235257|NCT04731220||Control group|No history of cancer in previous 5 years
62235258|NCT03029169|ACTIVE_COMPARATOR|Propafenone i.v.|"Patients in septic shock with a new onset supraventricular arrhythmia are randomized either to arm treated with propafenone or with amiodarone. Both arms will have standard treatment, there are no limits to indicated electric cardioversion as part of treatment.~Intervention: Bolus of 35-70 mg intravenous propafenone followed by continuous infusion of 400-840 mg/24h."
62235259|NCT03029169|ACTIVE_COMPARATOR|Amiodarone i.v.|"Patients in septic shock with a new onset supraventricular arrhythmia are randomized either to arm treated with propafenone or with amiodarone. Both arms will have standard treatment, there are no limits to indicated electric cardioversion as part of treatment.~Intervention: Bolus of 150-300 mg of intravenous amiodarone followed by continuous infusion of 600-1800 mg/24h."
62235260|NCT00577161|ACTIVE_COMPARATOR|Comparator|fludarabine and rituximab
62235261|NCT00577161|EXPERIMENTAL|Experimental|fludarabine, rituximab, pixantrone
62243213|NCT02947477|NO_INTERVENTION|Control|The control arm does nothing for 14 days and then receives the 14 day emotion tracking listed above.
62594278|NCT04015076|EXPERIMENTAL|Single Ascending Dose|Inzomelid or Placebo
62594279|NCT04015076|EXPERIMENTAL|Multiple Ascending Dose|Inzomelid or Placebo
62594280|NCT04015076|EXPERIMENTAL|Patients with CAPS|Inzomelid Open Label
62594281|NCT02076503|EXPERIMENTAL|PET-MR 18F-FACBC|
62594282|NCT00619567|EXPERIMENTAL|Cognitive Stimulation|Subjects will be given Internet access to the Smartbrain cognitive stimulation program. They will complete exercises for \~30 minutes, at least three times per week, for a period of 24 weeks.
62811510|NCT06394570|EXPERIMENTAL|Dose Level 0|Neoadjuvant therapy of Enfortumab Vedotin 1.25 mg/kg (3 cycles) and sequential Radiation Therapy starting on Cycle 3 Day 21 of EV treatment (32.5 Gray in 5 fractions)
62811511|NCT06394570|EXPERIMENTAL|Dose Level 1|Neoadjuvant therapy of Enfortumab Vedotin 1.25 mg/kg (3 cycles) and concurrent Radiation Therapy starting on Cycle 2 Day 15 of EV treatment (32.5 Gray in 5 fractions)
62235262|NCT03714204|EXPERIMENTAL|Transcendental Meditation Group|Participants assigned to this group each received the intervention of 5 initial class instructions in the Transcendental Meditation technique, followed by 6 additional classes over the 4-month study period. Group participants were expected to practice the technique for 20 minutes twice per day for 4-months.
62235263|NCT03714204|NO_INTERVENTION|Control Group|Participants assigned to this group served as wait-list controls
62235264|NCT01839500||Cohort I: HER2-Positive mGC Treated With Trastuzumab|HER2-positive metastatic gastric cancer (mGC) participants who are treated with trastuzumab will be included in this cohort. As this is an observational study, treatment schedule will be at the clinician's discretion in accordance with routine care practice and not dictated by the protocol.
62235265|NCT01839500||Cohort II: HER2-Positive mGC not Treated With Trastuzumab|HER2-positive mGC participants who are not treated with trastuzumab will be included in this cohort.
62811512|NCT06394570|EXPERIMENTAL|Dose Level 2|Neoadjuvant therapy of Enfortumab Vedotin 1.25 mg/kg (3 cycles) and concurrent Radiation Therapy starting on Cycle 1 Day 15 of EV treatment (32.5 Gray in 5 fractions)
62811513|NCT01486212||Healthy volunteers.|Male aged 18-40 years. Non-smokers. No known familiar disposition to vascular/heart diseases. No intake of prescription medicine.
62811514|NCT01784224|EXPERIMENTAL|Speaking Valves|"All participants will either have a Blom tracheotomy tube in place or have their current tracheotomy tube changed to a Blom tracheotomy tube to allow for use of both the Blom low profile voice inner cannula and the Passy-Muir one-way speaking valves.~The Blom low profile voice inner cannula and Passy-Muir speaking valves will be provided to participants in a random order. All valves will be placed by the PI. Duration of data collection trials will range from 10 to 30 minutes."
62811515|NCT01260493|NO_INTERVENTION|Conventional care, controlgroup|conventional care, control group
62235266|NCT01839500||Cohort III: HER2-Positive non-mGC|HER2-positive non-mGC participants will be included in this cohort.
62235267|NCT01839500||Cohort IV: HER2-Negative mGC|HER2-negative mGC participants will be included in this cohort.
62235268|NCT01839500||Cohort V: HER2-Negative non-mGC|HER2-negative non-mGC participants will be included in this cohort.
62235269|NCT04856644|EXPERIMENTAL|4-month regimen (2HZPM/2HPM)|"* Eight weeks of daily treatment with isoniazid (H), pyrazinamide (Z), rifapentine (P), and moxifloxacin (M), followed by~* Nine weeks of daily treatment with isoniazid, rifapentine and moxifloxacin"
62235270|NCT04856644|NO_INTERVENTION|Standard 6-month regimen (2HERZ/4HR) historical control|"a standard, six-month regimen, with~* Eight weeks of daily treatment with isoniazid (H), rifampin (R), pyrazinamide (Z) and ethambutol (E) followed by~* Eighteen weeks of daily treatment with isoniazid and rifampin, with or without ethambutol"
62235271|NCT01891721|EXPERIMENTAL|Specific Perceptual Training - Brain Fitness Program (BFP)|In each session, participants will work on 4 of the 6 BFP exercises (15 min per exercise). Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
62235272|NCT01891721|EXPERIMENTAL|Broad Cognitive Training - Cognitive Package (Cogpack)|In each session, participants will work on a different subset of 4 to 6 Cogpack exercises. Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
62235273|NCT01891721|ACTIVE_COMPARATOR|Control Treatment - Commercial Computer Games (Sporcle)|In each session, participants will play between 8 and 16 games (1 to 15 min per game). Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
62811516|NCT01260493|EXPERIMENTAL|integrated health care chain|integrated health care chain. Geriatric assessment at emergency department (ED), case manager with multiprofessional team in the community, support for informal caregivers
62426087|NCT06528990|OTHER|Standard of Care Arm|Arm 2 involves standard of care, where patients and family caregivers are managed by the oncology care team. Care may include clinic visits for follow-up, cancer directed treatments, referrals to other medical specialties as needed, and institutional ostomy nurse support before and after surgery as needed.
62426088|NCT03078192|EXPERIMENTAL|Training Set - PVD, Isolated Left Heart Failure, Isolated Lung Disease|Patients with Pulmonary Vascular Disease (10 subjects), isolated left sided heart failure (10 subjects), and isolated lung disease(10 subjects) will undergo Xe MRI scans with GE-141, Hyperpolarized 129Xenon gas to develop diagnostic criteria for optimizing the sensitivity and specificity of XeMRI for the diagnosis of PVD
62426089|NCT03078192|EXPERIMENTAL|Test Set - Pulmonary Vascular Disease|92 subjects being evaluated for undergoing right heart catheterization for evaluation of PAH or other cardiac or pulmonary disease for testing of diagnostic accuracy of XeMRI for diagnosis of PVD
62811517|NCT00365014||Blood disease patients|People with blood diseases presenting at Shanghai hospitals
62811518|NCT03236896|ACTIVE_COMPARATOR|Exercise Intervention|This group will participate in a weekly exercise regimen and actively log the physical activity in a diary. They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
62811519|NCT03236896|ACTIVE_COMPARATOR|No Exercise|They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
62811520|NCT03332381|ACTIVE_COMPARATOR|Attention training technique|
62811521|NCT03332381|ACTIVE_COMPARATOR|Mindful self-compassion|
62811522|NCT02848820|EXPERIMENTAL|Augmentin + Gentamicin|"Initial non-operative treatment strategy reserving an appendectomy for those not responding or with recurrent disease. It consist of:~Clinical observation for 48 hours with administration of Intravenous administration of amoxicillin/clavulanic acid 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) and gentamicin 7mg/kg once daily for 48 hours. If after 48 hours the patient fulfils the predefined discharge criteria, the antibiotics will be switched to oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days and discharge. An appendectomy is reserved for those patients with clinical deterioration, non-improvement after 72 hours or recurrent appendicitis.~Pain medication according to national protocol."
62811523|NCT02848820|ACTIVE_COMPARATOR|Operative treatment strategy|Clinical observation and semi-urgent appendectomy. Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics. Discharge if the patient fulfils the predefined discharge criteria. Pain medication according to national protocol.
62811524|NCT06553092||urkish-Speaking Patients Undergoing Shoulder Surgery|This cohort consists of Turkish-speaking patients who have undergone shoulder surgery. Participants will complete the Turkish version of the Hospital for Special Surgery Shoulder Surgery Expectations Survey.
62811525|NCT00726947|EXPERIMENTAL|1|Ultrasound imaging of Acute DVT (deep vein thrombosis)
62811526|NCT00726947|EXPERIMENTAL|2|Ultrasound imaging of Chronic DVT (deep vein thrombosis)
62811527|NCT02244541|EXPERIMENTAL|Anavex2-73 oral then the Anavex2-73 intravenous formulation|Participants first receive Anavex2-73 hard gelatin capsule each morning with a light breakfast for 11 days. After a washout period of 11 days they then receive the Anavex2-73 intravenous formulation each morning with a light breakfast for 11 days.
62811528|NCT02244541|EXPERIMENTAL|Anavex2-73 intravenous then the Anavex2-73 oral formulation|Participants first receive Anavex2-73 intravenous formulation each morning with a light breakfast for 11 days. After a washout period of 11 days then they receive the Anavex2-73 hard gelatin capsule each morning with a light breakfast for 11 days.
62811529|NCT02244541|EXPERIMENTAL|Anavex2-73 30 mg oral formulation|Participants will receive the 30 mg Anavex2-73 hard gelatin capsule orally once daily for 52 weeks.
62811530|NCT02244541|EXPERIMENTAL|Anavex2-73 50 mg oral formulation|Participants will receive the 50 mg Anavex2-73 hard gelatin capsule orally once daily for 52 weeks.
62811531|NCT00952302|PLACEBO_COMPARATOR|CMS - placebo first|Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive a placebo (saline) infusion first followed by iron infusion.
62811532|NCT00952302|EXPERIMENTAL|CMS - iron|Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive an iron infusion first followed by placebo (saline) infusion.
62811533|NCT00952302|PLACEBO_COMPARATOR|SLR - placebo|Sea level residents (SLR) taken to high altitude for one week, and receiving placebo (saline) infusion on Day 3 at high altitude.
62811534|NCT00952302|EXPERIMENTAL|SLR - iron|Sea level residents (SLR) taken to high altitude for one week, and receiving iron infusion on Day 3 at high altitude.
62811535|NCT02257593|EXPERIMENTAL|10 % Protein|10% Dietary protein energy
62811536|NCT02257593|EXPERIMENTAL|15% Protein|15% Dietary protein energy
62811537|NCT02257593|EXPERIMENTAL|25% Protein|25% Dietary protein energy
62811538|NCT04177706|EXPERIMENTAL|Group A (Ketamine)|
62811539|NCT04177706|PLACEBO_COMPARATOR|Group B (Placebo)|
62426090|NCT02623426|ACTIVE_COMPARATOR|Dexamethasone intravitreal implant 0.7mg|"Participants were randomized to a treatment group. A participant may have 1 or 2 eyes with macular edema (eligible eyes) receiving the same treatment.~Eligible eye(s) treated at study visit M01 (week 0).~Retreatment required at study visit M03 (8 weeks) if re-treatment criteria met.~Retreatment permitted at later time points if retreatment criteria met.~Re-treatment criteria:~1. Central subfield thickness greater than 1.1X upper limit of normal (330 μm for Zeiss and Topcon Spectral Domain (SD) Optical Coherence Tomography (OCT) and 352 μm for Heidelberg OCT) and/or cystoid space(s) within 1 mm central subfield.~2. IOP of \<25 mm Hg (treatment with ≤3 IOP-lowering agents permitted)~Minimum time between treatments: minimum target is 8 weeks after last injection but re-injection permitted as early as 51 days after last injection;"
62594283|NCT00619567|NO_INTERVENTION|Control|"These individuals will receive usual care during the 24 week follow-up period."
62034972|NCT05252767|EXPERIMENTAL|Cohort A - Patient Engagement Tools|Participants will be enrolled from the a pain management clinic. Participants randomized into the experimental cohort will receive access to a clinic brochure, clinic website, as well as 'My Pain Passport' and 'My Treatment Plan' tools.
62594284|NCT02253316|EXPERIMENTAL|Consolidation: Ixazomib, Lenalidomide, & Dexamethasone|Consolidation therapy will begin between Day 80 and Day 120 following ASCT and will consist of four 28-day cycles of IRD (ixazomib, lenalidomide, \& dexamethasone). Barring dose modifications for toxicity, 4 mg of ixazomib and 40 mg of dexamethasone will be administered on Days 1, 8, and 15, and 15 mg of lenalidomide will be administered on daily on Days 1-21.
62594285|NCT02253316|EXPERIMENTAL|Maintenance Arm 1: Ixazomib|Ixazomib will be administered on Days 1, 8, and 15 of a 28-day cycle at a starting dose of 4 mg until patient progresses or experiences an unacceptable toxicity.
62594286|NCT02253316|EXPERIMENTAL|Maintenance Arm 2: Lenalidomide|Lenalidomide will be administered daily continuously for a 28-day cycle at a starting dose of 10 mg. If lenalidomide is tolerated well (i.e. no dose modification required) during the first three cycles, lenalidomide dose will be increased to 15 mg daily and will continue until patient progresses or experiences an unacceptable toxicity.
62594287|NCT00792688|EXPERIMENTAL|1|GLYC-101 Gel, 0.1% on one eyelid and Placebo Gel on the other eyelid
62594288|NCT00792688|EXPERIMENTAL|2|GLYC-101 Gel, 1.0% on one eyelid and Placebo Gel on the other eyelid
62594289|NCT00792688|EXPERIMENTAL|3|GLYC-101 Gel, 0.1% on one eyelid and GLYC-101 Gel, 1.0% on the other eyelid
62235274|NCT04193488|ACTIVE_COMPARATOR|MTP block (Group MTP)|In the MTP Group, a high frequency HFL-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Using the parasaggital scan, the block needle (50 mm 22 Gauge will be advanced from the caudal to the cervical target of the paravertebral space. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml normal saline is performed. Once the needle tip has been confirmed, 20 ml of 0.25% bupivacaine will be given to the block. The same procedure will be applied 3 cm later than the incision line.
62594290|NCT02188472|ACTIVE_COMPARATOR|Penicillin V|Penicillin V 2 tablets of 330 mg twice dayly for 7 days
62811540|NCT05997602|EXPERIMENTAL|FCN-159|Experimental: FCN-159 Dosage form:tablet Specification: 1mg，4mg Dose: FCN-159 5mg/m² (Maximum dose does not exceed 8mg), orally, once daily
62811541|NCT03582215|EXPERIMENTAL|Part 1: Cream|"Part 1: Cream~Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule"
62811542|NCT03582215|EXPERIMENTAL|Part 1: Lotion|"Part 1: Lotion~Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene"
62811543|NCT03582215|EXPERIMENTAL|Part 1: Spray 1|"Part 1: Spray 1~Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate"
62811544|NCT03582215|EXPERIMENTAL|Part 1: Spray 2|"Part 1: Spray 2~Ingredients: 3% Avobenzone; 5% Oxybenzone; 10% Octocrylene"
62811545|NCT03582215|EXPERIMENTAL|Part 2: Lotion|"Part 2: Lotion~Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene"
62811546|NCT03582215|EXPERIMENTAL|Part 2: Aerosol Spray|"Part 2: Aerosol Spray~Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate"
62811547|NCT03582215|EXPERIMENTAL|Part 2: Nonaerosol Spray|"Part 2: Nonaerosol Spray~Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate"
62811548|NCT03582215|EXPERIMENTAL|Part 2: Pump Spray|"Part 2: Pump Spray~Ingredients: 3% Avobenzone; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate"
62811549|NCT06211608||Arm 1|Polycystic ovary syndrome (PCOS)
62811550|NCT06211608||Arm 2|Hypothalamic-pituitary-ovarian axis dysfunction (HPOD)
62811551|NCT00342446||Patients with Infertility|Patients of all races with primary or secondary infertility, including women with recurrent miscarriages.
62811552|NCT02096445|EXPERIMENTAL|Robot group|"Receive robot-assisted neurocognitive therapy instead of conventional neurocognitive therapy.~(4 x 45 min/week)"
62811553|NCT02096445|ACTIVE_COMPARATOR|Control group|Receive dose-matched conventional neurocognitive therapy
62235275|NCT04193488|ACTIVE_COMPARATOR|ESP block (Group ESP)|In the ESP group, a high-frequency 15-6 megahertz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Once the erector spinae muscle and transver projections have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane will open. Twenty milliliters of 0.25% bupivacaine will be given for the block. The same procedure will be applied from the other 3 cm lateral of the incision line.
62235276|NCT04193488|ACTIVE_COMPARATOR|no block (Group C)|No regional plan block will be applied to the control group. Conventional analgesic methods were applied.
62235277|NCT03919188|ACTIVE_COMPARATOR|air temperature control (ATC)|Incubator control using air temperature control (ATC) method
62235278|NCT03919188|ACTIVE_COMPARATOR|skin servocontrol (SSC)|Incubator control using skin servocontrol method
62594291|NCT02188472|ACTIVE_COMPARATOR|Trimethoprim|2 Tablet Trimethoprim of 100 mg twice daily for 7 days
62594292|NCT02188472|PLACEBO_COMPARATOR|Placebo|2 Placebo Tablets twice daily for 7 days
62811554|NCT00115570|EXPERIMENTAL|Insulin Glulisine|Insulin Glulisine (100UI/ml), at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine for a maximum of 26 weeks
62811555|NCT00115570|ACTIVE_COMPARATOR|Insulin Lispro|Insulin Lispro (100UI/ml) Subcutaneous (SC) injection , at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine ) for a maximum of 30 weeks
62811556|NCT02666781||Pilot Group|Postoperative surgical Patients with or without Obstructive Sleep Apnea
62811557|NCT02646826|PLACEBO_COMPARATOR|Placebo|Subjects are treated with placebo tablets.
62811558|NCT02646826|EXPERIMENTAL|Paxerol - Dose Level 1|Subjects are treated with the first dose level of Paxerol.
62811559|NCT02646826|EXPERIMENTAL|Paxerol - Dose Level 2|Subjects are treated with the second dose level of Paxerol.
62034973|NCT05252767|SHAM_COMPARATOR|Cohort B - Educational Guide|Participants randomized into the control cohort will receive a brief educational guide on general pain management.
62034974|NCT00928577||ACAM2000 Smallpox Vaccine Group|Participants are vaccinia vaccine-naive and have received ACAM2000 Smallpox vaccine as part of their Service Member readiness process.
62235279|NCT02041741|ACTIVE_COMPARATOR|Weekly tips|Daily small and concrete happiness tips
62235280|NCT02041741|ACTIVE_COMPARATOR|Daily Tips|Weekly more in-depth happiness tips involving an active (doing and experiencing) task
62235281|NCT02041741|NO_INTERVENTION|Wait-List Control|No intervention
62235282|NCT05781919|EXPERIMENTAL|Group A|Patients with L1, L2 or M INRGSS neuroblastoma in which their surgical planning will be performed using gold standard imaging (TC and/or MRI) and immersive virtual reality HMD device.
62235283|NCT05781919|ACTIVE_COMPARATOR|Group B|Patients with L1, L2 or M INRGSS neuroblastoma in which their surgical planning will be performed using only gold standard imaging (TC and/or MRI)
62235284|NCT04098354|ACTIVE_COMPARATOR|home-based BP telemonitoring|Patients will receive a Bluetooth-enabled and validated electronic upper arm oscillometric BP device (A\&D Ltd. UA-651BLE; San Jose, CA) that will be paired to their smartphone. Patients will be required to sit with their back rested for at least 5 minutes with the BP cuff around their arm. They will then be required to push the start button on the HBPT device to initiate BP measurement. HBPT values will be based on a series comprised of the mean of duplicate measures, for morning and evening, for a 7-day period and the first day home BP values will not be considered. The BP data will be auto transmitted via Bluetooth to their smartphone and relayed to a secure web portal for review.
62235285|NCT04098354|PLACEBO_COMPARATOR|usual care|Patients in the control arm will also follow the same BP measurement protocol as the 'active comparator (intervention) group, however, there will be no interactions with the case manager; they will share their BP readings with their primary care physicians or nurse practitioners at scheduled visits.
62235286|NCT01072877|EXPERIMENTAL|Polidocanol injectable foam 0.125%|Polidocanol injectable foam 0.125%
62235287|NCT01072877|EXPERIMENTAL|Polidocanol injectable foam 0.5%|Polidocanol injectable foam 0.5%
62235288|NCT01072877|EXPERIMENTAL|Polidocanol injectable foam 1.0%|Polidocanol injectable foam 1.0%
62235289|NCT01072877|EXPERIMENTAL|Polidocanol injectable foam 2.0%|Polidocanol injectable foam 2.0%
62235290|NCT01072877|PLACEBO_COMPARATOR|Vehicle|Injection of vehicle comparator
62235291|NCT03302000|EXPERIMENTAL|Visual stimulation|"Early visual stimulation (EVS) will be implemented by caregivers.~Three phases:~1. the caregiver will establish eye-to-eye contact with the infant. The caregiver will communicate with the infant talking, singing, changing facial expressions, touching his/her face. Total duration of this part of stimulation is between 2 and 3 minutes~2. the caregivers will present visual contrast cards at a distance of 15-20 centimetres~3. the caregiver will present two toys to the infant~Stimulation will last for 28 days (4 weeks) in total, one time a day for 10-15 minutes, all days week."
62235292|NCT03302000|OTHER|standard care|Caregivers will receive an Illustrated Handbook, according to the age range of birth to three months. Assessors will explain all information contained in the handbook after the first assessment and randomisation.
62235293|NCT03629951||Participants with Schizophrenia|Participants will not receive any intervention as a part of this study. Participants with a diagnosis of schizophrenia or schizoaffective disorder receiving oral antipsychotics (OAP) for example, risperidone (1 to 6 milligram \[mg\] once daily \[OD\] to twice a day \[BID\]), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to thrice a day \[TID\]) etc, per their treating physician/clinician instruction will be observed. The primary data source for this study will be the clinical assessments by the treating physician of each participant conducted as a part of routine clinical practice.
62235294|NCT04051827|EXPERIMENTAL|Part A: Midazolam + TAK-788|Midazolam 3 mg, solution, orally, once on Days 1 and 24 and midazolam 1 mg, infusion, intravenously, once on Days 2 and 25 along with TAK-788 160 mg, capsule, orally, once daily from Day 3 through 30 in Cycle 1.
62235295|NCT04051827|EXPERIMENTAL|Part B: TAK-788|TAK-788 160 mg, capsules, orally, once daily in a 28-day treatment cycle from Cycle 2 to Cycle 24, or until progressive disease (PD), intolerable toxicity, or another discontinuation criterion is met, whichever is sooner. Eligible participants from Part A may enter into Part B. Based on the investigator's opinion, if a participant continues to experience clinical benefit, treatment with TAK-788 may be continued after PD.
62811560|NCT02646826|EXPERIMENTAL|Paxerol - Dose Level 3|Subjects are treated with the third dose level of Paxerol.
62811561|NCT04033796|ACTIVE_COMPARATOR|25,000 IU|
62243214|NCT01177384|EXPERIMENTAL|Sitagliptin|Sitagliptin 100 mg daily (q.d.) + acarbose (continuing the current stable dose of at least 50 mg three times daily \[t.i.d.\])
62243215|NCT01177384|PLACEBO_COMPARATOR|Placebo|Placebo q.d. + acarbose (continuing the current stable dose of at least 50 mg t.i.d.)
62594293|NCT00020943|EXPERIMENTAL|Chemo/immuno/autolog transplant|Intensive chemotherapy followed by autologous stem cell transplant and immunotherapy for mantle cell lymphoma
62594294|NCT00656565||1|subjects with bronchiectasis
62811562|NCT04033796|ACTIVE_COMPARATOR|50,000 IU|
62811563|NCT04033796|PLACEBO_COMPARATOR|Placebo|
62811564|NCT00989911|EXPERIMENTAL|Bosentan|Bosentan
62811565|NCT05360069|EXPERIMENTAL|Linear stapler group|Linear stapler is adopted in esophagojejunostomy.
62811566|NCT05360069|ACTIVE_COMPARATOR|Circular stapler group|Circular stapler is adopted in esophagojejunostomy.
62811567|NCT02182622|EXPERIMENTAL|Dose Level -1|Docetaxel 60mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 200mg oral daily
62811568|NCT02182622|EXPERIMENTAL|Dose Level 1|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice a day LDE225 200mg oral daily
62811569|NCT02182622|EXPERIMENTAL|Dose Level 2|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 400mg oral daily
62811570|NCT02182622|EXPERIMENTAL|Dose Level 3|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 800mg oral daily
62235296|NCT03598088|OTHER|Healthy Sexually Active Women|Healthy, sexually active women who are not at risk for pregnancy due to previous female tubal sterilization will receive both Ovaprene and the Caya diaphragm throughout the course of the trial. The purpose of the Caya Post Coital Test (PCT) cycle is to ensure that in this study population and at these sites, results that are expected to be observed in a PCT cycle with an approved vaginal barrier can be replicated.
62235297|NCT01034839||acute myeloid leukemia, adults|Adults treated for acute myeloid leukemia in our hospital between 1978 and 2007
62235298|NCT04254185|ACTIVE_COMPARATOR|Simple decompression|In-situ decompression releases only the compressive ligamentous structures overlying the ulnar nerve.
62235299|NCT04254185|ACTIVE_COMPARATOR|Subcutaneous anterior transposition|Anterior transposition repositions the ulnar nerve, providing decompression and lengthening by moving the nerve anterior to the axis of elbow rotation
62594295|NCT03152331|EXPERIMENTAL|Receptive Awareness Training|
62235300|NCT03700749|ACTIVE_COMPARATOR|2%chlorhexidine + non-coated suture|2%alcoholic chlorhexidine + non-coated suture. Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with non-coated suture for abdominal fascial closure.
62235301|NCT03700749|ACTIVE_COMPARATOR|2%chlorhexidine + coated suture|2%alcoholic chlorhexidine + triclosan-coated suture. Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with triclosan-coated suture for abdominal fascia closure.
62235302|NCT03700749|ACTIVE_COMPARATOR|10% povidone-iodine + non-coated suture|10% povidone-iodine and non-coated suture. Intervention: skin preparation with 10% povidone-iodine in combination with non-coated suture for abdominal fascial closure.
62235303|NCT03700749|ACTIVE_COMPARATOR|10%povidone-iodine + coated suture|10%povidone-iodine/triclosan-coated suture. Intervention: skin preparation with 10% povidone-iodine in combination with triclosan-coated suture for abdominal fascial closure.
62235304|NCT04740892|EXPERIMENTAL|Wash and Cream Investigational Product (IP)|Parent participant will bathe the child participant with the investigational wash at least 3 times per week, but no more than once daily, for 4 weeks. Parent participant will apply the investigational cream on their child participant twice daily for 4 weeks.
62235305|NCT02025569|EXPERIMENTAL|Experimental group|Strain counterstrain intervention
62235306|NCT02025569|SHAM_COMPARATOR|Control Group|Sham Strain Counterstrain intervention
62235307|NCT03125213|ACTIVE_COMPARATOR|Peg-IFN plus AL-3778|
62235308|NCT03125213|PLACEBO_COMPARATOR|Peg-IFN plus matching placebo|
62235309|NCT00465725|EXPERIMENTAL|1|two-period crossover, open label study in which a single dose (Cycle 1) of picoplatin will be given either IV or PO, followed 4 weeks later by a single dose (Cycle 2) of picoplatin given by the route not used for Cycle 1. Subjects subsequently may continue to receive IV picoplatin commencing with Cycle 3 in a Continuation Study.
62235310|NCT03773822|PLACEBO_COMPARATOR|Placebo of hydrocortisone and placebo of fludrocortisone|Placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of enteral fludrocortisone given once a day for seven days
62235311|NCT03773822|EXPERIMENTAL|Combination of hydrocortisone + fludrocortisone|Hydrocortisone will be given as 50 mg iv bolus every 6 hours for seven days and a tablet of 50 µg of fludrocortisone will be given once a day enterally for seven days
62235312|NCT01762033|EXPERIMENTAL|ASONEP|ASONEP will be administered by intravenous infusion over 90 minutes at 15 mg/kg once a week every 4 consecutive weeks per cycle
62235313|NCT02090374|EXPERIMENTAL|Poly ICLC dose escalation|Poly ICLC nasal challenge dose escalation 10ug, 100ug, 500ug
62235314|NCT02090374|EXPERIMENTAL|Poly ICLC highest dose|Poly ICLC nasal challenge single dose of 1000ug
62235315|NCT02090374|EXPERIMENTAL|Poly I:C single dose|Poly I:C nasal challenge single dose 500ug
62735478|NCT02880228|EXPERIMENTAL|Treatment (lenalidomide, dexamethasone, pembrolizumab)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO daily on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of course 1, day 15 of course 2, and day 8 of course 3. Courses 1-3 repeat beyond 3 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo stem cell transplantation after 4 courses of treatment.
62811571|NCT05246046|EXPERIMENTAL|Tiotropium Easyhaler 10 microg/dose, Product variant J|Each subject will receive a single dose of 2 inhaled doses from Tiotropium Easyhaler Product variant J in one of the three periods (cross-over). The total dose is 20 micrograms of tiotropium (delivered dose) as Tiotropium Bromide Monohydrate.
62811572|NCT05246046|EXPERIMENTAL|Tiotropium Easyhaler 10 microg/dose, Product variant K|Each subject will receive a single dose of 2 inhaled doses from Tiotropium Easyhaler Product variant K in one of the three periods (cross-over). The total dose is 20 micrograms of tiotropium (delivered dose) as Tiotropium Bromide Monohydrate.
62811573|NCT05246046|ACTIVE_COMPARATOR|Spiriva HandiHaler 18 microg/capsule|Each subject will receive a single dose of 2 inhaled Spiriva capsules via HandiHaler device in one of the three periods (cross-over). The total dose is 20 micrograms of tiotropium (delivered dose) as Tiotropium Bromide Monohydrate.
62811574|NCT05314634|EXPERIMENTAL|concurrent exercise group, CE|Participants conduct 5-min warm up, 12-min aerobic exercise, 13-min resistance exercise, and 5-min cool down.
62811575|NCT05314634|EXPERIMENTAL|aerobic exercise group, AE|Participants conduct 5-min warm up, 25-min aerobic exercise, and 5-min cool down.
62811576|NCT05314634|NO_INTERVENTION|reading control group, RC|Participants conduct reading for 35 minutes.
62811577|NCT01387217|EXPERIMENTAL|Part A|Part A will be used to confirm the prediction of GSK2018682 PK, assess its effects on lymphocytes, and monitor its safety profile in a single cohort (Cohort 1). Cohort 1 will consist of 4 subjects and explore 4 doses of GSK2018682 in 4 study sessions. In each session, three subjects will receive GSK2018682 and one subject will receive placebo. Thus, when the cohort completes, each subject will receive placebo and 3 doses of GSK2018682.
62235316|NCT02090374|EXPERIMENTAL|R848 high dose|R848 nasal challenge 10ug
62235317|NCT02090374|EXPERIMENTAL|R848 low dose|R848 nasal challenge low dose 1-2ug (0.02ug/kg)
62235318|NCT02090374|EXPERIMENTAL|Grass pollen|Timothy grass pollen nasal challenge
62235319|NCT02090374|EXPERIMENTAL|Vitamin D supplementation|Vitamin D 4000U orally daily
62235320|NCT02090374|EXPERIMENTAL|Tuberculin|Tuberculin PPD nasal challenge
62235321|NCT03130010|PLACEBO_COMPARATOR|The control group|One hour before the end of the operation, the control group was received 20 ml of saline.
62235322|NCT03130010|ACTIVE_COMPARATOR|The Nefopam group|One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam.
62235323|NCT04495907||Group I|Group I- Asymptomatic patients with SARS-CoV-2 Infection
62426091|NCT02623426|ACTIVE_COMPARATOR|Intravitreal methotrexate 400µg in 0.1mL|"Participants were randomized to a treatment group. A participant may have 1 or 2 eyes with macular edema (eligible eyes) receiving the same treatment.~Eligible eye(s) treated at study visit M01 (week 0).~Retreatment required at M02 (4 weeks) and M03 (8 weeks) if retreatment criteria met.~Retreatment permitted at later time points if retreatment criteria met.~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection."
62594296|NCT02155517|EXPERIMENTAL|Propofol Infusion|"Propofol will be administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider and Cortinez (arcomed ag, Medical System, Switzerland )..~The study will make in two stages:~STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.~STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes."
62594297|NCT05803096|ACTIVE_COMPARATOR|Self-Administered Nitrous Oxide|"Patients will receive SANO in addition to periprostatic bupivacaine nerve block for the duration of prostate biopsy.~After the Urologist describes the procedure, the SANO group will have nitrous oxide turned on to 30%, ensuring that the patient is relaxed but still conversant through the procedure. The nitrous will be adjust up or down based on the patient's response to the question are you feeling the nitrous and are you happy at this level. The range will be between 25 - 45%. At the end of the procedure, the SANO group will be turned down to 0% nitrous oxide, and 100% oxygen will be administered through the mask for an additional 2-3 minutes as the patient is cleaned up and repositioned to the supine position."
62594298|NCT05803096|PLACEBO_COMPARATOR|Oxygen|Patients will receive 100% oxygen at 10 Liters/minute for the duration of prostate biopsy.
62594299|NCT01075230|ACTIVE_COMPARATOR|Standard TKA|Subjects in this arm will receive total knee replacement as standard of care without Platte Rich Plasma
62594300|NCT01075230|ACTIVE_COMPARATOR|Standard TKA with PRP|Subjects in this arm will receive total knee replacement as standard of care with Platte Rich Plasma
62594301|NCT05555979||Chronic Lymphocytic Leukemia (CLL) Participants|Participants treated with venetoclax+rituximab or bruton's tyrosine kinase inhibitors in accordance with approved local label.
62235324|NCT04495907||Group II|Group II-Symptomatic patients with SARS-CoV-2 Infection
62235325|NCT05908604|ACTIVE_COMPARATOR|Intervention group|In the IG, home care professionals load medications inside the robot, and it enabled older home care clients to carry out medication management by themselves.
62235326|NCT05908604|SHAM_COMPARATOR|Control group|In the CG, home care professionals manually dispensed medications to doset and administrating medications during their home visits.
62235327|NCT02354443|EXPERIMENTAL|ProHema-CB|ProHema-CB represents Ex Vivo Modulated Human Cord Blood Cells. Each subject will receive one administration of ProHema-CB unit transplant.
62235328|NCT01786174|EXPERIMENTAL|Gilenya (fingolimod)|0.5mg Gilenya (fingolimod) orally once daily for 28 days +/- 3 days
62235329|NCT01786174|PLACEBO_COMPARATOR|Placebo|0.5mg placebo (sugar pill) orally once daily for 28 days +/- 3 days
62235330|NCT01185925|PLACEBO_COMPARATOR|Placebo|Control Group
62235331|NCT01185925|ACTIVE_COMPARATOR|sildenafil, pde5 inhibitor|treatment group; sildenafil 50 mg three times a day for 1 year
62235332|NCT00407069||Active Atopic Dermatitis (AD)|Pediatric and adult subjects who fulfill the criteria for AD, a chronic inflammatory skin disease.
62235333|NCT00407069||Inactive Atopic Dermatitis (AD)|Adult subjects with a prior history of active AD that has been quiescent for at least 1 year.
62235334|NCT00407069||Psoriatics|Adult subjects who fulfill the criteria for plaque psoriasis, a chronic inflammatory skin disease.
62235335|NCT00407069||Asthmatics (without a history of AD)|Adult subjects who fulfill the criteria for asthma (reactive airway disease) and have a negative history of skin disease.
62235336|NCT00407069||Eczema Herpeticum (EH|Pediatric and adult AD subjects with a history of EH.
62235337|NCT00407069||Healthy Volunteers|Healthy individuals with no history of skin or respiratory disease.
62235338|NCT05643846|ACTIVE_COMPARATOR|(Group 1) will receive the intervention 'Bupivacaine at concentration of 0.125%, dose of 0.2 ml/kg'.|(Group 1) will receive bilateral QLB procedure with the intervention 'Bupivacaine local anesthetic drug at concentration of 0.125% concentration, at a dose of 0.2 ml/kg'.
62235339|NCT05643846|ACTIVE_COMPARATOR|(Group 2) will receive the intervention 'Bupivacaine concentration of 0.25%, dose of 0.2 ml/kg'.|(Group 2) will receive bilateral QLB procedure with the intervention 'Bupivacaine local anesthetic drug at a concentration of 0.25% concentration, at a dose of 0.2 ml/kg'.
62235340|NCT02051270||Elders|Older people living in nursing homes will undergo a descriptive study.
62235341|NCT02031289|ACTIVE_COMPARATOR|Anemia|Hb \< 120 g/L in women, Hb \< 130 g/L in men Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
62235342|NCT02031289|ACTIVE_COMPARATOR|Iron deficiency|ferritin \< 100 µg/l Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
62235343|NCT02031289|NO_INTERVENTION|Natural comparison group|Patients without anemia or iron deficiency will be observed and the same postoperative measurements performed
62235344|NCT04724226|EXPERIMENTAL|C-couple|Camrelizumab and Apatinib after Cryoablation
62426092|NCT02623426|ACTIVE_COMPARATOR|Intravitreal ranibizumab 0.5mg in 0.05mL|"Participants were randomized to a treatment group. A participant may have 1 or 2 eyes with macular edema (eligible eyes) receiving the same treatment.~Eligible eye(s) treated at study visits M01 (week 0), M02 (4 weeks), and M03 (8 weeks).~Retreatment permitted at M04 (12 weeks) and at later time points if retreatment criteria met.~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection.~Re-treatment permitted at later time points if re-treatment criteria met."
62235345|NCT03513874|EXPERIMENTAL|Metformin + Insulin|
62235346|NCT03513874|ACTIVE_COMPARATOR|Insulin alone|
62235347|NCT06277102|EXPERIMENTAL|Music|Music listening at postoperative day 1 and 2, 1 session per day, 20 minutes per session.
62235348|NCT06277102|NO_INTERVENTION|Control|Standard of care
62426093|NCT06112405|OTHER|App-based CCAAP|Patients in this group will be provided App-based CCAAP to remind them take medicine regularly and direct them what to do when asthma get worse.
62594302|NCT02354755||Cold room|Anesthesia providers intraoperatively placed in ambient room temperature of 65 degreees (cold room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
62594303|NCT02354755||Hot room|Anesthesia providers intraoperatively placed in ambient room temperature of 80 degreees (hot room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
62594304|NCT02354755||Control Room|as a control placed Anesthesia providers in ambient room temperature of 75 degreees (neutral room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
62235349|NCT04602377|EXPERIMENTAL|Pembrolizumab|Single arm study
62235350|NCT03525990|ACTIVE_COMPARATOR|Intervention Arm|Quality of life questionnaires (electronic patient reported outcomes) to be filled out by the patients at every visit. Quality of life data is fully available for physicians. Paper-based questionnaire (EORTC QLQ-COMU26) at baseline, after three months and after six months.
62235351|NCT03525990|PLACEBO_COMPARATOR|Control Arm|Quality of life questionnaires (electronic patient reported outcomes) only to filled out by the patients at baseline, after three months and after six months. Quality of life data is hidden for physicians. Paper-based questionnaire (EORTC QLQ-COMU26) at baseline, after three months and after six months.
62235352|NCT04209621|OTHER|Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Duvelisib with ibrutinib will be administered for the first six 28-day (± 7) cycles followed by duvelisib alone until disease progression or intolerance. Duvelisib is an orally administered at 15 mg twice a day (dose level 1) or 25 mg twice day (dose level 2). Subjects will continue the same dose of ibrutinib prior to study enrollment for the first six 28-day cycles. Ibrutinib is an orally administered and provided as 140 mg white opaque capsules or tablets in 4 strengths: 140 mg, 280 mg, 420 mg, and 560 mg.
62235353|NCT01539304|EXPERIMENTAL|CITUS Dry Syrup|Pranlukast dry syrup 10%
62235354|NCT01539304|PLACEBO_COMPARATOR|Placebo|Placebo
62235355|NCT04386343|PLACEBO_COMPARATOR|50% dose level arm - Phase I|4 healthy volunteer will use 50% dose level for Phase I in the left hand side and use placebo in the right hand side
62235356|NCT04386343|PLACEBO_COMPARATOR|100% dose level arm - Phase I|4 healthy volunteer will use 100% dose level for Phase I in the left hand side and use placebo in the right hand side
62235357|NCT04386343|ACTIVE_COMPARATOR|167% dose level arm - Phase I|4 healthy volunteer will use 167% dose level for Phase I in the left hand side and use placebo in the right hand side
62235358|NCT04386343|PLACEBO_COMPARATOR|Placebo arm - Phase II|20 Breast cancer patients will use Placebo in the radiation affected area right after radiation
62235359|NCT04386343|PLACEBO_COMPARATOR|50% dose level arm - Phase II|20 Breast cancer patients will use CH1701 with 50% of the expected dose level in the radiation affected area right after radiation
62235360|NCT04386343|PLACEBO_COMPARATOR|100% dose level arm - Phase II|20 Breast cancer patients will use CH1701 with 100% of the expected dose level in the radiation affected area right after radiation
62235361|NCT04386343|PLACEBO_COMPARATOR|167% dose level arm - Phase II|20 Breast cancer patients will use CH1701 with 167% of the expected dose level in the radiation affected area right after radiation
62235362|NCT01005225||Solid tumors|Participants 18 years of age or older who have been diagnosed with a solid tumor or benign hyperplasia that needs surgical removal will be included in this study.
62235363|NCT04682171|EXPERIMENTAL|Low level Laser Therapy|Low Level Laser Therapy and Conventional Exercise therapy
62426094|NCT06112405|OTHER|written CCAAP|Patients in this group will be provided written asthma action plan and direct them what to do when asthma get worse.
62426095|NCT01585831|EXPERIMENTAL|Testosterone gel 1%|Testosterone gel 1% applied to skin once per day for 1 year. Starting dose 1.25mL per day, titrated in 1.25mL increments for 1st 6 months of study after each study visit up to maximum of 5.0mL per day. Titration based on testosterone levels with target level in mid-range of normal for Tanner stage.
62426096|NCT01585831|PLACEBO_COMPARATOR|Placebo gel|Placebo gel applied to skin once per day for 1 year. Starting dose 1.25mL per day. Dose randomly adjusted in 1.25mL increments for 1st 6 months of study after each study visit up to maximum of 5.0mL per day.
62735479|NCT02039167|ACTIVE_COMPARATOR|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
62735480|NCT02039167|NO_INTERVENTION|OAC with a vitamin K antagonist|Oral anticoagulants (OAC) as Standard of Care (SOC) provided by primary care physician
62735481|NCT01539122|ACTIVE_COMPARATOR|TM Glenoid|Zimmer TM glenoid shoulder replacement component will be used for the glenoid component of the total shoulder replacement.
62735482|NCT01539122|ACTIVE_COMPARATOR|Cemented Glenoid|Cemented glenoid shoulder replacement component
62235364|NCT04682171|ACTIVE_COMPARATOR|Conventional ExerciseTherapy|Conventional ExerciseTherapy
62235365|NCT04803136|OTHER|Bone SPECT/CT|Gamma Camera with computed tomography
62235366|NCT04803136|OTHER|Spine surgeries|spine stabilization and fusion surgeries
62235367|NCT01699789|ACTIVE_COMPARATOR|Resources for Services|The Resources for Services condition offers time-limited technical assistance to individual agencies, coupled with outreach from a community engagement specialty, to participate in structured reviews of components of the Quality Improvement Program Intervention as implemented by the Resources for Services Expert Team.
62235368|NCT01699789|EXPERIMENTAL|Community Engagement and Planning|The Community Engagement and Planning arm supported 4 months of planning for the Community Engagement and Planning Council consisting representatives of all assigned programs in biweekly 2 hour meetings to fit trainings in the Quality Improvement Program to the community and develop strategies across programs to collaborate as a network. The CEP Council developed a written plan for training and monitoring and supported implementation of the training plan. CEP sites were provided with enrolled client lists.
62235369|NCT04071353||Interferon combined with ribavirin group|Interferon combined with ribavirin (PR) antiviral therapy (PR treatment for 6 months or more) in patients with chronic hepatitis C, collect basic data before antiviral therapy, and during the PR antiretroviral treatment period, Follow-up was performed every 3-6 months in March, June, September, December, DAAs antiviral treatment during January, March, and withdrawal follow-up, and clinical biochemistry, HCV RNA, and serological markers were used during follow-up ( anti-HCV), AFP and liver imaging (liver ultrasound) examination.
62426097|NCT02276911|ACTIVE_COMPARATOR|Intravenous (IV) ibuprofen|800mg IV ibuprofen before incision, followed by four total scheduled doses of IV ibuprofen every six hours for 24 hours, in addition to whatever narcotic or other pain control regimens prescribed by the treating physician to control postoperative pain.
62235370|NCT04071353||DAAs treatment group|Patients with chronic hepatitis C treated with direct acting antivirals (DAAs), collect basic data before antiviral therapy, and during the period of PR antiviral treatment, January, March, June, September, December Follow-up was performed every 3-6 months during January, March, and withdrawal follow-up during DAAs antiviral therapy. Clinical biochemistry, HCV RNA and serological markers (anti-HCV), AFP, and liver imaging were performed at follow-up. Liver ultrasound) check.
62426098|NCT02276911|PLACEBO_COMPARATOR|Intravenous (IV) normal saline|800mg normal saline before incision, followed by four total scheduled doses of IV ibuprofen every six hours for 24 hours, in addition to whatever narcotic or other pain control regimens prescribed by the treating physician to control postoperative pain.
62426099|NCT03435822|OTHER|asthma action plan management group|Patients in this group will be provided both written asthma action plan and mobile-based APP to remind them take medicine regularly and direct them what to do when asthma get worse.
62426100|NCT03435822|OTHER|conventional management group|Patients in this group will be provided conventional management method with prescriptions and asthma diaries.
62426101|NCT04060472|EXPERIMENTAL|albumin-bound paclitaxel + oxaliplatin|
62426102|NCT02840214|ACTIVE_COMPARATOR|tDCS rescue group|Subjects assigned to this arm will receive transcranial direct current stimulation (tDCS) that delivers a constant, small current (2 milliAmp) across specific regions of the brain through electrodes placed on the scalp half-way through the 3-hour fatigue task.
62426103|NCT02840214|PLACEBO_COMPARATOR|Sham Treatment Group|Subjects assigned to this arm will initially receive current of the same intensity for a period of 30 seconds and then gradually turned off.
62426104|NCT02840214|ACTIVE_COMPARATOR|tDCS prevent group|Subjects assigned to this arm will receive transcranial direct current stimulation (tDCS) that delivers a constant, small current (2 milliAmp) across specific regions of the brain through electrodes placed on the scalp at the beginning of the task.
62426105|NCT03304210|EXPERIMENTAL|Abraxane 35 mg/m²|PIPAC with Abraxane (35 mg/m²) will be administered every 4 weeks for 3 cycles.
62426106|NCT03304210|EXPERIMENTAL|Abraxane 70 mg/m²|PIPAC with Abraxane (70 mg/m²) will be administered every 4 weeks for 3 cycles.
62426107|NCT03304210|EXPERIMENTAL|Abraxane 90 mg/m²|PIPAC with Abraxane (90 mg/m²) will be administered every 4 weeks for 3 cycles.
62426108|NCT03304210|EXPERIMENTAL|Abraxane 112.5 mg/m²|PIPAC with Abraxane (112.5 mg/m²) will be administered every 4 weeks for 3 cycles.
62426109|NCT03304210|EXPERIMENTAL|Abraxane 140 mg/m²|PIPAC with Abraxane (140 mg/m²) will be administered every 4 weeks for 3 cycles.
62235371|NCT00345930||2|Individuals without drug induced liver disease
62235372|NCT00345930||1|Individuals with drug induced liver disease
62235373|NCT01289171|EXPERIMENTAL|Glycolic acid|All who met the study criteria commenced once daily use of 15% glycolic acid lotion.
62235374|NCT01809184|EXPERIMENTAL|Dose level 1|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
62235375|NCT01809184|EXPERIMENTAL|Dose level 2|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
62426110|NCT00730470|EXPERIMENTAL|1|
62426111|NCT06567236|NO_INTERVENTION|Traditional teaching method|Participants will be exposed to traditional teaching method.
62034975|NCT00928577||Other vaccinia vaccine Group|Participants did not receive ACAM2000 Smallpox vaccine as part of their Service Member readiness process because they are still protected by previous vaccinia vaccination or are ineligible for current ACAM2000 vaccination either because of recency of prior vaccinia vaccination or for reasons solely attributable to conditions or characteristics of their contacts (such as a healthy soldier who is married to someone with a contraindicated condition).
62034976|NCT01371851|EXPERIMENTAL|Doxazosin|Doxazosin extended release will be administered initially at 4 mg/day. On day 8 the dose is increased to 8 mg/day and the participant is maintained on the study until the end of the trial.
62034977|NCT01371851|PLACEBO_COMPARATOR|Placebo|Participants will be maintained on placebo (cellulose) throughout the trial.
62034978|NCT06411457|EXPERIMENTAL|SHR-A1811+Adebrelimab|Assess the efficacy and safety of the SHR-A1811 in combination with Adebrelimab regimen in HER2 low-expressing metastatic breast cancer
62034979|NCT04325750|PLACEBO_COMPARATOR|Control|The simulated mode technique is applied (machine off)
62034980|NCT04325750|EXPERIMENTAL|TECAR THERAPY|The intervention will be performed with the T-Care TECAR® therapy machine at the latent trigger points of both gastrocnemius. The professional will apply the therapy with the generator that emits radio frequency signals of 0.5 MHz at a variable power with a maximum of 300W. The frequency to be used will be 500MHz with an intensity of 40% and with direct current.
62034981|NCT05836766|ACTIVE_COMPARATOR|Y-6 sublingual tablets|Y-6 sublingual tablets (each tablet contains 25 mg cilostazol and 6 mg dexborneol) Manufacturer: Nanjing Neurodawn Pharmaceutical Co., Ltd.
62034982|NCT05836766|PLACEBO_COMPARATOR|Placebo tablets of Y-6 sublingual tablet|Y-6 strength: Placebo tablets of Y-6 sublingual tablet (each tablet contains 0 mg cilostazol and 0.06 mg dexborneol) Manufacturer: Nanjing Neurodawn Pharmaceutical Co., Ltd.
62034983|NCT02568241|EXPERIMENTAL|interferon Alfa-2b|High-risk acute leukemia patients after hematopoietic stem cell transplantation receive interferon Alfa-2b after prophylactic DLI
62034984|NCT05060328||Health services research (Google Translate Conversation Mode)|"Patients use Google Translate Conversation Mode translation application before and after surgery. Patients also complete survey over 10 minutes."
62034985|NCT05510843|EXPERIMENTAL|THB001 Dose Level A|
62034986|NCT05510843|EXPERIMENTAL|THB001 Dose Level B|
62426112|NCT06567236|EXPERIMENTAL|3D software teaching method.|Participants will be exposed to traditional teaching method and 3D software teaching method.
62034987|NCT05510843|EXPERIMENTAL|THB001 Dose Level C|
62034988|NCT02049086|EXPERIMENTAL|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
62034989|NCT02049086|ACTIVE_COMPARATOR|Pain Module Only|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
62034990|NCT02049086|NO_INTERVENTION|No Additional Referral|No intervention.
62735483|NCT06345261|ACTIVE_COMPARATOR|Diphenhydramine group|
62034991|NCT03204097|PLACEBO_COMPARATOR|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
62426113|NCT06373419|ACTIVE_COMPARATOR|Thulium Fibre Laser|Participants randomized to this arm will undergo bladder resection using the TFL laser
62735484|NCT06345261|PLACEBO_COMPARATOR|control group|
62735485|NCT00976287|ACTIVE_COMPARATOR|Conserved Therapy|Conserved Therapy
62034992|NCT03204097|ACTIVE_COMPARATOR|group 2|SRP followed by 1% Alendronate (ALN) gel
62034993|NCT03204097|ACTIVE_COMPARATOR|group 3|SRP followed by Aloevera (AV) gel
62235376|NCT01809184|EXPERIMENTAL|Dose level 3|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
62034994|NCT02263651|ACTIVE_COMPARATOR|Closure with conventional technique with drainage|The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.
62034995|NCT02263651|EXPERIMENTAL|Quilting suture without drainage|In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (\<2cm) are placed from the skin flaps to the underlying muscle.
62034996|NCT04320160|NO_INTERVENTION|Positive control group|Include the thirty patients before any treatment
62034997|NCT04320160|ACTIVE_COMPARATOR|PRP group|Include fifteen patients that will recieve PRP sessions .Patients will receive six treatment sessions with one month interval for 6 months and will be followed up after 6 months.
62034998|NCT04320160|ACTIVE_COMPARATOR|Fractional CO2 group|Include fifteen patients that will recieve FR: CO2 laser sessions.Patients will receive six treatment sessions with one month interval for 6 months and will be followed up after 6 months.
62034999|NCT05974696||Patients RECAPitNETT|All adult subjects with pituitary tumours whose file is presented to the national HYPOcare RCP. There is only one group.
62035000|NCT02245152|EXPERIMENTAL|PROMIS intervention|"* Small group behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly well-baby visits for children 0-17 months of age~* Caregivers with children 0-17 months of age that attend the well-baby visit will be provided with a monthly dose of LNS (20g/day)"
62235377|NCT01809184|EXPERIMENTAL|Dose level 4|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
62235378|NCT01809184|EXPERIMENTAL|Dose level 5|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
62235379|NCT01809184|EXPERIMENTAL|Dose level 6|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
62594305|NCT05113641|EXPERIMENTAL|Alkalizing Fruit and Vegetables|Participants randomized to fruit and vegetables (F+V) will receive weekly supplementation of alkalizing fruits and vegetables via home delivery in a box format. Participants will receive a 1-hour dietary counseling session in the first week from a registered dietitian (RD), either in person or via videoconference, depending on regional coronavirus disease (COVID) 19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the F+V into the participant's current diet. Intervention will last 12 months.
62594306|NCT05113641|ACTIVE_COMPARATOR|Sodium Bicarbonate|Participants randomized to the alkali therapy will receive oral sodium bicarbonate 500mg tablets three times a day, reflecting a common starting dose at clinical practice. Thereafter, decisions around dose titration for the sodium bicarbonate will then be transferred to the participant's nephrologist who will be responsible for monitoring the participants serum bicarbonate concentration with a goal of maintaining a serum bicarbonate level \>22 mEq/L. Participants will receive counselling from a registered dietician (RD) as part of the standard care. Intervention will last 12 months.
62594307|NCT05401110|EXPERIMENTAL|Osimertinib with Carotuximab|
62735486|NCT00976287|EXPERIMENTAL|Interventional Therapy|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
62035001|NCT02245152|ACTIVE_COMPARATOR|control|Monthly well-baby visits as prescribed by national policy This arm is the basic comparison arm. Caregivers are invited to frequent the health center once a month for well-baby visits. During these visits necessary vaccinations are administered, child growth and nutrition status is evaluated and preventive counseling on child nutrition and health is provided in large groups of caregivers.
62235380|NCT01809184|EXPERIMENTAL|Dose level 7|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
62235381|NCT04248270|OTHER|The relationship between image and AD disease|To evaluate the relationship between F-18-PMPBB3 PET image uptake pattern and AD disease classifications.
62035002|NCT05315193|EXPERIMENTAL|Structured In-patient and Home plan|Structured In-patient and Home plan
62035003|NCT05315193|PLACEBO_COMPARATOR|Conventional therapy|Conventional protocol as per guidelines
62035004|NCT01388816|PLACEBO_COMPARATOR|Placebo capsule|
62035005|NCT01388816|EXPERIMENTAL|DRL-17822 50 mg|
62035006|NCT01388816|EXPERIMENTAL|DRL-17822 150 mg|
62035007|NCT01388816|EXPERIMENTAL|DRL-17822 300 mg|
62035008|NCT00717990|EXPERIMENTAL|1|XELIRI/Avastin
62035009|NCT05312138|EXPERIMENTAL|Transcutaneous Posterior Tibial Nerve Stimulation Group|The treatment will be carried out by the physiotherapist using the TenStem Eco Basic device.
62035010|NCT05312138|ACTIVE_COMPARATOR|Repetitive Transcranial Magnetic Stimulation Group|The treatment will be applied with a Power Mag device.
62235382|NCT00913120|EXPERIMENTAL|YM150 group-1|YM150 low dose group
62235383|NCT00913120|EXPERIMENTAL|YM150 group-2|YM150 high dose group
62235384|NCT00913120|PLACEBO_COMPARATOR|Placebo group|
62235385|NCT00913120|ACTIVE_COMPARATOR|Enoxaparin group|
62235386|NCT03920709||Chronic HIV-1 infected subjects : 50 Viremic subjects|plasma HIV RNA \> 500 copies/mL, treatment-naive or treated (failing) regardless of the cause of persistent viremia
62235387|NCT03920709||Chronic HIV-1 infected subjects : 50 Treated Aviremic subjects|\< 50 copies/mL under treatment for at least 12 months
62235388|NCT03920709||Chronic HIV-1 infected subjects :10 Spontaneous Controllers|from the ANRS CO21 CODEX Cohort or not (5 last viral loads \< 400 copies /ml)
62235389|NCT05946278||Patients undergoing deformity correction surgery|Patients undergoing deformity correction surgery undergoing a multi-level spinal fusion (i.e. a T10 (or higher) fusion to the pelvis) -OR- a 3 column osteotomy with a corpectomy from for short segment surgeries -OR- a vertebral column resection (VCR) involving a corpectomy -OR- any deformity correction surgery wherein the attending surgeon determines that a large amount of bone containing trabecular elements will be removed and discarded
62235390|NCT05427812|EXPERIMENTAL|Phase 1: Dose escalation|Participants with R/R multiple myeloma (MM) will be administered ISB 1442 weekly by subcutaneous (SC) injection in each 28-day cycle. Dose escalation will begin with an accelerated titration dose escalation and should certain conversion criteria be met, escalation will convert to the standard (3 + 3) dose escalation
62235391|NCT05427812|EXPERIMENTAL|Phase 2 (Dose Expansion): R/R Multiple Myeloma|This cohort includes the participants with pathologically confirmed R/R MM and must have received at least 3 prior lines of therapy, including proteasome inhibitors (PIs), immunomodulators (IMiDs), and anti CD38 therapies either in combination or as a single agent; and must not be candidates for regimens known to provide clinical benefit. Participants will receive the recommended Phase 2 Dose (RP2D) of ISB 1442 SC injection determined in Phase 1 of the study for treatment of R/R MM. Each treatment cycle duration is 28 days. The anticipated total duration for each participant will vary, depending on the number of cycles of treatment completed. The treatment phase will extend until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met.
62811578|NCT01387217|EXPERIMENTAL|Part B|Part B will explore doses to refine the dose-response curve of GSK2018682 on lymphocyte suppression, as allowed by stopping criteria, in 1 or 2 cohorts of up to 15 subjects (Cohort 2 and Cohort 3). In Part B, up to six single ascending doses of GSK2018682 and one dose of placebo will be investigated in up to 8 sessions.
62035011|NCT04883632|EXPERIMENTAL|Volume Lidocaine HQ|Subjects randomized to be treated with Saypha Volume Lidocaine manufactured in the Croma Pharma HQ Facility
62035012|NCT04883632|ACTIVE_COMPARATOR|Volume Lidocaine C1|Subjects randomized to be treated with Saypha Volume Lidocaine manufactured in the Croma Pharma C1 Facility
62035013|NCT03827954|EXPERIMENTAL|Experimental Treatment|HeartMapp+CT
62035014|NCT01655030|EXPERIMENTAL|creatine monohydrate|6g qd for 6 weeks
62035015|NCT01655030|PLACEBO_COMPARATOR|placebo|6g qd for 6 weeks
62035016|NCT05795582|EXPERIMENTAL|diabetic patients with peripherial arterial disease|Patients will be included during a vascular medicine consultation for follow-up or screening for vascular pathology. Each subject will have their upstroke time measured by a new method of measurement using the device POPMETRE® (Axelife, France).
62735487|NCT04416334|EXPERIMENTAL|Colchicine plus symptomatic treatment (paracetamol).|"Patients in this arm will receive study medication colchicines 0.5 mg orally (PO) twice daily for the first 3 days and then once daily for the last 18 days. If a dose is missed, it should not be replaced.~All patients should also receive best symptomatic treatment (mainly paracetamol), based on clinical practice."
62035017|NCT00827450|PLACEBO_COMPARATOR|Ctl|control isocaloric diet; no coffee
62035018|NCT00827450|PLACEBO_COMPARATOR|HF|Hypercaloric. high fructose diet; no coffee
62235392|NCT01607801||non-absorbable suture NAS|having their umbilical hernia repaired with NAS
62035019|NCT00827450|EXPERIMENTAL|C1|Hypercaloric, high fructose diet; caffeine-free, torrefied coffee
62035020|NCT00827450|EXPERIMENTAL|C2|Hypercaloric, high fructose diet; caffeine-free, partially torrefied coffee
62035021|NCT00827450|EXPERIMENTAL|C3|Hypercaloric, high fructose diet; caffeinated, partially torrefied coffee
62235393|NCT01607801||Long-term-absorbable suture (LAS)|patients having their umbilical hernia repair with LAS
62235394|NCT01607801||Absorbable sutures (AS)|patients having their umbilical hernia repair with AS
62235395|NCT01607801||Mesh repair|Patients having umbilical hernia mesh repair
62235396|NCT01315223|NO_INTERVENTION|Conventional treatment CHF patients|One hundred and fifty patients with CHF will be treated according to current guidelines (conventional treatment).
62235397|NCT01315223|EXPERIMENTAL|Lung impedence-guided treatment|
62243216|NCT03612011|EXPERIMENTAL|Onco-Repair|Onco-Repair tube of 150 ml
62235398|NCT04225702||Group Aspirin|The elderly patients who using Aspirin at least three months before operation were in the Group Aspirin
62811579|NCT03877276|EXPERIMENTAL|3d Diet+Spinach Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to study site and drink a prepared blended spinach smoothie and be provided a breakfast meal.
62811580|NCT03877276|EXPERIMENTAL|5d Diet+Spinach Smoothie+Breakfast|5 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended spinach smoothie and be provided a breakfast meal.
62811581|NCT03877276|EXPERIMENTAL|3d Diet+Kale Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On the final day, participants will return to the study site and drink a prepared kale smoothie and be provided a breakfast meal.
62811582|NCT03877276|EXPERIMENTAL|3d Diet+V Spinach Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended spinach smoothie with varying amounts of spinach and be provided a breakfast meal.
62811583|NCT03877276|EXPERIMENTAL|3d Diet+Blended Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended smoothie and be provided a breakfast meal.
62811584|NCT03877276|EXPERIMENTAL|3d Diet+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and be provided a breakfast meal.
62811585|NCT03877276|EXPERIMENTAL|3d Diet+Sodium Oxalate Drink+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared sodium oxalate drink and be provided a breakfast meal.
62811586|NCT03877276|EXPERIMENTAL|3d Diet+Spinach Smoothie+Breakfast w/ 24 Hr Urine|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a blended spinach smoothie and be provided a breakfast meal.
62811587|NCT02723773|NO_INTERVENTION|LTFU Group|Participants who received at least 1 dose of the HZ/su vaccine in the ZOSTER-006/022 primary studies and no additional doses of the HZ/su vaccine in the current ZOSTER-049:EXT 006-022 study were followed up for long-term vaccine efficacy and safety.
62811588|NCT02723773|EXPERIMENTAL|1-Additional Dose Group|Participants who received 2 doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies received 1 additional dose of the HZ/su vaccine at Month 0 in the current ZOSTER-049:EXT 006-022 study.
62811589|NCT02723773|EXPERIMENTAL|Revaccination Group|Participants who received 2 doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies were revaccinated with 2 additional doses of the HZ/su vaccine at Month 0 and Month 2 in the current ZOSTER-049:EXT 006-022 study.
62811590|NCT02723773|NO_INTERVENTION|Control Group|Participants who received 2 doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and no additional doses of the HZ/su vaccine in the current ZOSTER-049:EXT 006-022 study, but who served as a control for the 2 groups that received 1 or 2 additional doses (1-Additional Dose Group and Revaccination Group).
62811591|NCT01718288|EXPERIMENTAL|iloprost + standard treat.(aspirin)|1B - patients unsuitable to surgical or endovascular vascular therapy: treatment with iloprost intravenous infusions for 10 days every 3 months, in addition to conventional treatment
62811592|NCT01718288|ACTIVE_COMPARATOR|Standard Treatment (aspirin....)|"1A - patients unsuitable to surgical or endovascular vascular therapy: conventional treatment~Conventional Treatments:correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin / low molecular weight heparin, hemorheological / vasodilators such as pentoxifylline / buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids"
62811593|NCT01718288|EXPERIMENTAL|Vascular surgery patients + iloprost|2B - patients suitable to vascular surgical or endovascular therapy: treatment with intravenous infusions iloprost for 10 days every 3 months, in addition to conventional treatment
62235399|NCT04225702||Group Control|The elderly patients who not using Aspirin before operation were in the Group Control
62235400|NCT04658459||Results at short term follow up|Functional and Radiological results at short-term follow up (one year at least)
62235401|NCT04658459||Results at middle term follow up|Functional and Radiological results at the last follow up of the patient (2 years at least)
62811594|NCT01718288|ACTIVE_COMPARATOR|Vasc. Surg.+ standard treat. (aspirin..)|2A - patients suitable to vascular surgical or endovascular therapy + standard treatment (aspirin...)
62811595|NCT00642356|EXPERIMENTAL|Carbidopa/levodopa/entacapone|
62811596|NCT00642356|ACTIVE_COMPARATOR|Immediate release carbidopa/levodopa|
62811597|NCT02249338|EXPERIMENTAL|BIIL 284 BS|
62811598|NCT02249338|PLACEBO_COMPARATOR|Placebo|
62811599|NCT05193214|EXPERIMENTAL|609A UPS|The 609A single-drug regimen (200mg Q3W) was used to treat unresectable or advanced undifferentiated pleomorphic sarcoma to evaluate the safety and effectiveness of 609A.
62235402|NCT00910351|EXPERIMENTAL|Arm 1|
62235403|NCT05292820||Transwomen vaginoplasty|Transgender women who underwent vaginoplasty
62811600|NCT05535504|EXPERIMENTAL|real rTMS|Use the real rTMS coil
62811601|NCT05535504|SHAM_COMPARATOR|sham rTMS|Use the sham rTMS coil
62811602|NCT01274793|ACTIVE_COMPARATOR|Mosapride|In the control group were orally administered 5 mg mosapride citrate tablet s three times a day for 4 continu ous weeks if no severe adverse effects were found.
62811603|NCT01274793|EXPERIMENTAL|Low-dose acupuncture|In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants
62235404|NCT05286697|OTHER|effect of increase intracranial pressure on postoperatve cognitive function|All patient will be given a mini mental test before and after the surgery and the optic nerve diameter will be measured 5 times during the surgery.
62235405|NCT02389114|ACTIVE_COMPARATOR|Low Protein Preload|The subjects consumed soybean curd preload containing low protein content.
62235406|NCT02389114|EXPERIMENTAL|Low Protein with Polydextrose Preload|The subjects consumed soybean curd preload containing low protein content and polydextrose.
62235407|NCT02389114|EXPERIMENTAL|High Protein Preload|The subjects consumed soybean curd preload containing high protein content.
62235408|NCT02389114|EXPERIMENTAL|High Protein with Polydextrose Preload|The subjects consumed soybean curd preload containing high protein content and polydextrose.
62243217|NCT03612011|PLACEBO_COMPARATOR|Placebo|Placebo tube of 150 ml
62811604|NCT01274793|EXPERIMENTAL|High-dose acupuncture|In this group,the current was strong enough to reach the patients'tolerance threshold value.
62035022|NCT01027546|PLACEBO_COMPARATOR|placebo, tranexamic acid|
62035023|NCT04013711|EXPERIMENTAL|Thermal Imaging|Patients will undergo non-invasive, thermal imaging of their whole breast or head and neck cancer site, during the course of the radiotherapy treatment, at weekly time intervals.
62035024|NCT05668728|ACTIVE_COMPARATOR|Group 1|Dry needling + standard exercise program with 4 sessions of stick and pull out method at 1 week intervals
62235409|NCT03141554|ACTIVE_COMPARATOR|Treatment Sequence Group 1|"Treatment Sequence Group 1 = A -\> B -\> C~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)~Treatment C = Normal saline gargle (lukewarm)."
62235410|NCT03141554|ACTIVE_COMPARATOR|Treatment Sequence Group 2|"Treatment Sequence Group 2 = B -\> C -\> A~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)~Treatment C = Normal saline gargle (lukewarm).~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle"
62235411|NCT03141554|ACTIVE_COMPARATOR|Treatment Sequence Group 3|"Treatment Sequence Group 3 = C -\> A -\> B~Treatment C = Normal saline gargle (lukewarm).~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)"
62235412|NCT02488889|ACTIVE_COMPARATOR|Varenicline vs placebo|Participants will be titrated on varenicline as follows: days 1-3, .5 mg per day; days 4-7, .5 mg twice per day, and days 7-12, 1 mg twice per day. Placebo and varenicline pills will be matched in number of pills and packaging of active medications.
62735488|NCT04416334|ACTIVE_COMPARATOR|Symptomatic treatment|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
62735489|NCT03312790|EXPERIMENTAL|augmented reality device|Tasks realized using augmented reality device
62811605|NCT00127634|EXPERIMENTAL|1|
62035025|NCT05668728|ACTIVE_COMPARATOR|Group 2|Dry needling + standard exercise program with 4 sessions of turn-and-wait method at 1-week intervals
62035026|NCT05668728|ACTIVE_COMPARATOR|Group 3|Dry needling + standard exercise program with 4 sessions of stick and turn and wait method 1-week intervals
62035027|NCT00653640|EXPERIMENTAL|1|body weight supported treadmill training
62035028|NCT00653640|PLACEBO_COMPARATOR|2|traditional physical therapy
62035029|NCT05292768||Patients with AID|
62035030|NCT05292768||Control patients with mastocytosis|
62235413|NCT02488889|ACTIVE_COMPARATOR|Alcohol beverage vs. placebo beverage|During each experimental session, participants will ingest a beverage containing placebo (0.0 g/kg; 1% volume of ethanol as taste mask) or alcohol (0.8 g/kg). The beverage will be administered in clear plastic-lidded cups in 2 equal portions that will be consumed during a 5-minute interval and separated by a 5-minute interim rest. The beverages will contain 190-proof ethanol prepared with water, flavored drink mix, and a sucralose-based sugar substitute. Doses for women will be 85% of those of men to adjust for sex differences in total body water.
62235414|NCT00996112||Historical|
62235415|NCT00996112||Prospective|
62235416|NCT02725099|ACTIVE_COMPARATOR|Oral Ticagrelor|
62235417|NCT02725099|EXPERIMENTAL|Chewing Ticagrelor|
62426114|NCT06373419|ACTIVE_COMPARATOR|MOSES Holmonium|Participants randomized to this arm will undergo bladder resection using the MOSES holmium laser.
62811606|NCT00127634|ACTIVE_COMPARATOR|2|
62811607|NCT05892224||MHO group|Metabolic healthy obesity
62811608|NCT05892224||HMO-U group|Hypermetabolic obesity-hyperuricemia
62035031|NCT05292768||Control patients with normal digestive biopsy|
62035032|NCT05292768||Control patients with renal biopsy|
62035033|NCT05292768||Control patients with inflammatory disease|
62035034|NCT05292768||Healthy control from healthcare workers|
62035035|NCT00205569||1|Individuals with traumatic brain injury requiring inpatient rehabilitation.
62035036|NCT00512395|ACTIVE_COMPARATOR|1|epidural analgesia
62035037|NCT00512395|NO_INTERVENTION|2|traditional analgesia with opioids
62811609|NCT05892224||HMO-I group|Hypermetabolic obesity-hyperinsulinemia
62426115|NCT06070168|EXPERIMENTAL|Telephone Counseling|"Mothers in labor after normal birth at the postpartum clinic At least 6 hours later and for cesarean births, the researcher will visit the patient after 12 hours.~Mothers will be interviewed according to the inclusion criteria and exclusion criteria, and will be informed about the study.~will be given and their consent will be taken, the mother information form and the depression form will be filled in, a pre-test will be done and the communication will be completed will get their numbers.~The researcher will contact the experimental group by phone. He will introduce himself and 6 weeks (during postpartum). It will provide the mother with the consultancy service she needs about herself and the newborn 24 hours a day. After 6 weeks, the training will end and the third researcher will make post-tests of the depression scale to both groups without knowing the experimental and control groups."
62594308|NCT04624958|EXPERIMENTAL|zanubrutinib, rituximab, consolidation chemotherapy and zanubrutinb maintenance|"Part A (Zanubrutinib and Rituximab): Patients receive zanubrutinib on days 1-28 and rituximab on day 1. Treatment cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or until patients achieve CR.~PART B (Consolidation chemotherapy of R-DHAOx): Patients receive R-DHAOx regimen every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Elderly patients (\> 65 years old) and patients who achieved CR and minimal residual disease negative after PART B receive zanubrutinb maintenance therapy. Young patients (\<65 years old) who achieved CR but minimal residual disease positive after PART B can receive autologous stem cell transplantation and then zanubrutinb maintenance therapy. Patients with PD, SD or PR after PART B quit the trial.~ZANUBRUTINB MAINTENANCE: Patients receive zanubrutinib every day for up to one year."
62594309|NCT03700333|EXPERIMENTAL|S-1 Group|Stage IIIB or IV non-small-cell lung cancer (NSCLC) population treated by Tegafur,Gimeracil and Oteracil Potassium Capsules (S-1)
62594310|NCT03700333|ACTIVE_COMPARATOR|Pemetrexed Group|Stage IIIB or IV non-small-cell lung cancer (NSCLC) population treated by Pemetrexed
62735490|NCT03312790|OTHER|Real condition|Same tasks than augmented reality realized in normal/real condition
62811610|NCT05892224||LMO group|Hypometabolic obesity
62735491|NCT00517010|EXPERIMENTAL|proton beam with ranibizumab|Intervention is 24Gy proton radiation in 2 fractions given within 6 weeks of first dose of intravitreal ranibizumab (0.5mg) drug combined with four monthly doses of intravitreal lucentis and monthly prn lucentis thereafter.
62811611|NCT05892224||control group|Healthy person
62811612|NCT00397501|ACTIVE_COMPARATOR|HER-2 positive subjects|HER-2 positive subjects treated with trastuzumab
62811613|NCT00397501|ACTIVE_COMPARATOR|HER-2 negative subjects|HER-2 negative subjects not treated with trastuzumab
62811614|NCT03649542|ACTIVE_COMPARATOR|Fluidotherapy® plus exercises group (FLO)|The Fluidotherapy® Unit and exercises group (FLO). They were required to complete wrist exercises in Fluidotherapy® Unit box for 15 minutes with the following exercises finger abduction/adduction, finger flexion/extension, forearm supination/pronation, wrist flexion/extension, and wrist radial deviation/ulnar deviation. Each patient performed two sets of fifteen repetitions for each exercise, totaling 15-minutes.
62811615|NCT03649542|NO_INTERVENTION|Exercises only group (EX)|They were required to complete wrist exercises in the air for 15 minutes, including abduction/adduction, finger flexion/extension, forearm supination/pronation, wrist flexion/extension, and wrist radial deviation/ulnar deviation. Each patient performed two sets of fifteen repetitions for each exercise, totaling 15-minutes.
62811616|NCT01826396|EXPERIMENTAL|high dose irinotecan|high dose irinotecan based on UGT1A1 genotype, 5-fluorouracil, and leucovorin (FOLFIRI) for first-line treatment of locally advanced colon cancer
62811617|NCT00472108|EXPERIMENTAL|Photodynamic Therapy (PDT) WIth Metvix Cream 160 milligrams/gram (mg/g)|Participants with BCC lesions were administered to PDT with Metvix® cream 160 mg/g applied topically for three hours, followed by illumination using noncoherent light with a fluency of 75 Joule per centimeter square (J/cm\*2) and fluency rate of less than 50-200 milliwatt per centimeter square (mW/cm\*2) up to 14 weeks. All participants received two consecutive treatments, one week apart thereby completing one PDT treatment cycle.
62811618|NCT00472108|PLACEBO_COMPARATOR|Placebo Cream|Participants with BCC lesions were administered to PDT with Placebo cream applied topically for three hours, followed by illumination using noncoherent light with a fluency of 75 J/cm\*2 and fluency rate of 50-200 mW/cm\*2 up to 14 weeks. All participants received two consecutive treatments, one week apart thereby completing one PDT treatment cycle.
62811619|NCT04388111|NO_INTERVENTION|Control Group|Patient receives an intraosseous injection of antibiotics into the tibia as per the standard of care for primary total knee arthroplasty under the study providers.
62243218|NCT02258503||numerical scale|Evaluation of the pain of elderly patient admitted in the emergency department by numerical scale and then taken care according to the usual practice of the emergency department.
62426116|NCT06070168|NO_INTERVENTION|control group|
62235418|NCT04328051|ACTIVE_COMPARATOR|Ocean E.C.®, Avinent Implant System S.L.|Dental implant with geometry adapted to the biologic architecture of the bone, with platform switching with a positive angle and machined surface with micro-threads in the cervical region. Asymmetric and progressive threads in its body with a double thread pitch. Point-ratio geometry on its apical region, Biomimetic Advanced Surface and external hexagon connection.
62235419|NCT04328051|ACTIVE_COMPARATOR|Ocean I.C.®, Avinent Implant System S.L.|Dental implant with geometry adapted to the biologic architecture of the bone, with platform switching with a positive angle and machined surface with micro-threads in the cervical region. Asymmetric and progressive threads in its body with a double thread pitch. Point-ratio geometry on its apical region, Biomimetic Advanced Surface and internal hexagon connection.
62235420|NCT04328051|ACTIVE_COMPARATOR|Ocean C.C.®, Avinent Implant System S.L.|Dental implant with geometry adapted to the biologic architecture of the bone, with platform switching with a positive angle and machined surface with micro-threads in the cervical region. Asymmetric and progressive threads in its body with a double thread pitch. Point-ratio geometry on its apical region, Biomimetic Advanced Surface and conical connection.
62235421|NCT03310268|EXPERIMENTAL|Test Product|Participants will be instructed to self administer experimental dentifrice containing 0.454% SnF2 and 0.072% sodium fluoride (NaF) (1450 parts per million \[ppm\] fluoride in total).
62235422|NCT03310268|ACTIVE_COMPARATOR|Negative Control|Participants will be instructed to self administer negative control dentifrice containing 1400 ppm fluoride as sodium monofluorophosphate (SMFP).
62235423|NCT03310268|ACTIVE_COMPARATOR|Positive Control|Participants will be instructed to self administer positive control dentifrice containing SnCl2 and 0.15% NaF (1450 ppm fluoride in total).
62235424|NCT05141214|ACTIVE_COMPARATOR|Dietary Consult with Virtual Reality (intervention)|Those in the VR group will receive the same educational dietary review by the registered dietician, and additionally participate in a VR experience through an application called Chaos Café. In Chaos Café, patients are immersed into a computer-generated kitchen environment. A humorous robotic chef serves children different food groups. Gameplay is advanced by choosing healthy foods, while eating unhealthy foods does not advance the application.
62235425|NCT05141214|NO_INTERVENTION|Dietary Consult without Virtual Reality (SOC)|Those in the SOC group will have the typical appointment, which includes a review of healthy diet choices with a registered dietitian and follow up according to clinic's SOC.
62243219|NCT02258503||algoplus scale|Evaluation of the pain of elderly patient admitted in the emergency department by numerical scale and by Algoplus® scale then taken care according to the usual practice of the emergency department.
62811620|NCT04388111|EXPERIMENTAL|Intarosseous Morphine|Patient receives an intraosseous injection of antibiotics + 10mg of morphine into the tibia during their total knee arthroplasty.
62811621|NCT02854046||Calciphylaxis Cases|Adult patients with advanced chronic kidney disease (DFG estimation \< 30 ml/min/1.73m² - beyond 3B stage) with/without substitute therapy who has presented a case of calciphylaxis (Calcific Uremic Arteriolopathy) between 2006 and 2016 in the Regions of Pays de la Loire, Centre Val de Loire, Bretagne and Poitou-Charentes
62811622|NCT02854046||Witness cases|"Selected anonymously in French national register REIN. Matched to Calciphylaxis Cases according to gender, age, treatment by extrarenal purification at the timepoint onset of the lesions and REIN regions belonging"
62426117|NCT02228031|EXPERIMENTAL|Oxytocin|The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session.
62426118|NCT02228031|PLACEBO_COMPARATOR|Placebo|The placebo comparator group will receive sterile saline through intranasal administration, consisting of the same salt solution in which the hormone will be dissolved , but lacking the hormone itself.
62811623|NCT04705688||Left Atrial Appendage Occlusion|Patients undergoing left atrial appendage occlusion.
62811624|NCT00505271|EXPERIMENTAL|1|Escalating doses of Rexin-G will be given two or three times a week for four weeks, with a 2 week rest period
62811625|NCT00956163|EXPERIMENTAL|Diagnostic (fluorine F 18 sodium fluoride PET)|Patients undergo technetium Tc 99m methylene diphosphonate bone scan, fluorine F 18 sodium fluoride PET/CT scan, and whole-body MRI for the detection of bone metastases. Patients with discordant imaging results (negative bone scan and positive PET/CT scan and/or MRI) undergo additional imaging at 6, 12, 18, and 24 months.
62811626|NCT04595552|EXPERIMENTAL|Study group|Children with cochlear implant were given Auditory training and language therapy
62811627|NCT04703686|EXPERIMENTAL|Obinutuzumab + RO7082859|
62426119|NCT01436669|EXPERIMENTAL|Home Monitoring|All participants will receive a home telemonitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home.
62811628|NCT03042117||No Coronary Artery Disease (CAD)|Patients with no known cardiovascular disease.
62811629|NCT03042117||CAD without Myocardial Infarction (MI)|Patients with cardiovascular disease without a myocardial infarction.
62811630|NCT03042117||CAD with MI|Patients with cardiovascular disease with previous history of a myocardial infarction.
62811631|NCT02953522|OTHER|191 mcg/day of Folate|Diet with 191 mcg/day of Folate
62811632|NCT02953522|OTHER|90 mcg/day of Folate|Diet with 90 mcg/day of Folate
62811633|NCT00599729||1|patient demonstrating degenerative changes in the knee joint (osteoarthritis)
62811634|NCT03636659|EXPERIMENTAL|Amphotericin B Liposome|Amphotericin B Liposome for Injection 50 mg/vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days
62035038|NCT02552004|EXPERIMENTAL|pCLE|Patients subject to endocrine or digestive surgery will have intraoperative pCLE examination. The installation and surgical opening will be performed according to standard protocols. The contrast agent, fluorescein, will be injected intravenously to allow tissue visualization with pCLE. During the surgery, the surgeon will perform the pCLE examination, to obtain and record video sequences of in situ structures. Frozen sections will be obtained on the same samples and will further guide the surgical decision-making.
62035039|NCT02676167|OTHER|Intervention|
62035040|NCT05314439|EXPERIMENTAL|ION904|Up to 4 monthly doses of ION904 will be administered by subcutaneous (SC) injection.
62811635|NCT03636659|ACTIVE_COMPARATOR|AmBisome Liposome|AmBisome Liposome for Injection 50 mg/ vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days
62811636|NCT01609348|ACTIVE_COMPARATOR|Venlafaxine|225 mg daily over 12 weeks
62811637|NCT01609348|PLACEBO_COMPARATOR|Sugar pill|
62811638|NCT04645147|EXPERIMENTAL|EBV gp_350 Ferritin Vaccination|Adult participants with or without prior EBV infection will receive 3 doses of vaccine
62811639|NCT01611792|EXPERIMENTAL|Stabilization|
62811640|NCT01611792|ACTIVE_COMPARATOR|Strengthening and Conditioning|
62035041|NCT05314439|PLACEBO_COMPARATOR|Placebo|Up to 4 monthly doses of placebo will be administered by SC injection.
62035042|NCT02866890|EXPERIMENTAL|Laryngeal Tube Suction size 1|Measurement of leak pressure
62035043|NCT02866890|EXPERIMENTAL|Laryngeal Tube Suction size 2|Measurement of leak pressure
62035044|NCT02866890|EXPERIMENTAL|Laryngeal Tube Suction size 2.5|Measurement of leak pressure
62035045|NCT03044301|OTHER|BMI < 25kg/m²|Subcutaneous high ZENEO® injection Intramuscular ZENEO® injection
62811641|NCT04077567|EXPERIMENTAL|TS-152 30mg SC|TS-152 30mg subcutaneously (SC) every 4 weeks
62035046|NCT03044301|OTHER|27.5 > BMI > 25 kg/m²|Intramuscular ZENEO® injection
62035047|NCT03044301|OTHER|BMI > 27.5 kg/m²|Intramuscular ZENEO® injection
62035048|NCT03044301|OTHER|No special BMI|Subcutaneous low ZENEO® injection
62035049|NCT05369975|EXPERIMENTAL|Imlifidase|Imlifidase, is provided as a freeze-dried powder for concentrate for solution for infusion, 11 mg per vial. After reconstitution with sterile water for injection, the concentrate contains 10 mg/mL imlifidase. Imlifidase is administered intravenously as one infusion of 0.25 mg/kg over 15 minutes within 24 hours prior to transplantation. A second dose of 0.25 mg/kg may be given if the first imlifidase dose is considered not to have had sufficient effect. The second dose can be administered within 24 hours after the first dose.
62035050|NCT05369975|OTHER|Non-Comparative Concurrent Reference Cohort|Patients in the non-comparative prospective concurrent reference cohort (with any grade of sensitization and negative XM) will receive medications, both pre- and post-transplant, in accordance with each clinic's routine for kidney transplanted patients.
62035051|NCT05369975|OTHER|Non-Comparative Historical Reference Cohort|Patients in the non-comparative historical reference cohort (with less sensitization and negative XM) randomly selected from the CTS registry have been transplanted and treated in accordance with standard-of-care for kidney transplanted patients. Patients transplanted in 2010 and onwards will be selected to optimize the probability that these patients will have received about the same maintenance immunosuppressive treatment as the patients in the current trial will receive.
62035052|NCT01786512|PLACEBO_COMPARATOR|Dose-escalation Cohort 1: Placebo|Participants received placebo tablets twice a day (BID) for 7 days.
62035053|NCT01786512|EXPERIMENTAL|Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1|Participants received 25 mg omecamtiv mecarbil (OM) Matrix F1 (M-F1) tablets twice a day for 7 days.
62811642|NCT04077567|EXPERIMENTAL|TS-152 80mg SC|TS-152 80mg subcutaneously (SC) every 4 weeks
62811643|NCT03371836|OTHER|Clobazam|open label (single treatment arm)
62811644|NCT03800095|EXPERIMENTAL|Conventional haematological care|Patients with haematological malignancy Conventional haematological care
62811645|NCT03800095|EXPERIMENTAL|Conventional care associated with a monthly consultation|Patients with haematological malignancy Conventional care associated with a monthly consultation realized by a palliative and supportive care team
62811646|NCT04785495||Cancer Patients Exposed to Highly Emetogenic Chemotherapy|Patients who will start chemotherapy with a high-grade emetogenic scheme and who have received adequate antiemetic prophylaxis.
62811647|NCT05618522|OTHER|the lens loaded with Omnigen|patients with acute chemical eye injury treated with omnigen
62811648|NCT03122639|ACTIVE_COMPARATOR|Treatment|OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
62811649|NCT03122639|PLACEBO_COMPARATOR|Control|OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
62811650|NCT01556399||Duodenal adenomas|Patients who consent to participate in this study will have a small sample of their adenoma and normal tissue sent for molecular testing.
62811651|NCT05966454|EXPERIMENTAL|Restricted Post-Operative Antibiotics Group|"Participants undergoing standard of care (SOC) with simple appendicitis will not receive post-operative antibiotics.~Participants undergoing standard of care with complicated (gangrenous or perforated) appendicitis will receive up to 24 hours of SOC post-operative antibiotics."
62811652|NCT05966454|ACTIVE_COMPARATOR|Liberal Post-Operative Antibiotics Group|"Participants undergoing standard of care with simple appendicitis will receive 24 hours of post-operative SOC antibiotics~Participants undergoing standard of care with complicated (gangrenous or perforated) appendicitis will receive 4 days of post-operative SOC antibiotics."
62811653|NCT04004897|OTHER|Preeclampsia group|Patients with preeclampsia will receive optic nerve sheath diameter measurement with a linear ultrasound probe carefully and gently placed on the closed upper eyelids of patients.
62811654|NCT04004897|OTHER|Pregnants without preeclampsia|Pregnant women without preeclampsia will receive optic nerve sheath diameter measurement with a linear ultrasound probe carefully and gently placed on the closed upper eyelids of patients.
62811655|NCT01009541|EXPERIMENTAL|Pregabalin controlled release, 82.5 mg|
62811656|NCT01009541|EXPERIMENTAL|Pregabalin controlled release, 165 mg|
62811657|NCT01009541|EXPERIMENTAL|Pregabalin controlled release, 330 mg|
62811658|NCT01009541|OTHER|Pregabalin immediate release, 150 mg|Reference Treatment
62811659|NCT03901170|EXPERIMENTAL|letrozole|patients with letrozole
62811660|NCT03901170|NO_INTERVENTION|control|patients without letrozole
62426120|NCT03092089|EXPERIMENTAL|Adult patients with high risk STEMI|Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)
62426121|NCT03746886||Breast-feeding women|A single breast-milk sample will be collected from 20 women who breast-feed their child (0-6 months old).
62426122|NCT03961945|OTHER|Screening Population|Those that have gastroesophageal reflux or other risk factors for Barrett's Esophagus will be contacted and if agreeable undergo sponge capsule procedure and fill out questionnaires.
62426123|NCT03961945|OTHER|Upper endoscopy - Barrett's Esophagus|Those that have a diagnosis of Barrett's Esophagus and are scheduled for an upper endoscopy will be approached and if agreeable undergo sponge capsule procedure as well as endoscopic biopsies and brushings of the esophagus.
62426124|NCT03961945|OTHER|Upper endoscopy - No Barrett's Esophagus|Those that have no known Barrett's Esophagus and are scheduled for an upper endoscopy will be approached and if agreeable undergo sponge capsule procedure as well as endoscopic biopsies and brushings of the esophagus.
62426125|NCT06537804|OTHER|Intervention|Low-dose CT scans are performed once a year from 2024 to 2026 to screen for lung cancer including a lung function test the first year of attendance (2024).
62426126|NCT06537804|NO_INTERVENTION|Control|Citizens from the cohort who are randomized to no intervention.
62426127|NCT04170049|EXPERIMENTAL|Behavioral: The sensory stimulative activity interventions|
62426128|NCT00004161|EXPERIMENTAL|Arm I|Patients receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients then receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients are followed every 3 months.
62426129|NCT00004161|EXPERIMENTAL|Arm II|Patients receive oral placebo daily (except days 1-3 each month) for 6 months. Patients then receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients are followed every 3 months.
62426130|NCT02232269|PLACEBO_COMPARATOR|Water plus Felodipine|Felodipine extended-release tablet ,10 mg, single dose, 8 hours
62426131|NCT02232269|ACTIVE_COMPARATOR|Black Coffee|Black Coffee, 300 ml, 0 and 1 hour
62426132|NCT02232269|EXPERIMENTAL|Black Coffee plus Felodipine|"Black Coffee, 300 ml, 0 and 1 hour~Felodipine extended-release tablet ,10 mg, single dose, 8 hours"
62426133|NCT02232269|ACTIVE_COMPARATOR|Grapefruit Juice plus Felodipine|"Grapefruit Juice, 300 ml, 0 and 1 hour~Felodipine extended-release tablet ,10 mg, single dose, 8 hours"
62811661|NCT01608711|EXPERIMENTAL|AGS-1C4D4 plus gemcitabine|Subjects will receive a maintenance dose of AGS-1C4D4 every 3 weeks (Q3W) in addition to the gemcitabine administration.
62811662|NCT01188772|EXPERIMENTAL|Sofosbuvir 200 mg (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive sofosbuvir 200 mg (2 x 100 mg tablets)+placebo to match sofosbuvir (2 tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
62811663|NCT01188772|EXPERIMENTAL|Sofosbuvir 400 mg (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive sofosbuvir 400 mg (4 x 100 mg tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
62035054|NCT01786512|EXPERIMENTAL|Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2|Participants received 25 mg omecamtiv mecarbil Matrix F2 (M-F2) tablets twice a day for 7 days.
62035055|NCT01786512|EXPERIMENTAL|Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2|Participants received 25 mg omecamtiv mecarbil swellable core technology F2 (SCT-F2) tablets twice a day for 7 days.
62035056|NCT01786512|PLACEBO_COMPARATOR|Dose-escalation Cohort 2: Placebo|Participants received placebo tablets twice a day for 7 days.
62035057|NCT01786512|EXPERIMENTAL|Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1|Participants received 50 mg omecamtiv mecarbil M-F1 tablets twice a day for 7 days.
62811664|NCT01188772|ACTIVE_COMPARATOR|Placebo (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive placebo to match sofosbuvir (4 tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
62811665|NCT01188772|EXPERIMENTAL|Sofosbuvir 400 mg (Genotype 2/3)|Participants with genotype 2 or 3 HCV infection received sofosbuvir 400 mg (4 x 100 mg tablets)+PEG+RBV for 12 weeks.
62811666|NCT00811161|EXPERIMENTAL|needle free injector of HA|
62811667|NCT04256694||Healthy Adult Subjects|
62811668|NCT04205006||STROKE CARD Cohort|Consecutive patients treated at the Department of Neurology of the University Hospital Innsbruck with ischemic stroke or high-risk TIA between 2013 and 2018 and enrolled in the Stroke Card trial, (except for those who aborted the previous trial).
62811669|NCT04068896|EXPERIMENTAL|NGM120 Dose 1|NGM120 Subcutaneous Injection
62811670|NCT04068896|EXPERIMENTAL|NGM120 Dose 2|NGM120 Subcutaneous Injection
62811671|NCT04068896|EXPERIMENTAL|NGM120 Dose 3|NGM120 Subcutaneous Injection
62811672|NCT04068896|EXPERIMENTAL|NGM120 Dose 4|NGM120 Subcutaneous Injection
62035058|NCT01786512|EXPERIMENTAL|Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2|Participants received 50 mg omecamtiv mecarbil M-F2 tablets twice a day for 7 days.
62035059|NCT01786512|EXPERIMENTAL|Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2|Participants received 50 mg omecamtiv mecarbil SCT-F2 tablets twice a day for 7 days.
62035060|NCT01786512|PLACEBO_COMPARATOR|Expansion Phase: Placebo|Participants received placebo tablets twice a day for 20 weeks.
62035061|NCT01786512|EXPERIMENTAL|Expansion Phase: Omecamtiv Mecarbil 25 mg M-F1|Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks.
62035062|NCT01786512|EXPERIMENTAL|Expansion Phase: OM M-F1 PK-based Titration|All participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL.
62035063|NCT02732418|EXPERIMENTAL|Depo-Provera CI 45 mg|a single subcutaneous (SC) injection of 45 mg/0.3 mL
62035064|NCT02732418|EXPERIMENTAL|Depo-Provera CI 75 mg|a single subcutaneous (SC) injection of 75 mg/0.5 mL
62035065|NCT02732418|EXPERIMENTAL|Depo-Provera CI 105 mg|a single subcutaneous (SC) injection of 105 mg/0.7 mL
62035066|NCT02732418|ACTIVE_COMPARATOR|Depo-subQ 104|a single subcutaneous (SC) injection of 104 mg/0.65 mL
62035067|NCT05160051|EXPERIMENTAL|68Ga-FAPI-46 PET Scan|A single-center prospective interventional single-arm clinical trial. All eligible subjects undergo FAPI-PET Scan
62035068|NCT01662310|EXPERIMENTAL|Paliperidone: Run-in or Stabilization phase|Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) once daily for 8 weeks. Dose will be increased from milligram per day (3 mg/day) after 5 days based on Investigator's discretion, up to maximum of 12 mg/day.
62035069|NCT01662310|EXPERIMENTAL|Paliperidone: Double blind (DB) phase|Participants who transitioned from run-in or stabilization phase received 3 to 12 mg fixed dose of paliperidone ER oral tablet once daily during DB phase of the study. Participants who will experience a relapse event during the DB phase or who will remain relapse free for the entire duration of the DB phase and participants, who will be enrolled at the time the study termination will enter in open label extension phase, wherein paliperidone ER oral tablet will be administered once daily as 3 to 12 mg.
62035070|NCT01662310|ACTIVE_COMPARATOR|Placebo: DB phase|Participants who transitioned from run-in or stabilization phase received matching placebo to paliperidone ER once daily during DB phase of the study. Participants who will experience a relapse event during the DB phase or who will remain relapse free for the entire duration of the DB phase and participants, who will be enrolled at the time the study termination will enter in open label extension phase, wherein paliperidone ER oral tablet will be administered once daily as 3 to 12 mg.
62035071|NCT06309953|EXPERIMENTAL|Miebo treatment|
62035072|NCT04210817||Patients|Patients who have been diagnosed with Rheumatoid Arthritis
62035073|NCT00737126|PLACEBO_COMPARATOR|1|Administration of an oral placebo pill
62811673|NCT04068896|EXPERIMENTAL|NGM120 Dose 5|NGM120 Subcutaneous Injection
62811674|NCT04068896|EXPERIMENTAL|NGM120 Dose 6|NGM120 Subcutaneous Injection
62811675|NCT04068896|PLACEBO_COMPARATOR|Placebo|Placebo
62811676|NCT05306626|EXPERIMENTAL|The BEAM program group|The BEAM Program is delivered via mobile application and weekly group telehealth sessions. BEAM includes approximately 20 minutes of weekly asynchronous video modules on parenting and mental health. Mental Health videos will provide information and emotion-regulation strategies that draw from the Unified Protocol, an evidence-based treatment for depression and anxiety disorders. Self-compassion and effective communication will also be central focuses of the mental health content. Supportive parenting videos will provide parents with emotion-focused parenting strategies and help parents understand and respond to their children's challenging emotions and behaviours. The weekly group telehealth sessions will allow participants to discuss content and ask questions, with the purpose of increasing a sense of community and social support. The online community forum will provide a space for participants to reflect on their learned skills and connect with other participants in the program.
62811677|NCT05306626|NO_INTERVENTION|Treatment as usual group|The treatment as usual (TAU) control arm of the study is designed to account for the potential effects of time on depression symptoms.
62811678|NCT04823988||Adults 18 and over|Adults 18 and over
62035074|NCT00737126|EXPERIMENTAL|2|Administration of oral folic acid
62035075|NCT04528511||Low burden of new-onset atrial fibrillation|Patients with MI who are free from a medical history of atrial fibrillation (AF) will be recognized as NOAF if they develop an atrial fibrillation (lasting for at least 30 seconds which are recorded by CEM) incident during hospitalization. Among this subset of patients, those who have a NOAF burden value\<10.87% (previously established) will be divided into the low burden group.
62035076|NCT04528511||High burden of new-onset atrial fibrillation|For patients with NOAF complicating AMI, those who have a NOAF burden value≥10.87% (previously established) will be divided into the high burden group.
62426134|NCT03448809|EXPERIMENTAL|MMM (Mind My Mind training)|Mind My Mind training
62735492|NCT04129983|EXPERIMENTAL|Prednisone acetate + somatosensory stimulation|Prednisone acetate 1 mg/kg body weight \* 7 days and somatosensory stimulation 30 days were given to sudden deafness patients.
62811679|NCT06044025|EXPERIMENTAL|Metformin + Turmeric|"Each subject will begin using metformin and turmeric within 7 days of consent. Subjects will start with metformin 500 mg by mouth (po) two times daily (bid) with meals for 14 days. Metformin titration will then increase to 850 milligram (mg) po bid for 14 days before increasing titration to a desired dosage of 1,000 mg po bid. For those subjects currently taking Metformin, they will continue current dose (if 1,000 mg po bid) or titrate dose as just described until maximum dose is achieved.~After two weeks of metformin titration, each subject will start with 1,500 mg turmeric po daily with meals. Dose can be temporarily reduced to 1,000 mg po daily for those who report GI discomfort. If GI discomfort has resolved within one month of the dose reduction, subjects will resume 1,500 mg po daily. If GI discomfort has not resolved the participant may be insturcted to stop taking the study treatment and be removed from the study."
62811680|NCT00359255|ACTIVE_COMPARATOR|1|
62035077|NCT01733004|EXPERIMENTAL|Arm A|MM-141 monotherapy
62035078|NCT01733004|EXPERIMENTAL|Arm B|MM-141 and Everolimus
62035079|NCT01733004|EXPERIMENTAL|Arm C|MM-141 and Abraxane and Gemcitabine
62035080|NCT00441610|EXPERIMENTAL|Gimatecan|
62035081|NCT04027556|EXPERIMENTAL|50 keV DLD images of the LBW-based low-dose group|Low CT contrast media dose calculated based on lean body weight and low monoenergetic images of dual-energy CT with deep learning-based denoising
62035082|NCT04027556|ACTIVE_COMPARATOR|ADMIRE images of the standard-contrast dose group|Standard CT contrast media dose calculated based on total body weight and conventional images with full model-based iterative reconstruction
62035083|NCT03789266|EXPERIMENTAL|Drain ablation - Non Aspiration mode|Drain ablation will be done in non Aspiration mode
62035084|NCT03789266|OTHER|Drain ablation - Aspiration mode|Drain ablation will be done in Aspiration mode
62035085|NCT05627180|EXPERIMENTAL|The Intervention Group|The intervention group will receive a tailored intervention based on each individuals health literacy needs. A project nurse with broad experience in cancer care will be trained in Motivational Interviewing techniques to provide follow-up for the patients in the intervention group in a period of 9 months.
62235426|NCT05192538|EXPERIMENTAL|Endoscopic endoloop pre-test treatment|Endoscopic endoloop pre-test treatment is a less invasive reversible endoscopic treatment to predict whether the gastroesophageal reflux can be alleviated in order to ultimately decide whether to undergo irreversible surgery or endoscopic treatment.
62235427|NCT05793177|EXPERIMENTAL|Intervention|
62235428|NCT05793177|NO_INTERVENTION|Control|
62426135|NCT03448809|ACTIVE_COMPARATOR|TAU (Treatment as Usual)|Treatment as Usual
62426136|NCT01083901|EXPERIMENTAL|Resistance training with Acetaminophen|Acetaminophen
62426137|NCT01083901|EXPERIMENTAL|Resistance Training with ibuprofen|Ibuprofen
62426138|NCT01083901|PLACEBO_COMPARATOR|placebo|Placebo
62735493|NCT04129983|EXPERIMENTAL|Prednisone acetate + hyperbaric oxygen|Prednisone acetate 1mg / kg body weight \* 7 days and hyperbaric oxygen 15 days were given to sudden deafness patients.
62735494|NCT03172299|ACTIVE_COMPARATOR|Injection of anti-VEGF|
62811681|NCT00359255|EXPERIMENTAL|2|
62811682|NCT04446637|EXPERIMENTAL|Ipratropium/Levosalbutamol|Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI
62811683|NCT04446637|ACTIVE_COMPARATOR|Salbutamol + Ipratropium|Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI
62035086|NCT05627180|NO_INTERVENTION|Usual care group|Usual care group will receive usual follow-up.
62235429|NCT00936104||SP in PDAC|Side population cells isolated from resection specimens obtained from patients with pancreatic cancer
62235430|NCT05708326|EXPERIMENTAL|5:2 Method|"Participants will follow the 5:2 Method (an intermittent fasting regimen) for a 90 day duration. This entails eating ad libitum for five days per week (normal days) and limiting total calorie intake to 800kcals per day (fasting days) for the remaining two days per week. The fasting days can be sequential or dispersed throughout the week, based on patient preference."
62235431|NCT05708326|ACTIVE_COMPARATOR|16/8 Method|Participants will have already followed the 16/8 Method (an intermittent fasting regimen) for a minimum of six days per week for a 90 day duration. This entailed limiting the eating hours to an 8-hour window, then fasting for the remaining 16 hours per day, with the last time of intake being 8pm.
62235432|NCT00186771|ACTIVE_COMPARATOR|True Transcranial Magnetic Stimulation|True treatment with TMS over the temporoparietal cortex.
62235433|NCT00186771|SHAM_COMPARATOR|Sham Transcranial Magnetic Stimulation|Sham treatment with rTMS over the temporoparietal cortex.
62235434|NCT04256330||Lean and metabolically healthy|
62235435|NCT04256330||Lean and metabolically unhealthy|
62235436|NCT04256330||Overweight and metabolically healthy|
62426139|NCT02354352|ACTIVE_COMPARATOR|Eplerenone|Eplerenone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Inspra. Eplerenone is a potassium-sparing diuretic.
62735495|NCT03172299|PLACEBO_COMPARATOR|false injection of anti-VEGF|
62035087|NCT05164744||Diagnosed with COVID-19|Participants in the study cohort will have been diagnosed with COVID-19 by a PCR (polymerase chain reaction) positive test
62035088|NCT06418633|ACTIVE_COMPARATOR|Control group|Subjects with neither a personal history nor family history of venous thromboembolism in first-degree relatives.
62235437|NCT04256330||Overweight and metabolically unhealthy|
62035089|NCT06418633|ACTIVE_COMPARATOR|Patients|Patients with a personal history of induced venous thromboembolism, the last attack dating back to more than 6 months, whose clinical phenotype did not justify long-term antithrombotic drug prophylaxis
62035090|NCT06418633|ACTIVE_COMPARATOR|"Individual reproducibility subgroup: controls"|10 subjects with neither a personal history nor family history of venous thromboembolism in first-degree relatives who have accepted to re-do the test one week later.
62035091|NCT06418633|ACTIVE_COMPARATOR|"Individual reproducibility subgroup: patients"|10 patients with a history of induced venous thromboembolism, the last attack dating back to more than 6 months, whose clinical phenotype did not justify long-term antithrombotic drug prophylaxis, who have accepted to re-do the test one week later.
62035092|NCT03071692|EXPERIMENTAL|Treatment Group|K-877 (pemafibrate) tablet twice daily.
62035093|NCT03071692|PLACEBO_COMPARATOR|Control Group|Matching K-877 placebo tablet twice daily.
62235438|NCT04256330||Obese and metabolically healthy|
62235439|NCT04256330||Obese and metabolically unhealthy|
62235440|NCT01500525||asthmatic children|children diagnosed by a specialist as asthmatic patients
62235441|NCT01500525||non-asthmatic children|children who are healthy and who do not have respiratory syndrom
62426140|NCT02354352|ACTIVE_COMPARATOR|Spironolactone|Spironolactone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Aldactone. Spironolactone is a potassium-sparing diuretic.
62811684|NCT02250742|EXPERIMENTAL|low back pain group|Dry needling to the lumbar multifidus muscles using a deep insertion technique with 4 needles (2 on each side of the spine) will be utielized. The needles will be left in situ for 10 minutes.
62811685|NCT02250742|ACTIVE_COMPARATOR|healthy group|Dry needling to the lumbar multifidus muscles using a deep insertion technique with 4 needles (2 on each side of the spine) will be utilized. The needles will be left in situ for 10 minutes.
62811686|NCT04361071|ACTIVE_COMPARATOR|Stent|Stent group
62811687|NCT04361071|ACTIVE_COMPARATOR|Atherectomy|Atherectomy group
62811688|NCT00591006|EXPERIMENTAL|Four Treatments Per Participant|This study has one arm due to a crossover design. All 17 subjects received 4 treatments: placebo then placebo, phenytoin then placebo, placebo then hydrocortisone, and phenytoin then hydrocortisone. Each treatment was randomly assigned and had a unique sequence out of 24 possible sequences.
62811689|NCT00141453|EXPERIMENTAL|1|Olmesartan medoxomil tablets 10mg to 40 mg
62811690|NCT00141453|PLACEBO_COMPARATOR|2|Matching placebo tablets
62811691|NCT00797381||1|
62811692|NCT00797381||2|
62811693|NCT04496817|EXPERIMENTAL|Enriched Egg Group|Participants will consume 2 medium sized docosahexaenoic acid and lutein enriched eggs daily (at least 5 days per week) for 6 weeks.
62811694|NCT04496817|PLACEBO_COMPARATOR|Regular Egg Group|Participants will consume 2 medium sized non-enriched eggs daily (at least 5 days per week) for 6 weeks.
62811695|NCT01101217|PLACEBO_COMPARATOR|placebo|placebo for 6 weeks
62811696|NCT01101217|ACTIVE_COMPARATOR|zinc|zinc sulfate 220 mg per day orally for 6 weeks
62811697|NCT05958446||Pregnant women with SSA Auto Ab|All patients over the age of 18, who will sign the informed consent for participation in the study, characterized by the positivity of autoantibodies against Ro/SSA who will become pregnant during the enrollment period.
62035094|NCT05808387|EXPERIMENTAL|Resveratrol|Trans-resveratrol, 1000mg daily for 90 days.
62035095|NCT05808387|PLACEBO_COMPARATOR|Control|Starch, 1000mg daily for 90 days.
62035096|NCT04303897||XEN Glaucoma Stent|
62426141|NCT00612794|EXPERIMENTAL|1|exenatide once weekly, 0.8mg
62035097|NCT06427772||group 1 diseased group(infected)|the presence of persistent discharge after 7 days diagnostic for early infection follow up period first 4 week postoperative bipolar hemiarthroplasty in fracture neck of femur study the risk factors in this group
62035098|NCT06427772||group 2 : control group (normal )|no infection after hemiarthroplasty follow up period first 4 week postoperative bipolar hemiarthroplasty in fracture neck of femur
62035099|NCT04788550|ACTIVE_COMPARATOR|Toothpaste group|Control group using fluoridated toothpaste
62035100|NCT04788550|EXPERIMENTAL|Fluoride Varnish group|Fluoride varnish (5% sodium fluoride) application on 3 months interval
62035101|NCT04788550|EXPERIMENTAL|CPP-ACP plus crème group|CPP-ACP plus crème application 2 times daily
62235442|NCT04756960|EXPERIMENTAL|CHF6001|single dose of CHF6001 dry-powder inhaler (DPI) co-administered with an intravenous microdose of \[14\^C\]-labelled CHF6001
62243220|NCT03099005|ACTIVE_COMPARATOR|Low CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.9% THC + 0.01% CBD. They will then undergo experimental testing as described below under Outcome Measures.
62426142|NCT00612794|EXPERIMENTAL|2|exenatide once weekly, 2.0mg
62426143|NCT00612794|PLACEBO_COMPARATOR|3|volume equivalent to 0.8mg of exenatide once weekly
62426144|NCT00612794|PLACEBO_COMPARATOR|4|volume equivalent to 2.0mg of exenatide once weekly
62426145|NCT02726373|EXPERIMENTAL|Intermittent walking training|
62426146|NCT02726373|ACTIVE_COMPARATOR|Continuous Walking Training|
62426147|NCT02535247|EXPERIMENTAL|Treatment|MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles
62811698|NCT03373578|ACTIVE_COMPARATOR|earmuffs|Preterm newborns with earmuffs during the Quiet time
62811699|NCT03373578|NO_INTERVENTION|control|Preterm newborns without earmuffs during de Quiet time
62811700|NCT03064802||BioBurst Fluid, Burst Allograft|Spinal Fusion with BioBurst Fluid or Burst Allograft
62811701|NCT03115359|EXPERIMENTAL|Mindfulness Based Therapy|Mindfulness Based Therapy intervention, adjunctive to usual care for opioid-treated chronic low back pain.
62811702|NCT03115359|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy intervention, adjunctive to usual care for opioid-treated chronic low back pain.
62811703|NCT02228941||gene mutation|
62811704|NCT02832648|EXPERIMENTAL|selenase 200mcg|selenium as selenase 200mcg once daily, oral
62811705|NCT02832648|EXPERIMENTAL|selenase 50mcg|selenium as selenase 50mcg once daily, oral
62811706|NCT02832648|PLACEBO_COMPARATOR|placebo|matched placebo, once daily, oral
62811707|NCT05379088|EXPERIMENTAL|Additional Follow-up|In addition to receiving an ActiGraph activity monitor, participants will complete weekly phone/zoom calls with research staff for a more in-depth monitoring of their activity level.
62811708|NCT05379088|NO_INTERVENTION|Activity Level Monitoring|Participants receive an ActiGraph activity monitor to track their activity level over a 6-week period.
62811709|NCT04148807|EXPERIMENTAL|Progressive walking program with gait retraining|Participant will receive 8 gait-retraining intervention sessions.
62811710|NCT04148807|ACTIVE_COMPARATOR|Progressive walking program|Participant receives 8 sessions of a graded walking program.
62811711|NCT06376526|EXPERIMENTAL|Linvoseltamab Group|"Participants in this group will be administered a fixed duration of Linvoseltamab for four to six 28-day cycles, depending on minimal residual disease (MRD) conversion status. After four cycles, participants that are MRD-negative will no longer receive study treatment. Participants that are MRD-positive will receive an additional two cycles of Linvoseltamab.~Total participation duration is up to 3 years."
62811712|NCT03354013|EXPERIMENTAL|AOA, genetic screening, calcium pattern|"Clinical setting: Patients will undergo ICSI-AOA. Furthermore, patients will give a saliva sample to do genetic screening. Genes important during oocyte activation and embryo development will be investigated.~Also, calcium pattern analysis of the patients' spermatozoa will be executed."
62811713|NCT03908034|NO_INTERVENTION|Uncontrollable factor ABSENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. For each round, the participant begins with having 130 points, each worth $0.5 (Hong Kong dollars). Different numbers of points are deducted depending on the outcome in each round. After the 10 rounds, the computer randomly selects 1 of the rounds and the points from this round is paid in cash.~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. A cause, X, is identified for the disease. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
62811714|NCT03908034|EXPERIMENTAL|Uncontrollable factor ABSENT; anticipated regret induced|"Same description as in the uncontrollable factor absent, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
62035102|NCT00074282|EXPERIMENTAL|Arm A (PCR)|"Treatment consisted of 6 cycles of pentostatin, cyclophosphamide, and rituximab (PCR) given every 28 days.~Rituximab administered as follows: For the first infusion, all patients receive 100 mg dose (regardless of weight/BSA). For subsequent infusions, all patients receive rituximab 375 mg/m2.~Pentostatin and cyclophosphamide administered as follows: Pentostatin given at 4 mg/m2 either as an IV push or IV over 10-30 minutes in 250 mL NS or D5W on day 1 every 4 weeks of cycles 1-6. Cyclophosphamide given at 600 mg/m2 IV over 30-60 minutes in 250 mL NS on day 1 every 4 weeks of cycle 1-6."
62035103|NCT00074282|EXPERIMENTAL|Arm B (Alemtuzumab: CR, nPR)|Patients who achieved a confirmed CR or nPR, were registered to receive Alemtuzumab (Arm B). When the patient was registered to Arm B, the drug was administered three times a week for four weeks. The dose was 30 mg per dose. A twelve-week treatment-free period had to elapse before CAMPATH-1H began following completion of PCR for Arm B patients
62426148|NCT02535247|ACTIVE_COMPARATOR|Combination|MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study
62426149|NCT06536816|EXPERIMENTAL|Game Profile-based training Group|1st group with players having only Game Profile Based training group
62811715|NCT03908034|EXPERIMENTAL|Uncontrollable factor PRESENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. For each round, the participant begins with having 130 points, each worth $0.5. Different numbers of points are deducted depending on the outcome in each round. After the 10 rounds, the computer randomly selects 1 of the rounds and the points from this round is paid in cash.~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. Two causes, X and Y, are identified for the disease. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
62235443|NCT03054480|EXPERIMENTAL|Fractional Micro-Needle Radiofrequency|each patient will be treated with FMR DeAge®, applicator device at 4-week intervals for 2 sessions of treatment. This applicator consists of rows of 36 (6x6 needles) insulated microneedles that form an array of positively and negatively charged electrodes. The microneedles will deliver bipolar radiofrequency energy in a fractional manner that extends from 3.0 mm below the surface of the skin. All subjects will be prepared by local anesthesia to induce numbness at the axilla prior to treatment. The targeted axillary side will be treated with a total of 4 passes.
62235444|NCT03054480|ACTIVE_COMPARATOR|Botulinum toxin type A|50 units of Botulinum toxin type A will be intradermal injected over axillary area. The protocol by using 1-2 units per 1 injection area with the coverage of 1x1 cm2 will be treated.
62235445|NCT03602066|EXPERIMENTAL|Arm I (chlorine dioxide sterilization)|Patients receive chlorine dioxide sterilization oral rinse over 30 seconds BID from the start of RT to the evening prior to the 1 month RT follow-up appointment.
62426150|NCT06536816|EXPERIMENTAL|Small-sided games Group|2nd group with players having only Small-Sided Games group
62426151|NCT06536816|EXPERIMENTAL|Combined training Group with both Game Profile-based training and Small-sided Games|3rd group with players having both Game Profile-based training and Small-Sided Games group
62426152|NCT06542471|EXPERIMENTAL|group 1|Intramedullary nail group
62426153|NCT06542471|EXPERIMENTAL|group 2|Plating group
62811716|NCT03908034|EXPERIMENTAL|Uncontrollable factor PRESENT; anticipated regret induced|"Same as the uncontrollable factor present, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
62811717|NCT03560882|EXPERIMENTAL|Atorvastatin|Atorvastatin 80 milligrams (mg) per day, orally for 1 - 4 weeks before surgery (surgery not part of clinical trial)
62811718|NCT03397979|ACTIVE_COMPARATOR|Infrequent soaking baths|Infrequent soaking baths, in this study, is defined as twice a week soaking baths for 10 minutes or less, over 2 weeks. However, this is a crossover study design with two interventions: 1) Infrequent soaking baths, as defined above, and 2) Frequent soaking baths (defined as twice daily soaking baths for 15-20 minutes, over 2 weeks). All subjects in the study will undergo both interventions, but in different order. Thus, this is a study comparing Infrequent Versus Frequent Soaking Baths. Each subject serves as their own control.
62811719|NCT03397979|ACTIVE_COMPARATOR|Frequent soaking baths|Frequent soaking baths, in this study, is defined as twice daily soaking baths for 15-20 minutes, over 2 weeks. However, this is a crossover study design with two interventions: 1) Infrequent soaking baths, as defined in the first arm description above, and 2) Frequent soaking baths, as defined above in this arm description. All subjects in the study will undergo both interventions, but in different order. Thus, this is a study comparing Infrequent Versus Frequent Soaking Baths. Each subject serves as their own control.
62811720|NCT02823509|EXPERIMENTAL|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62811721|NCT06420804|EXPERIMENTAL|Single-site monadic study|Single-site monadic study to evaluate the effect of a device on acne treatment.
62811722|NCT02122835|OTHER|heart failure|aerobic exercise training
62426154|NCT01758315|EXPERIMENTAL|Improvement Sessions|We will implement a context-sensitive collaborative improvement model that will emphasize training and in-office coaching by quality improvement, efficiency and safety experts, as well as shared learning methods to develop, test and implement changes in the following four key risk areas: medication management; test and lab results management; follow-up and referral management; and communication - within and between practices as well as with patients.
62426155|NCT01758315|NO_INTERVENTION|Control|Control practices will not receive training or in-office coaching.
62426156|NCT02602080||FA patients under popliteal block + spinal + sedation|Foot and ankle patients under popliteal block+ spinal+ sedation
62426157|NCT02602080||TSA patients under brachial plexus block + general (LMA)|Total shoulder arthroscopy patients under brachial plexus block + general (LMA)
62235446|NCT03602066|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo oral rinse over 30 seconds BID from the start of RT to the evening prior to the 1 month RT follow-up appointment.
62811723|NCT02122835|OTHER|heart failure plus type 2 diabetes|aerobic exercise training
62811724|NCT02758210|EXPERIMENTAL|Participants with MICRA Device|Participants that received the MICRA device prior to study enrollment will have monitored use of Smart Phone and Tablet at one study visit. Electrogram printing will take place during use of each device to see if there is any pacing inhibition or asynchronous pacing.
62235447|NCT02863887|EXPERIMENTAL|Weight loss intervention|Churches randomized to the intervention condition will receive the community health coach delivered church based intervention for 6 months followed by 6 months of weight maintenance.
62235448|NCT02863887|EXPERIMENTAL|Delayed Treatment Control Group|Churches in the delayed treatment control condition will receive information on various health topics relevant to African Americans, such as strokes, lupus, sickle cell, etc. via text message during the first six months. Participants in this group will not receive any behavioral strategies designed to alter weight, physical activity, or diet during this time. They will receive the community health coach delivered church based weight loss intervention after 6 months.
62235449|NCT04561752|EXPERIMENTAL|Treatment Sequence A-B|Participants will take ZN-c5 (150mg), single dose, under fasted conditions, and a week later, will take the same drug under fed conditions to determine the comparative bioavailability of ZN-c5 under these conditions.
62035104|NCT00074282|EXPERIMENTAL|Arm C (Alemtuzumab: PR, <PR, PD)|For those patients not achieving a CR or nPR (thus patients either achieved PR, SD, or PD), Alemtuzumab (Arm C) was administered three times a week for eighteen weeks at a dose of 30 mg TIW. For PR, SD and PD patients, the timing of CAMPATH-1H was left to the discretion of the investigator, and treatment could begin earlier but no less than two weeks and no longer than eight weeks after the completion of the last PCR course. Patients determined to have PD during treatment with PCR did not need to complete all 6 cycles of PCR to go on to Arm C, however, completing a minimum of 2 cycles was required.
62035105|NCT06257069|EXPERIMENTAL|Intervention Arm|All subjects will receive intervention with Tremor Retrainer smartphone application
62035106|NCT06535971|OTHER|Physiotherapy group|Individualized physiotherapy intervention based on manual therapy and exercise 1 session per week for 3 months
62035107|NCT02284438|OTHER|Biofilm formation on ETT|Three different endotracheal tubes uses on intubated mechanical ventilated patients will after extubation be examined regarding biofilm, structure and presence of microbes on the ETTs The different tubes will be used during consecutive time periods The study does not include any interventions concerning the treatment of these critically ill patients
62035108|NCT00594269|PLACEBO_COMPARATOR|A|Discontinuation of antipsychotic or antidepressants
62035109|NCT05736718|EXPERIMENTAL|Champion AAT|Staff in clinics randomized to this arm will receive an intervention called Announcement Approach Training (AAT). This training is designed to improve communication about HPV vaccination. The training will be organized and delivered by vaccine champions from participating healthcare systems.
62035110|NCT05736718|EXPERIMENTAL|Traditional AAT|Staff in clinics randomized to this arm will also receive Announcement Approach Training (AAT). The training will be organized and delivered by outside experts.
62035111|NCT01227889|EXPERIMENTAL|GSK2118436|Subjects in this arm will receive GSK2118436 150 mg twice daily.
62035112|NCT01227889|ACTIVE_COMPARATOR|Dacarbazine (DTIC)|Subjects will receive intravenous dacarbazine (DTIC) 1000 mg/m2 every 3 weeks
62035113|NCT01227889|EXPERIMENTAL|Crossover|Subjects who initially receive DTIC will be allowed to receive GSK2118436 after initial progression.
62426158|NCT02602080||TSA patients under brachial plexus block + sedation|Total shoulder arthroplasty patients under brachial plexus block + sedation
62426159|NCT03216954|PLACEBO_COMPARATOR|Placebo|Subjects will receive oral placebo capsules two times daily.
62426160|NCT03216954|EXPERIMENTAL|Low Dose n-Acetylcysteine|Subjects will receive 0.6 g oral n-acetylcysteine two times daily.
62811725|NCT05471765|EXPERIMENTAL|Moderate Obstructive Sleep Apnea|Patients whom have an apnea/hypopnea index above fifteen are classified to have moderate obstructive sleep apnea
62035114|NCT05197335||Study Group|Age of 65 at the time of signing the informed consent.
62035115|NCT01756092|EXPERIMENTAL|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
62035116|NCT01024569|EXPERIMENTAL|Wellness Recovery Action Planning (WRAP)|WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks. Topics include: Introduction to WRAP, Developing a Wellness Toolbox, Creating a Daily Maintenance Plan, Identifying Triggers, Identifying Early Warning Signs, Managing When Things Break Down, and Crisis Planning. Coursework is interactive, using lecture, question and answer, group discussion, and individual or group exercises. Each session includes a lecture on recovery topics such as self-esteem, changing negative thoughts to positive ones, peer support, and lifestyle issues.
62035117|NCT01024569|NO_INTERVENTION|Comparison Wait-List Group|Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend WRAP groups after their final research interview.
62035118|NCT00568529|EXPERIMENTAL|Combine Chemotherapy|XELOX(Xeloda and oxaliplatin combination)
62035119|NCT01603069|ACTIVE_COMPARATOR|AZD3241, 300 mg|AZD3241 300 mg BID
62035120|NCT01603069|ACTIVE_COMPARATOR|AZD3241, 600 mg|AZD3241 600 mg BID
62035121|NCT01603069|PLACEBO_COMPARATOR|Placebo|Placebo to AZD3241
62035122|NCT01694303|ACTIVE_COMPARATOR|Engaging computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
62035123|NCT01694303|EXPERIMENTAL|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
62235450|NCT04561752|EXPERIMENTAL|Treatment Sequence B-A|Participants will take ZN-c5 (150mg), single dose, under fed conditions, and a week later, will take the same drug under fasted conditions to determine the comparative bioavailability of ZN-c5 under these conditions.
62235451|NCT04950088|ACTIVE_COMPARATOR|Game|"Patients will be assigned into a Video Game group or a No Video Game group. All patients on any particular day will be assigned into the same group. This is done to prevent one patient from feeling disappointed after seeing another patient with a video game, and then learning they may not have one. Group assignment will alternate each day."
62426161|NCT03216954|EXPERIMENTAL|High Dose n-Acetylcysteine|Subjects will receive 1.2 g oral n-acetylcysteine two times daily.
62426162|NCT01825915|ACTIVE_COMPARATOR|Laparoscopic Hysterectomy|Laparoscopic hysterectomy involving removal of both uterine corpus and cervix
62426163|NCT01825915|ACTIVE_COMPARATOR|Laparoscopic Supracervical Hysterectomy|Laparoscopic hysterectomy involving removal of the uterine corpus alone with conservation of the cervix.
62811726|NCT05471765|EXPERIMENTAL|Severe Obstructive Sleep Apnea|Patients whom have an apnea/hypopnea index with a result higher than thirty are considered to have severe obstructive sleep apnea
62811727|NCT00132743|ACTIVE_COMPARATOR|1|Optimal Medical Care
62811728|NCT00132743|ACTIVE_COMPARATOR|2|Optimal Medical Care and Supervised Exercise
62811729|NCT00132743|ACTIVE_COMPARATOR|3|Optimal Medical Care and Stent
62811730|NCT04982562|OTHER|7T MRI|Seven tesla brain MRI (7T MRI) at day 7 in patients suffering from post concussionnal symptoms after mild traumatic brain injury admitted to emergency departement of Poitiers CHU (University Hospital
62811731|NCT05213832|EXPERIMENTAL|Inhalatory group|Patience with severe SAH (WFNS \> 3) are enrolled in the study. In these patients we administered a inhalatory dose of Isofluorane
62811732|NCT00474123|ACTIVE_COMPARATOR|Simvastatin 80 mg|Patients were treated with simvastatin 80 mg for 6 weeks
62811733|NCT00474123|ACTIVE_COMPARATOR|Ezetimibe 10 mg / Simvastatin 20 mg|Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks
62235452|NCT04950088|ACTIVE_COMPARATOR|no game|"Patients will be assigned into a Video Game group or a No Video Game group. All patients on any particular day will be assigned into the same group. This is done to prevent one patient from feeling disappointed after seeing another patient with a video game, and then learning they may not have one. Group assignment will alternate each day."
62811734|NCT02475590|EXPERIMENTAL|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
62811735|NCT02475590|EXPERIMENTAL|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
62811736|NCT04058444|EXPERIMENTAL|ERAS Group|Perioperative management follows the ERAS (Enhanced Recovery After Surgery) protocol
62811737|NCT04058444|EXPERIMENTAL|Control Group|Perioperative management follows the conventional program
62235453|NCT01048567|ACTIVE_COMPARATOR|Lactobacillus acidophilus/rhamnosus|
62235454|NCT01048567|PLACEBO_COMPARATOR|Placebo|
62426164|NCT00583245|EXPERIMENTAL|1|Gait training
62235455|NCT02679742|EXPERIMENTAL|β-hydroxymethylbutyrate|β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program
62235456|NCT02679742|PLACEBO_COMPARATOR|Placebo|Maltodextrin 3 grams once a day combined with a resistance training program
62811738|NCT05219162|OTHER|EGFRm Locally Advanced or Metastatic NSCLC patients post Osimertinib 1L treatment failure|participants with advanced or metastatic non-small cell lung cancer, who have already taken osimertinib as a first treatment option, but their cancer has continued to get worse
62811739|NCT02359318|EXPERIMENTAL|Resin infiltration and de-bonding|"Patients with brackets and white spots are included in this group. After removal of the old brackets the quadrants are randomized to this intervention arm and the no infiltration and de-bonding arm. The teeth that are included in this intervention arm are treated by resin infiltration using Icon (DMG, Germany) according to the manufacturers´ instruction. This is followed by bonding of new brackets (Gemini metal brackets, 3M Unitek). These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
62811740|NCT02359318|PLACEBO_COMPARATOR|No infiltration and de-bonding|"Patients with brackets and white spots are included in this group. After removal of the old brackets the quadrants are randomized to this intervention arm and the resin infiltration and de-bonding arm. The teeth that are included in this intervention arm are left untreated new brackets (Gemini metal brackets, 3M Unitek) are bonded. These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
62235457|NCT04100473|EXPERIMENTAL|Dance 501|Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered using the Dance 501 Inhaler.
62235458|NCT04100473|ACTIVE_COMPARATOR|Insulin Lispro|Insulin Lispro (Humalog®) will be administered by subcutaneous injection.
62235459|NCT03321487|EXPERIMENTAL|Stage I Cohort|Blood-Brain Barrier opening with MRgFUS. BBB opening of a small volume of the primary motor cortex
62426165|NCT01277406|EXPERIMENTAL|4SC-201+FOLFIRI|
62426166|NCT01277406|ACTIVE_COMPARATOR|FOLFIRI|
62426167|NCT04664283|EXPERIMENTAL|DCB group by OCT guided|
62426168|NCT04664283|ACTIVE_COMPARATOR|DES group by OCT guided|
62426169|NCT01128010||alcoholic liver disease|alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution
62426170|NCT01128010||controls|Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination
62426171|NCT03137485|ACTIVE_COMPARATOR|Conventional|Patients in this arm will have conventional open lumbar discectomy operation.
62426172|NCT03137485|ACTIVE_COMPARATOR|Endoscopic|Patients in this arm will have Percutaneous Endoscopic Translaminar lumbar discectomy operation using Easy Go system Endoscopy
62235460|NCT03321487|EXPERIMENTAL|Stage II Cohort|Blood-Brain Barrier opening with MRgFUS. BBB opening of a larger volume of the primary motor cortex
62235461|NCT01793220|EXPERIMENTAL|SMS Reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
62811741|NCT02359318|OTHER|Control and de-bonding|"Patients with brackets and without white spots are included in this group. After removal of the old brackets, new brackets (Gemini metal brackets, 3M Unitek) are bonded again. These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
62811742|NCT01517750|EXPERIMENTAL|APAP with humidification|ICON Auto CPAP™ with Thermosmart heated tube
62811743|NCT01517750|ACTIVE_COMPARATOR|APAP without humidification|ICON Auto CPAP™ without Thermosmart heated tube
62811744|NCT04481412|EXPERIMENTAL|Study group|(33) patients will apply topical minoxidil (5%) once daily and topical cetirizine (1%) once daily on their scalp for 6 months.
62035124|NCT04838899|EXPERIMENTAL|Treatment Arm|All metastases that fulfill the definition of oligoprogression seen on conventional imaging will be treated with standard SABR dose fractionation schemes routinely used at Sunnybrook Odette Cancer Centre. The prostate (if present and not previously treated) will be treated to a dose of 35 Gy in 5 fractions. Non-spine bone metastases will be treated to a dose of 30-40 Gy in 5 fractions. Spine metastases will be treated to a dose of 24 Gy in 2-3 fractions or 30-40 Gy in 5 fractions. Involved lymphadenopathy will be treated to a dose of 30-40 Gy in 5 fractions. Similarly, brain, lung, liver, and adrenal metastases will be treated with standard Sunnybrook SABR doses. Patients will remain on abiraterone during and after SABR treatments.
62035125|NCT01087008|EXPERIMENTAL|Zoledronate acid|
62035126|NCT01087008|OTHER|No treatment control|
62235462|NCT01793220|NO_INTERVENTION|No SMS Reminders|The service user will not be sent text message reminders prior to each appointment at their Psychosis Community Service
62235463|NCT03701113|ACTIVE_COMPARATOR|Milk-based protein matrix (MBPM)|Intervention: Dietary Supplement : Test Product Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover Composition of Test Product - 25g of milk-based proteins + 1000mg dairy-based calcium fortified with 40ug Vit D flavoured and textured supplied food grade and product tested by Dairygold Co-operative Society, Mitchelstown, Ireland.
62235464|NCT03701113|OTHER|CONTROL|Intervention: Habitual dietary behaviour Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover
62235465|NCT04687670|EXPERIMENTAL|Intervention group(pET)|Personalized embryo transfer of a single vitrified blastocyst in a HRT cycle according to the ERA test results.
62235466|NCT04687670|ACTIVE_COMPARATOR|Control group(FET)|Frozen embryo transfer of a single vitrified blastocyst in a HRT cycle according to the clinical standard practice.
62235467|NCT06026618||cohort 1|non-anemic patients (Hb \> 13 g/dL)
62235468|NCT06026618||cohort 2|mildly anemic patients (Hb 12-13 mg/dL) without criteria for IVI therapy
62426173|NCT04911660|ACTIVE_COMPARATOR|Empagliflozin + Placebo|1 capsule containing 25 mg empagliflozin per day for 14 days, followed by a 14-42 days wash-out phase and a second treatment phase with 1 capsule containing placebo for 14 days.
62811745|NCT04481412|ACTIVE_COMPARATOR|Control group|(33) patients will apply topical minoxidil (5%) once daily and placebo once daily on their scalp for 6 months.
62811746|NCT01793428||Injured patient admitted in vital emergency unit|
62811747|NCT00346216|EXPERIMENTAL|celecoxib|subject receives celecoxib and dummy (placebo) ibuprofen and naproxen
62811748|NCT00346216|ACTIVE_COMPARATOR|ibuprofen|subject receives ibuprofen and dummy (placebo) celecoxib and naproxen
62811749|NCT00346216|ACTIVE_COMPARATOR|naproxen|subject receives naproxen and dummy (placebo) celecoxib and ibuprofen
62235469|NCT06026618||cohort 3|patients treated with IVI (Hb \< 12mg/dL or Hb 12-13mg/dL with iron deficiency or risk factors for bleeding)
62594311|NCT01996865|EXPERIMENTAL|Arm A: Lenalidomide + rituximab followed by lenalidomide|Induction Period (12 cycles): Lenalidomide 20mg (10 mg if creatinine clearance ≥ 30 mL/min but \< 60mL/min) by mouth (PO) daily (QD) on Days 1 to 21 of every 28-day cycle during cycles 1 through 12 and rituximab 375mg/m\^2 intraveneously (IV) every week in Cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period (lasting 18 Cycles) that includes Lenalidomide 10 mg PO QD on Days 1 to 21 of every 28-day cycle during cycles 13 to 30 and rituximab 375 mg/m\^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29 followed by an optional Maintenance Period (up to Progressive Disease) receiving Lenalidomide 10mg PO QD on Days 1 through 21 of every 28 day cycle until the disease progresses
62235470|NCT01257789||gastric bypass patients|Consecutive series of 300 patients undergoing laparoscopic gastric bypass
62426174|NCT04911660|PLACEBO_COMPARATOR|Placebo + Empagliflozin|1 capsule containing placebo per day for 14 days, followed by a 14-42 days wash-out phase and a second treatment phase with 1 capsule containing 25 mg empagliflozin for 14 days.
62426175|NCT01956539||Heart Failure|All patients over 18 years with chronic heart failure, and all patients hospitalized for acute heart failure de novo or not. The diagnosis of heart failure is the responsibility of the cardiologist including patient.
62426176|NCT02851953|EXPERIMENTAL|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
62426177|NCT04629131|EXPERIMENTAL|Cohort 1 TNM002 10 μg/kg/Placebo|Sentinel dosing will be conducted for Cohort 1. Two participants will be dosed (1 with TNM002, 1 with placebo) at least 72 hours prior to subsequent dosing. The remaining participants will only be dosed if no significant safety signals are identified in the sentinel participants. In total, eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
62426178|NCT04629131|EXPERIMENTAL|Cohort 2 TNM002 35 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
62735496|NCT05302973|ACTIVE_COMPARATOR|Conventional rehabilitation|Inpatient rehabilitation - person-centred and tailored to individual participant needs - which take into account the different sequelae associated with the severity of COVID-19, the prolonged stay of people in the acute hospital or in the intensive care unit, and the pre-existing comorbidities.
62811750|NCT04233801|EXPERIMENTAL|Empagliflozin 10 mg|"1 table of 10 milligrams (mg) of Empagliflozin was administered orally once daily for a treatment period of 24 weeks.~Before the first dose of randomised drug, all participants went through a 2-week open label placebo run-in period, taking Placebo tablets orally once daily."
62426179|NCT04629131|EXPERIMENTAL|Cohort 3 TNM002 100 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
62811751|NCT04233801|EXPERIMENTAL|Empagliflozin 25 mg|"1 table of 25 milligrams (mg) of Empagliflozin was administered orally once daily for a treatment period of 24 weeks.~Before the first dose of randomised drug, all participants went through a 2-week open label placebo run-in period, taking Placebo tablets orally once daily."
62426180|NCT04629131|EXPERIMENTAL|Cohort 4 TNM002 250 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
62426181|NCT05675384|EXPERIMENTAL|TENS Active Treatment|Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Management (The Elira System)
62426182|NCT05675384|SHAM_COMPARATOR|Sham Control Device|Sham TENS unit that provides no actual therapy
62811752|NCT04233801|PLACEBO_COMPARATOR|Placebo|"Matching placebo was administered orally once daily for a treatment period of 24 weeks.~Before the first dose of randomised drug, all participants went through a 2-week open label placebo run-in period, taking Placebo tablets orally once daily."
62426183|NCT01777802||Prostate Cancer|Patients with prostate cancer will be treated with SBRT, IMRT or brachytherapy
62426184|NCT01777802||Breast Cancer|Patients with breast cancer will be treated with SBRT, IMRT or brachytherapy
62235471|NCT01019317|EXPERIMENTAL|Cytarabine + Fludarabine|Fludarabine 15 mg/m\^2 intravenous (IV) every 12 hours for 5 days; Cytarabine 0.5 grams/m\^2 IV over 2 hours every 12 hours for 5 days.
62235472|NCT04629001||with Covid-19 infection|
62235473|NCT04629001||without Covid-19 infection|
62235474|NCT00414128|EXPERIMENTAL|mycophenolate mofetil|Mycophenolate mofetil for 3-6 months until in stable remission, dose 2-3g/day
62594312|NCT01996865|ACTIVE_COMPARATOR|Arm B: Lenalidomide + rituximab followed by rituximab|Induction Period (12 Cycles): Lenalidomide 20 mg PO QD (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) on Days 1 to 21 of every 28-day cycle during cycles 1 to 12 and rituximab 375 mg/m\^2 IV every week in cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period for 18 Cycles that includes: Rituximab 375 mg/m\^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29
62594313|NCT05081843|ACTIVE_COMPARATOR|Usual Health Education Curriculum|Students will receive the school's usual health education curriculum.
62594314|NCT05081843|EXPERIMENTAL|Usual Health Education Curriculum plus Intervention|Students will receive the school's usual health education curriculum. Students will also receive the intervention. Delivery of the intervention (i.e., timing, frequency) will be determined by discussing the results of the Aim 1 focus groups with teachers and administrators.
62594315|NCT06622980|EXPERIMENTAL|Laparoscopic surgeons|Laparoscopic surgeons from any surgical subspecialty
62811753|NCT04239001|EXPERIMENTAL|PEG-rhG-CSF|Jin Youli(PEG-rhG-CSF): jinyouli injection was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight \<45 kg. Inject once every chemotherapy cycle
62811754|NCT00948753|EXPERIMENTAL|Phase 1: 150mg Maraviroc|150mg twice daily
62235475|NCT00414128|ACTIVE_COMPARATOR|cyclophosphamide|pulsed intravenous cyclophosphamide 15mg/kg for 3-6 months (6-10 doses)until in stable remission
62811755|NCT00948753|EXPERIMENTAL|Phase 1: 300mg Maraviroc|300mg twice daily
62811756|NCT00948753|EXPERIMENTAL|Phase 2: 300mg Maraviroc|300mg twice daily
62811757|NCT05383469|ACTIVE_COMPARATOR|Compression Group|Routine compression therapy will be administered.
62594316|NCT06522555|EXPERIMENTAL|Pola-ZR2|six courses of polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide induction therapy and lenalidomide maintenance therapy
62594317|NCT06522555|ACTIVE_COMPARATOR|ZR2|six courses of zanubrutinib, rituximab and lenalidomide induction therapy and lenalidomide maintenance therapy
62594318|NCT04697004|EXPERIMENTAL|SMR Stemless Reverse|
62594319|NCT04697004|ACTIVE_COMPARATOR|SMR Reverse Shoulder System|
62594320|NCT05059041|EXPERIMENTAL|Dilated first, non-dilated second|Each participant will perform vision testing first through a prescription determined from wavefront measurements obtained after dilation. Second, each participation will perform vision testing through a prescription determined from wavefront measurements obtained before dilation.
62594321|NCT05059041|EXPERIMENTAL|Non-dilated first, dilated second|Each participant will perform vision testing first through a prescription determined from wavefront measurements obtained before dilation. Second, each participation will perform vision testing through a prescription determined from wavefront measurements obtained after dilation.
62235476|NCT04307082|EXPERIMENTAL|Ibrexafungerp|Oral \[14C\]-Ibrexafungerp Single Dose
62235477|NCT01366495|EXPERIMENTAL|On-site Rapid HIV Testing|On-site rapid testing conducted by research staff co-located for the purposes of this study at the probation/parole office.
62235478|NCT01366495|NO_INTERVENTION|Off-site Referral for HIV Testing|Off-site referral for rapid HIV testing at a community health center or HIV testing clinic
62235479|NCT01366495|EXPERIMENTAL|Project Bridge|Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
62235480|NCT01366495|NO_INTERVENTION|Treatment as Usual|Passive referral to HIV community treatment provider.
62235481|NCT02532153|OTHER|Open-Label Ketamine|
62811758|NCT05383469|EXPERIMENTAL|Active Group|Exercise training will be administered.
62811759|NCT05383469|EXPERIMENTAL|Passive Group|Massageand neuromuscular electrical stimulation will be administered.
62811760|NCT01381016|OTHER|Group 1 - Normal Weight|"Group 1: Normal weight (BMI 18-25 kg/m2)~Subjects were instructed to apply 0.1 mg/d transdermal estrogen (Estradiol) for one month. Pituitary response was assessed to determine how estradiol administration altered pituitary sensitivity to Gonadotropin-releasing hormone - GnRH. Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary."
62811761|NCT01381016|EXPERIMENTAL|Group 2 - Obese|"Group 2: Obese (BMI \>30 kg/m2)~Subjects were instructed to apply 0.1 mg/d transdermal estrogen (Estradiol) for one month. Pituitary response was assessed to determine how estradiol administration altered pituitary sensitivity to Gonadotropin-releasing hormone - GnRH. Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary."
62811762|NCT06427213|EXPERIMENTAL|Elder Patients（≥65）|"Induction: Zanubrutinib and Obinutuzumab 1year~Maintenance: Zanubrutinib continued until progression"
62235482|NCT02475174|EXPERIMENTAL|Without upper limb elevation|Manual lymphatic drainage will be held with the voluntary supine without upper limb elevation.
62811763|NCT06427213|EXPERIMENTAL|Young Patients with High risk （≥18，<65）|"Induction: Zanubrutinib and R-BAC 6 cycles~Consolidation: ASCT（If eligible for transplantation），Otherwise, the patient was directly entered into maintenance treatment~Maintenance: Zanubrutinib continued until progression"
62594322|NCT03599856|NO_INTERVENTION|"Before control group"|Control group with observation of current local standard of care with paper checklist available at the bedside during the ICU rounds of the ICU physicians (as usual)
62235483|NCT02475174|EXPERIMENTAL|Upper limb elevation to 30º|Manual lymphatic drainage will be held with the voluntary supine with the upper limb elevation to 30º.
62235484|NCT03566810|EXPERIMENTAL|First Test GXR (Fasting), Then Reference GXR (Fasting)|Participants received a single oral dose of 500 milligrams (mg) of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.
62594323|NCT03599856|EXPERIMENTAL|"After Intervention group"|An mini Ipad providing TraceBook' intelligent dynamic clinical checklists during the ICU rounds of the ICU physicians.
62426185|NCT01777802||Lung Cancer|Patients with lung cancer will be treated with SBRT, IMRT or brachytherapy
62594324|NCT06620120|EXPERIMENTAL|One medical device as investigational device|
62594325|NCT06620120|EXPERIMENTAL|Without device|
62235485|NCT03566810|EXPERIMENTAL|First Reference GXR (Fasting), Then Test GXR (Fasting)|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.
62594326|NCT02720744|EXPERIMENTAL|Sodium Oxybate|Patients will undergo a screening period and will then be titrated to the following once-nightly doses: 4.5 g sodium oxybate, 6.0 g sodium oxybate, 7.5 g sodium oxybate, and 9.0 g sodium oxybate.
62235486|NCT03566810|EXPERIMENTAL|First Test GXR (Fed), Then Reference GXR (Fed)|Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.
62426186|NCT01777802||Melanoma Cancer|Patients with melanoma cancer will be treated with SBRT, IMRT or brachytherapy
62426187|NCT05786781|EXPERIMENTAL|Transarterial CT angiography|Transarterial catheter-directed CT angiography during interventional treatment of hemoptysis
62426188|NCT00601276|EXPERIMENTAL|1|
62426189|NCT00601276|ACTIVE_COMPARATOR|2|
62594327|NCT02720744|PLACEBO_COMPARATOR|Placebo|Patients will undergo a screening period and will then be titrated to the following once-nightly doses: 4.5 g placebo, 6.0 g placebo, 7.5 g placebo, and 9.0 g placebo.
62811764|NCT03693703|EXPERIMENTAL|bi-parametric MRI|Patients will undergo axial T2-weighted and diffusion-weighted imaging (no contrast agent injection)
62811765|NCT03693703|ACTIVE_COMPARATOR|multi-parametric MRI|Patients will undergo multiparametric MRI including morphological study (T2- and T1-weighted imaging) and functional acquisitions (diffusion-weighted and dynamic contrast-enhanced imaging)
62811766|NCT02738801|EXPERIMENTAL|GLPG1690 600 mg once daily (QD)|
62811767|NCT02738801|PLACEBO_COMPARATOR|Placebo QD|
62811768|NCT05416333|EXPERIMENTAL|azelaic acid treatment|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
62811769|NCT05416333|SHAM_COMPARATOR|control (no additional treatment)|Subjects will continue to use their current primary provider prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
62426190|NCT02319954|ACTIVE_COMPARATOR|Compression|Each patient will be randomized to receive compression of their nose on either the left or right for 5 continuous minutes after performing a lateral rhinotomy.
62426191|NCT02319954|NO_INTERVENTION|No compression|Each patient will serve as their own control with the other side not receiving any compression after a lateral rhinotomy.
62426192|NCT01896700|EXPERIMENTAL|Methylphenidate|"Intervention: An escalating dose of methylphenidate taken by mouth: 20mg for 2 weeks, 40mg for 2 weeks, 60mg for 2 weeks. All doses divided twice/day.~Other name: Ritalin"
62426193|NCT01896700|PLACEBO_COMPARATOR|Placebo|Placebo pill, bid for 6 weeks
62426194|NCT02715466|EXPERIMENTAL|Gelatine|Balanced gelatine solution
62426195|NCT02715466|ACTIVE_COMPARATOR|Electrolyte|Balanced electrolyte solution
62426196|NCT04471558||Music group|A part of the care is realized with music.
62426197|NCT04471558||Control group|The entire care is realized without music.
62426198|NCT04727619|EXPERIMENTAL|Experimental|Participants who participated in the SLEEP program.
62426199|NCT04727619|NO_INTERVENTION|Control|Participants who did not participate in the SLEEP program.
62426200|NCT00921219|EXPERIMENTAL|Ivermectin|ivermectin
62594328|NCT00831545|EXPERIMENTAL|Subjects with melanoma|
62594329|NCT00831545|EXPERIMENTAL|Subjects with breast cancer|
62594330|NCT00831545|EXPERIMENTAL|Subjects with non-small cell lung cancer|
62235487|NCT03566810|EXPERIMENTAL|First Reference GXR (Fed), Then Test GXR (Fed)|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.
62426201|NCT03232905|EXPERIMENTAL|PF-06651600|Multiple ascending doses of PF-06651600
62426202|NCT03232905|PLACEBO_COMPARATOR|Placebo|Multiple ascending doses of Placebo
62426203|NCT06271135|EXPERIMENTAL|Participants with rosacea|
62235488|NCT03540953|OTHER|Endoscopic injection of Mitomycin C|Endoscopy injection of Mitomycin C will be perform to the treatment of pharyngoesophageal stenosis refractory to endoscopic treatment with dilatation in patients with head and neck cancer
62235489|NCT05906823||benign pleural effusion|Patients with benign pleural effusion.
62235490|NCT05906823||malignant pleural effusion patients with bad prognosis|The OS time of malignant pleural effusion patients is\<1 year.
62235491|NCT05906823||malignant pleural effusion patients with good prognosis|The OS time of malignant pleural effusion patients is ≥1 year.
62426204|NCT04348344|EXPERIMENTAL|intervention group|"health education of pulmonary rehabilitation pulmonary rehabilitation including aerobic exercise，strength training and breath training.~Patients in stable stages using the home-based rehabilitation exercise prescription, taking home exercise, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training, intermittent strength training and inspiratory muscle training."
62426205|NCT04348344|NO_INTERVENTION|control group|health education of pulmonary rehabilitation
62235492|NCT06227663|EXPERIMENTAL|Access to the KOALOU(®) digital application|
62235493|NCT06227663|NO_INTERVENTION|No access|
62235494|NCT00710996||AcrySof Natural Intraocular Lens|"AcrySof Natural Intraocular Lens (IOL) - Patients with previous bilateral implant of any Alcon lens model starting with the letters SN"
62235495|NCT00710996||AcrySof clear intraocular lens|"AcrySof clear intraocular lens (IOL) - Patients with previous bilateral implant of any Alcon lens model starting with the letters SA"
62235496|NCT00710996||Phakic patients|Phakic patients - Age matched patients who have not had cataract surgery
62235497|NCT01561222|PLACEBO_COMPARATOR|placebo|
62426206|NCT00504127|EXPERIMENTAL|naproxcinod 375 mg bid|
62235498|NCT01561222|EXPERIMENTAL|Calcitriol|
62426207|NCT00504127|EXPERIMENTAL|naproxcinod 750 mg bid|
62811770|NCT05195307|EXPERIMENTAL|Music Group|Application Group Pregnant women in the application group were regularly listened to music for 20 minutes a day for 10 days. In addition, the pregnant women in the application group were trained by the researcher on preparing for normal delivery.
62811771|NCT05195307|NO_INTERVENTION|Control Group|In the study, pregnant women in the control group were trained by the researcher on preparing for normal delivery.
62811772|NCT04739644|EXPERIMENTAL|Experimental: WRISTBOT Group|"The patients in the WRISTBOT Group underwent to following interventions: 1. General Rehabilitation 2. Specific wrist rehabilitation by WRISTBOT device"
62811773|NCT04739644|ACTIVE_COMPARATOR|Control group|The patients in the Control Group underwent to following interventions: 1. General Rehabilitation 2. Specific wrist rehabilitation performed by physiotherapist.
62811774|NCT03164486|EXPERIMENTAL|18F-αvβ6-BP|Patients receive 18F-alphavbeta6-BP IV and then undergo 4 PET scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection.
62811775|NCT00723996||Group 1|Women receiving a CRC-related questionnaire and a CRC educational video.
62811776|NCT00723996||Group 2|Women who receive only a CRC-related questionnaire.
62811777|NCT00723996||Group 3|Women who receive neither questionnaire nor educational video.
62811778|NCT03519074|EXPERIMENTAL|TS-1 combined with cisplatin|Eligible patients will be stratified by degree of liver dysfunction into 4 cohorts, in accordance to the National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria
62811779|NCT06429150|EXPERIMENTAL|CAR-T cells to treat MM|
62811780|NCT02333461|PLACEBO_COMPARATOR|Placebo|333 mg capsule comprised of silicified microcrystalline cellulose, magnesium stearate, modified cellulose gum, silicon dioxide, dextrose, corn starch, and caramel color. Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
62811781|NCT02333461|EXPERIMENTAL|Apple|333 mg capsule comprised of apple peel extract (115:1, standardized to 80% polyphenol and 5% phlorizin). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
62811782|NCT02333461|EXPERIMENTAL|Grape|333 mg capsule comprised of grape extract (8000:1, standardized to 75% total polyphenol, 50% oligomeric proanthocyanidin). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
62811783|NCT02333461|EXPERIMENTAL|Red Raspberry|333 mg capsule comprised of red raspberry leaf extract (4:1, standardized to 6% ellagic acid). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
62811784|NCT02333461|EXPERIMENTAL|Apricot/Nectarine|333 mg capsule comprised of apricot/nectarine extract (40:1, standardized to 50% polyphenol).
62811785|NCT00837902|EXPERIMENTAL|Atenolol|"There is only 1 arm to this study. Intervention: All participants received atenolol. Genotyping for GRK5 was performed to identify if participants were GLN/GLN, GLN/LEU, or LEU/LEU.~Heart rates were measured at rest, and as participants performed graded incremental exercise on a supine bicycle ergometer (at 25, 50, and 75 W for 2 minutes each) twice, once before and once 2.5 hours after taking 25 mg of atenolol."
62235499|NCT02776345|ACTIVE_COMPARATOR|Ultrasound guided Needle Fragmentation|"Ultrasound guided Needle Fragmentation (Intervention):~Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudocapsule. The needle tip will be retracted into the subacromial bursa and 3 ml of 0.5% sensorcaine and 1 ml of steroid ( Depomedrol- 40mg/ml) will be injected into the bursa. The needle will then be removed."
62811786|NCT05476445|ACTIVE_COMPARATOR|Control|After the carious tissue was removed and the endodontic cavity was opened, isolation was provided with a rubber-dam. After the canal length was determined with the Apex locater, the canals were prepared using Ni-Ti endodontic rotary instrument files at the torque value recommended by the manufacturer in an endodontic motor. Irrigation needles were kept 4-5 mm shorter than the working length, and irrigation of the channels was performed. A total of 5 ml of 1% NaOCl was washed for each canal, with 2 ml between each pecking movement of the files. The final washing of the channels was carried out using 5 ml of saline at room temperature.After the canals were dried with the help of a paper cone, the canals were filled by injecting iodoform and calcium hydroxide-containing canals. Then the restoration was completed with compomer.
62819592|NCT03501082|EXPERIMENTAL|L. reuteri DSM20016T, Non-Industrialized-Type Diet Start|Participants will receive the non-industrialized-type diet for 3 weeks, followed by a crossover to 3 weeks of consuming their usual diet after a 3-week washout period. Participants will be provided with a one-time dose of L. reuteri DSM20016T strain on day 4 of each diet period. The L. reuteri DSM20016T strain will be provided as a drinkable solution (approximately 2.25x10\^10 viable cells will be provided in 50 ml of water).
62235500|NCT02776345|ACTIVE_COMPARATOR|US guided needle fragmentation & Lavage|Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.
62426208|NCT00504127|ACTIVE_COMPARATOR|naproxen 500 mg bid|
62426209|NCT00504127|PLACEBO_COMPARATOR|placebo|
62426210|NCT05322421|EXPERIMENTAL|Olive Oil|Will include10 patients receiving topical olive oil application, twice daily
62426211|NCT05322421|ACTIVE_COMPARATOR|Sodium Bicarbonate|Will include 10 patients receiving Sodium bicarbonate 5% solution, twice daily
62426212|NCT04419077|OTHER|Virtual reality exposure|Virtual reality exposure just before an oncological procedure (invasive act or a chemotherapy)
62035127|NCT06265103||Barrow Neurological Institute Comprehensive Epilepsy Center|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
62426213|NCT01003548|ACTIVE_COMPARATOR|Static culture|Embryos individually cultured in microdrops of 40 microliters of G-IVFplus series V
62811787|NCT05476445|EXPERIMENTAL|Low level laser therapy|After the carious tissue was removed and the endodontic cavity was opened, isolation was provided with a rubber-dam. After the canal length was determined with the Apex locater, the canals were prepared using Ni-Ti endodontic rotary instrument files at the torque value recommended by the manufacturer in an endodontic motor. A total of 5 ml of 1% NaOCl was washed for each canal, with 2 ml between each pecking movement of the files. The final washing of the channels was carried out using 5 ml of saline at room temperature.After the canals were dried with the help of a paper cone, the canals were filled by injecting iodoform and calcium hydroxide-containing canals. Then the restoration was completed with compomer. Following the restoration in the LLLT group, the diode laser was activated in biostimulation mode for a total of 1 minute, 30 seconds in the buccal and lingual/palatal regions at the root apex.
62035128|NCT06265103||Cincinnati Children's Hospital Medical Center|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
62426214|NCT01003548|EXPERIMENTAL|Smart plataform|Embryos culture in dynamics microfluidic culture system
62426215|NCT03065452||Patients who underwent open decompression surgery|Observational study on patients who underwent open decompression surgery
62426216|NCT03679845|EXPERIMENTAL|Sarilumab Arm|200 mg of sarilumab every two weeks
62426217|NCT03907475|ACTIVE_COMPARATOR|Arm I (durvalumab)|Patients receive durvalumab IV over 60 minutes on days 1 and 15 of cycles 1 and 2 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
62735497|NCT05302973|ACTIVE_COMPARATOR|Aerobic exercise|Addition of aerobic exercise to conventional inpatient rehabilitation treatment for people wtih post-COVID-19.
62235501|NCT02776345|PLACEBO_COMPARATOR|Ultrasound guided subacromial injection|Using local anesthetic and strict aseptic precautions, the tip of the 22 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 4 ml. of local anesthetic ( 0.5% xylocaine) and 1 ml of steroid( Depomedrol 40 mg/ml) will be injected into the bursa. The needle will then be removed. Post procedure US images in the short and long axis planes will be obtained and documented. The patient's post procedure pain on a scale of 10 and their range of shoulder movement (abduction) will be assessed and documented.
62426218|NCT03907475|EXPERIMENTAL|Arm II (gemcitabine hydrochloride, durvalumab)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and durvalumab IV over 60 minutes on days 8 and 22 of cycles 1 and 2 and day 8 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who discontinue gemcitabine hydrochloride continue receiving durvalumab alone as in Arm I. Patients undergo CT throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
62426219|NCT03907475|EXPERIMENTAL|Arm III (pegylated liposomal doxorubicin, durvalumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and durvalumab IV over 60 minutes on days 8 and 22 of cycles 1 and 2 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening. Patients undergo CT throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
62594331|NCT05742139||Patient group|Have been hospitalized or consulted for neuroborreliosis between 2010 and 2021; Have a diagnosis of probable neuroborreliosis (compatible clinical signs + lumbar puncture with positive intrathecal synthesis of immunoglobulins) or certain (compatible clinical signs + lumbar puncture with pleocytosis and positive intrathecal synthesis of immunoglobulins); Have received adequate treatment according to the recommendations (1st intention DOXYCYCLINE 100mgx2/day or 2nd intention CEFTRIAXONE IV 2g/day for 14 to 21
62811788|NCT05476445|EXPERIMENTAL|Cryotherapy|"After the carious tissue was removed and the endodontic cavity was opened, isolation was provided with a rubber-dam. After the canal length was determined with the Apex locater, the canals were prepared using Ni-Ti endodontic rotary instrument files at the torque value recommended by the manufacturer in an endodontic motor. Irrigation needles were kept 4-5 mm shorter than the working length, and irrigation of the channels was performed. A total of 5 ml of 1% NaOCl was washed for each canal, with 2 ml between each pecking movement of the files. The final washing of the channels was carried out using 5 ml of saline at room temperature.~After the last wash, in the cryotherapy group, unlike the first two groups, each canal was washed with 5 ml of 2°C cold physiological saline for 5 minutes. After the canals were dried with the help of a paper cone, the canals were filled by injecting iodoform and calcium hydroxide-containing canals. Then the restoration was completed with compomer."
62594332|NCT05742139||Control group|Be part of the entourage of the cases; Do not have ATCD of Lyme borreliosis (especially erythema migrans); Not having been bitten by a tick in the last 5 years;
62811789|NCT05246917|EXPERIMENTAL|Handsewn ileocolic anastomosis|"Randomised comparison of handsewn (end-to-end and the Kono-S) with the side-to-side stapled anastomosis.~to use a manual anastomosis technique avoiding stapled technique to verify if stapled anastomosis can cause ulcers at endoscopic follow up with systematic overscoring"
62811790|NCT05246917|NO_INTERVENTION|Side to side stapled anastomosis|"Randomised comparison of handsewn (end-to-end and the Kono-S) with the side-to-side stapled anastomosis.~to use a manual anastomosis technique avoiding stapled technique to verify if stapled anastomosis can cause ulcers at endoscopic follow up with systematic overscoring"
62594333|NCT03970148|EXPERIMENTAL|Nd: YAG laser treatment|Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.
62811791|NCT01155713|EXPERIMENTAL|Arm 1 - TKI258 - bioavailability|
62811792|NCT01155713|EXPERIMENTAL|TKI258 - food effect|
62811793|NCT05958901||pulmonary hypertension|
62811794|NCT05958901||healthy|
62811795|NCT03314493|EXPERIMENTAL|Spironolactone group|Spironolactone oral tablet 25mg/day, for 12 months
62811796|NCT03314493|NO_INTERVENTION|Control group|No spironolactone use
62811797|NCT05269914|EXPERIMENTAL|Autologous anti-CD19 CAR-T cell injection|with 1.00×106 CAR+T cells/kg, 3.00×106 CAR+T cells /kg and 9.00×106 CAR+T cells/kg
62811798|NCT05355571|ACTIVE_COMPARATOR|Active|Participants will consume a probiotic containing lactic acid bacteria and Saccharomyces boulardii at a dose of 35 billion per day for 10 days alongside an oral antibiotic at standard dosage administered for fixed period
62811799|NCT05355571|PLACEBO_COMPARATOR|Placebo|Participants will consume a placebo alongside an oral antibiotic at standard dosage administered for fixed period
62811800|NCT03947619|EXPERIMENTAL|Experimental|"Subjects randomized to the experimental arm will have their heart unloaded for 30 minutes on the Impella CP® device prior to PCI.~Each site is required to have one roll-in per arm to test the study protocol before beginning enrollment."
62811801|NCT03947619|NO_INTERVENTION|Control|"Primary PCI. Each site is required to have one roll-in per arm to test the study protocol before beginning enrollment."
62811802|NCT02324946||Study Group|Mass Screening
62811803|NCT06353178|EXPERIMENTAL|Cancer Connect Program|Participants assigned to this arm will be able to attend the online peer program upon entering the study.
62811804|NCT06353178|PLACEBO_COMPARATOR|Waitlist|Participants assigned to this arm will be on a waitlist and will be invited to join the online peer program in 3 months.
62811805|NCT00333125|EXPERIMENTAL|Travoprost/Timolol|
62811806|NCT00333125|ACTIVE_COMPARATOR|Dorzolamide/Timolol|
62235502|NCT03527914|ACTIVE_COMPARATOR|Treatment as Usual|Patients will receive their standard care at the Outpatient Mental Health Service
62035129|NCT06265103||Children's Hospital of Philadelphia (CHOP)|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
62426220|NCT03907475|EXPERIMENTAL|Arm IV (capecitabine, durvalumab)|Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14, and durvalumab IV over 60 minutes on days 8 of cycle 1, day 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
62235503|NCT03527914|EXPERIMENTAL|Goal Based Outcomes|Up to three goals can be tracked during treatment, although patients often decide to just focus on one. Progress on the goal is then quantitatively rated by the patient, with the provider, at every appointment. Adjustments in the care are then made in an iterative process to ensure that the goal will be met.
62235504|NCT03459014|EXPERIMENTAL|Stimulus rich VE|Participants will be tested during 1 RAG session in the Lokomat. Participants in the experimental group will walk in a stimulus rich VE such as walking in a park.
62235505|NCT03459014|ACTIVE_COMPARATOR|Stimulus poor VE|Participants will be tested during 1 RAG session in the Lokomat. Participants in the control group will walk in a stimulus poor VE, such as walking through an endless hallway.
62426221|NCT03907475|EXPERIMENTAL|Arm V (carboplatin, durvalumab)|Patients receive carboplatin IV over 30-60 minutes on day 1 and durvalumab IV over 60 minutes on day 8 of cycle 1, days 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
62426222|NCT03907475|EXPERIMENTAL|Arm VI (paclitaxel, durvalumab)|Patients receive paclitaxel IV over 60 minutes on day 1 and durvalumab IV over 60 minutes on day 8 of cycle 1, days 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
62426223|NCT03907475|EXPERIMENTAL|Arm VII (nab-paclitaxel, durvalumab)|Patients receive nab-paclitaxel IV over 30 minutes on day 1 and durvalumab IV over 60 minutes on day 8 of cycle 1, days 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
62235506|NCT01748487|EXPERIMENTAL|OZURDEX|24 patients will receive an intravitreal injection of OZURDEX at the end of cataract surgery.
62235507|NCT01176773|EXPERIMENTAL|Juvéderm® Ultra Lip Injectable Gel|
62235508|NCT00059839|EXPERIMENTAL|Standard APO with Vincristine (Arm I )|In courses 1-3, patients receive doxorubicin hydrochloride (30 mg/m2) IV over 15 minutes, vincristine sulfate (1.5 mg/m2 (maximum dose 2 mg)) IV, and methotrexate intrathecally (age-adjusted dosing) (IT) on day 1 and oral prednisone (40 mg/m2/day) three times daily and oral mercaptopurine (225 mg/m2) once daily on days 1-5. In courses 4 and 5, patients receive doxorubicin (30 mg/m2), vincristine sulfate (1.5 mg/m2 (Maximum dose 2 mg)), prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in courses 1-3. In courses 6-15, patients receive vincristine sulfate (1.5 mg/m2), prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in courses 1-3 and methotrexate (60 mg/m2) IV on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity.
62243221|NCT03099005|ACTIVE_COMPARATOR|Medium CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis 4 puffs will contain 1.9% THC + 0.01% CBD and 4 puffs will contain 1.4% THC + 5.1% CBD. They will then undergo experimental testing as described below under Outcome Measures.
62243222|NCT03099005|ACTIVE_COMPARATOR|High CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.4% THC + 5.1% CBD. They will then undergo experimental testing as described below under Outcome Measures.
62243223|NCT01554735|EXPERIMENTAL|lifestyle counselling|exercise and diet counselling for weight loss
62426224|NCT01677169|EXPERIMENTAL|59 mL noni juice|Ingestion of 59 mL of Tahitian Noni® juice (mixture of noni juice and grape and blueberry juices) twice daily (118 mL daily total) for 30 days.
62594334|NCT01437709|EXPERIMENTAL|patients receiving Immunotherapy (This arm is closed)|The proposed study is a Simon 2 stage optimal study design investigating the activity of ofatumumab alone or in conjunction with Bendamustine for patients with MCL who are either not candidates for ASCT or aged 65 or older. The study design will allow for an estimation of the single agent response of ofatumumab in patients at low biologic risk for immediate disease progression.
62811807|NCT05899153|EXPERIMENTAL|Audiovisual Biofeedback|Participants will complete 12 sessions (20 minutes of walking on a treadmill) over a 6-8 week period while receiving audiovisual biofeedback based on the muscle activity of their ankle plantarflexors. The visual feedback will be provided on a screen with a bar showing real-time muscle activity and the audio feedback will be a sound played when they reach the target level of muscle activity.
62811808|NCT05899153|EXPERIMENTAL|Sensorimotor Biofeedback|Participants will complete 12 sessions (20 minutes of walking on a treadmill) over a 6-8 week period while receiving sensorimotor biofeedback with an ankle exoskeleton that provides resistance to ankle plantarflexion during the stance phase of gait.
62811809|NCT05899153|EXPERIMENTAL|Audiovisual + Sensorimotor Biofeedback|Participants will complete 12 sessions (20 minutes of walking on a treadmill) over a 6-8 week period while receiving both audiovisual and sensorimotor biofeedback. Sensorimotor biofeedback will be provided with an ankle exoskeleton that provides resistance to ankle plantarflexion during the stance phase of gait. The visual feedback will be provided on a screen with a bar showing real-time muscle activity and the audio feedback will be a sound played when they reach the target level of muscle activity from the plantarflexors.
62811810|NCT05035524|ACTIVE_COMPARATOR|Sodium Bicarbonate|Adjuvant SB treatment Inhalation of SB 8.4% via a jet nebulizer (5 ml every 4 h) starting at 7:00 to 23:00 hours every day for 30 days together with instillation of SB 8.4% drops 4-times daily (three drops for each nostril) were offered to all patients in the study group
62811811|NCT05035524|PLACEBO_COMPARATOR|Placebo|Placebo
62811812|NCT04743362||Participants with muco-cutaneous lesions|Participants will have muco-cutaneous lesions for non-invasive evaluation (including normal skin or mucosa and benign lesions) and will be identified by their physicians or fellows during routine clinical care.
62811813|NCT04903210|EXPERIMENTAL|NMN group|NMN10000 WRIGHT LIFE® + lifestyle modification.
62811814|NCT04903210|OTHER|Control group|Lifestyle modification only.
62811815|NCT04309292|EXPERIMENTAL|Treatment Arm|protein supplementation plus prebiotic supplementation
62811816|NCT04309292|PLACEBO_COMPARATOR|Placebo Arm|Protein supplementation plus placebo
62811817|NCT02337413|ACTIVE_COMPARATOR|Urotherapy + Constipation Treatment|This group will be treated with standard behavioral urotherapy in addition to receiving active stool softening with PEG3350 and standard constipation instruction.
62811818|NCT02337413|OTHER|Urothearpy alone|This group will receive standard behavioral urotherapy alone
62811819|NCT02253914|EXPERIMENTAL|BILR 355 BS, solution|escalating doses
62811820|NCT02253914|EXPERIMENTAL|BILR 355 BS, tablet|escalating doses
62811821|NCT02253914|PLACEBO_COMPARATOR|Placebo|
62811822|NCT02666872|EXPERIMENTAL|Motivational interviewing on vaccination|An educational strategy based on motivational interviewing of approximately 15 minutes to promote vaccination, in maternity ward.
62811823|NCT02666872|NO_INTERVENTION|Brochure about vaccines for infants|Parents in the control group only received a brochure about vaccines for infants. This brochure is given to all fathers and mothers giving birth to the CHUS, participating or not at our study.
62811824|NCT01526499|EXPERIMENTAL|TC|Docetaxel plus Cyclophosphamide
62811825|NCT01526499|ACTIVE_COMPARATOR|T|Docetaxel
62811826|NCT06345716|EXPERIMENTAL|Paracétamol-tramadol|Each patient received 1 tablet \* 2/day synalvic (325 mg of paracetamol + 37.5 mg of tramadol) for 7 days.
62811827|NCT06345716|EXPERIMENTAL|Paracetamol-caffeine|Each patient received 1 tab \* 3/d stopalgic extra (65mgcaffeine+500mg paracetamol) for 7 days
62426225|NCT01677169|PLACEBO_COMPARATOR|Placebo|Ingestion of 59 mL of placebo (mixture of grape and blueberry juices and natural cheese flavor) twice daily (118 mL daily total) for 30 days.
62811828|NCT06345716|EXPERIMENTAL|Placebo|"Each patient received 1 tab \* 3 / d of placebo (flour) every day for 7 days.~\*For the three groups, the tablets were packaged hermetically in identical envelopes taken at random to respect double blinding."
62811829|NCT00884364|ACTIVE_COMPARATOR|Control|
62811830|NCT00884364|EXPERIMENTAL|Exercise|
62811831|NCT03111238|EXPERIMENTAL|REX-001|REX-001 is a cell suspension of autologous BM-MNCs composed of several mature cell types.
62243224|NCT02019420|EXPERIMENTAL|Tedizolid phosphate IV|Ventilated HABP/VABP participants receive tedizolid phosphate 200 mg IV once daily for 7 days, or for 14 days for concurrent bacteremia.
62243225|NCT02019420|ACTIVE_COMPARATOR|Linezolid IV|Ventilated HABP/VABP participants receive linezolid 600 mg IV every 12 hours for 10 days, or for 14 days for concurrent bacteremia.
62426226|NCT01677169|EXPERIMENTAL|29.5 mL noni dose|Ingestion of 29.5 mL of Tahitian Noni® juice (mixture of noni juice and grape and blueberry juices) daily for 30 days.
62426227|NCT04839315|OTHER|mRNA COVID19 vaccines|mRNA-based COVID19 vaccines
62426228|NCT04973839|EXPERIMENTAL|Video optimizing expectations before PMR (unguided)|watching a video aiming to optimize participants' expectations before undergoing a single PMR session without personal support of the experimenter (unguided)
62811832|NCT03111238|PLACEBO_COMPARATOR|Placebo|The final formulation of the placebo will be a diluted suspension of red blood cells.
62811833|NCT01245309|EXPERIMENTAL|scratching|endometrial scratching prior ivf cycle
62811834|NCT01245309|PLACEBO_COMPARATOR|PLACEBO|PLACEBO PROCEDURE
62811835|NCT00382668||A|
62811836|NCT00382668||B|
62811837|NCT00382668||C|
62811838|NCT00605852|EXPERIMENTAL|Subjects receiving treatment in cohort I|Eligible subjects will receive three single doses of GSK835726 and one single dose of placebo in cohort I.
62811839|NCT00605852|EXPERIMENTAL|Subjects receiving GSK835726 in cohort II|Eligible subjects will receive repeat doses of GSK835726 once daily for 7 days.
62811840|NCT00605852|PLACEBO_COMPARATOR|Subjects receiving placebo in cohort II|Eligible subjects will receive repeat doses of placebo once daily for 7 days.
62811841|NCT00605852|EXPERIMENTAL|Subjects receiving treatment in cohort III|Eligible subjects will receive two single doses of GSK835726 and one single dose of placebo in cohort III.
62811842|NCT01810770|EXPERIMENTAL|Radium-223 dichloride|
62811843|NCT03534609|EXPERIMENTAL|Genius System Neck Treatment|Lutronic Genius System treatment of lines, wrinkles, and texture concerns on the neck.
62811844|NCT06023394|OTHER|Cohort A: Receives Laryngeal Mask Airway Device|In this study arm, after induction of general anesthesia, the patients will receive a laryngeal mask airway device.
62811845|NCT06023394|OTHER|Cohort B: Receives Endotracheal Tube Device|In this arm, after induction of general anesthesia, the patients will receive an endotracheal tube airway device.
62811846|NCT02326285|EXPERIMENTAL|Treatment phase|Enrolled patients will be treated with 250mg/day Gefitinib for 11 days (day -12 until day -1) followed by 3 cycles (length 21 days) of chemotherapy with docetaxel (75mg/m2 d1) and cisplatin (50 mg/m2 d1+2) combined with intercalated gefitinib (250mg/day, d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
62811847|NCT03287791|EXPERIMENTAL|Generic Azelaic Acid Foam|A thin layer of generic azelaic acid, 15% topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
62811848|NCT03287791|ACTIVE_COMPARATOR|Finacea® (Azelaic Acid) Foam|A thin layer of Finacea (azelaic acid), 15% topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
62811849|NCT03287791|PLACEBO_COMPARATOR|Vehicle Foam|A thin layer of the vehicle topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
62811850|NCT04275323|EXPERIMENTAL|investigational produc|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
62811851|NCT04275323|PLACEBO_COMPARATOR|Placebo|Patients in this group will receive normal saline respective in D0、14、18
62811852|NCT01156662|ACTIVE_COMPARATOR|No aspiration|
62811853|NCT01156662|ACTIVE_COMPARATOR|Thrombus aspiration|
62811854|NCT02893917|EXPERIMENTAL|Arm A (olaparib, cediranib)|Patients receive olaparib PO BID and cediranib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62811855|NCT02893917|ACTIVE_COMPARATOR|Arm B (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62035130|NCT06265103||Children's Hospital of Orange County (CHOC)|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
62035131|NCT06265103||Mass General Hospital|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
62426229|NCT04973839|EXPERIMENTAL|Video optimizing expectations before PMR (guided)|watching a video aiming to optimize participants' expectations before undergoing a single PMR session with the personal support of the experimenter (guided)
62426230|NCT04973839|ACTIVE_COMPARATOR|Neutral video before PMR (unguided)|watching a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session without personal support of the experimenter (unguided),
62426231|NCT04973839|ACTIVE_COMPARATOR|Neutral video before PMR (guided)|watching a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session with the personal support of the experimenter (guided)
62426232|NCT03402165|EXPERIMENTAL|Normal Alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
62426233|NCT03402165|EXPERIMENTAL|Mild elevation of alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
62426234|NCT03402165|EXPERIMENTAL|High elevation of alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
62426235|NCT04948385|ACTIVE_COMPARATOR|Patients|Deep sedation for digestive endoscopy.
62426236|NCT04948385|OTHER|Escorts|Accompanying persons are the adults who accompany the patients home. They do not receive any medication or intervention.
62035132|NCT06265103||Penn State Hershey|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
62035133|NCT06265103||University of Cincinnati Gardner Neuroscience Institute|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
62035134|NCT06265103||University of Southern California (USC)|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
62035135|NCT06265103||UT Southwestern Children's Dallas|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
62811856|NCT05690984|EXPERIMENTAL|Isatuximab in combination with lenalidomide and dexamethasone.|The isatuximab, lenalidomide, and dexamethasone (IsaRD) therapy will be administered on an outpatient basis.
62811857|NCT03974048||Trauma patients|All trauma patients admitted to Rigshospitalet's trauma center will have a blood sample taken during the initial treatment and 30 days after the trauma.
62811858|NCT03974048||Patients admitted for elective orthopedic surgery|The patients will have a blood sample taken before and after surgery and again 30 days after the surgery.
62811859|NCT05161897|NO_INTERVENTION|Control Group|"This arm will receive generalized nutrition therapy throughout the study.~Participants will receive dietary recommendations based on their needs and will be educated about the recommended amount of carbohydrates for each meal and the carbohydrate choices. Participants will also be provided with a CGM device; however, participants will be blind to the CGM recordings until the end of the study."
62811860|NCT05161897|EXPERIMENTAL|Intervention Group|"This arm will receive both individualized nutrition therapy and generalized nutrition therapy throughout the study.~Participants will receive dietary recommendations based on their needs and will be educated about the recommended amount of carbohydrates for each meal and the carb choices. Participants will also be provided with a CGM device and will be educated to review their blood glucose measurements and record above range measures along with time, types and amount of food items consumed, cooking method, and any type of physical activity within one hour before or after the meal. This information will be reviewed by one of the research staff at each visit and will be used to set individualized goals for modifying diet and controlling blood glucose. Participants will visit every 10 days for 30 days to conduct measurements, replace their CGM, set new goals based on their food diary and CGM recordings, and receive further dietary recommendations."
62811861|NCT04069559|EXPERIMENTAL|Intervention Group|Intervention contain education and application about refugees health.
62811862|NCT04069559|NO_INTERVENTION|Control Group|Students of control group performed routine public health nursing practices.
62811863|NCT04423718|ACTIVE_COMPARATOR|Aflibercept 2q8|In the double-masked study part (Years 1 and 2), Aflibercept 2 mg administered every 8 weeks after a loading phase. (Active Comparator) In Year 3, high dose aflibercept administered according to individual patient response. (Experimental)
62811864|NCT04423718|EXPERIMENTAL|Aflibercept HDq12|Aflibercept high dose (HD) administered every 12 weeks after an initiation phase. Treatment intervals adjusted according to individual patient response.
62811865|NCT04423718|EXPERIMENTAL|Aflibercept HDq16|Aflibercept high dose administered every 16 weeks after an initiation phase. Treatment intervals adjusted according to individual patient response.
62811866|NCT01648712|OTHER|Balance Circuit|24 patients will be assigned to the Balance group , using a non -heparin extracorporeal pediatric device for operation . The intervention is to use the Balance circuit for this arm
62243226|NCT06012929|EXPERIMENTAL|Arm I - Presurgical|Participants who will be undergoing surgery to remove their meningioma will receive two doses of ONC201 prior to their surgery. ONC201 is taken by mouth at 625 mg per dose. ONC201 will be taken once per week with the second dose taken approximately 24 hours prior to surgery.
62243227|NCT06012929|EXPERIMENTAL|Arm II - ONC201 treatment only|Participants will receive one dose of ONC201 per week until progression. ONC201 is taken by mouth at 625 mg per dose.
62426237|NCT02996617|ACTIVE_COMPARATOR|rhG-CSF regimen|Patients weren't preventive use of rhG-CSF（ruibai 100ug）.If their WBC≤1×10\^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10\^ 9/L for total 4 courses.
62426238|NCT02996617|EXPERIMENTAL|Pegylated rhG-CSF regimen|Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle for total 4 courses.
62426239|NCT03361917|NO_INTERVENTION|Control Arm (Standard Colonscopy)|Standard colonoscopy with no device attachments
62811867|NCT01648712|OTHER|Carmeda Circuit|"24 patients will be assigned to the Carmeda group, using a coated heparin extracorporeal pediatric device for operation.~The intervention is to use the Carmeda circuit for this arm. The intervention is the Carmeda circuit."
62811868|NCT06446817|EXPERIMENTAL|LuxHighAdd|The experimental group will recieve the LuxHighAdd intraocular lens bilaterally.
62235509|NCT00059839|EXPERIMENTAL|Consolidation with Vinblastine|In courses 1-3, patients receive doxorubicin hydrochloride (30 mg/m2) IV, methotrexate (age adjusted dosing) IT, prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in arm I and vinblastine sulfate (4 mg/m2) IV over 1 minute on days 1, 8, and 15. In courses 4 and 5, patients receive doxorubicin hydrochloride (30 mg/m2) IV, prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in arm I and vinblastine sulfate (4 mg/m2) as in arm II (courses 1-3). In courses 6-15, patients receive prednisone (120 mg/m2/day) and mercaptopurine (225 mg/m2) as in arm I, vinblastine sulfate (4 mg/m2) IV as in arm II (courses 1-3), and methotrexate (60 mg/m2) IV on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity.
62426240|NCT03361917|EXPERIMENTAL|Endocuff Vision|Colonoscopy with Endocuff Vision attached to distal end of scope
62426241|NCT06506097|EXPERIMENTAL|Family-school Partnership Intervention (FSPI)|Participants include 20 non-teaching support staff (1-2 per program), 30 lead teachers (2-4 per program), and 60 children with social-communication deficits (two per teacher). FSPI creates new opportunities for teachers to partner with families, particularly parents of children with social-communication vulnerabilities. Specifically, teachers will be provided with a curriculum, training, and resources to engage two families from their classroom in three FSPI Playgroup meetings, scheduled over the course of the current school year. During each playgroup, teaches will help parents practice simple strategies for promoting communication during familiar routines such as play, book reading, preparing a snack, or completing a simple chore.
62426242|NCT01185639|EXPERIMENTAL|SBRT for metastatic NSCLC|SBRT for lung lesions, liver lesions, adrenal lesions, spinal lesions
62426243|NCT03516838|EXPERIMENTAL|ACTIVA™ BioACTIVE|Restoring cavity using ACTIVA filling material
62426244|NCT03516838|ACTIVE_COMPARATOR|Compomer|Restoring cavity using compomer filling material
62426245|NCT04243499|EXPERIMENTAL|IV ICT01 Monotherapy|Up to six ICT01 dose levels administered as IV monotherapy every 3 weeks will be tested in Part 1 Dose Escalation and up to 2 dose levels in Part 2 Cohort Expansion
62035136|NCT06265103||Brigham & Women's Hospital|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
62426246|NCT04243499|EXPERIMENTAL|IV ICT01 + IV Pembrolizumab|A range of IV ICT01 doses administered every 3 weeks will be tested in combination with 200 mg pembrolizumab in Part 1 Dose Escalation and up to 2 dose levels of ICT01 plus 200 mg pembrolizumab in Part 2 Cohort Expansion
62426247|NCT04662684|EXPERIMENTAL|Rivaroxaban|Rivaroxaban 10mg OD for 35+/- 4 days post-hospital discharge
62426248|NCT04662684|NO_INTERVENTION|No intervention|control
62594335|NCT01437709|EXPERIMENTAL|patients receiving Chemoimmunotherapy|The proposed study is a Simon 2 stage optimal study design investigating the activity of ofatumumab alone or in conjunction with Bendamustine for patients with MCL who are either not candidates for ASCT or aged 65 or older. The combined regimen will assess the response rates of the combined chemo- immunotherapy program in patients with need for cytoreductive therapy, or high risk for disease progression. Patients with a leukemic phase only presentation of mantle cell lymphoma generally have clinically low-risk disease, regardless of mantle cell IPI calculations. Upon reciew with the principal investigator, these patients may be stratified to the immunotherapy only arm if clinically appropriate.
62426249|NCT04860726|EXPERIMENTAL|GROUP A|Joint mobilization
62594336|NCT00885742|EXPERIMENTAL|FXIII|All subjects who received a dose of Factor XIII (FXIII) Concentrate (Human).
62594337|NCT05234086|ACTIVE_COMPARATOR|Advanced Healing|Activities related to wound washing, microbiological load control, care of peri-ulcer tissue and application of wound healing products in accordance to condition of the ulcer
62594338|NCT05234086|EXPERIMENTAL|InbioDerm + C plus advanced healing|For patient who are assigned treatment with InbioDerm+C plus advanced healing a section of skin tissue and peripheral venous blood will be taken. From the skin section and through an enzymatic process with cell proliferation, skin cells will be obtained that will be integrated into de the InbioDerm+C, then will be apply to the patients with the advanced wound healing every fourteen days in accordance application program.
62594339|NCT06622174|EXPERIMENTAL|Pulse Radiotherapy|Pulsed radiotherapy combined with PD(L)-1 inhibitors targeting 2 to 5 progressive extracranial lesions per cycle
62235510|NCT01653184|EXPERIMENTAL|Experimental: AREDS 2 Vitamin formula 1g|"Patients will receive oral supplementation with the commercially available AREDS2 vitamin formula (PreserVision AREDS 2 Eye Vitamin and Mineral Supplement. Bausch + Lomb Incorporated), consisting of vitamins C, E, zinc, lutein, zeaxanthin and 1g of omega-3 fatty acids in the ethyl ester formulation"
62235511|NCT01653184|EXPERIMENTAL|Eye Omega Advantage 2g|Patients will receive a similar vitamin combination in the second arm (Eye Omega Advantage® and Macular Vitamin Benefit. Physician Recommended Nutriceuticals) with 2g of omega-3 fatty acids in the triglyceride formulation (see attached document for supplement details)
62235512|NCT01117857|EXPERIMENTAL|Duloxetine|After a one-week placebo lead-in, all eligible subjects will receive Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg Duloxetine per day for 7 weeks.
62235513|NCT04208009|EXPERIMENTAL|Advance care planning animated videos|This arm consists of viewing four advance care planning videos: 1) Description of ACP; 2) Explanation of the importance of engaging in ACP now; 3) Communicating wishes to one's loved ones and family members; and 4) Communicating wishes to one's doctor.
62426250|NCT04860726|EXPERIMENTAL|GROUP B|Myofascial release
62426251|NCT04860726|EXPERIMENTAL|GROUP C|Joint Mobilization \& Myofascial release
62426252|NCT02055183||Participants treated with BAT®|Any patient of any age with a confirmed or suspected exposure to botulinum toxin who were treated with BAT®.
62426253|NCT06529458|EXPERIMENTAL|Intervention 1 Group|The researcher will apply pressure to the P6 acupressure point on both wrists for approximately 5 minutes at the same time as chemotherapy. He will also have the patient or a relative repeat the method and do it at home three times a day before meals for 5 days.
62426254|NCT06529458|EXPERIMENTAL|Intervention 2 Group|The researcher will apply drops of ginger oil to the P6 acupressure point on both wrists for approximately 5 minutes at the same time as chemotherapy, using circular motions. At the same time, the researcher will have the patient or a relative repeat the method and apply it at home three times a day before meals for 5 days.
62426255|NCT06529458|OTHER|Control Group|No interference will be made
62426256|NCT04200339||Adolescents|Adolescents between the ages of 12 and 17 years old (inclusive).
62594340|NCT03605862|ACTIVE_COMPARATOR|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily for 5 days
62594341|NCT03605862|PLACEBO_COMPARATOR|Placebo|Two placebo tablets orally twice daily for 5 days
62594342|NCT03931473|EXPERIMENTAL|Interceptor G2|Chlorfenapyr/alpha-cypermethrin
62594343|NCT03931473|EXPERIMENTAL|Royal Guard|Pyriproxyfen/alpha-cypermethrin
62594344|NCT03931473|ACTIVE_COMPARATOR|Interceptor|Alpha-cypermethrin
62735498|NCT01884181||Huntington Disease Group|Established diagnosis by a neurological examination and genetic assessment of CAG expansion in the Htt gene.
62811869|NCT06446817|ACTIVE_COMPARATOR|LuxGood group|The control group will recieve the LuxGood intraocular lens bilaterally.
62235514|NCT03890419|ACTIVE_COMPARATOR|Control Group|Control Group participants will be exposed to full spectrum light during the study.
62235515|NCT03890419|EXPERIMENTAL|Green light Group|Green light Group participants will be exposed to green light during the study.
62235516|NCT03890419|EXPERIMENTAL|Blue light Group|Blue light Group participants will be exposed to blue light during the study.
62235517|NCT03373487|EXPERIMENTAL|Early-intervention group|Patients follow the evidence-based cognitive rehabilitation program ReMind, which is provided via an iPad. It incorporates psychoeducation, strategy training and retraining. The intervention commenced 3 months after surgery and patients were advised to spend 3 hours per week on the program for 10 weeks.
62235518|NCT03373487|OTHER|Waiting-list control group|The waiting-list control group will be offered the same cognitive rehabilitation program after they have undergone all study assessments one year after surgery.
62235519|NCT02332109||ODM 5-group|
62235520|NCT03292718|EXPERIMENTAL|use of MyCyFAPP|use of MyCyFAPP during 6 months
62426257|NCT00614458|EXPERIMENTAL|Raltegravir and VPA to ART|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
62594345|NCT03776110|EXPERIMENTAL|GRT9906 80-mg dose group|"In one period, 80 mg GRT9906 (2 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4.~In the second period, a total of 7 doses of placebo (2 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
62426258|NCT01472315|ACTIVE_COMPARATOR|medroxyprogesterone acetate|
62594346|NCT03776110|EXPERIMENTAL|GRT9906 120-mg dose group|"In one period, 120 mg GRT9906 (3 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 80 mg was administered on the day before Day T. The dose administration on Day T was also performed twice daily with 12 hours apart and with non-carbonated water.~In the other period, a total of 7 doses of placebo (3 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
62594347|NCT03776110|EXPERIMENTAL|GRT9906 160-mg dose group|"In one period, 160 mg GRT9906 (4 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 80 mg was administered on Day T. The dose administration on Day T was also performed twice daily with 12 hours apart and with non-carbonated water.~In the other period, a total of 7 doses of placebo (4 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
62594348|NCT03776110|EXPERIMENTAL|GRT9906 200-mg dose group|"In one period, 200 mg GRT9906 (5 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 120 mg was administered on Day T. The dose administration on Day T was performed twice daily with 12 hours apart and with non-carbonated water.~In the other period, a total of 7 doses of placebo (5 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
62594349|NCT05310786|OTHER|Site Staff|Providers, Pharmacists, Pharmacy Technicians, Administrators to receive survey assessments
62811870|NCT05765422|OTHER|sedentary|Participant does not meet WHO's recommendations with the physical activity
62811871|NCT05765422|OTHER|OMS recommandations|Participant does not meet WHO's recommendations (2.5-5 hours per week of moderate physical activity OR 1.25-2.5 hours per week of vigorous physical activity);
62811872|NCT05765422|OTHER|More than the OMS recommandations|Participant is practicing physical activity more than the WHO recommendations
62811873|NCT01615250|NO_INTERVENTION|Standard therapy|Treatment with standard therapy. Cardiospec shock-wave therapy
62811874|NCT01615250|ACTIVE_COMPARATOR|Stem cells|Group of of intramyocardial implantation of peripheral mononuclear cells with CD34+ stem cells in patient with ischemic cardiomyopathy after preparatory course of shock - wave therapy.
62811875|NCT03253393|EXPERIMENTAL|Silicone hydrogel (with EDTA) in Smart Touch vs. in conventional packaging|Silicone hydrogel (with EDTA) in Smart Touch vs. in conventional packaging
62811876|NCT03253393|EXPERIMENTAL|Hydrogel (no EDTA) in Smart Touch vs. in conventional packaging|Hydrogel (no EDTA) in Smart Touch vs. in conventional packaging
62811877|NCT03253393|EXPERIMENTAL|Silicone hydrogel (no EDTA) vs. hydrogel (with EDTA) in Smart Touch|Silicone hydrogel (no EDTA) vs. hydrogel (with EDTA) in Smart Touch
62811878|NCT05611671|EXPERIMENTAL|Group 1|MORF-057 Dosing Regimen One for Induction and Maintenance Periods
62811879|NCT05611671|EXPERIMENTAL|Group 2|MORF-057 Dosing Regimen Two for Induction and Maintenance Periods
62811880|NCT05611671|EXPERIMENTAL|Group 3|MORF-057 Dosing Regimen Three for Induction and Maintenance Periods
62811881|NCT05611671|PLACEBO_COMPARATOR|Group 4|Matching Placebo Dosing Regimen for Induction and MORF-057 Dosing Regimen Four for Maintenance
62426259|NCT01472315|PLACEBO_COMPARATOR|Placebo|Placebo pills taken in the same way as the active comparator
62426260|NCT03958071||Subjects with Idiopathic Pulmonary Fibrosis|
62426261|NCT06346054|EXPERIMENTAL|Gastro-esophageal cancer group|Participants with gastroesophageal cancer providing a breath and blood sample for biomarker identification
62811882|NCT06152302|EXPERIMENTAL|Mobility Assessment|This study involves a single arm, without a comparator group. The comparison will be made between the data for movements in conditions outside the water and inside the water.
62811883|NCT04662567|ACTIVE_COMPARATOR|Oral acetaminophen group|the subjects in this group will receive 1000 mg oral acetaminophen 30-45min prior to oocyte retrieval
62426262|NCT06346054|ACTIVE_COMPARATOR|Barrett's esophagus group|Participants with Barrett's esophagus providing a breath and blood sample for biomarker identification
62243228|NCT06734585||External Comparator|Participants with R/R Feline McDonough Sarcoma-like Tyrosine Kinase 3 Mutation (FLT3)+AML who underwent HSCT after achieving any type of complete remission (CR) and who received best supportive care after HSCT.
62426263|NCT06346054|ACTIVE_COMPARATOR|Healthy controls|Healthy controls providing a breath and blood sample for biomarker identification
62426264|NCT02284295||occupational COPD|"Consists of 2 subgroups~1. COPD patients with history of exposure to respirable silica dust~2. COPD patients with history of exposure to aromatic hydrocarbons"
62426265|NCT02284295||smokers with COPD and healthy control|"1. patients with COPD, history of tobacco smoke and no history of occupational exposure~2. healthy subjects"
62426266|NCT00878137||APLA|Patients with antiphospholipid antibody syndrome.
62426267|NCT00878137||Control|Patients on warfarin therapy but without antiphosphilipid antibody syndrome.
62235521|NCT00001962|EXPERIMENTAL|Daclizumab in participants with a bone marrow failure syndrome|daclizumab, 1 mg/kg, will be given for a total of 5 intravenous infusions. These subjects may be diagnosed with moderate aplastic anemia, pure red cell aplasia, Diamond Blackfan anemia, relapse and refractory severe aplastic anemia will receive treatment. The subjects will be seen and receive the daclizumab infusion biweekly during the treatment period.
62811884|NCT04662567|ACTIVE_COMPARATOR|IV acetaminophen group|the subjects in this group will receive 1000 mg IV acetaminophen formulation intraoperatively
62811885|NCT01124110|OTHER|1-800-QUIT-NOW Telephone Hotline|The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
62426268|NCT02494310|EXPERIMENTAL|HRME - Prevention Mobile Unit|Procedures to be done in the mobile unit (van): Visual inspection will be performed with 5% acetic acid (VIA) applied to the cervix followed by standard colposcopy. Proflavine (0.01%) will then be applied topically. Lugol's solution will then be applied and colposcopy performed and abnormal lesions noted. HRME images will be acquired from any areas that are abnormal by VIA and/or colposcopy. VIA, colposcopy and HRME observations will recorded by quadrant. Any abnormal areas by VIA and/or colposcopy will be biopsied. If no abnormal areas are noted, one cervical biopsy will be obtained from a normal appearing area with a HRME image of this area obtained.
62811886|NCT01124110|EXPERIMENTAL|Tobacco Tactics Intervention|This intervention contains a website, medications, and nurse counseling.
62811887|NCT01449162|EXPERIMENTAL|Masitinib as add-on to oral corticosteroids|Participants receive masitinib (6 mg/kg/day), given orally twice daily, as add-on to oral corticosteroids
62811888|NCT01449162|PLACEBO_COMPARATOR|Placebo as add-on to oral corticosteroids|Participants receive placebo (6 mg/kg/day), given orally twice daily, as add-on to oral corticosteroids
62594350|NCT05310786|OTHER|Patients|Subset of patients receiving PrIMO care to receive survey assessments
62594351|NCT05104801|EXPERIMENTAL|Arm A: tislelizumab+sitravatinib|Patients will receive sitravatinib 100 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
62594352|NCT05104801|EXPERIMENTAL|Arm B: sitravatinib|Patients will receive sitravatinib 100 mg orally once daily until disease progression, unacceptable toxicity, or withdrawal of consent.
62235522|NCT04700046|ACTIVE_COMPARATOR|Mexiletine|Mexiletine 167 mg (equivalent to mexiletine HCl 200 mg)
62235523|NCT04700046|PLACEBO_COMPARATOR|Placebo|The placebo capsules contain the same ingredients as the active formulation with the exception of mexiletine
62594353|NCT00545246|EXPERIMENTAL|aflibercept + docetaxel|
62594354|NCT06138743|EXPERIMENTAL|ARO-DM1|ARO-DM1 for Injection
62594355|NCT06138743|PLACEBO_COMPARATOR|Placebo|(0.9% NaCl)
62594356|NCT02523066||Mitral Valve or Aortic Valve Replancement|One-arm group
62594357|NCT03477747|EXPERIMENTAL|Resistance Training Microcurrent|"Participants will combine a 10-week periodized and controlled resistance programme with 3 h of microcurrent after training.~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
62594358|NCT03477747|SHAM_COMPARATOR|Resistance Training Shadow|"Participants will combine a 10-week periodized and controlled resistance programme with 3 h of sham comparator after training.~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
62735499|NCT01884181||Healthy Controls|"1. The healthy control subjects without a clinically significant neuropsychiatric disorders.~2. Able to understand and provide signed informed consent.~3. Age range and gender matched with Patients with Huntington Disease Group."
62811889|NCT02126722||Patients with dyspepsia on PPI|One hundred patients on PPI will be enrolled among the patients with dyspepsia referred for gastroscopy at Homerton University Hospital. On the day of the endoscopic procedure the patients will bring a stool sample for the detection of faecal Helicobacter pylori antigen. Subsequently, a gastroscopy with multiple biopsies will be performed and during the exam NISO Biomed EndoFaster test, as well as the Clo test, will be carried out.
62235524|NCT01387919|EXPERIMENTAL|1|healthy young and lean men
62235525|NCT01681056|EXPERIMENTAL|Autosuggestion|
62235526|NCT01681056|NO_INTERVENTION|Standard medical theraphy|
62235527|NCT02042196|EXPERIMENTAL|Pre or Early perimenopausal 1|"Baseline experiment: Subjects randomized to either 1) KUVAN (10mg/kg body weight) crossover to placebo OR 2) placebo crossover to KUVAN~Hormone modification: GnRH antagonist with Cetrotide (0.25mg/d) + placebo transdermal patch, then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN"
62735500|NCT02434549|ACTIVE_COMPARATOR|Botulinum toxin-A (Dysport®)|Intramuscular injections of Botulinum toxin-A in spastic muscles with regional muscle-related pain
62426269|NCT02494310|EXPERIMENTAL|HRME - Barretos Cancer Hospital|Procedures to be done at Barretos Cancer Hospital: Visual inspection will be performed with 5% acetic acid (VIA) applied to the cervix followed by standard colposcopy. Proflavine (0.01%) will then be applied topically. Lugol's solution will then be applied and colposcopy performed and abnormal lesions noted. HRME images will be acquired from any areas that are abnormal by VIA and/or colposcopy. VIA, colposcopy and HRME observations will recorded by quadrant. Any abnormal areas by VIA and/or colposcopy will be biopsied. If no abnormal areas are noted, one cervical biopsy will be obtained from a normal appearing area with a HRME image of this area obtained.
62594359|NCT03477747|EXPERIMENTAL|Endurance Training Microcurrent|"Participants will combine a 10-week periodized and controlled endurance programme with 3 h of microcurrent after training.~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
62594360|NCT03477747|SHAM_COMPARATOR|Endurance Training Shadow|"Participants will combine a 10-week periodized and controlled endurance programme with 3 h of microcurrent after training.~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
62594361|NCT02964754|EXPERIMENTAL|the observation group|32 patients with complex long bone fractures will be randomized to undergo digital three-dimensional models will be established by CT scan for internal fixation in the observation group.
62594362|NCT02964754|EXPERIMENTAL|the control group|31 patients will be randomized to undergo conventional internal fixation in the control group.
62594363|NCT03808636||TB patients|Any patient with possible or diagnosed tuberculosis who is capable to give informed consent will be offered to be included in the trial
62235528|NCT02042196|EXPERIMENTAL|Pre or Early Perimenopausal 2|"Baseline experiment: Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN~Hormone modification: Estrogen add-back with Cetrotide + Climara (0.075mg/d), then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN"
62235529|NCT02042196|EXPERIMENTAL|Late Perimenopausal and Postmenopausal|"Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN~No hormone modification."
62426270|NCT01351727||Seniors with Seizures|Seniors aged 65 or older with newly diagnosed seizures (consistent with epilepsy) or epilepsy as of October, 2010.
62426271|NCT05160727|EXPERIMENTAL|Treatment group|"Concurrent Chemoradiotherapy:~Radiation: The dose is determined according to the treatment site and the purpose of treatment.~Irinotecan: 80mg/m2/w (UGT1A1\*28 and \*6: 6/6+GG) or 65mg/m2/w (UGT1A1\*28 and \*6: 6/7+GG or 6/6+GA) or 50mg/m2/w (UGT1A1\*28 and \*6: 7/7+GG or 6/6+AA or 6/7+GA) Tislelizumab: 200mg ivgtt d1 q3w~Consolidation therapy: 2 weeks after the completion of chemoradiotherapy. Irinotecan: 200mg/m2 ivgtt d1 q3w. Tislelizumab: 200mg ivgtt d1 q3w. Efficacy assessment every 3 cycles."
62426272|NCT01395693|EXPERIMENTAL|Salt Lake mask system|
62594364|NCT01909323|PLACEBO_COMPARATOR|sugary dessert cream|
62035137|NCT06265103||Children's Hospital Los Angeles|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
62235530|NCT01179451||Post streptococcal reactive arthritis (PSRA)|children who were diagnosed with psra at least one year before the study
62235531|NCT00634010|ACTIVE_COMPARATOR|Morphine Capsule|Morphine 15 mg slow release orally every 12 hours + additional doses as needed
62594365|NCT01909323|EXPERIMENTAL|maltitol alone|
62594366|NCT01909323|EXPERIMENTAL|maltitol 85% / FOS 15%|
62594367|NCT01909323|EXPERIMENTAL|maltitol 68% / FOS 32%|
62594368|NCT01909323|EXPERIMENTAL|maltitol 50% / FOS 50%|
62594369|NCT01909323|EXPERIMENTAL|FOS alone|
62594370|NCT02289287|EXPERIMENTAL|Self-Management group-intervention|Participants will receive Self-Management group-intervention + Standard Care
62594371|NCT02289287|ACTIVE_COMPARATOR|Standard Care|Participants will receive Standard Care only
62594372|NCT04483817|EXPERIMENTAL|A: Transcutaneous tibial nerve stimulation|The transcutaneous electrostimulation of the posterior tibial nerve (ETNTP) will be applied to group A: place two surface electrodes, one 32 mm in diameter, 5 cm cephalad of the internal malleolus and 1 cm medial posterior of the tibia; and another 50x50 mm electrode in the calcaneous. The flexion of the first toe will indicate the correct placement of the electrodes. Stimulation is performed according to the Stoller method with a stimulator programmed at 20Hz and 200 µs, with a continuous current, 12 sessions, 2 weekly are completed. The intensity of the current will be tolerance by the subject.
62235532|NCT00634010|ACTIVE_COMPARATOR|Methadone Capsule|Methadone 5 mg orally every 12 hours + additional as needed doses up to 40-50 mg/day
62235533|NCT03739931|EXPERIMENTAL|Arm A: mRNA-2752|Participants will be administered mRNA-2752 at an applicable dose as monotherapy.
62426273|NCT03969784|EXPERIMENTAL|colorectal cancer patient with peritoneal carcinosis|
62426274|NCT03969784|ACTIVE_COMPARATOR|colorectal cancer patient without metastasis|
62811890|NCT02126722||Patients with dyspepsia not on PPI|Fifty patients not on PPI will be enrolled among the patients with dyspepsia referred for gastroscopy at Homerton University Hospital. On the day of the endoscopic procedure the patients will bring a stool sample for the detection of faecal Helicobacter pylori antigen. Subsequently, a gastroscopy with multiple biopsies will be performed and during the exam NISO Biomed EndoFaster test, as well as the Clo test, will be carried out.
62235534|NCT03739931|EXPERIMENTAL|Arm B: mRNA-2752 + Durvalumab|Participants will be administered mRNA-2752 at an applicable dose in combination with durvalumab.
62235535|NCT03739931|EXPERIMENTAL|Arm C: mRNA-2752 Alone or mRNA-2752 + Durvalumab|Participants will be administered mRNA-2752 at an applicable dose as monotherapy or in combination with durvalumab.
62235536|NCT02626754|EXPERIMENTAL|Sunitinib|Sunitinib malate, 12.5mg/capsule, 50mg/day
62235537|NCT02652650|EXPERIMENTAL|Ethinylestradiol/Norethindrone|During the first oral contraceptive (OC) cycle participants will receive ethinylestradiol/norethindrone 35 microgram (mcg)/1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in). During the second OC cycle (from Day 29 to Day 56), participants will receive ethinylestradiol/norethindrone 35 mcg/1 mg alone qd for 21 days on Days 29 to 49 (Cycle II: OC alone, reference). During the third OC cycle (from Day 57 to Day 84), participants will receive ethinylestradiol/norethindrone 35 mcg/1 mg qd for 21 days on Days 57 to 77 and in addition JNJ-63623872, 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test).
62235538|NCT04723186|EXPERIMENTAL|Monotherapy of MT1002, 3 doses via intravenous (IV) + infusion|Three doses of MT1002 (IV loading + continuous IV infusion) will be sequentially tested. The first dose level is 0.90 mg/kg initial loading dose (bolus intravenous injection) + 1.8 mg/kg/h (infusion) for 4 hours. The second dose level will be based on the results from the first cohort (If the dose is escalated, then the second dose level is 1.2 mg/kg initial loading dose (bolus intravenous injection) + 2.3 mg/kg/h (infusion) for 4 hours; if the dose is de-escalated, then the second dose level is 0.6 mg/kg initial loading dose (bolus intravenous injection) + 1.2 mg/kg/h (infusion) for 4 hours). The third dose will be determined based on the results from the first 2 cohorts.
62235539|NCT04256434|EXPERIMENTAL|Dinabuphine sebacate|Each subject in cohort 1 will receive 150 mg Dinalbuphine sebacate (75 mg/mL x 2 mL) intramuscularly.
62426275|NCT02551302|OTHER|PLIF|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF).
62426276|NCT02551302|OTHER|Hybrid system (PLIF + flexible pedicle screw system above the|The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion.
62235540|NCT04256434|ACTIVE_COMPARATOR|Nalbuphine HCl|Each subject in cohort 2 will receive 20 mg Nalbuphine (20 mg x 1 mL) intramuscularly.
62235541|NCT01938469|OTHER|Solid Meal|Participants in this group will be administered only solid meals on both study visits completed before surgery (T0) and 12-15 months after (T1).
62235542|NCT01938469|OTHER|Liquid Meal|Participants in this group will be administered only liquid meals on both study visits completed before surgery (T0) and 12-15 months after (T1).
62235543|NCT05009745|EXPERIMENTAL|Intervention|"The intervention will be PGT-A strategy involving trophectoderm biopsy and comprehensive chromosome screening (CCS) using Next Generation Sequencing (NGS). All embryos will be frozen after the biopsy procedure and transferred in a subsequent frozen-thawed embryo transfer. Embryo selection for transfer will be based on morphological criteria and the genetic screening result.~Only euploid embryos or mosaic euploid embryos deemed suitable to be transferred will be replaced into the uterus in a subsequent frozen-thawed embryo transfer cycles."
62235544|NCT05009745|NO_INTERVENTION|Control arm|Women in the control arm will have the fresh embryo transfer procedure on day 5 following egg collection, or a frozen-thawed embryo transfer as first line over a fresh embryo transfer, if clinically indicated. Embryo selection for transfer will be based on morphological criteria.
62235545|NCT01728532|ACTIVE_COMPARATOR|Pulp Canal Sealer (Kerr)|zinc oxide eugenol sealer
62235546|NCT01728532|EXPERIMENTAL|PA0903|type C implant according to ISO 7405:2008 and ISO 10993 guidelines.
62235547|NCT02652962|EXPERIMENTAL|Gelesis200 x 2, 10 min|3 x 0.70g Gelesis200 capsules administered 10 minutes before each of 2 meals (breakfast, lunch).
62235548|NCT02652962|EXPERIMENTAL|Gelesis200 x 2, 30 min|3 x 0.70g Gelesis200 capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
62235549|NCT02652962|PLACEBO_COMPARATOR|Placebo x 2, 10 min|3 x Placebo capsules administered 10 minutes before each of 2 meals (breakfast, lunch).
62235550|NCT02652962|PLACEBO_COMPARATOR|Placebo x 2, 30 min|3 x Placebo capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
62235551|NCT02652962|EXPERIMENTAL|Gelesis200 x 3, 10 min|3 x 0.70g Gelesis200 capsules administered 10 minutes before each of 3 meals (breakfast, lunch, dinner).
62235552|NCT02652962|EXPERIMENTAL|Gelesis200 x 3, 30 min|3 x 0.70g Gelesis200 capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
62235553|NCT02652962|PLACEBO_COMPARATOR|Placebo x 3, 10 min|3 x Placebo capsules administered 10 minutes before each of 3 meals (breakfast, lunch, dinner).
62594373|NCT04483817|ACTIVE_COMPARATOR|B: Percutaneous tibial nerve stimulation|The percutaneous electrostimulation of the posterior tibial nerve (EPNTP) will be applied to group B: inserting a 0.25x30mm surgical steel needle at a 60º angle, 5 cm cephalad to the malleolus and 1 cm posterior of the tibia , and a surface electrode of 50x50 mm in the calcaneous. The flexion of the first finger will indicate its correct placement. The stimulation parameters will also follow the Stoller method.
62235554|NCT02652962|PLACEBO_COMPARATOR|Placebo x 3, 30 min|3 x Placebo capsules administered 30 minutes before each of 3 meals (breakfast, lunch, dinner).
62235555|NCT02045966|EXPERIMENTAL|Arm 1: Cocktail + DCV 3DAA FDC + BMS-791325|"Treatment A: Cocktail of CYP and transporter probe substrates orally as a single dose on Day 1~Treatment B: DCV 3DAA FDC tablet administered orally BID on Days 6 to 15~Treatment C: DCV 3DAA FDC tablet administered orally BID on Days 16 to 20, plus the cocktail of CYP and transporter probe substrates administered orally as a single dose on Day 16 only~Treatment D: DCV 3DAA FDC tablet plus BMS-791325 75-mg single-agent tablet administered orally BID on Days 21 to 30~Treatment E: DCV 3DAA FDC tablet plus BMS-791325 75-mg single-agent tablet administered orally BID on Days 31 to 35, plus the cocktail of CYP and transporter probe substrates administered orally as a single dose on Day 31 only"
62235556|NCT00728481|ACTIVE_COMPARATOR|Esomeprazole|Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks for subjects with positive 24 hour pH study (GERD)
62235557|NCT00728481|ACTIVE_COMPARATOR|Budesonide|Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose \[Splenda-registered trademark\]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
62235558|NCT04186299|EXPERIMENTAL|Clonidine + articaine/epinephrine|1.7mL of 4% articaine/epinephrine(1:100,000) + clonidine (15ug/ml)
62235559|NCT04186299|ACTIVE_COMPARATOR|articaine/epinephrine|1.7mL of 4% articaine with 1:100,000 epinephrine
62235560|NCT01135706||Pulmonary Hypertension|Patients having a right heart catheterization and CT pulmonary angiogram with a diagnosis of Pulmonary Hypertension
62235561|NCT01135706||Non Pulmonary Hypertension|Patients having a right heart catheterization and CT pulmonary angiogram without a diagnosis of Pulmonary Hypertension.
62235562|NCT03635333|EXPERIMENTAL|Low nicotine, tobacco|6 mg nicotine combined with tobacco flavored e-juice
62811891|NCT02326623|EXPERIMENTAL|iPad distraction|The intervention will be the use of an iPad that will include a selection of child-appropriate games. We will select popular, age-appropriate items to include on the iPad, chosen based on the most current online consumer ratings. Children and parents will be able to select their choice of distraction and can change their selection as desired during the course of the procedure. These choices will be recorded for study purposes.
62811892|NCT02326623|OTHER|standard care|The control group will receive standard care, which generally includes the use of topical anesthetic cream.
62811893|NCT03488095|OTHER|Behavior changing intervention|Thirty minutes behavior counselling (PPT.) to experimental group. BCI for SLT and BQ Use in Adolescents: A CRT
62235563|NCT03635333|EXPERIMENTAL|Low nicotine, menthol|6 mg nicotine combined with menthol flavored e-juice
62235564|NCT03635333|EXPERIMENTAL|Low nicotine, strawberry|6 mg nicotine combined with strawberry flavored e-juice
62235565|NCT03635333|EXPERIMENTAL|High nicotine, tobacco|18 mg nicotine combined with tobacco flavored e-juice
62235566|NCT03635333|EXPERIMENTAL|High nicotine, menthol|18 mg nicotine combined with menthol flavored e-juice
62235567|NCT03635333|EXPERIMENTAL|Hign Nicotine, strawberry|18 mg nicotine combined with strawberry flavored e-juice
62235568|NCT05988554|PLACEBO_COMPARATOR|Placebo sachet|
62235569|NCT05988554|EXPERIMENTAL|Hibiscus sabdariffa extract and collagen products|
62235570|NCT05300074|EXPERIMENTAL|Training two times per week|Training two times per week. IMT with 5 rounds and 12 repetitions in each round at 60-80% MIP. The primary protocol will end at 6 weeks and the self-administered long-term protocol will end at 12 months after intervention start.
62426277|NCT02038959|NO_INTERVENTION|Usual Care and Educational Materials|Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.
62426278|NCT02038959|EXPERIMENTAL|Virtual Visits and Educational Materials|Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.
62426279|NCT04234152|EXPERIMENTAL|MV Photo-protection|Includes infants in whom the new procedure of MV separation and photo-protection will be applied. This arm will be stratified to male and female 1:1
62426280|NCT04234152|PLACEBO_COMPARATOR|Standard of care|Includes infants in whom the standard method of preparation and infusion of PN will be applied. This arm will be stratified to male and female 1:1
62426281|NCT04064528|ACTIVE_COMPARATOR|Young|Young adults will be given a 10 g oral bolus of amino acids.
62426282|NCT04064528|EXPERIMENTAL|Older Adults|Older adults will be given a 10 g oral bolus of amino acids.
62426283|NCT01409018|EXPERIMENTAL|Itraconazole|
62811894|NCT03488095|NO_INTERVENTION|Control Cluster|No thirty minutes behavior counselling (PPT.) to control group
62811895|NCT06408870|EXPERIMENTAL|BI 1015550 Formulation C2 (Test, T) then BI 1015550 Formulation C1 (Reference, R)|
62811896|NCT06408870|EXPERIMENTAL|BI 1015550 Formulation C1 (Reference, R) then BI 1015550 Formulation C2 (Test, T)|
62811897|NCT06398210|EXPERIMENTAL|Group exercise|Patients will be included in group exercise, 36 sessions in total; He/she will attend BETY-group sessions lasting 1 hour, 3 times a week for 12 weeks.
62811898|NCT06398210|EXPERIMENTAL|Individual exercise|Patients will be included in individual exercise, 36 sessions in total; He/she will attend BETY-individual sessions lasting 1 hour, 3 times a week for 12 weeks.
62811899|NCT06398210|NO_INTERVENTION|Control|In the control group, exercise recommendations will be given as a home program according to the symptoms of the individuals.
62811900|NCT00445549|EXPERIMENTAL|Vandetanib treatment|300 mg daily oral dose, 28 day cycle
62235571|NCT05300074|EXPERIMENTAL|Training five times per week|Training five times per week. IMT with 5 rounds and 12 repetitions in each round at 60-80% MIP. The primary protocol will end at 6 weeks and the self-administered long-term protocol will end at 12 months after intervention start.
62426284|NCT01077531|ACTIVE_COMPARATOR|Otelixizumab|Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
62811901|NCT06068868|EXPERIMENTAL|ABBV-787|Participants will receive increasing doses of ABBV-787 until the maximum tolerated dose (MTD) during the 3 year treatment period.
62811902|NCT02560038|EXPERIMENTAL|Combination chemotherapy|Combination chemotherapy consisting of gemcitabine and cisplatin plus paclitaxel on a 21-day cycle.
62811903|NCT05440877|EXPERIMENTAL|Intervention group|Provided with a tutorial guide, and VR-based teaching materials in the tutorial session
62811904|NCT05440877|EXPERIMENTAL|Control group|Provided with the tutorial guide in the tutorial session.
62811905|NCT05574296|EXPERIMENTAL|Usual care + H2 therapy|Hydrogen administered via mechanical ventilator and sweep gas into ECMO membrane for 72 hours
62811906|NCT05574296|ACTIVE_COMPARATOR|Usual care|The current standard of care.
62811907|NCT04836468|EXPERIMENTAL|Experimental group|Application of Magnetic Tape transversely over the vertebral levels of L4 and L5
62811908|NCT04836468|PLACEBO_COMPARATOR|Placebo group|Application of kinesiology tape transversely over the vertebral levels of L4 and L5
62811909|NCT02558725|NO_INTERVENTION|one capsule of iron supplement|instructed to take one capsule at least 2 hours after consumption of dairy products
62811910|NCT02558725|ACTIVE_COMPARATOR|two capsules of iron supplement|instructed to take two capsules of Aktiferrin F at least 2 hours after consumption of dairy products
62811911|NCT01849510|EXPERIMENTAL|dose intensified|hypofractionated 12x3 Gy + integrated boost 12x4 Gy
62811912|NCT01849510|ACTIVE_COMPARATOR|standard|hypofractionated 10x3 Gy
62811913|NCT03313869|EXPERIMENTAL|Control|"Intervention: Reduction in daily steps up to 2000-3000 steps per day and no structured physical activity + High dose ingestion of fructose (3g/kg/day) glucose (0,5g/kg/day)in the last 10 days of the protocol No cocktail during the protocol~Healthy male volunteers in the active range of population (10000 to 15000 steps per day) aged 20-45 years, 22 BMI 27 158 cm height 190 cm, Certified as healthy by a comprehensive clinical assessment."
62811914|NCT03313869|EXPERIMENTAL|Cocktail intervention|"Intervention: Reduction in daily steps up to 2000-3000 steps per day and no structured physical activity + High dose ingestion of fructose (3g/kg/day) glucose (0,5g/kg/day)in the last 10 days of the protocol + Micronutrient cocktail supplementation with 560,7 mg/ day of polyphenols (3 pills/day), 2,1 g/day of omega-3 fatty-acids (3 pills/day), 168 mg/day of vitamin E and 80µg/day of selenium (1 pill/day)~Healthy male volunteers in the active range of population (10000 to 15000 steps per day) aged 20-45 years, 22 BMI 27 158 cm height 190 cm, Certified as healthy by a comprehensive clinical assessment."
62811915|NCT06061991|EXPERIMENTAL|Intervention group|Mobile instant messaging-based lifestyle intervention
62426285|NCT01077531|PLACEBO_COMPARATOR|Placebo|Matching placebo for intravenous infusion
62735501|NCT02434549|PLACEBO_COMPARATOR|Normal saline|Intramuscular injections of normal saline solution in spastic muscles with regional muscle-related pain
62811916|NCT06061991|ACTIVE_COMPARATOR|Control group|Brief advice on GDM prevention
62811917|NCT02782676|EXPERIMENTAL|Investigational Healon5 OVD|Subjects to receive investigational Healon5 OVD in one eye and control Healon5 in the fellow eye.
62811918|NCT02782676|ACTIVE_COMPARATOR|Approved Healon5 OVD|Subjects to receive investigational Healon5 OVD in one eye and control Healon5 in the fellow eye.
62426286|NCT03174509|ACTIVE_COMPARATOR|Positive Pressure Extubation|Positive pressure extubation is used for patients in this group.
62426287|NCT03174509|ACTIVE_COMPARATOR|Traditional Extubation|Traditional extubation is used for patients in this group.
62235572|NCT01097239|EXPERIMENTAL|High Intensity Focused Ultrasound|Transrectal High Intensity Focused Ultrasound (HIFU) treatment of the PelvicTumour
62426288|NCT02464085||Longitudinal evaluation of recovery|Stroke survivors with subacute and severe upper limb disability
62426289|NCT01523769|NO_INTERVENTION|Control|Control group, the cord was not milked
62426290|NCT01523769|EXPERIMENTAL|Umbilical Cord Milking|Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery
62426291|NCT05402319|EXPERIMENTAL|Antibiotic monotherapy|Single antibiotic is given intravenously or orally (systemically).
62811919|NCT03482726|OTHER|Cycling Cadence Modulation|3 initial visits to collect baseline information; 6-week HIIT indoor cycling program at the individual prescribed cadence; final study visit for post-intervention measures.
62811920|NCT06408662|EXPERIMENTAL|mindfulness-based intervention for tics (MBIT)|This is an 8-week mindfulness-based group intervention delivered via telehealth. It consists of mindfulness and meditative practice, didactics, inquiry, discussion and weekly therapeutic exercises and assignments (i.e., homework).
62811921|NCT06408662|ACTIVE_COMPARATOR|psychoeducation with relaxation and supportive therapy (PRST)|This is an 8-week educational and supportive therapy group intervention delivered via telehealth. It consists of psychoeducation, relaxation, discussion, and weekly therapeutic exercises and assignments (i.e., homework).
62594374|NCT04532190|EXPERIMENTAL|Active rTMS|Active repetitive TMS parameters will be intensity 120% resting motor threshold (RMT), 40 pulses over 4 seconds (frequency 10Hz), inter-trial interval of 26 seconds, 75 trains, 3000 pulses/session to the right superior frontal gyrus, duration of 37.5 minutes per session.
62594375|NCT04532190|SHAM_COMPARATOR|Sham rTMS|For sham rTMS, set-up, duration, and sound (i.e. clicking sound) will be the same, but no magnetic field will be emitted from the rTMS coil.
62594376|NCT04102254|EXPERIMENTAL|ANT recording and stimulation|Up to 15 adult patients who present to Duke Neurosurgery for routine seizure location using sEEG will be asked to enroll in this pilot study of ANT recording and stimulation. Once enrolled in the trial, subjects will have additional placement of two thalamic electrodes during the course of standard sEEG placement surgery. Patients routinely remain hospitalized for 7-14 days after sEEG placement, during which time their seizure medications are tapered. Continuous neural recordings are made through the sEEG electrodes for the purposes of seizure localization during the entire time the depth electrodes are in place. Up to three times daily, standard intermittent high-frequency stimulation \[130 Hertz (Hz), 90-millisecond pulse width, and 2 milliamps (mA) intensity\] will be performed with a 60-seconds on and a 300-seconds off cycle following surgery up to the entire length of sEEG monitoring.
62594377|NCT06137573|EXPERIMENTAL|[14C]TNP-2198|Participants will take a single dose of 600mg 150μCi of \[14C\]TNP-2198.
62426292|NCT05402319|EXPERIMENTAL|Antibiotic combination therapy|At least two different antibiotics are given intravenously or orally.
62426293|NCT05402319|EXPERIMENTAL|Topical antibiotic therapy|Single antibiotic bladder irrigation.
62426294|NCT02006407|OTHER|Primary Brain Tumor|Patients receiving standard cranial radiotherapy will undergo (1) Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI) and (2) Neuro-cognitive testing (CogState-a computerized software testing system that offers various cognitive assessments based on traditional expansive neurocognitive tests) at four timepoints (Baseline, 3 weeks, 6 weeks and 6 months).
62426295|NCT05721716|EXPERIMENTAL|Mindfulness Booster Course|
62594378|NCT06090903|EXPERIMENTAL|Screening (MRI)|Patients undergo one MRI scan over approximately 1 hour prior to surgery.
62594379|NCT05933200|EXPERIMENTAL|Triheptanoin|Participants will be given prescriptions for Triheptanoin in mL/day, which will be divided into approximately 4 administrations per day, with precise instructions for administration. Triheptanoin will be titrated up to the first 6 weeks of the study. After titration, the dose is to remain stable for the remainder of the Double-blind Treatment Period.
62594380|NCT05933200|ACTIVE_COMPARATOR|MCT|Participants will be given prescriptions for MCT in mL/day, which will be divided into approximately 4 administrations per day, with precise instructions for administration. MCT will be titrated up to the first 6 weeks of the study. After titration, the dose is to remain stable for the remainder of the Double-blind Treatment Period.
62811922|NCT02861612||Nerve Transfer|This is an observational study that looks at function and quality of life in patients before and after nerve transfer surgery.
62811923|NCT04066868|EXPERIMENTAL|PRO active|
62811924|NCT04066868|ACTIVE_COMPARATOR|PRO not active|
62811925|NCT04333563|ACTIVE_COMPARATOR|CPAP|respiratory stressed infants getting Continuous positive airway pressure (CPAP)
62811926|NCT04333563|EXPERIMENTAL|respiratory stressed infants getting NIV NAVA|respiratory stressed infants getting Non-invasive neurally adjusted ventilatory assist (NIV NAVA)
62811927|NCT01692184|EXPERIMENTAL|50 mg of AVL-292 and Placebo|50 mg AVL-292 (2 x 25 mg AVL-292 capsules and 6 placebo capsules) once daily for 7 days administered orally under fasted condition
62811928|NCT01692184|EXPERIMENTAL|100 mg of AVL-292 and Placebo|100 mg AVL-292 (4 x 25 mg AVL-292 capsules and 4 placebo capsules) once daily for 7 days administered orally under fasted condition
62811929|NCT01692184|EXPERIMENTAL|200 mg AVL-292|8 x 25 mg AVL-292 capsules orally once daily for 7 days under fasted condition
62811930|NCT01692184|EXPERIMENTAL|350 mg of AVL-292|350 mg AVL-292 (14 x 25 mg AVL-292 capsules) once daily for 7 days administered orally under fasted condition
62426296|NCT05721716|OTHER|Treatment as Usual Control|
62426297|NCT05013255|ACTIVE_COMPARATOR|Pioglitazone 15mg Dose|Subjects will be given PIO 15mg once daily, based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
62426298|NCT05013255|ACTIVE_COMPARATOR|Pioglitazone 30mg Dose|Subjects will be given PIO 30mg once daily, based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
62426299|NCT05013255|NO_INTERVENTION|No Drug|Subjects will be assigned to a no drug control group based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
62426300|NCT04716673|EXPERIMENTAL|Children (4-11y) with epilepsy|Down-phase-targeted closed-loop auditory stimulation is administered in each arm.
62426301|NCT04716673|EXPERIMENTAL|Teenagers (12-17y) with epilepsy|
62426302|NCT04716673|EXPERIMENTAL|Young adults (18-30y) with epilepsy|
62426303|NCT04716673|EXPERIMENTAL|Healthy children (4-11y)|
62426304|NCT04716673|EXPERIMENTAL|Healthy teenagers (12-17y)|
62426305|NCT04716673|EXPERIMENTAL|Healthy young adults (18-30y)|
62426306|NCT00569335|EXPERIMENTAL|1|S-1, Irinotecan, Bevacizumab
62426307|NCT02311543|NO_INTERVENTION|Arm A: no TachoSil®|After axillary lymph node dissection no surgical sealing patch (TachoSil®) is applied.
62426308|NCT02311543|ACTIVE_COMPARATOR|Arm B: TachoSil®|After axillary lymph node dissection, 3 large TachoSil® patches in the dissected axilla are positioned to cover as much of the axillary walls as possible.
62235573|NCT02797353|EXPERIMENTAL|Intervention Arm|Antenatal Care, Post natal care, Skilled birth attendance, recognition and referrals of complicated cases, immunization
62235574|NCT02797353|NO_INTERVENTION|Control|This arm will receive the standard MNCH services as outlined in the MNCH policy of Government of Pakistan
62811931|NCT01692184|PLACEBO_COMPARATOR|Placebo - 8 capsules|8 placebo capsules once daily for 7 days administered orally under fasted condition
62235575|NCT04335240|EXPERIMENTAL|Music Therapy Intervention|"This protocol is a Family Centered Care Music Therapy Intervention. The methodologies will provide early intervention from the first days of hospitalization in NICU and consist of music therapy sessions both active (parental chant, live music and lullaby) and receptive (listening to recorded tracks). The music therapy accompanies the newborn and the parents during the hospitalization and focuses its attention on the emotional-relational care, according to the different needs that they will develop over time.Therapy sessions will be performed starting from three times per week, on three different days of the week, during the entire hospitalization of the enrolled infants. After discharge music therapy treatment will be performed once a week until twelve months of corrected age.~Stress level of infants and parents and neurobehavioral and neurological development of children will be assessed."
62235576|NCT04335240|NO_INTERVENTION|No music therapy intervention|Music therapy is not administered in this group. Control group (no music therapy). During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit.
62235577|NCT00701233|ACTIVE_COMPARATOR|2|Corticosteroid injection into Carpal Tunnel
62235578|NCT00701233|ACTIVE_COMPARATOR|1|Botulinum toxin injection into Carpal Tunnel
62235579|NCT04571827|EXPERIMENTAL|Placebo Effect|"Group with positive expectation: it is a very effective technique that achieves excellent results in the improvement of the cervical musculature~Before the treatment, it will be explained to the patient that the study seeks to observe if pain appears after the dry needling. During the explanation, the desired expectation will be introduced."
62811932|NCT01692184|PLACEBO_COMPARATOR|Placebo - 14 capsules|14 placebo capsules once daily for 7 days administered orally under fasted condition
62811933|NCT01651481|EXPERIMENTAL|TR|HCP1102(Singulair and Xyzal combination tablet) -\> coadministration of Singulair and Xyzal
62811934|NCT01651481|EXPERIMENTAL|RT|coadministration of Singulair and Xyzal -\> HCP1102(Singulair and Xyzal combination tablet)
62811935|NCT06340295||new-onset COPD group|FEV1/FVC\<0.7 after bronchodilator inhalation during 3 years of follow-up
62811936|NCT06340295||Continuous PRISm group|After bronchodilator inhalation, FEV1/FVC≥70% and the percentage of FEV1pred%\<80% during 3 years of follow-up
62811937|NCT06340295||PRISm to normal group|After bronchodilator inhalation, FEV1/FVC≥0.7 and FEV1pred% ≥80% during 3 years of follow-up
62235580|NCT04571827|EXPERIMENTAL|Nocebo Effect|"Group with negative expectation: this is a technique that will cause discomfort in the area of intervention of the cervical muscles after applying it .~Before the treatment, it will be explained to the patient that the study seeks to observe if pain appears after the dry needling. During the explanation, the desired expectation will be introduced."
62235581|NCT04571827|EXPERIMENTAL|Neutral Effect|"Group with neutral expectations: It's a physical therapy technique used to treat neck pain and we're investigating its effects~Before the treatment, it will be explained to the patient that the study seeks to observe if pain appears after the dry needling. During the explanation, the desired expectation will be introduced."
62811938|NCT02021201|EXPERIMENTAL|1|Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound
62811939|NCT02021201|EXPERIMENTAL|2|Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound
62235582|NCT02277405|EXPERIMENTAL|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
62243229|NCT06734585||Gilteritinib|Participants with R/R FLT3+AML who were enrolled in the ADMIRAL and COMMORDORE phase 3 studies that resumed gilteritinib after HSCT to maintain remission.
62811940|NCT01706458|ACTIVE_COMPARATOR|sipuleucel-T|Patients receive sipuleucel-T IV on weeks 0, 2, and 4.
62811941|NCT01706458|EXPERIMENTAL|sipuleucel-T with DNA Vaccine|Patients receive sipuleucel-T as patients in arm I and pTVG-HP plasmid DNA vaccine ID on weeks 6, 8, 10, and 12, and then at 6 and 9 months.
62811942|NCT01512485|EXPERIMENTAL|Clopidogrel|Clopidogrel tablets 75 mg of Dr. Reddy's Laboratories Limited
62811943|NCT01512485|ACTIVE_COMPARATOR|Plavix|Clopidogrel Tablet 75 mg
62811944|NCT02660177|EXPERIMENTAL|metamizole|single IV metamizole (10mg/kg) administration
62811945|NCT06005415|ACTIVE_COMPARATOR|Test cookie|Wire-cut cookie portion (85 g) containing wheat flour, coarse wheat semolina, sucrose, vegetable shortening, water, sodium chloride, sodium bicarbonate and sodium octanoate.
62811946|NCT06005415|ACTIVE_COMPARATOR|Control cookie|Wire-cut cookie portion (85 g) containing wheat flour, wheat bran, sucrose, vegetable shortening, water, sodium chloride, sodium bicarbonate and sodium octanoate.
62811947|NCT01921205|EXPERIMENTAL|Lacosamide|
62811948|NCT01921205|PLACEBO_COMPARATOR|Placebo|
62811949|NCT05356286|EXPERIMENTAL|Electrical Stimulation group|Epidural Electrical Stimulation of the Cervical Spinal Cord
62811950|NCT02857517|EXPERIMENTAL|intravitreal 0.05ml conbercept for ICNV|0.05ml conbercept ,1 injection with PRN
62235583|NCT02277405|EXPERIMENTAL|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
62235584|NCT05050253|EXPERIMENTAL|SOS group|Peritoneal lavage with super-oxidized solution (SOS)
62235585|NCT05050253|ACTIVE_COMPARATOR|Control group|Peritoneal lavage with Ringer's solution
62811951|NCT06438822|EXPERIMENTAL|Cadonilimab+NIFU regimen|There will be two cohorts. Cohort 1 includes patients who have failed first-line treatment with gemcitabine-based chemotherapy combined with PD-L1/PD-1 monoclonal antibody immunotherapy. Cohort 2 includes patients who have failed chemotherapy with gemcitabine-based chemotherapy as a first-line treatment and who had not been treated with PD-L1/PD-1 monoclonal antibody immunotherapy.
62811952|NCT04836052|EXPERIMENTAL|omega-3-oil arm|patients admitted to ICU in HMC on any kind of oxygen support will get omega-3-oil 2 gm PO/NGT/OGT twice daily for 28 days or till ICU discharge or till death .
62811953|NCT04836052|NO_INTERVENTION|standard of care arm ( no omega -3-oil )|patients admitted to ICU in HMC on any kind of oxygen support will get ( standard of care= No Omega-3-oil ) but their labs will be monitored
62811954|NCT04558177|EXPERIMENTAL|Stimulation Group|Will receive \~1.5mA transcranial stimulation for 20 minutes, 5x per week from a direct current stimulator
62811955|NCT04558177|SHAM_COMPARATOR|Device placed only, no stim|Same as experimental group but the stimulation from the direct current stimulator will be initiated and then stopped
62811956|NCT05694390|EXPERIMENTAL|Experimental group: The group applied sterile transparent film dressing|The nurses in the unit were trained by the charge nurse of the clinic on catheter-related complications (infiltration, extravasation, phlebitis, and occlusion), the scales used in the study, and the use of sterile transparent film dressing. In the experimental group, a sterile transparent film dressing was used to fix the catheter and was monitored hourly until the catheter was removed.
62811957|NCT05694390|NO_INTERVENTION|Control group: The group applied fixed with a tape (blaster)|The nurses in the unit were trained by the charge nurse of the clinic on catheter-related complications (infiltration, extravasation, phlebitis, and occlusion), the scales used in the study, and the use of sterile transparent film dressing. In the control group, the catheter was fixed with a tape (blaster), routinely used in the clinic, and was monitored hourly until the catheter was removed.
62811958|NCT04281407|EXPERIMENTAL|Probiotics treatment on midazolam and acetaminophen metabolism|"Experimental:~Day 1: midazolam (2 mg oral) + acetaminophen (500 mg oral) + midazolam (1 mg IV) Days 1-28: Visbiome (2 capsules) administered BID Day 11: midazolam (2 mg oral) + acetaminophen (500 mg oral) + midazolam (1 mg IV)"
62811959|NCT05011942|PLACEBO_COMPARATOR|normal saline control arm|ii. normal saline used after initial skin incision prior to coming through fascia, after placement of instrumentation (screws, hooks), prior to placement of bone graft, and after fascial closure iii. Irrigation exposure/soak time to be 1 min for each irrigation time point.
62235586|NCT03188354|EXPERIMENTAL|CNS lymphoma patients|Patients included in the study will be examined with both 18F-FDG and 18F-Fluciclovine as well as standard MRI in the PET/MRI scanner on two consecutive days, both in primary staging and for therapy assessment
62235587|NCT04777747||viral infection|a child is infected by virus only
62811960|NCT05011942|ACTIVE_COMPARATOR|Irrisept irrigation solution|ii. Irrigation (Irrisept vs control of normal saline) used after initial skin inicision prior to coming through fascia, after placement of instrumentation (screws, hooks), prior to placement of bone graft, and after fascial closure iii. Irrigation exposure/soak time to be 1 min for each irrigation time point. iv. 1 bottle (450 mL) Irrisept irrigation to be used during case with normal saline rinse to follow at each irrigation time point in study subjects
62811961|NCT00674479|EXPERIMENTAL|INCB018424|The starting dose of INCB018424 will be 25 mg by mouth twice daily.
62811962|NCT05901701|EXPERIMENTAL|LASER group|Group A: Patients received applications of low-level laser therapy using semiconductor InGaAsp diode LASER type 940 nm with continuous mode of operation, with time of application 180 sec per session for 12 sessions.
62235588|NCT04777747||viral and bacterial infection|a child is infected by virus and progress to bacterial infection
62235589|NCT03008447|EXPERIMENTAL|LEM5; LEM10; PBO; ZOL|Participants will receive LEM5 (one lemborexant \[LEM\] 5 milligram \[mg\] tablet and one zolpidem \[ZOL\]-matched placebo \[PBO\] tablet) in Treatment Period 1. In Treatment Period 2, participants will receive LEM10 (one LEM 10 mg tablet and one ZOL-matched PBO tablet). In Treatment Period 3, participants will receive PBO (one LEM-matched PBO tablet and one ZOL-matched PBO tablet). In Treatment Period 4, participants will receive ZOL (one LEM-matched PBO tablet and one ZOL 6.25 mg tablet).
62426309|NCT00176501|EXPERIMENTAL|Irradiated allogeneic lymphocytes|
62426310|NCT03467971|EXPERIMENTAL|Metformin-Gliclazide (fasted), Then Metformin-Gliclazide (fed)|Participants received single dose of Metformin 1000 milligram (mg) and Gliclazide 30 mg fixed combination tablet in fasting state in treatment period 1 followed by single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fed state in treatment period 2. Each treatment period was separated by a 14-day wash-out period.
62426311|NCT03467971|EXPERIMENTAL|Metformin-Gliclazide (fed), Then Metformin-Gliclazide (fasted)|Participants received single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fed state in treatment period 1 followed by single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting state in treatment period 2. Each treatment period will be separated by a 14-day wash-out period.
62235590|NCT03008447|EXPERIMENTAL|LEM10; ZOL; LEM5; PBO|Participants will receive LEM10, ZOL, LEM5, and PBO in Treatments Periods 1, 2, 3, and 4, respectively.
62235591|NCT03008447|EXPERIMENTAL|ZOL; PBO; LEM10; LEM5|Participants will receive ZOL, PBO, LEM10, and LEM5 in Treatment Periods 1, 2, 3, and 4, respectively.
62235592|NCT03008447|EXPERIMENTAL|PBO; LEM5; ZOL; LEM10|Participants will receive PBO, LEM5, ZOL, and LEM10 in Treatment Periods 1, 2, 3, and 4, respectively.
62235593|NCT04426448|EXPERIMENTAL|Intervention group|Participants will receive the BREATHE intervention for three weeks
62235594|NCT04426448|NO_INTERVENTION|Control group|The participants will receive treatment as usual
62235595|NCT02701738|EXPERIMENTAL|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (\~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
62235596|NCT02573454|EXPERIMENTAL|Prosocial Exercise|Participants are provided with the intervention (App Assignment). In this arm, the participants are randomly assigned to the Prosocial Exercise group use a GPS exercise app named Charity Miles, in which users can earn donations for charities based on the miles they walk or run (approximately 25 cents for every mile).
62235597|NCT02573454|ACTIVE_COMPARATOR|Personal Exercise|Participants are provided with the intervention (App Assignment). In this arm, the participants are randomly assigned to the Personal Exercise group use a traditional GPS exercise app named Nike + Running, in which users can track the mileage that they walk or run (i.e., there is no opportunity to earn donations for charity through exercise behaviour).
62235598|NCT01808729||FMD or CAD (as appropriate)|The study group will either have FMD, early onset CAD, or other rare/unusual vascular disorder. These differing disorders will be sub-groups within the overall study
62235599|NCT01808729||Healthy control subjects without vascular disease|Healthy controls will not exhibit signs, symptoms or other evidence of vascular disease.
62235600|NCT03837379|OTHER|Treatment As Usual|Participants in the Treatment As Usual condition will receive educational material on quitting smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
62235601|NCT03837379|EXPERIMENTAL|Goal2Quit + NRT Sampling|"Participants in the Goal2Quit + NRT Sampling condition will receive a download code to download the Goal2Quit mobile application. Goal2Quit is a mobile app for cigarette smokers with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, rate mood daily, and track cigarette smoking. Participants in Group B will also receive a two-week starter kit sample of nicotine replacement therapy (NRT; 14mg patch and 4mg lozenge). Participants will be asked to utilize Goal2Quit regularly, at least once per day, as well as the NRT sample in an attempt to quit smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment."
62235602|NCT04354805|EXPERIMENTAL|Group A|The group of 50 patients are going to receive Chlorpromazine (oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days) every 24 hours for 14 days in addition to the convential treatment of COVID-19 according to the Egyptian Ministry of Health protocol.
62235603|NCT04354805|NO_INTERVENTION|Group B|A group of 50 patients control group who will recieve only the convential treatment of COVID-19 according to the Egyptian Ministry of Health protocol.
62235604|NCT02804243|ACTIVE_COMPARATOR|nasal high flow therapy|In this group, patients have undergone rehabilitation under the nasal high flow therapy (FiO2 100%, oxygen flow from 30 to 60 L/min) during four weeks.
62235605|NCT02804243|NO_INTERVENTION|oxygen therapy|In this group, patients have undergone rehabilitation under the oxygen therapy via a nasal canula (6 L/min) during four weeks.
62235606|NCT01207661|EXPERIMENTAL|Mesenchymal Injection|Intra Articular injection in Patients with osteoarthritis of knee joint
62235607|NCT05259254|PLACEBO_COMPARATOR|Standard Direct Observed Therapy (DOT)|After a patient was diagnosed with TB, they will be provided TB therapy which is consist of health education and anti-TB medication. Patient that is not in life-threatening condition typically will be treated as outpatient. Patient will receive medication that will be monitored closely through DOT, which is either by health facilities (by healthcare staff), or community (by family members or community members). Observation of medication will be conducted daily, and the health care staff will sign the DOT diary provided to the patient to verify the medication consumption.
62235608|NCT05259254|ACTIVE_COMPARATOR|Mobile application DOT|The mobile application will be consisting of four basic modules which are: 1) reminder system, 2) visual observed therapy, 3) feedback, and 4) health education. Researcher will teach patient on how to record, and send video of every dose of medication ingested every day. Participants also required to show their mouth is empty by opening their mouth and sticking out their tongue. The participants also are required to record and send the self-recorded video of ingesting the medication daily. Researcher will subsequently view the video through a password protected website. The observation of taking medication will be completed until the end of study period.
62235609|NCT04109196|EXPERIMENTAL|Intensive 5-day Cognitive Processing Therapy for PTSD|Participants who are eligible for and enrolled in the study will receive a 5-day CPT treatment for PTSD. All participants will be asked to complete clinician-rated and self-report assessments at multiple time points during the study. Participants will also be asked to provide fecal and saliva samples as part of the study, however, they may opt out of biological sample collection.
62235610|NCT00221195|OTHER|On-demand first|Patients receive 6 months of on-demand therapy with study drug followed by 6 months of prophylaxis therapy with study drug
62235611|NCT00221195|OTHER|Prophylaxis first|Patients receive 6 months of prophylaxis therapy with study drug followed by 6 months on-demand therapy with study drug
62426312|NCT05291156|EXPERIMENTAL|Cetuximab + avelumab|"Cetuximab + avelumab (115 patients) - cetuximab at 400 mg/m2, as loading dose, and, subsequently, at 250 mg/m2 weekly, and avelumab was given intravenously at flat dose of 800 mg, once every 2 weeks.~Treatment will continue until disease progression, significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled. Treatment may continue past the initial determination of disease progression per RECIST 1.1 if the subject's performance status has remained stable, and if in the opinion of the Investigator, the subject will benefit from continued treatment and if other criteria are fulfilled as outlined in the protocol."
62235612|NCT03099200||Cohort 1|Participants with early breast cancer currently undergoing treatment (either chemotherapy and targeted HER2 therapy OR targeted HER2 therapy alone) will be observed.
62811963|NCT05901701|ACTIVE_COMPARATOR|Splint group|Group B: Patients received hard occlusal splints (Michigan splints), used for 3 months during sleeping then the patient stops using it and told to only wear it if discomfort return usually during stressful times.
62035138|NCT06265103||University of Colorado Anshutz|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
62235613|NCT03099200||Cohort 2|Participants with early breast cancer who have completed treatment and are in disease-free survival (i.e. no longer receiving loco-regional treatment, chemotherapy or targeted HER2 therapy; participants may still be receiving hormone therapy) will be observed.
62811964|NCT03469752|EXPERIMENTAL|Intervention group|8 weekly education sessions 2.5 hours
62811965|NCT03469752|NO_INTERVENTION|Wait-list control group|No education sessions
62811966|NCT01691144||recently treated patients|
62594381|NCT05555524|EXPERIMENTAL|Baby oil|"A cool commercial baby oil at a temperature between 10°C and 15°C that composed of Paraffinum Liquidum, Isopropyl Palmitate, Parfumwill be applied to the affected area for a period of 15-20 min for three times a week before each hemodialysis session for 12 weeks.~the baby oil bottle will be stored at the refrigerator."
62811967|NCT01691144||2-3 years after treatment|
62235614|NCT03099200||Cohort 3|Participants receiving treatment for metastatic breast cancer will be observed.
62811968|NCT01933581||ACS undergoing CA and PCI|Patients with Acute Coronary Syndrome undergoing coronary angiography and PCI
62811969|NCT02025894||PCVCs|Cohort of cancer patients with indication PCVC under the usual practice
62811970|NCT05425602|EXPERIMENTAL|MAX40279-01+KN046|"This is an open-label Phase I/II clinical study.~Drug: Stage1: Dose1:MAX40279-01 (35mg BID)+KN046 ( 5mg/kg Q3Week)~Drug: Stage1: Dose2:MAX40279-01( 50mg BID)+KN046 ( 5mg/kg Q3Week)~Drug: Stage1: Dose3:MAX40279-01( 70mg BID)+KN046 ( 5mg/kg Q3Week)~Drug: Stage2: Dose3:MAX40279-01( RP2D BID)+KN046 ( 5mg/kg Q3Week)"
62811971|NCT01145534|ACTIVE_COMPARATOR|Glibenclamide|Patients used 5 mg glibenclamide daily for 60 days
62811972|NCT01145534|EXPERIMENTAL|Experimental|Patients ingested the infusion of Cissus verticillata L. prepared as 1 g in 150 mL of hot water for 10 min. This was done daily for 60 days
62235615|NCT00298909|EXPERIMENTAL|1|niacin
62235616|NCT00298909|ACTIVE_COMPARATOR|2|physical exercise
62235617|NCT00298909|PLACEBO_COMPARATOR|3|control
62235618|NCT05424913|OTHER|Subjects with Dunnigan's Lipodystrophy|
62235619|NCT05424913|OTHER|Non-lipodystrophic insulin-resistant subjects|
62235620|NCT05424913|OTHER|Insulin-sensitive non-lipodystrophic subjects|
62811973|NCT04590664|EXPERIMENTAL|Treatment (verteporfin)|Patients receive verteporfin IV over 83 minutes weekly for 6 weeks in cycle 1, then weekly for 5 weeks in subsequent cycles. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62811974|NCT04002960|EXPERIMENTAL|INVSENSOR00036|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00036 sensor
62811975|NCT04506840|EXPERIMENTAL|Training group|Participants will participate in a program of physical exercise during the adjuvant chemotherapy treatment
62811976|NCT04506840|NO_INTERVENTION|Not training group|Participants will not do any intervention, they only will be perform the pre and post-tests.
62811977|NCT05549726|EXPERIMENTAL|Dynamic choice prevention (including CAB LA)|The Dynamic Choice Delivery Model includes integrated PrEP and PEP services at outpatient clinics, antenatal clinics, and via VHT workers in community households. CAB-LA will be integrated into the dynamic choice delivery model as an additional biomedical prevention option in a patient-centered delivery model based on the precede framework.
62811978|NCT05549726|ACTIVE_COMPARATOR|Standard of Care|The standard of care for PEP or PrEP differs according to each country's guidelines.
62811979|NCT00574808|EXPERIMENTAL|intervention|Outreach Facilitation implementing elements of the Chronic Care Model. The facilitators will provide hands on support to practices and help to implement tools and processes designed to incorporate evidence-based practice into the routine delivery of cardiovascular care. Specifically, they will a) assist with practice performance assessment, feedback, and consensus building towards goal setting, b) offer clinical, technical, organizational resources and practical advice, and c) provide encouragement to face and overcome the challenges of implementing system change.
62811980|NCT00574808|NO_INTERVENTION|control|Baseline data before implementation of the program will serve as the control. Comparisons will be made between baseline and post-intervention within each divisions of primary care practices as well as between divisions (ie. baseline information from one division will serve as the control for another).
62235621|NCT04326127||Control|Healthy volunteers
62235622|NCT04326127||Case|Volunteers with diagnosed sleep apnea
62235623|NCT01208441|EXPERIMENTAL|Arm I|"Patients receive oral letrozole once daily on days 1-21. Beginning in course 2, patients also receive oral RO4929097 on days 1-3, 8-10, and 15-18. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Beginning 1 week after completion of neoadjuvant therapy, patients undergo surgery or tumor biopsy. Patients continue to receive oral letrozole once daily during surgery and for an additional 4 weeks."
62235624|NCT06186453|EXPERIMENTAL|Intervention group|Father-Preterm Newborn Bonding Program
62235625|NCT06186453|NO_INTERVENTION|Control group|Routine nursing care will be applied
62235626|NCT03057977|EXPERIMENTAL|Empagliflozin|
62235627|NCT03057977|PLACEBO_COMPARATOR|Placebo|
62235628|NCT04291352|EXPERIMENTAL|Taurine|675mg taurine four times daily
62235629|NCT04291352|PLACEBO_COMPARATOR|Placebo|placebo four times daily
62811981|NCT02763306|EXPERIMENTAL|Treatment with cryotherapy|Treatment with dermal cooling system.
62811982|NCT04254393|EXPERIMENTAL|Early Adolescent Skills for Emotions (EASE) Program|Early Adolescent Skills for Emotions (EASE) is a new, brief, targeted, group psychological intervention program (Dawson et al., 2019) based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (WHO, 2016).
62235630|NCT05519397||No response|The breast cancer patients with no response to neoadjuvant therapy
62235631|NCT05519397||Moderate response|The breast cancer patients with moderate response to neoadjuvant therapy
62235632|NCT05519397||Good response|The breast cancer patients with good response to neoadjuvant therapy
62235633|NCT02901041|EXPERIMENTAL|Zonisamide & Computerized Psychotherapy|Zonisamide capsules (with a target maintenance dose of 400 mg daily) and a seven module computerized psychotherapy for alcohol use disorders called Take Control (9 sessions) will be administered over the course of 12 weeks, followed by a two week medication taper.
62811983|NCT04254393|PLACEBO_COMPARATOR|Treatment as Usual (TAU)|Participants in control arm will be able to avail the routine services available in school settings.
62811984|NCT04647370|ACTIVE_COMPARATOR|Remote ischemic preconditioning|
62811985|NCT04647370|SHAM_COMPARATOR|Sham remote ischemic preconditioning|
62426313|NCT05291156|ACTIVE_COMPARATOR|Cetuximab|Cetuximab only (58 patients) - cetuximab at 400 mg/m2 intravenously, as loading dose, and, subsequently, at 250 mg/m2 weekly. Treatment will continue until disease progression, significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled. Treatment may continue past the initial determination of disease progression per RECIST 1.1 if the subject's performance status has remained stable, and if in the opinion of the Investigator, the subject will benefit from continued treatment and if other criteria are fulfilled as outlined in the protocol.
62426314|NCT00153868|ACTIVE_COMPARATOR|1|Darbepoetin alfa 200 mcg with escalation to 300 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 2 weeks for 12 weeks (weeks 1, 3, 5, 7, 9, and 11)
62426315|NCT00153868|ACTIVE_COMPARATOR|2|darbepoetin alfa 300 mcg with escalation to 500 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 3 weeks for 12 weeks (weeks 1, 4, 7, and 10)
62811986|NCT06132451|NO_INTERVENTION|Usual practice arm|Patients will be treated according to their treating physicians' decision.
62811987|NCT06132451|OTHER|Postponement of treatment arm|Antihypertensive treatment adaptions will be postponed until after a 24h ambulatory blood pressure measurement (ABPM) 4 weeks after hospital discharge.
62811988|NCT06144554||Omnipod User|All new users for the Omnipod 5 System will be required to register with Insulet's Podder Central. Users already in Podder Central will be required to log into their account before logging into the Omnipod 5 Controller if transitioning to the Omnipod 5 System. As part of the onboarding process, users will be invited to participate in this registry.
62811989|NCT00308139|EXPERIMENTAL|Exenatide Once Weekly|Subcutaneous injection (SC), once a week of long acting release (LAR) exenatide.
62811990|NCT00308139|ACTIVE_COMPARATOR|Exenatide Twice Daily|"subcutaneous injection (SC), twice a day for the first 30 weeks, followed by exenatide LAR SC injection weekly for the remainder of the study.~Sub-study: Exenatide 2 mg subcutaneous injection, Administered Using the Exenatide Once Weekly Single-Dose Tray , once a week for 11 visits, switch to Exenatide 2 mg subcutaneous injection, Administered Using the Dual chamber pen device. Exenatide 2mg SC injection administered using the Dual chamber pen device."
62235634|NCT02901041|ACTIVE_COMPARATOR|Placebo & Computerized Psychotherapy|Placebo capsules (for zonisamide) and a seven module computerized psychotherapy for alcohol use disorders called Take Control will be administered over the course of 14 weeks.
62235635|NCT02608281|OTHER|CEDEM|diagnostic contrast enhanced Dual Energy mammograms after Iodine based contrast media administration compared to CE MRI
62235636|NCT05264428|EXPERIMENTAL|Experimental group|Participants need to drink honey every day for four weeks.
62235637|NCT05264428|PLACEBO_COMPARATOR|Control group|Participants need to drink water every day for four weeks.
62235638|NCT01110811|ACTIVE_COMPARATOR|TIF procedure|Transoral Incisionless Fundoplication (TIF)
62235639|NCT01110811|SHAM_COMPARATOR|Sham procedure|The intervention on the Sham procedure consisted of an upper gastrointestinal endoscopy, or EGD.(esophagogastricduodenoscopy).
62235640|NCT01298518|EXPERIMENTAL|PF-04620110|
62235641|NCT01298518|PLACEBO_COMPARATOR|placebo|
62235642|NCT05798897|EXPERIMENTAL|Single Arm Study|Single arm study evaluating MT-601 investigational product at 200 million cells and 400 million cells per dose
62811991|NCT05490186|ACTIVE_COMPARATOR|Manual Adjusted Mechanical Alignment|"Usual care:~* Midline incision, no tourniquet, medial Parapatellar arthrotomy, resect anterior osteophytes~* Distal femoral cut with 3-5 degrees of valgus from the anatomical axis (Based on the angle measurement on the 4 foot standing Xray). Correct for flexion contracture.~* Measure the femoral size with the anterior referencing guides. Use 3 degrees external rotation to the Posterior condylar axis~* Perform anterior, posterior and chamfer cuts with the 4 in 1 in appropriate external rotation~* Extramedullary tibial alignment guide with 3-5 degrees posterior slope, and orthogonal cut to the tibial axis.~* Resect posterior osteophytes~* Place trial components and perform appropriate release/balance the gaps~* Patellar replacement based on surgeon's discretion~* Cementing the components with tourniquet inflation"
62035139|NCT05450848|EXPERIMENTAL|StrataXRT|Patients allocated to receive StrataXRT will be provided with StrataXRT gel to apply twice daily to the irradiated area until any radiation dermatitis that may occur has resolved. In case the patient develops radiation dermatitis that results in moist desquamation, IntraSiteTM gel (Smith and Nephew, UK) and secondary dressings will be provided.
62035140|NCT05450848|ACTIVE_COMPARATOR|Standard of care|Patients allocated to receive standard care will be provided with aqueous cream to apply daily to the irradiated area until any radiation dermatitis that may occur has resolved. In case the patient develops radiation dermatitis that results in moist desquamation, IntraSiteTM gel (Smith and Nephew, UK) and secondary dressings will be provided.
62235643|NCT04487574|EXPERIMENTAL|XC221|"XC221 100 mg orally.~1 tablet of XC221 100 mg 2 times a day during 14 days of treatment period."
62235644|NCT04487574|PLACEBO_COMPARATOR|Placebo|"Placebo orally.~1 tablet of Placebo 2 times a day during 14 days of treatment period"
62235645|NCT03823560|EXPERIMENTAL|GROUP A: medical device Celegyn®|"Medical device Celegyn® presents itself as a white ivory cream (cream-like oil-in-water topical emulsion) with a typical smell; it is intended for topical use.~Posology: It is to be applied preferably in the evening, once a day, for the first seven days, and every other day until the end of the study (i.e. during the second and third week) according to the following:~* for external (vulvar) use: it should be applied as needed directly to the affected area with a gentle massage;~* for internal (vaginal) use: use the vaginal applicators provided and follow the directions of use, according to package insert"
62243230|NCT03538353|OTHER|Pain Education Video|Participants will watch a pain education video and then answer several questions.
62594382|NCT05555524|PLACEBO_COMPARATOR|Placebo|"A cool distilled water at a temperature between 10°C and 15°C with added two drops of the baby oil to each 100 cc will be applied to the affected area for a period of 15-20 min for three times a week before each hemodialysis session for 12 weeks.~the distilled water will be put at an identical bottle as the baby oil bottle and stored at the refrigerator."
62811992|NCT05490186|EXPERIMENTAL|Robotic Assisted Adjusted Mechanical Alignment|"* Midline incision, no tourniquet, medial Parapatellar arthrotomy, resect anterior osteophytes~* Place the femoral pins in the proximal incision and the tibial pins 4 finger breadths under the joint line~* Map the knee and perform evaluation~* Assess gaps, adjust the femoral axis to decrease soft tissue release (+/- 2 degrees), correct for flexion contracture~* Verify and perform distal femoral cut, proximal tibial cut orthogonal (90 Degrees) to the tibial axis~* Assess and balance extension gap with appropriate releases~* Remap the posterior condylar axis, assess the flexion space, 3 degrees external rotation to the posterior condylar axis~* Perform anterior, posterior and chamber cuts with the 4 in 1 (appropriate external rotation), followed by posterior osteophyte resection~* Place trial components and balance the knee, soft tissue releases (1-2 mm)~* Patellar replacement based on surgeon's discretion~* Cementing the components with tourniquet inflation"
62819593|NCT03501082|PLACEBO_COMPARATOR|Placebo, Non-Industrialized-Type Diet Start|Participants will receive the non-industrialized-type diet for 3 weeks, followed by a crossover to 3 weeks of consuming their usual diet after a 3-week washout period. Participants will be provided with a one-time dose of a placebo solution on day 4 of each diet period. The placebo solution will be provided as a drinkable solution (2 g maltodextrin dissolved in 50 ml water in food grade conditions).
62035141|NCT03594448||Ancillary-correlative (Specimen collection)|Participants undergo collection of blood samples in addition to the usual amount collected when they come in for their regular cancer treatments or doctor?s appointment every 6-8 weeks until disease progression or stopping at 9 months.
62243231|NCT06734221|EXPERIMENTAL|PAK DCB catheter|Peripheral revascularization procedure using a PAK DCB catheter covered with paclitaxel.
62035142|NCT00909012|PLACEBO_COMPARATOR|1|
62035143|NCT00909012|EXPERIMENTAL|2|
62035144|NCT00909012|EXPERIMENTAL|3|
62035145|NCT00909012|EXPERIMENTAL|4|
62035146|NCT00909012|EXPERIMENTAL|5|
62035147|NCT04450108|EXPERIMENTAL|Test Cohort|Subjects age 7 to 80 with asthma
62035148|NCT06427226|NO_INTERVENTION|Control Group|23 breast cancer patients which will receive four cycles of AC regimen (Doxorubicin and Cyclophosamide; each cycle is given every 21 days) only.
62035149|NCT06427226|ACTIVE_COMPARATOR|Dapagliflozin group|23 breast cancer patients which will receive four cycles of AC regimen (Doxorubicin and Cyclophosamide; each cycle is given every 21 days) plus Dapagliflozin 10 mg once daily.
62035150|NCT04729257|OTHER|Group A1 (Norms + Validation, 18-49 years) + Group A2 (Validation, 50+ years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: Participants' cognition is measured using paper-pencil tests.
62426316|NCT04123483|EXPERIMENTAL|EnBrace HR for Acute Treatment of PMS and MRMD|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 8 weeks. Participants are currently experiencing clinically significant MRMD symptoms, defined as a ≥ 30% increase in the total Daily Record of Severity of Problems Scale (DRSP) score from the mid-follicular phase (average of DRSP scores for days 6-10) to the late-luteal phase (average of DRSP scores for last 5 days prior to menstrual bleeding).
62035151|NCT04729257|OTHER|Group B (Validation, 18+)|Visit 1: Participants' cognition is measured using paper-pencil tests. Visit 2: Participants' cognition is measured using digital tests.
62035152|NCT04729257|OTHER|Group C1 (Norms + Validation, 18-49 years) + Group C2 (Validation, 50+ years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: Participants' cognition is measured using digital tests.
62426317|NCT04144725||Suspected coronary artery disease|Patients hospitalized for suspected acute coronary syndrome who are referred to CCTA or patients referred to CCTA from outpatient clinics for evaluation of stable coronary artery disease.
62235646|NCT03823560|PLACEBO_COMPARATOR|GROUP B: matching placebo|"Investigational Product (IP) placebo presents itself as a white ivory cream (cream-like oil-in-water topical emulsion) with a typical smell; it is intended for topical use.~Posology: It is to be applied preferably in the evening, once a day, for the first seven days, and every other day until the end of the study (i.e. during the second and third week) according to the following:~* for external (vulvar) use: it should be applied as needed directly to the affected area with a gentle massage;~* for internal (vaginal) use: use the vaginal applicators provided and follow the directions of use, according to package insert"
62235647|NCT03295656|EXPERIMENTAL|IV Contrast-Enhanced US|IV sulfur hexafluoride lipid-type A microspheres, 0.03 mL/kg, 2 doses per examination, total dose not to exceed 4.8 mL. Single examination per patient.
62594383|NCT06521645|EXPERIMENTAL|Acupoint stimulation|electrodes are attached to the skin of Neiguan acupoint, and transcutaneous electrical acupoint stimulation is given
62594384|NCT06521645|SHAM_COMPARATOR|Control|electrodes are attached to the skin of Neiguan acupoint, but no transcutaneous electrical acupoint stimulation is given
62594385|NCT06593886|EXPERIMENTAL|Group A|This group will participate in active motor training at NIH while using the BabyG device immediately
62035153|NCT04729257|OTHER|Group D (Validation, 18+)|Visit 1: Participants' cognition is measured using paper-pencil tests. Visit 2: Participants' cognition is measured using paper-pencil tests.
62235648|NCT05928130|EXPERIMENTAL|Volume Training Group|Participants in this group will undergo a plyometric training protocol at a known effective volume that is expected to induce changes in lower limb strength, power, and muscle activity.
62235649|NCT05928130|EXPERIMENTAL|Reduced Volume Training Group|Participants in this group will undergo a plyometric training protocol at a lower volume than the Volume Training Group, aiming to determine if a lower volume still leads to significant improvements in lower limb strength, power, and muscle activity.
62235650|NCT05928130|NO_INTERVENTION|Control Group|Participants in this group will not undergo any plyometric training and will serve as a comparison to assess the natural progression of lower limb strength, power, and muscle activity without intervention.
62426318|NCT03665974||Women with gestational diabetes mellitus|GDM screening at this hospital involves a two-step procedure. The diagnosis of GDM was confirmed if at least 2 of 4 glucose levels exceed based on Carpenter-Coustan criteria: fasting ≥ 95 mg/dL (5.3 mmol/L), 1 hour ≥ 180 mg/dL ( 10.0 mmol/L), 2 hour ≥ 155 mg/dL (8.6 mmol/L), and 3 hour ≥ 140 mg/dL (7.8 mmol/L).
62819594|NCT03501082|EXPERIMENTAL|L. reuteri PB-W1, Usual Diet Start|Participants will consume their usual diet for 3 weeks, followed by a crossover to 3 weeks of consuming the provided non-industrialized-type diet after a 3-week washout period. Participants will be provided with a one-time dose of L. reuteri PB-W1 strain on day 4 of each diet period. The L. reuteri PB-W1 strain will be provided as a drinkable solution (approximately 2.25x10\^10 viable cells will be provided in 50 ml of water).
62426319|NCT03665974||Women non gestational diabetes mellitus|Women with normal serum glucose levels ≤129 mg/dL (7.2 mmol/L) after GCT.
62426320|NCT00827073|ACTIVE_COMPARATOR|Tetracaine 0.5% drop|Tetracaine 0.5% drop of betadine will be used on the operative eye after Tetracaine has been administered
62426321|NCT00827073|ACTIVE_COMPARATOR|Lidocaine 2% Jelly|Lidocaine 2% Jelly drop of betadine will be used on the operative eye after Lidocaine 2% Jelly has been administered
62426322|NCT05673369|EXPERIMENTAL|Group 1|Period 1: Reference drug Period 2: Test drug
62426323|NCT05673369|EXPERIMENTAL|Group 2|Period 1: Test drug Period 2: Reference drug
62426324|NCT03251209|EXPERIMENTAL|Group 1|Post-stroke participants receive the mental practice before the physical practice. The activities will be presented in a videotherapy way.
61088179|NCT06692907|EXPERIMENTAL|Cohort 1A|Participants will receive 45 mcg CssBA with 0.5 mcg dmLT vaccine intramuscular injection on Days 1, 22 and 43, outpatient. Participants who meet challenge criteria will orally receive 1x10\^10 cfu of ETEC strain B7A, inpatient, approximately 28 days after the third dose of study agent. N= 18.
62426325|NCT03251209|EXPERIMENTAL|Group 2|Post-stroke participants receive the mental practice after the physical practice. The activities will be presented in a videotherapy way.
62426326|NCT03251209|ACTIVE_COMPARATOR|Group 3|Post-stroke participants receive only physical practice. The activities will be presented in a videotherapy way.
62426327|NCT05567601|ACTIVE_COMPARATOR|Current Manufacturing Site|On Day 1 of Cycle 1 of the open-label treatment phase, patients will be randomized to receive drug from either current or new manufacturing site, and then after 28 days cross-over to the drug produced from the other manufacturing site in Cycle 2.
62426328|NCT05567601|EXPERIMENTAL|New Manufacturing Site|On Day 1 of Cycle 1 of the open-label treatment phase, patients will be randomized to receive drug from either current or new manufacturing site, and then after 28 days cross-over to the drug produced from the other manufacturing site in Cycle 2.
62594386|NCT06593886|EXPERIMENTAL|Group B|This group will participate in BabyG training after a 12 week baseline period
62594387|NCT02341495|EXPERIMENTAL|Drug Treatment|Deferasirox (20mg/kg/day)on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Cholecalciferol(4,000 units/day), on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol, repeated every four weeks for 8 cycles given either subcutaneously or IV
62819595|NCT03501082|EXPERIMENTAL|L. reuteri DSM20016T, Usual Diet Start|Participants will consume their usual diet for 3 weeks, followed by a crossover to 3 weeks of consuming the provided non-industrialized-type diet after a 3-week washout period. Participants will be provided with a one-time dose of L. reuteri DSM20016T strain on day 4 of each diet period. The L. reuteri DSM20016T strain will be provided as a drinkable solution (approximately 2.25x10\^10 viable cells will be provided in 50 ml of water).
62819596|NCT03501082|PLACEBO_COMPARATOR|Placebo, Usual Diet Start|Participants will consume their usual diet for 3 weeks, followed by a crossover to 3 weeks of consuming the provided non-industrialized-type diet after a 3-week washout period. Participants will be provided with a one-time dose of a placebo solution on day 4 of each diet period. The placebo solution will be provided as a drinkable solution (2 g maltodextrin dissolved in 50 ml water in food grade conditions).
62819597|NCT04500158|EXPERIMENTAL|Local anesthesia|Participants will receive local anesthesia in addition to the standard care general anesthesia
62035154|NCT04729257|OTHER|Group E (Norms, 18-49 years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: N/A
62035155|NCT04729257|OTHER|Group F (Norms, 80-95 years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: N/A
62035156|NCT05873114|EXPERIMENTAL|Muscle Energy Technique (MET)|
62035157|NCT05873114|OTHER|Mobilization|
62819598|NCT04500158|NO_INTERVENTION|Standard care|Participants will receive standard care general anesthesia
62819599|NCT06172959|EXPERIMENTAL|Vocal Therapy Group|Participants in this group will receive Vocal Intonation Therapy (VIT) and Therapeutic Singing (TS) for up to three weeks
61088180|NCT06692907|PLACEBO_COMPARATOR|Cohort 1B|Participants will receive 0.6 mL of 0.9% normal saline intramuscular injection on Days 1, 22 and 43, outpatient. Participants who meet challenge criteria will orally receive 1x10\^10 cfu of ETEC strain B7A, inpatient, approximately 28 days after the third dose of study agent . N= 18.
61088181|NCT06692907|EXPERIMENTAL|Cohort 2A|Participants will receive 45 mcg CssBA with 0.5 mcg dmLT vaccine intramuscular injection on Days 1, 22 and 43, outpatient. Participants who meet the challenge criteria will orally receive 1x10\^10 cfu of ETEC strain B7A, inpatient, approximately 28 days after the third dose of study agent. N= 18.
61088182|NCT06692907|PLACEBO_COMPARATOR|Cohort 2B|Participants will receive 0.6 mL of 0.9% normal saline intramuscular injection on Days 1, 22 and 43, outpatient. Participants who meet the challenge criteria will orally receive 1x10\^10 cfu of ETEC strain B7A, inpatient, approximately 28 days after the third dose of study agent. N= 18.
62819600|NCT06589219|ACTIVE_COMPARATOR|Part 1 SAD CMR316|Single ascending dose, nebulized administration of CMR316
62235651|NCT01306955|ACTIVE_COMPARATOR|methylprednisolone|patients who received methylprednisolone
62235652|NCT01306955|PLACEBO_COMPARATOR|dextrose water 5%|patients who received dextrose water 5% as placebo
62235653|NCT04725825|EXPERIMENTAL|Dry needling|"A single dry needling session will be performed on the dominant painful trapezius muscle, with the patient lying in prone position. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into skin surface, fascia, into the muscle tissue at the MTrP location, and will move the needle up and down (fast-in, fast-out technique) in three different directions.~In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct."
62235654|NCT04725825|SHAM_COMPARATOR|Sham needling|A single sham needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated.
62235655|NCT04490733|EXPERIMENTAL|Experimental group|Participants in the experimental group will receive 3 times interventions during 10th to 12th course of chemotherapy and 12 weekly phone-call to assess effect and barriers of dual-task walking.
62235656|NCT04490733|NO_INTERVENTION|Control group|Participants in control group will receive usual care.
62819601|NCT06589219|PLACEBO_COMPARATOR|Part 1 SAD Placebo|Single ascending dose, nebulized administration of matching placebo
62035158|NCT03843229|EXPERIMENTAL|treatment group|The treatment group receives Cinobufacini injection 20ml via hepatic artery during Transarterial Chemoembolization(TACE) operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
62035159|NCT03843229|OTHER|control group|The control group only receives Transarterial Chemoembolization (TACE).
62235657|NCT01163721|EXPERIMENTAL|Ranolazine|Participants were randomized to receive ranolazine for 12 weeks.
62235658|NCT01163721|PLACEBO_COMPARATOR|Placebo|Participants were randomized to receive placebo to match ranolazine for 12 weeks.
62819602|NCT06589219|ACTIVE_COMPARATOR|Part 2 MAD CMR316|Multiple ascending dose, nebulized administration of CMR316 once weekly for 4 weeks
62819603|NCT06589219|PLACEBO_COMPARATOR|Part 2 MAD Placebo|Multiple ascending dose, nebulized administration of matching placebo once weekly for 4 weeks
62235659|NCT03197363||Białystok PLUS|Participation in the study will be offered to 10000 inhabitants of Bialystok aged 20-80 years. They will be randomly selected from the registry of Bialystok inhabitants. The goal of study is to discover novel risk factors and mechanisms underlying civilization diseases.
62235660|NCT03130543|NO_INTERVENTION|Standard Formula|This is the group of subjects randomized to receive their standard formula
62594388|NCT06422104|ACTIVE_COMPARATOR|10 Hz rTMS to premotor cortex|10 Hz rTMS to premotor cortex
62819604|NCT06589219|EXPERIMENTAL|Part 3 IPF Patients|Open-label, nebulized administration of CMR316 once weekly for 4 weeks for patients with IPF
62819605|NCT03684616||Statin treatment prior to cardiac arrest|
62819606|NCT03684616||No Statin treatment prior to cardiac arrest|
62819607|NCT02227914|EXPERIMENTAL|Oprozomib with Sorafenib|"Phase 1b:~Oprozomib doses will be escalated in sequential groups of at least 2 subjects. Study subjects will receive oprozomib at dose levels of 90, 120, 150, 180, 210, or 240 mg + sorafenib to reach the dose levels of 600 or 800 mg total daily dose until the maximum tolerated dose (MTD) is reached.~Phase 2:~Study subjects who meet the entry criteria will receive oprozomib + sorafenib at the RP2D (recommended Phase 2 dose) established in the Phase 1b portion of the study."
62819608|NCT02227914|ACTIVE_COMPARATOR|Sorafenib|"Phase 2:~Study subjects who meet the entry criteria will receive sorafenib 400 mg twice a day (800 mg total daily dose)."
62819609|NCT03964727|EXPERIMENTAL|Sacituzumab Govitecan-hziy|Participants with non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), endometrial cancer, or metastatic small cell lung cancer (mSCLC) will receive sacituzumab govitecan-hziy 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle until disease progression (PD), toxicity or withdrawal of consent.
62819610|NCT04586478|EXPERIMENTAL|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
62819611|NCT02177695|EXPERIMENTAL|Gemcitabine & Cisplatin|Gemcitabine, 1000 mg/m2, IV, Days 1\&8, q 21 days x 4 cycles Cisplatin, 70 mg/m2, IV, Day 1, q 21 days x 4 cycles
62811993|NCT05490186|EXPERIMENTAL|Robotic Assisted Kinematic Alignment: (Joint line restoration)|"-- Midline incision, no tourniquet, medial parapatellar arthrotomy, resect anterior osteophytes~* Place femoral pins in proximal incision, tibial pins 4 finger breadths under joint line~* Map and evaluate the knee, ROM, varus valgus testing at 0 \& 90 degrees flexion~* Distal femoral cut based on cartilage loss on medial and lateral femoral condyle (9mm total cut/condyle).~* Perform distal femoral cut, maintain the joint line (femoral axis +/- 5 degrees)~* Perform proximal tibial cut within +/- 3 degrees, balance the gaps, differential between medial and lateral gaps = 1- 3mm.~* Assess extension space, resect posterior osteophytes~* Remap posterior condylar axis, place 4 in 1 at 0 degrees to the post condylar axis (aim = 9mm posterior condylar cuts)~* Resect posterior osteophytes, place trial components. Adjust cuts to achieve a balanced knee, maintain HKA axis +/- 3 degrees~* Patellar replacement per surgeon discretion~* Cement the components with tourniquet inflation"
62811994|NCT02570503|EXPERIMENTAL|ROP/KET/CLON/EPI/SAL|Ropivacaine (ROP) (5mg/ml)- 50ml Ketorolac (KET) (30mg/ml)- 1ml Clonidine (CLON) (0.1mg/ml)- 0.8ml Epinephrine (EPI) (1mg/ml)- 0.5ml 0.9% sodium chloride SAL)--47.7 ml
62235661|NCT03130543|EXPERIMENTAL|Standard Formula with Rice Cereal|This is the group of subjects randomized to receive their standard formula with rice cereal added
62235662|NCT03130543|EXPERIMENTAL|Enfamil AR|This is the group of subjects randomized to receive Enfamil AR
62235663|NCT06138340||Dex group|Participants will be sedated and maintained by dexmedetomidine.
62426329|NCT04943055|EXPERIMENTAL|Low temperature plasma ablation with lacrimal duct catheterization|The experimental group received low temperature plasma lacrimal duct obstruction ablation combined with lacrimal duct catheterization
62426330|NCT04943055|PLACEBO_COMPARATOR|YAG lacrimal duct laser combined with lacrimal duct catheter|Control group received YAG lacrimal duct laser combined with lacrimal duct catheterization
62811995|NCT02570503|PLACEBO_COMPARATOR|Placebo|0.9% Sodium Chloride- 100ml
62426331|NCT06568861|EXPERIMENTAL|Subjects with Moderate Hepatic Impairment (Child-Pughs Class B)|Subjects with moderate hepatic impairment will receive oral doses of 200 mg ALG-097558 twice daily (every 12 hours \[Q12H\]) for 6 days for 11 total doses.
62426332|NCT06568861|EXPERIMENTAL|Subjects with Normal Hepatic Function|Subjects with normal hepatic function will receive oral doses of 200 mg ALG-097558 twice daily (every 12 hours \[Q12H\]) for 6 days for 11 total doses.
62426333|NCT01752322|EXPERIMENTAL|Lidocaine plaster|Topical hydrogel plaster
62426334|NCT01752322|PLACEBO_COMPARATOR|Placebo plaster|Topical hydrogel plaster
62426335|NCT05341076|EXPERIMENTAL|Labor scale|Observation Amniotomy Oxytocin Cesarean Section (CS)
62594389|NCT06422104|ACTIVE_COMPARATOR|10 Hz rTMS to primary somatosensory cortex|10 Hz rTMS to primary somatosensory cortex
62811996|NCT05356234|EXPERIMENTAL|Treatment Intervention: Responsible Parenting, Relationships, and Employment Services|Experimental: A series of workshops addressing responsible parenting and marriage and relationships as well as a complement of employment services and comprehensive case management will be conducted over a 12-week period.
62811997|NCT05356234|NO_INTERVENTION|Wait-List Control|The Wait-List Control group will be placed on a wait-list and offered services as soon as they complete the study's final 24-week follow-up measures. Wait-List Control participants will not be assigned a Case Manager and will not receive any comparable services from our agency until they complete their 24-week measures.
62811998|NCT00772538|EXPERIMENTAL|tiotropium 5mcg/day|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
62811999|NCT00772538|EXPERIMENTAL|placebo|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
62812000|NCT00524485|EXPERIMENTAL|Arm 1 - ALA|Patients receive topical ALA topical (aminolevulinic acid) 2 hours before PDT.
62812001|NCT00524485|EXPERIMENTAL|Arm 2|Patients receive topical ALA topical (aminolevulinic acid) 4 hours before PDT
62235664|NCT06138340||Propofol group|Participants will be sedated and maintained by propofol.
62426336|NCT05341076|ACTIVE_COMPARATOR|WHO partograph|Observation Amniotomy Oxytocin Cesarean Section (CS)
62594390|NCT06422104|ACTIVE_COMPARATOR|0.7 Hz rTMS to premotor cortex|0.7 Hz rTMS to premotor cortex
62594391|NCT04998279||Intervention group|
62594392|NCT04998279||Control group|
62594393|NCT04025931|EXPERIMENTAL|chidamide combined with Toripalimab|"chidamide 30mg orally twice a week;~240 mg of toripalimab (fixed dose) every three weeks.~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment."
62426337|NCT00299273|EXPERIMENTAL|Low calorie high fat/protein diet|Low calorie high fat/protein diet
62426338|NCT02046499|ACTIVE_COMPARATOR|Oxytocin arm|Oxytocin alone administered which is current standard of care
62426339|NCT02046499|EXPERIMENTAL|Oxytocin + syntometrine|Oxytocin plus syntometrine administered
62035160|NCT02313428|EXPERIMENTAL|Standard of Care with Topical Oxygen Treatment|patients who have a chronic wound, will receive their receive standard treatment plus Topical Oxygen Therapy (Topical Oxygen Chamber for Extremities).
62035161|NCT02313428|NO_INTERVENTION|Standard of Care only|patients that have a chronic wound will receive only their standard of care treatment.
62035162|NCT06669143|EXPERIMENTAL|Zanubrutinib and Lenalidomide|
62035163|NCT03050346||CAD patients|Consecutive patients scheduled for a coronary angiography on the basis of cardiac symptoms and a test positive for inducible coronary ischemia, who are affected by one-vessel or two-vessel CAD at the time of the OS-CMR with breathing maneuvers (HVBH).
62035164|NCT03050346||Healthy subjects|Subjects without current or pre-existing cardiovascular and lung disease and absence of medication with cardiovascular effects.
62035165|NCT04852354||Cohort 1: Tumor patients undergoing neurosurgery|Samples of tumor tissue, blood, CSF, saliva, skull, and dura will be taken during neurosurgery from tumor patients meeting the inclusion criteria.
62035166|NCT04852354||Parents of tumor patients|Saliva samples will be taken from parents of tumor patients meeting the inclusion criteria.
62035167|NCT04852354||Cohort 2: Non-Tumor patients undergoing neurosurgery|Blood and CSF samples will be taken from non-tumor patients meeting the inclusion criteria.
62035168|NCT04852354||Cohort 3: Autopsy tumor tissue donation|Post-mortem biospecimens such as whole brain, spinal cord, biofluids (e.g., cerebrospinal fluid and blood) and skin biopsy will be collected through autopsy donation from brain tumor patients meeting the inclusion criteria.
62035169|NCT02351531|EXPERIMENTAL|New Thickened Extensively Hydrolyzed formula|
62035170|NCT06362681|NO_INTERVENTION|Group I: control (oral hygiene motivation only),|Participants will be advised to brush their teeth and enamel surfaces three times a day with a 1000 ppm fluoride toothpaste (stabilized Tin Fluoride), for which a 75ml/102g tube will be provided to each participant each time. months to ensure compliance and uniformity.
62035171|NCT06362681|EXPERIMENTAL|Group II: fluoride varnish (Flúor Protector Ivoclar Vivadent)|The selected participants will have the fluoride varnish applied once a month for the 24 months of the study. The varnish will only be applied to the teeth and molars with HIM.
62035172|NCT06362681|EXPERIMENTAL|Group III: fluoride varnish (Clinpro White Varnish 3M ESPE)|The selected participants will have the fluoride varnish applied once a month for the 24 months of the study. The varnish will only be applied to the teeth and molars with HIM.
62035173|NCT06362681|EXPERIMENTAL|Group IV: CPP-ACP|Participants will make a single daily application of 0.3 g of CPP-ACP cream (GC America, MI Paste™ Recaldent®) on the enamel surface. This will be done for 24 months, at night, to maintain prolonged contact of this agent with the surface of the tooth. The night time schedule is chosen because the longer the time in which both CPP-ACP and saliva are kept in the mouth, the more effective the result will be. A measuring spoon will be given to each participant to ensure standardized delivery of 0.3 g of CPP-ACP to each participant's enamel surface.
62035174|NCT05180760|ACTIVE_COMPARATOR|Smartphone app arm|Use the dedicated smartphone app for NAFLD patients
62035175|NCT05180760|OTHER|Standard of care|Standard of care
62035176|NCT01886924|EXPERIMENTAL|Brief Computer MI for Smoking Cessation|Brief computer MI intervention to motivate tobacco quitline use
62035177|NCT01886924|ACTIVE_COMPARATOR|Nutrition Control|Computer delivered nutrition education
62035178|NCT00374322|PLACEBO_COMPARATOR|Placebo|6 tablets daily for 12 months
62235665|NCT02905760|EXPERIMENTAL|Furosemide|Furosemide and Placebo filling (Glucose 5%).
62235666|NCT02905760|ACTIVE_COMPARATOR|Fluid expansion|"Placebo furosemide (Glucose 5%) and Vascular filling~The vascular filling is the gold standard in the treatment of acute myocardial infarction"
62035179|NCT00374322|EXPERIMENTAL|Lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
62035180|NCT05556525|ACTIVE_COMPARATOR|Arm I (EBUS TBNA)|Patients undergo robotic EBUS TBNA on study.
62035181|NCT05556525|EXPERIMENTAL|Arm II (EBUS TBNA, nCLE, fluorescein)|Patients undergo EBUS TBNA, nCLE, and receive fluorescein IV on study.
62035182|NCT03459430|EXPERIMENTAL|Low Intensity training group|Low Intensity training group will complete a 6 week core stability training program with low intensity/oscillation exercises
62035183|NCT03459430|EXPERIMENTAL|High Intensity training group|High Intensity training group will complete a 6 week core stability training program with high intensity/oscillation exercises
62235667|NCT01004380|EXPERIMENTAL|Farletuzumab|2.5 mg/kg once weekly administered i.v. during the Combination treatment period and 7.5 mg/kg Q3W administered i.v. during the Maintenance period
62035184|NCT03459430|NO_INTERVENTION|Control group|Control group will have 6 weeks with no intervention before post-test
62035185|NCT02883114|EXPERIMENTAL|single cohort|single dose of PF-06648671 in period 1 and 14-day dose of itraconazole plus single dose of PF-06648671 in period 2
62035186|NCT02962908|EXPERIMENTAL|Group 1|(n=74): FLU-v on Day 0 and Day 21
62035187|NCT02962908|EXPERIMENTAL|Group 2|(n=74): adjuvanted FLU-v on Day 0, saline (0.5mL) on Day 21
62035188|NCT02962908|PLACEBO_COMPARATOR|Group 3|(n=37): saline solution (0.5ml) on Day 0 and Day 21
62035189|NCT02962908|PLACEBO_COMPARATOR|Group 4|(n=37): Adjuvanted placebo on Day 0, saline (0.5mL) on Day 21
62035190|NCT06311708||Retrospective and Prospective|Patients who meet the eligibility criteria are observed and data collected both prospectively and retrospectively.
62035191|NCT00617760|EXPERIMENTAL|1|Concomitant administration of MenC-TT vaccine and PCV7, 170 subjects
62235668|NCT02580955|EXPERIMENTAL|LEGFLOW DCB|patients treated with the LEGFLOW Paclitaxel-Eluting Peripheral Balloon Dilatation Catheter
62235669|NCT01603186|EXPERIMENTAL|Quetiapine Fumarate Tablets 25 mg|Quetiapine Fumarate Tablets 25 mg of M/s Ipca Laboratories Limited, India
62235670|NCT01603186|ACTIVE_COMPARATOR|Seroquel®|Seroquel® (Quetiapine Fumarate) Tablets 25 mg of M/s AstraZeneca Pharmaceuticals LP, USA
62035192|NCT00617760|ACTIVE_COMPARATOR|2|PCV7 administration only, 85 subjects
62035193|NCT00617760|ACTIVE_COMPARATOR|3|MenC-TT vaccine only, 85 subjects
62035194|NCT05470868|EXPERIMENTAL|PRO-185|Healthy volunteers will apply one drop of PRO-185 ophthalmic solution (naphazoline / hypromellose) on both eyes, QID (four times per day) for 8 days.
62035195|NCT04183764|EXPERIMENTAL|MAX-40279-01|capsule, 5mg and 25mg
62426340|NCT01733186|EXPERIMENTAL|CARTISTEM®|Drug name and ingredients: CARTISTEM \[allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo cultured, combined with sodium hyaluronate\] Dosage: Administer 0.5 mL of the combination product per cm\^2 of the cartilage defect
62426341|NCT01225315|EXPERIMENTAL|Setipiprant - Dose 1|100 mg b.i.d.
62812002|NCT00524485|EXPERIMENTAL|Arm 3|Patients receive topical ALA (aminolevulinic acid) 24 hours before PDT. Each anatomic area is divided into subunits (e.g., right and left arm, right and left side of the face). The subunits are randomized to receive 1 or 2 pulses of the laser treatment
62035196|NCT01777854|ACTIVE_COMPARATOR|Omeprazole|"Yes. Omeprazole (generic) will be used. Children \>20 kg will be given 20 mg PO daily for 4 weeks prior to tonsillectomy. This is the normal standard pediatric dosing for reflux.~Omeprazole is authorized to treat reflux in children. The study focuses on laryngopharyngeal reflux that possibly contributes to post tonsillectomy pain."
62035197|NCT01777854|PLACEBO_COMPARATOR|Sugar pill|The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look.
62035198|NCT02308384|NO_INTERVENTION|Before intervention|GPs in this group have not yet received intervention.
62035199|NCT02308384|EXPERIMENTAL|After intervention|GPs in this group have received the intervention.
62035200|NCT03877445|OTHER|Melasma Group exposed left half-face by ORIEL solar simulator|Twelve patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control.
62035201|NCT03877445|OTHER|Melasma Group exposed right half-face by ORIEL solar simulator|Twelve patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control.
62035202|NCT03556462|EXPERIMENTAL|Sleep Health Interventions|"Sleep Health Interventions:~Parents- a) invited to 1 hour workshop about healthy sleep, b) invited to attend a brief (app. 20 minute) Sleep Health Flipchart education either 1-on-1 or in a small group.~Children: exposed to 2 week 40min/day healthy sleep curriculum in the classroom.Agency: Video and print material"
62035203|NCT03556462|NO_INTERVENTION|Control Period|No Intervention, but data collection
62035204|NCT01404520|EXPERIMENTAL|Exercise based multimodal intervention|The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme
62035205|NCT01404520|NO_INTERVENTION|Control Group|Control group receives usual care
62035206|NCT01166633|EXPERIMENTAL|Pitavastatin 2 mg|
62035207|NCT01166633|ACTIVE_COMPARATOR|Atorvastatin 10mg|
62035208|NCT02244866|ACTIVE_COMPARATOR|Pergoveris (FSH and LH)|150 IU of recombinant FSH and 75 IU of recombinant LH (Pergoveris) daily subcutaneous injection
62035209|NCT02244866|ACTIVE_COMPARATOR|Follitropin alpha (FSH)|150 IU of recombinant FSH (follitropin alpha or Gonal-F) daily subcutaneous injection
62426342|NCT01225315|EXPERIMENTAL|Setipiprant - Dose 2|500 mg b.i.d.
62035210|NCT03813940|EXPERIMENTAL|HPV Vaccine,135μg/0.5ml|Participants in this arm would receive 135μg/0.5ml HPV vaccines
62035211|NCT03813940|EXPERIMENTAL|HPV Vaccine,270μg/1.0ml|Participants in this arm would receive 270μg/1.0ml HPV vaccines.
62035212|NCT05873855|EXPERIMENTAL|Intervention|From baseline to 6 months, participants randomized to the intervention arm will have access to the P3 web app intervention and all of its contents (5 modules, resources, etc.), including post-baseline assessments that will occur at 3 months and 6 months.
62235671|NCT00529022|EXPERIMENTAL|Azacitidine + Valproic Acid + Carboplatin|Azacitidine 75 mg/m\^2 subcutaneous injection or by vein daily for 5 Days. Valproic Acid 40 mg/kg by mouth daily for 7 days. Carboplatin area under the curve (AUC) 2 by vein on Days 3 and 10 over 60 Minutes.
62235672|NCT05848505|EXPERIMENTAL|Dexmedetomidine group|Intranasal dexmedetomidine 2 mcg/kg administered before surgery
62426343|NCT01225315|EXPERIMENTAL|Setipiprant - Dose 3|1,000 mg b.i.d
62426344|NCT01225315|PLACEBO_COMPARATOR|Matching Placebo|Oral placebo
62426345|NCT01718301|EXPERIMENTAL|boceprevir + ribavirin + peginterferon|boceprevir 800 mg three times a day (v.o.) in combination with peginterferon (alfa-2b or alfa-2a) and ribavirin
62426346|NCT02488707|ACTIVE_COMPARATOR|LISR group|Cases which undergo rectal resection with laparoscopic intersphincteric resection.
62426347|NCT02488707|ACTIVE_COMPARATOR|TAMIS Group|Cases with rectal cancer which undergo Transanal minimally invasive Total mesorectal excision.
62426348|NCT02602561|ACTIVE_COMPARATOR|HMB|3 g HMB/day
62426349|NCT02602561|PLACEBO_COMPARATOR|Placebo|Placebo administered similar to the active comparator
62812003|NCT00524485|EXPERIMENTAL|Arm 4|Vbeam laser pulse (photodynamic therapy) is applied to the subunit
62812004|NCT00524485|EXPERIMENTAL|Arm 5|Vbeam laser pulses (photodynamic therapy) are applied to the subunit. Patients may receive up to 3 treatments (including pretreatment, ALA, and PDT) at least 1 month apart
62812005|NCT03032562||1|Patients with neuromuscular disease
62812006|NCT03032562||2|Patients with chronic obstructive pulmonary disease
62812007|NCT01320189|EXPERIMENTAL|Protein intake of 5 energy percent|
62812008|NCT01320189|EXPERIMENTAL|Protein intake of 15 energy percent|
62812009|NCT01320189|EXPERIMENTAL|Protein intake of 30 energy percent|
62594394|NCT00041106|EXPERIMENTAL|Treatment (gemcitabine, cisplatin, and gefitinib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 1 hour on day 1. Patients also receive gefitinib PO QD beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete remission, partial remission, or maintain stable disease continue gefitinib PO QD for 5 years or until disease progression or unacceptable toxicity occurs.
62812010|NCT02433626|EXPERIMENTAL|COTI2|COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week; 1 cycle will be defined as 4 weeks of treatment as described (5 days on, 2 days off per week). Participants will remain on treatment until they experience a lack of benefit.
62812011|NCT02433626|EXPERIMENTAL|COTI2 + cisplatin|COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week; 1 cycle will be defined as 3 weeks of treatment as described (5 days on, 2 days off per week). Cisplatin 60 mg/m2 IV will be administered on Day 1 of each 3 week cycle. Participants will remain on treatment until they experience a lack of benefit.
62812012|NCT00006016|EXPERIMENTAL|Treatment (thalidomide, chemoembolization)|Patients receive oral thalidomide daily beginning 4 weeks before the first planned chemoembolization procedure. Thalidomide administration is stopped 24 hours before each chemoembolization procedure, and then restarted at 24 hours after completion of each procedure OR when blood counts and levels of bilirubin and transaminases recover, whichever occurs later. Thalidomide treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo placement of a visceral arterial catheter. Patients receive doxorubicin as a chemoemulsion via the arterial catheter into 1 hepatic lobe only under angiographic guidance. Immediately after delivery of the chemoemulsion, patients undergo particulate embolization. The opposite lobe, if involved, is treated within 3-5 weeks of treatment of the initial lobe. Patients are reevaluated for repeat chemoembolization within 8-12 weeks of the last chemoembolization.
62812013|NCT01439789|ACTIVE_COMPARATOR|rhNRG-1|Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure
62812014|NCT01439789|PLACEBO_COMPARATOR|Plaebo|Excipient placebo in addition to basic therapy of chronic heart failure
62812015|NCT04384809|EXPERIMENTAL|Leukocyte rich platelet rich plasma injection|Patients will be injected with leukocyte rich platelet rich plasma in their common extensor tendon
62812016|NCT04384809|EXPERIMENTAL|Percutaneous tenotomy|Patients will undergo percutaneous tenotomy of the common extensor tendon using the Tenex tenotomy device
62812017|NCT00310765|ACTIVE_COMPARATOR|Pregabalin 150 or 300 mg daily for severe abdominal pain from adhesions|Patients were randomly assigned to active drug 75-150 mg of pregabalin po BID for 7 weeks followed by a 1 week wash out phase and then were given 150 mg of pregabalin BID for an additional 4 weeks. Daily pain and sleep scores were reported by the patient throughout the study.
62812018|NCT00310765|PLACEBO_COMPARATOR|Look alike placebo 150 or 300 mg daily for severe abdominal pain from adhesions|Patients were randomly assigned to look alike placebo 75 or 150 mg po BID for 7 weeks followed by a 1 week wash out phase and then were given 150 mg of pregabalin BID for an additional 4 weeks. Daily pain and sleep scores were reported by the patient throughout the study.
62812019|NCT05034913|EXPERIMENTAL|Photography to Measure Children's Height, Wrist Circumference, and Abdominal Circumference|Subjects will be given instructions on how to take two photographs at home and submit them securely. Subjects will also be given instructions on how to measure height, wrist circumference, and waist circumference and submit this data to the research team.
62812020|NCT03532542|EXPERIMENTAL|Casimersen|Patients amenable to exon 45 skipping who have completed a clinical trial evaluating casimersen will receive open-label casimersen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.
62812021|NCT03532542|EXPERIMENTAL|Golodirsen|Patients amenable to exon 53 skipping who have completed a clinical trial evaluating golodirsen will receive open-label golodirsen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.
62812022|NCT01938079|ACTIVE_COMPARATOR|Sedative without Ketamine|Subjects will receive sedative drug regimen without Ketamine.
62035213|NCT05873855|EXPERIMENTAL|Waitlist Control|"From baseline to 3-months, participants in the waitlist control condition will have access to the P3 web app for post-baseline assessment of 3 months and the resources section.~From 3 months to 6 months, participants randomized to the waitlist control arm will then have access to the P3 web app intervention and all of its contents (5 modules, resources, etc.), including post-baseline assessment that will occur at 6 months."
62235673|NCT05848505|PLACEBO_COMPARATOR|Control group|Intranasal saline 0.02 mL/kg administered before surgery
62235674|NCT01929980|EXPERIMENTAL|Bortezomib|"Four doses of bortezomib, 1.3mg/m2, will be given intravenously (through a needle in a vein) or subcutaneously (under the skin) on Days 1, 4, 8, 11.~The format of receiving medications is- Therapy Dose and Route Frequency Rituximab 375 mg/m2 intravenously Once on day 1. Plasmapheresis 2 hours prior to Bortezomib Day 1,4, 8 and 11 Bortezomib 1.3 mg/m2 intravenously Day 1,4,8 and 11"
62235675|NCT01868139|EXPERIMENTAL|Cryotherapy|Liquid nitrogen spray cryotherapy with the truFreeze device
62235676|NCT01834196|OTHER|retinal vascular occlusion arm|Patients with existing retinal microvascular disease will undergo imaging.
62235677|NCT06258330|EXPERIMENTAL|Cohort 1 - low dose|AM003 34 mg
62812023|NCT01938079|EXPERIMENTAL|Sedative with Ketamine|Subjects will receive sedative drug regimen with Ketamine.
62235678|NCT06258330|EXPERIMENTAL|Cohort 2 - mid dose|AM003 68 mg
62235679|NCT06258330|EXPERIMENTAL|Cohort 3 - high dose|AM003 136 mg
62235680|NCT01080287||Migraineurs with & w/out auras having orthostatic intolerance|Subjects between ages 18 and 65, having ICHD-II classification of migraine with or without aura, having symptoms of orthostatic intolerance
62235681|NCT01080287||Migraineurs with or without auras|Subjects between ages 18 and 65 having ICHD-II classification of migraine with or without auras
62235682|NCT02775669||intracranial ICP monitoring|invasive intracranial ICP monitoring
62426350|NCT01210742|EXPERIMENTAL|Viscosupplementation with routine management|
62426351|NCT01210742|ACTIVE_COMPARATOR|Routine management|Routine management for knee OA (NICE guidelines)
62594395|NCT01144676|EXPERIMENTAL|Group A1: Dapivirine Vaginal Ring|
62594396|NCT01144676|PLACEBO_COMPARATOR|Group A2: Placebo Vaginal Ring|
62594397|NCT01144676|EXPERIMENTAL|Group B1: Dapivirine Vaginal Ring|
62035214|NCT01549613|ACTIVE_COMPARATOR|standard treatment with daptomycin|Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol
62035215|NCT01549613|ACTIVE_COMPARATOR|standard treatment of vancomycin|Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.
62035216|NCT05716698|NO_INTERVENTION|Control Group|no Pleurotus citrinopileatus intervention
62235683|NCT02775669||tranfontanel ICP monitoring|Noninvasive transfontanel ICP monitoring
62235684|NCT05609409|EXPERIMENTAL|Digital Intervention|Eight 20-30 minute sessions of an online, multimedia application
62235685|NCT05882253|OTHER|MRI imaging using Siemens MRI|Participants enrolled will undergo routine Magnetic Resonance Imaging (MRI) to obtain Restricted Spectrum Mapping (RSM). These sequences are acquired at the same time as standard multi-parametric MRI sequences. Second post-processing software then transfers the acquired RSI images from DICOM format and applies a color-coded image that is then overlayed onto the anatomic T2 image.
62235686|NCT05882253|OTHER|MRI imaging using Phillips MRI|Participants enrolled will undergo routine MRI to obtain RSM. These sequences are acquired at the same time as standard multi-parametric MRI sequences. Second post-processing software then transfers the acquired RSI images from DICOM format and applies a color-coded image that is then overlayed onto the anatomic T2 image.
62426352|NCT02759627|NO_INTERVENTION|Conventional Training|Conventional physical therapy consisted of neurophysiological concepts such as Bobath and Brunnstrom.Training sessions focused on static and dynamic postural tasks, improving lower and upper extremity range of motion, strengthening and overground walking. During walking training, emphasis was on distance walked than on gait quality. Symmetrical weight distribution was encouraged through verbal and tactile cues and was made more difficult by the addition of arm activities or actions requiring trunk rotation. In an effort to improve rhythmic weight-shifting ability, subjects practiced shifting their weight in forward and backward directions and side to side while performing reaching tasks. A session lasted 45 minutes, for 5 days per week for 6 weeks.
62235687|NCT05882253|OTHER|MRI imaging using General Electric (GE) MRI|Participants enrolled will undergo routine MRI to obtain RSM. These sequences are acquired at the same time as standard multi-parametric MRI sequences. Second post-processing software then transfers the acquired RSI images from DICOM format and applies a color-coded image that is then overlayed onto the anatomic T2 image.
62235688|NCT01067157|OTHER|A|"Other = Lifestyle intervention~A: Medical examination before and after inpatient therapy (clinic staff), questionnaires.~Further medical examination and questionnaires after 6 months, 1, 2, 5 and 10 years at home by pediatrics or general practitioner.~The lifestyle intervention includes an age-specific diet (1200-1800 kcal/d), 11 h/wk physical activity (walking, swimming, sports) and behavioural therapy."
62235689|NCT01410136|OTHER|Chondrofix|Subjects with one or two confirmed knee articular cartilage lesion(s) each less than 8cm2, of the femoral condyle or trochlear groove
62235690|NCT03113253|EXPERIMENTAL|Tranexamic Acid|"Patient will receive:~* 1g of tranexamic acid by slow intravenous injection~* 1g of tranexamic acid by syringe pump during 8 hours"
62235691|NCT03113253|PLACEBO_COMPARATOR|Placebo|"Patient will receive:~* 10 mL of 0.9% sodium chloride by slow intravenous injection~* 48 mL of 0.9% sodium chloride by syringe pump during 8 hours"
62235692|NCT05938309||large group|laparoscopic resection of 5cm or larger gastric gastrointestinal stromal tumors
62235693|NCT05938309||small group|laparoscopic resection of less than 5cm gastric gastrointestinal stromal tumors
62426353|NCT02759627|EXPERIMENTAL|Robotic-Assisted Gait Training|Lokomat (Hocoma) was used in Robotic-Assisted Gait Training group with 20 % body weight reduced. The participants walked on device at 1.8 km/h (0.5 m/sec) velocity. For each participant body weight portion was ensured by a security belt while walking. Each session took 45 minutes including setup, commands and rest time. Verbal instructions were used for encouragement but no manual assistance was given to improve gait. Robotic-Assisted Gait Training sessions lasted 45-minute sessions, 2 days a week during 6 weeks.
62426354|NCT02759627|NO_INTERVENTION|Combined Training|Combined Training consisted of inpatient participants who were treated with 45 minute-conventional training, 5 days a week during 6 weeks. Additionally this group had 45 minute-Robotic-Assisted Gait Training, 2 days a week during 6 weeks.
62594398|NCT01144676|PLACEBO_COMPARATOR|Group B2: Placebo Vaginal Ring|
62035217|NCT05716698|EXPERIMENTAL|D2 10ug Pleurotus citrinopileatus Group|took D2 10ug Pleurotus citrinopileatus per day for a total of 4 weeks.
62035218|NCT05716698|EXPERIMENTAL|D2 100ug Pleurotus citrinopileatus Group|took D2 100ug Pleurotus citrinopileatus per day for a total of 4 weeks.
62035219|NCT03838042|EXPERIMENTAL|Nivolumab and Entinostat|Combination Study of Nivolumab and Entinostat
62035220|NCT03966157|EXPERIMENTAL|Nasal Bridle|Patients randomized to have nasal bridle.
62035221|NCT03966157|NO_INTERVENTION|Standard|Patients randomized with adhesive tape.
62235694|NCT06461403|EXPERIMENTAL|Inhaler Trainer Device|The Inhaler Trainer Device will monitor patients' inspiratory waveform to confirm technique compliance based on objective metrics and provide feedback on how to better perform technique. This intervention utilizes an instrumented training inhaler capable of accurately measuring the real-time inspiratory airflow achieved by the user when they perform their inhale maneuver. If a user's inspiratory flow fails to produce an inspiratory waveform with sufficient airflow parameters, the inhaler device may not optimally aerosolize the medication, and the delivered dosage to the lung will be negatively affected. The device measures the most important flow parameters in the users' real-time inspiration performance and translates them into an estimation of the dose delivered to the lung, based on detailed characterization of the user's inhaler product.
62035222|NCT01775228|NO_INTERVENTION|Regular follow up care|No intervention group - received routine follow up care following discharge from hospital after cardiac surgery (no peer support intervention).
62235695|NCT06461403|ACTIVE_COMPARATOR|Brief Interventions (BI)|During inpatient admission, participants randomized to the BI condition will receive the following: First, they will undergo an initial assessment of their respiratory inhaler technique using device-specific checklists. Participants will then be given step-by-step verbal instructions and a copy of written instructions by the trained educator describing appropriate inhaler technique for their respiratory inhalers. The educator will not demonstrate the appropriate use of each inhaler to the patient, though the educator will be free to answer questions about appropriate use if posed by the study subject.
62235696|NCT00915733|ACTIVE_COMPARATOR|triple group|"Additive cilostazol to dual antiplatelet therapy (triple antiplatelet therapy) in patients with acute myocardial infarction (AMI).~Received cilostazol 100 mg twice daily in addition to aspirin 100 mg and clopidogrel 75 mg once daily."
62235697|NCT00915733|ACTIVE_COMPARATOR|high maintenance dose group|"High maintenance dose dual antiplatelet therapy in patients with acute myocardial infarction (AMI).~Received clopidogrel 150 mg/day with aspirin 100 mg once daily."
62235698|NCT05428033|EXPERIMENTAL|Weight Based High Dose Centanafadine Capsules|"Cohort 1, (6 to 12 years of age)~Cohort 2, (4 to 5 years of age)~High dose - weight-based dosing"
62426355|NCT02172183|EXPERIMENTAL|CBT group|This group consist on a combined intervention: CBT group + psychopharmacological treatment. The group program was based on cognitive-behavioral principles and also motivational interviewing techniques to facilitate skills implementation. The treatment comprised 12 manualized sessions with an inattention module and an impulsivity module.
62426356|NCT02172183|ACTIVE_COMPARATOR|Psychopharmacological treatment|Participants were only visited to monitor their adherence and continuation on medications for ADHD (methylphenidate or atomoxetine) as prescribed by their psychiatrist.
62426357|NCT01564173||VT Ablation|Patients undergoing epicardial mapping and ablation procedure for a ventricular tachycardia
62812024|NCT02759757|EXPERIMENTAL|Kinesio Taping|"Patients from this group will receive the kinesio Taping® Tex Gold tape according to the manufacturer's instructions. Kinesio Taping will be applied for the purpose of inhibiting the erector spinal muscle from the twelfth thoracic vertebrae (longissimus portion) up to the first sacral vertebrae with 10 to 15% tension (paper-OFF) in a I position bilaterally."
62426358|NCT04405674|EXPERIMENTAL|Tislelizumab plus chemotherapy|Tislelizumab plus Carboplatin/Nab-paclitaxel as induction treatment and followed by Tislelizumab plus pemetrexed as maintenance treatment.
62594399|NCT02269410|ACTIVE_COMPARATOR|GBP-SPS|GBP Standard PRO-S (0.8g protein/kg ideal body weigh/day)
62594400|NCT02269410|EXPERIMENTAL|GBP-HPS|GBP High PRO-S (1.2g protein/ kg ideal body weight/ day)
62594401|NCT02269410|ACTIVE_COMPARATOR|VSG-SPS|VSG Standard PRO-S (0.8g protein/kg ideal body weigh/ day)
62594402|NCT02269410|EXPERIMENTAL|VSG-HPS|VSG High PRO-S (1.2g protein/ kg ideal body weight/ day)
62594403|NCT06622616|EXPERIMENTAL|Study Group|Los participantes consumirán 2 porciones de producto con polvo de A. domesticus (15 g. cada una) que podrán consumir al gusto en diferentes recetas. El producto estará incluido dentro de un plan de alimentación saludable normoproteico. Se les recomendará continuar con su actividad física habitual durante las 12 semanas de duración del estudio.
62812025|NCT02759757|PLACEBO_COMPARATOR|Placebo|Patient from this group will receive a 5cm-wide Micropore® tape from the twelfth thoracic vertebrae (longissimus portion) up to the first sacral vertebrae bilaterally.
62812026|NCT02759757|NO_INTERVENTION|Control|Patients allocated will not receive any intervention.
62235699|NCT05428033|EXPERIMENTAL|Weight Based Low Dose Centanafadine Capsules|"Cohort 1, (6 to 12 years of age)~Low dose - weight-based dosing"
62594404|NCT06622616|PLACEBO_COMPARATOR|Control Group|Participants will consume 2 portions of a product with a nutritional value similar to the study product, one at breakfast and one at dinner. The product will be included in a healthy, normoprotein diet plan. They will be advised to continue their usual physical activity during the 12 weeks of the study.
62235700|NCT05428033|PLACEBO_COMPARATOR|Matching Placebo|"Cohort 1 and Cohort 2~Children (4 to 12 years of age, inclusive) to receive Placebo capsules will be matching in size and color."
62594405|NCT06540079|EXPERIMENTAL|Solia CSP S LBB Lead|
62594406|NCT06648070|EXPERIMENTAL|NMR Group|"On group A we will perform NEUROMUSCULAR REEDUCATION TECHNIQUE:~we perform this technique on tight muscles which are:~1. levator scapulae~2. upper trapezius~3. pectoralis major"
62812027|NCT03930836|ACTIVE_COMPARATOR|control group|high/low dosage intervention, intensive or not (motor function rehabilitation)
62812028|NCT03930836|EXPERIMENTAL|interface group|high/low dosage intensive intervention using the interactive interface (motor function rehabilitation)
62812029|NCT03962465|EXPERIMENTAL|3-drug re-induction regimen with inotuzumab|"One cycle of a 3-drug regimen comprised of standard doses of prednisone, vincristine, and daunorubicin with inotuzumab ozogamicin at a reduced dose.~Intrathecal methotrexate (IT-methotrexate) and intrathecal cytarabine (IT-Ara-C) will be included for CNS prophylaxis.~IV inotuzumab ozogamicin will be given at a reduced dose (may vary from a total cycle dose of 0.4 mg/m\^2 to 0.9 mg/m\^2)"
62594407|NCT06648070|EXPERIMENTAL|PFS Group|"On group B we perform POST FACILITATION STRETCH TECHNIQUE on tight muscles same as group A~1. levator scapulae~2. upper trapezius~3. pectoralis major"
62594408|NCT05522881||HPV positive-Post treatment|The subject has received any anti-cancer treatment with pathological report of squamous cell carcinoma of oropharynx (soft palate, tonsil, base of tongue, pharyngeal wall, uvula or vallecula) and positive p16 immunohistochemical staining.
62594409|NCT05522881||HPV negative-Post treatment|The subject has received any anti-cancer treatment with pathological report of squamous cell carcinoma of oropharynx (soft palate, tonsil, base of tongue, pharyngeal wall, uvula or vallecula) and negative p16 immunohistochemical staining.
62594410|NCT05522881||HPV positive-Treatment-naïve|The subject has received no anti-cancer treatment with pathological report of squamous cell carcinoma of oropharynx (soft palate, tonsil, base of tongue, pharyngeal wall, uvula or vallecula) and positive p16 immunohistochemical staining.
62594411|NCT05522881||HPV negative-Treatment-naïve|The subject has received no anti-cancer treatment with pathological report of squamous cell carcinoma of oropharynx (soft palate, tonsil, base of tongue, pharyngeal wall, uvula or vallecula) and negative p16 immunohistochemical staining.
62235701|NCT05861154|EXPERIMENTAL|Photobiomodulation|
62235702|NCT05861154|ACTIVE_COMPARATOR|Topical anesthesia|
62594412|NCT05522881||reference subgroup|60 patients with head and neck SCC (excluding OPSCC)
62812030|NCT03962465|EXPERIMENTAL|4-drug re-induction regimen with inotuzumab|"One cycle of a 4-drug regimen comprised of standard doses of prednisone, vincristine, daunorubicin, and pegaspargase with inotuzumab ozogamicin at a reduced dose.~Intrathecal methotrexate (IT-methotrexate) and intrathecal cytarabine (IT-Ara-C) will be included for CNS prophylaxis.~IV inotuzumab ozogamicin will be given at a reduced dose (may vary from a total cycle dose of 0.4 mg/m\^2 to 0.9 mg/m\^2)"
62812031|NCT05110638|EXPERIMENTAL|SKX-16 (Luliconazole 10% Solution)|
62235703|NCT00683566|EXPERIMENTAL|1|A session in condition ON DOPAMINE and the other one in condition OFF DOPAMINE.
62426359|NCT04405674|EXPERIMENTAL|Tislelizumab plus chemotherapy plus Bevacizumab|Tislelizumab plus Nab-paclitaxel and Bevacizumab as induction treatment and followed by Tislelizumab plus Bevacizumab as maintenance treatment.
62426360|NCT02865473|NO_INTERVENTION|primary open angle glaucoma patients|
62426361|NCT02865473|NO_INTERVENTION|patients with primary angle closure|
62812032|NCT03165617|EXPERIMENTAL|QIVc (≥2 years to <18 Years of Age)|Cell-derived Seasonal Quadrivalent Influenza Vaccine
62035223|NCT01775228|ACTIVE_COMPARATOR|Peer Support intervention|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
62235704|NCT06475573|EXPERIMENTAL|Experimental group|Consume two 35g sachets of fermented dietary fiber probiotic solid beverages daily, replacing part of the staple food for lunch and dinner.
62235705|NCT06475573|ACTIVE_COMPARATOR|Control Group|Consume two 35g sachets of convenient whole grain porridge daily, replacing part of the staple food for lunch and dinner.
62235706|NCT00984425|EXPERIMENTAL|Lapatinib and Sorafenib 1° level of dose|Lapatinib 750 mg/die + Sorafenib 200 mg bid
62235707|NCT00984425|EXPERIMENTAL|Lapatinib and Sorafenib 2° level of dose|2° level (II cohort): Lapatinib 1000 mg/die + Sorafenib 200 mg bid
62235708|NCT00984425|EXPERIMENTAL|Lapatinib and Sorafenib 3° level of dose|3° level (III cohort): Lapatinib 1000 mg/die + Sorafenib 400 mg bid
62235709|NCT00984425|EXPERIMENTAL|Lapatinib and Sorafenib 4° level of dose|4° level (IV cohort): Lapatinib 1250 mg/die + Sorafenib 400 mg bid
62235710|NCT01175356|EXPERIMENTAL|Treatment (131I-MIBG, chemotherapy)|See Detailed Description.
62426362|NCT02865473|NO_INTERVENTION|patients with neovascular glaucoma|
62426363|NCT02865473|NO_INTERVENTION|PEX glaucoma patients|
62426364|NCT02865473|NO_INTERVENTION|glaucoma patients with filtering bleb|
62426365|NCT02865473|EXPERIMENTAL|healthy volunteers|instillation of antiglaucoma treatment in the study eye
62426366|NCT02952937|OTHER|Group 1|"1. Period 1: GLA5PR GLARS-NF1 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~2. wash-out period: over 7 days.~3. Period 2: GLA5PR GLARS-NF3 tablet 300mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
62594413|NCT05522881||recurrence subgroup|pairs of primary and recurrent tumors (at the first distal or local recurrence) of head and neck SCC
62594414|NCT03747315||Familial Mediterranean Fever (patients)|Patients with previously confirmed Familial Mediterranean Fever (based on clinical criteria)
62594415|NCT03747315||Control group (patients)|Patients with symptoms similar to that of Familial Mediterranean Fever (e.g. Behcet disease, Crohn, sepsis..) but without confirmed Familial Mediterranean Fever.
62594416|NCT03747315||Healthy donors|Patients without symptoms (anonymous blood donors)
62594417|NCT03937908|EXPERIMENTAL|2g CAP|Single administration of 2g of Centella asiatica water extract standardized product dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
62594418|NCT03937908|EXPERIMENTAL|4g CAP|Single administration of 4g of Centella asiatica water extract standardized product dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
62594419|NCT00899405||Patients with lung cancer|Collection of archival tumor specimen at the beginning of the study and collection of blood samples at the beginning of the study and then at regular intervals
62594420|NCT04747613|EXPERIMENTAL|Iptacopan|Participants will be receiving open label oral iptacopan 200 mg b.i.d monotherapy
62594421|NCT02889198|EXPERIMENTAL|Intervention group|Centers in this group will be granted immediate access to the Go NAP SACC website following randomization with minimal support from a local technical assistance provider. The center director will have 4 months to use Go NAPSACC tools.
62812033|NCT03165617|ACTIVE_COMPARATOR|Non-Influenza Comparator Vaccine|Non-Influenza Comparator Vaccine
62812034|NCT04471077||Favorable outcome of bariatric surgery|Excess weight loss above 50%
62812035|NCT04471077||Unfavorable outcome of bariatric surgery|Excess weight loss below 50%
62812036|NCT01459302||Familial and Sporadic ALS|Individuals with ALS and families with a history of two or more people in the family who have had ALS or other forms of motor neuron disease.
62812037|NCT06196736|EXPERIMENTAL|9MW2821|
62812038|NCT06196736|ACTIVE_COMPARATOR|Investigator's Choice of Chemotherapy|
62035224|NCT04690855|EXPERIMENTAL|Study Treatment Arm|"All patients will be treated with induction talazoparib of 1mg PO daily starting Day 1. Patients will then receive 8 Gy x 3 fractions to 1-4 metastatic lesions beginning Day 12,13, or 14 and given QOD. 840 mg of atezolizumab will be given intravenously (IV) on Day 15 of the 1st cycle and then on Day 1 and Day 15 of the remaining cycles. The sequence of administration is not specified on the days in which talazoparib and atezolizumab are given on the same day. Each cycle equals 28 days. Treatment will continue until progression or severe toxicity.~A safety lead in of up to 6 patients will be performed. Immune-related and non-immune related adverse events will be tracked up to 12 weeks post initiation of atezolizumab, as the majority of treatment-related toxicities from talazoparib, radiation, and atezolizumab occur within this time period."
62035225|NCT04988854|EXPERIMENTAL|Positive Condition|Children were exposed to a video of adult models eating a single piece of raw broccoli whilst showing a positive facial expression (positive video)
62235711|NCT04656509|EXPERIMENTAL|4-s sprint inertial load training|Participants trained three times a week for eight weeks following the training program consisting of 30 bouts of 4s all-out cycling on an inertial-load ergometer with progressively decreasing recovery time (30 to 24 to 15s).
62235712|NCT01572870||No ABPA nor Aspergillus infection|CF patients who had neither ABPA nor Aspergillus infection in the past (the control group)
62235713|NCT01572870||persistent Aspergillus infection, without ABPA|CF patients with persistent Aspergillus infection, without ABPA.
62235714|NCT01572870||Current or past ABPA infection|CF patients with current or past ABPA
62235715|NCT04716530||born before 2000|No patient treatment is associated with the study.
62235716|NCT04716530||born between 2000-2010|No patient treatment is associated with the study.
62235717|NCT04716530||born after 2010|No patient treatment is associated with the study.
62235718|NCT02949089|EXPERIMENTAL|ACH04|Dosage: 1 capsule, PO, 24/24h for 10 days.
62594422|NCT02889198|NO_INTERVENTION|Control group|During the study, centers in this group will receive no intervention. However, they will be granted delayed access to the Go NAP SACC website and technical assistance support after post-intervention measures are collected.
62594423|NCT00790231||men|observation of the urinary function with and without thoracic epidural anesthesia
62594424|NCT00790231||women|observation of the urinary function with and without thoracic epidural anesthesia
62594425|NCT05171296||abdominal trauma patients|blunt abdominal trauma patients planned for conservation.
62812039|NCT02099851|EXPERIMENTAL|Carotid body ablation|Patients undergoing the unilateral endovascular ablation of the right or left carotid body.
62812040|NCT04823403|EXPERIMENTAL|Patients with hepatocellular carcinoma|"1. Intravenous Nivolumab (1mg/kg) will be given every 6 weeks for a maximal period of 6 months within the study.~2. Ipilimumab, single intra-arterial (IA) injection per patient, at 3 dose-levels\*.~   * (D1) Starting dose : 50 mg; n=3 to 6~  * (D2) 2nd dose-level : 100 mg; n=3 to 6~  * (D3) Maximal tested dose : 150mg; n=3 to 6 (if no limiting toxicities) \*Dose level (D-1) : 25 mg will be tested if de-escalation is needed at D1 (\>1/3 DLT at D1)"
62812041|NCT04795778||Patients with breast cancer|Breast cancer patients with or without breast cancer surgery, with or without mastectomy, with or without lymphedema
62035226|NCT04988854|EXPERIMENTAL|Neutral Condition|Children were exposed to a video of adult models eating a single piece of raw broccoli whilst showing a neutral facial expression (neutral video)
62035227|NCT04988854|EXPERIMENTAL|No-Food Control Condition|Children were exposed to a video of adult models putting pens away whilst showing a neutral facial expression (no-food control video)
62235719|NCT05708625|ACTIVE_COMPARATOR|Intralesional Sodium stibogluconate|Patients will receive intralesional infiltration of (SSG) at a dose of 50 mg/0.5 ml (0.2-0.4ml) maximum dose per session 1-3 ml. Sessions will be held once weekly for a maximum of 6 weeks.
62235720|NCT05708625|EXPERIMENTAL|intralesional Cryotherapy|Patients will be treated with intralesional Cryotherapy. Sessions will be held every two weeks till complete cure or a maximum of 6 sessions
62235721|NCT05708625|EXPERIMENTAL|Intralesional Voriconazole|Patients will be treated with intralesional Voriconazole weekly till complete cure or a maximum of 6 sessions
62235722|NCT05708625|EXPERIMENTAL|Oral doxycycline|Patients will be treated with oral doxycycline, 200 mg daily, until complete cure or a maximum of 6 weeks
62235723|NCT04452487||Patient 2019|Patients hospitalized in selected centers during march and june 2019
62235724|NCT04452487||Patient 2020|Patients hospitalized in selected centers during march and june 2020 (during COVID-19 pandemia)
62426367|NCT02952937|OTHER|Group 2|"1. Period 1: GLA5PR GLARS-NF3 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~2. wash-out period: over 7 days.~3. Period 2: GLA5PR GLARS-NF1 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
62594426|NCT00308087|ACTIVE_COMPARATOR|Rituximab|
62594427|NCT00308087|EXPERIMENTAL|Rituximab + Sargramostim|
62594428|NCT02935504|EXPERIMENTAL|Program In Support of Moms PRISM|PRISM includes MCPAP for Moms and training, implementation support, and toolkits for Ob/Gyn practices on depression screening, assessment and treatment.
62594429|NCT02935504|ACTIVE_COMPARATOR|MCPAP for Moms|Consists of access to psychiatric consultation and resources and referrals through MCPAP for Moms - MCPAP for Moms is available free of charge to all Ob/Gyn practices in Massachusetts.
62594430|NCT00877942||1|Typically developing children drawn from the general population
62594431|NCT00877942||2|Children with Turner Syndrome
62812042|NCT04795778||Control group|Healty individuals with no disease
62235725|NCT04452487||Patient 2021|Patients hospitalized in selected centers during march and june 2021
62235726|NCT01859780|EXPERIMENTAL|Prescription packages (vials and blisters)|"Stage I Prescription vials and wallets (packaging) with three levels of distractor placement (hidden, absent and obvious) will be tested for an effect of placement on selection behavior and time to package selection.~Stage II Prescription vials and wallets (packaging) with and without distractors will be tested for an effect on time to open and number of successful openings."
62594432|NCT03627338||Norfloxacin|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
62594433|NCT03627338||Non-selective beta blockers|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
62812043|NCT00083889|ACTIVE_COMPARATOR|2|
62235727|NCT03082131|EXPERIMENTAL|Group 1|"Order of treatments:~A. Resistant Starch Wheat B. Regular Wheat"
62235728|NCT03082131|EXPERIMENTAL|Group 2|"Order of treatments:~A. Regular Wheat B. Resistant Starch Wheat"
62235729|NCT01354171|NO_INTERVENTION|TRUS guided biopsy|
62235730|NCT01354171|EXPERIMENTAL|MRI Assisted TRUS guided biopsy|
62812044|NCT00083889|EXPERIMENTAL|1|
62812045|NCT03485755||Children|Children 8-10 years of age
62594434|NCT03627338||diuretics|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
62812046|NCT03485755||Biological Mothers|Biological mothers of children now ages 8-10 years of age
62035228|NCT06635161|EXPERIMENTAL|TPS on AIC|1. Healthy adults aged 18-65 years old will receive ten sessions of real TPS (1000 pulses per session) on the bilateral anterior insula cortex (AIC) within 2 weeks (5 sessions per week). 2. Before and after TPS, participants will perform four psychological tasks (the reading the mind in the eyes test, the balloon analog risk task, the Go/No-go task, the counting stroop task). 3. The stimulation target on the bilateral AIC will be determined by transforming MNI coordinates (left AIC: x=-41, y=6, z=3; right AIC: x=44, y=9, z=2) into the individual T1-weighted space. 4. To optimize the penetration depth of TPS pulses, a standard stand-off device (Neurology) will be used when stimulating AIC.
62812047|NCT01413035|EXPERIMENTAL|MSC and the oral hypoglycemic drugs|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former oral hypoglycemic drugs, such as Dimethylbiguanide, Glurenorm and Acarbose, et al. and regulates the dosage for 1 year.
62812048|NCT01413035|EXPERIMENTAL|MSC and insulins|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former insulins and regulates the dosage for 1 year.
62812049|NCT01413035|EXPERIMENTAL|MSC and the combination of drugs and insulins|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former combination of the oral hypoglycemic drugs and insulins and regulates the dosage for 1 year.
62035229|NCT06635161|EXPERIMENTAL|TPS on dACC|1. Healthy adults aged 18-65 years old will receive ten sessions of real TPS (1000 pulses per session) on the bilateral dorsal anterior cingulate cortex (dACC) within 2 weeks (5 sessions per week). 2. Before and after TPS, participants will perform four psychological tasks (the reading the mind in the eyes test, the balloon analog risk task, the Go/No-go task, the counting stroop task). 3. The stimulation target on the bilateral dACC will be determined by transforming MNI coordinates (left dACC: x=-4, y=26, z=45; right dACC: x=7, y=30, z=40) into the individual T1-weighted space. 4. To optimize the penetration depth of TPS pulses, no stand-off device will be used when stimulating dACC.
62235731|NCT00863967||1|no cardiovascular events
62594435|NCT05343364|EXPERIMENTAL|Vonoprazan 10 mg|Participants will receive vonoprazan 10 mg once daily for 14 days.
62812050|NCT00740220||A|Each subject will be their own control. Each subject will perform three 6MWTs. Intra-subject reproducibility is being tested.
62812051|NCT05776017|EXPERIMENTAL|Test Vaccine|MSP3-CRM-Vac4All/ Alhydrogel®
62812052|NCT05776017|ACTIVE_COMPARATOR|Control Vaccine|Anti-rabies vaccine
62812053|NCT04653480|EXPERIMENTAL|Surufatinib, Toripalimab and Chemotherapy|Second line CRC patients received surufatinib 250mg po qd , toripalimab 3mg/kg ivgtt q2w and chemotherapy according to the first line treatment, until disease progression or intolerable toxicity
62812054|NCT01638455|EXPERIMENTAL|Test Group|All subjects will be enrolled in the test group and will receive the noninvasive device
62812055|NCT05711576|PLACEBO_COMPARATOR|non-surgical sub-marginal peri-implant instrumentation (NSPI) with placebo mouthwash|Patients received a one-session of non-surgical sub-marginal peri-implant instrumentation (NSPI) with placebo mouthwash
62812056|NCT05711576|ACTIVE_COMPARATOR|non-surgical sub-marginal peri-implant instrumentation (NSPI) with FMD|Patients received a one-session of non-surgical sub-marginal peri-implant instrumentation (NSPI) with full-mouth disinfection approach (FMD).
62812057|NCT04128137|EXPERIMENTAL|fludrocortisone|FLUCORTAC® 50 μg (tablet breackable). One tablet during the first week. Then 2 tablets during the second week. Then 3 tablets during the third week and finally 4 tablets during the 4th week. Maximum of 200μg/day.
62812058|NCT04128137|PLACEBO_COMPARATOR|Placebo|placebo of flucortac and same diagram of administration
62235732|NCT00863967||2|proven cardiovascular events
62235733|NCT00863967||3|possible cardiovascular events
62235734|NCT04525482|NO_INTERVENTION|Control Group|No intervention was implemented
62235735|NCT04525482|EXPERIMENTAL|Intervention Group|Early goal-directed sedation programs was implemented
62235736|NCT01067326|ACTIVE_COMPARATOR|Aliskiren|150 mg Aliskiren once daily for a period of 4 months.
62235737|NCT01067326|PLACEBO_COMPARATOR|Placebo|1 pill per day by mouth for 4 months.
62235738|NCT00979433|EXPERIMENTAL|Bubble CPAP|All neonates randomised to bubble CPAP will be put on Bubble CPAP following initial extubation in first week of life.
62235739|NCT00979433|OTHER|Conventional CPAP|All neonates randomly allocated to conventional/ventilator derived CPAP.
62235740|NCT01013285|EXPERIMENTAL|bevacizumab, temozolomide, external beam radiation|
62235741|NCT02215538|EXPERIMENTAL|OROS methylphenidate|This was a 4-week double-blind arm. Medication was initiated at 18 mg/day and increased every 2 or 3 days by 9 mg based on treatment response and side effects. Maximum dose - 90 mg/day. Patients were seen weekly. Generally a stable dose was seen in 2 weeks and maintained the last 2 weeks of the arm. Side effects were assessed at each visit.
62812059|NCT06041568|EXPERIMENTAL|Imvotamab (Dose Escalation)|Imvotamab administered intravenously
62812060|NCT01539759|NO_INTERVENTION|Interval IUD Placement|Women randomized to this arm will be scheduled for their IUD placement 4-8 weeks after their cesarean delivery
62812061|NCT01539759|EXPERIMENTAL|Immediate Postplacental IUD placement|Women randomized to this arm will receive on IUD at time of cesarean delivery, immediately after the delivery of the placenta
62235742|NCT02215538|PLACEBO_COMPARATOR|placebo|This arm was identical to the active medication arm except that placebo replaced the active medication.
62235743|NCT02340091|EXPERIMENTAL|HA IDF plus|cross-linked HA filler with lidocaine
62235744|NCT02340091|ACTIVE_COMPARATOR|HA IDF|cross-linked HA filler without lidocaine
62594436|NCT05343364|EXPERIMENTAL|Vonoprazan 20 mg|Participants will receive vonoprazan 20 mg once daily for 14 days.
62594437|NCT06370871|EXPERIMENTAL|Arm A: Ezabenlimab|
62035230|NCT06635161|SHAM_COMPARATOR|sham TPS on vertex|1. Healthy adults aged 18-65 years old will receive ten sessions of sham TPS (1000 pulses per session) on the vertex within 2 weeks (5 sessions per week). 2. Before and after TPS, participants will perform four psychological tasks (the reading the mind in the eyes test, the balloon analog risk task, the Go/No-go task, the counting stroop task). 3. The stimulation target on the vertex will be determined by transforming MNI coordinates (x=0, y=-30, z=60) into the individual T1-weighted space. 4. A sham stand-off device will be used when stimulating the vertex.
62035231|NCT02205944|NO_INTERVENTION|Control Group|The control group will receive routine vascular access pre-op teaching and care.
62035232|NCT02205944|EXPERIMENTAL|Normal Exercise Group|"Group 1 (Normal Exercise Group): progressive handgrip exercise~Group 2 (Restricted Blood Flow Exercise Group): progressive handgrip exercise with controlled tourniquet"
62594438|NCT06370871|EXPERIMENTAL|Arm B: Brigimadlin + ezabenlimab|
62426368|NCT05152407|EXPERIMENTAL|Active serum on right|Right hemi face or skull will receive active serum (containing 0.3% MRB) / Left hemi face or skull will receive placebo serum for 6 months
62426369|NCT05152407|EXPERIMENTAL|Active serum on left|Left hemi face or skull will receive active serum (containing 0.3% MRB) / Right hemi face or skull will receive placebo serum for 6 months
62426370|NCT05876208|EXPERIMENTAL|Group 1|Group 1 will be using the BAND CVCP both in the clinic and at home to supplement the treatment protocols used in the clinic today.
62426371|NCT05876208|PLACEBO_COMPARATOR|Group 2|Group 2 will receive standard-of-care physical therapy without the use of the BAND CVCP.
62426372|NCT03039205|ACTIVE_COMPARATOR|Chronic kidney dysfunction Clopidogrel|Patients with creatinine clearance \<60ml/min/m2 (estimated by MDRD formula) randomized to clopidogrel group
62426373|NCT03039205|ACTIVE_COMPARATOR|Chronic kidney dysfunction Ticagrelor|Patients with creatinine clearance \<60ml/min/m2 (estimated by MDRD formula) randomized to ticagrelor group
62426374|NCT03039205|ACTIVE_COMPARATOR|Normal kidney function Clopidogrel|Patients with creatinine clearance ≥60ml/min/m2 (estimated by MDRD formula) randomized to clopidogrel group
62426375|NCT03039205|ACTIVE_COMPARATOR|Normal kidney function Ticagrelor|Patients with creatinine clearance ≥60ml/min/m2 (estimated by MDRD formula) randomized to ticagrelor group
62426376|NCT03797222|EXPERIMENTAL|Vitamin E Supplementation|Daily oral supplementation with Vitamin E (alpha-tocopherol) for 2 weeks.
62594439|NCT06370871|ACTIVE_COMPARATOR|Arm C: Gemcitabine + docetaxel|
62594440|NCT06618716|ACTIVE_COMPARATOR|Endotoxin|The USP (United States Pharmacopeia Convention) Endotoxin RS (LPS; Endotoxin Reference Standard, Escherichia coli, Pharmacopeia, Rockville, MD, US) will be ordered.and comes as a lyophilized (freeze-dried) powder, and each vial contains 10,000 USP Endotoxin Units. Each vial contains approximately 1 microgram of Endotoxin. The lyophilized LPS will be dissolved in 5mL sterile water to obtain a solution at 200 ng/mL. This solution will be aliquoted in 400μL (thus containing 80ng endotoxin) and stored at -20°C. Aliquots will be sent for microbial safety testing routine and verification of endotoxin concentration to a certified laboratory. On the study day, 2100μL of physiological saline (sterile, pyrogen-free isotonic NaCl solution) will be added to the aliquot to obtain a final concentration of 32 ng/mL. The amount of solution to inject will then be calculated according to the participant's weight \[in mL = (0.8 x weight) / 32\].
62594441|NCT06618716|PLACEBO_COMPARATOR|Placebo|An equivolume of sterile physiological saline (NaCl 0.9%) will be used as placebo.
62594442|NCT03087097|EXPERIMENTAL|Fecal Microbiota Transplant|FMT by enema: 10mL/kg (maximum 150mL) of healthy donor human intestinal microbiota will be infused.
62594443|NCT03087097|NO_INTERVENTION|Standard of Care|Standard of care treatment for malnutrition as prescribed by local and national Department of Health Guidelines
62035233|NCT04011553|EXPERIMENTAL|Virtual group|This virtual realtiy was implemented with MarVAJED® (Marmara Visual Auditory Joint Education Device) system which was developed by Marmara University, Department of Physiotherapy and Rehabilitation, Istanbul,Turkey. MarVAJED® is a system that evaulates the range of motion of the joints, analyzes the sensation of joint position, provides biofeedback support to increase joint control and the same time allows exercises to be controlled. This device analyzes the joint motion with the help of small sensors (Figure 2). The obtained data transfers to your mobile phone, to the tablet or to your personal computer. It stores the data by downloading it to the central server via internet for storage.
62035234|NCT04011553|ACTIVE_COMPARATOR|Control group|Conventional physiotherapy consists of electrotherapy and exercise programs. Hotpack or coldpack, therapeutic ultrasound (US) and conventional TENS were applied as electrotherapy program.
62035235|NCT03142048|EXPERIMENTAL|Schools of Health for the Elderly|"Participants receiving the community intervention (explained in the section Intervention)"
62035236|NCT03142048|NO_INTERVENTION|Comparison Group|Participants in the study that do not receive the intervention
62035237|NCT01546896|EXPERIMENTAL|buspirone+alprazolam|
62035238|NCT01546896|ACTIVE_COMPARATOR|alprazolam|
62035239|NCT01546896|NO_INTERVENTION|healthy controls|
62426377|NCT06117982|EXPERIMENTAL|Patients with POI receiving G-CSF injections|"Patients will receive 0.5 ml SC injections of G-CSF (Neupogen, Amgen, USA) at 300 micrograms/day for 4 consecutive days. The first injection will be administered in our office with a 60-minute observation period. Subsequent injections can be self-administered at home for three days, with a return to our clinic for monitoring the following day. This 4-day Neupogen regimen will be repeated in one month.~Patients may undergo two rounds of G-CSF treatment one month apart. If no improvement is observed in gonadotropin, anti-Mullerian levels, and antral follicle count, a third treatment may be offered a month later. Follow-up includes blood assessment of AMH and FSH, as well as ultrasound measurement of basal antral follicle count for three months after the last G-CSF infusion."
62426378|NCT04506125|EXPERIMENTAL|Liberal Group|transfusion of an erythrocyte concentrate in case of haemoglobin below 9.5 g/dL
62426379|NCT04506125|ACTIVE_COMPARATOR|Restrictive group|transfusion of an erythrocyte concentrate in case of haemoglobin below 7.5 g/dL
62426380|NCT04283838|EXPERIMENTAL|Humanistic care|Psychological and physical rehabilitation based humanistic care regimen was used to prevent depression and PTSD in healthcare workers who participated in the treatment of COVID-19.
62594444|NCT06158997|EXPERIMENTAL|EyePeace+Heated eye mask group|Participants will received the HEM therapy for 10 minutes according to the manufacturer's instructions. This was followed immediately by 10 gentle squeezes of the eyelid massage device on one eye
62035240|NCT00581230|EXPERIMENTAL|Laryngoscopy without RAMP|First, laryngoscopy will be preformed utilizing a traditional Macintosh size 4 blade laryngoscope. The view of the laryngeal aperture will be recorded, and a photo will be taken by the Airway Cam™.
62035241|NCT00581230|EXPERIMENTAL|Laryngoscopy with RAMP|Next, the Rapid Airway Management Positioner (RAMP) will be positioned and inflated underneath the patient so that the patient is placed in the optimal sniffing position. The investigator will again perform laryngoscopy utilizing the same technique and the laryngeal view will be recorded.
62594445|NCT06158997|ACTIVE_COMPARATOR|Heated Eye Mask group|Participants in Heated Eye Mask group will use heated eye mask once.
62594446|NCT06410703|EXPERIMENTAL|CAN1012(0.01mg)+Toripalimab(240mg)|CAN1012(0.01mg)+Toripalimab(240mg)
62594447|NCT06410703|EXPERIMENTAL|CAN1012(0.017mg)+Toripalimab(240mg)|CAN1012(0.017mg)+Toripalimab(240mg)
62426381|NCT06136494|EXPERIMENTAL|Intervention group|The intervention group will receive an 8-week guided iCBT-program including goal setting, psychoeducation, physical activity, exposure, mindfulness, and acceptance.
62035242|NCT03146520||Colorectal (CRC)|stage I-IV CRC subjects
62426382|NCT06136494|ACTIVE_COMPARATOR|Control group|The control group will receive general support via weekly email contact to check how they are feeling and how they are dealing with their situation. The control group will be offered iCBT after 3 months.
62812062|NCT00790803|OTHER|Pegaptanib (Macugen)|Open label, non randomized, interventional controlled injection of 0.3mg of Pegaptanib (Macugen) every 6weeks with max of 5 injections over 30weeks.
62035243|NCT03146520||Polyps|subjects with adenoma or polyps
62035244|NCT03146520||Other cancers|subjects with other cancers
62035245|NCT03146520||Healthy|subjects with no evidence of CRC
62035246|NCT03068338|ACTIVE_COMPARATOR|Conventional therapy|Intermittent pneumatic compression devices are used for prevention of DVT.
62035247|NCT03068338|EXPERIMENTAL|Robotic Sock|Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
62035248|NCT04933955|ACTIVE_COMPARATOR|biodentine|pulptomy with biodentine
62035249|NCT04933955|ACTIVE_COMPARATOR|Theracal PT|pulpotomy with Theracal PT
62035250|NCT04933955|ACTIVE_COMPARATOR|Neo Putty|pulpotomy with Neo putty
62035251|NCT06378450|EXPERIMENTAL|10-minute dose|Daily guided mindfulness meditation practices of 10-minute duration.
62035252|NCT06378450|EXPERIMENTAL|20-minute dose|Daily guided mindfulness meditation practices of 20-minute duration.
62426383|NCT02619734|NO_INTERVENTION|Control|Conventional treatment established by the good clinical practice Patients received standard local care dressing method (compresses) to heal leg ulcers
62035253|NCT06378450|EXPERIMENTAL|30-minute dose|Daily guided mindfulness meditation practices of 30-minute duration.
62035254|NCT06378450|ACTIVE_COMPARATOR|3-4 minute minimal dose|Short daily meditation approximating 3-4 minute duration (akin to the breathing space practice in Mindfulness-based Cognitive Therapy or short practices in popular meditation apps).
62035255|NCT04027153|EXPERIMENTAL|Fee Arm|Participants in this arm will pay a fee (based on an income sliding scale) to have their medication delivered to their location of choice.
62035256|NCT04027153|ACTIVE_COMPARATOR|Standard of Care Arm|Participants in this arm will pick up their medication refill at the local clinic
62426384|NCT02619734|EXPERIMENTAL|Stem Cell Injection|Intramuscular implantation of Autologous bone marrow-derived mononuclear cells
62426385|NCT02643394|ACTIVE_COMPARATOR|Oral Acetaminophen|Oral Acetaminophen 1-hour before surgery
62426386|NCT02643394|ACTIVE_COMPARATOR|Intravenous Acetaminophen|Intravenous Acetaminophen within 1-hour prior to anesthetic emergence
62426387|NCT05292469|NO_INTERVENTION|Control arm|Routine hypertension care
62594448|NCT05994521|ACTIVE_COMPARATOR|ERCP alone|ERCP procedure alone and management of MGOO will be on a wait-and-see approach, using endoscopic interventions performed only if obstruction is clinically diagnosed
62594449|NCT05994521|EXPERIMENTAL|ERCP + ProEUS-GE|ERCP with prophylactic eus-guided gastroenterostomy
62594450|NCT04671381|EXPERIMENTAL|Audiology Best Practices plus Aural Rehabilitation (ABP+AR)|This experimental group will receive a hearing evaluation, an over-the-counter hearing aid fitting and orientation, and four-weeks of an aural rehabilitation program conducted by specially-trained community health workers. Additionally, these adults will complete pre- and post-questionnaires and speech perception testing.
62594451|NCT04671381|ACTIVE_COMPARATOR|Audiology Best Practices (ABP)|This comparison group of adults with hearing loss will receive a hearing evaluation and over-the-counter hearing aid fitting and orientation. The aural rehabilitation program will not be provided initially. These participants will complete pre- and post-questionnaires and speech perception testing.
62594452|NCT04671381|ACTIVE_COMPARATOR|Over-the-Counter Only (OTC-Only)|This comparison group of adults with hearing loss will receive a hearing evaluation. They will be provided with over-the-counter hearing aids but the audiologist will not assist with fitting the aids or providing an orientation. This arm mimics what would happen when a consumer privately purchases over-the-counter hearing aids. They will complete pre- and post-questionnaires and speech perception testing.
62594453|NCT04109287|EXPERIMENTAL|Two ultrasound scans and activation of NMES device|Participants will have their leg scanned using an ultrasound machine, before being asked to use the REVITIVE® device for 30 minutes. Their leg will then be scanned again.
62594454|NCT03655912|ACTIVE_COMPARATOR|Patch|Eye patch on the fellow eye and to near-vision activities (such as reading, drawing, etc)
62594455|NCT03655912|EXPERIMENTAL|Electronic Devices|Eye patch on the fellow eye and a electronic tablet
62594456|NCT03655912|EXPERIMENTAL|Red/Green Glasses|Red/green glasses and a electronic tablet
62594457|NCT03852628|ACTIVE_COMPARATOR|2mg Buprenex and 380mg Vivitrol|"2mg Buprenex and 380mg Vivitrol~Buprenex (buprenorphine) 2mg sublingual (SL) (taken every day for 12 weeks) , with Vivitrol (naltrexone) 380mg intramuscular injection (IM) (given every 4 weeks)"
62594458|NCT03852628|PLACEBO_COMPARATOR|Placebo|"Placebo (SL pill qd, IM injection q4weeks)~Placebo pill (taken sublingual every day for 12 weeks) and IM placebo (given intramuscular injection, every 4 weeks at baseline, week4 and week8)"
62594459|NCT02689869|EXPERIMENTAL|Ibrutinib and GA 101|"Initial therapy 6 cycles of Ibrutinib:~Ibrutinib 560 mg once daily every day until start of maintenance for a total of 24 weeks.~1000 mg of GA101 I.V. on days d 1, 8, 15 of cycle 1 and on day 1 of cycles 2-6 (21 day cycles).~Maintenance with another 24 months of ibrutinib plus GA101 in patients with clinical remission after the last induction cycle:~Ibrutinib 560 mg once daily every day. GA101 at a dose of 1000 mg I.V. every 2 months for a total of 24 months. The total duration of ibrutinib plus obinutuzumab therapy will therefore be 30 months.~In patients remaining MRD positive at 30 months without clinical progression, single agent ibrutinib therapy is continued for another 12 months."
62594460|NCT05229523||1/Children with diparetic and hemiparetic cerebral palsy|1/Children with diparetic and hemiparetic cerebral palsy aged 7-18 years with the Communication Function Classification System (CFCS) level ≤ 3 and Extended Gross Motor Function Classification System (GMFCS-E\&R) level ≤ 2
62594461|NCT05394792||Participants Receiving Upadacitinib|Participants receiving upadacitinib for moderate to severe atopic dermatitis.
62594462|NCT01038401|OTHER|HIV-1-infected patients on effective HAART|
62594463|NCT01038401|OTHER|Non Infected HIV Volunteers|
62594464|NCT05075824|EXPERIMENTAL|Crovalimab|Participants will receive a loading series of Crovalimab comprised of an intravenous (IV) loading dose on Day 1, followed by weekly Crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3 and 4. Maintenance SC dosing will begin at Week 5 and will continue every 4 weeks (Q4W) thereafter for a total of 48 weeks of treatment.
62594465|NCT05075824|PLACEBO_COMPARATOR|Placebo|Participants will receive matching Placebo administered by IV infusion and SC injection over the same duration as Crovalimab, for a total of 48 weeks of treatment.
62819612|NCT02177695|EXPERIMENTAL|Dose Dense MVAC|Methotrexate, 30 mg/m2, IV, Day 1, q 14 days x 4 cycles Vinblastine, 3 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Doxorubicin, 30 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Cisplatin, 70 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Filgrastim, 5 mcg/kg, SubQ/IV, Days 3-7, q 14 days x 4 cycles
62819613|NCT05864274|NO_INTERVENTION|OBSERVATION|PATIENTS WILL PARTICIPATE IN THE NEUROPSYCHOLOGY EVALUATION BUT WILL NOT USE THE COGNITIVE MOBILE TRAINING APPLICATION.
62819614|NCT05864274|EXPERIMENTAL|MOBILE COGNITIVE TRAINING APP|These patients will undergo neuropsychology evaluation and use the cognitive mobile training application
62819615|NCT05669716||parents of teens who vape|400 parent participants, defined as an adult who identifies as parenting an adolescent aged 13-17 whom they know/suspect is vaping.
62819616|NCT05669716||teens who formerly vaped|Adolescents N=400 (formerly vaped)
62819617|NCT05669716||teens who never vaped|Adolescents N=400 (never vaped).
62819618|NCT05669716||teens who vape|adolescent participants (minor subjects), comprised of N=400 (currently vaping, defined as vaping at least one day in the previous 30-day period
62819619|NCT05341817|EXPERIMENTAL|Letrozole|Day 1: Oral letrozole 10mg under direct observation therapy (DOT) in the clinic Day 2: Oral letrozole 10mg to self-administer at home Day 3: Oral letrozole 10mg to self-administer at home or at the hospital. Vaginal misoprostol 800mcg given in the ward, followed by vaginal misoprostol 400mcg, approximately 4 hours later, if subject showed no signs of abortion
62594466|NCT00576160|NO_INTERVENTION|A|"Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin.~Usual Care: Participants assigned to UCC will only receive the pre- and post-assessment session, and any adherence education or encouragement that is regularly provided by their treating physicians."
62594467|NCT00576160|EXPERIMENTAL|B|Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin. After Baseline, there is an initial session telephone session with PST therapist. Subsequent treatment sessions provide a context for the patient to discuss the problems and difficulties they face and that give rise to medication non-adherence.
62426388|NCT05292469|EXPERIMENTAL|Intervention arm|Comprehensive approach to hypertension management that includes BP audit and feedback by physician (nurse and doctor), and patient support to monitor BP, and home based patient care by community health workers to encourage self-monitoring of BP followed by tailored educational counselling on behavioral and lifestyle change in addition to routine care.
62426389|NCT03455335|EXPERIMENTAL|low dose cohort|20 million hMSCs .
62426390|NCT03455335|EXPERIMENTAL|mid dose cohort|40 million hMSCs
62594468|NCT03189667|EXPERIMENTAL|Drug coated balloon angioplasty|"* Vessel preparation with Pre dilatation~* Vessel treatment with Drug-coated balloon"
62426391|NCT03455335|EXPERIMENTAL|high dose cohort|80 million hMSCs .
62594469|NCT03189667|ACTIVE_COMPARATOR|Plain balloon angioplasty|"* Vessel preparation with Pre dilatation~* Vessel treatment with additional Plain balloon angioplasty:"
62594470|NCT01604863|EXPERIMENTAL|Arm A|HGS1036 + Paclitaxel + Carboplatin
62594471|NCT01604863|EXPERIMENTAL|Arm B|HGS1036 + Cisplatin + Etoposide
62594472|NCT01604863|EXPERIMENTAL|Arm C|HGS1036 + Docetaxel
62594473|NCT02222311||Autistic Children|Children diagnosed with autism spectrum disorder according to the criteria of the Diagnostic Statistical Manual-V will have blood samples taken for laboratory analysis.
62594474|NCT02222311||Healthy Children|Children with no developmental or physical diseases will have blood samples taken for laboratory analysis.
62594475|NCT02222311||Children with Attention Deficit Disorder|Blood samples from children with Attention Deficit Disorder will be measured for Vitamin D and oxidative stress markers.
62594476|NCT06665828|EXPERIMENTAL|REGN9533|Randomized as described in the protocol Escalating Cohorts including Optional Cohorts
62594477|NCT06665828|EXPERIMENTAL|Placebo|Randomized as described in the protocol
62426392|NCT01092390|EXPERIMENTAL|Lovaza|4 grams per day
62426393|NCT02010970|EXPERIMENTAL|Group 1 AZD3293-itraconazole|Subjects from Group 1 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 1, itraconazole will be administered orally twice daily starting on Day 5 for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the morning dose of itraconazole. Group 1 subjects will be discharged on Day 14.
62426394|NCT02010970|EXPERIMENTAL|Group 2 AZD3293-diltiazem|Subjects from Group 2 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 2, diltiazem will be administered orally once daily starting on Day 5, for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the diltiazem dose. Group 2 subjects will be discharged on Day 14.
62594478|NCT01053962|EXPERIMENTAL|SP-304 0.3 mg|SP-304 0.3 mg tablet by mouth once daily for 14 consecutive days.
62594479|NCT01053962|EXPERIMENTAL|SP-304 1.0 mg|SP-304 1.0 mg tablet by mouth once daily for 14 consecutive days.
62594480|NCT01053962|EXPERIMENTAL|SP-304 3.0 mg|SP-304 3.0 mg tablet by mouth once daily for 14 consecutive days
62594481|NCT01053962|EXPERIMENTAL|SP-304 9.0 mg|SP-304 9.0 mg tablet by mouth once daily for 14 consecutive days.
62594482|NCT01053962|PLACEBO_COMPARATOR|Placebo|Placebo tablet by mouth once daily for 14 consecutive days
62594483|NCT04112602||Patients with MPS|In this cohort are included patients under 18 years old with MPS (all types). The objective is to be representative of the diversity of MPS, and of this evolution.
62426395|NCT02010970|EXPERIMENTAL|Group 3 AZD3293-midazolam|Subjects from Group 3 will receive a single dose of midazolam on Day 1 . AZD3293 will be administered as an oral solution once daily starting on Day 2 for 9 consecutive days (Days 2 to 10) followed by a 7 day wash-out period. On Day 8 and Day 17 a single dose of midazolam will be administered. Group 3 subjects will be discharged on Day 18
62426396|NCT04099082||Cases|eligible patients with 10% decline in Forced Expiratory Volume (FEV1) at 2 months
62426397|NCT04099082||Controls|eligible patients free of 10% FEV1 decline at 2 months
62426398|NCT00567346|ACTIVE_COMPARATOR|grass pollen extract twice weekly|Current standard dose regimen of grass pollen immunotherapy (9,500 BU), given twice weekly. Note: patients in twice weekly dosing regimen will also receive placebo on days no active treatment is given.
62035257|NCT03698851|EXPERIMENTAL|Test Group|Guidor® and Guidor easy-graft® CRYSTAL Regeneration of the lesion will be performed with a synthetic membrane (Guidor®) with either Guidor easy-graft® CRYSTAL (Test).
62035258|NCT03698851|ACTIVE_COMPARATOR|Control Group (C)|Guidor® and Guidor easy-graft® CLASSIC Regeneration of the lesion will be performed with a synthetic membrane (Guidor®) with either Guidor easy-graft® CLASSIC (Test).
62035259|NCT05838534||Normal Skin|
62035260|NCT05838534||Mild Acne Vulgaris|
62035261|NCT05838534||Moderate Acne Vulgaris|
62035262|NCT05838534||Severe Acne Vulgaris|
62426399|NCT00567346|ACTIVE_COMPARATOR|Grass pollen extract, daily|Grass pollen immunotherapy, 9,500 BU, given daily
62426400|NCT00567346|ACTIVE_COMPARATOR|Increased dose of grass pollen extract|Increased dose of grass pollen immunotherapy, 19,000 BU, given daily
62426401|NCT00567346|PLACEBO_COMPARATOR|Placebo control|Patients randomized to placebo will receive placebo daily.
62426402|NCT04215107|OTHER|Control group|Crossover study Group. Each patient will be examined 2 seperate days. Randomized to standard breakfast meal or prolonged fasting. The examinator will be blinded to patient meal status.
62426403|NCT04215107|OTHER|IUGR group|Will only be examined one day. First ultrasound during fasting, and the second ultrasound 2 hours after a standard breakfast meal.
62426404|NCT00906685|ACTIVE_COMPARATOR|Intravitreal bevacizumab|
62426405|NCT00906685|SHAM_COMPARATOR|Sham injection|
62426406|NCT04220034||Patients receiving inhibitor checkpoint treatment|adult patients that will receive for the first time checkpoint inhibitor for a neoplasic disease in a center participating to the study
62426407|NCT05269056||Stage I-II gastric cancer|Cell-free DNA collected from plasma samples of 200 patients with stage I-II gastric cancer will undergo whole-genome sequencing
62426408|NCT05269056||Healthy controls|Cell-free DNA collected from plasma samples of 100 non-cancer individuals will serve as controls
62426409|NCT00563524|PLACEBO_COMPARATOR|1|
62426410|NCT01120522|EXPERIMENTAL|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
62426411|NCT03137095||Breast Cancer Patient Participants|Female breast cancer patients receiving chemotherapy
62426412|NCT03137095||Healthy, age-matched, female participants|Healthy, female, age-matched participants
62426413|NCT05627388|OTHER|Dreem 3 System|
62426414|NCT01966237||Acute kidney injury|AKI defined by an elevation in urinary AKI biomarkers
62426415|NCT01966237||No acute kidney injury|No AKI defined by normal urinary AKI biomarkers
62426416|NCT01055574||ProDisc-L|Subjects who received single-level ProDisc-L total disc replacement prior to physical capability evaluations
62812063|NCT04773951|EXPERIMENTAL|Dose escalation and extension group|"1. JS004 dose escalation: 1mg/kg, IV Q3W; 3mg/kg, IV Q3W; 10mg/kg, IV Q3W;~2. JS004 dose extension: 3mg/kg, IV Q3W; 200mg, IV Q3W;~3. JS004+Toripalimab Injection dose escalation: JS004 100mg+Toripalimab Injection 240mg, IV Q3W; JS004 200mg+Toripalimab Injection 240mg, IV Q3W;~4. JS004+Toripalimab Injection dose extension: JS004 100mg+Toripalimab Injection 240mg, IV Q3W or JS004 200mg+Toripalimab Injection 240mg, IV Q3W，to be determined."
62812064|NCT04956536||Group 1|Anterior cruciate ligament-injured patients
62812065|NCT00719641||Phase 1: Single Colonoscopy|Feasibility testing using the segmental stiffening wire
62035263|NCT02967627|EXPERIMENTAL|Incisional Negative Pressure Wound Therapy (iNPWT)|Patients in the iNPWT group will have their incision covered by a single layer of Mepitel wound contact layer followed by application of a KCI V.A.C Simplace ™ Dressing composed of a strip of black foam covering the entire length of the incision followed by coverage of the incision, Mepitel, and foam with an occlusive Tegederm ™ dressing to establish an airtight seal. Negative pressure will then be applied using a SensaT.R.A.C. Pad ™ to a setting of 100 mmHg continuous suction. Dressings shall remain in place and will be removed by the surgical team on the morning of the third post-operative day and left open to air thereafter. Any loss of seal of the dressing shall be reinforced using occlusive dressings.
62035264|NCT02967627|ACTIVE_COMPARATOR|Standard Therapy|Patients in the conventional dressings group will receive a standard Mepore ™ dressing applied to cover the entire incision. This will be left in place and and removed by the surgical team on the morning of the second postoperative day and will be left open to air thereafter. Dressings may be either reinforced or changed at the discretion of the surgical team due to drainage or saturation during the first two postoperative days.
62035265|NCT02552524|EXPERIMENTAL|rTMS active then rTMS placebo|"A 20 minute session of rTMS active at the frequency of 10 Hz then, 7 days later, a 20 minute session of rTMS placebo (rTMS active then rTMS placebo).~Patient will also have cognitive tests before and after rTMS session and HRV recording during visit."
62035266|NCT02552524|EXPERIMENTAL|rTMS placebo then rTMS active|"A 20 minute session of rTMS placebo then, 7 days later, a 20 minute session of rTMS active at the frequency of 10 Hz (rTMS placebo then rTMS active).~Patient will also have cognitive tests before and after rTMS session and HRV recording during visit"
62035267|NCT03215095|EXPERIMENTAL|Radioiodine (RAI) in Combination with Durvalumab (Medi4736)|Enrolled patients will be treated with durvalumab 1500 mg IV every 4 weeks. In Cycle 1/Week 3, Thyrogen 0.9 mg IM will be administered on two consecutive calendar days followed by 100 mCi (+/- 10 mCi) of RAI the next calendar day. Durvalumab will be continued every 4 weeks.
62035268|NCT01840267||laparoscopic surgery under general anesthesia|pediatric patients undergoing laparoscopic surgery under general anesthesia
62035269|NCT01968239|EXPERIMENTAL|OCT guided group|Patients randomized to this group will get the intravitreal injection of 0.5 mg ranibizumab if the morphological macular changes for recurrence of macular edema (microcystic changes with or without increase of central retinal thickness) will be detected by OCT.
62035270|NCT01968239|ACTIVE_COMPARATOR|Standard treatment|Patients randomized to this group will get the intravitreal injection of 0.5 mg ranibizumab according to the in SmPC defined re-treatment criteria (re-injection if decrease of BCVA will be detected).
62035271|NCT06669364||Epilepsy|"Device: BioEP~All patient's EEG will have the BioEP score conducted on it"
62035272|NCT06669364||Non-epilepsy|"Device: BioEP~All patient's EEG will have the BioEP score conducted on it"
62035273|NCT00864032|EXPERIMENTAL|Phase I|
62035274|NCT05061251|EXPERIMENTAL|BAY 2402234|Patients will receive 1 dose (5mg) orally, per day of BAY 2402234 for the 2 days prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery, for a total of 3 administered doses.
62035275|NCT05382780|EXPERIMENTAL|The breather respiratory muscle trainer group|40 patients (20 males and 20 females) will receive The breather respiratory muscle trainer for 30 minutes and mild interval aerobic training and respiratory training on treadmill 3 times / week for 12 weeks.
62035276|NCT05382780|EXPERIMENTAL|Diaphragmatic and localized breathing exercises group|40 patients (20 males and 20 females) will receive diaphragmatic and localized breathing exercises ( especially Middle \& Lower segments) and mild intensity interval aerobic training and respiratory training on treadmill 3 times / week for 12 weeks,
62035277|NCT04659980|ACTIVE_COMPARATOR|hilotherapy|
62035278|NCT04659980|ACTIVE_COMPARATOR|frozen gloves|
62035279|NCT05164159|ACTIVE_COMPARATOR|propofol group|During induction, the propofol group starts the effect site concentration at 4.0 ng/ml with TCI and adjusts it to around 3.0 \~ 4.0 ng/ml after intubation to maintain an appropriate EEG-based depth of anesthesia.
62035280|NCT05164159|EXPERIMENTAL|remimazolam group|Arm Description: In the remimazolam group, start remimazolam at 6 mg/kg/hr and adjust it to 1 mg/kg/hr after loss of consciousness to maintain an appropriate EEG-based depth of anesthesia.
62243232|NCT04585646|EXPERIMENTAL|Orion then Gemini|Subjects will be randomized to wear Orion daily disposable contact lens then Gemini daily disposable contact lens for 2 weeks in this randomized, cross-over bilateral dispensing study.
62812066|NCT00719641||Phase 2; Not randomized|Phase 2 participants who did not have looping during first colonoscopy
62426417|NCT01055574||anterior lumbar interbody fusion (AILF)|Subjects who received single-level anterior lumbar interbody fusion prior to physical capability evaluations
62812067|NCT00719641||Phase 2: Randomized to SSW during first colonoscopy|Phase 2 participants in whom looping occurred on first biopsy, randomized to subsequent use of segmental stiffening wire, then colonoscopy with no segmental stiffening wire upon repeat colonoscopy the next day.
62812068|NCT00719641||Phase 2: Randomized to SSW during second colonoscopy|Phase 2 participants in whom looping occurred on first biopsy, randomized to no subsequent use of the segmental stiffening wire that day, then colonoscopy with segmental stiffening wire upon repeat colonoscopy the next day.
62812069|NCT02321241||Group 1|According to the recommendations of the Summary of Products Characteristics (SmPC) Administration by intravitreal injection
62812070|NCT01935739||Primary Breast Tumor|Primary breast tumor were test for HER2/neu status.
62812071|NCT01935739||Axillary Lymph Nodes.|Axillary Lymph Nodes were tested for HER2/neu status.
62812072|NCT02361385||this is a pilot study|All patients will undergo PET-CT with PBR28, with the CT being localised to one group of joints only
62235745|NCT05083338||Observational (questionnaire, pain assessment, biospecimen)|Patients complete questionnaires over 15 minutes and undergo pain assessments prior to surgery and at 3, 6 and 12 months after surgery. Patients also undergo blood sample collection before surgery and optionally at 3, 6 and 12 months after surgery.
62594484|NCT04112602||Non-MPS patients|In this control group are included patients under 18 years old, with no respiratory problems, no MPS.
62594485|NCT02735525|EXPERIMENTAL|Smartphone monitoring|Intervention arm
62594486|NCT03592537|ACTIVE_COMPARATOR|fentanyl|Group F: will receive intrathecal 0.5% bupivacaine (0.3 mg/kg) + (5ug) of fentanyl intrathecally
62594487|NCT03592537|ACTIVE_COMPARATOR|midazolam|Group M: will receive intrathecal 0.5% bupivacaine (0.3 mg/kg) + 0.5 mg of midazolam intrathecally
62035281|NCT03281902||Ancillary-Correlative (genetic profile analysis)|Patents undergo collection of blood and stool samples at baseline, 7 days after letrozole monotherapy treatment, and at completion of each cycle, urine samples at baseline and completion of each cycle, and saliva samples at baseline. Patients also undergo collection of blood and urine samples at disease progression. Biopsy samples are analyzed for genetic profile via genome sequencing and RNA sequencing. Biopsy samples are also used for the generation of xenograft mice model.
62035282|NCT03424824|EXPERIMENTAL|BP1.3656 low dose|administration of BP1.3656 at 30 µg
62035283|NCT03424824|EXPERIMENTAL|BP1.3656 intermediate dose|administration of BP1.3656 at 60 µg
62035284|NCT03424824|PLACEBO_COMPARATOR|Placebo|administration of placebo
62235746|NCT00711529|EXPERIMENTAL|Hypnotherapy|"Patients randomized to the experimental arm were scheduled for three one-hour inductions by a single hypnotherapist, each one week apart. Standardized outlines were used for each induction. The second and third sessions also began with a standardized induction, followed by the establishment of an anchor, or physical reference point (forefinger to thumb), used to invoke images of coolness, which were individualized according to patient preference.~Patients were also instructed by the same hypnotherapist in self-hypnosis and guided imagery techniques to be used at home with the assistance of standardized audio compact disks. Participation lasted eight weeks."
62426418|NCT04624841|EXPERIMENTAL|ICG group|"Participants receive an intravenous injection of 0.05 mg/kg of ICG 45 minutes preoperatively.~A Pinpoint Endoscopic Fluorescence System (Novadac Technologies Inc., Canada) for ICG Fluorescence Observation with the easy switchable white light-fluorescent mode is used.~Before dividing any tubular structure, the fluorescence imaging mode is routinely used again, and fluorescent angiography is performed by re-injecting the same dose of ICG as initially used.~After the division of the cystic duct and artery, the fluorescence imaging mode is applied again to check for bile leakage."
62426419|NCT04624841|NO_INTERVENTION|No ICG Group|No ICG is administered after randomization of the patient to a control group and hence will not produce any enhancement of the image on A Pinpoint Endoscopic Fluorescence System for ICG Fluorescence Observation. This will continue as a routine Laparoscopic cholecystectomy without fluorescent imaging enhancement.
62594488|NCT03592537|PLACEBO_COMPARATOR|Bupivacaine|Group B:intrathecal 0.5% bupivacaine (0.3 mg/kg)
62035285|NCT03424824|EXPERIMENTAL|BP1.3656 high dose|administration of BP1.3656 at 90 µg
62594489|NCT01351480|OTHER|abatacept|open label use of abatacept for 12 months
62594490|NCT03421314|EXPERIMENTAL|Zinc|Participants in this arm will take a daily 30 mg dose of zinc gluconate during 6 months
62594491|NCT03421314|EXPERIMENTAL|Selenium|Participants in this arm will take a daily 200 mcg of selenium yeast during 6 months
62594492|NCT03421314|EXPERIMENTAL|Zinc + Selenium|Participants in this arm will take a daily 30 mg dose of zinc gluconate + 200 mcg of selenium yeast during 6 months
62594493|NCT03421314|NO_INTERVENTION|Control|Participants in this arm will not take supplementation as a control.
62594494|NCT03075891|EXPERIMENTAL|Ivermectin 1% cream + Doxycycline 40 mg MR capsules|
62594495|NCT03075891|PLACEBO_COMPARATOR|Ivermectin 1% cream + Oral placebo capsules|
62035286|NCT01570101|EXPERIMENTAL|CE Marked Sapheon Closure System in GSV|"CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting."
62035287|NCT06580626|EXPERIMENTAL|decompression group|
62035288|NCT06580626|EXPERIMENTAL|Ethoss group|
62035289|NCT06580626|EXPERIMENTAL|ridge splitting group|
62235747|NCT00711529|ACTIVE_COMPARATOR|Gabapentin|Patients randomized to the gabapentin arm were prescribed 900mg of the drug daily (300 mg by mouth three times daily).
62594496|NCT05253716|EXPERIMENTAL|immune nutrition support|In the immune nutrition support group, in addition to diet, and patients will also consume two bottles per day of a high-calorie, high-protein ONS and three capsules of fish oil after discharge lasted for 6 months.
62594497|NCT05253716|NO_INTERVENTION|control|In the control group, patients will receive nutrition counseling in addition to diet.
62035290|NCT06503211|EXPERIMENTAL|B cell injection targeting CD19 chimeric antigen receptor|UTAA09 Injection The subjects, who sign the informed consent forms and been screeneinclusion/exclusion criteria, will be assigned into 3 x 108\~1 x 1010 CD19-CAR - γδT cells.
62594498|NCT02991729|ACTIVE_COMPARATOR|Routine care|These patients will receive routine care at our institution for counseling on aneuploidy screening; they will be counseled by a genetic counselor on options, and following counseling, will select their test of choice. All patients will complete a knowledge and demographics questionnaire prior to genetic counseling. Patients in this arm will then complete a knowledge and decisional conflict survey immediately following genetic counseling.
62594499|NCT02991729|EXPERIMENTAL|Experimental|These patients will use an iPad-based decision aid explaining options for aneuploidy screening and testing. They will then immediately be counseled by a genetic counselor on their options as is routine at our institution, and following counseling, will select their test of choice. All patients will complete a knowledge and demographics questionnaire prior to genetic counseling. Patients in this arm will then complete a knowledge and decisional conflict survey following use of the decision aid, and again immediately following genetic counseling.
62812073|NCT03309020|ACTIVE_COMPARATOR|Control|Control with clinical need for cataract surgery
62235748|NCT05330338|OTHER|Congenital heart disease|
62235749|NCT04359875|EXPERIMENTAL|Management by a student/general practitioner tandem|Patients will receive a phone call from the medical student who will inquire about their health. The medical student will then transmit this information to the general practitioner who will decide on the most suitable management for the patient.
62594500|NCT05016141|NO_INTERVENTION|no intervention|Participants will be observed for 12 months. Participants will use the Health in Motion app to set goals and keep track of their health and health events, including falls. These participants will NOT receive the education modules or the exercise program.
62594501|NCT05016141|EXPERIMENTAL|digital fall prevention program|Participants will complete the Health in Motion digital fall prevention program for 12 months. This program consists of education modules (modified from the Matter of Balance Program) and exercises based on a digital translation of the Otago Exercise Program.
62426420|NCT00627458|EXPERIMENTAL|INFANRIX HEXA PF GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-free (PF) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
62426421|NCT00627458|EXPERIMENTAL|INFANRIX HEXA PC GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-containing (PC) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
62594502|NCT05981703|EXPERIMENTAL|Dose Escalation|Phase 1a: Sequential cohorts of increasing dose levels of BGB-26808 will be evaluated as monotherapy and in combination with tislelizumab.
62594503|NCT05981703|EXPERIMENTAL|Dose Expansion|Phase 1b: The recommended dose for expansion (RDFE) for BGB-26808 (alone or in combination with tislelizumab) from Phase 1a will be evaluated.
62594504|NCT06271668||Clinical Decision Support (CDS): Naloxone Alert|"Encounters where the naloxone clinical decision support (CDS) alert fired. CDS logic is programmed to fire alert when a provider places and order for a high-risk opioid analgesic prescription to a patient without an active naloxone prescription.~High-risk prescription logic to trigger the Naloxone CDS:~\[(NOT 1 AND (2 AND AT LEAST 1 OF (3, 4, 5, 6))) AND 7 AND NOT 8\]~1. ACTIVE OR PENDED NALOXONE PRESCRIPTION ORDER~2. OPIOID SCRIPT BEING PLACED CRITERIA~3. DAILY Milligram Morphine Equivalent (MME) \>=90 UNSIGNED ORDER~4. DAILY MME \>=90 EXISTING~5. DIAGNOSIS OF OPIOID USE DISORDER~6. DIAGNOSIS HISTORY OF OPIOID OVERDOSE~7. PROVIDER LOGGED INTO ELLIGIBLE DEPARTMENTS~8. DISCHARGE TO HOSPICE"
62594505|NCT06271668||Usual Care|Control group of contemporary encounters where clinical decision support (CDS) is not active. Usual care.
62594506|NCT04787471|ACTIVE_COMPARATOR|30 minute photoactivation|photoactivation of riboflavin 0.1% using 365-nm UV light, 3mW/cm2 for 30 minutes
62594507|NCT04787471|ACTIVE_COMPARATOR|10 minute photoactivation|photoactivation of riboflavin 0.1% using 365-nm UV light, 9mW/cm2 for 10 minutes
62594508|NCT05010512|OTHER|DT1, then Infuse|Delefilcon A contact lenses worn first, with kalifilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 (-0/+3) days on a daily wear, daily disposable basis.
62235750|NCT04359875|NO_INTERVENTION|Usual care|"Usual care, i.e. patients will call their general practitioner when needed, up to 1 month, which corresponds to the estimated time for the intervention to be delivered to all patients in the intervention group.~At the end of the intervention at 1 month, patients in the usual care group will also receive a phone-call from the medical student/general practitioner tandem."
62426422|NCT00627458|ACTIVE_COMPARATOR|CONTROL GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the licensed formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
62426423|NCT05640583|EXPERIMENTAL|IBD|10 patients diagnosed with colonic IBD (5 diagnosed with Ulcerative Colitis and 5 diagnosed with Crohn's Disease) scheduled for a surveillance colonoscopy
62426424|NCT05640583|ACTIVE_COMPARATOR|Control|10 patients scheduled for a routine screening colonoscopy who do not have a history of IBD symptoms or IBD diagnosis
62426425|NCT02876705|EXPERIMENTAL|Pain Patterns|In this vein, we tend to study and delineate individualized pain and discomfort patterns in exercise.
62426426|NCT01766310|PLACEBO_COMPARATOR|placebo|placebo tablet in the same appearance and taste with folic acid orally once a day for 8 weeks of the study
62235751|NCT02587429|EXPERIMENTAL|Patienteducation|(Patients with PCS\>22). An education in pain coping delivered by physiotherapists. The education consist of seven sessions over a four months period. Each session is individual and will last 30 minutes. Focus will be on pain behaviour and pain coping based on Cognitive Behavioral Therapy.
62235752|NCT02587429|NO_INTERVENTION|Control group 1|(Patients with PCS\>22). Patients randomly assigned to this arm will undergo usual treatment for total knee arthroplasty.
62235753|NCT02587429|NO_INTERVENTION|Control group 2|(Patients with PCS\<12). Patients in this arm will undergo usual treatment for total knee arthroplasty. Patients in this arm are not randomized but matched by age, gender and BMI with patients in control group 1.
62426427|NCT01766310|EXPERIMENTAL|folic acid|Folic acid tablet 5mg per day orally (5mg/tablet) once a day for 8 weeks of the study
62426428|NCT00176852|OTHER|RIC Bu/Flu (A) (discontinued)|Full Preparative Regimen for subjects with matched donors using Busulfan on Day -8 and -7, Fludarabine on Day -6 through -2, antithymocyte globulin (ATG) on Day -2 through -1, total lymphoid radiation (TLI) on Day -1, stem cell infusion on Day 0.
62426429|NCT00176852|EXPERIMENTAL|MA Bu/Cy (B)|Myeloablative Preparative Regimen for subjects with HLA identical sibling donors consists of Busulfan on day -9 through -6, Cyclophosphamide on day -5 through -2, ATG on day -3 through -1, stem cell infusion on Day 0 and Granulocyte Colony Stimulating Factor on day -3 until ANC \>2500 x 2 days.
62426430|NCT00176852|EXPERIMENTAL|RIC Cy/Flu/TBI (A2)|Patients with sickle cell disease or thalassemia who do not have an HLA-identical sibling donor or who has pre-existing organ dysfunction making myeloablative condition ineligible will receive Campath on day -10 through -6, Cyclophosphamide on day -7, Fludarabine on day -6 through -2, total body irradiation (TBI) on day -1, stem cell infusion on Day 0.
62426431|NCT02023788||Pneumostem®|"Low Dose Group (3 subjects): 1.0 x 10\^7 cells/kg, High Dose Group (6 subjects): 2.0 x 10\^7 cells/kg~Intervention: Biological: Pneumostem®"
62235754|NCT05167123|EXPERIMENTAL|Indirect Pulp Capping|TheraCal (LC) will be applied to affected dentin after excavation of infected dentin
62235755|NCT05167123|EXPERIMENTAL|Direct Pulp Capping|TheraCal (LC) will be applied to pinpoint pulp exposures (less than 1mm ) in vital pulps surrounded by sound dentin.
62812074|NCT03309020|EXPERIMENTAL|EVD Survivors|EVD survivors with need for cataract surgery
62812075|NCT01095289||Total Laryngectomized|
62812076|NCT01679288|EXPERIMENTAL|ultrasound arm|Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
62812077|NCT04041713|ACTIVE_COMPARATOR|Rett T|Rett T is a powder for oral suspension. Dosage is dependent on weight. For participants weighing \<30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in approximately 125 mL of water. For participants weighing ≥30 kg, a 8 g dose (i.e., two 4 g sachets) is intended to be administered orally once a day after dissolving in approximately 250 mL of water.
62812078|NCT04041713|PLACEBO_COMPARATOR|Placebo|Placebo is a powder for oral suspension. Dosage is dependent on weight. For participants weighing \<30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in approximately 125 mL of water. For participants weighing ≥30 kg, a 8 g dose (i.e., two 4 g sachets) is intended to be administered orally once a day after dissolving in approximately 250 mL of water.
62812079|NCT05817903|EXPERIMENTAL|ARM A|Axitinib (starting dose 5 mg BID orally) in addition to nivolumab (lat dose of 480 mg IV every four weeks as per standard clinical practice)
62812080|NCT05817903|ACTIVE_COMPARATOR|ARM B|Nivolumab (flat dose of 480 mg IV every four weeks as per standard clinical practice) after nivolumab plus ipilimumab induction as per standard clinical practice
62812081|NCT06131632|EXPERIMENTAL|Breast conserving surgery|
62426432|NCT01002131||Digital Volume tomography|three-dimensional digital imaging using cone beam tomography (CBCT)
62035291|NCT06497465|EXPERIMENTAL|Arm 1: DTG 50 mg/ 3TC 300mg (Dovato®) twice daily (BID)|Arm 1: DTG 50mg/3TC 300 mg fixed-dose-combination (FDC) tablet (Dovato®) twice daily during TB therapy and for 2 weeks after, then DTG 50mg/3TC 300 mg FDC tablet (Dovato®) once daily to week 52
62035292|NCT06497465|EXPERIMENTAL|Arm 2: DTG 50 mg/ 3TC 300mg (Dovato®) once daily (QD) in the morning with DTG 50 mg in the evening|Arm 2: DTG 50mg/300mg FDC tablet plus DTG 50mg at night during TB treatment and for 2 weeks after, then DTG 50 mg/ 3TC 300 mg FDC tablet (Dovato®) once daily to week 52
62035293|NCT06497465|ACTIVE_COMPARATOR|Arm 3: Standard of Care 3-drug ART (DTG+ TDF/3TC) plus DTG 50mg in the evening.|Arm 3: Local Standard of Care 3-drug ART (DTG 50mg + TDF/3TC) plus DTG 50 mg at night during TB treatment and for 2 weeks after, then DTG 50 mg + TDF/3TC FDC tablet once daily to week 52
62812082|NCT06131632|ACTIVE_COMPARATOR|Radical modified mastectomy|
62035294|NCT02248870|PLACEBO_COMPARATOR|Saline|Bupivacaine with adrenaline with 2 ml. of Saline added
62035295|NCT02248870|EXPERIMENTAL|Dexamethasone|Bupivacaine with adrenaline with 2 ml. of Dexamethasone added
62035296|NCT03835533|EXPERIMENTAL|Cohort A: NKTR-214 + Nivolumab|
62035297|NCT03835533|EXPERIMENTAL|Cohort B: SBRT + CDX-301 + Poly-ICLC + Nivolumab|
62235756|NCT04003857|EXPERIMENTAL|PNEUMOSTEM®|A single intratracheal administration of Pneumostem® (10.0 x 10\^6 cells/kg)
62235757|NCT04003857|PLACEBO_COMPARATOR|normal saline|A single intratracheal administration of normal saline
62235758|NCT05633732||Standardized View Group|The echocardiography view images of patients in this group are standardized.
62235759|NCT00292461|ACTIVE_COMPARATOR|zonisamide|tablet
62235760|NCT00292461|ACTIVE_COMPARATOR|lamotrigine|tablet
62812083|NCT00976807|NO_INTERVENTION|Control|
62812084|NCT00976807|EXPERIMENTAL|Intervention|Pulmonary Rehabilitation
62812085|NCT01486875||BIAsp 30|
62812086|NCT06334575|ACTIVE_COMPARATOR|ICS treatment|
62812087|NCT06334575|NO_INTERVENTION|No ICS treatment|
62812088|NCT05045768|EXPERIMENTAL|Postinfectious ibs and diarrhea predominant classical IBS|Capsule containing Tamarind seed polysaccharide containing xyloglucan, combined with a pea protein reticulated with grape seed extractand a prebiotic, the xilooligosaccharide (Gelsectan, Devintec sagl) twice daily
62812089|NCT04050553|EXPERIMENTAL|Tirzepatide|Participants received a starting dose of 2.5 mg tirzepatide once weekly (QW) for 2 weeks, followed by an increase to 5 mg QW for 2 weeks, and 10 mg QW for 4 weeks until the 15-mg dose was reached and maintained for the remainder of the treatment period (4 weeks) administered subcutaneously (SC) in one of two study periods.
62812090|NCT04050553|PLACEBO_COMPARATOR|Placebo|Participants received placebo QW administered SC in one of two study periods.
62812091|NCT03053375|EXPERIMENTAL|Acute/subacute; active device|MDCure active device
62812092|NCT03053375|PLACEBO_COMPARATOR|Acute/subacute; sham|MDCure sham device
62035298|NCT03835533|EXPERIMENTAL|Cohort C: CDX-301 + INO-5151 + Nivolumab|
62035299|NCT00689650|EXPERIMENTAL|A|
62035300|NCT00689650|NO_INTERVENTION|B|
62035301|NCT01638910|EXPERIMENTAL|EV/DNG (Qlaira, BAY86-5027)|
62035302|NCT05105295|EXPERIMENTAL|Experimental Group|Subjects receive a third dose of inactivated COVID-19 vaccine
62035303|NCT05711654|EXPERIMENTAL|Health coaching group|"The patients in the health coaching group will first be given data collection tools, and then the COPD patient information training created by the researcher will be given.~For the first eight weeks after the training, face-to-face meetings will be held with patients once a week.~Data collection tools will be applied to the patients again in the fourth week and 12 weeks after the interviews are over."
62035304|NCT05711654|NO_INTERVENTION|Control group|"Data collection tools will be applied to the patients in the control group first, and then the COPD patient information training created by the researcher will be given.~After the training, there will be no interviews with the patients, and data collection tools will be applied again in the 12th and 20th weeks."
62035305|NCT01347333|OTHER|liver metastases|Oligometastases (1-3) with aggregate tumor diameter \< 6 cm Metastases from neuroendocrine tumors with functional endocrine syndromes
62235761|NCT05057286|EXPERIMENTAL|Subjects with gummy smile|The study procedure consisted of recruitment, pre\&post-operative photography, gingivoplasty, BTX-A injection, recall visits, and data collecting.
62235762|NCT01813851|NO_INTERVENTION|control group|"Patients in the control group will receive:~Dietary counseling by a dietician and if necessary modification of the prescription of oral nutritional supplements or intradialytic parenteral nutrition to reach recommended targets according to the European Best Practice Guidelines on Nutrition (energy intake 30-40 kcal/kg of ideal weight/day, protein intake 1.1 g/kg of ideal weight/day"
62426433|NCT00656396|ACTIVE_COMPARATOR|Control|Standard care
62426434|NCT00656396|EXPERIMENTAL|Intervention|Point of care monitoring used
62812093|NCT03053375|EXPERIMENTAL|Chronic; active device|MDCure active device
62812094|NCT03053375|PLACEBO_COMPARATOR|Chronic; sham|MDCure sham device
62235763|NCT01813851|EXPERIMENTAL|activity group|"Patients in the group exercise will:~Dietary counseling by a dietician and if necessary modification of the prescription of oral nutritional supplements or intradialytic parenteral nutrition to reach recommended targets according to the European Best Practice Guidelines on Nutrition (energy intake 30-40 kcal/kg of ideal weight/day, protein intake 1.1 g/kg of ideal weight/day A program of physical activity consisting of progressive endurance and resistance training on a cycle ergometer, performed during the dialysis session under supervision and counseling by a qualified trainer"
62235764|NCT00827801||Group 1|MDASI-HF questionnaire provided to Doctor for symptom management.
62235765|NCT00827801||Group 2|MDASI-HF questionnaire collected not provided to Doctor.
62812095|NCT03372785||Complete revascularization group|Complete Revascularization of CTO and non-CTO lesions
62812096|NCT03372785||Non-CTO revascularization group|Non-CTO vessel revascularization
62812097|NCT02503592|ACTIVE_COMPARATOR|Cochlear Implant group - Vestibular testing|Adult patients who have been implanted with a Med-El Cochlear implant device within the last 3 months who completed pre-op vestibular testing as standard of care. These subjects will undergo a series of post-op vestibular testing, at the 3 month and 12 month follow up visits
62812098|NCT02503592|NO_INTERVENTION|Control Group - existing historical vestibular data|This group will consist of existing historical vestibular testing data only. No subjects will be enrolled on this arm.
62812099|NCT02489435|EXPERIMENTAL|10 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
62812100|NCT02489435|EXPERIMENTAL|20 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
62035306|NCT01347333|OTHER|Primary Liver Tumors|Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma
62235766|NCT01319214|EXPERIMENTAL|Inderal, neutral cues|
62235767|NCT01319214|EXPERIMENTAL|Inderal, drug cues|
62035307|NCT02813850|NO_INTERVENTION|control|standard medical care
62035308|NCT02813850|EXPERIMENTAL|oxygen therapy|
62426435|NCT06102837||glioma patients receiving tumor vaccine|
62426436|NCT06102837||glioma patients receiving conventional treatment|
62426437|NCT06102837||non-tumor patients|
62426438|NCT03250013|EXPERIMENTAL|Children and adolescents with ADHD|Children and adolescents medicating for ADHD of any subtype (presentation) with comorbidities
62426439|NCT01353105|EXPERIMENTAL|Ex vivo lung transplantation|single-group studies
62812101|NCT02489435|EXPERIMENTAL|30 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
62812102|NCT06060236|EXPERIMENTAL|ibuprofen|ibuprofen intravenous 800 mg
62812103|NCT06060236|EXPERIMENTAL|dexketoprofen|dexketoprofen intravenous 50 mg
62812104|NCT03353675|EXPERIMENTAL|TG4010/Chemotherapy/Nivolumab|
62035309|NCT00969033|EXPERIMENTAL|CS-1008 with irinotecan|CS-1008 and irinotecan
62035310|NCT00969033|ACTIVE_COMPARATOR|irintoecan|irinotecan alone
62235768|NCT01319214|EXPERIMENTAL|Placebo, neutral cues|
62426440|NCT06332365|EXPERIMENTAL|Group I experimental|Group I: Received a combination of 0.1% hyaluronic acid and 0.2% triamcinolone acetonide.
62426441|NCT06332365|ACTIVE_COMPARATOR|Group II|Was treated exclusively with 0.2% triamcinolone acetonide.
62426442|NCT06332365|ACTIVE_COMPARATOR|Group III|Received only 0.1% hyaluronic acid.
62426443|NCT00127192|PLACEBO_COMPARATOR|1|Placebo QD 12-week
62426444|NCT00127192|EXPERIMENTAL|2|25 mg QD 12-week
62426445|NCT00127192|EXPERIMENTAL|3|50 mg QD 12-week
62594509|NCT05010512|OTHER|Infuse, then DT1|Kalifilcon A contact lenses worn first, with delefilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 (-0/+3) days on a daily wear, daily disposable basis.
62594510|NCT05943288||CADe +|Olympus Endoscopy Computer-Aided Detection (CADe) system
62594511|NCT05943288||CADe -|Standard of Care Endoscopy (HD Whitelight)
62812105|NCT05461859||≥30% HR increase after CNA|Patients in whom ≥30% increase in HR after CNA of RAGP was achieved.
62594512|NCT06032052|EXPERIMENTAL|Metastatic NSCLC patients over 65 years old|In metastatic NSCLC patients over 65 years old, we employed gemcitabine or paclitaxel or vinorelbine plus immunotherapy for squamous cell carcinoma. Paclitaxel or pemetrexed plus immunotherapy are available for non-squamous and non-small cell lung cancer.
62594513|NCT01542723|EXPERIMENTAL|LMWH|750 patients with an arthroscopy or the knee will be randomized to receive treatment with a LMWH
62594514|NCT01542723|NO_INTERVENTION|No intervention|750 patients with an arthroscopy of the knee will be randomized to receive no treatment.
62594515|NCT01491204|EXPERIMENTAL|paclitaxel +HM30181|
62594516|NCT00003779|ACTIVE_COMPARATOR|BCG-Connaught|
62594517|NCT00003779|ACTIVE_COMPARATOR|BCG Onko-Tice|
62594518|NCT00539149|ACTIVE_COMPARATOR|1|
62594519|NCT00539149|PLACEBO_COMPARATOR|2|
62594520|NCT03731559|ACTIVE_COMPARATOR|DTG 50 mg OD with food|DTG 50 mg OD with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
62594521|NCT03731559|ACTIVE_COMPARATOR|DTG 50 mg BID|DTG 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
62594522|NCT02184585|EXPERIMENTAL|Cohort 1: Fasted state|Treatment will be administered orally to 42 subjects in the fasted state. Subjects will be required to fast overnight (minimum 10 hours) and for a minimum of 4 hours after each dose. Subjects will participate in 3 treatment periods and assigned to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) in accordance with the randomization schedule generated by Clinical Statistics. The three treatment periods will be separated by a minimum washout period of 28 days
62594523|NCT02184585|EXPERIMENTAL|Cohort 2 : Fed state|Treatment will be administered orally to 42 subjects in the fed state (high fat breakfast). Dosing will take place within 30 minutes of the start of the meal. Subjects will participate in 3 treatment periods and assigned to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) in accordance with the randomization schedule generated by Clinical Statistics. The three treatment periods will be separated by a minimum washout period of 28 days
62594524|NCT00648622|EXPERIMENTAL|1|Carvedilol Tablets 12.5 mg
62594525|NCT00648622|ACTIVE_COMPARATOR|2|Coreg® Tablets 12.5 mg
62594526|NCT02190032|ACTIVE_COMPARATOR|Control group|"Intubating a manufacturer-provided-angled double-lumen tube (=Conventional-angled group,MallinckrodtTM endotracheal tube, Covidien)"
62594527|NCT02190032|EXPERIMENTAL|Tube angle modification|The angle of the double lumen tube(MallinckrodeTM endotracheal tube) is modified individually.At sniffing position, the distal tip of the tube is placed at the patient's cricoid cartilage level and the tube is bent at the intersection point of the two airway axes (oropharyngeal axis and tracheal axis) with an angle between the two axes.
62812106|NCT05461859||<30% HR increase after CNA|Patients in whom ≥30% increase in HR after CNA of RAGP was \*not\* achieved.
62812107|NCT05039749|EXPERIMENTAL|Human Central Lighting (HCL) Room|This inpatient room was outfitted with lights that mimic the day/night cycle, thereby supporting circadian rhythm. Day time lights were automatically on during 0600 to 1900 and in use any time the patients would normally utilize their lights, with a goal of three hours of light exposure per day. The lights automatically transitioned to warmer toned evening lighting at 1900.
62812108|NCT05039749|NO_INTERVENTION|Standard Hospital Lighting (SL) Room|The lighting in this room was standard florescent hospital lighting. The only changes in the lighting was the on/off settings normally associated with lighting.
62812109|NCT04870762|EXPERIMENTAL|Arm I (3D printed oral stent)|Patients wear 3D printed oral stent during standard of care radiotherapy.
62812110|NCT04870762|ACTIVE_COMPARATOR|Arm II (standard of care)|Patients receive standard of care during treatment.
62812111|NCT05440097|OTHER|single-arm|GINA guideline education and implementation
62812112|NCT05862753|EXPERIMENTAL|Etomidate 0,2 mg/kg|8 patients recruited, to receive an injection of bolus of Etomidate at dosage 0,2 mg/kg,
62426446|NCT00127192|EXPERIMENTAL|4|100 mg QD 12-week
62235769|NCT01319214|EXPERIMENTAL|Placebo, drug cues|
62235770|NCT01509131|EXPERIMENTAL|2L PEG-CS plus bisacodyl|Patients will be asked to take 2L PEG-CS plus bisacodyl (10-20 mg according to patient bowel habit)
62235771|NCT01509131|ACTIVE_COMPARATOR|2L PEG-ASC|Patients will be asked to take PEG-ASC according to labeling instructions
62235772|NCT05059834|EXPERIMENTAL|online mindfulness resources + usual care|The mindfulness online resources consisted of 4 weekly modules. Mindfulness exercises, including body scan, mindful breathing, mindful eating, mindful walking, 3-min breathing space, and thought distancing exercise, are audio-recorded to facilitate participants to practice mindfulness. Readings and graphics are included to explain the concept of mindfulness and to share with participants the common difficulties that participants may come across during mindfulness practices.
62235773|NCT05059834|OTHER|usual care|patients will receive usual care from doctors
62426447|NCT00127192|EXPERIMENTAL|5|200 mg QD 12-week
62426448|NCT03242993|EXPERIMENTAL|treatment group|"all patients successfully enrolled will be assigned to the treatment group:~1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to \[18F\]-AzaFol"
62426449|NCT02248285|EXPERIMENTAL|Intervention|FilmArray™ GI Panel testing will be standard of care and provided at no cost. Additional testing may be ordered at the discretion of the clinician.
62426450|NCT02248285|NO_INTERVENTION|Pre-intervention|Testing will be at the discretion of the clinician using standard laboratory tests, and specimens will be collected as appropriate for these methods.
62426451|NCT04985942|EXPERIMENTAL|Lumateperone 42 mg|
62426452|NCT04985942|PLACEBO_COMPARATOR|Placebo|
62426453|NCT02846467|EXPERIMENTAL|Portable video media|Patients who receive informed consent trough portable video media around 10 minutes
62426454|NCT02846467|ACTIVE_COMPARATOR|Traditional IC|Patients who receive traditional IC (written consent) during 10 to 15 minutes
62426455|NCT01447979|EXPERIMENTAL|All patients|this is the only arm of the study, and concerns all patients.
62426456|NCT04312399|OTHER|oral hormonal therapy|Postmenopausal women who start with oral hormonal therapy (Progesteron + uterogestan) according to standard of care practice. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
62426457|NCT04312399|OTHER|transdermal hormonal therapy|Postmenopausal women who start with transdermal hormonal (Oestrogel + uterogestan) therapy according to standard of care practice. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
62812113|NCT05862753|EXPERIMENTAL|Etomidate 0,3 mg/kg|10 patients recruited, to receive an injection of bolus of Etomidate at dosage 0,3 mg/kg
62812114|NCT04365972|EXPERIMENTAL|Home-delivered attention bias modification (ABM)|A home-delivered ABM comprised of 5 sessions using a variant of the dot-probe task in which the target probe always replaces neutral rather than threat (health-related) stimuli to induce diversion of attention away from threat.
62812115|NCT05399069|EXPERIMENTAL|VGR-R01|Subretinal injection of VGR-R01
62426458|NCT04312399|OTHER|oral hormonal therapy + hysterectomy|Postmenopausal women who start with oral hormonal therapy (progesteron) according to standard of care practice and had a hysterectomy in the past. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
62426459|NCT04312399|OTHER|transdermal hormonal therapy + hysterectomy|Postmenopausal women who start with transdermal hormonal therapy (Oestrogel ) according to standard of care practice and had a hysterectomy in the past. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
62426460|NCT04312399|OTHER|oral hormonal therapy + IUD|Postmenopausal women who start with oral hormonal therapy (Progynova) according to standard of care practice and have already an intra-uterine device. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
62812116|NCT03290040||Metropolit Cohort|Danish birth cohort of men born in 1953 in the Metropolitan area of Copenhagen. These test-persons are divided into two groups based on performance in cognitive tests at late midlife compared to young adulthood; Positive expected performance and negative expected performance and sampled from a birth cohort of 11.532 men.
62812117|NCT03290040||Herlev Hospital, Memory Clinic|Persons from the Memory Clinic at Herlev Hospital. These subjects are diagnosed with either MCI or AD.
62812118|NCT06348771|ACTIVE_COMPARATOR|saturated fatty acids (SFA) meal|mixed meal test over 6 hours
62235774|NCT00820027|EXPERIMENTAL|Etoricoxib 90 mg|Participants received etoricoxib 90 mg once daily, matching placebo to etoricoxib 120 mg once daily, and matching placebo to ibuprofen 600 mg every 8 hours for 7 days.
62235775|NCT00820027|EXPERIMENTAL|Etoricoxib 120 mg|Participants received etoricoxib 120 mg once daily, matching placebo to etoricoxib 90 mg once daily, and matching placebo to ibuprofen 600 mg every 8 hours for 7 days.
62235776|NCT00820027|ACTIVE_COMPARATOR|Ibuprofen 1800 mg|Participants received ibuprofen 600 mg every 8 hours, matching placebo to etoricoxib 120 mg once daily, and matching placebo to etoricoxib 90 mg once daily for 7 days.
62235777|NCT00820027|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo to etoricoxib 90 mg and matching placebo to etoricoxib 120 mg once daily, and matching placebo to ibuprofen every 8 hours for 7 days.
62235778|NCT05373953|EXPERIMENTAL|mild impairment subjects|Administration of a single dose of CHF6001 800 µg in mild impairment subjects
62812119|NCT06348771|EXPERIMENTAL|monounsaturated fatty acids (MUFA) peanut meal|mixed meal test over 6 hours
62235779|NCT05373953|EXPERIMENTAL|moderate impairment subjects|Administration of a single dose of CHF6001 800 µg in moderate impairment subjects
62235780|NCT05373953|EXPERIMENTAL|severe impairment subjects|Administration of a single dose of CHF6001 800 µg in severe impairment subjects
62235781|NCT05373953|ACTIVE_COMPARATOR|healthy volunteers|Administration of a single dose of CHF6001 800 µg in healthy volunteers
62235782|NCT02656160|PLACEBO_COMPARATOR|Placebo|
62235783|NCT02656160|ACTIVE_COMPARATOR|Dalfampridine|
62235784|NCT06152861|EXPERIMENTAL|Travoprost Ophthalmic Topical Cream low-dose|Travoprost Ophthalmic Topical Cream low-dose administered once-daily in the evening for 28 days
62235785|NCT06152861|EXPERIMENTAL|Travoprost Ophthalmic Topical Cream mid-dose|Travoprost Ophthalmic Topical Cream mid-dose administered once-daily in the evening for 28 days
62235786|NCT06152861|EXPERIMENTAL|Travoprost Ophthalmic Topical Cream high-dose|Travoprost Ophthalmic Topical Cream high-dose administered once-daily in the evening for 28 days
62594528|NCT04510246|EXPERIMENTAL|Intervention|Practitioners randomised to the intervention arm will receive the standard of care surveillance letter if the notification is new. Both new and repeat notifications will receive further enhanced case support during the project if required. Support can be provided at the first phone call, or if accepted and required, in a 12-week period during which the DoH health care worker can do follow-up calls with the GP or directly with the patient to inform the patient and enhance linkage back to their GP. At the end of the 12-week period, a follow-up call we be carried out for the project evaluation.
62594529|NCT04510246|NO_INTERVENTION|Control|All practitioners randomised to this arm will be contacted by telephone approximately 12 weeks after an HCV notification has been made from the laboratory to the Department of Health.This is not current standard practise and will be performed by the DoH HCV health worker for the project evaluation purpose. At this phone call consent will be sought for the GP to provide information on their clinical management of the notified patient. The details of the clinical management survey are provided as Appendix B. Details provided or missing from the standard DoH surveillance form would be confirmed with the GP at this phone call. Three attempts will be made to contact the practitioner to complete the survey within a 30-day period before they are determined to be unable to be contacted.
62812120|NCT03563339|EXPERIMENTAL|P-POD|All participants will complete the prevention for postpartum onset distress (P-POD)
62812121|NCT03335384|EXPERIMENTAL|Measurement of Pdi|Two small balloons, which are attached to small, flexible tubes, will be put into the esophagus (food tube) and stomach through the nose. Each balloon is about 2 inches long (deflated) and about the width of a pencil tip. A gastric balloon will be inserted into subject's stomach while an esophageal balloon will be inserted into the subject's esophagus. To reduce any discomfort with this procedure, lidocaine gel or spray will be put into the subject's nose and administered to the back of the throat before the balloon. In addition, swallowing water during the procedure will help to reduce any gagging sensation and will assure that the balloon goes into the esophagus.
62235787|NCT06152861|ACTIVE_COMPARATOR|Timolol maleate ophthalmic solution, 0.5%|Timolol maleate ophthalmic solution, 0.5% administered twice daily, morning and evening, for 28 days
62235788|NCT06152861|ACTIVE_COMPARATOR|Travoprost ophthalmic solution, 0.004%|Travoprost ophthalmic solution, 0.004% administered once daily in the evening for 28 days
62235789|NCT02496910|ACTIVE_COMPARATOR|Group 1 - Period 1|Telmisartan/Amlodipine 80/5 mg (FDC) and Chlorthalidone 25mg
62235790|NCT02496910|EXPERIMENTAL|Group 2 - Period 1|YH22162 FDC tablet of Yuhan Corporation
62235791|NCT02496910|EXPERIMENTAL|Group 1 - Period 2|YH22162 FDC tablet of Yuhan Corporation
62235792|NCT02496910|ACTIVE_COMPARATOR|Group 2 - Period 2|Telmisartan/Amlodipine 80/5 mg (FDC) and Chlorthalidone 25mg
62594530|NCT01645878|EXPERIMENTAL|Hands on|breast feeding instructed by direct help of instructor
62235793|NCT02262923|NO_INTERVENTION|Control|"Poor responders will be defined as women who have undergone a previous IVF cycle with fewer than 4 oocytes retrieved and at least one of the following two criteria: (1) advanced age (≥40 years) or any other risk factor for poor ovarian response and (2) abnormal ovarian reserve testing (antral follicle count (AFC) \< 5-7 or anti-mullerian hormone (AMH) level \< 3.6-7.9 pmol/L). Poor responders who will be undergoing a repeat IVF cycle will be recruited for the study with informed consent.~In the control arm, patients will undergo the same ovarian stimulation protocol as the previous IVF cycle in which they experienced a poor response. Starting 3 weeks prior to the first day of stimulation until the time of ovulation trigger (approximately 5 weeks overall), these patients will receive an oral placebo three times daily."
62243233|NCT04585646|EXPERIMENTAL|Gemini then Orion|Subjects will be randomized to wear Gemini daily disposable contact lens then Orion daily disposable contact lens for 2 weeks in this randomized, cross-over bilateral dispensing study.
62594531|NCT01645878|EXPERIMENTAL|hands off|
62594532|NCT01645878|OTHER|Control|Routin breast feeding education
62812122|NCT03335384|EXPERIMENTAL|Measurement of SNIPs|While the gastric and esophageal balloon catheters are in place, the subject will be asked to perform a maximal sniff maneuver (SNIP) while one nostril is occluded with a plug containing a nasal pressure transducer to measure airway pressure during maximal inspiration. The distal end of the pressure catheter will be connected to a hand held pressure meter to display peak pressure and to provide you visual feedback. This maneuver will be performed 10 times.
62235794|NCT02262923|EXPERIMENTAL|Experimental|"Poor responders will be defined as women who have undergone a previous IVF cycle with fewer than 4 oocytes retrieved and at least one of the following two criteria: (1) advanced age (≥40 years) or any other risk factor for poor ovarian response and (2) abnormal ovarian reserve testing (antral follicle count (AFC) \< 5-7 or anti-mullerian hormone (AMH) level \< 3.6-7.9 pmol/L). Poor responders who will be undergoing a repeat IVF cycle will be recruited for the study with informed consent.~In the experimental arm, patients will undergo the same ovarian stimulation protocol as the previous IVF cycle in which they experienced a poor response. Starting 3 weeks prior to the first day of stimulation until the time of ovulation trigger (approximately 5 weeks in total), these patients will receive oral metoclopramide 5mg three times daily.."
62235795|NCT04508634|EXPERIMENTAL|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
62235796|NCT04508634|ACTIVE_COMPARATOR|Metformin Group|Metformin Group
62426461|NCT04312399|OTHER|transdermal hormonal therapy + IUD|Postmenopausal women who start with transdermal hormonal therapy (Oestrogel ) according to standard of care practice and have an intra-uterine device. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
62812123|NCT02160080|EXPERIMENTAL|Boc+Peg-int alfa+Rbv|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
62235797|NCT05900960|EXPERIMENTAL|Warm tea|50 degrees celsius hot tea.
62426462|NCT04312399|OTHER|selective oestrogenreceptor modulators|Postmenopausal women who start with hormonal therapy according to standard of care practice and take selective oestrogenreceptor modulators (Nolvadex) because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
62426463|NCT04312399|OTHER|aromatase inhibitors|Postmenopausal women who start with hormonal therapy according to standard of care practice and who taken aromatase inhibitors (Femara) because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
62594533|NCT06342999|EXPERIMENTAL|Intervention Group: Fetal Aortic Valvuloplasty|Women diagnosed with HLHS will undergo fetal aortic valvuloplasty between 21 and 29 weeks gestation.
62594534|NCT06342999|NO_INTERVENTION|Control Group: Expectant Management|Women diagnosed with HLHS will undergo expectant management with postnatal surgery.
62594535|NCT05930795|ACTIVE_COMPARATOR|Patients with pelvic organ prolapse undergone pectopexy surgery|
62594536|NCT05930795|ACTIVE_COMPARATOR|Patients with pelvic organ prolapse undergone lateral suspension surgery|
62594537|NCT06231693||Trastuzumab-deruxtecan|
62812124|NCT06070792|EXPERIMENTAL|NEURO LINGUISTIC PROGRAM|"first experimental group. It will be administered to primiparous mothers after caesarean section in the first 48 hours after the sixth postoperative hour, once every eight hours, for a total of six times. Each session will last 20 minutes.~In the NLP application; firstly, the most frequently used visual, auditory and/or tactile representation system of the woman will be determined. Then, the internal and external reactions caused by the symptoms after caesarean section, her feelings and thoughts about her baby and breastfeeding will be combined with the anchoring technique. Then, with the swish technique, the existing negative emotions will be reduced and tried to be deleted from the most frequently used representation system. The woman's negative thoughts about breastfeeding will be changed in a positive direction with the belief change model."
62235798|NCT05900960|ACTIVE_COMPARATOR|Cool tea|10 degrees celsius cool tea
62235799|NCT02496520|EXPERIMENTAL|Vaccines with autologous dendritic cells|Vaccines with autologous dendritic cells
62235800|NCT00225576|NO_INTERVENTION|1|Paper prescribing, 2005 and 2007
62235801|NCT00225576|EXPERIMENTAL|2|Paper prescribing 2005 vs. electronic prescribing 2007
62235802|NCT04805554|EXPERIMENTAL|Joint Insights Decision Aid|Participants view the entire Joint Insights decision aid for knee osteoarthritis including: Education Module with information about knee osteoarthritis and risks and benefits of various treatment options, Preferences and Values elicitation questions, and Personalized Risk/Benefit Report.
62235803|NCT04805554|ACTIVE_COMPARATOR|Education Module Only|Participants view the Joint Insights Education Module only
62235804|NCT03313453|EXPERIMENTAL|Aircleaner group|PuriCare (HEPA Air Cleaner) in active mode
62235805|NCT03313453|PLACEBO_COMPARATOR|Control comparator|Mock device of PuriCare in active mode
62235806|NCT03035266|EXPERIMENTAL|Blood Flow Restriction (BFR)|All subjects will perform traditional post-operative rehabilitation until discharge from the hospital following surgery and continue until formal discharge from physical therapy upon completion of rehabilitation. One week following surgery, subjects randomized to the BFR group will begin combining BFR with all lower extremity strengthening exercises supervised in clinic up to 3 times per week for 12 weeks.
62235807|NCT03035266|ACTIVE_COMPARATOR|Standard rehabilitation (control group)|All subjects will perform traditional post-operative rehabilitation until discharge from the hospital following surgery and continue until formal discharge from physical therapy upon completion of rehabilitation.
62235808|NCT02441062|OTHER|68Ga-DOTATOC PET/CT|Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study. Subjects may receive a second 68Ga-DOTATOC PET/CT for restaging after therapy 12-36 months following the first scan.
62594538|NCT01275755|PLACEBO_COMPARATOR|Placebo|Each participant received 1 placebo capsule orally every day (QD) during the Run-in Placebo Period (1 week), the Double-blind Treatment Period (4 weeks), and the Run-out Placebo Period (1 week).
62594539|NCT01275755|EXPERIMENTAL|ADL5945 0.25 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally QD for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.25-milligrams (mg) ADL5945 capsule orally QD for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally QD for 1 week.
62235809|NCT05217563|NO_INTERVENTION|Standard Care|Standard Care Control Group (Group 1). Parents in the standard care control group will receive a pamphlet containing evidence-based information on needle pain management. Parents in the standard care control group will not receive any information regarding pain memory reframing, nor will they be encouraged to talk about their children's pain vaccine injection experience. Parents in the standard care control group will receive text/email reminders to use needle pain management strategies before each second vaccination appointment.
62235810|NCT05217563|ACTIVE_COMPARATOR|Intervention Group (Pamphlet and video only)|Intervention Group (Group 2; Pamphlet and video Only). Parents in this intervention group will receive a pamphlet containing evidence-based information on needle pain management and a pamphlet summarizing memory reframing principles. The pamphlet will have a link to a video summarizing the memory reframing strategies.
62426464|NCT04312399|OTHER|Duavive|Postmenopausal women who start with hormonal therapy according to standard of care practice and who take duavive because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
62426465|NCT04312399|OTHER|Control|Postmenopausal women who don't start with hormonal therapy according to standard of care practice. At the first study visit blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
62235811|NCT05217563|ACTIVE_COMPARATOR|Intervention Group (Pamphlet, video, and verbal Instructions).|Intervention Group (Group 3; Handout and Verbal Instructions). Parents in this intervention group will receive a pamphlet containing evidence-based information on needle pain management, a pamphlet summarizing memory reframing principles (with a video link), and verbal instructions on how to use the intervention principles with their children. The instructions will be provided via telephone or video conferencing and will last approximately 10 to 15 minutes. Trained graduate students or post-doctoral fellows will deliver the instructions. Similar to previous interventions, to boost mastery of the material, the researcher will provide suggestions for specific questions and remarks to make while reminiscing. The instructions will be audio-recorded to allow fidelity coding.
62235812|NCT01969318|PLACEBO_COMPARATOR|Placebo/Metformin|
62812125|NCT06070792|EXPERIMENTAL|PROGRESSIVE MUSCLE RELAXATION EXERCISES|"second experimental group. It will be administered to primiparous mothers after caesarean section in the first 48 hours after the sixth postoperative hour, once every eight hours, for a total of six times. Each session will last 20 minutes.~PMRE; All muscles of the body will be tried to be relaxed respectively with the commands given gradually."
62812126|NCT06070792|NO_INTERVENTION|control|The control group will not receive NLP or PMRE.
62235813|NCT01969318|EXPERIMENTAL|SP2086 (50mg q.d)/Metformin|
62235814|NCT01969318|EXPERIMENTAL|SP2086 (100mg q.d.)/Metformin|
62812127|NCT03337308|EXPERIMENTAL|BA 180 mg + EZE 10 mg FDC|Bempedoic acid (BA) + ezetimibe (EZE) fixed-dose combination (FDC) 180 mg/10 mg tablets taken orally once daily for 12 weeks
62235815|NCT04331353|ACTIVE_COMPARATOR|Comparator 1 (tailored approach)|Multi-component intervention tailored to the participant's allergic profile.
62426466|NCT02156466|EXPERIMENTAL|MSB0010841 30 mg|
62426467|NCT02156466|EXPERIMENTAL|MSB0010841 60 mg|
62426468|NCT02156466|EXPERIMENTAL|MSB0010841 120 mg|
62594540|NCT01524939|EXPERIMENTAL|Investigational product|
62235816|NCT04331353|ACTIVE_COMPARATOR|Comparator 2 (insecticidal bait)|Insecticidal bait for cockroach reduction.
62235817|NCT00516451|EXPERIMENTAL|1|
62426469|NCT02156466|EXPERIMENTAL|MSB0010841 240 mg|
62426470|NCT02156466|PLACEBO_COMPARATOR|Placebo|
62426471|NCT04724928|ACTIVE_COMPARATOR|Non-metastatic MIBC|No signs of extra-pelvic metastasis on conventional imaging (abdominopelvic and thoracic CT/MRI) and 18F-FDG-PET-CT's
62426472|NCT04724928|EXPERIMENTAL|Oligo-metastatic MIBC on 18F-FDG-PET-CT|No signs of extra-pelvic metastasis on conventional imaging (abdominopelvic and thoracic CT/MRI) but presence of ≤ 3 metastasis on 1 or both 18F FDG PET-CT 's
62594541|NCT06344026|EXPERIMENTAL|ANPD001|
62594542|NCT04183153|EXPERIMENTAL|Healthy Arm|
62594543|NCT01871181|EXPERIMENTAL|Ilioinguinal block|Patients in this group will receive an ultrasound-guided ilioinguinal nerve block.
62594544|NCT01871181|ACTIVE_COMPARATOR|Local infiltration|Patients in this group will receive the standard method of local infiltration of local anesthetic around the surgical site.
62594545|NCT06517888|EXPERIMENTAL|Cohort 1|Adult participants to receive a single unilateral intracochlear administration of AAVAnc80-antiVEGF (dose level 1) in the study ear using a sterile, one-time use investigational medical device.
62594546|NCT06517888|EXPERIMENTAL|Cohort 2|Adult participants to receive a single unilateral intracochlear administration of AAVAnc80-antiVEGF (dose level 2) in the study ear using a sterile, one-time use investigational medical device.
62594547|NCT06517888|EXPERIMENTAL|Cohort 3|Adult participants to receive a single unilateral intracochlear administration of AAVAnc80-antiVEGF (dose level 3) in the study ear using a sterile, one-time use investigational medical device
62594548|NCT04068129||Burma|Patients from remote Burma clinic
62594549|NCT04068129||Alaska|Patients in pediatric ophthalmology clinic
62594550|NCT05800197||premenopausal women|premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer T4 Nany or Tany N2-3
62594551|NCT05800197||postmenopausal women|postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer T4 Nany or Tany N2-3
62594552|NCT04170348|EXPERIMENTAL|Daily oral vitamin D3|Oral vitamin D3, 3,333 IU
62594553|NCT04170348|ACTIVE_COMPARATOR|Monthly bolus oral vitamin D3|Bolus oral vitamin D3, 100,000 IU
62812128|NCT03337308|EXPERIMENTAL|BA 180 mg|Bempedoic acid (BA) 180 mg tablets taken orally once daily for 12 weeks
62035311|NCT04534595||Students attending SBHCs|The students enrolled in 5 schools with the school based health clinic implemented would be studied in terms of their experience during the COVID-19 pandemic.
62235818|NCT02537626|ACTIVE_COMPARATOR|Erchonia ALS Laser|The Erchonia ALS Laser is a mains powered variable hertz laser device made up of five independent red laser diodes mounted in scanner devices and positioned equidistant from each other. Each scanner emits 7.5 milliwatts (mW) ± 1.0 mW 640 nanometers (nm) with a tolerance of ±10 nm of red laser light.
62235819|NCT02537626|PLACEBO_COMPARATOR|Placebo Laser|The Placebo Laser is identical in appearance and operation to the Erchonia ALS Laser but does not emit any therapeutic light.
62594554|NCT06544707|EXPERIMENTAL|0.003% AR-15512|One drop in each eye in a staggered cadence (left eye followed by dosing of the right eye) approximately 2-4 hours apart
62594555|NCT01790828||Xyntha group|Xyntha will be administered according to physician's discretion.
62594556|NCT02394340|EXPERIMENTAL|Luliconazole Cream 1%|Participants will receive 1 oral capsule of omeprazole 40 milligrams (mg) on Day 1 and Day 8. Participants will also receive luliconazole cream 1% to cover the entire affected surface areas and adjacent areas once daily in the morning on Day 2 (24 hours after initial omeprazole dosing) through Day 8.
62594557|NCT04865601||CRC|Patient affected by any sporadic colorectal cancer
62812129|NCT03337308|ACTIVE_COMPARATOR|EZE 10 mg|Ezetimibe (EZE) 10 mg overencapsulated tablets taken orally once daily for 12 weeks
62812130|NCT03337308|PLACEBO_COMPARATOR|Placebos|Placebos to match identical bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or identical bempedoic acid 180 mg tablet, or identical ezetimibe 10 mg capsule, taken orally, once daily for 12 weeks
62812131|NCT03597347|EXPERIMENTAL|Group 1|Participants with chronic pulmonary MAC or MABSC infection who have not consistently achieved negative NTM sputum cultures while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months prior to the Baseline visit.
62812132|NCT03597347|EXPERIMENTAL|Group 2|Participants with chronic pulmonary MAC or MABSC infection who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance.
62035312|NCT04439422|EXPERIMENTAL|SAINT|
62035313|NCT04439422|ACTIVE_COMPARATOR|Self-help material|
62035314|NCT03195257|PLACEBO_COMPARATOR|Hypoglycemia-saline|
62035315|NCT03195257|EXPERIMENTAL|Hypoglycemia-GIP|
62035316|NCT03195257|ACTIVE_COMPARATOR|Hypoglycemia-GLP-1|
62035317|NCT03195257|EXPERIMENTAL|Hyperglycemia-GIP|
62235820|NCT04637477|EXPERIMENTAL|Virtual ELM|
62235821|NCT00026208|EXPERIMENTAL|Stanford V-C + Low-dose Radiotherapy|"Sanford V-C = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.~Radiotherapy = 20 Gy modified involved field radiotherapy"
62235822|NCT00026208|EXPERIMENTAL|Stanford V-C only|"Sanford V-C = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide."
62235823|NCT04223830|EXPERIMENTAL|Exalt DScope 01B|Subjects will have a clinically indicated per standard of care endoscopic retrograde cholangiopancreatography (ERCP) or other duodenoscope-based procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
62594558|NCT04865601||FAP|Patients affected by familial adenomatous polyposis coli
62594559|NCT04865601||HNPCC|Patient affected by hereditary non polyposis colorectal cancer
62594560|NCT04865601||Lynch|patient affected by lynch syndrome
62594561|NCT04865601||others|Patients affected by ulcerative colitis, chron disease, diverticulitis and other colon diseases, which represent the control
62594562|NCT05113888|EXPERIMENTAL|Qizhi Weitong granules high-dose group|interventions：Qizhi Weitong granules Specification: 5.0g/bag，the drug content is equivalent to 2 bags of Qizhi Weitong granules (2.5g/ bag commercially available).
62594563|NCT05113888|EXPERIMENTAL|Qizhi Weitong granules low-dose group|interventions：Qizhi Weitong granules Specification: 5.0g/bag，the drug content is equivalent to 1 bag of Qizhi Weitong granules (2.5g/ bag commercially available).
62594564|NCT05113888|PLACEBO_COMPARATOR|The control group|interventions：Qizhi Weitong granules placebo Specification: 5.0g/bag，Does not contain effective crude drug ingredients.
62594565|NCT04912440||MSE-ERCP|Group of patients, that received motorized spiral enteroscopy assisted ERCP in altered anatomy at the single study center
62812133|NCT03597347|EXPERIMENTAL|Group 3|Participants with chronic pulmonary MAC or MABSC infection not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen based on failure to meet American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic findings and clinical symptoms beyond what is expected from underlying CF).
62812134|NCT01943344|EXPERIMENTAL|Treatment|Subjects that receive VIVASURE CLOSURE DEVICE™
62035318|NCT03195257|PLACEBO_COMPARATOR|Hyperglycemia-Saline|
62035319|NCT00594854|EXPERIMENTAL|PN400|PN 400 (esomeprazole/naproxen) dosed twice daily
62035320|NCT00594854|ACTIVE_COMPARATOR|Diclofenac/Misoprostol|diclofenac 75mg/misoprostol 200 mcg dosed twice daily
62235824|NCT05336253|EXPERIMENTAL|EVERYbody Project-Connect Online Program|"Three weekly 90-minute online group sessions facilitated by expert peer leaders. Retains key dissonance activities and the inclusivity focus of the original EVERYbody Project (e.g., expanded gender focus, critically discussing the impact of limited diversity representation in cultural appearance norms). Additional activities were added, including an increased focus on body compassion (self-acceptance) and weight neutrality content to target weight bias.~College students with body image interest and lived or academic diversity and advocacy experience will complete 16 hours of training to become expert peer leaders. Training includes observation, practice, and feedback on using the program manual and managing groups. Students will self-assess and be evaluated by the primary trainer on facilitation readiness. Only peer leaders with sufficient expertise will be invited to facilitate groups."
62243409|NCT01726452|EXPERIMENTAL|B (CROSS)|Arm B consists of the multimodal CROSS arm, which includes a combination of chemotherapy and radiotherapy prior to surgery. The patient will receive four and a half (4.5) weeks of radiation therapy (41.4 Gy/23 fractions), and 5 weekly cycles of chemotherapy. The chemotherapy and radiotherapy will run concurrently over a 4 and a half-week period. Chemotherapy is given by intravenous infusion on days 1, 8, 15, 22 and 29. The radiation will generally commence on the 1st day of treatment and will run for 4 and a half weeks as follows: days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31 inclusive.
62426473|NCT04724928|EXPERIMENTAL|Poly-metastatic MIBC on 18F-FDG-PET-CT|No signs of extra-pelvic metastasis on conventional imaging (abdominopelvic and thoracic CT/MRI) but presence of \> 3 metastasis on 1 or both 18F FDG PET-CT 's
62426474|NCT04071392||Post-Essure Group|"Healthy women with history of Essure hysteroscopic permanent contraception.~Eligible participants will then undergo the HSG imaging study - a standard radiological imaging study to determine that the fallopian tubes are open and free of disease. It also checks the uterine cavity for any abnormalities."
62426475|NCT04071392||Control Group|"Healthy women with no history of permanent contraception.~Eligible participants will then undergo the HSG imaging study - a standard radiological imaging study to determine that the fallopian tubes are open and free of disease. It also checks the uterine cavity for any abnormalities."
62426476|NCT04394910|EXPERIMENTAL|Pomegranate Juice|Dietary supplementation with 8 oz. commercially-available pomegranate juice consumed daily.
62426477|NCT04394910|PLACEBO_COMPARATOR|Placebo Juice|Dietary supplementation with 8 oz. placebo juice (identical to pomegranate juice but lacking polyphenols) consumed daily.
62426478|NCT06515444|EXPERIMENTAL|10 minutes only|Group will only receive a socioemotional development material for teachers to implement with their students
62426479|NCT06515444|EXPERIMENTAL|10 minutes plus|Group will receive socioemotioanl devleopment material for teachers to implement with their students plus professional development for teachers
62426480|NCT06515444|OTHER|Delayed|While intervention in arms 1 and 2, this arm will not receive internvention. It will receive the 10 minutes plus, once the other two arms have their second year follow up measure.
62426481|NCT06365151|EXPERIMENTAL|experimental|"treatment will be carried out following a previously validated approach algorithm.~Articulatory techniques, soft tissue mobilization techniques, trigger point inhibition, etc. will be used."
62426482|NCT06365151|SHAM_COMPARATOR|sham|"A sham treatment will be performed following a previously validated approach algorithm.~techniques will be simulated in such a way that they will have no therapeutic effect."
62426483|NCT04643054|EXPERIMENTAL|Ovotransferrin|Dietary Supplement: Ovotransferrin
62426484|NCT04643054|NO_INTERVENTION|Standard of care|Standard of care
62426485|NCT02410031||Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)|Prescribers of Diane-35 who agree and fulfill the criteria inclusion to participate in the survey
62426486|NCT02789124|EXPERIMENTAL|Carotid Artery Flow Time|Patients with radial aline and flotrac vigileo will have carotid dopper measured for carotid flow time and a passive leg raise
62426487|NCT01032330|NO_INTERVENTION|Observation|Patients randomized to the observation group will receive no treatment (other than refractive correction).
62426488|NCT01032330|ACTIVE_COMPARATOR|Occlusion Therapy|Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
62426489|NCT00479765|EXPERIMENTAL|1|OncoGel administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel
62426490|NCT02221622|EXPERIMENTAL|Allopregnanolone 2 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
62426491|NCT02221622|EXPERIMENTAL|Allopregnanolone 4 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
62426492|NCT02221622|EXPERIMENTAL|Allopregnanolone 6-18 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
62426493|NCT02221622|PLACEBO_COMPARATOR|Placebo|Drug: Placebo injection (intravenous solution) once per week for 12 weeks
62426494|NCT01917188|ACTIVE_COMPARATOR|Full simulation and education|Patients who will receive full simulation and education session prior to discharge.
62426495|NCT01917188|OTHER|See simulation room, usual education|Patients will be shown the simulation room prior to discharge but will only receive usual education.
62426496|NCT01917188|NO_INTERVENTION|Usual care|Patients will receive usual care by bedside nurse.
62426497|NCT04765189|PLACEBO_COMPARATOR|Placebo|
62035321|NCT03902379|EXPERIMENTAL|Supportive Care (CCI intervention)|Patients complete 3 modules of online CCI intervention.
62035322|NCT02170987|EXPERIMENTAL|Dabigatran etexilate low|
62035323|NCT02170987|EXPERIMENTAL|Dabigatran etexilate high|
62035324|NCT02170987|PLACEBO_COMPARATOR|Placebo to dabigatran etexilate|
62035325|NCT02170987|ACTIVE_COMPARATOR|Moxifloxacin|
62235825|NCT05336253|ACTIVE_COMPARATOR|Self-Help Workbook|In this time-matched comparison intervention, participants will be provided with an online copy of The Body Is Not An Apology Workbook by author and activist Sonya Renee Taylor (2021). Weekly emails will assign workbook activities to complete on their own (90 minutes per week for three weeks). This low-dissonance comparison intervention covers many of the same topics within the EVERYbody Project-Connect (body acceptance and scrutinizing the diversity within body ideals) and its activities include reflective writing and drawing exercises to challenge media messages around bodies, identify systems of oppression underpinning body messages, challenge body stereotypes, and make peace with your own body. Activities within the workbook are considered low-dissonance since they will be done privately and not shared.
62235826|NCT02827253||Predialysis|Patients with CKD (4 and 5 stages by KDOQI guidelines) underwent MRI to obtain in vivo images of brain anatomy that were subsequently analyzed by the data processing package FreeSurfer (version 5.3). A MRI 6 months after starting haemodialysis will be performed to analyze changes in gray and white matter of the brain.
62235827|NCT02827253||Haemodialysis|Patients with end stage of renal disease (ESRD) in haemodialysis underwent MRI to obtain in vivo images of brain anatomy that were subsequently analyzed by the data processing package FreeSurfer (version 5.3). A one year follow up MRI will be performed to analyze the changes in gray and white matter of the brain.
62235828|NCT02207270|EXPERIMENTAL|Same day discharge|Patients who experienced uncomplicated PCI as well as an uncomplicated 6-hour observation period, will be randomly assigned to same day discharge.
62235829|NCT02207270|OTHER|Overnight stay standard care|Patients who experienced uncomplicated PCI, as well as an uncomplicated 6-hour observation period, will be randomly assigned to an overnight stay, generally considered standard care.
62235830|NCT04526197|EXPERIMENTAL|Treatment Sequence A-B|"Participants received 1 treatment during each study period in the following sequence:~* Treatment A: Celecoxib.~* Treatment B: Celecoxib plus ALXN1840."
62812135|NCT01205217|EXPERIMENTAL|Arm A|"Lapatinib in combination with epirubicin and cyclophosphamide followed by paclitaxel and lapatinib.~Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days Lapatinib 1000 mg orally once daily continuously Loperamide as required for the proactive management of diarrhoea~Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week Lapatinib 1000 mg orally once daily continuously Loperamide as required for the proactive management of diarrhoea"
62812136|NCT01205217|ACTIVE_COMPARATOR|Arm B|"Epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab.~Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days~Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week"
62235831|NCT04526197|EXPERIMENTAL|Treatment Sequence B-A|"Participants received 1 treatment during each study period in the following sequence:~* Treatment B: Celecoxib plus ALXN1840.~* Treatment A: Celecoxib."
62235832|NCT06334302|EXPERIMENTAL|Omega Galil O'Sweet hazelnut cocoa spread|Omega Galil O'Sweet hazelnut cocoa spread is composed of 8% sucrose, 26% MCT oil, 6% cocoa butter, 6% cocoa powder, 10% Hazelnut paste, 24% fibers, 13% rice flour. It contains a total of 27.3 gram carbohydrates/ 100gram, 520 kcals/100 grams, and very low estimated GL according to healthy adults
62235833|NCT06334302|ACTIVE_COMPARATOR|Nutella hazelnut cocoa spread|Nutella hazelnut cocoa spread is composed of 56% sugar, 30% vegetable fat, 13% Hazelnut paste, milk powder (8.7%), and cocoa powder (7.4%), containing a total of 57.5 grams carbohydrates /100grams, 532 kcals/100 grams, and an estimated GL of 4
62235834|NCT00151736|EXPERIMENTAL|Chlorambucil|Regime A
62235835|NCT00151736|EXPERIMENTAL|R-etodolac with chlorambucil|Regime B
62235836|NCT05001854|EXPERIMENTAL|Fludrocortisone|"100 μg every 6 hours of fludrocortisone per os~A pharmacokinetic study is performed in this arm"
62235837|NCT05001854|PLACEBO_COMPARATOR|Control|100 μg every 6 hours of placebo per os
62235838|NCT02007889|ACTIVE_COMPARATOR|L-carnitine|50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
62235839|NCT02007889|NO_INTERVENTION|Control|control group received just antibiotic regimens without L-carnitine
62235840|NCT02594826|EXPERIMENTAL|Culturally appropriate intervention|Culturally appropriate, church-based intervention focused on cervical cancer and navigation assistance.
62235841|NCT02594826|ACTIVE_COMPARATOR|General health education control|General health and cancer education on nutrition, regular check-ups, tobacco use, and cancer screening.
62243410|NCT06585267||Main patient Group|Patients who have undergone Total Knee Replacement (TKR) Surgery
62426498|NCT04765189|EXPERIMENTAL|Verum A|
62426499|NCT04765189|EXPERIMENTAL|Verum B|
62426500|NCT04765189|EXPERIMENTAL|Verum C|
62426501|NCT05224479|ACTIVE_COMPARATOR|Traditional workflow triage|Radiologists follow standard triage of chest radiographs.
62426502|NCT05224479|ACTIVE_COMPARATOR|Machine learning workflow triage|Radiologists follow machine learning triage of chest radiographs.
62426503|NCT05224479|SHAM_COMPARATOR|Random workflow triage|Radiologists follow randomly ordered triage of chest radiographs.
62426504|NCT04675073|EXPERIMENTAL|ABLATE arm|Ventricular tachycardia substrate ablation intending to: i) eliminate all the potential arrhythmogenic substrate, aiming for complete electrical isolation/elimination of all the electrograms with delayed components or showing hidden slow conduction properties, and ii) non-inducibility or ventricular tachycardias at the end of the procedure. Standard medical treatment will also be given for these patients.
62426505|NCT04675073|NO_INTERVENTION|NO-TREAT arm|Only standard medical treatment will be offered for these patients.
62426506|NCT01437137|ACTIVE_COMPARATOR|LMA group|
62426507|NCT01437137|EXPERIMENTAL|I-gel group|
62812137|NCT04479397|ACTIVE_COMPARATOR|Sling Arm|This arm of the study will receive a sling for 3 weeks in postoperative care.
62812138|NCT04479397|EXPERIMENTAL|No Sling Arm|This arm of the study will not receive a sling during the postoperative care,
62812139|NCT01384175|ACTIVE_COMPARATOR|intravenous analgesia|Patients received postoperative analgesia by intravenous fentanyl 10 µg/ml 3-8 mL/h.
62812140|NCT01384175|ACTIVE_COMPARATOR|epiduaral infusion|Patients received epidural analgesia intraoperatively with ropivacaine 0.75% 1 mg/kg and fentanyl 1 µg/kg followed by continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL postoperatively.
62812141|NCT01384175|ACTIVE_COMPARATOR|patient-controlled epidural analgesia|In addition to epidural anesthesia and epidural infusion, postoperatively patients received patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
62235842|NCT02752646|ACTIVE_COMPARATOR|nepafenac 0.3%|Patients in this arm will receive nepafenac 0.3% eye drops once daily following cataract surgery, combined with a topical antibiotic and steroid. This regimen is FDA approved and withing the standard of care.
62812142|NCT04477486|EXPERIMENTAL|Ibrutinib + Venetoclax|Participants will receive Ibrutinib Dose A + Venetoclax in various doses until a target dose is reached, for up to 104 weeks, followed by Ibrutinib monotherapy.
62594566|NCT05416515|EXPERIMENTAL|Carpal Tunnel Syndrome|Adult men and women who have a clinical diagnosis for Carpal Tunnel Syndrome (CTS) will receive Fisetin for 2 day periods for 2 months
62594567|NCT06491394|SHAM_COMPARATOR|Control|Normal saline will be administered once to rats intramuscularly (10 mL/kg).
62594568|NCT06491394|ACTIVE_COMPARATOR|RM|A single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and normal saline (4ml/kg) will be administered by gavage.
62594569|NCT06491394|ACTIVE_COMPARATOR|Lf-RM|A single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. before RM induction
62235843|NCT02752646|ACTIVE_COMPARATOR|ketorolac 0.5%|Patients in this arm will receive ketorolac 0.5% eye drops four times daily following cataract surgery, combined with a topical antibiotic and steroid. This regimen is FDA approved and withing the standard of care.
62235844|NCT00504010|ACTIVE_COMPARATOR|1|arnica containing cream
62812143|NCT04103216|ACTIVE_COMPARATOR|Intervention arm NItazoxanide with probiotics|"Child will be receive the Nitazoxanide treatment for 3 days with probiotics (L reuteri DSM 17938 ) for 7days. The doses of Nitazoxanide will be twice a day for 3 days and dosage will be 5 ml every 12 hours with food. The Nitazoxanide oral suspension contain 100mg/5ml.~L reuteri DSM 17938 will be 2×108 CFU and will receive 5 drops orally twice daily for a consecutive 7 days."
62812144|NCT04103216|PLACEBO_COMPARATOR|Intervention arm Nitazoxanide with placebo|"Child will be receive the Nitazoxanide treatment for 3 days with placebo for 7days. The doses of Nitazoxanide will be twice a day for 3 days and dosage will be 5 ml every 12 hours with food. The Nitazoxanide oral suspension contain 100mg/5ml.~Placebo will receive 5 drops orally twice daily for a consecutive 7 days."
62594570|NCT06491394|ACTIVE_COMPARATOR|RM-Lf|A single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. after RM induction.
62235845|NCT00504010|PLACEBO_COMPARATOR|2|carrier cream without arnica
62235846|NCT05197751|EXPERIMENTAL|3 µg dose cohort|3 µg MSP3-CRM-Vac4All/Alhydrogel®
62426508|NCT01122043||Endoglide|Patients with moderate degrees of corneal decompensation from a variety of disorders which require DSAEK corneal transplantation surgery, with or without concurrent cataract surgery, to restore visual acuity.
62426509|NCT05537142|EXPERIMENTAL|Group 1|Participants with Normal hepatic Function
62594571|NCT06618625|EXPERIMENTAL|Rotation|For nasotracheal intubation, the nasal RAE tube will be inserted with it rotated by 90 degrees in counter-clockwise direction for patients in the 'Rotation' arm.
62812145|NCT04103216|NO_INTERVENTION|Control arm|Child will received the standard supportive care normally provided for Cryptosporidium infections
62235847|NCT05197751|EXPERIMENTAL|10 µg dose cohort|10 µg MSP3-CRM-Vac4All/Alhydrogel®
62812146|NCT03784443|ACTIVE_COMPARATOR|Iluvien Arm|Participants assigned to the Iluvien treatment arm will receive Iluvien 0.19 MG Drug Implant to the study eye under aseptic condition at baseline visit with monthly Ranibizumab Injection \[Lucentis\] for first three visits followed by monthly Ranibizumab Injection \[Lucentis\] PRN.
62812147|NCT03784443|SHAM_COMPARATOR|Control Arm|To maintain double-masking, participants assigned to the control arm will receive Sham Intravitreal Injection at the baseline visit with monthly Ranibizumab Injection \[Lucentis\] for first three visits followed by monthly Ranibizumab Injection \[Lucentis\] PRN.
62426510|NCT05537142|EXPERIMENTAL|Group 2|Participants with mild hepatic impairment: Child-Pugh A (Score 5-6)
62812148|NCT01917617|EXPERIMENTAL|Oral rehydration group（Short Hydration）|"Gemcitabine； gemzer Cisplatin；Cispulan Oral Rehydration Solution(ORS)；OS-1~Short hydration via oral rehydration solution (OS-1)~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively."
62812149|NCT01917617|ACTIVE_COMPARATOR|Standard group（Long Hydration）|"Drug: Gemcitabine , Cisplatin~Other Names:~Gemcitabine； gemzer Cisplatin； Cispulan~Standard hydration via intravenous infusion~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more."
62812150|NCT04687475|EXPERIMENTAL|Clinical Tool (Mobile Spirometry and Survey)|All subjects enrolled will be placed into the clinical tool arm. The clinical tool is comprised of a mobile application based assessment of home spirometry and a survey measuring patient reported outcomes.
62426511|NCT05537142|EXPERIMENTAL|Group 3|Participants with moderate hepatic impairment: Child-Pugh B (Score 7-9)
62426512|NCT05537142|EXPERIMENTAL|Group 4|Participants with severe hepatic impairment: Child-Pugh C (Score 10-15)
62426513|NCT00295620|EXPERIMENTAL|Arm A: Anastrozol|1 mg per day for 2 years
62426514|NCT00295620|EXPERIMENTAL|Arm B: Anastrozol|1 mg per day for 5 years
62426515|NCT00972153|NO_INTERVENTION|No device used|
62426516|NCT00972153|SHAM_COMPARATOR|Device attached, not activated|
62426517|NCT00972153|EXPERIMENTAL|Device deployed and activated|
62426518|NCT04318535|EXPERIMENTAL|Participants receiving T1T2R|Participants will receive a single oral dose of Griseofulvin T1: 1 x 500 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin T2: 1 x 250 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin R: 1 x 500 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
62426519|NCT04318535|EXPERIMENTAL|Participants receiving T2RT1|Participants will receive a single oral dose of Griseofulvin T2: 1 x 250 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin R: 1 x 500 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin T1: 1 x 500 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
62235848|NCT05197751|EXPERIMENTAL|30 µg dose cohort|30 µg MSP3-CRM-Vac4All/Alhydrogel®
62235849|NCT01026454|ACTIVE_COMPARATOR|acyclovir|acyclovir 400 mg orally twice daily
62235850|NCT01026454|ACTIVE_COMPARATOR|valacyclovir|valacyclovir 1.5 g orally twice daily
62235851|NCT03092895|EXPERIMENTAL|SHR-1210+Apatinib(Arm A）|
62235852|NCT03092895|EXPERIMENTAL|SHR-1210+FOLFOX4 or GEMOX regimen(Arm B）|
62235853|NCT05737186|EXPERIMENTAL|Intervention group|
62235854|NCT05737186|NO_INTERVENTION|Control group|
62235855|NCT06503029|EXPERIMENTAL|Invisalign Cleaning Crystals|Invisalign Cleaning Crystals are used as a cleaning method for orthodontic clear aligners. It includes Sodium Sulfate as an active ingredient.
62235856|NCT06503029|EXPERIMENTAL|Fittey Dent Cleaning Tablet|Fittey Dent Cleaning Tablet is used as a cleaning method for orthodontic clear aligners. It includes Sodium Perborate as an active ingredient.
62235857|NCT06503029|EXPERIMENTAL|Listeren Mouthwash used as cleaning method|Listeren Mouthwash is used as a cleaning method for orthodontic clear aligners. It includes Eucalyptol and Menthol as active ingredients.
62235858|NCT06503029|ACTIVE_COMPARATOR|Toothbrush and water|Toothbrush and water is used as a cleaning method for orthodontic clear aligners that as recommended by the aligner manufacturer.
62235859|NCT03270566|EXPERIMENTAL|Domestic ion-exchange water softener|The intervention group will have a domestic ion-exchange water softener installed prior to birth.
62235860|NCT03270566|NO_INTERVENTION|Usual hard water supply|The control group will receive their usual domestic water supply.
62235861|NCT01353079|EXPERIMENTAL|Short Ragweed Pollen Allergenic Extract|
62235862|NCT01353079|PLACEBO_COMPARATOR|Glycero-COCAs|
62235863|NCT03279874||German dentists|Dentists who are working in dental offices in Germany
62812151|NCT04135807|EXPERIMENTAL|Microdevice|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Patients with newly found supratentorial lesions, or patients previously diagnosed with supratentorial gliomas at time of recurrence, whose treatment plan includes partial or total resection surgery as a component of standard-of-care treatment will be included.~- Placement of 1-3 microdevices (depending on the size of the tumor) before tumor resection is started.~-- The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs microdoses for intratumor release of the following 8 approved drugs: Temozolomide, Lomustine, Irinotecan, Carboplatin, Lapatinib, Osimertinib, Abenaciclib, and Everolimus. The drugs used in this study will only include drugs already used systemically for the treatment of gliomas."
62235864|NCT05863520|ACTIVE_COMPARATOR|Facing Your Fears - School Based|Facing Your Fears-School Based (FYF-SB) is a 12 week school based group program comprised of psychoeducation (somatic management, development of positive self-statements and strategies for managing emotions), and graded exposure (facing fears a little at a time).
62812152|NCT04325672|EXPERIMENTAL|Convalescent Plasma Group|Subjects will receive 1-2 units (300-600 mL) of plasma with an anti-SARS-CoV-2 titer of \>1:64.
62235865|NCT05863520|ACTIVE_COMPARATOR|Zones of Regulation|"Zones of Regulation (ZOR) focuses on four different emotional states called zones. Each zone is represented by different colors that represent different levels of emotions or arousal. ZOR includes psychoeducation about emotions and emotional states (e.g., reading facial expressions, identifying triggers for emotion dysregulations, using emotion regulation tools) and problem-solving strategies. In ZOR, students are also taught emotion regulation strategies (e.g., calming, cognitive and sensory strategies) to stay in a specific zone and/or to move from one zone to another."
62235866|NCT05239338||PREFACE: Vanderbilt-Ingram Cancer Center|Patient recruitment and follow-up, longitudinal collection of data and multiple biospecimen at pre-defined study timepoints, objective assessment of health behaviors/habits, individual interviews.
62243411|NCT02033603|ACTIVE_COMPARATOR|Femoral Nerve Block|Femoral Nerve block performed with 0.5% Ropivacaine 30mls (150mg)
62243412|NCT02033603|ACTIVE_COMPARATOR|Adductor Canal block|Adductor Canal block performed with 0.5% Ropivacaine 30mls (150mg)
62812153|NCT06374368|ACTIVE_COMPARATOR|obese patients with jejuno-ileal diversion|Jejuno-ileal diversion without gastric restriction using standard bariatric surgical technique with standard staplers and surgical suturing.
62812154|NCT06374368|ACTIVE_COMPARATOR|obese patients with jejuno-colic diversion|Jejuno-colic diversion without gastric restriction using standard bariatric surgical technique with standard staplers and surgical suturing
62594572|NCT06618625|ACTIVE_COMPARATOR|Neutral|For nasotracheal intubation, the nasal RAE tube will be inserted without tube rotation for patients in the 'Neutral' arm.
62812155|NCT03168477|EXPERIMENTAL|dry needling and spinal manipulation|
62594573|NCT04804748||Phase A|"Approximately 150 consecutive patients undergoing elective cardiac surgery (bypass and / or valve surgery)~* Data regarding standard of care post-operative pacing and treatment of POAF, if applicable, will be collected from time of surgery until discharge~* No use of an external bi-atrial pacing device~* No use of Defipace~* In-hospital data will be collected for all patients~* Patients that developed POAF (n=50) will be followed-up with a phone call 30 days after surgery"
62594574|NCT04804748||Phase B|"Approximately 300 consecutive patients undergoing elective cardiac surgery (bypass and / or valve surgery) with planned TMA implantation~* In-hospital data will be collected for all patients~* Use of the DefiPace system for the treatment (low-energy cardioversion) and post-operative prevention (bi-atrial pacing) of POAF will be documented (n=100). These patients will be followed-up with a phone call 30 days after surgery"
62594575|NCT04907669|EXPERIMENTAL|Group 1a|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 1, participants will receive brief contact intervention (BCI) monthly. If participants' suicide risk increased at 3 months after discharge, they will be re-randomized into Group 1a and Group 1b to receive BCIs weekly (Group 1a) and bi-weekly (Group 1b).
62594576|NCT04907669|EXPERIMENTAL|Group 1b|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 1, participants will receive brief contact intervention (BCI) monthly. If participants' suicide risk increased at 3 months after discharge, they will be re-randomized to receive BCIs weekly (Group 1a) and bi-weekly (Group 1b).
62594577|NCT04907669|EXPERIMENTAL|Group 1c|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 1, participants will receive brief contact intervention (BCI) monthly. If participants' suicide risk decreased or did not change, they will remain receiving BCIs monthly as Group 1c.
62594578|NCT04907669|EXPERIMENTAL|Group 2a|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 2, participants will receive brief contact intervention (BCI) weekly. If the suicide risk increased or did not change, they will remain receiving BCIs weekly as Group 2a.
62594579|NCT04907669|EXPERIMENTAL|Group 2b|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 2, participants will receive brief contact intervention (BCI) weekly. If the suicide risk decreased, they will be re-randomized to receive BCIs monthly (Group 2b) and bi-weekly (Group 2c).
62594580|NCT04907669|EXPERIMENTAL|Group 2c|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 2, participants will receive brief contact intervention (BCI) weekly. If the suicide risk decreased, they will be re-randomized to receive BCIs monthly (Group 2b) and bi-weekly (Group 2c).
62594581|NCT05566834|EXPERIMENTAL|Open-label, dose-escalation, safety, Pharmacodynamic, pharmacokinetic study.|One
62812156|NCT03168477|ACTIVE_COMPARATOR|mobilization, exercise, modalities|
62812157|NCT04482140||Genta-Foil resorb®|Genta-Foil resorb® is a transparent collagen foil that forms a temporary barrier between the functional structures during the critical phase of wound healing. As a result, the ability of the tissue layers to slide against each other is retained. The absorbability of equine collagen means the foil can be left in place and does not require removal. The addition of the antibiotic Gentamicin is for self-protection since collagen implants are prone to bacterial contamination.
62035326|NCT02703675|EXPERIMENTAL|adult healthy volunteer|Adult healthy volunteers will be recruited from staff in Dept. Neurology, medical students. They will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours.
62812158|NCT01043575|EXPERIMENTAL|1|Rifapentine
62812159|NCT01043575|ACTIVE_COMPARATOR|2|Rifampin
62812160|NCT04796714|SHAM_COMPARATOR|Double antiplatelet therapy group|Patient randomized in this group will receive 1 tablet containing clopidogrel 75 mg and 1 bag containing aspirin 160 mg as treatment. This treatment will start on the day of LAAC procedure and continued for 3 months.
62035327|NCT02703675|EXPERIMENTAL|adult normothermic patient|"Adult normothermic patients will be recruited from Neurocritical Care ICU in The Ohio State University Wexner Medical Center.~They will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours."
62035328|NCT02703675|EXPERIMENTAL|adult sick febrile patient|"Adult sick febrile patients will be enrolled from Neurocritical Care ICU in The Ohio State University Wexner Medical Center.~Five of the patients will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours.~Other five patients will received 2 rounds of cooling process each 2 hours long"
62035329|NCT03735329|EXPERIMENTAL|Pulse oximetry monitoring|
62035330|NCT05630274|EXPERIMENTAL|Selpercatinib (Dose level 1)|Selpercatinib administered as single dose orally.
62035331|NCT05630274|EXPERIMENTAL|Selpercatinib (Dose level 2)|Selpercatinib administered as single dose orally.
62035332|NCT05630274|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin administered as single dose orally.
62594582|NCT05697237|EXPERIMENTAL|Advanced or metastatic cholangiocarcinoma|In this study, carrilizumab combined with sovantinib in the second-line treatment of patients with advanced or metastatic cholangiocarcinoma with single arm, open, Exploratory clinical trials.The specific treatment regimen was carrilizumab 200mg Q3W d1; Sofantinib: 300mg,Take orally, once a day, continuously. Treatment continues or until disease progression occurs or the patient becomes intolerant to treatment regimens.The efficacy was evaluated every 2 cycles.
62235867|NCT03902847|EXPERIMENTAL|Motor imagery|All the subjects in this group were informed of the procedure at the beginning of the intervention, which consisted of the following: in the first phase (the first week), all participants had to perform the same motor control exercises program than the control group, but previously, a mental practice based on kinesthetic mental motor imagery was performed. To reinforce the process of motor imagery, a video with the exercises was shown to the subjects before performing the mental practice. All subjects had to imagine that he/she was performing each exercise during 1 set of 12 repetitions prior to the real execution of this. During the second phase (the second and third week), subjects had to complete the set both imagining, with visual mental motor imagery, and actively performing the exercises.
62235868|NCT03902847|EXPERIMENTAL|Action observation|"All the subjects in this group were informed of the procedure at the beginning of the intervention, which consisted of the following: in the first phase (the first week), all participants had to perform the same motor control exercises program than the control group, but prior to the real execution, a video was shown in third-person perspective. All subjects watched one person performing each exercise during 1 set of 12 repetitions. During the second phase (the second and third week), subjects had to perform actively the exercises while they watched the video.~All the participants also received a booklet with written information about the indications and exercises to be practiced at home to ensure that the training program was performed properly. Each week, participants received messages to remind and motivate them to undertake the exercise program daily."
62235869|NCT03902847|ACTIVE_COMPARATOR|Control group|The subjects in this group received an intensive training program based on stabilization exercises of lumbo-pelvic region, which are common exercises used in rehabilitation of patients with chronic non-specific low back pain.
62812161|NCT04796714|EXPERIMENTAL|Aspirin group|Patients randomized in this group: will receive 1 bag containing aspirin 160 mg as treatment. This treatment will start on the day of LAAC procedure and continued for 3 months.
62812162|NCT04261556|EXPERIMENTAL|Real tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of real anodal transcranial direct current stimulation (tDCS).~In the first 20 min of the 40 min-intervention, tDCS and CCT will be provided simultaneously."
62812163|NCT04261556|SHAM_COMPARATOR|Sham tDCS + CCT|40 min/day of CCT + 20 min/day of apparent (sham) tDCS. In the first 20 min of the 40 min-intervention, tDCS and CCT will be provided simultaneously.
62812164|NCT04689659|EXPERIMENTAL|chimeric antigen receptor T cell treatment|
62812165|NCT03350997|EXPERIMENTAL|Trial 1|Subjects will have two CGM devices placed on either side of the abdomen, near the belly button. Trial 1 Exercise - subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for \~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
62812166|NCT03350997|EXPERIMENTAL|Trial 2|Subjects will have one CGM device placed on one side of the abdomen. Trial 2 Exercise - subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).
62812167|NCT05500287|EXPERIMENTAL|Virtual Care Group|Children in virtual care group (VCG) were given distance asthma education for the first month. The education was given in groups of 5-6 children. Also, short videos were taken by the researcher on how to use medications and nebulizers and were shown in Zoom meetings. The education and videos were prepared by scanning the current literature and expert opinion was obtained from 2 experts in nursing education, 2 experts in pediatric nursing and a expert in the pediatric allergy field. Children and families sent asthma diaries to the researcher every 4 weeks. At the end of the first, third and sixth months, data from asthma diaries were collected via Google Forms. The Pediatric Asthma Child Quality of Life Scale score was also collected through Google Forms at the beginning and end of the sixth month. The patients received support from the researcher on case management via telephone or video call 24/7. Case management was multidisciplinary (a nurse and a specialist).
62035333|NCT05630274|PLACEBO_COMPARATOR|Placebo|Placebo administered orally.
62035334|NCT05124704|EXPERIMENTAL|Combined epidural with general anesthesia|Patients in this group received 5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction.Followed by a continuous infusion of 4-6 ml 0.375% ropivacaine was applied using micro-infusion pump after induction during surgery.
62035335|NCT05124704|SHAM_COMPARATOR|General anesthesia|In this group, same dose of normal saline was administered before induction and during surgery.
62235870|NCT06305000|NO_INTERVENTION|Peri-implant healthy group with sufficient keratinized mucosa (≥ 2mm)|
62235871|NCT06305000|EXPERIMENTAL|Peri-implant mucositis group with sufficient keratinized mucosa (≥ 2mm)|Only non-surgical therapy will apply
62235872|NCT06305000|EXPERIMENTAL|Peri-implant mucositis group with insufficient keratinized mucosa (< 2mm)|Only non-surgical therapy will apply
62594583|NCT02774122|ACTIVE_COMPARATOR|masking therapy|Masking intervention was a standard monophone tinnitus masking therapy.
62594584|NCT02774122|EXPERIMENTAL|CAABT|CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
62035336|NCT04878094|ACTIVE_COMPARATOR|Arm A|Randomized to standard technique and assessment of anastomosis without the use of NIR angiography
62035337|NCT04878094|EXPERIMENTAL|Arm B|Randomized to additional assessment of proximal colonic stump and anastomotic perfusion using NIR angiography
62035338|NCT01008033|EXPERIMENTAL|IDP-108|
62035339|NCT01008033|PLACEBO_COMPARATOR|Vehicle|
62594585|NCT02511314|EXPERIMENTAL|Intervention|"Tena Identifi is an integrated electronic monitoring system based upon a wearable continence pad which allows registration of resident's micturition patterns over a 72 hour period, allowing caregivers to construct an individualised continence care plan, including use of appropriate products.~To create a voiding report, a resident wears the Identifi Sensor Wear with an attached Identifi Logger for three consecutive days (72 hours). The logger continuously logs the moisture status of the brief. The resulting data is sent to a server via 3 G signal where it is mapped onto a graph indicating voiding times and volumes."
62594586|NCT02511314|NO_INTERVENTION|Control Intervention|"The control portion of the study is usual care, defined as the routine practices and procedures, including continence assessment approach, prescribed in the nursing home unit or facility."
62594587|NCT05675527|EXPERIMENTAL|Low-dose PRP|Patients will receive a single injection of 6 ml low-dose platelet-rich plasma (PRP) into the glenohumeral joint. Low-dose is defined as a platelet yield of 3X (i.e., 3-fold increase in platelets in PRP compared to whole blood).
62594588|NCT05675527|EXPERIMENTAL|High-dose PRP|Patients will receive a single injection of 6 ml high-dose platelet-rich plasma (PRP) into the glenohumeral joint. High-dose is defined as a platelet yield of 12X (i.e., 12-fold increase in platelets in PRP compared to whole blood).
62594589|NCT05675527|PLACEBO_COMPARATOR|Saline control|Patients will receive a single injection of 6 ml saline into the glenohumeral joint.
62594590|NCT05789589|EXPERIMENTAL|Azeliragon and Stereotactic Radiosurgery (SRS)|"In the Phase 1 portion of the study, three treatment regimens will be systematically evaluated:~1. Azeliragon + SRS + loading corticosteroid dose (LD) + corticosteroid taper (CT)~2. Azeliragon + SRS + loading corticosteroid dose (LD)~3. Azeliragon + SRS~The starting cohort will receive Regimen #2, and depending on the tolerability, participants will be allocated to subsequent cohorts as follows: if Regimen #2 is not well tolerated, participants will be allocated to Regimen #1; if #2 is well tolerated, participants will be allocated to Regimen #3.~Once a Regimen has been identified as safe and tolerable, it will be used for the Phase 2 portion of the study."
62819620|NCT05341817|ACTIVE_COMPARATOR|Control|Day 1: Oral mifepristone 200mg (control) under direct observation therapy (DOT) in clinic Day 2: NIL medication to be self-administered at home Day 3: NIL medication to be self-administered at home. Vaginal misoprostol 800mcg given in the ward, followed by vaginal misoprostol 400mcg, approximately 4 hours later, if subject showed no signs of abortion
62235873|NCT06305000|EXPERIMENTAL|Peri-implant mucositis group with insufficient keratinized mucosa (< 2mm) receiving FGG|Free gingival graft will apply following non-surgical therapy
62594591|NCT00858312|EXPERIMENTAL|1|Diet with 3-4 servings of dairy-rich foods/day
62594592|NCT00858312|PLACEBO_COMPARATOR|2|Low Dairy \< 1 serving of dairy food/day
62235874|NCT00366704|EXPERIMENTAL|A|
62235875|NCT00366704|ACTIVE_COMPARATOR|B|
62235876|NCT05882669||Knee arthroplasty|All adult patients undergoing primary total knee replacement surgery at the Traumatology, Orthopedics and Joint Pathology Clinic of the I.M. Sechenov First Moscow State Medical University (Sechenov University) who meet the inclusion criteria (described below) will be included.
62235877|NCT02211352|ACTIVE_COMPARATOR|Active(Korean Red Ginseng) first group:|Korean Red Ginseng Capsules 2g,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
62235878|NCT02211352|PLACEBO_COMPARATOR|Placebo capsules|placebo Capsules(2g),daily, 8 week and than crossover to Korean Red Ginseng capsules(2g), daily 8week
62235879|NCT05010187|EXPERIMENTAL|Behavioral: Motivational Interview (MI)|Participants will complete a brief motivational interview focusing on determinants of women's alcohol use, including a focus on normative perceptions as well as motives for drinking.
62235880|NCT05010187|ACTIVE_COMPARATOR|Behavioral: Health Coaching (HC)|Participants will complete a brief health coaching interview and session focusing on educational modules.
62235881|NCT04497909|EXPERIMENTAL|Pre-clerkship cohort|First- and second-year medical students
62235882|NCT04497909|EXPERIMENTAL|Clerkship cohort|Third- and fourth-year medical students
62594593|NCT00688935|EXPERIMENTAL|Melatonin|Subjects may opt to enroll in this treatment sub-study involving melatonin treatment (0.1 - 3 mg, daily) for up to 1 year, with a minimum of 6 weeks. Throughout treatment, subjects will continue their saliva, plasma, and/or urine sampling to test for treatment efficacy.
62819621|NCT05763043|EXPERIMENTAL|Ferric derisomaltose|
62235883|NCT04497909|EXPERIMENTAL|Resident cohort|Medical residents
62235884|NCT04309864|NO_INTERVENTION|Focus group-Veteran|Veterans will inform study staff regarding desired device design refinements
62594594|NCT05887843|EXPERIMENTAL|Mometasone + Azelastine, then Mometasone Furoate, then Azelastine Hydrochloride|
62594595|NCT05887843|EXPERIMENTAL|Mometasone Furoate, then Azelastine Hydrochloride, then Mometasone + Azelastine|
62812168|NCT05500287|NO_INTERVENTION|Control Group|Children and families who in the control group (CG), sent asthma diaries to the researcher every 4 weeks. At the end of the first, third and sixth months, data from asthma diaries were collected via Google Forms. The Pediatric Asthma Child Quality of Life Scale score was also collected through Google Forms at the beginning and end of the sixth month. In the CG, the education routinely given by the physician during the outpatient clinic visits continued in the same way. In the name of equality of opportunity, training presentations and videos were shared with the CG at the end of the study. Also, the training presentation was converted into a booklet (videos were added to the booklet in the form of QR codes) and delivered to the clinic in printed form.
62812169|NCT04294693||Recent Patients|Subjects that have undergone surgical intervention within the past two years from date of study approval and received a total joint arthroplasty and follow up care with Dr. Nathan Donaldson or Dr. Steven Thorpe in the Orthopedics Institute at Children's Hospital Colorado
62812170|NCT04294693||New Patients|Subjects that are scheduled to undergo a total joint arthroplasty and/or receive follow-up care with Dr. Nathan Donaldson or Dr. Steven Thorpe at Children's Hospital Colorado
62812171|NCT04294693||Long-term follow up Patients|Subjects that received a total joint arthroplasty for non-solid tumor malignancies before May 1, 2017 and no longer follow-up in clinic with Dr. Nathan Donaldson
62594596|NCT05887843|EXPERIMENTAL|Azelastine Hydrochloride, then Mometasone + Azelastine, then Mometasone Furoate|
62812172|NCT04294693||Control Group Patients|Subjects with a clinical relationship to Dr. Nathan Donaldson or Dr. Steven Thorpe at Children's Hospital Colorado to act as a control group for statistical matching of the above populations.
62812173|NCT04084171|EXPERIMENTAL|Artificial Pancreas Therapy|Subjects will use the Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their glycemia.
62812174|NCT01847521|EXPERIMENTAL|Capsule containing Luteolin, Quercetin, and Rutin|One capsule containing Luteolin (100 mg/capsule), Quercetin (70 mg/capsule), and Rutin (30 mg/capsule). 1 capsule per 10 kg weight per day with food
62235885|NCT04309864|NO_INTERVENTION|Focus group-Clinicians|Clinicians will inform study staff regarding desired app design changes
62594597|NCT01369108|EXPERIMENTAL|Flowable composite|Flowable composite
62594598|NCT01369108|ACTIVE_COMPARATOR|Conventional composite|Highly filled conventional composite restorative
62812175|NCT04552951|ACTIVE_COMPARATOR|Active|Receiving 1 dose of 100.000 iu of Cholecalciferol when the COVID 19 Disease is diagnosed
62812176|NCT04552951|NO_INTERVENTION|Control|No vitamin D
62812177|NCT01917058|ACTIVE_COMPARATOR|abatacept|
62812178|NCT01917058|PLACEBO_COMPARATOR|abatacept Subcutaneous vehicle|
62235886|NCT04309864|OTHER|Usability-inpatients|Clinicians will use the updated CMAP system during patient education for prevention of pressure injuries with Veterans with SCI who are completing their initial rehabilitation.
62235887|NCT04309864|OTHER|Usability-in-home|The Veteran will use the CMAP system at home for two weeks to use in their daily routines, along with wearing the acti-graph one week prior, two weeks during and one week after CMAP usage.
62235888|NCT04440410||Hidradenitis suppurativa|Subjects with active mild, moderate, or severe HS disease using the HS-PGA assessment
62235889|NCT04440410||Atopic Dermatitis|Subjects with active moderate or severe AD disease using the PGA assessment
62235890|NCT04001907|EXPERIMENTAL|exercise combined with β-hydroxy-β-methylbutyrate (HMB)|Resistance Exercise ( 3d/week) and HMB: 3g/d as three 1g capsules orally, for 9 weeks
62594599|NCT04409457|OTHER|Participants with Bulimia Nervosa|"Participants are randomly assigned (in even numbers across the two groups) to scan order:~A. These participants are first scanned after 16 hours of fasting on one day, and are next scanned after a standardized meal on a second day.~B. These participants are first scanned after a standardized meal on one day, and are next scanned after 16 hours of fasting on a second day."
62594600|NCT04409457|OTHER|Participants without Bulimia Nervosa|"Participants are randomly assigned (in even numbers across the two groups) to scan order:~A. These participants are first scanned after 16 hours of fasting on one day, and are next scanned after a standardized meal on a second day.~B. These participants are first scanned after a standardized meal on one day, and are next scanned after 16 hours of fasting on a second day."
62594601|NCT03858803|ACTIVE_COMPARATOR|FM2 first, LAST delayed|Parent intervention, Families Matter 2 (FM2), immediate, adolescent intervention, Living as a Safer Teen (LAST), delayed six months
62594602|NCT03858803|ACTIVE_COMPARATOR|FM2 and LAST simultaneous|Parents participate in Families Matter 2 (FM2) and adolescents in Living as a Safer Teen (LAST) intervention immediately following the baseline assessment.
62594603|NCT03858803|ACTIVE_COMPARATOR|Comparison arm|Comparison arm in which both parents and adolescents will be offered their respective interventions following the final assessment. Following the final assessment parents will be offered the Families Matter (FM2) intervention and youth the Living as a Safer Teen (LAST) intervention as an ethically justified service.
62812179|NCT04785443|EXPERIMENTAL|ICG group|Patient receiving 2 or 3 intraoperative injections of indocyanine green.
62812180|NCT04785443|OTHER|Control group|Patient benefiting from the traditional surgical act
62812181|NCT04712188||Arcing|"10 patients with traumatic spinal cord injury using the arcing stroke pattern to propel manual wheelchair"
62812182|NCT04712188||Semicirculer|"10 patients with traumatic spinal cord injury using the semicirculer stroke pattern to propel manual wheelchair"
62812183|NCT04712188||Single loop|"10 patients with traumatic spinal cord injury using the single loop stroke pattern to propel manual wheelchair"
62812184|NCT04712188||Double loop|"10 patients with traumatic spinal cord injury using the double loop stroke pattern to propel manual wheelchair"
62812185|NCT01868490|EXPERIMENTAL|drug|single-group studies
62812186|NCT04567069|EXPERIMENTAL|DC vaccine|Vaccine made from autologous dendritic cells loaded with MG-7 antigen.
62235891|NCT04001907|PLACEBO_COMPARATOR|exercise combined with placebo|Resistance exercise ( 3d/week) and placebo as 3g/d maltodextrin as three 1g capsules orally, for 9 weeks
62235892|NCT01686854|EXPERIMENTAL|Cognitive Behavioral (B)|a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.
62594604|NCT03823079|EXPERIMENTAL|rhTPO arm|"rhTPO: 300 u/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal)~Concurrent Chemoradiotherapy:~Radiation: judged according to the tumor site and radiotherapy purpose.~Irinotecan: 80 mg/m2 (UGT1A1\*28 6/6) or 65 mg/m2 (UGT1A1\*28 6/7)~Raltitrexed: 3 mg/m2 q3w"
62235893|NCT01686854|ACTIVE_COMPARATOR|Prescriptive Diet (A)|prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
62594605|NCT03823079|ACTIVE_COMPARATOR|rhIL-11 arm|"rhIL-11: 50 ug/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal)~Concurrent Chemoradiotherapy:~Radiation: judged according to the tumor site and radiotherapy purpose.~Irinotecan: 80 mg/m2 (UGT1A1\*28 6/6) or 65 mg/m2 (UGT1A1\*28 6/7)~Raltitrexed: 3 mg/m2 q3w"
62235894|NCT02203292|ACTIVE_COMPARATOR|Liberal|Liberal transfusion strategy. Patients will have red blood cells transfused only if Hb \< 9.0 g/dL
62235895|NCT02203292|EXPERIMENTAL|Restrictive|Restrictive transfusion strategy. Patients will have red blood cells transfused only if Hb \< 7.0 g/dL
62594606|NCT01936181|EXPERIMENTAL|SB2 (proposed biosimilar to inflixmab)|SB2 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion up to Week 70
62594607|NCT01936181|ACTIVE_COMPARATOR|Remicade (infliximab)|Remicade 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion up to Week 46
62594608|NCT01936181|EXPERIMENTAL|Remicade (infliximab), switch to SB2|SB2 3mg/kg at week 54, 62, 70
62594609|NCT01936181|ACTIVE_COMPARATOR|Remicade (infliximab), continue as Remicade|Remicade 3mg/kg at week 54, 62, 70
62594610|NCT06514053|ACTIVE_COMPARATOR|Full pulpotomy|
62594611|NCT06514053|ACTIVE_COMPARATOR|Root canal treatment|
62812187|NCT04567069|EXPERIMENTAL|DC vaccine + CTL (cytotoxic lymphocyte)|Cytotoxic lymphocytes are CD3+ T cells co-cultured with DCs.
62812188|NCT04567069|EXPERIMENTAL|DC vaccine + PD-1 monoclonal antibody (Sintilimab Injection)|Sintilimab injection is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1/ PD-1 Ligand-1 (PD-L1) pathway and reactivates T-cells to kill cancer cells.
62812189|NCT05748717||Paediatric patients with sickle cell disease with normal TCD velocity without clinical stroke|Patients in this group will be aged 4 to 16 years with sickle cell anaemia with no prior history of stroke or previous Transcranial Doppler study showing a maximum time-averaged mean velocity of greater than 169 cm/sec, and who have not received a red cell transfusion in the past two months and are considered to be at steady state.
62235896|NCT00435474|ACTIVE_COMPARATOR|1|Silver product
62594612|NCT06617182|EXPERIMENTAL|The thalidomide group|Patients in the thalidomide group will receive oral thalidomide at a dosage of 100 mg one time daily for 8 weeks.
62594613|NCT06617182|EXPERIMENTAL|The glutamine group|Patients in the glutamine group were given two enteric-soluble capsules of compound glutamine three times a day for 8 weeks.
62594614|NCT06617182|EXPERIMENTAL|The thalidomide combined with glutamine group|Patients in the thalidomide combined with glutamine group will receive oral thalidomide at a dosage of 100 mg one time daily and two enteric-soluble capsules of compound glutamine three times a day for 8 weeks.
62594615|NCT04390425|NO_INTERVENTION|Control - Standard pneumatic tourniquet pressure|This group receives the standard pneumatic tourniquet pressure during surgery like they would during standard of care.
62594616|NCT04390425|EXPERIMENTAL|Experimental - Limb occlusion pressure|This group receives a slightly lower tourniquet pressure than they would during standard of care. This lowered limb occlusion pressure is determined by the tourniquet device.
62812190|NCT05748717||Paediatric patients with sickle cell disease with an abnormal TCD velocity (with or without stroke)|Patients in this group will be aged 4 to 16 years with sickle cell anaemia with an abnormal TCD velocity, who have not received a red cell transfusion in the past two months and are considered to be at steady state.
62235897|NCT00435474|EXPERIMENTAL|2|Honey product
62235898|NCT01308333||XLHED children|
62235899|NCT01308333||XLHED adults|
62235900|NCT01308333||Control children|
62235901|NCT01308333||Control adults|
62594617|NCT01307137|EXPERIMENTAL|Telehealth (TAP)|
62594618|NCT01307137|EXPERIMENTAL|Peer-led care (PC)|
62594619|NCT06243601|EXPERIMENTAL|Intervention Group|Fresh AVG will be prepared. It will be placed as intracanal medicament after cleaning and shaping in patients with asymptomatic periapical lesions
62594620|NCT06243601|NO_INTERVENTION|Control Group|No intracanal medicament will be placed
62594621|NCT04172012|ACTIVE_COMPARATOR|Probiotic|Study subjects receive probiotic mixture for 4 weeks
62594622|NCT04172012|PLACEBO_COMPARATOR|Placebo|Study subjects receive placebo mixture for 4 weeks
62594623|NCT00703794||AXIUM Coils|
62594624|NCT00694252|EXPERIMENTAL|1|Lapatinib
62594625|NCT03495739|EXPERIMENTAL|RDG-17012® capsule|RDG-17012 ® capsule(dabigatran etexilate tosylate)
62594626|NCT03495739|ACTIVE_COMPARATOR|Pradaxa® capsule|Pradaxa® capsule(dabigatran etexilate mesylate)
62594627|NCT06667869||Hospital Clínico Red de Salud UC-Christus|Adult patients admitted to intensive care units at Hospital Clinico Red de Salud UC-Christus who require sedation and mechanical ventilation for more than 24 hours.
62812191|NCT03120884|EXPERIMENTAL|IVF|embryos are cultured using conventional in vitro fertilization.A maximum of 2 embryos will be transferred for each treatment cycle.
62812192|NCT03120884|EXPERIMENTAL|ICSI|embryos are fertilized using ICSI.A maximum of 2 embryos will be transferred for each treatment cycle.
62812193|NCT03205124|EXPERIMENTAL|Pre-operative stimulation|Patients randomized to this group will receive 1 hour of continuous electrical stimulation three days prior to scheduled surgical date. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit. As the nerve becomes accustomed to the sensation of the stimulation, the voltage is increased to the next tolerable threshold and this is repeated throughout the one-hour period. Once the stimulation is complete, the stimulator is detached and the patient is informed of the surgical date. The wires are taken out at the conclusion of the pre-operative appointment. These patients will have fine gauge wires for post-operative sham stimulation implanted at the time of surgery. In the post-operative recovery room the stimulator is attached to their wires. However, the voltage will only be increased to a level they are able to sense.
62812194|NCT03205124|SHAM_COMPARATOR|Sham stimulation|These patients will have the stimulator attached to their wires 3 days prior to scheduled surgical date and postoperatively as were in the previous groups. However, the voltage will only be increased to a level they are able to sense. The stimulator was then be turned off without the patients' knowledge. All connections are left in place for anhour duration. These patients will similarly have their wires removed after the conclusion of their pre-operative appointment and at the first post-operative follow-up within 1 week of surgery.
62812195|NCT03205124|EXPERIMENTAL|Pre and Post-operative stimulation|Patients randomized to this group will receive 1 hour of continuous electrical stimulation three days prior to scheduled surgical date and then again immediately post operatively. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit. As the nerve becomes accustomed to the sensation of the stimulation, the voltage is increased to the next tolerable threshold and this is repeated throughout the one-hour period. Patients randomized to this group will also receive 1 hour of continuous electrical stimulation post-operatively. These patients will have fine gauge wires for post-operative stimulation implanted at the time of surgery. In the post-operative recovery room the stimulator is attached to their wires. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit for one hour.
62812196|NCT01472640|ACTIVE_COMPARATOR|Liraglutid|Liraglutid
62812197|NCT01472640|PLACEBO_COMPARATOR|Placebo|Placebo
62812198|NCT06320054|NO_INTERVENTION|Standard Prenatal Care|Standard Prenatal Care, biometric screenings, and surveys (baseline, 4-12 weeks postpartum).
62812199|NCT06320054|EXPERIMENTAL|Maternal Health Management Program|Program participants will receive 10 fresh, local meals each week, delivered to their homes, health coaching including cooking and physical activity, biometrics screenings, and educational support to enable sustainable lifestyle change.
62812200|NCT02319330|EXPERIMENTAL|Phone counseling intervention|Treatment as usual (TAU) plus a nurse-delivered mobile phone counseling intervention delivered at weeks 1 to 12, 14, and 16 post-randomization.
62812201|NCT02319330|ACTIVE_COMPARATOR|Treatment as Usual|Routine HIV clinic-based counseling
62812202|NCT04735263|OTHER|Intermediate Age-Related macular degeneration patients|"Subjects can have either:~1. Bilateral high-risk iAMD~2. High-risk iAMD in one eye with GA and/or CNV in the fellow eye No control arm"
62594628|NCT06667869||Hospital Dr. Sotero del Rio|Adult patients admitted to intensive care units at Hospital Dr. Sotero del Rio who require sedation and mechanical ventilation for more than 24 hours.
62812203|NCT05222581|EXPERIMENTAL|Prototypes of Breast Shield and Freedom Double Electric Breast Pump|Prototypes of breast shield and Freedom Double Electric Breast Pump
62812204|NCT02655328|EXPERIMENTAL|athlete under asthma treatment|athlete suffering from asthma blood sample urine sample
62812205|NCT03725670|EXPERIMENTAL|Lentivirus-mediated delivery of ARSA to the CNS.|Intracerebral injection with lentiviral TYF-ARSA vector carrying the functional gene
62812206|NCT04123886|EXPERIMENTAL|SCB-313|
62235902|NCT05755074|EXPERIMENTAL|Ablation through upper extremity|Ablation through arm
62235903|NCT05755074|ACTIVE_COMPARATOR|Ablation through femoral vein|Ablation through vein
62594629|NCT02772874||Urge-predominant|All subjects who report fecal incontinence that is primarily urge-predominant will undergo self-administered questionnaires, pelvic examination, endoanal ultrasound, and anorectal manometry.
62594630|NCT02772874||Passive-predominant|All subjects who report fecal incontinence that is primarily passive-predominant will undergo self-administered questionnaires, pelvic examination, endoanal ultrasound, and anorectal manometry.
62594631|NCT05129137|EXPERIMENTAL|FDC nefopam hydrochloride 30mg / paracetamol 500mg|Single dose: 2 tablets
62594632|NCT05129137|ACTIVE_COMPARATOR|nefopam hydrochloride 30mg|Single dose: 2 tablets
62594633|NCT05129137|ACTIVE_COMPARATOR|paracetamol 500mg|Single dose: 2 tablets
62594634|NCT05129137|ACTIVE_COMPARATOR|nefopam hydrochloride 30mg and paracetamol 500mg|Single dose: 2 tablets
62812207|NCT02294383||Pre/post surgery pelvic floor assessment|
62812208|NCT02294383||Conservative treatmen monitoring|
62035340|NCT06670989|EXPERIMENTAL|Microsaccade adaptation|A fixation target will be presented at the center of the display and participants will be asked to keep the target visible at all time. The investigators will measure participants' fixational eye movements continuously and when a microsaccade (small fast eye movements that occur during fixation of a visual target) is detected, the fixation target (a small dot) will jump to a different location, depending on whether the training is to adapt the microsaccades to have smaller or larger amplitudes. With trials, participants would automatically correct for the spatial errors and thus adapting their microsaccade amplitudes. Training consists of 5-6 sessions of training (about 1 hour each). These training sessions will be scheduled weekly if possible, but it is alright if the sessions are not exactly weekly.
62035341|NCT05590819|EXPERIMENTAL|bilateral rTMS|5 hertz(Hz), 1000 pulses, 90% resting motor threshold(RMT) stimulation on bilateral motor cortex of suprahyoid muscle for 15 minutes.
62035342|NCT05590819|EXPERIMENTAL|unilateral rTMS|5 hertz(Hz), 1000 pulses, 90% RMT stimulation on motor cortex of suprahyoid muscle at ipsilateral side as the lesion for 15 minutes; sham stimulation on motor cortex of suprahyoid muscle at contra-lateral side as the lesion for 15 minutes.
62594635|NCT03247465|EXPERIMENTAL|"Group Fusion"|Trans aortic valve replacement with usual procedure with the addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
62594636|NCT03247465|NO_INTERVENTION|"Group Control"|Trans aortic valve replacement with usual procedure
62594637|NCT05296954|EXPERIMENTAL|Group 1|Tachycardia
62594638|NCT05296954|ACTIVE_COMPARATOR|Group 2|Without tachycardia
62594639|NCT02830958|EXPERIMENTAL|Kinesiotaping Group|applied next to the lymphatic system from the validated methods Kinesiotaping®.
62812209|NCT02294383||Pelvic floor muscle contrictions|
62594640|NCT02830958|PLACEBO_COMPARATOR|Ordinary tape Group|Installation of an ordinary tape (not having the characteristics of Curetape®).
62594641|NCT04362540||Pregnant women with GDM|Ultrasound liver scan in addition to routine foetal assessment (antenatal) Metabolic profile blood tests, Oral Glucose Tolerance Test, ELF blood test, repeat liver ultrasound scan and MRI scan (post partum)
62594642|NCT06066346|EXPERIMENTAL|Talquetamab|Subcutaneous Talquetamab
62594643|NCT05387460||Training cohort|The cohort of Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology is a training cohort Intervention/treatment
62035343|NCT05590819|PLACEBO_COMPARATOR|control group of rTMS|Sham stimulation on motor cortex of suprahyoid muscle at contra-lateral side as the lesion for 15 minutes.
62594644|NCT05387460||validation cohort|The cohort of Women's Hospital, School of Medicine, Zhejiang University is a validation cohort
62594645|NCT04763655|OTHER|Treatment as usual|
62812210|NCT02294383||Imaging reproducibility|
62035344|NCT05590819|EXPERIMENTAL|bilateral iTBS|600 pulses iTBS stimulation on bilateral motor cortex of suprahyoid muscle for 15 minutes.
62035345|NCT05590819|EXPERIMENTAL|unilateral iTBS|600 pulses iTBS on motor cortex of suprahyoid muscle at ipsilateral side as the lesion for 15 minutes; sham stimulation on motor cortex of suprahyoid muscle at contra-lateral side as the lesion for 15 minutes.
62035346|NCT05590819|PLACEBO_COMPARATOR|control group of iTBS|Sham stimulation on motor cortex of suprahyoid muscle at contra-lateral side as the lesion for 15 minutes.
62594646|NCT05551520|OTHER|Normative|ImPACT will be administered to participant's for a baseline test.
62594647|NCT05551520|OTHER|Reliability|ImPACT will be administered to participant's within 60 days of baseline test.
62594648|NCT02012738|ACTIVE_COMPARATOR|Assignment to FORNET|17 participants were randomly assigned to FORNET
62594649|NCT02012738|ACTIVE_COMPARATOR|Assignment to CBT|14 participants were randomly assigned to CBT
62812211|NCT03192176|PLACEBO_COMPARATOR|Placebo|Participants received fezolinetant matching placebo capsules orally, BID for a period of 12 weeks.
62812212|NCT03192176|EXPERIMENTAL|Fezolinetant 15 mg|Participants received fezolinetant 15 mg capsules orally, BID for a period of 12 weeks.
62812213|NCT03192176|EXPERIMENTAL|Fezolinetant 30 mg|Participants received fezolinetant 30 mg capsules orally, BID for a period of 12 weeks.
62812214|NCT03192176|EXPERIMENTAL|Fezolinetant 60 mg|Participants received fezolinetant 60 mg capsules orally, BID for a period of 12 weeks.
62812215|NCT03192176|EXPERIMENTAL|Fezolinetant 90 mg|Participants received fezolinetant 90 mg capsules orally, BID for a period of 12 weeks.
62812216|NCT03192176|EXPERIMENTAL|Fezolinetant 30 mg + Placebo|Participants received fezolinetant 30 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
62812217|NCT03192176|EXPERIMENTAL|Fezolinetant 60 mg + Placebo|Participants received fezolinetant 60 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
62235904|NCT04162223|EXPERIMENTAL|Subcutaneous Fat Vaccine Injection|Subcutaneous fat Hepatitis B vaccine injections on Days 0, 28, and 180.
62235905|NCT04162223|EXPERIMENTAL|Intramuscular Vaccine Injection|Intramuscular Hepatitis B vaccine injections on Days 0, 28, and 180.
62235906|NCT04201756|EXPERIMENTAL|Afatinib|
62235907|NCT06494605|EXPERIMENTAL|Experimental study|The experimental group consists of 33 children diagnosed with early signs of neurodivergence or diagnosis of autism. The sample is aged between 18 and 48 months
62235908|NCT04696042||Lanreotide|Patients treated with lanreotide
62235909|NCT05580419|EXPERIMENTAL|4PCP Course (for practitioners only)|All enrolled practitioners will be assigned to take the 4PCP course as the intervention. Patients will not be assigned to the course and will only be completing surveys before and after their practitioner completes 4PCP.
62426520|NCT04318535|EXPERIMENTAL|Participants receiving RT1T2|Participants will receive a single oral dose of Griseofulvin R: 1 x 500 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin T1: 1 x 500 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin T2: 1 x 250 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
62594650|NCT02012738|OTHER|Waiting List Control Group (camp)|7 participants were randomly assigned to the Waiting List Control Group (camp)
62594651|NCT02012738|OTHER|Waiting List Control Group (no camp)|36 participants were assigned to the Waiting List Control Group (no camp)
62812218|NCT03192176|EXPERIMENTAL|Fezolinetant 120 mg + Placebo|Participants received fezolinetant 120 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
62812219|NCT03827343||1|Retrospective chart review of children and adults with cancer enrolled on immunotherapy treatment protocols in the NCI.
62812220|NCT04125563|PLACEBO_COMPARATOR|Placebo capsules|Soft gel capsules with placebo: Sorbitol and colorant.
62812221|NCT04125563|ACTIVE_COMPARATOR|Active substance - oral capsaicin in soft gel capsules|"This is a phase 2 clinical study in humans for therapeutic use of Capsicum oleoresin - (capsaicin) in CIC. The study has a randomised, double-blind and cross-over design. During 4 weeks the participants take either active capsules (Capsicum oleoresin), or matching placebo capsules. This period follows by 2 weeks of wash out and then another 4 weeks with active capsules or placebo in accordance with the trial profile below."
62812222|NCT00963417|ACTIVE_COMPARATOR|Triptorelin plus tamoxifen|Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus tamoxifen for 5 years.
62812223|NCT00963417|EXPERIMENTAL|Triptorelin plus exemestane|Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus exemestane for 5 years.
62812224|NCT02931617|ACTIVE_COMPARATOR|Physiotherapy w/Positive end expiratory pressure training|Chest Physiotherapy w/Positive end expiratory pressure training; post therapy lung volume measurements
62812225|NCT02931617|EXPERIMENTAL|Physiotherapy w/Inspiratory force training|Chest Physiotherapy w/Inspiratory force training; post therapy lung volume measurements
62235910|NCT05280951|EXPERIMENTAL|Focused-PPC Group|Focused-PPC will be implemented in 12 groups (3 groups per health center), with each group having 8 postpartum women. Each group will meet at 1-2 weeks, 6 weeks, and monthly thereafter for up to 1 year postpartum following the Ghana Health Service (GHS) postnatal care schedule.
62235911|NCT05280951|ACTIVE_COMPARATOR|Standard PNC Group|The control group will contain parallel number of participants as the intervention group in each health center
62235912|NCT00662350||Symptomatic Benign Protate Hypertrophy|Symptom Score (IPSS) greater than 15, requiring invasive treatment, Prostate size greater than 25 g, Prostatic urethra length between 2.0 cm and 5.5 cm
62426521|NCT01900379|EXPERIMENTAL|OSA/CPAP|OSA patients intervention : CPAP treatment
62426522|NCT01900379|SHAM_COMPARATOR|OSA/sham CPAP|OSA patients intervention : Sham CPAP treatment
62426523|NCT01900379|NO_INTERVENTION|control group|Patients without any apnea syndrome
62426524|NCT06061718|EXPERIMENTAL|iDose TR|Travoprost Intraocular Implant administered intracamerally in the study eye at the Day 1 Visit following successful cataract surgery
62426525|NCT04347031|EXPERIMENTAL|group 1 cohort 1|"80 patients who receive Mefloquine prescribed according to the following scheme:~* 1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~* Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~* 3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
62426526|NCT04347031|EXPERIMENTAL|group 1 cohort 2|"80 patients who receive Hydroxychloroquine prescribed according to the following scheme:~• 1st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day; 2nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
62426527|NCT04347031|EXPERIMENTAL|group 2 cohort 1|A concomitant therapy consisting of Mefloquine in conjunction with azithromycin and tocilizumab will be given for 80 patients. Dosage of Mefloquine is same as for group 1 cohort 1.
62594652|NCT05329584|EXPERIMENTAL|Group I|InSpace device + accelerated rehabilitation in a formalized program (FP)
62235913|NCT03612284|EXPERIMENTAL|Device Feasibility|"Scleral lens insertion solution study. This is not an interventional study, but a study to test a new contact lens solution. Primary FDA Classification: 21 CFR 886.5928 Soft (Hydrophilic) Contact Lens Care Products Product Code: LPN~Secondary FDA Classification: 21 CFR 886.5918 - Rigid gas permeable contact lens care products Product Code: MRC~The FDA has previously made risk determinations (class II, non-significant risk) for devices classified under 21 CFR 886.5928 and 21 CFR 886.5918. As a non-significant risk device, the GatorFil Contact Lens Saline Solution is exempt from the IDE regulation (21 CFR 812)."
62235914|NCT06470594||Superficial Endometriosis|Laparoscopic excision of superficial (peritoneal) endometriotic implants
62235915|NCT06470594||Ovarian Endometriosis|Laparoscopic excision of ovarian endometrioma/s
62235916|NCT06470594||Deep Infiltrating Endometriosis (DIE)|Laparoscopic excision of DIE
62812226|NCT03301558|ACTIVE_COMPARATOR|Low dose sodium bicarbonate|Low dose 1500 mg sodium bicarbonate (Nephrotrans®) per day (500mg tablets 3x/day) for 14 ± 3 days. The patients will be advised to take one capsule with breakfast, one with lunch and one with dinner (schedule 1-1-1).
62812227|NCT03301558|ACTIVE_COMPARATOR|High Dose sodium bicarbonate|High dose 3000 mg of sodium bicarbonate (Nephrotrans®) per day (500mg tablets 3x/day) for 14 ± 3 days. The patients will be advised to take two capsules with breakfast, two with lunch and two with dinner (schedule 2-2-2).
62235917|NCT02110147|EXPERIMENTAL|Uridine Triacetate to Replace Uridine|Replacement therapy for oral uridine with oral administration of uridine triacetate in patients with hereditary orotic aciduria who have received (or would reasonably be expected to receive) clinical benefit from treatment with exogenous uridine. The starting dose of uridine triacetate will be 60 mg/kg/day which may be escalated to 300 mg/kg/day of oral uridine triacetate. The dose may be given once a day or as equally divided doses twice a day.
62235918|NCT02469896|PLACEBO_COMPARATOR|Placebo|8 subjects will receive matching IV placebo every 4 weeks for 3 months.
62235919|NCT02469896|ACTIVE_COMPARATOR|Active drug|14 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
62235920|NCT06264778|EXPERIMENTAL|Dabrafenib|This study is a single-arm study that does not involve randomization or blinding, nor does it establish a parallel control group and uses external control.
62235921|NCT01141348|EXPERIMENTAL|Special Intervention|
62235922|NCT01141348|EXPERIMENTAL|Delayed Intervention|
62594653|NCT05329584|EXPERIMENTAL|Group II|InSpace device + accelerated rehabilitation in an at-home program (AHP)
62594654|NCT03640975||case : eosinophilic esophagitis|Children with symptoms suggestive of EoE and requiring an upper gastrointestinal endoscopy with biopsies of the esophageal mucosa
62594655|NCT03640975||control|Children in whom an endoscopy performed to explore symptoms of EoE revealed another condition (peptic oesophagitis, achalasia), or children in whom an endoscopy with biopsies has been performed to explore chronic abdominal or epigastric pain or suspected chronic inflammatory bowel disease
62594656|NCT05502146|EXPERIMENTAL|Bolus 6 micrograms Noradrenaline group|Mothers in this group will receive a bolus of Norepinephrine 6 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride.
62594657|NCT05502146|ACTIVE_COMPARATOR|Bolus 8 micrograms Noradrenaline group|Mothers in this group will receive a bolus of Norepinephrine 8 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride.
62594658|NCT03028857|PLACEBO_COMPARATOR|Participants will take placebo|Participants will take placebo. Corn oil every day in place of choline
62812228|NCT05280717|EXPERIMENTAL|Part A: Treatment arm 1- Sotrovimab 62.5 mg/mL (Dorsogluteal)|Participants will receive a single 500 milligram (mg) of 62.5 milligram per milliliter (mg/mL) sotrovimab administered via two injections intramuscularly into the dorsogluteal muscle on Day 1.
62812229|NCT05280717|EXPERIMENTAL|Part A: Treatment arm 2- Sotrovimab 100 mg/mL (Dorsogluteal)|Participants will receive a single 500 mg of 100 mg/mL sotrovimab administered intramuscularly into the dorsogluteal muscle on Day 1.
62235923|NCT00514657|PLACEBO_COMPARATOR|P|
62235924|NCT00514657|EXPERIMENTAL|L|low dose (0.03 %)
62235925|NCT00514657|EXPERIMENTAL|M|medium dose (0.1 %)
62235926|NCT00514657|EXPERIMENTAL|H|high dose (0.3 %)
62594659|NCT03028857|ACTIVE_COMPARATOR|Drug: Choline|Participants will take 4500 mg of phosphatidylcholine twice per day, the equivalent of approximately 1250 mg of choline per day until delivery
62812230|NCT05280717|EXPERIMENTAL|Part A: Treatment arm 3- Sotrovimab 100 mg/mL (Anterolateral Thigh)|Participants will receive a single 500 mg of 100 mg/mL sotrovimab administered intramuscularly into the anterolateral thigh muscles on Day 1.
62235927|NCT01888835|ACTIVE_COMPARATOR|Mirtazapine|mirtazapine 30 mg orally per day
62235928|NCT01888835|PLACEBO_COMPARATOR|Placebo|placebo (30 mg) orally per day
62235929|NCT02248220||Parkinson's disease patients|
62235930|NCT00321659|EXPERIMENTAL|Aerobic and flexibility exercise|16 weeks of aerobic and flexibility exercise. Three days per week for 1 hour of walking and cycling.
62235931|NCT00321659|EXPERIMENTAL|Strength, aerobic, and flexibility|16 weeks of strength training, aerobic, and flexibility exercise (ST) intervention;
62235932|NCT00321659|EXPERIMENTAL|Fibromyalgia Self-Help Course|7 weeks of FSHC behavior change education
62235933|NCT00321659|EXPERIMENTAL|a Combination of ST and FSHC|16 wks of a combination of ST and FSHC (ST-FSHC) exercise and behavior change education
62235934|NCT04845633|OTHER|Healthy children using conventional toothbrush|
62235935|NCT04845633|EXPERIMENTAL|Healthy children using toothbrush with Customized Handle|
62235936|NCT04845633|OTHER|Children with Down syndrome using conventional toothbrush|
62235937|NCT04845633|EXPERIMENTAL|Children with Down syndrome using toothbrush with Customized Handle|
62235938|NCT04233736|ACTIVE_COMPARATOR|Treatment group|
62235939|NCT04233736|SHAM_COMPARATOR|Control group|
62235940|NCT03678103|EXPERIMENTAL|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00029 sensor
62235941|NCT03756350|EXPERIMENTAL|Treatment subjects|Single group of subjects which will have the treatment of a 1060nm diode laser administered to them.
62235942|NCT03385070||Salt-sensitive group|"Patients (n:163)with HT who presented at the emergency service at least once with a minimum increase in their systolic and diastolic blood pressure of 10% after consuming salty foods were included in the SSH group.~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
62235943|NCT03385070||Salt resistance group|"Patients(n:142) who did not exhibit this increase were included in the SRH group~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
62235944|NCT03385070||Control group|"Sex- and age-matched patients(n:124) without a HT diagnosis were included in the control group.~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
62235945|NCT02716467|EXPERIMENTAL|intercessory prayer group|Patients in the experimental group receive prayer of intercession during radiotherapy treatment.
62235946|NCT02716467|ACTIVE_COMPARATOR|Radiotherapy Treatment|Patients in the radiotherapy group not receive prayer of intercession during radiotherapy treatment.
62235947|NCT02172339|EXPERIMENTAL|Tiotropium|group comparison (healthy, renal impairment)
62426528|NCT04347031|EXPERIMENTAL|group 2 cohort 2|A concomitant therapy consisting of Hydroxychloroquine in conjunction with azithromycin and tocilizumab will be given for 80 patients. Dosage of Hydroxychloroquine is same as for group 1 cohort 2.
62426529|NCT05357209|OTHER|Arm A|Arm A of the Avidhrt study will contain subjects that have been/are diagnosed with AF. Arm A of the study will have the participants complete the Human Factors sub-study in addition to the primary clinical study.
62594660|NCT01253174|EXPERIMENTAL|EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|single oral administration of 1 film-coated SHT470FA tablet (Yasmin with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
62594661|NCT01253174|EXPERIMENTAL|EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|single oral administration of 1 film-coated SHT04532A tablet (with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium \[MTHF-Ca\])
62812231|NCT05280717|EXPERIMENTAL|Part A: Treatment arm 4- Sotrovimab 100 mg/mL (Deltoid)|Participants will receive a single 500 mg of 100 mg/mL sotrovimab administered two injections intramuscularly into the deltoid muscles on Day 1.
62235948|NCT03003559|EXPERIMENTAL|High flow nasal cannula|High flow nasal cannula(OptiflowTM); Flow 25-60 L/min is set according to patients' comfort; FiO2 is adjusted to maintain peripheral capillary oxygen saturation(SpO2) 90-95%; temperature is set at 37.
62235949|NCT03003559|NO_INTERVENTION|Nasal cannula|Nasal cannula;set oxygen flow to keep SpO2 90-95%
62235950|NCT03731832|EXPERIMENTAL|PId|Treatment of eligible patients with combination of Pomalidomide, Ixazomib, Dexamethasone for all patients until disease progression.
62235951|NCT03731832|EXPERIMENTAL|PICd|Treatment of patients showing an isolated biochemical relapse at disease progression with combination of Pomalidomide, Ixazomib, Dexamethasone plus Cyclophosphamide.
62235952|NCT01602523|ACTIVE_COMPARATOR|budesonide/formoterol|budesonide/formoterol 160/4.5 mcg (Symbicort)
62235953|NCT01602523|PLACEBO_COMPARATOR|Placebo|Symbicort placebo
62235954|NCT04719767|EXPERIMENTAL|visual|In the visual group, a visual laryngeal mask was placed and endotracheal intubation was guided under visual conditions. The endotracheal tube was removed 10 minutes before the end of the operation, and the laryngeal mask was retained.
62235955|NCT04719767|NO_INTERVENTION|Non-visual|In the non-visual group, laryngeal mask airway was inserted. After clinical judgment of good counterpoint, endotracheal intubation was inserted blindly through LMA. Endotracheal intubation was removed 10 minutes before the end of the operation, and the laryngeal mask airway was retained.
62235956|NCT01477086||Hip fracture|We included patients with traumatic hip fracture, with surgery and who are admitted for rehabilitation
62235957|NCT00523042|EXPERIMENTAL|A|
62235958|NCT00523042|ACTIVE_COMPARATOR|B|
62243413|NCT06335524|EXPERIMENTAL|Caregiver-implemented early developmental intervention (EDI) using finger puppets|Caregivers of infants in the intervention group will receive finger-puppets and additional training pertaining to infant parent interaction and developmentally appropriate infant communication training.
62426530|NCT05357209|OTHER|Arm B|Arm B of the Avidhrt study will contain all other subjects (those non diagnosed with AF), and participants will receive the option whether to participate in the Human Factors sub-study.
62426531|NCT04556838|EXPERIMENTAL|VVN001, 1%|VVN001, 1% ophthalmic solution
62426532|NCT04556838|EXPERIMENTAL|VVN001, 5%|VVN001, 5% ophthalmic solution
62426533|NCT04556838|PLACEBO_COMPARATOR|Vehicle|VVN001 Ophthalmic Solution Placebo
62243414|NCT06335524|ACTIVE_COMPARATOR|Routine EDI care including Bookworm training|All study participants will receive Bookworm reading intervention training and routine EDI care.
62426534|NCT04818151||ESRD patients with VTE treated with warfarin|Warfarin as primary treatment of VTE
62594662|NCT01253174|ACTIVE_COMPARATOR|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated tablet SHT04532C, containing 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium \[MTHF-Ca\])
62594663|NCT04085172|EXPERIMENTAL|Part A: Guanfacine hydrochloride (TAK-503)|Participants randomized to TAK-503 will receive initial dose of 1 milligram (mg), and up titrated with weekly incremental dose of 1 mg until an optimal dose is reached. Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg TAK-503 oral tablet once daily (QD) for 18 weeks.
62594664|NCT04085172|ACTIVE_COMPARATOR|Part A: Atomoxetine hydrochloride|Participants who weigh less than (\<) 70 kilograms (kg) at baseline will receive Atomoxetine hydrochloride capsule orally at an initial dose of 0.5 milligram per kilogram (mg/kg) which may be increased to the target dose of 1.2 mg/kg oral capsule QD during the treatment of 18 weeks. Permitted doses of Atomoxetine hydrochloride capsule will be 10, 18, 25, 40, 60, and 80 mg QD. Participants who weigh \>= 70 kg at baseline will receive Atomoxetine hydrochloride at an initial dose of 40 mg oral capsule QD which may be increased to 80 mg and then to 100 mg for 18 weeks. The total dose for participants who weigh \>= 70 kg at baseline will not exceed 100 mg.
62243415|NCT03692572|ACTIVE_COMPARATOR|Nitrate supplementation|Nitrate rich (6.8 mmol) beet root juice (70ml) twice a day
62594665|NCT04085172|PLACEBO_COMPARATOR|Part A: Placebo|Participants aged 6 to 12 years will receive a dose of 1 to 4 mg tablet of placebo matched to TAK-503 and aged 13 to 17 years will receive a dose of 5 to 7 mg tablets of placebo matched to TAK-503 orally QD for 18 weeks. Participants who weigh \< 70 kg at baseline will receive placebo matched to Atomoxetine hydrochloride oral capsule at an initial dose of 0.5 mg/kg which may be increased to the target dose of 1.2 mg/kg QD oral capsule during the treatment of 18 weeks. Permitted doses of placebo matched to Atomoxetine hydrochloride will be 10, 18, 25, 40, 60, and 80 mg QD and participants who weigh \>= 70 kg will receive placebo matched to Atomoxetine hydrochloride at an initial dose of 40 mg QD capsule orally which may be increased to 80 mg and then to 100 mg.
62594666|NCT04085172|EXPERIMENTAL|Part B: Guanfacine hydrochloride (TAK-503)|Participants from Part A will roll over into Part B directly after 18 weeks and will receive TAK-503 at an initial dose of 1 mg, and up titrated with weekly incremental dose of 1 mg until an optimal dose is reached. Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg TAK-503 oral tablet QD for 52 weeks of Part B.
62594667|NCT06647706||MPNs patients who have echocardiographic probability of PH|MPNs patients who have echocardiographic probability of PH
62594668|NCT06647706||MPNs patients who do not have echocardiographic probability of PH|MPNs patients who do not have echocardiographic probability of PH
62594669|NCT00815815|ACTIVE_COMPARATOR|Continued inpatient treatment|Participants will undergo inpatient hospital treatment until they have gained enough weight to be discharged.
62812232|NCT05280717|EXPERIMENTAL|Part B: Sotrovimab|Participants will receive 500 mg of 100 mg/mL and/or 62.5 mg/mL sotrovimab on Day 1.
62812233|NCT05280717|EXPERIMENTAL|Part C: Cohort 1-Sotrovimab|Participants will receive a single 3000 mg of sotrovimab intravenous (IV) infusion over 60 minutes on Day 1.
62812234|NCT05280717|EXPERIMENTAL|Part C: Cohort 2-Sotrovimab|Participants are planned to receive up to 3000 mg of sotrovimab intravenously on Day 1.
62812235|NCT00589225||1|Genetic Analysis
62812236|NCT03449511|ACTIVE_COMPARATOR|Ginger aromatherapy|Ginger essential oil (GIN-106) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
62812237|NCT03449511|ACTIVE_COMPARATOR|Orange aromatherpy|Orange essential oil (ORG-114) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
62812238|NCT03449511|ACTIVE_COMPARATOR|Lavender aromatherapy|Lavender essential oil (LAV-110) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
62812239|NCT03449511|PLACEBO_COMPARATOR|Jojoba aromatherapy|"Jojoba oil in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles. One drop of jojoba oil is on the other three aromatherapy inhalers. Jojoba oil is a carreir oil for essential oils which will be used as a comparator and placebo in this study."
62812240|NCT01628224||CCATT Team|Measurements will be taken on groups of 3 people each. There will be a total of 16 such teams, with total membership of 48 individuals
62035347|NCT03762473|EXPERIMENTAL|Study Group|Post transplant patients (kidney transplant alone) with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, and negative BK screening at month 1, whom have a concentration/dose of \< 1 and a steady state therapeutic level will be eligible. Patients will be converted to envarsus at 20% reduction in dose.
62243416|NCT03692572|PLACEBO_COMPARATOR|Placebo|Nitrate depleted (0.04 mmol) placebo juice (70ml) twice a day
62426535|NCT04818151||ESRD patients with VTE treated with apixaban|Apixaban as primary treatment of VTE
62426536|NCT06565728|ACTIVE_COMPARATOR|Group A: Vitamin D3 group|Consists of 33 pregnant women who received oral vitamin D3 (vitamin D-3 2000 IU) and low dose aspirin.
62426537|NCT06565728|ACTIVE_COMPARATOR|Group A: Sildenafil group|Consists of 33 pregnant women who received oral sildenafil citrate 20 mg (Respatio) and low dose aspirin
62426538|NCT06565728|ACTIVE_COMPARATOR|Group A: Control group|Consists of 33 pregnant women who received low dose aspirin only
62426539|NCT03084978|ACTIVE_COMPARATOR|General Anesthesia|Subjects will undergo general anesthesia with endotracheal intubation.
62426540|NCT03084978|EXPERIMENTAL|Conscious Sedation|Subjects will undergo conscious sedation anesthesia.
62426541|NCT03986164|ACTIVE_COMPARATOR|Guided surgery (GS)|Installation of dental implant with the aid of the virtually planned guide by means of specific software
62594670|NCT00815815|EXPERIMENTAL|Sequenced treatment|Participants will begin with inpatient treatment, transition to day patient treatment, and then transition to outpatient treatment.
62594671|NCT01589874||acute ill patients|
62594672|NCT03531528|EXPERIMENTAL|Experimental|A 4-week protein-sparing, very low-calorie, ketogenic diet and a subsequent 6-week hypocaloric, low glycemic index, Mediterranean-like diet
62594673|NCT00425061|EXPERIMENTAL|1|
62594674|NCT00425061|EXPERIMENTAL|2|
62594675|NCT00425061|PLACEBO_COMPARATOR|3|
62594676|NCT02544425|EXPERIMENTAL|VIDL+ASCT|"1. VIDL Induction (repeated 28 days) : VP-16, Ifosfamide, Dexamethasone, L-asparaginase~2. Peripheral blood stem cell mobilization:Etoposide~3. Conditioning regimen for autologous stem cell transplantation:Busulfan,Melphalan,Etoposide"
62594677|NCT00776113|ACTIVE_COMPARATOR|2|Carvedilol 12.5 mg tablets
62594678|NCT00776113|EXPERIMENTAL|1|Carvedilol 12.5 mg tablets
62594679|NCT05843058|EXPERIMENTAL|laughter yoga|The psychological well-being scale was filled in at the first encounter with the patient. Then, 12 sessions of laughter yoga were performed and after 12 sessions, the psychological well-being scale was applied again.(Laughter yoga was practiced twice a week for 6 weeks)
62812241|NCT01150526|PLACEBO_COMPARATOR|Placebo|Oral Placebo capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
62235959|NCT03963752|EXPERIMENTAL|Ziyinxiehuo Granules and Megestrol Acetate|Experimental：Group Ziyinxiehuo Granules and Megestrol Acetate Tablet Intervention :Subjects in Group Ziyinxiehuo Granules and megestrol acetate tablet will be treated with Ziyinxiehuo Granules and megestrol acetate tablet for 6 months.1 pack of Ziyinxiehuo granules Herbs includes shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g. Ziyinxiehuo Granules is administered after dissolved,1pack every time, 2 times per day after a meal; and the dosage of megestrol acetate is 6-8mg/d, which is taken in 3 times after a meal.
62426542|NCT03986164|ACTIVE_COMPARATOR|Conventional surgery (CS)|Installation of dental implant performed freehand using a conventional surgical guide made by study models
62426543|NCT00649155|EXPERIMENTAL|1|Ciprofloxacin Extended-Release Tablets 500 mg
62812242|NCT01150526|EXPERIMENTAL|CaHMB Pre|Oral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
62812243|NCT01150526|EXPERIMENTAL|CaHMB Pre and Post|Oral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A CaHMB capsule and placebo gel dosage are are then administered 3 times daily during the remainder of the study.
62812244|NCT01150526|EXPERIMENTAL|HMB Free Acid Gel Pre|Oral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
62812245|NCT01150526|EXPERIMENTAL|HMB Free Acid Gel Pre and Post|Oral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and HMB free acid gel dosage are then administered 3 times daily during the remainder of the study.
62812246|NCT04740983|EXPERIMENTAL|Heliotherapy|will receive 16-week heliotherapy regimen based on the predicted anti psoriasis effective irradiance values along with olive oil (in-house formulation)
62812247|NCT04740983|NO_INTERVENTION|Control|only will receive olive oil (in-house formulation)
62812248|NCT03631602|EXPERIMENTAL|Arm 1|posaconazole oral suspension
62812249|NCT03631602|ACTIVE_COMPARATOR|Arm 2|itraconazole oral solution
62812250|NCT05656339|SHAM_COMPARATOR|12 hours Fast - Fast Group|Participants will proceed in 12 hours fast condition for blood collection for laboratory assays
62812251|NCT05656339|ACTIVE_COMPARATOR|Carbohydrate plus whey protein supplement - CHO+WP group|After 12 hours fast participants will collect blood samples and immediately will drink an oral supplement containing carbohydrates plus whey protein. After 3 hours of ingesting the supplement blood samples will be collected again
62812252|NCT05656339|PLACEBO_COMPARATOR|Carbohydrate supplement - CHO group|After 12 hours fast participants will collect blood samples and immediately will drink an oral supplement containing carbohydrates alone without whey protein. After 3 hours of ingesting the supplement blood samples will be collected again
62812253|NCT05627479|EXPERIMENTAL|GIK Therapy|In patients randomized to the GIK Therapy Arm, a stepwise GIK infusion process will be performed. Baseline lab values that are markers of skeletal muscle injury (CPK), acute kidney injury (creatinine), and general tissue perfusion (lactate) will be obtained within the first 30 min of arrival to the ED. Subsequently, serial CPK, creatinine, myoglobin and lactate values will be obtained at regularly scheduled intervals until a minimum of 72 hours after definitive fixation or until rhabdomyolysis is resolved and/or kidney function has normalized
62812254|NCT05627479|PLACEBO_COMPARATOR|Placebo Control|Patients randomized to the control cohort will receive a normal saline infusion instead of GIK. Standard institutional ICU protocol will be used to monitor potassium and glucose levels per current standard-of-care practices and abnormal lab values will be treated accordingly per standard institutional protocols.
62426544|NCT00649155|ACTIVE_COMPARATOR|2|Cipro® XR Tablets 500 mg
62812255|NCT04386369||Airway Pressure Release Ventilation|Patients with COVID-19 ARDS requiring invasive mechanical ventilation in ICU, on Volume Assist Control ventilation (VAC) or Pressure Assist Control (PAC), are switched to airway pressure ventilation (APRV). If APRV doesn't lead to improvement in oxygenation the ventilatory mode is switched back to VAC or PAC ventilatory mode.
62812256|NCT00534365|ACTIVE_COMPARATOR|1|Tension-free vaginal tape procedure (TVT)
62812257|NCT00534365|ACTIVE_COMPARATOR|2|TVT-SECUR device
62426545|NCT03744065|ACTIVE_COMPARATOR|Lumbar plexus block|Patients randomized to receive an ultrasound-guided lumbar plexus block
62426546|NCT03744065|EXPERIMENTAL|Suprainguinal fascia iliaca block|Patients randomized to receive an ultrasound-guided suprainguinal fascia iliaca block
62812258|NCT02893566|EXPERIMENTAL|Mi Band Step Challenge|
62812259|NCT02216669|EXPERIMENTAL|DTP348|Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
62812260|NCT01392144||Nitric Oxide Breath Analysis|Nitric Oxide Breath Test + Questionnaires
62812261|NCT00793988|ACTIVE_COMPARATOR|1|Group receiving vibration-assisted anaesthesia
62812262|NCT00793988|PLACEBO_COMPARATOR|2|Group receiving switched-off vibrating device
62035348|NCT03762473|ACTIVE_COMPARATOR|Control Group|Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of \< 1 at month 1, and BK data available and month 2,3, 6,9,12.
62426547|NCT06309290|EXPERIMENTAL|Prehabilitation intervention program|All volunteers be subjected to 16 - 20 weeks of full body resistance exercise training (2 times per week. However, usual care program.
62426548|NCT06309290|ACTIVE_COMPARATOR|Usual Care Program|All volunteers be subjected usual care (diagnosis confirmation, chemotherapy treatment planning and an initial education session).
62426549|NCT02711189|ACTIVE_COMPARATOR|Oxytocin|Intranasal oxytocin will be delivered on twice daily basis in this crossover trial.
62426550|NCT02711189|PLACEBO_COMPARATOR|Placebo|Within Subject Design
62426551|NCT02212561|EXPERIMENTAL|Treatment Arm|Interventions: Selinexor, Fludarabine, and Cytarabine. Methotrexate/hydrocortisone/cytarabine (intrathecal triples) will be given prior to cycle 1.
62812263|NCT04915183|EXPERIMENTAL|1|Atorvasatatin (40 mg)
62812264|NCT04915183|PLACEBO_COMPARATOR|2|Placebo
62235960|NCT03963752|ACTIVE_COMPARATOR|Gonadotrophin|Active Comparator: Group Gonadotrophin Intervention: Subjects in Group Gonadotrophin will be treated with gonadotrophin releasing hormone agonist for 6months. In our study Leuprorelin Acetate 3.75mg Injection will be applied, the dosage of which is 80μg/kg every time by subcutaneous injection, every 4 weeks for once.
62235961|NCT01322984|ACTIVE_COMPARATOR|Normal controls|Normal children and youths
62426552|NCT01570218|EXPERIMENTAL|Music therapy|Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days.
62812265|NCT01798693|PLACEBO_COMPARATOR|Placebo (maltodextrin)|Maltodextrin
62812266|NCT01798693|ACTIVE_COMPARATOR|Multi-Nutrient Blend|Blend of vitamins, minerals, and amino acids, given twice daily
62426553|NCT01570218|NO_INTERVENTION|Control|
62426554|NCT01638637||Specimen Collection|
62426555|NCT05833373|EXPERIMENTAL|Verum group|Verum group - active vagal stimulation with the stimulation device tVNS from tVNS Technologies GmbH. The stimulation is performed with an ear-electrode at the Tragus. Minimal stimulation duration is 1 hour per day for 3 months.
62426556|NCT05833373|SHAM_COMPARATOR|Sham group|Sham group with ineffective vagal stimulation. Same stimulation procedure like in the verum group with the stimulation device tVNS from tVNS Technologies GmbH. The stimulation is performed with an ear-electrode at the Tragus, too. Minimal stimulation duration is 1 hour per day for 3 months, but with a non conducting ear electrode.
62426557|NCT03740685||Patients with acute pancreatitis|All patients will recive different lines of treatment {saline,antibiotics,dexamethasone}
62426558|NCT02007187|EXPERIMENTAL|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.
62426559|NCT02007187|PLACEBO_COMPARATOR|Placebo|Based on the standard medical care, placebo was 40ml of 0.9% saline, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.
62426560|NCT03970382|EXPERIMENTAL|NeoTCR-P1|Single dose of NeoTCR-P1
62426561|NCT03970382|EXPERIMENTAL|NeoTCR-P1 plus nivolumab|Single dose of NeoTCR-P1 plus nivolumab 480mg IV every four weeks for up to 6 doses.
62426562|NCT03970382|EXPERIMENTAL|NeoTCR-P1 plus IL-2|Single dose of NeoTCR-P1 plus IL-2 500,000 IU/m2 SC twice daily (BID) for 7 days.
62426563|NCT01895088|EXPERIMENTAL|Patients prev. impl. with ACI 7000 PDT|AcuFocus Corneal Inlay ACI 7000 PDT
62426564|NCT06419673|EXPERIMENTAL|Serplulimab + chemoradiotherapy , Serplulimab maintenance|Participants receive serplulimab 300 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 3 cycles followed by serplulimab 300 mg IV on Day 1 of each 6-week cycle (Q3W) for an additional 15 cycles. During the Q3W dosing period of serplulimab, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m\^2 IV or carboplatin (AUC=2) once per week (QW) for 5 or 6 weeks plus external beam radiotherapy followed by brachytherapy not to exceed 8 weeks.
62812267|NCT01866540|EXPERIMENTAL|Fluenz vaccine|LAIV vaccine
62812268|NCT06098482|EXPERIMENTAL|Delivery of speech perception materials in-clinic using the Mobile Research App (MRA)|Cochlear implant recipients will participate in this arm (sub-investigation AI5841A).
62812269|NCT06098482|EXPERIMENTAL|Delivery of speech perception materials in-clinic and at home using the Mobile Research App (MRA)|Cochlear implant and hearing aid recipients will participate in this arm (sub-investigation AI5841B).
62426565|NCT06419673|ACTIVE_COMPARATOR|Concurrent chemoradiotherapy|Participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m\^2 IV or carboplatin (AUC=2) once per week (QW) for 5 or 6 weeks plus external beam radiotherapy followed by brachytherapy not to exceed 8 weeks.
62426566|NCT05211752||Healthy young athletes (Eye-Tracker®T2 + e-VOG)|Subjects who first perform standard video-oculography assessment, followed by e-VOG digital assessment.
62426567|NCT05211752||Healthy young athletes (e-VOG + Eye-Tracker®T2)|Subjects who first perform e-VOG digital assessment, followed by the standard video-oculography assessment.
62426568|NCT03428048||Adults diagnosed with paroxysmal and persistent Afib|Adults diagnosed with paroxysmal and persistent Afib who are identified as candidates for an intervention either surgical (epicardial) known as the hybrid approach or an endocardial ablation with either laser, radio frequency or cryoablation energy source.
62812270|NCT01171859|EXPERIMENTAL|Doxycycline + Tauroursodeoxycholic acid|
62235962|NCT01322984|EXPERIMENTAL|ASD|Children and youths diagnosed with autism spectrum disorder (ASD)
62243417|NCT05671653|EXPERIMENTAL|Cohort 1: PF-07081532|Cohort 1 is an open-label, 9 period, fixed-sequence design to evaluate the effect of 2 steady state dose levels of PF-07081532 on the SD pharmacokinetics of midazolam and omeprazole, administered simultaneously, and an OC (LE/EE) in otherwise healthy obese adult female participants with a BMI ≥30 kg/m2.
62243418|NCT05671653|EXPERIMENTAL|Cohort 2: Semaglutide|Cohort 2 is an open label, 4-period, fixed-sequence design to evaluate the effect of steady state semaglutide on the SD PK of midazolam in obese adult female participants with a BMI ≥30 kg/m2
62812271|NCT05026528|EXPERIMENTAL|Digital DSME/S|Ten-week intervention during which the participant uses a digital diabetes self management education and support system together with the diabetes nurse.
62812272|NCT05026528|NO_INTERVENTION|Standard care|Control group continuing with regular standardized care.
62812273|NCT01811771|ACTIVE_COMPARATOR|Shanchol vaccine|Around 30,000 individuals will be vaccinated with two doses of oral cholera vaccine at least 14 days apart.All male and non-pregnant female residents above one year age will be targeted for vaccination.
62812274|NCT01811771|NO_INTERVENTION|Non-intervention|No intervention will be given. Health education will be provided to the study participants.
62812275|NCT01022736|EXPERIMENTAL|gabapentin|patients scheduled for cardiac bypass surgery will be administered gabapentin (600mg, orally). Blood will be drawn and plasma gabapentin levels determined 1 hour before surgery, 10 minutes into surgery, 10 minutes before separation from bypass, 30 minutes following bypass, and then before and 2 hours after each dose of gabapentin.
62812276|NCT03273426|EXPERIMENTAL|Core needle Biopsy|Ultrasound-guided core needle biopsy (14G, ≥5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.
62426569|NCT05355831|ACTIVE_COMPARATOR|Active Transcranial Direct Current Stimulation|Anodal TDCS 1mV for 2x 20 minutes.
62426570|NCT05355831|SHAM_COMPARATOR|Sham stimulation|2x 20 minutes of sham stimulation (30 sec ramp up, followed by current of 0 for 18.5 minutes followed by 30 sec ramp down).
62812277|NCT03273426|EXPERIMENTAL|Vacuum-assisted biopsy|Vacuum-assisted biopsy (10G, ≥5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.
62812278|NCT04034368|EXPERIMENTAL|Experimental Arm|Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
62235963|NCT03772353|EXPERIMENTAL|Dalpiciclib combined with Pyrotinib and Endocrine therapy|"Data from phase Ib showed the triplet of pyrotinib, SHR6390, and letrozole had an acceptable safety profile and encouraging efficacy, potentially offering a chemotherapy-sparing treatment option for patients with HER2-positive/HR-positive MBC. Based on DLTs and clinical efficacy, pyrotinib 320mg/d, SHR6390 125mg/d, and letrozole 2.5mg/d was declared as RP2D. The pharmacokinetic analysis had not yielded conclusive results and would involve more samples in phase II trial.~Dalpiciclib combined with Pyrotinib and Endocrine therapy (treatment of physician's choice: letrozole or fulvestrant) ER+/HER2+ metastatic breast cancer patients eligible for first- or second-line treatment were enrolled to receive dalpiciclib combined with pyrotinib and endocrine therapy (treatment of physician's choice: letrozole or fulvestrant)"
62235964|NCT00362453|EXPERIMENTAL|Tai Chi|The Tai Chi program was based on the classical Yang Style. Patients participated in 60-minute Tai Chi sessions twice a week for 12 weeks. Each session included warm up and review of Tai Chi principles and techniques; Tai Chi exercises; breathing techniques; and various relaxation methods. The classes were taught by a Tai Chi master with over 20 years' experience conducting Tai Chi Mind-Body exercise programs. Several modifications were developed to achieve the physical and mental goals of the study for knee OA, accommodate knee OA symptoms and limit dropouts. Subjects were instructed to practice Tai Chi at least 20 minutes a day at home and encouraged to maintain their usual physical activities, but not to participate in additional new strength training other than their Tai Chi exercises.
62235965|NCT00362453|PLACEBO_COMPARATOR|Wellness Education and Stretching|The wellness education and stretching program provided an active control for the attention being paid to the Tai Chi group. The control group attended two 60-minute class sessions per week for 12 weeks. Each session started with 40 minutes of didactic lessons on OA knowledge, nutrition, and physical and mental health education. The final 20 minutes consisted of stretching exercises involving the upper body, trunk and lower body, each stretch being held for 10 to 15 seconds. Participants were also instructed to practice at least 20 minutes of stretching exercises per day at home. They were encouraged to maintain their usual physical activities, but not to participate in additional strength and mind-body exercise programs other than their stretching exercise.
62035349|NCT04991168||Diabetic patients over 18 from the CHU Lapeyronie|Diabetic patients over 18 from the CHU Lapeyronie
62035350|NCT05163366|EXPERIMENTAL|GROUP A|Group A will receive rectal ketamine(Ket)
62035351|NCT05163366|ACTIVE_COMPARATOR|GROUP B|Group B will receive only traditional standard of care protocols.
62235966|NCT05224336|EXPERIMENTAL|Psilocybin|Participants will receive 25mg oral psilocybin one day to two weeks after baseline psychophysical and fMRI testing. Psychophysical and fMRI testing will then be employed one day to two weeks after drug administration.
62235967|NCT05224336|PLACEBO_COMPARATOR|Niacin|Participants will receive 100mg oral niacin one day to two weeks after baseline psychophysical and fMRI testing. Psychophysical and fMRI testing will then be employed one day to two weeks after drug administration.
62235968|NCT05494060|EXPERIMENTAL|Penpulimab + Anlotinib + XELOX|Penpulimab in combination with Anlotinib and XELOX (Capecitabine and Oxaliplatin)
62426571|NCT03820778|EXPERIMENTAL|Study Arm|Whole Body MRI along with standard of care regional MRI and blood draw at enrollment followed by Whole Body MRI along with standard of care regional MRI and blood draw after 4-6 months.
62426572|NCT02328001|NO_INTERVENTION|Pre-intervention phase/phase 1|No intervention will be applied in phase 1
62812279|NCT04515875|EXPERIMENTAL|Daily Engagement Meaningful Activity (DEMA)|This group will receive 7 individualized sessions, 1 face-to-face session at week 1 and via 6 bi weekly telephone sessions delivered by a trained intervener. DEMA will use the principles of problem-solving therapy and consistent with the overall goals of this intervention; and will provide autonomy support, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed. Each session consists: 1) MCI dyads are guided to use the principles of problem-solving therapy to review their personalized, self-selected meaningful activities and plan next steps to continue the activity, identify and establish a plan for additional activities; and 2) the intervener and dyad discuss one of the 6 topics in the Toolkit such as introducing of the intervention and meaningful activity concepts, understanding MCI, its treatments, management, resources, and planning for the future.
62819622|NCT04790474|EXPERIMENTAL|ixazomib-pomalidomide-dexamethasone as second or third-line combination treatment|Prospective study of ixazomib-pomalidomide-dexamethasone as second or third-line combination treatment for patients with relapsed and refractory multiple myeloma (RRMM) previously treated with daratumumab, lenalidomide and bortezomib
62819623|NCT06595095||Healthy individuals|
62819624|NCT06595095||Anxious Individuals|
62035352|NCT01723111||Peritoneal dialysis|start PD
62035353|NCT01723111||Hemodialysis|start HD
62035354|NCT03240848|EXPERIMENTAL|artificial intelligent clinic|"Procedure: the initial diagnosis from artificial intelligent clinic Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.~Procedure: the final definite diagnosis from experts After making the initial diagnosis in artificial intelligent clinic, participants in group A went to get the final definite diagnosis from experts with more than 10 years of clinical experience."
62035355|NCT03240848|ACTIVE_COMPARATOR|normal clinic|"Procedure: the initial diagnosis from normal clinic Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.~Procedure: the final definite diagnosis from experts After making the initial diagnosis in normal clinic, participants in group B went to get the final definite diagnosis from experts with more than 10 years of clinical experience."
62426573|NCT02328001|OTHER|Post-intervention phase/phase 2|Intervention will be applied in phase 2 i.e; Debriefing endoscopists of the procedure accessory costs and pathology specimen costs
62426574|NCT05190900|EXPERIMENTAL|Experimental|We will measure the stabilometric variables before and after the performance of a neuromeningeal mobilisation.
62594680|NCT05843058|NO_INTERVENTION|Standard care|The psychological well-being scale was filled in at the first encounter with the patient. Then, 6 weeks later, the psychological well-being scale was applied again.
62235969|NCT05494060|ACTIVE_COMPARATOR|XELOX|XELOX (Capecitabine and Oxaliplatin)
62235970|NCT03181451|ACTIVE_COMPARATOR|30 mg Ferric Maltol|12 subjects will receive 30 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 30mg dose on the morning of Day 10. PK study Day 1 \& Day 10.
62235971|NCT03181451|ACTIVE_COMPARATOR|16.6 mg Ferric Maltol|12 subjects will receive 16.6 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 16.6mg dose on the morning of Day 10. PK study Day 1 \& Day 10.
62594681|NCT04776018|EXPERIMENTAL|Phase 1b, Part 1 - Dose Escalation: Arm A - TAK-981 Twice Weekly (BIW) + Mezagitamab|"Mezagitamab: A fixed dose of 600 mg subcutaneous (SC) injection once weekly in Cycles 1 and 2 (each cycle is of 28 days), followed by once every 2 weeks in Cycle 3 through 6, then every 4 weeks up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.~TAK-981: Escalating doses of TAK-981 BIW intravenous (IV) infusion on Days 1, 4, 8, 11 and 15 in Cycle 1 and 2 (each Cycle is of 28 days) followed by every 2 weeks in Cycles 3 through 6, followed by once every 4 weeks up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first."
62594682|NCT04776018|EXPERIMENTAL|Phase 1b, Part 1 - Dose Escalation: Arm B - TAK-981 Weekly (QW) + Mezagitamab|"Mezagitamab: A fixed dose of 600 mg SC injection once weekly in Cycles 1 and 2 (each cycle is of 28 days), followed by once every 2 weeks from Cycle 3 through 6, then every 4 weeks up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.~TAK-981: Escalating doses of TAK-981 QW IV infusion on Days 1, 8, 15, and 22 in Cycles 1 and 2 (each cycle is of 28 days), followed by every 2 weeks in Cycles 3 through 6, followed by once every 4 weeks. up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first."
62812280|NCT04515875|PLACEBO_COMPARATOR|Information Support (IS)|This group will attend 1 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer disease educational brochure from the Alzheimer's Association (AA). The face-to-face sessions will take place at the IADC Clinical Core clinic, Indiana University Center of Excellence of Women's Health clinic, or Indiana School of Nursing conference room that based on patient-caregiver dyad's preference. Then they will receive 6 bi weekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials. After completing Time 4 data collection, the patient-caregiver dyads will receive DEMA Self-Management Tool kit package through mail.
62812281|NCT03151044|EXPERIMENTAL|EPI-90|"Participants in this arm shall be given high-dose Epirubicin Combined with CVP ± Rituximab for six 21-day cycles:~High-dose Epirubicin 90mg/m2, i.v., Day 1; Cyclophosphamide 750mg/m2, i.v., Day 1; Vincristine 1.4mg/m2, i.v., Day 1; Prednisolone 100mg/m2, p.o., Day 1-5;~Plus/not plus:~Rituximab 375mg/m2, i.v., Day 0"
62819625|NCT06595095||Depressive Individuals|
62235972|NCT03181451|ACTIVE_COMPARATOR|7.8 mg Ferric Maltol|12 subjects will receive 7.8 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 7.8mg dose on the morning of Day 10. PK study Day 1 \& Day 10.
62235973|NCT05127538|ACTIVE_COMPARATOR|Individuals diagnosed with neuropathic pain due to type 2 diabetes|"* Individuals between the ages of 40-65~* Individuals who take 4 points or more from the Douleur Neuropathique en 4 questions (DN4) questionnaire~* Individuals who take 12 points or more from the Leeds Assessment of Neuropathic Signs and Symptoms (LANSS) scale"
62235974|NCT05127538|ACTIVE_COMPARATOR|Individuals with type 2 diabetes but no neuropathic pain|"* Individuals between the ages of 40-65~* Individuals who take 4 points from the Douleur Neuropathique en 4 questions (DN4) questionnaire~* Individuals who take 12 points from the Leeds Assessment of Neuropathic Signs and Symptoms (LANSS) scale"
62235975|NCT05127538|ACTIVE_COMPARATOR|Healthy control group|"* Individuals between the ages of 40-65~* Individuals who have no pain (Taking 1 point or less according to the Visual Pain Scale)"
62235976|NCT02591199|EXPERIMENTAL|URG101|A single 15 mL dose of URG101,a mix of buffered Lidocaine (200 mg) and Heparin (50,000 IU), delivered to the bladder via catheter.
62235977|NCT02591199|PLACEBO_COMPARATOR|Placebo|A single 15 mL dose of placebo delivered to the bladder via catheter.
62235978|NCT02591199|EXPERIMENTAL|Lidocaine|A single 15 mL dose of buffered Lidocaine (200 mg) delivered to the bladder via catheter.
62235979|NCT02591199|EXPERIMENTAL|Heparin|A single 15 mL dose of buffered Heparin (50,000 IU) delivered to the bladder.
62235980|NCT04766931|EXPERIMENTAL|A1 FB2001 or Placebo|single dose
62235981|NCT04766931|EXPERIMENTAL|A2 FB2001 or Placebo|single dose
62235982|NCT04766931|EXPERIMENTAL|A3 FB2001 or Placebo|single dose
62235983|NCT04766931|EXPERIMENTAL|A4 FB2001 or Placebo|single dose
62235984|NCT04766931|EXPERIMENTAL|A5 FB2001 or Placebo|single dose
62235985|NCT04766931|EXPERIMENTAL|A6 FB2001 or Placebo|single dose
62235986|NCT04766931|EXPERIMENTAL|A7 FB2001 or Placebo|single dose
62812282|NCT03151044|ACTIVE_COMPARATOR|EPI-75|"Participants in this arm shall be given standard-dose Epirubicin, Combined with CVP ± Rituximab for six 21-day cycles:~Standard-dose Epirubicin 75mg/m2, i.v., Day 1; Cyclophosphamide 750mg/m2, i.v., Day 1; Vincristine 1.4mg/m2, i.v., Day 1; Prednisolone 100mg/m2, p.o., Day 1-5;~Plus/not plus:~Rituximab 375mg/m2, i.v., Day 0"
62235987|NCT04766931|EXPERIMENTAL|B1 FB2001 or Placebo|Once daily for 5 days
62235988|NCT04766931|EXPERIMENTAL|B2 FB2001 or Placebo|Once daily for 5 days
62235989|NCT04766931|EXPERIMENTAL|A8 FB2001 or Placebo|single dose
62426575|NCT01440023|EXPERIMENTAL|CBIT + Response Inhibition Training|CBIT is an 8 session treatment protocol held over 10 weeks. In CBIT, core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child. Each core component is briefly described below. HRT/CBIT involves three components, awareness training, competing response training, and social support training (Woods, Twohig, Roloff, \& Flessner, 2003). For this condition, CBIT will be combined with adjunctive computerized response inhibition training, which will be delivered over the first 4 weeks of the CBIT treatment.
62594683|NCT04776018|EXPERIMENTAL|Phase 1b, Part 2 - Lead-in Cohort: TAK-981 + Daratumumab and Hyaluronidase-fihj|"Daratumumab and hyaluronidase-fihj: 1800 mg SC injection QW once weekly in Cycles 1 and 2 , (each cycle is of 28 days) followed by every 2 weeks in Cycle 3 through 6 , followed by every 4 weeks up to Cycle 24 until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.~TAK-981: As per dose and schedule of TAK-981 defined in Phase 1b Part 1."
62812283|NCT03630991|EXPERIMENTAL|Cohort I (edetate calcium disodium, multivitamin)|During standard of care chemotherapy, patients receive edetate calcium disodium IV daily over 30 minutes for 4 doses for each cycle. Treatment continues for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive up to 12 multivitamin capsules PO daily while on study.
62812284|NCT03630991|EXPERIMENTAL|Cohort II (succimer, multivitamin)|During standard of care chemotherapy, patients receive succimer PO daily for 8 or 21 days of each cycle beginning day 1. Treatment continues for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive up to 12 multivitamin capsules PO daily while on study.
62235990|NCT04766931|EXPERIMENTAL|B3 FB2001 or Placebo|Twice daily for 5 days
62235991|NCT03457454||Primary Care Provider/Staff Participants Interviews|"* Up to two primary care providers and at least one staff person at each of the 16 clinics, with approximately 5 interviewees per clinic. Eligible providers and staff include physicians, nurse practitioners, nurses, case managers, medical assistants, administrative staff, or other employees of the clinic involved in the cancer screening and follow-up process.~* If the participant verbally consents, the research team member will conduct an interview with the provider to learn about the current processes used to support and monitor colorectal cancer screening (CRC) from screening initiation through follow-up; assess capacity and interest in implementing Evidence Based Practices for supporting and monitoring CRC screening, including any ideas interviewees have or find appealing; and engage the organizations as partners to build interest, capacity, and infrastructure for future intervention trial and other future studies."
62426576|NCT01440023|PLACEBO_COMPARATOR|Experimental: CBIT + Placebo Computer Training|In this condition, participants receive the same package of CBIT treatment, which consists of awareness training, competing response training, and social support training (Woods, Twohig, Roloff, \& Flessner, 2003). Additionally, the standard CBIT treatment is combined with computer-based placebo cognitive training that is irrelevant to the target cognitive ability (i.e., response inhibition). During the first 4 weeks of the CBIT treatment, participants will receive 8 sessions of placebo cognitive training.
62812285|NCT05055843|EXPERIMENTAL|Screening (3D MRI)|Patients undergo 3D MRI imaging over 15 minutes with standard of care MRI or at a separate time.
62812286|NCT03491059|EXPERIMENTAL|Full Study - Radiation|
62812287|NCT03491059|NO_INTERVENTION|Dress Rehearsal Only - No Radiation|
62812288|NCT01651728|EXPERIMENTAL|Simvastatin|Tablet 20 mg once daily for 30 days
62812289|NCT01651728|PLACEBO_COMPARATOR|Placebo|Placebo tablet once daily for 30 days
62812290|NCT05150028|EXPERIMENTAL|Intervention - Pediatric parent/caregiver|Questionnaires along with educational videos
62812291|NCT05150028|EXPERIMENTAL|Clinicians|Will complete pre and post survey about medication education practices
62812292|NCT01319669|EXPERIMENTAL|Treatment group|rhTPO(recombinant human thrombopoietin) is given on the second, 4th and 9th day of the chemotherapy cycle in a dosage of 15000U once subcutaneously.
62812293|NCT01319669|ACTIVE_COMPARATOR|Control group|15000U of rhTPO(recombinant human thrombopoietin) is given subcutaneously 6 to 24 hours within the end of chemotherapy cycle, that is, the 8th day for 3 consecutive days (d9 to d11)
62812294|NCT00777712||Diabetic wound study|Patients with diabetes or no diabetes
62812295|NCT06048302|ACTIVE_COMPARATOR|Active Comparitor: Subjects with Moderate Hepatic Impairment|8 patients with hepatic impairment of moderate Child Pugh Category
62812296|NCT06048302|OTHER|Active Comparator: Healthy Subjects|Healthy volunteers will be matched with impaired hepatic function patients
62812297|NCT01068340||SBO Patients|Patients who develop small bowel obstruction requiring or not surgical intervention
62812298|NCT01068340||No SBO Patients|Patients who do not develop small bowel obstruction
62812299|NCT04468646|PLACEBO_COMPARATOR|Placebo|matching placebo drug
62812300|NCT04468646|EXPERIMENTAL|NK-1R antagonist group|80 mg daily
62812301|NCT04755816|SHAM_COMPARATOR|Control Group 'A'|Standard heart failure educational information.
62812302|NCT04755816|EXPERIMENTAL|Dietary Sodium Intervention 'B'|The dietary sodium intervention facilitates lower sodium choices using tailored push notifications.
62035356|NCT04339192|EXPERIMENTAL|Surgery group|receiving minimally invasive tricuspid surgery including tricuspid valve replacement or repair plus medical treatment.
62235992|NCT03457454||Patient Participants Interviews|"* 10 patients across 5 clinics will be recruited for interviews, which will address the patient experience with screening and follow-up.~* If the participant verbally consents, the research team member will conduct an interview with the patient participant to gain a deeper understanding of the CRC screening process from the patient's perspective; the gaps, challenges, or road blocks/speed bumps to completing CRC screening steps; and what organizations can do better or differently to help people complete the CRC screening process."
62235993|NCT03457454||Patient Participants Anonymous Survey|-Patient participants will be recruited to take an anonymous mailed survey, which will address patient level barriers to screening and follow-up focusing on out of pocket costs.
62235994|NCT03457454||Colonoscopy Provider/Staff Participants Interviews|"* Colonoscopy providers and a staff or mid-level provider in each office will be recruited for interviews.~* If the participant consents, the research team member will conduct an interview to learn about current processes used to support and monitor colorectal cancer screening from the perspective of gastroenterology/colonoscopy sites and to learn about how gastroenterology/colonoscopy sites communicate and coordinate care with other healthcare organizations and patients to support and monitor colorectal cancer screening."
62235995|NCT05638893|EXPERIMENTAL|Placebo group|Placebo tablet twice daily + celecoxib 200mg capsule once daily for 12 weeks.
62235996|NCT05638893|EXPERIMENTAL|Metformin group|Metformin 500mg tablet twice daily + celecoxib 200mg capsule once daily for 12 weeks.
62235997|NCT05426759|EXPERIMENTAL|GP Ablation|Single arm study with GP ablations performed during open-chest surgery
62235998|NCT02285426||suspected lungcancer|"Patients will undergo a bronchoscopy with the Pentax EB1990i HD-bronchoscope investigating the entire bronchial tree. The HD+ bronchoscopy needs to be performed in a standardized way using 3 different imaging modes:~1. HD+bronchoscopy~2. HD+bronchoscopy + i-Scan 1~3. HD+bronchoscopy + i-Scan 2"
62235999|NCT00778622|EXPERIMENTAL|A1|Normal Weight by Body Weight Index
62236000|NCT00778622|EXPERIMENTAL|A2|Overweight by Body Weight Index
62236001|NCT00778622|EXPERIMENTAL|A3|Obese by Body Weight Index
62236002|NCT04445181||Patients with T2D|Active patients (defined as patients seen by an LMC endocrinologist between January 1, 2019 and December 31, 2019) with T2D (Type 2 Diabetes). Among the patients with T2D, those identified with CKD will be included in the renal registry.
62236003|NCT04445181||Healthcare providers|Healthcare providers caring for patients with CKD and T2D.
62236004|NCT01001923|EXPERIMENTAL|REGN475/SAR164877|REGN475/SAR164877, single injection, dose depending on the participant's body weight
62236005|NCT01001923|PLACEBO_COMPARATOR|Placebo|Placebo (for REGN475/SAR164877), single injection
62426577|NCT00297492|EXPERIMENTAL|Gradual reduction|Intervention: Reduction Phone Counseling. Intervention: Pre-Quit Nicotine Lozenges. Intervention: Post-Quit Nicotine Lozenges.
62426578|NCT00297492|ACTIVE_COMPARATOR|Abrupt cessation|Intervention: Abrupt Phone Counseling. Intervention: Post-Quit Nicotine Lozenges.
62426579|NCT00297492|ACTIVE_COMPARATOR|Minimal intervention|Intervention: Minimal Abrupt Phone Counseling. Intervention: Post-Quit Nicotine Lozenges.
62426580|NCT02458898|EXPERIMENTAL|Text Message Intervention|A series of 45 unique educational text messages sent over a period of 3 months in the evenings. Text messages include humorous reminders, links to online celiac disease resources, and bidirectional questions.
62426581|NCT02458898|NO_INTERVENTION|Control (No Text Messages)|Routine care by primary gastroenterologist with no text messages.
62426582|NCT03362242|ACTIVE_COMPARATOR|ARO-AAT|
62426583|NCT03362242|PLACEBO_COMPARATOR|Placebo|
62426584|NCT03134417|EXPERIMENTAL|Vitamin D and magnesium|Daily oral vitamin D (1000 IU) and magnesium (360 mg) supplement
62426585|NCT03134417|ACTIVE_COMPARATOR|Vitamin D|Daily oral vitamin D (1000 IU) supplement
62812303|NCT04755816|EXPERIMENTAL|Clinical Worsening Intervention 'C'|The clinical worsening intervention promotes self-monitoring and self-management and is linked tailored push notifications.
62035357|NCT04339192|NO_INTERVENTION|Medical group|receiving medical treatment only
62035358|NCT01474681|EXPERIMENTAL|HSC835|HSC835 infusion
62426586|NCT03134417|PLACEBO_COMPARATOR|Placebo|Daily oral placebo (cellulose)
62426587|NCT05535595|EXPERIMENTAL|Experimental|This group will perform genetic study for predicting adverse reaction to ACEI. Based on the result of genetic study, participants will receive ACEI or ARB.
62426588|NCT05535595|ACTIVE_COMPARATOR|Control|Participants will receive ACEI without genetic study.
62426589|NCT04031066|EXPERIMENTAL|Velmanase alfa|
62426590|NCT04031066|PLACEBO_COMPARATOR|placebo|
62812304|NCT04755816|EXPERIMENTAL|Dietary Sodium and Clinical Worsening 'D'|Full access to all content in the control, dietary sodium, and clinical worsening interventions.
62812305|NCT04658160|NO_INTERVENTION|Control|None- normal care
62236006|NCT03308409|ACTIVE_COMPARATOR|Protocol 1|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six sessions, one per week, with 3000 pulses at 0.20 mj/mm2, at a frequency of 4Hz. At all of the shockwave sessions, 2000 pulses will be distributed to the body of the penis and 1000 pulses will be applied to the base.
62236007|NCT03308409|EXPERIMENTAL|Protocol 2|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six initial sessions, one per week, with 3000 pulses at 0.20 mj/mm2, at a frequency of 4Hz for six weeks, followed by monthly maintenance sessions (every 4 weeks) for five months. At all of the shockwave sessions, 2000 pulses will be distributed to the body of the penis and 1000 pulses will be applied to the base.
62236008|NCT03308409|EXPERIMENTAL|Protocol 3|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six monthly sessions in which 3000 pulses will be applied at 0.20 mj/mm2, at a frequency of 4Hz, with 2000 pulses distributed to the body of the penis and 1000 pulses applied to the base
62236009|NCT00629655||1|healthy people, male
62236010|NCT00629655||2|male patients with cerebral infarction, chronic stage
62236011|NCT05285488|EXPERIMENTAL|"focused attention group"|adult subjects practicing focused attention meditation
62426591|NCT06146686|EXPERIMENTAL|Group I ( pulpectomy using single rotary file )|After opening the access cavity, a single rotary file (20 taper 4) will be adjusted on the desirable working length depending on a radiograph (1 mm shorter than the apex) and used in pulpectomy in a brushing motion at the rotational speed 300 rpm with torque set at the lowest level, irrigation with saline
62426592|NCT06146686|ACTIVE_COMPARATOR|Group II ( pulpectomy using multiple rotary files system )|After opening the access cavity, multiple rotary files system (Fanta AF baby rotary files 20 taper 4, 25 taper 4, 30 taper 4) will be adjusted on the desirable working length depending on a radiograph (1 mm shorter than the apex) and used in pulpectomy in a brushing motion at rotational speed 300 rpm with torque set at the lowest level, irrigation with saline
62426593|NCT03352219|EXPERIMENTAL|Reality Check|Received streamed 13-episode HIV risk reduction serial drama, Reality Check, developed based on Social Cognitive Theory integrated with findings from focus groups and community advisory boards. Each character has a behavioral trajectory related to HIV. For example, one character modeled negotiating condom use with his partner when she was against it. Messages in the serial drama showed that the characters had normative support for HIV testing and condom use. One character modeled a mastery experience when she overcame her fear and got tested for HIV. Homophobia is addressed when a mother discovers that her son is gay. Over the course of the episodes, the interweaving storylines play out, with all the characters eventually achieving their positive goals.
62812306|NCT04658160|EXPERIMENTAL|Intervention/Tracking|This group will have access to the longitudinal tracking and intervention platform for Medicare Advantage patients. Members of this group's care team will have access to the longitudinal data on the platform and will be able to intervene if any red flags emerge (i.e. if a patient displays signs of depression on a patient reported outcome measure/survey)
62812307|NCT05357573|EXPERIMENTAL|KRN23|KRN23 administered subcutaneously (SC) every 4 weeks for 48 weeks. The dose varies according to serum phosphorus level which include 0.3,0.6,1.0,1.4 and 2.0 mg/kg.
62812308|NCT04283669|OTHER|Open Label Continuous Treatment|Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles. Clinical response will be assessed by MRI (volumetrics, primary objective) and audiology at the end of every 3rd cycle. Subjects with volumetric tumor progression will be taken off protocol. Patients who complete 12 cycles of treatment without disease progression, but within the following 24 weeks show subsequent disease progression (defined as \>20% increase in target tumor volume compared to off-treatment volume), will be eligible for re-treatment on study for up to 48 additional weeks, provided they still meet study eligibility criteria.
62812309|NCT06378775|EXPERIMENTAL|Hybrid Coronary Revascularization|2 Step revascularization: Robotically-assisted minimally-invasive direct coronary artery bypass (RA-MIDCAB) followed by Percutaneous Coronary Intervention (PCI)
62236012|NCT05285488|ACTIVE_COMPARATOR|"Contemplation group"|adult subjects practicing contemplation meditation
62236013|NCT01886820|EXPERIMENTAL|[18F]NAV4694|Intravenous \[18F\]NAV4694 radioactive dose 8.1 mCi(300 MBq) given once
62236014|NCT00792805|EXPERIMENTAL|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62236015|NCT00792805|EXPERIMENTAL|Indacaterol 300 μg|Patients inhaled indacaterol 300 μg via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62812310|NCT06378775|ACTIVE_COMPARATOR|Coronary Artery Bypass Grafting (CABG)|Coronary Artery Bypass Grafting
62812311|NCT00584948|EXPERIMENTAL|Memantine|
62812312|NCT00584948|PLACEBO_COMPARATOR|Placebo|
62812313|NCT06213818|EXPERIMENTAL|Cohort 1: Dose|INCB160058 will be administered at protocol defined dose.
62812314|NCT06213818|EXPERIMENTAL|Cohort 2: Dose|INCB160058 will be administered at protocol defined dose.
62812315|NCT06213818|EXPERIMENTAL|Cohort 3: Dose|INCB160058 will be administered at protocol defined dose.
62812316|NCT06213818|EXPERIMENTAL|Cohort 4: Dose|INCB160058 will be administered at protocol defined dose.
62812317|NCT06213818|EXPERIMENTAL|Cohort 5: Dose|INCB160058 will be administered at protocol defined dose.
62812318|NCT06213818|EXPERIMENTAL|Cohort 6: Dose Treatment A|INCB160058 will be administered at protocol defined dose after an overnight fast.
62812319|NCT06213818|EXPERIMENTAL|Cohort 6: Dose Treatment B|INCB160058 will be administered at protocol defined dose after a high-fat-calorie meal.
62812320|NCT06213818|EXPERIMENTAL|Cohort 7: Dose|INCB160058 and Esomeprazole will be administered at protocol defined schedule and dose.
62236016|NCT00792805|PLACEBO_COMPARATOR|Placebo to indacaterol|Patients inhaled placebo to indacaterol via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62426594|NCT03352219|PLACEBO_COMPARATOR|Physical Activity Attention Control|Received streamed physical activity promotion videos designed to control for Hawthorne effects, including special attention, consisting of a series of 13 videos from YouTube on physical activity and exercise. The videos, selected to be appropriate for African Americans 18 to 24 years of age, were tailored to be gender specific and hence varied between men and women. The videos focused on the importance of physical activity, coping strategies for lack of motivation to engage in physical activity, and other challenges faced in becoming more physically active, provided specific knowledge and skills regarding how to engage in aerobic and muscle-strengthening exercises, and model aerobic and muscle-strengthening exercises in a variety of settings.
62426595|NCT00717873|EXPERIMENTAL|HFCWO Arm|Airway clearance provided by the Vest Airway Clearance System
62426596|NCT00717873|NO_INTERVENTION|CPT Arm|Airway clearance provided by manual CPT
62594684|NCT04776018|EXPERIMENTAL|Phase 2 - Dose Expansion: TAK-981 + Daratumumab and Hyaluronidase-fihj or Mezagitamab|TAK-981 at RP2D as determined in Phase 1b. Mezagitamab at a fixed dose of 600 mg SC injection or Daratumumab and Hyaluronidase-fihj at a fixed dose of 1800 mg weekly in Cycles 1 and 2 (each cycle is of 28 days), followed by every 2 weeks in Cycle 3 through 6, followed by every 4 weeks up to Cycle 24 or until disease progression unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
62594685|NCT01084668||Adalimumab|Participants with moderate to severe chronic plaque psoriasis treated with adalimumab after biologic disease modifying anti-rheumatic drug (BDMARD) failure
62594686|NCT03385044|ACTIVE_COMPARATOR|Cuff sealing by MOVT|MOVT (minimal occlusive volume technique). The cuff sealing will be confirmed with MOVT, then the intracuff pressure will be measured.
62594687|NCT03385044|ACTIVE_COMPARATOR|Cuff sealing by VE/VI ratio|VE/VI ratio of Spirometer. The cuff sealing will be confirmed with VE/VI ratio of a spirometer, then the intracuff pressure will be measured.
62594688|NCT06276777|EXPERIMENTAL|Varnish contains S-PRG (PRG Barrier Coat from Shofu)|Treatment of dentin hypersensitivity by application of tooth varnish containing S-PRG.
62594689|NCT06276777|ACTIVE_COMPARATOR|Varnish contains sodium fluoride and functionalized tri-calcium phosphate(Clinpro white varnish 3M)|Treatment of dentin hypersensitivity by application of tooth varnish containing sodium fluoride with functionalized tri-calcium phosphate.
62594690|NCT04756583|EXPERIMENTAL|Intervention|
62594691|NCT04756583|NO_INTERVENTION|Control|
62594692|NCT00310206|EXPERIMENTAL|ID injection-9 mcg|25 subjects to receive 9 mcg of inactivated influenza A/H5N1 vaccine intradermally on Days 0 and 28.
62594693|NCT00310206|EXPERIMENTAL|IM injection-15 mcg|25 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine intramuscularly on Days 0 and 28.
62812321|NCT06213818|EXPERIMENTAL|Cohort 8: Dose|INCB160058 will be administered at protocol defined dose after an overnight fast.
62812322|NCT06213818|EXPERIMENTAL|Cohort 9: Dose|INCB160058 will be administered at protocol defined dose after an overnight fast.
62812323|NCT05429216|EXPERIMENTAL|mEMR-C group|In mEMR-C group, enrolled patients will receive modified EMR-C without submucosal injection.
62812324|NCT05429216|ACTIVE_COMPARATOR|ESD group|In ESD group, enrolled patients will receive the standard treatment modality of ESD to remove the rectal NET
62236017|NCT04024774||index cases and their parents|
62594694|NCT00310206|EXPERIMENTAL|IM injection-45 mcg|25 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine intramuscularly on Days 0 and 28.
62594695|NCT00310206|EXPERIMENTAL|ID injection-3 mcg|25 subjects to receive 3 mcg of inactivated influenza A/H5N1 vaccine intradermally on Days 0 and 28.
62594696|NCT03188068|ACTIVE_COMPARATOR|Sirolimus|Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
62594697|NCT03188068|ACTIVE_COMPARATOR|Sirolimus plus prednisolone|"Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.~Prednisolone was administered 2 mg/kg administered once daily. Should satisfactory clinical responses and hematologic stabilization ensue, prednisolone may be tapered and discontinued within the following 4-6 weeks."
62594698|NCT06621017|PLACEBO_COMPARATOR|Placebo|Saline solution
62594699|NCT06621017|EXPERIMENTAL|ROSE-010 99 mcg|ROSE-010 solution, 99 mcg, 0.5 ml
62594700|NCT06621017|EXPERIMENTAL|ROSE-010 150 mcg|ROSE-010 solution, 150 mcg, 0.5 ml
62594701|NCT05069259||Patients with active Ulcerative Colitis|
62594702|NCT05929196|EXPERIMENTAL|Blood sample donator|The participant donates approximately 5 ml of blood sample.
62594703|NCT05210465||patients with stable angina pectoris and prior MI|
62819626|NCT03957954|EXPERIMENTAL|Cultivated Limbal Stem-Cells (cLSC)|One dose of cultivated limbal stem-cells (cLSC), size between 7.6 to 15 mm in the average diameter.
62035359|NCT01283412|ACTIVE_COMPARATOR|Arm P|Placebo infusion
62236018|NCT05961280||DCIS Mastectomy|Patients who undergo mastectomy with sentinel lymph node biopsy for DCIS at biopsy
62236019|NCT01918553|EXPERIMENTAL|Subject in the study ALIENOR|
62236020|NCT03658746|EXPERIMENTAL|Antimicrobial susceptibility guided therapy|"Patients in this group will receive a 14-day quadruple therapy for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin, and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.~Drugs: 1.one proton pump inhibitor: rabeprazole 10mg bid for 14d, 2.Colloidal Bismuth Pectin 200mg bid for 14d, 3.two sensitive antibiotics: amoxicillin 1000mg bid for 14d, clarithromycin 500mg bid for 14d, metronidazole 500mg tid for 14d, tinidazole 500mg tid for 14d, levofloxacin 500mg qd for 14d, furazolidone 100mg bid for 14d, tetracycline 500mg qid for 14d."
62236021|NCT03658746|ACTIVE_COMPARATOR|Empirical therapy according to medication history|"Patients in this group will receive a 14-day quadruple therapy based on personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics chosen according to medication history. If the patient hasn't been treated with levofloxacin in the previous eradication regimen, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.~Drugs: 1.one proton pump inhibitor: rabeprazole 10mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and levofloxacin 500mg qd for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
62236022|NCT03707925|EXPERIMENTAL|Diagnostic (bronchoscopic laser ablation, CBCT)|Patients undergo bronchoscopic laser ablation following standard bronchoscopy and endobronchial ultrasound. Patients also undergo CBCT before and after laser ablation. 48-72 hours after the procedure, patients undergo standard surgical resection of the lung tumor.
62426597|NCT05807347|EXPERIMENTAL|VACAG（Venetoclax Combined with Azacitidine and CAG）regimen|Participants will receive induction as azacitidine on days 1-7, venetoclax aily on days 1-28, cytarabine q12h on days 1-7, aclacinomycin on days 1,3,5,7, and granulocyte colony-stimulating factor on days 0-8. Participants will receive second induction if not reach complete remission.
62426598|NCT05590325|EXPERIMENTAL|single arm, two-stage|"Participants will be enrolled in two stages:~* Stage 1 will assess a single dose of the DTG-DT in two sequential cohorts: Cohort 1A (n=8) and Cohort 1B (n=8).~* Stage 2 will assess multiple-doses of the DTG-DT and the DTG-ODF in a single cohort: Cohort 2A (n=20) DTG-DT and Cohort 2B (n=20) DTG-ODF"
62426599|NCT04472065|ACTIVE_COMPARATOR|Subjects receiving Probiotic Dietary Supplement|
62426600|NCT04472065|PLACEBO_COMPARATOR|Subjects receiving Placebo|
62426601|NCT06045429|EXPERIMENTAL|Hydrogen Peroxide|Intervention group: daily oral care will be provided according to the local standard, with 3% hydrogen peroxide, oral assessment and teeth brushing will be completed twice daily (morning and evening).
62426602|NCT06045429|ACTIVE_COMPARATOR|Chlorhexidine|Control group: daily oral care will be provided according to the local standard, with 0,2% chlorhexidine, oral assessment and teeth brushing will be completed twice daily (morning and evening).
62426603|NCT02107963|EXPERIMENTAL|Arm 1|Dose escalation of anti-GD2 CAR T cells
62426604|NCT02107963|EXPERIMENTAL|Arm 2|Dose expansion of anti-GD2 CAR T cells
62812325|NCT02946437|EXPERIMENTAL|Sevoflurane|"Sevoflurane postconditioning will start after the bleeding source is excluded by coiling or clipping as soon as the patient returns to the ICU and will be continued for 4 hours. 0.5-1.5vol% sevoflurane will be administrated into the ventilation circuit by a MIRUS™System.~The used dose (0.5-1.5vol%) is a lower dose as used for anaesthesia for a surgical intervention (0.5-3vol%), but high enough to provide sufficient sedation."
62426605|NCT00179153|ACTIVE_COMPARATOR|1|
62426606|NCT06500299|EXPERIMENTAL|HDM1002 100mg BID|HDM1002 tablets 100mg twice daily, 12weeks
62035360|NCT01283412|EXPERIMENTAL|Arm D|Dexmedetomidine infusion
62426607|NCT06500299|EXPERIMENTAL|HDM1002 200mg BID|HDM1002 tablets 200mg twice daily, 12weeks
62426608|NCT06500299|EXPERIMENTAL|HDM1002 400mg QD|HDM1002 tablets 400mg once daily, 12weeks
62426609|NCT06500299|PLACEBO_COMPARATOR|placebo|Matching placebo will be provided， 12weeks
62426610|NCT02872337|EXPERIMENTAL|Experimental (Intervention): PreopPT Group|This group will undergo the group preoperative education session. Following this session (intervention) this group underwent a one-time, one-on-one preoperative PT session. They also were given access to a web-based microsite which was customized to surgeon
62426611|NCT02872337|PLACEBO_COMPARATOR|Control (standard of care): No PreopPT Group|This group underwent the current of standard of care at our institution. This only includes the group preoperative education session. No further preoperative education was given.
62812326|NCT02946437|ACTIVE_COMPARATOR|Propofol or Midazolam|Propofol or midazolam will be administrated intravenously before and after the postconditioning with sevoflurane as in the standard sedation regimen of the Neurointensive Care Unit, University Hospital Zurich (propofol 0.3-4.0mg/kg/h cont. i.v.; midazolam 0.03-0.2mg/kg/h cont. i.v.)
62812327|NCT02946437|OTHER|MIRUS™System|MIRUS™ is a newly developed device, considered as vaporizer system, which can be used in the setting of operating rooms or in intensive care units. The MIRUS™System is successfully in use in daily clinical practice. This type of device is similar to the well-known AnaConDa® system (AnaConDa®, Sedana Medical, Uppsala, S) with several advantages. Since 2005 the anaesthetic-conserving device AnaConDa® facilitates, from a technical viewpoint, the routine use of volatile anaesthetics in intensive care patients as part of prolonged sedation, using ICU ventilators (Soukup J et al., 2009). The MIRUS™System forms a closed loop. It measures the end-tidal concentration of the anaesthetic gas and governs the application of the anaesthetic gas according to these values and the ventilation parameters.
62812328|NCT03978130|EXPERIMENTAL|mHealth-CR|
62812329|NCT03978130|NO_INTERVENTION|Usual Care|
62812330|NCT04187118||Lymphoma patients|Patients being in complete response after a first therapy for malignant lymphoma.
62035361|NCT03479372|EXPERIMENTAL|PAN-90806 Eye Drops, dose 1|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
62035362|NCT03479372|EXPERIMENTAL|PAN-90806 Eye Drops, dose 2|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
62035363|NCT03479372|EXPERIMENTAL|PAN-90806 Eye Drops, dose 3|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
62426612|NCT05786053|ACTIVE_COMPARATOR|v pattern exotropia|v pattern exotropia patients with associated inferior oblique overreaction
62594704|NCT00343785|EXPERIMENTAL|Treatment (conditioning regimen, transplant, GVHD prophylaxis)|Patients receive a conditioning regimen comprising cyclophosphamide IV on days -5 to -2 and anti-thymocyte globulin IV over 4-10 hours on days -4 to -2. Patients undergo allogeneic bone marrow transplantation on day 0. Patients then receive GVHD prophylaxis comprising methotrexate IV on days 1, 3, 6, and 11 and cyclosporine IV over 1 hour or PO twice daily on days -1 to 50, followed by a taper until 6 months after grafting.
62594705|NCT06083727||primigravida|
62426613|NCT05786053|ACTIVE_COMPARATOR|Pattern esotropia|v pattern esotropia patients with inferior oblique overreaction
62426614|NCT03910582|EXPERIMENTAL|Experimental group|Subjects in this group will be treated with personalized frozen-thawed embryo transfer. The blastocysts were delayed or advanced transferred after ovulation depending on the endometrium dating in RIF group
62426615|NCT03910582|ACTIVE_COMPARATOR|Control group|Subjects in this group will be treated with routine frozen-thawed embryo transfer.The blastocysts were transferred 5 days after ovulation regardless of endometrium dating in control group.
62426616|NCT01259700|EXPERIMENTAL|High risk management|
62812331|NCT01796340|EXPERIMENTAL|Food cue exposure|
62812332|NCT01796340|ACTIVE_COMPARATOR|Psycho-education|
62812333|NCT02972931||LoViReT|HIV-infected subjects with extremely low or undetectable HIV-1 DNA levels in peripheral blood despite having initiated cART during chronic HIV-1 infection
62426617|NCT01259700|EXPERIMENTAL|Salt reduction|
62426618|NCT01259700|EXPERIMENTAL|high risk management and salt reduction|
62426619|NCT01259700|NO_INTERVENTION|Usual care|
62426620|NCT01143272|ACTIVE_COMPARATOR|Saccharomyces boulardii|Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
62594706|NCT06083727||multigravida|
62594707|NCT03828110||Children with neurological impairment|
62594708|NCT03455010|NO_INTERVENTION|Normal load|Healthy subjects walking for 30 minutes on a treadmill with normal body weight
62594709|NCT03455010|EXPERIMENTAL|Increased load|Healthy subjects walking for 30 minutes on a treadmill with 20% additional body weight
62594710|NCT03455010|EXPERIMENTAL|Reduced load|Healthy subjects walking for 30 minutes on a treadmill with 20% lower body weight
62594711|NCT06569667|EXPERIMENTAL|Intervention Arm-1: PRC supported text+ AI driven SDH-enhanced text|Participants in this arm will receive a combination of Peer Recovery Coaches (PRCs) supported text-based care/services coordination alongside AI-driven SDH-enhanced text messages to enhance the receipt of buprenorphine in Black/ Latin people who use opioids.
62594712|NCT06569667|EXPERIMENTAL|Intervention Arm-2: AI driven SDH-enhanced text only|Participants in this arm will receive AI-driven SDH-enhanced text messages to enhance the receipt of buprenorphine in Black/ Latin people who use opioids. Unlike Arm-1, this intervention does not include the additional support and coordination provided by Peer Recovery Coaches.
62594713|NCT06569667|PLACEBO_COMPARATOR|Control Arm 3- Treatment as Usual|Control Arm-3 will receive treatment as usual (i.e., verbal instructions, NYC Dept of Health pamphlets detailing access to OUD and social services, health system smartphone application EMR patient portal).
62594714|NCT02220179|NO_INTERVENTION|control|service as usual
62594715|NCT02220179|EXPERIMENTAL|Intervention group 1|Participants are offered access to the web based resilience program
62594716|NCT02220179|EXPERIMENTAL|Intervention group 2|Participants are offered access to the web based resilience program and are also invited to join a short introduction course about the program
62812334|NCT02972931||Standard Reservoir Level|HIV-infected subjects who initiated cART during chronic HIV-1 infection and that show standard HIV-1 DNA levels in peripheral blood
62426621|NCT01143272|PLACEBO_COMPARATOR|Microcristallin cellulose|Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
62819627|NCT03957954|ACTIVE_COMPARATOR|Scleral Contact Lens Device (SCL)|Scleral contact lens device (SCL) will be fitted to stabilize and improve ocular surface.
62426622|NCT06225778|NO_INTERVENTION|Control Group|Control group
62426623|NCT06225778|EXPERIMENTAL|Exercise Group|6-week online exercise group
62426624|NCT02455583|NO_INTERVENTION|Standard of Care|All Form 1 learners at 25 of the 50 schools will receive HIV prevention sessions from the Botswana life skills education program for junior secondary school students called LIVING.
62819628|NCT01746836|EXPERIMENTAL|Ponatinib hydrochloride|Patients receive ponatinib hydrochloride PO QD. Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity.
62426625|NCT02455583|EXPERIMENTAL|Intervention|Form 1 learners at the 25 intervention schools will receive the Project AIM intervention and LIVING (standard of care).
62426626|NCT01692080||Asthma Screenings and Camps|Children, ages 5-17 years who participate in one of the asthma screenings or camps are eligible to participate in this study.
62426627|NCT02076932|ACTIVE_COMPARATOR|Premenopausal women|The premenopausal women will be attending Spinning classes.
62426628|NCT02076932|EXPERIMENTAL|Postmenopausal Women|The postmenopausal women will be attending Spinning classes.
62426629|NCT00552526|ACTIVE_COMPARATOR|Ketogenic diet|
62594717|NCT01405417|EXPERIMENTAL|Peroral endoscopic myotomy|"Patients with achalasia who are designed to either have balloon dilatation or botulinum toxine injection, or to have surgical intervention (Heller myotomy) for therapy.~Peroral endoscopic myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips."
62426630|NCT00552526|ACTIVE_COMPARATOR|AED|Most appropriate antiepileptic drug
62426631|NCT02968641|ACTIVE_COMPARATOR|LNF 25 mg bid and RTV 100 mg bid|Patients will take lonafarnib 25 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
62035364|NCT05305157||Experts on forensic odontology|Experts on forensic odontology, members of AFIO (French Association of odontological identification) and UIO (Odontological identification Unit)
62035365|NCT05172765|ACTIVE_COMPARATOR|Active TENS Stimulation|
62236023|NCT04622189|EXPERIMENTAL|Action observation training for the upper limb rehabilitation|Neurorehabilitation training for the upper limb using AOT consists of watching videos related to every day actions. The subjects will be asked to reproduce, as accurately as possible, the actions proposed by the system, that will record their execution. In order to keep high motivation and participation in activities, simple games of skill will also be created that will involve the patient on both the motor and cognitive side. The training program includes 250 videos of every day transitive and intransitive actions: 20 consecutive sessions of 1 hour, five times a week over four weeks.
62236024|NCT00519961|EXPERIMENTAL|A|
62426632|NCT02968641|ACTIVE_COMPARATOR|LNF 50 mg bid and RTV 100 mg bid|Patients will take lonafarnib 50 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
62426633|NCT02968641|ACTIVE_COMPARATOR|LNF 100 mg bid|Patients will take lonafarnib 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
62426634|NCT00021229|EXPERIMENTAL|Imatinib mesylate|
62426635|NCT05294614|OTHER|A B B B B B B B B C C C C C C|"Considering the study design of a closed cohort study, the design of this study is composed by 3 sequences (3 different starts of the treatment phase). In this case, the following arm is established as de first arm of the study: A B B B B B B B B C C C C C C.~In this sequence A represent the control phase, B the treatment phase and the C the maintenance phase."
62426636|NCT05294614|OTHER|A A B B B B B B B B C C C C C|"Considering the study design of a closed cohort study, the design of this study is composed by 3 sequences (3 different starts of the treatment phase). In this case, the following arm is established as de first arm of the study: A A B B B B B B B B C C C C C.~In this sequence A represent the control phase, B the treatment phase and the C the maintenance phase."
62426637|NCT05294614|OTHER|A A A B B B B B B B B C C C C|"Considering the study design of a closed cohort study, the design of this study is composed by 3 sequences (3 different starts of the treatment phase). In this case, the following arm is established as de first arm of the study: A A A B B B B B B B B C C C C.~In this sequence A represent the control phase, B the treatment phase and the C the maintenance phase."
62426638|NCT00773552|EXPERIMENTAL|solifenacin succinate|Group randomized into solifenacin succinate treatment
62594718|NCT00262470|EXPERIMENTAL|1|Acetazolamide
62594719|NCT00262470|EXPERIMENTAL|2|Atomoxetine
62035366|NCT05172765|SHAM_COMPARATOR|Inactive TENS Stimulation|
62426639|NCT00773552|PLACEBO_COMPARATOR|placebo|Group randomized into placebo
62594720|NCT00262470|EXPERIMENTAL|3|NO Drug
62594721|NCT00262470|EXPERIMENTAL|4|Clonidine
62236025|NCT00519961|EXPERIMENTAL|B|
62426640|NCT02937038||Healthy Kids 3-13 y|Healthy boys and girls of 3-13 y of age
62426641|NCT02937038||Parents 20-50 y|One of their Parents 20-50 y of age
62426642|NCT03008031|EXPERIMENTAL|arm A (40%)|Patients randomized in arm A will receive a second CESM exam with 40% of the initial dose of the contrast agent.
62236026|NCT01439919|EXPERIMENTAL|SSR411298 200 mg|SSR411298 200 mg, one tablet once daily for 4 weeks
62594722|NCT00262470|EXPERIMENTAL|5|Entacapone
62236027|NCT01439919|PLACEBO_COMPARATOR|Placebo|Placebo (for SSR411298), one tablet once daily for 4 weeks
62426643|NCT03008031|EXPERIMENTAL|arm B (60%)|Patients randomized in arm A will receive a second CESM exam with 60% of the initial dose of the contrast agent.
62426644|NCT03008031|EXPERIMENTAL|arm C (80%)|Patients randomized in arm A will receive a second CESM exam with 80% of the initial dose of the contrast agent.
62426645|NCT06003491|EXPERIMENTAL|Intra-articular Group|Posterior intra-articular distraction and fusion
62426646|NCT06003491|NO_INTERVENTION|Posterior Group|Posterior direct distraction and fusion
62426647|NCT03937973|EXPERIMENTAL|Social rejection by in-group|One hour prior to bed, participants will be exposed to a social rejection paradigm that includes a computerized ball-tossing game (Cyberball) and a speech task. Participants are made to believe that they are being rejected by someone of their own race/ethnicity (e.g., African American rejected by another African American).
62426648|NCT03937973|EXPERIMENTAL|Social rejection by out-group|One hour prior to bed, participants will be exposed to a social rejection paradigm that includes a computerized ball-tossing game (Cyberball) and a speech task. Participants are made to believe that they are being rejected by someone not of their own race/ethnicity (e.g., Caucasian American rejected by another African American).
62594723|NCT00262470|EXPERIMENTAL|6|Indomethacin
62594724|NCT00262470|EXPERIMENTAL|7|Isosorbide Dinitrate
62594725|NCT00262470|EXPERIMENTAL|8|Mecamylamine
62594726|NCT00262470|EXPERIMENTAL|9|Memantine
62594727|NCT00262470|EXPERIMENTAL|10|Melatonin
62594728|NCT00262470|EXPERIMENTAL|11|Midodrine
62594729|NCT00262470|EXPERIMENTAL|12|Modafinil
62594730|NCT00262470|EXPERIMENTAL|13|Octreotide
62594731|NCT00262470|PLACEBO_COMPARATOR|14|Placebo (lactose tablet)
62594732|NCT00262470|EXPERIMENTAL|15|Propranolol
62594733|NCT00262470|EXPERIMENTAL|16|Sertraline
62594734|NCT00262470|EXPERIMENTAL|17|Normal Saline (0.9%) 1 liter
62594735|NCT00262470|EXPERIMENTAL|18|Drinking Water
62236028|NCT03855553|EXPERIMENTAL|FBT|10 families will be randomized to receive 10 - 16 weeks of eating disorder treatment for their adolescent.
62236029|NCT03855553|EXPERIMENTAL|CBT-E|10 families will be randomized to receive 10 - 16 weeks of eating disorder treatment for their adolescent.
62236030|NCT01419041|OTHER|Arm A|CLCR: Creatinine clearance
62236031|NCT01419041|OTHER|Arm B|CLCR: Creatinine clearance
62426649|NCT01862120|EXPERIMENTAL|interleukin-2|Dose D1 of interleukin-2
62426650|NCT01862120|EXPERIMENTAL|Dose D2 of interleukin-2|Dose D2 of interleukin-2
62426651|NCT01862120|EXPERIMENTAL|Dose D3 of interleukin-2|Dose D3 of interleukin-2
62426652|NCT01862120|PLACEBO_COMPARATOR|placebo|placebo
62426653|NCT00738920|ACTIVE_COMPARATOR|MC-CBT|Self Administered Cognitive Behavior Therapy
62426654|NCT00738920|ACTIVE_COMPARATOR|Standard-CBT|Therapist Administered Cognitive Behavior Therapy
62426655|NCT00738920|ACTIVE_COMPARATOR|Education/Support|Behavioral Patient Education/Counseling
62426656|NCT01345890|EXPERIMENTAL|electrical stimulation|stroke patients
62594736|NCT00262470|EXPERIMENTAL|19|Dead Space Breathing Device
62594737|NCT00262470|EXPERIMENTAL|Abdominal Binder|Abdominal binder with inflatable pressure over abdomen
62594738|NCT02339116|EXPERIMENTAL|Folfoxiri/bev --> folfoxiri/bev|"FOLFOXIRI plus bev (to be repeated every 2 weeks for a maximum of 8 cycles):~Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Irinotecan 165 mg/sqm iv over 60 minutes, day 1 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 At the time of disease progression, patients will re-introduce FOLFOXIRI plus bev at the same doses and schedule previously tolerated, for a maximum of 8 cycles. If no progression occurs during FOLFOXIRI plus bev, patients will receive maintenance 5-FU/LV plus bev at the same dose used in the last cycle of the induction treatment."
62819629|NCT04945746|EXPERIMENTAL|Software VX1 + Stability|Utilization of the software VX1 + Stability
62819630|NCT06218277|EXPERIMENTAL|ASTAR|Use of the early AST results for guidance of the antimicrobial therapy
62035367|NCT06470321|EXPERIMENTAL|Smoking Cessation Intervention|Participants receive Flexiquit, an avatar-led computerized smoking cessation program. Flexiquit is a self-delivered app providing: motivational interviewing, psychoeducation on addiction/withdrawal, cognitive-behavioral strategies for cravings, relapse prevention, stress/emotion regulation skills. Delivered over 6 months starting Day 2 after initial assessments. Adherence monitored. Biochemical verification of abstinence at 3 and 6 months post-quit.
62236032|NCT05703867|EXPERIMENTAL|Active microcurrent therapy|
62426657|NCT01908998|ACTIVE_COMPARATOR|Sandal|
62812335|NCT01893541|ACTIVE_COMPARATOR|EBL PLUS PROPRANOLOL|The EBL procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices were obliterated. The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.
62426658|NCT00669838||PL|Patients who receive local anesthesia with 2% lidocaine without epinephrine
62426659|NCT00669838||LE|Patients who receive local anesthesia with 2% lidocaine with 1:100.000 epinephrine
62812336|NCT01893541|ACTIVE_COMPARATOR|ENDOSCOPIC BAND LIGATION|The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.
62812337|NCT03909893|EXPERIMENTAL|Adaptive Radiation Therapy|
62812338|NCT04575506|NO_INTERVENTION|Control group|
62035368|NCT00377234|EXPERIMENTAL|1|
62035369|NCT00377234|ACTIVE_COMPARATOR|2|
62035370|NCT00882947||Group 1|
62035371|NCT01796574|EXPERIMENTAL|Ketogenic diet|Patients will receive the ketogenic diet as a formula delivered via feeding tube. Once able to tolerate food by mouth, patients will be switched to a modified Atkins diet.
62426660|NCT00727298||Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
62426661|NCT03673839|ACTIVE_COMPARATOR|Animal proteins (crossover)|
62426662|NCT03673839|EXPERIMENTAL|Plant-based protein blends type 1 (crossover)|
62426663|NCT03673839|EXPERIMENTAL|Plant-based protein blends type 2 (crossover)|
62812339|NCT04575506|ACTIVE_COMPARATOR|Obesity-Non-hepatic steatosis|Healthy lifestyle education program focused on dietary and lifestyle guidelines for both children and parents (2 days/month, 60 min), and exercise program based on high-intensity interval training which combine aerobic and resistance training (at least 3 days/week, from 38 to 44 min).
62812340|NCT04575506|EXPERIMENTAL|Obesity-Hepatic steatosis|Healthy lifestyle education program focused on dietary and lifestyle guidelines for both children and parents (2 days/month, 60 min), and exercise program based on high-intensity interval training which combine aerobic and resistance training (at least 3 days/week, from 38 to 44 min).
62812341|NCT02970799|EXPERIMENTAL|Intranasal then Extranasal Application|Intranasal Neurostimulator applied intranasally (active) followed by extranasal application on Day 1. Participants were randomized to determine the intranasal and extranasal sequence for Days 15 and 29.
62812342|NCT02970799|EXPERIMENTAL|Extranasal then Intranasal Application|Intranasal Neurostimulator applied extranasally (control) followed by intranasal application on Day 1. Participants were randomized to determine the intranasal and extranasal sequence at Days 15 and 29.
62812343|NCT00449696|EXPERIMENTAL|Gel-200|
62812344|NCT00449696|PLACEBO_COMPARATOR|PBS|
62035372|NCT03839251|OTHER|abilify maintena|aripiprazole 400mg or 300mg, IM, Once a month
62035373|NCT05316441|EXPERIMENTAL|Intervention Group|A total of 5 sessions of 1.5 hours of group therapy will be applied to the Intervention Group. Group therapies will be carried out over the internet once a week, after appropriate days and times are determined.
62035374|NCT05316441|NO_INTERVENTION|Control Group|The control group will not be interfered with.
62035375|NCT04982900|EXPERIMENTAL|EGFR-TKI Treatment Arm|After randomization, the enrolled patients in this arm should be completely free from the risk of perioperative complications or recovered from the effects of complications, usually no earlier than 4 weeks after surgery but no more than 10 weeks after surgery, before receiving baseline follow-up and starting oral administration of Furmonertinib on the day of baseline follow-up. Patients in the treatment group should take Furmonertinib (80 mg each time) orally on an empty stomach before breakfast once a day. The medicine should be taken about the same time each day, by swallowing the whole tablet with water, without crushing or chewing. Patients should maintain oral administration of Furmonertinib for 6 consecutive months, unless there is disease progression, death, new anti-tumor therapy received or intolerance of investigational drugs.
62236033|NCT02787525||A: patients on anticoagulation|Questionnaire to patients with non-valvular atrial fibrillation on OAC or NOAC
62236034|NCT02787525||B: patients treated by LAA-Closure|Questionnaire to patient with non-valvular atrial fibrillation who underwent LAAC between 2009 and 2014 at the University hospitals Bern or Zurich
62426664|NCT03673839|EXPERIMENTAL|Plant-based protein blends type 3 (crossover)|
62426665|NCT06106737||previous calculation formula|
62426666|NCT06106737||modified calculation formula|
62426667|NCT02096029|EXPERIMENTAL|Nicotine Replacement Therapy (NRT)|2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
62426668|NCT02096029|ACTIVE_COMPARATOR|Ask, Advise, Refer (physician brief advice)|Ask, Advise, Refer (physician brief advice)
62426669|NCT03358342||ED Patients treated using ePneumonia CDS|ED patients with community-acquired pneumonia treated in ED's after roll out of ePneumonia
62426670|NCT03358342||Usual care|ED patients with pneumonia receiving usual care without electronic CDS
62426671|NCT01461148|EXPERIMENTAL|FSP peptides|Vaccination with three FSP peptides
62426672|NCT00653887|ACTIVE_COMPARATOR|A|biofeedback (active group)
62426673|NCT00653887|PLACEBO_COMPARATOR|B|discussion about digestive tract (placebo group)
62035376|NCT04982900|PLACEBO_COMPARATOR|Control Arm|After randomization, the enrolled patients in this arm should be completely free from the risk of perioperative complications or recovered from the effects of complications, usually no earlier than 4 weeks after surgery but no more than 10 weeks after surgery, before receiving baseline follow-up and starting oral administration of placebo on the day of baseline follow-up. Patients in the treatment group should take placebo (80 mg each time) orally on an empty stomach before breakfast once a day. The medicine should be taken about the same time each day, by swallowing the whole tablet with water, without crushing or chewing. Patients should maintain oral administration of placebo for 6 consecutive months, unless there is disease progression, death, new anti-tumor therapy received or intolerance of investigational drugs.
62035377|NCT04259268||Web based questionnaire|Information registered by patient in the web based questionnaire
62035378|NCT04259268||Outpatient assessment|"Information registered by the anesthesiologist and based on the web based questionnaire, the electronic records of patient and the face to face interview"
62812345|NCT05783388||HIV-1 positive persons|
62812346|NCT01151488|EXPERIMENTAL|Resistance Training|16 weeks of moderate intensity resistance training, 3x/week
62812347|NCT02384551|ACTIVE_COMPARATOR|HTHS|High total carbohydrate with high total simple carbohydrate diet
62812348|NCT02384551|EXPERIMENTAL|HTLS|High total carbohydrate with low total simple carbohydrate diet
62812349|NCT02384551|EXPERIMENTAL|LTHS|Low total carbohydrate with high total simple carbohydrate diet
62812350|NCT02384551|EXPERIMENTAL|LTLS|Low total carbohydrate with low total simple carbohydrate diet
62812351|NCT04156061|NO_INTERVENTION|ASSIGN score|"The baseline assessment will be completed on the same day as consent is gained. Every patients will complete a comprehensive assessment including questionnaires and objective assessments.~Patients randomised to standard care with ASSIGN score alone (n=200) will be invited back approximately 6 months after baseline assessment. The detailed questionnaire, breath test, blood pressure monitoring, and 2-week activity monitor will be repeated. Bloods will be retaken to look at change in lipid levels and HbA1c where appropriate - no more than 30mls will be required."
62812352|NCT04156061|ACTIVE_COMPARATOR|CTCA - visual report|"Those in the CTCA group will be further randomised into review with or without CT images.~The review WITH images (VISUAL REPORT N=100) group will have results delivered by the principal investigator (a trained Cardiology Registrar) to ensure a standardised approach to relaying information. These results will be preliminary and focused only on whether the patient has evidence of coronary disease or not. A full report describing the extent of coronary disease, other cardiac problems and incidental findings will follow as per the SCOT-HEART-2 protocol. Patients will be made aware that the presented findings are a focused preliminary report and that a more detailed formal report will follow."
62035379|NCT04259268||Virtual assessment|Information registered by the anesthesiologist and based on the web based questionnaire and the electronic records of patient
62035380|NCT02561858|EXPERIMENTAL|acid load test|
62035381|NCT05208073|EXPERIMENTAL|Intervention group|The experimental group received 6-week cosmetic therapy.
62035382|NCT05208073|NO_INTERVENTION|Control group|The control group maintains the institution's original daily routine care.
62035383|NCT02355808|NO_INTERVENTION|Non Superfast|
62035384|NCT02355808|OTHER|Non Superfast GP intervention|
62035385|NCT02355808|OTHER|Non Superfast Tailored Leaflet|
62035386|NCT02355808|OTHER|Non Superfast GP + Tailored Leaflet|
62035387|NCT02355808|NO_INTERVENTION|Superfast|
62236035|NCT03147079|EXPERIMENTAL|Intervention|Lifestyle intervention
62236036|NCT03147079|EXPERIMENTAL|Internal controls|
62035388|NCT02355808|OTHER|Non Superfast GP|
62035389|NCT02355808|OTHER|Superfast Tailored Leaflet|
62035390|NCT02355808|OTHER|Superfast GP + Tailored Leaflet|
62035391|NCT03434951|EXPERIMENTAL|Intrathecal morphine and bupivacaine|0,2mg intrathecal morphine and 12,5mg bupivacaine administered
62236037|NCT03147079|EXPERIMENTAL|External controls|
62236038|NCT01290601|EXPERIMENTAL|Cohort 1 Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
62035392|NCT03434951|ACTIVE_COMPARATOR|Placebo|12,5mg bupivacaine and NaCl 0,9% to match the same volume administered
62035393|NCT01114568|EXPERIMENTAL|Ertugliflozin 10 mg: tablet→osmotic capsule (OC) fast→OC slow|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 6 hours (EP-Osmotic Capsule-Fast) and C) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 14 hours (EP-Osmotic Capsule-Slow). Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
62035394|NCT01114568|EXPERIMENTAL|Ertugliflozin 10 mg: tablet→OC slow→OC fast|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
62426674|NCT05969028|ACTIVE_COMPARATOR|Airway Strategy|Each of 28 first responder EMS agencies in King County will be randomly assigned to treat with either the BVM or i-gel for airway strategy
62426675|NCT05969028|ACTIVE_COMPARATOR|Compression Rate|Each of 28 first responder EMS agencies in King County will be randomly assigned with one of the three chest compression rates (100 vs 110 vs 120) at the outset.
62236039|NCT01290601|ACTIVE_COMPARATOR|Cohort 1-Chloroquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
62812353|NCT04156061|ACTIVE_COMPARATOR|CTCA - verbal report|"The baseline assessment will be completed on the same day as consent is gained. Every patients will complete a comprehensive assessment including questionnaires and objective assessments.~Those in the CTCA group will be further randomised into review with or without CT images.~The review WITHOUT images (VERBAL REPORT N=100) group will have results delivered by the principal investigator (a trained Cardiology Registrar) to ensure a standardised approach to relaying information. These results will be preliminary and focused only on whether the patient has evidence of coronary disease or not. A full report describing the extent of coronary disease, other cardiac problems and incidental findings will follow as per the SCOT-HEART-2 protocol. Patients will be made aware that the presented findings are a focused preliminary report and that a more detailed formal report will follow."
62812354|NCT03337230|EXPERIMENTAL|Physical Activity + Diet + Social media|Educational materials for the proposed study will be delivered via a secret social media Facebook group. These materials will promote simple, attainable forms of Physical Activity and lasting diet changes. A study moderator will deliver weekly communications to the Facebook group providing intervention content including social support, social competition and comparison, and social rewards
62035395|NCT01114568|EXPERIMENTAL|Ertugliflozin 10 mg: OC fast→tablet→OC slow|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
62236040|NCT01290601|EXPERIMENTAL|Cohort 2 Tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
62426676|NCT04622488|ACTIVE_COMPARATOR|Diclofenac Potassium|In the form of insitu gel can be applied as solution or suspension that undergoes gelation after administration.
62426677|NCT04622488|EXPERIMENTAL|Calcium Hydroxide|
62426678|NCT04793438|EXPERIMENTAL|Intervention group|Motive-specific intervention; three appointments within two weeks, 30-45 minutes per session.
62594739|NCT02339116|ACTIVE_COMPARATOR|folfox/bev-->folfiri/bev|"mFOLFOX-6 plus bev (to be repeated every 2 weeks for a maximum of 8 cycles) Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluoruracil 400 mg/sqm iv bolus, day 1 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1~At the time of disease progression patients will receive FOLFIRI plus bev (to be repeated every 2 weeks for a maximum of 8 cycles):~Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Irinotecan 180 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluoruracil 400 mg/sqm iv bolus, day 1 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion."
62594740|NCT02572596|EXPERIMENTAL|rhTPO treatment group|Subject will receive chemotherapy with intermediate-dose CTX 2.5/m2 for 2 days. 10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10\^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed. rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
62812355|NCT06094088|EXPERIMENTAL|Heated Yoga|The heated (i.e., \~105°F with 40% humidity) yoga will be 90 minutes long and consist of 26 Hatha yoga postures and 2 breathing exercises. The class starts with standing postures for approximately 45-50 minutes, followed by a 2-minute savasana (or corpse pose on the floor) and the remainder of the 90-minute class is completed on the mat. All yoga teachers will be heated yoga certified.
62236041|NCT01290601|ACTIVE_COMPARATOR|Cohort 2 Chloroquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
62426679|NCT04793438|ACTIVE_COMPARATOR|Control group|Supportive conversations; three appointments within two weeks; 30-45 minutes per session.
62426680|NCT01418352|PLACEBO_COMPARATOR|Matching Placebo|Participants received aripiprazole matching placebo, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
62426681|NCT01418352|EXPERIMENTAL|Aripiprazole 52.5 mg|Participants received aripiprazole 52.5 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
62035396|NCT01114568|EXPERIMENTAL|Ertugliflozin 10 mg: OC fast→OC slow→tablet|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
62426682|NCT01418352|EXPERIMENTAL|Aripiprazole 77.5 mg|Participants received aripiprazole 77.5 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
62426683|NCT01418352|EXPERIMENTAL|Aripiprazole 110 mg|Participants received aripiprazole 110 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
62426684|NCT05826769|EXPERIMENTAL|Energy- Protein Enriched Nutritional Formula|Liquid, ready-to-use Energy-Protein nutrition formula with energy density of 1 kCal/mL (EP formula)
62426685|NCT05826769|NO_INTERVENTION|Standard Nutritional Formula|Polymeric formula stage-1 and stage-2 for infants aged 0-6 months and 6-12 months accordingly, providing 0.67 kCal/mL (S-1/S-2 formula)
62594741|NCT02572596|ACTIVE_COMPARATOR|non- rhTPO treatment group|Subject will receive chemotherapy with intermediate-dose CTX 2.5/m2 for 2 days. 10 ug/kg/d of G-CSF was administered from the WBC was lower than 1×10\^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
62594742|NCT03439540|PLACEBO_COMPARATOR|Placebo|Individuals receive a placebo daily, for 12 weeks.
62812356|NCT06094088|ACTIVE_COMPARATOR|Non-heated Yoga|The non-heated (i.e., room temperature \< 80°F) yoga will be 90 minutes long and consist of 26 Hatha yoga postures and 2 breathing exercises. The class starts with standing postures for approximately 45-50 minutes, followed by a 2-minute savasana (or corpse pose on the floor) and the remainder of the 90-minute class is completed on the mat. All yoga teachers will be heated yoga certified.
62812357|NCT06308822|EXPERIMENTAL|Treatment (erdafitinib)|Patients receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout study. Patients may also undergo blood sample collection and tumor biopsy throughout the trial.
62812358|NCT05271981||Female who underwent uterine artery embolisation for uterine pathology|
62426686|NCT06568185|EXPERIMENTAL|Bionerve|The participants will receive a fixed dose combination of alpha lipoic acid and vitamin B preparations.
62426687|NCT06568185|NO_INTERVENTION|Placebo|The participants will receive a placebo (look-alike substance that contains no drug)l
62426688|NCT00136734|EXPERIMENTAL|1|methylphenidate
62594743|NCT03439540|EXPERIMENTAL|Plantago major|Individuals receive Plantago major daily, for 12 weeks.
62426689|NCT00136734|PLACEBO_COMPARATOR|2|placebo
62426690|NCT05244174|ACTIVE_COMPARATOR|Biliary stent|Biliary stent by ERCP is indicated both in palliative treatment, because of biliary duct decompression improves patient comfort by decreasing itching and jaundice, as in the treatment of the disease itself, because of it lets reach non-toxic levels of bilirubin which is necessary for chemotherapeutic treatment.
62426691|NCT05244174|EXPERIMENTAL|Biliary and pancreatic stent|During ERCP, the cannulation of the main pancreatic duct may be performed for the placement of a pancreatic duct stent, which is performed routinely as a prophylaxis of post-ERCP acute pancreatitis in patients at risk. In patients with pancreatic cancer, the placement of a pancreatic stent could improve pancreatic secretion by clearing the main pancreatic duct and thus it could improve fat digestion and nutritional status of patients, avoiding the need for PERT
62426692|NCT05645224|EXPERIMENTAL|VR-PAT|Participant wears the Pico Neo 3 Pro Eye headset and actively plays the VR-PAT game.
62426693|NCT05645224|NO_INTERVENTION|Control|Participant wears the Pico Neo 3 Pro Eye headset to protect eyes, but it is not turned on.
62594744|NCT04029363|OTHER|Single arm|Single arm, non-randomized
62594745|NCT02141815|EXPERIMENTAL|Arabinoxylan-oligosaccharides|Arabinoxylan-oligosaccharides 10g BID
62594746|NCT02141815|PLACEBO_COMPARATOR|Maltodextrine|Maltodextrine BID
62812359|NCT02616510||PCOS|Rotterdam criteria (at least 2 out of three criteria present) oligo-anovulation polycystic ovarian morphology hyperandrogenism
62812360|NCT02616510||POI|amenorrhea of at least 4 months prior to age 40 years, with follicle stimulating hormone (FSH) levels above 40 IU/L
62812361|NCT04580238|EXPERIMENTAL|Treatment Arm|The treatment group will consist of 40 patients randomly allocated to receiving Botox according to the treatment regime.
62594747|NCT06272864||Breast cancer|Patients with locally recurrent, unresectable or metastatic breast cancer
62594748|NCT06272864||NSCLC|Patients with unresectable stage III or metastatic non-small cell lung cancer
62594749|NCT06272864||Melanoma|Patients with unresectable or metastatic melanoma
62594750|NCT06272864||Sarcoma|Patients with locally advanced or metastatic sarcoma
62594751|NCT00890357||Triptan User|
62594752|NCT00890357||Triptan Discontinued|
62594753|NCT04627532|EXPERIMENTAL|Treatment|PF-07304814 assignment
62594754|NCT04627532|PLACEBO_COMPARATOR|Placebo|Placebo assigned
62812362|NCT04580238|ACTIVE_COMPARATOR|Control|The control group will consist of 40 patients randomly allocated to Non-Botox, standard of care treatments, to a total study population of 80 patients.
62594755|NCT02441270|EXPERIMENTAL|Cyclophosphamide|
62594756|NCT04675515|NO_INTERVENTION|Usual Tobacco Treatment|All individuals who are identified as tobacco users are offered tobacco treatment which includes proactive, as needed, contacts via in person, telehealth or telephone visits. for tobacco treatment, pharmacotherapy as indicated, and Quitline and SmokefreeTXT referrals
62812363|NCT05149404||ERAS group|
62812364|NCT05149404||Conventional group|
62236042|NCT06124053|EXPERIMENTAL|Group Voice Therapy|"In this research, a total of eight sessions of group voice therapy will be applied as the intervention approach. It is planned that each group will consist of three participants. Participants will be evaluated before the intervention, after the intervention, at the third-month follow-up assessment, and at the sixth-month follow-up assessment. Both formal and informal assessment tools have been preferred for the evaluation. Researchers will collect case histories and demographic information. For the acoustic assessment of the participants, voice recordings will be obtained through the ComputerizedSpeech Lab (CLS) program. GRBAS scores will be conducted by the researchers, while Pediatric Voice Handicap Index (pVHI) and Pediatric Voice Related Quality of Life (pVRQOL) scales will be filled out by parents."
62236043|NCT06124053|ACTIVE_COMPARATOR|Individual Voice Therapy|"In this research, a total of eight sessions of individual voice therapy will be implemented as the intervention approach. Participants will be evaluated before the intervention, after the intervention, at the third-month follow-up assessment, and at the sixth-month follow-up assessment. Both formal and informal assessment tools have been chosen for the evaluation. Researchers will collect case histories and demographic information. For the acoustic assessment of the participants, voice recordings will be obtained through the CLS program. GRBAS scores will be conducted by the researchers, while pVHI and pVRQOL scales will be filled out by parents or guardians."
62812365|NCT04984031||Generalized grade C periodontitis|generalized aggressive periodontitis ( generalized Grade C ,as in new classification) patients characterized with Bone loss/age index more than 1 and extent more 30 %
62035397|NCT01114568|EXPERIMENTAL|Ertugliflozin 10 mg: OC slow→tablet→OC fast|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
62035398|NCT01114568|EXPERIMENTAL|Ertugliflozin 10 mg: OC slow→OC fast→tablet|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
62035399|NCT04575896|EXPERIMENTAL|Deceased donor HCV RNA PCR+|Participants who receive a kidney from HCV RNA PCR + deceased donor will receive glecaprevir/pibrentasvir 300 mg/120 mg once daily by mouth for 2 weeks
62035400|NCT01386528|EXPERIMENTAL|Patients enrolled in trial|New patients will be included as well as transferred patients from Paradigm™ 2 or Paradigm™ 4 trial
62035401|NCT02047838||Cases.|Patients with recurrent unilateral endometrioma who were previously operated for the same condition.
62035402|NCT02047838||Controls.|Patients previously operated for unilateral endometrioma without recurrence.
62426694|NCT02488902|PLACEBO_COMPARATOR|Placebo|Placebo was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
62812366|NCT04984031||Molar-incisor grade C periodontitis|localized aggressive periodontitis ( Molar-incisor pattern Grade C ,as in new classification) patients characterized with limited affection on molars and incisors and their Bone loss/age index more than 1.
62812367|NCT04416568|EXPERIMENTAL|Solid Tumor (Stratum 1)|"* Patients will receive combination therapy with nivolumab at a predetermined dose and ipilimumab at a predetermined dose day 1 of a 21-day cycle for 4 cycles~* Starting with cycle 5, patients will receive nivolumab monotherapy at a predetermined dose on day 1 and day 15 of a 28-day cycle~* Patients with INI1-negative relapsed or refractory extracranial solid tumors"
62812368|NCT04416568|EXPERIMENTAL|CNS (Stratum 2)|"* Patients will receive combination therapy with nivolumab at a predetermined dose and ipilimumab at a predetermined dose day 1 of a 21-day cycle for 4 cycles~* Starting with cycle 5, patients will receive nivolumab monotherapy at a predetermined dose on day 1 and day 15 of a 28-day cycle~* Patients with INI1-negative relapsed or refractory CNS tumors"
62812369|NCT02113696|EXPERIMENTAL|Placebo group|Placebo Capsules
62812370|NCT02113696|EXPERIMENTAL|Omega 3 intake|Omega 3 intake, morbid obesity
62812371|NCT02745197|EXPERIMENTAL|Nutritional Supplement|2 nutritional supplement capsules, taken by mouth 3 times per day, for approximately 10 to 15 weeks.
62035403|NCT05462665|EXPERIMENTAL|intervention|Nursing intern students (n:39) will be given theory training about tPA treatment
62035404|NCT05462665|EXPERIMENTAL|Control|Nursing intern students (n:39) will be given theory training and simulation training about tPA treatment
62426695|NCT02488902|EXPERIMENTAL|Tafenoquine 25mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
62426696|NCT02488902|EXPERIMENTAL|Tafenoquine 50mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
62426697|NCT02488902|EXPERIMENTAL|Tafenoquine 100 mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
62426698|NCT02488902|EXPERIMENTAL|Tafenoquine 200 mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
62426699|NCT02488902|EXPERIMENTAL|Mefloquine 250 mg|Mefloquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
62812372|NCT02745197|PLACEBO_COMPARATOR|Placebo|2 placebo capsules, taken by mouth 3 times per day, for approximately 10 to 15 weeks.
62035405|NCT04622696||Prospective - Performance Cohort|Subjects will undergo an ultrasound-guided breast biopsy procedure with placement of HydroMARK Breast Biopsy Site Marker per site standard of care and will return to the office at 6-12 weeks post-implant for ultrasound imaging to evaluate device visibility.
62035406|NCT04622696||Retrospective - Safety Cohort|Device-related adverse events will be collected via retrospective medical chart review for a minimum of 90 days post-HydroMARK Breast Biopsy Site Marker implant (unless the subject was exited according to the medical records due to the implant being removed/explanted or subject death).
62035407|NCT02073396||Patients|Patients diagnosed with coronary disease or atrial fibrillation. All the patients will undergo Global Thrombosis Test.
62035408|NCT03028974|OTHER|Group A: 2-4 yo LAIV4 (Return)|Participants are given quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® . For children requiring 2 doses of vaccine, a second immunization will be given at Day 28-32 after Dose 1. All participants in this group will be asked to return annually for repeat immunization per ACIP guidelines and blood sample collection.
62812373|NCT00686101||1|Normal control subjects (Males and females between 18-65 years, who smoke cigarettes daily, have an expired CO measurement of \> 8 ppm to confirm cigarette smoking, who are not actively trying to quit smoking at the time of the interview, and who must be free from Axis I psychotic disorder.)
62812374|NCT00686101||2|Subjects with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder (Males and females between 18-65 years, who smoke cigarettes daily, have an expired CO measurement of \> 8 ppm to confirm cigarette smoking, and who are not actively trying to quit smoking at the time of the interview.)
62035409|NCT03028974|OTHER|Group B: 2-4 yo LAIV4 (Single Yr)|Participants are given LAIV4/ FluMist® and participate for single year. For children requiring 2 doses of vaccine, a second immunization will be given at Day 28-32 after Dose 1.
62035410|NCT03028974|OTHER|Group C: 2-4 yo LAIV4 (Swab/Single Yr)|Participants are given LAIV4/ FluMist® and participate for single year. NP swabs are collected; no blood samples will be collected for this group. For children requiring 2 doses of vaccine, a second immunization will be given at least 28 days after Dose 1.
62236044|NCT06124053|ACTIVE_COMPARATOR|Vocal Hygiene Education|"Participants will receive a one-session vocal hygiene training. Participants will be evaluated twice: once before the vocal hygiene training and again 8 weeks after the vocal hygiene training. Both formal and informal assessment tools have been preferred for the evaluation. Researchers will collect case histories and demographic information. For the acoustic assessment of the participants, voice recordings will be obtained through the CLS program. GRBAS scores will be conducted by the researchers, while pVHI and pVRQOL scales will be filled out by parents."
62236045|NCT01231516|EXPERIMENTAL|GSK1349572 + Raltegravir Placebo|Subjects will receive GSK1349572 50mg once daily plus raltegravir placebo twice daily.
62236046|NCT01231516|ACTIVE_COMPARATOR|Raltegravir + GSK1349572 Placebo|Subjects will receive raltegravir 400mg twice daily plus GSK1349572 placebo once daily.
62812375|NCT05312593|EXPERIMENTAL|Trial Group|A group of 30 patients will be randomly assigned to Hyaluronic Acid domiciliary treatment, applied into Peri-implant mucositis sites.
62035411|NCT03028974|OTHER|Group D: 6 - 23 mos old IIV4 (Return)|Participants are given a quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® . For children requiring 2 doses of vaccine (vaccine-naïve), a second immunization will be given at Day 28-32 after Dose 1. Participants are asked to return annually for repeat immunization per ACIP guidelines and blood sample collection.
62035412|NCT03028974|OTHER|Group E: 6 - 23 mos old IIV4 (Single Yr)|Participants are given IIV4/ Fluzone® and participate for a single year. For children requiring 2 doses of vaccine (vaccine-naïve), a second immunization will be given at Day 28-32 after Dose 1.
62035413|NCT03028974|OTHER|Group F: 9-13/18-49 yo LAIV4 (Single Yr)|Participants 9-13 year old and 18-49 year old are given LAIV4/ FluMist® . Participants will participate for a single year.
62035414|NCT03028974|OTHER|Group G: 9-13/18-49 yo IIV4 (Single Yr)|Participants 9-13 year old and 18-49 year old are given IIV4/ Fluzone® and participate for single year.
62035415|NCT04227782||NAFLD|
62035416|NCT04227782||NASH|
62236047|NCT02818088|EXPERIMENTAL|Cognitive Training|Cognitive Training - n Back.
62035417|NCT04227782||Cirrhosis|
62035418|NCT04227782||Healthy Volunteers|
62035419|NCT02675361|EXPERIMENTAL|Intervention group: transition program|Participants come from two clinics and will be randomly allocated to this group. Participants will go through a transition program which will last for 2 years. The intervention will be performed by specialist nurses.
62035420|NCT02675361|NO_INTERVENTION|Comparison group|"Participants allocated to this group will receive usual care, which includes follow-up visits according to the complexity of the congenital heart disease. Usual care can vary across clinics, however, they all include meeting with a nurse and a physician.~This is established as a comparison group since there is the risk of contamination in this group."
62236048|NCT00056862|EXPERIMENTAL|Low-dose pegIFN/standard-dose RBV|Patients receive a lower dose of peginterferon alfa-2a (90 mcg per week) and standard dose of ribavirin (800 mg/d) for chronic hepatitis C, genotype 2/3, for 24 weeks.
62236049|NCT00056862|ACTIVE_COMPARATOR|Standard-dose PegIFN/RBV|Patients receive the standard, recommended doses of peginterferon alfa-2a (180 mcg per week) and ribavirin (800 mg/d) for chronic hepatitis c, genotype 2/3, for 24 weeks.
62236050|NCT02831205|EXPERIMENTAL|ABSORB BVS|
62812376|NCT05312593|ACTIVE_COMPARATOR|Control Group|A group of 30 patients will be randomly assigned to Chlorhexidine mouthwash domiciliary treatment, applied into Peri-implant mucositis sites.
62236051|NCT02831205|ACTIVE_COMPARATOR|XIENCE EES|
62236052|NCT01211197|EXPERIMENTAL|A|3 treatments will be investigated in randomized order
62236053|NCT01211197|EXPERIMENTAL|B|3 treatments will be investigated in randomized order
62236054|NCT01211197|EXPERIMENTAL|C|3 treatments will be investigated in randomized order
62426700|NCT04264663|EXPERIMENTAL|furazolidone-tetracycline-containing quadruple|patients in furazolidone-tetracycline-containing quadruple group will receive Esomeprazole 40mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and furazolidone 100mg po bid for 14d
62426701|NCT04264663|ACTIVE_COMPARATOR|tinidazole-tetracycline-containing quadruple group|patients in tinidazole-tetracycline-containing quadruple group will receive Esomeprazole 40mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and tinidazole 500mg po tid for 14d.
62426702|NCT04671160||1|Group treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis.
62426703|NCT04671160||2|Group treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
62035421|NCT02675361|NO_INTERVENTION|Control group|"Participants in this group will receive usual care. Follow-up visits will depend on the complexity of the disease.~Five clinis comprise this section of the study and will be part of an longitudinal, observational study, which investigators will use as a control group."
62594757|NCT04675515|EXPERIMENTAL|Intensive Tobacco Treatment|"Patients who consent to study participation will meet with a tobacco treatment specialist in-person initially, then biweekly via telephone or telehealth or face-to-face (or more frequently as needed). They will receive tobacco treatment counseling and support from certified tobacco treatment specialist, which may include pharmacotherapy as indicated. At enrollment, participants will undergo carbon monoxide testing using a carbon monoxide monitor. At baseline, participants will complete the Fagerström Test for Nicotine Dependence, and the Cancer Patient Tobacco Use Questionnaire (C-TUQ).~These tobacco related survey measures will be completed at 3 additional time points: 30 days, 3 months and 6 months."
62594758|NCT05770102|EXPERIMENTAL|Treatment Arm 02: Atezolizumab|This atezolizumab treatment arm is for adult, TYA and paediatric participants with cancers with high TMB or high MSI or proven (previously diagnosed) CMMRD.
62594759|NCT04778059|EXPERIMENTAL|USB002|
62594760|NCT04778059|PLACEBO_COMPARATOR|Placebo|
62594761|NCT06061081|EXPERIMENTAL|Participants receiving VH3739937|
62812377|NCT02500849|EXPERIMENTAL|Cohort 1:|target busulfan AUC levels: 8,000 µM\*min (+/- 1,000)
62812378|NCT02500849|EXPERIMENTAL|Cohort 2:|busulfan AUC levels: 12,000 µM\*min (+/- 1,000)
62236055|NCT00979784|ACTIVE_COMPARATOR|1|
62812379|NCT03380650|OTHER|durg-coated balloon dilation|The drug-coated balloon will be used to treat the femoropopliteal occlusion.
62236056|NCT00979784|EXPERIMENTAL|2|
62236057|NCT05424003|EXPERIMENTAL|Semaglutide|Semaglutide administered subcutaneously (under the skin) once weekly. There will be a 20 week lead in period of dose escalation before reaching the target dose of 2.4mg weekly. Semaglutide will then be administered at the maximum tolerated dose for 52 weeks.
62426704|NCT04671160||3|Group not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis.
62426705|NCT04671160||4|Group not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
62426706|NCT02245360|EXPERIMENTAL|Grass tablet 75,000 SQ-T|Grass tablet 75,000 Standardized Quality units Tablet (SQ-T)
62236058|NCT05424003|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously (under the skin) once weekly.
62236059|NCT02854293||Booklet-Question List (BQL) group|76 patients
62426707|NCT02245360|PLACEBO_COMPARATOR|Placebo|Placebo
62426708|NCT04315818||study group|expermintal
62426709|NCT04315818||control group|placebo
62812380|NCT03380650|OTHER|directional atherectomy and LDD|The directional atherectomy and local drug delivery will be used to treat the femoropopliteal occlusion.
62236060|NCT02854293||control group|"Conventional palliative management~76 patients"
62236061|NCT05267860|EXPERIMENTAL|Patients with a prophylactic drain after cholecystectomy|
62236062|NCT05267860|NO_INTERVENTION|Patients without using any prophylactic Drainage after cholecystectomy|
62236063|NCT00975351|EXPERIMENTAL|IV dose of 5-methyltetrahydrofolic acid|IV test dose of 13C5-labelled 5-methyltetrahydrofolic acid to all eligible volunteers, followed by regular blood samplings over 2hr period taken via a cannula.
62426710|NCT02995694|EXPERIMENTAL|Test|Estradiol Vaginal Cream
62426711|NCT02995694|ACTIVE_COMPARATOR|Reference.|Estrace Vaginal Cream
62594762|NCT06061081|PLACEBO_COMPARATOR|Participants receiving Placebo|
62812381|NCT05828862|EXPERIMENTAL|hypotension prediction index guided|patients with hypotension prediction index guidance
62812382|NCT06602518|EXPERIMENTAL|Levelling and alignment|
62812383|NCT05696483|EXPERIMENTAL|Active|Active OLX-07010 in single ascending and multiple ascending dose cohorts
62812384|NCT05696483|PLACEBO_COMPARATOR|Placebo|OLX-07010 placebo in single ascending and multiple ascending dose cohorts
62812385|NCT03882060|EXPERIMENTAL|rHuEPO|recombinant human erythropoietin 500 U/kg IVS x 3 times Preoperative day (12-24 hour before surgery) During surgery Postoperative day (12-24 hour after surgery)
62812386|NCT03882060|PLACEBO_COMPARATOR|Control|Normal saline 50mL x 3 times Preoperative day (12-24 hour before surgery) During surgery Postoperative day (12-24 hour after surgery)
62812387|NCT05100342||Low-risk|Low-risk:score 0-6
62812388|NCT05100342||Intermediate-risk|Intermediate-risk: score 7-13
62812389|NCT05100342||High-risk|High-risk:score 14-20
62812390|NCT03960541|EXPERIMENTAL|Efprezimod alfa Treatment|Participants received an intravenous infusion of 240 mg of efprezimod alfa on Days 0, 14, and 28.
62812391|NCT03960541|PLACEBO_COMPARATOR|Placebo|Participants received an intravenous infusion of placebo (sterile saline solution) on Days 0, 14, and 28.
62236064|NCT06279065||GCA Patients|Primary diagnosis of giant cell arteritis
62236065|NCT06279065||Control|Control group without rheumatologic disease
62236066|NCT03457207|EXPERIMENTAL|combined minilaparotomy- laparoscopy approach|women undergo the new technique of surgical treatment of endometriomas of the ovary
62236067|NCT00887679|EXPERIMENTAL|Escitalopram|Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Open label, rater-blinded, prospective, 6-week trial of escitalopram.Subjects received escitalopram 10-20mg. Escitalopram was started at 10mg per day and augmented weekly in 10mg per day increments, the maximum dose being 20mg per day.
62236068|NCT05000892|EXPERIMENTAL|Sintilimab + Carboplatin + Nab-paclitaxel|"* Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days.~* Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days.~* Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
62236069|NCT02379481|EXPERIMENTAL|NS 550mg|NS 550mg/day
62426712|NCT02995694|PLACEBO_COMPARATOR|Placebos|Placebo with no active pharmaceutical ingredients. Topical vaginal cream
62426713|NCT06352398|ACTIVE_COMPARATOR|erector spina plan block (ESPB)|erector spina plan block (ESPB) : After providing asepsis and antisepsis conditions to the ESPB group in the sitting position, a high frequency linear USG probe will be placed approximately 2-3 cm lateral to the T5 spinous process in the longitudinal plane. After visualising the T5 transverse process with the in plane approach, the skin will be entered in the craniocaudal direction. Trapezius, rhomboid and erector spinae muscles will be passed and 5 ml of saline will be injected between the erector spinae muscle fascia and vertebral transverse process when the needle rests on the spinous process (approximately 3 cm deep) and the block site will be confirmed. Before the operation 30 ml of 0.25% bupivacaine (1mg/kg) will be injected by negative aspiration.
62594763|NCT06000501|EXPERIMENTAL|Adult ADHD Patients|Enrolled participants will begin with a two-week observation stabilization before starting treatment with Azstarys. Participants found to have ≥30% change in their total Adult ADHD Investigator Symptom Rating Scale (AISRS) scores during the two-week observation stabilization period treatment will be discontinued from the study. Remaining participants will be dispensed a three-week supply of Azstarys on a weekly basis.
62812392|NCT05472038|EXPERIMENTAL|Cohort 1: BNT162b5 Bivalent (WT/OMI BA.2)|Participants will receive 30 µg of BNT162b5 Bivalent (WT/OMI BA.2) at Visit 1.
62236070|NCT02379481|EXPERIMENTAL|NS 1100mg|NS 1100mg/day
62236071|NCT02379481|PLACEBO_COMPARATOR|placebo|placebo
62236072|NCT01522157|ACTIVE_COMPARATOR|All test patients|All test patients are given low-fat, low-carbohydrate and mediterranean diet, in randomised order on different days.
62812393|NCT05472038|EXPERIMENTAL|Cohort 1: BNT162b2 Bivalent (WT/OMI BA.1)|Participants will receive 30 µg of BNT162b2 Bivalent (WT/OMI BA.1) at Visit 1.
62812394|NCT05472038|EXPERIMENTAL|Cohort 2 -Group 1: 12-17 years; 30 µg|Participants 12-17 years old will receive 30 µg of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at Visit 1.
62812395|NCT05472038|EXPERIMENTAL|Cohort 2 - Group 2: 18-55 years; 30 µg|Participants 18-55 years old will receive 30 µg of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at Visit 1.
62812396|NCT05472038|EXPERIMENTAL|Cohort 2 - Group 3: 18-55 years; 60 µg|Participants 18-55 years old will receive 60 µg of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at Visit 1.
62812397|NCT05472038|EXPERIMENTAL|Cohort 2 - Group 4: >55 years; 30 µg|Participants over 55 years old will receive 30 µg of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at Visit 1.
62812398|NCT05472038|EXPERIMENTAL|Cohort 2 - Group 5: >55 years; 60 µg|Participants over 55 years old will receive 60 µg of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at Visit 1.
62812399|NCT05472038|EXPERIMENTAL|Cohort 3 - Group 1: 18-55 years; 30 µg|Participants will receive BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg at Visit 1.
62812400|NCT05472038|EXPERIMENTAL|Cohort 3 - Group 2: >55 years; 30 µg|Participants will receive BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg at Visit 1.
62812401|NCT05472038|ACTIVE_COMPARATOR|Cohort 4: BNT162b2 Bivalent (Original/OMI BA.4/BA.5)|Participants will receive 30 µg of BNT162b2 Bivalent (Original/OMI BA.4/BA.5) at Visit 1
62812402|NCT05472038|EXPERIMENTAL|Cohort 4: BNT162b5 Bivalent (Original/OMI BA.4/BA.5)|Participants will receive 30 µg of BNT162b5 Bivalent (Original/OMI BA.4/BA.5) at Visit 1
62812403|NCT05472038|EXPERIMENTAL|Cohort 4: BNT162b6 Bivalent (Original/OMI BA.4/BA.5)|Participants will receive 30 µg of BNT162b6 Bivalent (Original/OMI BA.4/BA.5) at Visit 1
62812404|NCT05472038|EXPERIMENTAL|Cohort 4: BNT162b7 Bivalent (Original/OMI BA.4/BA.5)|Participants will receive 30 µg of BNT162b7 Bivalent (Original/OMI BA.4/BA.5) at Visit 1
62812405|NCT05472038|EXPERIMENTAL|Cohort 4: BNT162b7 Monovalent (OMI BA.4/BA.5)|Participants will receive 30 µg of BNT162b7 Monovalent (OMI BA.4/BA.5) at Visit 1
62812406|NCT01697202||no intervention|
62236073|NCT02113241|EXPERIMENTAL|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
62236074|NCT02113241|PLACEBO_COMPARATOR|Placebo|Placebo capsules, 10 mg, one per day before breakfast during 90 days.
62236075|NCT00412971|ACTIVE_COMPARATOR|Hexvix cystoscopy group|
62236076|NCT00412971|OTHER|White light|Standard White light cystoscopy
62236077|NCT05486546|EXPERIMENTAL|Study: Phorcides|Contoura with Phorcides used for surgical planning of LASIK procedure
62236078|NCT05486546|ACTIVE_COMPARATOR|Control: Wavefront Optimized|WaveLight Wavefront Optimized used for surgical planning of LASIK procedure
62236079|NCT02885090|EXPERIMENTAL|RTT patient|Blood sampling
62236080|NCT02885090|EXPERIMENTAL|Parents|Blood sampling. To distinguish between inherited polymorphic variants and potentially deleterious new imbalances.
62236081|NCT03783546|EXPERIMENTAL|Immediate Acupuncture|"* Will receive a standardized acupuncture protocol for a 10-week period~* 20 sessions: twice a week for 10 weeks~* After the completion of the 10 weeks main study period, participants will cross over to the usual care as a follow-up without acupuncture for additional 10 weeks."
62236082|NCT03783546|ACTIVE_COMPARATOR|Delayed acupuncture|"* Will receive standard usual care without acupuncture for 10 weeks~* Participants will cross over to receive the same acupuncture protocol for 10 weeks --10 sessions: once a week for 10 weeks before exiting the study"
62236083|NCT02695641|EXPERIMENTAL|Stage 1 - Low dose administration|Ten hemodialysis patients will receive IV infusion treatment with 1.25mg bevacizumab and undergo serial blood draws on Days 0, 1, 3, 6, 10, 15, 22, and 29 during dialysis sessions. ELISA will be performed to evaluate drug serum concentration and corresponding plasma free VEGF-A levels (pg/ml). The safety and pharmacokinetic/dynamic (PK/PD) data will be analysed and ≥50% VEGF-A suppression retained from baseline by Day 15 will be considered successful. If target outcomes are met in stage 1, the study will be terminated, otherwise the study will progress to stage 2.
62236084|NCT02695641|EXPERIMENTAL|Stage 2 - Dose escalation|If outcomes are not met in stage 1, Ten additional hemodialysis patients will receive IV infusion treatment with 2.50mg bevacizumab treatment. They will undergo serial blood draws on Days 0, 1, 3, 6, 10, 15, 22, and 29 during dialysis sessions. ELISA will be performed to evaluate drug serum concentration and corresponding plasma free VEGF-A levels (pg/ml). The safety and PK/PD data will be analysed and ≥50% VEGF-A suppression retained from baseline by Day 15 will be considered successful. If target outcome is not met, the study will be terminated.
62236085|NCT03943862|EXPERIMENTAL|Intervention (2Share) + treatment as usual|"Study participants randomized to the experimental group receive the intervention (2Share) while maintaining their current treatment (treatment as usual). 2Share is a peer-led group intervention containing three two-hour sessions within two weeks plus an additional booster session four weeks later.~Fidelity to manual is rated in each session by study staff."
62236086|NCT03943862|NO_INTERVENTION|Treatment as usual|Participants randomized to the control group do not receive the group program but maintain their current treatment (treatment as usual).
62236087|NCT02712229|EXPERIMENTAL|CONNECT Intervention|At clinics randomized to the CONNECT intervention, oncology nurses will be selected by a nurse advisory panel to receive standardized primary palliative care training. A multi-step deployment strategy will be employed to orient oncologists and implement CONNECT processes. CONNECT nurses will administer CONNECT to enrolled patients and caregivers. An intervention fidelity monitoring and maintenance plan will be implemented to ensure high quality and consistent delivery of the intervention.
62236088|NCT02712229|NO_INTERVENTION|Usual Care Control|At clinics randomized to Usual Care, enrolled patients and caregivers will continue to receive supportive oncology care according to usual practice.
62236089|NCT00482924||Overweight/obese|"The cohort consists of age and sex matched normal weighted controls and overweight/obese persons.~Definition for overweight: BMI \>90th and \<97th percentile, if under 18 years of age, and BMI \>25 and \<29.9 kg/m2 if over 18 years of age.~Definition for obese: BMI \>97th percentile, if under 18 years of age, and BMI \>30kg/m2, if over 18 years of age."
62812407|NCT04970563|EXPERIMENTAL|Patients infected by SARS-COV-2 (RT-PCR +) and asymptomatic|
62035422|NCT01754662|EXPERIMENTAL|Soy protein with isoflavones and cocoa|Soy protein with isoflavones and cocoa bars. 2 bars daily for 8 weeks.
62035423|NCT01754662|EXPERIMENTAL|Soy protein alone with cocoa|Soy protein alone with cocoa with no isoflavones. 2 bars daily for 8 weeks.
62035424|NCT01754662|EXPERIMENTAL|Soy protein with soy isoflavones|Soy protein with isoflavones bar. 2 bars daily for 8 weeks.
62236090|NCT00482924||Interventional branch|A lifestyle intervention following a holistic schedule was done in a subgroup of obese juveniles.
62236091|NCT02196714|EXPERIMENTAL|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
62236092|NCT02196714|EXPERIMENTAL|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
62236093|NCT02196714|EXPERIMENTAL|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
62812408|NCT04970563|OTHER|"Control group: patients infected by SARS-COV-2 (RT-PCR +) and symptomatic"|
62812409|NCT04970563|OTHER|"Healthy controls group: not infected by SARS-COV-2 (RT-PCR-) and asymptomatic."|
62812410|NCT01736111|EXPERIMENTAL|Personal feedback|"This arm will receive all intervention components of Active Comparator group, plus the following:~1. Text messages to prompt participant to reply with self-monitoring entries~2. Human coach uses system to send personalized text messages with feedback on self-monitoring entries"
62594764|NCT04446650|EXPERIMENTAL|Fedratinib Administration|The fedratinib dose is 300 or 400 mg/day PO (3 or 4 x 100 mg capsules) to be self-administered orally once daily continuously on an outpatient basis, preferably together with food during an evening meal, the same time each day.
62594765|NCT01645891|ACTIVE_COMPARATOR|CDO with standard MWT|CDO (continuously supply pure oxygen) with standard Moist Wound Therapy
62594766|NCT01645891|SHAM_COMPARATOR|Moist Wound Therapy|Moist Wound Therapy. De-activated Sham device placed to wound in order to blind patient and study staff.
62812411|NCT01736111|ACTIVE_COMPARATOR|One Way Text|"1. Printed handouts from the Aim for a Healthy Weight booklet, which is published by National Heart, Lung, and Blood Institute and is frequently included in control conditions in primary care-based weight loss studies.~   Other handouts will discuss the use of prepackaged foods as well as setting goals for calorie intake, physical activity, and weight loss.~2. One to three text messages per week, based on topics from Aim for a Healthy Weight and other sources. The text messages will be pre-scheduled, automated, non-tailored, and one-way (no reply will be requested). The total dose of contact will be low because each text message is limited to 160 characters. The condition is comparable in intensity to control conditions in other weight loss trials in the primary care setting.~3. Usual medical care from the PCP.~4. Education on symptoms of hypoglycemia, hypotension, and cardiovascular disease, with instructions to contact their PCP in the event of those symptoms."
62236094|NCT02196714|EXPERIMENTAL|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
62812412|NCT00900978|EXPERIMENTAL|7v-PCV (Prevenar)|Biological/vaccine
62812413|NCT05696249|EXPERIMENTAL|Group with an OhmTrak device|The intervention group will be equipped with an OhmTrak device for home self-therapy and instructed in its correct use at least 5 times a week.
62812414|NCT05696249|OTHER|Group without an OhmTrak device|The control group will receive identical outpatient therapy and instruction in self-therapy, except they will not have access to the OhmTrak device.
62236095|NCT00465244|EXPERIMENTAL|1|Levetiracetam 1 g IV + Lorazepam 2 mg IV
62236096|NCT00465244|OTHER|2|Placebo + Lorazepam 3 mg IV
62812415|NCT00572377|ACTIVE_COMPARATOR|FemLife Gel|
62812416|NCT00572377|PLACEBO_COMPARATOR|Placebo|
62812417|NCT04103879|EXPERIMENTAL|ECT-001-Expanded CB|"Patients will receive a myeloablative conditioning regimen.~The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus)."
62812418|NCT05072639|EXPERIMENTAL|Meditation|Participants randomized to the meditation arm will receive an mp3 audio recording of the visual guided meditation will be sent an additional mp3 file specifically for the recovery phase of surgery. Participants will be asked to complete a series of pre-study questionnaires to determine their baseline anxiety, depression, stress, and quality of life scores. Subjects will then complete the same questionnaires at four additional time points: after 10 days of daily meditations, 1 day before their surgery, and day after discharge, and 4 weeks post-operation.
62812419|NCT05072639|NO_INTERVENTION|Control group|"Participants received standard of care, including the option to attend a free Prepare for Surgery workshop. Participants will be asked to complete a series of pre-study questionnaires to determine their baseline anxiety, depression, stress, and quality of life scores. Subjects will then complete the same questionnaires at four additional time points: after 10 days of daily meditations, 1 day before their surgery, and day after discharge, and 4 weeks post-operation."
62236097|NCT01759212|EXPERIMENTAL|Stem cells implantation|Patients with end-stage heart failure due to ischemic cardiomyopathy will undergo combined cellular and mechanical support with implantation of off-the-shelf allogeneic mesenchymal stem cells and left ventricular assist device.
62236098|NCT02422251|EXPERIMENTAL|Mobile high congruency bearing|Device B Braun Columbus total knee system using a rotating platform tibia and high congruency mobile bearing.
62594767|NCT05073328||COVID-19 patients|COVID-19 patients discharged from all French hospitals from 01 February to 30 June 2020
62812420|NCT04349891|EXPERIMENTAL|TEA at ST36 and PC6 first and then sham TEA|Patients in this group will be treated with TEA at ST36 and PC6 for 4 weeks, followed with a 2-week washout period and another 4-week period with sham TEA.
62236099|NCT02422251|EXPERIMENTAL|Fixed high congruency bearing|Device B Braun Columbus total knee system using a fixed tibial platform and high congruency bearing.
62236100|NCT02422251|EXPERIMENTAL|Fixed low congruency bearing|Device B Braun Columbus total knee system using a fixed tibial platform and low congruency bearing.
62236101|NCT02422251|NO_INTERVENTION|Control|Healthy control group
62236102|NCT04498065||A|COVID positive and Troponin positive
62594768|NCT05073328||"sub group The long COVID patients"|"this cohort will include patients with at least 4 weeks of claims and specific health care use after hospital admission from the initial cohort (COVID-19 patients)~According to the Haute Autorité de Santé (HAS), the most frequent symptoms in the context of long COVID are the following :~* Major fatigue~* Dyspnoea, cough~* Chest pain, often tightness type, palpitations~* Problems with concentration and memory, lack of words~* Headache, paraesthesia, burning sensation~* Disorders of smell, taste, tinnitus, dizziness, odynophagia~* Muscle, tendon or joint pain~* Sleep disorders (especially insomnia)~* Irritability, anxiety~* Abdominal pain, nausea, diarrhea, decrease or loss of appetite~* Pruritus, urticaria, pseudo-frostbite~* Fever, chills"
62594769|NCT05073328||"sub group non long COVID patients"|all other patients from the initial cohort (COVID-19 patients )
62594770|NCT00904865|OTHER|1|SPA cholecystectomy
62594771|NCT00904865|OTHER|2|laparoscopic cholecystectomy
62594772|NCT04811053|EXPERIMENTAL|Treatment group A|
62594773|NCT04811053|PLACEBO_COMPARATOR|Treatment group B|
62594774|NCT01583075|OTHER|Circumferential ablation|
62594775|NCT01583075|EXPERIMENTAL|Single ring ablation|
62594776|NCT03440307|PLACEBO_COMPARATOR|Email Only|Participants received weekly email about health and fitness education. No face-to-face intervention, and not provided any other information about bisphenol exposure.
62812421|NCT04349891|EXPERIMENTAL|Sham-TEA and then TEA ST36 and PC6|Patients in this group will be treated with sham-TEA for 4 weeks, followed with a 2-week washout period and another 4-week period with TEA at ST36 and PC6.
62812422|NCT05308875|EXPERIMENTAL|PD1-BCMA-CART|Each subject will accept one of the following dosages of PD1-BCMA-CART cells intravenously (IV) on day 0: 0.5-2\*10\^6/KgBW.
62812423|NCT00431561|EXPERIMENTAL|AP 12009 10 µM|
62812424|NCT00431561|EXPERIMENTAL|AP 12009 80 µM|
62812425|NCT00431561|ACTIVE_COMPARATOR|Chemotherapy|
62812426|NCT05051748|ACTIVE_COMPARATOR|In-office bleaching|40% hydrogen peroxide in-office bleaching (Opalescence™ boost™ PF 40%, Ultradent Products, Inc., South Jordan, UT, USA)
62812427|NCT05051748|ACTIVE_COMPARATOR|microabrasion|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste (Opalustre™, Ultradent Products, Inc., South Jordan, UT, USA).
62812428|NCT05051748|ACTIVE_COMPARATOR|Remineralization|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème (MI-Paste Plus®, GC America Inc., USA).
62812429|NCT05051748|ACTIVE_COMPARATOR|Microabrasion + In-office bleaching|teeth were treated with enamel microabrasion followed by in-office bleaching.
62812430|NCT05051748|ACTIVE_COMPARATOR|In-office bleaching + Remineralization|n-office bleaching was applied followed by MI-Paste Plus®
62812431|NCT05051748|ACTIVE_COMPARATOR|Microabrasion + Remineralization|microabrasion was applied followed by MI-Paste Plus®
62812432|NCT05051748|ACTIVE_COMPARATOR|Microabrasion + In-office bleaching + Remineralization|teeth were treated with microabrasion followed by in-office bleaching and lastly MI-Paste Plus®
62594777|NCT03440307|EXPERIMENTAL|Face-to-Face Meetings|Participants met with a counselor once per week for 3-weeks to reduce bisphenol exposure. Intervention included same weekly email about health and fitness education as Email only group, and a weekly face-to-face meetings to reduce bisphenol exposures from food, cosmetics, and packaged products. Women provided with bisphenol-free cosmetics, hygiene, and glass food/water containers.
62812433|NCT05051748|NO_INTERVENTION|Control|no treatment (control).
62812434|NCT05875532||Patients with an ILD other than IPF|Patients in Japan with data available in the Medical Data Vision (MDV) database, presenting an underlying pre-specified Interstitial Lung Disease (ILD) between 01-Jan-2012 to 28-May-2020 and received a second diagnosis of a fibrosing ILD other than Idiopathic Pulmonary Fibrosis (IPF) in the period of 01-Jan-2013 to 6 months before 28-May-2020.
62812435|NCT05403996|EXPERIMENTAL|Activa-Mente (Intervention)|The active break program involves the presentation of video (4.5 min) with moderate-to-vigorous physical activities. These active breaks will be performed 6 times per day during 6 weeks.
62236103|NCT04498065||B|COVID positive and Troponin negative
62236104|NCT01388790|EXPERIMENTAL|Cetuximab plus cisplatin plus S-1|
62236105|NCT05807607|EXPERIMENTAL|Patients who underwent the lower limb amputation and have phantom pain syndrome|
62236106|NCT01708213|EXPERIMENTAL|Dermal Filler - Aline HA|Single armed study
62594778|NCT01613222|EXPERIMENTAL|Pulse oximetry monitoring|The U-TruSignal with different sensors is feasible for noninvasive and continuous SpO2 monitoring and meets the specified measurement accuracy when compared to a co-oximetry gold reference.
62236107|NCT04251663||HS subjects|Subjects with active HS disease, among which at least 5 will be treatment-naïve
62594779|NCT05093985|EXPERIMENTAL|Neuromuscular electrical stimulation with blood flow restriction|This is the intervention condition
62812436|NCT05403996|NO_INTERVENTION|Control group|This group of students will not be exposed to the intervention.
62812437|NCT04272918|EXPERIMENTAL|CSM condition|Social Worker 1 of CSM conditions will work with caregivers according to the guidelines and template of the Care Support Model, including the formulation of the intervention plan based on CNA scores of different need domains, the use of the caregiver intervention plan template, service matching drawing reference from caregiver resource database, service formulation based on CNA scores of different strength domains, the use of the case monitoring template and guideline.
62812438|NCT04272918|NO_INTERVENTION|Non-CSM condition|Social Worker 2 of the Control Group will not be notified of the CNA scores of his/her caregivers. The intervention plan, services assignment and case management of participants of the control group will be based on Social Worker 2's own judgement using the information shared by the caregivers, and the social worker's own observation.
62812439|NCT04272918|EXPERIMENTAL|PP-E condition|Experimental Group will be led a consultant who is an expert, with the help of a degree-holder social worker to facilitate capacity building, empowerment and long-term well-being. Measurement of outcome variables will be conducted before the start of the program, at the end of the program, and 3 months after the program ended.
62812440|NCT04272918|NO_INTERVENTION|Non PP-E condition|Measurement of outcome variables will be conducted at the same point of time as PP-E condition. There will be no treatment or intervention for the control group.
62236108|NCT04251663||Healthy Controls|Healthy subjects
62236109|NCT02997371|PLACEBO_COMPARATOR|Placebo|Isotonic saline administered as an injection and infusion
62236110|NCT02997371|EXPERIMENTAL|1.5 g Kineret|Kineret provided as a 500 mg injection followed by a 1g infusion.
62236111|NCT02997371|EXPERIMENTAL|3.0 g Kineret|Kineret provided as a 500 mg injection followed by a 2.5g infusion.
62236112|NCT03067012|EXPERIMENTAL|Oncometabolic reconstruction|Patients undergoing oncometablic surgery
62594780|NCT05093985|NO_INTERVENTION|No intervention|This is the control condition
62594781|NCT06263998|EXPERIMENTAL|Single Ascending dose NCP112 Dose A|NCP112 is administered once at a specified time in Day 1
62594782|NCT06263998|PLACEBO_COMPARATOR|Single Ascending dose NCP112 Dose A, Placebo|NCP112 Placebo is administered once at a specified time in Day 1
62594783|NCT06263998|EXPERIMENTAL|Single Ascending dose NCP112 Dose B|NCP112 is administered once at a specified time in Day 1
62594784|NCT06263998|PLACEBO_COMPARATOR|Single Ascending dose NCP112 Dose B, Placebo|NCP112 Placebo is administered once at a specified time in Day 1
62819631|NCT05687851|EXPERIMENTAL|treatment arm|Participants receive Cadonilimab at a dose of 10 mg/kg, Q3W (Day 1 of each 21 day treatment cycle) via IV infusion, until disease progression, intolerable toxicity, investigator determines that the participant cannot continue to benefit, withdraw informed consent, or Cadonilimab treatment over 2 years. During the q3w dosing period of Cadonilimab, participants receive radiotherapy including external beam radiotherapy (EBRT) and followed by brachytherapy.
62236113|NCT04969887|EXPERIMENTAL|Ipilimumab and Nivolumab|All Subjects will be treated with: Nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg concurrently every 3 weeks for 4 doses followed by nivolumab only at 480mg every 4 weeks until progression (up to 2 years)
62236114|NCT00775450|EXPERIMENTAL|Group 1a: Fluzone ID After Fluzone ID|
62236115|NCT00775450|EXPERIMENTAL|Group 1b: Fluzone IM After Fluzone ID|
62236116|NCT00775450|ACTIVE_COMPARATOR|Group 2a: Fluzone IM After Fluzone IM|
62236117|NCT00775450|EXPERIMENTAL|Group 2b: Fluzone ID After Fluzone IM|
62236118|NCT00775450|ACTIVE_COMPARATOR|Group 3: Fluzone HD After Fluzone HD|
62426714|NCT06352398|ACTIVE_COMPARATOR|Serratus posterior superior intercostal plan block (SPSIPB)|In the SPSIPB group, the patient will be positioned in the lateral position, with the surgical side up and the upper extremity hanging over the patient's head for the USG-guided serratus posterior superior plan block. After asepsis and antisepsis conditions are provided, the spina scapula will be visualised above the scapula with our high frequency linear USG probe. The 3rd rib will be visualised with a high frequency probe medial to the scapula corresponding to the 3rd rib level. The ribs, pleura and the serratus muscle covering it will be determined and the needle tip will be advanced until it touches the 3rd rib.After the 3rd rib is visualised by USG, 5 ml isotonic is given and hydrodissection is performed, 30 ml 0.25% bupivacaine (1mg/kg) will be injected between the serratus posterior superior muscle and the 3rd rib.
62426715|NCT01858129|EXPERIMENTAL|Inhaled steroids (Budicort)|Inhaled Budicort
62426716|NCT01858129|PLACEBO_COMPARATOR|Control|Inhaled NS 0.9%
62426717|NCT02983227|EXPERIMENTAL|GDC-0853 (200mg BID) Cohort 1|Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 1 of Study GA29350. Cohort 1 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to previous methotrexate (MTX) therapy and then randomized to 12 weeks of GDC-0853 (50 mg daily, 150 mg daily, or 200 mg BID), adalimumab, or placebo.
62594785|NCT06263998|EXPERIMENTAL|Single Ascending dose NCP112 Dose C|NCP112 is administered once at a specified time in Day 1
62594786|NCT06263998|PLACEBO_COMPARATOR|Single Ascending dose NCP112 Dose C, Placebo|NCP112 Placebo is administered once at a specified time in Day 1
62594787|NCT06263998|EXPERIMENTAL|Multiple Ascending dose NCP112 Dose A|NCP112 is administered twice daily. \[time frame: Day 1- Day 14\]
62035425|NCT01754662|EXPERIMENTAL|Soy protein alone|Soy protein alone without soy isoflavone or cocoa polyphenol. 2 bars daily for 8 weeks.
62236119|NCT04658121||Senior Living Facilities|Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
62236120|NCT04658121||Outpatient Healthcare Facilities|Adults attending outpatient healthcare in neighborhoods of selected research sites
62236121|NCT04658121||General Communities|Adults and children (\>2 months of age) in neighborhoods of selected research sites
62236122|NCT02886767|EXPERIMENTAL|skin-to-skin contact (SSC)|Experimental: a daily skin-to-skin contact (SSC) at least 15 minutes in length
62236123|NCT02886767|NO_INTERVENTION|Control: hospital routine care|As the hospital routine. Allow the father to visit the neonate, touching the neonate
62236124|NCT04326647|EXPERIMENTAL|Kinesiotaping Group|We used kinesiotaping (gastrocnemius and lumbar back) plus exercise
62236125|NCT04326647|ACTIVE_COMPARATOR|Exercise Group|We used only exercise
62236126|NCT04592861|EXPERIMENTAL|Carbon ion radiotherapy|Carbon ion radiotherapy will be administered 5 days each week (Monday-Friday). The prescription dose will be 60 GyE in 20 fractions, to be delivered over four weeks.
62236127|NCT04592861|ACTIVE_COMPARATOR|Routine standard of care|Subjects on the control arm will not receive upfront radiotherapy but may receive radiotherapy (not carbon ion radiotherapy) if disease progression occurs.
62594788|NCT06263998|PLACEBO_COMPARATOR|Multiple Ascending dose NCP112 Dose A, Placebo|NCP112 Placebo is administered twice daily. \[time frame: Day 1- Day 14\]
62594789|NCT06263998|EXPERIMENTAL|Multiple Ascending dose NCP112 Dose B|NCP112 is administered twice daily.\[time frame: Day 1- Day 14\]
62594790|NCT06263998|PLACEBO_COMPARATOR|Multiple Ascending dose NCP112 Dose B, Placebo|NCP112 Placebo is administered twice daily. \[time frame: Day 1- Day 14\]
62035426|NCT01754662|PLACEBO_COMPARATOR|Placebo|Placebo bar without soy protein, isoflavones or cocoa polyphenols. 2 bars daily for 8 weeks
62236128|NCT04723862|EXPERIMENTAL|Spironolactone|Prior to the first or second admission (randomly determined), participants will be pretreated for 2 weeks with spironolactone (50 mg twice daily).
62426718|NCT02983227|EXPERIMENTAL|GDC-0853 (200mg BID) Cohort 2|Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 2 of Study GA29350. Cohort 2 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to one or two tumor necrosis factor (TNF) inhibitors and methotrexate (MTX) therapy, and then randomized to 12 weeks of GDC-0853 (200 mg BID) or placebo.
62594791|NCT06263998|EXPERIMENTAL|Multiple Ascending dose NCP112 Dose C|NCP112 is administered twice daily.\[time frame: Day 1- Day 14\]
62594792|NCT06263998|PLACEBO_COMPARATOR|Multiple Ascending dose NCP112 Dose C, Placebo|NCP112 Placebo is administered twice daily. \[time frame: Day 1- Day 14\]
62594793|NCT01928342|EXPERIMENTAL|Coenzyme A 400mg|Coenzyme A 400mg per day
62426719|NCT00757276||1|"All patients \> 18 years who are tested for the diagnosis of DI because of a history of polyuria (\> 40 ml/kg per 24 hours) in the presence of polydipsia Patients with known DI will be contacted whether they agree to participate in the study and to undergo again a water deprivation test to measure copeptin to confirm the diagnosis.~The investigators hypothesize that basal copeptin levels can reliably differentiate between the 5 groups(central, nephrogenic, psychogenic and partial forms) with a sensitivity and specificity \>80%."
62426720|NCT00488046|EXPERIMENTAL|1|Two, 0.5 ml doses of vaccine in nasal spray form administered at study entry and sometime between 4 and 8 weeks after initial vaccination
62426721|NCT04658446|EXPERIMENTAL|Augmented Reality-Assisted Bonding|The quadrant of the upper arch that shall use the AR-assisted bonding method. From the maxillary central incisor to the maxillary first permanent molar of the same quadrant.
62594794|NCT01928342|PLACEBO_COMPARATOR|Placebo|Capsule without coenzyme A.
62594795|NCT05257005||Patient cohort|Non interventional study
62594796|NCT05360446|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection
62594797|NCT05360446|EXPERIMENTAL|Inclisiran sodium|Subcutaneous injection
62594798|NCT05030194|EXPERIMENTAL|Order 1 - Oral Nicotine product - ZYN and Electronic Cigarettes|Participants will use each product for up to a 30 minute interval But will also be permitted to stop use before the end of the 30-minute ad lib use period
62594799|NCT05030194|EXPERIMENTAL|Order 2 - Electronic Cigarettes and Oral Nicotine product|Participants will use each prodcut for up to 30 minutes but will also be permitted to stop use before the end of the 30-minute ad lib use period
62594800|NCT05893147|ACTIVE_COMPARATOR|De-escalation VS No De-escalation|
62594801|NCT05893147|ACTIVE_COMPARATOR|Oral beta-lactams VS Oral Non-beta-lactams|
62594802|NCT05893147|ACTIVE_COMPARATOR|Central vascular catheter retention VS Central vascular catheter replacement|
62594803|NCT05893147|ACTIVE_COMPARATOR|Cephalosporin VS Carbapenem for low risk AmpC organisms|
62594804|NCT05893147|ACTIVE_COMPARATOR|Routine follow-up blood culture VS No routine follow-up blood culture|
62594805|NCT05412940||Primary total knee replacement patients|
62594806|NCT05531578|EXPERIMENTAL|TAVI TRANSFEMORAL|
62594807|NCT03192618|EXPERIMENTAL|treatment group|
62594808|NCT03192618|NO_INTERVENTION|control group|
62594809|NCT04629781|EXPERIMENTAL|Docetaxel micellar|Trial Treatment with Docetaxel micellar
62594810|NCT06268405|EXPERIMENTAL|Liquid Biopsy and Positron Emission Mammography (PEM)|"To perform the Liquid Biopsy assays, a baseline blood sample will be collected prior to the MRI-guided biopsy, and a follow-up blood and a tissue sample (if available) may be requested post-surgery If malignancy is confirmed by the standard of care histopathology results.~To perform the Positron Emission Mammography (PEM), participants will be injected with 74 megabecquerel (MBq) of commercially distributed 2-\[fluorine-18\]-fluoro-2-deoxy-D-glucose (F-18 FDG). Following a delay of one hour for F-18 FDG uptake, the study participants will undergo a bilateral 4-view combination PEM scan."
62035427|NCT01428648|ACTIVE_COMPARATOR|intervention|group of patients receiving ballroom dancing classes
62035428|NCT01428648|NO_INTERVENTION|control|group of patients who will not receive dancing classes.
62236129|NCT04723862|PLACEBO_COMPARATOR|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
62236130|NCT05786443|EXPERIMENTAL|Empagliflozin|Participants with end-stage kidney disease (ESRD) initiating hemodialysis will receive Empagliflozin 10 mg daily for 12 weeks.
62236131|NCT05786443|PLACEBO_COMPARATOR|Placebo|Participants with ESRD initiating hemodialysis will receive Empagliflozin-matching placebo daily for 12 weeks.
62236132|NCT04579601||ERAS group|We recruited 50 patients throughout 2018 and 2019, patients undergoing thoracic surgery within an ERAS program
62236133|NCT04579601||Standard group|A group of 50 patients selected randomly prior the implementation of the ERAS program, in 2016.
62594811|NCT03839875|EXPERIMENTAL|Active Treatment|
62812441|NCT05620433|EXPERIMENTAL|Joint Effort mobile application|The Joint Effort mobile application aims to support young adults in taking action on their cannabis use. Based on the Theory of Planned Behaviour, the content focuses on intention, attitude, and perceived behavioral control. Various intervention methods and strategies are used to address these determinants (e.g., personalized feedback, persuasive communication, self-observation, and activation of intention). The objectives include: to allow the individual to become aware (or more aware) of their cannabis use, to support the individual's decision-making process of taking action on their cannabis use, and to guide and support the establishment and sustainability of an action plan. An optional logbook-type feature (weekly journal of cannabis use) allows personalized monitoring and data collection throughout the course of the intervention.
62812442|NCT05620433|ACTIVE_COMPARATOR|Brief normative feedback and standard information|The comparator is composed of a brief normative feedback regarding last month's frequency of cannabis use and basic reliable non-personalized information on lower-risk cannabis use (official public websites).
62035429|NCT01691066|EXPERIMENTAL|Infant Toddler Years PRT|Infant Toddler PRT in an evidence-based, manualized treatment for children with autism spectrum disorder that involves specific motivational behavioral procedures adapted to be developmentally appropriate for 12-15 month old infants who present with developmental delays.
62236134|NCT04626895|OTHER|Scalp Cooling|Patients who be will using the scalp cooling device during chemotherapy will be enrolled in tis arm
62236135|NCT04626895|NO_INTERVENTION|Non Scalp-Cooling|Patients who do not use scalp cooling device during chemotherapy will be enrolled in this arm.
62812443|NCT04149912||Clinical psychologists in Germany|Clinical psychologists in Germany currently working with patients with mental disorders
62812444|NCT06430697|EXPERIMENTAL|Treatment with paracetamol|
62236136|NCT05914246|EXPERIMENTAL|CABG surgery with use of VIOLA|patients will be treated for routine CABG, using VIOLA for maintaining hemostasis during suturing of multiple aortic anastomoses
62236137|NCT01791803|EXPERIMENTAL|Hypnotherapy|Patients admitted with a cardiopulmonary illness received a 90 minute free hypnotherapy session within 2 weeks of discharge, and a standardized tape for smoking cessation and relaxation for continued use after the session. They also received self-help brochures, and counseling during hospitalization and by telephone at 1,2,4,8 and 12 weeks after discharge.
62426722|NCT04658446|ACTIVE_COMPARATOR|Digitally-Asssited Indirect Bonding|The quadrant of the upper arch that shall use the digitally-assisted bonding method utilizing a 3D printed tray. From the maxillary central incisor to the maxillary first permanent molar of the same quadrant.
62426723|NCT00831922|EXPERIMENTAL|1|masitinib (AB1010) 3 mg/kg/day
62035430|NCT01691066|NO_INTERVENTION|Community Treatment|Community Treatment includes the treatments offered by early intervention services (e.g., speech-language therapy, special education instruction).
62035431|NCT05842928|EXPERIMENTAL|Intervention Arm|Intensified and patient-centred cooperation between GPs and pharmacists including patient empowerment
62035432|NCT05842928|ACTIVE_COMPARATOR|Control Arm|Extended routine care
62236138|NCT01791803|EXPERIMENTAL|Nicotine Replacement Therapy|Patients recieved a free one month supply of Nicotine replacement therapy to include patches and Gum, lozenges or sprays. Patients also received self-help brochures, and counseling during hospitalization and by telephone at 1,2,4,8 and 12 weeks after hospitalization.
62236139|NCT01791803|EXPERIMENTAL|Hypnotherapy and Nicotine replacement|The group received similar hypnotherapy session and tape, similar brochure and counseling protocol, as well as free nicotine replacement supplies for a month after discharge.
62236140|NCT01791803|NO_INTERVENTION|Self-Quit group|Patients were given brief counseling during hospitalization and will not be contacted until 26 weeks after hospitalization.
62236141|NCT02284048|PLACEBO_COMPARATOR|control|nitrate,beta blocker
62236142|NCT02284048|ACTIVE_COMPARATOR|ticagrelor|ticagrelor 90mg qd
62426724|NCT00831922|EXPERIMENTAL|2|masitinib (AB1010) 6 mg/kg/day
62812445|NCT03044613|EXPERIMENTAL|Arm A|Nivolumab 240mg administered IV over 30 minutes every 2 weeks for 2 cycles and then standard of care chemoradiation (weekly carboplatin/paclitaxel and concurrent radiation
62236143|NCT02263534|EXPERIMENTAL|minisling|patients in this arm will undergo single incision minisling
62236144|NCT02263534|SHAM_COMPARATOR|tension free vaginal tape|patients in this arm will undergo tension free vaginal tape
62236145|NCT03525899||MH after diabetic pars plana vitrectomy|Recruited patients included, the persistent MH group, who had MH before the primary DV, and the newly-developed MH group, who developed MH after a successful primary DV
62236146|NCT00207389||Laparoscopic gastric bypass|Patients undergoing Laparoscopic gastric bypass
62594812|NCT01040195|ACTIVE_COMPARATOR|Combination DMARD|All patients included in the study, will be started on Sulfasalazine 1 gm once daily and in the absence of side effects increased to 2gm daily. All patients will also receive folic acid 5 mg thrice weekly. At the end of four weeks the patients will be reassessed with baseline hemogram, SGPT, SGOT and serum Creatinine. In the absence of any contraindication, patients will be randomized into two groups Group 1 to receive Combination Disease Modifying therapy with Sulfasalazine, Methotrexate and hydroxychloroquine (HCQ). Patient will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day.
62594813|NCT01040195|PLACEBO_COMPARATOR|Placebo|All patients included in the study, will be started on Sulfasalazine 1 gm once daily and in the absence of side effects increased to 2gm daily All patients will also receive folic acid 5 mg twice weekly. At the end of four weeks the patients will be reassessed with baseline hemogram, SGPT, SGOT and serum Creatinine. Group 2 patients will receive Sulfasalazine and placebo for methotrexate and hydroxychloroquine.
62812446|NCT03044613|EXPERIMENTAL|Arm B|Nivolumab 240mg administered IV over 30 minutes followed by relatlimab 80mg administered IV over 60 minutes on Day 1 every 2 weeks for 2 cycles and then standard of care chemoradiation (weekly carboplatin/paclitaxel and concurrent radiation).
62812447|NCT00388986|EXPERIMENTAL|1|
62812448|NCT00388986|EXPERIMENTAL|2|
62236147|NCT00207389||Open gastric bypass|Patients undergoing Open gastric bypass
62243234|NCT03274609||Suspected lung cancer|"* Patients referred as part of a first diagnostic evaluation of newly detected pulmonary lesion(s) or when an indication for an invasive diagnostic procedure is found during follow-up of earlier detected pulmonary lesion.~* Patients identified during per protocol CT imaging follow-up of known lesions when growth of the lesion is found and an indication for biopsy is determined by the treating physician and/or multidisciplinary board.~* Patients identified when referred for surgical biopsy in case of nodule location inaccessible for CT-guided TTNA.~These will be subjected to a combined approach of modalities with the main intervention being augmented fluoroscopy guided virtual navigation.)"
62594814|NCT05484154|ACTIVE_COMPARATOR|10mg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
62594815|NCT05484154|ACTIVE_COMPARATOR|15mg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
62594816|NCT05484154|ACTIVE_COMPARATOR|30mg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
62594817|NCT05484154|PLACEBO_COMPARATOR|Placebo|Matching placebo, q12h for up to 5 doses
62594818|NCT05571644|EXPERIMENTAL|mFOLFOXIRI+Cadonilimab|Patients will receive neoadjuvant treatment with mFOLFOXIRI plus cadonilimab for 6 cycles before surgey
62594819|NCT05571644|ACTIVE_COMPARATOR|mFOLFOX6|Patients will receive neoadjuvant mFOLFOX6 chemotherapy every two weeks for 6 cycles before surgery.
62594820|NCT05571644|ACTIVE_COMPARATOR|mFOLFOXIRI|Patients will receive neoadjuvant mFOLFOXIRI chemotherapy every two weeks for 6 cycles before surgery.
62594821|NCT05527093|EXPERIMENTAL|Patients with focal temporal lobe epilepsy for at least one year, drug-resistant|
62812449|NCT00388986|EXPERIMENTAL|3|
62812450|NCT06031519||Hypertrophic Obstructive Cardiomyopathy Patients underwent Liwen Procedure|
62812451|NCT05213975|EXPERIMENTAL|intervention group|kinesio taping group
62812452|NCT05213975|NO_INTERVENTION|control group|Standard of care
62812453|NCT04789603|ACTIVE_COMPARATOR|Without Mask Group|Patients who will perform the 6-min walk test without mask
62812454|NCT04789603|ACTIVE_COMPARATOR|Surgical Mask|Patients who will perform the 6-min walk test with surgical mask
62812455|NCT04789603|EXPERIMENTAL|Fpp2 Mask|Patients who will perform the 6-min walk test with Fpp2 mask
62812456|NCT01269593|EXPERIMENTAL|PET Imaging Using 124 IPUH71|Patients will receive an injection of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71, followed by serial PET scanning and blood draws, over a period of 3 days. Optional with a fourth day of PET scanning is to be pursued, in willing patients.
62812457|NCT05951400|EXPERIMENTAL|Dydrogestrone|For pituitary suppression, the patients will receive either Dydrogestrone (Duphaston 20 mg/d; Abbott Healthcare, USA) orally starting at day 2-3
62812458|NCT05951400|ACTIVE_COMPARATOR|GnRH antagonist|For pituitary suppression, the patients will receive GnRH antagonist Cetrorelix (CETROTIDE 0.25Mg/d, Merck Serono, Germany) 0.25 mg/day subcutaneously from day 6 of induction until trigger day.
62819632|NCT06119282|EXPERIMENTAL|Test İnhaler|After the cesarean section, at the 8th hour postpartum, the VAS/GCA is evaluated, 4 drops of carrier oil are dropped on the upper and lower parts of the wick of the aroma stick, and then 15-20 drops of the prepared essential mixture are dropped and the woman is explained about its use. By the 8th hour of the postop, 4\*1 women are allowed to sniff. Before the application, the 30th and 60th minutes VAS/GOC, vital parameters are evaluated.
62594822|NCT04892693|EXPERIMENTAL|Talazoparib|; Talazoparib should be taken orally once daily (ie, continuous daily dosing) at approximately the same time each day (preferably in the morning). Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered based on the discretion of the treating physician.
62819633|NCT06119282|EXPERIMENTAL|Test Massage|When the studies conducted with the massage method are examined, back massage is applied for 10-30 minutes. Considering the working conditions of the institution, it is thought that a 10-minute massage may be sufficient for the application. The massage application is started at the postpartum 8th hour and applied for 10 minutes on the postoperative 0th day 1\*1, 2 times on the postoperative 1st and 2nd days when the woman feels ready. 30 and 60 minutes before application. then VAS/GCS, vital parameters are monitored.
62035433|NCT00198562|ACTIVE_COMPARATOR|1|target morning home blood pressure (below 130 mmHg vs 130-139 mmHg)
62035434|NCT00198562|ACTIVE_COMPARATOR|2|antihypertensive drug (amlodipine vs losartan)
62035435|NCT04616768|NO_INTERVENTION|Arm A - Control|An arm of ≤42 patients will not receive PRO surveys, a Fitbit device, or patient feedback texts messages. They will receive shortened utility surveys at 3 and 6 months following enrollment, but their clinicians will not receive dashboards or utility surveys.
62236148|NCT02643836|EXPERIMENTAL|Treatment PEMF|The investigators will recruit and enroll 76 patients (between 18 and 30 years of age) who have had persistent symptoms consistent with PCS for at least 4 weeks, but not more than 6 months, after the initial injury. The experimental group will contain 38 subjects. Each study subject will receive two hats, which contain the integrated PEMF device, this will be done to ensure continuity of treatment in case that one of the hats stops working due to the battery running out. The subjects will receive PEMF treatment for 15 minutes three times per day for 6 weeks. Upon enrollment and at the end of the 6-week treatment period, all subjects will undergo a comprehensive assessment that will include symptom inventories, neuropsychological tests, qEEG measurement and near-infrared spectroscopy. The investigators will conduct a 3-month follow-up to assess longer-term outcomes.
62236149|NCT02643836|SHAM_COMPARATOR|Sham Treatment|The investigators will recruit and enroll 76 patients (between 18 and 30 years of age) who have had persistent symptoms consistent with PCS for at least 4 weeks, but not more than 6 months, after the initial injury. The sham group will contain 38 subjects. Each study subject will receive two hats, which contain a de-activated PEMF device, the device will still be blinking to show sham treatment activity. The sham subjects will receive the sham treatment for 15 minutes three times per day for 6 weeks. Upon enrollment and at the end of the 6-week treatment period, all subjects will undergo a comprehensive assessment that will include symptom inventories, neuropsychological tests, qEEG measurement and near-infrared spectroscopy. The investigators will conduct a 3-month follow-up to assess longer-term outcomes.
62236150|NCT02322138|EXPERIMENTAL|Experimental 1 Infant Formula|Milk-based infant formula without prebiotics
62236151|NCT02322138|EXPERIMENTAL|Experimental 2 Infant Formula|Milk-based infant formula with prebiotics
62236152|NCT02322138|OTHER|Human Milk-Fed Reference Group|Breast fed infants
62035436|NCT04616768|EXPERIMENTAL|Arm B - Intervention without text feedback|"An arm of ≤42 patients enrolled intervention patients will be randomized to receive weekly patient-reported outcome questionnaires, be given Fitbits to monitor weekly step counts and utility surveys at 3 and 6 months following enrollment. Their clinicians will receive a PROStep Dashboard prior to their appointments and utility surveys at 3 and 6 months."
62035437|NCT04616768|EXPERIMENTAL|Arm C - Intervention with text feedback|"An arm of ≤42 patients enrolled intervention patients will be randomized to receive weekly patient-reported outcome questionnaires, be given Fitbits to monitor weekly step counts and utility surveys at 3 and 6 months following enrollment. Their clinicians will receive a PROStep Dashboard prior to their appointments and utility surveys at 3 and 6 months. Patients in this arm will receive an additional text prior to appointments that summarizes their symptoms and incorporates an active nudge question."
62035438|NCT01898819|EXPERIMENTAL|dexmedetomidine|dexmedetomidine infusion from beginning of the anesthesia to just before returning to horizontal position
62236153|NCT01964807|EXPERIMENTAL|Cigarette smokers|Will smoke 1 cigarette, National Institute of Drug Abuse (NIDA) test type with 16.6 mg nicotine; 1 cigarette, NIDA test type with \<0.45 mg nicotine; perform sham smoking by puffing on a drinking straw. Each intervention will last 10 minutes, and each will take place one time, on one of 3 study visits, in random order.
62236154|NCT01964807|EXPERIMENTAL|Nonsmokers|Will undergo secondhand cigarette smoke (SHS) exposure and conditioned, filtered air exposure. Each intervention will last 180 minutes, and each will take place one time, on one of 2 study visits, in random order.
62426725|NCT04898400|EXPERIMENTAL|Subjects with Obesity|Subjects will be recruited to undergo endoscopic sleeve gastroplasty. The subjects will be studied at baseline, 30, 60, 90 days after procedure
62426726|NCT02073305||No sleep apnea|Subjects with no or light sleep apnea (AHI \< 15/h)
62594823|NCT02533102|EXPERIMENTAL|Part A: E7050 100 mg tablet under fasted conditions|Participants will receive a single tablet containing 100 mg E7050 following an overnight fast.
62594824|NCT02533102|EXPERIMENTAL|Part A: E7050 100 mg tablet with low-fat breakfast|Participants will receive a single tablet containing 100 mg E7050 with a standard low-fat meal.
62594825|NCT02533102|EXPERIMENTAL|Part A: E7050 100 mg tablet with high-fat breakfast|Participants will receive a single tablet containing 100 mg E7050 with a standard high-fat meal.
62594826|NCT02533102|EXPERIMENTAL|Part B: E7050 200 mg tablet under fasted conditions|Participants will receive a single dose of 200 mg (two 100 mg tablets) of E7050 under fasted conditions.
62594827|NCT02533102|EXPERIMENTAL|Part B: E7050 400 mg tablet under fasted conditions|Participants will receive a single dose of 400 mg (four 100 mg tablets) of E7050 under fasted conditions.
62035439|NCT01898819|PLACEBO_COMPARATOR|saline|Saline infusion from same time period.
62035440|NCT04910893|EXPERIMENTAL|Cytokine Adsorption Arm|Intervention with CytoSorb
62035441|NCT04910893|OTHER|Historical Comparison|Patients extracted from a septic shock population treated at the same institution between 2010 and 2018 and matched to the intervention group.
62812459|NCT05821699|EXPERIMENTAL|In Person LCS Intervention- With Opioid Risk Education|Patients will receive opioid education and Naloxone education. Therapeutic Intervention will include education on implementing mindfulness practices into postoperative recovery, known as the Community Resiliency Model CRM). Clinical Pain Coordination will include directed referrals for complex needs, including mental health and substance use disorders, as needed. All participants in the LCS intervention arm will also receive the current standard-of-care. The Community Resiliency Model (CRM) is a noncognitive variant of mindfulness, emphasizing attunement to interoceptive and exteroceptive signaling cues for regulation of autonomic responses to stress. CRM skills are introduced over a sixty-to-ninety-minute session, allowing for a brief introduction and application of skills by participants. These will be in person.
62035442|NCT06213454|ACTIVE_COMPARATOR|TAP Block plus Laparotomy|
62035443|NCT06213454|ACTIVE_COMPARATOR|Laparotomy plus Local Wound Anesthetic|
62035444|NCT01401751|OTHER|Single Arm|non-randomized, uncontrolled, feasibility study
62035445|NCT00829387|EXPERIMENTAL|Behavioral|Cognitive behavioral therapy - Ten sessions of individual treatment delivered by a doctoral level psychologist.
62035446|NCT00829387|ACTIVE_COMPARATOR|Educational|Diabetes Education - Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator
62035447|NCT01737580|ACTIVE_COMPARATOR|Intanza+resiquimod gel|Intanza 15mcg intradermal injection + resiquimod gel applied to the vaccination site immediately post vaccination.
62236155|NCT01964807|EXPERIMENTAL|Smokeless tobacco users|Will use 1 pouch of commercially available moist oral snuff and will chew gum (sham moist snuff). Each intervention will last 30 minutes, and each will take place one time, on one of 2 study visits, in random order.
62236156|NCT01964807|EXPERIMENTAL|e-cigarette users|Will use one electronic cigarette with 18 mg/ml nicotine, one electronic cigarette with no nicotine, and will perform sham smoking by puffing on a drinking straw. Each intervention will last 10 minutes, and each will take place one time, on one of 3 study visits, in random order.
62236157|NCT03770559|ACTIVE_COMPARATOR|Open-RAMPS|Patients with pancreatic cancer treated by traditional open surgery
62035448|NCT01737580|PLACEBO_COMPARATOR|Intanza + placebo gel|Intanza 15mcg intradermal injection + placebo gel applied to the vaccination site immediately post vaccination.
62035449|NCT02283931|ACTIVE_COMPARATOR|One handed uterine displacement|Uterine displacement using one hand
62035450|NCT02283931|ACTIVE_COMPARATOR|two handed uterine displacement|Uterine displacement using two hands
62035451|NCT02283931|ACTIVE_COMPARATOR|30 degrees uterine displacement|Uterine displacement using a 30 degrees wedge
62035452|NCT03130400||Normal|This group is control group. Participants in this group do not have knee diseases or any other bad injuries in lower limbs.
62035453|NCT03130400||KOA|Participants in this group have knee osteoarthritis and have no other bad injuries in lower limbs.
62035454|NCT03130400||ACLD|Participants in this group have anterior cruciate ligament deficiency with or without meniscus deficiency and have no other bad injuries in lower limbs.
62035455|NCT03130400||MD|Participants in this group have meniscus deficiency and have no other bad injuries in lower limbs.
62035456|NCT03130400||Plica|Participants in this group have plica syndrome and have no other bad injuries in lower limbs.
62812460|NCT05821699|EXPERIMENTAL|Virtual LCS Intervention-With Opioid Risk Education|Participants will receive opioid education, and Naloxone education. Therapeutic Intervention will include education on implementing mindfulness practices into postoperative recovery, known as the Community Resiliency Model CRM). Clinical Pain Coordination will include directed referrals for complex needs, including mental health and substance use disorders, as needed. All participants in the LCS intervention arm will also receive the current standard-of-care. The Community Resiliency Model (CRM) is a noncognitive variant of mindfulness, emphasizing attunement to interoceptive and exteroceptive signaling cues for regulation of autonomic responses to stress. CRM skills are introduced over a sixty-to-ninety-minute session, allowing for a brief introduction and application of skills by participants. These will be in performed virtually via a digital conferencing platform
62812461|NCT05821699|ACTIVE_COMPARATOR|No LCS intervention|Patients will receive the current standard-of-care for pain management in the aftermath of surgery, which includes: a standardized prescription protocol, hospital-system approved discharge instructions which provide written instruction on how to taper opioid use, links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
62426727|NCT02073305||Sleep Apnea - untreated|"Subjects with moderate to severe sleep apnea (AHI ≥15/h) and no specific treatment.~Decision to treat or not sleep apnea is left to the treating physician, independently of the study protocol."
62426728|NCT02073305||Sleep Apnea - treated|Subjects with treated moderate to severe sleep apnea (AHI ≥15/h). Decision to treat or not sleep apnea is left to the treating physician, independently of the study protocol.
62594828|NCT04660500|EXPERIMENTAL|PD Drivers Using AV Technologies On-road|Each driver will drive on-road, everybody will be exposed to two drives (Drive 1, Drive 2) one drive with and the other without in-vehicle technology. The order of technology (with vs. without IVIS or ADAS) and the order of the routes (Drive 1 vs. Drive 2) will be randomly allocated to control for order effects.
62812462|NCT01017484|EXPERIMENTAL|DASH|The Dietary Approaches to Stop Hypertension Dietary pattern.
62812463|NCT01017484|EXPERIMENTAL|Control|The typical American diet as estimated from the NHANES survey.
62812464|NCT05009498|PLACEBO_COMPARATOR|Placebo group|Patient will receive a placebo dosing, identical in appearance and at the same intervals as the interventional dose
62812465|NCT05009498|ACTIVE_COMPARATOR|Vitamin D3 supplementation group|Patient will receive high-dose Vitamin D3 supplementation in capsule form, identical in appearance and at the same intervals as the placebo dose
62812466|NCT02595983|EXPERIMENTAL|All Patients|All patients who received at least 1 dose of revusiran (ALN-TTRSC)
62812467|NCT01290458|EXPERIMENTAL|Vitamin|
62812468|NCT01290458|PLACEBO_COMPARATOR|Control|
62812469|NCT04355754|EXPERIMENTAL|mechanically ventilated patients|"Adult ICU patients who are mechanically ventilated and who do not require complex modes of ventilation.~A designated flow divider (Ventil) will be used to divide inspiratory gas flow from ventilator in two separate streams - one to the patient and the second to the artificial lung"
62812470|NCT00670553|EXPERIMENTAL|LBH589|
62812471|NCT01406886|EXPERIMENTAL|Energy density|Low or high energy density meal
62812472|NCT04111627|EXPERIMENTAL|Aerobic exercise plus Duloxetine|Participants will have a starting duloxetine dosage of 30 mg/day and be titrated up to a daily optimal dosage of 60 mg/day as tolerated during the first 12-weeks of the study. Twelve weeks after the receipt of their prescription, participants will be evaluated for the need to increase medication dosage to 90 mg/day. After duloxetine initiation, participants will be provided an exercise prescription that includes a progressive walking program aiming to achieve 50 minutes of moderate-intensity physical activity, three times per week, over 24 weeks.
62812473|NCT01147042|ACTIVE_COMPARATOR|gp91 CGD with relatively high baseline superoxide|"Patients with X-linked Chronic Granulomatous Disease (CGD) with a missense gp91phox mutation and relatively high baseline superoxide production.~IFN-gamma was the administered intervention."
62812474|NCT01147042|ACTIVE_COMPARATOR|Autosomal Recessive CGD with p47|Patients with Autosomal Recessive Chronic Granulomatous Disease (CGD) with p47 phox mutation. IFN-gamma was the administered intervention.
62426729|NCT00646100|ACTIVE_COMPARATOR|TACE|chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization
62426730|NCT00646100|NO_INTERVENTION|control|best support care
62426731|NCT06143319||Recurrent low back pain|20 non-specific recurrent LBP patients, both experiencing a period of pain remission or a pain flare at the moment of testing, will be included in the current study.
62426732|NCT06143319||Chronic low back pain|20 participants experiencing non-specific chronic LBP will be included in the current study.
62426733|NCT06143319||Healthy volunteers|20 healthy participants, matched for age and Body Mass Index (BMI) with the participants experiencing chronic/recurrent low back pain or fibromyalgia will be included in the current study.
62426734|NCT06143319||Fibromyalgia|20 participants diagnosed with fibromyalgia will be included in the current study
62426735|NCT01989195|EXPERIMENTAL|CORONARY DISEASE SUBJECT|ALL SUBJECTS IN THIS STUDY HAVE PREVIOUSLY DOCUMENTED CORONARY ARTERY DISEASE BY ANGIOGRAPHY
62426736|NCT04185701|EXPERIMENTAL|Eye examination by expert and SiVIEW software|Eye examination by an expert and by a technician with the SiVIEW system.
62594829|NCT01950104|ACTIVE_COMPARATOR|Day 3 embryo biopsy|Embryo biopsy is applied at day 3 of the embryo development
62594830|NCT01950104|EXPERIMENTAL|Blastocyst biopsy|Embryo biopsy is applied at the blastocyst stage of the embryo development (day 5 or 6)
62819634|NCT06119282|ACTIVE_COMPARATOR|Control Group|Pregnant women included in the control group will be left to clinical care, and pain and vital parameters will be monitored starting from the 8th postoperative hour. The scales applied to the experimental groups will be applied on the 2nd postoperative day. Women in the control group who completed the study will be informed about the postpartum use of aromatherapy. Women who want aromatherapy application will be directed to GETAT center.
62035457|NCT02622854|EXPERIMENTAL|plasma exchange|plasma exchange, with 1.5 estimated plasma volume exchanged with albumin solution, using citrate anticoagulation, performed daily until triglycerides \<=10 mmol/l
62236158|NCT03770559|EXPERIMENTAL|MI-RAMPS|Patients with pancreatic cancer treated by laparoscopic surgery
62236159|NCT04227548|EXPERIMENTAL|Healthy individuals|
62426737|NCT02561013|EXPERIMENTAL|3M™ Coban™ Custom Fit Compression System|3M™ Coban™ Custom Fit Compression System will be custom-fitted at first subject visit and will thereafter be applied and removed daily by the study subject. It will be worn throughout the day by the study subject and removed before bedtime. It will provide therapeutic compression for edema control to help in the healing of venous leg ulcers.
62426738|NCT02561013|ACTIVE_COMPARATOR|Profore|Profore multi-layer compression bandaging system will be applied at the first subject visit and will be worn by the study subject continuously for 7 days, at which time it will be replaced with a new system, or, in the case of a product or non-product reason, replaced before 7 days. It will provide therapeutic compression for edema control to help in the healing of venous leg ulcers
62426739|NCT06542757|EXPERIMENTAL|MRI-guided Intensity Modulated Radiotherapy|All patients will undergo the injection of a hydrogel rectal spacer (SpaceOAR) 1 week before simulation. Patients will undergo ultra-hypofractionated radiation utilizing MR-guided, daily online adaptive planning. Patients will receive 9 Gy/fraction for five fractions for a total dose of 45 Gy to the prostate DIL while the rest of the prostate will be treated to a minimum dose to the rest of the prostate of 30 Gy in five fractions. Radiation will be given every other day, Monday through Friday, until 5 treatments have been completed. Patients will be followed at three and six months after treatment, and every six months thereafter through month 24 (+/- 4 weeks).
62426740|NCT05027009|EXPERIMENTAL|Group I (low dose simulated sunlight)|Patients undergo total body exam. The minimum dose of simulated sunlight required to cause mild sunburn is determined. One of the patient's moles is exposed to 3 times that minimum dose of simulated sunlight. One day later, that mole, and an untreated mole, are removed by punch biopsy.
62426741|NCT05027009|EXPERIMENTAL|Group II (middle dose simulated sunlight)|Patients undergo total body exam. The minimum dose of simulated sunlight required to cause mild sunburn is determined. One of the patient's moles is exposed to 4 times that minimum dose of simulated sunlight. One day later, that mole, and an untreated mole, are removed by punch biopsy.
62035458|NCT02622854|ACTIVE_COMPARATOR|conservative treatment|infusion of 5% glucose and insulin, to maintain blood glucose at 5-8 mmol/l
62035459|NCT04977882|EXPERIMENTAL|Abdominal drainage|19 Fr abdominal drainage placed intraoperatevely in right paracolic gutter
62035460|NCT04977882|EXPERIMENTAL|Postoperative antibiotico-prophylaxis|postoperative antibiotico-prophylaxis with Ceftriaxone 2gr and Metronidazole 1.5gr
62035461|NCT04977882|SHAM_COMPARATOR|Control group|No drainage nor postoperative antibiotico-prophylaxis
62035462|NCT05234827|EXPERIMENTAL|Virtual Reality|VR sessions include a device (XBOX 360) and motion sensor (Kinect) and LED (tv screen) with speakers attached. Height of the device is 1m while tv screen is placed 2.5m away, motion sensor is placed 1.2m away from the patient, play area should be 1.8m wide and long. Instruction to play game is provided to each patient. Before starting each training session, the device was adjusted to correctly follow the movements of each patient. VR session includes games by Kinect Adventures (Microsoft games studios, Washington, US) which include minigames in which patients participated these mini games are 20000 Leaks, Curvy Creek, Rally Ball and Reflux Ridge.
62236160|NCT05155241|EXPERIMENTAL|Intervention|Participants will watch an online health promotion video tailored to their current stage of change related to SIV uptake once every two weeks for four times (at week 0, 2, 4, and 6)
62236161|NCT05155241|ACTIVE_COMPARATOR|Control|Participants will watch a same online video providing general advices related to SIV at week 0, 2, 4, and 6
62236162|NCT02438319||patients with open angle glaucoma|patients with open angle glaucoma who had their optic discs routinely documented by fundus photography. Optic disc photographs will be analyzied by manual planimetry or automated planimetry.
62236163|NCT00044915|ACTIVE_COMPARATOR|Arm 1|
62236164|NCT00044915|PLACEBO_COMPARATOR|Arm 2|
62236165|NCT03552822||ERAS Implemented Group|Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
62236166|NCT03552822||Pre-ERAS - Non-ERAS Implemented Group|Non-Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
62812475|NCT02994108|EXPERIMENTAL|txt2protect|"Content was delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants received 10-12 messages daily. During Phase 2 (weeks 4-36), message frequency decreased to monthly messages. Phase 1 content was presented in 3 modules. Module 1 addressed information about HPV infection and HPV vaccination. Module 2 addressed motivation to receive HPV vaccine. Module 3 addressed behavioral skills and self-efficacy for initiating and completing the 3-dose series (e.g., talking with their doctor about the vaccine). Phase 2 booster messages largely reinforced Phase 1 content to foster continued engagement with the program.~txt2protect: Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination."
62035463|NCT05234827|ACTIVE_COMPARATOR|Control|Total time duration for session is 40 minutes in which 5 min of warm up exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 min of bicycling and after that 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing
62236167|NCT01137955|EXPERIMENTAL|Rifaximin 400mg|Antibiotic ,Rifaximin 400mg, given 3 times a day for 10 days.
62236168|NCT01137955|PLACEBO_COMPARATOR|Placebo|Placebo pills given 3 times a day for 10 days.
62426742|NCT05027009|EXPERIMENTAL|Group III (high dose simulated sunlight)|Patients undergo total body exam. The minimum dose of simulated sunlight required to cause mild sunburn is determined. One of the patient's moles is exposed to 6 times that minimum dose of simulated sunlight. One day later, that mole, and an untreated mole, are removed by punch biopsy.
62426743|NCT06520228|EXPERIMENTAL|Active video games|
62426744|NCT06520228|EXPERIMENTAL|Traditional sports games|
62426745|NCT01089985|EXPERIMENTAL|Serum eye drops|Patient's autologous serum is diluted in saline solution
62035464|NCT06496945||Day program attendees & caregivers|Older adults (65+ years), living with a diagnosis of dementia in the community, and attending an adult day program in the Calgary Health Zone (Alberta), Interior Health Region (British Columbia), Winnipeg Regional Health Authority (Manitoba), or York Region (Ontario). Each older adult's primary caregiver (i.e., the person most involved with and informed about the care of the older adult) will also be recruited.
62236169|NCT01689220|EXPERIMENTAL|SP-02L|
62236170|NCT01568437|ACTIVE_COMPARATOR|Conventional management|On the ward, patients will be prescribed acetaminophen 1 g every 6 hours. If additional analgesia is required, patients will take oxycodone 5-10 mg up to every 2 hours or iv morphine. Patients with contraindications to oxycodone will be prescribed oral hydromorphone 1-2 mg instead. This is the current standard of care at Toronto Western Hospital.
62236171|NCT01568437|EXPERIMENTAL|TAP Block+Conventional Management|The TAP block will be performed after the induction, before the surgery, by an anesthesiologist with experience of at least 10 successful TAP blocks.Also patients will be prescribed acetaminophen 1 g every 6 hours. If additional analgesia is required, patients will take oxycodone 5-10 mg(oral hydromorphone 1-2 mg) up to every 2 hours or iv morphine.
62236172|NCT03491709|EXPERIMENTAL|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection 250mg/m2 single administration
62236173|NCT03491709|ACTIVE_COMPARATOR|Cetuximab injection|Cetuximab,Erbitux 250mg/m2 single administration
62236174|NCT03524300|EXPERIMENTAL|Robotic Assisted Total Gastrectomy|Robotic Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
62426746|NCT03497988|EXPERIMENTAL|Syntocinon (=Oxytocin), then Placebo|"1. Single-Dose Intranasal Oxytocin~2. Single-Dose Placebo"
62426747|NCT03497988|EXPERIMENTAL|Placebo, then Syntocinon (=Oxytocin)|"1. Single-Dose Placebo~2. Single-Dose Intranasal Oxytocin"
62426748|NCT04748809|ACTIVE_COMPARATOR|Arm_1|Anti-inflammatory diet 1
62426749|NCT04748809|EXPERIMENTAL|Arm_2|Anti-Inflammatory diet 2
62426750|NCT01825876|ACTIVE_COMPARATOR|Warfarin|15 milligrams (mg) warfarin administered as a single oral dose
62426751|NCT01825876|EXPERIMENTAL|Evacetrapib + Warfarin|130 mg evacetrapib administered once daily (QD), orally, for 16 days with 15 mg warfarin co-administered once orally on Day 10
62426752|NCT02846740|EXPERIMENTAL|Adjunctive CES|CES 100µA for one hour daily, five to seven days per week. Rating scales will be administered at baseline (i.e., pre-treatment), twice a week and at the end of the study.
62236175|NCT03524300|ACTIVE_COMPARATOR|Laparoscopic Assisted Total Gastrectomy|Laparoscopic Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
62812476|NCT02994108|ACTIVE_COMPARATOR|Sexual Health Control|"Content was delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants received 10-12 messages daily. During Phase 2 (weeks 4-36), message frequency decreased to monthly messages. Phase 1 content was presented in 3 modules; however, unlike the treatment group, content was topic-based rather than theory-based and focused on general sexual health. Module 1 addressed basic facts about HIV and sexually transmitted infections (STI), including HPV. Module 2 addressed HIV/STI prevention (e.g., condom use, PrEP) and will included basic facts about HPV vaccination currently available online. Module 3 addressed tips for healthy relationships. Phase 2 booster messages largely reinforced Phase 1 content to foster continued engagement with the program.~Sexual Health Control: Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination."
62812477|NCT05958615|EXPERIMENTAL|Intervention Condition|Participants will receive 8 weeks of ReConnect followed by 8 weeks check-in surveys/follow-ups, as well as 3 assessments (baseline, 8 weeks, 16 weeks).
62812478|NCT05958615|OTHER|Waitlist Control Condition|Participants will receive 8 weeks of check-in surveys/follow-ups followed by 8 weeks of ReConnect, as well as 3 assessments (baseline, 8 weeks, 16 weeks).
62812479|NCT04931069|EXPERIMENTAL|Microbiota analysis|Mircobiota analysis on blood, stool and saliva and bile, pancreatic and intestinal mucosa samples
62812480|NCT05971446||Participants with HIE|
62236176|NCT05624385|EXPERIMENTAL|MRgFUS treatment|
62236177|NCT03600857|EXPERIMENTAL|Home administration|Home administration of 0.8 mg misoprostol pv
62236178|NCT03600857|NO_INTERVENTION|Hospital administration|Hospital administration of 0.8 mg misoprostol pv
62236179|NCT03584113|ACTIVE_COMPARATOR|IR guided chest tube insertion with fibrinolytics|Image guided chest tube insertion by interventional radiology along with MIST 2 trial fibrinolysis which includes intrapleural dornase (5mg) and Alteplase (10mg) every twelve hours for a total of six doses as primary intervention for empyema.
62236180|NCT03584113|ACTIVE_COMPARATOR|VATS Decortication|Video assisted thorascopic surgery decortication (VATS) as primary intervention for empyema.
62236181|NCT02566161||Trio Cohort|families were from each of 5 exposure categories: A-father exposed, mother unexposed; B-mother exposed, father unexposed; C-both parents exposed; D-neither exposed; E-high dose emergency workers).
62236182|NCT02054325|ACTIVE_COMPARATOR|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml.
62236183|NCT02054325|ACTIVE_COMPARATOR|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5ml.
62236184|NCT04021251|EXPERIMENTAL|Short term collection of IMD data|Subjects will collect spectral raman data on P0.2 for minimum 10 hours per day with a maximum of 15 minutes between each measurement for 5 days distributed over a time period of 10 days. Spectral data will be compared to standard BG and/or FGM measurements.
62594831|NCT05652179|EXPERIMENTAL|Stellate ganglion block|For patients in Group S, left SGB was performed after the first TEE examination. The patient's head was tilted to the right. A high-frequency probe (6-13 MHz) was placed between the C6 and C7 transverse processes to obtain the best image of the longus colli muscle. After iodine disinfection, a 22-G atraumatic needle for peripheral nerve blocks (B. Braun Melsungen AG, Melsungen, Germany) was used to puncture the site posterior to the left carotid artery and on the surface of the longus colli muscle via an in-plane technique. Then,5 mL of 0.375% ropivacaine hydrochloride injection was administered provided that no blood, cerebrospinal fluid, or gas was suctioned out
62812481|NCT05971446||Healthy participants|
62812482|NCT00798200|OTHER|Exercise|All participants will take part in a supervised, structured, exercise program
62812483|NCT01777035|EXPERIMENTAL|Early physical therapy(PT) occupational therapy (OT)|Early PT OT assessments begin on first day of study. Therapy delivered by a team consisting of physical and occupational therapists and coordinated with daily sedative interruption
62812484|NCT01777035|NO_INTERVENTION|standard care|PT OT delivered as ordered by the primary ICU team
62812485|NCT01591200|NO_INTERVENTION|Control|This arm will receive standard protocol of care alone
62812486|NCT01591200|EXPERIMENTAL|Stem cells high dose|This arm will receive high dose of Allogeneic Mesenchymal Stem Cells
62812487|NCT01591200|EXPERIMENTAL|Stem cells intermediate dose|This arm will receive intermediate dose of Allogeneic Mesenchymal Stem Cells
62236185|NCT04021251|EXPERIMENTAL|Medium term collection of IMD data|Subjects will collect spectral raman data on P0.2 for four times a day for 30 days distributed over a time period of 40 days. Spectral data will be compared to standard BG measurements.
62236186|NCT04021251|EXPERIMENTAL|Long term collection of IMD data|Subjects will collect spectral raman data on P0.2 for four times a day for 90 days distributed over a time period of 6 months. Spectral data will be compared to standard BG measurements.
62236187|NCT04021251|EXPERIMENTAL|Medium term collection of IMD data, increased # of sessions|Subjects will collect spectral raman data on P0.2 four times a day for 30 days distributed over a time period of 40 days. Spectral data will be compared to standard BG measurements. The number of optical sessions performed each time measurements are done are increased compared to the investigation's second arm.
62236188|NCT03933774|EXPERIMENTAL|Tretinoin 0.05% cream group|Tretinoin 0.05% cream 25g for 1 month, applied on the half side of the face after randomization, once a day every night
62236189|NCT03933774|PLACEBO_COMPARATOR|Placebo|PHYSIOGEL Daily Moisture Therapy Creme 150ml for 1 month, applied on the other half side of the face once a day every night
62812488|NCT01591200|EXPERIMENTAL|Stem cells low dose|This arm will receive low dose of Allogeneic Mesenchymal Stem Cells
62236190|NCT02628756|EXPERIMENTAL|Endometrial injury|Hysteroscopic-guided endometrial injury (Karl Storz, Tuttlingen, Germany).
62594832|NCT05652179|NO_INTERVENTION|Control|Patients in Group C did not undergo the SGB procedure.
62236191|NCT00402038|EXPERIMENTAL|Arm 1|
62236192|NCT00402038|PLACEBO_COMPARATOR|Arm 2|
62236193|NCT02460666|EXPERIMENTAL|Tai-Chi Chih Classes|Participants will engage in 12 weekly 60 minute Tai-Chi-Chih classes.
62236194|NCT02460666|ACTIVE_COMPARATOR|Health Education and Wellness Classes|Participants will engage in 12 weekly 60 minute Health Education and Wellness classes.
62594833|NCT05390528|EXPERIMENTAL|Experimental Group(phase Ia)|Phase 1a uses accelerated titration design and Bayesian optimal interval (BOIN) design to investigate the safety of HLX301 and determine MTD.Six dose levels of 0.25 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, and 20mg/kg are planned for dose finding.
62594834|NCT04995653|EXPERIMENTAL|Cohort 1 - Open Label Study|Vancomycin \& SER-155
62594835|NCT04995653|EXPERIMENTAL|Cohort 2 - Randomized, Double-Blind, Placebo-Controlled Study|Vancomycin \& SER-155 OR Vancomycin placebo \& SER-155 placebo
62594836|NCT02832375|EXPERIMENTAL|Experimental: stannous fluoride|Participants will be instructed to dose a dry toothbrush containing 0.454% w/w of stannous fluoride (1000 parts per million \[ppm\] fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
62594837|NCT02832375|ACTIVE_COMPARATOR|Standard: sodium monofluorophosphate|Participants will be instructed to dose a dry toothbrush containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
62594838|NCT06291922|EXPERIMENTAL|Exercise Intervention|The exercise intervention focuses on walking and strengthening exercises with a standardized protocol to guide exercise prescription and exercise progression based on data obtained from the activity tracking watch and smartphone app.
62594839|NCT06291922|OTHER|Usual Care|The usual care group will be encouraged to increase daily walking activity as they tolerate, while complying with any activity restrictions from their clinical team. The Physical Activity Guidelines for Americans recommend increasing daily walking activity as tolerated to an average of 30 minutes daily, 5 times a week.
62812489|NCT01304264||combination topical glaucoma treatment|timolol or dorzolamide add on latanoprost monotherapy
62812490|NCT03451812||prostate cancer|The newly diagnostic number for the high-risk PCa patients in our hospital annually is \~70, it is clinically feasible to recruit 40 patients a year since the study begins. The study could be completed in 3 years with 120 cases.
62236195|NCT03651986||Prospective Cohort|This is a prospectively enrolling cohort study and a stratified case-cohort design will be employed to select malignant pulmonary nodules cases and benign pulmonary nodules subjects who will be assayed. All participants will be followed up with chest CT or low-dose computed tomography (LDCT) scans for 2-3 years, and take the diagnostic test, ctDNA methylation analysis by NGS, at each visit.
62236196|NCT01589354|EXPERIMENTAL|Interscalene brachial plexus block|
62236197|NCT01589354|EXPERIMENTAL|Intra-articular injection|
62236198|NCT03761446|EXPERIMENTAL|Older adults with pre-diabetes or type 2 Diabetes|Male and female older adults between the ages 60-80 with pre-diabetes or type 2 diabetes
62812491|NCT02278406|EXPERIMENTAL|Parkinson's patients with DBS|Patients with Parkinson's Disease who are at least 3-months post subthalamic deep brain stimulator surgery
62236199|NCT03761446|EXPERIMENTAL|Older adults without pre-diabetes or Type 2 Diabetes|Male and female older adults between the ages 60-80 without pre-diabetes or type 2 diabetes
62236200|NCT06270927||MRI|patients assigned to MRI
62236201|NCT06270927||CT|patients assigned to CT
62594840|NCT02956369|PLACEBO_COMPARATOR|Control|10 obese, non-diabetic candidates will serve as control-group. All assessments are carried out just as in the intervention groups. The control granulates consists of maize starch and long-chain fatty acids with powder.
62236202|NCT04578912|ACTIVE_COMPARATOR|CBIT + rTMS|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with 1 Hz repetitive Transcranial Magnetic Stimulation (rTMS).
62236203|NCT04578912|ACTIVE_COMPARATOR|CBIT + cTBS|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with continuous Theta Burst Stimulation (cTBS).
62812492|NCT02356458|EXPERIMENTAL|Ibrutinib & Bortezomib|Combination therapy (trial treatment of ibrutinib in combination with bortezomib) followed by ibrutinib maintenance therapy
62812493|NCT03121313|EXPERIMENTAL|Maintenance|"Eligible patient will be given maintenance tegafur-uracil for one year.~Dose of tegafur-uracil will be based on patient's body surface area (BSA):~* BSA \< 1.5 m2: tegafur-uracil 300 mg/day (1 capsule three times a day)~* BSA ≥ 1.5 m2: tegafur-uracil 400 mg/day (2 capsules twice a day) Tegafur-uracil will be started after patient has complete the adjuvant radiotherapy and been enrolled into the study."
62236204|NCT04578912|SHAM_COMPARATOR|CBIT + Sham|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with either a cTBS or rTMS sham treatment.
62236205|NCT03357952|EXPERIMENTAL|Part 1: JNJ-63723283 + Daratumumab|Participants in Safety Run-in cohort will receive daratumumab IV and JNJ-63723283 IV for 1 cycle (28 days). Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met. Participants who were previously receiving JNJ-283 plus daratumumab have the opportunity to continue daratumumab therapy alone.
62236206|NCT03357952|EXPERIMENTAL|Part 2 and Part 3: Daratumumab/ JNJ-63723283 + Daratumumab|Participants in Treatment Arm A will receive daratumumab IV and in Treatment Arm B will receive daratumumab IV and JNJ-63723283 IV for cycles of 28 days each. All participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met. Participants who were previously receiving JNJ-283 plus daratumumab have the opportunity to continue daratumumab therapy alone.
62236207|NCT02039791|EXPERIMENTAL|Nimotuzumab plus chemoradiotherapy|
62594841|NCT02956369|ACTIVE_COMPARATOR|SATIOSTAT|10 obese, non-diabetic candidates will ingest SATIOSTAT as meal replacement at lunch and as first course at dinner over a period of 6 weeks. The SATIOSTAT granulates consists of hydrocolloids (fibers) and long-chain fatty acids with powder.
62594842|NCT05157542|EXPERIMENTAL|Arm|"Durvalumab 1500mg, IV, Q3W, 2 cycles Albumin paclitaxel 260 mg/m2 +~Carboplatin AUC5, IV, Q3W, 2 cycles Chemoradiotherapy(CRT):~Cohort 1: 2 Gy in 5 Fraction~Cohort 2: 2 Gy in 10 Fraction~Cohort 3: 2 Gy in 15 Fraction"
62594843|NCT03754855||Rheumatoid Arthritis patients|patients affected by RA according to ACR/EULAR 2010 criteria
62594844|NCT02181322|EXPERIMENTAL|Meloxicam - low dose, fasted|
62594845|NCT02181322|EXPERIMENTAL|Meloxicam - medium dose, fasted|
62594846|NCT02181322|EXPERIMENTAL|Meloxicam - high dose, fasted|
62594847|NCT02181322|EXPERIMENTAL|Meloxicam - high dose, fed|
62594848|NCT04546009|EXPERIMENTAL|Giredestrant + Letrozole-matched Placebo + Palbociclib|
62594849|NCT04546009|ACTIVE_COMPARATOR|Letrozole + Giredestrant-matched Placebo + Palbociclib|
62812494|NCT03165487||Luminal A Breast Cancer|Luminal A Breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.
62236208|NCT02347228|EXPERIMENTAL|OB318 capsule|
62236209|NCT00963833||Group 1|
62236210|NCT06120348|EXPERIMENTAL|Experimental Group|Charge-Balanced, Symmetric Nerve Stimulation device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
62236211|NCT06120348|SHAM_COMPARATOR|Control Group|Sham device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
62594850|NCT04649736|EXPERIMENTAL|Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support|"Participants in the intervention arm will receive the conventional care given by the hospital that consists of discharged recommendations and a follow-up plan through telephone calls to verify treatment compliance. Discharged recommendations include performing respiratory exercises at home and medication. There is no plan for diagnosing mental illness or a strategy for respiratory o psychological rehabilitation at the hospital.~Additionally, these participants will receive the intervention program that involves home-based respiratory physiotherapy and telephone-based psychological support for 6 weeks."
62594851|NCT04649736|NO_INTERVENTION|Control|Participants in the control arm will only receive the conventional care given by the hospital that consists of discharged recommendations and a follow-up plan through telephone calls to verify treatment compliance. Discharged recommendations include performing respiratory exercises at home and medication. There is no plan for diagnosing mental illness or a strategy for respiratory o psychological rehabilitation at the hospital.
62594852|NCT02031640|EXPERIMENTAL|BDP 320 mcg BAI|Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.
62812495|NCT03165487||Triple Negative Breast Cancer|Triple Negative breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.
62812496|NCT05397327|NO_INTERVENTION|Conventional planning group|Conventional preoperative planning using x-rays and 2D and 3D CT scan
62812497|NCT05397327|EXPERIMENTAL|3D virtual planning group|Preoperative planning using x-rays, 2D and 3D CT scans and 3D virtual planning software
62812498|NCT06133244||VEDOSS|defined as RP, presence of SSc specific autoantibodies (ACA, ATA, ARA), puffy fingers and abnormal nailfold capillaroscopy (giant capillaries or capillary loss with or without haemorrhages), but not fulfilling the EULAR-ACR 2013 classification criteria for SSc
62812499|NCT06133244||SSc with disease duration of < 4 years without hand contractures|
62594853|NCT02031640|EXPERIMENTAL|BDP 640 mcg BAI|Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.
62594854|NCT02031640|ACTIVE_COMPARATOR|BDP 320 mcg MDI|Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.
62594855|NCT02031640|ACTIVE_COMPARATOR|BDP 640 mcg MDI|Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.
62594856|NCT02031640|PLACEBO_COMPARATOR|Placebo BAI and MDI|Placebo breath-actuated inhaler (BAI), twice daily. Plus placebo metered dose inhaler (MDI), twice daily.
62594857|NCT04566978|EXPERIMENTAL|Cohort 1|Up to 3 participants will be enrolled to receive a single dose of 89Zr-DFO-REGN3767 (total 2mg antibody mass). Participant to undergo 3 PET/CT scans and concurrent blood draws for PK
62594858|NCT04566978|EXPERIMENTAL|Cohort 2|Up to 3 participants will be enrolled to receive a total 5mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
62236212|NCT06236698||Essential hypertension|Adult patients meet the ACC/AHA hypertension guidelines for a diagnosis of essential hypertension but without other obvious features of PA.
62426753|NCT02846740|SHAM_COMPARATOR|Sham control CES|For the sham group the Alpha-Stim® will not emit electricity. All other procedures will be the same for both the sham group and the active CES group. The current intensity will be preset and locked by the manufacturer. The sham devices will appear identical to the active device.
62426754|NCT06528860|EXPERIMENTAL|Dual-focus CL|Wearing dual-focus CL for 2 years
62426755|NCT06528860|PLACEBO_COMPARATOR|Single-vision CL|Wearing single-vision CL for 2 years
62426756|NCT01963676|EXPERIMENTAL|transcranial direct current stimulation (tDCS)|13 subjects total. 2mA stimulation for 20 minutes.
62426757|NCT01963676|SHAM_COMPARATOR|Sham stimulation|13 subjects total. An initial 40sec of stimulation at 2mA followed by a small current pulse every 550msec for the remainder of the 20 minute period.
62426758|NCT00624975|EXPERIMENTAL|Vaccine|
62426759|NCT00624975|PLACEBO_COMPARATOR|Placebo|
62236213|NCT06236698||Primary aldosteronism|Adult patients meet the Endocrine Society Clinical Practice Guidelines for a diagnosis of primary aldosteronism.
62426760|NCT06527573|EXPERIMENTAL|Active repetitive transcranial magnetic stimulation on prefrontal lobes|Real stimulation will be delivered on individualized target using a real coil
62812500|NCT06133244||SSc with hand contractures|
62426761|NCT06527573|EXPERIMENTAL|Active repetitive transcranial magnetic stimulation on posterior parietal lobes|Real stimulation will be delivered on individualized target using a real coil
62426762|NCT06527573|SHAM_COMPARATOR|Sham repetitive transcranial magnetic stimulation|Sham stimulation will be delivered on individualized target using a sham coil
62426763|NCT06209424|ACTIVE_COMPARATOR|In-Person Phase|Habitual Activity + Resistance Exercise Metabolic Trials
62426764|NCT06209424|ACTIVE_COMPARATOR|At-Home Phase|Habitual Activity + Step-Reduction Metabolic Trials
62426765|NCT02239692|ACTIVE_COMPARATOR|PICOPREP day-before dosing schedule|Both doses administered the day before colonoscopy.
62594859|NCT04566978|EXPERIMENTAL|Cohort 3|Up to 3 participants will be enrolled to receive a total 10mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
62594860|NCT04566978|EXPERIMENTAL|Cohort 4|Up to 3 participants will be enrolled to receive a total 20mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
62594861|NCT02487771|PLACEBO_COMPARATOR|Placebo Capsule|
62236214|NCT04664010|EXPERIMENTAL|moderate COVID-19 group|patients with moderate COVID-19 receiving western medicine treatment
62236215|NCT04664010|EXPERIMENTAL|severe COVID-19 group|patients with severe COVID-19 receiving western medicine treatment
62236216|NCT04664010|EXPERIMENTAL|moderate COVID-19 with traditional Chinese medicine group|patients with moderate COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose
62594862|NCT02487771|EXPERIMENTAL|DHA Capsule|
62594863|NCT02247635|NO_INTERVENTION|Conventional medical treatment|Based on the clinical guidelines of the Ministry of Health, medical treatment was provided and consisted in counseling for chronic diseases such as obesity, hyperglycemia, hypertension, dyslipidemia
62812501|NCT04527952|EXPERIMENTAL|Time-restricted feeding (TRF)|Participants will eat the majority of their calories in the day. More specifically participants will consume 70% of their total calories before 5 pm and the remaining 30% after 5 pm.
62812502|NCT04527952|ACTIVE_COMPARATOR|Intermittent fasting (IF)|This involves eating all of one's meals within a specific time (e.g. 8 hours) frame and fasting for the remaining hours (16 hours) in a day.
62426766|NCT02239692|EXPERIMENTAL|PICOPREP tailored dosing schedule|First dose one day before colonoscopy or on the day of colonoscopy, dependent on the planned time for colonoscopy, and second dose on the day of colonoscopy.
62426767|NCT02277639|EXPERIMENTAL|Bone Marrow Failure Syndrome|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells. Reduced intensity conditioning will include Busulfan, Fludarbine, Cyclophosphamide followed by stem cell infusion.
62426768|NCT02277639|EXPERIMENTAL|Immunodeficiency / Dysregulation|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells. Reduced intensity conditioning will include Busulfan, Fludarbine, Cyclophosphamide followed by stem cell infusion.
62426769|NCT06540508||Observation group 1|Patients considered to have effective treatment after TACE combined with targeted immunotherapy, as assessed by mRECIST.
62426770|NCT06540508||Observation group 2|Patients considered to have ineffective treatment after TACE combined with targeted immunotherapy, as assessed by mRECIST.
62426771|NCT03186963|EXPERIMENTAL|No immobilization|Patients receive a conventional dressing made with gauze, cotton padding and inelastic bandage after the surgery. They are instructed to start light wrist movements on the first postoperative day and progress as tolerated, beginning rehabilitation with physiotherapy after 2 weeks postoperatively.
62426772|NCT03186963|ACTIVE_COMPARATOR|Volar splint|Patients receive a volar plaster splint with inelastic bandage after the surgery, and are instructed not to remove the immobilization for 2 weeks. After this period, the immobilization is removed and patients begin rehabilitation with physiotherapy.
62426773|NCT06567041|EXPERIMENTAL|NNC0519-0130|Participants will receive NNC0519-0130 once weekly (QW) subcutaneously(s.c.).
62594864|NCT02247635|ACTIVE_COMPARATOR|Healthy lifestyle and adherence|1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake \<30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.
62594865|NCT03285503|EXPERIMENTAL|400 mg group|Aripiprazole IM depot 400mg will be administered every four weeks for 20 weeks after drug switch / steady dose of oral aripiprazole tablets (each subject will receive 5 intramuscular injections totally).
62594866|NCT04092543||Stroke patients|All patients diagnosed with a stroke are collected in the database.
62426774|NCT06567041|PLACEBO_COMPARATOR|Placebo|Participants will receive once weekly s.c. volume-matched placebo to NNC0519-0130.
62426775|NCT05396443|EXPERIMENTAL|Intervention Adolescents-Caregiver Dyads|Adolescent-caregiver dyads receive 12 week telehealth lifestyle program consisting of a Wellness session, Cooking Experience, and Dance Classes.
62426776|NCT01467570|EXPERIMENTAL|Hipp ORS Apple 200|oral rehydration solution Hipp ORS 200 Apple
62426777|NCT01467570|ACTIVE_COMPARATOR|ESPGHAN ORS|ESPGHAN oral rehydration solution
62426778|NCT03208283|ACTIVE_COMPARATOR|Air insufflation group|During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
62594867|NCT00559403|EXPERIMENTAL|HIV/STD Sessions|The HIV/STD Risk-Reduction Intervention arm focuses on reducing the risk of STDs, including HIV.
62594868|NCT00559403|ACTIVE_COMPARATOR|Health Promotion Control Sessions|The Health Promotion Intervention arm focuses on physical activity, diet, and other behaviors linked to risk of heart disease, high blood pressure, stroke, diabetes, and certain cancers, which are all leading causes of morbidity and mortality among South Africans.
62594869|NCT06648876|EXPERIMENTAL|eGFR≥30+YG1699|patients with eGFR ≥30ml/min/1.73M2 will be treated with YG1699 10mg QD for 8 days.
62594870|NCT06648876|EXPERIMENTAL|Hemodialysis+YG1699|patients on hemodialysis will be treated with YG1699 10mg QD for 8 days.
62812503|NCT04527952|ACTIVE_COMPARATOR|Alternate day fasting (ADF)|This involves complete fasting (i.e. no food or caloric containing beverages, only water consumption) for roughly an entire 36-hour period, followed by an ad libitum feeding day.
62236217|NCT04664010|EXPERIMENTAL|moderate COVID-19 with combination therapy group|patients with moderate COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose containing high-dose vitamin C
62594871|NCT06648876|EXPERIMENTAL|eGFR<20+YG1699|patients with eGFR \<20ml/min/1.73M2 will be treated with YG1699 10mg QD for 8 days.
62236218|NCT04664010|EXPERIMENTAL|severe COVID-19 with traditional Chinese medicine group|patients with severe COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose
62236219|NCT04664010|EXPERIMENTAL|severe COVID-19 with combination therapy group|patients with severe COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose containing high-dose vitamin C
62236220|NCT04331054|ACTIVE_COMPARATOR|1: Usual practice|arm will be follow during 30 days
62236221|NCT04331054|EXPERIMENTAL|2: Usual practice + SYMBICORT RAPIHALER|Usual practice + SYMBICORT RAPIHALER 200/6 µg ( 2 puffs bid during 30 days)
62035465|NCT06496945||Non-attendees & caregivers|Older adults (65+ years), living with a diagnosis of dementia in the community in the Calgary Health Zone (Alberta), Interior Health Region (British Columbia), Winnipeg Regional Health Authority (Manitoba), or York Region (Ontario), with an initial Resident Assessment Instrument - Home Care (RAI-HC) completed, but who are not attending a day program. Each older adult's primary caregiver (i.e., the person most involved with and informed about the care of the older adult) will also be recruited.
62035466|NCT01754467|EXPERIMENTAL|NEAT!|Participants will use the NEAT! smartphone application and accelerometer over a 1 month period.
62035467|NCT00126438|EXPERIMENTAL|123I-mIBG (meta-iodobenzylguanidine)|Single dose
62035468|NCT02301143|EXPERIMENTAL|nab-Paclitaxel plus Gemcitabine|"nab-Paclitaxel 125 mg/m2 intravenous (IV) infusion over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle Subjects who complete 6 cycles of nab-paclitaxel and gemcitabine without disease progression or unacceptable toxicities, the Investigator will then determine the best option for the subject.~* Continuation of nab-paclitaxel and gemcitabine therapy to disease progression or unacceptable toxicity OR~* Chemoradiation therapy consisting of the concurrent use of capecitabine or gemcitabine with radiation according to institutional practice OR~* Surgical intervention"
62236222|NCT02265263||Surgical patients - 3 Tesla MRI|"A study group of at maximum n= 1200 is collected for measuring 3 Tesla MRI at two timepoints (Baseline and 90 days) in Berlin/Utrecht. They include surgical procedures within body cavity e.g. abdomen or thorax from departments of general surgery, urology, gynecology or thoracic surgery; orthopaedic operations (hip-, knee-, endoprosthesis or spine (including neurosurgical spine operations)); cardiac surgery and operation of extracranial/intracranial head and neck~Data collection from study center Utrecht ist within one year after initial hospital stay. Data collection from study center Berlin is within two years after initial hospital stay."
62236223|NCT02265263||Patients ASA II/III - 3 Tesla MRI|"A control group of at maximum n= 300 ASA II/III- patients is collected for measuring the learning experience during the cognitive testings. They are matched on age, education, and gender to the study patients. The 104 ASA II/III- patients should receive additionally MRI-scan (3 Tesla) at baseline, after 3 months and after 1 year in Utrecht, after 3 months, after 1, 2 years in Berlin.~Data collection from study center Utrecht ist within one year after initial hospital stay. Data collection from study center Berlin is within five years after initial hospital stay."
62236224|NCT02265263||Volunteers ASA I/II - 3 Tesla MRI|To analyze scanner variability we additionally measure at maximum 20 subjects (Age ≥ 65 years) from Utrecht in the MRI scanner (3-Tesla) in Berlin and vice versa.
62236225|NCT02265263||Surgical patients - 7 Tesla MRI|A study Group of at maximum n= 80 should be collected for measuring 7 Tesla MRI at two timepoints (Baseline and 90 days) in Berlin.
62236226|NCT06127056|ACTIVE_COMPARATOR|real stimulation|The central electrode was placed over F3, with return electrodes at Fp1, Fz, F7 and C3. Fourteen 2-mA sessions (ramp-up and ramp-down periods of 15 and 15 seconds, respectively) were applied for 20 minutes per session, twice daily over 7 consecutive days, and the stimulus frequency was set as IAF.
62426779|NCT03208283|ACTIVE_COMPARATOR|Water method group|During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
62426780|NCT01846832|EXPERIMENTAL|TMC435 + PegIFNα-2a + RBV|TMC435 will be administered as triple therapy with pegylated interferon alfa-2a (PegIFNα-2a) and ribavirin (RBV).
62426781|NCT01576627|EXPERIMENTAL|zinc citrate|
62035469|NCT04392544||Pediatric|Pediatric CF population age 10-18 years.
62035470|NCT04392544||Adult|Adult CF population age ≥ 18 years.
62426782|NCT01576627|ACTIVE_COMPARATOR|zinc gluconate|
62594872|NCT06648876|PLACEBO_COMPARATOR|eGFR<20+placebo|patients with eGFR \<20ml/min/1.73M2 will be treated with placebo 10mg QD for 8 days.
62812504|NCT05495932|EXPERIMENTAL|Eligible patients|
62426783|NCT01576627|ACTIVE_COMPARATOR|zinc oxide|
62426784|NCT04150926|EXPERIMENTAL|Black currant puree|Black currant puree
62426785|NCT04150926|ACTIVE_COMPARATOR|Black currant-quinoa product|Black currant-quinoa product
62426786|NCT04150926|ACTIVE_COMPARATOR|Quinoa base|Quinoa base is used for the black currant-quinoa product.
62812505|NCT01453049|EXPERIMENTAL|fix dose of rosiglitazone/glimepiride|4mg/1mg, 4mg/2mg, 4mg/4mg
62594873|NCT06410495|EXPERIMENTAL|NiteCAPP SINCC|Content includes both standard CBT-I techniques \[sleep hygiene, stimulus control, sleep restriction, cognitive therapy\] as well as those targeting children with ODD and their parents. Active child participation is a goal but may be limited due to age/abilities. Parents will work with children to implement behavioral strategies.
62594874|NCT06621589|EXPERIMENTAL|Nutritional Counseling Group|Participants in this arm will receive personalized nutritional counseling sessions aimed at improving their dietary habits, health knowledge, attitudes, and overall health outcomes. The counseling will take place over a 2-month period, and participants will undergo assessments before and after the intervention to evaluate changes in anthropometric measurements, body composition, and various health metrics.
62035471|NCT03834779|OTHER|DOORS-CHW Intervention|"The type of intervention is behavioral.~Participants randomized to the intervention arm will meet with the Community Health Worker (CHW) and a staff member from Unlocking DOORS. The Unlocking DOORS broker will complete a needs assessment, generate an individualized re-entry plan and make referrals to providers in the extensive Unlocking DOORS network. The CHW will assist the participant in navigating these referrals, specifically with regards to HIV care, substance use treatment and mental healthcare."
62035472|NCT03834779|NO_INTERVENTION|Treatment As Usual|TAU participants will receive standard of care, which involves passive referral by jail medical staff to the outpatient HIV clinic.
62035473|NCT02725632|NO_INTERVENTION|Control|"An age-matched control group will be enrolled and consented. A Data Collection Sheet will be used to document data from the subject's medical records including history, physical exam, active medications, laboratory data, polysomnogram, electrocardiogram, echocardiography and cardiac catheterization.~At the time of enrollment, one blood drawn through peripheral venipuncture will be collected. Another blood drawn will be collected after one month. The blood samples will be processed and analyzed to assess for levels of SCN5A mRNA splicing variants."
62035474|NCT02725632|ACTIVE_COMPARATOR|OSA|"Newly diagnosed OSA patients will be enrolled and consented. A Data Collection Sheet will be used to document data from the patient's medical records including history, physical exam, active medications, laboratory data, polysomnogram, electrocardiogram, echocardiography and cardiac catheterization.~At the time of enrollment, one blood drawn through peripheral venipuncture will be collected. The patients on CPAP treatment will be followed-up for 1 month. Another blood drawn will be collected after one month of CPAP treatment. The blood samples will be processed and analyzed to assess for levels of SCN5A mRNA splicing variants."
62594875|NCT06142942|EXPERIMENTAL|2 days per week group|Participants in this group complete 2 training sessions each week (Monday and Thursday).
62035475|NCT02238262||essential hypertension patients|
62035476|NCT04832503||Group 1|The PROMPT-treated group will include 12 children with idiopathic CAS. The pre-treatment assessment is aimed at evaluating the baseline speech and language level and at treatment planning. During a PROMPT session tactile-kinesthetic-proprioceptive inputs are consistently provided in order to shape speech movements, to give information on sequencing and timing, and to introduce constraints for the reduction of the degrees of freedom at the articulators' level in favour of motor control. In a PROMPT session the syllables, words and phrases are produced within a communicative context in play. Speech motor goals are, as soon as possible, integrated in goals for language and functional communication.
62426787|NCT04150926|NO_INTERVENTION|Liquid with glucose, fructose and sucrose|Liquid with glucose, fructose and sucrose
62426788|NCT01247974|EXPERIMENTAL|CorMatrix ECM for Pericardial Closure|Pericardial closure with CorMatrix ECM
62594876|NCT06142942|EXPERIMENTAL|3 days per week group|Participants in this group complete 3 training sessions each week (Monday, Wednesday, and Friday).
62594877|NCT06142942|EXPERIMENTAL|4 days per week group|Participants in this group complete 4 training sessions each week (Monday, Tuesday, Thursday, and Friday).
62594878|NCT06142942|NO_INTERVENTION|No-exercise Control group|This group does not complete any training intervention. They are asked to maintain their regular physical activity habits.
62594879|NCT03800836|EXPERIMENTAL|Arm A1: Ipat + Atezo + Pacl|Safety Run-In (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
62812506|NCT01453049|ACTIVE_COMPARATOR|glimepiride|1mg, 2mg, 4mg
62426789|NCT01247974|NO_INTERVENTION|Control|No Pericardial Closure
62426790|NCT05803538|EXPERIMENTAL|SMS|
62426791|NCT05803538|EXPERIMENTAL|Telephone interview|
62426792|NCT05803538|EXPERIMENTAL|Diary card|
62426793|NCT05803538|ACTIVE_COMPARATOR|Usual Care|
62426794|NCT03715673||Cases:Active IBD patients|23 patients with active inflammatory bowel disease for whom von willlebrand antigen and activity will be done
62426795|NCT03715673||Control:Inactive IBD patients|23 patients with inactive inflammatory bowel disease; VWF antigen and activity will be done for them
62426796|NCT04280393|EXPERIMENTAL|Endocuff|Colonoscopy procedure with the use of endocuff
62426797|NCT04280393|ACTIVE_COMPARATOR|Control|Standard Colonoscopy procedure
62812507|NCT05397730||TBP|Patients with definite or probable tuberculous pleuritis
62812508|NCT05397730||Non-TBP|Patients without tuberculous pleuritis
62812509|NCT06019624|ACTIVE_COMPARATOR|Cohort 1 Receipt of Food Box|Up to 80 individuals with diabetes or prediabetes with a history of food insecurity enrolled in a 6 month program offering free bimonthly fresh food boxes, nutrition education, and individualized support. Each enrolled individual will serve as their own control. The study will evaluate pre and post program changes in reported self-obtained home glucose levels, food security, and dietary intake.
62812510|NCT06019624|ACTIVE_COMPARATOR|Cohort 2 Receipt of Food Box|Up to 80 individuals with diabetes or prediabetes with a history of food insecurity enrolled in a 6 month program offering free bimonthly fresh food boxes, nutrition education, and individualized support. Each enrolled individual will serve as their own control. The study will evaluate pre and post program changes in reported self-obtained home glucose levels, food security, and dietary intake.
62812511|NCT06019624|ACTIVE_COMPARATOR|Cohort 3 Receipt of Food Box|Up to 80 individuals with diabetes or prediabetes with a history of food insecurity enrolled in a 6 month program offering free bimonthly fresh food boxes, nutrition education, and individualized support. Each enrolled individual will serve as their own control. The study will evaluate pre and post program changes in reported self-obtained home glucose levels, food security, and dietary intake.
62812512|NCT06019624|ACTIVE_COMPARATOR|Cohort 4 Receipt of Food Box|Up to 80 individuals with diabetes or prediabetes with a history of food insecurity enrolled in a 6 month program offering free bimonthly fresh food boxes, nutrition education, and individualized support. Each enrolled individual will serve as their own control. The study will evaluate pre and post program changes in reported self-obtained home glucose levels, food security, and dietary intake.
62812513|NCT05942365|EXPERIMENTAL|The DDI of ZSP1273 ,Warfarin and Midazolam|Warfarin and midazolam will be co-administered alone and in combination with ZSP1273.
62812514|NCT01690052|ACTIVE_COMPARATOR|Cevimeline|Cevimeline vs Pilocarpine
62236227|NCT06127056|SHAM_COMPARATOR|sham stimulation|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15 and 15 s); no current was delivered during the 20-minute intervention. Participants will receive sham tACS twice daily for two weeks.
62236228|NCT02174796|EXPERIMENTAL|Surgical treatment group|"patients who chose to undergo a surgical correction (Ravitch or Nuss type intervention).~intervention: surgical correction (Ravitch or Nuss type intervention)."
62426798|NCT06155669|NO_INTERVENTION|Standart Group|Participants will be selected from patients diagnosed with tension-type headache according to the International Classification of Headache Disorders, third edition (ICHD-3) criteria. All selected participants will be administered 25 mg of dexketoprofen.
62236229|NCT02174796|EXPERIMENTAL|Orthopedic treatment group|patients who chose an orthopedic treatment by vacuum bell. intervention : orthopedic treatment by vacuum bell.
62236230|NCT00084266|EXPERIMENTAL|1|Subjects receiving linezolid for the treatment phase of the study
62236231|NCT00084266|ACTIVE_COMPARATOR|2|Subjects receiving vancomycin for the treatment phase of the study
62426799|NCT06155669|EXPERIMENTAL|Virtual Reality|Participants will be selected from patients diagnosed with tension-type headache according to the International Classification of Headache Disorders, third edition (ICHD-3) criteria. Selected participants, in addition to being administered 25 mg of dexketoprofen, will also use virtual reality goggles.
62426800|NCT06334250|ACTIVE_COMPARATOR|Left atrial appendage occlusion alone|Left atrial appendage occlusions with the Watchman device (Boston Scientific)
62426801|NCT06334250|EXPERIMENTAL|Combined left atrial appendage occlusion and pulsed field ablation of atrial fibrillation|Left atrial appendage occlusion with the Watchman device (Boston Scientific) and catheter ablation of atrial fibrillation with the FaraPulse system (Boston Scientific)
62812515|NCT01690052|ACTIVE_COMPARATOR|Pilocarpine|Pilocarpine vs. Cevimeline
62812516|NCT05930821|EXPERIMENTAL|Aerobic and Resistance Exercise Program (GEMS program)|This intervention condition will deliver the Guidelines for Exercise in Multiple Sclerosis (GEMS) program. Participants in this condition will receive a 16-week home-based, remotely supported aerobic and resistance exercise training intervention.
62812517|NCT05930821|ACTIVE_COMPARATOR|Flexibility and Stretching Program (FLEX-MS program)|Participants in this condition will receive a 16-week home-based, remotely supported stretching program emphasizing flexibility and range of motion as important components of fitness based on Stretching for People with MS: An Illustrated Manual from the National MS Society.
62426802|NCT03138239|EXPERIMENTAL|16 patients diagnosed with HCC|"* 12 patients will be tested at the stage of diagnosis (staging)~* 4 patients who have tested at staging, will be tested again after treatment.~* 4 patients with treatment failure or recurrence."
62426803|NCT00899288|EXPERIMENTAL|tamoxifen and no bone fracture|Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have not had a bone fracture.
62594880|NCT03800836|EXPERIMENTAL|Arm A2: Ipat + Atezo + Pacl|Expansion (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
62594881|NCT03800836|EXPERIMENTAL|Arm A3: Ipat + Atezo + Pacl|Expansion (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
62594882|NCT03800836|EXPERIMENTAL|Arm B1: Ipat + Atezo + Nab-Pacl|Safety Run-In (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by IV infusion on Days 1 and 15 of each 28 day cycle. Nab-paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
62594883|NCT03800836|EXPERIMENTAL|Arm B2: Ipat + Atezo + Nab-Pacl|Expansion (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by IV infusion on Days 1 and 15 of each 28 day cycle. Nab-paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
62594884|NCT03800836|EXPERIMENTAL|Arm C1: (Ipat + Pacl) (2 weeks) + Atezo|Safety Run-In (Cohort 1): Participants will receive a 2-week lead in of ipatasertib in combination with paclitaxel, followed by atezolizumab in an initial 28-day (1 cycle) period. Ipatasertib will be administered orally daily on Days 1-21, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Atezolizumab will be administered by IV infusion on Day 15. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
62594885|NCT03800836|EXPERIMENTAL|Arm C2 (Ipat + Pacl) (2 weeks) + Atezo|Expansion (Cohort 1): Participants will receive a 2-week lead in of ipatasertib in combination with paclitaxel, followed by atezolizumab in an initial 28-day (1 cycle) period. Ipatasertib will be administered orally daily on Days 1-21, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Atezolizumab will be administered by IV infusion on Day 15. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
62594886|NCT03800836|EXPERIMENTAL|Arm D1: (Atezo + Pacl) (2 weeks) + Ipat|Safety Run-In (Cohort 1): Participants will receive a 2-week lead in of atezolizumab in combination with paclitaxel, followed by ipatasertib in an initial 28-day (1 cycle) period. Atezolizumab will be administered via IV infusion on Days 1 and 15, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Ipatasertib will be administered orally daily on Days 15-21. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
62426804|NCT00899288|EXPERIMENTAL|Letrozole and no bone fracture|Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have not had a bone fracture.
62426805|NCT00899288|EXPERIMENTAL|Tamoxifen and bone fracture|Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have had a bone fracture.
62426806|NCT00899288|EXPERIMENTAL|Letrozole and bone fracture|Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have had a bone fracture.
62426807|NCT02956005|OTHER|Envarsus|Open Label; Envarsus XR started at the time of transplant. Initial dosing of 0.17mg/kg. Target trough level of 8-10 ng/mL
62426808|NCT04622865|EXPERIMENTAL|Masitinib plus Isoquercetin plus Best Supportive Care|"Patients will receive oral masitinib dose of 3 mg/kg/day for 4 days then 4.5 mg/kg/day.~The dose of isoquercetin will be 1 g/day by oral route. Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs, or biologics drugs."
62426809|NCT04622865|ACTIVE_COMPARATOR|Best Supportive Care|Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs, or biologics drugs.
62426810|NCT00670267|EXPERIMENTAL|Open Label treatment with oral Nadolol|Dose escalation through 1.25mgs, 2.5mgs, 5.0mgs, 10mgs, 20mgs, and 40mgs of nadolol at 2 week intervals as tolerated.
62426811|NCT02446665|EXPERIMENTAL|PSC Patients|MR Elastography, Fibroscan and standard of care biopsy
62426812|NCT02446665|ACTIVE_COMPARATOR|Non-PSC Patients|MR Elastography, Fibroscan and standard of care biopsy
62426813|NCT01398137||Ragweed allergic subjects|
62236232|NCT02235974|EXPERIMENTAL|Acute/Early|Intervention: A 20-hour dose of early intensive upper extremity motor training therapy will be initiated within 30 days post-stroke.
62236233|NCT02235974|EXPERIMENTAL|Sub-acute/Outpatient|Intervention: A 20-hour dose of sub-acute intensive upper extremity motor training therapy will be initiated within 2 to 3 months post-stroke.
62236234|NCT02235974|EXPERIMENTAL|Chronic|Intervention: A 20-hour dose of chronic intensive upper extremity motor training therapy will be initiated 6 to 9 months post-stroke
62236235|NCT02235974|PLACEBO_COMPARATOR|Control|Intervention: Usual and customary care. No additional therapy will be initiated during the 1-year study.
62236236|NCT04242160|EXPERIMENTAL|Modified Clamshell Thoracotomy First|Participants randomized to perform the MCT first, then cross over to the perform the alternate LAT.
62236237|NCT04242160|ACTIVE_COMPARATOR|Left Anterolateral Thoracotomy First|Participants randomized to perform the LAT first, then cross over to the perform the alternate MCT.
62236238|NCT01504750|EXPERIMENTAL|lighting room|In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals.
62426814|NCT05492019|EXPERIMENTAL|Doxycyline- Patients receiving Doxycycline .|Drug generic name: Doxycycline Dosage form- oral capsule Dosage- (50mg) one capsule Frequency- twice daily Duration- 8 weeks.
62426815|NCT05492019|PLACEBO_COMPARATOR|Control- Patients receiving placebo|Patient will receive one capsule of placebo twice daily
62426816|NCT05265169|EXPERIMENTAL|Microwave ablation with margin confirmation|Patients who meet the eligibility criteria will undergo microwave ablation (MWA) of 1-3 colorectal cancer metastases with any FDA cleared/CE Marked Microwave Ablation System in accordance with the study site's standard-of-care (SOC) practices.
62426817|NCT01399125|EXPERIMENTAL|Rivastigmine patch|Once-daily target patch size 10 cm²
62426818|NCT01399125|ACTIVE_COMPARATOR|Rivastigmine capsules|Twice-daily target dose of 6 mg oral capsule
62426819|NCT02331069|ACTIVE_COMPARATOR|Dextrose 5% (D5W) Injection|Glucose injection in 5% concentration, administered weekly X 4 times in a volume of 12 ml or less.
62426820|NCT02331069|ACTIVE_COMPARATOR|Physical Therapy|Physical therapy for a month in the posterior deltoid region 3 times a week.
62426821|NCT02056405|PLACEBO_COMPARATOR|Placebo|Placebo arm: intake of placebo (Lactose). 1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
62426822|NCT02056405|ACTIVE_COMPARATOR|Mosapride|Mosapride arm: intake of active drug (Mosapride). 15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
62426823|NCT06539806|ACTIVE_COMPARATOR|Group I (locally advanced PC patients):|"Including three subset groups (A, B and C)~•Group I- A(control group): Fifteen hypertensive patients treated with antihypertensive agent except ARBS and ACEI with locally advanced PC on Folfirinox.~• Group I -B (are not treated with ARBs or ACEI prior PC diagnosis): Fifteen hypertensive patients with locally advanced PC and are not treated with ARBs or ACEI before PC diagnosis on the same chemotherapy treatment protocol as the control group in addition to losartan 50 mg once daily for one year after PC diagnosis.~• Group I-C (losartan was used for treatment of hypertension before and after PC diagnosis):Fifteen hypertensive patients with locally advanced PC and were treated with losartan one year before PC diagnosis on the same chemotherapy treatment protocol as the control group in addition to losartan 50 mg once daily for one year after PC diagnosis and the dose will be titrated up according to the patient's response."
62426824|NCT06539806|ACTIVE_COMPARATOR|Group II (metastatic PC patients):|"including three subset groups (A, B and C):~• Group II-A (control group): Fifteen hypertensive patients treated with antihypertensive agent except ARBS and ACEI with metastatic PC on Gemcitabine hydrochloride 1 gm. vial taken as 1000 mg/m2 IV over 30 min weekly for 7 weeks.~• Group II-B (are not treated with ARBs or ACEI prior diagnosis): Fifteen hypertensive patients with metastatic PC and are not treated with ARBs or ACEI before PC diagnosis on the same chemotherapy treatment protocol as the control group in addition to Losartan 50 mg once daily for one year after PC diagnosis.~• Group II-C (losartan was used for treatment of hypertension before and after PC diagnosis): Fifteen hypertensive patients with metastatic PC and were treated with losartan one year before PC diagnosis and on the same chemotherapy treatment protocol as the control group in addition to Losartan 50 mg once daily for one year after PC diagnosis"
62426825|NCT05801640|EXPERIMENTAL|Faciliated tucking position|Experiment group will receive faciliated tucking position throughout the OG inserting. The faciliated tucking position will be applied 3 minutes before the orogastric (OG) tube is inserted. This intervention will be applied throughout the OG inserting process. The application will continue for 3 more minutes after the OG is inserted.
62426826|NCT05801640|EXPERIMENTAL|Reiki|Experiment group will receive reiki throughout the OG inserting. This group will be take reiki 3 minutes before the orogastric (OG) tube is inserted. This intervention will be applied throughout the OG inserting process. The intervention will continue for 3 more minutes after the OG is inserted.
62426827|NCT05801640|NO_INTERVENTION|Control Group|The routine OG insertion procedure of the clinic will be performed for the control group infants without any intervention. The group will received no further intervention.
62426828|NCT02349009|PLACEBO_COMPARATOR|placebo|C-82 Topical Gel, Placebo
62426829|NCT02349009|ACTIVE_COMPARATOR|Active|C-82 Topical Gel, 1%
62426830|NCT00971685|EXPERIMENTAL|Lenalidomide plus Dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
62426831|NCT05697146||ribociclib + ET|Women prescribed ribociclib + Endocrine Therapy (ET)
62812518|NCT04989686||Cyclosporine A|"1. Males and females \<18 years of age~2. Weight greater than 5 kg~3. Receiving cyclosporine A as the standard of care~4. Has scheduled/anticipated blood draw to quantify the concentration of cyclosporine A for clinical indications~5. Parental/guardian permission (informed consent), and subject's assent if applicable."
62236239|NCT01504750|NO_INTERVENTION|control room|Normal lighted patient room
62236240|NCT01101477|ACTIVE_COMPARATOR|Titration by target effect site concentration (Cet) 0.5μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
62236241|NCT01101477|ACTIVE_COMPARATOR|Titration by Cet 0.2μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
62594887|NCT03800836|EXPERIMENTAL|Arm D2: (Atezo + Pacl) (2 weeks) + Ipat|Expansion (Cohort 1): Participants will receive a 2-week lead in of atezolizumab in combination with paclitaxel, followed by ipatasertib in an initial 28-day (1 cycle) period. Atezolizumab will be administered via IV infusion on Days 1 and 15, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Ipatasertib will be administered orally daily on Days 15-21. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
62594888|NCT03800836|EXPERIMENTAL|Arm E: Ipat + Atezo|Participants (Cohort 2) will receive Ipatasertib orally daily on Days 1-28 of Cycle 1 (35-day cycle) and on Days 1-21 of subsequent cycles (28-day cycles). Atezolizumab will be administered by IV infusion on Days 8 and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
62812519|NCT04989686||Tacrolimus|"1. Males and females \<18 years of age~2. Weight greater than 5 kg~3. Receiving tacrolimus as the standard of care~4. Has scheduled/anticipated blood draw to quantify the concentration of tacrolimus for clinical indications~5. Parental/guardian permission (informed consent), and subject's assent if applicable."
62236242|NCT01101477|ACTIVE_COMPARATOR|Titration by Cet 0.1μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
62812520|NCT04989686||Sirolimus|"1. Males and females \<18 years of age~2. Weight greater than 5 kg~3. Receiving sirolimus as the standard of care~4. Has scheduled/anticipated blood draw to quantify the concentration of sirolimus for clinical indications~5. Parental/guardian permission (informed consent), and subject's assent if applicable."
62236243|NCT03672422||Acute Recurrent Pancreatitis|At least 2 episodes of acute pancreatitis with complete resolution of pain and a \>1 month pain-free interval between episodes.
62812521|NCT01048008|EXPERIMENTAL|4-DM-CHOC-PEN|"DM-CHOC-PEN is an intervention and will be dosed @ 39 mg/M2,escalated in 1-patient cohorts at 40% dosage.~* At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~* The MTD will be where 2 DLTs are noted and the study is discontinued."
62236244|NCT03672422||Chronic Pancreatitis|"Children with at least:~1) One irreversible structural change\* in the pancreas with or without abdominal pain +/- exocrine pancreatic insufficiency +/- diabetes.~\*irreversible structural changes:~* Ductal calculi, dilated side branches, parenchymal calcifications found in any imaging (abdominal ultrasound (abd US), magnetic resonance imaging/magnetic resonance cholangiopancreatography (MRI/MRCP), computerized tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP), endoscopic US (EUS).~* Ductal obstruction or stricture/dilatation/irregularities that are persistent (for \>2 months) on any imaging.~* Parenchymal atrophy, irregular contour, accentuated lobular architecture, cavities alone are not diagnostic findings for CP.~* Surgical or pancreatic biopsy specimen demonstrating histopathologic features compatible with CP (acinar atrophy, fibrosis, protein plugs, infiltration with lymphocytes, plasma cells, macrophages)."
62426832|NCT03171610|EXPERIMENTAL|Sufentanil group|Arm Description: PCA with sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml
62426833|NCT03171610|ACTIVE_COMPARATOR|Fentanyl group|PCA with fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml
62426834|NCT01425931||Extracorporeal circulation|all patients were measured by microcirculation device O2C
62426835|NCT03888716|EXPERIMENTAL|KL1333|25 and 100 mg KL1333 encapsulated tablets for daily oral dosing
62426836|NCT03888716|PLACEBO_COMPARATOR|Matching placebo|25 and 100 mg KL placebo encapsulated tablets for daily oral dosing
62236245|NCT03193788|EXPERIMENTAL|pemetrexed maintenance|"Drug: Pemetrexed Maintenance therapy: 500 mg/m\^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.~Drug: folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment~Drug: vitamin B12 injection 1000 μg IM 7 days prior to treatment initiation and the every then every 3 cycles until the end of treatment~Drug: dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment"
62236246|NCT03193788|NO_INTERVENTION|observation|observation group will be observed with best supportive care until progressive disease
62236247|NCT05722054||Incidence of tropical infectious diseases|All study participants will be followed up for 12 months through active and passive detection visits. Active detection takes place every month for all pathogens except for P. falciparum which is detected every two weeks.
62426837|NCT02580201|EXPERIMENTAL|Oral Polio Vaccine|"Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.~The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container."
62594889|NCT03800836|EXPERIMENTAL|Arm F1: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Safety Run-In (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
62594890|NCT03800836|EXPERIMENTAL|Arm F2: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Expansion (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
62426838|NCT00981864|EXPERIMENTAL|Concurrent Boost RT|
62426839|NCT03001011|PLACEBO_COMPARATOR|Placebo|Participants received placebo (for Renvela) orally 3 times per day (TID) for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus less than or equal to (\<=) 4.6 mg/dL (\<=1.49 mmol/L).
62426840|NCT03001011|EXPERIMENTAL|Renvela|Participants received Renvela orally TID for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus \<=4.6 mg/dL (\<=1.49 mmol/L).
62812522|NCT01804478|EXPERIMENTAL|Pneumatic Compression|Both diabetic and control subjects will undergo mild pneumatic compression while tissue oxygenation and blood flow are recorded with a non-invasive NIRS and PPG device
62426841|NCT04821570||Chemotherapy (IV and oral)|
62426842|NCT04821570||Immunotherapy|
62426843|NCT04821570||Chemotherapy + Immunotherapy|
62426844|NCT04821570||Cyclin- dependent kinase (CDK) 4/6 inhibitors|
62426845|NCT04821570||Stem Cell Transplant recipients|
62426846|NCT02861352|EXPERIMENTAL|diet zinc|3 dietary zinc levels: 6 mg/d, 10 mg/d and 25 mg supplemental zinc/d
62812523|NCT06423950||Participants Reviewed by ETB|"Participants clinical history, available therapeutic options, and outcome expectations will be presented to the Evolutionary Tumor Board (ETB) along with images and pathology. Strategies and models will be presented regarding additional evolutionary ideas that can be applied.~These ideas will be characterized (e.g. first strike-second strike, adaptive, novel sequential therapy, novel combination, novel dosing schedule, etc.)."
62426847|NCT05011019|EXPERIMENTAL|AL2846 Capsules|"During the dose escalation phase, patients enrolled in the group will first receive a single fasting administration（AL2846 capsules 120-150mg，oral）. The observation period is 3 days. If dose-limited toxity (DLT) does not occur, they will continue to receive multiple consecutive fasting administrations (120mg-150mg，once a day，oral ),every 28 days as a treatment cycle.~During the dose expansion phase, patients will receive multiple consecutive fasting administrations (AL2846 capsules，120mg-150mg, oral ), every 28 days as a treatment cycle."
62236248|NCT05722054||Healthy and equilibrate diet|One-fourth of the study participants will be randomly assigned to receive an equilibrate diet for 21 days comprising breakfast, lunch and educational recommendations for an equilibrate diet
62236249|NCT05722054||In vitro|30 to 50 participants selected from the study population. The in vitro study procedures are performed at the screening visit and every two months+/- 1, and when an active case of tropical infection occurs
62426848|NCT00631800|PLACEBO_COMPARATOR|Placebo|Placebo
62426849|NCT00631800|EXPERIMENTAL|60 mg/kg|60 mg/kg was given on Days 0, 7, 14
62426850|NCT00631800|EXPERIMENTAL|90 mg/kg|90 mg/kg was given on Days 0, 7, 14
62426851|NCT05555186|EXPERIMENTAL|Experimental light: Sleep quality and well-being|Exposure to experimental systematic light exposure (BWL) in classroom where students are located every school day from 8:30 AM until the school finishes between 3 and 4 PM
62426852|NCT05555186|SHAM_COMPARATOR|Comparison light: Sleep quality and well-being|Exposure to comparison systematic light exposure (DWL) in classroom where students are located every school day from 8:30 AM until the school finishes between 3 and 4 PM
62426853|NCT05555186|NO_INTERVENTION|Unchanged lightning|Conventional lightning in classrooms where students are located every school day from 8:30 AM until the school finishes between 3 and 4 PM
62426854|NCT04408300|EXPERIMENTAL|Ophthalmological exam|
62426855|NCT02600273|ACTIVE_COMPARATOR|Usual brand cigarettes|During one session, participants will smoke their usual brand cigarettes
62426856|NCT02600273|EXPERIMENTAL|Lower nicotine content cigarettes|During one session, participants will smoke SPECTRUM Research Cigarettes
62426857|NCT02600273|EXPERIMENTAL|Electronic cigarettes 1|During one session, participants will use an electronic cigarette with 0 mg/mL nicotine e-liquid
62426858|NCT02600273|EXPERIMENTAL|Electronic cigarettes 2|During one session, participants will use an electronic cigarette with 18 mg/mL nicotine e-liquid
62426859|NCT06418087|EXPERIMENTAL|Patient with Pulmonary Large-cell Neuroendocrine Carcinoma|All enrolled patients will receive intravenous infusion of durvalumab 1500 mg on day 1 (induction phase) with carboplatin (AUC 5 on day 1), etoposide (100 mg/sqm on days 1-3) every 3 weeks, and durvalumab (1500 mg on day 1) administered every three weeks for up to 4 cycles (induction phase) or until progression of disease, unacceptable toxicity, patient refusal or loss of clinical benefit (for durvalumab). Treatment with intravenous durvalumab (1500 mg on day 1) every 4 weeks ± 3 days (maintenance phase) will continue until completion of 24 courses (for a total of 28 courses, including the 4 courses of induction phase) or 2 years of treatment whichever occurs first, disease progression, unacceptable toxicity, patient refusal or loss of clinical benefit.
62426860|NCT01000857|EXPERIMENTAL|Open label treatment with 2-period crossover design|"Group 1: Paroxetine CR 25 mg/day for 14 days / Paroxetine IR 20 mg/day for 14 days.~Group 2: Paroxetine IR 20 mg/day for 14 days / Paroxetine CR 25 mg/day for 14 days.,~PK results will be compared between the Paroxetine CR treatment period and the Paroxetine IR treatment period."
62812524|NCT00434226|EXPERIMENTAL|Bevacizumab + Carboplatin/Paclitaxel + Sunitinib|
62236250|NCT05722054||Adaptive in vitro|100 to 150 selected participants. The adaptive in vitro study procedures are performed at the screening visit and every two months+/- 1 and when an active case of tropical infection occurs.
62236251|NCT05722054||Ex vivo|All study participants. The ex vivo are performed at the screening visit and every two months+/- 1 and when an active case of tropical infection occurs.
62236252|NCT04747782||COVID positive|Patients admitted to the ICU with respiratory distress found to be COVID19 positive.
62236253|NCT04747782||COVID negative|Patients admitted to the ICU with respiratory distress found to be COVID19 negative
62236254|NCT04747782||COVID positive delayed|Patients admitted to the ICU for an indication other than respiratory distress, found to be COVID19 positive.
62236255|NCT04747782||never-ICU|Patients admitted to the internal medicine ward with respiratory distress found to be COVID19 positive.
62426861|NCT03031405|EXPERIMENTAL|Oxytocin and trauma film paradigm|
62426862|NCT03031405|PLACEBO_COMPARATOR|Placebo and trauma film paradigm|
62426863|NCT05885529||consecutive participants in the 15 centers|adult patients with mild traumatic brain injury admitted within 12 hours after the trauma. No interventions, observational study
62812525|NCT00434226|PLACEBO_COMPARATOR|Bevacizumab + Carboplatin/Paclitaxel|
62812526|NCT05623332||Maraciclatide imaging group|Women referred to the endometriosis clinic for suspected endometriosis undergoing a maraciclatide imaging scan
62812527|NCT05623332||Control|Control group (samples but no scan) - Women undergoing surgery for any other condition than endometriosis
62812528|NCT00102466|EXPERIMENTAL|Vildagliptin|
62236256|NCT03151317||With therapeutic education|Patients assigned to this group will have participated in a therapeutic education program.
62812529|NCT00102466|ACTIVE_COMPARATOR|Gliclazide|
62035477|NCT04832503||GROUP 2|The LNSOM-treated group will include 12 children with idiopathic CAS. The pre-treatment assessment is aimed at evaluating the baseline speech and language level and at the treatment planning. None of the SLTs treating this group are PROMPT trained. According to the standard care methods used in Italy, the intervention consists of a linguistic and articulatory approach that includes auditory discrimination of phonemic categories at the syllable and word level and non-speech oral motor exercises. Receptive and expressive lexicon and morphosyntax are targeted depending on the children's linguistic profile.Differently from the PROMPT, selection of speech sounds to be targeted, is based on developmental speech sounds acquisition rather than motor criteria. According to this treatment approach, the motor goal is usually identified with the placement of the main articulator involved in the production of a speech sound.
62236257|NCT03151317||Without therapeutic education (control)|Patients assigned to this (control) group have not had any kind of therapeutic education.
62236258|NCT04143750|EXPERIMENTAL|[14C]Vicagrel|
62426864|NCT03845322|EXPERIMENTAL|Curcumin pills group|24 Patient will receive Curcumin (CC) pills, within 24 hours post-operatively (as long as they are able to take oral medication). It will then be continued TID
62426865|NCT03845322|PLACEBO_COMPARATOR|Placebo group|24 Patient will receive Placebo pills, within 24 hours post-operatively (as long as they are able to take oral medication. It will then be continued TID.
62426866|NCT00201734|EXPERIMENTAL|Arm I|Patients receive paclitaxel IV over 60 minutes on days 1, 8, and 15, carboplatin IV over 1-2 hours on day 1, and capecitabine PO BID on days 8-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62426867|NCT00509340|NO_INTERVENTION|1|Participants will receive usual clinical care, which may or may not include mental health treatment
62426868|NCT00509340|EXPERIMENTAL|2|Participants will receive cognitive behavioral intervention
62812530|NCT02588599|EXPERIMENTAL|Erchonia LUNULA|The Erchonia LUNULA emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
62812531|NCT02249416|EXPERIMENTAL|TPV/RTV low + ZDV|
62812532|NCT02249416|EXPERIMENTAL|TPV/RTV high + ZDV|
62812533|NCT02343263|NO_INTERVENTION|Control|44 patients will be randomized to receive no topical treatment to their tonsillectomy (or adenotonsillectomy) wound bed as is the current standard of care at our institution. The wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis alone.
62812534|NCT02343263|ACTIVE_COMPARATOR|Fibrin Sealant Alone|44 patients will be randomized to receive application of topical fibrin sealant to their tonsillectomy (or adenotonsillectomy) wound bed to assess the pain reduction benefits of fibrin sealant alone. Prior to application of fibrin sealant, the wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis.
62812535|NCT02343263|EXPERIMENTAL|Bupivacaine-infused Fibrin Sealant|44 patients will be randomized to receive application of topical bupivacaine-infused fibrin sealant to their tonsillectomy (or adenotonsillectomy) wound bed to assess the pain reduction benefits of fibrin sealant alone. Prior to application of fibrin sealant, the wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis.
62812536|NCT03926286|EXPERIMENTAL|FMT for Sjogrens|FMT- active ingredient coming from participant's screening stool
62812537|NCT02285855|EXPERIMENTAL|Stereotactic body Radiotherapy (SBRT) + Metformin|Participants randomized to Metformin treatment receive Metformin for 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Metformin administered at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week. SBRTdelivered per standard of care practice.
62812538|NCT02285855|PLACEBO_COMPARATOR|Stereotactic Body Radiotherapy (SBRT) + Placebo|Participants randomized to placebo treatment 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day. SBRT delivered per standard of care practice.
62812539|NCT02189525||Sports induced concussion|Exposure to sports induced concussion
62812540|NCT02189525||Routine Athletic Exertion|Exposure to routine athletic exertion without sports-induced concussion (non-concussion control)
62812541|NCT01303913||Walking desaturation group|COPD patients that at the end of 6MWT have SO2 nadir \<88-90%
62812542|NCT01303913||Walking No-desaturation group|COPD patients that at the end of 6MWT have SO2 nadir \>88-90%
62812543|NCT06176261|EXPERIMENTAL|Cohort A: Estrogen Receptor Positive HER2-Negative Metastatic Breast Cancer|"24 participants will be enrolled and will complete study procedures as outlined below:~* Baseline visit with optional CSF collection via lumbar puncture and assessments.~* CT or MRI scans every 6 weeks for 24 weeks, then every 9 weeks.~* Cycle 1 Through End of Treatment:~  --Day 1 of 21 day cycle: Predetermined dose of Datopotamab Deruxtecan 1x daily.~* End of Treatment:~  * Follow up every 6 months.~ * Optional CSF collection via lumbar puncture.~ * CT or MRI scans every 12 weeks."
62236259|NCT01748357||Tuberculosis group|Patients with confirmed pulmonary infection with M. tuberculosis. At least 50% of the subjects should be tested before therapy is started. Patients with treatment for tuberculosis \>1 week are excluded.
62236260|NCT01748357||Inflammation group|Patients with another inflammatory disease of the lower respiratory tract, i.e. pneumonia, sarcoid or bronchial carcinoma. This group is required to detect VOC pattern caused by pulmonary inflammation.
62236261|NCT01748357||Healthy group|Healthy subjects without lung disease. These subjects should be recruited from outside the hospital / study site to avoid confounding VOC pattern caused by continuous exposure to the hospital environment.
62236262|NCT00253877|ACTIVE_COMPARATOR|Conserve Plus Hip Resurfacing|Conserve Plus Hip Resurfacing group. Complication rate will be compared between groups.
62236263|NCT00253877|OTHER|Total Hip Replacement|Historical Total Hip Replacement control group of recently published conventional total hip replacement results (Williams, 2002). Complication rate will be compared between groups.
62594891|NCT03800836|EXPERIMENTAL|Arm G1: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Safety Run-In (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
62594892|NCT03800836|EXPERIMENTAL|Arm G2: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Expansion (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
62594893|NCT03800836|EXPERIMENTAL|Arm H: Ipat + Atezo + Pacl|Participants (Cohort 4) will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
62594894|NCT00720512|ACTIVE_COMPARATOR|Arm I|Patients receive either irinotecan hydrochloride over 1 hour or oxaliplatin over 1 hour on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil IV over 46 hours continuously beginning on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62594895|NCT00720512|EXPERIMENTAL|Arm II|Patients receive combination chemotherapy as in arm I and bevacizumab IV on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62426869|NCT05517954||Subjects with TBI and PTE|10 subjects with a history of TBI, diagnosed with PTE (post-traumatic epilepsy). PTE is defined as acquired epilepsy with seizures that developed within ten years of TBI with no other clear cause
62426870|NCT05517954||Subjects with TBI, no PTE|"10 subjects with a history of TBI, and absent epilepsy, but TBI in the past two years and any of the following:~* Multifocal intracerebral hemorrhages (ICH)~* depressed skull fracture~* Subdural hematoma (SDH) requiring surgery~* SDH and ICH~* Penetrating wound"
62426871|NCT05517954||Healthy volunteers|10 healthy volunteers; absent epilepsy or TBI
62426872|NCT04385082|PLACEBO_COMPARATOR|Placebo|Smoked Cannabis (\~0% THC)
62426873|NCT04385082|EXPERIMENTAL|Low strength cannabis|Smoked Cannabis (\~4% THC)
62426874|NCT04385082|EXPERIMENTAL|Higher strength cannabis|Smoked Cannabis (\~10% THC)
62426875|NCT01298154|EXPERIMENTAL|Intact Pea Protein (20 g)|
62426876|NCT01298154|EXPERIMENTAL|Hydrolyzed Pea Protein (20 g)|
62426877|NCT01298154|EXPERIMENTAL|Intact Whey Protein|
62594896|NCT03946683|EXPERIMENTAL|Cyberknife for Early Stage Breast Cancer|Cyberknife Robotic Radiosurgery will be utilized as a 5-fraction post-lumpectomy adjuvant radiation treatment in the management of early stage breast cancer.
62594897|NCT05896462|ACTIVE_COMPARATOR|Povidone iodine (PI) group|10% povidone iodine-soaked gauze dressing was used to cover the apposed skin edge.
62594898|NCT05896462|NO_INTERVENTION|Control (C) group|The apposed skin edge covered with dry sterile gauze
62594899|NCT06667895|EXPERIMENTAL|taVNS|Electrodes will be attached to the outer ear. Electrical stimulation pulses with a width of 250ms will be applied at a frequency of 25Hz. Stimulation intensity will be individually adjusted to be clearly perceived but not painful.
62426878|NCT01298154|EXPERIMENTAL|Hydrolyzed Whey Protein|
62426879|NCT01298154|EXPERIMENTAL|Water|
62426880|NCT01528631|PLACEBO_COMPARATOR|Control Product|200 ml water with 50g of sucrose
62426881|NCT01528631|ACTIVE_COMPARATOR|Product 1|200 ml water with 50g of sucrose and supplemented with 30 mg of D-Fagomine
62426882|NCT01858558|EXPERIMENTAL|aMIL Arm|Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)
62426883|NCT01858558|ACTIVE_COMPARATOR|No aMIL|Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)
62426884|NCT02670200|EXPERIMENTAL|intervention arm / verum arm|Participants can work on ten modules specialized cognitive behavior treatments to learn and deal with mindfulness, acceptance and commitment. They should learn to handle their emotions, to accept the situation and to get in an active future. The participants can direct contact a psychotherapist via email, Chat or Skype/tokbox. The modules based on Cognitive Behavior Therapy.
62426885|NCT02670200|ACTIVE_COMPARATOR|non-intervention arm / control group|Participants can work on six modules with information und education goals for learning something about their possibilities to become a better mood, better psychovegetative or psychosocial situation as cancer patient. This modules are based on Cognitive Behavior Therapy. The non-intervention arm will only allow contact to the platform, no direct contact to a psychotherapist (in opposite to the intervention arm) is available.
62426886|NCT06154915||Healing Ulcer|"The patients will be recruited from the doctors and the nurses of the foot clinic of Department of Endocrinology. A complete medical history and physical parameters will be collected, moreover a peripheral circulation status will assess at the time of the enrolment. During the first visit blood samples and a biopsy from the site of foot ulcers will be taken together with a picture of the ulcer. All patients will follow the medical treatments, as recommended by the multidisciplinary clinical team (for example revascularization or ulcer debriding). Intervals between visits will range between 4 to 8 weeks according to the usual medical routine. During visits 1, 2 and 3 the ulcers status will be documented by pictures, physical parameter collected, biopsies, ulcer fluid and blood samples will be taken for further analysis.~At visit 3 the ulcers will be classified as healing if completely resolved or dramatically reduced (more than 50%), otherwise will be classified as non-healing."
62426887|NCT06154915||Non-Healing Ulcer|"The patients will be recruited from the doctors and the nurses of the foot clinic of Department of Endocrinology. A complete medical history and physical parameters will be collected, moreover a peripheral circulation status will assess at the time of the enrolment. During the first visit blood samples and a biopsy from the site of foot ulcers will be taken together with a picture of the ulcer. All patients will follow the medical treatments, as recommended by the multidisciplinary clinical team (for example revascularization or ulcer debriding). Intervals between visits will range between 4 to 8 weeks according to the usual medical routine. During visits 1, 2 and 3 the ulcers status will be documented by pictures, physical parameter collected, biopsies, ulcer fluid and blood samples will be taken for further analysis.~At visit 3 the ulcers will be classified as non-healing if not resolved or not dramatically reduced (more than 50%)."
62426888|NCT05862519|EXPERIMENTAL|Intervention Group|"Participants will begin taking the Reset supplement for 5 days. Then there will be a 2-day break with no products taken (wash out period).~Participants will then begin taking the following 2 supplements: Stay Ready Fiber and libido with a partial overlap of products.~Stay Ready Fiber will be taken from day 7 through 21, three capsules will be taken twice daily in the morning and afternoon.~Libido will be taken from day 7 through 28, 2 capsules will be taken daily, preferably with a meal.~Participants will then begin taking the Testosterone supplement. Testosterone will be taken from day 28 through to 84, 2 capsules will be taken daily, preferably with a meal."
62426889|NCT01339858|EXPERIMENTAL|N-Acetyl Cysteine|NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 600 mg of NAC. Dosing will begin at 600 mg/d and titrated up over 5 weeks until a maximum dose of 3600 mg/d is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose.
62426890|NCT01339858|PLACEBO_COMPARATOR|Sugar Pill|matched placebo
62426891|NCT01178112|EXPERIMENTAL|Trientine + Carboplatin MTD Group|Trientine starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group.
62426892|NCT01178112|EXPERIMENTAL|MTD Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group
62426893|NCT01178112|EXPERIMENTAL|Carboplatin PK Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group. PK testing blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
62426894|NCT01178112|EXPERIMENTAL|Trientine PK Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group. PK testing blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
62426895|NCT06538103|EXPERIMENTAL|Treatment|Kabat therapy home NMR, and eyelid surgery at 90 days (if lagophthalmos with epiphora or ectropion was present)
62426896|NCT06538103|ACTIVE_COMPARATOR|Control|Kabat therapy and neuromuscular reeducation (NMR) at home
62426897|NCT02119182||Comprehensive Assessment with MRI|"* In-Person Outcome Assessment at 2 weeks, 6 months, and 12 months.~* Phone Outcome Assessment at 3 months.~* 3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months.~* Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only)."
62426898|NCT02119182||Comprehensive Assessment without MRI|"* In-Person Outcome Assessment at 2 weeks, 6 months, and 12 months.~* Phone Outcome Assessment at 3 months.~* Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only)."
62426899|NCT02119182||Brief Assessment|• Telephone outcome assessment at 2 weeks, 3 months, 6 months, and 12 months.
62594900|NCT06667895|SHAM_COMPARATOR|Sham stimulation|Electrodes will be attached to the outer ear at a different position as for the taVNS. Electrical stimulation pulses with a width of 250ms will be applied at a frequency of 25Hz. Stimulation intensity will be individually adjusted to be clearly perceived but not painful.
62812544|NCT06176261|EXPERIMENTAL|Cohort B: Metastatic Triple-Negative Breast Cancer|"24 participants will be enrolled and will complete study procedures as outlined below:~* Baseline visit with optional CSF collection via lumbar puncture and assessments.~* CT or MRI scans every 6 weeks for 24 weeks, then every 9 weeks.~* Cycle 1 Through End of Treatment:~  --Day 1 of 21 day cycle: Predetermined dose of Datopotamab Deruxtecan 1x daily.~* End of Treatment:~  * Follow up every 6 months.~ * Optional CSF collection via lumbar puncture.~ * CT or MRI scans every 12 weeks."
62594901|NCT06619262|EXPERIMENTAL|TENS+NMES Group|The group in which TENS and NMES are applied concomitantly in the treatment
62812545|NCT06176261|EXPERIMENTAL|Cohort C: HER2-Negative Metastatic Breast Cancer (any ER Expression) with Leptomeningeal Metastases|"* Baseline visit with CSF collection via lumbar puncture and assessments.~* CT or MRI scans every 6 weeks for 24 weeks, then every 9 weeks.~* Cycle 1~  --Day 1 of 21 day cycle: Predetermined dose of Datopotamab Deruxtecan 1x daily.~* Cycle 2~  * Day 1 of 21 day cycle: Predetermined dose of Dato-DXd 1x daily.~ * Day 2 of 21 day cycle: CSF collection.~* Cycle 3 Through End of Treatment:~  --Day 1 of 21 day cycle: Predetermined dose of Datopotamab Deruxtecan 1x daily.~* End of Treatment:~  * Follow up every 6 months.~ * Optional CSF collection via lumbar puncture.~ * CT or MRI scans every 12 weeks."
62812546|NCT04742101|EXPERIMENTAL|S65487 with azacitidine|
62812547|NCT03663829||Participants RA who have received a TNFi|
62812548|NCT03663829||Participants with RA who have received abatacept|
62812549|NCT02636699|EXPERIMENTAL|Viaskin Peanut 250mcg|
62426900|NCT05012735|EXPERIMENTAL|Treatment Group: Prototype Ultrathin Hydrocolloid Bandage and Study Cleanser|Participants will wash their faces with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) in the evening prior to bandage application and in the morning after removing the bandage(s) on Days 0 through 7. On Days 7 through 14, no bandages will be worn and participants will wash their faces with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) in the morning and evening. Participants will cover their closed and popped pimples in the evening with 1 or 2 bandages on Days 0 through 6.
62812550|NCT02636699|PLACEBO_COMPARATOR|Placebo|
62426901|NCT05012735|ACTIVE_COMPARATOR|Control Group: Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)|Participants will wash their face twice daily using the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
62594902|NCT06619262|ACTIVE_COMPARATOR|TENS Group|The group in which TENS is applied concomitantly in the treatment
62594903|NCT06619262|ACTIVE_COMPARATOR|NMES Group|The group in which NMES is applied concomitantly in the treatment
62594904|NCT06619262|SHAM_COMPARATOR|Control|No additional electrical stimulation is applied for treatment in this group.
62594905|NCT04748458||Congenital hip pathologies|Conical tapered stem for osteoarthritis due to congenital hip pathologies
62812551|NCT04124939|ACTIVE_COMPARATOR|10 Botox Injections|100 units of Botox® (onabotulinumtoxinA) will be combined with 10 cc of sterile saline for the purpose of 10 injections. The bladder will be instilled with 2% lidocaine solution through a catheter for at least 5 minutes prior to the procedure. Cystoscopy with either a rigid or flexible cystoscope (per surgeon preference) will be performed using sterile technique. The Botox® will be injected in a grid like pattern avoiding the trigone.
62812552|NCT04124939|ACTIVE_COMPARATOR|20 Botox Injections|100 units of Botox® (onabotulinumtoxinA) will be combined with 20 cc of sterile saline for the purpose of 20 injections. The bladder will be instilled with 2% lidocaine solution through a catheter for at least 5 minutes prior to the procedure. Cystoscopy with either a rigid or flexible cystoscope (per surgeon preference) will be performed using sterile technique. The Botox® will be injected in a grid like pattern avoiding the trigone.
62812553|NCT06550375||TECNIS Odyssey IOL|
62812554|NCT01095549|PLACEBO_COMPARATOR|Control group|HD patients who will not receive far infrared therapy in this study.
62426902|NCT04829279|EXPERIMENTAL|Case|Emergency patient transferred by CONNECT AI system
62426903|NCT04829279|NO_INTERVENTION|Control|Emergency patient transferred by conventional EMS
62236264|NCT03693456|EXPERIMENTAL|Responders Without Epinephrine|Subjects experienced a positive response during previous oral food challenge without a severe adverse event and did not require epinephrine. Will be subjected to a conjunctival allergen challenge.
62236265|NCT03693456|EXPERIMENTAL|Responders With Epinephrine|Subjects experienced a positive response during previous oral food challenge and required epinephrine. Will be subjected to a conjunctival allergen challenge.
62236266|NCT03693456|EXPERIMENTAL|Non-Responders|Subjects did not experience a positive response during previous oral food challenge. Will be subjected to a conjunctival allergen challenge.
62236267|NCT04631796|EXPERIMENTAL|LID020098|Lehfilcon A contact lenses worn in both eyes for 2 weeks. Lenses will be removed nightly for cleaning and disinfection.
62236268|NCT06526832|EXPERIMENTAL|BST02|Patients who receive BST02 infusion.
62236269|NCT00872196|OTHER|1 - Follow-up Study|This is a follow-up study with no treatment and only samples being collected.
62236270|NCT06321549||Group A|Individuals who underwent surgery prior to November 2018
62812555|NCT01095549|EXPERIMENTAL|Far infrared therapy|In this study, a WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt\<mw\>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on maintenance HD.
62812556|NCT02325934|ACTIVE_COMPARATOR|Reference|Stribild Standardized breakfast followed by a single dose of STB (whole tablet).
62236271|NCT06321549||Group B|Individuals who underwent surgery after November 2018
62236272|NCT01975454|ACTIVE_COMPARATOR|chemotherapy|Patients receive chemotherapy until disease progression or unacceptable toxicity
62236273|NCT01975454|EXPERIMENTAL|Herbal therapy plus chemotherapy|Patients receive herbal therapy plus chemotherapy until disease progression or unacceptable toxicity
62236274|NCT04134364|NO_INTERVENTION|control|no medication after gastric biopsy
62236275|NCT04134364|EXPERIMENTAL|treatment|oral administration of sodium alginate (LaminaG) after gastric biopsy
62236276|NCT04743479||New Onset Diabetes|"New Onset Diabetes must meet one of the following criteria:~1. Documented diabetes diagnosed within the past 3 years.~2. Definite new-onset diabetes based on recent fasting blood glucose (FBG) values ≥126 mg/dl (7.0 mmol/L) or Hemoglobin A1c (HbA1c) ≥ 6.5%. All glycemic parameters must be measured in an outpatient setting."
62236277|NCT04743479||Familial pancreatic cancer|"Familial pancreatic cancer must meet one of the following criteria:~1. ≥ 2 blood relatives with pancreatic cancer (includes 1st-3rd degree relatives)~2. One 1st degree relative with PDAC diagnosed before age 60"
62236278|NCT04743479||Inherited syndromes associated with pancreatic cancer|"Family history includes with inherited syndromes associated with pancreatic cancer ( ≥ 2 blood relative, includes 1st-3rd degree relatives).~Inherited syndromes must meet one of the following criteria:~1. Hereditary pancreatitis~2. Familial atypical multiple mole and melanoma syndrome~3. Hereditary nonpolyposis colon cancer~4. Peutz-Jeghers syndrome~5. Hereditary breast and ovarian cancer syndromes"
62236279|NCT04743479||Pancreatic Cystic Neoplasm|Pancreatic Cystic Neoplasm, including intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN), which are defined by endoscopic ultrasound or serial imaging.
62426904|NCT01252836|PLACEBO_COMPARATOR|Control|Treatment with Tegaderm
62812557|NCT02325934|EXPERIMENTAL|Intervention I|Stribild, crushed Standardized breakfast followed by a single dose of crushed and suspended STB.
62812558|NCT02325934|EXPERIMENTAL|Intervention II|Stribild, crushed 350 mL of drip feed (type) followed by a single dose of crushed and suspended STB.
62812559|NCT02386020|PLACEBO_COMPARATOR|Placebo|After SRP, placebo gel was delivered subgingivally into periodontal pockets.
62812560|NCT02386020|ACTIVE_COMPARATOR|Aloe vera|After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.
62812561|NCT04055064|EXPERIMENTAL|Intervention|patients received nutrition education and nutritional supplements
62812562|NCT04055064|NO_INTERVENTION|Control|patients did not receive any intervention
62812563|NCT06706479|EXPERIMENTAL|Active stimulation|For the active stimulation, the current will be ramped up from 0 to 2 mA over the initial 30-s period and then maintain the current of 2 mA for 20 minutes, following by a 30-s ramp-down period.
62236280|NCT04743479||Chronic pancreatitis|Chronic pancreatitis, defined by cross-sectional imaging, endoscopic ultrasound, functional testing abnormalities OR as diagnosed by a gastroenterologist.
62236281|NCT00846339|EXPERIMENTAL|1|DRD2 Taq1A1 allele
62812564|NCT06706479|EXPERIMENTAL|Sham stimulation|The participants will receive the same intervention procedures, but the intervention will have no therapeutic effect. Specifically, for the sham stimulation, participants will only experience 30-s ramp-up and 30-s ramp-down periods at both the commencement and end of the stimulation.
62812565|NCT00974142|EXPERIMENTAL|Cyclosporine|
62812566|NCT00974142|PLACEBO_COMPARATOR|Placebo|
62812567|NCT03772899|EXPERIMENTAL|Study Intervention|Fecal Microbial Transplantation - all patients registered on study will receive one dose (80-100mg) of FMT. This is a single arm, unblinded study.
62812568|NCT03850353||OSAS|Patients with Obstructive Sleep Apnea (AHI\>15 in a sleep study)
62236282|NCT00846339|EXPERIMENTAL|2|DRD Taq1 A2 homozygote2
62426905|NCT01252836|EXPERIMENTAL|AWBAT-D|Application of AWBAT-D on donor site.
62426906|NCT02615873|EXPERIMENTAL|AP CD/LD|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
62426907|NCT06428006|EXPERIMENTAL|Cognitive behavioral therapy for insomnia|1x/week, 6-week 45-60 min one-one-one manualized program via video conferencing (HIPAA-compliant Zoom) with a trained research assistant that includes time in bed restriction, stimulus control, relaxation strategies, cognitive restructuring, and sleep health promotion education.
62594906|NCT06620796|EXPERIMENTAL|Arm1|Ivonescimab (20 mg/kg, IV, every 3 weeks) plus platinum-based chemotherapy (carboplatin \[area under the curve (AUC) 5 mg/mL per min, IV\] and etoposide \[100 mg/m2, IV, D1-D3\] for ES-SCLC) for up to four cycles, followed by maintenance therapy with cadonilimab (10 mg/kg, IV, every 6 weeks, D2) and Ivonescimab (20 mg/kg, IV, every 3 weeks, D1) .
62236283|NCT04729764|EXPERIMENTAL|GP681 Tablet 20mg|Two sentinel subjects were first enrolled in the trial (test drug: placebo=1:1). After the two sentinel subjects completed the 72h safety follow-up after the administration, it was judged that if there was no dose-limiting toxicity , Then start the trial of the remaining 6 subjects in the dose group (experimental drug: placebo = 5:1).
62594907|NCT06620796|EXPERIMENTAL|Arm2|Cadonilimab (10 mg/kg, IV, every 6 weeks, D2) and Ivonescimab (20 mg/kg, IV, every 3 weeks, D1) plus paclitaxel \[260 mg/m2, IV, D1\].
62236284|NCT04729764|EXPERIMENTAL|GP681 Tablet 40mg|10 subjects in 40mg group (including 2 placebo)
62594908|NCT06623955||Group 1 (Control)|This group consists of pregnant women who do not have pre-eclampsia or severe pre-eclampsia. These participants will be matched to the case group based on relevant characteristics such as age, gestational age, and other demographic factors.
62812569|NCT03850353||Dizziness|Patients with Dizziness (defined as a non-spinning sensation, without illusion of movement)
62812570|NCT03850353||No OSAS No Dizziness|Patients without dizziness and no evidence for OSAS (subjects referred for the ENT or the Sleep clinic with no dizziness and no evidence of OSAS )
62236285|NCT04729764|EXPERIMENTAL|GP681 Tablet 60mg|10 subjects in 60mg group (including 2 placebo)
62236286|NCT04729764|EXPERIMENTAL|GP681 Tablet 80mg|10 subjects in 80mg group (including 2 placebo)
62236287|NCT04729764|EXPERIMENTAL|GP681 Tablet 120mg|10 subjects in 120mg group (including 2 placebo)
62594909|NCT06623955||Group 2 (Case - Pre-eclampsia)|This group consists of pregnant women diagnosed with pre-eclampsia and severe preeclampsia.
62594910|NCT04679636|EXPERIMENTAL|Experimental group|receive biofeedback training for heart rate variability for eight weeks
62594911|NCT04679636|NO_INTERVENTION|Control group|receive conventional treatment
62735502|NCT04320212|ACTIVE_COMPARATOR|lumber epidural analgesia|: the patient will be placed in the lateral position, Lidocaine will be given using 5 ml syringe and a 18 G Tuohy needle will be introduced in the epidural space, using the ultrasound, under strict aseptic precautions. The ultrasound probe will be placed 90 degrees into transverse orientation and slided cephalad or caudad to obtain the transverse interspinous view (TI view) 2 levels above the operation level. patient will receive 20 ml of 0.25% plain bupivacaine after negative aspiration for blood or cerebrospinal fluid. Then, the patient will be placed in prone position to start the surgical procedure
62812571|NCT03260881|ACTIVE_COMPARATOR|L-group|• L-group will be started on liraglutide. Liraglutide will be started and administered for from a minimum of 4 weeks up to 12 weeks prior to CABG with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). The dose of 1.8 mg daily will be maintained until the end of the 12-week study. Other and current diabetes treatment will be continued
62812572|NCT03260881|PLACEBO_COMPARATOR|D-group|placebo will be administered in addition to current treatment prior to the CABG with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). D-group will be started on a supervised low calorie diet (LCD) to achieve approximately 5% of weight loss after from a minimum of 4 weeks up to 12 weeks.
62812573|NCT02144181|ACTIVE_COMPARATOR|Group A|Subjects will receive two low-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive one low-density Ulthera System Treatment.
62236288|NCT03812497|EXPERIMENTAL|Obese Children Group|To reduce the weight, every obese children will receive individualized education program about a way of dietary control and exercise in their usual life. This individualized education program, developed by investigators, specialized dietitian and exercise teacher, is scheduled once a month.
62735503|NCT04320212|ACTIVE_COMPARATOR|erector spinae analgesia|the patient will be placed in the prone position. Then, the Erector Spinae block will be given by a high-frequency linear ultrasound transducer. The Erector Spinae muscle and transverse process will be then identified, and a 18 G Tuohy needle will be advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. The block will be performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side)
62735504|NCT05026840||IADPSG|
62735505|NCT05026840||WHO '99|
62812574|NCT02144181|ACTIVE_COMPARATOR|Group B|Subjects will receive three low-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive two low-density Ulthera System Treatments.
62812575|NCT02144181|ACTIVE_COMPARATOR|Group C|Subjects will receive two high-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive one high-density Ulthera System Treatment.
62236289|NCT03812497|NO_INTERVENTION|Normal Weight Children Group|Normal weight children
62236290|NCT00509587|EXPERIMENTAL|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62236291|NCT01626703|EXPERIMENTAL|intervention|remiding call
62236292|NCT01626703|NO_INTERVENTION|Control|No intervention
62236293|NCT05608902||DOCTOBA cohort|Patients \> 18 years of age with suspected basal cell carcinoma requiring biopsy or skin resection in the dermatology department
62812576|NCT02144181|ACTIVE_COMPARATOR|Group D|Subjects will receive three high-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive two high-density Ulthera System Treatments.
62812577|NCT04070781|EXPERIMENTAL|Itacitinib + Tocilizumab|"A dose de-escalation design will be used to identify the MTD of both itacitinib and tocilizumab when given in combination. The following two levels will be tested with at least 6 patients per dose:~* Dose level 1: Itacitinib 200 mg daily + tocilizumab 8mg/kg on cycle 1, day 1 (can repeat cycle 2 day 1 if Partial Response (PR) - Starting dose level~* Dose level -1: Itacitinib 200 mg daily + tocilizumab 4mg/kg on cycle 1, day 1 (can repeat cycle 2 day 1 if Partial Response (PR) - Dose De-escalation level~Itacitinib will be given daily in 28-day long cycles, tocilizumab will be given every 4 weeks in 28-day cycles."
62812578|NCT04070781|EXPERIMENTAL|Dose Expansion|Once the MTD is determined, an additional 10 patients as an expansion cohort to further define the safety profile of the combination and estimate its response rate.
62812579|NCT03383601||Users of IQOS with HeatStick|Individuals (men and women) between the ages of 40 and 59 (inclusive) with a minimum of 10 pack-year smoking history who switched to and predominantly (\>70%) use Heated Tobacco product IQOS/heatstick
62812580|NCT03383601||Smokers of combustible cigarettes|Individuals (men and women) between the ages of 40 and 59 (inclusive) who are currently smoking combustible cigarettes with a minimum of 10 pack-year smoking history
62812581|NCT01442246|EXPERIMENTAL|Adjuvant treatment|Leuproreline acetate
62812582|NCT01442246|NO_INTERVENTION|Surveillance|Surveillance
62035478|NCT03593655|EXPERIMENTAL|Sequence A: Dapivirine vaginal ring + FTC/TDF|Participants will receive one 25 mg dapivirine vaginal ring inserted vaginally each month for 24 weeks, followed by one FTC/TDF oral tablet taken by mouth daily for 24 weeks, followed by participant's choice of either or neither study product for 24 weeks.
62035479|NCT03593655|EXPERIMENTAL|Sequence B: FTC/TDF + Dapivirine vaginal ring|Participants will receive one FTC/TDF oral tablet taken by mouth daily for 24 weeks, followed by one 25 mg dapivirine vaginal ring inserted vaginally each month for 24 weeks, followed by participant's choice of either or neither study product for 24 weeks.
62035480|NCT03194802|EXPERIMENTAL|Sleeping Without Pills Program|Cognitive behavioral therapy; Motivational Interviewing; Scheduled and gradual drug tapering
62236294|NCT05803590|ACTIVE_COMPARATOR|Green Tea Mouthwash ( intervention )|"Green tea (GT), obtained from the extracts of a small plant, Camelia sinesis, is common worldwide. It is rich in flavonoids such as catechins and various other polyphenols, contributing to its antioxidant and anti-inflammatory properties. Green tea consumption is also associated with lower incidences of diabetes, cardiovascular disease, and obesity. Moreover, its antibacterial property aids in the reduction of bacterial colonization and thereby prevents oral diseases such as gingivitis, periodontal diseases, dental caries, and malodor .~When used as a mouthwash, green tea preparations can obliterate bad breath by suppressing anaerobic bacteria and eradicating the production of volatile sulfur compounds. There is a lack of critically appraised summaries on the efficacy of green tea mouthwash for promoting dental hygiene ."
62426908|NCT06428006|ACTIVE_COMPARATOR|Sleep and lifestyle education|1x/week, 6 weekly 45-60 min one-on-one program via video conferencing (HIPAA-compliant Zoom) with a trained research assistant that includes gentle stretching activities for major muscle groups accompanied by sleep and lifestyle education.
62035481|NCT03194802|ACTIVE_COMPARATOR|Self-Monitoring|Daily Self-monitoring of sleep and sleep medication using sleep diary
62035482|NCT01953081|EXPERIMENTAL|TD-8954|TD-8954 single infusion for 1 hour and 4 injections of saline every 6 hours
62236295|NCT05803590|EXPERIMENTAL|Chlorhexidine Mouthwash ( control )|Chlorhexidine was developed in 1950 and is the most used anti-plaque agent. However, the long-term usage of chlorhexidine (CHX) is limited by altered taste perception and tooth staining with prolonged usage. Though CHX has been the gold standard mouthwash in controlling plaque formation, its undesirable side effects, such as the enhanced ability of calculus formation, bitter taste, and interference with taste, have inspired a search for alternatives
62236296|NCT04720222|EXPERIMENTAL|TENA-PROTO1|Investigational device. Early prototype
62236297|NCT06087016||Bladder cancer group|Bladder cancer group represents patients attending or hospitalized in Urology department, Reims University Hospital and in whom, tumor is visualized during cystoscopy and confirmed by the histological examination of entire resected lesion after Trans Urethral Resection of Bladder Tumor (TURBT).
62426909|NCT01335399|ACTIVE_COMPARATOR|Lenalidomide + Dexamethasone|
62426910|NCT01335399|EXPERIMENTAL|Lenalidomide + Dexamethasone + Elotuzumab|
62812583|NCT00402857|EXPERIMENTAL|1|Participants will receive the Incredible Years Program, a group parenting intervention
62812584|NCT00402857|OTHER|2|Participants assigned to the waitlist condition will receive the Incredible Years Program after a 1-year waiting period
62035483|NCT01953081|ACTIVE_COMPARATOR|Metoclopramide|Metoclopramide 4 doses every 6 hours for 24 hours and 1 hour infusion of saline
62035484|NCT03521960|ACTIVE_COMPARATOR|Buspirone oral capsule|Buspirone (15 milligrams) administered orally three times per day
62035485|NCT03521960|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo administered orally three times per day
62236298|NCT06087016||Control group|Control group includes patients consulting for cystoscopy examination in Urology department, Reims University Hospital without any tumor visualization during cystoscopy examination.
62594912|NCT05220462|EXPERIMENTAL|Remimazolam|"White to off-white lyophilised powder, presented in a 12 mL clear glass vial with a grey bromobutyl stopper, fitted with an aluminium crimp and a blue plastic flip-off cap. Each 20 mg vial of remimazolam, will be reconstituted with sterile 0.9% NaCl solution to yield a 2.5 mg/mL solution for injection.~An initial dose of 5mg (2mL) over 60 seconds, pausing for 90 seconds, followed by 2.5mg (1mL) over 30 seconds and waiting 30 seconds will be titrated to response end point. Subsequent doses of 2.5mg (1 mL) increments can be administered if required should the procedure take longer, or the patient recover more quickly than expected, to maintain the sedation level. Top-up doses will be administered slowly, at least 2 minutes apart. Top-up doses will be limited to a maximum of 5 doses in a 15-minute window. Additionally, a maximum dose of 40mg of remimazolam (16mL) will be set."
62594913|NCT05220462|ACTIVE_COMPARATOR|Midazolam|"Midazolam will be presented as a solution in a 5 mL ampoule. Each ampoule will contain 5 mg of midazolam, yielding a 1 mg/mL solution for injection.~Dosing of midazolam was based on local formulary and standard of care / local guidance. An initial dose of 2mg (2mL) over 60 seconds, pausing for 90 seconds, followed by 1mg (1mL) over 30 seconds and waiting 30 seconds will be titrated to response end point. Subsequent doses of 1mg (1 mL) increments can be administered if required should the procedure take longer, or the patient recover more quickly than expected, to maintain the sedation level. Top-up doses will be administered slowly at least 2 minutes apart. Top-up doses will be limited to a maximum of 5 doses in a 15-minute window. Additionally, a maximum of dose of 16mg of midazolam (16mL) will be set."
62594914|NCT05761210||cases; subjects with steatosis|
62594915|NCT05761210||controls; subjects without steatosis|
62594916|NCT06537076|EXPERIMENTAL|Experimental|AR1005 50 mg BID will be administered with rivastigmine 3 mg BID for 20 weeks.
62594917|NCT06537076|PLACEBO_COMPARATOR|Placebo|Placebo BID will be administered with rivastigmine 3 mg BID for 20 weeks.
62594918|NCT01785719|EXPERIMENTAL|Overweight Women|Regardless of reproductive history, each participant will be provided with six months of the commercial weight loss program, Nutrisystem® D. Nutrisystem® D is a portion-controlled, low calorie, and low glycemic index meal delivery system that provides 1250-1500 kcal/day. It has been proven to help overweight adults achieve real and sustainable weight loss results. When meals and snacks are consumed as instructed, average weight loss is 1-2 lbs per week or 15-20% body weight by the end of six months. Nutrisystem® D offers a balanced meal plan that is consistent with the nutrition recommendations of the USDA for Americans and American Diabetes Association. Each participant will be encouraged to take a daily multivitamin to help meet her micronutrient needs on the program.
62594919|NCT06265701|EXPERIMENTAL|Derailment-Focused Reflective Journaling Condition|Participants will be tasked with engaging in a 5-session journaling intervention where participants reflect on core aspects about their (participants') selves within traditional developmental stages (e.g., first semester in college, early childhood, etc.).
62594920|NCT06265701|PLACEBO_COMPARATOR|Everyday Tasks Reflective Journaling Condition|Participants will be tasked with engaging in a 5-session journaling intervention where they (participants) reflect on everyday tasks (e.g., their last trip to the grocery store, the last movie they saw, etc.).
62594921|NCT06647719|NO_INTERVENTION|Standard of Care|In-person group will be followed with standard -of-care postoperative clinic visits with a hand \& upper extremity orthopaedic surgeon at Carilion Clinic Institute for Orthopaedics and Neurosciences at 2 weeks and 6 weeks from date of service.
62594922|NCT06647719|EXPERIMENTAL|Video Management|Postoperative education will be provided with 3 short videos that will be accessible to patients on all social media platforms and through MyChart with no scheduled in person postoperative visits. Patients will have a one time visit with either nurse or orthopaedic technician for suture removal 10-14 days from surgery if the participant has nonabsorbable sutures placed during surgery.
62594923|NCT03891862|EXPERIMENTAL|Open-label Valbenazine|Participants received valbenazine 40 mg once daily for 1 week, then 80 mg once daily for the remainder of the 8-week open label period.
62594924|NCT03891862|PLACEBO_COMPARATOR|Placebo-controlled Placebo|Participants received placebo (matching valbenazine) once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.
62594925|NCT03891862|EXPERIMENTAL|Placebo-controlled Valbenazine|Participants received valbenazine 80 mg once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.
62035486|NCT06182995|ACTIVE_COMPARATOR|Usual Care|routine clinic visits
62035487|NCT06182995|EXPERIMENTAL|Anticipating Decline and Providing Therapy (ADAPT) care|The program includes a routine validated cognitive screen for high-risk older adults at 6 weeks and 6 months post-ICU discharge
62236299|NCT03699436|EXPERIMENTAL|Electric Stimulation Therapy Group|The experimental group will receive an electrotherapy treatment with galvanic current in their hands. Electrotherapy with galvanic current has vasodilator action.
62035488|NCT02327026|EXPERIMENTAL|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative
62236300|NCT03699436|ACTIVE_COMPARATOR|Control Group|The control group will be subjected to a conservative treatment. These patients will continue to take their usual medication and will not receive electrotherapy treatment
62594926|NCT02210247|ACTIVE_COMPARATOR|Cohort 1|Cohort 1 will receive a single dose of EXPAREL 266 mg on Day 1. No additional dose will be given.
62812585|NCT05963334|EXPERIMENTAL|Weekly dose of carboplatin / paclitaxel (n=21)|Patients in this group received the weekly dose regimen, where the dose of carboplatin administered intravenously once/week was calculated using the Calvert equation to yield an area under the curve (AUC) = 2
62236301|NCT05627713|OTHER|Individuals coming to CMIP for MONKEYPOX disease management|"* 300 individuals eligible for MPXV vaccination and~* 30 individuals suspected of MPXV infection."
62594927|NCT02210247|ACTIVE_COMPARATOR|Cohort 2|Cohort 2 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 4 at 72 hours.
62594928|NCT02210247|ACTIVE_COMPARATOR|Cohort 3|Cohort 3 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 3 at 48 hours.
62812586|NCT05963334|ACTIVE_COMPARATOR|3-Week collective dense dose of carboplatin / paclitaxel (n=28)|Patients in this group received the three-week collective dose regimen, where the dose of carboplatin was administered intravenously once on day 1/ every three weeks (21 days) and was calculated using the Calvert equation to yield an AUC = 6
62812587|NCT01404507|ACTIVE_COMPARATOR|Intracoronary abciximab|Intracoronary injection of bolus abciximab
62812588|NCT01404507|ACTIVE_COMPARATOR|Aspiration thrombectomy|Aspiration thrombectomy
62812589|NCT01404507|ACTIVE_COMPARATOR|Both use|Both use of intracoronary injection of bolus abciximab and aspiration thrombectomy
62812590|NCT05824650||Frail Congenital Heart Disease Group|Frailty Fried et al. will be evaluated according to the five-parameter criteria set in the Cardiovascular Health Study by Having 3 or more parameters positive is defined as fragility. Individuals who meet this criterion will be included in this group.
62812591|NCT05824650||Non-frail Congenital Heart Disease Group|Frailty Fried et al. will be evaluated according to the five-parameter criteria set in the Cardiovascular Health Study by Having 3 or more parameters positive is defined as fragility. Individuals who do not meet this criterion will be included in this group.
62594929|NCT02210247|ACTIVE_COMPARATOR|Cohort 4|Cohort 4 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 2 at 24 hours.
62594930|NCT02210247|ACTIVE_COMPARATOR|Cohort 5|Cohort 5 will receive a single dose of EXPAREL 266 mg on Day 1 followed immediately by a second dose of EXPAREL 266 mg (total of 532 mg/40 mL).
62594931|NCT05892718|EXPERIMENTAL|HCB101|"HCB101 in subjects with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.~Dosage levels: 0.08 mg/kg, 0.16 mg/kg, 0.32 mg/kg, 0.64 mg/kg, 1.28 mg/kg, 2.56 mg/kg, and 5.12 mg/kg sequentially."
62812592|NCT01944137|NO_INTERVENTION|Standard Care|Participant will receive standard cancer care
62812593|NCT01944137|EXPERIMENTAL|Nursing Intervention|Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy
62236302|NCT04576143|ACTIVE_COMPARATOR|epirubicin/CTX × 4 - docetaxel × 4, every 3 weeks a cycle|Cycle 1-4: Epirubicin i.v. 90 mg/m2, Cyclophosphamide i.v. 600 mg/m2 (One cycle = 21 days); Cycle 5-8: Docetaxel i.v. 100mg/m2 (One cycle = 21 days) .
62426911|NCT01213719|EXPERIMENTAL|creatine|will receive creatine monohydrate (20g/d) throughout 10 days
62594932|NCT01775358|EXPERIMENTAL|ALRN-5281 0.015 mg/kg|Dosage-0.015 mg/kg
62594933|NCT01775358|EXPERIMENTAL|ALRN-5281 0.05 mg/kg|Dosage- 0.05 mg/kg
62594934|NCT01775358|EXPERIMENTAL|ALRN-5281 0.15 mg/kg|Dosage- 0.15 mg/kg
62594935|NCT01775358|PLACEBO_COMPARATOR|Placebo 0.015 mg/kg|Dosage- 0.015 mg/kg
62594936|NCT01775358|PLACEBO_COMPARATOR|Placebo 0.05 mg/kg|Dosage- 0.05 mg/kg
62812594|NCT04741581|OTHER|Thicken up|Assess the effect of ThickenUp® Gel Express at increasing viscosities (slightly thick, nectar, honey, and pudding) on swallowing function compared to water using VFS (N=100), in patients affected by Oropharyngeal dysphagia (OD).
62426912|NCT01213719|EXPERIMENTAL|betaine|will receive betaine (2g/d) throughout 10 days
62426913|NCT01213719|PLACEBO_COMPARATOR|placebo (dextrose)|will receive dextrose(20g/d)throughout 10 days.
62594937|NCT01775358|PLACEBO_COMPARATOR|Placebo 0.15 mg/kg|Dosage - 0.15 mg/kg
62594938|NCT05749770||COVID-19|Patients affected with SARs-CoV-2 infection and hospitalized in the COVID wards of Auxologico
62594939|NCT05749770||CONTROLS|440 NON-COVID subjects collected retrospectively at other collaborating centers) University of Siena, Campus Biomedico Rome, University of Catania, San Giovanni Rotondo)
62735506|NCT03414203|ACTIVE_COMPARATOR|active tDCS|Active tDCS for 15 minutes for 10 days over 2 weeks. Intensity: 2 milliampere. Placement: anode - left DLPFC; cathode - right supraorbital region
62035489|NCT02327026|ACTIVE_COMPARATOR|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management.
62035490|NCT04021953|EXPERIMENTAL|Intervention Group|"The online intervention comprises a series of six videos, each about 10-minutes in length, entitled the People Like Us series. The intervention was developed by gayhealth.sg and Action for AIDS Singapore in 2018. The series follow the love and sex lives of four ethnically-diverse GBQ men of varying socioeconomic backgrounds, as they negotiate issues of sexual health, mental health, and relationships throughout the six-part miniseries.~The intervention group will also be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention."
62236303|NCT04576143|EXPERIMENTAL|epirubicin/CTX × 4 - paclitaxel × 4, every 2 weeks a cycle|Cycle 1-4: Epirubicin i.v. 90 mg/m2, Cyclophosphamide i.v. 600 mg/m2 (One cycle = 14 days); Cycle 5-8:Paclitaxel i.v. 175mg/m2 (One cycle = 14 days) .
62594940|NCT03108170|ACTIVE_COMPARATOR|3 programs group|The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her duo date
62236304|NCT02823756|EXPERIMENTAL|Physical Therapy|Treatment arm: manipulation, exercise, and education
62236305|NCT03722056||gastric GIST|patients with suspected gastric GIST with size \> 2cm are subjected for laparoscopic resection.
62594941|NCT03108170|ACTIVE_COMPARATOR|one program group|The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her duo date.
62594942|NCT03403751|EXPERIMENTAL|Reltecimod 0.5 mg/kg|Single IV infusion of Reltecimod 0.5 mg/kg
62594943|NCT03403751|PLACEBO_COMPARATOR|Placebo|Single IV infusion of 0.9% Sodium Chloride Injection (Normal Saline)
62594944|NCT01328899|EXPERIMENTAL|Lung Volume Reduction Coil (LVRC)|Lung Volume Reduction Coil (LVRC)
62594945|NCT03706885|PLACEBO_COMPARATOR|Placebo|Treatment with placebo - 1 pill per day for 20 weeks
62594946|NCT03706885|ACTIVE_COMPARATOR|Sustiva 50mg|Treatment with Sustiva 50mg - 1 pill per day for 20 weeks
62594947|NCT03706885|ACTIVE_COMPARATOR|Sustiva 200mg|Treatment with Sustiva 200mg - 1 pill per day for 20 weeks
62594948|NCT00375050|EXPERIMENTAL|Riluzole|
62594949|NCT00375050|PLACEBO_COMPARATOR|Placebo|
62594950|NCT02704520|OTHER|Control arm|Management according to national guidelines - conventional MDT, clinical assessment post-treatment planning
62594951|NCT02704520|EXPERIMENTAL|Intervention arm|mrTRG directed management 'Good response' (mrTRG 1\&2) - deferral of surgery (watch \& wait) offered. 'Poor response' (mrTRG 3-5) - local colorectal MDT is informed and uses information to discuss and agree next steps in treatment and surveillance.
62594952|NCT03902717||minimally invasive cardiac surgery|Group of patients that will undergo minimally invasive cardiac surgery
62594953|NCT01685489|EXPERIMENTAL|Docetaxel, PSK®|A 21-day lead-in oral PSK alone is followed by the addition of standard intravenous docetaxel at 75 mg/m2 evey 3 weeks for three cycles. After the third dose of docetaxel, study drug will be discontinued on day 14 to allow for a 7-day washout period before a fourth dose of docetaxel is administered.
62594954|NCT01685489|PLACEBO_COMPARATOR|Docetaxel, Placebo|A 21-day lead-in oral placebo alone is followed by the addition of standard intravenous docetaxel at 75 mg/m2 every 3 weeks for three cycles. After the third dose of docetaxel, the placebo will be discontinued on day 14 to allow for a 7-day washout period before a fourth dose of docetaxel is administered.
62594955|NCT04495504|EXPERIMENTAL|Ropivacaine group|Administration of a bolus dose of ropivacaine, followed by a continuous infusion of ropivacaine during the first 48 hours postoperatively.
62594956|NCT02721524|ACTIVE_COMPARATOR|Group R (ring)|Patients in Group R will undergo tricuspid ring annuloplasty
62594957|NCT02721524|ACTIVE_COMPARATOR|Group S (suture)|Patients in Group S will undergo De Vega's suture annuloplasty
62594958|NCT04186702|ACTIVE_COMPARATOR|visual acuity letter score|visual acuity letter score is used to compare between the two groups after interventional procedures
62594959|NCT04186702|ACTIVE_COMPARATOR|macular thickness(CST)|macular thickness(CST)is used to compare between the two groups after interventional procedures
62594960|NCT00129727|EXPERIMENTAL|Phase II|Paclitaxel carboplatin bevacizumab
62594961|NCT06358209|NO_INTERVENTION|Control group|"Conventional treatments for ventriculitis, including: external ventricular drainage or lumbar cistern drainage for continuous drainage, systemic and intrathecal antibiotics along with other supportive care. The treatment plan, including the type, dosage, and duration of antibiotics, follows guidelines 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis."
62594962|NCT06358209|EXPERIMENTAL|Ventricular irrigation group|Intervention group employs dual-catheter ventricular irrigation, with the lavage catheter placed in the frontal horn of lateral ventricle, and the drainage catheter placed through another burr hole in the ipsilateral occipital horn or in the contralateral ventricle. Lavage is performed twice daily, with each time 500ml of saline over a duration of one hour. Aside from lavage sessions, the lavage is paused, but continuous CSF drainage remains open. Additional treatments, including the administration of antibiotics, are consistent with those in the control group.
62236306|NCT05821751|EXPERIMENTAL|Arm A|Pembrolizumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
62426914|NCT01213719|ACTIVE_COMPARATOR|creatine plus betaine|will receive creatine (20g/d) plus betaine (2g/d) throughout 10 days
62426915|NCT06568198|EXPERIMENTAL|real tACS|
62426916|NCT06568198|SHAM_COMPARATOR|Sham tACS|
62426917|NCT01602198|ACTIVE_COMPARATOR|Exelon transdermal patch|Exelon \[rivastigmine\] transdermal patch
62594963|NCT06622759|OTHER|No Graft|In the control group, the implant will be placed without any kind of soft tissue graft. Also, it will be placed at the level of the bone and the flaps will be sutured with 5/0 absorbable sutures.
62594964|NCT06622759|EXPERIMENTAL|CTG|In the first experimental group, prosthetically guided implant placement will be performed as well as an increase of the soft tissue volume with an autologous Connective Tissue Graft (CTG). The implant will be placed up to the level of the bone. The autologous graft will be harvested either from the palate as a free gingival graft or as a subepithelial graft, or from the maxillary cusps. The graft will be immobilized in the buccal flap with two simple interrupted sutures and 5/0 absorbable sutures covering the buccal and coronal surfaces of the alveoral bone. Finally, the flap will be displaced coronally so that we have closure in the first place.
62426918|NCT01602198|PLACEBO_COMPARATOR|Placebo transdermal patch|Placebo transdermal patch
62594965|NCT06622759|EXPERIMENTAL|Collagen Matrix|In the second experimental group, prosthetically guided implant placement and simultaneous soft tissue volume augmentation with porcine Collagen Matrix (CM) - Geistlich FibroGide - will be performed. Initially, full-thickness flap will be raised mainly buccally but also palatally. The implant will then be placed at the level of the bone. The flap will buccally become partial thickness and full thickness again so that we can move it coronally to cover and perfuse the graft. The collagenous graft will be shaped to fit the surgical site, be covered by the periosteum, and will completely cover the buccal bone. Also, it should expand coronal to the alveoral crest. Two horizontal matress sutures (P.G.A 5/0 absorbable) will immobilize the graft. Finally, the buccal flap will be displaced coronally, so that we have convergence in the first place.
62594966|NCT01603745|ACTIVE_COMPARATOR|NOMAC-valerate estradiol|E/P therapy
62594967|NCT01603745|ACTIVE_COMPARATOR|Drospirenone/ethinylestradiol|E/P therapy
62735507|NCT03414203|EXPERIMENTAL|active tDCS with interval|Active tDCS for 15 minutes, interval of 20 minutes and more 15 minutes for 10 days over 2 weeks. Intensity: 2 milliampere. Placement: anode - left DLPFC; cathode - right supraorbital region
62735508|NCT03414203|SHAM_COMPARATOR|sham tDCS|Sham tDCS for 15 minutes for 10 days over 2 weeks. The stimulation is non-active. Placement: anode - left DLPFC; cathode - right supraorbital region
62236307|NCT05821751|EXPERIMENTAL|Arm B|Nivolumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
62236308|NCT04175002||Anovulatory PCOS women with a BMI greater than 27|
62735509|NCT02534025|EXPERIMENTAL|P group|Elevation of Cuff pressure to 200 mm Hg for 5 minutes four times 5 minutes apart
62236309|NCT04175002||Anovulatory PCOS women with a BMI lower than 25|
62236310|NCT04175002||Healthy fertile women with a BMI greater than 27|
62236311|NCT04175002||Healthy fertile women with a BMI lower than 25|
62236312|NCT02183532|EXPERIMENTAL|BI 1356 BS|
62236313|NCT02045654||MDS patients|MDS patients who were treated with decitabine
62426919|NCT01784419|EXPERIMENTAL|ivacaftor-placebo|The ivacaftor-placebo arm receives a 2 week course of ivacaftor 150 mg twice daily followed by a 2 week washout period followed by a 2 week placebo course.
62426920|NCT01784419|EXPERIMENTAL|placebo-ivacaftor|The placebo-ivacaftor arm receives a 2 week placebo course followed by a 2 week washout period followed by a 2 week course of ivacaftor 150 mg twice daily.
62426921|NCT01463566||1 - Gender Natural Knee|Patients suffering from severe knee pain and disability.
62426922|NCT03012620|EXPERIMENTAL|Pembrolizumab|Pembrolizumab 200 mg IV as a 30 minute infusion on Day 1 of every 21 day cycle
62426923|NCT03886428|EXPERIMENTAL|100% Portion Size|Test meal with portion size 100% of baseline
62426924|NCT03886428|EXPERIMENTAL|125% Portion Size|Test meal with portion size 125% of baseline
62426925|NCT03886428|EXPERIMENTAL|150% Portion Size|Test meal with portion size 150% of baseline
62426926|NCT03886428|EXPERIMENTAL|175% Portion Size|Test meal with portion size 175% of baseline
62426927|NCT01337609|EXPERIMENTAL|GanedenBC30|Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.
62236314|NCT02211144|EXPERIMENTAL|BIRB 796 BS|in escalating doses
62236315|NCT02211144|PLACEBO_COMPARATOR|Placebo|
62236316|NCT04510909|EXPERIMENTAL|Pilot arm|Mixed methods, acceptability and feasibility pilot of the COMMIT mHealth application
62236317|NCT03877432|EXPERIMENTAL|Dermatome stimulation|Check the effect of improving the function of bladder storage and bladder capacity before and after dermatome stimulation.
62426928|NCT01337609|PLACEBO_COMPARATOR|Sugar pill|Arm 2 will take placebo (sugar pill) for 60 days.
62426929|NCT01337609|OTHER|Ganeden BC30, Sugar pill|Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.
62426930|NCT04250519|EXPERIMENTAL|1% sodium hypochlorite & dexamethasone 4mg as irrigants|sodium hypochlorite is effective in any concentration as antimicrobial irrigant and dexamethasone is anti inflammatory drug
62812595|NCT02017197|OTHER|Sequence A|"Phase 1 (run-in): Marevan®~Phase 2: Marevan®~Phase 3: generic warfarin #1~Phase 4: generic warfarin #2"
62594968|NCT01647516|EXPERIMENTAL|Ozanimod 0.5 mg|Participants received 0.5 mg capsules of ozanimod hydrochloride daily during the induction period weeks 0-9 (an initial 8-day dose escalation regimen in the induction period that consisted of 4 days of ozanimod HCl 0.25 mg (equivalent to ozanimod 0.23 mg), followed by 3 days of ozanimod HCl 0.5 mg, (equivalent to ozanimod 0.46 mg) followed by the assigned treatment level for at least 8 weeks. Participants who completed the induction period and were responders at week 8, continued to receive the same dose of ozanimod during the maintenance period up to week 32. Participants who received ozanimod 0.5 mg capsules and completed the induction period and were non-responders at Week 8 and who completed the maintenance period or experienced a disease relapse, were given the option to enter the OLP and receive 1 mg ozaninod capsules daily up to 6 years. Participants who had not shown clinical improvement 8 weeks after initiation of the OLP were discontinued from the study.
62035491|NCT04021953|ACTIVE_COMPARATOR|Control Group|The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
62426931|NCT04250519|ACTIVE_COMPARATOR|1% sodium hypochlorite as irrigant &normal saline as placebo|sodium hypochlorite is effective in any concentration as irrigant
62426932|NCT04250519|EXPERIMENTAL|5.25% sodium hypochlorite and dexamethasone 4mg as irrigants|sodium hypochlorite is effective in any concentration as antimicrobial irrigant and dexamethasone is anti inflammatory drug
62594969|NCT01647516|EXPERIMENTAL|Ozanimod 1 mg|Participants received 1 mg capsules of ozanimod hydrochloride daily during the induction period weeks 0-9 (an initial 8-day dose escalation regimen in the induction period that consisted of 4 days of ozanimod HCl 0.25 mg (equivalent to ozanimod 0.23 mg), followed by 3 days of ozanimod HCl 0.5 mg, (equivalent to ozanimod 0.46 mg) followed by the assigned treatment level for at least 8 weeks. Participants who completed the induction period and were responders at week 8, continued to receive the same dose of ozanimod during the maintenance period up to week 32. Participants who received ozanimod 1 mg capsules and completed the induction period and were non-responders at Week 8 and who completed the maintenance period or experienced a disease relapse, were given the option to enter the OLP and receive 1 mg ozaninod capsules daily up to 6 years. Participants who had not shown clinical improvement 8 weeks after initiation of the OLP were discontinued from the study.
62594970|NCT01647516|PLACEBO_COMPARATOR|Placebo|Identically matching placebo capsules daily for 32 weeks followed by an optional open label treatment period.
62594971|NCT04939012|EXPERIMENTAL|MyPath Intervention|At the first visit participants randomized to this arm receive MyPath contraceptive decision tool.
62594972|NCT04939012|ACTIVE_COMPARATOR|Standard of Care|At the first visit participants randomized to this arm receive standard of care contraceptive counseling.
62594973|NCT06345157||Ofatumumab|Patients treated with Ofatumumab
62035492|NCT06275204||Protocol I|"H. pylori positive patients who will be treated by bismuth-based quadruple therapy.~Participating centers: KBC Rijeka, Croatia; KBC Zagreb, Croatia; Beacon Hospital, Ireland; Uniwersytet medyczny we Wrocławiu, Poland; UMF Cluj-Napoca, Romania; NIJZ, Slovenia"
62594974|NCT00542906|OTHER|1|healthy volunteers
62035493|NCT06275204||Protocol II|"In case there will be a treatment failure after bismuth-based quadruple therapy, the remaining patients with a positive infection will be referred to a levofloxacin based quadruple therapy.~Participating centers: KBC Rijeka, Croatia; KBC Zagreb, Croatia; Beacon Hospital, Ireland; Uniwersytet medyczny we Wrocławiu, Poland; UMF Cluj-Napoca, Romania; NIJZ, Slovenia"
62035494|NCT06275204||Standard triple therapy|"H. pylori positive participants who will offered standard triple therapy.~Participating center: University of Latvia, Latvia"
62236318|NCT04417374||Unvonluntary commitment from March 12th to April 09th 2019|Patients hospitalized with unvonluntary commitment procedure from March 12th to April 09th 2019
62812596|NCT02017197|OTHER|Sequence B|"Phase 1 (run-in): generic warfarin #1~Phase 2: generic warfarin #1~Phase 3: Marevan®~Phase 4: generic warfarin #2"
62812597|NCT02017197|OTHER|Sequence C|"Phase 1 (run-in): generic warfarin #1~Phase 2: generic warfarin #1~Phase 3: generic warfarin #2~Phase 4: Marevan®"
62812598|NCT02017197|OTHER|Sequence D|"Phase 1 (run-in): Marevan®~Phase 2: Marevan®~Phase 3: generic warfarin #2~Phase 4: generic warfarin #1"
62812599|NCT02017197|OTHER|Sequence E|"Phase 1 (run-in): generic warfarin #2~Phase 2: generic warfarin #2~Phase 3: Marevan®~Phase 4: generic warfarin #1"
62812600|NCT02017197|OTHER|Sequence F|"Phase 1 (run-in): generic warfarin #2~Phase 2: generic warfarin #2~Phase 3: generic warfarin #1~Phase 4: Marevan®"
62812601|NCT00303823|EXPERIMENTAL|Arm I|Patients receive oral green tea extract once daily for 16 weeks in the absence of unacceptable toxicity.
62812602|NCT00303823|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo once daily for 16 weeks in the absence of unacceptable toxicity.
62236319|NCT04417374||Unvonluntary commitment from March 12th to April 09th 2020|Patients hospitalized with unvonluntary commitment procedure from March 12th to April 09th 2020
62812603|NCT04083781|EXPERIMENTAL|Arm 1: No prophylaxis|Haemophilia A with inhibitors (HAwI) and haemophilia B with inhibitors (HBwI) patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis. In the extension part, patients in arm 1 will receive daily concizumab subcutaneous (s.c., under the skin) injections.
62812604|NCT04083781|EXPERIMENTAL|Arm 2: Concizumab prophylaxis|HAwI and HBwI patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis.
62812605|NCT04083781|EXPERIMENTAL|Arm 3: Concizumab prophylaxis|The HAwI and HBwI patients enrolled into the concizumab phase 2 trial (NN7415-4310) at time of transfer will be offered enrolment into this trial. It is required that these patients are on concizumab prophylaxis up until enrolment into the trial. These patients will continue concizumab prophylaxis.
62594975|NCT06621173|EXPERIMENTAL|HNF4α srRNA treatment|The subjects with metastatic colorectal cancer will be treated by HNF4α srRNA intravenously via a peripheral vein.
62812606|NCT04083781|EXPERIMENTAL|Arm 4: Concizumab prophylaxis|Patients previously on prophylaxis with by-passing agents and on-demand patients who are screened at a timepoint where the required number of patients in arms 1 and 2 have been randomised. These patients will, if eligible, be enrolled into the trial and will initiate concizumab prophylaxis at visit 2a (week 0).
62812607|NCT06214975|ACTIVE_COMPARATOR|EXOPULSE Mollii Suit Stimulation Active|This will be the EXOPULSE Mollii Suit Active Stimulation. Stimulation will go on for 60 minutes while control unit is on for 60 minutes
62426933|NCT04250519|ACTIVE_COMPARATOR|5.25% sodium hypochlorite &normal saline as placebo|sodium hypochlorite is effective in any concentration as irrigant
62594976|NCT03855020||observational cohort|Patients enrolled in this observational cohort would have regular blood taking for EBV DNA examination at baseline, after every cycle of chemotherapy, every week during radiotherapy, and 1-3 months after chemo-radiotherapy until EBV DNA becomes undetectable for at least two times.
62594977|NCT03579186|EXPERIMENTAL|Gait|Patients undergoing a routine clinical gait assessment at the Brain Fit Club at BIDMC will have their posture and gait measured before and during optokinetic stimulation (OKS).
62594978|NCT03425682||Cervical Fusion - ACDF|Up to 50 patients undergoing anterior cervical discectomy and fusion (ACDF) using ViBone will be enrolled.
62812608|NCT06214975|SHAM_COMPARATOR|EXOPULSE Mollii Suit Stimulation Sham|This will be the EXOPULSE Mollii Suit Sham Stimulation. Stimulation will go on for 1 minute then it turns off while the control unit will remain on for total of 60 minutes.
62812609|NCT03586765||Experimental group|Assess prevalence of urinary functional disorders in women of 40 and more, visiting a general practitioner, occupational medicine or health examination center in Puy-de-Dôme. Study conducted for a month using a self-filled survey distributed by secretaries or nurses.
62812610|NCT00005984|EXPERIMENTAL|Patients with CML|Patients treated for chronic accelerated phase and/or chronic myelogenous leukemia (CML)
62812611|NCT05843435||Alcohol Use Disorder/AUD|A group of 30 detoxified patients who are part of the specialized residential treatment program at the Clinic Suedhang in Kirchlindach in Switzerland.
62594979|NCT03425682||Lumbar Interbody Fusion|Up to 50 patients undergoing lumbar interbody fusion (TLIF, PLIF, ALIF, or LLIF) using ViBone will also be enrolled.
62594980|NCT00154804|EXPERIMENTAL|A|
62594981|NCT02205008|ACTIVE_COMPARATOR|Arm A|curative resection of the stomach with D2 plus intraperitoneal chemotherapy plus adjuvant systemic chemotherapy with S-1
62594982|NCT02205008|PLACEBO_COMPARATOR|Arm B|curative resection of the stomach with D2 plus adjuvant systemic chemotherapy with S-1
62594983|NCT01953874|EXPERIMENTAL|MV ASV+OMT|Minute Ventilation-targeted adaptive servo-ventilation therapy plus optimized medical treatment
62594984|NCT01953874|ACTIVE_COMPARATOR|OMT only|Optimized Medical Treatment for heart failure in accordance with applicable guidelines (ACCF/AHA Guideline for the Management of Heart Failure and HFSA Heart Failure Guidelines.
62594985|NCT04231877|EXPERIMENTAL|Arm A (polatuzumab vedotin, chemotherapy) [CLOSED TO ACCRUAL 05/23/2024]|"Patients receive rituximab IV on day 1, polatuzumab vedotin IV on day 1, prednisone PO BID on days 1-5, etoposide IV on days 1-4, doxorubicin IV on days 1-4, and cyclophosphamide IV on day 5. Patients also receive filgrastim SC 24-72 hours after the last dose of each treatment cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~Patients undergo MUGA scan or echocardiography during screening and FDG PET, CT scan, bone marrow biopsy and aspiration and blood sample collection throughout the study."
62594986|NCT04231877|EXPERIMENTAL|Arm B (polatuzumab vedotin, glofitamab, chemotherapy)|"Patients receive rituximab IV on day 1, polatuzumab vedotin IV on day 1, prednisone PO BID on days 1-5, etoposide IV on days 1-4, doxorubicin IV on days 1-4, and cyclophosphamide IV on day 5. Starting with cycle 2, patients also receive glofitamab, over 4 hours, on day 1 and 8 of cycle 2 and day 1 of subsequent cycles. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~Patients undergo MUGA scan or echocardiography during screening and FDG PET, CT scan, bone marrow biopsy and aspiration and blood sample collection throughout the study."
62594987|NCT04322019||"Amikacin treatment group"|Intensive care patients on renal replacement therapy with Amikacin treatment
62594988|NCT06622746||EHS|All individuals who underwent advanced endoscopic procedures followed by EHS from March 2023 to June 2024
62594989|NCT02963558|EXPERIMENTAL|Intervention|The intervention group will receive in-bed cycle ergometry within 48 hours of randomization if safety criteria are met. The intervention arm will receive early physical therapy (PT). This PT will be performed according to a protocol of additional ICU and hospital-administered rehabilitation strategies that have been previously developed. Patients will receive 30 minutes of PT at least 5 times per week while conscious. If unconscious, subjects will only receive passive range of motion (PROM) for 10 repetitions per body part daily. Once conscious, subjects will progress through PT with an emphasis on ambulation. Therapy for the intervention arm patients will continue while on the floor. Outpatient therapy will be provided at the discretion of the patient's treating physicians.
62812612|NCT05843435||Healthy Controls/HC|A group of 30 age- and gender-matched healthy control subjects who are recruited via advertisement in social media or local newspaper.
62594990|NCT02963558|NO_INTERVENTION|Usual Care|The control group will receive usual care physical therapy as ordered by the treating team both in the ICU and on the floor through hospital discharge. These subjects will also receive therapy as outpatients only as ordered by their regular physicians.
62594991|NCT05335031||Participants with relapsing-remitting multiple sclerosis (RRMS) treated with Ozanimod|
62594992|NCT03580408|EXPERIMENTAL|Experimental|"Induction treatment :Nivolumab will be given alone at 240 mg flat dose every 2 weeks (i.e. one cycle) Patients will be assessed after 3 months of therapy (after 6 injections of Nivolumab)~Consolidation treatment:~It depends on the induction evaluation by PET-CT and CT-scan (Lugano 2014 criteria) :~* For patients achieving CMR according to Lugano Classification : treatment by nivolumab 240 mg every 2 weeks for 9 months.~* Patients who reach PMR and NMR after 3 months (according to Lugano Classification) will be treated by the Nivolumab+Vinblastin regimen every 2 weeks for 9 additional months: Vinblastin(6 mg/m2 (IV) + Nivolumab 240 mg (IV)~* In case of progressive disease , patients will be considered in treatment failure."
62594993|NCT04981834|EXPERIMENTAL|Arm I (radical prostatectomy, vesicopexy)|Patients undergo standard RARP with anterior approach plus vesicopexy. Urethral catheters are removed 7-14 days following surgery at provider discretion.
62594994|NCT04981834|ACTIVE_COMPARATOR|Arm II (radical prostatectomy)|Patients undergo standard RARP with anterior approach without vesicopexy. Urethral catheters are removed 7-14 days following surgery at provider discretion.
62594995|NCT01968707|ACTIVE_COMPARATOR|ChloraPrep Hi-Lite Orange|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
62812613|NCT03803306|EXPERIMENTAL|Vedic Medical Astrology Group (VMA)|
62812614|NCT03803306|SHAM_COMPARATOR|Placebo vedic medical astrology (PMA)|
62812615|NCT04468061|EXPERIMENTAL|Sacituzumab Govitecan + Pembrolizumab|"Participants will receive Sacituzumab Govitecan + Pembrolizumab at a pre-determined dose during a 21 day cycle.~Sacituzumab Govitecan will be given on days 1 and 8 of the 21 day cycle Pembrolizumab will be given on day 1 of the 21 day cycle."
62812616|NCT04468061|EXPERIMENTAL|Sacituzumab Govitecan|"Participants will receive Sacituzumab Govitecan at a pre-determined dose during a 21 day cycle.~Sacituzumab Govitecan will be given on days 1 and 8 of a 21-day cycle"
62812617|NCT04468061|EXPERIMENTAL|Retreatment|"Participants randomized to the combination arm (Sacituzumab Govitecan + Pembrolizumab) who stop with CR after at least 24 weeks of treatment may be eligible for additional pembrolizumab and/or sacituzumab govitecan therapy if they progress after stopping study treatment. This is termed the Second Course Phase and is only available if the study remains open and the subject meets conditions.~."
62236320|NCT02720614|EXPERIMENTAL|Hypofractionated radiation/chemotherapy|"Hypofractionated radiation：Patients receive accelerated hypofractionated radiation: three-dimensional conformal radiation therapy (3-DCRT) with a total dose of 69 Gy, delivered at 3 Gy per fraction, once daily, five fractions per week, completed within 4.6 weeks.~Chemotherapy: Regimen 1 is as follows: vinorelbine (NVB) was administered by intravenous infusion at a dose of 25 mg/m2 on day 1 (d1) and day 8 (d8), and carboplatin (CBP) is administered at a concentration-time curve (AUC) of 5 mg/ml on d8. This treatment was repeated every 28 days. One cycle of chemotherapy is performed concurrently with the radiotherapy.~Chemotherapy: Regimen 2 is as follows: paclitaxel at 30 mg/m2 and cisplatin at 20 mg/m2 (TP) are administrated every week for 5 weeks continuously."
62236321|NCT02781272||Women with a pelvic mass|Women diagnosed with a pelvic mass (ovarian, uterine, retroperitoneal, etc.) who are scheduled for an imaging guided biopsy, surgical biopsy or surgical excision for evaluation of their pelvic mass. Must have a pelvic imaging study performed within 60 days prior to surgery and a research blood draw within 30 days prior to surgery.
62236322|NCT06038136|NO_INTERVENTION|Standard of Care Neuro Checks|If a patient is randomized to the control group, they will continue to have neuro-checks conducted every 2-4 hours as ordered by the primary team, as per standard of care on the acute stroke service.
62594996|NCT01968707|PLACEBO_COMPARATOR|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
62594997|NCT01968707|EXPERIMENTAL|3M CHG/IPA Prep Tint 10.5 mL|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
62594998|NCT01968707|EXPERIMENTAL|3M CHG/IPA Prep Tint 26-mL|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
62594999|NCT02985606|ACTIVE_COMPARATOR|Caffeine -60|Caffeine at 60 minutes prior to time trial
62595000|NCT02985606|ACTIVE_COMPARATOR|Caffeine -30|Caffeine at 30 minutes prior to time trial
62595001|NCT02985606|ACTIVE_COMPARATOR|Caffeine 0|Caffeine immediately prior to time trial
62595002|NCT02985606|PLACEBO_COMPARATOR|Placebo|Placebo drink at all time points
62236323|NCT06038136|EXPERIMENTAL|Absence of Neuro Checks|If a patient is randomized to the intervention group, the team will discontinue neuro-checks between 8pm and 4am. They will otherwise receive the same care, including overnight vital signs. If the patient has a neurologic or hemodynamic change, the primary team may elect to restart the overnight neuro-checks.
62236324|NCT04908605|ACTIVE_COMPARATOR|Mirtazapine group (Group I) (n=55)|
62236325|NCT04908605|ACTIVE_COMPARATOR|Melatonin group (Group II) (n=55)|
62595003|NCT05068674|ACTIVE_COMPARATOR|Cohort 1|Low dose (50M cells)
62595004|NCT05068674|ACTIVE_COMPARATOR|Cohort 2|Medium dose (150M cells)
62595005|NCT05068674|ACTIVE_COMPARATOR|Cohort 3|High dose (300M cells)
62595006|NCT02637895|PLACEBO_COMPARATOR|Placebo|Placebo pill once daily for 12 weeks of active treatment.
62595007|NCT02637895|ACTIVE_COMPARATOR|Vortioxetine|Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.
62595008|NCT03298945|ACTIVE_COMPARATOR|Golytely|4-L split-dose Golytely bowel prep
62812618|NCT03964350|EXPERIMENTAL|Ethanol|Subjects will receive ethanol (0.4 or 0.8 g/kg) which will be administered in a gelatin vehicle.
62812619|NCT03964350|PLACEBO_COMPARATOR|Placebo (gelatin vehicle)|Subjects will receive placebo of black cherry sugar-free jello.
62812620|NCT05086185||Orange Juice (control)|Orange juice providing a 0.35 mEq/kg dose of potassium
62812621|NCT05086185||Orange Juice plus Fiber|Same amount of orange juice as Orange Juice treatment with 0.15 g/kg of psyllium-based fiber added
62595009|NCT03298945|EXPERIMENTAL|Miralax-Gatorade prep|2-L split-dose Miralax-Gatorade bowel prep
62595010|NCT03814512|EXPERIMENTAL|Extended Sleep Intervention (ES)|Participants will receive a Standard Care Diet and Physical Activity Education Intervention (SC) and an Extended Sleep Intervention (ES). For the SC, participants will have their diet, physical activity, and screen time assessed by study interventionist. Prescribed goals will be determined collaboratively through discussion with participants and parents. For the ES, participants will subsequently be prescribed a sleep schedule that allows them to obtain 1.5 h more time in bed compared to their typical sleep. Prescribed bedtimes and wake times will be determined collaboratively.
62595011|NCT01684982|EXPERIMENTAL|everolimus eluting stent|second generation drug eluting stent
62595012|NCT01684982|ACTIVE_COMPARATOR|sirolimus eluting stent|first generation drug eluting stent
62595013|NCT06354361|EXPERIMENTAL|Trauma-Informed GMT (TI-GMT; offered online)|Participants randomly assigned to the TI-GMT condition will be asked to attend nine weekly, 2-hour virtual group sessions of TI-GMT via Zoom for Healthcare, a PHIPA-compliant video conferencing platform. Each group will consist of 1 or 2 facilitators and up to 10 participants.
62812622|NCT00001832|EXPERIMENTAL|Abl Cells in culture|"Peripheral blood mononuclear cells (PBMC) and/or tumor infiltrating lymphocytes (TIL) obtained by apheresis or lesion excision to be cloned and expanded in the lab.The patients underwent an apheresis and/or an excision of their tumor.~They didn't receive any drugs."
62812623|NCT00001832|EXPERIMENTAL|Abl Cells IV + Cyclophosphamide 30 mg/kg|Phase 1 Cyclophosphamide Dose Escalation: Fludarabine 5x25mg/m\^2 + Cyclophosphamide 2x30mg/kg + Cells intravenous (IV) Abl cells intravenous (IV) = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
62812624|NCT00001832|EXPERIMENTAL|Abl Cells IV + Cyclophosphamide 60 mg/kg|Phase 1 Cyclophosphamide Dose Escalation: Fludarabine 5x25mg/m2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
62812625|NCT00001832|EXPERIMENTAL|Abl Cells IV+Low Dose IV IL-2 (Initial)|Phase 1 interleukin-2 (IL-2) Dose Escalation: Fludarabine 5x25mg/m\^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV IL-2 (72,000 IU/kg q8h for a maximum of 15 doses) Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
62035495|NCT06275204||Second line treatment - levofloxacin-based|"In case there will be a treatment failure after standart triple therapy, the remaining patients with a positive infection will be referred to a second line treatment~Participating center: University of Latvia, Latvia"
62035496|NCT03031691|EXPERIMENTAL|Brontictuzumab and trifluridine/tipiracil|Brontictuzumab will be administered per protocol and trifluridine/tipiracil per label.
62035497|NCT06241326||retrospective cohort|The patients in the retrospective cohort are hepatocellular carcinoma patients who have been previously treated with immunotherapy-based combination regimens. It is anticipated that approximately 10,000 cases will be included.
62035498|NCT06241326||prospective cohort|The patients included in the prospective cohort are hepatocellular carcinoma patients who are being evaluated by researchers to determine the potential benefits of undergoing immunotherapy-based combination treatment regimens. It is anticipated that approximately 1,000 cases will be enrolled.
62035499|NCT06367621||iStatis Syphilis Antibody Test diagnostic device|Bio-banked plasma and serum samples available to Epicentre Health Research will be used for testing on iStatis Syphilis Antibody Test device.
62035500|NCT06367621||Reference test|Either serum or plasma samples were tested with Abbott Architect Syphilis Tp (EDA) and MD Macro-Vue Particle Agglutination (RPR)/Serodia Particle Agglutination (TPPA) where applicable
62035501|NCT02420002|ACTIVE_COMPARATOR|Usual care (MEOPA)|"Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing.~Intervention: Use of MEOPA during suturing Intervention: Stitch removal"
62035502|NCT02420002|EXPERIMENTAL|Experimental arm (Hypnosis)|"Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing will therefore take place under hypnosis (and MEOPA if necessary).~Intervention: Use of Hypnosis during suturing Intervention: Stitch removal"
62035503|NCT02313467|ACTIVE_COMPARATOR|1.5% Butenyl ALA|Topical application of 1.5% Butenyl ALA per every other day around acne lesions in the face
62035504|NCT02313467|SHAM_COMPARATOR|Control|Topical application of sham control per every other day around acne lesions in the face
62035505|NCT00716872|EXPERIMENTAL|ImmedSHUTi/ImmedHyp|In the first part of the trial, participants are assigned to the Immediate SHUTi group; that is, they receive access to the SHUTi program right away. In the second part of the trial (3 months later), participants are assigned to the Immediate Hypnosis group; that is, they receive access to the Hypnosis recordings right away.
62035506|NCT00716872|EXPERIMENTAL|ImmedSHUTi/DelayHyp|In the first part of the trial, participants are assigned to the Immediate SHUTi group; that is, they receive access to the SHUTi program right away. In the second part of the trial (3 months later), participants are assigned to the Delayed Hypnosis group; that is, they receive access to the Hypnosis recordings at the end of the study.
62035507|NCT00716872|EXPERIMENTAL|DelaySHUTi/ImmedHyp|In the first part of the trial, participants are assigned to the Delayed SHUTi group; that is, they receive access to the SHUTi program at the end of the study. In the second part of the trial (3 months later), participants are assigned to the Immediate Hypnosis group; that is, they receive access to the Hypnosis recordings right away.
62035508|NCT00716872|NO_INTERVENTION|DelaySHUTi/DelayHyp|In the first part of the trial, participants are assigned to the Delayed SHUTi group; that is, they receive access to the SHUTi program at the end of the study. In the second part of the trial (3 months later), participants are assigned to the Delayed Hypnosis group; that is, they receive access to the Hypnosis recordings at the end of the study.
62035509|NCT06371833||Adult patients requiring a primary TSA or RSA|Device: PRIMA humeral stem in anatomic or reverse configuration Shoulder arthroplasty according to the instruction for use.
62035510|NCT02470338|ACTIVE_COMPARATOR|MBP plus ankle arthroscopy (Group A)|Group A will receive a diagnostic ankle arthroscopy followed by the Modified Brostrӧm Procedure (MBP). In the ankle arthroscopy, multiple pictures are taken inside of the joint to note possible pathologic processes (for example - osteochondral lesions of the talus). Ankle arthroscopy involves one incision in the middle of the ankle anteriomedial (middle) incision and one incision on the outside of the ankle. Each incision (a small cut in the skin) is roughly 5mm in length (which is about 0.2 inches). After the incision is made, the participant will receive a diagnostic ankle arthroscopy.If the surgeon detects an abnormality inside the joint, he will operate on the abnormality with the arthroscope according to the generally accepted principles for treating the abnormality.
62236326|NCT04908605|PLACEBO_COMPARATOR|Placebo group (Group III) (n=55)|
62595014|NCT06354361|ACTIVE_COMPARATOR|Standard GMT (GMT; offered online)|Participants randomly assigned to the GMT condition will be asked to attend nine weekly, 2-hour virtual group sessions of GMT via Zoom for Healthcare, a PHIPA-compliant video conferencing platform. Each group will consist of 1 or 2 facilitators and up to 10 participants.
62236327|NCT04858139|PLACEBO_COMPARATOR|placebo|patients will be injected with placebo
62236328|NCT04858139|ACTIVE_COMPARATOR|Lactate|patients will be injected with lactate solution
62236329|NCT05282615|EXPERIMENTAL|Treatment Group (Emanate Tray)|Full mouth periodontal debridement + Emanate Tray (treatment group)
62236330|NCT05282615|NO_INTERVENTION|Control Group|Full mouth periodontal debridement alone (control group)
62236331|NCT06209671|EXPERIMENTAL|INS19 CAR-T Cells|After preconditioning with chemotherapy, INS19 CAR-T Cells will be evaluated
62236332|NCT05127369|EXPERIMENTAL|Test group|Dental pulp mesenchymal cell injection (dose: 0.1u/kg) + fluoxetine hydrochloride
62236333|NCT05127369|ACTIVE_COMPARATOR|control group|Dental pulp mesenchymal cell injection vehicle + fluoxetine hydrochloride capsule
62595015|NCT06510556|OTHER|Catheter ablation for Persistent Atrial Fibrillation|Subjects scheduled to undergo endocardial mapping and ablation in the treatment of persistent atrial fibrillation.
62595016|NCT03589976|EXPERIMENTAL|Sirolimus|2 mg/day (one 2-mg tablet/day). The dose of sirolimus will be adjusted throughout the trial based on sirolimus plasma levels and the presence of drug-related adverse events. The maximum dose of sirolimus will be6 mg/day (three 2-mg tablets/day).
62595017|NCT03589976|PLACEBO_COMPARATOR|Placebo|Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.
62236334|NCT01933113|EXPERIMENTAL|DBS of the Lateral Hypothalamic Area|"Single Arm: Deep Brain Stimulation of LHA for maximum RMR On days 1-4, subjects stayed in the inpatient unit to have metabolic weight, temperature, and resting metabolic rate (RMR) measured at different settings.~Metabolic testing RMR measurement: A clear plastic hood was placed over the head and chest Oxygen intake and carbon dioxide out-put were measured to determine how many calories were burned during the next 15-30 minutes. Each hour for the next seven hours, DBS settings were changed and the above process was repeated. On Day 4, a DXA scan was performed to assess body composition. Primary endpoint is the determination of optimal settings"
62236335|NCT03178929|EXPERIMENTAL|S-Adenosyl Methionine Treatment|"Patients will be treated with S-Adenosyl Methionine treatment after radical treatment.~2000mg, po"
62426934|NCT04282044|EXPERIMENTAL|Monotherapy Dose-Escalation Cohorts|Prior to the current amendment, no DLTs were observed at Dose Levels 1-5. Starting with the current protocol amendment, dosing decisions in monotherapy cohorts will utilize a 3+3 design for Dose Level 6. CRX100 infusion will occur every nine weeks (+/- 7 days). Subjects will receive up to a maximum of four infusions of CRX100 unless it is determined by the treating physician and the sponsor that it is in the best interest of the subjects to receive additional doses of CRX100 beyond four doses. A minimum of three DLT-evaluable subjects will be doses at Dose Level 6 and expanded to six subjects if determined necessary based on DLT incidence using the 3+3 design, and discussion with SRC and Sponsor.
62236336|NCT03178929|NO_INTERVENTION|control group|Patients will be treated without S-Adenosyl Methionine treatment after radical treatment.
62236337|NCT04218955||1|Asking parents if they can accept staining from treat their children by silver Diamine Flouride or Not
62236338|NCT04272970|ACTIVE_COMPARATOR|New gene / protein variant functional study|Morphological and functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to prove the pathogenicity of variants of new genes potentially involved in constitutional familial thrombocytopenia.
62236339|NCT04272970|SHAM_COMPARATOR|Normal gene / protein variant functional study|"Morphological and functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to provide control observations / analyses / measures for the Active Comparator arm"
62236340|NCT04085627|EXPERIMENTAL|T Test|Test drug(Valsartan / Amlodipine)1 tablet contains Valsartan 80mg\& Amlodipine 5mg
62236341|NCT04085627|ACTIVE_COMPARATOR|R Reference|Reference drug(Valsartan / Amlodipine)1 tablet contains Valsartan 80mg\& Amlodipine 5mg
62426935|NCT04282044|EXPERIMENTAL|Combination Therapy Cohorts|"Subjects with relasped or refractory solid tumors, as defined in the inclusion criteria, will be enrolled to evaluate the safety and anti-tumor activity of CRX100 in combination with Pembrolizumab in patients with advanced solid malignancies. The dose of CRX100 used will be determined from the monotherapy cohorts.~CRX100 infusion will occur every nine weeks (+/- 7 days). Subjects will receive up to a maximum of four doses of CRX100 unless it is determined by the treating physician and the sponsor that it is in the best interest of the subjects to receive additional doses of CRX100 beyond four doses.~Pembrolizumab will be administered at 200mg IV every three weeks (Q3W) per the approved label."
62236342|NCT03047759|ACTIVE_COMPARATOR|Intervention A|water flosser
62236343|NCT03047759|ACTIVE_COMPARATOR|Intervention B|air floss
62236344|NCT00419783|EXPERIMENTAL|1|Bilastine 20 mg
62236345|NCT00419783|EXPERIMENTAL|2|Bilastine 100 mg
62236346|NCT00419783|ACTIVE_COMPARATOR|3|Bilastine 20 mg + Ketoconazole 400 mg
62236347|NCT00419783|ACTIVE_COMPARATOR|4|Moxifloxacin 400 mg
62236348|NCT00419783|PLACEBO_COMPARATOR|5|Placebo
62243419|NCT06320405|EXPERIMENTAL|Treatment (axatilimab, retifanlimab, paclitaxel)|Patients receive axatilimab IV over 30 minutes on day -8, prior to cycle 1. Beginning in cycle 1 day 1, patients receive axatilimab IV over 30 minutes on days 8 and 21 of each cycle, retifanlimab IV over 30-60 minutes on day 1 of each cycle, and paclitaxel IV over 60 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsy, CT scan, and blood sample collection throughout the study and may undergo MRI and/or PET scan throughout the study.
62426936|NCT05096026|EXPERIMENTAL|Standard PCP Outreach|These patients were sent standard outreach messages to promote COVID-19 vaccination.
62735510|NCT02534025|NO_INTERVENTION|C group|no intervention will be added to routine anesthetic mangement
62035511|NCT02470338|SHAM_COMPARATOR|MBP alone (Group B)|Group B will receive sham skin incisions on the ankle a Modified Brostrӧm Procedure (MBP) alone (that is, there will be no diagnostic ankle arthroscopy) followed by the Modified Brostrӧm Procedure (MBP). If a participant is assigned to Group B, the participant will receive two small superficial skin incisions at the sites where the investigators would normally insert instruments for the ankle arthroscopy. As with Group A, there will be one anteriomedial (middle) incision on the middle of the ankle and one anteriolateral (side) incision to on the outside of the ankle. Each incision will be roughly 5mm in length and 5 mm in depth, but will not violate subcutaneous tissue. The width of these incisions will be the width of the blade, at 1mm. However, unlike Group A, the participants in Group B will not have any instruments inserted into their ankle and will not have any operation to repair or remove damaged tissue.
62035512|NCT03667950|EXPERIMENTAL|hyperspectral imaging|diagnostic hyperspectral Imaging of the gastrointestinal anastomosis and calculating the anastomotic Perfusion measures
62236349|NCT06430944|EXPERIMENTAL|Single limb spica casting:|"A folded towel was placed inside the tubular bandage over the centre of the abdomen, which helped create breathing space inside the cast. The towel's tail was brought towards the neck for easier removal.~Then, a layer of the padded cast was applied using a large width for the body and a narrower one for the lower limb. A thick felt was added over this padding along the free edges of the chest and the leg. The first layer of the cast was applied to the leg and body in an eight-figure manner, taking care to connect the leg to the body securely. The reinforced cast slabs were applied between the body and the lower limb segments. The thigh segment was moulded to maintain a good reduction by keeping the anterolateral of the cast flat or slightly concave. Some clinicians moulded the segment enough to result in ten degrees of initial valgus."
62426937|NCT05096026|EXPERIMENTAL|Culturally Tailored PCP Outreach|These patients were sent messages similar to those in the Standard PCP Outreach Group, but with additional culturally tailored content.
62426938|NCT05096026|NO_INTERVENTION|Usual Care|These patients were not sent the above study outreach messages, but may have received other messages from their local medical centers or counties.
62812626|NCT00001832|EXPERIMENTAL|Abl Cells IV+High Dose IV IL-2 (Initial)|Phase 1 interleukin-2 (IL-2) Dose Escalation: Fludarabine 5x25mg/m\^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV IL-2 (720,000 IU/kg q8h for a maximum of 12 doses) Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
62812627|NCT00001832|EXPERIMENTAL|Abl Cells IV + MTD IL-2|Phase 2 Fludarabine 5x25mg/m\^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) (to shorten time to neutrophil recovery) Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
62426939|NCT01831531|EXPERIMENTAL|S-1|"Patients will receive chemoradiation with S-1.~Interventions:~Drug: S-1 Radiation: Radiation therapy"
62426940|NCT01180842|OTHER|Alternative Treatment|The CF Patient Population receiving the specific yoga study treatment
62426941|NCT02523079|EXPERIMENTAL|Cognitive Behavioral Group Therapy for Insomnia|Includes 6 group sessions (90 minutes each). The groups are led by trained psychologist or nurse of occupational health services. The manualized treatment is based on the general CBT-I model and includes components such as sleep hygiene, relaxation, stimulus control, sleep restriction and cognitive restructuring. In addition, participants receive information on how to schedule sleep, wake and light based on circadian principles while working differently timed shifts.
62035513|NCT01913067|EXPERIMENTAL|Cabazitaxel|Eligible patients will receive intravenous 25mg/m2 cabazitaxel every 3 weeks. Contrast-enhanced whole brain MRI will be performed every two cycles. Patients who show ≥50% volumetric reduction in the size of the brain lesion(s) will continue on cabazitaxel until disease progression or unacceptable toxicity. Patients who show evidence of disease progression and/or developed progressive neurological symptoms will be taken off study and offered whole brain irradiation. Patients who do not meet both criteria can have the choice either to continue on study drug or to be taken off study according to the investigator discretion.
62035514|NCT00386880||Subjects with episodic migraine with allodynia|These are subjects with episodic migraine with allodynia
62035515|NCT00386880||Subjects with episodic migraine without allodynia|Subjects with episodic migraine without allodynia
62035516|NCT00754845|EXPERIMENTAL|Letrozole|Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
62236350|NCT06430944|ACTIVE_COMPARATOR|Double limb spica cast:|One and a half cast was applied in a single limb spica cast, extending to the opposite leg to the knee. Reinforced slabs were applied to hip joints in both limbs
62243420|NCT03422289|EXPERIMENTAL|Myo-inositol + folic acid|2 g myo-inositol and 0.2 mg folic acid orally twice a day for three months, in order to induce ovulation.
62595018|NCT02988440|OTHER|PDR001 + Sorafenib|PDR001 at 400 mg given intravenously every 4 weeks and sorafenib 400 mg taken orally once or twice per day (escalating doses)
62595019|NCT06619613|EXPERIMENTAL|Group 1|CM383 injection, Intravenous infusion
62595020|NCT06619613|EXPERIMENTAL|Group 2|CM383 injection, Intravenous infusion
62595021|NCT06619613|EXPERIMENTAL|Group 3|CM383 injection, Intravenous infusion
62595022|NCT06619613|EXPERIMENTAL|Group 4|CM383 injection, Intravenous infusion
62812628|NCT00001832|EXPERIMENTAL|Abl Cells IA + MTD (prior cells IV on 6)|Phase 2 Fludarabine 5x25mg/m\^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) Prior Cells IV + growth colony stimulating factor (G-CSF) Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
62426942|NCT02523079|EXPERIMENTAL|Cognitive Behavioral Self-help Therapy for Insomnia|Mainly computerized self-help intervention. Includes an individual session before and after the intervention (30 minutes each) led by trained psychologist or nurse of occupational health services. The self-help treatment is based on the general CBT-I model and includes components such as sleep hygiene, relaxation, stimulus control, sleep restriction and cognitive restructuring. In addition, participants receive information on how to schedule sleep, wake and light based on circadian principles while working differently timed shifts.
62426943|NCT02523079|EXPERIMENTAL|Sleep Hygiene Guidance|Includes one individual session (60 minutes) led by trained psychologist or nurse of occupational health services. The intervention is based on sleep hygiene guidance.
62426944|NCT03355222|NO_INTERVENTION|No Intervention|No intervention: The community receives no chickens and no special education is provided.
62595023|NCT02856607||Group I|patient for whom diagnosis and medical care are realized in a referent center with cardiac surgery
62595024|NCT02856607||Group II|patients secondary addressed to a referent center with cardiac surgery
62595025|NCT02856607||Group III|patients for which the totality medical care are performed in non-referent health center
62595026|NCT05299944|ACTIVE_COMPARATOR|Full-spectrum Cannabidiol|210mg/day of full-spectrum cannabidiol, containing less than 0.3%THC.
62595027|NCT05299944|ACTIVE_COMPARATOR|Broad-spectrum Cannabidiol|210mg/day of broad-spectrum cannabidiol, containing 0%THC.
62595028|NCT05299944|PLACEBO_COMPARATOR|Hemp Seed Oil Placebo|210mg/day of hemp-seed oil with no cannabinoids present.
62595029|NCT05483101||alternative units|In alternative birth units : personalized follow-up with a midwife from the beginning of pregnancy, birth and parenthood preparation classes and delivery (birth room).
62595030|NCT05483101||conventional units|In standard maternity care, most full time midwives are rostered to work. They follow women during their pregnancy but not through labour. All low-risk pregnant women benefit from 5 prenatal consultations with a general practitioner, a midwife or an obstetrician, then 2 consultations with a midwife in maternity hospital of delivery. Couples have got the option to elaborate a birth project if desired
62595031|NCT00226668|EXPERIMENTAL|I|Patients will receive hCRf (XERECEPT) 2mg/day and dexamethasone 4 mg/day along with any open-label dexamethasone that they may be taking
62035517|NCT00754845|PLACEBO_COMPARATOR|Placebo|Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
62035518|NCT05218967|EXPERIMENTAL|In-office procedure with VR-assistance|
62236351|NCT02553109||small unruptured paraclinoid aneurysm|Patients with newly diagnosed, small (less than 5mm) unruptured paraclinoid aneurysms who will visit one of the study centers during the period from January 2015 to February 2017. Patients would be eligible for enrollment if they were 20 years of age or older and had an unruptured paraclinoid aneurysm that is less than 5 mm in the largest dimension. All patients who would visit a study center during the enrollment period and meet these criteria will be asked to join the study. The cohort will consists of patients who agree to participate. Target population of this study is 645 aneurysms.
62236352|NCT00522912|EXPERIMENTAL|A|Immediate posterior lamella tarsal rotation surgery for minor trichiasis
62236353|NCT00522912|ACTIVE_COMPARATOR|B|Regular epilation by another person
62236354|NCT00477854|EXPERIMENTAL|Visual Analogue Scale Ratings|Food intake data and its coefficients, including total food intake, food not eaten, duration of the meal, and bite rate. A mixed model analysis of variance will also be conducted on ratings of food cravings and eating atttudes. Changes in hunger and satiety ratings between, before, and after the meals will be compared for difference across treatment conditions.
62595032|NCT00226668|PLACEBO_COMPARATOR|II|Patients will receive placebo hCRF (XERECEPT) 2mg/day and dexamethasone 4 mg/day along with any open-label dexamethasone they may be taking
62595033|NCT01054300|EXPERIMENTAL|Cohort 1: Ertu 2 mg/Placebo (Pbo)→Ertu 1 mg/Ertu 1 mg|Period 1: Ertu 2 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. There was a \>= 7 day washout period between Period 1 and Period 2.
62595034|NCT01054300|EXPERIMENTAL|Cohort 1: Ertu 1 mg/Ertu 1 mg→Ertu 2 mg/Pbo|Period 1: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Pbo in the PM for 1 day. There was a \>= 7 day washout period between Period 1 and Period 2.
62595035|NCT01054300|EXPERIMENTAL|Cohort 2: Ertu 4 mg/Pbo→Ertu 2 mg/Ertu 2 mg|Period 1: Ertu 4 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. There was a \>= 7 day washout period between Period 1 and Period 2.
62595036|NCT01054300|EXPERIMENTAL|Cohort 2: Ertu 2 mg/Ertu 2 mg→Ertu 4 mg/Pbo|Period 1: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. Period 2: Ertu 4 mg in the AM and Pbo in the PM for 1 day. There was a \>= 7 day washout period between Period 1 and Period 2.
62812629|NCT00001832|EXPERIMENTAL|Abl Cells IA + MTD IL-2|Phase 2 Fludarabine 5x25mg/m\^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
62812630|NCT00001832|EXPERIMENTAL|Abl Cells IA+MTD IL-2 (MART-1 reactive)|Phase 2 Fludarabine 5x25mg/m\^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) + melanoma- associated antigen recognized by T cells (MART-1):26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days gp100 = gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209-217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
62035519|NCT05218967|NO_INTERVENTION|In-office procedure without VR-assistance|
62236355|NCT00477854|EXPERIMENTAL|Consuming less Lunch allows consumption of more dinner|Test whether chromium picolinate supplementation affects food cravings, eating attitudes, and satiety in healthy, overweight and/or obese, adult women who are determinded to be carbohydrate cravers. Whether participants who eat less at a lunch test meal consume more food at an ad lib dinner test meal with a diversity of foods.
62236356|NCT05584228|EXPERIMENTAL|Medical treatment|Combination therapy with subcutaneous infliximab and azathioprine
62236357|NCT05584228|ACTIVE_COMPARATOR|Surgery|Intestinal resection
62236358|NCT04359251|EXPERIMENTAL|Optimizing oxygenation|Best oxygenation during PEEP titration
62236359|NCT04359251|EXPERIMENTAL|Optimizing compliance|Best compliance during PEEP titration
62236360|NCT04359251|EXPERIMENTAL|ARDSnet|PEEP settings according to ARDSnet table
62426945|NCT03355222|EXPERIMENTAL|Experimental: providing chickens and egg shell|"Experimental: Two chickens are given to each family so that eggs are available for children and of eggshell powder for mothers.~The community receives these chickens so each designated family has an egg to give to young child. In a subgroup the mother will receive ESP (1000 mg calcium). The community receives information on using egg and has help on caring for chickens."
62426946|NCT05948436|EXPERIMENTAL|Clamp|In these patients, we clamped the uterine artery by Darmklemmen clamp after the delivery of the baby before the delivery of placenta. We released the clamp after the suturing of the uterus is finished.
62426947|NCT05948436|NO_INTERVENTION|Control|Routine Cesarean section is done.
62595037|NCT05091736|EXPERIMENTAL|Subject glucometer measurement|
62595038|NCT06221592|EXPERIMENTAL|Full axis multi-point defocus spectacle lenses|
62595039|NCT06221592|EXPERIMENTAL|Innovative micro defocus spectacle lenses|
62595040|NCT06221592|EXPERIMENTAL|Circular multi-point optical micro transparent defocus spectacle lenses|
62236361|NCT05214196|EXPERIMENTAL|Hypochlorous acid group|The effect of 0.02% Hypochlorous acid solution on viral load was investigated by using 25 COVID-19 patients as an oral antiseptic for 30 seconds.
62236362|NCT05214196|ACTIVE_COMPARATOR|Povidone-iodine group|The effect on viral load was investigated by using 0.5% Povidone-iodine solution as an oral antiseptic for 30 seconds in 25 COVID-19 patients.
62236363|NCT05214196|PLACEBO_COMPARATOR|Saline group|The effect on viral load was investigated by using 0.9% isotonic saline solution as a placebo for 30 seconds in 25 COVID-19 patients.
62236364|NCT05615532|EXPERIMENTAL|LY3209590 (Part A - Upper Arm)|LY3209590 administered subcutaneously (SC) into the upper arm
62236365|NCT05615532|EXPERIMENTAL|LY3209590 (Part A - Thigh)|LY3209590 administered SC into the thigh
62236366|NCT05615532|EXPERIMENTAL|LY3209590 (Part A - Abdominal Wall)|LY3209590 administered SC into the abdominal wall
62236367|NCT05615532|EXPERIMENTAL|LY3209590 (Part B - IV Dose)|LY3209590 administered intravenously (IV)
62236368|NCT05615532|EXPERIMENTAL|LY3209590 (Part B - SC Dose)|LY3209590 administered SC into the abdominal wall
62236369|NCT00647322|EXPERIMENTAL|1|Reduction in anti-epileptic medications
62236370|NCT00647322|ACTIVE_COMPARATOR|2|No change in medication. Unchanged treatment
62426948|NCT02162511|EXPERIMENTAL|ARM A Malignant TBI|Malignant diseases Conditioning including total body irradiation and chemotherapy
62426949|NCT02162511|EXPERIMENTAL|ARM B Malignant Non-TBI|Malignant diseases chemotherapy based conditioning
62426950|NCT02162511|EXPERIMENTAL|ARM C Non-malignant|Non-malignant diseases Chemotherapy based conditioning
62426951|NCT03849794|EXPERIMENTAL|Experimental group|Chiropractic Care Plus Physiotherapy
62426952|NCT03849794|ACTIVE_COMPARATOR|Control group|Physiotherapy
62426953|NCT02014649|EXPERIMENTAL|20mg Laninamivir Octanoate|Dry Powder plus placebo
62426954|NCT02014649|EXPERIMENTAL|40mg Laninamivir Octanoate|Dry Powder
62426955|NCT00623909|EXPERIMENTAL|1|To demonstrate the safety of the AvicennaTM class IV laser for application over the skin of human subjects. This study was terminated prior to subject enrollment and closed.
62595041|NCT06221592|PLACEBO_COMPARATOR|High non spherical micro transparent defocus spectacle lenses|
62595042|NCT01393509|EXPERIMENTAL|PU-H71|This Phase 1 trial will be an open-label, dose-escalation study of single-agent PU-H71 in patients with advanced solid malignancies and lymphoma.
62035520|NCT04313881|EXPERIMENTAL|Magrolimab + Azacitidine|"Participants will receive the following magrolimab and azacitidine dosing regimens:~Magrolimab:~Magrolimab Priming Dose:~* 1 mg/kg on Days 1 and 4~* 15 mg/kg on Day 8~* 30 mg/kg on Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50)~Magrolimab Maintenance Dose:~* 30 mg/kg on Day 57 and 30 mg/kg every 2 weeks thereafter.~Azacitidine: 75 mg/m\^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each 28-day cycle."
62035521|NCT04313881|PLACEBO_COMPARATOR|Control Arm (Placebo + Azacitidine)|"Participants will receive the following placebo dosing regimens to mirror magrolimab dosing regimen in addition to azacitidine:~Placebo: On Days 1 and 4; Day 8; Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50). Additionally, placebo was administered on Day 57 and every 2 weeks thereafter.~Azacitidine: 75 mg/m\^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each cycle."
62236371|NCT04620525||Participants with the relevant condition|Participants with the relevant condition
62035522|NCT05483348||Patients who had successful endometrial ablation|Patients included in this group experienced abnormal uterine bleeding and underwent endometrial ablation. Successful ablation was defined as not undergoing subsequent gynecological procedures such as hysterectomy for any benign indication, D\&C or repeat ablation within 36 months after the endometrial ablation.
62035523|NCT05483348||Patients who had unsuccessful endometrial ablation|Patients included in this group experienced abnormal uterine bleeding and underwent endometrial ablation. Unsuccessful ablation was defined as undergoing subsequent gynecological procedures such as hysterectomy for any benign indication, D\&C or repeat ablation within 36 months after the endometrial ablation.
62035524|NCT04266782|EXPERIMENTAL|Physical exercise program and Long-walking|"A physical training will be started three months before the long-walking. The subjects will have to walk for at least 3 hours per week up to 6 hours per week during the training. THe long-distance capacity will be verified in 3 different one-day walking of 10, 15 and 18 Km before the long-walking performance.~The long-walking will be organized with the support of a physician, study nurse, physiotherapy with car support in case of need. The subject are request to complete the walk of 104 Km of Portuguese route of Santiago de Compostela walk."
62035525|NCT04266782|NO_INTERVENTION|Usual care|The subjects will be followed according to current standard.
62236372|NCT04620525||Healthy controls|Healthy controls
62236373|NCT02950324|EXPERIMENTAL|Prehabilitation|Patients in this (intervention) arm of the study will be enrolled into a multimodal programme that involves 15 weeks of exercise, nutritional support and psychological prehabilitation in the form of 'Medical Coaching'.
62236374|NCT02950324|ACTIVE_COMPARATOR|Standard care|Patients in the 'standard care' arm of the study will not receive the study intervention. The patients will continue to be offered the standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care.
62426956|NCT01804530|EXPERIMENTAL|PLX7486-TsOH, Dose escalation and RP2D|Part 1: Open-label, sequential PLX7486-TsOH single-agent dose escalation in approximately 60 patients with solid tumors.
62595043|NCT02698202|EXPERIMENTAL|Digital Breast Tomosynthesis|to the experimental arm will be offered twice screening examination: standard 2D mammography + Digital Breast Tomosynthesis
62812631|NCT00001832|EXPERIMENTAL|Abl Cells IV + MTD IL-2 no GCSF|Phase 2 Fludarabine 5x25mg/m\^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) without growth colony stimulating factor (G-CSF) (to determine if G-CSF has harmful effects when adoptively transferring lymphocytes following a nonmyeloablative chemotherapy regimen) Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
62812632|NCT00001832|EXPERIMENTAL|Abl Cells IV+MTD IL-2 no GCSF|"Abl Cells intravenous (IV) + maximum tolerated dose (MTD) interleukin-2 (IL-2) no growth colony stimulating factor (GCSF)(gp100 reactive).~Phase 2 Fludarabine 5x25mg/m\^2 + Cyclophosphamide 2x60mg/kg + Cells IV + IV IL-2 (720,000 IU/kg q8h for a maximum of 12 doses) without G-CSF + gp100:209-217(210M) 1mg/day (2-8 days) in patients with gp100 reactive cells Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days"
62426957|NCT02509520|NO_INTERVENTION|Mobility-based Physical Rehab (MPR)|ICU control group receiving only mobility based rehabilitation (MPR).
62426958|NCT02509520|ACTIVE_COMPARATOR|MPR and Neuromuscular Stimulation and HPRO|ICU group receiving mobility based rehabilitation and NMES and High protein supplementation.
62426959|NCT05700929|EXPERIMENTAL|Communication skills training|The intervention is a one-day face-to-face training to foster patient-centered communication skills of nursing professionals at the University Medical Center Hamburg-Eppendorf, Germany. The training is developed based on results of a previously conducted needs assessment with nurses, medical assistants and nursing service managers as well as literature research and will be rolled out after baseline assessment and randomization.
62595044|NCT02698202|NO_INTERVENTION|standard mammography|to the control arm the usual 2D standard mammography exam will be offered
62236375|NCT05031169|EXPERIMENTAL|A-PRF|Surgical treatment A-PRF membrane
62236376|NCT05031169|ACTIVE_COMPARATOR|SCTG|Surgical treatment with SCTG
62236377|NCT03545009|EXPERIMENTAL|Beetroot Juice|
62236378|NCT03545009|ACTIVE_COMPARATOR|Beetroot Juice no Nitrate|
62236379|NCT03545009|ACTIVE_COMPARATOR|Sodium Nitrate|
62236380|NCT03545009|NO_INTERVENTION|Control|
62735511|NCT03617601||> 4 MET|Patients with functional capacity over 4 MET
62735512|NCT03617601||< 4 MET|Patients with functional capacity under 4 MET
62735513|NCT01821066|EXPERIMENTAL|Two-Period Fixed-Sequence Arm|This arm is comprised of two treatment periods in fixed sequence. Period 1 is 7 days long, while Period 2 is 28 days long. In Period 1 the subjects receive a single 125 mg oral dose of PD-0332991 on Day 1. In Period 2 the subjects receive 4 daily 60 mg oral doses of tamoxifen (Days 1-4), followed by 23 daily 20 mg oral doses of tamoxifen (Days 5-27). On Day 22 of Period 2 the subjects receive a second 125 mg oral dose of PD-0332991.
62236381|NCT04973878|EXPERIMENTAL|Group A|EGD performed before the Colonoscopy
62236382|NCT04973878|EXPERIMENTAL|Group B|Colonoscopy performed before the EGD
62595045|NCT06622629|EXPERIMENTAL|Intervention Grop|"* Adults aged: 40-65 years~* Medical diagnosis of metabolic syndrome according to ATPIII criteria (Adult Treatment Panel III of the National Cholesterol Education Program): - Abdominal fat distribution: waist circumference \>102 cm (men), \>88 cm (women); - Serum triglycerides ≥150 mg/dL ; - HDL cholesterol: \<40 mg/dL (men), \<50 mg/dL (women); - Blood pressure: ≥130/≥85 mmHg; - Fasting blood glucose: ≥110 mg/dL: Sedentary/inactive lifestyle: Category 1 (low physical activity) of the International Physical Activity Questionnaire - Short Form (IPAQ- SF)~* Low nature engagement (low users of nature)~* Smartphone users."
62595046|NCT06622629|ACTIVE_COMPARATOR|Control group|The control group participants are assessed at the same time as those in the intervention group (t1, t2, and t3). Participants in the control group will be offered the opportunity to benefit from the NbT once the follow-up period is completed (day 70).
62595047|NCT03581734|ACTIVE_COMPARATOR|OPV only|The vaccine will be available in prefilled vials containing 10 doses. Each vial will be labelled with the study ID of the participant. Therefore, for participants randomized to arm A and arm C, there will be 3 vials per participant for the 3 doses of the bOPV vaccine to be given 28 weeks apart. Any remaining, non-used doses of vaccine in the vial will be discarded.
62236383|NCT03142763|EXPERIMENTAL|Egg intake|Consumption of 3 eggs per day for breakfast, 4 weeks
62812633|NCT00001832|EXPERIMENTAL|Abl Cells IV+MTD IL-2|"Abl Cells intravenous (IV)+ maximum tolerated dose (MTD) interleukin-2 (IL-2) no growth colony stimulating factor (GCSF) (melanoma-associated antigen recognized by T cells (MART-1)reactive).~Phase 2 Fludarabine 5x25mg/m\^2 + Cyclophosphamide 2x60mg/kg + Cells IV + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) without G-CSF + MART-1:26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days"
62236384|NCT03142763|EXPERIMENTAL|Choline Supplement intake|Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
62236385|NCT05601791|ACTIVE_COMPARATOR|Discoradicular contact+ESI TF|Patients with discorradicular contact who underwent ESI TF
62595048|NCT03581734|ACTIVE_COMPARATOR|Shanchol only|Each dose of vaccine is 1.5ml in volume. Each vial will be labelled with the study ID of the participant. One vial will be used per participant per study visit. OCV was studied in a double-blind, randomized, placebo-controlled trial in Kolkata, India. Participants were 1 year and above in age. In these studies, 100 children aged 1-17 were administered 2-doses of OCV or placebo separated by an interval of two weeks, with 80% of vaccinated showing over 4 fold rise in serum V. cholerae O1 antibody titers, showing that the 2-dose regimen was well-tolerated, safe and immunogenic
62595049|NCT03581734|EXPERIMENTAL|OPV-OCV co-administered|"Our primary analysis will be to compare seroconversion (defined as a change of status from seronegative to seropositive titers, or a ≥4-fold rise in antibody titer) for OPV1 and OPV 3 antibodies between Arm A and Arm C, to determine whether seroconversion to bOPV when administered with Shanchol is non-inferior to seroconversion to bOPV when bOPV is administered alone.~Our second objective will be to compare vibriocidal antibody seroconversion (also, ≥4-fold rise in antibody titers) to Shanchol when co-administered with OPV or when Shanchol is administered alone, Arm B compared to Arm C"
62812634|NCT00001832|EXPERIMENTAL|Abl Cells IV + SQ IL-2 with GCSF|Phase 2 Fludarabine 5x25mg/m\^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 (IL-2) (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + growth colony stimulating factor (G-CSF) (to shorten time to neutrophil recovery), reactivity not specified Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
62236386|NCT05601791|ACTIVE_COMPARATOR|Discoradicular contact+PLDD|Patients with discorradicular contact who underwent PLDD
62236387|NCT05601791|ACTIVE_COMPARATOR|Without discoradicular contact+ESI TF|Patients without discorradicular contact who underwent ESI TF
62236388|NCT05601791|ACTIVE_COMPARATOR|Without discoradicular contact+PLDD|Patients without discorradicular contact who underwent PLDD
62236389|NCT04635683|EXPERIMENTAL|Treatment (lenalidomide, umbralisib, ublituximab)|Patients receive lenalidomide PO QD on days 1-21 and umbralisib PO QD on days 1-28. Beginning in cycle 2, patients also receive ublituximab IV over 90 minutes to 4 hours on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve a partial or complete response after cycle 6 continue treatment of lenalidomide PO QD and umbralisib PO QD for 12 additional cycles, and ublituximab IV on day 1 of subsequent even cycles (8, 10, 12, 14, 16, and 18). Patients with stable disease after cycle 6 may continue on treatment for an additional 12 cycles at the discretion of the investigator.
62236390|NCT00662779|EXPERIMENTAL|1|15 mcg arformoterol nebulizer + 1 inhalation of placebo inhalation powder
62236391|NCT00662779|ACTIVE_COMPARATOR|2|1 inhalation of formoterol fumarate inhalation powder (12 mcg/inhalation) + 2 ml of normal saline nebulizer
62236392|NCT00662779|PLACEBO_COMPARATOR|3|1 inhalation of placebo inhalation powder + 2 ml of normal saline nebulizer
62236393|NCT06330168|EXPERIMENTAL|bupivacaine-calcitonin-fentanyl group|thoracic paravertebral block using 20 mL 0.25% bupivacaine, 100 micrograms of fentanyl (2ml), and 100 IU of calcitonin (1ml)
62236394|NCT06330168|PLACEBO_COMPARATOR|bupivacaine-fentanyl group|thoracic paravertebral block using 20 mL 0.25% bupivacaine, 100 micrograms of fentanyl (2ml), and 1 ml saline 0.9%.
62236395|NCT03242551|EXPERIMENTAL|Neoadjuvant chemotherapy|Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days.
62236396|NCT06073379|EXPERIMENTAL|Korean manupuncture|
62236397|NCT06073379|PLACEBO_COMPARATOR|Placebo/control|
62236398|NCT04580797|EXPERIMENTAL|PF-06700841: IR, MR1, MR2, MR1_fed|Participants receive single doses of immediate release (IR) followed by modified release (MR) MR1 and MR2, all in fasted condition followed by MR1 in fed condition in Periods 1-4
62236399|NCT04580797|EXPERIMENTAL|PF-06700841: MR1, MR2, IR, MR1_fed|Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR1 in fed condition in Periods 1-4
62035526|NCT04266782|ACTIVE_COMPARATOR|Control group-intervention|"A physical training will be started three months before the long-walking. The subjects will have to walk for at least 3 hours per week up to 6 hours per week during the training. THe long-distance capacity will be verified in 3 different one-day walking of 10, 15 and 18 Km before the long-walking performance.~The long-walking will be organized with the support of a physician, study nurse, physiotherapy with car support in case of need. The subject are request to complete the walk of 104 Km of Portuguese route of Santiago de Compostela walk."
62035527|NCT01490996|ACTIVE_COMPARATOR|Chemotherapy only|Patients receiving up to 12 cycles of therapy. Standard care pathway management.
62035528|NCT01490996|EXPERIMENTAL|Chemotherapy plus curcumin|Patients taking daily oral curcumin for up to 12 cycles of therapy. Standard care pathway management.
62035529|NCT03317600|ACTIVE_COMPARATOR|Lidocaine block|
62035530|NCT03317600|PLACEBO_COMPARATOR|Isotonic saline block|
62035531|NCT03421054|OTHER|nutraceutical containing HA|pain reduction of the affected knee in the patients assuming nutraceutical containing HA
62812635|NCT00001832|EXPERIMENTAL|Abl Cells IV + SQ|Abl Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 (IL-2) with growth colony stimulating factor (GCSF) (melanoma-associated antigen recognized by T cells (MART-1) reactive) Phase 2 Fludarabine 5x25mg/m\^2 + Cyclophosphamide 2x60mg/kg + Cells IV + SQ IL-2 (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + G-CSF + MART-1:26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
62812636|NCT00001832|EXPERIMENTAL|Abl Cells IV + SQ IL-2 with GCSF (no reactivity)|Phase 2 Fludarabine 5x25mg/m\^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 ( IL-2) (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + growth colony stimulating factor (G-CSF) in patients with no reactivity Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
62812637|NCT03217344|EXPERIMENTAL|1-week|patients undergoing 1-week immobilization period
62035532|NCT04814329||effective group|After treatment, tumor achieved complete response or partial response and the progression-free survival time was ≥6 months.
62035533|NCT04814329||stable group|After treatment, tumor remains stable and the progression-free survival time was more than 1 month and less than 6 months.
62035534|NCT04814329||Early progressed group|After treatment, tumor got progressed and the progression-free survival time was no more than 1 month.
62035535|NCT00440648|OTHER|1|sevelamer carbonate w(1-8) sevelamer hydrochloride w(9-16)
62595050|NCT01171781|ACTIVE_COMPARATOR|3 weekly CDDP based CCRT|radiation (conventioal or IMRT) with 3 cycles of 3-weekly cisplatin
62812638|NCT03217344|EXPERIMENTAL|3-week|patients undergoing 3-week immobilization period
62426960|NCT05700929|NO_INTERVENTION|Waitlist-control group|Participants of the waitlist-control group receive no specific study related intervention. Participants of this group will be offered a communication skills training after complete data collection of all participants of the RCT has been finished.
62812639|NCT05421949||Exercise|Patients who have been randomised to the exercise group will be asked to undertake a incremental shuttle walking test following their initial blood tests.
62812640|NCT05421949||No Exercise|Patients who have been randomised to the exercise group will be asked to rest for 60 minutes following their initial blood tests.
62812641|NCT01028443|ACTIVE_COMPARATOR|Cyclosporine A 2%|
62812642|NCT01028443|PLACEBO_COMPARATOR|Artificial tears|
62812643|NCT02647099|ACTIVE_COMPARATOR|Aspirin|One tablet acetylsalicylic acid (ASA) 160 mg, orally once daily for three years
62426961|NCT00267007|EXPERIMENTAL|001|PROCRIT 40 000 IU QW Epoetin alpha (PROCRIT) 40 000 IU every week (QW) for 18 weeks (IV or SC)
62426962|NCT00267007|PLACEBO_COMPARATOR|002|Placebo Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
62426963|NCT04175652|EXPERIMENTAL|Laughter yoga group, group doing laughter yoga|The duration of the laughter yoga was 30 minutes and a total of 16 sessions were performed on a twice-weekly basis.
62426964|NCT04175652|NO_INTERVENTION|No laughter yoga group, group not doing laughter yoga|
62426965|NCT01498900||Repaglinide|
62035536|NCT00440648|OTHER|2|sevelamer hydrochloride w(1-8) sevelamer carbonate w(9-16)
62035537|NCT01011829|ACTIVE_COMPARATOR|Varenicline|"Varenicline:~0.5 mg daily for days 1-3~0.5 mg twice daily for days 4-7~1 mg twice daily from day 8 until end of week 8."
62035538|NCT01011829|PLACEBO_COMPARATOR|Placebo|8 weeks of daily matching oral placebo in tablet form
62035539|NCT00344786|EXPERIMENTAL|CNF2024|
62035540|NCT03119857|ACTIVE_COMPARATOR|Antiandrogen|Antiandrogen (bicalutamide 150 mg x 1) p.o. alone,
62035541|NCT03119857|EXPERIMENTAL|Antiandrogen + docetaxel|Antiandrogen (bicalutamide 150 mg x 1) p.o. + Docetaxel 75 mg/m2 (maximum 2.0 m2 ) i.v. q 3 weeks x up to 8-10 cycles.
62035542|NCT02420470||healthy control group|fasting plasma glucose(FPG)\<6.11mmol/L，and 2-h plasma glucose(2hPG)\<7.77mmol/L；
62035543|NCT02420470||prodromal diabetes group|IFG：fasting plasma glucose(FPG) ≥5.6mmol/L (100mg/dl)，and\<7.0mmol/L (126mg/dl)，oral glucose tolerance test(OGTT) 2-h plasma glucose(2hPG) \<7.8 mmol/L ；IGT：oral glucose tolerance test(OGTT) 2-h plasma glucose(2hPG) ≥7.8mmol/L (140mg/dl)，and\<11.1mmol/L (200mg/dl)，fasting plasma glucose(FPG)\< 5.6mmol/L
62035544|NCT02420470||diabetes group|fasting plasma glucose(FPG)\>7.0mmol/L, or 2-h plasma glucose(2hPG)\>11.1mmol/L
62035545|NCT00791765|EXPERIMENTAL|Placebo BIW/Etanercept 50 mg BIW|Participants received placebo subcutaneous injections twice per week (BIW) for the first 12 weeks of the study. From Week 12 to Week 24, participants received etanercept 50 mg BIW.
62595051|NCT01171781|EXPERIMENTAL|weekly cisplatin based CCRT|radiation (conventional or IMRT) with 7 cycles of weekly cisplatin therapy
62595052|NCT03122743||Ancillary-Correlative (collection of samples, questionnaires)|Patients undergo collection of serum samples for epinephrine and cortisol levels at baseline and 4 clinical visits. Patients also receive the Self-Perceived Stress questionnaire and the Distress Thermometer questionnaire to measure perceived stress.
62595053|NCT00564837|EXPERIMENTAL|Home-based|Home-based post-operative rehabilitation program with 4 scheduled physiotherapy sessions over the first 3 post-op months
62426966|NCT04843800|EXPERIMENTAL|Acupuncture|The acupuncture treatments will consist of one 45-minute session weekly, for 3 consecutive weeks. The acupuncture treatment protocol will be semi standardized according to usual practice. All patients will be treated with a selection of local and distant points, comprising 10 minutes of insertion time, 30 minutes of needle retention and manipulation to achieve de qi (an irradiating feeling) if possible.
62595054|NCT00564837|ACTIVE_COMPARATOR|Physiotherapy supervised|Physiotherapy-supervised rehabilitation program including 17 scheduled physiotherapy sessions in the first 3 post-op months
62426967|NCT04843800|EXPERIMENTAL|Chiropractic|The chiropractic treatments will consist of one 20-minute session weekly, for 3 consecutive weeks. The Diversified technique is one of the most commonly practiced techniques by chiropractors. In the treatment of low back pain, this technique involves the application of a quick (high-velocity), short (low-amplitude) thrust (adjustment) to the lumbo-pelvic area.
62426968|NCT04843800|EXPERIMENTAL|Waiting list and Therapeutic Massage|The therapeutic massage treatments will consist of one 45-minute session weekly, for 3 consecutive weeks. A technique called Fascial Release will be used. Tension related to back pain is believed to be present not only in the back but also in various parts of the body such as the legs, through the connection of fascia, the membrane that surrounds the muscles. The purpose of this treatment is to reduce the tension connected to the lower back.
62426969|NCT00947609||HIV-infected and HIV-uninfected children|HIV-infected and HIV uninfected children with recent exposure to adults with active tuberculosis will be referred to the two study sites (HIV-NAT/Chulalongkorn and Queen Sirikit) for eligibility screening and enrollment in the study.
62426970|NCT06497361|EXPERIMENTAL|CAR T cells therapy|"The study was divided into two phases: dose exploration phase and dose extension phase. Three dose levels (35×10\^6 CAR-T, 100×10\^6 CAR-T, 300×10\^6 CAR-T) were planned for the dose-exploration phase, and 3 to 6 LN or IgG4-RD subjects were included in each dose group. When 1 out of 3 subjects in a dose group showed DLT, 3 subjects were re-enrolled at that dose level. If DLT occurs in ≥2 of 6 subjects, dose reduction or study termination should be considered.~The safe and effective fixed dose of PRG-2311 was determined through the dose-exploration phase, and after evaluation by the investigators, the dose-expansion phase was conducted, in which an additional 3-6 subjects were included in the safe and effective fixed dose for each of the two indications (Lupus Nephritis and IgG4-Related Disease) to further determine the safety and efficacy of this dose for each indications."
62595055|NCT05204160|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62595056|NCT01537874|EXPERIMENTAL|Motivational Interview Intervention|Motivational interviewing session (1 hour in home) plus 2 follow-up phone calls
62595057|NCT01537874|OTHER|Usual Best Practices|Standard care delivered using informational materials
62595058|NCT03138252|ACTIVE_COMPARATOR|Cervical Ripening Balloon Alone|Multiparous women will begin cervical ripening with a cervical ripening balloon alone. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.
62812644|NCT02647099|PLACEBO_COMPARATOR|Placebo|One tablet placebo orally once daily for three years
62812645|NCT03992053|ACTIVE_COMPARATOR|Group 1|conventional 2-D fluoroscopy guidance as the first choice of guidance
62812646|NCT03992053|ACTIVE_COMPARATOR|Group 2|3-D CT guidance as the first choice of guidance
62812647|NCT01064063|ACTIVE_COMPARATOR|AGC knee|Patients were randomised to receive an AGC Cruciate Retaining cement knee. This is the control group in the study; the AGC is the gold standard of Biomets' knee products.
62426971|NCT03241407|PLACEBO_COMPARATOR|Placebo toothpaste|Fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.
62595059|NCT03138252|ACTIVE_COMPARATOR|Cervical Ripening Balloon + Oxytocin|Multiparous women will begin cervical ripening with a cervical ripening balloon and simultaneous oxytocin. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.
62595060|NCT00380081|EXPERIMENTAL|placebo/zolpidem 3.5/zolpidem 1.75|
62426972|NCT03241407|EXPERIMENTAL|triclosan/copolymer/fluoride toothpaste|triclosan/copolymer/fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min. During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
62595061|NCT00380081|EXPERIMENTAL|placebo/zolpidem 1.75/zolpidem 3.5|
62595062|NCT00380081|EXPERIMENTAL|zolpidem 3.5/placebo/zolpidem 1.75|
62595063|NCT00380081|EXPERIMENTAL|zolpidem 3.5/zolpidem 1.75/placebo|
62595064|NCT00380081|EXPERIMENTAL|zolpidem 1.75/placebo/zolpidem 3.5|
62595065|NCT00380081|EXPERIMENTAL|zolpidem 1.75/zolpidem 3.5/placebo|
62595066|NCT06618872|EXPERIMENTAL|Amyloid-PET and then Tau-PET|The participant will have the Amyloid-PET (standard of care) and then Tau-PET (experimental)
62735514|NCT02199470||C-peptide minimal detectable|C-peptide level between 0,01-0,08 ng/mL
62812648|NCT01064063|EXPERIMENTAL|Vanguard CR|Patients were randomised to receive a Vanguard Cruciate Retaining Knee from the Vanguard system which encompasses concepts used in the AGC family of knees. The Vanguard is specifically designed to give greater knees stability through use of more anatomic patello-femoral kinematics.
62595067|NCT06618872|EXPERIMENTAL|Tau-PET and then Amyloid-PET|The participant will have the Tau-PET (experimental) and then the Amyloid-PET (standard of care)
62426973|NCT01676311|EXPERIMENTAL|Huperzine A|Huperzine A will be administered to patients, titrating dose up from 100mcg/day to 600mcg per day over the course of 20 days - and remaining on the dose of 600mcg/day for the remainder of the drug phase (64 days) - for a total of 12 weeks on Huperzine A.
62426974|NCT01676311|PLACEBO_COMPARATOR|Placebo|Placebo will be administered to patients at the same frequency/intervals as the experimental arm (Huperzine-A).
62426975|NCT05636774|EXPERIMENTAL|Heart failure medication arm|Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin
62426976|NCT05636774|PLACEBO_COMPARATOR|Placebo arm|Placebo tables / infusion
62426977|NCT06087185|EXPERIMENTAL|Mindful Eating Group|Mindful Eating practices will be taught during a weekly meeting lasting 150 minutes and individuals will be encouraged to integrate the practices learned into their daily lives, for at least 15 minutes a day, being progressively integrated into the other practices that will be taught in subsequent weeks. There will be a WhatsApp group with reminders during the week and audio for guided practice.
62426978|NCT06087185|ACTIVE_COMPARATOR|Video Group|"Composed of 5 videos sent weekly produced by trained professionals. The topics discussed will be relevant to the management of anxiety in general and lifestyle changes.~Video 1: Psychoeducation of anxiety. Video 2: Healthy eating. Video 3: Sleep hygiene. Video 4: Physical activity. Video 5: Substance use. This protocol used as a control was effective as a Psychoeducation Group in improving anxiety symptoms in patients with generalized anxiety disorder."
62426979|NCT00612079|EXPERIMENTAL|2|Healthy volunteers with high sensory gating levels.
62426980|NCT00612079|EXPERIMENTAL|1|Healthy volunteers with low sensory gating levels.
62426981|NCT03438331|EXPERIMENTAL|CBT-I|
62426982|NCT03438331|ACTIVE_COMPARATOR|CBT-D|
62426983|NCT03438331|NO_INTERVENTION|Waiting-list control|
62426984|NCT06420401|EXPERIMENTAL|Dietary supplement: araboxylan|Eligilable subjects are instructed to take one pocket of araboxylan during the first week, followed by two pockets of araboxylan during the remaining 11 weeks.
62426985|NCT06420401|EXPERIMENTAL|Dietary supplement: inulin|Eligilable subjects are instructed to take one pocket of inulin during the first week, followed by two pockets of inulin during the remaining 11 weeks.
62426986|NCT06420401|EXPERIMENTAL|Dietary supplement: inulin and araboxylan|Eligilable subjects are instructed to take one pocket of inulin and arabosylan during the first week, followed by two pockets of inulin and araboxylan during the remaining 11 weeks.
62812649|NCT06056310|EXPERIMENTAL|Xevinapant + Cisplatin + IMRT|Participants will receive xevinapant once daily from Day 1 to Day 14, per 3-week cycle (Each cycle is of 3 weeks). The first three cycles are given in combination with weekly cisplatin and radiotherapy, followed by 3 cycles of monotherapy xevinapant.
62812650|NCT04481243|EXPERIMENTAL|Pneumovax 23|Type 1 Diabetes subjects will receive Pneumovax 23-pneumococcal polysaccharide (PPSV23)
62426987|NCT06420401|PLACEBO_COMPARATOR|Dietary supplement: placebo|Eligilable subjects are instructed to take one pocket of maltodextrin during the first week, followed by two pockets of maltodextrin during the remaining 11 weeks.
62812651|NCT00991861|EXPERIMENTAL|LAS41007 o.d.|Once daily
62812652|NCT00991861|EXPERIMENTAL|LAS41007 b.i.d.|Twice daily
62426988|NCT03082820||Patients|Pain-related evoked potentials (PREP), Quantitative Sensory Testing (QST) and nerve conduction studies (NCS) were performed with patients with peripheral nerve injury.
62426989|NCT03082820||Controls|Pain-related evoked potentials (PREP) and Quantitative Sensory Testing (QST) were performed with healthy adults.
62426990|NCT05925569|EXPERIMENTAL|BPA Alert Intervention|An on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the clinician that their patient should be screened for Primary Aldosteronism and provides an order set for the corresponding laboratory evaluation. Details of the electronic alert are provided in the Intervention description.
62595068|NCT00658775|EXPERIMENTAL|1|
62595069|NCT00658775|ACTIVE_COMPARATOR|2|
62595070|NCT06206551||Prospective patients|Patients who are on the palliative care ward or who are being treated by the palliative consultation service at the University Hospital Muenster.
62595071|NCT06206551||Restrospective patients|Patients who were on the palliative care ward or were treated by the palliative consultation service at University Hospital Muenster during the same period in the previous year.
62595072|NCT01463592|EXPERIMENTAL|Group II a|TRIPPLE THERAPY
62812653|NCT00991861|ACTIVE_COMPARATOR|LAS106521|
62812654|NCT01161940|EXPERIMENTAL|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited
62812655|NCT01161940|ACTIVE_COMPARATOR|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
62595073|NCT01463592|ACTIVE_COMPARATOR|Group II b|DUAL THERAPY
62595074|NCT01463592|EXPERIMENTAL|Group I|ORAL RENESSANS
62812656|NCT02571712|OTHER|GANFORT®|One drop of GANFORT® (bimatoprost 0.03% plus timolol 0.5%) instilled in each affected eye once daily in the evening for 24 weeks.
62812657|NCT05149235|ACTIVE_COMPARATOR|early mobilization group|this group will perform early mobilization exercises using a cycle ergometer.
62812658|NCT05149235|EXPERIMENTAL|game tech group|this group will use physio adventure device instead of a cycle ergometer
62595075|NCT02836236|EXPERIMENTAL|Double-Blind TAF|Tenofovir alafenamide (Vemlidy®; TAF) 25 mg tablet + tenofovir disoproxil fumarate (Viread®; TDF) placebo tablet once daily for up to 144 weeks (per amendment 3.1).
62595076|NCT02836236|ACTIVE_COMPARATOR|Double-Blind TDF|TDF 300 mg tablet + TAF placebo tablet once daily for up to 144 weeks (per amendment 3.1).
62595077|NCT02836236|EXPERIMENTAL|Open-label TAF|All participants who complete the double-blind period will be eligible to receive open-label TAF until Week 384 of the study.
62426991|NCT05925569|NO_INTERVENTION|No Alert Intervention|No electronic alert will be issued in the No Intervention group. Providers will continue standard of care with their patients.
62426992|NCT03606239|EXPERIMENTAL|isotoxic hypofractionated group|"Hypofractionated radiation:~1. Split mode: 3Gy/f. 2,Individualized prescriptions for different patients:~(1) Spinal cord: 0%\>45 Gy, and ≤2 Gy each time Lung: V20≤30%, V5≤65%, MLD≤16Gy Esophagus: highest dose ≤ 69Gy 3. Maximum limit: If the limit of any A is not reached, the maximum radiation dose is 69 Gy. The lowest radiation dose: 45Gy.~Chemotherapy:~Platinum-containing two-drug regimen: docetaxel + lobaplatin: Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1; repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.~The same chemotherapy regimen is used up to 4 cycles as consolidation after the completion of radiotherapy."
62595078|NCT05035667||Observational (questionnaires)|Patients complete questionnaires over 30 minutes about level of anxiety and social media use and management.
62595079|NCT04631484|EXPERIMENTAL|Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)|Patients will receive treatment with the study drug, 20 ml twice a day IV, dissolved in 200 ml of 0.9% NS, for 10 days;patients will stay in the hospital for the the entire period of therapy. Observation of patients and assessment of the main parameters of the efficacy and safety will continue for 14 days.
62595080|NCT04631484|PLACEBO_COMPARATOR|Placebo|Patients will receive 20 ml placebo (0.9% sodium chloride solution) twice a day IV, dissolved in 200 ml of 0.9% NS, for 10 days; patients will stay in the hospital for the the entire period of therapy. Observation of patients and assessment of the main parameters of the efficacy and safety will continue for 14 days.
62595081|NCT06621134||Control Group|Participants will be asked to consent to randomization on their first access to our system. Users ask questions covered by the question bank and specific questions not covered by the question through a telephone hotline.
62426993|NCT03014531|EXPERIMENTAL|almond|In this group, participants were provided with 56 g of almonds per day either as preload before meals or snack between meals. A snack was defined as an eating event that occurred between participants' regular meals, specifically two hours before and after meals. All the participants in almond group were provided daily portions of packaged almonds.
62426994|NCT03014531|OTHER|high-carbohydrate control food item|In this group, participants were provided with high-carbohydrate control food item that had a similar number of calories as 56 g of almonds.
62426995|NCT01155284|EXPERIMENTAL|Sitagliptin and Lansoprazole|Sitagliptin 50mg co-administered with Lansoprazole 30mg. Subjects age 11-17 years at Visit 2 will take 1 capsule of each once daily Subjects age 18-45 years at Visit 2 will take 2 capsules of each once daily
62595082|NCT06621134||Intervention Group|Participants will be required to provide consent for randomization when they first access our system. Users can ask questions covered by the question bank, as well as specific questions not covered by the bank, through an AI chatbox.
62595083|NCT04773184||Healthy adults|132 individuals with no history of swallowing impairment or any health conditions known to impact swallowing function will be included in this study to serve as a comparative control group or reference standard group here and in future studies.
62595084|NCT04773184||Adults at risk for swallowing impairment.|132 individuals with an underlying condition documented to lead to dysphagia will be enrolled in this study. 2) Confirmed medical diagnosis associated with an increased risk of dysphagia including but are not limited to: head and neck cancer, neurologic (e.g., stroke, traumatic brain impairment), neurodegenerative (e.g., Parkinson's disease, amyotrophic lateral sclerosis), neuromuscular disorders (e.g., myotonic dystrophy, Pompe disease, inclusion body myositis) rheumatologic diseases (e.g., dermatomyositis, inclusion body myositis, scleroderma), chronic respiratory illnesses (e.g., chronic obstructive pulmonary disease), structural (e.g., mass or trauma to the upper aerodigestive tract) and iatrogenic conditions (e.g., post-surgical such as anterior cervical discectomy/fusion or cardiac, post-radiation treatment to the upper aerodigestive tract).
62595085|NCT04456868|ACTIVE_COMPARATOR|Healthy volunteers|Healthy volunteers at least 18 years old and without a history of psychiatric or neurological disorders
62595086|NCT04456868|EXPERIMENTAL|Anhedonic drug-resistant bipolar depression patient|Adult patients at least 18 years old with drug-resistant bipolar depression of the anhedonic type
62595087|NCT04456868|ACTIVE_COMPARATOR|Non-anhedonic drug-resistant bipolar depression Pat|Adult patients at least 18 years old with drug-resistant bipolar depression of the non-anhedonic type
62595088|NCT04456868|ACTIVE_COMPARATOR|Mild to moderate Parkinson's disease patient|Adult patients at least 18 years of age with mild to moderate Parkinson's disease
62735515|NCT02199470||C-peptide sustained|C-peptide level between higher or equal to 0,08 ng/mL
62035546|NCT00791765|EXPERIMENTAL|Etanercept 50 mg BIW/Etanercept 50 mg QW|Participants received etanercept 50 mg by subcutaneous injection twice per week (BIW) for the first 12 weeks of the study. From Week 12 to Week 24, participants received etanercept 50 mg once per week (QW) and placebo once per week.
62035547|NCT05897437||ADHD group|Children with ADHD
62735516|NCT02199470||C-peptide not detectable|C- peptide level equal to or lower than 0,01 ng/mL
62735517|NCT04514627|ACTIVE_COMPARATOR|Active percutaneous neurostimulation|Subject randomized to 5 days of active vs sham neurostimulation therapy during hospitalization.
62735518|NCT04514627|SHAM_COMPARATOR|Sham percutaneous neurostimulation|Each subject randomized to 5 days of active vs sham neurostimulation therapy during hospitalization.
62236400|NCT04580797|EXPERIMENTAL|PF-06700841: MR2, IR, MR1, MR1_fed|Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR1 in fed condition in Periods 1-4
62236401|NCT04580797|EXPERIMENTAL|PF-06700841: IR, MR1, MR2, MR2_fed|Participants receive single doses of IR followed by MR1 and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4
62236402|NCT04580797|EXPERIMENTAL|PF-06700841: MR1, MR2, IR, MR2_fed|Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR2 in fed condition in Periods 1-4
62426996|NCT01155284|PLACEBO_COMPARATOR|Placebo|Sitagliptin Placebo and Lansoprazole placebo capsules will be administered. Subjects age 11-17 years at Visit 2 will take 1 placebo capsule of each once daily Subjects age 18-45 years at Visit 2 will take 2 placebo capsules of each once daily
62426997|NCT03031431|EXPERIMENTAL|Non-Electric Infant Warmer|In line with current recommended practice, mothers will be encouraged to provide Kangaroo Mother Care (KMC) whenever possible. If an infant's temp is not rising by ½ degree C per hour with KMC alone, the infant warmer will be offered as an addition by the study team. If the mother is not available for KMC at any time, the infant will be warmed exclusively with the warmer. Bundling in clothes will only be used in addition to the warmer per carer preference. Temp measurement of the infant, warmer, and ambient air will be measured every 15 mins for the first hr, then hrly and as needed for the remainder of use or until warmer endpoint is reached (warmer temp below 36 degrees or phase-change material hardens \[soft, semisoft, or hardened\]).
62426998|NCT02736526|EXPERIMENTAL|Surgical treatment|The recession or resection of the horizontal extraocular muscles will be processed in the beginning of the trial.
62426999|NCT02736526|NO_INTERVENTION|Observation only|
62427000|NCT01672814|ACTIVE_COMPARATOR|Keraflex combined with Crosslinking|Vedera KXS microwave system used in conjunction with corneal collagen crosslinking performed with VibeX (Riboflavin ophthalmic solution)and the KXL UV System
62427001|NCT01672814|ACTIVE_COMPARATOR|Corneal collagen crosslinking alone|Corneal collagen crosslinking alone performed with VibeX (Riboflavin Ophthalmic Solution)and the KXL UV system
62427002|NCT03115060|EXPERIMENTAL|normal saline|Intravenous fluid used in these patients would be normal saline which would be given intravenously during intraoperative and postoperative period
62427003|NCT03115060|EXPERIMENTAL|ringer lactate|Intravenous fluid used in these patients would be ringer lactate which would be given intravenously during intraoperative and postoperative period
62427004|NCT03115060|EXPERIMENTAL|plasmalyte A|Intravenous fluid used in this arm in patients would be plasmalyte A which would be given intravenously during intraoperative and postoperative period
62427005|NCT02438865|ACTIVE_COMPARATOR|Single instillation group|will receive single intravesical dose of epirubicin intravesical therapy (50 mg) within 48 hours of radical nephroureterectomy with open bladder cuff excision.
62427006|NCT02438865|ACTIVE_COMPARATOR|Maintainance therapy group|will receive a single intravesical dose of epirubicin and an additional 6 weekly doses of intravesical therapy (50 mg) after surgery then monthly maintenance therapy for 1 year.
62427007|NCT03661294|OTHER|GE Healthcare Metabolic Oxygenator|The actual and predicted energy expenditure of tetraplegic (ventilated/non-vent) and paraplegic patients will be measured at three time points during the patient's rehabilitation in hospital.
62035548|NCT05897437||Control Group|Typically developing children
62035549|NCT00907153|EXPERIMENTAL|Vitamin D|
62035550|NCT00907153|PLACEBO_COMPARATOR|Placebo|
62035551|NCT00417079|ACTIVE_COMPARATOR|Mitoxantrone + Prednisone|Mitoxantrone + Prednisone
62035552|NCT00417079|EXPERIMENTAL|Cabazitaxel + Prednisone|Cabazitaxel + Prednisone
62236403|NCT04580797|EXPERIMENTAL|PF-06700841: MR2, IR, MR1, MR2_fed|Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4
62236404|NCT04580797|EXPERIMENTAL|PF-06700841 MR3 (Dose A) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose A) or matching placebo for 7 days under fasted condition
62236405|NCT04580797|EXPERIMENTAL|PF-06700841 MR3 (Dose B) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose B) or matching placebo for 7 days under fasted condition
62236406|NCT04580797|EXPERIMENTAL|PF-06700841 MR3 (Dose C) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose C) or matching placebo for 7 days under fasted condition
62236407|NCT03892993|EXPERIMENTAL|Supportive care (decision aid)|Participants use decision aid and complete questionnaires.
62595089|NCT01700075|ACTIVE_COMPARATOR|Conventional treatment|"Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day."
62595090|NCT01700075|EXPERIMENTAL|Weight loss treatment|Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
62236408|NCT06248931|ACTIVE_COMPARATOR|valproate arm|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive valproate 500-1000mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of valproate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
62236409|NCT06248931|ACTIVE_COMPARATOR|topiramate arm|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive topiramate 50-100mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of valproate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
62236410|NCT02013505|NO_INTERVENTION|Instructions printed on a paper.|There will be no intervention.
62427008|NCT01655433|EXPERIMENTAL|Therapeutic Hypothermia Treatment|
62427009|NCT01655433|ACTIVE_COMPARATOR|No Hypothermia Treatment|control group is no hypothermia treatment
62812659|NCT05149235|PLACEBO_COMPARATOR|placebo group|this group is placebo control and will receive routine respiratory physiotherapy
62595091|NCT01176695|EXPERIMENTAL|1|fish oil containing lipid emulsion
62427010|NCT00975273|EXPERIMENTAL|Breathing Training|Patients will receive biofeedback assisted breathing training
62595092|NCT01176695|ACTIVE_COMPARATOR|2|MCT/LCT containing lipid emulsion
62427011|NCT00975273|ACTIVE_COMPARATOR|Breathing Awareness|Patients will receive biofeedback assisted breathing awareness training.
62427012|NCT04120714|EXPERIMENTAL|Active tDCS group|Active tDCS
62427013|NCT04120714|PLACEBO_COMPARATOR|Placebo tDCS group|Inactive tDCS
62427014|NCT04664569||Cohort of bacterial meningitis in children|
62427015|NCT06545448||Patients undergoing elective PCI|Patients undergoing elective PCI for chronic coronary syndrome in a tertiary hospital in a single center in Brazil between 2017-2020.
62427016|NCT01176474|EXPERIMENTAL|Nivolumab and Peptide Vaccine|"Cohorts 1 through 3: Participants will receive nivolumab with the peptide vaccine within 8 days after their first apheresis procedure.~Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG with Escalating Doses of Anti-PD-1 Antibody Nivolumab (BMS-936558). Level 1: 1 mg/kg Nivolumab + peptide vaccine. Level 2: 3 mg/kg Nivolumab + peptide vaccine. Level 3: 10 mg/kg Nivolumab + peptide vaccine."
62595093|NCT02449317|OTHER|Control|standard hydration : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
62595094|NCT02449317|EXPERIMENTAL|Bioimpedance guided|"Bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water~* extracellular water/total body water \< 0.36 : 4 ml/kg/hr~* extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr~* extracellular water/total body water \> 0.4 : 1 ml/kg/hr"
62595095|NCT04360174|EXPERIMENTAL|OTX-TIC-Cohort 1|15 µg (formulation1) implant
62812660|NCT05633563|ACTIVE_COMPARATOR|Active Drug|Study participants receiving Trimetazidine
62812661|NCT05633563|PLACEBO_COMPARATOR|Placebo|Study participants receiving placebo (calcium)
62427017|NCT01176474|EXPERIMENTAL|Nivolumab and Ipilimumab|Cohorts 4 and 5. Participants will receive their first dose of nivolumab with ipilimumab within 28 days after screening blood draws. Both drugs will be given. Cohort 4: nivolumab 1mg/kg plus ipilimumab 3mg/kg. Cohort 5: nivolumab 3mg/kg plus ipilimumab 1mg/kg.
62427018|NCT03881579|OTHER|Usual care|one random half of patients will receive usual care
62812662|NCT03253679|EXPERIMENTAL|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62812663|NCT03460886|EXPERIMENTAL|Bihemispheric stimulation|"1. Anodal stimulation on ipsilesional leg motor primary cortex and supplementary motor area~2. Anodal stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
62812664|NCT03460886|EXPERIMENTAL|Ipsilesional stimulation|"1. Anodal stimulation on ipsilesional leg motor primary cortex and supplementary motor area~2. Sham on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
62812665|NCT03460886|EXPERIMENTAL|Contralesional stimulation|"1. Sham stimulation on ipsilesional leg motor primary cortex and supplementary motor area~2. Anodal stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
62812666|NCT03460886|ACTIVE_COMPARATOR|Sham|"1. Sham stimulation on ipsilesional leg motor primary cortex and supplementary motor area~2. Sham stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
62236411|NCT02013505|EXPERIMENTAL|Paper and video instructions|.Instructions printed on paper and a educational video.
62035553|NCT01016769|EXPERIMENTAL|Temsirolimus + Weekly Paclitaxel + Carboplatin|"In Part 1 (Phase I) of the study, the primary endpoint is to establish the phase II recommended dose for the combination of temsirolimus + weekly paclitaxel + carboplatinPart 1 (Phase I) features a standard 3 + 3 phase I dose escalation design. Up to 3 dose levels are planned in the Phase I portion of the study.~In Part 2 (Phase II) of the study, the primary endpoint is to determine the objective response rate (CR or PR) after two cycles (approximately 6 weeks) of treatment with the combination of temsirolimus + weekly paclitaxel + carboplatin as palliative therapy for recurrent or metastatic HNSCC. A two-stage design will be employed."
62427019|NCT03881579|EXPERIMENTAL|intervention arm|one random half of patients will receive enhanced usual care (usual care plus nurse-led supportive care intervention)
62236412|NCT02629289|OTHER|Treatment A|HSP-130, 6 mg, single subcutaneous (SC) injection in the deltoid region
62236413|NCT02629289|OTHER|Treatment B|US-approved Neulasta, 6 mg, single SC injection in the deltoid region
62236414|NCT02629289|OTHER|Treatment C|EU-approved Neulasta, 6 mg, single SC injection in the deltoid region
62427020|NCT06394921||People with Long COVID|"Eligibility~* Aged 18 to 65 years old~* Diagnosed with COVID-19~* Still suffering from symptoms and experiencing functional limitations beyond 3 months after initial COVID-19 infection (quantified as PCFS grade 1 or greater).~* Sufficient English language comprehension and cognitive ability to understand the study protocol, give informed consent and follow instructions."
62427021|NCT01286688|EXPERIMENTAL|Terbinafine Hydrochloride|Terbinafine Hydrochloride Tablets, 250 mg of Dr.Reddy's Laboratories Limited
62427022|NCT01286688|ACTIVE_COMPARATOR|Lamisil® 250 mg Tablets|Lamisil® 250 mg Tablets of Novartis
62427023|NCT05181761|EXPERIMENTAL|Left Hand with gel polish|The participants will receive gel nail polish on their left hand. The right hand will remain natural (no gel polish)
62427024|NCT05181761|EXPERIMENTAL|Right Hand with gel polish|The participants will receive gel nail polish on their right hand. The left hand will remain natural (no gel polish).
62427025|NCT02038101|EXPERIMENTAL|Education and Feedback Intervention|"This intervention includes the following components:~1. Formal Rounds on AUC for TTE:~2. Appropriate Use for TTE Application for Smartphone~3. Individualized Feedback Reports provided by email"
62427026|NCT02038101|NO_INTERVENTION|Control|Usual echocardiography ordering pratice.
62427027|NCT04171986|EXPERIMENTAL|Test Group|
62427028|NCT05525299|EXPERIMENTAL|Intervention|A brief reminiscence-based life review with six themes to recall subjects' memory through the life review reminiscence intervention will be given. A total of six reminiscence chatting sessions (30-60 minutes per session) covering these themes will be conducted weekly.
62427029|NCT05525299|NO_INTERVENTION|Control|The subjects allocated in the Control group will not receive any intervention.
62427030|NCT05787210|ACTIVE_COMPARATOR|Control group|
62427031|NCT05787210|EXPERIMENTAL|Strength|
62427032|NCT06567938|EXPERIMENTAL|IVUS-guidance PCI|In the IVUS-guidance group, the optimal stent deployment criteria for non-left main lesion will include the following: : (1) the minimal lumen area (MLA) in the stented segment \> 5.0 mm\^2 or \> 90% of the MLA at the distal reference segments, (2) plaque burden 5 mm proximal or distal to the stent edge is \< 55%, and (3) absence of medial dissection over 3 mm in length. In the setting of a two-stent approach for distal left main bifurcation lesions, the optimal stent deployment criteria are an absolute minimal stent area (MSA) greater than 8 mm\^2 for the left main, greater than 7 mm\^2 for carina, greater than 6 mm\^2 for the ostial or proximal left anterior descending artery, and greater than 5 mm\^2 for the ostial or proximal left circumflex artery. For left main lesion treated with single-stent technique, the criteria are greater than 7mm\^2 for distal and greater than 8mm\^2 for proximal. Further treatment will be required if the criteria are not met.
62427033|NCT06567938|ACTIVE_COMPARATOR|Angiography-guidance PCI|Angiographic success is defined as thrombolysis in myocardial infarction (TIMI) flow grade 3, and residual stenosis \< 20%.
62427034|NCT02757131|EXPERIMENTAL|Intervention|"Patients randomized to the intervention group will be asked to participate in the ambulation protocol outlined by the Physical Therapy (PT) staff 3 times daily under the supervision of the dedicated ambulator PCNA.~The ambulator will be trained by the physical therapy team on how to implement the protocol prior to initiation of the study."
62595096|NCT04360174|EXPERIMENTAL|OTX-TIC-Cohort 2|26 µg (formulation1) implant
62595097|NCT04360174|EXPERIMENTAL|OTX-TIC-Cohort 3|15 µg (formulation 2) implant
62595098|NCT04360174|EXPERIMENTAL|OTX-TIC-Cohort 4|5 µg (formulation 3) implant
62595099|NCT03219359|EXPERIMENTAL|Experimental|Hematopoietic Stem Cell Transplant followed by maintenance Vedolizumab
62236415|NCT04171622|EXPERIMENTAL|Treatment (pembrolizumab, lenvatinib)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive lenvatinib PO daily on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62236416|NCT04624373||Identified mutation|The sensitivity of supernatant to identify the mutations detected on cell block (Gold standard).
62236417|NCT04624373||Non identified mutation|The sensitivity of supernatant to identify the mutations detected on cell block (Gold standard).
62236418|NCT04727086|EXPERIMENTAL|Medication (BP1.3656)|Participants will receive BP1.3656 in tablet form once daily at a dose of 30 µg/day for the first 4 days, followed by 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg.
62236419|NCT04727086|PLACEBO_COMPARATOR|Placebo pills|Participants will receive matching placebo pills for 14 days.
62812667|NCT06415890|EXPERIMENTAL|Breathing Exercise Group|In addition to the routine treatment and care practices of the clinic, the patients included in the study group will be taught the 4-7-8 breathing technique by the researcher and applied after surgery. They will be provided to complete one set (4 breaths) by practicing the 4-7-8 breathing technique first with the researcher and then alone. The training will last approximately 15 minutes for each patient. Patients will be asked to start the first breathing exercise at the 4th hour after coming to the clinic after laparoscopic cholecystectomy and perform one set (4 breaths) every two hours.
62035554|NCT00517712|ACTIVE_COMPARATOR|A|Duration of maintenance therapy with single agent ATO of 12 months
62236420|NCT05564351|EXPERIMENTAL|Ear plug group|
62236421|NCT05564351|EXPERIMENTAL|Eye mask group|
62236422|NCT05564351|EXPERIMENTAL|Eye mask+Ear plug group|
62427035|NCT02757131|NO_INTERVENTION|Control|"The cohort of patients randomized to usual care will not be seen by the dedicated ambulator, but will not otherwise be restricted in nursing's baseline ability to execute nursing specific recommendations placed by the PT team."
62427036|NCT04816422|EXPERIMENTAL|Proprioceptive neuromuscular facilitation|Bilateral upper extremity pattern for trunk by Chopping, Lifting 2. Bilateral lower extremity pattern for trunk. 3. Trunk lateral flexion. 4. Combination patterns for the trunk by Upper and lower trunk flexion, Upper trunk flexion with lower trunk extension, Upper and lower trunk extension, Upper trunk extension with lower trunk flexion.
62427037|NCT04816422|ACTIVE_COMPARATOR|Conventional treatment|"Procedure Group 2 has received conventional trunk exercise program for 45 min/day, 4 days~/ week for the period of 4 weeks the intervention includes static and dynamic functional trunk movement and strengthening exercise to the trunk muscles which includes motor developmental patterns, basic trunk movement, trunk-arm linked movements, trunk-leg linked patterns in sitting, transfer activities, with 2 minutes rest in between the repetition of each set, Progression will be made by increasing the repetition and resistance According to individual ability."
62812668|NCT06415890|NO_INTERVENTION|Control Group|Patients in the control group will receive routine treatment and care after laparoscopic cholecystectomy. In the clinic, patients are not trained on postoperative breathing exercises and the use of triflow is recommended. However, there is no planned training for the use of this tool and the patients' use of the tool is not monitored.
62812669|NCT05318001||First trimester pregnant women (first pregnancy)|This group will consist of women in the first trimester and in first trimester of pregnancy
62812670|NCT05318001||Second trimester pregnant women (first pregnancy)|This group will consist of women in the second trimester and in first trimester of pregnancy
62812671|NCT05318001||Third trimester pregnant women (first pregnancy)|This group will consist of women in the third trimester and in first trimester of pregnancy
62236423|NCT05564351|NO_INTERVENTION|Control group|
62236424|NCT01561781|EXPERIMENTAL|digoxin then digoxin + vandetanib|Digoxin alone followed by digoxin in combination with vandetanib
62236425|NCT04748796|EXPERIMENTAL|Experimental group|2 days with landiolol IV + usual care
62236426|NCT04748796|ACTIVE_COMPARATOR|Control group|usual care according to the attending physician and following the guidelines of surviving sepsis campaign.
62236427|NCT01504308|EXPERIMENTAL|MR-HIFU treatment|Patients receiving MR-HIFU treatment
62427038|NCT03586037|EXPERIMENTAL|Sequence 1|Period 1: AD-2011 10/20mg QD Period 2: AD-2012 80mg QD Period 3: AD-2011 10/20mg + AD-2012 80mg QD
62427039|NCT03586037|EXPERIMENTAL|Sequence 2|Period 1: AD-2011 10/20mg QD Period 2: AD-2011 10/20mg + AD-2012 80mg QD Period 3: AD-2012 80mg QD
62427040|NCT03586037|EXPERIMENTAL|Sequence 3|Period 1: AD-2012 80mg QD Period 2: AD-2011 10/20mg + AD-2012 80mg QD Period 3: AD-2011 10/20mg QD
62595100|NCT03692975|EXPERIMENTAL|CIS patients|Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially suggestive of multiple sclerosis (MS) whatever the mode of presentation
62236428|NCT01504308|SHAM_COMPARATOR|Sham Treatment|Patients receiving sham treatment
62236429|NCT00231153|ACTIVE_COMPARATOR|Povidone-Iodine 10%|
62236430|NCT00231153|EXPERIMENTAL|omiganan 1% gel|
62236431|NCT03844490|OTHER|CONTROL|In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivery)
62427041|NCT03586037|EXPERIMENTAL|Sequence 4|Period 1: AD-2012 80mg QD Period 2: AD-2011 10/20mg QD Period 3: AD-2011 10/20mg + AD-2012 80mg QD
62427042|NCT03586037|EXPERIMENTAL|Sequence 5|Period 1: AD-2011 10/20mg + AD-2012 80mg QD Period 2: AD-2011 10/20mg QD Period 3: AD-2012 80mg QD
62595101|NCT03692975|ACTIVE_COMPARATOR|Control|50 Healthy controls
62035555|NCT00517712|ACTIVE_COMPARATOR|B|Duration of maintenance therapy with single agent ATO for 6 months
62035556|NCT02216058|EXPERIMENTAL|NOYA|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System
62236432|NCT03844490|EXPERIMENTAL|CESSATION OF CORD PULSE|"In this group the umbilical cord will remain unclamped until the spontaneous pulsation stops.~At this time, cord clamping will be made."
62236433|NCT05937633|EXPERIMENTAL|Tranformational Education|A total of 82 Participants will be assigned to experimental group. Transformational educational programme is administered to all the participants.
62236434|NCT05937633|NO_INTERVENTION|Educational Booklet|Study participants (Charge Nurses and Acting Charge Nurses) of educational booklet group will be distributed with educational booklet.
62236435|NCT05360498|EXPERIMENTAL|Intervention Arm|Adaptive Need-based Sequence
62812672|NCT06568016|ACTIVE_COMPARATOR|Arm I (usual care)|Patients receive clinical care consistent with current practice at NEVHC. Patients have their EHRs reviewed monthly by the Primary Care FIT Tracker for abnormal FIT results and patients with abnormal FIT results receive standardized communication from FIT QI champions about their results and receive a referral to gastroenterology.
62236436|NCT05360498|ACTIVE_COMPARATOR|Attention control|"This group will be participants that were randomized to the Attention control arm and will not receive the SMSH + TIP-C adaptive intervention."
62812673|NCT06568016|EXPERIMENTAL|Arm II (Usual care + Primary Care - GI Connect)|Patients receive clinical care consistent with current practice at NEVHC as described in Arm I. Patients also receive enhanced GI care coordination from GI liaisons, who generate GI FIT Tracker reports and use the GI FIT Tracker reports to follow patients with abnormal FIT results. Patients receive navigation services including contact from GI liaisons about making a GI appointment and enhanced communication between GI specialists and the NEVHC. Patients receive referral to gastroenterology following a standardized referral template and receive colonoscopy education including an informational sheet at the time of referral and a 20-minute pre-colonoscopy educational video. Patients receive a text message at the time of colonoscopy referral emphasizing the importance of colonoscopy after abnormal FIT result.
62812674|NCT01172535|EXPERIMENTAL|Lopinavir/ritonavir|Participants will receive lopinavir/ritonavir in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.
62812675|NCT01723735|EXPERIMENTAL|Alirocumab + Ezetimibe Placebo|Subcutaneous (SC) injections of alirocumab added to oral administration of ezetimibe placebo
62812676|NCT01723735|EXPERIMENTAL|Alirocumab + Ezetimibe|Subcutaneous (SC) injections of alirocumab added to oral administration of ezetimibe
62812677|NCT01723735|EXPERIMENTAL|Alirocumab + Fenofibrate|Subcutaneous (SC) injections of alirocumab added to oral administration of fenofibrate
62812678|NCT03382613||Quality Improvement (QI) Program|Hospitals assigned to the QI program arm will begin the 4-month Preparatory Phase which is designed to introduce the institutional baseline reporting tools and materials related to performance improvement, and gain insight into their gaps in treatment, followed by 15 month Implementation Phase, which will consist of education, process, and engagement activities that are targeted at the hospital and healthcare provider level and then the Measurement Period at which time hospitals will complete a final survey to document specific interventions that were successfully implemented and perform a final retrospective chart review on selected patients.
62035557|NCT04222348|EXPERIMENTAL|Metformin|850-2550 mg every 24h.
62236437|NCT02823808|EXPERIMENTAL|ALO+PIO|Group who takes Alogliptin 25mg+Pioglitazone 15mg, once daily.
62427043|NCT03586037|EXPERIMENTAL|Sequence 6|Period 1: AD-2011 10/20mg + AD-2012 80mg QD Period 2: AD-2012 80mg QD Period 3: AD-2011 10/20mg QD
62035558|NCT04222348|ACTIVE_COMPARATOR|Insulin Detemir|Individual doses according to glycemic controls.
62035559|NCT03847324|ACTIVE_COMPARATOR|Usual Care|Group-based preoperative biomedical education, postoperative hospital and home rehabilitation.
62035560|NCT03847324|EXPERIMENTAL|PNE|Usual care + Preoperative Pain Neuroscience Education
62035561|NCT03847324|EXPERIMENTAL|Multimodal Physiotherapy|Usual care + Preoperative Multimodal physiotherapy
62035562|NCT02098200|EXPERIMENTAL|Percutaneous treatment of TR by TriCinch|Percutaneous treatment of Tricuspid Regurgitation with TriCinch System
62236438|NCT02823808|ACTIVE_COMPARATOR|GMPD+MET|Group who takes Glimepiride 2mg+Metformin 500mg, once daily.
62236439|NCT05309434|EXPERIMENTAL|Study group with standing coach|The team performs the simulated CPR with the coach standing next to the defibrillator
62236440|NCT05309434|EXPERIMENTAL|study group with mobile coach|The team performs the simulated CPR with the coach free to move around the simulation room
62236441|NCT05309434|NO_INTERVENTION|control group without coach|The team performs the simulated CPR without the coach
62427044|NCT01745484|EXPERIMENTAL|Arm 1|SPECT scan will be performed at baseline. Patients will receive radiotherapy according to standard CT-based plan with conventional dose-volume histogram
62427045|NCT02369627|EXPERIMENTAL|Rapid HIV Self-Test|Participants will perform a rapid HIV self-test using the OraQuick® In-home HIV Test.
62427046|NCT02369627|ACTIVE_COMPARATOR|Conventional Home-Based HIV Test|Participants will perform a conventional home-based HIV test using the Home Access Express HIV-1 Test System.
62035563|NCT04377165|ACTIVE_COMPARATOR|Newsfeed|This will provide you with reliable accurate information on the pandemic.
62236442|NCT06211335|EXPERIMENTAL|Treatment (losartan, SBRT, pembrolizumab)|Patients receive losartan PO QD. One week later patients receive SBRT 2-3 times per week for approximately 2 weeks. Within 1 week of completing SBRT, patients receive pembrolizumab IV and repeat every 3 weeks. Treatment continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo PET, tumor biopsy, and blood sample collection throughout the study.
62427047|NCT02369627|ACTIVE_COMPARATOR|Community/Medical-Based HIV Test|Participants will receive a link to a CDC website (https://gettested.cdc.gov) that allows them to search for HIV testing locations of their choice.
62236443|NCT00564018|EXPERIMENTAL|Detemir|24 subjects randomized to therapy with a combination of insulins detemir and aspart at diagnosis of diabetes.
62236444|NCT00564018|EXPERIMENTAL|Glargine|24 subjects randomized to therapy with a combination of insulins glargine and aspart at diagnosis of diabetes.
62236445|NCT00564018|EXPERIMENTAL|NPH|24 subjects randomized to therapy with a combination of insulins NPH and aspart at diagnosis of diabetes.
62427048|NCT05250947|EXPERIMENTAL|PRP Injection Arm|The FDA cleared Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP. The targeted final PRP volume of 6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint.
62427049|NCT01202994|EXPERIMENTAL|Flute|Flutemetamol PET scan.
62427050|NCT00411801|EXPERIMENTAL|Uniplas|Participants will receive Uniplas intravenously in 4 cycles of 7 to 9 days each for 1 month. The first cycle will consist of 1.5 plasma volume exchanges (= 75 mL/kg) for 3 consecutive days, followed by a minimum of 4 and a maximum of 6 daily single volume plasma exchanges (= 50 mL/kg). Subsequent treatment will depend upon the response of the participant to the first cycle, as assessed by a blinded assessor.
62427051|NCT00411801|ACTIVE_COMPARATOR|Cryosupernatant plasma|Participants will receive cryosupernatant plasma intravenously in 4 cycles of 7 to 9 days each for 1 month. The first cycle will consist of 1.5 plasma volume exchanges (= 75 mL/kg) for 3 consecutive days, followed by a minimum of 4 and a maximum of 6 daily single volume plasma exchanges (= 50 mL/kg). Subsequent treatment will depend upon the response of the participant to the first cycle, as assessed by a blinded assessor.
62427052|NCT05400200|OTHER|questionnary with patients Definite diagnosis of PTSD|only patients with diagnosis of PTSD answered questionaries
62427053|NCT02850445|EXPERIMENTAL|Integrated Treatment|
62427054|NCT02850445|ACTIVE_COMPARATOR|antipsychotic medication alone treatment|
62427055|NCT05033379|EXPERIMENTAL|Control Arm|Instruction about importance of sleep.
62427056|NCT05033379|EXPERIMENTAL|Coaching|Undergo resilience coaching
62427057|NCT04769128|ACTIVE_COMPARATOR|Group (A) (control group)(traditional physical therapy programme)|Group (A) (control group): Fifteen patients with CRPS I received traditional physical therapy program in the form of transcutaneous electrical neuromuscular stimulation (TENS), mirror therapy, and exercises for upper limb exercises in the form of gradual weight-bearing exercises by using different equipment such as balls, balloons, or silk-like cloths, combined with different positions of the patient (i.e. lying, sitting, or standing), range of motion exercises (active and self-Assisted), resisting exercises (manual and mechanical), stretching exercises (manual and self-stretching) and fine motor control training. 3 sessions/ week for 12 weeks.
62427058|NCT04769128|EXPERIMENTAL|Group (B) (experimental or manipulative group)|"Fifteen patients with CRPS I received traditional physical therapy program in the form of transcutaneous electrical neuromuscular stimulation (TENS), mirror therapy, and exercises for upper limb exercises in the form of gradual weight-bearing exercises by using different equipment such as balls, balloons, or silk-like cloths, combined with different positions of the patient (i.e. lying, sitting, or standing), range of motion exercises (active and self-Assisted), resisting exercises (manual and mechanical), stretching exercises (manual and self-stretching) and fine motor control training in addition to T3-T4 thoracic manipulation (Maitland screw technique grade V) 3 sessions/ week for 12 weeks."
62427059|NCT00730288|EXPERIMENTAL|1|Received monovalent Vero dengue vaccine in Study DIV12
62427060|NCT00730288|EXPERIMENTAL|2|Received Yellow fever vaccine in Study DIV12
62236446|NCT00759330|PLACEBO_COMPARATOR|Placebo Tape (Arm 1)|Placebo tape remained on for 12 hours of continuous treatment per day.
62427061|NCT00730288|EXPERIMENTAL|3|Flavivirus-naive subjects
62427062|NCT01856374|ACTIVE_COMPARATOR|Cypher group|
62427063|NCT01856374|EXPERIMENTAL|Xience group|
62427064|NCT01856374|ACTIVE_COMPARATOR|Pravastatin group|
62427065|NCT01856374|EXPERIMENTAL|Atorvastatin group|
62427066|NCT02798783||Diagnosed with EVA|Self-reported Enlarged Vestibular Aqueduct (EVA), or, when available, radiological diagnosis of EVA will be used to define the cohort.
62236447|NCT00759330|EXPERIMENTAL|Flurbiprofen Tape (Arm 2)|Flurbiprofen tape remained on for 12 hours of continuous treatment per day.
62236448|NCT00759330|PLACEBO_COMPARATOR|Placebo Tape (Arm 3)|Placebo tape remained on for 24 hours of continuous treatment per day.
62236449|NCT00759330|EXPERIMENTAL|Flurbiprofen Tape (Arm 4)|Flurbiprofen tape remained on for 24 hours of continuous treatment per day.
62236450|NCT06005818|NO_INTERVENTION|Arm 1: MRD negative patients|
62236451|NCT06005818|ACTIVE_COMPARATOR|Arm 2 MRD positive patients|Patients are treated with Pembrolizumab 400 mg IV q 6 weeks for a total of 1 year
62427067|NCT02228746|EXPERIMENTAL|Alpha-galacto-oliosaccharides|
62427068|NCT02228746|PLACEBO_COMPARATOR|Placebo|
62595102|NCT02909231||Foothills Medical Centre|Patients admitted to the Foothills Medical Centre trauma service (Calgary, AB) over four months.
62236452|NCT04973254|EXPERIMENTAL|Cohort 1- HIV injection at a community-based site|CAB-RPV LA administered to patients in an alternative community-based site
62236453|NCT04973254|ACTIVE_COMPARATOR|Cohort 2- HIV injection at a HIV clinic|CAB-RPV LA administered to patients in the HIV clinic
62236454|NCT04973254|ACTIVE_COMPARATOR|Cohort 3- Standard of care for HIV|Individuals who share characteristics of cohort 1 and are engaged in standard of care
62236455|NCT02463825|EXPERIMENTAL|Group 1 Pimozide (2mg per day)|Pimozide will be initiated at 1 mg twice daily and maintained on 2mg/day for 50 days. End of study dose reduction will begin following the Final Outcome Measure Visit (Day 65). Pimozide will then be stopped.
62236456|NCT02463825|EXPERIMENTAL|Group 2 Pimozide (4mg per day)|Pimozide will be initiated at 1 mg twice daily then increased by 1mg twice daily every five days to 4 mg/day) for 45 days. End of study dose reduction will begin following the Final Outcome Measure Visit (Day 65). Pimozide will be titrated by reducing the dose by 1 mg twice daily every day to full discontinuation (over 2 days).
62427069|NCT00297986||1|healthy subjects
62427070|NCT02844179|EXPERIMENTAL|dose escalation|Single dose administration of (+)-alpha-Dihydrotetrabenazine (HTBZ), escalating dosage amounts 7.5 - 30 mg orally
62427071|NCT03862937|EXPERIMENTAL|Experimental|The experimental group will perform 12 weeks of strength training twice a week associated with whey protein supplementation.
62595103|NCT02909231||Vancouver General Hospital|Patients admitted to the Vancouver General Hospital trauma service (Vancouver, BC) over four months.
62595104|NCT06647563|EXPERIMENTAL|Toripalimab + Chemotherapy + Cetuximab + SOC (Immunotherapy+ chemotherapy+targeted therapy, ICT)|Participants will receive an intravenous (IV) infusion of Toripalimab 240mg on Day 1, Albumin-bound Paclitaxel 125mg/m\^2 on Days 1 and 8, Carboplatin with an area under the curve (AUC) of 5 on Day 1, and Cetuximab 400mg/m\^2 on Day 1, followed by Cetuximab 250mg/m\^2 on Day 1 of each subsequent week. The treatment is given in 21-day cycles for a total of two cycles. Afterward, participants will proceed to the standard of care (SOC), which includes surgical intervention and postoperative radiotherapy. Following surgical resection, high-risk participants will receive standard radiotherapy plus Cisplatin 100 mg/m\^2 via intravenous infusion on Day 1, every 3 weeks (Q3W) for three 21-day cycles. Low-risk participants will receive only standard radiotherapy. Subsequently, participants will receive Toripalimab 240mg every 21-day cycle for a total of 15 cycles.
62236457|NCT02463825|PLACEBO_COMPARATOR|Group 3 Placebo (Lactose tablet)|Placebo tablets will be utilized and administered in an identical manner for subjects in Group 3
62236458|NCT05713279|EXPERIMENTAL|FM+SOC|
62236459|NCT05713279|PLACEBO_COMPARATOR|FM安慰剂 +SOC|
62427072|NCT03862937|PLACEBO_COMPARATOR|Placebo|The placebo group will perform 12 weeks of strength training twice a week associated with maltodextrin supplementation.
62595105|NCT06647563|EXPERIMENTAL|Toripalimab + Chemotherapy + SOC (Immunotherapy+ chemotherapy, IC)|Participants will receive an intravenous (IV) infusion of Toripalimab 240mg on Day 1, Albumin-bound Paclitaxel 125mg/m\^2 on Days 1 and 8, Carboplatin with an area under the curve (AUC) of 5 on Day 1. The treatment is given in 21-day cycles for a total of two cycles. Afterward, participants will proceed to the standard of care (SOC), which includes surgical intervention and postoperative radiotherapy. Following surgical resection, high-risk participants will receive standard radiotherapy plus Cisplatin 100 mg/m\^2 via intravenous infusion on Day 1, every 3 weeks (Q3W) for three 21-day cycles. Low-risk participants will receive only standard radiotherapy. Subsequently, participants will receive Toripalimab 240mg every 21-day cycle for a total of 15 cycles.
62735519|NCT03180333|EXPERIMENTAL|PNA 1|Multiple dosing tolerance test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 7 days;
62236460|NCT00823901|EXPERIMENTAL|Clindamycin/Tretinoin Gel|Participants applied Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel on entire face (forehead, nose, chin, cheeks) once daily at night for 12 weeks
62236461|NCT00823901|PLACEBO_COMPARATOR|Placebo gel|Participants applied Placebo gel with no active medication on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks.
62427073|NCT01746563|EXPERIMENTAL|Ranibizumab|Ranibizumab 0,05 mg intravitreal injection
62427074|NCT01746563|ACTIVE_COMPARATOR|Laser Therapy|Laser Therapy alone
62427075|NCT05661656|EXPERIMENTAL|Advanced breast cancer patients|Tumors are staged according to the criteria of the Union for International Cancer Control (UICC). Tumor volume was determined by mammography or magnetic resonance imaging (MRI). Patients will be cannulated via the femoral artery. Then, a 4F fixed-curve catheter (Cobra catheter, Cook Corporation, Bloomington) was advanced to the ipsilateral subclavian artery. Digital subtraction angiography (DSA) was performed to determine tumor arterial blood supply. Super selection of the internal mammary artery done by micro-catheter. Chemo-infusion was decided by the major feeding artery. The intra-arterial chemoinfusion regimen consisted of docetaxel 75 mg/m2 and epirubicin 50 mg/m2 in 200 mL of normal saline and 5% glucose; the drugs were slowly infused via the catheter over at least 15 minutes. Intraarterial infusion was performed once every 3 weeks on average.
62427076|NCT04693182|NO_INTERVENTION|With quick returns|The control condition in this trial implies that employees maintain the same number of quick returns as in previous years for the six-month intervention period. Hospital units in the control group are not expected to experience any increase in the number of quick returns.
62236462|NCT04065009|PLACEBO_COMPARATOR|Placebo|Normal saline administered intraperitoneally at defined times during upfront surgery and intermittently postoperatively for 72 hours
62236463|NCT04065009|EXPERIMENTAL|Experimental|Local anesthetic (ropivacaine) administered intraperitoneally at defined times during upfront surgery and intermittently postoperatively for 72 hours
62236464|NCT01490645||one group (all patients)|
62427077|NCT04693182|EXPERIMENTAL|Without quick returns|The intervention entails implementing a shift schedule which abolishes quick returns for a six-month intervention period. The number of quick returns in the various hospital units in this trial varies from 329-2356 per year. The intervention means that this number is abolished or reduced as much as possible. For practical reasons it is reasonable to expect that for many of the units it may be a matter of reducing rather than completely abolishing quick returns, as ensuring adequate staffing (e.g., due to sickness absence), often on short-notice make it impossible to comply with the rule of avoiding quick returns. The human resources department at the hospital assisted shift planners in scheduling shift schedules without quick returns.
62427078|NCT01514656|ACTIVE_COMPARATOR|Video Self-Instruction (VSI) kit|Individuals will learn CPR using American Heart Association's Video Self-Instruction kit. Main data points being collected at various increments over 12 months are: 1) CPR quality at 6 to 12 months 2) Comfort Level using the skills they learned
62735520|NCT03180333|PLACEBO_COMPARATOR|PNA placebo|Multiple dosing tolerance test:Metacavir Enteric-coated Capsules placebo 160mg/320mg,once a day,continuous administration for 7 days
62812679|NCT03382613||Usual Care|Hospitals assigned to the Usual Care arm will not participate in the structured QI program but will continue with their standard hospital practice in treating patients with atrial fibrillation (AF) at risk for ischemic stroke. Hospitals will also complete a final survey and final retrospective chart reviews during the Measurement Period.
62236465|NCT01530022|OTHER|LCM 300 mg/CBZ-IR 600 mg|Crossover sequence of experimental treatment and active comparator
62236466|NCT01530022|OTHER|CBZ-IR 600 mg/LCM 300 mg|Crossover sequence of active comparator and experimental treatment
62236467|NCT01464229|EXPERIMENTAL|Iloperidone addition to SSRI antidepressant|
62236468|NCT01464229|PLACEBO_COMPARATOR|Placebo addition to standard SSRI antidepressant|
62427079|NCT01514656|EXPERIMENTAL|Video-only|Individuals will learn CPR skills using a Video training method. Main data points being collected at various increments over 12 months are: 1) CPR Skills at 6 to 12 months 2) Comfort Level with using CPR
62427080|NCT01514656|ACTIVE_COMPARATOR|Recruitment with Volunteers|Volunteer subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
62812680|NCT03497663|EXPERIMENTAL|VIA Family intervention|VIA Family is a family based intervention. A multidisciplinary team of specialists from adult mental health services, child and adolescent mental health services and social services will be responsible for providing the basic treatment elements that are: case management and regular contact with the case manager, psychoeducation for the whole family, parental training (Triple P) and early intervention for mental problems of the child.
62035564|NCT04377165|EXPERIMENTAL|Gamification|The gamification function will allow users to earn points for actions completed. The gamification function has links to resources for infection control, watching or completing tasks or playing games to earn points. Points can be viewed at a facility level, state level or national level.
62035565|NCT02297308||SoloPath Sheath|The study focuses on subjects that underwent TAVI with a SoloPath Sheath used for femoral vascualar access
62035566|NCT03774186|ACTIVE_COMPARATOR|Sensor-augmented pump therapy (SAPT)|Pregnant women with T1D with use an insulin pump and a continuous glucose monitor but there will be no automated insulin adjustments made by the system.
62035567|NCT03774186|EXPERIMENTAL|Hybrid closed-loop therapy (HCL)|Pregnant women with T1D with use an insulin pump and a continuous glucose monitor with automated insulin adjustments made by the system, but continued meal boluses from the women.
62035568|NCT02478619|ACTIVE_COMPARATOR|IMT group|The volunteers will do the respiratory muscle training through a linear inspiratory pressure resistance device (POWERbreathe®) at 50% of the maximal inspiratory pressure.
62236469|NCT03425981|EXPERIMENTAL|WB-EMS-SRT|Training with basic global electrostimulation
62236470|NCT03425981|EXPERIMENTAL|WB-EMS-WT|Training with specific global electrostimulation for runners
62236471|NCT03425981|PLACEBO_COMPARATOR|CG|The participants in the control group will maintain the volume and intensity of the training prior to the intervention study and the subjects of the WB-EMS and WB-EMS-AC groups will substitute one conventional training day for one with global electrostimulation for six weeks; the training of the first group will be non-specific and that of the second specific for runners and the duration of both will be 20 minutes.
60311071|NCT06728397|EXPERIMENTAL|StratCare|Treatment recommendation made by the StratCare-2 App using stratified care principles.
60311072|NCT06728397|NO_INTERVENTION|Usual Stepped Care|Treatment recommendation made using usual stepped care principles.
62035569|NCT02478619|PLACEBO_COMPARATOR|Control group|Patients will do a placebo respiratory muscle training through a load pressure resistance device (POWERbreathe®) with the minimum load available (10cmH20).
62035570|NCT00003857|ACTIVE_COMPARATOR|Observation +/- tamoxifen for 5 years|Observation +/- tamoxifen 20 mg per day for 5 years
62236472|NCT04668586|EXPERIMENTAL|Holmium:YAG laser machine|The ureteral or renal stones planned for treatment with URS and laser lithotripsy are fragmented or dusted using a Holmium:YAG laser machine.
62236473|NCT04668586|EXPERIMENTAL|Thulium Fiber laser machine|The ureteral or renal stones planned for treatment with URS and laser lithotripsy are fragmented or dusted using a Thulium Fiber laser machine.
62236474|NCT03010930|EXPERIMENTAL|Increased exposure to MSG|Subjects consume vegetable broth daily containing MSG
62035571|NCT00003857|EXPERIMENTAL|Radiation therapy +/- tamoxifen for 5 years|Radiation therapy to the whole breast +/- tamoxifen 20 mg per day for 5 years
62035572|NCT05983822|EXPERIMENTAL|Experimental Group (GA)|The experimental group (GA) will perform specific rehabilitation for the recovery of hand function using the end-effector robot Amadeo® (Tyromotion, Austria) 3 times a week, for 4 weeks (12 total sessions), for 45 minutes of treatment in addition to conventional treatment. In particular, the technological rehabilitation performed using the robot will mostly aim at improving finger mobility and strength, and flexion-extension exercises will be proposed in passive, active assisted and active mode, exercises for improving strength and muscle tone.
62035573|NCT05983822|ACTIVE_COMPARATOR|Conventional Group (GC)|GC patients will undergo conventional rehabilitation treatment only, using the main rehabilitation methods (e.g. neurocognitive theory, progressive neuromuscular facilitation, etc.).
62236475|NCT03010930|SHAM_COMPARATOR|No change in exposure to MSG|Subjects consume low glutamate vegetable broth daily, sodium-matched to the broth of the experimental group with NaCl
62035574|NCT02109367||Pelvic mass|Women who present to the Gynecologic Oncology clinic with a pelvic mass who are scheduled to undergo surgical excision.
62035575|NCT03543254|EXPERIMENTAL|BoNT-A injected|BoNT-A (Botulinum toxin A) injected in the head on specific sites and in half the usual concentration
62035576|NCT03157713|EXPERIMENTAL|Goal-Directed|Patients will receive enhanced usual care and also be informed that they will receive goal-directed financial incentives.
62236476|NCT02407366|EXPERIMENTAL|Icotinib with concurrent radiotherapy|Icotinib (125 mg ,three times daily)with concurrent thoracic radiotherapy(TRT) (66 Gy/33 fractions), followed by maintenance icotinib (125 mg ,Three times daily) until disease progression or unacceptable toxicity.
62236477|NCT02407366|ACTIVE_COMPARATOR|Chemoradiotherapy|Pemetrexed(500mg/m2) + carboplatin (AUC，5) every 21 days for three cycles with concurrent thoracic radiotherapy(TRT) (66 Gy/33 fractions), followed by consolidation chemotherapy with two cycles of pemetrexed(500mg/m2) + carboplatin (AUC，5) every 21 days.Maintenance pemetrexed(500mg/m2) will be administered after consolidation chemotherapy until disease progression or unacceptable toxicity .
62236478|NCT06147635|EXPERIMENTAL|Intervention group|Micro-encapsulated tributyrin granules, 4 grams three times daily, for a maximum of 14 days
62236479|NCT06147635|PLACEBO_COMPARATOR|Control group|Micro-encapsulated sunflower oil granules, 4 grams three times daily, for a maximum of 14 days
62236480|NCT01791257||SAH with DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
62035577|NCT03157713|EXPERIMENTAL|Outcome-Based|Patients will receive enhanced usual care and be informed that they will receive outcome-based financial incentives for significant weight losses.
62035578|NCT03157713|OTHER|Control-Enhanced Usual Care|Patients will only receive enhanced usual care.
62035579|NCT02071004|OTHER|Aspirin|Dispersible tablet, 300mg \& 75 mg, once daily for 5 days
62236481|NCT01791257||SAH without DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
62236482|NCT01791257||Neurological healthy controls|12 patients (ASA 1) undergoing spinal anesthesia for orthopedic surgery have 2 ml of cerebrospinal fluid drawn preceding injection of local analgetic.
62236483|NCT02456662|PLACEBO_COMPARATOR|Placebo|160 Patients will randomly be assigned, using sealed numbered opaque envelopes to receive placebo tablet 30 minutes prior to taking 200mg PO doxycycline
62236484|NCT02456662|ACTIVE_COMPARATOR|Ondansetron|160 Patients will randomly be assigned, using sealed numbered opaque envelopes to receive 8mg ondansetron tablet 30 minutes prior to taking 200mg PO doxycycline
62812681|NCT03497663|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|TAU is defined as any kind of help and support focusing on high risk children and parental mental illness. At present, the municipalities and the mental health services do not offer any kind of family focused intervention addressing parental mental illness that can be compared to the VIA Family program.
62812682|NCT01701206|EXPERIMENTAL|HIV intervention Group|Experimental arm receives peer-led HIV information on social media
62035580|NCT02071004|EXPERIMENTAL|DS-1040b|IV of 6 mg given once over 30 minutes
62035581|NCT04478968||Active AVF|Patients after kidney transplantation with functioning AVF
62035582|NCT04478968||No AVF|Patients after kidney transplantation without AVF (thrombosed AVF, history of HD with catheter, history of PD, preemptive transplantation)
62035583|NCT03488901||methotrexate sensitive|patients with gestational choriocarcinoma cured with methotrexate alone
62236485|NCT02338349|EXPERIMENTAL|Elacestrant|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of elacestrant.~Part B, Safety Expansion: Once the MTD has been identified and/or a RP2D has been selected, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary efficacy of the RP2D.~Part C, Tablet Introduction: A cohort of patients will be enrolled to evaluate the safety, tolerability, and PK of a tablet dosage form at 400 mg QD.~Part D, Dose Expansion: A cohort of patients will be enrolled to evaluate the safety, tolerability, PK and preliminary anti-tumor effect of elacestrant in tablet dosage form at 400 mg QD PO in a group of patients with a more homogeneous prior treatment history"
62236486|NCT01266135|EXPERIMENTAL|Arm 1: QAX576 10 mg/kg|
62236487|NCT01266135|PLACEBO_COMPARATOR|Arm 2: Placebo|
62243421|NCT03422289|EXPERIMENTAL|Myo-inositol + folic a. + α-lactalbumin|2 g myo-inositol and 0.2 mg folic acid plus 50 mg α-lactalbumin, twice a day for three months in order to test if α-lactalbumin addition allows to induce ovulation
62243422|NCT01604603||Control|
62243423|NCT01604603||Oligomenorrhea|
62243424|NCT01604603||Amenorrhea|
62812683|NCT01701206|NO_INTERVENTION|Control arm|
62812684|NCT03808090|EXPERIMENTAL|Normal Individuals|Normal individuals: no prior history of kidney stones
62035584|NCT03488901||methotrexate resistant|patients with gestational choriocarcinoma not cured with methotrexate alone
62035585|NCT03488901||polychemotherapy sensitive|patients with gestational choriocarcinoma cured with polychemotherapy
62236488|NCT05049486|NO_INTERVENTION|MRI sequences and (DTI)|The aim of this study is to obtain finer details of tissues surrounding a lead in the pelvis using a combination of high resolution anatomical MRI sequences and diffusion tensor imaging (DTI). To do so, the patient will undergo a MRI scan (3 Tesla) of the pelvis using sequences including anatomical sequences and diffusion tensor imaging technique for construction of sacral nerve tractography prior to permanent SNS. This will be performed over an hour: first 30 minutes for anatomical sequences and the second 30 minutes for DTI sequencing.
62595106|NCT06647563|ACTIVE_COMPARATOR|No Neoadjuvant + SOC (Control)|Participants will receive the standard of care (SOC) with no neoadjuvant prior to surgery. Following surgical resection, high-risk participants will receive standard radiotherapy plus Cisplatin 100 mg/m\^2 via intravenous infusion on Day 1, every 3 weeks (Q3W) for three 21-day cycles. Low-risk participants will receive only standard radiotherapy.
62812685|NCT05656417||Haplotype 1|Participants will attend a screening visit where they will provide a saliva sample for DNA sequencing. Participants will then be separated into two groups based on their gene profile. Participants in Group 1 will have a specific haplotype of the gene of interest. The groups will undergo a 2-week period of thorough oral hygiene and prophylactic treatment to achieve excellent gingival health. Participants in both groups will then cease all oral hygiene for a period of 3 weeks, where a state of gingivitis will develop. At the end of the 3 weeks, normal oral hygiene will be reinstated and prophylactic treatment offered as required for a further 2 weeks.
62812686|NCT05656417||Haplotype 2|Participants will attend a screening visit where they will provide a saliva sample for DNA sequencing. Participants will then be separated into two groups based on their gene profile. Group 2 will comprise of participants who possess a second distinct haplotype in the same gene of interest as Group 1. This group will undergo the same study procedures as Haplotype Group 1.
62812687|NCT01323582|ACTIVE_COMPARATOR|erythromycin|200mg/5ml elixir administered orally three times a day half an hour prior to meals.
62035586|NCT03488901||polychemotherapy resistant|patients with gestational choriocarcinoma not cured with polychemotherapy
62236489|NCT05049486|ACTIVE_COMPARATOR|CT scan|Three to 4 weeks after the procedure the patient will undergo a limited CT scan of the pelvis to visualise the position of the SNS lead. The scan will focus only on the sacrum, implanted lead, and rectum and will not be extended beyond this area. Imaging from this CT will be superimposed to the MRI imaging the patient had pre-operatively, and a computational simulation will be performed.
62236490|NCT06265766|EXPERIMENTAL|Active cTBS|Active cTBS delivered with an active TMS coil
62427081|NCT01514656|ACTIVE_COMPARATOR|Recruitment with Nurses|Nurse subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
62427082|NCT01514656|ACTIVE_COMPARATOR|Prompting to practice skills|Individuals will be prompted every two months and encouraged to practice the skills that they learned. Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) CPR Skills at 6 to 12 months.
62035587|NCT03488901||hydatidiform moles without malignant transformation|patients treated for hydatidiform moles but who did not turn into trophoblastic tumors (=controls)
62427083|NCT01514656|ACTIVE_COMPARATOR|No prompting to practice skills|Individuals will not be prompted to practice skills. Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) CPR Skills at 6 to 12 months.
62427084|NCT03208257|EXPERIMENTAL|Esmolol|Intravenous esmolol will be administered as a continuous infusion according to protocol to control tachycardia with maximal infusion rates in the range of 10-40 mcg/kg/min.
62427085|NCT02299674||Persons with unilateral transfemoral amputation|
62427086|NCT05602233|EXPERIMENTAL|Balance training:|It is planned to apply hop to stabilization exercises developed by Mckeon et al. The training will be given for 6 weeks, 3 times a week for 20 minutes. This phased balance training program is based on the participant's ability to maintain a single limb posture while performing balance activities. The program includes: 1) hop to stabilization, 2) hop to stabilization and reach, 3) hop to stabilization box drill, 4) progressive single-limb stance balance activities with eyes open, and 5) progressive single-limb stance activities with eyes closed. Participants will be followed up with a physiotherapist and will be able to proceed to the next stage of the test after completing the previous level without errors.
62427087|NCT05602233|EXPERIMENTAL|STARS|A combination of STARS developed by Mckeon et al. is planned for the STARS group. The training will be given for 6 weeks, 3 times a week for 5 minutes. STARS includes; joint mobilization, plantar massage and triceps surae stretching.
62595107|NCT05764733|EXPERIMENTAL|Resistance Training (RT) + Bisphosphonate (BIS)|"Progressive Resistance Training (RT) and Bone-Loading Exercise~+ 70 mg/weekly dose alendronate"
62236491|NCT06265766|SHAM_COMPARATOR|Sham cTBS|Sham cTBS delivered with a sham TMS coil
62236492|NCT02231853|EXPERIMENTAL|-1|1x10e4 MVST/kg infusion
62236493|NCT02231853|EXPERIMENTAL|1|1x10e5 MVST/kg infusion
62236494|NCT02231853|EXPERIMENTAL|2|5x10e5 MVST/kg infusion
62236495|NCT02231853|EXPERIMENTAL|3|1x10e6 MVST/kg infusion
62236496|NCT02231853|EXPERIMENTAL|3B|1x10e6 MVSTr/kg infusion
62236497|NCT02231853|EXPERIMENTAL|4|5x10e6 MVSTr/kg infusion
62236498|NCT00867113|EXPERIMENTAL|Imatinib|All subjects received in tablet form imatinib (STI571) 400 mg once daily.
62236499|NCT02039726|EXPERIMENTAL|Quizartinib|Participants who were randomized to receive 20 or 30 mg quizartinib tablets administered orally once daily.
62243425|NCT01604603||premature ovarian failure|
62595108|NCT05764733|EXPERIMENTAL|No RT + BIS|"No Resistance Training~+ 70 mg/weekly dose alendronate"
62595109|NCT05764733|ACTIVE_COMPARATOR|No RT + Placebo (PL)|No Resistance Training + Weekly Placebo
62595110|NCT05764733|ACTIVE_COMPARATOR|RT + PL|Progressive RT and Bone-Loading Exercise + Weekly Placebo
62595111|NCT00725608||Patients|Opioid dependent patients currently in maintenance treatment with another medication who are switched to Suboxone (buprenorphine plus naloxone)
62812688|NCT01323582|EXPERIMENTAL|Azithromycin|The dose of Azithromycin was determined based on our dose response curve obtained on 10 healthy subjects who were given three different doses of Azithromycin, 50 mg, 100 mg and 133 mg and underwent breath testing to determine the gastric emptying half-time. These doses were determined based on a maximum safe dosage per day of Azithromycin of 400 mg given the medication would then be administered three times daily before meals. The appearance of the medication (azithromycin) and administration period was then identical to that of Erythromycin, i.e. 5ml elixir administered orally three times a day half an hour prior to meals. The total daily dosage of Azithromycin was determined after obtaining the dose- response analysis.
62812689|NCT02905097||Arthroplasty cohort|A cohort of patients who will undergo knee replacement surgery and will receive Triathlon Tritanium (cementless) tibial implant.
62812690|NCT03382132|EXPERIMENTAL|momHealth|Participants will receive support and information via the momHealth program.
62236500|NCT02039726|ACTIVE_COMPARATOR|Salvage chemotherapy|Participants who were randomized to receive salvage chemotherapy, such as low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA), were administered during 28-day cycles.
62236501|NCT00954421|EXPERIMENTAL|Deep Brain Stimulation|Multiple Sclerosis Tremor treated with VIM and VO Deep Brain Stimulation
62812691|NCT03382132|ACTIVE_COMPARATOR|Control|Participants will receive the normal support they would normally receive if they were not in a study.
62812692|NCT00334217|EXPERIMENTAL|1|PSS CogRehab exercises
62812693|NCT00334217|NO_INTERVENTION|2|On-line computer games
62812694|NCT06297187||CUSA Excel®|Subjects having had treatment for Vulvar Intraepithelial Neoplasia (VIN) and/or condyloma acuminata using CUSA® Excel system.
62812695|NCT06297187||CUSA Clarity®|Subject having had treatment for Vulvar Intraepithelial Neoplasia (VIN) and/or condyloma acuminata using CUSA® Clarity system.
62812696|NCT00924521|ACTIVE_COMPARATOR|Refined grain|Participants in this group will receive only refined grains as typically consumed in the average American diet.
62812697|NCT00924521|EXPERIMENTAL|Whole grain diet|Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
62812698|NCT03715517|EXPERIMENTAL|Intrathecal morphine|"Spinal anesthesia with intrathecal morphine~Bolus (pre-induction): High-spinal anesthesia with 0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75% plus 3 mcg⋅kg-¹ intrathecal morphine (preservative-free)~Postoperative analgesia: IV-PCA hydromorphone (bolus: 0.2 mg \[range: 0.1-0.4 mg\]; 5 min lockout; no infusion)"
62035588|NCT03488901||placental site trophoblastic tumors|patients with placental site trophoblastic tumors not cured with polychemotherapy
62236502|NCT01968070|EXPERIMENTAL|LY3127760 (Single)|Single oral dose of up to 900 milligram (mg) LY3127760 administered in up to 3 of 3 study periods.
62236503|NCT01968070|PLACEBO_COMPARATOR|Placebo (Single)|Single oral dose of placebo administered in up to 2 of 3 study periods. Placebo matches LY3127760 in appearance.
62035589|NCT01733654|ACTIVE_COMPARATOR|RO4995819 5mg|RO4995819 5mgX6wks
62035590|NCT01733654|ACTIVE_COMPARATOR|RO4995819 15mg|RO4995819 15mg X 6 weeks
62035591|NCT01733654|ACTIVE_COMPARATOR|RO4995819 30mg|RO4995819 30mg X 6 weeks
62236504|NCT01968070|EXPERIMENTAL|LY3127760 (Multiple)|Multiple ascending oral doses of up to 900 mg LY3127760 administered once or twice daily (QD or BID) for 28 days.
62595112|NCT04677140||experiment group|By a specialist physician with existing anteroposterior and lateral radiographs have been diagnosed with adolescent idiopathic scoliosis
62595113|NCT02541669|EXPERIMENTAL|TAK-491 40 mg (Open Label)|TAK-491 40 milligram (mg), tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
62595114|NCT02541669|EXPERIMENTAL|TAK-491 80 mg (Open-label)|TAK-491 80 mg, tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
62595115|NCT02541669|EXPERIMENTAL|TAK-491 40 mg (Double-blind)|TAK-491 40 mg, tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
62595116|NCT02541669|EXPERIMENTAL|TAK-491 80 mg (Double-blind)|TAK-491 80 mg, tablet, orally, once daily and TAK-491 40 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
62595117|NCT02541669|PLACEBO_COMPARATOR|Placebo|TAK-491 40 mg placebo-matching tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10.
62595118|NCT06307496|EXPERIMENTAL|Videos|Participants will be sent links to smoking cessation videos to watch.
62595119|NCT06307496|ACTIVE_COMPARATOR|NCI Pamphlet|"Participants will be sent links to NCI's Clearing the Air to read."
62595120|NCT05341206|EXPERIMENTAL|Treatment group|The treatment group receive Herbal gargle 150ml and are instructed to hold the gargle in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
62595121|NCT05341206|SHAM_COMPARATOR|Control group|The control group receive Normal saline 150ml and are instructed to hold the normal saline in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
62236505|NCT01968070|PLACEBO_COMPARATOR|Placebo (Multiple)|Multiple oral doses of placebo administered QD or BID for 28 days. Placebo matches LY3127760 in appearance.
62236506|NCT01968070|ACTIVE_COMPARATOR|Celecoxib (Multiple)|Multiple oral doses of 400 mg celecoxib administered QD for 28 days.
62035592|NCT01733654|PLACEBO_COMPARATOR|Placebo|Placebo X 6 weeks
62236507|NCT02366013|EXPERIMENTAL|Group 1|1 dose of rcAd26.MOS1.HIV-Env 1x10\^8 vp or placebo
62236508|NCT02366013|EXPERIMENTAL|Group 2|1 dose of rcAd26.MOS1.HIV-Env 1x10\^9 vp or placebo
62035593|NCT02834780|EXPERIMENTAL|H3B-6527 (escalation and expansion)|Hepatocellular Carcinoma
62236509|NCT02366013|EXPERIMENTAL|Group 3|1 dose of rcAd26.MOS1.HIV-Env 1x10\^10 vp or placebo
62427088|NCT05602233|EXPERIMENTAL|Combined Training|Each participant in the combined training program will receive 4 weeks of balance training after 2 weeks of STARS treatment. STARS and hop to stabilization treatment protocol will be applied in the same way.
62427089|NCT05205668|EXPERIMENTAL|F-652 Dosage Level 1|IL-22 fusion protein administered intravenously
62427090|NCT05205668|PLACEBO_COMPARATOR|Placebo|Placebo administered intravenously
62427091|NCT05205668|EXPERIMENTAL|F-652 Dosage Level 2|IL-22 fusion protein administered intravenously
62427092|NCT00333073|EXPERIMENTAL|Bulkamid|Submucosal injection of Bulkamid into urethra
62427093|NCT00627627|EXPERIMENTAL|1|IPI-504
62427094|NCT01834690||liver transplantation recipients|adult liver transplantation recipients (\>=20 years at the date of surgery)
62427095|NCT00991042|OTHER|cytokine levels|Serum levels of pro-inflammatory cytokines were measured using the Enzyme Linked Immuno Sorbent Assay (ELISA) technique in 23 patients with pain due to herniated disk disease (G1) as well as in 10 control healthy subject
62427096|NCT03506854|EXPERIMENTAL|Normal Renal Function|Subjects with normal renal function will be matched by age (±10 years), weight (± 20%), and gender to the pooled mean values of subjects with the moderate renal impairment. Subjects will receive 1 dose of ISIS 681257.
62427097|NCT03506854|EXPERIMENTAL|Moderate Renal Impairment|Presence of moderate renal impairment (eGFR 30-59 mL/min/1.73m2). Subjects will receive 1 dose of ISIS 681257.
62035594|NCT06406569|OTHER|Home Robotics Upper Limb Training|"The patients will first familiarize in the clinic with the 3 devices (H-MAN, ReHandyBot and MyoPanda) with initial assistance of the therapists and then take the devices home for independent, self-administered training under caregiver supervision.~During the 6 weeks training (home phase), patients will be provided with two devices at any one time: with only the MyoPanda being used by the patient for 6 weeks. The H-MAN and ReHandyBot will stay with the patient for 3 weeks (i.e., 21 days) each."
62236510|NCT02366013|EXPERIMENTAL|Group 4|1 dose of rcAd26.MOS1.HIV-Env 1x10\^11 vp or placebo
62236511|NCT02115425||Age 10-17|Participants age 5 - 17 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA)
62427098|NCT05741983|EXPERIMENTAL|AMIC®|Bone Marrow Stimulation (Microfracture) with Chondro-Gide®
62427099|NCT05741983|ACTIVE_COMPARATOR|Microfracture (MFx)|Microfracture alone
62427100|NCT04048174|SHAM_COMPARATOR|Saline irrigation|"Each participant performed nasal saline irrigation at 2 periods:~* Day -14 to Day 0~* Day 14 to Day 28"
62236512|NCT02115425||Age 18-80|Age 18-80 years Participants age 18-80 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA)
62236513|NCT04731766|ACTIVE_COMPARATOR|Citrine 5% Sodium Fluoride|It was developed to prolong the contact between the tooth surface and fluoride to increase the resistance against caries attack and manage tooth hypersensitivity; the active ingredient of fluoride varnish is mostly 5% sodium fluoride.
62236514|NCT04731766|EXPERIMENTAL|concocuted Nano-silver fluoride|Nano-silver fluoride (NSF) is a laboratory synthesized solution
62427101|NCT04048174|EXPERIMENTAL|Probiotic lactococcus lactis W136 irrigation|Each participant performed Probiotic lactococcus lactis W136 nasal irrigation from Day 0 to D14
62427102|NCT01808014|EXPERIMENTAL|The addition of Nefopam|The addition of Nefopam for intravenous patient-controlled analgesia in patients with lumbar spinal surgery would reduce the side effects seen in monotherapy with opioid analgesia and result in effective pain management.
62595122|NCT06619353||Residual CardioVascular Risk|Residual cardiovascular risk is assessed in patients undergoing PCI.
62595123|NCT02111746|EXPERIMENTAL|Exparel®|Patients in this group will receive will receive the study drug \[bupivacaine liposomal injectable suspension (Exparel®)\] and Patient Controlled Analgesia (PCA). Exparel® is an FDA-approved bupivacaine liposome injectable suspension produced by Pacira Pharmaceuticals.
62595124|NCT02111746|ACTIVE_COMPARATOR|Regular Bupivacaine|Patients in this group will receive will receive the standard regular bupivacaine hydrochloride (HCl) and PCA. Bupivacaine HCl is an FDA-approved injectable suspension. The standard non-liposomal bupivacaine will be from Hospira pharmaceuticals
62595125|NCT06511206|EXPERIMENTAL|25g MCT-based nutrient mix|
62595126|NCT06511206|EXPERIMENTAL|25g MCT-based nutrient mix + cofactors|
62595127|NCT06511206|PLACEBO_COMPARATOR|non-ketogenic control|
62595128|NCT01298726|OTHER|PHARMACEUTICAL CARE|
62595129|NCT01298726|OTHER|HEALTH USUAL CARE|
62595130|NCT01659970||Cohort|
62595131|NCT04805697|PLACEBO_COMPARATOR|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
62595132|NCT04805697|EXPERIMENTAL|fermented grape drinks|subjects drank 50 ml , 1 bottle a day for 8 week
62595133|NCT00282906|EXPERIMENTAL|PET-CT|
62595134|NCT05846399|PLACEBO_COMPARATOR|Placebo (microcrystalline cellulose)|Placebo capsules by mouth twice daily x 5 days (5 days of placebo microcrystalline cellulose capsules)
62595135|NCT05846399|ACTIVE_COMPARATOR|Antibiotic x 1 day|"Amoxicillin-clavulanate 875-125mg capsules by mouth twice daily x 1 day (4 days of placebo capsules)~-Penicillin allergy: ciprofloxacin 500mg by mouth twice daily + clindamycin 300mg by mouth three times daily x 1 day"
62595136|NCT05846399|ACTIVE_COMPARATOR|Antibiotic x 5 days|"Amoxicillin-clavulanate 875-125mg capsules by mouth twice daily x 5 days (0 days of placebo capsules)~-Penicillin allergy: ciprofloxacin 500mg by mouth twice daily + clindamycin 300mg by mouth three times daily x 5 days"
62595137|NCT04305249|EXPERIMENTAL|Module A (ATG-017 Monotherapy)|Dosing will begin at 5 mg QD ATG-017 as starting dose. A treatment cycle will be 21 days for continuous dosing and 28 days for 7 days on/7 days off intermittent dosing of ATG-017 treatment.
62595138|NCT04305249|EXPERIMENTAL|Module B (ATG-017+Nivolumab Combination Therapy in Solid Tumors)|With the combination with nivolumab, a cycle of study treatment will be defined as 28 days. ATG-017 is planned initially to be continuously given 28 days in each cycle. ATG-017 dosing schedule in combination therapy will follow a similar dose escalation principle as with monotherapy but starting at 5 mg BID. Nivolumab will be given at fixed dosing, 480 mg Q4W, on D1 of each cycle.
62035595|NCT01210391|EXPERIMENTAL|New hydrolyzed infant formula|New, extensively hydrolyzed infant formula
62035596|NCT01210391|ACTIVE_COMPARATOR|Commercially available infant formula|Commercially available, extensively hydrolyzed infant formula.
62595139|NCT01389479|EXPERIMENTAL|Fluviral Group|
62595140|NCT01389479|ACTIVE_COMPARATOR|Fluzone Group|
62595141|NCT04042922|EXPERIMENTAL|Exposure to active stimulation for 30 - 60 min|Subjects in this arm will receive 30 - 60 minutes of active stimulation
62595142|NCT04042922|SHAM_COMPARATOR|Exposure to control stimulation for 30 - 60 min|Subjects in this arm will receive 30 - 60 minutes of control stimulation
62595143|NCT04653337|EXPERIMENTAL|Robot-assisted accelerated iTBS-1800 and Antidepressants|MDD patients with suicidal ideation will receive antidepressants combined with robot-assisted accelerated iTBS-1800(10 sessions per day over 5 consecutive days). This group is in order to determine the safety, tolerability and feasibility of accelerated iTBS protocol.
62035597|NCT06046274|EXPERIMENTAL|Cohort A: pembrolizumab + acasunlimab|Pembrolizumab will be administered in combination with acasunlimab as second-line (2L) or third-line (3L) therapy for dMMR/MSI-H in checkpoint inhibitor (CPI) naïve participants.
62595144|NCT04653337|ACTIVE_COMPARATOR|Robot-assisted accelerated iTBS-600 and Antidepressants|MDD patients with suicidal ideation will receive antidepressants combined with robot-assisted accelerated iTBS-600(6 sessions of iTBS with 30 min interval per day over 5 consecutive days).
62595145|NCT04653337|SHAM_COMPARATOR|Sham accelerated iTBS-600 and Antidepressants|MDD patients with suicidal ideation and depression will receive antidepressants combined with sham accelerated iTBS-600(6 sessions of sham iTBS with 30 min interval per day over 5 consecutive days).
62595146|NCT03361865|EXPERIMENTAL|Pembrolizumab 200 mg + epacadostat 100 mg BID|Pembrolizumab + epacadostat
62595147|NCT03361865|ACTIVE_COMPARATOR|Pembrolizumab 200 mg + placebo BID|Pembrolizumab + placebo
62595148|NCT06618222||Wingspan stent|All patients had received Percutaneous transluminal angioplasty and stenting with Wingspan stent system.
62595149|NCT06605222|EXPERIMENTAL|Single Group: SHR-7787 injection|
62595150|NCT00841347|NO_INTERVENTION|1|Study of habitual sleep length on non obese teen group
62595151|NCT00841347|EXPERIMENTAL|2|Study of habitual sleep length period followed by extended sleep length period on obese teen group
62595152|NCT00841347|EXPERIMENTAL|3|Study of extended sleep length period followed by habitual sleep length period on obese teen group
62595153|NCT05273060|NO_INTERVENTION|Standard of Care Nasal Reconstruction Planning|Subjects undergoing nasal reconstruction will have standard planning for procedure.
62035598|NCT06046274|EXPERIMENTAL|Cohort B: pembrolizumab + acasunlimab|Pembrolizumab will be administered in combination with acasunlimab as 2L or 3L therapy for mismatch repair deficient/ microsatellite instability-high (dMMR/MSI-H) participants who had prior exposure to programmed cell death protein/ programmed death ligand 1 (PD-1/PD-L1) inhibitors.
62236515|NCT03298321||Vidaza patients|This study will be performed on adults with Acute Myeloid Leukemia and atrial fibrillation. Only patients treated for the first time with vidaza® within an hospital hematology unit will be included.
62595154|NCT05273060|EXPERIMENTAL|3D Nasal Reconstruction Planning|Subjects undergoing nasal reconstruction will have 3D planning utilized by the surgical team for the procedure.
62595155|NCT05481723|ACTIVE_COMPARATOR|Control group|The control group will be treated according to the usual protocol of the department (standard group)
62595156|NCT05481723|EXPERIMENTAL|pulmonary ultrasound group|the experimental group follows an algorithm incorporating the number of B-lines occurring after a filling test (pulmonary ultrasound group).
62236516|NCT00909454|EXPERIMENTAL|Daily 2000 IU vitamin D supplement|
62236517|NCT00909454|ACTIVE_COMPARATOR|Daily Vitamin D supplement 400 IU|
62236518|NCT04195958|EXPERIMENTAL|Omalizumab|
62236519|NCT05482152|NO_INTERVENTION|Standard physician led care|Consultation by physician (pain specialist)
62236520|NCT05482152|EXPERIMENTAL|Nurse-led care|Preclinical nurse-led consultation and standard care by physician (pain specialist)
62236521|NCT03837314|EXPERIMENTAL|Deep Brain Stimulation|"Deep Brain stimulation using a novel device. Bioinduction Picostim Deep Brain Stimulation system"
62236522|NCT05406804|EXPERIMENTAL|Breast milk olfactory stimulation care|Let premature babies smell their mother's breast milk
62427103|NCT01485224|EXPERIMENTAL|Thalidomide|"Single arm study:~Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.~Treatment will be continued until one of the following criteria is met:~* 8 additional weeks of treatment after the achievement of complete response~* 16 additional weeks of treatment after the achievement of partial response~* 24 weeks of treatment completed without response~* unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks."
62595157|NCT04070690|OTHER|Intervention-Control group|"In this group, the participants will receive intervention for 2 months first, followed by a wash-out period of 1 month and control for 2 months.~In the intervention period, the investigators will provide the participants with lower dialysate HCO3 concentrations. (dialysate HCO3 to 28 mmol/L for half of the HD session and 30 to the second half of their HD session.) Besides, the investigators will give the participants with pre-HD HCO3\<22 mEq/L oral Na-bicarbonate 650 mg 1#-2# three times a day as supplements.~In the control period, the investigators will provide the participants with dialysate HCO3 concentration of 38-40 mEq/L (as we usually provide to patients)."
62236523|NCT05406804|ACTIVE_COMPARATOR|Routine care|Prevent premature babies from smelling their mother's breast milk
62236524|NCT06027125|EXPERIMENTAL|Action Observation Therapy group|The patients in the action observation therapy group will be required to observe the upper limb movements or functional actions in video clips (i.e., the observation phase) and to execute what they had observed to the best of their ability (i.e., the execution phase.
62236525|NCT06027125|EXPERIMENTAL|Mirror Therapy Group|During the mirror therapy, the patients were seated in front of a mirror box placed at their midsagittal plane. The affected arm of the participants was placed inside the mirror box, and the unaffected arm was in front of the mirror. The patient was instructed to watch the mirror reflection of the movement performed by his/her unaffected hand carefully and to imagine that the movement was performed by the affected hand.
62427104|NCT04252508|EXPERIMENTAL|With animated film|An animated film depicts the child and the caregivers in the form of avatars and retraces his journey from his room to the transfer area, then to the the operating room and finally to the post-intervention ward.
62236526|NCT04876118|EXPERIMENTAL|Fat Reduction|The treatments are designed to see if the appearance of cellulite can be reduced on the outer thigh with a new applicator design.
62427105|NCT04252508|NO_INTERVENTION|Standard route|"The information about the surgery will be given by the surgeon during the consultation.~Those about anaesthesia will be delivered by anaesthesiologist during the anaesthetic consultation."
62427106|NCT04113538|ACTIVE_COMPARATOR|Standard|2 ml (40 mg/ml) of Eylea solution : loading dose of 3 intravitreal injections every 4 weeks for the first 3 months followed by an injection every 8 weeks until the end of the study
62236527|NCT04478656|EXPERIMENTAL|BBV121-2.5 µg|BBV121: Each 0.5ml vial contain purified10 µg inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5mL
62236528|NCT04478656|PLACEBO_COMPARATOR|Placebo|Each 0.5ml vial contain purified 2.5 µg, 5 µg or 10 µg inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5mL
62236529|NCT04478656|EXPERIMENTAL|BBV121-5 µg|BBV121: Each 0.5ml vial contain purified inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5mL
62236530|NCT04478656|EXPERIMENTAL|BBV121-10 µg|BBV121: Each 0.5ml vial contain purified inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5ml
62236531|NCT00650572|EXPERIMENTAL|ARRY-380|
62236532|NCT00893126||Subjects with severe psoriasis|Subjects 18 to 55 with severe psoriasis. Subject will undergo a CCTA (Coronary CT Angiogram) scan.
62236533|NCT00893126||Subjects without psoriasis|Subjects 18 to 55 who do not have psoriasis or rheumatologic conditions, including rheumatoid arthritis and systemic lupus erythematosus. This group of subjects will complete a CCTA (Coronary CT Angiogram)scan.
62236534|NCT02684279|EXPERIMENTAL|Dasotraline|4, 6, 8 mg flexibly dosed
62236535|NCT00738309||Operative|Diagnosis of classical Scheuermann's Kyphosis (3 successive vertebrae wedged 5 degrees or more, +/- end plate deformities) or idiopathic structural Kyphosis (rigid structural kyphosis without classic Scheuermann's Kyphosis findings) for which surgical treatment is recommended to prevent progression of the curvature or to correct trunk deformity (unacceptable cosmesis).
62236536|NCT00738309||Non-operative|Diagnosis of classical Scheuermann's Kyphosis (3 successive vertebrae wedged 5 degrees or more, +/- end plate deformities) or idiopathic structural Kyphosis (rigid structural kyphosis without classic Scheuermann's Kyphosis findings) for which surgical treatment was not undertaken.
62236537|NCT03840226|ACTIVE_COMPARATOR|Magnesium|oral magnesium oxide tablets \[Magnox 520 TM (magnesium oxide monohydrate, 520 mg/day of elemental magnesium), Naveh Pharma, Israel\]
62236538|NCT03840226|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62595158|NCT04070690|OTHER|Control-Intervention group|"In this group, the participants will receive control for 2 months first, followed by a wash-out period of 1 month and intervention for 2 months.~In the control period, the investigators will provide the participants with dialysate HCO3 concentration of 38-40 mEq/L (as we usually provide to patients).~In the intervention period, the investigators will provide the participants with lower dialysate HCO3 concentrations. (dialysate HCO3 to 28 mmol/L for half of the HD session and 30 to the second half of their HD session.) Besides, the investigators will give the participants with pre-HD HCO3\<22 mEq/L oral Na-bicarbonate 650 mg 1#-2# three times a day as supplements."
62236539|NCT05198687|ACTIVE_COMPARATOR|overdentures|implant overdentures
62236540|NCT05198687|ACTIVE_COMPARATOR|sinus lift|sinus lift and long implants and screw-retained prosthesis
62812699|NCT03715517|ACTIVE_COMPARATOR|Thoracic epidural analgesia|"Continuous thoracic epidural analgesia~Bolus (pre-induction): 0.25 mg⋅kg-¹ bupivacaine 0.25% plus 1 mcg⋅kg-¹ hydromorphone (0.1 mL⋅kg-¹)~Infusion (initial): 0.25 mg⋅kg-¹⋅h-¹ bupivacaine 0.25% plus 1 mcg⋅kg-¹⋅h-¹ hydromorphone (0.1 mL⋅kg-¹⋅h-¹)~Infusion (range): 0.19-0. 3 mg⋅kg-¹⋅h-¹ bupivacaine 0.25% plus 0.75-1.25 mcg⋅kg-¹⋅h-¹ hydromorphone (0.075-0.125 mL⋅kg-¹⋅h-¹) (3-10 mL⋅h-¹)~Postoperative analgesia: (1) Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range as above (0.075-0.125 mL⋅kg-¹⋅h-¹) (3-10 mL⋅h-¹), continued for a maximum of 72 h postoperatively; (2) IV-PCA hydromorphone (bolus: 0.2 mg \[range: 0.1-0.4 mg\]; 5 min lockout; no infusion)."
62236541|NCT05198687|ACTIVE_COMPARATOR|short implants|short implants and screw-retained prosthesis
62236542|NCT02328287|EXPERIMENTAL|ALLOB® Implantation|
62595159|NCT02780024|EXPERIMENTAL|Registered one arm study|Two weeks of neo-adjuvant Metformin+Temozolomide followed by accelerated hypofractionation using an IMRT technique+TMZ \& Metformin followed by TMZ, and Metformin as adjuvant component.
62735521|NCT03180333|EXPERIMENTAL|PNA 2|Single dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 80mg/160mg/320mg,single-dose;
62236543|NCT03425838|ACTIVE_COMPARATOR|Strategy A CDK4/6 inhibitor in 1st line|Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician) plus CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib, depending on availability and physician's preference) in first line followed by fulvestrant in second line.
62236544|NCT03425838|ACTIVE_COMPARATOR|Strategy B CDK4/6 inhibitor in 2nd line|Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician) in first line followed by fulvestrant plus CDK4/6 inhibitor in second line (palbociclib, ribociclib or abemaciclib, depending on availability and physician's preference).
62236545|NCT00389857|EXPERIMENTAL|Influenza vaccine-naive group|Participants have never received Influenza virus vaccine in the past. They will receive a single dose of Fluzone vaccine on Day 0 and Day 28, respectively.
62236546|NCT00389857|EXPERIMENTAL|Influenza vaccine-primed group|Participants have received Influenza virus vaccine in the past. They will receive a single dose of Fluzone vaccine on Day 0.
62236547|NCT05042037|ACTIVE_COMPARATOR|Double-blind, placebo-controlled interventional study|Active treatment group will receive a 3-gram sachet of probiotics containing multi-strain of lactobacillus and Bifidobacterium 30 Colony Forming Unit x 109 to be taken twice daily for 12 weeks.
62812700|NCT05952349|ACTIVE_COMPARATOR|Combination Therapy Group|ARM# 1 OLIVE OIL 5ML/5MG (BD) NUTRITIONAL SACHET 2100MG (BD)
62812701|NCT05952349|OTHER|Standard Therapy Group|ARM # 2 METFORMIN 1000MG (BD)
62236548|NCT05042037|PLACEBO_COMPARATOR|Placebo|Patients will be given placebo sachet (exactly the same packaging as active comparator) to be taken 1 sachet twice daily for 12 weeks.
62236549|NCT00639561|EXPERIMENTAL|A|diet composed of 10g of fibre per day
62236550|NCT00639561|EXPERIMENTAL|B|diet composed of 40g of fibre per day
62243426|NCT03166163|EXPERIMENTAL|Azadirachta indica (Neem extract)|its herbal mouthwash that will be given to a group a Egyptian children twice a day(10 ml each) for 3 weeks
62243427|NCT03166163|ACTIVE_COMPARATOR|chlorhexidine mouthwash|its an antimoicrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily(10 ml each) for 3 weeks
62243428|NCT05059236|EXPERIMENTAL|Darolutamide+ADT|Participants will receive darolutamide plus ADT in the ARASEC treatment arm. The control arm for the study will be derived from the participants treated with ADT alone in the CHAARTED trial using a matching approach
62236551|NCT03199937|EXPERIMENTAL|Flexible Futures|Flexible Futures uses cognitive behavioral therapy (CBT) techniques to target flexibility and planning by teaching core skills through personal goals chosen by students during treatment. Flexible Futures focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, how thoughts and feelings affect planning and flexibility, self-advocacy skills necessary to promote independence, application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities. Guided practice begins with concrete interventionist support, and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support. Generalization is maximized with school staff as interventionists, parent training, home and classroom extension activities, and role-playing use of strategies in novel situations. Motivation is developed using student choice and natural motivators.
62236552|NCT03199937|ACTIVE_COMPARATOR|Waitlist control group|Current standard of care
62236553|NCT04615767|EXPERIMENTAL|D-chiro-inositol|Volunteers are orally administered with 1 g D-chiro-inositol per day (two doses in capsules of 500 mg each, one in the morning and the other one in the evening) for thirty days
62236554|NCT05146687||Aflibercept|Patients/patient eyes who were treated only with aflibercept in 2019
62236555|NCT05146687||Ranibizumab|Patients/patient eyes who were treated only with ranibizumab in 2019
62236556|NCT05146687||Bevacizumab|Patients/patient eyes who were treated only with bevacizumab in 2019
62236557|NCT05146687||≥2 Different Anti- VEFGFs|Patients/patient eyes who were treated with ≥2 different anti-VEGFs in 2019
62236558|NCT03002519|EXPERIMENTAL|PLX-R18|Dose Escalation- first three subjects will be enrolled in the low dose cohort, 6 subjects in the intermediate-dose cohort, and 15 subjects in the high dose cohort.
62236559|NCT05651750|EXPERIMENTAL|Montelukast tab|
62236560|NCT05651750|EXPERIMENTAL|Fluticasone nasal spray|
62812702|NCT05288309|OTHER|RAİNSTİCK|In the 1st experimental group, the sound of the rain stick was played to distract attention. The rainstick, used by traditional societies, is a rhythm instrument that makes the sound of rain by moving it up and down. The length of the rain stick made of bamboo is 40 cm. There are spiral-shaped spines inside the tool, which is closed at both ends. It makes the sound of drizzling rain by moving it up and down.
62236561|NCT02076750|EXPERIMENTAL|Vitamin D3 (cholecalciferol) 10,000 IU per 10 kg body weight|Vitamin D3 (cholecalciferol) will be administered orally at a dose of 10,000 IU per 10 kg body weight weekly for 6 consecutive weeks. The maximum dose will be 50,000 IU weekly for patients weighing 50 kg or greater.
62236562|NCT02076750|ACTIVE_COMPARATOR|Vitamin D3 (cholecalciferol) 5,000 IU per 10 kg body weight|Vitamin D3 (cholecalciferol) will be administered orally at a dose of 5,000 IU per 10 kg body weight weekly for 6 consecutive weeks. The maximum dose will be 25,000 IU weekly for patients weighing 50 kg or greater.
62236563|NCT04427553|EXPERIMENTAL|Percutaneous Peripheral Nerve Stimulation|"Participants assigned to this group will received two sessions (once per week) of ultrasound guided Percutaneous Peripheral Nerve Stimulation targeting the femoral nerve. We will apply a biphasic compensated electrical current at a frequency of 10 Hz, a pulse width of 240 µs and intensity allowed over a pain-free motor threshold (muscle contraction). Each participant will receive 10 repetitions of 10 seconds each one with 10 seconds rest- period between series (total treatment session 1.40 min).~After that participants will walk during 3 minutes."
62236564|NCT04427553|PLACEBO_COMPARATOR|Control|Participants in the control group will walk during 5 minutes, without receiving any intervention
62236565|NCT02709525|EXPERIMENTAL|hyaluronic acid|Immediately after the extractions, one socket was randomly filled with 1% hyaluronic acid gel.
62236566|NCT02709525|PLACEBO_COMPARATOR|Blood clot|Immediately after the extractions, the other side socket was naturally filled with blood clot.
62236567|NCT04032769|EXPERIMENTAL|Modified strategy MODS|"the threshold of D-dimer will depend on the YEARS rule (MODS strategy):~1. If all the three items of YEARS are negative (i.e. No hemoptysis, No clinical sign of deep venous thrombosis and PE is not the most likely diagnosis), then the threshold of D-dimer will be raised at 1000 ng/ml.~2. If at least one item of YEARS is positive, then the threshold will remain unchanged (\>500 ng/ml for patients aged \< 50 and \> agex10 for patients aged 50 and over).~   * A positive result of D-dimer and the absence of other obvious cause for PE will mandate a CTPA, or V/Q scan if CTPA is contra-indicated.~  * A negative result of D-dimer will rule out PE."
62236568|NCT04032769|NO_INTERVENTION|Control group|All included patients will be tested with D-Dimer, threshold for ordering a CTPA as usual
62236569|NCT02023255|EXPERIMENTAL|Part A: Cohort 1|8 participants will be included in this cohort. 6 participants will receive a single dose of 50 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
62236570|NCT02023255|EXPERIMENTAL|Part A: Cohort 2|8 participants will be included in this cohort. 6 participants will receive a single dose of 150 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
62812703|NCT05288309|OTHER|KALEİDOSCOPE|In the second experimental group, kaleidoscope was used to distract attention. A kaleidoscope, or kaleidoscope, is a device that sees colorful patterns when looked into. Inside, there are three mirrors adjacent to each other with an inclination of 60 degrees between them. There are pieces of colored glass between the mirrors. When viewed from one end of this binocular, shape-shifting polygons are seen, often with images that will never be the same again. These patterns are created by the reflection of light and change constantly as the binoculars are moved.
62236571|NCT02023255|EXPERIMENTAL|Part A: Cohort 3|8 participants will be included in this cohort. 6 participants will receive a single dose of 450 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
62812704|NCT05638932||Interleukin-6 receptor inhibitor (IL6Ri) initiators vs Janus kinase inhibitor (JAKi) initiators|Hospitalized patients who initiate an IL6Ri versus JAKi in addition to a corticosteroid of interest
62236572|NCT02023255|EXPERIMENTAL|Part A: Cohort 4|8 participants will be included in this cohort. 6 participants will receive a single dose of 1,350 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
62236573|NCT02023255|EXPERIMENTAL|Part A: Cohort 5|8 participants will be included in this cohort. 6 participants will receive a single dose of 2,700 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
62236574|NCT02023255|EXPERIMENTAL|Part B: Cohort A|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the pharmacokinetic (PK) data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
62236575|NCT02023255|EXPERIMENTAL|Part B: Cohort B|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the PK data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
62595160|NCT06646328|ACTIVE_COMPARATOR|Heparin|"Central venous access will be achieved with a 13 Fr double lumen catheter placed into the internal jugular or femoral vein.~The patient will be connected to the Fresenius multiFiltrate (Fresenius Medical Care GmbH, Bad Homburg v.d.H., Germany) pump-assisted circuit with a high-flux synthetic membrane. In the heparin arm the anticoagulation technique to be used will be non-fractional heparin.~Blood and ultrafiltrate samples will be taken from the prefilter (inlet filter plasma concentration \[Ci\]) and postfilter (outlet filter plasma concentration \[Co\]) sites of the extracorporeal circulation circuit at different times."
62735522|NCT03180333|EXPERIMENTAL|PNA 3|Multiple dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 6 days;
62812705|NCT03866746|ACTIVE_COMPARATOR|Group A|received aflibercept injections alone
62812706|NCT03866746|EXPERIMENTAL|Group B|received 3 aflibercept injections followed by micropulsed laser
62236576|NCT02023255|EXPERIMENTAL|Part B: Cohort C|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the PK data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
62236577|NCT01372410|ACTIVE_COMPARATOR|Tiotropium|18 mcg, inhaled long acting muscarinic antagonist
62236578|NCT01372410|EXPERIMENTAL|GSK573719|inhaled medication
62236579|NCT01372410|PLACEBO_COMPARATOR|Placebo|inactive/excipients only
62236580|NCT04220125|EXPERIMENTAL|Ketamine Group|Ketamine 0.5 mg/kg over 40 min via intravenous catheter.
62236581|NCT04220125|ACTIVE_COMPARATOR|MIdazolam Group|Midazolam 0.045 mg/kg administered via intravenous catheter.
62236582|NCT03412370||Observational (questionnaires, cognitive assessment)|Patients complete questionnaires and cognitive assessments over 45-60 minutes within 3 weeks following mammography and at about 3 months in patients for whom biopsy is not required, before biopsy and at about 3 months in patients for whom biopsy is required, and at 4-6 weeks after first chemotherapy infusion in patients receiving chemotherapy.
62236583|NCT02877758|EXPERIMENTAL|Experimental|Tomorrowlabs cosmeceutical formulation is applied to the face of the subjects twice daily for 3 consecutive months.
62236584|NCT02877758|SHAM_COMPARATOR|Control|Tomorrowlabs cosmeceutical formulation without the active ingredient is applied to the face of the subjects twice daily for 3 consecutive months.
62735523|NCT03180333|EXPERIMENTAL|PNA 4|The effect of diet:Metacavir Enteric-coated Capsules 160mg,before and after meal.
62735524|NCT04778891|EXPERIMENTAL|Intervention group|In addition to usual care provided by general practitioner (GP) and other health care providers, a pharmacist-practitioner in collaboration with GPs from the study setting provided CMM services to patients in the intervention group. Based on the pre-defined inclusion criteria, GPs were selecting patients and referring them to the pharmacist. The individual consultation with the patient was held at the private counselling area where pharmacist and patient were able to talk face-to-face apart from the other patients. The initial assessment lasted 60-90 minutes and the follow-up evaluations 30-60 minutes. Alternatively, patients were followed-up by telephone. Communication with GPs took place in a written (electronic consultation system Health net. PRO; e-mail) and, if needed by face-to-face conversation. Each patient in the intervention group needed to agree to participate in the study by signing an Informed consent form.
62735525|NCT04778891|NO_INTERVENTION|Control group|Patients in the control group received the usual care which includes GP and other health care provider visits. Data for the patients pertaining to the control group were provided by the 'control' GP and collected parallel with the intervention group. 'Control' GP profile corresponded to the profile of GPs included in the intervention group - the number of years of professional experience in the primary health care less than ten.
62735526|NCT00705445|ACTIVE_COMPARATOR|A|This group will not receive any of the intervention supplements. The group will only receive nutritional counselling and education, and treatment provided for any encountered illness according to IMCI guidelines.
62735527|NCT00705445|EXPERIMENTAL|B|"This group will receive micronutrient supplements containing microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid.~This group will also receive Nutritional Counselling and Education and treatment according to IMCI Guidelines for any serious illness."
62735528|NCT00705445|EXPERIMENTAL|C|"This group will receive Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, Folic Acid, and Zinc.~This group will also receive nutritional counselling, education and treatment according to IMCI Guidelines in case of any untoward illness."
62735529|NCT04105088||Randomly-Sampled|Adults aged 30+ living in one of the First Nations communities whose household was randomly-sampled.
62735530|NCT04105088||Walk-in Volunteers|Adults aged 30+ living in one of the First Nations communities who is a walk-in study volunteer, not randomly-sampled.
62735531|NCT01995500|EXPERIMENTAL|BioNIR|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:~* Stent - a mounted Cobalt Chromium (CoCr) alloy based stent~* Delivery System - Rapid Exchange (RX) Coronary System~* Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~* Ridaforolimus drug - CAS Registry Number: 572924-54-0 The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
62236585|NCT02685670|EXPERIMENTAL|Mixed CD19CAR transfer|All subjects will be infused with αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T cells in equal number
62812707|NCT01552070|EXPERIMENTAL|With recruitment maneuver group|Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds. Blood gases were sampled and blood samples taken for culture before, within 2 minutes, 5 minutes, and 30 minutes after intubation. Haemodynamic and respiratory parameters were continuously recorded throughout the study.
62812708|NCT01552070|ACTIVE_COMPARATOR|Without recuritment maneuver|After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
62812709|NCT03047941||All patients|All patients included in the present study
62236586|NCT00519155|EXPERIMENTAL|1|Open flap debridement + MD05
62236587|NCT00519155|ACTIVE_COMPARATOR|2|Open flap debridement
62236588|NCT05447533|OTHER|Geriatric tailored assessment and intervention|"The geriatric tailored intervention consists of the following components:~1. Comprehensive Geriatric Assessment~2. Continued geriatric care during 8 weeks follow-up or until cured."
62236589|NCT05447533|ACTIVE_COMPARATOR|Standard care|Standard care: Patients are not contacted by the geriatric team. They receive usual treatment at the treating physician's discretion. Standard care of Clostridioides difficile infection in Denmark is described in the National clinical guideline.
62812710|NCT03052790|ACTIVE_COMPARATOR|manually instrumented total knee arthroplasty|Manually instrumented implantation of a total knee prosthesis involves use of cutting guides or jigs that are secured to the femur and the tibia. The femoral guide is secured to the femur after an intramedullary referenced guide is placed into the femur and the rotational alignment is then assessed with use of the epicondylar axis. An extra-medullary tibial alignment guide will be used to create the tibial cut.
62236590|NCT04265924|ACTIVE_COMPARATOR|>0.85 FIO2 group|This group receives FIO2 \>0.85 during the surgery.
62236591|NCT04265924|ACTIVE_COMPARATOR|<0.7 FIO2 group|This group receives FIO2 \<0.7 during the surgery.
62236592|NCT05863312|ACTIVE_COMPARATOR|Pars plana vitrectomy + sulfur hexafluoride gas tamponade|
62236593|NCT05863312|EXPERIMENTAL|Pars plana vitrectomy with scleral buckle + sulfur hexafluoride gas tamponade|
62236594|NCT05863312|EXPERIMENTAL|Pars plana vitrectomy + perfluoropropane gas tamponade|
62236595|NCT05863312|EXPERIMENTAL|Pars plana vitrectomy with scleral buckle + perfluoropropane gas tamponade|
62236596|NCT03963687|ACTIVE_COMPARATOR|Control Group|Participants will receive the Standard Nursing Education Intervention first
62427107|NCT04113538|EXPERIMENTAL|Treat and Extend|2 ml (40 mg/ml) of Eylea solution : loading dose of 3 intravitreal injections every 4 weeks for the first 3 months followed and, until the end of the study, retreatment interval based on disease stability
62595161|NCT06646328|EXPERIMENTAL|Citrate|"Central venous access will be achieved with a 13 Fr double lumen catheter placed into the internal jugular or femoral vein.~The patient will be connected to the Fresenius multiFiltrate (Fresenius Medical Care GmbH, Bad Homburg v.d.H., Germany) pump-assisted circuit with a high-flux synthetic membrane. In the citrate arm regional citrate anticoagulation of the extracorporeal purification system will be used to avoid coagulation of the circuit.~Blood and ultrafiltrate samples will be taken from the prefilter (inlet filter plasma concentration \[Ci\]) and postfilter (outlet filter plasma concentration \[Co\]) sites of the extracorporeal circulation circuit at different times."
62812711|NCT03052790|EXPERIMENTAL|robotic assisted total knee arthroplasty|Robotically assisted surgery is used in conjunction with the preoperative CT scan and intra-operative bony registration of the patient's knee. Femoral and tibial trackers are placed and then the bone is registered using bony landmarks to allow the computer and robot to know where the patients' femur and tibia are in space. Once this is complete the preoperative templated surgical plan (performed by the PI) is used to register where to make the bony cuts in order to implant the knee components. The cutting process is performed by the surgeon with the robot assisting in guiding the cuts based on the registered CT anatomy. The surgeon has complete control of the cutting process with the assistance of the robot for placement of the cuts.
62812712|NCT04869982|EXPERIMENTAL|RZV Group|Participants randomized to the RZV Group were scheduled to receive two doses of RZV, one at Day 1 and one at Month 2.
62812713|NCT04869982|PLACEBO_COMPARATOR|Placebo Group|Participants randomized to the Placebo Group were scheduled to receive two doses of placebo, one at Day 1 and one at Month 2.
62812714|NCT05236517|EXPERIMENTAL|Semaglutide|
62812715|NCT05236517|PLACEBO_COMPARATOR|Placebo|
62812716|NCT03795571|EXPERIMENTAL|R2-GOD|
62236597|NCT03963687|EXPERIMENTAL|Intervention Group|Participants will receive the New Nursing Education Intervention first
62236598|NCT06108804|EXPERIMENTAL|mulligan pain release phenomenon with tapping.|Participants in group A will receive mulligan pain release phenomenon with tapping.
62236599|NCT06108804|ACTIVE_COMPARATOR|mulligan pain release phenomenon|Participants in group B will receive mulligan pain release phenomenon
62236600|NCT04770311|NO_INTERVENTION|Control|In a typical Healthy Lifestyless Nutrition visit, dietitians provide medical nutrition therapy to patients and their families. This includes addressing abnormal, nutrition-related lab values and providing targeted nutrition advice (foods to include, foods to limit) in order to resolve said labs. Motivational interviewing techniques will be used to help families identify barriers to Lifestyles change and provide strategies to help overcome these barriers. Families will receive compensation per each nutritional visit.
62236601|NCT04770311|OTHER|Intervention|Besides the usual standard of care during the nutrition visits, participants will have guidance on a microbiome-friendly diet and will receive groceries 1 time per week for 4 weeks.
62236602|NCT00594529|OTHER|1|
62236603|NCT00633061|EXPERIMENTAL|A-randomized to treatment|Patients diagnosed with asymptomatic catheter-related DVT who are randomized to treatment with enoxaparin for 6 weeks
62236604|NCT00633061|NO_INTERVENTION|B-randomized to close|Patients diagnosed with asymptomatic catheter-related DVT who are randomized to close observation for 6 weeks
62427108|NCT01392586|EXPERIMENTAL|Upfront surgery|Upfront surgery followed by systemic treatment
62427109|NCT01392586|OTHER|Systemic therapy|Systemic therapy possibly followed by local treatment of the breast tumor
62427110|NCT01293409|PLACEBO_COMPARATOR|Placebo|The amount of photic energy of light is considered to be non-therapeutical
62427111|NCT01293409|EXPERIMENTAL|Intermediate dose|"The amount of photic energy of bright light is considered to be intermediate"
62427112|NCT01293409|EXPERIMENTAL|High dose bright light|The amount of photic energy of bright light is considered to be fully therapeutic
62595162|NCT04760041|ACTIVE_COMPARATOR|nebulized midazolam group|36 children will receive nebulized midazolam 0.2 mg/kg in 3 ml normal saline plus 5 ml clear juice 30 min before undergoing general anesthesia
62595163|NCT04760041|ACTIVE_COMPARATOR|oral midazolam group|36 children will receive oral midazolam 0.5 mg/kg in 5 ml clear juice plus nebulizer of 3 ml normal saline 30 min before undergoing anesthesia
62595164|NCT03045276|ACTIVE_COMPARATOR|Arm 1 - No Feedback, Minimum Incentive|Subjects will receive daily text message reminders and report real-time treatment adherence with photos. They will receive compensation to encourage real-time adherence reporting. Subjects will also be able to log into a personal dashboard with a visual display of their weekly adherence performance and educational resources related to their primary disease. Every month, participants will receive a text encouraging them to visit their personal dashboard. The dashboard is able to track usage of the modules by individual. Parents/legal guardians will have access to these same educational materials via their own portals. Additionally, to mitigate the minimal risk of this study, parents/legal guardians will be notified if their child is excessively non-adherent.
62812717|NCT02799836|EXPERIMENTAL|Light deprived study subjects|Study subjects who are blindfolded for 48 hours
62812718|NCT05025839||C healthy|Healthy control group
62812719|NCT05025839||C pneum|Control group of patients who were hospitalised and diagnosed with pneumonia ( COVID-19 pneumonia excluded)
62812720|NCT05025839||Mild|Outpatients presenting to the hospital with COVID-19
62812721|NCT05025839||Moderate|In-patients with COVID-19 not requiring ICU admission
62812722|NCT05025839||Severe|Patients with COVID-19 admitted to the ICU
62236605|NCT04673565|NO_INTERVENTION|Control|Control groups that undergo standard audiological care
62236606|NCT04673565|EXPERIMENTAL|Treatment|Treatment groups that undergo motivational interviewing with audiological care
62236607|NCT05486117|EXPERIMENTAL|Delgocitinib cream 20 mg/g|Twice-daily topical application for 8 days
62236608|NCT00323297|PLACEBO_COMPARATOR|placebo|
62236609|NCT00323297|EXPERIMENTAL|Active|
62236610|NCT04866654|EXPERIMENTAL|Study group|Nivolumab, total dose 5760 mg milligram
62236611|NCT04515069|ACTIVE_COMPARATOR|Traditional technique for tooth preparation.|Tooth preparation performed directly on the tooth structure
62243429|NCT05931003|EXPERIMENTAL|Carotid artery stenting|Carotid artery stenting
62243430|NCT05931003|ACTIVE_COMPARATOR|Carotid endarterectomy|Carotid endarterectomy
62427113|NCT06389565|ACTIVE_COMPARATOR|PST alone|Patients randomized to PST alone will receive PST delivered using a stepped-care approach. Subsequent care will be determined based on participant PHQ-9 score at the week 6 evaluation. All participants who do not achieve remission (PHQ-9 \<12) after completion of the additional six-week therapy sessions, will be required to have a referral to either the general MD or psychiatrist at the clinic to determine need for pharmacologic treatment or additional intervention based on local clinical practice guidelines. During each PST session, the HIV counselor will ask the participant structured questions to identify those at risk of suicide, or with adverse reactions to prescribed antidepressants. Participants who indicate suicidality (plan/attempt) during PST sessions, or ongoing refractory disease (at reassessment points) will require immediate consultation by the psychiatry clinic.
62812723|NCT01857219|EXPERIMENTAL|Role of Tai Chi in Fibromyalgia|"Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM.~In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. For the remaining sessions, the subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm-up and self-massage and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture.30"
62812724|NCT04991870|EXPERIMENTAL|Group 1 (CB-NK-TGF-betaR2-/NR3C1- )|Patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes weekly for up to 8 doses in the absence of disease progression or unacceptable toxicity.
62812725|NCT04991870|EXPERIMENTAL|Group 2 (CB-NK-TGF-betaR2-/NR3C1-, resection)|Patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes on days 0, 7, and 14. Patients undergo standard of care surgical resection on day 15. Beginning 2 weeks after surgery, patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes weekly for up to 5 doses (total of 8 doses) in the absence of disease progression or unacceptable toxicity.
62812726|NCT01393158|EXPERIMENTAL|20 mg BID|Patients dosed with 20 mg orally of Apremilast BID for 3 months.
62812727|NCT01393158|EXPERIMENTAL|30 mg BID|Patients dosed with 30 mg orally of Apremilast BID for 6 months.
62236612|NCT04515069|ACTIVE_COMPARATOR|Aesthetic preevaluative temporary technique|Aesthetic pre-evaluative temporary (APT) was fabricated according the planned wax-up. Once the APT was approved both aesthetically and functionally, tooth preparation was performed through the APT.
62236613|NCT03193489|EXPERIMENTAL|Exercise therapy|Parkinson's group takes part in a treadmill treatment that takes place 3 times a week for 2 years.
62236614|NCT01300195||lung cancer surgery|Patients undergoing video-assisted thoracic surgery
62427114|NCT06389565|EXPERIMENTAL|PST with Change My Story|In addition to all activities described in the PST alone arm, at enrollment, participants in the arm with Change My Story, will download the game onto their phones, receive instructions about the game and receive recommendations on how to play the game (at least one narrative for one of the three characters) each week within 48 hours of the PST session. Participants will be encouraged to set a weekly reminder alarm for their game play session. Participants will have an opportunity to explore the game at will according to these loose parameters prior to the first PST session.
62812728|NCT03261336|EXPERIMENTAL|Calcitriol, Ketoconazole, Hydrocortisone|Patients receive calcitriol (10mcg QD X3 weekly) in addition to ketoconazole (400mg QD) and hydrocortisone (20mg AM, 10 mg PM).
62236615|NCT06235931|EXPERIMENTAL|Treatment group|Dalcilib +AI (letrozole/anastrozole/exemestane) + pyrrolizinib
62812729|NCT05688059|EXPERIMENTAL|Absorbable Suture|Absorbable suture for sacrospinous ligament suspension
62812730|NCT05688059|EXPERIMENTAL|Permanent Suture|Permanent suture for sacrospinous ligament suspension
62236616|NCT02927418|EXPERIMENTAL|Strength & Conditioning|Supervised S \& C program based on the Long Term Athlete Development Model. Participants will attend 2-3 sessions per week for about one hour each session for 4 months. The comprehensive program will include strength and power training as well as plyometrics, agility and flexibility exercises.
62236617|NCT02927418|ACTIVE_COMPARATOR|Control|Athletes in the control group will continue with their usual sports and activities but will not receive any type of training.
62236618|NCT01601483|EXPERIMENTAL|MC-1101 1% Ophthalmic Solution|
62236619|NCT01601483|PLACEBO_COMPARATOR|Vehicle control|
62236620|NCT02718807||Post-partum Women|Post-partum women following an atraumatic pregnancy.
62812731|NCT05403606|EXPERIMENTAL|Experimental Group (GASPARD®)|Spinal cord injured patient with the connected electronic seat pressure measurement device (GASPARD®), a traditional follow-up and having received therapeutic education at the end of the treatment
62236621|NCT02718807||Co-Parents|Co-parents to post-partum women following an atraumatic pregnancy.
62236622|NCT01416688||Observation and Questionnaires|Patients will be given questionnaires for the assessment of therapy complications, psychosocial assessment and care, and quality-of-life assessment.
62236623|NCT05568602||GFR<30 ml/min|Patients screened for hypercortisolism and GFR\<30ml/min
62236624|NCT05568602||GFR>30 ml/min|Patients screened for hypercortisolism and GFR\>30ml/min
62236625|NCT00309556|ACTIVE_COMPARATOR|A (experimental group)|Epirubicin/Docetaxel/Capecitabine-containing chemotherapy ± trastuzumab in HER-2 positive disease
62236626|NCT00309556|ACTIVE_COMPARATOR|B (control group)|Epirubicin/Docetaxel-containing chemotherapy ± trastuzumab in HER-2 positive disease
62427115|NCT01600014|ACTIVE_COMPARATOR|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days on the face or scalp
62812732|NCT05403606|NO_INTERVENTION|Control group:|Spinal cord injured patient with traditional follow-up with therapeutic education at discharge from initial care
62812733|NCT03318549|OTHER|Glaucoma group|Patients with diagnosed glaucoma will be in the group for up to 5 years.
62236627|NCT01128894|EXPERIMENTAL|albiglutide|weekly albiglutide subcutaneous injection
62236628|NCT01128894|ACTIVE_COMPARATOR|liraglutide|liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
62236629|NCT00288509|EXPERIMENTAL|Dysport|250-1000 units
62236630|NCT01721005|OTHER|pulse palpation education|The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model
62427116|NCT01600014|PLACEBO_COMPARATOR|Vehicle gel|Topical field treatment once daily for 3 consecutive days on the face or scalp
62427117|NCT04373161|EXPERIMENTAL|Suspected COVID-19 patients being discharged to home|Patients will be given a portable, fingertip pulse oximeter to take home. Patients will monitor their resting home oxygen saturation three times per day.
62427118|NCT01626131|EXPERIMENTAL|Exercise treatment|Aerobic and resistance training
62427119|NCT01626131|EXPERIMENTAL|Stretching treatment|
62427120|NCT00593931|EXPERIMENTAL|A|Normal Subjects
62427121|NCT00884663|EXPERIMENTAL|1 Candesartan|
62427122|NCT00884663|ACTIVE_COMPARATOR|2 propranolol|
62427123|NCT00884663|PLACEBO_COMPARATOR|3 Placebo|
62427124|NCT00642031|EXPERIMENTAL|Triciribine|Triciribine 15 mg/m\^2 intravenous (IV) Weekly Over 1 Hour On Days 1, 8, and 15.
62427125|NCT02197221|EXPERIMENTAL|Bortezomib-Melphalan|Bortezomib will be administered on days: -6, -3 +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
62427126|NCT02197221|ACTIVE_COMPARATOR|Melphalan|Melphalan will be administered on day -2. The PBSC will be injected on day 0.
62427127|NCT03797365|ACTIVE_COMPARATOR|Classical rehabilitation|Twenty women will benefit from two-phases perineal rehabilitation: first phase pelvic floor muscles (PFM)'s analytic rehabilitation, then a functional rehabilitation.
62812734|NCT03318549|OTHER|Suspicious of having glaucoma group|Patients with suspicious of having glaucoma will be in the group for up to 5 years.
62236631|NCT02894112|EXPERIMENTAL|Oral glucose tolerance test|100 g of glucose in a fruit punch flavored 8 oz drink
62236632|NCT02894112|EXPERIMENTAL|High fat tolerance test|single high fat load determined by body weight.
62236633|NCT01170546|EXPERIMENTAL|KLCIR|plate-loaded kneeling leg curl with internal rotation
62427128|NCT03797365|EXPERIMENTAL|Classical and cognitive associated rehabilitation|Twenty women will receive, added to the classic perineal rehabilitation, the cognitive rehabilitation and will have to execute twice a day the rehabilitation protocol.
62427129|NCT00908531|ACTIVE_COMPARATOR|Postoperative letrozole|Definitive surgery without preoperative AI treatment
62427130|NCT00908531|EXPERIMENTAL|Preoperative letrozole|Treatment with letrozole for 4 months before definitive surgery.
62427131|NCT03061773|EXPERIMENTAL|Exercise group|Exercise group: physical training lasting 12 weeks, after detraining and in the end the control group receives physical training
62427132|NCT03061773|ACTIVE_COMPARATOR|Group did not exercise|Group did not exercise: conventional hospital treatment
62427133|NCT04463745||Liver Transplant Recipients|adult patients undergoing liver transplantation
62427134|NCT04685941|OTHER|Drug-mediated hyperemia|Patients presenting with slow flow after PPCI undergo to at least 200 mcg of intracoronary nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes
62236634|NCT01170546|EXPERIMENTAL|SP (Squat Press)|plate-loaded squat press
62236635|NCT01170546|EXPERIMENTAL|KLC (Kneeling Leg Curl)|plate-loaded kneeling leg curl
62236636|NCT00147823|EXPERIMENTAL|Vitoss with bone marrow aspirate|Addition of Vitoss to the bone marrow aspirate
62236637|NCT00147823|ACTIVE_COMPARATOR|Vitoss Alone|vitoss alone
62236638|NCT06473376|OTHER|Group I (Control)|Hegab TMJ splint
62236639|NCT06473376|OTHER|Group II|arthrocentesis
62236640|NCT06473376|OTHER|GROUP III|arthroscopy
62427135|NCT04685941|EXPERIMENTAL|Flow-mediated hyperemia|Patients presenting with slow flow after PPCI undergo to controlled saline intracoronary infusion by a dedicated microcatheter (RayFlow) at 20 ml/min during 2 minutes
62427136|NCT02761265|EXPERIMENTAL|Surgical Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
62427137|NCT02761265|OTHER|Control Group|Gait and balance testing to be administered once in healthy subjects
62427138|NCT04979065|EXPERIMENTAL|Experimental Group|Probiotics and Vitamin D
62427139|NCT04979065|PLACEBO_COMPARATOR|Control Group|Placebo and placebo
62427140|NCT04543305|EXPERIMENTAL|PRT1419|PRT1419 will be administered orally
62812735|NCT03318549|OTHER|Non-glaucomatous optic neuropathies group|Patients with optic neuropathies that do not look glaucomatous-like will be in the group for up to 5 years.
62812736|NCT03318549|OTHER|Age-related macular degeneration (AMD) group|Patients with diagnosed age-related macular degeneration will be in the group for up to 5 years.
62812737|NCT03318549|OTHER|Retinal degenerations group|Patients with other retinal degenerations excluding AMD will be in the group for up to 5 years.
62595165|NCT03045276|ACTIVE_COMPARATOR|Arm 2 - Feedback, Maximum Incentive|Subjects will receive daily text message reminders and report real-time treatment adherence with photos, and will have web access to the educational modules through their portal. Every month, participants will receive a text encouraging them to visit their portals. In contrast to Arm 1, they will receive their weekly performance results by text to their phone with tailored feedback. In Arm 2, subjects will receive a larger incentive if they perform their desired treatment behavior. Incentive notification will be texted to participants. Similarly to Arm 1, parents/legal guardians will have access to the same educational materials via their own WTH portals. Additionally, to mitigate the minimal risk of this study, parents/legal guardians will be notified if their child is excessively non-adherent.
62595166|NCT03141229|EXPERIMENTAL|Intervention|One school semester MBSR training for teacher; followed by one school semester mindfulness training for children and one school semester follow-up period.
62595167|NCT03141229|OTHER|Waitlist|One school semester waitlist; followed by one school semester MBSR training for teacher and one school semester MBSR training for children.
62595168|NCT04536857||Parkinson's Disease|Subjects who have a PD diagnosis
62595169|NCT04536857||Multiple System Atrophy|Subjects who have an MSA diagnosis
62812738|NCT03318549|OTHER|Other diseases of visual pathways group|Other diseases of the visual pathway not included in the previous groups will be in the group for up to 5 years.
62812739|NCT03318549|OTHER|Healthy control group|Patients labeled as healthy controls for not having any other eye diseases that would be included on the other groups will be in the group for up to 5 years.
62812740|NCT01071681||Group 1|
62812741|NCT05295212|NO_INTERVENTION|Cohort A|MRD revealed negative
62236641|NCT05227222|EXPERIMENTAL|PEP-device|Positive expiratory pressure device: continuous treatment with PEP-device breathing air for 20 minutes followed by 10 minutes rest and assessment. Inspiration through nose/mouth, expiration through device.
62236642|NCT05227222|NO_INTERVENTION|spontaneous recovery|Control group: Resting and breathing air for 20 + 10 minutes.
62595170|NCT04536857||Progressive Superanuclear Palsy|Subjects who have a PSP diagnosis
62595171|NCT04536857||Age-matched controls|Subjects who do not have a diagnosed neurological disorder
62595172|NCT06649422||Reduced-dose chemotherapy followed by blinatumomab induction treatment group|Patients aged 15-65 with newly diagnosed Ph-negative B-ALL undergoing frontline induction therapy with reduced-dose chemotherapy followed by blinatumomab.
62595173|NCT03694418|OTHER|Cluster 1|Cluster 1 is 1 school on the Fort Peck Reservation that will be randomized into the intervention in 2019. Cluster 1 will receive all four levels of the intervention including: 1) A school-based SRH curriculum called Native Stand, designed to address individual-level factors that lead to sexual risk behaviors; 2) a family-level curriculum called Native Voices, tailored to increase communication between adult family members and youth about SRH topics; 3) a cultural mentoring component at the community level that pairs AI youth with adults and elders to discuss traditional AI beliefs and practices about SRH; and 4) a mobilizing strategy to activate a multi-sectoral network of youth-servicing organizations at the systems level in Fort Peck to coordinate SRH services for AI youth.
62595174|NCT03694418|OTHER|Cluster 2|Cluster 2 includes 2 schools on the Fort Peck Reservation that will be randomized in the intervention in 2019-2020. Cluster 2 will receive all four levels of the intervention including: 1) A school-based SRH curriculum called Native Stand, designed to address individual-level factors that lead to sexual risk behaviors; 2) a family-level curriculum called Native Voices, tailored to increase communication between adult family members and youth about SRH topics; 3) a cultural mentoring component at the community level that pairs AI youth with adults and elders to discuss traditional AI beliefs and practices about SRH; and 4) a mobilizing strategy to activate a multi-sectoral network of youth-servicing organizations at the systems level in Fort Peck to coordinate SRH services for AI youth.
62812742|NCT05295212|EXPERIMENTAL|Cohort B|MRD revealed positive
62812743|NCT05263739|EXPERIMENTAL|ESG206 dose level 1|ESG206 will be administered intravenously at dose level 1 every two weeks in a 28-day cycle.
62812744|NCT05263739|EXPERIMENTAL|ESG206 dose level 2|ESG206 will be administered intravenously at dose level 2 every two weeks in a 28-day cycle.
62812745|NCT05263739|EXPERIMENTAL|ESG206 dose level 3|ESG206 will be administered intravenously at dose level 3 every two weeks in a 28-day cycle.
62812746|NCT05263739|EXPERIMENTAL|ESG206 dose level 4|ESG206 will be administered intravenously at dose level 4 every two weeks in a 28-day cycle.
62236643|NCT03187977|ACTIVE_COMPARATOR|Cognitive Training|Participants will participate in computer-based cognitive training at the end of therapy.
62812747|NCT05263739|EXPERIMENTAL|ESG206 dose level 5|ESG206 will be administered intravenously at dose level 5 every two weeks in a 28-day cycle.
62812748|NCT06593353|EXPERIMENTAL|SAIA MOUD clinics in Jail Health Services|MOUD clinics within Jail Health Services implementing the Systems Analysis and Improvement Approach (SAIA)
62812749|NCT04213300||Low carbohydrate dietary group|"Participants n = 23~Participants:~* Male, female or unspecified gender;~* 18 years of age or over;~* Type 1 diabetes for ≥1 year from diagnosis date and~* Individuals who administer insulin using multiple daily injections."
62812750|NCT03293108|EXPERIMENTAL|AryoGen Pharmed Denosumab|"Arylia (Denosumab Prefilled Syringe produced by AryoGen Pharmed) 60 mg/1 ml in a prefilled syringe.~Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12. Along with, all women will receive daily supplements containing at least 1000 mg of elemental calcium (divided into two doses) and at least 400 IU vitamin D daily during 18 months of the study."
62236644|NCT03187977|NO_INTERVENTION|Standard-of-Care|At the end of therapy, participants will participate in the current standard-of-care which does not include computer-based cognitive training.
62236645|NCT05873946||Operated gliomas|Patients consecutively operated with a pathological diagnosis of glial tumor
62236646|NCT00410397|EXPERIMENTAL|A|Osteopathic Manipulative Medicine
62236647|NCT00410397|PLACEBO_COMPARATOR|B|
62236648|NCT05221463|EXPERIMENTAL|Educational group|Video-assisted breastfeeding training was given to the educational group.
62035599|NCT02820623|EXPERIMENTAL|Self-report|Therapists randomized to this condition will complete a brief self-report measure, the Therapy Process Observational Coding System for Child Psychotherapy Strategies Scale-Self Report version (TPOCS-SR) for each of the recorded clinical encounters with enrolled youth. The TPOCS-SR will be a self-report version of the Therapy Process Observational Coding System for Child Psychotherapy-Strategies Scale (TPOCS-S) and will be created in collaboration with the instrument developer (McLeod). In this condition, the investigators will (a) provide an operational definition for each item on the TPOCS-SR (e.g., cognitive education: teaches client the cognitive model (e.g., thoughts influence behavior)/identifies how the cognitive model applies to a specific aspects of the client's life), and (b) provide therapists with a 30-minute training session that includes sample vignettes of particular behaviors and information about how those vignettes should be rated.
62236649|NCT05221463|OTHER|Control group|Only the hospital's routine general breastfeeding training was given to the control group, and no other intervention was made.
62236650|NCT06258915|EXPERIMENTAL|Adalimumab|
62035600|NCT02820623|EXPERIMENTAL|Chart Stimulated Recall|"Therapists randomized to this condition will be asked to bring the charts of three enrolled youth to the chart-stimulated recall interview. A trained interviewer will ask the therapists how well they recall the encounter (rating of memory quality) followed by an open-ended question (Talk me through your last session with your client. Tell me what you did.). While the therapists are speaking, the interviewer will note any elements that represent a prescribed CBT strategy. The interviewer will go through a list of cognitive-behavioral strategies based upon the TPOCS-S and probe to determine if the therapists completed any of the strategies. Follow-up questions will be used to explore to what degree an element was used and how skillfully and responsively the strategies were used."
62035601|NCT02820623|EXPERIMENTAL|Behavioral Rehearsal|"Therapists randomized to this condition will be asked to engage in role-plays demonstrating the CBT strategies used with the three enrolled youth. The investigators will provide therapists with a list of the TPOCS-S CBT strategies and ask them to identify the CBT strategies used in their recorded encounter. The investigators will randomly select one of the strategies they report for each role-play. The investigators will then tell them, Please role-play how you used this strategy in session with your client, with the trained actor in front of you. Later, an independent rater will rate therapists' adherence and skill based on established scoring criteria."
62035602|NCT00837863|EXPERIMENTAL|1|ALTU-238
62035603|NCT00837863|EXPERIMENTAL|2|ALTU-238
62035604|NCT00837863|EXPERIMENTAL|3|ALTU-238
62035605|NCT00837863|ACTIVE_COMPARATOR|4|Nutropin AQ
62035606|NCT01667601|EXPERIMENTAL|Mindfulness-based program|A structured, researcher-designed mindfulness-based psycho-education program (6 months), comprised of 12 bi-weekly, 2-hour group sessions (10-12 patients per group). The program was based on the psycho-education programs by Chien et al. (2010) and Lehman et al. (2004), as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn (1990).
62035607|NCT01667601|OTHER|Routine Care|Routine psychiatric outpatient care, including medication, psychiatric consultation in outpatient clinic, brief education by psychiatric nurses, financial and social welfare advices by social workers, and individual counseling by clinical psychologist.
62236651|NCT06258915|ACTIVE_COMPARATOR|Mycophenolate mofetil|
62427141|NCT04754321|EXPERIMENTAL|Arm A (pembrolizumab, salvage surgery, IORT)|Patients receive pembrolizumab IV on day 1 of week 1, and undergo salvage surgery during week 4. Beginning week 8, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 9. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
62427142|NCT04754321|EXPERIMENTAL|Arm B (pembrolizumab, EBRT, salvage surgery, IORT)|Patients receive pembrolizumab IV on day 1 of week 1, and undergo low dose EBRT for 2 fractions on 2 consecutive days during week 4. Patients also undergo salvage surgery during week 8. Beginning week 11, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 11. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
62427143|NCT04754321|EXPERIMENTAL|Arm C (pembrolizumab, EBRT, salvage surgery, IORT)|Patients receive pembrolizumab IV on day 1 of week 1, and undergo high dose EBRT for 2 fractions on 2 consecutive days during week 4. Patients also undergo salvage surgery during week 8. Beginning week 11, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 11. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
62595175|NCT03694418|OTHER|Cluster 3|Cluster 3 are the remaining 2 schools on the Fort Peck reservation that will be randomized into the intervention in 2020-2021. Cluster 3 will receive all four levels of the intervention including: 1) A school-based SRH curriculum called Native Stand, designed to address individual-level factors that lead to sexual risk behaviors; 2) a family-level curriculum called Native Voices, tailored to increase communication between adult family members and youth about SRH topics; 3) a cultural mentoring component at the community level that pairs AI youth with adults and elders to discuss traditional AI beliefs and practices about SRH; and 4) a mobilizing strategy to activate a multi-sectoral network of youth-servicing organizations at the systems level in Fort Peck to coordinate SRH services for AI youth.
62236652|NCT00041067|EXPERIMENTAL|Trastuzumab, docetaxel, vinorelbine and filgrastim|Trastuzumab, docetaxel, vinorelbine and filgrastim
62236653|NCT03283280|EXPERIMENTAL|Short fiber RC|Short fiber reinforced resin composite restoration (Ever X Posterior, Gc Europe) that is used in high stress bearing areas as direct onlay restoration.
62236654|NCT03283280|ACTIVE_COMPARATOR|Nanohybrid RC|Nanohybrid resin composite (GrandioSO, VOCO GmbH Germany ) that can be used to make indirect restorations in posterior teeth.
62236655|NCT00301522|EXPERIMENTAL|Arm 1|
62236656|NCT00301522|ACTIVE_COMPARATOR|Arm 2|
62236657|NCT06224608|EXPERIMENTAL|Pulmonary tuberculosis patients|Experimental drug of low-dose (2.5 μg/ml), medium-dose (5 μg/ml), and high-dose (10 μg/ml) will be conducted separately for 30 Pulmonary tuberculosis patients aged 18-65 years old ，each dose for10 cases.
62236658|NCT06224608|EXPERIMENTAL|Healthy subjects|Experimental drug of low-dose (2.5 μg/ml), medium-dose (5 μg/ml), and high-dose (10 μg/ml) will be conducted separately for 30 healthy subjects aged 18-65 years old ，each dose for10 cases.
62236659|NCT06081452||Public|General public to be approached to answer this survey via GPs, charities and exhibitions such as Great Exhibition Road Festival.
62236660|NCT04768387|EXPERIMENTAL|Personalized microbiome diet|Six weeks of AI-based microbiome diet was introduced.
62236661|NCT04768387|ACTIVE_COMPARATOR|Standard IBS diet|Six weeks of standard IBS diet was introduced.
62236662|NCT00671554|EXPERIMENTAL|Melaxin and BCG|Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million Colony Forming Units (CFU) of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration
62236663|NCT05862571||Mild traumatic brain injury group|Consist of patients who have been diagnosed with mTBI by a doctor at an emergency room or in general practice. The patients must still have symptoms related to their trauma ≥ 2 months and ≤ 24 months after trauma origin. They must not have received any vision therapy from an optometrist in relation to resent mTBI.
62236664|NCT05862571||Non-injured group|The control group will primarily consist of relatives of the individuals with mTBI, preferably a partner or a sibling. The subjects in the control group have to meet the same inclusion and exclusion criteria as the mTBI group, except that they must not be diagnosed with mild traumatic brain injury.
62236665|NCT03537287|ACTIVE_COMPARATOR|17 alpha hydroxyprogestrone caproate Group|Patients will receive 250 mg of 17 alpha hydroxyprogestrone caproate intramuscularly once weekly starting from 16 weeks till delivery or 36 weeks.
62236666|NCT03537287|ACTIVE_COMPARATOR|Vaginal progesterone Group|Patients will receive vaginal progesterone 200 mg once per day starting from 16 weeks till delivery or 36 weeks.
62236667|NCT03537287|ACTIVE_COMPARATOR|Oral dydrogesterone Group|Patients will receive 2 tablets of oral dydrogesterone daily starting from 16 weeks till delivery or 36 weeks
62236668|NCT02674594||Patient treated with Dabigatran|
62236669|NCT02674594||Patient treated with Rivaroxaban|
62236670|NCT02674594||Patient treated with Apixaban|
62236671|NCT02674594||Patient treated with Warfarin|
62236672|NCT01320267|EXPERIMENTAL|SILS right hemicolectomy|Single arm with intervention only.
62236673|NCT02776449||Normal Tension Glaucoma|Patients with manifest normal tension glaucoma
62236674|NCT06015451|ACTIVE_COMPARATOR|Follow-up face-to face|"Home-based and in-house exercise, supervised both by telephone and face-to-face.~Every week the first three weeks participants will exercise one session at the hospital, and the BCTT/BCCT will be performed every 3rd week, at the hospital in order to be able to shape the intervention."
62236675|NCT06015451|ACTIVE_COMPARATOR|Follow-up over the phone|Home-based exercise only, supervised by telephone. The participants will exercise solely in the home setting and will be contacted by telephone, every week during the first three weeks, thereafter every third week. Based on the therapist's evaluation during these calls, the intervention is shaped.
62236676|NCT04209699|EXPERIMENTAL|Treatment A: BMS-986165 alone, fasted|
62236677|NCT04209699|EXPERIMENTAL|Treatment B: BMS-986165 alone, fed|
62236678|NCT04209699|EXPERIMENTAL|Treatment C: BMS-986165 with famotidine pretreatment, fasted|
62236679|NCT01080378|OTHER|Higher Birth Weight|3447g to 3879g
62236680|NCT01080378|OTHER|Lower Birth Weight|2624g to 2964g
62236681|NCT01080378|OTHER|Normal Birth Weight|2965g to 3446g
62236682|NCT02407184|NO_INTERVENTION|Scheduled C-section|Babies that are scheduled to be born in a hospital via standard C-section procedure.
62236683|NCT02407184|NO_INTERVENTION|Vaginal Delivery|Babies that are born via vaginal delivery, either at home, at a birthing center or hospital. Drugs may be administered during labor.
62236684|NCT02407184|EXPERIMENTAL|Scheduled C-section with Exposure|Babies that are scheduled to be born in a hospital via standard C-section procedure, as well as are swabbed with gauze containing their mother's vaginal microbiota just after delivery. The intervention: Newborn exposure to mother vaginal microbiota.
62236685|NCT03249025|EXPERIMENTAL|Lidocaine-Ketamine Infusion|Lidocaine-Ketamine Infusions 1 time per month for 6 months. Pretreatment with Midazolam 1-3 mg IV Push or Subcutaneously and Clonidine 0.1 mg PO prior to infusion.
62236686|NCT05251818|ACTIVE_COMPARATOR|Acupressure grubu|"The first thing after the operation is to apply the thumb tool for approximately seven minutes, with 15 seconds of preparation and 1.5 minutes of application at each point of the LI4 and TH6 acupuncture points (the equivalent of working each point).The second application will be repeated three hours after the first application, with the same procedure.~By the researcher, hourly monitoring will be done until the bowel sounds of the puerperant are heard, and the puerperant will be followed up until the gas and defecation output. The gas and defecation time of the puerperants will be questioned every 12 hours, and the information will be obtained by making a phone call with those who are discharged without defecation."
62236687|NCT05251818|ACTIVE_COMPARATOR|Control Group|"No application will be made to the control group.. From the first postoperative hour, the researcher will follow the bowel sounds every hour until the first bowel sounds of the patient are heard.~Postpartum women will be followed until gas and defecation are released. The gas and defecation time of the puerperants will be questioned every 12 hours, and the information will be obtained by making a phone call with those who are discharged without defecation."
62236688|NCT02309060|EXPERIMENTAL|Storytelling Video Intervention (sTVi)|"We will develop a series of 4 videos, each episode approximately 30 minutes long, which will illustrate the key principles of Acceptance and Commitment Therapy.~We will add a short, non-narrative, epilogue at the end of each of the 4 episodes that summarizes key messages and provides information on identifying signs of depression and suggestions for efficacious treatments.~In addition, we will develop an accompanying personal journal for participants that includes a brief self-help guide which encourages participants to write about what they learned in the videos and how they will take similar steps in their own lives to cope with depression."
62243431|NCT04866368|ACTIVE_COMPARATOR|The erector spinae plane block|The ultrasound-guided Erector spinae plane block (ESPB) with 1 ml/kg 0,25 % bupivacaine at the lumbar vertebral level will perform before surgery to all patients in the ESPB group.
62243432|NCT04866368|ACTIVE_COMPARATOR|The penile block|The penile block with 0,5ml/kg 0,25 % bupivacaine will be performed after the patients give standard general anesthesia and a laryngeal mask is applied.
62035608|NCT01667601|ACTIVE_COMPARATOR|Psychoeducation group|"A psychoeducation group program (12 sessions, bi-weekly) based on Dr. Macpherson's Family Psychoeducation Program in 1996 and Chien and Bressington's one in 2014/15 will be used.~References:~Chien WT, Bressington D. A randomized controlled trial of a nurse-led structured psychosocial intervention program for people with first-onset mental illness in psychiatric outpatient clinics. Psychiatry Res 2015;229:277-86.~Macpherson R, Jerrom B, Hughes AA. controlled study of education about drug treatment in schizophrenia. Br J Psychiatry 1996;168:709-17."
62035609|NCT04459026|EXPERIMENTAL|group A - combination|Group A patients will receive intra-abdominal instillation 0.75% Ropivacaine 2 mg / kg in 200 ml of NaCl through the trocars and 2) Infiltration of the surgical wounds at the trocar sites with 0.75% Ropivacaine 1 mg / kg in 20 ml of NaCl
62035610|NCT04459026|EXPERIMENTAL|Group B - infiltration|Group B patients will receive infiltration of the surgical wounds at the trocar sites with 0.75% Ropivacaine 3 mg / kg in 20 ml of NaCl.
62035611|NCT04459026|ACTIVE_COMPARATOR|Group C - instillation|Group C patients will receive intra-abdominal instillation 0.75% Ropivacaine 3 mg / kg in 200 ml of NaCl through the trocars.
62243433|NCT06322056|ACTIVE_COMPARATOR|Intensive SBP control and Intensive LDL-C control|Targeting SBP \<120 mmHg and targeting LDL-C \<70 mg/dL
62812751|NCT03293108|ACTIVE_COMPARATOR|Amgen Denosumab|"Prolia® (Denosumab Prefilled Syringe produced by Amgen) 60 mg/1 ml in a prefilled syringe.~Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12. Along with, all women will receive daily supplements containing at least 1000 mg of elemental calcium (divided into two doses) and at least 400 IU vitamin D daily during 18 months of the study."
62812752|NCT01095640|EXPERIMENTAL|adapalene 0.3% topical gel (Actavis Mid-Atlaqntic LLC)|
62812753|NCT01095640|ACTIVE_COMPARATOR|Differin® (adapalene 0.3% topical gel)|
62812754|NCT01095640|PLACEBO_COMPARATOR|Vehicle Control|
62812755|NCT04860323|EXPERIMENTAL|Analytical Treatment Interruption|Participants who received VRC01 or placebo and got HIV while enrolled in HVTN 703/HPTN 081 (NCT02568215).
62812756|NCT03872375|EXPERIMENTAL|Intermittent Calorie Restriction + Dietary Counseling|"Participants will be asked to consume a single 530 kilocalorie shake (i.e., High Calorie Boost shake) on a given day for two consecutive days each week. Participants will eat ad libitum during the remaining 5 days. Participants will also receive Registered Dietitian of Nutrition (RDN) consultations about dietary modifications to induce moderate weight loss. Participants will utilize these recommendations in addition to shake consumption.~Subjects are also asked to follow RDN dietary recommendations."
62812757|NCT03872375|ACTIVE_COMPARATOR|Dietary Counseling|A Registered Dietitian of Nutrition (RDN) will consult with subjects about dietary modifications to induce moderate weight loss. Participants will utilize these recommendations.
62812758|NCT05222958|EXPERIMENTAL|Experimental:|The intervention consists of using a smoking cessation app. Patients assigned to the intervention group will be given the access code to the Gestobb App and advice on how to use it.
62812759|NCT05222958|NO_INTERVENTION|No intervention|Patients in the control group will continue their follow-up visits at ASSIR and will be offered smoking cessation treatment following standard practice protocols.
62812760|NCT06525415||PAD group|patients of peripheral artery disease who underwent endovascular treatment
62812761|NCT00379847|EXPERIMENTAL|1|Lower dose
62812762|NCT00379847|EXPERIMENTAL|2|Higher dose
62812763|NCT03863886|EXPERIMENTAL|Crohn's Disease|20 patients with Crohn's disease with at least colonic involvement will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
62812764|NCT03863886|EXPERIMENTAL|Ulcerative Colitis|20 patients with ulcerative colitis will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
62812765|NCT03863886|EXPERIMENTAL|Non-IBD Controls|20 patients without inflammatory bowel disease (controls) will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
62812766|NCT03269526|EXPERIMENTAL|EGFR BATs after standard of care chemo|Subjects will undergo apheresis to collect peripheral blood mononuclear cells. Cells will be cultured for up to 2 weeks before activated T-cells will be harvested, armed with EGFR Biarmed activated T-cells, washed to remove unbound EGFRBi, and cryopreserved. Subjects will then receive one dose of standard of care chemotherapy prior to receiving EGFR BATs.
62243434|NCT06322056|ACTIVE_COMPARATOR|Intensive SBP control and Standard LDL-C control|Targeting SBP \<120 mmHg and targeting LDL-C \<100 mg/dL
62812767|NCT06223334||GTCS (generalized Tonic Clonic Seizures)|
62812768|NCT06223334||Tonic Seizures|
62812769|NCT06223334||Clonic Seizures|
62812770|NCT06223334||Myoclonic Seizures|
62812771|NCT06223334||Absence Seizures|
62812772|NCT06223334||Focal Seizures|
62812773|NCT06706388|EXPERIMENTAL|Open Label|
62812774|NCT00828243||Genetic association|Infants with and without neonatal respiratory distress syndrome undergo surfactant gene sequencing to identify genomic variants associated with neonatal respiratory distress syndrome
62812775|NCT00828243||Nutrient|To newborn infants with respiratory distress syndrome, we administer stable isotopically labeled nutrients (precursors of surfactant phospholipids or proteins) to permit mass spectrometry-based comparison of surfactant phospholipid and protein turnover.
62812776|NCT04296760||Women with suspicious of deep posterior pelvic endometriosis|
62812777|NCT02923141|ACTIVE_COMPARATOR|Neutral Writing + Contingency Management|Participants will attend four attention-matched control sessions, consisting of face-to-face administration of psychological measures and neutral writing exercises. Participants will also take part in 36 contingency management sessions in which they provide self-collected urine for toxicology screening and receive financial incentives for each negative drug result.
62812778|NCT02923141|ACTIVE_COMPARATOR|Expressive Writing + Contingency Management|Participants will attend four expressive writing sessions focusing on traumatic or stressful events. Participants will also take part in 36 contingency management sessions in which they provide self-collected urine for toxicology screening and receive financial incentives for each negative drug result.
62812779|NCT03289208|EXPERIMENTAL|mild renal impairment|
62812780|NCT03289208|EXPERIMENTAL|moderated renal impairment|
62812781|NCT03289208|EXPERIMENTAL|normal renal function|
62812782|NCT03863184|EXPERIMENTAL|ALR in Combination|Acalabrutinib, lenalidomide, and rituximab in combination
62812783|NCT04602403|PLACEBO_COMPARATOR|placebo group|people who given placebo to become agroup of comparison with the other group
62812784|NCT04602403|ACTIVE_COMPARATOR|tamsulosin group|people who given tamsulosin to know the effect on ureteroscopy and compare with the control group
62812785|NCT04923477|EXPERIMENTAL|Exercise Group|Therapeutic exercise of resistance and mobility training delivered by a trained health professional x 8 weeks.
62812786|NCT06579430|EXPERIMENTAL|Multicenter cohort|Patients undergoing total thyroidectomy are included in this arm. Patients are included in the University Medical Center Groningen and the Erasmus Medical Center Rotterdam. After total thyroidectomy, the perfusion in the parathyroid glands is imaged utilizing ICG-NIRF. Postoperatively; perfusion curves are drawn for each parathyroid gland. Perfusion parameters are compared between patients and correlated to postoperative parathyroid function (PTH).
62812787|NCT06579430|EXPERIMENTAL|Root cause analysis|Patients undergoing total or hemi-thyroidectomy are included in this arm. Patients are included in the University Medical Center Groningen. After (total/hemi)thyroidectomy, the perfusion in the parathyroid glands is imaged utilizing ICG-NIRF. A second measurement is performed in order to compare the influence of injection speed, camera and ICG dose on the curves. Postoperatively; perfusion curves are drawn for each parathyroid gland. Perfusion parameters are compared between the two measurements in the same patient.
62812788|NCT00686777|EXPERIMENTAL|PEG-IFN + Ribavirin|Pegylated Interferon alfa-2b was administered to participants at 1.5 μg/kg subcutaneously once weekly for 48 weeks. Ribavirin was administered orally every day after morning and evening meals for 48 weeks at 400 mg/day.
62035612|NCT02549898|EXPERIMENTAL|Vascular inflammation|Subjects with habitual unilateral migraine without aura, undergo a baseline MRI scan, undergo pharmacological induction of a migraine attack, and subsequently are MRI scanned prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI ).
62035613|NCT02549898|EXPERIMENTAL|Effect of sumatriptan|Subjects with habitual unilateral migraine without aura, undergo a baseline MRI scan and then undergo pharmacological induction of a migraine attack. Sumatriptan is given and subjects subsequently undergo MRI scans prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI).
62035614|NCT02549898|EXPERIMENTAL|Pilot w/o cilostazol|Subjects without habitual unilateral migraine without aura undergo a baseline MRI scan. Subjects are then MRI scanned prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI).
62035615|NCT02549898|EXPERIMENTAL|Pilot w/ cilostazol|Subjects without habitual unilateral migraine without aura undergo a baseline MRI scan and then receive cilostazol. Subjects are then MRI scanned prior (BBI-MRI) to and after Feraheme infusion (USPIO-MRI).
62035616|NCT04146714|EXPERIMENTAL|Substance use screening|Participants complete a substance use questionnaire (=intervention).
62035617|NCT04146714|ACTIVE_COMPARATOR|Physical activity screening|Participants complete a physical activity questionnaire (=control).
62035618|NCT06230848|NO_INTERVENTION|Attention Control|Infants in the attention control group will receive standard of care.
62035619|NCT06230848|EXPERIMENTAL|M-MILK|Infants in the M-MILK group will receive the M-MILK intervention in addition to standard of care.
62035620|NCT02004782|ACTIVE_COMPARATOR|Prenisolone|Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
62035621|NCT02004782|PLACEBO_COMPARATOR|Placebo|Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
62035622|NCT00054353|EXPERIMENTAL|Related Donor|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors)."
62035623|NCT00054353|EXPERIMENTAL|Unrelated Donor|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors)."
62035624|NCT05136820|ACTIVE_COMPARATOR|Randomization to 6mm AFR device|AFR Device 6mm vs Sham procedure
62035625|NCT05136820|ACTIVE_COMPARATOR|Randomization to 8mm AFR device|AFR device 8mm vs Sham procedure
62035626|NCT05136820|SHAM_COMPARATOR|Randomization to sham procedure|Sham procedure to AFR device (6mm or 8mm)
62035627|NCT05136820|OTHER|Roll-in Arm|Patients in the Roll-in Arm will receive the AFR device
62035628|NCT02836808|NO_INTERVENTION|Control|Patients attended with the standard model of care for diabetes, as out-patients in the Internal Medicine area
62035629|NCT02836808|EXPERIMENTAL|CAIPaDi|Patients attended in the Center of Comprehensive Care for the Patient with Diabetes, where they receive attention from 9 specialists in 1 day
62812789|NCT04392323|EXPERIMENTAL|Study Group|Patients will be recruited as an outpatient prior to their surgical procedure or during their hospital admission. If they consent, they will provide signed informed consent and will receive testing with serology and PCR for COVID-19 infection at pre-surgical testing 24-48 hours prior to their scheduled procedure. If they consent while inpatient postoperatively, signed informed consent will be procured after they have completed their pre-operative COVID-19 testing. PCR for COVID entails obtaining a nasopharyngeal swab to determine whether there is active viral replication and viral shedding. They will then have a second test with serology and PCR for COVID-19 infection 12-16 days after discharge from the hospital.
62812790|NCT01308541|ACTIVE_COMPARATOR|LUSEDRA (arm 1)|
62236689|NCT05711966|EXPERIMENTAL|IN-REC-SUR-E|INRECSURE infants will receive preintubation medications and HFOV starting at MAP 8 cmH2O; frequency 15 Hz, with volume-guarantee (1.5-1.7 mL/kg). The I:E will be 1:1. An oxygenation guid-ed lung recruitment procedure will be performed using stepwise increments then decrements in MAP. The starting MAP will be increased stepwise as long as SpO2 improves reducing the FiO2 keeping SpO2 within the target range (90-94 %) until the oxygenation no longer improves or the FiO2 is equal to or less than 0.25 (opening MAP). Next, the MAP will be reduced stepwise until the SpO2 deterio-rates (closing MAP). After a second recruitment maneuver at the opening pressure, the optimal MAP will be set 2 cmH2O above the closing MAP. Then 200 mg/kg of poractant alfa (Chiesi Farmaceutici S.p.A., Parma, Italy) via a closed administration system will administrate. Infants with sufficient res-piratory drive will be extubated within 30 minutes after surfactant administration starting nCPAP (7-9 cm H2O) or NIPPV.
62236690|NCT05711966|ACTIVE_COMPARATOR|Less Invasive Surfactant Administration|By contrast, infants allocated to the LISA group will receive 200 mg/kg of poractant alfa (Chiesi Farmaceutici S.p.A., Parma, Italy) according to the following protocol: during nasal CPAP with a pressure of 7-8 cm H2O, surfactant will be administered over 0.5-3 min using the SurfCath™ tracheal instillation catheter (VYGON S.A. - Ecouen, France), or a 4- 6 F end-hole catheter, according to local protocols. After the same pre-procedural medications, the catheters will be positioned during laryngoscopy with or without Magill forceps. The catheter will be connected to a syringe pre-filled with the surfactant, and the surfactant is instilled slowly. The infant's mouth will be closed. In cases of apnoea or bradycardia, positive pressure ventilation will be performed until recovery. After surfactant administration, CPAP (7-9 cm H2O) therapy (16) or NIPPV will be continued.
62236691|NCT02138721|NO_INTERVENTION|No local treatment|Routine care in metastatic prostate cancer.
62236692|NCT02138721|EXPERIMENTAL|Local treatment|Radical Prostatectomy (RP) + routine care in metastatic prostate cancer.
62236693|NCT00725634|EXPERIMENTAL|AV-299 Dose Escalation Arm|AV-299 Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma
62236694|NCT00725634|EXPERIMENTAL|AV-299 in combination with erlotinib|AV-299 Administered by IV Infusion in Combination with Erlotinib (150 mg daily) in Advanced Solid Tumors
62595176|NCT04323306|ACTIVE_COMPARATOR|Cohort 1 SAD|5 mg MMV533 with single ascending dose
62236695|NCT05232123|PLACEBO_COMPARATOR|Placebo|Participants will ingest 3ml of non-CBD containing MCT (medium-chain triglycerides) oil.
62236696|NCT05232123|EXPERIMENTAL|Cannabidiol 25 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 25 mg of CBD.
62236697|NCT05232123|EXPERIMENTAL|Cannabidiol 50 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 50 mg of CBD.
62236698|NCT05232123|EXPERIMENTAL|Cannabidiol 200 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 200 mg of CBD.
62236699|NCT05805098|EXPERIMENTAL|Venetoclax Combined With Homoharringtonine and Cytarabine|All recipients in this arm received Venetoclax, Homoharringtonine and Cytarabine. Venetoclax was uesd as 100 mg on day 1, 200 mg on day 2, 400mg from day-3 to day-28. Homoharringtonine was uesd as 1 mg/m2 qd from day-1 to day-5. Cytarabine was uesd as 100 mg/m2 qd from day-1 to day-5.
62595177|NCT04323306|ACTIVE_COMPARATOR|Cohort 2 SAD|Single ascending dose to be determined after SRC review of previous cohort.
62595178|NCT04323306|ACTIVE_COMPARATOR|Cohort 3 SAD|Single ascending dose to be determined after SRC review of previous cohort.
62595179|NCT04323306|ACTIVE_COMPARATOR|Cohort 4 SAD|Single ascending dose to be determined after SRC review of previous cohort.
62595180|NCT04323306|ACTIVE_COMPARATOR|Cohort 5 SAD|Single ascending dose to be determined after SRC review of previous cohort.
62595181|NCT04323306|ACTIVE_COMPARATOR|Cohort 6 SAD|Single ascending dose to be determined after SRC review of previous cohort.
62236700|NCT04334434|EXPERIMENTAL|Study Group|The group to which the exercise protocol consisting of aerobic and strengthening exercises will be applied.
62236701|NCT04334434|NO_INTERVENTION|Control Group|Control group where evaluations will be made.
62595182|NCT04323306|ACTIVE_COMPARATOR|Cohort 7 SAD|Single ascending dose to be determined determine after SRT review of previous cohort. Dose will not exceed 400 mg.
62595183|NCT04323306|ACTIVE_COMPARATOR|Part 2: Food Effect|Open label, 2-period cross-over, randomized, pilot food effect study to provide preliminary information on the effect of a high-fat meal on the pharmacokinetics of a single-dose oral administration of MMV533 determined to be safe in Part 1.
62595184|NCT01609439|PLACEBO_COMPARATOR|Placebo|
62595185|NCT01609439|EXPERIMENTAL|Treatment|Pre-operative Vitamin D 800 units x 4 weeks
62595186|NCT03755869|EXPERIMENTAL|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
62595187|NCT02892604|EXPERIMENTAL|insulin delivery driven by inControl|"Closed-loop insulin delivery using inControl AP system is assessed for two weeks, 24/7.~Connection of continuous glucose monitoring (CGM) system and insulin pump to inControl AP platform, all wireless and wearable, in free-life conditions Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data."
62595188|NCT05279729|NO_INTERVENTION|Control|
62595189|NCT05279729|EXPERIMENTAL|Weight Watchers (WW)|
62595190|NCT05279729|EXPERIMENTAL|Healthi app|
62595191|NCT06002529|OTHER|HFR treatment|patient received HFR treatment
62595192|NCT03747068||anti-TNF|UC patients treated with maintenance anti-TNF therapy who underwent IPAA surgery
62595193|NCT03747068||CONTROL GROUP|UC patients who were not exposed to anti-TNF therapy
62595194|NCT06624163|EXPERIMENTAL|Study Participants|
62595195|NCT03917472|EXPERIMENTAL|Brolucizumab 6mg q4w|Brolucizumab 6 mg/0.05 mL every 4 weeks.
62595196|NCT03917472|ACTIVE_COMPARATOR|Aflibercept 2mg q4w|Aflibercept 2mg/0.05 mL every 4 weeks
62595197|NCT02872610|EXPERIMENTAL|Self-help Online|6 weeks of internet-based self-help intervention
62595198|NCT02872610|NO_INTERVENTION|Wait-list|Waiting list control condition
62595199|NCT06252701|EXPERIMENTAL|Intervention diet then regular diet|4 weeks eating a diet low in ultra-processed foods in diet followed by 4 weeks of eating the participant's regular diet.
62595200|NCT06252701|EXPERIMENTAL|Regular diet then intervention diet|4 weeks of eating the participant's regular diet followed by 4 weeks of eating a diet low in ultra-processed foods.
62595201|NCT06621303|EXPERIMENTAL|Single-Arm, Open-Label Clinical Study Protocol for the Treatment of Diabetic Foot with Autoregulator|
62595202|NCT02870816|ACTIVE_COMPARATOR|Tissue engineered skin substitute|Application of tissue engineered skin substitute with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional application of skin substitute will be applied weekly at weeks 2-11.
62035630|NCT01205594|EXPERIMENTAL|ITPR device|the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
62035631|NCT00115700|EXPERIMENTAL|Radiotherapy+ Chemotherapy|Involved field Radiotherapy (RT) 30-36 GY plus Cyclophosphamide, Vincristine and Prednisolone (CVP) + rituximab × 6 cycles
62035632|NCT00115700|ACTIVE_COMPARATOR|Radiotherapy alone|Involved field Radiotherapy (30-36 GY) alone
62595203|NCT02870816|EXPERIMENTAL|Amnionic membrane graft|Application of amnionic membrane graft with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional piece of amnionic membrane graft will be applied weekly at weeks 2-11
62595204|NCT02792114|EXPERIMENTAL|T-cell infusion|A single blood volume leukapheresis for harvesting of PBMCs will be performed, As the transduced T cells will be frozen, the timing of leukapheresis is not defined \& can vary from patient to patient. Subsequently, a single dose of mesothelin-targeted T cells will be infused via intravenous catheter or central line (i.e., mediport). Patients will be monitored in the hospital and discharged home after a minimum of 48 hours. Patients will be monitored closely as outpatients for the next 2 months. Patients will be followed weekly as outpatients for the first 8 weeks after treatment. All patients will be hydrated intravenously, premedicated with acetaminophen \& diphenhydramine, \& administered cyclophosphamide at 1.5 g/m2 2 to 7 days (Day -7 to Day -2) before administration of mesothelin-targeted T cells.
62595205|NCT05780970||Non-targeted individuals|Non-targeted children and caregivers living in the same household as the target parent/adolescent dyad. Non-targeted meaning they did not receive the TEENS+ intervention.
62595206|NCT02196376||orthostatic tachycardia syndrome|participants with postural orthostatic tachycardia syndrome
62595207|NCT02196376||control subjects|participants not diagnosed with postural orthostatic tachycardia syndrome
62595208|NCT01486472||GC patients receiving adjuvant S-1 chemotherapy|
62595209|NCT04050124|EXPERIMENTAL|Promogran Prisma|Following standard of care split thickness skin grafting, patients randomized to the intervention group will receive Promogan Prisma as the primary contact dressing at the donor grafting site.
62595210|NCT04050124|ACTIVE_COMPARATOR|Standard of care (SOC) dressings|
62595211|NCT05820711|EXPERIMENTAL|Mesenchymal Stem Cell (MSC) injection|
62595212|NCT04998721|EXPERIMENTAL|Maternal Infant Dyadic Care|Perinatal collaborative care and Promoting First Relationships-Brief
62595213|NCT04998721|ACTIVE_COMPARATOR|Control|Perinatal collaborative care only
62595214|NCT00996411|EXPERIMENTAL|Salvinorin A|
62595215|NCT05684510|EXPERIMENTAL|Experimental : clear aligners with class II elastics technique|clear aligners technique A group of patients in which participants will be undergo to clear aligners treatment with class II elastics ( clear aligners will be applied to the upper and lower arch, then a class II elastics 1\\4 and 6,5 oz will be use from the precision-cut Hook on the maxillary aligner to the button of mandibular first molar
62595216|NCT05684510|EXPERIMENTAL|: traditional treatment Fixed appliances with class II elastics.|A group of patients in which participants will be undergo to the fixed multibracket treatment (with slot size 0.022 × 0.028 and MBT prescription , after completing leveling and alignment , Elastics will be applied from the hooks of canines brackets to the hooks of lower first molar when the 0.019× 0.025-inch stainless steel archwires placed.
62812791|NCT01308541|ACTIVE_COMPARATOR|LUSEDRA (arm 2)|
62812792|NCT01308541|ACTIVE_COMPARATOR|Propofol (arm 3)|
62035633|NCT04637412|EXPERIMENTAL|Control label|"Participant will see a QR code and footnote saying, Scan the QR code for more menu information. The label will be applied to all menu items displayed."
62035634|NCT04637412|EXPERIMENTAL|Icon plus text added sugars label|Participant will see a label containing an icon plus text label with an explanatory footnote. The label will be applied to items high in added sugars (exceeding half the daily value). Participants will randomly view one of 18 variations of icons and text in this arm.
62035635|NCT04637412|EXPERIMENTAL|Icon only added sugars label|Participant will see a label containing an icon only with an explanatory footnote. The label will be applied to items high in added sugars (exceeding half the daily value). Participants will randomly view one of 6 variations of icons in this arm.
62035636|NCT00944138|EXPERIMENTAL|Mindful meditation|Participants assigned to the mindful meditation plus standard care arm will receive individualized instruction on mindful meditation at the time they are randomized to this arm. The participants will be led through a 20 minute relaxation exercise. They will then be led through a brief eating exercise where they will be instructed to eat the food very slowly and pay attention to how the food tastes and the sensations of swallowing the food. This is done to enhance the person's awareness of what and how they are eating and enhance their intuitive sense of satiety. Finally, they will receive an MP3-player with several relaxation instructional audios loaded on the MP3 player.
62236702|NCT03196232|EXPERIMENTAL|Treatment (epacadostat, pembrolizumab)|Participants receive oral epacadostat BID on Days 1 to 21 and pembrolizumab IV over 30 minutes on Day 1, with cycles repeating every 21 days for up to 24 months, in the absence of disease progression or unacceptable toxicity.
62236703|NCT06512272|NO_INTERVENTION|Control group|Usual hospital discharge include medical discharge letter and verbal advice from healthcare team.
62595217|NCT05397067|EXPERIMENTAL|Peer specialist and Vouchers|Intervention arm
62595218|NCT05397067|NO_INTERVENTION|Standard of care|
62595219|NCT02370628|EXPERIMENTAL|Percutaneous vertebroplasty (PV)|The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae.
62595220|NCT02370628|ACTIVE_COMPARATOR|Facet block|injection of anti-inflammatory and analgesic drugs
62595221|NCT00791661|EXPERIMENTAL|Panel A: MK-1006 15/30/45|Participants received a single rising dose of MK-1006 (dosed at 15 mg, 30 mg, and 45 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
62812793|NCT00739401|EXPERIMENTAL|1|Test subjects requiring endovascular treatment of abdominal aortic or aorto-iliac aneurysms including a proximal cuff extension.
62812794|NCT00983346|EXPERIMENTAL|All patients|All participants enrolled.
62035637|NCT00944138|ACTIVE_COMPARATOR|Music for relaxation|Participants assigned to the control arm will receive the dietary counseling and will be told that relaxation can help reduce appetite. However, techniques to relax will not be taught. Instead, participants will be encouraged to sit quietly listening to music (of their choice) every day for 20 minutes. Participants assigned to the standard care arm will receive an MP3-player and will be given a choice of selection of music that they can load on their MP3 player (classical music, country music, jazz, etc.).
62035638|NCT04298138|EXPERIMENTAL|Low dose DENV-3-LVHC|Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single low dose (0.5 mL of 1.4 x 10\^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
62035639|NCT04298138|EXPERIMENTAL|Medium dose DENV-3-LVHC|Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single medium dose (0.5 mL of 1.4 x 10\^4 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
62035640|NCT04298138|EXPERIMENTAL|High dose DENV-3-LVHC|Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single high dose (0.5 mL of 1.4 x 10\^5 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
62035641|NCT01383733|EXPERIMENTAL|Single Arm|
62035642|NCT04075123||CPAP GROUP|Suggested PEEP range 5-10 cmH2O; Minimum required PEEP WILL BE 8 cm water (7 cm water if using bubble CPAP); Maximum allowable† PEEP: 12 cmH2O
62035643|NCT04075123||NIPPV GROUP|Suggested Ranges: PIP 12 to 24 cm water; PEEP 5 to 10 cm water; Rates 20-40 bpm; iTime 0.4-1.0 seconds; Minimum required settings on NIPPV: PEEP 8 cm water; Difference of pressure 6 cm water; Rate 20 bpm; Maximum allowable settings: PEEP 10 cm water; PIP 24 cm water; Rate 60 bpm
62035644|NCT03066336|EXPERIMENTAL|Erchonia LunulaLaser|The Erchonia LunulaLaser emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
62236704|NCT06512272|OTHER|Intervention group|Usual hospital discharge + video recorded medical advice from the healthcare team uploaded in a mobile app
62236705|NCT05829928||Cryopreservation|Participants will have gonadal tissue removed and cryopreserved for future fertility applications.
62236706|NCT02652143|EXPERIMENTAL|sibling oocytes in vivo|randomized oocytes assigned to in vivo culture
62427144|NCT02387307|EXPERIMENTAL|Cohort: Dose-Escalation and Expansion|"Dose-Escalation: Dose escalation in solid tumors utilizing a 3+3 design with intra-subject dose escalation. 4 dose levels of rSIFN-co are planned for determining the RD. Dose of rSIFN-co: 15, 21, 24, 27 and 30 ug.~Dose-Expansion: The Expansion Cohort will be initiated at the RD. Depending on the RD, the lead in period will occur accordingly. After the lead in period, a period from Cycle 1 to the final administration will be performed as the Treatment Phase during which subjects will undergo a standardized evaluation for the safety and efficacy of rSIFN-co at the RD. Follow-up evaluations will be performed 28 days (±5 days) after the last rSIFN-co administration."
62595222|NCT00791661|EXPERIMENTAL|Panel B: MK-1006 60/80/60 fed|Participants received a single rising dose of MK-1006 (dosed at 60 mg, 80 mg, and 60 mg fed state) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
62812795|NCT01316523|EXPERIMENTAL|Lenalidomide + Rituximab|Patients will receive lenalidomide 20 mg daily (oral), on days 1-21 of a 28 day cycle. Rituximab 375 mg/m2 (into the vein) will be administered weekly for 4 doses starting day 15 of cycle 1, to be repeated if patient does not achieve a complete response after cycle 4, on days 1, 8, 15 and 22 of cycle 5.
62035645|NCT05110092|EXPERIMENTAL|The exercise group|The exercise group received usual care and breathing-based leg resistance exercise program for 12 weeks.
62035646|NCT05110092|NO_INTERVENTION|The control groups|The control group received usual care
62035647|NCT01090453|EXPERIMENTAL|GSK2202083A Group|Subjects aged between and including 8 and 12 weeks of age at the time of first vaccination received 3 doses of GSK2202083A vaccine, co-administered with Prevenar 13® at 2, 4 and 12 months of age. The GSK2202083A and Prevenar 13® vaccines were administered intramuscularly into the right and left sides of the thigh, respectively. An optional 2-dose vaccination with Rotarix™ was offered to the study participants at 2 and 4 months of age.
62236707|NCT02652143|ACTIVE_COMPARATOR|sibling oocyte in vitro|randomized oocytes assigned to in vitro culture
62236708|NCT03093779||Deaf|Individuals who are deaf and use sign language to communicate.
62236709|NCT03093779||Hearing|Individuals with no hearing loss and who communicate in spoken English.
62812796|NCT05890248||Erector spinea block|-ESPB Group (n=12): Received erector spinae plane block.
62812797|NCT05890248||Thoracic Paravertebral block|TPVB Group (n=12) : Received thoracic paravertebral block.
62812798|NCT05890248||Control group|Control Group (n=12): Received morphine (0.1 mg/kg iv) before skin incision .
62812799|NCT05890248||QLB group|Quadratus lamborum block n=12
62812800|NCT05757141|EXPERIMENTAL|Fosigotifator - Cohort 1|Cohort 1: VWM adults ≥18 years
62236710|NCT05650320|EXPERIMENTAL|0.3% OPA-15406 Ointment|The 0.3% formulation of OPA-15406 ointment will be administered twice-daily (approximately 12 hours apart between morning and night administration) for 4 weeks. The amount of IMP (g) per dose is 10 g/m2 BSA and calculated.
62236711|NCT05650320|EXPERIMENTAL|1% OPA-15406 Ointment|The 1% formulation of OPA-15406 ointment will be administered twice-daily (approximately 12 hours apart between morning and night administration) for 4 weeks. The amount of IMP (g) per dose is 10 g/m2 BSA and calculated.
62236712|NCT05650320|PLACEBO_COMPARATOR|0% OPA-15406 Vehicle|The 0% formulation of OPA-15406 venicle will be administered twice-daily (approximately 12 hours apart between morning and night administration) for 4 weeks. The amount of IMP (g) per dose is 10 g/m2 BSA and calculated.
62236713|NCT04183972|EXPERIMENTAL|Image collecting Group|An computer algorithm will be developed and evaluated by these image data.
62236714|NCT02592512||NIV-NAVA|4 hour NIV-NAVA, followed by 4 hour NIV-PS/PC
62236715|NCT02592512||NIV-PS/PC|4 hour NIV-PS/PC, followed by 4 hour NIV-NAVA
62236716|NCT04868539|EXPERIMENTAL|Sleep Restriction with Extended Duration Artificial Light at Night (ALAN)|In the Sleep Restriction Group with Extended Duration Artificial Light At Night (ALAN) first, the sleep episodes will be shortened to 5 hours, centered at the same time as the baseline sleep (with bedtime 2.5 hours later and wake time 2.5 hours earlier).
62595223|NCT00791661|EXPERIMENTAL|Panel C: MK-1006 100/140/170|Participants received a single rising dose of MK-1006 (dosed at 100 mg, 140 mg, and 170 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
62595224|NCT04157114|ACTIVE_COMPARATOR|MAP4343|Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling
62035648|NCT01090453|ACTIVE_COMPARATOR|Infanrix hexa Group|Subjects aged between and including 8 and 12 weeks of age at the time of first vaccination received 3 doses of Infanrix hexa™ vaccine, co-administered with Prevenar 13® and Menjugate® at 2, 4 and 12 months of age. The Infanrix hexa™ and Prevenar 13® vaccines were administered intramuscularly into the right and upper left sides of the thigh, respectively and the Menjugate® vaccine was administered intramuscularly in the lower left thigh. An optional 2-dose vaccination with Rotarix™ was offered to the study participants at 2 and 4 months of age.
62035649|NCT02199262|EXPERIMENTAL|control groupe|agitation diagnosis and management according to implemented guidelines= reminder implementation
62243435|NCT06322056|ACTIVE_COMPARATOR|Standard SBP control and Intensive LDL-C control|Targeting SBP \<140 mmHg and targeting LDL-C \<70 mg/dL
62243436|NCT06322056|ACTIVE_COMPARATOR|Standard SBP control and Standard LDL-C control|Targeting SBP \<140 mmHg and targeting LDL-C \<100 mg/dL
62812801|NCT05757141|EXPERIMENTAL|Fosigotifator - Cohort 1b|Cohort 1: VWM adults ≥18 years
62812802|NCT05757141|EXPERIMENTAL|Fosigotifator - Cohort 2|Cohort 2: VWM children ≥12 y and \<18 years
62812803|NCT05757141|EXPERIMENTAL|Fosigotifator - Cohort 3|Cohort 3: VWM children ≥6 y and \<12 years
62812804|NCT04587518|EXPERIMENTAL|Immediate Treatment|Participants in this group will receive the intervention immediately.
62812805|NCT04587518|EXPERIMENTAL|Waitlist/Delayed Treatment|Participants in this group will receive the intervention after an 18-week wait.
62812806|NCT03860792|EXPERIMENTAL|Ketogenic Diet|Study partners will be instructed to assist participants in adherence to a 1:1 ketogenic diet (approximately 70% fat, \<10% carbohydrate, and 20% protein as energy). The diet will encourage ≥4 servings of non-starchy vegetables and 1/2 cup of berries daily. Participants will be provided an emulsified medium chain triglyceride supplement with a target intake of 1-2 tablespoons per day and micronutrient supplements consisting of multivitamin, vitamin D, calcium, and phosphorus. After the 3-month ketogenic diet, participants will complete a 1-month washout period in which they halt adherence to the ketogenic diet and resume their normal diet.
62812807|NCT03860792|ACTIVE_COMPARATOR|Therapeutic Lifestyles Changes Diet|Study partners will be instructed to assist participants in adherence to the Therapeutic Lifestyles Changes diet. The diet consists of 20-35% fat, 50-60% carbohydrate, and \~15% protein as energy. Fat intake will comprise \<7% saturated fat, ≤20% monounsaturated fat, and ≤10% polyunsaturated fat as total energy. Cholesterol consumption will be ≤200mg per day. Participants are encouraged to eat ≥2 servings of fruit and ≥5 servings of vegetables per day.
62812808|NCT03267368|EXPERIMENTAL|Comprehensive Care Program|Pulmonary rehab and smoking cessation program/intervention/assessment
62812809|NCT05484804|NO_INTERVENTION|Standard Care|Pregnant patients with Medicaid insurance are screened for risk factors for low birthweight, and high-risk patients receive intensive care management.
62812810|NCT05484804|ACTIVE_COMPARATOR|Data Accountability and Transparency|Pregnant patients with Medicaid insurance are screened for risk factors for low birthweight, and high-risk patients receive intensive care management. Additionally, practices receive 2 additional patient-level interventions, including: 1) support from a Practice Facilitator to help implement the interventions and build workflows and quality improvement cycles; 2) use of a Maternal Warning System for missed visits/parameters and abnormal values with real-time feedback; 3) use of a Perinatal Equity Dashboard that displays outcome data stratified by race; and 2) Racial Equity Training.
62812811|NCT05484804|ACTIVE_COMPARATOR|Community-Based Doula (CBD) Support|Pregnant patients with Medicaid insurance are screened for risk factors for low birthweight, and high-risk patients receive intensive care management. Additionally, practices receive 2 additional patient-level interventions, including: 1) shared care of high-risk patients with Community-Based Doulas; and 2) Racial Equity Training.
62812812|NCT05484804|ACTIVE_COMPARATOR|Data Accountability and Transparency + Community-Based Doula Support|Pregnant patients with Medicaid insurance are screened for risk factors for low birthweight, and high-risk patients receive intensive care management, and practices receive all the Data Accountability and Doula Interventions described in Arms 2 and 3.
62812813|NCT04907682|ACTIVE_COMPARATOR|Intravenous ribavirin|"standard treatment: Irrua regimen~* 100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day)~* 25 mg/kg days 2-7~* 12.5 mg/kg days 8-10"
62812814|NCT04907682|EXPERIMENTAL|Oral favipiravir|"Oral favipiravir~* Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16)~* Day 2-10 1200mg twice daily (BD)"
62035650|NCT02199262|EXPERIMENTAL|music intervention + reminder|agitation diagnosis and management according to implemented guidelines+ music intervention
62035651|NCT02199262|EXPERIMENTAL|reflexology + reminder|agitation diagnosis and management according to implemented guidelines + reflexology
62595225|NCT04157114|PLACEBO_COMPARATOR|Placebo|Subjects will receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling
62595226|NCT04725812|EXPERIMENTAL|Eculizumab|Twelve subjects in the interventional arm will receive eculizumab at an induction dose of 900mg IV weekly (q7 days) for 4 weeks followed by a dose of 1200mg IV at week 5. Thereafter, patients will receive a maintenance dose of 1200mg IV every two weeks (q14 days). The last dose of eculizumab will be given up to 48 hours post-partum, with a dose that is dependent on the dosing schedule (i.e. whether the last dose is given within the 4-week induction period or is during the maintenance phase).
62812815|NCT06381804|EXPERIMENTAL|shotblocker|shotblocker
62812816|NCT06381804|EXPERIMENTAL|palm stimulator|palm stimulator
62812817|NCT06381804|NO_INTERVENTION|control|control
62236717|NCT04868539|EXPERIMENTAL|Sleep Restriction without Extended Duration Artificial Light at Night (ALAN)|In the Sleep Restriction group without Extended Duration ALAN, the sleep episodes will be shortened to 5 hours as in the ALAN Condition (centered at the same time as the baseline sleep with bedtime 2.5 hours later and wake time 2.5 hours earlier), but the participant will remain sitting in bed in near darkness (\< 1 lux) for the 2.5 hours before and after the 5-hour sleep episode, such that their exposure to room lighting and activity (14 hours/day) will remain similar to that in the Baseline condition.
62236718|NCT02827630|ACTIVE_COMPARATOR|DH-4|Subjects will use Proteus Discover, the digital health offering (DH) for 4 weeks
62236719|NCT02827630|ACTIVE_COMPARATOR|DH-12|Subjects will use Proteus Discover, the digital health offering (DH) for 12 weeks
62236720|NCT02827630|OTHER|Usual Care|Subjects received usual medical care including all normal interventions such as medication titration, adherence counseling, lifestyle coaching, and additional clinic visits per their providers' discretion.
62236721|NCT06277336|EXPERIMENTAL|Healthy Volunteers Intervention Order: Placebo, Apelin Low Dose, Apelin High Dose|"The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.~Artificial SIAD induction (water loading and desmopressin administration) is performed."
62812818|NCT03852602||Group Control|Analgesic application15 minutes before the end of the treatment will constitute the control group.
62812819|NCT03852602||Group preemptive|Patients who underwent analgesic 15 minutes after the induction of general anesthesia .
62427145|NCT05940688|EXPERIMENTAL|Digital Health Intervention|This group will receive routine prenatal care services. Additionally, those randomized to this arm will receive a DHI intervention. A modified DHI will be utilized that was developed by Memora Health in conjunction with EQUATE partners at UPenn and feedback from the POPPY Study Team and Community Advisory Board. All content is designed for 7th grade Flesch-Kincaid level or lower.
62427146|NCT05940688|EXPERIMENTAL|Community health worker (CHW)|"Individuals randomized to this group will receive routine prenatal care services. Additionally, they will receive a CHW intervention. The CHW intervention will be adapted from an ongoing CHW program in Jefferson County, AL called From Day One (FDO), a comprehensive patient-centered program designed to educate and provide non-clinical, psychosocial, emotional support to expectant mothers from the 1st trimester of pregnancy through their child's first year of life. The intervention has been modified by the POPPY Study Team and Community Advisory Board."
62595227|NCT06620809|EXPERIMENTAL|Extracellular vesicles group|Patients in this group will receive extracellular vesicles derived from human-induced neural stem cells for intrathecal injection once a day for 1 day.
62595228|NCT06620809|PLACEBO_COMPARATOR|Extracellular vesicles placebo group|Patients in this group will receive a placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection once a day for 1 day.
62595229|NCT06545916|EXPERIMENTAL|Sunobinop|
62595230|NCT06545916|PLACEBO_COMPARATOR|Placebo to match sunobinop|
62595231|NCT06353126|EXPERIMENTAL|DEB-TACE prior to living donor liver transplantation|Patients with HCC scheduled for living donor liver transplantation treatment receive DEB-TACE 2 weeks prior to the surgery
62243437|NCT03876171|EXPERIMENTAL|CIFFTA|Family-Based Adolescent Therapy, Individual Therapy, and Psycho-educational Modules
62243438|NCT03876171|ACTIVE_COMPARATOR|Standard of Care|The Diversion Programs used by the Juvenile Services Department in Miami-Dade.
62427147|NCT05940688|EXPERIMENTAL|DHI Plus CHW|This group will receive routine prenatal care services. Additionally, this group will receive both DHI and CHW interventions.
62427148|NCT05940688|NO_INTERVENTION|Usual Care|This group will receive routine prenatal care services.
62595232|NCT04504825|EXPERIMENTAL|CAEL-101 combined with SoC plasma cell dyscrasia|CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. It is planned that all patients will continue their double-blind treatment until the last patient is randomized in the study plus 18 months. The study is divided into 2 parts, the Primary Evaluation Treatment period part and the Open-Label Extension period of Study.
62595233|NCT04504825|PLACEBO_COMPARATOR|Placebo combined with SoC plasma cell dyscrasia|Patients randomized to receive placebo will receive 0.9% normal saline in an equivalent volume to a CAEL-101 infusion (approximately 250 cc). It is planned that all patients will continue their double-blind treatment until the last patient is randomized in the study plus 18 months.
62595234|NCT04332341|EXPERIMENTAL|Nicotinamide riboside (NR)|
62812820|NCT03701958|OTHER|Exalt DScope 01|Subjects will have a clinically indicated per standard of care ERCP procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
62236722|NCT06277336|EXPERIMENTAL|Healthy Volunteers Healthy Patients Intervention Order: Apelin Low Dose, Apelin High Dose, Placebo|"The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.~Artificial SIAD induction (water loading and desmopressin administration) is performed."
62236723|NCT06277336|EXPERIMENTAL|Healthy Volunteers Intervention Order: Apelin High Dose, Placebo, Apelin Low Dose|"The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.~Artificial SIAD induction (water loading and desmopressin administration) is performed."
62595235|NCT04205409|EXPERIMENTAL|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62595236|NCT03863171||Ocular ischemia syndrome|Patients with ocular ischemia syndrome
62595237|NCT03863171||Control|Patients with age-related macular degeneration
62812821|NCT03820609|EXPERIMENTAL|Digital Intervention|Make a Change is a universal sexual assault (SA) prevention program that aligns with best-practices in prevention, utilizes the theory and strategies of serious games for health, and addresses risk and protective factors for SA across the social ecology of individual, peer and community factors that foster SA. This novel digital application also leverages theories of behavior change within serious games for health, and integrates successful practices in videogame design to promote engagement, learning and skill-building.
62812822|NCT04776317|EXPERIMENTAL|Stage 1 (Naïve) Group 1|5 x 10\^10 viral particles of ChAdV68-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 29 in participants from 18 to 60 years of age. N=4
62812823|NCT04776317|EXPERIMENTAL|Stage 1 (Naïve) Group 3A|30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 29 in participants from 18 to 60 years of age. N=3
62812824|NCT04776317|EXPERIMENTAL|Stage 1 (Naïve) Group 3B|30 mcg SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 3 mcg of SAM-LNP-S administered through 0.25 mL intramuscular injection in the deltoid muscle on or after Day 85 and no later than Day 130 in participants from 18 to 60 years of age. N=7
62236724|NCT06277336|EXPERIMENTAL|Healthy Volunteers Intervention Order: Placebo, Apelin High Dose, Apelin Low Dose|"The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.~Artificial SIAD induction (water loading and desmopressin administration) is performed."
62236725|NCT06277336|EXPERIMENTAL|Healthy Volunteers Intervention Order: Apelin Low Dose, Placebo, Apelin High Dose|"The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.~Artificial SIAD induction (water loading and desmopressin administration) is performed."
62243439|NCT06735235|OTHER|Period 1|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
62595238|NCT01945697||normal oral mucosa|
62595239|NCT01945697||oral precancerous lesion or oral cancer|
62812825|NCT04776317|EXPERIMENTAL|Stage 1 (Naïve) Group 4|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on or after Day 85 and no later than Day 130 in participants from 18 to 60 years of age. N=3
62035652|NCT06670768|EXPERIMENTAL|Consecutive patients with moderate pre-test probability according to CAD consortium|Patients undergo dynamic and static MPI SPECT and cardiac CT within 30-days.
62035653|NCT01440153|EXPERIMENTAL|Active Intervention|
62035654|NCT01440153|ACTIVE_COMPARATOR|passive intervention|
62236726|NCT06277336|EXPERIMENTAL|Healthy Volunteers Intervention Order: Apelin High Dose, Apelin Low Dose, Placebo|"The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.~Artificial SIAD induction (water loading and desmopressin administration) is performed."
62236727|NCT06277336|EXPERIMENTAL|Chronic SIAD Patients Intervention Order: Placebo, Selected Apelin Dose|The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.
62236728|NCT06277336|EXPERIMENTAL|Chronic SIAD Patients Intervention Order: Selected Apelin Dose, Placebo|The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.
62236729|NCT01486953|ACTIVE_COMPARATOR|sevoflurane|Anesthesia with sevoflurane
62236730|NCT01486953|EXPERIMENTAL|Desflurane|Anesthesia with desflurane
62236731|NCT04258527|EXPERIMENTAL|Patients with advanced malignancies with FGF/FGFR alterations|
62236732|NCT05532748|EXPERIMENTAL|"Modified Pachon's incentive, then Branded incentive Triflo II®"|The first measurement with the tomograph will be made using the modified Pachon's incentive, and a week later the measurement will be made using the branded incentive
62236733|NCT05532748|ACTIVE_COMPARATOR|"Branded incentive Triflo II®, then modified Pachon's incentive"|The first measurement with the tomograph will be made using the branded incentive, and a week later the measurement will be made using the modified Pachon's incentive.
62236734|NCT01881750|EXPERIMENTAL|Pivotal Response Training (PRT)|12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
62236735|NCT01881750|PLACEBO_COMPARATOR|Parent Education Group (PEG)|12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
62236736|NCT04642768|EXPERIMENTAL|3-Hydroxybutyrate treatment|KetoneAid Ketone Ester 0,5g/kg (max. 50g) bolus
62735532|NCT01995500|ACTIVE_COMPARATOR|Resolute|"The Endeavor Resolute Zotarolimus-Eluting Coronary Stent System consists of four subsystems:~* Endeavor Resolute Stent - a premounted cobalt alloy based stent~* Delivery system - Rapid Exchange (RX) Coronary System~* Polymer system~* Zotarolimus - drug The Resolute has a nominal drug dose of 1.6 µg zotarolimus per mm2 of the stent surface area."
62236737|NCT04642768|PLACEBO_COMPARATOR|Placebo Treatment|Maltodextrin-base isocaloric placebo
62236738|NCT02909491||Cases|Inpatient with severe behavioural disorders
62236739|NCT02909491||Controls|Inpatients without severe behavioural disorder and taking no antipsychotics
62236740|NCT04563000|EXPERIMENTAL|Vitamin C|Group of patients that will receive vitamin C (ascorbic acid 1,5 g mixed with 0,9 % solution of sodium chloride 100 ml every 12 hours for 4 days intravenously).
62236741|NCT04563000|PLACEBO_COMPARATOR|Placebo|Group of patients that will receive placebo (0,9 % solution of sodium chloride 100 ml every 12 hours for 4 days intravenously).
62236742|NCT03507790|ACTIVE_COMPARATOR|Active Treatment- CT1812 100 mg|CT1812 at a dose of 100 n=48 group
62236743|NCT03507790|ACTIVE_COMPARATOR|Active Treatment- CT1812 300 mg|CT1812 at a dose of 300mg, n=48 group
62236744|NCT03507790|PLACEBO_COMPARATOR|Placebo Comparator - Placebo|Placebo, n=48 group
62236745|NCT02998736|EXPERIMENTAL|Intervention|"Cialis 20 mg daily by mouth for 16 day. 5 days prior to surgery, day of surgery and 10 days post surgery.~Influenza vaccine 0.5mL day of surgery"
62236746|NCT02998736|NO_INTERVENTION|Control|No intervention in the perioperative period
62236747|NCT04717284|EXPERIMENTAL|Self-compassion intervention (SCI)|Self-compassion prompt.
62236748|NCT04717284|OTHER|Control condition|Neutral prompt during the initial administration and no intervention during the two-week follow-up.
62236749|NCT05032079|EXPERIMENTAL|Treatment Arm|
62236750|NCT01423253|EXPERIMENTAL|Lurasidone 20, 40, 60 mg|Lurasidone 20, 40, or 60 mg/day flexibly dosed
62236751|NCT02247908|EXPERIMENTAL|Graphic Warning|Graphic warnings that include text and an image depicting a health effect of smoking will be applied on labels that cover the top half of the front and back of participants' cigarette packs each week for 4 weeks. Within the graphic warning condition, participants will be assigned to receive 1 of 4 warnings for 4 weeks. The text for these warnings was selected from the 2009 Family Smoking Prevention and Tobacco Control Act and the images were proposed by the FDA.
62236752|NCT02247908|ACTIVE_COMPARATOR|Surgeon General's Warning|Labels with Surgeon General's Warning text will be applied to the side of participants' cigarette packs each week for 4 weeks, on top of the Surgeon General's Warning printed by the manufacturer.
62236753|NCT05171101|EXPERIMENTAL|MAVEN|
62236754|NCT05171101|NO_INTERVENTION|Control|Participants enrolled in the control group will receive no mentoring activities but will complete all study measures and assessments.
62236755|NCT00435890|NO_INTERVENTION|1|No triage liaison physician
62236756|NCT03346057|EXPERIMENTAL|Sugammadex 2 mg/kg|Sugammadex 2 mg/kg administered as a single intravenous (IV) dose
62236757|NCT03346057|EXPERIMENTAL|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg administered as a single IV dose
62735533|NCT03899233|ACTIVE_COMPARATOR|Fractional CO2 laser combined with Tranexamic acid|one side of the face of all participants will be subjected to low power fractional CO2 laser with a power of 12 watts, spacing 800 micrometer (7.3% density), and dwell time 300 microsecond for 3 sessions every 6 weeks. In addition to Tranexamic acid intradermal microinjections using tranexamic acid 500mg/5ml ampoules, the dose of 1ml syringe with 100mg/ml with maximum of 4ml per session, on the 2nd and the 4th week of each laser session. With total treatment time for each patient of 4 months and another month free of sessions for followup.
62735534|NCT03899233|ACTIVE_COMPARATOR|Tranexamic acid alone|the other side of the face of all participants will be subjected Tranexamic acid intradermal microinjections using tranexamic acid 500mg/5ml ampoules, the dose of 1ml syringe with 100mg/ml with maximum of 4ml per session, every 2 weeks for 4 months then another month free of sessions for followup.
62735535|NCT02520388|EXPERIMENTAL|HLD200 (methylphenidate)|"Experimental: HLD200 (methylphenidate)~The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core. Following a minimum 72-hour washout, subjects will be randomized (1:1) to double-blind HLD200 to be taken once daily during the evening for a period of 3-weeks prior to testing."
62427149|NCT02622503||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis receiving rituximab will be observed for treatment responses.
62812826|NCT04776317|EXPERIMENTAL|Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 13|5 x 10\^10 viral particles of ChAdV68-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and on or after Day 113 in participants older than 60 years of age. N=7-10
62812827|NCT04776317|EXPERIMENTAL|Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 14|1 x 10\^11 viral particles of ChAdV68-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=7-10
62236758|NCT03346057|EXPERIMENTAL|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg administered as a single IV dose
62427150|NCT04783792|EXPERIMENTAL|ascorbic acid / phytochemical supplement|A mixture of active phenolic compounds with ascorbic acid
62427151|NCT04783792|EXPERIMENTAL|ascorbic acid|Ascorbic acid group
62427152|NCT03822936|EXPERIMENTAL|Preoperatory chemoradiation therapy with carbon ions|Chemoradiation followed by surgery
62427153|NCT05294198|EXPERIMENTAL|Beet protocol|Beta vulgaris L. extract (600mg)
62427154|NCT05294198|PLACEBO_COMPARATOR|Placebo protocol|Starch (600mg)
62595240|NCT05888441|EXPERIMENTAL|Low Vision Group|At a single study visit, the group of low vision participants will be asked to perform a series of short walking trials. During each trial they will walk at a self-selected speed along a walkway (6 meters in length) that may or may not contain an obstacle to step over. The trials will be randomly varied with regard to an obstacle's presence, height, and contrast from the walkway surface. Repeated trials of each condition variation will be performed during the visit.
62812828|NCT04776317|EXPERIMENTAL|Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 15|5 x 10\^11 viral particles of ChAdV68-S-TCE administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=7-10
62236759|NCT03346057|ACTIVE_COMPARATOR|Neostigmine + Glycopyrrolate|Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose
62236760|NCT03865147|EXPERIMENTAL|Phase 1 open, pilot phase|A pilot group of 10 patients who will receive Tri-Solfen only (non-randomised) once, prior to debridement
62427155|NCT00303381|EXPERIMENTAL|Interferon-beta-1a, 44 microgram|
62236761|NCT03865147|EXPERIMENTAL|Phase 2 - Tri-Solfen|A group of 20 patients who will receive EMLA cream (60 minute application) to anaesthetise the leg ulcer prior to surgical wound debridement, followed on completion of surgery by a single application of Tri-Solfen.
62236762|NCT03865147|ACTIVE_COMPARATOR|Phase 2 - Standard Care|A group of 20 patients who will receive EMLA Cream (60 minute application) to anaesthetise the leg ulcer prior to surgical wound debridement, followed on completion of surgery by standard of care post-operative analgesia.
62236763|NCT03865147|EXPERIMENTAL|Phase 3 - Tri-Solfen|A group of 20 patients who will receive two applications of Tri-Solfen (2mL/10cm2), once prior to debridement and once on completion of the procedure.
62236764|NCT03865147|ACTIVE_COMPARATOR|Phase 3 - EMLA|A group of 20 patients who will receive EMLA Cream (60-minute application) prior to surgical debridement
62427156|NCT00303381|EXPERIMENTAL|Interferon-beta-1a, 66 microgram|
62427157|NCT00303381|PLACEBO_COMPARATOR|Placebo|
62427158|NCT00667719|EXPERIMENTAL|Aliskiren/Amlodipine/Hydrochlorothiazide|Participants received aliskiren 300 milligrams (mg) plus hydrochlorothiazide 12.5 mg for one week, at Week 1 followed by combination of aliskiren 300 mg plus amlodipine 5 mg plus hydrochlorothiazide 12.5 mg for one week, at Week 2. Following Week 2, participants were force titrated up to aliskiren 300 mg plus amlodipine 10 mg plus hydrochlorothiazide 25 mg for 26 to 52 weeks (Weeks 28 to 54). All study medications were taken orally with water, once daily in the morning.
62427159|NCT03503227|ACTIVE_COMPARATOR|Aspirin|Patients will receive daily oral low dose Acetylsalicylic acid (75 mg) starting day 20 of the previous cycle withGonadotrophin releasing hormone agonist (GnRH agonist)
62427160|NCT03503227|ACTIVE_COMPARATOR|Aspirin and prednisolone|Patients will receive daily oral low dose Acetylsalicylic acid (75 mg) and Low dose prednisolone (10 mg/day) starting day 20 of the previous cycle withGonadotrophin releasing hormone agonist (GnRH agonist).
62427161|NCT05350098|EXPERIMENTAL|A dietary intervention of plant-protein based diets|
62427162|NCT05350098|ACTIVE_COMPARATOR|A dietary intervention of control diets|
62812829|NCT04776317|EXPERIMENTAL|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 10A,B|6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=8-12
62035655|NCT03320070|EXPERIMENTAL|Acthar Gel in DBT Then Acthar Gel in OLE|Participants received Acthar Gel as a 1 milliliter (mL) injection under the skin, twice weekly, for 24 weeks in the double-blind treatment (DBT) phase. Participants, who chose to continue into the optional OLE phase, then received Acthar Gel as a 1 mL injection under the skin, twice weekly, for another 24 weeks in the optional open-label extension (OLE) phase.
62035656|NCT03320070|EXPERIMENTAL|Placebo in DBT Then Acthar Gel in OLE|Participants received Acthar Gel matching placebo as a 1 mL injection under the skin, twice weekly, for 24 weeks in the DBT phase. Participants, who chose to continue into the optional OLE phase, then received Acthar Gel as a 1 mL injection under the skin, twice weekly, for another 24 weeks in the optional OLE phase.
62035657|NCT02247427|EXPERIMENTAL|Off-pace group|Deactivated device group
62035658|NCT02247427|NO_INTERVENTION|On-Pace group|Ongoing device activity group
62035659|NCT05080569|EXPERIMENTAL|MOH/IUI treatment with LPS|(Mild) Ovarian stimulating treatment and insemination are according to regular treatment protocol. Females assigned to the treatment group start LPS, applying 3dd200mg Utrogestan in vaginal capsules, on the day of IUI. Treatment is continued until the onset of menstruation, a negative pregnancy test, miscarriage or confirmed vital intra-uterine pregnancy at 7 weeks gestation
62035660|NCT05080569|PLACEBO_COMPARATOR|MOH/IUI treatment with placebo|"Females will receive regular MOH/IUI treatment. The female cycle is mildly stimulated and monitored until the desired amount of ripe follicles is achieved. In the absence of other reasons to cancel the treatment, ovulation is triggered and subsequently pre-washed semen is inseminated into the uterus.~Females assigned to the placebo group start placebo, applying 3dd1 vaginal capsules, on the day of IUI. Treatment is continued until the onset of menstruation, a negative pregnancy test, miscarriage or confirmed vital intra-uterine pregnancy at 7 weeks gestation"
62035661|NCT00881387|EXPERIMENTAL|Group 1 (eligible for SCT)|Patients receive rituximab IV, vinorelbine ditartrate IV over 6-10 minutes, and gemcitabine hydrochloride IV over 30 minutes on day 1 and pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response (CR) or partial response (PR) undergo SCT.
62035662|NCT00881387|EXPERIMENTAL|Group 2 (ineligible for SCT)|Patients receive rituximab, vinorelbine ditartrate, gemcitabine hydrochloride, and pegfilgrastim as in group 1. Patients with CR, PR, or stable disease after 3 courses continue to receive therapy in the absence of disease progression or unacceptable toxicity.
62035663|NCT06167187|ACTIVE_COMPARATOR|Study group (IAN block group)|patients will receive bilateral inferior alveolar nerve block. 23 patients
62035664|NCT06167187|ACTIVE_COMPARATOR|control group|"patients will not receive the block and will receive intravenous multimodal analgesia according to standard protocol.~23 patients"
62035665|NCT05922358|EXPERIMENTAL|hypersensitivity group|Corresponding intervention measures are given for different levels of hypersensitivity reactions
62035666|NCT03734627||Upper Gastrointestinal Surgery - Transit|
62035667|NCT03734627||Control - Transit|
62035668|NCT03734627||Upper Gastrointestinal Surgery - Gut Function|
62035669|NCT03734627||Control - Gut Function|
62035670|NCT01747187||Septic shock|
62035671|NCT01003899|EXPERIMENTAL|afatinib (BIBW 2992)|patient to receive afatinib(BIBW 2992) po QD in an open-label manner
62035672|NCT01043770|EXPERIMENTAL|Group lifestyle education|Multi-component behaviour change intervention
62035673|NCT01043770|NO_INTERVENTION|Routine care|Routine care
62035674|NCT02212704|EXPERIMENTAL|Vestibular stimulation|This is the experimental paradigm applied in all participants
62035675|NCT05247996|EXPERIMENTAL|"Transcatheter arterial chemoembolization Combined With Target Immune Therapy"|Transcatheter arterial chemoembolization combined with immune checkpoint inhibitors and multi-target drugs was used for treatment.
62035676|NCT05247996|ACTIVE_COMPARATOR|Traditional Systemic Intravenous Chemotherapy Group|Traditional systemic intravenous chemotherapy with GEMOX regimen was used for comparison.
62236765|NCT02115451||Surgical treatment|Patients who undergo rehabilitation and anterior cruciate ligament reconstruction, other surgical interventions may be performed
62427163|NCT02583178|EXPERIMENTAL|Aegis Sierra Ligation System|The Aegis Sierra Ligation System is a series of devices designed for epicardial ligation of the Left Atrial Appendage through a minimally invasive transcatheter approach.
62427164|NCT03782584|EXPERIMENTAL|Modified Pilates Exercise Group|they will be involved in a modified pilates exercise training for a total of 6 weeks a day, 2 days a week.
62735536|NCT02520388|PLACEBO_COMPARATOR|Placebo|Placebo capsules will be composed of microcrystalline cellulose beads in place of MPH containing beads found in the HLD200 capsules. Following a minimum 72-hour washout, subjects will be randomized (1:1) to double-blind placebo to be taken once daily during the evening for a period of 3-weeks prior to testing.
62812830|NCT04776317|EXPERIMENTAL|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 11A,B|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=8-12
62035677|NCT04838262|EXPERIMENTAL|Assessment of Daily Stress Processes|Subjects will report cumulative exposure, perceived severity, and emotional responsiveness to commonly occurring everyday psychosocial stressors utilizing an ecological momentary assessment approach for 8 consecutive days.
62035678|NCT01189916|EXPERIMENTAL|Transrectal NOTES appendectomy|These patients will undergo an experimental surgical procedure that uses flexible endoscopic instruments (i.e., inserted through the rectum).
62035679|NCT02010840|EXPERIMENTAL|Psychodeucation program|Both couples receive the father inclusive psychoeducation program which consists of a single 3-hour session during pregnancy and two telephone follow up at postpartum.
62035680|NCT02010840|ACTIVE_COMPARATOR|Mother only|Only the women receives the psychoeducation program.
62427165|NCT03782584|OTHER|Control Group|they will be given daily life advises to prevent neck pain
62735537|NCT03565250|EXPERIMENTAL|ADHD patients|children aged 8-12 ans with ADHD
62735538|NCT03565250|ACTIVE_COMPARATOR|control|children aged 8-12 ans without ADHD
62812831|NCT04776317|EXPERIMENTAL|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 12A,B|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants older than 60 years of age. N=8-12
62812832|NCT04776317|EXPERIMENTAL|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 9|3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=8
62812833|NCT04776317|EXPERIMENTAL|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 5|3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
62812834|NCT04776317|EXPERIMENTAL|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 6|6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
62812835|NCT04776317|EXPERIMENTAL|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 7A,B|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=8-12
62812836|NCT04776317|EXPERIMENTAL|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 8A,B|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants from 18 to 60 years of age. N=8-12
62035681|NCT02010840|NO_INTERVENTION|Control group|Receives usual perinatal care services only
62035682|NCT06722053|OTHER|intervention group 1|Receiving breastfeeding skills training and gamified digital foundation training with virtual reality.
62035683|NCT06722053|OTHER|intervention group 2|With virtual reality breastfeeding skills training, gamified digital-based breastfeeding training will be provided, and in addition, there will be a lemon oil scent in the environment during virtual reality breastfeeding skills training and in the postpartum period.
62035684|NCT06722053|NO_INTERVENTION|control group|No training or intervention will be applied and will receive the hospital's standard treatment, care and education.
62035685|NCT03953092|EXPERIMENTAL|SAD Cohort 1|5 mg YG1699 or Placebo
62035686|NCT03953092|EXPERIMENTAL|SAD Cohort 2|10 mg YG1699 or placebo
62035687|NCT03953092|EXPERIMENTAL|SAD Cohort 3|25 mg YG1699 or placebo
62035688|NCT03953092|EXPERIMENTAL|SAD Cohort 4|50 mg YG1699 or placebo
62035689|NCT03953092|EXPERIMENTAL|SAD Cohort 5|100 mg YG1699 or placebo
62035690|NCT03953092|EXPERIMENTAL|MAD Cohort 1|5 mg YG1699 or placebo
62035691|NCT03953092|EXPERIMENTAL|MAD Cohort 2|20 mg YG1699 or placebo
62035692|NCT03953092|EXPERIMENTAL|MAD Cohort 3|50 mg YG1699 or placebo
62236766|NCT02115451||Nonsurgical treatment|Patients who undergo rehabilitation without anterior cruciate ligament reconstruction, other surgical interventions may be performed
62427166|NCT01316588|EXPERIMENTAL|Plastic adesive drape|Intraoperative: Plastic adhesive drape on the chest and bare skin on the leg
62427167|NCT01316588|EXPERIMENTAL|Microbial Sealant|Intraoperative: Microbial Sealant on the leg and bare skin on the chest
62427168|NCT01070277|PLACEBO_COMPARATOR|Placebo arm|"2 placebo pills X2 /day for 2 days followed by~1 placebo Pill X2 / day for 7 days"
62735539|NCT00720356|EXPERIMENTAL|Treatment|erlotinib and bevacizumab
62236767|NCT03471871|EXPERIMENTAL|HV Cohort,Sequence A:Placebo,Lemborexant 10mg,Lemborexant 25mg|Eligible healthy adult and elderly participants will receive lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 1, followed by lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 2, and then lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
62236768|NCT03471871|EXPERIMENTAL|HV Cohort,Sequence B:Lemborexant 10mg,Lemborexant 25mg,Placebo|Eligible healthy adult and elderly participants will receive lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 1, followed by lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 2, and then lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
62236769|NCT03471871|EXPERIMENTAL|HV Cohort,Sequence C:Lemborexant 25mg,Placebo,Lemborexant 10mg|Eligible healthy adult and elderly participants will receive lemborexant 25 mg (2 lemborexant 10 mg tablet and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 1, followed by lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 2, and then lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
62236770|NCT03471871|EXPERIMENTAL|OSA Cohort, Sequence D: Placebo, Lemborexant 10mg|Eligible adult and elderly participants with mild OSA will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each Treatment Period.
62427169|NCT01070277|EXPERIMENTAL|Tinidazole and Albendazole treatment|Tinidazole 1 gram BID for 2 days followed by Albendazole 400mg BID for 7 days
62427170|NCT02118207|EXPERIMENTAL|Control dives 1st|Subjects in this group complete the first 3 dives as control dives and the second 3 dives preceded by aerobic exercise
62427171|NCT02118207|EXPERIMENTAL|Predive exercise 1st|Subjects complete the first 3 dives preceded by the intervention of aerobic exercise and the second 3 with no exercise as control dives
62427172|NCT03666546|EXPERIMENTAL|Laevolac crystals 20 g|Lactulose crystals, oral intake, 20 g single dose
62427173|NCT03666546|EXPERIMENTAL|Laevolac crystals 30 g|Lactulose crystals, oral intake, 30 g single dose
62427174|NCT03666546|EXPERIMENTAL|Laevolac liquid 20 g|Lactulose liquid, oral intake, 20 g single dose
62427175|NCT03666546|EXPERIMENTAL|Laevolac liquid 30 g|Lactulose liquid, oral intake, 30 g single dose
62427176|NCT03666546|ACTIVE_COMPARATOR|Glucose 30 g|Glucose Monohydrate, oral intake, 33 g single dose
62427177|NCT03666546|PLACEBO_COMPARATOR|Water|Still water, oral intake, 250 mL single dose
62427178|NCT03860519|EXPERIMENTAL|Intervention Group|"The components of the intervention unique to the treatment group include: 1) access to the Propeller Health Asthma App on his/her phone, which includes tracking of ICS and SABA usage; 2) receipt of NorthShore Connect physician alerts (these will be sent by the asthma nurse on behalf of the NS physician) if he/she has poor adherence ie missed 4 consecutive days of all of his/her controller medication dosages and their sensor has sent heartbeat to application OR at risk alerts if a patient transitions to a not well controlled or poorly controlled status (defined by the NHLBI guidelines); and 3) monthly phone calls with a nurse from his/her asthma doctor's office to review ICS and SABA usage reports (provided by Propeller Health on their Propeller Health dashboard)."
62427179|NCT03860519|EXPERIMENTAL|Control Group|The control group will not receive access to view the contents of the Propeller Health Asthma App on his/her phone, NorthShore Connect alerts for missing ICS or overuse of SABA, or for his/her asthma doctor (the asthma nurse will be viewing this information on behalf of the asthma doctor) to view his/her ICS and SABA use on the Propeller Health dashboard until after the 3-month study has been completed.
62243440|NCT06735235|OTHER|Period 2|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
62427180|NCT00913471||Acute-Longitudinal SCI|
62735540|NCT01864148|EXPERIMENTAL|BIIB033, 3 mg/kg|"BIIB033 3 mg/kg once every 4 weeks intravenous (IV) infusion up to Week 72.~Avonex once-weekly intramuscular (IM) injection up to Week 84."
62812837|NCT02482376|OTHER|Single arm 21Gy stereotactic radiotherapy|Subjects will receive a single fraction of 21Gy of stereotactic radiotherapy before proceeding to surgery.
62812838|NCT04053335||Cohort 1: Multicomponent Physician Performance Peer-Comparison|"Cohort 1 (6 groups):~Inova/Signature Parters, Sentara/Sentara Quality Care Network, Ballad Health, Carilion Clinic, Health Care Associates Virginia/Virginia Care Partners, and Virginia and Commonwealth University Health System~Note that the original design for the intervention was a step-wedge randomization. However, this was changed due to the COVID-19 pandemic, which necessitated a delay in all study activities from March 2020 - September 2020. The intervention began in September 2020. Data collection concluded in December 2022."
62812839|NCT04053335||Cohort 2: Multicomponent Physician Performance Peer-Comparison|Cohort 2 (6 groups): Six comparable control health systems identified via matching
62812840|NCT03553901|EXPERIMENTAL|Acupressure|Acupressure is applied before injection
62812841|NCT03553901|NO_INTERVENTION|Control group|acupressure is not applied before injection
62812842|NCT01274026||evaluation of benefit of sapropterin|Intervention 'sapropterin dihydrochloride': 20 individuals, either known to be non-responsive, or naive to sapropterin, are given a 4 week administration of sapropterin. Pre-, and Post- evaluation of behavior, executive function, neurotransmitter function, and genomic expression are assessed and evaluated for change.
62812843|NCT05790551|ACTIVE_COMPARATOR|Control|Patients in this arm will undergo standard at-home OUD treatment (n = 5/group) over 14-days.
62427181|NCT00913471||Chronic SCI|
62427182|NCT00913471||Healthy volunteers|
62427183|NCT04446819|OTHER|Cohort|Patients diagnosed with solid tumors who are about to received albumin-binding paclitaxel monotherapy are recruited. Dominant hands and non-dominant hands are treated with small-size compression gloves and suitable-size compression gloves, respectively, during the administration of albumin-binding paclitaxel.
62035693|NCT05962853|EXPERIMENTAL|Experimental group ( TENS will be applied )|After 30 minutes of TENS application 2 hours after the surgery, TENS will be applied 3 times at 8 hour intervals. Postoperatively at the 2nd hour (just before TENS), at the 3rd hour (1 hour after the onset of TENS), at the 10th hour (just before the TENS), at the 11th hour (1 hour after the start of TENS), at the 18th hour ( Just before TENS) at the 19th Hour (1 hour after the start of TENS). TENS application hours will be arranged according to the patient in order to protect sleep integrity.
62427184|NCT05448768|ACTIVE_COMPARATOR|Amyloid-positive MCI|The subjects will receive active stimulation of standard intermittent TBS (iTBS) protocol.
62595241|NCT05888441|ACTIVE_COMPARATOR|Control Group|At a single study visit, the group of age-matched participants without low vision will be asked to perform a series of short walking trials. During each trial they will walk at a self-selected speed along a walkway (6 meters in length) that may or may not contain an obstacle to step over. The trials will be randomly varied with regard to an obstacle's presence, height, and contrast from the walkway surface. Repeated trials of each condition variation will be performed during the visit.
62595242|NCT05330702|EXPERIMENTAL|Tuberosity Connective Tissue Graft (CTG)|Subjects in this arm will have a tuberosity connective tissue graft at the time of immediate implant placement.
62595243|NCT05330702|EXPERIMENTAL|Xenogeneic Volume-Stable Collagen Matrix (VCMX) graft|Subjects in this arm will have Xenogeneic Volume-Stable Collagen Matrix (VCMX) graft at the time of immediate implant placement.
62595244|NCT05330702|NO_INTERVENTION|No Soft Tissue Augmentation|Subjects in this arm will have no soft tissue augmentation at the time of immediate implant placement.
62812844|NCT05790551|EXPERIMENTAL|Active - App|Patients in this arm will undergo standard at-home OUD treatment in combination with the Addinex dispenser and app (n = 5/group) over 14-days.
62812845|NCT03717688|PLACEBO_COMPARATOR|Placebo|No treatment. Participants are subjected to a standardized meal
62812846|NCT03717688|ACTIVE_COMPARATOR|Entrestro as single dose|194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal
62812847|NCT03717688|ACTIVE_COMPARATOR|Sitagliptin as single dose|200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
62812848|NCT03717688|ACTIVE_COMPARATOR|Entrestro + sitagliptin as single dose|194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
62812849|NCT05794425|EXPERIMENTAL|Cyclosporine A|
62735541|NCT01864148|EXPERIMENTAL|BIIB033, 10 mg/kg|"BIIB033 10 mg/kg once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
62735542|NCT01864148|EXPERIMENTAL|BIIB033, 30 mg/kg|"BIIB033 30 mg/kg once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
62735543|NCT01864148|EXPERIMENTAL|BIIB033, 100 mg/kg|"BIIB033 100 mg/kg once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
62035694|NCT05962853|NO_INTERVENTION|Control Group ( TENS will not be applied )|Application of the control group: TENS will not be applied to this group.
62035695|NCT04666168|EXPERIMENTAL|Auto CAR-T|Patients will be treated with Auto CAR-T cells
62035696|NCT03229369|ACTIVE_COMPARATOR|Isolated ACL|Standard Anterior Cruciate Ligament Reconstruction only
62035697|NCT03229369|EXPERIMENTAL|Combined ACL and ALL|Anterior Cruciate Ligament Reconstruction associated with Anterolateral Ligament Reconstruction
62035698|NCT04351867|EXPERIMENTAL|experimental group|docetaxel plus oxaliplatin and capecitabine
62035699|NCT04351867|ACTIVE_COMPARATOR|control group|oxaliplatin plus capecitabine
62427185|NCT05448768|ACTIVE_COMPARATOR|Amyloid-negative MCI|The subjects will receive active stimulation of standard intermittent TBS (iTBS) protocol.
62427186|NCT00918229|OTHER|balloon implantation|implantation of an absorbable perirectal spacer balloon
62735544|NCT01864148|PLACEBO_COMPARATOR|Placebo|"Placebo once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
62735545|NCT01336855||HIV Positive|HIV-1 positive subjects
62735546|NCT01336855||HIV negative subjects|HIV-1 seronegative control group
62735547|NCT01458743|EXPERIMENTAL|Ceftaroline q12h|Ceftaroline 600mg q12h
62735548|NCT01458743|EXPERIMENTAL|Ceftaroline q8h|ceftaroline 600mg q8h
62735549|NCT03680833|OTHER|prospective cohort study|"Prospective cohort study with detection of sentinel lymph nodes followed by a full pelvic lymphadenectomy. Patients will act as their own controls.~The intervention is the detection and removal of sentinel lymph nodes"
62735550|NCT05146219|EXPERIMENTAL|TY-9591 Tablets|TY-9591 Tablets 160mg/d
62735551|NCT04635254|ACTIVE_COMPARATOR|Halophites-based cream 24 hours|A 2 gram amount of Halophites-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
62735552|NCT04635254|ACTIVE_COMPARATOR|Halophites-based cream 48 hours|A 2 gram amount of Halophites-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
62812850|NCT05794425|EXPERIMENTAL|UCB+UC-MSCs|
62812851|NCT02140047|EXPERIMENTAL|MT-2301-Low|
62812852|NCT02140047|EXPERIMENTAL|MT-2301-High|
62427187|NCT03838588||T-MENC Study Group|"In the study, 200 of stage IB,II and IIIA non-small cell lung cancer patients obtained radical resection will be recruited. All the patients will receive biopsy genotype assay and ctDNA liquid biopsy. The abundance of mutations of ctDNA was tracked at 4 time points, including:~1. st: 10 Days after patients received radical resection.~2. nd: When patients finished the chemotherapy or target drug delivery two cycles.~3. rd: 10 Days after patients finished the chemotherapy or target drug delivery four cycles.~4. th: When tumor recrudescence / 2 years after radical resection. Tumor genomic clonal evolution was assessed by analyzing the relative abundance of mutations in plasma circulating tumor DNA (ctDNA)."
62427188|NCT05115331|ACTIVE_COMPARATOR|Conventional Radiation Dose|8 Gy in a single fraction
62427189|NCT05115331|EXPERIMENTAL|Experimental Radiation Dose|16 Gy in 2 fractions
62427190|NCT04901871|ACTIVE_COMPARATOR|1 (0.02 mg/kg, age<65)|Remimazolam of 0.02 mg/kg will be infused in patients aged\<65.
62427191|NCT04901871|ACTIVE_COMPARATOR|2 (0.07 mg/kg, age<65)|Remimazolam of 0.07 mg/kg will be infused in patients aged\<65.
62427192|NCT04901871|ACTIVE_COMPARATOR|3 (0.12 mg/kg, age<65)|Remimazolam of 0.12 mg/kg will be infused in patients aged\<65.
62427193|NCT04901871|ACTIVE_COMPARATOR|4 (0.17 mg/kg, age<65)|Remimazolam of 0.17 mg/kg will be infused in patients aged\<65.
62427194|NCT04901871|ACTIVE_COMPARATOR|5(0.22 mg/kg, age<65)|Remimazolam of 0.22 mg/kg will be infused in patients aged\<65.
62427195|NCT04901871|ACTIVE_COMPARATOR|6(0.27 mg/kg, age<65)|Remimazolam of 0.27 mg/kg will be infused in patients aged\<65.
62427196|NCT04901871|ACTIVE_COMPARATOR|7 (0.02 mg/kg, age≥65)|Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.
62427197|NCT04901871|ACTIVE_COMPARATOR|8 (0.07 mg/kg, age≥65)|Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.
62427198|NCT04901871|ACTIVE_COMPARATOR|9 (0.12 mg/kg, age≥65)|Remimazolam of 0.12 mg/kg will be infused in patients aged≥65.
62427199|NCT04901871|ACTIVE_COMPARATOR|10 (0.17 mg/kg, age≥65)|Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.
62427200|NCT04901871|ACTIVE_COMPARATOR|11 (0.22 mg/kg, age≥65)|Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.
62427201|NCT04901871|ACTIVE_COMPARATOR|12 (0.27 mg/kg, age≥65)|Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.
62035700|NCT02468427|EXPERIMENTAL|hands-on Teaching|Medical students receive a 30 minutes hands-on training session. All study probands perform assisted delivery (operative vaginal delivery) by vacuum extraction on a pelvic model immediately after the training.
62035701|NCT02468427|ACTIVE_COMPARATOR|Frontal teaching|Medical students receive a 30 minutes frontal teaching session using a training video demonstrating how to perform assisted delivery (operative vaginal delivery) by vacuum extraction on a pelvic model immediately after the training.
62035702|NCT00223860|OTHER|1|
62035703|NCT05185310|EXPERIMENTAL|CTI/AAD (control)|In all arms, patients are undergoing first redo AF ablation and the pulmonary veins are chronically isolated and no non-PV triggers elicited during provocation. Arm 1- Cavo-tricuspid isthmus (CTI) ablation with adjustment and/or optimization of antiarrhythmic drug regimen where possible (control arm)
62035704|NCT05185310|EXPERIMENTAL|Posterior wall isolation|In all arms, patients are undergoing first redo AF ablation and the pulmonary veins are chronically isolated and no non-PV triggers elicited during provocation. Arm 2-LA Posterior wall isolation by creation of a LA roof and floor line
62035705|NCT05185310|EXPERIMENTAL|Empiric Isolation of common trigger sites|In all arms, patients are undergoing first redo AF ablation and the pulmonary veins are chronically isolated and no non-PV triggers elicited during provocation. Arm 3-empiric ablation of common sites of non-PV triggers of AF in both the right and left atria.
62035706|NCT01667432||Peginterferon alfa-2a|Participants received peginterferon alfa-2a (PEGASYS®) 180 µg subcutaneously in the abdomen or thigh once weekly for 12 weeks.
62427202|NCT04496882|EXPERIMENTAL|Switching therapy cohort|single arm, open label Patients will receive Vemlidy (tenofovir alafenamide, TAF) 25mg, daily for 48 weeks
62427203|NCT04496882|NO_INTERVENTION|Historical continuing therapy cohort|By retrospectively review medical records, The patients continued the original regimen (ETV, TDF) for retreatment (within 3 months of clinical relapse)
62427204|NCT01834573|ACTIVE_COMPARATOR|Intervention|Patients of the intervention arm receive a 10 week exercise program
62427205|NCT01834573|NO_INTERVENTION|Control|Patients of the control arm do not participate in exercise
62735553|NCT04368013||Experimental|The difference from the standard of care is extended sample collection and study related procedures during the study.
62735554|NCT03699397|EXPERIMENTAL|Dry electrode cap EEG|In this diagnostic accuracy study, all patients that are included in the study will undergo a dry electrode electroencephalography (EEG).
62735555|NCT06393270||Equia Forte Fil|High-viscosity glass ionomer cement
62812853|NCT02140047|ACTIVE_COMPARATOR|ActHIB|
62035707|NCT01852539|EXPERIMENTAL|dexmedetomidine|After intravenous infusion of dexmedetomidine for 2 min, propofol 2.0 mg/kg was administrated. And laryngeal mask airway device was inserted(LMA # 3,4).
62035708|NCT01990950|EXPERIMENTAL|Zenith® Fenestrated AAA Endovascular Graft|
62035709|NCT06635681|EXPERIMENTAL|venetoclax combined with intensive chemotherapy|"Induction therapy: daunorubicin, cytarabine, combined with venetoclax for 1 course.~Consolidation therapy: cytarabine combined with venetoclax for 3 courses.~Maintenance therapy: azacitidine combined with venetoclax for 6 courses."
62035710|NCT01834066|OTHER|STEM CELL|Intra thecal transplantation of autologous Stem Cell MNCs
62035711|NCT00209417|ACTIVE_COMPARATOR|Iodixanol 320-Arm 1|Iodixanol 320 mg I/mL
62035712|NCT00209417|ACTIVE_COMPARATOR|Iopamidol 300-Arm 2|Iopamidol 300 mg I/mL
62035713|NCT00794612|EXPERIMENTAL|1|Dermacyd Femina Pocket BR (Lactic Acid)
62427206|NCT06567093|EXPERIMENTAL|Experimental|All registered participants in the intervention group, will receive the leg and heel massage before the the heel blood collection.
62427207|NCT06567093|NO_INTERVENTION|Control|All registered participants in the intervention group, will receive the routine care before the leg and heel massage before the the heel blood collection.
62427208|NCT00973037||CYP2D6|CYP2D6 genotype
62735556|NCT06393270||Tetric Bulk Fill|Bulk-fill composite material
62735557|NCT06393270||Filtek Bulk Fill|Bulk-fill composite material
62735558|NCT01373008|EXPERIMENTAL|Inhaled QVAR|Inhaled QVAR 100 mic via aerochamber twice daily until 3 month post discharge
62236771|NCT03471871|EXPERIMENTAL|OSA Cohort, Sequence E: Lemborexant 10mg, Placebo|Eligible adult and elderly participants with mild OSA will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each Treatment Period.
62236772|NCT02311946|EXPERIMENTAL|Cohort 1|Cohort 1 will receive a 125 mg round yellow palbociclib tablet containing succinic acid
62236773|NCT02311946|EXPERIMENTAL|Cohort 2|Cohort 2 will receive a 125 mg oval yellow palbociclib spray-dried dispersion tablet containing HMPC E3
62236774|NCT02311946|EXPERIMENTAL|Cohort 3|Cohort 3 will receive a 125 mg oval yellow palbociclib spray-dried dispersion tablet with HMPC E3 and succinic acid.
62236775|NCT02311946|EXPERIMENTAL|Cohort 4|Cohort 4 will receive a 125 mg oval white/yellow palbociclib bilayer tablet with tartaric and succinic acid.
62236776|NCT02311946|EXPERIMENTAL|Cohort 5|Cohort 5 will receive a 125 mg oval yellow palbociclib fluid bed granulation tablet with succinic acid.
62236777|NCT02311946|EXPERIMENTAL|Cohort 6|Cohort 6 will receive a 125 mg palbociclib oral solution
62236778|NCT04056936||Infants diagnosed with a tongue-tie and a frenotomy|If a tongue-tie is present at the routine newborn examination, the infant can be included in the study. If the infant also has breastfeeding problems and there is a decreased tongue mobility and poor sucking ability, the pediatrician may find indication for frenotomy. If the frenotomy is performed before discharge the infant is included in this group. All Mother-infant dyads will get breastfeeding support.
62236779|NCT04056936||Infants diagnosed with a tongue-tie and no frenotomy|The infants that are recruited to the tongue-tie cohort that do not receive treatment before discharge. The pediatrician evaluates that the tongue tie does not cause any functional problems and no treatment is performed before discharge. All Mother-infant dyads will get breastfeeding support.
62236780|NCT04056936||All infants born in Telemark and Vestfold Counties|All the infants born in the study period that will contribute to the prevalence study.
62236781|NCT01890148|EXPERIMENTAL|1|oral BD administration of 45 mg AZD5069
62427209|NCT03527537|ACTIVE_COMPARATOR|20% cutoff group|Treatment intervention will be initiated with insulin if 20% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.
62427210|NCT03527537|ACTIVE_COMPARATOR|40% cutoff group|Treatment intervention will be initiated with insulin if 40% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.
62735559|NCT01373008|PLACEBO_COMPARATOR|Inhaled placebo|Inhaled nonmedicated MDI \[metered dose inhaler\] in a similarly marked aerosol chamber using the same delivery technique, obtained from the drug manufacturer
62735560|NCT06174012|EXPERIMENTAL|Sodium Fluoride Group|
62735561|NCT06174012|NO_INTERVENTION|Conventional care group|
62735562|NCT01014936|EXPERIMENTAL|MSC2156119J Regimen 1|Subjects will be administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.
62427211|NCT04810507|EXPERIMENTAL|Anagliptin arm|Anagliptin 100 mg twice a day
62427212|NCT04810507|ACTIVE_COMPARATOR|Sitagliptin 100mg|Sitagliptin 100mg once a day
62427213|NCT05799859|ACTIVE_COMPARATOR|CAF + CM|Coronally advanced flap (CAF) and collagen matrix (CM)
62427214|NCT05799859|EXPERIMENTAL|CAF + CM +EMD|Coronally advanced flap (CAF), collagen matrix (CM) and additional application of enamel matrix derivatives (EMD).
62427215|NCT01918982||Aortic aneurysm|Patients with aortic aneurysm \>30mm and \< 50mm
62427216|NCT01589029|OTHER|CANAKINUMAB (ILARIS®)|
62427217|NCT04603079|EXPERIMENTAL|Currently practicing nurses who will receive intervention|An intervention for COVID-19 preventive protocols will be delivered to the nurses in the experiment group.
62427218|NCT04603079|NO_INTERVENTION|Currently practicing nurses who will not receive intervention|No intervention for COVID-19 preventive protocols will be delivered to the nurses in the control group.
62427219|NCT06007573|EXPERIMENTAL|treatment group|On the basis of the control group treatment, the treatment group also adopted the acupuncture treatment
62427220|NCT06007573|OTHER|control group|The control group received oral nimodipine tablets
62735563|NCT01014936|EXPERIMENTAL|MSC2156119J Regimen 2|Subjects will be administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.
62812854|NCT06532643|EXPERIMENTAL|Anti-CD20/CD30-CAR-T Cell Therapy|Investigational product: anti-CD20/CD30-CAR-T cells Route of administration: Intravenous injection Lymphodepleting chemotherapy regimen: A combination of fludarabine and cyclophosphamide will be administered prior to the infusion of anti-CD20/CD30-CAR-T cells.
62236782|NCT00185250|EXPERIMENTAL|Arm 1|
62236783|NCT00185250|EXPERIMENTAL|Arm 2|
62236784|NCT00185250|PLACEBO_COMPARATOR|Arm 3|
62236785|NCT00185250|PLACEBO_COMPARATOR|Arm 4|
62427221|NCT02915588|ACTIVE_COMPARATOR|Primary Active|Early postoperative isometric activation of the rotator cuff
62427222|NCT02915588|ACTIVE_COMPARATOR|Primary Passive|Standard postoperative passive movement rehabilitation protocol
62427223|NCT04175873|NO_INTERVENTION|Group C|Control group.
62427224|NCT04175873|EXPERIMENTAL|Group M|Music group.Preoperative 1 hour and during the operation of Classical Turkish Music (Acemaşiran makam) listening group
62427225|NCT05970809|EXPERIMENTAL|Device A|Device configuration A has metal and novel microneedles and lasers.
62035714|NCT02372396|EXPERIMENTAL|Compassion Meditation|Compassion Meditation delivered in 10 2-hour group treatment sessions.
62427226|NCT05970809|EXPERIMENTAL|Device B|Device configuration B has novel microneedles and lasers.
62035715|NCT02372396|ACTIVE_COMPARATOR|Relaxation|Relaxation delivered in 10 2-hour group treatment sessions.
62035716|NCT05283317|ACTIVE_COMPARATOR|Patients received MSCs|10 patients with sepsis and septic shock and received MSCs\&standart therapy
62035717|NCT05283317|NO_INTERVENTION|Patients not received MSCs|20 patients with sepsis and septic shock and not received MSCs, only received standart therapy
62236786|NCT00693316|EXPERIMENTAL|ORM-12741|
62236787|NCT00693316|PLACEBO_COMPARATOR|Placebo|
62236788|NCT01744951|EXPERIMENTAL|ADAPT|ADAPT is a manualized intervention with eight treatment modules designed as an early intervention for children, ages 5-14, who are being adopted from foster care and their adoptive parent/s.
62236789|NCT01744951|NO_INTERVENTION|Care as usual|Children, ages 5-14, and their adoptive parent/s will receive care as usual in the treatment setting.
62236790|NCT02129920||NVAF, acute ischemic stroke/TIA|Consecutive acute ischemic stroke/TIA patients with nonvalvular atrial fibrillation and treated with rivaroxaban
62236791|NCT00508248|ACTIVE_COMPARATOR|A1|1 g omega 3 fatty acid supplements
62236792|NCT00508248|PLACEBO_COMPARATOR|A2|
62236793|NCT03985085|EXPERIMENTAL|Intervention arm|
62236794|NCT04549025|EXPERIMENTAL|Monotherapy Cohort 1 (MC1)|Enrolled patients will receive 1000 mg pimivalimab (JTX-4014) administered alone every 6 weeks (q6w).
62236795|NCT04549025|EXPERIMENTAL|Combination Therapy Cohort 1 (CC1)|For Cycle 1, enrolled patients will receive 0.1 mg/kg vopratelimab (JTX-2011) on Day 1, followed by 1000 mg pimivalimab (JTX-4014) on Day 8. For Cycle 2 and beyond, vopratelimab and pimivalimab will be administered in combination (on Day 1) q6w.
62236796|NCT04549025|EXPERIMENTAL|Combination Therapy Cohort 2 (CC2)|For Cycle 1, enrolled patients will receive 0.03 mg/kg vopratelimab (JTX-2011) on Day 1, followed by 1000 mg pimivalimab (JTX-4014) on Day 8. For Cycle 2 and beyond, vopratelimab and pimivalimab will be administered in combination (on Day 1) q6w.
62427227|NCT02253654|EXPERIMENTAL|Epoetin alfa Alternative Titration|Participants received epoetin alfa administered intravenously three times a week during hemodialysis for up to 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose changes may have occurred every 2 weeks according to the alternative dosing algorithm, where smaller, frequent dose adjustments were permitted based on six hemoglobin categories.
62427228|NCT02253654|ACTIVE_COMPARATOR|Epoetin alfa USPI Titration|Participants received epoetin alfa administered intravenously three times a week during hemodialysis for 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose decreases were permitted every 2 weeks and beginning at week 5 dose increases could only occur ≥ 4 weeks from the last dose increase, according to the United States package insert (USPI) dosing algorithm which includes four categories of hemoglobin levels.
62427229|NCT04765852|EXPERIMENTAL|Experimental Group 1|High dose probiotic supplement and maltodextrin as the excipient
62427230|NCT04765852|EXPERIMENTAL|Experimental Group 2|Low dose probiotic supplement and maltodextrin as the excipient
62427231|NCT04765852|PLACEBO_COMPARATOR|Control Group|Placebo supplement containing only maltodextrin but having the same appearance as the probiotic supplements
62735564|NCT01014936|EXPERIMENTAL|MSC2156119J Regimen 3|Subjects will be administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.
62735565|NCT03863561||Waiting room sample|Patients with type 1 or type 2 diabetes attending an LMC Diabetes \& Endocrinology specialist clinic in Ontario completed the SCPI in the waiting room while attending their usual appointment with their healthcare provider.
62735566|NCT03863561||DSME Intervention|Patients with poor glycemic control (A1C \>8.0%) were enrolled into a diabetes self-management education (DSME) program. The SCPI was completed at their first and last visit and and their individual results were incorporated into the care paths that were then customized for that participant. The patient met with a diabetes educator five to seven times over the course of three to four months.
62735567|NCT03246516|EXPERIMENTAL|Questionnaire|Auto and hetero questionnaire
62735568|NCT04307069|EXPERIMENTAL|Immediate oxytocin infusion|Once the patient will arrive at the maternity ward with prelabor rupture of membranes, she will receive oxytocin for augmentation of labor.
62236797|NCT04464265|EXPERIMENTAL|Functional Magnetic Resonance Imaging|"While music is played Noninvasive functional magnetic resonance (fMRI) imaging will be performed at the University of Michigan Health System, University Hospital, Department of Radiology.~The fMRI is done under anesthesia using propofol. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations of 1.2, 1.6, 2.0, and 2.4 μg/ml in a stepwise fashion."
62236798|NCT02447757||Parturients with remifentanil analgesia|Parturients after induction of remifentanyl analgesia during the delivery
62236799|NCT05744271|EXPERIMENTAL|FES+VFBT|Functional electrical stimulation combined with visual feedback balance training
62236800|NCT04758182|EXPERIMENTAL|Experimental group|Experimental group: HILT + sham ultrasound therapy In the experimental group, participants received HILT treatment 1 session per day over a period of 2 consecutive weeks (5 days/week); total 10 sessions. In this study we used HIRO 3.0 device applied to the hemiplegic shoulder and the area of following muscles include upper trapezius, supraspinatus, deltoid, pectoralis minor muscles and the tender points. The treatment consisted of high peak power (3kW), a wavelength of 1064 nm. Two phases of treatment were performed according to Rotator cuff tendinopathy protocol of the device. The total energy administered will be approximately 2500 J. The total treatment time was approximately 10 minutes. They also received sham ultrasound therapy, which performed by applying probe with gel without turning on the device, for 10 minutes.
62236801|NCT04758182|ACTIVE_COMPARATOR|Control group|"Control group: sham HILT + ultrasound therapy In control group, participants received continuous ultrasound therapy for 10 minutes in the same area as an experimental group with Chattanooga intellect mobile ultrasound device. The device was operated at the frequency of 1 MHz, an intensity of 2 W/cm2 and a duty cycle of 100% in the same area of the HILT group. They also received sham HILT, by applying the applicator with pre-recorded sound without starting the device, for 10 minutes. Ultrasound therapy and sham ultrasound were delivered according to the predefined protocol by the physiotherapists.~Both groups received 3 ROM exercise sessions per day. Participants and their caregiver were educated about proper positioning and manual handling"
62236802|NCT00969046|EXPERIMENTAL|Bolus|20 min bolus infusion
62236803|NCT00969046|EXPERIMENTAL|CIV-1d|1 day continuous infusion
62236804|NCT00969046|EXPERIMENTAL|CIV-5d|5 day continuous infusion
62236805|NCT01507558|EXPERIMENTAL|Intervention|Perivascular administration of dexamethasone following endovascular superficial femoral and popliteal artery angioplasty or atherectomy.
62236806|NCT03545776||Educational program|"Medical and nursing staff will be given a 10-points EEG face-to-face initial training course that will be preceded by a pre-test evaluation and followed by delayed post-test evaluations.~Training will be followed by an online teaching consisting on additional questions and answers quizzes based on the 10 educational goals already described elsewhere.~In order to avoid any risk of intrasite contamination, all the learners benefiting from the training in the same department will be trained in a uniform time, with respect to the training schedule regarding post-test evaluations (day-1, day-15 and day-30). A final evaluation will be performed at day-90 after beginning of the training course."
62236807|NCT02411578|EXPERIMENTAL|G-Pen Mini™ (glucagon injection)|"Participants are to check blood glucose (BG) with study meter once their continuous glucose monitor (CGM) reads \<70 mg/dl or they experience symptoms. Participants will be instructed to treat using mini-dose glucagon for certain phases/periods when BG is 40 to 69 mg/dl (considered a non-severe hypoglycemic event).~For every event, participant will check BG with meter 3 times and treat according to protocol instructions based on BG measurement."
62236808|NCT02411578|ACTIVE_COMPARATOR|Glucose Tabs|"Participants are to check their blood glucose (BG) with study meter once their continuous glucose meter reads \<70 mg/dl or they experience symptoms. Participants will be instructed to treat using oral glucose tablets for certain phases/periods when BG is 40 to 69 mg/dl (considered a non-severe hypoglycemic event).~For every event, participant will check BG with meter 3 times and treat according to protocol instructions based on BG measurement."
62735569|NCT04307069|EXPERIMENTAL|Expectant management for 24 hours|Once the patient will arrive at the maternity ward with prelabor rupture of membranes, we will wait for spontaneous delivery to occur. After 24 hours of rupture of membranes, the woman will receive oxytocin for augmentation of labor.
62812855|NCT03806192|EXPERIMENTAL|Group A (psychoeducational counseling sessions via telephone)|Participants attend 5 psychoeducational counseling sessions over 30-60 minutes via telephone.
62236809|NCT03715309|EXPERIMENTAL|Revlimd|
62236810|NCT05722132|ACTIVE_COMPARATOR|One cycle-no monetary incentive|
62735570|NCT01415583|PLACEBO_COMPARATOR|Saline|Placebo is described in chart
62735571|NCT01415583|EXPERIMENTAL|Dexamethasone|Dexamethasone is described in chart
62735572|NCT02701244||Permanent Breast Seed Implant (PBSI)|Women with eligible early stage breast cancer who received a permanent breast seed implant status post lumpectomy
62735573|NCT02160249|EXPERIMENTAL|Community-based rehabilitation and facility based care|"Community-based rehabilitation is delivered to participants and their caregivers at their home by a specialist CBR worker. It comprises psychoeducation, adherence support, rehabilitation (including self-care and social skills), family support groups and accessing existing community organisations. It also involves community awareness raising and education and mobilisation of community leaders.~Facility based care (usual care) consists of anti-psychotic medication prescribed by a nurse or clinical officer in a health centre and basic psycho-education."
62735574|NCT02160249|ACTIVE_COMPARATOR|Facility-based care|Facility based care (usual care) consists of anti-psychotic medication prescribed by a nurse or clinical officer in a health centre and basic psycho-education.
62735575|NCT01760499|EXPERIMENTAL|Immunotherapy Followed by Surgery|PV-10 administration, adverse events assessment, surgery to remove melanoma tumors, follow-up visit.
62735576|NCT02046837|EXPERIMENTAL|Supervised 1:1 exercise|This intervention arm will include 3 one-on-one, supervised sessions per week for 6 months with a certified exercise specialist. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
62595245|NCT06618937|EXPERIMENTAL|Biomarker-guided drug withdrawal|"Patients with inactive disease, absence of sublinical synovitis at the joint level and normal S100A8/9 and hs-CRP leves will be randomly assigned to either an early biomarker-guided drug withdrawal protocol (interventional arm) or continuation of ongoing therapy at unchanged dose for an additional 6 months and then gradual tapering (control arm).~Patients will be evaluated at baseline, then every 3 months if still on treatment and every 6 months after drug withdrawal. At each timepoint the following procedures will be performed: joint assessment, Physician's Global Assessment of Overall Disease Activity, JAMAR, Uveitis assessment (in ANA positive patients), Hematology, chemistry, CRP, ESR, urine analysis according to drug specific schedule and Good Clinical Practice (GCP). Drug Adverse Events will be collected (MedDRA).~MSUS and serum biomarkers quantification (S100A8/9, hs-CRP) will be repeated every 3 months until month 18 in patients with subclinical synovitis and pathologic values"
62236811|NCT05722132|ACTIVE_COMPARATOR|One cycle-fixed amount of incentive|
62236812|NCT05722132|ACTIVE_COMPARATOR|One cycle-raffle as incentive|
62236813|NCT05722132|ACTIVE_COMPARATOR|4 cycles- no monetary incentive|
62595246|NCT06618937|NO_INTERVENTION|Gradual tapering|The control arm will continue ongoing therapy at unchanged dose for an additional 6 months and then will gradually taper the therapy.
62595247|NCT04603768|EXPERIMENTAL|Theraband exercises|Group A: baseline physical therapy treatment along with theraband exercises
62236814|NCT05722132|ACTIVE_COMPARATOR|4 cycles- fixed amount of incentive|
62236815|NCT05722132|ACTIVE_COMPARATOR|4 cycles- raffle as incentive|
62236816|NCT01608542|EXPERIMENTAL|Fostamatinib 100mg|Up to two cohorts of Japanese subjects are planned to receive fostamatinib 100mg single and multiple twice daily doses
62236817|NCT01608542|EXPERIMENTAL|Fostamatinib 200mg|Up to two cohorts of Japanese subjects are planned to receive fostamatinib 200mg single and multiple twice daily doses
62236818|NCT05439434|EXPERIMENTAL|intervention group|
62427232|NCT02595528|EXPERIMENTAL|AGN-199201 and AGN-190584 Vehicle|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
62595248|NCT04603768|EXPERIMENTAL|Co-contraction exercises|Group B: baseline physical therapy treatment along with co-contraction exercises
62812856|NCT03806192|EXPERIMENTAL|Group B (psychoeducational counseling sessions in person)|Participants attend 5 psychoeducational counseling sessions over 30-60 minutes via video teleconference.
62812857|NCT00547508|PLACEBO_COMPARATOR|1|Placebo
62812858|NCT00547508|PLACEBO_COMPARATOR|2|Placebo
62812859|NCT00547508|ACTIVE_COMPARATOR|3|tadalafil
62812860|NCT00547508|ACTIVE_COMPARATOR|4|tadalafil
62812861|NCT00547508|ACTIVE_COMPARATOR|5|tadalafil
62812862|NCT00547508|ACTIVE_COMPARATOR|6|tadalafil
62812863|NCT05001035|EXPERIMENTAL|Zinc carbonated hydroxy apatite|Toothpaste to be added on white spot lesions in dental enamel
62236819|NCT06323122||group (I)|ORIF was done using two 2.0 miniplates
62236820|NCT06323122||Group II|ORIF was done using 2.3 high profile miniplates
62236821|NCT06323122||Group III|ORIF was done using 3D miniplates.
62236822|NCT00483314|EXPERIMENTAL|1|
62236823|NCT02909270|EXPERIMENTAL|Mediclore|adhesion barrier Mediclore 5cc, to apply medical device fully around thyroid gland following thyroidectomy
62236824|NCT02909270|NO_INTERVENTION|No treatment|No treatment, standard treatment for thyroidectomy
62236825|NCT04890678|EXPERIMENTAL|22 residentsat risk for PU development|"22 residents at risk for PU development, defined by a Braden score \< 12 and/or a Braden subscale 'Mobility' score ≤ 2 and/or the presence of non-blanchable erythema in the sacral area.~aged 65 years or over"
62236826|NCT04890678|EXPERIMENTAL|18 residents at least one PU category III-IV in the sacral area|18 residents at least one PU category III-IV in the sacral area aged 65 years or over
62236827|NCT02069210||Blood transfusion|Patients receive blood transfusion during operation
62236828|NCT04683640|EXPERIMENTAL|Daily Oral GABA|You will take, by mouth, 2 pills of GABA (500 mg) (Capsule 250mg) daily at home for 4 weeks
62236829|NCT04683640|PLACEBO_COMPARATOR|Daily Placebo|You will take, by mouth, 2 pills of Placebo daily at home for 4 weeks
62236830|NCT00551902|EXPERIMENTAL|1|Trabeculectomy with anterior chamber infusion system
62236831|NCT00551902|ACTIVE_COMPARATOR|2|Trabeculectomy without anterior chamber infusion system
62236832|NCT04261582||AERD participants|Participants with aspirin exacerbated respiratory disease. Adults with aspirin allergy, nasal polyps and adult-onset severe asthma.
62236833|NCT04261582||Healthy controls|Healthy participants that do not have asthma.
62812864|NCT05001035|EXPERIMENTAL|Bioactive glass|Toothpaste to be added on white spot lesions in dental enamel
62595249|NCT04603768|EXPERIMENTAL|isometric exercises|Group C: baseline physical therapy treatment along with isometric exercises
62035718|NCT06431282|ACTIVE_COMPARATOR|CO2 laser + HA|Probands are treated with a CO2 laser. Afterwards a HA gel will be applied.
62236834|NCT04261582||Non-aspirin sensitive asthma participants|Participants with asthma, but that do not have a sensitivity to aspirin.
62236835|NCT01486771|EXPERIMENTAL|IV Macugen Q6|Will receive 3 intravitreal pegaptanib injections at 6-week intervals, then 3 additional injections at 12-week intervals
62236836|NCT01486771|EXPERIMENTAL|IV Mac Q6 Arm|Will Selective Laser Photocoagulation after 3 intravitreal pegaptanib injections
62427233|NCT02595528|EXPERIMENTAL|AGN-199201 and AGN-190584 Dose A|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
62595250|NCT02984969||Slow transit constipation|subjects met the Rome III criteria for STC
62595251|NCT02984969||Healthy subjects|Healthy controls
62595252|NCT03699462|ACTIVE_COMPARATOR|Plasma A group|The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
62595253|NCT03699462|EXPERIMENTAL|Albumin group|The group receiving receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
62595254|NCT04264390|EXPERIMENTAL|M2M|Participants will receive and be instructed to follow-along with 4 weeks of movement-to-music videos. Participants will also receive periodic behavioral coaching calls from a telecoach.
62812865|NCT05001035|EXPERIMENTAL|Poly amido amine|Resinous material to be painted on white spot lesions in dental enamel
62595255|NCT04264390|NO_INTERVENTION|Wait-list control|Participants will wait 4 weeks before starting the M2M program. Participants will be instructed to resume their normal daily activities during the wait-period.
62595256|NCT01413789|EXPERIMENTAL|Patients and healthy volunteers|Patients with healed full thickness burns and healthy volunteers will be included in the study
62595257|NCT05911828|ACTIVE_COMPARATOR|ZY19489 + Ferroquine (FQ)|"A single daily dose 600 mg ZY19489 + 600 mg FQ, or 900 mg ZY19489 + 900 mg FQ are selected as the doses to be evaluated in Cohort 1 and 2, respectively. A daily dose of 600 mg ZY19489 + 600 mg FQ will be administered daily for 2 days in Cohort 3.~ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h."
62595258|NCT05911828|PLACEBO_COMPARATOR|Placebo|ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
62035719|NCT06431282|ACTIVE_COMPARATOR|Thulium laser + HA|Probands are treated with a thulium laser. Afterwards a HA gel will be applied.
62035720|NCT05216094|EXPERIMENTAL|smart phone intervention group|smart phone intervention group stroke subjects completed smart phone App tasks with affected upper limb or bilateral arm movement for 12 weeks
62035721|NCT05216094|ACTIVE_COMPARATOR|conventional group|stroke subjects receive conventional rehabilitation home program for 12 weeks
62035722|NCT01229098|EXPERIMENTAL|LEO 80185|
62035723|NCT04876248|EXPERIMENTAL|Treatment (belantamab mafodotin, lenalidomide)|Patients receive belantamab mafodotin IV over 30 minutes on day 1 and lenalidomide PO QD on days 1-28. Treatment repeats every 8 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity.
62236837|NCT01486771|EXPERIMENTAL|Pan Retinal Photocoagulation|Will act as the control group, thus subjects in this group will receive standard PRP (modified ETDRS protocol)
62236838|NCT01178671|EXPERIMENTAL|Sertraline and Mirtazapine|Flexible dose of both medications for up to 24 weeks
62236839|NCT01178671|ACTIVE_COMPARATOR|Sertraline and Sugar pill|Sertraline and Sugar pill for up to 24 weeks
62236840|NCT00499629|ACTIVE_COMPARATOR|1|Arm 1: FXR 450
62236841|NCT00499629|PLACEBO_COMPARATOR|2|Placebo
62236842|NCT02745392|EXPERIMENTAL|ZP-Zolmitriptan 1 mg|ZP-Zolmitriptan 1 mg patch single administration
62236843|NCT02745392|EXPERIMENTAL|ZP-Zolmitriptan 1.9 mg|ZP-Zolmitriptan 1.9 mg patch single administration
62236844|NCT02745392|EXPERIMENTAL|ZP-Zolmitriptan 3.8 mg|ZP-Zolmitriptan 3.8 mg (1.9 mg x 2 patches) single administration
62236845|NCT02745392|PLACEBO_COMPARATOR|Placebo|Placebo (either single or double patch) single administration
62243441|NCT06735235|OTHER|Period 3|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
62595259|NCT06418477|EXPERIMENTAL|Dara-CyBorD|"Daratumumab:~Cyclophosphamide Bortezomib Dexamethasone"
62595260|NCT04237844||no BPD|In preterm infants(GA\<32 weeks and hospital day\>14 days )，infants without BPD
62595261|NCT04237844||classic BPD|In preterm infants(GA\<32 weeks and hospital day\>14 days )，There are clinical manifestations and imaging evidence of RDS after birth, the condition is not relieved, FiO2 lasts \>25%
62812866|NCT05001035|NO_INTERVENTION|Control|No material to be added
62812867|NCT02134223|EXPERIMENTAL|dialectical behavior therapy|Primary intervention group: receiving one year of dialectical behavior therapy
62812868|NCT02134223|PLACEBO_COMPARATOR|treatment as usual|Comparison group: receiving one year of treatment as usual
62812869|NCT02134223|NO_INTERVENTION|Receiving no treatment at all|Healthy control group
62812870|NCT06253702|EXPERIMENTAL|Placebo First: Hormone Suppression|Participants drug (placebo vs Indo) are randomized prior to first set of MRI visits, while experiencing hormone suppression.
62812871|NCT06253702|EXPERIMENTAL|Indo First: Hormone Suppression|Participants drug (placebo vs Indo) are randomized prior to first set of MRI visits, while experiencing hormone suppression.
62812872|NCT06253702|EXPERIMENTAL|Placebo First: Hormone Add-Back|Participants drug (placebo vs Indo) are randomized prior to second set of MRI visits, while experiencing hormone add-back.
62035724|NCT04551378||Observational (survey)|Patients and survivors complete a survey online over 20-30 minutes at baseline about COVID-19 specific psychological distress, health care utilization, health behavior, social and financial disruptions, HRQoL, their social support, perceived benefits under times of stress, and the ability to manage stress. Patients and survivors may be contacted again at 6 months and 1 year for COVID-19 research.
62812873|NCT06253702|EXPERIMENTAL|Indo First: Hormone Add-Back|Participants drug (placebo vs Indo) are randomized prior to second set of MRI visits, while experiencing hormone add-back.
62035725|NCT01250977|PLACEBO_COMPARATOR|Placebo|Participants are instructed to take one placebo pill every night before going to bed with a glass of water for 28 days.
62035726|NCT01250977|EXPERIMENTAL|Donepezil|Participants are instructed to take one 5mg pill (donepezil HCL \[Aricept®\]) every night before going to bed with a glass of water for 28 days.
62035727|NCT03664687|ACTIVE_COMPARATOR|Zoledronate one dose (4 mg)|One 4 mg dose of Zoledronate
62035728|NCT03664687|ACTIVE_COMPARATOR|Zoledronate 4 mg every 6 months x 3 years|One 4 mg dose of Zoledronate given every 6 months for 3 years
62035729|NCT01538550|EXPERIMENTAL|Flexible sigmoidoscopy|70,000 men and women at age 50-74 years are randomised from the population registry to be invited to have a screening examination using flexible sigmoidoscopy once-only
62035730|NCT01538550|EXPERIMENTAL|iFOBT|70,000 men and women at age 50-74 years randomised from the population registry to be invited to have a screening examination biennially using an immunochemical test for fecal occult blood testing (iFOBT).
62035731|NCT04068753|EXPERIMENTAL|Niraparib + dostarlimab|
62595262|NCT04237844||BPD after RDS|In preterm infants(GA\<32 weeks and hospital day\>14 days )，There are clinical manifestations and imaging evidence of RDS after birth. FiO2\<23% within 7 days, and the condition is aggravated to FiO2\>25%.
62236846|NCT04757350||cataract|Research subjects should meet the following criteria: Signed and dated informed consent form Commitment to abide by the research procedures and cooperate with the implementation of the whole process of research 18-90-year-old cataract patients or patients after cataract surgery
62236847|NCT01198353|EXPERIMENTAL|Ziprasidone|During the 12-week study period, patients were prescribed ziprasidone at 20 to 160 mg/day flexibly based on their effectiveness and tolerability. Fifty to one hundred percent of the past antipsychotic dose was maintained in the first week; during next 3 weeks, flexible dosing of 0-100% was used; then, ziprasidone was discontinued. This study included four visits: baseline, week 4, week 8, and week 12. Concomitant benzodiazepines (oral formula or injection) were allowed up to a dose of 4 mg of lorazepam-equivalents per day for anxiety and agitation.
62236848|NCT03602456||Kentucky HEALTH|This group will consist of 90% of eligible beneficiaries who will receive Kentucky HEALTH benefits throughout the 5-year demonstration waiver.
62236849|NCT03602456||Traditional Medicaid (control)|This group will consist of 10% of eligible beneficiaries who will continue receiving traditional Medicaid benefits as in place before July 1, 2018 throughout the 5-year demonstration waiver.
62812874|NCT03820596|EXPERIMENTAL|Sintilimab+Chidamide|"Sintilimab：200mg(fixed dosage), ivd, qd, q21d~Chidamide:~Phase I: 20mg-30mg,biw,continued oral，to evaluate RP2D. Phase II：RP2D，continued oral"
62236850|NCT01810237|EXPERIMENTAL|Dabigtran instead of LMWH for perioperative bridging.|
62236851|NCT06079489|ACTIVE_COMPARATOR|Control Group|Participants were advised to repeat the brochure-based exercises 3 days a week for 8 weeks. Correct sitting and standing positions and ergonomic materials were also explained in detail. Participants' adherence to the exercise program was tracked by an exercise diary.
62243442|NCT06735235|OTHER|Period 4|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
62243443|NCT00633711|ACTIVE_COMPARATOR|fixed CPAP|
62812875|NCT03608319|EXPERIMENTAL|Single dose following overnight fast|
62812876|NCT03608319|EXPERIMENTAL|Single dose following high fat breakfast|
62812877|NCT03608319|EXPERIMENTAL|Single dose sprinkled on applesauce following overnight fast|
62812878|NCT01908426|EXPERIMENTAL|Cabozantinib (XL184)|Cabozantinib (XL184) 60 mg tablet once daily
62035732|NCT01221987||Cohort A|Females \> 21 years of age, diagnosed with invasive cervical cancer
62035733|NCT01221987||Cohort B|Females \> 21 years of age, diagnosed with moderate or severe cervical intraepithelial neoplasia
62035734|NCT04778033||Vaccinated Men|Fertile men who were vaccinated with the BNT162b2 COVID-19 Vaccine
62035735|NCT02114593|EXPERIMENTAL|Parent support program|Parent support program
62035736|NCT02114593|NO_INTERVENTION|Standard activities|Standard activities
62035737|NCT02570490|EXPERIMENTAL|CEM-102 (Sodium fusidate)|1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy (10 days total)
62035738|NCT02570490|ACTIVE_COMPARATOR|Linezolid|600 mg by mouth every 12 hours for 10 days
62035739|NCT05556681|EXPERIMENTAL|Treated with the investigational BD™ Sirolimus Drug Coated Catheter|Patients treated with the BD™ Sirolimus Drug Coated Catheter
62035740|NCT03624101|EXPERIMENTAL|Trikafta|If the participant is not on a current modulator, they will take Trikafta for 28 days followed by a 28 day off period. This cycle will be continued for 168 days
62243444|NCT00633711|EXPERIMENTAL|Auto-CPAP|"Auto-CPAP Weinmann Somnosmart2"
62595263|NCT04237844||Delayed BPD|In preterm infants(GA\<32 weeks and hospital day\>14 days )，There is no RDS performance after birth, FiO2 lasts \<25%
62595264|NCT04237844||Early, lethal BPD|In preterm infants(GA\<32 weeks and hospital day\>14 days )，Some infants who die before 36 weeks PMA (between 14 days of postnatal age and 36 weeks) due to persistent parenchymal lung disease and respiratory failure that can not be attributable to other neonatalmorbidities
62812879|NCT01908426|PLACEBO_COMPARATOR|Placebo|Oral cabozantinib-matched placebo tablet once daily
62812880|NCT00647517|EXPERIMENTAL|ultracet|
62812881|NCT00647517|PLACEBO_COMPARATOR|placebo|
62812882|NCT04482517|OTHER|Density Gradient Centrifugation (DGC)|Using the routine DGC sperm processing only
62812883|NCT04482517|ACTIVE_COMPARATOR|Physiological ICSI (PICSI)|Using PICSI dish for selecting sperm with lower sperm DNA fragmentation
62812884|NCT04482517|ACTIVE_COMPARATOR|Magnetic Activated Cell Sorting (MACS)|Using MACS for selecting sperm with lower sperm DNA fragmentation
62812885|NCT04482517|ACTIVE_COMPARATOR|Testicular sperm (Testi)|Using testicular sperm not ejaculated sperm
62812886|NCT05306964|ACTIVE_COMPARATOR|Restrictive UFnet Strategy|Fluid removal will be titrated to keep net ultrafiltration rate between 0.5-1.5 mL/kg/h
62236852|NCT06079489|EXPERIMENTAL|Experimental Group|Progressive physical fitness and posture exercises were given via telerehabilitation 3 days a week for 8 weeks. Specific exercises for upper extremities, lower extremities, neck, trunk and lower back were selected and progressed by changing the frequency, duration and variety within the program. All exercises were performed under the supervision of a physiotherapist during video conference calls lasting an average of 40 minutes. Correct sitting and standing positions and ergonomic materials were also explained in detail. Participants' adherence to the exercise program was tracked by an exercise diary.
62812887|NCT05306964|ACTIVE_COMPARATOR|Liberal UFnet Strategy|Fluid removal will be titrated to keep net ultrafiltration rate between 2.0-5.0 mL/kg/h
62812888|NCT03867214|EXPERIMENTAL|Experimental|"Receiving TXA, Study group~Tranexamic acid, Study group tranexamic acid 1g,~intravenous injection, pre-operationally"
62812889|NCT03867214|PLACEBO_COMPARATOR|Placebo Comparator|"Normal saline, Control group~Not receiving tranexamic acid, Control group Normal~saline 100mL, intravenous injection, pre-operationally"
62812890|NCT06322849|EXPERIMENTAL|Arm 1|"Experimental: Breathing exercise + active elements 1, 2, 3~In this arm, all three factors are set to active (i.e. yes):~* Psychoeducation~* Testimonials and Saying is believing exercises~* Action planning"
62427234|NCT02595528|EXPERIMENTAL|AGN-199201 and AGN-190584 Dose B|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
62236853|NCT01037907|EXPERIMENTAL|BGC20-0134 (Pleneva TM)|Structured lipid
62236854|NCT01037907|PLACEBO_COMPARATOR|Placebo control|Placebo - dummy pill
62595265|NCT05731037|ACTIVE_COMPARATOR|Short restitution group (SR)|Resistance training for knee extensors three training session per week.
62595266|NCT05731037|EXPERIMENTAL|Extended restitution group (ER)|Resistance training for knee extensors on training session per week (greater restitution from loading).
62812891|NCT06322849|EXPERIMENTAL|Arm 2|"Experimental: Breathing exercise + active elements 1, 2~In this arm, two factors are set to active (i.e. yes):~* Psychoeducation~* Testimonials and Saying is believing exercises"
62812892|NCT06322849|EXPERIMENTAL|Arm 3|"Experimental: Breathing exercise + active elements 1, 3~In this arm, two factors are set to active (i.e. yes):~* Psychoeducation~* Action planning"
62812893|NCT06322849|EXPERIMENTAL|Arm 4|"Experimental: Breathing exercise + active elements 2, 3~In this arm, two factors are set to active (i.e. yes):~* Testimonials and Saying is believing exercises~* Action planning"
62812894|NCT06322849|EXPERIMENTAL|Arm 5|"Experimental: Breathing exercise + active element 1~In this arm, one factor is set to active (i.e. yes):~• Psychoeducation"
62812895|NCT06322849|EXPERIMENTAL|Arm 6|"Experimental: Breathing exercise + active element 2~In this arm, one factor is set to active (i.e. yes):~• Testimonials and Saying is believing exercises"
62812896|NCT06322849|EXPERIMENTAL|Arm 7|"Experimental: Breathing exercise + active element 3~In this arm, one factor is set to active (i.e. yes):~• Action planning"
62812897|NCT06322849|EXPERIMENTAL|Arm 8|"Experimental: Breathing exercise only~In this arm, none of the three factors are set to active (i.e. yes)"
62812898|NCT01447654|ACTIVE_COMPARATOR|Losartan|
62812899|NCT01447654|PLACEBO_COMPARATOR|Placebo|
62595267|NCT02107105||Observational (questionnaire)|Patients complete quality of life questionnaires over 20-30 minutes at baseline, 6 and 12 months after surgery, and 2, 3, 4, and 5 years after surgery.
62595268|NCT03070340|EXPERIMENTAL|Breast MRI and Contrast Enhanced Mammography (CEDM)|Breast MRI and CEDM will be performed within 30 days of one another after neoadjuvant therapy
62236855|NCT06394440|EXPERIMENTAL|Self-Adhesive Bulkfill Composite Restoration|Surefil One from Dentsply will be applied to one side of teeth that contain cervical cavities.
62236856|NCT06394440|ACTIVE_COMPARATOR|Nano-hybrid Composite|Neospectra from Dentsply will be added after etching \& bonding to the other side of the teeth that contain cervical cavities.
62236857|NCT02463188|EXPERIMENTAL|Sleep Fitness Intervention|The intervention consists of 5-7 sessions on sleep science, the connection between sleep and substance use, behavior change strategies, and motivation to change behavior.
62595269|NCT01181544|EXPERIMENTAL|Heparin dose titration|
62595270|NCT03806699|EXPERIMENTAL|Low dose ID93+GLA-SE|Participants will receive 0.5 mL (2 μg ID93 + 5 μg GLA-SE) intramuscular injection (IM) into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
62595271|NCT03806699|EXPERIMENTAL|High dose ID93+GLA-SE|Participants will receive 0.5 mL (10 μg ID93 + 5 μg GLA-SE) IM injection into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
62595272|NCT03806699|PLACEBO_COMPARATOR|Control group|Participants will receive 0.5 mL (physiological saline) IM injection into deltoid area, three times on 4-week intervals on Days 0, 28, and 56.
62595273|NCT00532194|PLACEBO_COMPARATOR|A (reference)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral placebo tablet for the duration of chemotherapy and then until protocol defined disease progression occurs.
62595274|NCT00532194|ACTIVE_COMPARATOR|B (concurrent cediranib)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy only and then an oral daily placebo tablet until protocol defined disease progression occurs.
62035741|NCT03624101|EXPERIMENTAL|Symdeko/Trikafta|If the participant currently takes Symdeko , they will take Trikafta for a 28 day period followed by Symdeko for a 28 day period. This cycle will be continued for 168 days
62236858|NCT02463188|NO_INTERVENTION|Psychoeducation (PE)|The control classes will receive an 1-session psycho-educational (PE) intervention that provides information on sleep but does not provide guidance for implementing behavior change and does not explicitly teach about sleep's relationship to substance use.
62236859|NCT05828043|NO_INTERVENTION|Usual care group|Provide conventional health educations in every three-month interval
62236860|NCT05828043|EXPERIMENTAL|Multidomain intervention group|The multidomain intervention program is designed as structural training sessions of 2-hour training sessions two times per week.
62236861|NCT00647673|EXPERIMENTAL|1|Verapamil HCL Extended-Release Capsules 300 mg
62236862|NCT00647673|ACTIVE_COMPARATOR|2|Verelan® PM Extended-release Capsules 300 mg
62236863|NCT00895674||Group 1|
62236864|NCT00429312|EXPERIMENTAL|Single Arm|Intratumoral injection(s) of Recombinant Vaccinia GM-CSF, JX-594
62595275|NCT00532194|ACTIVE_COMPARATOR|C (concurrent and maintenance cediranib)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy until protocol defined disease progression occurs.
62595276|NCT06621095|EXPERIMENTAL|anlotinib + benmelstobart + nab-paclitaxel + gemcitabine|Initial treatment: anlotinib + benmelstobart + nab-paclitaxel + gemcitabine. Maintenance treatment (after 8 cycles): anlotinib + benmelstobart + gemcitabine.
62595277|NCT06621095|ACTIVE_COMPARATOR|nab-paclitaxel + gemcitabine|Initial treatment: nab-paclitaxel + gemcitabine. Maintenance treatment (after 8 cycles): gemcitabine.
62595278|NCT00567489|ACTIVE_COMPARATOR|Non glucose sparing|Dianeal only
62595279|NCT00567489|EXPERIMENTAL|glucose sparing|PEN solutions: Nutrineal, Extraneal, and Physioneal
62236865|NCT00150969|EXPERIMENTAL|phyloquinone|5 mg Vitamin K1
62236866|NCT00150969|PLACEBO_COMPARATOR|placebo|
62812900|NCT00774046|EXPERIMENTAL|Induction chemotherapy followed by stem cell transplant|Ara-C Mitoxantrone Etoposide Stem cell mobilization Autologous transplant
62595280|NCT01088880|EXPERIMENTAL|Canakinumab|
62595281|NCT01486901|EXPERIMENTAL|Formulation A|
62595282|NCT01486901|ACTIVE_COMPARATOR|Formulation B|
62812901|NCT05400317|EXPERIMENTAL|Active Comparator : Test group|AD-218
62812902|NCT05400317|ACTIVE_COMPARATOR|Active Comparator : Control group|AD-218A
62812903|NCT00988832||Infliximab|Infliximab as prescribed by a physician in normal practice for Crohn's disease
62812904|NCT00994552|ACTIVE_COMPARATOR|Pressure support ventilation|Pressure support ventilation
62812905|NCT00994552|ACTIVE_COMPARATOR|Pressure control ventilation|Pressure control ventilation
62812906|NCT04498221|EXPERIMENTAL|Imaging Phase|During routine examination under anaesthetic 4 x peritumoural injection of investigator's choice of 99mTc-human albumin colloidal particles or Lymphoseek (lymphatic mapping tracer) followed by freehand SPECT scan
62236867|NCT01475578|EXPERIMENTAL|STA-1|"STA-1 capsule (Cistanche tubulosa), 2 capsules/time, 3 times/day, orally~Dummy Ergoloid Mesylates tablet (Placebo), 2 tablets/time, 3 times/day, orally"
62035742|NCT03624101|EXPERIMENTAL|Ivacaftor/Trikafta|If the participant currently takes Ivacaftor , they will take Trikafta for a 28 day period followed by Ivacaftor for a 28 day period. This cycle will be continued for 168 days
62035743|NCT00423176|EXPERIMENTAL|MFNS + Antibiotic|Mometasone furoate nasal spray (MFNS) twice daily (BID) for 29 days, plus antibiotic. Appropriate antibiotic therapy amoxicillin/clavulanic acid BID.
62236868|NCT01475578|ACTIVE_COMPARATOR|Ergoloid Mesylates|"Ergoloid Mesylates tablet, 2 tablets/time, 3 times/day, orally before meal~Dummy STA-1 capsule (Placebo), 2 capsules/time, 3 times/day, orally"
62236869|NCT01603537||PHTLS|The exposure is defined from the dichotomization of the probability in each event/accident that at least one of the caring ambulance crew members was PHTLS certified.
62236870|NCT01603537||No PHTLS|Not exposed to PHTLS
62236871|NCT00339170|EXPERIMENTAL|1|Participants receive a 12-month cognitive enhancement training program plus a 12-month work therapy program.
62236872|NCT00339170|ACTIVE_COMPARATOR|2|Participants receive a 12-month work therapy program alone.
62236873|NCT01742598|EXPERIMENTAL|Portico Implant|
62236874|NCT02827136|EXPERIMENTAL|Patch group|Lidocaine patch and Hypafix
62236875|NCT02827136|PLACEBO_COMPARATOR|Control group|Just Hypafix
62595283|NCT05672017|ACTIVE_COMPARATOR|Dietary Instructions: Increase sweet food consumption|Participants are asked to increase their consumption of sweet foods throughout their diet. Participants will be provided with clear instructions, where sweet foods will be highlighted and additional means of increasing sweet food consumption will be offered.
62595284|NCT05672017|ACTIVE_COMPARATOR|Dietary Instructions: Decrease sweet food consumption|Participants are asked to decrease their consumption of sweet foods throughout their diet. Participants will be provided with clear instructions, where sweet foods will be highlighted and means of decreasing sweet food consumption will be offered.
62035744|NCT00423176|PLACEBO_COMPARATOR|Placebo|Matching placebo nasal spray BID for 29 days, plus amoxicillin/clavulanic acid BID
62035745|NCT05022680|EXPERIMENTAL|Participants were used app to record their diet and steps every day|Experimental group was the mHealth with peer led to improved their physical activity during pregnancy. Participants received app to record and monitor their physical activity every days and using it until childbirth.
62035746|NCT05022680|NO_INTERVENTION|non-mhealth|control group was the traditional prenatal care during pregnancy.
62236876|NCT00638612|EXPERIMENTAL|A resectable|Arm A is for resectable tumors. The first AdV-tk course is given prior to surgery by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery again followed by 14 days of valacyclovir.
62035747|NCT05278455|EXPERIMENTAL|Lifestyle Medicine Group|Lifestyle medicine smartphone app The lifestyle medicine app contains eight weekly modules that cover healthy eating, exercise, stress management, sleep management, lifestyle psychoeducation, and goal setting.
62035748|NCT05278455|NO_INTERVENTION|Waitlist Control Group|The waitlist control group will receive access to the lifestyle medicine app at the end of the study.
62595285|NCT05672017|PLACEBO_COMPARATOR|Dietary Instructions: Usual Diet|Participants are asked to retain their consumption of sweet foods throughout their diet.
62595286|NCT04662528|PLACEBO_COMPARATOR|Placebo|
62595287|NCT04662528|EXPERIMENTAL|MAT9001 (omega-3-pentaenoic acid)|
62595288|NCT03696108|EXPERIMENTAL|Gefapixant 15 mg BID|Participants will receive gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg twice daily (BID) during the study period (52 weeks).
62035749|NCT05260801|EXPERIMENTAL|Bright lighting followed by Placebo lighting|Each lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The order of conditions will be randomized.
62236877|NCT00638612|EXPERIMENTAL|B locally advanced|"Arm B is for locally advanced tumors for which chemoradiation is the planned standard of care treatment. AdV-tk is delivered by CT or EUS guided injection into the tumor. The first AdV-tk injection is given prior to starting chemoradiation and the second in week 3 of chemoradiation. Both injections are followed by 14 days of valacyclovir.~Enrollment has been completed for Arm B."
62236878|NCT04847960|EXPERIMENTAL|L.reuterii probiotic lozenges from BioGaia|Subjects were willing to provide 2 samples of saliva, dental plaque and gingival fluid (gum fluid), on the first day (before consuming lozenges) and on the 14th day after the subject consumed lozenges containing L. reuteri probiotic. Probiotics are taken once a day for two weeks after breakfast and brushing their teeth.
62236879|NCT04556643|EXPERIMENTAL|Intervention Group|Two sessions will be given to pregnant women in Intervention group. One session breathing exercises training will be given during first stage of labor by the investigator. During training all participants in Intervention group will be instructed to perform breathing exercises during the second stage of labor.
62236880|NCT04556643|NO_INTERVENTION|Control Group|Usual hospital delivery protocol will be followed.
62236881|NCT01195142||PCOS-CSAT|Women with PCOS
62236882|NCT01195142||Control-CSAT|Control population consisting of women without PCOS, matched for age and BMI with the PCOS cohort
62243445|NCT04555837|EXPERIMENTAL|Treatment (alisertib, pembrolizumab)|Patients receive alisertib PO BID on days 1-7 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62812907|NCT04498221|EXPERIMENTAL|Surgical Phase|Excision of contralateral nodes identified on imaging \*(fhSPECT or SPECT/CT\*) during routine examination under anaesthetic. Serial sectioning of excised (sentinel) nodes to identify micrometastasis.
62812908|NCT02641925|ACTIVE_COMPARATOR|Omentum preserving|Omentum preserving: The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed.
62236883|NCT04750356||Cohort A1|Healthcare workers and patients that have previously undertaken a swab or serology test to detect for the presence of SARS-CoV-2. Without the need to seek retrospective consent for the SARS CoV 2 Longitudinal Study, residual samples and derivatives from the Crick COVID -9 Consortium Testing centre and data will be used for the study
62035750|NCT05260801|EXPERIMENTAL|Placebo lighting followed by bright lighting|Each lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The order of conditions will be randomized.
62812909|NCT02641925|EXPERIMENTAL|Total omentectomy|Total omentectomy: Whole omentum will be removed.
62035751|NCT01338363||All first time users of esomeprazole|
62035752|NCT01338363||All first time users of other PPIs|
62035753|NCT01338363||All first time users of H2-receptor antagonists|
62035754|NCT03586102|EXPERIMENTAL|High protein supplementation|Infants will receive a diet that consists of mother's own milk or donor human milk and bovine-based human milk fortifier plus a fixed amount of commercially available hydrolyzed bovine protein. The study intervention will begin the day after fortification is ordered and will be continued until postnatal day 50 or 32 weeks postmenstrual age, whichever occurs first.
62035755|NCT03586102|ACTIVE_COMPARATOR|Standard protein supplementation|Infants will receive a standard diet that consists of mother's own milk or donor human milk (DHM) and bovine-based human milk fortifier. The study intervention will be continued until postnatal day 50 or 32 weeks postmenstrual age, whichever occurs first.
62236884|NCT04750356||Cohort A2|3,000 SARS-CoV-2 positive and 3,000 SARS-CoV-2 negative participants (randomly selected) from cohort A1 will be prospectively consented to the study. In addition, vaccine status will also be used to stratify the participants and recruit to the study.
62595289|NCT03696108|EXPERIMENTAL|Gefapixant 45 mg BID|Participants will receive gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the study period (52 weeks).
62595290|NCT04497870|ACTIVE_COMPARATOR|540 mg|Peppermint oil at a dose of 180 mg thrice daily orally
62035756|NCT01308918||GlideScope DLT intubation|Patients having a thoracic surgery (non cardiac) via either thoracoscopy or thoracostomy. Patients were all 18 years old or over, and have read, understood and signed an informed consent at the preoperative evaluation or on surgery morning.
62035757|NCT05150704|EXPERIMENTAL|Experimental arm|Pulsed corticosteroid therapy (methylprednisolone 1 g IV qd for 3 days diluted in saline solution 250 mL) on top of standard therapy and maximal supportive care
62035758|NCT05150704|PLACEBO_COMPARATOR|Control arm|Placebo (saline solution 250 mL IV qd for 3 days) on top of standard therapy and maximal supportive care.
62035759|NCT03827187|EXPERIMENTAL|Motor imagery based Brain computer interfacing|Brief assessment of motor imagery in response to command, auditory feedback training and responding to binary yes-no closed questions through Electroencephalography based Brain-computer interfacing.
62236885|NCT04750356||Cohort B|Employees at participating centres including but not limited to UCLH and The Francis Crick Institute who have their serology tested and/or are swabbed for viral (SARS-CoV-2 and seasonal viruses) detection as well as participants who are vaccinated will be prospectively consented to the study.
62236886|NCT04750356||Cohort C|Individuals recruited to other REC approved research studies where their samples are processed by the Crick COVID 19 Consortium Testing centre will also be consented in their existing study to allow the use of leftover study samples already collected and to be collected, for use in this longitudinal study.
62035760|NCT01835886|EXPERIMENTAL|Performs stair-climbing|Performs stair climbing
62236887|NCT05372822|EXPERIMENTAL|Burst SCS|Burst Spinal cord stimulation. SCS system implanted and burst stimulation given
62236888|NCT05372822|SHAM_COMPARATOR|Sham SCS|Sham spinal cord stimulation. SCS system implanted but no stimulation given.
62236889|NCT02120716|EXPERIMENTAL|Health Check-Up of Expectant Moms|Participants receive computer delivered intervention (Health Check-up for Expectant Moms)
62595291|NCT04497870|EXPERIMENTAL|900 mg|Peppermint oil at a dose of 180 mg five times daily orally
62236890|NCT02120716|NO_INTERVENTION|Time and attention matched control group|Participants will be presented a brief series of videos of television shows, with subsequent ratings of subjective preference
62236891|NCT02858349|EXPERIMENTAL|Arm 1|4-week control period with no intervention and 4-weeks of high-intensity interval training
62236892|NCT04297098||Asthmatic patients|
62595292|NCT01868698|EXPERIMENTAL|Kinesiotherapy|Will be made active and resisted exercises of the lower limbs.
62812910|NCT05732467|EXPERIMENTAL|experimental group|
62812911|NCT05732467|OTHER|control group|
62812912|NCT02356276|EXPERIMENTAL|HIPEC group|"Postoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is performed after radical surgery, followed by 6-8 cycles of systemic chemotherapy. The first HIPEC is conducted within 48 h after surgery: Paclitaxel 75 mg/m\^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m\^2, 43°C, 60min.~Systemic chemotherapy (XELOX or SOX regimens):~XELOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; Capecitabine: 1 g/m\^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~If XELOX regimen is not conducted in some collaborators, SOX regimen is also permitted. The regimen is Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40-60 mg/m\^2 bid, po, day 1-14, every 3 weeks for a total of 6-8 cycles."
62812913|NCT02356276|PLACEBO_COMPARATOR|Control group|"6-8 cycles of systemic chemotherapy (XELOX or SOX regimens) were performed after radical gastrectomy with D2 lymphadenectomy.~XELOX regimen is Oxaliplatin: 130 mg/m\^2, IV, d1; Capecitabine: 1 g/m\^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~If XELOX regimen is not conducted in some collaborators, SOX regimen as comment systemic chemotherapy in Asia is also permitted to treat the patients. The treatment bundles are listed as follows: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40-60 mg/m\^2 bid (S-1: BSA \<1.25m\^2, 40mg bid, 1.25m\^2≤ BSA ≤1.5m\^2, 50mg bid, BSA\>1.5m\^2, 60 mg bid), po, day 1-14, every 3 weeks for a total of 6-8 cycles."
62812914|NCT06166056|EXPERIMENTAL|Experimental: CHF6333|"CHF6333 active (Part I - SAD): once daily inhaled single dose of CHF6333 at each period (three dose levels for HVs and one dose level for BE subjects).~CHF6333 active (Part II - MD): once daily inhaled multiple dose of CHF6333 for 28 days consecutive days (two dose levels for BE subjects)."
62812915|NCT06166056|PLACEBO_COMPARATOR|Placebo comparator: CHF6333 Placebo|"CHF6333 placebo (Part I - SAD): once daily inhaled single dose of placebo matching CHF6333 at each period.~CHF6333 placebo (Part II - MD): once daily inhaled multiple dose of placebo matching CHF6333 for 28 days consecutive days."
62812916|NCT05920798|EXPERIMENTAL|Treatment (apheresis, FRalphaDC, pembrolizumab)|Patients undergo apheresis for multi-epitope folate receptor alpha-loaded dendritic cell vaccine manufacturing on study. Patients then receive multi-epitope folate receptor alpha-loaded dendritic cell vaccine ID on day 1 of cycles 1-5 and pembrolizumab IV over 30 minutes on day 1 of cycles 1-8. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patient then receive multi-epitope folate receptor alpha-loaded dendritic cell vaccine ID on day 1 of odd cycles and pembrolizumab IV over 30 minutes on day 1 of remaining cycles. Cycles repeat every 42 days for up to cycle 22 in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI as well as blood sample collection throughout the trial. Patients undergo biopsy on study.
62812917|NCT01909440|EXPERIMENTAL|Arm I (RT + PS)|Patients undergo total body high-intensity RT thrice weekly and perform static stretching exercises after each session. Exercises progress from low intensity and high volume to higher intensity and lower volume over the course of the 12-week program. Patients also receive whey protein supplementation orally twice a day for 12 weeks.
62812918|NCT01909440|EXPERIMENTAL|Arm II (total body RT)|Patients undergo total body RT and stretching as in Arm I.
62812919|NCT01909440|EXPERIMENTAL|Arm III (protein supplementation)|Patients receive whey protein supplementation as in Arm I. Patients also undergo a home flexibility program 3 times per week, consisting of the same static stretching exercises performed after RT. After 12 weeks, patients may undergo the RT program as in Arm I.
62812920|NCT01909440|ACTIVE_COMPARATOR|Arm IV (attention control)|Patients undergo the home flexibility program as in Arm III. After 12 weeks, patients may undergo total body RT as in Arm I.
62812921|NCT02423850||Diabetic foot ulcers|Newly referred patients with diabetic foot ulcers from the multidisciplinary clinic: University Centre for Wound healing, Odense University Hospital, Denmark.
62812922|NCT04783350|EXPERIMENTAL|Transcranial alternating current stimulation (tACS)|Participants (Ps) will undergo 20min of daily home-based tACS intervention at 40Hz over the left angular gyrus for 4 weeks by trained administrators (As) (phase 1). In case of cognitive and mental improvement participants will undergo further 10 weeks of 20 minutes session of tACS daily (phase 2). Additionally, those P/A pairs who completed the 14 weeks of home-based tACS intervention and express an interest in an open label extension may be enrolled in further 34 weeks of 20 minutes tACS sessions.
62236893|NCT04297098||Allergic patients|
62236894|NCT04297098||Control group|
62427235|NCT02595528|EXPERIMENTAL|AGN-199201 and AGN-190584 Dose C|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
62427236|NCT05663931|EXPERIMENTAL|DM Discharge Toolkit|Up to 60 participants will be recruited for the intervention group. Participants will receive the current standard of care DM education for insulin at Northwestern Memorial Hospital and the adjunctive education with the DM Discharge Toolkit.
62236895|NCT04923841|NO_INTERVENTION|Control|Subjects in control will receive single vision spectacle lenses and a placebo desk lamp
62236896|NCT04923841|EXPERIMENTAL|BLT monotherapy|Subjects in BLT monotherapy group will receive a high intensity light box for bright light therapy and single vision spectacle lenses
62236897|NCT04923841|EXPERIMENTAL|BLT and DIMS|Subjects in BLT and DIMS group will receive a high intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses
62236898|NCT04923841|EXPERIMENTAL|BLT and atropine|Subjects in BLT and atropine group will receive a high intensity light box for bright light therapy, single vision spectacle lens, and atropine 0.01% eye drop (twice a day)
62427237|NCT05663931|NO_INTERVENTION|Current Standard of Care Discharge DM Training|Up to 60 participants will be recruited for the control group. Participants will receive the current standard of care DM education for insulin use during current discharge care processes at Northwestern Memorial Hospital.
62427238|NCT03933839|EXPERIMENTAL|PainCOACH|This group will take part in an 8-week pain coping skills training (PCST) intervention.
62427239|NCT03933839|NO_INTERVENTION|Wait List Control|The other group will be the wait list group and will receive the pain CST program after completing all study measures.
62595293|NCT01868698|EXPERIMENTAL|shortwave diathermy|Will be applied for 20 minutes on the lower limbs.
62236899|NCT04923841|EXPERIMENTAL|Atropine monotherapy|Subjects in atropine group will receive atropine 0.01% eye drop (twice a day) and single vision spectacle lenses
62236900|NCT04242511||Cases|"Tuberculosis patients with diabetes mellitus:~1. Subject aged 18 years of age or over~2. Written, informed consent obtained.~3. New diagnosis of tuberculosis and started on anti-tuberculosis treatment~4. Known diagnosis of diabetes or two consecutive raised IFCC HbA1c levels (\>= 48 mmol/mol) at the time of TB diagnosis"
62812923|NCT02066363|ACTIVE_COMPARATOR|Best nutritional Care|Best supportive nutritional care and dietician advise
62236901|NCT04242511||Controls|"Tuberculosis patients without diabetes mellitus:~1), 2), 3) as above 4) IFCC HbA1c level \< 48mmol/mol 5) Weight matched to cases (+/- 2kg)"
62427240|NCT01268319|EXPERIMENTAL|(+)HR-LCP and EPD|These subjects will meet all angiographic criteria.The target plaque will contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 27 Subjects who meet this criteria will be randomized to standard pre-dilation and stent implantation with an embolic protection device (EPD)in place prior to any angioplasty.
62427241|NCT01268319|PLACEBO_COMPARATOR|(+)HR-LCP and No EPD (standard of care)|These subjects will meet all angiographic criteria.The target plaque will contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 27 Subjects who meet this criteria will be randomized to standard pre-dilation and stent implantation without an embolic protection device (EPD)in place prior to any angioplasty.
62595294|NCT01868698|EXPERIMENTAL|high-voltage electrical stimulation|The therapeutic current will be applied for 20 minutes on lower limbs.
62595295|NCT03287284|ACTIVE_COMPARATOR|LLLT Group|Active Low Level Laser Therapy application with a dose of 240 Joules before resistance training
62595296|NCT03287284|PLACEBO_COMPARATOR|Placebo Group|Placebo Low Level Laser Therapy application before resistance training
62595297|NCT04792593|EXPERIMENTAL|Senl-h19 CAR-T|Patients will be treated with Senl-h19 CAR-T cells
62595298|NCT04017832|EXPERIMENTAL|Oral semaglutide 3 mg and placebo (sitagliptin)|Oral semaglutide tablets 3 mg and sitagliptin placebo tablets for 26 weeks
62812924|NCT02066363|EXPERIMENTAL|Parenteral nutrition|Supplemental Parenteral Nutrition and dietician advise. Supplemental parenteral Nutrition 30% of estimated needs. Parenteral nutrition given at home, administered by a nurse. The patient will be seen at the Outpatient Clinic every 6th week, talk to dietician and a doctor.
62812925|NCT06571305|EXPERIMENTAL|Phase 2 BBTI Intervention Group|Participants (patient-sleep-partner caregiver dyads) in this group will receive the Brief Behavioral Treatment for Insomnia (BBTI). Total participation is up to 4 weeks.
62812926|NCT06571305|EXPERIMENTAL|Phase 2 MSOS Intervention Group|Participants (patient-sleep-partner caregiver dyads) in this group will receive the My Sleep Our Sleep (MSOS) intervention. Total participation is up to 4 weeks.
62812927|NCT03495661|ACTIVE_COMPARATOR|Surgical (Decompression)|Central decompression of the stenotic segment(s) with undercutting of the lateral recesses.
62812928|NCT03495661|NO_INTERVENTION|Non-surgical|"Physical therapy according to the Östersund model: training on stationary bicycle 30 min, 3 times/week under 4 months."
62812929|NCT04417673||Sickle Cell Disease|Individuals with sickle cell disease
62812930|NCT04711655|EXPERIMENTAL|(ARMA) antireflux ablation of the cardiac mucosa|The ARMA (Ablation with electrocoagulation current or by argon gas fulguration) technique will be performed in patients assigned to this treatment arm.
62812931|NCT04711655|PLACEBO_COMPARATOR|upper digestive endoscopy|Quality diagnostic upper gastrointestinal endoscopy will be performed without intervention in patients assigned to this treatment arm.
62236902|NCT05351853|OTHER|Control Group|20 healthy individual will be in the control group. Participants of control group will not change their diet and will continue omnivore diet.
62236903|NCT05351853|OTHER|Vegetarian|20 healthy individual will be in the control group. Participants of this group will change their diet from omnivore to vegetarian (no meat /meat products) after the beginning of the study.
62236904|NCT05351853|OTHER|Vegan|20 healthy individual will be in the control group. Participants of this group will change their diet from omnivore to vegan (%100 plant based) after the beginning of the study.
62427242|NCT01268319|PLACEBO_COMPARATOR|(-)HR-LCP and No EPD (standard of care)|These subjects will meet all angiographic criteria.The target plaque will NOT contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 54 Subjects who meet this criteria will be assigned (not randomized) to standard pre-dilation and stent implantation without an embolic protection device (EPD)in place prior to any angioplasty.
62427243|NCT02522754|PLACEBO_COMPARATOR|Placebo|Placebo
62427244|NCT02522754|EXPERIMENTAL|Protesomal Vaccine 1 x 30 µg|Protesomal Vaccine 1 x 30 µg
62427245|NCT02522754|EXPERIMENTAL|Protesomal Vaccine 2 x 30 µg|Protesomal Vaccine 2 x 30 µg
62427246|NCT02522754|EXPERIMENTAL|Protesomal Vaccine 2 x 15 µg|Protesomal Vaccine 2 x 15 µg
62427247|NCT05177237|EXPERIMENTAL|Endostar combined with Methylprednisolone|Endostar combined with Methylprednisolone lasts for 10 weeks
62427248|NCT04895228|ACTIVE_COMPARATOR|SpA patients recieving local steroid injection|the active group will receive triamcinilone 40 mg injection (Kenacort) + 4 ml of .5 % lidocaine hydrochloride (Xylocaine) under ultrasound guidance.
62427249|NCT04895228|PLACEBO_COMPARATOR|placebo group|Group 2 will receive similar amount of saline injecteed subcutaneously
62427250|NCT02123069||Women with uterine fibroids|"* Brachial artery catheter~* Acetylcholine~* Nitroprusside~* Norepinephrine~* Nitroprusside and phenylephrine"
62427251|NCT02123069||Women without uterine fibroids|"* Brachial artery catheter~* Acetylcholine~* Nitroprusside~* Norepinephrine~* Nitroprusside and phenylephrine"
62427252|NCT00783562|EXPERIMENTAL|1|
62427253|NCT00783562|ACTIVE_COMPARATOR|2|
62427254|NCT06284707|OTHER|swimming training|Participants complete 2 swimming training sessions per week. Total program time 10 weeks
62427255|NCT06284707|EXPERIMENTAL|swimming training and rhythmic gymnastics training|"Participants perform 2 swimming training sessions per week and 2 rhythmic gymnastics training sessions.~Total program time 10 weeks"
62427256|NCT02434575||PAE|Men with LUTS BPE who have opted for PAE at a participating site, and have consented to take part in the UK ROPE Register Study.
62427257|NCT02434575||TURP|Men with LUTS BPE who have consented to TURP at a participating site, and have consented to the UK ROPE Register Study.
62427258|NCT02434575||Other|Men with LUTS BPE who have had an Open Prostatectomy or laser surgery at a participating site, and have consented to the UK ROPE Study.
62427259|NCT02897453||The Spinal Tethering System group|Patients with adolescent idiopathic scoliosis that have been implanted with the Spinal Tethering System in an anterior vertebral body tethering construct.
62427260|NCT05165433|EXPERIMENTAL|All cohorts|NG-350A and pembrolizumab
62812932|NCT00282035|EXPERIMENTAL|APBI utilizing 3D-CRT radiation|Accelerated partial breast irradiation utilizing 3D-CRT
62812933|NCT00282035|OTHER|Whole breast irradiation|Whole breast irradiation
62035761|NCT06293157|EXPERIMENTAL|Transpedicular spinal stabilization using carbon system + SBRT|Transpedicular spinal stabilization using a radiolucent composite system made of carbon fibers and PEEK followed by stereotactic radiotherapy of the spine at a dose of 5x5 Gy (25 Gy in the total dose)
62035762|NCT06293157|ACTIVE_COMPARATOR|Transpedicular spinal stabilization using titanium system + SBRT|Transpedicular spinal stabilization using a titanium system followed by stereotactic radiotherapy of the spine at a dose of 5x5 Gy (25 Gy in the total dose)
62035763|NCT06293157|SHAM_COMPARATOR|SBRT + Transpedicular spinal stabilization using titanium system|Transpedicular spinal stabilization using a titanium system preceded with stereotactic spine radiotherapy at a dose of 5x5 Gy (25 Gy in the total dose) as the first stage of treatment
62035764|NCT02779153|EXPERIMENTAL|Acthar low dose (40 U)|
62035765|NCT02779153|EXPERIMENTAL|Acthar high dose (80 U)|
62035766|NCT04541134|OTHER|Group 1|
62035767|NCT04541134|OTHER|Group 2|
62035768|NCT03412669|EXPERIMENTAL|Counselling|Supporting Addiction Affected Families Effectively is a contextually adapted version of the 5-Step Method, a psychosocial intervention based on the principles of the Stress-Strain-Coping-Support model. The intervention is manualised, and is delivered by lay counsellors over 5 sessions at a weekly basis. The 5 steps (covered in the 5 steps) include: 1) Exploring stresses and strains, 2) Providing relevant information, 3) Exploring and discussing coping behaviours, 4) Exploring and enhancing social support, and 5) Exploring additional needs, and further sources of help. The intervention is delivered in settings based on convenience of the participant: which might be a place outside the home (e.g. field office, neighbour's home), or the participant's home.
62035769|NCT03412669|ACTIVE_COMPARATOR|Enhanced Usual Care|In the study setting, usual care for affected family members is no care at all, as detection rates of stress/strain in affected family members are extremely low. Hence, Enhanced Usual Care for the control group consists of a minimal intervention, namely a leaflet. The leaflet focuses on the burden that affected family members experience in relation to a relative who drinks alcohol, and on various informal and formal sources of support that are available in the local community.
62427261|NCT04445129||Narcolepsy Type 1 Participants|Participants with NT1 on stable wake-promoting medications and exclusive of any sleep promoting medications will be fitted with the portable electrocardiogram (ECG) device combined with wrist accelerometry and undergo a 2-night nPSG combined with the portable EEG device.
62427262|NCT04445129||Healthy Participants|Participants who are healthy sex- and age (plus or minus 5 years)-matched controls will be fitted with the portable ECG device combined with wrist accelerometry and undergo a 2-night nPSG combined with the portable EEG device.
62812934|NCT01179724|EXPERIMENTAL|high dose proton pump inhibitor|
62812935|NCT01179724|ACTIVE_COMPARATOR|H2 receptor antagonist|
62812936|NCT04978350|EXPERIMENTAL|Educational Workbook Arm|Participants in the Educational Workbook Arm will receive an electronic PDF version of an educational workbook via email on cascade screening in families with Lynch Syndrome. Genetic counselors will introduce the workbook to enrolled patients with Lynch Syndrome. Patient participants will use the activities and information in the workbook to communicate about Lynch Syndrome with family members.
62812937|NCT03964103|EXPERIMENTAL|gQ-lab daily|
62812938|NCT03964103|PLACEBO_COMPARATOR|Placebo|
62812939|NCT02403557|EXPERIMENTAL|Tailored Internet-delivered CBT|Tailored Internet-delivered CBT during 8 weeks.
62812940|NCT02403557|ACTIVE_COMPARATOR|Waitlist|Weekly check-up.
62812941|NCT06333106|OTHER|Patient suspected to suffer from fecal impaction|Any patients aged 75 years or older coming to the ED and for whom the emergency physician suspects fecal impaction.
62812942|NCT05359172||Tranexamic acid|They will receive preoperative intravenous tranexamic acid infusions.
62812943|NCT05359172||Controls|They will not receive intravenous tranexamic acid infusions.
62236905|NCT01245075|ACTIVE_COMPARATOR|Deep Brain Stimulation|Stimulator setting is ON
62427263|NCT00787670|EXPERIMENTAL|Gastric Bypass Surgery|Gastric Bypass Surgery consists of a laparoscopic approach and includes the creation of an isolated 10-15-ml proximal gastric pouch, a retro-colic, retro-gastric Roux-en-Y gastrojejunostomy with linear stapler technique, a 100-cm Roux-limb, a 30-cm biliopancreatic limb, and a stapled end-side enteroenterostomy.
62595299|NCT04017832|EXPERIMENTAL|Oral semaglutide 7 mg and placebo (sitagliptin)|Oral semaglutide tablets and sitagliptin placebo tablets. The dose of oral semaglutide will be escalated over 4 weeks, after which the target dose of 7 mg is taken for 22 weeks
62236906|NCT01245075|SHAM_COMPARATOR|Placebo|Stimulator setting is OFF
62812944|NCT03816033|ACTIVE_COMPARATOR|Cryotherapy|Cryotherapy ablation energy will be utilised in the catheter ablation procedure
62812945|NCT03816033|ACTIVE_COMPARATOR|Radiofrequency|Radiofrequency ablation energy will be utilised in the catheter ablation procedure
62812946|NCT04810650|EXPERIMENTAL|PREP/PEP at Outpatient Clinics Dynamic Prevention Intervention|
62812947|NCT04810650|ACTIVE_COMPARATOR|PREP/PEP at Outpatient Clinics Control|
62812948|NCT04810650|EXPERIMENTAL|PREP/PEP at Antenatal Clinics Dynamic Prevention Intervention|
62812949|NCT04810650|ACTIVE_COMPARATOR|PREP/PEP at Antenatal Clinics Control|
62812950|NCT04810650|EXPERIMENTAL|PREP/PEP at Community Households Dynamic Prevention Intervention|
62236907|NCT05123963|ACTIVE_COMPARATOR|Morning exercise|Participant to perform high-intensity interval training in the morning (\~9 am)
62236908|NCT05123963|EXPERIMENTAL|Afternoon exercise|Participant to perform high-intensity interval training in the morning (\~4 pm)
62236909|NCT00956514|EXPERIMENTAL|Transcranial Magenetic Stimulation|All subjects will be assigned to active, open-label treatment with the NeuroStar TMS System for 6 weeks (30 treatment sessions).
62236910|NCT01648738|EXPERIMENTAL|Spa therapy, exercise and educational therapy|Spa therapy, exercise and educational therapy
62236911|NCT01648738|ACTIVE_COMPARATOR|Usual care and counselling (Back book)|Usual care and counselling (Back book)
62236912|NCT03236246|EXPERIMENTAL|Group 1|KRX-0502 1 tablet thrice daily (TID) with meals
62236913|NCT03236246|EXPERIMENTAL|Group 2|KRX-0502 2 tablets twice daily (BID) with the largest 2 daily meals
62427264|NCT00787670|ACTIVE_COMPARATOR|Diabetes Support and Education|Diabetes Support and Eduction. Subjects attend three educational/social support sessions for 1 year after enrollment. The educational sessions offered for diabetes support and education including informational sessions on diet/nutrition and exercise. These sessions are informational only and do not teach behavioral self-regulation skills. Different nutrition and exercise topics are covered each session. Education
62812951|NCT04810650|ACTIVE_COMPARATOR|PREP/PEP at Community Households Control|
62812952|NCT04810650|EXPERIMENTAL|Mobility Dynamic Treatment Intervention|
62812953|NCT04810650|ACTIVE_COMPARATOR|Mobility Control|
62812954|NCT04810650|EXPERIMENTAL|Healthy Living for Heavy Alcohol Users Intervention|
62812955|NCT04810650|ACTIVE_COMPARATOR|Heavy Alcohol Users Control|
62812956|NCT04810650|EXPERIMENTAL|Hypertension Linkage Intervention|
62812957|NCT04810650|ACTIVE_COMPARATOR|Hypertension Linkage Control|
62236914|NCT04112654|ACTIVE_COMPARATOR|Conventional laparoscopy|Laparoscopy realized at the conventional pressure (12-15 mmHg) using conventional insufflator.
62236915|NCT04112654|EXPERIMENTAL|Low pressure laparoscopy|Laparoscopy realized at low pressure (6-8mmHg) using pressure-controlled insufflator AirSeal®
62236916|NCT05968287||patient group|patients admitted to hospital with various infection conditions with or without sepsis
62812958|NCT04810650|EXPERIMENTAL|Hypertension Community Intervention|
62812959|NCT04810650|ACTIVE_COMPARATOR|Hypertension Community Control|
62812960|NCT04818658||Preformed Metal Crowns using Hall Technique|
62236917|NCT05968287||control group|patients admitted to hospital with various non-infectious diseases and outpatients who admitted to the outpatient clinics
62236918|NCT05311098|EXPERIMENTAL|Vestibule Group|Cryoablation
62236919|NCT03099317|EXPERIMENTAL|Sinew acupuncture|Subject in the arm will receive real acupuncture intervention.
62236920|NCT03099317|SHAM_COMPARATOR|Sham acupuncture|Subject in the arm will receive sham acupuncture intervention.
62236921|NCT06026085|EXPERIMENTAL|CE FERULIC|fraxel laser therapy combined with Skinceuticals skin care product(CE FERULIC) and routine sun protection
62236922|NCT06026085|PLACEBO_COMPARATOR|0.9% normal saline|fraxel laser therapy combined with 0.9% normal saline and routine sun protection
62236923|NCT00544362|EXPERIMENTAL|Neoadjuvant chemoradiotherapy|Weekly cetuximab (400 mg/m2 one week before start of radiotherapy RT and 250 mg/m2 during radiotherapyRT), and 5 FU (500 mg/m2 per day D1-D4) combined with cisplatin CDDP (40 mg/m2 D1) on week 1 and 5
62236924|NCT04547049|ACTIVE_COMPARATOR|Non-first-degree donor|Each patient receive graft from a non-first degree donor aged ≤40
62236925|NCT04547049|ACTIVE_COMPARATOR|First-degree donor|Each patients receive graft from a first-degree donor aged \>50
62236926|NCT00135759|PLACEBO_COMPARATOR|Group 1|Drug
62236927|NCT00135759|EXPERIMENTAL|2|experimental
62236928|NCT00135759|EXPERIMENTAL|3|experimental
62812961|NCT04818658||Compomer Restoration|
62812962|NCT03351842|ACTIVE_COMPARATOR|Arm I|Undergo surgery, followed by observation. Patients receive no further therapy
62812963|NCT03351842|EXPERIMENTAL|Arm II|Undergo surgery, followed by chemotherapy (cis Platinum/Carboplatin, Pemetrexed Disodium). Patients receive chemotherapy comprising cisplatin 75mg/m2 or Carboplatin AUC=5mg/ml/min, and pemetrexed 500mg/m2 in day 1. Treatment continues every 3 weeks for 4 courses.
62236929|NCT01566656|EXPERIMENTAL|TLI and anti-thymocyte globulin|
62236930|NCT00458809|EXPERIMENTAL|Hyperthermic Chemoperfusion with Oxaliplatin 200 mg/m2|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin 200 mg/m2
62236931|NCT00458809|EXPERIMENTAL|Hyperthermic Chemoperfusion with Oxaliplatin 250 mg/m2|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin 250 mg/m2
62236932|NCT02557321|EXPERIMENTAL|Phase 1b|PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
62236933|NCT02557321|EXPERIMENTAL|Phase 2 (Arm 1)|PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
62236934|NCT02557321|ACTIVE_COMPARATOR|Phase 2 (Arm 2)|Pembrolizumab (2 mg/kg every 3 weeks)
62236935|NCT01121679||Patients aged 80 years and older|Patients aged 80 years and older and hospitalized in a cardiology department
62243446|NCT01572922|OTHER|Iron-overloaded|"Patients with iron overload or excessive body iron burden, a serious condition resulting from increased dietary gastro¬intestinal absorption, multiple erythrocyte transfusions, or both.~Interventions: R2\*-UTE, R2\*-GRE, and if clinically indicated, liver biopsy."
62812964|NCT04642625||wound infiltration analgesia|25 patients who underwent wound infiltration analgesia
62812965|NCT04642625||ultrasound-guided bilateral erector spina plan block analgesia|25 patients who underwent ultrasound-guided bilateral erector spina plan block analgesia
62812966|NCT04642625||wound infiltration and ultrasound-guided bilateral erector spina plan block analgesia both together|25 patients who underwent wound infiltration and ultrasound-guided bilateral erector spina plan block analgesia
62236936|NCT05419063|EXPERIMENTAL|weight loss program|Participants will receive recommendations on how to decrease caloric intake, monitor their weight and track the related behaviors and progress. The weight loss program will provide asynchronous support (information, automated texting feedback, tailored emails) for adopting and maintaining lifestyle-based strategies for safe and effective weight loss.
62236937|NCT00287339|EXPERIMENTAL|1|40mg Esomeprazole BID
62236938|NCT00287339|PLACEBO_COMPARATOR|2|placebo capsules
62236939|NCT01369511|PLACEBO_COMPARATOR|Placebo|Administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
62236940|NCT01369511|EXPERIMENTAL|35 mg LY2495655|LY2495655: 35 milligrams (mg) administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
62236941|NCT01369511|EXPERIMENTAL|105 mg LY2495655|LY2495655: 105 mg administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
62236942|NCT01369511|EXPERIMENTAL|315 mg LY2495655|LY2495655: 315 mg administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
62236943|NCT00780754|EXPERIMENTAL|dutasteride|treatment group
62236944|NCT00780754|ACTIVE_COMPARATOR|watchful waiting strategy|
62236945|NCT00506233||Chronic Graft-Versus Host Disease (GvHD)|Participants with chronic graft-versus host disease (GvHD)
62236946|NCT00732628||Boomerang percutaneous closure unit|patients having a Boomerang percutaneous closure device after a Neurointerventional study
62236947|NCT05716659||Healthy subjects group|150 healthy subjects
62236948|NCT05716659||Metabolic syndrome group|100 patients with clinical diagnosis of metabolic syndrome.
62236949|NCT05716659||Heart failure group|100 patients with clinical diagnosis of heart failure.
62812967|NCT05096624|EXPERIMENTAL|DD-TENS (Digital Denture-Transcutaneous Electrical Nerve Stimulation)|Patient with Complete Removable Prostheses according to DD-TENS system
62812968|NCT05096624|ACTIVE_COMPARATOR|Gold standard|Patient with Complete Removable Prostheses according to usual care
62812969|NCT05096624|ACTIVE_COMPARATOR|Digital denture System|Patient with Complete Removable Prostheses according to Digital Denture system
62812970|NCT03991312|EXPERIMENTAL|Part 1|"Period 1: Day 1, participants will receive 20 milligrams (mg) of mitapivat sulfate.~Period 2: Day 1 to Day 9, participants will receive 200 mg of itraconazole, once daily and 20 mg of mitapivat sulfate on Day 5."
62812971|NCT03991312|EXPERIMENTAL|Part 2|"Period 1: Day 1, participants will receive 50 milligrams (mg) of mitapivat sulfate.~Period 2: Day 1 to Day 12, participants will receive 600 mg of rifampin, once daily and 50 mg of mitapivat sulfate on Day 8."
62812972|NCT02969798|NO_INTERVENTION|Healthy normal glucose tolerance (NGT) subjects|Subjects (Fasting Plasma Glucose or FPG \< 100 mg/dl and 2-h PG \< 140 mg/dl) without FH (family history) of diabetes in a first degree relative
62812973|NCT02969798|ACTIVE_COMPARATOR|Isolated IGT with Dapagliflozin|Healthy subjects with isolated IGT (FPG \< 100; 2-h PG = 140-199) will receive dapagliflozin, 10 mg/day
62812974|NCT02969798|ACTIVE_COMPARATOR|Isolated IGT with Saxagliptin|Healthy subjects with isolated IGT (FPG \< 100; 2-h PG = 140-199) will receive saxagliptin, 5 mg/day
62812975|NCT02969798|ACTIVE_COMPARATOR|Isolated IGT with Pioglitazone|Healthy subjects with isolated IGT (FPG \< 100; 2-h PG = 140-199) will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two
62812976|NCT02969798|ACTIVE_COMPARATOR|Isolated IGT with Metformin|Healthy subjects with isolated IGT (FPG \< 100; 2-h PG = 140-199) will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
62812977|NCT02969798|ACTIVE_COMPARATOR|Isolated IFG with Dapagliflozin|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG \< 140) will receive dapagloflozin, 10mg/day
62812978|NCT02969798|ACTIVE_COMPARATOR|Isolated IFG with Saxagliptin|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG \< 140) will receive saxagliptin, 10mg/day
62812979|NCT02969798|ACTIVE_COMPARATOR|Isolated IFG with Pioglitazone|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG \< 140) will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two
62236950|NCT05716659||Heart failure with metabolic syndrome group|100 patients with clinical diagnosis of heart failure with metabolic syndrome.
62236951|NCT05716659||Severe aortic valve stenosis group|100 patients with clinical diagnosis of severe aortic valve stenosis.
62236952|NCT05716659||Ischemic stroke group|200 patients with clinical diagnosis of ischemic stroke.
62236953|NCT04271787||strongly dissatisfied|
62236954|NCT04271787||dissatisfied|
62812980|NCT02969798|ACTIVE_COMPARATOR|Isolated IFG with Metformin|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG \< 140) will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
62236955|NCT04271787||neutral|
62427265|NCT00787670|ACTIVE_COMPARATOR|Tissue Control Group|Tissue control group includes subjects who are undergoing other non-gastric bypass abdominal surgery. A pea size piece of omentum and subcutaneous fat will be collected.
62427266|NCT05001399|EXPERIMENTAL|Holographic Memory Resolution® (HMR) Intervention|Intervention will be comprised of 4 sessions lasting approximately 90 minutes at one of two sites, Billings Clinic in Billings, Montana or Healing Dimensions AAC in Tucson, Arizona. The 4 sessions will be completed in approximately 9 weeks.
62595300|NCT04017832|EXPERIMENTAL|Oral semaglutide 14 mg and placebo (sitagliptin)|Oral semaglutide tablets and sitagliptin placebo tablets. The dose of oral semaglutide will be escalated over 8 weeks, after which the target dose of 14 mg is taken for 18 weeks
62595301|NCT04017832|EXPERIMENTAL|Sitagliptin 100 mg and placebo (oral semaglutide)|Sitagliptin tablets and oral semaglutide placebo tablets for 26 weeks
62812981|NCT02969798|ACTIVE_COMPARATOR|IGT plus IFG with Dapagliflozin|Healthy subjects with IGT plus IFG will receive dapagliflozin, 10mg/day
62812982|NCT02969798|ACTIVE_COMPARATOR|IGT plus IFG with Saxagliptin|Healthy subjects with IGT plus IFG will receive saxagliptin, 10mg/day
62812983|NCT02969798|ACTIVE_COMPARATOR|IGT plus IFG with Pioglitazone|Healthy subjects with IGT plus IFG will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two
62035770|NCT04380454|EXPERIMENTAL|Fast treadmill walking with functional electrical stimulation (FastFES)|Participants with post-stroke hemiparesis who are randomized to receive 12 sessions of FastFES. FastFES is a targeted intervention that provides motor level stimulation-induced cues to improve ankle propulsion. FES is delivered only to the paretic ankle muscles, enhancing afferent ascending as well as descending corticomotor drive. Increased corticomotor drive in lesioned corticomotor circuits in turn promotes improved timing and intensity of muscle activation in the paretic plantar- and dorsi-flexor muscles, increasing plantarflexor moment and propulsion from the paretic ankle.
62236956|NCT04271787||satisfied|
62236957|NCT04271787||strongly satisfied|
62236958|NCT04271787||don't know|
62812984|NCT02969798|ACTIVE_COMPARATOR|IGT plus IFG with Metformin|Healthy subjects with IGT plus IFG will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
62812985|NCT02592291|EXPERIMENTAL|MHealth Group|Participants randomized into this group will use the mHealth system throughout the study in conjunction with their standard of care
62236959|NCT04680494|EXPERIMENTAL|Rest|Participants rest quietly for 30 minutes, sitting on a chair. They may read magazines not involving motion-related elements
62236960|NCT04680494|EXPERIMENTAL|Moderate intensity exercise|Participants cycle on a cycle ergometer during 30 minutes at 65% of their maximal cardiac frequency
62236961|NCT04680494|EXPERIMENTAL|High intensity exercise|Participants cycle on a cycle ergometer during 15 minutes at 75% of their maximal cardiac frequency. This session also includes 3 minutes of warm-up and three minutes of cool down at 50% of their maximal cardiac frequency
62236962|NCT02655302|OTHER|Bacterial exacerbations|Patients with at least 10\^7 UFC/ml bacteria in their sputum during their first COPD exacerbation.
62236963|NCT02655302|OTHER|Non-bacterial exacerbations|Patients without detected bacteria or below 10\^7 UFC/ml in sputum during their first COPD exacerbation.
62236964|NCT01141738|EXPERIMENTAL|Caregiver Problem-Solving Intervention (CPSI)|The experimental treatment will provide structured information, guided problem-solving, and training in skills for coping with stress and emotional responses (e.g., relaxation, cognitive reframing, changing negative problem orientation, problem-solving (PS) skills).
62236965|NCT01141738|ACTIVE_COMPARATOR|Wait List Control (WLC)|WLC subjects will be offered an intervention after the 6 month assessment. Both groups will receive standard services provided by the rehabilitation team to caregivers (CGs) of stroke survivors.
62236966|NCT01744353|EXPERIMENTAL|Dose level 1|Abraxane 125 mg/m2, day 1 Oxaliplatin 85 mg/m2, day 1 leucovorin 400 mg/m2, day 1 5-FU Infusion 1200 mg/m2/ days 2 days IV infusion
62236967|NCT01744353|EXPERIMENTAL|Dose level 2/ MTD|Abraxane 150 mg/m2, day 1 Oxaliplatin 85 mg/m2, day 1 leucovorin 400 mg/m2, day 1 5-FU Infusion 1200 mg/m2/ days 2 days IV infusion
62595302|NCT04197674||Peritoneal dialysis group|Patients who randomized to peritoneal dialysis
62595303|NCT04197674||Hemodialysis group|Patients who randomized to conventional in-center hemodialysis
62236968|NCT01744353|EXPERIMENTAL|Dose level 3|Abraxane 175 mg/m2, day 1 Oxaliplatin 85 mg/m2, day 1 leucovorin 400 mg/m2, day 1 5-FU Infusion 1200 mg/m2/ days 2 days IV infusion
62236969|NCT05689723|EXPERIMENTAL|Manipulation|Left and right sidelyiing gaping high velocity low amplitude thrust mobilization
62236970|NCT05689723|SHAM_COMPARATOR|Sham Manipulation|The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension PROM without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
62236971|NCT00364156|EXPERIMENTAL|Extended Patch Treatment|Participants in this treatment arm receive 24 weeks of 21mg nicotine patch in addition to 8 smoking cessation counseling sessions.
62236972|NCT00364156|ACTIVE_COMPARATOR|Standard Patch Treatment|Participants receive 8 weeks of 21mg nicotine patch followed by 16 weeks of placebo patch.
62236973|NCT01910805|EXPERIMENTAL|Lifestyle and Risk Awareness class|Women will attend a 3- and 9-month postpartum group nutrition and physical activity education class.
62035771|NCT04380454|ACTIVE_COMPARATOR|Fast treadmill walking (Fast)|Participants with post-stroke hemiparesis who are randomized to receive 12 sessions of Fast. Fast is a non-targeted intervention that provides similar structure, dose, and intensity of stepping practice as FastFES, but does not include FES, and no specific instructions are provided to target practice to the paretic leg or specific ankle deficits
62236974|NCT01910805|NO_INTERVENTION|Standard Care|Women will receive standard postpartum care for gestational diabetes mellitus.
62236975|NCT04556058|EXPERIMENTAL|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
62236976|NCT04556058|ACTIVE_COMPARATOR|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
62236977|NCT01294683|EXPERIMENTAL|Sequence 1: MK-0524B 2g/40g→MK-0524A 2g + Simvastatin 40 mg|After a 2-week placebo run-in, participants received extended release (ER) niacin/laropiprant (N/LRPT) 1 g/20 mg combination tablet (MK-0524B) once daily for 4 weeks, then ERN/LRPT/Simvastatin (SIM) 2 g/40 mg combination tablet once daily for 8 weeks. Participants then received ERN/LRPT 2 g (MK-0524A) co-administered with SIM 40 mg once daily for 8 weeks.
62236978|NCT01294683|EXPERIMENTAL|Sequence 2: MK-0524A 2g + Simvastatin 40 mg→ MK-0524B 2g/40g|After a 2-week placebo run-in, participants received ERN/LRPT 1 g (MK-0524A) co-administered with SIM 20 mg once daily for 4 weeks then received ERN/LRPT 2 g (MK-0524A) co-administered with SIM 40 mg once daily for 8 weeks. Participants then received ERN/LRPT/SIM 2 g/40 mg combination tablets (MK-0524B) once daily for 8 weeks.
62236979|NCT03473704|EXPERIMENTAL|Treatment group (TG)|The treatment group (TG) will receive the web treatment, which consists of 9 weekly sessions.
62236980|NCT03473704|PLACEBO_COMPARATOR|Control group (CG)|The control group (CG) will be evaluated in the same phases as the TG.
62236981|NCT02685943|EXPERIMENTAL|CAMS treatment|Psychotherapy using the Collaborative Assessment and Management of Suicidality framework
62236982|NCT02685943|ACTIVE_COMPARATOR|Treatment as usual|Ordinary treatment for suicidal patients
62236983|NCT00506545|EXPERIMENTAL|SCH 619734|
62236984|NCT00506545|PLACEBO_COMPARATOR|Placebo|
62236985|NCT00315939|EXPERIMENTAL|Group A Order: SMBG, IBMF-1, IBMF-2|Group A performed routine self-monitored blood glucose (SMBG) alone (level 1), followed sequentially by Integrated Biobehavioral Monitoring \& Feedback - 1 (IBMF-1) level 2 and Integrated Biobehavioral Monitoring \& Feedback - 2 (IBMF-2) level 3. Each level continued for 3 months.
62595304|NCT02234596|EXPERIMENTAL|Nintedanib|
62595305|NCT02002039|ACTIVE_COMPARATOR|erythropoietin, perinatal asphyxia,|Treatment group
62595306|NCT02002039|PLACEBO_COMPARATOR|Normal saline, perinatal asphyxia|Normal saline on alternate days for 5 doses starting from first 6 hours of life
62595307|NCT05108077|EXPERIMENTAL|Cytokine-induced killer cells|Patients with the metastatic tumors of the urogenital area receiving standard treatment and autologous cytokine-induced killer cells
62595308|NCT05108077|ACTIVE_COMPARATOR|Control|Patients with metastatic tumors of the urogenital area receiving standard treatment
62595309|NCT06619873|EXPERIMENTAL|Medication regimen A-D-B-C|
62812986|NCT02592291|NO_INTERVENTION|Control|Participants randomized into this group will not use the mHealth system throughout the study, but will continue with their standard of care.
62595310|NCT06619873|EXPERIMENTAL|Medication regimen B-A-C-D|
62595311|NCT06619873|EXPERIMENTAL|Medication regimen C-B-D-A|
62595312|NCT06619873|EXPERIMENTAL|Medication regimen D-C-A-B|
62427267|NCT02688309||Clinic Patients|"Patients from the clinic will be considered for enrollment if they are receiving an intraocular injection of a steroid as part of standard care for macular edema or progressive fibrosis.~Clinic patients who are receiving an intraocular injection of steroid (Ozurdex) as part of standard care who agree to participate will have an anterior chamber (AC) tap just prior to the intraocular injection of steroid and a second AC tap at a follow up visit 6 ± 2 weeks after the steroid injection."
62427268|NCT02688309||OR Patients|Patients undergoing surgery for one of the following conditions: (1) Proliferative Diabetic Retinopathy, (2) rhegmatogenous retinal detachment with PVR, (3) rhegmatogenous retinal detachment without PVR, (4) macular pucker, (5) macular hole. Surgical patients who agree to participate will have an anterior chamber (AC) tap at the beginning of surgery.
62812987|NCT04975841|NO_INTERVENTION|Standard of Care|Standard of Care (SOC) Study: The 6 subjects in the late injection group will start on Part 1. - The Part 1 study subject participation is 12 months. Two subjects will be enrolled at each of Months 0, 3 and 6. This will include an initial assessment and SOC follow-up. Subjects will continue standard of care treatment. Part 1 study duration (with staggering included) will be 18 months. After Part 1, the late injection subjects may proceed to Part 2 depending on safety data from the early injection group (see 3. below).
62812988|NCT04975841|ACTIVE_COMPARATOR|Stem Cell Injection|Stem Cell Injection: The three subjects randomized to early injections will proceed directly to Part 2 with staggered enrollment of 1 subject every 3 months. Once the safety data of the first subject at Month 3 is assessed, the second subject will be enrolled. Once the safety data of the first 2 subject (Subject 1 at Month 6 and Subject 2 at Month 3) are assessed, the third early injection subject will be enrolled in Part 2.
62035772|NCT03543826|OTHER|Subjects undergoing orthopedic or abdominal surgery|Subjects undergoing orthopedic or abdominal surgery requiring neuromuscular blockade. Subjects all receive the neuromuscular blockade drug Rocuronium based on study protocol. Depending on depth of block (subjectively assessed by TOF response), Neostigmine, Sugammadex, or no reversal drug is used to reverse block prior to extubation.
62427269|NCT00844727|ACTIVE_COMPARATOR|1|Rofexocib 25 mg OD, 1 year treatment
62035773|NCT03659838||Participants|Schoolchildren from the canton of Zürich aged 6 to 16 years
62035774|NCT04483050|EXPERIMENTAL|experimental group|
62427270|NCT00844727|PLACEBO_COMPARATOR|2|Placebo
62035775|NCT00272857|EXPERIMENTAL|Single arm|
62035776|NCT01362738|ACTIVE_COMPARATOR|Ablation of PV and extra-PV triggers|Conventional approach which includes pulmonary vein isolation (PVI) and ablation of extra-pulmonary triggers
62035777|NCT01362738|ACTIVE_COMPARATOR|LAA isolation along with the conventional ablation strategy|LAA isolation along with the conventional ablation strategy
62035778|NCT05258162|EXPERIMENTAL|Mobilization|"Mobilizations are performed with minimum 6 seconds distraction stretch followed by partial release then followed by slow intermittent stretch at 3-4 seconds intervals.~Oscillations for 2 minutes at 2-3 oscillations per second."
62427271|NCT05532046|EXPERIMENTAL|Treatment arm 1|Participants will receive BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
62595313|NCT04804267|EXPERIMENTAL|Experimental|Linaclotide Manufactured by Jiangsu Hansoh Pharmaceutical Co., Ltd. Drug: Linaclotide 145μg orally once daily
62812989|NCT03253796|EXPERIMENTAL|GLM SC QM (Full Treatment Regimen)|Period 1: participants are treated with open-label (OL) GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded SC GLM QM for up to 12 months
62812990|NCT03253796|EXPERIMENTAL|GLM SC Q2M (Reduced Treatment Regimen)|Period 1: participants are treated with OL GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded GLM SC every other month alternating with matching placebo to GLM every other month for up to 12 months
62812991|NCT03253796|PLACEBO_COMPARATOR|Placebo (Treatment Withdrawal Regimen)|Period 1: participants are treated with OL GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded placebo for up to 12 months
62812992|NCT03253796|EXPERIMENTAL|OL GLM Retreatment|Participants who experience a disease flare during double-blinded treatment in Period 2 will discontinue blinded treatment and receive OL GLM SC QM.
18320386|NCT05845606|EXPERIMENTAL|CBT + BZ-TP|Participants in this condition will receive telehealth-delivered Cognitive Behavioral Therapy (CBT) in addition to the benzodiazepine taper (BZ-TP) treatment.
18320387|NCT05845606|ACTIVE_COMPARATOR|HE + BZ-TP|Participants in this condition will receive telehealth-delivered health education in addition to the benzodiazepine taper (BZ-TP) treatment.
62812993|NCT02883569|ACTIVE_COMPARATOR|HIVD-OP|open or endoscopic discectomy
62812994|NCT02883569|EXPERIMENTAL|HIVD-NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
62035779|NCT05258162|EXPERIMENTAL|Muscle Energy Technique|Muscle Energy Technique is given in the form of post isometric relaxation with 5-7 sec hold for 8-10 repetitions followed by a gentle passive stretch. Only 20% resistance is offered to the isometric contraction.
62035780|NCT05077579||metabolically abnormal overweight & obese|
62035781|NCT05077579||metabolically normal overweight|
62427272|NCT05532046|EXPERIMENTAL|Treatment arm 2|Participants will receive BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
62427273|NCT05532046|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo to BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
62595314|NCT04804267|ACTIVE_COMPARATOR|Active Comparator|LINZESS® Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily
62812995|NCT02883569|ACTIVE_COMPARATOR|LSS w/o instability -OP|decompression, instrumentation and fusion
62427274|NCT01631370|EXPERIMENTAL|Renal denervation|The patients will be examined prior to renal denervation and 6 months after. Thus the patients are their own controls.
62427275|NCT00508235||Quality of Friendships|Patients with Neurofibromatosis, type 1 (NF-1) between the ages of 8 and 18 years old.
62427276|NCT03362528|EXPERIMENTAL|Short term collection of IMD data|Subjects will collect spectral raman data on WM3.4NR four times a day for 30 days distributed over a time period of 60 days. Each timepoints are conducted in duplicate. Spectral data will be compared to standard BG measurements.
62595315|NCT04804267|PLACEBO_COMPARATOR|Placebo Comparator|Placebo Drug: Placebo orally once daily
62595316|NCT03409107|EXPERIMENTAL|Daprodustat receivers|Participants will receive oral daprodustat once daily
62035782|NCT05077579||obese and metabolically normal lean|
62595317|NCT03409107|PLACEBO_COMPARATOR|Placebo receivers|Participants will receive oral placebo once daily
62035783|NCT01060293|ACTIVE_COMPARATOR|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
62035784|NCT01060293|ACTIVE_COMPARATOR|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
62035785|NCT01060293|ACTIVE_COMPARATOR|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
62035786|NCT05131048|ACTIVE_COMPARATOR|Conventional group|"Patients will be given thermal therapy with the hot pack for 20 minutes followed by Conventional physiotherapy will consist of a set of exercises. The exercise components willl be chosen based on previous studies (Deyle 2000) and will comprises of~* stretches of lower limb muscles (gastrocnemius, soleus and hamstring)~* isometric quadriceps work~* straight leg raising~* Joint mobilization includes anteroposterior (AP) glide of the tibia on the femur~* the patella glides in all directions Subjects will participate in a 45-minute physical therapy session, on alternate days weekly for 6 weeks, in our centre under the close surveillance of a physical therapist. A total of 24 sessions will be given to this group."
62595318|NCT04715542|EXPERIMENTAL|Stibium metallicum praeparatum 6x|Patients are treated with Stibium metallicum praeparatum 6x (subcutaneus injection), which is authorized in Switzerland and is listed by Swissmedic as an authorized anthroposophic medicinal product.
62595319|NCT04715542|PLACEBO_COMPARATOR|Saline subcutaneous injection|Placebo (a saline subcutaneous injection) is chosen as comparator to the treatment group.
62035787|NCT05131048|EXPERIMENTAL|interventional group|"Patients in this group will perform home-based hip Strengthening exercises to strengthen hip abductor and adductor muscles. Six different home-based exercises will be taught. This group will have 3 sessions in 1st week in the hospital under the supervision of a trained physiotherapist just to teach them and ensure that patients are doing exercises correctly on their own. After that, patients will perform exercises 5 days at home and 1 session at the hospital per week. The therapist will be trained to deliver different exercises and adjust the intensity of exercise accordingly advise the participants to complete 10 repetitions of every exercise at home96.~* Abduction in side-lying~* Abduction in standing~* Standing wall isometric hip abduction~* Hip Adduction in side-lying~* Hip abduction in a standing position~* Towel press"
62035788|NCT04868266|EXPERIMENTAL|end tidal carbon dioxide monitoring|
62035789|NCT04868266|NO_INTERVENTION|Oxygen saturation monitoring|
62812996|NCT02883569|EXPERIMENTAL|LSS w/o instability -NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
62812997|NCT02883569|ACTIVE_COMPARATOR|LSS w/ instability - OP|decompression, instrumentation and fusion
62035790|NCT06548555||Interventional arm|Patients receiving the systematic educational intervention
62035791|NCT06548555||Control arm|Patients treated in the clinical routine mode (the education of the patient follows routine practice and no added education is provided by the Healthcare Professionals).
62035792|NCT04513990|EXPERIMENTAL|Diagnostic (biospecimen collection)|Participants undergo collection of nasopharyngeal (back of the nose) samples by a medical provider and self-collection of oral, saliva, and nasal samples.
62035793|NCT06497400|ACTIVE_COMPARATOR|Group A|Jiu Jitsu intervention for ten weeks
62035794|NCT06497400|ACTIVE_COMPARATOR|Group B|Yoga intervention for ten weeks
62595320|NCT01701193|PLACEBO_COMPARATOR|Physiological saline- Laparoscopic|Participants receiving intraperitoneal administration of physiological saline at the time of laparoscopic myomectomy.
62812998|NCT02883569|EXPERIMENTAL|LSS w/ instability - NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
62812999|NCT02883569|ACTIVE_COMPARATOR|No intervention group|exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
62595321|NCT01701193|EXPERIMENTAL|L-Alanyl/L-Glutamine- Laparoscopic|Participants receiving intraperitoneal administration of L-Alanyl-L-Glutamine at the time of laparoscopic myomectomy.
62813000|NCT02883569|EXPERIMENTAL|Intervention group|epidural block, epidural adhesiolysis
62813001|NCT01673529|EXPERIMENTAL|study population|All subjects will receive 1%, 3%, 5% (w/w) of SB705498 and a placebo comparator
62813002|NCT04451785|ACTIVE_COMPARATOR|Healthy individuals|20 healthy subjets aged 6 years minimum will be included in this study. This is the control group.
62813003|NCT04451785|EXPERIMENTAL|Patients with hereditary spherocytosis|60 patients with hereditary spherocytosis will be included in this study.
62035795|NCT06497400|ACTIVE_COMPARATOR|Group C|Waitlist group for 5 weeks, then allowed to chose if they want to be in Group A Jiu Jitsu or Group B Yoga for ten week intervention
62427277|NCT03362528|EXPERIMENTAL|Long term collection of IMD data|Subjects will collect spectral raman data on WM3.4NR four times a day for the initial 30 days, distributed over a time period of 60 days. Subjects will for the remaining 60 days of measurements, distributed over 120 days collect spectral data twice a day. Each timepoints are conducted in duplicate. Spectral data will be compared to standard BG measurements.
62595322|NCT01701193|PLACEBO_COMPARATOR|Physiological saline- Laparotomy|Participants receiving intraperitoneal administration of physiological saline at the time of myomectomy (laparotomy).
62595323|NCT01701193|EXPERIMENTAL|L-Alanyl/L-Glutamine- Laparotomy|Participants receiving intraperitoneal administration of L-Alanyl-L-Glutamine at the time of myomectomy (laparotomy).
62595324|NCT05613998|EXPERIMENTAL|GR1. GPR intervention|Patients who will receive the GRP treatment protocol
62595325|NCT05613998|EXPERIMENTAL|GR2. Non-specific Aerobic exercice intervention|Patients who will receive the non-specific aerobic exercise treatment protocol
62595326|NCT05613998|NO_INTERVENTION|GR3. No physiotherapy intervention|Patients who will not receive physiotherapy treatment
62035796|NCT02792075||VH-IVUS|Patients with IVUS-derived virtual histology
62035797|NCT02792075||OCT|Patients with Optical coherence tomography
62595327|NCT00797628|EXPERIMENTAL|Information Prescription|"Providers will give usual care to patients who smoke and a paper prescription with the name and url of the Smoking Coach website. The smoking coach website is a tailored, public health intervention for smoking cessation."
62427278|NCT05269017|EXPERIMENTAL|Case group|The case group patients will receive vitamin D3 nasal drops
62427279|NCT05269017|ACTIVE_COMPARATOR|Control group|The control group will remove local corticosteroid spray
62035798|NCT02792075||NIRS|Patients with Near-infrared spectroscopy
62035799|NCT02792075||gray scale IVUS|Patients with gray-scale IVUS(Intravascular ultrasound)
62035800|NCT06187753||Children with Eosinophilic Esophagitis|Children with Eosinophilic Esophagitis The first group will consist 30 children with definite EoE diagnoses who were between ages 3 and 10 years. The Sensory Profile will used to evaluate sensory processing. This questionnaire will be completed by parents who record a child's responses to sensory events in daily life.
62427280|NCT04667273|EXPERIMENTAL|Exercise Training (ET) + Neuromuscular Electrical Stimulation (NMES) group|volunteer patients with Subacromial Impingement Syndrome
62595328|NCT00797628|EXPERIMENTAL|QUIT-PRIMO|Providers will give usual care to patients who smoke and then refer patients to the online smoking cessation system electronically.
62595329|NCT06321068|EXPERIMENTAL|BAT1308|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W)
62595330|NCT01005940|EXPERIMENTAL|Mandibular advancement device|Subject is evaluated when receiving intervention with mandibular advancement device.
62595331|NCT01005940|NO_INTERVENTION|No mandibular advancement device|Subject is evaluated when not receiving treatment with mandibular advancement device.
62595332|NCT03643289||Cohort A|Patients with stage 4 melanoma due to commence immunotherapy. Patients should be naïve to immunotherapy.
62595333|NCT03643289||Cohort B|Patients with stage 3 melanoma who are naïve to immunotherapy
62595334|NCT01064258|ACTIVE_COMPARATOR|fixed CPAP|subject will sleep with a fixed CPAP device at minimal pressure
62035801|NCT06187753||Children with Typically Developing|Typically Developing Children The second group will consist of 30 children with typically developing who were between ages 3 and 10 years. The Sensory Profile will used to evaluate sensory processing. This questionnaire will be completed by parents who record a child's responses to sensory events in daily life.
62595335|NCT01064258|EXPERIMENTAL|autoCPAP|the subject will sleep connected to an autoCPAP device
62595336|NCT06201975|EXPERIMENTAL|Thyme honey|The experimental group will receive scaling and root debridement and locally delivered 0.5 ml non-diluted Thyme honey on sites with PPD ≥ 5 mm. Thyme honey will be delivered to the sites until overflows using a syringe with plastic catheter of cannula 20 g (B Braun) attached to it. Patients will be reviewed at 6 weeks to re-evaluate the clinical periodontal parameters (Ibrahim et al., 2021).
62236986|NCT00315939|EXPERIMENTAL|Group B Order: IBMF-1, IBMF-2, SMBG|Group B began with Integrated Biobehavioral Monitoring \& Feedback - 1 (IBMF-1) level 2, followed by level 3, Integrated Biobehavioral Monitoring \& Feedback - 2 (IBMF-2) and then level 1 (SMBG only). Each level continued for 3 months.
62595337|NCT06201975|PLACEBO_COMPARATOR|Saline|The control group will receive scaling and root debridement with normal saline irrigation on sites with PPD ≥ 5 mm.
62595338|NCT03018496|EXPERIMENTAL|Older Men|Healthy male adults aged 18-35 Subjects will receive both HMB and placebo on separate visits in a crossover fashion
62427281|NCT04667273|OTHER|Exercise Training (ET) group|volunteer patients with Subacromial Impingement Syndrome
62427282|NCT06439264|EXPERIMENTAL|test group|In test group, after reflection of flap and degranulation, bone graft i.e., bentonite clay gel with hydroxyapatite will be placed in the void created by the defect and sutures will be placed
62427283|NCT06439264|ACTIVE_COMPARATOR|control group|In control group, after reflection of flap and degranulation, bone graft i.e., hydroxyapatite will be placed in the defect and sutures will be placed.
62595339|NCT03018496|EXPERIMENTAL|Younger Men|Healthy male adults aged 65-85 Subjects will receive both HMB and placebo on separate visits in a crossover fashion
62427284|NCT02072174|EXPERIMENTAL|Anaferon for Children|On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily.
62427285|NCT02072174|PLACEBO_COMPARATOR|Placebo|On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily.
62427286|NCT01355523|ACTIVE_COMPARATOR|Melatonin|6 mg oral melatonin daily
62427287|NCT01355523|PLACEBO_COMPARATOR|Placebo|6 mg oral placebo daily
62595340|NCT05591066|NO_INTERVENTION|Usual care|Unstructured communication during rounds and unstandardized interpretation at provider discretion.
62813004|NCT02163902|EXPERIMENTAL|ATX-101|Participants treated with ATX-101 in previous studies ATX-101-11-22 and ATX-101-11-23.
62813005|NCT02163902|PLACEBO_COMPARATOR|Placebo|Participants treated with placebo in previous studies ATX-101-11-22 and ATX-101-11-23.
62813006|NCT04134416|EXPERIMENTAL|Anodal transcranial direct current stimulation|Transcortical direct current stimulation (tDCS) will be applied using a STARSTIM neurostimulation device (Neuroelectrics, Barcelona). Each participant will receive 10 20-minute sessions while receiving REGIAplus (online). Group 1 will receive active stimulation (anodal stimulation, A-tDCS).The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (REGIAplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the trial.
62813007|NCT04134416|SHAM_COMPARATOR|Sham transcranial direct current stimulation|Group 2 will receive sham stimulation (S-tDCS). In the sham stimulation, the same helmet and electrode that is used in the active stimulation will be placed but, in this case, we will apply only a slight current at the beginning and end of the session with the objective of simulating the effects that are experienced with the active stimulation without producing significant cortical stimulation. The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (REGIAplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the assay.
62813008|NCT02772601|EXPERIMENTAL|All patients|
62035802|NCT02866565|EXPERIMENTAL|Diabetic foot ulcer|
62236987|NCT00553956|EXPERIMENTAL|1|Intervention group A treatment combination of Narrative Exposure Therapy and Interpersonal Psychotherapy (5 individual sessions NET in addition to 3 individual sessions IPT)
62236988|NCT00553956|NO_INTERVENTION|2|Waiting list control
62427288|NCT06481423|EXPERIMENTAL|Intervention Group|Participants receive digital cognitive behavioral intervention for insomnia(dCBT-I) via their smartphone, and can freely access relaxing music in the app
62427289|NCT06481423|OTHER|Control Group|Participants can only freely access relaxing music in the app. They don't have access to dCBT-I
62427290|NCT00831467|EXPERIMENTAL|CV9103|CV9103 is applied intradermally into the thigh and upper arm of either side of the body at week 1, week 3, week 7, week 15, week 23
62427291|NCT04093167|ACTIVE_COMPARATOR|Pembrolizumab alone|
62427292|NCT04093167|EXPERIMENTAL|Pembrolizumab + standard platinum-based chemotherapy|
62427293|NCT05976217|EXPERIMENTAL|treatment|Venetoclax 100 mg daily for 3 weeks
62813009|NCT00812994|PLACEBO_COMPARATOR|Placebo|
62813010|NCT00812994|EXPERIMENTAL|Escitalopram|
62595341|NCT05591066|EXPERIMENTAL|PFC I-PASS Intervention|Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
62595342|NCT05591066|EXPERIMENTAL|PFC I-PASS+ Intervention|PFC I-PASS+ includes all parts of PFC I-PASS plus having interpreters on and after rounds and training doctors about communication and cultural humility.
62595343|NCT02100670|EXPERIMENTAL|1% diclofenac sodium plus 3% menthol|1% diclofenac sodium plus 3% menthol gel supplied in 30 gram (g) tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
62595344|NCT02100670|EXPERIMENTAL|1% diclofenac sodium plus 0.09% menthol|1% diclofenac sodium plus 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
62595345|NCT02100670|EXPERIMENTAL|3% menthol|3% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
62595346|NCT02100670|PLACEBO_COMPARATOR|Placebo with 0.09% menthol gel|Placebo with 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
62595347|NCT04159415|EXPERIMENTAL|Treatment A|
62236989|NCT05755490|EXPERIMENTAL|PROWESS|"Participants will complete study procedures as outlined:~* Wear FitBit watch during the 12-week study period.~* Group intervention sessions, in-person or virtually.~* One optional follow-up session.~* One-on-one, semi-structured interview with trained study staff to assess participant experience with intervention."
62236990|NCT02839954|EXPERIMENTAL|CAR-pNK Cell immunotherapy|Enrolled patients will receive CAR-pNK cell immunotherapy with a novel specific chimeric antigen receptor targeting MUC1 antigen by infusion.
62236991|NCT05467774|EXPERIMENTAL|Training group|Participants receive 24 sessions of operant H-reflex conditioning of the rectus femoris.
62595348|NCT04159415|EXPERIMENTAL|Treatment B|
62236992|NCT00140231|ACTIVE_COMPARATOR|Metreleptin|r-metHuLeptin self-administered subcutaneously
62236993|NCT00140231|PLACEBO_COMPARATOR|Placebo|Placebo, administered in same method as active arm.
62236994|NCT03537950|EXPERIMENTAL|PLC, CBD, CBDV|Dose order: PLC, CBD, CBDV
62595349|NCT03697759|EXPERIMENTAL|Usual care + selfBACK|Participants will use the selfBACK system and app
62595350|NCT02070731|NO_INTERVENTION|unprotected TAVI|standard unprotected Transcatheter Aortic Valve Implantation
62595351|NCT02070731|EXPERIMENTAL|TAVI with the TriGuard HDH|TAVI with the TriGuard HDH embolic deflection device
62595352|NCT05503602|OTHER|Control Group|An average of 20 people will be taken into the control group.
62595353|NCT05503602|EXPERIMENTAL|IASTM Treatment Group|An average of 20 people will receive IASTM application treatment.
62595354|NCT05503602|EXPERIMENTAL|Foam Roller Treatment Group|An average of 20 people will receive Foam Roller application treatment.
62595355|NCT01943968|OTHER|Systemic sclerosis patients|Systemic sclerosis patients will have blood tested for fibrotic enzyme levels
62595356|NCT03073694|ACTIVE_COMPARATOR|Mitomycin C Group|Mitomycin-C initial dose of 15 mg/m2 (milligrams per meter squared) 45 minutes into the perfusion, a maintenance dose of 5 mg/m2 will be administered.
62236995|NCT03537950|EXPERIMENTAL|PLC, CBDV, CBD|Dose order: PL, CBDV, CBD
62595357|NCT03073694|EXPERIMENTAL|Melphalan Group|Melphalan 60 mg/m2 (milligrams per meter squared) 45 minutes into the perfusion.
62595358|NCT01907295||Patients|Patients diagnosed with idiopathic, anorexigen-induced, heritable PAH and PVOD/PCH
62595359|NCT01907295||Relatives and controls|Relative has a family member diagnosed with idiopathic, anorexigen-induced, heritable PAH and PVOD/PCH Self declared healthy individuals
62595360|NCT06620198|EXPERIMENTAL|Active-assisted therapy with an upper limb robotic exoskeleton|"Patients will receive upper limb neurorehabilitation training using a robotic exoskeleton administered by the therapist. The assistance provided by the device is adjusted based on the maximum force (as a percentage of the upper limb's weight) the robot needs to exert to assist the patient's movements. The computer-robot interface is designed to offer various exergames that require specific upper limb movements.~All movements performed by the patient using the exoskeleton will provide immediate audiovisual feedback on the computer screen. The training will consist of 20 sessions, with five 45-minute sessions per week."
62813011|NCT06079138|EXPERIMENTAL|Active tDCS and telerehabilitation exercise program|Participants will receive active tDCS with an intensity 2 mA for 20 minutes and a telerehabilitation exercise program for 50 minutes. The program will be implemented over 12 sessions, occurring three times a week for four weeks).
62813012|NCT06079138|SHAM_COMPARATOR|Sham tDCS and Telerehabilitation exercise|Participants will receive sham tDCS for 20 minutes. The program will be implemented over 12 sessions, occurring three times a week for four weeks.
62595361|NCT06620198|ACTIVE_COMPARATOR|Passive mobilization with an upper limb robotic exoskeleton|Patients will undergo a neurorehabilitation intervention with a SHAM treatment under the guidance of the experimental therapist.
62595362|NCT03596606|EXPERIMENTAL|Myofunctional Motor Control Exercises|"Both groups will be treated with Manual treatment and in one of them the myofunctional motor control treatment will be added as intervention. The experimental group will be the one that will receive the combined treatment.~The patient will receive five sessions, one session every week."
62595363|NCT03596606|ACTIVE_COMPARATOR|Manual Treatment|The control group will receive only Manual treatment (TO). The patient will receive five sessions, one session every week.
62595364|NCT05759520|EXPERIMENTAL|2-month-old experimental group|Vaccination of 4 doses of experimental vaccine(0,2,4,1 booster dose)
62595365|NCT05759520|ACTIVE_COMPARATOR|2-month-old control group|Vaccination of 4 doses of control vaccine(0,2,4,1 booster dose)
62595366|NCT05759520|EXPERIMENTAL|3-month-old group|Vaccination of 4 doses of experimental vaccine(0,1,2,1 booster dose)
62595367|NCT05662059|EXPERIMENTAL|Treatment|Two therapy sessions (active stimulation) per day for 12 weeks with Treatment device
62595368|NCT05662059|SHAM_COMPARATOR|Sham|Two therapy sessions per day for 12 weeks with Sham device (no active stimulation)
62236996|NCT03537950|EXPERIMENTAL|CBD, PLC, CBDV|Dose order: CBD, PLC, CBDV
62236997|NCT03537950|EXPERIMENTAL|CBD, CBDV, PLC|Dose order: CBD, CBDV, PLC
62236998|NCT03537950|EXPERIMENTAL|CBDV, PLC, CBD|Dose order: CBDV, PLC, CBD
62236999|NCT03537950|EXPERIMENTAL|CBDV, CBD, PLC|Dose order: CBDV, CBD, PLC
62237000|NCT02484339|EXPERIMENTAL|Treatment Group A|"Radium-223 dichloride (Xofigo®) 55 kilobecquerel (kBq)/kgbw (6 i.v. injections every 4 weeks)~External beam radiotherapy (EBRT)-\>conventional or high dose radiotherapy"
62237001|NCT02484339|OTHER|Treatment Group B|External beam radiotherapy (EBRT) -\>conventional or high dose radiotherapy
62237002|NCT04488497|EXPERIMENTAL|Peer coach guided online learning program|
62237003|NCT04488497|PLACEBO_COMPARATOR|Self-administered online learning program|
62595369|NCT06547424|EXPERIMENTAL|Chondroitin sulfate|Neonates with Bell's Stage 2 NEC will receive chondroitin sulfate (20mg/kg/day) dissolved in 1-2 mil of milk or formula for 2 days
62595370|NCT06547424|PLACEBO_COMPARATOR|Placebo|Neonates with Bell's Stage 2 NEC will receive 1-2 ml of milk or formula placebo for 2 days
62595371|NCT03096769|OTHER|Study Arm|
62595372|NCT02951221|EXPERIMENTAL|Cohort 1|Treatment sub groups A and B
62595373|NCT02951221|EXPERIMENTAL|Cohort 2|Treatment sub groups C and D
62035803|NCT01726868|EXPERIMENTAL|Liposorber LA-15 System|
62237004|NCT02564939|ACTIVE_COMPARATOR|ramelteon|receive ramelteon
62237005|NCT02564939|PLACEBO_COMPARATOR|placebo|receive placebo
62237006|NCT02691260|NO_INTERVENTION|no incentives|Participants do not receive financial incentives.
62427294|NCT05474937|ACTIVE_COMPARATOR|inhalational Sevoflurane|In the field of pediatric gastroenterology, upper gastrointestinal endoscopy has established itself as a diagnostic and therapeutic tool. In order to increase patient tolerance during this procedure, deep sedation is essential. Children are at a higher risk of serious adverse effects from procedural sedation; thus, their safety is a primary issue throughout this procedure. Multiple studies have been done to find the ideal method for procedural sedation in terms of ease of administration, quality, safety of sedation and recovery profile, but the consensus seems lacking. In this study we will compare between nasal inhalation of sevoflurane versus intravenous ketamine, midazolam and propofol for pediatrics undergoing upper gastrointestinal endoscopy.
62427295|NCT05474937|ACTIVE_COMPARATOR|Intravenous Ketamine, Midazolam and Propofol group|Preoxygenation with 100% O2 for 1 minute, by proper sized face mask. Patients in Ketamine -midazolam -propofol (KMP) group will receive 1-1.5 mg/kg IV ketamine and 0.05mg/kg IV Midazolam and 1mg/kg IV Propofol as induction dose then followed by incremental doses of 0.5 mg/kg IV Propofol alone for maintenance and if procedure is prolonged propofol infusion at 100 μg/kg/min is given for maintenance of sedation. Induction dose will be considered as adequate if adequate jaw relaxation for endoscope insertion and Modified Ramsay Sedation Score (MRSS) ≥7 occurs with maintenance of spontaneous respiration. Induction time will be considered as time from beginning of IV agent to achievement of MRSS ≥7. After endoscope insertion, maintenance of oxygenation by nasal cannula at flow twice the minute ventilation of the patient.
62595374|NCT05401448|PLACEBO_COMPARATOR|Placebo|sterile 0.9% NaCl
62595375|NCT05401448|EXPERIMENTAL|Influenza|Influenza (tetravalent vaccine)
62595376|NCT05401448|EXPERIMENTAL|MMR|measles, mumps, and rubella vaccine
62813013|NCT05830058|EXPERIMENTAL|ARM I: (standard care SBRT)|Patients undergo 5 SBRT treatments every other day on study. Patients also undergo CT or PET/CT and blood collection throughout study.
62237007|NCT02691260|ACTIVE_COMPARATOR|incentives for dietary self-monitoring|Participants receive financial incentives for dietary self-monitoring.
62595377|NCT05013879|EXPERIMENTAL|Kinesiotape leg plus standard rehabilitation|Kinesio(R)Tape for edema management applied to a randomly selected lower extremity plus standard inpatient rehabilitation after bilateral total knee arthroplasty
62595378|NCT05013879|NO_INTERVENTION|Control leg with standard rehabilitation alone|Control leg receiving standard inpatient rehabilitation alone.
62595379|NCT01457586|ACTIVE_COMPARATOR|Transfusion|Patient who received blood transfusion in the perioperative period
62813014|NCT05830058|EXPERIMENTAL|ARM II: (PET guided SBRT)|ARM II: Patients undergo 3 SBRT treatments every other day week 1, undergo PET/CT and replanning one month post SBRT, then undergo 2 additional treatments with SIB on study. Patients also undergo CT or PET/CT and blood collection throughout study.
62813015|NCT02352480|EXPERIMENTAL|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment plus usual and customary care, which can include any advanced therapeutics.
62035804|NCT02324933|EXPERIMENTAL|Fentanyl Challenge Dosing|"In the operating room a fentanyl infusion will be started at 2 mcg/kg/min. The time from start of the infusion to respiratory depression(rate \< 5 breaths/minute) will be used to calculate the effect-site concentration (Ce).Using the pharmacodynamic model calculated by the Stanpump PCA software, the infusion will continue intraoperatively to achieve a fentanyl Ce of 30%. In the Post Anesthesia Care Unit (PACU), the rate would be changed with the following parameters:~1. 50% of the hourly dose is given as a basal infusion~2. The remainder of the hourly dose is ordered as a demand dose q 15 minutes. Post-operatively, the basal rate is adjusted according to the average demand dose use. In patients using \< 1 demand dose per hour, the basal rate is decreased by 20%. In patients using \> 3 demand doses per hour, the basal rate is increased by 20%. Patients whose pain cannot be managed by this protocol will be removed from the study and pain management will revert to the primary service."
62237008|NCT02691260|ACTIVE_COMPARATOR|incentives for interim weight loss|Participants receive financial incentives for interim weight loss.
62237009|NCT02691260|EXPERIMENTAL|incentives for both|Participants receive incentives for dietary self-monitoring and interim weight loss.
62237010|NCT03118349|EXPERIMENTAL|Escalation Cohorts|MVT-5873 blocking dose and MVT-1075 dose escalation; Initial to maximum tolerated dose
62237011|NCT03118349|EXPERIMENTAL|Expansion Cohort - no subjects enrolled|MVT-5873 blocking dose and MVT-1075 Maximum tolerated dose
62237012|NCT03645057|EXPERIMENTAL|Crisaborole|The topical treatment will be applied to all affected areas twice daily for 12 weeks.
62237013|NCT03645057|ACTIVE_COMPARATOR|Tacrolimus 0.03%|The topical treatment will be applied to all affected areas twice daily for 12 weeks.
62595380|NCT01457586|NO_INTERVENTION|No Transfusion|Patients who did not receive blood transfusion in the perioperative period
62237014|NCT04251650||low severity|patient with periodontitis stage I and II
62237015|NCT04251650||high severity|patient with periodontitis stage III and IV
62237016|NCT03045042||Treated patients|Patients with late onset Pompe disease treated with the enzyme replacement therapy
62237017|NCT03045042||Non treated patients|Patients with late onset Pompe disease non treated with the enzyme replacement therapy
62427296|NCT04403373|PLACEBO_COMPARATOR|Waitlist control group|Participants in this group receive no intervention during the 12-week period.
62237018|NCT00813163|EXPERIMENTAL|PEP02|Liposome Irinotecan
62237019|NCT00373750|EXPERIMENTAL|Family Spirit Intervention|The Family Spirit Intervention included 43 structured lessons and followed a culturally congruent format. Positive parenting lessons were focused on reducing behaviors (i.e., poor monitoring; coercive interactions;harsh, unresponsive, or rejecting parenting; and abuse/ neglect) associated with early childhood behavior problems, including externalizing, internalizing, and dysregulation problems.
62237020|NCT00373750|NO_INTERVENTION|Optimized Standard Care Control Group|Optimized standard care consisted of transportation to recommended prenatal and well-baby clinic visits, pamphlets about child care and community resources, and referrals to local services. It also addressed access barriers to health care for young mothers and children, and it overcame concerns that home-visiting programs have operated in parallel, not in partnership, with pediatric care. Family health liaisons conducted the optimized standard care and were not trained in the Family Spirit intervention, to avoid contamination of the control condition.
62595381|NCT05103904|EXPERIMENTAL|Treatment (Lenvatinib)|Patients receive lenvatinib PO QD. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the protocol therapy
62595382|NCT03357133|EXPERIMENTAL|Tirofiban and alteplase|
62595383|NCT03357133|PLACEBO_COMPARATOR|Alteplase|
62595384|NCT04569422||ephedrine drop|
62237021|NCT01033253|EXPERIMENTAL|Computerized Tailored Intervention|Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
62237022|NCT01033253|NO_INTERVENTION|Control|Computerized assessments of Transtheoretical Model constructs at 0, 2, 6, and 12 months
62237023|NCT02678013|EXPERIMENTAL|Radiofrequency ablation(RFA)|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
62243447|NCT02717663|EXPERIMENTAL|Static goals with delayed incentives|Participants will receive static physical activity goals with delayed, non-contingent incentives
62243448|NCT02717663|EXPERIMENTAL|Adaptive goals with delayed incentives|Participants will receive adaptive physical activity goals with delayed, non-contingent incentives
62427297|NCT04403373|EXPERIMENTAL|Moderate-intensity walking group|Participants in this group will perform a thrice-a-week walking exercise at a moderate intensity (\~3.5 METs). The training will be conducted outdoors. Each training session lasts for 50 minutes.
62427298|NCT04403373|EXPERIMENTAL|Vigorous-intensity walking group|Participants in this group will perform a thrice-a-week walking exercise at a vigorous intensity (\~7 METs). The training will be conducted outdoors. Each training session lasts for 25 minutes.
62427299|NCT01067859|EXPERIMENTAL|Arm 1|
62427300|NCT01067859|EXPERIMENTAL|Arm 2|
62427301|NCT01067859|PLACEBO_COMPARATOR|Arm 3|
62595385|NCT01378377|EXPERIMENTAL|Pimasertib 45 mg+Temsirolimus 12.5 mg|
62595386|NCT01378377|EXPERIMENTAL|Pimasertib 45 mg+Temsirolimus 25 mg|
62595387|NCT01378377|EXPERIMENTAL|Pimasertib 75 mg+Temsirolimus 25 mg|
62595388|NCT04367870||Non immune patient|Patients with a negative SARS-CoV-2 immunoassay
62595389|NCT04367870||Immune patient|Patients with a positive SARS-CoV-2 immunoassay
62035805|NCT02324933|ACTIVE_COMPARATOR|Standard of Care (Control)|"Patients in the best practice arm would receive pre-operative sedation in the operating room comparable to the dose normally given in the Ambulatory Surgery Unit as a simulated fentanyl challenge. Best practice (control) patients will be followed by the Pain \& Palliative Care team in order to make adjustments in pain management as required by the patients."
62237024|NCT02678013|ACTIVE_COMPARATOR|RFA+CTL|RFA was performed the same as RFA Arm.Peripheral blood (20-30mL) for manufacturing the individualized highly-purified CTL agent was collected from the respective patients who were randomized to the immunotherapy group before starting treatment. The highly-purified CTL agent was prepared at a central manufacturing facility. Patients in the immunotherapy group received 5\*10E9 of the highly-purified CTL agent intravenously over 60 minutes without any premedication and then were observed for at least 30 minutes. They were scheduled to receive highly-purified CTL: 4-6 treatments at a frequency of once two-week during 6 months after receiving RFA, followed by 6-9 treatments during 6 months to 2 years after receiving RFA.
62237025|NCT04111432|EXPERIMENTAL|Group I-EV71 and EPI vaccines Concomitant administration|EV71 Vaccine (intramuscular injection,0.5ml,first dose)/measles mumps, and rubella combined live attenuated vaccine (subcutaneous injection,0.5ml) on day 0 and EV71 Vaccine (intramuscular injection, 0.5ml,second dose)/ encephalitis live attenuated vaccine (subcutaneous injection, 0.5ml) on day 30
62237026|NCT04111432|ACTIVE_COMPARATOR|Group II-EPI vaccine only Single injection of EPI vaccine:|measles mumps, and rubella combined live attenuated vaccine (subcutaneous injection,0.5ml) on day 0 and encephalitis live attenuated vaccine (subcutaneous injection, 0.5ml) on day 30
62237027|NCT04111432|ACTIVE_COMPARATOR|Group III-EV71 vaccine only EV71 Vaccine only|the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 andday 30 respectively
62237028|NCT01463384|ACTIVE_COMPARATOR|Minocycline|Subjects will be administered 50mg minocycline twice daily.
62237029|NCT01214538||Control group - culture negative|50 children with pneumococcal culture-negative Acute Otitis Media
62237030|NCT01214538||study group- culture positive|50 children with pneumococcal culture-positive Acute Otitis Media
62237031|NCT04298723|EXPERIMENTAL|Left Atrial Appendage Occlusion|Percutaneous closure of the LAA by use of CE-mark approved LAA occlusion device Watchman / Watchman FLX
62595390|NCT04842188|ACTIVE_COMPARATOR|L-PRF|Leukocyte platelet rich fibrin as a sole graft material in class II furcation
62595391|NCT04842188|ACTIVE_COMPARATOR|L-PRF with aPDT|Leukocyte platelet rich fibrin combined with antibacterial photodynamic therapy in class II furcation
62595392|NCT04079257||Patients with paroxysmal nocturnal hemoglobinuria|Patients are already treated with eculizumab. The only intervention is the collection of extra blood samples to measure peak concentrations of eculizumab
62595393|NCT00655148|EXPERIMENTAL|A|DTaP-IPV vero vaccination at 2, 3½, 5 and 16 months of age
62595394|NCT00655148|ACTIVE_COMPARATOR|B|DTaP-IPV mkc vaccination at 2, 3½, 5 and 16 months of age
62035806|NCT05446987|EXPERIMENTAL|Position change and back massage group|The patients received changing of position every two hours as follows in the same order: supine position with a head angle of 15°, semi-fowler position with a head angle of 30°, lateral right or left position with a head angle of 15°. Also, the patients received a simple stroke of lower back massage for 5 minutes every 2 hours
62035807|NCT05446987|EXPERIMENTAL|Early ambulation|The patient are allowed to ambulate after 3 hours of complete bed rest in the supine position with a zero head of bed elevation angle.
62035808|NCT03199625|EXPERIMENTAL|Cognitive Therapy group|treatment with Cognitive Therapy
62035809|NCT03199625|EXPERIMENTAL|Behavior Therapy group|treatment with Behavior Therapy
62035810|NCT03199625|ACTIVE_COMPARATOR|SSRI antidepressants|treatment by SSRI antidepressant
62035811|NCT06326515|EXPERIMENTAL|Experimental: Treatment Group|"Experimental: Treatment Group~Experimental Group:~Participants in the experimental group would receive 8-10 session of psychoeducational based Program.~Waitlist control Group:~Participants in the Control group would not receive psychoeducational Intervention"
62035812|NCT06326515|NO_INTERVENTION|No Intervention: Control Group|"No Intervention: Control Group~Control Group:~Participants in the control group did not receive the said psychoeducational intervention"
62035813|NCT01641978||ICU patients|neurological level in critical patients
62035814|NCT05881616||GDM group|Pregnant women aged 20-40 with positive oral glucose tolerance test (OGTT) results at 24-28 weeks.
62035815|NCT05881616||non-GDM group|Pregnant women aged 20-40 with negative OGTT results at 24-28 weeks.
62035816|NCT05881616||Control group|Healthy non-pregnant women aged 20-40.
62035817|NCT02639130|ACTIVE_COMPARATOR|Vildagliptin|"After a screening examination, patients were treated with vildagliptin and participated in meal tests (day 9 and 10, respectively), in a crossover design. Between the two treatment periods, there was a ≥ 5 week wash-out period.~Experimental procedures: Meal test, determination of the rate of gastric emptying. On days 9 and 10 of treatment, the volunteers underwent a mixed meal (one scrambled egg, a slice of ham, 10 g of butter, two slices of toast, 20 g strawberry jam, and 200 ml of unsweetened tea) test in the morning after fasting overnight. 13C-octanoic acid (110 µl/100 mg) was used as label.~Meal tests were performed (days 9 and 10), without and with a high dose intravenous infusion of exendin \[9-39\]."
62035818|NCT02639130|PLACEBO_COMPARATOR|Placebo|"After a screening examination, patients were treated with placebo, and participated in meal tests (day 9 and 10, respectively), in a crossover design. Between the two treatment periods, there was a ≥ 5 week wash-out period.~Experimental procedures: Meal test, determination of the rate of gastric emptying. On days 9 and 10 of treatment, the volunteers underwent a mixed meal (one scrambled egg, a slice of ham, 10 g of butter, two slices of toast, 20 g strawberry jam, and 200 ml of unsweetened tea) test in the morning after fasting overnight. 13C-octanoic acid (110 µl/100 mg) was used as label.~Meal tests were performed (days 9 and 10), without and with a high dose intravenous infusion of exendin \[9-39\]."
62035819|NCT05176808|ACTIVE_COMPARATOR|Telehealth Parent Coaching (TC)|"A family-centered, collaborative coaching approach, Practice-Based Coaching (Snyder et al., 2015), will be used. Coaches will use an NDBI coaching curriculum to support parents in targeting the child social-communication skills during interactions with their toddlers with ASD. The duration of the coaching period is 12 weeks with 2 sessions per week. Parents will be coached to implement NDBI strategies during daily routines with their young child with ASD following the coach and parent NDBI manuals developed in the primary principal investigator's lab.~Trained study coaches will join families in their homes remotely via Kennedy Krieger Institute's secure Zoom password-protected account to provide coaching."
62035820|NCT05176808|ACTIVE_COMPARATOR|In-person Coaching(IPC)|"A family-centered, collaborative coaching approach, Practice-Based Coaching (Snyder et al., 2015), will be used. Coaches will use an NDBI coaching curriculum to support parents in targeting child social-communication skills during interactions with their toddlers with ASD. The duration of the coaching period is12 weeks with sessions 2 times per week. Parents will be coached to implement NDBI strategies during daily routines with their young child with ASD following the coach and parent NDBI manuals developed in the primary principal investigator's lab.~Coaching will be delivered in families' homes by trained study coaches to support parent implementation of NDBI strategies during daily life activities with their toddler with ASD."
62813016|NCT02352480|NO_INTERVENTION|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week there after while receiving usual and customary care, but actual frequency of visits will be determined by the treating physician. Usual and customary care, which can include any advanced therapeutics.
62237032|NCT04298723|NO_INTERVENTION|Best medical therapy for anticoagulation|Standard of care (according to current guidelines)
62237033|NCT01002365|ACTIVE_COMPARATOR|Post op care|
62237034|NCT01002365|ACTIVE_COMPARATOR|Oxygen administration- different %|
62237035|NCT00730561|NO_INTERVENTION|1|
62813017|NCT02438176|EXPERIMENTAL|single puncture group|single trans-septal puncture
62035821|NCT03894865|EXPERIMENTAL|urban school|Male students from selected urban schools undergo screening for idiopathic scoliosis
62035822|NCT03894865|EXPERIMENTAL|countryside schools|Male students from selected countryside schools undergo screening for idiopathic scoliosis
62237036|NCT00730561|EXPERIMENTAL|2|Hematopoietic stem cell transplantation
62237037|NCT03099668|EXPERIMENTAL|OSAC|Single visit to a multidisciplinary clinic (the One Stop Arthritis Clinic, OSAC), followed by routine care
62237038|NCT03099668|NO_INTERVENTION|Routine care|Routine care
62237039|NCT05509933|EXPERIMENTAL|Budesonide|
62813018|NCT02438176|ACTIVE_COMPARATOR|conventional group|conventional bilateral groin puncture
62813019|NCT01088789|OTHER|Cohort 1|"Arm A: Vaccine only. Arm B receives vaccine as well as a single dose of intravenous cyclophosphamide. Arm C: In addition to Vaccine Cohort 3 receives a daily dose of metronomic cyclophosphamide orally.~Only patients from the J0810 study are eligible.~Closed to enrollment."
62813020|NCT01088789|OTHER|Cohort 2|"Cohort 2 receives vaccine as well as a single dose of intravenous cyclophosphamide. Vaccine-naïve cohort.~Closed to enrollment."
62427302|NCT00084617|EXPERIMENTAL|Treatment (oxaliplatin, irinotecan, capecitabine)|Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on days 1, 8, 15, and 22 and oral capecitabine twice daily on days 1-5, 8-12, 15-19, and 22-26. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
62427303|NCT05200806|OTHER|Intervention|Pre-Op Enhanced Recovery After Surgery (ERAS): Gabapentin (900mg capsule), Acetaminophen (1,000mg tablet), Dexamethasone (8mg IV), Granisetron (1mg IV), Morphine (0.15mg Intrathecal) Intraoperatively: Appropriate medications administered at discretion of the treating anesthesiologist during colectomy, with Ketamine use encouraged if not contraindicated. Post-Op (PACU, Onward during inpatient stay): Acetaminophen (Oral) (650mg, q4hrs), Gabapentin (300mg, q6hours), Methocarbamol (750mg, QID), 5% Lidocaine Patch (q12hrs PRN) One time rescue dose (Hydromorphone, Morphine, Oxycodone) available for breakthrough pain during hospital stay (differs from traditional ERAS protocol where medications can be administered as needed). If one-time rescue dose is needed, the covering physician will be notified and can choose to order an appropriate narcotic regimen for remainder of patient's hospitalization. All patients are discharged with a narcotics prescription that they can choose to fill.
62427304|NCT05761132|EXPERIMENTAL|Neoadjuvant pembrolizumab|"Patients receive pembrolizumab, 200 mg IV Q3W for a total of 2 administrations per patient over a period of 6 weeks prior to surgery.~Responders have the option to fall into an extension cohort and, after consultation with the multidisciplinary team, will be treated with adjuvant pembrolizumab from week 16 until week 58 (400 mg IV, Q6W, 7 times)."
62595395|NCT02756780|EXPERIMENTAL|Tenovus Cancer Choir|Participants will be asked to attend 12 weeks of weekly choir rehearsals lasting approximately 1 hour. Following the first 12 weeks, participants will no longer be asked to attend rehearsals, but are welcome to do so. Whether or not they do and how many they attend will be measured as an outcome variable to assess whether initial 3-month involvement leads to long-term engagement.
62813021|NCT01088789|OTHER|Cohort 3|"Cohort 3 receives vaccine as well as a single dose of intravenous cyclophosphamide.~Only participants from J1568 study are eligible."
62813022|NCT01088789|OTHER|Cohort 4|"Cohort 4 receives vaccine as well as a single dose of intravenous cyclophosphamide.~Only participants from J15237 study are eligible."
62035823|NCT00649194|EXPERIMENTAL|1|Rabeprazole Sodium Delayed-Release Tablets 20 mg
62035824|NCT00649194|ACTIVE_COMPARATOR|2|Aciphex® Tablets 20 mg
62035825|NCT01512862|EXPERIMENTAL|Calcitriol|
62035826|NCT01512862|NO_INTERVENTION|Placebo|
62035827|NCT06231173|EXPERIMENTAL|Experimental|Visual feedback therapy and conventional therapy
62237040|NCT05509933|NO_INTERVENTION|nothing|
62237041|NCT06296745|EXPERIMENTAL|Group|Intra-pemetrexed
62035828|NCT06231173|ACTIVE_COMPARATOR|Controlled|Conventional therapy
62035829|NCT03872102||Aim 1: Develop a biomarker of PD disease progression rate|"For Aim 1, we will enroll PD subjects spanning a range of progression rates that have been tracked at UT Southwestern Medical Center.~Multimodal neuroimaging will be acquired from each subject. We will evaluate imaging data and known data on clinical progression using statistical techniques to determine a biomarker that associates with progression rate."
62237042|NCT02326012|EXPERIMENTAL|Emotion Regulation Individual Therapy for Adolescents|
62237043|NCT04156230|EXPERIMENTAL|Deep vein thrombosis|Subjects with Deep vein thrombosis will receive a single IV injection of \[18F\] GP1
62237044|NCT01281007|EXPERIMENTAL|Famciclovir 125 mg|1 tablet every 12 hours for 5 days
62237045|NCT01281007|ACTIVE_COMPARATOR|Aciclovir 200 mg|1 tablet every 4 hours (excluding nocturnal dose) for 5 days
62237046|NCT02141789|EXPERIMENTAL|Outpatient Cognitive Behavioral Psychotherapy|Outpatient Cognitive Behavioral Therapy is a well-known and frequently applied psychotherapy approach that does not need further description.
62237047|NCT03641105||lung adenocarcinoma|patients with lung adenocarcinoma
62237048|NCT05753553||Heart Failure with preserved Ejection Fraction (HFpEF)|After signing informed consent, clinical and echocardiographic data will be collected. Thereafter, they will be followed up for major clinical events (cardiovascular death, HF requiring hospitalization, myocardial infarction, and atrial fibrillation) for a period of 12 months.
62237049|NCT01776424|EXPERIMENTAL|Rivaroxaban 2.5mg + Aspirin 100mg|Participants received rivaroxaban 2.5 mg twice daily (bid) and aspirin 100 mg once daily (od). All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a proton pump inhibitor (PPI), were additionally randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.
62237050|NCT01776424|EXPERIMENTAL|Rivaroxaban 5mg + Aspirin Placebo|Participants received rivaroxaban 5 mg bid and aspirin placebo od. All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a PPI, were additionally randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.
62237051|NCT01776424|ACTIVE_COMPARATOR|Rivaroxaban Placebo + Aspirin 100mg|Participants received rivaroxaban placebo bid and aspirin 100 mg od. All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a PPI, were randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.
62237052|NCT05137860|NO_INTERVENTION|Standard Care Group|Each patient will receive their standard chemotherapy treatment for patients with relapsed Acute Lymphoblastic Leukemia based on the HyperCVAD scheme for a period of 12 weeks. Each chemotherapy cycle will be monitored by the health team corresponding to the Hematology service and the principal investigator.
62243449|NCT02717663|EXPERIMENTAL|Static goals with immediate rewards|Participants will receive static physical activity goals with immediate rewards
62243450|NCT02717663|EXPERIMENTAL|Adaptive goals with immediate rewards|Participants will receive adaptive physical activity goals with immediate rewards
62813023|NCT01088789|OTHER|Cohort 5|"Cohort 5 receives vaccine as well as a single dose of intravenous cyclophosphamide.~Only participants from J1766 study are eligible."
62813024|NCT00453895|EXPERIMENTAL|Sunitinib|"Sunitinib will be administered 50 mg per day for 4 weeks followed by 2 weeks off.~treatment will continue until progressive disease or unacceptable toxicity"
62035830|NCT03872102||Aim 2: Develop a biomarker to distinguish between PD, PSP, MSA|"For Aim 2, we will recruit subjects with PD, MSA, and PSP. We will also recruit healthy age/sex-matched controls. All subjects will complete a series of clinical assessments at three different time points, roughly 6-8 months apart:~* Levodopa Equivalent Daily Dose~* Parkinson disease questionnaire~* Schwab and England ADL Scale~* MDS-UPDRS (PD and healthy controls only)~* UMSARS (MSA subjects only)~* PSPRS (PSP subjects only)~Multimodal neuroimaging will be acquired from each subject. We will evaluate imaging data from the participants along with prospectively collected information on clinical progression using statistical techniques to determine a biomarker that associates with the differentiation of PD, MSA, and PSP."
62035831|NCT01923155|ACTIVE_COMPARATOR|Nurse endoscopists|Colonoscopy performed by nurse endoscopists supervised by senior medical endoscopists
62035832|NCT01923155|ACTIVE_COMPARATOR|Medical endoscopists|Colonoscopy performed by senior medical endoscopists
62035833|NCT05188573|EXPERIMENTAL|EpiDetect Arm|"Each subject can undergo to up to 3 blood draws; at the time of enrollment (T0), at 6 months (T1) and 12 months (T2) from diabetes diagnosis. After 24 months from diabetes diagnosis, a review of the electronic medical records (EMR) will be performed for all subjects with a not detected test result."
62035834|NCT05188573|EXPERIMENTAL|"EpiDetect not detected MRI Arm"|"A pre-specified number of cases with test results not detected will be randomly selected, gender ratio and age matched to subjects with test results detected and will undergo MRI imaging at T0 (n=226), at T1 (n=208 ) at T2 (n=208 ) and 24 months (n=208) from diabetes diagnosis."
62035835|NCT06392776|EXPERIMENTAL|Early diagnosis of previously undiagnosed asthma or COPD|On the day of randomization the participant will receive a copy of their interpreted spirometry report with a listed diagnosis. This report will be sent to their primary-care practitioner. In addition to the spirometry interpretation, the primary-care practitioner will be provided with a brief one-page guideline-based tool providing advice for pharmacologic and non-pharmacologic treatment of newly diagnosed asthma or COPD. The primary-care practitioner will be encouraged to see the participant as soon as possible to provide care. The participant will similarly be encouraged to make an appointment with the primary-care practitioner as soon as possible to access care for their condition
62035836|NCT06392776|NO_INTERVENTION|Delayed diagnosis of previously undiagnosed asthma or COPD|At the 12 week visit, participants randomized to the delayed diagnosis will complete the trial outcome assessments. After completing the 12 week final trial assessments they will be seen by the study respirologist and treated for their newly diagnosed asthma or COPD.
62035837|NCT06382350||Study group|Type 1 diabetes patients with insulin pump MiniMed 780 G +CGM (continuous glucose monitoring)
62035838|NCT06382350||Control group|Type 1 diabetes patients with patients treated by multiple daily injections (MDI) + CGM
62035839|NCT06580808|NO_INTERVENTION|Control Group|The control group consisted of 18 healthy children. These children underwent cardiopulmonary testing, spirometry, chest ultrasound to assess the diaphragm, 6-minute walk test, respiratory muscle strength and quality of life. These tests were performed to assess the results of these tests in patients without previous illnesses.
62035840|NCT06580808|ACTIVE_COMPARATOR|Fontan Training Group|The Fonta training group consisted of 14 children in the late postoperative period of Fontan surgery. These children underwent cardiopulmonary testing, spirometry, chest ultrasound to assess the diaphragm, 6-minute walk test, respiratory muscle strength and quality of life. These tests were performed at the initial stage and after two months of inspiratory muscle training to assess the results of these in postoperative patients and what changes the training could bring. The training was performed with the Power Breath device, the carda was quantified at 40% of the force exerted at maximum inspiratory pressure by manovacuometry. The patient was asked to perform 3 sets of 20 repetitions twice over the course of 7 days of the week. Monitoring was done in person and virtually, and the carda was increased according to the evaluator's perception of the ease of the exercise or if the patient reported it to be easy. The training lasted 2 months.
62237053|NCT05137860|EXPERIMENTAL|Bortezomib Treatment Group|Each patient will receive their standard chemotherapy treatment for patients with relapsed Acute Lymphoblastic Leukemia based on the HyperCVAD scheme in combination with Bortezomib for a period of 12 weeks. Each chemotherapy cycle will be monitored by the health team corresponding to the Hematology service and the principal investigator.
62237054|NCT03539341|EXPERIMENTAL|PLH-Thailand parenting programme|Trained facilitators and coaches will deliver the programme over eight weekly sessions at the Udon Thani Regional Hospital during the feasibility pilot and the RCT. During the RCT, the 60 parents/primary caregivers in the intervention group will be divided into 4 groups of 15 participants, with each group overseen by 2 facilitators and 1 coach. Core session activities may include discussion about assigned home activities, core parenting principles, illustrated stories, role-plays, and problem solving. Home visits will be conducted by facilitators to those parents/primary caregivers who miss sessions or require additional support, and SMS/LINE messages will be delivered to all participants twice per week with relevant parenting tips and reminders to attend the upcoming session.
62237055|NCT03539341|OTHER|Control (care as usual)|The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand. The delivery of services at Parent Schools are guided by the Ministry of Public Health Handbook for Parent Schools, which appear to be open to adaptation at the local level. At Parent Schools, three to five sessions are provided to parents in groups or one-on-one by hospital health personnel.
62595396|NCT02756780|NO_INTERVENTION|Control (no choir) Group|If eligible participants are unable to make the dates and times or live too far away but fulfil all the same criteria (including expressing an interest in singing) they will become part of the control group. This will involve the same data collection as the Cancer Choir Group but participants will not sing in a weekly choir.
62595397|NCT06648057||Len/Pemb|lenvatinib plus pembrolizumab combination therapy.
62595398|NCT06461715||Left bundle branch pacing group|Patients who underwent left bundle branch pacing
62813025|NCT02847377|EXPERIMENTAL|[18F]-ODS2004436|Two TEP will be performed with the radiotracer \[18F\]-ODS2004436
62813026|NCT06439095||Patients prior to placement of stainless steel crowns|Salivary IL-2, IL-5 and IL-17 expression levels of patients will be recorded
62813027|NCT06439095||Follow-up patients after placement of stainless steel crowns|Salivary IL-2, IL-5 and IL-17 expression levels of patients will be recorded
62813028|NCT06240052|EXPERIMENTAL|Conditioning and active avoidance paradigm (CAAP)|
62813029|NCT04291651||Retrospective|The registry will be populated with a retrospective cohort of patients previously identified as having pancreatic cysts.
62237056|NCT04029961|ACTIVE_COMPARATOR|Video Education|Participants will receive video education on radiation therapy.
62237057|NCT04029961|EXPERIMENTAL|VR-based Education|Participants will receive VR-based education on radiation therapy.
62237058|NCT00984035||Prospecitive Analysis|Patients currently receiving cisplatin as treatment for their cancer.
62595399|NCT00522691|EXPERIMENTAL|A: sacral first|Phase 1: sacral nerve stimulation crossover Phase 2 : sham stimulation
62035841|NCT06580808|NO_INTERVENTION|Fonta Control Group|The Fonta Control Group consisted of 13 children in the late postoperative period of Fontan surgery. These children underwent cardiopulmonary testing, spirometry, chest ultrasound to assess the diaphragm, 6-minute walk test, respiratory muscle strength and quality of life. These tests were performed at the initial stage and after two months to assess the results of these tests in postoperative patients and whether there was any normal behavior.
62035842|NCT01200212|EXPERIMENTAL|A|A Taxane (80mg/m2 Paclitaxel weekly or 75mg/m2 Docetaxel day1 q22) + 15mg/kg Bevacizumab day1 q22 + 1800 mg/m2 Capecitabine day 1-14 q22
62237059|NCT00984035||Restrospective Analysis|Patients that have previously received cisplatin as treatment for their cancer.
62237060|NCT04011956||Retrospective Cohort of Aortic Coarctation|Patients diagnosed as aortic coarctation and undergone corrected procedures from 2002 to Feb 28th 2019 were recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
62427305|NCT05660473|EXPERIMENTAL|Pediatric-inspired Regimen Combined With Venetoclax|Induction therapy is administered as follows：Vincristine (VCR) 1.4 mg/m2 (maximum dose 2 mg) IV on D1,8,1,5,22; Daunorubicin (DNR) 30 mg/m2/day IV on D1-3; Cyclophosphamide (CTX) 1200 mg/m2 IV on D1,15; Pegaspargase 2500u/m2 IM on D5; Prednisone 1 mg/kg/d PO on D1-14, 0.5 mg/kg/d PO on D15-28; Venetoclax 100 mg PO on D6，200 mg on D7, 400mg on D8-14, All patients underwent bone marrow aspiration on day 14 during induction. Patients with bone marrow blasts ≥10% on day 14 of induction received 7 additional days of Venetoclax on day 15-22. Consolidation therapy is a combination of multi-drug pediatric-inspired regimen chemotherapy and Venetoclax. Maintenance therapy consisted of a monthly VMMP regimen (vincristine, mercaptopurine, methotrexate, prednisone) continuing until 3 years for male and 2.5 years for female patients.
62427306|NCT04778007||Globus pharyngeus patients|The first group consists of 80 globus pharyngeus patients who have at least a year of globus sensation complaints. The participants will given the Turkish Version of the Laryngopharyngeal Measure of Perceived Sensation Questionnaire (T-LUMP), consist of 8 questions, Glasgow Edinburg Throat Scale, and Visual analog scale. After the two weeks, 80 participants will given the T-LUMP and Visual analog scale for sampling.
62427307|NCT04778007||Healty subjects|The second group consists of 80 healty participants will given the T-LUMP consist of 8 questions, Glasgow Edinburg Throat Scale, and Visual analog scale
62595400|NCT00522691|EXPERIMENTAL|B: sham first|Phase 1: sham stimulation crossover Phase 2: sacral nerve stimulation
62595401|NCT06623604|EXPERIMENTAL|Physical Activity Program|The physical activity program consists of two parts: exercise and education. Exercises in the program include light and moderate movements that may be performed by a healthy student between the ages of 9 and 11. The exercises were carried out three days a week for 30 minutes in the school garden and gym by the same researcher, and the education was carried out in the classrooms one day a week. During the program, students did a total of 180 hours of physical activity. In addition, the students' teachers also participated in the program and did exercises with their students. Throughout the program, exercises included 'belly and abdominal movement sets' in the first four weeks, 'leg and hip movement sets' in the following four weeks, and 'arms, shoulder, and chest movement sets' in the final four weeks, as well as yoga movements.
62595402|NCT06623604|NO_INTERVENTION|Control Group|Measurements and questionnaires were applied to the control group.
62813030|NCT04291651||Prospective|The prospectively enrolled patients in this study are the primary population of interest.
62813031|NCT03596034|EXPERIMENTAL|JUUL 5%, Virginia Tobacco, ENDS product|Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and combustibles per day (CPD) throughout the 15 day product use period.
62237061|NCT04011956||Perspective Cohort of Aortic Coarctation|Patients diagnosed as aortic coarctation and undergone corrected procedures after Mar. 1st 2019 will be recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
62237062|NCT02598752||functional performance testing|This observational study will evaluate the feasibility and safety of functional performance testing in patients undergoing HCT. In addition to standard of care procedures, participants will undergo a CPET with a rest and stress echo, pulmonary function, and patient reported outcome questionnaires within 30 days of HCT.
62237063|NCT00132613|ACTIVE_COMPARATOR|1|Procedure/Surgery: Observation alone after pericardial drainage
62237064|NCT00132613|EXPERIMENTAL|2|Drug: Pericardial instillation of bleomycin after drainage
62813032|NCT01832636|ACTIVE_COMPARATOR|Alanyl-Glutamine 3g/d|Alanyl-Glutamine orally 3g/day for 10 days
62035843|NCT01200212|ACTIVE_COMPARATOR|B|A Taxane (80mg/m2 Paclitaxel weekly or 75mg/m2 Docetaxel day1 q22) + 15mg/kg Bevacizumab day1 q22
62237065|NCT02593786|EXPERIMENTAL|Nivolumab monotherapy|Nivolumab specified dose on specified days
62237066|NCT02593786|EXPERIMENTAL|Cohort Expansion|Nivolumab specified dose on specified days
62237067|NCT05997251||Patients with spinal cord injury|
62237068|NCT05997251||Healthy group|
62427308|NCT00525564|PLACEBO_COMPARATOR|A|Placebo diskus
62813033|NCT01832636|ACTIVE_COMPARATOR|Alanyl-Glutamine 6g/d|Alanyl-Glutamine orally 6g/day for 10 days
62813034|NCT01832636|ACTIVE_COMPARATOR|Alanyl-Glutamine 12g/d|Alanyl-Glutamine orally 12g/d for 10 days
62813035|NCT01832636|PLACEBO_COMPARATOR|Glycine 12.5g/d|Glycine orally 12.5 g/d for 10 days. This dose is calculated to be isonitrogenous to 12g of Alanyl-Glutamine.
62813036|NCT00773448|ACTIVE_COMPARATOR|Limited Malignancy Screening|
62595403|NCT05642429|ACTIVE_COMPARATOR|AV-1959D 500 μg|
62813037|NCT00773448|EXPERIMENTAL|Extensive Malignancy Screening|Limited screen as described above in combination with comprehensive computed tomography of the abdomen/pelvis
62813038|NCT06204341|EXPERIMENTAL|HYPOPRIME treatment|Hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate with elective lymph node irradiation and minimized androgen deprivation therapy
62035844|NCT00517738|EXPERIMENTAL|Physical training - No encephalopathy|Patients randomized to the physical training program and diet intervention
62035845|NCT00517738|ACTIVE_COMPARATOR|Control - No encephalopathy|Patients not allocated to exercise program, but undergoing diet intervention
62595404|NCT05642429|ACTIVE_COMPARATOR|AV-1959D 1000 μg|
62237069|NCT00604279|EXPERIMENTAL|Paliperidone palmitate|Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion.
62237070|NCT00604279|ACTIVE_COMPARATOR|Risperidone long acting injection (LAI)|Risperidone LAI intramuscular at a dose of 25 milligram (mg) on Day 8 and Day 22; flexible dose of either 25 or 37.5 mg on Day 36 with same dose on Day 50; and either 25, 37.5, or 50 mg on Day 64 with same dose on Day 78; along with oral risperidone 2 mg tablet on Day 1, flexible doses (1-6 mg/day) for first 28 days; and 1-2 mg/day during Day 36-57 and Day 64-85 if the dose of risperidone LAI was increased on Day 36 and Day 64.
62237071|NCT01605695||Normal healthy adults|The concentration of iNOS will be measured in plasma samples obtained at the time of blood donation from normal healthy adult humans
62237072|NCT04867889|ACTIVE_COMPARATOR|Active Treatment iTBS|Magnetic pulses of 120% of visual motor threshold applied in triplets of 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 20 s over the left DLPFC (F3), given in 20 sessions on 20 week days, one session per day.
62427309|NCT00525564|ACTIVE_COMPARATOR|B|Salmeterol diskus powder
62595405|NCT05642429|ACTIVE_COMPARATOR|AV-1959D 2000 μg|
62595406|NCT05642429|PLACEBO_COMPARATOR|Placebo|
62237073|NCT04867889|SHAM_COMPARATOR|Sham treatment|Sham treatment given either with a sham stimulation coil or by flipping an active coil 90 degrees.
62595407|NCT06391541|NO_INTERVENTION|Group Control|
62595408|NCT06391541|ACTIVE_COMPARATOR|Group mTLIP|
62595409|NCT06391541|ACTIVE_COMPARATOR|Group ITP|
62595410|NCT06621030|EXPERIMENTAL|Single Arm|Exposure to various glycaemic states at different rates of change by administering glucose solution, insulin, or a standardized meal.
62237074|NCT04369989||Hydroxychloroquine - NO|Did not receive / are not receiving any Hydroxychloroquine
62237075|NCT04369989||Hydroxychloroquine - YES - started before|Hydroxychloroquine date started was before the date recorded for signs of respiratory distress
62595411|NCT06126835||Ozanimod exposed|
62427310|NCT03634488|EXPERIMENTAL|SCD - Ready-to-use therapeutic food and Hydroxyurea|50-75 children (5-12 years old) with SCA and severe malnutrition will be randomly allocated to receive ready-to-use therapeutic food and hydroxyurea (20mg/kg/day)
62427311|NCT03634488|PLACEBO_COMPARATOR|SCD - Ready-to-use therapeutic food alone|50-75 children (5-12 years old) with SCA and severe malnutrition will be randomly allocated to receive ready-to-use therapeutic food alone
62427312|NCT03634488|PLACEBO_COMPARATOR|Non-SCD siblings with severe malnutrition|To decrease the likelihood of sharing limited food resources, we will enroll up to 100 malnourished non-SCD siblings.
62595412|NCT06126835||Conventional therapy exposed|
62595413|NCT06126835||Advanced therapy exposed|
62595414|NCT03523143|EXPERIMENTAL|Early-screen Group|The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). The time of early screening and intervention will be 6-8 weeks earlier than that of standard screening and intervention.
62595415|NCT03523143|ACTIVE_COMPARATOR|Standard-screen Group|The standard screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 24-28 weeks of gestational age (GA). The time of standard screening and intervention will be 6-8 weeks later than that of early screening and intervention.
62595416|NCT00922467|PLACEBO_COMPARATOR|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
62595417|NCT00922467|EXPERIMENTAL|Esmolol|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and esmolol
62813039|NCT01889667|EXPERIMENTAL|ORMD-0801 Dose # 1|Oral Insulin Formulation
62813040|NCT01889667|EXPERIMENTAL|ORMD-0801 Dose # 2|Oral Insulin Formulation
62813041|NCT01889667|PLACEBO_COMPARATOR|Placebo|Oil Capsules
62813042|NCT03452540|EXPERIMENTAL|1000mg DS102 (BID)|Participants assigned to the open label pilot phase received 1000mg DS102 (BID)for 28 days.
62813043|NCT03392103|EXPERIMENTAL|postoperative CRT|postoperative CRT: Treatment including postoperative radiotherapy (IMRT) with concurrent chemotherapy of Raltitrexed. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on w1 and w4).
62813044|NCT03259230||Malignancy-Associated Hemophagocytic Lymphohistiocytosis|Patients diagnosed with HLH in the context of a malignancy. The diagnosis of M-HLH was established by the treating physician.
62813045|NCT03259230||Absence of HLH in patients diagnosed with malignancy|Patients with a diagnosis of hematological malignancy and never diagnosed with HLH or no suspicion of HLH (at any time, including time after sample collection in case of use of retrospective sample).
62595418|NCT06313086|EXPERIMENTAL|DP303c|DP303c injection, 3.0 mg/kg, Q3W.
62813046|NCT04453657|EXPERIMENTAL|Intervention|There is only one arm in this study. All recruited and consented participants will fill out a pre-survey, engage with the digital toolkit for 15 weeks, then fill out a post-survey.
62237076|NCT04369989||Hydroxychloroquine - YES - started same|Hydroxychloroquine date started was the same as the date recorded for signs of respiratory distress
62813047|NCT01288235|EXPERIMENTAL|Proton Radiotherapy|Proton Radiotherapy
62813048|NCT05112575||Early imaging: within 36 hours postoperatively.|Patients fulfilling eligibility criteria between 18 and 80 years old who receive MRI or CT follow-up after craniotomy for resection of a space occupying lesion (benign or malignant) or vascular within 36 hours after neurosurgical procedure.
62813049|NCT05112575||Late imaging: between 36 and 72 hours postoperatively|Patients fulfilling eligibility criteria between 18 and 80 years old who receive MRI or CT follow-up after craniotomy for resection of a space occupying lesion (benign or malignant) or vascular between 36 and 72 hours after neurosurgical procedure.
62237077|NCT04369989||Hydroxychloroquine - YES - started after|Hydroxychloroquine date started was after the date recorded for signs of respiratory distress
62237078|NCT04886453|EXPERIMENTAL|Intervention|
62237079|NCT04886453|ACTIVE_COMPARATOR|Controle|
62237080|NCT05722704|EXPERIMENTAL|Cryotherapy|Final irrigation with cold saline (2.5C-4C) without occlusal reduction
62237081|NCT05722704|ACTIVE_COMPARATOR|Occlusal reduction|Normal room temperature saline irrigation protocol with occlusal reduction
62237082|NCT05722704|NO_INTERVENTION|Control|Normal room temperature saline irrigation protocol without occlusal reduction
62237083|NCT01324323|EXPERIMENTAL|Romidepsin and rifampin|"Romidepsin 14 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.~Rifampin 600 mg oral once daily on Days 4-8"
62237084|NCT01289821|EXPERIMENTAL|Regorafenib + oxaliplatin/folinic acid/5-FU (mFOLFOX6)|On Day 1, participants received 85 mg/m\^2 oxaliplatin as a 2-hour intravenous (IV) infusion and folinic acid (either 400 mg/m\^2 D/L-folinic acid or 200 mg/m\^2 L-folinic acid) as a 2-hour IV infusion. Once the initial infusion was completed, participants received 5-FU 400 mg/m\^2 IV bolus injection immediately followed by a 5-FU 2400 mg/m\^2 IV infusion for 46 hours. The next cycle of mFOLFOX6 was administered on Day 15 to 17. Participants received Regorafenib (Stivarga, BAY73-4506) 160 mg orally (po) once daily (qd) on Days 4 to 10 and Days 18 to 24. One cycle comprised 28 days.
62595419|NCT06313086|ACTIVE_COMPARATOR|trastuzumab emtansine|trastuzumab emtansine,3.6 mg/kg, Q3W.
62595420|NCT02046083|EXPERIMENTAL|treatment|Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance
62813050|NCT02313766|NO_INTERVENTION|spontaneous breathing (SB)|"preoxygenation through a face mask firmly applied and connected to the anaesthesia machine delivering a fresh gas flow of 12 l min-1. The inspired O2 concentration was set at 100%.~End of preoxygenation FEO2=90%"
62237085|NCT04337333|OTHER|Two-in-one stent|Endoscopic placement of a Two-in-one stent into the extrahepatic bile duct, considering the longitudinal location of the stricture segment and predicted safety margin
62035846|NCT00517738|EXPERIMENTAL|Physical training - Early encephalopathy|Patients with early hepatic encephalopathy (minimal or clinical grade 1-2) randomized to the physical training program
62035847|NCT00517738|ACTIVE_COMPARATOR|Control - Early encephalopathy|Patients with early hepatic encephalopathy (minimal or clinical grades 1-2) not allocated to the physical training program, but undergoing diet intervention
62035848|NCT05052801|EXPERIMENTAL|Bemarituzumab with mFOLFOX6|
62035849|NCT05052801|ACTIVE_COMPARATOR|Placebo with mFOLFOX6|
62813051|NCT02313766|EXPERIMENTAL|positive pressure ventilation (PPV)|"PPV : positive pressure ventilation : preoxygenation with noninvasive positive inspiratory pressure ventilation (12 cmH2O) without PEEP.~Preoxygenation through a face mask firmly applied and connected to the anaesthesia machine - non invasive inspiratory ventilation mode - inspiratory trigger sensitivity was set at -2 l min-1, the adjustable pressure limiting valve was opened, and maximal airway pressure was limited at 18 cmH2O - PEEP=0 cmH2O End of preoxygenation FEO2=90%"
62237086|NCT03351166|EXPERIMENTAL|Molidustat (BAY85-3934)|Molidustat group
62237087|NCT02315027|EXPERIMENTAL|1 dose of 1 × 10(7) MSCs|Group 1: Participants will receive a single intrathecal dose of 1 × 10(7) mesenchymal stem cells (MSCs)
62813052|NCT02313766|EXPERIMENTAL|PPV + PEEP|"PEEP : PPV + PEEP : preoxygenation with noninvasive positive inspiratory pressure ventilation (12 cmH2O) with PEEP at 6 cmH2O.~Preoxygenation through a face mask firmly applied and connected to the anaesthesia machine - non invasive inspiratory ventilation mode - inspiratory trigger sensitivity was set at -2 l min-1, the adjustable pressure limiting valve was opened, and maximal airway pressure was limited at 18 cmH2O - PEEP=6 cmH2O End of preoxygenation FEO2=90%"
62237088|NCT02315027|EXPERIMENTAL|2 doses of 5 × 10(7) MSCs|Group 2: Participants will receive one intrathecal dose of 5 × 10(7) mesenchymal stem cells (MSCs), followed by a second intrathecal dose of 5 × 10(7) MSCs approximately one month later
62237089|NCT02315027|EXPERIMENTAL|2 doses of 1 × 10(8) MSCs|Group 3: Participants will receive one intrathecal dose of 1 × 10(8) mesenchymal stem cells (MSCs), followed by a second intrathecal dose of 1 × 10(8) MSCs approximately one month later
62237090|NCT02315027|EXPERIMENTAL|10 doses of 5 x 10(7) (±20%) MSCs|Group 4: Participants will receive up to 10 doses of 5 x 10(7) (±20%) mesenchymal stem cells (MSCs) approximately 6 months apart.
62237091|NCT02315027|EXPERIMENTAL|10 doses of 2.5 x 10(7) (±20%) MSCs|Group 5: Participants will receive up to 10 doses of 2.5 x 10(7) (±20%) mesenchymal stem cells (MSCs) approximately 6 months apart.
62035850|NCT02672631||Median Nerve injury hand|Participants will be randomly called; and that 10 participants which had unilateral median nerve transection totally and repaired primely in our clinic at 2014. In the sample, correlations between physical examination (Tinnel Test, motor strength assessment (Medical Research Council (MRC) Scale), static two-point discrimination test (S2PD), Semmes-Weinstein (SW) monofilament test, the Disability of the Arm, Shoulder and Hand (DASH) test), ENMG with the DTI results will be assessed.
62035851|NCT02672631||Healthy Hand|Control group will be taken from patients other hand which had not injured before. And we will compare with first group's results.
62035852|NCT04824404|NO_INTERVENTION|Standard Treatment As Usual (TAU)|Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly or bi-weekly visits (at the discretion of the provider) to the clinic to meet with their provider and provide a sample of blood.
62035853|NCT04824404|EXPERIMENTAL|CBT4CBT-Buprenorphine + Recovery Coach|This condition will consist of the CBT4CBT-Buprenorphine intervention alongside weekly coaching sessions from a recovery professional
62035854|NCT06195917|EXPERIMENTAL|Experimental group|Robotic-assisted Interventional Percutaneous transhepatic puncture
62237092|NCT01644344|ACTIVE_COMPARATOR|X-ray|Control group: patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks. Each time radiographs are completed, the surgeon or resident will document if a change in fixation position is noted and if a change in patient management will be entertained (addition, modification or maintenance of cast or splint use, modification of or decision not to advance activity level, need for further surgery to adjust fixation or fracture reduction). The patients' time spent in clinic will be recorded upon arrival and upon completion of the patient-physician interaction.
62813053|NCT02262585|EXPERIMENTAL|BIBR 277 tablet|(Mannitol based)
62813054|NCT02262585|ACTIVE_COMPARATOR|BIBR 277 capsule|
62237093|NCT01644344|ACTIVE_COMPARATOR|No X-ray|
62813055|NCT03728868|PLACEBO_COMPARATOR|Placebo|One capsule containing placebo (identical to the capsule with active product (F. prausnitzii and D. piger) in taste and appearance but without the active component) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
62813056|NCT03728868|ACTIVE_COMPARATOR|High dose F. prausnitzii and D. piger|One capsule (containing F. prausnitzii and D. piger at a dose of 1E9-5x1E9 colony forming units per bacterial strain) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
62237094|NCT02491268|EXPERIMENTAL|Cilostazol 50mg B.I.D.|"After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration.~Protocol treatment defines as follows;~Investigational Treatment:~Cilostazol 50mg B.I.D. p.o. 96 Weeks"
62813057|NCT03728868|ACTIVE_COMPARATOR|Low dose F. prausnitzii and D. piger|One capsule (containing F. prausnitzii and D. piger at a dose of 1E8-5x1E8 colony forming units per bacterial strain) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
62813058|NCT03446625|EXPERIMENTAL|Resveratrol|Resveratrol will be administered orally at the dose of 2 g/day for 9 days, starting on the day of ovulation triggering.
62813059|NCT03446625|PLACEBO_COMPARATOR|Control|Placebo treatment will be administered for 9 days, starting on the day of ovulation triggering.
62035855|NCT00674986|OTHER|Active Control Group (ACG)|Participants in the Active Control Group received enhanced standard of care (more frequent clinic visits, free blood glucose meters and strips and point-of-care Hemoglobin A1c (HbA1c) test) for management of their Type 2 diabetes.
62813060|NCT06102096|EXPERIMENTAL|Active group|Tailored iCBT for mild to moderate common mental health problems over a period ranging from 6 to 10 weeks.
62813061|NCT06102096|NO_INTERVENTION|Waiting-list|control group
62813062|NCT06492005|EXPERIMENTAL|Treatment Cohort A:9MW2821|Drug：9MW2821
62813063|NCT06492005|EXPERIMENTAL|Treatment Cohort B:9MW2821+PD-1 inhibitior|Drug: 9MW2821,PD-1 inhibitior
62813064|NCT06492005|EXPERIMENTAL|Treatment Cohort C:9MW2821 ±PD-1 inhibitior|Drug: 9MW2821,PD-1 inhibitior
62813065|NCT05980806|EXPERIMENTAL|Selinexor 60 mg (Arm 1)|Participants will receive selinexor 60 milligrams (mg) oral tablets once weekly (QW) (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first and followed by optional add-on medication dosing may be initiated based on Spleen Volume Reduction (SVR) values.
62813066|NCT05980806|EXPERIMENTAL|Selinexor 40 mg (Arm 2)|Participants will receive selinexor 40 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first and followed by optional add-on medication dosing may be initiated based on SVR values.
62813067|NCT05980806|EXPERIMENTAL|Selinexor 60 mg (Optional Expansion Arm)|Participants will receive selinexor 60 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first. Optional add-on medication (ruxolitinib \[5 mg or 10 mg twice daily\], pacritinib \[200 mg twice daily\], or momelotinib \[200 mg once daily\]) may be initiated for participants whose SVR is less than (\<) 10% at Week 12 or \<35% at Week 24 based on the participants platelet count values (i.e., ruxolitinib if platelets greater than or equal to \[\>=\] 50 x 10\^9/L, pacritinib if platelets \<50 x 10\^9/L, momelotinib if platelets is \>=50 x 10\^9/L and hemoglobin level is \< 10 gram per deciliter \[g/dL\]).
62813068|NCT05980806|EXPERIMENTAL|Selinexor 40 mg (Optional Expansion Arm)|Participants will receive selinexor 40 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first. Optional add-on medication (ruxolitinib \[5 mg or 10 mg twice daily\], pacritinib \[200 mg twice daily\], or momelotinib \[200 mg once daily\]) may be initiated for participants whose SVR is \<10% at Week 12 or \<35% at Week 24 based on the participants platelet count values (i.e., ruxolitinib if platelets \>= 50 x 10\^9/L, pacritinib if platelets \<50 x 10\^9/L, momelotinib if platelets is \>=50 x 10\^9/L and hemoglobin level is \< 10 g/dL).
62595421|NCT02046083|PLACEBO_COMPARATOR|placebo|Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance
62035856|NCT00674986|EXPERIMENTAL|Structured Testing Group (STG)|Participants in the Structured Testing Group in addition to enhanced standard of care for the treatment of their Type 2 diabetes used the ACCU-CHEK® 360° View blood glucose analysis system (Tool) to monitor glucose levels at least quarterly.
62813069|NCT02856412|EXPERIMENTAL|Veterans Group Exercise|Exercise 3 times weekly (for 12 weeks), with each total workout lasting approximately 60 minutes. Integrative Exercise incorporates elements of strength training, flexibility, cardiovascular training, and controlled breathing exercises.
62813070|NCT02856412|ACTIVE_COMPARATOR|Illness Management and Recovery|Attend 3 health education classes weekly (for 12 weeks), with each class lasting approximately 60 minutes. Illness Management and Recovery is an educational program focused on helping individuals more effectively manage their illnesses to pursue their personal recovery goals. The classes include the following topic areas which have been adapted for use in PTSD: recovery, practical facts about PTSD, stress-vulnerability, building social support, medications for PTSD, drug and alcohol use, reducing relapse, coping with stress, coping with persistent symptoms, getting needs met in the VA healthcare system, and living a healthy lifestyle.
62237095|NCT02491268|PLACEBO_COMPARATOR|Placebo B.I.D.|"After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration.~Protocol treatment defines as follows;~Comparative Treatment:~Placebo B.I.D. p.o. 96 Weeks"
62237096|NCT04771585|NO_INTERVENTION|Study Part A|Aerosol number and size spectrum characterization of 30 subjects, stratified by age groups, including 10 professional singers. Subjects will be examined twice within 14 days to assess reproducibility of aerosol emission.
62237097|NCT04771585|EXPERIMENTAL|Study Part B|From the 30 subjects of Part A, the 10 highest-emitting subjects will be assessed a third time, wearing four different classes of face masks consecutively with increasing aerosol filtering capacity.
62237098|NCT05518864|EXPERIMENTAL|Placebo - Intervention - Intervention|"Treatment period 1: placebo for 1x/week for 6 weeks, followed by two treatment periods of 6 weeks receiving GAG-therapy (Ialuril) 1x/week.~Finally this arm continues with unblinded GAG-therapy (Ialuril) instillations 1x/month for 6 instillations."
62237099|NCT05518864|EXPERIMENTAL|Intervention - Placebo - Intervention|"Treatment period 1: GAG-therapy (Ialuril) for 1x/week for 6 weeks, followed by treatment period 2: Placebo for 1x/week for 6 weeks and afterwards treatment period 3: GAG-therapy (Ialuril) for 1/x week for 6 weeks.~Finally, this arm continues with unblinded GAG-therapy (Ialuril) instillations 1x/month for 6 instillations."
62237100|NCT05518864|EXPERIMENTAL|Intervention - Intervention - Placebo|"Treatment period 1: GAG-therapy (Ialuril) for 1x/week for 6 weeks, followed by treatment period 2: GAG-therapy (Ialuril) for 1x/week for 6 weeks and afterwards treatment period 3: placebo for 1/x week for 6 weeks.~Finally, this arm continues with unblinded GAG-therapy (Ialuril) instillations 1x/month for 6 instillations."
62813071|NCT00777140|ACTIVE_COMPARATOR|1. Deferoxamine|Intravenous deferoxamine: bolus of 10mg/Kg (initiated during tPA infusion) and perfusion of 20/40/60 mg/Kg/day during 72h. Three different doses (3 steps), 15 patient in the active arm for each dose.
62813072|NCT00777140|PLACEBO_COMPARATOR|2. Placebo|Saline solution: Bolus and perfusion during 72h. 5 patients in the placebo arm in each step (randomization 3:1)
62813073|NCT06093906|EXPERIMENTAL|Positive Processes and Transition to Health (PATH)|PATH includes six 60-90 min, weekly sessions, with two booster sessions for partial responders. Session 1 provides the PATH rationale and a review of life events (PATH of life: negative and positive). A rationale for an explicit focus on positive events/emotions will be provided. Sessions 2-4 focus on a verbal narrative of the destabilizing life event, reminiscence and processing of a major positive life event, and real-life practice to enact what was taught. Sessions 5 focuses on constructive processing and provides opportunity for integration and consolidation of learning. Session 6 focuses on future negative and positive events to promote application of new learning and resilience. Booster sessions focus on positive and negative life events since the last session and adaptive processes (constructive processing, approach, and reward). All sessions will include cultivation and elaboration of positive emotions to promote engagement and to build on the benefits of positive emotions.
62237101|NCT04322942||Non-infection|
62237102|NCT04322942||Infection without sepsis|
62237103|NCT04322942||Sepsis-2|
62237104|NCT04322942||Sepsis-3|
62237105|NCT02842892|OTHER|Squat Jump|
62035857|NCT06496529|EXPERIMENTAL|DoF Group|The experimental group with control of the degrees of freedom will receive treatment for 4 weeks using an exoskeleton and also it will be supervised by a physiotherapist.The exoskeleton will restrict the movement of the trunk and upper extremity to leave only the joint free to work in the plane of interest. The training will be selective in an articular plane with biofeedback of movement through videogames and external movement sensors installed in the upper extremity. This movement sensor will allow to interact with the videogames through the movement of the trained movement.
62035858|NCT06496529|ACTIVE_COMPARATOR|Task Group|"The group without control of the degrees of freedom (Task Group) will receive a therapeutic intervention equivalent in dose, but without any restriction of joint movement (without the exoskeleton). Each session will be divided into two parts. In the first part, participants will train with combined planes and in a multi-joint manner with the same video games as DoF Group but with the movement sensor in your hand performing 4 direction movements with the upper limb (horizontal, vertical and diagonals).~In the second training part, patients will perform functional tasks: raise and lower your hand on the table, cleaning a table, put cream on the non-paretic arm, hold a bottle, put a piece of bread or something similar in your mouth, wash your face, brush your hair, store items in a basket, brush teeth, wrote and serve water in glass."
62035859|NCT03655353|EXPERIMENTAL|ABY-PET|68Ga-ABY-025 is used as tracer for PET scan
62237106|NCT02842892|OTHER|Drop Jump|
62237107|NCT02842892|OTHER|Countermovement Jump|
62237108|NCT04702282||unilateral Total knee arthroplasty|Patients receiving unilateral Total knee arthroplasty
62237109|NCT04702282||simultaneous bilateral Total knee arthroplasty|Patients receiving simultaneous bilateral Total knee arthroplasty y
62237110|NCT02393274||28-day Survival|survive for at least 28 days after placement of extra-corporeal membrane oxygenation life support
62237111|NCT02393274||28-day Nonsurvival|not survive for 28 days after placement of extra-corporeal membrane oxygenation life support
62427313|NCT04434638|EXPERIMENTAL|Transitions of Care Coordinator Group|We developed the Transition of Care Coordinator (TOCC) program to aid in the completion of the diagnostic evaluations as well as in the transition out of the acute care hospital setting. In the TOCC intervention, the stroke nurse navigator completed eight specific tasks: (1) met the patient and family within 48 hours of admission, (2) identified patient home location and insurance status, (3) coordinated communication between treating providers (neurologists, cardiologists, etc.) regarding pending diagnostic tests, (4) followed up physical, occupational, and speech therapy teams' recommendations for rehabilitation, (5) attended daily multi-disciplinary rounds, (6) facilitated referrals to acute and subacute rehabilitation facilities with case managers, (7) assisted beside nurses in providing tailored stroke education and discharge instructions to patients and families, and (8) arranged stroke clinic follow-up appointments.
62813074|NCT06093906|ACTIVE_COMPARATOR|Progressive Muscle Relaxation (PMR)|PMR will be adapted from Berstein, Borkoveck, and Hazlett- Stevens (2000). PMR will be conducted in six, 60-90 min individual weekly sessions with a study therapist. Muscle groups are tightened and then relaxed with the attention of the patient focused on the contrast between tension and relaxation. Through regular practice, the person becomes more aware of tension in the body and can induce relaxation as needed (Field, 2009). During the six sessions of training, patients will be encouraged to practice PMR and learn how to deliberately induce physical relaxation to reduce stress and mental tension. Sessions will move from relaxation of 16-muscle groups to 7 muscle groups, 4 muscle groups, and finally to relaxation by recall. Patients will be instructed to practice daily, if possible, but at least two or three times a week, and to integrate the practice into their daily life. They will be provided with audio recordings and homework reporting forms to assist their home PMR exercises.
62427314|NCT04434638|ACTIVE_COMPARATOR|Usual Care Group|Patients in the usual care group, which served as the control, received the current, ongoing method of care coordination by members of the multi-disciplinary stroke team. The current practice is that members of this multi-disciplinary team meet with each other every weekday morning to discuss the discharge plan of care for each stroke patient on the inpatient stroke service. Physicians, nurses, rehabilitation therapists and case managers are then individually responsible for talking to patients and their families/caregivers about the different aspects of the plan of care.
62427315|NCT04831801||Female patients with overactive bladder (OAB)|Patients with urgency and frequency syndrome with or without pelvic pain (Group A) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
62813075|NCT05963672|SHAM_COMPARATOR|Usual Care|
62813076|NCT05963672|EXPERIMENTAL|EEG-guided sleep protection|
62813077|NCT05192200|EXPERIMENTAL|Anti-Beta Interferon drug (PF-06823859)|IV infusion
62237112|NCT01096342|EXPERIMENTAL|Treatment|Patients receive dinaciclib IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62237113|NCT02141074|EXPERIMENTAL|50 EDs (exposure days)|
62237114|NCT04113668|EXPERIMENTAL|Arm A: Single Dose (BMS-986165)|
62237115|NCT04113668|EXPERIMENTAL|Arm B:Diflunisal and Single Dose (BMS-986165)|
62237116|NCT02477579|EXPERIMENTAL|NovaCross|NovaCross microcatheter will be used.
62237117|NCT02745262||Controlled ovarian stimulation|No drugs are administered. It is an observational study. Collect retrospectively the follow-up data
62237118|NCT02745262||Non Controlled ovarian stimulation|No drugs are administered. It is an observational study. Collect retrospectively the follow-up data
62237119|NCT05413174|EXPERIMENTAL|Hypnosis arm|The experimental group will receive an hypnosis session during the ultrasound-guided hepatic biopsy.
62237120|NCT05413174|NO_INTERVENTION|Habitual Care|The control group will receive the usual medical management during the ultrasound-guided hepatic biopsy.
62237121|NCT04544345|EXPERIMENTAL|His bundle pacing, AV optimized|Pacemaker programmed to DDD mode with ventricular lead placed on the bundle of His and echocardiographically optimized AV delay.
62237122|NCT04544345|SHAM_COMPARATOR|Backup VVI pacing|Pacemaker programmed to ventricular only pacing with low base rate (40/min) to allow intrinsic rhythm.
62237123|NCT00710827|EXPERIMENTAL|Arm 1|
62427316|NCT04831801||Female control patients without LUTS|Patients without LUTS (Group B) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
62813078|NCT03446755|EXPERIMENTAL|Intrauterine balloon (Cook medical)|Insertion of a hearth shaped intrauterine balloon immediately after hysteroscopic adhesiolysis and left in place for 7 days under antibiotic prophylaxis.
62813079|NCT01716286|EXPERIMENTAL|yoghurt type|low fat yoghurt vs. essence yoghurt
62813080|NCT04149834|ACTIVE_COMPARATOR|Modified Minimally Invasive Surgical Technique|Comparator: Modified Minimally Invasive Surgical Technique The defect will be gained through the tiny buccal triangular ﬂap: from the buccal 'window' the soft tissue ﬁlling the defect (i.e. the so-called granulation tissue) will be sharply dissected from the papillary supra-crestal connective tissue and from the bony walls with a micro-blade and will be removed with a mini-curette (The soft tissue will be sharply dissected from the osseous defect)
62813081|NCT04149834|OTHER|Non- incised papilla surgical approach|intervention: Non- incised papilla surgical approach Apical horizontal incision on the buccal mucosa, as far as possible from the interdental papillae and marginal KT will be performed. Soft tissue will be reflected apico-coronally by a full-thickness flap showing the granulation tissue filling the bony defect after exposing the coronal limit of the intra-bony component of the defect, while the marginal tissue will be kept unaltered.
62813082|NCT04068402|EXPERIMENTAL|Treatment|
62813083|NCT00261365|ACTIVE_COMPARATOR|A1|
62035860|NCT04897776|EXPERIMENTAL|Therapeutic Thalamic Stimulation|"Four months post implant, the neurostimulator device will provide patients with hippocampal stimulation for all seizures. For seizures longer than five seconds, thalamic stimulation will be administered at a therapeutic level established based on the physician's evaluation and patient specific parameters established at a previous visit. This will occur in half of the seizures the patient experiences and will be randomly assigned during this phase of the study.~If no benefit is experienced during this phase of the study, patients may participate in an optional randomized CL stimulation phase for an additional four months."
62237124|NCT00710827|PLACEBO_COMPARATOR|Arm 2|
62237125|NCT04127422||Study group|"Patients presenting with current symptoms related to the breast. Adult females aged 18-39 years presenting to the breast outpatient clinic with either mastalgia, nodularity and/or discharge.~A questionnaire, physical examination and bilateral breast ultrasonography will be obtained for all patients.~A- The questionnaire will contain the following items:~1. symptoms related to the breast.~2. other medical history.~3. menstrual history.~4. obstetric history.~5. rapid screener for beverages and fast food consumption.~6. rapid screener for vegetables and fruit consumption.~B- Physical examination will specifically records the following:~1. breast tender point(s).~2. breast nodularity.~3. nipple discharge.~4. weight, height, body mass index (BMI).~C- bilateral breast ultrasonography for all patients.~D- breast biopsy when clinically indicated as per hospital policy."
62237126|NCT04127422||Control group|"Age-matched healthy volunteers with no current medical conditions. Adult females aged 18-39 years with no current breast problems. These healthy volunteers will be asked to complete the same questionnaire as per the Study group and have anthropometric measure.~A- The questionnaire will contain the following items:~1. other medical history.~2. menstrual history.~3. obstetric history.~4. rapid screener for beverages and fast food consumption.~5. rapid screener for vegetables and fruit consumption.~B- Physical examination will specifically records the following:~1- weight, height, body mass index (BMI)."
62237127|NCT01491048|ACTIVE_COMPARATOR|THA Physiotherapy|Physiotherapy care during the period of hospitalization after THA.
62427317|NCT04521439|EXPERIMENTAL|MS Patients Group|
62427318|NCT04521439|SHAM_COMPARATOR|Healthy Volunteers Group|
62427319|NCT00367679|EXPERIMENTAL|Single Arm|800 mg pazopanib oral daily
62427320|NCT03325452|EXPERIMENTAL|cardio-respiratory arrest|
62427321|NCT00850005|EXPERIMENTAL|IVIG|Active treatment will be intravenous immunoglobulin G (Gamunex, immune globulin intravenous \[human\], 10%), at a dose of 2 g/kg divided over five days (0.4 g/kg/day).
62427322|NCT00850005|PLACEBO_COMPARATOR|Placebo|The placebo treatment will be intravenous normal saline and will be infused in a similar manner.
62427323|NCT01711671|EXPERIMENTAL|DKN-01 300mg|DKN-01 plus lenalidomide (Revlimid)/dexamethasone
62427324|NCT01711671|EXPERIMENTAL|DKN-01 600mg|DKN-01 plus lenalidomide (Revlimid)/dexamethasone
62427325|NCT01711671|ACTIVE_COMPARATOR|Standard of Care|Lenalidomide (Revlimid)/dexamethasone
62427326|NCT03763617|ACTIVE_COMPARATOR|Test group|A d-ptfe membrane will be placed between the buccal bone and periosteum of an extraction socket during a 4 months healing time before it is surgically removed.
62427327|NCT03763617|NO_INTERVENTION|Control group|The extraction socket will be left to heal naturally without a socket preservation intervention.
62427328|NCT03612401|OTHER|Neurogenic Bladder|Spinal Cord Injury patients with known neurogenic bladder on treatment with Anticholinergic Agents at baseline switched to mirabegron as the study intervention
62813084|NCT00261365|ACTIVE_COMPARATOR|A2|
62813085|NCT05872685|EXPERIMENTAL|Group A (Chemotherapy+Serplulimab )|"Drug: Oxaliplatin，S-1，Serplulimab~Chemotherapy (SOX): Oxaliplatin, administered as a 2-hour intravenous infusion (130 mg/m2) S-1, orally twice daily for 2 weeks followed by a 7-day rest period. The dose of S-1 was 80 mg/day for body surface area less than 1.25 m2, 100 mg/day for body surface area greater than or equal to 1.25 to less than 1.5 m2, and 120 mg/day for body surface area greater than or equal to 1.5 m2 Chemotherapy will be repeated each 21 day for 3 cycles prior to surgery and 3 cycles after surgery.~Serplulimab: 300 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery."
62813086|NCT05872685|ACTIVE_COMPARATOR|Group B (Chemotherapy+Placebo )|"Drug: Oxaliplatin，S-1，Placebo~Chemotherapy (SOX): Oxaliplatin, administered as a 2-hour intravenous infusion (130 mg/m2) S-1, orally twice daily for 2 weeks followed by a 7-day rest period. The dose of S-1 was 80 mg/day for body surface area less than 1.25 m2, 100 mg/day for body surface area greater than or equal to 1.25 to less than 1.5 m2, and 120 mg/day for body surface area greater than or equal to 1.5 m2 Chemotherapy will be repeated each 21 day for 3 cycles prior to surgery and 3 cycles after surgery.~Placebo: 300 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery."
62813087|NCT03663517||pregnant women|pregnant women in Hong Kong
62035861|NCT04897776|SHAM_COMPARATOR|Non-Therapeutic Thalamic Stimulation|"Four months post implant, the neurostimulator device will provide patients with hippocampal stimulation for all seizures. For seizures longer than five seconds, thalamic stimulation will be administered at below therapeutic threshold to control for implant and placebo effects. This will occur in half of the seizures the patient experiences and will be randomly assigned during this phase of the study.~If no benefit is experienced during this phase of the study, patients may participate in an optional randomized CL stimulation phase for an additional four months."
62427329|NCT01155635|ACTIVE_COMPARATOR|Beta-blocker|Use of Carvedilol with any dose
62427330|NCT01155635|ACTIVE_COMPARATOR|Non Beta-blocker|No use of Carvedilol
62813088|NCT03866070|EXPERIMENTAL|Experimental|The subjects that are part of the experimental group will carry out the intervention thought the performance of strengthening exercises of the shoulder and scapula, and capsular stretches.
62813089|NCT03866070|ACTIVE_COMPARATOR|Control|Subjects that are part of the control group will perform shoulder strengthening exercises exclusively.
62813090|NCT01589796|ACTIVE_COMPARATOR|classic TAP|classic US-guided TAP block in a space between iliac crest and the costal margin in the region of the anterior axillary line
62813091|NCT01589796|ACTIVE_COMPARATOR|Medial TAP|US-guided TAP block in a space between iliac crest and the costal margin within 1 inch lateral to transversus abdominis muscle origination
62813092|NCT05557916|ACTIVE_COMPARATOR|Standard rehab group|This group will follow the clinics standard rehab protocol, wherein they have a knee orthosis for six weeks, with flexion limited to 0-30 degress week 0-2, 0-60 degrees week 2-4 and 0-90 degrees week 4-6. Crouching is not permitted week 6-12.
62813093|NCT05557916|ACTIVE_COMPARATOR|Accelerated rehab group|accelerated rehab group, wherein they are permitted to perform range of motion training within their comfort zone. Running is permitted after 8 weeks, contact sports 4 months postoperatively
62813094|NCT02446977|EXPERIMENTAL|Vitamin B2 Streuli®|20mg IV
62813095|NCT02446977|PLACEBO_COMPARATOR|Solution for injection|4ml IV
62813096|NCT04937985||UULEX Test Group|Patients with chronic neck pain
62813097|NCT03496259|EXPERIMENTAL|On-Q Group|Patients in this group will have an On-Q pump placed at the end of the operation
62813098|NCT03496259|ACTIVE_COMPARATOR|Epidural Group|Patients in this group will have an epidural catheter placed at the end of the operation
62813099|NCT03593902|EXPERIMENTAL|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, fludarabine, cyclophosphamide, Mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
62035862|NCT02748915|EXPERIMENTAL|Patients using cochlear implants|All patients using cochlear implants included in the study will take electrophysiological and psychoacoustic tests to measure auditive parameters regarding the study objectives : ECAP, EABR, speech recognition and MCL.
62237128|NCT01491048|ACTIVE_COMPARATOR|No physiotherapy after THA|No Physiotherapy care during the period of hospitalization after THA.
62237129|NCT05266586|PLACEBO_COMPARATOR|Placebo|once-daily placebo tablet and placebo capsule
62813100|NCT05581173||Endoscopic resection of gastrointestinal lesion(s)|Endoscopic mucosal resection or endoscopic submucosal dissection is an outpatient procedure to remove superficial neoplasia(precancerous lesions and early cancer) throughout the gastrointestinal tract.
62237130|NCT05266586|EXPERIMENTAL|monotherapy|once-daily obicetrapib 10 mg tablet and placebo capsule
62237131|NCT05266586|EXPERIMENTAL|combination therapy|once-daily obicetrapib 10 mg tablet and ezetimibe 10 mg capsule
62237132|NCT04474223|EXPERIMENTAL|Mothers with Fetuses Who Have 2° AVB or AV interval > 170ms|
62237133|NCT02136420|EXPERIMENTAL|Tilt perception, Training, placebo|placebo
62237134|NCT02136420|PLACEBO_COMPARATOR|Tilt perception, No training, placebo|subject does test with no hypergravity training and placebo drug only
62237135|NCT02136420|EXPERIMENTAL|Tilt perception, Training, promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
62237136|NCT02136420|EXPERIMENTAL|Tilt perception,No training,promethazine|promethazine 25 mg, one time 120 minutes prior to experiment. No hypergravity training
62813101|NCT03727815|EXPERIMENTAL|Mindfulness Pain Management Arm|Mindfulness meditation intervention - pain management module: patients will be asked to complete a guided mindfulness meditation phone application intervention that was designed to target pain management through mindfulness.
62813102|NCT03727815|EXPERIMENTAL|Mindfulness Self Esteem Arm|Mindfulness meditation intervention - pain management module: patients will be asked to complete a guided mindfulness meditation phone application intervention that was designed to target self esteem through mindfulness.
62813103|NCT03727815|NO_INTERVENTION|Non-intervention Arm|Patients assigned to the non-intervention arm will not be instructed to use a mindfulness meditation phone application and instead will listen to educational materials.
62813104|NCT04006288|ACTIVE_COMPARATOR|Aspirin and clopidogrel|aspirin 81 mg/qd plus clopidogrel 75mg/qd for 30 days
62813105|NCT04006288|EXPERIMENTAL|Aspirin and rivaroxaban from aspirin and clopidogrel|aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
62813106|NCT04006288|ACTIVE_COMPARATOR|Aspirin and prasugrel|aspirin 81 mg/qd plus prasugrel 10mg/qd for 30 days
62237137|NCT02136420|EXPERIMENTAL|Manual Control, Training, placebo|placebo
62427331|NCT06291259||Confirmed positive for mpox|Participants with laboratory test results confirming the diagnosis of Mpox. This includes the total number of unique participants who complete the main part 1 study, those who complete the baseline visit only, those who agree to frequent sampling, and those who only participate in part 2.
62427332|NCT06291259||Confirmed negative for mpox|Participants in whom the clinician feels that the diagnosis of Mpox has been clearly ruled out.
62813107|NCT04006288|EXPERIMENTAL|Aspirin and rivaroxaban from aspirin and prasugrel|aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
62813108|NCT04006288|ACTIVE_COMPARATOR|Aspirin and ticagrelor|aspirin 81 mg/qd plus ticagrelor 60mg/bid for 30 days
62813109|NCT04006288|EXPERIMENTAL|Aspirin and rivaroxaban from aspirin and ticagrelor|aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
62813110|NCT01841281|ACTIVE_COMPARATOR|Low Exhaled Nitric Oxide (NO)|"Subjects with a baseline exhaled NO level less than or equal to 20 ppb will be enrolled in the Low Exhaled Nitric Oxide arm.~All subjects will receive L-arginine and placebo in this cross-over design study."
62427333|NCT04413669|EXPERIMENTAL|white light bronchoscopy and autofluorescence bronchoscopy|White light bronchoscopy and autofluorescence bronchoscopy were carried out for people at high risk for lung cancer with heavy smoking (smoking history\> 400 years).Biopsy was taken for abnormal bronchial mucosa.
62427334|NCT00348569|EXPERIMENTAL|64 Channel VCT|All subjects underwent Coronary Computed Tomographic Angiography (CCTA) after receiving an intravenous (IV) administration of Visipaque (320 mgI/mL), to be followed 2 to 21 days later by catheter coronary angiography (CATH).
62595422|NCT00142740||1 - HIV Positive|Participant in parent study ATN 024, aged 12-24 years, testing HIV positive. All eligible youths must be negative for HBV core antibody, HBV surface antigen, and HBV surface antibody at the time of enrollment in to ATN 024.
62595423|NCT00142740||2 - HIV Negative|Participant in parent study ATN 025, aged 12-24 years and testing negative for HIV infection. All eligible youths must be negative for HBV core antibody, HBV surface antigen, and HBV surface antibody at the time of enrollment in to ATN 025.
62595424|NCT03671564|EXPERIMENTAL|Milademetan (90 mg/Day)|Participants who received milademetan 90 mg daily (QD) Day 1 - 14 followed by 14-day rest in a 28-day cycle.
62595425|NCT03671564|EXPERIMENTAL|Milademetan (120 mg/Day)|Participants who received milademetan 120 mg daily (QD) Day 1 - 14 followed by 14-day rest in a 28-day cycle.
62595426|NCT03671564|EXPERIMENTAL|Milademetan (160 mg/Day)|Participants who received milademetan 160 mg daily (QD) Day 1 - 14 followed by 14-day rest in a 28-day cycle.
62595427|NCT03134846|EXPERIMENTAL|Phase 1: 10mg Cetuximab-IRDye800CW|Three patients will receive 10mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
62595428|NCT03134846|EXPERIMENTAL|Phase 1: 25mg Cetuximab-IRDye800CW|Patients will receive 25mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
62813111|NCT01841281|ACTIVE_COMPARATOR|High Exhaled Nitric Oxide (NO)|"Subjects with a baseline exhaled NO level greater than or equal to 25 ppb will be enrolled in the High Exhaled Nitric Oxide arm.~All subjects will receive L-arginine and placebo in this cross-over design study."
62035863|NCT02748915|EXPERIMENTAL|Patients using EAS device|Patients using EAS device for more than 11 months will take electrophysiological and psychoacoustic tests with the implant functioning only with electrical pulses or in bimodal mode to measure ECAP, EABR, speech recognition and MCL ; this will allow to perform bimodal comparison.
62237138|NCT02136420|PLACEBO_COMPARATOR|Manual Control, No training, placebo|subject does test with no hyper gravity training and placebo drug only
62237139|NCT02136420|EXPERIMENTAL|Manual Control, Training, promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
62427335|NCT04895631|EXPERIMENTAL|Fluorocholine PET Imaging|Patients will undergo a single fluorocholine PET imaging study prior to surgery.
62427336|NCT01058044|EXPERIMENTAL|adherence assessment group|evaluation of adherence using MEMS
62595429|NCT03134846|EXPERIMENTAL|Phase 1: 50 mg Cetuximab-IRDye800CW|Patients will receive 50mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
62595430|NCT03134846|EXPERIMENTAL|Phase 1: 75mg cetuximab + 15 mg Cetuximab-IRDye800CW|Patients will receive 75mg cetuximab + 15 mg Cetuximab-IRDye800CW I.V. four days prior to surgery.
62595431|NCT03134846|EXPERIMENTAL|Phase 1: 75mg cetuximab + 25 mg Cetuximab-IRDye800CW|Patients will receive 75mg cetuximab + 25 mg Cetuximab-IRDye800CW I.V. four days prior to surgery.
62595432|NCT03134846|EXPERIMENTAL|After having established the optimal cetuximab-IRDye800CW dose|After having established the optimal cetuximab-IRDye800CW dose we will extent the study by including up to 70 patients for this specific dose (as determined in phase 1).
62595433|NCT03470558||Sleeve gastrectomy patients|Patients electing to undergo sleeve gastrectomy will monitor their dietary habits.
62595434|NCT05251363|OTHER|Solia S LBB lead|
62595435|NCT06328400|EXPERIMENTAL|Deuremidevir Hydrobromide for Suspension 900mg group, twice a day|9 subjects will receive Deuremidevir Hydrobromide for Suspension 900mg, orally, Q12h, 5.5 days; 3 subjects will receive Deuremidevir Hydrobromide for Suspension Placebo 900mg, orally, Q12h, 5.5 days.
62595436|NCT06328400|EXPERIMENTAL|Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day|9 subjects will receive Deuremidevir Hydrobromide for Suspension 900mg, orally, Q8h, 5.5 days; 3 subjects will receive Deuremidevir Hydrobromide for Suspension Placebo 900mg, orally, Q8h, 5.5 days.
62595437|NCT06328400|EXPERIMENTAL|Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day|9 subjects will receive Deuremidevir Hydrobromide for Suspension 1200mg, orally, Q12h, 5.5 days; 3 subjects will receive Deuremidevir Hydrobromide for Suspension Placebo 1200mg, orally, Q12h, 5.5 days.
62595438|NCT05958004||Non-Prostate Cancer|Participants who are suspected of prostate cancer due to elevated PSA but have not received any treatment and eventually confirmed non-prostate cancer after biopsies
62595439|NCT05958004||Prostate Cancer|Participants who are suspected of prostate cancer due to elevated PSA but have not received any treatment and eventually confirmed prostate cancer after biopsies
62595440|NCT06209398|EXPERIMENTAL|Combined immunization Group|The first dose of inactivated EV71 vaccine and the third dose of hepatitis B vaccine were combined administered on day 0, and the second dose of EV71 vaccine and Group A meningococcal polysaccharide vaccine were jointly administered on day 30.
62595441|NCT06209398|ACTIVE_COMPARATOR|Single immunization Group|On the 0th and 30th day, receive two doses of inactivated EV71 vaccine respectively. On the 60th day, both hepatitis B vaccine and Group A meningococcal polysaccharide vaccine were administrated.
62595442|NCT06209398|ACTIVE_COMPARATOR|hepatitis B and Group A meningococcal polysaccharide vaccine Group|Administrate hepatitis B vaccine on day 0, and Group A meningococcal polysaccharide vaccine on day 30.
62595443|NCT06414824|EXPERIMENTAL|FreeStyle Libre|"FreeStyle Libre for 4 weeks.~All subjects will wear a masked sensor (FreeStyle Libre Pro) for 14 days prior to randomisation."
62813112|NCT03650621|EXPERIMENTAL|Intervention - Magnetic acupuncture|"Infants randomized to the intervention arm will have 5 magnetic stickers placed on both ears approximately 1 hour before the eye-exam and will stay in place for approximately 1 hour after the eye-exam.~Total duration of study 2.5-3 hours"
62813113|NCT03650621|PLACEBO_COMPARATOR|Control - Placebo control|"In this arm the infants will have 5 stickers (magnets removed) placed on their ear approximately 1 hour before the eye-exam and will stay in place for approximately 1 hour after the eye-exam.~Total duration of study 2.5-3 hours"
62813114|NCT03377582|ACTIVE_COMPARATOR|Conventional therapy|Exercise-based cardiac rehabilitation
62813115|NCT03377582|EXPERIMENTAL|Virtual reality based therapy|Exercise-based virtual reality
62035864|NCT02748915|EXPERIMENTAL|Patients with bilateral cochlear implant|Patients with bilateral cochlear implant for more than 11 months will take electrophysiological and psychoacoustic tests to measure ECAP, EABR, speech recognition, and MCL. The binaural interaction component will also be measured ; this will allow to perform binaural comparison.
62035865|NCT01045629||SchizoComp|Competence Ability of schizophrenia
62237140|NCT02136420|EXPERIMENTAL|Manual Control,No training,promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
62035866|NCT01045629||NonSchizoComp|Competence of Non-schizophrenia
62035867|NCT02576678|EXPERIMENTAL|Open label apremilast|"Apremilast doses of 10-mg, 20-mg or 30-mg tablets have been selected to determine the dose range in adolescents and children with moderate to severe plaque psoriasis. These pediatric dosages are expected to achieve exposures similar to those achieved in adult psoriasis and psoriatic arthritis (PsA) subjects treated with apremilast 30 mg orally twice daily (BID).~A staggered, stepwise approach by age range and weight (starting with older and heavier subjects) is considered appropriate for this first-time-in-children study. Doses for younger and lower body weight subjects will be adjusted based on safety and PK data from older and heavier subjects.~Subjects will be divided into 2 age groups with at least 16 subjects in each group. Dosing within and between groups will be staggered, based on PK data collected and on a minimum of 2 weeks of safety data."
62813116|NCT05933746|EXPERIMENTAL|Sleep Hygiene Intervention|1-hour, on-line set of three modules pertaining to various sleep hygiene behaviors
62813117|NCT05933746|PLACEBO_COMPARATOR|Non-behavioral Sleep Education|active, matched placebo condition that controls for engagement and rationale
62237141|NCT02136420|EXPERIMENTAL|Perceptual thresholds,drug then placebo|"Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with promethazine then once with placebo, separated by \>4 days.~This arm corresponds to results published in Diaz-Artiles et al 2017."
62237142|NCT02136420|EXPERIMENTAL|Perceptual thresholds,placebo then drug|"Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with placebo then once with promethazine, separated by \>4 days.~This arm corresponds to results published in Diaz-Artiles et al 2017."
62237143|NCT02804178|EXPERIMENTAL|ATR-101|Ascending dose levels of ATR-101 beginning with 125 mg by mouth twice per day up to 1000 mg twice per day.
62237144|NCT04896138||ILD Cohort|Patients with Interstitial Lung Disease seen at the UVA ILD or Pulmonary Clinic
62237145|NCT04896138||Control Cohort|Control group of patients and family members of those with an Interstitial Lung Disease
62237146|NCT01228955||Yoga Group|Group will enter a 10 week yoga class
62035868|NCT04461977|EXPERIMENTAL|A - true acupuncture|"The selection of acupuncture points is based on Traditional Chinese Medicine (Wen 2011) and on previous studies (Jeong, 2018; Bao,2018), selected as main points: bilateral baxie, SJ5, bafeng, KID3 and ST36. Modifications or additional secondary points may be indicated according to clinical judgment throughout treatment."
62035869|NCT04461977|SHAM_COMPARATOR|B - sham acupuncture|"Patients will receive needling at non-acupuncture points with superficial needling without manipulation to obtain de qi, located near the real points in the hands and feet."
62237147|NCT00327054|EXPERIMENTAL|Nigella sativa seed|
62237148|NCT00327054|NO_INTERVENTION|Control|
62427337|NCT03569020|EXPERIMENTAL|Dietitian-Directed Diet|Participants will be provided $105/week ($15/day) to purchase foods in servings that correspond to the DASH diet and thus include fruits, vegetables, lean meat, low fat dairy, and high fiber foods. Participants will also be asked to restrict red meat, sweets, and sugary beverages during this intervention period. A dietitian will help participants order foods from a digital supermarket. Foods will be delivered to the Johns Hopkins ProHealth Research Clinic for weekly pick-up. This study period will last 4 weeks.
62813118|NCT04620785|EXPERIMENTAL|methylene blue/IPL|"will undergo photodynamic therapy using intralesional 4%methylene blue solution ,after a period of 15 minutes the patient will be subjected to IPL session.~This will be repeated biweekly until complete clearance of the lesion or a maximum four sessions."
62813119|NCT04620785|EXPERIMENTAL|IPL|will undergo biweekly IPL sessions only until complete clearance of the lesion or a maximum four sessions.
62035870|NCT02475096|EXPERIMENTAL|Internet-delivered CBT|Children and parents will receive 10 weekly modules of internet-delivered CBT (Cognitive Behavior Therapy). Parents will also receive 10 weekly specific modules for parents. Main components in the modules directed at children and parents are exposure for symptoms, feared stimuli and situations. The parents modules contain information on how they can support their children in the treatment and is based on social learning theory. Therapist support is provided through written messages within the secure platform. Therapists are trained CBT-psychologists.
62035871|NCT03591068|EXPERIMENTAL|OPN-375 186 mcg BID|
62237149|NCT02608541||Retrospective rib fracture fixation|patients presenting since 2006 with multiple rib fractures or flail chest, managed operatively or non-operatively
62237150|NCT02608541||Prospective rib fracture fixation|patients presenting from October 2015 to October 2017 with multiple rib fractures or flail chest, managed operatively or non-operatively
62237151|NCT02448056||Pre-treatment|All enrolled HCC patients.
62813120|NCT04620785|PLACEBO_COMPARATOR|saline|will undergo intralesional saline.
62813121|NCT05301985|NO_INTERVENTION|Fasting group|conventional preoperative fasting protocol The participants in the Fasting group stopped oral intake at 12:00 pm, the night before surgery. After surgery the participants fasted until the recovery of function of the bowel.
62237152|NCT02448056||Post-treatment one week|All enrolled HCC patients.
62237153|NCT02448056||Post-treatment one month|All enrolled HCC patients.
62427338|NCT03569020|NO_INTERVENTION|Self-Directed Diet|Participants will be asked to consume their typical diet for 4 weeks. There will be no subsidy during this period.
62427339|NCT01431378||CNS|CNS: Known or suspected pathology in the posterior fossa
62813122|NCT05301985|EXPERIMENTAL|Carbohydrate group|preoperative nutrition The participants of experimental group consumed 400 ml of a clear carbohydrate drink (12,5 gr/100 ml carbohydrate, 50 kcal/100 ml, pH 5.0) at 10:00 pm the evening before surgery and 200 ml of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
62237154|NCT00768391|EXPERIMENTAL|IMC-3G3|All patients will receive intravenous infusions of IMC-3G3, with the dose depending on which cohort they are enrolled into.
62237155|NCT04008758|EXPERIMENTAL|sono group|Evaluate the participant's lung condition using ultrasound and do recruitment maneuver if it is necessary
62237156|NCT04008758|NO_INTERVENTION|control group|If participants need recruitment maneuver (decreasing saturation, peak airway pressure \> 35 mmHg) by clinical judgement, do recruitment maneuver not using lung ultrasound
62595444|NCT06414824|ACTIVE_COMPARATOR|SMBG|"Subjects randomised to the control group will monitor their blood glucose with standard blood glucose meters.~A 14-day FreeStyle Libre Pro is included for these subjects from day 14 to day 28 to collect glycaemic data for comparison to the intervention group of the study.~All subjects will wear a masked sensor (FreeStyle Libre Pro) for 14 days prior to randomisation."
62595445|NCT05225675|EXPERIMENTAL|ARGX-117|Intravenous administration of ARGX-117
62813123|NCT02151487||Ropivacaine|Ropivacaine 0.5% 25 ml alone for supraclavicular block
62813124|NCT02151487||Ropivacaine and dexamethasone|25 ml 0.5% ropivacaine + 4 mg dexamethasone
62237157|NCT00514761|ACTIVE_COMPARATOR|1|Xeloda
62237158|NCT00514761|EXPERIMENTAL|2|AZD6244
62595446|NCT05225675|PLACEBO_COMPARATOR|Placebo|Intravenous administration of placebo
62595447|NCT06027554|PLACEBO_COMPARATOR|Placebo capsule|Gelatin capsules
62595448|NCT06027554|EXPERIMENTAL|MitoQ capsule|Capsules containing mitoquinone mesylate (MitoQ, 5 mg/capsule) totaling 20 mg taken every day for 12 weeks.
62595449|NCT00786331|ACTIVE_COMPARATOR|A|Monochemotherapy
62595450|NCT00786331|EXPERIMENTAL|B|Combination chemotherapy
62595451|NCT06619379|OTHER|plastic speculum|metal speculum
62595452|NCT06619379|OTHER|metal speculum|metal speculum will be used in this group
62595453|NCT01543763|EXPERIMENTAL|Panobinostat with PC124871|
62237159|NCT00556153||Phase I|Children, ages 5-15 years with brain tumors
62595454|NCT02279745|EXPERIMENTAL|Oral Ralinepag|Ralinepag immediate-release (IR) capsules of 10, 20, 30, 40, and 100 mcg or extended-release (XR) tablets of 50, 250, and 400 mcg for oral administration.
62813125|NCT02151487||Ropivacaine and clonidine|25 ml 0.5% ropivacaine + 100 mcg clonidine
62813126|NCT02151487||Ropivacaine, dexamethasone and clonidine|25 ml 0.5% ropivacaine + 4 mg dexamethasone + 100 mcg clonidine
62813127|NCT04722900||non-GDM|
62813128|NCT04722900||GDM|
62813129|NCT00525512|EXPERIMENTAL|tiotropium 18mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
62813130|NCT00525512|PLACEBO_COMPARATOR|Placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
62813131|NCT03082690|EXPERIMENTAL|DuoGel|IQP-0528 1% gel administered rectally one time
62813132|NCT02616991|EXPERIMENTAL|Cohort|computed tomography venography
62237160|NCT03252054||Patients aged 70 or over|Patients eligible for the study will undergo screening for memory disorders, attention disorders, and malnutrition
62595455|NCT05259150|EXPERIMENTAL|Internal Champion (IC) Strategy|In the Planning for Health intervention, the IC implementation strategy will include trainings on transformational leadership principles that address challenges that health leaders face in the church setting to assist them in independently planning the cardiovascular health programming for congregants. Limited assistance from staff will be provided in the Preparing for Health and the Delivery of Health interventions.
62595456|NCT05259150|EXPERIMENTAL|Expert Professional (EP) Strategy|In the Planning for Health intervention, the EP implementation strategy will include the use of external professionals to assist health leaders in the planning of cardiovascular health programming for congregants. Staff will assist health leaders in the Preparing for Health and the Delivery of Health interventions.
62595457|NCT05259150|ACTIVE_COMPARATOR|Comparison Group Strategy|In the Planning for Health intervention, the Comparison Group strategy will include process activities with the health leaders (identification of health leaders, meetings of health leaders, assistance of health leaders with recruitment of congregants for research). Except for data collection, participants (health leaders and congregants) will not be involved in the Preparing for Health or the Delivery of Health interventions.
62595458|NCT00251303|EXPERIMENTAL|riluzole|Active drug put into 10-mg capsule form,,prepared by Clinical Center Pharmacy. Dose up to 120 mg daily, divided. Brand name Rilutek.
62595459|NCT00251303|PLACEBO_COMPARATOR|placebo|Placebo Capsules designed to mimic active drug capsules
62035872|NCT01142206|ACTIVE_COMPARATOR|Physical Activity|A standard behavioral weight loss intervention with a physical activity prescription of 200 minutes of moderate intensity physical activity per week.
62035873|NCT01142206|EXPERIMENTAL|Physical Activity & TV Watching|A standard behavioral weight loss intervention with a physical activity prescription of 200 minutes of moderate intensity physical activity per week and an additional prescription of reducing TV watching to 10 hours per week or less.
62237161|NCT00690833|EXPERIMENTAL|topical desonide hydrogel 0.05%|Approximately 40 male and female subjects (about 20 age 3 months to \<13 years and 20 age 13 and up) with mild to moderate atopic dermatitis will apply desonate gel twice daily to ATD
62035874|NCT04338100||Chest Ultrasound|Only one arm, all included patients having chest ultrasonography.
62035875|NCT06011590||Study Cohort|All patients treated at the Department of Internal Medicine at the Medical University of Innsbruck between 01.01.2000 and 31.07.2022, in whom a 10 second 12-lead ECG is available from clinical routine.
62035876|NCT02001857|EXPERIMENTAL|TachoSil|TachoSil
62035877|NCT02001857|NO_INTERVENTION|No TachoSil|No TachoSil
62035878|NCT01640808|EXPERIMENTAL|NIK-333(peretinoin)|
62035879|NCT01640808|PLACEBO_COMPARATOR|Placebo|
62237162|NCT05387226|EXPERIMENTAL|Oncolytic Virus Injection(RT-01)|RT-01 will be administered intravenously
62237163|NCT04003935||Control|Continuing habitual diet and lifestyle.
62237164|NCT04003935||Active 1|Ingestion of a macro- and micro-nutrient rich shake, otherwise continuing habitual diet and lifestyle.
62237165|NCT04003935||Active 2|Ingestion of an encapsulated vitamin and phytonutrient supplement, otherwise continuing habitual diet and lifestyle.
62813133|NCT02681809|EXPERIMENTAL|Ocriplasmin 0.0625mg|
62813134|NCT02681809|EXPERIMENTAL|Ocriplasmin 0.125mg|
62813135|NCT02681809|SHAM_COMPARATOR|Sham injection|
62035880|NCT01987648||All study participants|Included are all patients who 18 years or older, who get an elective craniotomy (no biopsy, no awake surgery, no re-operation) and who are treated at the Department of Neurosurgery
62035881|NCT02035280||Elderly suffering of spine deformity|Spinal deformity patients over the age of 60 years undergoing elective surgery and requiring fusion of at least 5 levels.
62237166|NCT04026139|EXPERIMENTAL|experimental group|Patients in the experimental and control group were instructed by clinical staff to perform home-based exercises and followed up through phone calls. The experimental group performed exercises using an elastic resistance band with 10 repetitions/set × 5 sets/day × 3 days/week.
62427340|NCT01431378||Thorax|Thorax: Patients referred for staging of a known or suspected lung cancer
62813136|NCT04404179||CASE|59 COVID-19 POSITIVE PRISONERS WHO UNDERWENT TREATMENT AT THE COVID-19 CARE FACILITY AT CAMP JAIL.
62035882|NCT06669221||Early drug intervention group|Patients who had at least one prescription record associated with any of the drug treatments of interest (cyclosporine A, eltrombopag, romiplostin, danazol, or methenolone) during each period of interest before the first transfusion record during the follow-up period.
62595460|NCT03376971|EXPERIMENTAL|Diagnostic (lung biopsy)|Patients undergo extraction of up to 3 additional lung biopsies from target lesions that are at least 2-3 cm in diameter using the 19 gauge SuperCore biopsy needle or the 20 gauge Rotax needle. The extracted tissue is imaged via confocal fluorescence microscopy using a variety of fluorescent contrast agents, such as fluorescein sodium, methylene blue, indocyanine green and then undergo hematoxylin and eosin processing.
62595461|NCT04810494|EXPERIMENTAL|test drug|2% Lidocaine
62595462|NCT04810494|PLACEBO_COMPARATOR|Placebo|0.9% Normal Saline
62595463|NCT03360409|EXPERIMENTAL|grade 1|ACD
62035883|NCT06669221||Watchful observation group|Patients with no prescription record associated with any of the drug treatments of interest (cyclosporine A, eltrombopag, romiplostin, danazol, or methenolone) during the follow-up period and before the first transfusion record, if any.
62035884|NCT06211400|EXPERIMENTAL|Vibration Exercise|
62035885|NCT06211400|NO_INTERVENTION|Control|
62427341|NCT01431378||Abdomen 1|Abdomen: Patients with acute flank pain and suspected urolithiasis
62427342|NCT01431378||Abdomen 2|Abdomen: Patients with a known or suspected focal liver lesion
62595464|NCT03360409|ACTIVE_COMPARATOR|grade 2|ACDF
62035886|NCT01929967||Heterotaxy syndrome|Patients with a diagnosis of heterotaxy syndrome, as objectively defined by visceral heterotaxy (malrotation, interrupted inferior vena cava) with either documented polysplenia or asplenia by radiological imaging
62035887|NCT00934466|EXPERIMENTAL|1|MK2637 120 mg
62035888|NCT00934466|EXPERIMENTAL|2|MK2637 50 mg
62035889|NCT00934466|PLACEBO_COMPARATOR|3|Placebo
62035890|NCT00934466|ACTIVE_COMPARATOR|4|Dextromethorphan 220 mg
62427343|NCT02556099|EXPERIMENTAL|Hydroxyurea Treatment|Hydroxyurea will be administered once daily by mouth. Participants will be monitored monthly to maximum tolerated dose and quarterly thereafter with periodic clinical evaluations, laboratory tests, and transcranial doppler examinations every 6 months.
62595465|NCT03360409|ACTIVE_COMPARATOR|grade 3|ACDA
62035891|NCT00934466|ACTIVE_COMPARATOR|5|Dextromethorphan 110 mg
62237167|NCT04026139|ACTIVE_COMPARATOR|control group|The control group underwent active joint range-of-motion exercises and isometric contraction exercises.
62237168|NCT00597077|ACTIVE_COMPARATOR|Rate control|
62427344|NCT05066100|EXPERIMENTAL|Pregnant women with FIRN|Women desiring to breastfeed and identified during their pregnancy as having flat, inverted or retracted nipples
62427345|NCT03952663|EXPERIMENTAL|Group I|inferior alveolar nerve lateralization for dental implant placement ,and platelet rich fibrin membrane is placed around the nerve.
62427346|NCT03952663|ACTIVE_COMPARATOR|Group II|inferior alveolar nerve lateralization for dental implant placement without placement of platelet rich fibrin membrane around the nerve.
62427347|NCT01946971|EXPERIMENTAL|PL|Placebo once a day orally for 7 days, then lansoprazole 1mg/kg once a day orally for 7 days
62595466|NCT02197832|EXPERIMENTAL|EA|in the cycle immediately preceding the scheduled FET treatment, an endometrial biopsy would be arranged on day 21-23 of the menstrual cycles and they will be instructed to use non-hormonal means of contraception during that cycle.
62595467|NCT02197832|PLACEBO_COMPARATOR|Control|The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix but not into the uterine cavity, only entering the endocervical canal as control.
62237169|NCT00597077|ACTIVE_COMPARATOR|Rhythm control|
62427348|NCT01946971|EXPERIMENTAL|LP|Lansoprazole 1mg/kg orally once a day for 7 days, then placebo orally once a day for 7 days
62427349|NCT05331846|EXPERIMENTAL|SMELL OF BREAST MILK|the smell of breast milk will reduce pain and stress
62427350|NCT05331846|NO_INTERVENTION|control|pain and stress will not decrease
62595468|NCT05002959||TESS Anatomic|Subjects who received the Anatomic T.E.S.S.® V3 Modular Total Shoulder System to relieve pain and restore the joint function and who met the inclusion/exclusion criteria.
62813137|NCT02897921||Carriers of recessive gene mutations of myopathies|"Patients with several different kinds of recessively inherited myopathy genes, such as for example Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, Limb Girdle limb girdle muscle dystrophy (LGMD) type 2A and 2L etc.~Investigated by blood sampling, Biodex 4 Isokinetic Dynamometer, MRI analysis, ECG, Holter monitoring, and echocardiography."
62813138|NCT02897921||Healthy controls|Healthy controls, investigated by blood sampling, Biodex 4 Isokinetic Dynamometer and MRI analysis.
62813139|NCT03577275|PLACEBO_COMPARATOR|Placebo oral capsule|Single dose of placebo to match NST-4016
62813140|NCT03577275|ACTIVE_COMPARATOR|Moxifloxacin 400mg|Single 400mg dose of active comparator moxifloxacin (open label)
62813141|NCT03577275|EXPERIMENTAL|NST-4016 600mg|Likely therapeutic dose of NST-4016
62813142|NCT03577275|EXPERIMENTAL|NST-4016 2000mg|Supratherapeutic dose of NST-4016
62813143|NCT05594459|ACTIVE_COMPARATOR|Opioids|
62595469|NCT05002959||TESS Reverse|Subjects who received the Reverse T.E.S.S.® V3 Modular Total Shoulder System to relieve pain and restore the joint function and who met the inclusion/exclusion criteria.
62813144|NCT05594459|EXPERIMENTAL|Mini invasive|
62813145|NCT03901495|EXPERIMENTAL|Diaana|"1. The patient fullfill Diaana~2. The resident physician takes connaissance of the Diaana summary~3. The resident physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)~4. The senior physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)"
62813146|NCT03901495|NO_INTERVENTION|Control|"1. The resident physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)~2. The senior physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)"
62813147|NCT01366768|EXPERIMENTAL|Oral amino acid mixture|Oral administration of amino acid mixture in healthy volunteers
62595470|NCT04613193|ACTIVE_COMPARATOR|Strict BP intervention group|SBP \< 120 mmHg and a reduction in SBP of \>= 15 mmHg
62595471|NCT04613193|OTHER|Conventional BP control group|In patients \< 75 years: SBP = 135 mmHg In patients \>/= 75 years: SBP = 145 mmHg
62813148|NCT01366768|EXPERIMENTAL|Intravenous amino acid administration|Intravenous infusion of amino acid mixture in healthy volunteers
62813149|NCT01422096|EXPERIMENTAL|leuprolide|leuprolide 11.25 mg IM with adrenal suppression/stimulation testing with dexamethasone/Cortrosyn and ovarian stimulation testing with r-hCG before and 3 weeks after injection
62035892|NCT03558048||Men with Inflammatory Bowel Disease|Men with a confirmed diagnosis of IBD between the ages of 40-69 years old. These subjects will have their prostate specific antigen checked via a blood draw during clinic visits over the course of the study period.
62237170|NCT00861263|OTHER|spiral overtube|Any subject that has been referred for spiral enteroscopy will be asked to participate in this study. The purpose is to gather data about the technical aspects of the procedure,diagnostic capability and treatment as well as long term follow up.
62237171|NCT05418218||Migraine|Patients with migraine (including vestibular migraine), including all types of migraine as defined by ICHD-3.
62237172|NCT05418218||Other Primary Headache Disorders|Patients with other primary headache disorders (excluding migraine), including all types of other primary headache disorders (such as Tension-Type Headache, Cluster Headache) as defined by ICHD-3.
62237173|NCT05418218||Vertigo|Patients with other vertigo disorders (excluding vestibular migraine).
62237174|NCT05418218||Secondary Headache Disorders|Patients with secondary headache disorders as defined by ICHD-3.
62237175|NCT05418218||Normal control|Normal people do not have headache and vertigo.
62237176|NCT01152762|EXPERIMENTAL|Standardized Respiratory Physiotherapy|Standardized Respiratory Physiotherapy is the intervention in all selected patients
62237177|NCT06493812|ACTIVE_COMPARATOR|Fascia lata|Participants in this group will undergo skull base reconstruction using fascia lata harvested from the thigh. The surgical team will perform endoscopic endonasal surgery to treat sellar region pathology and utilize fascia lata to repair the skull base defect. The procedure involves the extraction of the graft from the left thigh, followed by standard reconstruction techniques to ensure optimal healing and function of the skull base. Postoperative pain and other outcomes will be closely monitored and recorded using standardized measures.
62237178|NCT06493812|ACTIVE_COMPARATOR|Temporal fascia|Participants in this group will undergo skull base reconstruction using temporal muscle fascia harvested from the temporal region of the head. The surgical team will perform endoscopic endonasal surgery to treat sellar region pathology and utilize temporal fascia to repair the skull base defect. The procedure involves the extraction of the graft from the left temporal region, followed by standard reconstruction techniques to ensure optimal healing and function of the skull base. Postoperative pain and other outcomes will be closely monitored and recorded using standardized measures.
62237179|NCT04100850|EXPERIMENTAL|Aquatic Exercises|Aquatic Exercises (AE) are water aerobics exercises and resistance exercises, classes will be supervised by a Physical Educator, in collective sessions of up to 30 people per class, twice a week, lasting 50 minutes, for two months.
62813150|NCT05057065||Hyperlipidemia|"* HBsAg(+) patients~* TC\>5.17mmol/L（200mg/dl）and（or）TG\>2.3mmol/L（200mg/dl）"
62813151|NCT05057065||diabetes|"* HBsAg(+) patients~* FPG\>126 mg/dL(7.0 mmol/L)Fasting is defined as no caloric intake for at least 8 h."
62237180|NCT04100850|ACTIVE_COMPARATOR|Watsu|The Watsu (water shiatsu) will be applied by a physical therapist, in individual sessions, twice a week, lasting 50 minutes, for two months in a warn pool (± 34°C). Watsu in particular prescribes transition of movements, once they are instituted, the therapist can create and adapt according to the limitations and restrictions that are encountered.
62237181|NCT04100850|NO_INTERVENTION|Control|The control group will not receive any of these treatments (aquatic exercises and Watsu).
62237182|NCT01051700|EXPERIMENTAL|5 mg|GW786034
62237183|NCT01051700|EXPERIMENTAL|10 mg|GW786034
62237184|NCT01051700|EXPERIMENTAL|20 mg|GW786034
62237185|NCT01051700|PLACEBO_COMPARATOR|Placebo|Placebo
62237186|NCT04207866|EXPERIMENTAL|Remote AT services|Experimental group will consist of participants who access auditory therapy services from a remote location. Services will be conducted with this group via teleconferencing over the Ontario Health Network.
62237187|NCT04207866|ACTIVE_COMPARATOR|In House AT|This group will receive auditory therapy services face-to-face at the treatment site.
62595472|NCT06408220|EXPERIMENTAL|Part I (initial risk assessment)|Participants complete questionnaires, undergo collection of a blood sample, and undergo an H. pylori breath test for gastric cancer risk assessment at baseline.
62595473|NCT06408220|EXPERIMENTAL|Part II, Cohort I (EGD, biopsy)|Participants may undergo EGD with possible tissue biopsy within 3 months of baseline risk assessment and complete questionnaires annually up to 3 years.
62813152|NCT05057065||CHB without metabolic disease|"* HBsAg(+) patients~* without diabetes/ obesity/hyperlipidemia"
62813153|NCT06211439|ACTIVE_COMPARATOR|Transcranial electrical stimulation HD-tES|real HD-tACS:anodal transcranial alternating current stimulation were delivered over the left DLPF cortex for patients in different frequencies (40Hz gamma, 4Hz theta) , with a current intensity of 2mA for 20 minutes per day.
62813154|NCT06211439|SHAM_COMPARATOR|sham Transcranial electrical stimulation HD-tES|sham HD-tACS: sham transcranial alternating current stimulation were delivered over the left DLPF cortex for patients in different frequencies (40Hz gamma, 4Hz theta) , with a current intensity of 2mA for 20 minutes per day.
62035893|NCT05973071|EXPERIMENTAL|Tuune|Participants complete the Tuune contraceptive decision aid health questionnaire as part of their standard OBGYN clinic appointment.
62237188|NCT04417101|EXPERIMENTAL|JBT treatment|The participants will be instructed to take their Chinese herbal medicine formula (CHM), which named Juan Bi Tang, and take it as a dose of 3 g (per bag) each time, trice daily for 4 weeks.
62237189|NCT04417101|NO_INTERVENTION|No treatment|Participants in the non-treatment period will receive conventional self-care management for myofascial pain syndrome.
62237190|NCT00460057|PLACEBO_COMPARATOR|Alendronate, Placebo|All subjects were given 600 mg of calcium and 400 IU of vitamin D supplements. The subjects were randomized to receive weekly alendronate 20 mg (n = 31) or placebo (n = 32).
62237191|NCT00651157|EXPERIMENTAL|Treatment (viral therapy)|Patients receive wild-type reovirus (Reolysin®) IV administered at a dose of 3 x 10\^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62237192|NCT01849666|ACTIVE_COMPARATOR|A: phenprocoumon single dose|
62237193|NCT01849666|EXPERIMENTAL|B: vemurafenib + phenprocoumon single dose|
62427351|NCT02453867|ACTIVE_COMPARATOR|Standard immunosuppression|starting immunosuppression: tacrolimus (Advagraf) (target trough levels \>5 ng/ml), mycophenolate mofetil \>1g/d in MMF or \>720 mg/d in mycophenolic acid, steroids from month 1-3 dosing according to local practice; 200 pts are planned to carry on with standard immunosuppression (tacrolimus (Advagraf), Mycophenolate, steroids) as stated above according to international guidelines for kidney transplant recipients from month 3 posttransplant to month 12 posttransplant
62813155|NCT03446235|EXPERIMENTAL|Connected Health|This group will get 2 interviews about physical exercise (exercise instruction with motivational interview) and 6 communications with individualized instruction and counseling of their physical exercise (investigators can access activity data and exercise log) including the usage of the monitoring device.
62427352|NCT02453867|EXPERIMENTAL|Reduced immunosuppression|"The Intervention is stopping medication:~200 pts are planned to receive a reduced immunosuppression after month 3: carry on with tacrolimus (Advagraf; trough levels \>5 ng/ml) steroids stop at month 3 mycophenolate stop at month 6"
62427353|NCT06542770|EXPERIMENTAL|Atrial cardiomyopathy by echocardiogram intervention|"Presence of Atrial cardiomyopathy is defined by echocardiogram if ANY of the following is present:~1. LA dilatation: indexed volumen \>32 ml/m2~2. PALS (Peak atrial longitudinal strain) \<21%~3. PACS ( Peak atrial contraction strain ) \<13%~4. Atrial ejection fraction \<55%"
62427354|NCT06542770|NO_INTERVENTION|Atrial cardiomyopathy by echocardiogram standard practice|"Presence of Atrial cardiomyopathy is defined by echocardiogram if ANY of the following is present:~1. LA dilatation: indexed volumen \>32 ml/m2~2. PALS (Peak atrial longitudinal strain) \<21%~3. PACS ( Peak atrial contraction strain ) \<13%~4. Atrial ejection fraction \<55%"
62427355|NCT06542770|EXPERIMENTAL|Non atrial cardiomyopathy by echocardiogram intervention|"Absence of atrial cardiomyopathy is defined by echocardiogram if none of the characteristics bellow were accomplished.~1. LA dilatation: indexed volumen \>32 ml/m2~2. PALS (Peak atrial longitudinal strain) \<21%~3. PACS ( Peak atrial contraction strain ) \<13%~4. Atrial ejection fraction \<55%"
62427356|NCT06542770|NO_INTERVENTION|Non atrial cardiomyopathy by echocardiogram standard practice|"Absence of atrial cardiomyopathy defined by echocardiogram if none of the characteristics bellow were accomplished.~1. LA dilatation: indexed volumen \>32 ml/m2~2. PALS (Peak atrial longitudinal strain) \<21%~3. PACS ( Peak atrial contraction strain ) \<13%~4. Atrial ejection fraction \<55%"
62427357|NCT05101356|EXPERIMENTAL|Phase 1 Treatment (sargramostim, LabVax 3(22)-23)|Patients receive sargramostim SC and LabVax 3(22)-23 ID on weeks 1, 2, 4, 8, and 12 in the absence of disease progression or unacceptable toxicity.
62427358|NCT05101356|EXPERIMENTAL|Phase 2 Treatment (sargramostim, LabVax 3(22)-23, pembrolizumab)|Pembrolizumab will be given intravenously every 3 weeks for up to 12 cycles on Day 1 of Weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, and 34. Participants will be given LabVax 3(22)-23 (intradermally) and adjuvant GM-CSF (subcutaneously) on weeks 7, 8, 10, 14, and 18.
62427359|NCT01893151|EXPERIMENTAL|Iguratimod|Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
62427360|NCT01893151|PLACEBO_COMPARATOR|Iguratimod placebo|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week;Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week
62427361|NCT05223439||Individuals diagnosed with neuropathic pain due to lumbar disc degeneration|Individuals with neuropathic pain due to lumbar disc degeneration were included in this group.
62237194|NCT00880035|EXPERIMENTAL|Group A|Group A: day 1 = music, day 2 = washout, day 3 = headphone without music
62427362|NCT05223439||Individuals with lumbar disc degeneration but no neuropathic pain|Individuals without neuropathic pain due to lumbar disc degeneration were included in this group.
62427363|NCT05223439||Healthy Controls|Healthy individuals who did not have any problems that would affect gait were included.
62427364|NCT01749033|ACTIVE_COMPARATOR|Group 1 classic|Group 1 Using the classic inserting technique and completely deflated LMA (Laryngeal Mask Airway)recommended in the LMA manual.
62427365|NCT01749033|ACTIVE_COMPARATOR|Group 2 pre inflated|Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA (Laryngeal Mask Airway) from the manufacturer
62813156|NCT03446235|ACTIVE_COMPARATOR|Self-Monitoring|This group will do physical exercise following the initial instruction and self-monitor them. Investigators can access activity data and exercise log but will not discuss with the subjects about the data.
62813157|NCT03819985|EXPERIMENTAL|Treatment (hypofractionated RT)|Patients receive hypofractionated radiation therapy in 15 daily fractions over 3 weeks in the absence of disease progression or unacceptable toxicity.
62813158|NCT05968586|EXPERIMENTAL|Prone positioning|
62237195|NCT00880035|EXPERIMENTAL|Group B|Group B: day 1 = headphone without music, day 2 = washout, day 3 = music
62237196|NCT02906839|EXPERIMENTAL|Intervention group|Just after AF ablation, nocturnal polygraphy will be performed to diagnose SAS. If present and AHI \>15/h, the SAS will be treated, based on type and severity of SAS and on patient tolerance to treatment.
62237197|NCT02906839|NO_INTERVENTION|Control group|No SAS screening will be performed in this group before the end of the 2 year follow up period.
62237198|NCT03678987||SSc on MMF|"Patients with systemic sclerosis using mycophenolate mofetil (mycophenolic acid, MMF) since \>3 months.~During a 6 hour time period, P-MPA concentration will be measured 4 times."
62237199|NCT04687449|ACTIVE_COMPARATOR|Active Comparator: Curcumin therapy added to standard COPD care|Subjects will be given instructions to take 1 capsule twice daily for 90 days, 30 min before or 1 hour after meals, with a glass of water; if they develop upset stomach or diarrhea, then to take the medication with meals. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the COPD.
62035894|NCT05973071|ACTIVE_COMPARATOR|Control|Participants will complete a standard OBGYN clinic appointment without using the Tuune contraceptive decision aid health questionnaire.
62035895|NCT03173040|EXPERIMENTAL|NiuBangZi pill group|Drug: NiuBangZi pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi pill and methotrexate
62035896|NCT03173040|PLACEBO_COMPARATOR|Placeo group|Drug: NiuBangZi placebo pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi placebo pill and methotrexate
62035897|NCT03905655|PLACEBO_COMPARATOR|Group 1|Three placebo tablets administered orally twice daily with food in addition to continuing TDF, TAF or ETV therapy
62035898|NCT03905655|ACTIVE_COMPARATOR|Group 2|Two 300 mg NTZ tablets and one placebo tablet administered orally in the morning and three placebo tablets in the evening in addition to continuing TDF, TAF or ETV therapy
62035899|NCT03905655|ACTIVE_COMPARATOR|Group 3|Two 300 mg NTZ tablets and one placebo tablet administered orally twice daily with food in addition to continuing TDF, TAF or ETV therapy
62035900|NCT03905655|ACTIVE_COMPARATOR|Group 4|Three 300 mg NTZ tablets administered orally twice daily with food in addition to continuing TDF, TAF or ETV therapy
62035901|NCT03283904|EXPERIMENTAL|Multicomponent PA intervention|Intervention schools will adopt a multicomponent intervention by integrating physical activities into different parts of the school day
62427366|NCT01749033|ACTIVE_COMPARATOR|Group 3 ELL-PIC technique|Group 3 (ELL-PIC): Using the ELL-PIC technique.
62035902|NCT01724671||Cefatroline|Investigators will retrospectively capture patient cases that have been treated for MRSA with ceftaroline. Cases will only be included if the isolate was tested against vancomycin and ceftaroline
62035903|NCT01724671||Vancomycin|Investigators will retrospectively capture patient cases that were been treated for MRSA with Vancomycin.
62035904|NCT04680455|EXPERIMENTAL|Intervention|Participants in the intervention group were asked to exercise three times per week while performing four basic bodyweight exercises in a circuit manner for 12 weeks while supervised online via the Microsoft TEAMs platform. Participants were eased into the program by completing 120 minutes of exercise in week one, 150 minutes in week two, and 180 minutes in the following weeks. Participants were supervised 3X/week for the first four weeks, then 2X/week for the next four weeks and 1X/week for the remaining four weeks. At each session, participants performed the four prescribed exercises (squats, tricep dips, lunges, and push-ups) for 45 seconds each, then switched immediately (15 seconds) to the next exercise followed by one minute of rest at the end of each circuit. Following this exercise program, men living with obesity were able to reach moderate intensity.
62035905|NCT04680455|NO_INTERVENTION|Control|Participants allocated to the control group received an online exercise resource for a 12-week workout plan covering fitness components required to reach both components of the weekly physical activity guidelines on their own. It was recommended that they do a minimum of 150 minutes of moderate to vigorous aerobic activities and two sessions of muscle-strengthening activities using an online program. No supervision was offered and no contact was permitted between the research team and participants from this group.
62427367|NCT02269007|EXPERIMENTAL|0.5ml influenza vaccine|0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
62427368|NCT04632628|EXPERIMENTAL|NiteCAPP: Online Cognitive Behavioral Therapy for Insomnia|This is a pilot trial with one treatment condition (CBT-I).
62427369|NCT00736060||1|Sickle cell anemia
62427370|NCT00736060||2|Sickle cell thalassemia
62427371|NCT02884011||No chronic antihypertensives|not on either a chronic β-blocker or ACE-Inhibitor
62427372|NCT02884011||β-blocker|on chronic β-blocker
62427373|NCT02884011||ACE-Inhibitor|on chronic ACE-Inhibitor
62427374|NCT02884011||Both β-blocker and ACE-inhibitor|on both chronic β-blocker and ACE-inhibitor
62813159|NCT05968586|ACTIVE_COMPARATOR|Supine positioning|
62813160|NCT04251117|EXPERIMENTAL|GNOS-PV02 + INO-9012 + Pembrolizumab|"First line therapy with standard of care tyrosine kinase inhibitors (TKI) during which patient-specific GNOS-PV02 will be manufactured.~GNOS-PV02 + INO-9012 + Pembrolizumab will be administered upon disease progression or intolerance to TKI."
62427375|NCT04998773|ACTIVE_COMPARATOR|Group Bilateral|32 patients, bilateral active TBS stimulation, Will receive an intensive-spaced protocol Intermittent TBS in left DLPFC and Continuous TBS in right DLPFC
62427376|NCT04998773|ACTIVE_COMPARATOR|Group Unilateral|32 patients, unilateral left DLPFC active TBS stimulation. Will receive an intensive-spaced protocol Intermittent TBS in left DLPFC and Sham Continuous TBS in right DLPFC
62427377|NCT04998773|PLACEBO_COMPARATOR|Group Placebo|32 patients, bilateral sham TBS stimulation. Will receive an intensive-spaced protocol of Sham Intermittent TBS in left DLPFC and Sham Continuous TBS in right DLPFC
62427378|NCT04247594|EXPERIMENTAL|Period 1|1500 mg per day
62427379|NCT04247594|EXPERIMENTAL|Period 2|2000 mg per day
62427380|NCT04247594|EXPERIMENTAL|Period 3|2500 mg per day
62427381|NCT04247594|EXPERIMENTAL|Period 4|3000 mg per day
62427382|NCT04399720||BPS group|patients under Bisphosphonate therapy for at least 24 months
62427383|NCT04399720||healthy patients|healthy patients not assuming with no previous Bisphosphonate assumption
62427384|NCT05567094|EXPERIMENTAL|Dexamethasone|Patients will receive 0.2 mg/kg dexamethasone, administered as an intravenous bolus within 5 minutes after induction of anesthesia
62427385|NCT05567094|PLACEBO_COMPARATOR|Saline placebo|Patients will receive 2ml saline placebo, administered as an intravenous bolus within 5 minutes after induction of anesthesia
62427386|NCT02820935|EXPERIMENTAL|Part 1, Period 1: CC-220|Single dose of 0.6mg CC-220
62427387|NCT02820935|EXPERIMENTAL|Part 1, Period 2: itraconazole with CC-220|Multiple does of 200 mg itraconazole alone, with a single dose of 0.6 mg CC-220 plus itraconazole
62813161|NCT02113709|EXPERIMENTAL|Visual improvement|To see how efficiently visual improvement occurs by Full-time Occlusion therapy with an eye patch in severe amblyopia.
62813162|NCT00708292|EXPERIMENTAL|Single Agent AUY922|
62813163|NCT00708292|EXPERIMENTAL|AUY922 + Bortezomib|
62813164|NCT00708292|EXPERIMENTAL|AUY922 + Bortezomib + Dexamethasone|
62813165|NCT05595837||COVID-19 positive donors|
62035906|NCT02968420|ACTIVE_COMPARATOR|Group 1|Group 1: girls who received 2 doses of Q-HPV vaccine at 0, 6 month schedule 8-10 years ago when they were between 9-13 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
62035907|NCT02968420|ACTIVE_COMPARATOR|Group 2|Group 2: girls who received 3 doses of Q-HPV vaccine at 0, 2, 6 month schedule 8-10 years ago when they were between 9-13 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
62035908|NCT02968420|ACTIVE_COMPARATOR|Group 3|Group 3: young women who received 3 doses of Q-HPV vaccine at 0, 2, 6 month schedule 8-10 years ago when they were between 16-26 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
62035909|NCT00891267|EXPERIMENTAL|Olmesartan medoxomil low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
62035910|NCT00891267|EXPERIMENTAL|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
62035911|NCT00891267|ACTIVE_COMPARATOR|Amlodipine|Amlodipine taken once daily for 6 weeks
62237200|NCT04687449|ACTIVE_COMPARATOR|Active Comparator: Placebo with Standard COPD care|Subjects will be given instructions to take 1 capsule twice daily for 90 days, 30 min before or 1 hour after meals, with a glass of water; if they develop upset stomach or diarrhea, then to take the medication with meals. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the COPD.
62237201|NCT05649033||"group recently graduated midwives practicing in the delivery room"|Midwives graduated for less than three years and practicing in the delivery room
62237202|NCT01056133|EXPERIMENTAL|Omega-3 capsules-Fish Oil|Omega-3 fatty acids in the form of fish oil capsules (2g/d)
62427388|NCT02820935|EXPERIMENTAL|Part 2, Period 1: CC-220|Single dose of 0.6mg CC-220
62035912|NCT04217863|EXPERIMENTAL|The experimental intervention (GDP): It includes three writing|"1. Participants will be required to describe memories associated with traumatic event in a sequential order, with an objective and detached attitude~2. They will be asked to describe~   1. Their opinion regarding the traumatic event and emotions perceived during the experience~  2. Its impact on their daily lives, and how it has altered their attitudes toward life.~3. The actual situation will be focused, while reviving the whole traumatic event experience which aids in exploring the following aspects:~   * Present thoughts and feelings regarding the traumatic experience, and also clarify the differences between the ones felt at the time of traumatic event in comparison to the current feelings.~  * How much they understand and appreciate themselves for successfully dealing with the traumatic event~  * To what extent the traumatic event has modified their vision, attitude, knowledge, and skills, and how it can help in their future;~  * What will be their future reactions to other similar events."
62035913|NCT04217863|NO_INTERVENTION|The control intervention:|A day prior to each writing session, the researcher will communicate with each study subject via telephone in order to give them a reminder to perform the writing task and to check their understanding regarding the instructions given in the booklet. Details regarding the inability to contact the subject will also be recorded in the patient form.
62237203|NCT04496986||Cardiovascular Surgical Patients Preoperative Exam|All enrolled participants will undergo a baseline Fiberoptic Endoscopic Evaluation of Swallowing (FEES) before their surgery to determine baseline / preoperative swallowing function. Those with confirmed dysphagia will not be asked to complete the postoperative swallowing exam, given our desire to examine contributing risk factors for dysphagia development and mechanisms within cardiovascular surgical patients. In addition to the instrumental exam, systematic collection of demographic, medical, surgical, and intubation-related candidate predictor variables will be conducted over the entire perioperative period.
62427389|NCT02820935|EXPERIMENTAL|Part 2, Period 2: rifampin with CC-220|Multiple doses of 600 mg rifampin alone, with a single dose of 0.6 mg CC-220 plus rifampin
62427390|NCT04518319|EXPERIMENTAL|omega-3 polyunsaturated fatty acids|Patients randomized to the omega-3 polyunsaturated fatty acids will receive treatment with 1200mg per day plus on-going olanzapine.
62427391|NCT04518319|EXPERIMENTAL|Xbox aerobic exercise|Patients randomized to the Xbox aerobic exercise will do Xbox aerobic exercise 30min per day plus on-going olanzapine.
62427392|NCT04518319|EXPERIMENTAL|transcranial direct current stimulation|Patients randomized to the transcranial direct current stimulation will be applied for transcranial direct current stimulation 5 session/week at 2mA, 20min plus on-going olanzapine. The anodal electrode will be placed over the left dorsolateral prefrontal cortex.
62595474|NCT06408220|ACTIVE_COMPARATOR|Part II, Cohort II (questionnaires)|Participants complete questionnaires for re-assessment annually up to 3 years and may undergo EGD at year 2.
62427393|NCT04518319|EXPERIMENTAL|olanzapine|Patients randomized to the olanzapine will receive conventional treatment-olanzapine.
62427394|NCT02611245|EXPERIMENTAL|Indocyanine green|This group of patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. Before systematic lymphadenectomy, four-point of ICG with 10mg was injected in normal lung tissue around the tumor. After 3-5 minutes, fluorescence and white-light images were collected and recorded in real-time. With the guidance of intraoperative images, all fluorescent lymph nodes were removed and sent to routine pathological confirmation.
62427395|NCT03218631|OTHER|Oxandrin|Administration of a single dose of approximately 0.1 mg/kg of a medium chain triglyceride (MCT) oil Oxandrin (oxandrolone) solution vs. 01.mg/kg tablets in a small cohort of healthy adults. Participants will be dosed at two time points one week apart.
62427396|NCT05233371||Infants at high risk of developmental delay|
62427397|NCT06539065|EXPERIMENTAL|VR group|The experimental group received a twelve-week intervention of 36 sessions using VR interactive games in their exercise prescription
62427398|NCT06539065|NO_INTERVENTION|Non-VR group|control group followed the original instructor-led exercise intervention as the course content.
62427399|NCT03783845|EXPERIMENTAL|test group|"Metronidazole 400mg,three times daily for two weeks~Amoxicillin 500mg,three times daily for two weeks."
62595475|NCT06615258|EXPERIMENTAL|DNS Based breathing exercises+PFMT|Dynamic Neuromuscular Stabilization (DNS)-based respiratory training and pelvic floor muscle training (PFMT) will be applied.
62595476|NCT06615258|ACTIVE_COMPARATOR|PFMT|Pelvic floor muscle training (PFMT) will be applied.
62595477|NCT06615258|NO_INTERVENTION|Control Group|No intervention will be made to the participants in this group.
62035914|NCT02750254|EXPERIMENTAL|Arm 1: Azacitidine|"* Treating physician must choose from one of these conditioning regimens (will be given per standard of care)~  * fludarabine and fractionated total body irradiation (Flu/FrTBI)~ * fludarabine and busulfan (Flu/Bu4)~ * fludarabine, cyclophosphamide, and single dose total body irradiation (Flu/Cy/sdTBI)~ * fludarabine and melphalan (Flu/Mel)~ * reduced-intensity fludarabine and busulfan (Flu/Bu2)~* G-CSF from Day -5 through Day -1 per standard of care~* On Day 0, the allograft will be infused per standard of care.~* Azacitidine will be administered on Day +1 and +2 post-stem cell transfusion days~* Cyclophosphamide on Days +3 and +4 post-transplant"
62035915|NCT04158531|EXPERIMENTAL|REC2Stim|Use electrocorticography (ECoG)-based seizure detection and cortical network stimulation upon seizure onset detection.
62035916|NCT06082037|EXPERIMENTAL|Belumosudil + Azithromycin|Participants will receive 200 mg belumosudil orally once daily
62237204|NCT04496986||Cardiovascular Surgical Patients Postoperative Exam|All remaining participants without preoperative dysphagia will be seen for a postoperative exam performed within 48 hours of extubation. Simultaneous imaging using FEES and videofluoroscopy will be performed at the bedside, as well as a battery of clinical tests. Completion of these postoperative tests will indicate study completion for participants without evidence of dysphagia, while participants who demonstrate acute-phase postoperative dysphagia will continue to participate if they desire. During their standard of care one-month follow-up appointment, a third research evaluation will be offered for participants with previously identified postoperative dysphagia. During this exam, the same imaging and clinical tests from the previous research exam will be performed. Finally, participants with persisting dysphagia will be offered the opportunity to continue to be studied for a fourth and final research exam during their standard of care six-month follow up clinic visit.
62237205|NCT01052688||Pregnant Women|Pregnant women who have been definitively diagnosed as carrying a fetus with aneuploidy.
62237206|NCT01679249||Hemodialysis patients|Stable prevalent patients on 3-times-per-week hemodialysis
62035917|NCT06082037|PLACEBO_COMPARATOR|Placebo + Azithromycin|Participants will receive placebo orally once daily
62035918|NCT01037920|EXPERIMENTAL|Intervention|subjects in the intervention arm will complete a self-affirmation exercise prior to a physician visit
62237207|NCT02465463|EXPERIMENTAL|FMT arm|Patients in the experimental arm with undergo a fecal microbiota transplant (FMT) after finishing a course of antibiotics.
62237208|NCT02465463|NO_INTERVENTION|Control|Patients in the non-interventional group will not receive a FMT but will be followed over the course of 6 months to assess for recurrence of C.difficile.
62237209|NCT02579174|OTHER|Manual (tibia) and manual (femur)|Knee replacement with Medacta GMK Sphere implants using manual instrumentation for both the tibia component and the femur component
62237210|NCT02579174|OTHER|Manual (tibia) and custom (femur)|Knee replacement with Medacta GMK Sphere implants using manual instrumentation for the tibia component and custom instrumentation for the femur component
62237211|NCT02579174|OTHER|Custom (tibia) and custom (femur)|Knee replacement with Medacta GMK Sphere implants using custom instrumentation for both the tibia component and the femur component
62427400|NCT03783845|NO_INTERVENTION|control group|no intervention during study period
62595478|NCT01787487|EXPERIMENTAL|Arm I (MF patients)|Patients with MF receive ruxolitinib phosphate PO BID on days 1-28. Beginning course 4, patients also receive azacytidine SC or IV for 5 days. Treatment repeats every 28 days for 15 courses in the absence of disease progression or unacceptable toxicity.
62035919|NCT01037920|ACTIVE_COMPARATOR|Control|subjects in the intervention arm will complete a sham exercise prior to a physician visit
62035920|NCT02211716|EXPERIMENTAL|BeGraft|Patient's treated with the BeGraft PMCF Stent Graft System from Bentley Innomed for the treatment of iliac lesions.
62035921|NCT04160780|EXPERIMENTAL|L-PRF as sole graft material|lateral sinus augmentation using L-PRF as sole graft material
62035922|NCT04160780|EXPERIMENTAL|xenograft as sole graft material|lateral sinus augmentation using xenograft as sole graft material
62035923|NCT04160780|EXPERIMENTAL|Xenograft mixed with L-PRF as graft material|lateral sinus augmentation using L-PRF mixed with xenograft as graft material
62237212|NCT02579174|OTHER|Custom (tibia) and manual (femur)|Knee replacement with Medacta GMK Sphere implants using custom instrumentation for the tibia component and manual instrumentation for the femur component
62237213|NCT01993446|EXPERIMENTAL|DRM02|DRM02 Topical Gel, 0.25%
62237214|NCT01993446|PLACEBO_COMPARATOR|Vehicle|DRM02 Topical Gel, Vehicle
62237215|NCT02472080|EXPERIMENTAL|gemcitabine -oxaliplatine combination|
62237216|NCT03080688||Prizma|Measurement of oxyhemoglobin saturation by OSM-3 oximeter and Prizma oxygen saturation measurement
62237217|NCT04637022||3D laparoscopy arm|Patients submitted to vaginal cuff closure after total laparoscopic hysterectomy using a 3D laparoscopic camera
62237218|NCT04637022||4k laparoscopy arm|Patients submitted to vaginal cuff closure after total laparoscopic hysterectomy using a 4k laparoscopic camera
62237219|NCT02005081|OTHER|Actifuse SHAPE|Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
62237220|NCT02005081|OTHER|Autograft with Demineralized Bone Matrix|autograft mixed with demineralized bone matrix in cervical spine fusion.
62427401|NCT06542744|EXPERIMENTAL|Subjects using the Emagina Medical device|Emagina Medical device
62427402|NCT06542744|OTHER|Control group|Standard of Care (SOC)
62427403|NCT05141279||1|Stable
62427404|NCT05141279||2|Partial response
62427405|NCT05141279||3|Moderate response
62427406|NCT05141279||4|Excellent response
62427407|NCT05141279||5|Complete response
62427408|NCT04726514|EXPERIMENTAL|SleepFlex Treatment|
62427409|NCT01997099||Library Creation|Individuals responsible for creating the drug library
62595479|NCT01787487|EXPERIMENTAL|Arm II (MDS/MPN patients)|Patients with MDS/MPN receive ruxolitinib phosphate and azacytidine as in Arm I.
62595480|NCT01725932|EXPERIMENTAL|Culturally adapted CBT based Self Help|Culturally sensitive cbt based self help intervention, which consists of 6 regular chapters and 2 additional chapters. The self help intervention involves family to improve compliance with the intervention
62595481|NCT01725932|NO_INTERVENTION|Care As Usual|Control Group
62035924|NCT05615298||Cancer|"* Negative image data: Has been interpreted as negative in screening mammograms~* Benign image data: Has a suspicious lesion for breast cancer in screening mammograms but confirmed as a benign through the follow-up biopsy or has been interpreted as a benign in screening mammograms and confirmed as a benign in the further diagnostic images taken after at least two years from the screening mammograms."
62035925|NCT05615298||Non-cancer|Has a suspicious lesion for breast cancer in screening mammograms and confirmed as a cancer (malignant) through the follow-up biopsy.
62035926|NCT05234684|EXPERIMENTAL|Orelabrutinib+ R-CHOP|Participants will receive 150 mg of oral orelabrutinib once daily with R-CHOP on day 1 of each cycle (21 days).
62035927|NCT05234684|PLACEBO_COMPARATOR|Placebo+ R-CHOP|Participants will receive 150 mg placebo once daily with R-CHOP on day 1 of each cycle (21 days).
62035928|NCT00682734|ACTIVE_COMPARATOR|1|Metoclopramide 10 mg+ diphenhydramine 25 mg. This medication was administered as an intravenous drip over 20 minutes
62035929|NCT00682734|EXPERIMENTAL|2|metoclopramide 20 mg + diphenhydramine 25 mg. Administered as an intravenous drip over 20 minutes.
62035930|NCT00682734|EXPERIMENTAL|3|metoclopramide 40 mg + diphenhdyramine 25mg. Administered as an intravenous drip over 20 minutes.
62035931|NCT02330042||Group A|"Patients with:~* Type 1 or Type 2 diabetes mellitus~* severe non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR)."
62035932|NCT02330042||Group B|"Patients with:~* Type 1 or Type 2 diabetes mellitus~* with or without mild to moderate NPDR"
62237221|NCT02069353|EXPERIMENTAL|Cardiac arrest|Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
62237222|NCT02336178|EXPERIMENTAL|Benefix|This is a single arm study. Subjects will be treated with Benefix by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.
62237223|NCT01098136|ACTIVE_COMPARATOR|Chiropractic treatment|Management for one-sided pelvic pain, as decided by the chiropractor
62237224|NCT01098136|ACTIVE_COMPARATOR|Conventional health care|Conventional health care for one-sided pelvic pain
62237225|NCT01098136|ACTIVE_COMPARATOR|Conventional and alternative treatment|Treament of pregnant women with other pelvic pain syndromes.
62237226|NCT00760669||Participants Receiving Infiximab|Participants with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PA) receiving infliximab injection will be observed.
62237227|NCT04992962|EXPERIMENTAL|CBD/CBN|Participants will receive a 28-day supply of CBD/CBN sublingual tablets to be taken 3 times a day for 28 days.
62237228|NCT04992962|EXPERIMENTAL|CBD/THC|Participants will receive a 28-day supply of CBD/THC sublingual tablets to be taken 3 times a day for 28 days.
62237229|NCT04992962|PLACEBO_COMPARATOR|Placebo|A placebo sublingual tablet to be taken three times a day for 28 days
62595482|NCT02389790|EXPERIMENTAL|MT-1303|
62237230|NCT04833322|EXPERIMENTAL|Single arm group|Galactose supplementation
62237231|NCT04214301|EXPERIMENTAL|BLI800|BLI800
62237232|NCT03744754||Women with endometriosis|Women with endometriosis disease aged 18-36 years, with appropriate endometriosis diagnosis, based on transvaginal sonography, magnetic resonance imaging and/or previous surgery.Ovarian reserve was assessed by antral follicle counting (AFC) and measurement of serum anti-Mullerian hormone (AMH) levels Enrolled after preservation fertility procedure (vitrification of mature oocytes)
62237233|NCT02702973||Observe the fundus characteristics|Observe the fundus characteristics after high doses of interferonα-2b therapy in patients with melanomas of the skin.
62595483|NCT05433909|EXPERIMENTAL|Endometriosis group|The endometriosis group will include women who will undergo surgery for endometriosis.
62035933|NCT02330042||Group C (controls)|Patients without diabetes or evidence of any form of eye disease
62035934|NCT01212770|EXPERIMENTAL|Apremilast 20 mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
62035935|NCT01212770|EXPERIMENTAL|Apremilast 30 mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
62035936|NCT01212770|PLACEBO_COMPARATOR|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
62237234|NCT00496795|OTHER|epirubicin/docetaxel sequential|Epirubicin/docetaxel sequential, i.e. one arm study with Epirubicin 4 cycles 60 mg/m2 q2w, followed by docetaxel 4 cycles, 100 mg/m2 q2w. Each course with pegfilgrastim.
62237235|NCT02099903|NO_INTERVENTION|Medical therapy for heart failure|Standard optimized medical therapy for heart failure.
62237236|NCT02099903|EXPERIMENTAL|Renal denervation + medical therapy.|Transcatheter Renal Denervation with irrigated radiofrequency catheter + standard medical therapy.
62237237|NCT00109720|EXPERIMENTAL|1|Patients in the experimental group received the services of a Diabetes Self-Management Consultant (DSC)
62237238|NCT00109720|ACTIVE_COMPARATOR|2|This Arm was a Enhanced Usual Care Control group who continued with their usual care but also they and their physicians received the results of all metabolic assessments obtained during the study.
62237239|NCT05179720|EXPERIMENTAL|puncture stent-assisted transperineal prostate biopsy|This group of patients underwent puncture stent-assisted transperineal prostate biopsy.
62237240|NCT05179720|ACTIVE_COMPARATOR|transperineal free-hand biopsy|This group of patients underwent perineal free-hand biopsy
62237241|NCT05898464|EXPERIMENTAL|HIV #1|CD4+ T cell count \<300 cells/µL
62237242|NCT05898464|ACTIVE_COMPARATOR|HIV #2|CD4+ T cell count≥300 cells/µL
62237243|NCT05898464|ACTIVE_COMPARATOR|non-HIV|Healthy adult
62237244|NCT02203123|OTHER|Ultrasound, inferior vena cava, aorta, normal saline|
62237245|NCT04159350|EXPERIMENTAL|Rectal Expulsion Device (RED) - Feasibility|Feasibility Phase.
62237246|NCT04159350|EXPERIMENTAL|Rectal Expulsion Device (RED) - Validation|Validation Phase.
62595484|NCT05433909|EXPERIMENTAL|Control Group|The control group include women who will undergo surgery for other gynecological diseases in which the presence of endometriosis will be excluded during the operation.
62595485|NCT02677038|EXPERIMENTAL|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62595486|NCT03991897|EXPERIMENTAL|Ketogenic diet|"the intervention will consist of 3 phases: a one week run-in period, 24 weeks strict KD and 24 weeks Modified Atkins Diet.~Every day, 40 g of KetoCal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals and to ensure ketosis during the night (some patients drink some sips of the shake during the night). During this run-in period, patients will become familiar with their diet and, in particular, they will learn which foods are allowed and which are not."
62595487|NCT03991897|ACTIVE_COMPARATOR|Isocaloric diet|During the run-in period, the dietician will discuss the diet and maintenance of an isocaloric diet with the patients. As such, the diet of the control group will not change from their normal dietary pattern, unless a patient is following an Atkins-like diet. In the latter case, the patient will be asked to change the diet to a normal Belgian diet.
62035937|NCT01212770|PLACEBO_COMPARATOR|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
62595488|NCT06471946|EXPERIMENTAL|Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT|Patients were treated by Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT
62035938|NCT04559789|EXPERIMENTAL|Digital Lifestyle Intervention|Participants randomized to the intervention arm will receive access to a digital intervention consisting of the MindMate cognitive health app and Neurotrack's personalized health coaching platform.
62595489|NCT04376086|ACTIVE_COMPARATOR|General anesthesia|Patients will receive general anesthesia
62595490|NCT04376086|EXPERIMENTAL|Epidural anesthesia|Patients will receive epidural anesthesia
62595491|NCT00743730|ACTIVE_COMPARATOR|I|Parent and Nurse Controlled Analgesics with basal
62813166|NCT05595837||COVID-19 negative donors|
62035939|NCT04559789|ACTIVE_COMPARATOR|Health Education|Participants randomized to the control arm will receive digital health education materials that mirror the content in the app.
62035940|NCT04745182|EXPERIMENTAL|MASTERY|For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and will contain space to write a specific physical activity goal and to track physical activity (e.g., through step counter data) over the subsequent week. At the in-person visit #2, interventionists will explain PP exercise 1 and MI session 1 to the participants. Calls will last \~30 minutes. Participants will then independently complete PP exercises and MI-based goals and review them at phone sessions over 12 weeks. PP and MI components will be delivered stepwise within sessions (rather than intertwined) based on our experience, participant feedback, and pilot work.
62035941|NCT01562574|EXPERIMENTAL|Activated recombinant human factor VII|
62035942|NCT01562574|PLACEBO_COMPARATOR|Placebo|
62035943|NCT05734560|EXPERIMENTAL|D2C7-IT + 2141-V11|Single D2C7-IT intratumoral infusion (6920 ng/mL in 36 mL) over 72 hours followed by single 2141-V11 infusion (5 dose levels) over 7 hours followed by an injection of 2141-V11 in the cervical perilymphatic subcutaneous area ipsilateral to the tumor at week 2, radiation, and further injections of 2141-V11 in the cervical perilymphatic subcutaneous area ipsilateral to the tumor.
62035944|NCT02287935|ACTIVE_COMPARATOR|Limberg flap|Patients were divided into two groups, group 1 were treated with Limberg flap technique
62035945|NCT02287935|ACTIVE_COMPARATOR|Karydakis procedure|Patients were divided into two groups, group 2 were treated with Karydakis procedure
62237247|NCT05509985|EXPERIMENTAL|ASKG315|Single or multiple ascending dose of ASKG315
62237248|NCT05205057||Pre-menopausal|Pre-menopausal women
62237249|NCT05205057||Post-menopausal women|post-menopausal women
62237250|NCT05074849|EXPERIMENTAL|Smart insoles + Education|Participants in this group will receive a 90-minute group session education on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch)
62237251|NCT05074849|NO_INTERVENTION|Smart Insoles|Participants in this group will not receive a 90-minute group session education on foot self-care, but will receive foot care supplies, insoles and smart watch
62595492|NCT00743730|ACTIVE_COMPARATOR|II|Parent and Nurse Controlled Analgesics without basal
62595493|NCT00743730|ACTIVE_COMPARATOR|III|"Intermittent opioid administered IV on an as needed basis"
62595494|NCT02197286|EXPERIMENTAL|Vitamin D (cholecalciferol)|Intervention: Capsules containing the active ingredient, cholecalciferol @ 4,000 international units (IU). One capsule daily, oral administration for 10 weeks.
62595495|NCT02197286|PLACEBO_COMPARATOR|Placebo|"Daily matching placebo gelatin capsule (also contains microcrystalline cellulose).~Capsules are identical in size, color and taste to experimental drug."
62813167|NCT00635414|EXPERIMENTAL|1|40mg administered orally
62813168|NCT00635414|EXPERIMENTAL|2|15 minute intravenous infusion
62813169|NCT02490436|EXPERIMENTAL|A: active drug first|Cetuximab in treatment period 1, placebo in treatment period 2, and open-label cetuximab in treatment period 3.
62813170|NCT02490436|EXPERIMENTAL|B: placebo first|Placebo in treatment period 1, cetuximab in treatment period 2, and open-label cetuximab in treatment period 3.
62237252|NCT05074849|NO_INTERVENTION|Usual Care|Participants will not receive foot self-care education or the use of insoles and smart watch.
62237253|NCT02974088|EXPERIMENTAL|Neem-based lotion plus louse comb|Neem-based conditioning lotion plus head louse detection and removal comb
62237254|NCT02974088|EXPERIMENTAL|Neem-based lotion plus grooming comb|Neem-based conditioning lotion plus regular grooming comb
62237255|NCT03015441|OTHER|Arm 1: Fermented milk product containing probiotics|
62237256|NCT03015441|OTHER|Arm 2: Milk-based non-fermented dairy product|
62237257|NCT02729623|EXPERIMENTAL|Single CannaHALER dose 10 ± 0.1 mg|Single dose 10 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
62237258|NCT02729623|EXPERIMENTAL|Single CannaHALER dose 15 ± 0.1 mg|Single dose 15 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
62237259|NCT02729623|EXPERIMENTAL|Single CannaHALER dose 20 ± 0.1 mg|Single dose 20 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
62237260|NCT02729623|EXPERIMENTAL|Single CannaHALER dose 25 ± 0.1 mg|Single dose 25 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
62237261|NCT04470609|EXPERIMENTAL|Low dosage vaccine on a 0- and 28-day schedule|Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
62237262|NCT04470609|EXPERIMENTAL|Medium dosage vaccine on a 0- and 28-day schedule|Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
62427410|NCT01997099||Pump Programming|Individuals responsible for programming ambulatory infusion pumps
62427411|NCT01997099||Home Implementation|Individuals responsible for implementing ambulatory infusion pumps in patients' homes
62427412|NCT01997099||Workflow|Individual at the facility responsible for describing the workflow of processing and implementing an ambulatory infusion pump prior to and after introducing the CADD®-Solis VIP System.
62427413|NCT01997099||Ambulatory Infusion Pump Patients|Patients that receive a prescription requiring use of the CADD®-Solis VIP pump
62427414|NCT00840541||DR|Type-2 diabetic subjects diagnosed with diabetic retinopathy (DR).
62427415|NCT02421809||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
62427416|NCT02421809||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group.
62427417|NCT02421809||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group.
62427418|NCT04181216|EXPERIMENTAL|anatomically aligned total knee arthroplasty prosthesis|Total knee arthroplasty with anatomically aligned total knee arthroplasty implant (Journey II Bi-cruciate substituting total knee system, JII-BCS, Smith \& Nephew)
62427419|NCT04181216|ACTIVE_COMPARATOR|Conventaional total knee arthroplasty group|Total knee arthroplasty with conventional total knee arthroplasty implant (Legion total knee system, Smith \& Nephew)
62427420|NCT04058431|EXPERIMENTAL|Osteopathic group|Treatment will be compromised of 8 weeks of standard care plus OMT. Each physician will maintain the same patient at recurring sessions. Osteopathic treatment is performed for 30 minutes and the techniques applied are highly individualized to the patient needs (i.e., techniques are selected based on structure/function, and techniques change over time based on treatment response). In an effort to standardize treatment, we will limit the study protocol to the following designated techniques: facilitated positional release treatment, high velocity low amplitude treatment, articulatory treatment, strain-counterstrain, muscle energy treatment, myofascial release treatment, soft tissue treatment.
62427421|NCT01782950|OTHER|anti-tuberculosis drugs|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide tablets 3 to 5 tablets once daily for 2 months followed by Rifampicin, Isoniazid 3 to 5 tablets once daily for 4 months
62427422|NCT05244382|EXPERIMENTAL|Overcome group|Three-month multimodal program. Aerobic exercise will be combined with the use of TRAG (AlterG® Anti-Gravity Treadmill®), functional recovery of motor control with feedback ultrasound and occupational therapy.
62427423|NCT05244382|NO_INTERVENTION|Usual treatment|Usual medical treatment for the same period of time
62237263|NCT04470609|EXPERIMENTAL|High dosage vaccine on a 0- and 28-day schedule|Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
62237264|NCT04470609|PLACEBO_COMPARATOR|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0, 28
62427424|NCT03329586|EXPERIMENTAL|Training|
62237265|NCT04907695||Video Laryngoscopy|Seeking all patients undergoing intubation for which the clinician chooses to use Video Laryngoscopy. The participants will undergo intubation with the investigators chosen device.
62237266|NCT01523639|ACTIVE_COMPARATOR|Metformin|FOLFIRI + cetuximab + metformin every 2 weeks for 12 cycles
62427425|NCT02918825|EXPERIMENTAL|Paliperidone|Drug: Paliperidone, 75-150mg/month, once a month, 12 weeks
62427426|NCT02918825|ACTIVE_COMPARATOR|Olanzapine|Drug: Olanzapine, 20mg/day, twice a day, 12 weeks
62595496|NCT05705154|ACTIVE_COMPARATOR|Standard treatment|"Standard treatment consists of virtual MDT discussion with referrer and advice signposting into local services for specific issues. If a patient is severely affected enough to be seen face to face, they are offered an interdisciplinary consultation, and tailored input from PT OT and psychological services.~Access to standardised information covering the following topics: sleep, pacing, activity management, school reintegration, managing friendships, eating well and emotional wellbeing.~More complex or severely affected patients will receive one to one treatment with members of the MDT as required."
62595497|NCT05705154|EXPERIMENTAL|Intervention|"As above standard intervention plus the new co-designed intervention.~Based on clinical expertise and theory, it is anticipated the following elements may be included in the intervention:~* Progressive breathing pattern retraining, including education, self-observation, relaxation, body scanning, postural re-alignment~* Identifying the connections between body and mind to address anxiety and breathlessness~* Coping skills for managing anxiety using principles from narrative therapy and mindfulness~* Online materials to improve self-efficacy with home practice~* Social connection with other CYP for peer support, and resource sharing~* Activities to help CYP reconnect with their usual activities, skills, abilities, interests, support systems."
62035946|NCT05576987|EXPERIMENTAL|intervention group|Experimental group will be selected from the branches 3rd and 4th grade. 3 branches will be selected for the experimental group. Branches will be determined by drawing. In order not to interfere with the education of students during the training, the groups will be designated as class branches.
62427427|NCT02073188|EXPERIMENTAL|iBGStar (Group A)|Self-Monitoring Blood Glucose will be managed with iBGStar and iBGStar Diabetes Manager Application (App) uploaded on iPhone for all duration of the study (6 months of experimental phase plus 6-months of observational phase). In the first 3 months, the patients in Group A will send their glycemic test values and notes by mail to the physician through Diabetes Manager App every 2 weeks. Afterwards until the visit V2 (six months), the patients in Group A will send their glycemic test values and notes by mail monthly. 9 reports in total.
62237267|NCT01523639|PLACEBO_COMPARATOR|Placebo|FOLFIRI + cetuximab + placebo every 2 weeks for 12 cycles
62237268|NCT06165939|EXPERIMENTAL|Intra-articular corticosteroid injection and hydrodilation with 15% hypertonic dextrose|The patient receives ultrasound-guided intra-articular corticosteroid injection treatment in the shoulder joint (2 ml SHINCORT INJ 10 MG/ML + 2 ml 2% Xylocaine). Subsequent assessments occur at the second and fourth weeks, followed by a second round of ultrasound-guided shoulder joint injection with 15% hypertonic dextrose (6 ml 50% Dextrose + 2 ml 2% Xylocaine + 12 ml Normal saline, totaling 20 ml). The entire treatment comprises two sessions.
62237269|NCT06165939|PLACEBO_COMPARATOR|Intra-articular corticosteroid injection and hydrodilation with Normal saline|The patient receives ultrasound-guided intra-articular corticosteroid injection treatment in the shoulder joint (2 ml SHINCORT INJ 10 MG/ML + 2 ml 2% Xylocaine). Subsequent assessments occur at the second and fourth weeks, followed by a second round of ultrasound-guided shoulder joint injection with 15% hypertonic dextrose ( 2 ml 2% Xylocaine + 18 ml Normal saline, totaling 20 ml). The entire treatment comprises two sessions.
62427428|NCT02073188|ACTIVE_COMPARATOR|Traditional Glucometer (Group B)|Self-Monitoring Blood Glucose will be managed with a traditional glucometer according to usual care for the first 6 months (experimental phase). In the 6 months post-trial follow-up (observational phase), Self-Monitoring Blood Glucose will be managed with iBGStar and iBGStar Diabetes Manager App.
62595498|NCT06622564|ACTIVE_COMPARATOR|After CPB Tranexamic Acid/Placebo|In the intervention group, patients will receive intravenous administration (10-100 mL of saline placebo) at the induction of anesthesia as a bolus and/or continuous infusion. In addition, patients will receive intravenous administration (5 g of TxA) after heparin reversal (i.e., after CPB).
62595499|NCT06622564|ACTIVE_COMPARATOR|Before CPB Tranexamic Acid/Placebo|In the control group, patients will receive an intravenous administration (1-10 g of TxA) at the induction of anesthesia as a bolus and/or continuous infusion (i.e., before CPB). In addition, patients will receive an intravenous administration (50 mL of saline placebo) after heparin reversal.
62595500|NCT00752258|EXPERIMENTAL|1|Mentor Purified Toxin Botulinum Toxin Type A
62595501|NCT03397329|ACTIVE_COMPARATOR|Sequence A|
62595502|NCT03397329|ACTIVE_COMPARATOR|Sequence B|
62595503|NCT06407661|EXPERIMENTAL|intervention|"In this study, the Disaster Nursing course, which was integrated into the nursing curriculum, was an elective course, and it was carried out as a theoretical course for two hours a week. The purpose of its development was to educate students on disaster management and disaster nursing \[54\]. The course content included identification of risks and resources for disasters at the primary protection level, nurse's caregiver (triage and holistic care) and case manager role at the secondary protection level, reassessment of individuals' care needs at the tertiary level, and review of education and the current disaster plan at the protection level. The disaster nursing course was intended to develop students' perception of disaster awareness, preparedness, and response self-efficacy by providing them with primary, secondary, and tertiary level protection roles"
62595504|NCT05709353|EXPERIMENTAL|COPE + MDMA|"4x COPE sessions~Dose 1:~2x MDMA capsules (80mg) + 1x niacin-matched placebo capsule~Optional supplementary dispense:~1x MDMA capsule (40mg)~4x COPE sessions~Dose 2:~2x MDMA capsules (80mg) + 1x niacin-matched placebo capsule~Optional supplementary dispense:~1x OR 2x white MDMA capsule (40 or 80mg)~4x COPE sessions"
62595505|NCT05709353|OTHER|COPE + Niacin (Control)|"4x COPE sessions~Dose 1:~2x MDMA-matched placebo capsules + 1x niacin capsule (250mg)~Optional supplementary dispense:~1x MDMA-matched placebo capsule~4x COPE sessions~Dose 2:~2x MDMA-matched placebo capsules + 1x niacin capsule (250mg)~Optional supplementary dispense:~1x OR 2x MDMA-matched placebo capsule~4x COPE sessions"
62813171|NCT05273567|EXPERIMENTAL|Guanfacine-ER|Participants will start on guanfacine-ER 1mg nightly for 1-week (week 1) and slowly increase by 1mg/per week to a max dose of 4mg per day or maximum dose as tolerated. Medication taper to discontinuation will begin in week 11 and continue into week 12 until complete by end of study, decreasing the dose by 1mg every 4 days until stopped.
62237270|NCT05158556|EXPERIMENTAL|myofascial release technique|Myofascial Release Technique will be applied with forearm/ ulnar border of palm. deep pressure will be applied and glided medially towards the thoraco-lumbar region.ins
62813172|NCT05273567|PLACEBO_COMPARATOR|Placebo|Placebo will be taken nightly and titrated and tapered similar to the active arm.
62237271|NCT05158556|EXPERIMENTAL|Instrument Assisted Soft Tissue Mobilization|instrument assisted soft tissue mobilization is done via M2T Blade. it is a multifunctional instrument consisting of many planes and is very effective in treating pain and spasm. Its efficacy is proven over soft tissues that it releases fascial tightness.
62237272|NCT01346488||Adalimumab|Participants with RA treated with adalimumab who are either engaged in paid work for more than 35 hours per week (paid workers) or those who are either engaged in paid work for less than 35 hours per week or who perform basic activities of daily life other than paid work (home workers).
62237273|NCT06420895||Group of patients with aortic insufficiency|Patients already assessed at GHICL's Valvulopathy Centre from 2011 to October 2023 will be identified retrospectively, by queries based on keywords and/or diagnostic codes in echocardiography interpretation software (Viewpoint/EchoPAC, ISCV). GHICL's Medical Information Department will also be involved.
62237274|NCT00670189|EXPERIMENTAL|BMS-833923|
62237275|NCT02569554|EXPERIMENTAL|PF-06463922|each subject will receive four single doses of PF-06463922 without food, with food, with rabeprazole (without food), and one of the two new formulations without food.
62427429|NCT05182931|EXPERIMENTAL|BRAFv600E mutant radioiodine refractory thyroid cancer|"Prior to commencing interventional treatment, participants will commence a low iodine diet and undergo thyroxine withdrawal and commence T3 replacement from day -27. On day -5 they will receive an oral dose of 124I (40MBq/1.08 mCi) with imaging at 24 hours (+/-6) post dose and a second imaging assessment within 120 hours.~Participants will receive Dabrafenib (oral, 150mg BD) and Trametinib (oral, 2mg OD) from day 1-30.~A second oral dose of I124 will be administered at day 24 followed by imaging at the same interval as baseline.~Participants achieving \>20Gy tumour uptake of I124 will be administered 6GBq (3.3Gy/GBq) 131I, I131 wb scan and SPECT/CT will be performed within 24 hours and at hospital discharge.~Participants who do not achieve \>20Gy tumour update of I-124 will move into follow up.~Follow up will occur every 12 weeks for 12 months."
62595506|NCT04606992|EXPERIMENTAL|CELS resection|All patients included in the study will be in this arm
62595507|NCT01791946|EXPERIMENTAL|Treatment Group A (Post-Surgery)|Subjects enrolled in this arm will first have eye alignment corrective surgery and then complete six weeks of the investigational binocular treatment training.
62813173|NCT05419583|NO_INTERVENTION|Standard care|Patients will continue to be treated by the clinical team based on NHS guidelines. They will receive no additional visits from the study however may be asked to participate in qualitative interviews at the end of the study about their usual care. The standard care pathway may involve further investigation with clinically indicated tests or treatments and no appropriate tests or treatments will be withheld.
62813174|NCT05419583|EXPERIMENTAL|Complex intervention|A structured risk assessment for coronary disease or left ventricular impairment and management plan delivered by a cardiologist to guide targeted investigation and treatment. This may include imaging with coronary computed tomography angiography (CCTA), invasive coronary angiography, transthoracic echocardiography or cardiac MRI. Treatments may include antiplatelet and anticoagulant therapy, statin therapy or treatments for heart failure as indicated in line with international guidelines.
62813175|NCT02212639|EXPERIMENTAL|Digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients \<75 years and between 0.5-0.8 ng/ml in patients older than 75 years
62813176|NCT03046186||Gastric sleeve operated subjects|12 patients who have undergone gastric sleeve operation \>12 month prior to inclution.
62813177|NCT03046186||Control Subjects|12 Healthy un-operated control subjects matched to the gastric sleeve group in a one to one manner with respect to BMI, sex and age
62813178|NCT03046186||Gastric bypass operated subjects|12 patients, who have undergone Roux-en-Y gastric bypass \>12 month prior to inclution, matched to the gastric sleeve group in a one to one manner with respect to pre-operative BMI, post-operative BMI, sex and age.
62813179|NCT04361708|EXPERIMENTAL|High Risk UGT1A1 genotype|
62813180|NCT04361708|EXPERIMENTAL|Intermediate Risk UGT1A1 genotype|
62813181|NCT04361708|EXPERIMENTAL|Low Risk UGT1A1 genotype|
62813182|NCT05829070|EXPERIMENTAL|CHAT-S|CHAT-S consists of 4 bi-weekly 35-45 minute videoconferencing sessions with a patient navigator and a patient booklet on insurance, costs, and survivorship care.
62813183|NCT05829070|PLACEBO_COMPARATOR|Usual Care|Usual care will consist of a resource list sent by the navigator.
62237276|NCT05579158|EXPERIMENTAL|Mobile application-supported both calorie restriction and time-restricted eating (mCR/TRE)|This arm receives wearable device and mobile application-supported nutritional counseling for four months. The nutritional counseling consists of both calorie restriction (500kcal below estimated energy requirement) and time-restricted eating (an 8-hour period (from 10 a.m. to 6 p.m.) each day).
62237277|NCT05579158|ACTIVE_COMPARATOR|Mobile application-supported calorie restriction (mCR)|This arm receives wearable device and mobile application-supported nutritional counseling for four months. The nutritional counseling consists of only calorie restriction (500kcal below estimated energy requirement).
62237278|NCT05579158|NO_INTERVENTION|Calorie restriction (CR)|Standard of care. This arm receives a brief counseling of calorie restriction.
62237279|NCT03165539||Thoracic surgery patient|Pre-operatively, patients will have baseline cognitive assessment done using the Mini-mental status test and MOCA test. Intra-operatively patients' baseline cerebral saturation (%) will be measured, and continuously monitored throughout the procedure. Post-operatively, patients will be assessed for delirium using the CAM score.
62237280|NCT01936142|NO_INTERVENTION|No RenalGuard|Control group will undergo CRT implantation without using RenalGuard
62237281|NCT01936142|EXPERIMENTAL|RenalGuard|Use of the RenalGuard system during CRT implantation
62237282|NCT00594802||CHART REVIEW ONLY|CHART REVIEW OF PATIENTS WITH SYSTEMIC REACTIONS
62813184|NCT06705244|ACTIVE_COMPARATOR|trans-nasal sphenopalatine ganglion block (TNSGB)|
62237283|NCT05277129||Stroke patients|
62813185|NCT06705244|ACTIVE_COMPARATOR|greater and lesser occipital nerve block (GALONB)|
62237284|NCT02810899|EXPERIMENTAL|Dexmedetomidine group|A loading dose of dexmedetomidine (0.5 ug/kg IV infusion in 15 minutes) will be administered after induction of general anesthesia, followed by continuous infusion at a rate of 0.5 ug/kg/h until the closure of the duramater of the brain.
62237285|NCT02810899|PLACEBO_COMPARATOR|Control group|Normal saline will be administered in the same rate and volume as that in the dexmedetomidine group.
62813186|NCT03201068|EXPERIMENTAL|Probiotic supplement|Renew Life Formulas, Inc
62813187|NCT03201068|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62813188|NCT00582361|ACTIVE_COMPARATOR|1, A|Group A patients will have a standard dressing applied following initial treatment of their open fracture.
62813189|NCT00582361|EXPERIMENTAL|2, B|Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture.
62813190|NCT04819126|EXPERIMENTAL|Nintendo Wii Virtual Reality Application In Older People With Alzheimer's Dementia|"The study included a total of 32 volunteers between the ages of 65-80, who stayed in Karaman Ahmet Mete Nursing Home, Elderly Care and Rehabilitation Center, with mild or moderate Alzheimer's dementia diagnosed by a neurologist. As a result of the power analysis, it was calculated that at least 16 individuals could be included in each group (at least 32 individuals in total). Randomization was performed by the sealed-envelope method. According to this method, 4 females and 12 males were determined to be in the control group, while 5 females and 11 males were determined to be in the training group.~The evaluation was completed before the intervention. The same evaluation was conducted after 6 weeks.~The training group was trained with games from different categories such as balance and aerobic exercises with a Nintendo Wii virtual reality device 2 times a week for a period of 6 weeks, with 1 session lasting for 30 minutes, and each patient was trained with the same games."
62237286|NCT02812901|OTHER|morning group|cardiac surgery scheduled in the morning
62595508|NCT01791946|EXPERIMENTAL|Treatment Group B (Pre-Surgery)|Subjects enrolled in this arm will first complete six weeks of the investigational binocular treatment training and then have eye alignment corrective surgery.
62237287|NCT02812901|OTHER|afternoon group|cardiac surgery scheduled in the afternoon
62237288|NCT04897451||Women with cervical ripening in the context of artificial labor induction|
62237289|NCT05281965|EXPERIMENTAL|Experimental group|
62237290|NCT05281965|PLACEBO_COMPARATOR|Placebo group|
62237291|NCT06017141|ACTIVE_COMPARATOR|Arm I (sevoflurane, fentanyl citrate, propofol)|Patients receive SOC sedation with sevoflurane via inhalation and fentanyl IV on study during to SOC surgery. All patients also undergo blood sample collection throughout the study and collection of tissue sample during surgery.
62427430|NCT05182931|EXPERIMENTAL|RAS mutant radioiodine refractory thyroid cancer|"Prior to commencing interventional treatment, participants will commence a low iodine diet and undergo thyroxine withdrawal and commence T3 replacement from day -27. On day -5 they will receive an oral dose of 124I (40MBq/1.08 mCi) with imaging at 24 hours (+/-6) post dose and a second imaging assessment within 120 hours.~Participants will receive Trametinib (oral, 2mg OD) from day 1-30.~A second oral dose of I124 will be administered at day 24 followed by imaging at the same interval as baseline.~Participants achieving \>20Gy tumour uptake of I124 will be administered 6GBq (3.3Gy/GBq) 131I, I131 wb scan and SPECT/CT will be performed within 24 hours and at hospital discharge.~Participants who do not achieve \>20Gy tumour update of I-124 will move into follow up.~Follow up will occur every 12 weeks for 12 months."
62427431|NCT02059369|ACTIVE_COMPARATOR|CFAE ablation|Intervention: Complex fractionated atrial electrograms (CFAE) Ablation
62427432|NCT02059369|ACTIVE_COMPARATOR|CFAE + Lines|CFAE Ablation followed by linear lesions (anterior and Roof line)
62427433|NCT06538363|ACTIVE_COMPARATOR|Control|
62427434|NCT06538363|EXPERIMENTAL|Intervention|
62427435|NCT04676919|EXPERIMENTAL|pulsed mode phonophoresis group|Phonophoresis therapy with pulsed mode ultrasound.
62595509|NCT01791946|SHAM_COMPARATOR|Sham Treatment|Subjects enrolled in this arm will first complete six weeks of the sham binocular treatment and then undergo eye alignment corrective surgery.
62237292|NCT06017141|EXPERIMENTAL|Arm II (fentanyl citrate, propofol)|Patients receive SOC sedation with fentanyl IV and propofol IV on study during to SOC surgery. Patients also undergo blood sample collection throughout the study and collection of tissue sample during surgery.
62595510|NCT04238143|EXPERIMENTAL|tSVF + PRP Arm1|Tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) Concentrate
62595511|NCT04238143|EXPERIMENTAL|tSVF + PRP + cSVF Arm 2|Tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) Concentrate + Cellular Stromal Vascular Fraction (cSVF)
62237293|NCT04932538|NO_INTERVENTION|Control Group|Every group received routine traditional physiotherapy twice a week over the period of 4 weeks. This routine traditional treatment consisted of stretching, weight bearing, functional reaching, walking, and electrotherapy.
62595512|NCT04238143|EXPERIMENTAL|Normal Saline IV + cSVF Arm 3|Cellular Stromal Vascular Fraction (cSVF); Sterile Normal Saline Intravenous (IV) Introduction
62427436|NCT04676919|EXPERIMENTAL|continuous mode phonophoresis group|Phonophoresis therapy with continuous mode ultrasound.
62427437|NCT04676919|SHAM_COMPARATOR|sham group|Sham ultrasound
62427438|NCT01697397||Patients with and without FGIDs/IBS|Patients with functional gastro-intestinal disorders (FGIDs) undergo recording of myoelectric signals before, during, and after a meal. In addition, patients without FGIDs undergo recording of myoelectric signals before, during, and after a meal.
62427439|NCT00890227|ACTIVE_COMPARATOR|Traditional technique|All level open instrumented posterior spinal fusions
62427440|NCT00890227|ACTIVE_COMPARATOR|Minimally invasive technique|Open surgery for all the levels except the proximal segment (most proximal instrumented level) where minimally invasive technique will be used.
62427441|NCT02873468|EXPERIMENTAL|Florence 30|
62427442|NCT02873468|EXPERIMENTAL|Florence 60|
62427443|NCT02873468|EXPERIMENTAL|Florence 90|
62427444|NCT02873468|PLACEBO_COMPARATOR|Placebo|
62427445|NCT02079922|EXPERIMENTAL|Cohort 1|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
62035947|NCT05576987|NO_INTERVENTION|control group|"Control group will be selected from the branches 3rd and 4th grade. 3 branches for the control group. Branches will be determined by drawing. In order not to interfere with the education of students during the training, the groups will be designated as class branches.~After the training of the experimental group is completed and the final data are obtained, a 40-minute training will be given to the control group about prevention from school accidents. This training was planned so that the control group would not be devoided of the intervention."
62035948|NCT06302166|ACTIVE_COMPARATOR|High Intensity circuit training (HICT)|"For the group allocated with exercise, high intensity circuit training (HICT) of three supervised sessions per week for 20-30 mins will be given. HICT commenced after 10 mins low to moderate intensity warm up and after completing session ended with 10 mins cool down. Intensity of exercise will be measured on borg rating of perceived exertion (RPE). Perceived exertion is how hard you feel like your body is working. Although this is a subjective measure your exertion rating based on a 0 to 10 modified borg rating scale may provide a fairly good estimate of your actual heart rate during physical activity. 0 perceiving no exertion at all to 10 perceiving a maximal exertion of effort. A moderate intensity activity will be at 3-5 perceiving somewhat hard, similarly 6-10 will be perceived as high intensity activity."
62035949|NCT06302166|ACTIVE_COMPARATOR|Intermittent fasting (IF)|For the group allocated with intermittent fasting, a time restricted feeding (TRF) methodology will be administered. The Fasting protocol will begin with a 12-hour eating window (12:12) and will gradually go down to 8 hours eating window over a period of 8 weeks (16:8).
62237294|NCT04932538|EXPERIMENTAL|Kinesio Taping|Every group received routine traditional physiotherapy twice a week over the period of 4 weeks. This routine traditional treatment consisted of stretching, weight bearing, functional reaching, walking, and electrotherapy. Sessions were 40 minutes. The children in the taping group were taped 6 days per week for 4 weeks. The children were checked for allergies before applying the tape. A 5-cm tape was applied and kept in position for 3 days, and the region was then left to rest for 24 hours.
62427446|NCT02079922|EXPERIMENTAL|Cohort 2|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
62035950|NCT06302166|ACTIVE_COMPARATOR|Combination of HICT and IF|The group allocated with both exercise and intermittent fasting will be provided with both HICT for three sessions per week and 8 hours' time restricted eating.
62035951|NCT00785369|OTHER|1|Device: In vivo reflectance confocal microscopy of pigmented lesions in vivo
62035952|NCT05800132|NO_INTERVENTION|L2 - Standard second read|Interpretation of mammograms done by a radiologist accredited to do second reading in France.
62035953|NCT05800132|EXPERIMENTAL|L2-AI - AI-assisted second read|Interpretation of mammograms done by the AI-based device. Mammograms deemed suspicious by the AI (i.e., receiving an AI global score higher than a defined threshold) will be interpreted by a radiologist accredited to do second reading in France. Mammograms assessed as negative or low suspicious by the AI won't be further interpreted by a radiologist.
62035954|NCT02489500|ACTIVE_COMPARATOR|melphalan|Neupogen 16mcg/kg x 4 days Stem cell collection Drug: high dose melphalan 140 or 200 mg/m2 stem cell infusion
62427447|NCT02079922|EXPERIMENTAL|Cohort 3|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
62035955|NCT02489500|EXPERIMENTAL|melphalan + Bortezomib|Neupogen 16mcg/kg x 4 days Stem Cell collection drug: high-dose melphalan 140 or 200 mg/m2 drug: Bortezomib 1.0 mg/m2/dose x 4 doses stem cell infusion
62237295|NCT03484520|EXPERIMENTAL|Venetoclax + Dinaciclib|Venetoclax and dinaciclib will be administered in combination. Different combinations of dose levels for venetoclax and dinaciclib will be explored.
62237296|NCT02025946||Total Ankle Arthroplasty|
62427448|NCT02079922|EXPERIMENTAL|Cohort 4|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
62427449|NCT02079922|EXPERIMENTAL|Cohort 5|Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
62427450|NCT02079922|EXPERIMENTAL|Cohort 6|Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
62427451|NCT04901130|EXPERIMENTAL|AQCS-aided group|Patients in AQCS-aided group will go through colonoscopy examination with the assitance of AQCS.
62237297|NCT02025946||Tibiotalar Arthrodesis|
62237298|NCT00892372||1 (type 2 diabetes, body weight, HbA1c)|The investigators analyzed the recorded data (body weight and glycohemoglobin) of 70 type 2 diabetic patients treated with the diet therapy. Recorded values at 0, 2 and 4 months for body weight (BW) and glycohemoglobin (HbA1c) were used. And changes from baseline (0 month) in BW (ΔBW) were plotted against those of HbA1c (ΔHbA1c).
62237299|NCT00892372||2 (type 2 diabetes, pioglitazone, HbA1c)|The investigators analyzed the recorded data (body weight and glycohemoglobin) of 23 type 2 diabetic patients treated with pioglitazone. Recorded values at 0, 2 and 4 months for body weight (BW)and glycohemoglobin (HbA1c) were used. And changes from baseline (0 month) in BW (ΔBW) were plotted against those of HbA1c (ΔHbA1c).
62237300|NCT05119426|EXPERIMENTAL|Vi-TT|Single dose of Vi-TT to children 9 months to \<16 years of age
62237301|NCT01939054|EXPERIMENTAL|Nimotuzumab,docetaxel,capecitabine|Nimotuzumab 400mg/w,IV,once a week and Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
62427452|NCT04901130|NO_INTERVENTION|Control group|Patients in control group will go through conventional standard colonoscopy examination without the assistance of the AQCS.
62427453|NCT02872155|EXPERIMENTAL|Oral hydratation|
62427454|NCT02872155|ACTIVE_COMPARATOR|Endovenous hydratation|
62427455|NCT04553692|EXPERIMENTAL|Ph1a: Aplitabart Single Agent Alternate Dosing Escalation|Aplitabart will be administered intravenously as a single agent on an alternate dosing schedule.
62813191|NCT04819126|NO_INTERVENTION|Older People With Alzheimer's Dementia|In the control group, no application was performed during this period, and routine medical treatments were continued. The training group was evaluated before and after the training, while the control group was re-evaluated at the end of the 6th week after the first evaluation. After the study was completed, the volunteers from the control group were also given training.
62813192|NCT05887882|EXPERIMENTAL|Dose Level 2 (3x10^6) - Starting Dose|Enrolled participants must proceed to surgery for tumor resection and Ommaya placement into the resection cavity within 14 days of enrollment. Starting dose of 3x10\^6 of TGFβi NK cells (first dose) may be administered at least 14 days after the Ommaya reservoir placement and may not start until all acute surgical complications have resolved (maximum of 6 weeks after enrollment). TGFβi NK cell infusions through the Ommaya reservoir will occur once weekly for three weeks followed by one rest week. If participants have stable or improved disease, participants may continue to receive therapy for a total of 3 cycles.
62035956|NCT05200195||International Cohort Training Set|The Training Set of the International Cohort (N=3,670) was composed of the 80% (n=2936) HCC patients transplanted from 2000 to 2018 across 17 centers in Europe and Asia.
62035957|NCT05200195||International Cohort Test Set|The Test Set of the International Cohort (N=3,670) was composed of the 20% (n=734) HCC patients transplanted from 2000 to 2018 across 17 centers in Europe and Asia.
62035958|NCT05200195||Validation Cohort|The external Validation Cohort was composed of 356 HCC patients transplanted at the Columbia University, New York, during the period 2000-2018.
62035959|NCT00709969|EXPERIMENTAL|1|Artemether-lumefantrine
62035960|NCT00963365|EXPERIMENTAL|AZD6765 oral solution|Active
62035961|NCT00963365|EXPERIMENTAL|AZD6765 IV infusion|Active
62813193|NCT05887882|EXPERIMENTAL|Dose Level 3 (3x10^7)|If no safety or toxicity events are demonstrated by the starting dose cohort, enrolled participants in the next dosing cohort must proceed to surgery for tumor resection and Ommaya placement into the resection cavity within 14 days of enrollment. The dose of 3x10\^7 of TGFβi NK cells (first dose) may be administered at least 14 days after the Ommaya reservoir placement and may not start until all acute surgical complications have resolved (maximum of 6 weeks after enrollment). TGFβi NK cell infusions through the Ommaya reservoir will occur once weekly for three weeks followed by one rest week. If participants have stable or improved disease, participants may continue to receive therapy for a total of 3 cycles.
62035962|NCT00963365|PLACEBO_COMPARATOR|Placebo to AZD6765 oral solution|Placebo
62035963|NCT00963365|PLACEBO_COMPARATOR|Placebo to AZD6765 IV infusion|Placebo
62035964|NCT03512327|EXPERIMENTAL|Autoimmune protocol (AIP) diet|Adult patients with active Crohn's disease or ulcerative colitis, undergoing 11 week autoimmune protocol diet, to examine therapeutic efficacy
62035965|NCT00506064|EXPERIMENTAL|Melatonin|0.15 mg/kg capsules by mouth daily
62035966|NCT00506064|PLACEBO_COMPARATOR|Placebo|Starch capsules by mouth daily
62035967|NCT00778648|EXPERIMENTAL|Juice Plus|
62035968|NCT00778648|PLACEBO_COMPARATOR|Placebo|
62035969|NCT03046459|EXPERIMENTAL|BNZ132-1-40|a range of IV doses
62035970|NCT00829257|EXPERIMENTAL|Fine particle steroid inhaler|HFA-BDP plus Fluticasone/Salmeterol Combination
62035971|NCT00829257|ACTIVE_COMPARATOR|Coarse Particle Inhaler|FP plus Fluticasone/Salmeterol combination
62035972|NCT04440566|EXPERIMENTAL|Systemic lupus erythematosus (SLE)|
62035973|NCT03806153|ACTIVE_COMPARATOR|Conventional morphology arm (reference method)|
62035974|NCT03806153|EXPERIMENTAL|Morphokinetic arm|
62035975|NCT04022668||STEMI|Current international ECG criteria (New ST-segment elevation at the J-point in two contiguous leads with the cut-points: ≥0.1 mV millivolts (mV) in all leads other than leads V2-V3; for leads V2-V3: ≥2 mm in men ≥40 years; ≥2.5 mm in men \<40 years, or ≥1.5 mm in women regardless of age) with troponin rise above 99th percentile in a clinical situation suggestive of myocardial ischemia.
62427456|NCT04553692|EXPERIMENTAL|Ph1a: Aplitabart + FOLFIRI ± bevacizumab Escalation and Expansion|Aplitabart will be administered intravenously in combination with FOLFIRI± bevacizumab.
62595513|NCT05492006|ACTIVE_COMPARATOR|Group A: intentional contact with nature|Group A volunteers will take a light walk along the park with green space in a single 1-hour session with an emphasis on sense-directed appreciation guided by research team.
62595514|NCT05492006|ACTIVE_COMPARATOR|Group B: indirect contact with nature|The members of Group B will watch a video with the images of nature during 4 consecutive 15-minute sessions accompanied by the researcher, totaling 1 hour.
62595515|NCT03133273|NO_INTERVENTION|Usual care|Patient is followed within the usual care for stage 4 colorectal cancer
62595516|NCT03133273|EXPERIMENTAL|Oncogramme®|For patients in the Oncogramme® group, chemotherapy will be adapted to Oncogramme® results.
62595517|NCT02822573|ACTIVE_COMPARATOR|Donepezil|Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5 mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
62595518|NCT02822573|PLACEBO_COMPARATOR|Placebo|Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
62595519|NCT06288399||Obesity Group|Adults with diagnosis of obesity and obesity-related comorbidities
62813194|NCT05887882|EXPERIMENTAL|Dose Level 4 (3x10^8)|If no safety or toxicity events are demonstrated by the previous dose cohort, enrolled participants in the next dosing cohort must proceed to surgery for tumor resection and Ommaya placement into the resection cavity within 14 days of enrollment. The dose of 3x10\^8 of TGFβi NK cells (first dose) may be administered at least 14 days after the Ommaya reservoir placement and may not start until all acute surgical complications have resolved (maximum of 6 weeks after enrollment). TGFβi NK cell infusions through the Ommaya reservoir will occur once weekly for three weeks followed by one rest week. If participants have stable or improved disease, participants may continue to receive therapy for a total of 3 cycles.
62813195|NCT02490735|NO_INTERVENTION|No-CIK|After accepting chemotherapy, patients will regularly follow up.
62813196|NCT02490735|EXPERIMENTAL|CIK|After accepting chemotherapy, patients will receive at least 3 cycles of Cytokine-induced Killer Cells treatment per year
62035976|NCT04022668||NSTEMI|Troponin rise above 99th percentile in a clinical situation suggestive of myocardial ischemia without abovementioned criteria.
62035977|NCT04022668||Normal|Emergency department admission with a clinical picture compatible with acute coronary syndrome, but no change in serial ECGs and no rise in cardiac biomarkers
62427457|NCT04553692|EXPERIMENTAL|Ph1a: Aplitabart + Birinapant Escalation and Expansion|Aplitabart will be administered intravenously in combination with Birinapant which will also be administered intravenously.
62813197|NCT03804528|EXPERIMENTAL|Exercise group (All participants)|Each participant will engage in 60 minute in-person daily sessions delivered 3 times/week for 8 consecutive weeks (a total of 24 sessions). Participants were provided with option to participate remotely due to COVID-19 pandemic.
62237302|NCT01939054|ACTIVE_COMPARATOR|docetaxel,capecitabine|Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
62813198|NCT03753334|EXPERIMENTAL|MAG-EPA group|5g/day of omega-3-rich fish oil capsules, which include 4g of purified EPA, to be taken once a day, for 12 months.
62237303|NCT00593801|ACTIVE_COMPARATOR|2: late rhEPO|late EPO treatment from the fourth week for 6 weeks
62237304|NCT00593801|NO_INTERVENTION|3: no EPO|control group, no EPO treatment
62237305|NCT00593801|ACTIVE_COMPARATOR|1: early rhEPO|early rhEPO treatment from the first week until 9 weeks
62237306|NCT00829582|EXPERIMENTAL|ETI-204|ETI-204, Anthim
62237307|NCT00829582|SHAM_COMPARATOR|placebo|
62237308|NCT00919555|ACTIVE_COMPARATOR|Tretionoin and Pioglitazone HCL|20 patients will be randomized blindedly to Tretinoin and Pioglitazone HCL
62237309|NCT00919555|PLACEBO_COMPARATOR|Sugar Pill|10 Patients will randomly receive placebo
62595520|NCT03921970|ACTIVE_COMPARATOR|Group ESP = ESP group|ESP block (Group ESP) will be performed in the preoperative block room. US probe will be placed longitudinally 2-3 cm lateral to the T7 transvers process. From superior to inferior; trapezius (upper), rhomboideus major (middle), erector spinae (lower) muscles will be visualized on the hyperechoic transverse process. The 22G, 50 mm block needle (Braun Stimuplex Ultra 360, Germany) will be inserted in a cranio caudal direction and then for correction of the needle 5 ml normal saline solution will be enjected into the erector spina muscle fascia (figure). Following confirmation of the correct position of the needle, a dose of 20 ml %0.25 bupivacaine was administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine).
62595521|NCT03921970|NO_INTERVENTION|Group C = Control group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
62035978|NCT04151082|EXPERIMENTAL|Supportive care (steroid therapy)|Patients receive prednisone PO (or by feeding tube) QD on days 1-5 and then taper off over 2 weeks or methylprednisolone IV over 1 hour on days 1-5 in the absence of disease progression or unacceptable toxicity.
62813199|NCT03753334|PLACEBO_COMPARATOR|Placebo group|5g/day of high-oleic sunflower oil capsules, to be taken once a day, for 12 months.
62427458|NCT04553692|EXPERIMENTAL|Ph1a: Aplitabart + Venetoclax Escalation and Expansion|Aplitabart will be administered intravenously in combination with Venetoclax.
62813200|NCT04218201|EXPERIMENTAL|Subthreshold Opioid Use Disorder Prevention(STOP) Intervention|At baseline, patient participants in the STOP arm will receive the intervention components of brief advice from their PCP and a video doctor , printed educational materials, interaction with the NCM, and telephone health coaching. Brief advice will be delivered by the patient participant's PCP as part of the medical visit or via phone call. Before the encounter with the patient participant, PCPs will receive a brief printed summary report from the research staff. During the baseline visit, patient participants also meet with the research staff to view a video on tablet or desktop computer that reinforces the PCP's counseling.
62813201|NCT04218201|NO_INTERVENTION|Enhanced Usual Care (EUC)|PCPs will conduct primary care as usual, without the support of the NCM. At the baseline visit, patient participants receive an educational pamphlet and view a short video on overdose and cancer screening. The pamphlet includes information about preventing opioid-related overdose, including how to obtain a naloxone kit. The video content will feature the health benefits of exercise. It will be viewed on a tablet or desktop computer and will be approximately 2 minutes long. All EUC patient participants receive the same video, which is not tailored to the responses given on their questionnaires. There is no study intervention after the baseline visit.
62813202|NCT02005549|EXPERIMENTAL|Neoadjuvant Therapy|
62427459|NCT04553692|EXPERIMENTAL|Ph1a: Aplitabart + Docetaxel + Gemcitabine Escalation and Expansion|Aplitabart will be administered intravenously in combination with Docetaxel and Gemcitabine.
62035979|NCT01343550|EXPERIMENTAL|Creativity group for persons diagnosed with BPD|
62035980|NCT04302727|EXPERIMENTAL|Med-South Weight Loss Intervention|The intervention will be delivered in 3 phases over 24 months: Phase I (4 months) provides a foundation for adopting and maintaining a healthful dietary pattern (Med-style, tailored for the southeastern United States); Phase II (8 months) focuses on weight loss; and Phase III (12 months) on maintenance of or continued weight loss, as appropriate.
62427460|NCT04553692|EXPERIMENTAL|Ph1a: Aplitabart + Venetoclax + Azacitidine Escalation and Expansion|Aplitabart will be administered intravenously in combination with Venetoclax and Azacitidine.
62427461|NCT04553692|EXPERIMENTAL|Ph1b: Aplitabart + FOLFIRI + Bevacizumab|Aplitabart will be administered intravenously in combination with FOLFIRI + bevacizumab
62427462|NCT04553692|EXPERIMENTAL|Ph1b: FOLFIRI + Bevacizumab|Standard of Care FOLFIRI + bevacizumab will be administered intravenously
62427463|NCT04911673|EXPERIMENTAL|Music group|"Participants listened a song with headphones that lasts 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation). The song was composed by Juan Martin Saavedra.~In the first month, music group was filled the State Anxiety Inventory (SAI) between 10 and 20th of the menstruation that SAI consists of 20 statements that ask people to describe how they generally feel. In the second month, pain scores were measured on the first day of menstruation using a visual analogue scale (VAS) of 10 cm (0 no pain at all, and 10 the worst possible pain) and Trait Anxiety Inventory (TAI) was filled to assess the anxiety.In the third month, after the participants were listening the music in three days before menstruation and the first day of menstruation (during four days), pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the anxiety."
62035981|NCT04302727|ACTIVE_COMPARATOR|Augmented Usual Care (WW)|The intervention that will be offered to control group participants is WW™ (formerly known as Weight Watchers). The study will provide access to the 'Workshop + Digital' option of WW™ during the 2 year intervention.
62035982|NCT01092273||Bimatoprost versus Travoprost|
62035983|NCT03095040|EXPERIMENTAL|CM082 combined with everolimus|
62035984|NCT03095040|EXPERIMENTAL|CM082|
62035985|NCT03095040|ACTIVE_COMPARATOR|Everolimus|
62035986|NCT00672074|ACTIVE_COMPARATOR|1 Ipamorelin|
62035987|NCT00672074|PLACEBO_COMPARATOR|2 Placebo|
62595522|NCT03727152|OTHER|generic single tablet regimen of tenofovir alafenamide/e|HIV infected adults currently on protease inhibitor/ritonavir will switch to use generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir to see if the single tablet can continue to suppress viral replication and be used as a maintenance regimen
62595523|NCT06648811|EXPERIMENTAL|Study group|Kinesio tape will be applied postoperatively to the patients in this group
62595524|NCT06648811|NO_INTERVENTION|Control group|These patients will only get routine postoperative management.
62595525|NCT06322576|EXPERIMENTAL|SPECT CT Dosimetry|Absorbed dose in tumor and normal organs will by measured using SPECT/CT dosimetry in Cohort 1.
62595526|NCT02580669|EXPERIMENTAL|Progressive Multiple Sclerosis|22 patients with Progressive Multiple Sclerosis will be included and they get an Neuropsychological assessment, a Neurologic consultation and MRIs (with vasoreactivity testing)
62595527|NCT02580669|EXPERIMENTAL|Multiple Sclerosis, Relapsing-Remitting|22 patients with Multiple Sclerosis, Relapsing-Remitting will be included and they get an Neuropsychological assessment, a Neurologic consultation and MRIs (with vasoreactivity testing)
62595528|NCT02580669|EXPERIMENTAL|Healthy volunteers (22 patients)|22 healthy volunteers will be included and they get an Neuropsychological assessment and MRIs (with vasoreactivity testing)
62595529|NCT01321138|ACTIVE_COMPARATOR|Femoral nerve block|Continuous femoral nerve block with bolus of ropivacaine 0.5% and then continuous infusion of ropivacaine 0.2 % 4 - 6 ml/h, associated with paracetamol and ibuprofen. Each group will contain 30 patients.
62595530|NCT01321138|PLACEBO_COMPARATOR|PCA morphine|Patients with iv morphine with self administration with a PCA-system, associated with paracetamol and ibuprofen.
62595531|NCT03148457|EXPERIMENTAL|Early treatment|Early treatment of patients with ischaemic stroke related to atrial fibrillation (AF) with direct oral anticoagulations (DOACs).
62595532|NCT03148457|OTHER|Late treatment|Treatment with direct oral anticoagulations (DOACs) according the current standard practice in patients with acute ischemic stroke related to atrial fibrillation (AF).
62595533|NCT04669951|EXPERIMENTAL|uPAR expression|Immunohistochemistry
62595534|NCT04735081||First group before practice change|Infectious spondylodiscitis when prolonged immoblization in bed was recommanded in our hospital
62595535|NCT04735081||Second group after practice change|Infectious spondylodiscitis when early verticalization was recommanded in our hospital
62595536|NCT01167049|EXPERIMENTAL|CAPECITABINE|"Single arm:~Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; repeat three cycles (approximately 3- months);"
62595537|NCT04873102|EXPERIMENTAL|Danazol in Treatment of Cytopenias|AGENT: Danazol 600mg, Oral, Daily for 24 months
62595538|NCT06617156||Group 1|RSBI Value Acquisition: All patients will undergo four methods to obtain the RSBI value Measurement Procedure: (1) The method of priority for measurement will be determined by random sampling (by drawing from an opaque envelope). (2) After each measurement, settings will return to baseline, and the next measurement can only occur after 10 minutes. (3) Collecting Ventilation Data: After changing the ventilation mode, wait 2 minutes to ensure stable breathing, then divide MV by RR to obtain tidal volume, and use RR divided by VT to obtain the RSBI value. (4)Simultaneous Measurement of EELI Changes Using Four Methods with EIT
62595539|NCT03665922|EXPERIMENTAL|BroccoMax®|Following randomization, subjects will begin to take four BroccoMax® tablets in the morning with breakfast and four tablets in the evening with dinner. The eight BroccoMax® tablets will provide a daily internal dose of 64 mg of SFN.
62595540|NCT03665922|PLACEBO_COMPARATOR|Placebo|Following randomization, subjects will begin to take four placebo tablets in the morning with breakfast and four tablets in the evening with dinner.
62595541|NCT01435096|EXPERIMENTAL|BN80927|
62595542|NCT06070857|EXPERIMENTAL|LV232|Subjects will receive LV232 orally for single dose.
62595543|NCT06070857|EXPERIMENTAL|Placebo|Subjects will receive placebo orally for single dose.
62595544|NCT06564506|EXPERIMENTAL|Active electroacupuncture group|Participants will receive 30 minutes of active electroacupuncture before anaesthesia induction. Experienced acupuncturists will administer electroacupuncture at Shenting (GV24, 0.5 cun \[≈10 mm\] above the anterior hairline midpoint) and bilateral Benshen (GB13, 3 cun \[≈60 mm\] lateral to GV24). After skin preparation and pad placement, patients will close their eyes. Needles will be inserted 20 to 24 mm into the subgaleal layer at a flat angle, then manually manipulated to elicit de qi sensations (eg, fullness, numbness and soreness). Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.
62595545|NCT06564506|SHAM_COMPARATOR|Sham electroacupuncture group|Participants will receive 30 minutes of sham electroacupuncture before anaesthesia induction.The sham group will use non-acupuncture points: 20 mm above GV24 and 20 mm lateral to GB13. These points, in different dermatomes from true acupoints, minimise location-specific effects. The procedure will match the active group, excluding needle manipulation, de qi sensation and electrical output.
62595546|NCT03928756|EXPERIMENTAL|Within-participant randomization|Each day, each available participant will be randomly assigned to receive either: a push notification with tailored intervention content; a push notification with engaging, nontherapeutic content; or no push notification.
62595547|NCT00614523|EXPERIMENTAL|Romiplostim|Weekly subcutaneous dosing based on platelet count for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period. Starting dose is at 750 μg, up to a maximum dose of 1000 μg, or reduced to a minimum of 250 μg.
62595548|NCT00614523|PLACEBO_COMPARATOR|Placebo|Weekly subcutaneous dosing with blinded matching placebo dose level for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period.
62595549|NCT04123106|EXPERIMENTAL|ESP block|Ultrasound-guided, performed below erector spinae plane (ropivacaine 0.5% 20 mL each side).
62035988|NCT05826392|EXPERIMENTAL|Adolescent/Young Adult Self-Administered Web-Based Single-Session Intervention|Project Personality is a 30- minute, self-administered, web-based single-session intervention that was developed to help adolescents understand what growth mindsets are and provide them with information about self-changing strategies and coping skills (Schleider \& Weisz, 2019). Participants learn about how the brain functions (neuroplasticity), how personality is fluid, and read testimonials from other adolescents about how growth mindsets helped them in school and in their personal lives. Participants also have the opportunity to write notes to other youth, providing them with the advantages of using growth mindsets.
62237310|NCT03988322|EXPERIMENTAL|Quantitative assessment of imaging biomarkers|This is the intervention arm. In this arm, the participants will be scanned with low-dose CT with pre-defined scanning parameters for two rounds (at baseline and in the second year). The screen-detected lung nodules will be managed according to the volume of the nodule. The quantitative assessment of imaging biomarkers of lung cancer, COPD and cardiovascular disease will be recorded.
62237311|NCT03988322|ACTIVE_COMPARATOR|Visual assessment of imaging biomarkers|This is the control arm. In this arm, the participants will be scanned with low-dose CT with routine scanning parameters used for lung cancer screening in the hospital for two rounds (at baseline and in the second year). The screen-detected lung nodules will be managed according to the diameter of the nodule. The imaging biomarkers related to lung cancer, COPD and cardiovascular disease will be visually assessed.
62035989|NCT03725683|EXPERIMENTAL|Incrementing groups|Each of the Increased caliber balloon capsules was predilated one by one, and the order of the increased balloon capsules was as follows: Balloon 2 diameter = target lesion reference vessel diameter minus 1; Balloon 3 diameter = target lesion reference vessel diameter;
62237312|NCT05987722|EXPERIMENTAL|Enoxolone|The experimental group (N=15) returned home after the operation and used BGA toothpaste (Enoxolone) three times a day for oral cleaning for 12 weeks.
62237313|NCT05987722|ACTIVE_COMPARATOR|Sensodyne|The control group (N=12) used BGA-free toothpaste (Sensodyne) for oral cleaning for 12 weeks.
62237314|NCT03096366|EXPERIMENTAL|Physical therapy (PT) plus blood flow restriction (BFR)|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion. With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
62237315|NCT03096366|ACTIVE_COMPARATOR|Physical therapy|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
62237316|NCT01057498|EXPERIMENTAL|1a - RNS60 in Healthy Subjects|Single dose administration of nebulized RNS60 testing for bronchoconstriction in healthy human subjects.
62237317|NCT01057498|EXPERIMENTAL|1b: RNS60 in Mild Asthmatics|Single-dose administration of nebulized RNS60 testing for bronchoconstriction in mild asthmatics.
62237318|NCT01057498|EXPERIMENTAL|2e: RNS60 in mild-to-moderate asthmatics|RNS60 in mild-to-moderate asthmatics who are not currently taking a chronic asthma medication.
62237319|NCT00521742|EXPERIMENTAL|Pioglitazone 15 mg to 45 mg QD|
62427464|NCT04911673|EXPERIMENTAL|Chocolate group|Participants ate 40 mg of dark chocolate with 60% cocoa per day for four days (three days before menstruation and the first day of menstruation) that was given by researchers to them. In the first month, chocolate group was filled the SAI to assess state anxiety between 10 and 20th of the menstruation.In the second month, pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the trait anxiety.In the third month, after the participants were eating 40 mg of dark chocolate per day in three days before menstruation and the first day of menstruation (during four days/total 160 mg), pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the anxiety.
62427465|NCT04911673|NO_INTERVENTION|Control group|Control group had no intervention. In the first month, control group was filled the SAI to assess state anxiety between 10 and 20th of the menstruation. In the second month, pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the trait anxiety. In the third month, pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the anxiety.
62427466|NCT00569231|EXPERIMENTAL|Candida Antigen|
62595550|NCT04123106|ACTIVE_COMPARATOR|Wound infiltration|Ropivacaine 0.5% 20-40 mL, performed by surgeon.
62595551|NCT06190730|NO_INTERVENTION|Control|Besides the consent process, subjects in this arm will have no other research-specific activities until after 40 days after the surgery for an exit interview.
62595552|NCT06190730|EXPERIMENTAL|Voice-Assisted Remote Symptom Monitoring System (VARSMS) group|Subjects in this group will be issued the device, to be activated 1 day after discharge. The device will administer a set of questions daily.
62237320|NCT00521742|ACTIVE_COMPARATOR|Glyburide 2.5 mg to 15 mg, QD|
62237321|NCT00521742|EXPERIMENTAL|Pioglitazone 15 mg or 30 mg QD|
62427467|NCT01230437||asthmatic patients taking montelukast|asthma with or without rhinitis
62595553|NCT03494062|EXPERIMENTAL|Exercise|Home-based exercise intervention
62595554|NCT03494062|NO_INTERVENTION|Control|Usual care
62035990|NCT03725683|EXPERIMENTAL|matching groups|Pre-dilatation of the matched caliber balloon, whose diameter = the target lesion's diameter as a reference vessel, was applied.
62595555|NCT03308136|EXPERIMENTAL|subcutaneous anesthesia group (group A)|
62035991|NCT05003531|EXPERIMENTAL|IBI112 dose 1|Participants will receive IBI112 dose 1 subcutaneous injection(SC)
62035992|NCT05003531|EXPERIMENTAL|IBI112 dose 4|Participants will receive IBI112 dose 4 subcutaneous injection(SC)
62035993|NCT05003531|EXPERIMENTAL|IBI112 dose 2|Participants will receive IBI112 dose 2 subcutaneous injection(SC)
62595556|NCT03308136|ACTIVE_COMPARATOR|muscle anesthesia group (group B)|
62035994|NCT05003531|EXPERIMENTAL|IBI112 dose 3|Participants will receive IBI112 dose 3 subcutaneous injection(SC)
62035995|NCT05003531|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo subcutaneous injection(SC)
62237322|NCT00521742|ACTIVE_COMPARATOR|Glyburide 5 mg or 10 mg, QD|
62427468|NCT03494205|EXPERIMENTAL|Test group|"For the patients of the test-group Urtica comp gel is applied three times per day locally on the skin as soon as the patient senses itching, tingling and/or reddening. Otherwise the skincare is exactly as the control group in line with the departments general guidelines.~In case of marked worsening, e.g. epitheliolysis, the patient may receive Flammazine and Ialugen plus as rescue-care.~Rescue care: according to the departments therapeutic guidelines patients will receive Flammazine and/or Ialugen plus as clinically indicated at the discretion of the treating physician (usually in cases of marked worsening of the skin condition like e.g. epitheliolysis)."
62595557|NCT05723328|EXPERIMENTAL|Treatment Group|The intervention consists of a sequence of five music therapy song-writing and recording groups, one per day. Internalized stigma will be assessed within 3 days of admission (pretest/baseline), at ten days (posttest), and at 3 weeks from baseline (follow-up), using the Internalized Stigma of Mental Illness Inventory.
62595558|NCT05723328|NO_INTERVENTION|Control Group|Access to standard of care services that include several groups per day focused on topics of coping skills, mindfulness, journaling, creative arts, wellness recovery, recreation, and at least one music therapy group.
62035996|NCT01917669||Lean Non-Diabetic Group|Variables measured will also include serum analyses (HbA1c, adiponectin, cholesterol) and patient vital signs.
62035997|NCT01917669||Pre-diabetics|These patients are anticipated to have elevated BMI, yet not be diabetics.
62237323|NCT02789735|ACTIVE_COMPARATOR|Device: LiteCure LCT-1000®|Treatment with 10 J/cm²
62237324|NCT02789735|SHAM_COMPARATOR|Device: Sham LiteCure|Sham i.e. visible red light
62237325|NCT04005053|EXPERIMENTAL|Low-Dose NAC|3600 NAC mg/day
62237326|NCT04005053|EXPERIMENTAL|High-Dose NAC|5400 NAC mg/day
62237327|NCT04005053|PLACEBO_COMPARATOR|Placebo|Placebo
62427469|NCT03494205|ACTIVE_COMPARATOR|Control group|"Control group receiving the institutional standard skin care Excipial-Hydrolotion - all other therapeutic interventions, assessments and rescue-care will be the same in both groups."
62427470|NCT02487173|EXPERIMENTAL|Respirio Flu Test|"Upper respiratory tract samples from participants will be tested with:~* Respirio Flu Test~* Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)~* Sofia® Influenza A+B Fluorescent Immunoassay (FIA)"
62595559|NCT04119076|EXPERIMENTAL|Intervention Group|Teacher delivered a 10 minute classroom-based physical activity on school days for eight weeks.
62595560|NCT04119076|OTHER|Control Group|Children in the control schools continued with their usual school routine
62035998|NCT01917669||Diabetic Patients|These patients will have good glucose control.
62035999|NCT01917669||Diabetic patients with poor glucocontrol|These patients are anticipated to have poor glucose control. They are usually taking insulin.
62036000|NCT02710799|ACTIVE_COMPARATOR|Control|Referrals will be evaluated through the state's protocols
62036001|NCT02710799|EXPERIMENTAL|Intervention|Referrals will be evaluated through the state's protocols associated with telephone-based teleconsultations.
62036002|NCT01626248||Group A TX Naive|Patient decided to start disease modifying treatment, either interferon beta-1a, glatiramer acetate or natalizumab. If interested and consented they would be assigned to Group A. Patient would have blood specimens taken up to 5 times over the next 19 months: Day 0; Day 28; Day 84: Day 336 and Day 508.
62237328|NCT01695915||Healthy|Transabdominal ultrasound
62237329|NCT01695915||Constipated|Transabdominal ultrasound
62237330|NCT00555542|EXPERIMENTAL|1|Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15.
62237331|NCT03519165|NO_INTERVENTION|Control group (Group C)|"Conventional Fluid therapy guided by clinical parameter~Intraoperative fluid therapy will include maintenance fluid and replacement of the surgical loss. Aim to maintain MAP \> 65 mmHg, CVP 8-12 cm H2O and urine output \> 0.5 ml/kg/h."
62237332|NCT03519165|ACTIVE_COMPARATOR|Goal directed group (Group G)|"Intervention: Machine guided fluid therapy using EV1000 (FloTrac System 4.0 Edward Lifesciences, Irvine, CA, USA)~Intraoperative fluid therapy will be targeted to SVV \<13%, SVI \> 35ml/m2/ beat, SVRI more than equal to 1900 dynes-sec/cm-5/m2 using EV1000 floTrac monitor in addition to clinical parameters like MAP, CVP and urine output"
62595561|NCT05121051|EXPERIMENTAL|Group I (broccoli seed and sprout extract)|Patients receive broccoli seed and sprout extract PO QD for 12 weeks in the absence of unacceptable toxicity. Patients undergo the collection of blood, nasal epithelial cell, and buccal cell samples throughout the study.
62237333|NCT05023395|EXPERIMENTAL|Investigational Medicinal Product|Patients will be assigned to receive oral MEE-HU Medicus with the empirical antibiotic. A study pharmacist will prepare visually matched packages in identical, sequentially numbered treatment packs according to a previously done computer-generated randomization list, using block randomization with variable blocks of length 4 and 6. To be dispended, in sequential order, as participants will be recruited. All participants, enrolling physicians and investigators will be blinded to the treatment allocations. Attending physicians will be responsible for enrolling the participants and ensuring that the study medications are given from the appropriate treatment pack. Selection bias is minimized by randomization, while performance bias is minimized by blinding.
62237334|NCT05023395|PLACEBO_COMPARATOR|Placebo|Patients will be assigned to receive oral matching placebo with the empirical antibiotic. A study pharmacist will prepare visually matched packages in identical, sequentially numbered treatment packs according to a previously done computer-generated randomization list, using block randomization with variable blocks of length 4 and 6. To be dispended, in sequential order, as participants will be recruited. All participants, enrolling physicians and investigators will be blinded to the treatment allocations. Attending physicians will be responsible for enrolling the participants and ensuring that the study medications are given from the appropriate treatment pack. Selection bias is minimized by randomization, while performance bias is minimized by blinding.
62237335|NCT06473324||hyperglycaemia group|Blood glucose level ≥ 6.1 mmol/L
62237336|NCT06473324||hypoglycaemic group|Blood glucose level \< 6.1 mmol/L
62237337|NCT05516823||Group: Psychedelics-only Group|"A group of participants who reported using in their past psychedelic substances only (both classical and non-classical psychedelics are included). Specifically, in the current study this group included reports on the following substances:~Psilocybin (magic mushrooms, truffles) LSD (acid) Mescaline (peyote, San Pedro) Dimethyltryptamine (DMT) Ayahuasca 5-MeO-DMT 3-MMC Ibogaine Salvia Phenethylamines (2C family)"
62427471|NCT06039098||Participants|Participants are patients who are undergoing invasive ICP and ABP measurement as part of their normal medical treatment.
62427472|NCT02577900|EXPERIMENTAL|Acticoat absorbent|Apply Acticoat absorbent onto the ulcer
62427473|NCT02577900|ACTIVE_COMPARATOR|Honey gel sheet|Apply Honey gel sheet onto the ulcer
62427474|NCT02577900|OTHER|Jelonet|Apply Jelonet onto the ulcer
62427475|NCT02522949|ACTIVE_COMPARATOR|ColdZyme|ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
62427476|NCT02522949|PLACEBO_COMPARATOR|Placebo|Sugar based mouth spray manufactured to mimic ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
62427477|NCT01208168|EXPERIMENTAL|Active drug|
62595562|NCT05121051|ACTIVE_COMPARATOR|Group II (placebo)|Patients receive placebo PO QD for 12 weeks in the absence of unacceptable toxicity. Patients undergo the collection of blood, nasal epithelial cell, and buccal cell samples throughout the study.
62595563|NCT06619041|EXPERIMENTAL|Treatment Arm|Receives the brief, virtual, dyadic HealthyTogether weight management intervention in addition to usual care.
62595564|NCT06619041|NO_INTERVENTION|Usual Care Arm|Receives a brief letter with information about weight management resources in addition to usual care.
62427478|NCT01208168|PLACEBO_COMPARATOR|Vehicle alone|
62427479|NCT04133090|ACTIVE_COMPARATOR|Autogenous block bone graft|Surgical site as control group was treated with autogenous block bone graft. Augmentation site was covered with a mixture of particulate allograft and leukocyte and platelet-rich fibrin (L-PRF) membrane.
62595565|NCT06618079|EXPERIMENTAL|Cohort A|Evaluate the effect of S-Amlodipine on the pharmacokinetic properties of Azilsartan under steady states.
62595566|NCT06618079|EXPERIMENTAL|Cohort B|Evaluate the effect of Azilsartan on the pharmacokinetic properties of S-amlodipine under steady states.
62237338|NCT05516823||Group: Stimulants-only Group|"A group of participants who reported using in their past drugs identified as stimulating compounds only (both recreational and prescribed usages are included). Stimulating compounds are considered, in the context of the current study, substances that increase the overall activity of the central nervous system. Specifically, in the current study this group included reports on the following substances:~Cocaine Crack Amphetamines Methamphetamines Prescription stimulants (e.g., Adderall, Ritalin, Concerta)"
62595567|NCT05180019||Patient COS IVI Bilbao|Patients will come to the IVIRMA Bilbao clinic to start their respective ART cycles (vitrification, IVF/ICSI, donors) following usual clinical practice.
62595568|NCT05448365|ACTIVE_COMPARATOR|EGCG, Vit D, DCI, Vit B6|Women with uterine fibroids randomized to treatment group
62595569|NCT05448365|PLACEBO_COMPARATOR|Placebo|Women with uterine fibroids randomized to placebo group
62237339|NCT05516823||Depressants-only Group|"A group of participants who reported using in their past drugs identified as depressing compounds only (both recreational and prescribed usages are included). Depressing compounds are considered, in the context of the current study, substances that decrease the overall activity of the central nervous system. Specifically, in the current study this group included reports on the following substances:~Benzodiazepines Opiates (recreational use of heroin, opium, hydrocodone, oxycodone, oxymorphone, codeine, fentanyl) Prescription opioids"
62237340|NCT05516823||Cannabinoids Group|"A group of participants who reported using in their past cannabinoids compounds only (both recreational and prescribed usages are included). Specifically, in the current study this group included reports on the following substances:~THC (cannabis, marijuana) CBD Medical Cannabis (both THC and CBD)"
62595570|NCT04530058|PLACEBO_COMPARATOR|Control|
62595571|NCT04530058|EXPERIMENTAL|Metformin|
62595572|NCT00200109|OTHER|Group 1|See protocol
62427480|NCT04133090|ACTIVE_COMPARATOR|i-PRF enriched allograft material+screw tent pole technique|Surgical site as test group was treated with injectable platelet rich-fibrin (i-PRF) enriched allograft material. To avoid soft tissue collapse, screws were used. Augmentation site was covered with leukocyte and platelet-rich fibrin (L-PRF) membrane.
62595573|NCT00200109|OTHER|Group 2|See protocol
62595574|NCT00200109|OTHER|Group 3|See protocol
62427481|NCT04785833|EXPERIMENTAL|T cell injection targeting CD7 chimeric antigen receptor|
62427482|NCT04316299||AKI|COVID-19 patients with acute kidney injury
62427483|NCT04316299||non-AKI|COVID-19 patients without acute kidney injury
62427484|NCT01317420|EXPERIMENTAL|Monotherapy|BI 836845 dose escalation, infusion, once every three weeks, monotherapy
62427485|NCT05474560|EXPERIMENTAL|Allopurinol group|Allopurinol (100 mg/day) plus lifestyle intervention
62427486|NCT05474560|EXPERIMENTAL|Febuxostat group|Febuxostat (40 mg/day) plus lifestyle intervention
62427487|NCT05474560|ACTIVE_COMPARATOR|lifestyle intervention|diet and exercise
62427488|NCT00970931|PLACEBO_COMPARATOR|placebo|
62427489|NCT00970931|EXPERIMENTAL|chlortalidone-amiloride|
62427490|NCT01973842|ACTIVE_COMPARATOR|0.2 mg triptorelin|0.2 mg triptorelin compared with 0.1 mg triptorelin and 0.4 mg triptorelin
62427491|NCT01973842|ACTIVE_COMPARATOR|0.1 mg triptorelin|0.1 mg triptorelin compared with 0.2 mg triptorelin and 0.4 mg triptorelin
62427492|NCT01973842|ACTIVE_COMPARATOR|0.4 mg triptorelin|0.4 mg triptorelin compared with 0.1 mg triptorelin and 0.2 mg triptorelin
62595575|NCT00200109|OTHER|Group 4|See protocol
62595576|NCT02996552|EXPERIMENTAL|M & T Repair Group|Both mitral and tricuspid valves repair
62595577|NCT02996552|ACTIVE_COMPARATOR|Mitral-Only Group|Only mitral valve repair
62595578|NCT05469048||Critically ill patients sepsis suspected|Patients suspected of sepsis and admitted to ICU
62595579|NCT01028638||Renal Cancer|Renal Cancer patients treated with everolimus
62595580|NCT06649305||Experimental group|NIRS-OCT examination
62595581|NCT01676155||Patient with active tuberculosis|
62595582|NCT01676155||Patients with diagnosis of latent tuberculosis infection|
62595583|NCT01676155||Patient without latent tuberculosis or active tuberculosis|
62595584|NCT03228524|EXPERIMENTAL|D-aspartato+ET|Patients will be administered oral D-aspartate (2660 mg once daily) for 6 weks. Moreover, patients will receive therapeutic exercise.
62595585|NCT03228524|PLACEBO_COMPARATOR|Placebo+ET|Patients will be administered oral placebo for 6 weks. Moreover, patients will receive therapeutic exercise.
62595586|NCT04861285|EXPERIMENTAL|RACESTYPTINE Solution with cord|The participant will receive RACESTYPTINE Solution into the sulcus. The solution is used in combination with a non-medicated gingival retraction cord.
62595587|NCT04861285|EXPERIMENTAL|RACEGEL with cord|The participant will receive RACEGEL into the sulcus. The gel is used in combination with a non-medicated gingival retraction cord.
62595588|NCT04861285|EXPERIMENTAL|RACEGEL without cord|The participant will receive RACEGEL into the sulcus. No cord will be added.
62595589|NCT01839617|ACTIVE_COMPARATOR|Early parenteral nutrition|Parenteral nutrition starts at 2nd postoperative day.
62813203|NCT04771832||ERAS|Perioperative care with Enhanced Recovery After Surgery (ERAS) protocol
62595590|NCT01839617|ACTIVE_COMPARATOR|Late parenteral nutrition|Parenteral nutrition starts at 7th postoperative day.
62595591|NCT03922737|ACTIVE_COMPARATOR|In-person office visit|
62813204|NCT00579033|SHAM_COMPARATOR|1|
62813205|NCT00579033|ACTIVE_COMPARATOR|2|
62813206|NCT04909736|EXPERIMENTAL|Music Exposure|Patient will listen to a specified duration of music.
62813207|NCT04909736|NO_INTERVENTION|No-Music Exposure|Patient will not listen to music to for specified duration of time.
62427493|NCT04608578|EXPERIMENTAL|Intervention group|The intervention group gain access to the game after filling in the baseline online questionnaire. The participants are asked to play at least two characters in the game. They have two weeks to play the game.
62427494|NCT04608578|NO_INTERVENTION|Control group|Waitlist control group
62427495|NCT01852773||Blunt Aortic Injury Patients|Trauma patients with blunt aortic injury. This Cohort of trauma patients will require management with one of two interventions. They will require either; Open repair of thoracic aorta injury (Intervention #1) or TEVAR (Intervention #2). As of yet the short term and long term outcomes of these two treatments have not been directly compared.
62427496|NCT00931385|EXPERIMENTAL|BI 1744 (Olodaterol) Low Dose|BI1744 Low Dose once daily
62427497|NCT00931385|EXPERIMENTAL|BI 1744 (Olodaterol) Med Dose|BI 1744 Med Dose once daily
62427498|NCT00931385|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62427499|NCT00931385|ACTIVE_COMPARATOR|Foradil|Foradil 12 mcg twice daily
62427500|NCT03124173|OTHER|Behavioral Tasks|Each subject will conduct 4 sessions, i.e. a training session and three fMRI sessions. The first session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
62427501|NCT00644098|PLACEBO_COMPARATOR|Placebo|cellulose and soybean oil
62427502|NCT00644098|EXPERIMENTAL|Intervention|soluble fibre complex and medium chain triglycerides
62427503|NCT04794452|ACTIVE_COMPARATOR|Battery operated toothbrush|battery operated toothbrush
62427504|NCT04794452|ACTIVE_COMPARATOR|Manual toothbrush|Manual toothbrush
62427505|NCT02579369|EXPERIMENTAL|ALLO-ASC-DFU|
62427506|NCT02579369|ACTIVE_COMPARATOR|Conventional Therapy|
62427507|NCT01086735|EXPERIMENTAL|donor lymphocyte infusion|Donor T-cell transduction
62427508|NCT06304545|EXPERIMENTAL|Chemoradiotherapy combined with immunotherapy for early rectal cancer.|Radiotherapy and Chemotherapy combined with Camrelizumab
62595592|NCT03922737|ACTIVE_COMPARATOR|Telehealth visit with provider|
62595593|NCT05554913|EXPERIMENTAL|QL0911|The study in a 2:1 randomization ratio(40 subjects to QL0911). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
62595594|NCT05554913|PLACEBO_COMPARATOR|Placebo|The study in a 2:1 randomization ratio(20 subjects to Placebo ). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
62595595|NCT03648437|EXPERIMENTAL|Pedea 5mg/mL and Paracetamol 10mg/mL|Intravenous (IV) ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
62595596|NCT03648437|PLACEBO_COMPARATOR|Pedea 5mg/mL and 0.45 sodium chloride|IV ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
62595597|NCT03648437|EXPERIMENTAL|Indomethacin 25mg/mL and Paracetamol10mg/mL|Intravenous (IV) indometahcin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
62813208|NCT01267799||photocopier exposure|
62813209|NCT01267799||control|
62813210|NCT02163239||10mm Cannula|Subjects that are scheduled for a robot-assisted laparoscopic single-incision surgery for cholecystectomy, benign hysterectomy or salpingo-oophorectomy under the care of the study investigator
62813211|NCT04551989||Participants with EGPA who have received NUCALA treatment|Data will be collected of participants who have already received NUCALA for 96 weeks in routine clinical practice.
62813212|NCT00490087|EXPERIMENTAL|Hysteroscopic resection plus IUD|
62813213|NCT00490087|NO_INTERVENTION|Hysteroscopic resection without IUD|
62813214|NCT03080857|EXPERIMENTAL|Virtual Platform|Patients will be provided with a computer simulated tool to assist with education and support relating to atrial fibrillation.
62813215|NCT01762410|EXPERIMENTAL|P7170|Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design.
62813216|NCT00383552|EXPERIMENTAL|MF/F MDI 100/10 mcg BID|
62813217|NCT00383552|EXPERIMENTAL|MF MDI 100 mcg BID|
62813218|NCT00383552|EXPERIMENTAL|F MDI 10 mcg BID|
62813219|NCT00383552|PLACEBO_COMPARATOR|Placebo BID|
62813220|NCT05918640|EXPERIMENTAL|Ewing Sarcoma|The first part of this study is a standard 3+3 design to test the safety, tolerability and pharmacokinetic profile of lurbinectedin administered on a day 1, 4 schedule in patients with FET-fusion tumors.
62813221|NCT04020029|EXPERIMENTAL|Mindset Intervention|Mindset Intervention will include watching three brief \~10-25 minute films and respond to a number of short reflection activities after viewing the films.
62813222|NCT04020029|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|TAU Control Arm will complete the same assessments as those participants in the Mindset Intervention Arm, but will not view the short films or complete the corresponding response activities.
62036003|NCT01626248||Group B TY 4-12 doses|Patient is currently prescribed and is taking natalizumab, has 4 to 12 doses. If interested patient could be consented and assigned to Group B. Patients will have their blood drawn Day 0; and around the time of the patient's 18th dose.
62813223|NCT00379535|EXPERIMENTAL|1|Daily dose of 200 µg of potassium iodide
62813224|NCT00379535|PLACEBO_COMPARATOR|2|Daily dose of placebo
62813225|NCT01241864|EXPERIMENTAL|Allogenic islet cells (human, U. Chicago)|
62813226|NCT03995147|EXPERIMENTAL|Treatment Arm|
62813227|NCT06009965|EXPERIMENTAL|Severe aplastic anemia group|CsA: 3-5 mg/kg/day, monitor trough concentration monthly, maintain trough concentration at 100-200 ng/ml.ATG: rabbit anti-thymocyte immunoglobulin (r-ATG) 3 mg/kg/d x 5 days or porcine anti-lymphocyte immunoglobulin ((p-ATG) 25 mg/kg/d x 5 days.TPO-RA: Heptapepto-Papa 7.5 mg qd to start. Monitor blood every 2 weeks and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15mg) qd.
62813228|NCT06009965|EXPERIMENTAL|Non-severe aplastic anemia group|CsA: 3-5 mg/kg/day, monitor trough concentrations monthly, maintain trough concentrations at 100-200 ng/ml.TPO-RA: Start with Hetropoxyphene 7.5 mg qd, monitor blood every 2 weeks, and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15 mg) qd.
62036004|NCT01626248||Group C 18 plus TY|Patient currently or close to being at 18 doses or 18 plus doses of natalizumab. If interested patient consented and assigned to Group C. Patient will have their blood drawn once: Day 0.
62427509|NCT06129565|EXPERIMENTAL|Q-collar Intervention|All patients with low-pressure hydrocephalus that qualify for the study and agree to participate will receive the Q-collar for intervention
62427510|NCT06330077|EXPERIMENTAL|Ifenprodil|Ifenprodil : 20mg three time a day (60mg/day). Patients will have an escalation of dose over 48 hours (from Day 1) in order to achieve at the end of the 144 hours (6 days, Day 6) a dose of 60mg/day.
62595598|NCT03648437|PLACEBO_COMPARATOR|Indomethacin 25mg/mL and 0.45 sodium chloride|Intravenous (IV) indomethacin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
62595599|NCT06322095|EXPERIMENTAL|'GH21+PD-1'Group|GH21 combined with previous PD-1.
62813229|NCT01198886|PLACEBO_COMPARATOR|Successful Aging Program|
62813230|NCT01198886|EXPERIMENTAL|Exercise-Nutrition Program|
62813231|NCT04201431|EXPERIMENTAL|Group 1|Up to 12 volunteers in Group 1 will receive three doses of the PvDBPII 50ug/Matrix M1 50ug candidate vaccine at 1, 2 and 12-18 months prior to blood-stage CHMI 2-4 weeks after the third vaccination.
62813232|NCT04201431|EXPERIMENTAL|Group 2|If fewer than 8 volunteers complete the study in Group 1, then new volunteers will be recruited into Group 2, to make up a total of 10 to 12 volunteers who complete 3 vaccinations and CHMI between Groups 1 and 2. Group 2 volunteers will receive three doses of the PvDBPII 50ug/Matrix M1 50ug candidate vaccine at monthly intervals, prior to blood-stage CHMI 2-4 weeks after the third vaccination.
62036005|NCT01626248||Group D Other DMT 18 plus|Patient is close to or currently at 18 doses or more of interferon beta-1a or glatiramer acetate. If interested patient consented and assigned to Group D. Patient will have their blood drawn once: Day 0.
62036006|NCT01626248||Group E - Non-MS|10 participants without Multiple Sclerosis or other immunological illness. If interested participants consented and assigned to Group E. Participants will have their blood drawn once: Day 0.
62427511|NCT06330077|PLACEBO_COMPARATOR|Placebo|Placebo of ifenprodil : 20mg three time a day (60mg/day). Patients will have an escalation of dose over 48 hours (from Day 1) in order to achieve at the end of the 144 hours (6 days, Day 6) a dose of 60mg/day.
62595600|NCT06322095|EXPERIMENTAL|'GH21+ALK Inhibitor'Group|GH21 combined with previous ALK inhibitor.
62813233|NCT04201431|EXPERIMENTAL|Group 3|Up to 6 volunteers from Group 1 will receive a fourth dose of PvDBPII 50ug/Matrix M1 50ug, at 5 months post the third dose, prior to a second CHMI 2-4 weeks later.
62813234|NCT06312150|OTHER|Patients with tumour (age 0-20 years)|Patients affected by Wilms' tumour, Ewing's Sarcoma, Osteosarcoma, Soft tissue sarcomas, Carcinomas, Neuroblastoma age between 0-20 years
62036007|NCT06580028||0-3 months|EEG was collected during the whole perioperative period, including preoperative conscious period (or preoperative sedation period) , anesthesia period and anesthesia recovery period.
62036008|NCT06580028||3-6 months|EEG was collected during the whole perioperative period, including preoperative conscious period (or preoperative sedation period) , anesthesia period and anesthesia recovery period.
62036009|NCT06580028||6-9 months|EEG was collected during the whole perioperative period, including preoperative conscious period (or preoperative sedation period) , anesthesia period and anesthesia recovery period.
62036010|NCT06580028||9-12 months|EEG was collected during the whole perioperative period, including preoperative conscious period (or preoperative sedation period) , anesthesia period and anesthesia recovery period.
62036011|NCT06580028||1-1.5 years|EEG was collected during the whole perioperative period, including preoperative conscious period (or preoperative sedation period) , anesthesia period and anesthesia recovery period.
62036012|NCT06580028||1.5-2 years|EEG was collected during the whole perioperative period, including preoperative conscious period (or preoperative sedation period) , anesthesia period and anesthesia recovery period.
62036013|NCT06580028||2-2.5 years|EEG was collected during the whole perioperative period, including preoperative conscious period (or preoperative sedation period) , anesthesia period and anesthesia recovery period.
62036014|NCT06580028||2.5-3 years|EEG was collected during the whole perioperative period, including preoperative conscious period (or preoperative sedation period) , anesthesia period and anesthesia recovery period.
62036015|NCT06580028||3-3.5 years|EEG was collected during the whole perioperative period, including preoperative conscious period (or preoperative sedation period) , anesthesia period and anesthesia recovery period.
62036016|NCT06580028||3.5-4 years|EEG was collected during the whole perioperative period, including preoperative conscious period (or preoperative sedation period) , anesthesia period and anesthesia recovery period.
62036017|NCT06580028||4-4.5 years|EEG was collected during the whole perioperative period, including preoperative conscious period (or preoperative sedation period) , anesthesia period and anesthesia recovery period.
62036018|NCT06580028||4.5-5 years|EEG was collected during the whole perioperative period, including preoperative conscious period (or preoperative sedation period) , anesthesia period and anesthesia recovery period.
62036019|NCT06580028||5-5.5 years|EEG was collected during the whole perioperative period, including preoperative conscious period (or preoperative sedation period) , anesthesia period and anesthesia recovery period.
62036020|NCT06580028||5.5-6 years|EEG was collected during the whole perioperative period, including preoperative conscious period (or preoperative sedation period) , anesthesia period and anesthesia recovery period.
62036021|NCT03966833|EXPERIMENTAL|group-based interpersonal therapy (IPT-G)|14 weeks of group-based interpersonal therapy (IPT-G): StrongMinds is focused on treating depression in Uganda by training community members (in this case ELA club mentors) to act as mentors in IPT-G techniques. This intervention will be offered to 13-19 year old young women who score a 10 or higher on the PHQ-8. These adolescents who take up the offer will then be enrolled in the 14 weeks of therapy. Group therapy sessions build bonds between young women and encourage them to actively engage in the healing process and to support each other in the exploration of their depression triggers. With new healthier patterns and skills, women can learn to manage their current depression and ensure future depressive episodes can be quickly identified and resolved before the onset of any long-term consequences.
62036022|NCT03966833|EXPERIMENTAL|IPT-G + Unconditional Cash Transfer:|A one time lump sum of 200,000 UGX (\~$54) be provided to all study participants in a random sub-set of intervention (IPT-G) clusters near or at the conclusion of the 14-week therapy. This treatment variation will allow for determination of whether complimentary income support enhances the effects of IPT-G on psychological wellbeing and other outcomes of interest.
62036023|NCT03966833|NO_INTERVENTION|control|ELA clubs function as normal
62036024|NCT00379613|PLACEBO_COMPARATOR|1|rocuronium + 16.0 mg/kg Org 25969
62036025|NCT00379613|EXPERIMENTAL|2|rocuronium + 2.0 mg/kg Org 25969
62036026|NCT00379613|EXPERIMENTAL|3|rocuronium + 4.0 mg/kg Org 25969
62813235|NCT06312150|OTHER|Patients with tumour (age 0-75 years)|Patients affected by Ewing's Sarcoma, Neuroblastoma, Paediatric leukaemia, Breast, lung, colon and ovarian cancers between 0-75 years
62036027|NCT00379613|EXPERIMENTAL|4|rocuronium + 8.0 mg/kg Org 25969
62036028|NCT00379613|EXPERIMENTAL|5|rocuronium + 12.0 mg/kg Org 25969
62036029|NCT01353313|PLACEBO_COMPARATOR|Placebo|Saline placebo
62813236|NCT06312150|OTHER|Control Patients group|Patients underwent their diagnostic pathway, which made it possible to exclude the presence of any ongoing pathological process
62813237|NCT03621813|OTHER|Control|Participants maintain their current activity level.
62237341|NCT05516823||Psychedelic and Non-psychedelic Substances Group|"A group of participants who reported using in their past drugs identified as psychedelics and stimulants and/or depressants (both recreational and prescribed usages are included). In this group participants will be included who reported using at least one non-psychedelic drug additionally to a psychedelic one. Specifically, the following options were provided:~Psychedelic compounds:~Psilocybin (magic mushrooms, truffles) LSD (acid) Mescaline (peyote, San Pedro) Dimethyltryptamine (DMT) Ayahuasca 5-MeO-DMT 3-MMC Ibogaine Salvia Phenethylamines (2C family)~Non-psychedelic compounds:~THC (cannabis, marijuana) CBD Medical Cannabis (both THC and CBD) MDMA (ecstasy) Ketamine Cocaine Crack Amphetamines Methamphetamines Prescription stimulants (e.g., Adderall, Ritalin, Concerta) Benzodiazepines Opiates (e.g., heroin, opium, hydrocodone, oxycodone, oxymorphone, codeine, fentanyl) Prescription opioids"
62595601|NCT06322095|EXPERIMENTAL|'GH21+MET Inhibitor'Group|GH21 combined with previous MET inhibitor.
62595602|NCT06322095|EXPERIMENTAL|'GH21+BRAF Inhibitor+MEK Inhibitor'Group|GH21 combined with previous BRAF inhibitor and MEK inhibitor.
62813238|NCT03621813|ACTIVE_COMPARATOR|Exercise Rehabilitation|Participants will exercise 2x/week at training facilities and at home one day a week.
62813239|NCT00520962||1,2,3|"1. First degree relatives of patients with type 2 diabetes~2. Patients with cardiovascular disease and stroke~3. patients with heart valve disease"
62595603|NCT06322095|EXPERIMENTAL|'GH21+EGFR Monoclonal Antibody'Group|GH21 combined with previous EGFR Monoclonal Antibody.
62595604|NCT05667974|EXPERIMENTAL|PIKA Rabies|Receive 1 of the 3 lots of PIKA rabies vaccine via IM administration that 2-2-1 schedule with a double-dose injection on Day 0 and 3 and a single-dose injection on Day 7
62813240|NCT00520962||4|Healthy controls
62595605|NCT05667974|ACTIVE_COMPARATOR|Control|Receive ChiroRab via IM administration that the classic Essen 5-dose regimen 1-1-1-1-1 schedule on Days 0, 3, 7, 14 and 28
62237342|NCT05516823||Substance-naive Group|"A group of participants who reported no past experience with any of the substances listed in the current study nor reported using other substances (excluding alcohol and nicotine). Participants will be assigned to this group if and only if they choose the None of the above option from the Substance Use Survey (item 1)."
62237343|NCT01030679|EXPERIMENTAL|CKD-501 0.5mg|
62237344|NCT01030679|EXPERIMENTAL|CKD-501 1mg|
62237345|NCT01030679|EXPERIMENTAL|CKD-501 2mg|
62237346|NCT01030679|PLACEBO_COMPARATOR|Placebo|
62237347|NCT00935779||Gastric cancer|patients with operable local gastric adenocarcinoma were studied
62595606|NCT06386068|EXPERIMENTAL|Baseline phase|There are three baseline phases of 1, 2, or 3 weeks to which participants are block-randomized followed by a 10-week intervention phase. Hence, participants are their own case-controls.
62813241|NCT05541926|EXPERIMENTAL|e-Connect|County receives training and materials and subsequently begins the e-Connect intervention
62813242|NCT05541926|NO_INTERVENTION|Standard of Care|Standard of care practice in counties prior to the implementation of e-Connect
62813243|NCT03388034||Index case (WP1a)|"Infant under 6 months old with clinical signs of whooping cough syndrome.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by swabbing"
62237348|NCT00935779||Control group|patients operated on for benign diseases served as controls, randomly selected among patients with chronic gastro-esophageal reflux disease who were considered good candidates for antireflux surgery and properly matched in sex and age to study group
62237349|NCT02579707|ACTIVE_COMPARATOR|Treatment A: Unfed|Treatment A: Single oral dose of AG-120 at Hour 0 on Day 1, following a 10-hour overnight fast.
62237350|NCT02579707|ACTIVE_COMPARATOR|Treatment B: Fed|Treatment B: Single oral dose of AG-120 at Hour 0 on Day 1, 30 minutes after the start of a high-fat breakfast.
62595607|NCT04513080|EXPERIMENTAL|Phase 1, Level 1: Incentive 1 + Video-chat psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
62595608|NCT04513080|EXPERIMENTAL|Phase 1, Level 1: Incentive 2 + Video-chat psychotherapy (VCP)|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
62595609|NCT04513080|EXPERIMENTAL|Phase 1, Level 2: MBP with weekly VCP|Phase 1 participants who do not show 50% reduction in PHQ9 scores will be randomized to either weekly VCP augmented with unlimited MBP (augmentation arm), monthly VCP with unlimited MBP (switch/minimal augmentation arm).
62036030|NCT01353313|EXPERIMENTAL|Hydrocortisone|hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents)
62036031|NCT06089811|EXPERIMENTAL|Prebiotic|
62036032|NCT06089811|EXPERIMENTAL|L-Tryptophan|
62036033|NCT06089811|PLACEBO_COMPARATOR|Placebo|
62036034|NCT06352957||Etecalcetide Group|"Drug: Etelcalcetide Administered intravenously at the end of each dialysis session. Dosing ranges from 2.5 mg to 15 mg set by the patient's physician.~Other Name: Parsabiv"
62036035|NCT06352957||Standard of Care|Drug: Vitamin D or Vitamin D analogs
62237351|NCT02579707|EXPERIMENTAL|Part 2 Single Dose|PART 2 is an open-label study to determine the safety and PK parameters of a single 1000-mg oral dose of AG-120.
62813244|NCT03388034||Control case (WP1b)|"Contact cases of infant with a positive diagnosis for whooping cough.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by swabbing~Blood sampling:~A blood sample collected by fingerprick"
62036036|NCT06530823|EXPERIMENTAL|Pemigatinib and Durvalumab|"The combination of targeted drugs and immunotherapies has demonstrated their clinical value in the treatment of various tumors, and pemigatinib and durvalumab are such a promising combination product. In this combination, Pemigatinib is used according to the following rules:13.5mg, oral administration, once daily, swallow the entire tablet with or without food. Take for 2 weeks and then discontinue for 1 week.~Durvalumab is used as this: 1500mg, intravenous infusion, once every three weeks. Each infusion should take over 60 minutes."
62036037|NCT05141669||Fingolimod|Participants who initiated fingolimod to treat multiple sclerosis (MS)
62036038|NCT05141669||Non-fingolimod Disease Modifying Treatment (DMT)|All patients with ≥ 1 medical or pharmacy claim for a DMT other than fingolimod. Among patients included in the study that those with ≥ 1 pharmacy or medical claim for any MS DMT during pre-index would be excluded.
62036039|NCT04050189|ACTIVE_COMPARATOR|prenatal probiotic|will take probiotics every day from the 34th week of pregnancy until delivery; taking placebo for 10 days after delivery
62036040|NCT04050189|ACTIVE_COMPARATOR|postnatal probiotic|will take placebo every day from the 34th week of pregnancy until delivery; taking probiotics for 10 days after delivery
62036041|NCT04337814|EXPERIMENTAL|COTA Arm|Patients getting combined (C) oral (O) and topical (T) analgesics (A)
62036042|NCT04337814|EXPERIMENTAL|OA Arm|Patients getting oral (O) analgesics (A) and topical placebo
62036043|NCT04337814|PLACEBO_COMPARATOR|Placebo Arm|Patients getting oral placebo and topical placebo
62237352|NCT02881957|PLACEBO_COMPARATOR|Control|Placebo control (simple oral syrup)
62427512|NCT04056299|ACTIVE_COMPARATOR|AR201 powder|Subjects were randomized to active arm of AIME01 and administered AR201 in escalating doses for approximately 6 months, followed by a maintenance dose for approximately 12 weeks
62427513|NCT04056299|PLACEBO_COMPARATOR|Placebo powder|Subjects were randomized to placebo arm of AIME01 and administered placebo for approximately 6 months, followed by maintenance placebo for approximately 12 weeks.
62813245|NCT03388034||Seroepidemiological cohort (WP2)|"Children between 3 and 15 years old with complete primo-vaccination against B.Pertussis~Blood sampling:~A blood sample collected by fingerprick"
62813246|NCT05379179|ACTIVE_COMPARATOR|Fentanyl|"Drug administration: A single dose of fentanyl 1mcg/kg IV, maximum 100 mcg, over 15 minutes.~Time drug given will be documented Data obtained prior to med administration and then following medication administration at intervals of 15, 30, 60 and 120 minutes~* Record vital signs (HR, B/P, resp rate, O2 sat)~* Obtain and assess pain response scores~  1. Pain Numerical Rating Score (NRS - 0-10)~ 2. Richmond Agitation Sedation Scale (RASS)~ 3. Side Effect Rating Scale for Dissociative Anesthesia (SERSDA)~* Record any airway interventions required? If yes what? new supplemental O2/BVM/intubation, jaw thrust~* Record any rescue meds, dose and time (Rescue medication - Fentanyl):~* 1 mcg/kg IV fentanyl (0.5 mcg/kg if age \>55 yrs)~* Defined as rescue if given \<30 min post study intervention for pain score \>5 or patient requesting additional medication.~* Patient pain satisfaction score at discharge"
62036044|NCT06669468|ACTIVE_COMPARATOR|Group 1: PFME|The patients were instructed to do as an home exercise program in first 2 weeks, 5 s contraction and 10 s relaxation, including two sets of 5 repetition daily, in following 2 weeks 10 s contraction and 20 s relaxation, including two sets of 10 repetition daily, and after 4 weeks, 10 s contraction and 20 s relaxation including three sets of 10 repetition daily in three different position (lying, sitting, and standing). So in the first 2 weeks 30 contractions daily, in following 2 weeks 60 contractions daily and upward 4th weeks, 90 contractions daily with progressively increasing intensity was done. All patients were asked to mark the exercise at a daily home schedule. Patients who did not complete more than 20% of the list according to the daily home program were excluded from the study.
62427514|NCT03751527|EXPERIMENTAL|ZENFLEX stent Group|subjects applying ZENFLEX peripheral stent system
62595610|NCT04513080|EXPERIMENTAL|Phase 1 Level 2: MBP with monthly VCP|Phase 1 participants randomized to VCP who do not show 50% reduction in PHQ9 scores will be randomized to either weekly VCP augmented with unlimited MBP (augmentation arm) or monthly VCP with unlimited MBP (switch/minimal augmentation arm).
62036045|NCT06669468|EXPERIMENTAL|Group 2: PFME + Anal ES|Anal ES was applied in the lithotomy position by means of a combined electrotherapy (stimulation) device with anal electrodes. Anal ES was applied 3 days a week, 20 minutes a day, for a total of 24 sessions for 8 weeks. Stimulation parameters were 50 Hz frequency, 5-10 s work-rest cycle and 300 µs pulse amplitude. Symmetrical biphasic pulse wave was given in the range of 1-100 mA (according to the patient's discomfort level feedback). In this procedure, it was applied with an anal probe placed in the anal region. Patients did not perform voluntary contractions during ES. Anal probes were used separately for each patient. Anal ES sessions were performed by an investigator participating in the study. Men who missed any treatment session for the stimulation group were excluded from the study.
62036046|NCT06669468|EXPERIMENTAL|Group 3: PFME + Perineal ES|Perineal ES was applied in the lithotomy position by means of a combined electrotherapy (stimulation) device with surface electrodes. Anal ES was applied 3 days a week, 20 minutes a day, for a total of 24 sessions for 8 weeks. Stimulation parameters were 50 Hz frequency, 5-10 s work-rest cycle and 300 µs pulse amplitude. Symmetrical biphasic pulse wave was given in the range of 1-100 mA (according to the patient's discomfort level feedback). In this procedure, five surface electrodes with a diameter of 2 cm will be used, four electrodes symmetrically in the perianal region and one electrode in the leg (ground-neutral electrode). Patients will not perform voluntary contractions during ES. Surface electrodes will be used separately for each patient. Perineal ES sessions were performed by an investigator participating in the study. Men who missed any treatment session for the stimulation group were excluded from the study.
62036047|NCT05690009||Patients with albuminuria|Patients aged 40 or older without preexisting diagnoses of chronic kidney disease, type 1 diabetes, and type 2 diabetes with positive albuminuria by dipsticks and/or microalbuminuria test or albumin-to-creatinine ratio in a single urine sample.
62036048|NCT01509729|PLACEBO_COMPARATOR|Sham operation|
62036049|NCT01509729|ACTIVE_COMPARATOR|Knee arthroscopic surgery|
62036050|NCT03753438||Intragastric Balloon|Intragastric Balloon will be placed for 6 months
62427515|NCT04385199|EXPERIMENTAL|Convalescent Plasma Intervention|Convalescent plasma 200mL transfusion
62237353|NCT02881957|EXPERIMENTAL|Vitamin D3|Cholecalciferol/Vitamin D3 (540,000 IU orally or by feeding tube once)
62036051|NCT04364646|ACTIVE_COMPARATOR|Usual Care|Women in the usual care group receive medications and/or talk therapy. Sleep and light levels are monitored at home with wrist actigraphy during 3rd trimester of pregnancy (weeks 28-40) and weeks 2-6 and18 after the baby is born (postpartum weeks 2-6 and 18).
62237354|NCT01382264|EXPERIMENTAL|CADS|
62237355|NCT01798277|ACTIVE_COMPARATOR|Catheter Ablation|Radiofrequency ablation procedure
62427516|NCT04385199|NO_INTERVENTION|Standard Therapy Control|Standard therapy for COVID-19 disease as defined by institutional protocols
62427517|NCT04896723||Chronic liver disease|
62427518|NCT04896723||Healthy volunteers|
62427519|NCT06008977|NO_INTERVENTION|Standard Group- No Exercise (Adjuvant)|Patients randomized to the standard arm will receive clinical care following AH standards for the patient's disease type and therapeutic setting. This includes history and physical and laboratory studies to be conducted on each infusion day before clearing the patient for infusion.
62427520|NCT06008977|ACTIVE_COMPARATOR|Intervention Group- Moderate Exercise (adjuvant)|Patients randomized to the exercise arm will complete up to 30 minutes of same-day exercise prior to each administration of checkpoint blockade immunotherapy across all cycles. The preferred exercise is 30 minutes of moderate exertion on a cycle ergometer.
62427521|NCT06008977|NO_INTERVENTION|Standard Group- No Exercise (Neoadjuvant)|Patients randomized to the standard arm will receive clinical care following AH (AdventHealth) standards for the patient's disease type and therapeutic setting. This includes history and physical and laboratory studies to be conducted on each infusion day before clearing the patient for infusion.
62427522|NCT06008977|ACTIVE_COMPARATOR|Intervention Group- Moderate Exercise (Neoadjuvant)|Patients randomized to the exercise arm will complete up to 30 minutes of same-day exercise prior to each administration of checkpoint blockade immunotherapy across all cycles. The preferred exercise is 30 minutes of moderate exertion on a cycle ergometer.
62427523|NCT05930509|EXPERIMENTAL|Treatment|tDCS stimulation
62427524|NCT00654888|ACTIVE_COMPARATOR|1|Group one submitted to automated lamellar keratectomy(ALK) with mitomycin (0,02% in 30 seconds after keratectomy).
62427525|NCT00654888|ACTIVE_COMPARATOR|2|automated lamellar keratectomy without mitomycin
62036052|NCT04364646|EXPERIMENTAL|Personalize Integrated Chronotherapy|Women in the integrated chronotherapy group receive usual care (medications and/or talk therapy, as above) and also receive a bright light box to sit with every morning for up to 60 minutes as prescribed by the study doctor.
62036053|NCT03036163|EXPERIMENTAL|Cohort 1|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 40 mg (1 capsule)
62036054|NCT03036163|EXPERIMENTAL|Cohort 2|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 80 mg (2 capsules)
62036055|NCT03036163|EXPERIMENTAL|Cohort 3|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 160 mg (4 capsules)
62036056|NCT03036163|EXPERIMENTAL|Cohort 4|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 320 mg (8 capsules)
62036057|NCT03036163|EXPERIMENTAL|Cohort 5|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 640 mg (16 capsules)
62036058|NCT03036163|EXPERIMENTAL|Cohort 6|5 male healthy volunteers each of whom received once daily for 14 days 320 mg of PBTZ169 (8 capsules 40 mg)
62036059|NCT03036163|EXPERIMENTAL|Cohort 7|5 male healthy volunteers each of whom received once daily for 14 days 640 mg of PBTZ169 (16 capsules 40 mg)
62036060|NCT04352179|EXPERIMENTAL|Virtual Education Simulation|All participants will have access to the virtual education simulations.
62427526|NCT06385665|EXPERIMENTAL|accompanying group|
62036061|NCT04360148|EXPERIMENTAL|Very-low-calorie-ketogenic-diet|Very-low-calorie-ketogenic-diet (VLCKD) for 12 weeks; hypocaloric-balanced-diet (HBD)
62036062|NCT04360148|ACTIVE_COMPARATOR|Hypocaloric-balanced-diet|Hypocaloric-balanced-diet (HBD)
62036063|NCT03240692|EXPERIMENTAL|Accelerated theta burst treatment|All participants will receive theta-burst TMS.
62036064|NCT00517491|EXPERIMENTAL|1|
62036065|NCT01464203|EXPERIMENTAL|CT coronary angiography|Patients in this arm will undergo CT coronary angiography to assess the patency of coronary arteries and their clinical management will be decided by the results of CT coronary angiography.
62237356|NCT01798277|ACTIVE_COMPARATOR|Medical therapy|Antiarrhythmic drug therapy will include amiodarone or sotalol. Which antiarrhythmic drug will prescribed per patient depends on the observing physician.
62237357|NCT03653533|OTHER|MiniMed™ 640G alone|MiniMed™ 640G (insulin pump) is used without Captor CGM Enlite® (captor) at phase 1 and phase 4 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
62427527|NCT06385665|NO_INTERVENTION|non-accompanied group|
62595611|NCT04513080|EXPERIMENTAL|Phase 2 Level 1: Message-Based Psychotherapy (MBP)|Phase 2 participants who respond to MBP after 6 weeks of care will continue in this condition for another 6 weeks. Participants who do not respond by week 6 will be randomized to one of two augmentation arms, MBP plus monthly video chat (Premium Plan: PP) or MBP plus weekly video chat (Ultimate Plan: UP) for another 6 weeks of care.
62595612|NCT04513080|EXPERIMENTAL|Phase 2, Level 1: Video-Chat Psychotherapy (VCP)|Phase 2: Weekly psychotherapy appointments that last between 30-45 minutes. Participants who do not respond to this model will be randomized to switch (PP) or augment (UP) VCP.
62595613|NCT04513080|EXPERIMENTAL|Phase 2, Level 2: MBP with monthly VCP|"Phase 2: This intervention will serve as the switch arm for participants who do not respond to VCP by week 6, and one of two augmentation arms for participants who do not respond to MBP. The Premium plan allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist."
62595614|NCT04513080|EXPERIMENTAL|Phase 2, Level 2: MBP with weekly VCP|Phase 2: This intervention will serve as an augmentation arm for participants who do not respond to either MBP or VCP after 6 weeks of care. Like the Premium Plan, participants will have access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist.
62595615|NCT04513080|EXPERIMENTAL|Phase 1, Level 1: Incentive 1 + Message-based psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
62813247|NCT05379179|EXPERIMENTAL|Ketamine|"Drug administration: A single dose of ketamine 0.3 mg/kg IV over 15 minutes. Time drug given will be documented Data obtained prior to med administration and then following medication administration at intervals of 15, 30, 60 and 120 minutes~* Record vital signs (HR, B/P, resp rate, O2 sat)~* Obtain and assess pain response scores~  1. Pain Numerical Rating Score (NRS - 0-10)~ 2. Richmond Agitation Sedation Scale (RASS)~ 3. Side Effect Rating Scale for Dissociative Anesthesia (SERSDA)~* Record any airway interventions required? If yes what? new supplemental O2/BVM/intubation, jaw thrust~* Record any rescue meds, dose and time (Rescue medication - Fentanyl):~* 1 mcg/kg IV fentanyl (0.5 mcg/kg if age \>55 yrs)~* Defined as rescue if given \<30 min post study intervention for pain score \>5 or patient requesting additional medication.~* Patient pain satisfaction score at discharge"
62813248|NCT03628092|ACTIVE_COMPARATOR|CO2 Fractional Ablative Laser|3 treatments approximately 4 weeks apart with vaginal/vulval laser
62813249|NCT03628092|PLACEBO_COMPARATOR|Placebo|"3 treatments approximately 4 weeks apart with sham laser"
62813250|NCT04412759|NO_INTERVENTION|Porcine xenograft|porcine xenograft derived from dermal porcine skin. Standard of care treatement for partila thickness burn at the specfic centre
62813251|NCT04412759|EXPERIMENTAL|Microbial cellulose|Novel dressing consisting of a biopolymer spun by the bacteria Acetobacter xylinum (later removed).
62813252|NCT03904017|EXPERIMENTAL|Hyperoxia|Will receive 15liters per minute supplemental oxygen via a partial non-rebreather facemask.
62813253|NCT03904017|PLACEBO_COMPARATOR|Placebo|will receive 15liters per minute medical air via a partial non-rebreather facemask.
62813254|NCT02047812||High volume hospitals|The hospitals in the upper tertile for procedural volume
62813255|NCT02047812||Medium volume hospitals|The hospitals in the middle tertile for procedural volume
62237358|NCT03653533|OTHER|MiniMed™ 640G + Captor CGM Enlite®|insulin pump coupled with captor without SmartGuard® function tat phase 2 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
62813256|NCT02047812||Low volume hospitals|The hospitals in the lowest tertile for procedural volume.
62427528|NCT01358708|EXPERIMENTAL|LACTEOL® 340 mg|
62427529|NCT01358708|PLACEBO_COMPARATOR|PLACEBO|
62427530|NCT00822263|PLACEBO_COMPARATOR|2|control
62427531|NCT00822263|EXPERIMENTAL|1|Active medicine
62427532|NCT02549274|EXPERIMENTAL|self-rehabilitation + physiotherapy|Patients will have, in addition to conventional physiotherapy, to visit two training sessions in self-rehabilitation at the hospital. They will then perform a self-rehabilitation / day session.
62427533|NCT02549274|ACTIVE_COMPARATOR|physiotherapy|Patients will have only conventional physiotherapy
62427534|NCT02331030|EXPERIMENTAL|Combined (C)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.5% 20ml and Pecs II block with Ropivacaine 0.5% 10ml.
62427535|NCT02331030|ACTIVE_COMPARATOR|Supraclavicular (S)|Ultrasound-guided supraclavicular BPB with Ropivacaine 0.5% 20ml and sham block (grade 1)
62427536|NCT02366065|EXPERIMENTAL|Acetaminophen|study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
62427537|NCT02112422|ACTIVE_COMPARATOR|Control|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR. The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
62427538|NCT02112422|EXPERIMENTAL|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR. The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
62427539|NCT00755508|EXPERIMENTAL|Ramelteon 4 mg QD and Gabapentin 400 mg QD|
62595616|NCT04513080|EXPERIMENTAL|Phase 1, Level 1: Incentive 2 + Message-based psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
62595617|NCT02613039|OTHER|female outpatient subjects|Patients requiring combined Oral Contraceptives therapy.
62036066|NCT01464203|ACTIVE_COMPARATOR|Control Arm|"Patients in this arm will receive the standard of care (SoC). They will undergo either coronary angiography, myocardial perfusion scan or stress echocardiography as decided by the physician in charge, depending on the local availability of individual investigations and the patient's clinical scenario."
62036067|NCT05414682|EXPERIMENTAL|MIND+SOUL Diet|The MIND+SOUL diet is an adapted brain-healthy soul food diet. Participants follow the diet for 12 weeks.
62237359|NCT03653533|OTHER|MiniMed™ 640G + Captor + SmartGuard®|insulin pump + captor + SmartGuard® function are used at phase 3 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
62237360|NCT02267356|EXPERIMENTAL|Low dose 12-week|2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
62427540|NCT00755508|EXPERIMENTAL|Ramelteon 8 mg QD and Gabapentin 800 mg QD|
62595618|NCT03868748|PLACEBO_COMPARATOR|Placebo|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the placebo treatment arm will consume one placebo capsule per day for 12 weeks
62813257|NCT04508946|ACTIVE_COMPARATOR|Hydrocortisone Monotherapy|Hydrocortisone Monotherapy
62813258|NCT04508946|EXPERIMENTAL|triple therapy regimen (vitamin c - thiamine- hydrocortisone)|triple therapy regimen (vitamin c - thiamine- hydrocortisone)
62237361|NCT02267356|EXPERIMENTAL|Low dose 24-week|2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks
62427541|NCT00755508|EXPERIMENTAL|Ramelteon 8 mg QD and Gabapentin Placebo QD|
62036068|NCT04763850|EXPERIMENTAL|Walking decline|Walking decline on an instrumented treadmill under 3 different conditions
62036069|NCT02959632|EXPERIMENTAL|Patients receiving AAT|"Hospitalized patients receiving Animal Assisted Therapy (AAT).~Animal Assisted Therapy (Pet Visit) will be provided to the hospitalized patients."
62036070|NCT04899518|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution|
62036071|NCT04899518|EXPERIMENTAL|ALY688 Ophthalmic Solution Concentration 1|
62036072|NCT04899518|EXPERIMENTAL|ALY688 Ophthalmic Solution Concentration 2|
62036073|NCT06222450|ACTIVE_COMPARATOR|Standard VRT|The gaze stabilization, habituation and balance/gait HEP will be delivered using standard paper handouts
62427542|NCT00755508|ACTIVE_COMPARATOR|Gabapentin 800 mg QD|
62036074|NCT06222450|EXPERIMENTAL|Digital VRT|The gaze stabilization, habituation and balance/gait HEP will be delivered using a digital home program using the Health in Motion platform
62036075|NCT01499329||Patient receiving stent therapy|
62036076|NCT04669158|EXPERIMENTAL|Idebenone|Participants will take Idebenone 200 mg for 48 weeks, with study visits in clinic for physical and laboratory assessments at weeks 0, 2, 4, 12, 24, 36, and 48 weeks during treatment period and at 4, and 12 weeks after the last dose.
62427543|NCT00755508|PLACEBO_COMPARATOR|Placebo|
62427544|NCT03519022|PLACEBO_COMPARATOR|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
62427545|NCT03519022|ACTIVE_COMPARATOR|Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Cocaine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.
62427546|NCT06468735|EXPERIMENTAL|cholecystectomy|Ultrasonography-guided assessment of sarcopenia and measurement of visceral, preperitoneal, subcutaneous maximum and subcutaneous minimum fat thickness in cholecystectomised participants
62427547|NCT06468735|EXPERIMENTAL|Control|Ultrasonography-guided assessment of sarcopenia and measurement of visceral, preperitoneal, subcutaneous maximum and subcutaneous minimum fat thickness in participants without cholecystectomy
62427548|NCT04438629||Mild disease|COVID-19 hospitalized patients
62427549|NCT04438629||Severe disease|COVID-19 hospitalized patients in intensive care unit
62427550|NCT04438629||paucisymptomatic syndrome|Mild symptomatic patients in home quarantine
62427551|NCT05041244|EXPERIMENTAL|Interventional arm|NPWT will be delivered through devices (ActiVac and InfoVac) according to FDA protocol in conjunction with the polyurethane foams. Dressing changed will be on a weekly basis.
62427552|NCT05041244|OTHER|Control|Standard of care Participants will be given the standard care provided in specialist foot care clinics or in-patients.
62427553|NCT05819931|EXPERIMENTAL|Mechanical In-Exsufflator treatment|
62427554|NCT05816044||preeclamptic pregnant woman|
62427555|NCT05816044||healty preagnant woman|
62237362|NCT02267356|EXPERIMENTAL|High dose 12-week|4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
62237363|NCT02267356|EXPERIMENTAL|High dose 24-week|4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 22 weeks
62427556|NCT05336682|EXPERIMENTAL|LSTR with radicular instrumentation.|
62427557|NCT05336682|EXPERIMENTAL|LSTR with no radicular instrumentation.|
62427558|NCT05336682|ACTIVE_COMPARATOR|Conventional pulpectomy.|
62427559|NCT01987024|ACTIVE_COMPARATOR|group A-usual procedure|
62427560|NCT01987024|EXPERIMENTAL|groupB- actim partus|
62427561|NCT04649801|NO_INTERVENTION|conventional|
62427562|NCT04649801|ACTIVE_COMPARATOR|interventional|
62427563|NCT02445989|ACTIVE_COMPARATOR|Cyclic NuvaRing CVR Use|CVR use for 3 weeks, remove for 1 week, then replace
62427564|NCT02445989|EXPERIMENTAL|Continuous NuvaRing CVR Use|CVR use for 4 weeks, then replace
62427565|NCT01958593|PLACEBO_COMPARATOR|Placebo with therapy|Participants will receive placebo with therapy during each of two experimental sessions.
62427566|NCT01958593|EXPERIMENTAL|MDMA-assisted therapy|Participants will receive MDMA (initial dose of 125 mg followed by a supplemental dose of 62.5 mg) with therapy during each of two experimental sessions.
62237364|NCT02267356|PLACEBO_COMPARATOR|Placebo|4 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks
62237365|NCT04026204||Coronary cannulation after TAVR|Coronary ostia cannulation after TAVR
62237366|NCT01885325|EXPERIMENTAL|Physical Activity Preschool Intervention|Preschools randomized to the multi-component physical activity preschool intervention received four major components: Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical Activity in classroom, academic lessons), and enhancing the social environment to promote Physical Activity.
62237367|NCT01885325|NO_INTERVENTION|Control|The preschools in the control group did not receive the intervention
62427567|NCT05171699|EXPERIMENTAL|electroacupuncture|The investigators choose Zusanli (ST36) and Baihui (DU20) acupoints to investigate the effect of electroacupuncture on patients with sepsis-associated brain injury.
62427568|NCT05171699|SHAM_COMPARATOR|shame electroacupuncture|The shame electroacupuncture were performed at a shallow depth and 1 mm lateral to Zusanli (ST36) and Baihui (DU20) acupoints.
62427569|NCT04535271|EXPERIMENTAL|Single arm|Trabectedin 24 h CIV 0.5 mg/m2 D1 and D8 Gemcitabine i.v. 250 mg/m2 D1 and D8 Dacarbazine i.v. 250 mg/m2 D1 and D8
62427570|NCT01637675|ACTIVE_COMPARATOR|20 mg sildenafil citrate tablets by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
62427571|NCT01637675|EXPERIMENTAL|sodium tanshinone IIA sulfonate, sildenafil citrate tablets|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection also permitted if necessary) 250ml ivdrip once a day for 8 weeks,20mg sildenafil citrate tablets by mouth three times a day for the same duration
62427572|NCT05589428|PLACEBO_COMPARATOR|Placebo|Normal bread
62427573|NCT05589428|EXPERIMENTAL|Low sodium bread|Low sodium bread
62427574|NCT03471182|ACTIVE_COMPARATOR|Psychiatric and Cognitive Testing|All participants will complete psychiatric assessment and cognitive testing.
62427575|NCT03471182|ACTIVE_COMPARATOR|Cocaine Self-adminstration|This arm plans to assess the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug in a human laboratory study of self-regulated cocaine administration.
62427576|NCT03471182|ACTIVE_COMPARATOR|Positron Emission Tomography|All participants will complete a PET scan to assess mGluR5 receptors using \[18-F\]FPEB
62427577|NCT03471182|ACTIVE_COMPARATOR|Magnetic Resonance Imaging|All participants will complete one MRI scan to assess brain structure and function.
62237368|NCT04234425|EXPERIMENTAL|Experimental Group|18 high school students in a weight training class will be assigned to this experimental group and will receive the one-hour intervention twice weekly for 8 weeks.
62595619|NCT03868748|EXPERIMENTAL|Low Dose, 12 weeks|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the low dose treatment arm will consume one 150 mg beta-arbutin capsule per day for 12 weeks.
62036077|NCT04669158|PLACEBO_COMPARATOR|Placebo|Participants will take Placebo for 48 weeks, with study visits in clinic for physical and laboratory assessments at weeks 0, 2, 4, 12, 24, 36, and 48 weeks during treatment period and at 4, and 12 weeks after the last dose.
62036078|NCT06695546||Experimental|Patients over one year of age treated at Toulouse University Hospital and receiving extrarenal purification, bloodletting or vascular filling \> 10 ml/kg.
62036079|NCT06470854|ACTIVE_COMPARATOR|Group One|
62036080|NCT06470854|ACTIVE_COMPARATOR|Group Two|
62036081|NCT01554072|PLACEBO_COMPARATOR|Placebo|Patients will receive a booklet of exercises, besides containing an explanation of his illness and the importance of exercise in their quality of life, an exercise routine physical to be held three times a week for two consecutive months. Patients will be instructed individually on each exercise, performing with supervisor that there be no doubt about execution, thereby minimizing any possible mistake in practice at home. For each day of the year ended data should be recorded in a daily monitoring. At the end of two months of the PR program semi-home patients will be subject to review so that all tests should be applied again.
62036082|NCT01554072|ACTIVE_COMPARATOR|exercise|Patients will receive a booklet of exercises, besides containing an explanation of his illness and the importance of exercise in their quality of life, an exercise routine physical to be held three times a week for two consecutive months. For each day of the year ended data should be recorded in a daily monitoring. Is also scheduled a visit to the laboratory biweekly in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused. At the end of two months of the PR program semi-home patients will be subject to review so that all tests should be applied again.
62036083|NCT02921815||Patients with myeloid leukemia|All del(5q) Myelodysplastic syndrome (MDS) patients in the all-case surveillance in whom transformation to acute myeloid leukemia has not been documented at the end of the observation period of the all-case surveillance.
62036084|NCT04783467|EXPERIMENTAL|Time Restricted Eating (TRE) Schedule|For 6-weeks out of the 16-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calorie-containing beverages within an 8 to 10-hour period that fits their schedule. The meal plans will be individualized to meet weight maintenance energy requirements.
62036085|NCT04783467|NO_INTERVENTION|Control Schedule|For 4 weeks out of the 16-week randomized dietary crossover study, women will receive frozen lunch and dinner meals, and a standardized breakfast and snacks menu. The meal plans will be individualized to meet weight maintenance energy requirements. There are no restrictions on timing of eating.
62036086|NCT03386968|EXPERIMENTAL|Video gaming|A child's usual physical therapy session will be replaced with a session utilizing Active video games and the Rutger's V-step.
62237369|NCT05364372|ACTIVE_COMPARATOR|Attention control|Dyads will receive mailed print education materials regarding healthy lifestyle (nutrition and physical activity) disseminated by ACS and NCI. They will also receive 12 weekly phone calls to assess post-treatment related symptoms.
62237370|NCT05364372|EXPERIMENTAL|Symptom management and lifestyle intervention|Dyads will receive 12 weekly telephone-based coaching sessions, a participant educational handbook, and a pedometer for self-monitoring physical activity.
62595620|NCT03868748|EXPERIMENTAL|High Dose, 4 weeks|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the high dose treatment arm will consume one placebo capsule per day for 8 weeks followed by one 400 mg beta-arbutin capsule per day for 4 weeks.
62237371|NCT03528863|EXPERIMENTAL|Supportive Care (web-based mindfulness meditation)|Participants practice with web-based mindfulness meditation over 10-15 minute guided audio sessions for 5 days a week for 8 weeks. Participants also attend meditation webinars over 60 minutes once a week, for 8 weeks.
62595621|NCT06332573|EXPERIMENTAL|"Early intervention group"|
62595622|NCT06332573|OTHER|"Late intervention group"|
62036087|NCT03386968|ACTIVE_COMPARATOR|Usual care|Children will receive their usual care in the physical therapy program at Blythedale.
62036088|NCT01093898||No intervention|
62036089|NCT04180657||Patients with protein C deficiency|Patient and control group are compared regarding ghrelin, growth hormone levels and appetite, and no other intervention is made.
62237372|NCT01197833|EXPERIMENTAL|Endovenous ablation+polidocanol injectable microfoam 0.125%|Endovenous ablation followed by an injection of polidocanol injectable microfoam 0.125% to target vein
62595623|NCT05623670||Patients after minimally invasive cardiac surgery using a VJI cannula.|
62237373|NCT01197833|EXPERIMENTAL|Endovenous ablation+polidocanol injectable micrfoam, 1.0%|Endovenous ablation followed by injection of polidocanol injectable microfoam, 1.0% to the target vein
62237374|NCT01197833|ACTIVE_COMPARATOR|endovenous ablation+vehicle (placebo)|endovenous ablation followed by injection of vehicle (placebo) to target vein
62237375|NCT01505010|OTHER|Control group|Standard antihypertensive drug treatment
62237376|NCT01505010|EXPERIMENTAL|Intervention group|Renal denervation plus standard antihypertensive drug treatment
62595624|NCT04881032|EXPERIMENTAL|AGuIX + chemoradiotherapy (radiotherapy + temozolomide)|addition of AGuIX nanoparticles to standard radiotherapy and concomitant treatment by temozolomide (TMZ) for patients of phase I and patients randomized in experimental arm of phase II
62595625|NCT04881032|SHAM_COMPARATOR|chemoradiotherapy (radiotherapy + temozolomide)|standard of care : chemoradiotherapy (radiotherapy + temozolomide) for patients randomized in control arm of phase II
62595626|NCT01000220|ACTIVE_COMPARATOR|Omeprazole|
62595627|NCT01000220|PLACEBO_COMPARATOR|placebo|
62595628|NCT05963633|EXPERIMENTAL|Episodic Future Thinking (EFT)|Parents who are receiving residential substance use disorder (SUD) treatment will receive an adapted episodic future thinking focused condition. Parents will meet with peer recovery coaches (PRCs) who will administer the intervention, focused on generating future, pleasant milestones with their children. The participant will also be allowed to draw or write about the scene, to help them envision it, which they will keep to refer to if they choose. After the intervention session, PRCs will check-in with parents daily over the course of two weeks to practice episodic future thinking (EFT) intervention by asking participants to further elaborate on the milestones they identified in the intervention to prompt these episodes in vivid detail.
62595629|NCT05963633|ACTIVE_COMPARATOR|Episodic Recent Thinking (ERT)|Parents who are receiving residential substance use disorder (SUD) treatment will receive an adapted episodic recent thinking intervention. Parents will meet with peer recovery coaches (PRCs) who will administer the intervention. During the intervention, the participant will be asked to describe in detail two things they struggled with and two things that went well that occurred during the last few days. The participant will also be allowed to draw or write about the scene, to help them envision it, which they will keep to refer to if they choose. After the intervention session, or present-oriented thinking (in the comparison condition, by asking participants to discuss an event that happened that day PRCs will check-in with parents daily over the course of two weeks to practice episodic future thinking (EFT) intervention by asking participants to further elaborate on the milestones they identified in the intervention to prompt these episodes in vivid detail.
62595630|NCT06620744|EXPERIMENTAL|Sponsor MCG Device|All participants will receive a scan from the sponsor's MCG device.
62813259|NCT02481154|EXPERIMENTAL|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression, development of other unacceptable toxicity or Investigator discretion
62813260|NCT06088498|EXPERIMENTAL|Aim 1: Update an existing smartphone App|An existing study app will be updated to be engaging, user-friendly treatment tool, and verify user satisfaction.
62813261|NCT06088498|EXPERIMENTAL|Aim 2: Quit Line Only|Participants randomized to this arm will receive usual care for smoking cessation via the quitline and a smartphone app that will allow them to track smoking urges and abstinence.
62813262|NCT06088498|EXPERIMENTAL|Aim 2:Quitline plus smartphone App|Participants randomized to this arm will receive usual care for smoking cessation via the quitline and a smartphone app that will allow them to track smoking urges and abstinence. After 48 hours of self-reported abstinence, they will be exposed to smoking extinction trials through the study smartphone app.
62237377|NCT04384848|EXPERIMENTAL|Chronic myeloid leukemia (CML) patients|CML patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy
62237378|NCT04888130||Cases|This study comes following an outbreak signal that occurred in May 2020, after the detection of numerous cases of cutaneous leishmaniasis in military personnel probably contaminated during a training course (Training Center in the Equatorial Forest, CEFE) in the town of Regina. To date, around 40 cases have been detected.
62237379|NCT04888130||Controls|A case-control study can therefore be carried out using a questionnaire offered to all course participants over the 1st semester of 2020. The controls will then be participants who have not been infected. A comparison can also be made between the military personnel present in French Guiana during the first half of 2020 and having carried out missions in the forest, by opposing the participants and non-participants of the CEFE.
62237380|NCT06236529|NO_INTERVENTION|Control|Participants receive no intervention.
62237381|NCT06236529|ACTIVE_COMPARATOR|Self-management program (SMP)|Participants engage in a nurse-led evidence-based web-enabled group self-management class for 6 weeks.
62427578|NCT00802529|EXPERIMENTAL|Steroid (Methylprednisolone)|Steroid (Methylprednisolone)
62427579|NCT00802529|ACTIVE_COMPARATOR|Gentamicin|Gentamicin
62427580|NCT03860571|PLACEBO_COMPARATOR|Placebo|
62427581|NCT03860571|EXPERIMENTAL|BT-11|
62427582|NCT06237699||ICU survivors without an ICU diary|
62427583|NCT06237699||ICU relatives without an ICU diary|
62427584|NCT06237699||ICU survivors with a digital ICU diary|
62427585|NCT06237699||ICU relatives with a digital ICU diary|
62427586|NCT05792865||Paxlovid（Within 5 days after the diagnosis of COVID-19）|According to the patient's medical records, the time from the diagnosis of COVID-19 to the prescription of PAXLOVID is within 5 days.
62427587|NCT05792865||Paxlovid （More than 5 days after the diagnosis of COVID-19）|According to the patient's medical records, the time from the diagnosis of COVID-19 to the prescription of PAXLOVID exceeds 5 days.
62237382|NCT06236529|EXPERIMENTAL|Self-management program (SMP) with Health Behavior Change Counseling (HBCC)|Participants engage in a nurse-led evidence-based web-enabled group self-management class for 6 weeks and receive three telephone-based health behavioral change counseling sessions based on the principles and practices of motivational interviewing.
62237383|NCT03844542|EXPERIMENTAL|Therapeutic plasma exchange|Perform therapeutic plasma exchange in addition to standard care for patients with sepsis induced multi-organ failure
62237384|NCT03844542|NO_INTERVENTION|Standard care alone for sepsis|Standard care for patients with sepsis induced multi-organ failure
62237385|NCT00520104|EXPERIMENTAL|A|intranasal ketamine
62237386|NCT00520104|EXPERIMENTAL|B|oxymetazoline plus intranasal ketamine
62237387|NCT00520104|EXPERIMENTAL|C|intranasal steroid plus intranasal ketamine
62036090|NCT04180657||Healthy controls|Patient and control group are compared regarding ghrelin, growth hormone levels and appetite, and no other intervention is made.
62036091|NCT04292327||The ordinary COVID-19|Consistent with the diagnosis of ordinary COVID-19.
62036092|NCT04292327||The heavy COVID-19.|Consistent with the diagnosis of heavy COVID-19.
62036093|NCT04292327||The critical COVID-19|Consistent with the diagnosis of critical COVID-19
62036094|NCT06304766|ACTIVE_COMPARATOR|Open ablation|Laparotomy performed for open ablation of the tumor
62036095|NCT06304766|EXPERIMENTAL|Laparoscopic ablation|Ablation of the tumor performed by laparoscopic approach
62036096|NCT02293538|EXPERIMENTAL|FID 114657|FID 114657 eye drops (10 ml), 1-2 drops instilled in each eye 10 minutes prior to inserting a new pair of habitual contact lenses and after removing them, daily for 2 weeks.
62036097|NCT02293538|ACTIVE_COMPARATOR|Saline Control|Saline control eye drops (15 ml), 1-2 drops instilled in each eye 10 minutes prior to inserting a new pair of habitual contact lenses and after removing them, daily for 2 weeks.
62036098|NCT05268133|EXPERIMENTAL|Aronia|An aronia melanocarpa extract. Study volunteers will receive a daily oral dose of 160 mg AME for 6 weeks.
62036099|NCT05268133|PLACEBO_COMPARATOR|Control|Cellulose. Study volunteers will receive a daily oral dose of 160 mg cellulose for 6 weeks.
62036100|NCT06496932|EXPERIMENTAL|Listen to music group|The study group will be played music during the cesarean section.
62036101|NCT06496932|NO_INTERVENTION|Standart cesarean procedure|The control group continued to receive the routine care
62595631|NCT01113645||Cerebral perfusion evaluation|All patients are evaluated by GOS (Glasgow Outcome Score) and neurocognitive tests by FAB (frontal assessment battery) and MMSE (mini mental state examination) scores. Hemodynamic monitoring by CT perfusion scan, as well as by trans-cranial Doppler.
62036102|NCT02139033|EXPERIMENTAL|Arm 1|Retain 1-2 drops, bilaterally, BID
62036103|NCT02701218|EXPERIMENTAL|Single cycle|single cycle of canalith repositioning procedure
62036104|NCT02701218|EXPERIMENTAL|multiple cycles of CRP|multiple cycles of canalith repositioning procedure CRP will be stopped if 1) no nystagmus and vertigo in all positions 2) complications exited 3) stable nystagmus in the 2 last cycles
62036105|NCT00361543|ACTIVE_COMPARATOR|1|Raloxifene Hydrochloride
62036106|NCT00361543|PLACEBO_COMPARATOR|2|placebo tablet
62036107|NCT00978601|EXPERIMENTAL|Multimodal analgesic protocol group|Women who received the multimodal analgesic protocol during minimally invasive myomectomy.
62036108|NCT00978601|NO_INTERVENTION|No use of multimodal analgesic protocol group|Women who did not receive the multimodal analgesic protocol during minimally invasive myomectomy.
62036109|NCT00960466|ACTIVE_COMPARATOR|Usual Care Arm|The usual care group will receive their Chemotherapy or Radiotherapy as normal.
62036110|NCT00960466|EXPERIMENTAL|DT&PL arm|"During the second week of radiotherapy/second cycle of chemotherapy, patients in the Distress Thermometer and Problem List (DT\&PL) arm of the study will complete the DT\&PL (estimated 15 minutes to complete) with the trained radiographer/nurse.~The DT\&PL assessment will be repeated at the end of therapy fractions/cycles. This will elicit concerns about post-therapy issues and facilitate continuity of care between the cancer team and primary care. Depending on the duration of therapy, therapists may choose to use the DT\&PL at other points during patient care. A copy of the DT\&PL will be stored in the medical record to track the frequency of use and to check that those assigned to usual care were not monitored with the DT\&PL."
62036111|NCT02403726||osteoporosis associated vertebral fractures|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures.
62036112|NCT03936855|ACTIVE_COMPARATOR|Incremental filling technique|Glass ionomer in the pulp chamber and incremental filling technique using composite resin
62036113|NCT03936855|EXPERIMENTAL|Bulk Fill|Bulk fill composite resin filling all the cavity
62036114|NCT06129747|EXPERIMENTAL|Radiation Therapy(RT)|There will be one treatment cohort. Radiation therapy will be delivered daily for 15 daily fractions, 2.67Gy per fraction, delivered using a 3-D or IMRT(Intensity Modulate Radiation Therapy) plan. For participants with high-risk features deemed by the radiation oncologist who would otherwise be a candidate for a boost (age \<50, high grade, poor biology, close margins), 48 Gy delivered in fifteen fractions of 3.2 Gy is allowed.
62036115|NCT00564122||All subjects|
62036116|NCT02724553|OTHER|Vertical orientation of Haptic orientation|The orientation of the IOL haptic will be implanted in the vertical position during routine cataract surgery
62036117|NCT02724553|OTHER|Horizontal orientation of Haptic orientation|The orientation of the IOL haptic will be implanted in the horizontal position during routine cataract surgery
62813263|NCT05685043|EXPERIMENTAL|best medical treatment and mechanical thrombectomy based on perfusion CT criteria|In the experimental treatment group, mechanical thrombectomy is only performed when prespecified perfusion CT criteria are fulfilled. If not, the patient will only receive best medical treatment (intravenous fibrinolysis if applicable).
62813264|NCT05685043|NO_INTERVENTION|best medical treatment and mechanical thrombectomy|All patients in the active control arm will receive the combination of best medical treatment (intravenous fibrinolysis if applicable) and mechanical thrombectomy, regardless of the results from the perfusion CT scan. This is the current standard of care for stroke patients arriving in hospital within 6 hours after onset.
62036118|NCT03314415|EXPERIMENTAL|Early robotic intervention|Participants randomized to the early robotic intervention will attend robotic assistance sessions for a two-week period earlier in the study (during the first half of the study, approximately). Each participant will attend ten 15-minute robotic assistance sessions to interact with a robot (Aldebaraan Nao H25).
62036119|NCT03314415|EXPERIMENTAL|Late robotic intervention|Participants randomized to the late robotic intervention will attend robotic assistance sessions for a two-week period later in the study (during the latter half of the study, approximately). Each participant will attend ten 15-minute robotic assistance sessions to interact with a robot (Aldebaraan Nao H25).
62036120|NCT05878197|EXPERIMENTAL|Experimental group 1 - Straw Phonation|Short-term intensive voice therapy program of one week (3 hours a day for 4 consecutive days): straw phonation and vocal hygiene recommendations
62427588|NCT05792865||No paxlovid used|Patients have never used Paxlovid after being diagnosed with COVID-19, whether before or after hospitalization.
62427589|NCT00750009|EXPERIMENTAL|Arm I (PRE-ACT)|Patients receive tailored feedback and video content to address clinical trial barriers following baseline assessment.
62427590|NCT00750009|ACTIVE_COMPARATOR|Arm II (control)|Patients receive generic clinical trials educational feedback taken from NCI publications following baseline assessment.
62427591|NCT02910453||VATS group|Pulmonary lobectomy via VATS. VATS starts with a utility incision, approximately 4 cm in length, anterior to the latissimus dorsi muscle at the 4th intercostal space. Muscle fibers are split without cutting and a wound protector is regularly placed in site. The camera port is placed in the 6th or 7th intercostal space at the anterior axillary line and a third 10-mm access is made at the same intercostal space at the posterior axillary line. The hilum is approached anteriorly
62813265|NCT01579903|EXPERIMENTAL|Sequence 1|Subjects randomized to receive Treatment A during Period 1, then Treatment B during Period 2.
62036121|NCT05878197|EXPERIMENTAL|Experimental group 2 - Resonant Voice Therapy|Short-term intensive voice therapy program of one week (3 hours a day for 4 consecutive days): resonant voice therapy and vocal hygiene recommendations
62036122|NCT05878197|SHAM_COMPARATOR|Control group|Short-term intensive voice therapy program of one week (3 hours a day for 4 consecutive days): vocal hygiene recommendations
62036123|NCT00955357|EXPERIMENTAL|First Add-on|Lacosamide added to first adequate monotherapy (no history of Antiepileptic Drug \[AED\] polytherapy) and epilepsy diagnosis \< or = 24 months at Screening.
62036124|NCT00955357|EXPERIMENTAL|Later Add-on|Lacosamide added to 1 to 3 Antiepileptic Drugs (AEDs) (with tentatives of at least 2 prior AED treatment regimens) and epilepsy diagnosis \> or = 5 years at Screening.
62036125|NCT00941330|EXPERIMENTAL|A: Exemestane|ARM A: Patients will be treated with exemestane.
62036126|NCT00941330|ACTIVE_COMPARATOR|B: Docetaxel and Cytoxan|ARM B: Patients will be treated with docetaxel and cytoxan.
62036127|NCT06304818|EXPERIMENTAL|SCTB14|SCTB14 of different doses,IV,every 3 weeks
62036128|NCT03524040|EXPERIMENTAL|Acne patients|Application of gold microparticles to 2-3 facial areas
62036129|NCT03524040|EXPERIMENTAL|Heatlhy volunteers|Application of gold microparticles to 2 facial areas
62036130|NCT04477642|EXPERIMENTAL|AbataceptTreatment Arm|Enrolled patients who will receive treatment with abatacept
62036131|NCT03460977|EXPERIMENTAL|Dose Escalation (Part 1A)|Participants with SCLC, CRPC and FL will receive mevrometostat at escalating dose levels
62036132|NCT03460977|EXPERIMENTAL|Dose Escalation (Part 1B)|Participants with FL will receive mevrometostat at escalating dose levels
62427592|NCT02910453||Open group|Pulmonary lobectomy via posterolateral thoracotomy (PLT). PLT consists in a standard 10-15 muscle-sparing incision at 4th intercostal space, rib divaricators are utilized and the hilum is approached posteriorly as previously described
62813266|NCT01579903|EXPERIMENTAL|Sequence 2|Subjects randomized to receive Treatment B during Period 1, then Treatment B during Period 2.
62036133|NCT03460977|EXPERIMENTAL|Dose Escalation (Part 1C)|Participants with mCRPC will receive PF-06821497 at escalating dose levels.
62036134|NCT03460977|EXPERIMENTAL|Dose Escalation (Part 2A)|Participants with mCRPC and SCLC will receive mevrometostat at escalating dose levels in combination with SOC.
62036135|NCT03460977|EXPERIMENTAL|Dose Expansion (Part 2B)|Participants with CRPC will receive mevrometostat in combination with SOC or SOC alone.
62036136|NCT03460977|EXPERIMENTAL|Japan Cohort|Participants with CRPC will receive mevrometostat at one or two doses
62036137|NCT03460977|EXPERIMENTAL|China cohort|Participants will receive mevrometostat at one or two doses
62036138|NCT03460977|EXPERIMENTAL|Dose Expansion (Part 2C)|Participants with mCRPC will receive mevrometostat at a different dose/dosing regimen than that of Part 2B in combination with SOC
62036139|NCT04323813||Cases|CRC patients: primary, Stage I-IV (localized, node negative or node positive) colon carcinoma confirmed by tissue biopsy, and patients with advanced adenoma (including high-grade dysplasia, HGD).
62427593|NCT01884116|ACTIVE_COMPARATOR|NSAID patch group|administer the NSAID patch
62427594|NCT01884116|EXPERIMENTAL|NSAID patch + transcutaneous electric nerve stimulation group|
62427595|NCT01884116|EXPERIMENTAL|NSAID patch + heating pad group|
62427596|NCT01884116|EXPERIMENTAL|NSAID patch + topical capsaicin group|
62427597|NCT06330428|EXPERIMENTAL|Experimental group|Sexuality-based family planning education will be provided through podcasts.
62427598|NCT06330428|NO_INTERVENTION|Control group|Control
62813267|NCT05830500|EXPERIMENTAL|Anlotinib capsules|Anlotinib: 12 mg once daily for 2 weeks, followed by a discontinuance of 1 week (21-daya as a cycle)
62036140|NCT04323813||Controls|Controls subjects as well as healthy clean colonoscopy subjects or with hyperplastic polyps, and healthy subjects with diminutive adenoma-low grade dysplasia (LGD) and with inflammatory bowel disease (IBD).
62036141|NCT05713617|EXPERIMENTAL|Intervention group|Participants will receive 10 remote sessions with the curriculum with a promotora, and 3 in-person group workshops.
62036142|NCT05713617|NO_INTERVENTION|control group|Participants will receive community services as usual
62036143|NCT02158299|EXPERIMENTAL|Avitene,Drainaging,reexamine|
62427599|NCT05741775|EXPERIMENTAL|Aerobic training|Participants in the aerobic group will undergo a training that includes walking, static bicycle, and neck exercise. The participants start the session with a warm-up for 5 minutes followed by 30 minutes of aerobic exercise and end with 5 minutes of cool-down exercise. 40 minutes/ session, 3 times per week for 6 weeks.
62427600|NCT05741775|EXPERIMENTAL|Biofeedback training|Participants in this group will undergo an electromyography (EMG) biofeedback training for trapezius and frontalis using rose for relaxation 3 times per week for 6 weeks. Each session will be for 30 minutes with a 5-minute resting period between each muscle session.
62427601|NCT05741775|NO_INTERVENTION|Waitlist Control group|"The control group will receive the patient education sheet with the basic information about migraine in terms of symptoms, triggers, and prevention tips. This group is also called as waitlist control group who will receive intervention after the active treatment group."
62427602|NCT00849524|EXPERIMENTAL|Ad-ISF35|Ad-ISF35, intranodal injection, 3.3 x 10\^10 ISF35 viral particles, every 2-4 weeks up to six total injections.
62427603|NCT05447429|EXPERIMENTAL|TAP Block|In this group ,TAP block will be performed with 0.5% 15 ml bupivacaine + 5 ml .
62427604|NCT05447429|PLACEBO_COMPARATOR|Placebo|In this group , 20 ml saline solution will injected into the transversus abdominis plane.
62427605|NCT00561405|EXPERIMENTAL|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner.
62427606|NCT00561405|ACTIVE_COMPARATOR|Body weight supported treadmill training|Body Weight Supported Treadmill Training. Participants walk on a treadmill while partially supported with an overhead harness system. Mass repetition of the normal gait cycle is encouraged through the support of the harness, the movement of the treadmill, and the assistance of one or two trainers to position limbs and trunk.
62427607|NCT02746029||Children with cardiac murmur|
62427608|NCT06134739||Patients with embolism after ablation for atrial fibrillation (or left atrial flutter).|"The EMBOL-AF is a multicenter, international, observational study designed as a retrospective registry that will investigate the characteristics of systemic arterial embolic events after treatment of atrial fibrillation by catheter ablation. Due to the retrospective nature of the study, the registry is specially focused on cerebral embolism (stroke and TIA) because these are not only the most frequent and clinically relevant but also the most susceptible to underreporting. However, all embolism associated to AFAbl will be included.~This study will gather all clinically relevant aspects and data of all cases of arterial embolism that have occurred over the last 5 years in the centers that will participate in the registry. Based on these reported cases, the incidence, management and outcomes of embolic events (particularly stroke and TIA) will be studied."
62427609|NCT04072744||Participants|General Study Participants
62427610|NCT05277922|EXPERIMENTAL|C21|15 µg C21 (infusion rate 3 µg/min) 50 µg C21 (infusion rate 10 µg/min) 150 µg C21 (infusion rate 30 µg/min) 500 µg C21 (infusion rate 100 µg/min) 1000 µg C21 (infusion rate 200 µg/min)
62427611|NCT05277922|EXPERIMENTAL|Control group|4 µg nitroprusside (infusion rate 0.8 µg/min) 8 µg nitroprusside (infusion rate 1.6 µg/min) 16 µg nitroprusside (infusion rate 3.2 µg/min)
62427612|NCT00709475||A|
62427613|NCT06540300|EXPERIMENTAL|Effects of rTMS on NSSI|Exploring the effectiveness of rTMS intervention in NSSI patients using the Ottawa Self Injury Scale and other scales as research subjects
62427614|NCT06540300|EXPERIMENTAL|rs-fMRI-functional connectivity|Based on rs fMRI technology, imaging methods were used to analyze the brain images of patients and explore the changes in functional connectivity of brain regions before and after intervention in two groups of subjects.
62036144|NCT02158299|EXPERIMENTAL|Sapylin,Drainaging,reexamine|
62036145|NCT02158299|ACTIVE_COMPARATOR|Drainaging,reexamine|
62036146|NCT04126226|EXPERIMENTAL|Study group|
62036147|NCT04126226|NO_INTERVENTION|Control Group|
62036148|NCT01538381|EXPERIMENTAL|Afatinib|Afatinib given orally for 2 weeks after randomization till day -1 prior to surgery (day 0) at a dose of 40 mg/day
62036149|NCT01538381|OTHER|Observation|No treatment only observation
62036150|NCT05744895||Prospective Group- Robotic TKA Arm|Prospective TKA patient receiving total knee arthroplasty using the MAKO robotic machine
62036151|NCT05744895||Control- manual total Knee arthroplasty|Patients who have had a manual total knee arthroplasty
62036152|NCT04625712|EXPERIMENTAL|Group A (experimental arm, surgery intervention)|Cholecystectomy within the first week after a mild acute biliary pancreatitis.
62036153|NCT04625712|ACTIVE_COMPARATOR|Group B (active comparator, surgery intervention)|Cholecystectomy four weeks later a mild acute biliary pancreatitis.
62036154|NCT00818753|EXPERIMENTAL|Dabigatran 110 mg|experimental drug therapy in this indication
62036155|NCT00818753|EXPERIMENTAL|Dabigatran 150 mg|experimental drug therapy in this indication
62036156|NCT00818753|ACTIVE_COMPARATOR|Unfractionated Heparin|standard therapy in this indication as comparator
62036157|NCT00605436|EXPERIMENTAL|A|Restorative yoga therapy group: one orientation workshop for 3 hours, then twice-weekly group yoga therapy classes for first 5 weeks followed by once-weekly group yoga classes for another 5 weeks. The group will also be asked to practice their yoga postures at home for 30 minutes three times per week.
62036158|NCT00605436|NO_INTERVENTION|B|The control group is a wait-list control group with no active intervention.
62036159|NCT02085252|EXPERIMENTAL|Leuprorelin 11.25 mg|Active surveillance after a single subcutaneous injection of leuprorelin 11.25 mg and bicalutamide 50 mg, tablet, orally, once daily, to prevent flare-up for 15 days.
62036160|NCT02085252|NO_INTERVENTION|Active surveillance|Active surveillance is close medical monitoring of prostate cancer for any changes.
62813268|NCT05830500|NO_INTERVENTION|Observation|Observational group: prospectively and retrospectively collect data for patients who did not receive anlotinib hydrochloride capsules or similar small-molecule antivascular inhibitors (including Rearranged during transfection (RET) inhibitors, etc.).
62036161|NCT02844946|EXPERIMENTAL|ACT on Life|One day workshop aimed at providing Veterans with new tools and skills needed to pursue valued goals and directions in the face of life's challenges. Mindfulness, acceptance, values clarification, and goal-setting will be taught.
62036162|NCT02844946|NO_INTERVENTION|Treatment as Usual|Veterans will continue receiving care as usual.
62036163|NCT01409538|PLACEBO_COMPARATOR|Placebo|Asymptomatic control participants receive Natural History and Placebo instructions in a within-subject design. There are no patients, or active agents in this study. It is not a Clinical Trial.
62036164|NCT01409538|ACTIVE_COMPARATOR|Control condition|"The control condition represents a no-intervention, repeated baseline control, since the active intervention in this study is placebo."
62036165|NCT03753061|EXPERIMENTAL|Aspiration Catheter|Mechanical thrombectomy with Aspiration Catheter.
62036166|NCT03753061|ACTIVE_COMPARATOR|Stent Retriever (Solitaire FR)|Mechanical thrombectomy with Solitaire FR.
62036167|NCT04238806|ACTIVE_COMPARATOR|Desflurane Continuous|In Group 1 of 60 patients, desflurane inhalational agent was administered continuously during coronary artery bypass graft surgery with cardiopulmonary bypass. Anesthesia induction was administered to all patients with intravenous midazolam at a dose of 0.2 mg/kg, fentanyl at a dose of 5 to 10 µg/kg and rocuronium bromide at a dose of 0.1 mg. For maintenance, in Group 1 patients, desflurane inhalational agent was administered at an end-tidal concentration of 1 to 4% during the whole surgical procedure and intravenous maintenance midazolam at a dose of 0.03 mg/kg and fentanyl at a dose of 1 to 2 µg/kg every half an hour. In Group 1 of patients, during the whole surgical procedure, attention to keep mean arterial pressure above 50 mmHg was provided.
62036168|NCT04238806|ACTIVE_COMPARATOR|Desflurane Intermittent|In Group 2 of 60 patients, desflurane inhalational agent was administered intermittently during coronary artery bypass graft surgery with cardiopulmonary bypass. Anesthesia induction was administered to all patients with intravenous midazolam at a dose of 0.2 mg/kg, fentanyl at a dose of 5 to 10 µg/kg and rocuronium bromide at a dose of 0.1 mg/kg. For maintenance, in Group 2 patients, desflurane inhalational agent was administered at an end-tidal concentration of 1 to 4% before and after the cardiopulmonary bypass procedure as intermittently with the addition of intravenous maintenance midazolam at a dose of 0.03 mg/kg and fentanyl at a dose of 1 to 2 µg/kg every half an hour. In Group 2 of patients, during the whole surgical procedure, attention to keep mean arterial pressure above 50 mmHg was provided.
62036169|NCT02535273|EXPERIMENTAL|Low-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery"
62036170|NCT02535273|EXPERIMENTAL|Moderate-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery"
62427615|NCT04507789|EXPERIMENTAL|exercise intervention group|This group will be taken an exercise intervention during their radiotherapy programme.
62427616|NCT04507789|ACTIVE_COMPARATOR|routine radiotherapy protocol|This group will not be taken into an exercise intervention during their radiotherapy programme.
62427617|NCT01854073|ACTIVE_COMPARATOR|Group A|Group A, will receive injection Hyoscine butyl bromide 20 mg first dose at the time of amniotomy, and second dose 2 hours after.
62427618|NCT01854073|PLACEBO_COMPARATOR|Group B|Group B, will receive normal saline same volume first dose at the time of amniotomy, and second dose 2 hours after.
62427619|NCT05136456|ACTIVE_COMPARATOR|SHR1459 Low Dose|Drug: SHR1459 SHR1459 oral 24weeks
62427620|NCT05136456|ACTIVE_COMPARATOR|SHR1459 High Dose|Drug: SHR0302 SHR1459 oral 24 weeks
62427621|NCT05136456|PLACEBO_COMPARATOR|Placebo|Drug: Placebo Placebo oral 24 weeks
62427622|NCT04768023|PLACEBO_COMPARATOR|Control group|The group will receive placebo treatment.
62427623|NCT04768023|EXPERIMENTAL|Vitamin D3 group|The group will receive vitamin D3 supplementation.
62427624|NCT04189289|ACTIVE_COMPARATOR|ESP block group|Before anaesthesia induction; bilateral ESP block will be performed under the guidance of USG. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Standardized postoperative tramadol i.v. patient controlled analgesia (PCA) protocol will be performed (3 mg/ml, total volume 100 ml, 10 mg bolus dose, 20 min locked period, without continuous delivery, no basal infusion).
62427625|NCT04189289|SHAM_COMPARATOR|Control group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Standardized postoperative tramadol i.v. PCA analgesia protocol will be performed (3 mg/ml, total volume 100 ml, 10 mg bolus dose, 20 min locked period, without continuous delivery, no basal infusion).
62427626|NCT02390466|EXPERIMENTAL|VAC-3S|32µg/ml corresponding to 16µg/vaccination
62427627|NCT05355337|ACTIVE_COMPARATOR|Pramipexole|Pramipexole prolonged-release tablet, 0.26 mg base to 3.15 mg base / day for 9 weeks (individually varying dose titrating during these weeks).
62427628|NCT05355337|PLACEBO_COMPARATOR|Placebo|Tablets in appearance identical to the active comparator tablets, but without the the active substance (pramipexole).
62427629|NCT05355337|NO_INTERVENTION|Healthy controls|40 healthy controls who will carry out blood sampling, lumbar puncture and fMRI according to the same protocol as the depressed patients.
62813269|NCT04507412|EXPERIMENTAL|arm A|• 9 mg of i.v. dexamethasone
62813270|NCT04507412|NO_INTERVENTION|arm B|• no steroid supplementation
62813271|NCT02511665|EXPERIMENTAL|Metformin|Metformin given , 1g twice a day for 4 weeks until prostatectomy +/- one week
62036171|NCT02535273|EXPERIMENTAL|High-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery"
62036172|NCT02535273|PLACEBO_COMPARATOR|normal saline Control group|Intravenous injection normal saline equal quantity，completed within 10 minutes. Local anesthesia: lidocaine Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
62595632|NCT04446845|EXPERIMENTAL|Double Stimulation (Elonva+rFSH) in luteal /follicular phase|"A first stimulation Stimulation will initiate in the luteal phase of the menstrual cycle On day 21 of the previous cycle150mcg of corifollitropin alfa (Elonva, Merck Sharp \& Dohme (MSD), Spain) will be administrated and from day 8 of the stimulation when necessary, r-FSH of 250 IU per day will start until the day of ovulation trigger in a flexible gonadotropin-releasing hormone (GnRH) antagonist protocol. The first ovulation triggering will be induced with GnRH-agonist (triptorelin 0.2 ml). The embryos obtained from the first stimulation will be cryopreserved in a freeze-all approach.~A second stimulation will start on day 2 of bleeding after the first oocyte retrieval.~This time will correspond to a conventional COS where corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of Recombinant Human Chorionic Gonadotropin (rhCG)"
62595633|NCT04446845|ACTIVE_COMPARATOR|Conventional Stimulation (Elonva+rFSH) in follicular phase|A conventional COS where Corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of rhCG
62595634|NCT06400459|EXPERIMENTAL|IVW-1001 0.1%|IVW-1001 Ophthalmic Eyelid Wipe 0.1%
62595635|NCT06400459|EXPERIMENTAL|IVW-1001 0.2%|IVW-1001 Ophthalmic Eyelid Wipe 0.1%
62595636|NCT06400459|PLACEBO_COMPARATOR|IVW-1001 Placebo|Vehicle
62595637|NCT01047826|EXPERIMENTAL|M.I.P.O. Group|subjects who have been randomized to the M.I.P.O. group
62595638|NCT01047826|EXPERIMENTAL|Intramedullary Nail group|Subjects who have been Randomized to the I.M. group
62595639|NCT05748392|OTHER|Veraflo™ Cleanse Choice Complete™ Dressing Use with Assessments|Subject will have Veraflo™ Cleanse Choice Complete™ dressing applied and used per instructions for use. 3D imaging and wound / peri-wound skin characteristics will be taken during the treatment.
62595640|NCT00348790|EXPERIMENTAL|Vatalanib|"Patients will be treated with 500 mg of vatalanib, administered orally, twice a day for 28 days (1 cycle). Patients will start at a dose of 250 mg twice a day and increase by 250 mg per day every 7 days until 500 mg twice a day is reached.~Patients who are responding may remain on study treatment for 12 months."
62813272|NCT02511665|PLACEBO_COMPARATOR|Placebo|placebo given , 1g twice a day for 4 weeks until prostatectomy +/- one week
62813273|NCT02511665|EXPERIMENTAL|PET-MRI|5 patients in this arm will all receive metformin and undergo two additional PET- MRI scans, one before and one after treatment
62036173|NCT03371420|EXPERIMENTAL|124I-PU-AD|A single dose of 124I-PU-AD will be administered by intravenous (IV) injection
62595641|NCT01446133|EXPERIMENTAL|Untreated 65 +|"Patients with untreated SLL/CLL with indications for treatment that are age 65 or older.~Rituximab (375 mg/m2) will be given intravenously on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2. Lenalidomide will be started on Day 9 of cycle 1 at the dose of 10 mg/day and will be continued daily. Treatment duration will be 12 cycles and it will be possible to continue beyond 12 cycles if there is a significant benefit such as an ongoing Partial Response or Complete Response."
62036174|NCT06063135|NO_INTERVENTION|Control|Single life-style coaching session
62813274|NCT00774761|EXPERIMENTAL|1|
62813275|NCT00774761|EXPERIMENTAL|2|
62813276|NCT00774761|ACTIVE_COMPARATOR|3|
62813277|NCT00774761|ACTIVE_COMPARATOR|4|
62036175|NCT06063135|EXPERIMENTAL|Exercise Time 1|Physical exercise intervention taking place at one time of the day
62036176|NCT06063135|EXPERIMENTAL|Exercise Time 2|Physical exercise intervention taking place at another time of day
62237388|NCT03838107||Inpatients|Observation and measure of trajectory of recovery in CRPS. This group will include children diagnosed with CRPS and undergoing regular therapy at the inpatient FIRST clinic at CCHMC and one of their parents or legal guardian.
62237389|NCT03838107||Outpatients|Observation and measure of trajectory of recovery in CRPS. This group will include children diagnosed with CRPS and undergoing regular therapy at the outpatient Pain Management Center at CCHMC and one of their parents or legal guardian.
62813278|NCT00774761|ACTIVE_COMPARATOR|5|
62813279|NCT05605678||All Eligible Participants|All Participants diagnosed with severe HemA with or without inhibitors, moderately severe to severe HemB, or HemB with inhibitors will be enrolled and continue to receive their usual hemophilia treatment regimen under SOC therapy. Bleeding episodes and treatment data will be collected during the prospective follow up period in a diary. No intervention will be administered as part of this study.
62813280|NCT02819921|EXPERIMENTAL|Desvenlafaxine succinate 100mg|Titration with 50 mg Desvenlafaxine succinate tablet once daily for 1 week, then 2 tablets of 50mg Desvenlafaxine succinate tablet once daily for 3 weeks, then taper with 50 mg Desvenlafaxine succinate tablet once daily for 3 days.
62813281|NCT02819921|EXPERIMENTAL|Desvenlafaxine succinate 50mg|50 mg Desvenlafaxine succinate tablet once daily for 1 week, then 1 tablets of 50mg Desvenlafaxine succinate tablet and 1 tablet of 50mg placebo tablet once daily for 3 weeks, then 50mg placebo tablet once daily for 3 days.
62813282|NCT02819921|PLACEBO_COMPARATOR|Placebo|50 mg placebo tablet once daily for 1 week, then 2 tablets of 50mg placebo tablet once daily for 3 weeks, then 50 mg placebo tablet once daily for 3 days.
62813283|NCT04921982|EXPERIMENTAL|Propranolol|
62813284|NCT04921982|PLACEBO_COMPARATOR|Placebo|
62813285|NCT00582439|OTHER|1|Repair of Orthopaedic Trauma Fractures and Non-Unions
62813286|NCT06551051|EXPERIMENTAL|duloxetine|Patients were treated with duloxetine at a recommended dose of 40mg/day, increasing to a maximum dose of 60mg/day after seven days of non-significant discomfort.
62813287|NCT05408338|EXPERIMENTAL|Low Added Sugar Meal|Participants will be provided a meal low in added sugars.
62813288|NCT05408338|EXPERIMENTAL|High Added Sugar Meal|Participants will be provided a meal high in added sugars.
62427630|NCT06005337|ACTIVE_COMPARATOR|Group A - Sore Throat Swab, Cough and Cold, Asthma|"Group A will receive three of six blogshots (different to Group B) over a 4-week period (a different blogshot will be sent by email to them each week for three weeks, then in the final week they will receive the same three blogshots in one summary email to review). They will act as their own control group.~All participants from both groups will be asked to complete one baseline questionnaire at the start of the study and a follow-up questionnaire at week 5, month 3 and month 6 about different common acute childhood conditions, the blogshots and their content.~All participants can also participate in an optional semi-structured interview to give their thoughts on the blogshots and their experience in the study."
62427631|NCT06005337|ACTIVE_COMPARATOR|Group B - Ear Infection, Bronchiolitis, Antibiotics for Sore Throat|"Group B will receive three of six blogshots (different to Group A) over a 4-week period (a different blogshot will be sent by email to them each week for three weeks, then in the final week they will receive the same three blogshots in one summary email to review). They will act as their own control group.~All participants from both groups will be asked to complete one baseline questionnaire at the start of the study and a follow-up questionnaire at week 5, month 3 and month 6 about different common acute childhood conditions, the blogshots and their content.~All participants can also participate in an optional semi-structured interview to give their thoughts on the blogshots and their experience in the study."
62813289|NCT02962401|EXPERIMENTAL|Idelalisib and Obinutuzumab|"6 cycles of Idelalisib and Obinutuzumab~Cycle 1 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. (2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15~Cycle 2 - 6 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. day 1~Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment"
62813290|NCT01922544||Conventional group|In this group CS lead was implanted in a conventional manner.
62813291|NCT01922544||EP-catheter group|In this group coronary sinus was canulated using a steerable electrophysiology catheter.
62813292|NCT03496493||All patients|All patients enrolled in trial will have peripheral oxygen saturation simultaneously recorded with both study devices on non-adjacent (second and fourth) fingers of the same hand.
62813293|NCT04463771|EXPERIMENTAL|Group A - retifanlimab|Select participants naïve to checkpoint inhibitors will be administered retifanlimab intravenously
62427632|NCT05201820|NO_INTERVENTION|Standard of care|Epidural analgesia
62427633|NCT05201820|EXPERIMENTAL|Cryoanalgesia|Cryoanalgesia
62427634|NCT00515385|EXPERIMENTAL|1a|Cohort 1 completed
62427635|NCT00515385|PLACEBO_COMPARATOR|1b|Cohort 1 placebo completed
62427636|NCT00515385|EXPERIMENTAL|2a|Cohort 2 completed completed
62427637|NCT00515385|PLACEBO_COMPARATOR|2b|Cohort 2 placebo completed
62427638|NCT00515385|EXPERIMENTAL|3a|Cohort 3 active
62813294|NCT04463771|EXPERIMENTAL|Group B - retifanlimab|Select participants naïve to checkpoint inhibitors will be administered retifanlimab intravenously
62036177|NCT05238233|EXPERIMENTAL|Eye Dilation and Constriction|"Participants screened for hyperopia \>+1 diopter using a phoropter, have their intraocular pressures measured using a tono pen, and have their iridocorneal angle measured with a gonio lens.~Proparacaine hydrochloride 0.5% eye drops will be used to numb the eyes before measuring intraocular pressures and prior to gonio lens.~The following day, the participant will receive one drop of tropicamide and one drop of 1% pilocarpine in the left eye.~If the left eye has no response to the 1% pilocarpine, or if the diameter of the pupil returned to baseline size, we will ask participants to come back to the clinic on another day to have the process repeated in the right eye."
62036178|NCT01798927|OTHER|Ankle foot orthosis fitting|All participants will receive ankle foot orthosis or orthoses. Outcomes will be compared to pre-bracing findings.
62036179|NCT06605079|EXPERIMENTAL|Intervention|Intensive care unit patients in the intervention phase.
62427639|NCT00515385|PLACEBO_COMPARATOR|3b|Cohort 3 placebo
62427640|NCT00515385|EXPERIMENTAL|4a|Cohort 4 active
62427641|NCT00515385|PLACEBO_COMPARATOR|4b|Cohort 4 placebo
62427642|NCT00515385|EXPERIMENTAL|5a|Cohort 5 active
62427643|NCT00515385|PLACEBO_COMPARATOR|5b|Cohort 5 placebo
62427644|NCT05958810||Patients detected with Plasmodium falciparum (Artemether-lumefantrine)|Patients with mono-infection of Plasmodium falciparum with 1,000-100,000 asexual forms per µl
62427645|NCT02669628||Surgical technique|Laparoscopic ovarian cystectomy
62427646|NCT02669628||Alcohol sclerotherapy|US-aspiration and alcohol sclerosis
62427647|NCT05036239|EXPERIMENTAL|Exercised|One bout of 50 eccentric biceps curls
62427648|NCT05036239|NO_INTERVENTION|Control|No eccentric biceps curls
62813295|NCT04463771|EXPERIMENTAL|Group C - retifanlimab + epacadostat|Select participants who are allowed on prior checkpoint inhibitors will be administered retifanlimab intravenously in combination with oral epacadostat (IDO1 inhibitor)
62427649|NCT01665573|ACTIVE_COMPARATOR|PF-04457845|Acquisition of conditioning Administration of drug Extinction of conditioning
62036180|NCT06605079|ACTIVE_COMPARATOR|Control|Intensive care unit patients with routine treatment in the control phase.
62427650|NCT01665573|PLACEBO_COMPARATOR|Placebo|Placebo
62427651|NCT04591769|EXPERIMENTAL|Group T(Tapered- shaped)|Tracheal intubation using TaperedGuard Tracheal Tube
62036181|NCT01608074|EXPERIMENTAL|BRCA mutation carriers|"Women with BRCA1 or BRCA 2 mutation or a family history of breast/ovarian cancer.~Radical fimbriectomy. Histopathology SEE-FIM"
62036182|NCT00624299|EXPERIMENTAL|Botox|Botox
62427652|NCT04591769|ACTIVE_COMPARATOR|Group C(Cylindrical-shaped)|Tracheal intubation using Hi-Contour Tracheal Tube
62813296|NCT04463771|EXPERIMENTAL|Group D - retifanlimab + pemigatinib|Select participants who are allowed on prior checkpoint inhibitors will be administered retifanlimab intravenously in combination with oral pemigatininb (FGFR 1,2,3 inhibitor)
62813297|NCT04463771|EXPERIMENTAL|Group E - retifanlimab + epacadostat|Select participants naïve to checkpoint inhibitors will be administered retifanlimab intravenously in combination with oral epacadostat
62813298|NCT04463771|EXPERIMENTAL|Group F - retifanlimab + INCAGN02385 and INCAGN02390|Select participants who are allowed on prior checkpoint inhibitors will be administered retifanlimab in combination with INCAGN02385 and INCAGN02390 intravenously
62036183|NCT00624299|PLACEBO_COMPARATOR|Placebo|Saline injection
62036184|NCT06496997|EXPERIMENTAL|Group 1|100 ARDS patients
62036185|NCT06496997|EXPERIMENTAL|Group 2|100 ARDS patients
62036186|NCT06496997|EXPERIMENTAL|Group 3|100 ARDS patients
62036187|NCT03112018|ACTIVE_COMPARATOR|Standard care|"* Data strengthening~* modified Safe Childbirth Checklist (mSCC) implementation"
62237390|NCT03838107||Healthy Controls|For comparison purposes, healthy controls and one of their parents or legal guardian will be enrolled in this study as well.
62237391|NCT00559442|EXPERIMENTAL|1|high altitude exposure without prior acclimatization
62237392|NCT04773613|EXPERIMENTAL|Experimental SLP|Infant placed in a SLP on the researcher's lap. Head of the infant symmetrically placed between the shoulders, supported by the researcher's. Shoulder girdle higher than the pelvic girdle, head and back in a straight line - a slight natural bend of the body is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands)
62237393|NCT04773613|OTHER|Experimental SEP|Infant placed in a SEP on the researcher's lap. The head rests on the researcher's hand. Shoulder girdle higher than the pelvic girdle, head and back in a straight line at an angle of 30-45° to the ground - slight, natural body bend is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands)
62237394|NCT05997524|EXPERIMENTAL|Tras-Capox|
62813299|NCT04673318|NO_INTERVENTION|Control|Course of recovery with standard of care.
62813300|NCT04673318|ACTIVE_COMPARATOR|Exercise training|low resistance velocity based exercise training \~40 min, 3 times a week at home for 8 weeks
62036188|NCT03112018|EXPERIMENTAL|Enhanced care (intervention)|"* Data strengthening~* modified Safe Childbirth Checklist (mSCC) implementation~* Health provider training (PRONTO)~* Quality Improvement (QI) Cycles"
62237395|NCT03168386|EXPERIMENTAL|Intensive motor rehabilitation group|
62813301|NCT04673318|EXPERIMENTAL|heat therapy|heat therapy (\~40C skin temperature) with a leg garment 5 times a week for 40-55 min for 8 weeks
62813302|NCT06237725|EXPERIMENTAL|Nutrition of Continuous|Experimental: Intervention Group to Nutrition of Continuous
62813303|NCT06237725|NO_INTERVENTION|Control Group Nutrition of Continuous|Control Group to Nutrition of Continuous
62813304|NCT06237725|EXPERIMENTAL|Nutrition of Bolus|Experimental: Intervention Group to Nutrition of Bolus
62813305|NCT06237725|NO_INTERVENTION|Control Group Nutrition of Bolus|Control Group to Nutrition of Bolus
62036189|NCT05455099||obese group|Participants will be assigned to obese group (body mass index 24.0-27.9 kg/m²). Based on the inclusion criteria, 1200 overweight Han people（body mass index 24.0-27.9 kg/m²）and both sexes will be recruited in the analysis. The values of ultrafast pulse wave velocity will be obtained.
62237396|NCT02711488|EXPERIMENTAL|Intervention group|Combine primary prevention activities at the school level with secondary prevention at the household level
62237397|NCT02711488|NO_INTERVENTION|Control group|No intervention
62813306|NCT01866332|ACTIVE_COMPARATOR|Conventional Physical Therapy|Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
62813307|NCT01866332|EXPERIMENTAL|Conventional Physical Therapy plus Kinesiotaping|"Patients will receive conventional physical therapy plus an application of Kinesiotaping in their lumbar spine.~Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)."
62813308|NCT02070575||Pts with prostate cancer|This study is planned to determine the kallikrein panel of 200 patients presenting with biochemical recurrence (PSA ≥ 0.05ng/ml) after radical prostatectomy prior to any additional therapy or minimum post 1 year additional therapy.
62813309|NCT02962700|EXPERIMENTAL|CVVHF|CVVHF for 48 h interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
62237398|NCT02651077||Case Group|38 women with severe and deep endometriosis, aged 18 to 45 years old and hospitalized at Nantes University Hospital for surgical indication of endometriosis lesions ablation.
62237399|NCT02651077||Control Group|38 women aged 18 to 45 years old without suggestive signs of endometriosis
62237400|NCT00705835|EXPERIMENTAL|1|This is an ascending, multiple dose study in up to 18 patients. As many as eight patients are planned at each of two dose levels, intrapatient dose escalation is not allowed. Six patients will start on 50μg rsPSMA +0.5 mg Alhydrogel® Weeks 1,2,3 and 7.
62813310|NCT02962700|ACTIVE_COMPARATOR|IHD for 4 hours|"Intermittent haemodialysis was carried out during the first 4 h at day 1 and day 2 of the study period.~Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis."
62813311|NCT05605808|EXPERIMENTAL|Aerobic exercises and diet protocol group|The participant will be managed by aerobic exercise by using a treadmill, two times per week. Its intensity was equivalent to 60-85% of each patient's maximum heart rate and lasted 20 minutes in the first week and 30 minutes after the second week in addition to the diet protocol specific diet designed to boost the immune system through edible seeds and nuts which are rich in proteins, fats, fibers, minerals, and vitamins for twelve weeks.
62237401|NCT00705835|EXPERIMENTAL|2|This is an ascending, multiple dose study in up to 18 patients. As many as eight patients are planned at each of two dose levels, intrapatient dose escalation is not allowed. Eight patients will start on 250μg rsPSMA + 1.0 mg Alhydrogel Weeks 1,2,3 and 7
62036190|NCT05455099||overweight group|Participants will be assigned to overweight group (body mass index ≥ 28.0 kg/m²). Based on the inclusion criteria, 1200 obese Han people（body mass index ≥28.0 kg/m²） and both sexes will be recruited in the analysis. The values of ultrafast pulse wave velocity will be obtained.
62237402|NCT00553579||DE|All subjects will have clinically significant dry eye.
62427653|NCT05614388|EXPERIMENTAL|Study participants|The study procedure is universal to all the participants from both the institutes. There are no control arms defined separately. The groups within the participants include - include health care workers, non-medical hospital staff and medical students at ZMC; and faculty, students and supporting staff at the Pacchunga University College.
62427654|NCT01219088|NO_INTERVENTION|Controlled group|Spinal anesthesia with 0.5% bupivacaine alone
62595642|NCT01446133|EXPERIMENTAL|Prior Treatment Any Age|"Patients of any age with previously treated CLL/SLL and recurrent disease.~Rituximab (375 mg/m2) will be given intravenously on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2. Lenalidomide will be started on Day 9 of cycle 1 at the dose of 10 mg/day and will be continued daily. Treatment duration will be 12 cycles and it will be possible to continue beyond 12 cycles if there is a significant benefit such as an ongoing Partial Response or Complete Response."
62595643|NCT01103453|EXPERIMENTAL|Intervention Group|Study group are persons diagnosed as suffering from Mild Cognitive Impairment will undergo a series of 9 sessions on a computer program of a virtual supermarket to improve their Executive and IADL functions.
62595644|NCT06347900||Control group (Group1)|Normal control subjects
62595645|NCT06347900||Mild OSA (Group 2)|Cases with mild obstructive sleep apnea (RDI) with respiratory distress index 5-15
62237403|NCT05429151|ACTIVE_COMPARATOR|group 1|will be treated with intralesional injection of acyclovir (Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd) 250 mg acyclovir vial diluted with 3.5 ml saline to get approximately 70 mg/ml solution. During the study, the dosage of the drug and frequency of treatment were uniform in all patients. The base of each wart was injected with 0.1 ml of intralesional acyclovir (70 mg/ml) using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until the resolution of warts or for a maximum of 5 sessions
62595646|NCT06347900||Moderate OSA (Group 3)|Cases with mild obstructive sleep apnea (RDI) with respiratory distress index 15-30
62595647|NCT06347900||Sever OSA (Group4)|Cases with mild obstructive sleep apnea (RDI) with respiratory distress index \>30
62237404|NCT05429151|ACTIVE_COMPARATOR|group 2|will be treated by intralesional Candida antigen injection (candida antigen ) at a dose of 0.2 mL. injected into the largest wart using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until complete clearance of warts or for a maximum of 5 treatment sessions.
62427655|NCT01219088|ACTIVE_COMPARATOR|Femoral nerve block|Spinal anesthesia plus femoral nerve block with 20 mL of 0.25% bupivacaine
62595648|NCT02656290|EXPERIMENTAL|Edwards Pericardial Aortic Bioprosthesis Model 11000A|Pulmonary valve replacement
62237405|NCT05411367|EXPERIMENTAL|SI-614|
62427656|NCT01219088|ACTIVE_COMPARATOR|Intrathecal morphine|Spinal anesthesia plus 0.1 mg of intrathecal morphine
62427657|NCT01219088|ACTIVE_COMPARATOR|Periarticular bupivacaine infiltration|Spinal anesthesia plus periarticular infiltration with 20 mL of 0.25% bupivacaine
62427658|NCT04909125|ACTIVE_COMPARATOR|Hypofractionation Arm|40Gy / 15 fractions, 2.67Gy per fraction, over 3.5 week (9 fractions per fortnight)
62427659|NCT04909125|OTHER|Standard /Conventional fractionation Arm|50Gy / 25 fractions, 2Gy per fraction, over 5.5 week (9 fractions per fortnight)
62427660|NCT02768220|ACTIVE_COMPARATOR|Linagliptin|Eligible patients were randomized to receive linagliptin 5mg daily for 30 days.
62427661|NCT02768220|EXPERIMENTAL|Empagliflozin|Eligible patients were randomized empagliflozin 25mg daily for 30 days.
62427662|NCT01799213|EXPERIMENTAL|Active Treatment|Eligible subjects will be randomized to Meloxicam 15 mg po per day (QD) vs placebo
62427663|NCT01799213|PLACEBO_COMPARATOR|Placebo|Eligible subjects will be randomized to Meloxicam 15 mg po QD vs placebo
62427664|NCT01675869|EXPERIMENTAL|ETAM group|Executive Function/Metacognitive Training Program: An 8-week program, which addresses major areas of deficit in ADHD; namely, attention (the ability to concentrate and focus), inhibition (the ability to control ones behaviors), and memory (the ability to remember information).
62427665|NCT01675869|ACTIVE_COMPARATOR|Attention Control|Attention control group: An 8-week program which provides education regarding several topics relevant for preschool children including nutrition, sleep, temperament, etc.
62427666|NCT05422235|OTHER|Control Group|Subjects in this group will be asked to continue their routine medical treatment for 24 weeks.
62427667|NCT05422235|EXPERIMENTAL|Aerobic Exercise|In order to determine the exercise capacity of subjects, submaximal exercise test will be performed.Aerobic training will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks.
62427668|NCT05422235|EXPERIMENTAL|Aerobic Exercise+ Foot-Related Exercises|In addition to walking training specific to the subject in the 2nd group, special exercises will be given to the feet and ankles. These exercises will be aimed at stretching, strengthening, increasing sensory input. Treatment program will be done 3 days a week for 12 weeks. Participants will be followed for 24 weeks.
62427669|NCT00481871|EXPERIMENTAL|Pralatrexate & Gemcitabine - Sequential Days|
62595649|NCT01614782|EXPERIMENTAL|0.35 mg MK-5823 - Healthy Participants|
62595650|NCT01614782|EXPERIMENTAL|0.7 mg MK-5823 - Healthy Participants|
62595651|NCT01614782|EXPERIMENTAL|1.4 mg MK-5823 - Healthy Participants|
62036191|NCT03089918|EXPERIMENTAL|Part A (Healthy Adult Male Participants)|Participants will receive intravenous (IV) injection with 370 megabecquerel (MBq) 11C-JNJ-63779586 on Day 1 of Part A.
62595652|NCT01614782|EXPERIMENTAL|2.8 mg MK-5823 - Healthy Participants|
62813312|NCT05605808|ACTIVE_COMPARATOR|Diet protocol group|The participant will be managed by a specific diet protocol designed to boost the immune system through edible seeds and nuts which are rich in proteins, fats, fibers, minerals, and vitamins for twelve weeks.
62813313|NCT05605808|ACTIVE_COMPARATOR|Aerobic exercises group|The participant will be managed by aerobic exercise by using a treadmill, two times per week. Its intensity was equivalent to 60-85% of each patient's maximum heart rate and lasted 20 minutes in the first week and 30 minutes after the second week for twelve weeks as a total treatment time.
62427670|NCT00481871|EXPERIMENTAL|Pralatrexate & Gemcitabine - Same Day|
62427671|NCT03941223|EXPERIMENTAL|pectoral PECS II block|Ultrasound-guided PECS II block with ropivacaine 0.75% 20 ml (patients N = 75) + Parasternal ultrasound-guided block at T2, T4 levels with ropivacaine 0.375% 10 ml
62427672|NCT03941223|ACTIVE_COMPARATOR|Paravertebral nerve block|Ultrasound-guided paravertebral block with ropivacaine 0.75% 20 ml at T1-T2 and T3-T4 levels (10 ml each) (patients N = 75)
62427673|NCT01964898|EXPERIMENTAL|BA for cardiac patients who smoke|Behavioral Activation Treatment for cardiac patients who smoke (BAT-CS). Participant will receive (a) 1 hour of standard smoking cessation counseling in the hospital and (b) 5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management after they leave the hospital. BA sessions will occur over the 12 weeks after hospital discharge. An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
62595653|NCT01614782|EXPERIMENTAL|1.4 mg MK-5823 - Participants with T2DM|
62813314|NCT05298722|OTHER|Study arm|Imaging with CT-scan and MRI-DWI and peripheral blood samples for liquid biopsy
62813315|NCT03816696|EXPERIMENTAL|DTG followed by GSK3640254 followed by DTG+GSK3640254|Subjects will receive DTG 50 mg QD on Days 1 through 5 in Period 1 followed by a wash-out period of 4 days. Subjects will then receive GSK3640254 200 mg QD on Days 1 through 7 in Period 2 followed by co-administration of DTG 50 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Period 3.
62813316|NCT02590796||Hospitalised patients with delirium|hospitalised patients with delirium in general wards.
62813317|NCT02590796||Hospitalised patients with dementia/ no delirium|Hospitalised patients with a diagnosis of dementia who do not have delirium in general wards.
62813318|NCT02590796||Hospitalised patients with no delirium or dementia|Hospitalised patients with no delirium or dementia in general wards.
62036192|NCT03089918|EXPERIMENTAL|Part B (Mild AD and Healthy age- and Gender-Matched Controls)|Participants will receive single IV injection of 11C-JNJ-63779586 on Day 1 of Part B followed by saline flush. During Part B, the dose may be reduced based on whole body dosimetric findings and image quality seen in Part A.
62036193|NCT02389972||CML patients treated with dasatinib|Cohort of chronic myeloid leukemia patients treated with second-line dasatinib (Sprycel)
62237406|NCT05411367|PLACEBO_COMPARATOR|Vehicle|
62427674|NCT01964898|ACTIVE_COMPARATOR|Standard Care|Participant will receive (a) 1 hour of standard smoking cessation counseling in the hospital and (b) 5 packets of printed self-help materials for smoking cessation mailed 1, 3, 6, 9, and 12 weeks after hospital discharge. An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
62427675|NCT01897558|ACTIVE_COMPARATOR|Ventricular pacemaker electrode|receives an active fixation ventricular pacemaker electrode
62427676|NCT01897558|ACTIVE_COMPARATOR|Passive fixation ventricular pacemaker electrode|receives a passive fixation ventricular pacemaker electrode
62595654|NCT01614782|EXPERIMENTAL|2.8 mg MK-5823 - Participants with T2DM|
62595655|NCT03845361|EXPERIMENTAL|C. hand|Radial artery cannulation
62036194|NCT00988312|EXPERIMENTAL|s.c. vaccination|vaccine given subcutaneously
62036195|NCT00988312|EXPERIMENTAL|i.v. vaccination|vaccines are given intravenously
62036196|NCT01763944|ACTIVE_COMPARATOR|Low carbohydrate, lifestyle counseling|The Low carbohydrate arm will receive counseling to follow a carbohydrate restriction diet (\<20 grams per day) for 6 months.
62595656|NCT03845361|NO_INTERVENTION|N.C. hand|No cannulation of the radial artery
62595657|NCT02589249|PLACEBO_COMPARATOR|Placebo|placebo
62595658|NCT02589249|ACTIVE_COMPARATOR|AyuFlex1|AyuFlex1 (500 mg/d)
62595659|NCT02589249|ACTIVE_COMPARATOR|AyuFlex2|AyuFlex2 (1000 mg/d)
62813319|NCT02590796||Outpatients with dementia|People with a diagnosis of dementia who are living in the community.
62813320|NCT02590796||Healthy volunteers|Healthy volunteers who are living in the community who do not have a cognitive impairment.
62813321|NCT02590796||ICU delirium|Patients with delirium who are hospitalised in the intensive care units.
62813322|NCT02590796||ICU no delirium|Patients who do not have delirium who are hospitalised in intensive care units.
62813323|NCT04522895|EXPERIMENTAL|Consolidation Arm|Enasidenib (investigational product) will be started on day 1 for 28 days every 28 days for a maximum of 12 cycles. The starting dose of Enasidenib will be 100 mg once daily in every patient and may be reduced individually according to a dose modification scheme.
62813324|NCT06432634|SHAM_COMPARATOR|standard care group|Participants randomize to the standard care group (SC) receive the standard care already established in Chiayi Chang Gung Memorial Hospital. Standard care comprises one therapeutic education session conducted by a respiratory therapist 1-2 weeks before surgery.
62595660|NCT01891162||Control|Assessment will be carried out general quality of life beyond the functional evaluation of the pelvic floor through the PERFECT
62237407|NCT06341153|EXPERIMENTAL|Odor stimulation group|In the breast milk odor stimulation group, one or two drops of breast milk were placed on a sponge in accordance with the literature. Breast milk was obtained from each infant's own mother by hand expressing. The mothers were asked to express two drops of breast milk from their breasts onto the sponge. The sponge on which the breast milk was dripped was placed as close to the baby's nose as possible without touching the baby's nose. Since breast milk odor stimulation is recommended to be given to the baby for 1 minute in the literature, the baby was allowed to smell the odor of breast milk for 1 minute. The baby was then given to the mother for breastfeeding and breastfeeding was initiated as in routine practice.
62036197|NCT01763944|NO_INTERVENTION|Control|The control arm will receive no dietary intervention.
62237408|NCT06341153|EXPERIMENTAL|Odor + Taste Stimulation Group|In this group in which the breast milk sniffing method was applied; two drops of breast milk were dripped onto a sponge in accordance with the literature and this sponge was placed as close to the nose as possible without touching the nose and the baby was allowed to smell the smell of breast milk for about 1 minute. Then the baby was given to the mother. The mother was asked to express milk manually and to apply/drip approximately 0.2 ml (approximately two drops) of the expressed colostrum starting from the tip of the baby's tongue, along the tongue surface, on both cheeks of the baby, as applied in studies using oral colostrum as a reference. The mother was also asked to express a drop of milk from her breast and manually apply it to the areola. Breastfeeding was then initiated as in routine practice.
62427677|NCT05695079|ACTIVE_COMPARATOR|No cooling intervention (control)|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension
62427678|NCT05695079|EXPERIMENTAL|Fan generating low airflow|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension
62427679|NCT05695079|EXPERIMENTAL|Fan generating high airflow|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension
62427680|NCT06293573|EXPERIMENTAL|whole body vibration group|Group A (Study group): Will receive whole body vibration exercises with conventional progressive resistance exercises and diet modification life style
62427681|NCT06293573|EXPERIMENTAL|aerobic exercise group|Group B (Study group): Will receive aerobic exercises training with conventional progressive resistance exercises and diet modification life style.
62427682|NCT06293573|ACTIVE_COMPARATOR|conventional resistance exercise group|Group C (Control Group): will receive conventional progressive resistance exercises and diet modification life style
62595661|NCT01891162||Study|Will be held evaluate the quality of life for general and specific pelvic floor dysfunction beyond the functional assessment of the pelvic floor through the PERFECT.
62036198|NCT06303739|EXPERIMENTAL|Single Psilocybin Treatment|Participants will be administered one dose of a 25mg capsule of psilocybin. This will be administered one time.
62427683|NCT04965402|EXPERIMENTAL|Panel 1: Dose 1|
62427684|NCT04965402|EXPERIMENTAL|Panel 2: Dose 2|
62427685|NCT04965402|PLACEBO_COMPARATOR|Placebo|
62427686|NCT01682278||Amalgam cohort|Patients with medically unexplained physical symptoms attributed to dental amalgam restorations which the patient wish to have removed.
62595662|NCT05831696|EXPERIMENTAL|Powered Microprocessor-controlled Knee (PMPK)|"the Power Knee is a commercially available PMPK."
62036199|NCT06303739|ACTIVE_COMPARATOR|Two Psilocybin Treatments|Participants will be administered one dose of a 25mg capsule of psilocybin. Two weeks later, the participant will be administered one more dose of a 25mg capsule of psilocybin.
62036200|NCT04289818|NO_INTERVENTION|Control|Conventional Education Class
62036201|NCT04289818|EXPERIMENTAL|Coaching|Health Coaching
62036202|NCT01505296|ACTIVE_COMPARATOR|Antiarrhythmic drug|Class I or III antiarrhythmic drug
62036203|NCT01505296|EXPERIMENTAL|Catheter ablation|Pulmonary vein isolation
62595663|NCT00782184|EXPERIMENTAL|ezetimibe/simvastatin 10/40|Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, ezetimibe/simvastatin 10/40 was administered once daily in tablet form during the 6-week double-blind treatment period
62813325|NCT06432634|EXPERIMENTAL|comprehensive pulmonary rehabilitation program group|Participants randomize to the comprehensive pulmonary rehabilitation program group (CPRP) undergo an evidence-based and hospital-based comprehensive pulmonary rehabilitation program developed by the research group. This program is administered in addition to the standard care provided and spans across the preoperative, peri-operative, and postoperative periods, covering a total of 1-2 weeks preoperatively and 3-6 weeks postoperatively. CPRP involves warm-up and cool-down exercises, the aerobic training, and the resistance training. Additionally, participants are encouraged to continue exercising at home or in community sports facilities.
62813326|NCT00770653|EXPERIMENTAL|Pioglitazone 15 mg and Metformin 850 mg BID|
62237409|NCT06341153|NO_INTERVENTION|Control Group|The control group did not receive any intervention other than the routine initiation of breastfeeding at the clinic. They were provided with breastfeeding education by the lactation counselor.
62237410|NCT04846374||PowerPort Subjects|This study will involve a chart review of patients at UNC who were referred for change from a vortex port to a powerflow port.
62427687|NCT01682278||MUPS-cohort|Patients with medically unexplained physical symptoms without attribution to amalgam and no explicit wish to remove amalgam.
62813327|NCT00770653|ACTIVE_COMPARATOR|Glimepiride 2 mg and Metformin 850 mg BID|
62036204|NCT06193252|EXPERIMENTAL|Intervention|Large proportional increase in step count and minutes exerting moderate to vigorous physical activity (MVPA) relative to baseline level.
62813328|NCT06155526||active rest|patients taking an active rest after swimming sets
62813329|NCT06155526||passive rest|patients taking a passive rest after swimming sets
62813330|NCT01998750||Early-onset severe obesity|The study will enroll individuals with early onset severe obesity (BMI \> 99th percentile noted at an age \< 6 years of age). Individuals with a known history of early onset obesity are eligible, regardless of their current age.
62813331|NCT00841841|EXPERIMENTAL|Dipyrone|"Analgesic affectiveness using Dipyrone (500mg) as a postoperative drug for pain relief.~Intervention: Drug: dipyrone and acetaminophen"
62036205|NCT06193252|ACTIVE_COMPARATOR|Active control|Small proportional increase in step count and minute exerting moderate to vigorous physical activity (MVPA) relative to baseline level.
62237411|NCT03575143||PLWH+OSA|Subjects diagnosed with both Human Immunodeficiency Virus and Obstructive Sleep Apnea based on overnight sleep study
62237412|NCT03575143||PLWH-OSA|Subjects diagnosed with both Human Immunodeficiency Virus without Obstructive Sleep Apnea based on overnight sleep study
62237413|NCT03575143||PLWH?OSA|Those who signed consent but did not complete all the baseline assessments and overnight sleep study
62237414|NCT05114915|EXPERIMENTAL|Docetaxel for Injection-qw 3/4 regimen|Docetaxel for Injection (Albumin-bound) will be administrated once every week in the first three weeks (Day 1, 8 and 15) in every 28-day cycle, starting at a dose of 30 mg/m\^2.
62237415|NCT05114915|EXPERIMENTAL|Docetaxel for Injection-q2w 2/4 regimen|Docetaxel for Injection (Albumin-bound) will be administrated once every week every other week (Day 1 and 15) in every 28-day cycle, starting at a dose of 50 mg/m\^2.
62427688|NCT01682278||Dental cohort|Healthy comparison group: Subjectively healthy without diagnosed chronic disease or prescribed medication.
62427689|NCT00005578|EXPERIMENTAL|Arm 1|Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin hydrochloride and etoposide on days 0 and 1, bleomycin sulfate and vincristine sulfate on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Patients assigned to arm I receive only these drugs.
62427690|NCT00005578|EXPERIMENTAL|Arm 2|Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin hydrochloride and etoposide on days 0 and 1, bleomycin sulfate and vincristine sulfate on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Dexrazoxane hydrochloride on days 0, 1, and 7
62813332|NCT00841841|EXPERIMENTAL|Acetaminophen|"Analgesic affectiveness using Acetaminophen (750mg) as a postoperative drug for pain relief.~Intervention: Drug: dipyrone and acetaminophen"
62813333|NCT01260649|EXPERIMENTAL|ketamine|ketamine (0.5 mg/kg) followed by anesthetic agent titrated to sedation and succinylcholine titrated to muscle relaxation Right unilateral ECT at 5-6x seizure threshold three times a week
62813334|NCT01260649|PLACEBO_COMPARATOR|placebo|"IV saline, followed by anesthestic agent titrated to sedation and succinylcholine titrated to muscle relaxation.~Right unilateral ECT at 5-6x seizure threshold three times a week"
62813335|NCT05442840|NO_INTERVENTION|Control Arm|The participants in this arm will receive standard of care from their physician as they would have been doing previously. This still may involve blood work, referrals to other health providers (except pharmacist) and medication adjustments driven by the pharmacist.
62036206|NCT04154956|EXPERIMENTAL|SAR408701 (tusamitamab ravtansine)|Participants received tusamitamab ravtansine 100 milligrams per square meter (mg/m\^2) by intravenous (IV) infusion, once every 2 weeks (Q2W) until objective progressive disease (PD), unacceptable adverse event/toxicity, upon participant's request to stop treatment, or Investigator decision, whichever occurred first (maximum exposure: 147 weeks).
62036207|NCT04154956|ACTIVE_COMPARATOR|Docetaxel|Participants received docetaxel 75 mg/m\^2 by IV infusion, once every 3 weeks (Q3W) until objective PD, unacceptable adverse event/toxicity, upon participant's request to stop treatment, or Investigator decision, whichever occurred first (maximum exposure: 115 weeks).
62036208|NCT04344769||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
62036209|NCT04344769||Healthy individuals as controls|Age and gender-matched healthy controls
62237416|NCT05114915|EXPERIMENTAL|Docetaxel for Injection-qw 2/3 regimen|Docetaxel for Injection (Albumin-bound) will be administrated once every week in the first two weeks (Day 1 and 8) in every 21-day cycle, starting at a dose of 30 mg/m\^2.
62237417|NCT02959450|EXPERIMENTAL|Modified consistency and volume diet|Modified consistency diet, with a certain viscosity and controlled volume. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP.
62237418|NCT02959450|NO_INTERVENTION|Control Group|Standard treatment consisting of a modified consistency diet with adequate intake of energy and protein and general recommendations on diet prescribed by the treating physician
62237419|NCT00903955||Chronic Obstructive Pulmonary Disease|Subjects diagnosed with COPD are classified according to standards set forth by the Global Initiative on Obstructive Lung Disease. This study recruits subjects in each of three GOLD categories.
62237420|NCT04727320|EXPERIMENTAL|patient+TUDCA|
62237421|NCT04727320|PLACEBO_COMPARATOR|patient+placebo|
62237422|NCT06502873|OTHER|Crohn disease cohort|60 patients diagnosed with colonic or ileocolic Crohn disease
62237423|NCT06502873|OTHER|Control cohort|60 control patients without inflammatory bowel diseases
62237424|NCT01165645|EXPERIMENTAL|Arm I|Patients receive oral lopinavir and ritonavir twice daily for 28 days in the absence of disease progression or unacceptable toxicity.
62237425|NCT01165645|NO_INTERVENTION|Arm II|Patients receive no therapy.
62237426|NCT04731077|OTHER|Avenir Complete Femoral Stem|All enrolled subjects receive the study implant
62237427|NCT03819010|ACTIVE_COMPARATOR|Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Letrozole (2,5 mg/day during 28 days of each Cycle) + Palbociclib (125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer interventions: Letrozol (2,5 mg/day during 28 days of each Cycle)+ Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer
62237428|NCT03819010|ACTIVE_COMPARATOR|Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib|Letrozole (2,5 mg/day during 28 days of each Cycle) + Palbociclib (125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer interventions: Letrozol (2,5 mg/day during 28 days of each Cycle)+ Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer
62595664|NCT00782184|ACTIVE_COMPARATOR|atorvastatin 40 mg|Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, 40 mg atorvastatin was administered once daily in tablet form during the 6-week double-blind treatment period
62036210|NCT03902587||Cervical Elastography|During each sonogram in which cervical lengths are measured, 5 additional cervical indices will be collected using Samsung's E-cervix technology. Each index will then be separated based on characteristics to create a nomogram for singletons, twins, and those with interventions already in place (i.e. cerclage and/or progesterone) at the time of their E-cervix assessment.
62036211|NCT01857531|EXPERIMENTAL|Ganaxolone -- Nicotine Patch|"Pre-Quit Period:~Ganaxolone -- 400mg daily for the first 3 days, 800mg daily for the next 3 days and 1200mg daily for the remainder of the first 2 wks.~Nicotine Patches -- 21mg/24h nicotine patches applied daily during wks. 3 and 4.~Post-Quit Period:~Ganaxolone -- 1200mg daily for wk. 5, 800mg daily for 3 days, and 400mg daily for 3 days.~Nicotine Patches -- 21mg/24h for 4 wks., 14mg/24h for 1 wk., and 7mg/24h for 1 wk."
62036212|NCT02635880|EXPERIMENTAL|Investigational Enlighten Device|Laser treatment for removal of benign pigmented lesions (BPLs) with Nd:YAG dual-wavelength, dual-pulse duration laser.
62036213|NCT05812157|EXPERIMENTAL|Experimental group|Patients with aSp receiving fiber supplements in the form of Fibruline® Instant (Fagron laboratories)
62036214|NCT05812157|PLACEBO_COMPARATOR|Control group|Patients with aSp receiving fake fiber supplements (placebo) in the form of Maltodextrine (laboratoire Fagron).
62036215|NCT02916732||Module 1|Identification and monitoring of pregnant women who develop clinical signs of acute infection due to ZIKV (standard monitoring report)
62427691|NCT05882968||H. Pylori in CKD patients|100 0f patients with H.pylori with ckd according to GFR more than 60 according to kdigo guide lines
62595665|NCT03207542|EXPERIMENTAL|B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)|"Participants receive Daratumumab by vein over about 4 hours on Days 1, 8, 15, and 22 of Cycles 1 and 2, Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond.~Each cycle is 28 days."
62036216|NCT02916732||Module 2|Monitoring of pregnant women with a suspected embryofetopathy (standard monitoring report)
62427692|NCT05882968||H.pylori in normal renal function|100 of patients with H.pylori with normal renal function according to GFR less than 60 according to kdigo guide lines
62595666|NCT03207542|EXPERIMENTAL|T-Cell Precursor Acute Lymphoblastic Leukemia (ALL)|"Participants receive Daratumumab by vein over about 4 hours on Days 1, 8, 15, and 22 of Cycles 1 and 2, Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond.~Each cycle is 28 days."
62595667|NCT05445232|EXPERIMENTAL|LY3437943 + Drug Cocktail|"Midazolam in combination with warfarin and caffeine (drug cocktail) administered orally followed by LY3437943 administered subcutaneously (SC) in week 1.~At weeks 8, 12, \& 16, the LY3437943 will be administered SC on Day 1 followed by midazolam in combination with warfarin and caffeine (drug cocktail) administered orally on Day 2."
62595668|NCT06482723|EXPERIMENTAL|mGlobal L+AS|The investigated product mGlobal L+AS was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. Both sessions were conducted within 14 day intervals.
62595669|NCT01686191||Cardiac transplant recipients|
62595670|NCT03479359||Group 1|In this group, internship are given the pathology outcome of each prostate biopsy regularly twice a month.
62595671|NCT03479359||Group 2|In this group, internship are not given the pathology outcome of each prostate biopsy.
62595672|NCT04448132|EXPERIMENTAL|IPV-Al AJV|One dose of 0.5 mL of IPV-Al AJV injected intramuscularly perpendicular to the skin in the RIGHT deltoid muscle.
62595673|NCT05845567|EXPERIMENTAL|Givinostat + Clarithromycin|Givinostat and Clarithromycin Days 1 and 8, Givinostat 50 mg as oral suspension was administered as a single dose, 1 hour after Clarithromycin administration. From Day 4 to Day 10, Clarithromycin 500 mg film-coated tablet was administered twice a day.
62595674|NCT06393257|EXPERIMENTAL|Oscillation and Lung Expansion|
62036217|NCT02916732||Module 3|Trimester biological collection of all pregnant women during the outbreak of Zika (standard monitoring report)
62036218|NCT02916732||Module 4|Biological collection of maternal blood and cord blood collected during the delivery
62036219|NCT02916732||Module 5|Biological collection of maternal blood and fetal tissues of pregnant women whose pregnancies started during the outbreak of Zika , ends in an spontaneous abortion, Induced abortion or intrauterine fetal demise
62036220|NCT02998281|ACTIVE_COMPARATOR|Treatment Group|The treatment group received Inspiratory muscle training (IMT) at 40% of maximal mouth pressure (PImax) by using Threshold IMT and training loads were adjusted to maintain 40% of the PImax weekly. The PImax was measured at supervised sessions each week, and 40% of the measured value was determined as the new training work load.
62036221|NCT02998281|SHAM_COMPARATOR|Control Group|The control group received sham Inspiratory muscle training (IMT) at a fixed work load, 5% of PImax by using Threshold IMT.
62036222|NCT06395662||ARISE cohort|n=87, clinicaltrials.gov NCT02739542
62036223|NCT06395662||TERIS cohort|n=90, clinicaltrials.gov NCT03122652
62036224|NCT06395662||OFSEP cohort|OFSEP, n=75
62036225|NCT06395662||SFSEP cohort|SFSEP, n=75
62427693|NCT02257827|EXPERIMENTAL|IMRT- Hypofractionated schedule 70 Gy/25 fx|The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.By the linear-quadratic formula, considering an α/β ratio of 1.5 Gy for prostate cancer, 70 Gy/25 fractions is equivalent to 86 Gy in 43 fractions of 2 Gy. All patients were simulated on CT simulator.
62427694|NCT02257827|ACTIVE_COMPARATOR|3DCRT-Hypofractionated schedule 70 Gy/25 fx|The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy. By the linear-quadratic formula, considering an α/β ratio of 1.5 Gy for prostate cancer, 70 Gy/25 fractions is equivalent to 86 Gy in 43 fractions of 2 Gy. All patients were simulated on CT simulator.
62595675|NCT06393257|ACTIVE_COMPARATOR|postural drainage|
62595676|NCT01128218|EXPERIMENTAL|Phase 1 Dose Level 1 (10mg/kg)|Dose Level 1: Participants were given a one-time, single-dose administration of oral 10mg/kg Aminolevulinic Acid (5-ALA)
62595677|NCT01128218|EXPERIMENTAL|Phase 1 Dose Level 2 (20mg/kg)|Dose Level 2: Participants were given a one-time, single-dose administration of oral 20mg/kg Aminolevulinic Acid (5-ALA)
62595678|NCT01128218|EXPERIMENTAL|Phase 1 Dose level 3 (30mg/kg)|Dose Level 3: Participants were given a one-time, single-dose administration of oral 30mg/kg Aminolevulinic Acid (5-ALA)
62595679|NCT01128218|EXPERIMENTAL|Phase 1 Dose level 4 (40mg/kg)|Dose Level 4: Participants were given a one-time, single-dose administration of oral 40mg/kg Aminolevulinic Acid (5-ALA)
62595680|NCT01128218|EXPERIMENTAL|Phase 1 Dose level 5 (50mg/kg)|Dose Level 5: Participants were given a one-time, single-dose administration of 50mg/kg Aminolevulinic Acid (5-ALA)
62595681|NCT01128218|EXPERIMENTAL|Phase 2 (40mg/kg)|Phase 2: Participants were given a one-time, single-dose administration of 40mg/kg Aminolevulinic Acid (5-ALA)
62036226|NCT06395662||Subset of serum and cerebrospinal biomarkers|As a validation group, the best subset of serum and cerebrospinal biomarkers from Objective 2a will be tested in a separate group of RIS patients. Their association with the same outcomes (clinical relapse and magnetic resonance imaging measurements of disease severity/activity) will be measured using the same regression techniques as in Objective 2a. This subset will consist of the remaining third of RIS patients from the SFSEP, OFSEP, and ARISE cohorts with serum and cerebrospinal fluid available (n=60)
62036227|NCT04989959|EXPERIMENTAL|Pre-Surgical|Patients with suspected RCC planned for surgery
62036228|NCT04989959|EXPERIMENTAL|Metastatic or VHL Syndrome|Patients with metastatic ccRCC or VHL syndrome and RCC
62036229|NCT04989959|EXPERIMENTAL|Planned belzutifan treatment|Patients with VHL syndrome with RCC, CNS hemangioblastoma, and/or pancreatic neuroendocrine tumor(s) planning to start belzutifan.
62036230|NCT06358573|EXPERIMENTAL|Cohort A experimental|"Intervention 1-2 weeks:~- 2 Injections of INT230-6 into primary tumor of the breast~Thereafter~* Standard of Care including surgery (30 weeks)~* Immuno-chemotherapy -\> 24 weeks~Neoadjuvant therapy as Keynote-522 (Standard of Care) - 24 Weeks~Pembrolizumab q3W in combination with~* Cycles 1-4: Paclitaxel q1W + Carboplating q1W or q3W~* Cycle 5-8: Doxorubicin or Epirubicin q3W + Cyclophospahmide q3W~* MRI~* Surgery"
62036231|NCT06358573|OTHER|Cohort B Standard of Care|"Intervention 1-2 weeks:~- No intervention - start of immune-chemotherapy after randomization~Thereafter~* Standard of Care including surgery (30 weeks)~* Immuno-chemotherapy -\> 24 weeks~Neoadjuvant therapy as Keynote-522 (Standard of Care) - 24 Weeks~Pembrolizumab q3W in combination with~* Cycles 1-4: Paclitaxel q1W + Carboplating q1W or q3W~* Cycle 5-8: Doxorubicin or Epirubicin q3W + Cyclophospahmide q3W~* MRI~* Surgery"
62036232|NCT06541262|EXPERIMENTAL|Phase I- Dose level 1|Silmitasertib 600 mg/m2 twice a day plus Neuroblastoma: Regimen A: Irinotecan and Temozolomide Sarcoma: Regimen B: Vincristine, Irinotecan and Temozolomide
62036233|NCT06541262|EXPERIMENTAL|Phase I- Dose level 2|Silmitasertib 800 mg/m2 twice a day plus Neuroblastoma: Regimen A: Irinotecan and Temozolomide Sarcoma: Regimen B: Vincristine, Irinotecan and Temozolomide
62237429|NCT03907410|EXPERIMENTAL|Arm 1: Incentives, plus reminders & feedback (IRF)|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).~During the Experiment period (Months 1-3), Arm 1 will receive the IRF intervention.~During the Observation period (Months 4-6), all the arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
62237430|NCT03907410|ACTIVE_COMPARATOR|Arm 2: Reminders & feedback ONLY|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).~During the Experiment period (Months 1-3), Arm 2 will receive ONLY reminders and feedback, without nominal financial incentives.~During the Observation period (Months 4-6), all three arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
62237431|NCT03907410|NO_INTERVENTION|Arm 3 (Control)|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).~During the Experiment period (Months 1-3), Arm 3 will not receive any component of the IRF intervention.~During the Observation period (Months 4-6), all three arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
62237432|NCT04023721|EXPERIMENTAL|Cohort 1 - Inarigivir Soproxil Alone|Cohort 1, 400 mg Inarigivir daily for 24 weeks and after treatment discontinuation will be followed for a further 18 months.
62237433|NCT04023721|EXPERIMENTAL|Cohort 2 Arm A - Inarigivir Soproxil and NUC|Cohort 2, Arm A, 400 Inarigivir daily in addition to their prestudy nucleoside/nucleotide (NUC) analogue inhibitors for 48 weeks. At Week 48 subjects will stop both inarigivir and the NUC and be followed for a further 48 weeks off treatment.
62237434|NCT04023721|EXPERIMENTAL|Cohort 2 Arm B - Inarigivir Soproxil and NUC|Cohort 2, Arm B, 400 mg Inarigivir daily plus prestudy nucleoside/nucleotide (NUC) analogue inhibitors for at least 24 weeks and up to 48 weeks. After treatment discontinuation of both inarigivir and the NUC, subjects will be followed off treatment up to Week 96.
62237435|NCT04190420||Patients|250 patients with primary hypertension
62237436|NCT04190420||Healthy Controls|60 healthy control subjects, matched in age and gender
62237437|NCT01907802|EXPERIMENTAL|Treatment (dabrafenib)|Patients receive dabrafenib PO BID on days 1-28 (QD on day 1 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62237438|NCT01601847|ACTIVE_COMPARATOR|Sustained|Infants will remain on 400 IU/day of cholecalciferol until 6 months of age adjusted for prematurity, regardless of dietary intake
62237439|NCT01601847|PLACEBO_COMPARATOR|Diet-Limited|Infants will receive placebo once their dietary intake of vitamin D has exceeded 200 IU/day
62237440|NCT00409253|ACTIVE_COMPARATOR|Urapidil|
62237441|NCT00409253|ACTIVE_COMPARATOR|Nicardipine|
62237442|NCT05332184||Patients prior to aortic valve surgery|
62237443|NCT05329545|EXPERIMENTAL|XMT-1536 (upifitamab rilsodotin)|XMT-1536 (upifitamab rilsodotin)
62427695|NCT00795782|EXPERIMENTAL|UniCND|Limited/ipsilateral central lymph node dissection
62237444|NCT05329545|PLACEBO_COMPARATOR|Placebo|Saline placebo will be administered with same schedule and stopping rules as for the assigned interventions in the Experimental Arm.
62237445|NCT02882932|OTHER|Super Oxidized Solution|Procedure/Surgery: Super Oxidized Solution(SOS) in group I - SOS with normal saline solution was used
62427696|NCT00795782|ACTIVE_COMPARATOR|BiCND|Comprehensive/bilateral central lymph node dissection
62427697|NCT00795782|NO_INTERVENTION|NoCND|No central lymph node dissection
62427698|NCT04157361||Asthma|Children/adults with moderate or IgE mediated asthma with inhaled and/or food allergies before and during inhaled corticosteroid, leukotriene modifiers or long-acting beta agonists treatment.
62813336|NCT05442840|ACTIVE_COMPARATOR|Pharmacist Intervention Arm|The participants in this arm will receive standard of care from their physician in addition to pharmacist intervention. The pharmacist or pharmD intern leads the diabetes care for the patient typically, conducting a medication review, recommending medication changes, frequent follow up and requesting blood work and providing referrals to other health care providers as needed,which is standard care
62813337|NCT02547311|EXPERIMENTAL|Team Clinic Intervention|Middle School and High School Team Clinic Intervention
62237446|NCT02882932|OTHER|normal saline|"Procedure/Surgery: normal saline~In group II - patients underwent normal saline wash and bacterial load was noted."
62427699|NCT04157361||Cystic fibrosis|Children/adults with cystic fibrosis before and after antibiotics treatment and during clinical deterioration.
62813338|NCT02547311|NO_INTERVENTION|Standard Clinical Care - Control|Standard Clinical Care - Control
62036234|NCT06541262|EXPERIMENTAL|Phase II- Relapsed/refractory Neuroblastoma|Silmitasertib RP2D twice a day plus Irinotecan and Temozolomide
62036235|NCT06541262|EXPERIMENTAL|Phase II- Relapsed/refractory Ewing sarcoma|Silmitasertib RP2D twice a day plus Vincristine, irinotecan and temozolomide
62036236|NCT05942001|EXPERIMENTAL|HRS-5041|
62036237|NCT05596045|EXPERIMENTAL|ASC10|Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
62036238|NCT05596045|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive placebo
62036239|NCT02363556|EXPERIMENTAL|Misoprostol Alone|Subjects enrolled into this arm of the study will receive misoprostol 400-mcg only.
62036240|NCT02363556|EXPERIMENTAL|Dilapan with Misoprostol|Subjects enrolled into this arm of the study will receive Dilapan with 400-mcg misoprostol.
62036241|NCT04240366|OTHER|Group 1|Balloon-based ablation of atrial fibrillation by pulmonary vein isolation alone
62036242|NCT04240366|EXPERIMENTAL|Group 2|Balloon-based ablation of atrial fibrillation by pulmonary vein and left atrial appendage isolation
62237447|NCT05342220|ACTIVE_COMPARATOR|Remote Ischemic Preconditioning|Remote ischemic preconditioining
62237448|NCT05342220|SHAM_COMPARATOR|Control|Sham preconditioning
62237449|NCT04029350|EXPERIMENTAL|Anlotinib Combined With Osimertinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle. Osimertinib 80mg p.o, qd. It should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
62237450|NCT00913354|EXPERIMENTAL|1|30 minutes of acupuncture just before and just after embryo replacement
62427700|NCT04157361||Healthy control|Healthy control children/adults without chronic or autoimmune disease
62813339|NCT05665036|EXPERIMENTAL|SIG-005|SIG-005 is comprised of human native alpha-L-iduronidase enzyme (hIDUA) producing spheres
62813340|NCT04761601|EXPERIMENTAL|Dose Finding as Monotherapy - Part 1|
62813341|NCT04761601|EXPERIMENTAL|Expansion as Monotherapy - Part 2|
62813342|NCT04761601|EXPERIMENTAL|Dose Finding in Combination - Part 3|
62813343|NCT05400135|EXPERIMENTAL|Qungasvik Intervention Group|Qungasvik implements intervention modules creating episodes of Yup'ik cultural engagement. In traditional Yup'ik practices prior to formal western schooling, the education and training of young people included introduction to cultural protocols, knowledge, and values while learning skills through participation in daily activities of family and community life such as subsistence, tool-building, and ceremony (Rasmus, Charles, \& Mohatt, 2014). The intervention manual provides outlines for 18 modules described as teachings, and conducted at the individual, family, or community level through one or more 1-3 hour sessions. Each module promotes 2-4 of a total of 13 protective factors.
62813344|NCT03732339|EXPERIMENTAL|GILUPI CellCollector®|
62237451|NCT00913354|PLACEBO_COMPARATOR|2|Sham acupuncture for 30 minutes just before and just after embryo transfer
62427701|NCT01755611|EXPERIMENTAL|A(reference)/B(test)|initial administration of reference and cross-over to test
62595682|NCT02879656|OTHER|Cohort 1|"Early ustable fracture:~Phase 1:~After closed reduction, if satisfactory reduction is not achieved fulfilling the inclusion criteria, the patient is allocated to Cohort 1. The patient is randomized to either non-operative (=Arm 1) or operative treatment (=Arm 2). Patients allocated to non-operative treatment will undergo a standard treatment protocol. Patients allocated to operative treatment will undergo a surgery with volar locking plate with modified Henry's volar approach."
62036243|NCT06351566|ACTIVE_COMPARATOR|Vitamin D3 + Prebiotics|
62427702|NCT01755611|EXPERIMENTAL|B(test)/A(reference)|initial administration of test and cross-over to reference
62427703|NCT01188161||Normal subjects|Volunteers without a history of dizzyness or vertigo
62427704|NCT00256100|ACTIVE_COMPARATOR|One|Enoxaparin Sodium (Clexane ) is to be used in the control arm of the study
62427705|NCT00256100|ACTIVE_COMPARATOR|Two|Fondaparinux will be used as the anticoagulant in the sencond arm of the study
62427706|NCT02533323|EXPERIMENTAL|P-Gemox|P-Gemox:gemcitabine :1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days.
62427707|NCT03779685|ACTIVE_COMPARATOR|General anesthesia|Breast cancer surgery (Tumor Stage 1-3, Nodes 0-2 as determined according to the NCI stage definitions http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page3/print)
62427708|NCT03779685|EXPERIMENTAL|Regional anesthesia|Breast cancer surgery (Tumor Stage 1-3, Nodes 0-2 as determined according to the NCI stage definitions http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page3/print)
62427709|NCT00085852|EXPERIMENTAL|Single|Treatment with BLVR
62427710|NCT03611751|EXPERIMENTAL|BMS-986165|BMS-986165 oral administration
62595683|NCT02879656|OTHER|Cohort 2|"Early stable fracture:~Phase 1:~After closed reduction, if satisfactory position is achieved, the patient is allocated to Cohort 2 and conservative treatment is performed as usually.~Phase 2:~Patients allocated to Cohort 2, will visit orthopedic outpatient clinic in 1 week in the hospital where the treatment was initially started. If reduction is maintained the patient will undergo standard follow-up visits. If reduction is lost to fulfill the inclusion criteria for surgery the patient is asked to participate to phase 2 of this study. After the patient´s enrollment has been confirmed and informed consent is signed, the patient is randomized to either non-operative (=Arm 3N) or operative treatment (=Arm 3O). If allocated to non-operative treatment patient will undergo the same protocol as those in the Arm 1. Patients allocated to operative treatment will undergo surgery with volar locking plate with standard volar approach."
62595684|NCT06560229|EXPERIMENTAL|Intervention|Monthly $100 grocery gift cards for 12 months
62595685|NCT06560229|NO_INTERVENTION|Standard of Care|Can receive in-hospital social work referral if determined appropriate by clinical care team (also true for intervention group)
62036244|NCT06351566|ACTIVE_COMPARATOR|Vitamin D3 + Prebiotics placebo|
62237452|NCT04536753||Suspected large for gestational age (LGA)|Women with pregnancies suspected to be complicated by fetuses weighing more than the 90th centile on customised growth chart and induced for this reason prior to 287 days as the main indication without diabetes.
62427711|NCT03611751|PLACEBO_COMPARATOR|Placebo|Placebo oral administration
62237453|NCT04536753||Women with diabetes (DM)|Women with diabetes in pregnancy induced at between 259 and 266 days if on treatment and 273 days if gestational diabetes managed with diet alone.
62427712|NCT03611751|ACTIVE_COMPARATOR|Active comparator|Active comparator oral administration
62427713|NCT05991570|OTHER|case|Use of vedio assisted thoracoscopic surgery in exploration in diagnosis and treatment of chest trauma patients whos heamodynamically stable
62427714|NCT05991570|OTHER|control|exploratory thoracotomy inchest trauma patients in failure of vedio assisted thoracoscopic surgery or in haemodynamically instable patients
62427715|NCT03334526|EXPERIMENTAL|healthy volunteers|
62427716|NCT01431417||Healthy volunteers|Healthy volunteers, less than 35 years old and presenting with no shoulder condition
62427717|NCT01431417||Patients with rotator cuff condition|Patients with rotator cuff condition, conservative treatment indicated
62237454|NCT04536753||Control|All other women induced at or after 280 days of gestation
62427718|NCT01431417||Patients with shoulder instability|Patients with shoulder instability, conservative treatment indicated
62427719|NCT01431417||Patients with proximal humerus fracture|Patients with diaphyseal humerus fracture or subcapital humerus fracture treated surgically or conservatively, at 6 weeks post stabilization. (Surgical and conservative treatment will be considered as the same population from the functional point of view as functional outcome is similar) (Handoll et al. 2003).
62036245|NCT06351566|ACTIVE_COMPARATOR|Prebiotics +Vitamin D3 placebo|
62036246|NCT06351566|PLACEBO_COMPARATOR|Vitamin D3 placebo + Prebiotics placebo|
62237455|NCT00438347||group 1|Intervention Group- aerobic exercise
62237456|NCT00438347||group 2|Control Group- stretching and toning
62427720|NCT01431417||Patients with frozen shoulder|Patients with frozen shoulder, conservative treatment indicated
62595686|NCT05045027|EXPERIMENTAL|Basic science (MRI, metabolic imaging, tissue collection)|"AIM 1: Previous scan data from healthy subjects is collected and analyzed.~AIM 2: Patients undergo MRI. Patients also undergo collection of tissue samples for IHC analysis.~AIM 3: Patients undergo multinuclear metabolic imaging before and after immunotherapy and prior to surgical resection."
62595687|NCT06163742|ACTIVE_COMPARATOR|Standard-of-Care|
62595688|NCT06163742|EXPERIMENTAL|Product X|
62813345|NCT02945579|EXPERIMENTAL|Cohort A|"* Neoadjuvant chemotherapy therapy~* Biopsy: if no disease remaining - stay on the study and receive radiation (skip breast surgery)~* H\&P and Imaging every 6 months~Treatment (whole breast irradiation, EBRT) Within 12 weeks of completing neoadjuvant systemic therapy, patients undergo whole breast irradiation over 15-25 fractions on consecutive days. Patients then undergo EBRT boost over 7 fractions on consecutive days beginning the day following completion of whole breast irradiation."
62237457|NCT05295888|EXPERIMENTAL|Experimental Arm|130Hz TI stimulation (total 2700 sec): ramp-up (30-60 sec) =\> stimulation (130Hz, 2mA per electrode pair, 4mA total, 2580-2640 sec) =\> ramp-down (30-60sec)
62595689|NCT01070667|EXPERIMENTAL|Dronedarone|Patients will receive 400 mg of dronedarone per day for 3 months.
62813346|NCT02945579|EXPERIMENTAL|Cohort B|"* Neoadjuvant endocrine therapy for 6 months~* Radiation if there is less than 25% tumor increase~* Biopsy: if negative - additional endocrine therapy under the guidance of medical oncologist (skip breast surgery)~* H\&P and Imaging every 6 months~Cohort B Radiation:~Treatment (Stereotactic ablative radiotherapy -SABR) Following 3-6 months of endocrine therapy, if less than 25% tumor increase, patients undergo SABR irradiation over 10 fractions every other business day."
62813347|NCT02945579|EXPERIMENTAL|Cohort C|"* Optional biopsy for nanomechanical biomarker assessment~* Neoadjuvant chemotherapy therapy~* Surgery (\& optional biopsy nanomechanical biomarker assessment): if no disease remaining - stay on the study and skip radiation~* H\&P and Imaging every 6 months"
62813348|NCT02945579|EXPERIMENTAL|Cohort D|"* Optional biopsy for nanomechanical biomarker assessment~* Chart review every year after surgery for 5 years~* Eligible patients who have undergone the optional biopsy may later move to Cohort A or C if they meet all eligibility requirements and desire radiation omission."
62813349|NCT06262152||Patients with Septo-optic dysplasia, visual deficit and agenesis of corpus callosum|"* age 3-18 years~* availability of at least 2 serial sleep EEGs performed during clinical follow-up~* stable drug therapy in the last three months"
62813350|NCT00387881|PLACEBO_COMPARATOR|Placebo|
62813351|NCT00387881|EXPERIMENTAL|Treximet|
62813352|NCT06378021|EXPERIMENTAL|Calcium chloride injection in ganglionated plexis for Atrial Fibrillation alleviation post CABG|The Patients in the intervention arm will be injected with Calcium chloride in the 4 major atrial ganglionated plexis after the by pass is completed.
62813353|NCT06378021|PLACEBO_COMPARATOR|patients who will receive their regular standard of care without calcium chloride injection|A group of patients who will undergo Coronary artery bypass graft surgery will be injected with normal saline in the ganglionic Plexus during Coronary artery bypass graft to act as a comparator to determine if calcium chloride injection alleviate Atrial fibrillation post surgery
62813354|NCT02991183|EXPERIMENTAL|Acceptance and Commitment Therapy|Two half day (2.5 hours) group ACT sessions delivered one week apart followed by a third session 2 weeks following the second session.
62813355|NCT05526560||Patients requiring replacement of their native or prosthetic mitral valve|Patients requiring replacement of their native or prosthetic mitral valve
62813356|NCT03058120|NO_INTERVENTION|Stress testing|Patient with chest pain, low risk by modified HEART score, undergoes whatever admission and stress testing plan is determined by ED and inheriting decision unit physicians.
62237458|NCT05295888|SHAM_COMPARATOR|Sham Arm|Sham stimulation (total 2700 sec): ramp-up (30-60 sec) =\> ramp-down (30-60 sec) =\> stimulation (130Hz, 0mA, 2520-2610 sec) =\> ramp-down (30-60 sec)
62237459|NCT04342832|ACTIVE_COMPARATOR|Early invasive treatment (cryoballoon ablation)|
62813357|NCT03058120|ACTIVE_COMPARATOR|Early discharge|Patient with chest pain, low risk by modified HEART score, is discharged from the emergency room without admission nor stress testing.
62813358|NCT05302674|EXPERIMENTAL|Hot Dry|The participant will complete four hours of work at a 45:15 work rest cycle in a 98°F (36.7°C) and 20% relative humidity environment.
62237460|NCT04342832|NO_INTERVENTION|Standard medical care|
62237461|NCT01062633|EXPERIMENTAL|A, observation|dietary supplement
62237462|NCT01062633|EXPERIMENTAL|B|dietary supplement
62237463|NCT01062633|EXPERIMENTAL|C|dietary supplement
62595690|NCT01070667|PLACEBO_COMPARATOR|Placebo|Patients will receive a placebo tablet once per day for 3 months. AF burden and other parameters described will be monitored from the participants permanent pacemaker. Participants will also be asked to fill out symptom diaries and questionaires.
62427721|NCT01000545|PLACEBO_COMPARATOR|placebo gelcaps + best medical treatment|Patient will receive 4 placebo gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c \< 7.0%) and BP control (BP\< 130/80)
62595691|NCT06623812|ACTIVE_COMPARATOR|Animal Protein|A standardized typical lunch test meal consists of an animal-based protein source (Animal Protein). The total weight of meal, total energy served, as well as energy from macronutrients are standardized across the three test meals.
62595692|NCT06623812|ACTIVE_COMPARATOR|Plant Protein 1 with lower DIAAS Score (lower protein quality)|A standardized typical lunch test meal consists of a plant-based protein source with a lower DIAAS Score (Plant protein 1- lower protein quality). The total weight of meal, total energy served, as well as energy from macronutrients are standardized across the three test meals.
62595693|NCT06623812|ACTIVE_COMPARATOR|Plant Protein 2 with higher DIAAS Score (higher protein quality)|A standardized typical lunch test meal consists of a plant-based protein source with a higher DIAAS Score (Plant protein 2- higher protein quality). The total weight of meal, total energy served, as well as energy from macronutrients are standardized across the three test meals.
62595694|NCT04737395|EXPERIMENTAL|"Device-assisted therapy (Meditouch,MSQUARE)"|40 hours of therapy with the the Hand Tutor (MediTouch) device and a wearable vest (MSQUARE) for arm rehabilitation
62595695|NCT04676958|PLACEBO_COMPARATOR|Placebo|380 mg capsule/day micro-crystalline cellulose
62813359|NCT01983475|PLACEBO_COMPARATOR|Placebo|A group of participants will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
62813360|NCT01983475|EXPERIMENTAL|Denosumab|A group of participants will be randomized to the experimental group and will have Denosumab (Prolia, 60 mg SC) administered at baseline, 6 and 12 months.
62813361|NCT00079326|EXPERIMENTAL|Treatment (trastuzumab, ixabepilone)|Patients receive trastuzumab IV over 30-90 minutes and ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62595696|NCT04676958|ACTIVE_COMPARATOR|Vitamin K2|380 mg capsule/day micro-crystalline cellulose including 240ug/day Vitamin K2
62595697|NCT06041308||Bioprothetic valve|Groups undergoing cardiac valve surgery with bioprothetic valve.
62595698|NCT06041308||Mechanical valve|Groups undergoing cardiac valve surgery with mechanical valves.
62595699|NCT06018558|EXPERIMENTAL|Phase1 Dose Escalation- Low Dose (2.5×10E10 vg/mL):|Low Dose (2.5×10E10 vg/mL): Subjects will receive a subretinal injection of OCU410 in the low dose concentration.
62813362|NCT00555958|EXPERIMENTAL|A|All study subjects will be implanted with the Maestro System, and all will receive VBLOC therapy.
62595700|NCT06018558|EXPERIMENTAL|Phase1 Dose Escalation- Medium Dose (5×10E10 vg/mL):|Medium Dose (5×10E10 vg/mL): Subjects will receive a subretinal injection of OCU410 in the medium dose concentration.
62595701|NCT06018558|EXPERIMENTAL|Phase1 Dose Escalation- High Dose (1.5×10E11 vg/mL):|High Dose (1.5×10E11 vg/mL): Subjects will receive a subretinal injection in the high dose concentration.
62813363|NCT06676657|EXPERIMENTAL|iPancreas automated insulin delivery system|Participants will use the iPancreas automated insulin delivery system for 4 weeks at home. After 3 weeks of collecting high blood sugar pattern data, the high blood sugar pattern detection and dosing feature will be turned on.
62813364|NCT04237467||Older transgender men|This cohort will consist of transgender men aged 50-75 years old who have taken testosterone for at least one year.
62813365|NCT04237467||Younger transgender men|This cohort will consist of transgender men aged 18-40 years old who have taken testosterone for at least one year.
62813366|NCT00298324|ACTIVE_COMPARATOR|Myfortic|Patients in this arm will receive Myfortic + Prednisone + Cyclosporine
62813367|NCT00298324|OTHER|Standard Care/ Placebo|In this arm patients will receive Prednisone + Cyclosporine + Placebo or Prednisone + Cyclosporine
62813368|NCT02534376|EXPERIMENTAL|Treatment|Vytorin (ezetimibe 10mg-simvastatin 40mg)
62427722|NCT01000545|ACTIVE_COMPARATOR|SLX 500LRU/day + best medical treatment|Patient will receive 1 SLX gelcap and 3 placebo gelcaps twice a day.Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c \< 7.0%) and BP control (BP\< 130/80)
62427723|NCT01000545|ACTIVE_COMPARATOR|SLX 1000LRU/day + best medical treatment|Patient will receive 2 SLX gelcaps and 2 placebo gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c \< 7.0%) and BP control (BP\< 130/80)
62813369|NCT05672251|EXPERIMENTAL|Treatment (oncastuximab tesirine, mosunetuzumab)|Patients receive loncastuximab tesirine IV and mosunetuzumab IV on study. Patients also undergo PET/CT scan, biopsy, and collection of blood samples on study.
62813370|NCT01298479||Group 1|All subjects
62813371|NCT06482346|EXPERIMENTAL|MT-3534|Intravenous (IV)
62813372|NCT06482346|PLACEBO_COMPARATOR|Placebo|Intravenous (IV)
62813373|NCT02544321|ACTIVE_COMPARATOR|Bromocriptine QR|4 weeks of investigational drug Bromocriptine QR
62813374|NCT02544321|PLACEBO_COMPARATOR|Placebo|4 weeks of placebo
62813375|NCT00474812|EXPERIMENTAL|Dasatinib Treatment|Patients receive oral dasatinib twice daily on days 1-28.
62813376|NCT01546103|ACTIVE_COMPARATOR|Vitamin D3 supplementation of 1000 IU|
62813377|NCT01546103|ACTIVE_COMPARATOR|Vitamin D3 supplementation of 5000 IU|
62427724|NCT01000545|ACTIVE_COMPARATOR|SLX 2000LRU/day + best medical treatment|Patient will receive 4 SLX gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c \< 7.0%) and BP control (BP\< 130/80)
62427725|NCT05088824||patients diagnosed with oblique inguinal hernia|
62427726|NCT06539273|EXPERIMENTAL|Experimental|Intervention group
62427727|NCT02020655||10 healthy volunteers|Shear- force model
62427728|NCT04268784|EXPERIMENTAL|DNL343|Cohort A: Single-ascending dose; Cohort B: Multiple-ascending doses
62427729|NCT04268784|PLACEBO_COMPARATOR|Placebo|Cohort A: Single-ascending dose; Cohort B: Multiple-ascending doses
62427730|NCT06485492|EXPERIMENTAL|Single arm|
62427731|NCT02105831||CEU skeletal muscle perfusion imaging|Heart failure with LVAD Contrast ultrasound skeletal muscle perfusion imaging
62427732|NCT04437537||Pilot Group|Ten subjects with a DFU non-responsive to standard of care for a minimum of treatment period of 28 days.
62427733|NCT02665611|EXPERIMENTAL|intervention group|"intervention for improvement of treatment adherence Intervention group- This group will be followed by the MOMA call center (By the MOMA nures every couple weeks and by the study coordinatore and the treating Doctor at special visits as the study required.) The group will be monitored according to number of parameters, including treatment Adherence."
62427734|NCT02665611|EXPERIMENTAL|control group|"treatment as usual Control group- Treatment will continue as usual by the Doctor.(This group will allso be followed by the Study Coordinator at the same visits as the Intervention group.The group will be monitored according to number of parameters, including treatment Adherence."
62595702|NCT06018558|EXPERIMENTAL|Phase 2 Dose Expansion: Maximum tolerated dose (MTD) from Phase 1-Randomized Arm|Maximum tolerated dose (MTD) from Phase 1: Subjects will receive a subretinal injection in the MTD concentration.
62813378|NCT02367573|ACTIVE_COMPARATOR|2D TAPP|Trans-abdominal pre-peritoneal laparoscopic inguinal hernia repair operated with two dimensional view
62813379|NCT02367573|EXPERIMENTAL|3D TAPP|Trans-abdominal pre-peritoneal laparoscopic inguinal hernia repair operated with three dimensional view
62813380|NCT01279434|EXPERIMENTAL|Vitamin E plus Pentoxiphyllin|
62813381|NCT01279434|ACTIVE_COMPARATOR|Vitamin E|
62813382|NCT02122016|EXPERIMENTAL|SmartCare|A computer driven weaning ventilator, using closed-loop ventilation, taking into account patients lung mechanics and exhaled CO2.
62813383|NCT02122016|ACTIVE_COMPARATOR|Conventional weaning protocol|A conventional weaning protocol consisting of a daily weaning screen, which is performed by physiotherapist. All patients who are mechanically ventilated for more than 24 hours are given a spontaneous breathing trial.
62427735|NCT01715415|EXPERIMENTAL|ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62813384|NCT00107653|EXPERIMENTAL|Latino|Participants received peginterferon alfa-2a 180 microgram (mcg)/0.5 mL by subcutaneous injection once a week in combination with ribavirin 1000 or 1200 mg per day, which was taken orally in split doses for 48 weeks. Participants with \<75 kg (165 lbs) of body weight received 1000 mg/day (400 mg in the morning and 600 mg in the evening). Participants with \>=75 kg (165 lbs) of body weight received 1200 mg/day (600 mg in the morning and 600 mg in the evening).
62813385|NCT00107653|EXPERIMENTAL|Non-Latino White|Participants received peginterferon alfa-2a 180 mcg/0.5 mL by subcutaneous injection once a week in combination with ribavirin 1000 or 1200 mg per day which was taken orally in split doses. Participants with \<75 kg (165 lbs) of body weight received 1000 mg/day. Participants with \>=75 kg (165 lbs) of body weight received 1200 mg/day for 48 weeks.
62813386|NCT05716477||Screening (biospecimen collection)|Participants undergo blood specimen collection and complete survey on study. Participants may optionally undergo standard of care FIT testing on study.
62813387|NCT03724942|EXPERIMENTAL|Brexpiprazole|
62595703|NCT06018558|EXPERIMENTAL|Phase 2 Dose Expansion: Lower Dose from Phase 1-Randomized Arm|Subjects will receive a subretinal injection of OCU410 in a Lower Dose concentration.
62595704|NCT06018558|NO_INTERVENTION|Control Arm|No Intervention Control Arm: Subject will not receive any active study intervention
62595705|NCT06090409|EXPERIMENTAL|Free/Subsidized Community Supported Agriculture (CSA) produce along with education.|Patients who self-elect to enroll in subsidized/free Community-supported agriculture produce shares will also receive Education on the benefits of a plant-based diet.
62595706|NCT06090409|ACTIVE_COMPARATOR|Education Alone|Patients will receive educational information about the benefits of plant-based eating.
62595707|NCT01232881||Tumor and Serum Collection|"Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.~Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib."
62595708|NCT06622447|EXPERIMENTAL|βGluCnCs arm|"After a two-week run-in phase, participants (N=60) were randomly assigned to the βGluCnCs arm (N=40)~During the intervention period, βGluCnCs arm participants received 1 stick (1.4 g/stick) of βGluCnCs product three times daily for a total of 12 weeks."
62237464|NCT03979560|NO_INTERVENTION|Control|"The control group will benefit from the usual support (depending on the practices of the department, prescription or not of oral nutritional supplements and physiotherapy at home, but without home intervention of adapted physical activity professionals or dieticians).~In addition to screening/inclusion visits (D0), three follow-up home visits are scheduled at D7, D45 and D90 for both study groups."
62036247|NCT04339036|EXPERIMENTAL|Oral CapTem + Y90 Radioembolization|"Capecitabine 750 mg/m2 twice daily orally for 14 days and temozolomide 200 mg/m2 orally on Days 10-14, with 14 days between cycles, to be continued until 1) disease progression or 2) intolerable toxicities.~Trans-arterial radioembolization (TARE) on Day 7 of cycle 2 and, if needed for the other lobe, Day 7 of either cycle 3 or 4."
62036248|NCT00889538|PLACEBO_COMPARATOR|Placebo|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
62036249|NCT00889538|ACTIVE_COMPARATOR|Glutathione|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
62036250|NCT00889538|ACTIVE_COMPARATOR|Glutathione, Vit C and NAC|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
62595709|NCT06622447|EXPERIMENTAL|Placebo arm|"After a two-week run-in phase, participants (N=60) were randomly assigned to the placebo arm (N=20)~During the intervention period, placebo arm participants received 1 stick (1.4 g/stick) of placebo product (microcrystalline cellulose ) three times daily for a total of 12 weeks."
62595710|NCT04993508|EXPERIMENTAL|Arm A|Men with PI-RADS 4/5 or PI-RADS 3 in conjunction with PSAD ≥ 0.15 that are randomized into arm A will undergo only targeted MRI/US fusion-guided biopsies. Men with PI-RADS 3 and PSAD \> 0.15 with negative biopsy results will receive a follow-up MRI annually and PSA every 6 months for 3 years. In case of upgrade to PI-RADS 4/5, men will be re-biopsied. Men with PI-RADS 4/5 without cancer diagnosis or with clinically insignificant cancer in the subsequent biopsy will be offered an additional MRI inbore biopsy. If MRI inbore biopsy is negative or with clinically insignificant cancer, men will be followed-up with MRI annually and PSA every 6 months for 3 years. In the case of persistent PI-RADS 4/5, men will be re-biopsied.
62036251|NCT04211038|EXPERIMENTAL|healthy subjects|Firstly, increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive. Secondly, do incremental cycle ergometry test with the assisstance of NPPV.
62036252|NCT04211038|EXPERIMENTAL|COPD subjects|Firstly, increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive. Secondly, do incremental cycle ergometry test with the assisstance of NPPV.
62036253|NCT03756103|EXPERIMENTAL|SPH3127 tablet Dose 1|Low-dose group
62036254|NCT03756103|EXPERIMENTAL|SPH3127 tablet Dose 2|Mid-dose group
62036255|NCT03756103|EXPERIMENTAL|SPH3127 tablet Dose 3|High-dose group
62036256|NCT03756103|PLACEBO_COMPARATOR|SPH3127 tablet Placebo|Placebo Control group
62036257|NCT05077787|EXPERIMENTAL|Experimental Group|Neonates recruited in experimental group will receive massage therapy and kinaesthetic stimulation for 15 minutes along with phototherapy for consecutive days . It will be given in three phases first massage therapy will be given for 5 minutes, followed by movement of limbs for 5 minutes and then again massage therapy will be repeated for 5 minutes.
62036258|NCT05077787|NO_INTERVENTION|Control Group|Neonates recruited in control group will receive phototherapy alone along with regular care
62427736|NCT01715415|EXPERIMENTAL|Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62813388|NCT03562195|EXPERIMENTAL|Mepolizumab 100mg|Participants received 100mg of Mepolizumab subcutaneously every 4 weeks during the total treatment period of 52 weeks in addition to their baseline Standard of Care (SOC) treatment for asthma. Participants received salbutamol as a rescue medication on need basis.
62813389|NCT03562195|PLACEBO_COMPARATOR|Placebo|Participants received placebo matching to Mepolizumab administered subcutaneously every 4 weeks during the total treatment period of 52 weeks in addition to their baseline SOC treatment for asthma. Participants received salbutamol as a rescue medication on need basis
62813390|NCT06379789|EXPERIMENTAL|Part 1: Cohort 1 Dose Escalation for RDE|Starting dose to determine the RDE of REGV131-LNP1265 and further assess the safety, tolerability, and FIX functional activity data at the RDE
62813391|NCT06379789|EXPERIMENTAL|Part 1: Cohort 2 Dose Escalation for RDE|Dose 2 of ascending dose level cohorts to determine the RDE of REGV131-LNP1265 and further assess the safety, tolerability, and FIX functional activity data at the RDE
62813392|NCT06379789|EXPERIMENTAL|Part 1: Cohort 3 Dose Escalation for RDE|Dose 3 of ascending dose level cohorts to determine the RDE of REGV131-LNP1265 and further assess the safety, tolerability, and FIX functional activity data at the RDE
62036259|NCT04699266|EXPERIMENTAL|Experimental: POD F GF IOL Implantation|Experimental: POD F GF IOL Implantation experimental Multi-center, single-arm, non-masked study Mono- or bilateral implantation of trifocal intraocular lenses POD F GF
62036260|NCT03203369|EXPERIMENTAL|Part 1: Dose Escalation|A single intravenous administration of UCART123. Dose escalation in Part 1 will include 3 doses ranging from 6.25 x 10\^5 cells/kg to 6.25 x 10\^6 cells/kg and continue until the Recommended Phase 2 Dose (RP2D) is identified.
62036261|NCT03203369|EXPERIMENTAL|Part 2: Dose Expansion|A single intravenous administration of UCART123 at the RP2D. 2 Cohorts: Patients with Relapsed/Refractory BPDCN and Newly Diagnosed BPDCN.
62427737|NCT02911779|OTHER|change of medilateral angle line|change of medilateral angle line during crowning of the head
62427738|NCT03969667||healthy young adults|healthy young adults
62427739|NCT00566215|EXPERIMENTAL|1|Duodenal exclusion plus total omentectomy
62427740|NCT00566215|ACTIVE_COMPARATOR|2|Duodenal exclusion without omentectomy
62427741|NCT04244994|OTHER|Intervention and Control|Self-taken penile meatal swabs versus first-catch urine for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium using Aptima-Combo2 and Aptima Mgen
62427742|NCT05647200|ACTIVE_COMPARATOR|T (Treatment)|The most optimal prime fluid from part I (based on the effect on perfused vessel density) + additional albumin during cardiopulmonary bypass.
62595711|NCT04993508|ACTIVE_COMPARATOR|Arm B|Men with PI-RADS 4/5 or PI-RADS 3 in conjunction with PSAD ≥ 0.15 that are randomized into arm B will undergo targeted MRI/US fusion-guided biopsies and systematic biopsies (standard of care). Men with PI-RADS 3 and PSAD \> 0.15 with negative biopsy results will receive a follow-up MRI annually and PSA every 6 months for 3 years. In case of upgrade to PI-RADS 4/5, men will be re-biopsied. Men with PI-RADS 4/5 without cancer diagnosis or with clinically insignificant cancer in the subsequent biopsy will be offered an additional MRI inbore biopsy. If MRI inbore biopsy is negative or with clinically insignificant cancer, men will be followed-up with MRI annually and PSA every 6 months for 3 years. In the case of persistent PI-RADS 4/5, men will be re-biopsied.
62813393|NCT06379789|EXPERIMENTAL|Part 1: Cohort 4 Dose Escalation for RDE|Dose 4 of ascending dose level cohorts to determine the RDE of REGV131-LNP1265 and further assess the safety, tolerability, and FIX functional activity data at the RDE
62427743|NCT05647200|SHAM_COMPARATOR|C (control)|The most optimal prime fluid from part I (based on the effect on perfused vessel density) + additional ringers during cardiopulmonary bypass.
62427744|NCT05777070|EXPERIMENTAL|Remote Ischemic Conditioning (RIC)|RIC is achieved via blood pressure cuff inflation to at least 20 mmHg above systolic blood pressure to 250 mmHg on the more involved arm. RIC involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. RIC is performed on visits 1-7.
62813394|NCT06379789|EXPERIMENTAL|Part 2: Dose Expansion A|Participants ≥18 Years of Age will receive the RDE of REGV131-LNP1265 determined by Part 1
62813395|NCT06379789|EXPERIMENTAL|Part 2: Dose Expansion B|Participants ≥12 to \<18 Years of Age will receive the administered weight-adjusted RDE of REGV131-LNP1265 determined by Part 1
62813396|NCT06379789|EXPERIMENTAL|Part 2: Dose Expansion C|Participants ≥2 to \<12 Years of Age will receive the administered weight-adjusted RDE of REGV131-LNP1265 determined by Part 1
62813397|NCT02787928|EXPERIMENTAL|Intrathecal Dilaudid|This will be a prospective up/down dosage study. After obtaining informed consent, eligible participants will be part of an up/down dose titration study. This first phase of our study will be conducted using intrathecal (spinal) hydromorphone to determine an appropriate dose range for our study population. Study drug dose will initially be 40 mcg. The only deviation from the current standard of care will be that patients will be given hydromorphone intrathecally instead of morphine. The rest of the care provided will be standard of care and per current practices at VCU labor and delivery floor.
62813398|NCT00442169|EXPERIMENTAL|Group 1: WN02 Low Dose (Part 1)|Low Dose in healthy adults in Part 1 against a placebo control.
62813399|NCT00442169|EXPERIMENTAL|Group 2: WN02 Medium Dose (Part 1)|Medium dose level in part one healthy subjects against a placebo control.
62813400|NCT00442169|EXPERIMENTAL|Group 3: WN02 High Dose (Part 1)|High dose level in part one healthy subjects against a placebo control
62813401|NCT00442169|PLACEBO_COMPARATOR|Group 4: Placebo (Part 1)|Participants will receive a single dose of saline in Part 1 on Day 0
62813402|NCT00442169|EXPERIMENTAL|Group 5: WNO2 High Dose (Part 2)|Participants enrolled in Part 2 and received a single dose of West Nile Virus vaccine.
62813403|NCT00442169|PLACEBO_COMPARATOR|Group 6: Placebo (part 2)|Participants will receive a single dose of saline in Part 2 on Day 0
62813404|NCT00691613|EXPERIMENTAL|1|EPO
62813405|NCT00691613|PLACEBO_COMPARATOR|2|NaCl
62595712|NCT04993508|OTHER|Arm C|Men with PI-RADS 3 in conjunction with PSAD \< 0.15 will not be biopsied, but followed-up with MRI annually and PSA every 6 months for 3 years.
62595713|NCT04993508|OTHER|Arm D|Men with PI-RADS 1 or 2 will not be biopsied, but followed-up with PSA every 6 months for 3 years. A control MRI will be performed after 3 years. At any time, a follow-up can be performed in case of clinical suspicion of PCa or a relevant PSA increase (\> 1.0 ng/ml/a).
62595714|NCT05370586|EXPERIMENTAL|PENG block: Study group|Patients enrolled in the study group will receive a PENG block with 20 mL of 0,375% levobupivacaine with 4 mg of dexamethasone. The block will be performed with the patient in a supine position using an 18-gauge, 90 mm needle, inserted with an in-plane lateral to medial approach. Operators will use the original technique described by Girón-Arango L et al. The aim of this block is to inject the local anaesthetic between the psoas tendon and the iliopubic eminence. We will instruct operators to routinely use a curvilinear probe (2-6 MHz) or a linear probe (4-16 MHz) in particularly lean or cachectic patients.
62595715|NCT05370586|OTHER|Infrainguinal fascia iliaca block: Control group|"Patients allocated in the control group will receive an infrainguinal fascia iliaca block with 30 mL of 0,25 % levobupivacaine with 4 mg of dexamethasone, using an 18-gauge, 90 mm needle, inserted with an in-plane lateral to medial approach.~The probe (linear 4-16 MHz) is placed transversely at the inguinal crease to identify the femoral artery, femoral nerve, iliopsoas muscle and the fascia iliaca over the psoas muscle. Moving the probe laterally the sartorius muscle and the anterior inferior iliac spine (AIIS) can be identified. After skin disinfection the needle is inserted placing the tip beneath the fascia iliaca at the lateral third of a line between the AIIS and pubic tubercle. Correct needle placement is confirmed by separation of the fascia iliaca from the iliopsoas muscle upon injection, with local anaesthetic spreading towards the FN medially and the iliac crest laterally."
62427745|NCT05777070|SHAM_COMPARATOR|Sham conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 25 mmHg on the more involved arm. RIC involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. RIC is performed on visits 1-7.
62427746|NCT01543607|EXPERIMENTAL|Treatment|Radiofrequency ablation catheter
62427747|NCT04127968|EXPERIMENTAL|intervention group|Septic children with vitamin A deficiency who will receive vitamin A supplementation.
62427748|NCT04127968|PLACEBO_COMPARATOR|control group|Septic children with vitamin A deficiency who will receive placebo.
62427749|NCT03853356||Lumbar spondylodesis involving 1-2 levels (L4-L5 and/or L5-S1)|All surgical procedures to be performed during this clinical trial are part of the routine procedures for lumbar spondylodesis by using transforaminal lumbar interbody fusion (TLIF) and posterior lumbar interbody fusion (PLIF) techniques in the 1-2 levels (L4-L5 and/or L5-S1). Patients will receive surgery according to standard procedures.
62427750|NCT04717999|EXPERIMENTAL|UWN2D CAR-T|
62427751|NCT05756868|EXPERIMENTAL|Time restricted feeding|The participants in the intervention group will receive a time restricted feeding intervention (first meal at 10:00, last meal at 18:00) for 6 weeks. Meals of the participants are planned as 8 hours of eating and 16 hours of fasting.
62427752|NCT05756868|NO_INTERVENTION|Control|Participants in the control group will not receive any dietary intervention. All participants were asked to continue in the same way they were fed before starting the study throughout the study.
62427753|NCT00667498|EXPERIMENTAL|1|
62595716|NCT05685134|EXPERIMENTAL|Ablation|Radiofrequency catheter ablation of the abnormal - prolonged and fragmented - electrophysiologic substrate of Brugada syndrome
62595717|NCT05685134|SHAM_COMPARATOR|Control|Femoral venous punctions, catheter insertion, programmed electrical stimulation and electroanatomic mapping, with a similar duration to the ablation procedure
62595718|NCT05367271|EXPERIMENTAL|Botulinum Toxin A (BTX-A)|20 units of Onabotulinum A in 200 µL of saline
62595719|NCT05367271|ACTIVE_COMPARATOR|Corticosteroid|1 mL of 4 mg/mL dexamethasone with 2 mL of 1% lidocaine OR 1 mL of 4 mg/mL dexamethasone, 1 mL of 2% lidocaine and 1 mL saline
62427754|NCT00667498|PLACEBO_COMPARATOR|2|
62427755|NCT05417490||Group with PRADO|"All patients seen in hospital and for whom the doctor will choose whether or not to offer one of the 2 solutions, alone or in combination, will be considered as included in the study, and their non-objection will be collected.~Subsequently, patients will benefit from follow-up for 6 months: V0 inclusion visit- V1 telephone contact at 1 month only for patients participating in one of the 2 programs and V2 consultation at 6 months. The 0 and 6M (6 months) visits are part of the usual follow-up of patients hospitalized for heart failure.~Administration of questionnaires:~* Girerd's questionnaire : The objective is to measure the medication compliance of patients during treatment~* SSQ6 (Social Support Questionnaire 6) : which measures two dimensions of social support (satisfaction and availability). SSQ6 is an abbreviated form of SSQ (Social Support Questionnaire). A high SSQ score indicates more optimism about life than a low score."
62427756|NCT05417490||Group with PRADO + remote monitoring|"All patients seen in hospital and for whom the doctor will choose whether or not to offer one of the 2 solutions, alone or in combination, will be considered as included in the study, and their non-objection will be collected.~Subsequently, patients will benefit from follow-up for 6 months: V0 inclusion visit- V1 telephone contact at 1 month optional only for patients participating in one of the 2 programs and V2 consultation at 6 months. The 0 and 6M visits are part of the usual follow-up of patients hospitalized for heart failure.~Administration of questionnaires:~* Girerd's questionnaire~* SUTAQ (Service User Technology Acceptability Questionnaire) : only for patients with remote monitoring.~the questionnaire has 22 items, measured on a Likert scale from 1 to 6, reflecting respectively more or less agreement with the statements of the items. The questionnaire has 5 subscales, each containing between 3 and 9 items.~* SSQ6"
62595720|NCT01500187|ACTIVE_COMPARATOR|Pediagel|1.23% Acidulated Phosphate Fluoride Gel
62595721|NCT01500187|EXPERIMENTAL|3M Vanish Varnish|5% sodium fluoride varnish
62595722|NCT02720679||Study Participants|Participants will be (1) individuals with a non-malignant hematologic disorder confirmed or suspected to have a genetic basis, and (2) affected and unaffected family members of those individuals who are willing to provide clinical data and undergo genetic testing.
62595723|NCT02289781||Zirconia posterior crowns|Monolithic zirconia crowns which are polished and non-glazed
62595724|NCT02289781||Metal-Ceramic posterior crowns|Metal-supported glass-ceramic veneered crowns which are polished and non-glazed
62595725|NCT02289508||acute decompensated heart failure|Patients who fulfill Framingham criteria will be classified as acute decompensated heart failure (adHF). For this study we define this as an acute change in symptoms and signs within the previous 24 hours. When symptoms gradually deteriorate between one day and one month, it is described as gradual decompensated heart failure (gdHF). Some patients may have both.
62595726|NCT02289508||compensated heart failure|compensated heart failure (cHF) is defined as the existence of heart failure in the absence of any acute exacerbation but which may either include typical chronic symptoms and signs or may be asymptomatic but with evidence of cardiac dysfunction i.e. a reduced ejection fraction.
62595727|NCT02289508||non-heart failure patients|Non-heart failure patients (nHFp) are a patient control group with suspected heart failure but who after further assessment are found not to meet the criteria. Such patients may subsequently be found to have COPD, anaemia, over transfusion. As the purpose of this study is to assess the potential value of USCOM parameters in the assessment of patients with possible heart failure in the clinical setting, it is important to include patients without heart failure.
62036262|NCT03929029|EXPERIMENTAL|Cohort 1: Nivolumab, NeoVax + Montanide, Ipilimumab 2.5 mg per injection site|"* Patients will receive Nivolumab at a 480 mg flat dose I.V. infusion every 4 weeks (28 days)~* Patients will receive NeoVax plus Montanide injection on weeks 12, 15, 18, and 21~* Patients will receive concurrent Ipilimumab (2.5 mg per injection site) on weeks 12, 15, 18, and 21"
62036263|NCT03929029|EXPERIMENTAL|Cohort 2: Nivolumab, NeoVax + Montanide, Ipilimumab 5.0 mg per injection site|"* Patients will receive Nivolumab at a 480 mg flat dose I.V. infusion every 4 weeks (28 days)~* Patients will receive NeoVax plus Montanide injection on weeks 12, 15, 18, and 21~* Patients will receive concurrent Ipilimumab (5.0 mg per injection site) on weeks 12, 15, 18, and 21"
62036264|NCT00867217|EXPERIMENTAL|High Dose Vitamin D|High Dose Vitamin D3 capsule (3 x 10,000 IU capsules weekly). All subjects also received standard dose vitamin D3 (600 IU daily) and letrozole (2.5 mg daily).
62427757|NCT05417490||Group with remote monitoring|"All patients seen in hospital and for whom the doctor will choose whether or not to offer one of the 2 solutions, alone or in combination, will be considered as included in the study, and their non-objection will be collected.~Subsequently, patients will benefit from follow-up for 6 months: V0 inclusion visit- V1 telephone contact at 1 month optional only for patients participating in one of the 2 programs and V2 consultation at 6 months. The 0 and 6M visits are part of the usual follow-up of patients hospitalized for heart failure.~Administration of questionnaires:~* Girerd's questionnaire on therapeutic compliance~* SUTAQ inspired digital tools acceptability questionnaire: only for patients with remote monitoring~* SSQ6 social support questionnaire"
62427758|NCT05417490||Group without intervention|"All patients seen in hospital and for whom the doctor will choose whether or not to offer one of the 2 solutions, alone or in combination, will be considered as included in the study, and their non-objection will be collected.~Subsequently, patients will benefit from follow-up for 6 months: V0 inclusion visit- V1 telephone contact at 1 month optional only for patients participating in one of the 2 programs and V2 consultation at 6 months. The 0 and 6M visits are part of the usual follow-up of patients hospitalized for heart failure.~Administration of questionnaires:~* Girerd's questionnaire on therapeutic compliance~* SSQ6 social support questionnaire"
62427759|NCT04372888|OTHER|rare genetic disease|Hypothetical scenario 1: rare, life-altering genetic condition (congenital hypogonadotropic hypogonadism)
62427760|NCT04372888|OTHER|common genetic disease|Hypothetical scenario 2: common, life-threatening genetic condition (hereditary breast and ovarian cancer)
62427761|NCT01731574|ACTIVE_COMPARATOR|Dapivirine Ring + Miconazole|Dapivirine Ring + miconazole
62595728|NCT02289508||healthy controls|Healthy controls are subjects with not acute or chronic illness.
62595729|NCT06324071|EXPERIMENTAL|Control group|Group supplemented with a daily dose of placebo
62595730|NCT06324071|EXPERIMENTAL|Experimental group|Group supplemented with 125 mg/day of TetraSOD®
62036265|NCT00867217|PLACEBO_COMPARATOR|Placebo|Placebo matched for High Dose Vitamin D3 capsules. All subjects also received standard dose vitamin D3 (600 IU daily) and letrozole (2.5 mg daily).
62427762|NCT01731574|EXPERIMENTAL|Dapivirine Ring|Dapivirine Ring
62427763|NCT02020785|ACTIVE_COMPARATOR|Higher phosphorus period|Commercially-available unaltered food/beverage products containing phosphorus additives (\~1gm/d of phosphorus) will be given for 3 weeks
62427764|NCT02020785|PLACEBO_COMPARATOR|Lower phosphorus period|Commercially-available unaltered food/beverage products without phosphorus additives (\<10mg/d of phosphorus) will be given for 3 weeks
62427765|NCT02222285|PLACEBO_COMPARATOR|Sequence 3: placebo/placebo|Placebo/placebo consists of placebo for 7 weeks followed by 7 weeks of placebo treatment
62427766|NCT02222285|ACTIVE_COMPARATOR|Sequence 2: placebo/ Treatment|Sequence 2: placebo/ Treatment , consists of placebo for 7 weeks followed by 7 weeks of treatment with Vayarin_005
62595731|NCT05969223|EXPERIMENTAL|Study G Risankizumab|Participants with moderate to severe genital psoriasis will receive risankizumab during the 52 week treatment period, with an 8-week follow-up period after the 52 week treatment period.
62595732|NCT05969223|EXPERIMENTAL|Study G Placebo for Risankizumab|Participants with moderate to severe genital psoriasis will receive placebo for risankizumab during the 16 week treatment period followed by risankizumab during the 36 week treatment period, with an 8-week follow-up period after the 52 week treatment period.
62595733|NCT05969223|EXPERIMENTAL|Study S Risankizumab|Participants with moderate to severe scalp psoriasis will receive risankizumab during the 52 week treatment period, with an 8-week follow-up period after the 52 week treatment period.
62595734|NCT05969223|EXPERIMENTAL|Study S Placebo for Risankizumab|Participants with moderate to severe scalp psoriasis will receive placebo for risankizumab during the16 week treatment period followed by risankizumab during the 36 week treatment period, with an 8-week follow-up period after the 52 week treatment period.
62595735|NCT04270864|EXPERIMENTAL|Regimen A1|Combination between nivolumab IV Q3W and dual intratumoral injections of Ipilimumab and Tilsotolimod Q3W
62595736|NCT04270864|EXPERIMENTAL|Regimen A2|Combination between nivolumab IV Q3W and dual intratumoral injections of Ipilimumab and Tilsotolimod QW
62595737|NCT05959096|EXPERIMENTAL|LY3437943 (Part A)|LY3437943 administered subcutaneously (SC) in either thigh, upper arm, or abdomen
62237465|NCT03979560|EXPERIMENTAL|Nutrition intervention with appropriate physical activity|"Intervention at home of professionals:~Patients in this arm will benefit from 14 home interventions~* 7 home nutrition support (NS) sessions in 3 months or 1 session every 10 days (+/-4 days). These sessions will be conducted by a dietician from the company Saveurs et Vie.~* 7 home sessions of adaptive physical activity (APA) in 3 months, one session every 10 days (+/-4 days). These sessions will be conducted by professionals from association group Siel Bleu.~In addition to screening/inclusion visits (D0), three follow-up home visits are scheduled at D7, D45 and D90 for both study groups."
62237466|NCT01060826|EXPERIMENTAL|somatostatin, intravenous bolus|A double- blind study designed to evaluate if the treatment with somatostatin in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will be randomized in two groups of treatment, one will receive somatostatin and another placebo.
62427767|NCT02222285|ACTIVE_COMPARATOR|Sequence one: Treatment/Treatment|Treatment/Treatment- consists of PS_005 for 7 weeks followed by 7 weeks of additional treatment with Vayarin_005
62427768|NCT04972071|OTHER|CSRS practice recommendation|Knowledge translation of the Canadian Syncope Risk Score (CSRS) based practice recommendations
62427769|NCT05475678|EXPERIMENTAL|（Carrelizumab + TCb） regimen|The experimental group received 6 cycles of TCb+carrelizumab (docetaxel 75mg/m2 on the first day + carboplatin AUC=6, on the first day; camrelizumab 200mg on the third day) regimen neoadjuvant chemotherapy, every 21 days is a cycle.
62427770|NCT05475678|PLACEBO_COMPARATOR|TCb regimen|The control group received 6 cycles of TCb (docetaxel 75mg/m2 on the first day + carboplatin AUC=6 on the first day) regimen neoadjuvant chemotherapy, every 21 days as a cycle.
62427771|NCT01246973|EXPERIMENTAL|curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
62427772|NCT01246973|PLACEBO_COMPARATOR|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
62427773|NCT03263871|EXPERIMENTAL|Intervention|PTM202 and micro-nutrient sprinkles
62595738|NCT05959096|EXPERIMENTAL|LY3437943 (Part B)|LY3437943 administered intravenously (IV)
62595739|NCT01531530|EXPERIMENTAL|Vaccine-recipients|
62595740|NCT01531530|PLACEBO_COMPARATOR|Placebo|
62595741|NCT02643849|EXPERIMENTAL|Spanner|
62595742|NCT02247596|PLACEBO_COMPARATOR|Placebo|Sugar pill 1g tds for 2 weeks
62595743|NCT02247596|EXPERIMENTAL|Resveratrol|Trans-resveratrol extract from Polygonum Cuspidatum 1g three times a day for 2 weeks
62427774|NCT03263871|OTHER|Control|micro-nutrient sprinkles
62595744|NCT02370589|EXPERIMENTAL|Group A|Day 0: Base Dose EBOV GP Vaccine; IM Day 21: Base Dose EBOV GP Vaccine; IM
62595745|NCT02370589|EXPERIMENTAL|Group B|Day 0: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
62595746|NCT02370589|EXPERIMENTAL|Group C|Day 0: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
62595747|NCT02370589|EXPERIMENTAL|Group D|Day 0: 2x Base Dose EBOV GP Vaccine; IM Day 21: 2x Base Dose EBOV GP Vaccine; IM
62595748|NCT02370589|EXPERIMENTAL|Group E|Day 0: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
62595749|NCT02370589|EXPERIMENTAL|Group F|Day 0: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
62595750|NCT02370589|EXPERIMENTAL|Group G|Day 0: 4x Base Dose EBOV GP Vaccine; IM Day 21: 4x Base Dose EBOV GP Vaccine; IM
62595751|NCT02370589|EXPERIMENTAL|Group H|Day 0: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
62595752|NCT02370589|EXPERIMENTAL|Group J|Day 0: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
62595753|NCT02370589|EXPERIMENTAL|Group K|Day 0: 8x Base Dose EBOV GP Vaccine; IM Day 21: 8x Base Dose EBOV GP Vaccine; IM
62595754|NCT02370589|EXPERIMENTAL|Group L|Day 0: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
62595755|NCT02370589|EXPERIMENTAL|Group M|Day 0: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
62595756|NCT02370589|PLACEBO_COMPARATOR|Group N|Day 0: Placebo; IM Day 21: Placebo; IM
62237467|NCT01060826|PLACEBO_COMPARATOR|Placebo, intravenous bolus|A double- blind study designed to evaluate if the treatment with somatostatin in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will be randomized in two groups of treatment, one will receive somatostatin and another placebo.
62427775|NCT05189483|EXPERIMENTAL|Albumin-bound paclitaxel plus camrelizumab therapy arm|Enrolled patients will receive the following treatment: 300 mg/m2 of nab-paclitaxel (Hengrui Pharmaceutical, Lianyungang, China) and 200 mg of PD-1 inhibitor (camrelizumab; Hengrui Pharmaceutical, Lianyungang, China) via a 30-min intravenous infusion on day 1. The treatment was repeated every three weeks.
62427776|NCT02009982|EXPERIMENTAL|Cardioneuroablation|Patients in this group will receive the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
62427777|NCT02009982|NO_INTERVENTION|Standard Medical Thearpy|Patients in this group will not receive the cardioneuroablation and will continue to be managed using standard medical therapy
62427778|NCT04726761||Frequent/Non-frequent|Patients randomized to this order will first have an ABPM conducted with the frequent measuring intervals (3 times an hour during day and 2 times an hour at night) and then a few days later have another ABPM conducted with the non-frequent measuring interval (1 time an hour during all 24 hours)
62427779|NCT04726761||Non-frequent/frequent|Patients randomized to this order will first have an ABPM conducted with the non-frequent measuring interval (1 time an hour during all 24 hours) and then a few days later have another ABPM conducted with the frequent measuring intervals (3 times an hour during day and 2 times an hour at night)
62427780|NCT03358732|EXPERIMENTAL|Mock embryo transfer|The patients underwent a mock embryo transfer one day before the scheduled actual transfer
62427781|NCT03358732|NO_INTERVENTION|No mock embryo transfer|The patients did not undergo mock embryo transfer one day before the scheduled actual transfer
62595757|NCT06364215|ACTIVE_COMPARATOR|Pulmonary Vein Isolation (PVI) only|Pulsed field ablation of the pulmonary veins only.
62595758|NCT06364215|ACTIVE_COMPARATOR|Pulmonary Vein Isolation and Posterior Wall Isolation ( PVI+PWI)|Pulsed field ablation of the pulmonary veins and the posterior wall of the left atrium.
62595759|NCT06621940|EXPERIMENTAL|High Protein Diet|The energy composition of the high protein diet will be calculated as 40% carbohydrate, 30% protein and 30% fat. It will be stated that individuals should not eat anything other than the foods to be sent during the weeks of the diet.
62595760|NCT06621940|EXPERIMENTAL|Normal Protein Diet|The energy composition of the high protein diet will be calculated as 55% carbohydrate, 15% protein and 30% fat. It will be stated that individuals should not eat anything other than the foods to be sent during the weeks of the diet.
62595761|NCT04018456|EXPERIMENTAL|Biodentine|Intervention group: application of biodentine as pulp space barrier during regenerative endodontic treatment.
62595762|NCT04018456|ACTIVE_COMPARATOR|White MTA|Control group: application of White MTA as pulp space barrier during regenerative endodontic treatment.
62237468|NCT04745767|EXPERIMENTAL|Group 1: A1(T1), B(T2), C(T2 Fed)|Participants will be randomly placed into 6 sequences within Group 1. All participants in Group 1 will receive TAK-994 as Treatment A1 (T1 Formulation) and Treatment B (T2 Formulation) under fasted conditions and Treatment C (T2 Formulation) under fed conditions at different times within three periods.
62237469|NCT04745767|EXPERIMENTAL|Group 2: A2(T1), D(T3), E(T3 Fed)|Participants will be randomly placed into 6 sequences within Group 2. All participants in Group 2 will receive TAK-994 as Treatment A2 (T1 Formulation) and Treatment D (T3 Formulation) under fasted conditions and Treatment E (T3 Formulation) under fed conditions at different times within three periods.
62237470|NCT04745767|EXPERIMENTAL|Group 3: A3(T1), F(T4), G(T4 Fed), H(T5)|Participants will be randomly placed into 6 sequences within Group 3. Participants in Group 3 will receive TAK-994 as Treatment A3 (T1 Formulation), Treatment F (T4 Formulation), and Treatment F (T5 Formulation) under fasted conditions and Treatment G (T4 Formulation) under fed conditions at different times within 4 periods.
62237471|NCT05098613|EXPERIMENTAL|CD19x22 CAR T Cell Infusion|Lymphodepleting chemotherapy following by infusion of CD19x22 CAR T Cells
62237472|NCT02273726|EXPERIMENTAL|Roxadustat|Participants will receive roxadustat tablets, administered orally 3 times weekly (TIW). Initial roxadustat dose will be based on the participant's average prescribed erythropoietin stimulating agent (ESA) dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments will be permitted to maintain a hemoglobin (Hb) level of approximately 11 grams (g)/deciliter (dL). The maximum roxadustat dose is 3.0 milligrams (mg)/kilogram (kg) per dose or 400 mg per administration (whichever is lower).
62036266|NCT06485817|PLACEBO_COMPARATOR|Placebo_Control|"Control state induction:~Participants answer simple questions about their color or music preferences in a hybrid (zoom-lab) session with a friendly experimenter (The Repeatable Social Stress Test (ReSST) control conditions).~Drug administration:~A sampling dose of intravenous (i.v.) saline administered over 15 seconds through a venous catheter after the state induction. 45 minutes later participants receive the second dose of saline (0-100% of the initial sampling dose) determined by a behavioral self-administration task."
62036267|NCT06485817|ACTIVE_COMPARATOR|Oxycodone_Control|"Control state induction:~Participants answer simple questions about their color or music preferences in a hybrid (zoom-lab) session with a friendly experimenter. (The Repeatable Social Stress Test (ReSST) control conditions).~Drug administration:~A sampling dose of i.v. oxycodone administered over 15 seconds through a venous catheter after the state induction. 45 minutes later participants receive the second dose of oxycodone (0-100% of the initial sampling dose) determined by a behavioral self-administration task."
62813406|NCT02928679|EXPERIMENTAL|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
62237473|NCT02273726|ACTIVE_COMPARATOR|Epoetin Alfa|Participants on hemodialysis (HD) will receive epoetin alfa, administered intravenously (IV) TIW and participants on home HD or peritoneal dialysis (PD) will receive epoetin alfa, administered subcutaneously (SC). Initial epoetin alfa dose will be based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa will be determined by the investigator per local standard of care (SOC). Dose adjustments will follow the recommendations as per the approved country-specific product label (United States Package Insert \[USPI\] or Summary of Product Characteristics \[SmPC\]) or local SOC.
62036268|NCT06485817|ACTIVE_COMPARATOR|Placebo_Stress|"State induction: Stress The Repeatable Social Stress Test (ReSST) was used to induce psychosocial stress (mock job talk in stress session 1 and singing task in stress session 2).~Drug administration:~A sampling dose of i.v. saline administered over 15 seconds through a venous catheter after the state induction. 45 minutes later participants receive the second dose of saline (0-100% of the initial sampling dose) determined by a behavioral self-administration task."
62036269|NCT06485817|EXPERIMENTAL|Oxycodone_Stress|"State induction: Stress ReSST was used to induce psychosocial stress (mock job talk in stress session 1 and singing task in stress session 2).~Drug administration:~A sampling dose of i.v. oxycodone administered over 15 seconds through a venous catheter after the state induction. 45 minutes later participants receive the second dose of oxycodone (0-100% of the initial sampling dose) determined by a behavioral self-administration task."
62427782|NCT03765944|ACTIVE_COMPARATOR|NPC-12 granule|NPC-12 granules (1.0g: 2mg sirolimus)
62427783|NCT03765944|ACTIVE_COMPARATOR|NPC-12T tablet|NPC-12T 2 tablets (2mg sirolimus)
62427784|NCT00751998||Arm 1|Test of SpyGlass device
62427785|NCT03539731|ACTIVE_COMPARATOR|Group I ([18F]DASA-23, PET)|Healthy volunteers receive \[18F\]DASA-23 IV and undergo brain PET scan over 15 minutes and 4 vertex-to-toe PET scans over 30 minutes each.
62427786|NCT03539731|EXPERIMENTAL|Group II ([18F]DASA-23, PET)|Intracranial tumor participants receive \[18F\]DASA-23 IV and undergo brain PET scan over 60 minutes and 1 vertex-to-toe PET scan over 30 minutes.
62427787|NCT03539731|EXPERIMENTAL|Group III ([18F]DASA-23, PET)|Patients with at least a 1cm3 contrast-enhancing lesion suspicious for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM) on a standard-of-care (SOC) brain MRI scan. If the patient undergoes a biopsy or resection for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM) then the remaining contrast-enhancing lesion is at least 1cm3 in size on the post-operative scan. These patients will undergo one \[18F\]DASA 23 PET/MRI scan before the initiation of therapy, and a second/final \[18F\]DASA 23 PET/MRI scan within 2-6 weeks after initiation of therapy for their GBM.
62427788|NCT03539731|ACTIVE_COMPARATOR|Group IV ([18F]DASA-23, PET)|Healthy volunteers receive \[18F\]DASA-23 IV and undergo brain PET/MRI brain scan for 60 mins
62813407|NCT02928679|PLACEBO_COMPARATOR|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
62813408|NCT06159621|ACTIVE_COMPARATOR|Arm A: PD1|Subjects in this arm will receive one dose of LVGN3616 (300mg).
62813409|NCT06159621|ACTIVE_COMPARATOR|Arm B: PD1 + CD40|Subjects in this arm will receive one dose of LVGN3616 (300mg) followed by one dose of CD40 LVGN7409 (1mg/kg).
62813410|NCT00823862|EXPERIMENTAL|Active (SD-101)|SD-101 in cohorts of escalating doses
62813411|NCT05183061||Hypotensive group|Hypotenson is defined as systolic blood pressure (SBP) \< 80 mmHg or a drop more than 20% from baseline SBP for longer than 10 minutes or a drop that requires treatment either vasopressor or inotropic drugs.
62813412|NCT05183061||Non-hypotensive group|The pateints who did not develop hypotensive episodes as aforementioned.
62237474|NCT02729103||Treatment patterns, healthcare resource utilization and costs|Part 1 - Assessment of treatment patterns, healthcare resource utilization and costs. The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date. All patients must have no diagnosis of other cancers, no diagnosis of bone metastases or a claim for a treatment indicative of bone metastases, and no skeletal-related events (SREs) in the 12-month pre-index period. Additionally, all subjects must be continuously enrolled for at least 12 months before and at least 6 months after the index date.
62237475|NCT02729103||Mortality|Part 2 - Assessment of mortality. The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date. All patients must have no diagnosis of other cancers, no diagnosis of bone metastases or a claim for a treatment indicative of bone metastases, and no SREs in the 12-month pre-index period. Additionally, all subjects must be continuously enrolled for at least 12 months before the index date. Unlike in Part 1, there will be no required minimum follow-up time after the index date (in order to assess mortality).
62595763|NCT05299931|OTHER|Subcutaneous (SC) ustekinumab every 8 weeks (Q8w)|"Patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm will continue ustekinumab 90 mg SC Q8w if they are Q8w responders at the end of REScUE~Patients treated with a OLE treatment regimen of ustekinumab 90 mg SC Q8w will be able to cross-over to a OLE treatment regimen of ustekinumab 90 mg SC Q4w if they meet the criteria of CD worsening at week 12 or at any timepoint beyond week 12 after entering REScUE-OLE"
62813413|NCT05093855|EXPERIMENTAL|Treatment group|
62036270|NCT03359265|ACTIVE_COMPARATOR|Test|The test group used underpants made of precious metal fibers (germanium, titanium and phosphorus), developed by Green Energy Nano Technology Co., Ltd.
62237476|NCT04058613|EXPERIMENTAL|Albumin|Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy
62237477|NCT04058613|PLACEBO_COMPARATOR|Placebo|Placebo
62427789|NCT02612415|EXPERIMENTAL|High flow nasal cannula (HFNC)|Heated humidified high flow nasal cannula therapy delivered at 2 L/kg/min gas flow rate (for children older than 10 kg in weight, an additional 0.5 L/kg/min per kilogram over 10 kg). Any approved device can be used to deliver HFNC
62427790|NCT02612415|ACTIVE_COMPARATOR|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure delivered using any interface (hood, mask or prongs)
62427791|NCT02039817|EXPERIMENTAL|Healthy Volunteers|All subjects receive a single 50 mg oral dose of IDN-6556
62427792|NCT02039817|EXPERIMENTAL|Severe Renal Impairment|All subjects receive a single 50 mg oral dose of IDN-6556
62427793|NCT01654471||Medical treatment|only medical treatment (regardless of the kinds of medicine)
62427794|NCT01654471||Surgical or endovascular treatemnt group|patients underwent surgery or endovascular therapy
62427795|NCT04366778||patients hospitalized for Covid-19|Patients with Covid-19 infection hospitalized in Lyon University Hospitals
62427796|NCT04366778||patients hospitalized for Covid-19 who present thrombosis|Patients with Covid-19 infection hospitalized in Lyon University Hospitals who present thrombosis during hospitalization
62595764|NCT05299931|OTHER|Subcutaneous (SC) ustekinumab every 4 weeks (Q4w)|"Patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm will switch to ustekinumab 90 mg SC Q4w (Cross-over) if they are Q8w non-responders at the end of REScUE OR Patients previously enrolled to the ustekinumab 90 mg SC Q4w-arm will continue ustekinumab 90 mg SC Q4w if they are Q4w responders at the end of REScUE"
62036271|NCT03359265|PLACEBO_COMPARATOR|Control|The control group used commercially available underpants.
62036272|NCT01290432|EXPERIMENTAL|Inofolic Plus|Patients are given Inofolic Plus to see if the AMH changes over a period of up to 90 days.
62036273|NCT03681626|ACTIVE_COMPARATOR|tracheal suction|After a standardized protocol during the thirty minutes before extubation, extubation was performed with a standardized tracheal suction.
62036274|NCT03681626|EXPERIMENTAL|no tracheal suction|After a standardized protocol during the thirty minutes before extubation, extubation was performed without tracheal suction.
62427797|NCT01186952|NO_INTERVENTION|Optimized usual care|participants will attend one visit with the dietician (30mn) and the physical activity specialist (30mn) when they will be given Canadian guidelines pamphlets for physical activity and food consumption. They will also receive a phone call once a month to discuss about issues in guidelines following.
62427798|NCT01186952|ACTIVE_COMPARATOR|Diet intervention alone|Participants will attend one visit with the physical activity specialist (30mn) when they will receive the physical activity guidelines. Monthly phone call will be make to discuss about issues in physical activity guidelines following.These individuals will also be enrolled in a supervised caloric restriction program. They will have to visit the dietician once a week for the first months and then twice a month for 3 months. The diet intervention will focus on a low fat diet. At each session participants will be weighed and taken the blood pressure.
62813414|NCT00758771||Cystic Fibrosis|People who have been diagnosed with cystic fibrosis
62813415|NCT00758771||Healthy|People who do not have cystic fibrosis and who do not have any other lung conditions
62813416|NCT06173336|ACTIVE_COMPARATOR|Single pyloromyotomy gastric per-oral endoscopic myotomy (G-POEM)|Single cut pyloromyotomy technique during gastric per-oral endoscopic myotomy (G-POEM) procedure
62813417|NCT06173336|ACTIVE_COMPARATOR|Double pyloromyotomy gastric per-oral endoscopic myotomy (G-POEM)|Double cut pyloromyotomy technique during gastric per-oral endoscopic myotomy (G-POEM) procedure
62813418|NCT04024150||Newborns exposed|Newborns exposed in-utero to raltegravir
62036275|NCT04243317|ACTIVE_COMPARATOR|Control|The control group will adhere to a 1200 kcal restriction daily for 12 weeks.
62595765|NCT01909518||pCLE examination|pCLE is used to distinguish the suspected lesions detected by I-SCAN in esophagus
62036276|NCT04243317|EXPERIMENTAL|Experimental|The experimental group will adhere to a 1200 kcal restriction daily for 12 weeks and will maintain sleep improvement
62237478|NCT00149422|ACTIVE_COMPARATOR|NT-proBNP guided treatment group|In this group, management was guided by an individually set NT-proBNP, defined by the lowest level at discharge or 2 weeks thereafter. If NT-proBNP levels were elevated above the individually set NT-proBNP interventions were performed according to the ESC heart failure guidelines.
62813419|NCT04024150||Newborns controls|Newborns exposed to antiretroviral therapy without anti-integrase
62036277|NCT02278094|EXPERIMENTAL|Experimental group|Subjects will be in random cluster assign to walking exercise (WE), Threshold Inspiratory Muscle Trainer (TIMT) and Tongue Muscle Trainer (TMT) treatment groups.
62036278|NCT02278094|ACTIVE_COMPARATOR|Control group|Up to 95% of OSAS cases are treated with continuous positive airway pressure (CPAP), CPAP treatment group will be the control group.
62237479|NCT00149422|PLACEBO_COMPARATOR|Clinically guided arm|Heart failure treatment guided by clinical assessment.
62813420|NCT04891614|EXPERIMENTAL|Treatment|Subjects diagnosed with PTSD will be recruited from the community and from local clinical programs. All subjects will undergo Prism neurofeedback training.
62237480|NCT06108180|EXPERIMENTAL|Dry Needling group|
62237481|NCT06108180|NO_INTERVENTION|Control group|
62237482|NCT00752622|EXPERIMENTAL|Shortened interval|Infliximab 5 mg/kg, then Infliximab 5 mg/kg every 6 weeks
62237483|NCT00752622|EXPERIMENTAL|Increased dose|Infliximab 5 mg/kg, then Infliximab 7 mg/kg every 8 weeks
62237484|NCT06414252||Patients with hereditary angioedema|Patients with documented diagnosis of hereditary angioedema due to C1 inhibitor deficiency and aged between 18 and 65 years.
62237485|NCT06414252||Healthy individuals|Healthy individuals with an age between 18 and 65 and matched with patients with hereditary angioedema by age and gender.
62427799|NCT01186952|ACTIVE_COMPARATOR|diet intervention and exercise program|"Participants will attend diet intervention as described for group 2. They will also follow a supervised exercise program three days per week for 4 months. The exercise training is an interval high intensity aerobic (85-90% heart rate reserve) program with resistance exercises (15RM, 2-3 repetitions). Each session will last one hour. At the end of month 1, 2, and 3, all participants will receive the SWA armband for 7 days to record physical activity and estimate energy expenditure.~At the end of Month 4, all participants will attend a study visit for repeat baseline testing."
62813421|NCT04662385|EXPERIMENTAL|aloe vera toothpaste group|a recently available aloe vera toothpaste for gingival care, offers a completely improved approach for treatment of gingivitis. aloe vera toothpaste was certified as an antibacterial .This innovative toothgel is made using stabilized aloe vera gel from Forever's own plantations and can help you fight plaque as part of a regular brushing routine.
62813422|NCT04662385|ACTIVE_COMPARATOR|colegate total toothpaste group|Active Ingredient: Stannous fluoride 0.454% (0.15% w/v fluoride ion) Purposes: Anticavity, Antigingivitis, Antisensitivity. Inactive ingredients: Zinc phosphate, Water, Sorbitol, Hydrated silica, Glycerin, PEG-12, Tetras
62036279|NCT04649398||oral nimodipine|60mg of nimodipine is orally administered every 4 h,
62427800|NCT03836365|ACTIVE_COMPARATOR|Preoperative counseling office visit|Participants will present for an in-person preoperative counseling office visit (preoperative counseling session). This will occur within a few weeks of surgery. Preoperative counseling topics are standardized and will be identical with each arm.
62813423|NCT05241262|EXPERIMENTAL|Active drug (NAC)|Participants will receive NAC for 3 months.
62813424|NCT00231816|EXPERIMENTAL|Concomitant|Zostavax concomitantly with influenza vaccine on Day 1, placebo at week 4
62813425|NCT00231816|EXPERIMENTAL|Nonconcomitant|Influenza vaccine and Zostavax placebo on Day 1, Zostavax at week 4
62813426|NCT05134688||Grup 1|Group receive magnesium sulphate IV(4gm loading dose over 20 minutes followed by 1gm /hour for 6 hours
62036280|NCT04649398||intra-venous nimodipine|nimodipine is continuously administered intra-venously, starting with 0.5 mg/h on day 1 and increased every day for 0.5 mg/h to a maximum dose of 2.0mg/h on day 4
62036281|NCT04649398||intra-arterial nimodipine|during endovascular procedure 2mg of nimodipine is infused via a microcatheter into the internal carotid artery for 20 minutes
62036282|NCT00802074|ACTIVE_COMPARATOR|Group A|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 1400mg BID Period 3- Fosamprenavir 1400mg BID + Raltegravir 400mg BID
62237486|NCT02523560|EXPERIMENTAL|telerehabilitation group|1 week hospital rehabilitation and 8 weeks home-based telerehabilitation and telemanagement (including HomeMonitoring)
62237487|NCT02523560|NO_INTERVENTION|control group|Patients qualified to the control group will undergo a 9-week procedure appropriate to their clinical condition/status standardized for a particular center (usual care).
62237488|NCT02279862|EXPERIMENTAL|Arm 1: Ipilimumab 3 mg/kg|Ipilimumab 3 mg/kg injection intravenously every 3 weeks for 4 doses in Induction phase. Subjects that are eligible to receive Ipilimumab in the Maintenance phase will be dosed every 12 weeks for a maximum of 3 years since the first induction dose
62237489|NCT02279862|EXPERIMENTAL|Arm 2: Ipilimumab 10 mg/kg|Ipilimumab 10 mg/kg injection intravenously every 3 weeks for 4 doses in Induction phase. Subjects that are eligible to receive Ipilimumab in the Maintenance phase will be dosed every 12 weeks for a maximum of 3 years since the first induction dose
62237490|NCT05956054|ACTIVE_COMPARATOR|S1 transforaminal injection with a straight needle|
62237491|NCT05956054|EXPERIMENTAL|S1 transforaminal injection with a curved needle|
62237492|NCT02929797|EXPERIMENTAL|AKT + gemcitabine|gemcitabine dose 1000mg/M\^2, d1,8,15，q4w ×6 AKT 5\*10\^8/M\^2, d16,q4w ×6 Drug: gemcitabine Biological: AKT, CD8+NKG2D+ AKT Cell
62237493|NCT02929797|ACTIVE_COMPARATOR|gemcitabine|gemcitabine hydrochloride dose 1000mg/M2 d1,8,15，q4w ×6 Drug: gemcitabine
62237494|NCT03502954|EXPERIMENTAL|ABY-039 IV|
62237495|NCT03502954|EXPERIMENTAL|ABY-039 SC|
62237496|NCT03502954|PLACEBO_COMPARATOR|Placebo IV|
62813427|NCT05134688||Group 2|Receive no further treatment than conservative mangement( antibiotics and steroids)
62595766|NCT02153671|EXPERIMENTAL|Primed with H5N2|Subjects who received A(H5N1) inactivated influenza vaccine as well as primed with H5N2 live attenuated influenza vaccine approximately 1.5 years before
62595767|NCT02153671|ACTIVE_COMPARATOR|Did not receive A(H5N2)|Subjects who received A(H5N1) inactivated influenza vaccine and did not receive A(H5N2) live attenuated influenza vaccine in a previous study.
62595768|NCT05970588|NO_INTERVENTION|Wait-list Control Group|Fitted with inclinometers/accelerometers at week 0 and week 4 of the intervention period for 7 consecutive days of wear. Measures of cognition and blood pressure regulation will occur at these same timepoints. Daily activities of participants will not be restricted if patients are assigned to the control group.
62595769|NCT05970588|EXPERIMENTAL|Intervention Group|Fitted with inclinometers/accelerometers at week 0 and week 4 of the intervention period for 7 consecutive days of wear. Measures of cognition and blood pressure regulation will occur at these same timepoints.
62595770|NCT06620991|EXPERIMENTAL|Phentolamine|A loading dose of 1-5 mg IV bolus over 1 minute is given followed by an IV infusion of a rate of 0.1-2 mg/min according to patient desired target mean arterial pressure (MAP) 50-60 mmHg over a volume of 10ml.
62595771|NCT06620991|EXPERIMENTAL|Esmolol|A loading dose of 1 mg/kg IV infused over 1 minute is given followed by an IV infusion of 0.15-0.3 mg/kg/min according to patient desired target mean arterial pressure (MAP) 50-60 mmHg over total volume of 10ml.
62595772|NCT06350318|EXPERIMENTAL|Cohort A: Untreated Marginal Zone Lymphoma|"Rituximab (Standard of Care) will be administered for up to 6 cycles (28-day cycles).~Cycle 1: Days 1, 8, 15, and 22. Cycle 2-6: Day 1, every 28 days.~Rituximab: Intravenous rituximab formulations (IV rituximab or IV rituximab biosimilars will be administered by IV infusion at a dose of 375 mg/m2 per local institutional guidelines) or subcutaneous rituximab formulations (RITUXAN HYCELA) 1,400 mg/23,400 Units (1,400 mg rituximab and 23,400 Units hyaluronidase human) subcutaneously at a fixed dose per local institutional guidelines.~Zanubrutinib 320 mg will be administered orally once daily starting on day 1 of cycle 1.~Zanubrutinib will be continued once daily for up to 24 cycles or until disease progression or unacceptable toxicity occurs."
62595773|NCT06350318|EXPERIMENTAL|Cohort B: Untreated Follicular Lymphoma|"Rituximab (Standard of Care) will be administered for up to 6 cycles (28-day cycles).~Cycle 1: Days 1, 8, 15, and 22. Cycle 2-6: Day 1, every 28 days.~Rituximab: Intravenous rituximab formulations (IV rituximab or IV rituximab biosimilars will be administered by IV infusion at a dose of 375 mg/m2 per local institutional guidelines) or subcutaneous rituximab formulations (RITUXAN HYCELA) 1,400 mg/23,400 Units (1,400 mg rituximab and 23,400 Units hyaluronidase human) subcutaneously at a fixed dose per local institutional guidelines.~Zanubrutinib 320 mg will be administered orally once daily starting on day 1 of cycle 1.~Zanubrutinib will be continued once daily for up to 24 cycles or until disease progression or unacceptable toxicity occurs."
62595774|NCT04441684|EXPERIMENTAL|PCR+ group|This group includes any symptomatic person with a positive COVID result, with a RT-PCR test carried out at least 10 days before inclusion.
62595775|NCT04441684|EXPERIMENTAL|PCR- group|This group includes any symptomatic person with a negative RT-PCR COVID 19 test carried out at least 10 days before inclusion.
62813428|NCT01064440|EXPERIMENTAL|Low Dose VM202|Patients in this group received 8mg total of VM202. Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
62813429|NCT01064440|EXPERIMENTAL|High Dose VM202|Patients in this treatment group received a total of 16mg VM202. Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 4mg of VM202 (16 injections of 0.5ml of VM202) Day42: 4mg of VM202 (16 injections of 0.5ml of VM202)
62427801|NCT03836365|ACTIVE_COMPARATOR|Preoperative counseling phone call|Participants will receive a preoperative counseling phone call (preoperative counseling session). This will occur within a few weeks of surgery. Preoperative counseling topics are standardized and will be identical with each arm.
62427802|NCT02586545|EXPERIMENTAL|Shared care model|Four visits a year: one annual comprehensive check-up at the outpatient diabetes clinic and three quarterly visits at the general practitioner.
62427803|NCT02586545|NO_INTERVENTION|Mono sectorial care|Treament as usual including four visits a year with the diabetes team at the outpatient clinic: an annual comprehensive check-up, identical to the one received by the intervention group, and three quarterly visits.
62427804|NCT01038882|ACTIVE_COMPARATOR|Midazolam|The patients of this arma receives midazolam before the flexible bronchoscopy to maintain conscious sedation
62427805|NCT01038882|PLACEBO_COMPARATOR|Physiological serum|
62237497|NCT03502954|PLACEBO_COMPARATOR|Placebo SC|
62427806|NCT03458026|EXPERIMENTAL|connected object + SMS of physical activity reminders|"The patients will be included during their visit of follow-up and will receive a watch connected. They will have an information meeting for their to explain how step shows it. They will also receive advice to practise an adapted physical activity. During 12 weeks of SMS (text messages) every week to motivate them to realize these exercises.~At the end of 12 weeks the connected watch will be deprived of them as well as SMS (text messages). They will have to realize an activity in autonomy during 12 weeks.~At the end of the twenty-fourth week, they will get back their watch. They will have in more 1 session with a coach and 2 sessions to be made in autonomy during 12 weeks.~In 36 week, they return the watch and finish the study."
62595776|NCT04441684|EXPERIMENTAL|No PCR|This group includes any person, for which no COVID 19 RT- PCR testing was performed.
62595777|NCT04216589|EXPERIMENTAL|Semaglutide|All participants received a dose of 0.25 mg of semaglutide weekly starting at study entry, followed by 0.5 mg weekly starting at Week 2, and then 1.0 mg weekly from Weeks 4 through 24.
62813430|NCT01064440|SHAM_COMPARATOR|Placebo|Patients in this group received a total of 8ml normal saline. Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
62427807|NCT03458026|OTHER|Without connected object|"The patients will be included during their visit of follow-up.They will have an information to practice suitable activity during 12 weeks At the end of 12 weeks, they realised follow-up. They will have to realize an activity in autonomy during 12 weeks.~At the end of the twenty-fourth week, they will have 1 session with a coach and 2 sessions to be made in autonomy during 12 weeks.~In 36 week, the study will be finished."
62427808|NCT01477957||Surgery|bariatric surgery
62427809|NCT05529628||Control|Healthy volunteers with no known chronic or cancer disease
62427810|NCT05529628||Fournier's gangrene|Fournier's gangrene patients
62427811|NCT05529628||Perianal abscess|Perianal abscess patients
62427812|NCT02855632|EXPERIMENTAL|G-CSF|G-CSF(1.8ml) will be injected into the uterine cavity by insemination catheter 7 days after first hysteroscopic adhesiolysis.
62427813|NCT02855632|PLACEBO_COMPARATOR|Normal saline|equal volume of normal saline(1.8ml) will be injected into the uterine cavity by insemination catheter 7 days after first hysteroscopic adhesiolysis.
62427814|NCT04529161|EXPERIMENTAL|Group A|Diet followed by routine eating
62427815|NCT04529161|EXPERIMENTAL|Group B|Routine eating followed by diet
62427816|NCT00520494|EXPERIMENTAL|Vivaglobin|Vivaglobin: 16% (160 mg/mL) liquid formulation of human IgG for SC use. Loading dose: 100 mg/kg for 5 consecutive days; maintenance dose: 100 mg/kg 1 to 2 times a week for 24 weeks.
62427817|NCT03156582||"all participants included Milan criteria  and AFP score"|"The first arm is made of liver recipients or dropped off list patients at the time of the Milan criteria (fixed until 2013/06/01 for transplanted patients because mandatory three months reevaluation of patients obliged the various teams to respect the criteria at this time, but until 2013/03/01 for dropped off patients because we did not want to count dropped of because of the AFP score in this arm).~The second arm is made of liver recipients or dropped off list patients at the time of the AFP score (fixed after 2013/06/01)for transplanted patients and after 2013/03/01 for dropped off patients)"
62427818|NCT02869295|EXPERIMENTAL|NKTR-214 Dose Escalation|This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR--214 in adult patients with locally advanced and metastatic solid tumors. The Phase 1 stage of the study is designed as an open-label dose escalation trial of NKTR--214 in participants with locally advanced or metastatic solid tumors. The goal of the dose escalation stage of the study is to find the recommended phase 2 dose, to evaluate the efficacy of NKTR--214 by assessing the objective response rate and to evaluate the safety of NKTR-214. Immunological biomarkers in plasma and tumor samples will also be measured.
62427819|NCT01470586|OTHER|Surgery for colorectal cancer|Colorectal cancer patients
62427820|NCT01470586|NO_INTERVENTION|Controls|Controls
62427821|NCT00744601||1|Patients with Cocaine Addiction
62427822|NCT00744601||2|Healthy Control Volunteers
62427823|NCT01179139|ACTIVE_COMPARATOR|Healthy Control|
62427824|NCT01179139|EXPERIMENTAL|CRS|
62427825|NCT05437484|EXPERIMENTAL|Intervention group: peer-led BASICS session|Participants randomized to the intervention group received a peer-led BASICS session.
62427826|NCT05437484|NO_INTERVENTION|Control group|Participants randomized to the control group did not receive any specific intervention.
62427827|NCT03252574|OTHER|Sequence AB|No mask, followed by AIR+ Smart Mask only (A), then AIR+ Smart Mask with micro-ventilator (B)
62427828|NCT03252574|OTHER|Sequence BA|No mask, followed by AIR+ Smart Mask with micro-ventilator (B), then AIR+ Smart Mask only (A).
62427829|NCT02143089|ACTIVE_COMPARATOR|Group 1|Use of urinary catheterization in Cesarean section
62427830|NCT02143089|NO_INTERVENTION|Group 2|NO urinary catheterization during Cesarean section
62427831|NCT04637685|ACTIVE_COMPARATOR|Standard pressure|Infusion pressures during phacoemulsification surgeon using the Alcon active sentry system with the Centurion - 70mmHg
62427832|NCT04637685|ACTIVE_COMPARATOR|Low or physiological pressure|Infusion pressures during phacoemulsification surgeon using the Alcon active sentry system with the Centurion - 30mmHg
62427833|NCT05827783|EXPERIMENTAL|Bee Buzzy|Bee Buzzy Group: Bee Buzzy was attached to the 3-6-year-old child included in this group by the researcher on the arm of the nurse to perform the phlebotomy procedure. Bee Buzzy reduces pain thanks to its cold wings and vibration. It helps to distract attention during phlebotomy and reduces the feeling of pain and fear. Bee Buzzy was tied 5 cm above the area from which blood will be drawn, and after waiting for 15 seconds, the nurse performed a phlebotomy.
62427834|NCT05827783|EXPERIMENTAL|Puppet Zuzu|While the nurse was going to perform the phlebotomy operation on the 3-6-year-old child included in this group, one of the researchers (no. 2) tried to distract the child by putting the puppet on her hand and making her talk. The puppet used is an easy-to-use and hand-held puppet that will not cause fear in children. The puppet was named 'Zuzu' by researchers.
62595778|NCT00070382|EXPERIMENTAL|Darbepoetin alfa|darbepoetin alfa administered once every two weeks at a dose of 200 ug over a 16 week treatment period.
62595779|NCT00070382|ACTIVE_COMPARATOR|Epoetin alfa|epoetin alfa administered at 40,000 unites, once per week over a 16-week treatment period.
62595780|NCT05176483|EXPERIMENTAL|Zanzalintinib + Nivolumab Dose-Escalation Cohorts|"Approximately 12 subjects will accrue across 1-2 dose levels of Zanzalintinib following the rolling 6 design."
62813431|NCT06117930||Observational|Participants undergo blood, tissue, saliva, urine and stool sample collection and complete questionnaires on study.
62237498|NCT04327492||Carotid endarterectomy|"This study is a non-interventional prospective cohort study. The population corresponds to patients submitted to CEA under regional anesthesia. Consecutive patients from a tertiary referral center who undergo CEA for carotid artery stenosis (CS) will be prospectively recruited. The expected patient follow-up will be of 5 years.~The demographics will be recorded in a prospective, protected database. Blood samples will be collected in clot activator serum tubes at three timepoints: timepoint 1 - before surgery (until 15 days before surgery); timepoint 2 up to 48h postoperatively; timepoint"
62036283|NCT00802074|ACTIVE_COMPARATOR|Group B|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg BID + Raltegravir 400mg BID Period 3 Fosamprenavir 1400mg BID
62237499|NCT04586517|EXPERIMENTAL|Intervention group|Participants will receive supervised heavy-load resistance training twice a week during treatment with chemotherapy (approximately 16-weeks). After end of chemotherapy, participants will be encouraged to continue the training program and are provided with 12-month membership at a local gym.
62036284|NCT00802074|ACTIVE_COMPARATOR|Group C|Period 1-Raltegravir 400mg BID Period2- Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3- Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID
62237500|NCT04586517|ACTIVE_COMPARATOR|Control group|Participants will be encouraged to continue with their usual activities during chemotherapy and not start resistance training (approximately 16-weeks). After end of chemotherapy participants will be offered to attend a 2-week introduction to the strength-training program and provided with a 12-month membership at a local gym.
62036285|NCT00802074|ACTIVE_COMPARATOR|Group D|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID
62036286|NCT00802074|ACTIVE_COMPARATOR|Group E|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3- Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID
62036287|NCT00802074|ACTIVE_COMPARATOR|Group F|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
62036288|NCT01767740|EXPERIMENTAL|ULTRABRAID PLUS SUTURE|ULTRABRAID Plus Suture manufactured by Smith \& Nephew used in subjects undergoing rotator cuff repair.
62036289|NCT01767740|ACTIVE_COMPARATOR|ULTRABRAID SUTURE|ULTRABRAID Suture is a marketed suture manufactured by Smith \& Nephew used in subjects undergoing rotator cuff repair.
62036290|NCT06535048||Fatty Liver|Hepatitis B patients with fatty liver
62427835|NCT05827783|NO_INTERVENTION|Control|No attempt was made to the 3-6-year-old child included in this group, during the process when the nurse performed the phlebotomy. Routine phlebotomy was performed. Pain and fear of the child during the procedure were evaluated.
62427836|NCT04395885||study group|health care staff, regardless of gender, who is actively working during the outbreak
62427837|NCT04395885||control group|age matched group of non-health worker individuals.
62427838|NCT03966573|OTHER|Evaluating function, Radiographic imaging, Forms|"* Tests for lower extremity function~* Evaluating arthritis of hip and knee, leg length discrepancy and axis deviation radiographically~* Evaluating quality of life, function and pain by forms"
62427839|NCT04497090|ACTIVE_COMPARATOR|Fixed-EPAP|EPAP was kept fixed at the prescribed level throughout the night
62427840|NCT04497090|EXPERIMENTAL|Auto-EPAP|EPAP was continuously adjusted using the experimental approach aimed at abolishing tidal expiratory flow limitation
62427841|NCT02080533|EXPERIMENTAL|Single|Slow-paced respiration therapy
62595781|NCT05176483|EXPERIMENTAL|Zanzalintinib + Nivolumab + Ipilimumab Dose-Escalation Cohorts|"Approximately 12 subjects will accrue across 1-2 dose levels of Zanzalintinib following the rolling 6 design."
62595782|NCT05176483|EXPERIMENTAL|Zanzalintinib + Nivolumab Expansion Cohorts|The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.
62595783|NCT05176483|EXPERIMENTAL|Zanzalintinib + Nivolumab + Ipilimumab Expansion Cohorts|The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.
62036291|NCT06535048||Non-Fatty Liver|Hepatitis B patients without fatty liver
62036292|NCT06580691|ACTIVE_COMPARATOR|Subcision plus Plasma gel|The gel was injected into the scarred areas immediately after subcision.
62237501|NCT02229045|EXPERIMENTAL|Albumin Bound Paclitaxel With 5-FU/CF|Albumin Bound Paclitaxel 150 mg/m2 (on day 1),5FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
62427842|NCT06522230|EXPERIMENTAL|Fascial Stretch Therapy Intervention|Participants receive 3 x 30 Minutes of Fascial Stretch Therapy (FST). FST is designed to enhance flexibility and functional range of motion. During these sessions, participant will be lying down comfortably while a trained therapist gently stretches their body. The therapist will use a mix of pulling, gentle movements, and controlled stretches to loosen up the connective tissue around your muscles and joints.
62427843|NCT03372083|EXPERIMENTAL|Deferasirox|Crushed deferasirox (ICL670) FCT for oral use daily. Deferasirox FCT dosing was based on subject's weight.
62427844|NCT01039584|PLACEBO_COMPARATOR|Placebo|vehicle of the test product; applied intravaginally once within 48 hours of randomization
62427845|NCT01039584|EXPERIMENTAL|Test Product|Butoconazole Nitrate Vaginal Cream; applied intravaginally once within 48 hours of randomization
62427846|NCT01039584|ACTIVE_COMPARATOR|Reference Product|Gynazole 1 Vaginal Cream; applied intravaginally once within 48 hours of randomization
62427847|NCT00611741|EXPERIMENTAL|Drug intervention, longitudinal|Furosemide and Na supplements
62427848|NCT02458365|EXPERIMENTAL|Teen Choices|Teen Choices: A Program for Healthy Nonviolent Relationships
62427849|NCT02458365|OTHER|Comparison|Health In Motion
62427850|NCT05678699|OTHER|Medicaid healthcare quality interventions (equity payment and obstetric bundled payment) Only|The investigators will employ a quasi-experimental study design to test two hypotheses: H1: SMM rates among Black people will decline after the interventions (equity payment and obstetric bundled payment), relative to people of other race groups within Pennsylvania (PA); and H2: Racial inequities in SMM will decline among those exposed to the interventions in PA, relative to those in similar states. The investigators will collect qualitative data to assess the effects of the Medicaid healthcare interventions on beneficiaries' experiences.
62813432|NCT04291846|EXPERIMENTAL|A|
62595784|NCT05176483|EXPERIMENTAL|Zanzalintinib Single-Agent Expansion Cohorts|
62595785|NCT05176483|EXPERIMENTAL|Zanzalintinib + Nivolumab + Relatlimab Dose-Escalation Cohorts|"Approximately 12 subjects will accrue across 1-2 dose levels of Zanzalintinib following the rolling 6 design."
62595786|NCT05176483|EXPERIMENTAL|Zanzalintinib + Nivolumab + Relatlimab Expansion Cohorts|The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.
62595787|NCT00382590|ACTIVE_COMPARATOR|5-Aza + VPA|5-Azacytidine (5-Aza) 75 mg/m\^2 subcutaneously daily + Valproic Acid (VPA) 50 mg/m\^2 orally daily, each for 7 days
62595788|NCT00382590|ACTIVE_COMPARATOR|Ara-C|Low-Dose Ara-C 20 mg twice daily subcutaneously for 10 days.
62595789|NCT06039371|ACTIVE_COMPARATOR|Cohort Ia (testosterone cypionate, carboplatin)|Patients continue to receive ADT per standard of care and receive testosterone cypionate IM on day 1 of cycle 1. Patients then receive testosterone cypionate IM and carboplatin IV on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
62595790|NCT06039371|ACTIVE_COMPARATOR|Cohort Ib (testosterone cypionate, carboplatin)|Patients continue to receive ADT per standard of care and receive carboplatin IV on day 1 of cycle 1. Patients then receive testosterone cypionate IM and carboplatin IV on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
62595791|NCT06039371|EXPERIMENTAL|Cohort Ic (testosterone cypionate, carboplatin)|Patients continue to receive ADT per standard of care and receive testosterone cypionate IM and carboplatin IV on day 1 of cycle 1. Patients then receive testosterone cypionate IM and carboplatin IV on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
62813433|NCT04291846|EXPERIMENTAL|B|
62237502|NCT01758263||Metoprolol to Nebivolol|Patients with high blood pressure (hypertension) who were continuously treated with metoprolol for a minimum of 6 months prior to switching to nebivolol. Patients were then continuously treated with nebivolol for a minimum of 6 months.
62036293|NCT06580691|ACTIVE_COMPARATOR|Subcision plus Cog PDO threads|"Cog PDO threads were inserted using a blunt-tipped cannula in a Z pattern within the scarred areas, filling the pockets created by subcision."
62237503|NCT01162213|EXPERIMENTAL|100 mg of Lychee fruit extract|
62237504|NCT01162213|EXPERIMENTAL|200 mg of Lychee fruit extract|
62237505|NCT01162213|EXPERIMENTAL|600 mg of Lychee fruit extract|
62237506|NCT01162213|EXPERIMENTAL|2000 mg of Lychee fruit extract|
62595792|NCT06039371|ACTIVE_COMPARATOR|Cohort IIa (testosterone cypionate, etoposide)|Patients continue to receive ADT per standard of care and receive testosterone cypionate IM on day 1 of cycle 1. Patients then receive testosterone cypionate IM on day 1 and etoposide PO QD on days 1-14 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
62595793|NCT06039371|ACTIVE_COMPARATOR|Cohort IIb (testosterone cypionate, etoposide)|Patients continue to receive ADT per standard of care and receive etoposide PO QD on days 1-14 of cycle 1. Patients then receive testosterone cypionate IM on day 1 and etoposide PO QD on days 1-14 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
62237507|NCT01274013||Study Group|Individuals with chronic Hepatitis C
62237508|NCT01274013||Control Group|Healthy individuals
62237509|NCT01660126|ACTIVE_COMPARATOR|Levothyroxine|Oral Levothyroxine, starting dose 25 or 50 micrograms increased to a maximum of 150 micrograms once daily.
62237510|NCT01660126|PLACEBO_COMPARATOR|Placebo|Matched placebo
62237511|NCT04461808|EXPERIMENTAL|Tomosynthesis + synthetic 2D|"Women will be screened for one round with tomosynthesis + synthetic 2D, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
62036294|NCT01356875|EXPERIMENTAL|HIDRA/VPA|In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycles of hydralazine and valproic acid.
62036295|NCT01356875|ACTIVE_COMPARATOR|best supportive care (BSC)|The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
62813434|NCT02457390|EXPERIMENTAL|CE-LUS|"Laparoscopic ultrasound examination (LUS) of the liver during robot assisted CRC surgery. The liver is systematically scanned for unrecognized liver metastases.~After the laparoscopic LUS procedure, the liver is then systematically scanned with contrast enhancement with SonoVue® containing Sulphurhexafluoride. A bolus of 2.5 ml is injected into a peripheral vein followed by 10 ml of isotonic saline. The liver is then systematically scanned in 3 phases (arterial, venous and parenchymatous phase) searching for unrecognized liver metastases. The procedure is repeated after 5 minutes.~The time it takes to do the scan is measured and any technical challenges are reported. Time, challenges and findings of liver metastases (number, segment and size) are entered on a registration form."
62813435|NCT02845323|EXPERIMENTAL|Nivolumab in combination with Urelumab|"Nivolumab and Urelumab combination:~Nivolumab 240 mg will be administered by 1 hour intravenous infusion on day 1 and day 15 for two cycles~Urelumab 8mg will be administered by 1 hour intravenous infusion on day 1 for two cycles"
62813436|NCT02845323|ACTIVE_COMPARATOR|Nivolumab monotherapy|Nivolumab 240 mg will be administered by 1 hour intravenous infusion on day 1 and day 15 for two cycles
62813437|NCT05409209||Carotid plaque length|Patients underwent carotid ultrasonography and first coronary angiography simultaneously
62813438|NCT04094597|PLACEBO_COMPARATOR|placebo|saline is given orally in dose of 2 ml per day for one month
62813439|NCT04094597|ACTIVE_COMPARATOR|lacoferrin|Pravotin is given orally 100 mg per sachet dissolved in 5 ml water given for one month
62813440|NCT00951353||Pediatric Renal Transplant Recipients|
62813441|NCT03744910|ACTIVE_COMPARATOR|Clazakizumab|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6 that is administered subcutaneously.
62036296|NCT02811861|EXPERIMENTAL|Lenvatinib 18 mg plus Everolimus 5 mg|Lenvatinib 18 milligrams (mg) administered orally, once daily, plus everolimus 5 mg administered orally, once daily in each 21-day cycle.
62813442|NCT03744910|PLACEBO_COMPARATOR|Placebo|Physiologic saline solution that is administered subcutaneously.
62036297|NCT02811861|EXPERIMENTAL|Lenvatinib 20 mg plus Pembrolizumab 200 mg|Lenvatinib 20 mg administered orally, once daily, in each 21-day cycle plus pembrolizumab 200 mg administered intravenously (IV), every 3 weeks on Day 1 of each 21-day cycle.
62036298|NCT02811861|ACTIVE_COMPARATOR|Sunitinib 50 mg|Sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment in each 21-day cycle.
62813443|NCT05535894||Unresectable Pancreatic Cancer|Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion
62237512|NCT04461808|ACTIVE_COMPARATOR|Digital Mammography|"Women will be screened for digital mammography, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
62813444|NCT00003714|EXPERIMENTAL|Pyrazoloacridine|
62813445|NCT03921749|EXPERIMENTAL|Focused shock wave|The extracorporeal shock wave will be applied to the patellofemoral and tibiofemoral borders and the subchondral bone of the medial tibia condyle of the affected knee joint. The intensities used will be focused shock wave therapy (0.20 mJ/mm 2 )
62813446|NCT03921749|EXPERIMENTAL|Raidal shock wave|The extracorporeal shock wave will be applied to the patellofemoral and tibiofemoral borders and the subchondral bone of the medial tibia condyle of the affected knee joint. The intensities used will be radial shock wave therapy (3 bar)
62036299|NCT06273423|EXPERIMENTAL|Group dance fitness, OULA|Mind-body dance fitness group
62036300|NCT06273423|NO_INTERVENTION|Waitlist Control|Waitlist control group
62036301|NCT05170165||Enrolled Subjects|Test a clinical decision support (CDS) tool that provides clinicians (cardiologists and nurse practitioners) recommendations regarding guideline directed medical therapy (GDMT) in patients with heart failure and reduced ejection fraction (HFrEF).
62813447|NCT05097820||Cisgender patients|All cisgender patients in which one or two testicular prostheses are to be implanted for various reasons.
62813448|NCT05097820||Transgender patients|All transgender patients in which one or two testicular prostheses are to be implanted for gender reassignment surgery.
62813449|NCT01884051||PAH patients|Patients diagnosed with WHO Group 1 PAH
62813450|NCT01884051||Healthy subjects|Subjects who have been evaluated for heart and lung disease and found to be healthy
62813451|NCT03309969||observation group|Subjects with suspicious iliac vein compression syndrome were included in the observation group.
62237513|NCT02513420|EXPERIMENTAL|Perineal muscle training|This group will recibe a training of a combination of perineal massage and pelvic floor muscle excersice that will start after 33 weeks of gestation. Every week until the childbith, They will be evaluated with a diary.
62036302|NCT04079621|EXPERIMENTAL|(P.f)|patients with falciparum malaria will receive artemether-lumefantrine (AL) twice daily over three days plus a low dose course of primaquine (PQ) (3.5mg/kg total dose) given 7 days during schizontocidal treatment
62036303|NCT04079621|EXPERIMENTAL|(P.v)|patients with vivax malaria will receive chloroquine (CQ) daily for three days plus a low dose course of PQ (3.5mg/kg total dose) given over 7 days during schizontocidal treatment.
62237514|NCT02513420|NO_INTERVENTION|Usual prental care|Usually pregnant women have not a training focused in pelvic floor muscle, so this group won't receive any indication of pelvic floor training except if They complains of urinary incontinence.
62237515|NCT01603082|EXPERIMENTAL|Ticagrelor|Ticagrelor - 180 mg loading dose
62237516|NCT01603082|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel - 600 mg loading dose
62237517|NCT01862133||Patient Preferences|Patients were eligible if they had visited their primary care physician at least twice in the previous 1 year and were fluent in English. Each patient subject used an online program to record their preferences what each of their providers can see. The electronic medical record (EMR) will then apply them to data displays.
62237518|NCT01862133||Primary Care Providers|All healthcare providers (physicians, nurses, and other clinic staff) were eligible to participate in this study. For those enrolled, display of patient data in the EMR was dictated by the patient subject's preferences for who should see what data.
62237519|NCT06298812|OTHER|REFLECT|Enrolled patients are treated with the REFLECT Scoliosis System. This is an HDE-approved device.
62237520|NCT05188326|EXPERIMENTAL|Azacitidine|Vidaza consists of 50 mg/ m2 s.c or i.v for 7 days (5 + weekend off + 2) every 28 days and increase after 1st cycle, if well tolerated, to 75 mg/m2 s.c or i.v. for 7 days (5 + weekend off + 2) every 28 days for further 5 cycles followed by cycles every 56 days for 4 years and six months
62237521|NCT05188326|PLACEBO_COMPARATOR|Best supportive care|No drug administration
62237522|NCT02862860|EXPERIMENTAL|patients with type-1 diabetes|
62427851|NCT05678699|OTHER|Doula Only|The investigators will test two hypotheses: H1: SMM rates among Black people will decline more after the addition of doula care in PA, relative to healthcare quality interventions alone. H2: Racial inequities in SMM will decline more among those exposed to both healthcare quality and doula care interventions in PA, relative to states implementing doula care only. The investigators will collect qualitative data to assess the effects of the Medicaid healthcare and service interventions on beneficiaries' experiences.
62427852|NCT05678699|OTHER|Medicaid healthcare quality interventions (equity payment and obstetric bundled payment) + Doula|
62427853|NCT05678699|NO_INTERVENTION|Standard Care|
62427854|NCT01656967|EXPERIMENTAL|AMBU Aura-I/aScope 2|First, the AMBU Aura-I LMA will be inserted. Then, the patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
62427855|NCT01656967|EXPERIMENTAL|LMA Fastrach|The LMA Fastrach Single Use Laryngeal Mask Airway will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
62427856|NCT01453374|EXPERIMENTAL|VIVITROL|380 mg IM injection
62813452|NCT05230940|EXPERIMENTAL|TURKOVAC|The dose of the TURKOVAC vaccine will be 3 μg/0.5 mL. It will be administered by injection to the left deltoid muscle of the upper arm, two doses are given 28 days apart.
62813453|NCT05230940|ACTIVE_COMPARATOR|CoronaVac|The dose of the CoronaVac vaccine will be 3 μg/0.5 mL. It will be administered by injection to the left deltoid muscle of the upper arm, two doses are given 28 days apart.
62813454|NCT02916186|EXPERIMENTAL|Tunnel technique with acellular dermal matrix|the tunnel technique involves separation of the gingiva, then acellular dermal matrix interposed between the flap and the root surface.
62036304|NCT04079621|NO_INTERVENTION|Standard care (P.f)|patients with falciparum malaria will receive artemether-lumefantrine (AL) twice daily over three days (plus a single dose PQ)
62036305|NCT04079621|NO_INTERVENTION|Standard care (P.v)|patients with vivax malaria will receive chloroquine (CQ) daily for three days plus a low dose course of PQ (total dose 3.5mg/kg) over 14 days
62237523|NCT02862860|PLACEBO_COMPARATOR|Controls|
62427857|NCT01384864|EXPERIMENTAL|treatment|fluorescent imaging with proflavine
62427858|NCT01250626||a single-group study|Pediatric OPD, age \< 18 y/o.
62427859|NCT04564040|EXPERIMENTAL|Acalabrutinib Treatment Sequence 1|"Part 1: Participants will receive Treatment A (100 mg AT suspension in water via NG administration) in Period 1, Treatment B (100 mg acalabrutinib capsule suspension via NG administration) in Period 2, and Treatment C (100 mg AT suspension in water via NG administration plus 20 mg rabeprazole) in Period 3.~Part 2: Participants will receive Treatment D (100 mg AT suspension in water via NG administration) in Period 1 and Treatment A in Period 2."
62036306|NCT03112382|ACTIVE_COMPARATOR|zinc supplement plus vitamin A and E|patients will be receiving zinc supplement plus vitamin A and E for 3 months.
62036307|NCT03112382|ACTIVE_COMPARATOR|vitamin A and E|patients will be receiving equivalent dose of vitamin A and E only for 3 months
62427860|NCT04564040|EXPERIMENTAL|Acalabrutinib Treatment Sequence 2|"Part 1: Participants will receive Treatment B in Period 1, Treatment A in Period 2, and Treatment C in Period 3.~Part 2: Participants will receive Treatment A in Period 1 and Treatment D in Period 2."
62813455|NCT02916186|ACTIVE_COMPARATOR|subepithelial connective tissue graft|Tunnel is prepared and sub-epithelial connective tissue graft is harvested from the palate and placed under the flap.
62813456|NCT06123377|EXPERIMENTAL|39 weeks|Patients with gestational hypertension and angiogenic factors (sFlt-1/PIGF) below 33 will be evaluated weekly until 39 weeks, when termination of pregnancy will be scheduled.
62813457|NCT06123377|ACTIVE_COMPARATOR|37 weeks|Patients with gestational hypertension and angiogenic factors (sFlt-1/PIGF) below 33 will be evaluated weekly until 37 weeks, when termination of pregnancy will be scheduled.
62813458|NCT05836441|ACTIVE_COMPARATOR|White spot irradiation group|Exposure to white patches
62813459|NCT05836441|EXPERIMENTAL|White spot edge irradiation group|Exposure to edge of white patches and normal skin around white patches
62813460|NCT04579991|ACTIVE_COMPARATOR|Active Group|Apply small amount of topical visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel on mucosal surface of vulva included clitoris every day before bedtime for 8-week period.
62036308|NCT03112382|NO_INTERVENTION|no vitamins|patients will be observed for 3 months
62036309|NCT06115733|EXPERIMENTAL|Capecitabine combined with fuquitinib|"Phase Ⅰb dose exploration trial of fuquinitinib combined with capecitabine (n=6-9) :~1. Capecitabine: 1000 mg/m² orally, twice a day on days 1-21 of each cycle, 28 days for one treatment cycle.~2. Fuquinitinib: 1 to 21 days per cycle, orally, once a day, 28 days for a treatment cycle. There are two dose gradients of fuquintinib: 2mg/d, and the initial dose of 3mg/d is 2mg/d. According to the 3+3 dose climbing principle, dose exploration is carried out in the order of 2mg/d→3mg/d, The recommended dose of fuquinitinib combined with capecitabine, as determined in phase I b, continued to enroll 47 patients in the dose-expansion phase trial until the patient became intolerant of toxicity or disease progression."
62036310|NCT04897074|EXPERIMENTAL|AKL-T01|Digital Treatment
62237524|NCT03142971|EXPERIMENTAL|Intervention:f-ESWT (focused shock wave therapy)|In the study-group, a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf) was used . At the beginning of each treatment session, the enthesis of the gluteal tendons at the greater trochanter (at the anterior half of its lateral facet) was targeted through a non-inline sonographic focusing, using a linear probe (7.5-12 MHz) connected to an ultrasound scanner (ESAOTE MYLAB FIVE, Genova and Florence, Italy). All patients received 1800 pulses (frequency=4Hz) of an energy flux density of 0.15 mJ/mm2 once a week for three consecutive weeks. At the first treatment session, the energy flux density was gradually increased from 0.05 to 0.15 mJ/mm2 during the first 500 pulses.
62237525|NCT03142971|ACTIVE_COMPARATOR|Intervention:UST (ultrasound therapy)|In the control-group, we used a mono-frequency device (ROLAND, RT-20 series, frequency=1MHz). We treated an area of 5cm2, softly moving the US-probe around the most painful point of the greater trochanter at the clinical palpation. UST was supplied in a continuous modality, with an intensity of 1.5 W/cm2, for ten consecutive daily sessions of ten minutes each.
62595794|NCT06039371|EXPERIMENTAL|Cohort IIc (testosterone cypionate, etoposide)|Patients continue to receive ADT per standard of care and receive testosterone cypionate IM on day 1 and etoposide PO QD on days 1-14 of cycle 1. Patients then receive testosterone cypionate IM on day 1 and etoposide PO QD on days 1-14 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
62595795|NCT05797415||Sebaceous carcinoma|patients with sebaceous carcinoma both primary and relapsed after surgical and/or radiation-chemotherapy treatment at Fondazione Policlinico Universitario A. Gemelli IRCCS
62427861|NCT06541210||Observational|Participants complete surveys and may participate in an interview on study.
62595796|NCT05797415||Merkel's carcinoma|patients with Merkel's carcinoma both primary and relapsed after surgical and/or radiation-chemotherapy treatment at Fondazione Policlinico Universitario A. Gemelli IRCCS
62595797|NCT05797415||Porocarcinoma|patients with Porocarcinoma both primary and relapsed after surgical and/or radiation-chemotherapy treatment at Fondazione Policlinico Universitario A. Gemelli IRCCS
62595798|NCT05797415||Conjunctival Melanoma|patients with Conjunctival Melanoma both primary and relapsed after surgical and/or radiation-chemotherapy treatment at Fondazione Policlinico Universitario A. Gemelli IRCCS
62595799|NCT05797415||Squamous cell Carcinoma|patients with squamous cell Carcinoma of the ocular surface and adnexa both primary and relapsed after surgical and/or radiation-chemotherapy treatment at Fondazione Policlinico Universitario A. Gemelli IRCCS
62595800|NCT04725058|EXPERIMENTAL|Medical Group Visit|Participants receive obesity management in a group setting let by endocrinologist and nutritionist.
62036311|NCT01456026|EXPERIMENTAL|Glycated beta-lactoglobulins|In this randomized, double blind,cross-over study, half of the subjects will receive on one day a beverage with a high AGE content and will be switched after a wash-out of min. 7 days to receive a low-AGE beverage (comparator). The other half will receive the beverages in inverse sequence.
62595801|NCT04725058|EXPERIMENTAL|Dietitian-Led Visit|Participant receives obesity management in an individual setting lead by registered dietitian.
62595802|NCT01521156|ACTIVE_COMPARATOR|1 = Control product|
62237526|NCT00524212||IE confirmed IE rejected|Prospective, controlled, blinded study of clinical/TEE criteria of IE compare to clinical/blood test criteria of IE.
62237527|NCT00524212||IE confirmed IE rejected|
62813461|NCT04579991|PLACEBO_COMPARATOR|Placebo Group|Apply small amount of topical emulgel-only on mucosal surface of vulva included clitoris every day before bedtime for 8-week period.
62813462|NCT04090918||Group 1: Abdominal surgery with POAF|Twenty patients undergoing abdominal surgery with new-onset atrial fibrillation
62595803|NCT01521156|EXPERIMENTAL|2 = Tested product|
62595804|NCT01652430||PTSD cohort|
62595805|NCT01652430||No PTSD cohort|
62595806|NCT00864825|EXPERIMENTAL|Allopurinol|
62036312|NCT01456026|ACTIVE_COMPARATOR|Non-glycated beta-lactoglobulins|In this randomized, double blind,cross-over study, half of the subjects will receive on one day a beverage with a high AGE content and will be switched after a wash-out of min. 7 days to receive a low-AGE beverage (comparator). The other half will receive the beverages in inverse sequence.
62813463|NCT04090918||Group 2: Abdominal surgery without POAF|Twenty patients undergoing abdominal surgery without new-onset atrial fibrillation matching patients in group 1 on age, sex and comorbidities.
62813464|NCT05718947||MS scan cohort|10 patients with a known clinical diagnosis of relapsing remitting MS according to the 2017 McDonald criteria between ages of 18-65 years, who had a new lesion on their clinical brain MRI in the prior 15 months. The investigators intend to include patients on low-efficacy medication (interferon β, peginterferon, glatiramer acetate, teriflunomide) as well as patients on high-efficacy medication (natalizumab, ocrelizumab, alemtuzumab, fingolimod) to have a varied and representative study population.
62036313|NCT02057900|EXPERIMENTAL|Human embryonic stem cell|Patients with ischemic heart failure receiving a fibrin gel embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors in addition to coronary artery bypass grafting and/or a mitral valve procedure.
62237528|NCT06076486|EXPERIMENTAL|Elagolix 200 mg BID|Participants received elagolix 200 mg tablets twice a day (BID)
62237529|NCT06076486|PLACEBO_COMPARATOR|Elagolix placebo|Participants received elagolix placebo twice a day (BID)
62237530|NCT03217149|EXPERIMENTAL|heliox combined with mechanical ventilation (MV)|heliox combined with mechanical ventilation (MV) is given to infant with ARDS
62237531|NCT03217149|ACTIVE_COMPARATOR|mechanical ventilation|mechanical ventilation (MV) is given to infant with ARDS
62237532|NCT00568321|EXPERIMENTAL|1|
62237533|NCT00568321|ACTIVE_COMPARATOR|2|
62237534|NCT00568321|PLACEBO_COMPARATOR|3|
62237535|NCT02767375|ACTIVE_COMPARATOR|HAIC treatment group|HAIC treatment after resection Intervention: Drug: Oxaliplatin, 5-fluorouracil (5-FU) Procedure/Surgery: Hepatic arterial catheter implantation
62237536|NCT02767375|NO_INTERVENTION|No HAIC treatment group|Best support care and follow up
62237537|NCT00548054|EXPERIMENTAL|Vaccine Group for Vibriocidal Assay|Killed whole cell cholera vaccine bled at day 42 for vibriocidal assay
62595807|NCT00864825|PLACEBO_COMPARATOR|Placebo|
62595808|NCT06473597|ACTIVE_COMPARATOR|Rimegepant (Nurtec ODT)|Rimegepant (Nurtec ODT) 75 mg orally disintegrating tablets
62595809|NCT06473597|ACTIVE_COMPARATOR|Rizatriptan Benzoate (Maxalt MLT-ODT)|Rizatriptan ODT 10mg orally disintegrating tablets
62595810|NCT00875199|ACTIVE_COMPARATOR|A|Participants assigned to Group A will receive the DPP manual (Wing \& Gillis, 1996), a behavioral weight-loss program with demonstrated efficacy in facilitating weight loss. Participants in Group A will be instructed to read a section of the manual each week and complete suggested activities. They will also meet with the research staff once a week for weigh-in and supportive counseling.
62595811|NCT00875199|EXPERIMENTAL|B|Participants assigned to Group B will receive the DPP manual and will meet with research staff each week for weigh-in and supportive counseling. They will also receive contingency management or the opportunity to earn draws with the chance of winning prizes for losing weight and completing healthy activities.
62595812|NCT03130673||hip fracture|fracture of proximal femur
62595813|NCT03249597||1. Suspected Infection.|Adult (≥18 years), non-trauma patient transported by the ambulance, who according to the EMS suffer from an infection.
62595814|NCT03249597||2. Control|Adult (\>18 years of age), non-trauma patient immediately following the included patient with suspected infection, transported in the same ambulance but without infection.
62595815|NCT06255522|EXPERIMENTAL|Fully guided implant placement|Through guided surgery implant placement will be performed in maxilla or mandibula in a one stage surgery. The final position will be compare with the initial digital implant planning.
62595816|NCT06522282|EXPERIMENTAL|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
62813465|NCT04427527|EXPERIMENTAL|Multi-level Intervention|Receives the project intervention first
62813466|NCT04427527|NO_INTERVENTION|Delayed Multi-level Intervention|Offered the intervention later in the project
62813467|NCT04640441|NO_INTERVENTION|Control group|Participants in the control group received usual care.
62813468|NCT04640441|EXPERIMENTAL|Sit-to-stand care group|Intervention was provided once daily by trained nurses for a maximum of 14 days or until hospital discharge or death.
62595817|NCT06522282|PLACEBO_COMPARATOR|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
62813469|NCT03177902||Observational group|Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy
62813470|NCT03177902||Control group|Healthy Volunteers
62813471|NCT05511181|EXPERIMENTAL|BioWave|BioWaveGO is a FDA 510(k) cleared high frequency neurostimulator. Patients that are first randomized to the BioWave arm will receive a 30 minute treatment in the clinic with a BioWaveGO device followed by a 30 minute washout and ending with a final 30 minute treatment. Data will be collected before, and after the final treatment. Patients will then be instructed to take the BioWaveGO device home and perform two 30 minute treatment sessions daily at home for 2 weeks. Follow-up in the clinic will be after the 2-week treatment period and the patients will be assessed in clinic for physiologic measures of pain response. A washout period of 2 weeks will follow, the patients will return to the clinic at week 4 and the patients will crossover to receive the TENS treatment (as described in the TENS arm).
62813472|NCT05511181|ACTIVE_COMPARATOR|TENS|Patients that are first randomized to the TENS arm will receive a 30 minute treatment in the clinic with an Intensity 5000 TENS device followed by a 30 minute washout and ending with a final 30 minute treatment. Data will be collected before, and after the final treatment. Patients will then be instructed to take the TENS device home and perform two 30 minute treatment sessions daily at home for 2 weeks. Follow-up in the clinic will be after the 2-week treatment period and the patients will be assessed in clinic for physiologic measures of pain response. A washout period of 2 weeks will follow, the patients will return to the clinic at week 4 and the patients will crossover to receive the BioWaveGO treatment (as described in the BioWave arm).
62813473|NCT03001557|EXPERIMENTAL|Lemborexant 2.5 milligrams (mg)|Participants will take one lemborexant 2.5 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
62813474|NCT03001557|EXPERIMENTAL|Lemborexant 5 mg|Participants will take one lemborexant 5 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
62813475|NCT03001557|EXPERIMENTAL|Lemborexant 10 mg|Participants will take one lemborexant 10 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
62813476|NCT03001557|EXPERIMENTAL|Lemborexant 15 mg|Participants will take one lemborexant 5 mg tablet and one lemborexant 10 mg tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
62813477|NCT03001557|PLACEBO_COMPARATOR|Lemborexant-matched placebo|Participants will take two lemborexant-matched placebo tablets orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
62813478|NCT05645718|EXPERIMENTAL|Leukemia CNS1 or 2|Each study block, or cycle, is 28 days. Between every cycle below, Participants will have a 7-day rest period in which no study drug is given.
62813479|NCT05645718|EXPERIMENTAL|Leukemia CNS 3|Each study block, or cycle, is 28 days. Between every cycle below, Participants will have a 7-day rest period in which no study drug is given.
62813480|NCT06151522|OTHER|Standard group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62813481|NCT06151522|OTHER|Intensive group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62813482|NCT06138899|EXPERIMENTAL|Club 25|Club 25 donation programs will be set up in schools randomized to this arm. Three blood donation events per school year will take place at study schools. Each donation event will be preceded by a motivational talk intended to inform students of the importance of blood donation and encourage students to donate blood. Donation events and motivational talks will be planned and conducted by the Malawi Blood Transfusion Services (MBTS).
62237538|NCT00548054|EXPERIMENTAL|Vaccine Group for EPI Assay|Killed whole cell cholera vaccine bled at day 56 for EPI immunogenicity testing
62595818|NCT06431399|EXPERIMENTAL|JLP-2004 FAST|Thin arm is JLP-2004 FAST condition
62595819|NCT06431399|EXPERIMENTAL|JLP-2004 FED|Thin arm is JLP-2004 FED condition
62595820|NCT04616573|ACTIVE_COMPARATOR|Ab-interno transluminal viscoelastic delivery with trabeculotomy using OMNI surgical System|Ab-interno transluminal viscoelastic delivery with trabeculotomy using OMNI surgical System
62595821|NCT04616573|ACTIVE_COMPARATOR|Ab-interno transluminal viscoelastic delivery using OMNI surgical System|Ab-interno transluminal viscoelastic delivery using OMNI surgical System
62595822|NCT04616573|ACTIVE_COMPARATOR|iStent Inject implantation|iStent Inject implantation using the iStent device
62595823|NCT02078895|EXPERIMENTAL|Botox|The experimental group will include ureteral stent placement with three peri-ureteral injections of Botox A and fourteen site-specific intradetrusor injections of Botox A.
62595824|NCT02078895|NO_INTERVENTION|Control|The control group will involve a ureteral stent placement with no injection.
62595825|NCT05803070||A|patients with alopecia areata who will be treated with topical cetirizine 1%
62813483|NCT06138899|NO_INTERVENTION|Standard procedures|Schools in this arm will not take part in a Club 25 donation program. Three blood donation events per school year will take place at study schools. Each donation event will be preceded by a motivational talk intended to inform students of the importance of blood donation and encourage students to donate blood. Donation events and motivational talks will be planned and conducted by the Malawi Blood Transfusion Services (MBTS).
62813484|NCT00910104|EXPERIMENTAL|Omegaven|1g/kg/day for duration of study participation for all participants
62813485|NCT01725906|ACTIVE_COMPARATOR|Empirical therapy|selection of antibiotic according to medication history
62595826|NCT05803070||B|patients with alopecia areata who will be treated with topical betamethasone valerate 0.1%
62595827|NCT06423963|EXPERIMENTAL|Physical activity, nutrition counseling and monitoring group (PA/N)|
62595828|NCT06423963|EXPERIMENTAL|Physical activity, tele-resistance training, nutrition counseling and monitoring group (RT/N)|
62813486|NCT01725906|EXPERIMENTAL|Genotypic resistance guided therapy|selection of antibiotics according to genotypic resistance
62813487|NCT03664297|EXPERIMENTAL|SHR1459|Oral administration, once a day, 28 days for a cycle, until the disease progression or the intolerable toxicity occurs.
62813488|NCT05198817|EXPERIMENTAL|Single Group|
62813489|NCT03820544|EXPERIMENTAL|SEMS|Patients undergo Endoscopic Retrograde Cholangiopancreatography (ERCP) with Self Expanding Metal Stents (SEMS) placement before standard of care surgical resection.
62813490|NCT03820544|ACTIVE_COMPARATOR|Standard of care surgical resection|Patients undergo standard of care surgical resection.
62813491|NCT04532268|EXPERIMENTAL|Administration of Humanized CD19 CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
62237539|NCT00548054|PLACEBO_COMPARATOR|Placebo Group for Vibriocidal Assay|Placebo bled at day 42 for vibriocidal assay
62237540|NCT00548054|PLACEBO_COMPARATOR|Placebo Group for EPI Assay|Placebo bled at day 56 for EPI immunogenicity testing
62237541|NCT00548054|EXPERIMENTAL|Vaccine Group for Vibriocidal and Measles Assay|Killed whole cell cholera vaccine bled at day 14 and 28 for measles immunogenicity testing
62595829|NCT06320015||SMART Participant|Emergency department patients at with a substance use disorder who have received SMART services
62813492|NCT03363737|ACTIVE_COMPARATOR|Static|
62813493|NCT03363737|EXPERIMENTAL|Dynamic|
62813494|NCT05620667|PLACEBO_COMPARATOR|placebo|Placebo 25mL, without any ingredients of immature ponkan extract. Drink 25mL for once, and once a day.
62813495|NCT05620667|EXPERIMENTAL|immature ponkan (Citrus reticulate) extract|Immature ponkan (Citrus reticulate) extract 25 mL, drink 25mL for once, and once a day.
62813496|NCT05620667|EXPERIMENTAL|immature ponkan (Citrus reticulate) extract with time restricted feeding|Immature ponkan (Citrus reticulate) extract 25 mL, drink 25mL for once, and once a day, adding time restricted feeding.
62237542|NCT00548054|PLACEBO_COMPARATOR|Placebo Group for Vibriocidal and Measles Assay|Placebo bled at day 14 and 28 for measles immunogenicity testing
62595830|NCT06320015||Usual Care|Emergency department patients with a substance use disorder who have not received SMART services
62595831|NCT03632629|ACTIVE_COMPARATOR|study group|3 months of individualized interactive cognitive training, 2 times per week, 15 min per session, a total of 24 sessions, in addition to traditional rehabilitation programs.
62595832|NCT03632629|NO_INTERVENTION|control group|3 months of traditional rehabilitation programs, without individualized interactive cognitive training.
62595833|NCT05989711|EXPERIMENTAL|Pemvidutide 1.2 mg (n=38)|
62595834|NCT05989711|EXPERIMENTAL|Pemvidutide 1.8 mg (n=76)|
62595835|NCT05989711|PLACEBO_COMPARATOR|Placebo (n=76)|
62595836|NCT03003039|EXPERIMENTAL|GB241|GB241:375 mg/m2, iv, one infusion
62595837|NCT03003039|ACTIVE_COMPARATOR|Rituximab|Rituximab: 375 mg/m2, iv, one infusion
62595838|NCT05587829|EXPERIMENTAL|Group A|Group A: will be treated with basic breathing technique.
62595839|NCT05587829|EXPERIMENTAL|Group B|Group B: will be treated by will be breathing technique along with diaphragm and abdominal training.
62595840|NCT06623825||ARTS|the teleconsultation by AR telemedicine system group
62595841|NCT06623825||non-ARTS|no teleconsultation by AR telemedicine system groups,but by the traditional methods like radios, telephonecalls
62595842|NCT04184362|EXPERIMENTAL|Experimental group tested at the active treatment site|The theranova empower device will be tested at the active treatment site.
62595843|NCT04184362|SHAM_COMPARATOR|Control sham group tested at the sham control treatment site|The theranova empower device will be tested the sham control treatment site.
62595844|NCT06347861|EXPERIMENTAL|single dose of vepdegestrant (3-period, 3-treatment, 6-sequence, crossover)|Vepdegestrant administered as a single dose in Period 1, 2 and 3.
62813497|NCT03482622||Patients undergoing Mohs surgery|Skin samples excised during Mohs surgery will be measured by the Fast Raman device. The Fast Raman measurements will be compared to gold standard histopathology to determine measurement accuracy.
62595845|NCT02573766|EXPERIMENTAL|Neurofeedback Training|Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
62036314|NCT05063838|EXPERIMENTAL|Pharmacogenomic group|The perioperative (anesthetic and postoperative pain management) plan for each patient will be determined preoperatively by the treating anesthesia team. Thereafter, the pharmacogenomic results of the patient will be released and a personalised anesthetic plan formulated based on international pharmacogenomic guidelines. The treating anesthesia team will then modify the perioperative care plan based on the patients' pharmacogenomic results and the international pharmacogenomic guidelines.
62036315|NCT05063838|NO_INTERVENTION|Control group|Perioperative care will be managed according to current 'standard care' practice at Peter MacCallum Cancer Centre.
62036316|NCT05695053|EXPERIMENTAL|with LLLT|
62036317|NCT05695053|PLACEBO_COMPARATOR|without LLLT|
62036318|NCT05653466|EXPERIMENTAL|Adaptive spacing, then high-item non-adaptive spacing, then low-item non-adaptive spacing|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
62036319|NCT05653466|EXPERIMENTAL|Adaptive spacing, then low-item non-adaptive spacing, then high-item non-adaptive spacing|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
62036320|NCT05653466|EXPERIMENTAL|High-item non-adaptive spacing, then adaptive spacing, then low-item non-adaptive spacing|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
62595846|NCT02573766|SHAM_COMPARATOR|Sham Neurofeedback Training|Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
62595847|NCT02573766|OTHER|Standard of Care|Seven questionnaires regarding symptoms and quality of life completed at baseline, at follow up, and again in one month. Participants receive EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.
62595848|NCT05201534|EXPERIMENTAL|Integrative Symbolic Non-Symbolic (iSNS) Training|Integrative symbolic non-symbolic (iSNS) training: Over a period of 6 weeks, participants will complete activities that progressively strengthen the mapping of symbolic numerical representations to non-symbolic numerical quantities and enhance fluency in symbolic numerical skills.
62595849|NCT05201534|ACTIVE_COMPARATOR|Active Comparator: Active Control Intervention (Working Memory Training)|Active control intervention: Over a period of 6 weeks, participants will complete activities that enhance short-term storage and maintenance of visuospatial or verbal information.
62813498|NCT05220722|EXPERIMENTAL|SD-101|Three weekly doses of SD-101 given over two cycles via HAI using the PEDD method of administration.
62813499|NCT04635449|ACTIVE_COMPARATOR|Intervention|age-specific information, complemented by a follow-up targeted telephone call
62036321|NCT05653466|EXPERIMENTAL|High-item non-adaptive spacing, then low-item non-adaptive spacing, then adaptive spacing|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
62036322|NCT05653466|EXPERIMENTAL|Low-item non-adaptive spacing, then high-item non-adaptive spacing, then adaptive spacing|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
62036323|NCT05653466|EXPERIMENTAL|Low-item non-adaptive spacing, then adaptive spacing, then high-item non-adaptive spacing|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
62036324|NCT05855980|ACTIVE_COMPARATOR|Closed wound|Wound is closer immediately after amputation (instead healing secondarily)
62036325|NCT05855980|NO_INTERVENTION|Open wound|Wound is left to heal secondarily
62036326|NCT05726929|EXPERIMENTAL|Osteopathic treatment (OT)|Osteopathic treatment, 3 sessions of 1h + Treatment As Usual (TAU)
62036327|NCT05726929|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Treatment As Usual, Capsaicin Qutenza Patch (Conventionnal Treatment in algology in supportive care)
62237543|NCT01674751|EXPERIMENTAL|Immediate intervention|Group begins the 4 week Pre-Ordering Program intervention immediately following a 4-wk baseline period.
62237544|NCT01674751|OTHER|Wait-listed control|Group begins the 4 week Pre-Ordering Program intervention following an 8-wk baseline period.
62237545|NCT03353558||Study Group (CML group)|"This group will be CML patients. In this group each participant will be asked to wear a watch Actigraph for one week.~He will be asked to fill the appropriate questionnaires, and a daily sleep diary."
62813500|NCT04635449|NO_INTERVENTION|Treatment as usual|usual information given at PICU discharge
62813501|NCT01998256|SHAM_COMPARATOR|Group I|All patients were programmed in the same nominal AV delay settings (sensed AV delay 120ms, paced AV delay 150 ms) before randomization. Patients in group I received a sham AV optimization; patients in group II received a real AV optimization. Baseline echocardiography measurements were repeated after (sham)optimization. At 4 weeks cross-over was done by AV optimization in group I and resetting pacemaker settings to nominal values in group II. At 8 weeks patients were evaluated with the same investigations as at week 4; every pacemaker was programmed in the most optimal AV setting. All optimizations were performed by 2 unblinded echocardiographists with experience in the field.
62237546|NCT03353558||Control Group|"The control group will be non-CML patients, also without any known malignancy or known sleep disturbances.~They will be asked to wear the watch Actigraph for one week, and to fill the appropriate questionnaires and a daily sleep diary."
62237547|NCT02860663|ACTIVE_COMPARATOR|Vitamin D3|10 ug/d of vitamin D3 for 6 weeks
62237548|NCT02860663|ACTIVE_COMPARATOR|Vitamin D2|10 ug/d of vitamin D2 for 6 weeks
62813502|NCT01998256|ACTIVE_COMPARATOR|Group II|All patients were programmed in the same nominal AV delay settings before randomization. Patients in group I received a sham AV optimization; patients in group II received a real AV optimization. Baseline echocardiography measurements were repeated after (sham)optimization. At 4 weeks cross-over was done by AV optimization in group I and resetting pacemaker settings to nominal values in group II. At 8 weeks patients were evaluated with the same investigations as at week 4; every pacemaker was programmed in the most optimal AV setting. All optimizations were performed by 2 unblinded echocardiographists with experience in the field.
62595850|NCT02530411|EXPERIMENTAL|Experimental|Fulvestrant 500mg Intra Muscular (IM) Day 1 (D1), D15, then D1 of every 28 day cycle Vandetanib 300 mg Per os (po) daily Clinician review D1, D15, weeks 4, 8, 12, 16, 20, 24 then 12 weekly. Computerised Axial Tomography (CT) at week 8, 16, 24 then 12 weekly.
62237549|NCT02860663|ACTIVE_COMPARATOR|25OHD|10 ug/ of 25OHD for 6 weeks
62813503|NCT00832663|EXPERIMENTAL|NSAID|receive NSAID
62595851|NCT02530411|PLACEBO_COMPARATOR|Control|Fulvestrant 500mg IM D1, D15, then D1 of every 28 day cycle Placebo po daily Clinician review D1, D15, weeks 4, 8, 12, 16, 20, 24 then 12 weekly. CT at week 8, 16, 24 then 12 weekly.
62595852|NCT06622603|PLACEBO_COMPARATOR|Discontinuing group|They (n=15) will take a placebo once daily for 6 months, followed by febuxostat 20 mg once daily for the next 6 months. Randomization is stratified based on the urinary urate excretion rate (≤5.5% vs. \>5.5%).
62813504|NCT00832663|PLACEBO_COMPARATOR|Placebo|receive placebo
62237550|NCT00873353|EXPERIMENTAL|Unique arm|"6 cycles (3 weeks each one) of :~* capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~* erlotinib (Tarceva®) 150mg/day, oral. Days: every days"
62237551|NCT03208322||DCV + ASV at a sentinel site|patients with chronic hepatitis C (CHC) who are being given at least 1 dose of daclatasvir (DCV) and asunaprevir (ASV) for the treatment and cure of CHC at the sentinel sites for the National Pharmacovigilance Center (CNFV) in Mexico.
62237552|NCT05016856|ACTIVE_COMPARATOR|Reminder Only Condition|To promote adherence, participants will receive generic reminders when home-based cognitive training has not been completed. This will be in the form of a text message to participants' smart phone.
62237553|NCT05016856|EXPERIMENTAL|Smart Adherence Support Condition|To promote adherence, participants will receive reminders when home-based cognitive training has not been completed. This will be in the form of a text message to participants' smart phone. In this condition, participants will receive adaptive and tailored reminders based on dynamic algorithms that deploy reminders in a way that considers participant preferences, days and times of previous successful assessments, the success of previous reminder attempts, and answers to brief questions contained within reminder prompts. Parameter weights for these variables will be adjusted dynamically over a 6-month assessment period to ensure that reminders are deployed when they are most likely to be acted upon.
62427862|NCT05829382|ACTIVE_COMPARATOR|DailyColors™ group|"Capsules of 150 mg of the DailyColors™ blend~The investigational product is a capsule containing 150mg of the following phytonutritients:~Item Name Percent of Formula Apple Extract 10.0% Pomegranate Extract 10.0% Tomato Powder 2.5% Beet - Spray Dried 2.5% Olive Extract 7.5% Rosemary Extract 7.5% Green Coffee Bean Extract (C.A) 7.5% Kale - Freeze Dried 2.5% Onion Extract 10.0% Ginger Extract 10.0% Grapefruit Extract 2.5% Carrot - Air Dried 2.5% Grape Skin Extract 17.5% Blueberry Extract 2.5% Currant - Freeze Dried 2.5% Elderberry - Freeze Dried 2.5%"
62427863|NCT05829382|PLACEBO_COMPARATOR|Placebo group|Micro crystalline cellulose will be used as the placebo, which will be produced with similar appearance as the active compound visually and regarding smell and taste.
62036328|NCT03640650|EXPERIMENTAL|Dropless Therapy|Single used, pre-mixed, centrally compounded injectable that contains 15 mg/ml of triamcinolone acetonide and 1 mg/ml of moxifloxacin. This preservative-free suspension is injected at a dose of 0.2 mg into the posterior chamber, for a total drug delivery of 3 mg of triamcinolone acetonide and 0.2 mg of moxifloxacin. At the time of cataract surgery, Dropless is intended to be injected as a single administration into the anterior vitreous after the insertion of the IOL implant, with a 27 or 30-gauge cannula via a transzonular or transsceral pars plana injection, just before rinsing the viscoelastic fluid.
62237554|NCT03404765|EXPERIMENTAL|Tai Chi group|The Tai Chi group (i.e. the intervention group) received a 16-week Tai Chi program, of 32 sessions (2 sessions per week), each being one hour long.
62813505|NCT03392935|EXPERIMENTAL|All Subjects|All subjects will be treated with the laser at week 0 and week 4. Only assessors will be blinded and rate the dermatofibromas in photographs, they will not know which photos were taken pre-treatment vs. post-treatment to determine efficacy.
62237555|NCT03404765|NO_INTERVENTION|Ususal care group|The control group received the usual care offered by the respective centers. No intervention had been arranged for the control group during the study period. Participants in the control group were advised to attend different kinds of recreational activities provided by their community centers and to continue with their daily activities, including their usual general physical mobility and social activities.
62427864|NCT00574379|EXPERIMENTAL|1|Bilastine 20mg once per day
62427865|NCT00574379|EXPERIMENTAL|2|Bilastine 20mg twice per day
62427866|NCT00574379|EXPERIMENTAL|3|Bilastine 10mg once per day
62427867|NCT00574379|EXPERIMENTAL|4|Bilastine 10mg twice per day
62427868|NCT00574379|PLACEBO_COMPARATOR|5|
62427869|NCT02633761|ACTIVE_COMPARATOR|Group 1|200mg mifepristone followed in 24 hours by repeated doses of 200mcg buccal misoprostol given every 3 hours
62427870|NCT02633761|PLACEBO_COMPARATOR|Group 2|placebo followed in 24 hours by 200mcg buccal misoprostol given every three hours.
62427871|NCT02121405|EXPERIMENTAL|Primary surgery|The patients receive primary rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with TME. To patients with pathological confirmed positive circumferential margin (CRM), postoperative concurrent radiochemotherapy is required that starts in 3 months post operation with capecitabine. Capecitabine and Oxaliplatin (CapeOx) chemotherapy starts in 4 weeks post operation to total of 6 cycles/18 weeks. To patients with pathological confirmed negative CRM, radiotherapy is omitted. The stage III patients receive 8 cycles/6 months CapeOx chemotherapy. The stage II patients with low microsatellite instability (MSI) receive 8 cycles/6 months Capecitabine chemotherapy. The stage II patients with high MSI and stage I patients do not receive adjuvant therapy.
62427872|NCT02121405|ACTIVE_COMPARATOR|Preoperative radiochemotherapy|All of the patients receive conventional concurrent radiochemotherapy with capecitabine for 5 weeks. Then all of the patients receive 2 cycles/6 weeks capecitabine ± Oxaliplatin chemotherapy. Patients receive rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with total mesorectal excision 8 weeks post radiotherapy. All of the patients receive 5 cycles/15 weeks capecitabine ± Oxaliplatin adjuvant chemotherapy. The use of Oxaliplatin depends on the doctor's decision.
62427873|NCT04892342|EXPERIMENTAL|ESG401 dose level 1|
62427874|NCT04892342|EXPERIMENTAL|ESG401 dose level 2|
62237556|NCT06428136|EXPERIMENTAL|Clamshell exercises with Electrical Muscle Stimulation (CT + EMS)|
62237557|NCT06428136|OTHER|Conservative Treatment (CT)|
62427875|NCT04892342|EXPERIMENTAL|ESG401 dose level 3|
62427876|NCT04892342|EXPERIMENTAL|ESG401 dose level 4|
62427877|NCT04892342|EXPERIMENTAL|ESG401 dose level 5|
62427878|NCT04892342|EXPERIMENTAL|ESG401 dose level 6|
62427879|NCT05870826|SHAM_COMPARATOR|Sham laser therapy|The control group (PL group) is subjected to a laser sham (placebo), employing a device identical to the one under investigation but lacking the laser emission capability, and the same mode of administration in terms of time and place. Both the sham laser and the test device emit visible light of the same color and are not distinguishable in any way.
62813506|NCT05485740|EXPERIMENTAL|study group|the study group received the same exercise training program in addition to cognitive multisensory rehabilitation program
62813507|NCT05485740|EXPERIMENTAL|control group|the control group which received the selected exercise program
62813508|NCT00625131|ACTIVE_COMPARATOR|Active Nicotine Patch Group|Transdermal nicotine patch
62813509|NCT00625131|PLACEBO_COMPARATOR|Placebo Patch Group|Transdermal placebo patch
62237558|NCT06059781|EXPERIMENTAL|Rhtyhmical auditory stimulation and Visual cues (Experimental group)|"For auditory stimulation, walking exercises are performed on a flat floor walking path without rhythmic or musical influence. Rhythmical auditory stimulation (RAS) is produced by using Metronome App on a mobile phone.~For visual stimulation, white chalk will use to draw visual signals on the ground. For gait recovery, a 10-meter walkway will draw on the floor with parallel lines 2.5cm broad and 90cm long. Interline distance will maintain at 110% of the length of the initial step.~Routine rehablitation treatment includes a range of motion exercises for the lower extremity, passive stretching of tight muscles and conventional march exercises including marching, forward, backward and sideways walking.~Experimental group will be treated for 45 minutes per session, 3 days per week for 6 weeks."
62237559|NCT06059781|OTHER|Rhtyhmical auditory stimulation (control group)|"For auditory stimulation, walking exercises are performed on a flat floor walking path without rhythmic or musical influence. Rhythmical auditory stimulation (RAS) is produced by using Metronome App on a mobile phone.~Routine rehablitation treatment includes a range of motion exercises for the lower extremity, passive stretching of tight muscles and conventional march exercises including marching, forward, backward and sideways walking.~Control group will be treated for 45 minutes per session, 3 days per week for 6 weeks."
62427880|NCT05870826|EXPERIMENTAL|Laser therapy|"The MLS group receives MLS synchronized diode laser therapy emitted by the MLS M8 robotic device (ASA, Italy).~MLS M8 (ASA, Arcugnano, Italy), a Class IV (high-power) laser approved by the Food Drug Administration (FDA) and CE certified, characterized by a combined, synchronized two-wavelength (CPW) emission: a continuous emission with a wavelength of 808 nm and a pulsed emission at 905 nm.~The duration of each session is 5 min 45 sec.seconds, delivering a total energy of 1500 J and an energy dose of 5 J/cm2, for an area of 300 cm2.~The robotic device is placed in the lumbar area, oriented on the muscles erector spinae and quadratus lumborum. The target area set on the device is lumbar area. The parameters set on the device are Synchronized Emission of Continuous Pulsed Wave (CPW), intensity of 100%, time of 5 minutes and 45 seconds, and area of 1x300 cm2."
62813510|NCT04828421|EXPERIMENTAL|Probiotic group|Participants will be treated with a daily capsule of a multi-species probiotic (3.3 billion Lactobacillus rhamnosus and Bifidobacterium lactis) during 10 weeks.
62813511|NCT04828421|PLACEBO_COMPARATOR|Placebo group|Participants will receive a harmless substance (potato starch) during 10 weeks.
62813512|NCT00938158|EXPERIMENTAL|Stage 1 normal renal function|Subject with estimated glomerular filtration rate (GFR) greater than 80 milliliter per minute (mL/min)
62813513|NCT00938158|EXPERIMENTAL|Stage 1 moderate/severe renal function|Subject with estimated GFR \>= 20 mL/min and less than 50 mL/min
62813514|NCT00938158|EXPERIMENTAL|Stage 2 normal renal function|Subject with GFR greater than 80 mL/min
62813515|NCT00938158|EXPERIMENTAL|Stage 2 moderate renal impairment|Subject with estimated GFR \>= 30 mL/min and less than 50 mL/min
62813516|NCT00938158|EXPERIMENTAL|Stage 2 subjects requiring hemodialysis|Subjects who require hemodialysis
62813517|NCT00938158|EXPERIMENTAL|Stage 2 severe renal impairment not requiring hemodialysis|Subjects with GFR less than 30 mL/min
62813518|NCT00938158|EXPERIMENTAL|Stage 2 mild renal impairment|Subjects with GFR \>= 50 mL/min and \<= 80 mL/min
62813519|NCT01048879|OTHER|ECMO alone|Patients receiving oseltamivir and Extracorporeal Membrane Oxygenation (ECMO) therapy (patients were already receiving oseltamivir and ECMO due to an illness)- Procedure/Surgery: pharmacokinetic blood sampling
62427881|NCT06403566|EXPERIMENTAL|hand massage application|hand massage will be applied before and after surgery
62427882|NCT06403566|ACTIVE_COMPARATOR|back massage application|back massage will be applied before and after surgery
62427883|NCT06403566|NO_INTERVENTION|control group|no intervention will be made
62427884|NCT00913588|EXPERIMENTAL|1|Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)
62813520|NCT01048879|OTHER|CVVHD Alone|"Patients receiving Continuous Venovenous Hemodialysis(CVVHD) and oseltamivir (Patients were already receiving oseltamivir and CVVHD as a result of an illness).~Procedure/Surgery: pharmacokinetic blood and dialysate sampling"
62036329|NCT03640650|ACTIVE_COMPARATOR|Usual Care|This therapy usually comprises an antibiotic, a steroid and in some cases a nonsteroidal anti-inflammatory drug (NSAID). Antibacterial drops are usually given at the end of surgery and are continued for one week after the surgery. Steroid drops are usually started the day of surgery and then tapered down over 3 to 4 weeks. When prescribed, NSAIDs are usually started 2 or 3 days before surgery, or started the day of surgery, and continued for 3 or 4 times a day for 3 to 4 weeks.
62427885|NCT00913588|EXPERIMENTAL|2|Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)
62427886|NCT00913588|ACTIVE_COMPARATOR|3|Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)
62813521|NCT01048879|OTHER|CVVHD + ECMO|"Patient receiving oseltamivir and ECMO and CVVHD (patients were already receiving oseltamivir, ECMO, and CVVHD as part of an illness).~Procedure/Surgery: pharmacokinetic blood and dialysate sampling"
62237560|NCT04633915||Dialysis|Patients with CKD stage 5, treated with maintenance hemodialysis
62237561|NCT04633915||Healthy|Volunteers who are not dialysis-dependent
62237562|NCT02864381|EXPERIMENTAL|Andecaliximab + Nivolumab|Andecaliximab 800 mg plus nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 34 weeks at the time of the primary efficacy analysis; up to 101 weeks at the time of the safety follow-up analysis).
62813522|NCT04890652|OTHER|Risky drinkers|All participants will receive the same 4-week intervention program.
62813523|NCT01898455|EXPERIMENTAL|Intranasal Cooling|RhinoChill Intranasal cooling, administered for 20 minutes. 10 treatment sessions per participant.
62813524|NCT04321018|EXPERIMENTAL|Meal with medium chain triglycerdies first|Arm 1: participants randomized to receive the mixed meal with medium chain triglycerides first.
62813525|NCT04321018|ACTIVE_COMPARATOR|Meal with medium chain triglycerdies second|Arm 2: participants randomized to receive the mixed meal without medium chain triglycerides first.te
62813526|NCT06179108|EXPERIMENTAL|LB-102, 50 mg QD|Oral LB-102: 50 mg (n \~ 105)
62036330|NCT02115958|PLACEBO_COMPARATOR|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62036331|NCT02115958|EXPERIMENTAL|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62036332|NCT02115958|EXPERIMENTAL|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62036333|NCT02115958|EXPERIMENTAL|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62237563|NCT02864381|ACTIVE_COMPARATOR|Nivolumab|Nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 41 weeks at the time of the primary efficacy analysis; up to 97 weeks at the time of the safety follow-up analysis).
62237564|NCT06209346|EXPERIMENTAL|TeleRehab Group|"The duration of treatment for the TeleRehab Group will be 8 weeks and will consist of a total of 20 sessions, with between 2 and 3 sessions per week depending on the week they are in.~Weeks 2, 4, 6 and 8 will have 2 sessions per week and weeks 1, 3, 5 and 7 will have 3 sessions per week.~These sessions will consist of videos that will make up the educational material, videos that will guide the TE program and respiratory control practices. All the sessions mentioned above will be in online format, through the TRAK platform."
62237565|NCT06209346|ACTIVE_COMPARATOR|Advices Group|They will receive informative material in weeks 1, 3, 5 and 7 about their pathology and with recommendations for them to achieve healthy lifestyle habits that do not further damage their disease. o Participants in the Advices Group will have the same follow-up assessments as the TeleRehab Group and will receive informative material. They will not have access to the audiovisual material generated for the TeleRehabGroup.
62237566|NCT01026142|ACTIVE_COMPARATOR|A: Capecitabine + Trastuzumab|
62237567|NCT01026142|EXPERIMENTAL|B: Capecitabine + Trastuzumab + Pertuzumab|
62237568|NCT04178967|PLACEBO_COMPARATOR|Placebo|"Induction Period (Baseline-Week 16):~Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.~Maintenance Period (Week 16-Week 52):~Two placebo SC injections as loading dose on Week 16 and Week 18. One placebo SC injection Q2W until Week 50."
62427887|NCT06354465||Incarcerated Individuals|Incarcerated individuals will be recruited across the Rhode Island Department of Corrections (RIDOC)facility during the required group sessions for treatment; this is consistent with previous NIH-funded studies at RIDOC. The interviews will be described and participants will be able to sign up confidentially. Participants who are eligible for Medications for Opioid Use Disorder (MOUD) but decide not to pursue treatment will still be interviewed to provide better understanding of the key factors that drive program participation. These individuals can be recruited through routine clinical care by addiction medicine providers. Every precaution will be taken to ensure confidentiality and protection of all participants.
62427888|NCT06354465||Stakeholders|Organizational stakeholders (clinicians, Wardens, leadership and/or other staff) will be recruited through snowball sampling. I will individually approach leaders of each facility to recruit correctional individuals interested in participating and will also allow participants to confidentially sign up at administrative meetings related to Medication for Addiction Treatment (MAT).
62427889|NCT03007537|PLACEBO_COMPARATOR|control group|0.9% sodium chloride 1ml, subcutaneous injection, once, applied 1day before cardiac surgery
62427890|NCT03007537|EXPERIMENTAL|Erythropoietin group|10000 IU erythropoietin, subcutaneous injection, once, applied 1day before cardiac surgery
62427891|NCT04626557||Women with astma|At the 7th -14th cycle day, an endometrium sample from the uterus lining will be obtained together with sputum, as indicators of the system inflammation expressed both in the lungs and the uterus, and blood samples.
62427892|NCT04626557||Women without asthma|At the 7th - 14th cycle day, an endometrium sample from the uterus lining will be obtained together with sputum, as indicators of the system inflammation expressed both in the lungs and the uterus, and blood samples.
62427893|NCT03676894|SHAM_COMPARATOR|Sham Treatment|Sham Fotona SP Dynamis Treatment - minimum energy delivered through sham handpiece.
62427894|NCT03676894|ACTIVE_COMPARATOR|Intravaginal Treatment|Intravaginal Fotona SP Dynamis Treatment - energy delivered intravaginally.
62427895|NCT03676894|EXPERIMENTAL|Intravaginal and intraurethral Treatment|Intravaginal and intraurethral Fotona SP Dynamis Treatment Intravaginal Treatment - energy delivered intravaginally and intraurethrally.
62427896|NCT02491619|EXPERIMENTAL|Orthodontic decompensation|Orthodontic decompensation in patients with class III dentofacial deformities
62427897|NCT04024085||Participants|adult with a multiple sclerosis diagnosis, able to walk 50 meters without human help, Expanded Disability Status Scale (EDSS) \< 7, consulting in a neuro-urology department
62427898|NCT03491319|PLACEBO_COMPARATOR|Group C Control|spinal anaesthesia was given with table in neutral positon. Same position was maintained after spinal anaesthesia
62036334|NCT05110885||Individuals living in Turkey|Individuals from different regions of Turkey who meet inclusion criteria
62036335|NCT03768167|OTHER|patients with metastatic spinal lesions|corpectomy
62036336|NCT05192525|EXPERIMENTAL|mChemotherapy group|"The intervention group participants will adopt an app mChemotherapy to self-manage their symptoms under nurse-led supervision for six weeks."
62427899|NCT03491319|ACTIVE_COMPARATOR|Group X|spinal anaesthesia was given with table in neutral positon. 10 degree head low position was maintained for 10 minutes following spinal
62595853|NCT06622603|ACTIVE_COMPARATOR|Reducing group|They (n=29) will take febuxostat 20 mg once daily for 12 months. Randomization is stratified based on the urinary urate excretion rate (≤5.5% vs. \>5.5%).
62595854|NCT06622603|NO_INTERVENTION|Maintaining group|To serve as an observational reference group, they (n=15) will continue their urate-lowering agents for 12 months. Randomization is stratified based on the urinary urate excretion rate (≤5.5% vs. \>5.5%).
62595855|NCT03221426|EXPERIMENTAL|Pembrolizumab+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS cisplatin 80 mg/m\^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m\^2 via oral tablets twice each day (BID) on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m\^2 via IV infusion on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m\^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m\^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m\^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m\^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m\^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle, followed by pembrolizumab monotherapy 200 mg via IV infusion on Day 1 Q3W for up to 11 additional cycles."
62595856|NCT03221426|PLACEBO_COMPARATOR|Placebo+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m\^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m\^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m\^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m\^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of placebo via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m\^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m\^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m\^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m\^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle, followed by placebo monotherapy via IV infusion on Day 1 Q3W for up to 11 additional cycles."
62595857|NCT03221426|EXPERIMENTAL|Pembrolizumab+FLOT Cohort|"FLOT=docetaxel+oxaliplatin+5FU+leucovorin (calcium folinate). Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m\^2 via IV infusion, oxaliplatin 85 mg/m\^2 via IV infusion, 5FU 2600 mg/m\^2 via IV infusion, and leucovorin (calcium folinate) 200 mg/m\^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations).~Adjuvant: 4 to 10 weeks postsurgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion Day 1 Q3W PLUS docetaxel 50 mg/m\^2, oxaliplatin 85 mg/m\^2, 5FU 2600 mg/m\^2, and leucovorin 200 mg/m\^2 Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations), followed by pembrolizumab monotherapy 200 mg via IV infusion on Day 1 Q3W for up to 11 additional cycles."
62813527|NCT06179108|EXPERIMENTAL|LB-102, 75 mg QD|Oral LB-102: 75 mg (n \~ 105)
62813528|NCT06179108|EXPERIMENTAL|LB-102, 100 mg|Oral LB-102: 100 mg (n \~ 35)
62237569|NCT04178967|EXPERIMENTAL|Lebrikizumab Q2W|"Induction Period (Baseline-Week 16):~500 milligram (mg) Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 visits followed by a single 250 mg Lebrikizumab injection Q2W from Week 4 until Week 14.~Maintenance Period (Week 16-Week 52):~One 250 mg Lebrikizumab SC injection and one placebo SC injection as maintenance loading dose on Week 16 and Week 18.~One 250 mg Lebrikizumab SC injection Q2W until Week 50."
62237570|NCT04178967|EXPERIMENTAL|Lebrikizumab Q4W|"Maintenance Period (Week 16-Week 52):~One 250 mg Lebrikizumab SC injection and one placebo SC injection as maintenance loading dose on Week 16 and two placebo SC injections on Week 18.~One 250 mg Lebrikizumab SC injection Every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48.~One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50."
62237571|NCT04178967|EXPERIMENTAL|Escape Arm (Lebrikizumab Q2W)|"Maintenance Period (Week 16-Week 52):~Participants who require topical or systemic rescue treatment for atopic dermatitis during the Induction Period, or are non-responders at Week 16, will be eligible for treatment in an Escape Arm where participants will receive open-label lebrikizumab Q2W from Week 16 through Week 52. In addition, participants who do not maintain an acceptable response during the Maintenance Period (have an EASI score \<50% of baseline), will be eligible for the Escape Arm."
62237572|NCT00814112||1 septic shock|septic shock, ICU
62237573|NCT00814112||2 controls|matched controls
62237574|NCT04364334||Knee registry patients|
62237575|NCT05217082||Cohort 1|Participants with relapsed/refractory multiple myeloma (RRMM) who have already received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody
62237576|NCT03717948|EXPERIMENTAL|CTL - BFR|CTL Exercise then BFR Exercise
62237577|NCT03717948|EXPERIMENTAL|BFR - CTL|BFR Exercise then CTL Exercise
62237578|NCT00906360|EXPERIMENTAL|Treatment (enzyme inhibitor and monoclonal antibody therapy)|Patients receive sunitinib malate orally or by percutaneous gastrostomy tube once daily, cetuximab IV over 60-120 minutes once weekly, and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 7-9 weeks in the absence of disease progression or unacceptable toxicity. Patients with persistent disease undergo surgical resection.
62237579|NCT03492788|ACTIVE_COMPARATOR|ECGI-optimized VV-offset|
62237580|NCT03492788|PLACEBO_COMPARATOR|Zero VV-offset|
62237581|NCT03553654|EXPERIMENTAL|CT monitoring arm|18-75 year old patients with newly-diagnosed cancer, scheduled to undergo anthracycline-based chemotherapy.
62237582|NCT06178237|NO_INTERVENTION|Standard of care|Standard of care post-neck dissection
62237583|NCT06178237|EXPERIMENTAL|Standard of care plus Purabond|Standard of care post-neck dissection plus Purabond
62595858|NCT03221426|PLACEBO_COMPARATOR|Placebo+FLOT Cohort|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m\^2 via IV infusion, oxaliplatin 85 mg/m\^2 via IV infusion, 5FU 2600 mg/m\^2 via IV infusion, and leucovorin 200 mg/m\^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations).~Adjuvant: 4 to 10 weeks postsurgery, participants receive 3 cycles of placebo via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m\^2 via IV infusion, oxaliplatin 85 mg/m\^2 via IV infusion, 5FU 2600 mg/m\^2 via IV infusion, and leucovorin 200 mg/m\^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations), followed by placebo monotherapy via IV infusion on Day 1 Q3W for up to 11 additional cycles."
62237584|NCT03037164|EXPERIMENTAL|INTERCEPT (Test)|Red blood cell components treated with the INTERCEPT Blood System for Red Blood Cells ordered and administered to study patients by their treating physicians according to the local standards of care
62595859|NCT05784974|EXPERIMENTAL|Cadonilimab|Participants receive two cycles of Cadonilimab as neoadjuvant therapy prior to surgery; followed by surgery; followed by standard adjuvant chemotherapy +/- adjuvant Cadonilimab for 6 months.
62427900|NCT03491319|ACTIVE_COMPARATOR|Group Y|the table was put in 10 degree head low position before proceeding to give spinal anaesthesia. Head low position was maintained for 10 minutes following spinal
62427901|NCT00415142|EXPERIMENTAL|Saredutant 100 mg|Saredudant100 mg once daily for a maximum of 32 weeks
62427902|NCT00415142|ACTIVE_COMPARATOR|Escitalopram 10 mg|Escitalopram 10 mg once daily for a maximum of 32 weeks
62427903|NCT00415142|PLACEBO_COMPARATOR|Placebo|Placebo once daily for one week during screening phase and a maximum of 8 weeks during the acute phase
62427904|NCT05258435||Simplify Disc|Extended follow-up of subjects treated with the Simplify Disc during IDE G140154 and followed in the post-approval study NCT04630626.
62427905|NCT04538768|EXPERIMENTAL|Mesh Augmentated|
62427906|NCT04538768|OTHER|Direct Suture|
62427907|NCT05402631||New patient with lower back pain|
62813529|NCT06179108|PLACEBO_COMPARATOR|Placebo comparator|"Drug: Placebo~Matched placebo tablets"
62427908|NCT05402631||known patient with lower back pain|
62427909|NCT00267020|EXPERIMENTAL|Enzastaurin+Gemcitabine|
62427910|NCT00267020|ACTIVE_COMPARATOR|Gemcitabine|
62427911|NCT02067988|EXPERIMENTAL|Treatment arm|Holmium-166 microspheres hepatic radioembolization, adjuvant to systemic 177Lu-dotatate.
62595860|NCT06621563|EXPERIMENTAL|Cohort A|NSCLC
62237585|NCT03037164|ACTIVE_COMPARATOR|Conventional (Control)|Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
62427912|NCT01704235||Primary health care providers|medical physicians and nurse practitioners
62595861|NCT06621563|EXPERIMENTAL|Cohort B|NSCLC, CRC or other advanced tumors
62813530|NCT02927301|EXPERIMENTAL|Atezolizumab|Participants received two cycles of atezolizumab as neoadjuvant therapy prior to surgery. Participants who demonstrated clinical benefit were eligible to receive up to 12 months of atezolizumab.
62813531|NCT04839510|EXPERIMENTAL|MRG002|MRG002 will be administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle).
62813532|NCT02515747|NO_INTERVENTION|conservative treatment|Men and women with stable CHD verified by angiography from one center and allocated to three treatment arms in real-world practice: 1. conservative treatment with statins, antiaggregants, antianginal drugs in standard dosage
62813533|NCT02515747|ACTIVE_COMPARATOR|percutaneous coronary intervention|2. elective balloon angioplasty alone or stent implanation on the basement of drugs treatment
62427913|NCT01925807|EXPERIMENTAL|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
62427914|NCT03235765||Cohort A|Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy
62427915|NCT03235765||Cohort B|Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.
62427916|NCT05734170|OTHER|Cheerio breakfast|Patient consumes 1 serving of cheerios for breakfast every day for 1 month. Blood is drawn to assess lipid panels before diet and after 1 month of diet.
62427917|NCT05734170|OTHER|Instant Oatmeal Breakfast|Patient consumes 1 package instant oatmeal for breakfast each day for 1 month. Blood is drawn to assess lipid panels before diet and after 1 month of diet.
62427918|NCT05734170|EXPERIMENTAL|Chia Seeds and Instant Oatmeal breakfast.|Patient consumes 1 package instant oatmeal with 2 tbsp chia seeds everyday for breakfast for 1 month. Blood is drawn to assess lipid panels before diet and after 1 month of diet.
62427919|NCT01244607|PLACEBO_COMPARATOR|Placebo|
62813534|NCT02515747|ACTIVE_COMPARATOR|coronary artery bypass grafting|elective surgery myocardial revascularisation on the basement of drugs treatment
62237586|NCT03679806|EXPERIMENTAL|Halliwick|Exercises were performed in a private pool owned by the local MS society twice in a week for 8 weeks. Pool depth was 120 cm 30-31°C Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.
62595862|NCT06621563|EXPERIMENTAL|Cohort C|CRC or other advanced tumors
62595863|NCT06621563|EXPERIMENTAL|Cohort D1|NSCLC
62595864|NCT06621563|EXPERIMENTAL|Cohort D2|NSCLC
62237587|NCT03679806|EXPERIMENTAL|Aquatic Plyometric Exercise|Exercises were performed in a private pool owned by the local MS society twice in a week for 8 weeks. Pool depth was 120 cm 30-31°C. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase included.
62237588|NCT02926131||Infants|Infants requiring serum bilirubin (SBR) measurement seen in Wang Pha clinic (WPA) clinic.
62427920|NCT01244607|EXPERIMENTAL|NI-0801|
62427921|NCT03296774|PLACEBO_COMPARATOR|Usual Care|Usual postpartum care
62595865|NCT06621563|EXPERIMENTAL|Cohort E1|NSCLC
62427922|NCT03296774|EXPERIMENTAL|Healthy Beyond Pregnancy|Web-based program for postpartum care and education and scheduling. Incentive for committing and returning for postpartum care.
62427923|NCT04527003|PLACEBO_COMPARATOR|Group A - Placebo|Norethindrone acetate (5mg daily) + Placebo
62595866|NCT06621563|EXPERIMENTAL|Cohort E2|CRC
62595867|NCT06621563|EXPERIMENTAL|Cohort F|CRC
62595868|NCT06053398|ACTIVE_COMPARATOR|Phenylephrine|Patients receiving phenylephrine for intraoperative hypotension
62595869|NCT06053398|ACTIVE_COMPARATOR|Norepinephrine|Patients receiving norepinephrine for intraoperative hypotension
62813535|NCT03983733|EXPERIMENTAL|Dietary Intervention|Dietary intervention using standardised test meals, on up to 8 days within the study period.
62813536|NCT00291616|ACTIVE_COMPARATOR|1|Pegylated Interferon-alpha2a
62813537|NCT00291616|ACTIVE_COMPARATOR|2|Thymosin alpha1 \& Pegylated Interferon-alpha2a
62427924|NCT04527003|ACTIVE_COMPARATOR|Group B - Low Dose CBD|Norethindrone acetate (5mg daily) + Low dose CBD (10mg sublingual daily)
62427925|NCT04527003|ACTIVE_COMPARATOR|Group C - High Dose CBD|Norethindrone acetate (5mg daily) + High dose CBD (20mg sublingual daily)
62813538|NCT04368026||Group 1|"Responders currently working in a COVID-19-dedicated hospital, which was transformed by Polish Ministry of Health during SARS-CoV-2 pandemic into institution designated only for SARS-CoV-2 patients, including those developing symptoms and quarantined."
62237589|NCT02521467|ACTIVE_COMPARATOR|PRF|Platelets Rich Fibrin
62237590|NCT02521467|PLACEBO_COMPARATOR|palatal stent|Palatal stent
62237591|NCT06082089|EXPERIMENTAL|Postdivorce Intervention Program|The experimental arm will receive the 5- or 6-session online group intervention program developed for divorced women.
62427926|NCT04023318|EXPERIMENTAL|Integrated Lifestyle Intervention|
62595870|NCT04284930|EXPERIMENTAL|Depobupivacaine|Group 1 will receive an injection of 166mg of Depobupivacaine diluted in 60 ml.
62595871|NCT04284930|ACTIVE_COMPARATOR|OnQ Pump|Group 2 : The OnQ group will receive an infiltration via an OnQ soaker catheter of 0.25% bupivacaine at 4 ml/hour.
62237592|NCT06082089|NO_INTERVENTION|Wait List and Delayed Intervention|In this arm, participants in the wait list control group will complete outcome measures without the intervention program being implemented. After the post intervention assessments are completed, this group will receive either the online intervention program or booklets including detailed information about the program, depending on their preference.
62427927|NCT05186350|ACTIVE_COMPARATOR|SpyGlass group|ERCP plus SpyGlass group
62427928|NCT05186350|ACTIVE_COMPARATOR|ESWL group|ERCP plus ESWL
62595872|NCT04284930|ACTIVE_COMPARATOR|bupivacaine|Group 3: The 0.25% bupivacaine patients will receive 2mg/kg of 0.25% bupivacaine.
62595873|NCT02402023|ACTIVE_COMPARATOR|Standard Care (SC)|Patients in the SC arm will receive 4 counseling sessions and nicotine patches as part of typical cessation measures delivered to patients.
62813539|NCT04368026||Group 2|"Responders currently working in non-COVID-19-dedicated hospital."
62427929|NCT00183469|ACTIVE_COMPARATOR|lamotrigine plus divalproex ER|Participants will take active lamotrigine and active divalproex ER
62427930|NCT00183469|PLACEBO_COMPARATOR|lamotrigine plus placebo divalproex ER|Participants will take active lamotrigine and placebo
62427931|NCT02475980||Adolescent girls|Adolescent post-menarchal girls ages 13-18 with Medicaid insurance presenting to a pediatric emergency department for a non-emergent complaint who receive comprehensive contraception counseling
62427932|NCT04399850|EXPERIMENTAL|Patients who receive hypnosis|Patients who receive hypnosis during procedure by experiment physician
62427933|NCT04399850|NO_INTERVENTION|Control arm|Patient with conventional pain management
62595874|NCT02402023|EXPERIMENTAL|Contingency Management (CM)|Patients in the CM arm will receive monetary payment contingent on smoking abstinence (in addition to SC: 4 counseling sessions and nicotine patches).
62595875|NCT06620497|EXPERIMENTAL|SFI group|
62595876|NCT06620497|ACTIVE_COMPARATOR|milled bar group|
62595877|NCT05629234|EXPERIMENTAL|Osimertinib|Participants will receive Osimertinib
62595878|NCT02179606|EXPERIMENTAL|Dermalax Implant Plus|Subject injected in the nasolabial folds of one side of the face in the initial treatment period.
62595879|NCT02179606|ACTIVE_COMPARATOR|Restylane Sub-Q|Subject injected in the nasolabial folds of one side of the face in the initial treatment period.
62595880|NCT03343717|EXPERIMENTAL|rehabilitation|"Phase 1 passive mobilization with 10 repetitions on each joint motion and muscle stretching to the upper.~Phase 2 - ability to respond to 3 of 5 simple verbal commands. Beginning with passive, active-assisted or active exercises with 5 repetitions in each joint movement in the MMSS and MMII, following the sequence of phase 1.~Phase 3 - exercises of MMSS with cycle ergometer - 1 series of 1 minute or passive, active-assisted, active or active-resistidos with 5 repetitions in each joint movement, following the sequence of phase 1."
62595881|NCT03343717|ACTIVE_COMPARATOR|chest physical therapy|respiratory exercises that include techniques of bronchial hygiene maneuvers with the objective of airway clearance, pulmonary reexpansion techniques for reversal of atelectasis, passive mobilization techniques with the aim of reducing deformities and preserving joint mobility
62595882|NCT01878812|EXPERIMENTAL|Fluarix/Influsplit Tetra® Adult Group|Subjects 18-60 years of age receiving Fluarix/Influsplit Tetra® 2013-2014, administered intramuscularly in the deltoid region of the non-dominant arm.
62595883|NCT01878812|EXPERIMENTAL|Fluarix/Influsplit Tetra® Elderly Group|Subjects \>60 years of age receiving Fluarix/Influsplit Tetra® 2013-2014, administered intramuscularly in the deltoid region of the non-dominant arm.
62595884|NCT06419686|PLACEBO_COMPARATOR|Saline|Intravenous administration of saline for 90 minutes.
62427934|NCT04466696||t4 colorectal cancer treated with ERAS protocol|prospective from January 2016 to May 2020
62595885|NCT06419686|EXPERIMENTAL|GIP|Intravenous administration of GIP for 90 minutes (priming dose 6 pmol/kg/min for 10 minutes and 4 pmol/kg for 80 minutes.
62595886|NCT06419686|EXPERIMENTAL|Alanine|Intravenous administration of alanine for 90 minutes (28 umol/kg/min).
62595887|NCT06419686|EXPERIMENTAL|GIP + Alanine|Intravenous administration of GIP and alanine for 90 minutes. GIP is given at a priming dose of 6 pmol/kg/min for 10 minutes and then 4 pmol/kg for 80 minutes. Alanine is given at 28 umol/kg/min for 90 minutes.
62595888|NCT03326349|EXPERIMENTAL|Guttmann, NeuroPersonalTrainer|Guttmann NeuroPersonalTrainer (GNPT) 5 days per week over 6 weeks.
62595889|NCT03326349|SHAM_COMPARATOR|Ictus.online|Itus.online 5 days per week over 6 weeks
62595890|NCT06141616|SHAM_COMPARATOR|Control group|Sessions once a week, covering information about the pathophysiology of asthma, medication instructions, self-monitoring techniques, environmental control techniques, and prevention strategies for children, adolescents, and families. They will also receive physical activity recommendations, as well as information about the importance and benefits of being physically active and maintaining a healthy lifestyle. The sessions will feature educational and playful videos, presentations, and participants will be able to clarify their doubts about the topic addressed.
62595891|NCT06141616|EXPERIMENTAL|Experimental group|Rehabilitation program performed 3x/week. Each session will last 60 minutes, with a minimum interval of 24 hours, for a period of three months. The main focus of the intervention is aerobic training, which will be carried out in three stages, treadmill with a warm-up (10 minutes), load (20 minutes), and cool-down (5 minutes). With an initial intensity of 65% of the maximum load obtained in the incremental shuttle walk test (ISWT). The intensity will be gradually increased up to 115%, keeping dyspnea and fatigue values between 4 and 6, according to the modified Borg scale. In addition, we will do a circuit focused on aerobic activities, maintaining target heart rate during its performance for 20 minutes. When necessary, supplemental oxygen will be provided during training. Volunteers in this group will receive a bronchodilator dose before starting each day's session. This group will hold educational sessions as well.
62595892|NCT01513109|EXPERIMENTAL|Treatment arm|Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic combined with Treg depletion
62595893|NCT06564519|OTHER|Residents|This is a single arm study. All Resident participants will use the posture biofeedback device.
62595894|NCT00110227|EXPERIMENTAL|Tai Chi|12-week tai chi program
62595895|NCT00110227|ACTIVE_COMPARATOR|Heart Health Education|12-week attention control
62595896|NCT02968433|EXPERIMENTAL|Infusions of Young Plasma|"All participants will undergo neuropsychological, neuropsychiatric, and kinematic assessments prior to receiving infusions of young plasma as the treatment.~Participants will receive 1 unit of young plasma, twice a week over a four week duration.~After the four weeks of plasma infusions, participants will undergo neuropsychological, neuropsychiatric and kinematic reassessments. No deception will be used."
62595897|NCT03824132|EXPERIMENTAL|Intervention Group|
62595898|NCT03824132|ACTIVE_COMPARATOR|Waitlist Control Group|
62595899|NCT03832790||adolescents with type 1 diabetes|Adolescents ages 14-19 with type 1 diabetes
62595900|NCT00995046|ACTIVE_COMPARATOR|usual prophylaxis regimen|All patients will receive their usual prophylaxis regimen during the first 6 months
62595901|NCT00995046|EXPERIMENTAL|individually tailored prophylaxis regimen|All patients will receive an individually tailored prophylaxis regimen in accordance with TGT results during the second 6 month-period.
62427935|NCT04466696||t4 colorectal cancer treated with standards of care|retrospective from January 2010 to December 2015
62595902|NCT06597617|NO_INTERVENTION|Group Control|
62595903|NCT06597617|EXPERIMENTAL|GEA (Aerobic training)|
62427936|NCT06149195||positive|positive imaging, referring to the tracer absented in the left myocardium whether diffuse or localized on 18F-FMBG cardiac imaging.
62427937|NCT00115258|EXPERIMENTAL|parenteral nutrition titrated to measured REE|parenteral nutrition titrated to measured REE
62427938|NCT00115258|NO_INTERVENTION|standard of care|
62595904|NCT06597617|EXPERIMENTAL|GRM (Strength training)|
62595905|NCT03452046||PS 10 mmHg, PEEP 5 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
62595906|NCT03452046||PS 10 mmHg PEEP 0 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
62595907|NCT03452046||PS 0 mmHg PEEP 5 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
62036337|NCT05192525|NO_INTERVENTION|Control group|"Participants in control group will receive routine care, with no use of mChemotherapy during six weeks. Routine care is composed of a pre-chemotherapy visit and two follow-up visits. Through the Official WeChat platform, the patients in control group will be informed about the chemotherapy regimen, and chemotherapy-related symptoms and how to deal with them, during the pre-chemotherapy visit. The control group will have two scheduled visits by telephone with the follow-up nurse. Patients will be given a phone number for consulting the follow-up nurse should they have questions related to their symptoms, or concerns related to the chemotherapy. Patients in the control group cannot access the mChemotherapy until they have completed the pilot study."
62036338|NCT03506958||General Practice|Hundred patients with an X-ray confirmed diagnosis of a non-complex fracture or dislocation and planned to be treated in the general practice Zorgplein Lemmer.
62036339|NCT03506958||Hospital|Hundred patients with an X-ray confirmed diagnosis of a non-complex fracture or dislocation and planned to be treated in the Antonius Hospital Sneek.
62237593|NCT00934141|EXPERIMENTAL|Interest Circle Call + Website|Interest Circles are monthly teleconferences where agency change leaders discuss change-related issues and progress. Circles address how to improve timeliness, continuation, admissions, dropouts and transitions. They also address specialty topics (e.g., programs for women, adolescents). Participants discuss successes, failures, and challenges, and get advice and assignments for their improvement plans. Meeting summaries appear on the Web site. Interest Circles are inexpensive, but are they are sufficient? Should Interest Circles prove effective, they would provide a low-cost, convenient diffusion approach.
62237594|NCT00934141|EXPERIMENTAL|Coaching + Website|Coaching assigns an expert in process improvement to work with an agency to make, sustain, and spread process improvement efforts. Consultations focus on executive directors, change leaders and improvement teams. Coaches help agencies address key issues, but also broker relationships with other agencies, offer process improvement training, and promote the innovations to make and how to make them. Coaching takes place during site visits, monthly phone conferences, and via email.
62036340|NCT04364958|EXPERIMENTAL|Intervention group|Patients who agree participant and will sign the informed consent, will complete the baseline assessment. Then, those allocated to the intervention group will review the web-based PtDA (shown on the computer), with the help of a researcher if necessary, and then will fill the questionnaires assessing the outcome measures in the same web interface.
62036341|NCT04364958|ACTIVE_COMPARATOR|Control group|Patients allocated to the control group will receive a web-based fact sheet (one page shown on the computer) with general information on mental health as a part of usual care, and they will also complete the same questionnaires.
62036342|NCT02871648|PLACEBO_COMPARATOR|Placebo|Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital
62036343|NCT02871648|ACTIVE_COMPARATOR|Fludrocortisone|Subjects will receive 0.1 mg of fludrocortisone (Florinef) on one of three study days.
62036344|NCT02871648|ACTIVE_COMPARATOR|Epleronone|Subjects will receive 100 mg of epleronone on one of three study days.
62036345|NCT02395939|ACTIVE_COMPARATOR|CT guided core biopsy|In patients allocated to this arm a CT guided core biopsy will be performed
62036346|NCT02395939|ACTIVE_COMPARATOR|Cryo-biopsy via Radial EBUS navigation|"If the patient is randomised to this arm, the lesion will be located via R-EBUS.~Each patient will have 3 cryo biopsies and 3 forceps biopsies. The order of the cryo biopsy and forcep biopsy will be randomly allocated at the time of initial randomisation."
62036347|NCT06669689||the TREND group (Trendelenburg position)|In the Trendelenburg position, the operating table was tilted head down at an angle of 20-25°.
62036348|NCT06669689||the Reverse Trendelenburg position|In the Reverse Trendelenburg position, the operating table was tilted head up at an angle of 20-25°
62036349|NCT04758312|EXPERIMENTAL|MY-Skills Mobile Intervention|MY-Skills Mobile is an 8-week intervention merging yoga and self-management offered via remote tools including Zoom (video-conferencing software), Canvas (education software), and Qualtrics (survey software) that can be accessed via a computer or tablet. The self-management content is delivered primarily through asynchronous tools that include educational videos and interactive activities for goal setting, action plan, monitoring goals, and problem-solving practice. Yoga is offered synchronously via Zoom two-times per week for 60 minutes (120 minutes per week). The synchronous yoga sessions will be offered at a time that best accommodates participants' schedules. Yoga will become progressively challenging over the eight weeks and will include seated and standing postures.
62237595|NCT00934141|EXPERIMENTAL|Full: LS, Coaching, ICC, Website|Learning Session, Coaching, Interest Circle Calls, Website, see descriptions above
62237596|NCT00934141|EXPERIMENTAL|Learning Session + Website|Learning Sessions occur bi-annually as change teams convene to learn and gather support from each other and outside experts who offer advice on how best to adopt the innovations and learn about new directions for the collaborative (e.g., the need to create business cases for improvements). Learning Sessions and Interest Circles (see below) have similar objectives-to help agencies learn and gather support from each other and from outside experts.
62427939|NCT02169531|EXPERIMENTAL|ex vivo activated immune cells|Up to 20 patients diagnosed with type 2 diabetes mellitus and hyperglycemia will be enrolled and assigned to a single treatment group. Patients will give a small amount of peripheral blood and the blood will be processed and cultured in our laboratory. The ex vivo activated autologous blood cells will be infused intravenously back to patients. The treatment will be done twice a week for consecutive 4 weeks. The metabolic parameters of patients before and after the therapy will be compared to determine if the therapy is safe and effective.
62427940|NCT02690584|EXPERIMENTAL|Metacognitive therapy|Metacognitive therapy, one 45-60 min session weekly during 10 weeks.
62427941|NCT06312774||Individuals with Chronic Lung Disease|
62427942|NCT06312774||Healthy Controls|
62036350|NCT06202066|EXPERIMENTAL|ARM I (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days until disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT scans or MRI scans throughout study.
62427943|NCT03732729|EXPERIMENTAL|Massage chair|lifestyle modification education(once)+ Using massage chair
62427944|NCT03732729|NO_INTERVENTION|Control|lifestyle modification education(once)
62595908|NCT03452046||t tube (PS 0 mmHg PEEP 0mmHg)|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
62237597|NCT04994327|EXPERIMENTAL|Beta-glucan bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
62813540|NCT05711810|EXPERIMENTAL|Experiment Participant|"COVID-19 recombined vaccinated, 3 dose, no intervention. Nifedipine, oral, 30 mg per day for 2 days, active comparative. Angiotensin-converting enzyme inhibitor, oral, gradually increase to 20 mg per day at night.~Beta blocker, oral, 23.75 - 95 mg per day in the morning. Proton-pump inhibitor, oral, 30 mg per day. Duloxetine hydrochloride, oral, placebo, 20 mg per day before sleep. Acetaminophen (sham comparator), oral, 250 mg four times per day for 8 days. Cefuroxime (sham comparator), oral, 100 mg twice per day for 6 days. Papaverine, oral, low-dosage in coughing pills for 4 days. Superoxide Dismutase (active comparator), oral, to be introduced. Bafilomycin A1 (active comparator), oral, 100 ug per kilogram per day, unlikely to be introduced for lack of funding."
62036351|NCT06202066|EXPERIMENTAL|ARM II (temozolomide, SurVaxM)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days until disease progression or unacceptable toxicity and can be continued at investigators discretion at end of treatment. Patients also receive SurVaxM with Montanide ISA-51 SC and sargramostim SC once every 2 weeks for 4 doses. Patients with clinical benefit after 4 doses of SurVaxM and remain free of tumor progression and unacceptable toxicity may receive 3 additional doses on weeks 24, 36, and 48. Additionally, patients undergo blood sample collection, CT scans or MRI scans throughout study.
62036352|NCT06202066|EXPERIMENTAL|PART 1 (temozolomide, SurVaxM)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity and can be continued at investigators discretion at end of treatment. Patients also receive SurVaxM with montanide ISA-51 SC and sargramostim SC once every 2 weeks for 4 doses. Patients with clinical benefit after 4 doses of SurVaxM and remain free of tumor progression and unacceptable toxicity may receive 3 additional doses on weeks 24, 36, and 48. Additionally, patients undergo blood sample collection, CT scans or MRI scans throughout study.
62036353|NCT06243146|EXPERIMENTAL|Titration|During OLV, FiO2 starts at 80%. Titration of inspired oxygen using blood gas analysis and SpO2 monitoring. The titration target is arterial blood gas analysis with PaO2 ≤ 150mmHg and 93% ≤ SpO2 ≤ 97%.
62036354|NCT06243146|ACTIVE_COMPARATOR|Control|During OLV, FiO2 starts at 80% and remains until the end of OLV.
62237598|NCT04994327|PLACEBO_COMPARATOR|Control bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
62595909|NCT04116827||Tamoxifen group|Pre-menopausal breast cancer patients who underwent proper surgical treatment, chemotherapy, or radiation therapy, and are scheduled for application of tamoxifen and goserelin
62595910|NCT04990323|EXPERIMENTAL|ECT-001-Expanded CB|"Patients will receive a myeloablative conditioning regimen (Preferred: Clo/Flu/Bu90, Alternative: MIDI)~The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus)."
62813541|NCT02149914|EXPERIMENTAL|PPI treatment|Patients with GERD would be assessed by ANSWatch. Ryodoraku, UGI endoscopy, and GerdQ before taking PPIs and after taking PPI 20mg tablet by mouth everyday for 4 weeks.
62813542|NCT04392739|OTHER|TPOXX|TPOXX 600 mg BID x 7 days
62036355|NCT05926401||Planned elective cardioversion for atrial fibrillation|
62036356|NCT04704375|EXPERIMENTAL|Bio Electro-Magnetic Regulation (BEMER) Therapy|Subjects in the BEMER group received treatment 5 times per week for a period of 3 weeks.
62036357|NCT04704375|ACTIVE_COMPARATOR|OMT (Osteopathic Manipulative Treatment)|Each subject in the OMT group received treatment 3 times per week for a period of 3 weeks.
62036358|NCT04704375|EXPERIMENTAL|BEMER + OMT|Each subject in the BEMER + OMT group received treatment 3 times per week for a period of 3 weeks.
62036359|NCT04704375|SHAM_COMPARATOR|Control|Finally, subjects in the Placebo group will receive the light touch and BEMER sham treatments at same intervals as the corresponding experimental groups.
62036360|NCT06670846|EXPERIMENTAL|Lollipop arm|Distraction using a lollipop (group L) 15 minutes before entering the operating room
62036361|NCT06670846|ACTIVE_COMPARATOR|Midazolam arm|Intranasal midazolam at 0.3 mg/kg 15 minutes before anesthesia
62036362|NCT04474626|EXPERIMENTAL|ISOQUERCETIN|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits~- ISOQUERCETIN: Oral Study Drug, 1 time per day, per predetermined dosed per 28 treatment cycle.~This will continue for up to 337 days."
62237599|NCT04632472|ACTIVE_COMPARATOR|Active fixation bipolar lead|Left ventricular bipolar pacemaker lead, fixated by a side helix
62237600|NCT04632472|PLACEBO_COMPARATOR|Passive fixation quadripolar lead|Left ventricular quadripolar passive fixation pacemaker lead
62237601|NCT03744325|ACTIVE_COMPARATOR|Hen's egg OIT|Daily intake of gradually increasing doses of egg white protein under a 32 weeks period, continued by regular, daily intake of 1000 mg egg white protein.
62813543|NCT03327493|OTHER|Refractory cardiogenic shock under ECLS|
62813544|NCT05332600|EXPERIMENTAL|pre and post fatigue assessment|assessment pre and post fatigue protocol
62813545|NCT00908986|EXPERIMENTAL|Rituximab|Subjects receive rituximab in an open label manner
62237602|NCT03744325|NO_INTERVENTION|Hen's egg avoidance|Hen's egg is avoidance diet is continued.
62237603|NCT03224325|OTHER|Placebo (Pooled)|TAK-831 placebo-matching suspension, orally, once daily (QD) for up to Day 16.
62237604|NCT03224325|EXPERIMENTAL|TAK-831 100 mg|TAK-831 100 mg, tablets, orally, QD on Days 1 and 3 to 16.
62237605|NCT03224325|EXPERIMENTAL|TAK-831 300 mg|TAK-831 300 mg, tablets, orally, QD on Days 1 and 3 to 16.
62237606|NCT03224325|EXPERIMENTAL|TAK-831 600 mg|TAK-831 600 mg, tablets, orally, QD on Days 1 and 3 to 16.
62237607|NCT03224325|EXPERIMENTAL|TAK-831 15 mg|TAK-831 15 mg, suspension, orally, multiple doses (MD) daily, on Days 1 and 3 to 16.
62237608|NCT03224325|EXPERIMENTAL|TAK-831 800 mg|TAK-831 800 mg, suspension, orally, QD on Day 1, MD on Days 3 to 16.
62595911|NCT06596460|EXPERIMENTAL|Computerised Tomography (CT) Intervention|Transpercutaneous Aortic Valve Implantation (TAVI) planning CT (adapted) of the heart and aortic arch at 6 months post TAVI
62813546|NCT00783523|ACTIVE_COMPARATOR|Doxycycline|Patients undergoing elective vascular malformation surgery will receive doxycycline100 mg twice a day, a dose shown to effectively decrease MMP or placebo, treatment for two weeks prior to surgery
62813547|NCT00783523|PLACEBO_COMPARATOR|Placebo|Patients undergoing elective vascular malformation surgery will receive doxycycline100 mg twice a day, a dose shown to effectively decrease MMP or placebo, treatment for two weeks prior to surgery
62813548|NCT03763032|EXPERIMENTAL|Stepped Interventions|Patient navigation intervention, plus various psychosocial interventions
62427945|NCT04209218|PLACEBO_COMPARATOR|Routine blood pressure management + placebo|Blood pressure is maintained according to routine practice. Placebo (normal saline 2 ml) is administered before anesthesia induction.
62813549|NCT06316830|EXPERIMENTAL|High Maintenance Daily Dose (24mg)|The experimental intervention is a high daily maintenance dose of buprenorphine (24 mg) plus any usual clinical care the participant receives at the clinic. This high daily dose is the upper limit of the FDA-approved dose range and was selected based on preclinical studies, clinician anecdotes, case reports, and retrospective analyses suggesting improved effectiveness of higher buprenorphine doses among patients with a history of fentanyl use. Underlying pharmacodynamic principles support that the 24 mg daily dose of buprenorphine is likely to be well-tolerated, safe, and better control cravings among people with a history of fentanyl use.
62427946|NCT04209218|EXPERIMENTAL|Routine blood pressure management + dexamethasone|Blood pressure is maintained according to routine practice. Dexamethasone (10 mg/2 ml) ia administered before anesthesia induction.
62813550|NCT06316830|ACTIVE_COMPARATOR|Standard Maintenance Daily Dose (16mg)|The control intervention is the FDA-recommended target daily maintenance dose of buprenorphine (16 mg) plus any usual clinical care the participant receives at the clinic.
62036363|NCT03620344|EXPERIMENTAL|ADH-Me Book|"Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure. Families assigned to this condition will also receive the ADH-Me! book. Written by a pediatrician and health literacy expert, ADH-Me! is an accessible, rhyming narrative that describes an empathetic journey from the perspective of a child learning to live and succeed with ADHD. The book is intended to help families know what to expect from diagnosis through all stages of treatment, while attempting to foster love and support."
62036364|NCT03620344|SHAM_COMPARATOR|No ADH-Me Book|"Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure."
62036365|NCT04508894|PLACEBO_COMPARATOR|Control group|Supraclavicular Brachial Plexus Block using 20 ml 0.5%bupivacaine and 20 ml 0.9% normal saline
62036366|NCT04508894|ACTIVE_COMPARATOR|Ketamine group|Supraclavicular Brachial Plexus Block using 20 ml 0.5%bupivacaine and 20 ml 0.9% normal saline plus 1 mg\\kg ketamine
62595912|NCT06648564||Group 1|Bone regenerativ surgery with a bone graft material (Algipore) and a resorbable membrane (Osseoquest)
62595913|NCT06648564||Group 2|Bone regenerativ surgery with a bone graft material (Algipore)
62595914|NCT01570270|EXPERIMENTAL|regular cheese|This study was a 3-week, randomized, single blind, controlled, cross over clinical trial. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. T
62595915|NCT05889585|OTHER|high-dose of chemotherapy with autologous transplant and relapse-free after a minimum of 3 years.|Men with a histologically-confirmed (or high level serum tumor marker-based) diagnosis of germ-cell tumor, treated for relapse with high-dose of chemotherapy (HDCT) with autologous transplant at Gustave Roussy and relapse-free after a minimum of 3 years.
62036367|NCT04508894|ACTIVE_COMPARATOR|Dexmedetomidine group|Supraclavicular Brachial Plexus Block using 20 ml 0.5% bupivacaine and 20 ml 0.9% normal saline plus 1µg\\kg dexmedetomidine
62036368|NCT02638038|EXPERIMENTAL|Oral INT 131 3 mg|Oral INT-131 Double blind study
62036369|NCT02638038|EXPERIMENTAL|Oral INT-131 1 mg|Oral INT-131 Double blind
62036370|NCT02638038|PLACEBO_COMPARATOR|Placebo|Oral placebo Double blind
62237609|NCT03224325|EXPERIMENTAL|TAK-831 1200 mg|TAK-831 1200 mg, suspension, orally, QD on Day 1, MD on Days 3 to 16.
62237610|NCT02643160|EXPERIMENTAL|Functional Trunk Training Group|Functional Trunk Training which includes strengthening of trunk muscle and functional activities including trunk region.
62237611|NCT02643160|NO_INTERVENTION|Control Group|No intervention, the continued their regular physical therapy
62237612|NCT00186069|ACTIVE_COMPARATOR|Magnesium Sulfate|Magnesium Sulfate 4 gram bolus, followed by 2 grams per hour
62237613|NCT00186069|PLACEBO_COMPARATOR|Normal Saline|Normal Saline 4 gram bolus, followed by 2 grams per hour
62237614|NCT04051788|EXPERIMENTAL|Step Aerobics|Step Aerobics Training (120 to 126 foot steps per min)
62427947|NCT04209218|EXPERIMENTAL|Targeted blood pressure management + placebo|Blood pressure is maintained within ±10% from baseline. Placebo (normal saline 2 ml) is administered before anesthesia induction.
62427948|NCT04209218|EXPERIMENTAL|Targeted blood pressure management + dexamethasone|Blood pressure is maintained within ±10% from baseline. Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.
62427949|NCT01532011|EXPERIMENTAL|Erlotinib + Pralatrexate|"Dose escalation group starting dose: Erlotinib 75 mg by mouth daily for a 28 day cycle. Starting dose of Pralatrexate 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
62427950|NCT04657237|NO_INTERVENTION|control group|all patients will receive general anesthesia and will receive intravenous paracetamol (1 g) before skin closure and then given every 6 hrs in the 1st postoperative day
62813551|NCT04762511|EXPERIMENTAL|HSV lower dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV lower dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
62036371|NCT03991611|EXPERIMENTAL|IPREA3 program|Application of the IPREA 3 program (multicomponent intervention to reduce perceived discomforts in critically ill patients) for at least 5 months
62237615|NCT04051788|ACTIVE_COMPARATOR|Aerobic exercise (Lower limb Cycling)|Lower Limb Aerobic cycling
62237616|NCT04376853||COVID-19|Patients with COVID-19, who have cardiovascular diseases or receive medication with arrhythmogenic risk.
62036372|NCT03991611|OTHER|Intermediate group|Application of the IPREA 3 program (multicomponent intervention to reduce perceived discomforts in critically ill patients) for less than 5 months
62036373|NCT03991611|ACTIVE_COMPARATOR|Standard care|Standard care
62036374|NCT03991611|OTHER|PTSD-REA_COVID cohort|ICU admission between March 1, 2020 and April 30, 2020.
62036375|NCT05571631|EXPERIMENTAL|Arm ergometer-balance training|Combination of arm ergometer exercise and balance training
62036376|NCT05571631|EXPERIMENTAL|arm ergometer|Only arm ergometer exercise training
62427951|NCT04657237|ACTIVE_COMPARATOR|TPVB group|Patients will receive total volume (20 ml) 0.25% bubivicaine divided equally at each level of T4 and T6 at thoracic paravertebral space then they will recive general anesthesia.
62036377|NCT04647851|EXPERIMENTAL|Remote exercise intervention Down syndrome|Intervention: The program we will be using is specifically developed for individuals with Down syndrome based on the Mann Method PT Principles. The MMPT Principles TM focus on a progressive program of therapeutic activity (cardiovascular activity), therapeutic exercise (foundational strengthening and hip strengthening activities), and neuromuscular rehabilitation (visual/vestibular and balance activities) to address the unique needs of individuals with Down syndrome. This program has been developed and successfully implemented in Down syndrome activity centers across the country. This program will be offered through Zoom. Intensity will be submaximal for both data collection and during the exercise sessions, and recorded with Polar heart rate monitors.
62595916|NCT05889585|OTHER|Treated by orchidectomy only and no evidence of relapse after a minimum of 3 years|Men with a histologically confirmed (or high level serum tumor marker-based) stage I germ cell tumor, treated by orchidectomy only and no evidence of relapse after a minimum of 3 years.
62595917|NCT05889585|OTHER|Treated by first line cisplatin-based chemotherapy and relapse-free after a minimum of 3 years.|Men with a histologically confirmed (or high level serum tumor marker-based) germ cell tumor and good or intermediate prognosis metastatic disease according to the International Germ-Cell Cancer Collaborative Group (IGCCCG), treated by first line cisplatin-based chemotherapy (and surgery of residual masses if needed), with no evidence of relapse after a minimum of 3 years.
62595918|NCT04654754|EXPERIMENTAL|high-flow high humidity oxygen device with tracheostomy adapter|This device provides high-flow gas to tracheostomy patients with heat and humidification. A special adapter is used to connect the tracheostomy tube and circuit.
62595919|NCT04654754|ACTIVE_COMPARATOR|large-volume nebulizer (cool aerosol) with trach collar|This device is the conventional device that is commonly utilized to provide humidification for spontaneous breathing patients with tracheostomy.
62036378|NCT02854943||Critically ill patients|Male and female critically ill patients admitted to the Charité - University Medicine Berlin during 2000 and 2018.
62427952|NCT06519734||Patients|Adult women registered in the Center for Hereditary Immune Deficits (CEREDIH), hospital Necker-Enfants Malades, Paris.
62427953|NCT01520766|EXPERIMENTAL|glass fiber|
62595920|NCT04654754|PLACEBO_COMPARATOR|Venturi-adapter with trach collar|This device did not provide any humidification but only oxygen
62813552|NCT04762511|PLACEBO_COMPARATOR|Placebo Step 1 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
62813553|NCT04762511|EXPERIMENTAL|HSV low dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV low dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
62813554|NCT04762511|PLACEBO_COMPARATOR|Placebo Step 2 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
62813555|NCT04762511|EXPERIMENTAL|HSV medium dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV medium dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
62813556|NCT04762511|PLACEBO_COMPARATOR|Placebo Step 3 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
62813557|NCT04762511|EXPERIMENTAL|HSV high dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV high dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
62813558|NCT04762511|PLACEBO_COMPARATOR|Placebo Step 4 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
62813559|NCT03392064|EXPERIMENTAL|AMG 119 Treatment|AMG 119 administered as a one-time intravenous infusion at different cell dose levels
62813560|NCT01075243|EXPERIMENTAL|Paracetamol 1000mg|Paracetamol 1000mg
62813561|NCT01075243|EXPERIMENTAL|Paracetamol 650 mg|Paracetamol 650 mg
62813562|NCT01075243|PLACEBO_COMPARATOR|Placebo|Placebo
62813563|NCT01780311|ACTIVE_COMPARATOR|Antiarrhythmic drugs|Flecainide or Propafenone or Sotalol (oral, standard dosage)
62427954|NCT01520766|EXPERIMENTAL|titanium|
62427955|NCT06006351|ACTIVE_COMPARATOR|control|classical physiotherapy protocol will be applied.
62427956|NCT06006351|EXPERIMENTAL|Massage|In addition to the classical physiotherapy protocol, a Hypervolt Device will be applied.
62813564|NCT01780311|EXPERIMENTAL|ABLATION|Catheter Ablation
62813565|NCT02022059|EXPERIMENTAL|Lidocaine|patient nécessitant une SNG pour nutrition entérale bénéficiant d'une pré-médication par vaporisateur de lidocaïne lors de l'insertion (group A = lidcoaine)
62813566|NCT02022059|PLACEBO_COMPARATOR|Placebo|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion (group B)
62427957|NCT04528277|EXPERIMENTAL|LGTB treatment group|The LGTB treatment group will receive the 1-month regimen of three times weekly rifapentine (150mg per capsule, 450mg po tiw) plus isoniazid (100mg per tablet, 400mg po tiw).
62427958|NCT04528277|NO_INTERVENTION|LGTB no treatment group|The LGTB no treatment group will not take any medication related to preventive treatment of tuberculosis.
62036379|NCT03477318||Patients undergoing screening colonoscopy|Patients undergoing first-time colonoscopy using white light with at least 1 polyp resected.
62036380|NCT05403801|EXPERIMENTAL|STAMP+CBT PILOT|"Patients in this Pilot Cohort will be in the research study for 6 weeks total including:~* a 4-week intervention period and 2-week post intervention period.~* Patients will use the app for a total of 4 weeks (4-week intervention period), and will complete surveys at baseline, 4 weeks (end of intervention period), and at 6 weeks (end of 2-week post intervention period)."
62036381|NCT02733900|EXPERIMENTAL|Osteonecrosis group|Patients with an aseptic osteonecrosis of the femoral head
62036382|NCT02733900|OTHER|Control group|Patients with coxarthrosis
62036383|NCT03819153|EXPERIMENTAL|Semaglutide|Participants are to receive semglutide for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint.
62036384|NCT03819153|PLACEBO_COMPARATOR|Placebo|Participants are to receive placebo (semglutide) for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint.
62036385|NCT06029400||Retrospective cohort|The retrospective arm of the study will include 200 patients meeting the inclusion criteria who have received a cardiac CT from January 2013 to date of approval amendment. (2013 was chosen as starting year to retrieve CT and clinical date in order to have at least 5 years of follow-up per patients).
62036386|NCT06029400||Prospective cohort|The prospective arm of the study will include 2000 consecutive patients meeting the inclusion criteria, candidate to cardiac CT along the 7 years after date of approval.
62036387|NCT06009081|EXPERIMENTAL|postural exercise|An 8-week home exercise program consisting of neck exercises was applied for group 1. The exercise program was carried out three times a week for eight weeks.
62036388|NCT06009081|ACTIVE_COMPARATOR|aerobic exercise|An 8-week walking program was planned for Group 2 using pedometer feedback as a motivational tool.
62237617|NCT04286698|ACTIVE_COMPARATOR|Complex decongestive physiotherapy program group|Manuel lymph drainage, compression mask, exercises and skin care
62237618|NCT04286698|ACTIVE_COMPARATOR|Home program group|Self-manuel lymph drainage and home exercises
62237619|NCT04286698|NO_INTERVENTION|Control group|No intervention
62237620|NCT04237922||Clopidogrel 75 mg|Reference group
62237621|NCT04237922||Prasugrel 10 mg|Exposure group
62036389|NCT01339585|EXPERIMENTAL|Timing of tDCS|
62036390|NCT01339585|EXPERIMENTAL|Alternative timing of tDCS|
62036391|NCT06241274|EXPERIMENTAL|Moxibustion|Subjects received symptomatic supportive treatment combined with moxibustion covering Shenque, Zhonggong, Guanyuan, and Qihai for 30 minutes every day for 14 days.
62036392|NCT04192981|EXPERIMENTAL|Concurrent GDC-0084 with Radiation|GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily, with a potential de-escalation cohort to 30mg, to determine MTD in combination with whole brain radiation therapy radiation therapy to 30Gy in 10 fractions. Once MTD is determined, 12 additional patients will be treated with GDC-0084 at MTD in combination with whole brain radiation therapy.
62036393|NCT02035800|EXPERIMENTAL|Adalimumab (humira)|As standard of care.
62036394|NCT06064227|EXPERIMENTAL|intervention group.|"Multi-module training intervention.~The intervention group, patients identified as pre-frail or frail, will be included in a multi-module educational program created specifically for this study."
62237622|NCT00106522|EXPERIMENTAL|1|
62237623|NCT00106522|EXPERIMENTAL|2|
62237624|NCT00106522|PLACEBO_COMPARATOR|3|
62427959|NCT04528277|NO_INTERVENTION|non-LGTB group|The non-LGTB group will not take any medication related to preventive treatment of tuberculosis.
62427960|NCT06160479|NO_INTERVENTION|Normal calcium level with no receiving calcium supplement|Pregnant women with normal calcium level in the first half of pregnancy do not receive calcium supplement.
62427961|NCT06160479|EXPERIMENTAL|Normal calcium level with receiving calcium supplement 1g/day|Pregnant women with normal calcium level in the first half of pregnancy receive calcium supplement 1g/day.
62427962|NCT06160479|EXPERIMENTAL|Hypocalcemia with receiving calcium supplement 1g/day|Pregnant women with hypocalcemia in the first half of pregnancy receive calcium supplement 1g/day.
62427963|NCT06160479|EXPERIMENTAL|Hypocalcemia level with receiving calcium supplement 2g/day|Pregnant women with hypocalcemia in the first half of pregnancy receive calcium supplement 2g/day.
62427964|NCT02845635||Relapsing Remitting Multiple Sclerosis|Those who document during the study on-boarding process that they suffer from relapsing-remitting multiple sclerosis.
62427965|NCT02845635||Primary Progressive Multiple Sclerosis|This who document during the on-boarding process that they suffer from primary progressive multiple sclerosis.
62427966|NCT02845635||Secondary Progressive Multiple Sclerosis|This who document during the on-boarding process that they suffer from secondary progressive multiple sclerosis.
62427967|NCT02845635||Control|This who document during the on-boarding process that they do not suffer from multiple sclerosis.
62237625|NCT01774084|ACTIVE_COMPARATOR|PreOp, NutriciaNordica AB|PreOp: 50 kcal/100 mL in the form of maltodextrin and fructose. One bottle of 800 ml to be ingested at bedtime, and at midnight by the latest, and another bottle with 400 ml approximately 2 hours before surgery started.
62237626|NCT01774084|PLACEBO_COMPARATOR|Water|Water: One bottle of 800 ml to be ingested at bedtime, and at midnight by the latest, and another bottle with 400 ml approximately 2 hours before surgery started.
62237627|NCT01366287|EXPERIMENTAL|Suspension/fasted|
62237628|NCT01366287|EXPERIMENTAL|Tablet/fasted|
62237629|NCT01366287|EXPERIMENTAL|Tablet/fed|
62237630|NCT00622882|ACTIVE_COMPARATOR|ID|Patients receiving an early Infectious disease consultation ( within first 48 hours of a positive blood culture)
62237631|NCT00622882|NO_INTERVENTION|NO ID|Includes those patients who do not receive an Infectious disease consultation in the first 48 hours
62237632|NCT02367365||Treatment Naive NVAMD Patients|Patients with treatment naive NVAMD diagnosed in the last three months
62427968|NCT02162901|EXPERIMENTAL|Choice-Class with IVR Calls|Participants enrolled in this arm of the study will have chosen to attend one 2-hour class to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months.
62427969|NCT02162901|EXPERIMENTAL|Choice-DVD with IVR calls|Participants enrolled in this arm of the study will have chosen to watch a DVD at home to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
62427970|NCT02162901|EXPERIMENTAL|Random-Class with IVR calls|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will attend one 2-hour class to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
62427971|NCT02162901|EXPERIMENTAL|Random-DVD with IVR calls|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will be given a DVD to watch at home to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
62427972|NCT02162901|ACTIVE_COMPARATOR|Random-Class only|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will attend one 2-hour class to be introduced to the intervention and will receive a workbook to use at home.
62427973|NCT00533884||Treatment|Patients undergoing treatment for head and neck, lung, and esophagus cancers
62427974|NCT02253758|EXPERIMENTAL|Sedation|Volunteers will be sedated to Ramsay score 4-5 with propofol, and data will be recorded during arousal
62237633|NCT02367365||Newly Reactivated NVAMD Patients|Patients with newly reactivated NVAMD which has been previously quiescent off treatment
62237634|NCT04201821|EXPERIMENTAL|FMT Administration|This is a single arm study in which all eligible participants will receive FMT.
62237635|NCT05843513||Monitoring|"From every participant the following information was recorded for further analysis:~* State Trait Anxiety Inventory (STAI) questionnaire.~* A questionnaire is carried out to assess:~  1. Endogenous abrasion: presence or absence of wear facets; carrier of occlusal splint; presence of harmful oral habits; day and/or night grinding.~ 2. Exogenous abrasion: whether they bite hard or soft things.~ 3. Exogenous erosion: - Environmental factors: frequent swimming. - Ingestion of acidic drinks or substances: fizzy drinks, juices, alcohol, dressings, etc.~ 4. Endogenous erosion: reflux, vomiting, heartburn, nighttime drooling, etc.~* An examination of the temporomandibular joint (TMJ) is carried out; palpation of the muscles most frequently related to bruxism and/or alterations of the TMJ.~* 2 Intra oral scans (IOS): Baseline and follow up (1 year after baseline) to perform a quantification of tissue loss (over 100 microns) using Geomagic software."
62237636|NCT05743322|EXPERIMENTAL|3D printing arm|A bi-atrial 3D printed model will be manufactured before the procedure
62237637|NCT05197023|EXPERIMENTAL|SHR-1819 injection|
62237638|NCT05197023|PLACEBO_COMPARATOR|placebo|
62237639|NCT04646590|EXPERIMENTAL|Investigational Vaccine|Recombinant Novel Coronavirus Vaccine (CHO cell), 0.5mL/vial, contains 25 μg NCP-RBD protein. After mixing, take all the liquid and inject intramuscularly into deltoid muscle of upper arm.
62427975|NCT04790409|EXPERIMENTAL|Sintilimab with anlotinib|Patients received sintilimab (anti-PD-1) combined with anlotinib (multi-target anti-angiogenesis).
62036395|NCT06064227|NO_INTERVENTION|control group|The control group will be selected by single-blind, stratified randomization (coin-flip) from among patients identified as pre-frail or frail and will not receive any intervention.
62427976|NCT04084912|ACTIVE_COMPARATOR|Dexamethasone group|this group will receive one ampoule Intravenous injection of Dexamethasone Sodium Phosphate 2 ml . 8 mg once by the anesthesiologist immediately before skin incision
62427977|NCT04084912|PLACEBO_COMPARATOR|Placebo group|this group will receive one ampoule Intravenous injection of Saline once by the anesthesiologist immediately before skin incision
62427978|NCT01875133|OTHER|A: low-intermediate-high altitude|Altitude exposure sequence A, 490-1630-2590m
62427979|NCT01875133|OTHER|B: low-high-intermediate altitude|Altitude exposure sequence B, 490-2590-1630 m
62595921|NCT04654754|EXPERIMENTAL|large-volume nebulizer (cool aerosol) with T-piece and a filter|this device is added with a filter, in order to reduce aerosol particle concentrations in the surrounding environment
62595922|NCT04654754|EXPERIMENTAL|high-flow high humidity device with a scavenger or a surgical mask|this device is added with a scavenger or a surgical mask over the adapter, in order to reduce aerosol particle concentrations in the surrounding environment
62595923|NCT02144480|EXPERIMENTAL|Intensive training|intensive aerobic training in moderate intensity day5 postoperatively. 30 minutes per sessions, 2 sessions per day, 10 sessions per week. There will be 20 sessions in total.
62595924|NCT02144480|SHAM_COMPARATOR|traditional training|traditional rehabilitation
62595925|NCT06623708|NO_INTERVENTION|Control|This group of participants should follow the general recommendations for the management of Type 1 or Type 2 Diabetes.
62595926|NCT06623708|EXPERIMENTAL|SMARTCLOTH|This group will use SMARTCLOTH for 3 months.
62595927|NCT04064242|EXPERIMENTAL|CMK389|CMK389 10 mg/kg i.v. every 4 weeks for a total of 4 doses
62036396|NCT02527798|EXPERIMENTAL|Furosemide Cohort 1|Within cohort 1, infants will be randomized using a 3:1 scheme to receive furosemide or placebo. Those randomized to receive furosemide will receive (1mg/kg daily intravenously or 2 mg/kg daily enterally for 28 days.
62237640|NCT04646590|PLACEBO_COMPARATOR|Placebo comparator|Placebo for Recombinant Novel Coronavirus Vaccine (CHO cell), 0.5mL/vial, contains 0.25mg Aluminum hydroxide adjuvant. After mixing, take all the liquid and inject intramuscularly into deltoid muscle of upper arm.
62237641|NCT00866697|PLACEBO_COMPARATOR|Placebo|matched placebo tablet administered orally once daily for up to 24 months
62237642|NCT00866697|EXPERIMENTAL|Pazopanib|Pazopanib tablet administered orally at 800 mg once daily for up to 24 months
62237643|NCT05147883|EXPERIMENTAL|Exercise|Patients will be given an aerobic exercise program for 1 hour, 3 days a week for 12 weeks.
62237644|NCT05147883|NO_INTERVENTION|Control|No intervention will be applied to the patients
62427980|NCT01875133|OTHER|C: intermediate-high-low altitude|Altitude exposure sequence C, 1630-2590-490 m
62427981|NCT01875133|OTHER|D: high-intermediate-low altitude|Altitude exposure sequence D, 2590-1630-490 m
62427982|NCT01253889|ACTIVE_COMPARATOR|Oral Glucose with soother|Oral Glucose 25% first given two minutes before the first contact by the physician performing the np-ECHO. A soother will be held in the infant's mouth to ensure that continuous contact is maintained throughout the testing period. Repeat application of solution as per study protocol. No other non-pharmaceutical interventions for stress reduction will be applied. During each np-ECHO, infants have additional handling only if it is required to maintain physiological stability.
62427983|NCT01253889|PLACEBO_COMPARATOR|Oral water with soother|Oral water first given two minutes before the first contact by the physician performing the np-ECHO. A soother will be held in the infant's mouth to ensure that continuous contact is maintained throughout the testing period. Repeat application of solution as per study protocol. No other non-pharmaceutical interventions for stress reduction will be applied. During each np-ECHO, infants have additional handling only if it is required to maintain physiological stability.
62427984|NCT01253889|ACTIVE_COMPARATOR|Oral glucose with soother and tucking|For the infants randomized to receive facilitated tucking throughout the procedure, the bedside nurse will provide gentle, firm containment of the extremities. The facilitated tucking will commence immediately after the baseline BIIP score is taken, but before the glucose/water is administered.
62595928|NCT04064242|PLACEBO_COMPARATOR|Placebo|Placebo i.v. every 4 weeks for a total of 4 doses
62595929|NCT05356533|ACTIVE_COMPARATOR|Intervention|A total of 60 young adults will be randomized to the 4-week, web-based drinking to cope intervention.
62595930|NCT05356533|NO_INTERVENTION|Assessment Control|A total of 60 young adults will be randomized to the assessment only control condition.
62595931|NCT04424212|EXPERIMENTAL|Experimental: Intervention group CoronaCope|ICBT, were participants receive 8 out of 15 possible modules depending on their current problems and needs, 7 week long internet intervention for reducing mental health issues related to the coronavirus pandemic.
62595932|NCT04424212|NO_INTERVENTION|Control group|Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention.
62237645|NCT05313126|EXPERIMENTAL|sterile male Aedes albopictus-exposed|Sterile male Aedes albopictus are released in the area.
62237646|NCT05313126|NO_INTERVENTION|control|Sterile male Aedes albopictus are not released in the area.
62237647|NCT03408782||No drainage|Those patients that underwent surgery and no drain was inserted at the end of the procedure
62237648|NCT03408782||Drainage|Those patients that underwent surgery and one or several drains were inserted at the end of the procedure.
62237649|NCT05785702|EXPERIMENTAL|The anti-wandering system|The experimental group will use the anti-wandering system 4-6-week of pre-test and 12-week of test trial.
62595933|NCT05340933|EXPERIMENTAL|Arm 1|intervention correspond to the voice registration
62813567|NCT05597202|EXPERIMENTAL|Treatment arm|Will receive semaglutide treatment for 6 months, at the highest tolerable dose, up to a maximum of 2.0mg weekly.
62813568|NCT04722614|ACTIVE_COMPARATOR|Control group|Mechanically ventilated patients who will be subjected to the routine unit intervention for agitation
62595934|NCT03140072|EXPERIMENTAL|AZD9898|In Part 1 of the study, 5 single dose cohorts are planned to be evaluated, where AZD9898 will be administered. Eight subjects will participate in each cohort. Within each cohort, 6 (alternatively 8 or 10) subjects will be randomized to receive a single dose of AZD9898. Fifteen asthma patients are planned to participate in 3 cohorts in Part 2. Five patients will participate in each cohort. Within each cohort, 4 (alternatively 6 or 8) patients will be randomized to receive a single dose of AZD9898. In Part 3, 3 dose cohorts are planned. Nine healthy subjects will participate in each cohort. Within each cohort, 6 (alternatively 8, 10 or 12) subjects will be randomized to receive AZD9898. The subjects taking part in one of the MAD cohorts under fasted conditions will also take part in Part 3B in order to explore the influence of food on the PK of AZD9898.
62595935|NCT03140072|PLACEBO_COMPARATOR|Placebo|In Part 1 of the study, 5 single dose cohorts are planned to be evaluated, where matching placebo will be administered. Eight subjects will participate in each cohort. Within each cohort, 2 (alternatively 3) subjects will be randomized to receive a single dose of matching placebo. Fifteen asthma patients are planned to participate in 3 cohorts in Part 2. Five patients will participate in each cohort. Within each cohort, one patient (alternatively 2 or 3 patients) will be randomized to receive a single dose of matching placebo. In Part 3, 3 dose cohorts are planned. Nine healthy subjects will participate in each cohort. Within each cohort, 3 (alternatively 4) subjects will be randomized to receive matching placebo.
62595936|NCT02218736|EXPERIMENTAL|CERC-501|Oral dosing of 10 mg CERC-501 (formerly known as LY2456302) administered daily for 8 weeks
62595937|NCT02218736|PLACEBO_COMPARATOR|Placebo|Oral daily administration of 10 mg placebo for 8 weeks
62595938|NCT01654653|EXPERIMENTAL|HSL(Totilac)|Hypertonic Sodium Lactate
62595939|NCT01654653|ACTIVE_COMPARATOR|6% HES (Voluven)|6% Hydroxyethyl Starch
62036397|NCT02527798|PLACEBO_COMPARATOR|Placebo Cohort 1|Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
62036398|NCT02527798|EXPERIMENTAL|Furosemide Cohort 2|Cohort 2 Infants will receive furosemide (1mg/kg every 6 hours intravenously or 2 mg/kg every 6 hours daily enterally) for 28 days.
62237650|NCT00972777|EXPERIMENTAL|Besifloxacin|0.6% ophthalmic suspension
62427985|NCT01253889|PLACEBO_COMPARATOR|Oral water with soother and tucking|For the infants randomized to receive facilitated tucking throughout the procedure, the bedside nurse will provide gentle, firm containment of the extremities. The facilitated tucking will commence immediately after the baseline BIIP score is taken, but before the glucose/water is administered.
62427986|NCT05883020|SHAM_COMPARATOR|Standard physical therapy program|all participants will receive strengthing, stretching, facilitation and inhibitory techniques, splinting, developmental techniques, gait, and balance training. The duration of each session will be 1 hour, 3 times per week for 4 weeks.
62427987|NCT05883020|ACTIVE_COMPARATOR|Radial shockwave therapy (rSWT)|One session per week of rSWT will be applied using shockwave device. The following parameters will be used: Shocks number: 1500 per muscle, will be applied over the belly of the calf muscle using the 15 mm applicator head. The pressure will be 2 bar and the frequency will be 4 Hz. Patients will receive shock wave from prone position.
62427988|NCT00133094|OTHER|Arm 1|
62427989|NCT05351281|NO_INTERVENTION|Standard of care|Patients in the standard of care arm will receive the usual treatment
62427990|NCT05351281|EXPERIMENTAL|CDSS-OPTIMED|In the experimental arm, attending physicians will receive weekly medication alerts from the Clinical Decision Support System (CDSS) within 1 week after inclusion of the patient. The CDSS-OPTIMED will send a medication advice on a weekly basis, based on a weekly analysis of patient's medication. The medication alerts will be sent to the physician's email address. The physician is free to follow or ignore the advice in the alerts. If the physicians thinks these alerts are relevant for the patient, the physician will discuss these alerts with the patient and/or relatives. After this conversation, the physician will prescribe or deprescribe medications based on the alerts.
62427991|NCT03307707||Heart Failure (HF)|subjects with a Left Ventricular Ejection Fraction (LVEF) \<50% or LVEF \>50% and E/e'\>10.
62427992|NCT03307707||No Heart Failure (NHF)|subjects with LVEF\>50%
62427993|NCT03045029||Oral treprostinil|Sustained-release oral tablets for three times daily (TID) administration in prostacyclin naive and prostacyclin transition patients
62427994|NCT02638961|PLACEBO_COMPARATOR|Standard treatment|Only standard medical treatment
62427995|NCT02638961|ACTIVE_COMPARATOR|IMT group|Standard medical treatment associated to Inspiratory muscle training
62427996|NCT02638961|ACTIVE_COMPARATOR|FES group|Standard medical treatment associated to functional electrostimulation of both legs for 45 minutes a day, 2 days per week for a total of 12 weeks.
62427997|NCT02638961|ACTIVE_COMPARATOR|IMT+FES group|Standard medical treatment associated to combination of inspiratory muscle training and functional electrostimulation of both legs
62427998|NCT03181178|ACTIVE_COMPARATOR|KokoPlus and Nutrition Education|Macro-micronutrient complementary food supplement and Nutrition Education
62427999|NCT03181178|ACTIVE_COMPARATOR|Micronutrient and Nutrition Education|A micronutrient powder and Nutrition Education
62428000|NCT03181178|ACTIVE_COMPARATOR|Nutrition Education Only|Nutrition Education
62428001|NCT03181178|NO_INTERVENTION|Growth Monitoring Only|Growth monitoring
62428002|NCT02832882|EXPERIMENTAL|No-touch RFA arm|No-touch RFA arm indicates RFA procedure using Octopus electrode and no touch technique.
62428003|NCT02832882|ACTIVE_COMPARATOR|Conventional tumor puncture RFA arm|Conventional tumor puncture RFA arm indicates RFA procedure using Octopus electrode and conventional tumor puncture technique.
62428004|NCT05161663|EXPERIMENTAL|PDI group|In this group, participants will receive education about HIV and pre-exposure prophylaxis (PrEP) and be referred to our study by peer educators. Referred participants will have free PrEP counseling and receive referrals if interested. We will follow up at three and six months and check participants' PrEP status.
62237651|NCT00972777|PLACEBO_COMPARATOR|Vehicle|
62237652|NCT01475552|EXPERIMENTAL|abciximab|
62428005|NCT05161663|NO_INTERVENTION|Control group|In the control group, participants do not receive any education from peers and will be directly recruited by research assistants from venues (e.g. gay bars, LGBTQ communities, LGBTQ events, and social media advertisements). Participants will receive PrEP counseling and referral if interested. We will follow up at three and six months and check participants' PrEP status.
62237653|NCT01475552|ACTIVE_COMPARATOR|control|
62595940|NCT01803503|ACTIVE_COMPARATOR|Docetaxel|Docetaxel 75mg/m2 day 1, every 3 weeks. Patients will be treated for a maximum of 6 cycles of chemotherapy in the absence of tumor progression or unacceptable toxicities.
62237654|NCT05781633|EXPERIMENTAL|eutidrone+ etoposide+ bevacizumab|Eligible patients received a regimen of eutidrone(30mg/m2/d,iv,d1-5,21d/cycle), etoposide(30mg/m2/d,iv,d1-3,21d/cycle), and bevacizumab (10mg/kg,d1,21d/cycle).At least 4 to 6 cycles were administered, and if patients had a response or stable disease, bevacizumab was used as maintenance therapy until disease progression or intolerable toxicity.
62237655|NCT04631627|ACTIVE_COMPARATOR|aspirin group|aspirin,tablet,100/150mg per day,(BMI\<30 100mg/d，BMI≥30 150mg/d)，from pregnancy weeks\<16 to 35 weeks or the day of delivery.
62428006|NCT06526767|EXPERIMENTAL|Control group|Subjects in control group took Vibrabot capsules twice a week, one pill/time (on Monday and Thursday), for six weeks.
62428007|NCT06526767|EXPERIMENTAL|Trial group 1|Subjects in trial group 1 took Vibrabot capsules three times a week, one pill/time (Monday, Wednesday, and Friday) for six consecutive weeks.
62428008|NCT06526767|EXPERIMENTAL|Trial group 2|Subjects in trial group 2 took Vibrabot capsules five times a week, one pill/time (Monday, Tuesday, Wednesday, Friday, and Saturday), for six weeks.
62428009|NCT06526767|EXPERIMENTAL|Trial group 3|Subjects in trial group 3 took Vibrabot capsules one pill/time, five times a week (Monday, Tuesday, Wednesday, Friday, and Saturday) during the first two weeks, three times a week (Monday, Wednesday, and Friday) during the middle two weeks, and two times a week (Monday and Thursday) during the last two weeks.
62428010|NCT05891873||Neurointensive/neurocritical group (N-ICU)|
62428011|NCT05891873||Paediatric intensive/critical group (P-ICU)|
62428012|NCT04135573||New untreated GD patients|Before treatment and application of anti-thyroid drugs (methimazole) or radioactive iodine treatment
62428013|NCT04135573||Healthy control|No thyroid related diseases and other immune diseases
62428014|NCT03750825|EXPERIMENTAL|Vapers|Smokers will switch to NIDA Standard Research E-cigarette (SREC).
62428015|NCT03750825|NO_INTERVENTION|Smokers|Smokers will continue to smoke.
62428016|NCT03750825|NO_INTERVENTION|Nonsmokers non-vapers|Control nonsmokers non-vapers will continue to refrain from smoking or vaping.
62428017|NCT04765254||control group|COVID-19 infected patients with no other comorbidities and they take the routine protocol from the Egyptian ministry of health
62428018|NCT04765254||diabetic group|COVID-19 infected patients with diabetes comorbidity and they receive the routine protocol for covid treatment in addition to their hypoglycemic drugs
62428019|NCT05880628||Any patient with aneurysmal or simple bone cyst who benefit a sclerotherapy by Discogel®|"Any patient with aneurysmal or simple bone cyst who benefit a sclerotherapy by Discogel® will be included.~Analysis datas of medical record."
62428020|NCT04829409|ACTIVE_COMPARATOR|paravertebral block|Patients receive ultrasound-guided paravertebral block
62428021|NCT04829409|ACTIVE_COMPARATOR|ESP block|Patients receive ultrasound-guided erector spinae plane (ESP) block
62428022|NCT04829409|EXPERIMENTAL|MTP block|Patients receive ultrasound-guided mid-point transverse process to pleura (MTP) block
62428023|NCT00439751|OTHER|Immediate ADT|
62428024|NCT00439751|OTHER|Deferred ADT|
62428025|NCT01949207|EXPERIMENTAL|EVLA, phlebectomies & Trlop closure of incompetent perforators|endovenous laser ablation (EVLA) of great saphenous vein (GSV) plus phlebectomies plus TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
62428026|NCT01949207|EXPERIMENTAL|EVLA & phlebectomies|endovenous laser ablation (EVLA) of great saphenous vein (GSV) + phlebectomies.
62428027|NCT06469138|EXPERIMENTAL|Single Dose Cohort - 200 mg containing approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib|This is the only treatment arm in this study. Up to 8 participants will receive a single oral dose of 200 mg containing approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib, 30 minutes after starting a standard high-fat breakfast.
62428028|NCT06537167|EXPERIMENTAL|"Stimulation Experimental Group"|
62428029|NCT06537167|SHAM_COMPARATOR|"Sham Stimulation Control Group"|
62595941|NCT01803503|EXPERIMENTAL|Docetaxel + Sunitinib|"Docetaxel 75mg/m2 day 1, every 3 weeks, preceded by 7 days of sunitinib 12.5mg orally daily during each cycle.~Patients will be treated for a maximum of 6 cycles of chemotherapy in the absence of tumor progression or unacceptable toxicities."
62813569|NCT04722614|EXPERIMENTAL|Music group|Mechanically ventilated patients who will listen to classic music
62813570|NCT04722614|EXPERIMENTAL|Essential oil group|Mechanically ventilated patients who will inhale bergamot oil
62036399|NCT02527798|EXPERIMENTAL|Furosemide Cohort 3|Cohort 3 Infants will receive furosemide (2mg/kg every 6 hours intravenously or 4 mg/kg every 6 hours daily enterally) for 28 days.
62237656|NCT04631627|SHAM_COMPARATOR|control group|with no intervention
62237657|NCT04283981|ACTIVE_COMPARATOR|Control Group|
62237658|NCT04283981|EXPERIMENTAL|Treatment Group|
62428030|NCT00033631|ACTIVE_COMPARATOR|70.2 Gy|70.2 Gy 3D-CRT/IMRT
62428031|NCT00033631|EXPERIMENTAL|79.2 Gy|79.2 Gy 3D-CRT/IMRT
62428032|NCT06204276|EXPERIMENTAL|Asymmetrical high-flow nasal cannula|"* Asymmetrical nasal cannula (Optiflow+ Duet nasal cannula)~* Airvo-2 (Fisher\&Paykel)"
62428033|NCT06204276|ACTIVE_COMPARATOR|Conventional high-flow nasal cannula|"* Conventional nasal cannula (Optiflow+ nasal cannula)~* Airvo-2 (Fisher\&Paykel)"
62428034|NCT01929369||CONTROL GROUP|Control group: index intervention guided by DSA; IVUS post-intervention only (50 patients)
62428035|NCT01929369||TEST GROUP|Test group: index intervention guided by IVUS + DSA (50 patients
62428036|NCT02059187|EXPERIMENTAL|MK-1293|MK-1293 administered subcutaneously once daily in the evening.
62428037|NCT02059187|ACTIVE_COMPARATOR|Lantus™|Lantus™ administered subcutaneously once daily in the evening.
62428038|NCT00534209|EXPERIMENTAL|Arm I: Allogeneic B7.1/HLA-A1|"Patients will receive Allogeneic B7.1/HLA-A1 vaccine once every other week for 2 courses over 12 weeks, for a maximum of 6 vaccines.~Given intradermally."
62428039|NCT00534209|PLACEBO_COMPARATOR|Arm II: Placebo|Patients receive a placebo vaccine intradermally once every other week for 2 courses over 12 weeks, for a maximum of 6 vaccines.
62428040|NCT03151785|ACTIVE_COMPARATOR|Face-to-face BLS training|Pupils will receive CPR training by standardised face-to-face BLS training only
62428041|NCT03151785|ACTIVE_COMPARATOR|Lifesaver training|Pupils will receive CPR training by Lifesaver programme only
62237659|NCT00999713|EXPERIMENTAL|Calfactant|Endotracheal calfactant administration
62813571|NCT00675181|ACTIVE_COMPARATOR|A, 1|A, 1 = Melatonin
62237660|NCT00999713|PLACEBO_COMPARATOR|Placebo (air)|Endotracheal air administration
62237661|NCT02031939|ACTIVE_COMPARATOR|Standard chemoradiotherapy|Standard chemoradiotherapy (Capecitabine 825mg/m2 combined with radiotherapy )
62237662|NCT02031939|EXPERIMENTAL|induction and gap chemotherapy|induction chemotherapy (Capecitabine 2000mg/m2 +oxaliplatine 130mg/m2) + 2 cycles of chemoradiotherapy (Capecitabine 2000mg/m2 +oxaliplatine 100mg/m2 combined with radiotherapy) + gap chemotherapy (Capecitabine 2000mg/m2 + oxaliplatine 130mg/m2)
62237663|NCT06037369|EXPERIMENTAL|intervention|At each visit of the research subjects to plastic clinic, the research team record the attending prescriptions and patient educations given by the medical team members, and evaluate whether the research subjects and caregivers need additional mental support or not. Then, according to the above evaluation and records, items of a designed patient education menu will be selected, and the selected patient education messages will be sent according to the transmission frequency and time period proposed by the research object
62237664|NCT06037369|NO_INTERVENTION|comparison|Routine care
62428042|NCT03151785|ACTIVE_COMPARATOR|Lifesaver and Face-to-Face BLS training|Pupils will receive CPR training by Lifesaver and standardised face-to-face BLS training
62595942|NCT01254318||Participants at high risk for IFI|Participants will be considered high risk if they are undergoing high dose chemotherapy for leukemia. This includes, but is not limited to participants with acute myelogenous leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. Participants are also considered to be at high risk for IFI if they have undergone allogeneic hematopoietic stem-cell transplantation.
62595943|NCT06620666|EXPERIMENTAL|Water-based power resistance training + Dietary supplement I (WPowDSI)|
62813572|NCT00675181|PLACEBO_COMPARATOR|A, 2|A,2 = Placebo
62813573|NCT04044690|EXPERIMENTAL|IgPro20|human immunoglobulin G administered subcutaneously
62813574|NCT04044690|PLACEBO_COMPARATOR|Placebo|human albumin solution administered subcutaneously
62237665|NCT03421431|EXPERIMENTAL|EDP-305 Dose 1|Subjects will take 2 tablets once a day orally for 12 weeks
62428043|NCT02625207|EXPERIMENTAL|Cohort 1|African-Americans with No CYP3A5\*1 alleles (poor metabolizer)
62428044|NCT02625207|EXPERIMENTAL|Cohort 2|African-Americans with One CYP3A5\*1 allele (intermediate metabolizer)
62428045|NCT02625207|EXPERIMENTAL|Cohort 3|African-Americans with Two CYP3A5\*1 alleles (extensive metabolizer)
62428046|NCT02625207|EXPERIMENTAL|Cohort 4|Caucasians with No CYP3A5\*1 alleles (poor metabolizer)
62428047|NCT01887379|EXPERIMENTAL|GRDF furosemide fasting conditions|Subjects will be tested under fasting conditions after administration of GRDF Furosemide.
62428048|NCT01887379|EXPERIMENTAL|GRDF furosemide fed conditions|Subjects will be tested under fed conditions after administration of GRDF Furosemide.
62595944|NCT06620666|ACTIVE_COMPARATOR|Water-based power resistance training + Placebo (WPowPl)|
62813575|NCT03858101||PKU subjects|
62813576|NCT03858101||Age and sex-matched non-PKU comparison subjects|
62813577|NCT00761475|PLACEBO_COMPARATOR|1|primary closure of the midline
62813578|NCT00761475|ACTIVE_COMPARATOR|2|onlay mesh supported closure
62813579|NCT00761475|ACTIVE_COMPARATOR|3|sublay mesh supported closure
62813580|NCT03255408|ACTIVE_COMPARATOR|CBF Lowering and Normoxia Sleep|Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
62813581|NCT03255408|EXPERIMENTAL|CBF Lowering and IH Sleep|Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
62237666|NCT03421431|EXPERIMENTAL|EDP-305 Dose 2|Subjects will take 2 tablets once a day orally for 12 weeks
62237667|NCT03421431|PLACEBO_COMPARATOR|Placebo|Subjects will take 2 tablets once a day orally for 12 weeks
62237668|NCT04014361|EXPERIMENTAL|LY3154885 - Part A|15, 45, 100, 200, 300 or 375 milligrams (mg) LY3154885 administered orally in two of three study periods.
62237669|NCT04014361|PLACEBO_COMPARATOR|Placebo - Part A|Placebo administered orally in one of three study periods.
62428049|NCT05978999||Subject use both BPM1 Arm Automatic Electronic BPM and mercury sphygmomanometers|
62428050|NCT06064409||Acute hypoxemic respiratory failure group|Patients with hypoxemic respiratory failure, defined as decreased PaO2.
62428051|NCT06064409||Acute hypercapneic respiratory failure group|Patients with hypercapneic respiratory failure, defined as increased PaCO2.
62428052|NCT01583803||Males|
62428053|NCT01583803||Females|
62428054|NCT04421066||Peri-implantitis|Patients with at least one dental implant diagnosed with peri-implantitis undergoing treatment for peri-implantitis as their standard of care will be included in this study.
62595945|NCT06620666|EXPERIMENTAL|Elastic band-based power resistance training + Dietary supplement I (EBPowDSI)|
62595946|NCT06620666|ACTIVE_COMPARATOR|Elastic band-based power resistance training + Placebo (EBPowPl)|
62595947|NCT06620666|EXPERIMENTAL|Elastic band-based eccentric resistance training + Dietary supplement II (EBEccDSII)|
62813582|NCT03255408|SHAM_COMPARATOR|Placebo and Normoxia Sleep|Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
62813583|NCT03255408|PLACEBO_COMPARATOR|Placebo and IH Sleep|Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
62813584|NCT06343831|EXPERIMENTAL|Patients Receiving Autologous Fat Transfer of the Breast or Chest Wall|Participants will undergo standard photographs (2-D imaging) of their chest wall and torso, including the breasts, and complete a validated questionnaire (BREAST-QTM) to evaluate patient satisfaction, and quality of life, all standard of care. The 3D photographs, MRI, and US are routinely used in practice but will be performed for research purposes in this study.
62813585|NCT04413071||Health care workers|Health care workers from the University Hospital of Salamanca who have passed SARS-CoV-2 infection.
62813586|NCT01537666|EXPERIMENTAL|Aerovanc 16 mg in healthy volunteers|
62813587|NCT01537666|EXPERIMENTAL|AeroVanc 32 mg in healthy volunteers|
62813588|NCT01537666|EXPERIMENTAL|AeroVanc 80 mg in healthy volunteers|
62813589|NCT01537666|ACTIVE_COMPARATOR|IV vancomycin in healthy volunteers|
62813590|NCT01537666|EXPERIMENTAL|AeroVanc 32 mg in CF patients|
62595948|NCT06620666|ACTIVE_COMPARATOR|Elastic band-based eccentric resistance training + Placebo (EBEccPl)|
62595949|NCT06620666|EXPERIMENTAL|Elastic band-based maximum strength resistance training + Dietary supplement II (EBMaxDSII)|
62595950|NCT06620666|ACTIVE_COMPARATOR|Elastic band-based maximum strength resistance training + Placebo (EBMaxPl)|
62595951|NCT06620666|ACTIVE_COMPARATOR|Control + Dietary supplement I (CDSI)|
62428055|NCT04421066||Healthy|Patients with general good health and health gingiva undergoing extraction of wisdom tooth will be included in this study group.
62428056|NCT02270905|EXPERIMENTAL|dCELL® Meniscus|
62428057|NCT04259801|EXPERIMENTAL|NNC0480-0389 and semaglutide|"Part 1: 6 subjects will receive a single subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide.~Part 2: 12 subjects will receive 4 doses of s.c. NNC0480-0389 co-administered with s.c. semaglutide, after 8 weeks of dosing with s.c semaglutide."
62428058|NCT04259801|EXPERIMENTAL|NNC0480-0389 and placebo (semaglutide)|"Part 1: 4 subjects will receive a single dose of s.c. NNC0480-0389 co-administered with semaglutide placebo.~Part 2: 4 subjects will receive 4 doses of s.c. NNC0480-0389, co-administered with semaglutide placebo after 8 weeks of dosing with semaglutide placebo."
62428059|NCT04259801|ACTIVE_COMPARATOR|Placebo (NNC0480-0389) with semaglutide|"Part 1: 2 subjects will receive a single dose of placebo (NNC0480-0389), co-administered with s.c. semaglutide.~Part 2: 4 subjects will receive 4 doses of placebo (NNC0480-0389), co-administered with s.c. semaglutide, after 8 weeks of dosing with s.c. semaglutide"
62428060|NCT04259801|PLACEBO_COMPARATOR|Placebo (NNC0480-0389) with placebo (semaglutide)|"Part 1: 3 subjects will receive a single dose of placebo (NNC0480-0389), co-administered with semaglutide placebo.~Part 2: 2 subjects will receive 4 doses of placebo (NNC0480-0389), co-administered with semaglutide placebo, after 8 weeks of dosing with semaglutide placebo."
62428061|NCT04768764|ACTIVE_COMPARATOR|Group 1 Middle Adductor Canal Block|"Ultrasound Guided Middle Adductor Canal Block:~20 ml Bupivacaine 0.25% Injectable Solution will be administered for middle adductor canal block.~10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution."
62428062|NCT04768764|ACTIVE_COMPARATOR|Group 2 Femoral Nerve Block.|"Ultrasound Guided Femoral Nerve Block:~20 ml Bupivacaine 0.25% Injectable Solution will be administered for femoral nerve block.~10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution."
62428063|NCT05571657|EXPERIMENTAL|Intervention|Reminder/recall
62428064|NCT05571657|NO_INTERVENTION|Usual Care|No Reminder/Recall
62595952|NCT06620666|ACTIVE_COMPARATOR|Control + Dietary supplement II (CDSII)|
62595953|NCT06620666|PLACEBO_COMPARATOR|Control + Placebo (CPl)|
62595954|NCT06620666|ACTIVE_COMPARATOR|Aerobic training + Placebo (AerPl)|
62595955|NCT04722367|EXPERIMENTAL|Art Pedagogy and Mindfulness|Each participant will take part in four 1-hour sessions. Study activities include guided meditation, close looking, drawing, writing, and storytelling. Each session will begin with a guided meditation that is followed by an exercise inspired by two works of art, and end with an opportunity for students to reflect on the experience.
62428065|NCT05003128|EXPERIMENTAL|LED screen|
62428066|NCT03883971|EXPERIMENTAL|3D model|patient is given 3D printed model of her fetus's face
62428067|NCT03883971|PLACEBO_COMPARATOR|picture|patient is given a fetal picture only.
62428068|NCT05423301|EXPERIMENTAL|experimental|
62428069|NCT05423301|ACTIVE_COMPARATOR|control|
62428070|NCT01909388|EXPERIMENTAL|MRI-TRUS fusion guided real time HDR|Patients treated with dose escalation to Dominant Intraprostatic Lesions
62428071|NCT04067024|ACTIVE_COMPARATOR|Local anesthesia by the surgeon (LAS)|Local infiltration (ropivacaine 3,75 mg/ml) by surgeon
62428072|NCT04067024|EXPERIMENTAL|Regional anesthesia group (LRA):|By ultrasound, a pecs block I associated with a supraclavicular nerf block is performed. (Ropivacaine 3,75 mg/ml)
62595956|NCT02686866|EXPERIMENTAL|Body composition measurement|All patients will undergo body composition measurement with dual-energy X-ray absorptiometry and bioelectrical impedance analysis methods. Hand grip strength will also be performed.
62595957|NCT05026905|OTHER|GASL arm|"eligible patients will receive gemcitabine 800 mg/m2 on day 1, nab-paclitaxel 125 mg/m2 on day 1, S-1 orally 60-100 mg/day \[depending on patient's baseline body surface area (BSA)\] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~* BSA \< 1.25 m2: 60 mg/day~* 1.25 m2 ≤ BSA \< 1.5 m2: 80 mg/day~* BSA ≥ 1.5 m2: 100 mg/day"
62595958|NCT05026905|OTHER|GAP arm|eligible patients will receive gemcitabine 800 mg/m2, nab-paclitaxel 125 mg/m2 and oxaliplatin 75mg/m2 on day 1 in a 2-week cycle.
62595959|NCT03185715|OTHER|Counseling policy embryo transfer|All recipients completed a validated self-report questionnaire on the preference on the number of embryos to be transferred and the relevance for the decision-making process attributed to certain factors. The questionnaire also included questions on sociodemographic characteristics, medical-reproductive background and cycle's results and risks perception. All recipients received oral and written counselling. After counselling, during the treatment, the recipients completed a second questionnaire in order to check if their decision had changed.
62595960|NCT06247384|NO_INTERVENTION|Group A - FloTrac group|Patients receiving standard therapy with the arterial pressure cardiac output hemodynamic monitoring
62595961|NCT06247384|EXPERIMENTAL|Group B - HPI - Hypotension Prediction Index group|Patients receiving therapy according to the hypotension prediction index hemodynamic monitoring.
62813591|NCT01537666|EXPERIMENTAL|AeroVanc 80 mg in CF patients|
62428073|NCT02833558|EXPERIMENTAL|PuraStat®|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to stop bleeding during ESD.
62036400|NCT02527798|PLACEBO_COMPARATOR|Placebo Cohort 2|Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
62036401|NCT02527798|PLACEBO_COMPARATOR|Placebo Cohort 3|Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
62036402|NCT06665607|EXPERIMENTAL|Training Group|
62036403|NCT06665607|SHAM_COMPARATOR|Control Group|
62036404|NCT06670157|EXPERIMENTAL|Detachable Clip-assisted|After the varicose vessel is closed with a removable titanium clamp, the more varicose target vessel is located，After the varicose vessels basically disappeared under the endoscope, the removable titanium clamp was removed
62036405|NCT05833750|ACTIVE_COMPARATOR|reflexology|Patients in the reflexology group were applied twice a week for eight weeks.
62036406|NCT05833750|NO_INTERVENTION|Control group|No intervention was made
62036407|NCT00905918|NO_INTERVENTION|Arm I|Patients receive no intervention before undergoing planned surgery.
62036408|NCT00905918|EXPERIMENTAL|Arm II|Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 1 week before undergoing planned surgery.
62428074|NCT02833558|OTHER|Standard Electrocautery|Control arm where standard electrocautery delivered via the endoscopic knife tip or coag grasper is used to achieve haemostasis during ESD
62428075|NCT01780688|ACTIVE_COMPARATOR|smoking conventional cigarettes (CC)|After a 1-day nicotine deprivation, subjects are smoking one single cigarette (usual own brand) on one day and then smoking ad libitum on the subsequent day
62428076|NCT01780688|EXPERIMENTAL|using the Tobacco Heating System 2.1 (THS 2.1)|After a 1-day nicotine deprivation, subjects are puffing one single tobacco stick using the THS 2.1 on one day and then puffing ad libitum on the subsequent day
62036409|NCT00905918|EXPERIMENTAL|Arm III|Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 2 weeks before undergoing planned surgery.
62036410|NCT01140880|EXPERIMENTAL|Contingency Management|"Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for stimulant metabolites. Increasingly valuable incentives will be provided for urine samples that lack metabolites of stimulant drugs.~Participants reporting recent (i.e., \< 48 hours) exposure to HIV viral inoculum will have the opportunity to initiate Truvada (1 pill daily for 28 days)."
62036411|NCT01140880|SHAM_COMPARATOR|Yoked Contingency Management|"Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for stimulant metabolites. Incentives will be provided to participants independent of stimulant drug use and determined in the same rate and timing as a randomly selected participant in the active CM condition.~Participants reporting recent (i.e., \< 48 hours) exposure to HIV viral inoculum will have the opportunity to initiate Truvada (1 pill daily for 28 days)."
62036412|NCT06030674|EXPERIMENTAL|Exposure to secondhand cannabis smoke in public places|The research staff and participants will travel together to a public location by either ride share vehicles, taxis or public transit. The study will arrange and pay for the transit. Staff and participants will be exposed to ambient air in public places where cannabis products are being consumed by smoking, vaporizing or dabbing. Participants will remain in the company of the laboratory staff throughout the exposure. The exposures will last 0.5-4 hours, depending on the nature and duration of the event. Staff and participants will travel together back to the laboratory for the post-exposure study measures.
62036413|NCT02941302|EXPERIMENTAL|determine the biological boundaries|Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
62036414|NCT03535935|ACTIVE_COMPARATOR|Standard medical care|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker and oral hypoglycemic agents or insulin
62036415|NCT03535935|EXPERIMENTAL|Add on astragalus powder|3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks.
62036416|NCT02414191|NO_INTERVENTION|Control|Participants in this study arm will receive no form of feedback.
62036417|NCT02414191|OTHER|Benchmarked Feedback|Participants in this study arm will receive benchmarked feedback regarding their perioperative temperature management.
62036418|NCT02414191|OTHER|Ranked Feedback|Participants in this study arm will receive ranked feedback regarding their perioperative temperature management.
62595962|NCT02331550|EXPERIMENTAL|Expectant treatment|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions that were managed with observation and evaluation at 6 and 12 months after diagnosis.
62595963|NCT02331550|EXPERIMENTAL|Ablative treatment|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions that were managed with an ablative treatment and evaluated at 6 and 12 months after diagnosis.
62595964|NCT04822194|EXPERIMENTAL|Distancing|Participants will receive structured cognitive emotion regulation training from an experimenter during an approximately 10-minute interaction in which detailed instructions for implementation of the distancing strategy is explained (i.e. appraising an emotional stimulus as an objective, impartial observer).
62595965|NCT04822194|ACTIVE_COMPARATOR|Reinterpretation|Participants will receive structured cognitive emotion regulation training from an experimenter during an approximately 10-minute interaction in which detailed instructions for implementation of the reinterpretation strategy is explained (i.e. imagining a better outcome than what initially seemed apparent).
62595966|NCT06066723||Children with CF|All subjects to receive inhaled perfluoropropane during MRI procedures, including standard breath hold and free-breathing technique. Subjects will breathe the gas for 5 breath hold cycles (variable volumes as lung capacity/size varies per participant).
62595967|NCT06066723||Healthy Children|All subjects to receive inhaled perfluoropropane during MRI procedures, including standard breath hold and free-breathing technique. Subjects will breathe the gas for 5 breath hold cycles (variable volumes as lung capacity/size varies per participant).
62595968|NCT06623747|ACTIVE_COMPARATOR|CONTROL|
62595969|NCT06623747|EXPERIMENTAL|LOW ENERGY AVAILABILITY|
62813592|NCT03655132|NO_INTERVENTION|Waitlist Control Group|Veterans in the waitlist control will be provided with a list of common pain resources at the Bedford VAMC.
62813593|NCT03655132|EXPERIMENTAL|VACT-CP Group|Veterans randomized to VACT-CP will receive 7 online-module based weekly sessions of treatment via personal computer or provided tablet with wireless accessibility at the Bedford VAMC.
62595970|NCT06157164||Simultaneous UroLift™ and HoLEP|UroLift System
62813594|NCT03813355|EXPERIMENTAL|Active stimulation|Brain stimulation by Transcranial Direct Current Stimulation (tDCS) with active stimulations
62813595|NCT03813355|SHAM_COMPARATOR|Sham stimulation|Brain stimulation by Transcranial Direct Current Stimulation (tDCS) with inactive stimulations
62813596|NCT05746611|EXPERIMENTAL|Cohort 1|"Recombinant Mycobacterium Tuberculosis Fusion Protein (EC):~Dosage form: injection. Main ingredients and contents: Recombinant Mycobacterium tuberculosis fusion protein, 0.3ml, 0.5ml, 1.0ml per bottle.~1. This product is used alone: 0.1ml (5U) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method. 2. This product combined with TB-PPD: 0.1ml(5U) of this product and 0.1ml(5U) of TB-PPD were inhaled respectively, and the product was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm.~Purified protein derivative (TB-PPD) :~Dosage form: Injection. Main components and contents: Purified protein derivative of tuberculin 50IU/ml. 0.1ml (5U) of the product was inhaled and injected into the palmar skin of the forearm by the Mondu's method."
62813597|NCT05746611|EXPERIMENTAL|Cohort 2|"Recombinant Mycobacterium Tuberculosis Fusion Protein (EC):~Dosage form: injection. Main ingredients and contents: Recombinant Mycobacterium tuberculosis fusion protein, 0.3ml, 0.5ml, 1.0ml per bottle.~1. This product is used alone: 0.1ml (5U) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method. 2. This product combined with TB-PPD: 0.1ml(5U) of this product and 0.1ml(5U) of TB-PPD were inhaled respectively, and the product was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm."
62813598|NCT04196686|EXPERIMENTAL|Ice bath Control then VR/AR|Participants will be randomized with a 1:1 allocation to use their dominant or non-dominant hand with VR or control (no VR) for the cold pressor test and then crossed over. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
62813599|NCT04196686|EXPERIMENTAL|Ice bath with VR/AR then Control|Participants will be randomized with a 1:1 allocation to use their dominant or non-dominant hand with VR or control (no VR) for the cold pressor test and then crossed over. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
62595971|NCT06620965|ACTIVE_COMPARATOR|Mulligan Mobilization Group|Mulligan mobilization techniques will be applied
62595972|NCT06620965|ACTIVE_COMPARATOR|PNF group|Proprioceptive Neuromuscular Facilitation techniques will be applied
62036419|NCT06614504|EXPERIMENTAL|RC 1 + REC 1|Research cigarettes #1 plus research e-cigarettes #1
62595973|NCT00455559|EXPERIMENTAL|Perifosine 100 mg/d + imatinib mesylate|Perifosine 100 mg/d x 28 days Oral daily dose of perifosine 100 mg and oral daily dose of imatinib mesylate (current dose at time of progression of disease \[PD\] without interruption). Both drugs will be taken on a continuous basis and should be taken with food. Each cycle will be defined as 28 days.
62595974|NCT00455559|EXPERIMENTAL|Perifosine 900 mg/d + imatinib mesylate|Perifosine 900 mg/d (300 mg tid), 1 x weekly Oral once-weekly dose of perifosine 900 mg (300 mg tid) + oral daily dose of imatinib mesylate (current dose at time of PD without interruption). Perifosine will be taken on days 1, 8, 15, and 22 of a 28-day cycle. Both medications should be taken with food.
62595975|NCT05398952||Long-COVID|Patients with previous COVID-19 disease, and having long COVID symptoms 3 months after the active infection.
62595976|NCT05398952||Post-COVID-19 without long-COVID syndrome|Patients with previous COVID-19 disease, without long COVID symptoms
62595977|NCT05398952||IcMP (positive control)|Patients with ischemic heart disease without COVID-19 disease, and vaccinated at least with one injection
62595978|NCT05398952||Healthy (negative control)|Healthy individuals without COVID-19 disease, and vaccinated at least with one injection
62595979|NCT00604942|EXPERIMENTAL|Achalasia|Long vs Short Myotomy repair of Achalasia
62595980|NCT00604942|EXPERIMENTAL|Dysphagia control|Conservative Management
62595981|NCT00604942|EXPERIMENTAL|GORD for surgery|Partial vs Full Fundoplication repair
62595982|NCT00604942|EXPERIMENTAL|GORD not for surgery|esomeprazole 40 mg vs no esomeprazole
62595983|NCT04453072|EXPERIMENTAL|Supportive Care (app, scales, coaching, questionnaire)|Patients receive an iPhone with W8Loss2Go app, a body scale and a digital food scale to weigh themselves and food daily. Patients interact with coaches via text messages for 4 days weekly and receive weekly 15 minute phone calls for appointment reminders, emotional support, progress discussion, and follow up on items discussed in a prior visit or phone call. Patients also have telemedicine interviews with the coach lasting 60 minutes at 2 and 4 months to elicit both positive and negative impacts on weight management and to identify barriers such as emotional eating, displacement behaviors, poor coping skills to life stressors, and social challenges. Patients who opt to extend the intervention until month 12 attend an additional telemedicine meeting with the coach. Patients also complete questionnaires over approximately 1.5 hours.
62036420|NCT06614504|EXPERIMENTAL|RC 1 + REC 2|Research cigarettes #1 plus research e-cigarettes #2
62036421|NCT06614504|EXPERIMENTAL|RC 2 + REC 1|Research cigarettes #2 plus research cigarettes #1
62036422|NCT06614504|EXPERIMENTAL|RC 2 + REC 2|Research cigarettes #2 + research e-cigarettes #2
62595984|NCT01170026|EXPERIMENTAL|Family Check-up/Individual MI|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use plus 2 session Individual Motivational Intervention for the adolescent
62595985|NCT01170026|ACTIVE_COMPARATOR|Psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors especially substance use
62595986|NCT05460221|ACTIVE_COMPARATOR|Optimized oil group|Each participant will consume 25 mL/day during 6 months of an Optimized extra virgin olive oil obtained by mixing different varieties of oils rich in bioactive compounds (it contains approx. 490 ppm of bioactive compounds).
62595987|NCT05460221|EXPERIMENTAL|Functional oil group|Each participant will consume 25 mL/day during 6 months of a Functional olive oil prepared with the same Optimized oil and enriched with triterpenic acids obtained from the olive tree (approx. 490 ppm of polyphenols and 380 ppm of triterpenic acids).
62595988|NCT05460221|PLACEBO_COMPARATOR|Control Group|Each participant will consume 25 mL/day during 6 months of a Control extra virgin olive oil prepared from the same Optimized oil washed to eliminate bioactive compounds (approx. 125 ppm of polyphenols).
62595989|NCT02389569|EXPERIMENTAL|Adhesive system treatment|Four groups ( Two will be treat with Etch-and-Rinse Adhesive System and two will be treated with two step Self-Etch Adhesive System).
62595990|NCT02389569|EXPERIMENTAL|Restoration protocol|Four groups ( Two will be treat with experimental Biosilicate and two will be the control groups).
62595991|NCT00539162|EXPERIMENTAL|CA 125 Analysis|"Experimental: CA 125, HE4, HE4 antigen autoantibody complexes, and Osteopontin Analysis Participants will have blood (3-4 tablespoons) drawn for CA125 and other tumor markers.~Depending on CA-125 level and other tumor markers:~Blood (3-4 tablespoons) drawn for CA-125 testing and other tumor markers in 1 year.~Blood (3-4 tablespoons) drawn for CA-125 testing and other tumor markers in 3 months, OR~Blood (3-4 tablespoons) drawn for CA-125 testing and other tumor markers, and a transvaginal ultrasound in 6 weeks +/- 2 weeks."
62813600|NCT01358877|EXPERIMENTAL|Pertuzumab + Trastuzumab + Chemotherapy|Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\^2 + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).
62813601|NCT01358877|PLACEBO_COMPARATOR|Placebo + Trastuzumab + Chemotherapy|Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram \[mg/kg\] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m\^2) + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin AUC 6 (up to 900 milligrams \[mg\]).
62036423|NCT05314517|EXPERIMENTAL|Treatment Arm 1|Namilumab
62036424|NCT05314517|PLACEBO_COMPARATOR|Treatment Arm 2|Placebo
62036425|NCT04334668|ACTIVE_COMPARATOR|Oral Sodium Chloride|Subject will be given 2 grams of oral sodium chloride three times daily with meals for approximately 4 days
62036426|NCT04334668|PLACEBO_COMPARATOR|Placebo|Subject will be given a placebo orally three times daily with meals for approximately 4 days
62813602|NCT03159416|EXPERIMENTAL|Inclisiran (normal renal function)|Participants will receive a single dose of 300 milligram (mg) inclisiran administered by SC injection on Day 1. Normal renal function is defined as estimated creatinine clearance (CrCl) of ≥90 milliliter (mL)/minute (min).
62036427|NCT02311712|ACTIVE_COMPARATOR|Capsule sponge|Capsule sponge cytology examination coupled with H\&E staining analysed for the presence of atypia and p53 immunohistochemistry
62036428|NCT02311712|NO_INTERVENTION|Control|No intervention
62036429|NCT05625958|EXPERIMENTAL|Cilioscleral Interposition Device|Any patients corresponding to inclusion / exclusion criteria
62036430|NCT05422326|EXPERIMENTAL|Group 1|Eligible subjects who received 2 doses of aH5N1c in the parent study V89_18 and have been randomized to receive two aH5N6c vaccinations, 3 weeks apart
62036431|NCT05422326|EXPERIMENTAL|Group 2|Eligible subjects who received 2 doses of aH5N1c in the parent study V89_18 and have been randomized to receive an aH5N6c vaccination on Day 1 and saline placebo on Day 22
62036432|NCT05422326|EXPERIMENTAL|Group 3|Eligible subjects who received placebo in the parent study V89_18 receive two aH5N6c vaccinations, 3 weeks apart.
62813603|NCT03159416|EXPERIMENTAL|Inclisiran (mild renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Mild renal impairment is defined as CrCl ranging from 60 to 89 mL/min.
62237670|NCT04014361|EXPERIMENTAL|45 mg LY3154885 + Itraconazole - Part B|45 mg LY3154885 administered orally in period 1 followed by 200 mg Itraconazole administered orally on 10 consecutive days and then 45 mg LY3154885 co-administered with 200 mg itraconazole orally during period 2.
62036433|NCT00990990|EXPERIMENTAL|Cohort 1|
62036434|NCT00990990|EXPERIMENTAL|Cohort 2|
62036435|NCT00990990|EXPERIMENTAL|Cohort 3|
62237671|NCT04014361|PLACEBO_COMPARATOR|Placebo + Itraconazole - Part B|Placebo administered orally during period 1 followed by 200 mg Itraconazole administered orally on 10 consecutive days and then placebo co-administered with 200 mg itraconazole orally during period 2.
62237672|NCT04014361|EXPERIMENTAL|LY3154885 - Part C|Part C was not initiated.
62237673|NCT04014361|PLACEBO_COMPARATOR|Placebo - Part C|Part C was not initiated.
62237674|NCT04014361|EXPERIMENTAL|LY3154885 - Part D|Part D was not initiated.
62428077|NCT01586624|EXPERIMENTAL|Dose Escalation Phase Cohort 1 (Steady state dose of 100 mg OD Vandetanib + 25 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
62428078|NCT01586624|EXPERIMENTAL|Dose Escalation Phase Cohort 2 (Steady state dose of 100 mg OD Vandetanib + 50 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
62428079|NCT01586624|EXPERIMENTAL|Dose Escalation Phase Cohort 3 (Steady state dose of 100 mg OD Vandetanib + 75 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
62428080|NCT01586624|EXPERIMENTAL|Dose Escalation Phase Cohort 4 (Steady state dose of 100 mg OD Vandetanib + 100 mg OD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
62428081|NCT01586624|EXPERIMENTAL|Dose Escalation Phase Cohort 5a (Steady state dose of 100 mg OD Vandetanib + 125 mg OD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
62428082|NCT01586624|EXPERIMENTAL|Dose Escalation Phase Cohort 5b (Steady state dose of 200 mg OD Vandetanib + 50 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
62428083|NCT01586624|EXPERIMENTAL|Dose Escalation Phase Cohort 6 (Steady state dose of 300 mg OD Vandetanib + 50 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
62428084|NCT01586624|EXPERIMENTAL|Expansion Phase (Steady state dose of 200 mg OD Vandetanib + 50 mg BD Selumetinib)|Expansion cohort at the recommended phase 2 dose of vandetanib and selumetinib defined in the escalation phase.
62428085|NCT02232139|NO_INTERVENTION|Standard therapy group|Participant who will not receive midazolam for pharmacological anxiolytic premedication before general surgery
62428086|NCT02232139|EXPERIMENTAL|Midazolam group|Participant who will receive midazolam for pharmacological anxiolytic premedication before general surgery
62428087|NCT03774173|EXPERIMENTAL|Aramchol 300 mg|Aramchol 300 mg twice daily (every 12 hours)
62428088|NCT03774173|EXPERIMENTAL|Aramchol 600 mg|Aramchol 600 mg once daily (every 24 hours)
62428089|NCT04478370|EXPERIMENTAL|An. minimus|"This arm will be divided into 2 groups; the low-exposure groups and the high-exposure group.~In the low-exposure group, participants will be exposed to 5 mosquito bites at weekly intervals from day 14 to day 56 (seven challenges with 5 mosquito bites/challenge over six weeks, yielding a total of 35 mosquito bites).~In the high-exposure group, participants will be exposed to 5 mosquito bites on day 14 and then to 50 mosquito bites at weekly intervals from day 21 to day 56 (one challenge with 5 mosquito bites and six challenges with 50 mosquito bites/challenge over 6 weeks, yielding a total of 305 mosquito bites)."
62428090|NCT04478370|EXPERIMENTAL|An. maculatus|Same as above
62428091|NCT04478370|EXPERIMENTAL|An. dirus|Same as above
62428092|NCT04478370|EXPERIMENTAL|Ae. aegypti|Same as above
62428093|NCT04478370|EXPERIMENTAL|Ae. albopictus|Same as above
62428094|NCT01984229|EXPERIMENTAL|Cohort A|There will be 3 dosing periods in the study: Period 1 (Days 1 to 7), Period 2 (Days 8 to 14), and Period 3 (Days 15 to 18). Alectinib will be administered as a 40 milligrams (mg) single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants). On Days 8 to 14 (Period 2) and Days 15 to 18 (Period 3) posaconazole will be administered as a 400-mg twice daily (BID) oral dose after a high-fat meal. The follow-up assessments will occur within 10 to 14 days after the last dose of posaconazole.
62428095|NCT01984229|EXPERIMENTAL|Cohort B|There will be 3 dosing periods in the study: Period 1 (Days 1 to 7), Period 2 (Days 8 to 14), and Period 3 (Days 15 to 21). Alectinib will be administered as a single oral dose at the dose selected based on Cohort A data on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants). On Days 8 to 14 (Period 2) and Days 15 to 21 (Period 3) posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal. The follow-up assessments will occur within 10 to 14 days after the last dose of posaconazole.
62813604|NCT03159416|EXPERIMENTAL|Inclisiran (moderate renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Moderate renal impairment is defined as CrCl ranging from 30 to 59 mL/min.
62036436|NCT00990990|EXPERIMENTAL|Cohort 4|
62237675|NCT01659372|EXPERIMENTAL|Low level laser therapy|this arm recieves low level laser therapy treatment for 12 sessions.
62237676|NCT01659372|EXPERIMENTAL|naproxen|this arm takes naproxen 500 mg twice daily for 3weeks
62036437|NCT00990990|EXPERIMENTAL|Cohort 5|
62036438|NCT00990990|EXPERIMENTAL|Cohort 6 (optional)|
62036439|NCT00990990|EXPERIMENTAL|Linezolid Cohort|
62036440|NCT04794803|EXPERIMENTAL|Reparixin|Reparixin oral tablets 1200 mg TID for 7 days
62036441|NCT04794803|ACTIVE_COMPARATOR|Standard of care|Standard of care
62237677|NCT03255837|EXPERIMENTAL|Transcranial direct current stimulation (tDCS) - anodal|Transcranial direct current stimulation - anodal (positive) 1.5 millamps for 15 minutes
62237678|NCT03255837|EXPERIMENTAL|Transcranial direct current stimulation (tDCS) - cathodal|Transcranial direct current stimulation - cathodal (negative) 1.5 millamps for 15 minutes
62813605|NCT03159416|EXPERIMENTAL|Inclisiran (severe renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Severe renal impairment is defined as CrCl ranging from 15 to 29 mL/min.
62813606|NCT00232765|EXPERIMENTAL|1|Cypher Bx Velocity
62813607|NCT00232765|ACTIVE_COMPARATOR|2|Uncoated Bx Velocity
62813608|NCT05541458|EXPERIMENTAL|Educational sessions plus a nutrition box and recipes|Monthly nutrition education sessions will be attended by the subjects and then each subject will receive a free nutrition box that includes recipes that pertain to the food contents in the prepackaged box
62813609|NCT02493439|EXPERIMENTAL|Best Possible Self|Participants are asked to write and imagine about a future in which they have reached all their goals in four different domains: personal, professional, social and health. The participants are instructed to practice the BPS intervention for a month, 5 minutes/day.
62813610|NCT02493439|PLACEBO_COMPARATOR|Daily Activities|Participants are asked to think and write about the activities carried out in the last 24 hours. The participants are instructed to practice the Daily Activities exercise for a month, 5 minutes/day.
62036442|NCT02638948|PLACEBO_COMPARATOR|Placebo|Placebo + Methotrexate dose as specified
62036443|NCT02638948|EXPERIMENTAL|Dose Level 1|BMS-986142 at dose level 1+ Methotrexate as specified
62036444|NCT02638948|EXPERIMENTAL|Dose Level 2|BMS-986142 at dose level 2 + Methotrexate as specified
62428096|NCT06339008|EXPERIMENTAL|Lebrikizumab every 2 weeks (Q2W)/ every 4 weeks (Q4W)|Lebrikizumab will be given as a subcutaneous (SC) injection. Participants will receive background therapy with intranasal corticosteroids (INCS).
62237679|NCT03255837|SHAM_COMPARATOR|Transcranial direct current stimulation (tDCS) - sham|Transcranial direct current stimulation - sham session 15 minutes
62237680|NCT02796820|EXPERIMENTAL|Huaier Granule|Huaier Granule will be administrated from 4 to 48 weeks after surgery or until study termination. Huaier Granule is continuously taken three times per day, 20g per time.
62237681|NCT02796820|NO_INTERVENTION|Regular follow-up observation|Regular follow-up observation after surgery.
62237682|NCT06029725|ACTIVE_COMPARATOR|RFMN+Thulium|
62237683|NCT06029725|ACTIVE_COMPARATOR|RFMN|
62237684|NCT03516357||low myopia|-3.00D \< spherical equivalent refractive error \< -0.50D
62237685|NCT03516357||moderate myopia|-6.00D \< spherical equivalent refractive error ≤ -3.0D
62237686|NCT03516357||high myopia|spherical equivalent refractive error ≤ -6.0D
62428097|NCT06339008|EXPERIMENTAL|Lebrikizumab Q2W/every 8 weeks (Q8W)|Lebrikizumab will be given as an SC injection. Participants will receive background therapy with INCS.
62428098|NCT06339008|PLACEBO_COMPARATOR|Placebo Q2W/Q4W|Placebo matching Lebrikizumab will be given as an SC injection. Participants will receive background therapy with INCS.
62428099|NCT03987022|EXPERIMENTAL|"ICE-T"|"Regimen #1 ICE-T Opioid Sparing Regimen At the end of surgery patients will receive 30mg of intravenous (IV) toradol. Once out of the post anesthesia care unit (PACU) patients will receive~1. ICE PACKS applied to the surgical sites every hour for 20 minutes Around the clock (ATC) until discharge.~2. 6 hours from the time of first dose of surgery patients will receive 30mg of IV toradol ATC until discharge.~3. Once out of the PACU will receive 1 gram of Tylenol per os (PO) every 6 hours for a total of 4 grams daily ATC until discharge~4. Patients will receive dilaudid 0.2mg IV every 3 hours as needed (PRN) for breakthrough pain.~5. Patients will be discharged home with (PO) Tylenol and PO toradol as needed (PRN)."
62428100|NCT03987022|ACTIVE_COMPARATOR|Standard of care|"Regimen #2 STANDARD Postoperative Regimen~1. Once out of the PACU patients will receive Standard postoperative regimen~2. Motrin 600mg PO every 4 hours PRN pain scale 1-3 pain~3. Percocet 1 tab PO every 4-6 hours PRN pain scale 4-6 pain~4. Percocet 2 tabs PO every 7-10 hours PRN pain scale 7-10 pain~5. Patients will receive dilaudid 0.2mg IV every 3 hours PRN for breakthrough pain.~6. Patients will be discharged home with Motrin and Percocet for pain PRN."
62428101|NCT04537585|EXPERIMENTAL|Tomeka|Number of participants with treatment-TOMEKA® usage as assessed by Education \[ Time Frame: 18 months \] Change people's behaviour
62428102|NCT04537585|EXPERIMENTAL|"Vernonia amygdalina"|"Number of participants with Vernonia amygdalina herbs usage as assessed by Education \[ Time Frame: 18 months \] Change people's behaviour"
62428103|NCT04749810||Elizaria®|Eculizumab
62428104|NCT02543736|OTHER|Instrumented Treadmill System|The Instrumented Treadmill System records vertical ground reaction force and pressures.
62428105|NCT03241966||People with Parkinson's Disease|Individuals diagnosed with idiopathic Parkinson's disease without dementia.
62428106|NCT03241966||Informant|Family member, spouse, significant other, caregiver, or other close associate of someone with Parkinson's disease.
62428107|NCT02116413||The study population|"The study population consists of patients admitted to intensive care, sedated and under controlled ventilatory support with septic shock criteria defined by severe sepsis associated with hypotension despite fluid resuscitation of 20-40 ml / kg and requiring vascular filling according to the following criteria:~oliguria \<0.5 ml / kg / h for at least 2h skin mottling Arterial Lactate \> 2 mmol / l SvcO2 \<70% or SvO2 \<65% Patient on noradrenaline.~Severe sepsis is defined as a systemic inflammatory response associated with a suspected or proven infection and hypotension before filling, a lactate\> 4 mmol / l or organ dysfunction.~Intervention: Fluid challenge Intervention: Cardiac ultrasound"
62428108|NCT01364298|EXPERIMENTAL|Gabapentin/B-complex|
62428109|NCT01364298|ACTIVE_COMPARATOR|Pregabalin|
62428110|NCT04440098||Isolated Observational group|All participants socially restricted as a result of COVID-19
62428111|NCT03301428|EXPERIMENTAL|Retrain pain educational website|Participants will be invited to consult an educational website developped for patients with chronic pain
62428112|NCT03301428|EXPERIMENTAL|Booklet|Participants will be invited to read an educational booklet for patients with chronic pain
62428113|NCT03301428|NO_INTERVENTION|Control|Participants in this group will receive the 2 educational tools at the end of the study
62428114|NCT03050528|EXPERIMENTAL|Combined Exercise and ACT treatment|Participants will attend a weekly group-based multidisciplinary pain programme for a period of eight weeks. The programme will combine exercise with the psychological approach acceptance and commitment therapy (ACT).
62428115|NCT03050528|ACTIVE_COMPARATOR|Standalone supervised exercise|Participants will attend a weekly group-based supervised exercise class for a period of eight weeks.
62428116|NCT04394052||Soft-tissue tumors|Benign and malignant soft tissue masses
62036445|NCT06498661|EXPERIMENTAL|Prevention (self-collected and clinician-collected samples)|Patients undergo self-collection of two vaginal samples and then undergo clinician-collection of a cervical test sample. Patients then undergo standard of care colposcopy with biopsy/endocervical curettage and/or cervical excisional procedures as clinically indicated.
62036446|NCT02017340|PLACEBO_COMPARATOR|Placebo|250 patients will receive the placebo
62036447|NCT02017340|ACTIVE_COMPARATOR|Nilvadipine|250 patient will receive the active drug Nilvadipine 8mg
62036448|NCT05208138|EXPERIMENTAL|Intervention|Bariatric operation with the Senhance surgical system
62036449|NCT04584060||Conventional|Fatsing for at least 6 hours pre-operative, No restriction of IV fluids and traditional analgesia including opiates. Post-operative Ambulation-as per patients' own request, Removal of urinary catheter when patient ambulates, patient will keep fasting for 3 days postoperative, oral fluids for 3 days, semi-solid for another 3 days and then can take full diet, removal of nasogastric tube just before starting oral fluids, drain removal just before discharge.
62036450|NCT04584060||ERAS|Preoperative information, education and counselling, If possible, Clear fluids are allowed up to 2 h and solids up to 6 h prior to induction of anaesthesia, Short acting anesthetic agents,avoid opioid agents, Post operative nausea and vomiting prophylaxis, Patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with LMWH. Encourage to mobilize out of bed after effect of general anesthesia has weaned off, Chewing gum, oral magnesium and alvimopan can be started early postoperatively, Initiation of feeding-Oral sips on day 1, step up day 2 onward, Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube, Removal of urinary catheter-after weaning from the effect of general anesthesia and drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.
62036451|NCT02039037|ACTIVE_COMPARATOR|Acupuncture group|This group perform acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
62428117|NCT04394052||Bone tumors|Benign and malignant bone focal bone lesions
62036452|NCT02039037|ACTIVE_COMPARATOR|Electroacupuncture group|Electro Group, will be added through the use of electrical stimulation of electroacupuncture using the apparatus Accurate pulse 585 at the same points.
62036453|NCT04006327||Palliative care patients and their family caregivers|The present study is a cross-sectional study with single group study design. Only palliative care patients and their family caregivers will be recruited.
62036454|NCT06302751|EXPERIMENTAL|Care 4 Today ® (Johnson and Johnson) mobile app|Patients will undergo standard perioperative management. Additionally, patients will use the Care 4 Today ® (Johnson and Johnson) mobile app for remote monitoring from the preoperative assessment day to 30 days after surgery. The Care 4 Today Care ® (Johnson and Johnson) mobile app will include daily reminds for preoperative recommendations adherence (water intake, medications adherence, mobilization, smoking quit...) and postoperative monitoring of symptoms (fever, pain, and mood deflections).
62036455|NCT06302751|NO_INTERVENTION|Standard perioperative management|The historic cohort include patients who underwent standard perioperative management from March 2020 to April 2023.
62595992|NCT02063945|ACTIVE_COMPARATOR|Methylphenidate|"Participants in this arm will be given either Concerta - a long acting (12 hours) Methylphenidate pill - once daily, in the morning (starting dose 1 mg/kg, max dose 2 mg/kg), or Ritalin LA - a long acting (10 hours) Methylphenidate pill - once daily, in the morning (starting dose 0.6 mg/kg, max dose 1.5 mg/kg) for children who can not swallow pills."
62595993|NCT02063945|ACTIVE_COMPARATOR|Risperidone|Participants in this arm will be given a low dose of Risperidone. Starting dose will be 0.5 mg/d, max dose will be 2 mg/d.
62595994|NCT02347891|EXPERIMENTAL|Belimumab + Standard of Care|"Patients in this arm will be given belimumab with a background of standard of care therapy during the randomized controlled treatment period.~Patients in this arm will continue to receive belimumab during the open label phase of the study (week 40 - week 64)"
62237687|NCT01983839||Pharmacokinetics Moxifloxacin|Patients with community-acquired pneumonia treated with moxifloxacin
62237688|NCT02249767|ACTIVE_COMPARATOR|Generic Tretinoin|Treatment of acne once daily over 12 weeks
62237689|NCT02249767|ACTIVE_COMPARATOR|Brand Tretinoin|Treatment of Acne once daily over 12 weeks
62428118|NCT02733601||Breast Cancer Patients|Newly diagnosed with breast cancer all stages confirmed during the study period by an anatomopathologist, defined as a first diagnosis of breast cancer based on anatomopathological results from at least a microbiopsy
62428119|NCT05710315|EXPERIMENTAL|ReliZORB|ReliZORB enzyme cartridges will be used with enteral feedings for 5 days
62428120|NCT05710315|PLACEBO_COMPARATOR|Placebo|Placebo enzyme cartridges will be used with enteral feedings for 5 days
62428121|NCT03086083|EXPERIMENTAL|EMDR standard protocol|Standard EMDR protocol, once.
62595995|NCT02347891|ACTIVE_COMPARATOR|Placebo + Standard of Care|"Patients in this arm will be given a placebo with a background of standard of care therapy during the randomized controlled treatment period.~Patients in this arm will receive belimumab during the open label phase of the study (week 40 - week 64)."
62428122|NCT03086083|ACTIVE_COMPARATOR|protocol without brain stimulation|Standard EMDR protocol without brain stimulation, once
62813611|NCT04648280|EXPERIMENTAL|Fostemsavir|Fostemsavir in combination with optimized background therapy (OBT) in HIV-1 infected children and adolescents who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class ARV resistance
62428123|NCT04694131|OTHER|MS|All participants will receive all conditions and the order of all conditions will be counterbalanced across participants. Statistical comparisons will be within-subjects. There will be two experiment days, during which TMS will be delivered during the behavioral tasks (spatial task trials and encoding phase of the memory task). Participants will receive TMS delivered to parietal cortex on one day and vertex stimulation on the other day. Each experiment day will include one block of TMS delivered prior to task trial onsets and one block delivered simultaneously with trial onsets.
62428124|NCT02454309|EXPERIMENTAL|Cranberry concentrate|Each capsule contains 500 mg of cranberry powder at a concentration ratio of 36:1 (36 grams of cranberries equals 1 gram of concentrate)
62428125|NCT02454309|PLACEBO_COMPARATOR|Placebo|A capsule containing control formulation
62595996|NCT01056991|EXPERIMENTAL|warming mattress|Patient warmed with electric mattress
62428126|NCT04023747||Cohort 1|Participants with Monoclonal B-Cell Lymphocytosis or Asymptomatic Chronic Lymphocytic Leukaemia
62428127|NCT04023747||Cohort 2|Participants with IgM Monoclonal Gammopathy or Asymptomatic Waldenstrom's Macroglobulinaemia
62428128|NCT04023747||Cohort 3|Participants with IgA or IgG Monoclonal Gammopathy or Smouldering Myeloma
62428129|NCT05980988|EXPERIMENTAL|Probiotic group|2B CFU/capsule/day BLa80, before meals； Storage: Store in a cool, dry place without sun exposure.
62428130|NCT05980988|PLACEBO_COMPARATOR|placebo|Maltodextrin, one capsule/day, before meals； Storage: Store in a cool, dry place without exposure to the sun.
62428131|NCT04660409|OTHER|Child Pugh A|
62036456|NCT01921439|ACTIVE_COMPARATOR|Feedback|Participants in this group will receive individualized feedback based on their stage of change. Feedback will include health effects of smoking, money spent per month and per year on cigarettes, time spent smoking compared with time spent doing other daily tasks, and how the participant compares to past study participants in average number of cigarettes per day used and level of addiction.
62428132|NCT04660409|OTHER|Child Pugh B|
62428133|NCT04660409|OTHER|Child Pugh C|
62428134|NCT04660409|OTHER|HCC|
62428135|NCT04660409|OTHER|Healthy|
62428136|NCT03695406|EXPERIMENTAL|Mind-Body Group Intervention|
62428137|NCT05807048|EXPERIMENTAL|Patients with STK11/LKB1-Mutated NSCLC|"Participants will receive daratumumab 1800mg and hyaluronidase 30,000 units (combined product DARZALEX Faspro) administered subcutaneously per the following dosing schedule:~* Once per week for 8 administrations (Week 1-8)~* Once every two weeks for 8 administrations (Week 9-16)~* Once every 4 weeks until disease progression or unacceptable toxicity."
62595997|NCT01056991|ACTIVE_COMPARATOR|warming blanket|Forced air warming blanket
62813612|NCT06177977|ACTIVE_COMPARATOR|Group 1 - Progressive Inherited retinal dystrophy (IRD)|50 participants with progressive IRD; the most common IRD seen at Duke Clinics.
62595998|NCT06169137|EXPERIMENTAL|Premenopausal women (lean and obese)|Ages 18-50 yearsBMI 18.0-24.5 mg/k\^2 or BMI \> 30 mg/k\^2
62428138|NCT06540573||Patients who were diagnosed with osteoarthritis and applied to outpatient clinic|Patients diagnosed with osteoarthritis (meeting the American College of Rheumatology (ACR) criteria
62813613|NCT06177977|ACTIVE_COMPARATOR|Group 2 - Non-progressive Inherited Retinal Dystrophy (IRD)|20 participants with non-progressive IRD (n=20), a subset of IRDs that are less frequently referred to Duke Clinics
62813614|NCT06177977|ACTIVE_COMPARATOR|Group 3 - Control participants|10 participants with normal retinal anatomy undergoing anesthesia for strabismus surgery as part of their clinically-indicated care.
62813615|NCT05188586|OTHER|Pancreatic Cancer Signal Detection = Detected|"Subjects with test results detected will undergo MRI/Imaging"
62813616|NCT05188586|NO_INTERVENTION|Pancreatic Cancer Signal Detection = Not Detected|
62813617|NCT01288573|EXPERIMENTAL|Plerixafor 160 μg/kg|Patients will receive subcutaneous (SC) injection of 160 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
62813618|NCT01288573|EXPERIMENTAL|Plerixafor 240 μg/kg|Patients will receive subcutaneous (SC) injection of 240 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
62813619|NCT01288573|EXPERIMENTAL|Plerixafor 320 μg/kg|Patients will receive subcutaneous (SC) injection of 320 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
62813620|NCT05280340|EXPERIMENTAL|Anakinra|"First 6 enrolled infants given 1.0mg/kg anakinra alternate daily IV for first 3 weeks of life.~Remaining 18 enrolled infants given 0.8mg/kg anakinra daily IV for the first 3 weeks of life, if infant is ≥ 26 weeks gestation.~If infant is \< 26 weeks gestation, dosing of 1.0mg/kg anakinra alternate daily IV for the first 3 weeks of life, will continue (3 infants only)."
62813621|NCT00774371|EXPERIMENTAL|1|The intervention program consists of group sessions provided according to the following schedule: weekly for 4 months, every other week for two months, and follow-up monthly sessions through 18 months of active subject participation. The time points for data collection from all subjects are baseline, 6 months, and 18 months. The group sessions offered to the treatment study arm are closed-group contingents with an average of 12-15 women assigned to each group.
62813622|NCT05763810|OTHER|Erector Spinae Plane Block group|Erector Spinae Plane Block
62813623|NCT05763810|OTHER|Superficial Parasternal Intercostal Plane Block and Rectus Sheath Block group|Superficial Parasternal Intercostal Plane Block and Rectus Sheath Block
62813624|NCT01380353|EXPERIMENTAL|Breast Group|Diclofenac epolamine patch applied to the breast
62813625|NCT01380353|EXPERIMENTAL|Abdomen Group|Diclofenac epolamine patch applied to the abdomen
62813626|NCT04516746|EXPERIMENTAL|AZD1222|Approximately 20,000 participants randomized to the AZD1222 arm
62428139|NCT06540573||Patients who were diagnosed with rheumatoid arthritis and applied to outpatient clinic|Patients diagnosed with rheumatoid arthritis (meeting the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria
62428140|NCT06540573||Healthy volunteers|Healthy who were volunteers applied to the physical treatment and rehabilitation outpatient clinic
62428141|NCT01382927||General Anesthesia|
62428142|NCT01382927||Spinal Anesthesia|
62428143|NCT01210885|EXPERIMENTAL|Group I: Investigational MenABCWY Formulation 1|
62428144|NCT01210885|EXPERIMENTAL|Group II: Investigational MenABCWY Formulation 2|
62813627|NCT04516746|PLACEBO_COMPARATOR|Placebo|Approximately 10,000 participants randomized to the saline placebo arm
62813628|NCT03252769|OTHER|Self-sampling|Invitation to self-sample
62813629|NCT00517296|EXPERIMENTAL|Adalimumab with EUS guided therapy|Patients will be randomized to adalimumab treatment with EUS guided therapy decisions. Colorectal surgeon will have access to EUS data prior to EUA with possible seton placement.
62813630|NCT00517296|ACTIVE_COMPARATOR|Adalimumab|Patients will be randomized to adalimumab treatment. Colorectal surgeon will not have access to EUS data prior to EUA with possible seton placement.
62813631|NCT05736666|EXPERIMENTAL|Training Group|The intervention consists of disturbances delivered on a treadmill that simulates tripping over an obstacle or being perturbed to the side.
62813632|NCT05736666|ACTIVE_COMPARATOR|Education Group|This group will receive educational materials related to fall prevention in older adults.
62237690|NCT02249767|PLACEBO_COMPARATOR|Placebo Vehicle|Treatment of acne once daily over 12 weeks
62428145|NCT01210885|EXPERIMENTAL|Group III: Investigational MenABCWY Formulation 3|
62428146|NCT01210885|EXPERIMENTAL|Group IV: Investigational MenABCWY Formulation 4|
62428147|NCT01210885|ACTIVE_COMPARATOR|Group V: Active comparator investigational MenB|
62428148|NCT01210885|ACTIVE_COMPARATOR|Group VI: Active comparator MenACWY|
62428149|NCT02514031|EXPERIMENTAL|ARQ-761|"A 2 week lead-in monotherapy of ARQ-761 (The amount of ARQ-761 that will be given to the participant will depend on the time at which the participant was enrolled in the study~Afterwards the 28-day cycle of combination treatment of ARQ-761 along with gemcitabine (1000 mg/m2) + nab-paclitaxel (125 mg/m2) will begin."
62595999|NCT02276053||BTRE patients|Patients with brain tumor-related epilepsy (BTRE) routinely treated with lacosamide as add on to one or two baseline anti-epileptic drugs.
62596000|NCT06610045||Patients with multiple myeloma|Patients with multiple myeloma member of Myeloma Canada database
62596001|NCT06610045||Caregivers of patients with myeloma|Caregiver of a multiple myeloma patient member of Myeloma Canada database
62596002|NCT06570343|EXPERIMENTAL|Fentanyl-Morphine|Spinal anesthesia with heavy bupivacaine, fentanyl and morphine
62813633|NCT05094622|EXPERIMENTAL|Physical exercise|Physical exercise program
62813634|NCT00837382|EXPERIMENTAL|1|MEDVAMC Nightmare Treatment
62813635|NCT00837382|EXPERIMENTAL|2|Videoconferencing nightmare Treatment
62813636|NCT02714400|ACTIVE_COMPARATOR|Venlafaxine|50mg of Venlafaxine before sleep
62813637|NCT02714400|PLACEBO_COMPARATOR|Placebo|One piece of placebo before sleep
62813638|NCT03114319|EXPERIMENTAL|TNO155|TNO155 for oral administration
62428150|NCT04887974|EXPERIMENTAL|Canine retraction|The canines will be retracted by extending short silver elastomeric chains between the power arms in the canine brackets and the TADs. The applied force will be checked and adjusted to 150 g.
62428151|NCT04444752|EXPERIMENTAL|CBP-201 Dose 1|CBP-201 Dose 1 subcutaneous (SC) injection
62813639|NCT03114319|EXPERIMENTAL|TNO155 in combination with EGF816 (nazartinib)|TNO155 in combination with EGF816 (nazartinib) in patients with advanced EGFR mutant NSCLC
62813640|NCT01045967|EXPERIMENTAL|Invesigational Test Product|Lansoprazole 30 mg delayed-release Capsules
62813641|NCT01045967|ACTIVE_COMPARATOR|Reference Listed Drug|Prevacid® 30 mg delayed-release Capsules
62813642|NCT04730908|PLACEBO_COMPARATOR|G0 - placebo|Dental gel without fluoride in the composition
62813643|NCT04730908|SHAM_COMPARATOR|G1: Daily Regenerator Dentalclean Neutro (RDCN)|1450 ppm F- of sodium fluoride and tetrasodium pyrophosphate (Refix technology). NEUTRAL pH
62813644|NCT04730908|ACTIVE_COMPARATOR|G2: Sensodyne Repair & Protect (SRP)|1426 ppm of sodium fluoride and calcium sodium phosphosilicate 5% (NOVAMIN technology).
62813645|NCT04730908|EXPERIMENTAL|G3: Daily Regenerator Dentalclean Acid (RDCA)|1450 ppm F- of sodium fluoride and tetrasodium pyrophosphate (Refix technology). ACIDIC FORMULA
62813646|NCT04730908|ACTIVE_COMPARATOR|G4: Colgate Total Daily Repair (CTDR)|1450 ppm F- of as sodium fluoride, 0.30% triclosan, arginine, tetrasodium pyrophosphate.
62813647|NCT02914158|EXPERIMENTAL|Ovarian Suppression and aromatase inhibitors|"Ovarian Suppression：Goserelin 3.6 mg or Leuprolide 3.75 mg administered intravenously every 28 days, for 5 years.~AI: no restriction of specific drugs, oral by standard dose of post-menopause breast cancer, for 5 years."
62813648|NCT02914158|ACTIVE_COMPARATOR|Ovarian Suppression and tamoxifen|"Ovarian Suppression：Goserelin 3.6 mg or Leuprolide 3.75 mg administered intravenously every 28 days, for 5 years.~Tamoxifen: 20mg oral for every day, for 5 years."
62813649|NCT03429335|EXPERIMENTAL|Teaching session & Just TRAC It|"Youth will attend a single one-on-one teaching session with a cardiology nurse (RN) the same day as their pediatric cardiology clinic visit. The RN will also explain Just TRAC It! and help the youth to enter their health information into their phone."
62813650|NCT03429335|ACTIVE_COMPARATOR|Teaching session & MyHealth Passport|"Youth will attend a single one-on-one teaching session with a cardiology nurse (RN) the same day as their pediatric cardiology clinic visit. The RN will help youth complete and print out a MyHealth Passport to track their medical information."
62596003|NCT06570343|ACTIVE_COMPARATOR|Morphine|Spinal anesthesia with heavy bupivacaine and morphine
62428152|NCT04444752|EXPERIMENTAL|CBP-201 Dose 2|CBP-201 Dose 2 subcutaneous (SC) injection
62428153|NCT04444752|EXPERIMENTAL|CBP-201 Dose 3|CBP-201 Dose 3 subcutaneous (SC) injection
62596004|NCT00174967|PLACEBO_COMPARATOR|Placebo QD|
62596005|NCT00174967|EXPERIMENTAL|Febuxostat 40 mg QD|
62596006|NCT00174967|EXPERIMENTAL|Febuxostat 80 mg QD|
62036457|NCT01921439|NO_INTERVENTION|No Feedback- Treatment as Usual (TAU)|Participants will take the computer based survey, but will only receive a number to the Oklahoma Tobacco Helpline (Treatment-as-usual condition) instead of feedback.
62036458|NCT04597268|EXPERIMENTAL|dexmedetomidine|IV dexmedetomidine
62036459|NCT04597268|EXPERIMENTAL|ketamine|IV ketamine
62036460|NCT04597268|ACTIVE_COMPARATOR|Midazolam|IV midazolam
62036461|NCT01009931|EXPERIMENTAL|TPA + Dexamethasone and CMT|12-O-tetradecanoylphorbol-13-acetate (TPA) plus Dexamethasone \& Choline magnesium trisalicylate (Trilisate)
62428154|NCT04444752|PLACEBO_COMPARATOR|placebo|subcutaneous (SC) injection
62428155|NCT03917563|EXPERIMENTAL|Intervention group|WATCHMAN LAA occluder treatment
62428156|NCT00785278||1|Able-bodied participants: Able-bodied individuals will be asked to propel a wheelchair at a self-selected speed for a period of time during which data will be collected on their propulsion biomechanics. It is assumed, for the purpose of the study, that un-learned able-bodied individuals learning to propel a wheelchair reflect newly injured individuals who are just getting accustomed to a new chair.
62596007|NCT00174967|EXPERIMENTAL|Febuxostat 120 mg QD|
62596008|NCT01460654|PLACEBO_COMPARATOR|Testosterone and Placebo Alendronate|
62813651|NCT01404819|EXPERIMENTAL|Experimental arm|Patients in this arm undergo anesthesia with Xenon.
62813652|NCT01404819|ACTIVE_COMPARATOR|Standard arm|Patients in this arm undergo standard anesthesia
62813653|NCT02456012|EXPERIMENTAL|The D group|After 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment, patients receive oral esomeprazole 20 mg twice daily for 36 weeks.
62813654|NCT02456012|EXPERIMENTAL|The S group|After 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment, patients receive oral esomeprazole 20 mg once daily for 36 weeks.
62813655|NCT02456012|NO_INTERVENTION|The C group|The cohort control group includes patients from a previous study who had peptic ulcer bleeding and Rockall scores ≥ 6 but who did not receive esomeprazole or other proton pump inhibitors after 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment.
62813656|NCT05057091|EXPERIMENTAL|Lomber Roll techniques group|Direct manipulation will be applied to the lumbar region with the lumbar Roll technique. Painful segment will be determined.
62813657|NCT05057091|EXPERIMENTAL|Posterior- anterior central vertebral manipulation techniques group|Another technique that we will use as a specific vertebral manipulation technique will be Maitland's posterior-anterior central vertebral manipulation and posterior - anterior unilateral central vertebral mobilization technique.
62813658|NCT05000294|EXPERIMENTAL|Atezolizumab + Tivozanib|
62813659|NCT02868112|EXPERIMENTAL|Transdisciplinary Intervention|"Patients randomized to the Transdisciplinary Intervention will undergo evaluation with a board-certified geriatric clinician, who will tailor their care based on the results of a brief geriatric screening tool.~-Investigators will test a two-visit Transdisciplinary Intervention with the first visit occurring within four weeks of enrollment and the second visit four weeks after the initial visit."
62813660|NCT02868112|ACTIVE_COMPARATOR|Usual Care|Participants receiving Usual Oncology Care will not meet routinely with geriatric clinicians, though they may receive a geriatrics consult at their request or at the discretion of their treating team.
62813661|NCT01994252|ACTIVE_COMPARATOR|Optimal Medical therapy plus ICD|Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter only group will receive an ICD + optimal medical therapy
62813662|NCT01994252|ACTIVE_COMPARATOR|Optimal Medical therapy plus CRT/ICD|Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter plus cardiac resynchronisation therapy (CRT) group will receive an ICD + CRT and optimal medical therapy
62813663|NCT05517135||Arm 1|Arm 1: Pre-treatment EBV DNA \<4000 copies/mL AND N0-1 or T4N0 (TNM AJCC/UICC 8th edition)
62813664|NCT05517135||Arm 2|Arm 2: Pre-treatment EBV DNA ≥4000 copies/mL OR N2-N3 OR T4N+ (TNM AJCC/UICC 8th edition) AND EBV DNA UNDETECTABLE after 2-3 cycles of induction chemotherapy (IC)
62813665|NCT05517135||Arm 3|Arm 3: Pre-treatment EBV DNA ≥4000 copies/mL OR N2-N3 OR T4N+ (TNM AJCC/UICC 8th edition) AND EBV DNA DETECTABLE after 2-3 cycles of IC
62813666|NCT05517135||Group 1|Group 1: Recurrent/metastatic NPC, EBV DNA \<4000 copies/mL
62813667|NCT05517135||Group 2|Group 2: Recurrent/metastatic NPC, EBV DNA ≥4000 copies/mL
62813668|NCT05454735||Group 1|patients with known insulin-requiring type 2 diabetes mellitus undergoing planned on-pump coronary artery bypass graft surgery
62036462|NCT01387880|EXPERIMENTAL|Cetuximab, everolimus, irinotecan|
62813669|NCT05454735||Group 2|patients with known non-insulin-requiring type 2 diabetes mellitus undergoing planned on-pump coronary artery bypass surgery
62813670|NCT05454735||Group 3|non-diabetic patients undergoing planned aortic valve replacement surgery
62813671|NCT05454735||Group 4|non-diabetic patients undergoing planned on-pump coronary artery bypass graft surgery
62813672|NCT00860002||1|Ultramini laparotomy (UMLT) myomectomy (UMLT-M) versus laparoscopic myomectomy (LM)
62813673|NCT00860002||2|Laparoscopically aided myomectomy (LAM) versus LM
62813674|NCT00860002||3|LAM versus UMLT-M
62813675|NCT00860002||4|Mini laparotomy myomectomy (ML-M) versus UMLT-M
62813676|NCT00860002||5|Laparoscopic uterine artery occlusion with blockage of anastomosis between the uterine and ovarian vessels (LUVO) versus laparoscopic uterine artery occlusion without blockage of anastomosis between the uterine and ovarian vessels (LUAO)
62813677|NCT00860002||6|LUVO+LAM versus LUAO+LAM
62237691|NCT03249714|EXPERIMENTAL|OMB 20 mg|Ofatumumab 20 mg subcutaneous injection on Days 1,7, 14 and every 4 weeks for 24 weeks in Core. Core placebo patients received loading dose at Weeks 25 and 26 and then all Extension patients received dose every 4 Weeks up to Week 48.
62813678|NCT00860002||7|LUVO+LM versus LUAO+LM
62813679|NCT00860002||8|LUVO+UMLT-M versus LUAO+UMLT-M
62813680|NCT00860002||9|LUVO versus UMLT-UVO
62813681|NCT00860002||10|UMLT-UVO versus UMLT-UAO
62813682|NCT00860002||11|LUAO versus UMLT-UAO
62813683|NCT00860002||12|UMLT-UVO+UMLT-M versus UMLT-UAO+UMLT-M
62813684|NCT00860002||13|LUVO versus LM
62036463|NCT01387880|ACTIVE_COMPARATOR|Cetuximab, everolimus and Irinotecan.|"Patients with metastatic colorectal cancer with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan.~Patients with KRAS wildtype colorectal cancer that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, irinotecan and everolimus."
62036464|NCT01944904|PLACEBO_COMPARATOR|Sugar Pill|Subjects will be asked to take the dietary supplement daily for 8 weeks. Blood samples will be taken at screen, baseline and week 8. An oral glucose tolerance test will be taken at baseline and week 8. Additionally subjects will be asked to collect their stool samples at Baseline, week 4, and 8. Subjects will also undergo a test to determine their body composition at baseline and week 8. Subjects will be asked to keep a diary of their bowel habits and any symptoms that might be related to the supplement. Subjects will be asked to recall the foods that they have eaten in the past 24 hours and to avoid any foods that contain XOS and probiotic bacteria during the study.
62036465|NCT01944904|ACTIVE_COMPARATOR|XOS 2.8|Subjects will be asked to take the dietary supplement daily for 8 weeks. Blood samples will be taken at screen, baseline and week 8. An oral glucose tolerance test will be taken at baseline and week 8. Additionally subjects will be asked to collect their stool samples at Baseline, week 4, and 8. Subjects will also undergo a test to determine their body composition at baseline and week 8. Subjects will be asked to keep a diary of their bowel habits and any symptoms that might be related to the supplement. Subjects will be asked to recall the foods that they have eaten in the past 24 hours and to avoid any foods that contain XOS and probiotic bacteria during the study.
62036466|NCT06630039||patients with Rotator cuff injury|Patients with roatator cuff injury who are aged over 18 years
62036467|NCT04464928||User interests|Facebook advertisements arm
62036468|NCT04464928||User characteristics|Google advertisements arm
62036469|NCT02278328|EXPERIMENTAL|A. Placebo then 15mg then 30mg|"Subjects will receive a single dose of placebo on week 1, 15 mg of STX209 on week 2 and 30 mg of STX209 on week 3.~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
62813685|NCT00860002||14|LUVO versus LAM
62813686|NCT00860002||15|LUVO versus LUAO+LM
62813687|NCT00860002||16|LUVO versus LUAO+UMLT-M
62813688|NCT00860002||17|LUVO versus LUAO+LAM
62813689|NCT06275451||Semi-structured interview|Semi-structured interview
62813690|NCT00788216||Healthy Volunteers|Women over the age of 18 without the diagnosis of cervical cancer.
62596009|NCT01460654|PLACEBO_COMPARATOR|Alendronate and Placebo Testosterone|
62813691|NCT00788216||Cervical Cancer Patients|Women over the age of 18 with a history of cervical cancer treated with surgery or chemoradiation.
62813692|NCT01089504|ACTIVE_COMPARATOR|Phenobarbital|Phenobarbital, 4-5 mg/kg/day, for 4 months
62813693|NCT01089504|PLACEBO_COMPARATOR|Placebo|Placebo in a volume equivalent to active drug for 4 months
62813694|NCT06294795|EXPERIMENTAL|Toric|A folding hydrophobic acrylic intraocular lens (IOL) AcrySof IQ SN60WF and Clareon SY60WF
62813695|NCT06294795|ACTIVE_COMPARATOR|Non-toric|A folding hydrophobic acrylic IOLs AcrySof IQ Toric SN6ATx and Clareon Toric CNW0Tx
62813696|NCT01925560|EXPERIMENTAL|Group A- agave inulin or placebo|Participant in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo.
62813697|NCT01925560|EXPERIMENTAL|Group B- agave inulin or placebo|Participants in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo
62036470|NCT02278328|EXPERIMENTAL|B. 15mg then placebo then 30mg|"Subjects will receive a single dose of 15 mg of STX209 on week 1, placebo on week 2 and 30 mg of STX209 on week 3.~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
62036471|NCT02278328|EXPERIMENTAL|C. 15mg then 30mg then placebo|"Subjects will receive a single dose of 15 mg of STX209 on week 1, 30 mg of STX209 on week 2 and placebo on week 3.~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
62237692|NCT03249714|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection matching to ofatumumab every 4 weeks for 24 weeks in Core
62813698|NCT01925560|EXPERIMENTAL|Group C-agave inulin or placebo|Participants in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo
62813699|NCT00656357|PLACEBO_COMPARATOR|A|SYN117 placebo and Ascending doses of cocaine (10, 20, 40 mg) and placebo
62813700|NCT00656357|EXPERIMENTAL|B|Ascending doses of SYN117 (placebo, 80 mg, 160 mg) and ascending doses of cocaine (10 mg, 20 mg, 40 mg) and placebo
62813701|NCT06065488|EXPERIMENTAL|1.Group A (Ankle KT group):|This group includes 35 patients with chronic unhealed plantar foot ulcers for longer than three months; they will receive functional ankle taping, medical treatment, and dressing according their cases. The tape was applied for 5 days and then removed for 1 day to allow skin perspiration. This process was repeated for successive 8 weeks. The patient was instructed to avoid vigorous activities for 30 min, which is required for the glue to become fully activated (Andrýsková et al., 2020)
62813702|NCT06065488|SHAM_COMPARATOR|2.Group B (Control group Ankle shame KT ):|This group includes 35 patients with chronic unhealed plantar foot ulcers for longer than three months. Shame taping group, a placebo taping method considered to be ineffective ( not from insertion to origin of muscles) with the same material without tension , they will receive medical treatment, and dressing according their cases The shame tape was applied for 5 days and then removed for 1 day to allow skin perspiration. This process was repeated for successive 8 weeks. The patient was instructed to avoid vigorous activities for 30 min, which is required for the glue to become fully activated. (Andrýsková et al., 2020)
62813703|NCT00979901|EXPERIMENTAL|1|montelukast
62813704|NCT00979901|EXPERIMENTAL|2|loratadine
62596010|NCT01460654|EXPERIMENTAL|Testosterone and Alendronate|
62813705|NCT00979901|PLACEBO_COMPARATOR|3|placebo
62813706|NCT00979901|EXPERIMENTAL|4|montelukast/loratadine
62813707|NCT02074826||Atrial fibrillation|"* Genotyping of the AF associated variants~* Measurement of the amount of left atrial fibrosis"
62813708|NCT03566602|OTHER|Dura Sealant Patch|Application of Dura Sealant Patch after closure of the dura mater
62813709|NCT03596216|EXPERIMENTAL|Percutaneous Electrial Stimulation (PES group).|"This intervention consisted in the application of an asymmetric biphasic rectangular current. The subject lay prone with her feet outside the table. The FHL muscle was located at 50% of the distance between the fibular head and inferior border of the lateral malleolus on the posterior aspect of the fibular by ultrasound machine (cross-section) (Logiq, GE Healthcare, USA) and then, a needle (0.30mm x 0.40mm) was inserted, perpendicular to the surface of the skin, until the muscle belly. Prior to inserting a neddle, the underlying skin was cleaned with isopropyl alcohol. The intensity of the current was necessary to cause an exacerbated muscle contraction, during 1.5 min acording to the Valera and Minaya protocol´s.~This intervention was performed once in each participant, on one leg only (stance limb), It's only once, it was not a treatment"
62813710|NCT03596216|EXPERIMENTAL|Transcutaneous Electrial Stimulation (TENS group)|"This intervention consisted in the application of an asymmetric biphasic rectangular current. The subject lay prone with her feet outside the table. The FHL muscle was located at 50% of the distance between the fibular head and inferior border of the lateral malleolus on the posterior aspect of the fibular by ultrasound machine (cross-section) (Logiq, GE Healthcare, USA),and then, one self-adhesive electrode was placed on the back of the leg and the other on the sole of the foot. The intensity of the current was necessary to cause an exacerbated muscle contraction, during 1.5 min.~This intervention was performed once in each participant, on one leg only (stance limb), It's only once, it was not a treatment"
62036472|NCT04791449|EXPERIMENTAL|Treatment-as-usual plus medically-supervised exercise (TAU-EX)|This group attends normal wound care appointments as scheduled with the wound care provider, generally 2 - 3 times per week. Coincident with these appointments, ideally, they will also attend a medically-supervised exercise program supervised by the exercise physiologists of the Cardiac Rehabilitation facility. The exercise sessions will last no more than 1-hr per session. The maximum number of sessions possibly attended over the 12-wk intervention period is 36. In addition, participants in this group will maintain their activities of daily life unless contraindicated by the would care provider.
62036473|NCT04791449|NO_INTERVENTION|Treat-as-usual (TAU)|This group attends normal wound care appointments as scheduled with the wound care provider, generally 2 - 3 times per week. In addition, participants in this group will maintain their activities of daily life unless contraindicated by the would care provider.
62813711|NCT05110872|EXPERIMENTAL|Menthol cigarette smokers|Adults (21 y.o. and older) who smoke ate least 10 menthol cigarettes per day will be recruited.
62813712|NCT05110872|EXPERIMENTAL|Non-menthol cigarette smokers|Adults (21 y.o. and older) who smoke ate least 10 non-menthol cigarettes per day will be recruited.
62813713|NCT04559568|EXPERIMENTAL|LY3522348 (Part A)|LY3522348 administered orally.
62813714|NCT04559568|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered orally.
62036474|NCT03630874|EXPERIMENTAL|Experimental arm|
62036475|NCT03630874|NO_INTERVENTION|Control arm|"Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (without the tool) the right prescription of ATs by answering a multiplechoice question, with the number, type, duration and dosage of AT provided."
62036476|NCT01802372|ACTIVE_COMPARATOR|WHO CVD Risk Assessment package|Arm#1 (Intervention Group): Provided Ghana's National Health Insurance and the WHO CVD Risk Assessment package for 12 months.
62036477|NCT01802372|SHAM_COMPARATOR|Health Insurance only|Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline,and usual care.
62237693|NCT06347653|EXPERIMENTAL|linperlisib combined with CHOP regimen|
62813715|NCT04559568|EXPERIMENTAL|LY3522348 (Part B)|LY3522348 administered orally. Some participants will also receive midazolam.
62428157|NCT00785278||2|Participants with paraplegia: Individuals who are at least 1-year post injury and have used a manual wheelchair as their primary means of locomotion during this time, will be assumed to be, for the purpose of this study, experienced wheelchair users.
62428158|NCT01945554|EXPERIMENTAL|Cervical disc herniation|Patients with cervical disc herniation and compression of nerve roots C3-C8.
62428159|NCT01945554|EXPERIMENTAL|Lumbar disc herniation|Patients with lumbar disc herniation and compression of nerve roots L1-S1.
62428160|NCT00575328|EXPERIMENTAL|Maca Root|Subjects in this arm will be given 3g/day of Maca Root.
62428161|NCT00575328|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive inactive placebo.
62428162|NCT04322227|EXPERIMENTAL|Healthy|
62428163|NCT04322227|EXPERIMENTAL|PD|
62813716|NCT04559568|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered orally. Some participants will also receive midazolam.
62813717|NCT01007201|EXPERIMENTAL|H1N1 vaccine of 15 μg HA on Day 0 and 21|15 μg HA (0.5 mL) per injection, 2 injections 50 children (aged over 3 years old to 6 years old) and 50 children/teenagers (aged over 6 years old to 18 years old) were assigned to receive two injections of H1N1 vaccine 3 weeks apart
62813718|NCT01007201|EXPERIMENTAL|H1N1 vaccine of 7.5 μg HA on Day 0 and 21|7.5 μg HA (0.25 mL) per injection, 2 injections 50 toddlers (aged over 1 year old to 3 years old) were assigned to receive two injections of H1N1 vaccine 3 weeks apart
62813719|NCT02437916|EXPERIMENTAL|AMG 228 monotherapy|Part 1 and Part 2 of the study will both be with single agent AMG 228 in different selected tumor types.
62813720|NCT04889417|EXPERIMENTAL|Intervention|Computerized brain game training and online interactive physical exercise training
62813721|NCT04889417|ACTIVE_COMPARATOR|Control|Control computer games and online interactive stretching exercises.
62813722|NCT05132153|ACTIVE_COMPARATOR|(Group A) will receive milrinone|Patients will receive milrinone 50 microgram/kg in 5ml volume, over 5 min by nebulization
62813723|NCT05132153|PLACEBO_COMPARATOR|(Group B) will receive normal saline|Patients will receive 5 ml saline by nebulization over 5 min
62813724|NCT00703456|EXPERIMENTAL|1|Balance Training, 3 times a week for 4 weeks
62813725|NCT00703456|NO_INTERVENTION|2|Education/No intervention
62813726|NCT02602366|OTHER|Month 1|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
62813727|NCT02602366|OTHER|Month 2|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
62813728|NCT02602366|OTHER|Month 3|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
62813729|NCT02602366|OTHER|Month 4|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
62813730|NCT00322777|EXPERIMENTAL|Spirituality Group|Arm where participants began the intervention (the Spirituality Teaching Program) upon recruitment for an 8 week period. Therefore, the program was initiated at week 1 of the trial.
62813731|NCT00322777|ACTIVE_COMPARATOR|Waitlist Control Group|Arm where participants began the intervention (the Spirituality Teaching Program) after an 8 week wait period. Therefore, the program was initiated at week 8 of the trial. Between week 1 and week 8, participants did not complete the program and were instructed to carry out their day to day activities as before.
62813732|NCT03585660|EXPERIMENTAL|Interventional Arm|Participants will undergo diagnostic MRI exam followed by clinical biopsies of suspected prostate cancer tumors.
62813733|NCT05622630|ACTIVE_COMPARATOR|Four-cell bathroom|Four-cell bath:Treatment with direct current
62813734|NCT05622630|ACTIVE_COMPARATOR|Gravel bath|Gravel bath:In this procedure, the patients are given a footbath with heated stones (granules) of different sizes for a period of 20 minutes, during which the patients are encouraged to move their feet (and, if applicable, hands) evenly.
62813735|NCT06212804|EXPERIMENTAL|VIS954 Dose 1|A single VIS954 Dose 1 will be administered subcutaneously on Day 1
62813736|NCT06212804|EXPERIMENTAL|VIS954 Dose 2|A single VIS954 Dose 2 will be administered subcutaneously on Day 1
62813737|NCT06212804|EXPERIMENTAL|VIS954 Dose 3|A single VIS954 Dose 3 will be administered subcutaneously on Day 1
62813738|NCT06212804|EXPERIMENTAL|VIS954 Dose 4|A single VIS954 Dose 4 will be administered subcutaneously on Day 1
62813739|NCT06212804|EXPERIMENTAL|VIS954 Dose 5|A single VIS954 Dose 5 will be administered subcutaneously on Day 1
62813740|NCT06212804|EXPERIMENTAL|VIS954 Dose 6|A single VIS954 Dose 6 will be administered subcutaneously on Day 1
62813741|NCT06212804|PLACEBO_COMPARATOR|Placebo|A single Placebo dose will be administered subcutaneously on Day 1 for 2 participants in each cohort.
62237694|NCT06339619|EXPERIMENTAL|Adebrelimab+Apatinib+Tegafur|
62428164|NCT03179501|EXPERIMENTAL|NP001|NP001
62036478|NCT02810054|SHAM_COMPARATOR|Control Group (MIST without EMD)|Those participants who will receive the minimally invasive surgical techniques but without application Enamel Matrix Derivative (EMD) .
62036479|NCT02810054|EXPERIMENTAL|Test Group (MIST with EMD)|Those participant who will receive the minimally invasive surgical techniques with the application of Enamel Matrix Derivative (EMD) .
62735180|NCT03572959|EXPERIMENTAL|experimental group|"OLP lesions were irradiated with a 970-nm diode laser (SIRO Laser Advance class III b, SIRONA, Germany) with a 2 W irradiation power in a continuous non-contact mode. The laser beam was delivered using a fiber-optic tip with a 320 µm diameter with defocused mode directed at the lesions plus 0.5 cm peri- lesional tissues with a slight overlapping in order to evenly distribute energy covering all the lesional and peri-lesional tissues until blanching of the area was observed.14 Diode laser was calibrated to an output power of 3W, frequency of 30 Hz, energy of 180 joule and time interval of 8 minutes divided into 4 sessions , two min each with one minute rest in between to allow for tissue relaxation.~Irradiation was done twice weekly for two months until the resolution of signs for a maximum of ten sessions.11 After each session, patients were advised to have a cold diet and use chlorhexidine oral gel postoperatively twice a day to the lesion for one week."
62036480|NCT01661348||Prevena System placement|Subjects randomized to this group will receive standard skin preparation and closure followed by application of Prevena Incision Management System (Kinetic Concepts, Inc; San Antonio, TX) negative pressure wound therapy unit (experimental group).
62036481|NCT01661348||Standard of care postoperative care|Subjects randomized to this group will receive a standard surgical skin preparation, closure, and dressing (control group).
62428165|NCT03179501|PLACEBO_COMPARATOR|Placebo|Normal saline
62036482|NCT03210805|EXPERIMENTAL|Supplementation|Omega-3 Polyunsaturated Fatty Acids
62036483|NCT03031938|OTHER|Cohort 1|Long term observational study of subjects from tanezumab parent study
62036484|NCT02506179||Open-label cohort|Patients will be followed for 52 weeks post initiation of adalimumab (Week 0).
62428166|NCT05918575|EXPERIMENTAL|Intervention Group (NIV with HFNC)|Patients randomized to the intervention group will receive NIV alternating with HFNC for 24 hours after extubation
62428167|NCT05918575|ACTIVE_COMPARATOR|Control Group (HFNC alone)|Patients randomized to the intervention group will receive HFNC only for 24 hours after extubation
62596011|NCT04779580|EXPERIMENTAL|Intervention Group (Only Group)|"Only one group in this study. 10 participants to have intervention.~Lateral femoral cutaneous nerve block and evaluation:~Routine ECG, pulse oximetry and blood pressure monitoring will be available. Using a sterile technique, the lateral femoral nerve will be approached using an in-plane ultrasound-guided technique, using a Stimuplex Ultra 360 50mm needle (B Braun, UK). Following negative aspiration, a one off STAT injection of 5mls lidocaine 1% will be administered subcutaneously.~After 10 minutes, any altered sensation will be assessed using ice to differentiate normal and altered sensation. This area will be marked on the skin using a black marker pen. Photographs will be taken and images of the procedure will be recorded.~The above will then be repeated for the subcostal nerve block.~The total area of anaesthesia will then be compared to the standard surgical incision for hip surgery to assess whether the subcostal nerve block will offer any further analgesia."
62596012|NCT01689246|EXPERIMENTAL|TRx0237 250 mg/day|
62596013|NCT01689246|PLACEBO_COMPARATOR|Placebo|
62596014|NCT01689246|EXPERIMENTAL|TRx0237 150 mg/day|
62596015|NCT05681468|EXPERIMENTAL|KETO-Can|KETO diet supplemented with Canola oil (high in MUFA and omega-3 FA).
62813742|NCT04055220|EXPERIMENTAL|Regorafenib|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by regorafenib followed by a 7-day period of rest.~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
62813743|NCT04055220|PLACEBO_COMPARATOR|Placebo|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by placebo followed by a 7-day period of rest.~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
62813744|NCT04975906||Participants|All inpatient admissions with serum lactate, ketones and/or salicylates performed, and with urea, electrolytes and creatinine at the same time. The patients will be grouped into patients with organic (gap) acidosis (elevated serum lactate, ketones and/or salicylates) and patients with no organic acidosis.
62813745|NCT05095961|EXPERIMENTAL|Pre-operative oral steroids|Patients will be given a course of oral prednisone (30mg daily) for 5 days.
62813746|NCT05095961|NO_INTERVENTION|Control|No pre-operative medication will be prescribed
62813747|NCT03647930|EXPERIMENTAL|Intervention|Application of Microporous Polysaccharide Hemospheres (MPH)
62813748|NCT03647930|NO_INTERVENTION|Control|No MPH
62813749|NCT02474446|EXPERIMENTAL|1|"Anthropometry measurement, Skin colour grading using Fitzpatrick scale, Dietary intake of calcium and vitamin D using food frequency questionnaire (FFQ), Baseline fasting blood samples for vitamin D, VDBP, VDBP genotype, Calcium, Phosphorus, Albumin, Parathyroid Hormone(PTH), Alkaline Phosphatase, Bone turnover markers(P1NP, CTX).~Fasting urine for Calcium Creatinine ratio. Saliva for bio-available Free Vitamin D measurement.~Vitamin D administration under direct supervision. Spot Urine sample for calcium : creatinine ratio after a week. Repeat all measurements done at baseline except VDBP genotype 4 weeks from baseline."
62596016|NCT05681468|EXPERIMENTAL|KETO-Sat|KETO diet supplemented with butter and coconut oil (high in SFA).
62596017|NCT05681468|ACTIVE_COMPARATOR|Low fat diet (LFD)|Low fat diet supplemented with whole grain foods (pasta or brown rice) and oatmeal.
62596018|NCT00525811|EXPERIMENTAL|A|Interactive decision aid
62596019|NCT00525811|ACTIVE_COMPARATOR|B|Regular patient information
62596020|NCT04306744|EXPERIMENTAL|Vorso PROTECT System- ON|The subject will use the Vorso PROTECT System daily. This experimental group will have the stimulation turned on for all of the daily sessions.
62596021|NCT04306744|SHAM_COMPARATOR|Sham Arm|The subject will use the Vorso PROTECT System daily. This experimental group will have the stimulation turned off for all of the daily sessions.
62813750|NCT04637386|ACTIVE_COMPARATOR|TAP block group|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
62813751|NCT04637386|ACTIVE_COMPARATOR|LAWI group|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
62596022|NCT01491685||Pregnant|
62596023|NCT01491685||Non- Pregnant|
62596024|NCT04852679|OTHER|lanreotide Autogel 120 mg|Subjects will be treated with lanreotide Autogel® 120mg, every 28 days (+/- 3 days).
62596025|NCT02855359|EXPERIMENTAL|denintuzumab mafodotin + RCHOP|Part A: denintuzumab mafodotin (SGN-CD19A) + RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
62596026|NCT02855359|EXPERIMENTAL|denintuzumab mafodotin + RCHP|Part A: denintuzumab mafodotin (SGN-CD19A) + RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone)
62428168|NCT05282355|EXPERIMENTAL|Astaxanthin|The astaxanthin group received 12 mg/day of astaxanthin. Each capsule contained 6 mg of astaxanthin and sunflower oil, and each subject ingested one capsule in the morning and one in the evening.
62596027|NCT02855359|EXPERIMENTAL|denintuzumab mafodotin + RCHOP or RCHP|Part B: denintuzumab mafodotin (SGN-CD19A) + RCHOP or RCHP
62596028|NCT02855359|ACTIVE_COMPARATOR|RCHOP|Part B: RCHOP alone: (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
62813752|NCT02211560|PLACEBO_COMPARATOR|Placebo|Identical looking cellulose capsules
62596029|NCT04402996||Healthy|Individuals with Periodontally Healthy
62596030|NCT04402996||Gingivitis|Individuals with Gingival Inflammation
62596031|NCT04402996||Periodontitis|Individuals with Periodontitis
62596032|NCT02642003|EXPERIMENTAL|GCSF+SMT|5-day course of GCSF (5 μg/kg/d) plus standard medical therapy for 6 months
62596033|NCT02642003|NO_INTERVENTION|SMT|
62596034|NCT06144606|EXPERIMENTAL|Autologous CAR T-cell immunotherapy|Tecartus will be delivered at a target dose of 1x106 cells / kg. For those \>100 kg, a flat dose of 1 x108 cells will be used. Tecartus will be administered on day 0, following 1 day of rest from conditioning chemotherapy.
62813753|NCT02211560|EXPERIMENTAL|Phosphatidylserine|Phosphatidylserine-omega-3, DHA enriched
62813754|NCT03864835|EXPERIMENTAL|Moderate intensity aerobic exercise|All subjects will undergo DXA and CRF measurement (relative VO2max) under the supervision of an American College of Sports Medicine (ACSM)-certified fitness professional and study physician at the Penn State PM\&R Research Laboratories. Subjects selected for the interventional pilot trial will receive a FitBit Charge2 HR and be instructed on how to use a FitBit Hear Rate monitor, Fitbit application, Fitbit website, and Fitabase (secure data management platform utilized by \>400 clinical trials). Participants will record their daily food and beverage intake through the Fitbit app. Individualized feedback will be provided by a registered dietician (RD). Subjects that meet requirements for the exercise arm (12 total) will be required to exercise 30 minutes, five days per week at a moderate intensity (HR target corresponding to 45-55% of their relative VO2max). Each session will be supervised in-person at the Penn State University Fitness Center with an ACSM certified exercise physiologist.
62813755|NCT00360230|EXPERIMENTAL|SB257049 F2 0-1 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1-month schedule administered intramuscularly (IM) in the left deltoid muscle.
62596035|NCT02409745|EXPERIMENTAL|Young age group-Luteal phase|Endometrial injury in luteal phase (previous menstrual cycle) for patients undergoing Frozen thawed embryo transfer.
62813756|NCT00360230|EXPERIMENTAL|SB257049 F1 0-1 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1-month schedule administered intramuscularly (IM) in the left deltoid muscle.
62596036|NCT02409745|ACTIVE_COMPARATOR|Young age group-Early follicular phase|Endometrial injury in early follicular phase for patients undergoing Frozen thawed embryo transfer.
62596037|NCT02409745|EXPERIMENTAL|Advanced age group-Luteal phase|Endometrial injury in luteal phase (previous menstrual cycle) for patients undergoing Frozen thawed embryo transfer.
62813757|NCT00360230|EXPERIMENTAL|SB257049 F2 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
62596038|NCT02409745|ACTIVE_COMPARATOR|Advanced age group-Early follicular phase|Endometrial injury in early follicular phase for patients undergoing Frozen thawed embryo transfer.
62596039|NCT04931485|EXPERIMENTAL|Intervention: REDUCE Protocol|Fluid resuscitation and de-resuscitation is based on the REDUCE fluid management protocol.
62596040|NCT04931485|ACTIVE_COMPARATOR|Standard of Care|Fluid resuscitation and de-resuscitation according to the standard of care
62596041|NCT06272136|EXPERIMENTAL|Interventional arm|Induction of hyperglycaemia and hypoglcemia states and measurements of transcutaneous spectral data with the investigational device and reference blood glucose values measured by Super GL and Freestyle Libre 3.
62036485|NCT02190331|EXPERIMENTAL|Interventional program|The training protocol is constituted by 4 strengthening exercises (Side Lying External Rotation, Prone Horizontal Abduction with External Rotation, Y to I exercise and Chin Tuck) and 3 stretching exercises(one- Sided Unilateral Self Stretch Exercise, one-sided Unilateral Self Stretch Exercise, Static Sternocleidomastoid Stretch and Static Levator Scapulae Stretch
62036486|NCT02190331|ACTIVE_COMPARATOR|Control group|The control group will only participate in the Physical Education classes
62036487|NCT06225765|EXPERIMENTAL|Transoral endoscopic thyroidectomy vestibular approach (TOETVA)|Test group receiving surgery under transoral endoscopic thyroidectomy vestibular approach (TOETVA)
62813758|NCT00360230|EXPERIMENTAL|SB257049 F1 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
62036488|NCT06225765|ACTIVE_COMPARATOR|Traditional open surgery|Control group receiving traditional open thyroidectomy
62036489|NCT01891916|NO_INTERVENTION|extensively hydrolysed casein formula|extensively hydrolysed casein formula
62036490|NCT01891916|ACTIVE_COMPARATOR|Extensively hydrolyzed casein formula + LGG|Extensively hydrolized formula plus LGG
62036491|NCT00675766||Group 1|HIV-positive adults 50 and older/ HIV-positive adults 18-40 years old
62036492|NCT00675766||Group 2|HIV-negative controls 50 and older / HIV-negative controls 18-40 years old
62036493|NCT00675766||Group 3|HIV-negative controls 50 and older / HIV-negative controls 18-40 years old
62036494|NCT00675766||Group 4|HIV-negative controls 18-40 years old
62036495|NCT02349295|EXPERIMENTAL|Ixekizumab 80 milligram (mg) every 2 Weeks (Q2W)|Blinded Treatment Period (Week(wk) 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22, and 24.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q2W and IR from ixekizumab 80 mg Q2W who continued on ixekizumab 80 mg Q2W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q2W given on Wks 16,18,20,22,24. Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q2W at week 0 and continued on ixe 80 mg Q2W during the Extension Period. Pts who received ixekizumab 80 mg Q2W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
62428169|NCT05282355|PLACEBO_COMPARATOR|Placebo|The placebo group ingested two capsules per day, one in the morning and one in the evening. Each capsule contained sunflower oil and mimicked the size and appearance of the astaxanthin supplement.
62428170|NCT03276533|EXPERIMENTAL|Intravenous saline, dexmedetomidine and lidocaine|
62428171|NCT03276533|EXPERIMENTAL|Intravenous saline, dexmedetomidine, lidocaine and combination|
62428172|NCT03276533|EXPERIMENTAL|Intravenous saline,dexmedetomidine plus lidocaine|
62428173|NCT03276533|EXPERIMENTAL|Intravenous saline, dexmedetomidine combined with lidocaine|
62428174|NCT06122272|EXPERIMENTAL|Test products:|New formula for healthy term infants
62428175|NCT06122272|ACTIVE_COMPARATOR|Control products|Standard, commercially available infant formula for healthy term infants
62428176|NCT05491278|EXPERIMENTAL|Fospropofol disodium for injection|Fospropofol disodium continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for analgesia.The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
62428177|NCT05491278|ACTIVE_COMPARATOR|propofol|Propofol continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for analgesia. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
62428178|NCT00612482|NO_INTERVENTION|1|"Participants in the no intervention condition will receive the usual high school science curriculum."
62428179|NCT00612482|EXPERIMENTAL|2|"Participants in the experimental arm will receive the 5-lesson, science-based substance abuse prevention curriculum in their science classes."
62428180|NCT00449930|EXPERIMENTAL|1|Drug
62428181|NCT00449930|ACTIVE_COMPARATOR|2|Active comparator
62428182|NCT04628143|NO_INTERVENTION|Standard of Care|Standard of Care Treatment for COVID-19 Infection
62428183|NCT04628143|EXPERIMENTAL|Nafamostat + Standard of Care|Nafamostat mesylate on top of standard of care
62036496|NCT02349295|EXPERIMENTAL|Ixekizumab 80 mg Q4W|Blinded Treatment Period (Week 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q4W given on Wks 4, 8 and 12 alternating with placebo for ixe injections Q4W given on Wks 2,6,10,14,18, and 22.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q4W and IR from ixekizumab 80 mg Q4W who continued on ixekizumab 80 mg Q4W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q4W given on Wks 16 and 20 alternating with placebo for ixe injections Q4W given on Wks 18 and 22.Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q4W at week 0 and continued on ixe 80 mg Q4W during the Extension Period.Pts who received ixekizumab 80 mg Q4W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
62036497|NCT02349295|PLACEBO_COMPARATOR|Placebo|Blinded Treatment Period (Wk 0-24): Pts received placebo for Ixe as 2 SC injections followed by 1 SC injection Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22 and 24. Pts initially randomized to placebo treatment group in the double blind treatment period,flagged as IR at Wk 16,re-randomized to ixe 80 mg Q2W/Q4W for the remainder of the current period and following period. Extended Treatment Period (Wk 24-156): Pts who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q2W/Q4W during the Extension Period.Pts who remained on placebo at the completion of the double blind treatment period received the first dose of ixe (160 mg starting dose) at Wk 24.Pts who were IRs at Wk 16 and were re-randomized to ixe at Wk 16 received the first dose of ixe (160 mg starting dose) at Wk 16. Pts who received placebo,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
62036498|NCT05642481||Antiretroviral drugs with marketing authorisation in Europe|This study includes subjects who already take antiretroviral drugs to treat HIV-1 with a marketing authorisation in Europe. These drugs already have a marketing authorisation and are prescribed by the treating physician of the subject. No adjustments to their treating regimen are made in order to participate in this study. All antiretrovirals with a marketing authorisation in Europe are eligible for inclusion in this study, but most subjects are expected to use a backbone of nucleoside reverse transcriptase inhibitors combined with either dolutegravir, raltegravir, darunavir or rilpivirine
62036499|NCT03561090|EXPERIMENTAL|1500 mg IW-3718 BID + PPI|Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
62428184|NCT01581762|SHAM_COMPARATOR|Conventional 22G Needle|Device: EUS-FNA with conventional 22G Needle
62428185|NCT01581762|ACTIVE_COMPARATOR|22G Procore Needle|Device: EUS-FNA with 22G Procore Needle which has a reverse bevel at the tip of the needle to enhance tissue collection
62428186|NCT01804192|EXPERIMENTAL|Acu-TENS to LI4 and LI11|"Acu-TENS Group (Experimental Group), subjects received TENS over right L14 and LI11.~Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV."
62813759|NCT00360230|EXPERIMENTAL|SB257049 F2 0-1-7 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1, 7-month schedule administered intramuscularly (IM) in the left deltoid muscle.
62813760|NCT00360230|ACTIVE_COMPARATOR|SB257049 F1 0-1-7 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1, 7-month schedule administered intramuscularly (IM) in the left deltoid muscle.
62813761|NCT00360230|ACTIVE_COMPARATOR|Rabipur 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
62428187|NCT01804192|ACTIVE_COMPARATOR|Control group|"Control Acu-TENS Group (Control Group), subjects received TENS over tips of bilateral knee caps.~Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV."
62596042|NCT01158040||Insulin pump|Women suffering from pregestational diabetes mellitus and being treated with insulin pump during pregnancy and delivery
62596043|NCT01158040||IV insulin|Women suffering from pregestational diabetes mellitus and being treated with insulin sub-cutan (SC) during pregnancy and IV insulin during delivery
62596044|NCT01158040||Healthy|Healthy women accepted for delivery in our institute
62735181|NCT01878578|EXPERIMENTAL|Eslicarbazepine acetate|ESL 600 mg tablets
62813762|NCT02700308|ACTIVE_COMPARATOR|Conventional vertebroplasty|Conventional vertebroplasty (device's trade at the discretion of the investigator)
62813763|NCT02700308|EXPERIMENTAL|Kyphoplasty|Vertebroplasty with balloon placement and inflation prior to cement injection (device's trade at the discretion of the investigator)
62813764|NCT05769296||Concussed|Diagnosis of concussion
62813765|NCT05769296||Controls|Athletes with no concussion within the preceding year
62036500|NCT03561090|PLACEBO_COMPARATOR|Placebo + PPI|Three placebo tablets administered BID immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
62813766|NCT05444556|EXPERIMENTAL|Imlunestrant + Repaglinide|Repaglinide administered orally alone on day 1 followed by imlunestrant administered orally in combination with repaglinide orally on day 3.
62036501|NCT02023970|OTHER|Phase A: Diagnostic Study|Objective: to assess the differential immune response in patients with or without SVD (given the low rate of SVD) a matched cases-controls study allows a powerful statistical analysis avoiding main confounding factors for a first discovery of a SVD-specific immune response. Results will be validated in prospective Phase B.
62036502|NCT02023970|OTHER|Phase B1 (Prospective Study): Cohort of prevalent patients|This cohort is specifically designed to study the kinetics of the immune response before and after implantation of an aortic BHV. Eight of the most frequently implanted BHV worldwide will be assessed:
62813767|NCT05444556|EXPERIMENTAL|Imlunestrant + Omeprazole & Dextromethorphan|Omeprazole administered in combination with dextromethorphan orally on day 1 followed by imlunestrant administered orally in combination with omeprazole and dextromethorphan orally on day 3.
62036503|NCT02023970|OTHER|Phase B2 (Prospective Study): Cohort of incident patients|Due to the low incidence of SVD during the first 4 post-operative years, a second cohort will be constituted by patients undergone biological aortic valve replacement at least 5 years before. The objective of this second cohort is to cover a period of time where risk of SVD occurrence is potentially high.
62428188|NCT01804192|PLACEBO_COMPARATOR|Placebo group|Placebo Acu-TENS Group (Placebo Group), subjects received the same protocol as the Acu-TENS group and TENS was applied over right LI4 and LI11 that covered with non-conducting plastics (with the same dimension as the TENS electrodes) Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV.
62428189|NCT02406703||Chloroprocaine|Patient undergoing popliteal block with chloroprocaine
62596045|NCT04032106|ACTIVE_COMPARATOR|Group A (standard HPV information)|Participants receive standard information about HPV and HPV vaccine via a mobile-friendly website.
62813768|NCT05444556|EXPERIMENTAL|Imlunestrant + Quinidine|"Imlunestrant administered orally on day 1 followed by quinidine alone orally on day 15 to 17.~On day 18, imlunestrant administered orally in combination with quinidine followed by quinidine administered orally on day 19 to 24."
62813769|NCT05444556|EXPERIMENTAL|Imlunestrant + Rosuvastatin & Digoxin|Rosuvastatin administered in combination with digoxin administered orally on day 1 followed by imlunestrant administered orally in combination with rosuvastatin and digoxin orally on day 10.
62428190|NCT02406703||Mepivacaine|Patient undergoing popliteal block with mepivacaine
62735182|NCT01878578|ACTIVE_COMPARATOR|phenytoin|Hidantina® 100 mg tablets
62735183|NCT01878578|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62813770|NCT06406712|ACTIVE_COMPARATOR|dexamethasone with bupivacaine in retroclavicular block|40patients received 40 ml of bupivacaine 0.25%(in total 100 mg)+1 ml of dexamethasone)
62813771|NCT06406712|ACTIVE_COMPARATOR|bupivacaine in retroclavicular block (control group)|: 40patients received. 40 ml of bupivacaine 0.25%(in total 100 mg)+1 ml saline
62813772|NCT02669810|EXPERIMENTAL|PROTHERACYTES|"The interventional investigators will perform the ProtheraCytes® cardiac injections using a catheter introduced via the femoral route up to the left ventricle cavity for intraventricular injections (Helix/Biocardia).~Intracoronary injection will be possible with OTW catheter or microcatheter (UK only) if patient presents a contraindication to intramyocardial injection"
62813773|NCT02669810|ACTIVE_COMPARATOR|Standard of Care|Patients will be treated as standard treatment for CHF post - AMI.
62813774|NCT01999478||Patients undergoing colonoscopy|Patients undergoing colonoscopy per standard of care.
62036504|NCT01511848|ACTIVE_COMPARATOR|arm 1|30 Patients will be treated with combined DFP and deferasirox.
62036505|NCT01511848|ACTIVE_COMPARATOR|arm 2|Patients will be treated for 6 days with a combination of deferoxamine and DFP
62036506|NCT00956865|ACTIVE_COMPARATOR|Voucher|Voucher for transportation reimbursement
62036507|NCT00956865|ACTIVE_COMPARATOR|Voucher and call|Voucher for transportation and telephone calls
62036508|NCT00956865|ACTIVE_COMPARATOR|Voucher and call and contact|Voucher for transportation, telephone calls, and a contact at the senior center
62036509|NCT01379066||Tuberculosis Patients|Suspected Tuberculosis patients
62036510|NCT01379066||Control|Healthy volunteers
62036511|NCT00036569|EXPERIMENTAL|Interferon Alfa|0.3 mg/kg subcutaneously once a week for 4 weeks beginning 2-10 weeks after completion of radiation therapy and continued until disease progression or one of the other off study criteria.
62036512|NCT00221442|ACTIVE_COMPARATOR|zonisamide|zonegran (zonisamide)
62036513|NCT00221442|PLACEBO_COMPARATOR|Sugar pill|fake pill
62428191|NCT00141531|ACTIVE_COMPARATOR|Apaziquone|
62036514|NCT05449834|EXPERIMENTAL|Fibrinogen Concentrate (FC)|"Fibrinogen Replacement using 3g Fibrinogen Concentrate as per:~ROTEM FIBTEM A5 ≤ 10mm or TEG FF A10 ≤ 15mm or FibC ≤ 2g/L"
62036515|NCT05449834|ACTIVE_COMPARATOR|Cryoprecipitate (Cryo)|"Fibrinogen Replacement using 10 Units WB or 4U Apheresis Cryo (Australia) as per:~ROTEM FIBTEM A5 ≤ 10mm or TEG FF A10 ≤ 15mm or FibC ≤ 2g/L"
62036516|NCT01880723|EXPERIMENTAL|Albuterol|2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
62036517|NCT01880723|PLACEBO_COMPARATOR|Saline (healthy only)|nebulized 3 ml normal saline using a Power Neb2 nebulizer
62036518|NCT05962242|EXPERIMENTAL|Reduce Dose without Concurrent Chemotherapy Non- Rapid Responder|A reduced dose regimen of 24 Gy in 12 fractions to gross disease and intermediate nodes. Then 36 Gy in 18 fractions to entire volume. Non-responders will receive an additional boost of 10 Gy in 5 fractions to entire volume.
62036519|NCT05962242|EXPERIMENTAL|Reduce Dose with Concurrent Chemotherapy Non-Rapid Responder|A reduced dose regimen of 24 Gy in 12 fractions to gross disease and intermediate nodes. Then 30 Gy in 15 fractions to entire volume. Non-responders will receive an additional boost of 10 Gy in 5 fractions to entire volume.
62036520|NCT05962242|EXPERIMENTAL|Reduce Dose without Concurrent Chemotherapy Rapid Responder|A reduced dose regimen of 24 Gy in 12 fractions to gross disease and intermediate nodes. Then 36 Gy in 18 fractions to entire volume.
62036521|NCT05962242|EXPERIMENTAL|Reduce Dose with Concurrent Chemotherapy Rapid Responder|A reduced dose regimen of 24 Gy in 12 fractions to gross disease and intermediate nodes. Then 30 Gy in 15 fractions to entire volume.
62036522|NCT04341116|EXPERIMENTAL|TJ003234 Medium Dose|
62036523|NCT04341116|EXPERIMENTAL|TJ003234 Low Dose|Part 1 only
62036524|NCT04341116|PLACEBO_COMPARATOR|Placebo|
62036525|NCT04341116|EXPERIMENTAL|TJ003234 High Dose|Part 2 Phase 3 only
62036526|NCT01791218|EXPERIMENTAL|CABG, AVR or CABG+AVR and PVI|Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis (AVR) or combination (CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation (PVI) in CBP prior to occlusion and CABG
62036527|NCT01791218|ACTIVE_COMPARATOR|CABG, AVR or CABG+AVR|Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis(AVR) or combination(CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. No operative procedures for the treatment of atrial fibrillation
62036528|NCT03276351|ACTIVE_COMPARATOR|Long-Stemmed with Hybrid Fixation|Participants will receive the Long-Stemmed revision implant with Hybrid Fixation during their surgery.
62428192|NCT04297488|EXPERIMENTAL|INR(oral probiotic capsules containing 3 billion Bifidobacterium and 1 billion Lactobacillus)|Participants will receive oral probiotic capsules containing 3 billion Bifidobacterium and 1 billion Lactobacillus once daily for 6 months.
62428193|NCT04283487|EXPERIMENTAL|Fructans solution|Fructans (FODMAP) are oligosaccharides containing fructose chains. Since the human body lacks hydrolases to break down these saccharides, fructans are poorly absorbed molecules in everybody.The fructans solution used in this study is 500 ml water containing 40g fructans
62036529|NCT03276351|EXPERIMENTAL|Short-Stemmed with Augmented Fixation|Participants will receive the Short-Stemmed primary implant with Augmented Fixation during their surgery.
62813775|NCT05478408||Questionnaires assessed general population|"① Internet users over the age of 18；~② Be able to read and communicate in Chinese."
62036530|NCT05640349||Case|Patients with positive blood culture recorded at the microbiology laboratory of University Hospital of Nice during the Covid-19 Pandemic lockdown (between 23/03/2020 and 24/05/2020).
62036531|NCT05640349||Control|Patients with positive blood culture recorded at the microbiology laboratory of University Hospital of Nice between 23/03/2019 and 24/05/2019.
62036532|NCT00682487||1|patients admitted to the cardiology department with acute Myocardial infarction.
62036533|NCT00682487||2|patients admitted to an internal medicine department due to reasons other than an acute thrombotic event
62428194|NCT04283487|ACTIVE_COMPARATOR|Glucose solution|Glucose is a carbohydrate that is not classified as FODMAP, and is therefore used as a positive control in this study. The glucose solution used in this study is 500 ml water containing 40g glucose.
62428195|NCT04283487|PLACEBO_COMPARATOR|Saline solution|The saline solution does't contain any sugar and used in this study is 500ml 0.9% normal saline.
62428196|NCT00245427|OTHER|1 All macrolide antibiotics|
62428197|NCT00245427|OTHER|2 All beta lactam antibiotics|
62428198|NCT02272881|EXPERIMENTAL|immediate surgical intervention|immediate surgical reconstruction of the pressure ulcer via flap closure or comparable procedure
62428199|NCT02272881|OTHER|wound care|conservative wound management directed by certified wound care experts
62036534|NCT01491854|OTHER|Monitoring of long-term safety|Long-term safety follow-up after the end of treatment with Omnitrope (single arm)
62036535|NCT03288116||patient|Scheimplug imaging and contrast and sensitivity test
62036536|NCT03288116||early disease|Scheimplug imaging and contrast and sensitivity test
62036537|NCT03288116||normal|Scheimplug imaging and contrast and sensitivity test
62036538|NCT01414387|ACTIVE_COMPARATOR|Carotid filter|For this intervention group, patients will receive FDA-approved filter devices for cerebral embolic protection during carotid artery stenting intervention.
62036539|NCT01414387|ACTIVE_COMPARATOR|Carotid reversal of flow|For this intervention group, patients will receive reversal of flow with the FDA-approved Gore Neuroprotection System for cerebral protection during carotid artery stenting.
62428200|NCT04972006|EXPERIMENTAL|One week baseline|Participants randomized to baseline one will go through a one-week baseline period before beginning the treatment.
62813776|NCT04125095||Head Scans|Includes patients receiving proton therapy for tumors in the brain, skull, and head and neck region. The same patient could potentially contribute to both cohorts if he/she receives radiation to both head and body sites.
62813777|NCT04125095||Body Scans|Includes proton irradiation to shoulders, thorax, abdomen, pelvis, spine (thoracic or lumbar), extremities, and other body sites. The same patient could potentially contribute to both cohorts if he/she receives radiation to both head and body sites.
62813778|NCT02997215|EXPERIMENTAL|intravenous lidocaine|intravenous lidocaine 1.5mg/kg during induction then infused at 2mg/kg/h until the end of procedure.
62813779|NCT02997215|PLACEBO_COMPARATOR|saline placebo|same amount volume saline infusion
62813780|NCT04637568||Maxillary Deficiency|59 CT scans of patients with maxillary deficiency requiring Le Fort osteotomy
62813781|NCT04637568||Control|61 CT scans of healthy patients
62813782|NCT04865159|OTHER|Single Group Assignment|Single Arm - Drug administered on Days 1-7 and Days 15-21 of a 28-day treatment cycle. Series of Pharmacokinetics and ECGs will be done during cycle 1.
62036540|NCT01734304|EXPERIMENTAL|DC vaccination|Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
62036541|NCT04994457||Adults with Glaucoma or Suspected Glaucoma|Adults with Glaucoma or Suspected Glaucoma, who have previously had standard automated perimetry (SAP) and will receive virtual reality visual field (VRVF) as part of the standard of care
62036542|NCT04994457||Visual Field Naive Adults|Visual Field Naive Adults will receive SAP and VRVF
62036543|NCT04994457||Children with Glaucoma or Suspected Glaucoma|Children with Glaucoma or Suspected Glaucoma, who have previously had SAP and will receive VRVF as part of the standard of care
62036544|NCT04994457||Visual Field Naive Children|Visual Field Naive Children will receive SAP and VRVF
62036545|NCT04994457||Remote Care Arm|Glaucoma or Suspected Glaucoma participants, who have previously had SAP and will receive VRVF at their home
62036546|NCT04994457||Ptosis Arm|Patients diagnosed with Ptosis, brow ptosis, or dermatochalasis, will receive a specialized version of VRVF and SAP, specifically to detect ptosis
62036547|NCT05054374|EXPERIMENTAL|Arm 1, Part 1 - mirdametinib in combination with fulvestrant|"Postmenopausal patients with estrogen receptor positive metastatic breast cancer harboring NF1 loss of function or another alteration of the MAPK pathway.~Part 1: safety run-in (confirmation of the RP2D for mirdametinib in combination with the standard recommended dose of fulvestrant). This part may include the mirdametinib dose de-escalation according to the 3+3 design if necessary"
62036548|NCT05054374|EXPERIMENTAL|Arm 1, Part 2 - mirdametinib in combination with fulvestrant|"Postmenopausal patients with estrogen receptor positive metastatic breast cancer harboring NF1 loss of function or another alteration of the MAPK pathway.~Part 2: dose expansion cohorts where the mirdametinib RP2D will be administered in combination with the standard recommended dose of fulvestrant"
62036549|NCT05054374|EXPERIMENTAL|Arm 2, Part 1 - mirdametinib as single agent|"Adult patients with advanced solid cancers driven by the alteration of the MAPK pathway~Part 1: mirdametinib dose escalation to MTD or RP2D according to the 3+3 design"
62036550|NCT05054374|EXPERIMENTAL|Arm 2, Part 2 - mirdametinib as single agent|"Adult patients with advanced solid cancers driven by the alteration of the MAPK pathway~Part 2: dose expansion cohorts"
62813783|NCT01544296|EXPERIMENTAL|KHK6188, high dose|
62813784|NCT01544296|EXPERIMENTAL|KHK6188, low dose|
62813785|NCT01544296|PLACEBO_COMPARATOR|Placebo|
62813786|NCT00894803|ACTIVE_COMPARATOR|rt-PA only|Subject will receive the standard dose (0.9mg/kg) of IV rt-PA given over 60 minutes. One out of 6 subjects will be in this group.
62428201|NCT04972006|EXPERIMENTAL|Two week baseline|Participants randomized to baseline two will go through a two-week baseline period before beginning the treatment.
62428202|NCT04972006|EXPERIMENTAL|Three week baseline|Participants randomized to baseline three will go through a three-week baseline period before beginning the treatment.
62813787|NCT00894803|EXPERIMENTAL|rt-PA and Eptifibatide|Subject will receive the standard dose (0.9mg/kg) of IV rt-PA. This IV dose will be discontinued at 40 minutes. The subject will immediately receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours. Five out of six subjects will be in this group.
62813788|NCT03533673|EXPERIMENTAL|Cohort 1|A one-time intravenous infusion of ACTUS-101 (dose level 1)
62813789|NCT03533673|EXPERIMENTAL|Cohort 2|A one-time intravenous infusion of ACTUS-101 (dose level 2)
62036551|NCT04885062|EXPERIMENTAL|UH-Participant|Potential participants with suspected OSA will be identified from the schedule of the UH Beachwood and Bolwell sleep labs.Those subjects who satisfy the study inclusion and exclusion criteria will be approached and invited to participate in the study.
62036552|NCT00014820||Patients with a diagnosis of asthma (new) (Cases)|Patients with a physician diagnosis of asthma during the 7.5 years being studied who were working at the time of diagnosis, as determined by patient interviews.
62237695|NCT02730988|EXPERIMENTAL|Weight Loss Lifestyle Counseling|The high protein weight loss group follows the Medifast 4 \& 2 \& 1 Plan™, a 1200 calorie, high protein diet targeting \~10% weight loss over 24-weeks through a combination of meal replacement products (MRPs), meal plans, and individual nutrition/behavioral counseling. Participants are guided by the study RD on food purchasing and preparation and encouraged to consume only what is approved from the menu. Participants meet bi-weekly for RD-lead behavioral counseling group classes to provide support and introduce new topics in behavioral weight control. Weight is also measured at each session with progress feedback provided to increase motivation. Participants complete daily food logs to verify compliance to the diet.
62428203|NCT03707522|EXPERIMENTAL|Growth mindset + MRF Information|Online growth mindset interactive article followed by equal length interactive article describing the relationship between modifiable risk factors (MRF) and mental health outcomes
62428204|NCT03707522|EXPERIMENTAL|Control + MRF information|Online daily activity scheduling interactive article (control) followed by equal length interactive article describing the relationship between modifiable risk factors and mental health outcomes
62428205|NCT03707522|EXPERIMENTAL|Control + Growth mindset|Online growth mindset interactive article followed by equal length online daily activity scheduling interactive article (control)
62428206|NCT03707522|PLACEBO_COMPARATOR|Control + Control|2 doses online daily activity scheduling interactive article (control)
62813790|NCT03533673|EXPERIMENTAL|Cohort 3|A one-time intravenous infusion of ACTUS-101 (dose level 3)
62813791|NCT04477265|EXPERIMENTAL|combination of drug and exercise|Participant will be prescribed with oral medication in combination with biofeedback-assisted pelvic floor muscle training (PFMT) during the first month, participant will continue to have biofeedback assisted PFMT for another 2 months
62813792|NCT04477265|ACTIVE_COMPARATOR|drug only|Participant will be prescribed with oral medication for 3 months
62813793|NCT04477265|ACTIVE_COMPARATOR|exercise only|Participant will be doing biofeedback-assisted pelvic floor muscle training for 3 months
62036553|NCT00014820||Patients with a diagnosis other than asthma (Controls)|Patients (age-matched to a case patient) with a physician diagnosis other than asthma who were working at the time of diagnosis.
62036554|NCT00014820||Patients with a diagnosis of asthma (previous)|Patients with a physician diagnosis of asthma prior to the 7.5 years being studied
62036555|NCT01641250|EXPERIMENTAL|Part A: RO5429083|
62036556|NCT01641250|EXPERIMENTAL|Part B: RO5429083 + cytarabine|
62036557|NCT06159634|EXPERIMENTAL|ESD with traction device|ESD of target lesion will be performed with the assistance of a traction device.
62036558|NCT06159634|ACTIVE_COMPARATOR|Control arm|ESD of target lesion will be performed without the use of a traction device
62428207|NCT02576054|EXPERIMENTAL|V501|0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
62428208|NCT01532037|EXPERIMENTAL|Guided Self Help|Participant receives usual care and 4, 45 minute sessions with a therapist to support them to complete the cognitive behavioural therapy based workbook for fatigue in Multiple Sclerosis.
62428209|NCT01532037|EXPERIMENTAL|Pure Self Help|Participant receives usual care and cognitive behavioural therapy based self help work book for fatigue in multiple sclerosis to complete alone
62428210|NCT01532037|PLACEBO_COMPARATOR|Treatment as Usual|Participants receive usual care from healthcare professionals
62428211|NCT06089850|EXPERIMENTAL|HSC donors|Completion of questionnaires + socio-demographic data
62428212|NCT04618952|ACTIVE_COMPARATOR|treatment|patients received calcium D
62813794|NCT06360458|EXPERIMENTAL|Methylprednisolone sodium succinate group|
62813795|NCT06360458|PLACEBO_COMPARATOR|Placebo group|Methylprednisolone sodium succinate simulant
62813796|NCT03224208|EXPERIMENTAL|Single arm|"Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28. Cobimetinib will be given orally at 60 mg qd on Days 1-21 of each 28-day treatment cycle until disease progression.~Treatments will be continued until the development of progressive disease (as per Investigator assessment), unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination by the Sponsor."
62813797|NCT00758732|EXPERIMENTAL|1|Docetaxel/carboplatin
62813798|NCT00758732|EXPERIMENTAL|2|Docetaxel/Caelyx
62813799|NCT05498649||Bilateral use of DT1fA contact lenses|DT1fA contact lenses
62813800|NCT05195164||Older transgender women|This cohort will consist of healthy transgender women aged 45 and above who have not undergone but desire orchiectomy, who have been on estrogen (history of oral, transdermal or injectable) and spironolactone for at least one year.
62813801|NCT05195164||Younger transgender women|This cohort will consist of healthy transgender women aged 18-44 who have not undergone but desire orchiectomy, who have been on estrogen (history of oral, transdermal or injectable) and spironolactone for at least one year.
62036559|NCT02636634|OTHER|diagnostic imaging strategy|PET-FET (positron emission tomography using 1-Fluoro-Ethyl-Tyrosine) and MSR (magnetic resonance spectroscopy) before biopsy
62036560|NCT06670872||Eravacycline combination therapy group|Eravacycline is administered intravenously at a dosage of 1mg/kg, once every 12 hours. The duration of intravenous infusion is approximately 60 minutes.The combined drugs include sulbactam or compound preparations containing sulbactam, polymyxin B, beta-lactam antibiotics, etc., used according to their instructions for use or clinical practice guidelines.
62036561|NCT05374980|EXPERIMENTAL|Yogurt|Drink a bottle of 200ml yogurt every morning and evening for 8 weeks
62036562|NCT05374980|PLACEBO_COMPARATOR|Placebo|Drink a bottle of 200ml placebo every morning and evening for 8 weeks
62813802|NCT02171221|EXPERIMENTAL|Oral DFP-11207|DFP-11207: daily oral dosing, 28 day treatment cycle
62036563|NCT05374980|NO_INTERVENTION|Healthy volunteer|Patients with Helicobacter pylori negative (ΔUBT\<2%) need blood test and collect stool samples at first, and collect stool samples again after 2 months.
62036564|NCT00957476|ACTIVE_COMPARATOR|Omega-3 Fish Oil|800mg DHA \& 1200mg EPA
62036565|NCT00957476|PLACEBO_COMPARATOR|Placebo|Wheat germ oil
62237696|NCT02730988|ACTIVE_COMPARATOR|Weight Stable Lifestyle Counseling|The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 \& 2 \& 1 Plan.
62237697|NCT02715167|ACTIVE_COMPARATOR|Group Budesonide|Inhaled corticoids
62237698|NCT02715167|PLACEBO_COMPARATOR|Group Placebo|Placebo by inhalation
62428213|NCT04618952|PLACEBO_COMPARATOR|control|patients received placebo
62428214|NCT04992338|EXPERIMENTAL|Intervention group - CarpeDiem app|Participants will receive at their home the activity tracker of Fitbit brand, model Inspire HR 2, as well as instructions to download and use the CarpeDiem application and the Fitbit application in their mobile phones and synchronize the bracelet. The intervention consists of detecting unhealthy user behaviors and, through contextualized and personalized recommendations and strategies based on gamification, modifying said behaviors and motivating individuals to maintain this modification over time in order to prevent illnesses associated with bad habits. The intervention is performed through the CarpeDiem application, participants will be able to answer follow-up questionnaires, carry out missions designed to improve their eating habits, monitor their physical activity and sleep.
62428215|NCT04992338|NO_INTERVENTION|Control group - Activity tracker + general recommendations|"Participants will receive the Fitbit activity tracker, model Inspire HR 2. They will also receive instructions to download the Fitbit application from their mobile phone and synchronize the bracelet. Additionally, this group will receive general recommendations on healthy lifestyle habits through standardized documents that contain general guidelines, such as: Get in the habit of going to sleep and always waking up at the same time, even on weekends."
62428216|NCT04726839||Stroke suspicion|Patients with stroke suspicion within 24 hours of stroke's symptoms
62428217|NCT05949216|EXPERIMENTAL|Musical engagement sessions|The single group of this study will participate in four musical engagement sessions as described in the intervention section.
62428218|NCT02482571|EXPERIMENTAL|Mild Hypoxia|Subjects are exposed to an intervention that controls the composition of breathed air by using a gas blender (RespirAct). Subjects undergo MRI and MRS while breathing air with both normal oxygen concentration (normoxia) and reduced oxygen concentration (mild hypoxia).
62428219|NCT05279326|EXPERIMENTAL|Intervention arm|Participants will receive virtual SMAs and usual care. Virtual SMAs will last 90 minutes, every 3 weeks, in 18 weeks through an online platform, at no cost to participants beyond the use of the device and the internet.
62428220|NCT05279326|NO_INTERVENTION|Control arm|Participants will be at usual care and follow their usual contact with health services.
62813803|NCT02421172|EXPERIMENTAL|Period 1: CJM112 High Dose|Period 1: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses
62813804|NCT02421172|PLACEBO_COMPARATOR|Period 1: Placebo|Period 1: Placebo subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses
62428221|NCT01721967|EXPERIMENTAL|Ranolazine|Ranolazine, 500 mg for 60 days
62036566|NCT00961090|OTHER|Single-Arm|Single-Arm All subjects received 20mg/kg of Aminolevulinic Acid diluted in 50cc of water, orally, approximately 3 hours prior to surgery.
62735184|NCT00428935|EXPERIMENTAL|Low Dose|Low dose cohort - 2.0E10 vg/kg
62735185|NCT00428935|EXPERIMENTAL|High Dose|High Dose - 1.0E11 vg/kg
62735186|NCT02291783|EXPERIMENTAL|HTL0009936|HTL0009936 single and multiple ascending oral doses.
62735187|NCT02291783|PLACEBO_COMPARATOR|HTL0009936 Placebo|HTL0009936 matching placebo
62735188|NCT01236261||Fungemia|Patients with a fungal isolate from a blood culture
62735189|NCT03388801|EXPERIMENTAL|Spa therapy|Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).
62735190|NCT04499781|EXPERIMENTAL|HIV-infected youth: Intervention|"Sample population of perinatally and behaviorally, HIV-infected youth (ages 18-29 years).~Characteristics of the target study population include ethnic minority, Black and Hispanic HIV+AYA; both males and females are eligible for participation."
62036567|NCT03466333|EXPERIMENTAL|Investigational medicinal product|Oral enalapril maleate once daily: 5mg for 1 week, then 10mg for 2 weeks, then 20mg maintenance (for total of 6 months postpartum)
62036568|NCT03466333|PLACEBO_COMPARATOR|Placebo|Oral placebo once daily for 6 months postpartum
62813805|NCT02421172|PLACEBO_COMPARATOR|Period 2: CJM112 High Dose (Period 1) / Placebo (Period 2)|Period 2: Placebo subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on CJM112 High Dose in Period 1
62428222|NCT02357407|EXPERIMENTAL|Patients in intensive care|30 patients in intensive care treated with ciprofloxacin IV
62813806|NCT02421172|EXPERIMENTAL|Period 2: Placebo (Period 1)/CJM112 Low Dose (Period 2)|Period 2: CJM112 Low Dose subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on Placebo in Period 1
62428223|NCT02357407|EXPERIMENTAL|Osteoarticular infected patients|30 patients in orthopedics treated with oral ofloxacin
62813807|NCT02421172|EXPERIMENTAL|Period 2: Placebo (Period 1)/CJM112 High Dose (Period 2)|Period 2: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on Placebo in Period 1
62813808|NCT01673308|EXPERIMENTAL|Treatment arm|Lenalidomide treatment arm
62813809|NCT04842747|EXPERIMENTAL|9mg of VERU-111 Oral daily|9mg of VERU-111
62813810|NCT04842747|NO_INTERVENTION|Placebo Capsule once daily|Subjects in the Placebo treatment group will receive standard of care, plus a placebo capsule for 21 days or until released from hospital.
62036569|NCT03466333|NO_INTERVENTION|Observational arm|For participants who decline to be take part in the interventional part of the study (decline randomisation to IMP/placebo) however they consent to the observational components of the study (serial echocardiography and biomarkers postpartum).
62036570|NCT02889991|EXPERIMENTAL|High Intensity Dry Needling|Maneuver of Input-Output with the acupuncture needle, until the disappearance of local twitch responses or patient tolerance.
62036571|NCT02889991|EXPERIMENTAL|Low Intensity Dry Needling|Maximum 10 input-output maneuvers with acupuncture needle or maximum 3 local twitch responses or patient tolerance.
62428224|NCT00747422|EXPERIMENTAL|I|
62428225|NCT02493088||Antisocial personality|Individuals Diagnosed with Antisocial Personality Disorder
62428226|NCT01797952|ACTIVE_COMPARATOR|Lactobacillus CD 2 lozenges|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
62813811|NCT03893071|EXPERIMENTAL|Hydroxypropyl-β-cyclodextrin IV|Hydroxypropyl-β-cyclodextrin will be administered as Trappsol® Cyclo 25% (250mg/mL) by slow intravenous infusion over a period of 8 up to 9 hours.
62813812|NCT03728907|ACTIVE_COMPARATOR|Audiologist-adjusted first|This arm will complete the field trial with the audiologist-adjusted fitting first, followed by the user-adjustment fitting.
62813813|NCT03728907|EXPERIMENTAL|User-adjusted first|This arm will complete the trial with the user-adjusted fitting first followed by the audiologist-adjusted fitting.
62813814|NCT00623948|OTHER|Arm 1|
62813815|NCT03441477|EXPERIMENTAL|Adults 18 years old or older|Nidek Tonoref III
62813816|NCT00937352|ACTIVE_COMPARATOR|Bapineuzumab 0.5 mg/kg|0.5 mg/kg
62813817|NCT00937352|ACTIVE_COMPARATOR|Bapineuzumab 1.0 mg/kg|1.0 mg/kg
62813818|NCT00436332|EXPERIMENTAL|Erlotinib and Bevacizumab|
62813819|NCT06366737|ACTIVE_COMPARATOR|KILBON appliance|en-mass retraction by lingual retractor
62813820|NCT06366737|ACTIVE_COMPARATOR|CAT appliance|en-mass retraction by clear aligner
62813821|NCT03777358||Three-dimensional transvaginal ultrasonography (3D-TVS)|The 3D-TVS will be done by an experienced gynecological sonographer. The uterine cavity will be assessed by obtaining a mid-coronal view. Then, hysteroscopy will be performed.
62813822|NCT03223402|EXPERIMENTAL|nevirapine plus lamivudine|patients from one Center switching from a Nevirapine based Regimen on Nevirapine + 3TC
62036572|NCT02889991|EXPERIMENTAL|Fascial mechanotransduction Dry needling|Maneuver of input, screwing and pulling out of the needle acupuncture.
62036573|NCT02889991|SHAM_COMPARATOR|Placebo Dry Needling Technique|"Technique is performed with the Park´s Sham device."
62036574|NCT01889953|OTHER|EUS-guided biliary drainage|Patients in this arm will receive EUS-guided biliary drainage.
62036575|NCT04866173|EXPERIMENTAL|Dog|Being subjected to two standardised stress situations with a dog and its handler present
62428227|NCT01797952|PLACEBO_COMPARATOR|Placebo lozenges|The placebo is a mix of sugars and salts used as excipients in the active formulation
62428228|NCT04567173|EXPERIMENTAL|Anti-SARS-CoV-2 convalescent plasma|About 500 mL of type-specific anti-SARS-CoV-2 convalescent plasma collected by whole blood donation or standard pheresis from a volunteer who recovered from COVID-19 transfused intravenously as 2 aliquots of 250 mL
62428229|NCT04567173|NO_INTERVENTION|Standard of care|Patients in the control group are those will only receive local standard of care as deemed appropriate by the primary attending physicians and guided by institutional pathways
62428230|NCT05672134|EXPERIMENTAL|Experimental arm|Patients will receive 13 weeks of experimental treatment, followed by a 7 week wash-out period, continuing with 13 weeks of placebo as per crossover design.
62813823|NCT04978883||pSS-ILD|diagnosis of pSS-ILD was based on abnormal HRCT and PFTs
62813824|NCT04978883||pSS non-ILD|pSS patients after exclusion of pSS-ILD and concomitant pulmonary diseases were considered as pSS non-ILD
62813825|NCT05329246|EXPERIMENTAL|Experimental Intervention Group|AI-assisted interpretation of the ECG including the predicted ECG diagnoses, disease-specific anamnestic questions, and patient management recommendations for referral to secondary care, including suggestions for procedures and further diagnostic tests
62813826|NCT05329246|NO_INTERVENTION|Control Group|The usual standard of care, with NO AI-based diagnosis or treatment recommendation available.
62813827|NCT01349959|EXPERIMENTAL|Treatment (entinostat and azacitidine)|Patients receive azacitidine SC on days 1-5 and 8-10, and entinostat PO on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may continue azacitidine and entinostat in combination with hormonal therapy, at treating physician discretion, or undergo event monitoring.
62813828|NCT04306471|EXPERIMENTAL|Treatment arm|16 Patients with Critical Limb Ischemia on maximum statin therapy will receive in addition the study intervention involving a monthly subcutaneous injection of evolocumab 420 mg for 12 months
62036576|NCT04866173|EXPERIMENTAL|No Dog|Being subjected to two standardised stress situations without a dog present, but in the presence of a person (dog handler)
62036577|NCT06423846|EXPERIMENTAL|total intravenous anesthesia group|Patients in the TIVA group had anesthesia induced with propofol 2 mg/kg , fentanyl 1 ug/kg and maintained with propofol.
62036578|NCT06423846|EXPERIMENTAL|sevoflurane group|general anesthesia was induced with propofol 2 mg/kg, fentanyl 1 ug/kg and then maintained with sevoflurane in air and oxygen, dexmedetomidine 1 ug/kg/hour.
62036579|NCT02083133||End Stage Renal Disease|GFR 15 ml/min or less or on Dialysis
62036580|NCT02083133||Chronic Kidney Disease Stage 4|GFR 15-30 ml/min
62036581|NCT02083133||Chronic Kidney Disease Stage -3|GFR 30-60 ml/min
62036582|NCT02492100|EXPERIMENTAL|Multi-modality sexual dysfunction intervention|"- Patients in remission \> 6 months after allogeneic bone marrow transplant~* Patient Enrollment and Baseline Data Collection~* First Intervention Visit:~  * Comprehensive assessment of sexual dysfunction~ * Normalization \& Education~ * Therapeutic interventions~ * Referral to Sexual Health Clinic if applicable~* Follow-Up Intervention Visit --- Referral to Sexual Health Clinic if applicable"
62036583|NCT00902304|ACTIVE_COMPARATOR|Usual care|Physicians applied their usual pattern of patient visits and treatment strategies to achieve individualized blood pressure target
62036584|NCT00902304|EXPERIMENTAL|Monotherapy (initial monotherapy arm)|Physicians utilized valsartan 160mg per day for 6 weeks, followed by (if required) dose titrations every 4 weeks thereafter until week 14 (valsartan 320mg per day, then valsartan 320mg plus hydrochlorothiazide (HCTZ) 12.5mg per day, then valsartan 320mg plus HCTZ 25mg per day (maximal dose)). For patients not at blood pressure target at week 18, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
62036585|NCT00902304|EXPERIMENTAL|Combination (initial combination therapy arm)|Physicians initially utilized single tablet combination products of either valsartan plus hydrochlorothiazide (HCTZ) or valsartan plus amlodipine for an initial 6 weeks of therapy (based on the treating physician's preference), with dose titrations (if required) every 4 weeks thereafter until week 10. The maximum dose for the HCTZ combination was valsartan 160mg plus HCTZ 25mg per day. The maximum dose for the amlodipine combination was valsartan 160mg plus amlodipine 10mg per day. For patients who were not at blood pressure target at week 14, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
62036586|NCT01688700|EXPERIMENTAL|Nimotuzumab plus chemotherapy|
62036587|NCT06407388||Cases|"Criteria for inclusion of subjects~* Patients who enter pregnancy with a diagnosis of type I or type II diabetes mellitus.~* Pregnant women between the ages of 18-45~* Live, singleton gestation~* Understanding and ability to give informed consent~Criteria for exclusion of subjects~* Patient unwilling or unable to provide consent~* Intrauterine fetal demise (no fetal heart beat identified and documented by two physicians)~* Age less than 18 years of age~* Multifetal gestation~* Chromosomal abnormality~* Congenital infection (Toxoplasmosis, Cytomegalovirus, Rubella, Varicella Zoster, Parvovirus B19~* Major fetal congenital malformations (such as: major congenital heart defect, omphalocele, open neural tube defect, etc)"
62813829|NCT04306471|PLACEBO_COMPARATOR|Control arm|16 Patients with Critical Limb Ischemia on maximum statin therapy will receive in addition a Placebo subcutaneous injection for 12 months.
62237699|NCT01765192|EXPERIMENTAL|Roflumilast plus montelukast, then placebo plus montelukast|Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks.
62237700|NCT01765192|EXPERIMENTAL|Placebo plus montelukast, then roflumilast plus montelukast|Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks.
62237701|NCT01071135|EXPERIMENTAL|Quetiapine XR|
62813830|NCT04236427|EXPERIMENTAL|Treatment Group|Chinese Medicine of Angong Niuhuang Wan
62813831|NCT04236427|PLACEBO_COMPARATOR|Placebo Group|Placebo of Angong Niuhuang Wan
62813832|NCT06269224||There are 3 groups. 2 groups consist of runners and 1 group consists of sedentary individuals.|Participants were recreational runners who run between 20 to 50 km weekly; one group consisted of 35 runners who had been RTY, the second group consisted of 35 runners who had been running for RSM; the third group was composed of 35 sedentary individuals identified using the Sedentary Behavior Questionnaire. Participants were within the age range of 30 to 45. Exclusion criteria encompassed a history of lower extremity or lumbar-related surgery within the last year and a body mass index (BMI) exceeding the normal threshold of 24.5 kg/m².
62813833|NCT04715620|EXPERIMENTAL|niraparib|
62813834|NCT01391364|EXPERIMENTAL|SofLens in investigational solution|Bausch + Lomb SofLens daily disposable contact lens packaged in an investigational storage solution.
62813835|NCT01391364|ACTIVE_COMPARATOR|SofLens in currently marketed solution|SofLens daily disposable contact lens packaged in currently marketed storage solution.
62237702|NCT04583085||CP + CHD group|This was further divided into CP + CHDa (Subgingival plaque) and CP + CHDb (Coronary plaque) based on the nature of plaque collected.
62237703|NCT04583085||CP group|25 patients with chronic periodontitis who were systemically healthy were selected
62237704|NCT04583085||HP group|25 patients who were systemically and periodontally healthy, were considered as HP group.
62237705|NCT02437734|OTHER|Coronary angiography|Selected patients will be asked to undergo Coronary angiography with cardiac magnetic resonance imaging before and after Percutaneous Coronary Intervention. Clinical data collection will happen over a 30 month period.
62428231|NCT05672134|PLACEBO_COMPARATOR|Placebo arm|Patients will receive 13 weeks of placebo treatment, followed by a 7 week wash-out period, continuing with 13 weeks of experimental treatment as per crossover design.
62813836|NCT01861808|OTHER|lumbar puncture|That's not really an arm label because the only intervention on the patients is the lumbar puncture
62813837|NCT04199221|NO_INTERVENTION|Lecture|an initial brief lecture with no further training
62813838|NCT04199221|EXPERIMENTAL|Stress management|an initial brief lecture with stress management lecture
62813839|NCT04199221|ACTIVE_COMPARATOR|Hands-on training|an initial brief lecture with addition hands-on training for the task
62237706|NCT04390750|NO_INTERVENTION|Treatment Group 1|Treatment Group 1 will receive a standard educational booklet, a clinical oral health evaluation and a smart electronic toothbrush with no instruction on oral hygiene technique. The study coordinator will download the toothbrush data for data collection. The dental hygienist will observe the participant's normal toothbrushing technique, interdental cleaning procedures and the cleaning of partial dentures. No instruction is provided. The hygienist will provide basic instruction on proper use of the smart electronic toothbrush.
62237707|NCT04390750|EXPERIMENTAL|Treatment Group 2|Treatment Group 2 will receive a standard educational booklet, a smart electronic toothbrush, a clinical oral health evaluation with tailored instruction on oral hygiene technique and care partner coaching. The study coordinator will download the toothbrush data for data collection. The dental hygienist and interventionist will work together to fulfill the following intervention components: tailored instruction and coaching.
62237708|NCT04390750|NO_INTERVENTION|Control Group|The Control group will receive a standard educational booklet and a clinical oral health evaluation with no instruction on oral hygiene technique. The dental hygienist will observe the participant's normal toothbrushing technique, interdental cleaning procedures and the cleaning of partial dentures. No instruction is provided.
62237709|NCT04569383|EXPERIMENTAL|1x10E7 IU (low dose)|1x10E7 IU MVA-SARS-2-S. Subgroup will receive additionally Comirnaty
62813840|NCT04199221|EXPERIMENTAL|Stress management and hands-on training|an initial brief lecture with both stress management lecture and additional hands-on training
62237710|NCT04569383|EXPERIMENTAL|1x10E8 IU (high dose)|1x10E8 MVA-SARS-2-S. Subgroup will receive additionally Comirnaty
62237711|NCT02949960|EXPERIMENTAL|DMT210 Topical Gel|DMT210 Topical Gel 5% applied to target lesion twice daily
62428232|NCT03492580||Cohort 1: Canagliflozin|A target cohort which includes new users of canagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. Truven Health MarketScan Commercial Claims and Encounters Database (CCAE) 2. Truven Health MarketScan Medicare Supplemental and Coordination of Benefits Database (MDCR) 3. Truven Health MarketScan Multi-state Medicaid Database (MDCD) 4. OptumInsight's de-identified Clinformatics Datamart, Extended-Date of Death (Optum).
62428233|NCT03492580||Cohort 2: Canagliflozin with Cardiovascular Disease (CVD)|A target cohort which includes new users of canagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
62428234|NCT03492580||Cohort 3: Empagliflozin|A comparator cohort which includes new users of empagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
62813841|NCT02332538|ACTIVE_COMPARATOR|Greenlight (532nm-laser) PVEP|532nm-laser photoselective vapo-enucleation of the prostate)
62813842|NCT02332538|ACTIVE_COMPARATOR|Holmium laser enucleation of prostate|Holmium-Yag laser enucleation of the prostate
62237712|NCT02949960|PLACEBO_COMPARATOR|Vehicle Control|Topical Gel vehicle applied to target lesion twice daily
62237713|NCT01666288||IT Anaphylaxis|Blood samples will be taken from patient that develop anaphylaxis to routine outpatient allergen or venom immunotherapy.
62813843|NCT02332538|ACTIVE_COMPARATOR|Bipolar TURP|Bipolar transurethral resection of the prostate in saline
62813844|NCT02123303||Veterans|
62813845|NCT01187017|EXPERIMENTAL|Fludarabine/Cyclophosphamide in Participants with Severe Aplastic Anemia|Participants with Severe Aplastic Anemia will receive Fludarabine at 125 mg/m squared plus Cyclophosphamide at 60 mg/kg (Flu/Cy).
62813846|NCT04087018|EXPERIMENTAL|TMB-H|Participants with a tumor biomarker status of TMB-H will receive zimberelimab every 3 weeks.
62813847|NCT04087018|EXPERIMENTAL|Strata Immune Signature positive|Participants with a tumor biomarker status Strata Immune Signature positive will receive zimberelimab every 3 weeks.
62036588|NCT06407388||Controls|"The control group will be a referent population of the Human Placenta Project. This reference population consists of patients who meet the following criteria:~Maternal:~* Pregnancy Conceived Without Assisted Reproduction~* Singleton gestation~* Delivery: \>37 0/7 weeks gestation~* No gestational diabetes~* No fetal growth restriction~* No Smoking/ Alcohol/Drugs History;~* Placenta Implantation: Normal~* Fetal Umbilical Cord abnormalities: None;~Fetal- Newborn Outcomes:~* Gestational Age at Delivery: \>37 0/7~* No Congenital infection (Toxoplasmosis, Cytomegalovirus, Rubella, Varicella Zoster, Parvovirus B19~* No Major fetal congenital malformations (such as: major congenital heart defect, omphalocele, open neural tube defect, etc)~* Fetal -Newborn Weight \>10 percentile ( no Hx of FGR or SGA)"
62036589|NCT00529399|EXPERIMENTAL|1|3 injections of GAD-Alum vaccine
62036590|NCT00529399|EXPERIMENTAL|2|2 injections of GAD-Alum vaccine and one injection with Aluminum hydroxide alone
62237714|NCT03392506|EXPERIMENTAL|EBUS-TBNA-RTE|Patients do CT、 PETCT examination and EBUS-TBNA-RTE
62237715|NCT05073887|EXPERIMENTAL|3 nerve|3 genicular nerve blockade and radio frequency ablation
62237716|NCT05073887|ACTIVE_COMPARATOR|5 nerve|3 genicular nerve blockade and radio frequency ablation 2 genicular nerve blockade and pulse radio frequency
62237717|NCT03085108||SIBAT, the S-STS CMCM, and the C-SSRS + CGI-SS-R|Participants randomized to Cohort A will be consented for video-recorded interviews on 3 distinct suicide assessment instruments (the Suicide Ideation and Behavior Assessment Tool \[SIBAT\], the Sheehan-Suicidality Tracking Scale Clinically Meaningful Change Measure \[S-STS CMCM\] and the Columbia-Suicide Severity Rating Scale \[C-SSRS\] + Clinical Global Impression of Severity of Suicidality (Revised) \[CGI SS-R\]). These participants will be interviewed 3 times within the single study visit by 3 different trained clinical raters, using semi-structured interviews that have been developed for each of the 3 suicide assessment instruments.
62237718|NCT03085108||SIBAT|Participants who are not videotaped for the 3 interviews will only be assessed by SIBAT.
62237719|NCT02016833||Cancer patients|Patient with histologically confirmed diagnosis of cervical cancer or cervical intraepithelial neoplasia (grade 3) or of high-grade serous (or undifferentiated) ovarian cancer or patients with AML or CML confirmed by bone marrow biopsy or peripheral blood Not treated - prior standard of care therapy acceptable one blood sampling performed on the visit day
62237720|NCT00512304|EXPERIMENTAL|Preoperative chemoradiotherapy|
62813848|NCT04889846|EXPERIMENTAL|SAFE early intervention group|A family collaborative treatment program based on sensory strategies, activity-based motor training and environmental enrichment principles was created for the infants in the treatment group. Within the scope of the SAFE treatment approach, appropriate activities were explained to the families. Families were asked to do these activities every day for 10 weeks. The compliance of the families with the program was monitored every week via phone calls or the WhatsApp phone program. In addition, families were asked to keep a diary and note the duration of the activity. The homes of the families in the treatment group were visited at least once. During this visit, home environment was evaluated. In order to create an enriched home environment, families were informed about the toys and materials that can be obtained. The family's questions about the program were answered.
62237721|NCT00512304|EXPERIMENTAL|Postoperative chemoradiotherapy|
62237722|NCT01869257|ACTIVE_COMPARATOR|control|regular suture not coated with triclosan
62813849|NCT04889846|EXPERIMENTAL|Control group|Within the scope of this study, the infants in the control group were given an NDT-based family training program in accordance with their corrected months and current functional levels. In this context, appropriate activities were taught to families. Families were asked to do these activities every day for 10 weeks. The compliance of the families with the program was monitored every week via phone calls or the WhatsApp phone program. In addition, families were asked to keep a diary and note the duration of the activity. One visit was made to the homes of the families in the control group. The family's questions about the program were answered.
62036591|NCT00529399|PLACEBO_COMPARATOR|3|3 injections of Aluminum hydroxide alone
62036592|NCT02025881|EXPERIMENTAL|Treatment|Carboplatin + etoposide then thiotepa then Cyclophosphamide + Busilvex. If insufficient response: TEMIRI + etoposide/radiotherapy + temozolomide
62036593|NCT00951483|EXPERIMENTAL|Intervention Cohort|Patients will undergo baseline psychological and laboratory tests then receive Quetiapine-XR(Seroquel-XR) with flexible dosing at the discretion of the treating physician based on clinical response and tolerability. The dose range will be from 50-300mg. The total duration of the treatment will be 12 weeks.
62036594|NCT00951483|NO_INTERVENTION|Healthy Control|Participants without major depressive disorder or anxiety are enrolled as a comparison group without intervention.
62237723|NCT01869257|EXPERIMENTAL|triclosan|Experimental group will receive abdominal wound closure with suture matherial that is coated with triclosan
62237724|NCT02537938|EXPERIMENTAL|NGP 555|NGP 555 given once a day for 14 days as a capsule; 100 mg, 200 mg, or 400 mg
62036595|NCT05478655||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation In all patients, the assessment of anesthetic risk was carried out according to the ASA scale.The basic tool for pain intensity research was a visual analog scale.The study of the neuropathic component of pain was carried out using the diagnostic questionnaire for the detection of neuropathic pain Didier Bouhassiraa, Nadine Attala et al. Pain, 2005, 114: 29-36. Study of the presence of an acute stress reaction scale The Hospital Anxiety and Depression Scale. The presence of post-traumatic stress disorders was studied using the Mississippi scale of post-traumatic stress disorders (military version). Satisfaction with the results of treatment was studied using the Chaban Quality of Life Scale.
62036596|NCT05478655||prospective study|"Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022. Data collection was carried out during the Russian invasion of Ukraine and the offensive on Kyiv. All patients with gunshot wounds were evacuated to the stage of treatment - the National Military Medical Clinical Center Main Military Clinical Hospital. The research was conducted using the same methods as during the retrospective analysis. The exception was the study period during treatment at the military medical clinical center: here it was 14 days."
62036597|NCT01507168|PLACEBO_COMPARATOR|Placebo|
62036598|NCT01507168|EXPERIMENTAL|GC33 (RO5137382)|
62036599|NCT01371331|EXPERIMENTAL|Tacrolimus granules|oral
62036600|NCT03616548|OTHER|Intestinal transplantation|Magnifying endoscopy under NBI system via chimney ileostomy after intestinal transplantation using a novel VENCH scoring system
62036601|NCT04100005||Crohn's disease|Patients who have been diagnosed with Crohn's disease
62036602|NCT00796770|EXPERIMENTAL|Dendritic Cell Vaccine|Autologous dendritic cells generated using GM-CSF and interferon alpha, loaded with HIV lipopeptides and activated with lipopolysaccharide
62036603|NCT04014608||Baseline Control|Standard Practice before the intervention was introduced
62813850|NCT03297957|EXPERIMENTAL|Arm 1: Goggle Imaging|-Patient will then be taken to the operating room for this surgical procedure. Prior to starting the operation, the patient will undergo injection of ICG around the tumor per standard techniques while in the operating room. Those undergoing intraoperative visualization of parathyroid glands will not have any administration of ICG as these glands autofluoresce. Patients will then undergo the standard SLN biopsy procedure (those undergoing parathyroid visualization will not undergo this). The surgeon will put on the goggle system to attempt to identify the SLN using fluorescence guidance or parathryroid visualization. After this is performed, the goggle system will be removed and the procedure will be completed per normal.
62237725|NCT02537938|NO_INTERVENTION|Placebo|Placebo comparator given once a day for 14 days as a capsule.
62237726|NCT02821468|EXPERIMENTAL|Droglican|Chondroitin Sulfate 1,200mg + Glucosamine Hydrochoride 1,500mg
62813851|NCT00935181|EXPERIMENTAL|exercise training program|The exercise training program consisted of three 90-minute sessions per week for eight weeks. Each session consisted of a stretching exercise, resistance that patients started at 70% of the initial one-repetition maximum (1RM: the maximum load which can be moved only once over the full range of motion without compensatory movements) in the first week (3x8 repetitions). Every week the load was increased by 5% of the 1RM, and endurance training (treadmill walking speed was set at 60% of the average speed obtained from the 6MWT (6MWTpeak) for 10 mins in the first week and was increased to 20 mins in week 8
62813852|NCT01952132|EXPERIMENTAL|OMS643762 Low Dose|Orally administering OMS643762 low dose daily for 14 days
62813853|NCT01952132|EXPERIMENTAL|OMS643762 High Dose|Orally administering OMS643762 high dose daily for 14 days
62237727|NCT02821468|EXPERIMENTAL|Control|Untreated arm
62428235|NCT03492580||Cohort 4: Empagliflozin with CVD|A comparator cohort which includes new users of empagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
62813854|NCT01952132|PLACEBO_COMPARATOR|Placebo|Orally administering placebo daily for 14 days
62036604|NCT04014608||Intervention initiative|Standard Practice plus Admission Surveillance for toxigenic C. difficile.
62036605|NCT04351256|EXPERIMENTAL|Arm A (HYPO group)|"* Durvalumab at a fixed dose of 1,500 mg as an IV infusion over 1 hour, on day 1, to be repeated every 4 weeks (Q4W) for a maximum of 12 cycles~* Thoracic radiation therapy (TRT): hypofractionated thoracic radiotherapy consisting of 20 x 2,75 Gy (55 Gy) within 4 weeks (+9 days)"
62237728|NCT05918939|EXPERIMENTAL|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|Study product are provided in the form of liquid in vial (1 ml per vial). The vaccine will be given 1 dose (0.5 ml) once.
62237729|NCT05918939|ACTIVE_COMPARATOR|CoronaVac Biofarma COVID-1 9 Vaccine 3 µg|Control vaccine is CoronaVac Bio Farma vaccine, supplied by Ministry of Health of Indonesia, in the form of one dose vial (0.5 ml) once.
62237730|NCT05350878|EXPERIMENTAL|Implementation Intervention|Through virtual and in-person meetings, the internal/external facilitation team will support sites in utilizing the multi-component implementation strategy for 7 months
62036606|NCT04351256|ACTIVE_COMPARATOR|Arm B (CON group)|"* Durvalumab at a fixed dose of 1,500 mg as an IV infusion over 1 hour, on day 1, to be repeated every 4 weeks (Q4W) for a maximum of 12 cycles~* Thoracic radiation therapy (TRT): conventional fractions of 30 x 2 Gy (60 Gy) within 6 weeks (+9 days)"
62036607|NCT05935787|EXPERIMENTAL|Cytoflavin|
62036608|NCT05935787|PLACEBO_COMPARATOR|Placebo|
62036609|NCT03950739|EXPERIMENTAL|Tyvaso to TreT|Each subject received a corresponding dose of TreT for 3 weeks during the Treatment Phase based on the subject's current stable Tyvaso dose.
62036610|NCT05022030|EXPERIMENTAL|Arm A|mCapOX (capecitabine+oxaliplatin) plus cetuximab
62036611|NCT05022030|ACTIVE_COMPARATOR|Arm B|mFOLFOX6 (fluorouracil+leucovorin+oxaliplatin) plus cetuximab
62036612|NCT06430567|NO_INTERVENTION|Control|Patient will not use BFR
62036613|NCT06430567|PLACEBO_COMPARATOR|Placebo 10% of pressure for arterial occlusion|Patient will use BFR sub optimally as described in the literature
62036614|NCT06430567|EXPERIMENTAL|Interventional 50% of pressure for arterial occlusion|Patient will use the minimal pressure of 50% of arterial occlusion known to be effective in the literature
62036615|NCT06294184|EXPERIMENTAL|lDLPFC tdcs stimulation group|The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3, cathode is on the FP2.
62036616|NCT06294184|EXPERIMENTAL|rVLPFC tdcs stimulation group|The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F6, cathode is on the FP1.
62036617|NCT06294184|SHAM_COMPARATOR|Sham group|The current only persist in the fisrt 30s, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3/F6, cathode is on the FP2/1.
62036618|NCT01163097|EXPERIMENTAL|Palifermin 40 µg/kg and heparin IV infusion|Treatment A: palifermin 40 µg/kg/day for three consecutive days as IV bolus injections and continuous heparin IV infusion
62036619|NCT01163097|EXPERIMENTAL|Palifermin 40 µg/kg|Treatment B: palifermin 40 µg/kg/day for three consecutive days as IV bolus injections
62813855|NCT01952132|EXPERIMENTAL|OMS643762 Medium Dose|Orally administering OMS643762 medium dose daily for 14 days
62813856|NCT02777021||Early Discharge Patients|Patients receiving or having received chemotherapy for AML who are discharged to outpatient management within 3 days after chemotherapy completion. Subjects will complete a health related quality of life (HRQOL) survey at baseline and again at the start of the next treatment course. Survey questions will collect information such as patient race and educational level.
62813857|NCT02777021||Inpatient Management Patients|Patients receiving or having received chemotherapy for AML who remain in the hospital more than 3 days after chemotherapy completion. Subjects will complete a health related quality of life (HRQOL) survey at baseline and again at the start of the next treatment course. Survey questions will collect information such as patient race and educational level.
62813858|NCT01628146|EXPERIMENTAL|SUPRACOR LASIK treatment|SUPRACOR LASIK treatment
62036620|NCT01163097|NO_INTERVENTION|Control group without any treatment|Treatment C: control group without any treatment administered.
62036621|NCT01083251|EXPERIMENTAL|Peg + Vitamin D|Treatment arm with vitamin D will be treated first with vitamin D supplement for 3 months before the initiation of antiviral therapy. Vitamin D levels will be measures at baseline and three months after. The serum vitamin D-25-OH levels should be \> 32 ng/ml before the initiation of antiviral treatment). HBV DNA levels will be also measure at baseline and after 3 months of mono therapy with vitamin D
62036622|NCT01083251|ACTIVE_COMPARATOR|Peginterferon|
62036623|NCT01083251|ACTIVE_COMPARATOR|Sebivo|Nucleotide Analog Telbivudine 600 mg daily
62036624|NCT01083251|ACTIVE_COMPARATOR|entecavir + vitamin d|baraclude 1 mg x1/ day + vitamin d
62036625|NCT04494516||Pre-trial|This cohort of participants will be recruited preceding evaluation of the community-based pediatric TB prevention intervention (CHIP-TB; NCT04369326) to assist with design of the intervention and implementation strategy. Participants will include four stakeholder groups including: (1) policy makers, program managers, (2) nurse and physician clinicians, (3) community health team members, and (4) caregivers of child contacts from both South African and Ethiopian sites.
62036626|NCT04494516||Post-trial|This cohort of participants will be recruited after evaluation of the community-based pediatric TB prevention intervention (CHIP-TB; NCT04369326) to assist with future scale up and dissemination of the intervention. Participants will include four stakeholder groups including: (1) policy makers, program managers, (2) nurse and physician clinicians, (3) community health team members, and (4) caregivers of child contacts from both South African and Ethiopian sites.
62036627|NCT02648581|EXPERIMENTAL|Subcutaneous Ustekinumab|
62036628|NCT06246409|ACTIVE_COMPARATOR|Arm 1: Existing patient instructions|
62036629|NCT06246409|EXPERIMENTAL|Arm 2: Modernized patient instructions|
62596046|NCT04032106|EXPERIMENTAL|Group B (Outsmart HPV, unidirectional vaccine reminders)|Participants receive Outsmart HPV with unidirectional vaccine reminders (i.e. reminders that do not give participants the option to respond).
62596047|NCT04032106|EXPERIMENTAL|Group C (Outsmart HPV, interactive vaccine reminders)|Participants receive Outsmart HPV with interactive vaccine reminders (i.e. reminders that allow participants to respond).
62596048|NCT06420492|EXPERIMENTAL|BRS201 Arm|"In Group 1 of the study, subjects will take oral study drug at 1.2g twice daily, PO (2.4g daily) with 120mg oral butyrate twice daily (240mg daily) for 4 weeks.~In Group 3 of the study, subjects will take oral study drug at 2g twice daily, PO (4g daily) with 120mg oral butyrate twice daily (240mg daily) for 4 weeks.~In Group 3 of the study, subjects will take oral study drug at 2g twice daily, PO (4g daily) with 120mg oral butyrate twice daily (240mg daily) for 4 weeks. Subjects will also receive a one time 2.5g dose of study drug at initiation.~In Group 4 of the study, subjects will repeat the previous conditions of the group that proves to be the most effective."
62596049|NCT04926103|EXPERIMENTAL|Open label FMT therapy|FMT from a related or unrelated healthy donor screened for known communicable disease
62596050|NCT04967547|EXPERIMENTAL|Intervention group|be evaluated by using the self-care PD feasibility assessment in addition to education on renal replacement therapy and dialysis
62036630|NCT05163574|EXPERIMENTAL|High dose|20 patients
62036631|NCT05163574|ACTIVE_COMPARATOR|Low dose|20 patients
62036632|NCT05959122||group A|group (A) thirty-six non-anemic children
62036633|NCT05959122||group B|group (B) twenty five children with mild IDA
62237731|NCT05350878|NO_INTERVENTION|Implementation as Usual|In control 'implementation as usual' sites, no facilitation or implementation strategies will be provided. Controls will receive 1) an informational session on the text intervention during grand rounds/staff meetings and 2) flyers to provide patients with intervention enrollment information.
62596051|NCT04967547|ACTIVE_COMPARATOR|Control group|education on renal replacement therapy and dialysis
62596052|NCT04318522|EXPERIMENTAL|Stimulation Group|
62596053|NCT04318522|SHAM_COMPARATOR|Control Group|
62596054|NCT05285995|EXPERIMENTAL|The music group|In the music group, on the basis of the routine preoperative care, the preferred music was selected from the music library as the intervention content on the day of surgery according to the preference of the children in the 1-day preoperative visit. If there was no preference, the music was played randomly. During the intervention, the same multimedia audio system (Wanderer EDIFIER R1700BT) was used to play music for 30-40 minutes, the volume was controlled at 35-80dB, and adjusted in time according to the feedback of the children.
62596055|NCT05285995|EXPERIMENTAL|The animation group|The children in animation group also chose their favorite cartoons as the intervention content on the basis of preoperative care. The same pad (Lenovo TB3-850F) was used to play pre-selected cartoons, and volume as the music group. During the intervention period, the children in intervention group were also accompanied by a nurse, who was also responsible for the implementation and maintenance of the intervention program.
62036634|NCT05959122||Group C|group (C) 26 children with moderate
62036635|NCT05511363|EXPERIMENTAL|KarXT|Xanomeline and Trospium Chloride Capsules
62036636|NCT05511363|PLACEBO_COMPARATOR|Placebo|Placebo Capsules
62036637|NCT01556373||severe sepsis|patients with severe sepsis
62036638|NCT01556373||Controls|Controls matched to patients on age, sex and cardiovascular risk factors
62036639|NCT03185533||to reduce ED length of stay|to reduce ED length of stay to lessen ED crowding by using Lean-sigma management and quality improvement interventions including reducing boarding time and medical decision time.
62036640|NCT01417026|ACTIVE_COMPARATOR|Intranasal Oxytocin|"* Intranasal oxytocin (Trade name: Syntocinon)~* Pharmacological class: The pharmacologic and clinical properties of Syntocinon are identical with the naturally occurring hormone oxytocin, which is released from the posterior pituitary.~* Route of administration: Intranasal~* Planned exposure: Each participant will receive one dose of intranasal oxytocin (24 IU) per day for 5 days.~* One dose of 24 IU equals 6 spray puffs (3 puffs in each nostril).~* Oxytocin will be imported from Victoria Pharmacy Zurich- Switzerland."
62036641|NCT01417026|PLACEBO_COMPARATOR|Intranasal Placebo|"* Intranasal placebo~* The placebo is identical to the oxytocin formulation with the exception of the active compound.~* Route of administration: Intranasal~* Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~* One dose equals 6 spray puffs (3 puffs in each nostril).~* Placebo will be imported from Victoria Pharmacy Zurich- Switzerland."
62036642|NCT05476146|EXPERIMENTAL|Rerouting of track of high anal fistula|
62237732|NCT06513286|EXPERIMENTAL|Arm A1|HEPLISAV B® (low dose) and MVA-HBVac (low dose)
62237733|NCT06513286|EXPERIMENTAL|Arm A2|HEPLISAV B® (low dose) \& HBcoreAg (low dose) and MVA-HBVac (low dose)
62237734|NCT06513286|EXPERIMENTAL|Arm A3|HEPLISAV B® (low dose) \& HBcoreAg (low dose) and MVA-HBVac (high dose)
62237735|NCT06513286|EXPERIMENTAL|Arm A4|HEPLISAV B® (medium dose) \& HBcoreAg (medium dose) and MVA-HBVac (high dose)
62237736|NCT06513286|EXPERIMENTAL|Arm A5 (Europe)|HEPLISAV B® (low dose) \& HBcoreAg (low dose) and MVA-HBVac (high dose) or HEPLISAV B® (medium dose) \& HBcoreAg (medium dose) and MVA-HBVac (high dose
62237737|NCT06513286|EXPERIMENTAL|Arm A6 (Tanzania)|HEPLISAV B® (low dose) \& HBcoreAg (low dose) and MVA-HBVac (high dose) or HEPLISAV B® (medium dose) \& HBcoreAg (medium dose) and MVA-HBVac (high dose)
62237738|NCT06513286|EXPERIMENTAL|Arm B1|HBsAg (high dose) \& HBcoreAg (high dose) and MVA-HBVac (high dose)
62237739|NCT06513286|EXPERIMENTAL|Arm B2|HBsAg (medium dose) + c-di-AMP (low dose) \& HBcoreAg (medium dose) and MVA-HBVac (high dose)
62237740|NCT06513286|EXPERIMENTAL|Arm B3|HBsAg (high dose) + c-di-AMP (high dose) \& HBcoreAg (high dose) and MVA-HBVac (high dose)
62237741|NCT06513286|EXPERIMENTAL|Arm B4|HBsAg (medium dose) + c-di-AMP (low dose) \& HBcoreAg (medium dose) and MVA-HBVac (high dose) or HBsAg (high dose) + c-di-AMP (high dose) \& HBcoreAg (high dose) and MVA-HBVac (high dose)
62237742|NCT01087112|ACTIVE_COMPARATOR|Child Health Centre care|TAU involved scheduled health visitor calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The health visitor is encouraged to promote attachment and to detect postnatal depressions. Mothers may be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Additional treatment was initiated in 1/3 of the cases. This was registered at the end-point interview.
62237743|NCT01087112|EXPERIMENTAL|Mother-Infant Psychoanalytic tmt|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. The analyst strives to recruit the baby for an emotional interchange, though this does not imply any belief that the infant understands verbal communication. The analyst addresses the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst takes great care in enrolling the participant mother. This is to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her all space needed to vent her own frustration, depression and anxiety.
62237744|NCT04047654||Non vitamin K oral anticoagulants (NOACs)|Patients who were prescribed with apixaban, dabigatran, edoxaban, or rivaroxaban for stroke secondary prevention.
62428236|NCT03492580||Cohort 5: Dapagliflozin|A comparator cohort which includes new users of dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
62428237|NCT03492580||Cohort 6: Dapagliflozin with CVD|A comparator cohort which includes new users of dapagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
62428238|NCT03492580||Cohort 7: Empagliflozin or Dapagliflozin|A target cohort which includes new users of empagliflozin or dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
62428239|NCT03492580||Cohort 8: Empagliflozin or Dapagliflozin with CVD|A target cohort which includes new users of empagliflozin or dapagliflozin with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
62428240|NCT03492580||Cohort 9: DPP-4 inhibitor (i)/ GLP-1 agonist (a)/ other AHA|A comparator cohort which includes new users of any dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonist, or other select antihyperglycemic agents (AHA) for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
62428241|NCT03492580||Cohort 10: DPP-4 (i)/ GLP-1 (a)/ other AHA with CVD|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
62428242|NCT03492580||Cohort 11: DPP-4 (i),GLP-1 (a),TZD, SU, insulin, other AHA|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, thiazolidinediones (TZD), sulfonylureas (SU), insulin, or other select AHA for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
62428243|NCT03492580||Cohort 12: DPP-4(i), GLP-1(a), TZD, SU, insulin, AHA with CVD|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
62596056|NCT05285995|NO_INTERVENTION|The control group|No interventions except routine preoperative visits and conventional care were performed for the control group.
62596057|NCT06614465|EXPERIMENTAL|1.Experimental Group|The intervention group will receive a multimodal rehabilitation programme including therapeutic exercise, health education and manual therapy.
62237745|NCT04047654||Warfarin|Patients who were prescribed with warfarin for stroke secondary prevention.
62237746|NCT00215878|PLACEBO_COMPARATOR|1|Adjuvant 6 weeks treatment with placebo (\~2g /day)
62596058|NCT06614465|NO_INTERVENTION|2.Control Group|The control group will not receive this intervention.
62596059|NCT06649253|EXPERIMENTAL|Patients|All included patients. Bone and blood sampling
62428244|NCT02824991|EXPERIMENTAL|Deep Dry Needling|"Deep Dry Needling (DN) with the purpose of obtaining local twitch responses (LTRs). Description: Latent MTrPs were identified in both MG using according the presence of a palpable taut band and hypersensitive spot in the palpable taut band as diagnostic criteria.~The deep DN was administered by a physical therapist with three years of experience in the technique. The ultrasound video (SonoSite Titan; Sonosite, Bothell, WA, USA) was recorded at 60 frames per second captured through an external capture device from Epiphan Systems Inc. (Ottawa, Ontario, Canada). According to the perception of the physical therapist and the ultrasound assessment, the filament needle was inserted into the MTrP to achieve three LTRs. Posterior to DN application, the ROMs of the MG and HA were measured"
62813859|NCT03740048|EXPERIMENTAL|Hemodialysis and Pharmacologic Therapy|Hemodialysis regimen at the initiation of dialysis treatment: Twice-weekly hemodialysis plus adjunctive pharmacologic therapy (loop diuretic, potassium-binding agent, and sodium bicarbonate) for six consecutive weeks, continued by thrice-weekly hemodialysis (intervention group)
62813860|NCT03740048|ACTIVE_COMPARATOR|Conventional Hemodialysis Regimen|Hemodialysis regimen at the initiation of dialysis treatment: thrice-weekly hemodialysis
62813861|NCT02234843|EXPERIMENTAL|BAY59-7939|Rivaroxaban (tablets and oral suspension) Dose: Age and body weight-adjusted dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban.
62813862|NCT02234843|EXPERIMENTAL|Standard of Care|Subcutaneous low molecular weight heparin (LMWH), subcutaneous fondaparinux and/or oral vitamin K antagonist (VKA) Dose : as per standard of care
62813863|NCT02719808||Tenofovir1|100 patients receive tenofovir （300mg/d）from (28±2） weeks of pregnancy to one week after delivery.
62813864|NCT02719808||Tenofovir2|100 patients receive tenofovir （300mg/d）from (28±2） weeks of pregnancy to one month after delivery.
62813865|NCT02719808||Tenofovir3|100 patients receive tenofovir （300mg/d）from （24±2）weeks of pregnancy to one week after delivery.
62813866|NCT02719808||Tenofovir4|100 patients receive tenofovir （300mg/d）from （24±2）weeks of pregnancy to one month after delivery.
62813867|NCT02719808||Group without any treatment|100 patients don't receive any blockade therapies
62813868|NCT01131975|EXPERIMENTAL|Lamotrigine (chewable, dispersible)|Lamotrigine Tablets (chewable, dispersible),25 mg of Dr. Reddy's Laboratories Limited
62813869|NCT01131975|ACTIVE_COMPARATOR|Lamictal|Lamictal Tablets 25 mg of Glaxo SmithKline
62813870|NCT05595707|EXPERIMENTAL|Early Percutaneous dilatational tracheostomy|PDT reccomended for patients with high risk for prolonged mechanical ventilation.
62813871|NCT01218334||1|Cardiac Inpatient
62813872|NCT01218334||2|Cardiac Outpatient
62813873|NCT01218334||3|Cardiac Clinic Patient
62036643|NCT00686166|EXPERIMENTAL|Chemo + Chemo and radiation + Surgery|"Chemotherapy Cycle 1 (1 cycle is 35 days):~* Oxaliplatin, 50 mg/m\^2, IV, Days 1,8,15,22,29~* Cetuximab, 400 mg/m\^2, IV, Day 1~* Cetuximab, 250 mg/m\^2, IV, Days 8,15,22,29~* Capecitabine, 1650 mg/m\^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2:~* Oxaliplatin, 50 mg/m\^2, IV, Days 50,57,71,78~* Cetuximab, 250 mg/m\^2, IV, Days 50,57,64,71,78~* Capecitabine, 1650 mg/m\^1, PO, Monday-Friday (Day 50-84)~* Radiation therapy: Planning target value 1: 4500 cGy (centigray) in 25 fractions; Planning target value 2 (stage T3 patients): Boost of 540 cGy in 3 fractions; Planning target value 2 (stage T4 patients): Boost of 900 cGy in 5 fractions.~Therapeutic Surgical procedure: Resection"
62237747|NCT00215878|EXPERIMENTAL|2|Adjuvant 6 weeks treatment with D-serine (\~2g /day)
62237748|NCT04239521||Cases|Patients with a confirmed diagnosis of Alopecia areata within the study period will be included as cases for analysis.
62428245|NCT06311539|EXPERIMENTAL|Morning chronotype|Participants who score between 59-70 in the Morningness Eveningness Questionnaire will be assigned to the morning chronotype group.
62428246|NCT06311539|EXPERIMENTAL|Evening chronotype|Participants who score between 16-41 in the Morningness Eveningness Questionnaire will be assigned to the evening chronotype group.
62428247|NCT05818163||with postoperative complications|Patients who experience postoperative complications after anesthesia, with symptoms such as pain, nausea and vomiting, delirium, and agitation.
62428248|NCT05818163||without postoperative complications|Patients who do not experience postoperative complications after anesthesia, free from symptoms such as pain, nausea and vomiting, delirium, and agitation.
62813874|NCT06240234|OTHER|Capnodynamic method arm|Only one arm will be used since all patients will be ventilated using the novel capnodynamic method. The algoritm will then be developed by including or omitting the capnodynamic data in addition to the curve data from the arterial line.
62813875|NCT05732298|EXPERIMENTAL|active treatment|intermittent theta burst stimulation
62428249|NCT06542211|EXPERIMENTAL|Plantar Fasciitis Test Group|The experimental group received intervention and rehabilitation training directly for the limited ankle dorsiflexion function, which mainly included subtalar joint loosening (increasing the joint activity space), plantar flexor muscle group relaxation (releasing the tension of antagonist muscles), ankle dorsiflexor muscle strengthening (enhancing the strength of agonist muscles), and integrated exercises (integrating ankle dorsiflexion function into gait training).
62813876|NCT05732298|NO_INTERVENTION|waiting list|patients waiting for intervention
62813877|NCT00949468||Keratitis group|37 patients with keratitis
62813878|NCT00949468||Control Study Group|37 control volunteers
62813879|NCT04731636|EXPERIMENTAL|G-Branch Thoracoabdominal Aortic Stent System|Patients with Crawford type I-V thoracoabdominal aortic aneurysms and Pararenal abdominal aortic aneurysm, and passed the screening and signed the Informed Consent Form
62813880|NCT00286728|EXPERIMENTAL|Arm 1|Intensive referral to dual-focused self-help groups
62813881|NCT00286728|NO_INTERVENTION|Arm 2|Usual care
62813882|NCT01349608|EXPERIMENTAL|Health coaching|
62813883|NCT02125396|EXPERIMENTAL|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
62813884|NCT02125396|ACTIVE_COMPARATOR|Transarterial chemoembolization|Adjuvant transarterial chemoembolization \[5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)\]
62813885|NCT02426580|EXPERIMENTAL|Intervention with wechat group|The wechat model will provide information of protein, calcium, phosphorus and sodium intake, which were suggested by the current KDIGO/ KDOQI guideline.
62813886|NCT02426580|NO_INTERVENTION|Controlled group|Only conventional education every 3 months during routing clinical visit
62813887|NCT01873937|EXPERIMENTAL|Red LED|Irradiation parameters: 630 nm, 60 sec and 18 J/cm² per point.
62813888|NCT01873937|EXPERIMENTAL|infrared LED|Irradiation parameters: 850 nm, 60 sec and 18J/cm² per point
62813889|NCT01873937|ACTIVE_COMPARATOR|LASER|Irradiation parameters: 780 nm, 60 sec and 105 J/cm²
62813890|NCT06460545|EXPERIMENTAL|sIPV + HepA-L (coconmitant vaccination cohort)|Concomitant administration of sIPV and HepA-L at 18 months of age
62813891|NCT06460545|EXPERIMENTAL|sIPV + HepA-I (coconmitant vaccination cohort)|Concomitant administration of sIPV and HepA-I at 18 months of age, and another dose administration of HepA-I at 24 months of age
62036644|NCT05228600|EXPERIMENTAL|YL-13027|"YL-13027 is a novel small molecule TGF-βR1 inhibitor. 1.1.1. Chemical Properties~Chemical Name:~6-(5-fluoro-2-(6-methylpyridin-2-yl)phenyl)imidazo\[1,2-a\]pyridine-3-carboxamide Molecular Formula C20H15FN4O Molecular Weight 346.36 Formulation YL-13027 is provided as pink film coated tablets for oral administration in two strengths, 30 mg and 120 mg.~Packaging and Storage YL-13027 tablets are packaged (30 tablets/bottle) in the 45 mL opaque HDPE bottles with child resistant polypropylene caps, induction-sealed inner polypropylene liners. YL-13027 tablets should be protected from light in a closed container and stored at room temperature.~Stability The shelf-life of YL-13027 oral tablets is tentatively set at 24 months when stored at room temperature."
62036645|NCT02111590||IVIG to SCIG|Patients with CIDP or MMN in maintenance therapy with IVIG every 3rd to 6th week are shifted to weekly SCIG treatment in unaltered dose.
62813892|NCT06460545|EXPERIMENTAL|sIPV (individual vaccination cohort)|One booster dose of sIPV at 18 months of age
62813893|NCT06460545|EXPERIMENTAL|HepA-L (individual vaccination cohort)|One dose of Hep-L at 18 months of age
62813894|NCT06460545|EXPERIMENTAL|HepA-I (individual vaccination cohort)|Two doses of Hep-I at 18 and 24 months of age, respectively
62813895|NCT01943643|EXPERIMENTAL|CT angiography, coronary bifurcations|
62813896|NCT03507257||Early Onset Alzheimer's Disease (EOAD)|"* Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia~* Amyloid positive status (florbetaben PET scan with evidence of elevated amyloid as determined by a central read)~* CDR score ≤ 1.0~* flortaucipir (18F-AV-1451) PET scanning"
62813897|NCT03507257||Cognitively Normal (CN) Controls|"* Meets criteria for cognitively normal, based on an absence of significant impairment in cognitive functions and activities of daily living~* Mini-Mental State Exam score between 26-30~* CDR score = 0~* flortaucipir (18F-AV-1451) PET scanning"
62813898|NCT03507257||Early Onset non-Alzheimer's Disease (EOnonAD)|"* Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia~* Amyloid negative status (florbetaben PET scan with no evidence of elevated amyloid as determined by a central read)~* CDR score ≤ 1.0~* flortaucipir (18F-AV-1451) PET scanning"
62813899|NCT04855916|EXPERIMENTAL|ABLE Exoskeleton - KAFO|Participants belonging to this arm start the study by performing the training program using the ABLE Exoskeleton. After the resting period, they repeat the training program using KAFO orthoses.
62813900|NCT04855916|EXPERIMENTAL|KAFO - ABLE Exoskeleton|Participants belonging to this arm start the study by performing the training program using the KAFO orthoses. After the resting period, they repeat the training program using the ABLE Exoskeleton.
62036646|NCT02111590||SCIG to SCIG|Patients with CIDP or MMN in maintenance therapy with SCIG (Subcuvia(R) or Hizentra(R)) are shifted to treatment with Gammanorm(R) in unaltered weekly dose.
62036647|NCT03955601|EXPERIMENTAL|TBI free Haploidentical HSCT|Recipients will receive a reduced intensity conditioning regimen of ''Fludarabine'' 30 mg/m2 IV daily from day -7 to -3, ''Cyclophosphamide'' 14.5-30 mg/kg IV daily on day -6 and -5 , ''rabbit Antithymocyte globulin'' 5 mg /kg/day from day -6 to day-3; ''Busulphan'' IV 3.2 mg per kg/day in 02 divided doses on day -3 and day-2, ''Granulocyte Colony Stimulating factor primed Bone marrow harvest'' and/OR ''PBSC'' graft on day 0 and day +1 respectively and Graft versus host disease prophylaxis with ''post-transplant cyclophosphamide'' administered at a dose of 50mg/kg/day given daily on days +3 and +5 post-transplant and ''cyclosporine'' from day +5, ''mycophenolate mofetil'' from day+5 to day+35.
62596060|NCT06076304|ACTIVE_COMPARATOR|antibiotic|amoxicillin/clavulanate
62813901|NCT03828032|EXPERIMENTAL|Mannitol injection|The participant receive mannitol injection to decrease intracranial pressure in the ward with optical probes on his/her forehead.
62596061|NCT06076304|PLACEBO_COMPARATOR|placebo antibiotic|placebo antibiotic
62813902|NCT03828032|EXPERIMENTAL|Hypertonic saline injection|The participant receive hypertonic saline of specific concentration injection to decrease intracranial pressure in the ward with optical probes on his/her forehead.
62813903|NCT04938908|EXPERIMENTAL|Ophthalmic probiotic|1 active drop in each eye/ 5 hours plus oral placebo capsule, for 4 weeks
62813904|NCT04938908|PLACEBO_COMPARATOR|Placebo|1 placebo drop in each eye/ 5 hours plus oral placebo capsule, for 4 weeks
62813905|NCT04938908|EXPERIMENTAL|Opthalmic Probiotic + Oral Probiotic|1 active drop in each eye/ 5 hours plus oral probiotic capsule, for 4 weeks
62813906|NCT04938908|EXPERIMENTAL|Oral Probiotic|1 placebo drop in each eye/ 5 hours plus oral probiotic capsule, for 4 weeks
62596062|NCT06076304|ACTIVE_COMPARATOR|antibiotic plus intranasal corticosteroid|amoxicillin/clavulanate plus budesonide
62596063|NCT06076304|OTHER|placebo antibiotic plus intranasal corticosteroid|placebo antibiotic plus budesonide
62813907|NCT03659266|ACTIVE_COMPARATOR|Group 1|"D0: Injection of Botulinum toxin A in triceps surae, according to pre-established modalities (no influence of the experimental protocol on this stage) W2-W4: Robotic walking rehabilitation by Lokomat® in the functional rehabilitation department (conventional hospitalization) W4-W6: Return to home, wash-outperiod W6-W8: Conventional walking rehabilitation in the functional rehabilitation department (conventional hospitalization)"
62813908|NCT03659266|ACTIVE_COMPARATOR|group 2|"D0: Injection of Botulinum toxin A in triceps surae W2-W4: Conventional walking rehabilitation in the functional rehabilitation department (conventional hospitalization) W4-W6: Return to home, wash-outperiod W6-W8: Robotic walking rehabilitation by Lokomat® in the functional rehabilitation department (conventional hospitalization)"
62813909|NCT02306330|EXPERIMENTAL|Malditof|Specimens of patients (diagnostic aspirates from normally sterile sites: cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies) in Malditof arm will be performed by Malditof instrument to identify the pathogens. It takes 20 minutes for Malditof to identify the pathogens. Then patients will be treated based on these results.
62813910|NCT02306330|ACTIVE_COMPARATOR|Routine clinical microbiology|Specimens of patients (diagnostic aspirates from normally sterile sites: cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies) in routine clinical microbiology arm will be conducted by the routine clinical microbiologies and followed the treatment process of the hospital.
62813911|NCT05933135||Normal factor XIII acitivity|Patients with GI bleeding and normal factor XIII activity
62813912|NCT05933135||Reduced factor XIII activity|Patients with GI bleeding and reduced factor XIII activity
62813913|NCT02649413|EXPERIMENTAL|Early response to prednisone treatment|intervention -children that will have a remission in 8 days (response) will get an adjusted steroids dose treatment.children that have a remission between 9-28 days will get a regular steroid dose.
62813914|NCT02404961||Control (no vulvodynia)|Clinically-confirmed as a woman with no history of vulvodynia.
62813915|NCT02404961||Vulvodynia Case|Clinically-confirmed as a woman with vulvodynia.
62813916|NCT01025908|EXPERIMENTAL|Cognitive Behavioral Therapy|25 panic disorder patients
62813917|NCT01025908|ACTIVE_COMPARATOR|Supportive psychotherapy|25 panic disorder agoraphobia
62813918|NCT03341299|EXPERIMENTAL|LY900014 Before Meal|Individualized dose of LY900014 administered subcutaneously (SC) immediately before meal in one of four study periods.
62813919|NCT03341299|EXPERIMENTAL|LY900014 After Meal|Individualized dose of LY900014 administered SC 20 minutes after start of meal in one of four study periods.
62237749|NCT04239521||Controls|The control cohorts will be defined by matching cases with patients who have never been diagnosed with Alopecia areata either prior to or during the study period, by age and sex, at General Practice practice level.
62237750|NCT01138007|EXPERIMENTAL|323U66 SR 150 mg cohort|323U66 SR 150 mg tablet is orally administered once in the morning and 323U66 SR 150 mg placebo tablet is orally administered once in the evening throughout the treatment phase.
62813920|NCT03341299|ACTIVE_COMPARATOR|Insulin Lispro (Humalog) Before Meal|Individualized dose of insulin lispro administered SC immediately before meal in one of four study periods.
62813921|NCT03341299|ACTIVE_COMPARATOR|Insulin Lispro (Humalog) After Meal|Individualized dose of insulin lispro administered SC 20 minutes after start of meal in one of four study periods.
62813922|NCT04108364|EXPERIMENTAL|VoiceAdapt Intervention|PWA who train with VoiceAdapt app
62813923|NCT04108364|NO_INTERVENTION|No Intervention|PWA who are on the waitlist and not training with VoiceAdapt app
62813924|NCT04401371||Hybrid learning group|students enrolled in hybrid learning pediatric dentistry course
62813925|NCT04401371||distance learning group|students enrolled in distance learning pediatric dentistry course
62813926|NCT01821079|EXPERIMENTAL|PF-05175157 PIC in fed state|200 mg single dose of PF-05175157 administered as PIC in the fed state (following a standard high fat meal).
62813927|NCT01821079|EXPERIMENTAL|PF-05175157 tablet in fed state|200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).
62813928|NCT01821079|EXPERIMENTAL|PF-05175157 tablet in fed state (repeat)|200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).
62813929|NCT01821079|EXPERIMENTAL|PF-05175157 tablet in fasted state|200 mg single dose of PF-05175157 administered as tablet formulation in the fasted state (following at least a 10 hour fast).
62813930|NCT00104585||Young onset Parkinson's disease|People with young onset Parkinson's disease and their family members
62813931|NCT06473727|ACTIVE_COMPARATOR|Omnichoroma|Anterior non-carious cervical lesions restored with Omnichoroma single-shade resin composite.
62596064|NCT01891565|EXPERIMENTAL|Activity Feedback|Feedback
62596065|NCT01891565|NO_INTERVENTION|No Feedback|
62596066|NCT05293873|EXPERIMENTAL|Treatment (BM-MNC trasnplatation)|Autologous bone marrow-derived mononuclear cell will transplant at baseline, and the second transplantation will be performed 6 months after the first transplantation and combination with rehabilitation therapy
62813932|NCT06473727|ACTIVE_COMPARATOR|Charisma Topaz One|Anterior non-carious cervical lesions restored with Charisma Topaz One single-shade resin composite.
62813933|NCT04663607|NO_INTERVENTION|Control|Participants will receive paper-based health education as part of standard of care
62237751|NCT01138007|EXPERIMENTAL|323U66 SR 300 mg cohort|323U66 SR 150 mg tablet is orally administered once in the morning and 323U66 SR 150 mg placebo tablet is orally administered once in the evening during the first week of the treatment phase. At the second week, 323U66 SR 300mg cohort is up-titrated to a daily dose of 323U66 SR 300 mg, administered as 323U66 SR 150 mg tablet twice daily in the morning and in the evening, and the same daily dose is maintained to administer until the end of the treatment phase.
62596067|NCT05293873|OTHER|Control group|rehabilitation therapy
62813934|NCT04663607|EXPERIMENTAL|PretermConnect App|Participants will receive health education via a mobile app, PretermConnect
62813935|NCT05953181|EXPERIMENTAL|Active surveillance|
62813936|NCT05953181|ACTIVE_COMPARATOR|Standard esophagectomy|
62036648|NCT03594669|EXPERIMENTAL|Intervention|"When enrolled into the study, the participants will be asked to join a group in WhatsApp for purposes of the research study. The application will be used to: deliver reminders for each treatment session; deliver daily prompts for the home exercise program; and present a web-link to the home exercise program (HEP).~Participants will receive physical therapist delivered multi-modal sensorimotor training interventions. The exercises delivered at each intervention will be delivered in a group format, using a circuit of exercises that each athlete will complete in a session. Subsequent sessions will build upon previous sessions to work the sensorimotor control system in progressively more challenging and sport-specific scenarios. This present study will complete 8 sessions over 4 weeks."
62036649|NCT02557152||Patients that were treated with the GentleWave System|
62036650|NCT05557045|EXPERIMENTAL|Dose Exploration (Part A): JZP815|Participants will receive JZP815 with a starting dose of 20 mg twice daily (BID).
62036651|NCT05557045|EXPERIMENTAL|Expansion (Part B): JZP815|Participants with advanced or metastatic solid tumors who will receive JZP815 at the RP2D established in Dose Exploration (Part A).
62036652|NCT02925455|EXPERIMENTAL|Stimulation + Video Games|Contralaterally-controlled functional electrical stimulation (CCFES) enables patients with upper extremity hemiplegia to open their paretic hand by stimulating finger and thumb extensors with surface electrodes. CCFES is used during functional task practice and hand therapy video games to link motor intent with execution. Four intuitive and engaging games were developed to provide goal-oriented motor skill training, impairment-appropriate difficulty, and performance feedback that motivates iterative play and skill improvement.
62036653|NCT02925455|ACTIVE_COMPARATOR|Video Games (no stimulation)|Participants receive duration-matched, identical hand therapy video games and task practice therapy as the experiment arm, but do not receive CCFES to assist hand opening.
62596068|NCT05743101|EXPERIMENTAL|Levofloxacin group|Levofloxacin 200mg twice per day is administrated.
62596069|NCT05743101|PLACEBO_COMPARATOR|Levofloxacin simulant group|Levofloxacin simulant 200mg twice per day is administrated.
62596070|NCT02089958||Laparoscopic incisional hernia repair|Incisional hernia, LIPOM
62596071|NCT01946893|EXPERIMENTAL|Mindfulness Meditation|One session per week for 6 weeks online through study iPAD. The intervention is a standardized and structured program. The objectives are to: 1) help participants understand their personal reactions to stress, 2) teach them skills to modify their stress reactions, and 3) promote their desire for self-care and feelings of competence and mastery.
62036654|NCT05338333|OTHER|LID210464, then AOHG MF|Lehfilcon A multifocal contact lenses (LID210464) worn in Period 1, with lotrafilcon B multifocal contact lenses (AOHG MF) worn in Period 2, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 30 days. CLEAR CARE® will be used for nightly contact lens cleaning and disinfecting.
62036655|NCT05338333|OTHER|AOHG MF, then LID210464|Lotrafilcon B multifocal contact lenses (AOHG MF) worn in Period 1, with lehfilcon A multifocal contact lenses (LID210464) worn in Period 2, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 30 days. CLEAR CARE® will be used for nightly contact lens cleaning and disinfecting.
62036656|NCT01788748|ACTIVE_COMPARATOR|bipolar radiofrequency and infrared|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only bipolar radiofrequency potentiated by infrared, 3 treatments one month apart.
62036657|NCT01788748|ACTIVE_COMPARATOR|fractional bipolar radiofrequency|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only fractional bipolar radiofrequency , 3 treatments one month apart.
62036658|NCT01788748|ACTIVE_COMPARATOR|combined treatment|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive first bipolar radiofrequency potentiated by infrared, followed in the same session by fractional bipolar radiofrequency, 3 treatments one month apart.
62036659|NCT01952626|ACTIVE_COMPARATOR|ondansetron|Intravenous administration of ondansetron 4mg 15 minutes before spinal anesthesia
62036660|NCT01952626|EXPERIMENTAL|palonosetron|Intravenous administration of palonosetron 0.075mg 15 minutes before spinal anesthesia
62036661|NCT06063226|EXPERIMENTAL|Probiotics|Patients who will be assigned to oral consumption of one stick of probiotics with L. plantarum and L. rhamnosus for 30 days, in adjucntion to routinary oral hygiene procedures.
62036662|NCT06063226|PLACEBO_COMPARATOR|Positive Control|Patients who will be assigned to oral consumption of one stick of placebo for 30 days, in adjucntion to routinary oral hygiene procedures.
62036663|NCT06063226|OTHER|Negative control|Patients who will be assigned to routinary oral hygiene procedures esclusively.
62036664|NCT05019430|PLACEBO_COMPARATOR|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
62036665|NCT05019430|EXPERIMENTAL|Zolmitriptan Dose 1|Subjects will be maintained on oral zolmitriptan dose 1. Cocaine will be administered acutely during zolmitriptan dose 1 maintenance. Placebo will be administered acutely during zolmitriptan dose 1 maintenance.
62036666|NCT05019430|EXPERIMENTAL|Zolmitriptan Dose 2|Subjects will be maintained on oral zolmitriptan dose 2. Cocaine will be administered acutely during zolmitriptan dose 2 maintenance. Placebo will be administered acutely during zolmitriptan dose 2 maintenance.
62036667|NCT05019430|EXPERIMENTAL|Zolmitriptan Dose 3|Subjects will be maintained on oral zolmitriptan dose 3. Cocaine will be administered acutely during zolmitriptan dose 3 maintenance. Placebo will be administered acutely during zolmitriptan dose 3 maintenance.
62036668|NCT00615043||TURBT group|Subjects undergoing transurethral resection of bladder tumor or other transurethral biopsy procedure who agree to provide bladder tissue specimens
62596072|NCT01946893|ACTIVE_COMPARATOR|Education|Education sessions- 1 session per week for 6 weeks on study iPAD.
62813937|NCT03972059|EXPERIMENTAL|Experimental group|A 12-week high intensity interval circuit training program for weight management in overweight adults.
62036669|NCT06703060|EXPERIMENTAL|Intervention Group (Peer Navigation)|Participants randomized to this arm will receive 4 weekly group sessions and 4 one-on-one sessions with a peer navigator
62036670|NCT06703060|PLACEBO_COMPARATOR|Control Group|Participants randomized to this group will receive a single group session
62036671|NCT01270126|EXPERIMENTAL|rtACS (Verum condition)|Repetitive transorbital alternating current stimulation (rtACS)
62036672|NCT01270126|NO_INTERVENTION|Sham stimulation (placebo condition)|A clicking sound was presented and the same electrode montage set-up was used during rtACS- and placebo-stimulation, except that placebo patients received no current (stimulator turned off)
62036673|NCT03896035|NO_INTERVENTION|Waitlist Control Group|The waitlist control group will continue with management of chronic back pain and depression per usual care. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant. Subjects randomized to the waitlist control group will be offered the same intervention once the active intervention group has completed the active sessions and assessments.
62237752|NCT01138007|PLACEBO_COMPARATOR|Placebo cohort|323U66 SR placebo tablet is orally administered twice daily throughout the treatment phase.
62237753|NCT04643509||cardiac surgery|patients benefiting from pulmonary arterial catheter monitoring after cardiac surgery
62237754|NCT02593591||Biomarker group|Advanced cancer undergoing genomic profiling
62237755|NCT02536703|EXPERIMENTAL|Lotus Valve System|Transcatheter Aortic Valve Implantation (TAVI) with Lotus Valve System
62428250|NCT06542211|ACTIVE_COMPARATOR|Plantar fasciitis conventional rehabilitation group|Conventional rehabilitation for plantar fasciitis mainly focuses on relaxing the plantar fascia, gastrocnemius and plantar flexor muscles and strengthening the small muscle groups of the plantar foot.
62428251|NCT00309413|ACTIVE_COMPARATOR|1|Cannabidiol/Placebo
62428252|NCT00309413|PLACEBO_COMPARATOR|2|Placebo/Cannabidiol
62428253|NCT03548324|ACTIVE_COMPARATOR|HHHFNC|Heated Humidified High Flow Nasal Cannulae
62428254|NCT03548324|ACTIVE_COMPARATOR|NCPAP|Nasal Continuous Positive Air Pressure
62428255|NCT00770354|EXPERIMENTAL|1|AS1402 plus letrozole
62813938|NCT03972059|NO_INTERVENTION|Control group|No intervention for 12 weeks, participants perform all tests.
62036674|NCT03896035|EXPERIMENTAL|Behavioral Intervention Group|For participants assigned to the intervention arm, trained health coaches will deliver the intervention via telephone. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant.
62237756|NCT05147623||Principal cohort|All patients recruited in one week who underwent to any surgical procedure that meet inclusion criteria of the study.
62237757|NCT04217590|EXPERIMENTAL|Sodium Zirconium Cyclosilicate (SZC)|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.
62237758|NCT04217590|PLACEBO_COMPARATOR|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
62237759|NCT03493841|EXPERIMENTAL|Group A|Group A will receive racemic lipoic acid first and R-lipoic acid second
62237760|NCT03493841|EXPERIMENTAL|Group B|Group B will receive R- lipoic acid first and racemic lipoic acid second
62237761|NCT01594866|PLACEBO_COMPARATOR|Escitalopram, 20mg, placebo|escitalopram 20mg + placebo (same taste, appearance, texture of escitalopram 10mg)
62237762|NCT01594866|EXPERIMENTAL|Escitalopram 20mg, escitalopram 10mg|Escitalopram 20mg + Escitalopram 10mg
62237763|NCT02231125|EXPERIMENTAL|Abelmoschus manihot (AM)|Abelmoschus manihot (AM): Huangkui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
62237764|NCT02231125|EXPERIMENTAL|Losartan|Losartan potassium (Hangzhou MSD Pharmaceutical Co., Ltd.), 100 mg × 7 capsules/box.
62428256|NCT00770354|ACTIVE_COMPARATOR|2|Letrozole
62428257|NCT01072916||IBS|Subjects with IBS-D
62428258|NCT01072916||Healthy|Healthy Subjects
62428259|NCT00724074|EXPERIMENTAL|S|Patients receive the On-Q local continuous wound infusion system intra-operatively and use it for up to three days post-operatively.
62428260|NCT00724074|ACTIVE_COMPARATOR|C|Usual care - post operative pain medications as per the knee arthroplasty care map.
62428261|NCT05723341|ACTIVE_COMPARATOR|Paravertebral Block Group|In this group, preoperative ultrasound-guided paravertebral block will be performed ipsilateraly via peripheral block needle with 20 ml bupivacaine %0,25 in the paravertebral space.
62428262|NCT05723341|ACTIVE_COMPARATOR|Subcostal Transversus Abdominis Plane Block Group|In this group, preoperative ultrasound-guided subcostal transversus abdominis plane block will be performed ipsilateraly via peripheral block needle with 20 ml bupivacaine %0,25 into the fascial plane between erector spine muscle and transverse process
62813939|NCT03874546|EXPERIMENTAL|Prognostic evaluation|Questionnaire at Day1, Day7 and 6 months.
62813940|NCT04006041|EXPERIMENTAL|Toripalimab group|All patients will receive standard fractionation radiation therapy (RT) scheme: 44Gy in 20 fractions over 4 weeks, concurrently with 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 and 2 cycles of toripalimab 240 mg on days 1, 22. Esophagectomy is performed 6-8 weeks after CRT completion.
62428263|NCT05723341|ACTIVE_COMPARATOR|Intravenous Patient Controlled Analgesia|In this group, postoperative patient controlled analgesia with morphine will be preferred for postoperative analgesia method.
62428264|NCT04975282||Bottle Feeding|The bottle feeding method was being used in the NICU (1 January -31 December 2018).
62036675|NCT00045110|EXPERIMENTAL|Phase 1 Dose Escalation|"Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~erlotinib hydrochloride given orally~Other: pharmacological study."
62596073|NCT00003134|EXPERIMENTAL|Arm I: irinotecan|"Patients receive irinotecan IV over 90 minutes on days 1, 8, 15, and 22. This is followed by a 2 week rest and continues for a maximum of 6 courses. Patients who received prior nitrosoureas, also receive reduced starting doses of irinotecan. The dosages may be increased once per patient after the first course if toxic effects are acceptable.~Patients are followed every 3 months for the first year, every 6 months for the next 4 years, then annually until death."
62596074|NCT00003134|EXPERIMENTAL|Arm II: irinotecan|"Patients receive irinotecan on day 1 every 3 weeks for up to 12 courses. Patients who received prior nitrosoureas receive reduced starting doses of irinotecan. The dosages may be increased once per patient after the first course if toxic effects are acceptable.~Patients are followed every 3 months for the first year, every 6 months for the next 4 years, then annually until death."
62036676|NCT00045110|EXPERIMENTAL|Phase 2 recurrent malignant gliomas and nonprogressive GBM|"Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose (150mg/day.~patients requiring surgery treated 7 days prior to tumor removal (150mg/day)~PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR)~erlotinib hydrochloride given orally~Other: pharmacological study, laboratory biomarker analysis."
62237765|NCT02673151|EXPERIMENTAL|68Ga-PSMA-11 PET/CT|Patients receive 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11). Participant will be injected IV with 3 to 7 millicurie (mCi) of 68Ga-PSMA-11. Beginning 50 to 100 minutes later, a low-dose computed tomography (CT) scan will be obtained from vertex to mid thighs; followed by a static positron emission tomography (PET) scan over the same .
62237766|NCT01375361|EXPERIMENTAL|Inhaled Albuterol|Patients identified to have Cardiogenic Pulmonary Edema, will receive 2.5mg of Albuterol nebulizer on enrollment in the study and again at 4 hours. Patients will be monitored on telemetry in the emergency department during and after study drug administration. Although study drug administration will cease after 4 hours, we will continue to record ongoing data during the patient's hospitalization.
62428265|NCT04975282||Cup Feeding|The cup feeding method was being used in the NICU (1 January -31 December 2019).
62596075|NCT02899559|EXPERIMENTAL|Control|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. The control group will read only summary information about the David Pottruck Health and Fitness Center.
62596076|NCT02899559|EXPERIMENTAL|Nudge Message|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. The nudge message encourages participants to make a plan for when they will exercise at the gym during the next week.
62596077|NCT02899559|EXPERIMENTAL|Boost Message|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. Those in the Boost condition will also have summary information about the Pottruck gym but will also be given information about why an implantation intention is an effective way to attain long term goals. They will also be given a prompt to form an implementation intention.
62036677|NCT00874861|EXPERIMENTAL|Vaccine + Poly-ICLC|Peptide Vaccine + Poly-ICLC
62428266|NCT00568152|EXPERIMENTAL|Low PA apple puree|230grams of low PA apple puree (Golden Delicious) consumed daily for 14 days.
62428267|NCT00568152|EXPERIMENTAL|High PA apple puree|High PA apple puree (Mitchalin) 230grams consumed daily for 14 days
62428268|NCT00568152|PLACEBO_COMPARATOR|Aspirin|75mg dispersable aspirin taken daily for 14 days
62428269|NCT06256731||Single cohort of MS patients with EDSS 1.0-4.5|Confirmed diagnosis of MS with an EDSS score ranging from 1.0 and 4.5.
62596078|NCT03598920||AspireAssist|Patients undergoing the endoscopic bariatric procedure using the AsspireAssist device
62596079|NCT03598920||Nutritional consulting|Patients undergoing nutritional consulting
62596080|NCT05172973|EXPERIMENTAL|Transcatheter Aortic Valve Replacement (TAVR) - Surgical Valve|TAVR implant in subjects with a failing aortic surgical valve.
62596081|NCT05172973|EXPERIMENTAL|Transcatheter Aortic Valve Replacement (TAVR) - THV|TAVR implant in subjects with a failing aortic transcatheter heart valve (THV).
62237767|NCT01375361|PLACEBO_COMPARATOR|Inhaled Placebo.|Patients identified to have Cardiogenic Pulmonary Edema will receive 2.5mg Normal saline inhaled (Placebo) on enrollment and at 4 hours in the emergency department. Patient will be monitor on telemetry in the emergency department during and after placebo administration.
62237768|NCT01050348|ACTIVE_COMPARATOR|Atorvastatin calcium|Patients will receive study medication upon admission to hospital prior to percutaneous intervention of the culprit artery
62237769|NCT01050348|PLACEBO_COMPARATOR|Sugar Pill|Patients will receive study medication upon admission to hospital prior to percutaneous intervention of the culprit artery
62237770|NCT06027723|EXPERIMENTAL|Nicotine|Participants will follow a standard vape protocol designed to deliver the approximate nicotine typically consumed from 1 cigarette (1.25 mg)
62428270|NCT04416828||Suspected ganglion cyst of the wrist or hand|Patients with suspected ganglion cyst of the wrist or hand receive portable wireless ultrasound imaging AND cart-based ultrasound imaging before surgery.
62428271|NCT05385471|EXPERIMENTAL|Group 1|8+1 volunteers receiving three doses of 10 µg R78C with 50 µg of Matrix-M on days 0, 28 and 182 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
62428272|NCT05385471|EXPERIMENTAL|Group 2|8+1 volunteers receiving three doses of 10 µg R78C + 10 µg RH5.1 with 50 µg of Matrix-M on days 0, 28 and 182 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
62428273|NCT05385471|EXPERIMENTAL|Group 3|8+1 volunteers receiving three doses of 10 µg RH5.1 with 50 µg of Matrix-M on days 0, 28 and 56 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
62428274|NCT05385471|EXPERIMENTAL|Group 4|8+1 volunteers receiving two doses of 10 µg R78C + 10 µg RH5.1 with 50 µg of Matrix-M on days 0, 28, one dose of 10 µg R78C with 50 µg of Matrix-M on day 182 and one dose of 10 µg RH5.1 with 50 µg of Matrix-M on day 210, all administered via intramuscular (IM) injection in the deltoid region of the non-dominant arm
62428275|NCT05124431|EXPERIMENTAL|Anlotinib hydrochloride+Everolimus|"Anlotinib hydrochloride: ,12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).~Everolimus:5mg po. qd in 21-day cycle"
62428276|NCT03162354|EXPERIMENTAL|Intervention Sites|"At the four intervention sites, investigators will deploy active, multifaceted, implementation strategies designed to promote CDR acceptability and application as an AHT screening tool. These strategies will include physician training with onsite visits, monthly booster training emails, access to an AHT probability calculator, audit and site-specific feedback, and local information sharing sessions designed to address local barriers to CDR acceptance and application."
62428277|NCT03162354|NO_INTERVENTION|Control Sites|"At the four matched control sites, physicians will engage in AHT screening as usual."
62428278|NCT02127229|NO_INTERVENTION|Blinded observation of ERCP|Blind observation of disposable accessories use.
62428279|NCT02127229|EXPERIMENTAL|Endoscopist informed of cost per procedure|Endoscopists informed following each ERCP.
62428280|NCT04185831|EXPERIMENTAL|NF1/MAP2K1|Cobimetinib, 60mg po daily. 28 day cycle; day 1-21 60mg daily, day 22-28 rest period.
62596082|NCT01943851|EXPERIMENTAL|Part 1: GSK525762 QD Cohort|Subject will be administered a 5 milligram (mg) starting dose of GSK525762, oral tablets, QD. Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM for QD dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.
62596083|NCT01943851|EXPERIMENTAL|Part 1: GSK525762 BID Cohort|Subject will be administered a starting dose of GSK525762, oral tablets, 20 mg BID (12 hours apart, total daily dose of 40 mg). Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM, for BID dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.
62036678|NCT04447326|EXPERIMENTAL|IC＋CCRT＋Toripalimab＋Endostar|Three cycles of induction chemotherapy with GP regimen (Q3W): Gem 1000 mg/m2 d1,8; DDP 80mg/m2 d1, Q3W; IMRT (6-7 weeks, 5 times each week) combined with cisplatin for 2-3 cycles (Q3W): DDP 100 mg/m2, Q3W, 2-3 cycles; IMRT: GTVnx 70-74Gy/30-33f, 5d/w, 6-7 w; Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles; Endostar: 7.5 mg/m2/d, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles.
62428281|NCT04185831|EXPERIMENTAL|MTOR/TSC1/TSC2|Everolimus, 10mg po daily.
62237771|NCT06027723|PLACEBO_COMPARATOR|Placebo|Participants will follow a standard vape protocol that is equal inhalation to that used in the nicotine condition.
62237772|NCT01244243|EXPERIMENTAL|Active therapy|All subjects receive the same active robotic therapy, there is no placebo arm, as a key goal of this study is to define predictors of response to active treatment.
62237773|NCT03140774||Cohort 1: Phase 1 participants|Previously exposed to Ebola vaccine Ad26-ZEBOV and MVA-BN-Filo.
62237774|NCT03140774||Cohort 2: Received r-VSV-ZEBOV vaccine|Previously exposed to Ebola vaccine rVSV-EBOV.
62237775|NCT03140774||Cohort 3: Phase 2 participants|Previously exposed to Ebola vaccine Ad26-ZEBOV and MVA-BN-Filo
62237776|NCT01174238|EXPERIMENTAL|Arm A|Patients enrolled in Arm A and Arm B will receive the same treatment with study drugs axitinib, carboplatin, and paclitaxel. Patients enrolled in Arm A and Arm B will have tumor imaging assessments: PET-CT, CT Scan, and/or MRI. In addition patients enrolled in Arm A will also have FLT-PET scans.
62428282|NCT04185831|EXPERIMENTAL|Mutation burden|Atezolizumab. 1200mg iv every 3 weeks.
62428283|NCT04185831|EXPERIMENTAL|PPARi|Niraparib. 300mg po daily.
62596084|NCT01943851|EXPERIMENTAL|Part 2: GSK525762 dose expansion cohort|After the MTD has been determined in Part1, Part 2 dose expansion cohorts will be opened for AML, NHL and MM.
62036679|NCT04447326|ACTIVE_COMPARATOR|IC＋CCRT|Three cycles of induction chemotherapy with GP regimen (Q3W): Gem 1000 mg/m2 d1,8; DDP 80mg/m2 d1, Q3W; IMRT (6-7 weeks, 5 times each week) combined with cisplatin for 2-3 cycles (Q3W): DDP 100 mg/m2, Q3W, 2-3 cycles; IMRT: GTVnx 70-74Gy/30-33f, 5d/w, 6-7 w.
62036680|NCT04567472|EXPERIMENTAL|Online HEADS: UP|HEADS: UP online is a group-based mindfulness course with an accompanying text-based manual. HEADS: UP comprises 9 x 2.5 hour mindfulness sessions, which incorporate a 30-minute break. A 6-hour silent retreat is offered in week 7. A follow-up session will be offered 6 - 8 weeks after the end of the course. Course materials include accessible information packs delivered weekly, electronically, and CD/audio resources to complement the sessions. The accompanying text-based manual will be delivered 'up front' (hard copy and electronic). A summary email and reminder of personal practice will be sent to participants after each session, including links to audio resources complementing class-based sessions. Signposting to other resources and media, including sites with downloadable voice files e.g. Mindfulness Scotland will be included.
62428284|NCT01296152|EXPERIMENTAL|Depo-medroxyprogesterone acetate (DMPA)|At study entry/ Day 0, subjects will receive depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
62428285|NCT02199834|EXPERIMENTAL|Peer group|24 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support to this group under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support. Half of the patients in this group will be randomized to receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
62428286|NCT02199834|OTHER|Refused peer group|Patients who fit the criteria of peers but refuse to be contacted by peer supporters will be signed as refused group. Half of the patients in this group will be randomized to receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
62813941|NCT06705751|EXPERIMENTAL|Prospective study|"The prospective phase aims to validate the entire model developed during the retrospective phase and to evaluate the role of autonomic response in subjects with Anomalous Aortic Origin of a Coronary Artery (AAOCA). The prospective recruitment of the cohort of AAOCA patients for autonomic assessment and validation will span the entire duration of the study. Our objective is to recruit 38 patients with AAOCA to obtain consistent and uniform data from at least 32 participants. Patients in this cohort will undergo an active standing test to elicit an autonomic response, and the results will be compared with reference normal values.~During this examination, the following data will be collected: continuous ECG, non-invasive blood pressure, and respiratory measurements in both supine and prone positions."
62237777|NCT01174238|EXPERIMENTAL|Arm B|Patients enrolled in Arm A and Arm B will receive the same treatment with study drugs axitinib, carboplatin, and paclitaxel. Patients enrolled in Arm A and Arm B will have tumor imaging assessments: PET-CT, CT Scan, and/or MRI. Patients enrolled in Arm B will not have FLT-PET scans.
62428287|NCT02199834|EXPERIMENTAL|Report group|Patients in this group will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values twice a year through mails.
62428288|NCT02199834|NO_INTERVENTION|Usual care|Patients will receive standard usual care with clinicians' follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
62428289|NCT05928273|EXPERIMENTAL|Corheart 6 LVAS|Corheart 6 Left Ventricular Assist System (Corheart 6 LVAS) to be used on patients with advanced refractory heart failure.
62428290|NCT05053919|EXPERIMENTAL|SR device group|
62428291|NCT05053919|PLACEBO_COMPARATOR|placebo device group|
62428292|NCT04367922|EXPERIMENTAL|Positive emotion skills invervention|Participants will go through a 6-week positive emotion skills course where 1 new skill opens each week.
62428293|NCT06044259|ACTIVE_COMPARATOR|Hemiarch-AMDS|Patient with acute DeBakey I aortic dissection will be put on GA and conventional CPB. During circulatory arrest, the aorta will be trimmed to the level of the distal ascending or proximal arch The AMDS device will be implanted into the aortic arch and descending thoracic aorta. The distal anastomosis will be done between a vascular graft and the distal ascending aorta/aortic arch including the AMDS device sewing cuff. After the distal anastomosis is completed, visceral and cerebral systemic perfusion and rewarming will be started. Proximal anastomosis will be performed and the patient will be weaned from cardiopulmonary bypass and decannulated.
62596085|NCT05050734|EXPERIMENTAL|CBIT-E|For those randomized to CBIT-E, treatment will be administered according to the standard CBIT manual, which includes psychoeducation, functional assessment/interventions, habit reversal training, relaxation techniques, and a motivational reward program. However, there will be two modifications. CBIT-E will include additional in-session and out of session practice of exercises, called competing response. Treatment will include a screening visit, baseline assessment, 11 weeks (9 sessions) of CBIT-E, a post treatment assessment, and a three-month follow up assessment. Further, starting after session 3, there will be four 15-minute practice periods scheduled each week between sessions. During these practice periods, the child and therapist will meet over Microsoft Teams and the therapist will administer an enhanced reward task.
62237778|NCT03064386|EXPERIMENTAL|plate group|internal fixation with the plate
62813942|NCT00928486|EXPERIMENTAL|Lenalidomide and Dexamethasone|Lenalidomide 25mg by mouth (PO) once daily (QD) on Days 1-21 of each 28 day cycle; When creatinine (CrCl) clearance \<60 mL/min, the initial dose was 10mg and the dose could be increased to 15mg after 2 cycles if the investigator judged therapeutic effect was insufficient and tolerability was acceptable. Dexamethasone 40 mg by PO once QD on days 1-4, 9-12 and 17-20 of each 28 day cycle for the first 4 cycles and Days 1-4 for the remaining cycles beginning at Cycle 5.
62813943|NCT06705556|EXPERIMENTAL|The intervention group|"The intervention group:~The intervention group (n=36) was instructed to perform the ACBT with routine chest physical therapy pre and postoperatively. The preoperative chest physical therapy was conducted 3 days before surgery and the postoperative CPT, including ACBT, was performed 3 times in the ICU for up to 5 days after surgery.~Preoperative routine chest physical therapy sessions were followed as:~* Incentive spirometer, 3 sessions per day, 10 repetitions~* Percussions, 3 sessions per day, 20 repetitions~* 3-minutes walking, 2 sessions per day~* ACBT, 3 sessions per day~The preoperative chest physiotherapy treatment plan was continued after CABG surgery. In addition to these, the following were included postoperatively:~* Nebulization, 3 sessions per day~* 3 minutes of walking, 2 sessions per day~* ACBT, 3 sessions per day"
62813944|NCT06705556|EXPERIMENTAL|The control group|"The control group:~The routine Chest physical therapy was performed 3 days before surgery at the preoperative bay and 5 days after surgery in the ICU with 3 sessions each day.~Preoperative chest physical therapy sessions were followed as:~* Incentive spirometer, 3 sessions per day, 10 repetitions.~* Percussions, 3 sessions per day, 20 repetitions.~* 3-minutes walking, 2 sessions per day The preoperative chest physiotherapy treatment plan was continued after CABG surgery. In addition to these, the following were included postoperatively:~* Nebulization, 3 sessions per day~* 3-minutes walking, 2 sessions per day"
62813945|NCT02065830|EXPERIMENTAL|Robot Safety and Efficacy|"The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training."
62813946|NCT05539027|ACTIVE_COMPARATOR|Group 1 (Treatment group)|
62813947|NCT05539027|ACTIVE_COMPARATOR|Group 2 (Control group)|
62813948|NCT00556569|EXPERIMENTAL|Intervention|2 Intervention schools are cluster randomized to receive CHAM JAM (previously known as the Moving Smart Program) in Year 1
62813949|NCT00556569|NO_INTERVENTION|Wait-Listed Control|2 Wait-Listed Control Schools will receive CHAM JAM (previously known as the Moving Smart Program) in Year 2 of the study
62813950|NCT06393296||Breasting Feeding Mothers|New mothers in the immediate postpartum period and breastfeeding their newborn will be asked to collect a sample of breast milk at 14 days postpartum between 6 am and 9 am. In addition to providing a breast milk sample, they will complete a series of questionnaires related to their emotional well-being and lifestyles.
62813951|NCT00576355|ACTIVE_COMPARATOR|2|Participants will receive treatment as usual
62813952|NCT00576355|EXPERIMENTAL|1|Participants will receive interpersonal and social rhythm therapy for adolescents
62813953|NCT01319708|EXPERIMENTAL|mild ovarian stimulation|100 mg CC by day 2 till 6, plus antagonist plus gonadotrophin 150-200IO until HCG triggering
62813954|NCT01319708|ACTIVE_COMPARATOR|conventional ovarian stimulation|300-450 IU of FSH starting by day 2 of menstrual cycle together with a fixed dose of GnRH antagonist starting by day 6 till egg recovery, or same doses using a GnRH agonist long protocol
62036681|NCT04461301|EXPERIMENTAL|Intervention|Patients that meet the inclusion criteria will be randomised and scheduled for surgery at least 2 weeks after the diagnosis/decision to proceed to surgery. This timeframe allows the implementation of a minimal 2 weeks (up to 4 weeks) multidisciplinary prehabilitation program. Prehabilitation program is composed of 4 elements: exercise training, nutritional intervention, correction of anaemia and smoking cessation. An individual treatment strategy will be proposed to the patient by a multidisciplinary team consisting of surgeon, anesthesiologist, dietitian and physiotherapist.
62428294|NCT06044259|ACTIVE_COMPARATOR|Hemiarch-C|Patient with acute DeBakey I aortic dissection will be put on GA and conventional CPB. During circulatory arrest, the aorta will be trimmed to the level of the distal ascending or proximal arch The AMDS device will be implanted into the aortic arch and descending thoracic aorta. The distal anastomosis will be done between a vascular graft and the distal ascending aorta/aortic arch as per routine. After the distal anastomosis is completed, visceral and cerebral systemic perfusion and rewarming will be started. Proximal anastomosis will be performed and the patient will be weaned from cardiopulmonary bypass and decannulated.
62428295|NCT03423589|EXPERIMENTAL|VSL#3|Participants will be given the probiotic supplement VSL#3, a commercially available product. VSL#3 is taken by mouth, either once or twice daily, and is dispensed in sachets, each containing 450 billion colony forming units of bacterial strains. Participants will undergo a screening visit. They will be asked to provide a stool sample by the next visit. Within 3 weeks they will return with a stool sample and receive the VSL#3 sachets as well as another stool collection kit. After 6 weeks of taking VSL#3, they will return for their final visit, with their stool sample. Blood will be drawn at the second and third visits.
62428296|NCT05016765|EXPERIMENTAL|Active MNS|Active, self-directed electrical stimulation of the right median nerve
62596086|NCT05050734|NO_INTERVENTION|Waitlist Control (WLC)|These participants will not receive treatment during the 11-week period. Instead, they will be placed on a waitlist to receive standard CBIT following the end of the study period. The final assessment will be approximately 11 weeks after baseline.
62813955|NCT02685319|EXPERIMENTAL|muscle biopsy|a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
62596087|NCT02662764|EXPERIMENTAL|Zalviso™ 15 mcg|Zalviso™(sufentanil sublingual tablet system) 15 mcg
62237779|NCT03064386|EXPERIMENTAL|screw group|internal fixation with the screw
62813956|NCT01626014|EXPERIMENTAL|Intervention Group|Using the Prototype System website: An interactive educational system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
62735191|NCT04499781|ACTIVE_COMPARATOR|HIV-infected youth: control|"Sample population of perinatally and behaviorally, HIV-infected youth (ages 18-29 years).~Characteristics of the target study population include ethnic minority, Black and Hispanic HIV+AYA; both males and females are eligible for participation."
62813957|NCT01626014|ACTIVE_COMPARATOR|Control Group|Using the Usual Care Educational Website : a website which will contain information regarding ovarian cancer however it will not be interactive. It will contain pdf documents of the material handed out in clinic (usual care).
62813958|NCT02174965|EXPERIMENTAL|MiniHip (Corin U.K.)|MiniHip (Corin U.K.) femoral component
62813959|NCT02174965|ACTIVE_COMPARATOR|Metafix (Corin, U.K)|Metafix (Corin, U.K) conventional cementless stem
62813960|NCT05017415|EXPERIMENTAL|Standard toilet chair (hip angle 90°)|uroflow measurement with subsequent post void residual measurement, conducted on a standard toilet chair.
62813961|NCT05017415|EXPERIMENTAL|Toilet chair with decreased hip angle|uroflow measurement with subsequent post void residual measurement, conducted on a toilet chair with decreased hip angle.
62813962|NCT02015273||Growth Disorders|
62813963|NCT01446159|EXPERIMENTAL|MEDI-573 10 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort A of the study will receive intravenous infusion of MEDI-573 10 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
62036682|NCT04461301|NO_INTERVENTION|Control|Perioperative care of the control group will be based on standardized, multi-element, ERAS recommendations as already implemented in the different participating clinics.
62237780|NCT01832363|EXPERIMENTAL|HXe MRI guided treatment sequence for BT|Patients in this arm will undergo bronchial thermoplasty treatment where the first session of the procedure will target the six most problematic airways as determined with HXe imaging. Patients will have the remaining of the airways treated in the two subsequent sessions.
62237781|NCT01832363|ACTIVE_COMPARATOR|Standard treatment sequence for BT (control)|Patients in this arm will undergo standard treatment sequence of bronchial thermoplasty. To preserve the blind of the procedure to the subjects, the same timeline and clinical measures will be followed as for HXe guided patients.
62237782|NCT03628365|ACTIVE_COMPARATOR|HMB (beta-hydroxy beta-methylbutyrate)|HMB, 1.5 g b.i.d., from day 4 to day 30 after ICU admission
62237783|NCT03628365|PLACEBO_COMPARATOR|Placebo|Maltodextrin, 1.5 g b.i.d., from day 4 to day 30 after ICU admission
62237784|NCT00047203|EXPERIMENTAL|Treatment (flavopiridol)|Patients receive flavopiridol IV over 1 hour on days 1-3. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. After 12 months, patients achieving at least a partial response may continue treatment in the absence of disease progression or unacceptable toxicity.
62237785|NCT03258333||Stented bioprosthesis|Standard aortic valve replacement with stented bioprosthesis. Surgery is performed through median sternotomy, aortic and right or bicaval venous cannulation, normothermic perfusion, antegrade cardioplegia with use cardioplegic solution Custodiol. A transverse aortotomy was performed 1 to 2 cm above the right coronary artery. The aortic annulus was thoroughly débrided of calcium. Valve sizing was performed with standard manufacturers' sizers, with selection of the size that would comfortably fit within the aortic annulus. A noneverting suture technique was used in all patients with interrupted horizontal mattress 2-0 braided sutures placed around the aortic annulus, with the pledgets on the ventricular aspect.
62237786|NCT03258333||Ozaki procedure|Aortic valve reconstruction using autologus pericardium (Ozaki procedure). The autologous pericardium is harvested after routine median sternotomy. Harvested pericardium is then treated with a 0.6% glutaraldehyde solution for 10 min and then rinsed 3 times with sterilized saline each time for 6 min. After resection of the diseased aortic valve cusps, the distance between each commissure is measured using a self-developed sizing instrument. Glutaraldehyde-treated autologous pericardium is trimmed with a self-developed template corresponding to the measured value. The annular margin of the pericardial leaflet is then running-sutured to each annulus with 3-0 monofilament sutures. Commissural coaptation is secured with additional 4-0 monofilament sutures. The coaptation of the 3 cusps is then checked with negative pressure on the left ventricular vent.
62237787|NCT05493839||Plateau Criteria|mild ： 142mmHg \< PaO2/ FiO2 ≤ 213 mmHg moderate ： 71mmHg \< PaO2/ FiO2 ≤ 142mmHg severe： PaO2/ FiO2 ≤ 71 mmHg
62237788|NCT05493839||Berlin Definition|mild ： 200mmHg \< PaO2/ FiO2 ≤ 300 mmHg moderate ： 100mmHg \< PaO2/ FiO2 ≤ 200mmHg severe： PaO2/ FiO2 ≤ 100 mmHg
62813964|NCT01446159|EXPERIMENTAL|MEDI-573 30 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort B of the study will receive intravenous infusion of MEDI-573 30 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
62813965|NCT01446159|EXPERIMENTAL|MEDI-573 45 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort C and Phase 2 Arm 1 of the study will receive intravenous infusion of MEDI-573 45 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
62036683|NCT00496041|EXPERIMENTAL|Smart Stent in the Superficial Femoral Artery .|
62036684|NCT04653103||Patients with obesity|Subjects with different classes of obesity
62036685|NCT03330379|EXPERIMENTAL|continuous adjustment strategy|patients assigned to the continuous adjustment strategy, in addition to standard care, the Tracoe Smart CuffmanagerTM will be connected to the tracheal cuff
62036686|NCT03330379|NO_INTERVENTION|usual care|patients with usual care
62036687|NCT02346383|ACTIVE_COMPARATOR|program 1|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
62036688|NCT02346383|ACTIVE_COMPARATOR|program 2|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
62036689|NCT02346383|ACTIVE_COMPARATOR|program 3|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
62036690|NCT00541515|EXPERIMENTAL|closed loop system|Device: continuous glucose sensors and insulin pump
62036691|NCT01445938|EXPERIMENTAL|Step 1 (SAR97276A od)|1 group of paediatric patients will receive 0.5 mg/kg SAR97276A administration once daily (od) for 3 days
62036692|NCT01445938|EXPERIMENTAL|Step 1 (SAR97276A bid)|1 group of paediatric patients will receive 0.25 mg/kg SAR97276A administration twice daily (bid) for 3 days
62036693|NCT01445938|ACTIVE_COMPARATOR|Step 1 (ACTs)|1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days
62036694|NCT01445938|EXPERIMENTAL|Step 2 (SAR97276A)|1 or 2 groups of paediatric patients will receive SAR97276A once daily (od) or twice a day (bid) administration for 3 days (the choice of the od or bid regimen will be based on the results obtained in step 1)
62036695|NCT01445938|ACTIVE_COMPARATOR|Step 2 (ACTs)|1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days
62237789|NCT05493839||zhang|ARDS：PaO2/FiO2≤100mmHg ALI ：100mmHg\<PaO2/FiO2≤150mmHg
62237790|NCT03975023||hockey players|"During each study visit, the participants will undergo the following procedures:~* NeuroCatch Platform (NCP) assessment (only if participant meets NCP-specific criteria)~* RightEye's eye-tracking battery~* Highmark Interactive's EQ application~* Cambridge Brain Science's neuropsychological tests"
62596088|NCT06483815||The percentages of fungus positivity in the SARS CoV-2 pandemic and SARS CoV-2 post-pandemic period|The study was conducted retrospectively, analyzing a total of 1441 patients. Among these, 623 were during the SARS-CoV-2 pandemic and 818 were in the post-pandemic period. Fungal positivity rates were calculated separately for different fungal agents including Candida species and Aspergillus. These rates were presented as percentages and statistically compared between the two periods.
62596089|NCT05599984|EXPERIMENTAL|Part 1: ABBV-706 Monotherapy Dose Escalation|Participants will receive escalating doses of ABBV-706 until doses for optimization are determined, as part of an approximately 1 year treatment period.
62036696|NCT01445938|EXPERIMENTAL|Step 3 (SAR97276A)|1 group of paediatric patients (2 to 11 years old) will receive: SAR97276A od or bid administration for 3 days (depending on results of step 1)
62036697|NCT05187676|EXPERIMENTAL|Oxygen cutaneous saturation rate (ScO2) then transcutaneous oxygen partial pressure (TcPO2)|ScO2 values will be measured using IPAM first then TcPO2 values will be measured using Periflux6000. ALways in the same order.
62036698|NCT00160433|EXPERIMENTAL|1|
62237791|NCT00455325|PLACEBO_COMPARATOR|First Intervention (3 weeks)|Cohort 1: Chloroquine placebo one tablet daily for 3 weeks, followed by 5-7 week rest period.
62596090|NCT05599984|EXPERIMENTAL|Part 2: ABBV-706 Monotherapy Dose Optimization and Expansion|Participants with small cell lung cancer will receive varying doses of ABBV-706 in a randomized manner until the recommended phase 2 dose (RP2D) is achieved, as part of an approximately 1 year treatment period..
62596091|NCT05599984|EXPERIMENTAL|Part 3a: ABBV-706 + Budigalimab|Participants will receive ABBV-706 in combination with budigalimab, as part of an approximately 1 year treatment period.
62596092|NCT05599984|EXPERIMENTAL|Part 3b: ABBV-706 + Platinum Chemotherapy|Participants will receive ABBV-706 in combination with carboplatin or cisplatin, as part of an approximately 1 year treatment period.
62036699|NCT00160433|EXPERIMENTAL|2|
62036700|NCT00160433|EXPERIMENTAL|3|
62735192|NCT03583359|EXPERIMENTAL|Treatment with Radiesse (+)|
62735193|NCT03583359|OTHER|Control/Delayed Treatment with Radiesse (+)|
62735194|NCT05404191|EXPERIMENTAL|burn wound receiving low level laser therapy|
62036701|NCT00160433|PLACEBO_COMPARATOR|4|
62036702|NCT06500481|ACTIVE_COMPARATOR|Arm 1 (IFRT)|Patients undergo involved-field radiation therapy delivered to specific areas of LM that are causing and/or may cause symptoms 5 days a week for a total of 10 days of treatment in the absence of disease progression or unacceptable toxicity. Patients undergo CT or PET/CT during screening and MRI as well as LP throughout the study. Patients may optionally undergo research blood sample and CSF collection throughout the study.
62237792|NCT00455325|ACTIVE_COMPARATOR|Second Intervention (3 weeks)|Cohort 2: 80mg chloroquine or placebo tablet once daily for Weeks 3, followed by 5-7 week rest period.
62237793|NCT00455325|ACTIVE_COMPARATOR|Third Intervention (3 weeks)|Cohort 3: 80mg chloroquine tablet daily: for 3 weeks, followed by 5-7 week rest period.
62237794|NCT00455325|ACTIVE_COMPARATOR|Fourth Intervention (3 weeks)|Cohort 4: 250mg chloroquine tablet daily: for 3 weeks, followed by 5-7 week rest period.
62237795|NCT03673865|EXPERIMENTAL|Treatment Group|Patients undergo orbital reconstruction using pre-adjusted patient-specific orbital implants with office-based 3-dimensional printers (OB3DP)
62237796|NCT03673865|ACTIVE_COMPARATOR|Control Group|Patients undergo orbital reconstruction with non-patient-specific orbital implants (traditional approach, Control Group) which is a standard stock orbital plate
62237797|NCT03937726|EXPERIMENTAL|Boiled peanut Oral Immunotherapy|Desensitisation using boiled peanut
62036703|NCT06500481|EXPERIMENTAL|Arm 2 (pCSI)|Patients undergo pCSI radiation therapy delivered to the entire space containing the CSF, brain, and spinal cord 5 days a week for a total of 10 days of treatment in the absence of disease progression or unacceptable toxicity. Patients undergo CT or PET/CT during screening and MRI as well as possible LP throughout the study. Patients may optionally undergo research blood sample and CSF collection throughout the study.
62036704|NCT01850225|EXPERIMENTAL|Device implantation|Implantation of device
62036705|NCT01152580|PLACEBO_COMPARATOR|Sugar pill|
62036706|NCT01152580|ACTIVE_COMPARATOR|melatonin|
62036707|NCT05619601||500 women|500 women discharged alive after a hospitalization for a type 1 acute myocardial infarction with significant coronary artery disease.
62036708|NCT05619601||500 men|500 age (±2 years) and ECG (STEMI/NSTEMI) locally matched men discharged alive after a hospitalization for a type 1 acute myocardial infarction with significant coronary artery disease.
62237798|NCT03937726|ACTIVE_COMPARATOR|Conventional Oral immunotherapy|Desensitisation using defatted peanut flour
62237799|NCT04379050|EXPERIMENTAL|ABBV-951|Participants will receive ABBV-951 solution by continuous subcutaneous infusion (CSCI), at the discretion of the investigator, for up to 96 weeks.
62596093|NCT05599984|EXPERIMENTAL|Part 4a: ABBV-706 Monotherapy Dose Expansion CNS Tumors|Participants with relapsed/refractory (R/R) central nervous system (CNS) tumors will receive ABBV-706 as a monotherapy at or below the maximum tolerated dose (MTD) maximum administered dose (MAD), as part of an approximately 1 year treatment period.
62596094|NCT05599984|EXPERIMENTAL|Part 4b: ABBV-706 Monotherapy Dose Expansion NECs|Participants with R/R neuroendocrine carcinomas (NECs) will receive IV Infused ABBV-706 as a monotherapy at or below the MTD/MAD, as part of an approximately 1 year treatment period.
62596095|NCT04756154|EXPERIMENTAL|CHG/IPA Surgical skin preparation|Apply topically to the inguinal region for 2 minutes
62596096|NCT04756154|ACTIVE_COMPARATOR|CHG/IPA Film-Forming Surgical skin preparation|Apply topically to the inguinal region for 2 minutes
62237800|NCT04024748||Patients already scheduled for a FDG test|Subjects will be selected from patients already scheduled for a routine FDG PET/CT test. Only adult patients, 40 years old or older, capable of providing their informed consent, will be selected. Any adult female patients that are pregnant and/or could become pregnant will be excluded. Twenty patients will be recruited.
62237801|NCT06233721|NO_INTERVENTION|Control group|Identifying Information Form (IIF), Medication Adherence Report Scale (MARS), and Duke Anticoagulation Satisfaction Scale (DASS) were applied to the control group two times, once in the first interview and once in the interview held a month later. The control group was not provided with education. In line with ethical principles, education and education booklet was provided to this group after the scales were applied in the last interview held in the outpatient clinic control. The application of the scales took 20-25 minutes on average.
62596097|NCT04756154|PLACEBO_COMPARATOR|Normal saline|Apply topically to the inguinal region for 2 minutes
62596098|NCT03348475|EXPERIMENTAL|Experimental Group|Binge Focused Therapy (BFT) Intervention
62596099|NCT00725647||Treated PDA|Infants who had a PDA which the attending physicians treated medically or surgically.
62036709|NCT05326464|EXPERIMENTAL|Tofacitinib 10 mg|Participants will take the 10mg Tofacitinib twice daily until evidence of progression, intolerance of treatment, withdrawal of consent, or death.
62036710|NCT00092534|EXPERIMENTAL|Quadrivalent Human Papillomavirus (HPV) Vaccine|The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
62036711|NCT00092534|PLACEBO_COMPARATOR|Placebo|The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
62036712|NCT02657980|EXPERIMENTAL|YBand(YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 5 days a week for 2 weeks (total of 10 applications)
62036713|NCT02657980|SHAM_COMPARATOR|Sham-Yband(YDT-201N)|sham-tDCS application 5 days a week for 2 weeks (total of 10 applications)
62735195|NCT01643265|ACTIVE_COMPARATOR|Whey Milk Protein|
62735196|NCT01643265|EXPERIMENTAL|Bovine Albumin Concentrate|
62735197|NCT01872585|EXPERIMENTAL|Mentalization based therapy|Women who are the primary caregivers of a child between the ages of 0-7 years and are involved with mental health services for themselves or a child.
62735198|NCT02349659|NO_INTERVENTION|Conservative Medical Management|Continued medical management restricted to exclude interventional pain treatments
62596100|NCT06648538|EXPERIMENTAL|Phonix Care experimental group|"The experimental arm involves modifying the functionalities of the user's digital devices (e.g., computer, smartphone, tablet, gaming console). The objective is to allow individuals access only to essential digital functionalities such as calls, alarms, work tools, camera, and unlock recreational digital functionalities only if the user engages in non-digital leisure activities (e.g., cultural, sports, family, artistic activities). The smartphone sensors validate the activities performed to earn digital time that can be spent by the user. Gradually, the user progresses a virtual animal until reaching the third stage of therapeutic education.~A phoenix will evolve simultaneously with the user when they engage in non-digital recreational activities.~For 5 months, all participants' cross-platform screen-usage data are monitored with fine granularity, including the frequency of app openings, schedules of opening, and names of app openings."
62036714|NCT06333925|EXPERIMENTAL|Cognitive Restructuring + High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS)|30 eligible participants will receive training in Cognitive Restructuring (CR). These participants will use CR while being exposed to misophonic trigger sounds and also receiving high frequency rTMS over their personalized right dorsal lateral prefrontal cortex (dlPFC) target. These participants will partake in short term and long term follow-up testing.
62036715|NCT06333925|ACTIVE_COMPARATOR|Cognitive Restructuring + Shame Repetitive Transcranial Magnetic Stimulation (rTMS)|30 eligible participants will receive training in Cognitive Restructuring (CR). These participants will use CR while being exposed to misophonic trigger sounds and also receiving placebo rTMS over their personalized right dorsal lateral prefrontal cortex (dlPFC) target. These participants will partake in short term and long term follow-up testing.
62036716|NCT01362140|EXPERIMENTAL|Darbepoetin alfa|Participants received darbepoetin alfa 500 µg every three weeks (Q3W) for 24 weeks in the double-blind treatment period, and continued to receive darbepoetin alfa 500 µg Q3W during the active treatment period for an additional 48 weeks.
62428297|NCT03229382|EXPERIMENTAL|Obinutuzumab 1000 mg IV infusion, day: 1, 8, 15, 22|Patients with evidence of MCL molecular relapse defined as an increasing copy number in quantitative real-time polymerase chain reaction (RQ-PCR) of clone-specific immunoglobulin heavy chain (IGH) gene rearrangements or BCL1-IGH fusion genes according to BIOMED-2 methodology and protocols in peripheral blood or/and bone marrow without evidence of clinical relapse/progression after auto-HCT procedure with all inclusion and no exclusion clinical trial criteria will receive 4 weekly infusions of obinutuzumab.
62596101|NCT06648538|NO_INTERVENTION|Observational group|For 5 months, all participants' cross-platform screen-usage data are monitored with fine granularity, including the frequency of app openings, schedules of opening, and names of app openings.
62036717|NCT01362140|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injection every 3 weeks (Q3W) for 24 weeks during the double-blind treatment period. From week 25 participants received darbepoetin alfa 500 µg Q3W during the active treatment period for 48 weeks.
62596102|NCT05740683||People with idiopathic olfactory dysfunction|
62036718|NCT03195010|EXPERIMENTAL|Group I (lower dose platelet transfusion)|Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10\^9/L for up to 30 days or until the platelet count spontaneously recovers to \> 50 x 10\^9 for 3 consecutive days in the absence of transfusions.
62036719|NCT03195010|EXPERIMENTAL|Group II (higher dose platelet transfusion)|Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10\^9/L for up to 30 days or until the platelet count spontaneously recovers to \> 50 x 10\^9 for 3 consecutive days in the absence of transfusions.
62036720|NCT06298903|ACTIVE_COMPARATOR|Hip activation|Participants will perform a hip muscle activation program 2 days per week for 8 weeks. The HEP consists of 5 exercises that target the gluteal muscles.
62036721|NCT06298903|EXPERIMENTAL|Hip activation + Single leg balance|Participants will perform a hip muscle activation program as in the active comparator group, plus a single leg balance training HEP 2 days per week for 8 weeks. The hip HEP consists of 5 exercises that target the gluteal muscles. The single leg balance HEP consists of a variety of eyes open and eyes closed single leg balance exercises.
62036722|NCT03088267|ACTIVE_COMPARATOR|Active Treatment|Double blind amphetamine extended-release oral suspension, 2.5 mg/mL, 6, 7 or 8 mL po QAM
62036723|NCT03088267|PLACEBO_COMPARATOR|Placebo Treatment|Double blind placebo, 6, 7 or 8 mL po QAM
62813966|NCT01446159|EXPERIMENTAL|Aromatase Inhibitor|Participants who will be enrolled in Phase 2 Arm 2 of the study will receive oral AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
62036724|NCT00608582|EXPERIMENTAL|Real rTMS|These patients receive a series of 10 Real Transcranial Magnetic Stimulation, Repetitive (rTMS), treatments, only. There is pre-testing, and post-testing at 2 months after the last Real rTMS treatment.
62428298|NCT02464527|EXPERIMENTAL|Stimulus-stimulus pairing (SSP)|Minimally verbal children between 2.0 and 3.9 years with autism spectrum disorder (ASD) and who do not emit vocalizations, will be randomly assigned to the treatment group and will begin the stimulus-stimulus pairing (SSP) procedure. Subjects will be recorded by a vocal recorder at home by the parent/guardian at home or in the community setting.
62428299|NCT02464527|ACTIVE_COMPARATOR|Waitlist Control (Delayed Treatment)|Minimally verbal children between 2.0 and 3.9 years with autism spectrum disorder (ASD) and who do not emit vocalizations will be randomly assigned to the Waitlist Control group. During the waitlist control subject's assigned session block of six weeks, s/he will not receive any treatment. The subjects will receive the stimulus-stimulus pairing procedure (delayed procedure) after the completion of the assigned 6-week block as a waitlist control participant. Subjects will be recorded by a vocal recorder at home by the parent/guardian at home or in the community setting.
62428300|NCT05954338|EXPERIMENTAL|Intervention: DWC202307 + DWJ1543|
62428301|NCT05954338|EXPERIMENTAL|Intervention: DWC202307 + DWC202216|
62596103|NCT05740683||People without olfactory dysfunction|
62735199|NCT02349659|ACTIVE_COMPARATOR|Axium Group|As the CMM group but also treated with Dorsal Root Ganglion stimulation using the Axium neurostimulator
62237802|NCT06233721|EXPERIMENTAL|Face-to-face education group|Identifying Information Form (IIF), Medication Adherence Report Scale (MARS), and Duke Anticoagulation Satisfaction Scale (DASS) were applied to the face-to-face group in the first interview. They were provided with face-to-face education on the determined date and in the specified environment. At the end of the education, education booklet was given to the individuals. Then, an appointment was made for a month later in hospital environment. In the interview held one month later, the scales were applied again for the last time.
62237803|NCT06233721|EXPERIMENTAL|Online education group|IIF, MARS, and DASS were also applied to the online education group in the first interview. On the predetermined date and time, online education was given to individuals through video calls held on TEAMS, Google MEET, or WhatsApp. Then, the education booklet was sent to the participants through the application. An appointment date was determined to have another interview a month later. In the interview held a month later, the relevant scales were applied for the last time. At the end of the education, an evaluation was made, and the parts that were seen to be deficient and the issues/questions that the participants raised were repeated. Accordingly, the individuals in both intervention groups were requested to come for control a month later, and the scales were applied for the last time. Education was provided to the participants by the same researcher using the two methods, and the same education content and booklet was used.
62237804|NCT01058967||major trauma victims|Code 3 patients (highest acuity) admitted to hospital via air ambulance service
62237805|NCT01394471|EXPERIMENTAL|oxytocin|Twice daily treatment of oxytocin will be administered by subjects
62237806|NCT01394471|PLACEBO_COMPARATOR|Control spray|Self administration twice daily of intranasal spray that does not contain oxytocin
62237807|NCT01585636|EXPERIMENTAL|5 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
62237808|NCT01585636|EXPERIMENTAL|10 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
62237809|NCT01585636|EXPERIMENTAL|20 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
62237810|NCT01585636|EXPERIMENTAL|50 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
62237811|NCT01585636|EXPERIMENTAL|100 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
62596104|NCT06621888|EXPERIMENTAL|Active NTI164 Group|Participants in this group receive Full-Spectrum Medicinal Cannabis Plant Extract containing 0.08% THC (NTI164) to treat pediatric acute-onset neuropsychiatric syndrome (PANS). The treatment begins with an up-titration phase where doses start at 5 mg/kg daily and increase to a maximum of 20 mg/kg. This is followed by an 8-week treatment phase at the maximum tolerated dose. Participants have the option to extend this phase up to 54 weeks. The study concludes with a down-titration phase, gradually reducing the dose over 4 weeks. Efficacy is assessed through psychological questionnaires and immune function tests.
62237812|NCT01585636|EXPERIMENTAL|200 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
62237813|NCT01585636|EXPERIMENTAL|300 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
62237814|NCT01585636|EXPERIMENTAL|Food effect group|6 Subjects received single, 300 mg SQ109 after high-fat, high-calorie meal.
62237815|NCT03638934|EXPERIMENTAL|Videos about ACP|Subjects in experimental group get three videos about advanced care planning based on Smart Management Strategy for Health (SMASH). After they finish watching the materials, they fill out the questionnaire.
62237816|NCT03638934|ACTIVE_COMPARATOR|Brochure for Life-Sustaining Treatment|Subjects in the group get 13-page brochure entitled, Understanding the Life-Sustaining Treatment Act. After they finish watching the materials, they fill out the questionnaire.
62237817|NCT01215422||children intubated with Glidescope|children intubated with Glidescope
62237818|NCT01215422||children intubated with DCI|children intubated with DCI
62237819|NCT02209337|EXPERIMENTAL|SRS-I|Implantation of SRS-I
62813967|NCT06279741|EXPERIMENTAL|EXOB-001 (Phase 1)|EXOB-001 will be administered via the endotracheal route in an already intubated newborn. EXOB-001 will be administered in three dose levels (low dose, medium dose and high dose) with one or three administrations.
62237820|NCT03926156|EXPERIMENTAL|Rivaroxaban|Rivaroxaban will be used as the anticoagulation drug for the intervention group. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no approved antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food.
62237821|NCT03926156|ACTIVE_COMPARATOR|Warfarin|Warfarin will be used as the anticoagulation drug for the control group. Warfarin decreases blood clotting by blocking an enzyme called vitamin K epoxide reductase that reactivates vitamin K1. Without sufficient active vitamin K1, clotting factors II, VII, IX, and X have decreased clotting ability. The anticlotting protein C and protein S are also inhibited but to a lesser degree. A few days are required for full effect to occur and these effects can last for up to five days, and the final dose will be adjusted according to PT and related INR.
62237822|NCT03359590|EXPERIMENTAL|Sitagliptin arm|Sitagliptin 100 mg
62237823|NCT03359590|PLACEBO_COMPARATOR|Placebo arm|Placebo comparator
62237824|NCT03240913|EXPERIMENTAL|Treatment Group|
62237825|NCT03240913|PLACEBO_COMPARATOR|Non Treatment Group|Conventional information
62237826|NCT02832700|ACTIVE_COMPARATOR|Casein glycomacropeptide (CGMP)|During 4 weeks a daily oral intake of CGMP-protein-shake.
62237827|NCT02832700|PLACEBO_COMPARATOR|Placebo|During 4 weeks a daily oral intake of placebo-shake consisting of milk powder.
62237828|NCT03665896|ACTIVE_COMPARATOR|VivaSight DLT group|Thoracic surgery patient is intubated with VivaSight double-lumen tube (intubation with VivaSight double-lumen tube). The intubation time, duration between the passage of the tube through the vocal cords and the confirmation of proper tube positioning by the embedded camera, is recorded. The tube position is reconfirmed by fiberoptic bronchoscopy.
62036725|NCT00608582|SHAM_COMPARATOR|Sham rTMS|Patients receive a series of 10 Sham Transcranial Magnetic Stimulation, Repetitive (rTMS) treatments, followed by a series of 10 Real rTMS treatments. Sham rTMS treatments are identical to the Real rTMS treatments, however, no magnetic pulse is released. There is pre-testing, and post-testing at 2 months after the last Sham rTMS treatment.
62036726|NCT04789668|EXPERIMENTAL|Treatment (bintrafusp alfa, pimasertib)|Patients receive bintrafusp alfa IV over 1 hour every 2 weeks and pimasertib PO BID on days 1-28. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
62036727|NCT06724991|ACTIVE_COMPARATOR|Conventional Dose Therapy|Traditional treatment involves a higher insulin dose with dextrose to mitigate hypoglycemia risk while effectively lowering potassium. Ingredients: Actrapid insulin, Dextrose 50% Dosage: 10 units of Actrapid insulin with 50 cc of Dextrose 50% Route of Administration: Intravenous (IV) Frequency: Administered as a single dose at the start of treatment Procedure: The conventional dose has been the standard of care but carries a significant risk of hypoglycemia.
62036728|NCT06724991|EXPERIMENTAL|Lower Dose Therapy|Standard treatment of hyperkalemia includes insulin to shift potassium intracellularly and dextrose to mitigate the risk of hypoglycemia. This arm will be active intervention which means to compare with traditional dose of insulin and investigate if lower dose of insulin is non inferior in reducing serum potassium level in patient with mild and moderate hyperkalemia. Ingredients: Actrapid insulin, Dextrose 50% Dosage: 5 units of Actrapid insulin with 25 cc of Dextrose 50% Route of Administration: Intravenous (IV) Frequency: Administered as a single dose at the start of treatment Procedure: Lower-dose insulin is administered with dextrose to potentially reduce hypoglycemic risk while achieving effective potassium reduction.
62813968|NCT06279741|EXPERIMENTAL|Active group 1 EXOB-001 (Phase 2)|In phase 2, active group 1 consists of administering the first (out of two) of the safest selected dose/regimen of EXOB-001 based on phase 1 interim results.
62036729|NCT02776358|EXPERIMENTAL|High Fidelity Simulation|Students will receive a 1 hour High fidelity simulation session
62036730|NCT02776358|EXPERIMENTAL|Video Case|Students will receive a 1 hour assisted Video Case learning session
62036731|NCT02154763|PLACEBO_COMPARATOR|Intraperitoneal Normal Saline|Intraperitoneal Normal Saline: 100mL (Milliliter) normal saline administered as in intervention arm
62036732|NCT02154763|EXPERIMENTAL|Intraperitoneal ropivacaine|The abdomen will be entered and trocars placed in the usual manner. Using a standard suction/irrigation device and tubing, 200mg of Ropivacaine (0.2% Ropivacaine in 100mL Normal Saline) will be instilled into the abdomen at the start of the case, prior to dissection as follows. Under direct visualization, 50mL (Milliliter) (of the 100mL) will be infused over the esophageal hiatus. The remaining 50mL will be infused throughout the abdomen. The infusion line will then be flushed with 30mL (Milliliter) of Normal Saline to ensure the entire treatment dose is delivered, and no Ropivacaine remains in the tubing. The remainder of the surgery will proceed as usual.
62036733|NCT03266809||Breast Cancer Patients|"Eligible participants will be women aged 18 years or over who have the following main characteristics:~* Early invasive breast cancer (stage I-III)~* Due to start SAT (adjuvant or neoadjuvant chemotherapy +/- trastuzumab +/- pertuzumab)~* WHO performance status 0-2."
62036734|NCT05526105|EXPERIMENTAL|Standard ASA NPO Protocol|Patients will be made NPO at midnight prior to date of surgery.
62428302|NCT02805582|ACTIVE_COMPARATOR|Anterior musculus serratus block|"Proximal nerve block above the second intercostal space between Musculus serratus anterior and Musculus pectoralis minor.~Intervention: 10ml ropivacain 0.5%"
62596105|NCT06115044|EXPERIMENTAL|Intermittent|Bolus feeding over 30 to 60 minutes at 0800, 1300 and 1800
62813969|NCT06279741|EXPERIMENTAL|Active group 2 EXOB-001 (Phase 2)|In phase 2, active group 2 consists of administering the second (out of two) of the safest selected dose/regimen of EXOB-001 based on phase 1 interim results.
62813970|NCT06279741|PLACEBO_COMPARATOR|Placebo (Phase 2)|In phase 2, the saline solution for infusion is used as a placebo.
62813971|NCT06533475|EXPERIMENTAL|Treatment A-B-C|Participants will be randomized to receive single doses of minzasolmin with and without food on different Days with a 4-day Washout Period between doses. A: Granules in capsule (fasting); B: Tablet formulation (fasting); C: Tablet formulation (fed).
62036735|NCT05526105|EXPERIMENTAL|Liberal Feeding Protocol|Patients will be fed enterally up until call to OR at which time their stomachs will be decompressed with a pre-existing gastric tube.
62036736|NCT01959724|OTHER|Vitrectomy|Vitreous surgery to treat macular detachment
62036737|NCT04340206|EXPERIMENTAL|face-to-face support and Chatbot online support group|Experimental, Intervention Group A: face-to-face support and Chatbot online support group: 5-week intervention according to ACT principles with the web- and mobile-based Youth Compass plus program, face-to-face support (2 meetings) and weekly online support and feedback from the Chabot eCoach built within the program (one third of the participants is randomly assigned to this group)
62036738|NCT04340206|EXPERIMENTAL|only chat-robot online support group|Experimental, Intervention Group B: only chat-robot online support group: 5-week intervention according to ACT principles with the web-and mobile-based Youth Compass plus program, no face-to-face support, and weekly online support and feedback from the chatbot eCoach built within the program (one third of the participants is randomly assigned to this group)
62036739|NCT04340206|EXPERIMENTAL|Experimental Control|"Experimental Control:~Control group, no intervention (one third of the participants is randomly assigned to this group)"
62036740|NCT03602131|EXPERIMENTAL|ChiCGB|Treated with chidamide, cladribine, gemcitabine and busulfan(ChiCGB) therapy followed by autologous hematopoietic stem cell transplantation.
62036741|NCT05214872||PREDIALYSIS GROUP|(n = 48) - patients in the pre-dialysis period (stages G3b-G4 of chronic kidey disease (CKD)) with moderate or severe decrease in estimated glomerular filtration rate (eGFR) (eGFR 44-29 ml/min/1.73 m\^2)
62036742|NCT05214872||END-STAGE RENAL DISEASE (ESRD) GROUP|"Patients with ESRD (n=106) - (eGFR \<15 ml/min /1.73 m\^2) undergoing renal replacement therapy have formed this group.~Depending on the method of renal replacement therapy used, two subgroups have been distinguished: (1) peritoneal dialysis (PD) subgroup (n=35) including patients treated by peritoneal dialysis. In this subgroup, due to the treatment technique, two groups have been distinguished, a group (n=15) treated with the automatic peritoneal dialysis (APD) technique and a group (n = 20) using the technique of continuous cycling peritoneal dialysis (CCPD), (2) hemodialysis (HD) subgroup (n = 71) including patients treated with repeated hemodialysis. The duration of hemodialysis was at least 10 hours/week using standard bicarbonate dialysis fluids and polysulfone low-flux dialyzers. The blood flow during hemodialysis was 200-350 ml/min, with an average dialysis fluid flow of 500 ml/min."
62036743|NCT05214872||CARDIOLOGY (CARD) GROUP|"CARD group (n = 37) - patients with at least one history of a cardiovascular event, admitted to hospital for elective angiography, without any signs of impaired kidney function.~The studies in this group were conducted to check the changes that occur as a result of cardiovascular disease (CVD) but without kidney disease."
62036744|NCT05214872||Chronic kidney disease (CKD) 1-2 GROUP|"CKD1-2 (n=29) (stage G1-G2 CKD) with mild decrease in eGFR (eGFR \>90-60 ml/min/1.73 m\^2)~The studies in this group were performed to disclose the changes that occur as a consequence of the beginning of kidney function deterioration."
62036745|NCT05214872||Healthy volunteers (HV)|HV (n = 32) - this group was composed of healthy people, with no evidence of impairment in renal function and cardiovascular disorders in the history and at the time of enrollment in the study.
62237829|NCT03665896|PLACEBO_COMPARATOR|Standard DLT group|Thoracic surgery patient is intubated with standard double-lumen tube (intubation with standard double-lumen tube). The intubation time, duration between the passage of the tube through the vocal cords and the confirmation of proper tube positioning by fiberoptic bronchoscopy, is recorded.
62428303|NCT02805582|ACTIVE_COMPARATOR|Subpectoral block|"Distal nerve block under the Musculus pectoralis major at the medial border of the axillary triangle.~Intervention: 10ml ropivacain 0.5%"
62813972|NCT06533475|EXPERIMENTAL|Treatment B-C-A|Participants will be randomized to receive single doses of minzasolmin with and without food on different Days with a 4-day Washout Period between doses. B: Tablet formulation (fasting); C: Tablet formulation (fed); A: Granules in capsule (fasting).
62813973|NCT06533475|EXPERIMENTAL|Treatment C-A-B|Participants will be randomized to receive single doses of minzasolmin with and without food on different Days with a 4-day Washout Period between doses. C: Tablet formulation (fed); A: Granules in capsule (fasting); B: Tablet formulation (fasting).
62596106|NCT06115044|ACTIVE_COMPARATOR|Continuous|Continuous feeding over 24 hours
62596107|NCT05774795||Mitral valve surgery only|
62596108|NCT05774795||Mitral valve surgery + Aortic valve surgery|
62813974|NCT06533475|EXPERIMENTAL|Treatment A-C-B|Participants will be randomized to receive single doses of minzasolmin with and without food on different Days with a 4-day Washout Period between doses. A: Granules in capsule (fasting); C: Tablet formulation (fed); B: Tablet formulation (fasting).
62813975|NCT06533475|EXPERIMENTAL|Treatment B-A-C|Participants will be randomized to receive single doses of minzasolmin with and without food on different Days with a 4-day Washout Period between doses. B: Tablet formulation (fasting); A: Granules in capsule (fasting); C: Tablet formulation (fed).
62237830|NCT01217268|EXPERIMENTAL|Training and supervision of staff|Staff members get training in person centered care by supervision using video-conference kit
62237831|NCT02850211|EXPERIMENTAL|Celecoxib|1 capsule of 200mg Celebrex twice a day for 14 days
62428304|NCT06558201|EXPERIMENTAL|Ketogenic diet|Participants will be asked to follow the ketogenic diet (KD) for 12 weeks in addition to any ongoing medications (e.g., mood stabilizers and/or second-generation antipsychotics). Participants will receive diet counseling from a registered dietitian. Participants will be asked to monitor and report their blood ketone and glucose levels each day via a finger-prick device provided by the study team.
62596109|NCT06267976||Healthy volunteers|Health adult volunteers will undergo a controlled desaturation to collect data for validation of the RPMO2 device.
62596110|NCT03442478|EXPERIMENTAL|2D/3D Tomosynthesis|2D/3D Tomosynthesis images will be obtained in addition to standard mammographic images.
62596111|NCT02928783|EXPERIMENTAL|Intervention|In interventional group, we arranged individualized rehabilitation programs including home-based cardiac rehabilitation, diet education and management of daily activity for 3 months.
62596112|NCT02928783|NO_INTERVENTION|Control|We didn't arrange individualized rehabilitation programs including home-based cardiac rehabilitation, diet education and management of daily activity for 3 months.
62596113|NCT02826668|NO_INTERVENTION|Control|Baseline ultrasound only, with no markings placed. No ultrasound prior to epidural placement.
62596114|NCT02826668|EXPERIMENTAL|Ultrasound|Baseline and pre-puncture ultrasound with markings placed.
62596115|NCT06466590|EXPERIMENTAL|Single Group|Participants will be asked to use the measurement instrument VRSQ-F on two separate occasions under identical conditions to assess its test-retest reliability and asked to use the SSQ for validity. Each session will involve completing the measurement protocol as specified.
62596116|NCT01937091||Participants in trials|Participated in a trial of HAART for duration of \> 48 weeks.
62596117|NCT01937091||Non-participants in trials|Never participated in clinical trials of HAART Must have been offered participation in a clinical trial and declined
62036746|NCT05696899|EXPERIMENTAL|Aromatherapy|Patients will be given STILL QuickTAB Medipack blended scent aromatherapy in addition to standard supportive measures, which include numbing cream, Child Life support, distraction, caregiver hold, or any combination of these, based on patient preference.
62036747|NCT05696899|NO_INTERVENTION|Control Group|Participants will be offered standard supportive measures, which include numbing cream, Child Life support, distraction, caregiver hold, or any combination of these, based on patient preference.
62036748|NCT06176196|EXPERIMENTAL|VX-548|Participants will receive VX-548 up to 12 weeks.
62237832|NCT02850211|ACTIVE_COMPARATOR|Traditional NSAIDs|1 tablet of 385mg Ibuprofen twice a day for 14 days
62237833|NCT02850211|ACTIVE_COMPARATOR|Opioid drug|1 tablet of 50mg Tramadol twice a day for 14 days
62237834|NCT05810272|OTHER|Habitual Activity|Following three days of habitual activity, a metabolic trial will be completed wherein participants (10M/10F) will be assessed for their anabolic response to a protein-carbohydrate meal.
62428305|NCT02523807||Patients with Parkinson's Disease|Patients with tremor due to Parkinson Disease
62428306|NCT02523807||Patients with Essential tremor|Patients with tremor due to Essential tremor
62428307|NCT05430282|ACTIVE_COMPARATOR|Vestibular rehabilitation|Patients in the vestibular rehabilitation group will be asked to do vestibular exercises 3 times a day for 20 minutes, every day for one month.
62428308|NCT05430282|EXPERIMENTAL|Cervical exercise in addition to vestibular rehabilitation|Patients in this group will receive the same vestibular exercise program and will be asked to do additional neck exercises and they will be asked to do these exercises twice a day for ten minutes.
62428309|NCT01866982|ACTIVE_COMPARATOR|Umbilical Cord Milking|Milking the umbilical cord 4 times towards the infants at a speed of 20cm/2 seconds
62428310|NCT01866982|ACTIVE_COMPARATOR|Delayed Cord Clamping|Delayed clamping of the umbilical cord for 45-60 seconds
62596118|NCT02648477|EXPERIMENTAL|Cohort 1 (pembrolizumab, doxorubicin hydrochloride)|"Patients receive pembrolizumab IV over 30 minutes on day 1 and doxorubicin hydrochloride IV on day 1. Treatment repeats every 3 weeks for 6 courses, and then continues for up to 24 months with pembrolizumab alone in the absence of disease progression or unacceptable toxicity.~Patients who stop pembrolizumab with stable disease or better may receive additional pembrolizumab therapy for up to 1 year if they progress after stopping study treatment."
62596119|NCT02648477|EXPERIMENTAL|Cohort 2 (pembrolizumab, anti-estrogen therapy)|"Patients receive pembrolizumab IV over 30 minutes on day 1 and an aromatase inhibitor (exemestane, anastrozole, or letrozole) PO QD on days 1-21. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity.~In both arms, patients who stop pembrolizumab with stable disease or better may receive additional pembrolizumab therapy for up to 1 year if they progress after stopping study treatment."
62596120|NCT03896529|NO_INTERVENTION|No-stress control group|Participants in this group will perform the psychology tasks (virtual navigation) without any manipulation of psychological stress
62596121|NCT03896529|EXPERIMENTAL|Stress group|Participants in this group will perform the psychology tasks (virtual navigation) under manipulated psychological stress (anticipatory threat of shock)
62596122|NCT03575299|EXPERIMENTAL|Study group|Patients will be treated with anti-tuberculosis drugs, and meanwhile will be treated with Allogeneic γδT cells.
62596123|NCT03575299|PLACEBO_COMPARATOR|Control Group|Patients will be treated with anti-tuberculosis drugs, and meanwhile will not be treated with allogeneic γδT cells.
62596124|NCT01335074|EXPERIMENTAL|Temsirolimus + Sorafenib|
62036749|NCT06176196|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to VX-548 up to 12 weeks.
62036750|NCT01557413|EXPERIMENTAL|Intramedullary nail|Intramedullary nail
62036751|NCT01557413|EXPERIMENTAL|Locked plate|Locked plate
62036752|NCT03671837|EXPERIMENTAL|Oyxgen|Nasal Insufflation with 15 L/min O2 and a nasopharyngeal airway
62036753|NCT03671837|ACTIVE_COMPARATOR|Air|Nasal Insufflation with 15 L/min air and a nasopharyngeal airway
62036754|NCT03545854|EXPERIMENTAL|T3 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the T3 vertebral level
62036755|NCT03545854|EXPERIMENTAL|T3 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the T3 vertebral level
62036756|NCT03545854|EXPERIMENTAL|T3 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the T3 vertebral level
62036757|NCT03545854|EXPERIMENTAL|T12 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the T12 vertebral level
62036758|NCT03545854|EXPERIMENTAL|T12 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the T12 vertebral level
62036759|NCT03545854|EXPERIMENTAL|T12 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the T12 vertebral level
62036760|NCT03545854|EXPERIMENTAL|L4 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the L4 vertebral level
62036761|NCT03545854|EXPERIMENTAL|L4 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the L4 vertebral level
62036762|NCT03545854|EXPERIMENTAL|L4 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the L4 vertebral level
62036763|NCT03538015|EXPERIMENTAL|Carvedilol 3.125 mg|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of low-dose carvedilol treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
62036764|NCT03538015|EXPERIMENTAL|Carvedilol 2.5 mg|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of low-dose carvedilol treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
62036765|NCT03538015|PLACEBO_COMPARATOR|Placebo capsule|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of placebo treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
62428311|NCT06181682|ACTIVE_COMPARATOR|dexmedetomidine group|patients will receive intranasal dexmedetomidine (1 microgram/kg) -Intranasal dexmedetomidine will be prepared from the 100 mcg/ml parenteral preparation in a 1-ml syringe, and 0.9% saline will be added to make a final volume of 1 ml- (0.5 ml will be administrated in each nostril) before starting the anesthesia with monitoring of sedation level and oxygen saturation.
62596125|NCT02588651|EXPERIMENTAL|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg intravenously (IV) once every 3 weeks
62596126|NCT06614998||Screening patients with suspected hemophagocytic syndrome|Preliminary screening of patients with elevated ferritin and low fibrinogen, and then continue to improve triglycerides, abdominal color ultrasound and other examinations to further clarify, for some very suspicious patients, timely improve genes, NK cell activity and other tests, as soon as possible to determine whether they are patients with hemophagocytic syndrome
62237835|NCT05810272|EXPERIMENTAL|Step-Reduction|Participants will undergo three days of reduced physical activity (\<1,500 steps/day) prior to a metabolic trial to establish their anabolic response to a protein-carbohydrate meal.
62237836|NCT04974515|EXPERIMENTAL|Low intensity application of eXciteOSA|Participants will receive the eXciteOSA device intervention at low intensity application for 20 minutes per day for 6 consecutive weeks.
62237837|NCT04974515|ACTIVE_COMPARATOR|High intensity application of eXciteOSA|Participants will receive the eXciteOSA device intervention at high intensity application for 20 minutes per day for 6 consecutive weeks.
62596127|NCT05580978|EXPERIMENTAL|GEM + CGM + Activity Monitor|GEM plus CGM and Activity Monitor (FitBit)
62596128|NCT05580978|ACTIVE_COMPARATOR|Routine Care|Usual care already being received for prediabetes as treated by their care team.
62596129|NCT05670236|EXPERIMENTAL|Knee Osteoarthritis|Individuals with clinically defined unilateral symptomatic knee osteoarthritis.
62596130|NCT05670236|NO_INTERVENTION|Healthy|Individuals who serve as healthy controls.
62596131|NCT01508052|ACTIVE_COMPARATOR|sequential compression device|Apply sequential compression device during the thyroidectomy
62596132|NCT01508052|EXPERIMENTAL|elastic stockings|Apply elastic stockings during the thyroidectomy
62596133|NCT05218356|EXPERIMENTAL|Codivir treatment|20 mg administrated by subcutaneous (SC) injection, twice a day, for 7 days
62596134|NCT05218356|PLACEBO_COMPARATOR|Placebo treatment|Placebo administrated in subcutaneous (SC) injection, twice a day, for 7 days
62596135|NCT02068781|ACTIVE_COMPARATOR|Start with low-sodium diet|One week of low-sodium diet, followed by a two-week wash-out period and subsequently, another week of high-sodium diet
62036766|NCT04461951||Community dwelling seniors|Participants are visited at the research facility in their residence town by a trained team. Informed consent form is completed at the research facility prior to data collection. In those individuals without capacity to give full informed consent, proxy consent is collected from relatives or caregivers. This 2-hours interview includes a face-to-face administration of a neuropsychological battery of tests and questionnaires to inquire about socio-demographic, occupational, and social-economic data, education, medical conditions and drug use, lifestyle habits, functional status, and dietary behaviours.
62596136|NCT02068781|ACTIVE_COMPARATOR|Start with high-sodium diet|One week of high-sodium diet, followed by a two-week wash-out period and subsequently, another week of low-sodium diet
62596137|NCT02829723|EXPERIMENTAL|BLZ945 single agent|BLZ945 administered as single agent
62036767|NCT01818479|EXPERIMENTAL|All participants|
62428312|NCT06181682|ACTIVE_COMPARATOR|midazolam group|patients will receive intranasal midazolam (0.2 mg/kg) up to 5 mg - Intranasal midazolam will be prepared from a 5 mg/ml parenteral preparation, and 0.9% saline will be added to make a final volume of one ml in a 1-ml syringe- (0.5 ml will be administrated in each nostril) before starting the anesthesia with monitoring of sedation level and oxygen saturation.
62428313|NCT06543160|EXPERIMENTAL|Immediate SSC and early breastfeeding during CS group|Receiving immediate SSC and early breastfeeding during CS and routine newborn care
62428314|NCT06543160|OTHER|control group|Receiving delayed SSC and breastfeeding and routine newborn care
62596138|NCT02829723|EXPERIMENTAL|BLZ945 + PDR001|BLZ945 administered in combination with PDR001
62596139|NCT02062944|EXPERIMENTAL|Single-arm study Sirolimus Withdrawal|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
62428315|NCT03262545|EXPERIMENTAL|experimental group|apatinib 500 mg p.o. once daily
62428316|NCT03262545|PLACEBO_COMPARATOR|control group|placebo p.o. once daily
62428317|NCT02527616|EXPERIMENTAL|IV followed by IC (investigation)|The patient undergoes the FFR measurement with the standard measurement first followed by FFR measurement using the FFR Infusion Microcatheter
62428318|NCT02527616|EXPERIMENTAL|IC (investigation) followed by IV|The patient undergoes the FFR measurement using the FFR Infusion Microcatheter measurement first followed by measurement via the standard measurement
62428319|NCT00681824|EXPERIMENTAL|FS VH S/D 500 s-apr|Application of FS VH S/D 500 s-apr on top of suture
62428320|NCT00681824|ACTIVE_COMPARATOR|Standard of Care (Control group)|The treatment of the control group consisted of Standard of Care (SoC) which was defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen based dura substitute.
62428321|NCT00823459|EXPERIMENTAL|Single-Arm Everolimus|Single-arm study with patients receiving Everolimus orally once daily dosing of 10 mg continuously from Day 1 of study until progression of disease or unacceptable toxicity. In addition archival tissue will be analysed for markers of P13K/mTOR pathway activation.
62813976|NCT06533475|EXPERIMENTAL|Treatment C-B-A|Participants will be randomized to receive single doses of minzasolmin with and without food on different Days with a 4-day Washout Period between doses. C: Tablet formulation (fed); B: Tablet formulation (fasting); A: Granules in capsule (fasting).
62813977|NCT00981656|EXPERIMENTAL|3DCRT + CT|Concurrent three-dimensional conformal radiation therapy (3DCRT) and radiosensitizing chemotherapy (CT) consisting of either cisplatin alone or the combination of mitomycin and 5-fluorouracil. Protocol treatment must begin with 15 weeks after a transurethral resection of the tumor (TURBT).
62813978|NCT00699036|EXPERIMENTAL|1|avandia
62813979|NCT00699036|EXPERIMENTAL|2|avandia plus metformin
62428322|NCT03875560|EXPERIMENTAL|Part A/Single Dose|IC14 0.5, 1.0 or 2.0 mg/kg IV as a single dose (subjects are assigned and not randomized to this arm. When Part A is complete, Enrollment to Part B will commence).
62428323|NCT03875560|EXPERIMENTAL|Part B/Cohort 1|IC14 4 mg/kg/day IV or placebo IV x 1 day.
62428324|NCT03875560|EXPERIMENTAL|Part B/Cohort 2|IC14 8 mg/kg/day IV or placebo IV x 1 day.
62428325|NCT03875560|EXPERIMENTAL|Part B/Cohort 3|IC14 2 mg/kg/day IV x 1 day followed by IC14 1 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
62428326|NCT03875560|EXPERIMENTAL|Part B/Cohort 4|IC14 4 mg/kg/day IV x 1 day followed by IC14 2 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
62036768|NCT04662554|EXPERIMENTAL|Novel PET Camera|Patients already undergoing a PET/CT scan for HNC will afterwards undergo a PET scan with the proposed device, thus no additional radioactivity is needed as part of this study.
62036769|NCT03479320|EXPERIMENTAL|Lidocaine group|Lidocaine group will receive intravenous bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the completion of surgery
62036770|NCT03479320|PLACEBO_COMPARATOR|Placebo|They will receive the same volume of 0.9% of normal saline as calculated for the experimental group
62428327|NCT00681577|EXPERIMENTAL|A|
62428328|NCT02419469|EXPERIMENTAL|Augmented BFM Therapy + Ofatumumab or Rituximab|Participants receive the study drugs in Induction, Consolidation, and Maintenance Courses.
62428329|NCT03627182|EXPERIMENTAL|CKD-501 0.5mg|CKD-501 0.5mg
62428330|NCT03627182|PLACEBO_COMPARATOR|Placebo|Placebo
62428331|NCT01472809|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62428332|NCT01472809|EXPERIMENTAL|ZYGK1|"ZYGK1 tablets; 0.125, 0.25, 0.5, 1, 2, ... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved"
62813980|NCT00699036|EXPERIMENTAL|3|avandia plus losartan
62813981|NCT02064673|ACTIVE_COMPARATOR|Curcumin|Curcumin 500 mg orally twice a day
62036771|NCT05271864||Group A|diabetes mellites
62433657|NCT02291107|ACTIVE_COMPARATOR|Control group|Participants received 25 sessions of conventional physiotherapy. Training occurred approximately 5 days/week for 5 weeks, and each training session lasted 1 hour and half. Patients allocated to the Control Group performed the same conventional physiotherapy training of the other group: a general exercise program and a conventional gait training. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and static/dynamic balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation concept, training in walking on different surfaces with or without appropriate walking aids, exercises for the restoration of a correct gait pattern, implementation of residual compensatory strategies and progressive increase of walking resistance
62813982|NCT02064673|PLACEBO_COMPARATOR|sugar pill|placebo orally twice a day
62813983|NCT05068908||Low-impact chronic painful temporomandibular disorder (TMD) cases|Participants whose chronic painful TMD is determined to be low-impact. Visits include a standardized clinical examination using the Diagnostic Criteria for TMD (DC/TMD) protocol, psychosocial questionnaires completion, sensory and endogenous pain modulation (EPM) testing and a multi-modal Magnetic Resonance Imaging (MRI) data acquisition.
62036772|NCT05271864||Group B|hypertension
62036773|NCT05271864||Group C|hyperlipidemia
62428333|NCT06276894|OTHER|Stepping on a Virtual Reality Treadmill with a Functional Near-infrared Spectroscopy (fNIRS) Device|This is a single-arm safety and feasibility study that will enroll up to 15 participants. Those meeting inclusion/exclusion criteria will be invited to enroll in the study. Following a thorough informed consent process, each participant will participate in one session of data acquisition. fNIRS data will be acquired with the NIRSport2, which is a fully-portable system as the device (weighs less than 2 pounds) is secured to the participant's back with backpack-like straps. Following signal optimization and signal quality checks, baseline fNIRS data will be obtained during 60-second periods of quiet, static standing. Then, each participant will complete up to 24 minutes of stepping on a treadmill with and without VR wearing the fNIRS cap. This training will be carried out in two 12-minute sessions with individuals being offered a sitting rest break in between. Training will be completed using the Motek C-Mill™ treadmill, which provides optional body weight support and VR feedback.
62813984|NCT05068908||High- impact chronic painful temporomandibular disorder (TMD) cases|Participants whose chronic painful TMD is determined to be high-impact. Visits include a standardized clinical examination using the Diagnostic Criteria for TMD (DC/TMD) protocol, psychosocial questionnaires completion, sensory and endogenous pain modulation (EPM) testing and a multi-modal Magnetic Resonance Imaging (MRI) data acquisition.
62036774|NCT02040116|OTHER|rituximab infusion|Every patient is getting the same therapy of rituximab. If day 1 is tolerated at standard infusion then day 14 and beyond will be given as rapid infusion over 90 minutes
62237838|NCT01134016|EXPERIMENTAL|Antroquinonol|"6 dose levels, Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~A maximum of 36 patients were planned based on a criteria of a maximum of 6 patients per cohort: 1 to 6 patients were planned for each dose group in the accelerated phase; 3 to 6 patients for each dose group in the standard phase .~The method of dose escalation in the accelerated titration phase continued to the next higher dose level until a patient experienced MT or a DLT. Standard titration phase start with 3+3 patients. Dose escalation proceeded sequentially between cohorts."
62428334|NCT00934037|OTHER|Combined CT Angiography and Myocardial Perfusion|Single Arm study. All patients underwent combined CT Angiography and Myocardial Perfusion.
62428335|NCT02536131|OTHER|Study group|7-10 sessions gut-directed hypnotherapy within 12 weeks
62596140|NCT02714088|EXPERIMENTAL|Intervention|Participants will undertake a high-intensity interval training intervention, completing two exercise sessions per week for 12 weeks. The exercise sessions will consist of 4 sets of 4-6 repetitions of 60s (45s high-intensity exercise, followed by 15s rest), interspersed with 3 minutes rest. During each exercise repetition participants will be encouraged to reach \>90% of their maximal heart rate.
62036775|NCT06113250|ACTIVE_COMPARATOR|shortwave diathermy|
62596141|NCT02714088|NO_INTERVENTION|Control|Participants will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet.
62036776|NCT06113250|ACTIVE_COMPARATOR|ultrasound waves|
62036777|NCT06113250|SHAM_COMPARATOR|therapeutic exercises|
62036778|NCT06258967|ACTIVE_COMPARATOR|Propofol|Propofol is administered at a rate of 15mg/kg\*h for patient induction. After 60 seconds, a sedation assessment is initiated until the patient loses consciousness.Then adjust the propofol dose to 5mg/kg/h and make further dose adjustments based on the patient's response and BIS value, with increments or decrements ranging from 1mg/kg/h, within a total range of 3-8mg/kg/h.
62036779|NCT06258967|EXPERIMENTAL|Ciprofol|Cprofol is administered at a rate of 3mg/kg\*h for patient induction. After 60 seconds, a sedation assessment is initiated until the patient loses consciousness.Then adjust the propofol dose to 1mg/kg/h and make further dose adjustments based on the patient's response, with increments or decrements ranging from 0.2mg/kg/h, within a total range of 0.6-1.6mg/kg/h.
62036780|NCT01595295||Hypomethylating Agents|Patients treated with hypomethylating agents
62036781|NCT05245929|ACTIVE_COMPARATOR|Skeletally anchored Distal Jet appliance|
62596142|NCT02368379|OTHER|Assessment of Central Adrenal Insufficiency|Patients will undergo low dose ACTH stimulation test followed by overnight metyrapone test to assess for central adrenal insufficiency.
62735200|NCT02501148||Carotid artery stenting|Symptomatic and asymptomatic subjects requiring carotid artery stenting, post-dilation performed using the Paladin System with integrated embolic protection
62813985|NCT05068908||Pain-free controls|Participants without chronic painful TMD. Visits include a standardized clinical examination using the Diagnostic Criteria for TMD (DC/TMD) protocol, psychosocial questionnaires completion, sensory and endogenous pain modulation (EPM) testing and a multi-modal Magnetic Resonance Imaging (MRI) data acquisition.
62813986|NCT05068908||Pilot study-MRI optimization group|"A pilot study will be conducted separately from the main project for optimization of MRI parameters, where up to five participants will be recruited as a separate group to undergo only MRI sessions (single study visit). The goal is to optimize the parameters of the main project's MR imaging protocol in order to minimize imaging distortions related to the presence of the thermodes in close proximity to the field of view for the brain."
62813987|NCT06172452|EXPERIMENTAL|Project Body Neutrality SSI|Project Body Neutrality is a digital, self-guided SSI that teaches adolescents about body neutrality. It contains self-reflection exercises, vignettes from fictional peers, and psychoeducation that support users in understanding why body positivity may be a difficult mindset for some individuals to obtain; additional self-reflection exercises and vignettes that present body neutrality as a well-rounded alternative to body positivity; exercises that culminate in a user-generated list of activities that their body allows them to enjoy as well as statements they can use to counter negative thoughts about their body; writing prompts where users provide advice based on body neutrality principles to fictional peers struggling with their body image; and an opportunity to contribute their advice or reflections anonymously to a lab-run social media campaign as a form of body neutrality advocacy. See all materials for this intervention here: https://osf.io/7qtuj.
62596143|NCT03053063|EXPERIMENTAL|SEL 6 mg|"Randomized Phase: SEL 6 mg plus placebo to match SEL 18 mg for up to 240 weeks.~Open-Label (OL) Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
62237839|NCT00987688|EXPERIMENTAL|Hypothermia|Early and sustained hypothermia.
62596144|NCT03053063|EXPERIMENTAL|SEL 18 mg|"Randomized Phase: SEL 18 mg plus placebo to match SEL 6 mg for up to 240 weeks.~Open-Label Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
62813988|NCT06172452|PLACEBO_COMPARATOR|Supportive Therapy SSI|The Sharing Feelings SSI is a digital, self-guided SSI that is structurally similar to Project Body Neutrality, but it is designed to mimic supportive therapy (ST). The goals of the ST intervention are to encourage participants to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. The ST-SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program, reading and writing exercises, and vignettes from fictional peers. See all materials for this intervention here: https://osf.io/u4axs/.
62036782|NCT05245929|ACTIVE_COMPARATOR|Skeletally anchored Hyrax screw distalizer|
62036783|NCT02126098||Adults who diagosed ANCA-vasculitis|"Patients with Wegener's granulomatosis or microscopic polyangiitis were eligible to participate in the study if they had~1. Positive serum assays for proteinase 3-ANCA or myeloperoxidase-ANCA~2. manifestations of severe disease,11 and a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 3 or more (scores range from 0 to 63, with higher scores indicating more active disease)"
62036784|NCT02449200|EXPERIMENTAL|Multimodal physiotherapy group|4 week multimodal physiotherapy treatment programme provided by an experienced musculoskeletal physiotherapist
62036785|NCT02449200|NO_INTERVENTION|Advice to stay active group|Advice to stay active and continue use of prescribed medication as appropriate, via weekly phone calls from a physiotherapist over a 4 week period.
62036786|NCT00739349|EXPERIMENTAL|1|Cyclosporine 0.05%
62237840|NCT00987688|NO_INTERVENTION|Normothermia|Standard management
62596145|NCT03053063|PLACEBO_COMPARATOR|Placebo|"Randomized Phase: Placebo to match SEL 6 mg plus placebo to match SEL 18 mg for up to 240 weeks.~Open-Label Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
62036787|NCT00739349|EXPERIMENTAL|2|Cyclosporine 0.1%
62036788|NCT00739349|PLACEBO_COMPARATOR|3|vehicle/placebo
62036789|NCT05130151|EXPERIMENTAL|Intervention|Participants in this arm will receive the mobile phone-based intervention.
62036790|NCT05130151|NO_INTERVENTION|Standard of care|Participants in this arm will receive only standard of care.
62237841|NCT02900469|EXPERIMENTAL|Denosumab & surgery|"denosumab: 120 mg subcutaneous injection~Surgery: 2-4 weeks after denosumab"
62237842|NCT00196872|EXPERIMENTAL|ETC-with Ibandronat|ETC follwoed by Ibandronat
62237843|NCT00196872|EXPERIMENTAL|ETC without Ibandronat|ETC not followed by Ibandronat
62237844|NCT00196872|EXPERIMENTAL|EC-TX with Ibandronat|EC-TX followed by Ibandronat
62237845|NCT00196872|EXPERIMENTAL|EC-TX without Ibandronat|EC-TX not followed by Ibandronat
62428336|NCT01367821||Patients with obstructive jaundice|Patients with obstructive jaundice
62428337|NCT01367821||Healthy volunteers|Healthy volunteers
62428338|NCT03147001|EXPERIMENTAL|Protein ingestion|Subjects ingested protein drinks
62428339|NCT03147001|PLACEBO_COMPARATOR|Placebo|Subjects ingested a non-caloric placebo drink
62433658|NCT00162435|EXPERIMENTAL|Genetic|
62596146|NCT05098210|EXPERIMENTAL|Treatment (poly ICLC, PNV21 vaccine, nivolumab)|"Patients receive poly ICLC IM once weekly in weeks when no vaccine is given. Beginning 2 weeks after starting poly ICLC, patients receive personalized neo-antigen peptide vaccine IM once every 4 weeks and nivolumab every 2 or 4 weeks. Treatment continues for 25 weeks in the absence of disease progression or unacceptable toxicity. Patients determined to have clinical benefit on a first course of treatment may repeat a 6 month course of treatment as described above. Patients then receive nivolumab every 2 or 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.~Patients also undergo ECHO or MUGA during screening as well as tumor biopsy, blood sample collection, and MRI, CT and/or PET throughout the study."
62596147|NCT01673412|EXPERIMENTAL|interventional arm|Psychological tests
62596148|NCT03568682|EXPERIMENTAL|Nutritional counseling + urban gardening|Participants in the intervention clinic will receive: 1) nutritional counseling from peer counselors in their clinic (approximately 4-5 sessions administered monthly); 2) training from the Ministry of Agriculture on how to plant and maintain a garden in their home (training workshop and monthly follow-up); and 3) a cooking and nutrition workshop facilitated by project nutritionists once garden produce are available.
62596149|NCT03568682|NO_INTERVENTION|Usual care control|Participants in the control clinic will receive their usual care from the clinic. After 12 month follow-up, they will be offered the opportunity to receive the intervention.
62596150|NCT03962790|EXPERIMENTAL|Test/Control|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to one of two sequences, (Test/Control) or (Control/Test).
62596151|NCT03962790|EXPERIMENTAL|Control/Test|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to one of two sequences, (Test/Control) or (Control/Test).
62596152|NCT00731562|EXPERIMENTAL|Varenicline Controlled Release, Fasted|
62596153|NCT00731562|EXPERIMENTAL|Varenicline Controlled Release, Fed|
62596154|NCT06619600|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10 mg qd
62596155|NCT06619600|PLACEBO_COMPARATOR|Placebo|Matched placebo qd
62813989|NCT04011540|EXPERIMENTAL|Intervention|Participants will receive a personalized digital data dashboards throughout the two-month study period.
62036791|NCT01711203|EXPERIMENTAL|Motor Control|"Pilates-based exercise with verbal cues to facilitate motor control Plank progression, use of feedback tool VERBAL CUES FOR MOTOR CONTROL GROUP (could also include above cues) Maintain neutral spine Not too arched, not too flexed Remember your pilates position Inhale, exhale Let me hear your breath"
62596156|NCT02952131|EXPERIMENTAL|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
62813990|NCT04011540|NO_INTERVENTION|Usual Care|Usual care
62813991|NCT02923973|EXPERIMENTAL|TVU CL screening|TVU CL screening: serial TVU CL scan from 16 0/7 to 24 6/7 every week, for a total of nine scans Vaginal progesterone 200mg suppository daily from 14 0/7 to 20 6/7 weeks for the history of prior spontaneous preterm delivery
62428340|NCT05202522|NO_INTERVENTION|Control Group|During the study. participants in the control group will not receive the virtual GERAS DANCE intervention. However, they will receive the virtual GERAS DANCE intervention following study completion for equal opportunity to participate in the program.
62596157|NCT02952131|EXPERIMENTAL|AD-cSVF Arm 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
62813992|NCT02923973|NO_INTERVENTION|No TVU CL screening|no screening Vaginal progesterone 200mg suppository daily from 14 0/7 to 20 6/7 weeks for the history of prior spontaneous preterm delivery
62428341|NCT05202522|EXPERIMENTAL|Virtual GERAS DANCE Group|Virtual GERAS DANCE will be delivered for 1-hr twice weekly for 6 weeks.
62433659|NCT00162435|EXPERIMENTAL|Control|
62237846|NCT04317560|ACTIVE_COMPARATOR|Arthrocentesis|2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.
62237847|NCT04317560|EXPERIMENTAL|Arthrocentesis plus i-PRF injection|2 tubes of blood were collected from the patients with the help of vacuumed 10 mL special liquid PRF tubes (Choukroun I-PRF Collection Tubes, Dr. Choukroun) after arthrocentesis. Blood tubes were centrifuged at 700rpm for 3 minutes. 3 mL of liquid PRF was obtained at the top of each tube. Only the second needle was removed without removing the first needle inserted. I-PRF was injected into the joint areas of all patients in the experimental group, with a maximum dose of 2 mL per joint.
62237848|NCT03182166|EXPERIMENTAL|Patients treated with golimumab|"The optimization procedure is:~* For patients treated at 50 mg of golimumab every 4 weeks (less than 80 kg) will have an increase dose of golimumab: 100 mg every 4 weeks for 8 weeks. They will have rectosigmoidoscopy for measured mayo score and blood samples for measured the concentration of golimumab antibodies.~* For patients treated at 100 mg of golimumab every four weeks (more than 80 kg) will have an increase dose of golimumab: treated at 100 mg every 2 weeks for 4 weeks.~They will have rectosigmoidoscopy for measured mayo score and blood samples for measured the concentration of golimumab antibodies."
62428342|NCT06208852|NO_INTERVENTION|Qualitative phase|The qualitative phase of the sub-study will consist of semi-structured interviews. During the semi-structured interviews, 10 eligible women will be recruited to identify barriers and facilitators to accessing virtual mental health services during the pandemic. This information will be used to adapt an evidence-based patient navigation intervention for virtual use. Investigators will also use information from this qualitative study to adapt a measure of engagement in early intervention services for use among women with postpartum depression to measure engagement with mental health services.
62428343|NCT06208852|EXPERIMENTAL|Intervention Phase|For the intervention phase of the sub-study, 30 women with persistent postpartum depression symptoms will be recruited to participate in the adapted virtual navigator program using rapid cycle testing over a 2-month period.
62596158|NCT02952131|EXPERIMENTAL|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
62596159|NCT01084200|EXPERIMENTAL|Propofol|anesthesia maintenance with propofol and remifentanil
62596160|NCT01084200|EXPERIMENTAL|Sevoflurane|Sevoflurane and Remifentanil for anesthesia maintenance
62596161|NCT01084200|EXPERIMENTAL|Sevoflurane+Propofol|Sevoflurane+Propofol for anesthesia maintenance
62596162|NCT05209048||VTE of Derivation group|VTE of Derivation group includes patients who underwent orthotopic liver transplantation on 2018.8-2020.12 and developed VTE within 30 days after operation
62428344|NCT04522011||Group A|D1/2 radical gastrectomy combines intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel + oxaliplatin
62596163|NCT05209048||No-VTE of Derivation group|No-VTE of Derivation group includes patients who underwent orthotopic liver transplantation on 2018.8-2020.12 and did not develop VTE within 30 days after surgery or after 30 days
62813993|NCT02339922|EXPERIMENTAL|Treatment (ixazomib citrate, rituximab)|Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.
62813994|NCT01419002|EXPERIMENTAL|Neoadjuvant RTx|
62596164|NCT05209048||VTE of Validation group|VTE of Validation group includes patients who underwent orthotopic liver transplantation on 2021.1-2021.12 and developed VTE within 30 days after operation
62596165|NCT05209048||No-VTE of Validation group|No-VTE of Validation group includes patients who underwent orthotopic liver transplantation on 2021.1-2021.12 and did not develop VTE within 30 days after surgery or after 30 days
62596166|NCT06068829||Exposed group 1|Intravenous methylprednisolone (IVMP) plus Inebilizumab
62596167|NCT06068829||Exposed group 2|IVMP plus Rituximab (RTX)
62596168|NCT02071862|EXPERIMENTAL|CB-839|CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity
62735201|NCT02534012|EXPERIMENTAL|PVB group|Patients will receive nerve stimulator guided paravertebral block
62237849|NCT03196986|EXPERIMENTAL|mil60|mil60 (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent mil60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
62237850|NCT03196986|ACTIVE_COMPARATOR|Bevacizumab|Bevacizumab (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent mil60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
62237851|NCT00861835|EXPERIMENTAL|ROSE for TBNA|
62237852|NCT00861835|NO_INTERVENTION|NR|no on-site cytopathology assessment (NR)
62036792|NCT01711203|ACTIVE_COMPARATOR|General strengthening|"Patient group that will receive active strengthening without specific verbal cueing to recruit deeper abdominal musculature. Core strengthening and lower quarter strengthening is the focus of this group.~Verbal cuing will include:~VERBAL CUEING FOR NON-MOTOR CONTROL GROUP~Keep your back straight Don't slouch Don't arch your back Don't let your body move Nothing should move but your arms tighten up your abs suck in your stomach feet shoulder-width apart, knees bent, shoulders back, hold your stomach tight Time will be kept the same as the intervention group."
62237853|NCT00307528|ACTIVE_COMPARATOR|Group A|
62237854|NCT00307528|EXPERIMENTAL|Group B|
62237855|NCT00307528|EXPERIMENTAL|Group C|
62237856|NCT00307528|EXPERIMENTAL|Group D|
62237857|NCT00307528|EXPERIMENTAL|Group E|
62237858|NCT00307528|EXPERIMENTAL|Group F|
62237859|NCT05222763|EXPERIMENTAL|Experimental: Interventional group|The web-supported interactive nursing program intervention will take 3 weeks. The first week of the training will begin with the patient's admission to the clinic. Shoulder and Arm Exercises, Lymphedema in the Arm and Prevention of Its Development, and qualitative study, the themes of misperception determined in this area will be emphasized. In the second week, they will be asked to continue their Shoulder and Arm Exercises training, to examine the Other Side Breast Examination Training and Adaptation Process to Life Activities, Skin Care and Post-Surgery Cancer Treatment and Breast Reconstruction. In the last week of the training, it will be requested to review the contents again. Correct perceptions that may emerge as a result of the qualitative study will be supported in the relevant parts of the training. During the study, short mobile phone messages containing reminders and motivations will be sent regularly twice a week (8 times).
62237860|NCT05222763|ACTIVE_COMPARATOR|Behavioral:|"The handbook developed within the scope of the Women's Return to Social Life After Mastectomy Project on the website of the Continuing Education, Research and Solidarity Association will be used on the website of the participants assigned to the control group."
62237861|NCT03431181|EXPERIMENTAL|MAP target 60-65 mmHg|Treating teams will adjust vasopressors to a target MAP range of 60 to 65 mmHg, avoiding vasopressor-induced MAP above this range.
62237862|NCT03431181|ACTIVE_COMPARATOR|Usual Care|Patients in the control arm will receive usual care (as per local practices).
62237863|NCT01068353|PLACEBO_COMPARATOR|Placebo|
62237864|NCT01068353|EXPERIMENTAL|Etanercept|
62237865|NCT00474669|EXPERIMENTAL|Docetaxel|Intraperitoneal Docetaxel administered with heat
62237866|NCT05659355|EXPERIMENTAL|Treatment Group|Constraint Induced Movement Therapy
62237867|NCT05659355|EXPERIMENTAL|Control Group|Mirror Therapy
62237868|NCT00928746|OTHER|ATROVENT 42mcg|
62036793|NCT04819269|ACTIVE_COMPARATOR|Tivanisiran sodium ophthalmic solution|
62237869|NCT03370848|EXPERIMENTAL|Psyllium plus Aspirin and Niacin ER|"Niacin ER 500mg tablet - take 1 niacin ER 500mg tablet at least two hours before bedtime for two weeks, then increase niacin ER to two 500mg tablets (1,000 mg total) for two weeks, then increase to three niacin ER 500mg tablets (1,500 mg total) for two weeks.~Aspirin 325mg tablet - take 1 aspirin 325 mg tablet 30 minutes prior to niacin ER~Psyllium 1.7gm wafers - take 2 wafers (3.4 grams total) along with aspirin 30 minutes prior to niacin ER"
62237870|NCT03370848|ACTIVE_COMPARATOR|Aspirin and Niacin ER|"Niacin ER 500mg tablet - take 1 niacin ER 500mg tablet at least two hours before bedtime for two weeks, then increase niacin ER to two 500mg tablets (1,000 mg total) for two weeks, then increase to three niacin ER 500mg tablets (1,500 mg total) for two weeks.~Aspirin 325mg tablet - take 1 aspirin 325 mg tablet 30 minutes prior to niacin ER"
62237871|NCT00036686|EXPERIMENTAL|Soy protein isolate|"Administration Prior to Mastectomy or Lumpectomy.~Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.~Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure."
62237872|NCT00036686|PLACEBO_COMPARATOR|Placebo|"Administration Prior to Mastectomy or Lumpectomy.~Patients receive oral placebo twice daily and oral multivitamins once daily.~Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure."
62237873|NCT04184440|PLACEBO_COMPARATOR|placebo|corn starch；capsule，2 g/day，2 times/day；3 months
62036794|NCT04819269|PLACEBO_COMPARATOR|Vehicle ophthalmic solution|
62237874|NCT04184440|EXPERIMENTAL|Cyclocarya paliurus extract|aqueous extract of Cyclocarya paliurus；capsule，2 g/day，2 times/day；3 months
62428345|NCT04522011||Group B|D1/2 radical gastrectomy combines postoperative hyperthermic intraperitoneal chemotherapy with docetaxel + oxaliplatin
62596169|NCT02071862|EXPERIMENTAL|Pac-CB|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose paclitaxel in 28-day cycles until disease progression or unacceptable toxicity
62596170|NCT02071862|EXPERIMENTAL|CBE|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose everolimus in 28-day cycles until disease progression or unacceptable toxicity
62596171|NCT02071862|EXPERIMENTAL|CB-Erl|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose erlotnib in 28-day cycles until disease progression or unacceptable toxicity
62596172|NCT02071862|EXPERIMENTAL|CBD|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose docetaxel in 21-day cycles until disease progression or unacceptable toxicity
62596173|NCT02071862|EXPERIMENTAL|CB-Cabo|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose cabozantinib in 28-day cycles until disease progression or unacceptable toxicity
62596174|NCT05031650|ACTIVE_COMPARATOR|openCPAP|"Immediately after birth, early nCPAP will be started with a nasal mask with a T-piece resuscitator with 8 cm H2O pressure and 0.30 fiO2. The heart rate (HR) and preductal saturation (SpO2) will be evaluated every 30 seconds. Individually, the following steps will be done according to the situation:~* If the HR \> 120 / min and SpO2 not measured yet or be in the target range: The pressure will be continue as 8 cmH2O.~* If the HR between 100-120 but SpO2 below the target range or not measured yet : First the pressure will be increased to 10 cm H2O; than fiO2 will be increased gradually if the patient will not respond to 10 cmH2O pressure. Pressure will be reduced to 8 cmH2O if the HR remains\> 120 / min and oxygen requirement \<0.30 for more than 60 seconds."
62596175|NCT05031650|ACTIVE_COMPARATOR|standardCPAP|"Immediately after birth, early nCPAP will be started with a nasal mask with T-piece resuscitator at 6 cmH2O pressure and 0.30 fiO2. HR and preductal saturation will be evaluated every 30 seconds. The following steps will be performed according to the situation:~* If the HR \> 120 / min and SpO2 be in the target range or not measurable yet: The pressure will be continue as 6 cmH2O.~* If the HR between 100-120 but SpO2 below the target range or not measured yet : The pressure will increased up to 8 cm H2O. FiO2 will be increased gradually if the patient will not respond to 8 cmH2O pressure. Pressure will be reduced to 6 cmH2O if the HR remains\> 120 / min and oxygen requirement \<0.30 for more than 60 seconds."
62596176|NCT01259895||Obesity|BMI \> 30kg/m2
62813995|NCT01419002|ACTIVE_COMPARATOR|Surgery|
62428346|NCT04522011||Group|without hyperthermic intraperitoneal chemotherapy
62428347|NCT00904501|PLACEBO_COMPARATOR|A|A bone marrow harvest (500 mL under general anaesthesia) is performed and BM-MNC are separated and concentrated (30mL). A placebo cell-product (30 mL saline with 4 ml peripheral blood) is implanted and the BM-MNC are cryo-conserved. Only the cell therapy unit, neither the patient, nor the clinician, know whether BM-MNC or placebo is implanted. After 6 months, it is possible to use previously cryo-conserved BM-MNC.
62428348|NCT00904501|EXPERIMENTAL|B|A bone marrow harvest (500 mL under general anaesthesia) is performed and BM-MNC are separated and concentrated (30mL) . The BM-MNC are implanted on the same day. Only the cell therapy unit, neither the patient, nor the clinician, know whether BM-MNC or placebo is implanted
62428349|NCT05134259|ACTIVE_COMPARATOR|Study Group|The children in this group will receive traditional treatment of hemiplegic CP including medical treatment and physiotherapy in addition to repetitive transcranial magnetic stimulation sessions for 4 weeks.
62428350|NCT05134259|NO_INTERVENTION|Control Group|The children in this group will receive traditional treatment of hemiplegic CP including medical treatment and physiotherapy for 4 weeks.
62428351|NCT06377865||1|Beta thalassemia ( major)
62428352|NCT06377865||2|Beta thalassemia (intermediate)
62428353|NCT06140615|EXPERIMENTAL|Lung ultrasound|Participants undergo pre- and post-extubation lung ultrasound
62428354|NCT01212731||Cohort 1|Subjects with a histological diagnosis of malignancy of the base of skull necessitating irradiation to a minimum of 60 Gy, ECOG PS 0-1 with no evidence of metastatic disease and an estimate life expectancy of at least 1 year and who is able to provide informed consent. Subjects will undergo standard CT simulation and radiotherapy treatment planning.
62428355|NCT01212731||Cohort 2|Subjects with a histological diagnosis of low grade glioma requiring radiotherapy. ECOG PS 0-1 with no evidence of metastatic disease and an estimated life expectancy of at least 1 year and who is able to provide informed consent. Subjects will undergo standard CT simulation and radiotherapy treatment planning.
62428356|NCT01542736|EXPERIMENTAL|Reduced radiation with concurrent chemotherapy|Reduced dose craniospinal radiation with concurrent carboplatin and vincristine administration
62428357|NCT03533920|EXPERIMENTAL|UNI-DEB|
62813996|NCT01176201|EXPERIMENTAL|A|400 mg suspension
62428358|NCT00039416|EXPERIMENTAL|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity.
62596177|NCT01259895||Normal weight|BMI between 19 and 24,9kg/m2
62596178|NCT06481891|EXPERIMENTAL|Sotagliflozin|Following a 2-week screening period, sotagliflozin 400 milligrams (mg) tablets will be administered as two 200 mg tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 26 weeks.
62735202|NCT02534012|EXPERIMENTAL|GA group|Patients will receive general anesthesia
62813997|NCT01176201|ACTIVE_COMPARATOR|B|5 x 200 mg immediate release capsule
62237875|NCT04184440|EXPERIMENTAL|Cyclocarya paliurus compounds|mixed aqueous extract of Cyclocarya paliurus and other traditional Chinese herbal medicines including Astragalus propinquus Schischkin，Dioscorea oppositifolia L.，Dendrobium nobile Lindl.，Salvia miltiorrhiza Bge. and Inulin；capsule，2 g/day，2 times/day；3 months
62237876|NCT00281021|EXPERIMENTAL|Erlotinib and Digoxin|Erlotinib plus Digoxin
62237877|NCT01380639|EXPERIMENTAL|Rehabilitation with vibration training|
62237878|NCT01380639|NO_INTERVENTION|Rehabilitation without vibration training|
62036795|NCT03822533|OTHER|Physiotherapist as primary assessor|"The healthcare process will be started with a physiotherapist assessment and treatment. Treatments could involve individual or group treatment including patient education and physical exercise.~Patients can seek a physician anytime after the first assessment with the physiotherapist."
62036796|NCT03822533|OTHER|Physician as primary assessor|"The healthcare process will be started with a physician assessment and treatment. Treatments could involve drug prescription, referral to x-ray, referral to other healthcare providers and sick-leave.~Patients can seek a physiotherapist anytime after the first assessment with the physician."
62036797|NCT01487681||Invasive cervical cancer|
62036798|NCT01487681||Cervical intraepithelial neoplasia 2/3|
62036799|NCT01487681||Cervical intraepithelial neoplasia 1|
62036800|NCT06173778|EXPERIMENTAL|semaglutide|
62036801|NCT06173778|PLACEBO_COMPARATOR|placebo|
62036802|NCT01114854|OTHER|Topiramate IR followed by Topiramate ER|Dosing with IR followed by dosing with ER
62036803|NCT00755482|ACTIVE_COMPARATOR|1|Subjects were given Aquamin F
62036804|NCT00755482|PLACEBO_COMPARATOR|2|Subjects were given a maltodextran placebo
62237879|NCT04575480|ACTIVE_COMPARATOR|Group 1|Group 1 will undergo SWL with 3 days between each session.
62237880|NCT04575480|ACTIVE_COMPARATOR|Group 2|Group 2 will undergo SWL with 7 days between each session
62428359|NCT02729493|EXPERIMENTAL|Single-arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days,the first day,the second day,28days,29days Duration:total five times
62428360|NCT01027884|PLACEBO_COMPARATOR|Placebo|Placebo 900 mg/day
62428361|NCT01027884|EXPERIMENTAL|Idebenone|Idebenone 900 mg/day
62596179|NCT06481891|PLACEBO_COMPARATOR|Placebo|Following a 2-week screening period, sotagliflozin-matching placebo 400 mg tablets will be administered as two 200 mg tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 26 weeks.
62036805|NCT02965950|EXPERIMENTAL|TP53 mutated, LABC|Patients with locally advanced breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide, after taxanes +/- anthracyclines.
62036806|NCT02965950|EXPERIMENTAL|TP53 mutated, MBC, first line|Patients with metastatic breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide first line metastatic disease
62036807|NCT02965950|EXPERIMENTAL|TP53 wt, LABC|Patients with locally advanced breast cancer, TP53 wt disease. Dose-dense cyclophosphamide, after taxanes and anthracyclines.
62036808|NCT02965950|EXPERIMENTAL|TP53 wt, MBC|Patients with metastatic breast cancer, TP53 wt disease. Dose-dense cyclophosphamide, after taxanes and anthracyclines.
62036809|NCT02965950|EXPERIMENTAL|TP53 mutated, MBC|Patients with metastatic breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide, after taxanes +/- anthracyclines.
62036810|NCT05956301|ACTIVE_COMPARATOR|Group I|Conventional Oxygen Therapy
62036811|NCT05956301|EXPERIMENTAL|Group II|High-flow nasal oxygen
62036812|NCT05956301|EXPERIMENTAL|Group III|Supraglottic jet oxygenation and ventilation
62036813|NCT06236503|EXPERIMENTAL|Real Stimulation|Time A. Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Time B. Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 20 minutes with the anode placed on the international electrode 10-20 position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. Time C. Behavioral assessment using the coma recovery scale-R (CRS-R). Rest Period 2 months.
62036814|NCT06236503|PLACEBO_COMPARATOR|Placebo Stimulation|Time A. Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Time B. Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 5 seconds with the anode placed on the international electrode position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. · Time C: Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Time D: Behavioral assessment using the coma Recovery Scale-R (CRS-R).
62036815|NCT00005076|EXPERIMENTAL|EgFR antibody|
62237881|NCT04575480|ACTIVE_COMPARATOR|Group 3|Group 3 will undergo SWL with 14 days between each session.
62237882|NCT03623685|EXPERIMENTAL|voluson 8|
62237883|NCT04315987|EXPERIMENTAL|NestaCell®|A dose of 2x10\^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.
62237884|NCT04315987|PLACEBO_COMPARATOR|Placebo|Matching placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.
62237885|NCT02301936|EXPERIMENTAL|LDV/SOF 12 weeks|Treatment-naive or treatment-experienced participants without cirrhosis will receive LDV/SOF for 12 weeks.
62237886|NCT02301936|EXPERIMENTAL|LDV/SOF 24 weeks|Treatment-experienced participants with cirrhosis will receive LDV/SOF for 24 weeks.
62237887|NCT00725140||Single|
62237888|NCT05255081|EXPERIMENTAL|Treatment Arm|Application of AdSpray™ over all organs under the laparotomy incision at the end of operation
62237889|NCT05255081|PLACEBO_COMPARATOR|Control Arm|Spray with saline would be applied to organs under incision
62237890|NCT01266525|EXPERIMENTAL|SAR110894 - 0.5 mg|SAR110894, 0.5 mg once daily along with Donepezil.
62237891|NCT01266525|EXPERIMENTAL|SAR110894 - 2 mg|SAR110894, 2 mg once daily along with Donepezil.
62237892|NCT01266525|EXPERIMENTAL|SAR110894 - 5 mg|SAR110894, 5 mg once daily along with Donepezil.
62237893|NCT01266525|PLACEBO_COMPARATOR|Placebo|Placebo (for SAR110894) once daily along with Donepezil.
62237894|NCT06512168|EXPERIMENTAL|Treatment Group|AAC Generative Language Intervention
62428362|NCT05775263||A-NRP|
62428363|NCT05775263||TA-NRP|
62813998|NCT00727467|EXPERIMENTAL|A|"On Days 1-8 of the trial, participants in Group A will be given the iPod with some music on the device to allow all participants to become familiar with the device i.e. turning device on and off, increasing and decreasing the volume. They will be instructed to use the device only when sitting at home, and that the device should not be turned on when walking or performing any mobility related or daily tasks.~On Days 8-15, participants in Group A will be allocated to the 'intervention' phase. Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks. On Days 15-23, participants in Group A will be allocated to the 'control' phase. During this time period, participants will be provided with the iPod shuffle containing no music or metronome beat."
62813999|NCT00727467|ACTIVE_COMPARATOR|B|"On Days 1-8 of the trial, participants in Group B will be given the iPod with some music on the device to allow all participants to become familiar with the device. They will be instructed to use the device only when sitting at home, and that the device should not be turned on when walking or performing any mobility related or daily tasks.~On Days 8-15, participants in Group B will be allocated to the 'control' phase. During this time period, participants will be provided with the iPod shuffle containing no music or metronome beat. On Days 15-23, participants in Group B will be allocated to the 'intervention phase'. Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks."
62814000|NCT03768414|EXPERIMENTAL|Arm I (nab-paclitaxel, cisplatin, gemcitabine hydrochloride)|Patients receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62814001|NCT03768414|EXPERIMENTAL|Arm II (cisplatin, gemcitabine hydrochloride)|Patients receive cisplatin IV over 60 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62814002|NCT02979977|EXPERIMENTAL|All subjects|Advanced squamous cell carcinoma of the head and neck region, having previously been treated on a platinum based regimen or with an immune checkpoint inhibitor. Subjects will receive Afatinib dose 30 mg per day and weekly/bi-weekly intravenous cetuximab.
62814003|NCT05699187|EXPERIMENTAL|Face Transplant Recipient|The procedure will be carried out simultaneously by two teams of transplant surgeons for each face transplanted in the operation. The teams will be divided between the functions of tissue recovery (donor operation) and transplant surgery (recipient operation). In most cases the facial graft will include the entire nose; the soft tissues of the mid-face, including all its blood vessels, muscles, and nerves; and a significant portion of the mid-facial skeleton.
62428364|NCT01995006|EXPERIMENTAL|Metamizole|Metamizole 1000mg TID Day 1 till Day 7
62814004|NCT04504500|NO_INTERVENTION|Observation phase|Routine practice assessment
62814005|NCT04504500|ACTIVE_COMPARATOR|Intervention phase|Clinical practice assessment after the application of the trial's educational, behavioral and organizational interventions
62814006|NCT04601818|EXPERIMENTAL|Interventional arm|During our study period, transplants with a planned recipient anesthesia starting time between 10:00pm-6:00am will be allowed to move to a 6:00-8:00am start at the earliest. To be eligible, donor lungs cross clamp time have to occur between 6pm and 4am and lungs need to be suitable for transplantation without the need for ex vivo lung evaluation. Lungs meeting criteria for direct transplantation will be transported in the usual fashion in a cooler of ice at 4oC and upon arrival to Shands UF Health they will immediately be transferred to cold static preservation at 10oC within a specific refrigerator placed in the Shands UF Health OR. The maximum preservation time from donor cold flush (cross clamp) to recipient anesthesia start should be 12 hours and the recipient procedure should not start before 6am.
62814007|NCT04601818|NO_INTERVENTION|Retrospective arm|Outcomes will be compared to conventional transplant patients matched by age, medical diagnosis, BMI, lung allocation score and donor type ( DCD vs. NDD) using a 1:2 matching.
62814008|NCT05580523|EXPERIMENTAL|Aspirin 75 mg and placebo|A capsule of 75 mg aspirin plus an aspirin identical-appearing capsule of placebo to be taken orally once per night from enrolment until 36 weeks' gestation and metformin identical-appearing placebo capsules to be taken orally twice per day from enrolment until delivery.
62428365|NCT01995006|ACTIVE_COMPARATOR|Naproxen|Naproxen 500 mg BID Day 1 till Day 7
62237895|NCT05890872|EXPERIMENTAL|Aliya PEF|Pulsed electric field treatment using the Aliya System
62596180|NCT01992653|EXPERIMENTAL|Polatuzumab Vedotin (1.4mg) + G-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
62596181|NCT01992653|EXPERIMENTAL|Polatuzumab Vedotin (1.0mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
62237896|NCT02783716|ACTIVE_COMPARATOR|Cardiac Resynchronization Therapy (CRT) Group|Participants undergoing Cardiac Resynchronization Therapy Implantation (CRT) implantation for heart failure as part of standard of care will receive EndoPAT testing and collection of subcutaneous adipose tissue
62237897|NCT02783716|ACTIVE_COMPARATOR|Control Group|Participants undergoing device pacemaker or implantable cardioverter-defibrillator (ICD) implantation or pack change for sinus node dysfunction or Atrioventricular (AV) block as part of standard of care will receive EndoPAT testing and collection of subcutaneous adipose tissue
62428366|NCT02643966|EXPERIMENTAL|Whole breast ultrasound|All women will receive both 3D mammography and whole breast ultrasound for breast cancer screening; the order of interpretation will vary for each of two radiologists
62428367|NCT05851482|EXPERIMENTAL|GERD|Patients with GERD symptoms
62428368|NCT02898766|ACTIVE_COMPARATOR|Enteral Nutrition Formula 1|Enteral Nutrition Formula
62428369|NCT02898766|ACTIVE_COMPARATOR|Enteral Nutrition Formula 2|Enteral Nutrition Formula
62428370|NCT06412068|EXPERIMENTAL|Patients diagnosed with PMBCL.|
62428371|NCT05762510|EXPERIMENTAL|LentiRed|LentiRed Drug Product
62428372|NCT03177642||Data Repository Group|All adults presenting to the hand and upper extremity service at Massachusetts General Hospital.
62428373|NCT02913508|EXPERIMENTAL|Vedolizumab 300 mg IV Q8W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, and then every 8 weeks (Q8W) (Weeks 6 and 14).
62814009|NCT05580523|EXPERIMENTAL|Aspirin 150 mg and placebo|Two capsules of 75 mg aspirin to be taken orally once per night from enrolment until 36 weeks' gestation and metformin identical-appearing placebo capsules to be taken orally twice per day from enrolment until delivery.
62237898|NCT01884233|EXPERIMENTAL|Text Messaging CBT (TXT-CBT)|This condition will receive CBT based text messaging (TXT-CBT). Those assigned to TXT-CBT will also be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have an initial meeting with a CBT clinician to review the Life-Steps concepts. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
62237899|NCT01884233|ACTIVE_COMPARATOR|Standard Care|Those assigned to the Standard Care condition will receive the standard monthly medical management physician visit typically associated with HIV care. In addition, a pamphlet with information about HIV, the importance of ART adherence, and relapse prevention will be provided to participants in this condition.
62814010|NCT05580523|EXPERIMENTAL|Aspirin 75 mg and Metformin 1.5 g|A capsule of 75 mg aspirin plus an aspirin identical-appearing capsule of placebo to be taken orally once per night from enrolment until 36 weeks' gestation and metformin capsules (up to 750 mg) to be taken twice per day from enrolment until delivery
62814011|NCT02025686|EXPERIMENTAL|Hyperbaric Oxygen|Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min
62237900|NCT02024165||Electrode Sensor, FSE|Pregnant women between the ages of 18-50 with a single viable fetus in cephalic presentation monitored with Electrode Sensor, and/or FSE
62237901|NCT02024165||Electrode Sensor, Ultrasound|Pregnant women between the ages of 18-50 with a single viable fetus in cephalic presentation monitored with Electrode Sensor, and/or Ultrasound
62428374|NCT02913508|EXPERIMENTAL|Vedolizumab 300 mg IV / 160 mg SC Q3W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, then vedolizumab 160 mg, subcutaneously (SC), every 3 weeks (Q3W) (Weeks 6, 9, 12, 15 and 18).
62428375|NCT02913508|EXPERIMENTAL|Vedolizumab 300 mg IV / 108 mg SC Q2W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, then vedolizumab 108 mg, subcutaneously, every 2 weeks (Q2W) (Weeks 6, 8, 10, 12, 14, 16, 18 and 20).
62428376|NCT02913508|EXPERIMENTAL|Vedolizumab 480 mg SC / 160 mg SC Q3W|Vedolizumab 480 mg, subcutaneously, at Weeks 0 and 2, then vedolizumab 160 mg, subcutaneously, every 3 weeks (Weeks 6, 9, 12, 15 and 18).
62428377|NCT02913508|EXPERIMENTAL|Vedolizumab 324 mg SC / 108 mg SC Q2W|Vedolizumab 324 mg, subcutaneously, at Weeks 0 and 2, then vedolizumab 108 mg, subcutaneously, every 2 weeks (Weeks 6, 8, 10, 12, 14, 16, 18 and 20).
62428378|NCT02007746||Subjects with sickle cell disease and iron overload|Patients will have blood tests done to evaluate liver function and general health, then have FibroScan and Ferriscan. A blinded (no access to laboratory parameters or available data) radiologist will interpret the Ferriscan. Liver biopsy will be also obtained (if not done within the previous year). Otherwise, the results of the recent liver biopsy will be collected.
62428379|NCT02007746||control patients with sickle cell disease|Patients 10 years and older with sickle cell disease without history of chronic transfusions (less than 4 transfusions in a lifetime) and without obvious liver disease. Will have liver function blood tests and general health check ups. Then will have FibroScan performed. No liver biopsy will be performed in control patients.
62428380|NCT05727280|EXPERIMENTAL|Intervention Group|After the first meeting with the patients in the intervention group, the patients will be informed about the application of the Progressive Relaxation Exercise and the exercise application will be taught. After open heart surgery, progressive relaxation exercise will be applied to the patient on the 1st, 2nd and 3rd days of his admission to the service. The patient will be asked to perform the progressive relaxation exercise twice a day, once during the day and once in the evening. Before each daytime application, the score given by the patient to the SF-MPQ will be recorded. Patients will be asked to repeat the same application two hours after dinner. In the morning of the next day after each application, the score given by the patient to the RCSQ will be recorded by the researcher.
62428381|NCT05727280|NO_INTERVENTION|Control Group|After the first meeting with the patients in the control group, the routine care and treatment practices planned by the service will continue. No additional intervention is planned for the patients in this group. After open heart surgery, patients will be asked to fill out the SF-MPQ and RCSQ on the 1st, 2nd and 3rd days of the patient's admission to the service. After the completion of the study, progressive relaxation exercise training will be given to the patients in the control group.
62428382|NCT03398460|OTHER|Health Care Providers|Bellevue hospital Medical Intensive Care Unit; 30 Nurses and 50 physcians
62428383|NCT04202354|EXPERIMENTAL|ARO-HSD|
62428384|NCT04202354|PLACEBO_COMPARATOR|Placebo|
62428385|NCT01154127|EXPERIMENTAL|NVA237 followed by Placebo|"Period 1: 50 μg NVA237 via NEOHALER inhaler device for 21 days~Period 2: Matching placebo via NEOHALER inhaler device for 21 days~The washout period ran for 14 to 28 days between treatment periods. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study.~Salbutamol (albuterol) was used as rescue medication throughout the study."
62428386|NCT01154127|EXPERIMENTAL|Placebo followed by NVA237|"Period 1: Matching placebo of NVA237 via NEOHALER inhaler device for 21 days~Period 2: 50 μg NVA237 via NEOHALER inhaler device for 21 days~The washout period ran for 14 to 28 days between treatment periods. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study.~Salbutamol (albuterol) was used as rescue medication throughout the study."
62428387|NCT01256346||Babies|Preterm newborn infants thought to be 24-32 weeks gestational age.
62814012|NCT06247995|EXPERIMENTAL|Dose A: [177Lu]Lu-NeoB 150mCi q6w + capecitabine|\[177Lu\]Lu-NeoB 150mCi q6w + Capecitabine 1000mg/ m2 BID Day1-14 in a 21-day schedule
62814013|NCT06247995|EXPERIMENTAL|Dose B: [177Lu]Lu-NeoB 100mCi q3w + capecitabine|\[177Lu\]Lu-NeoB 100mCi q3w+ Capecitabine 1000mg/m2 BID Day1-14 in a 21-day schedule
62814014|NCT06247995|EXPERIMENTAL|Dose C: [177Lu]Lu-NeoB 200mCi q6w + capecitabine|\[177Lu\]Lu-NeoB 200mCi q6w + Capecitabine 1000mg/m2 BID Day1-14 in a 21-day schedule
62814015|NCT06247995|EXPERIMENTAL|Dose D: [177Lu]Lu-NeoB 100mCi q6w + capecitabine|\[177Lu\]Lu-NeoB 100mCi q6w + Capecitabine 1000mg/m2 BID Day1-14 in a 21-day schedule
62814016|NCT00617734|EXPERIMENTAL|IMC-A12 (cixutumumab)|
62814017|NCT00617734|EXPERIMENTAL|IMC-A12 (cixutumumab) + cetuximab|
62036816|NCT05487664|ACTIVE_COMPARATOR|Auricular Neurostimulation (Active 1)|"•Within the MRI scanner, each participant will be connected to a series of tAN electrodes that stimulate the following ear target~-ABVN Only stimulation (15Hz stimulation of cymba conchae)"
62428388|NCT04934891|EXPERIMENTAL|ION547|Ascending single multiple doses of ION547 will be administered by SC injection.
62428389|NCT04934891|PLACEBO_COMPARATOR|Placebo|Ascending single multiple doses of ION547-matching placebo will be administered by SC injection.
62428390|NCT00251771|EXPERIMENTAL|I|
62814018|NCT06581705|ACTIVE_COMPARATOR|Group A: (video laryngoscope Group)|About 50 anesthetists in charge must be older than 40 years; each anesthetist had to manage at least 10 patients from both groups received endotracheal intubation (ETI) using the SL and VL group had intubated using the C-MAC® (Karl Storz, Germany) VL with the standard Miller blade and flexible Stylet (2 mm PORTEX® stylet; Smiths Medical International Ltd., UK) to strengthen the endotracheal tube (ETT) and adjust its curvature as C-shaped. The study outcomes included the frequency of successful intubation within 30 s (30-s SR) and the number of intubation attempts. .
62814019|NCT06581705|ACTIVE_COMPARATOR|Group B: (Standard laryngoscope Group)|About 50 anesthetists in charge must be older than 40 years; each anesthetist had to manage at least 10 patients from both groups received endotracheal intubation (ETI) using the SL and VL group had intubated using the C-MAC® (Karl Storz, Germany) VL with the standard Miller blade and flexible Stylet (2 mm PORTEX® stylet; Smiths Medical International Ltd., UK) to strengthen the endotracheal tube (ETT) and adjust its curvature as C-shaped. The study outcomes included the frequency of successful intubation within 30 s (30-s SR) and the number of intubation attempts. .
62036817|NCT05487664|ACTIVE_COMPARATOR|Auricular Neurostimulation (Active 2)|"•Within the MRI scanner, each participant will be connected to a series of tAN electrodes that stimulate the following ear target~-ATNS Only stimulation (100Hz stimulation of the tragus)"
62036818|NCT05487664|ACTIVE_COMPARATOR|Auricular Neurostimulation (Active 3)|"•Within the MRI scanner, each participant will be connected to a series of tAN electrodes that stimulate the following ear target~-Combo stimulation (stimulation of both the 15Hz cymba conchae and 100HZ tragus)"
62428391|NCT00251771|NO_INTERVENTION|II|
62428392|NCT00501696|OTHER|1|A randomized placebo-controlled, parallel-group study, crossover-design
62428393|NCT00501696|OTHER|2|A randomized placebo-controlled, parallel-group study, crossover-design
62596182|NCT01992653|EXPERIMENTAL|Polatuzumab Vedotin (1.8mg) + G-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
62814020|NCT02903914|EXPERIMENTAL|INCB00158 was administered as monotherapy at 50mg twice daily|Monotherapy Part 1a: INCB001158 administered orally in patients with advanced/metastatic solid tumors. Escalating doses will be explored to determine the recommended phase 2 dose (RP2D).
62814021|NCT02903914|EXPERIMENTAL|INCB00158 was administered as monotherapy at 75mg twice daily|Monotherapy Part 2a: INCB001158 administered orally at the RP2D in patients with advanced/metastatic NSCLC (EGFR and Anaplastic Lymphoma Kinase (ALK) negative) previously treated with Standard of Care (SOC).
62814022|NCT02903914|EXPERIMENTAL|INCB00158 was administered as monotherapy at 100mg twice daily|Monotherapy Part 2b: INCB001158 administered orally at the RP2D in patients with advanced/metastatic CRC previously treated with SOC.
62814023|NCT02903914|EXPERIMENTAL|INCB00158 was administered as monotherapy at 150mg twice daily|Monotherapy Part 2c: INCB001158 administered orally at the RP2D in patients with Bladder Cancer, Gastric or Gastroesophageal Junction (GEJ) Cancer, Renal Cell Cancer (RCC), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Urothelial Cell Cancer (UCC), or Melanoma, previously treated with SOC.
62814024|NCT02903914|EXPERIMENTAL|INCB00158 was administered in combination with pembroluzimab at 50mg twice daily|Monotherapy Part 2d: INCB001158 administered orally at the RP2D in patients with any tumor types in Parts 2a, 2b, or 2c.
62814025|NCT02903914|EXPERIMENTAL|INCB00158 was administered in combination with pembroluzimab at 75mg twice daily|Combination Part 1b: INCB001158 and Pembrolizumab administered in patients with advanced/metastatic NSCLC, Melanoma, Urothelial Cell Cancer, MSI CRC, MSS CRC, Gastric or Gastroesophageal Junction (GEJ) Cancer, SCCHN and Mesothelioma. Multiple dose levels will be explored to determine the recommended phase 2 dose (RP2D).
62428394|NCT00383019|EXPERIMENTAL|Xalatan|
62428395|NCT00383019|EXPERIMENTAL|Xalacom|
62428396|NCT04121299|EXPERIMENTAL|Carvedilol 40mg Extended Release Once Daily|participants will be randomized to carvedilol 40 mg extended release once daily for the 1st or 2nd 4 week treatment period
62428397|NCT04121299|ACTIVE_COMPARATOR|Amlodipine 10mg Once Daily|participants will be randomized to amlodipine 10 mg once daily for the 1st or 2nd 4 week treatment period
62814026|NCT02903914|EXPERIMENTAL|INCB00158 was administered in combination with pembroluzimab at 100mg twice daily|Part 3a: INCB001158 and Pembrolizumab the combination RP2D in patients with advanced/metastatic NSCLC (EGFR and ALK negative) with disease progression on anti-PD-1 therapy or prolonged stable disease on Pembrolizumab in the immediate prior line of therapy.
62814027|NCT02903914|EXPERIMENTAL|INCB001158 50 mg BID in combination with pembrolizumab|Part C: evaluated a reduced dose of INCB001158 50 mg BID in combination with pembrolizumab with patients with moderately impaired renal function.
62814028|NCT06116149|ACTIVE_COMPARATOR|In-person health coach strategy|"Delivery of 24 health coaching sessions in-person by health coaches over 1 year.~Standard delivery of 24-sessions of the Group Lifestyle Balance (GLB) behavioral intervention in WIC clinics. The GLB was adapted from the original Lifestyle Balance behavioral intervention used in the original Diabetes Prevention Program trial for use in community translation and group settings. It focuses on improving diet and physical activity and promoting moderate weight loss through health coaching on behavioral change, including self-monitoring of food intake, physical activity, and weight."
62428398|NCT05143086|PLACEBO_COMPARATOR|Placebo|Mouthwash without fluoride.
62428399|NCT05143086|ACTIVE_COMPARATOR|Mouthwash standard|Mouthwash with 225ppm sodium fluoride (NaF). Positive control.
62428400|NCT05143086|EXPERIMENTAL|Mouthwash 50% Nano-F|Mouthwash experimental with Fluoride being half of fluoride Nanoencapsulated and other half freeform of NaF.
62428401|NCT05143086|EXPERIMENTAL|Mouthwash 100% Nano-F|Mouthwash experimental with fluoride 100% Nanoencapsulated.
62428402|NCT00438958|ACTIVE_COMPARATOR|Arm I|Patients undergo filgrastim (G-CSF)-mobilized sibling donor peripheral blood SCT on day 0.
62428403|NCT00438958|EXPERIMENTAL|Arm II|Patients undergo G-CSF-mobilized sibling donor bone marrow transplantation on day 0.
62428404|NCT02156518|EXPERIMENTAL|Vocal Function Exercises|Vocal Function Exercises
62428405|NCT02156518|ACTIVE_COMPARATOR|Vocal hygiene|Vocal hygiene
62428406|NCT03365219|EXPERIMENTAL|Alexis Retractor|This group received an Alexis O-Ring Wound Retractor during cesarean delivery.
62428407|NCT03365219|ACTIVE_COMPARATOR|Standard Surgical Retractors|This group received routine hand-held metal retractors as needed by the surgical team during cesarean delivery.
62596183|NCT01992653|EXPERIMENTAL|Polatuzumab Vedotin (1.4mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
62596184|NCT01992653|EXPERIMENTAL|Polatuzumab Vedotin (1.8mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
62596185|NCT01992653|EXPERIMENTAL|Polatuzumab Vedotin (2.4mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
62428408|NCT03880331|ACTIVE_COMPARATOR|Aggressive Debridement|Aggressive and frequent debridement of fibrin and crust from the wound base down to pinpoint bleeding, both by the patient as part of daily wound care at home, and also by the clinician (either physician or experienced dermatologic surgery nurse) during follow-up visits. Silver nitrate will be used to treat excessive granulation tissue only if the granulation tissue is higher than the level of surrounding skin. Patients will return weekly until healed. Patients will be provided with detailed instructions and guidelines to help determine whether healing has taken place.
62428409|NCT03880331|ACTIVE_COMPARATOR|Minimal Debridement|No debridement of fibrin by the patient or the clinician. Exceptions include debridement of dried crust or eschar. Silver nitrate will be used to treat excessive granulation tissue only if the granulation tissue is higher than the level of surrounding skin. Patients will return every two weeks until healed. In between visits at weekly intervals, the patient will be contacted by phone to determine if healing has occurred in between clinic visits11. Patients will be provided with detailed instructions and guidelines to help determine whether healing has taken place.
62428410|NCT06267677|EXPERIMENTAL|High protein liquid formula|Patients allocated in the intervention group (n=15) received 4 high-protein shakes and the corresponding standard vitamin-mineral (VM) supplementation according to our post BS protocol, then progressed towards a diet that combines traditional foods with 2 hLF shakes per day and VM supplementation for 15 days. Over the following 15 days, patients continued to normalize their diet, including a single hLF shake per day and continued with VM supplementation.
62428411|NCT06267677|NO_INTERVENTION|Standard care diet|Patients in the control group (n=35) followed the traditional protocol after bariatric surgery (sCD-group) consisting of a progressive diet with traditional foods, recommendation of 23g/d of protein powder and standard vitamin-mineral supplementation during the first 2 weeks after the surgery. From then on and according to current dietary protocols, the recommendation for protein powder decreases from 23g to 15g up to the end of the study.
62428412|NCT03470909|OTHER|Skin-Sparing Mastectomy (SSM)|
62428413|NCT03470909|OTHER|Nipple-Sparing Mastectomy (NSM)|
62428414|NCT04923269|EXPERIMENTAL|LY3532226|Single ascending doses of LY3532226 administered subcutaneously (SC).
62428415|NCT04923269|PLACEBO_COMPARATOR|Placebo|Placebo administered SC.
62428416|NCT05540977|EXPERIMENTAL|Donepezil|Patients were randomly divided into experimental group and control group. The experimental group received routine postoperative treatment and took donepezil 5mg orally before going to bed every night from the first day after surgery.
62428417|NCT05540977|OTHER|Usual care|Usual care
62428418|NCT01406275||Pediatrics patients prescribed amoxicillin and clavulanate|Pediatrics patients prescribed amoxicillin and clavulanate for treatment of diseases other than otitis media during study period
62428419|NCT03576430|ACTIVE_COMPARATOR|active|active stress handling
62428420|NCT03576430|NO_INTERVENTION|control|no stress handling
62428421|NCT01977352|ACTIVE_COMPARATOR|Bupivacaine 0.25%|20 cc of bupivacaine 0.25%
62428422|NCT01977352|EXPERIMENTAL|Liposomal bupivacaine|liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
62428423|NCT05103397|ACTIVE_COMPARATOR|low dose group|low dose group. Group (A) (25 patients) patients will receive 10 mg/Kg methyl prednisolone after induction before separation to (CPB).
62428424|NCT05103397|ACTIVE_COMPARATOR|high dose group|high dose group. Group (B) (25 patients) patients will receive 30 mg/Kg methyl prednisolone after induction before separation to (CPB).
62428425|NCT05103397|PLACEBO_COMPARATOR|Placebo group|placebo group. Group (C) (control group)(25 patients) patients will receive placebo in form of normal saline.
62428426|NCT05861440|EXPERIMENTAL|Adjunct corticosteroid and standard anti-tuberculosis agent|Prednisolone dosing and duration per study protocol
62428427|NCT05861440|ACTIVE_COMPARATOR|Standard of care with standard anti-tuberculosis agent|standard anti-tuberculosis agent
62428428|NCT02648399|PLACEBO_COMPARATOR|control group|only unilateral center lymph node dissection
62428429|NCT02648399|EXPERIMENTAL|experimental group|bilateral center lymph node dissection
62428430|NCT06539455||DILI group|Anti-TB DILI was defined by: 1) AST or ALT level \> 5 times the ULN in patients with the absence of symptoms or with a total BIL level \> 2 times the ULN; or 2) AST or ALT level \> 3 times the ULN and total BIL level \> 3 times the ULN in patients who show symptoms compatible with hepatitis.
62428431|NCT06539455||Non-DILI group|Subjects who had no hepatotoxicity events during the therapeutic regimen
62428432|NCT01972542|ACTIVE_COMPARATOR|Type 2 DM|"Intervention : Oral fat tolerance test~well or moderately controlled type 2 diabetes mellitus (HbA1c \< 10%) No dipeptidyl peptidase-4 -inhibitor, Glucagon-like peptide-1 agonist, thiazolidinediones"
62428433|NCT01972542|ACTIVE_COMPARATOR|Prediabetes|"Intervention : Oral fat tolerance test~Glucose 140-199 mg/dL after 75g oral glucose tolerance test HbA1c 5.7-6.4%"
62428434|NCT01972542|SHAM_COMPARATOR|Normal glucose tolerance|"Intervention : Oral fat tolerance test~No impaired fasting glucose and impaired glucose tolerance"
62428435|NCT04517981||Drug intervention|Antidepressant
62428436|NCT04517981||Psychological intervention|Cognitive behavior therapy, sand table therapy
62428437|NCT04517981||Comprehensive intervention|Psychological intervention, community intervention combined with drug intervention
62428438|NCT04630366|EXPERIMENTAL|NST-1024|NST-1024 capsules given once daily for up to 14 days
62428439|NCT04630366|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules to NST-1024 given once daily for up to 14 days
62428440|NCT05741268|EXPERIMENTAL|Dialectical behavior therapy|Dialectical behavior therapy will be applied through psychoeducation, discussion, rehearsal, and homework assignments. Four modules were administered in Mindfulness, Emotion Regulation, Emotion Regulation, and Emotion Regulation.
62596186|NCT01992653|EXPERIMENTAL|Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP|Dose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
62735203|NCT02016391|EXPERIMENTAL|Dexmedetomidine|
62036819|NCT05487664|SHAM_COMPARATOR|Auricular Neurostimulation (Sham 1)|"•Within the MRI scanner, each participant will be connected to a series of tAN electrodes that stimulate the following ear target~-Sham (15Hz stimulation of the earlobe)"
62237902|NCT03427333|EXPERIMENTAL|The Rook® Epicardial Access Kit|The Rook® Epicardial Access Kit will be used to gain access the epicardial surface of the heart via a subxiphoid approach in adult patients with a normal, non-distended pericardial space.
62814029|NCT06116149|ACTIVE_COMPARATOR|Multifaceted technology-assisted health coach implementation strategy|"Delivery of 12 health coaching GLB sessions in-person by health coaches over one year; supplemental technology support, including tools for self-monitoring, health coach monitoring, asynchronous delivery of intervention materials, and asynchronous coach and group connection.~The GLB was adapted from the original Lifestyle Balance behavioral intervention used in the original Diabetes Prevention Program trial for use in community translation and group settings. It focuses on improving diet and physical activity and promoting moderate weight loss through health coaching on behavioral change, including self-monitoring of food intake, physical activity, and weight."
62237903|NCT03474471|EXPERIMENTAL|Group 1:PR-EBV treatment|Follow a Pulmonary rehabilitation program PRIOR to the EBV treatment
62237904|NCT03474471|EXPERIMENTAL|Group 2: EBV treatment-PR|Follow a Pulmonary rehabilitation program AFTER the EBV treatment
62237905|NCT03474471|ACTIVE_COMPARATOR|Group 3: EBV treatment|Only EBV treatment
62237906|NCT02210377|EXPERIMENTAL|Tianjiu (auto-moxibustion)|The participants in the Tianjiu group will be treated with Chinese herbal patches at acupoints on the abdomen and plantar, three times per week, for 4 hours each time during HD.
62428441|NCT05741268|ACTIVE_COMPARATOR|Routine psychological care|they will receive psychological care such as stress management and social skills training.
62428442|NCT00051636|EXPERIMENTAL|Zoledronic Acid and Placebo to Risedronate|Participants received zoledronic acid 5 mg intravenous infusion one dose, 60 days of oral placebo to risedronate, calcium 500 mg twice a day and vitamin D 400 to 1000 international units daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
62596187|NCT01992653|EXPERIMENTAL|Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP|Dose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
62814030|NCT05019690|EXPERIMENTAL|Apatinib Combined With Albumin-Bound Paclitaxel|Participants will receive apatinib combined with albumin-bound paclitaxel until predefined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
62814031|NCT05071209|EXPERIMENTAL|Treatment (elimusertib)|Patients receive elimusertib PO BID on days 1-3, 8-10, 15-17, and 22-24 of each cycle. Treatment repeats every 28 days for 26 cycles in the absence of disease progression or unacceptable toxicity.
62814032|NCT04663321|EXPERIMENTAL|MK-1942 Daily Dose Group|Participants receive a total daily dose titrated from 5 mg to 20 mg of MK-1942 twice daily (BID), orally, over 4 weeks of treatment duration: 5 mg in Week 1, 10 mg in Week 2, and 20 mg in Weeks 3 and 4. Participants receive MK-1942 and matching placebo packaged in blister cards with an equal number of capsules administered in the morning and evening regardless of treatment assignment.
62814033|NCT04663321|EXPERIMENTAL|MK-1942 Intermittent Dose Group|Participants receive a total daily dose of 10 mg of MK-1942 twice weekly (BIW), orally, for Weeks 1-4. Participants receive MK-1942 and matching placebo packaged in blister cards with an equal number of capsules administered in the morning and evening regardless of treatment assignment.
62814034|NCT04663321|PLACEBO_COMPARATOR|Placebo|Participants receive a dose-matched placebo BID, orally, for 4 weeks. Participants receive matching placebo packaged in blister cards with an equal number of capsules administered in the morning and evening regardless of treatment assignment.
62814035|NCT04031599|ACTIVE_COMPARATOR|Carbohydrate counting|Rapid acting insulin analogue with carbohydrate counting
62237907|NCT02210377|PLACEBO_COMPARATOR|Non-Tianjiu (Non auto-MO)|The participants in the control group will be given placebo patches (brown clay patches) on the same sites.
62237908|NCT01549366|EXPERIMENTAL|Aspen Spinous Process Fixation Device|Subjects randomized to the Aspen study arm will have the Aspen device implanted as supplemental posterior fixation only and according to the manufacturer's recommendations.
62237909|NCT01549366|ACTIVE_COMPARATOR|Pedicle Screws|Subjects randomized to the pedicle screw group will have polyaxial top loading pedicle screws implanted according to the standard procedures and practices at that institution. The procedure may be performed according to surgeon preference, including a traditional open, minimally invasive or percutaneous approach. Only pedicle screws cleared by FDA for this indication will be used in this study.
62596188|NCT04497376|EXPERIMENTAL|Upgraded '2C3L'|Patients randomized to the upgraded '2C3L' arm will first undergo ethanol infusion in the vein of Marshall (EI-VOM) followed by the '2C3L' ablation step which includes bilateral circumferential PV antral ablation and linear ablations across the left atrial roof, mitral isthmus (MI), and cavotricuspid isthmus (CTI).
62237910|NCT00646061|EXPERIMENTAL|1|morphine, ketorolac, and buscopan
62237911|NCT00646061|NO_INTERVENTION|2|morphine and ketorolac
62237912|NCT03500250||Nurses|Nurses working on the neurological wards of three hospitals (one university hospital and two general hospitals)
62237913|NCT03780426|EXPERIMENTAL|tSMS left motor cortex (sham right)|30 min of tSMS applied to the left motor cortex with sham on the right motor cortex
62237914|NCT03780426|EXPERIMENTAL|tSMS right motor cortex (sham left)|30 min of tSMS applied to the right motor cortex with sham on the left motor cortex
62237915|NCT04532853||COPD patients|
62237916|NCT05161832|EXPERIMENTAL|nocebo|Ultrasound with fake results of rotator cuff injury.
62237917|NCT05161832|ACTIVE_COMPARATOR|placebo|Ultrasound with fake results of the healthy rotator cuff.
62237918|NCT02897401|EXPERIMENTAL|Smocker|Cigarette consumption in the context of their habit (not related to the particiapion under study).
62237919|NCT02897401|EXPERIMENTAL|Electronic cigarette|Electronic cigarette consumption in the context of their habit (not related to the particiapion under study).
62814036|NCT04031599|ACTIVE_COMPARATOR|Simplified qualitative meal size estimation|Rapid acting insulin analogue with simplified qualitative meal size estimation
62237920|NCT02897401|EXPERIMENTAL|Nicotine replacement therapy|Nicotine replacement therapy (only patch) consumption in the context of their habit (not related to the particiapion under study).
62237921|NCT02897401|PLACEBO_COMPARATOR|Without nicotine|No consumption in the context of their habit (not related to the particiapion under study).
62237922|NCT00233805|ACTIVE_COMPARATOR|1|Bare metal Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system
62237923|NCT00233805|EXPERIMENTAL|2|Sirolimus coated modified Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system
62237924|NCT05934851|EXPERIMENTAL|Frozen-Section Directed Excision Vulvectomy|The surgeon(s) will identify the lesion and make a 1 mm excision around the lesion site.
62428443|NCT00051636|ACTIVE_COMPARATOR|Risedronate and Placebo to Zoledronic Acid|Participants received 60 days of oral risedronate 30 mg, one intravenous infusion of placebo to zoledronic acid, calcium 500 mg twice a day and vitamin D 400 to 1000 international units daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
62428444|NCT05576909|EXPERIMENTAL|Donafenib|"Donafenib combine with TACE for downstaging treatment;~Donafenib for adjuvant therapy."
62428445|NCT02266966|EXPERIMENTAL|F2695|Single dose - 2 capsules / Day on Day 1 and Day 8
62428446|NCT02266966|PLACEBO_COMPARATOR|placebo|Single dose - 2 capsules / Day on Day 1 and Day 8
62814037|NCT03205800|EXPERIMENTAL|Mini-screw placement|One mini-screw (8 mm length) will be placed at the buccal plate of the extraction socket one week after the atraumatic extraction of maxillary first or second premolars in one side.
62814038|NCT03205800|NO_INTERVENTION|No treatment|No treatment after tooth extraction
62814039|NCT06100562|EXPERIMENTAL|Dance Program|10-week adapted dance program (20 hours)
62237925|NCT05934851|ACTIVE_COMPARATOR|Wide Local Excision Vulvectomy|The surgeon(s) will visually identify the abnormal lesion. A Wide Local Excision with 5 mm margins will be made through the dermis per standard of care.
62237926|NCT00626964||Lifestyle or bariatric surgery|Morbid Obesity with BMI \>= 40 kg/m2 or BMI \>= 35 with Comorbidity
62237927|NCT01261754|ACTIVE_COMPARATOR|Metastatic prostate adenocarcinoma|
62428447|NCT01334736|PLACEBO_COMPARATOR|Usual care|
62814040|NCT05818488|EXPERIMENTAL|Experimental mind-body intervention|subjects will be randomized into intervention (one session of mindbody exercise), where they will be asked to sit in a comfortable armchair and remain in a comfortable posture with eyes closed. Cognitive evaluation will be done before and after the intervention.
62814041|NCT05818488|NO_INTERVENTION|Control group|This group will be submitted to the same evaluation. However, they will wiat for 15 minutes with no intervention.
62814042|NCT05789745|EXPERIMENTAL|rhu-pGSN|Treated with 5 doses of rhu-pGSN
62237928|NCT01261754|ACTIVE_COMPARATOR|Healthy Volunteers|
62237929|NCT01261754|ACTIVE_COMPARATOR|Newly Diagnosed, High-Risk Prosate Cancer Patients|
62237930|NCT06472219|PLACEBO_COMPARATOR|Placebo + usual care|Placebo tablets administered once a day for five days.
62237931|NCT06472219|ACTIVE_COMPARATOR|Active Treatment I + usual care|Prednisolone 30mg tablets administered once a day for five days.
62237932|NCT03498846|EXPERIMENTAL|Modified EA and AMLK|Modified corneal epithelial autograft (EA) combined with allogeneic middle lamellar keratoplasty (AMLK) is used for the treatment of patients with severe corneal burn.
62428448|NCT01334736|ACTIVE_COMPARATOR|Lung Age|
62428449|NCT01334736|ACTIVE_COMPARATOR|Contingency Management|
62428450|NCT01334736|ACTIVE_COMPARATOR|Lung age + Contingency Management|
62428451|NCT03182686|EXPERIMENTAL|AMPION™ 4 mL dose|4 mL injection of Ampion
62428452|NCT03182686|PLACEBO_COMPARATOR|Placebo 4 mL dose|4 mL injection of Placebo
62428453|NCT04499235|EXPERIMENTAL|Mometasone furoate + AKST4290|Subjects will receive mometasone furoate concurrently with AKST4290, 400 mg twice daily, until disease control is reached.
62428454|NCT04499235|PLACEBO_COMPARATOR|Mometasone furoate + Placebo|Subjects will receive mometasone furoate concurrently with placebo until disease control is reached.
62428455|NCT05966636|OTHER|Observational Single Arm|All subjects will have scars, quality of life, function assessed pre and post laser treatment
62428456|NCT06118671|EXPERIMENTAL|Intervention group|giving personalized lifestyle intervention suggestions through AI
62428457|NCT06118671|NO_INTERVENTION|Control group|giving routine lifestyle suggestions
62428458|NCT02260141|EXPERIMENTAL|Treatment with d-ribose|Treatment with ribose 5 gm TID
62237933|NCT03498846|ACTIVE_COMPARATOR|LA and AMLK|Limbal autograft (LA) combined with AMLK is used for the treatment of patients with severe corneal burn.
62428459|NCT00833547|EXPERIMENTAL|Eszopiclone|3mg of eszopiclone on two consecutive nights
62428460|NCT00833547|PLACEBO_COMPARATOR|placebo|placebo capsule that looks identical to eszopiclone capsule on two consecutive nights
62428461|NCT01168700|PLACEBO_COMPARATOR|Placebo|Placebo 1.2 g per day for 12 weeks, followed by a second treatment period with aged garlic extract during 12 more weeks.
62596189|NCT04497376|ACTIVE_COMPARATOR|Pulmonary vein antral isolation (PVI)|Patients randomized to the PVI arm will undergo right PV antrum ablation, followed by the left PVA ablation. Radiofrequency should be applied 1 cm proximal to the PV ostia in a wide-area circumferential pattern. Complete PVI will be achieved when all PV potentials within each antrum recorded by the high-density mapping catheter are abolished.
62814043|NCT05789745|PLACEBO_COMPARATOR|normal saline|Treated with 5 doses of saline
62596190|NCT05581641|EXPERIMENTAL|BNT165b1|Escalating dose levels
62814044|NCT06445543|EXPERIMENTAL|MFeast ENHANCED|MFeast ENHANCED (a hybrid MTF intervention with a patient-activated transition from prepared meal to fresh food delivery, adaptations for postpartum people, structural and nutritional lactation support, cultural adaptations for engagement and adherence, and food provision for dependents)
62237934|NCT01050205|ACTIVE_COMPARATOR|Current Intervention|"Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD). Upon choosing, participants will be randomly assigned to Current intervention Arm in which case they will receive the intervention immediately."
62428462|NCT01168700|EXPERIMENTAL|Aged garlic extract (Kyolic ®)|Aged garlic extract, 1.2 g per day for 12 weeks, followed by a second treatment period with placebo during 12 more weeks.
62428463|NCT04947020||Rectal cancer|Patients with primary rectal cancer operated on between 2013 and 2019.
62428464|NCT02067715|EXPERIMENTAL|Sealed bleaching Protocol|The 35% hydrogen peroxide gel will be mixed and applied over the buccal surfaces of teeth. The bleaching agent will remain for 45-min application without replacement of peroxide. However, a customized tray will be placed over the bleaching agent during entire permanence of peroxide (45 minutes).
62596191|NCT05581641|PLACEBO_COMPARATOR|Placebo|
62596192|NCT04289207|EXPERIMENTAL|Romiplostim and danazol|Treatment group (romiplostim and danazol)
62596193|NCT04531254|EXPERIMENTAL|Masking at all times|Children in this group will be asked to wear a face mask/covering in the classroom and common areas during the simulation
62814045|NCT06445543|ACTIVE_COMPARATOR|MFeast Usual Care|MFeast Usual Care (prepared medically tailored meals only).
62814046|NCT04830137|EXPERIMENTAL|Phase 1a Dose Escalation|Multiple dose levels of NX-2127 to be evaluated; determination of MTD/Phase 1b recommended dose
62814047|NCT04830137|EXPERIMENTAL|Phase 1b Dose Optimization Stage 1 in CLL or SLL (Dose A)|CLL/SLL patients whose disease has failed treatment with a BTK inhibitor
62237935|NCT01050205|ACTIVE_COMPARATOR|Delayed Intervention|"Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD). Upon choosing, participants will be randomly assigned to Delayed Intervention Arm in which case they will receive delayed intervention at 6 months."
62237936|NCT01249937|PLACEBO_COMPARATOR|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
62237937|NCT01249937|ACTIVE_COMPARATOR|Ranibizumab and Triamcinolone acetonide|"Recent research has discovered that persons with wet or dry ARMD show an immune response, as if the body is fighting off an infection. The body creates a complex immune response to the growth of blood vessels into the eye tissue, which triggers side effects. It is believed that preventing this inflammation can lead to greater visual gains and a need for fewer treatment injections.~Animal studies have shown that Triamcinolone Acetonide, a corticosteroid (class of drugs that reduce inflammation) can prevent damage to vision from this inflammation. The hypothesis is that treatment with both Ranibizumab and Triamcinolone Acetonide will allow even greater vision improvements than Ranibizumab treatment alone for wet age-related macular degeneration."
62237938|NCT00082745||Observational (genetic analysis)|DNA from peripheral blood or saliva sample of patients is analyzed for the presence of polymorphisms in genes associated with an increased risk of late-occurring complications.
62237939|NCT03511547|ACTIVE_COMPARATOR|Intervention group 1: Pitch-Patch|Reconstruction with patch augmentation using a synthetic patch
62237940|NCT03511547|ACTIVE_COMPARATOR|Intervention group 2: ArthroFlex|Reconstruction with patch augmentation using a biological human dermis patch
62237941|NCT03511547|NO_INTERVENTION|Control|
62237942|NCT04213924|ACTIVE_COMPARATOR|Group ESPB|Ultrasound-guided erector spinae plane block with 10 ml %0.5 bupivacaine and 10 ml %2 lidocaine
62237943|NCT04213924|ACTIVE_COMPARATOR|Group NSAII|lidocaine 5% gel and 800 mg ibuprofen intravenously
62428465|NCT02067715|ACTIVE_COMPARATOR|Conventional Bleaching Protocol|The 35% hydrogen peroxide gel will be mixed and applied over the buccal surfaces of teeth. The bleaching agent will remain for 45-min application without replacement of peroxide.
62237944|NCT01012479|EXPERIMENTAL|Candesartan QD + Hydrochlorothiazide QD|
62596194|NCT04531254|NO_INTERVENTION|No mask/masking when physical distancing is not maintained|Children in this group will not be asked to wear a mask (JK-Grade 4) or only asked to wear a mask when physical distancing in the classroom cannot be maintained (Grade 5-Grade 12) during the simulation
62428466|NCT05465707|EXPERIMENTAL|CM313 2 mg/kg|Once 1 week, intravenous infusion.
62428467|NCT05465707|EXPERIMENTAL|CM313 4 mg/kg|Once 1 week, intravenous infusion.
62428468|NCT05465707|EXPERIMENTAL|CM313 8 mg/kg|Once 1 week, intravenous infusion.
62428469|NCT05465707|EXPERIMENTAL|CM313 16 mg/kg|Once 1 week, intravenous infusion.
62428470|NCT05465707|PLACEBO_COMPARATOR|Placebo|Once 1 week, intravenous infusion.
62596195|NCT04086212|EXPERIMENTAL|IXC Peritoneal dialysis solution|IXC (Icodextrin, Xylitol and L-Carnitine) Peritoneal dialysis solution
62814048|NCT04830137|EXPERIMENTAL|Phase 1b Dose Optimization Stage 1 in MCL (Dose A)|MCL patients whose disease has failed treatment with a BTK inhibitor and an anti-CD20 monoclonal antibody (mAb) based regimen
62814049|NCT04830137|EXPERIMENTAL|Phase 1b Dose Optimization Stage 1 in FL, MZL or WM (Dose A)|FL or MZL patients whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTK inhibitor
62814050|NCT04830137|EXPERIMENTAL|Phase 1b Dose Optimization Stage 1 in DLBCL (Dose A)|DLBCL patients whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen; or another/palliative regimen
62814051|NCT04830137|EXPERIMENTAL|Phase 1b Dose Optimization Stage 1 in PCNSL (Dose A)|PCNSL patients whose disease has failed at least 1 prior line of treatment
62428471|NCT00344305|EXPERIMENTAL|Cohort 1: Participants Between 6 to < 24 Months Age|Participants received a single, intranasal dose of 0.2 millilitre (mL) (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 fluorescent focus units (FFU) of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
62428472|NCT00344305|EXPERIMENTAL|Cohort 2: Participants Between 24 to < 60 Months Age|Participants received a single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 FFU of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
62428473|NCT00827359|EXPERIMENTAL|Treatment|This is a single-arm study. All patients will receive everolimus.
62596196|NCT04086212|ACTIVE_COMPARATOR|Icodextrin|Extraneal® (7.5% Icodextrin) Peritoneal dialysis solution
62596197|NCT04413552|EXPERIMENTAL|Part I: INDV-2000|Participants will receive a single dose of INDV-2000. The starting dose is 1 mg with dose escalation dependent upon observed clinical safety, tolerability and pharmacokinetics.
62596198|NCT04413552|PLACEBO_COMPARATOR|Part I: Placebo|Participants will receive a single dose of matching placebo.
62814052|NCT04830137|EXPERIMENTAL|Phase 1b Dose Optimization Stage 2 in CLL or SLL (Randomized to Dose A or Dose B)|CLL/SLL patients whose disease has failed treatment with a BTK inhibitor
62814053|NCT04830137|EXPERIMENTAL|Phase 1b Dose Optimization Stage 2 in MCL (Randomized to Dose A or Dose B)|MCL patients whose disease has failed treatment with a BTK inhibitor and an anti-CD20 monoclonal antibody (mAb) based regimen
62596199|NCT04413552|EXPERIMENTAL|Part II: INDV-2000 Fasted/Fed|Participants will receive a single dose of INDV-2000 orally on Day 1 under fasted conditions and a single dose of INDV-2000 after a high-fat breakfast on Day 8. Dose to be determined based on a well-tolerated dose studied in Part I.
62237945|NCT02057120|ACTIVE_COMPARATOR|Grupo A (Kinesio Taping)|Will be held the application of Kinesio Taping (Tex Gold) in the region of the rectus femoris dominant lower limb by a physical therapist trained in the technique (KT1 KT2 and) and with experience in this type of application to be designed without knowing in which group fits this patient. In the sequence, the athlete will be oriented to remain at rest for 30 min to get a better grip on the tape and one of the first tests and rest, only after this period will conduct a new evaluation of jump tests (single leg Hop test and Triple Hop Test) and, finally, a new test of strength in the isokinetic dinamomêtro in conjunction with the electromyographic assessment.
62237946|NCT02057120|PLACEBO_COMPARATOR|Placebo Taping|The volunteer will receive a Placebo application tape, being in this case the physical therapist will apply a strip of Kinesio Taping perpendicular to the muscle fibers of the rectus femoris of the dominant member of the individual.
62237947|NCT02335125|EXPERIMENTAL|Intervention|The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both TBI and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, medication, and psychotherapy elements.
62237948|NCT02335125|NO_INTERVENTION|Usual Care|Only standard care practices will be administered to this arm.
62814054|NCT04830137|EXPERIMENTAL|Phase 1b Dose Optimization Stage 2 in FL, MZL or WM (Randomized to Dose A or Dose B)|FL or MZL patients whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTK inhibitor
62814055|NCT04830137|EXPERIMENTAL|Phase 1b Dose Optimization Stage 2 in DLBCL (Randomized to Dose A or Dose B)|DLBCL patients whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen; or another/palliative regimen
62814056|NCT04830137|EXPERIMENTAL|Phase 1b Dose Optimization Stage 2 in PCNSL (Randomized to Dose A or Dose B)|PCNSL patients whose disease has failed at least 1 prior line of treatment
62814057|NCT06704828|EXPERIMENTAL|SHR-4602|
62814058|NCT02348476||Simbrinza™|Patients treated with Simbrinza™ (brinzolamide 1%/brimonidine 0.2%) as standard of care in clinical practice. No study drug is administered in this study.
62814059|NCT04281290|EXPERIMENTAL|Experimental group|Cliniporator Vitae® and chemotherapy drug Bleomycin PHC 15 e. (United States Pharmacopeia - USP)
62814060|NCT06536023|EXPERIMENTAL|362-dose1-4mg|The starting dose for the subjects is 2 mg, administered once weekly for 4 consecutive weeks. If the subject shows good tolerability, the dose will then be escalated to 4 mg, also given once weekly, for another 8 weeks (with an escalation rate of increasing 2 mg every 4 weeks until reaching the target dose).
62814061|NCT06536023|EXPERIMENTAL|362-dose2-6mg|Subjects start at a dose of 2 mg, administered once weekly for 4 consecutive weeks. Following this, if the subject demonstrates good tolerability#, the dose will be escalated to 4 mg, also administered once weekly, for another 4 weeks. After observing the subject's tolerability again, if it remains favorable#, the dose will be further escalated to 6 mg, administered once weekly, for another 4 weeks (dosing will increase by 2 mg every 4 weeks until reaching the target dose of 6 mg)
62814062|NCT06536023|EXPERIMENTAL|362-dose3-Placebo|Administration is via subcutaneous injection once weekly; the mode and form of placebo administration are consistent with those of IBI362, with continuous dosing over a 12-week period.
62814063|NCT00002649|EXPERIMENTAL|Arm I (autologous PBSCT, TBI, etoposide, cyclophosphamide)|"Part I: Autologous PBSC are harvested before study entry. Patients undergo total body irradiation twice a day on days -8 to -5, high-dose etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 1 hour on day -2. PBSC are reinfused on day 0 and then G-CSF may be administered subcutaneously or IV on days 0-21.~Part II: Within 28-80 days after PBSC transplantation and after recovery from any toxic effects, patients with no active recurrent or progressive disease are randomized to 1 of 2 treatment arms.~Patients receive interleukin-2 IV continuously on days 1-4 and 9-18."
62814064|NCT00002649|NO_INTERVENTION|Arm II (observation only)|Patients undergo observation only.
62814065|NCT03188016|EXPERIMENTAL|Intensive Interaction with music|Weekly Intensive Interaction (Nind \& Hewett) from a trained support worker plus music improvised by a music therapist with the aim of enhancing child - support worker interaction
62814066|NCT03188016|ACTIVE_COMPARATOR|Standard Intensive Interaction|Weekly Intensive Interaction (Nind \& Hewett) from a trained support worker
62814067|NCT05009875|EXPERIMENTAL|SBD111|
62814068|NCT05009875|PLACEBO_COMPARATOR|Placebo|
62814069|NCT04986163|ACTIVE_COMPARATOR|non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor|non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor: the monitoring will be done in different periods. In each period the two monitors will monitoring the pain in a serial way. Period 1: awake patient, Period 2: sedated patient with propofol, Period 3 : monitoring during standardized pain stimulus; Period 4: monitoring during surgery
62814070|NCT04986163|ACTIVE_COMPARATOR|non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDSTORM monitor|non invasive analgesia monitoring with ANSPEC-PRO and MEDSTORM the monitoring will be done in different periods. In each period the two monitors will monitoring the pain in a serial way. Period 1: awake patient, Period 2: sedated patient with propofol, Period 3 : monitoring during standardized pain stimulus; Period 4: monitoring during surgery
62036820|NCT05487664|SHAM_COMPARATOR|Auricular Neurostimulation (Sham 2)|"•Within the MRI scanner, each participant will be connected to a series of tAN electrodes that stimulate the following ear target~-Sham (100Hz stimulation of the earlobe)"
62237949|NCT05181865|EXPERIMENTAL|Phase 1 - Cohort 1|
62237950|NCT05181865|EXPERIMENTAL|Phase 1 - Cohort 2|
62237951|NCT05181865|EXPERIMENTAL|Phase 1 - Cohort 3|
62237952|NCT05181865|EXPERIMENTAL|Phase 1 - Cohort 4|
62237953|NCT05181865|EXPERIMENTAL|Phase 1 - Cohort 5|
62237954|NCT05181865|EXPERIMENTAL|Phase 2a - Group 1|
62036821|NCT02519010|EXPERIMENTAL|A Test|Test drug (Amlodipine/Valsartan) 1 tablet contains Amlodipine 10 mg \& valsartan 160 mg
62428474|NCT01779908|EXPERIMENTAL|Vitamin D supplementation|5000 IU of vitamin D3 for 6 months
62428475|NCT01779908|PLACEBO_COMPARATOR|Placebo|Placebo pill for 6 months
62036822|NCT02519010|ACTIVE_COMPARATOR|B Reference|Reference drug (Exforge) 1 tablet contains Amlodipine 10 mg \& valsartan 160 mg
62036823|NCT00646477|EXPERIMENTAL|A|Phase 1 : manual Phase 2 : automatic Descent rate pressure : slow
62036824|NCT00646477|EXPERIMENTAL|B|Phase 1 : manual Phase 2 : automatic Descent Rate Pressure : fast
62036825|NCT00646477|EXPERIMENTAL|C|Phase 1 : automatic Phase 2 : manual Descent rate pressure : slow
62036826|NCT00646477|EXPERIMENTAL|D|Phase 1 : automatic Phase 2 : manual Descent Rate Pressure : fast
62428476|NCT05320614|EXPERIMENTAL|case 1|Case Group:Web-Based Education Information about the operation that the child will undergo; animation films about the hospital, the operating room and the medical equipment to be used; training with presentation including methods of coping with anxiety, fear and pain, postoperative wound care, possible complications in nutrition and nursing care; educational games Education with Therapeutic Play Method Training with the therapeutic game method for 30-45 minutes in the game room in the service one day before the surgery
62428477|NCT05320614|EXPERIMENTAL|control 1|Control Group: Explaining the routine care given in the service by the pediatric surgery nurse to the child and parent in the control group.
62428478|NCT03061279|EXPERIMENTAL|Fixation by Acutrak headless screw|
62428479|NCT03061279|ACTIVE_COMPARATOR|Fixation by headed screws, plates and or wire|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes LC-DCP Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire.
62428480|NCT00690768|EXPERIMENTAL|A|Preoperative Intravitreal bevacizumab and pars plana vitrectomy
62814071|NCT04986163|ACTIVE_COMPARATOR|non-invasive analgesia monitoring with MEDSTORM and MEDASENSE|non-invasive analgesia monitoring with MEDSTORM and MEDASENSE the monitoring will be done in different periods. In each period the two monitors will monitoring the pain in a serial way. Period 1: awake patient, Period 2: sedated patient with propofol, Period 3 : monitoring during standardized pain stimulus; Period 4: monitoring during surgery
62036827|NCT01308242|EXPERIMENTAL|Treatment|Patients enrolled will receive Renvela for a 3 month time frame.
62036828|NCT05377580|EXPERIMENTAL|Period 2 IBI112 dose 4|
62036829|NCT05377580|PLACEBO_COMPARATOR|Period 1 IBI112 Placebo|
62036830|NCT05377580|EXPERIMENTAL|Period 2 IBI112 dose 3|
62036831|NCT05377580|EXPERIMENTAL|Period 1 IBI112 dose 2|
62036832|NCT05377580|PLACEBO_COMPARATOR|Period 2 IBI112 Placebo|
62036833|NCT05377580|EXPERIMENTAL|Period 1 IBI112 dose 1|
62036834|NCT01835457|EXPERIMENTAL|Concentration/meditation group|Subjects in this arm will be performing the concentration/meditation technique of Wim Hof (The Iceman) prior to, during and after intravenously injected 2 ng/kg Lipopolysaccharide
62428481|NCT00690768|ACTIVE_COMPARATOR|B|Pars plana vitrectomy only
62428482|NCT01159119|EXPERIMENTAL|EUR-1066-A|Treatment with Eur-1006-A.
62428483|NCT01159119|EXPERIMENTAL|EUR-1066-B|Treatment with Eur-1066-B
62428484|NCT01159119|ACTIVE_COMPARATOR|Zenpep|Control Group: Consist of treatment with Zenpep
62433660|NCT04050800|EXPERIMENTAL|Healthy Controls|Subjects will be administered two sequential doses of the radiopharmaceutical under nearly zero-biological-change conditions.
62433661|NCT02332135|EXPERIMENTAL|microwave ablation group|patients in ultrasonic ablation will be treated by ultrasound guided percutaneous parathyroid gland microwave ablation
62814072|NCT02873871|OTHER|Control group|Standardized compressive dressing
62814073|NCT02873871|EXPERIMENTAL|Intervention group|Hemostasis with TerumoBand®
62596200|NCT00271011|EXPERIMENTAL|Mitomycin C, Irinotecan and Cetuximab|"Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.~Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.~Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1\*28 allele will receive irinotecan 110 mg/m2."
62596201|NCT02777970|EXPERIMENTAL|Tramadol/Dexketoprofen|"Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose;~Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x \[37.5mg/325mg\] film-coated tablets, oral single dose."
62814074|NCT05284773|EXPERIMENTAL|intervention + standard of care|Caretakers of children 6-59 months old living in communities assigned to the intervention arm will be trained to detect malnutrition using MUAC on their children weekly. Caretakers living in communities assigned to the intervention will also receive usual standard of care.
62814075|NCT05284773|NO_INTERVENTION|standard of care|Caretakers of children 6-59 months living in communities assigned to the standard of care arm will receive usual acute malnutrition screening. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the Centre de Sante et Promotion Sociale (CSPS).
62036835|NCT01835457|ACTIVE_COMPARATOR|Control group|Subjects in this group will be intravenously injected with 2 ng/kg Lipopolysaccharide
62036836|NCT05418036|OTHER|Consecutive patients elegible for outpatient sotalol indication|Single Group
62036837|NCT02414477|EXPERIMENTAL|Smokeless tobacco study product|Smokeless tobacco product spiked with deuterated NNN.
62428485|NCT02766088|EXPERIMENTAL|Total Group|Subjects aged between 6 months and 50 years at the time of enrolment living in geographically-defined communities in Latin America and Southeast Asia. The study population comprised household members and should include between 30% and 50% of adults (aged 18 years or above) per site.The appropriate recruitment strategy was selected by each participating site. Two approaches might be considered: a school-based approach and a community-based approach without school involvement The expected period for recruiting the target sample size was approximately three months.
62036838|NCT02457039|ACTIVE_COMPARATOR|Comprehensive acupuncture (CAI)|Breast cancer patients receiving Cytoxan-containing chemotherapy regimens (Chemo) will receive Dense cranial electroacupuncture stimulation (DCEAS) and Body acupuncture (BA).
62237955|NCT05181865|EXPERIMENTAL|Phase 2a - Group 2|
62596202|NCT02777970|ACTIVE_COMPARATOR|Tramadol/Paracetamol|"Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x \[37.5mg/325mg\] film-coated tablets, oral single dose;~Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose.~."
62596203|NCT02777970|PLACEBO_COMPARATOR|Placebo|"Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;~Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose."
62596204|NCT00793624|EXPERIMENTAL|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
62596205|NCT00793624|EXPERIMENTAL|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
62814076|NCT04763980|ACTIVE_COMPARATOR|Cohort A (survey, genetic testing)|Patients complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Patients may also undergo genetic testing.
62036839|NCT02457039|SHAM_COMPARATOR|Least acupuncture stimulation (LAS)|Breast cancer patients receiving Cytoxan-containing chemotherapy regimens (Chemo) will receive Least acupuncture stimulation (LAS)
62036840|NCT03549910|EXPERIMENTAL|Early use of APRVplus protocol in ARDS|physiology-driven APRVplus protocol
62237956|NCT05181865|EXPERIMENTAL|Phase 2a - Group 3|
62237957|NCT04726462|EXPERIMENTAL|Functional exercise group|
62237958|NCT04726462|EXPERIMENTAL|Posture exercises group|
62596206|NCT00793624|ACTIVE_COMPARATOR|Formoterol 12mcg|12mcg inhaled twice daily from the Aerolizer inhaler
62596207|NCT00793624|PLACEBO_COMPARATOR|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
62814077|NCT04763980|EXPERIMENTAL|Cohort B (educational session, survey, genetic testing)|Patients participate in educational session with health coach over 60 minutes. Patients also complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Patients may undergo genetic testing.
62814078|NCT04819945|EXPERIMENTAL|GATT-Patch|GATT-Patch will be used to control bleeding during open liver surgery. Each surgery will be performed according to the standard procedures at the hospital, with the exception of the use of GATT-Patch.
62814079|NCT05034367|EXPERIMENTAL|Healthy persons|The responses of the healthy subjects are utilized to create reference ranges for a normal cough response to mannitol
62814080|NCT04351542|EXPERIMENTAL|Ayurveda Care Group|Individualised ayurveda treatment was given to participants based on individual constitution.
62814081|NCT04351542|ACTIVE_COMPARATOR|Usual Care Group|Participants followed the usual care.
62814082|NCT06251167|EXPERIMENTAL|Lateral wedge insoles (LWIs)|The LWIs will incorporate a 6 degree wedge along the lateral edge of the insole.
62814083|NCT06251167|EXPERIMENTAL|Lateral wedge plus custom arch support (LWAS)|The LWAS insoles will incorporate custom arch support along the medial edge as well as a 6 degree wedge along the lateral edge of the insole.
62814084|NCT04337580|EXPERIMENTAL|Omeprazole Plus Standard of Care for Prostate Cancer Regimen|This intervention will be given on an outpatient basis. Omeprazole, 80 mg twice daily.
62036841|NCT03549910|OTHER|Low tidal volume ventilation|Low tidal volume lung protective ventilation
62036842|NCT02666547|OTHER|68Ga-NODAGA-RGD,18F-FDG,18F-FET PET/CTs|Active Comparator: 68Ga-NODAGA-RGD radiotracer All patients will undergo a 68Ga-NODAGA-RGD PET/CT, a 18F-FDG PET/CT or a 18F-FET PET/CT
62237959|NCT02629471|EXPERIMENTAL|response time due to light flashs pulses|light flashing effects on response time to random target appearance
62237960|NCT04012437|EXPERIMENTAL|Experimental|.The groups completed Sphincter Control Training over 8 weeks. The SCT consists of 8 different exercises into a mobile app and an educational videos. Its objective is to provide patients with greater knowledge, awareness, and control of the external urethral sphincter. The groups use of a masturbation aid device called Myhixel I from the spanish company New Wellness Concept SL.
62036843|NCT01295554||Peripheral arterial disease|Peripheral arterial disease
62036844|NCT06378554|ACTIVE_COMPARATOR|Cereset Intervention Group|This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM).
62036845|NCT06378554|NO_INTERVENTION|No Intervention|No Intervention
62428486|NCT01548183|EXPERIMENTAL|Lifestyle counseling|Weekly SMS assessing risky sexual encounters and providing feedback including concern, goal-setting and tools to reduce risk
62428487|NCT01548183|NO_INTERVENTION|Usual care|Usual care includes ED provider counseling as per normal clinical care
62814085|NCT06617312|EXPERIMENTAL|Cytisinicline|3mg cytisinicline oral capsule 3 times daily for 2-to-3 weeks
62036846|NCT05972096|EXPERIMENTAL|Combination of DBT-ST, self-compassion, and contextual-based skills.|Combination of DBT-ST, self-compassion, and contextual-based skills.
62428488|NCT00935896|NO_INTERVENTION|high VT group|
62428489|NCT00935896|EXPERIMENTAL|Low tidal volume|
62428490|NCT01952639|EXPERIMENTAL|30 g of wheat protein|Subjects will consume 30 g of wheat protein protein type and amount
62428491|NCT01952639|EXPERIMENTAL|30 g of wheat protein hydrolysate|Subjects will consume 30 g of wheat protein hydrolysate protein type and amount
62428492|NCT01952639|ACTIVE_COMPARATOR|30 g of whey protein|Subjects will consume 30 g of whey protein protein type and amount
62814086|NCT06617312|PLACEBO_COMPARATOR|Placebo|matched to experimental drug
62814087|NCT03299959|EXPERIMENTAL|Agili-C|
62814088|NCT03299959|ACTIVE_COMPARATOR|Surgical Standard of Care (SSOC)|
62814089|NCT02721940|EXPERIMENTAL|Treatment group|In the treatment group, patients will be given local injection of enriched autologous mononuclear cells and zoledronic acid into the necrotic area following core decompression by drilling.
62814090|NCT02721940|EXPERIMENTAL|Control group|In the control group, core decompression will be performed, but no treatment will be given.
62814091|NCT04773392|ACTIVE_COMPARATOR|Twice-daily Regimen|Twice-daily regimen of immediate release tacrolimus, mycophenolate mofetil (MMF)/mycophenolic acid (MPA) plus daily methylprednisolone or prednisone.
62814092|NCT04773392|ACTIVE_COMPARATOR|Once-daily Regimen|Once-daily regimen of Envarsus, azathioprine plus methylprednisolone or prednisone.
62428493|NCT01952639|ACTIVE_COMPARATOR|30 g of casein|Subjects will consume 30 g of casein protein type and amount
62428494|NCT01952639|EXPERIMENTAL|60 g of wheat protein hydrolysate|Subjects will consume 60 g of wheat protein hydrolysate protein type and amount
62814093|NCT03080155|EXPERIMENTAL|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
62814094|NCT06304103|EXPERIMENTAL|AND017 capsules 4 mg|
62814095|NCT06304103|EXPERIMENTAL|AND017 capsules 12 mg|
62814096|NCT06304103|EXPERIMENTAL|AND017 capsules 30 mg|
62814097|NCT06552286|EXPERIMENTAL|Surviving and Thriving in the Real World - Telehealth (STRW-T)|randomized to STRW-T intervention
62814098|NCT06552286|ACTIVE_COMPARATOR|Program for the Education and Enrichment of Relational Skills - Telehealth (PEERS-T)|randomized to PEERS-T intervention
62428495|NCT02214498|ACTIVE_COMPARATOR|Enalapril/hydrochlorothiazide|This arm will start with six weeks of administration of enalapril/hydrochlorothiazide in the evening and placebo in the morning, followed by six weeks of active treatment in the morning and placebo in the evening
62237961|NCT04012437|ACTIVE_COMPARATOR|Control|.The groups completed Sphincter Control Training over 8 weeks. The SCT consists of 8 different exercises into a video tutorial and an educational videos. Its objective is to provide patients with greater knowledge, awareness, and control of the external urethral sphincter.
62428496|NCT02214498|PLACEBO_COMPARATOR|Placebo|This arm will start with six weeks of morning administration of enalapril/hydrochlorothiazide in the morning and placebo in the evening, followed by six weeks of placebo in the morning and active treatment in the evening
62428497|NCT01105260||control|group with classical rehabilitation program
62428498|NCT01105260||training|group with an 8 weeks interval training program on wheelchair independence
62428499|NCT05508074|EXPERIMENTAL|IFB-088 50 mg/day + riluzole 100 mg/day|"The test product, IFB-088, will be administered orally in 50 mg/day dosage consisting of two uptakes of 25 mg each (morning and evening uptakes), as an add-on therapy to riluzole 100 mg.~Intervals for dosing should ideally be about 12 hours (± one hour). Tablets will be swallowed with a glass of water 30 minutes before the meal, in fasting condition.~Administration of riluzole 100 mg, tablet or suspension, will be at the patient's and/or investigator's choice, as per summary of product characteristics. The daily dose of 100 mg will be taken in two 50 mg doses every 12 hours, at the same time than the IMPs.~Patients will be treated for a period of 6 months (26 weeks)."
62428500|NCT05508074|PLACEBO_COMPARATOR|placebo + riluzole 100 mg/day|"The placebo will be administered orally in two uptakes (morning and evening uptakes), as an add-on therapy to riluzole 100 mg.~Intervals for dosing should ideally be about 12 hours (± one hour). Tablets will be swallowed with a glass of water 30 minutes before the meal, in fasting condition.~Administration of riluzole 100 mg, tablet or suspension, will be at the patient's and/or investigator's choice, as per summary of product characteristics. The daily dose of 100 mg will be taken in two 50 mg doses every 12 hours, at the same time than the IMPs.~Patients will be treated for a period of 6 months (26 weeks)."
62814099|NCT01657864||Patients with aseptic meningitis|All patients of the study population with a record/diagnosis of aseptic meningitis during the study period
62237962|NCT04641780||Rexulti Tablets|Target is 300 patients in the Philippines diagnosed with Schizophrenia and Major Depressive Disorder
62237963|NCT05514821|EXPERIMENTAL|Experimental condition 1|Acute supplementation with 140 ml Beet It Sport Shots, James White Ltd (\~400mg dietary nitrate)
62237964|NCT05514821|EXPERIMENTAL|Experimental condition 2|Acute supplementation with 140 ml Beet It Sport Shots, James White Ltd (\~400mg dietary nitrate)
62237965|NCT05514821|PLACEBO_COMPARATOR|Control condition 1|Acute supplementation with 140 ml nitrate-depleted Beet It Sport Shots, James White Ltd (\~0mg dietary nitrate)
62237966|NCT05514821|PLACEBO_COMPARATOR|Control condition 2|Acute supplementation with 140 ml nitrate-depleted Beet It Sport Shots, James White Ltd (\~0mg dietary nitrate)
62428501|NCT03250065|EXPERIMENTAL|ETT Study Group|The Sensing ET Tube study Group
62428502|NCT01120600|EXPERIMENTAL|Odanacatib 50 mg once weekly|Participants will receive one Odanacatib 50 mg tablet once weekly. In addition, they will receive a weekly dose 5600 IU of open-label Vitamin D3 as well as a sufficient supply of open-label calcium carbonate so that their total daily calcium intake from both dietary and supplemental sources is approximately 1200 mg.
62428503|NCT01120600|PLACEBO_COMPARATOR|Placebo once weekly|Participants will receive one Placebo tablet once weekly. In addition, they will receive a weekly dose 5600 IU of open-label Vitamin D3 as well as a sufficient supply of open-label calcium carbonate so that their total daily calcium intake from both dietary and supplemental sources is approximately 1200 mg.
62428504|NCT04681222||LFCN|Patients received LFCN + PENG blocks
62428505|NCT04681222||Wound Infiltration|Patients received wound infiltration + PENG blocks
62428506|NCT02495870|EXPERIMENTAL|Pork, 58°C, 72 minutes|Pork muscle (semitendinosus) sous-vide cooked at 58°C for 72 minutes
62428507|NCT02495870|EXPERIMENTAL|Pork, 58°C, 17 hours|Pork muscle (semitendinosus) sous-vide cooked at 58°C for 17 hours
62428508|NCT02495870|EXPERIMENTAL|Meat balls, 58°C, 17 hours|Meat balls made from pork Semitendinosus. Sous-vide cooked at 58°C for 17 hours
62428509|NCT02495870|ACTIVE_COMPARATOR|Pork, 160°C (until 58°C in core)|Pork muscle (semitendinosus) oven cooked at 160°C until 58° in core.
62428510|NCT05698420||The Theranova 400 group, also known as the MCO group.|Patients undergoing maintenance hemodialysis will receive dialysis treatment using the Theranova 400 device.
62428511|NCT05698420||The FX80 group, also known as the high-flux group.|Patients undergoing maintenance hemodialysis will receive dialysis treatment using the FX80 device.
62596208|NCT03322774|SHAM_COMPARATOR|Attention Control|This group receives sleep hygiene education, which serves as a credible control intervention to digital cognitive behavioral therapy for insomnia (dCBT-I). This intervention mimics the web-based patient contact inherent in dCBT-I but is inert with respect to sleep outcomes.
62237967|NCT06085651||PSI group|we divided all patients into two groups according to their RSH in the final follow-up time: PSI group (RSH≥20mm)
62237968|NCT06085651||Non-PSI|we divided all patients into two groups according to their RSH in the final follow-up time: Non-PSI group (RSH≤20mm)
62428512|NCT05416359|EXPERIMENTAL|TQB3915 tablets|Take 300mg, 450mg, 600mg, 750mg, 900mg each time, once a day;Oral administration on an empty stomach, 28 days as a cycle. Duration of medication: Continue medication until disease progression or intolerable toxicity occurs.
62596209|NCT03322774|EXPERIMENTAL|Stepped Care Model|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Following initial treatment with dCBT-I, individuals who do not experience remission of their insomnia will begin treatment with face-to-face Cognitive Behavioral Therapy for Insomnia with a trained staff member in behavioral sleep medicine."
62814100|NCT01657864||Patients without aseptic meningitis|All patients of the study population without a record/diagnosis of aseptic meningitis during the study period
62814101|NCT03562273||GammaPod Quality of Life Evaluations|This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.
62428513|NCT05040815|EXPERIMENTAL|chemo-radiation treatment|"Radiotherapy with concurrent 5-fluorouracil and mitomycin-C combination treatment.~Radiotherapy consists of 5400 cGy delivered in 30 fractions over 6 weeks. The investigators will be using the current standard regimen for the study or no change in the current CCI treatment regimen. However, the radiotherapy target will be smaller than current practice since the investigators will be omitting prophylactic inguinal irradiation."
62237969|NCT06486311|EXPERIMENTAL|Assessment stability of satellite implant|"Satellite implant is connecting microplate is attached to the implant's supra structure placed on the adjacent alveolus. Miniature satellite implant screws are inserted at approximal cortical sites to give the implant additional stability"
62428514|NCT05186922|EXPERIMENTAL|CM326 55 mg, once every two weeks (Q2W)|55mg for 6 doses, every 2 weeks, subcutaneous (SC)
62428515|NCT05186922|EXPERIMENTAL|CM326 110 mg, once every two weeks (Q2W)|110mg for 6 doses, every 2 weeks, subcutaneous (SC)
62237970|NCT02349451|ACTIVE_COMPARATOR|Adalimumab|Double-blind adalimumab 40 mg administered every other week (EOW) for 12 weeks
62237971|NCT02349451|PLACEBO_COMPARATOR|Placebo|Double-blind placebo administered every week (EW) for 12 weeks
62428516|NCT05186922|EXPERIMENTAL|CM326 110 mg, once every four weeks (Q4W)|110mg for 3 doses, every 4 weeks, subcutaneous (SC)
62814102|NCT06105060|ACTIVE_COMPARATOR|Group 1 (Rosuvastatin group):|40 patients will receive Crestor (Rosuvastatin 20mg/day orally for 6 months).
62036847|NCT05972096|PLACEBO_COMPARATOR|Control Group|Treatment as usual. Although these individuals did not receive any new specific psychotherapeutic intervention for BPD, they valued the higher frequency of psychiatric visits, attention in crisis, family care, and greater experience and sensitivity in the management of BPD.
62036848|NCT02575885|EXPERIMENTAL|Arm I (different type of ENDS product at each visit)|Participants are asked to smoke ad lib a single cigarette of their own brand and provided with a different type of ENDS product at each visit (e-cigarette, disposable e-cigarette, eGo, personal vaporizer, e-cigar, and e-pipe) over 3.5-4 hours at least 7 days apart for 7 weeks. Participants are provided with cartridges of the same amounts of nicotine with regular (tobacco) or menthol flavor according to smoker's preference, instructed on how to use the product, asked to practice using it for 7 days, and return to the study center for their next visit.
62814103|NCT06105060|ACTIVE_COMPARATOR|Group 2 (N-acetyl cysteine group (NAC):|40 patients will receive high dose of NATURAL TRUTH'S NAC cap 2400 mg /day for 6 months.
62814104|NCT06105060|ACTIVE_COMPARATOR|"Group 3 Two separate drugs (N-acetyl cysteine and Rosuvastatin group):"|"40 patients will receive NAC dose 2400 mg and Rosuvastatin 20mg /day for 6 months."
62814105|NCT06105060|PLACEBO_COMPARATOR|Group 4 (Control group):|40 patients will receive Vitamin E 400 mg twice daily for 6 months.
62814106|NCT05254678|ACTIVE_COMPARATOR|Standard exercise program|Participants in this group will take part the general exercise program delivered through the Active Living module of the HEAL-ME application. The program comprises (1) supervised group exercise sessions (connection via zoom platform embedded in HEAL-ME), (2) independent exercise workouts within the application, and (3) exercise specific education within the Education Module of the HEAL-ME application.
62814107|NCT05254678|EXPERIMENTAL|Integrated physiotherapy and exercise|Participants in this group will take part in an integrated physiotherapy and exercise intervention delivered through the Active Living module of the HEAL-ME application. The program comprises (1) supervised group physiotherapeutic exercise sessions (connection via zoom platform embedded in HEAL-ME), (2) independent physiotherapeutic exercise workouts, and (3) breast cancer specific physiotherapy education delivered through weekly modules.
62814108|NCT06632639|EXPERIMENTAL|Corrective exercise protocol + Lateral wedged insoles with subtalar strapping|They will receive the corrective exercise protocol in addition to the lateral wedged insoles with subtalar strapping for 12 weeks.
62814109|NCT06632639|ACTIVE_COMPARATOR|Corrective exercise protocol|They will receive the same corrective exercise protocol alone for 12 weeks.
62428517|NCT05186922|EXPERIMENTAL|CM326 220 mg, once every two weeks (Q2W)|220mg for 6 doses, every 2 weeks, subcutaneous (SC)
62814110|NCT04685798|EXPERIMENTAL|DWI MRI + Standard of care FDG PET/CT|-The patients will undergo an optimized research neck DWI MRI, up to 3 weeks post-treatment and then a standard-of-care 3-month post-treatment FDG PET/CT examination.
62814111|NCT04706208|OTHER|One time testing - able-bodied healthy adults|"Participants in this arm will be able-bodied healthy adults who will not receive an intervention.~This is just a one time testing of clinical assessments (over zoom), one MRI scan, and an optional blood draw test."
62814112|NCT04706208|EXPERIMENTAL|Usual Care, then Cognitive Multisensory Therapy - adults with spinal cord injury + neuropathic pain.|This is a delayed treatment arm phase I randomized controlled trial (RCT) for participants with spinal cord injury and neuropathic pain. Participants in this arm will first receive usual care and then switch over to the experimental cognitive multisensory therapy training.
62036849|NCT02575885|EXPERIMENTAL|Arm II (BLU e-cigarette ENDS product with different flavors)|Participants are asked to smoke ad lib a single cigarette of their own brand and provided with the BLU e-cigarette ENDS product with nicotine solution of one of five flavors over 3.5-4 hours at least 7 days apart for 6 weeks. Participants are provided with cartridges of maximum available amounts of nicotine and different flavors at each visit, instructed on how to use the product, asked to practice using it for 7 days, and return to the study center for their next visit.
62036850|NCT05632146|ACTIVE_COMPARATOR|Patients with hollow viscus perforation|
62036851|NCT05632146|ACTIVE_COMPARATOR|Patient with hollow viscus perforation|
62237972|NCT02349451|EXPERIMENTAL|ABT-122 120 mg|Double-blind ABT-122 120 mg administered EW for 12 weeks
62428518|NCT05186922|EXPERIMENTAL|CM326 220 mg, once every four weeks (Q4W)|220mg for 3 doses, every 4 weeks, subcutaneous (SC)
62428519|NCT05186922|PLACEBO_COMPARATOR|Placebo|Placebo for 6 doses, every 2 weeks, subcutaneous (SC) and placebo for 3 doses, every 4 weeks, subcutaneous (SC)
62237973|NCT02349451|EXPERIMENTAL|ABT-122 240 mg|Double-blind ABT-122 240 mg administered EW for 12 weeks
62814113|NCT04706208|EXPERIMENTAL|Cognitive Multisensory Therapy, then Usual Care - adults with spinal cord injury + neuropathic pain.|This is a delayed treatment arm phase I randomized controlled trial (RCT) for participants with spinal cord injury and neuropathic pain. Participants in this arm will first receive the experimental cognitive multisensory therapy training and then switch over to usual care.
62814114|NCT06362746|EXPERIMENTAL|Non-immunogenic recombinant staphylokinase|lyophilisate for preparation of a solution for intravenous administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, intravenously as a quick single bolus injection for 10-15 seconds, regardless of body weight.
62814115|NCT06362746|PLACEBO_COMPARATOR|Placebo|15 mg of placebo reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
62814116|NCT03344757|EXPERIMENTAL|Cultural-Cognitive Behavioral Stress Management (CCBSM)|Participants randomized to this arm will receive 10 weekly group-based C-CBSM intervention.
62814117|NCT03344757|ACTIVE_COMPARATOR|Cognitive Behavioral Stress Management (CBSM)|Participants randomized to this arm will receive 10 weekly group-based standard CBSM intervention.
62036852|NCT01708850|OTHER|Rivaroxaban|Rivaroxaban 15 mg po bid x 3 weeks, followed by rivaroxaban 20 mg po daily x 9 weeks. Then up to discretion of investigator to decide regarding further anticoagulation as study length is limited to 12 weeks.
62428520|NCT02341963|EXPERIMENTAL|Oral Ketamine|Subjects will receive Oral Ketamine (1.0 mg/kg) ) presurgery and 3 days postsurgery (including surgery day).
62428521|NCT03568526|EXPERIMENTAL|Supportive Care (sensorimotor rehabilitation program)|Patients attend 1 therapy session to receive education and training in the use of the home program. Patients then complete exercises over 90 minutes per week for 6 weeks.
62814118|NCT05371613|EXPERIMENTAL|Cohort A: Participants with nMPS II|
62036853|NCT03816748|EXPERIMENTAL|intervention|Patients who underwent minimally invasive esophagectomy surgery in our hospital and transfer to intensive care unit, and accept HFNC treatment
62036854|NCT03816748|NO_INTERVENTION|control|Patients who underwent minimally invasive esophagectomy surgery in our hospital and transfer to intensive care unit, and accept usual care
62428522|NCT00553748|EXPERIMENTAL|I|
62036855|NCT00908479|EXPERIMENTAL|LE|Leg Exercise group
62428523|NCT04073693|ACTIVE_COMPARATOR|BRCA|They were in treatment with BRCA and standard treatment based on nutritional intervention and physical exercise.
62428524|NCT04073693|PLACEBO_COMPARATOR|Placebo|They only were on standard treatment based on nutritional intervention and physical exercise.
62428525|NCT03523013|EXPERIMENTAL|CPAP pressure (determied by DISE)|
62428526|NCT03523013|ACTIVE_COMPARATOR|CPAP pressure (determined by physician)|
62428527|NCT05906498|ACTIVE_COMPARATOR|mix acetylcysteine with vitamin E|Standard treatment for mild psoriasis, plus N acetyl cysteine (600 mg a day) oral effervescent sachet,30 minutes before breakfast Plus, vitamin E (1000 mg) daily, oral soft gelatin capsule for 8 weeks
62814119|NCT05371613|EXPERIMENTAL|Cohort B: Participants with nnMPS II|
62814120|NCT05371613|EXPERIMENTAL|Open-label Treatment Phase|Participants who meet pre-specified criteria may receive DNL310 or idursulfase
62814121|NCT04056416|EXPERIMENTAL|HIIT Exercise Program|Exercise on a MedBIKE 3 times a week for 8 weeks with pre- and post-CPET testing, questionnaires and qualitative interviews.
62814122|NCT05663710|EXPERIMENTAL|Cohort 1 (Biopsy)|Participants within 2 weeks of starting the first dose of 177Lu-girentuximab
62814123|NCT05663710|EXPERIMENTAL|Cohort 2 (Biopsy)|Participants within 2 weeks of Cycle 4
62814124|NCT05663710|EXPERIMENTAL|Cohort 3 (Biopsy)|Participants at the time of progression or at 20 months post treatment
62814125|NCT06706492||Patients with inspiratory muscle weakness|
62814126|NCT06706492||Patients without inspiratory muscle weakness|
62814127|NCT05553509||ANGIOPLASTY GROUP|All patients undergoing PTA are going to be classified according to GLASS staging system
62814128|NCT05553509||DEBRIDEMENT GROUP|The most commonly used technique for diabetic foot ulcers is sharp or surgical debridement using a scalpel, tissue forceps or similar instruments. It should be sufficiently extensive to remove all infected and necrotic tissue;
62814129|NCT03751241|EXPERIMENTAL|Intraocular lens types|Patients with different types of IOLs (EROV, monofocal, minimonovision) are tested for their reading quality using the EyeTracker device
62428528|NCT05906498|ACTIVE_COMPARATOR|acetylcysteine|Standard treatment for mild psoriasis, plus N acetyl cysteine (600 mg a day) oral effervescent sachet, 30 minutes before breakfast, for 8 weeks
62428529|NCT05906498|NO_INTERVENTION|standard treatment alone|Standard treatment for mild psoriatic patients (topical steroid and salicylic acid
62237974|NCT03605563|EXPERIMENTAL|FSN: Fu's subcutaneous needling|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
62237975|NCT03605563|ACTIVE_COMPARATOR|TENS: Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of TENS on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
62428530|NCT06543212||group continues with physiotherapy|Group continues with physiotherapy training in follow up period after last session of physiotherapy program post strabismus surgery.
62428531|NCT06543212||group doesn't continue with physiotherapy|Group doesn't continue with physiotherapy training in follow up period after last session of physiotherapy program post strabismus surgery
62428532|NCT01147016|EXPERIMENTAL|HER2Bi-armed activated T cells + Neoadjuvant Chemotherapy|"HER2Bi-armed activated T cells - Total of 4 of the T cell infusions IV over a period of 1 month~Cyclophosphamide, doxorubicin hydrochloride, paclitaxel -As prescribed by physician, standard of care."
62428533|NCT01824108|ACTIVE_COMPARATOR|control group: Lumbar discectomy|Lumbar discectomy alone
62428534|NCT01824108|EXPERIMENTAL|Treatment group: lumbar discectomy + Wallis implant|lumbar discectomy combined with Wallis interspinous dynamic stability system
62428535|NCT01845701|EXPERIMENTAL|Artesunate-Amodiaquine|As a fixed-dose combination of artesunate-amodiaquine developed by Sanofi-Aventis (France). It has the advantage of being a 3-day regimen usable by all age groups and potentially low cost. tablets are administered per every day at dose of 25mg/67.5mg for those between 4,5kg and 9kg for 48H
62428536|NCT01845701|EXPERIMENTAL|Dihydroartemisinine_Piperaquine|As a fixed-dose combination of dihydroartemisinin-piperaquine which is produced by Fouley (China). It is a potentially low cost 2-day regimen that has been used in children between 5-10kg as half a tablet of 40mg/320mg every day for 48H
62428537|NCT01845701|ACTIVE_COMPARATOR|Artemeter-Lumefantrine|This is the active comparator as a fixed-dose combination of artemether and lumefantrine which is produced by Novartis (Switzerland). The drug will be used as the comparator because it is the only fixed-dose combination with artemether currently available. Administered in children as tablets containing Artemether-Lumefantrine at (20mg/120mg) for body weights of 5-10kg every 12H within 48H.
62428538|NCT05799378|EXPERIMENTAL|Hydroxychloroquine (HCQ)|Patients will receive a 90-day supply of HCQ at their screening visit, at 2 months, 4 months, 6 months, 8 months, and 10 months. All patients will return their current supply along with a completed dosing diary at each visit and receive a new supply in exchange. The HCQ dose administered will match each patient's dosage of HCQ at enrollment.
62814130|NCT01623102|EXPERIMENTAL|Arm I: bevacizumab plus chemotherapy|Patients in the experimental arm receive cisplatin and gemcitabine combination with Bevacizumab. GP chemotherapy (gemcitabine 1250mg/m2 IV D1 and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle) plus bevacizumab (7.5 mg/kg IV on D1 of every 21-day cycle).
62036856|NCT00908479|EXPERIMENTAL|LM|Leg Management (Control group)
62036857|NCT06683742|EXPERIMENTAL|EYP-1901 2686 µg|EYP-1901
62237976|NCT03617965||Mild thrombocytopenia|Patients with a platelet count of 100 × 10e9 to 149 × 10e9/L.
62814131|NCT01623102|ACTIVE_COMPARATOR|Arm II: chemotherapy|Patients receive gemcitabine combined with cisplatin chemotherapy((gemcitabine 1250mg/m2 IV D1 and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle) ) every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62428539|NCT05799378|PLACEBO_COMPARATOR|HCQ-Matching Placebo|Patients will receive a 90-day supply of HCQ-matching placebo at their screening visit, at 2 months, 4 months, 6 months, 8 months, and 10 months. All patients will return their current supply along with a completed dosing diary at each visit and receive a new supply in exchange. The HCQ-matching placebo dose administered will match each patient's dosage of HCQ at enrollment.
62428540|NCT03744988||control group|serum androgen levels will be measured in 25 normotensive pregnant women
62596210|NCT03322774|SHAM_COMPARATOR|Stepped Care Model Control|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Following initial treatment with dCBT-I, individuals who do not experience remission of their insomnia will receive sleep hygiene education, serving as a credible control intervention for comparison to the Stepped Care Model."
62237977|NCT03617965||Moderate thrombocytopenia|Patients with a platelet count of 50 × 10e9 to 99 × 10e9/L
62237978|NCT03617965||Severe thrombocytopenia|Patients with a platelet count\<50 × 10e9/L
62237979|NCT03617965||Control group|Patients with normal platelet count (i.e.150 × 10e9 to 399 × 10e9/L)
62237980|NCT00047320|EXPERIMENTAL|Radiation Therapy (CR from Induction)|Patients will receive 6 cycles of Induction chemotherapy consisting of carboplatin and etoposide (Cycles 1, 3, and 5) alternating with ifosfamide and etoposide (Cycles 2, 4, and 6). The entire length of Induction is 18 weeks unless delay occurs due to myelosuppression or unanticipated toxicity. Each cycle of Induction will begin when ANC \> 750/L and platelets \> 75,000/L and when off filgrastim (G-CSF) for at least 48 hours. Following the Induction phase (weeks 0-18) those patient in CR will undergo radiation therapy.
62237981|NCT04069351|EXPERIMENTAL|Overfeeding Plus Resistance Training Arm|6-week overfeeding plus resistance training arm
62237982|NCT03024177|EXPERIMENTAL|Vapendavir 528 mg|
62237983|NCT03024177|PLACEBO_COMPARATOR|Placebo|
62237984|NCT01128738|ACTIVE_COMPARATOR|GSK1358820|Onabotulinum toxin type A
62237985|NCT01128738|PLACEBO_COMPARATOR|Placebo|Placebo
62237986|NCT05880017|ACTIVE_COMPARATOR|Modified Group|A total of 20 patients undergoing lumber spine surgery receiving modified ultrasound guided thoracolumbar interfascial plane (TLIP) block.
62814132|NCT03352635||Native Hawaiians|One parent of Hawaiian descent.
62814133|NCT03352635||Japanese Americans|Two parents of Japanese descent.
62814134|NCT03352635||Non-Hispanic Whites|Two parents of non-Hispanic white descent.
62814135|NCT02083471|ACTIVE_COMPARATOR|SOTI|Specific Oral Tolerance Induction with Egg or Cow's milk
62814136|NCT02083471|NO_INTERVENTION|Food Allergy follow-up|
62814137|NCT04917146||Caregivers (CG)|Caregivers of patients with systemic Scleroderma
62814138|NCT01810341||Development Group|In the Development Phase, analyses will be performed until the classification algorithm is finalized.
62814139|NCT01810341||Validation Group|The Validation Phase will assess the performance of the finalized classification algorithm in 300 subjects.
62237987|NCT05880017|ACTIVE_COMPARATOR|Conventional Group|A total of 20 patients undergoing lumber spine surgery receiving conventional ultrasound guided thoracolumbar interfascial plane (TLIP) block.
62237988|NCT05880017|ACTIVE_COMPARATOR|Morphine Group|A total of 20 patients undergoing lumber spine surgery receiving morphine for peritoperative analgesia (control group).
62237989|NCT04785339|EXPERIMENTAL|one-arm, pre-post design|This study will test an intervention in adult Latinx immigrants. There will be no control condition or other comparators. One condition will only provide data at pre (baseline) and post. The only comparison will be across time, but not across conditions as this will be the only condition and all participants will receive the same intervention.
62237990|NCT02344433|EXPERIMENTAL|VICKY|"Relational agent, virtual counselor for collecting family health history (VICKY: VIrtual Counselor for Knowing Your Family History)."
62237991|NCT02344433|ACTIVE_COMPARATOR|MFHP|Online family health history collection tool (MFHP: My Family Health Portrait).
62237992|NCT05146362|EXPERIMENTAL|RETAIN Programming|The experimental group receives the full set of RETAIN intervention activities.
62428541|NCT03744988||mild preeclampsia|serum androgen levels will be measured in 25 mild preeclamptic patients
62428542|NCT03744988||severe preeclampsia|serum androgen levels will be measured in 25 severe preeclamptic patients
62814140|NCT04749940|EXPERIMENTAL|Hospitalized burn patients|Half of the donor site area will be dressed with PRF dressing, and half with Aquacel®.
62814141|NCT04544813|EXPERIMENTAL|Cohort A: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 subcutaneously (SC).
62428543|NCT02780921|EXPERIMENTAL|Prehab Group|In the experimental group (Prehab group) compared to the control group, the main objective will be to demonstrate an improvement of the percentage of patients reaching the complete oncological treatment fixed in a multidisciplinary tumour board
62596211|NCT03322774|EXPERIMENTAL|digital CBT-I|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Treatment includes weekly sessions of CBT-I administered over the internet in hour-long video sessions. Daily sleep diaries are recorded online for individual tailoring of treatment."
62596212|NCT06534255|EXPERIMENTAL|MegaLT injection|"Dosage Form: ex vivo three-dimensional induced umbilical cord blood mononuclear cells differentiated megakaryocyte injection (MegaLT injection).~Administration Route: Intravenous Infusion Regimen: Single or Multiple Infusions"
62596213|NCT05525442||patients with recurrence|Recurrence in the first year after percutaneous cholecystostomy catheter removal
62596214|NCT05525442||patients without recurrence|No recurrence within the first year after percutaneous cholecystostomy catheter removal
62237993|NCT05146362|NO_INTERVENTION|Control|This arm receives information about American Job Center services and assistance with opening a JobLink account if an individual doesn't have one. Medical providers at all practices will receive training on how to identify early and then manage the risk of work disability to help prevent long-term unemployment
62237994|NCT00559585|ACTIVE_COMPARATOR|Subcutaneous (SC) Abatacept|Participants received 125 mg weekly SC abatacept injections (with an intravenous \[IV\] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
62428544|NCT02780921|OTHER|control group|The control group will be treated according to conventional care; will not receive any specific intervention before surgery except nutritional support and physiotherapy at the surgeon's discretion
62428545|NCT06545526|ACTIVE_COMPARATOR|celecoxib monotherapy|celecoxib \[400mg, twice a day\] for 6 months
62428546|NCT06545526|EXPERIMENTAL|celecoxib and metformin combination|celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] for 6 months
62428547|NCT00640822|EXPERIMENTAL|Calcipotriol plus Hydrocortisone ointment|Calcipotriol plus Hydrocortisone ointment once daily for up to 8 weeks
62814142|NCT04544813|EXPERIMENTAL|Cohort B: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 SC.
62814143|NCT04544813|EXPERIMENTAL|Cohort C: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 SC.
62036858|NCT06683742|ACTIVE_COMPARATOR|Aflibercept|
62036859|NCT01066221||Clostridium difficile patients|observational study
62237995|NCT00559585|ACTIVE_COMPARATOR|Intravenous (IV) Abatacept|Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).
62237996|NCT03996499|EXPERIMENTAL|Stress echocardiography|"The course of the examination corresponds to the welcome of the patient, the search for contraindications and the performance of the stress ultrasound. During this stress ultrasound, the 3 indices (segmental kinetics, coronary reserve and myocardial perfusion) will be analyzed. The duration of the ultrasound is not lengthened (examination time: 20 minutes).~The evaluation of the myocardial perfusion is carried out thanks to the use of the flash, modality not being part of the usual care.~Indeed, during the examination, the power of the probe will be increased to evaluate the myocardial perfusion. The bubbles of the contrast medium are destroyed by applying a flash, that is to say a transient increase in the power of the ultrasonic beam. Systole after systole, on a recorded loop, the filling rate of the myocardium, which depends on the myocardial blood flow, is analyzed. The evaluation of the infusion is visual and qualitative."
62237997|NCT03402919||Normal healthy elderly|participants with no subjective or objective cognitive deficits or decline.
62237998|NCT03402919||Subjective Cognitive Decline|Participants with a complaint of subjective cognitive impairment, but no objective evidence of such.
62237999|NCT03402919||Mild Cognitive Impairment (MCI)|Participants with objective evidence of cognitive impairment, but it does not impact on daily function.
62238000|NCT03402919||Vascular MCI|Participants meeting criteria of MCI who also show signs of cerebrovascular disease on imaging but have no history of stroke.
62238001|NCT03402919||Alzheimer's Disease|Participants with dementia of the Alzheimer's type according to the National Institute of Aging-Alzheimer's Association criteria
62238002|NCT03402919||Dementia of Mixed Etiology|Participants with dementia and evidence of more than one etiology.
62428548|NCT00640822|ACTIVE_COMPARATOR|Tacalcitol|Tacalcitol once daily for up to 8 weeks
62428549|NCT00640822|PLACEBO_COMPARATOR|Calcipotriol plus Hydrocortisone ointment vehicle|Calcipotriol plus Hydrocortisone ointment vehicle once daily for up to 8 weeks
62428550|NCT05407337|EXPERIMENTAL|Experimental group|Beneficiaries of NET therapy + standard Sindiane program management.
62428551|NCT05407337|NO_INTERVENTION|Control group|Beneficiaries of the standard care of the Sindiane program.
62814144|NCT04544813|EXPERIMENTAL|Cohort D: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 SC.
62238003|NCT03402919||Lewy Body/Parkinson's spectrum|Participants with Parkinson's disease who show mild or moderate cognitive impairment and/or dementia.
62238004|NCT03402919||Frontotemporal dementia (FTD) spectrum|Participants with behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, or corticobasal syndrome
62238005|NCT05196581|NO_INTERVENTION|No intervation|Thirty-four subjects receive no intervention.
62238006|NCT05196581|ACTIVE_COMPARATOR|Experimental intervation one|Thirty-three subjects receive dispersible NaCl powder, 8 mg per session per hour (one administration in each nostril and two oral inhalations), totaling 10 times a day, for ten days.
62814145|NCT04544813|EXPERIMENTAL|Cohort E: JNJ-77474462 IV (Wave 1)|Participants will receive single dose of JNJ-77474462 intravenously (IV).
62814146|NCT04544813|EXPERIMENTAL|Cohort F: JNJ-77474462 SC (Wave 2)|Participants will receive single dose of JNJ-77474462 SC.
62238007|NCT05196581|ACTIVE_COMPARATOR|Experimental intervation two|Thirty-three subjects will receive dispersible NaCl powder, 8 mg per session (one administration in each nostril and two oral inhalations) every 3 hours, totaling 5 times a day, for ten days.
62428552|NCT02033577|EXPERIMENTAL|Distal gastrojejunal bypass|RYGB with 200 cm BP limb and 150 cm common limb
62428553|NCT02033577|ACTIVE_COMPARATOR|RYGB|RYGB with 60 cm BP limb and 150 cm alimentary limb
62814147|NCT04544813|EXPERIMENTAL|Cohort G: JNJ-77474462 SC (Wave 2)|Participants will receive single dose of JNJ-77474462 SC.
62814148|NCT04544813|EXPERIMENTAL|Cohort H: JNJ-77474462 IV (Wave 2)|Participants will receive single dose of JNJ-77474462 IV.
62428554|NCT05350982||Hospital Arm|Participants will be recruited to use the SalivaBio +/- SaliPac in a hospital setting. They will be provided with collecting instructions and will be guided by a member of the research team.
62433662|NCT02332135|ACTIVE_COMPARATOR|control group|patients in control group will be treated by active vitamin D and other general treatments according to the suggestions in K/DOQI guidelines
62433663|NCT05401331|OTHER|Hemodynamic changes due to mask use|Hemodynamic changes due to mask use
62814149|NCT04544813|EXPERIMENTAL|Cohort I: JNJ-77474462 IV (Wave 2)|Participants will receive single dose of JNJ-77474462 IV.
62814150|NCT04544813|ACTIVE_COMPARATOR|Cohort J: Anakinra SC|Participants will receive a SC injection of anakinra once daily for 3 days.
62814151|NCT02341560|ACTIVE_COMPARATOR|single dose or multiple dose|QPI-1007 Injection - 1.5 mg
62814152|NCT02341560|ACTIVE_COMPARATOR|single or multiple dose|QPI-1007 Injection - 3.0 mg
62814153|NCT02341560|SHAM_COMPARATOR|Sham|Sham injection procedure
62814154|NCT06151418||Novel hormonal therapy cohort|Patients initiating novel hormonal therapy (abiraterone, apalutamide or enzalutamide) for mCSPC
62814155|NCT00771914|EXPERIMENTAL|Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza|First Placebo, then 4 grams of Lovaza, then 81mg of Aspirin, then both 4 grams of Lovaza and 81 mg of Aspirin
62814156|NCT00771914|EXPERIMENTAL|Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo|First 81mg of Aspirin, then 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo
62036860|NCT04219670||Patient Group|Individuals diagnosed with stroke admitted to the Shirley Ryan AbilityLab (inpatient), or individuals in the community who had a stroke (chronic)
62238008|NCT03884998|EXPERIMENTAL|Treatment (copanlisib and nivolumab)|Patients receive copanlisib IV over 60 minutes on days 1, 8, and 15 and nivolumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62814157|NCT00771914|EXPERIMENTAL|Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin|First 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 81mg of Aspirin
62814158|NCT00771914|EXPERIMENTAL|Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin|First both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 4 grams of Lovaza, then 81mg of Aspirin
62814159|NCT01032616|EXPERIMENTAL|Study Period 1|AA given by parenteral and enteral routes with tracer 1-13C phenylalanine given to observe differences
62814160|NCT01032616|EXPERIMENTAL|Study Period 2|AA given by parenteral and enteral routes with tracer 1-13C phenylalanine given to observe differences
62814161|NCT02929953||Diabetes mellitus type 1|"all T1DM patients in Israel, born during 2000-2013 and diagnosed prior to January 2015.~chart review"
62814162|NCT02929953||Non-diabetic|non-diabetic general population born in Israel during 2000-2013, according to the Israeli Health Ministry's Birth Registry (IHMBR) chart review
62036861|NCT04219670||Healthy Control Group|Individuals without any known significant health problems
62814163|NCT04230187|EXPERIMENTAL|mFOLFOXIRI Plus Bevacizumab|Patients will receive mFOLFOXIRI plus bevacizumab once every two weeks for 8 cycles as the first-line treatment.
62814164|NCT04230187|ACTIVE_COMPARATOR|mFOLFOX6 Plus Bevacizumab|Patients will receive mFOLFOX6 plus bevacizumab once every two weeks for 8 cycles as the first-line treatment.
62814165|NCT06706375|EXPERIMENTAL|interventional|Dorsal penile nerve block using ultrasound
62814166|NCT06706375|ACTIVE_COMPARATOR|Control|Dorsal penile nerve block using anatomical landmarks
62036862|NCT06315595||Observational|Participants undergo a non-contrast MRI on study and may optionally undergo a second non-contrast MRI on study. Participants may also undergo blood sample collection on study.
62036863|NCT06161675|EXPERIMENTAL|QuitAid + SmokefreeTXT + NRT (Patch + Lozenge)|Participants will receive QuitAid, a medication therapy management delivered by their pharmacist, a texting intervention to help quit smoking, and up to 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch + lozenge.
62036864|NCT06161675|ACTIVE_COMPARATOR|SmokefreeTXT + NRT (Patch + Lozenge)|Participants will receive a texting intervention to help quit smoking and up to 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch + lozenge.
62238009|NCT04918238|ACTIVE_COMPARATOR|conventional treatment Arm|All the participants will receive the conventional physical therapy protocol per session as following: Infrared radiation on the low back area for 15 minutes, Ultrasound waves (Digi sonic device) for 10 minutes on the trigger areas of the low back, Myofascial release of the thoracolumbar fascia, Stretching of the Paraspinal muscles and the hamstrings, Mobilization of the lumbar and thoracic spine from a prone lying position and strengthening of abdominal muscles, multifidus and transversal's abdominal muscle.
62238010|NCT04918238|EXPERIMENTAL|muscle energy technique arm|Group A received muscle energy technique with lateral recumbent positioning along with Conventional Physiotherapy Program
62428555|NCT05350982||Stimulated Home Arm|10 participants will be randomly selected by a random number generator. This arm will also be conducted in the Hospital, and the collection using a SalivaBio +/- SaliPac will still be observed by a member of the research team. These participants will receive the same information as those in the Hospital Arm, but will receive minimal input. This is to establish whether the collection instructions provided would be suitable to use in the home environment.
62238011|NCT04646512|ACTIVE_COMPARATOR|Taurine group and exercise|Intervention with taurine supplementation and physical training.
62428556|NCT01731860|EXPERIMENTAL|Patients receiving PET/CT|Patients already scheduled for a clinically necessary PET/CT scan.
62428557|NCT02766400|EXPERIMENTAL|Guided Training|"Guided training is a rehabilitation training approach that maximizes the expertise of the patient, by teaching patients to identify and prioritize activities, identify barriers to performing activities, generate their own strategies for addressing these barriers, and apply this process through iterative practice. Guided training equips patients with practical skills that have the potential to generalize beyond activities addressed during the intervention program to novel problematic activities that arise after the intervention program, thereby promoting long-term independence."
62814167|NCT02099240|ACTIVE_COMPARATOR|Intravenous antibiotics|Intravenous antibiotics for the full duration of therapy
62814168|NCT02099240|ACTIVE_COMPARATOR|oral antibiotics|intravenous antibiotic therapy plus early switch to oral antibiotic therapy
62814169|NCT04861129|EXPERIMENTAL|Bowen therapy group|The experimental group will receive Bowen therapy according to ISBT Bowen Therapy® (Black \& Murray, 2005). It may include sequences 1, 4, 2, hamstrings (movements 1-6) and sacrum sequences in the prone position, and hamstrings sequence (7-18 movements) and 3 in the supine position,. The sequences may also include Bowen movements in the scalenes, trapezius, all erector spinae, sacro-iliac joint ligaments, gluteus maximus and medius, tensor fasciae latae, and gastrocnemius. The application of Bowen sequences is varied between sessions and participants depending on the presenting functional deficit and treatment response.
62596215|NCT03093649|EXPERIMENTAL|patient reported group|Patients reported adverse events using patient reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) through Application (APP) during the treatment. The summary report was transferred to their clinician immediately. Oncologists would be alarmed if patients reports exceeding the pre-defined threshold.
62596216|NCT03093649|ACTIVE_COMPARATOR|non-reported group|Patients in this group received normal care during the treatment without completing patient reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE)
62814170|NCT04861129|SHAM_COMPARATOR|Sham Bowen Therapy group|The control group will receive a sham Bowen therapy with the same number of treatment session, treatment time and rest time, that received in the experimental group. However, it consists of gently placing the hands over the areas just enough to maintain contact for the desired time as required by Bowen Therapy, without applying Bowen movement, which is considered the active principle of this technique.
62238012|NCT04646512|PLACEBO_COMPARATOR|Placebo group and exercise|Intervention with placebo supplementation and physical training.
62238013|NCT04201132|EXPERIMENTAL|Carotid artery stenting|Carotid artery stenting procedure with Neuroguard IEP System
62814171|NCT06304961|EXPERIMENTAL|Tozorakimab Dosage form A (Test)|Participants will receive a single dose of Tozorakimab Dosage form A via subcutaneous (SC) injection.
62036865|NCT04403698|EXPERIMENTAL|24 weeks|Subject receiving alendronate treatment for 24 weeks (n = 20)
62238014|NCT02602054|EXPERIMENTAL|Surgical treatment|Implement surgical treatment for closure of patent ductus arteriosus
62238015|NCT02602054|ACTIVE_COMPARATOR|Control group|"- Indomethacin: Administer 1 full cycle (3 doses) of indomethacin (1 dose every 12 hours) for 2 days Dose 0.1 - 0.25 mg / kg~- Ibuprofen: Administer 1 full cycle (3 doses) of ibuprofen (1 dose every 24 hours) for 2 days Dose 05 - 10 mg / kg~- Acetaminophen: Administer 1 full cycle (12 doses) of acetaminophen (1 dose every 6 hours) for 3 days Dose 15 mg / kg"
62238016|NCT04640389||Urban|Urban adolescents living in Moshi District, Tanzania, who are between 10-14 years of age.
62596217|NCT02428049||Lung cancer patients|Lung cancer patients in stages IA-IIIA destined to have stereotactic radiotherapy or conventional radiotherapy and chemotherapy in curative intent
62596218|NCT03048695|EXPERIMENTAL|Goal Management Training|Cognitive rehabilitation
62596219|NCT03048695|NO_INTERVENTION|Waiting list|
62596220|NCT03911661|ACTIVE_COMPARATOR|Standard Management|The standard management phase will be historical and consist of warfarin management during the 12-months prior to signing informed consent.
62596221|NCT03911661|EXPERIMENTAL|Fearon Algorithm (FA) Anticoagulation Management Service|Once study patients have received an approved FA report, the FA AMS phase of the study will commence. An investigator will communicate the new warfarin tablet size, if necessary, and use the FA report to determine warfarin doses for the patient.
62596222|NCT03911661|EXPERIMENTAL|Fearon Algorithm (FA) Patient Self Management|At the conclusion of the six-month FA anticoagulation management service phase, patients will be trained to use the FA for patient self management (PSM) and after successfully demonstrating the ability to engage in PSM the FA PSM phase of the study will commence.
62036866|NCT04403698|EXPERIMENTAL|48 weeks|Subject receiving alendronate treatment for 48 weeks (n = 20)
62036867|NCT02560948|PLACEBO_COMPARATOR|Placebo|
62036868|NCT02560948|EXPERIMENTAL|gpASIT+TM|
62036869|NCT05349617|EXPERIMENTAL|Group 1 - PXVX0317|PXVX0317 vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant.
62238017|NCT04640389||Rural|Rural adolescents living in Kilosa District, Tanzania, who are between 10-14 years of age.
62238018|NCT00197808|EXPERIMENTAL|Vaccine schedule 1|Menjugate vaccine at 2 and 3 months
62036870|NCT05349617|PLACEBO_COMPARATOR|Group 2 - Placebo|Placebo is comprised of formulation buffer.
62036871|NCT01049126||Late stage endometrial cancer|
62036872|NCT04892355|EXPERIMENTAL|Conventional Syringe Irrigation Group|During the final irrigation procedure, a 30 - G side vented needle was placed 2 mm shorter than the working length and was applied without agitation. 5 mL of 2.5% NaOCl was applied for 1 minute for each channel. Each canal was then washed with 2 mL of 17% EDTA for 1 minute.
62036873|NCT04892355|EXPERIMENTAL|Xp Endo Finisher Group|Xp Endo Finisher file was used with VDW Silver (VDW) endomotor at 800 rpm speed and 1 Ncm torque according to the manufacturer's instructions. The Xp Endo Finisher file was placed in the canal, 2 mm shorter than the working length, and was used with slow movements of 7-8 mm amplitude in the canal during activation. 5 mL of 2.5% NaOCl was applied for 1 minute for each channel. Each canal was then washed with 2 mL of 17% EDTA for 1 minute.
62036874|NCT04892355|EXPERIMENTAL|EDDY Group|An EDDY tip of size 25/04 was used for sonic activation. The EDDY was placed in the duct 2 mm shorter than the working length and the activation process was performed with slow movements with an amplitude of 2-4 mm. In the irrigation process, 5 mL of 2.5% NaOCI was applied for 1 minute for each channel. Each canal was then washed with 2 mL of 17% EDTA for 1 minute.
62036875|NCT04892355|EXPERIMENTAL|Endoactivator Group|Medium Endoactivator tip of 25 / .04 size was used for irrigation activation. Medium type was placed in the canal 2 mm shorter than the working length and activation was performed by making short strokes of 2-3 mm. 5 mL of 2.5% NaOCl was applied for 1 minute for each channel. Each canal was then washed with 2 mL of 17% EDTA for 1 minute.
62036876|NCT01654549|NO_INTERVENTION|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
62036877|NCT01654549|EXPERIMENTAL|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
62036878|NCT04231812|OTHER|open lable|Prospective, open-label
62036879|NCT06534632|EXPERIMENTAL|Colostrum group|The interventional group received their mother's colostrum through the oropharyngeal route beginning within the first 24 hours of birth and for 5 days at a dose of 0.2 mL/6 hours
62238019|NCT00197808|EXPERIMENTAL|Vaccine schedule 2|Menjugate vaccine at 2 and 4 months
62814172|NCT06304961|EXPERIMENTAL|Tozorakimab Dosage form B (Reference)|Participants will receive a single dose of Tozorakimab Dosage form B via SC injection.
62814173|NCT05410522|EXPERIMENTAL|Experimental lung transplant|The training time will be 30 minutes in the morning and 30 minutes in the afternoon with a total daily work time of 60 minutes. The frequency of work will be different in each session, seeking in the morning routine a vascularization and improvement of muscle trophism and in the afternoon an aerobic endurance, activation of the working capacity of the tonic muscles to improve the stabilizing muscles and postural fitness.
62814174|NCT05410522|NO_INTERVENTION|Control lung transplant|Electro stimulation therapy will not be performed.
62814175|NCT01346358|EXPERIMENTAL|IMC-CS4 Weight Based Dosing|Participants received 2.5 mg/kg once weekly (QW), 0.3 mg/kg QW, 0.6 mg/kg QW, 1.25 mg/kg every two weeks (Q2W) and1.25 mg/kg QW of IMC CS4 by intravenous infusion in Part A.
62814176|NCT01346358|EXPERIMENTAL|IMC-CS4 Non-Weight Based Dosing|Participants received 100 mg QW, 100 mg QW on weeks 1, 2, 4 and 5 and 150 mg QW of IMC CS4 by intravenous infusion in Part B.
62814177|NCT06033547|EXPERIMENTAL|Part A: Participants receiving Cabotegravir Formulation F|
62814178|NCT06033547|EXPERIMENTAL|Part B: Participants receiving Cabotegravir Formulation G|
62036880|NCT06534632|PLACEBO_COMPARATOR|Placebo group|The placebo group received sterile water through the oropharyngeal route beginning in the first 24 hours of birth and for 5 days at a dose of 0.2 mL/6 hours
62036881|NCT01993069|EXPERIMENTAL|Iyengar-based Yoga Training|6 weekly Iyengar-based yoga classes
62036882|NCT05175755|EXPERIMENTAL|Patients|The procedure involves taking a total of 12 ml of blood.
62036883|NCT05684328|EXPERIMENTAL|WLI Then NBI Withdrawal Group|After successful intubation of the cecum, carefully inspect the whole colorectal mucosa by white light imaging(WLI) during the first colonoscopy withdraw. Then reinsert to the cecum and withdraw with narrow band imaging(NBI). Stop watch will be utilized to remind endoscopists.
62036884|NCT05684328|ACTIVE_COMPARATOR|NBI Then WLI Withdrawal Group|After successful intubation of the cecum, carefully inspect the whole colorectal mucosa by narrow band imaging(NBI) during the first colonoscopy withdraw. Then reinsert to the cecum and withdraw with white light imaging(WLI). Stop watch will be utilized to remind endoscopists.
62036885|NCT04408573|NO_INTERVENTION|Regular Continuous High Frequency|Patient remains 2 weeks in the currently chosen stimulation protocol.
62238020|NCT00197808|EXPERIMENTAL|vaccine schedule3|Neissvacc at 2 and 3 months
62238021|NCT00197808|EXPERIMENTAL|vaccine schedule 4|Neissvacc at 2 and 4 months
62814179|NCT02492035|EXPERIMENTAL|Physical activity|Tailoring intervention with kinesiologist
62814180|NCT02492035|EXPERIMENTAL|Diet|Tailoring intervention with nutritionist
62814181|NCT02492035|EXPERIMENTAL|Physical activity and diet|Tailoring intervention with kinesiologist and nutritionist
62814182|NCT02492035|NO_INTERVENTION|Standard medical care|Follow with family doctor as usual care.
62814183|NCT05831033|EXPERIMENTAL|BEN101|BEN101 infusion single dose level between 1x10\^9 to 1x 10\^11，not lower than 1×10\^9 cells, final dose is affected by the starting amount of TILs cells isolated from the tumor tissue sample.
62814184|NCT04085575|ACTIVE_COMPARATOR|tranexamic acid - The G1 group|The G1 group received 1 g of intra-articular tranexamic acid (TXA). The G1 group received 15 mg / kg IV at 20 min at induction and then 10 mg / kg in oral administration 6 and 12 hours after induction dose IV of tranexamic acid.
62814185|NCT04085575|ACTIVE_COMPARATOR|tranexamic acid - The G2 group|The G2 group received 2 g of intra-articular tranexamic acid (TXA). The G2 group received 15 mg / kg IV at 20 min at induction and then 10 mg / kg in oral administration 6 and 12 hours after induction dose IV of tranexamic acid.
62238022|NCT00197808|EXPERIMENTAL|Vaccine schedule 5|Meningitec at 2 and 3 months
62238023|NCT00197808|EXPERIMENTAL|Vaccine schedule 6|Meningitec at 2 and 4 months
62238024|NCT04697121|PLACEBO_COMPARATOR|Placebo|
62238025|NCT04697121|ACTIVE_COMPARATOR|Combined Bergamot Phytosome and Artichoke leaf dry extract|600 mg of Bergamot Phytosome and 100 mg of Artichoke leaf standardized dry extract
62814186|NCT05306925|NO_INTERVENTION|Standard parenteral nutrition|These infants will form the control group and will receive standard parenteral nutrition. They will be sub-stratified into gestational brackets - preterm (born \<30 weeks) and term/near term.
62238026|NCT05408104||tolvaptan (TLV)|LVAD recipients with post-operative hyponatremia (Na \< 135 mEq/L). Eligible patients took tolvaptan 15 mg daily as part of a routine care treatment plan.
62596223|NCT05136339|EXPERIMENTAL|Immediate Community-Based Mentoring and Education Sessions|Subjects will receive the intervention of community-based mentoring and education sessions immediately after enrollment.
62238027|NCT05408104||no tolvapton (no-TLV)|LVAD recipients with post-operative hyponatremia (Na \< 135 mEq/L). Eligible patients did not take tolvaptan as part of routine care.
62238028|NCT02700204|EXPERIMENTAL|PicoWay 532nm fractional treatment|subjects will receive one treatment for peri auricular and/or Buttocks by 532nm hand-piece
62814187|NCT05306925|EXPERIMENTAL|Arginine supplementation (combined)|These infants will form an intervention group and will receive parenteral nutrition with additional arginine (up to 18% of amino acid make-up) for up to 14 days post-op and oral arginine supplementation up to 30 days post-op. They will be sub-stratified into gestational brackets - preterm (born \<30 weeks) and term/near term.
62814188|NCT05306925|EXPERIMENTAL|Arginine supplementation (oral only)|These infants will form an intervention group and will receive standard parenteral nutrition and oral arginine supplementation up to 30 days post-op. They will be sub-stratified into gestational brackets - preterm (born \<30 weeks) and term/near term.
62814189|NCT05795166||People with obesity|Patients with obesity coming into the clinic as part of routine visit to their treating physician/general practitioner
62814190|NCT02570984|ACTIVE_COMPARATOR|Active|omalizumab 0.016 mg/kg/IU total IgE
62814191|NCT02570984|PLACEBO_COMPARATOR|Placebo|looks like active drug
62814192|NCT02169518||Diabetes Arm|Patients with Type 1 and Type 2 diabetes
62814193|NCT02169518||Bariatric Arm|Obese patients scheduled for bariatric surgery
62814194|NCT06301958|EXPERIMENTAL|Dextrose prolotherapy|A subject received a single intra-articular injection of 25% hypertonic glucose solution 10 mL (1:1 of 50% dextrose and normal saline) into one knee with arthritis after aspiration of all synovial fluid.
62814195|NCT06705309|EXPERIMENTAL|Web-Based Education Group|Web-Based Education Group
62238029|NCT02700204|EXPERIMENTAL|PicoWay 1064nm fractional treatment|subjects will receive one treatment for peri auricular and/or Buttocks by 1064nm hand-piece
62814196|NCT06366607||nurses|Nurses worked in surgical intensive and critical care units
62814197|NCT03996070|ACTIVE_COMPARATOR|Treatment arm|Therapeutic dose regime
62814198|NCT03996070|PLACEBO_COMPARATOR|Sham arm|Sub-therapeutic dose regime
62814199|NCT05043363||Observational cohort|"1. Patients with an established diagnosis of inflammatory bowel disease who have been identified as being 'at risk' by either their secondary care doctor or GP and now require endoscopic assessment for ongoing disease symptoms but are unable to access endoscopy services urgently.~2. Patients presenting directly to their GP practice with symptoms of anorectal disease (e.g. rectal bleeding or pain) or symptoms that would warrant referral to a hospital under a 2WW appointment according to NICE criteria~Recruited patients will undergo rectal examination in primary care with the LumenEye X1 with either contemporaneous or retrospective image review by a secondary care clinician. This will require a glycerine suppository to be administered. Patient feedback will be sought with a post-procedural questionnaire."
62238030|NCT04876534|EXPERIMENTAL|Tocilizumab|32 patients with active moderate-severe GO treated with i.v. tocilizumab; Tocilizumab weight adjusted, 8 mg/kg, 1 intravenous infusion every four weeks (+/- 72 hours) for 12 weeks
62238031|NCT04876534|ACTIVE_COMPARATOR|Methylprednisolone|32 patients with active moderate-severe GO treated with i.v. methylprednisolone; Methylprednisolone, 500 mg infusion weekly (+/- 48 hours) for 6 weeks, followed by 250 mg infusion weekly (+/- 48 hours) for another 6 weeks
62238032|NCT03963453||Interventional|Regular physical exercise group
62238033|NCT03963453||Control|Standards of care treatment
62238034|NCT01083628|EXPERIMENTAL|Group CBT for Depression with MoodText'|Group cognitive behavioral therapy utilizing the BRIGHT manual for depression along with automated text messaging for mood monitoring and reminder of session content
62814200|NCT00784563|ACTIVE_COMPARATOR|Continuous training|Aerobic walking using continuous heart rate training.
62814201|NCT00784563|ACTIVE_COMPARATOR|Interval training|Aerobic walking using interval heart rate training
62814202|NCT05000021|EXPERIMENTAL|Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD) with Continuous Glucose Monitoring|Participants randomized to this arm will receive Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD), enhanced by review of Continuous Glucose Monitoring (CGM) data. Participants will wear study-supplied CGM for the first 6 months of their participation in the trial.
62814203|NCT05000021|ACTIVE_COMPARATOR|Continuous Glucose Monitoring (CGM) Only|Participants randomized to receive Continuous Glucose Monitoring (CGM) will continue to receive their usual care and will also wear CGM throughout the first 6 months of their participation in the trial.
62814204|NCT03210948|EXPERIMENTAL|RTE-guided EUS-FNA|"The needle will be then inserted into the most suspicious part (dark blue) of the lesion as assessed at real time elastography."
62814205|NCT03210948|ACTIVE_COMPARATOR|Conventional EUS-FNA|A 25 G needle with a central stylet to protect the aspiration channel of the needle will be introduced though the endoscope's working channel.
62238035|NCT01083628|ACTIVE_COMPARATOR|Group CBT for Depression|Standard group cognitive behavioral therapy utilizing the BRIGHT manual for depression
62238036|NCT04151953||Subjects with cardiac implantable electronic device (CIED)|Subjects with previously implanted cardiac implantable electronic device (CIED) who are undergoing an MRI Scan for clinically indicated, diagnostic purposes.
62238037|NCT00643669|EXPERIMENTAL|AL-3789|AL-3789 Sterile Suspension, single depot administration of 0.8 mL in the study eye
62238038|NCT00643669|NO_INTERVENTION|No treatment|Fellow eye, as randomized
62596224|NCT05136339|EXPERIMENTAL|Delayed Community-Based Mentoring and Education Sessions|Subjects will receive the intervention of community-based mentoring and education sessions approximately 12 months after enrollment.
62596225|NCT01077739|EXPERIMENTAL|Avastin (bevacizumab) + standard of care|
62036886|NCT04408573|EXPERIMENTAL|Cycling High Frequency|Patient is stimulated with the same polarity, voltage/current, pulse width and frequency as the currently chosen stimulation protocol, but with cycling stimulation: 40sec On - 02 sec OFF
62036887|NCT04408573|EXPERIMENTAL|Continuous Low Frequency|Patient is stimulated with the same polarity and pulse width as the currently chosen stimulation protocol, but with low frequency (80Hz). Voltage/current will be adjusted to maintain TEED similar to that on the regular stimulation protocol.
62036888|NCT04408573|EXPERIMENTAL|Cycling Low Frequency|Patient is stimulated with the same polarity and pulse width as the currently chosen stimulation protocol, but with low frequency (80Hz) and cycling stimulation: 40sec On - 02 sec OFF. Voltage/current will be adjusted to maintain TEED similar to that on the regular stimulation protocol.
62036889|NCT04518878|EXPERIMENTAL|Fixed Low-dose Eltrombopag and rhTPO|Fixed Low-dose Eltrombopag and rhTPO
62596226|NCT02589236|PLACEBO_COMPARATOR|Placebo|Placebo Capsule
62814206|NCT05109364|EXPERIMENTAL|terazosin therapy extension|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and terazosin medication. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the alpha1- adrenergic receptor antagonist terazosin, resulting in a decreased clinical conversion rate to parkinsonism.
62814207|NCT01242423|EXPERIMENTAL|superficial 2nd degree burn|Group A (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who have sustained a superficial 2nd degree burn on ≥1% and ≤30% of the surface of the body.
62036890|NCT02464189||Children with asthma|
62814208|NCT01242423|EXPERIMENTAL|deep 2nd degree burn|Group B (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who have sustained a deep 2nd degree burn on ≥1% and ≤30% of the surface of the body.
62036891|NCT04707053||Intraaxial lesion group|Patients with intraaxial brainstem lesions (lesions located in the brainstem) + experienced brainstem surgery in our department during the study period
62036892|NCT04707053||Extraaxial lesion group|Patients with extraaxial brainstem lesions (lesions close to the brainstem) + experienced brainstem surgery in our department during the study period
62814209|NCT01242423|EXPERIMENTAL|skin excision for the purpose of a skin graft|Group C (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of BBS.
62814210|NCT03043313|EXPERIMENTAL|Cohort A: Tucatinib + Trastuzumab|Non-randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.
62036893|NCT05227742|PLACEBO_COMPARATOR|Placebo (0 mg psilocybin)|Participants in this arm will receive 0 mg of psilocybin once per week for 5 weeks.
62596227|NCT02589236|EXPERIMENTAL|Cavosonstat (N91115) 200 mg|Cavosonstat (N91115) 200 mg twice daily (BID)
62596228|NCT02589236|EXPERIMENTAL|Cavosonstat (N91115) 400 mg|Cavosonstat (N91115) 400 mg BID
62596229|NCT06646159|EXPERIMENTAL|Experimental: REThink|To ensure age-appropriate interventions, students below the age of 18 in the experimental group will receive the REThink game, while college-aged participants will engage with the REThink LIFE game.
62596230|NCT06646159|NO_INTERVENTION|Control|The students randomized in the control group will access the intervention after finalizing the post-test measurement
62036894|NCT05227742|EXPERIMENTAL|1 mg psilocybin|Participants in this arm will receive 1 mg psilocybin once per week for 5 weeks.
62036895|NCT05227742|EXPERIMENTAL|2.5 mg psilocybin|Participants in this arm will receive 2.5 mg psilocybin once per week for 5 weeks.
62036896|NCT05227742|EXPERIMENTAL|5 mg psilocybin|Participants in this arm will receive 5 mg psilocybin once per week for 5 weeks.
62036897|NCT02962687|EXPERIMENTAL|Videoconference care management|12-week nurse care management for medically complex Veterans with CI delivered via videoconferencing
62036898|NCT02962687|ACTIVE_COMPARATOR|Telephone care management|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
62238039|NCT01119001|EXPERIMENTAL|P300 Brain Computer Interface for people with ALS|
62596231|NCT01328106|EXPERIMENTAL|1|
62596232|NCT06329687|EXPERIMENTAL|Nasal Pump|Tyrvaya nasal pump with additional silicone lubricant
62596233|NCT00006398|EXPERIMENTAL|Timolol Maleate|Dose titrated from 5 mg per day to up to 80 mg per day depending on heart rate
62596234|NCT00006398|PLACEBO_COMPARATOR|Placebo|Timelol placebo
62596235|NCT03886779|ACTIVE_COMPARATOR|Prolensa (Bromfenac Ophthalmic Solution) 0.07%|Bausch and Lomb, Rochester, NJ Dose: Subjects will instill one drop into the study (operative) eye once daily for a maximum of 16 days. Dosing will begin one days prior to surgery (Day 1), continue on the day of surgery plus 1 hour before surgery and for 14 days after surgery.
62036899|NCT03084055|EXPERIMENTAL|eMotion intervention|Subjects randomised to the intervention arm will receive eMotion for two months. eMotion is comprised of a series of weekly audio visual modules designed to increase exposure to positive activities and physical activity.
62036900|NCT03084055|NO_INTERVENTION|Waiting list control|Subjects in the waiting list control group will be given no intervention for two months; the control group will then be able to access eMotion if they wish but this will not form part of the research project
62036901|NCT03609762|EXPERIMENTAL|Intervention group|EQ-5D-5L HRQOL results be available to the attending doctor
62596236|NCT03886779|ACTIVE_COMPARATOR|Ilevro® (nepafenac ophthalmic suspension ) 0.3%|Alcon Laboratories, Inc., Fort Worth, TX Dose: Subjects will instill one drop of test article into the study (operative) eye once daily for a maximum of 16 days. Dosing will begin one day prior to surgery (Day 1), continue on the day of surgery plus1 hour before surgery and for 14 days after surgery.
62596237|NCT02468154|EXPERIMENTAL|splint|Splint is placed under the cast of children affected by spasticity who have to keep the heel unloaded.
62596238|NCT02468154|ACTIVE_COMPARATOR|standard care|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
62596239|NCT03809468|NO_INTERVENTION|control|Routine follow up of a clinic visit at 1-2 weeks postop, and 6-8 weeks postop.
62036902|NCT03609762|NO_INTERVENTION|Control group|usual care. All subjects attending the control clinics will not need to complete the electronic EQ-5D-5L before seeing the doctor during their follow-up visits. The doctor will manage the patient as usual, based on the usual clinical information. The doctor will complete the clinician-reported follow-up clinical data form (CRF) for each subject at the end of the consultation.
62036903|NCT01832116|EXPERIMENTAL|Tracerinjection|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
62238040|NCT02400034|ACTIVE_COMPARATOR|FAST voiding trial method|1) Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water. 2) catheter is removed; 3) Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction). 4) The patient will subjectively quantify their FOS via VAS scale. 5) If VAS scale \>50 (=50%) the catheter will remain out, patient is discharged home without measuring a PVR 6) If VAS scale is from 0-49 (= 0-49%) a PVR will be checked via bladder scan. If PVR is \<500 the patient will be discharged WITHOUT a catheter; If PVR is \>500 the patient will be discharged WITH a catheter. If she is discharged with an indwelling foley catheter, she will have an in-office retrograde voiding trial in 2-5 days
62428558|NCT02766400|ACTIVE_COMPARATOR|Directed Training|Directed training is a rehabilitation approach that maximizes the expertise of the rehabilitation practitioner. Rehabilitation practitioners identify and prioritize problematic activities, identify barriers to performing these activities, generate strategies to address these barriers and instruct patients in these strategies, and repeat the process with a variety of problematic activities identified during the rehabilitation program. Directed training promotes independence with training activities, however the benefits of direct training are likely to be activity-specific (i.e., only promote improvement on the trained activity) and not generalizable to other daily activities. This therapist-directed approach is currently the method used most frequently in acute rehabilitation.
62596240|NCT03809468|EXPERIMENTAL|study|phone call follow up instead of clinic visit follow up at 1-2 weeks, followed by 6-8 week clinic follow up
62596241|NCT06618820|PLACEBO_COMPARATOR|Placebo|Patients will receive 10 doses of microcrystalline cellulose (3 capsules per dose) from postoperative day (POD) 1 to POD 10.
62596242|NCT06618820|EXPERIMENTAL|3-day tranexamic acid (TXA)|Patients will receive three 1950 milligram (mg) doses of Oral TXA (three 650mg capsules per dose) from POD 1 to POD 3 and 7 doses of Placebo from POD 4 to POD 10.
62238041|NCT02400034|ACTIVE_COMPARATOR|Retrograde fill voiding trial method|1) Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water. 2) catheter is removed; 3) Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction). 4) The patient will subjectively quantify their FOS via VAS scale (however this information will only be used for research purposes). 5) If she voids \>/= 2/3 (200cc) the catheter will remain out as she will have passed her voiding trial. If she voids \< 200cc she will be discharged home with a catheter and instructed to follow-up in 2-5 days for an in-office retrograde voiding trial in 2-5 days.
62596243|NCT06618820|EXPERIMENTAL|10-day TXA|Patients will receive ten 1950mg doses of Oral TXA (three 650mg capsules per dose) from POD 1 to POD 10.
62596244|NCT03716843||Pressure monitoring system for AIS|"Adolescent idiopathic scoliosis (AIS) patients~(1) all target subjects are aged 10 to 15 years old with immature skeletons (Risser grade 0-2); (2) they are diagnosed with AIS with a Cobb angle between 25-45° and high risk for curve progression; (3) the types of scoliosis are classified by the Lenke classification system; and (4) the subjects have received rigid brace treatment."
62596245|NCT03290547|OTHER|arm-1|Cutera enLighten laser treatments that allows the user to choose a wavelength between 640nm to 800nm.
62596246|NCT05969314|EXPERIMENTAL|Cannabis|Cannabis capsules containing 5 mg of THC and CBD each or 2.5 mg of THC and CBD each.
62596247|NCT06620705|EXPERIMENTAL|Left bundle branch area pacing|6 months of left bundle branch area pacing.
62596248|NCT06620705|ACTIVE_COMPARATOR|Biventricular pacing|6 months of biventricular pacing using a RV apex lead and LV lead in the coronary sinus.
62596249|NCT03026140|EXPERIMENTAL|group 1 - closed|drug: ipilimumab 1 mg/kg day 1 (IV) drug: nivolumab 3 mg/kg on day 1 and day 15 (IV)
62036904|NCT03502382|OTHER|radilogical|Radiological: standing antero-posterior full-length digital images of the lower extremities
62036905|NCT03381495|EXPERIMENTAL|Epidural analgesia during labor|The epidural analgesia technique was used to maintain analgesia for parturients who request labor analgesia.First, we injected a test dose of 5ml 1% lidocaine . If not adverse effects were observed 10 minutes after the test dose, the parturient then received a bolus injection of an initial dose of 8-10 ml mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate. We then connected the epidural catheter with a patient-controlled epidural analgesia (PCA) pump, which provided patients the same mixed solution at 8-10ml/h until the delivery of neonates.
62596250|NCT03026140|EXPERIMENTAL|group 2 - closed|drug: ipilimumab 1 mg/kg day 1 (IV) drug: nivolumab 3 mg/kg on day 1 and day 15 (IV) drug: celecoxib 200 mg daily (oral)
62596251|NCT03026140|EXPERIMENTAL|Anti-IL8 cohort 4 (pMMR/MSS tumors) - closed|drug: nivolumab 3 mg/kg day 1 and day 15 (IV) drug: BMS-986253 (anti-IL8) 2400mg on day 1 and day 15 (IV)
62596252|NCT03026140|EXPERIMENTAL|Relatlimab cohort 5 (pMMR/MSS tumors)|drug: nivolumab 240mg IV on day 1 and day 15 drug: relatlimab 240mg IV on day 1 and day 15
62036906|NCT03381495|NO_INTERVENTION|Non-epidural analgesia during labor|Women who refused epidural labor analgesia were included in the non-epidural analgesia group, and they don't receive epidural analgesia during labor
62036907|NCT01803893||Embryo culture media|measurement using immunoassay
62036908|NCT01803893||maternal serum|measurement by immunoassay
62036909|NCT03078270|OTHER|Open-label|10 participants will be recruited for an open-label study. All will receive the active medication and complete depression and anxiety surveys at baseline, 4-weeks, and 8-weeks post injection. All participants will receive botulinum toxin A.
62036910|NCT03078270|PLACEBO_COMPARATOR|Double-Blind|30 participants will be recruited for a double-blind, comparison study. Participants will be randomized to the active or control groups. Each will receive an injection (active medication or placebo) and will complete a depression and anxiety survey at baseline, 4-weeks and 8-weeks post injection. Participants in the active group will receive botulinum toxin A; participants in the control group will receive a placebo.
62238042|NCT05904054|EXPERIMENTAL|Adult-CoronaVac® group|Aged 18-59 AND received 2 to 4 homologous doses of CoronaVac® at least 3 months prior to enrollment AND without SARS-CoV-2 infection history.
62238043|NCT05904054|EXPERIMENTAL|Adult-Comirnaty® group|Aged 18-59 AND received 2 to 4 homologous doses of Comirnaty® at least 3 months prior to enrollment AND without SARS-CoV-2 infection history.
62238044|NCT05904054|EXPERIMENTAL|Adult-mixed group|Aged 18-59 AND received 2 to 4 heterologous doses of CoronaVac® and Comirnaty® at least 3 months prior to enrollment AND without SARS-CoV-2 infection history; OR Aged 18-59 AND received 2 to 4 heterologous doses of CoronaVac® and Comirnaty® at least 3 months prior to enrollment AND recovered from SARS-CoV-2 infection at least 3 months prior to enrollment; OR Aged 18-59 AND received 2 to 4 homologous doses of CoronaVac® or Comirnaty® at least 3 months prior to enrollment AND recovered from SARS-CoV-2 infection at least 3 months prior to enrollment.
62596253|NCT03026140|EXPERIMENTAL|Relatlimab cohort 6 (dMMR/MSI tumors) - closed|drug: nivolumab 480mg IV on day 1 and day 29 drug: relatlimab 480mg IV on day 1 and day 29
62735204|NCT04583436|EXPERIMENTAL|Endovascular recanalization|"Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.~n=45"
62428559|NCT01001715|EXPERIMENTAL|REGN475/SAR164877|REGN475/SAR164877, single injection, dose depending on the participant's body weight
62596254|NCT00055770|EXPERIMENTAL|Arm I|"PHASE I: Patients receive oral erlotinib once daily on days 1-28 and docetaxel IV over 1 hour on days 8, 15, and 22. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity.~Patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional cohort of 6 patients receives erlotinib at the MTD.~PHASE II: Patients receive erlotinib at the MTD and docetaxel as in phase I."
62596255|NCT02267772|EXPERIMENTAL|IV Acetaminophen|IV acetaminophen for pain control
62596256|NCT02267772|ACTIVE_COMPARATOR|IV morphine|IV morphine for pain control
62036911|NCT06041035|EXPERIMENTAL|QLS31905 + nab-paclitaxel + gemcitabine (Part A/B)|Pancreatic cancer participants will be treated with QLS31905 in combination with nab-paclitaxel and gemcitabine for part A of the study to establish the recommended dose of QLS31905 for part B. In part B, the participants will be treated with QLS31905 at a dose determined by the part A of the study in combination with nab-paclitaxel and gemcitabine.
62036912|NCT06041035|EXPERIMENTAL|QLS31905 + oxaliplatin + capecitabine (Part B)|In part B, gastric/gastroesophageal junction cancer participants will be treated with QLS31905 at dose determined by part A of the study in combination with oxaliplatin and capecitabine.
62428560|NCT01001715|PLACEBO_COMPARATOR|Placebo|Placebo (for REGN475/SAR164877), single injection
62428561|NCT03429374|ACTIVE_COMPARATOR|Liquiband Fix8 glue mesh fixation|
62428562|NCT03429374|ACTIVE_COMPARATOR|Mesh fixation with absorbable tacks|
62428563|NCT03799874|EXPERIMENTAL|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide at 200 ppm for up to 90 minutes daily for 3 days.
62428564|NCT03799874|PLACEBO_COMPARATOR|Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
62428565|NCT06160882|OTHER|Evaluation of Powered Prosthesis for use with Transfemoral Osseointegration Recipients|Perform Osseointegration (OI)Surgery and Targeted Muscle Reinnervation (TMR) and evaluate powered prosthesis training and use. The participant will complete non-weightbearing neural control tasks along with functional, biomechanical, metabolic and qualitative patient-reported outcome measures using the OI interface and the powered leg prosthesis.
62428566|NCT05680311|ACTIVE_COMPARATOR|Breast Cancer Patients|Group of patients with verified breast cancer diagnosis
62428567|NCT05680311|SHAM_COMPARATOR|Non-Cancer patients|Group of healthy patients with no verified any type of cancer.
62428568|NCT03552679||LVAD recipients|Consecutive patients accepted for elective LVAD implantation in the context of routine care, will undergo routinely scheduled echocardiography before, within 1 week, 1 month, 3 months and 1 year after LVAD implantation. Echocardiography will be performed using ultrasound machines that are capable of acquisition of two-, three-dimensional and Multiplane Echocardiography of the right ventricle. Invasive hemodynamic data will be collected in the perioperative period.
62596257|NCT02773212|EXPERIMENTAL|d-Amphetamine and Contingency Management|Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine with contingency management treatment for cocaine use disorder.
62238045|NCT05904054|EXPERIMENTAL|Elderly-mixed group|Aged 60-75 AND received 2 to 4 heterologous doses of CoronaVac® and Comirnaty® at least 3 months prior to enrollment AND without SARS-CoV-2 infection history; OR Aged 60-75 AND received 2 to 4 heterologous doses of CoronaVac® and Comirnaty® at least 3 months prior to enrollment AND recovered from SARS-CoV-2 infection at least 3 months prior to enrollment; OR Aged 60-75 AND received 2 to 4 homologous doses of CoronaVac® or Comirnaty® at least 3 months prior to enrollment AND without SARS-CoV-2 infection history; OR Aged 60-75 AND received 2 to 4 homologous doses of CoronaVac® or Comirnaty® at least 3 months prior to enrollment AND recovered from SARS-CoV-2 infection at least 3 months prior to enrollment.
62238046|NCT00849654|EXPERIMENTAL|PCI-32765|
62428569|NCT02280356|EXPERIMENTAL|radiation therapy in combination with brachytherapy|Patients will undergo low dose rate (LDR) prostate brachytherapy using Pd-103 followed approximately 4 weeks later with hypofractionated image-guided external beam radiation therapy (25Gy in 5 fractions; 5Gy x 5 fractions every other day) to the prostate \& seminal vesicles. Both brachytherapy as well as external beam will be performed according to our current standards of practice using the same equipment, techniques, \& treatment planning procedures. Pts will be followed post-treatment at 1, 3, 6 (+/- 4 weeks) \& every 6 months (+/- 4 weeks) thereafter until 36 months. During the post-treatment followup, pts will be evaluated for urinary, bowel/rectal \& sexual toxicity. Baseline measures of these domains will be obtained prior to treatment at the time of enrollment. Serum PSA levels will be drawn on the same schedule as clinical followup. Post-treatment prostate biopsies will be obtained once between 24-36 months post-treatment to evaluate pathologic response to therapy
62428570|NCT05725564|EXPERIMENTAL|FAST-BCT|FAST exercise intervention without behavior change techniques applied. Daily exercise intervention including functional resistance training and personalized coaching.
62428571|NCT05725564|EXPERIMENTAL|FAST+BCT|FAST exercise intervention with behavior change techniques applied. Daily exercise intervention including functional resistance training and personalized coaching with added reminders, education, goal setting, self monitoring, and feedback to encourage adherence and effort.
62238047|NCT03875989|ACTIVE_COMPARATOR|Arm A|
62238048|NCT03875989|EXPERIMENTAL|Arm B|
62428572|NCT05725564|ACTIVE_COMPARATOR|BT-BCT|Band Together exercise intervention without behavior change techniques applied. 3 times weekly group exercise intervention held over Zoom featuring strength and balance exercises for 45 minutes.
62428573|NCT05725564|ACTIVE_COMPARATOR|BT+BCT|Band Together exercise intervention with behavior change techniques applied. 3 times weekly group exercise intervention held over Zoom featuring strength and balance exercises for 45 minutes with added reminders, education, goal setting, self monitoring, and feedback to encourage adherence and effort.
62428574|NCT04904601|ACTIVE_COMPARATOR|Experimental Group: Kale|This group will be given one scoop of powder of (Kale) three times a day for a total of 10g/day for 6 weeks.
62428575|NCT04904601|PLACEBO_COMPARATOR|Placebo Group: Green Peas|This group will be given one scoop of powder of (Green Peas) three times a day for a total of 10g/day for 6 weeks.
62433664|NCT05401331|OTHER|Hemodynamic responses when we do not use masks|Hemodynamic responses when we do not use masks
62238049|NCT02620267|EXPERIMENTAL|tDCS Stimulation|Each subject will receive all three types of stimulation on separate days- anodal, cathodal, and sham stimulation
62238050|NCT04625998|EXPERIMENTAL|Intervention|Elementary schools and Head Start centers in the intervention catchment areas implemented (1) an enhanced Coordinated Approach To Child Health (CATCH) program for elementary schools using the CATCH Coordination Guide (Enhanced CATCH Elementary School Program), and (2) CATCH Early Childhood program for Head Start Centers.
62814211|NCT03043313|EXPERIMENTAL|Cohort B: Tucatinib + Trastuzumab|Randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.
62814212|NCT03043313|EXPERIMENTAL|Cohort C: Tucatinib Monotherapy|Randomized cohort. Participants take tucatinib twice per orally every day. Participants who do not respond to therapy may have the option to receive tucatinib and trastuzumab.
62036913|NCT06041035|EXPERIMENTAL|QLS31905 + gemcitabine+cisplatin(Part B)|In part B, other solid tumor participants including but not limited to biliary tract cancer will be treated with QLS31905 at dose determined by part A in combination with standard chemotherapy recommended by guidelines.QLS31905 plus gemcitabine+ cisplatin as the first-line treatment of advanced biliary tract cancer.
62036914|NCT03939052|EXPERIMENTAL|Protein intake|Free amino acids vs. Glycomacropeptide (GMP)
62814213|NCT06202365|EXPERIMENTAL|Group A (WBV Group)|A vibrating platform (WBV) will be used in this study with 6 training exercises for 4 minutes, 2 times /week for 6 weeks. Feet should be parallel at shoulder width apart and knees hold constant. WBV sessions were conducted from low to medium-vibration mode
62814214|NCT06202365|SHAM_COMPARATOR|Group B (Sham WBV Group)|They will receive the same intervention while the device turned off for 4 minutes, 2 session/ week for 6 weeks.
62814215|NCT00168844|OTHER|Tiotropium Respimat 5mcg (Tio R5)|
62814216|NCT00168844|OTHER|Tiotropium Respimat 10mcg (Tio R10)|
62036915|NCT01284465|EXPERIMENTAL|Intervention group|Education and patient liaison combination
62036916|NCT01284465|EXPERIMENTAL|Control group|Education only
62036917|NCT02522494|ACTIVE_COMPARATOR|Intervention|Patients randomized to the intervention will view the video
62036918|NCT02522494|OTHER|Pamphlet alone|Patients randomized to the pamphlet alone will only receive the pamphlet
62238051|NCT04625998|NO_INTERVENTION|Comparison|Elementary schools and Head Start centers in the comparison catchment area used their regular school and early care and education (ECE) nutrition and physical activity programs. Elementary schools were required by law to implement a coordinated school health program.
62428576|NCT06119074|EXPERIMENTAL|Gifted Savings|Participants in the treatment group will receive an unconditional Gifted Savings account with $2,000 of assets ($100 USD available upon enrollment; $500 USD available for emergency use each year for two years).
62428577|NCT06119074|NO_INTERVENTION|No Gifted Savings|Participants in the control group will not receive a Gifted Savings account.
62428578|NCT00990028|EXPERIMENTAL|Rosuvastatin|20 mg oral during 10 days
62428579|NCT00990028|PLACEBO_COMPARATOR|Placebo|
62428580|NCT03724968|EXPERIMENTAL|Arm A|Nivolumab and Relatlimab
62428581|NCT03724968|EXPERIMENTAL|Arm B|Nivolumab and Ipilimumab
62428582|NCT01162018|EXPERIMENTAL|Acupuncture Arm|
62596258|NCT02773212|ACTIVE_COMPARATOR|d-Amphetamine alone|Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine but will not receive contingency management treatment for cocaine use disorder.
62814217|NCT00168844|OTHER|Placebo|
62814218|NCT01447381||mycophenolate mofetil|Moderate to severe atopic dermatitis being treated with systemic mycophenolate mofetil
62814219|NCT01447381||cyclosporine|Moderate to severe atopic dermatitis being treated with systemic cyclosporine
62814220|NCT01447381||azathioprine|Moderate to severe atopic dermatitis being treated with systemic azathioprine
62428583|NCT01162018|SHAM_COMPARATOR|Sham Acupuncture|Sham Acupuncture
62036919|NCT02297581||GFC: Geriatric Fracture Center|"Patient treatment in a geriatric fracture center~A GFC is defined as follows:~* General geriatrician or ortho-geriatrician available in trauma/orthopaedic department~* Geriatrician sees the patient prior to surgery (except if the patient is admitted over night or during weekends)~* Local medical guidelines, consented by orthopedic surgeons and geriatrician~* Pre-defined order set for assessing laboratory values~* Pre-defined patient pathway to guarantee a fast track in the emergency room~* Daily communication among involved specialists~* Postoperative phase up to discharge from orthopaedic / trauma department (i.e. Discharge 1):~  * Daily patient visit by geriatrician~ * Daily patient visit by orthopedic surgeon in combination with nurse~ * Daily therapy by physiotherapists, except for weekends~ * Access to social workers, if required"
62814221|NCT01447381||methotrexate|Moderate to severe atopic dermatitis being treated with systemic methotrexate
62036920|NCT02297581||UCC: Usual Care Center|"Patient treatment in an usual care center~A UCC is defined as follows:~* No geriatrician available in trauma/orthopaedic department~* No pre-operative visit by a geriatrician as a standard~* No pre-defined medical guidelines for geriatric fracture patients~* Postoperative phase up to discharge from orthopaedic / trauma department (i.e. Discharge 1):~  * No daily patient visits by a geriatrician as a standard"
62036921|NCT03577210|OTHER|computer-guided augmentation genioplasty|patient-specific PEEK implant
62596259|NCT02773212|ACTIVE_COMPARATOR|Placebo and Contingency Management|Participants in this group will receive 4 weeks of of placebo treatment, paired with contingency management treatment for cocaine use disorder.
62596260|NCT03546972|ACTIVE_COMPARATOR|Group A (DPP)|Participants take part in DPP once a week over 1 hour for 16 weeks.
62814222|NCT03023449|EXPERIMENTAL|Healthy Controls|The protocol will be a 35-minute monitoring session, during which cerebral hemodynamics will be monitored with both DCS and TCD, while blood pressure, heart rate, cardiac output, respiratory rate, end oxygen saturation, and inhaled nitric oxide concentration, are continuously monitored. 5 minutes of baseline hemodynamics will be assessed, after which the subject will breath iNO for 5 minutes, followed by 5 minutes of room air. This iNO/room air cycle will be repeated with a total of 3 different iNO concentrations. The full protocol will require 35 minutes. Subjects will be called at 24 hours after the monitoring session to determine any tolerability issues or adverse events.
62036922|NCT06644573|EXPERIMENTAL|Single-Arm - PROSOMNIA Sleep Therapy|"Description: All eligible participants in this study will be assigned to a single arm and receive the same intervention, PROSOMNIA Sleep Therapy. This involves a controlled, anesthesia-induced sleep session using Diprivan/Propofol, administered under the supervision of an Anesthesiologist. Monitoring will include American Society of Anesthesiologists (ASA) standard monitoring and real-time EEG to track sleep stages and brain activity during the procedure.~Interventions: PROSOMNIA Sleep Therapy, involving the administration of Diprivan/Propofol, a FDA-approved anesthetic, to induce sleep in individuals with chronic insomnia, sleep deprivation and/or REM sleep disparities. This treatment is intended to reduce sleep pressure, decrease sleep onset latency, enhance REM sleep duration, and improve overall sleep quality. Continuous EEG monitoring to track sleep architecture and blood serum uric acid tests to identify adenosine release."
62428584|NCT00366678|EXPERIMENTAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
62428585|NCT00366678|ACTIVE_COMPARATOR|7-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine
62428586|NCT02071758|EXPERIMENTAL|20 mcg LEISH-F3 + 5 mcg SLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + SLA-SE at Days 0, 28, and 56. High dose of antigen and low dose of SLA-SE adjuvant.
62428587|NCT02071758|EXPERIMENTAL|20 mcg LEISH-F3 + 10 mcg GLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + GLA-SE at Days 0, 28, and 56. High dose of antigen and high dose of GLA-SE adjuvant.
62428588|NCT02071758|EXPERIMENTAL|5 mcg LEISH-F3 + 10 mcg GLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of GLA-SE adjuvant.
62428589|NCT02071758|EXPERIMENTAL|20 mcg LEISH-F3 + 10 mcg SLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + SLA-SE at Days 0, 28, and 56. High dose of antigen and high dose of SLA-SE adjuvant.
62433665|NCT06541392|EXPERIMENTAL|Breakfast1|This group will have breakfast time at 6.30 to 7.30 am
62596261|NCT03546972|EXPERIMENTAL|Group B (DPP-HT)|Participants take part in DPP once a week over 1 hour for 16 weeks and hunger training once a week during weeks 2-6.
62596262|NCT06451835||Patients with MDD|Patients who are prescribed a course of 30 rTMS sessions to treat an episode of MDD at one of the nine participating centres
62596263|NCT03465774||Group 2 (IPC alone)|Patients undergo IPC placement.
62596264|NCT03465774||Group I (IPC, doxycycline)|Patients undergo IPC placement and receive doxycycline via IPC 5 days later.
62596265|NCT02140216||Day 0 blood transfusion|Patients undergoing elective spine surgery receiving intra- or immediate-postoperative red cell blood transfusion.
62596266|NCT02140216||Day 1 or 2 blood transfusion|Patients undergoing elective spine surgery receiving first red cell blood transfusion on day 1 or 2 after surgery.
62596267|NCT02140216||No blood transfusion|Patients undergoing elective spine surgery receiving no blood transfusion.
62596268|NCT03078179|EXPERIMENTAL|Commercial Cow Milk with Probiotic|"Probiotic enriched cow milk:~200 ml of commercial nutritive milk fortified with probiotic Lactobacillus rhamnosus and Bifidobacterium longum once a day."
62596269|NCT03078179|PLACEBO_COMPARATOR|Commercial Dairy Cow Milk|200 ml of commercial nutritive milk without probiotic, once a day,
62596270|NCT06090643|ACTIVE_COMPARATOR|Arm II (usual care)|Physicians and clinic staff provide and patients receive CRC screening usual care throughout the trial.
62596271|NCT06090643|EXPERIMENTAL|Group I (education, feedback, consult, FIT kit, text message)|Physicians and clinic staff receive ongoing training, education, and feedback on CRC screening, and utilize point-of-care clinical decision support tool throughout the trial. Patients receive CRC screening recommendations from provider, a FIT kit with culturally tailored instructions, consultation with clinic staff, and text message reminders throughout the trial.
62596272|NCT04791319|PLACEBO_COMPARATOR|Group 1: Placebo|Participants will receive subcutaneous (SC) placebo once a week (qw) through Week 15. At Week 16, participants will crossover to receive SC bermekimab Dose 2 qw through Week 31.
62596273|NCT04791319|EXPERIMENTAL|Group 2: Bermekimab|Participant will receive SC bermekimab Dose 1 qw from Week 0 through Week 31.
62428590|NCT01931137|EXPERIMENTAL|Coating A|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
62596274|NCT04791319|EXPERIMENTAL|Group 3: Bermekimab|Participants will receive SC bermekimab Dose 2 qw from Week 0 through Week 15. At Week 16, participants who achieve an eczema area and severity index (EASI)-75 response (responders) will be rerandomized either to continue to receive bermekimab Dose 2 qw, or to receive bermekimab Dose 1 qw, through Week 31 and participants who do not achieve an EASI-75 response (non responders) will continue to receive bermekimab Dose 2 qw through Week 31.
62238052|NCT05953779|EXPERIMENTAL|Personalized Intervention|"The intervention approach taken in this RCT is focused on unmet psychological needs (predictability, belonging, competence, self-worth, autonomy, and playfulness). For each need, a specific 90-minute intervention has been developed.~The primary unmet need for each individual will be determined by a conditional entropy algorithm. Simply, the presence versus absence of subjective distress will be measured eight times per day for 30 days. Concurrently, the presence versus absence of need frustration will also be measured eight times per day for 30 days. Utilizing a k-fold cross-validated estimation, conditional entropy will be used to determine the need that best reduces the uncertainty in subjective distress (that is, best explains its presentation probabilistically).~At both sites, the experimental condition will consist of an algorithmically-chosen intervention. The choice will be made based on data collected during thirty days of ecological momentary assessment."
62596275|NCT04791319|ACTIVE_COMPARATOR|Group 4: Dupilumab|Participants will receive a loading dose of SC dupilumab Dose 1 at Week 0, SC placebo every two week (q2w) from Week 1 through Week 15 and then dupilumab Dose 2 q2w from Week 2 through Week 14. At Week 16, participants who achieve EASI-75 response (dupilumab responders) will continue on dupilumab Dose 2 q2w through Week 30 and placebo q2w from Week 17 through Week 31. Participants who do not achieve an EASI-75 response (dupilumab non-responders) will receive placebo qw from Week 16 through Week 18 (washout period) and bermekimab Dose 2 qw from Week 19 through Week 31.
62596276|NCT06647758||preoperative anemia-postoperative anemia|
62596277|NCT06647758||preopertive anemia-postoperitve non-anemia|
62596278|NCT06647758||preoperative non-anemia-postoperative anemia|
62596279|NCT06647758||preopeartive non-anemia-postopertive non-anemia|
62596280|NCT01729000|NO_INTERVENTION|Hand hygiene|All staff that have interaction with subjects will perform hand hygiene with all patient contact and before all contact with the intravenous line.
62596281|NCT01729000|EXPERIMENTAL|Hand hygiene plus gloving|All staff that have interaction with subjects will perform hand hygiene and wear gloves with all patient contact and before all contact with the intravenous line.
62596282|NCT06284395||Control Group|Thalidomide 100mg-200mg PO daily alone or in combination with dexamethasone 40mg PO every 24 hours on days 1-4, 8-11 of each cycle.
62596283|NCT06284395||Bortezomib Group|Bortezomib 1.3mg/m2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (VTD).
62238053|NCT05953779|ACTIVE_COMPARATOR|Non-personalized Intervention|"The intervention approach taken in this RCT is focused on unmet psychological needs (predictability, belonging, competence, self-worth, autonomy, and playfulness). For each need, a specific 90-minute intervention has been developed.~At the BIU site, the active control condition will consist of an intervention chosen randomly (out of the six mentioned above).~At the UCB site, the active control condition will consist of a standard intervention addressing emotion regulation difficulties."
62238054|NCT05640466|OTHER|Adult patient with displaced metatarsal head fractures|"A Kirschner wire with its distal end is placed showing a small bend into the medullar cavity through the lateral margin of the proximal metaphysis of the affected metatarsal using a 5mm skin incision at that level. The skin incision was made over the interosseus space, so as to use one incision for the two neighbouring metatarsal bones. The diameter of the Kirschner wires to be used should be related to the size of the fractured metatarsal medullar cavity. Kirschner wire will be driven anterograde, with the help of an X-ray image intensifier.~Subsequently, the wire will be rotated 180 to direct its end to the dorsum of the foot so as to provoke a translation effect on the metatarsal head in order to obtain the head reduction, and maintained this reduction with the Kirschner wire."
62238055|NCT02036216||Hepatocellular Carcinoma|The mutation will be found in the DNA samples from the plasma and solid tumor tissues in the patients with HCC.
62238056|NCT02523053|ACTIVE_COMPARATOR|Hepatectomy|Surgical removal of all lesions
62238057|NCT02523053|EXPERIMENTAL|Hepatectomy plus 5-Fluorouracil|Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
62238058|NCT06151145|ACTIVE_COMPARATOR|Usual care|Usual care
62238059|NCT06151145|EXPERIMENTAL|Text-message intervention with digital tools (SELF)|Text-message intervention
62238060|NCT06151145|EXPERIMENTAL|Stepped Care (STEP)|Stepped care
62238061|NCT05060289||Modeling group|The data of modeling group is used to construct a predictive model of DILI endpoint events.
62238062|NCT05060289||Validation group|Validation group is used to validate the predictive model externally.
62238063|NCT01473160|EXPERIMENTAL|delefilcon A|Delefilcon A randomly assigned to one eye, with narafilcon A assigned to the fellow eye for contralateral wear. Both products will be worn for one day for 16 hours (+/- 1 hour).
62238064|NCT01473160|ACTIVE_COMPARATOR|narafilcon A|Narafilcon A randomly assigned to one eye, with delefilcon A assigned to the fellow eye for contralateral wear. Both products will be worn for one day for 16 hours (+/- 1 hour).
62428591|NCT01931137|EXPERIMENTAL|Coating B|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
62596284|NCT04143594|EXPERIMENTAL|Lenacapavir, F/TAF, and TAF|"Induction phase: Participants will receive lenacapavir (LEN) 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus emtricitabine/ tenofovir alafenamide (F/TAF) (200/25 mg) fixed-dose combination (FDC) tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via subcutaneous (SC) injection on Day 15.~Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus TAF 25 mg tablets once daily orally at Week 28 and will continue up to Week 80.~Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily TAF 25 mg tablets from Week 80 onwards."
62596285|NCT04143594|EXPERIMENTAL|Lenacapavir, F/TAF, and BIC|"Induction phase: Participants will receive LEN 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus F/TAF (200/25 mg) FDC tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Day 15.~Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus bictegravir (BIC) 75 mg tablets once daily orally at Week 28 and will continue up to Week 80.~Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily BIC 75 mg tablets from Week 80 onwards."
62596286|NCT04143594|EXPERIMENTAL|Lenacapavir and F/TAF|"Induction phase: Participants will receive LEN 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus F/TAF (200/25 mg) FDC tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Day 15.~Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus bictegravir (BIC) 75 mg tablets once daily orally at Week 28 and will continue up to Week 80.~Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily BIC 75 mg tablets from Week 80 onwards."
62814223|NCT03023449|EXPERIMENTAL|Acute Ischemic Stroke|Patients will be enrolled in the study within 72 hours of stroke symptom onset. The protocol will be a 35-minute monitoring session, during which cerebral hemodynamics will be monitored with both DCS and TCD, while blood pressure, heart rate, cardiac output, respiratory rate, end oxygen saturation, and inhaled nitric oxide concentration, are continuously monitored. 5 minutes of baseline hemodynamics will be assessed, after which the subject will breath iNO for 5 minutes, followed by 5 minutes of room air. This iNO/room air cycle will be repeated with a total of 3 different iNO concentrations. The full protocol will require 35 minutes. Subjects will be undergo a final assessment at 24 hours after the monitoring session to determine any tolerability issues or adverse events.
62814224|NCT01848015||CTCs positive|
62814225|NCT02722564|EXPERIMENTAL|all study participants|subject will self estimate breath alcohol content and their actual BrAC will be recorded as measured by the Alco Sensor IV after each beer ingested.
62238065|NCT05100485||Training cohort|Training cohort was used to developement the new algorithm for predicting liver decompensation.
62238066|NCT05100485||Validation cohort|Validation cohort was used to test the performance of the new algorithm in predicting liver decompensation.
62428592|NCT01931137|EXPERIMENTAL|Coating C|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
62428593|NCT05357781||MS patients with IgG deficiency (serum IgG-concentration <7g/L).|MS patients with IgG deficiency (serum IgG-concentration \<7g/L).
62428594|NCT05357781||MS patients with normal IgG serum concentration (serum IgG-concentration ≥7g/L).|MS patients with normal IgG serum concentration (serum IgG-concentration ≥7g/L).
62428595|NCT04974359|EXPERIMENTAL|Lu AG06466|Participants will receive an oral titrated dose of Lu AG06466 once daily for 22 days in 1 of 2 treatment periods.
62238067|NCT05100485||HVPG cohort|HVPG cohort, a cross-section cohort was used to study the diagnostic value of novel score for clinically significant portal hypertension.
62238068|NCT02479334|PLACEBO_COMPARATOR|Fat challenge breakfast|200 ml control drink (non-energy flavored water) and high fat breakfast (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
62238069|NCT02479334|EXPERIMENTAL|Fat challenge breakfast+spices|200 ml spices drink (non-energy flavored water + spices extract) and high fat breakfast (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
62238070|NCT02479334|PLACEBO_COMPARATOR|Carbohydrate challenge breakfast|200 ml control drink (non-energy flavored water) and high carbohydrate breakfast (% Energy Carbohydrate:Fat:Prot / 60:20:20), acute study / one time administration
62596287|NCT04143594|ACTIVE_COMPARATOR|B/F/TAF|Participants will receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (50/200/25 mg) FDC tablets once daily orally from Day 1 and throughout their participation in the study up to Week 80
62596288|NCT02876991|OTHER|Sodium fluoride PET|"Before inclusion, patients undergo choline PET to assess an occult recurrence of prostate cancer.~After inclusion, they undergo sodium fluoride PET."
62596289|NCT05224960|EXPERIMENTAL|Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)|UC-MSCs plus standard of care (SOC).
62596290|NCT05224960|PLACEBO_COMPARATOR|Placebo|Placebo plus SOC.
62596291|NCT00387751|EXPERIMENTAL|Arm I|Patients receive oral sorafenib tosylate on days 1-5, 8-12, 15-19, and 22-26 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression.
62596292|NCT00992628|ACTIVE_COMPARATOR|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
62596293|NCT00992628|ACTIVE_COMPARATOR|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
62596294|NCT01639547|EXPERIMENTAL|PEGASYS® plus ROBATROL® for 36 weeks|
62596295|NCT01639547|ACTIVE_COMPARATOR|PEGASYS® plus ROBATROL® for 48 weeks|
62596296|NCT03451916|EXPERIMENTAL|PLX-PAD|• Arm 1 - PLX-PAD (120 subjects): 150×10\^6 PLX-PAD cells (10×10\^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte.
62428596|NCT04974359|PLACEBO_COMPARATOR|Placebo|Participants will receive an oral dose of placebo matching to Lu AG06466 once daily for 22 days in 1 of 2 treatment periods.
62428597|NCT01140620|EXPERIMENTAL|ketamine and risperidone|Oral risperidone pretreatment and intravenous ketamine infusion
62428598|NCT01140620|ACTIVE_COMPARATOR|ketamine and placebo|Oral placebo risperidone pretreatment and intravenous ketamine infusion
62596297|NCT03451916|PLACEBO_COMPARATOR|Placebo|Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO \[v/v\], 5% HSA \[w/v\], and PlasmaLyte, without cells).
62596298|NCT05633979|EXPERIMENTAL|Group 1|Participants will receive the same drugs at the same schedule, and the same dose of trastuzumab deruxtecan
62596299|NCT05633979|EXPERIMENTAL|Group 2|Participants will only receive 1 dose level of valemetostat.
62596300|NCT03004170|EXPERIMENTAL|Tele-Motivational Interviewing Plus Behavioral Skills Training|The Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training (teleMI+BST) intervention comprises 5 sessions lasting approximately 45-50 minutes each. Sessions occur in weeks 3, 4, 8, and 12 post-enrollment, with a follow-up booster session in week 24. The Information-Motivation-Behavioral Skills (IMB) Model (Fisher \& Fisher, 1992) provides the theoretical framework for behavior change mechanisms of teleMI+BST. The IMB posits that knowledge about condom use practices, condom use motivation, and acquisition and application of requisite condom use skills lead to engagement in condom-protected sex. The focus of this intervention is to help participants process ambivalence about engaging in condomless sex acts that risk HIV transmission.
62596301|NCT03004170|ACTIVE_COMPARATOR|Tele-Coping Effectiveness Training|The Telephone-Administered Coping Effectiveness Training (teleCET) intervention is the attention-equivalent comparator and also comprises 5 sessions lasting approximately 45-50 minutes each. The teleCET intervention is based on the Lazarus and Folkman Transactional Model of Stress and Coping (Lazarus \& Folkman, 1984) and uses cognitive-behavioral principles to: (a) appraise stressor severity, (b) develop problem- and emotion-focused coping skills, (c) determine the match between coping strategies and stressor controllability, and (d) optimize coping through use of social support resources.
62596302|NCT04197102|ACTIVE_COMPARATOR|CBD Isolate|300 mg/day of CBD isolate
62596303|NCT04197102|ACTIVE_COMPARATOR|CBD Broad Spectrum|300 mg/day of CBD Broad Spectrum Oil
62596304|NCT04197102|PLACEBO_COMPARATOR|Placebo oil|Matched Placebo Oil
62596305|NCT05674916|EXPERIMENTAL|Point-of-care ultrasound-driven diagnostic pathway|The intervention is focused lung and cardiac ultrasound performed as an extension to physical examinations plus diagnostic decision recommendations based on those test results (a point-of-care ultrasound-driven diagnostic pathway). Final decision on next-line imaging and further diagnostic testing should incorporate history and other physical examinations and will remain upon the treating physicians' discretion.
62596306|NCT05674916|NO_INTERVENTION|Standard diagnostic pathway|Standard diagnostic pathway will include, but not be limited to, blood samples, blood gases, electrocardiogram, and chest x-ray. Focused lung and cardiac ultrasound cannot be performed while the patients stay in the emergency department.
62814226|NCT03027310||Healthy Volunteers|adult healthy volunteers
62814227|NCT03027310||tremor patients|adult patients with tremor
62814228|NCT05858086|ACTIVE_COMPARATOR|Conventional Postoperative Physical Therapy Clearance|Patients will be evaluated and cleared by physical therapy after total joint replacement surgery prior to home discharge
62428599|NCT01140620|ACTIVE_COMPARATOR|saline and risperidone|Oral risperidone pretreatment and intravenous saline infusion
62428600|NCT01140620|PLACEBO_COMPARATOR|saline and placebo|Oral placebo risperidone pretreatment and intravenous saline infusion
62428601|NCT01140620|NO_INTERVENTION|Patients with Schizophrenia|Patients with schizophrenia will not receive study drug and will not undergo randomisation.
62428602|NCT06567587||Group I|35 Patients came to ICU with exaggerated COPD and suffer delirium and agitation
62428603|NCT06567587||Group II|35 psychotic patients on medical treatment came to ICU with exaggerated COPD and suffer delirium and agitation.
62428604|NCT02830230|EXPERIMENTAL|Intervention group/Case|"women with clinical cervicitis or cervicovaginitis as per NACO Guidelines will be enrolled in intervention group.~women with clinical cervicitis or cervicovaginitis as per NACO Guidelines will be enrolled in intervention group.A cervico-vaginal swab shall be taken for Lab diagnosis of RTIs along with HPVDNA test on day 1.Women shall be treated with Tab Azithromycin 1gm and Tab Cefixime 400mg stat along with barrier contraception advised.The women will be followed up after 7-14 days .A repeat cervicovaginal swab and HPVDNA shall be repeated."
62428605|NCT02830230|NO_INTERVENTION|Control group|Women without signs and symptoms of cervicitis or cervico-vaginitis.No intervention will be done in this group
62428606|NCT02594345|EXPERIMENTAL|Intervention group|
62238071|NCT02479334|EXPERIMENTAL|Carbohydrate challenge breakfast+spices|200 ml spices drink (non-energy flavored water + spices extract) and high carbohydrate breakfast (% Energy Carbohydrate:Fat:Prot / 60:20:20), acute study / one time administration
62428607|NCT00524576|EXPERIMENTAL|Engerix 2 Doses + Challenge Dose|Subjects received 2 doses of Engerix™-B (Month 0 and 6) in the primary study and a single dose of Engerix™-B during the booster study.
62036923|NCT05396248|EXPERIMENTAL|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for five weeks (10 training sessions).
62238072|NCT04600700||CDSS weaning group|This group will be exposed to the CDSS to inform inotrope weaning
62238073|NCT05532254|EXPERIMENTAL|Test Product (T)|subjects were administered a single tablet of 10 mg Aripiprazole with approximately 240 ml water after an overnight fast of 10 hours
62238074|NCT05532254|ACTIVE_COMPARATOR|Reference Product (R)|subjects were administered a single tablet of 10 mg Aripiprazole with approximately 240 ml water after an overnight fast of 10 hours
62238075|NCT03296891|ACTIVE_COMPARATOR|PoCUS Guided Resuscitation of Shock|Participants randomized to this arm of the study will undergo PoCUS guided resuscitation of shock.
62238076|NCT03296891|NO_INTERVENTION|Usual Care|Participants randomized to the 'usual care' arm of the study will be suggested to have the following guide resuscitation: 1) Pulse pressure variation (PPV), stroke volume variation (SVV) and/or systolic pressure variation (SPV) on their arterial line, 2) central venous pressure (CVP) and oxygen saturation(ScvO2) measurement, 3) Passive leg raise (PLR) maneuver, and/or 4) pulmonary artery catheter
62238077|NCT05428254|ACTIVE_COMPARATOR|Exercise and Manual therapy|"Group I will be treated with stretching exercises (EX), manual therapy (EX group) and serves as a control group.~Stretching of the neck extensor, upper fibers of trapezius, levator scapulae and scalenus muscles. stretching is applied for at least 15 seconds and repeated ten times in each session. Mobilization of the facet joint of the cervical vertebrae is performed after neck exercises."
62238078|NCT05428254|ACTIVE_COMPARATOR|Exercise and radiofrequency therapy|"Group II will be treated with capacitive and resistive radiofrequency therapy plus EX without manual therapy (CRRT+ EX group).~In addition to neck stretching exercises, they will receive 20 minutes of CRRT. Both the capacitive and resistive electrodes. CRRT is applied by the INDIBA radiofrequency therapy. INDIBA radiofrequency therapy has a long wavelength diathermy with frequency of 488 KHz range. The integration of two operational modes capacitive electrode (CAP) and (RES), makes it possible to combine sub-thermal (electric) and thermal effects. Indiba radiofrequency has output frequency: 448kHz ± 1 kHz with Maximum output power in RES mode: 100 W and in CAP mode: 350 VA. Capacitive electrodes will be applied for five minutes. Then the resistive electrodes will be applied for 10 minutes and finally the capacitive will be applied again for another five minutes."
62428608|NCT00524576|EXPERIMENTAL|Engerix 3 Doses + Challenge Dose|Subjects received 3 doses of Engerix™-B (Month 0, 1 and 6) in the primary study and a single dose of Engerix™-B during the booster study.
62428609|NCT03764553|EXPERIMENTAL|Liposomal irinotecan, leucovorin and 5FU|"IV Nal-IRI 80 mg/m² (expressed as irinotecan hydrochloride (HCl) salt), folinic acid 400 mg/m², fluorouracil 2400 mg/m² over 46 h, every 2 weeks.~No addition of nivolumab is possible for this arm"
62428610|NCT03764553|EXPERIMENTAL|Carboplatin and capecitabine|"IV and PO Capecitabine 1000 mg/m2 and carboplatin area under the curve (AUC5), every three weeks.~In case of PD-L1 CPS ≥5 only: nivolumab, dose according to local standard, iv day 1"
62814229|NCT05858086|EXPERIMENTAL|Preoperative Physical Therapy, Postoperative Ambulation with Nursing|Patients will receive gait/stair training from physical therapy prior to total joint arthroplasty, then ambulate with nursing postoperatively prior to home discharge
62036924|NCT05396248|PLACEBO_COMPARATOR|Placebo Control Group|The placebo control group will receive placebo memory exercises administered on a laptop computer twice a week for five weeks (10 placebo control sessions).
62036925|NCT03755830|ACTIVE_COMPARATOR|vitiligo patients|Two skin biopsies (lesional and non-lesional) will be taken from every patient.
62428611|NCT03764553|EXPERIMENTAL|oxaliplatin and capecitabine|"IV and PO Capecitabine 1000 mg/m2 and oxaliplatin 130 mg/m2, every three weeks.~In case of PD-L1 CPS ≥5 only: nivolumab, dose according to local standard, iv day 1"
62433666|NCT06541392|EXPERIMENTAL|Breakfast2|This group will have breakfast time from 7.31 am to 8.31 am
62814230|NCT05842031||Semi-structured interviews|Participants with penile cancer who have undergone invasive inguinal lymph node procedure will be recruited to participate in study via telephone recruitment.
62036926|NCT03755830|EXPERIMENTAL|healthy controls|A skin biopsy will be taken from each control subject.
62433667|NCT06541392|NO_INTERVENTION|Control|This group will have breakfast time according to their wishes.
62814231|NCT03304678|OTHER|Treatment with sirolimus|Lymphangioleiomyomatosis (LAM) is a cystic lung disease characterized by proliferation of cells with mutations in the tuberous sclerosis complex (TSC) which leads to activation of the mTORC pathway.
62814232|NCT05108246|EXPERIMENTAL|Dual-Task Training|Dual-Task Exercise
62814233|NCT05108246|NO_INTERVENTION|Control|No Exercise
62814234|NCT02035761||MSA Case|The screening evaluation will take less than 1 to 2 hours, and is usually conducted over the telephone. The visit for testing will take approximately 3 days, consisting (usually) of a day for clinical examinations and questionnaires and one day each for PET and MRI brain imaging and the third day for PET imaging of the heart and autonomic testing. If some checklists and questionnaires could not be completed conveniently in the time available, they may be finished over the telephone on a later day. At the completion of the 3-day evaluation, subjects are asked to return home and keep a log of their MSA symptoms and medication responses for 2 days. This will complete the active participation of MSA subjects in all aspects of the entire research program. The average time the subjects will be followed could be up to 1 week during which time the subjects are undergoing research related procedures.
62814235|NCT05020028|EXPERIMENTAL|CBD Group|The first cohort will take two 25mg cannabidiol (total dose: 50mg) Orally Disintegrating Tablets (CBD ODT) three times daily for a maximum dose of 150mg per day.
62814236|NCT05020028|PLACEBO_COMPARATOR|Placebo Group|Cohort 2 will receive the same instructions, but with the placebo Orally Disintegrating Tablets (ODT) instead.
62238079|NCT05428254|ACTIVE_COMPARATOR|Exercise, Manual and Radiofrequency therapy|Patients in this group will receive the same program of exercises as in group one. in addition, patients will receive the CRRT as in group two and the mobilization of the facet joints of the cervical vertebrae is applied while applied the CRRT by a trained physiotherapist. The same protocol of mobilization is applied for group one and three.
62238080|NCT00004239|EXPERIMENTAL|Compound 506U78|Compound 506U78 will be administered intravenously over 2 hours on days 1, 3 and 5 of each 28 day treatment cycle.
62238081|NCT00308269|EXPERIMENTAL|Vintafolide 1.2 mg IV Bolus|Vintafolide 1.2 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
62238082|NCT00308269|EXPERIMENTAL|Vintafolide 2.5 mg IV Bolus|Vintafolide 2.5 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
62238083|NCT00308269|EXPERIMENTAL|Vintafolide 4.0 mg IV Bolus|Vintafolide 4.0 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
62238084|NCT00308269|EXPERIMENTAL|Vintafolide 2.5 mg IV Infusion|Vintafolide 2.5 mg administered by a 1-hour IV infusion on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
62238085|NCT00308269|EXPERIMENTAL|Vintafolide 3.0 mg IV Infusion|Vintafolide 3.0 mg administered by a 1-hour IV infusion on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
62238086|NCT02196363||Pregnant mothers|No intervention
62238087|NCT02918604|OTHER|B : veinsite access|infrared technology vein access
62238088|NCT02918604|ACTIVE_COMPARATOR|A: control group|conventional vein access
62428612|NCT05180344|EXPERIMENTAL|Mobile Application to Prevent Suicide (MAPS)|"Participants receiving MAPS will receive the Safety Planning Intervention (SPI) which will be uploaded into the smartphone app. They will be prompted four times per day to complete a brief ecological momentary assessment check-in inquiring about their cognitions, affect, and behavior, including suicidal thoughts and behaviors. Based on these responses, they will be provided with coping strategies from their safety plans and from a database of coping strategies created by study staff. They will also have access to emergency phone numbers, the coping strategies database, and can communicate with their study clinician through a text-like interface in the app. They will receive this intervention for one month."
62428613|NCT02424656||1|"Patients with TBI and DOC.~Experimental measures (MRI, TMS-EEG, and clinical scales) will be performed at 4 time points: within 2 weeks of admission, 6-10 weeks after admission, at discharge, 1-year follow-up after TBI episode. FDG-PET will be performed in a subset of 25 patients at 3 time points: at admission, at discharge, and at 1-year follow-up."
62428614|NCT02424656||2|"Healthy patient-matched controls.~Experimental measures (MRI, TMS-EEG, and FDG-PET) will be performed at 2 time points: within patient admission, and within patient discharge."
62238089|NCT02725957|EXPERIMENTAL|Trehalose 9%|Single dose administration of Trehalose 9% for IV infusion.
62428615|NCT04931147|EXPERIMENTAL|Part A SAD - Cohort 1|This is the first treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive 2 mg of RXC007 on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
62428616|NCT04931147|EXPERIMENTAL|Part A SAD - Cohort 2|This is the second treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Cohort 1 Dose Escalation Data Review) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
62428617|NCT04931147|EXPERIMENTAL|Part A SAD - Cohort 3|This is the third treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
62428618|NCT04931147|EXPERIMENTAL|Part A SAD - Cohort 4|This is the fourth treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
62428619|NCT04931147|EXPERIMENTAL|Part A SAD - Cohort 5|This is the fifth treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
62428620|NCT04931147|EXPERIMENTAL|Part A SAD - Cohort 6|This is the sixth treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
62814237|NCT05757505|EXPERIMENTAL|experimental group|Intracranial Stent (Tonbridge)
62814238|NCT05757505|ACTIVE_COMPARATOR|control group|Wingspan Stent System (Stryker Neurovascular)
62238090|NCT02725957|PLACEBO_COMPARATOR|Saline 0.9%|Single dose administration of 0.9% saline in the same volume and duration as Treatment Arm 1 (9% trehalose)
62238091|NCT04538612|EXPERIMENTAL|measure capillary refill time|
62238092|NCT01106027|EXPERIMENTAL|Eculizumab|"Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery. Patients will be given 900 mg of eculizumab on Day 1 post-transplant. Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant.~At week 4, patients will be assessed for donor specific anti-donor human leukocyte antigen (HLA) antibody (DSA). Patients with total DSA normalized values \<5000 will stop eculizumab treatment. Patients with total DSA normalized values \>5000 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly."
62596307|NCT03484936|ACTIVE_COMPARATOR|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to 2014 chinese guideline for the diagnosis and treatment of intracerebral hemorrhage.
62596308|NCT03484936|PLACEBO_COMPARATOR|Sham RIC+Standard medical treatment|Sham remote ischemic conditioning (Sham RIC) is simulated by the measurement of blood pressure twice daily for 7 days.Additionally,the patients will be treated with standard medical treatment according to 2014 chinese guideline for the diagnosis and treatment of intracerebral hemorrhage.
62428621|NCT04931147|EXPERIMENTAL|Part A SAD - Optional Cohort 7|This is an optional seventh treatment arm in Part A (Single Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
62596309|NCT05260385|EXPERIMENTAL|QD regimen|KC1036 was administered orally in 60 mg once daily, 21 days as a cycle.
62596310|NCT05260385|EXPERIMENTAL|BID regimen|"Dose-Escalation part : KC1036 was administered orally in 20 mg BID, 30 mg BID, or 40 mg BID.~Dose-Expansion part : According to the results of Dose-Escalation, an appropriate BID regimen was selected for Dose-Expansion ."
62428622|NCT04931147|EXPERIMENTAL|Part A SAD - Optional Cohort 8|This is an optional eighth treatment arm in Part A (Single Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
62428623|NCT04931147|EXPERIMENTAL|Part B MAD - Cohort 1|This is the first treatment arm in Part B (Multiple Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of SAD cohort data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
62428624|NCT04931147|EXPERIMENTAL|Part B MAD - Cohort 2|This is the second treatment arm in Part B (Multiple Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of SAD and previous MAD cohort data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
62428625|NCT04931147|EXPERIMENTAL|Part B MAD - Optional Cohort 3|This is an optional third treatment arm in Part B (Multiple Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
62596311|NCT03275259|EXPERIMENTAL|Extracorporeal shock waves|Composed of 30 female patients with glandular lipodystrophy in the buttocks and posterior thigh and fat located in abdomen and flanks that received the treatment of extracorporeal shock waves with energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
62596312|NCT06540664|EXPERIMENTAL|Auricular Acupuncture|Participants received Auricular Acupuncture every 5 days for 2 weeks combined with sleep hygiene, then stopped acupuncture and monitored for effectiveness after 4 weeks.
62596313|NCT06540664|SHAM_COMPARATOR|Sham Auricular Acupuncture|Participants received sham Auricular Acupuncture every 5 days for 2 weeks combined with sleep hygiene, then stopped acupuncture and monitored for effectiveness after 4 weeks.
62814239|NCT04207034|EXPERIMENTAL|flap surgery and diode laser|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1: 80,000 epinephrine) , Laser application will be carried out , with the help of 810 nm (A.R.C LASER FoxTM) diode laser with a flexible optic tip of 300µm . The sulci will be lased with a repeated beam ( 0.2 sec on 0.3 sec off) at an output power of 1.0 W.~Intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure."
62238093|NCT06261086|ACTIVE_COMPARATOR|patient with vitiligo group|"Patients with vitiligo ≥ 18 years old, both male and female patients will be included.~Exclusion criteria:~Patients with the following criteria will be excluded from our study:~1. Pregnancy and breast-feeding women.~2. patients on antioxidants or anti-inflammatory drugs~3. Patients on topical/systemic treatment for vitiligo in the last 4weeks prior to enrollment in the study~4. Patients with other dermatological diseases as psoriasis, lichen planus, viral infection, etc.~5. Patients suffering from chronic medical illness such as; diabetes mellitus, thyroid disease, and cancer."
62238094|NCT06261086|ACTIVE_COMPARATOR|control group|"control criteria with the following criteria will be excluded from our study:~1- Pregnancy and breast-feeding women."
62238095|NCT01280461||Experimental Group|
62238096|NCT01280461||Control Group|
62428626|NCT04931147|EXPERIMENTAL|Part B MAD - Optional Cohort 4|This is an optional fourth treatment arm in Part B (Multiple Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
62428627|NCT04931147|EXPERIMENTAL|Part A SAD - Optional Cohort 9|This is an optional ninth treatment arm in Part A (Single Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
62433668|NCT01947556|OTHER|insujet is tested first|first procedure: experiment with the investigational product (Insujet pen)containing insulin aspart; second procedure: control device (conventional Novopen III insulin pen) contains insulin aspart.
62238097|NCT03321734|EXPERIMENTAL|Extended Caffeine Treatment|Infants in the extended caffeine treatment arm will, beginning the next day after stopping routine caffeine treatment, receive 5 mg/kg/day of caffeine base and increase to 5 mg/kg/twice-a-day (BID) of caffeine base beginning at 36 weeks + 0 days PMA and continuing the BID doses through 42 weeks + 6 days PMA.
62238098|NCT03321734|PLACEBO_COMPARATOR|Placebo|Infants in the placebo arm will, beginning the next day after stopping routine caffeine treatment, receive the equivalent (to study drug) volume of placebo daily and increase to the equivalent (to study drug) volume placebo BID through 42 weeks + 6 days PMA.
62238099|NCT04008355|EXPERIMENTAL|60mg/day/84 days|Patients randomized in this arm will receive 60 mg of study investigational drug AZP2006 once daily during 84 days.
62036927|NCT05245344||Patients with RRMS (untreated)|"* Relapsing-remitting MS, as diagnosed by the revised 2010 McDonald Criteria;~* EDSS score ≤ 5.5;~* Age between 18 and 55 years (exclusive);~* no disease modifying therapies for at least 3 months or treatment naïve;~* no corticosteroid administration in the previous month;~* disease duration \<10 years;~* Ability to provide written informed consent."
62238100|NCT04008355|EXPERIMENTAL|80mg/day/10 days followed by 50mg/day/74 days|Patients randomized in this arm will receive 80 mg of study investigational drug AZP2006 once daily during 10 days followed by 50 mg of study investigational drug AZP2006 once daily during the next 74 days.
62238101|NCT04008355|PLACEBO_COMPARATOR|Placebo/84 days|Patients randomized in this arm will receive placebo solution once daily during 84 days.
62238102|NCT06125249||Patients with AKI after heart transplantation|AKI occurs in patients after heart transplantation
62428628|NCT04931147|EXPERIMENTAL|Part A SAD - Optional Cohort 10|This is an optional tenth treatment arm in Part A (Single Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
62428629|NCT04931147|EXPERIMENTAL|Part B MAD - Optional Cohort 5|This is an optional fifth treatment arm in Part B (Multiple Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
62433669|NCT01947556|OTHER|insujet is tested second|first procedure: experiment with the conventional Novopen III insulin pen containing insulin aspart; second procedure: investigational device (Insujet) contains insulin aspart.
62814240|NCT04207034|ACTIVE_COMPARATOR|flap surgery|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1:80,000 epinephrine) ,intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure"
62814241|NCT04526106|EXPERIMENTAL|Part 1: Dose Escalation|Multiple doses of RLY-4008 for oral administration.
62814242|NCT04526106|EXPERIMENTAL|Part 2: Dose Expansion|Oral dose of RLY-4008 as determined during Part 1 Dose Escalation.
62814243|NCT04526106|EXPERIMENTAL|Part 3: Extension|Oral dose of RLY-4008 as determined during Part 1 Dose Escalation.
62036928|NCT05245344||Patients with Neuromyelitis Optica Spectrum Disorders (NMOSD)|"Main inclusion criteria of NMOSD patients (Wingerchuk et al., 2015):~* Positive test for Aquaporin 4 IgG;~* Age between 18 and 55 years (exclusive);~* no immunosuppressive therapies for at least 3 months or treatment naïve.~* no corticosteroid administration in the previous month~* disease duration \<10 years~* Ability to provide written informed consent"
62036929|NCT05245344||Healthy subjects (HD)|"* Age between 18 and 55 years (exclusive), matched by gender, age and ethnicity towards the MS groups.~* Ability to provide written informed consent."
62036930|NCT00689546||I/A|All cases of acute viral hepatitis irrespective of type (A, B, E) with underlying Type 2 diabetes mellitus
62036931|NCT00689546||I/B|Age and sex matched non- diabetic patients with acute viral hepatitis (irrespective of type) recruited from all the patients of acute viral hepatitis registered during the time period in which cases were recruited.
62238103|NCT06125249||Patients did not develop AKI after heart transplantation|Patients who do not develop AKI after heart transplantation
62238104|NCT01717989||Cohort|Patients with end-stage renal disease (ESRD) treated at small dialysis organizations (SDOs).
62814244|NCT04526106|EXPERIMENTAL|Part 4: Rollover|Oral dose of RLY-4008 as determined during Part 1 Dose Escalation.
62814245|NCT06103396|EXPERIMENTAL|Autologuos MSCs transplantation in nonunion defects|Autologuos MSCs harvested and cultured in osteogenic medium are seeded on collagen scaffold, and mixed with autologous rich plasma clot. The MSCs construct (MSCs/Col/PRP clot), is implanted in the nonunion defect.
62814246|NCT06103396|EXPERIMENTAL|Allogeneic MSCs transplantation in nonunion defects|Allogeneic MSCs harvested and cultured in osteogenic medium are seeded on collagen scaffold, and mixed with autologous rich plasma clot. The MSCs construct (MSCs/Col/PRP clot), is implanted in the nonunion defect.
62238105|NCT02885805|EXPERIMENTAL|SPF evaluation + Control|Fair-skinned subjects in good health with Skin Types I, II or III.
62238106|NCT02674191|EXPERIMENTAL|Group 1|Device: mini-plates supported molar intrusion (Stryker, Leibinger, GmbH\& Co., Freiburg, Germany) for molar intrusion using miniplates to treat hyperdivergent adolescence Procedure/Surgery: Application of ULTRACARE benzocaine 20%, topical anesthesia (Ultradent Products, Inc) Procedure/Surgery: Administration of , Mepivacaine-l local anesthesia Procedure/Surgery: BETADINE povidone-iodine 10% a local disinfectant Drug: (150g Clindamycin/tds) for 1 week Postoperative antibiotic Drug: (Cataflam 25mg), are prescribed post-operatively an analgesic
62238107|NCT02674191|NO_INTERVENTION|Group 2|hyperdivergent adolescence with no intervention
62814247|NCT02371044||Rivaroxaban|N=20
62238108|NCT04142450|EXPERIMENTAL|CoolSculpting® System|Participants underwent a single CoolSculpting® treatment session on Day 1 that was comprised of timed segments of cooling followed by 2 minutes of manual massage. Each treated arm had up to two timed segments (or cycles) in the treatment session, each treated thigh had one timed segment (or cycle) in the treatment session.
62238109|NCT04774991|ACTIVE_COMPARATOR|Azithro 1-59 fixed point|Azithromycin distribution to children 1-59 months of age using a fixed-point delivery approach via existing community health workers
62814248|NCT02371044||Apixaban|N=20
62814249|NCT02371044||Dabigatran|N=20
62814250|NCT04478201|EXPERIMENTAL|Back lying sleep position|sleep on the back
62036932|NCT00689546||II/A|All diabetic who have acute icteric viral hepatitis due to HEV infection
62036933|NCT00689546||II/B|Age and sex matched diabetic who have acute icteric viral hepatitis due to hepatiits virus other than HEV.
62036934|NCT06003803|EXPERIMENTAL|digital learning in motivational interviewing|Receive digital learning in motivational interviewing for three months, once a week, 40 minutes each time
62036935|NCT06003803|NO_INTERVENTION|conventional education|Receive conventional education for three months.
62036936|NCT01352338|EXPERIMENTAL|lenalidomide, endoxan, prednisone|"lenalidomide 25mg, oral therapy, once a day, 4 weeks cycles. Lenalidomide is used 3 of the 4 weeks.~Lenalidomide is combined with endoxan and prednisone"
62036937|NCT04756687||All Participants|RRMS participants treated with DMF will be identified in the Observatoire Français de la Sclérose en Plaques (OFSEP) database for OFSEP sites.
62036938|NCT05283694|EXPERIMENTAL|Risankizumab Dose A|Participants will receive 3 Subcutaneous (SC) injections of risankizumab Dose A administered via prepared syringe at Day 1 and followed for 140 days.
62036939|NCT05283694|EXPERIMENTAL|Risankizumab Dose B|Participants will receive 1 SC injection of risankizumab Dose B administered via syringe pump at Day 1 and followed for 140 days.
62036940|NCT05283694|EXPERIMENTAL|Risankizumab Dose C|Participants will receive 1 SC injection of risankizumab Dose C administered via syringe pump at Day 1 and followed for 140 days.
62238110|NCT04774991|ACTIVE_COMPARATOR|Azithro 1-59 door-to-door|Azithromycin distribution to children 1-59 months of age using a door-to-door delivery approach via existing community health workers
62238111|NCT02779725|ACTIVE_COMPARATOR|Group 1 SCC/SSR|This arm includes self-care coaching (SCC) message during daily self-reported symptom severity report (SSR) calls to the automated system.
62428630|NCT04931147|EXPERIMENTAL|Part B MAD - Optional Cohort 6|This is an optional sixth treatment arm in Part B (Multiple Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
62428631|NCT04931147|EXPERIMENTAL|Part C DDI - Cohort 1 Rosuvastatin|This is the first treatment arm in Part C (Drug-Drug Interaction) of the study. All participants within the cohort (12 participants) will to receive a selected dose of RXC007 (following Dose Escalation Data Review from Part A and Part B) and 10 mg rosuvastatin as follows: single dose of rosuvastatin (10 milligrams) on Day 1 followed by three single doses of RXC007 on Day 6, Day 7 \& Day 8 before taking a single dose of both RXC007 and rosuvastatin together on Day 9.
62596314|NCT01512069|EXPERIMENTAL|Web-based, Stage-matched Exercise and Diet Planning program|The experimental arm is a group that assigned to use web-based, stage-matched exercise and diet planning program.
62433670|NCT05642611|EXPERIMENTAL|Arm 1 (Cryocompression)|Patients undergo cryocompression (cooling plus moderate and low pressure to the arms and legs) for 30-minutes pre-taxane chemotherapy infusion, during taxane chemotherapy infusion, and for 30 minutes after completion of each taxane infusion. Patients may also undergo collection of blood, serum and plasma samples during screening and on study.
62596315|NCT01512069|ACTIVE_COMPARATOR|Non-tailored booklet on exercise and diet|The control group is provided a booklet containing same information on exercise and diet as in the experimental group's web-based program, but the information on a booklet is not tailored to participants' stage of motivational readiness for exercise and diet based on the TTM.
62596316|NCT05247099||children with systemic diseases|Systemic diseases such as Nephritic syndrome, and other systemic diseases that can affect the eyes.
62814251|NCT04478201|EXPERIMENTAL|Side lying sleep position|sleep on the side
62814252|NCT05642351||Alzheimer's Disease|recruited according to criteria by National Institute on Aging (McKhann et al., 2011).
62036941|NCT05283694|EXPERIMENTAL|Risankizumab Dose D|Participants will receive 1 SC injection of risankizumab Dose D administered via prepared syringe at Day 1 and followed for 140 days.
62036942|NCT04299672|EXPERIMENTAL|Postural reconstruction|"Maximum external rotation of the hip in lower limb elevation and the dorsal flexion of the ankle with flexion of the toes, performed in both lower limbs alternately and independent.~Participant must control breathing. The detail phases of a general intervention are:~1. PASSIVE displacement of the segment until reaching CRITICAL AMPLITUDE, which corresponds to the light myofascial stress or to the appearance of evoked responses.~2. ACTIVE MAINTENANCE of the critical amplitude.~3. WORK BREATHING.~4. INDUCTIVE ACTIVE APPLICATIONS with movements of great relative amplitude.~5. FINISHING CRITERIA: reduction or extinction of evoked responses, patient fatigue or execution of the technique for 15 minutes without any of the above premises having been reached."
62238112|NCT02779725|ACTIVE_COMPARATOR|Group 2 NP/SSR|Alert reports are generated during the patient's daily symptom severity monitoring call if alert thresholds are reached. These alerts are monitored and follow-up care is given by a nurse practitioner.
62238113|NCT02779725|ACTIVE_COMPARATOR|Group 3 NP/DSS/SSR|Alert reports are generated during the patient's daily symptom severity monitoring call if alert thresholds are reached. Nurse practitioner follow-up calls utilize the evidenced based SCH decision support system (DSS) when symptoms exceed alert thresholds
62036943|NCT01053182|ACTIVE_COMPARATOR|Ivor-Lewis|Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach
62596317|NCT05247099||healthy children|"The exclusion criteria for the subjects were eye diseases or other systemic diseases that can affect the quality or volume of tears or the secretion of tears. These included~1. eyelid diseases: eyelid entropion, eyelid ectropion, ptosis, and palpebral dyskinesia;~2. conjunctival diseases: pterygium and conjunctivitis;~3. history of ocular surface chemical injury;~4. history of eye surgery within 6 months or history of retinal laser photocoagulation;~5. systemic diseases: Sjogren syndrome, Parkinson's disease, rheumatoid arthritis, Grave's disease, systemic lupus erythematosus, and others."
62596318|NCT03142152|EXPERIMENTAL|Intervention Group|Carillon Mitral Contour System and Guideline Directed Heart Failure Medication
62238114|NCT02779725|ACTIVE_COMPARATOR|Group 4 Full Intervention SSR/SCC/NP/DSS|Complete intervention with all components used in prior efficacy study (Symptom Severity Report (SSR)+Self Care Coaching (SCC) +Nurse Practitioner (NP) +Decision Support System (DSS))
62238115|NCT02779725|ACTIVE_COMPARATOR|Group 5 SSR/SCC/AT|Symptom severity reporting (SSR), automated self-care coaching (SCC) based on daily symptom reporting plus activity tracker (AT)
62596319|NCT03142152|ACTIVE_COMPARATOR|Control Group|Guideline Directed Heart Failure Medication
62596320|NCT04831697|EXPERIMENTAL|Multi-Caregiving Intervention|The multi-caregiving intervention consists of individual-based, social support, and health-educator facilitation and includes: a. Storytelling/sharing of experiences (5 minutes); social support and problem solving (15 minutes); Coping strategies (15minutes); and Structured Diabetes Education and Skills Training (15 minutes). The final 5min will be used for debriefing/reviewing goals.
62596321|NCT04831697|ACTIVE_COMPARATOR|Diabetes Enhanced Usual Care Intervention|This is composed of individual-based, health educator-facilitated diabetes education and skills training and general health education and will receive structured diabetes education and skills training as described above (30 minutes) and an additional discussion on general health topics (i.e., back pain, dyspepsia, etc.) (30 minutes).
62814253|NCT05642351||Behavioral variant of frontotemporal dementia|recruited following criteria by Rascovsky et al. (2011)
62596322|NCT06623461|ACTIVE_COMPARATOR|Standard-of-care ICB|Assigned single agent or combination ICB treatment
62596323|NCT06623461|EXPERIMENTAL|LND101 for FMT + Standard-of-care ICB|Bowel preparation; LND101(single-dose); Assigned single agent or combination ICB treatment.
62814254|NCT03017963|EXPERIMENTAL|dose-escalation cohort|Patients are divided in 6 groups of 3 patients to receive the following intervention: 0 gram (g), 2.5 g, 5 g, 10 g, 12.5 g and 15 g of sodium thiosulfate pentahydrate (STS) intravenous. The first dose is given in 15 min immediately after inclusion at the cath-lab. In the absence of dose-limiting toxicity (DLT), a second gift of STS is given in 30 min, 6 hours later at the coronary care unit (CCU). When no DLT is observed in any of the patients after 2 gifts of the same dose an extra 3 subjects are enrolled into the next higher dose cohort. If 1 out of 3 patient develops DLT at a specific dose, an extra 3 subjects are enrolled into the same dose cohort. When more than 1 out of 6 patients develop DLT the trial will be terminated because the maximum tolerable dose (MTD) has been exceeded.
62814255|NCT06049641||13 to 15 Year-Old|"* Normotensive (Normal BP): SBP and/or DBP values below the 90th percentile for teens of the same age and sex.~* Prehypertensive (High-normal BP): SBP and/or DBP values at or above the 90th percentile and/or below the 95th percentile for for teens of the same age and sex.~* Hypertensive: SBP and/or DBP values at or above the 95th percentile for teens of the same age and sex."
62036944|NCT01053182|ACTIVE_COMPARATOR|Sweet|Esophagectomy via Left Side Thoracotomy
62036945|NCT02686268||Individuals diagnosed with known positive C9ORF72 ALS|Individuals diagnosed with known positive C9ORF72 ALS
62036946|NCT06189976|OTHER|Rapid atrial pacing|Diagnostic test group (single group)
62036947|NCT06123286|NO_INTERVENTION|Group 1 : Wait list control|No supplement but will be offered supplements after finishing the study
62036948|NCT06123286|EXPERIMENTAL|Group 2 : Tart Cherry and Omega 3 FA (Fish Oil)|
62036949|NCT06410157|EXPERIMENTAL|Increase Oscillation|"Participants will breath at a slow resonance frequency during a breath-focused mindfulness practice and receive biofeedback to increase heart rate oscillation."
62036950|NCT06410157|EXPERIMENTAL|Decrease Oscillation|Participants' breathing will not be fixed to particular frequency during a breath-focused mindfulness practice and they will receive biofeedback to decrease heart rate oscillation.
62036951|NCT03343236||Patients with head and neck cancer|All patients with newly diagnosed and untreated head and neck cancer. Exclusion criteria: previous treatment for malignant disorder except for skin cancer, severe alcohol abuse, psychiatric disorder, inability to understand Swedish
62428632|NCT04931147|EXPERIMENTAL|Part C DDI - Cohort 2 Metformin|This is the second treatment arm in Part C (Drug-Drug Interaction) of the study. All participants within the cohort (12 participants) will to receive a selected dose of RXC007 (following Dose Escalation Data Review from Part A and Part B) and 500 mg metformin as follows: single dose of metformin (500 milligrams) on Day 1 followed by three single doses of RXC007 on Day 4, Day 5 \& Day 6 before taking a single dose of both RXC007 and metformin together on Day 7.
62596324|NCT03819322|EXPERIMENTAL|HCV seropositive non-viremic (HCV Ab+/NAT-) donor|"Liver recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.~Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg)."
62428633|NCT03125629|EXPERIMENTAL|18F-FDG PET/CT Scan|Participants will undergo a PET/CT scan with radiolabel 18F-FDG.
62428634|NCT03125629|EXPERIMENTAL|18F-FDG PET/MRI Scan|Participants will undergo a PET/MRI scan with radiolabel 18F-FDG.
62428635|NCT03125629|EXPERIMENTAL|68Ga-DOTA-TATE PET/CT Scan|Participants will undergo a PET/CT scan with radiolabel 68Ga-DOTA-TATE.
62596325|NCT03819322|EXPERIMENTAL|HCV seropositive viremic (HCV Ab+/NAT+) donor|Post-operative day 1, liver recipients will be treated with 12-week oral course of sofosbuvir/ velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
62596326|NCT02866149|OTHER|"Cohort 1 - Anti checkpoint"|"Monitoring of patients with tumours treated by immune therapy.~Timing of blood sampling:~* inclusion~* after #8 weeks on therapy~* at progression or 6 months from inclusion for patient without progressive disease~* if toxicity grade 3 or 4, or grade 2 until 1 month."
62814256|NCT06049641||16 to 19 Year-Old|"* Normotensive (Normal BP): SBP \<130 mmHg and/or DBP \<85 mm Hg.~* Prehypertensive (High-normal BP): SBP 130 to 139 mmHg and/or DBP 85 to 89 mm Hg.~* Hypertensive: SBP ≥140 mm Hg and/or DBP ≥90 mmHg."
62814257|NCT06243198|EXPERIMENTAL|Lebrikizumab|
62428636|NCT03125629|EXPERIMENTAL|68Ga-DOTA-TATE PET/MRI Scan|Participants will undergo a PET/MRI scan with radiolabel 68Ga-DOTA-TATE.
62428637|NCT04397250|EXPERIMENTAL|High-intensity interval training|Participants will be asked to perform four 30 minutes bouts of high-intensity interval exercise per week.
62428638|NCT04397250|NO_INTERVENTION|Control|Participants will be asked to continue their habitual lifestyle
62428639|NCT04821492||Hyperhomocysteinemia|
62814258|NCT06243198|PLACEBO_COMPARATOR|Placebo|
62036952|NCT05898867||Responders|"Participants from the trial Reinforcement of Treatment Response in Knee Osteoarthritis: A Randomised Trial will be defined as responders if they belong to the upper quartile of the change to the pain Visual Analogue Scale (VAS) (those who had the greatest positive changes)"
62036953|NCT05898867||Non-responders|"Participants from the trial Reinforcement of Treatment Response in Knee Osteoarthritis: A Randomised Trial will be defined as non-responders if they belong to the lower quartile of the change to the pain Visual Analogue Scale (VAS) (those who had the smallest change)."
62036954|NCT05938647||Dengue hemorrhagic fever group 3|Risk factor (severity 3): no diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes.
62036955|NCT05938647||DHF group 4 (DSS);|Risk factor (group 4): no diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes.
62428640|NCT04821492||Normal Hcy levels|
62596327|NCT02866149|OTHER|"Cohort 2 - Oncoscan®"|"Monitoring of patients with HER 2+/- breast cancer and correlation with genome-wide copy number, loss of heterozygosity detection, as well as identification of frequently tested somatic mutations (Oncoscan® assays).~Timing of blood sampling:~* inclusion~* after 1 cycle of therapy (weeks 3-4)~* up to 2 other samples, timepoints decided by the investigator"
62814259|NCT00786669|EXPERIMENTAL|Bevacizumab+TEM/VCR/IRN/CEF|"Bevacizumab(IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles~Temozolomide (TEM) 100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.~Vincristine (VCR) 1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients \<0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).~Irinotecan (IRN) 90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles~Cefexime (CEF) 8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity"
62814260|NCT01457651|ACTIVE_COMPARATOR|Recruitment 40x40|The group where recruitment is performed by increase in airway pressure up to 40 cm H2O for 40 seconds
62814261|NCT01457651|ACTIVE_COMPARATOR|Recruitment PEAK40|Increase in peak airway pressure up to 40 cm H2O during tidal ventilation
62814262|NCT01457651|ACTIVE_COMPARATOR|Recruitment 15x300|Recruitment by increase in airway PEEP up to 15 cm H2O for 300 sec
62814263|NCT01457651|ACTIVE_COMPARATOR|No recruitment|No recruitment is performed: standard respiratory support.
62814264|NCT05559450|EXPERIMENTAL|Blinatumomab arm|On the 1st to 3rd day, Blinatumomab should be continuous intravenous use for 24 hours with 9ug/ day for those whose weight are equal to or greater than 45kg, and 5ug/ m2 / day for those whose weight are less than 45kg (maximum dosage is 9ug/ day) per 24 hours. On the 4th to 14th day, for the patients who are equal to or greater than 45kg, they will receive Blinatumomab at the dose of 28ug/ day with continuous intravenous administration, and those below 45kg are given a 24h continuous infusion of 15ug/ m2 / day (maximum dose is 28ug/ day). Bucy-based myeloablative conditioning regimen will be performed on the 15th day.
62814265|NCT05559450|OTHER|Conventional therapy|Bucy-based myeloablative conditioning regimen will be given to those patients are enrolled into control group.
62814266|NCT02675946|EXPERIMENTAL|Arm 1: CGX1321 Single Agent dose escalation and dose expansion|"Arm 1: Dose Escalation Phase: Ascending doses of CGX1321 once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle~Dose Expansion Phase: CGX1321, at the MTD (identified in the Dose Escalation Phase), once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle."
62428641|NCT00120068|OTHER|Arm 1|
62428642|NCT02068404|OTHER|Nifedipine|
62428643|NCT06272370|OTHER|Enhanced Usual Care|"Participants will be asked to use an online Asthma Symptom Monitoring tool to enhance communication with the medical team as well as self-awareness of their asthma symptoms. There are no study drugs in this arm. All 4 arms of the study will use these tools"
62428644|NCT06272370|ACTIVE_COMPARATOR|Rescue Inhaled Corticosteroids|Participants in this arm will either have budesonide/formoterol (Symbicort) or mometasone/formoterol (Dulera), or a stand-alone ICS (beclomethasone/QVAR, or budesonide/Pulmicort, or fluticasone Flovent HFA, Flovent Diskus, ArmonAir RespiClick, Arnuity Ellipta, or mometasone, Asmanex HFA, Asmanex Twisthaler or ciclesodine Alvesco HFA) added to the participants usual treatment or a combination inhaler of corticosteroid and albuterol (AirSupra) that was recently approved
62428645|NCT06272370|ACTIVE_COMPARATOR|Azithromycin|Participants will use azithromycin (Zithromax) 500mg three times a week (10mg.kg for participants under 50Kg) which can be dropped to 250 mg three times a week for dose related side effects
62428646|NCT06272370|ACTIVE_COMPARATOR|Rescue Inhaled Corticosteroids and azithromycin|This arm includes both the inhaled corticosteroid comparator and the azithromycin comparator as described in those two arms Participants in this arm will either have budesonide/formoterol (Symbicort) or mometasone/formoterol (Dulera), or a stand-alone ICS (beclomethasone/QVAR, or budesonide/Pulmicort, or fluticasone Flovent HFA, Flovent Diskus, ArmonAir RespiClick, Arnuity Ellipta, or mometasone, Asmanex HFA, Asmanex Twisthaler or ciclesodine Alvesco HFA) added to the participants usual treatment or a combination inhaler of corticosteroid and albuterol (AirSupra) that was recently approved AND Participants will use azithromycin (Zithromax) 500mg three times a week (10mg.kg for participants under 50Kg) which can be dropped to 250 mg three times a week for dose related side effects
62428647|NCT02107937|EXPERIMENTAL|DCVAC/OvCa with Standard of Care|DCVAC/OvCa in parallel with chemotherapy (Standard of Care)
62428648|NCT02107937|EXPERIMENTAL|DCVAC/OvCa sequentially chemotherapy|DCVAC/OvCa sequentially after chemotherapy
62036956|NCT02628210|OTHER|map3® Cellular Allogeneic Bone Graft|Patients will receive map3® Cellular Allogeneic Bone Graft
62036957|NCT01527929|EXPERIMENTAL|Cohort A|Normal renal function - Cabazitaxel administered once every 3 weeks
62428649|NCT02107937|ACTIVE_COMPARATOR|Standart of Care|Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
62428650|NCT01255696|EXPERIMENTAL|ALV003|ALV003 is an orally administered mixture of two recombinant proteases (cysteine endoprotease B-isoform 2 and prolyl endopeptidase) engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues common in gluten.
62036958|NCT01527929|EXPERIMENTAL|Cohort B|Moderate renal dysfunction - Cabazitaxel administered once every 3 weeks
62428651|NCT01255696|PLACEBO_COMPARATOR|Placebo|Excipients for ALV003 absent the experimental compounds
62428652|NCT02280642||Both doses on time|An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2.
62428653|NCT02280642||Dose 2 delayed|A delayed dose 2 was defined as \> 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2.
62036959|NCT01527929|EXPERIMENTAL|Cohort C|Severe renal dysfunction - Cabazitaxel administered once every 3 weeks
62428654|NCT02280642||Dose 3 delayed|An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and a delayed dose 3 was defined as \>180 days after dose 2.
62428655|NCT02280642||Both doses delayed|A delayed dose 2 was defined as \> 90 days after dose 1 and a delayed dose 3 was defined as \>180 days after dose 2.
62428656|NCT04267016||All Subjects Enrolled|Renal transplant recipients who are undergoing routine management
62428657|NCT03522090||No neck CT|Cohort of patients with suspected lung cancer where the lower neck is not routinely included in CT
62036960|NCT01921673|EXPERIMENTAL|Dovitinib plus docetaxel|"In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off~In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used."
62036961|NCT03364127|ACTIVE_COMPARATOR|Experimental: Active Acupuncture|Active Acupuncture two times per week for 5 weeks
62036962|NCT03364127|PLACEBO_COMPARATOR|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
62036963|NCT02739438||E Cigarette users|Subjects who use electronic cigarettes daily and have not used conventional cigarettes in the previous 3 months. Total pack years of smoking should be less than 20 for their smoking history, with normal lung function (FEV1 and FEV1/FVC) and no clinical symptoms of airway obstruction/inflammation (cough, dyspnea, sputum and wheeze).
62036964|NCT02739438||Cigarette smokers|Subjects who smoke at least ¼ pack cigarettes per day for the past 1 year, with no history of electronic cigarette use in the last 30 days.
62428658|NCT03522090||Neck CT|Cohort of patients with suspected lung cancer where the lower neck is routinely included in CT
62596328|NCT02866149|EXPERIMENTAL|"Cohort 3 - CirCe-PLA"|"Feasibility of Proximity-Ligation Assay (PLA) to study membrane proteins dimerisation by on isolated tumour cells in patients with HER2+/- breast cancer (HER 2+/-).~One tumor sampling.~Timing of blood sampling:~* Inclusion~* up to 3 other samples, timepoints decided by the investigator."
62596329|NCT02866149|OTHER|"Cohort 4 - CDX PDX"|"Establishment of xenografts from tumor (PDX) and from Circulating Tumour Cell (CDX) by tumour and blood sampling.~One tumor sampling.~Timing of blood sampling:~* Inclusion~* up to 3 other samples, timepoints decided by the investigator."
62036965|NCT02739438||Control group|Subjects with no history of prior conventional cigarette (\< 100 cigarettes lifetime) or electronic cigarette use.
62238116|NCT01400789|EXPERIMENTAL|ListroMix 50/50®|Insulin Lispro/ insulin Lispro protamine ( ListroMix 50/50®; 100 U/mL), DispoPen 3.0 mL.
62433671|NCT05642611|EXPERIMENTAL|Arm 2 (Continuous Compression)|Patients undergo continuous compression (moderate, steady pressure to the arms and legs) for 30-minutes pre-taxane chemotherapy infusion, during taxane chemotherapy infusion, and for 30 minutes after completion of each taxane infusion. Patients may also undergo collection of blood, serum and plasma samples during screening and on study.
62814267|NCT02675946|EXPERIMENTAL|Arm 2: CGX1321 in combination with pembrolizumab dose escalation, dose expansion and Roll-over,|"Arm 2: Roll-over Cohort: CGX1321 at a dose identified in Phase 1b, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle).~Arm 2: Phase 1b: Ascending doses of CGX1321, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle)."
62814268|NCT02675946|EXPERIMENTAL|Arm 3: CGX1321 in combination with encorafenib + cetuximab, dose escalation and dose expansion|Arm 3: Phase 1b: Ascending doses of CGX1321, once daily, orally for 3 weeks (21 days) followed by a one-week (7 day) washout period in combination with enocrafenib administered orally once daily and cetuximab administered IV once weekly
62428659|NCT00769782|EXPERIMENTAL|therapeutic conventional surgery|All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
62428660|NCT00878449|EXPERIMENTAL|ABT-263 + etoposide/cisplatin|
62428661|NCT00197184|EXPERIMENTAL|Twinrix Junior|Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).
62428662|NCT00197184|ACTIVE_COMPARATOR|Twinrix Adult|Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).
62428663|NCT01183845|EXPERIMENTAL|Exam with colon capsule|Colon Capsule Endoscopy
62428664|NCT00879424|EXPERIMENTAL|1|
62428665|NCT00879424|PLACEBO_COMPARATOR|2|
62428666|NCT02914496|EXPERIMENTAL|Diabetes in Balance|"The intervention consists of the manual-based CBT-group intervention Diabetes in Balance. It is given in a group format with six to ten participants and consists of 7 sessions. The sessions are given bi-weekly for two hours. Each session has a specific theme such as Stress and acceptance The life-compass; what is important in my life. The participants also conduct assignments related to the themes between the sessions. A licensed psychologist specialised in CBT and a diabetes specialist nurse, both trained in ACT-stress management will be leading the intervention group."
62428667|NCT02914496|NO_INTERVENTION|Control|The control group receives regular care including regular visits at the out-patient clinic, 3-4 times per year.
62428668|NCT06242873|EXPERIMENTAL|Transcutaneous Spinal Cord Stimulation and Gait Training|Transcutaneous Spinal Cord Stimulation (TSCS), TSCS will be applied using an oval electrode placed midline on the skin on the back and two rectangular electrodes placed on the skin over the lower abdomen. There will be a small electrical current through those electrodes for 30 minutes.
62428669|NCT06242873|SHAM_COMPARATOR|Transcutaneous Spinal Cord Stimulation within a single session|Electrodes will be placed as they are in the Transcutaneous Spinal Cord Stimulation condition. Stimulation will be applied at subject's maximum intensity for 30 seconds and then discontinued.
62428670|NCT05852587|EXPERIMENTAL|Dose A of Xylitol|Patients in this arm will be receiving 7.5g/day of Xylitol over a 4 week period.
62428671|NCT05852587|EXPERIMENTAL|Dose B of Xylitol|Patients in this are will be receiving 15g/day of Xylitol over a 4 week period.
62428672|NCT05852587|PLACEBO_COMPARATOR|Placebo|Patients in this arm will be receiving placebo over a 4 week period.
62428673|NCT04737915|EXPERIMENTAL|Virtual Reality Exposure|Participants completed a single session of exposure administered via a virtual reality headset. The exposure exercise involved looking over virtual railings into an atrium at various floor levels (the virtual environment was designed to look like the atrium in the in vivo exposure condition). Exposure was conducted in six 6-minute trials for a total of 36 minutes of exposure.
62428674|NCT04737915|EXPERIMENTAL|In Vivo Exposure|Participants completed a single session of exposure administered in vivo. The exposure exercise involved looking over actual railings into an atrium at various floor levels. Exposure was conducted in six 6-minute trials for a total of 36 minutes of exposure.
62428675|NCT04737915|NO_INTERVENTION|Waitlist Control|Participants watched a neutral video during the time participants in other conditions were completing the exposure exercise. Participants received no exposure-based intervention.
62428676|NCT02686489|EXPERIMENTAL|Heated humidification (HH)|Addition of water vapor (molecular water) to the inspired gas of spontaneously breathing tracheostomy patients.
62596330|NCT02866149|OTHER|"Cohort 5 - Post-TP53"|"Follow-up of patients previously treated by neoadjuvant chemotherapy for triple negative breast cancer.~Timing of blood sampling:~* Inclusion~* up to 3 other samples, timepoints decided by the investigator."
62596331|NCT02866149|OTHER|"Cohort 6 - Palbociclib"|"Monitoring of patients treated with palbociclib~Timing of blood sampling:~* Inclusion day (2 samples)~* after #2 weeks of therapy~* after #4 weeks of therapy~* at progression."
62428677|NCT02686489|ACTIVE_COMPARATOR|Cool bland aerosol (LVN)|Addition of particulate water to the inspired gas of spontaneously breathing tracheostomy patients.
62428678|NCT00822861|EXPERIMENTAL|Dose level No.1|TPI ASM8 1 mg BID
62428679|NCT00822861|EXPERIMENTAL|Dose level No.2|TPI ASM8 2 mg BID
62428680|NCT00822861|EXPERIMENTAL|Dose level No.3|TPI ASM8 4mg BID
62428681|NCT00822861|EXPERIMENTAL|Dose level No.4|TPI ASM8 8 mg Die
62238117|NCT01400789|ACTIVE_COMPARATOR|Humalog Mix50/50®|Insulin Lispro/ insulin Lispro protamine (Humalog Mix50/50® ; 100 U/mL), Humalog Mix 50/50® Kwik PenTM 3.0 mL.
62428682|NCT00561184|EXPERIMENTAL|1|
62428683|NCT00561184|EXPERIMENTAL|2|
62428684|NCT05496595|EXPERIMENTAL|Part 1: Dose Escalation|Dose escalation to investigate safety, tolerability, and determine recommended phase 2 dose (RP2D) for DCBY02.
62428685|NCT05496595|EXPERIMENTAL|Part 2: Dose Expansion|Dose expansion to further investigate safety, tolerability, and preliminary evidence of antitumor activity and characterize PK and PD of DCBY02.
62428686|NCT01283711|EXPERIMENTAL|apollo|
62428687|NCT05805774|ACTIVE_COMPARATOR|Group A - DFR|
62428688|NCT05805774|ACTIVE_COMPARATOR|Group B - ORIF|
62428689|NCT02972970|OTHER|Aveera|This is a prospective, open label study to assess the scan, print and fit process to see if the Aveera will be able to be used with conventional CPAP therapy devices
62428690|NCT01533051||Chronic hepatitis B|
62428691|NCT00012194|EXPERIMENTAL|Treatment (7-hydroxystaurosporine, cisplatin)|Patients receive cisplatin IV over 1 hour on day 1 and UCN-01 IV continuously over 36-72 hours on day 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62428692|NCT03124797|EXPERIMENTAL|RD DCI Sensor|All subjects are enrolled into the test group and all subjects received the RD DCI Sensor
62428693|NCT03264066|EXPERIMENTAL|Cohort 1 - SCCHN - Treatment Naive|In participants with recurrent or advanced / metastatic SSCHN who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
62428694|NCT03264066|EXPERIMENTAL|Cohort 2 - UC - Treatment Naive|In participants with advanced / metastatic UC who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
62428695|NCT03264066|EXPERIMENTAL|Cohort 3 - RCC - Treatment Naive|In participants with metastatic RCC who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 milligrams (mg) once daily (QD) for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
62428696|NCT03264066|EXPERIMENTAL|Cohort 4 - SCCHN - Previous Treatment Exposure|In participants with SCCHN whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
62428697|NCT03264066|EXPERIMENTAL|Cohort 5 - UC - Previous Treatment Exposure|In participants with UC whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
62428698|NCT03264066|EXPERIMENTAL|Cohort 6 - RCC - Previous Treatment Exposure|In participants with RCC whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
62814269|NCT06704555|EXPERIMENTAL|Experimental: Treatment arm|"Radiation (dose:18～24Gy) ，chemoimmunotherapy 1～2 weeks later than radiation. Tiselizumab (200 mg iv d1) R-CHOP (rituximab 375 mg/m2 intravenous \[IV\] day 2, cyclophosphamide 750 mg/m2 IV day 3, doxorubicin 50 mg/m2 IV day 3, vincristine 1.4 mg/m2 \[maximum 2.0 mg total\] IV day 3, and prednisone 100 mg oral days 3-7, 21～28 days for one cycle ) for six cycles.~Rituximab was given every 2 months to patients who were complete metabolic response /partial metabolic response（CMR/PMR）after first-line chemo until 2 years."
62814270|NCT02014324||(suspected) NSCLC, mediastinal staging, endosonography|Patients with potentially medically operable and resectable NSCLC are eligible if there is an indication for pathological evaluation of mediastinal lymph nodes.
62814271|NCT05714267|EXPERIMENTAL|Active noise cancelling|Patients corresponding to the number 1 blocks in the randomization table according to the order of surgery were included in the active noise control group. Preoperative care of the patients was performed by clinical nurses. After transferring to the operating room and performing spinal anesthesia, the active noise control headset (Sony WH1000xm4) was placed on the patient's head. The active noise control feature of the headset was turned on and it was not removed until the dressing of the patient was closed at the end of the operation. In this group, the vital signs of the patients were followed up during the surgery. At the end of each surgery, the researcher disinfected the earplugs with an antiseptic solution containing 2% chlorhexidine. In addition, the battery level of the headset was checked and charged by the researcher when necessary. This ensures that the headset is ready for the next patient.
62814272|NCT05714267|EXPERIMENTAL|Passive noise cancelling|The patients corresponding to the number 2 blocks in the randomization table according to the order of operation were included in the passive noise control group. Preoperative care of the patients was performed by clinical nurses. After transferring to the operating room and performing spinal anesthesia, passive noise control headset (3M Peltor Optime II) was placed on the patient's head. The earphone was not removed until the dressing of the patient was closed at the end of the surgery. In this group, the vital signs of the patients were followed up during the surgery. At the end of each operation, the earplugs were disinfected by the researcher with an antiseptic solution containing 2% chlorhexidine and prepared for the next patient.
62814273|NCT05714267|EXPERIMENTAL|Active noise cancelling with music therapy|Patients corresponding to blocks numbered 3 in the randomization table according to the order of surgery were included in the music therapy group. Preoperative care of the patients was performed by clinical nurses. After transferring to the operating room and performing spinal anesthesia, the headset (Sony WH1000xm4) was positioned on the patient's head as shown in Figure 3.7-5 (A). iPod Touch 7th Generation music player with Spotify mobile application was used for music application. The connection between the headset and the music player was provided via Bluetooth. Music chosen by the patient; Active noise control was turned on and the patient was listened to until the dressing was removed at the end of the operation. The vital signs of the patient during the operation were followed up. In addition, the battery level of the headset was checked and charged by the researcher when necessary. This ensures that the headset is ready for the next patient.
62814274|NCT05714267|NO_INTERVENTION|Control group|Patients corresponding to blocks numbered 0 in the randomization table according to the order of surgery were included in the control group. The patients, whose preoperative care was performed by clinical nurses, were transferred to the operating room and spinal anesthesia was administered. No intervention was made in this group during the surgery. The vital signs of the patients were followed up during the operation.
62814275|NCT05805631|EXPERIMENTAL|Experimental arm|Intrathecal pemetrexed combined with EGFR-TKI (physician choice)
62238118|NCT05794750|EXPERIMENTAL|AK104 injection++chemotherapy|Local CRC with short-course radiotherapy followed by sequential chemotherapy and AK104
62428699|NCT03264066|EXPERIMENTAL|Cohort 7 - Biopsy Cohort|In participants with solid non-melanoma, non- hematologic tumors who previously developed primary or secondary resistance to an anti-PD-1 or anti-PD-L1 agent, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle. The first dose of atezolizumab of 840 mg by IV infusions on Day 15 of Cycle 1. Thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles.
62238119|NCT05794750|EXPERIMENTAL|TME surgery|Local CRC with short-course radiotherapy followed by sequential chemotherapy and AK104
62238120|NCT05794750|EXPERIMENTAL|chemotherapy|Local CRC with short-course radiotherapy followed by sequential chemotherapy and AK104
62238121|NCT04567550|NO_INTERVENTION|Observation Control Arm|Observation Control
62238122|NCT04567550|EXPERIMENTAL|RGX-314 Treatment Arm (Dose 1)|RGX-314 Dose 1
62238123|NCT04567550|EXPERIMENTAL|RGX-314 Treatment Arm (Dose 2)|RGX-314 Dose 2
62238124|NCT04567550|EXPERIMENTAL|RGX-314 Treatment Arm (Dose 3) and Topical Steroid|RGX-314 Dose 3 and Topical Steroid
62238125|NCT00328822|EXPERIMENTAL|A|Quetiapine
62036966|NCT03961568|EXPERIMENTAL|Core Study Placebo|"Subjects who did not receive Cenobamate in the Core Study will receive Cenobamate 12.5 mg tablet once a day for two weeks, 25 mg tablet once a day for two weeks, 50 mg tablet once a day for two weeks, 100 mg tablets once a day for two weeks, 150 mg tablets once a day for two weeks and 200 mg tablets once a day for twelve weeks.~Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight."
62036967|NCT03961568|EXPERIMENTAL|Core Study Active|"Subjects who received cenobamate in the Core study will continue to receive the same daily dose (150 mg or 200mg).~Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight."
62036968|NCT06151964|EXPERIMENTAL|Part A: AZD9550|Multiple repeat doses of AZD9550 given as 4 once weekly SC doses for 4 weeks to 2 sequential cohorts in overweight/obese participants with or without T2DM, evaluating 2 low dose levels of AZD9550
62238126|NCT00328822|PLACEBO_COMPARATOR|B|Placebo
62814276|NCT01231984|EXPERIMENTAL|4 mm vs. 8 mm|Subjects randomized to this study arm first used either the 4 mm x 32G Pen Needle or the 8mm x 31G Pen Needle for 12 weeks (Period 1), then switched to the alternate pen needle (PN) for another 12 weeks (Period 2). Order of PN use was randomly determined.
62814277|NCT01231984|EXPERIMENTAL|4 mm vs. 12.7 mm|Subjects randomized to this study arm first used either the 4 mm x 32G Pen Needle or the 12.7mm x 29G Pen Needle (PN) for 12 weeks (Period 1), then switched to the alternate PN for another 12 weeks (Period 2). Order of PN use was randomly determined.
62428700|NCT02889536||Focus group interview, stoma clinics|Qualitative data collection. Patients attending stoma clinics in the capital region
62814278|NCT06538584|EXPERIMENTAL|Dexmedetomidine +/- Caffeine Sedation|Eligible subjects will be given 10 mg/kg caffeine citrate (equivalent to \~5 mg/ kg caffeine base) \~ 15 min after terminating Dex's infusion.
62814279|NCT06538584|PLACEBO_COMPARATOR|Dexmedetomidine +/- Placebo Sedation|Eligible subjects will be given 9 mg/ml saline placebo) \~ 15 min after terminating Dex's infusion.
62814280|NCT01140308|PLACEBO_COMPARATOR|Sugar Pill|Simvastatin 20mg + Placebo
62036969|NCT06151964|EXPERIMENTAL|Part B: AZD9550|Once weekly up-titration over 5 doses of AZD9550 in overweight/obese participants with or without T2DM
62428701|NCT02889536||Focus group interview, referred|Qualitative data collection. Patients referred to repair surgery at a specific hospital in the capital region
62428702|NCT01074307|EXPERIMENTAL|Low Dose Bisoprolol|
62428703|NCT01074307|EXPERIMENTAL|High Dose Bisoprolol|
62428704|NCT05525637|EXPERIMENTAL|YZJ-1139 20mg|
62428705|NCT05525637|EXPERIMENTAL|YZJ-1139 40mg|
62428706|NCT05525637|PLACEBO_COMPARATOR|Placebo|
62036970|NCT06151964|EXPERIMENTAL|Part C: AZD9550|Bi-weekly/monthly up-titration of AZD9550 for 24 weeks in overweight/obese participants with or without T2DM.
62036971|NCT06151964|EXPERIMENTAL|Part D: AZD9550|Bi-weekly/monthly up-titration of AZD9550 for 24 weeks in overweight/obese Japanese participants with T2DM (Part D).
62036972|NCT06151964|EXPERIMENTAL|Part A: placebo|Multiple repeat doses of placebo given as 4 once weekly SC doses for 4 weeks to 2 sequential cohorts in overweight/obese participants with or without T2DM, evaluating 2 low dose levels of AZD9550
62036973|NCT06151964|EXPERIMENTAL|Part B: placebo|Once weekly up-titration over 5 doses of placebo in overweight/obese participants with or without T2DM
62238127|NCT05192304|EXPERIMENTAL|0.2mg single dose|single dose of TPN-672 0.2mg, 2 subjects
62428707|NCT04156867|EXPERIMENTAL|simple discectomy|traditional simple discectomy
62433672|NCT05642611|ACTIVE_COMPARATOR|Arm 3 (Low Cyclic Compression)|Patients undergo low cyclic compression (low pressure that comes and goes to the arms and legs) for 30-minutes pre-taxane chemotherapy infusion, during taxane chemotherapy infusion, and for 30 minutes after completion of each taxane infusion. Patients may also undergo collection of blood, serum and plasma samples during screening and on study.
62814281|NCT01140308|ACTIVE_COMPARATOR|Co Q10|Simvastatin 20mg + CoQ10
62814282|NCT00771394|PLACEBO_COMPARATOR|1. Tamsulosin alone|
62814283|NCT00771394|EXPERIMENTAL|2. Tamsulosin + solifenacin (low dose)|
62814284|NCT00771394|ACTIVE_COMPARATOR|3. Tamsulosin + solifenacin (high dose)|
62814285|NCT03851445|OTHER|Lung-MAP Screening|This is a screening study and does not have an intervention. LUNGMAP is an overarching umbrella study to which patients are screened and then assigned to a treatment sub-study. The treatment sub-studies are standalone trials and have their own NCT numbers. The Lung-MAP Study is considered a single study under one IND, consisting of the Screening Protocol and multiple sub-studies. Each sub-study protocol operates independently and has its own version date.
62814286|NCT04765371|ACTIVE_COMPARATOR|DEXAMETHASONE Arm|Patients will take 6 mg per day of Dexamethasone during 10 days
62036974|NCT06151964|EXPERIMENTAL|Part C: placebo|Bi-weekly/monthly up-titration of placebo for 24 weeks in overweight/obese participants with or without T2DM.
62036975|NCT06151964|EXPERIMENTAL|Part D: placebo|Bi-weekly/monthly up-titration of placebo for 24 weeks in overweight/obese Japanese participants with T2DM (Part D).
62814287|NCT04765371|ACTIVE_COMPARATOR|PREDNISOLONE Arm|Patients will take 60 mg per day of Prednisolone during 10 days
62814288|NCT05935553|EXPERIMENTAL|Baclofen 30 microgram (mg) treatment|baclofen treatment (30 mg/per day)
62814289|NCT05935553|EXPERIMENTAL|Baclofen 60 mg|baclofen treatment (60 mg/per day)
62814290|NCT05935553|PLACEBO_COMPARATOR|Placebo|
62814291|NCT04811703|EXPERIMENTAL|Combined PIPAC / IV chemotherapy treatment|Patients will undergo 3 cycles of combined chemotherapy, consisting of PIPAC (cisplatin-doxorubicin, escalating doses) and systemic chemotherapy (paclitaxel-carboplatine, standard doses). First patient will be treated at the lowest dose: doxorubicin 2.1 mg/m² and cisplatin 10.5 mg/m². Subsequent patients will be treated at the dose recommended by the CRM algorithm in the absence of dose-limiting toxicity. A total of 11 dose levels with a factor between 1 and 3 are considered. The maximum dose considered will be doxorubicin, 6.3 mg/m² and cisplatin, 31.5 mg/m². The doses of intravenous chemotherapy will be defined in a standard way, according to the habits of the investigating clinicians and in accordance with the doses received previously. Each cycle will last 28 days and will begin at day 1 with PIPAC procedure and will be completed at day 8 with systemic chemotherapy. Combined chemotherapy will be repeated every 4 weeks for up to 3 cycles in the absence of unacceptable toxicity.
62814292|NCT04997317|ACTIVE_COMPARATOR|Phase 0: Group A|"Cycle 1: 4.5 GBq 177Lu-DOTA-JR11 (300-1300 μg) will be administered once intravenously.~Cycle 2: 4.5 GBq 177Lu-DOTATOC (≈200 μg) will be administered once intravenously (following a cross-over design).~Cycle 3 and Cycle 4 will be performed for group A patients with 7.4 GBq 177Lu-DOTATOC (clinically established amount of activity). Cycle 3 and 4 are standard of care (i.e. not part of the study)."
62814293|NCT04997317|ACTIVE_COMPARATOR|Phase 0: Group B|"Cycle 1: 4.5 GBq 177Lu-DOTATOC (≈200 μg) will be administered once intravenously.~Cycle 2: 4.5 GBq 177Lu-DOTA-JR11 (300-1300 μg) will be administered once intravenously (following a cross-over design).~Cycle 3 and Cycle 4 will be performed for group B patients with 7.4 GBq 177Lu-DOTATOC (clinically established amount of activity). Cycle 3 and 4 are standard of care (i.e. not part of the study)."
62814294|NCT04997317|ACTIVE_COMPARATOR|Phase I/II|3 cycles of 177Lu-DOTA-JR11 will be administered with an activity of 4.5-7.4 GBq. Two additional 177Lu-DOTA-JR11 treatment cycles can be performed if clinically indicated
62814295|NCT06472661|EXPERIMENTAL|FUSA + polyICLC|Focused Ultrasound Ablation plus intratumoral injection of polyICLC
62814296|NCT06585878|EXPERIMENTAL|Experimental group|SBRT radiotherapy for all lesions/all metastatic lesions
62814297|NCT02028806|EXPERIMENTAL|FOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
62036976|NCT04321226|EXPERIMENTAL|Femtosecond Laser guided Arcuate Keratotomy|Arcuate keratotomy will be performed together with Laser cataract surgery
62036977|NCT01835626|EXPERIMENTAL|Vismodegib and Radiation Therapy|150mg Vismodegib will be taken once a day, daily. Radiation therapy will be started after the patient has completed taking vismodegib for 12 weeks. The patient will take daily vismodegib through the completion of radiation therapy. The patient will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
62036978|NCT02228265||Ancillary-Correlative (genetic analysis)|Patients undergo collection of blood and tissue samples at baseline, during administration of enzalutamide and after the time of disease progression for analysis via immunohistochemistry, comparative genome hybridization, and sequencing.
62238128|NCT05192304|EXPERIMENTAL|0.3mg single dose|single dose of TPN-672 0.3mg, 12 subjects（9 for TPN-672, 3 for placebo）
62238129|NCT05192304|EXPERIMENTAL|0.4mg single dose|single dose of TPN-672 0.4mg, 12 subjects（9 for TPN-672, 3 for placebo）
62238130|NCT05192304|EXPERIMENTAL|0.5mg single dose|single dose of TPN-672 0.5mg, 12 subjects（9 for TPN-672, 3 for placebo）
62238131|NCT05192304|EXPERIMENTAL|0.6mg single dose|single dose of TPN-672 0.6mg, 12 subjects（9 for TPN-672, 3 for placebo）
62036979|NCT04999813|EXPERIMENTAL|Comprehensive intensive intervention|On the basis of routine management, carry out individualized cerebrovascular risk factor assessment and comprehensive intervention in a medical-nursing cooperation model, and require corresponding control indicators to be achieved. A comprehensive intervention team is established by specialized medical staff to monitor blood pressure, heart rate, exercise and other data through smart wearable devices, and automatically upload them to the cloud platform, conduct comprehensive data analysis every week, timely feedback and online reminders, establish health management files, and improve the target population The blood-brain tube risk factor control and self-management ability.
62036980|NCT04999813|NO_INTERVENTION|Routine management|Only routine management was carried out for the subjects without special intervention.
62036981|NCT00651664|EXPERIMENTAL|Alisertib 5 mg QD 7D|Alisertib 5 mg, capsules, orally, once daily (QD) for 7 days (D) followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 3 cycles).
62036982|NCT00651664|EXPERIMENTAL|Alisertib 80 mg QD 7D|Alisertib 80 mg, capsules, orally, QD for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 4 cycles).
62036983|NCT00651664|EXPERIMENTAL|Alisertib 150 mg QD 7D|Alisertib 150 mg, capsules, orally, QD for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles).
62036984|NCT00651664|EXPERIMENTAL|Alisertib 50 mg BID 7D|Alisertib 50 mg, capsules, orally, twice daily (BID) for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 29 cycles).
62036985|NCT00651664|EXPERIMENTAL|Alisertib 60 mg BID 7D|Alisertib 60 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles).
62036986|NCT00651664|EXPERIMENTAL|Alisertib 75 mg BID 7D|Alisertib 75 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 8 cycles).
62036987|NCT00651664|EXPERIMENTAL|Alisertib 100 mg BID 7D|Alisertib 100 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 21 cycles).
62036988|NCT00651664|EXPERIMENTAL|Alisertib 50 mg QD 14D|Alisertib 50 mg, capsules, orally, QD for 14 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 25 cycles).
62036989|NCT00651664|EXPERIMENTAL|Alisertib 50 mg QD 21D|Alisertib 50 mg, capsules, orally, QD for 21 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 10 cycles).
62238132|NCT05192304|EXPERIMENTAL|0.7mg single dose|single dose of TPN-672 0.7mg, 12 subjects（9 for TPN-672, 3 for placebo）
62428708|NCT01794156|ACTIVE_COMPARATOR|Cognitive behavior therapy|"1. The cognitive-behavioral model is presented and individualized.~2. Cognitive correction: beliefs are addressed by explaining their roles in maintaining cognitive biases. Next, clients are trained to identify and to challenge their key beliefs~3. Exposure and response prevention (ERP) using imaginal and in vivo exposure and to both over and covert neutralization is implemented according to hierarchies developed following the individual assessment. Extended periods of exposure permits emotional discomfort to dissipate.~4. Combined phase: continues ERP while making explicit links to the cognitive targets.~5. Relapse prevention included a written individualized guide to encourage the maintenance of treatment gains. Self-directed ERP continues."
62036990|NCT00651664|EXPERIMENTAL|Alisertib 70 mg QD 21D|Alisertib 70 mg, capsules, orally, QD for 21 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).
62036991|NCT01597050|ACTIVE_COMPARATOR|Drug: R932333|R333 6% (60 mg/g), bid
62036992|NCT01597050|PLACEBO_COMPARATOR|Placebo|Placebo, bid
62036993|NCT04594161|ACTIVE_COMPARATOR|Percutaneous Nephrostomy|drainage of the kidney by means of a percutaneous Nephrostomy
62036994|NCT04594161|ACTIVE_COMPARATOR|Double J catheter|drainage of the kidney by means of a double J catheter
62238133|NCT05515120|ACTIVE_COMPARATOR|Rivaroxaban plus Aspirin|"Drug: Rivaroxaban 15 mg Rivaroxaban 15 mg BID~Other Names:~Xarelto 15 mg Rivaroxabana 15 mg Drug: Aspirin 300 mg"
62238134|NCT05515120|PLACEBO_COMPARATOR|Acenocoumarol|Drug: Acenocoumarol Other Name: Vitamin K antagonist
62238135|NCT01332565|EXPERIMENTAL|Single Arm|All subjects will receive a 50 mg single dose of GSK1349572
62238136|NCT00779051|EXPERIMENTAL|1|Zolipidem 10mg tablets of Ranbaxy
62238137|NCT00779051|ACTIVE_COMPARATOR|2|Ambien® 10mg tablets
62238138|NCT00628251|EXPERIMENTAL|1|AZD2281 Oral 200 mg BID
62238139|NCT00628251|ACTIVE_COMPARATOR|2|Liposomal Doxorubicin
62238140|NCT00628251|EXPERIMENTAL|3|AZD2281 Oral 400 mg BID
62238141|NCT05745675||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
62238142|NCT01609751|EXPERIMENTAL|Yakult 62 ml daily|
62238143|NCT00874770|EXPERIMENTAL|Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A)|Active Comparator
62238144|NCT00874770|EXPERIMENTAL|Daclatasvir, Peginterferon alpha-2a, ribavirin (B)|Active Comparator
62238145|NCT00874770|EXPERIMENTAL|Daclatasvir, Peginterferon alpha-2a, ribavirin (C)|Active Comparator
62238146|NCT00874770|ACTIVE_COMPARATOR|Placebo, Peginterferon alpha-2a, ribavirin (D)|
62238147|NCT01207232|EXPERIMENTAL|Time Plan Condition|A basic reminder mailing prompted each subject to write down a planned date and time for getting their flu shot.
62238148|NCT01207232|EXPERIMENTAL|Date Plan Condition|A basic reminder mailing prompted each subject to write down a planned date for getting their flu shot.
62036995|NCT01208454|EXPERIMENTAL|Treatment (isotretinoin and vorinostat)|"Patients receive isotretinoin PO BID on days 1-14, PO suspension\* of vorinostat QD on days 1-4 of course 1, and capsules of vorinostat PO QD on days 1-4 and 8-11 of course 2 and subsequent courses. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~EXPANSION COHORT 1 (=\< 21 years of age): Once the MTD has been determined, patients are treated at that dose level as above.~EXPANSION COHORT 2 (22-30 years of age): Patients receive isotretinoin as above and vorinostat at the MTD on days 1-3 and 8-10."
62036996|NCT05188001||Inpatient non-cardiac surgery patients|Patients aged 45 years and older undergoing inpatient non-cardiac surgery who had MINS protocol ordered for postoperative high sensitivity troponin monitoring based on the CCS guidelines from January 2020 to June 2021.
62036997|NCT01192438|EXPERIMENTAL|Procedure/surgery|
62036998|NCT05414591|EXPERIMENTAL|Sequence group A|DWP16001 A mg 1T
62036999|NCT05414591|EXPERIMENTAL|Sequence group B|DWP16001 B mg 3T
62037000|NCT05093036|NO_INTERVENTION|Arm 1: routine PrEP care at the CSH, monitoring 4 times per year (standard-of-care)|"Study participants in arm 1 follow routine care procedures, i.e. the number of monitoring visits is four times a year.~* Experienced PrEP users: first monitoring visit is three months after the enrolment into the study.~* PrEP-naïve participants: first monitoring visit is one month after enrolment in the study and start of PrEP use. The second monitoring visit is 2 months after the first monitoring contact (3 months after enrolment)."
62238149|NCT01207232|ACTIVE_COMPARATOR|Control Condition|A basic reminder mailing prompted each subject to receive a flu shot.
62238150|NCT04078165|EXPERIMENTAL|Zero-Gravity|In this group, the operator uses the Zero-Gravity protection system
62238151|NCT04078165|ACTIVE_COMPARATOR|Conventional|In this group, the operator uses conventional radiation protection
62596332|NCT02866149|OTHER|"Cohort 7 - CTC_PD-L1_Breast"|"Detection of PD-L1 in metastatic breast cancer patients~Timing of blood sampling:~* Inclusion~* up to 3 other samples, timepoints decided by the investigator."
62238152|NCT02480790||Patients with malignant disease|Patients with ovarian, tubar or primary peritoneal cancer
62238153|NCT02480790||Patients with benign disease|Patients with suspected ovarian cancer where the final pathologic diagnosis is benign
62238154|NCT00569816|ACTIVE_COMPARATOR|Group 1|Propofol as the primary anesthetic
62238155|NCT00569816|EXPERIMENTAL|Group 2|Sevoflurane administered continuously after induction of anesthesia until initiation of cardiopulmonary bypass.
62238156|NCT00569816|EXPERIMENTAL|Group 3|Sevoflurane administered repetitive up to 1 MAC from induction of anesthesia until initiation of cardiopulmonary bypass. Wash in and wash out performed twice.
62238157|NCT00194844|EXPERIMENTAL|1|Nurse Caring
62238158|NCT00194844|EXPERIMENTAL|2|Self Caring
62596333|NCT02866149|OTHER|"Cohort 8 - CTC_PD-L1_Broncho-Pulmonary"|"Detection of PD-L1 in metastatic lung cancer patients~Timing of blood sampling:~* Inclusion~* up to 3 other samples, timepoints decided by the investigator."
62596334|NCT02866149|OTHER|"Cohort 9 - NSCLC"|"Monitoring of patients with Non-Small Cell lung Cancer treated by immune therapy.~Blood sampling at 4 timepoints."
62596335|NCT02866149|OTHER|"Cohort 10 - Palbociclib II"|"Monitoring of patient with a metastatic breast cancer treated by palbociclib.~Timing of blood sampling:~* Inclusion~* after #4 weeks of therapy~* at the first tumoral evaluation (month 3 or 4)~* at progression."
62596336|NCT02866149|OTHER|Cohort 11 - Sarcomas|The cohort includes all patients with bone or soft tissue sarcoma. Timing of blood sampling depending on disease staging.
62596337|NCT02866149|OTHER|Cohort 12 - Faslorad|"Monitoring of patient with a metastatic breast cancer initiating a treatment by Faslodex-Afinitor.~Timing of blood sampling:~* Inclusion~* after #3-5 weeks of therapy~* at the first tumoral evaluation (month 2 or 3)~* at progression."
62814298|NCT04960527|EXPERIMENTAL|Tart cherry juice|30 mL tart cherry concentrate (CherryActive, UK, 100% Montmorency) diluted with 220 mL water (totalling 250 mL). According to available manufacturers data, this is equivalent to consuming 90-100 fresh cherries.
62814299|NCT04960527|OTHER|Water|250 mL water (neutral control)
62596338|NCT02866149|OTHER|Cohort 13 - MUm|"The cohort concerns patients with uveal melanoma in the 1st systemic line at the metastatic stage (may have had prior adjuvant therapy or surgery/radiofrequency).~Timing of blood sampling:~* J1C1~* J2C1~* J1C2~* J1C5 (first tumoral evaluation)."
62814300|NCT05382494|EXPERIMENTAL|Intranasal Steroids|
62238159|NCT00194844|EXPERIMENTAL|3|Combined Caring
62238160|NCT00194844|NO_INTERVENTION|4|This group is not treated and serves as control.
62238161|NCT06295835|OTHER|Method comparison for K and iCa Tests using capillary whole blood specimens.|Compare the performance of the K and iCa Tests using the IUO i-STAT CG8+ Cartridge on the i-STAT 1 Analyzer to the performance of the K and iCa Tests on the comparator device using capillary whole blood specimens collected from two separate fingersticks.
62596339|NCT02866149|OTHER|Cohort 14 - CNBC Snipe|"This cohort concerns patients with metastatic Non-Small Cell lung Cancer receiving anti-PD-1/PD-L1.~One tumour sampling.~Timing of blood sampling:~* before treatment~* at W8 of treatment (after radiological examination)~* at W12 of treatment~* at progression or 18 months after the beginning of treatment"
62596340|NCT02866149|OTHER|Cohort 15 - Breast CLI|"This cohort concerns patients with metastatic lobular breast cancer One tumour sampling.~Timing of blood sampling:~* At inclusion~* After biopsy post inclusion (or in 15 days after)~* after 1 or 2 months of treatment~* at progression or 18 months after inclusion"
62596341|NCT02866149|OTHER|Cohort 16 - Mum immunothérapie|"This cohort concerns patients with metastatic uveal melanoma before immunotherapy treatment.~Timing of blood sampling :~* at inclusion~* at cycle 2 or 3 of treatment~* at the first tumoral evaluation (C5D1)~* at progression"
62596342|NCT02194712||travellers|travellers with recent (\<12 weeks) high risk water contact are included in the study and asked to provide samples for CAA testing
62596343|NCT02141568|EXPERIMENTAL|Intervention Group for Prospective Study|"Intervention: Medical and psychological treatment at the Soroka UMC functional neurology outpatient clinic. Treatment will be conducted by a multidisciplinary staff. Patients will undergo an initial meeting with a neurologist and afterwards will be directed to other members of the team (psychologist, physical therapist) on a case by case basis."
62238162|NCT00195858|ACTIVE_COMPARATOR|Diet and Aerobic Exercise|
62238163|NCT00195858|ACTIVE_COMPARATOR|Diet and Resistane Exercise|
62238164|NCT00195858|ACTIVE_COMPARATOR|Diet and Combined Aerobic and Resistance Exercise|
62596344|NCT02141568|NO_INTERVENTION|No Intervention|Patient records will be analyzed via Clalit Health Service electronic records. No additional intervention will occur
62596345|NCT06619522|EXPERIMENTAL|INCB+ R|
62596346|NCT03183713|ACTIVE_COMPARATOR|Comparison Group|Patients with a zero risk score will serve as a comparison group (N=20).
62596347|NCT03183713|ACTIVE_COMPARATOR|Sham Treatment|All patients at risk will be stratified by risk rating and randomly assigned to 2 groups; sham treatment (N=20) or CBT (N=20).
62596348|NCT03183713|ACTIVE_COMPARATOR|CBT|All patients at risk will be stratified by risk rating and randomly assigned to 2 groups; sham treatment (N=20) or CBT (N=20).
62814301|NCT05382494|PLACEBO_COMPARATOR|Intranasal Saline|
62814302|NCT00689039|EXPERIMENTAL|A|AZD1305 ER tablet
62814303|NCT00689039|PLACEBO_COMPARATOR|B|Placebo tablet
62814304|NCT01667900|EXPERIMENTAL|0.5 mg Dulaglutide (Part A-Healthy)|0.5 milligrams (mg) dulaglutide administered once subcutaneously (SQ) to healthy participants in 1 of 3 treatment periods
62814305|NCT01667900|EXPERIMENTAL|0.75 mg Dulaglutide (Part A-Healthy)|0.75 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods
62428709|NCT01794156|ACTIVE_COMPARATOR|Mindfulness-based stress reduction (MBSR)|The entire intervention is based on systematic and intensive training in MBSR following Santorelli and Kabat-Zinn and their applications to everyday life. The program is divided in 8 consecutive blocks with daily homework in mindfulness-based stress reduction skills. The main activity of MBSR is a cognitive and intervention-based process characterized by self-regulation of attention to the present moment and an open and accepting orientation towards one's experience.
62814306|NCT01667900|EXPERIMENTAL|1.5 mg Dulaglutide (Part A-Healthy)|1.5 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods
62814307|NCT01667900|PLACEBO_COMPARATOR|Placebo (Part A-Healthy)|Placebo administered once SQ to healthy participants in 1 of 3 treatment periods
62238165|NCT00195858|OTHER|Diet-only control group|
62238166|NCT04563585||Muscle strength|Maximal voluntary isometric (MVIC) knee flexion and extension strength were measured using a handheld dynamometer (HDD) (Lafayette Instrument Company, Lafayette, IN).
62238167|NCT04563585||Lower Extremity Vertical Power|Lower extremity vertical power was identified through the use of the VertiMetric (Lafayette Instrument Company, Lafayette, IN) according to protocols suggested by Ambegaonkar et al.
62238168|NCT04563585||Trunk Extension Endurance|Trunk extension endurance was measured using the Biering-Sorensen test as previously described
62238169|NCT04563585||Upper Limb Performance|The Davies test (DT) was used to assess upper body agility and stabilization.The Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST) was utilized to assess shoulder performance function and stability according to protocol suggested by Goldbeck and Davies.
62238170|NCT04563585||Lower Limb Performance|The Shark Skill Test (SST) was developed in order to assess lower extremity agility and neuromuscular control.
62238171|NCT06418438|ACTIVE_COMPARATOR|Laparoscopic uterosacral ligament suspension with hysterectomy|
62238172|NCT06418438|EXPERIMENTAL|Laparoscopic uterosacral ligament suspension with cervical amputation|
62814308|NCT01667900|EXPERIMENTAL|0.5 mg Dulaglutide (Part B-T2DM)|0.5 mg dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM) once weekly SQ for 4 weeks
62428710|NCT01794156|EXPERIMENTAL|Inference-based therapy|"The inference-based therapy will be delivered in 10-step~The client will:~* learn that the compulsions, anxiety and discomfort are driven by an initial obsessional doubt~* learn why this doubt is 100% irrelevant here and now~* learn the inferential confusion process~* have to recognize that the doubt originates from him/her~* have to identify/describe the narrative leading him/her to the doubt~* have to identify the cross-over point when he/she leaves reality~* learn to be aware of the reasoning devices~* learn how personal themes dictate the idiosyncratic nature of the person's obsession~* explore and reinforced an alternative self-view~* be trained to use properly his/her senses in the face of obsessional triggers situations"
62428711|NCT00493181|EXPERIMENTAL|Interleukin-11|Starting dose 10 mcg/kg subcutaneously 3 times a week
62428712|NCT05103085||Experimental|Patient undergoing digestive endoscopy and aged 50 years and over
62428713|NCT00907465||Calibration study|These individuals were used to develop cut points for sedentary behavior using accelerometers and a metabolic chamber.
62814309|NCT01667900|EXPERIMENTAL|0.75 mg Dulaglutide (Part B-T2DM)|0.75 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks
62428714|NCT02917837|ACTIVE_COMPARATOR|Usual QCNL report group|Physicians receive the usual Quality of Care Newfoundland and Labrador utilization report: This reports ranks the physician on a figure of their peers according to the total number of tests ordered in a one-year period.
62814310|NCT01667900|EXPERIMENTAL|1.5 mg Dulaglutide (Part B-T2DM)|1.5 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks
62814311|NCT01667900|PLACEBO_COMPARATOR|Placebo (Part B-T2DM)|Placebo administered to participants with T2DM once weekly SQ for 4 weeks
62814312|NCT01360697|EXPERIMENTAL|JADE- JA|Use the JADE portal to monitor the delivery of structured care.
62814313|NCT01360697|ACTIVE_COMPARATOR|Usual care|Patients will receive usual care in between two annual comprehensive assessments.
62814314|NCT03201796|EXPERIMENTAL|Group 1|Prulifloxacin 600 mg
62814315|NCT03201796|ACTIVE_COMPARATOR|Group 2|Levofloxacin 500 mg
62814316|NCT05644834|EXPERIMENTAL|Mobile Medical Unit|Participants utilizing the mobile medical unit will be offered an appointment with a university system healthcare provider to receive blood pressure check, blood glucose check, HIV testing and/or Pre-exposure Prophylaxis (PrEP) consultation.
62814317|NCT03917849|EXPERIMENTAL|Heavy slow resistance training|"The program is performed 3 times per week using resistance equipment in a fitness center. Each session consists of three 2-legged loaded quadriceps and lower limb kinetic chain exercises. The patients complete 3 or 4 sets in each exercise with a 2- to 3-minute rest between sets and a 5-minute rest period between the 3 exercises.~The number of repetitions decreases, and load gradually increases, every week. The repetitions and loads are as follows: 3 times, 15-repetition maximum (15RM ), in week 1; 3 times, 12RM , in weeks 2 to 3; 4 times, 10RM , in weeks 4 to 5; 4 times, 8RM , in weeks 6 to 8; and 4 times, 6RM , in weeks 9 to 12."
62238173|NCT00257686|EXPERIMENTAL|Pitavastatin 1 mg|Pitavastatin 1 mg once daily
62238174|NCT00257686|ACTIVE_COMPARATOR|Pravastatin 10 mg|Pravastatin 10 mg once daily
62238175|NCT00257686|EXPERIMENTAL|Pitavastatin 2 mg|Pitavastatin 2 mg once daily
62238176|NCT00257686|ACTIVE_COMPARATOR|Pravastatin 20 mg|Pravastatin 20 mg once daily
62238177|NCT00257686|EXPERIMENTAL|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
62238178|NCT00257686|ACTIVE_COMPARATOR|Pravastatin 40 mg|Pravastatin 40 mg once daily
62238179|NCT06359951|EXPERIMENTAL|Project YES|"This is a digital, self-guided SSI that has 3 options, Project Personality, Project CARE, and the ABC project. These teach adolescents about CBT skills including growth mindset, neutral self-talk and behavioral activation. Each option contains self-reflection exercises, vignettes from fictional peers, and psychoeducation that support users in understanding each CBT skill.~See all materials for this intervention here: https://www.schleiderlab.org/yes.html"
62238180|NCT02701088|EXPERIMENTAL|Concomitant chemotherapy and radiotherapy|Chemoradiotherapy with two cycles of 5FU and Mitomycin-C plus radiotherapy by SIB-IMRT (for simultaneous integrated boost intensity modulated radiation therapy) day 1 to day 50 in 36 fractions
62814318|NCT03917849|EXPERIMENTAL|Inertial flywheel resistance training|The program is performed 3 times per week using resistance equipment in a fitness center. Inertial flywheel resistance is a type of strength training; which is based on the increasing demands on eccentric action (breaking) after a concentric action (acceleration), due to the inertial load caused during the return movement. The patients complete 12 repetition máximum (RM) with moment inertia 0.05 m² from week 1-6 and 8 repetition máximum (RM) with moment inertia = 0.10 m² from week 6-12.
62814319|NCT03469947|EXPERIMENTAL|Prehospital Tranexamic Acid|1 gram of Tranexamic Acid will be given during medical transport
62814320|NCT03469947|NO_INTERVENTION|Matched Controls|Retrospective matched controls
62814321|NCT02363335|PLACEBO_COMPARATOR|Placebo|randomized, double-blind, placebo-controlled cross-over study
62814322|NCT02363335|EXPERIMENTAL|Roflumilast|randomized, double-blind, placebo-controlled cross-over study
62814323|NCT02363335|EXPERIMENTAL|Roflumilast/Sitaglip|randomized, double-blind, placebo-controlled cross-over study
62814324|NCT02363335|EXPERIMENTAL|Sitagliptin|randomized, double-blind, placebo-controlled cross-over study
62814325|NCT04003285|EXPERIMENTAL|Placebo|ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)
62814326|NCT04003285|EXPERIMENTAL|ALLO 50 nM|ALLO 50 nM (lower dose ALLO: loading dose, 4 hour infusion, taper)
62814327|NCT04003285|EXPERIMENTAL|ALLO 150 nM|ALLO 150 nM (higher dose ALLO: loading dose, 4 hour infusion, taper)
62814328|NCT01893463||Patients which received the iTClamp as treatment|Use of the iTClamp50 will be determined by the EMS and ER physicians. Patients who have received treatment will be tracked from pre-hospital to patient discharge (chart review). EMS care providers and physicians will answer a survey about their experience with the iTClamp50.
62814329|NCT01344941||Group 1|The first group will comprise individuals who have received a St. Jude HIV-1 vaccine and who have exhibited sustained immune responses
62814330|NCT01344941||Group 2|Groups 2 will be HIV-1-infected. The first visit of individuals in groups 2 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.
62814331|NCT01344941||Group 3|Groups 3 will be HIV-1-uninfected. The first visit of individuals in groups 3 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.
62814332|NCT01598766|EXPERIMENTAL|Diagnostic Coil|This coil is a lightweight, flexible coil which can be used for many pediatric MRI exams
62814333|NCT00703014||Mothers Corifollitropin Alfa 150 µg|Participants from the Base Trial P05787 who received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recombinant Follicle Stimulating Hormone (recFSH); followed by daily SC injections with 200 IU recFSH up to the day of human chorionogonadotropin (hCG); multiple daily SC injections of Ganirelix from Stimulation Day 5 to the day of hCG; a single dose of hCG (5000 or 10,000 IU/USP) was administered when 3 follicles \>= 17 mm were observed; and on the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the Base Trial were enrolled in Follow Up Trial P05712, where no study treatments were given, and pregnancy, delivery and neonatal outcome were monitored.
62238181|NCT02952001||4 mg CLS-TA Suprachoriodal Injection|Those subjects randomized to the CLS-TA 4 mg arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.
62238182|NCT02952001||Sham procedure|Those subjects randomized to the sham procedure arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.
62238183|NCT03496181||Bilingual Participants with Glioma|"Bilingual (English and Spanish speaking) patients will be recruited from the clinical service of the Department of Neurosurgery of MSK. All patients on the Neurosurgery service scheduled to undergo a resection of a tumor in or adjacent to the primary language areas will be screened to participate in this study.~The study will be performed in concert with patient's regularly scheduled clinical care for his/her brain tumor. Clinical care (which will be performed whether or not the patient participates in the current study) will include: 1) pre-operative routine (anatomical) MRI and fMRI, 2) the surgery to remove the tumor, 3) intra-operative cortical stimulation to identify the essential motor and/or language areas. It should be stressed that neither the brain tumor surgery, nor the intra-operative cortical mapping will be changed in any way from routine practice."
62428715|NCT02917837|EXPERIMENTAL|Usual QCNL report plus detailing.|This group receives the usual QCNL report described above. Shortly after the reports are sent, this group will be contacted at least three times to attempt to arrange a single in-person detailing session.
62428716|NCT02917837|EXPERIMENTAL|New utilization report|This group will receive a new type of report that shows individual physician ordering per 100 patients compared to the mean of all physicians, adjusted for patient complexity (age, sex, comorbidity, education, income, rurality).
62428717|NCT02917837|EXPERIMENTAL|New utilization report plus detailing|New type of report plus detailing as described above.
62428718|NCT02932384|ACTIVE_COMPARATOR|Control-Passport Only|"Complete a needs assessment and develop a written Passport to Wellness, an itemized set of health promoting behaviors and services aligned with lifestyle and goals. Participants are compensated based on the items they complete, services they attend."
62428719|NCT02932384|EXPERIMENTAL|Intervention-Passport and Peer Mentor|"In addition to the Passport to Wellness developed with project staff, study participants will select a peer mentor trained in motivational interviewing. The peer mentor will help guide the participant to complete passport items. Part of passport development will include compensation for meeting with peer mentors to form strategies for meeting goals and addressing barriers/challenges that arise."
62428720|NCT01422720|EXPERIMENTAL|Eslicarbazepine Acetate tablets (800 mg)|
62428721|NCT06542094|EXPERIMENTAL|deep brain stimulation|
62428722|NCT00503932|EXPERIMENTAL|Proton Therapy + Capecitabine|Capecitabine 825 mg/m\^2 by mouth twice daily on Proton Therapy (radiation) days.
62428723|NCT05262933||coffee (n= 70)|Patients are planned to drink brewed coffee 2 hours before surgery.
62428724|NCT05262933||control (n=70)|Patients are planned to drink water 2 hours before surgery.
62428725|NCT04739956||Patient: point of care (POC) result not shared|Patients in this phase of the study will not be provided with the POC BhCG result. They will await the laboratory result. Simultaneously we will ascertain reliability of POC in clinical practice during this time.
62428726|NCT04739956||Partner: point of care (POC) result not shared|Partners in this phase of the study will not be informed of the POC BhCG result. They will await the laboratory result to be provided to the patient. Simultaneously we will ascertain reliability of POC in clinical practice during this time.
62814334|NCT00703014||Mothers recFSH 200 IU|Participants from the Base Trial P05787 who received a single SC injection of placebo Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 200 IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG; multiple daily SC injections of Ganirelix from Stimulation Day 5 to the day of hCG; a single dose of hCG (5000 or 10,000 IU/USP) was administered when 3 follicles \>= 17 mm were observed; and on the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the Base Trial were enrolled in Follow Up Trial P05712, where no study treatments were given, and pregnancy, delivery and neonatal outcome were monitored.
62814335|NCT02474797|EXPERIMENTAL|Diaphragmatic ultrasonography in septic patient|Diaphragmatic Thickening Fraction
62814336|NCT03107481|ACTIVE_COMPARATOR|Acetaminophen|
62814337|NCT03107481|ACTIVE_COMPARATOR|Hydromorphone|
62814338|NCT00987376|EXPERIMENTAL|1|Prostate cancer patients
62814339|NCT05449821||Periodontitis group|35 subjects had periodontitis. Periodontitis will be staged by including patients with a periodontal pocket (PD) measurement of 4 mm and above, accompanied by attachment loss and radiographic bone loss.
62814340|NCT05449821||Healthy group|30 subjects had healthy periodontal tissue.Healthy controls included volunteers with clinically healthy gingiva on an intact periodontium who had BOP \< 10% and PD ≤ 3 mm, no sites with attachment loss, no radiographic sign of alveolar bone destruction, and no history of periodontitis.
62814341|NCT05835505|ACTIVE_COMPARATOR|BRS201 Arm|"In Group 1 of the study, subjects will take oral study drug at 1.2g twice daily, PO (2.4g daily) for 4 weeks.~In Group 2 of the study, subjects will take oral study drug at 2g twice daily, PO (4g daily) for 4 weeks.~In Group 3 of the study, subjects will take receive a one-time 5g IV dose of the study drug using the FDA-approved IV product followed by the oral study drug at 2g twice daily, PO (4g daily) for 4 weeks.~In Group 4 of the study, subjects will repeat the previous conditions of the group that proves to be the most effective."
62814342|NCT05835505|PLACEBO_COMPARATOR|Placebo Arm|"In Group 1 of the study, subjects will take oral placebo at 1.2g twice daily, PO (2.4g daily) for 4 weeks.~In Group 2 of the study, subjects will take oral placebo at 2g twice daily, PO (4g daily) for 4 weeks.~In Group 3 of the study, subjects will take receive a one-time 5g IV dose of the study drug using the FDA-approved IV product followed by the oral placebo at 2g twice daily, PO (4g daily) for 4 weeks.~In Group 4 of the study, subjects will repeat the previous conditions of the group that proves to be the most effective."
62814343|NCT05236270|NO_INTERVENTION|Condition 1|Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
62814344|NCT05236270|EXPERIMENTAL|Condition 2|Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.
62814345|NCT05236270|EXPERIMENTAL|Condition 3|Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
62814346|NCT05236270|EXPERIMENTAL|Condition 4|Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.
62814347|NCT05236270|EXPERIMENTAL|Condition 5|Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.
62428727|NCT04739956||Patient: point of care (POC) result shared|Patients in this phase will be informed of the POC test result, which will reduce the time to which they receive the result. Prior to transfer to this phase, correlation between POC and laboratory BhCG levels will be calculated in order to confirm its reliability by creating a correlation curve using the data.
62037001|NCT05093036|EXPERIMENTAL|Arm 2: routine PrEP care at the CSH, monitoring 2 times per year|"Study participants in arm 2 follow routine care procedures but with a reduced frequency of monitoring visits, i.e. the number of monitoring visits is reduced from four to two times a year. Timing of the first monitoring visit differs per PrEP user type:~* Experienced PrEP users: first monitoring visit is six months after the enrolment into the study.~* PrEP-naïve participants: first monitoring visit is one month after enrolment in the study and start of PrEP use. The second monitoring visit is five months after the first monitoring visit (6 months after enrolment)."
62037002|NCT05093036|EXPERIMENTAL|Arm 3: online PrEP care, monitoring 4 times per year|"Study participants in arm 3 receive internet-based PrEP care, i.e. video consultations and online-mediated testing for HIV, STIs and renal function, online PrEP ordering and (at home) delivery of PrEP. Monitoring occurs four times per year.~* Experienced PrEP users: first monitoring contact is three months after the enrolment into the study.~* PrEP-naïve participants: first monitoring contact is one month after enrolment in the study and start of PrEP use. The second monitoring visit is 2 months after the first monitoring contact (3 months after enrolment)."
62037003|NCT05093036|EXPERIMENTAL|Arm 4: online PrEP care, monitoring 2 times per year|"Study participants in arm 4 receive internet-based PrEP care, i.e. video consultations and online-mediated testing for HIV, STIs and renal function, online PrEP ordering and (at home) delivery of PrEP. Monitoring occurs two times per year.~* Experienced PrEP users: first monitoring contact is six months after the enrolment into the study.~* PrEP-naïve participants: first monitoring contact is one month after enrolment in the study and start of PrEP use. The second monitoring visit is five months after the first monitoring contact (6 months after enrolment)."
62037004|NCT04395105|EXPERIMENTAL|High dose Dexamethasone|Intravenous Dexamethasone 16 mg qd from day 1 to 5 followed by 8 mg qd from day 6 to 10
62037005|NCT04395105|NO_INTERVENTION|Usual care - low dose Dexamethasone|Intravenous Dexamethasone 6 mg qd for 10 days based on RECOVERY trial
62037006|NCT04335682|ACTIVE_COMPARATOR|Darolutamide (DARO)|Patients will take DARO at a dose of 600 mg (300 mg ×2 tablets) by mouth twice daily beginning on Day 1, of Week 1. Patients will take DARO throughout planned treatment period or withdrawal of consent or progression of disease requiring change in therapy.
62037007|NCT04335682|ACTIVE_COMPARATOR|Enzalutamide (ENZ)|Patients will take ENZ at a dose of 160 mg PO once daily (QD), beginning on Day 1, of Week 1. Patients will take ENZ throughout planned treatment period or withdrawal of consent or progression of disease requiring change in therapy.
62037008|NCT00473798||A|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
62428728|NCT04739956||Partner: point of care (POC) result shared|Partners in this phase will be informed of the POC test result with the patient, which will reduce the time to which they receive the result. Prior to transfer to this phase, correlation between POC and laboratory BhCG levels will be calculated in order to confirm its reliability by creating a correlation curve using the data.
62428729|NCT00457665|ACTIVE_COMPARATOR|Nelfinavir (Viracept)|
62428730|NCT00457665|ACTIVE_COMPARATOR|Efavirenz (Sustiva)|
62428731|NCT04147611|EXPERIMENTAL|Remote Microphone (RM) Technology Group|"The RM technology group will limited to the pediatrics participants.~Participants will be tested separately on the three following conditions:~1. Bone Conduction Device (BAHA) only~2. BAHA + Wireless Audio-Streaming Accessory~3. BAHA + Digital Adaptive RM System"
62814348|NCT05236270|EXPERIMENTAL|Condition 6|Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an attention control educational message.
62037009|NCT00473798||A'|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
62037010|NCT00473798||B|Patients who have consented to participate in a randomized trial of optical spectroscopy.
62037011|NCT00473798||C|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
62037012|NCT00473798||D|Health care providers.
62428732|NCT04147611|ACTIVE_COMPARATOR|Normal Hearing Controls|"The normal hearing controls will be limited to 15 adults.~Participants will be tested separately on the six following conditions:~1. Unaided~2. Unilateral hearing aid with contralateral plug.~3. Unilateral hearing aid + Digital Adaptive RM System (using Roger™, Sonova)~4. Bone Conduction Device (BAHA) only~5. BAHA + Wireless Audio-Streaming Accessory~6. BAHA + Digital Adaptive RM System"
62428733|NCT03179371||1|Mothers whose fetus has CDH
62037013|NCT06116903|EXPERIMENTAL|Detection of molecular abnormalities|Blood samples will be taken from 2 + 3 Cell-Free DNA Collection tubes (Roche): for the comparative performance of the two methods (main objective) 3 Cell-Free DNA Collection tubes will be collected at 3 months (post chemotherapy) to evaluate the clinical relevance of a new analysis of molecular alterations on exosomes
62428734|NCT00123487|EXPERIMENTAL|dasatinib Twice a Day (BID)|70 mg dasatinib twice a day (BID)
62428735|NCT00123487|EXPERIMENTAL|dasatinib Once a Day (QD)|140 mg dasatinib once a day (QD)
62814349|NCT05236270|EXPERIMENTAL|Condition 7|Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
62596349|NCT06073054|EXPERIMENTAL|Research Pharmacist Monitoring|The pharmacist will help the mother find a primary care physician if she doesn't have one, obtain health insurance if she doesn't have any, and discuss any health-related information about herself or her child, as needed. These pharmacist interactions will occur 7 days after baseline and again 1 month later (the participant will be asked to measure and text their blood pressure again 1 time per day for 3 days during the follow-up month). If the participant's blood pressures become elevated, the pharmacist will provide behavioral and lifestyle interventions to attempt to lower the blood pressure. They may also recommend medications to the participant's physician. The pharmacist will have access to the participant's electronic medical record to obtain any blood pressure-related medications that the mother is prescribed as well as throughout the follow up to ensure any health-related conditions can be discussed, as necessary.
62428736|NCT02543086|EXPERIMENTAL|Multiple Sequential Cohort|"This study is divided in 2 parts (Part A and part B). Each participant in each of the cohorts will be inoculated with viable parasites of Plasmodium falciparum-infected human erythrocytes administered intravenously. For Part A \& Part B, commencement of treatment will be determined by Quantitative-Polymerase Chain Reaction results.~The First cohort of Part A (A1) will be dosed with a single dose of KAE609. During Part A, an additional second single-dose of KAE609 may be tested (\~15 days after first dose of KAE609 but may vary) if sexual parasitemia is identified. Subsequent cohorts of part A (An) will be dosed based on the results of first cohort (A1).~Subjects enrolled in Cohort B will receive a pre-treatment with Piperaquine followed by KAE609 (\~15 days)."
62428737|NCT01386619|EXPERIMENTAL|NK cell DLI|
62596350|NCT02327338|EXPERIMENTAL|continuous low level heat for neck|30 subjects to use ThermaCare heat wraps on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where heat wraps are not used.
62596351|NCT02327338|EXPERIMENTAL|Ibuprofen and continuous low level heat|30 subjects to use 1200 mg per day Ibuprofen dosed in 3 dosages 4 hours apart on the same days as heat wraps were to be used. ThermaCare heat wraps to be used on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where heat wraps and ibuprofen are not used.
62596352|NCT02327338|NO_INTERVENTION|control|15 subjects with no heat or ibuprofen just physical therapy 2 times per week.
62596353|NCT02327338|SHAM_COMPARATOR|sham heat and sham ibuprofen|30 subjects to use 1200 mg per day Ibuprofen sham dosed in 3 dosages 4 hours apart on the same days as sham heat wraps were to be used. ThermaCare heat sham wraps to be used on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where sham heat wraps andsham ibuprofen are not used.
62596354|NCT05353582|EXPERIMENTAL|Chemotherapy group|6 cycles of mFOLFOXIRI±Bev is followed by cytoreductive surgery. Postoperative 6 cycles of mFOLFOX is scheduled.
62596355|NCT05353582|ACTIVE_COMPARATOR|Upfront surgery group|Upfront surgery group is followed by 12 cycles of mFOLFOX+Bev
62596356|NCT00850304|EXPERIMENTAL|Arm one|
62596357|NCT06618911|EXPERIMENTAL|5 Hz Electroacupuncture Group|"Participants will receive electroacupuncture at a frequency of 5 Hz at four acupoints: Liangmen (ST21) and Tianshu (ST25) (local acupoints), and Zusanli (ST36) and Xiajuxu (ST39) (distal acupoints). Disposable needles will be inserted until the deqi sensation is achieved. The needles will be connected to an SDZ-IIB electroacupuncture device set at 5 Hz, with stimulation lasting 30 minutes per session. Participants will receive 3 sessions per week for 4 weeks (total: 12 sessions). This group aims to evaluate the efficacy of low-frequency electroacupuncture for treating functional dyspepsia."
62596358|NCT06618911|EXPERIMENTAL|100 Hz Electroacupuncture Group|"Participants will receive electroacupuncture at a frequency of 100 Hz at the same four acupoints: Liangmen (ST21), Tianshu (ST25), Zusanli (ST36), and Xiajuxu (ST39). Needles will be inserted to induce the deqi sensation and connected to an SDZ-IIB device set at 100 Hz, with stimulation lasting 30 minutes per session. Participants will receive 3 sessions per week for 4 weeks (total: 12 sessions). This group assesses the efficacy of high-frequency electroacupuncture for functional dyspepsia."
62428738|NCT02869828|OTHER|monitoring by arterial catheter and Spot-on|
62596359|NCT06618911|SHAM_COMPARATOR|Sham Electroacupuncture (Control) Group|"Participants will receive sham electroacupuncture at the same acupoints: Liangmen (ST21), Tianshu (ST25), Zusanli (ST36), and Xiajuxu (ST39). Non-penetrating needles will touch the skin but will not induce deqi. A sham electroacupuncture device (no actual current) will be used, and treatment will last 30 minutes per session. Participants will receive 3 sessions per week for 4 weeks (total: 12 sessions). This arm serves as a placebo control to evaluate the true effect of electroacupuncture."
62596360|NCT04513847||Control|Psoriasis patients treated with non-biologic
62037014|NCT06217328|OTHER|Device: Revi System Treatment Arm|Subjects will be implanted with a Revi System and activation of therapy will occur \~4 weeks post implantation and continue for the duration of the study.
62037015|NCT06217328|OTHER|Device: Revi System - Delayed Activation Control Arm|Subjects will be implanted with a Revi System and activation of therapy will be delayed until 4 months post implantation. At this time the Revi System will be activated to begin therapy and will continue for the duration of the study.
62428739|NCT02869828|OTHER|monitoring by oesophagus tube and Spot-on|
62596361|NCT04513847||Non-Control|Psoriasis patients treated with biologic
62596362|NCT06502964|EXPERIMENTAL|ALTO-101|10 days administration of ALTO-101T transdermal delivery system (18-27 mg/day as a total of 6 patches/day)
62037016|NCT04989790|NO_INTERVENTION|Baseline/Pre-implementation|Usual PICU care
62037017|NCT04989790|ACTIVE_COMPARATOR|Intervention/Post-implementation|PICU Up! is a multifaceted, inter-professional pathway that is integrated into routine PICU practice to safely optimize early and progressive patient mobility.
62037018|NCT06564441|EXPERIMENTAL|All participants|In Period 1: Bupropion, Caffeine, Midazolam are given as a reference treatment. In Period 2: Survodutide, Bupropion, Caffeine, Midazolam are given as a test treatment.
62428740|NCT03174041|EXPERIMENTAL|Part 1|Participants will receive a single dose of midazolam followed by multiple doses of GDC-0853 coadministered with a single dose of midazolam.
62814350|NCT05236270|EXPERIMENTAL|Condition 8|Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.
62814351|NCT01303341|EXPERIMENTAL|Treatment (riluzole and sorafenib tosylate)|Patients receive riluzole PO BID and sorafenib tosylate PO QD or BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62428741|NCT03174041|EXPERIMENTAL|Part 2|Participants will receive a single dose of rosuvastatin followed by multiple doses of GDC-0853 coadministered with a single dose of rosuvastatin.
62428742|NCT03174041|EXPERIMENTAL|Part 3|Participants will receive a single dose of simvastatin followed by multiple doses of GDC-0853 coadministered with a single dose of simvastatin.
62596363|NCT06502964|PLACEBO_COMPARATOR|Placebo|10 days administration of placebo transdermal delivery system (with a total of 6 placebo patches/day)
62596364|NCT02590575|OTHER|CO2 removal|
62596365|NCT06649266|EXPERIMENTAL|Active group|Participants will receive RBD1016 (subcutaneous injections).
62596366|NCT06649266|OTHER|Deferred active group|Participants will receive 4 doses of placebo (subcutaneous injections) followed by RBD1016 (subcutaneous injections).
62596367|NCT05303194|OTHER|Patient Priorities Care (PPC) Adaptation|5 Hispanic patients with multiple chronic conditions (MCC) and no dementia. In order to adapt PPC for Hispanics with MCC, five Hispanics with MCC will go through the 2 parts of the PPC approach: 1) Priority setting; and 2) Care alignment.
62596368|NCT05303194|OTHER|PPC Feasibility Testing|20 Hispanic patients with multiple chronic conditions (MCC), including dementia. In order to adapt PPC for Hispanics with MCC and dementia, twenty Hispanics with MCC and dementia will go through the 2 parts of the PPC approach: 1) Priority setting; and 2) Care alignment.
62596369|NCT04985448||Conbercept|In clinical treatment and research, the applied doses of Conbercept in patients with retinopathy of prematurity have been reduced compared with adults, mostly half of the adult dose. The commonly used exposure dose of intravitreal injection of Conbercept ophthalmic injection is 0.25mg/0.025ml.In addition, possible exposure doses are but not limited to 0.15mg/0.15ml, 0.1mg/ 0.1ml, 0.2mg/0.2ml, etc.
62596370|NCT04985448||Ranibizumab|In clinical treatment and research, the applied doses of Ranibizumab in patients with retinopathy of prematurity have been reduced compared with adults, mostly half of the adult dose. The commonly used exposure dose of intravitreal injection of Ranibizumab ophthalmic injection is 0.25mg/0.025ml.In addition, possible exposure doses are but not limited to 0.15mg/0.15ml, 0.1mg/ 0.1ml, 0.2mg/0.2ml, etc.
62428743|NCT03174041|EXPERIMENTAL|Part 4|Participants will receive a single dose of GDC-0853 followed by multiple doses of itraconazole coadministered with a single dose of GDC-0853.
62428744|NCT02120482|EXPERIMENTAL|Combined apheresis|Patients will be treated by semiselective immunoadsorption combined with membrane filtration
62596371|NCT04985448||Laser Treatment|In clinical and research studies, lasers are used to treat patients with retinopathy of prematurity.
62814352|NCT04545749|EXPERIMENTAL|Group A (Low dose)|20 subjects will be enrolled to receive low dose of UB-612 vaccine.
62814353|NCT04545749|EXPERIMENTAL|Group B (Medium dose)|20 subjects will be enrolled to receive medium dose of UB-612 vaccine.
62814354|NCT04545749|EXPERIMENTAL|Group C (High dose)|20 subjects will be enrolled to receive high dose of UB-612 vaccine.
62814355|NCT05723653|EXPERIMENTAL|Project nGage Condition|"The Project nGage condition will be delivered by trained Intervention Case Managers to n=300 men (referred to as Index men) and their Support Confidant (SC).~The Project nGage intervention consists of (1) selection and invitation of a SC, (2) a face-to-face intervention between the Intervention Case Manager and the Index and SC, and (3) quarterly interactive mini-booster sessions delivered to the Index and SC via text or telephone, based on participant preference.~At 12 months, Index men in the experimental condition will be re-randomized to either continue receiving quarterly interactive mini-booster sessions or to stop receiving mini-boosters and return to treatment as usual."
62596372|NCT06618417|EXPERIMENTAL|Intervention|The intervention will be sleep apnea home-evaluation
62037019|NCT02172755|EXPERIMENTAL|Elderly subjects|14 Elderly subjects aged 65 years or more; During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
62037020|NCT02172755|EXPERIMENTAL|Young subjects|16 young subjects aged between 18 and 40 years During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
62037021|NCT02540018|ACTIVE_COMPARATOR|Paclitaxel-coated Luminor® Balloon Catheter|The balloon dilatation procedure, including deployment to the target lesion and balloon inflation, deflation and retrieval, is performed under fluoroscopic observation. An endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion is mandatory. After pre-dilatation of the target lesion an angiographic assessment will be performed (DSA or XA). Randomization will be performed by envelope pull. The treatment group represents the Luminor® DEB PTA. After dilation of the target lesion, the PTA catheter is withdrawn through the introducer sheath, and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.
62037022|NCT02540018|ACTIVE_COMPARATOR|Uncoated Balloon Catheter|Identical procedure also for control arm with PTA balloon (see below): After pre-dilatation, randomization will be performed by envelope pull. The control group requires an uncoated balloon catheter. After dilation of the target lesion, the PTA catheter is withdrawn and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.
62037023|NCT03541070|EXPERIMENTAL|Kinesiology taping|For tibialis anterior muscle taping, each children's feet were placed at plantar flexion and eversion position while knees were extended, and I-shaped band was applied over tibialis anterior from origin to insertion of muscle with approximately 25-50% tension of the original length of the band. No tension was applied to the first and last 5 cm section of the bands in both applications because it were used as anchor. The tapes were remained for 1 hour on skin of both quadriceps and tibialis anterior muscles, and in this time the children were rested.
62238184|NCT03496181||Healthy Volunteers|Normal, healthy volunteers who express interest in participation and who meet the eligibility criteria will be recruited for this study. It is anticipated that healthy volunteers will mostly consist of medical professionals. They will consist of 10 monolinguals (defined as native English speakers), 10 early bilinguals (defined as acquiring proficiency in the second language before 10 years of age), and 10 late bilinguals (defined as acquiring proficiency in the second language after 10 years of age).
62238185|NCT00909792|OTHER|Lotrafilcon B / Senofilcon A|Lotrafilcon B, followed by Senofilcon A
62238186|NCT00909792|OTHER|Senofilcon A / Lotrafilcon B|Senofilcon A, followed by Lotrafilcon B
62238187|NCT00898443|OTHER|Spinal Anesthetic Group|This group will receive spinal anesthetic for the surgical procedure and will serve as the control group for this study.
62238188|NCT00898443|EXPERIMENTAL|Epidural Anesthetic Group|This is the experimental group for this study.
62238189|NCT01055262|EXPERIMENTAL|Heatwrap 1|Experimental heatwrap device for the lower back
62238190|NCT00826111|ACTIVE_COMPARATOR|Eszopiclone|Lexapro for 10 weeks together with eszopiclone.
62238191|NCT00826111|PLACEBO_COMPARATOR|Placebo|Lexapro for 10 weeks together with placebo.
62238192|NCT04940065||Kesimpta|Patients treated with Kesimpta
62238193|NCT01884649||Group of Hashimoto thyroiditis patients|
62238194|NCT01884649||Healty control group|
62238195|NCT03594851|EXPERIMENTAL|Administration of individualized advice|"Administration of individualized advice to improve the quality of older people's sleep, based on the following interventions :~Pittsburgh Sleep Quality Index, Sleep diary, Mini Mental State Examination, Autonomy assessment (Katz Index of Independence in Activities of Daily Living~\& Lawton Instrumental Activities of Daily Living), Neuropsychiatric Inventory (Cummings) for the caregiver, if applicable, Mini Zarit Caregiver Burden Scale, for the caregiver, if applicable, Cornell Scale for Depression in Dementia, Quality of Life in Alzheimer's Disease, Neuropsychiatric Inventory"
62238196|NCT01268722|ACTIVE_COMPARATOR|Balloon|
62238197|NCT01268722|EXPERIMENTAL|Stent|
62238198|NCT06288321|PLACEBO_COMPARATOR|Standard Mydrin-P Group|Subjects allocated to the Standard Mydrin P group will receive standard Mydrin-P (0.5% tropicamide / 0.5% phenylephrine HCl) which is the standard eyedrops used for dilation of pupil before retinopathy of prematurity examination.
62238199|NCT06288321|EXPERIMENTAL|Microdrop group|Those allocated to the microdrop group will receive microdrop Mydrin-P for pupil dilation before retinopathy of prematurity exam.
62238200|NCT00610597||1|alcoholic liver disease
62238201|NCT00610597||2|chronic hepatitis C virus infection
62596373|NCT06618417|NO_INTERVENTION|Control|This arm will not undergo sleep apnea home-evaluation
62596374|NCT05954845|EXPERIMENTAL|colonic biopsies|participants will have colonic biopsies taken following a colonoscopy/rectosigmoidoscopy previously indicated for spinal cord injured patients.
62596375|NCT06644469|PLACEBO_COMPARATOR|Control Group with placebo vibration therapy|Participants will perform the same activities as the experimental group, but with a vertical displacement of 0.22 mm, deemed therapeutically insufficient.
62238202|NCT01562171|EXPERIMENTAL|Cooked Lentils|The study group will be asked to consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
62238203|NCT01562171|ACTIVE_COMPARATOR|Potato-Based Foods|The control group will be asked to consume one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
62428745|NCT02097368||neuromuscular patient|Patients affected by neuromuscular pathology will be explored by tongue strength measurement, respiratory function measurement, swallowing tests and Magnetic resonance imaging
62428746|NCT01770782|OTHER|Laser Scanner|Laser Scanner (Vivid 9i® - Konica Minolta)was used to digitize the study casts. After scanning the dental casts a 3D virtual dental casts was used to realize all measurements (pre-treatment, 4 months and 10 months).
62428747|NCT01770782|OTHER|SARME|Surgically Assisted rapid Maxillary Expansion -SARME was used for the treatment of transverse maxillary deficiency.This procedure is a combination of a surgical procedure and orthopedic expansion of the maxilla.
62428748|NCT02007369|EXPERIMENTAL|WhatsApp|Provide peer support and deliver relapse prevention messages through WhatsApp for 8 weeks and telephone follow ups
62428749|NCT02007369|EXPERIMENTAL|Facebook|Provide peer support and deliver relapse prevention messages through Facebook for 8 weeks and telephone follow ups
62428750|NCT02007369|NO_INTERVENTION|Control|Telephone follow ups and received a self-help book only
62428751|NCT03726437|EXPERIMENTAL|RealConsent|A 3-hour web-based program designed to teach female college freshmen strategies to reduce their risk of sexual violence victimization.
62428752|NCT03726437|PLACEBO_COMPARATOR|Stress and Mood Management|A 3-hour general mental health web-based program.
62428753|NCT01800669|EXPERIMENTAL|Intervention|Use of the complete CHICA MLP module in routine clinical care. The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
62428754|NCT01800669|ACTIVE_COMPARATOR|Control|CHICA without the MLP module. This version includes a module that screens families for medical-legal issue but does not provide additional guidance or referrals to resolve them.
62428755|NCT02902666|EXPERIMENTAL|Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet|"A single dose of the experimental drug will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 1) or after (treatment arm 2) a wash-out interval of at least 7 days between the active comparator administration.~Test formulation will be administered as a single dose of one paracetamol 1000 mg/codeine 30 mg tablet."
62428756|NCT02902666|ACTIVE_COMPARATOR|paracetamol 500mg/codeine phosphate hemihydrate 30mg 2 tablets|A single dose of active comparator will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 2) or after (treatment arm 1) a wash-out interval of at least 7 days between the experimental drug administration. Reference formulation will be administered as a single dose of two 500 mg/30 mg tablets.
62428757|NCT05617573||Patients undergone TKA due to advanced knee osteoarthritis|
62428758|NCT05474261||GROUP A-NO Valsalva maneuver|
62428759|NCT05474261||GROUP B- Valsalva maneuver|
62428760|NCT03648086|EXPERIMENTAL|IMT|30 non-alcoholic fatty liver disease（NAFLD） patients will be recruited for the study, which involved a 6 times intestinal microbiota transplant(IMT) and the time interval is generally 2 weeks.
62428761|NCT03648086|NO_INTERVENTION|control|30 non-alcoholic fatty liver disease(NAFLD) patients without any treatment
62428762|NCT03912688|EXPERIMENTAL|single acupoint stimulation|
62428763|NCT03912688|EXPERIMENTAL|dual acupoints stimulation|
62428764|NCT03912688|NO_INTERVENTION|no stimulation|
62428765|NCT01774695|OTHER|Control and intervention|In the first study half of the subjects first served as controls for 12 weeks and then they went through the intervention. The other half only went through the intervention.
62428766|NCT02184507|EXPERIMENTAL|Supplement pre CABG|Consumption of the supplement 7 days before surgery and placebo 30 days post surgery
62037024|NCT03492281|EXPERIMENTAL|Vibegron + Placebo to match Tolterodine|
62037025|NCT03492281|PLACEBO_COMPARATOR|Placebo to match vibegron + Placebo to match Tolterodine|
62037026|NCT03492281|ACTIVE_COMPARATOR|Tolterodine + Placebo to match vibegron|
62037027|NCT05197894|EXPERIMENTAL|VR experience|Participants will be given a list of VR applications to choose from. They will then be given instructions by a research assistant (approximately 10 minutes) on how to use the selected application they have chosen, as well as time for any questions they may have before starting their VR experience. They will then have an approximately 30-minute session of that VR experience. They may or may not be accompanied by a family member or significant other and will also have a research assistant available to aid them in any difficulties experienced during the VR experience.
62037028|NCT05074628|EXPERIMENTAL|Nitrofurantion|is the drug of choice for the treatment of infections caused by multidrug resistant pathogens.
62037029|NCT05074628|ACTIVE_COMPARATOR|Calcium Hydroxide|Most commonly used intracanal medicaments . Antimicrobial activity of calcium hydroxide is related to the release of hydroxyl ions in an aqueous environment.
62037030|NCT03299010||DM patient|Patients with a documented clinical diagnosis of DM and were receiving care in the Hospital Authority (HA) primary care General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) on or before 1 July 2006 identified from the HA clinical management system (CMS) database.
62037031|NCT03328754|EXPERIMENTAL|Group 1 Powerscope|Powerscope placed bilaterally for class II correction
62238204|NCT03510988|EXPERIMENTAL|Women with newly diagnosed breast cancer|Women with newly diagnosed breast cancer recruited for hybrid dedicated breast PET/MRI for extent of disease staging prior to management in lieu of breast MRI alone. IV FDG and Gadolinium was injected once prior to the study as per protocol and weight. In each second consecutively recruited patient FDG dosage was decreased by 20% up to 40% of weight-based dosage to ascertain feasibility of imaging at lower FDG dosages. IV Gadolinium was injected once with weight dependent dosages as per clinical standard of care.
62428767|NCT02184507|EXPERIMENTAL|Supplement post CABG|Consumption of placebo 7 days before surgery and supplement 30 days post surgery
62428768|NCT02184507|EXPERIMENTAL|Supplement pre and post CABG|Consumption of the supplement 7 days before and 30 days post surgery
62428769|NCT02184507|PLACEBO_COMPARATOR|Placebo|Consumption of placebo 7 days before and 30 days post surgery
62238205|NCT04312464||Discharged group|The individual which is defined as patient discharged from hospital
62238206|NCT04312464||Dead group|The individual which is defined as patient with all-cause death
62238207|NCT00356460|EXPERIMENTAL|1 - Part 1|Dose Group
62238208|NCT00356460|EXPERIMENTAL|2 - Part 1|Dose Group
62428770|NCT06514924||young Turkish males|Aged between 18 - 26 years old Istanbul University students Gender: Male
62428771|NCT06514924||young Turkish females|Aged between 18 - 26 years old Istanbul University students Gender: Female
62037032|NCT03328754|EXPERIMENTAL|Group 2 Forsus|Forsus placed bilaterally for class II correction
62037033|NCT01108848||Berinert|Patients requiring treatment with Berinert®
62037034|NCT01460940|EXPERIMENTAL|Lenalidomide and Panobinostat|In the phase I trial, three patients will be enrolled at each dose level, starting at dose level 1 using a standard 3 + 3 dose escalation phase I design.
62037035|NCT00974324|EXPERIMENTAL|treatment|endostar combined with CHOP regimen
62037036|NCT02157805|ACTIVE_COMPARATOR|rare beef meat|beef meat cooked during 5 minutes at 55°C
62037037|NCT02157805|ACTIVE_COMPARATOR|well cook beef meat|beef meat cooked during 30 minutes à 90°C
62037038|NCT04656834||Hand incision closure type 1|The participating surgeon closes the hand surgical incision via the standard method based on personal preference: buried monocryl sutures and skin glue
62037039|NCT04656834||Hand incision closure type 2|The participating surgeon closes the hand surgical incision via the standard method based on personal preference: simple nylon sutures
62037040|NCT03214562|EXPERIMENTAL|Treatment (venetoclax, FLAG-IDA)|See detailed description.
62037041|NCT01774149|ACTIVE_COMPARATOR|Delayed Diastat|Mobile phone application Few Touch Application (FTA) in the regular version, with Diastat turned on in week 12 post-enrollment.
62037042|NCT01774149|EXPERIMENTAL|Diastat|Few Touch Application with Diastat module turned on in week 4 post-enrollment.
62037043|NCT05662033|EXPERIMENTAL|Part 1 (SAD): Cohort 1|6 Healthy participants will receive a single oral dose A of AZD6793 and 2 healthy participants will receive placebo
62037044|NCT05662033|EXPERIMENTAL|Part 1 (SAD): Cohort 2|6 Healthy participants will receive a single oral dose B of AZD6793 and 2 healthy participants will receive placebo
62037045|NCT05662033|EXPERIMENTAL|Part 1 (SAD): Cohort 3|6 Healthy participants will receive a single oral dose C of AZD6793 and 2 healthy participants will receive placebo
62037046|NCT05662033|EXPERIMENTAL|Part 1 (SAD): Cohort 4|6 Healthy participants will receive a single oral dose D of AZD6793 and 2 healthy participants will receive placebo
62037047|NCT05662033|EXPERIMENTAL|Part 1 (SAD): Cohort 5|6 Healthy participants will receive a single oral dose E of AZD6793 and 2 healthy participants will receive placebo
62238209|NCT00356460|EXPERIMENTAL|3 - Part 1|Dose Group
62238210|NCT00356460|EXPERIMENTAL|4 - Part 1|Dose Group
62238211|NCT00356460|EXPERIMENTAL|5 - Part 1|Dose Group
62238212|NCT00356460|EXPERIMENTAL|6 - Part 1|Dose Group
62238213|NCT00356460|EXPERIMENTAL|1 (Part 2)|
62037048|NCT05662033|EXPERIMENTAL|Part 2 (MAD): Cohort 1|6 Healthy participants will receive dose W of AZD6793 and 2 healthy participants will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7
62238214|NCT00356460|EXPERIMENTAL|2 (part 2)|
62238215|NCT05066698|EXPERIMENTAL|ST266|Topical ocular application: one drop in the study eye four times a day for 8 weeks
62238216|NCT05066698|PLACEBO_COMPARATOR|Placebo|Topical ocular application: one drop in the study eye four times a day for 8 weeks
62428772|NCT01521767|EXPERIMENTAL|A|4 mg tolterodine extended release capsules, administered with water and under fasting condition.
62428773|NCT01521767|EXPERIMENTAL|B|4 mg microspheres in powder blend release rate 2 (MPB-RR2), administered without water and under fasting condition.
62428774|NCT01521767|EXPERIMENTAL|C|4 mg microspheres in powder blend release rate 1 (MPB-RR1), administered without water and under fasting condition.
62428775|NCT01521767|EXPERIMENTAL|D|4 mg MPB-RR1, administered without water and under fed condition.
62428776|NCT01521767|EXPERIMENTAL|E|4 mg MPB-RR1, administered with water and under fasting condition.
62428777|NCT06254391|OTHER|Very low-dose aspirin first|"Patients will receive ASA 30mg per day (in the morning) for 14 days, followed by ASA 75mg per day (in the morning) for the next 14 days.~All the participants will receive standard maintenance dose of ticagrelor 90mg twice a day as part of the DAPT therapy. All the participants will receive the loading dose of ASA 300mg before the PCI procedure."
62428778|NCT06254391|OTHER|Standard low-dose aspirin first|"Patients will receive ASA 75mg per day (in the morning) for 14 days, followed by ASA 30mg per day (in the morning) for the next 14 days.~All the participants will receive standard maintenance dose of ticagrelor 90mg twice a day as part of the DAPT therapy. All the participants will receive the loading dose of ASA 300mg before the PCI procedure."
62428779|NCT05766215|EXPERIMENTAL|Therapeutic patients education|3 sessions of structured therapeutic patient education (TPE) in which diet, exercise, alcohol abuse and insulin or pharmacological treatment management advise is given.
62428780|NCT03843255||Part 1: Dilated Cardiomyopathy patients|Approximately 1200 patients recruited prospectively from participating sites with a diagnosis of Dilated Cardiomyopathy (DCM). Will also include approximately 800 retrospective patients diagnosed with DCM currently biobanked by the lead site.
62428781|NCT03843255||Part 2: Heritable Cardiovascular Disease|Patients may be recruited with other diagnosed heritable cardiovascular disorders. Family members of patients may be invited to take part in the study. Children may also be approached to take part in the study.
62428782|NCT04288011||Clinical EDSS|The Kurtzke EDSS, is a clinical rating scale for multiple sclerosis having scores between 0 to 10 that are assigned by a trained clinician. Smaller impairments are assessed at lower scores and disability is assessed at higher scores. It is important to note, however, that despite being denoted on an ordinal scale, each level on the scale is not indicative of an equal change in disability.
62428783|NCT04288011||MLA EDSS|The Kurtzke EDSS, is a clinical rating scale or multiple sclerosis having scores between 0 to 10 that are assigned by a technique based upon several different Machine Learning Algorithms that are combined to produce a single score
62428784|NCT03285334|EXPERIMENTAL|XP-endo Shaper|The XP-endo Shaper is an innovative single instrument manufactured from Max wire. Its special ability to shift crystalline structure at body temperature in order to adapt to the root canal wall, has provided a unique instrument with the promise of anatomical shaping.
62037049|NCT05662033|EXPERIMENTAL|Part 2 (MAD): Cohort 2|6 Healthy participants will receive dose X of AZD6793 and 2 healthy participants will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7
62037050|NCT05662033|EXPERIMENTAL|Part 2 (MAD): Cohort 3|6 Healthy participants will receive dose Y of AZD6793 and 2 healthy participants will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7
62238217|NCT00424866|PLACEBO_COMPARATOR|Placebo|The dosing groups correspond to total doses of 0 µg/kg of FGF-1.
62238218|NCT00424866|ACTIVE_COMPARATOR|Human FGF-1|The dosing groups correspond to total doses of either 3, 10 or 30 µg/kg of FGF-1.
62238219|NCT01774851|EXPERIMENTAL|Arm 1a|MM-111 + Paclitaxel + Trastuzumab
62238220|NCT01774851|ACTIVE_COMPARATOR|Arm 1b|Paclitaxel + Trastuzumab
62238221|NCT01956500|EXPERIMENTAL|Instaflex|Instaflex Joint Support supplement (3 capsules per day for 8 weeks)
62238222|NCT01956500|PLACEBO_COMPARATOR|Placebo|Placebo (3 capsules per day for 8 weeks)
62238223|NCT01764113|EXPERIMENTAL|Mindful Eating|Subjects and at least one of their parents will receive mindful eating based behavioral modification program
62238224|NCT01764113|ACTIVE_COMPARATOR|Standard Dietary Couseling|Subjects and their parents will receive standard nutritional counseling provided by a registered dietician
62238225|NCT03023228|EXPERIMENTAL|diabetes self-management education|Diabetes survival skills self-management education (DSME) program content was aligned with American Diabetes Association and Joint Commission suggested key areas for hospital diabetes education. Content areas were as follows: when and how to take diabetes medications; glycemic goals and self-blood glucose monitoring; definition, prevention, recognition, and treatment of hypoglycemia and hyperglycemia; what to do before you see the dietitian; sick day management; and when to call the doctor or go to the ED. Program content was created for delivery via either DVD or print format.
62238226|NCT03291704|EXPERIMENTAL|Thermal Therapy|Heat application using at home thermal therapy device
62238227|NCT01765179|EXPERIMENTAL|Oral testosterone undecanoate|
62238228|NCT05555511|ACTIVE_COMPARATOR|N-acetylcysteine group|(23 Patients) Patients will recieve N-acetylcysteine 600 mg intravenous(IV) every 12 hours 24 hours before surgery and will be continued for 48 hours after surgery
62428785|NCT03285334|ACTIVE_COMPARATOR|iRace|rotary files
62428786|NCT03151993|EXPERIMENTAL|Recombinant staphylokinase|Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
62814356|NCT05723653|NO_INTERVENTION|Treatment as Usual Condition|Treatment as Usual (TAU) is comprehensive and follows Department of Health and Human Services (DHHS) guidelines and local protocols on the provision of HIV primary care, which include scheduling one HIV primary care visit and lab tests (including viral load) once every six months, i.e., two HIV primary care visits per year. In addition, all sites provide standard case management and mental health and psychosocial support services to all patients.
62814357|NCT03674528||Control Group|Subjects with a BMI of 35 or more will be asked to undergo a single MRE imaging session.
62814358|NCT03674528||Patient Group|Adults that are candidates for weight loss surgery will be asked to participate in four study visits that include MRE imaging and 1 - 2 liver biopsy procedures.
62238229|NCT05555511|NO_INTERVENTION|Standard group|Patients will not receive N-Acetylcysteine and will receive standard care according to our institutional protocol
62238230|NCT00550368|EXPERIMENTAL|Helicobacter pylori negative|Persons who tested negative for H. pylori by both serology and Urea breath test. All participants will receive the Biological intervention: Enteropathogenic E. coli.
62238231|NCT00550368|EXPERIMENTAL|Helicobacter pylori positive|Persons who tested positive for H. pylori by both serology and Urea breath test. All participants will receive the Biological intervention: Enteropathogenic E. coli.
62238232|NCT05689983|ACTIVE_COMPARATOR|As needed inhaled corticosteroid and long-acting beta-agonist|Symptom-driven ICS/LABA treatment strategy
62238233|NCT05689983|PLACEBO_COMPARATOR|Standard therapy: maintenance inhaled corticosteroid and as needed short-acting beta-agonist|Continue maintenance ICS and SABA therapy
62238234|NCT03953703|EXPERIMENTAL|Experimental: Levocarnitine, Placebo|1000 mg of levocarnitine twice per day for six weeks, a two week washout period, 1000 mg of placebo twice per day for 6 weeks
62238235|NCT03953703|EXPERIMENTAL|Experimental: Placebo, Levocarnitine|1000 mg of placebo twice per day for six weeks, a two week washout period, 1000 mg of levocarnitine twice per day for 6 weeks
62238236|NCT04777253|EXPERIMENTAL|Biofeedback method and Health-resort based rehabilitation|Health-resort based treatments supplemented with biofeedback training
62238237|NCT04777253|OTHER|Health-resort based rehabilitation|Control group - health-resort based treatments, without biofeedback training.
62238238|NCT05325697|EXPERIMENTAL|Single - Arm|12 weeks intervention with a combined physical exercise program (vivifrail) and oral nutritional supplementation (Moltein Plus)
62238239|NCT00533741|EXPERIMENTAL|1c (10 mcg)|4 subjects randomized in a 1:3 fashion to receive a two dose regimen of placebo or vaccine with 10 mcg of antigen and no adjuvant.
62238240|NCT00533741|EXPERIMENTAL|2 (dose comparison stage)|54 subjects (9 per vaccine group) randomized 1:1:1:1:1:1 to receive vaccines containing, 2.5, 5.0, or 10.0 mcg of antigen without adjuvant, or 2.5 or 5.0 mcg of antigen with Alum, or placebo.
62238241|NCT00533741|EXPERIMENTAL|1a (2.5 mcg)|7 subjects randomized in a 1:3:3 fashion to receive a 2 dose regimen of placebo, vaccine containing 2.5 mcg of antigen and no adjuvant, or 2.5 mcg of antigen and Alum adjuvant.
62428787|NCT03151993|ACTIVE_COMPARATOR|Actilyse|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
62428788|NCT05472857|EXPERIMENTAL|anti-claudin18.2 chimeric antigen receptor T-cell therapy|anti-claudin18.2 chimeric antigen receptor T-cell therapy，infusion
62428789|NCT02684669|EXPERIMENTAL|High-dose naloxone|naloxone 4 mg/ml i.v. infusion, total 3.25 mg/kg, target controlled infusion with three infusion rates (0.25 mg/kg; 0.75 mg/kg; 2.25 mg/kg) each of 25 min duration.
62814359|NCT06459479|EXPERIMENTAL|AI Group|Participant will be using OpenAI's ChatGPT4o's application. For the purposes of this medical error scenario, the CAI will have a standardized prompt to simulate an upset parent whose child recently had surgery in which there was a medical error involving a tooth injury from an intubation. Following a scripted briefing, simulation will be initiated.
62596376|NCT06644469|EXPERIMENTAL|Experimental Group|Participants will undergo an 8-week WBV therapy program using a Dynatronics VF5 Model vibration platform. Each session will last 4 minutes, with vibration frequencies progressively increased from 25 Hz to 40 Hz without rest intervals.
62238242|NCT00533741|EXPERIMENTAL|1b (5.0 mcg)|7 subjects randomized in a 1:3:3 fashion to receive a 2 dose regimen of placebo, vaccine containing 5.0 mcg of antigen and no adjuvant, or 5.0 mcg of antigen and Alum adjuvant.
62037051|NCT05662033|EXPERIMENTAL|Part 2 (MAD) : Cohort 4|6 Healthy participants will receive dose Z of AZD6793 and 2 healthy participants will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7
62238243|NCT05442762||Global Database of Vaccine Related Posts|Tweets in English from Twitter and posts from weico from 2015 to 2022 for all vaccines. The investigators only included posts from individual accounts and excluded those from news, organizational accounts, or verified users.
62238244|NCT05442762||Global Database of HPV Vaccine Related Posts|Tweets in English from Twitter and posts from weico from 2015 to 2022 for HPV vaccine. The investigators only included posts from individual accounts and excluded those from news, organizational accounts, or verified users.
62814360|NCT02056743|EXPERIMENTAL|Fermented-red ginseng|"At period 1, the fermented-red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the first day. At second day, they administered Fexofenadine 30mg under fasting conditions.~During 4\~17th days they administered fermented-red ginseng. At period 2, the fermented-red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the 15th day. At 16th day, they administered Fexofenadine 30mg under fasting conditions."
62238245|NCT03114007|EXPERIMENTAL|Preventure, Equipe and Inter-Action|Preventure program, Equipe program and Inter-Action services: Early personality-targeted interventions for students most at risk of mental health problems and substance misuse (Preventure program), parent program mainly for parents of high risk youth, especially those reporting discord at home (Equipe program) and integrated services for youth with significant internalizing and externalizing problems (Inter-Action services).
62238246|NCT03114007|EXPERIMENTAL|Preventure program and Equipe program|Early personality-targeted interventions for students most at risk of mental health problems and substance misuse (Preventure program) and parent program mainly for parents of high risk youth, especially those reporting discord at home (Equipe program)
62238247|NCT03114007|NO_INTERVENTION|Control|Treatment as usual
62238248|NCT06048354|EXPERIMENTAL|Wheat Polar Lipid Complex Oil|Dietary supplement - Wheat Polar Lipid Complex (Oil)
62238249|NCT06048354|EXPERIMENTAL|Wheat Polar Lipid Complex Powder|Dietary supplement - Wheat Polar Lipid Complex (Powder)
62596377|NCT02999230|ACTIVE_COMPARATOR|Caries Free|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Study toothpaste will be assigned.
62596378|NCT02999230|PLACEBO_COMPARATOR|Caries Free- Placebo|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Marketed Toothpaste will be assigned.
62596379|NCT02999230|ACTIVE_COMPARATOR|Caries Active|Gums will be examined and caries assessment performed. On some visits Saliva and plaque will be collected. Study toothpaste will be assigned.
62037052|NCT05662033|EXPERIMENTAL|Part 3: Treatment sequence 1|Participants will receive a single oral dose of test formulation AZD6793 in fasted state, test formulation AZD6793 in fed state following reference formulation AZD6793 in fasted state once on Day 1 of each treatment period.
62037053|NCT05662033|EXPERIMENTAL|Part 3: Treatment sequence 2|Participants will receive a single oral dose of test formulation AZD6793 in fed state, reference formulation AZD6793 in fasted state following test formulation AZD6793 in fasted state once on Day 1 of each treatment period.
62238250|NCT06048354|PLACEBO_COMPARATOR|Placebo|Dietary supplement - Placebo
62238251|NCT06435754|EXPERIMENTAL|Intervention group Vestibular Socket Preservation|Alveolar ridge preservation following atraumatic extraction using Vestibular Socket preservation.
62814361|NCT02056743|EXPERIMENTAL|Red ginseng|"At period 1, the red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the first day. At second day, they administered Fexofenadine 30mg under fasting conditions.~During 4\~17th days they administered red ginseng. At period 2, the red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the 15th day. At 16th day, they administered Fexofenadine 30mg under fasting conditions."
62814362|NCT04803383|EXPERIMENTAL|Tele-Yoga Group|Patients in the tele-yoga group will participate in tele-yoga sessions with a maximum of 5 people in each group by video-conference method for 8 weeks, 3 days a week. Assessments will perform just before starting to study and after the 8-week tele-yoga program
62238252|NCT06435754|ACTIVE_COMPARATOR|Control group ice cream cone technique|Alveolar ridge preservation following atraumatic extraction using ice cream cone technique.
62238253|NCT02549560|ACTIVE_COMPARATOR|tDCS GROUP|These patients will be submitted to 2 daily sessions of cerebral stimulation, starting from the first day after the surgery, for 4 consecutive days, with each session having 20 minutes, and a minimum break of 8 hours between them. Will be applied a direct current stimulus of 2 milliampere (mA) in the right anode and in the left cathode on the prefrontal right region.
62238254|NCT02549560|SHAM_COMPARATOR|CONTROL GROUP|In these patients will be applied, with the same equipment used in tDCS, a simulated stimulus similar to the active one. They will also be submitted to some psychological test to evaluate theirs mnemonics, attentional, executive and global functions.
62238255|NCT05467878||Group I|Patients undergoing regional anesthesia were studied. It can be in the form of combined spinal epidural or epidural anesthesia.
62238256|NCT05467878||Group 2|Patients in whom general anesthesia and iv analgesic methods are preferred are in this group.
62238257|NCT05467878||Group 3|Patients who prefer peripheral block under general anesthesia and ultrasound are in this group.
62238258|NCT06348940|EXPERIMENTAL|Behavioral activation + Care as usual|Cohort 1-5: Intervention Group
62238259|NCT06348940|NO_INTERVENTION|Care as usual|Cohort 1-5: Control Group
62238260|NCT00931554|ACTIVE_COMPARATOR|Early drain removal|Drain removal in postoperative day 3
62428790|NCT02684669|PLACEBO_COMPARATOR|Normal saline|0.9% physiological saline, i.v. infusion, total 0.81 ml/kg, target controlled infusion with three infusion rates (0.06 ml/kg; 0.19 ml/kg; 0.56 ml/kg) each of 25 min duration.
62428791|NCT00148694|EXPERIMENTAL|Intervention single arm|Cisplatin 75mg/m2 q21 days x 4 pre-surgery
62814363|NCT04803383|NO_INTERVENTION|Control group|Patients in the waiting list control group will be asked to continue their normal physical activities during the 8-week study, not to start a new exercise program, and to report any changes in the drug or dosage used. Control group's assessments will be performed when they are included in the study and at the end of 8 weeks. After these assessments, patients who wish will participate in the tele-yoga program.
62428792|NCT02614885||Prophylactic Mastectomy|Females undergoing prophylactic mastectomy with RFA performed on the excised tissue.
62428793|NCT01373476|EXPERIMENTAL|Qideng Mingmu capsule|High dosage group,Middle dosage group,Low dosage group.
62238261|NCT00931554|ACTIVE_COMPARATOR|Standard drain removal|Drain removal on postoperative day 5
62238262|NCT02272855|EXPERIMENTAL|HF10 plus ipilimumab|
62238263|NCT03675672|ACTIVE_COMPARATOR|Group 1|Misoprostol Oral tablet, 200mcg, QID
62238264|NCT03675672|PLACEBO_COMPARATOR|Group 2|Placebo Oral Tablet, 1 tab, QID
62428794|NCT01373476|PLACEBO_COMPARATOR|Placebo|Placebo group
62428795|NCT01371890||Intradialytic hypertension|Patients with systolic blood pressure increases \> 10 mmHg during 4/6 hemodialysis sessions
62596380|NCT02999230|PLACEBO_COMPARATOR|Caries Active- Placebo|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Marketed Toothpaste will be assigned.
62814364|NCT06459375|EXPERIMENTAL|Modified Otago exercise group|patients in this group will receive modified Otago exercises with conventional treatment.
62814365|NCT06459375|ACTIVE_COMPARATOR|Action Observation Training group|patients in this group will receive Action Observation Training with conventional treatment.
62814366|NCT00657319||A|
62238265|NCT03898115|EXPERIMENTAL|CHG Bathing Implementation|In a step-wedged design, ICUs and BMT units will be enrolled into a educational program to improve knowledge/compliance with daily CHG bathing
62596381|NCT00990392|EXPERIMENTAL|Polysporin Triple Therapy|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
62814367|NCT05948267|ACTIVE_COMPARATOR|Propofol (P) group|Propofol(2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml in 2 separate syringes.
62814368|NCT05948267|ACTIVE_COMPARATOR|Ketamine-Dexmedetomidine (KD5) group|ketamine (1mg/kg) prepared for concentration 10mg/ml, Dexmedetomidine (0.5microg/kg slow IV) prepared for concentration of 5mic /ml in 2 separate syringes.
62814369|NCT05948267|ACTIVE_COMPARATOR|Ketamine-Dexmedetomidine (KD3) group|ketamine (1mg/kg) prepared concentration 10mg/ml, Dexmedetomidine (0.3microg/kg slow IV) prepared for concentration of 3mic /ml in 2 separate syringes.
62814370|NCT06579755|EXPERIMENTAL|Cohort 1: Tetravalent Dengue Vaccine (TDV) 0.5 mL|Participants with the age group greater than (\>) 60 to 79 years will receive TDV, 0.5 mL subcutaneous (SC) injections, on Day 1 and Day 90.
62814371|NCT06579755|PLACEBO_COMPARATOR|Cohort 1: Placebo|Participants with the age group \>60 to 79 years will receive placebo (normal saline), 0.5 mL SC injections, on Day 1 and Day 90.
62814372|NCT06579755|EXPERIMENTAL|Cohort 2: TDV 0.5 mL|Participants with the age group 45 to 60 years will receive TDV, 0.5 mL SC injection, on Day 1 and Day 90.
62814373|NCT03919396|EXPERIMENTAL|OrthoK (orthokeratology)|Group wearing Breath-O corrected orthokeratology lenses for 2 years
62814374|NCT03919396|NO_INTERVENTION|SV Lenses (Single vision)|Group wearing spectacle with single vision lenses for 2 years
62814375|NCT05359458|EXPERIMENTAL|Emotional Freedom Liberation Technique Applied to Laparoscopic Cholecystectomy Patients|The intervention group is the group in which the investigators applied Emotional Freedom Liberation Technique Intervention: Behavioral: Emotional Freedom Liberation Technique
62814376|NCT05359458|NO_INTERVENTION|Standard Clinical Care Applied to Laparoscopic Cholecystectomy Patients|The control group is the group that receives standard clinical care
62814377|NCT04391374||Conservative treatment|Subjects with atherosclerotic peripheral artery disease (PAD) who undergo standard of care conservative treatment according to the current PAD guidelines.
62814378|NCT04391374||Peripheral artery bypass grafting|Subjects with atherosclerotic peripheral artery disease who undergo an open bypass grafting with synthetic prosthesis in aorto-iliac or femoro-popliteal position
62814379|NCT04391374||Peripheral artery balloon angioplasty and stenting|Subjects with atherosclerotic peripheral artery disease who undergo endovascular balloon angioplasty and stenting with bare-metal stents in aorto-iliac or femoro-popliteal position
62238266|NCT03898115|NO_INTERVENTION|Control|In a step-wedged design, ICUs and BMT units will be enrolled over a rolling 4 month time frame; when not enrolled, this data will serve as control data
62814380|NCT00668421|EXPERIMENTAL|CEP-701 (Lestaurtinib)|Subject is to receives Lestaurtinib, in Phase 1: standard cohort dose escalation; Phase 2: single stage design to estimate the percentage of subjects with a 15% or greater reduction in JAK2 V617F allele frequency in peripheral blood granulocytes in 6 months of treatment
62814381|NCT03963765|ACTIVE_COMPARATOR|Group I (Standard DL-PDT)|"1. Superficial skin curettage all face with a dermatological curette~2. All exposed skin was covered with pure chemical sunscreen~3. After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
62238267|NCT00934804|EXPERIMENTAL|Comparative Diagnostic system|Galilei dual Scheimpflug analyzer
62596382|NCT00990392|PLACEBO_COMPARATOR|Placebo|Petroleum jelly
62037054|NCT05662033|EXPERIMENTAL|Part 3: Treatment sequence 3|Participants will receive a single oral dose of reference formulation AZD6793 in fasted state, test formulation AZD6793 in fasted state following test formulation AZD6793 in fed state once on Day 1 of each treatment period.
62037055|NCT05662033|EXPERIMENTAL|Part 4 (COPD): Cohort 1|10 participants with COPD will receive AZD6793 once daily and 5 participants with COPD will receive placebo
62037056|NCT04934865|OTHER|Patients treated for their lung cancer and Moovcare® Lung follow-up.|
62037057|NCT05931692||Individuals without Parkinson's disease|People over 40 years old
62037058|NCT05931692||Parkinson Disease|People over 40 years old who have Parkinson's Disease at stage I to III Hoehn and Yahr scale
62037059|NCT04389099||Healthy placenta (control)|Pregnant women without preeclampsia and/or fetal growth restriction
62238268|NCT02904434||Voriconazole|Children (2-17 years old) will receive oral voriconazole as prescribed by their physicians as standard of care for the duration of the study.
62238269|NCT05898386|NO_INTERVENTION|Control Group|No intervention was made in the control group. The women in the control group were called during the 3-month follow-up to ask whether they received treatment for urinary incontinence simultaneously with the telephone calls of the intervention group.
62238270|NCT05898386|EXPERIMENTAL|Intervention Group|"A training and counseling program based on the pender's health promotion model was applied to the intervention group.~After the training, 3 home visits and 3 phone calls were made to support the implementation of behavioral and lifestyle changes in coping with urinary incontinence."
62238271|NCT04910646|EXPERIMENTAL|orange peel fermentation|
62238272|NCT04910646|PLACEBO_COMPARATOR|placebo|
62238273|NCT05227547|OTHER|Thoracic resection surgery|Smokers (active or ex-smokers) and non-smokers with COPD and without COPD undergoing thoracic resection surgery
62238274|NCT06493604|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%) administered six times over two consecutive days|
62428796|NCT04890704|EXPERIMENTAL|Curcumioids|The investogators prescribed curcuminoids 1,500 mg/day . The regimen was curcuminoids 500 mg three times a day from three days before the procedure until two days after. All patients also received standard prophylaxis protocol which included 0.9% sodium chloride 1 mL/kg/hour, given 12 hours before and 12 hours after CAG unless contraindicated.
62428797|NCT04890704|PLACEBO_COMPARATOR|Placebo|The placebo was identical capsule given three times daily and the remaining protocols were the same as the active group
62428798|NCT00701935|PLACEBO_COMPARATOR|1|
62428799|NCT00701935|EXPERIMENTAL|2|
62428800|NCT03333460|EXPERIMENTAL|Active Comparator: Active rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive active stimulation targeting the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 15 Hz and 100% of the individual resting motor threshold, for a total of 40 trains (60 stimuli per train, inter-train interval of 15 second, total duration 13 minutes). Each session will be repeated twice/daily for 10 consecutive days for 2 weeks, during the continued treatment phase. Following this, the participants will receive the maintenance intervention of 2 sessions per week for 3 months (rTMS follow-up), at the same parameters described above. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
62037060|NCT04389099||Pathological placenta|Pregnant women with preeclampsia and/or fetal growth restriction divided into two subgroups : preeclampsia with or without fetal growth restriction ; fetal growth restriction without preeclampsia.
62037061|NCT00002574|EXPERIMENTAL|Arm I|Single-Agent Chemotherapy plus Biological Response Modifier Therapy. Homoharringtonine, HH, NSC-141633; plus Interferon alfa (Schering), IFN-A, NSC-377523.
62037062|NCT05729763||Patients with localized renal tumor|Patients with localized renal tumor scheduled for minimally invasive partial nephrectomy in which 2D- and 3D-PADUA nephrometric score assessment was performed preoperatively
62037063|NCT02280044|EXPERIMENTAL|rifaximin|Subjects receiving rifaximin prophylaxis will be challenged with C. jejuni
62238275|NCT06493604|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution administered six times over two consecutive days|
62238276|NCT05101616|EXPERIMENTAL|camrelizumab+chemotherapy|neoadjuvant treatment with camrelizumab+chemotherapy
62238277|NCT05101616|ACTIVE_COMPARATOR|chemotherapy|neoadjuvant treatment with chemotherapy
62037064|NCT02280044|PLACEBO_COMPARATOR|placebo|Subjects receiving placebo will be challenged with C. jejuni
62037065|NCT02650869|EXPERIMENTAL|Standard care + Breast milk+ Probiotics|The study group will be fed with probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU) dissolved with 6 ml of milk then give 3 ml (3 billion probiotics) once daily with breast milk from first feeding.
62037066|NCT02650869|ACTIVE_COMPARATOR|Standard care|The control group will be given standard care without the addition of probiotics
62238278|NCT01431534|EXPERIMENTAL|Ridaforolimus 22 mg/m^2|Participants receive 22 mg/m\^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
62238279|NCT01431534|EXPERIMENTAL|Ridaforolimus 28 mg/m^2|Participants receive 28 mg/m\^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
62238280|NCT01431534|EXPERIMENTAL|Ridaforolimus 33 mg/m^2|Participants receive 33 mg/m\^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
62238281|NCT00863863|EXPERIMENTAL|A|Griseofulvin 125 mg/5 mL Suspension, single dose
62428801|NCT03333460|PLACEBO_COMPARATOR|Sham Comparator: Sham rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation (Sham). rTMS will be used with the software necessary for the operator to remain blind to the stimulation condition. Also, the software will be pre-programmed by a staff member that will not be involved in data collection and analysis. The sham condition will match the number of pulses delivered during the 15Hz session and will use the same coil placement but the intensity of stimulation will be set a 3% of the individual resting motor threshold so to ensure that the participant will feel similar scalp sensations experienced by participants receiving active rTMS, but brain tissue will not be stimulated. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
62428802|NCT01004900|ACTIVE_COMPARATOR|Trabeculoplasty|
62428803|NCT01004900|ACTIVE_COMPARATOR|Control (Medication)|
62428804|NCT01387308|EXPERIMENTAL|A|Fostamatinib 50 mg tablet x 2 (Phase 3 batch)
62428805|NCT01387308|SHAM_COMPARATOR|B|Fostamatinib 50 mg tablet x 3 (Phase 3 batch)
62428806|NCT01387308|EXPERIMENTAL|C|Fostamatinib 100 mg tablet (new formulation)
62428807|NCT01387308|EXPERIMENTAL|D|Fostamatinib 150 mg tablet (new formulation)
62428808|NCT01387308|EXPERIMENTAL|E|Fostamatinib 50 mg tablet x 2 (Phase 3 batch)
62428809|NCT05199831||Participants living with HIV|Clinical, functional and cognitive evaluations; questionnaires on disability, social participation, mental health and physical activity
62428810|NCT05199831||Controls not infected with HIV|Clinical, functional and cognitive evaluations; questionnaires on disability, social participation, mental health and physical activity
62428811|NCT01528566|EXPERIMENTAL|Tai Chi|
62428812|NCT01528566|PLACEBO_COMPARATOR|Attentation control|
62428813|NCT06438237||Patients undergoing colonoscopy|Patients were informed to eat semi-liquid and non-slag diet for breakfast and lunch and full-liquid diet for dinner on the day before colonoscopy, and be fasting on the day of colonoscopy. A split-dose 3 L PEG regimen was used for all patients.
62814382|NCT03963765|EXPERIMENTAL|Group II (DL-PDT with microneedles)|"1. Superficial skin curettage all face with a dermatological curette~2. All exposed skin was covered with pure chemical sunscreen~3. After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion~4. A motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) was applied without bleeding~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
62428814|NCT04515511|EXPERIMENTAL|standard care|ICU septic shock patients with refractory hypotension with indwelling pulmonary artery catheter received five sequential intravenous boluses of 100 mL 4% gelatin. Cardiac output measured by thermodilution of PAC before fluid challenge (baseline) and three minutes after each bolus. Fluid responsiveness (FR) was defined as an increase in CO greater than 10% after 500 mL fluid infusion. The smallest volume which can perform an effective fluid challenge was analyzed.
62428815|NCT04711278|EXPERIMENTAL|hypnosis group|Mask-wearing as hypnosis method for patients in this arm.
62428816|NCT04711278|SHAM_COMPARATOR|comparator group|No hypnosis for patients in this arm.
62037067|NCT04681339||Pneumonia with antibiotics|Children with non-severe community acquired pneumonia and fever: managed with antibiotics
62238282|NCT00863863|ACTIVE_COMPARATOR|B|Grifulvin V® 125 mg/5 mL Suspension, single dose
62037068|NCT04681339||Pneumonia without antibiotics|Children with non-severe community acquired pneumonia and fever: managed without antibiotics
62037069|NCT04618185||p.Phe508del homozygous genotype|People with CF with 2 copies of p.Phe508del and previously eligible for Symkevi (Tezacaftor/Ivacaftor)
62596383|NCT06215183|EXPERIMENTAL|Intervention Group|Women in the intervention group applying for IUD application will listen to music for 5 minutes before, during and after the procedure.
62596384|NCT06215183|NO_INTERVENTION|Control Group|Women in the control group applying for IUD application will not be subjected to any intervention other than routine IUD insertion procedures.
62814383|NCT03963765|EXPERIMENTAL|Group III (DL-PDT with CO2 laser)|"1. Superficial skin curettage all face with a dermatological curette~2. All exposed skin was covered with pure chemical sunscreen~3. After 15 minutes and removing excess sunscreen, Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density \<1% (Pixel Alma Lasers ®) was applied, single-pass~4. A uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
62238283|NCT00719563|EXPERIMENTAL|Arm I|Patients receive oral American ginseng twice daily for 14 days. Treatment repeats every 2 weeks for 4 courses.
62428817|NCT01168128|EXPERIMENTAL|Tailored Action Plan|A Tailored Action Plan is an intervention selected to overcome barriers identified before the design and delivery of the intervention.
62814384|NCT03963765|EXPERIMENTAL|Group IV (DL-PDT with microdermabrasion)|"1. Superficial skin curettage all face with a dermatological curette~2. Microdermabrasion with aluminum oxide crystal (Pan Eletronic®) was performed after superficial skin curettage. Three passes on the skin in different directions (vertical, horizontal, and oblique) were applied~3. All exposed skin was covered with pure chemical sunscreen~4. After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
62428818|NCT05529719|OTHER|Control group|Patients assigned to the control group were given theoretical training and a brochure containing MBA information. The control group patients participating in the evaluation session were recommended to be included in the same clinical Pilates training conducted by the intervention group after the study was completed.
62428819|NCT05233774|PLACEBO_COMPARATOR|Placebo|Group 1 will receive four infusions of Placebo on Day 0, Week 4, Week 8, and Week 12.
62814385|NCT04228471|EXPERIMENTAL|Spontaneous Breathing Group|"Spontaneous breathing activity will be allowed during APRV within one hour after randomization throughout the first 48 hours.~After 48 hours, standard routine care should be provided in both groups, although we suggest moderate sedation while spontaneous breathing is maintained with APRV, pressure support ventilation (PSV), or other assisting ventilator modes. Weaning off mechanical ventilation will be performed after 48 hours according to a protocol using spontaneous breathing trials."
62428820|NCT05233774|EXPERIMENTAL|Lomecel-B Dose 1|Group 2 will receive an infusion of Lomecel-B at a dose of 25 x 10\^6 cells (25M) on Day 0, followed by Placebo infusions at Week 4, Week 8, and Week 12.
62596385|NCT06142877|EXPERIMENTAL|Social Media Use Reduction|
62596386|NCT06142877|NO_INTERVENTION|Social Media Use as Usual|
62037070|NCT04618185||p.Phe508del heterozygous genotype|People with CF with 1 copy of p.Phe508del and not previously eligible for any CFTR modulator
62037071|NCT05735067||Group 1|RRMS patients who received Interferon beta 1a and have normal weight
62037072|NCT05735067||Group 2|RRMS patients who received Interferon beta 1a and have are obese
62238284|NCT00719563|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo twice daily for 14 days. Treatment repeats every 2 weeks for 4 courses.
62238285|NCT00490009|EXPERIMENTAL|Bexxar + Total Body Irradiation (TBI)|Bexxar will be administered with pre-medications acetaminophen, diphenhydramine, and potassium iodide (KI).
62238286|NCT02616523|ACTIVE_COMPARATOR|dexmedetomidine|The investigators will compare fentanyl consumption in participants undergoing laparoscopic intestine resection intra and postoperatively. Dexmedetomidine group will receive dexmedetomidine infusion 0,5 mcg/kg/h beside boluses of fentanyl.
62037073|NCT02100176||Rotigotine and MIRT|Group 1 - 20 Patients with PD (H\&Y stages 1,5-2) in therapy only with Rotigotine will undergo a Multidisciplinary intensive rehabilitation treatment (MIRT).
62037074|NCT02100176||Control group, only Rotigotine|Group 2 - 20 Patients with PD (H\&Y stages 1,5-2)
62238287|NCT02616523|ACTIVE_COMPARATOR|lidocaine|Lidocaine group will receive lidocaine infusion 1,5 mg/kg/h during the laparoscopic intestine resection.
62238288|NCT02616523|PLACEBO_COMPARATOR|placebo|The placebo group will receive intravenous infusion of normal saline only.
62238289|NCT02411682|ACTIVE_COMPARATOR|YesB|On YesB day the patients will consume breakfast , lunch and dinner
62238290|NCT02411682|EXPERIMENTAL|NoB|On NoB Day The patient will consume only lunch and dinner
62428821|NCT05233774|EXPERIMENTAL|Lomecel-B Dose 2|Group 3 will receive four infusions of 25M Lomecel-B on Day 0, Week 4, Week 8, and Week 12.
62428822|NCT05233774|EXPERIMENTAL|Lomecel-B Dose 3|Group 4 will receive four infusions of Lomecel-B at a dose of 100 x 10\^6 cells (100M) on Day 0, Week 4, Week 8, and Week 12.
62428823|NCT05139173|EXPERIMENTAL|Experimental: Injured Worker Population|Participants that have a confirmed rotator cuff pathology, and are undergoing physiotherapy at the Holland Centre for a work-related shoulder injury as part of the Working Condition Program.
62596387|NCT01978470|EXPERIMENTAL|Active|Trigeminal nerve stimulation
62596388|NCT06144736|EXPERIMENTAL|Low risk|"Criteria for low risk:~* Absence of high risk criteria~* Previous carboplatin therapy post orchiectomy~* Exclusion of malignancy in the RPLND histology"
62596389|NCT06144736|EXPERIMENTAL|High risk|"Criteria for high risk:~* Clinical stage II at initial diagnosis~* Primary tumor \> 4 cm~* Infiltration of the rete testis in the primary tumor"
62037075|NCT03025906|EXPERIMENTAL|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
62238291|NCT02870413|EXPERIMENTAL|Telelactation support|Participants in the experimental group will receive unlimited, free telelactation visits with lactation consultants (IBCLCs) as demanded up to 12 weeks post-partum. Services will be available through mobile phone app.
62238292|NCT02870413|NO_INTERVENTION|Usual care|Participants in the control arm will receive care as usual.
62238293|NCT00986440|EXPERIMENTAL|CS-7017|
62596390|NCT03062527|EXPERIMENTAL|Low Glycemic Index Diet|"Group consuming low glycemic index diet. Calculated glycemic index of daily diet was lower than 40. Carbohydrate- containing foods included whole rye bread, pumpernickel bread, whole oats, wheat brans, brown rice, buckwheat, vegetables (besides corn, cooked carrots, potatoes and pumpkin) and fruit such as apples, pears, grapefruits, tangerines, prunes, dried apricots and unripe bananas.~Interventions:~The experimental procedure for each participant included a 3-week low glycemic index diet. Between the 3-week low and moderate glycemic index diets or a moderate and low glycemic index treatment, a 14-day washout period was introduced."
62596391|NCT03062527|EXPERIMENTAL|Moderate Glycemic Index Diet|"Group consuming moderate glycemic index diet. Calculated glycemic index of diet was higher than 60. Carbohydrate- containing foods included wheat bread, wheat rolls, potatoes, instant oats, cornflakes, white rice, millet, boiled carrots and fruit (ripe bananas, grapes, raisins, dates, cranberry, honey and high sugar jams)~Interventions:~The experimental procedure for each participant included a 3-week moderate glycemic index diet. Between the 3-week low and moderate glycemic index diets or a moderate and low glycemic index treatment, a 14-day washout period was introduced."
62596392|NCT03933670|EXPERIMENTAL|Diagnostic (HP C-13 MRI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over less than one minute, then undergo MRSI after 1-2 minutes. Within 15-60 minutes, patients may receive optional hyperpolarized carbon C 13 pyruvate and undergo MRSI. Patients also undergo MR/US fusion-guided prostate biopsy within 12 weeks following HP C-13 MRSI.
62037076|NCT03025906|EXPERIMENTAL|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
62037077|NCT06236022|NO_INTERVENTION|Control|patients with dilated cardiomyopathy infected with Kaposi sarcoma-associated virus to receive standard DCM therapy
62238294|NCT00986440|PLACEBO_COMPARATOR|Placebo|Placebo matching CS-7017
62596393|NCT06621706||Diabetic term pregnant group|Compare the antral cross-sectional area (CSA) with gastric ultrasonography and estimated gastric volumes
62596394|NCT06621706||Non-diabetic term pregnant group|Compare the antral cross-sectional area (CSA) with gastric ultrasonography and estimated gastric volumes
62238295|NCT00142051|EXPERIMENTAL|1|inhaled NO
62238296|NCT00142051|PLACEBO_COMPARATOR|2|room air inhalation
62238297|NCT06032936|EXPERIMENTAL|BBP-398 + Osimertinib|"Phase Ia (Dose Escalation):~Dose level 1: (starting dose level) The one lower dose level than RP2D of BBP-398 monotherapy in Chinese patients (RP2D -1) with Osimertinib 80 mg Dose level 2: RP2D The same dose level to RP2D of BBP-398 monotherapy in Chinese patients with Osimertinib 80 mg Note: The dosing interval and regimen might be changed based on emerging data of Study NAV-1001, LB1002-101 and this study. The proposed new dosing regimen will be submitted in a memo to EC for approval before execution.~Phase Ib (Efficacy Expansion):~Osimertinib 80mg QD + BBP-398 RP2D QD"
62238298|NCT05066009|EXPERIMENTAL|Prescribed medication followed by drug holiday|Participants will complete the study assessments on a day when they take their prescribed medication(s) to promote wakefulness and then will repeat the study assessments on a day when they do not take the medication.
62238299|NCT05066009|EXPERIMENTAL|Drug holiday followed by prescribed medication|Participants will complete the study assessments on a day when they do not take their prescribed medication(s) to promote wakefulness and then will repeat the study assessments on a day when they take their medication as prescribed.
62238300|NCT01240083|EXPERIMENTAL|Thetaburst Stimulation|1: Thetaburst stimulation: right DLPFC continuous TBS followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 stimuli, 80% motorthreshold
62428824|NCT05139173|ACTIVE_COMPARATOR|Active Comparator: OHIP (funded) Patient Population|Participants that have a confirmed rotator cuff pathology, and are undergoing physiotherapy at the Holland Centre as part of the Shoulder Program.
62596395|NCT03005223|EXPERIMENTAL|Study effect of DWC20163 on DWC20155/DWC20156 PK|To study effect of DWC20163 on DWC20155/DWC20156 PK
62596396|NCT03005223|EXPERIMENTAL|Study effect of DWC20155/DWC20156 on DWC20163 PK|To study effect of DWC20155/DWC20156 on DWC20163 PK
62037078|NCT06236022|EXPERIMENTAL|Sirolimus|patients with dilated cardiomyopathy infected with Kaposi sarcoma-associated virus to receive sirolimus (at a dose of 2 mg once daily) in addition to standard DCM therapy
62037079|NCT02394782||Relapsing-remitting Multiple Sclerosis|
62037080|NCT05861934|EXPERIMENTAL|Distant reiki group|To examine the effect of distant reiki application on pain, functional status and sleep quality in rheumatoid arthritis patients.
62037081|NCT05861934|NO_INTERVENTION|Control group|Control group; routine care and treatment will be applied.
62037082|NCT04546581|EXPERIMENTAL|Intervention Group|Participants in this group will receive the investigational product and standard of care (SOC).
62037083|NCT04546581|PLACEBO_COMPARATOR|Control Group|Participants in this group will receive a placebo and standard of care (SOC).
62037084|NCT05103020|EXPERIMENTAL|HAI oxaliplatin and systemic FOLFIRI plus targeted therapy (bevacizumab or cetuximab)|HAI-oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab)
62238301|NCT01240083|EXPERIMENTAL|High frequency rTMS|2: Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC, 110% motor threshold, followed by 1000 stimuli of 10 Hz over the left DLPFC , 110% motorthreshold
62238302|NCT01240083|EXPERIMENTAL|Placebo Stimulation|3: Sham Stimulation (Sham coil): right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
62238303|NCT02300909|EXPERIMENTAL|dHACM|Lumbar Decompression Surgery or Microdiscectomy Surgery with Application of Dehydrated Human Amnion/Chorion Membrane (dHACM)
62238304|NCT02300909|OTHER|Surgery without dHACM|Control Group - Lumbar Decompression Surgery or Microdiscectomy Surgery without application of dHACM
62428825|NCT04397354|ACTIVE_COMPARATOR|Group 1|intracochlear dexamethasone application during cochlear implantation
62238305|NCT01922479|EXPERIMENTAL|Ferric Carboxymaltose|1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
62238306|NCT01922479|ACTIVE_COMPARATOR|Placebo|20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
62238307|NCT00647751|EXPERIMENTAL|1|Lamotrigine Tablets 25 mg
62238308|NCT00647751|ACTIVE_COMPARATOR|2|Lamictal® Tablets 25 mg
62814386|NCT04228471|EXPERIMENTAL|Controlled Mechanical Ventilation Group|"Pressure controlled mechanical ventilation will be applied throughout the first 48 hours.~After 48 hours, standard routine care should be provided in both groups, although we suggest moderate sedation while spontaneous breathing is maintained with APRV, pressure support ventilation (PSV), or other assisting ventilator modes. Weaning off mechanical ventilation will be performed after 48 hours according to a protocol using spontaneous breathing trials."
62814387|NCT05621330|EXPERIMENTAL|QL0911|
62238309|NCT00707850|EXPERIMENTAL|1|Thalassemic Patients with HCV
62238310|NCT03318939|EXPERIMENTAL|Poziotinib|"* Cohort 1: Previously treated participants with EGFR exon 20 insertion mutant positive NSCLC (closed to enrollment)~* Cohort 2: Previously treated participants with HER2 exon 20 insertion mutant positive NSCLC (closed to enrollment)~* Cohort 3: Treatment naïve participants with EGFR exon 20 insertion-mutant positive NSCLC (fully enrolled)~* Cohort 4: Treatment naïve participants with HER2 exon 20 insertion mutant positive NSCLC~* Cohort 5: Participants who meet the criteria for enrollment in Cohort 1 to 4, but the enrollment in the respective cohort has been closed~* Cohort 6: Participants with acquired EGFR mutation who progressed while on treatment with first-line osimertinib~* Cohort 7: Participants with EGFR or HER2 activating mutations"
62814388|NCT05621330|PLACEBO_COMPARATOR|Placebo|
62037085|NCT05103020|ACTIVE_COMPARATOR|Systemic FOLFIRI plus targeted therapy (bevacizumab or cetuximab)|IV FOLFIRI+ target agent (bevacizumab or cetuximab)
62238311|NCT02350179|EXPERIMENTAL|cases|Women assigned to the study group will receive 1 gr of Tranexamic acid injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.
62238312|NCT02350179|PLACEBO_COMPARATOR|control|The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
62037086|NCT01489033|EXPERIMENTAL|Group A active|"6 administrations and 5 weeks duration~1. Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~2. Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
62037087|NCT01489033|PLACEBO_COMPARATOR|Group A placebo|"6 administrations and 5 weeks duration~1. Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~2. Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
62037088|NCT01489033|EXPERIMENTAL|Group B active|"8 administrations and 7 weeks duration~1. Vial 1: 0.2 ml at 1 week intervals~2. Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~3. Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
62428826|NCT04397354|ACTIVE_COMPARATOR|Group 2|intratympanic dexamethasone application during cochlear implantation
62037089|NCT01489033|PLACEBO_COMPARATOR|Group B placebo|"8 administrations and 7 weeks duration~1. Vial 1: 0.2 ml at 1 week intervals~2. Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~3. Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
62428827|NCT04397354|SHAM_COMPARATOR|Group 3|No drugs during cochlear implantation
62428828|NCT02038400|EXPERIMENTAL|group A|KINETUBE medical Device
62428829|NCT02038400|ACTIVE_COMPARATOR|group B|insertion of tympanic ventilation tubes (tympanostomy)
62428830|NCT02887482|EXPERIMENTAL|Placebo|Placebo at 0 mg DNA/dose
62428831|NCT02887482|EXPERIMENTAL|GLS-5700|GLS 5700 at 2 mg DNA/dose. GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
62428832|NCT02744625|ACTIVE_COMPARATOR|Shock lower Mean Arterial Pressure (MAP)|Vasopressor-dependent treated to lower MAP (65 mmHg)
62428833|NCT02744625|EXPERIMENTAL|Shock higher MAP|Vasopressor-dependent treated to higher MAP (75 mmHg)
62428834|NCT02744625|NO_INTERVENTION|Healthy participant awake|Healthy participant awake
62428835|NCT02744625|EXPERIMENTAL|Healthy participant sedated|Healthy participant Under light sedation
62814389|NCT05433246|NO_INTERVENTION|Control Group|The patients received routine care.
62596397|NCT02103959|EXPERIMENTAL|CMX-2043 2.4 mg/Kg|Bolus injection of investigational product given prior to the cardiac catheterization and placebo given 24 hours after the first dose.
62814390|NCT05433246|EXPERIMENTAL|Massage therapy group|The patients in the massage group were given classical massage for 2 consecutive days in each chemotherapy cycle (with an interval of two weeks). Massage therapy was performed with a classical massage technique using effleurage, petrissage, and superficial friction techniques for a total of 40 minutes on the areas below the elbow-forearm-hand (20 minutes), and below the knee-lower leg-foot (20 minutes). The patients in the massage group received 16 sessions of classical massage performed by the research nurse, who had classical massage training and certification.
62814391|NCT01904188||SIRS positive|Adult (\> or = 18 years) patients with 3 of 4 systemic inflammatory response syndrome (SIRS) characteristics (1. tachycardia, 2. fever or hypothermia, 3. tachypnea, 4. leukocytosis), who have blood cultures drawn and urine collected for the evaluation of suspected sepsis, along with any other bodily fluid suspected to be the source of infection. May also include others without SIRS criteria but with bodily fluid production or infection of a bodily fluid
62596398|NCT02103959|EXPERIMENTAL|CMX-2043 3.6 mg/kg|Bolus injection of investigational product given prior to the cardiac catheterization and placebo given 24 hours after the first dose.
62037090|NCT01489033|EXPERIMENTAL|Group C active|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~1. Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~2. Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~3. Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~4. Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
62037091|NCT01489033|PLACEBO_COMPARATOR|Group C placebo|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~1. Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~2. Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~3. Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~4. Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
62037092|NCT04760418|EXPERIMENTAL|4 week baseline|Participants in this arm are randomized to a 4-week baseline period with repeated weekly assessment after the initial intake. This is followed by 12 sessions of weekly individual manualized Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
62596399|NCT02103959|EXPERIMENTAL|CMX-2043 2.4 mg/kg given twice|Bolus injection of investigational product given prior to the cardiac catheterization and again 24 hours after the first dose.
62596400|NCT02103959|PLACEBO_COMPARATOR|Placebo comparator|Placebo comparator (PBS) given prior to cardiac catheterization and again 24 hours after the first dose.
62596401|NCT06462482|EXPERIMENTAL|Testosterone Arm|The testosterone group will receive a 200mg dose of intramuscular testosterone cypionate (also known as Nandrolone) weekly for 8 weeks beginning 2 weeks prior to surgery.
62596402|NCT06462482|PLACEBO_COMPARATOR|Saline Arm|The saline group will receive a 200mg dose of intramuscular saline weekly for 8 weeks beginning 2 weeks prior to surgery.
62596403|NCT01287468||Experimental Group|
62596404|NCT01287468||Control Group|
62596405|NCT06189157|EXPERIMENTAL|Dose Level 0|Phase I: DL 0: 0,1x10e6 MB-CART19.1 cells Dose finding algorithm will start at dose level 1, with dose level 0 as a rescue dose.
62596406|NCT06189157|EXPERIMENTAL|Dose Level 1|Phase I: DL 1: 0,5x10e6 MB-CART19.1 cells Patients will be treated in cohorts of 3. If no DLT is determined, the dose can be escalated.
62037093|NCT04760418|EXPERIMENTAL|6 week baseline|Participants in this arm are randomized to a 6-week baseline period with repeated weekly assessment after the initial intake. This is followed by 12 sessions of weekly individual manualized Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
62596407|NCT06189157|EXPERIMENTAL|Dose Level 2|Phase I: DL 2: 1,0x10e6 MB-CART19.1 cells At the highest dose level 3 additional patients will be treated.
62814392|NCT05911542||General Dental Practitioners|Participants are asked to complete a survey about pain management strategies.
62037094|NCT04087538||Patients treated using troponin T|
62037095|NCT04087538||Patients treated using troponin I|
62037096|NCT02372201|EXPERIMENTAL|Hydro Colon Therapy plus probiotic|Hydro Colon therapy including 2-5 washes in 3 weeks, probiotic intervention for 5 weeks after end of hydro Colon therapy
62037097|NCT01625897|EXPERIMENTAL|MP-214 1.5-9mg|
62037098|NCT01625897|ACTIVE_COMPARATOR|Risperidone 2-12mg|
62037099|NCT02901457|EXPERIMENTAL|Healthy Body Image|Students receive the Healthy Body Image intervention containing 3x90 minutes of interactive workshops with the addition of related homework after each workshop.
62037100|NCT02901457|NO_INTERVENTION|Control group|Students do not receive the intervention program.
62037101|NCT06361147|EXPERIMENTAL|Psychoeducational program (group A - Ex. gr)|"This group of volunteers is going to participate in the online psychoeducational training program for ASD. Number of participants:11.~To evaluate the effectiveness of the program, participants will be asked to complete the online questionnaires three times (before the start, after completion and three months later)."
62037102|NCT06361147|NO_INTERVENTION|Psychoeducational program (group A - Co. gr)|Concurrently with the experimental group A, the no-interventional group will be asked to complete the online questionnaires three times (before the start, after completion and three months later). Number of participants:11.
62428836|NCT03823677|NO_INTERVENTION|control group 15|"Protein expression and emotional test~15 minutes normoxia~Interventions:~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
62596408|NCT06189157|EXPERIMENTAL|Phase II - Recommended dose MB-CART19.1|Phase II will evaluate the efficacy and safety in patients treated with the recommended dose
62596409|NCT04726644||patients|cirrhotic patients with ventral hernia
62596410|NCT06616051|EXPERIMENTAL|intervention arm|Among Intervention arm, children who tested positive for vision impairment will be handed referral forms, and mHealth referral reminder will be sent to identified visually impaired school children in intervention arm'. The participant will get messages on thrice a week basis until they visit the hospital for a maximum duration of eight weeks.
62814393|NCT05911542||Specialist Paediatric Dentists|Participants are asked to complete a survey about pain management strategies.
62814394|NCT06549478|EXPERIMENTAL|Treatment (BgRT)|Patients undergo a single fraction of BgRT on day 0. Patients undergo PET/CT on study and optionally during follow up.
62238313|NCT04709822|EXPERIMENTAL|Trauma exposed women|"No Intervention: Baseline phase ('A'):~Measurements collected in a daily diary four times a day (morning, afternoon, evening and night) over one week (number of intrusive memories of trauma). Individual baseline phases will be used as control periods for the primary outcome.~Experimental: Intervention phase ('B'):~Measurements collected in a daily diary four times a day during the fifth week after the second intervention session for the primary outcome (number of intrusive memories of trauma)."
62814395|NCT02506894|ACTIVE_COMPARATOR|magnesium sulfate|this group will receive magnesium sulfate loading dose 6 g in 500 cc of ringer solution over 20 minutes then maintenance dose of 1 g/ hour for 24 hours.
62814396|NCT02506894|PLACEBO_COMPARATOR|placebo group|this group will receive sodium chloride 0.9% solution for 24 hours.
62238314|NCT02245126|EXPERIMENTAL|Lignocaine-bupivacaine lower dosage mix|"Men who received the 3-3-4 local anaesthetic mix( 3 cc of lignocaine 2% , 3cc of bupivacaine 0.5% and 4cc of water for injection)~3-3-4 mix was administered"
62238315|NCT02245126|ACTIVE_COMPARATOR|Lignocaine-bupivacaine higher dosage mix|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
62238316|NCT04589182|EXPERIMENTAL|Verum|Patients will receive all-night auditory stimulation during sleep over 3 nights using a portable, safe, in-home device (MSHL-SleepBand). This device records biosignals (EEG) and precisely plays tones (between 45-65 dB, maximum 80 dB) targetted to the up-phase of sleep slow waves.
62428837|NCT03823677|NO_INTERVENTION|control group 30|"30 minutes normoxia~Interventions:~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
62596411|NCT06616051|NO_INTERVENTION|Control arm|Among control arm, the participants screened positive for visual impairment in the control group will receive a referral form. There will be no mHealth referral reminder sent to the identified visual impaired children.
62037103|NCT06361147|EXPERIMENTAL|Psychoeducational program (group Β - Ex. gr)|"This group of volunteers is going to participate in the online psychoeducational training program for ASD. Number of participants:11.~To evaluate the effectiveness of the program, participants will be asked to complete the online questionnaires three times (before the start, after completion and three months later)."
62238317|NCT04589182|SHAM_COMPARATOR|Sham|Patients will receive all-night sham stimulation over 3 nights, i.e. the wearable stimulation device will be applied (EEG will be recorded), but no tones will be played.
62428838|NCT03823677|NO_INTERVENTION|control group 60|"60 minutes normoxia~Interventions:~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
62428839|NCT03823677|EXPERIMENTAL|hypoxia 5000ft group 15|Intervention: 15 minutes hypoxia
62428840|NCT03823677|EXPERIMENTAL|hypoxia 5000ft group 30|Intervention: 30 minutes hypoxia
62428841|NCT03823677|EXPERIMENTAL|hypoxia 5000ft group 60|Intervention: 60 minutes hypoxia
62596412|NCT04888429|EXPERIMENTAL|Camrelizumab + Famitinib|Patients received camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day.
62814397|NCT02395458|EXPERIMENTAL|Sequential therapy|Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
62814398|NCT02395458|ACTIVE_COMPARATOR|Triple therapy|Patient receive Omeprazole plus clarithromycin and amoxicillin during 14 days
62238318|NCT04946903|EXPERIMENTAL|Sequence 1|"Period 1: Fasted state + RLD2007 +RLD2008,~Period 2: Fasted state + HCP1902"
62238319|NCT04946903|EXPERIMENTAL|Sequence 2|"Period 1: Fasted state + HCP1902,~Period 2: Fasted state + RLD2007 + RLD2008"
62238320|NCT02297360|ACTIVE_COMPARATOR|Viviscal Extra-Strength Supplement|Viviscal Extra-strength tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 90 days.
62238321|NCT02297360|PLACEBO_COMPARATOR|Placebo Tablet|Placebo tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 90 days.
62238322|NCT06146023|ACTIVE_COMPARATOR|Conventional|Conventional microsurgery with conventional microsurgical instruments and conventional surgical microscope
62238323|NCT06146023|EXPERIMENTAL|Robotic|Robot-assisted microsurgery with microsurgery robot and robotic microscope
62238324|NCT03930368|EXPERIMENTAL|Intervened arm|as in a single-arm before-and after study, the only one arm will receive intervention of low GI diet with supplementation of RCS.
62238325|NCT03570853|EXPERIMENTAL|Intervention|Participants will receive the 8-week SMART-3RP intervention within a few weeks of enrolling in the study.
62428842|NCT03823677|EXPERIMENTAL|hypoxia 8000ft group 15|Intervention: 15 minutes hypoxia
62428843|NCT03823677|EXPERIMENTAL|hypoxia 8000ft group 30|Intervention: 30 minutes hypoxia
62596413|NCT02520427|EXPERIMENTAL|Group 1: Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)|
62814399|NCT05083416|EXPERIMENTAL|A: Prolonged Nightly Fasting|"Participants will be educated on Prolonged Nightly Fasting (PNF) and the mycircadianapp. Participants be allowed to choose any 10-hr period that falls between 6 AM- 6 PM, as feeding period. Participants will be recommended to follow study diet guidelines, eat to satiety and not count calories. Participants will be allowed to have water, beverages (\<4 kcal) during the fasting period."
62814400|NCT05083416|ACTIVE_COMPARATOR|B: Regular Eating pattern|Participants will follow a traditional eating pattern with no time restrictions.
62814401|NCT06706531|ACTIVE_COMPARATOR|Standard treatment + Sham Dry needling|Participants will receive standard treatment of plantar facitis along with sham dry needling
62814402|NCT06706531|EXPERIMENTAL|Standard treatment + Dry needling|Participants will receive standard treatment of plantar facitis along with dry needling
62814403|NCT01274949|EXPERIMENTAL|LI-ESWT|Low intensity shock wave treatment- 12 sessions
62814404|NCT03213340|EXPERIMENTAL|Catechin Cohort 1|2 treatment - Experimental Catechin Blend; Control 1 Placebo
62238326|NCT03570853|NO_INTERVENTION|No Intervention|Participants will not receive the SMART-3RP program and will only complete study questionnaires..
62428844|NCT03823677|EXPERIMENTAL|hypoxia 8000ft group 60|Intervention: 60 minutes hypoxia
62428845|NCT03823677|EXPERIMENTAL|hypoxia 10000ft group 15|Intervention: 15 minutes hypoxia
62238327|NCT00494858|ACTIVE_COMPARATOR|CBT-EF|Participants will receive cognitive behavioral therapy - focused
62238328|NCT00494858|EXPERIMENTAL|CBT-EB|Participants will receive cognitive behavioral therapy - broad
62428846|NCT03823677|EXPERIMENTAL|hypoxia 10000ft group 30|Intervention: 30 minutes hypoxia
62428847|NCT03823677|EXPERIMENTAL|hypoxia 10000ft group 60|Intervention: 60 minutes hypoxia
62428848|NCT03823677|EXPERIMENTAL|hypoxia 15000ft group 15|Intervention: 15 minutes hypoxia
62428849|NCT03823677|EXPERIMENTAL|hypoxia 15000ft group 30|Intervention: 30 minutes hypoxia
62428850|NCT03823677|EXPERIMENTAL|hypoxia 15000ft group 60|Intervention: 60 minutes hypoxia
62428851|NCT00807625|ACTIVE_COMPARATOR|IUCD|Assigned to use a copper intrauterine device
62428852|NCT00807625|ACTIVE_COMPARATOR|DMPA|Assigned to use Depo Provera
62814405|NCT03213340|EXPERIMENTAL|Curcuminoid Cohort 2|2 treatment - Experimental Curcuminoid Blend; Control 1 Placebo
62428853|NCT02402933|EXPERIMENTAL|Nasal Glucagon|A single dose of 3mg glucagon nasal powder administered using a nasal powder delivery device for the treatment of moderate or severe hypoglycemic events; a maximum of 4 events per participant during the study.
62428854|NCT04211272|EXPERIMENTAL|Part A: Macitentan + Substrate Drug (Sildenafil/Riociguat)|Participants will receive a single dose of film-coated tablet of sildenafil under fasted condition (Treatment A1), then riociguat under fasted condition (Treatment A2) followed by macitentan under fed condition (Treatment B1), then riociguat along with macitentan under fasted conditions followed by macitentan under fed conditions (Treatment B2) and then sildenafil along with macitentan under fasted condition (Treatment B3). Macitentan will be administered in an up-titration regimen.
62428855|NCT04211272|EXPERIMENTAL|Part B: Macitentan + Substrate Drug (Rosuvastatin)|Participants will receive a single dose of film-coated tablet of rosuvastatin under fasted condition (Treatment A1), then macitentan under fed condition (Treatment B1) followed by rosuvastatin along with macitentan under fasted condition followed by macitentan under fed condition (Treatment B2). Macitentan will be administered in an up-titration regimen. Part B of the study will be conducted depending on the results of Part A and feedback from Health Authorities.
62814406|NCT03213340|EXPERIMENTAL|Flavonoid Cohort 3|2 treatment - Experimental Flavonoid Blend; Control 2 Low-Flavonoid Blend
62814407|NCT03270943|EXPERIMENTAL|Mindful Self-Compassion (MFY)|An 8-week mindfulness self-compassion course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
62814408|NCT03270943|ACTIVE_COMPARATOR|Healthy Lifestyles (HLG)|An 8-week healthy lifestyles course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
62814409|NCT02632799|EXPERIMENTAL|NHF small cannula|NHF 8 L/min (Airvo2) , Smaller cannula (neonatal, yellow)
62814410|NCT02632799|EXPERIMENTAL|NHF big cannula|NHF 8 L/min (Airvo2) , Bigger cannula (neonatal, purple)
62814411|NCT02632799|EXPERIMENTAL|Mask CPAP|CPAP 5cm H2O
62814412|NCT02632799|NO_INTERVENTION|no intervention|control
62814413|NCT04923867||Supratentorial Procedure Group|Subjects that have undergone a supratentorial procedure with the use of Suturable DuraGen™.
62814414|NCT04923867||Infratentorial Procedure Group|Subjects that have undergone a infratentorial procedure with the use of Suturable DuraGen™.
62814415|NCT04923867||Spinal Procedure Group|Subjects that have undergone a spinal procedure with the use of Suturable DuraGen™.
62814416|NCT06599736|EXPERIMENTAL|RhinAer Stylus treatment|The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nostrils treated in the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve.
62814417|NCT03431532||neuraxial anesthesia|Patients with total knee replacement surgery having neuraxial anesthesia along with the procedure.
62814418|NCT03431532||general anesthesia|Patients with total knee replacement surgery having General anesthesia along with the procedure.
62814419|NCT05641545|EXPERIMENTAL|IVAC-RCC-001|Individual peptide vaccination with adjuvant GM-CSF and Imiquimod Intradermal injection of a cocktail of 3-5 individual HLA-binding peptides. Subcutaneous injection of adjuvant GM-CSF at vaccination site. Topical administration of Imiquimod at vaccination site.
62238329|NCT01509326|ACTIVE_COMPARATOR|Chiropractic|spinal manipulation, mobilization, massage, advice, exercises
62238330|NCT01509326|EXPERIMENTAL|Chiropractic PLUS pillow|spinal manipulation, mobilization, massage, advice, exercises, pillow
62238331|NCT05395104|EXPERIMENTAL|Cefiderocol Plus Midazolam|A total of 2 doses of midazolam and 45 doses of cefiderocol was administered to each participant per specified dosing schedule.
62238332|NCT00892177|EXPERIMENTAL|Arm I|Patients receive bevacizumab on Day 1 and dasatinib on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62238333|NCT00892177|ACTIVE_COMPARATOR|Arm II|Patients receive bevacizumab on Day 1 and placebo on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62238334|NCT00975715|EXPERIMENTAL|TRI476|Participants received TRI476 based on body weight with titration up to the maintenance dose, in addition to their traditional antiepileptics dosage.
62238335|NCT00975715|PLACEBO_COMPARATOR|Placebo|Participants received placebo to TRI476 without any adjustment to the dosing regimen, in addition to their traditional antiepileptics dosage.
62238336|NCT01966393|ACTIVE_COMPARATOR|Dual-hormone closed-loop strategy|In dual-hormone closed-loop strategy, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels
62596414|NCT02520427|EXPERIMENTAL|Group 2: Minimal Residual Disease Positive (MRD+) AML|
62596415|NCT02520427|EXPERIMENTAL|Group 3: Myelodysplastic syndrome (MDS)|
62596416|NCT02520427|EXPERIMENTAL|Group 4: R/R AML with alternative pretreatment|
62596417|NCT02520427|EXPERIMENTAL|Group 5: R/R AML with alternative dose schedule|
62596418|NCT06021951|EXPERIMENTAL|Bempedoic acid|
62596419|NCT06021951|EXPERIMENTAL|Bempedoic acid/ezetimibe fixed combination drug product|
62238337|NCT01966393|ACTIVE_COMPARATOR|Single-hormone closed-loop strategy|In single-hormone closed-loop strategy, variable subcutaneous insulin infusion rate will be used to regulate glucose levels
62428856|NCT02268331|EXPERIMENTAL|Active Surveillance|"For 60 consecutive pediatric visits, patients will be asked to complete a PRE \& POST form to capture adverse events (AEs) that occur up to 1 week after treatment. The PRE-treatment form will be completed prior to the start of the visit. The POST-treatment form will be completed after the treatment visit and mailed directly to the investigative team.~The providers will collect data on the treatment provided on the same 60 pediatric patients. The treatment provided is at the discretion of the doctors. If a moderate, serious, or severe AE occurs, the provider will complete the AE form with detailed information about potential risk factors and patient outcomes."
62814420|NCT05119777|EXPERIMENTAL|HArmonyCa Injectable Gel|HArmonyCa injected at the discretion of the Treating Investigator (TI) to the midface for initial treatment and an optional touch-up treatment 14 days later
62814421|NCT06487260||Biathletes 16 years of age|Norwegian, competetive biathletes of both sexes, aged 16 years of age
62238338|NCT01966393|ACTIVE_COMPARATOR|Conventional insulin pump therapy|In control visit, subjects will use conventional pump therapy to regulate glucose levels.
62596420|NCT04173728|OTHER|Standardized mixed macronutrients tolerance test|Subjects with different age and BMI will be included. 1) 20 subjects aged 20-29 years with normal body weight (18.5 ≤BMI\<24kg/m2); 2) 40 20 subjects aged 30-70 49 years with normal body weight (18.5 ≤ BMI\<24kg/m2); 3) 40 20 subjects aged 30-70 49 years with overweight or obesity (BMI\<24kg/m2).); 4) 20 subjects aged 50-70 years with normal body weight (18.5 ≤ BMI\<24kg/m2); 5) 20 subjects aged 30-49 years with overweight or obesity (BMI\<24kg/m2); 6) 20 subjects aged 30-70 years with MetS.
62814422|NCT06487260||Biathletes 17 years of age|Norwegian, competetive biathletes of both sexes, aged 17 years of age
62814423|NCT06487260||Biathlete 18 years of age|Norwegian, competetive biathletes of both sexes, aged 18 years of age
62814424|NCT03291067|EXPERIMENTAL|MT-8554 1mg|
62238339|NCT05933187|EXPERIMENTAL|Sequence 1: A-B-C-D|Participants will receive emraclidine, 30 mg IR tablets, in the treatment sequence A-B-C-D orally, on Day 1 of each 5-day treatment period (up to 26 days)
62238340|NCT05933187|EXPERIMENTAL|Sequence 2: B-C-D-A|Participants will receive emraclidine, 30 mg IR tablets, in the treatment sequence B-C-D-A orally, on Day 1 of each 5-day treatment period (up to 26 days)
62238341|NCT05933187|EXPERIMENTAL|Sequence 3: C-D-A-B|Participants will receive emraclidine, 30 mg IR tablets, in the treatment sequence C-D-A-B orally, on Day 1 of each 5-day treatment period (up to 26 days)
62596421|NCT02599909||1/ Cohort 1|Subjects with hepatocellular carcinoma
62596422|NCT06640985|EXPERIMENTAL|Diabetic Foot Ulcer (DFU)|DFU treatment with EDX110 wound dressing
62596423|NCT06640985|ACTIVE_COMPARATOR|Venous Leg Ulcer (VLU)|VLU treatment with EDX110 wound dressing
62596424|NCT05523232|EXPERIMENTAL|42 Hz group|Vibration training with 42 Hz was given to participants.
62814425|NCT03291067|EXPERIMENTAL|MT-8554 5mg|
62814426|NCT03291067|EXPERIMENTAL|MT-8554 10mg|
62814427|NCT03291067|PLACEBO_COMPARATOR|Placebo|
62814428|NCT01605006|OTHER|NeuRx Diaphragm Pacing System (DPS)|Surgical implantation of the NeuRx DPS (on label use).
62814429|NCT02250222|EXPERIMENTAL|Part 1: LGD-6972 15 mg|15 mg LGD-6972 administered once daily (QD) for 14 days.
62814430|NCT02250222|PLACEBO_COMPARATOR|Part 1: Placebo (Captisol ®)|Placebo administered once daily (QD) for 14 days.
62814431|NCT02250222|EXPERIMENTAL|Part 2: LGD-6972 5 mg|5 mg LGD-6972 administered orally QD for 14 days.
62814432|NCT02250222|EXPERIMENTAL|Part 2: LGD-6972 10 mg|10 mg LGD-6972 administered orally QD for 14 days.
62814433|NCT02250222|EXPERIMENTAL|Part 2: LGD-6972 15 mg|15 mg LGD-6972 administered orally QD for 14 days.
62238342|NCT05933187|EXPERIMENTAL|Sequence 4: D-A-B-C|Participants will receive emraclidine, 30 mg IR tablets, in the treatment sequence D-A-B-C orally, on Day 1 of each 5-day treatment period (up to 26 days)
62238343|NCT01873495|EXPERIMENTAL|Omacetaxine: Consolidation/Maintenance|
62238344|NCT02635022||FLS|Patients with new hip fracture or newly identified vertebral fractures
62238345|NCT02635022||MMS|Patients prescribed with anti-osteoporosis medications but not fit FLS requirements
62596425|NCT05523232|ACTIVE_COMPARATOR|63 Hz group|Vibration training with 63 Hz was given to participants.
62596426|NCT03492398|EXPERIMENTAL|Cohort A HY209 0.05% gel|single dose of HY209 0.05% gel or single dose of placebo
62596427|NCT03492398|EXPERIMENTAL|Cohort A HY209 0.1% gel|single dose of HY209 0.1% gel or single dose of placebo
62596428|NCT03492398|EXPERIMENTAL|Cohort A HY209 0.3% gel|single dose of HY209 0.3% gel or single dose of placebo
62596429|NCT03492398|EXPERIMENTAL|Cohort A HY209 0.5% gel|single dose of HY209 0.5% gel or single dose of placebo
62596430|NCT03492398|EXPERIMENTAL|Cohort B HY209 0.1% gel|multiple dose of HY209 0.1% gel or multiple dose of placebo
62596431|NCT03492398|EXPERIMENTAL|Cohort B HY209 0.3% gel|multiple dose of HY209 0.3% gel or multiple dose of placebo
62596432|NCT03492398|EXPERIMENTAL|Cohort B HY209 0.5% gel|multiple dose of HY209 0.5% gel or multiple dose of placebo
62814434|NCT02250222|PLACEBO_COMPARATOR|Part 2: Placebo (Captisol ®)|Placebo administered orally QD for 14 days.
62814435|NCT06577259|ACTIVE_COMPARATOR|Treatment A: BMS-986435 Reference Dose 1|
62814436|NCT06577259|EXPERIMENTAL|Treatment B: BMS-986435 Test Dose 1|
62814437|NCT06577259|EXPERIMENTAL|Treatment C: BMS-986435 Test Dose 2|
62428857|NCT02268331|ACTIVE_COMPARATOR|Passive Surveillance|"All doctors allocated to this arm will be provided with a username and password with an established chiropractic passive surveillance reporting and learning online system (CPiRLS) in the UK. If a patient safety incident occurs in their office or an adverse event (AE), the provider will complete a report on the CPiRLS website. The providers can record events that occur during the time period of 60 pediatric visits.~Treatment provided during these treatments is at the doctor's discretion."
62596433|NCT06449001|EXPERIMENTAL|Danicopan|Participants will receive a 12-week weight-based open-label treatment period at Day 1 for up to 1 year open-label long term extension period.
62814438|NCT05948735|EXPERIMENTAL|Physical Therapy Exercise and Dance Movement Therapy (PTE+DMT)|The intervention include 12 face-to-face group sessions of 45 minutes each, twice a week for 6 weeks. The intervention integrates Otago Exercise Program (OEP)-based techniques and DMT techniques to address the emotional experience that arises during physical exercise. This include encouragement for spontaneous and creative movement on the part of the participants, and an invitation to verbally share the feelings, sensations, and thoughts that arose in the participants following the movement. At the end of the sessions, participants will be instructed to perform nine exercises independently at home, at a minimum of twice per week for six months
62814439|NCT05948735|ACTIVE_COMPARATOR|Physical Therapy Exercise (PTE)|The intervention include 12 face-to-face group sessions of 45 minutes each, twice a week for 6 weeks. The intervention include OEP-based techniques only. At the end of the sessions, participants will be instructed to perform nine exercises independently at home, at a minimum of twice per week for six months.
62037104|NCT06361147|NO_INTERVENTION|Psychoeducational program (group B - Co. gr)|Concurrently with the experimental group B, the no-interventional group will be asked to complete the online questionnaires three times (before the start, after completion and three months later). Number of participants:11.
62037105|NCT06361147|EXPERIMENTAL|Psychoeducational program (group C - Ex. gr)|"This group of volunteers is going to participate in the online psychoeducational training program for ASD. Number of participants:11.~To evaluate the effectiveness of the program, participants will be asked to complete the online questionnaires three times (before the start, after completion and three months later)."
62428858|NCT00729365|PLACEBO_COMPARATOR|Dippers - Placebo Treated|Subjects with normal nighttime blood pressure profile that decreases at night (Dippers). This group are all given placebo.
62428859|NCT00729365|PLACEBO_COMPARATOR|NonDippers - Placebo Treated|Subjects with nighttime blood pressure that does not drop during the night (non-dippers). This group will be given placebo.
62428860|NCT00729365|ACTIVE_COMPARATOR|NonDippers - Ramipril Treated|Subjects with nighttime blood pressure that does not drop during the night (non-dippers). This group will be given ACE inhibitor (study medication).
62428861|NCT01860768||acute aortic dissectin patients|definite diagnosis by computed tomography arteriography (CTA).
62814440|NCT05948735|NO_INTERVENTION|Control without intervention|Participants in the control group will be instructed to maintain their daily routine. At the end of the sessions, participants will be directed to independently perform nine exercises at home, a minimum of twice per week for six months.
62428862|NCT01860768||acute chest pain patients|aortic dissection is exclude by aorta CTA
62596434|NCT00730119||Neonates|Subjects ages birth to 30 days
62814441|NCT03285724|EXPERIMENTAL|Harpoon Medical Transapical device TSD-5|This is a prospective, single arm, nonrandomized, early feasibility study to evaluate the safety and performance of the Harpoon Medical Device.
62037106|NCT06361147|NO_INTERVENTION|Psychoeducational program (group C - Co. gr)|Concurrently with the experimental group C, the no-interventional group will be asked to complete the online questionnaires three times (before the start, after completion and three months later). Number of participants:11.
62037107|NCT06361147|EXPERIMENTAL|Psychoeducational program (group D - Ex. gr)|"This group of volunteers is going to participate in the online psychoeducational training program for ASD. Number of participants:11.~To evaluate the effectiveness of the program, participants will be asked to complete the online questionnaires three times (before the start, after completion and three months later)."
62037108|NCT06361147|NO_INTERVENTION|Psychoeducational program (group D - Co. gr)|Concurrently with the experimental group D, the no-interventional group will be asked to complete the online questionnaires three times (before the start, after completion and three months later). Number of participants:11.
62238346|NCT05398250|ACTIVE_COMPARATOR|Safety Planning Intervention Tailored for Autistic Individuals|The Safety Planning Intervention Tailored for Autistic individuals (SPI-A) is a brief collaborative intervention that results in an individually tailored plan designed to lower the short-term risk of suicide in autistic youth.
62238347|NCT05398250|ACTIVE_COMPARATOR|Safety Planning Intervention Tailored for Autistic Individuals Plus Structured Follow-Up Contacts|The Safety Planning Intervention Tailored for Autistic individuals plus structured follow-up contacts (SPI-A+) is a multi-component intervention comprised of SPI-A and structured follow-up consisting of at least 2 brief contacts.
62238348|NCT02678416|EXPERIMENTAL|IV Acetaminophen|All participants receive IV acetaminophen as one of 4 interventions in random sequence
62238349|NCT02678416|EXPERIMENTAL|Oral Acetaminophen|All participants receive oral acetaminophen as one of 4 interventions in random sequence
62238350|NCT02678416|EXPERIMENTAL|Placebo|All participants receive placebo as one of 4 interventions in random sequence
62428863|NCT05626010|ACTIVE_COMPARATOR|control group|acetaminophen 1g iv dripping
62428864|NCT05626010|EXPERIMENTAL|experimental group|the combination of acetaminophen 1g and ibuprofen 300mg iv dripping
62428865|NCT04744064|EXPERIMENTAL|Soccer and protein supplementation|Soccer training and post exercise supplementation of protein enriched beverage
62428866|NCT04744064|EXPERIMENTAL|Soccer and carbohydrate supplementation|Soccer training and post exercise supplementation of carbohydrate enriched beverage
62428867|NCT04744064|NO_INTERVENTION|Control group|A preliminary control group continueing normal lifestyle
62596435|NCT00730119||Infants|Subjects aged \>30 days to 2 years
62596436|NCT00730119||Adults|Subjects aged 18 years of age or older
62596437|NCT04507802|EXPERIMENTAL|Non invasive ventilation via helmet|Patients who require noninvasive ventilation via Face mask for more than 8 hours will continue using noninvasive ventilation via facemask.
62814442|NCT06375200||Individuals with suicidal thoughts (Questionnaire)|"Anticipated n=274~* Adults (≥18y/o)~* Experienced suicidal thoughts in the past three year~* Access to internet administered a one time online questionnaire (15-20 min.)"
62238351|NCT02678416|EXPERIMENTAL|Morphine|All participants receive morphine as one of 4 interventions in random sequence
62814443|NCT06375200||Individuals with suicidal thoughts (Focus Group)|"Anticipated n=60~* Adults (≥18y/o)~* Experienced suicidal thoughts in the past three year~* Access to internet administered a one time online background questionnaire (5-10min.) and partake in a focus group (2h)"
62428868|NCT04494282|ACTIVE_COMPARATOR|Same day|The ERP will be performed the same day of the endoscopic drainage of PP
62428869|NCT04494282|ACTIVE_COMPARATOR|Other day|The ERP will be performed 6 weeks after the endoscopic drainage of PP.
62428870|NCT06320899|EXPERIMENTAL|SpineShape System IV straight rod elastic|Dynamic stabilization of lumbar segments using SpineShape System IV straight rod elastic (high-flex)
62428871|NCT06320899|EXPERIMENTAL|SpineShape System IV straight rod medium|Dynamic stabilization of lumbar segments using SpineShape System IV straight rod medium (mid-flex)
62428872|NCT06320899|ACTIVE_COMPARATOR|SpineShape System IV straight rod stiff|Dynamic stabilization of lumbar segments using SpineShape System IV straight rod stiff (low-flex)
62428873|NCT02415868||Low pH|Post Menopausal women with vaginal pH of 4.5 or below
62238352|NCT05893277|EXPERIMENTAL|Intervention|Four sessions with husband containing standard primary care based Motivational Interviewing techniques to reduce AUD in community populations. Wife joins 4th session on relapse prevention and support. This is followed by six Behavioral Couples Therapy sessions - see intervention description for content. All sessions are weekly, 1 hour in duration, delivered in person by a trained study nurse and include role plays and assignments to practice between sessions. Comic strips and graphics reinforce lessons and skills taught throughout the sessions.
62428874|NCT02415868||High pH|Post Menopausal women with vaginal pH of 5.5 or above
62428875|NCT05450042|EXPERIMENTAL|SELUTION SLR DCB|Sustained Limus Release drug eluting balloon
62428876|NCT05450042|ACTIVE_COMPARATOR|Paclitaxel eluting balloon|Conventional: Medtronic INpact
62428877|NCT05114265|EXPERIMENTAL|Part 1: Single ascending dose|Single dose of oral KUR-101 or oral placebo
62428878|NCT05114265|EXPERIMENTAL|Part 2: Three-way crossover|Single dose of oral KUR-101, oral placebo and oral OxyNorm
62428879|NCT04358731|EXPERIMENTAL|NmCV-5|"A total of 1640 subjects 18 to 85 years of age will be accrued contemporaneously across three age groups - 18 to 29 years, 30 to 60 years, and 61 to 85 years.~Within each age group subjects will be randomly assigned in a 3:1 ratio to receive either NmCV-5 or Menactra.~The NmCV-5 subjects in 18-29 year age group will be further randomized 1:1:1 into three different lots (Lot A, B \& C) of NmCV-5.~Total 1230 subjects will be enrolled in NmCV-5 arm."
62428880|NCT04358731|ACTIVE_COMPARATOR|Menactra|"Subjects will be randomly assigned in a 3:1 ratio to receive either NmCV-5 or Menactra.~In Menactra arm, total 410 subjects will be enrolled."
62428881|NCT01508351||Propofol Induction|All patients receiving propofol induction of anesthesia who are ASA 1-3
62428882|NCT01016496|EXPERIMENTAL|Action observation plus repetition|Observation of actions and repetition of the same actions
62428883|NCT01016496|ACTIVE_COMPARATOR|repetition only|repetition of gestures
62428884|NCT04952441|EXPERIMENTAL|Intervention Group|Intervention group will attend the RISE program which consists of eight 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor
62428885|NCT04952441|ACTIVE_COMPARATOR|Wait-list Control Group|The control group will attend the RISE program after the 3 month wait-list period (study months 6-7)
62428886|NCT03605771||Advanced Melanoma|"Patients of legal age with stage III, metastatic, or unresectable melanoma at first diagnosis after January 8, 2018. First diagnosis is understood as:~1. Disease onset as metastatic or unresectable disease.~2. First metastatic or unresectable relapse in the pre-established dates (after January 8, 2018) in a patient with previous localised melanoma and completely resected on dates before the pre-inclusion period."
62428887|NCT03364985|EXPERIMENTAL|Cohort 1: DWP16001 Amg|DWP16001 Amg, tablets, orally, single dose administration
62814444|NCT06375200||Healthcare providers (Questionnaire)|"Anticipated n=360~* Healthcare providers (eg GP's, psychiatrists, medical doctors, psychologists, psychotherapists, and nurses working in healthcare) (≥18y/o)~* Previously encountered men with suicidal thoughts and/or behaviour professionally administered a one time online questionnaire (10-15 min.)"
62814445|NCT06375200||Healthcare providers (Focus group)|"Anticipated n=20~* Healthcare providers (eg GP's, psychiatrists, medical doctors, psychologists, psychotherapists, and nurses working in healthcare) (≥18y/o)~* Previously encountered men with suicidal thoughts and/or behaviour professionally administered a one time online questionnaire (10-15 min.) and optionally partake in an online focus group (2h)"
62596438|NCT04507802|NO_INTERVENTION|Non invasive ventilation via facemask|Patients assigned to the conventional ventilation group will continue noninvasive ventilation via facemask
62596439|NCT03440762|OTHER|AF awareness education|AF awareness education face to face
62596440|NCT05091931||Guidance® UTI pathway (standard lab workflow)|Guidance® UTI pathway with antibiotic sensitivity and microbial testing results available to ordering provider within 48 hours of lab receipt. Includes confirmation by the clinical lead that the ordering provider has acted upon results as soon as they are made available. The lab will follow current workflows in terms of result reporting. Treatment based on local standard clinical antibiotic selection with or without empiric therapy.
62428888|NCT03364985|EXPERIMENTAL|Cohort 2: DWP16001 Bmg|DWP16001 Bmg, tablets, orally, single dose administration
62428889|NCT03364985|EXPERIMENTAL|Cohort 3: DWP16001 Cmg|DWP16001 Cmg, tablets, orally, single dose administration
62814446|NCT01447589|EXPERIMENTAL|Nelfinavir plus radical radiotherapy|Nelfinavir given in combination with radical RT
62428890|NCT03364985|EXPERIMENTAL|Cohort 4: DWP16001 Dmg|DWP16001 Dmg, tablets, orally, single dose administration
62428891|NCT03364985|EXPERIMENTAL|Cohort 5: DWP16001 Emg|DWP16001 Emg, tablets, orally, single dose administration
62428892|NCT03364985|EXPERIMENTAL|Cohort 6: DWP16001 Fmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
62428893|NCT03364985|EXPERIMENTAL|Cohort 7: DWP16001 Gmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
62428894|NCT03364985|EXPERIMENTAL|Cohort 8: DWP16001 Hmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
62428895|NCT03364985|EXPERIMENTAL|Cohort 9: DWP16001 Img|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
62428896|NCT03364985|EXPERIMENTAL|Cohort 10: DWP16001 Jmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
62428897|NCT03882216|EXPERIMENTAL|test group pouch technique|free connective tissue graft augmentation using pouch technique
62428898|NCT03882216|EXPERIMENTAL|test group modified pouch technique|free connective tissue graft augmentation using modified pouch technique
62428899|NCT00139490|EXPERIMENTAL|A|The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
62596441|NCT05091931||Guidance® UTI pathway (modified lab workflow)|Guidance® UTI pathway with antibiotic sensitivity and microbial testing results reporting to a clinical lead specialist at the urology office within 14 hours of lab receipt. Includes confirmation by the clinical lead that the ordering provider has acted upon results as soon as they are made available. Treatment based on local standard clinical antibiotic selection with or without empiric therapy.
62596442|NCT05091931||Traditional clinical pathway|Local standard clinical practice pattern for UTI testing (e.g., urine analysis, urine culture and sensitivities or molecular testing as available). Treatment based on local standard clinical antibiotic selection with or without empiric therapy
62596443|NCT03555864||Obese|Patients need two intravenous access with infra red
62814447|NCT04988295|EXPERIMENTAL|Arm A: LACP/ACP-L|LACP dosing (study start until 6 November 2022): Participants will receive Lazertinib orally along with Amivantamab, Pemetrexed, and Carboplatin as IV infusion starting on Cycle 1 Day 1 for 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression. ACP-L dosing (from 7 November 2022 until study completion): Participants will receive Amivantamab, Pemetrexed, and Carboplatin starting on Cycle 1 Day 1 for 4 cycles. Lazertinib in ACP-L will start on Cycle 5 Day 1 or sooner if carboplatin is discontinued before cycle 4 (each cycle consists of 21 days). Beginning with Cycle 5 Day 1, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression.
62428900|NCT00139490|ACTIVE_COMPARATOR|B|"The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay."
62428901|NCT00139490|PLACEBO_COMPARATOR|C|Usual Care group
62428902|NCT03252132|ACTIVE_COMPARATOR|12-week resistance training|
62428903|NCT03252132|NO_INTERVENTION|No training|
62428904|NCT00973856|EXPERIMENTAL|PURELL Left Hand/ Placebo Right Hand|"One product will be assigned to each hand to minimize treatment confusion for the participants.~PURELL VF481 Left Hand/ Placebo Right Hand"
62428905|NCT00973856|PLACEBO_COMPARATOR|Placebo Solution Left Hand/ PURELL Right hand|"One (1) product will be assigned to each hand to minimize treatment confusion for the participants PURELL VF481 Right Hand/ Placebo Left Hand~One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed"
62428906|NCT00786266|ACTIVE_COMPARATOR|NIOSH shiftwork booklet|
62037109|NCT04644250|EXPERIMENTAL|Arm1|Arm1:preoperative Toripalimab with chemoradiotherapy group Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31. And radiotherapy will start from day 1 to 31 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy. Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45. After the above neoadjuvant therapy is over, the short-term efficacy evaluation will be performed first, and then a scheduled radical radical resection will be performed from days 59 to 73.
62814448|NCT04988295|ACTIVE_COMPARATOR|Arm B: CP (Carboplatin and Pemetrexed)|Participants will receive Pemetrexed in combination with Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Pemetrexed as maintenance until disease progression.
62814449|NCT04988295|EXPERIMENTAL|Arm C: ACP (Amivantamab, Carboplatin and Pemetrexed)|Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression.
62814450|NCT04988295|EXPERIMENTAL|Arm A2 (Extension Cohort): ACP-L|Participants will receive Amivantamab, Pemetrexed and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days), Lazertinib will start on C5D1 or sooner if carboplatin is discontinued earlier). After 4 cycles, participants will receive Pemetrexed, Amivantamab, Lazertinib as maintenance until disease progression.
62238353|NCT05893277|NO_INTERVENTION|Enhanced usual care|For ethical reasons, to ensure participants in the control arm receive care for IPV and AUD, a) trained staff will conduct initial safety assessments for all patients; b) for IPV, wives will be referred to a legal cell at NIMHANS, a one-stop IPV center, and given information re. their options and local resources such as contact information for local organizations that can provide legal advice, counseling, and shelters; c) for AUD, participants will receive a brief educational session based on the World Health Organization's (WHO) manual for managing AUD in PHCs and referral to NIMHANS, a tertiary care mental health and addictions treatment center that has a dedicated referral system with the PHCs.
62428907|NCT00786266|EXPERIMENTAL|Sleep Enhancement Training System|
62814451|NCT04988295|EXPERIMENTAL|Arm C2 (Extension Cohort): ACP|Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression.
62428908|NCT05097378|EXPERIMENTAL|EncoBini Arm|Oral encorafenib 450mg once daily and oral binimetinib 45mg twice daily for 8 weeks pre-operative and for up to 44 weeks post-operative.
62814452|NCT04166812||patients with early COPD|diagnosis according to current GOLD recommendations
62814453|NCT04166812||patients at risk for COPD|no current diagnosis according to GOLD recommendations, but at risk for COPD
62238354|NCT05815290|EXPERIMENTAL|dMMR/MSI-H colon cancer|
62428909|NCT05097378|ACTIVE_COMPARATOR|Standard Arm|Immediate surgery followed by Investigator's choice of standard adjuvant therapy to commence within 12 weeks of surgery and to continue for up to 52 weeks.
62428910|NCT02713243|EXPERIMENTAL|LJN452 followed by placebo|Randomized patients in this arm will receive single oral dose of LJN452 daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of placebo daily for 14 days.
62596444|NCT05109442|EXPERIMENTAL|Escalation Phase|The Escalation phase will determine the MTD/RP2D of AFM24 in combination with atezolizumab. A traditional 3+3 design will be used to determine the RP2D.
62814454|NCT00781768|PLACEBO_COMPARATOR|Standard PO (Zofran + Dexamethasone)|Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron (Zofran) 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion.
62037110|NCT04806880||users|Users of web-application
62428911|NCT02713243|EXPERIMENTAL|Placebo followed by LJN452|Randomized patients in this arm will receive single oral dose of placebo daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of LJN452 daily for 14 days.
62428912|NCT00765323|ACTIVE_COMPARATOR|1|84 mg octreotide implant for 6 months
62428913|NCT00765323|ACTIVE_COMPARATOR|2|Injections of Sandostatin LAR Depot(20, 30, 40 mg) every 4 weeks
62428914|NCT00283686|ACTIVE_COMPARATOR|Study A, Arm 1|Lisinopril + Telmisartan (ACE-I + ARB) and standard blood pressure control of 120-130/70-80 mm Hg
62428915|NCT00283686|ACTIVE_COMPARATOR|Study A, Arm 2|Lisinopril + Telmisartan (ACE-I + ARB) and low blood pressure control of 95-110/60-75 mm Hg
62428916|NCT00283686|PLACEBO_COMPARATOR|Study A, Arm 3|Lisinopril + Placebo (ACE-I + Placebo) and standard blood pressure control of 120-130/70-80 mm Hg
62428917|NCT00283686|PLACEBO_COMPARATOR|Study A, Arm 4|Lisinopril + Placebo (ACE-I + Placebo) and low blood pressure control of 95-110/60-75 mm Hg
62428918|NCT02476734||Diffuse Large B-cell Lymphoma|There is no intervention. Will undergo baseline FDG-PET/CT to be performed within 6 weeks of infusion of CART-19 autologous T-cell therapy in a different study and then undergo repeat FDG-PET/CT at approximately 1 month after infusion. Infusion of CART-19 autologous T-cell therapy is not part of this study.
62596445|NCT05109442|EXPERIMENTAL|Expansion Phase|The expansion phase will collect preliminary evidence of efficacy and further confirm the safety of AFM24 in combination with atezolizumab.
62596446|NCT05117281|ACTIVE_COMPARATOR|spinal group|Plain, isobaric levobupivacaine(0.25%) 0.25 mg/kg
62814455|NCT00781768|ACTIVE_COMPARATOR|Aprepitant (MK-869) + Standard PO|Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO \[blinded\] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO \[blinded\] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
62814456|NCT05981196||Liver Transplant Patients|Subjects with end-stage liver disease and being referred for transplant evaluation will fill out questionnaires about their background, emotions, and behaviors.
62814457|NCT06334393|EXPERIMENTAL|VLA1601 Low dose|
62814458|NCT06334393|EXPERIMENTAL|VLA1601 Low dose + CpG 1018®|
62814459|NCT06334393|EXPERIMENTAL|VLA1601 Low dose + 3M-052-AF|
62814460|NCT06334393|EXPERIMENTAL|VLA1601 Medium dose|
62814461|NCT06334393|EXPERIMENTAL|VLA1601 High dose|
62814462|NCT06112171|OTHER|Intravascular lithotripsy arm|Treatment with Lithotripsy system followed by Supera stent implantation in lesion segments with severe calcification.
62814463|NCT06112171|OTHER|Standard lesion preparation arm|Treatment with Balloon angioplasty with a conventional and/or high-pressure balloon angioplasty followed by Supera stent implantation in lesion segments with severe calcification.
62814464|NCT03938311|EXPERIMENTAL|very early rehabilitation|early mobilization initiates within 24h from the onset of the disease
62814465|NCT03938311|EXPERIMENTAL|relative early rehabilitation|early mobilization initiates between 24-72h from the onset of the disease
62814466|NCT03938311|EXPERIMENTAL|late mobilization group|early mobilization initiates after 72h from the onset of the disease
62238355|NCT05815290|EXPERIMENTAL|dMMR/MSI-H rectal cancer|
62238356|NCT01210079|EXPERIMENTAL|Gabapentin|
62238357|NCT01210079|PLACEBO_COMPARATOR|Placebo|
62814467|NCT05968820|EXPERIMENTAL|Sleep Health Enhancement Intervention|The sleep health enhancement intervention is a 4-week, 1x/week one-one-one program with a graduate research assistant who will be trained and supervised by the PI in provision of the sleep health enhancement intervention.
62814468|NCT05968820|NO_INTERVENTION|Wait-List Control Group|The wait-list control group will be encouraged to continue with their usual activities and sleep habits during the wait period between baseline and reassessment and will undergo the sleep health enhancement intervention following the initial reassessment.
62814469|NCT04874714|EXPERIMENTAL|MM09-MG01(30.000-30.000)|30,000 AU/mL of MM09 and 30,000 AU/mL of MG01 of subcutaneous immunotherapy once a month for 11 months
62814470|NCT04874714|EXPERIMENTAL|MG01(30.000)|30,000 AU/mL of MG01 of subcutaneous immunotherapy once a month for 11 months
62814471|NCT04874714|EXPERIMENTAL|MM09(30.000)|30,000 AU/mL of MM09 of subcutaneous immunotherapy once a month for 11 months
62428919|NCT02476734||Follicular Lymphoma|There is no intervention. Will undergo baseline FDG-PET/CT to be performed within 6 weeks of infusion of CART-19 autologous T-cell therapy in a different study and then undergo repeat FDG-PET/CT at approximately 1 month after infusion. Infusion of CART-19 autologous T-cell therapy is not part of this study.
62428920|NCT01389206||Standard of care|Observational study to improve the management of PAH patients through an evidence-based approach aimed at achieving optimal WHO functional class (FC) treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi.
62428921|NCT02015468|EXPERIMENTAL|Early mobilization|
62428922|NCT02015468|EXPERIMENTAL|Late mobilization|
62428923|NCT00990119|EXPERIMENTAL|High FLow Therapy|Use of High Flow Therapy for support of Respiratory Insufficiency
62238358|NCT05419843|EXPERIMENTAL|HSCT arm group|"1. Conditioning regimen~2. Stem cell source Only Bone Marrow With a minimal target dose of 4x108 nucleated cells/kg recipient ideal body weight. If the graft is less rich than the minimum target dose, it can be administered at the discretion to the physician.~3. GVHD Prophylaxis~4. Prevention of EBV reactivation : Rituximab 150mg/m2 IV at Day+5 post HSCT."
62238359|NCT05386784|ACTIVE_COMPARATOR|Raloxifen plus cholecalciferol|Raloxifene 60mg + Cholecalciferol 800 IU
62238360|NCT05386784|ACTIVE_COMPARATOR|Cholecalciferol|Cholecalciferol 800 IU
62238361|NCT06026228|PLACEBO_COMPARATOR|Control group|The control group will receive daily a placebo capsule per os at mealtime (just before or after) for a period of 6 months
62428924|NCT00990119|ACTIVE_COMPARATOR|NiPPV|
62428925|NCT00964223|EXPERIMENTAL|Duac gel|Subjects will apply Duac gel once a day to one-half of their face and and apply Epiduo gel on the other side of their face once daily for the first 2 weeks.
62596447|NCT05117281|ACTIVE_COMPARATOR|caudal group|Plain, isobaric levobupivacaine (0.25%) 1 ml/kg
62428926|NCT00964223|ACTIVE_COMPARATOR|Epiduo gel|Subjects will apply Duac gel once a day to one-half of their face and and apply Epiduo gel on the other side of their face once daily for the first 2 weeks.
62428927|NCT03523507|EXPERIMENTAL|Active: rTMS|Participants will receive 20 bilateral treatment sessions provided over approximately a 5-week period. Daily sessions entail approximately 60 minutes of time.
62428928|NCT03523507|SHAM_COMPARATOR|Sham: rTMS|Sham: Repetitive Transcranial Magnetic Stimulation; Participants will receive sham treatment designed to have similar sound and tactile sensation, without producing active stimulation.
62596448|NCT00754520|EXPERIMENTAL|Ceramic On Metal|This arm utilizes the ceramic on metal articulation using the M2a-38™ mm cup.
62596449|NCT00754520|ACTIVE_COMPARATOR|Metal on Metal|This arm utilizes the metal on metal articulation using M2a-38™ mm cup.
62596450|NCT01305889|EXPERIMENTAL|problem solving therapy|subjects will receive 12 weeks of weekly problem solving therapy
62596451|NCT01305889|EXPERIMENTAL|sertraline|12 weeks of sertraline
62596452|NCT04483492||1|newborns under 32 weeks with respiratory support if they are decided to start caffeine treatment
62596453|NCT06433661|EXPERIMENTAL|Sequence 1: Etavopivat: fed-fasted|Participants will receive a single dose of Etavopivat in fed condition in period 1 and a single dose of Etavopivat in fasted condition in period 2.
62596454|NCT06433661|EXPERIMENTAL|Sequence 2: Etavopivat: fasted-fed|Participants will receive a single dose of Etavopivat in fasted condition in period 1 and a single dose of Etavopivat in fed condition in period 2.
62596455|NCT06622395|EXPERIMENTAL|Remote Diagnosis Arm|"Remote Diagnostic Arm (Teleconsultation):~First Teleconsultation (V1): A child psychiatrist or psychologist specializing in ASD conducts the ADI-R (short version) interview with the parents or legal guardian via teleconsultation. The professional will score the items from the algorithm. After the consultation, the professional completes a questionnaire assessing the technical aspects of the remote interview (e.g., video quality, connection stability).~Second Teleconsultation (V2): During the BOSA remote assessment, the professional sends the parent/caregiver instructions and a video link. The parent watches the video and follows guidance on how to position themselves and the child for optimal visibility. The parent then carries out the BOSA activities under supervision. The professional observes the child's behavior and provides time guidance. Two questionnaires are completed: one on the technical aspects of the consultation and the second on parent-child interaction."
62596456|NCT06622395|NO_INTERVENTION|In person Arm|"In-person Arm (as usual) :~Visit V0 (In-person ADI-R): The ADI-R interview is conducted in person by a psychiatrist or psychologist.~Visit V3 (In-person ADOS-2): A different randomly assigned professional will perform an in-person ADOS-2 evaluation."
62596457|NCT03367052|EXPERIMENTAL|Two level Prodisc-C vivo|Two level Prodisc-C vivo cervical artificial disc replacement.
62596458|NCT03367052|ACTIVE_COMPARATOR|Hybrid|This group of patients will be treated with hybrid construct, i.e., one level of Prodisc-C vivo and one level of anterior cervical discectomy fusion (ACDF).
62596459|NCT02183259|EXPERIMENTAL|ESR 1150 CL capsule|
62596460|NCT02183259|EXPERIMENTAL|ESR 1150 CL ampoule|
62596461|NCT02510105|EXPERIMENTAL|ARDS patients|
62596462|NCT05161455|EXPERIMENTAL|A-PRF|
62814472|NCT04874714|PLACEBO_COMPARATOR|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
62814473|NCT03631485||parents having children with cancer|No intervention.
62814474|NCT05249140|EXPERIMENTAL|Active Repetitive Transcranial Magnetic Stimulation|rTMS parameters are intensity 110% resting motor threshold (RMT), frequency 1Hz, duration = 30 minutes (1800 stimulations), targeting the right DLPFC. To target the dorsolateral prefrontal cortex (DLPFC) for rTMS treatment we will use the traditional method (i.e. the 5cm rule; George et al., 1995, 1996; Herwig et al., 2001, 2003; MacMaster et al., 2019), in which the TMS coil is placed 5 cm anterior to the participant's motor cortex along a line to the nasion. Treatments will occur on weekdays at the same time of day for 4 weeks (20 total).
62814475|NCT05249140|SHAM_COMPARATOR|Sham Repetitive Transcranial Magnetic Stimulation|For the sham rTMS group, a sham coil is used: this sham method does not emit any magnetic field, and therefor does not affect brain activity, but it does produce auditory sensations that is indistinguishable from active rTMS in naïve subjects
62814476|NCT05986916||Single arm|This is a single arm study in which all participants undergo the same research procedures.
62814477|NCT04604600|EXPERIMENTAL|amyloid PET、T807 PET|PET/CT
62814478|NCT04410497|EXPERIMENTAL|Porcine xenograft|Conformité Européenne/European Conformity (CE)-marked dressing product used in clinical practise (Standard of care).
62814479|NCT04410497|ACTIVE_COMPARATOR|Silver foam|Conformité Européenne/European Conformity (CE)- marked dressing product used in clinical practise
62814480|NCT02948855||Tm group|Simple thymoma group：The patients have suffered thymoma only and have no other complications.
62814481|NCT02948855||Tm+MG group|Thymoma complicated with myasthenia gravis (MG) group: The patients have suffered thymoma and myasthenia gravis in the mean time.
62814482|NCT02948855||Tm+MG+AD group|"Thymoma complicated with myasthenia gravis and other autoimmune diseases (AD) group:~The patients have suffered thymoma, myasthenia gravis and other autoimmune diseases in the mean time."
62814483|NCT03010696||Healthy subjects|Normal kidney function
62814484|NCT03010696||ESRD patients|Diagnosed as ESRD with hemodialysis
62814485|NCT03842696|EXPERIMENTAL|Vorinostat|
62814486|NCT03290443|EXPERIMENTAL|Enasidenib (CC-90007) tablet|Subjects will receive one 100 mg enasidenib (CC-90007) tablet the morning of Day 1 which will be administered in the fasted state.
62814487|NCT03272750|EXPERIMENTAL|Bioscalin® new formulation with Galeopsis Segetum|2 placebo capsules + 1 Bioscalin with Galeopsis Segetum table
62814488|NCT03272750|ACTIVE_COMPARATOR|REFERENCE PRODUCT|2 reference product capsules + 1 placebo tablet
62596463|NCT05161455|EXPERIMENTAL|A-PRF+ allograft bone|
62596464|NCT05161455|ACTIVE_COMPARATOR|allograft bone+crosslinked collagen membrane|
62596465|NCT05161455|SHAM_COMPARATOR|collagen plug|
62596466|NCT04685460|EXPERIMENTAL|3D-printed bolus|
62814489|NCT03272750|PLACEBO_COMPARATOR|PLACEBO|2 placebo capsules + 1 placebo tablet
62596467|NCT04685460|NO_INTERVENTION|Conventional bolus|
62596468|NCT05724628|EXPERIMENTAL|Operative Arm|Operation (laparoscopic appendectomy) will be performed to remove appendix.
62596469|NCT05724628|EXPERIMENTAL|Non-Operative Arm|No operation will be performed, and instead, will receive intra-venous (IV) antibiotics, transitioned to by mouth (oral) antibiotics
62596470|NCT01747889|EXPERIMENTAL|Electronic system|patients managed with an electronic chest drainage system
62596471|NCT01747889|NO_INTERVENTION|traditional system|patients managed with a traditional analogue chest drainage system
62596472|NCT01335217|OTHER|Open-label TNS treatment|There is only one arm in this open label treatment of MDD co-occuring with PTSD.
62596473|NCT00536549|EXPERIMENTAL|A|Guardina RT monitoring
62596474|NCT00536549|ACTIVE_COMPARATOR|B|
62814490|NCT00481832|EXPERIMENTAL|T & B Cell Mobilization Auto & Allo HCT|A transplant regimen that conditions the subjects using total lymphoid irradiation (TLI) and anti-thymocyte globulin(ATG) which will reduce acute graft-vs-host disease to negligible rates while maintaining the anti-tumor graft vs lymphoma GvL benefit. Along with TLI/ATG regiment; Solumedrol will be used as pre-medication and anti-emetic for any side effects. For stem cell mobilization, participants will be given either B Cell NLH or T Cell NHL. Before the filgrastim (G-CSF) mobilized PBPC infusion: acetaminophen, diphenhydramine and hydrocortisone will also be given as another set of pre-medications. BCNU, Etoposide, and Cyclophosphamide will be used as a preparative regimen. Cyclosporine and mycophenolate mofetil will be administered as an immunosuppressant after transplantation. Lastly, rituximab will be infused at the end of the transplantation regimen.
62814491|NCT02043756|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome|Dose escalation will begin at 6mg/m2 to 16mg/m2,4 weeks apart
62814492|NCT02043756|ACTIVE_COMPARATOR|Mitoxantrone ,injection|When the dose of experiment drup up 10mg/m2,10mg/m2 of Mitoxantrone as active comparator
62814493|NCT01820299|EXPERIMENTAL|Grape Seed Extract and Vitamin D|All patients will take Grape Seed Extract from Day 1 to Day 21. All patients will take Grape Seed Extract and Vitamin D together from Day 22 until Day 64. For all patients on the study, patients will take Vitamin D once a day at a dose of 4000IU.
62814494|NCT03220971||proposed cross-section study|"1. 100 subjects with NAFLD/NASH and negative anti-HCV Ab~2. 50 subjects with HCC and negative anti-HCV Ab~3. 50 subjects with HCC and positive for genotype-1 HCV~4. 50 controls with all negative for NAFLD/NASH but positive for genotype-1 HCV~5. 50 controls with all negative for NAFL, NASH and HCV"
62238362|NCT06026228|EXPERIMENTAL|Experimental group|The experimental group will receive daily per os one capsule of BioGaia® Gastrus probiotic (combination of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475) dosed at 108 colony forming units (CFU)/day (distributed by the laboratory PEDIACT France), taken at mealtime (just before or after) for a period of 6 months
62814495|NCT03220971||proposed longitudinal study|"1. 50 NAFLD/NASH patients and positive for genotype-1 HCV with SVR~2. 10 NAFLD/NASH patients and positive for genotype-1 HCV without SVR~3. 10 HCC patients and positive for genotype-1 HCV with SVR~4. 10 HCC patients and positive for genotype-1 HCV without SVR~5. 50 chronic hepatitis C but not NAFLD patients with SVR~6. 10 chronic hepatitis C but not NAFLD patients without SVR"
62814496|NCT04818268|EXPERIMENTAL|Adaptation to Altered Auditory Feedback|Adaptation to Altered Auditory Feedback
62814497|NCT04818268|EXPERIMENTAL|Auditory Sensory Memory|Auditory Sensory Memory
62814498|NCT04818268|EXPERIMENTAL|Somatosensory Sensory Memory|Somatosensory Sensory Memory
62238363|NCT03431857||TESS V2 Prosthesis|Single study patient cohort, including 106 patients who meet the inclusion/exclusion criteria and who received the TESS V2 shoulder prosthesis.
62596475|NCT03721952|EXPERIMENTAL|Facilitator-Based Intervention|The 'Facilitator-Based Intervention' includes patient and family member subjects.
62596476|NCT03721952|NO_INTERVENTION|Usual Care|The 'Usual Care' arm includes patient and family member subjects.
62596477|NCT06622200|EXPERIMENTAL|Mindfulness-based intervention|"The standardized, theory based MBI was introduced to the experimental group (Smith, 2005). This 30-minute protocol involves a series of activities, including paying attention to and being aware of breath, body sensations, thoughts, and sounds without judgment. This protocol is a widely recognized and utilized method due to its simplicity and accessibility, making it an ideal choice for this study (Alhawatmeh et al., 2022; Smith, 2005).~Participants completed three weekly sessions of MBI for five weeks during their hemodialysis treatments (Alhawatmeh et al., 2022). Participants were provided with audio recordings of the MBI protocol, which they could practice during hemodialysis sessions. These recordings were delivered via email and WhatsApp, depending on their preference. This audio recording was developed based on the Smith's protocol by a certified study researcher who had a higher degree in nursing and extensive experience in practicing MBI."
62238364|NCT02887807|EXPERIMENTAL|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
62238365|NCT02887807|PLACEBO_COMPARATOR|Control|Single intravenous bolus of placebo (2.5 mg/kg) at the onset of resuscitation
62428929|NCT00673322|EXPERIMENTAL|Gene Modified T Cells|Modified T cells
62814499|NCT04818268|EXPERIMENTAL|Adaptation to Altered Auditory Feedback + cTBS to 46v|Adaptation to Altered Auditory Feedback + cTBS to 46v
62238366|NCT05529823|EXPERIMENTAL|Experimental group|The women in this group will have a warm shower during the labor process.
62428930|NCT03313479||Group 1|GA and Dexmedetomidine
62428931|NCT03313479||group 2|GA and peribulbar
62428932|NCT03313479||group3|GA and xylocaine gel
62596478|NCT06622200|NO_INTERVENTION|Control Group|The control group did not receive any intervention from the researcher.
62814500|NCT04818268|EXPERIMENTAL|Sensory Memory + cTBS to 46v|Sensory Memory + cTBS to 46v
62814501|NCT01394055|ACTIVE_COMPARATOR|RM-131|
62814502|NCT01394055|PLACEBO_COMPARATOR|Placebo|
62814503|NCT01961505|EXPERIMENTAL|Topical Tripterygium group|Patients were treated with topical compound tripterygium for 1 hour, twice per day. Area dosages were as followed that each 1st to 5th metacarpophalangeal joints (MCPJs), 1st to 5th proximal interphalangeal joints (PIPJs) and wrist was 3 ml, each elbow and ankle was 5 ml, each knee was 10 ml.
62238367|NCT05529823|NO_INTERVENTION|Control group|Women in the control group will not be interfered with and will be followed in line with the routine follow-up protocol of the clinic.
62238368|NCT01196533|EXPERIMENTAL|Non Invasive Monitoring|Intervention: Device: Non invasive peripheral blood monitoring
62238369|NCT05032768||Severe radiation dermatitis|RTOG/EORTC grade 2 and above
62238370|NCT05032768||No or mild radiation dermatitis|RTOG/EORTC grade 0 or 1
62238371|NCT05198479|EXPERIMENTAL|Arm 177 Lu-DOTA0-Tyr3-Octreotate|Treatment with 177Lu-DOTATATE consist of a cumulative dose of 23.68 - 29.6 GBq (640 - 800 mCi) 177Lu-DOTA0-Tyr3-Octreotate; Four administrations of 5.92 - 7.4 GBq (160 - 200 mCi) 177Lu-DOTA0-Tyr3-Octreotate; Concomitant amino acids will be given with each administration for kidney protection; 177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity.
62238372|NCT04209465|EXPERIMENTAL|Phase 1 - Dose escalation|In Part A, cohorts of patients with select HER2, HER3, or EGFR alterations will receive increasing doses of BDTX-189. It is expected that up to approximately 70 patients will be enrolled in this dose escalation arm. If an alternative schedule is explored, up to 24 additional patients may be enrolled.
62238373|NCT04209465|EXPERIMENTAL|Phase 2 - Dose expansion|In Part B, patients with a solid tumor harboring specific allosteric HER2 mutations or an HER2 or EGFR exon 20 insertion mutation will receive the recommended Phase 2 dose of BDTX-189. It is expected that approximately 100 participants will be enrolled in this phase 2 portion.
62238374|NCT01344746||Snoring group|"1. Subjects with snoring and AHI ≥ 20 episodes/h (severe SDB).~2. Snorers with AHI \< 20 episodes/h and ≥ 5 episodes/h (moderate SDB)~3. Snorers with AHI \< 5 episodes/h and ≥ 1 episodes/h (mild SDB)"
62238375|NCT01344746||Non-snoring group|"* When testing serum and urinal samples, healthy children without snoring will be chosen as controls.~* When testing lymphoid tissue samples, patients with recurrent infectious tonsillitis (at least five tonsillar infections in less than 6 months) but without snoring will be selected as controls before surgery and recruited to the study, because adenotonsillar tissue can't be obtained from normal children for obvious ethical reasons."
62238376|NCT05099653|EXPERIMENTAL|patients with physical activity|A group of patients with physical activity (protocolized)
62238377|NCT05099653|NO_INTERVENTION|patients without physical activity|A group of patients without physical activity (protocolised)
62238378|NCT06170112||Spinal Orthosis|There are pressure forces applied by the design of the spinal orthosis in changing the biomechanics of the scoliotic spine. In the design of the spinal orthosis designed with the 3-point principle, there is a corrective lateral force applied to the main curvature area and two support forces opposing this force. There are breathing spaces in the back area.
62238379|NCT02920086|EXPERIMENTAL|Nutrition Education Program|Nutrition education for family members of an elderly critically ill patient
62238380|NCT02920086|EXPERIMENTAL|Decision Support Program|Decision support education for family members of an elderly critically ill patient
62238381|NCT02920086|NO_INTERVENTION|Usual Care|No intervention
62238382|NCT05848622|ACTIVE_COMPARATOR|Real-time gait biofeedback (RTGBF)|The RTGBF regimen delivers biofeedback that cues a personalized target to normalize vertical ground reaction force (vGRF) of each limb.
62238383|NCT05848622|SHAM_COMPARATOR|Sham real-time gait biofeedback (Sham RTGBF)|The Sham RTGBF regimen will receive biofeedback that cues their habitual step length determined during the accommodation period on the first session of treadmill walking.
62238384|NCT02505581|EXPERIMENTAL|Oral + Parenteral prophylaxis|
62238385|NCT02505581|ACTIVE_COMPARATOR|Only Parenteral prophylaxis|
62238386|NCT00443638|NO_INTERVENTION|Control Group|Control Group
62238387|NCT00443638|EXPERIMENTAL|Home visitation through pregnancy|Nurse home visitation through pregnancy
62238388|NCT00443638|EXPERIMENTAL|Home visitation through age 2|Nurse home visitation through child age 2.
62238389|NCT00651872||Marx|
62238390|NCT02101450|NO_INTERVENTION|Intra-abdominal removal of the placenta|The uterus will be left in the abdominal cavity and the placenta will be manually removed with uterine massage as soon as possible. After removal of the placenta, the uterus will be dragged out of the abdominal cavity. The cesarean incision will be sutured with no. 1 Vicryl ®. Uterus will be replaced in the abdominal cavity. Intra-abdominal cavity will be cleaned by aspirator and mounted-gauze tampon. The weight of the placenta will be measured. The weight of the gauze tampons will be measured with gravimetric method before and after use.
62238391|NCT02101450|EXPERIMENTAL|Extra-abdominal removal of the placenta|"No drug or device is used. The uterus will be dragged out of the abdominal cavity, prior to removal of the placenta.~The placenta will be manually removed with uterine massage as soon as possible. The cesarean section will be completed as described in No intervention group."
62238392|NCT05860023|NO_INTERVENTION|Control Group|In this group, mothers will only take routine gynecologic. No additional treatment will be applied to the mothers in this group.
62596479|NCT05249322|EXPERIMENTAL|Follow-up alternating between face-to-face consultation and teleconsultation every three months|Patients of this arm will be followed alternating between face-to-face consultation and teleconsultation respecting the recommended frequency (every three months) during 12 months (M+3:teleconsultation - M+6:in-hospital consultation - M+9:teleconsultation - M+12 : in-hospital consultation)
62596480|NCT04476407|EXPERIMENTAL|G1|subjects with nomal renal function
62596481|NCT04476407|EXPERIMENTAL|G2|subjects with mild renal impairment
62596482|NCT04476407|EXPERIMENTAL|G3|subjects with moderate renal impairment
62596483|NCT05356364|ACTIVE_COMPARATOR|Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)|PUMAS combines behavioral sleep strategies with elements from mindfulness-based interventions, and is tailored specifically to meet the unique needs of pregnant women. Behavioral sleep strategies include sleep restriction and stimulus control. Mindfulness elements include guided meditations and engaging in mindful activities. PUMAS consists of 6 60-minute sessions with a therapist along with self-monitoring with sleep diaries. All sessions are delivered via telemedicine during pregnancy.
62596484|NCT05356364|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy for Insomnia (CBTI)|CBTI combines behavioral sleep strategies with cognitive therapy. It is the first-line treatment for insomnia as recommended by the American College of Physicians and the American Academy of Sleep Medicine. Behavioral sleep strategies include sleep restriction and stimulus control. Cognitive therapy includes scheduled worry time and challenging dysfunctional beliefs about sleep. CBTI consists of 6 60-minute sessions with a therapist along with self-monitoring with sleep diaries. All sessions are delivered via telemedicine during pregnancy.
62596485|NCT04558775||Observational Cohort|
62596486|NCT03663465|EXPERIMENTAL|Hawthorn and SGAs|SGAs has a dose of 3-20 gm/day, Hawthorn at a dose of 3 gm/day for six months.
62596487|NCT03663465|ACTIVE_COMPARATOR|Hawthorn|Hawthorn at a dose of 3 gm/day for six months.
62596488|NCT06186830||Patients with temporomandibular disorder|
62596489|NCT03454828|EXPERIMENTAL|obese carbohydrate diet|Obese adolescents with a body mass index (BMI) \>95th percentile.
62596490|NCT03454828|ACTIVE_COMPARATOR|lean carbohydrate diet|Lean adolescents with a body mass index (BMI) \<85th percentile.
62814504|NCT01961505|PLACEBO_COMPARATOR|Topical Placebo group|Patients were treated with topical placebo for 1 hour, twice per day. The dosage was the same as the topical tripterygium group.
62814505|NCT06349798|EXPERIMENTAL|"Nefopam bolus group"|
62814506|NCT06349798|EXPERIMENTAL|"Nefopam CIVI group"|
62814507|NCT06349798|PLACEBO_COMPARATOR|Control group|
62814508|NCT05814185|EXPERIMENTAL|Canine retraction was done by periodontal distractor with two activations per day.|group 1
62596491|NCT06620900|EXPERIMENTAL|Integrated Model of Care|Participants will engage in interdisciplinary intensive outpatient program (IOP) treatment for mild traumatic brain injury with individualized support for substance use (SU) following which they will receive support for SU in the transition support program.
62238393|NCT05860023|EXPERIMENTAL|Aerobic Exercise Group|This group will attend to seven days aerobic exercise program with 65% to 75% of their maximum heart rate monitored with pulse oximeter. Aerobic exercise will take 30 minutes consisting of 5 minute warm up, 20 minute jogging and 5 minute cool down. Prior to discharge pulse oximeter will be given to the participants for self monitorization. Their compliance to exercise will be questioned with daily phone calls.
62428933|NCT04672057|ACTIVE_COMPARATOR|Right hemiparetics|right-sided affected hemiparetic individuals
62596492|NCT05205343||Standard of Care|"questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery.~The questionnaire will ask about your health, appetite, and quality of life. It should take about 3-5 minutes to complete."
62596493|NCT05205343||Control group|"questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery.~The questionnaire will ask about your health, appetite, and quality of life. It should take about 3-5 minutes to complete."
62596494|NCT05117554|EXPERIMENTAL|SAD-casdatifan Dose 1|"Participants will receive Dose 1 of casdatifan orally with water under fasting conditions."
62596495|NCT05117554|EXPERIMENTAL|SAD-casdatifan Dose 2|"Participants will receive Dose 2 of casdatifan orally with water under fasting conditions."
62596496|NCT05117554|EXPERIMENTAL|SAD-casdatifan Dose 3|"Participants will receive Dose 3 of casdatifan orally with water under fasting conditions."
62596497|NCT05117554|EXPERIMENTAL|SAD-casdatifan Dose 4|"Participants will receive Dose 4 of casdatifan orally with water under fasting conditions."
62596498|NCT05117554|PLACEBO_COMPARATOR|SAD-Placebo|Participants will receive matching placebo orally with water under fasting conditions.
62596499|NCT05117554|EXPERIMENTAL|MAD-casdatifan Dose 1|"Participants will receive Dose 1 of casdatifan orally with water under fasting conditions."
62814509|NCT05814185|EXPERIMENTAL|Canine retraction was done by periodontal distractor with four activations per day.|group 2
62814510|NCT05564104|EXPERIMENTAL|Part A: Participants with normal hepatic function|Participants with normal hepatic function will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
62814511|NCT05564104|EXPERIMENTAL|Part A: Participants with mild hepatic impairment|Participants with mild hepatic impairment (Child Pugh Grade A) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
62814512|NCT05564104|EXPERIMENTAL|Part A: Participants with moderate hepatic impairment|Participants with moderate hepatic impairment (Child-Pugh Grade B) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
62814513|NCT05564104|EXPERIMENTAL|Part A: Participants with severe hepatic impairment|Participants with severe hepatic impairment (Child-Pugh Grade C) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
62428934|NCT04672057|ACTIVE_COMPARATOR|Left hemiparetics|left-sided affected hemiparetic individuals
62596500|NCT05117554|EXPERIMENTAL|MAD-casdatifan Dose 2|"Participants will receive Dose 2 of casdatifan orally with water under fasting conditions."
62596501|NCT05117554|PLACEBO_COMPARATOR|MAD-Placebo|Participants will receive matching placebo orally with water under fasting conditions.
62596502|NCT05117554|EXPERIMENTAL|DDI-casdatifan Dose + Midazolam|Participants will receive highest safe dose level of casdatifan from MAD and midazolam orally with water under fasting conditions
62596503|NCT03030144|NO_INTERVENTION|Control group|Routine nursing care
62814514|NCT05564104|EXPERIMENTAL|Part B: Sequence 1|Healthy participants will receive a single dose of cagrilintide Dose 1 intravenously (i.v) at the first dosing visit (Day 1), followed by a single dose of cagrilintide Dose 2 s.c. at the second dosing visit (Day 53).
62814515|NCT05564104|EXPERIMENTAL|Part B: Sequence 2|Healthy participants will receive a single dose of cagrilintide Dose 2 s.c. at the first dosing visit (Day 1), followed by a single dose of cagrilintide Dose 1 i.v at the second dosing visit (Day 53).
62814516|NCT00301808|EXPERIMENTAL|Cisplatin, Docetaxel & Radiation Therapy|Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43; Docetaxel 75 mg/m2 on day 1 of each cycle; Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
62814517|NCT05475249|PLACEBO_COMPARATOR|white yttria-stabilized zirconia abutment|white yttria-stabilized zirconia abutment (PYRCA; BioHorizons, Birmingham, EEUU) without immersion in fluorescent liquid
62814518|NCT05475249|EXPERIMENTAL|fluorescence white yttria-stabilized zirconia abutment|white yttria-stabilized zirconia abutment (PYRCA; BioHorizons, Birmingham, EEUU) with immersion in fluorescent liquid
62037111|NCT03694639|NO_INTERVENTION|Pregabaline group|where patients received pregabaline 150 mg twice daily.
62037112|NCT03694639|ACTIVE_COMPARATOR|Pregabaline plus ganglion impar block group|where patients received pregabaline 150 mg twice daily plus ganglion impar block using 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone.
62428935|NCT04672057|ACTIVE_COMPARATOR|Control|healthy individuals
62428936|NCT05578222|EXPERIMENTAL|treatment group|All patients who met the inclusion criteria and did not meet the exclusion criteria were enrolled in the treatment group
62428937|NCT00002594|EXPERIMENTAL|Ablative chemo followed by autologous bone marrow (ABM) rescue|Autologous bone marrow and/or peripheral blood stem cells (PBSC) are harvested. Patients then receive intensive cyclophosphamide IV over 1 hour on days -8 to -5 and melphalan IV over 15 minutes on days -4 to -2. Bone marrow is reinfused on day 0. PBSC are reinfused on day 0 if used alone or on day 1 if used after autologous bone marrow transplantation (ABMT). Sargramostim (GM-CSF) is administered IV over 2 hours daily beginning 4 hours after ABMT and continuing until blood counts recover.
62428938|NCT06541717|EXPERIMENTAL|İntervention group (n:40)|Students will be shown 3 15-minute videos created by researchers on the anatomy and physiology of the male and female reproductive systems, the physiology of pregnancy, fertility awareness development and its importance in terms of infertility.
62428939|NCT06541717|NO_INTERVENTION|Control group (n:40)|Students will be trained for 2 hours using the classical method on the anatomy and physiology of the male and female reproductive systems, the physiology of pregnancy, fertility awareness development and its importance in terms of infertility.
62596504|NCT03030144|OTHER|Intervention group|Evidence based nursing recommendations for the management of urinary incontinence will be introduced.
62596505|NCT01567566|ACTIVE_COMPARATOR|Local lumbopelvic stabilizers|
62596506|NCT01567566|EXPERIMENTAL|Local lumbopelvic plus hip stabilizers|
62596507|NCT06665295|NO_INTERVENTION|Usual Care|Usual care at our institution involves a teaching visit with a nurse navigator and written handouts.
62814519|NCT00006319||ADA deficient SCID|Patients with ADA deficient SCID
62814520|NCT00006319||Wiskott-Aldrich syndrome|Male patients with Wiskott-Aldrich syndrome
62814521|NCT06098469|EXPERIMENTAL|Neurofeedback|10 neurofeedback sessions + depressive rating scales
62814522|NCT05937841|EXPERIMENTAL|assessment of microvascular function|The investigators use intradermal microdialysis to deliver compound 21 and L-NAME to the cutaneous microvasculature
62814523|NCT05757713|EXPERIMENTAL|teplizumab injection|teplizumab injection, sterile solution for intravenous use
62814524|NCT05473026|EXPERIMENTAL|Gratitude Intervention|"Each participant will receive a gratitude journal (paperback or electronic journal based on preference) for eight weeks and will have the following journaling prompt to complete at least twice a week: There are many things in our lives, both large and small, that we might be grateful about. Think back over the day and write down on the line below all that you are grateful for today (maximum six reasons). The educational goal-setting component will be drawn from the American Cancer Society's Nutrition, Physical Activity, and Cancer toolkit. Participants will be able to choose the order in which they complete the goal-setting modules. Both exercises will be administered daily over eight weeks."
62596508|NCT06665295|EXPERIMENTAL|THRIVE-CAR-T plus usual care|Patients receiving the THRIVE-CAR-T intervention will receive usual care and will use the THRIVE-CAR-T digital application on an iPad when planned to receive CAR-T.
62596509|NCT05893004|EXPERIMENTAL|Test-Retest|sample of convenience headache suffereres will be tested twice
62596510|NCT05248113|EXPERIMENTAL|Intraoperative electrical stimulation of cochlear nerve|Electrical stimulation of the cochlear nerve will be tested intraoperatively in patients undergoing vestibular schwannoma resection.
62814525|NCT05473026|NO_INTERVENTION|Attention Control|"Each participant will receive a journal (paperback or electronic journal based on preference) Participants will receive the following general journaling prompt to complete at least twice a week: What are some memorable events that happened to you today, big, or small (maximum six memories). Write a brief statement about it."
62814526|NCT02251262|EXPERIMENTAL|Whole-body 18FDG-PET-CT scan|18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
62814527|NCT04308421|EXPERIMENTAL|Low level red light/laser|Patients will be treated twice a week for 12 weeks with low irradiation 650 nm +/- 5 nm red light on one randomly allocated side of the face or body
62814528|NCT04308421|NO_INTERVENTION|Control side|An affected area on the contralateral side of the face or body or within a single patch will not be treated
62814529|NCT05245435|OTHER|planned to undergo cytoreductive prostatectomy|planned to undergo cytoreductive prostatectomy
62814530|NCT05245435|OTHER|newly diagnosed metastatic hormone-sensitive prostate cancer patients|planned to undergo androgen deprivation therapy, and/or treatment with abiraterone acetate, and/or enzalutamide and/or docetaxel
62428940|NCT02052037|EXPERIMENTAL|Egg inclusion|Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week) in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions.
62037113|NCT02477696|EXPERIMENTAL|Acalabrutinib|Participants will receive oral acalabrutinib 100 mg twice daily (BID) until disease progression (PD), or unacceptable toxicity, or other reasons for discontinuation, whichever occurs first.
62037114|NCT02477696|ACTIVE_COMPARATOR|Ibrutinib|Participants will receive oral ibrutinib 420 mg once daily (QD) until PD, or unacceptable toxicity, or other reasons for discontinuation, whichever occurrs first.
62037115|NCT06657326|EXPERIMENTAL|BioFreedom™ Ultra DCS|Coronary artery disease patients with high-bleeding risk (HBR) will receive the BioFreedom™ Ultra stent if randomized to this arm (1:1 ratio)
62037116|NCT06657326|ACTIVE_COMPARATOR|BioFreedom™ DCS|Coronary artery disease patients with high-bleeding risk (HBR) will receive the BioFreedom™ stent if randomized to this arm (1:1 ratio)
62037117|NCT02808364|EXPERIMENTAL|Personalized cellular vaccine|Subjects will undergo tumor resection. They will receive biweekly cellular vaccines consisting of mRNA tumor antigen pulsed autologous DCs.
62037118|NCT05596370||biliary cancer|cholangiocarcinoma gallbladder cancer
62428941|NCT02052037|EXPERIMENTAL|Egg exclusion|"Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products.~During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained."
62428942|NCT02758587|EXPERIMENTAL|Dose - escalation|"Does-escalation in an all-comers phase I population, with treatment-refractory advanced solid malignancies, unselected by tumour type. Two cohorts of up to evaluable 6 patients in each:~* Cohort 1: 200mg (IV) pembrolizumab every 3 weeks; plus 200mg (oral) defactinib twice daily~* Cohort 2: 200mg (IV) pembrolizumab every 3 weeks; plus 400mg (oral) defactinib twice daily~Interventions:~* Drug: Defactinib~* Drug: Pembrolizumab"
62428943|NCT02758587|EXPERIMENTAL|Pancreatic|Pancreatic expansion for response assessment (single arm). Optional paired biopsies prior to treatment and after 14 days of treatment. All would have concurrent therapy with pembrolizumab + defactinib (VS-6063) from the start (c.f. NSCLC \& mesothelioma expansions below). 15 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 6
62814531|NCT05245435|OTHER|metastatic castration-resistant prostate cancer patients|who were not pre-treated with enzalutamide or abiraterone acetate and planned treatment with those drugs
62596511|NCT03425266|EXPERIMENTAL|Interactive decision support tool|Online interactive multimedia decision support tool that the patient interacts with before seeing their provider that helps them learn more about chronic pain, identify treatment goals and preferences, and communicate more effectively with their provider. The tool takes between 20-45 minutes to use. It generates and transmits a preference summary for the patient and a summary of relevant shared decision making elements and medical history elements intended for sharing with providers if the patient chooses.
62814532|NCT05245435|OTHER|primary oligometastatic hormone-sensitive prostate cancer patients|who refuse to undergo cytoreductive radical prostatectomy will serve as control group
62814533|NCT04892641|EXPERIMENTAL|Epetraborole for Dose Ranging|Epetraborole hydrochloride 250 mg, 500 mg, 750 mg, or 1000 mg PO q24h or 500 mg or 1000 mg PO q48h
62814534|NCT04892641|PLACEBO_COMPARATOR|Placebo for Dose Ranging|Matching placebo for dose ranging
62814535|NCT04892641|EXPERIMENTAL|Epetraborole for Food Effect|Food effect cohort, single dose in fed and fasted conditions, dosage to be determined based on pharmacokinetics data obtained from previous cohorts
62037119|NCT05596370||pancreatic tumor|pancreatic cancer pancreatic ductal adenocarcinoma pancreatic neuroendocrine tumor
62037120|NCT06723574||EAU section|EAU section chairs,board members and working group members
62037121|NCT06672991||ERCP, EST and LC in one hospitalization|
62037122|NCT06672991||ERCP, EST and LC on rehospitalization|
62037123|NCT02450318|EXPERIMENTAL|Slow-paced walking|Subjects will complete 47 minutes of walking at slow pace.
62037124|NCT00858065|ACTIVE_COMPARATOR|RCT FM|Random control trial- Family Matters. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to Family Matters program.
62037125|NCT00858065|ACTIVE_COMPARATOR|Choice SFP|Half the families were assigned to the choice condition in which they can choose between two prevention programs. This arm chose the Strengthening Families Program (SFP).
62814536|NCT04892641|PLACEBO_COMPARATOR|Placebo for Food Effect|Food effect cohort, single dose in fed and fasted conditions, dosage to be determined based on pharmacokinetics data obtained from previous cohorts
62814537|NCT04675593|EXPERIMENTAL|iTAB-CV + Self Monitoring|Receives iTAB-CV intervention plus self-monitoring (SM), blood pressure home monitoring, eCAP, and weekly mood rating
62814538|NCT04675593|ACTIVE_COMPARATOR|Self Monitoring|Receives self-monitoring (SM), blood pressure home monitoring, eCAP, and weekly mood rating
62814539|NCT04675593|EXPERIMENTAL|iTAB-CV + Self Monitoring - High Intensity Booster|Following the 4-month assessment, subjects in the iTAB-CV group will be re-randomized to receive either a high intensity booster or low intensity booster. Those in the high intensity booster group will start off receiving 1 reminder per day and taper down to 1 reminder per week over 2 months, in addition to self monitoring.
62814540|NCT04675593|EXPERIMENTAL|iTAB-CV + Self Monitoring - Low Intensity Booster|Following the 4-month assessment, subjects in the iTAB-CV group will be re-randomized to receive either a high intensity booster or low intensity booster. Those in the low intensity booster group will receive 1 reminder per week for 2 months, in addition to self monitoring.
62814541|NCT00659412|EXPERIMENTAL|Course A1|
62428944|NCT02758587|EXPERIMENTAL|NSCLC|NSCLC paired-biopsy expansion for tissue biomarkers. Mandatory biopsies prior to treatment and after around 14 days of treatment. 1:1 randomised split of patients having their mandatory on-treatment biopsy after concurrent therapy, or after a defactinib (VS-6063) monotherapy run-in. 16 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 11.
62428945|NCT02758587|EXPERIMENTAL|Mesothelioma|Mesothelioma paired-biopsy expansion for tissue biomarkers. Mandatory biopsies prior to treatment and around 14 days of treatment. 1:1 randomised split of patients having thier on-treatment biopsy after concurrent therapy, or after defactinib (VS-6063) monotherapy run-in. 16 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 11.
62428946|NCT05818631||MRI +|PI-RADS 3-5
62428947|NCT05818631||MRI -|PI-RADS 1-2
62428948|NCT05564702|EXPERIMENTAL|Opt-IVF predicted drug dosage|In this arm, OPT-IVF will use the patient's age and day three serum day AMH and AFC levels to decide the starting dose for the patient's cycle. It will also use the first day and day 5 data collected (Follicular size distribution, estrogen levels) for that patient to determine the optimal dosage profile for the entire cycle for that patient. The dosage predicted by Opt-IVF will be used for the patient in this arm.
62428949|NCT05564702|ACTIVE_COMPARATOR|Traditional drug treatment|The current practice of Physician specified dosage will be used in this arm.
62428950|NCT06345742|OTHER|Control group (no parental participation)|In the control group, infant diaper care will be carried out without parental participation.
62814542|NCT00659412|PLACEBO_COMPARATOR|Course A2|
62037126|NCT00858065|ACTIVE_COMPARATOR|RCT SFP|Random control trial- Strengthening Families Program. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to Strengthening Families Program.
62814543|NCT00659412|EXPERIMENTAL|Course B|Open-label extension
62814544|NCT05705947||Patients with osteoarthritis receiving radiation treatment|"Patients with osteoarthritis receiving standard of care radiation treatment at UNC Radiation Oncology clinic. Radiation dose and fractionation prescription is at the physician's discretion.~Typically, this prescription is delivered in 6 fractions, every other day, over 2 weeks."
62596512|NCT03425266|NO_INTERVENTION|Control|Our control arm is a leading consumer-facing website designed for people with chronic pain (the ACPA). Subjects randomly assigned to this arm will be directed to the page focusing on communication tools, which also includes links to other parts of the website. The specific page is: https://theacpa.org/Communication-Tools
62428951|NCT06345742|EXPERIMENTAL|Experimental group (mother participation)|In the experimental group, infant diaper care will be provided with the mothers.
62428952|NCT06345742|EXPERIMENTAL|Experimental group (father participation)|In the experimental group, infant diaper care will be provided with the fathers.
62238394|NCT05860023|EXPERIMENTAL|Pelvic Floor Muscle Strengthening Group|This group will attend to seven days pelvic floor muscle strengthening programme with moderate intensity consisting of 6 exercises recommended by the national association for incontinence. Prior to discharge exercise sheets will be given to the participants. Their compliance to exercise will be questioned with daily phone calls.
62428953|NCT01850303|OTHER|Surveillance|
62428954|NCT01850303|EXPERIMENTAL|Maintenance|Pemetrexed for non squamous NSCLC Gemcitabine for squamous NSCLC
62596513|NCT00727844|EXPERIMENTAL|Delayed Start Linezolid|Subjects continued their existing regimen for 2 months after which LZD (600 mg once daily) was added. After 2 consecutive AFB negative sputum smears (not to exceed 4 months of LZD therapy), subjects were randomized to continue on 600 mg LZD once daily or to de-escalate to 300 mg once daily. Regardless of the dosage, subjects remained on LZD treatment for 18 months after sputum culture conversion or until they could no longer tolerate therapy.
62596514|NCT00727844|EXPERIMENTAL|Immediate Start Linezolid|Upon completion of entry criteria, subjects had LZD (600 mg once daily) added to their regimen. After 2 consecutive AFB negative sputum smears (or at 4 months) subjects were randomized to continue on 600 mg LZD once daily or to de-escalate to 300 mg once daily. Regardless of the dosage, subjects remained on LZD treatment for 18 months after sputum culture conversion or until they could no longer tolerate therapy.
62428955|NCT01819584||Patients below 15 years old|
62428956|NCT01819584||Patients above 15 years old|
62428957|NCT02958748||ARDS|Patients admitted to ICU with diagnosis of ARDS,which happened in 48hours.
62428958|NCT02958748||Control|Heathy vonlunteers
62596515|NCT02535130|EXPERIMENTAL|Nebulization combined to positive expiratory pressure|Experimental arm
62596516|NCT02535130|ACTIVE_COMPARATOR|Nebulization|Control arm
62596517|NCT03309657|EXPERIMENTAL|Ceftolozane Tazobactam|Infected patients with external intraventricular drain will receive a single dose of Ceftolozane/ tazobactam (3000mg) over 1 hour and will undergo blood , csf and urine sampling at specific times over an 8 hour period.
62037127|NCT00858065|NO_INTERVENTION|RCT Control|Random control trial- Control Group. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to the control group and received no prevention program. However, this group and all groups received an informational pamphlet about youth alcohol and other drug use.
62238395|NCT03150316|EXPERIMENTAL|Treat Regimen|CKD-581(investigational Drug) Lenalidomide Dexamethasone
62238396|NCT02907931|EXPERIMENTAL|Subjects|Lower Body Negative Pressure
62238397|NCT00174265|EXPERIMENTAL|asenapine|
62596518|NCT05449535|EXPERIMENTAL|JYB1904/JYB1904 Placebo|single-dose; subcutaneous injection in the deltoid region of the upper arm.
62596519|NCT05449535|ACTIVE_COMPARATOR|Omalizumab|single-dose; subcutaneous injection in the deltoid region of the upper arm.
62238398|NCT00174265|ACTIVE_COMPARATOR|olanzapine|
62238399|NCT05928091|NO_INTERVENTION|Control group|Doctors will manage bleeding as usual.
62238400|NCT05928091|EXPERIMENTAL|Experimental group|Investigators will call a phone number, and an expert will guide them to manage the bleeding.
62238401|NCT02741583|EXPERIMENTAL|altitude rehabilitation program|3 weeks rehabilitation program at high altitude (3200m)
62238402|NCT02741583|ACTIVE_COMPARATOR|rehabilitation program|3 weeks rehabilitation program at low altitude (760m)
62238403|NCT03327116|EXPERIMENTAL|Methotrexate|
62238404|NCT00470210|EXPERIMENTAL|1|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week Ribavirin (Copegus®) 1600 mg/day Epoetin β (450 UI/kg/week)
62238405|NCT00204971|EXPERIMENTAL|1|Nutritional supplement
62238406|NCT00204971|PLACEBO_COMPARATOR|2|placebo
62238407|NCT05629195|EXPERIMENTAL|tunneled PICC|Placement of PICC catheter through tunnel technology
62238408|NCT05629195|ACTIVE_COMPARATOR|conventional PICC|Placement of PICC catheter through conventional technology
62238409|NCT05426850||ctDNA(+) Cohort|ctDNA(+) Cohort in pretreatment and posttreatment plasma samples was defined by accessing the presence of one or more mutations identified in match tumor samples.
62238410|NCT05426850||ctDNA(-) Cohort|ctDNA(-) Cohort in pretreatment and posttreatment plasma samples was defined by the absence of one or more mutations identified in match tumor samples.
62238411|NCT01679366|NO_INTERVENTION|Penicillin G|hospitalization of 30 patients given penicilline intraveniously for 72 hours
62238412|NCT01679366|PLACEBO_COMPARATOR|Placebo|30 hospitalized patients will be given placebo with a regular penicillin treatment
62596520|NCT03326128|ACTIVE_COMPARATOR|BUP-300|Participants will receive Bupropion hydrochloride for 10 weeks and titrate to a maximum dose of 300 mg/day and will also receive standard smoking cessation counseling for 8 weeks.
62037128|NCT00858065|ACTIVE_COMPARATOR|Choice FM|Half the families were assigned to the choice condition in which they can choose between two prevention programs. This arm chose the Family Matters (FM) program.
62596521|NCT03326128|EXPERIMENTAL|BUP-450|Participants will receive Bupropion hydrochloride for 12 weeks and titrate to a maximum dose of 450 mg/day and will also receive standard smoking cessation counseling for 8 weeks.
62596522|NCT03277053|SHAM_COMPARATOR|control|Patients receive an ipad with no app.
62814545|NCT06035562|EXPERIMENTAL|PVSET|Participants will receive a course of individual therapy through the Operational Stress Injury Clinic (OSIC) at Deer Lodge Centre. Therapy will consist of a validated treatment protocol known as Positive Valence System Enhancement Treatment for Anxiety and Depression (PVSET), which will consist of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors. Therapy sessions will be facilitated by psychologists, licensed therapists (e.g., MSW, RPN), and/or graduate students in psychology under supervision at the OSIC. PVSET will consist of 6 sessions, each lasting one hour, and will be delivered either virtually or in-person at OSIC depending on patient preference.
62596523|NCT03277053|EXPERIMENTAL|Mobile application no stoma|Patients who did not receive a stoma receive an ipad containing the app and are instructed how to use it.
62814546|NCT03863795||Observational (survey)|Participants are recruited and pre-screened via an online crowdsourcing program MTurk, and then respond to a one-time research survey over 20 minutes on SurveyGizmo, an on-line survey software platform
62814547|NCT04829734|EXPERIMENTAL|Active PBMT-sMF|Active PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
62428959|NCT03191019|EXPERIMENTAL|Mobile-phone app for smoking cessation|"The intervention arm will receive a smoking cessation program based on a mobile-phone app. The program contains strategies to support smoking cessation, including motivational messages, tips on stress management, on how to ask support from friends and family, how to use distraction techniques and how to deal with cravings, lapses and early relapse. It also includes a saving calculator, a help button which provides extra messages in case of cravings and a lapse button, which provides advice about what to do if the participant presents lapses or relapse after being abstinent at least 24 hours."
62428960|NCT03191019|PLACEBO_COMPARATOR|Control mobile-phone app|The control arm will receive a mobile-phone app which will send 1 message every two weeks thanking participants for taking part in the study, and encouraging them to stay in the study for the 6 month follow-up period.
62037129|NCT04916535|EXPERIMENTAL|diagnostic flow|all patients with MAD as assessed during routine transthoracic echocardiography will undergo to the following further exams: i) 12-lead electrocardiogram (ECG), ii) 24-hour ECG monitoring, iii) cardiac magnetic resonance imaging (CMR), iv) cardiological visit
62428961|NCT00615628||family members|family members of the proband and father identified
62428962|NCT01135108|PLACEBO_COMPARATOR|A1: Placebo|Placebo
62428963|NCT01135108|EXPERIMENTAL|A2: KAI-1678|Experimental
62428964|NCT04590898||significant peri-device leakage after LAA occlusion|Peri-device leakage closure after left atrial appendage occlusion
62814548|NCT04829734|PLACEBO_COMPARATOR|Placebo PBMT-sMF|Placebo PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
62037130|NCT05598216||Fasting state|based on the sampling time and the serum's aspect
62037131|NCT05598216||non-fasting state|based on the sampling time and the serum's aspect
62814549|NCT03316196|EXPERIMENTAL|COGENT|Participants will be Veterans assigned to the active cognitive training (see below for details).
62814550|NCT03316196|SHAM_COMPARATOR|Non-Training|Participants will be Veterans assigned to a non-training cognitive program matched for time and memory demands (see below for details).
62814551|NCT04131413|OTHER|Vaccination Arm Level 1|The dose escalation of pNGVL4aCRTE6E7L2 will be conducted to evaluate the safety of three escalating doses; Level 1 dose of 0.3 mg
62814552|NCT04131413|OTHER|Vaccination Arm Level 2|The dose escalation of pNGVL4aCRTE6E7L2 will be conducted to evaluate the safety of three escalating doses; level 2 at dose 1.0 mg
62814553|NCT04131413|OTHER|Vaccination Arm Level 3|The dose escalation of pNGVL4aCRTE6E7L2 will be conducted to evaluate the safety of three escalating doses; level 3 dose of 3.0 mg
62037132|NCT05050136|EXPERIMENTAL|Volixibat 20mg|Participants randomized to this arm will receive volixibat 20mg twice daily.
62596524|NCT03277053|EXPERIMENTAL|Mobile application stoma|Patients who receive a stoma receive an ipad containing the app and are instructed how to use it.
62596525|NCT03471728||Irritable Bowel Syndrome|Patients with Irritable Bowel Syndrome with Constipation (IBS-C) who have used linaclotide for the first time
62596526|NCT03471728||Chronic Constipation|Patients with Chronic Constipation (CC) (excluding constipation due to organic diseases) who have used linaclotide for the first time
62596527|NCT02381301||Venous blood sampling prior to CCTA.|In patients undergoing routine Cardiac Computed Tomography Angiography (CCTA) and given written informed consent blood sampling will be performed. The samples will be stored for a period of 15 years at the Biobank for future analyses.
62596528|NCT06074809|EXPERIMENTAL|Traditional Chinese medicine treatment group|Chinese medicine will be administered to patients in this group.
62037133|NCT05050136|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.
62037134|NCT03044379|ACTIVE_COMPARATOR|Dapivirine Gel|Participants will be randomized to receive a single dose of dapivirine gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.
62037135|NCT03044379|PLACEBO_COMPARATOR|Placebo Gel HEC|Participants will be randomized to receive the universal HEC placebo gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.
62037136|NCT06035029||Case group|Children with appendectomy for appendicitis
62037137|NCT06035029||Control group|Children with no digestive disease or medical history
62037138|NCT01188434|EXPERIMENTAL|Integrated Behavioral Treatment|Combined substance abuse, parenting skills, and basic needs intervention
62037139|NCT01188434|ACTIVE_COMPARATOR|casework treatment as usual|services as usual as referred by child welfare
62037140|NCT01640522|EXPERIMENTAL|Collaborative Care Intervention|Care coordinator facilitates the assessment and treatment of cancer-related symptoms
62037141|NCT01640522|ACTIVE_COMPARATOR|Enhanced Usual Care|Upon evaluation of symptoms the patient will be referred for further assessment or treatment if indicated
62037142|NCT00884585|EXPERIMENTAL|Cyclosporine Ophthalmic Solution (COS) followed by COS|Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
62037143|NCT00884585|OTHER|Placebo followed by COS|Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months followed by cyclosporine ophthalmic solution 0.010% up to 9 additional months; at Month 9 the dose may be adjusted to 2 times a day.
62596529|NCT06074809|PLACEBO_COMPARATOR|Placebo group|Placebo will be administered to patients in this group.
62596530|NCT06667648|NO_INTERVENTION|Group (A)|") attended the program of walking on a treadmill machine for eight weeks according to the following parameters: -~* Mode of exercise: aerobic exercise.~* Intensity: according to heart rate (60-75% of maximum heart rate) MHR=220-age.~* Heart rate: determined by the sensor of a treadmill.~* Duration: 40-50 min per session. Each session consisted of 5-10 minutes of warming up exercise on a treadmill without increasing speed or intensity and the same for the cooling down phase"
62037144|NCT04524468||hemodialysis patients|end-stage renal disease patients on hemodialysis
62037145|NCT04524468||peritoneal dialysis patients|end-stage renal disease patients on peritoneal dialysis
62037146|NCT00913484|EXPERIMENTAL|Disulfiram|Disulfiram 250 mg per day
62037147|NCT00913484|PLACEBO_COMPARATOR|Placebo|Placebo
62037148|NCT05812651|EXPERIMENTAL|IMF arm|"The interventional protocol will include healthy older adults age above 60 years. At baseline - all measurements will be collected. After 3 days to one week, as per feasibility, participants will come to the lab again and perform inspiratory Muscle training according to the protocol that tends to induce inspiratory muscle fatigue. (60-80%MIP).~Inspiratory resistive loading by starting at 60-80% (MIP) increasing every 10 minutes by 10% then measure Maximum Inspiratory Pressure (MIP), until MIP measurement decrease of more than 10% from baseline will be performed. When report a lower score of MIP and participants could no longer worked out, performed the functional mobility tests and see if there any variation. After the consent of participants an initial evaluation, Anthropometric measurements, Pulmonary function tests, PASE Questionnaire will be taken."
62814554|NCT02195765|EXPERIMENTAL|enamel matrix derivative|Open flap debridement associated with Enamel matrix derivative gel (Emdogain, Straumann)
62814555|NCT02195765|ACTIVE_COMPARATOR|Open flap debridment|Open flap debridement
62814556|NCT06044675|EXPERIMENTAL|MDMA-Assisted CBCT Condition|Dyads will undergo a 7-week course of CBCT psychotherapy for PTSD with two sessions that integrate MDMA-assisted psychotherapy. MDMA will be administered in two separate sessions and integrated into the psychotherapy protocol. The two doses of MDMA during this study will be used as an adjunct to psychotherapy.
62814557|NCT06044675|ACTIVE_COMPARATOR|CBCT-Only Condition|Dyads will undergo a 7-week course of CBCT psychotherapy for PTSD. Dyads who have undergone the CBCT-Only condition will have the option to do a crossover and have the two MDMA sessions after follow-up.
62428965|NCT04062461|EXPERIMENTAL|self-care promotion|"multifaceted strategy based on sending text messages(SMS) to patients with heart failure.~Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity).~The text messages are about how the patient should take your drugs (evem diuretics), measure blood pressure and weight in Kg, and about signals and symptoms (shorthbreathness during the night), and about how important is practice physical exercises and don't drink alcohol."
62814558|NCT03919773|ACTIVE_COMPARATOR|Treatment IVIG Arm|IVIG (Gammunex-C) infusion (0.4 gm/kg) every week for 4 weeks, then every 2 weeks for 8 weeks (12 weeks total).
62428966|NCT04062461|ACTIVE_COMPARATOR|Control group|routinely management in the HF. Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)
62814559|NCT03919773|PLACEBO_COMPARATOR|Treatment Albumin Arm|albumin infusion (0.4 gm/kg) every week for 4 weeks then every 2 weeks for 8 weeks (12 weeks total) during
62428967|NCT02760784||Early Weight Bearing|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from day 1. The orthosis was worn 24 hours / day the first 2 weeks.~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
62814560|NCT03151629||Castrate Resistant Prostate Cancer|
62814561|NCT03151629||Hormone Sensitive Prostate Cancer|
62814562|NCT05935761|ACTIVE_COMPARATOR|Pregnenolone|Pregnenolone dosing will begin at 500mg/day x 7 days, and will increase by 500mg each following week as tolerated (to a potential maximum dose 2000mg/day).
62814563|NCT05935761|ACTIVE_COMPARATOR|DHEA|DHEA dosing will begin at 100mg/day x 7 days, and will increase by 100mg each following week as tolerated (to a potential maximum dose 400mg/day).
62814564|NCT05935761|PLACEBO_COMPARATOR|Placebo|Same as active comparator arms, except placebo dispensed
62814565|NCT02371057||patients under follow-up known to have sleep apnoea|
62814566|NCT02371057||patients attending the sleep apnoea clinic for assessment|Patients who are attending clinic who have not yet been diagnosed.
62814567|NCT05977413|EXPERIMENTAL|Patient-Clinician CAC Notification|The CAC Notification intervention sent to both patients and clinicians has five features. 1) Results of a high CAC score (\>100 AU) detected on the patient's prior chest CT, 2) an image of the patient's CAC clearly marked, 3) a recommendation to have a patient-clinician risk discussion, 4) specific statin dosing recommended by guidelines, and 5) a link to the prevention gidelines.
62428968|NCT02760784||Control|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Weight bearing was allowed from week 6. The orthosis was worn 24 hours / day the first 2 weeks.~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
62814568|NCT05977413|OTHER|Clinician Guideline Reminder|The Guideline Reminder intervention sent to primary care clinicians has five features. 1) A reminder that all patients should have their 10-year risk for ASCVD events calculated, 2) a figure of the recommended treatment algorithm according to ASCVD 10-year risk, 3) a nudge that patients who qualify for lung cancer screening are generally at high ASCVD risk, 4) a reminder that patients at elevated risk should be engaged in shared decision-making to discuss statin therapy and other preventive interventions, and 5) access to the complete ACC/AHA Primary Prevention Guidelines and the online 10-year ASCVD risk estimator.
62814569|NCT04541589|ACTIVE_COMPARATOR|Arm 1|Arm 1 - Iscalimab Dose 1
62814570|NCT04541589|ACTIVE_COMPARATOR|Arm 2|Arm 2 - Iscalimab Dose 2 and Placebo
62814571|NCT04458636|ACTIVE_COMPARATOR|Standard care|Blinded prednisolone 30mg orally once per day for 14 days
62814572|NCT04458636|PLACEBO_COMPARATOR|Biomarker care|Blinded prednisolone 30mg orally once per day for 14 days if peripheral eosinophil count is equal or greater than 2%. Placebo equivalent if peripheral blood eosinophil count is \<2%.
62814573|NCT01844765|EXPERIMENTAL|Newly diagnosed and untreated Ph+ CML in first CP|Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.
62596531|NCT06667648|OTHER|Group (B)|Each cupping session takes about 30-40 min and can be conducted in five steps. The first step includes primary suction. In this phase, the therapist allocates specific points or areas for cupping and disinfects the area, which located at the upper back (opposite to C7), Para spinal and below scapula. A cup with a suitable size is placed on the selected site and sucked the air inside the cup by manual suction. Then the cup was applied to the skin and left for a period of 3 to 5 min. The second step is about puncturing. Puncturing with a needle to get out of blood the third step is about suction and bloodletting. The cup is placed back on the skin using the similar procedure described above for 3 to 5 min. The fourth step includes the removal of the cup, followed by the fifth step which includes dressing the area after cleaning and disinfecting with FDA-approved skin disinfectant.
62596532|NCT02568228|EXPERIMENTAL|Krill group|Krill oil capsules. 4 g/day encapsulated krill oil (Rimfrost Sublime) corresponding to \~900 mg/day EPA + DHA + DPA for 8 weeks. The participants will be instructed to take the capsules with the breakfast and dinner meals.
62428969|NCT06098222|EXPERIMENTAL|Slow breathing exercise training|Slow breathing exercise training will be given to patients in the experimental group. After discharge, patients will be asked to do slow breathing exercises twice a day for 10 minutes every day for eight weeks. Daily and/or weekly online, weekday, weekend, daytime, evening, video phone calls will be made with patients who are discharged at the end of the training to practice the slow breathing exercise every day according to the patients' demand. It will be provided that breathing exercises will be performed together with a video call in the form of a conference call. Patients will be asked to take measurements a total of two days a week, one day on weekdays and one day on weekends, in the morning, after a light breakfast, at least five minutes of rest and breathing exercises. Pulse and blood pressure measurements at home on weekdays will be asked to be measured Decouply from breathing exercise, and on weekends before and after breathing exercise.
62596533|NCT02568228|EXPERIMENTAL|Fish group|Lean and fatty fish. Three weekly test-meals, containing two meals of fatty fish and one meal of lean fish for 8 weeks corresponding to \~900 mg/day EPA + DHA + DPA.
62596534|NCT02568228|PLACEBO_COMPARATOR|Control group|Placebo capsules. 4 g/day encapsulated high oleic sunflower oil (HOSO) for 8 weeks. The participants will be instructed to take the capsules with the breakfast and dinner meals.
62596535|NCT03676114|EXPERIMENTAL|ketamine group|
62596536|NCT03676114|PLACEBO_COMPARATOR|normal saline group|
62596537|NCT05123092|ACTIVE_COMPARATOR|Group ( ultrasound guided erectae spinae block)|The same anesthesiologist who is experienced in US guided regional anesthesia will perform the block. In the group ESP, a high frequency linear US probe (HFL_50, 15_6MHz) will be placed vertically and nearly 3 cm lateral to the vertebra in the middle of the incision line. The transverse process and the overlaying erector spinae muscles (ESM) will be identified under parasagittal scanning A22 G,50 mm block needle (SONOTAP,Pajunk, Geisingen,Germany) will be inserted at a 30-40° angle in the cranial to caudal direction via an in-plane approach and advanced into the plane between the fascia of ESM and transverse process under sterile conditions. The correct needle position will be confirmed after a hydro dissection with 3 ml of isotonic saline, and then 20 ml of 0.25% bupivacaine will be injected in the interfascial plane between the rhomboideus major muscle and ESM. The local anesthetic spread will be visualized in a fascial longitudinal pattern deep to the ESM.
62814574|NCT01844765|EXPERIMENTAL|Resistant/intolerant Ph+ CML in CP|Resistant or Intolerant to either imatinib or dasatinib
62814575|NCT01844765|EXPERIMENTAL|Resistant/intolerant Ph+ CML in AP|Resistant or intolerant to either imatinib or dasatinib - at the end no patients were enrolled in this arm.
62814576|NCT00468169|EXPERIMENTAL|A: Cetuximab+FHX|Cetuximab \[250mg/m2 (day 1, weekly x10)\] + FHX (5-FU \[CI: 600mg/m2/day; days 0-5 (120h total) every other week x5\], Hydroxyurea \[500 mg PO BID, days 0-5 (=11 doses), every other week x5\] and twice-daily radiation \[150 cGy per fraction - days 1-5, every other week x5 (70-72 Gy total dose)\]). Total duration is 10 weeks.
62814577|NCT00468169|EXPERIMENTAL|B: Cetuximab + PX|Cetuximab \[250 mg/m2 (day 1, weekly x7)\] + PX (Cisplatin \[100mg/m2 (week 1 \& 4 on day 1 (or 2))\], Accelerated fraction radiotherapy with concomitant boost \[AFX-CB (72 Gy/42 F/6 W) (3-D or IMRT based)\]). Total duration: 7 weeks.
62814578|NCT05583773|ACTIVE_COMPARATOR|ShengXian-QuYu Decoction|"Patients will be randomized 1:1 to either ShengXian-QuYu Decoction or placebo. ShengXian-QuYu Decoction (calculated by a medicine): 30g of Astragalus membranaceus (Huangqi), 12g of Cornus officinalis (Shanzhuyu), 9g of Talinum paniculatum (Jacq.) Gaertn. (Hongshen), 12g of Rhizoma Anemarrhena (Zhimu), 8g of Rhizoma Cimicifugae (Shengma), 8g of Radix Bupleuri (Chaihu), 10g of Platycodon grandiflorum (Jiegeng), 10g of Rhizoma Sparganii (Sanleng), 9g of Rhizoma Curcumae (Ezhu)."
62814579|NCT05583773|PLACEBO_COMPARATOR|placebo|Placebo matching ShengXian-QuYu Decoction
62814580|NCT01874197|OTHER|B -TEVAR|Implantation of the B-TEVAR device
62814581|NCT03922100|EXPERIMENTAL|NMS-03592088|"Phase I Dose Escalation~* Schedule A - Starting dose of 20 mg/day~* Schedule B - Starting dose of 120 mg/day~Only one dose level open for enrollment except EU backfill cohorts.~Phase II Dose Expansion (Exploratory) - (EU)~Recommended Phase II Dose (RP2D) of NMS-03592088 in Phase 1~* Cohort 1: Patients who have failed standard of care including venetoclax and gilteritinib based therapies~* Cohort 2: Patients who have failed standard of care"
62596538|NCT05123092|ACTIVE_COMPARATOR|Group (Intrathecal morphine)|In the group of intrathecal morphine , a lumbar puncture will be done in the lateral position via a midline approach into the level of the vertebra which exists in the middle of the incision with complete aseptic condition using 25 gauge Quincke spinal needle to give 0.3 mg of morphine (preservative free form) suspended in 0.4 ml of normal saline .
62596539|NCT02438605||Treatment group|Patients eligible for AAA repair using Nellix and willing to participate in this trial.
62596540|NCT06647784|EXPERIMENTAL|Lateral and alterning positioning|
62596541|NCT05250531|EXPERIMENTAL|GROUP 1|33 patients in the multicomponent treatment group selected to group 1 (G1) will be treated with telerehabilitation for a total of 6 sessions of two hours once a week for 3 weeks. After 1 month, one more session will be applied for a two-hour follow-up and sustainability.
62037149|NCT01801020|EXPERIMENTAL|temperature measuremts|A temporal artery measurement will be taken from two points a strait line across the forehead and an additional measurement behind the earlobe. In addition tympanic temperature will be measured.
62238413|NCT01679366|EXPERIMENTAL|Probiotic|Probiotics will be given to 30 hospitalized patients with regular penicillin treatment
62596542|NCT05250531|ACTIVE_COMPARATOR|GROUP 2|As a control group, 33 patients selected to Group 2 (G2) will be given exercise and training with telerehabilitation.
62596543|NCT02520882|EXPERIMENTAL|68Ga-NOTA-Aca-BBN(7-14) PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-Aca-BBN(7-14) in one dose intravenously and underwent PET/CT scan 30 min later.
62814582|NCT04421053||women with GDM|After participants enrollment, we conducted follow-up visit every two weeks. Blood glucose values, body weight, life style record and clinical information are collected. Blood samples and stool samples are collected from participants in Beijing.
62814583|NCT05158270|ACTIVE_COMPARATOR|Ultrasound Guided Erector Spinae Plane Block|Patient will be placed in lateral decubitus position. By palpation of spinous processes starting from C7 downward, T7 spinous process will be located. Under complete aseptic precautions, linear probe of US machine will be placed in a transverse orientation at this level to identify tip of T7 transverse process (TP). By probe rotation into a longitudinal orientation, a parasagittal view will visualize skin and subcutaneous tissue, trapezius, and erector spinae (ES) muscle layers superficial to TPs. After local anesthetic (LA) infiltration, a 20 gauge spinal needle will be inserted in-plane and directed cranio-caudally until it contacts T7 TP. Target site for injection will be fascial plane deep to ES muscle. 1 mL saline will be injected to confirm correct needle-tip position by visualization of lifting of ES muscle off TP without distending the muscle and spreading cranio-caudally. 30 mL of 0.25% bupivacaine will be injected. Procedure will be performed bilaterally.
62238414|NCT06225635|EXPERIMENTAL|Test|Ezerosu tablet(double layer tablet)
62238415|NCT06225635|ACTIVE_COMPARATOR|Control|Ezerosu tablet(monolayer tablet)
62238416|NCT02687425|EXPERIMENTAL|pioglitazone|The patients under the long-term treatment of imatinib mesylate acquire pioglitazone additionally.
62238417|NCT02993653|EXPERIMENTAL|Intensity-modulated radiotheapy arm|Intensity-modulated radiotheapy with stereotactic boost or intracavitary radiotherapy
62238418|NCT06175546|EXPERIMENTAL|Compression regimen 6-8 hours per day 4 weeks|40 participants. A physical examination and duplex ultrasound of the veins of the lower extremities are performed. It is suggested to wear the compression socks 6-8 hours a day for 4 weeks
62238419|NCT06175546|ACTIVE_COMPARATOR|Compression regimen 10-12 hours per day 4 weeks|40 participants. An physical examination and duplex ultrasound of the veins of the lower extremities are performed. It is suggested to wear the compression socks 10-12 hours a day for 4 weeks
62238420|NCT01480284|EXPERIMENTAL|GSK548470 300 mg|GSK548470 300 mg tablet and ETV placebo capsule are administered once daily
62238421|NCT01480284|ACTIVE_COMPARATOR|ETV 0.5 mg|ETV 0.5 mg capsule and GSK548470 placebo tablet are administered once daily
62596544|NCT05509569||Icatibant|Participants will be recieved Icatibant 10 to 30 mg injection subcutaneously.
62596545|NCT04809857|EXPERIMENTAL|Plyometric Exercise Group|Plyometric exercise training 3 days a week for 6 weeks
62596546|NCT04809857|ACTIVE_COMPARATOR|Isokinetic Exercise Group|Isokinetic exercise training 3 days a week for 6 weeks
62596547|NCT04809857|NO_INTERVENTION|Control Group|no exercise intervention
62596548|NCT00102648|EXPERIMENTAL|Treatment (temozolomide and lonafarnib)|Patients receive temozolomide PO QD on days 1-7 and 15-21 and lonafarnib PO BID on days 8-14 and 22-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62596549|NCT02760212|EXPERIMENTAL|Group 1 - Radial Shockwave Therapy Group|Participants in Group 1 will receive RSWT to the most painful spot within each of the 3 most painful regions as described by the participant. Treatments will be spaced one week apart over a 5 week period of time. 5 weekly sessions with treatment to the painful areas will be undertaken with 500 shocks (1.5 bar, 15 Hz), then 1000 shocks (2 bar, 8 Hz), and finally 500 shocks (1.5 bar, 15 Hz) to the most painful spot.
62596550|NCT02760212|PLACEBO_COMPARATOR|Group 2 - Placebo Group|Participants in Group 2 will receive a placebo treatment with a soft rubber cap applied to the applicator, leaving air between the transmitter and the cap and the participant's skin so that no shockwave will be generated nor applied to the participant's skin. Treatments will be spaced one week apart over a 5 week period of time. 5 weekly sessions with placebo treatment to the painful areas will be undertaken with 2000 placebo shocks (15 Hz) producing an audible sound but no therapeutic dosage to the most painful spot. Upon completion of the placebo treatment, participant's will be offered the experimental treatment but this data will not be used for comparison and analysis.
62596551|NCT06621693|EXPERIMENTAL|Transcutaneous electrical diaphragmatic stimulation intervention and traditional physiotherapy group|This group will receive transcutaneous electrical diaphragmatic stimulation intervention and traditional physiotherapy three times per week for 4 weeks
62596552|NCT06621693|ACTIVE_COMPARATOR|Traditional physiotherapy group|This group will receive traditional physiotherapy only, three times per week for 4 weeks
62596553|NCT02280616|EXPERIMENTAL|Low dose budesonide tablet|
62596554|NCT02280616|EXPERIMENTAL|High dose budesonide tablet|
62596555|NCT02280616|EXPERIMENTAL|High dose budesonide suspension|
62596556|NCT02280616|PLACEBO_COMPARATOR|Placebo|
62596557|NCT00927511|EXPERIMENTAL|A - Dose Tritation|Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity
62428970|NCT06098222|NO_INTERVENTION|Control group|In the control group, patients will be shown and told self-blood pressure and pulse measurement at home at discharge. A reminder text message will be sent to the mobile phones of patients for blood pressure and pulse measurement at home. The control group will also be asked to perform their own blood pressure and pulse monitoring at home and record a Self-Monitoring Form (for the Control group).During home follow-up, patients will be sent reminder text messages to their mobile phones two days a week. According to the request of patients, daily and/or weekly online, weekdays, weekends, daytime, evening, phone calls will be made to measure pulse and blood pressure values two days a week.
62428971|NCT03474289|EXPERIMENTAL|Escalation|SHR-1316 administrated intravenously(IV) at protocol defined dose levels
62428972|NCT03474289|EXPERIMENTAL|Expansion|SHR-1316 administrated IV in advanced solid tumors and selected tumor type
62428973|NCT01669668|EXPERIMENTAL|RFA|Patients undergo laparoscopic ultrasound followed by RFA.
62428974|NCT03291678|EXPERIMENTAL|new laparoscopic orchiopexy|this group will subjected to classic laparoscopic orchiopexy by delivery of abdominal undescended testis to subdartos pouch of scrotum with closure of internal ring
62428975|NCT03291678|ACTIVE_COMPARATOR|classic laparoscopic orchoipexy|this group will subjected to classic laparoscopic orchiopexy by delivery of abdominal undescended testis to subdartos pouch of scrotum
62428976|NCT05079152|EXPERIMENTAL|Experimental group|Experimental Group (468 subjects) will receive: 1st dose : combined vaccination of COVAX+PPV23; 2nd dose: combined vaccination of COVAX+IIV4
62428977|NCT05079152|ACTIVE_COMPARATOR|Control group A|Control Group A (468 subjects) will receive: 1st dose: COVAX only; 2nd dose: COVAX only
62428978|NCT05079152|ACTIVE_COMPARATOR|Control group B|Control Group B (468 subjects) will receive: 1st dose: PPV23 only; 2nd dose: IIV4 only
62428979|NCT04507529|EXPERIMENTAL|Peer-mentoring|Peer-mentoring
62428980|NCT01523522|ACTIVE_COMPARATOR|myoblast injection|autologous myoblast
62428981|NCT01523522|PLACEBO_COMPARATOR|saline solution injection|saline solution injection in anal sphincter
62596558|NCT00927511|ACTIVE_COMPARATOR|B- Control|Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
62596559|NCT05766488|EXPERIMENTAL|Continuous Glucose Monitoring Arm|Participants in this arm will use a Freestyle Libre 2 monitoring device for 6 months to track their blood glucose levels while receiving usual patient care within an interprofessional primary care team.
62596560|NCT05766488|ACTIVE_COMPARATOR|Traditional Glucometer Arm|Participants in this arm will use a traditional glucose monitoring device (glucometer) to self-monitor their blood glucose for 6 months while receiving usual patient care within an interprofessional primary care team.
62814584|NCT05158270|ACTIVE_COMPARATOR|Ultrasound Guided Subcostal Anterior Quadratus Lumborum Block|Patients will be positioned lateral decubitus. A curvilinear 2-5 MHz ultrasound transducer (SonoSite S-Nerve, Bothell, WA) will be positioned posteriorly below the 12th rib in a parasagittal oblique plane at L1-2 level. The QL muscle was visualized and its point of insertion on the 12th rib identified. An 18-gauge Tuohy needle was advanced in the caudal-to-cranial direction between QL muscle and the psoas major muscle until a click could often be felt as the needle tip penetrated the anterior investing fascia of the QL muscle. After a negative aspiration, 30 mL of 0.25% bupivacaine was injected through the needle to help confirm the final needle tip position, anterior to the QL muscle at close proximity to the 12th rib.
62428982|NCT02720224|EXPERIMENTAL|Estetrol|A single oral dose of 15 mg carbon 14 labelled estetrol (\[14C\]-estetrol), containing approximately 2.8 MBq (76 µCi) 14C
62428983|NCT02412956|NO_INTERVENTION|Control|pamphlet
62428984|NCT02412956|EXPERIMENTAL|Intervention (text)|SmokefreeMOM text messaging program
62428985|NCT02412956|EXPERIMENTAL|Intervention Plus (text+quitline)|SmokefreeMOM text messaging program + state quitline
62428986|NCT05956171|EXPERIMENTAL|Ultrasound Guided Hydrodilatation with corticosteroid injection|"15 ml intra-articular injection to shoulder via anterior approach under ultrasound guidance~Drugs:~* betamethasone dipropionate/ betamethasone sodium phosphate(diprospan) (5 mg+2mg/ml) (1 ml)~* prilocaine hydrochloride %2 (4 ml)~* Sodium chloride %0,9 (10 ml)"
62428987|NCT05956171|ACTIVE_COMPARATOR|Blind intra-articular corticosteroid injection|"5 ml intra-articular blind injection to shoulder via posterior approach~Drugs:~* betamethasone dipropionate/ betamethasone sodium phosphate(diprospan) (5 mg+2mg/ml) (1 ml)~* prilocaine hydrochloride %2 (4 ml)"
62596561|NCT05249114|EXPERIMENTAL|Cohort 1|Cabozantinib 20 mg daily with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 20 mg qd.
62596562|NCT05249114|EXPERIMENTAL|Cohort 2|Cabozantinib 40 mg qod alternating with 20 mg qod with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 40 mg qd.
62428988|NCT05573373|EXPERIMENTAL|Pamilarib in combination with Chemotherapy Drugs|The specific chemotherapy regimen was formulated by the investigator. The dosage of chemotherapy drugs is selected according to the drug use guidelines. Combination medication, the initial dose is 40mg each time (2 capsules), 2 times a day, the total daily dose is 80mg. Can be taken with a meal or on an empty stomach. If the patient misses a dose, no additional dose should be taken, and the next prescribed dose should be taken normally at the planned time. Continue the treatment until the disease progresses or unacceptable adverse reactions occur, and the dose is adjusted.
62596563|NCT05249114|EXPERIMENTAL|Cohort 3|Cabozantinib 40 mg qd with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 40 mg qd.
62596564|NCT05249114|EXPERIMENTAL|Cohort 4|Cabozantinib 60 mg qod alternating with 40 mg qod with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 60 mg qd.
62596565|NCT05249114|EXPERIMENTAL|Cohort 5|Cabozantinib 60 mg qd with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 60 mg qd until disease progression.
62596566|NCT04521621|EXPERIMENTAL|Part 1, Cohort A: Triple-Negative Breast Cancer|This arm will enroll participants with triple-negative breast cancer (TNBC) solid tumors. Participants receive 3 X 10\^8 50% tissue culture infectious dose (TCID50) of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
62037150|NCT03668080||surgical residents|Surgical specialties included general surgery, plastic surgery, urology, vascular surgery, obstetrics and gynecology, orthopedic surgery, pediatric surgery, cardiothoracic surgery and otolaryngology.
62596567|NCT04521621|EXPERIMENTAL|Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma|This arm will enroll participants with head and neck squamous cell carcinoma (HNSCC) solid tumors. Participants receive 3 X 10\^8 TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
62238422|NCT03272568|EXPERIMENTAL|Hemophilia A symptomatic female carriers|"Hemophilia A symptomatic female carriers with a baseline FVIII activity of ≤60% receive recombinant FVIII Fc fusion product Eloctate.~Some of participants will be taught to perform a hemoglobin check using a patient-operated diagnostic device for anemia AnemoCheck every other day during 2 consecutive menstrual cycles."
62596568|NCT04521621|EXPERIMENTAL|Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma|This arm will enroll participants with cutaneous squamous cell carcinoma (cSCC) solid tumors. Participants receive 3 X 10\^8 TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
62814585|NCT05158270|OTHER|Intravenous Multimodal Analgesia|Postoperative pain in the post-anesthesia care unit (PACU) and on the ward will be treated with a combination of IV multimodal analgesia in the form of Acetaminophen (15 mg/kg 4/day) and Ketorolac (0.5 mg/kg 3/day) using a fixed scheme. In addition, Nalpuphine, as 3 mg IV bolus at each dose, will be given when Numerical Rating Scale (NRS) ≥ 3. VAS will be assessed 5 - 10 min. after each opioid dose to assess the need for additional opioid doses.
62814586|NCT02570178|NO_INTERVENTION|standard practice advice|standard practice advice
62814587|NCT02570178|OTHER|balance training|balance training using the Nintendo™ Wii console and its balance board.
62814588|NCT05178173|PLACEBO_COMPARATOR|Sterile Water|Subject participants will rinse mouth one time for 60 seconds with 20 mL of sterile water.
62814589|NCT05178173|ACTIVE_COMPARATOR|27% Ethanol plus essential oils|Subject participants will rinse mouth one time for 60 seconds with 20 mL 27% ethanol plus essential oils.
62814590|NCT05178173|ACTIVE_COMPARATOR|0.075% Cetylpyridinium Chloride|Subject participants will rinse mouth one time for 60 seconds with 20 mL 0.075% Cetylpyridinium Chloride.
62814591|NCT05724277|EXPERIMENTAL|Mindfulness Meditation Group|Mindfulness meditation will be applied to the patients in the Mindfulness Meditation Group for 15 minutes in the preoperative period, in both evening and morning.
62814592|NCT05724277|EXPERIMENTAL|Virtual Reality Group|Virtual reality will be experienced to the patients in the Virtual Reality Group for 15 minutes in the preoperative period, in both evening and morning.
62814593|NCT05724277|NO_INTERVENTION|Control Group|The patients in the Control Group will not undergo any intervention in the preoperative period and will receive the routine nursing care of the clinic.
62238423|NCT03272568|EXPERIMENTAL|Hemophilia B symptomatic female carriers|"Hemophilia B symptomatic female carriers with a baseline FIX activity of ≤60% receive recombinant FIX Fc fusion product Alprolix.~Some of participants will be taught to perform a hemoglobin check using a patient-operated diagnostic device for anemia AnemoCheck every other day during 2 consecutive menstrual cycles."
62814594|NCT05034146|EXPERIMENTAL|68Ga-FAPI PET/CT in malignant tumors|Investigators select subjects from patients who have underwent whole-body 18F-FDG PET/CT scan for suspected or confirmed malignancy, or suspected recurrence and metastasis after treatment for malignant tumors, focusing on malignant tumors with low FDG uptake including glioma, hepatocellular carcinoma, renal cancer, gastrointestinal cancer, and peritoneal metastases. Then the subjects receive whole-body 68Ga-FAPI PET/CT scan with time interval of one to four week.
62037151|NCT03668080||non-surgical residents|Non-surgical specialties included cardiology, rheumatology, neurology, pulmonary disease, endocrinology, nuclear medicine, pediatrics, psychiatry, internal medicine, oncology, nephrology, hygiene and preventive medicine, anesthesiology, child and adolescent psychiatry, radiology, radiation oncology, infectious disease, dermatology, pathology, microbiology, hematology, gastroenterology, geriatric medicine, medical genetics, sports medicine, occupational and environmental medicine.
62428989|NCT05573373|EXPERIMENTAL|Pamiparib in combination with Targeted Therapy Drugs|The specific targeted therapy plan is formulated by the investigator. The dosage of targeted therapeutic drugs is selected according to the drug use guidelines. Combination medication, the initial dose is 40mg each time (2 capsules), 2 times a day, the total daily dose is 80mg. Can be taken with a meal or on an empty stomach. If the patient misses a dose, no additional dose should be taken, and the next prescribed dose should be taken normally at the planned time. Continue the treatment until the disease progresses or unacceptable adverse reactions occur, and the dose is adjusted.
62428990|NCT04844307|ACTIVE_COMPARATOR|Standard PT group|The standard PT group (control) will be receiving the standard 30 minute PT sessions 5 days a week. There will be no variations from standard inpatient PT treatment except that subjects may receive more days of PT than patients who are not participating in study.
62428991|NCT04844307|EXPERIMENTAL|Divided session PT group|The divided session PT group (experimental) will be receiving 15 minute sessions twice a day, five days a week. The total number of minutes of PT time per day/week will be identical to the standard PT group, but divided into shorter and more frequent sessions.
62428992|NCT05103514||Cohort 1|Participants in this group started their recovery process \< 1 year ago
62428993|NCT05103514||Cohort 2|Participants in this group started their recovery process 1 to \<2 years ago
62428994|NCT05103514||Cohort 3|Participants in this group started their recovery process 2 to \<3 years ago
62428995|NCT03005379|ACTIVE_COMPARATOR|1|Fecal Microbiota Therapy (FMT)
62596569|NCT04521621|EXPERIMENTAL|Part 2 Dose Level 1, Solid Tumors + Liver Metastases|This arm will enroll participants with solid tumors with liver metastases. Participants receive 3 X 10\^7 TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
62037152|NCT01107184|EXPERIMENTAL|Preconditioning|The remote ischemic stimulus will be applied after induction of anaesthesia, but before cardiopulmonary bypass.
62037153|NCT01107184|EXPERIMENTAL|Postconditioning|The remote ischemic stimulus during cardiopulmonary bypass.
62428996|NCT03005379|PLACEBO_COMPARATOR|2|Placebo
62428997|NCT04971915|EXPERIMENTAL|minimalist footwear|The participants in the experimental group will receive one pair of minimalist footwear and will be asked to use them for the interventional period.
62428998|NCT04971915|NO_INTERVENTION|control|The participants in the control group will be asked to wear their standard footwear as before participating in the study.
62814595|NCT03113851|EXPERIMENTAL|Radiotherapy and rhGM-CSF|Patients with metastatic non-small cell lung cancer received 3.5 Gy per fraction to a total dose of 35 Gy/ 10 fractions over 2 weeks, combined with rhGM-CSF (125 μg/m2).
62596570|NCT04521621|EXPERIMENTAL|Part 2 Dose Level 2, Solid Tumors + Liver Metastases|This arm will enroll participants with solid tumors with liver metastases. Participants receive 1 X 10\^8 TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
62596571|NCT04521621|EXPERIMENTAL|Part 2 Dose Level 3, Solid Tumors + Liver Metastases|This arm will enroll participants with solid tumors with liver metastases. Participants receive 3 X 10\^8 TCID50 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
62596572|NCT04521621|EXPERIMENTAL|Part 2, Cohort D: Hepatocellular Carcinoma (HCC)|This arm will enroll participants with hepatocellular carcinoma (HCC) solid tumors. Participants receive the gebasaxturev recommended phase 2 dose (RP2D) intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
62596573|NCT04521621|EXPERIMENTAL|Part 2, Cohort E: Gastric Carcinoma|This arm will enroll participants with gastric carcinoma solid tumors. Participants receive the gebasaxturev recommended phase 2 dose (RP2D) intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
62596574|NCT06617884|EXPERIMENTAL|4 x 20 minutes training per week|During the three-week training phase, the video-based training should be carried out at home four times a week for 20 minutes each time. The access to the training videos is provided via links.
62596575|NCT06617884|EXPERIMENTAL|2 x 40 minutes training per week|During the three-week training phase, the video-based training should be carried out at home two times a week for 40 minutes each time. The access to the training videos is provided via links.
62814596|NCT05708911|EXPERIMENTAL|Pharyngeal exerciser group|"Test that application of the pharyngeal exerciser increases the workload of muscles involved in pharyngeal phase of swallowing as evidenced manometrically by changes in~Pharyngeal peak pressures Pharyngeal (velopharynx, oropharynx and hypopharynx) contractile duration Pharyngeal (velopharynx, oropharynx and hypopharynx) contractile integral Hypopharyngeal intrabolus pressure and duration UES nadir pressure UES relaxation time Baseline UES pressure"
62814597|NCT02996344|ACTIVE_COMPARATOR|Didactic training|Behavioral; participants will view the approximately one hour Commitment to Living: Primary Care (CTL:PC) didactic training videos.
62596576|NCT06617884|NO_INTERVENTION|control group|During the three weeks between study visit two and study visit three, no additional training is conducted. Patients who were assigned to the group without training are given access to the training material after the end of the study and can carry it out afterwards.
62596577|NCT01734915||NSCLC|Subjects with advanced NSCLC, will undergo blood draw
62596578|NCT05178641|EXPERIMENTAL|Ninjamas Pyjama Pant, Then Participant's Overnight Current Standard of Care|For the first 3 weeks participants use Ninjamas Pyjama Pants, then for the next 3 weeks they switch to the Overnight Current Standard of Care.
62814598|NCT02996344|EXPERIMENTAL|Didactics and standardized patients|Behavioral; participants will view the approximately one hour Commitment to Living: Primary Care (CTL:PC) didactic training videos plus two practice standardized patient interactions.
62814599|NCT04688450|EXPERIMENTAL|Intervention group|The investigational system will be evaluated for safety and user acceptance in 20 patient-subjects and associated nurse-subjects
62814600|NCT04056819|EXPERIMENTAL|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of heart attack.
62814601|NCT05428332|NO_INTERVENTION|No Brace Group|50% of the participants in the study that will not be receiving a TCU brace.
62814602|NCT05428332|EXPERIMENTAL|Tri-Compartment Unloader Brace Group|50% of the participants in the study that will be receiving a TCU brace.
62814603|NCT04617782|EXPERIMENTAL|Treatment A|5 mg/day Donepezil Transdermal Delivery System (TDS) 1-week wear and applied weekly for 5 consecutive weeks
62037154|NCT01107184|EXPERIMENTAL|Pre and postconditioning|The remote ischemic stimulus will be applied twice, after induction of anaesthesia and during cardiopulmonary bypass.
62428999|NCT05699811|EXPERIMENTAL|MSC-IFNα monotherapy|Subjects will be enrolled for safety evaluation of MSC-IFNα monotherapy. Subjects will receive MSC-IFNα infusion from a dose of 2×10\^6 cells/kg 1-4 times every 4-6 weeks. All treatment-related adverse events(TRAE) will be recorded for at least 28 days after the cell infusion.
62814604|NCT04617782|EXPERIMENTAL|Treatment B|10 mg/day Donepezil TDS 1-week wear and applied weekly for 5 consecutive weeks
62814605|NCT04617782|ACTIVE_COMPARATOR|Treatment C|10 mg/day Aricept® donepezil tablet administered QD for 5 consecutive weeks
62037155|NCT01107184|SHAM_COMPARATOR|Control|
62238424|NCT06227208||Opioid-naive patients|Opioid-naive patients are defined as the absence of any documented opioid use in the available preoperatively medical records, and are receiving opioids postoperatively
62238425|NCT06227208||Chronic opioid patients|Chronic opioid patients were defined as current or previous use of the following medications, re-gardless of the duration of use: morphine, tramadol, tapentadol, fentanyl, oxycodone, ketobe-midone, methadone, or buprenorphine. This was verified through patients' preoperative medical records. All chronic opioid users received postoperative opioids.
62238426|NCT06227208||Control group|Patients who did not receive pre- or postoperative opioids were served as the overall control group.
62238427|NCT06190795|EXPERIMENTAL|Smartphone Application|AMPLIFY Programme delivered via smartphone application with 2 levels. Level 1 is catered for people with stroke with ARAT score \<34, while Level 2 is catered for people with stroke with ARAT score \>=34. Five to 6 exercises will be prescribed to the stroke participants for each session to be performed independently or with the help of caregiver. Stroke participants are to performed exercises 3 sessions per day for 6 days per week. Stroke participants are to use paretic UL to perform functional activities prescribed whenever needed throughout the day. AMPLIFY programme will last for 4 weeks. If the stroke participants are discharged before 4 weeks, the participants will continue at home with the reviews being performed by the therapists via tele-rehabilitation. Frequency of reviews for the experimental group will be: Week1 (2x); Week2 (1x); Week3 (x0); Week4 (x1).
62238428|NCT06190795|ACTIVE_COMPARATOR|Hardcopy Manual|AMPLIFY Programme will be delivered via hardcopy manual. AMPLIFY Programme consists of two booklets (Booklet 1 and Booklet 2). Booklet 1 is catered for people with stroke with ARAT score \<34, while Booklet 2 is catered for people with stroke with ARAT score \>=34. Five to 6 exercises will be prescribed to the stroke participants for each session to be performed independently or with the help of caregiver. Stroke participants are to performed the exercises 3 sessions per day for 6 days per week. Stroke participants are to use paretic UL to perform functional activities prescribed whenever needed throughout the day. AMPLIFY programme will last for 4 weeks. If stroke participants are discharged before AMPLIFY programme ends, the participants will continue at home with the reviews being performed by the therapists via tele-rehabilitation. Frequency of reviews for the control group will be as follows: Week1 (3x); Week2 (2x); Week3 (x1); Week4 (x1).
62429000|NCT05699811|EXPERIMENTAL|MSC-IFNα combined with immunochemotherapy|"Subjects will be enrolled and received MSC-IFNα combined with immunochemotherapy, namely nab-paclitaxel (125 mg/m2, 5 days before infusion), cyclophosphamide (200 mg/m2,4 days before infusion) and anti-PD-1 antibody (200mg, 7 days after infusion) for 4 cycles.~From the 5th cycle, subjects will receive MSC-IFNα combined with anti-PD-1 antibody every 4-6 weeks for another 4 cycles for efficacy consolation. From the 9th cycle, subjects will receive anti-PD-1 antibody alone every 3 weeks for another 4 cycles for efficacy maintenance."
62238429|NCT05373303|EXPERIMENTAL|Test Drug|Recombinant Human Erythropoietin Alfa, dosage : 50 IU/Kg body weight three times per week, and continued to titrated dose closely to achieve baseline Hb level 10-12g/dL
62238430|NCT05373303|ACTIVE_COMPARATOR|Reference Drug|Recombinant Human Erythropoietin Alfa, dosage : 50 IU/Kg body weight three times per week, and continued to titrated dose closely to achieve baseline Hb level 10-12g/dL
62814606|NCT03524846|ACTIVE_COMPARATOR|Ascorbic acid 300 mg|Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
62429001|NCT04407468||COVID|Patients with or without prone position
62238431|NCT01409616|EXPERIMENTAL|Treatment arm A|ASA, wash-out (w.o.), ASA + darexaban
62429002|NCT04664829|EXPERIMENTAL|Bexarotene and Capecitabine|
62429003|NCT02966522|EXPERIMENTAL|Thalidomide|Patient with cardiac amyloidosis receive thalilomide with dexamethasone
62429004|NCT02124746|EXPERIMENTAL|Cohort 1|Participants previously enrolled in Study CCL09191E will receive momelotinib for approximately 4 years.
62429005|NCT02124746|EXPERIMENTAL|Cohort 2|Participants previously enrolled in Study YM387-II-02 will receive momelotinib for approximately 4 years.
62429006|NCT02124746|EXPERIMENTAL|Cohort 3|"Participants previously enrolled in Study GS-US-354-0101 will receive momelotinib for up to 4 years.~Cohort 3 was closed and all enrolled participants were discontinued from this study because parent Study GS-US-354-0101 was terminated."
62429007|NCT02124746|EXPERIMENTAL|Cohort 4|Participants previously enrolled in Study GS-US-352-1672 will receive momelotinib for approximately 4 years.
62429008|NCT02751242||Usual Care|All patients will receive a dose of intravenous furosemide.
62429009|NCT01160198|EXPERIMENTAL|ferrous bisglycinate chelate 1 OD|ferrous bisglycinate chelate 1 tablet daily
62429010|NCT01160198|ACTIVE_COMPARATOR|ferrous ascorbate|ferrous ascorbate, 1 tablet daily
62429011|NCT01160198|EXPERIMENTAL|ferrous bisglycinate chelate 2 OD|ferrous bisglycinate chelate 2 tablets daily
62429012|NCT04429373|EXPERIMENTAL|Implant installation with PRF|PRF membrane over the buccal aspect of implant site
62814607|NCT03524846|ACTIVE_COMPARATOR|Ascorbic acid 600 mg|Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
62814608|NCT03524846|PLACEBO_COMPARATOR|Placebo|Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
62814609|NCT06544174||Successful CTO-PCI|Success was defined as a procedure achieving a final residual stenosis \< 30% (by visual estimation) and a TIMI flow grade 3 after CTO recanalization in all living patients within 24h following angioplasty.
62238432|NCT01409616|EXPERIMENTAL|Treatment arm B|ASA + darexaban, w.o., ASA
62238433|NCT01409616|EXPERIMENTAL|Treatment arm C|ASA, w.o., darexaban (double dose) + ASA
62238434|NCT01409616|EXPERIMENTAL|Treatment arm D|darexaban (double dose) + ASA, w.o., ASA
62238435|NCT01409616|EXPERIMENTAL|Treatment arm E|ASA + clopidogrel, w.o., ASA + clopidogrel + darexaban
62429013|NCT04429373|ACTIVE_COMPARATOR|Implant installation without PRF|Implant installation contralateral to the the experimental implant, without PRF membrane
62814610|NCT06544174||Failed CTO-PCI|Success was defined as a procedure achieving a final residual stenosis \< 30% (by visual estimation) and a TIMI flow grade 3 after CTO recanalization in all living patients within 24h following angioplasty.
62814611|NCT04889872|EXPERIMENTAL|TAVR|Transcatheter Aortic Valve Replacement (TAVR)
62814612|NCT04889872|NO_INTERVENTION|CS|Clinical Surveillance (CS)
62814613|NCT03182374|ACTIVE_COMPARATOR|nSTRIDE APS|The nSTRIDE APS Kit is designed to be used for the safe and rapid preparation of APS from a small sample of blood at the patient's point of care. The APS is to be injected intra-articularly for the treatment of knee osteoarthritis and associated symptoms.
62238436|NCT01409616|EXPERIMENTAL|Treatment arm F|ASA + clopidogrel + darexaban, w.o., ASA + clopidogrel
62238437|NCT01409616|EXPERIMENTAL|Treatment arm G|ASA + clopidogrel, w.o., darexaban (double dose) + ASA + clopidogrel
62238438|NCT01409616|EXPERIMENTAL|Treatment arm H|darexaban (double dose) + ASA + clopidogrel, w.o., ASA + clopidogrel
62238439|NCT00888433|EXPERIMENTAL|Renal Denervation|Renal Denervation and maintenance of anti-hypertensive medications
62429014|NCT06517732||Secukinumab|Patients prescribed with secukinumab in the treatment of Hidradenitis Suppurativa
62429015|NCT03811249|EXPERIMENTAL|Implantation-Non-randomized|Subjects that previously participated in the VIS-2014 clinical trial that had VisAbility™ Micro Inserts surgically implanted in the eye(s) will be followed prospectively for an additional 36 month period to measure long term safety and effectiveness outcomes.
62429016|NCT05795517|EXPERIMENTAL|HSK31679 low dose|
62429017|NCT05795517|EXPERIMENTAL|HSK31679 medium dose|
62429018|NCT05795517|EXPERIMENTAL|HSK31679 high dose|
62429019|NCT05795517|PLACEBO_COMPARATOR|Placebo|
62238440|NCT00888433|NO_INTERVENTION|Control|Maintenance of anti-hypertensive medications with option for cross-over treatment after 6-months
62429020|NCT05795517|ACTIVE_COMPARATOR|Ezetimibe|
62429021|NCT01829295|EXPERIMENTAL|Methotrexate|oral methotrexate
62814614|NCT03182374|ACTIVE_COMPARATOR|Synvisc-One|Synvisc-One is only intended for intra-articular use by a physician to treat pain associated with osteoarthritis of the knee
62814615|NCT06114121|EXPERIMENTAL|erector spinae plane block|participants will be in this group for up to 9 months and receive erector spinae plane (ESP) block
62814616|NCT06114121|EXPERIMENTAL|standard of care|participants in this group will receive the standard of care treatment and will be in this group for up to 9 months.
62238441|NCT02173041|OTHER|Standard Usual Care|Community program which follows with referral services
62238442|NCT02173041|EXPERIMENTAL|Prevention Awareness Groups (PAG)|Prevention Awareness Groups (PAG) is a community based integrated substance abuse prevention program targeting vulnerable populations. It comprises of community programs, physician led counseling followed by treatment follow up in community based clinic.
62238443|NCT01800357|EXPERIMENTAL|mildronate|infusion of mildronate
62238444|NCT01800357|PLACEBO_COMPARATOR|placebo|infusion of placebo mildronate
62429022|NCT01829295|EXPERIMENTAL|Mycophenolate Mofetil|oral mycophenolate mofetil
62429023|NCT01278199|OTHER|2|Medicals measures in the treatment of non-severe acute hemoptysis
62429024|NCT01278199|EXPERIMENTAL|1|bronchial artery embolization (BAE)
62429025|NCT00142454|EXPERIMENTAL|Imiquimod + NY-ESO-1|Patients applied topical imiquimod followed by vaccination with intradermal injections of the NY-ESO-1 protein.
62596579|NCT05178641|EXPERIMENTAL|Participant's Overnight Current Standard of Care, Then Ninjamas Pyjama Pant|For the first 3 weeks participants use their Overnight Current Standard of Care, then for the next 3 weeks they switch to Ninjamas Pyjama Pants.
62596580|NCT01915667|EXPERIMENTAL|GLPG0634 capsule fasted|Single dose of GLPG0634 as capsules in fasted condition
62596581|NCT01915667|EXPERIMENTAL|GLPG0634 tablet fasted|Single dose of GLPG0634 as tablets in fasted condition
62596582|NCT01915667|ACTIVE_COMPARATOR|GLPG0634 tablet fed|Single dose of GLPG0634 as tablets in fed condition
62596583|NCT04790162|ACTIVE_COMPARATOR|Meditation Intervention|Heartfulness meditation
62596584|NCT04790162|NO_INTERVENTION|Control|Wait listed control group
62596585|NCT04199767|EXPERIMENTAL|20 IU Insulin first, then 40 IU Insulin|Participants will be randomly assigned to receive regular insulin (U100, 20 IU) administered with an intranasal nebulizer-like device. Participants in this arm will then receive regular insulin (U100, 40 IU) at visit 3 during second intervention period.
62596586|NCT04199767|EXPERIMENTAL|40 IU Insulin first, then 20 IU Insulin|Participants will be randomly assigned to receive regular insulin (U100, 40 IU) administered with an intranasal nebulizer-like device. Participants in this arm will then receive regular insulin (U100, 20 IU) at visit 3 during second intervention period.
62596587|NCT05496413|EXPERIMENTAL|Active comparator Within group|This project will use the StarStim DC stimulator manufactured by Neuroelectrics that was imported with TFDA approval. At the beginning, the participants would be allowed to perform the task which would be followed by application of tACS. The tACS application would be comprised of sham vs active where the sham condition would be given for 30 seconds while the active session would be applied for 15 mins. In tACS, 1mA of theta (6Hz) tACS would be given at the right F4 and P4 electrodes (5\*5 cm2, Sponstim® 25). After tACS, the participants would be asked to perform the same task again and the scores (before and after tACS) will be compared and analyzed statistically. Therefore, each patient will need to participate in 2 sessions (active vs. sham), and they will not know which day is which (randomized order).
62596588|NCT05496413|SHAM_COMPARATOR|Sham comparator Within group|This project will use the StarStim DC stimulator manufactured by Neuroelectrics that was imported with TFDA approval. At the beginning, the participants would be allowed to perform the task which would be followed by application of tACS. The tACS application would be comprised of sham vs active where the sham condition would be given for 30 seconds while the active session would be applied for 15 mins. In tACS, 1mA of theta (6Hz) tACS would be given at the right F4 and P4 electrodes (5\*5 cm2, Sponstim® 25). After tACS, the participants would be asked to perform the same task again and the scores (before and after tACS) will be compared and analyzed statistically. Therefore, each patient will need to participate in 2 sessions (active vs. sham), and they will not know which day is which (randomized order).
62596589|NCT01271101||anticoagulant|
62596590|NCT04357912|EXPERIMENTAL|Experimental group|
62596591|NCT04357912|ACTIVE_COMPARATOR|Control Group|
62037156|NCT04110613|ACTIVE_COMPARATOR|noFast: Start tube feeds within 1 hour of procedure|The noFAST group will have post-PEG tube feeds initiated \<1 hour after the procedure. Feeds are to be initiated at the rate and with the formula the patient was tolerating prior to the procedure.
62238445|NCT02624765|ACTIVE_COMPARATOR|RCT A (1st arm): AF without hydrops|Atrial Flutter (AF) without hydrops: Treatment with Digoxin as monotherapy.
62238446|NCT02624765|ACTIVE_COMPARATOR|RCT A (2nd arm): AF without hydrops|Atrial Flutter (AF) without hydrops: Treatment with Sotalol as monotherapy.
62238447|NCT02624765|ACTIVE_COMPARATOR|RCT B (1st arm): SVT without hydrops|Supraventricular Tachycardia (SVT) without hydrops: Treatment with Digoxin as monotherapy.
62238448|NCT02624765|ACTIVE_COMPARATOR|RCT B (2nd arm): SVT without hydrops|Supraventricular Tachycardia (SVT) without hydrops: Treatment with Flecainide as monotherapy.
62596592|NCT01310517||Radial Coronary Angiography|The subjects enrolled in this study will be adults referred for radial coronary angiography with left ventriculography for clinical indications.
62596593|NCT06426472|EXPERIMENTAL|Intervention|Interventional group which will be given the web-based fertility support
62596594|NCT06426472|NO_INTERVENTION|Control|Control group will not be given any intervention
62596595|NCT03201874|ACTIVE_COMPARATOR|Education Control|In addition to standard medical care, youth in the education control group will be provided with access to a self-guided education study website, which will contain static education about SCD (no self-management skills, goal-setting, or social support content) to access over 8-weeks.
62037157|NCT04110613|NO_INTERVENTION|FAST: Start tube feeds 4 hours after procedure|The FAST group will have post-PEG tube feeds initiated 4 hours after the procedure. Feeds are to be initiated at the rate and with the formula the patient was tolerating prior to the procedure.
62238449|NCT02624765|ACTIVE_COMPARATOR|RCT C (1st arm): SVT with hydrops|Supraventricular Tachycardia (SVT) with hydrops: Treatment with Digoxin and Sotalol.
62596596|NCT03201874|EXPERIMENTAL|Pain Self-Management Intervention|In addition to standard medical SCD care, youth in the pain self-management intervention group will receive the iCanCope with SCD mobile intervention including goal-setting, peer social support, and pain self-management skills over a period of 8 weeks.
62596597|NCT06513962|EXPERIMENTAL|Arm A (triptorelin)|Patients receive triptorelin IM up to 14 days prior to standard chemotherapy. For patients whose chemotherapy exceeds 24 weeks, a second dose of triptorelin may be given 24 weeks after the first dose at the treating physician's discretion. Patients also undergo blood sample collection throughout the study.
62596598|NCT06513962|ACTIVE_COMPARATOR|Arm B (usual care)|Patients receive standard chemotherapy. Patients also undergo blood sample collection throughout the study.
62037158|NCT04230499|EXPERIMENTAL|Cohort 1|Cohort 1 will receive 0.5mg of eRapa every other day.
62037159|NCT04230499|EXPERIMENTAL|Cohort 2|Cohort 2 will receive 0.5mg of eRapa daily with 7 days on therapy, followed by 7 days off therapy.
62037160|NCT04230499|EXPERIMENTAL|Cohort 3|Cohort 3 will receive 0.5 mg of eRapa daily.
62238450|NCT02624765|ACTIVE_COMPARATOR|RCT C (2nd arm): SVT with hydrops|Supraventricular Tachycardia (SVT) with hydrops: Treatment with Digoxin and Flecainide.
62238451|NCT01256125||Allogene MSCs transplantation|Allogene MSCs transplantation were performed in patients with chronic liver diseases through peripheral vein plus the same medical treatments.
62238452|NCT01256125||control|only medical treatments were performed in patients with chronic liver diseases.
62238453|NCT06398860|EXPERIMENTAL|Intervention-arm|Cluster of 3-6 workplaces will start intervention at either baseline, 4 or 8 month from the start.
62238454|NCT06398860|EXPERIMENTAL|Wait-list group|Wait-listed group, will await intervention for either 4 or 8 months.
62238455|NCT04112329|EXPERIMENTAL|Exergaming|Will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks
62596599|NCT06279533|EXPERIMENTAL|PK characteristics of multiple ascending doses study|There are 24 subjects devided into 3 dose groups (15mg, 25mg and 40mg).8 subjects will be enrolled in each dose group and the ratio of investigational product to placebo is 3:1. LV232/Placebo is administered sequentially from low-dose to high-dose and each subject can only orally receive one dose level. Investigational product is orally administrated QD for day1, day3\~day9. When 7th day visit after last dose (D15) is completed for previous dose group, investigator and sponsor will evaluate the safety and determine whether the next dose group can be started or adjusted.
62596600|NCT06279533|EXPERIMENTAL|FE study|24 healthy subjects divided into 2 group (25mg and 40mg) will be enrolled once all eligibility criteria are met after screening within 14 days prior to investigation product administration. Informed consent should be obtained before any protocol defined procedures can be started.Investigational product administration plan given below: 12 healthy subjects in each group will be randomized to 3 sub-groups, i.e., Group A, Group B, Group C, with 4 subjects in each sub-group. For group A, investigation product will be given after fasting for Period 1, after standard diet for Period 2, and after high-fat diet for Period 3; For group B, investigation product will be given after high-fat diet for Period 1, after fasting for Period 2, and after standard diet for Period 3; For group C, investigation product will be given after standard diet for Period 1, after high-fat diet for Period 2, and after fasting for Period 3. Wash-out period is 5 days.
62596601|NCT01582178|EXPERIMENTAL|Warm Water Immersion Colonoscopy|Colonoscopy using purely warm water (37°C) infusion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
62814617|NCT05595655|NO_INTERVENTION|control group|The dyads will receive traditional educational treatment only and will complete the questionnaires after 3, 6, 9 and 12 months follow-up post-intervention. Enrolled dyads will be monitored by the research team responsible for recruitment and follow-up.
62814618|NCT05595655|OTHER|First interventional arm|MI intervention will be administered to patients only and caregivers will receive standard education. The intervention will last approximately 30 minutes. Thereafter, the nurse who performed the MI will contact the patients over the phone 3 times during the first 2 months after MI, to strengthen the intervention. Then, the intervention will be employed again after 3, 6, 9 and 12 months from enrolment. After each MI session, both patients and caregivers will be asked to complete the questionnaires of follow-up post-intervention
62037161|NCT04230499|EXPERIMENTAL|Food Effect|Upon identification of the RP2D, after a 2 week washout (14 days), subjects will be randomized into a fed and fasted (2 weeks - 14 days) two period cross over, with an intervening 2 week washout (14 days) for a total of 2 months (8 weeks).
62238456|NCT04112329|NO_INTERVENTION|Control|Asked to continue with their normal daily routine
62429026|NCT01869712|EXPERIMENTAL|Cupping therapy (randomized)|Use retained cupping as the main cupping method, supplemented with flash cupping and/or moving cupping. First use empty cupping, which means the cups are removed after suction without delay, then practitioners should control the suction by gently moving the cup toward direction of DU and/or BL, repeat this moving for several times, finally cupping practitioners utilize the flaming heating power to achieve suction (minus pressure) inside the cups to make them apply on the desired part of the body. Cups should retain for 10 minutes daily, patients accept the treatment three times weekly for totally 15 times.
62429027|NCT01869712|EXPERIMENTAL|Cupping therapy (non-randomized)|Use retained cupping as the main cupping method, supplemented with flash cupping and/or moving cupping. First use empty cupping, which means the cups are removed after suction without delay, then practitioners should control the suction by gently moving the cup toward direction of DU and/or BL, repeat this moving for several times, finally cupping practitioners utilize the flaming heating power to achieve suction (minus pressure) inside the cups to make them apply on the desired part of the body. Cups should retain for 10 minutes daily, patients accept the treatment three times weekly for totally 15 times.
62037162|NCT06194227|EXPERIMENTAL|High-speed, Cognitive Challenge Yoga|Participants in this group will receive high-speed yoga training for 24 consecutive weeks for a total of 72 training sessions.
62596602|NCT01582178|ACTIVE_COMPARATOR|Cool Water Immersion Colonoscopy|Colonoscopy using purely room temperature water (20-24°C) infusion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
62037163|NCT06194227|ACTIVE_COMPARATOR|Traditional Yoga|Participants will perform standard Hatha yoga with slow controlled speed movements for 24 consecutive weeks for a total of 72 training sessions.
62037164|NCT03528018|OTHER|Control|Conventional physical therapy
62037165|NCT03528018|EXPERIMENTAL|Experimental|Combined tDCS and VR-based intervention
62238457|NCT02887937||Breast Mass 4a-cystic|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4a-cystic breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
62429028|NCT01869712|ACTIVE_COMPARATOR|Acupuncture (non-randomized)|Sterilize the selected points with alcohol, and then select the specific size of needles to do the acupuncture. Do the manual stimulation for seconds after needles' insertion, including twist, pull up and deeper insert. Needles should be withdrawn after 30 minutes. Patients accept the treatment three times weekly for totally 15 times.
62429029|NCT01869712|ACTIVE_COMPARATOR|Acupuncture (randomized)|Sterilize the selected points with alcohol, and then select the specific size of needles to do the acupuncture. Do the manual stimulation for seconds after needles' insertion, including twist, pull up and deeper insert. Needles should be withdrawn after 30 minutes.
62429030|NCT03556917|ACTIVE_COMPARATOR|group 1|topical gel base + caffeine.
62429031|NCT03556917|ACTIVE_COMPARATOR|group 2|iontophoresis + caffeine
62596603|NCT06498622|EXPERIMENTAL|Donafenib 100mg PO bid + Envafolimab 300mg IH D1 q3w|Donafenib：100mg，PO，bid；Treatment cycle 6-12 months Envafolimab：300mg, IH，D1，q3w；Treatment cycle 6-12 months or 8-16 sessions Donafenib and Envafolimab will be administered until the disease recurrence, intolerable toxicity, death, withdrawal of consent or completion of 16 cycles of Envafolimab.
62596604|NCT01740271|EXPERIMENTAL|Epirubicin|Following genetic analysis, depending on results, participants will receive either standard or increased epirubicin dosing for cycles 2 - 4.
62429032|NCT03556917|ACTIVE_COMPARATOR|Group 3|iontophoresis
62596605|NCT01021761|ACTIVE_COMPARATOR|Xibrom|Xibrom to be given 1 drop 2 times (BID) the day before surgery and 3 doses pre op the day of surgery prior to surgery
62037166|NCT05687474||Newborns with consent|Newborns with parent's consent
62037167|NCT01016210|EXPERIMENTAL|60 infertile women|Candidates for IVF-ET treatment
62429033|NCT06257576|EXPERIMENTAL|Tamusolin|Participants will receive tamsulosin postoperatively for two days.
62429034|NCT06257576|OTHER|Control Group|Participants will be randomized to the standard of care, with no medication given.
62429035|NCT00971399|EXPERIMENTAL|RMS|ramosetron 0.1mg q.d. SL on D1-5
62429036|NCT00971399|ACTIVE_COMPARATOR|ODS|ondansetron 8mg, b.i.d SL on D1-5
62429037|NCT05229315|EXPERIMENTAL|PD-1 Immune Checkpoint Inhibitor Combined With Intensity Modulated Radiation Therapy|Intensity modulated radiation therapy combined with toripalimab in the treatment of nasopharyngeal carcinoma，once every 2 weeks, 10 cycles in total
62596606|NCT01021761|ACTIVE_COMPARATOR|Nevanac|Nevanac to be given 1 drop 2 times (BID) the day before surgery and 3 doses pre op the day of surgery prior to surgery
62596607|NCT01021761|ACTIVE_COMPARATOR|Acuvail|Acuvail to be given preoperatively. One drop 2 times (BID), 1 day pre op and day of surgery 3 doses prior to surgery.
62596608|NCT01759849||Allergen challenge|Determination of the effects of a β-chain monoclonal antibody (MAb) on the function of cells naturally activated by in vivo allergen exposure, from donors with allergen-induced asthma
62596609|NCT00893997|EXPERIMENTAL|PR-1 vaccine|4 injections of 0.5 mg PR1 peptide vaccine every 3 weeks.
62037168|NCT01016210|NO_INTERVENTION|control|no treatment
62037169|NCT06496048|EXPERIMENTAL|Lurbinectedin monotherapy|
62238458|NCT02887937||Breast Mass 4a- non cystic|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4a-non cystic breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration..
62429038|NCT01901146|EXPERIMENTAL|ABP 980|"Participants received ABP 980 at an initial dose of 8 mg/kg by intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase.~Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase.~After surgery (adjuvant phase) participants continued receiving 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase."
62814619|NCT05595655|EXPERIMENTAL|Second interventional arm|MI intervention will be administered both to patients and caregivers. The intervention will be administered to the dyad in one session and patients and their caregivers will receive the reinforcing educational treatment calibrated on the specific lacking areas of patients' self-care behaviours. After each MI session, both patients and caregivers will be asked to complete the questionnaires of follow-up post-intervention.
62429039|NCT01901146|ACTIVE_COMPARATOR|Trastuzumab|"Participants received trastuzumab at an initial dose of 8 mg/kg IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase.~Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase.~After surgery (adjuvant phase) participants were re-randomized to either continue receiving 6 mg/kg trastuzumab IV Q3W or transition to 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase."
62429040|NCT00568776|PLACEBO_COMPARATOR|1|
62429041|NCT00568776|ACTIVE_COMPARATOR|2|
62814620|NCT05574322|EXPERIMENTAL|Training group (PRP)|Participants benefiting from an 8-week muscle strengthening program (PRP)
62814621|NCT05574322|SHAM_COMPARATOR|Control group|Participants in the control group will be asked to maintain their habits and lifestyle (without training program) for the duration of the study.
62814622|NCT00476125|EXPERIMENTAL|3 day ketogenic diet|
62429042|NCT00568776|ACTIVE_COMPARATOR|3|
62429043|NCT00568776|ACTIVE_COMPARATOR|4|
62429044|NCT03826771|EXPERIMENTAL|POWER training|high velocity strength training
62429045|NCT03826771|ACTIVE_COMPARATOR|Stretching|Upper and lower body range of motion exercises
62429046|NCT05266976|EXPERIMENTAL|Resistance Exercise|Participants will perform total body resistance training 3x per week for 10 weeks. Each exercise session will last approximately 1 hour.
62429047|NCT05266976|EXPERIMENTAL|Endurance Exercise|Participants will complete 60 minutes of stationary cycling 3x per week at 70-80% of maximal heart rate for 10 weeks.
62429048|NCT04313023|EXPERIMENTAL|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution given by nebulization on Study Days 1, 3, 6, and 10
62429049|NCT04313023|PLACEBO_COMPARATOR|Sterile saline for inhalation|Sterile saline for inhalation given by nebulization on Study Days 1, 3, 6, and 10
62429050|NCT03755700|PLACEBO_COMPARATOR|Placebo|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with the placebos of both vitamin E and NAC (i.e. the placebo of vitamin E as a soft gel capsule and the placebo of NAC as an effervescent tablets along with a glass of water with the same consumption order used in the groups 2 and 3, respectively).
62814623|NCT00476125|EXPERIMENTAL|12 day ketogenic diet|
62814624|NCT00476125|EXPERIMENTAL|16 hour fast|
62814625|NCT06705504||Institut de Cancérologie de l'Ouest (ICO) Cohort|Patients with HR+/HER2- advanced or metastatic BC who were registered in IQVIA's oncology evidence network (OEN), ICO, and initiated treatment with ribociclib or alpelisib.
62814626|NCT06705504||L'Institut Curie (Curie) Cohort|Patients with HR+/HER2- advanced or metastatic BC who were registered in IQVIA's OEN, Curie, and initiated treatment with ribociclib or alpelisib.
62814627|NCT06705504||Instituto Português de Oncologia do Porto (IPO-Porto) Cohort|Patients with HR+/HER2- advanced or metastatic BC who were registered in IQVIA's OEN, IPO-Porto, and initiated treatment with ribociclib or alpelisib.
62429051|NCT03755700|ACTIVE_COMPARATOR|Vitamin E|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention plus the placebo of NAC with a consumption order similar to group 3.
62429052|NCT03755700|ACTIVE_COMPARATOR|NAC|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention plus the placebo of vitamin E with the consumption order similar to group 2.
62429053|NCT01142466|EXPERIMENTAL|Rebif (3x44 mcg) Group|
62814628|NCT06705504||Czech Republic Cohort|Patients with HR+/HER2- advanced or metastatic BC who were registered in Czech Republic local sites or clinics proposed by Novartis affiliates and initiated treatment with ribociclib or alpelisib.
62429054|NCT01142466|NO_INTERVENTION|No treatment Group|
62814629|NCT01572207|EXPERIMENTAL|Immediate Exercise|Subjects assigned to the immediate group will be prescribed a home exercise program during the first meeting. During the 12 week training period, the subject will read pamphlets (sent by mail) once to twice a month about developing skills to manage MS symptoms and motivational pamphlets about physical activity. In addition, the subject will have a phone conversation every two to three weeks with research staff to discuss the progress of the exercise program and to complete a short survey about his/her physical activity level.
62037170|NCT06496048|EXPERIMENTAL|Lurbinectedin + Irinotecan combined therapy|
62037171|NCT06496048|ACTIVE_COMPARATOR|Topotecan|
62814630|NCT01572207|EXPERIMENTAL|Delayed exercise|Subjects assigned to the delayed group will be asked to begin the same home exercise program 12 weeks following the first meeting. During the 12 week training period, the subject will receive pamphlets, have phone conversations with research staff, and complete physical activity surveys as described above.
62814631|NCT06362850|NO_INTERVENTION|No-Support|Participants randomized to Group 1 will perform the simulation scenario without tele-support.
62814632|NCT06362850|OTHER|Tele-Support|Participants randomized to Group 2 will perform the simulation scenario with tele-support.
62814633|NCT05983458|OTHER|patients with severe symptomatic aortic stenosis|Real-world patients with severe symptomatic aortic stenosis allocated to TAVI treatment by local heart Team will be included in the study according to the inclusion and exclusion criteria specified below.
62814634|NCT06486103|EXPERIMENTAL|Bacterial Vaginosis|Take one slow-release capsule twice a day, after meal, orally.
62814635|NCT02249364|ACTIVE_COMPARATOR|Control|Standard care without hypnosis session followed by closed-loop administration of propofol for anesthesia induction
62814636|NCT02249364|EXPERIMENTAL|Hypnosis|Hypnosis session followed by closed-loop administration of propofol for anesthesia induction
62814637|NCT06475664|EXPERIMENTAL|Experimental group|adult patients with advanced colorectal cancel
62814638|NCT04045535|EXPERIMENTAL|Intervention group|Intervention with nurse and patients
62814639|NCT04045535|ACTIVE_COMPARATOR|Usual care|Usual clinical care based on current clinical practice guidelines.
62238459|NCT02887937||Breast Mass 4b|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4b breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
62814640|NCT02219464|ACTIVE_COMPARATOR|Nasopharyngeal catheter|Patients in this arm will receive oxygen supplementation through the use of a Nasopharyngeal catheter. Sedation will be standardized to ensure consistency between groups.
62037172|NCT04118530||Hematopoietic Stem Cell Transplant (HSCT) Patients|- Patients with incidence of AF/AFL in the first 30 days of transplant
62429055|NCT05674071|EXPERIMENTAL|Articulation/HVT|This intervention will use articulation and high-velocity thrust techniques
62429056|NCT05674071|EXPERIMENTAL|Soft-tissue massage|This intervention will use soft-tissue massage
62429057|NCT05674071|EXPERIMENTAL|Craniosacral techniques|This intervention will use craniosacral techniques
62429058|NCT05674071|EXPERIMENTAL|Combination|This intervention will use a combination of the three interventions: HVT, soft-tissue and craniosacral
62814641|NCT02219464|OTHER|Nasal Cannula|Patients will receive oxygen supplementation through the use of a traditional nasal cannula. Sedation will be standardized to ensure consistency between groups.
62814642|NCT06404112|ACTIVE_COMPARATOR|Active TL + Oral Melatonin|The Complex PASC-Related Sleep Disturbances (CPSD) Appendix B combines brief education and a tailored sleep timing prescription for CPSD (referred to as RESET-PASC) with therapies that modify circadian timing for participants who report poor sleep quality. The intervention therapies involve tailored lighting (TL) and melatonin. Participants will be randomly assigned to one of four groups: (a) active TL + oral melatonin, (b) active TL + placebo melatonin, (c) placebo TL + oral melatonin, and (d) placebo TL + placebo melatonin. All groups will receive RESET-PASC. The intervention duration will be 8 weeks.
62814643|NCT06404112|ACTIVE_COMPARATOR|Active TL + Placebo Melatonin|The Complex PASC-Related Sleep Disturbances (CPSD) Appendix B combines brief education and a tailored sleep timing prescription for CPSD (referred to as RESET-PASC) with therapies that modify circadian timing for participants who report poor sleep quality. The intervention therapies involve tailored lighting (TL) and melatonin. Participants will be randomly assigned to one of four groups: (a) active TL + oral melatonin, (b) active TL + placebo melatonin, (c) placebo TL + oral melatonin, and (d) placebo TL + placebo melatonin. All groups will receive RESET-PASC. The intervention duration will be 8 weeks.
62814644|NCT06404112|ACTIVE_COMPARATOR|Placebo TL + Oral Melatonin|The Complex PASC-Related Sleep Disturbances (CPSD) Appendix B combines brief education and a tailored sleep timing prescription for CPSD (referred to as RESET-PASC) with therapies that modify circadian timing for participants who report poor sleep quality. The intervention therapies involve tailored lighting (TL) and melatonin. Participants will be randomly assigned to one of four groups: (a) active TL + oral melatonin, (b) active TL + placebo melatonin, (c) placebo TL + oral melatonin, and (d) placebo TL + placebo melatonin. All groups will receive RESET-PASC. The intervention duration will be 8 weeks.
62814645|NCT06404112|PLACEBO_COMPARATOR|Placebo TL + Placebo Melatonin|The Complex PASC-Related Sleep Disturbances (CPSD) Appendix B combines brief education and a tailored sleep timing prescription for CPSD (referred to as RESET-PASC) with therapies that modify circadian timing for participants who report poor sleep quality. The intervention therapies involve tailored lighting (TL) and melatonin. Participants will be randomly assigned to one of four groups: (a) active TL + oral melatonin, (b) active TL + placebo melatonin, (c) placebo TL + oral melatonin, and (d) placebo TL + placebo melatonin. All groups will receive RESET-PASC. The intervention duration will be 8 weeks.
62814646|NCT05179252|EXPERIMENTAL|SFI intervention group|shenfu injection used during surgery, day one and two after surgery, 50ml,iv drop.
62814647|NCT05179252|SHAM_COMPARATOR|Control group|same volume of normal saline used during surgery, day one and two after surgery, 50ml,iv drop.
62814648|NCT01950416|EXPERIMENTAL|Ticagrelor|Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD) starting 12±6 hours post LD, until discharge.
62814649|NCT01950416|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 600mg loading dose (LD), followed by a 150mg once daily maintenance dose (MD) starting 12±6 hours post LD, until discharge.
62814650|NCT01274858||lung cancer surgery|
62814651|NCT04001244||Endometriosis (EAP)|Surgical diagnosis of endometriosis (aim equal distribution of stage I/II and stage III/IV disease); at least one pelvic pain \>3/10; pain not perceived by the patient as arising from the bladder; no urinary symptoms (e.g. urge, frequency)
62814652|NCT04001244||Bladder Pain Syndrome (BPS)|Bladder pain syndrome (as defined by ESSIC criteria: pelvic pain, pressure or discomfort for greater than 6 months, perceived to be related to the urinary bladder accompanied by at least one other urinary symptom like persistent urge to void or frequency); no history of endometriosis
62814653|NCT04001244||Endometriosis and Bladder Pain (EABP)|Surgical diagnosis of endometriosis; at least one pelvic pain \>3/10; pain perceived by the patient as arising from the bladder AND from other area(s) of the pelvis; at least one urinary symptom (e.g. urge, frequency)
62814654|NCT04001244||Controls|No endometriosis; No pelvic pain (or dysmenorrhea; NRS \<3/10)
62814655|NCT04001244||Pelvic Pain (PP)|At least one pelvic pain \>3/10; no endometriosis; pain not perceived by the patient as arising from the bladder; no urinary symptoms (e.g. urge, frequency)
62814656|NCT04487041|ACTIVE_COMPARATOR|Young HIV negative group|HIV uninfected participants that are 18-35 years of age will receive the standard dose flu vaccine. Participants who did not respond to the standard dose flu vaccination, as defined by less than a four-fold increase in flu antibody titer from baseline, will then receive the high dose flu vaccination 1 year after initial standard dose flu vaccination. Participants who respond to the standard dose flu vaccination will not receive the high dose flu vaccination.
62037173|NCT01669629|EXPERIMENTAL|Delefilcon A/ Etafilcon A|6-10 days of delefilcon A soft contact lens wear first, then 6-10 days of etafilcon A soft contact lens wear
62429059|NCT00581386|EXPERIMENTAL|LTS-D|All the cases were divided into one of the group LTS-D, PLMA, and ETC
62814657|NCT04487041|EXPERIMENTAL|Young HIV positive group|HIV infected viral suppressed participants, who are on anti-retroviral therapy (ART) aged 18-35 years of age, will receive the standard dose flu vaccine first followed by the high dose flu vaccine 1 year after initial standard dose.
62814658|NCT04487041|EXPERIMENTAL|Old HIV negative group|HIV uninfected participants that are 65 years and older will receive the standard dose flu vaccine first followed by the high dose flu vaccine 1 year after initial standard dose.
62429060|NCT00581386|EXPERIMENTAL|ProSeal Laryngeal Mask Airway|All patients were divided into either LTS-D, PLMA, or the ETC group.
62429061|NCT00581386|EXPERIMENTAL|Esophageal Tracheal Combitube (ETC)|All patients are divided into one of the group, LTS-D, PLMA, or the ETC.
62429062|NCT01625286|EXPERIMENTAL|Part A: Intermittent schedule (2/5)|See intervention description below.
62429063|NCT01625286|EXPERIMENTAL|Part A: Intermittent schedule (4/3)|See intervention description below.
62596610|NCT01780402|EXPERIMENTAL|Hand feeding intervention delivery|Trained Research Feeding Assistants (TRFA), blind to the study outcomes, will assist enrolled PWDs with all three meals for two days using a pre-specified hand feeding technique. Videotaping will occur for two enrolled PWD during the six day time frame to promote efficiency. Coding of the video will be done by a trained Data Technician after meals have been recorded to determine frequency of aversive feeding behaviors, calculate meal intake, and time spent assisting with the meal.
62596611|NCT04638881|EXPERIMENTAL|Magnesium sulfate 50 mg/kg bolus + 25 mg/kg/hr infusion|Bolus to be administered at start of mucosal incision, followed by infusion. Infusion to be terminated at extubation.
62596612|NCT04638881|PLACEBO_COMPARATOR|Normal saline 0.9% 50 mg/kg bolus + 25 mg/kg/hr infusion|Bolus to be administered at start of mucosal incision, followed by infusion. Infusion to be terminated at extubation.
62596613|NCT06547086|EXPERIMENTAL|Stimulation followed by no stimulation|Phase 2 participants will receive stimulation during their nap at the first visit, and no stimulation during their nap at the second visit.
62596614|NCT06547086|EXPERIMENTAL|No stimulation followed by stimulation|Phase 2 participants will not receive stimulation during their nap at the first visit, and receive stimulation during their nap at the second visit.
62596615|NCT02733185|ACTIVE_COMPARATOR|Active/Active|Active disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
62596616|NCT02733185|ACTIVE_COMPARATOR|Active/Placebo|Active disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
62596617|NCT02733185|ACTIVE_COMPARATOR|Placebo/ Active|Placebo disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
62596618|NCT02733185|PLACEBO_COMPARATOR|Placebo/Placebo|Placebo disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
62596619|NCT05636787|EXPERIMENTAL|Arm B - TreoMel|Chemotherapy regime consisting of treosulfan on three days at 14 g/m2 followed by 200 mg/m2 melphalan given on two days at 100 mg/m2.
62596620|NCT05636787|ACTIVE_COMPARATOR|Arm A - Mel|Chemotherapy regime consisting of 200 mg/m2 melphalan, split into two days à 100 mg/m2.
62596621|NCT01945437|PLACEBO_COMPARATOR|Control|Control group receive same volume of normal saline as in the magnesium group
62596622|NCT01945437|EXPERIMENTAL|magnesium|This group receive magnesium sulfate perioperatively.
62429064|NCT01625286|ACTIVE_COMPARATOR|Part B: AZD5363 combined with paclitaxel|See intervention description below.
62596623|NCT00748189|EXPERIMENTAL|ofatumumab + chlorambucil|ofatumumab dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days; chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
62596624|NCT00748189|ACTIVE_COMPARATOR|chlorambucil|chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
62596625|NCT00813683|EXPERIMENTAL|1|"Stimulation of 67 Bladder point"
62596626|NCT00813683|SHAM_COMPARATOR|2|"Stimulation of 45 Stomach point (sham)"
62596627|NCT05207917|ACTIVE_COMPARATOR|Gastric bypass|Gastric bypass
62429065|NCT01625286|PLACEBO_COMPARATOR|Part B: paclitaxel combined with placebo|See intervention description below.
62596628|NCT05207917|ACTIVE_COMPARATOR|Sleeve gastrectomy|Sleeve gastrectomy
62596629|NCT05207917|EXPERIMENTAL|Single anastomosis sleeve ileal (SASI) bypass|Exploratory small arm with a small number of particpants
62596630|NCT06605430|EXPERIMENTAL|Early Cannabis|
62596631|NCT06605430|EXPERIMENTAL|Delayed Cannabis|
62596632|NCT03007290|EXPERIMENTAL|Treatment group|Group with therapeutic drug monitoring
62596633|NCT04255732|OTHER|Extent of retinal periphery area viewing|For the 30 patients fundus photography will be performed using two ultra-wide-field imaging systems.
62814659|NCT04487041|EXPERIMENTAL|Old HIV positive group|HIV infected viral suppressed participants, who are on anti-retroviral therapy (ART) aged 65 years and older, will receive the standard dose flu vaccine first followed by the high dose flu vaccine 1 year after initial standard dose.
62814660|NCT05411211||Pediatric Participants receiving adalimumab|Pediatric Participants receiving adalimumab for polyarticular juvenile idiopathic arthritis (pJIA)
62429066|NCT00096486|EXPERIMENTAL|Gefitinib and Everolimus (RAD001)|"Phase I: Patients receive oral everolimus once on day 1. Beginning on day 8, patients receive oral gefitinib once daily. Beginning on day 22, patients receive oral everolimus once daily. Both drugs are then given concurrently for the rest of the treatment. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of everolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.~* Phase II: Patients receive oral everolimus at the MTD determined in phase I and oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity."
62596634|NCT06202625|EXPERIMENTAL|avatrombopag|"Avatrombopag 20 mg/d will be taken orally from +D7 after haplo-HSCT until reaching the adjustment indication or to +D60 after haplo-HSCT. Routine treatment is allowed.~Adjustment indication:~When PLT\<50×10\^9/L or PLT transfusion dependent on the +D30 after haplo-HSCT, increase the dosage to 40 mg/d; When the dosage has been increased to 40 mg/d, and PLT≥80×10\^9/L excluding the factor of PLT transfusion, decrease the dosage to 20 mg/d; When PLT≥80×10\^9/L for 7 consecutive days excluding the factor of PLT transfusion, or PLT≥300×10\^9/L excluding the factor of PLT transfusion, stop administration; When PLT\<50×10\^9/L or become PLT transfusion dependent after stopping administration, initiate administration again at the dosage 40 mg/d.~PLT transfusion Indication: When PLT\<20×10\^9/L, and/or with the symptom or risk of bleeding."
62735577|NCT02046837|EXPERIMENTAL|Supervised group exercise|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
62814661|NCT01740830|ACTIVE_COMPARATOR|Anodal tDCS|
62814662|NCT01740830|SHAM_COMPARATOR|Sham tDCS|
62814663|NCT05482308|EXPERIMENTAL|Test tablet followed by Reference tablet|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.
62814664|NCT05482308|EXPERIMENTAL|Reference tablet followed by Test tablet|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug
62814665|NCT03709680|EXPERIMENTAL|Phase 2 Arm A|Palbociclib in combination with irinotecan and temozolomide.
62814666|NCT03709680|EXPERIMENTAL|Phase 1|Palbociclib in combination with temozolomide and irinotecan and/or with topotecan and cyclophosphamide.
62238460|NCT02887937||Breast Mass 4c|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4c breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
62238461|NCT05620043|ACTIVE_COMPARATOR|Poly L-Lactic Acid (PLLA)|Lyophilized PLLA with sodium carboxymethylcellulose, non-pyrogenic mannitol. Treatment needs to be reconstituted prior to injection, following product instruction.
62238462|NCT05620043|ACTIVE_COMPARATOR|Calcium Hydroxylapatite (CaHA)|Opaque, sterile, non-pyrogenic, semi-solid, cohesive implant whose component is synthetic CaHA suspended in a gel carrier of glycerin, sodium carboxymethylcellulose, 0.3% lidocaine hydrochloride, and sterile water. Treatment injection follows product instruction.
62814667|NCT03709680|ACTIVE_COMPARATOR|Phase 2 Arm B|Irinotecan and temozolomide alone.
62814668|NCT03709680|EXPERIMENTAL|Phase 1 Tumor specific cohort - Neuroblastoma|Palbociclib in combination with topotecan and cyclophosphamide.
62429067|NCT02050607|NO_INTERVENTION|Control group|Control group
62238463|NCT06503094|EXPERIMENTAL|Effective of CD19&CD20 bispecific CAR-T cells|The infusion dose range of cells in this trial is recommended: 2 to 6 10\^6 And CAR-T cells / kg.
62429068|NCT02050607|EXPERIMENTAL|Fecal microbiota transplantation|Fecal microbiota transplantation from healthy lean donors
62429069|NCT05585268|ACTIVE_COMPARATOR|MedSafer-supplemented medication reconciliation|This unit will act as an intervention unit for the MedRec where MedSafer deprescribing reports will be handed to the treating team and deprescribing brochures from the Canadian Deprescribing Network will be given to patients.
62429070|NCT05585268|NO_INTERVENTION|Standard of care medication reconciliation|This unit will serve as the control unit where standard of care will be provided and no deprescribing reports nor brochures will be delivered. MedSafer reports will be generated but withheld from the clinical team. This will serve as a comparator to determine if the intervention unit was more successful in deprescribing compared to this control unit.
62429071|NCT04912635|NO_INTERVENTION|Control|
62429072|NCT04912635|EXPERIMENTAL|Intervention|
62429073|NCT01653470|EXPERIMENTAL|Arm A: Paclitaxel + BMS-906024|Paclitaxel 80 mg/m2 solution and BMS-906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity
62429074|NCT01653470|EXPERIMENTAL|Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024|5FU Bolus 400 mg/m2, 5FU Infusion 2400 mg/m2, Irinotecan 180 mg/m2 solution, Leucovorin 400 mg/m2 solution intravenously once every 2 weeks and BMS- 906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity
62429075|NCT01653470|EXPERIMENTAL|Arm C: Carboplatin/Paclitaxel + BMS-906024|Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once weekly intravenously continuously until disease progression or unacceptable toxicity
62429076|NCT01653470|EXPERIMENTAL|Arm D: Paclitaxel + BMS-906024|Paclitaxel 80 mg/m2 solution once weekly and BMS-906024 4 mg or 6 mg solution once every 2 weeks intravenously continuously until disease progression or unacceptable toxicity
62814669|NCT05288816|EXPERIMENTAL|Cohort 1: ALXN1210 400 mg (Single)|A single dose of ALXN1210 was administered intravenously.
62814670|NCT05288816|EXPERIMENTAL|Cohort 2: ALXN1210 800 mg (Single)|A single dose of ALXN1210 was administered intravenously.
62814671|NCT05288816|EXPERIMENTAL|Cohort 3: ALXN1210 800 mg (Multiple)|ALXN1210 (800 mg) was administered intravenously every 4 weeks for a total of 5 doses.
62238464|NCT02415465|ACTIVE_COMPARATOR|Combined Spinal Epidural|Spinal Intraoperative Anesthesia with standard Epidural (0.1% bupivacaine with fentanyl 5 mcg/mL running at 6mL/hr with 1mL q15 bolus) with standard post-operative analgesics.
62238465|NCT02415465|ACTIVE_COMPARATOR|General+Continuous Adductor Canal Block|General Intraoperative Anesthesia with standard post-operative Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr) with standard post-operative analgesics.
62814672|NCT00005906|EXPERIMENTAL|Octreotide|Patients with lymphangioleiomyomatosis and lymphatic tumors, ascites or pleural effusions who are symptomatic will receive subcutaneous injections of octreotide starting at a dose of 100 micrograms per day. Doses will be gradually increased to a maximum of 800 micrograms per day, two months after enrollment, if there is no response to lower doses.
62814673|NCT00683436|EXPERIMENTAL|1|adipiplon 6 mg
62238466|NCT02415465|ACTIVE_COMPARATOR|Spinal+Continuous Adductor Canal Block|Spinal Intraoperative Anesthesia with standard post-operative Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr) with standard post-operative analgesics.
62238467|NCT04157140|EXPERIMENTAL|Anlotinib+ TACE+ RFA|Anlotinib+ TACE+ RFA
62238468|NCT03726762|EXPERIMENTAL|Diet Beverages|'Diet beverages' after the main meal
62238469|NCT03726762|EXPERIMENTAL|Water|'Water' after the main meal
62814674|NCT00683436|EXPERIMENTAL|2|adipiplon 9 mg
62814675|NCT00683436|PLACEBO_COMPARATOR|3|Placebo
62814676|NCT00683436|EXPERIMENTAL|4|Ambien CR 12.5 mg
62814677|NCT02950350||radiation and chemotherapy|The patients will receive radiation and chemotherapy
62814678|NCT02950350||removal of pelvic lymph nodes and abdominal aorta lymph nodes|The patients will receive removal of pelvic lymph nodes and abdominal aorta lymph nodes ,and receive concurrent radiation and chemotherapy
62814679|NCT06125522|EXPERIMENTAL|ARV-471 in combination with Samuraciclib|ARV-471 administered orally QD continuously and Samuraciclib administered orally QD continuously on 28-day cycles
62814680|NCT03945383|EXPERIMENTAL|Treatment with IPL device|The Emerald IPL device is applied by the Investigator or designee to the right and left side of the body. Treatment areas are 2x4 cm2 for the leg and bikini line areas. The entire axilla and face (upper lip) area will be treated due to the small area involved.
62814681|NCT04738786|ACTIVE_COMPARATOR|Wide surgical safety margin|1.5 cm safety margin surgery for cT1-2N0 oral tongue cancer
62814682|NCT04738786|ACTIVE_COMPARATOR|Narrow surgical safety margin|1.0 cm safety margin surgery for cT1-2N0 oral tongue cancer
62814683|NCT05490017|EXPERIMENTAL|Part 1: Single Ascending Dose Cohort 1|
62814684|NCT05490017|EXPERIMENTAL|Part 1: Single Ascending Dose Cohort 2|
62814685|NCT05490017|EXPERIMENTAL|Part 1: Single Ascending Dose Cohort 3|
62238470|NCT05171439|EXPERIMENTAL|Surufatinib|All subjects will receive study treatment in 28-day cycle, Surufatinib 300mg, orally, QD , the treatment will continue until one of the following conditions occurs: progression of disease, death, intolerable toxicity, or the end of study treatment (as other criteria specified in the protocol are met), whichever occurs first.
62238471|NCT02199808||7-9 year olds|These are children who are between 7 and 9 years old when they are tested.
62238472|NCT02199808||10-12 year olds|These are children who are between 10 and 12 years old when they are tested.
62238473|NCT03972007|EXPERIMENTAL|Immediate LEDT Group|The 940nm LED blanket will be positioned across the full length of the biceps brachii muscle in the dominant limb immediately before the muscle fatigue protocol.
62238474|NCT03972007|EXPERIMENTAL|LEDT Group 15Min|The 940nm LED blanket will be positioned across the length of the biceps brachii muscle in the dominant limb 15 minutes before the muscle fatigue protocol.
62238475|NCT03972007|SHAM_COMPARATOR|Immediate Sham Group|The 940nm LED blanket will be positioned throughout the biceps brachii muscle in the dominant limb, however, it will not be ligated, with no light emission, immediately prior to the muscle fatigue protocol.
62238476|NCT03972007|SHAM_COMPARATOR|Sham Group 15Min|The 940nm LED blanket will be positioned throughout the biceps brachii muscle in the dominant limb, however, it will not be ligated, with no light emission, 15 minutes before the protocol of muscle fatigue.
62814686|NCT05490017|EXPERIMENTAL|Part 1: Single Ascending Dose Cohort 4|
62814687|NCT05490017|EXPERIMENTAL|Part 1: Single Ascending Dose Cohort 5|
62814688|NCT05490017|EXPERIMENTAL|Part 1: Single Ascending Dose Cohort 6|
62037174|NCT01669629|EXPERIMENTAL|Etafilcon A / Delefilcon A|6-10 days of etafilcon A soft contact lens wear first then 6-10 days of delefilcon A soft contact lens wear
62238477|NCT03538379|ACTIVE_COMPARATOR|Combat Application Tourniquet (CAT)|The combat application tourniquet (CAT) is the type of commercial tourniquet taught in the B-Con course as administered by the investigators. It will serve as the control group to which all other types of tourniquets, which are not explicitly taught in the course, are compared to.
62814689|NCT05490017|EXPERIMENTAL|Part 1: Single Ascending Dose Cohort 7|
62814690|NCT05490017|EXPERIMENTAL|Part 2: Multiple Ascending Dose Cohort 1|
62814691|NCT05490017|EXPERIMENTAL|Part 2: Multiple Ascending Dose Cohort 2|
62814692|NCT05490017|EXPERIMENTAL|Part 2: Multiple Ascending Dose Cohort 3|
62814693|NCT05490017|PLACEBO_COMPARATOR|Part 1: Placebo|
62814694|NCT05490017|PLACEBO_COMPARATOR|Part 2: Placebo|
62814695|NCT04935957|OTHER|Non-interventional. Open Label.|GLUCUBE system performance in the monitoring and measurement of the blood glucose compared to the standard glucometer (blood capillary glucometer - Bayer Contour®Next).
62814696|NCT00178477|EXPERIMENTAL|Breath-holding|MRI with breath-holding
62814697|NCT02217163|EXPERIMENTAL|Single Arm|The combination therapy of Carfilzomib, cyclophosphamide and dexamethasone (KCyd) will be used to treat eligible patients for up to 6 cycles.This will be followed by an autologous bone marrow transplantation and 2 further consolidation cycles of KCyd. Depending on their disease response, patients will be managed expectantly or be started on maintenance.
62814698|NCT04935385||Study Cohort|Patients aged 18 and above undergoing elective surgeries (including general surgery, neurosurgery, ear nose and throat surgeries, cardiac surgery, orthopedic surgeries, vascular surgeries and urological surgeries) at Rabin Medical Center under general anesthesia
62814699|NCT03726489|OTHER|Office Based Phototherapy|Patients randomized to this arm will receive narrow band phototherapy in a clinical setting via narrow band phototherapy clinic units.
62814700|NCT03726489|ACTIVE_COMPARATOR|Home Based Phototherapy|Patients randomized to this arm will receive narrow band phototherapy in a home setting via Daavlin 7 series 3 panel narrow band phototherapy home units.
62814701|NCT03896139||VUMC EHR cohort|De-identified version of the electronic health record (EHR) at Vanderbilt University Medical Center (VUMC).
62814702|NCT03896139||Toxicity induced by kinase inhibitors in Vigibase database|Case reported in the World Health Organization (WHO) of toxicity or complication of patient treated by KIs, with a chronology compatible with the drug toxicity
62037175|NCT05704075|OTHER|Control Group|Conventional Treatment: Dressing + Negative Pressure Wound Therapy
62037176|NCT05704075|EXPERIMENTAL|TTT Group|Dressing + Negative Pressure Wound Therapy + Transverse Tibial Transport
62037177|NCT01995461|EXPERIMENTAL|BTESI|a prospective, non-randomized, case series investigating bilateral transforaminal epidural steroid injections (BTESI)
62037178|NCT03302338|EXPERIMENTAL|SAFE group|SAFE group: simulated amniotic fluid 20cc/kg/day enterally divided according to number of feds (syringe for every fed). This amount provides enteral 4.5μg rhG-CSF / kg/day and enteral 88IU rhEPO / kg/day.
62814703|NCT04885569|EXPERIMENTAL|Motivational Interviewing with CBT (MICBT)|Participants in this arm will receive a total of 12 weekly sessions of CBT based Motivational Interviewing over a period of 12 weeks.
62596635|NCT06202625|PLACEBO_COMPARATOR|Placebo|"Placebo 20 mg/d will be taken orally from +D7 after haplo-HSCT until reaching the adjustment indication or to +D60 after haplo-HSCT. Routine treatment is allowed.~Adjustment indication:~When PLT\<50×10\^9/L or PLT transfusion dependent on the +D30 after haplo-HSCT, increase the dosage to 40 mg/d; When the dosage has been increased to 40 mg/d, and PLT≥80×10\^9/L excluding the factor of PLT transfusion, decrease the dosage to 20 mg/d; When PLT≥80×10\^9/L for 7 consecutive days excluding the factor of PLT transfusion, or PLT≥300×10\^9/L excluding the factor of PLT transfusion, stop administration; When PLT\<50×10\^9/L or become PLT transfusion dependent after stopping administration, initiate administration again at the dosage 40 mg/d.~PLT transfusion Indication: When PLT\<20×10\^9/L, and/or with the symptom or risk of bleeding."
62596636|NCT04827082|EXPERIMENTAL|Diacutaneous fibrolysis group|Diacutaneous fibrolysis is a physiotherapeutic instrumental technique, used to treat musculoskeletal conditions causing pain and/or movement restriction. It is applied by means of metallic hooks, ending in a spatula with beveled edges. Regardless of its own dominance, diacutaneous fibrolysis will be applied to de following muscles and intermuscular septums: gluteus maximus, biceps femoris and semitendinosus to de lower experimental limb. A single session of 10 minutes will be applied.
62596637|NCT04827082|NO_INTERVENTION|Control group|Participants will be used as their own controls, with one lower extremity randomly receiving intervention. The control extremity will not receive any intervention
62596638|NCT03751800||Women with HMB|Women with a diagnostic of HMB according to medical criteria and based on clinical judgment that have freely chosen a chronic hormonal treatment under therapeutic indication of HMB in Spain
62596639|NCT05525988|EXPERIMENTAL|Hemi-Hamate Graft for Proximal Pole Scaphoid Reconstruction|\[All participants enrolled in this study for proximal pole scaphoid reconstruction using the Hemi-Hamate autograft\]
62596640|NCT00742872|EXPERIMENTAL|1|Mosapride
62596641|NCT00742872|PLACEBO_COMPARATOR|2|Placebo
62596642|NCT06618703|EXPERIMENTAL|Study Arm|"Specific interventions:~For all patients, an insulin level is added every 2 years. For patients under 8 years of age, additional elements such as testosterone (in male patients), Luteinizing hormone , Follicle-stimulating hormone, estradiol (in female patients), inhibin B +/- Anti-Müllerian hormone are measured during the usual blood test.~A urinary check-up is systematically added for all patients, whereas it is usually only prescribed after certain chemotherapies (platinum salts, ifosfamide), nephrectomy, radiotherapy to the flanks as part of routine care. This check-up will be carried out at 2 and 4 years post-radiotherapy.~For patients aged 12 and over, a second bone densitometry is performed at the end of follow-up, even if the first is normal. In routine care, international guidelines recommend this first bone densitometry, and the second is usually performed only if the first was abnormal."
62596643|NCT06374277|ACTIVE_COMPARATOR|Med AAAction intervention|The Med AAAction intervention will include the following components: 1) medications with zero copay, 2) bedside delivery and subsequent home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up after hospital discharge. The intervention will be provided for one-year.
62596644|NCT06374277|PLACEBO_COMPARATOR|Usual care Intervention|As part of the usual care, the participating hospitals provide medication reconciliation services before hospital discharge. Usual care may also include MTM services for patients discharged on specialty medications or Medicare beneficiaries. Patients in both groups will receive financial incentives for completing their baseline survey ($15), and 3-month ($15), 6-month ($15), and 12-month ($25) follow-up visits.
62596645|NCT02947204|ACTIVE_COMPARATOR|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge.
62596646|NCT02947204|EXPERIMENTAL|Intermittent oxygen monitoring|Oxygen saturation will be measured intermittently, every 4 hours, through the child's hospital stay until discharge.
62596647|NCT05971602|EXPERIMENTAL|Stage 1: Arm 1: DS-TB Participants receiving DBOS for 4 months (17 Weeks)|
62596648|NCT05971602|EXPERIMENTAL|Stage 1: Arm 2: DS-TB Participants receiving PBOS for 4 months (17 Weeks)|
62238478|NCT03538379|ACTIVE_COMPARATOR|Sof Tourniquet (Sof-T)|The Sof-Tourniquet (Sof-T) is a commercial windlass type tourniquet similar to the CAT tourniquet in that it is based on a windlass mechanism. Its application not explicitly taught in the B-Con course.
62238479|NCT03538379|ACTIVE_COMPARATOR|Stretch-Wrap-And-Tuck (SWAT) Tourniquet|The Stretch-Wrap-And-Tuck (SWAT) Tourniquet is a commercial elastic tourniquet. Its application not explicitly taught in the B-Con course.
62238480|NCT03538379|ACTIVE_COMPARATOR|Rapid Application Tourniquet (RAT)|The Rapid Application Tourniquet (RAT) is a commercial elastic tourniquet similar to a bungee cord. Its application not explicitly taught in the B-Con course.
62238481|NCT03538379|ACTIVE_COMPARATOR|Improvised Tourniquet|The improvised tourniquet arm will involve participants being given supplies to enable them to fashion a tourniquet. The supplies will include a leather belt, gauze, shoestring, and a rod to act as a windlass.
62238482|NCT05202717|EXPERIMENTAL|PHENIX U4+|Electrical stimulation treatment for patients with urinary incontinence using a new type of pelvic floor therapy instrument
62596649|NCT05971602|EXPERIMENTAL|Stage 1: Arm 3: DS-TB Participants receiving 2HRZE/4HR for 6 months (26 weeks)|Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E) - refers to standard regimen of 8 weeks of HRZE followed by 18 weeks of HR (2HRZE/4HR)
62037179|NCT03302338|PLACEBO_COMPARATOR|Placebo|Placebo group: distilled water 2.5 ml/kg every 3 hours enterally given.
62238483|NCT05202717|ACTIVE_COMPARATOR|Traditional pelvic floor electrical stimulation therapy instrument|Electrical stimulation treatment for patients with urinary incontinence using traditional pelvic floor therapy instrument
62238484|NCT00509665|EXPERIMENTAL|Gemcitabine+doxorubicin|
62037180|NCT03588026|EXPERIMENTAL|Arm 1 - 9 months of treatment (rVA576 plus SOC)|6 months (SOC plus rVA576), Followed by a further 3 months of (SOC plus rVA576).
62037181|NCT03588026|EXPERIMENTAL|Arm 2 - 6 months on SOC|6 months on SOC only. Followed by 3 months (SOC plus rVA576).
62238485|NCT02797210|EXPERIMENTAL|Sham then Active Stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks, then active rTMS to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks
62429077|NCT01653470|EXPERIMENTAL|Arm F: Carboplatin/Paclitaxcel and BMS-906024|Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once every 3 weeks intravenously continuously until disease progression or unacceptable toxicity
62429078|NCT00331773|ACTIVE_COMPARATOR|Conventional 3D-CRT|Conventional 3D-CRT or IMRT to 73.8 Gy in 41 fractions
62037182|NCT05895266|EXPERIMENTAL|Part 1: Period 1|In Period 1 on Day 1, participants will receive liquid midazolam.
62037183|NCT05895266|EXPERIMENTAL|Part 1: Period 2|In Period 2 on Day 1, participants will receive ABBV-903 oral tablets. In Period 2 on Day 10, participants will receive liquid midazolam and ABBV-903 oral tablets. Participants will be followed-up for approximately 30 days.
62037184|NCT05895266|EXPERIMENTAL|Part 2: Period 1|In Period 1 on Day 1, participants will receive liquid midazolam.
62037185|NCT05895266|EXPERIMENTAL|Part 2: Period 2|In Period 2 on Day 1, participants will receive ABBV-903 oral tablets. In Period 2 on Day 5, participants will receive liquid midazolam and ABBV-903 oral tablets. Participants will be followed-up for approximately 30 days.
62037186|NCT05155865|EXPERIMENTAL|Resynchronization with conduction system pacing|Implantation of permanent pacemaker with conduction system pacing (preferably left bundle branch) with or without defibrillator lead placement. Optimal guidelines-based heart failure treatment and antiarrhythmic drugs.
62429079|NCT00331773|EXPERIMENTAL|Hypofractionated 3D-CRT|Hypofractionated 3D-CRT or IMRT to 70 Gy in 28 fractions
62429080|NCT03841565|EXPERIMENTAL|Treatment (pomalidomide, daratumumab, dexamethasone)|Patients receive pomalidomide PO QD on days 1-21 and daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, days 1-15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8, 15, and 22 of cycles 1-12. Cycles every 28 days in the absence of disease progression or unacceptable toxicity.
62429081|NCT02164539|EXPERIMENTAL|Treatment Phase A|Eligible subjects will enter a 4-week run-in period and will receive fluticasone propionate/salmeterol. Subjects will then be randomized to receive fluticasone furoate 100 mcg, fluticasone furoate/umeclidinium bromide 100/15.6 mcg, fluticasone furoate/umeclidinium bromide 100/62.5 mcg, fluticasone furoate/umeclidinium bromide 100/125 mcg, fluticasone furoate/umeclidinium bromide 100/250 mcg, or fluticasone furoate/vilanterol 100/25 mcg, respectively for 4 weeks
62037187|NCT05155865|ACTIVE_COMPARATOR|Cardiac resynchronization therapy with biventricular stimulation|Implantation of cardiac resynchronization therapy with biventricular stimulation with or without defibrillator lead placement. Optimal guidelines-based heart failure treatment and antiarrhythmic drugs.
62429082|NCT02164539|EXPERIMENTAL|Treatment Phase B|Subjects completing Treatment Phase A will be randomized to receive either fluticasone furoate/umeclidinium bromide100/250 mcg or fluticasone furoate/umeclidinium bromide/vilanterol 100/250/25 mcg for 1 week.
62429083|NCT02164539|EXPERIMENTAL|Treatment Phase C|Subjects completing Treatment Phase B will be randomized to receive either the same treatment as in Treatment Phase B, or the same treatment minus the umeclidinium bromide component, for 1 week.
62429084|NCT03536468||Patients pending complete tooth loss|Will be recruited patients pending tooth loss, ages between 18 and 65 years, whose dental conditions have previously been identified
62429085|NCT02252484|EXPERIMENTAL|Weight loss intervention Group|Participants will receive tailor weight loss program. Participants will complete 8-weeks of the weight loss intervention prior to having their prostatectomy (weight loss phase). Program includes individual weight coaching, tailored diet and exercise plan, weight coaching and tracking of daily activities. Sessions will be held weekly during the weight loss phase. The groups will be facilitated by a registered dietitian with genitourinary (GU) oncology experience.
62429086|NCT02252484|ACTIVE_COMPARATOR|Comparison Group|All patients who are unwilling or not ready to engage in a weight loss program will be offered entry into the comparison group arm.
62429087|NCT05644938|ACTIVE_COMPARATOR|Standard workflow (SW)|Acute ischemic stroke caused by large vessel occlusion was diagnosed by Magnetic resonance imaging (MRI) and Magnetic resonance angiography (MRA) at admission in MRI room + Recanalization therapy in angiosuite
62429088|NCT05644938|EXPERIMENTAL|One-stop (OS)|Acute ischemic stroke caused by large vessel occlusion was diagnosed + Recanalization therapy by the ﬂat-detector computed tomography in angiosuite at the same time.
62429089|NCT06521606|EXPERIMENTAL|temporary external fixation|In our study, 15 patients were managed by the two stages protocol in which they underwent temporary external fixation, and after 7-21 days, they underwent open reduction and internal fixation. The patients were chosen according to the previous criteria; history taking, counselling, general and local examination, and radiological evaluation, and all laboratory investigations were ordered.
62037188|NCT01683864|EXPERIMENTAL|positive cytology with HIPEC|gastric cancer cytology positive with HIPEC Mytomycin and cisplatin intraoperative
62596650|NCT05971602|EXPERIMENTAL|Stage 2: Arm 1: DS-TB Participants receiving XBOS for 2 months (9 Weeks)|Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (Regimen from Stage 1 that advances to Stage 2 \[XBOS\])
62596651|NCT05971602|EXPERIMENTAL|Stage 2: Arm 2: DS-TB Participants receiving XBOS for 2.5 months (11 Weeks)|
62596652|NCT05971602|EXPERIMENTAL|Stage 2: Arm 3: DS-TB Participants receiving XBOS for 3 months (13 Weeks)|
62037189|NCT01683864|NO_INTERVENTION|positive cytology without HIPEC|gastric cancer cytology positive without HIPEC
62037190|NCT01683864|NO_INTERVENTION|negative cytology without HIPEC|gastric cancer with negative cytology
62037191|NCT00707031|EXPERIMENTAL|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
62037192|NCT00707031|ACTIVE_COMPARATOR|Exenatide|1-step initiation regimen of exenatide: 5 mcg twice daily (BID) for 4 weeks, followed by 10 mcg BID up to the end of treatment.
62037193|NCT02863926|EXPERIMENTAL|Day 7|BKA performed at 7 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
62596653|NCT05971602|EXPERIMENTAL|Stage 2: Arm 4: DS-TB Participants receiving XBOS for 3.5 months (15 Weeks)|
62814704|NCT04885569|EXPERIMENTAL|Mindfulness based Relapse Prevention Group (MBRP)|Participants in this arm will receive a total of 12 weekly sessions of mindfulness intervention over a period of 12 weeks.
62429090|NCT06521606|ACTIVE_COMPARATOR|Primary open reduction and internal fixation|"Reconstruction and fixation of the metaphyseal shell~The percutaneous pin was used to manipulate the fragment to achieve reduction; then, a lag screw fixation was done by antegrade technique through a stab incision posteriorly and directly over the fragment. The medial fragment was fixed after the reconstruction of the tibial articular surface to facilitate the anatomic reduction of joint fragments. Again, an image intensifier was used to check the reduction and fixation and to avoid errors of penetration of the joint by screws, malalignment, and inadequate reconstruction of the articular surface; then, the necessary changes were adjusted and made."
62814705|NCT04885569|EXPERIMENTAL|Integrated MICBT and MBRP Group (CAMIAB)|This will be integrated MICBT plus MBRP intervention. Participants will receive a total of 12 weekly sessions of this integrated CAMIAB intervention.
62429091|NCT00044005|EXPERIMENTAL|Lurasidone 20 mg|Lurasidone 20 mg oral tablet
62814706|NCT04885569|NO_INTERVENTION|Treatment as usual (TAU)|This will be routine care psychological treatment that they will be receiving.
62814707|NCT01607502||Patients of our outpatient clinic|Patients who have an investigation in our outpatient clinic for pulmonary hypertension like a echocardiography, a right heart catheterization or a cardio pulmonary exercise testing
62814708|NCT04027855|OTHER|collection of PBMC from healthy donors|"1. Screening period: All volunteers are required to sign a written informed consent form for the study; after the signing of informed consent form, the demographic data and medical history of the volunteers will be collected, and physical examinations and local laboratory tests will be performed to assess the eligibility of the volunteers. Volunteers who meet all the inclusion criteria and do not meet any exclusion criteria (except for the basic biological indicators of UCAR-T product preparation) will receive peripheral venous whole blood sampling, and the volunteers receiving apheresis based on the assessment results will be enrolled.~2. Apheresis period: 5 volunteers who meet the inclusion criteria will undergo collection of peripheral blood mononuclear cells (PBMC) by means of apheresis."
62814709|NCT05732116||Exposure: With PTSD|Surgeons or anesthesiologists with PTSD
62814710|NCT05732116||Comparator: Without PTSD|Surgeons or anesthesiologists without PTSD
62814711|NCT05371769|SHAM_COMPARATOR|Control group|The students in the control group will be given a pre-test, and two weeks later, the post-test will be applied. After the chronic pain education group completes the research, the chronic pain education program will be opened to the students in the control group, too.
62814712|NCT05371769|EXPERIMENTAL|Chronic pain education group|The pre-test will be opened to the students in the chronic pain education group simultaneously with the opening of the post-tests for the control group.After the students in the chronic pain education group completed the pre-test, the chronic pain management training program developed for nursing students will be applied for 2 weeks. Post test will be applied at the end of all training videos and evaluation questions.
62429092|NCT00044005|EXPERIMENTAL|Lurasidione 40 mg|Lurasidone 40 mg oral tablet
62814713|NCT00671658|EXPERIMENTAL|HYPER-CVAD|Rituximab 375 mg/m\^2 intravenous (IV), Cyclophosphamide (CTX) 300 mg/m\^2 IV, Doxorubicin 50 mg/m\^2 IV, Vincristine 2 mg IV, Dexamethasone 40 mg IV or oral (PO). Methotrexate (MTX) 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7 - 200 mg/m\^2 IV followed by 800 mg/m\^2 for Courses 2,4,6,8. Cytarabine 100 mg intrathecal for Courses 1,3,5,7 - 3 gm/m\^2 IV for Courses 2,4,6,8. G-CSF 10 ug/kg subcutaneous injection. Mesna 600 mg/m2 a day IV, Pegylated asparaginase 2000 International units/m\^2 IV. Pegfilgrastim 6 mg (flat dose) within 72 hrs after completion of chemotherapy. Solumedrol 40 mg IV for Courses 2,4,6,8.
62814714|NCT02407808|ACTIVE_COMPARATOR|THC|Active THC (0.0015mg/kg-0.03mg/kg) administered over 20 minutes.
62037194|NCT02863926|EXPERIMENTAL|Day 14|BKA performed at 14 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
62037195|NCT02863926|EXPERIMENTAL|Day 21|BKA performed at 21 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
62814715|NCT02407808|PLACEBO_COMPARATOR|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
62814716|NCT02343835|EXPERIMENTAL|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
62814717|NCT02343835|NO_INTERVENTION|Control|The patients without treatment
62429093|NCT00044005|EXPERIMENTAL|Lurasidone 80mg|Lurasidone 80mg oral tablet
62429094|NCT03817632||A Standard|Computer assisted primary total knee replacement with OrthoPilot FS 101 navigation system and Software 5.1
62037196|NCT05986175|EXPERIMENTAL|Motor Imagery Training Group|The Motor Imagery Training Group will receive motor imagery training in addition to Jeffreys' core (body) stabilization training protocol.
62037197|NCT05986175|ACTIVE_COMPARATOR|Core Stabilization Exercises Group|The Core Stabilization Exercises Group will receive only Jeffreys' core (body) stabilization training protocol.
62037198|NCT01604538||patients with acute pulmonary embolism|
62037199|NCT02446158|EXPERIMENTAL|Chlorhexidine gluconate|PD (peritoneal dialysis) paitents with daily chlorhexidine exit site care
62429095|NCT03817632||B Elite|Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0
62429096|NCT03296553|EXPERIMENTAL|Valganciclovir|Oral Valgancyclovir 900 mg twice in a day during 4 weeks prior to initiation of cART (combined antirretroviral therapy) until suppression of HHV-8.
62429097|NCT03296553|ACTIVE_COMPARATOR|Antiretroviral combinations|Standard treatment with cART according to current HIV Therapy Mexican guidelines.
62429098|NCT01358019|EXPERIMENTAL|LY2523355|
62596654|NCT05971602|EXPERIMENTAL|Stage 2: Arm 5: DS-TB Participants receiving XBOS for 4 months (17 Weeks)|
62814718|NCT04079439|OTHER|Intervention|Tailored e-heath support for physical activity with a focus on communication and rewards, using commercial accelerometers for measurements
62814719|NCT04079439|NO_INTERVENTION|Control group|Standard care
62814720|NCT01028989|OTHER|Reduced Glycemic Load Diet|"36-40% fat; 40-42% carbohydrate; 18-22% protein~Glycemic Load \<=46 per 1000 calories"
62238486|NCT02797210|EXPERIMENTAL|Active then Sham Stimulation|Active repetitive transcranial magnetic stimulation (rTMS) to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks, then sham rTMS to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks
62429099|NCT04399902|EXPERIMENTAL|Study blanket|Two standard warmed hospital blankets will be placed on top of the patient and the study blanket on top of the standard warmed blankets, covering as much of the patient as possible, at the discretion of the care team. At all times, clinicians should ensure that the study blanket does not touch the patient's bare skin.The blanket will remain on the patient through their path of care, and removed from the patient at arrival to the ICU/final phase of care, or if the patient temperature exceeds 38˚C at any point.
62429100|NCT00698425|EXPERIMENTAL|1: 0 mA-min (0 mA for 4 min)|Ocular iontophoresis 0 mA-min (0 mA for 4 minutes)
62429101|NCT00698425|EXPERIMENTAL|2: 4 mA-min (2 mA for 2 min), + polarity|Ocular iontophoresis 4 mA-min (2 mA for 2 minutes), positive polarity
62429102|NCT00698425|EXPERIMENTAL|3: 5 mA-min (2.5 mA for 2 min), +|Ocular iontophoresis 5 mA-min (2.5 mA for 2 minutes), positive polarity
62429103|NCT00698425|EXPERIMENTAL|4: 6 mA-min (3 mA for 2 min), + polarity|Ocular iontophoresis 6 mA-min (3 mA for 2 minutes), positive polarity
62429104|NCT00698425|EXPERIMENTAL|5: 7 mA-min (3.5 mA for 2 min), +|Ocular iontophoresis 7 mA-min (3.5 mA for 2 minutes), positive polarity
62429105|NCT00698425|EXPERIMENTAL|6: 8 mA-min (4 mA for 2 min), + polarity|Ocular iontophoresis 8 mA-min (4 mA for 2 minutes), positive polarity
62238487|NCT02884765||Bicondylar Fracture|Patients presenting a bilateral condylar fracture of the mandible with or without additional symphyseal fracture. Bilateral condylar fractures will be treated non-surgical, surgical or combining both.
62238488|NCT01704833|EXPERIMENTAL|Cognitive Behavioral Therapy|This group receives 15 weeks of Paranoia-Focused Cognitive Behavioral Therapy (PFCBT) in addition to standard care.
62238489|NCT01704833|NO_INTERVENTION|Treatment as Usual|This group receives standard care only.
62429106|NCT00698425|EXPERIMENTAL|7: 7 mA-min (3.5 mA for 2 min), -|7 mA-min (3.5 mA for 2 minutes), negative polarity
62429107|NCT00698425|EXPERIMENTAL|8: 8 mA-min (4 mA for 2 min), - polarity|Ocular iontophoresis 8 mA-min (4 mA for 2 minutes), negative polarity
62429108|NCT00698425|EXPERIMENTAL|9: 20 mA-min (4 mA for 5 min), +|Ocular iontophoresis 20 mA-min (4 mA for 5 minutes), positive polarity
62429109|NCT00698425|EXPERIMENTAL|10: 20 mA-min (2 mA for 10 min), +|Ocular iontophoresis 20 mA-min (2 mA for 10 minutes), positive polarity
62429110|NCT00698425|EXPERIMENTAL|11: 20 mA-min (4 mA for 5 min), -|Ocular iontophoresis 20 mA-min (4 mA for 5 minutes), negative polarity
62429111|NCT00698425|EXPERIMENTAL|12: 20 mA-min (2 mA for 10 min), -|Ocular iontophoresis 20 mA-min (2 mA for 10 minutes), negative polarity
62429112|NCT00698425|EXPERIMENTAL|13: 0 mA-min (0 mA for 10.5 min)|Ocular iontophoresis 0 mA-min (0 mA for 10.5 minutes)
62037200|NCT02446158|NO_INTERVENTION|Control group|PD (peritoneal dialysis) patients with usual (Normal saline) exit site care
62037201|NCT05770999|EXPERIMENTAL|Lavender massage|A mixture of 20 cc of sweet almond oil and 1 cc of lavender oil will be used. Sweet almond oil has been used to dilute lavender oil. lavender massage lasted about 10 minutes.
62037202|NCT05770999|EXPERIMENTAL|Lavender bath|A mixture of 20 cc bath water and 1 cc lavender oil will be used. lavender bath lasted about 10 minutes.
62037203|NCT05770999|NO_INTERVENTION|Control group|The newborns in the control group did not receive any treatment other than their clinical routines (vital signs monitoring, skin care with sunflower oil, eye and mouth care, changing diapers, changing bed linen, feeding and clinical treatments).
62037204|NCT00537966||Primo - Cohort|The patients with primary HIV-1 infection will receive combination antiretroviral therapy with standard drugs approved by Swiss Medic.
62037205|NCT03511755|EXPERIMENTAL|TEN 1-11 kHz|Transdermal Electrical Neuromodulator (TEN) waveform pulsed biphasic current (1-11 kHz)
62037206|NCT03511755|ACTIVE_COMPARATOR|TEN 1-3 kHz|Transdermal Electrical Neuromodulator (TEN) waveform pulsed biphasic current (1-3 kHz)
62037207|NCT02683096||SGA Infants|
62037208|NCT02683096||Failed Hearing Screen Infants|
62238490|NCT03521414|ACTIVE_COMPARATOR|Group I=13-15 mildly injured|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery. use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.~Group I (n=15)=13-15 mildly injured"
62238491|NCT03521414|ACTIVE_COMPARATOR|Group 2 =9-12 moderately damaged|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery.use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.~Group 2 (n=15)=9-12 moderately damaged"
62429113|NCT00698425|EXPERIMENTAL|14: 13.5 mA-min (4.5 mA for 3 min), +|Ocular iontophoresis 13.5 mA-min (4.5 mA for 3 minutes), positive polarity
62037209|NCT02405221|EXPERIMENTAL|TA-CIN administration via thigh|Each dose of TA-CIN vaccine is fixed, 100µg. Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9), administered in the thigh. Patients will be followed for 2 years after the 1st dose is given.
62037210|NCT02405221|EXPERIMENTAL|TA-CIN administration via arm|Each dose of TA-CIN vaccine is fixed, 100µg. Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9), administered in the arm. Patients will be followed for 2 years after the 1st dose is given.
62429114|NCT00698425|EXPERIMENTAL|15: 15 mA-min (5 mA for 3 min), +|Ocular iontophoresis 15 mA-min (5 mA for 3 minutes), positive polarity
62429115|NCT00698425|EXPERIMENTAL|16: 16.5 mA-min (5.5 mA for 3 min), +|Ocular iontophoresis 16.5 mA-min (5.5 mA for 3 minutes), positive polarity
62429116|NCT00698425|EXPERIMENTAL|17: 18 mA-min (6 mA for 3 min), +|Ocular iontophoresis 18 mA-min (6 mA for 3 minutes), positive polarity
62429117|NCT00698425|EXPERIMENTAL|18: 19.5 mA-min (6.5 mA for 3 min), +|Ocular iontophoresis 19.5 mA-min (6.5 mA for 3 minutes), positive polarity
62596655|NCT05971602|EXPERIMENTAL|Stage 2: Arm 6: DS-TB Participants receiving 2HRZE/4HR for 6 months (26 Weeks)|
62596656|NCT05971602|EXPERIMENTAL|Observational cohort: RR/MDR-TB Participants receiving XBOS for 4 months (17 Weeks)|
62037211|NCT01525732|OTHER|POEM|Per Oral Endoscopic Myotomy
62037212|NCT01791933||CAM treatment|
62037213|NCT04037501|EXPERIMENTAL|Intervention|
62037214|NCT04037501|NO_INTERVENTION|care as usual|
62037215|NCT00226239|EXPERIMENTAL|Head and neck cancer patients|Induction chemotherapy consists of 3 cycles of cisplatin 75 mg/m\^2, on day 1, docetaxel 75 mg/m\^2, on day 1, and cetuximab weekly days 1,8,15, repeated every 21 days (cetuximab dose is 400 mg/m\^2 on day 1 and 250 mg/m\^2 on subsequent weekly treatments). After 3 cycles of induction, patients receive standard radiation 70 Gy/200 cGy/daily, 5 days/week with concurrent weekly cisplatin 30 mg/m\^2 and cetuximab 250 mg/m\^2. After completing radiation therapy, patients receive cetuximab weekly as maintenance therapy for 6 months (see section 5 for detailed treatment plan and dose modifications)
62037216|NCT06700915|EXPERIMENTAL|Diaberine|Participants in this arm will receive the Diaberine supplement, which contains Vitamin B12, berberine, magnesium citrate, water-extracted cinnamon bark (Cinnamomum cassia) at a 10:1 ratio, chromium (picolinate), rice flour, dicalcium phosphate, l-leucine, and HPMC (capsule).
62037217|NCT06700915|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive a placebo capsule containing rice flour, dicalcium phosphate, l-leucine, and HPMC (capsule).
62037218|NCT06580834||Neonatal Intensive care Unit|50% of the babies recruited will be from the Neonatal Intensive Care Unit. All term neonates ≥ 37 and ≤ 45 weeks corrected gestation age are eligible for the NBT study that do not have head trauma or broken skin on the scalp.
62037219|NCT06580834||Post Natal Ward|50% of the babies recruited will be from the Post Natal Ward. All term neonates ≥ 37 and ≤ 45 weeks corrected gestation age are eligible for the NBT study that do not have head trauma or broken skin on the scalp.
62037220|NCT03610126||volume controlled ventilation|after induction of anesthesia and insertion of BASKA laryngeal mask airway mechanical ventilation of patients will be maintained with volume controlled ventilation mode
62238492|NCT03521414|ACTIVE_COMPARATOR|Group 3=3-8 severely damaged.|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery. use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.~Group 3 (n=15)=3-8 severely damaged."
62238493|NCT00375219|EXPERIMENTAL|omacetaxine|Treatment was the same for all cohorts: induction therapy was subcutaneous (SC) administration of omacetaxine at 1.25 mg/m\^2 twice a day (BID), administered for 14 consecutive days every 28 (±3) days for up to 6 cycles. Maintenance therapy was subcutaneous (SC) administration of omacetaxine at 1.25 mg/m\^2 twice a day (BID), administered for 7 consecutive days every 28 (±3) days for up to 3 years.
62238494|NCT04903808|EXPERIMENTAL|Allium sativum oil|The pulp stumps of the molars are dressed with a cotton pellet that is made damp with Allium Sativum oil for 1 min .
62238495|NCT04903808|ACTIVE_COMPARATOR|Mineral Trioxide Aggregate|The material will be prepared according to the manufacturer's instructions , applied to the pulp chamber and a moistened cotton pellet was placed over the MTA paste to allow the material to set.
62238496|NCT01222637|EXPERIMENTAL|CetuGEX™, weekly|application weekly
62238497|NCT01222637|EXPERIMENTAL|CetuGEX™ 2-weekly|application biweekly
62037221|NCT03610126||pressure controlled ventilation|after induction of anesthesia and insertion of BASKA laryngeal mask airway and mechanical ventilation of patients will be maintained with pressure controlled ventilation mode
62238498|NCT00874666|ACTIVE_COMPARATOR|1|Positive control with 100% allicin bioavailability
62238499|NCT00874666|EXPERIMENTAL|2|garlic powder tablet
62238500|NCT05111847|ACTIVE_COMPARATOR|Short-term Baseplate|
62238501|NCT05111847|ACTIVE_COMPARATOR|Long-term Baseplate|
62037222|NCT03625570|EXPERIMENTAL|PT³|Power Training combined with interval treadmill training
62238502|NCT03558256|EXPERIMENTAL|Mindfulness-based Cognitive Therapy|MBCT group is a treatment group used mindfulness- based cognitive therapy added to the usual medication treatment, and guided by two therapists for 8 sessions. Every group of 6 people can form a closed structural group. Each session lasts 2 hours once a week, and has daily homework assignments.
62238503|NCT03558256|ACTIVE_COMPARATOR|Medication|Medication group is a control group that can choose to use the serotonin reuptake inhibitors (SSRIs) approved by China food and Drug Administration (SFDA) for the treatment of depression (fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram and escitalopram).
62429118|NCT00698425|EXPERIMENTAL|19: 20 mA-min (7 mA for 3.84 min), +|Ocular iontophoresis 20 mA-min (7 mA for 3.84 minutes), positive polarity
62429119|NCT00926653||Depressed|Elderly participants with depression
62429120|NCT00926653||Control|Elderly participants who have never experienced depression
62429121|NCT01332513|EXPERIMENTAL|ABFCED sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 milligram (mg) twice daily (BID) dosing of ezogabine modified release (MR) tablet in periods A, B, C, D and E and will receive 200 mg three times daily (TID) dosing of ezogabine immediate release (IR) tablet in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
62814721|NCT01028989|OTHER|Standard Diet|"25-27% fat; 55-57% carbohydrate; 18-22% protein~Glycemic Load \>=77 per 1000 calories"
62814722|NCT02780401|EXPERIMENTAL|Treatment (WOKVAC with sargramostim)|"Patients receive WOKVAC with sargramostim ID on day 1. Courses repeat every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients with ALND will have vaccine administered to the contralateral arm. Patients with bilateral ALND will have vaccine administered in the thigh. As much as possible each vaccine dose will be given within the same draining lymph node site. Patients will be monitored for a minimum of 60 minutes post vaccine administration."
62238504|NCT06234254|EXPERIMENTAL|Virtual Reality|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
62238505|NCT06234254|NO_INTERVENTION|Control|No intervention (i.e. virtual reality headset) will be applied to the participant.
62238506|NCT01778660|ACTIVE_COMPARATOR|Standard Counselling|Patients in this arm are randomised to standard counselling.
62238507|NCT01778660|EXPERIMENTAL|Mnemonic Counselling|Patients in this arm are randomised to counselling with the aid of a mnemonic.
62238508|NCT01581541|EXPERIMENTAL|PU-H71|PU-H71 will be administered intravenous (IV) over one hour, once weekly, 2 weeks out of 3, (i.e., on days 1 and 8) every 21 days
62238509|NCT02842840|EXPERIMENTAL|Patients based intervention|A multifaceted intervention program will use to improve adherence and clinical outcomes in Stroke patients. This intervention focus on behavioral treatment in the patients.
62238510|NCT02842840|EXPERIMENTAL|Family based intervention|Patients and their families will receive a series of educational/motivational interventions.
62238511|NCT02842840|ACTIVE_COMPARATOR|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 30 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
62238512|NCT04377828|EXPERIMENTAL|Laser intervention|1 to 2 sessions of pigment laser1
62814723|NCT03432325|EXPERIMENTAL|Neural Enabled Prosthesis|Neural Enabled Prosthesis Treatment Group
62814724|NCT05384249|PLACEBO_COMPARATOR|Group 1: Placebo subcutaneous once weekly|Participants will receive placebo every week to week 51.
62814725|NCT05384249|EXPERIMENTAL|Group 2: Izokibep subcutaneous once weekly|Participants will receive izokibep every week to week 51.
62596657|NCT03948035|EXPERIMENTAL|E-KRd/ Arm A|Induction/ Consolidation: Elotuzumab, Carfilzomib, Lenalidomide, Dexamethasone (E-KRd), autologous stem cell transplant, Maintenance: Elotuzumab, Lenalidomide
62037223|NCT03625570|ACTIVE_COMPARATOR|Traditional training|Strength training combined with traditional treadmill training
62037224|NCT02234869|EXPERIMENTAL|Peginterferon beta-1a|Participants will receive peginterferon beta-1a, 125 µg subcutaneously once every 2 weeks during the 6-month comparator period of the study and during the 12-month extension period.
62037225|NCT02234869|ACTIVE_COMPARATOR|Interferon-β|Participants will continue to receive their standard-of-care interferon beta treatment for the first six months. During the 12-month extension period participants will switch to receive peginterferon beta-1a, 125 µg subcutaneously once every 2 weeks.
62037226|NCT05420155||Surgical group|Patients operated on liver hydatidic cyst
62037227|NCT02242474|ACTIVE_COMPARATOR|Anti-TNF suspended perioperatively|Patients randomized to Group B will have their anti-TNFα therapy interrupted before surgery. Different authors suggested that anti-TNFα therapies should be suspended between two and five half-lives prior to surgery. In the current trial, anti-TNFα will be suspended three half-lives (± seven days) prior to surgery. All other medications used in the treatment of the disease (methotrexate, hydroxychloroquine, corticosteroid, etc.) will be documented and continued in the perioperative period. Non-steroidal anti-inflammatory drugs (NSAID) will be suspended seven days prior to surgery and will be restarted postoperatively. Anti-TNFα will be restarted once wound healing is completed.
62037228|NCT02242474|EXPERIMENTAL|Anti-TNFα continued perioperatively|Patients randomized to Group A will continue their anti-TNFα treatment unaltered during the whole perioperative period. Surgery will be performed without consideration in regards to the timing of the treatment. The time elapsed between the last anti-TNFα administration and the surgery will nonetheless be documented.
62037229|NCT02724631|EXPERIMENTAL|TubeClear® (Phase I)|To determine feasibility and tolerability, 15 subjects will receive the TubeClear® intervention. If the TubeClear® intervention is unable to restore Enteral Access Device patency, further steps to restore patency of the occluded EAD will be determined by the clinical team per usual practice.
62037230|NCT05200871||Adult patients|Adult patients (at least 18 years old) with FSGS or IgAN located in each of the six countries
62037231|NCT05200871||Adult patient care-partners of adult patients|Adult care-partners (paired with adult patients) (at least 18 years old) of adult patients with FSGS or IgAN located in each of the six countries
62037232|NCT05200871||Adult patient care-partners of pediatric/adolescent patients|Adult parents/care-partners (paired with adult patients) (at least 18 years old) of pediatric/ adolescent patients with FSGS or IgAN located in each of the six countries
62037233|NCT01467180|EXPERIMENTAL|HCO CVVHD|treatment of rhabdomyolysis pts with septeX dialyzer
62037234|NCT01467180|ACTIVE_COMPARATOR|HF CVVH|treatment of rhabdomyolysis pts with standard high flux dialyzer
62037235|NCT06613217|EXPERIMENTAL|zelenirstat intervention in R/R AML at 40mg daily|Three patients will be treated at 40 mg daily dose level. If 0/3 patients experience DLT, 3 patients will be treated at the next dose level.
62238513|NCT03749603|EXPERIMENTAL|TIBAY meter|Non-invasive measurement of red blood cell Zinc Protoporphyrin (ZnPP/haem ratio-µmol/mol haem) fluorescence in the microcirculation of the lower lip.
62238514|NCT00388154|EXPERIMENTAL|Gemcitabine + Cisplatin|Gemcitabine 900 mg/m\^2 by vein (IV) over 1 hour on Day 1 and Day 8. Cisplatin 30 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.
62238515|NCT03142438|EXPERIMENTAL|F&P Seal Improvement Project|participants will be placed on this arm for a total of 14 +- 4 days from visit 1. participants will be using the trial mask during this treatment arm
62238516|NCT01688583||Fentanyl matrix|
62238517|NCT06102577|EXPERIMENTAL|1gr. Vitamine C|Take 1g. of vitamin C at the end of an osteopathic manual treatment
62238518|NCT06102577|PLACEBO_COMPARATOR|1gr.Placebo|Take 1g. of placebo at the end of an osteopathic manual treatment
62238519|NCT06102577|SHAM_COMPARATOR|control group|control
62596658|NCT03948035|ACTIVE_COMPARATOR|KRd/ Arm B|Induction/ Consolidation: Carfilzomib, Lenalidomide, Dexamethasone (KRd), autologous stem cell transplant, Maintenance: Lenalidomide
62596659|NCT06523881|ACTIVE_COMPARATOR|Group P|Group P received propofol Propofol (Propofol-PF® 1% (Polifarma Pharmaceuticals, Tekirdag, Turkey) at a dosage of 75-100 µg/kg/min and remifentanil (Opiva vial®, Tum Ekip Pharmaceuticals Inc., Istanbul, Turkey) IV at a dosage of 0.05-0.2 µg/kg/min.
62037236|NCT06613217|EXPERIMENTAL|zelenirstat intervention in R/R AML at 70mg daily|Three patients will be treated at 70 mg daily dose level. If 0/3 patients experience DLT, 3 patients will be treated at the next dose level.
62037237|NCT06613217|EXPERIMENTAL|zelenirstat intervention in R/R AML at 100mg daily|Three patients will be treated at 100 mg daily dose level. If 0/3 patients experience DLT, 3 patients will be treated at the next dose level.
62238520|NCT06491407||Geriatrics|\>65 years old individuals
62238521|NCT01009203|EXPERIMENTAL|Temsirolimus and Erlotinib|Erlotinib (Tarceva) at 150 mg by mouth daily + Temsirolimus (Torisel) at 15 mg intravenously weekly. Each cycle is comprised of 28 days
62238522|NCT05265910|ACTIVE_COMPARATOR|Pataday® Once Daily Relief Extra Strength and Placebo tablet|Pataday® Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%) will be administered bilaterally and Placebo tablet will be administered orally (within 5 minutes of eyedrop) at Visits 3 and 4a.
62238523|NCT05265910|ACTIVE_COMPARATOR|Tears Naturale® II and Claritin® Tablet 24-Hour|Tears Naturale® II will be administered bilaterally and Claritin® Tablet 24-Hour (loratadine 10 mg) will be administered orally (within 5 minutes of eyedrop) at Visits 3 and 4a.
62238524|NCT04260009|EXPERIMENTAL|Phase 1: Brigatinib|Brigatinib tablet or age-appropriate formulation (AAF), orally once daily in 28-day Cycles with reference to adult dose of 90 mg in Week 1 and 180 mg starting in Week 2 based on participant's weight as dose level 1. Participants could receive dose level 2 based on safety and tolerability of dose level 1 in dose escalation phase (Ph).
62238525|NCT04260009|EXPERIMENTAL|Ph 2:Brigatinib (Unresectable/Recurrent ALK+ IMT) Participants|Brigatinib recommended phase 2 dose (RP2D) determined during phase 1, tablet or AAF orally QD in participants with Unresectable/ Recurrent ALK+ IMT for up to 2 years in dose expansion phase.
62238526|NCT04260009|EXPERIMENTAL|Ph 2 :Brigatinib (Relapsed/Refractory ALK+ ALCL) Participants|Brigatinib RP2D determined during phase 1, tablet or AAF orally QD in participants with Relapsed/ Refractory ALK+ ALCL for up to 2 years in dose expansion phase.
62814726|NCT05397717||Spontaneous pneumothorax|A. Inclusion criteria i. All patients with a confirmed diagnosis of spontaneous pneumothorax on admission or during the hospital stay ii. Age greater than 18 years old iii. Chinese ethnicity iv. Able to sign written informed consent to participate in the study B. Exclusion criteria i. Pneumothorax was not found by thoracic imaging ii. Traumatic pneumothorax (including iatrogenic pneumothorax) iii. Pneumothorax with recent (within one month) lung resection surgery, that may be due to staple line issues iv. Trapped lung or non-expandable lungs, without evidence of air leakage v. Patients with psychiatric disease or cognitive impairment that may limit their ability of understanding or giving consent to the study
62814727|NCT00933699|EXPERIMENTAL|Dermacyd PH_DESILSTY_FL (Lactic Acid)|Treatment duration: 21 consecutive days
62429122|NCT01332513|EXPERIMENTAL|BCADFE sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
62814728|NCT01622439|EXPERIMENTAL|Single, open labeld.|
62814729|NCT00837252|EXPERIMENTAL|Finasteride|
62596660|NCT06523881|ACTIVE_COMPARATOR|Group S|Group S utilized sevoflurane (Sevorane® liquid 100%, Abbvie Pharmaceuticals, Istanbul, Turkey) for anesthesia maintenance, with an end-tidal sevoflurane concentration ranging from 1 to 1.5 minimal alveolar concentrations. Furthermore, remifentanil (Opiva vial®, Tum Ekip Pharmaceuticals Inc., Istanbul, Turkey) was administered IV at an infusion rate ranging from 0.05 to 0.2 µg kg/min.
62814730|NCT05763563|EXPERIMENTAL|Exercise prehabilitation|Participants will take part in an exercise program in which they will be encouraged to perform approximately 30 minutes of resistance training exercises approximately twice per week until they undergo CAR-T therapy (Approximately 4-6 weeks). Participants will also be encouraged to perform moderate aerobic exercise such as brisk walking or using stationary aerobic equipment at least 3 times per week. Participants will wear a FitBit fitness watch to monitor aerobic exercise.
62814731|NCT03572920||Patients with hip/knee arthroplasty.|RAR description by actgraphy Objective sleep evaluation by actigraphy. Subjective sleep quality with sleep diary Pittsburgh Sleep Quality Index (PSQI).
62814732|NCT02136979|ACTIVE_COMPARATOR|Propofol group|patients with propofol-based anesthesia
62814733|NCT02136979|ACTIVE_COMPARATOR|Sevoflurane group|patients with sevoflurane-based anesthesia
62238527|NCT03299751|EXPERIMENTAL|NICU newborns of at least 7 days of life with suggestive signs|
62814734|NCT03688269|EXPERIMENTAL|Intravenous dexamethasone|"Axillary Brachial Plexus Block with perineural Ropivacaine. Concentration determined by sequential up and down method.~Intravenous injection of 8mg/2ml Dexamethasone during the regional anesthesia"
62814735|NCT03688269|PLACEBO_COMPARATOR|Intravenous saline|"Axillary Brachial Plexus Block with perineural Ropivacaine. Concentration determined by sequential up and down method.~Intravenous injection of 2ml Saline 0.9% during the regional anesthesia"
62814736|NCT06092762|EXPERIMENTAL|AK120 300mg|AK120 loading dose 600mg, then 300mg subcutaneous injection every 2 weeks thereafter until week 14.
62814737|NCT06092762|EXPERIMENTAL|AK120 450mg|AK120 loading dose 600mg, then 450mg subcutaneous injection every 2 weeks thereafter until week 14.
62814738|NCT04951115|EXPERIMENTAL|Radiation + Chemo-Immunotherapy|
62238528|NCT02798263|EXPERIMENTAL|Group I kinesiotherapy|Treated with standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes
62238529|NCT02798263|EXPERIMENTAL|: Group II Acupuncture|Treated with 30 minutes of classical acupuncture using predefined points
62429123|NCT01332513|EXPERIMENTAL|CDBEAF sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
62596661|NCT04421560|EXPERIMENTAL|Pembrolizumab + Ibrutinib + Rituximab|"Phase 1b~Dose escalation will occur using a standard 3+3 dose-escalation approach, beginning at dose level I (560 mg daily) and potentially escalating to dose level 2 (840mg) with rules for escalation and de-escalation.~* Ibrutinib: orally 2x daily~* Pembrolizumab: 200 mg intravenously every 3 weeks~* Rituximab/biosimilar: 375mg/m\^2 intravenously once per week for 4 weeks (4 total doses).~Phase 2~Participants will receive Pembrolizumab, Rituximab and Ibrutinib at the pre-determined dosage level established in Phase 1b.~* Ibrutinib: orally maximum tolerated dose from phase 1 daily (560 mg or 840mg)~* Pembrolizumab: 200 mg intravenously every 3 weeks~* Rituximab/biosimilar: 375 mg/m\^2 intravenously once per week for 4 weeks (4 total doses)."
62596662|NCT05129475|EXPERIMENTAL|Treatment A|Single oral dose of ritonavir at -12 hours prior to PF-07321332/ritonavir dosing, followed by single oral dose of PF-07321332/ritonavir under fasted conditions. Ritonavir will continue to be dosed at 12 hours PF-07321332 dosing.
62429124|NCT01332513|EXPERIMENTAL|DECFBA sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
62596663|NCT05129475|EXPERIMENTAL|Treatment B|Single oral dose of ritonavir at -12 hours prior to PF 07321332/ritonavir dosing, followed by single oral dose of PF-07321332/ritonavir under fed conditions. Ritonavir will continue to be dosed at 12 hours PF-07321332 dosing.
62596664|NCT05331248|EXPERIMENTAL|LIA Household Training|This treatment arm is an 8-session training with a tailored schedule at the household level that targets couples at risk of domestic violence. The sessions are delivered by Community Health Volunteers: 1 Facilitator and 1 Community Agent. The training aims to raise awareness of IPV and social norms around domestic violence and is delivered at the household level in a private environment. Additionally, the intervention includes sessions on soft skills and conflict resolution. The session topics are: i) gender roles, beliefs and stereotypes; ii) violence, cultural patterns and human rights; iii) healthy relationships within the family; iv) good treatment between family members and self-care; v) Assertive communication; vi) resolution and conflict management; vii) resources for domestic violence cases; and viii) leadership and women's agency.
62596665|NCT05331248|EXPERIMENTAL|LIA Group Training|This treatment arm is an 4-session training delivered in gender-segregated groups at the village level that targets couples at risk of domestic violence in separate spaces. The sessions are delivered by Community Health Volunteers: 1 Facilitator and 1 Community Agent. The training aims to raise awareness of IPV and social norms around domestic violence and is delivered at the household in a private environment. The sessions topics are: i) gender roles, beliefs and stereotypes; ii) violence, cultural patterns and human rights; iii) healthy relationships within the family; iv) good treatment between family members and self-care; v) assertive communication; vi) resolution and conflict management; vii) resources for domestic violence cases; and viii) leadership and women's agency.
62596666|NCT05331248|EXPERIMENTAL|LIA Household and Group Training|This treatment arm combines LIA Household and Group training. Villages in this arm will first receive the 8-sessions household-level intervention, then the 4-sessions of village-level gender-segregated group intervention will follow. The session topics for both interventions are: i) gender roles, beliefs and stereotypes; ii) violence, cultural patterns and human rights; iii) healthy relationships within the family; iv) good treatment between family members and self-care; v) assertive communication; vi) resolution and conflict management; vii) resources for domestic violence cases; and viii) leadership and women's agency.
62596667|NCT05331248|NO_INTERVENTION|Control group|Villages in the control group will not receive any intervention.
62814739|NCT05829551|EXPERIMENTAL|RAY1216 dose 1|SAD
62814740|NCT05829551|EXPERIMENTAL|RAY1216 dose 2|SAD
62814741|NCT05829551|EXPERIMENTAL|RAY1216 dose 3|SAD
62814742|NCT05829551|EXPERIMENTAL|RAY1216 dose 4（DDI）|drug-drug interaction
62814743|NCT05829551|EXPERIMENTAL|RAY1216 dose 5|MAD
62814744|NCT05829551|EXPERIMENTAL|RAY1216 dose 6|MAD
62429125|NCT01332513|EXPERIMENTAL|EFDACB sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
62814745|NCT05829551|EXPERIMENTAL|RAY1216 dose 7|MAD
62814746|NCT05829551|EXPERIMENTAL|RAY1216 dose 8|MAD
62814747|NCT05829551|EXPERIMENTAL|RAY1216 dose 9（food effect）|food effect on single dose
62814748|NCT05829551|EXPERIMENTAL|RAY1216 dose 10（food effect）|food effect on single dose
62814749|NCT03246971|EXPERIMENTAL|Wafermine™|
62238530|NCT02798263|EXPERIMENTAL|Group III Stiper|They will be used the same acupuncture points of the group II, but using the needles in place Stiper®
62238531|NCT03445923|NO_INTERVENTION|Morphology|Embryos for transfer will be selected based on standard morphological evaluation.
62238532|NCT03445923|ACTIVE_COMPARATOR|TLM|Embryos for transfer will be selected base on standard morphological evaluation and information from time-lapse monitoring.
62814750|NCT03246971|PLACEBO_COMPARATOR|Placebo|
62814751|NCT06347731|OTHER|single-arm objective performance criteria (OPC)|According to the National Medical Products Administration (NMPA) Guidance on Proton and Carbon Ion treatment system clinical evaluation and clinical trial, the objective performance criteria for the validity of medical device treatment for trial use should be at least 80%, with an expected target of 95% in which the validity is defined as: Complete Response (CR)+ Partial Response (PR)+ Stable Disease (SD), and the definition of tumor disease control rate in this clinical trial is basically identical. Therefore, the clinical trial does not have a control group, but using single-arm objective performance criteria, when evaluating ProBeam radiotherapy for tumor patients, the main validity evaluation index of tumor disease control rate whether reach the objective performance criteria (80%); the main safety evaluation index of CTCAE grade 3 toxic reaction ratio is lower than the acceptable value (5%), CTCAE grade 4 and 5 toxic reaction ratio is acceptable value (0%).
62814752|NCT03000244||1/Patients|Patients who underwent hematopoietic stem cell transplant for any indication (malignant or non-malignant).
62037238|NCT06613217|EXPERIMENTAL|zelenirstat intervention in R/R AML at 140mg daily|Three patients will be treated at 140 mg each dose level. If 0/3 patients experience DLT, 3 patients will be treated at the next dose level.
62037239|NCT06613217|EXPERIMENTAL|zelenirstat intervention in R/R AML at 210mg daily (if needed)|Three patients will be treated at 210 mg daily dose level. If 0/3 patients experience DLT, 3 patients will be treated at the next dose level.
62429126|NCT01332513|EXPERIMENTAL|FAEBDC sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
62814753|NCT03000244||2/Donors|Related stem cell donors of those in Patients cohort.
62814754|NCT03000244||3/Parents of patients|Parents/guardians of minors enrolled in cohort 1
62037240|NCT06613217|EXPERIMENTAL|zelenirstat intervention in R/R AML at 280mg daily (if needed)|Three patients will be treated at 280 mg daily dose level. If 0/3 patients experience DLT, 3 additional patients will be treated at the same dose and the study will be concluded.
62037241|NCT04253743|EXPERIMENTAL|Nevada Healthy, Hunger-Free Kids Demonstration Benefits|SNAP households were randomly assigned to receive either: (1) $40 extra in SNAP benefits per eligible child (\<5 years) per month (n=1,919); (2) $40 extra in SNAP benefits per eligible child per month plus case management and nutrition education (n=1,919); or (3) only regular monthly SNAP benefit (n=7,467). The first two groups were the treatment arms and the third was the control group.
62037242|NCT04253743|NO_INTERVENTION|Control Group|The control group received regularly allotted SNAP benefits.
62037243|NCT04546308|EXPERIMENTAL|Exercise training|The participants will undergo 8 weeks of whole-body resistance exercise training followed by a 4-week detraining. The central hemodynamic and muscle stiffness variables will be measured pre, post-training, and post-detraining.
62037244|NCT04546308|NO_INTERVENTION|Sedentary control|The participants will undergo 12 weeks of intervention without exercise training. The central hemodynamic and muscle stiffness variables will be measured pre, 8th, and 12th week.
62429127|NCT02529085|EXPERIMENTAL|Infants with PWS|Blood samples for the bank in link with a multicenter database including clinical data on birth, auxology, endocrine functions and feeding behaviour
62037245|NCT06164717|EXPERIMENTAL|Auditory feedback perturbation during speech|The intervention consists of manipulating real-time auditory feedback during speech production. In our lab, such feedback perturbations can be implemented with either a stand-alone digital vocal processor (a device commonly used by singers and the music industry) or with software-based signal processing routines (see Equipment section for details). Note that the study does not investigate the efficacy of these hardware or software methods to induce behavioral change in subjects' speech. Rather, the study addresses basic experimental questions regarding the general role of auditory feedback in the central nervous system's control of articulatory speech movements.
62429128|NCT02529085|OTHER|control group|Blood samples for the bank in children hospitalized for a planned surgery for malformation, orthopaedic or visceral surgery
62429129|NCT03140085|ACTIVE_COMPARATOR|Anbiotica|
62429130|NCT03140085|ACTIVE_COMPARATOR|Bacteriophages|
62596668|NCT05053048|EXPERIMENTAL|STD-SL-PLUS stem|Rectangular SL straight stems made of titanium alloy (Ti-6Al-7Nb). The control stem (STD-SL-PLUS stem) underwent alumina grit blasting to reach the adequate roughness of 4-6 micron.
62814755|NCT03897426|NO_INTERVENTION|Standard-of-care arm|Patients randomized to the Standard-of-care-arm were provided 60 minutes of RD time for consultation through in person visits.
62814756|NCT03897426|EXPERIMENTAL|Intervention arm|"Mediterranean Diet - Remote Coaching using a Mobile App.~Patients randomized to the intervention arm were allotted 60 minutes of RD time through a Mobile App (for remote consultation), given an instruction booklet on using Mobile App, directed to a website for additional instruction on its use, and have the app set up to establish connectivity to the RD. Remote coaching by RD was the intervention."
62238533|NCT01822977|NO_INTERVENTION|Proton pump inhibitor|"We will recruit 10 healthy adult individuals and 5 adult patients with an initial episode of CDI cared for at Mayo Clinic in Arizona. A baseline stool sample will be collected from the healthy individuals. They will then be given a PPI, omeprazole 20 mg, to be taken once (n=5) or twice (n=5) daily for 1 month. Stool samples will be collected after 1 week and again after 1 month. A final stool sample will be collected 1 month after stopping the omeprazole.~A stool sample will be collected from the CDI subjects before treatment of the infection and again 2 months after treatment to avoid enrolling those at risk for relapse (which most commonly occurs during the first 2 months after treatment)."
62238534|NCT05543655|EXPERIMENTAL|simulated|The 'Simulation training', using high fidelity simulation with a simulated patient, is composed of 2 training sessions of 3 hours each. The training will include a high-fidelity scenario whose events will be adapted to medication administration in conventional care services. This scenario is developed by a multidisciplinary team of healthcare professionals, experts in simulation and risk management
62238535|NCT03159741|EXPERIMENTAL|Inhibitor + GLP-2|
62238536|NCT03159741|EXPERIMENTAL|Placebo + GLP-2|
62238537|NCT03159741|ACTIVE_COMPARATOR|Placebo + GIP|
62238538|NCT03159741|PLACEBO_COMPARATOR|Placebo + Saline|
62814757|NCT02574403|EXPERIMENTAL|without eculizumab|
62814758|NCT05620108|EXPERIMENTAL|Intubation at TOFC=1|Subjects scheduled for an elective surgical procedure will have endotracheal intubation performed when muscles are almost relaxed and monitoring shows only a single count of muscle twitch (in response to a monitor that assesses muscle relaxation)
62814759|NCT05620108|ACTIVE_COMPARATOR|Intubation 2 minutes after rocuronium administration|Subjects scheduled for an elective surgical procedure will have endotracheal intubation performed 2 minutes after the anesthesia provider gives muscle relaxing medication
62814760|NCT06359652|OTHER|Prehabilitation Program Participant|
62814761|NCT06186323||congenital muscular torticollis|"40 children diagnosed with congenital muscular torticollis, aged 0-15 months, with parental consent, without any vision or hearing problems, will be included in the study. Children with chromosomal anomalies, serious congenital problems and whose parents do not volunteer to participate will not be included in the study.~During the evaluations, the demographic characteristics of the babies (gender, gestational age, birth weight, parental information, mother's pregnancy type, pregnancy history, Apgar score) will be recorded from the file and by interviewing the family. Photographs will be taken to ensure an objective evaluation. The Affordances in the Home Environment for Motor Development-Infant Scale will be used to explore and evaluate the home environment. It was planned to use the Test of Sensory Functions in Infants to evaluate the sensory development of babies. It is planned to use Peabody Motor Development Scale-2 to evaluate motor development."
62814762|NCT02023424|EXPERIMENTAL|Copaxone|Glatiramer Acetate (Copaxone® , Teva Pharmaceutical Industries Ltd.) 20 mg daily or in an interval determined in the Dose Setting period. Administration will be subcutaneous to various areas on the body: back of the upper arms (2 areas), front and outside of thighs (2 areas), upper buttocks/rear hips (2 areas), and stomach (the abdomen).
62814763|NCT06045988|EXPERIMENTAL|Long-Term Care Facility Residents with Alzheimer's Disease or other Related Dementias|
62238539|NCT04181944|EXPERIMENTAL|Exercise Treatment Group|
62238540|NCT02080455|EXPERIMENTAL|Lomitapide & Atorvastatin - Taken Together|"2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 \& Day 15)~11 single oral doses of atorvastatin (80 mg) (Day 11 through day 21)"
62238541|NCT02080455|EXPERIMENTAL|Lomitapide & Atorvastatin - Approx. 12 hours between|"2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 \& Day 15)~11 single oral doses of atorvastatin (80 mg) (Day 12 through day 22)"
62238542|NCT02883530||Biomarker optimised patients|Optimised biomarker/Th2 low n=40
62238543|NCT02883530||non -optimised/Th2 low patients|Patients identified in clinic with FeNO \<30 ppb. Those who at screening demonstrate FeNO \<30 ppb and blood eosinophil count ≤0.20 x109/L will be considered to be non-optimised biomarker-low patients (Th2-low) and will proceed to bronchoscopy n=80
62238544|NCT02883530||corticosteroid-resistant biomarker|Patients identified in clinic with FeNO \>45 ppb who have failed to suppress their FeNO during FeNO suppression testing. These patients are considered adherent to inhaled corticosteroids. Those who at screening also demonstrate blood eosinophils of \>0.3x109/L n=40
62429131|NCT03140085|PLACEBO_COMPARATOR|Placebo|
62429132|NCT04133545||DOAC|Direct oral anticoagulant
62429133|NCT04133545||OAC|Vitamin K anticoagulant
62429134|NCT03927781|EXPERIMENTAL|Pregabalin 300mg|300mg pregabalin, PO, once, 1 hr before surgery
62429135|NCT04583904||Adults - inpatient|
62037246|NCT06164717|EXPERIMENTAL|Visual feedback perturbation during reaching|The intervention consists of manipulating real-time visual feedback during upper limb reaching movements. In our lab, such feedback perturbations can be implemented with a virtual reality display system.
62429136|NCT04583904||Adults- ambulatory|
62429137|NCT04583904||Children|
62429138|NCT06110221||Periodontitis|This group consisted of patients with generalized stage III periodontitis, who had interproximal CAL≥5 mm and PD≥6 mm as well as radiographical bone loss extending to the mid-third of the root or beyond at 30% of the teeth or more. CAL was not caused by trauma-related gingival recession, dental caries extending into the cervical areas of the teeth, endodontic lesions draining through the marginal periodontium, and the distal bone loss in adjacent second molars due to extractions of third molars. They showed no more than four teeth loss due to periodontitis.
62037247|NCT06164717|EXPERIMENTAL|Deep brain stimulation|This intervention consists of toggling the deep brain stimulation (DBS) implant ON/OFF prior to participation in the speech auditory-motor learning tasks and speech sequence learning tasks. This intervention can be implemented by the subject themselves as all patients have a hand- held controlled that they use to switch stimulation ON/OFF.
62037248|NCT01542918|EXPERIMENTAL|Study intervention|Lenalidomide Plus Rituximab
62238545|NCT05097716|EXPERIMENTAL|Ritlecitinib and tolbutamide|In Period 1, participants will be dosed with a single administration of tolbutamide 500 mg tablet on Day 1. Period 1 will be immediately followed by Period 2 with no washout. In Period 2, participants will be dosed with oral 200 mg ritlecitinib QD for 10 days followed by administration of a single dose of 500 mg tolbutamide oral tablet within approximately 5 minutes after administration of a 200 mg dose of ritlecitinib on the morning of Day 10.
62814764|NCT01924845|EXPERIMENTAL|BMN 701 20 mg/kg|BMN 701 IV Infusion 20mg/kg every 2 weeks for 24 weeks followed by an optional extension of 240 weeks (total duration of therapy 264 weeks)
62814765|NCT05528705|EXPERIMENTAL|LAENNEC|4ml once a week for 3 weeks of Subacromial spatial administration + conservative treatment
62814766|NCT05528705|ACTIVE_COMPARATOR|0.9% Normal saline|4ml once a week for 3 weeks of Subacromial spatial administration + conservative treatment
62238546|NCT00538304|EXPERIMENTAL|1|bimatoprost eye drops
62429139|NCT06110221||Gingivitis|This group demonstrated no detectable interproximal CAL or radiographical bone loss. PD was ≤3 mm and BOP (%) was ≥30% in the entire mouth.
62814767|NCT05493709|EXPERIMENTAL|FP-001 42 mg|All subjects will be pediatric patients with central precocious puberty. They will be injected twice with a depot formulation containing 42 mg of Leuprolide. The first dose on day 0 the second dose on week 24 (six months apart).
62814768|NCT01364896||Inflammatory bowel disease, Immunosuppressive agent|Men and women 18 years + with a histological diagnosis of IBD (ulcerative colitis or Crohn's disease) who are undergoing a colonoscopy prior to starting a non-corticosteroid immunosuppressive agent
62814769|NCT06566118|EXPERIMENTAL|Intervention Group|Active auricular VSS was applied to the participants in Group 1 after exercise loading.
62814770|NCT06566118|SHAM_COMPARATOR|Sham Group|Sham auricular VSS was applied to the participants in Group 2. During the application, the device was shown to the participants while it was being operated, but no current was given to the participants because non-conductive headphones were used.
62814771|NCT04416204|EXPERIMENTAL|Type 2 diabetes|Participants with Type 2 Diabetes received Glycogen loading (GL) and Non-Glycogen loading (NGL) meal in a randomized manner.
62814772|NCT04416204|EXPERIMENTAL|Participants without diabetes|Participants with no Diabetes received Glycogen loading (GL) and Non-Glycogen loading (NGL) meal in a randomized manner.
62814773|NCT01702974|ACTIVE_COMPARATOR|Vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
62429140|NCT06110221||Periodontal health|This healthy control group had an intact periodontium without detectable CAL and radiographical bone loss. PD was ≤3 mm and BOP (%) was \<10% in the entire mouth.
62814774|NCT01702974|PLACEBO_COMPARATOR|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
62238547|NCT00538304|PLACEBO_COMPARATOR|2|placebo
62429141|NCT01197456||Exposed/chemotherapy|Breast cancer patients who will undergo chemotherapy
62429142|NCT01197456||Unexposed|Breast cancer patients who will not undergo chemotherapy
62429143|NCT05221385|EXPERIMENTAL|Experimental cohort|Gentulizumab monotherapy 0.1, 0.3, 1, 3, 10, 30, 45 mg/kg administered intravenously once every week.
62429144|NCT04495465|EXPERIMENTAL|Experimental group: manual therapy + shock waves|Four sessions (one per week along one month) of manual therapy (25 minutes of massage on neck muscles) and 3 minutes (2000 shocks aproximately) of extracorporeal radial shock waves therapy on painful points of neck muscles at 2 bars and 10 Hetzs.
62429145|NCT04495465|PLACEBO_COMPARATOR|Control group: manual therapy + placebo shock waves|Four sessions (one per week along one month) of manual therapy (25 minutes of massage on neck muscles) and 3 minutes (2000 shocks aproximately) of placebo extracorporeal radial shock waves therapy on painful points of neck muscles.
62429146|NCT00619619|EXPERIMENTAL|A|
62238548|NCT01494454|EXPERIMENTAL|rhBMP-2/BCP|
62429147|NCT04167488|EXPERIMENTAL|Actigraphic measurement|
62814775|NCT06479343|EXPERIMENTAL|Liquid Embolic System (Tonbridge)|
62814776|NCT06479343|ACTIVE_COMPARATOR|Onyx Liquid Embolic System (Medtronic)|
62814777|NCT00681382||1|Asthma patients using inhaled steroids as maintenance treatment
62814778|NCT05226507|EXPERIMENTAL|Part A: Dose Escalation|Escalating doses of NXP800 administered orally once or twice daily.
62814779|NCT05226507|EXPERIMENTAL|Part B: Expansion in Ovarian Cancers Cohort 1|Subjects will be treated with NXP800 at 50 mg/day orally.
62814780|NCT05226507|EXPERIMENTAL|Part B: Expansion in Ovarian Cancers Cohort 2|Subjects will be treated with NXP800 at 75 mg/day orally.
62814781|NCT05589389|EXPERIMENTAL|High Healthy Eating Index Diet with Minimally Processed Meat|Participants will consume a diet with a high Healthy Eating Index along with meat that is minimally processed.
62814782|NCT05589389|EXPERIMENTAL|High Healthy Eating Index Diet with Further Processed Meat|Participants will consume a diet with a high Healthy Eating Index along with meat that is further processed.
62814783|NCT05589389|EXPERIMENTAL|Typical Healthy Eating Index Diet with Minimally Processed Meat|Participants will consume a diet with a typical Healthy Eating Index along with meat that is minimally processed.
62814784|NCT05589389|EXPERIMENTAL|Typical Healthy Eating Index Diet with Further Processed Meat|Participants will consume a diet with a typical Healthy Eating Index along with meat that is further processed.
62814785|NCT04864522|EXPERIMENTAL|SLAMF7 FPBMC|Participants will undergo apheresis to collect cells to make SLAMF7 fresh peripheral blood mononuclear cells (FPBMC). These cells will be activated in the lab to fight against multiple myeloma. About 3-4 days after apheresis, participants will start receiving infusions of SLAMF7 FPBMC. Throughout treatment, participants will have blood taken for labs, to check disease status and also to look at immune response. Study treatment will stop if the participant has disease progression.
62814786|NCT05460754|EXPERIMENTAL|Organic grass-fed beef, then conventional-fed beef|Participants receive an organic grass-fed steak meal in the morning. After a washout period of at least 7 days, they then receive the alternative meal, conventional-fed steak meal in the morning.
62814787|NCT05460754|EXPERIMENTAL|Conventional-fed beef, then organic grass-fed beef|Participants receive a conventional-fed steak meal in the morning. After a washout period of at least 7 days, they then receive the alternative meal, an organic grass-fed steak meal in the morning.
62238549|NCT01494454|ACTIVE_COMPARATOR|Autograft|
62238550|NCT02868177|EXPERIMENTAL|Totum-63|The studied active product is a food supplement formula in shape of capsule which contains Totum-63 (a patented mixture of dry extracts from 5 plants), active ingredient of Valedia
62238551|NCT02868177|PLACEBO_COMPARATOR|Placebo|The comparative product is a placebo with the same characteristics of appearance and packaging in which all ingredients are replaced by maltodextrin.
62238552|NCT04190433|ACTIVE_COMPARATOR|Group I (carvedilol, lisinopril)|Patients receive carvedilol orally (PO) and lisinopril orally (PO), up-titrated to maximum tolerated doses as per standard clinical practice for 6 months.
62238553|NCT04190433|EXPERIMENTAL|Group II (pravastatin, spironolactone)|Patients receive standard clinical practice therapy as in Group I. Patients also receive pravastatin PO and spironolactone PO for 6 months.
62238554|NCT02009891||Control|Control couples who will not use predictive model
62238555|NCT02009891||Predictive model|Couples who will use predictive model
62238556|NCT00954174|EXPERIMENTAL|Arm I (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1.
62238557|NCT00954174|EXPERIMENTAL|Arm II (paclitaxel, ifosfamide)|Patients receive ifosfamide IV over 1 hour on days 1-3 followed by paclitaxel as in Arm I.
62238558|NCT04286568|EXPERIMENTAL|WOW Intervention|"Participants will receive blood pressure monitor and health passport to record blood pressure readings for 3 months.~Participants will receive daily text message reminders to take and record blood pressure readings.~Participants will receive health education and health care navigation. Participants will be assessed for social determinants of health. Participants will take surveys 3 times over 3 months. Participants will receive home visits or phone calls to collect data and receive health coaching."
62238559|NCT02711618|EXPERIMENTAL|UltraShape Contour I V3 treatment|Up to 60 healthy adult volunteers seeking noninvasive fat reduction, male and females at up to four sites, age of 18 to 60, with BMI above 28
62429148|NCT01354639||Group 1|Group 1 : conventional open thyroidectomy group (papillary thyroid carcinoma patient who underwent conventional open bilateral total thyroidectomy procedure and postoperative low dose RAI therapy)
62814788|NCT04627818||patients with a mullerian variation|
62814789|NCT04426929|EXPERIMENTAL|Conventional Group|Electrotherapy program will be applied to all individuals. conventional exercise therapy will be applied to this group.
62238560|NCT05659433|ACTIVE_COMPARATOR|B-mode Ultrasound-guided Biopsy|
62238561|NCT05659433|EXPERIMENTAL|Contrast-enhanced Ultrasound-guided Biopsy|
62814790|NCT04426929|EXPERIMENTAL|Closed Chain Exercise Group|An exercise program consisting of 3 phases that runs from simple to difficult and includes closed kinetic chain exercises and proprioceptive exercises will be implemented in this group.
62814791|NCT04426929|EXPERIMENTAL|Video Based Exercise Group|Video based exercise program will be applied to the this group.
62238562|NCT02292368|EXPERIMENTAL|Acupuncture - One Type|"Participants recruited between weeks 3-5 of radiotherapy. Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.~At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.~Participants also have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes."
62429149|NCT01354639||Group 2|Group 2 : robotic thyroidectomy group (papillary thyroid carcinoma patient who underwent robotic bilateral total thyroidectomy procedure and postoperative low dose RAI therapy)
62429150|NCT04001205||No oral anticoagulation|Patients without oral anticoagulation for AF
62814792|NCT05998369|EXPERIMENTAL|Empowered Relief for Youth|Empowered Relief for Youth is a single-session pain management class focused on pain science education and teaching self-regulatory skills for pain management based on the evidence-based adult ER class.
62814793|NCT02498925|EXPERIMENTAL|Anhedonic teens receiving Behavioral Activation (BA)|"12 weeks (1 50-min session per week) of Behavioral Activation for the anhedonic adolescents.~Behavioral Activation is a psychosocial treatment for depression focused on gradually re-engaging patients with sources of reinforcement and reward in their environment (e.g., increasing activites and interpersonal interactions). In contrast to Cognitive Behavioral Therapy, and as the name implies, Behavioral Activation focuses on behavioral strategies to improve mood and places little emphasis on cognitive restructuring techniques."
62429151|NCT04001205||Oral anticoagulation|Patients with long term oral anticoagulation
62429152|NCT03056352|EXPERIMENTAL|Metoclopramide|Metoclopramide 20mg + diphenhydramine 25mg administered intravenously over 15 minutes
62429153|NCT01315366|ACTIVE_COMPARATOR|High dose vitamin D|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) Ci-Cal D daily, plus a supplement of vitamin D3 EuroD (20,000 IU/wk) for one year.
62429154|NCT01315366|PLACEBO_COMPARATOR|Low dose Vitamin D|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) Ci-Cal D daily, plus a weekly placebo (EURO D Placebo) supplement for one year.
62429155|NCT03446079|EXPERIMENTAL|Primary Subjects|Male or female subjects 21 or older that meet the specified inclusion/exclusion criteria taking genetic test and applying topical anti aging cream per the protocol.
62814794|NCT02498925|NO_INTERVENTION|Non-anhedonic teens (not receiving BA)|A group of adolescents with no anhedonia were recruited
62429156|NCT04800900|EXPERIMENTAL|Pharmaceutical intervention|A pharmacist will analyse patient's prescription, identify if there is prescribing omission and inappropriated drug prescribed and when necessary will require to doctors
62596669|NCT05053048|ACTIVE_COMPARATOR|NT-SL-PLUS Stem|Rectangular SL straight stems made of titanium alloy (Ti-6Al-7Nb). The experimental stem (NT SL-PLUS) underwent alumina grit blasting to reach the adequate roughness of 4-6 micron. The surface of the NT SL-PLUS stem was thereafter additionally treated chemically by short-acid etching with HF and mechanically by dry ice blasting in order to loosen and remove the residual alumina particles up to 96% without changing the existing surface microtopography.
62596670|NCT06313476||Patients|Premenopausal patients with early breast cancer who received chemotherapy (neoadjuvant chemotherapy or adjuvant chemotherapy) and did not use OFS ovarian suppression at the Breast Cancer Center of Sun Yat-sen Memorial Hospital, Sun Yat-sen University
62596671|NCT06553729|ACTIVE_COMPARATOR|Vitamin D3 + Prebiotics|Vitamin D3 (cholecalciferol), 1600 IU per day. Prebiotics (inulin), 10g per day.
62596672|NCT06553729|ACTIVE_COMPARATOR|Vitamin D3 + Prebiotics placebo|Vitamin D3 (cholecalciferol), 1600 IU per day. Prebiotics placebo.
62596673|NCT06553729|ACTIVE_COMPARATOR|Prebiotics +Vitamin D3 placebo|Prebiotics (inulin), 10g per day. Vitamin D3 placebo.
62596674|NCT06553729|PLACEBO_COMPARATOR|Vitamin D3 placebo + Prebiotics placebo|Vitamin D3 placebo. Prebiotics placebo.
62596675|NCT06305676||Case Group|Case group will consist of early and late disease pre-treatment Oropharyngeal Cancer cases.
62596676|NCT06305676||Control Group|Controls will be enrolled from members of the catchment area to ensure geographic comparability of cases and controls. Controls will be matched by sex, age, race/ethnicity, and tobacco use.
62814795|NCT06464458|NO_INTERVENTION|Arm A (Control)|DDepending on haematological tolerance (MTD), dose adjustment is proposed if necessary to achieve neutrophils between 1.5 - 3.0 G/L and reticulocytes between 100 - 200 G/L, without exceeding the maximum dose of 35 mg/kg. The titration step is 5 mg/kg except in the case of CrCl ≤ 60 ml/min; 2.5 mg/kg step in this case.
62243451|NCT03829709|EXPERIMENTAL|Intervention Group|The inspiratory muscle training (IMT) will be performed in the morning shift for 30 minutes, 3 times a week for 5 weeks. The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).
62429157|NCT05951517|EXPERIMENTAL|mycophenolate mofetil in refractory gastrointestinal Henoch-Schönlein purpura|patients who were resistant to steroid were treated with MMF
62429158|NCT04553484||All subjects enrolled|The feasibility of conducting all three tests, echocardiography (Echo), Brain Natriuretic Peptide (BNP) and volume plethysmography (VP), on all subjects met the enrollment criteria.
62429159|NCT02801851|EXPERIMENTAL|Intervention SCREEN-ED|This is the arm that will receive the SCREEN-ED. SCREEN-ED is an innovative, yet practical intervention that combines screening with informing clinicians of the results and provides a checklist for delirium management that is tailored to the time-limited ED setting.
62429160|NCT06253754||Postdural puncture headache after lumbar puncture|Group of patients with aged 20-40 years undergoing planned neurological work-up including a lumbar puncture (LP). The group will include 40 subjects with and 40 subjects without PDPH.
62596677|NCT04570852|EXPERIMENTAL|Intensive monitoring of patients|State of the art biochemical assessment of patients with acute pancreatitis including multi-OMICS focusing on transcriptomics and proteomics.
62596678|NCT02977325||Physical activity|One group participated in therapeutic programs centered on the physical activity
62596679|NCT02977325||water cure exclusively|This group followed exclusively the water cure
62596680|NCT05186636||ICU patients receiving renal replacement therapy|All patients in participating ICU's receiving CRRT or IRRT during the study period
62596681|NCT03936465|EXPERIMENTAL|Arm 1 Cohort A|"* Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.~* Patients with unselected relapsed or refractory solid tumors or lymphoma"
62596682|NCT03936465|EXPERIMENTAL|Arm 1 Cohort B|"* Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.~* Patients with relapsed or refractory solid tumors or lymphoma that have defined molecular features predicted to increase sensitivity to BET inhibition"
62596683|NCT03936465|EXPERIMENTAL|Arm 2 Cohort A|"* Patients will receive BMS-986378 (also known as CC-90010) monotherapy orally for 4 days every 28 days.~* Patients with relapsed or refractory CNS tumors or CNS metastatic tumors"
62596684|NCT03936465|EXPERIMENTAL|Arm 2 Cohort B|"* Patients will receive BMS-986378 (also known as CC-90010) monotherapy orally for 4 days every 28 days.~* Patients with relapsed or refractory CNS tumors or CNS metastatic tumors that have defined molecular features predicted to increase sensitivity to BET inhibition"
62596685|NCT06464848||FEP|Participants recruited from PEPsy-CM trial
62814796|NCT06464458|EXPERIMENTAL|Arm B|"HU dose adaptation according:~* HU AUC with a target AUC and subject to haematological tolerance.~* T2H (at V2, V3, V4), subject to haematological tolerance."
62814797|NCT01885429|EXPERIMENTAL|Positive Control|Group 1 (Positive(+) Control) will receive: 25g of whey protein. Positive Control
62814798|NCT01885429|EXPERIMENTAL|Negative Control|Group 2 (Negative(-) Control) will receive: 6.25g whey. Negative Control
62596686|NCT06464848||Chronic|Participants recruited from psychiatric department of CHU de Nimes
62814799|NCT01885429|EXPERIMENTAL|Low Protein + Low Leucine Spike|Group 3 (Low Protein + Low Leucine Spike) will receive: 6.25g whey + low added leucine. Low Protein Low Leucine Spike
62814800|NCT01885429|EXPERIMENTAL|Low Protein + High Leucine Spike|Group 4 (Low Protein + High Leucine Spike) will receive: 6.25g whey + high added leucine. Low Protein High Leucine Spike
62814801|NCT01885429|EXPERIMENTAL|Low Protein + High Leucine + BCAA Spike|Group 5 (Low Protein + High Leucine + BCAA Spike) will receive: 6.25g whey + added branched-chain amino acids. Low Protein + High Leucine + BCAA Spike
62037249|NCT06337175|ACTIVE_COMPARATOR|Hemorragic transformation group|One hundred fifty-two acute ischemic stroke (AIS) patients who had hemorrhagic transformation of brain infarction after 24-36 hours of receiving alteplase.
62814802|NCT05224271||Observational (surveys, medical records & Fitbit collection)|Patients complete surveys via the Hugo Platform at baseline (before treatment), after treatment, and at 3 and 6 months after treatment. Patients' medical records and Fitbit information are also collected into the Hugo Platform.
62814803|NCT05441384|EXPERIMENTAL|CBT/Existential Group Therapy for Fear of Cancer Recurrence|Participants will receive 7 weekly group therapy sessions consisting of psychoeducation on fear of cancer recurrence, relaxation training, CBT, and evidenced-based tips to decrease avoidance and anxiety surrounding fear of cancer recurrence.
62814804|NCT05441384|NO_INTERVENTION|Wait-list Control Group|Participants assigned to this arm wait about 3-months to receive the intervention.
62814805|NCT00521950|EXPERIMENTAL|Intervention, TPMT genotyping|Pre-treatment TPMT genotyping to optimize initial thiopurine treatment dose. Intervention is based on the genotype.
62037250|NCT06337175|ACTIVE_COMPARATOR|non-hemorragic transformation group|Four hundred sixty-four acute ischemic stroke (AIS) patients did not have a hemorrhagic transformation of brain infarction after 24-36 hours of receiving alteplase.
62037251|NCT04938245||Observed Cohort|Participants with chronic pain scheduled to undergo externalized trial for assessment of spinal cord stimulation will undergo intraoperative stimulation and up to three postoperative visits where already externalized electrodes (used clinically for stimulation) will be used to record and stimulate using evoked complex action potentials (ECAPs) while also measuring other electrophysiological responses.
62429161|NCT06253754||Postdural puncture headache after accidental dural puncture|Group of parturients with EDA. The group will include 40 subjects with accidental dural puncture (ADP) with PDPH and 40 subjects without ADP and PDPH.
62037252|NCT01261611|EXPERIMENTAL|Dysport NG|"500U (1mL) administered as intramuscular injection on day 1 of treatment cycle 1 and 2.~250U (0.5mL), 500U (1mL) or 750U (1.5mL) administered as intramuscular injection on day 1 of treatment cycle 3.~250U (0.5mL), 500U (1mL), 750U (1.5mL) or 1000U (2mL) administered as intramuscular injection on day 1 of treatment cycle 4 and 5."
62037253|NCT01261611|ACTIVE_COMPARATOR|Dysport|500U (1mL) injected as intramuscular injection on day 1 of treatment cycle 1.
62814806|NCT00521950|ACTIVE_COMPARATOR|control|Standard thiopurine treatment
62814807|NCT06015945|EXPERIMENTAL|Transcutaneous Electrical Acustimulation (TEA)|
62814808|NCT01105819|OTHER|Standard oral care with chlorhexidine|The control group will receive a standard oral care. This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed
62814809|NCT01105819|ACTIVE_COMPARATOR|Lactobacillus plantarum 299|The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
62814810|NCT01710345|EXPERIMENTAL|Sufentanil NanoTab 20 mcg|Sufentanil NanoTab 20 mcg as needed every 60 minutes for 12 hours
62814811|NCT01710345|EXPERIMENTAL|Sufentanil NanoTab 30 mcg|Sufentanil NanoTab 30 mcg as needed every 60 minutes for 12 hours
62037254|NCT01261611|PLACEBO_COMPARATOR|Placebo|1mL administered as, intramuscular injection on day 1 of treatment cycle 1.
62037255|NCT05737875||Distal pancreatectomy|Patients who have undergone a distal pancreatectomy, retrospective analysis of post pancreatectomy fistula risk factors
62814812|NCT01710345|PLACEBO_COMPARATOR|Placebo NanoTab|Placebo NanoTab as needed every 60 minutes for 12 hours
62814813|NCT04543396|EXPERIMENTAL|Physical Thearpy + Resistance Training|Subjects will receive standard of care treatments from their physical therapist. In addition, an investigative team member will customize a program of core-strengthening resistance exercises that will be prescribed to all intervention group subjects. Subjects will be expected to complete the protocol twice (2x) per week for an 8 week period. The protocol was approved by the Mayo Clinic IRB. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
62037256|NCT04116437|EXPERIMENTAL|Zanubrutinib|"Cohort 1: Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) previously treated with ibrutinib~Cohort 2: Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) previously treated with acalabrutinib alone/with ibrutinib"
62037257|NCT02546661|EXPERIMENTAL|Module A: AZD4547 Monotherapy|"AZD4547 will be given orally twice daily until disease progression.~Patients who receive AZD4547 as monotherapy will have the option to cross over to durvalumab as monotherapy at the point of objective progression, as long as the following criteria are met:~* The investigator believes it is in the patient's interest to receive durvalumab;~* The patient consents to the continued treatment;~* It is clinically appropriate for the patient to continue on durvalumab treatment;~* The patient satisfies the key eligibility criteria for receiving durvalumab treatment."
62037258|NCT02546661|EXPERIMENTAL|Module A: MEDI4736 (durvalumab) + AZD4547|AZD4547 will be given orally twice daily until disease progression. Patients will also receive MEDI 4736 (durvalumab) by IV infusion once every 4 weeks.
62814814|NCT04543396|NO_INTERVENTION|Physical Thearpy|Subjects will receive standard of care treatments from their physical therapist. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
62243452|NCT06506266|EXPERIMENTAL|HFA-152a followed by HFA-134a|
62814815|NCT04543396|EXPERIMENTAL|Chiropractic Care + Resistance Training|Subjects will receive standard of care treatments from their chiropractor. In addition, an investigative team member will customize a program of core-strengthening resistance exercises that will be prescribed to all intervention group subjects. Subjects will be expected to complete the protocol twice (2x) per week for an 8 week period. The protocol was approved by the Mayo Clinic IRB. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
62814816|NCT04543396|NO_INTERVENTION|Chiropractic Care|Subjects will receive standard of care treatments from their chiropractor. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
62429162|NCT06424678||Cradiorespiratory arrest in paediatric patients|The epidemiology of the data collected in the Utstein template will be described in patients who suffer cardiac arrest in the surgical block and have an age between 1 month and 1 day to 18 years.
62814817|NCT06032065|EXPERIMENTAL|Supervised treadmill exercise + nitrate rich beetroot juice|This group will be participating in Supervised Treadmill Exercise and drinking nitrate rich beetroot juice for 12 weeks.
62814818|NCT06032065|PLACEBO_COMPARATOR|Supervised treadmill exercise + placebo|This group will be participating in Supervised Treadmill Exercise and drinking placebo beetroot juice with nitrate removed for 12 weeks.
62814819|NCT06032065|EXPERIMENTAL|Home-based walking exercise + nitrate rich beetroot juice|This group will be participating in Home-Based Exercise and drinking nitrate rich beetroot juice for 12 weeks.
62814820|NCT06032065|PLACEBO_COMPARATOR|Home-based walking exercise + placebo|This group will be participating in Home-Based Exercise and drinking placebo beetroot juice with nitrated removed for 12 weeks.
62814821|NCT03388632|EXPERIMENTAL|lead-in doublet A|lead-in doublet for initial safety evaluation: rhIL-15 given SC days 1-8 and 22- 29 + ipilimumab (anti- CTLA-4) given IV on day 8 (IL-15 doses are limited to first 4 cycles only)
62814822|NCT03388632|EXPERIMENTAL|lead-in doublet B|lead-in doublet for initial safety evaluation: rhIL-15 given SC days 1-8 and 22- 29 + nivolumab (anti-PD1) given IV on days 8, 22, and 36 (IL-15 doses are limited to first 4 cycles only)
62814823|NCT03388632|EXPERIMENTAL|triplet|triplet combination
62429163|NCT06424678||cardiorespiratory arrest in adult patients|The epidemiology of the data collected in the Utstein template will be described in patients who suffer cardiac arrest in the surgical block and are aged from 18 years and 1 day to 11o years.
62429164|NCT01789008|OTHER|Transient elastography|evaluation of fibrosis stage by transient elastography
62429165|NCT01789008|ACTIVE_COMPARATOR|liver biopsie|evaluation of fibrosis stage by liver biopsie
62429166|NCT01493531|EXPERIMENTAL|lesinurad 200 mg + allopurinol|
62429167|NCT01493531|EXPERIMENTAL|lesinurad 400 mg + allopurinol|
62429168|NCT01493531|PLACEBO_COMPARATOR|Placebo + allopurinol|
62429169|NCT02173626|OTHER|GSH Medical Staff|Volunteers from the Good Samaritan Hospital medical staff were included on a first come first serve basis
62429170|NCT06552377||All participants|Ultrasound attenuation imaging measurement
62429171|NCT03402620|ACTIVE_COMPARATOR|four ampoules group|gonadotropin starting dose is 4 ampoules daily
62243453|NCT06506266|EXPERIMENTAL|HFA-134a followed by HFA-152a|
62429172|NCT03402620|ACTIVE_COMPARATOR|six ampoules group|gonadotropin starting dose is 6 ampoules daily
62429173|NCT03865524|EXPERIMENTAL|Experimental|Total knee arthroplasty implanted with GPS navigation system.
62429174|NCT03865524|ACTIVE_COMPARATOR|Control|Total knee arthroplasty implanted with standard guides.
62429175|NCT06295575|ACTIVE_COMPARATOR|Treatment group|In treatment group, patients received 1×109 colony forming units (CFU) /day of probiotic, which was provided by Hangzhou Grand Biologic Pharmaceutical INC (Zhejiang, China) in the form of freeze-dried powder containing Bifidobacterium infantis and Lactobacillus with a density of 109 CFU/g. The probiotic powder was mixed with lactose and portioned into sachets with the help of Nanjing Medical University Central Pharmacy.
62429176|NCT06295575|PLACEBO_COMPARATOR|Control group|Patients in the control group received lactose as placebo. The placebo was packed in sachets and provided in the same way as treatment group.
62429177|NCT01957631|ACTIVE_COMPARATOR|Corticosteroid injection|Corticosteroid injection
62429178|NCT01957631|EXPERIMENTAL|Platelet rich plasma injection|Platelet rich plasma injection
62429179|NCT03719729|EXPERIMENTAL|Single|Each subject will receive rifaximin 550 mg twice a day for up to one year.
62429180|NCT04493060|EXPERIMENTAL|Treatment (niraparib, dostarlimab)|Patients receive niraparib PO QD on days 1-21. Patients also receive dostarlimab IV over 30 minutes on day 1 Q3W for cycles 1-4 and Q6W for subsequent cycles. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62596687|NCT06464848||Controls|Recruited from social media and word of mouth
62596688|NCT06080594|EXPERIMENTAL|Exercise leg|High-intensity exercise training for one leg
62037259|NCT02546661|EXPERIMENTAL|Module B: MEDI4736 (durvalumab) + Olaparib|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. Olaparib will be given orally twice daily.
62037260|NCT02546661|EXPERIMENTAL|Module C: MEDI4736 (durvaluamb) + AZD1775|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. AZD1775 will be given orally in approximate 12 hour intervals over 3 days (6 doses) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
62238563|NCT02292368|EXPERIMENTAL|Acupuncture - Different Type|"Participants recruited between weeks 3-5 of radiotherapy. Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.~At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.~Participants also have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes."
62429181|NCT03680482|OTHER|Intervention ingest a 48 mg of sucralose|Intervention: Subjects with type 2 diabetes who ingest a 48 mg of sucralose. Sucralose is a non-caloric sweetener derived from sucrose and is 600 times more sweet than sucrose.
62429182|NCT03680482|NO_INTERVENTION|Intervention ingest a water (control group)|Subjects with type 2 diabetes who ingest a water (control group)
62037261|NCT02546661|EXPERIMENTAL|Module D: MEDI4736 (durvalumab) monotherapy|MEDI 4736 (durvalumab) will be given by IV infusion once every 4 weeks.
62429183|NCT03680482|OTHER|Intervention ingest a 96 mg of stevia|"Intervention: Subjects with type 2 diabetes who ingest a 96 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet."
62814824|NCT05027594|EXPERIMENTAL|Dose Escalation Part|Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
62814825|NCT05027594|EXPERIMENTAL|Dose Expansion Part - NMS-03597812 single agent|Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
62037262|NCT02546661|EXPERIMENTAL|Module E: MEDI4736 (durvalumab) + Vistusertib|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. Vistusertib will be given orally twice per day on an intermittent schedule (2 days on, 5 days off).
62037263|NCT02546661|EXPERIMENTAL|Module F: MEDI4736 (durvaluamb) + AZD9150|AZD9150 will be given as monotherapy on Days -7, -5, and -3 of a one week lead-in period. Combination dosing with IV AZD9150 followed by IV MEDI4736 (durvalumab) begins on Day 1 of each 28 day cycle. Thereafter AZD9150 is given weekly and MEDI4736 is given once every 4 weeks.
62814826|NCT05027594|EXPERIMENTAL|Dose Expansion Part - NMS-03597812 in combination with dexamethasone|Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
62814827|NCT06334822|EXPERIMENTAL|Standard Care + Heartfelt device|In addition to standard care activities, participants have the Heartfelt device at home. During this arm, the device sends alerts and measurement data to the patient, carers and clinicians.
62037264|NCT02546661|EXPERIMENTAL|Module G: MEDI4736 + Selumetinib|
62037265|NCT00362518|PLACEBO_COMPARATOR|1|Study Arm A - Control: no vitamins (placebo only).
62238564|NCT01031264||Social drinkers|
62238565|NCT01209312|EXPERIMENTAL|full bolus -20|Will administer full insulin bolus 20 minutes prior to meal
62238566|NCT01209312|EXPERIMENTAL|Full bolus, T0|Will administer full meal bolus at the start of the meal
62238567|NCT01209312|EXPERIMENTAL|1/2 bolus, T-20|Will only give half the insulin dose 20 minutes before meal
62238568|NCT01209312|EXPERIMENTAL|1/2 bolus T0|Will give half the amount of insulin at the time of the meal
62238569|NCT00982007|EXPERIMENTAL|Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)|Intravenous (IV) iron
62596689|NCT06080594|NO_INTERVENTION|Control leg|No exercise training for the controlateral leg
62596690|NCT04425473|EXPERIMENTAL|Esketamine|
62596691|NCT04425473|PLACEBO_COMPARATOR|Placebo|
62037266|NCT00362518|ACTIVE_COMPARATOR|2|Study Arm B - Low Dose: Vitamin C 250 mg, Vitamin E 200 IU
62037267|NCT00362518|ACTIVE_COMPARATOR|3|Study Arm C - Medium Dose: Vitamin C 500 mg, Vitamin E 400 IU
62238570|NCT00982007|ACTIVE_COMPARATOR|Cohort 1 (Group B) - Ferrous Sulfate|Oral iron - Ferrous Sulfate tablets
62238571|NCT00982007|ACTIVE_COMPARATOR|Cohort 2 (Group D) - IV Iron (standard of care)|Other IV iron
62238572|NCT00982007|EXPERIMENTAL|Cohort 2 (Group C) - Ferric Carboxymaltose (FCM)|Intravenous (IV) iron
62814828|NCT06334822|ACTIVE_COMPARATOR|Standard care (control)|In addition to standard care activities, participants have the Heartfelt device at home. During this arm, data is captured without sending health alerts or measurement data to the patient, carers and clinicians.
62814829|NCT06334822|EXPERIMENTAL|Standard Care + Heartfelt device in pharmacy|Participants will follow standard care advice, and have monthly measurements taken at the pharmacy using the Heartfelt device. The pharmacist will receive the measurements and alerts and be able to communicate this to the participant.
62814830|NCT00802581|EXPERIMENTAL|1|Ensuring circumferential spread of local anesthetic around the sciatic nerve.
62814831|NCT00802581|ACTIVE_COMPARATOR|2|Single shot injection of local anesthetic near the sciatic nerve will be performed, without ensuring circumferential spread.
62429184|NCT01327638||Patients with SpA/AS and etoricoxib treatment|
62814832|NCT02452307|EXPERIMENTAL|Peptide vaccine|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51
62814833|NCT02452307|EXPERIMENTAL|Peptide vaccine + GM-CSF|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with Granulocyte macrophage colony stimulating factor (GM-CSF)
62814834|NCT02452307|EXPERIMENTAL|Peptide vaccine + local hyperthermia|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with local hyperthermia
62814835|NCT02452307|EXPERIMENTAL|Peptide vaccine + Imiquimod|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with Imiquimod
62814836|NCT02452307|EXPERIMENTAL|Peptide vaccine + mRNA/Protamin|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with mRNA/Protamin
62814837|NCT03573882|OTHER|Voxelotor|Participants will receive voxelotor (GBT440) at the highest dose (either 900 mg or 1500 mg) deemed safe by the Data Safety Monitoring Board (DSMB).
62814838|NCT01246674||Hypothesis generating study|Consecutive total hip arthroplasty patients
62814839|NCT06091475|EXPERIMENTAL|Withdrawal of treatment with eplerenone or spironolactone, and empagliflozin and dapalgiflozin|Gradual, supervised withdrawal of ineralocorticoid receptor antagonists (spironolactone or eplerenone) and sodium glucose cotransporter 2 inhibitor (dapagliflozin or empagliflozin) over 4-16 weeks. Continued monitoring off study therapies during the cross-over phase.
62238573|NCT06287723||Stage IV colorectal liver metastasis patients|Stage IV colorectal liver metastasis patients treated with curative intent
62238574|NCT01881581|EXPERIMENTAL|Lower dose DNA or Placebo|2.0 mL lower dose D-GPEi (0.5mg) or Saline solution at weeks 0
62238575|NCT01881581|EXPERIMENTAL|Medium dose DNA or Placebo|2.0 mL medium dose D-GPEi (2mg) or Saline solution at weeks 0
62238576|NCT01881581|EXPERIMENTAL|High dose DNA or Placebo|2.0 mL high dose D-GPEi (4mg) or Saline solution at weeks 0
62429185|NCT01327638||Patients with SpA/AS and other COX-2 inhibitor treatment|
62238577|NCT01881581|EXPERIMENTAL|Lower dose MVA or Placebo|100μL lower dose M-GPE (3×10\^7pfu) or Saline solution at weeks 0
62238578|NCT01881581|EXPERIMENTAL|Medium dose MVA or Placebo|100μL medium dose M-GPE (1×10\^8pfu) or Saline solution at weeks 0
62238579|NCT01881581|EXPERIMENTAL|High dose MVA or Placebo|300μL high dose M-GPE (3×10\^8pfu) or Saline solution at weeks 0
62429186|NCT01327638||Patients with SpA/AS and nsNSAIDs treatment|
62238580|NCT01881581|EXPERIMENTAL|Low dose DNA+MVA or Placebo control|The dose below the maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1; The dose below the maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
62238581|NCT01881581|EXPERIMENTAL|High dose DNA+MVA or Placebo control|The maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1;The maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
62238582|NCT03035903|EXPERIMENTAL|Not holding, then holding the MedGem®|Subjects will be seated in an armless chair and have a RMR measurement taken while not holding, then holding a MedGem® Indirect Calorimeter.
62238583|NCT03035903|ACTIVE_COMPARATOR|Holding, then not holding the MedGem®|Subjects will be seated in an armless chair and have a RMR measurement taken holding, then not holding a MedGem® Indirect Calorimeter.
62429187|NCT02017535|ACTIVE_COMPARATOR|6 IPT-A Sessions|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) only.~During the Continuation IPT-A sessions, the therapist will continue to emphasize the interpersonal strategies that were learned and practiced during the acute phase, and address any current interpersonal problems before they result in a recurrence of depressive symptoms. Adolescents who have responded to acute phase treatment (CGI-I = much improved or very much improved) will attend 4 biweekly IPT-A sessions followed by 2 monthly sessions."
62814840|NCT06091475|NO_INTERVENTION|Continued treatment with eplerenone or spironolactone, and empagliflozin and dapagliflozin|Continuation of usually prescribed pharmacological therapy over 16 weeks followed by cross-over to withdrawal of SGLT2i and MRA over the subsequent 4-16 weeks.
62814841|NCT04800965|NO_INTERVENTION|Holdout Arm|In the Holdout arm, patients will not receive text messages about COVID-vaccine.
62814842|NCT04800965|EXPERIMENTAL|Simple Text Sub-arm|In the Simple Text sub-arm, participants will not receive any additional information.
62814843|NCT04800965|EXPERIMENTAL|Simple Text + Video Sub-arm|In the Simple Text+Video sub-arm, together with the appointment link, participants will also receive a link to a 2-minute video in the text message. The video contains information about the prevalence of COVID-19 and the effectiveness and safety of the COVID-19 vaccine.
62596692|NCT06271603|EXPERIMENTAL|Intervention Arm: Management performed with an initial diagnosis based on the LC-OCT device|The interventional procedure involves the management of BCC with an initial diagnosis based on the deepLive™ device. The imaging is performed by placing the probe tip in contact with the patient\&#39;s skin after applying an immersion oil (paraffin) to the imaging area. The examination lasts only a few minutes and is painless. An integrated dermoscopic targeting system allows the operator to ensure proper positioning of the probe on the lesion and to ensure that the entire lesion has been captured for an accurate diagnosis. The images are displayed in real-time during the examination and directly evaluated by the investigator, who has the option to save images/videos at their discretion. A final evaluation with the deepLive™ device will also be performed during the 1-year follow-up, and intermediate evaluations may also be performed with the deepLive™ device depending on the initial management of BCC.
62596693|NCT06271603|ACTIVE_COMPARATOR|Control Arm: Standard management with an initial diagnosis based on skin biopsy|The control procedure corresponds to standard management of BCC with an initial diagnosis based on skin biopsy (standard management arm). The biopsy will be performed according to the standard practice of each center, using a 2 to 6 mm punch or shave biopsy, with prior injection of a local anesthetic. A final evaluation with the deepLive™ device will also be performed during the 1-year follow-up.
62814844|NCT04800965|EXPERIMENTAL|Enhanced Text sub-Arm|In the Enhanced Text sub-arm, in addition to the appointment link, the text message will use enhanced language aimed at reducing psychological barriers that prevent patients from scheduling their appointment.
62814845|NCT04800965|EXPERIMENTAL|Enhanced Text + Video Sub-arm|In the Enhanced Text+Video sub-arm, in addition to the appointment link, the text message will encourage patients to watch a 2-minute video (the same as in the Simple Text+Video sub-arm) and use enhanced language aimed at reducing patients' psychological barriers of following through on scheduling an appointment.
62814846|NCT00259909||Subjects with COPD|Subject has a confirmed clinical diagnosis of COPD, with or without chronic bronchitis.
62814847|NCT00702481|EXPERIMENTAL|Nimotuzumab/CDDP/RT|Open label treatment arm of Nimotuzumab and cisplatin and radiation
62596694|NCT05350332|EXPERIMENTAL|Negative Pressure Ventilator|Participants with obstructive sleep apnea (OSA) who are being evaluated for surgical treatment of their OSA and having a routine clinical DISE will have their lung volume increased with a non-invasive negative pressure ventilator. Participants will also have a pulmonary function test performed per routine clinical protocol, but for research purposes only (i.e., not part of usual care).
62814848|NCT01237756|EXPERIMENTAL|pediatric|
62814849|NCT05668234||Parents|Parent having carried out and completed parent-child psychotherapy with a child in CHU Minjoz (child under 5 years old).
62238584|NCT05211739|OTHER|LID205255 Toric, then Biofinity Toric|Lehfilcon A toric contact lenses worn first, with comfilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) during waking hours for at least 5 days per week, with up to 10-12 hours wear time per day over a 30-day period. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
62429188|NCT02017535|ACTIVE_COMPARATOR|6 IPT-A Sessions + Continue Current Dose of Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.~Adolescents who have responded to acute phase treatment (CGI-I = much improved or very much improved) will attend 4 biweekly IPT-A sessions followed by 2 monthly sessions and will continue their acute phase fluoxetine dosing regimen and will meet with the psychiatrist on a monthly basis."
62596695|NCT05350332|EXPERIMENTAL|Transcutaneous Phrenic Nerve Stimulation|Participants with obstructive sleep apnea (OSA) who are being evaluated for surgical treatment of their OSA and having a routine clinical DISE will have their lung volume increased with transcutaneous phrenic nerve stimulation. Participants will also have a pulmonary function test performed per routine clinical protocol, but for research purposes only (i.e., not part of usual care).
62596696|NCT00790998|EXPERIMENTAL|Moxidectin|Moxidectin 8mg
62596697|NCT00790998|ACTIVE_COMPARATOR|Ivermectin|Ivermectin 150 mcg/kg
62596698|NCT05831839|OTHER|Cognitive training 1|Randomized wait-list controlled pilot trial
62814850|NCT03033277|PLACEBO_COMPARATOR|Control group|Hormone replacement therapy, placebo transplantation.
62814851|NCT03033277|EXPERIMENTAL|Experimental group|Hormone replacement therapy,HUC-MSCs transplantation.
62814852|NCT02638116|EXPERIMENTAL|Ibrutinib + Omeprazole|Participants will receive a dose of Ibrutinib 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7 and Omeprazole at a dose of 40 mg tablets orally once on Days 3 through 7.
62814853|NCT00206635||Group 1|
62037268|NCT00362518|ACTIVE_COMPARATOR|4|Study Arm D - High Dose: Vitamin C 1000 mg, Vitamin E 800 IU.
62037269|NCT01751438|EXPERIMENTAL|Best Systemic Therapy (BST)|Group 1 will continue to receive best systemic therapy (BST). Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete. Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
62814854|NCT06199635|EXPERIMENTAL|SNAP-S|Self-Forming Magnetic (SFM) Anastomosis Device and Delivery System being used to to Create a Primary Sleeve Gastrectomy Duodenal-Ileal Anastomosis
62814855|NCT06199635|EXPERIMENTAL|SNAP-PS|Self-Forming Magnetic (SFM) Anastomosis Device and Delivery System being used to to Create a Duodenal-ileal Anastomosis years after a Primary Sleeve Gastrectomy)
62814856|NCT06199635|EXPERIMENTAL|J-J|Self-Forming Magnetic (SFM) Anastomosis Device and Delivery System being used to to Create a Jejuno-Jejunostomy in a Roux-en-Y Gastric Bypass
62814857|NCT01649895|EXPERIMENTAL|D-Cycloserine|D-Cycloserine, 5 pills (50mg), once per week in 5 weeks.
62814858|NCT01649895|PLACEBO_COMPARATOR|Placebo|Placebo: 5 pills for 5 weeks, once per week.
62814859|NCT01733420|EXPERIMENTAL|Biodentine|Pulpotomy using Biodentine as pulpotomy medicine.
62429189|NCT02017535|EXPERIMENTAL|10 IPT-A Sessions + Begin Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.~Adolescents who received only IPT-A during acute phase and who showed a partial response (CGI-I = minimally improved) will attend 8 weekly IPT-A sessions followed by 2 monthly sessions and will begin treatment with fluoxetine during the continuation phase.The dosage schedule will be 10mg per day for the first week and 20mg per day for the following 5 weeks. If no treatment response is observed by the 6th week, the dosage can be increased to 40mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and biweekly thereafter. Pharmacotherapy sessions will include assessment of vital signs, adverse effects, safety, and symptomatic response."
62429190|NCT02017535|EXPERIMENTAL|10 IPT-A Sessions + Increase Dose of Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.~Adolescents who received IPT-A and fluoxetine during the acute phase and were partial responders (CGI-I = minimally improved) will attend 8 weekly IPT-A sessions followed by 2 monthly sessions and will have their fluoxetine dose increased to 60mg. Partial responders will meet with the psychiatrist biweekly for the first 2 months and monthly for the second 2 months."
62429191|NCT04322968|EXPERIMENTAL|Chronic pain with PTSD+IV ketamine infusion|
62429192|NCT04322968|ACTIVE_COMPARATOR|Chronic pain with PTSD+IV ketorolac infusion|
62814860|NCT01733420|ACTIVE_COMPARATOR|White Mineral trioxide Aggregate (MTA)|Pulpotomy using white MTA as pulpotomy medicine.
62814861|NCT01733420|ACTIVE_COMPARATOR|Tempophore|Pulpotomy using Tempophore as pulpotomy medicine in a control group.
62429193|NCT04322968|EXPERIMENTAL|Chronic pain without PTSD+IV ketamine infusion|
62429194|NCT04322968|ACTIVE_COMPARATOR|Chronic pain without PTSD+IV ketorolac infusion|
62429195|NCT03580759|EXPERIMENTAL|Exergaming|Subjects in the exergaming group will participate in three exergaming training sessions with the Wii Fit U exergaming system. The Wii Fit U will then be left in the subjects' homes for a minimum of four weeks prior to left ventricular assist device implantation or heart transplant.
62429196|NCT03580759|NO_INTERVENTION|Usual Care|Subjects in the usual care group will be encouraged to partake in physical activity as recommended in the 2017 AHA/ACC/HFSA guidelines for heart failure.
62429197|NCT05578885|PLACEBO_COMPARATOR|Group A|will receive Lidocaine
62429198|NCT05578885|ACTIVE_COMPARATOR|Group B|will receive Lidocaine Plus fentanyl
62429199|NCT05578885|ACTIVE_COMPARATOR|Group C|will receive lidocaine Plus dexamethasone
62429200|NCT02077959|EXPERIMENTAL|Treatment (lenalidomide, pidilizumab)|Patients receive lenalidomide PO daily on days 1-21 and pidilizumab IV over 1-2 hours on day 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62596699|NCT05831839|OTHER|Cognitive training 2|Randomized wait-list controlled pilot trial
62596700|NCT00588211||1|We will recruit fifteen New York University College of Dentistry (NYUCD) clinic patients who report current tobacco use.
62814862|NCT05408377|EXPERIMENTAL|MA group|Manual Acupuncture
62814863|NCT05408377|PLACEBO_COMPARATOR|SA group|Sham acupuncture
62596701|NCT00588211||2|Second, we will recruit thirty dental clinic smokers (10 per day for 3 days) from the NYUCD waiting room.
62814864|NCT02760459|ACTIVE_COMPARATOR|Dexamethasone|The steroid group will receive Dexamethasone 10 mg IV immediately prior to induction of spinal anesthesia and will receive a second and third dose of Dexamethasone 10 mg IV postoperatively at 24 and 48 hrs.
62596702|NCT00588211||3|Third, we will survey 200 student participants from Adelphi University.
62596703|NCT00588211||4|Queens Hospital Center with 800 patients.
62814865|NCT02760459|PLACEBO_COMPARATOR|Placebo|The control group will receive sterile normal saline solution, serving as placebo, IV immediately prior to induction of spinal anesthesia and will receive a second and third dose of placebo IV postoperatively 24 and 48 hrs. Both Dexamethasone and normal saline solution will be administered as an IV push.
62814866|NCT01874236|ACTIVE_COMPARATOR|1st sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
62814867|NCT01874236|ACTIVE_COMPARATOR|2nd sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
62814868|NCT01874236|ACTIVE_COMPARATOR|3rd sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
62814869|NCT06030596||coronary artery disease|Suspected or known coronary artery disease
62814870|NCT01766050|EXPERIMENTAL|Arm: Inje Cocktail + Belatacept|"Inje Cocktail consisting of (200 mg Caffeine, 50 mg losartan tablet, 40 mg Omeprazole capsule, 30 mg Dextromethorphan capsule and 5 mg Midazolam oral syrup) administered on Days 1, 4, 7 and 11~Belatacept 10 mg/kg Intravenous (IV) solution, administered on Day 4"
62814871|NCT02249806||PH target therapy|Patients receiving PH target therapy
62814872|NCT06066034||Normal group|With the informed consent of the patient, venous blood was extracted on an empty stomach in the morning, and follicular fluid from multiple follicles was extracted during the 5-9 day menstrual cycle
62814873|NCT06066034||Insulin resistance group|With the informed consent of the patient, venous blood was extracted on an empty stomach in the morning, and follicular fluid from multiple follicles was extracted during the 5-9 day menstrual cycle
62814874|NCT06066034||PCOS group|With the informed consent of the patient, venous blood was extracted on an empty stomach in the morning, and follicular fluid from multiple follicles was extracted during the 5-9 day menstrual cycle
62814875|NCT06066034||PCOS with insulin resistance group|With the informed consent of the patient, venous blood was extracted on an empty stomach in the morning, and follicular fluid from multiple follicles was extracted during the 5-9 day menstrual cycle
62814876|NCT03118414|EXPERIMENTAL|Physical Exercise Group|Physical Exercise (PE) is an intervention that aim to improve balance and muscle strength of the elders. It composed of 3 steps; warming up exercise, core content of the exercise (strength and balance training) and cool down exercise program.
62814877|NCT03118414|EXPERIMENTAL|Virtual Reality|Virtual Reality (VR) VR is an intervention that aim to improve balance of the elders. It stimulates the auditory and visual function and concentration of the participants throughout the training. It composed of 10 games that included weight shifting from side to side, stepping into different directions, trunk flexion, extension and side bending, movements of the upper and lower limbs, and trunk twisting in this study.
62814878|NCT03118414|EXPERIMENTAL|Brain Exercise|"Brain Exercise (BE) BE is an intervention that aim to stimulate the cognitive function of the elders.~It stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training"
62429201|NCT02757300|EXPERIMENTAL|Hypopharyngeal packing|"Patients with indication for surgery of the sinuses were randomly assigned to one of the two study groups.~After standardized anaesthetic management and PONV prophylaxis routinely applied the patients were screened for mucosal injury on second postoperative day. Furthermore, the amount of analgetic and anti-emetic drugs and the severity of pain and PONV were recorded throughout the hospital stay."
62429202|NCT02757300|ACTIVE_COMPARATOR|Without hypopharyngeal packing|"Patients with indication for surgery of the sinuses were randomly assigned to one of the two study groups.~After standardized anaesthetic management and PONV prophylaxis routinely applied the patients were screened for mucosal injury on second postoperative day. Furthermore, the amount of analgetic and anti-emetic drugs and the severity of pain and PONV were recorded throughout the hospital stay."
62429203|NCT04695639||cohort group|A convenient sample of children with spastic hemiparetic CP of both genders will participate in this study. To avoid type II error, sample size calculation was performed prior to the study, based on data of pilot study, using G\*POWER statistical software (version 3.1.9.2; Franz Faul, Universitat Kiel, Germany) \[Exact tests- correlational study, α=0.05, β=0.2, and effect size = 0.4\] and revealed that the appropriate sample size for this study is N=46.
62429204|NCT02323139|EXPERIMENTAL|Combination of azacitidine and LDE255|Combination of azacitidine at maximum tolerated dose and LDE255 at dose escalation, the starting dose will be 400 mg
62596704|NCT05839405||Non Allergic|Recruited patients whose medical records indicate they are not allergic to the foods they were in clinic for
62814879|NCT03118414|NO_INTERVENTION|Control Group|No Intervention: Healthy control No intervention was given to this group of participants. The control group was reminded not to participate in any other exercise or intervention program except their routine daily activities.
62814880|NCT04356222|EXPERIMENTAL|Leptomeningeal Metastasis|Durvalumab + Intrathecal chemotherapy
62814881|NCT02654782|ACTIVE_COMPARATOR|Lactated Ringer's|Subjects randomized to Lactated Ringer's for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.
62814882|NCT02654782|ACTIVE_COMPARATOR|5% Human Albumin|Subjects randomized to 5% human albumin for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.
62238585|NCT05211739|OTHER|Biofinity Toric, then LID205255 Toric|Comfilcon A toric contact lenses worn first, with lehfilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) during waking hours for at least 5 days per week, with up to 10-12 hours wear time per day over a 30-day period. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
62238586|NCT02755623|ACTIVE_COMPARATOR|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|low-frequency (1 Hertz) rTMS
62238587|NCT02755623|SHAM_COMPARATOR|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|sham TMS
62429205|NCT05199311|EXPERIMENTAL|Starting Dose -1|"CC-220/Iberdomide: 1.1 mg \[CC-220 dosing schedule: daily for 21 days of each 28-day cycle\]~Carfilzomib: 20 mg/m2 C1D1 56 mg/m2 thereafter \[Days 1, 8, 15 per 28-day cycle\]~Dexamethasone: 40 mg (≤ 75 years) 20 mg (\> 75 years) \[Days 1, 8, 15, 22 per 28-day cycle\]~Treatment will continue with carfilzomib, iberdomide, and dexamethasone for up to 4 cycles (28 days) at the physician's discretion followed by the Autologous Stem Cell Transplant. Patients will be followed every 3 months for up to 2 years, or until PD or the start of a new line of therapy."
62429206|NCT05199311|EXPERIMENTAL|Dose Level 1|"CC-220/Iberdomide: 1.3 mg \[CC-220 dosing schedule: daily for 21 days of each 28-day cycle\]~Carfilzomib: 20 mg/m2 C1D1 56 mg/m2 thereafter \[Days 1, 8, 15 per 28-day cycle\]~CC-220 dose level 1 enrollment will occur following an independent safety review two months after the first 10 patients have completed at least 2 cycles of therapy at dose level -1.~Dexamethasone: 40 mg (≤ 75 years) 20 mg (\> 75 years) \[Days 1, 8, 15, 22 per 28-day cycle\]~Treatment will continue with carfilzomib, iberdomide, and dexamethasone for up to 4 cycles (28 days) at the physician's discretion followed by the Autologous Stem Cell Transplant. Patients will be followed every 3 months for up to 2 years, or until PD or the start of a new line of therapy."
62596705|NCT05839405||Mild Allergic|Recruited patients whose medical records indicate they are allergic to the foods they were in clinic for, but only to a mild degree where they would be expected to experience mild, non-life threatening symptoms on exposure to the allergen
62814883|NCT02969122|ACTIVE_COMPARATOR|Chemotherapy-first|Patients will receive hyperthermic intraperitoneal chemotherapy (HIPEC) during laparoscopic staging. Then 3 cycles of preoperative chemotherapy and clinical evaluation of chemotherapy will be performed. If the patient's disease is evaluated as progressed, the patient will receive systemic therapy. If it's stable or remission, a second time laparoscopic staging and peritoneal cytology examination will be performed. If peritoneal implant is observed, the patients will receive systemic therapy. If the peritoneal cytology is still positive, the treatment will be decided according to the suggestion of MDT discussion. If the peritoneal cytology is converted negative, standard gastrectomy with D2 lymphadenectomy and extensive intraperitoneal lavage (EIPL) will be performed. Postoperative chemotherapy will be determined according to the pathological evaluation of preoperative chemotherapy response.
62596706|NCT05839405||Severe Allergic|Recruited patients whose medical records indicate they are allergic to the foods they were in clinic for, to a severe degree where they would be expected to experience severe symptoms on exposure to the allergen
62596707|NCT05629494|ACTIVE_COMPARATOR|Repeat serum PSA test|Repeat PSA test at 6 (± 1) weeks, without any treatment
62596708|NCT05629494|EXPERIMENTAL|Treatment with NSAIDS|Treatment with Ibuprofen 400 mg, 3 times per day, then repeat PSA test at 6 (± 1) weeks
62814884|NCT02969122|EXPERIMENTAL|Surgery-first|Patients in this arm will receive standard gastrectomy with D2 lymphadenectomy after randomization. Hyperthermic intraperitoneal chemotherapy (HIPEC) and extensive intraperitoneal lavage (EIPL) will be applied before abdominal closure. After surgery, 8 cycles of postoperative chemotherapy will be performed.
62814885|NCT04414241|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine prophylaxis plus standard measures of personal protection.
62814886|NCT04414241|NO_INTERVENTION|Control|Standard measures of personal protection.
62596709|NCT04805580|ACTIVE_COMPARATOR|intrathecal block|patients (25) will receive unilateral intrathecal block using 1.5 ml of hyperbaric bupivacaine
62814887|NCT06706362|ACTIVE_COMPARATOR|Bactrim or Macrobid (single dose)|Bactrim (800/160mg) or Macrobid (100 mg) depending on participants' allergies
62814888|NCT06706362|PLACEBO_COMPARATOR|Placebo|Identical appearing placebo for a single dose
62814889|NCT02381561|EXPERIMENTAL|Treatment (ropidoxuridine, IMRT)|Beginning 30 minutes to 2 hours before radiation therapy, patients receive ropidoxuridine PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. Beginning on day 8, patients undergo IMRT 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity.
62814890|NCT05705024|ACTIVE_COMPARATOR|Medium dose of allogenic MSC drops|Dose of allogeneic MSC subconjunctival injection will be assigned 3,000,000 cells/150 µL.
62814891|NCT05705024|SHAM_COMPARATOR|Control Group|For the control group, 50 µL of the freezing media (vehicle) will be injected.
62814892|NCT02228681|EXPERIMENTAL|Everolimus and Letrozole|Everolimus 10 mg daily and Letrozole 2.5 mg PO daily
62814893|NCT02228681|ACTIVE_COMPARATOR|Hormonal Therapy|Tamoxifen 20 mg PO BID; on alternating weeks (even numbered) weeks, Medroxyprogesterone Acetate 200 mg PO daily with Tamoxifen 20 mg PO BID
62238588|NCT04817891|EXPERIMENTAL|Experimental: HD-tDCS|Maximum 4 milliAmp (mA) per channel of HD-tDCS treatment for 20 minutes, for 10 sessions. Total mA dose determined by individualized computational models.
62238589|NCT05051137||Infliximab initiators|Rheumatoid arthritis patients initiating infliximab after treatment with methotrexate for a minimum of 30 days.
62238590|NCT05051137||Sulfasalazine + Hydroxychloroquine initiators|Rheumatoid arthritis patients initiating sulfasalazine and hydroxychloroquine after treatment with methotrexate for a minimum of 30 days.
62814894|NCT01003301|EXPERIMENTAL|Omalizumab|Active treatment: Experimental This arm will receive treatment with omalizumab at the dose FDA-approved for the treatment of allergic asthma.
62814895|NCT01003301|PLACEBO_COMPARATOR|Placebo|This arm will receive treatment with a placebo injections based on the FDA-approved dosing schedule approved for omalizumab for the treatment of allergic asthma.In general injection number and frequency are determined by a subject's weight and IgE level.
62814896|NCT06492330|ACTIVE_COMPARATOR|4mg CS0159|4mg CS0159 (oral, once daily) + 0.5mg Semaglutide (subcutaneous injection, once weekly) for 16 weeks
62814897|NCT06492330|PLACEBO_COMPARATOR|CS0159 Placebo|CS0159 placebo (oral, once daily) + 0.5mg Semaglutide (subcutaneous injection, once weekly) for 16 weeks
62814898|NCT04842903|EXPERIMENTAL|Experimental Group|Therapeutic touch and standard nursing care of the clinic (such as breathing exercise, postural drainage) was applied.
62596710|NCT04805580|ACTIVE_COMPARATOR|Quadratus lumborum block|patients (25) will receive quadratus lumborum block by an anterior approach using 30 ml of bupivacaine 0.25%
62238591|NCT03876990|EXPERIMENTAL|Multiplex PCR + Current strategy|Results of the multiplex PCR will be send as soon as possible to the infectious disease phycian for quick adaptation of antibiotic treatment. Positive blood cultures will also undergo current diagnosis strategy for bacteremia and fungemia.
62238592|NCT03876990|ACTIVE_COMPARATOR|Current strategy alone|Current diagnostic strategy based on the identification of bacteria and micromyces isolated in blood cultures after subculture by mass spectrometry (MALDI-TOF) and determination of their sensitivity to antibiotics or antifungals by antibiotic susceptibility testing or antifungigram
62596711|NCT06375746|EXPERIMENTAL|Personalized video group|In the video group patients will watch a personalized video prior to initiation of IOL in addition to standard counseling.
62596712|NCT06375746|NO_INTERVENTION|Control group|Patients will receive only standard counselling prior to initiation of IOL.
62596713|NCT05963386|EXPERIMENTAL|177Lu-DOTA-EB-FAPI|177Lu-DOTA-EB-FAPI A maximum of 4 cycles of 90 mCi (3.3 GBq) 177Lu-DOTA-EB-FAPI, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 4 cycles, every 6 weeks
62596714|NCT01008956|EXPERIMENTAL|Single Group|Subjects enrolled in this group will be stratified by age (18 to 40 years and 41 to 64 years)
62238593|NCT03127150||CL group|Subjects who had CL after pancreatic operation will be observed.
62238594|NCT03127150||Observation group|Subjects without CL after pancreatic operation will be observed.
62429207|NCT05199311|EXPERIMENTAL|Dose Level 2|"CC-220/Iberdomide: 1.6 mg \[CC-220 dosing schedule: daily for 21 days of each 28-day cycle\]~Carfilzomib: 20 mg/m2 C1D1 56 mg/m2 thereafter \[Days 1, 8, 15 per 28-day cycle\]~CC-220 dose level 2 enrollment will occur following an independent safety review two months after the first 10 patients have completed at least 2 cycles of therapy at dose level 1.~Dexamethasone: 40 mg (≤ 75 years) 20 mg (\> 75 years) \[Days 1, 8, 15, 22 per 28-day cycle\]~Treatment will continue with carfilzomib, iberdomide, and dexamethasone for up to 4 cycles (28 days) at the physician's discretion followed by the Autologous Stem Cell Transplant. Patients will be followed every 3 months for up to 2 years, or until PD or the start of a new line of therapy."
62429208|NCT05199311|EXPERIMENTAL|Dose Level -2|"CC-220/Iberdomide: 0.75 mg \[CC-220 dosing schedule: daily for 21 days of each 28-day cycle\]~Carfilzomib: 20 mg/m2 C1D1 56 mg/m2 thereafter \[Days 1, 8, 15 per 28-day cycle\]~Dexamethasone: 40 mg (≤ 75 years) 20 mg (\> 75 years) \[Days 1, 8, 15, 22 per 28-day cycle\]~Treatment will continue with carfilzomib, iberdomide, and dexamethasone for up to 4 cycles (28 days) at the physician's discretion followed by the Autologous Stem Cell Transplant. Patients will be followed every 3 months for up to 2 years, or until PD or the start of a new line of therapy."
62429209|NCT05234242||stationary/inpatient|
62596715|NCT01785511|SHAM_COMPARATOR|Sham UVA|sham exposure will be provided by covering the UVA lamps with space blanket.
62814899|NCT04842903|NO_INTERVENTION|Control Group|Only standard nursing care of the clinic (such as breathing exercise, postural drainage) was applied.
62429210|NCT05234242||ambulatory/outpatient|
62596716|NCT01785511|EXPERIMENTAL|UVA Radiation|Patients will be exposed to UVA radiation for 20 minutes
62596717|NCT05740189|EXPERIMENTAL|C2 CryoBalloon 180 Ablation System|C2 CryoBalloon 180 Ablation System will be used to ablate visible Barrett's esophagus
62596718|NCT02128347|OTHER|Electronic Patient Portal|RelayHealth is a web-based application that allows patients and healthcare workers to communicate through a secure, password protected online portal with data transfer capabilities. Effectiveness of the portal in improving several health outcomes from baseline-12 months will be assessed in this study.
62596719|NCT05634954|EXPERIMENTAL|[18F]GEH121224 - Group 1 - Biodistribution|
62596720|NCT05634954|EXPERIMENTAL|[18F]GEH121224 - Group 2 - Reproducibility|
62596721|NCT01684579|EXPERIMENTAL|Exercise and psychosocial counseling|Patients will participate in a psychosocial counseling session, 1 day/week for 20 weeks. Patients will be invited to participate in a progressive aerobic and resistance exercise program designed to achieve moderate and then vigorous levels of exercise, 5 days/week for 20 weeks.
62596722|NCT00468442|EXPERIMENTAL|Allogeneic Pancreatic Islet Cells|Participants will receive up to three islet transplants and maintenance immunosuppressive therapy.
62596723|NCT06463652|EXPERIMENTAL|Combined therapy group (cervical cerclage plus vaginal progesterone)|"Women will be receiving the cervical cerclage according to local protocol within a week after randomization, using the McDonald technique.~Within one day after the procedure, they will be receiving 200 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 200mg, Actavis, United Kingdom), once daily at bedtime. Participants will be asked to record their drug application in a patient diary sheet."
62814900|NCT01983202||Women with PCOS|208 women diagnosed with PCOS and giving birth after singleton pregnancies at Odense University Hospital during 2003-2011.
62238595|NCT01419353|EXPERIMENTAL|Follicular Estrogen, Antagonist, IVF|Follicular Estrogen in Antagonist IVF protocol
62596724|NCT06463652|ACTIVE_COMPARATOR|Progesterone only group|Women allocated to the progesterone only group will be receiving 200 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 200mg, Actavis, United Kingdom), once daily at bedtime. Participants will be asked to record their drug application in a patient diary sheet.
62596725|NCT06648720|EXPERIMENTAL|Group 1 (1-Month DAPT): DAPT De-escalation (Intervention Group)|Patients in this group will receive DAPT (aspirin and a P2Y12 inhibitor) for 1 month, followed by monotherapy with a P2Y12 inhibitor for the remaining 11 months.
62596726|NCT06648720|NO_INTERVENTION|Group 2 (12-Month DAPT): Standard DAPT (Control Group)|Patients in this group will continue with DAPT (aspirin and a P2Y12 inhibitor) for the full 12 months.
62238596|NCT01419353|ACTIVE_COMPARATOR|long IVF protocol|long IVF protocol
62238597|NCT04256603|OTHER|Gabapentin early|Gabapentin prior to admission
62238598|NCT04256603|OTHER|Gabapentin late|Gabapentin during admission
62238599|NCT04256603|OTHER|No gabapentin|No gabapentin
62238600|NCT06072560|EXPERIMENTAL|Treatment group|
62238601|NCT06072560|PLACEBO_COMPARATOR|Control group|
62238602|NCT00064389|EXPERIMENTAL|1|levalbuterol 90 mcg MDI QID
62238603|NCT00064389|ACTIVE_COMPARATOR|2|racemic albuterol HFA MDI 180 mcg QID
62238604|NCT04695496|EXPERIMENTAL|Theta bust stimulating group|Theta burst stimulation with Magstim super rapid 2, over SMA. 3 section per day, for 5 days, total 15 sections.
62037270|NCT01751438|EXPERIMENTAL|Best Systemic Therapy (BST) + Surgery or Radiation Therapy|Group 2 will receive best systemic therapy (BST) in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice. Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete. Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
62596727|NCT06328010||Wound Treatment with Advanced Therapies|Only treatments with advanced therapies, post standard care (SOC).
62596728|NCT06328010||Wound Treatment with Standard of Care|Only treatments with SOC, no human derived biological grafting treatments, no hyperbaric treatment, no synthetic grafting treatment, and no animal product biological grafting treatment.
62596729|NCT06328010||Retrospective wound care treatment and heal times|Only retrospective wound care treatment data irrelevant to treatment modality.
62596730|NCT05856994|EXPERIMENTAL|Tacrolimus Ointment 0.03% with hydrocolloid dressing|Standard out-patient wound cleaning followed by application of tacrolimus ointment over the burn and hydrocolloid dressing on the treated area.
62596731|NCT05856994|NO_INTERVENTION|Bacitracin ointment|Standard out-patient wound cleaning followed by application of bacitracin ointment over the burn and hydrocolloid dressing on the treated area.
62814901|NCT01983202||Controls|1040 women giving birth after singleton pregnancies at Odense University Hospital during 2003-2011, matched 1:5 to women with PCOS according to date-of-childbirth.
62037271|NCT05572138||Critically ill patients|
62037272|NCT05378633|EXPERIMENTAL|Experimental Treatment Arm|Best Supportive Care + Stereotactic Radiotherapy of all Brain Metastases
62596732|NCT05856994|NO_INTERVENTION|Hydrocolloid dressing|Standard out-patient wound cleaning followed by application of hydrocolloid dressing on the burned area.
62238605|NCT04260802|EXPERIMENTAL|Drug: Phase 1b: Dose Escalation (monotherapy)|Escalating doses of OC-001 administered intravenously (IV)
62238606|NCT04260802|EXPERIMENTAL|Drug: Phase 1b Dose: Escalation (Combination therapy)|Escalating doses of OC-001 administered by IV in combination Avelumab.
62238607|NCT04260802|EXPERIMENTAL|Drug: Phase 2a|Doses of OC-001 administered by IV in combination with Avelumab b)
62238608|NCT00340210||Serum Bank Participants|The Columbia MO Serum Bank recruited 6915 women living in and around Columbia MO between 1977-1987 who were cancer-free except for non-melanoma skin cancer and at least 18 years of age.
62238609|NCT04560569|EXPERIMENTAL|Group A|ABT weekly and 3BNC117 bi-weekly
62238610|NCT04560569|EXPERIMENTAL|Group B|both ABT and 3BNC117 treatment bi-weekly
62238611|NCT05536609|EXPERIMENTAL|Epineural suture|The injured digital nerve is exposed during a surgical intervention and sutured with 2 or three epineural sutures 8.0 or 9.0 synthetic monofilament non-resorbable suture. Postoperative treatment includes 3 weeks in a plaster cast followed by rehabilitation.
62238612|NCT05536609|ACTIVE_COMPARATOR|Non-operative treatment|The injured digital nerve is not surgically exposed. The skin is closed over the injury site and the finger is protected in a plaster cast for three weeks followed by rehabilitation.
62814902|NCT06251557|EXPERIMENTAL|Lumbopelvic Massage and Exercise Training in addition to Standard Urotherapy and Biofeedback Therapy|Group 1 will receive lumbopelvic massage and exercise training in addition to standard urotherapy and pelvic floor EMG biofeedback therapy.
62814903|NCT06251557|ACTIVE_COMPARATOR|Standard Urotherapy and Biofeedback Therapy|Group 2 will receive only standard urotherapy and pelvic floor EMG biofeedback therapy.
62238613|NCT03587857|EXPERIMENTAL|Arm 1: Intervention|All YLWH who choose to enroll in the study will receive access to WYZ, the mobile health application. The participants will be asked to use the app for 6 months, during which the investigators will assess the feasibility and acceptability of WYZ. Based on this initial data, the investigators will refine and release a new version of the app (WYZ 3.0).
62596733|NCT04288141||Group 1: Early HER2 positive breast cancer|Study participants in Group 1 will include patients prescribed neoadjuvant systemic therapy (including trastuzumab and pertuzumab) by their treating oncologist for a diagnosis of HER2 positive early breast cancer.
62596734|NCT04288141||Group 2: Metastatic HER2 positive breast cancer|Study participants in Group 2 will include patients prescribed systemic therapy (including trastuzumab and pertuzumab) by their treating oncologist for a diagnosis of HER2 positive metastatic breast cancer.
62814904|NCT05119036|NO_INTERVENTION|Observation|If patients have negative margins and have all negative nodes or only a single positive node, patients will be placed in the observation arm and will not receive further adjuvant treatment, only postoperative follow-up visits and a surveillance visit 3 months after surgery with a CT or PET-CT.
62596735|NCT05942105||ROLL technique|Radioguided occult lesion localization
62037273|NCT05378633|OTHER|Standard Treatment Arm|Best Supportive Care ± Whole Brain Radiotherapy
62037274|NCT06632301|EXPERIMENTAL|DEXA|DEXA bone density analysis to analyze the loading concept of the CoreHip® Prosthesis System
62037275|NCT00504270|PLACEBO_COMPARATOR|Placebo|po daily
62037276|NCT00504270|EXPERIMENTAL|RG3421 120mg|120mg po daily
62037277|NCT00504270|EXPERIMENTAL|RG3421 20mg|20mg po daily
62037278|NCT03254082|EXPERIMENTAL|F-1000 (fontanelle flour)|Fontenel sorghum flour
62037279|NCT03254082|EXPERIMENTAL|Sumac|Sumac sorghum flour
62037280|NCT03254082|EXPERIMENTAL|Wheat|Wheat flour
62037281|NCT03254082|EXPERIMENTAL|MMR|MMR cultivar of sorghum flour -- from MMR Genetics, a company that produces sorghum seed.
62037282|NCT03254082|ACTIVE_COMPARATOR|Sucrose|Table sugar
62238614|NCT05683249|EXPERIMENTAL|NRCT-101SR|Two-tiered fixed dose of 1,500 or 2,000 mg/day. Two NRCT-101SR tablets (375 mg or 500 mg based on lean body mass) by mouth twice daily
62238615|NCT05683249|PLACEBO_COMPARATOR|Matching Placebo|
62596736|NCT05942105||MAGNETIC SEED|Magnetic seed localization
62596737|NCT05942105||WGL technique|Wire guided localization for non-palpable breast lesions
62596738|NCT05942105||CARBON|Carbon dye localization for non-palpable breast lesions
62037283|NCT02860143||studying ventilation during sedation|Comparing ventilation during sedation with capnography
62037284|NCT04568434|EXPERIMENTAL|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
62238616|NCT05559021|EXPERIMENTAL|Myofascial Treatment Approach|"Patients will have 1 session per week, during 4 weeks, making 4 sessions in total. Each session will last 30 minutes. Each session consists of:~* Transverse planes in the thoracolumbar fascia and abdomen: The physical therapist place his hands facing each other so that one hand is between the tables and the patient's thoracolumbar fascia and the other on the abdomen~* Transverse planes at C7-D3 and sternum: The physical therapist, places one hand between the table and the patient's first 4 thoracic vertebrae (C7-T4) and the other on the sternum.~* Suboccipital inhibition: the physical therapist, places his hands under the patient's head transversely between the occipital and the spinous process of C2. After, the head is lowered in such a way that the occipital bone rests on the tenar eminences and a slight traction is maintained cranially."
62596739|NCT03805451|EXPERIMENTAL|Life Steps for PrEP for Youth|Life Steps for PrEP for Youth was derived from our prior PrEP work supported by the National Institute of Mental Health and will be tailored for YMSM/TWSM based on the findings from 20 qualitative interviews with YMSM and TWSM and 10 qualitative interviews with key informants. It will likely consist of four weekly sessions at the time of PrEP initiation and two booster sessions, which occur two and three months after PrEP initiation. Overall, the core components of the intervention will focus on medication adherence, sexual behavior, and problem solving barriers to adherence, using motivational interviewing when needed.
62596740|NCT03805451|NO_INTERVENTION|Standard of Care|After being prescribed PrEP, participants will receive standard-of-care adherence support for PrEP. They will have blood collected for medication adherence measures and will complete computer assisted behavioral surveys during study visits. Participants in this arm will also be followed for 6 months.
62596741|NCT06249854|EXPERIMENTAL|Bojungikkitang & Pembrolizumab combination treatment group|"Pembrolizumab is administered intravenously every 3 weeks for 45 weeks according to standard procedures until disease progression (PD) or unacceptable toxicity occurs.~Bojungikgitang is used in combination with immune checkpoint inhibitor treatment(Pembrolizumab) and is taken 1 bag twice a day before or between meals."
62596742|NCT06249854|ACTIVE_COMPARATOR|Pembrolizumab monotherapy group|Pembrolizumab is administered intravenously every 3-week for 45 weeks according to routine practice until disease progression (PD) or unacceptable toxicity occurs.
62596743|NCT06215560||Usual Care|Control group to enable tracking of temporal changes in prescribing. Providers will not see any alert.
62596744|NCT06215560||CDS Alert|"Providers will see a pop-up alert within the electronic health record (EHR) when they initiate an opioid or benzodiazepine prescription without recording use of the prescription drug monitoring program (PDMP) database.~Alerts do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders."
62596745|NCT06618443|EXPERIMENTAL|Scapular mobilization with movement|The treatment consisted of scapular mobilization with arm movement in all directions for 15 min/session for 3 sessions/week for 4 weeks. Scapular mobilization included scapular upward glide and downward glid. Scapular upward glide was performed with shoulder adduction and extension, while scapular downward glide was performed with shoulder abduction and flexion.
62596746|NCT06618443|NO_INTERVENTION|Control|
62596747|NCT02366234||Fracture of Distal Tubercle of Scaphoid|"Questionnaires~* Quick DASH after trauma (\< 2 weeks)~* 11-point ordinal measure of overall pain intensity 6 months after trauma~* 11-point ordinal measure of satisfaction with treatment 6 months after trauma"
62596748|NCT04376125|EXPERIMENTAL|Suboccipital inhibition in tension headache|"Two groups of patients suffering from tension headache associated with cervicalgia are selected.~The control group performs conventional therapy. The experimental group performs conventional therapy plus the technique of suboccipital inhibition"
62596749|NCT04376125|ACTIVE_COMPARATOR|study of results|We compared data from both groups
62814905|NCT05119036|EXPERIMENTAL|Adjuvant Radiation 44 Gray|If patients have 4 or fewer positive nodes and 2 mm or less of cancer spread extending outside the lymph nodes, patients will receive 44 gray fractions (the full dose of radiation divided into smaller doses) of adjuvant radiation.
62814906|NCT05119036|EXPERIMENTAL|Adjuvant Radiation 54 Gray|If patients have 4 or fewer positive nodes with greater than 2 mm of cancer spread extending outside the lymph nodes or 5 or more positive nodes with 2 mm or less of cancer spread extending outside the lymph nodes, patients will receive 54 gray fractions (the full dose of radiation divided into smaller doses) of adjuvant radiation.
62037285|NCT04568434|PLACEBO_COMPARATOR|Placebo|Olezarsen-matching placebo will be administered once every 4 weeks by SC injection from Week 1 through Week 49.
62596750|NCT03713008|EXPERIMENTAL|Fluid bolus|Patients included in the study will receive fluid bolus.
62596751|NCT06642519|EXPERIMENTAL|ECoG implantation|Patients will be implanted with high-density cortical ECoG arrays during DBS surgery.
62037286|NCT00962728|EXPERIMENTAL|ITD breathing device|Breathing through the Res-Q-Gard ITD device from Advanced Circulatory Systems Inc.
62037287|NCT00962728|SHAM_COMPARATOR|Sham Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
62596752|NCT04887090|EXPERIMENTAL|Acupuncture and drug compound technology group|Routine perioperative management and transcutaneous electrical acupoints stimulation treatment
62596753|NCT04887090|OTHER|Control group|Routine perioperative management
62814907|NCT05282550|ACTIVE_COMPARATOR|Trazodone First|Trazodone (50 mg at bedtime) and then placebo after a 4-week washout period.
62814908|NCT05282550|PLACEBO_COMPARATOR|Placebo First|Placebo and then Trazodone (50 mg at bedtime) after a 4-week washout period.
62037288|NCT06520111||patients underwent surgery for secreting adrenal lesion|
62037289|NCT06520111||patients underwent surgery for non- secreting adrenal lesion|
62037290|NCT05686070|EXPERIMENTAL|Asundexian|Participants will receive asundexian.
62037291|NCT05686070|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62037292|NCT03169387|EXPERIMENTAL|Virtual Reality|Microsoft's Xbox 360® will be used with Kinect™,
62037293|NCT03169387|ACTIVE_COMPARATOR|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training
62596754|NCT03492671|EXPERIMENTAL|Chemotherapy and SBRT|"Pre-Operative Chemotherapy: Within 28 days of study enrollment, subjects will receive a combination of Gemcitabine and Nab-paclitaxel for a maximum of four 28-day cycles. Gemcitabine 1000 mg/m2 IV on Days 1,8,15. Nab-paclitaxel 125 mg/m2 on Days 1,8,15.~Post-Operative Chemotherapy: Within 5-10 weeks after surgery, subjects will receive a combination of Gemcitabine and Nab-paclitaxel for a maximum of two 28-day cycles. Gemcitabine 1000 mg/m2 IV on Days 1,8,15. Nab-paclitaxel 125 mg/m2 on Days 1,8,15.~Standard Stereotactic Body Radiation Therapy (SBRT) fractionation of 6 Gy per day will be used for all patients to a total dose of 30 Gy."
62596755|NCT04161079||MAR population|Subjects, who underwent MV repair operation with successful MAR implantation in clinical investigation 2010-040
62596756|NCT03895606||HIPEC|patients undergoing cytoreductive surgery and hyperthermic intraoperative chemotherapy due to carcinomatosis.
62596757|NCT04316039|EXPERIMENTAL|RT+TMZ|
62037294|NCT02216175|EXPERIMENTAL|SLIT followed by Conventional OIT|Participants will receive up to 7 months of SLIT followed by 6 months conventional OIT to cow's milk
62429211|NCT04636398|EXPERIMENTAL|MESSAGE mHealth group intervention|Participants in the one arm will be exposed to the mHealth group intervention. As this is a pilot developmental study, the participants will be exposed to various strategies for information delivery (live presentation at a scheduled time versus voice recording accessible at any time), discussion facilitation (heavily managed with request to speak vs. natural discussion participation), and text communication management (moderator-facilitated vs. group-led).
62596758|NCT04316039|ACTIVE_COMPARATOR|RT|
62596759|NCT01344577||Group1#|bone graft material used: Apatos Cortical® (porcine cortical bone 600-1000 µm)
62596760|NCT01344577||Group2#|bone graft material used: MP3® (porcine cortic-cancellous collagenated bone mix 600-1000 µm)
62596761|NCT01344577||Group3#|control group
62596762|NCT04058535|EXPERIMENTAL|ALT-L9|Intravitreal injection of ALT-L9 50 ul, every 4 weeks
62596763|NCT04058535|ACTIVE_COMPARATOR|Eylea|Intravitreal injection of Eylea 50 ul, every 4 weeks
62596764|NCT03490461||Statin group|Statin therapy was defined as the administration of statins for more than 30 days after liver transplantation
62596765|NCT03490461||Non-statin group|the administration of statins for less than 30 days after liver transplantation
62037295|NCT02216175|ACTIVE_COMPARATOR|Conventional OIT|Participants will receive up to 7 months of low dose OIT, followed by 6 months conventional OIT to cow's milk
62814909|NCT02253225||Bipolar Disorder|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 patients with bipolar disorder (BPAD).
62814910|NCT02253225||Major Depressive Disorder|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 patients with major depression (MDD).
62037296|NCT02216175|PLACEBO_COMPARATOR|Delayed start OIT|Participants will receive up to 7 months placebo, followed by 6 months conventional OIT to cow's milk
62429212|NCT04715386||Group 1- StrataXRT|
62429213|NCT00764049|EXPERIMENTAL|1: Single pass albumin dialysis|Patients entered in the pilot study.
62596766|NCT00702442|PLACEBO_COMPARATOR|A|Placebo Administrated 30min prior to operation
62596767|NCT00702442|EXPERIMENTAL|B|0.625 mg Droperidol administrated i.v 30 min prior surgery
62596768|NCT05214586|EXPERIMENTAL|Spiculotomy and application of a Gel Nail|A nail spicule removal technique will be performed of the edge or nail edges affected by ingrown toenail. After, a gel nail will be applied to remodeling the nail apparatus and avoid damage of the nail in the lateral fold.
62596769|NCT05214586|ACTIVE_COMPARATOR|Spiculotomy and Nail Re-education with Gauze Bandage|A nail spicule removal technique will be performed and a cord of gauze bandage between the nail channel and the sheet will be applied. This technique consists in the removal of the portion of the nail sheet that causes ingrown toenail in order to release the soft parts.
62596770|NCT06204094|EXPERIMENTAL|Treatment Arm|"Participants will receive 5\*5Gy node-sparing short-course radiation (radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes) concurrently with total neoadjuvant CAPOX and sintilimab regimens: Oxaliplatin, 130mg/m2, intravenous infusion,d1 of each cycle; Capecitabine, 1000mg/m2, PO, BID, d1-14 and sintilimab, 200mg intravenous infusion d1 of each cycle. CAPOX and sintilimab are repeated every 3 weeks for 8 cycles. Patients with cCR will be managed with a WW strategy, and patients who did not achieve cCR will receive TME surgery.~Interventions:~* Radiation: node-sparing short-course radiation~* Drug: PD-1 antibody (Sintilimab)~* Drug: Capecitabine~* Drug: Oxaliplatin"
62596771|NCT05496283|EXPERIMENTAL|Corega|Complete denture patients given Corega denture adhesive.
62596772|NCT05496283|EXPERIMENTAL|OlivaFix|Complete denture patients given OlivaFix denture adhesive.
62596773|NCT05496283|EXPERIMENTAL|Sea.Bond|Complete denture patients given Sea.Bond denture adhesive.
62037297|NCT00864903||pediatric ER|any child undergoing a spinal tap due to suspected meningitis
62429214|NCT06248034|EXPERIMENTAL|Participants for Smartphone Home-based Rehabilitation Program (N=15)|Study participants will be recruited from orthopaedic surgeons in Singapore General Hospital. Study participants will be recruited during their outpatient appointment session at the outpatient orthopaedic specialist clinic pre-admission clinic.
62596774|NCT04036305||EDS Patients|Patients meeting the diagnostic criteria (2017) for Ehlers-Danlos Syndrome
62596775|NCT04036305||Healthy Volunteers|Healthy control volunteers who do not meet the criteria for Ehlers-Danlos Syndrome
62814911|NCT02253225||Healthy Control|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 normal, healthy volunteers.
62814912|NCT05752760|EXPERIMENTAL|Lp299v|Subjects will consume 20 billion colony forming units of Lp299v (2 capsules) once daily for 12 weeks.
62814913|NCT05752760|PLACEBO_COMPARATOR|Placebo Control|Subjects will consume potato starch (2 capsules) once daily for 12 weeks.
62814914|NCT04007666|EXPERIMENTAL|Cognitive Processing Therapy (CPT)|CPT is a gold-standard evidence-based psychotherapy for PTSD that combines education about trauma with strategies to challenge the trauma-related cognitions that are theorized to maintain PTSD symptoms. It can be delivered in group and individual formats, but will be delivered in a group format in this project due to feasibility in the setting. Structure will be based on feedback obtained during completion of Aim 2 while remaining within the range evaluated in prior research (i.e., 8-12 sessions, 1-2x per week, each lasting 1.5-2 hours).
62814915|NCT04007666|ACTIVE_COMPARATOR|Coping Skills Group|The Coping Skills Group will match for attention and dose, without adding any cost to the system. Exact content will be determined during completion of Aim 2; however, project sites already provide coping-focused programming and coping-skill approaches to trauma treatment are a common alternative to evidence-based therapies for PTSD, such as CPT, that deal more directly with the index trauma. To provide an enhanced standard of care, the investigator will review treatment materials (workbooks, handouts) already used in prison settings and arrange a curriculum of skills similar to those in coping-focused trauma-informed interventions (e.g., psychoeducation, assertiveness).
62238617|NCT05559021|EXPERIMENTAL|Mobilization Approach.|"Patients will have 1 session per week, for 4 weeks, which means 4 sessions in total. Each session will last 30 minutes. Each session consists of:~* Postero-anterior cervical sliding: the patient's cervical vertebrae will be evaluated with the 4 degrees of postero-anterior sliding, and the pain at each vertebral level is recorded. Then, the most painful vertebra previously detected will be treated.~* Postero-anterior lumbar slippage: the patient's lumbar vertebrae will be evaluated with the 4 degrees of postero-anterior slippage, and the pain at each vertebral level is recorded. Afterwards, the most painful vertebra previously detected will be treated.~* Postero-anterior dorsal slippage: the patient's dorsal vertebrae will be evaluated with the 4 degrees of postero-anterior slippage, and the pain at each vertebral level is recorded. Then, Afterwards, it will treat during the most painful vertebra previously detected."
62037298|NCT06085248|ACTIVE_COMPARATOR|Walking without personalized rhythmic auditory stimulation|Subjects will complete a 6MWT without any auditory cues
62238618|NCT04401969||Patients with eumycetoma lesions|Patients with eumycetoma lesions
62238619|NCT04401969||Patients with actinomycetoma lesions|Patients with actinomycetoma lesions
62238620|NCT04401969||Patients with lesions of unknown causality|Patients with lesions of unknown causality
62238621|NCT01351623|EXPERIMENTAL|Carfilzomib|A single arm, open-label, single institution phase 2 clinical trial is planned.
62238622|NCT04087954|EXPERIMENTAL|Intervention vs control|
62238623|NCT04087954|NO_INTERVENTION|Control|
62238624|NCT02870569|EXPERIMENTAL|Donafenib1|This is the lower dose group. Donafenib 200mg bid
62238625|NCT02870569|ACTIVE_COMPARATOR|Donafenib2|This is the higher dose group. Donafenib 300mg bid
62238626|NCT06072287||Participants|Participants will answer two short questionnaires, 1 week apart.
62238627|NCT00782288|ACTIVE_COMPARATOR|1|low dose 0.05mg digitoxin given once daily for 28 days
62238628|NCT00782288|ACTIVE_COMPARATOR|2|higher dose 0.1mg digitoxin daily for 28 days
62814916|NCT05644119|EXPERIMENTAL|V-looped Wire Retainer (LWR)|The LWR is a 0.569-mm (0.022-inch) Blue Elgiloy (soft) round wire (RMO). The retainer will extend from the left canine to the right central incisor.
62814917|NCT05644119|ACTIVE_COMPARATOR|Straight Wire Retainer (SWR)|The SWR is 0.8-mm twisted stainless steel wire (3M Unitek, Monrovia, Calif). The retainer will extend from the right canine to the left central incisor.
62814918|NCT01099696|EXPERIMENTAL|B. infantis 35624|B. infantis 35624 in white capsules
62238629|NCT00782288|PLACEBO_COMPARATOR|3|placebo given daily for 28 days
62238630|NCT05427721|EXPERIMENTAL|Group A|Thymol
62238631|NCT05427721|PLACEBO_COMPARATOR|Group B|Calcined magnesia
62238632|NCT02778256|EXPERIMENTAL|Vestibular stimulation|Patients of this group will receive a specific vestibular stimulation technique.
62814919|NCT01099696|PLACEBO_COMPARATOR|placebo|white placebo capsules (inert)
62814920|NCT03253692||Patients|People ages 18 years and older who need a computed tomography (CT) scan of the heart.
62814921|NCT03272802|EXPERIMENTAL|Case group|"ALS patients who receive the usual treatment option (Riluzole) for this disease and Edaravone. Instructions:~1. Tab. Rilutek 50 mg PO q12hr on empty stomach.~2. Amp. Edaravone 60 mg per day IV infusion (in normal saline during 1 hour) for 14 days in the first 28 day cycle.~3. Amp. Edaravone 60 mg per day IV infusion (in normal saline during 1 hour) for 10 days in the following 28 day cycles after the first cycle (for 11 cycles)."
62037299|NCT06085248|EXPERIMENTAL|Walking with personalized rhythmic auditory stimulation|Subjects will complete a 6MWT with personalized rhythmic auditory cues
62037300|NCT04913753|EXPERIMENTAL|No systematic CBEU|Patients will not have bacterial culture performed before double J removal.
62037301|NCT04913753|ACTIVE_COMPARATOR|Systematic CBEU|Patients will have a systematic urine culture performed before double J removal.
62238633|NCT02778256|SHAM_COMPARATOR|Sham vestibular stimulation|This group of patients will receive sham vestibular stimulation, similar to experimental group vestibular stimulation in the range of under threshold frequencies undistinguished from real vestibular stimulation. The absence of vestibular nystagmic response confirms that the stimulus is sham.
62238634|NCT03990857|EXPERIMENTAL|Intervention|Group of participants with a recent DM2 debut (less than 5 months) treated according to the comprehensive care protocol in DM2 with comorbidities attended in Primary care nurse office
62238635|NCT03990857|NO_INTERVENTION|comparison group|Participants in the study that do not receive the intervention. usual care.
62238636|NCT05541211|ACTIVE_COMPARATOR|Coeliac plexus neurolysis (CPN)|Coeliac plexus neurolysis (CPN) will be performed bilaterally. Neurolytic solution will be injected around the coeliac plexus (a network of nerves located in the abdomen).
62238637|NCT05541211|EXPERIMENTAL|Splanchnic nerve neurolysis (SNN)|Splanchnic nerve neurolysis (SNN) will be performed bilaterally. Neurolytic solution will be injected around the splanchnic nerves (a nerve located at thoracic trunk).
62238638|NCT03672877|EXPERIMENTAL|Immediate training group|Children will participate in intensive exercise intervention for 3 months and will be followed for 9 months following the intervention
62429215|NCT06248034|EXPERIMENTAL|Participants for Hospital-based rehabilitation program (N=15)|Study participants will be recruited from orthopaedic surgeons in Singapore General Hospital. Study participants will be recruited during their outpatient appointment session at the outpatient orthopaedic specialist clinic pre-admission clinic.
62429216|NCT01318785|ACTIVE_COMPARATOR|Compression ArmsleevesType A|Product A: armsleeves of type SoraLife KKl. 2 according to RAL GZ 387
62429217|NCT01318785|ACTIVE_COMPARATOR|Compression Armsleeves Type B|Product B: armsleeves of type Elvarex KKl. 2 according to RAL GZ 387
62429218|NCT02145572||Obese adolescents with type 2 diabetes|No intervention
62429219|NCT02145572||Obese adolescents without diabetes|No intervention
62429220|NCT02145572||Healthy non-obese adolescents|No intervention
62429221|NCT03844568|EXPERIMENTAL|nasal CPAP group|Applying nocturnal nasal continuous positive airway pressure in additional to usual pneumonia treatment
62429222|NCT03844568|NO_INTERVENTION|Control group|Usual pneumonia treatment
62429223|NCT01981629||Shock|Defined by systolic blood pressure less than 95 mmHg or shock index (heart rate/systolic blood pressure) greater than 0.9
62429224|NCT02766231||Physica CR|Patients who have undamaged and functional collateral and posterior cruciate ligaments for the group requiring Physica CR
62429225|NCT02766231||Physica PS|Patients who have undamaged and functional collateral ligaments for the group requiring Physica PS
62814922|NCT03272802|ACTIVE_COMPARATOR|Control group|"ALS patients who receive the usual treatment option (Riluzole) for this disease.~Instructions:~1. Tab. Rilutek 50 mg PO q12hr on empty stomach."
62814923|NCT03978936|EXPERIMENTAL|MTM-EAM|Medication Therapy Management Video Telehealthcare plus Electronic Adherence Self-Management \[MTM-EAM\]
62814924|NCT03978936|ACTIVE_COMPARATOR|EAM only|Electronic Adherence Self-Management \[EAM\] only
62814925|NCT04375384|EXPERIMENTAL|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once every week in the absence of disease progression or unacceptable toxicity.
62814926|NCT06547437|ACTIVE_COMPARATOR|oxytocin plus papaverine|Intervention Group: Combined use of papaverine (80 mg intravenous mg in 100 mL saline once concurrent with the start of oxytocin) and oxytocin.
62814927|NCT06547437|PLACEBO_COMPARATOR|oxytocin alone|Control Group: Oxytocin plus 100 mL saline.
62814928|NCT00758017|EXPERIMENTAL|Acupuncture 1|
62814929|NCT00758017|ACTIVE_COMPARATOR|Acupuncture 2|
62814930|NCT02755428|EXPERIMENTAL|retinal pigment epithelium transplantation|Subretinal transplantation of human embryonic stem cell derived retinal pigment epitheliums.
62814931|NCT03737123|EXPERIMENTAL|Chemotherapy and Atezolizumab|Subjects that received a PD 1 or PD-L1 inhibitor with no prior platinum chemotherapy for metastatic disease will be treated with atezolizumab + carboplatin + gemcitabine on trial. Subjects that received sequential or concurrent PD1/PDL1 inhibitor and carboplatin-based regimen will be treated with atezolizumab + docetaxel on trial.
62814932|NCT05400291||Renal Cell Carcinoma|patients undergoing radical nephrectomy because of renal clear cell carcinoma, tissue will be collected after the organ is removed.
62037302|NCT05339529|EXPERIMENTAL|Thymosin alpha 1|1.6 mg q12h for 5 days
62037303|NCT05339529|SHAM_COMPARATOR|Blank control|
62429226|NCT03536247|ACTIVE_COMPARATOR|Intraductal lithotripsy|Cholangioscopy enables therapeutic intervention including intracorporeal electro-hydraulic and laser lithotripsy for biliary stone disease with favorable efficacy and safety.
62429227|NCT03536247|ACTIVE_COMPARATOR|Papillary Balloon dilation|Balloon dilation of the Ampulla of Vater after a small sphincterotomy is an alternative technique that allows for removal of large bile duct stones in a safe and effective manner.
62429228|NCT03793595|EXPERIMENTAL|Seated Battle Ropes Protocol|
62429229|NCT03793595|ACTIVE_COMPARATOR|Seated Upper Extremity Arm Bike|
62429230|NCT00789828|EXPERIMENTAL|Everolimus|Everolimus was administered orally at a starting dose of 4.5mg/m\^2 daily and subsequently titrated to attain whole blood trough concentration of 5 to 15 ng/mL. Dose adjustments were permitted based on safety and whole blood trough concentrations.
62429231|NCT00789828|PLACEBO_COMPARATOR|Placebo|Matching Placebo administered orally.
62429232|NCT05717088|EXPERIMENTAL|Oral sucrose + soother group (group A)|"Group A: Infants will receive oral sucrose (24%) followed by a soother 2 minutes before the procedure LUS scan. The dose will be 0.2 mL, 0.5 mL and 1 mL for infants with current weight \< 1500g, 1500-2500g, and \> 2500g respectively."
62429233|NCT05717088|NO_INTERVENTION|Soother alone group (group B)|Group B (control group): infants will receive a soother 2 minutes before LUS scan.
62429234|NCT01051999|EXPERIMENTAL|Glutamine|Patients randomized to the glutamine arm will receive 0.7g/kg of oral glutamine powder per day
62429235|NCT01051999|PLACEBO_COMPARATOR|Placebo|Patients randomized to the placebo arm will receive 0.7g/kg of oral isonitrogenous L-alanine powder per day
62429236|NCT02100852|EXPERIMENTAL|TGR-1202 + Obinutuzumab + Chlorambucil|TGR-1202 is an oral daily dose with obinutuzumab at a fixed IV infusion and chlorambucil as an oral dose on specified days.
62429237|NCT04676516|EXPERIMENTAL|Experimental Arm|Participants randomized to treatment with GSK3326595 will be requested to take 15 +/- 3 days of the medication at the dose of 200 mg orally daily (2 capsules of 100 mg) prior to their breast cancer surgery or repeat biopsy. GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
62814933|NCT05400291||Muscle Invasive Bladder Cancer|patients underoing radical cystectomi because of muscle-invasive bladder cancer, tissue will be collected after the organ is removed.
62814934|NCT06464497|NO_INTERVENTION|Whole Foods Counseling Group|"Participants randomized to the usual care group will receive a MyPlate Plan that follows a conventional Dietary Guidelines for Americans (DGA) diet which is considered a healthy diet pattern for adolescents with obesity. This diet intervention will encourage the consumption of a whole foods dietary patterns such as a wide variety of fruits, vegetables, proteins, seafood, dairy and whole grains. Physical activity will be encouraged per MyPlate guidelines and will be reported on the MyPlate plan daily. At the end of each week, study personnel and/or the study RDN will follow up with the participants to review the food checklists. At this time personnel will address diet-related questions and provide guidance on diet adherence."
62037304|NCT00450411|EXPERIMENTAL|Brachytherapy|Prostate brachytherapy delivered using either 125-iodine (I-125) or 103-palladium (Pd-103)
62596776|NCT02600845|EXPERIMENTAL|ACCU-CHEK|All participants will utilize ACCU-CHEK Connect Diabetes Management System containing three primary components: ACCU-CHEK Aviva Connect Blood Glucose Monitoring System intended to be used for the quantitative measurement of glucose, ACCU-CHEK Connect Diabetes Management App indicated as an aid in the treatment of diabetes, and ACCU-CHEK Connect Online Diabetes Management System indicated for use by persons with diabetes or by healthcare professionals in the home or in healthcare facilities.
62814935|NCT06464497|EXPERIMENTAL|Whole Foods MyPlate Group|"Adolescents and adults randomized to the intervention group will receive a MyPlate Plan to support daily food group and macronutrient goals that align with the whole foods diet per caloric needs. The 8-week intervention will consist of rotating menus (per above) and bi-weekly groceries of mostly fruits and vegetables delivered to family's homes that align with the study menus to support adherence."
62596777|NCT02976675|EXPERIMENTAL|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
62596778|NCT02976675|EXPERIMENTAL|PEG-somatropin per two weeks|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
62814936|NCT04261439|EXPERIMENTAL|Arm 1|Single agent arm. NIZ985 is administered as a single agent (subjects may be treated with the NIZ985-Spartalizumab combination after their first disease re-evaluation)
62814937|NCT04261439|EXPERIMENTAL|Arm 2|Combination arm. NIZ985 and Spartalizumab combination is administered starting at Cycle 1 Day 1 in dose escalation. NIZ985 and tislelizumab combination is administered starting at Cycle 1 Day 1 in dose expansion.
62814938|NCT04895254||Experimental: Motorized spiral Enteroscopy|Consecutive patients with difficult colonoscopies to be enrolled to achieve total colonoscopy using the motorized spiral enteroscope.
62814939|NCT06615076|EXPERIMENTAL|Intervention|The intervention group will have scheduled structured postpartum visits at 3, 6, and 12 months with obstetric care providers. These structured visits will be targeted at both managing current hypertensive and/or diabetes disorders and decreasing the risk of developing these disorders. Additional postpartum and primary care concerns will also be addressed as they arise.
62238639|NCT03672877|NO_INTERVENTION|Delay training group|Children will be assessed for 6 months with no intervention. After the 6 month period children will be given the same intervention as the immediate group and followed for 3 months after the intervention.
62238640|NCT04292002|EXPERIMENTAL|Health Checks|Workplace health checks - in this intervention employees can select from a range of optional health checks/tests and receive tailored health advice and a health resource pack.
62238641|NCT00324129|EXPERIMENTAL|1|
62238642|NCT01842685|EXPERIMENTAL|Bladder Thermal Distention|Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using a specific 3 ways catheter. The procedure will last 1 hour. Saline will be irrigated by the PelvixTT system.
62238643|NCT00293722||Patients with Psoriatic Arthritis|
62596779|NCT02976675|ACTIVE_COMPARATOR|Jintropin AQ|Jintropin AQ, injection, 30IU/10 mg/3ml/cartridge, 0.25mg/kg/w, once per day for 26 weeks
62037305|NCT05371496|ACTIVE_COMPARATOR|Semaglutide Treatment|Subjects will receive Semaglutide once weekly in addition to counselling on healthy lifestyle intervention
62037306|NCT05371496|PLACEBO_COMPARATOR|Placebo Treatment|Subjects will receive matching placebo once weekly in addition to counselling on healthy lifestyle intervention
62238644|NCT04580862|EXPERIMENTAL|group 1 Non-surgical endodontic retreatment in single visit|Single visit treatments have gained more popularity. Completing the treatment in a single appointment has many advantages including reduction in treatment time and cost, lower risk of micro leakage and recontamination of root canals between appointments
62238645|NCT04580862|ACTIVE_COMPARATOR|group 2 Non-surgical endodontic retreatment in Two-visit|Two-visit endodontic treatment with intra-canal medication was traditionally found to be effective in decreasing the number of flare-up in all retreatment cases and in reducing postoperative pain of previously symptomatic teeth
62596780|NCT06622187|PLACEBO_COMPARATOR|Sodium Chloride|
62596781|NCT06622187|EXPERIMENTAL|Desmopressin (DDAVP)|
62814940|NCT06615076|ACTIVE_COMPARATOR|Control|The control group will have study assessment visits at 3, 6, and 12 months during the first postpartum year, conducted by a Registered Nurse (RN).
62596782|NCT01594892|EXPERIMENTAL|Dose intensified SBRT|Depending on the modified Mizumoto Score (0-4 points or 5-9 points) patients will be treated with 10 fractions of 4.85Gy in involved parts of the vertebra and 3Gy in not-involved parts using a simultaneous integrated boost or with 5 fractions of 7Gy in involved parts of the vertebra and 4Gy in not-involved parts using a simultaneous integrated boost, respectively.
62596783|NCT05146986||Non-surgical group|Patients will receive analgesia and symptomatic management treatment
62596784|NCT05146986||Surgical group|Patients will receive surgical treatment using RibFix Blu Thoracic Fixation System
62596785|NCT04403503|ACTIVE_COMPARATOR|Gelatine Sponge|After local anesthesia (2% articaine HCl with epinephrine 1:100,000) administration, palatal thickness was measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area and mean value was recorded as 'palatal tissue thickness (PTT)'. Epithelialized gingival graft was harvested with the method described by Zucchelli et al.19 After a rectangular shaped initial incision, graft with 1-1.5 mm thickness was harvested approximately 1.5 to 3 mm away from gingival margins of upper teeth. After harvesting, excess fatty tissues were removed and de-epithelialization was performed to obtain DGG. Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA)
62238646|NCT05615324|EXPERIMENTAL|Family Talk|families will receive a manualized, family-based intervention Family Talk of approximately 8 sessions with a trained, Family Talk interventionist.
62596786|NCT04403503|ACTIVE_COMPARATOR|Gelatine sponge +Cyanoacrylate|After local anesthesia (2% articaine HCl with epinephrine 1:100,000) administration, palatal thickness was measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area and mean value was recorded as 'palatal tissue thickness (PTT)'. Epithelialized gingival graft was harvested with the method described by Zucchelli et al.19 After a rectangular shaped initial incision, graft with 1-1.5 mm thickness was harvested approximately 1.5 to 3 mm away from gingival margins of upper teeth. After harvesting, excess fatty tissues were removed and de-epithelialization was performed to obtain DGG. Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) and GS covered with high viscosity CY (PeriAcryl®, Glustitch Inc., Delta, Canada) (GS+CY group)
62596787|NCT06105749|EXPERIMENTAL|contrast-enhanced mammography|Enrolled participants will receive a baseline contrast-enhanced mammography exam for breast cancer screening, along with their scheduled 3D mammography exam, then they will receive another CEM exam for breast cancer screening at 24 months after their baseline CEM exam, and then again at 48 months. All the while, participants will still receive their annual 3D mammography exam as per their usual routine care.
62596788|NCT05274581||Course participants|Course participants er general practitioners who have signed-up to participate in an ultrasound course
62814941|NCT05533671|EXPERIMENTAL|Operative Group|This group will have surgical procedure called a medial patellofemoral reconstruction where the kneecap is anchored back into its correct position)
62814942|NCT05533671|ACTIVE_COMPARATOR|Non-operative group|This group will have physical therapy for their knee dislocation by following a specific rehabilitation plan.
62814943|NCT06384079||Endoscopic Evaluation|Antegrade and retrograde pyelogram will be completed prior to definitive ureteral repair
62814944|NCT05549895|EXPERIMENTAL|Drug arm|45 patients will receive 8mg dexamethasone in addition to bupivacaine intrathecally .
62814945|NCT05549895|OTHER|control arm|45 patients will receive only bupivacaine intrathecally as a control group.
62814946|NCT06595888|EXPERIMENTAL|Computed Tomography|Human subjects having CT scans
62814947|NCT01572597|EXPERIMENTAL|Acetylcystein|10-day triple therapy plus N-acetyl-cystein to remove the biofilm.
62814948|NCT01572597|ACTIVE_COMPARATOR|Metronidazole|10-day triple therapy plus metronidazole (concomitant therapy) as active comparator
62238647|NCT05615324|NO_INTERVENTION|Service as usual|Families in this arm will not receive any intervention from the research team but they may receive other services. It is likely that many will receive two sessions of talk intervention concerning parental mental health and child well-being from professionals in the mental health sector where the parent is treated.
62814949|NCT04332822|ACTIVE_COMPARATOR|Arm A - R-mini-CHOP|"Cycles 1-6, duration 21 days~* Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~* Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~* Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~* Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6~* Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6"
62814950|NCT04332822|EXPERIMENTAL|Arm B - R-pola-mini-CHP|"Cycles 1-6, duration 21 days~* Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~* Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~* Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~* Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6~* Polatuzumab vedotin 1.8 mg/kg i.v day 1 cycles 1-6"
62814951|NCT06561919|OTHER|DBS-group|Within indication and clinical routine: bilateral high frequency deep brain stimulation of the subthalamic necleus combined with best medical treatment
62814952|NCT06561919|OTHER|BMT-group|Within indication and clinical routine: best medical treatment
62814953|NCT05054075|EXPERIMENTAL|Vaccinated|Subjects that received a vaccine against COVID-19 lineage virus
62238648|NCT04630756|EXPERIMENTAL|Module 1: Part A and Part B|"Participants will receive intravenous ascending doses of AZD4573 once weekly with oral acalabrutinib twice daily continuously in Part A. For Part A, cohorts 1, 2, and 3 have different target dose levels respectively.~In Part B, participants will receive the RP2D of AZD4573 from Part A."
62238649|NCT04630756|EXPERIMENTAL|Module 2: Part A and Part B|"Participants will receive AZD4573 as monotherapy for Period 1 and AZD4573 + acalabrutinib as combination therapy for Period 2.~Part B of Module 2 will be determined from the data emerging from Part A."
62238650|NCT03167957|EXPERIMENTAL|CAMB 200 mg|200 mg CAMB Oral Amphotericin B
62238651|NCT03167957|EXPERIMENTAL|CAMB 400 mg|400 mg CAMB Oral Amphotericin B
62814954|NCT05054075|EXPERIMENTAL|Non-vaccinated|Subjects that did not receive a vaccine against COVID-19 lineage virus
62814955|NCT05054075|EXPERIMENTAL|Infected|Subjects that are infected with a COVID-19 lineage virus
62814956|NCT05607407|EXPERIMENTAL|Surgical Resection, Pharmacodynamic Assays, and Methimazole|Participants with recurrent glioblastoma for whom surgical resection is indicated will have baseline peripheral blood pharmacodynamic assays (PBPD) followed by oral mehimazole at least 5 days pre-operatively or until lower circulating theyroid hormone levels are achieved. PBPD assays will then be repeated. After surgical resection, PBPD will be repeated a day later. When the participant is deemed able to begin methimazole (no sooner than 10 days post-op) PBPD assays will be repeated and the participant will begin methimazole for 4 weeks. At the end of the first 4 week cycle, an MRI will be performed. PBPD assays will be repeated after which secondary chemotherapy will be added at the treating physician's discretion. After 4 weeks, PBPD will be repeated and the participant will undergo another MRI at 8 weeks.
62814957|NCT05427344|EXPERIMENTAL|Water exercise group|Water exercise group where the Ai Chi technique was selected as the exercise method of choice. The activity will take place in a hydrotherapy pool approved by the Ministry of Health and will be led by a hydrotherapist who has been trained in Ai Chi
62814958|NCT05427344|EXPERIMENTAL|Land exercise group|Land exercise group who will perform the same Ai Chi movements on land in order to standardize the groups. The activity will take place in a hall and will be led by a physiotherapist who has been trained to teach Ai Chi on land
62814959|NCT05427344|EXPERIMENTAL|Control group|Control group who will not perform additional physical activity or receive any extra treatments
62037307|NCT06462989|EXPERIMENTAL|ECHONEXT interpretation|The ECHONeXT algorithm was trained to predict the presence of SHD on TTE using a single 12-lead ECG. It was developed at Columbia hospital, released as open-weights and validated at the MHI. It was trained on 800,000 ECG and TTE pairs.
62238652|NCT03782142||Group A NRTI + NNRTI|Based on current regimens that are commonly used (2017-2018 ART guidelines), our groups will include NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and an NNRTI (Non-nucleoside reverse transcriptase inhibitor, Rilpivirine
62238653|NCT03782142||Group B NRTI + boosted PI|NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and a boosted Protease Inhibitor: Prezcobix- \[darunavir+cobicistat combination\]
62429238|NCT04676516|NO_INTERVENTION|No Intervention Arm|Participants will receive no treatment for 15 +/- 3 days prior to breast surgery. There is no placebo in this trial.
62429239|NCT02755233||Pulmonary function|Patients in whom treatment with ipilimumab due to metastatic melanoma is indicated
62429240|NCT01098734|PLACEBO_COMPARATOR|Group 1|0%; vehicle cream
62429241|NCT01098734|ACTIVE_COMPARATOR|Group 2|0.5% WBI-1001 cream
62429242|NCT01098734|ACTIVE_COMPARATOR|Group 3|1.0% WBI-1001 cream
62429243|NCT03373409|EXPERIMENTAL|Albuterol DPI 90mcg|Participants will receive albuterol 90mcg via the albuterol DPI
62429244|NCT03373409|EXPERIMENTAL|Albuterol DPI 180mcg|Participants will receive albuterol 180mcg via the albuterol DPI
62429245|NCT03373409|ACTIVE_COMPARATOR|Albuterol HFA MDI|Participants will receive albuterol 180mcg via the HFA MDI inhaler
62596789|NCT00382525||Patients with Cardiac Rhythm Management device|Patients receiving a Medtronic Cardiac Rhythm Device, worldwide
62596790|NCT06621108||Focus group session|All participants in this study will take part in a focus group session.
62596791|NCT04651049||Propranolol treatment group|
62596792|NCT05496959|ACTIVE_COMPARATOR|Arm 1 (SBRT)|Beginning on day 1, patients undergo SBRT to all lesions for 1, 3, or 5 treatment doses (fractions) over the span of 10-20 days in the absence of disease progression or unacceptable toxicity.
62037308|NCT06462989|NO_INTERVENTION|No ECHONEXT interpretation|Not displaying the ECHONEXT algorithm interpretation.
62037309|NCT01782066|EXPERIMENTAL|Menveo, dose escalating|
62037310|NCT01782066|EXPERIMENTAL|Nimenrix, dose escalating|
62238654|NCT03782142||Group C NRTI + II|NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and an Integrase inhibitor (dolutegravir)
62238655|NCT01903018|EXPERIMENTAL|P276-00|
62238656|NCT04169386|EXPERIMENTAL|AK102 75mg|AK102 75mg
62238657|NCT04169386|EXPERIMENTAL|AK102 150mg|AK102 150mg
62037311|NCT05319067||Cases|Children aged 1 to 3 years with vesico ureteral reflux of grade 3 or higher, under antibiotic prophylaxis
62037312|NCT05319067||Controls|Children aged 1 to 3 years with uropathy, without antibiotic prophylaxis
62037313|NCT05319067||Healthy Controls|Healthy children aged 1 to 3 years.
62596793|NCT05496959|EXPERIMENTAL|Arm 2 (177Lu-PNT2002, SBRT)|Patients receive 177Lu-PNT2002 IV over 1-10 minutes on days -112 and -56 in the absence of disease progression or unacceptable toxicity. Beginning on day 1, patients then undergo SBRT to all lesions for 1, 3, or 5 treatment doses (fractions) over the span of 10-20 days in the absence of disease progression or unacceptable toxicity.
62814960|NCT04443244|EXPERIMENTAL|Botulinum Toxin Type A(Botulax®) 24Units|Botulinum Toxin Type A (Botulax®) 24Units total dose administered intramuscularly to the bilateral masseter muscles.
62814961|NCT04443244|EXPERIMENTAL|Botulinum Toxin Type A(Botulax®) 48Units|Botulinum Toxin Type A (Botulax®) 48Units total dose administered intramuscularly to the bilateral masseter muscles.
62814962|NCT04443244|EXPERIMENTAL|Botulinum Toxin Type A(Botulax®) 72Units|Botulinum Toxin Type A (Botulax®) 72Units total dose administered intramuscularly to the bilateral masseter muscles.
62429246|NCT06398145|EXPERIMENTAL|Treatment|Patients will undergo 3 months treatment with 1200 mg D-chiro-inositol and 120 mg lactalbumin, than 3 months treatment with 600 mg D-chiro-inositol and 60 mg lactalbumin
62814963|NCT04443244|EXPERIMENTAL|Botulinum Toxin Type A(Botulax®) 96Units|Botulinum Toxin Type A (Botulax®) 96Units total dose administered intramuscularly to the bilateral masseter muscles.
62814964|NCT04443244|PLACEBO_COMPARATOR|Placebo(Normal Saline)|Placebo(Normal saline) administered intramuscularly to the bilateral masseter muscles.
62037314|NCT04642508|OTHER|Prepectoral Reconstruction|Women with breast cancer or with high risk for breast cancer in whom a sparing mastectomy and prepectoral reconstruction was performed
62814965|NCT05405920|EXPERIMENTAL|Team-based Care Strategy for Hypertension Control|The core component of the intervention is a stepped-care protocol, based on the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Clinical Practice Guideline for High Blood Pressure and the 2021 World Health Organization (WHO) Hypertension Guideline. Using a team-based care model, a physician-nurse-CHW team will work with patients to implement clinical guideline-based treatment in all intervention clinics. Team-based care components will include task sharing and shifting, health care team training, home BP monitoring, BP audit and feedback, and CHW-led health coaching on lifestyle modification and medication adherence.
62814966|NCT05405920|ACTIVE_COMPARATOR|Enhanced Usual Care|We will train the primary care physicians, nurses, and other clinic staff in performing standardized BP measurements. We will offer physician education on clinical guidelines for hypertension management and issue continuing medical education credits. Patient educational materials will be distributed. We will not conduct any other interventions in the enhanced usual care clinics.
62596794|NCT06461247|EXPERIMENTAL|Very Low Calorie Diet Ready-to-eat (VLCD RTE) meals|"Participants (n=70) in the VLCD RTE meals group will be advised to follow a calorie-restricted healthy ketogenic diet , consuming a maximum of 800 calories and 50g net carbohydrate intake daily.~Participants will be provided with VLCD RTE meals for lunch and dinner for 4 weeks and advised on a healthy keto breakfast.~The participants will be expected to self-monitor their weight, physical activity and diet logs via the nutritionist buddy keto app. There will be in app virtual reminders (automated and by dietitians via the chat function) sent via the nutritionist buddy keto application for the 1 month for participants to log in their weight and meals."
62814967|NCT05608434|EXPERIMENTAL|Floreo VR group|This group will undergo up to 20 daily sessions (20 minutes each) of the Floreo VR training.
62814968|NCT03797651|ACTIVE_COMPARATOR|Standard DAPT|Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.
62814969|NCT03797651|EXPERIMENTAL|Very-short DAPT within 1 month|Patient will stop aspirin after discharge (DAPT less than 1 months after PCI) (ticagrelor monotherapy). Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
62814970|NCT01500590|EXPERIMENTAL|renin-angiotensin system blockers|Those eligible patients will be randomized into 2 groups. One group use renin-angiotensin systems (RAS) blockers to control their blood pressure, the other group will use other types of anti-hypertensive agents other than RAS blockers
62814971|NCT01500590|ACTIVE_COMPARATOR|non-renin angiotensin system blockers|"These includes norvasc adalat retard natrilix betaloc aldomet~amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg once daily to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg once daily to 500mg twice daily"
62238658|NCT04169386|EXPERIMENTAL|AK102 300mg|AK102 300mg
62037315|NCT05646186|EXPERIMENTAL|Personalised diet based on microbiome analysis|Personalized diet application based on artificial intelligence-assisted microbiome analysis. After the microbiome analysis is made from the stool samples to be taken from the individuals, a personalized diet program will be created with an artificial intelligence-based algorithm and a diet will be applied for 6 weeks with the support of a professional dietitian.
62037316|NCT05646186|ACTIVE_COMPARATOR|Low FODMAP diet|After the microbiome analysis is made from the stool samples to be taken from the individuals, low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet will be applied for 6 weeks with the support of a professional dietitian.
62037317|NCT06061510|EXPERIMENTAL|fish oil group|Fish oil supplement capsules contained omega-3 polyunsaturated fatty acids supplied by Royal DSM Group, the Netherlands. Each 100 grams of fish oil capsules contains mainly 36.86 grams of EPA, 17.47 grams of DHA and other types of fatty acids.
62238659|NCT04169386|EXPERIMENTAL|AK102 500mg|AK102 500mg
62238660|NCT04169386|PLACEBO_COMPARATOR|Placebo|Matching placebo
62238661|NCT02547233|EXPERIMENTAL|LEO 43204 gel|Treatment once daily for 3 days
62238662|NCT02547233|PLACEBO_COMPARATOR|Vehicle gel|Treatment once daily for 3 days
62238663|NCT02801903|EXPERIMENTAL|SB204 4%|Topically Once Daily (AM)
62429247|NCT02580318|EXPERIMENTAL|all study participants|subjects consumed alcohol to a BrAC of 0.1 and then performed the following manipulations while using the breathalyzer: poor effort, hyperventilation (immediate), hyperventilation (after 5 minutes), hyperventilation (after 10 minutes), drinking water (immediate), drinking water (after 5 minutes)
62429248|NCT01559818|EXPERIMENTAL|IMM-101|IMM-101 1.0 mg administered intradermally
62596795|NCT06461247|ACTIVE_COMPARATOR|Liquid Meal Replacement|"Participants (n=70) in the liquid meal replacement group will be advised to follow very low-calorie diet, with a maximum of 800 calories and 50g net carbohydrate intake daily.~Participants will be provided with a liquid meal replacement for breakfast, lunch, and dinner for 4 weeks. Additionally, patients are to prepare 1 serving of non-starchy vegetables are to be included for lunch and dinner.~The participants will be expected to self-monitor their weight, physical activity and diet logs via the nutritionist buddy keto app. There will be in app virtual reminders (automated and by dietitians via the chat function) sent via the nutritionist buddy keto application for the 1 month for participants to log in their weight and meals."
62596796|NCT02900105|EXPERIMENTAL|Letrozole|Participants will be assigned to receive Letrozole 2.5 mg once a day for 4 months
62596797|NCT01223469|EXPERIMENTAL|Atrial Fibrillation|
62596798|NCT01223469|EXPERIMENTAL|Right-sided Supraventricular Tachycardia|
62596799|NCT06144320|EXPERIMENTAL|Treatment group|Practicing acupuncture on specific acupoints. The retention time of the needle is 30 minutes every time and the frequency of treatment is 3 times per week for 8 weeks.
62596800|NCT06144320|SHAM_COMPARATOR|Placebo group|"Practicing sham acupuncture on specific acupoints is the same as the treatment group, and also the same retention and frequency.~This study used the specifically made needle with a blunt tip, the Streitberger device, as the sham acupuncture. The needle does not penetrate the skin and retracts in the handle while the acupuncturist needles into the skin."
62429249|NCT01282827|EXPERIMENTAL|rtACS (Verum condition)|Repetitive transorbital alternating current stimulation (rtACS)
62429250|NCT01282827|PLACEBO_COMPARATOR|Placebo stimulation|no intervention (Sham stimulation)
62429251|NCT06274125||NGAL measurement for evaluating kidney damage in patients undergoing robotic radical prostatectomy.|For the evaluation of kidney damage in patients undergoing robotic radical prostatectomy, blood samples will be collected at preoperative and perioperative 2nd and 6th hours to measure NGAL values.
62429252|NCT01336608|EXPERIMENTAL|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
62429253|NCT01336608|EXPERIMENTAL|vilanterol|Inhaled long acting beta-agonist
62429254|NCT01336608|PLACEBO_COMPARATOR|placebo|Placebo
62596801|NCT05856149|EXPERIMENTAL|STEPS|Participants will have access to the mobile, web-based diabetes prevention program-- STEPS--for a total of three months or twelve weeks. They will be able to access all program modules and tools during this period.
62596802|NCT05856149|NO_INTERVENTION|Usual Care|Participants in the Usual Care control group will not receive an intervention.
62596803|NCT02781753|EXPERIMENTAL|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C.
62596804|NCT02781753|ACTIVE_COMPARATOR|Pegasys|Peginterferon 180 μg single dose S.C.
62596805|NCT03096678||LBBB without LV dysfunction|LVEDD\>55mm or LVEF\<55%
62596806|NCT03096678||LBBB with LV dysfunction|LVEDD\<55mm and LVEF\>55%
62596807|NCT05856370|OTHER|Receiving eligible Medtronic Powered Systems, Instruments, and Imaging device(s)|
62596808|NCT05856370|OTHER|Receiving eligible Advanced Energy device(s)|
62596809|NCT05856370|OTHER|Receiving eligible device(s) from all other product groups|Robotics and Navigation, Rods and Screws, Interbodies and Biologics, Spinal Tethers, and Other Spinal Hardware device(s)
62596810|NCT00312481|EXPERIMENTAL|1|MOVIPREP
62596811|NCT00312481|ACTIVE_COMPARATOR|2|Picolax
62814972|NCT06478667|PLACEBO_COMPARATOR|control group|"will receive the traditional supportive treatment according to (PCC-ASUH) protocol~• Interventions: Inotropic agent: Dobutamine Vasopressor: norepinephrine N-acetylcysteine: antioxidant Magnesium Sulphate: antiarrhythmic Sodium Bicarbonate Powder and ondansetron hydrocortisone 100 mg every 4-6h"
62238664|NCT05817760|EXPERIMENTAL|Z-scrotoplasty|Pediatric patients with congenital penoscrotal web who will be treated by Z-scrotoplasty
62238665|NCT05817760|EXPERIMENTAL|Heineke-Mikulicz scrotoplasty|Pediatric patients with congenital penoscrotal web who will be treated by Heineke-Mikulicz scrotoplasty
62238666|NCT04757532|EXPERIMENTAL|Bupropion|Subjects receive a single-dose treatment. Urine samples will be collected until 3 days after administration in 6 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h post-administration.
62238667|NCT04757532|EXPERIMENTAL|Anastrozole|Subjects receive a single-dose treatment. Urine samples will be collected until 7 days after administration in 7 fractions: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h post-administration.
62238668|NCT04757532|EXPERIMENTAL|Testosterone cyclopentylpropionate|Subjects receive a single-dose treatment. Urine samples will be collected until 20 days after administration in 20 fractions: first urine of the day, every day.
62238669|NCT04757532|EXPERIMENTAL|Danazol|Subjects receive a single-dose treatment. Urine samples will be collected until 2 days after administration in 6 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h post-administration.
62238670|NCT04757532|EXPERIMENTAL|Chlorthalidone|Subjects receive a single-dose treatment. Urine samples will be collected until 3 days after administration in 4 fractions: 0-12h, 12-24h, 24-48h y 48-72h post-administration.
62238671|NCT04815954|EXPERIMENTAL|Early group|Early urinary catheter removal: 24±6 hours after completion of surgery.
62238672|NCT04815954|ACTIVE_COMPARATOR|Delayed group|Delayed urinary catheter removal: 72±6 hours after completion of surgery.
62238673|NCT01143103|EXPERIMENTAL|Respiratory therapy with cough assist|
62238674|NCT01143103|ACTIVE_COMPARATOR|Usual respiratory therapy|
62238675|NCT02882919|EXPERIMENTAL|Check Yourself v2.0|In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
62238676|NCT02882919|NO_INTERVENTION|Usual care|In the usual care group, patients are asked to complete health risk screening on a computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors
62238677|NCT04322422|EXPERIMENTAL|ICS/LABA plus Montelukast|
62238678|NCT04322422|ACTIVE_COMPARATOR|ICS/LABA only|
62238679|NCT01788267|EXPERIMENTAL|Healthy volunteers|Volunteers realize a HR-pQCT scanner
62596812|NCT06648967|EXPERIMENTAL|Baseline exercise tests with carbohydrate feeding and after supplementation|This arms includes the assessment for difference between two different boluses of carbohydrate after a hiking test in the heat on fructose malabsorption measured by determining a hydrogen breath curve, as well as taking multiple self-reported gastrointestinal symptom ratings during exercise test 1 and 2. In addition, this arm will assess hydrogen breath response and gastrointestinal symptom ratings (using one of the previously determined carbohydrate boluses) after supplementing a multi-ingredient whey protein for 3 weeks, followed by 2 more weeks of supplementation.
62814973|NCT06478667|ACTIVE_COMPARATOR|levosemindan group|will receive the traditional supportive treatment without dobutamine as inotropic agent instead levosimendan will be started in bolus dose of 6-12 µg/kg over 10 minutes followed by infusion of 0.05 - 0.2µg/kg/min with adjusting infusion rate according to response and adverse events.
62814974|NCT06466577|OTHER|Image quality performance|
62814975|NCT04467736|NO_INTERVENTION|Control|No further treatment after alveolar ridge preservation
62814976|NCT04467736|ACTIVE_COMPARATOR|Test|In case the test group comes out, instructions for the daily application of hyaluronic acid (Gengigel Forte©) will be given. Hyaluronic acid will be administered by the patient 3 times per day during 7 days.
62238680|NCT01788267|EXPERIMENTAL|Cystic Fibrosis patient|Patients realize a HR-pQCT scanner
62238681|NCT02563093|EXPERIMENTAL|Study Group 1|Adults 18 to \< 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine
62429255|NCT01999790|EXPERIMENTAL|Blepharothomy|Patients treated with blepharotomy to correct upper lid retraction secondary to Grave's orbitopathy
62429256|NCT01999790|EXPERIMENTAL|posterior approach|Patients treated with a posterior approach to correct upper lid retraction secondary to Grave's orbitopathy
62429257|NCT02293811|OTHER|biopsy|"We will use colonic biopsies performed in the gastroenterology after obtaining consent from the patient and the agreement of the committee for the protection of persons. 5 biopsy will be performed for all patients except those with colon cancer for xhich we realize only 3 colonic biopsy (1 in healthy area and 2 in cancerous area )~To obtain statistically significant results we will establish the following six study groups, as far as possible matched for age and sex:~* healthy patients;~* patients with colonic Crohn disease in acute phase;~* patients with colonic Crohn disease in chronic phase;~* patients with ulcerative colitis in acute phase;~* patients with ulcerative colitis in chronic phase;~* patients with colon cancer"
62429258|NCT02011802|ACTIVE_COMPARATOR|Algosteril TM|Calcium alginate dressings are made from seaweed. Calcium alginate dressings form a natural gel of the exudates against the healing tissue that keeps it moist and supple, aiding in healing and tissue growth. In addition, this gel material forms a natural barrier to bacteria that may complicate healing with secondary infections of the wound. Alginates are the reference of dressing after sinus pilonidal excision.
62429259|NCT02011802|EXPERIMENTAL|Sorbact TM|DACC (dialkylcarbamoyle chloride) is a main component of the bacterial binding wound dressing: Sorbact. DACC is a hydrophobic fatty acid derivative that can be used to coat dressing materials, resulting in a dressing with highly hydrophobic pathogen binding properties. This is a primary wound interface dressing and is effective when in close contact with the wound bed in a moist environment.
62429260|NCT03631459||Kanglaite Injection/Capsules|Kanglaite injection 200ml, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
62429261|NCT00175383|EXPERIMENTAL|Leuprolide preparations|One versus three-month Leuprolide preparations in patients otherwise suitable for our Brachytherapy Program
62429262|NCT04711863|EXPERIMENTAL|Fluvoxamine|Start fluvoxamine 50 mg once, then 100 mg twice daily until discharge from community treatment center or for approximately 10 days. The maintenance dose may be reduced for tolerability reasons.
62429263|NCT04711863|PLACEBO_COMPARATOR|Placebo|Start ursodeoxycholate (UDCA) 100 mg once, then 100 mg twice daily until discharge from community treatment center or for approximately 10 days. The maintenance dose may be reduced for tolerability reasons.
62429264|NCT05975463|EXPERIMENTAL|HAIC+Adebrelimab+Bevacizumab|hepatic artery infusion of Adebrelimab 1200mg, d1, q3w, combined with hepatic artery infusion of Bevacizumab 5mg/kg, d1, q3w, HAIC treatment for 3-4 times.
62429265|NCT06538129|EXPERIMENTAL|Experimental Group|The participants will receive the hypersensitivity prevention protocol with Er:YAG laser in cervical region (central incisor, lateral incisor and canine).
62429266|NCT06538129|EXPERIMENTAL|Control Group|The participants will receive the hypersensitivity prevention protocol with neutral sodium fluoride gel for 4 minutes (central incisor, lateral incisor and canine).
62429267|NCT00420160|EXPERIMENTAL|Exercise|3x/wk 50 minutes of moderate intensity walking on treadmills + health education videos
62429268|NCT00420160|OTHER|Health Education|Contact control group attending 3x/wk 50 minutes of health education videos
62429269|NCT02465580|ACTIVE_COMPARATOR|hrIL-2 active|Intervention：Add hrIL-2 according to the protocol to original treatment. HrIL-2 active: 1 million U doses of human recombinant interleukin-2 s.c. injection
62429270|NCT02465580|PLACEBO_COMPARATOR|hrIL-2 placebo|1 million U doses of placebo s.c. injection
62429271|NCT05613335|EXPERIMENTAL|fibrin glue group|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement
62429272|NCT05613335|EXPERIMENTAL|sticky bone group|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement
62429273|NCT02803645|EXPERIMENTAL|healthy|blood sample
62814977|NCT05616104||FLEX Vessel Prep followed by angioplasty|Eligible subjects will be treated with the FLEX Vessel Prep system followed by balloon angioplasty.
62238682|NCT02563093|EXPERIMENTAL|Study Group 2|Adults 18 to \< 65 years of age randomly assigned to receive an intradermal injection of one dose of Fluzone Intradermal Quadrivalent vaccine
62238683|NCT02563093|EXPERIMENTAL|Study Group 3|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine
62238684|NCT02563093|EXPERIMENTAL|Study Group 4|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone High-Dose vaccine
62238685|NCT01009034||12 male HIV-positive patients|Male HIV-positive patients who have been receiving stable antiretroviral therapy that includes maraviroc for a minimum of three months.
62238686|NCT02460497|EXPERIMENTAL|Treatment|
62429274|NCT04811222|EXPERIMENTAL|Ga-DOTATATE PET/MRI scan|Patients with abdominal aortic aneurysm will undergo Ga-DOTATATE PET/MRI scan
62429275|NCT01407679|EXPERIMENTAL|Alitretinoin|
62429276|NCT03767673|EXPERIMENTAL|Patients after esophageal atresia|Patients older than 12 years following surgical repair of congenital esophageal atresia will be included after written informed consent. Patients will be subjected to spirometry to determine their age, weight (determined by Kilogram (kg) on a medical weight scale) and Vital Capacity before (initial Spirometry) and after (final Spirometry) exercise performance testing. Bicycle ergospirometer will be applied to determine the Maximum Oxygen Uptake and the Maximum Performance. Thereafter deep induced sputum will be harvested for measurements of the pulmonary microbiome (Pulmonary Microbiome 16S rDNA profiling).
62429277|NCT03767673|ACTIVE_COMPARATOR|Control group|Age and sex matched adolescents will be recruited as control group and will be included after written informed consent. Adolescents will be subjected to spirometry to determine their age, weight (determined by Kilogram on a medical weight scale) and Vital Capacity before (initial Spirometry) and after (final Spirometry) exercise performance testing. Bicycle ergospirometer will be applied to determine the Maximum Oxygen Uptake and the Maximum Performance. Thereafter deep induced sputum will be harvested for measurements of the pulmonary microbiome (Pulmonary Microbiome 16S rDNA profiling).
62429278|NCT03371238|EXPERIMENTAL|Floorball|
62429279|NCT03371238|NO_INTERVENTION|Control|
62429280|NCT00078819|PLACEBO_COMPARATOR|Placebo|"Participants received placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a \> 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.~Participants received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36).~At week 36, participants with PASI 50 at week 24 or PASI 75 at week 36 were re-randomized to placebo or etanercept in the 12-week double-blind, withdrawal-retreatment period (weeks 37 to 48)."
62238687|NCT05687643||Diabetic Foot Ulcer (DFU) group|"Inclusion criteria:~1. Age \>18~2. A diagnosis of diabetes mellitus~3. A diagnosis of diabetic peripheral neuropathy~4. Recently healed plantar ulcer (within the last 3 months)"
62429281|NCT00078819|EXPERIMENTAL|Etanercept|"Participants received 0.8 mg/kg etanercept administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a \> 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.~Participants received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36).~At week 36, participants with PASI 50 at week 24 or PASI 75 at week 36 were re-randomized to placebo or etanercept in the 12-week double-blind, withdrawal-retreatment period (weeks 37 to 48)."
62814978|NCT06705361|EXPERIMENTAL|Transparent Radial Band Compression Device (Screw-Type)|To perform TR Band Compression Device (Screw Type) placement after radial arterial line removal, position the patient with the forearm and wrist exposed, ensuring privacy. Place an absorbent pad under the area and clean the puncture site with povidone. Withdraw the radial arterial line by 2-3 cm and secure the TR Band Compression Device with the strap, ensuring it is tight enough to prevent spinning. Adjust the screw cap to control pressure, gradually removing the line while maintaining hemostasis. Use the reverse Barbeau's test to confirm radial artery patency and adjust pressure as needed. After bleeding stops, unfasten the band while stabilizing the site, clean any blood, and apply a sterile gauze dressing. Reassess hand perfusion to ensure adequate blood flow.
62238688|NCT05687643||Low risk group|"Inclusion criteria:~1. Age \>18~2. A diagnosis of diabetes mellitus~3. Low risk for DFU according to the NG19 guidelines (no risk factors for ulceration except callus alone)"
62238689|NCT00472329|NO_INTERVENTION|Fludarabine and 400cGY TBI|
62429282|NCT01164397||Dislipidemic Population|People with high levels of total cholesterol, LDL, C-HDL and triglycerides
62238690|NCT03272542|EXPERIMENTAL|Prebiotic: soluble corn fiber|SCF (PromotorTM Soluble Corn Fiber 85, provided by manufacturer Tate \& Lyle) will be dispensed to participants as a dry powder in sachets of 12 g SCF85 product (which is approximately 10 g fiber). Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be asked to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
62238691|NCT03272542|PLACEBO_COMPARATOR|Placebo|The placebo control will be maltodextrin powder in identical sachets. Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be requested to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
62238692|NCT04620811|EXPERIMENTAL|3.0 mg/kg of Lirentelimab (AK002)|Subjects in this arm will receive up to 18 monthly doses (3mg/kg) of lirentelimab (AK002)
62596813|NCT06643416|ACTIVE_COMPARATOR|Timolol combination treatment|Patients will received topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.
62596814|NCT06643416|OTHER|Routine Arm|Patients in routine arm would receive the management according to routine clinical practice, including prescription of betamethasone valerate 0.1% cream twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.
62596815|NCT05672407|EXPERIMENTAL|Tranexamic Acid Group|Participants undergoing standard of care periorbital procedures will be randomized to receive tranexamic acid with lidocaine/epinephrine on one of their eyelids at the beginning of the scheduled operation before incision.
62814979|NCT06705361|EXPERIMENTAL|Transparent Radial Band Compression Device (Air-Type)|To perform TR Band Compression Device (Air Type) placement after radial arterial line removal, position the patient with the forearm and wrist exposed, ensuring privacy. Place an absorbent pad under the area and clean the puncture site with povidone. Withdraw the radial arterial line by 2-3 cm and secure the TR Band with the strap, aligning the green marker 1-2 mm proximal to the puncture site. Inflate the balloon with 15-18 mL of air using the syringe, removing the arterial line as the balloon inflates. Titrate air by removing 1 mL per minute while monitoring for bleeding or deflate in one step. Use the reverse Barbeau's test to confirm radial artery patency and adjust air volume as needed. Once hemostasis is achieved, deflate the band, unfasten it, clean the site, and apply a sterile gauze dressing. Reassess hand perfusion to ensure adequate blood flow.
62814980|NCT06705361|EXPERIMENTAL|Ice-Bag Pressure|Titrate pressure using the TR Band's mechanical screw cap to maintain patent hemostasis. If bleeding occurs during pressure release, restore compression. Confirm radial pulse and evaluate artery patency using the reverse Barbeau's test. Place an oxygen saturation probe on the thumb or index finger and compress the ulnar artery, observing the waveform. If absent, reduce pressure until the waveform returns, ensuring antegrade flow. Once pressure is fully released, confirm bleeding has stopped. Stabilize the access site, unfasten, and remove the band slowly. Clean any blood with sterile gauze, apply a dressing (not encircling the wrist), and reassess hand perfusion. Ensure proper positioning for left or right wrist use.
62596816|NCT05672407|PLACEBO_COMPARATOR|Placebo Group|Participants undergoing standard of care periorbital procedures will be randomized to receive balanced salt solution with lidocaine/epinephrine on one of their eyelids at the beginning of the scheduled operation before incision.
62814981|NCT06034210|EXPERIMENTAL|ZOLES insoles|Participants allocated to the intervention group will receive customised 3D-printed insoles (Zoles ApS, Espergærde, DK-3060, Denmark) to mitigate running-related pain and discomfort. Being a pragmatic trial, all participants are permitted to continue or initiate any usual care of their choice.
62814982|NCT06034210|NO_INTERVENTION|Do-as-usual|"Participants allocated to the control group are a do-as-usual comparator. This implies, that the participants can treat and prevent running-related pain and discomfort in any way they wish, except using the Zoles 3D-printed insoles."
62238693|NCT05665088|EXPERIMENTAL|Cohort 1- 40 Micrograms|Sublingual film containing 40 Micrograms Dexmedetomidine
62037318|NCT06061510|PLACEBO_COMPARATOR|The placebo group|The placebo for fish oil contained corn oil (Each 100 grams of corn oil contained 45.64 grams of linoleic acid, 25.62 grams of oleic acid, 17.0 grams of palmitic acid, and other fatty acids).
62037319|NCT04769427|EXPERIMENTAL|PDO Max thread injection to nose|
62238694|NCT05665088|EXPERIMENTAL|Cohort 2- 60 Micrograms|Sublingual film containing 60 Micrograms Dexmedetomidine
62238695|NCT05665088|PLACEBO_COMPARATOR|Placebo|Sublingual Placebo film
62238696|NCT03798223|EXPERIMENTAL|180/low|SLT treatment in the lower half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
62238697|NCT03798223|EXPERIMENTAL|180/high|SLT treatment in the lower half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
62238698|NCT03798223|EXPERIMENTAL|360/low|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
62238699|NCT03798223|EXPERIMENTAL|360/high|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
62238700|NCT05138523||Non-cirrhotic|Non-cirrhotic HCV patients; 12 weeks treatment
62238701|NCT05138523||Cirrhotic|Cirrhotic HCV patients; 24 weeks treatment
62238702|NCT01103635|EXPERIMENTAL|Arm I|Patients receive tremelimumab over 1 hour on day 1 and CD40 agonist monoclonal antibody CP-870,893 IV over 30 minutes on days 2, 22, 43, and 64. Treatment repeats every 12 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62238703|NCT03539783||PARDS|Children \<18 years of age with PARDS and expected duration of hospitalization seven days or greater.
62814983|NCT06175767|EXPERIMENTAL|Screening Phase (Day -28 to Day -1, up to 28 days):|"Screening phase is designed to determine subject's eligibility to proceed to Randomization and the Treatment Phase of the study. During this phase, a series of assessments will be performed to determine subject eligibility as per inclusion and exclusion criteria.~Subjects who meet eligibility criteria, but have some abnormal laboratory values, based on PI review a repeat laboratory sample may be collected. The repeat laboratory reports should be reviewed by the PI to confirm eligibility prior to randomization.~Subjects who fail to meet eligibility criteria during the Screening phase will be considered screen failures and will be exited from the study. Subjects who meet the eligibility criteria will be scheduled for randomization visit."
62037320|NCT00712023|ACTIVE_COMPARATOR|1|warming by circulating-water mattress
62037321|NCT00712023|NO_INTERVENTION|2|Forced-air warming mattress
62037322|NCT03919383|EXPERIMENTAL|Lenvatinib Plus Toripalimab|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\<) 60 kg at baseline, orally, once daily (QD) in continuous 21-day treatment cycles, and received 240mg toripalimab intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62037323|NCT06670664||Head Start Program|Recruited Head Start program and its program director, a staff member in charge of recruitment, selection, and enrollment, and community partners who help support those efforts, and parents/caregivers of students enrolled in one classroom.
62037324|NCT02024906|EXPERIMENTAL|soy protein isolate (SPI)|25 grams soy protein isolate (SPI) containing approximately 30 mg/d isoflavones
62037325|NCT02024906|ACTIVE_COMPARATOR|milk protein isolate (MPI)|milk protein isolate (MPI) containing 0 mg/d isoflavones
62037326|NCT00862134|ACTIVE_COMPARATOR|Docetaxel 75 mg/m^2|Subjects randomized to the docetaxel arm will be administered 75 mg/m\^2, IV, every 21 days (an approved dose and schedule)
62037327|NCT00862134|EXPERIMENTAL|PR104 + 60 mg/m^2 docetaxel|Subjects randomized to the PR104/docetaxel arm will be administered 60 mg/m\^2 docetaxel, IV, every 21 days plus 770 mg/m\^2 PR104, IV, every 21 days and prophylactic G-CSF.
62238704|NCT03539783||Control|Children \<18 years of age without PARDS or other lung disease and expected duration of hospitalization 7 days or greater.
62429283|NCT03020836|OTHER|Hypertension patient referral|Referral to primary care physician for hypertension control: Patients with uncontrolled hypertension were referred to a primary care physician for treatment.
62429284|NCT03020836|OTHER|Smoking cessation patient referral|Referral to smoking quit line: Patients that were current smokers were referred to the Maryland smoking cessation quit line if they were willing.
62429285|NCT03156270|EXPERIMENTAL|Vivaer Stylus Treatment|Thermal treatment of the submucosal tissue including cartilage in the internal nasal valve area
62429286|NCT01698762||Osteoarthritis (OA)|"One OA group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One OA group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
62429287|NCT01698762||Osteoporosis (OP)|"One OP group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One OP group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
62596817|NCT05880082|EXPERIMENTAL|tislelizumab, Q3W with TP regimen|Tislelizumab 200mg, Q3W, 2-4 cycles Albumin paclitaxel 240 mg/m², adjusted according to the patient Carboplatin: AUC=5 Q3W, d1 or cisplatin: 20mg/m² iv, D1-3 Q3W or Nedaplatin: 70mg d1 Q3W
62037328|NCT04180618|EXPERIMENTAL|Patients(Care givers)|"1. 1,000 patients(caregivers) are enrolled and use the personal health wallet service.~2. They fill out questionnaire to evaluate the service~3. Some of them are invited for an in-depth interview."
62037329|NCT04180618|EXPERIMENTAL|Medical staffs|"1. 12 medical staffs are enrolled and use the personal health wallet service.~2. After that, they are invited for an in-depth interview."
62037330|NCT05656950||Observed|Oral health of the patient was evaluated by the researcher using a flashlight, tongue depressor and Oral Evaluation Guide. Patient's age, gender, day of hospitalization in pediatric intensive care units, medical diagnosis/diagnoses, presence of chronic disease, state of consciousness, body temperature, oral care application method, oral care application frequency, oral care product used, amount taken/extracted, drugs used, albumin and haemoglobin data on values were obtained from the observation form of the patient.
62243454|NCT06735690|EXPERIMENTAL|Part 1 (allo CMV-specific CD19-CAR T cells|Patients receive HSCT conditioning regimen followed by alloHSCT per standard of care. Starting 28-49 days after alloHSCT, patients receive allo CMV-specific CD19-CAR T cells IV over 10-15 minutes on day 0. Patients undergo ECHO or MUGA, blood and optional CSF sample collection and bone marrow biopsy and aspiration throughout the study. Patient may also undergo chest x-ray and lumbar puncture as needed per PI discretion and PET/CT or CT as clinically indicated throughout the study. Additionally, patients with neurological abnormalities at baseline may undergo MRI of brain throughout the study.
62238705|NCT06046755|EXPERIMENTAL|Energy restriction-ketogenic intervention (VLCKD)-breast cancer arm|Breast cancer patients with obesity will follow an energy-restricted-ketogenic dietary five steps program, which includes lifestyle and behavioral modification support. The first three steps consist of a VLCKD (600 -800 kcal/day), low in carbohydrates (\< 50 g daily from vegetables) and lipids (only 10 g of olive oil per day). Throughout these ketogenic phases, supplements of vitamins and minerals supplements, such as K, Na, Mg, Ca, and omega-3 fatty acids will be administered. These three steps will be maintained until the patient lost the target amount of weight, ideally 80%. In steps 4 and 5, the patient started a low-calorie diet (800 -1500 kcal/day) and followed by a maintenance diet that will consist of an eating plan balanced in carbohydrates, protein, and fat (1500 and 2000 kcal/day).
62238706|NCT06046755|EXPERIMENTAL|Group educational intervention program (IGOBE)-breast cancer arm|Breast cancer patients with obesity will follow structured program of change of habits that will consist of a balanced hypocaloric diet, following the criteria of both the recommendations from Spanish Society of Study of Obesity (SEEDO) 2007, the American Dietetic Guidelines 2010, the Consensus SEEDO 2012 and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society Guideline for the Management of Overweight and Obesity in Adults 2014. Coinciding all in pointing out that the hypocaloric diet should represent a deficit of about 500 to 1000 kcal / day with respect to the habitual intake of the patient in question. The intervention group will be included in a structured program of habits change and exercise. In the intensive phase of the intervention patients will assist to 6 additional weekly visits, with 15 patients per group and a duration of 60 minutes each.
62238707|NCT06046755|EXPERIMENTAL|Energy restriction-ketogenic intervention (VLCKD)-tumor free arm|Tumor-free patients with obesity will follow an energy-restricted-ketogenic dietary five steps program, which includes lifestyle and behavioral modification support. The first three steps consist of a VLCKD (600 -800 kcal/day), low in carbohydrates (\< 50 g daily from vegetables) and lipids (only 10 g of olive oil per day). Throughout these ketogenic phases, supplements of vitamins and minerals supplements, such as K, Na, Mg, Ca, and omega-3 fatty acids will be administered. These three steps will be maintained until the patient lost the target amount of weight, ideally 80%. In steps 4 and 5, the patient started a low-calorie diet (800 -1500 kcal/day) and followed by a maintenance diet that will consist of an eating plan balanced in carbohydrates, protein, and fat (1500 and 2000 kcal/day).
62238708|NCT06046755|EXPERIMENTAL|Group educational intervention program (IGOBE)-tumor free arm|Tumor-free patients with obesity will follow structured program of change of habits that will consist of a balanced hypocaloric diet, following the criteria of both the recommendations from Spanish Society of Study of Obesity (SEEDO) 2007, the American Dietetic Guidelines 2010, the Consensus SEEDO 2012 and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society Guideline for the Management of Overweight and Obesity in Adults 2014. Coinciding all in pointing out that the hypocaloric diet should represent a deficit of about 500 to 1000 kcal / day with respect to the habitual intake of the patient in question. The intervention group will be included in a structured program of habits change and exercise. In the intensive phase of the intervention patients will assist to 6 additional weekly visits, with 15 patients per group and a duration of 60 minutes each.
62238709|NCT06046755|NO_INTERVENTION|Non intervention arm-breast cancer arm|This arm will include patients with obesity and normal weight women with breast cancer that will follow the normal clinical practice in their oncological therapy without intervention to lose weight in the group of patients with excess body weight.
62238710|NCT06101953|NO_INTERVENTION|Control|
62238711|NCT06101953|EXPERIMENTAL|Intervention|
62429288|NCT01698762||Rheumatoid Arthritis (RA)|"One RA group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One RA group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
62596818|NCT03820817|EXPERIMENTAL|Treatment (rifaximin)|Patients receive rifaximin PO TID on days 1-14 in the absence of disease progression or unacceptable toxicity.
62596819|NCT03683186|EXPERIMENTAL|Ralinepag|Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the highest tolerated dose.
62596820|NCT01778738|EXPERIMENTAL|Sleeve gastrectomy|Sleeve gastrectomy.
62037331|NCT01702337||HPV-1 Group|Hypothetical group of women vaccinated with HPV-1 vaccine in Taiwan.
62037332|NCT01702337||HPV-2 Group|Hypothetical group of women vaccinated with HPV-2 vaccine in Taiwan.
62037333|NCT04117035|PLACEBO_COMPARATOR|Control arm|Standard care
62037334|NCT04117035|EXPERIMENTAL|Intervention|
62596821|NCT01778738|EXPERIMENTAL|Gastric bypass|Gastric bypass surgery.
62596822|NCT01778738|NO_INTERVENTION|Control group|This is an extra control group without diabetes. All subjects are morbidly obese patients recruited from the Morbid Obesity Centre.
62037335|NCT02573974|OTHER|Case group|the intervention, specific to the study, is to take samples on patients with advanced gastrointestinal cancer
62037336|NCT02573974|OTHER|Control group|the intervention, specific to the study, is to take samples on non-undernourished patients supported for adjuvant chemotherapy as part of colorectal cancer
62037337|NCT05346289||Women|
62037338|NCT05346289||Men|
62238712|NCT00528866|EXPERIMENTAL|Androgen suppression + RT + docetaxel|LHRH agonist and oral antiandrogen (flutamide or bicalutamide), radiation therapy (RT), and docetaxel
62429289|NCT02464059|EXPERIMENTAL|Vitamin D3|Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks
62429290|NCT02759211|ACTIVE_COMPARATOR|Forwards Walking Group (FWG)|The intervention will consist of three (3), treadmill exercise sessions per week, for eight (8) weeks, for a total of 24 exercise sessions.
62429291|NCT02759211|EXPERIMENTAL|Backwards Walking Group (BWG)|The intervention will consist of three (3), treadmill exercise sessions per week, for eight (8) weeks, for a total of 24 exercise sessions.
62429292|NCT03302299|EXPERIMENTAL|Isoniazid & pyridoxine|Isoniazid 300 mg oral tablet: 300 mg daily by mouth for 6 months. Pyridoxine 25 mg oral tablet: 25mg daily by mouth for 6 months.
62429293|NCT02060552|PLACEBO_COMPARATOR|Febuxostat|Febuxostat 40mg once a day
62429294|NCT02060552|EXPERIMENTAL|Febuxostat plus diacerein|Febuxostat 40mg once a day plus diacerein 50mg twice a day
62429295|NCT02060552|EXPERIMENTAL|Febuxostat plus Colchicine|Febuxostat 40mg once a day plus Colchicine 0.5mg twice a day
62429296|NCT00869089|EXPERIMENTAL|CC-10004|"CC-10004 treament:~30mg,oral medication, BID, for 24 weeks (60mg total DAILY)"
62429297|NCT05778708|EXPERIMENTAL|Tai-Chi intervention group|The standardized 16-form Yang-style Tai-Chi exercise set will be adopted.
62429298|NCT05778708|EXPERIMENTAL|Aerobic exercise intervention|The aerobic exercise class will be designed to cover both aerobic and resistance exercises.
62429299|NCT05778708|NO_INTERVENTION|Self-management control group|Patients in this group will receive written information regarding the recommended levels of exercise (i.e., at least 150 min of moderate-intensity or 75 min of vigorous-intensity aerobic exercise every week) that they can perform at home (self-management) while continuing to receive their standard treatment. They will also be provided with a daily exercise log to record their exercise type, frequency, and intensity.
62429300|NCT03207360|EXPERIMENTAL|Pain Coping Skills|
62429301|NCT04703530|EXPERIMENTAL|Hot footbath effect on schizophrenia patient' sleep quality|Participants were randomly allocated to the experimental group. The experimental group was given a hot footbath with a temperature of 41℃±1℃ for 20 minutes at about 1-2 hours before sleep, and this was repeated five times a week for four weeks. The CPSQI was used to collect the pre- and post-test data.
62429302|NCT04703530|NO_INTERVENTION|Routine care on schizophrenia patient' sleep quality|Participants were randomly allocated to the control group. They were given routine care for four weeks. The CPSQI was used to collect the pre- and post-test data.
62429303|NCT00891878|EXPERIMENTAL|Arm I|Patients receive oral capecitabine twice daily on days 1-14. Patients experiencing disease progression may crossover to arm II at the physician's discretion.
62596823|NCT05481593|EXPERIMENTAL|Scheduled Coaching Calls & Gamified Rewards|
62596824|NCT05481593|EXPERIMENTAL|No Scheduled Coaching Call & Gamified Rewards|
62596825|NCT05481593|EXPERIMENTAL|Scheduled Coaching Calls & Independent rewards (No Gamification)|
62596826|NCT05481593|EXPERIMENTAL|No Scheduled Coaching Calls & Independent Rewards (No Gamification)|
62238713|NCT05091723|EXPERIMENTAL|Administration Scenario A|Single dose of TD-0903 at Dose A on Day 1, Period 1 delivered by nasal inhalation via nebulizer device with a high-flow nasal cannula delivering supplemental oxygen
62238714|NCT05091723|EXPERIMENTAL|Administration Scenario B|Single dose of TD-0903 at Dose A on Day 1, Period 2 delivered by oral inhalation via nebulizer device with supplemental oxygen delivery via low-flow nasal cannula
62238715|NCT05091723|EXPERIMENTAL|Administration Scenario C|Single dose of TD-0903 at Dose A on Day 1, Period 3 delivered by oral inhalation via nebulizer device with supplemental oxygen delivery via high-flow nasal cannula
62238716|NCT05091723|EXPERIMENTAL|Administration Scenario D|Single dose of TD-0903 at Dose B on Day 1, Period 4 delivered by a route to-be-determined based on data from Scenarios A, B and C.
62238717|NCT01605253|ACTIVE_COMPARATOR|Eszopiclone|The total study duration is 16 weeks, with subjects taking 3mg eszopiclone at bedtime for 12 weeks. There is one follow-up visit after the 12 week treatment phase.
62429304|NCT00891878|EXPERIMENTAL|Arm II|Patients receive oral capecitabine as in arm 1 and oral sunitinib malate once daily on days 1-21.
62429305|NCT00272961|PLACEBO_COMPARATOR|placebo|
62429306|NCT00272961|EXPERIMENTAL|ARM 1|
62429307|NCT00272961|EXPERIMENTAL|ARM 2|
62429308|NCT00272961|EXPERIMENTAL|ARM 3|
62429309|NCT00272961|EXPERIMENTAL|ARM 4|
62429310|NCT05347030|EXPERIMENTAL|Acupuncture Group|"The acupuncture points are: EX-B3, BL18, BL20, BL21, GV20, GV29, LI11, CV12, CV10, ST25, CV6, CV4, ST40, SP6.~After piercing 15-35mm into the skin, the needles will be gently rotated and lifted three times to achieve a sense of sourness, distention, and heaviness (de qi). For EX-B3, BL18, BL20, and BL21, withdrawn afterward immediately. For GV20, GV29, LI11, CV12, CV10, ST25, CV6, CV4, ST40 and SP6, The needles will be maintained for 30 minutes."
62037339|NCT06501781|EXPERIMENTAL|Peer Activate-LAI|Peer Activate-LAI, is a peer recovery specialist-delivered (PRS) behavioral activation (BA) and problem solving intervention aimed at improving adherence to LAI-PrEP/ART. BA was originally developed as an efficacious treatment for depression, with accumulating empirical support for SUD outcomes, including SUD treatment retention and HIV medication adherence, particularly when integrated with problem solving strategies. BA offers important advantages compared to other psychosocial interventions by being feasible and potentially sustainable for PRS delivery, appropriate for low-income individuals with OUD and other non-opioid SUD, and focused on building positive reinforcement in the current environment through engagement in adaptive, valued behaviors.
62429311|NCT05347030|SHAM_COMPARATOR|Sham Acupuncture Group|"sham acupoints are located at a horizontal distance of 20 mm to those points used in the acupuncture group, and no manipulation was carried out after piercing the skin for 1-2mm to avoid de-qi sensation.~For sham EX-B3, BL18, BL20, and BL21, withdraw immediately after piercing. For sham GV20, GV29, LI11, CV12, CV10, ST25, CV6, CV4, ST40 and SP6, The needles will be maintained for 30 minutes after puncture."
62429312|NCT02883387|EXPERIMENTAL|Preoperative CT Angiography|Patients will receive preoperative CT angiography to map the blood vessels potentially used for reconstruction
62429313|NCT02883387|ACTIVE_COMPARATOR|No Imaging Preoperatively|No preoperative vessel mapping will be done
62429314|NCT01612702|EXPERIMENTAL|Dexamethasone|dexamethasone 10 mg administration 1 hour before surgery
62429315|NCT01612702|NO_INTERVENTION|Control|No dexamethasone
62429316|NCT05297071|OTHER|Dental Loupes|The surgeon will use dental loupes with a head lamp during the subject's tooth extraction and socket grafting.
62037340|NCT06501781|ACTIVE_COMPARATOR|Enhanced Treatment As Usual|Participants in the Enhanced Treatment As Usual (ETAU) arm receive access to standard clinical care, including access to a clinician with expertise in HIV and PrEP, opportunity for co-located treatment of OUD, and STI testing and treatment, and general peer support. Enhanced treatment includes reminder phone calls and facilitated referrals to psychosocial, housing, financial benefits and legal services.
62037341|NCT02212028|EXPERIMENTAL|Prasugrel crush|Prasugrel 60mg loading dose as crushed tablets
62037342|NCT02212028|ACTIVE_COMPARATOR|Prasugrel tablets|Prasugrel 60 mg loading dose as whole tablets
62037343|NCT00003298|EXPERIMENTAL|Experimental Arm|Patients receive 3 courses of preoperative neoadjuvant chemotherapy given on day 1 every 21 days. Courses consist of an intravenous infusion of cisplatin and a 3 hour intravenous infusion of paclitaxel on day 1. Patients then undergo surgery for tumor removal on day 63, followed 4-6 weeks later by one course of daily intravenous bolus leucovorin calcium and fluorouracil for 5 days. Chemotherapy is repeated 4-6 weeks later for the first 4 days of week 1 and the last 3 days of week 5 of radiation therapy given 5 days a week for 5 weeks. Patients receive two more courses, 4 weeks apart, of fluorouracil and leucovorin calcium for 5 days 4-6 weeks after completing radiation treatment.
62037344|NCT06732908|ACTIVE_COMPARATOR|Berberine LipoMicel|1000 mg of LipoMicel Berberine (2 soft gel capsules) administered daily to randomized healthy participants for 30 days.
62037345|NCT06732908|PLACEBO_COMPARATOR|Placebo|Placebo capsules containing microcrystalline cellulose administered daily to randomized healthy participants for 30 days.
62037346|NCT05231798|EXPERIMENTAL|Down Syndrome|Adults between 18-55 with Down Syndrome.
62037347|NCT05885672||Young Adults|Adults between the ages of 18 and 39 years
62037348|NCT06426550|EXPERIMENTAL|Photodynamic therapy and 0.005% methylene blue (PDT)|After conventional periodontal treatment, photosensitization will be performed with 0.005% methylene blue gel (Fórmula e Ação Farmácia, São Paulo, SP, Brazil) for 5 minutes, and photodynamic therapy will be applied with a red laser (660 nm) using a DuoⓇ laser (MMOptics, São Carlos, SP, Brazil) with the optical fiber inside the periodontal pocket in back and forth movements, according to the manufacturer's protocol, for 90s, 9 joules of energy, dose of 508.5J/cm2, irradiance of 5.65W/cm2 and power of 100mW.
62037349|NCT06426550|EXPERIMENTAL|Photobiomodulation with a red laser (PBMV)|After conventional periodontal treatment, photobiomodulation will be performed with a red laser (660 nm) using a DuoⓇ laser (MMOptics, São Carlos, SP, Brazil) with the optical fiber inside the periodontal pocket in back and forth movements, according to the manufacturer's protocol, for 90s, 9 joules of energy, dose of 508.5J/cm2, irradiance of 5.65W/cm2 and power of 100mW. As no gel will be applied, the application of the gel with an empty syringe will be simulated, and waited 5 minutes, to keep patients blind to the intervention received.
62037350|NCT06426550|EXPERIMENTAL|Photobiomodulation with an infrared laser (PBMIV)|After conventional periodontal treatment, photobiomodulation will be performed with an infrared laser (808 nm) using a DuoⓇ laser (MMOptics, São Carlos, SP, Brazil) with the optical fiber inside the periodontal pocket in back and forth movements, according to the manufacturer's protocol, for 90s, 9 joules of energy, dose of 508.5J/cm2, irradiance of 5.65W/cm2 and power of 100mW. As no gel will be applied, the application of the gel with an empty syringe will be simulated, and waited 5 minutes, to keep patients blind to the intervention received.
62037351|NCT06426550|PLACEBO_COMPARATOR|Saline solution - Control (C)|After conventional periodontal treatment, saline gel will be applied in the periodontal pocket and, after 5 minutes, the laser application will be simulated, with the device in inactive mode, in order to maintain blinding of the patients.
62238718|NCT01605253|PLACEBO_COMPARATOR|Placebo|The total study duration is 16 weeks, with subjects taking placebo at bedtime for 12 weeks. There is one follow-up visit after the 12 week treatment phase.
62238719|NCT01478360|EXPERIMENTAL|AIN457|AIN457 10 mg/kg
62429317|NCT05297071|OTHER|Surgical microscope|The surgeon will use a surgical microscope (with built-in lighting) during the subject's tooth extraction and socket grafting.
62429318|NCT01032759|ACTIVE_COMPARATOR|Memantine|
62429319|NCT01032759|PLACEBO_COMPARATOR|Placebo|Placebo
62429320|NCT04773171|EXPERIMENTAL|CACR Group|Participants of CACR group will attend individual computer-assisted cognitive remediation sessions. Researcher will give instruction in the use of the computerized training programs and assists participants during their training sessions.
62596827|NCT03719287||Hospital #1|Patients who meet inclusion criteria in the first of three participating Brazil hospitals
62429321|NCT04773171|ACTIVE_COMPARATOR|TAU Group|Participants of TAU group will attend usual training sessions offered by the training centres with similar intensity and frequency as the CACR training.
62429322|NCT05028751|EXPERIMENTAL|LANRA 20 mg QD + Gilteritinib 120 mg QD|Participants received LANRA 20 mg once daily (QD) as oral tablets in consecutive 28-day cycles starting from Cycle 1 Day 1. Participants also received gilteritinib 120 mg QD as oral tablets in consecutive 28-day cycles starting from Cycle 1 Day 2. Participants received treatment until progression/relapse or lack of at least a partial remission (PR) after 6 months of study treatment, intolerance, or withdrawal from treatment by the participant or study investigator.
62596828|NCT03719287||Hospital #2|Patients who meet inclusion criteria in the second of three participating Brazil hospitals
62596829|NCT03719287||Hospital #3|Patients who meet inclusion criteria in the third of the three participating Brazil hospitals
62596830|NCT05715489|OTHER|Patients with pelvic organ prolapse undergone pectopexy without using mesh|
62596831|NCT02584998|NO_INTERVENTION|Usual care|These patients will continue to receive the current practice at the Philadelphia VA Medical Center (VAMC) of offering screening during an office visit. Other interventions will be embedded within this existing program for a pragmatic approach. However, all participants in the trial, including those in usual care (UC), will receive follow-up of test results and navigation to diagnostic colonoscopy for positive FIT results.
62596832|NCT02584998|ACTIVE_COMPARATOR|Screening invitation-reminder|Participants will receive UC and also receive an invitation letter with information about CRC testing. The information will include lay-audience description of screening tests and symptoms that should prompt diagnostic work-up. The packet will have instructions to contact the study team if participants believe they are not eligible and to update the contact information on record. The letter will inform participants that a telephone reminder will follow in 4 weeks from invitation letter if screening is not completed. They will also receive notification of test results and navigation to colonoscopy, if needed. For the purposes of this intervention, Week 1 will be the week the invitation letter was sent (time zero).
62814984|NCT06175767|EXPERIMENTAL|Randomization and Double-Blind Treatment Phase (TV0- TV3, 12 weeks):|Subjects who have successfully completed the Screening phase will enter the Randomization and Double-Blind treatment phase of the study. Subjects will take the assigned randomized treatment, MT101-5 at 400 mg, 600 mg or placebo for 12 weeks. MT101-5 and matching placebo are oral tablets that will be taken as six tablets two times a day (b.i.d.) at least 2 hours before or 2 hours after meal in the morning and evening daily during this study.
62814985|NCT06175767|EXPERIMENTAL|Follow-up Phase (FUV, 4 weeks ± 3 days)|The follow-up phase will consist of a follow-up visit at the end of the Double-Blind Treatment phase.
62814986|NCT04366349|EXPERIMENTAL|Participants receiving melrilimab (GSK3772847) 70 milligram (mg)|Participants will receive a single dose of melrilimab (GSK3772847) 70 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP).
62814987|NCT04366349|EXPERIMENTAL|Participants receiving melrilimab (GSK3772847) 140 milligram (mg)|Participants will receive a single dose of melrilimab (GSK3772847) 140 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP).
62238720|NCT01478360|PLACEBO_COMPARATOR|Placebo|Placebo intravenous injection
62238721|NCT01572701|EXPERIMENTAL|20 (±3) mCi of study drug|
62814988|NCT04366349|PLACEBO_COMPARATOR|Participants receiving Placebo|Participants will receive a single dose of placebo subcutaneously (SC) injection by an health care professional (HCP).
62238722|NCT00168480|EXPERIMENTAL|1|Botulinum Toxin Type A
62238723|NCT05165147||physical examination population|From January 2019 to December 2019, who underwent physical examination in Peking University Third Hospital were included in the study.
62238724|NCT03933397|EXPERIMENTAL|Patient-Specific Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on the pain medicine(s) they take at home, what was needed during their past hospital and emergency department visits to treat pain and doses that have been effective and safe in the past.
62238725|NCT03933397|EXPERIMENTAL|Weight-based Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on their weight.
62238726|NCT02690805||Breast cancer patients receiving neoadjuvant chemotherapy|One arm: Combined MRI-SMM Imaging
62238727|NCT02315677|ACTIVE_COMPARATOR|Nasal intubation-Standard RAE ETT|This arm will receive nasal intubation with the standard RAE endotracheal tube with bevel facing left.
62238728|NCT02315677|ACTIVE_COMPARATOR|Nasal intubation-Parker Flex-Tip ETT|This arm will receive nasal intubation with the Parker Flex-tip ETT with bevel facing posteriorly.
62238729|NCT06243471||Group 1|Minimally Invasive Surgery Group with Zigzag EHL Tenotomy
62814989|NCT03918850|EXPERIMENTAL|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
62238730|NCT06243471||Group 2|Minimally Invasive Surgery Group without Zig-zag EHL Tenotomy
62238731|NCT04062253||HCV or HIV negative|Individuals who test negative for HCV or HIV are given information regarding ways of transmission.
62238732|NCT04062253||HCV and HIV positive|Individuals with a positive test for HCV o HIV are offered delivery or accompaniment to specialist health care.
62238733|NCT05777096||registered|"Paragliding pilots over the age of 18. Registered at the Fédération Française de Vol Libre (FFVL) in the year 2022 and/or 2023 Paragliding in the year 2022 and/or 2023"
62238734|NCT01335919||Neonate|Subjects admitted for surgery or to the pediatric intensive care unit (PICU) or neonatal intensive care unit (NICU) who require daily and/or multiple blood samples for hemoglobin measurement.
62238735|NCT04760886||Urban trauma cohort|All paediatric trauma admissions in an urban, MTC treated operatively, isolated from a departmental trauma list between 1st April 2019- 1st April 2021
62238736|NCT04760886||Rural trauma cohort|All paediatric trauma admissions in a rural district general, treated operatively, isolated from a departmental trauma list between 1st April 2019- 1st April 2021
62596833|NCT02584998|ACTIVE_COMPARATOR|Mailed-FIT|Participants randomized to Mailed-FIT will receive a mailed FIT pre-notification letter (plus a screening invitation) followed by the kit 1 week later. Participants will receive instructions to contact the study team if they believe they are not eligible and to update their contact information. They will be informed that a telephone reminder will follow 4 weeks from notification letter if screening is not completed. Participants who do not return their kit within 4 weeks after their pre-notification letter was mailed will receive a live telephone reminder, followed by 2 additional calls at the end of weeks 5 and 6, if needed. For the purposes of this intervention, Week 1 will be the week the pre-notification letter was sent (time zero).
62238737|NCT04968197|EXPERIMENTAL|Stochastic Vestibular Stimulation (SVS) Condition|Subjects will perform standard clinical testing for balance and gait while wearing the Vestibular Intervention via Portable Electrical Stimulator (VIPES) system. The SVS device will be active throughout the testing at the respective current levels (i.e., 0.2mA to 1 mA at 0.2 mA increments).
62238738|NCT04968197|NO_INTERVENTION|Control Condition|Subjects will perform standard clinical testing for balance and gait without SVS
62238739|NCT00122928|EXPERIMENTAL|High intensity environmental intervention|Intense intervention
62238740|NCT00122928|EXPERIMENTAL|Moderate intensity environmental intervention|Moderate intervention
62596834|NCT02883075|SHAM_COMPARATOR|Supine position|Supine position Supine position after placement of spinal anesthetic
62596835|NCT02883075|ACTIVE_COMPARATOR|Right lateral position|Right lateral position Right lateral after placement of spinal anesthetic
62596836|NCT02883075|ACTIVE_COMPARATOR|Left lateral position|Left lateral position Left lateral after placement of spinal anesthetic
62596837|NCT00438243|PLACEBO_COMPARATOR|1|1 drop affected eye twice daily.
62238741|NCT00122928|NO_INTERVENTION|Individual intervention only|Control
62238742|NCT04293289|OTHER|Treatment|"BNCT(Boron Neutron Capture Therapy)~SPM-011 iv administrates at 200 mg/kg/hr for 2 hours before neutron irradiation. During neutoron irradiation with CICS-1, SPM-011 iv continues at 100mg/kg/hr."
62238743|NCT02710773|EXPERIMENTAL|Backward Walking Treadmill Training|The subjects will perform a backward walking training on treadmill device
62238744|NCT02710773|ACTIVE_COMPARATOR|Treadmill training|The subjects will perform a walking training on treadmill device
62238745|NCT04193267|EXPERIMENTAL|Repetitive Transcranial Magnetic Stimulation (rTMS)|30 sessions of high-frequency (10Hz) repetitive stimulation applied over the posterior region of the left superior temporal gyrus in patients with logopenic primary progressive aphasia (PPA-L) using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
62238746|NCT04338555|EXPERIMENTAL|TEAS group|Patients in the TEAS group will receive electrical stimulation of acupoints at Neiguan and Shenmen points for 30min every hour. The stimulation will repeat until the end of surgery.
62238747|NCT04338555|NO_INTERVENTION|control group|In patients from the control group, the electrodes will only be attached to the corresponding sites, with no TEAS electrical stimulation given during the operation.
62238748|NCT01108250|EXPERIMENTAL|polypoidal choroidal vasculopathy|patients with polypoidal choroidal vasculopathy
62238749|NCT01108250|ACTIVE_COMPARATOR|control|control group with no polypoidal choroidal vasculopathy
62238750|NCT03358511|EXPERIMENTAL|Breast Cancer Patients|All subjects will be given 2-4 weeks of probiotics prior to surgery in operable stage I-III breast adenocarcinoma tumors ≥1.0 cm. Subjects will take the probiotic three times a day.
62596838|NCT00438243|EXPERIMENTAL|2|Bromfenac (Xibrom) 1 drop to affected eye twice a day.
62596839|NCT04207931|ACTIVE_COMPARATOR|Topical steroid plus oral antibiotic group|Participants in this group receive topical steroid (class I-II applied once daily) plus oral antibiotic group (doxycyline 100 mg twice daily for 6 months), and then topical minoxidil (5% solution or foam) after 8 months of treatment.
62238751|NCT00350662|EXPERIMENTAL|Deferiprone + Desferrioxamine|
62596840|NCT04207931|ACTIVE_COMPARATOR|Topical steroid plus intralesional steroid injection group|Participants in this group receive topical steroid (class I-II applied once daily) plus intralesional steroid group (7.5mg/cc of kenaolog, max dose of 3 cc), and then topical minoxidil (5% solution or foam) after 8 months of treatment
62596841|NCT05088590|EXPERIMENTAL|Growing Up Formula (GUF)|
62429323|NCT05028751|EXPERIMENTAL|LANRA 40 mg QD + Gilteritinib 120 mg QD|Participants received LANRA 40 mg QD as oral tablets in consecutive 28-day cycles starting from Cycle 1 Day 1. Participants also received gilteritinib 120 mg QD as oral tablets in consecutive 28-day cycles starting from Cycle 1 Day 2. Participants received treatment until progression/relapse or lack of at least a PR after 6 months of study treatment, intolerance, or withdrawal from treatment by the participant or study investigator.
62037352|NCT01577979|EXPERIMENTAL|Reminder/Recall Strategy|The experimental group will consist of patients randomly selected from participating clinics. Patients from private practices and the safety net provider may be exposed to a reminder/recall strategy involving text messaging. Text messages will be used to notify parents that their child is due for an immunization or well-care visit. Parents will be able to reply with one of three response options. Patients presenting to the randomly selected experimental managed care clinics for the first HPV vaccination dose will be offered the ability to provide the clinic with their preferred contact method. The preferred method of contact will be used for the second and third HPV dose reminder/recalls.
62037353|NCT01577979|NO_INTERVENTION|Usual Care|The patients in the usual care group will receive the clinic's usual care in terms of immunization and well-care reminder/recall.
62238752|NCT00350662|EXPERIMENTAL|Deferiprone single agent|
62429324|NCT05028751|EXPERIMENTAL|LANRA 60 mg QD + Gilteritinib 120 mg QD|Participants received LANRA 60 mg QD as oral tablets in consecutive 28-day cycles starting from Cycle 1 Day 1. Participants also received gilteritinib 120 mg QD as oral tablets in consecutive 28-day cycles starting from Cycle 1 Day 2. Participants received treatment until progression/relapse or lack of at least a PR after 6 months of study treatment, intolerance, or withdrawal from treatment by the participant or study investigator.
62429325|NCT05028751|EXPERIMENTAL|LANRA 90 mg QD + Gilteritinib 120 mg QD|Participants received LANRA 90 mg QD as oral tablets in consecutive 28-day cycles starting from Cycle 1 Day 1. Participants also received gilteritinib 120 mg QD as oral tablets in consecutive 28-day cycles starting from Cycle 1 Day 2. Participants received treatment until progression/relapse or lack of at least a PR after 6 months of study treatment, intolerance, or withdrawal from treatment by the participant or study investigator.
62596842|NCT05088590|ACTIVE_COMPARATOR|Standard Nutritional Supplement (NS)|
62596843|NCT04294706|EXPERIMENTAL|Hemp arm|Randomly assignment to Hemp arm (60 mg/day of hemp oil extract x 6 weeks)
62596844|NCT04294706|PLACEBO_COMPARATOR|Placebo arm|Randomly assigned to Placebo arm (60 mg/day of cellulose x 6 weeks)
62596845|NCT00432276|EXPERIMENTAL|Alogliptin 25 mg + Pioglitazone 30 mg add-on to Metformin|Alogliptin 25 mg, tablets, orally, once daily; pioglitazone 30 mg, tablets, orally, once daily; and the maximum tolerated dose of metformin, tablets, orally, for up to 52 weeks.
62596846|NCT00432276|ACTIVE_COMPARATOR|Pioglitazone 45 mg add-on to Metformin|Alogliptin placebo-matching tablets, orally, once daily; pioglitazone 45 mg, tablets, orally, once daily; and the maximum tolerated dose of metformin, tablets, orally, for up to 52 weeks.
62596847|NCT00665587||A = MAZE|Patients indicated to a cardiac surgery (bypass, valve repair or combinated surgery)with documented atrial fibrillation in 6 preoperative months undergo the operation together with MAZE procedure
62596848|NCT00665587||B = non-MAZE|Patients indicated to a cardiac surgery (bypass, valve repair or combinated surgery)with documented atrial fibrillation in 6 preoperative months undergo the operation (without MAZE procedure).
62596849|NCT03430401|EXPERIMENTAL|Perceptual-based memory encoding|It will involve the use of visual imagery and the method of loci. To achieve this, each of the 15 daily tasks will be filmed and a short video created. In addition, each task will be broken down into 5-6 photographed steps based on activity analysis and task breakdown. The program will prompt the user to indicate in which room of the house the task would usually be completed. Once correct location is identified, the program will prompt the user to watch a chosen daily task video and then visualise themselves completing the task in their home environment.
62596850|NCT03430401|EXPERIMENTAL|Semantic-based memory encoding|It will incorporate association-based strategies to assist with recalling the steps of daily tasks. The steps of a given daily task will be provided and the user will be prompted to link the steps using a honeycomb concept, which makes use of the chunking method to encode the sequenced steps. Following this, the program will prompt the user to categorise the steps according to their association with given words cues. The word cues will represent time, places, objects, and people. The program will then take the user response and form a verbal and visual story according to the responses given. The program will help identify any problems in the sequencing and prompt the user to re-categorise if required.
62596851|NCT03430401|ACTIVE_COMPARATOR|Cognitive stimulation|Participants will complete an online cognitive exercise program, Lumosity (Sarkar, Scanlon, \& Drescher, 2007). A study conducted by Hardy, Drescher, Sarkar, Kellett, and Scanlon (2011) indicated that participants who engaged in Lumosity showed greater improvements in memory in comparison to a non-intervention control group.
62596852|NCT02484651|NO_INTERVENTION|Standard Group|Standard Clinical Practice Group - standard neuromuscular block, with a standard rocuronium dose for intubation (0.6 mg/kg). If required, the reversal of neuromuscular block is performed with neostigmine.
62596853|NCT02484651|EXPERIMENTAL|Deep NMB group|Deep Neuromuscular Block group - with a standard rocuronium dose for intubation (0.6 mg/kg), followed by a constant infusion of rocuronium (10-15 ug/kg/min) to guarantee a PTC less or equal to 2 on the TOF monitor (PTC is evaluated every 5 minutes). The reversal of neuromuscular block is performed with Sugammadex (4 mg/kg).
62596854|NCT06454591||TBI patients|
62238753|NCT00350662|ACTIVE_COMPARATOR|Desferrioxamine single agent|
62238754|NCT05107050|ACTIVE_COMPARATOR|Normal saline wash and an amorphous gel (NSS-HG)|Normal Saline Wash and Amorphous Gel
62238755|NCT05107050|EXPERIMENTAL|synergistic antimicrobial cleanser (AMC) and antimicrobial gel (AMG)|"Antimicrobial Skin \& Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site. BIAKOS™~BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel."
62596855|NCT06454591||Individuals with chronic TBI|
62596856|NCT06454591||Caregivers of individuals with chronic TBI|
62596857|NCT06454591||Clinicians who treat individuals with TBI|
62596858|NCT06454591||Legal and insurance personnel|
62429326|NCT05783609|EXPERIMENTAL|Epcoritamab + Rituximab|"Participants will undergo study procedures as outlined:~* PET/CT scans at baseline and after cycles 2, 5, and 9 of treatment.~  * Cycle 1:~    * Days -14, -7, 1, 8 of 6 week cycle: Predetermined dose of Rituximab.~   * Days 1, 8, 15, 22 of 6 week cycle: Predetermined dose of Epcoritamab. (Day 15 of Epcoritamab dosage will be administered in the hospital.)~ * Cycles 2 - 3:~    --Days 1, 8, 15, 22 of 4 week cycle: Predetermined dose of Epcoritamab.~ * Cycles 4 - 9:~    * Day 1 of 4 week cycle: Predetermined dose of Epcoritamab.~   * Day 15 of 4 week cycle: Predetermined dose of Epcoritamab.~* Surveillance imaging (PT/CT scans) at months 13, 18, and 24 after initiation of treatment.~* Follow up visits for up to 5 years."
62429327|NCT03292133|EXPERIMENTAL|EGF816 + Gefitinib|"* All patients will receive gefitinib orally once daily~* EGF816 will be administered orally once daily~* Participant will be requested to maintain a medication diary of each dose of medication"
62596859|NCT03597009|EXPERIMENTAL|Open-label, single-arm Phase I|Talimogene laherparepvec (TVEC) administered into the intrapleural space of subjects with malignant pleural effusion (MPE) via a pleurX catheter with or without nivolumab
62596860|NCT05200013|EXPERIMENTAL|Cohort 1|Dose 0.3mg/kg
62596861|NCT05200013|EXPERIMENTAL|Cohort 2|Dose 1mg/kg
62814990|NCT03918850|ACTIVE_COMPARATOR|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
62037354|NCT05903651||Single Group Assignment|The subjects will undergo a single retinal imaging session with the Optina MHRC device, on one or both eyes.
62238756|NCT04916041||Vivity|Patients who have undergone bilateral implantation of Vivity intraocular lens
62238757|NCT04916041||Eyhance|Patients who have received bilateral implantation of an Eyhance intraocular lens
62238758|NCT04916041||EMV|Patients who have undergone bilateral implantation of Vivity intraocular lens
62429328|NCT01801085||FOLFOX4|Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
62429329|NCT01801085||XELOX|Capecitabine (Xeloda) 1000 mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hrs d1 Q3w x 8 cycles
62596862|NCT05200013|EXPERIMENTAL|Cohort 3|Dose: 3 mg/kg
62596863|NCT05200013|EXPERIMENTAL|Cohort 4|Dose: 10 mg/kg
62596864|NCT05200013|EXPERIMENTAL|Cohort 5|Dose: 20 mg/kg
62596865|NCT05200013|EXPERIMENTAL|Cohort 6|Dose: 40 mg/kg
62596866|NCT06621628|EXPERIMENTAL|Study group A|This group included 20 patients who had CREST syndrome with scleroderma in the dorsum of hands and who received the BLT with traditional physical therapy program (stretching, strengthening and active exercise) patients received 3 sessions per week for 12 weeks (3 months),time of session is 15 minutes.
62596867|NCT06621628|EXPERIMENTAL|study group B|This group included 20 patients who have CREST syndrome with scleroderma in the dorsum of hands and who received resisted exercise with traditional physical therapy program (stretching, strengthening and active exercise) patients received 3 sessions per week for 12 weeks (3 months), time of session is 15 minutes
62814991|NCT00971659|EXPERIMENTAL|insulin glargine + exenatide + metformin|
62238759|NCT04916041||Panoptix|Patients who have undergone bilateral implantation of Panoptix intraocular lens
62238760|NCT04916041||Rayner Trifocal|Patients who have undergone bilateral implantation of Rayner trifocal intraocular lens
62238761|NCT02717754|EXPERIMENTAL|Oseltamivir 100 mg|Participants will receive 100 mg oseltamivir intravenous BID for 5 days.
62238762|NCT02717754|EXPERIMENTAL|Oseltamivir 200 mg|Participants will receive 200 mg oseltamivir intravenous BID for 5 days.
62238763|NCT02717754|PLACEBO_COMPARATOR|Placebo|Participants will receive oseltamivir matched placebo intravenous BID for 5 days.
62238764|NCT06041386|OTHER|All Participants|All participants with clinical diagnosis of Severe asthma prescribed Mepolizumab as part of routine care.
62814992|NCT00971659|EXPERIMENTAL|Insulin glargine + sitagliptin + metformin|
62814993|NCT00971659|ACTIVE_COMPARATOR|insulin glargine + metformin|
62814994|NCT06102954|EXPERIMENTAL|Intervention group|"12-weeks active intervention session includes exercise and educational components.~9 months maintenance phase"
62814995|NCT06102954|NO_INTERVENTION|Control group|No intervention for 12 months during intervention period.
62814996|NCT05225311||Patients with Fetal Ebstein's Anomaly or Tricuspid Valve Dysplasia|Patients will be followed for life-long outcomes.
62238765|NCT03226405|EXPERIMENTAL|Patient Navigation Program|"* The study team will identify, track, and provide navigation for all adult patients referred to Cancer Center from the CHC and community partners for cancer treatment.~* The Patient Navigation Program include~  * Education,~ * Appointment reminders,~ * Help with insurance,~ * Transportation,~ * Navigating the Cancer Center,~ * Assisting in finding appropriate child care,~ * Interpreting,~ * Connecting the patient to psychosocial and/or palliative care teams,~ * Physically escorting the patient to appointments"
62238766|NCT03226405|ACTIVE_COMPARATOR|Standard of Care|"* The patients will receive enhanced usual care,~* This consist of personal phone call reminders about upcoming appointments at the MGH Cancer Center"
62238767|NCT06143085|EXPERIMENTAL|Generalized periodontitis|Patients diagnosed with generalized periodontitis of different severities exhibiting periodontal pockets not exceeding 6mm.
62238768|NCT01397864||Hereditary Angioedema|
62238769|NCT04657419||Participant|Patient or health professional coming to the Bordeaux University Hospital screening center for COVID-19 screening
62238770|NCT02204566|EXPERIMENTAL|OFDI Capsule Imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI Imaging system.
62238771|NCT01691391||Advanced CRC, candidates for anti-EGFR antibody monotherapy|Patients with histopathologically confirmed advanced CRC with K-Ras and BRAF wild type, aged ≥ 18 years, with a life expectancy of at least 12 weeks, who are candidates for anti-EGFR antibody monotherapy (3rd line palliative treatment).
62238772|NCT05370066|EXPERIMENTAL|CS6BP and cuff|CS6BP watches will be used in the study with Commercially available FDA approved Blood pressure monitors:
62238773|NCT03483558|EXPERIMENTAL|Control|Participants were fed a standardized diet (without any vegetables) in this experiment.
62238774|NCT03483558|EXPERIMENTAL|Spinach|Participants were fed a standardized diet with 200g spinach in this experiment.
62238775|NCT03483558|EXPERIMENTAL|Celery|Participants were fed a standardized diet with 200g celery in this experiment.
62238776|NCT03483558|EXPERIMENTAL|Onion|Participants were fed a standardized diet with 200g onion in this experiment.
62238777|NCT03483558|EXPERIMENTAL|Mixed Vegetables|Participants were fed a standardized diet with 200g of mixed vegetables (spinach, celery, and onion) in this experiment.
62238778|NCT00162032|OTHER|Children (Ages 4-11)|Children 4-11 years of age, intervention Sestamibi
62814997|NCT03629964|EXPERIMENTAL|Head stabilizer group|Patients will be receiving standard brain radiation. The experimental head holder device (called the Wiersma Head Stabilizer) will be attached to treatment table and will make small movements to adjust the position of the head in response to movement by the patient. In addition, the AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the patient's head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
62814998|NCT04993859||Male Cancer Survivors with DVSS Score ≥ 9|Childhood cancer survivors treated with DOX and/or VCR with evidence of BD on DVSS
62814999|NCT04993859||Female Cancer Survivors with DVSS Score ≥ 6|Childhood cancer survivors treated with DOX and/or VCR with evidence of BD on DVSS
62815000|NCT04993859||Male Cancer Survivors with DVSS Score < 9|Childhood cancer survivors treated with DOX and/or VCR without evidence of BD on DVSS
62815001|NCT04993859||Female Cancer Survivors with DVSS Score < 6|Childhood cancer survivors treated with DOX and/or VCR without evidence of BD on DVSS
62815002|NCT06352723|EXPERIMENTAL|Cenobamate|400mg load plus 100mg a day for maximum of 14 days
62815003|NCT03245203|EXPERIMENTAL|Experimental group|beacizumab+ neoadjuvant chemotherapy (FOLFIRI+beacizumab)
62815004|NCT03245203|ACTIVE_COMPARATOR|Control group|neoadjuvant CRT for consecutive 5 weeks
62815005|NCT00062439|EXPERIMENTAL|Etoposide, Cisplatin, Thoracic RT, Surgery, Docetaxel|
62815006|NCT04808115|EXPERIMENTAL|KDS-1001|KDS-1001 is infused on Day 1 of each 14 day cycle. Patients will receive 6 cycles of KDS-1001 treatment.
62238779|NCT00162032|OTHER|Adolescents (Ages 12-16)|Adolescents 12-16 years of age, intervention Sestamibi
62238780|NCT02800226|EXPERIMENTAL|10Hz|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4-6 weeks
62238781|NCT02800226|ACTIVE_COMPARATOR|iTBS|intermittent Theta Burst Stimulation (iTBS) five days per week for 4-6 weeks
62238782|NCT02701426|EXPERIMENTAL|participant|agree to participate to the program combining physical activity and nutritional counseling
62238783|NCT02701426|NO_INTERVENTION|no participant|disagree to participate to the program
62815007|NCT02236286|EXPERIMENTAL|Exercise|Subjects will participate in a 90-minute, group (6 per group) exercise session 3 days per week for 6 weeks (18 sessions). The theoretical basis for our novel Agility Boot Camp (ABC) exercise program is based on research that identified the primary neurophysiological and cognitive constraints that limits balance and mobility in PD. The exercises are designed as a circuit with several types of movement-skills specifically focused on improving different postural domains with cognitive challenges such as memorized sequences and dual tasking.
62815008|NCT02236286|ACTIVE_COMPARATOR|Chronic Disease Management Education|Subjects will also receive (cross-over) six weeks of educational classes. The Education program will teach subjects, chronic disease self-management - how to live better with their parkinsonism. Classes will consist of 6 subjects per group meeting for 90 minute sessions, once a week for six weeks. Subject will do an additional 120 minutes of relaxation at home/week.
62815009|NCT03028311|OTHER|Treatment (angiography, yttrium Y-90 radioembolization)|"The first 2 patients enrolled receive standard of care diagnostic and treatment during 2 visits for approximately 6 hours each within 2-4 weeks. During the first visit, patients undergo diagnostic angiography with embolization of potential hepatoenteric collaterals, receive technetium Tc-99m albumin aggregated as a surrogate to the therapy microspheres via catheter, and undergo planar imaging. During the second visit, patients undergo a second angiography and receive yttrium Y 90 resin microspheres via arterial microcatheter. Patients then undergo single-photon emission computed tomography-computed tomography (SPECT-CT) Bremsstrahlung imaging.~All subsequent patients enrolled undergo the same previously described diagnostic and treatment during 1 visit over about 8 hours."
62238784|NCT01213589||Descending thoracic aortic dissection|Patients diagnosed with a descending thoracic aortic dissection and who are amenable to stent-graft operation. The patient had an indication for treatment by either endovascular stent graft implantation for either an acute, sub-acute or chronic Type B dissection.
62238785|NCT00576836|EXPERIMENTAL|Cultured Thymus Tissue Implantation w Parathyroid Transplant|"Cultured Thymus Tissue Implantation With Parathyroid Tissue Transplantation. Subjects who were enrolled in this arm underwent cultured thymus tissue implantation with parathyroid transplantation, if eligible.~No specific dose was assigned. The thymus tissue dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the recipient.~There was a one time administration of the cultured thymus tissue and parathyroid tissue."
62815010|NCT03900832|PLACEBO_COMPARATOR|PAD without heating|Subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
62815011|NCT03900832|EXPERIMENTAL|PAD warm bath|Subjects will take a warm bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
62815012|NCT03900832|PLACEBO_COMPARATOR|PAD neutral bath|Subjects will take a neutral bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
62815013|NCT03900832|EXPERIMENTAL|PAD heating suit|Whole body heating with the suit will be performed. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
62815014|NCT03900832|EXPERIMENTAL|PAD lower limb warm water immersion|Subjects will place their lower legs in warm water. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
62815015|NCT03900832|PLACEBO_COMPARATOR|Healthy subjects without heating|Subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
62815016|NCT03900832|EXPERIMENTAL|Healthy subjects warm bath|Subjects will take a warm bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
62815017|NCT03900832|PLACEBO_COMPARATOR|Healthy subjects neutral bath|Subjects will take a neutral bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
62238786|NCT00576836|EXPERIMENTAL|Cultured Thymus Tissue Implantation|"Cultured Thymus Tissue Implantation. Subjects who were enrolled in this arm underwent cultured thymus tissue implantation (CTTI) only.~No specific dose was assigned. The thymus tissue dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the recipient.~There was a one time administration of the cultured thymus tissue.~."
62238787|NCT04498455|PLACEBO_COMPARATOR|Placebo|Dietary Supplement: Placebo
62238788|NCT04498455|ACTIVE_COMPARATOR|Prebiotin|Dietary Supplement: Prebiotin (oligofructose enriched inulin)
62238789|NCT03725163|EXPERIMENTAL|Treatment|This arm will begin treatment immediately after completing the initial intake assessment.
62238790|NCT03725163|OTHER|Waitlist Control|Participants assigned to the waitlist control condition will begin a 12-week waiting period after completing the initial intake assessment before starting treatment.
62429330|NCT05726773|EXPERIMENTAL|Robot Assisted Therapy Group|In the RAT group, it was planned to perform robotic rehabilitation with a hand-finger robot \[Amadeo (Tyromotion, Graz, Austria)\] for 30 minutes for both upper extremities, accompanied by a physiotherapist who is trained in robotic rehabilitation and has at least 5 years of experience. In robotic rehabilitation, continuous passive range of motion (CPM), active assistive exercises and assistive continuous passive range of motion (CPM Plus) programs will be used.
62429331|NCT05726773|ACTIVE_COMPARATOR|Conventional Therapy Group|In the Conventional Therapy group, an exercise program consisting of passive and active assistive range of motion exercises, strengthening exercises and task-oriented exercises for 30 minutes for both hands was planned, accompanied by a physiotherapist experienced in spinal cord injury rehabilitation for at least 5 years.
62429332|NCT00503854||Observational (questionnaire)|Patients complete a questionnaire on days 1, 2, and 6 regarding fatigue, sleep disturbance, depression, and other symptoms.
62429333|NCT05666674|EXPERIMENTAL|TSA-ON|The trial will be composed of two arms: an experimental group with VR with activated Tremor Stabilization Algorithms (TSA-ON). And an active comparator group that is exposed to VR without Tremor Stabilization Algorithms (TSA-OFF control). In both arms, study subjects will be immersed in a stock VR testing environment and will perform a tremor eliciting PTT test.
62429334|NCT05666674|ACTIVE_COMPARATOR|TSF-OFF control|The trial will be composed of two arms: an experimental group with VR with activated Tremor Stabilization Algorithms (TSA-ON). And an active comparator group that is exposed to VR without Tremor Stabilization Algorithms (TSA-OFF control). In both arms, study subjects will be immersed in a stock VR testing environment and will perform a tremor eliciting PTT test.
62429335|NCT02039583||full cohort|All singleton births in England. See 'statistical analysis' for denominator specification for individual outcomes.
62429336|NCT00397839|PLACEBO_COMPARATOR|Placebo|
62815018|NCT03900832|EXPERIMENTAL|Healthy subjects heat suit|Whole body heating with the suit will be performed. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
62815019|NCT03900832|EXPERIMENTAL|Healthy subjects lower limb immersion|Subjects will place their lower legs in warm water. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
62815020|NCT05830864||Main cohort|Adult patients with refractory status epilepticus treated by Isoflurane as third anticonvulsive therapy
62429337|NCT00397839|EXPERIMENTAL|Ibandronate|
62429338|NCT03722537|ACTIVE_COMPARATOR|Ligament Reconstruction Tendon Interposition (LRTI)|Selected randomly, 100 patients will receive this treatment. During the LRTI (standard of care procedure), the arthritic bone that the thumb rests on (the trapezium) is removed. A small cut is made in the forearm to release a tendon, which is moved to the base of the thumb to fill in the area from which the trapezium bone was removed. A small suture anchor is then placed into a thumb bone which holds everything together.
62429339|NCT03722537|EXPERIMENTAL|Osteochondral Allograft|Selected randomly,100 patients will receive this treatment. In this procedure, the arthritic bone that the thumb rests on (the trapezium) is removed and replaced with femoral trochlear osteochondral allograft that is designed to be similar in morphology to the human trapezium articular surface, known as the 'Cartibend©' .
62238791|NCT02838485|EXPERIMENTAL|Amputees|The subjects will receive both mirror and imagery treatments in a cross-over design.
62238792|NCT06153771||Extremely premature newborn|(born before 32 weeks' gestation)
62238793|NCT02187809|EXPERIMENTAL|Clobazam|A maximum of 2.0 mg/kg/day (maximum 80 mg/day) twice daily (BID); clobazam oral suspension (2.5 mg/mL) or clobazam scored tablets (10 mg), orally
62238794|NCT04079166|EXPERIMENTAL|SCIB1 or iSCIB1+|SCIB1 or iSCIB1+ administered by intramuscular needle-free injection
62238795|NCT06502899||diagnosed with MINOCA and completed with cardiac magnetic resonance|
62238796|NCT05355233|EXPERIMENTAL|bebo concept|it is a technique to deal urinary incontinence
62238797|NCT05355233|EXPERIMENTAL|diaphragmatic breathing|breathing technique to strengthen core muscles
62238798|NCT02642510|EXPERIMENTAL|DVD Structured Education|Participants in this group will watch an educational DVD in addition to standard teaching by nursing staff.
62238799|NCT02642510|ACTIVE_COMPARATOR|Standard Educational Teaching|Participants in this group will receive educational teaching by their assigned nursing staff.
62429340|NCT00821457|ACTIVE_COMPARATOR|Group 1|250ng Juvista vs placebo
62429341|NCT00821457|ACTIVE_COMPARATOR|Group 2|500 ng Juvista vs placebo
62429342|NCT04087785||Positive metastasis|Positive occult lymph node metastasis pathology
62429343|NCT04087785||Negative metastasis|Without lymph node metastasis pathology
62429344|NCT05584774|PLACEBO_COMPARATOR|PELD|
62429345|NCT05584774|ACTIVE_COMPARATOR|PELD and annuloplasty and nucleoplasty|
62429346|NCT04500691||FBSS patients|FBSS patients who are treated with high frequency Spinal Cord Stimulation
62429347|NCT02908828|EXPERIMENTAL|Calanus oil|4 capsules of 500 mg Calanus oil once every day
62815021|NCT05230134|EXPERIMENTAL|Cervical sympathetic block|"Patients hospitalized in the ICU and developing clinical manifestations of cerebral vasospasm will undergo a computerized tomography (CT) angiography and a CT perfusion scan. If the vasospasm will be confirmed by the CT imaging, a cervical sympathetic nerve block under ultrasound guidance will be performed. The block consists in the deposition of local anesthetic at the cervical sympathetic ganglion that will be visualized with an ultrasound device. A periganglionar catheter will be left in place. A CT angiography and CT perfusion will be repeated to check the effect of the block on the brain vasculature after the block is done.~Patients will have a daily monitoring of their neurological function and of their cerebral blood flow with transcranial doppler in the ICU."
62815022|NCT05493202||Study group|30 patients undergoing gonadotropin stimulation for IVF or egg freezing.
62238800|NCT00305175||Patients With Prior Hydroxyurea|Patients who have received hydroxyurea therapy before entering the study.
62238801|NCT00305175||Patients Without Prior Hydroxyurea|Patients who have not received hydroxyurea before study entry.
62238802|NCT04950725|EXPERIMENTAL|Low respiratory muscle training|Low dose of RMT and fewer repetitions and use of RMT device per week
62238803|NCT04950725|EXPERIMENTAL|Respiratory muscle training for strengthening|Higher number of sets with a slightly lower number of repetitions per set
62238804|NCT04950725|EXPERIMENTAL|Respiratory muscle training for strengthening and nasal breathing|Higher number of sets with a slightly lower number of repetitions per set RMT accompanied with sets of nasal breathing
62238805|NCT04950725|EXPERIMENTAL|Respiratory muscle training for endurance|One set of RMT with a higher number of repetitions
62238806|NCT04950725|EXPERIMENTAL|Respiratory muscle training for endurance and nasal breathing|One set of RMT with a higher number of repetitions accompanied with sets of nasal breathing
62238807|NCT01353456|ACTIVE_COMPARATOR|Dexmedetomidine|
62238808|NCT01353456|PLACEBO_COMPARATOR|Normal saline|
62238809|NCT04864509|ACTIVE_COMPARATOR|Melatonin 10mg|Nightly oral dose
62238810|NCT04864509|PLACEBO_COMPARATOR|Placebo|nightly oral dose
62238811|NCT01106404|OTHER|6-week AdaptiveStim followed by 6-week manual programming|
62429348|NCT02908828|PLACEBO_COMPARATOR|Placebo|4 capsules of 500 mg dietary oil once every day
62238812|NCT01106404|OTHER|6-week manual followed by 6-week AdaptiveStim programming|
62238813|NCT03874325|EXPERIMENTAL|Safety Run In: Durvalumab + Aromatase Inhibitor|Participants will be administered 1500 mg Durvalumab intravenously every 4 weeks for 6 cycles. Participants will also take standard of care 1 mg anastrozole daily by mouth for 6 months. Letrozole 2.5 mg or exemastane 25 mg may be substituted for anastrozole if an intolerance to anastrozole is exhibited. Six participants will be enrolled in the safety run in stage. If 1 or fewer of six participants have a DLT, expansion stage will open to enrollment.
62238814|NCT03874325|EXPERIMENTAL|Expansion: Durvalumab + Aromatase Inhibitor|Participants will be administered 1500 mg Durvalumab intravenously every 4 weeks for 6 cycles. Participants will also take standard of care 1 mg anastrozole daily by mouth for 6 months. Letrozole 2.5 mg or exemastane 25 mg may be substituted for anastrozole if an intolerance to anastrozole is exhibited.
62238815|NCT01544023||Breast Reconstruction with TilOOP|
62238816|NCT01975428|OTHER|Control|All study participants, including participants randomized to the control arm, were enrolled in the HealthComp disease management program, which involved outreach by HealthComp nursing staff for purposes of relaying medical education and wellness information with regard to disease prevention and chronic disease management.
62238817|NCT01975428|ACTIVE_COMPARATOR|DM Pgm + device|"Disease management (DM) program plus a device corresponding to an individual's disease(s):~iBGStar - iPhone enabled capillary blood glucose meter. Subjects test blood glucose up to 4 times per day, every day.~Withings BP monitor - iPhone enabled home blood pressure monitor. Subjects test their blood pressure 2 times per day, up to 3 days per week.~iPhone enabled Alive Cor ECG monitor. Participants take an ECG reading only when symptomatic."
62238818|NCT04034550|EXPERIMENTAL|hospitalized patients diagnosed with leptospirosis|hospitalized patients diagnosed with leptospirosis: 12 months of follow up with biological samples and data collection
62238819|NCT05317754|EXPERIMENTAL|Mindful breathing|
62429349|NCT05086120|EXPERIMENTAL|Remote Electronically Delivered Integrated Care Pathway (ICP)|The remote electronically-delivered ICP (also known as eCARIBOU) will consist of psychiatry appointments through telemedicine every 4 weeks over 16 weeks, where the youth is at home. Prior to these appointments, measures (i.e., Mood and Feelings Questionnaire - MFQ) will be sent to the youth to be completed. Change in measure scores will be reviewed collaboratively between the psychiatrist and the youth to assist in making treatment decisions. The medication algorithm in the in-person ICP will be used to guide these decisions. The psychiatrist will also administer the Columbia Suicide Severity Rating Scale (C-SSRS) at each telepsychiatry appointment to monitor risk. Concurrently, youth will be offered internet-based Cognitive Behavioural Therapy (iCBT) and health-coaching via text.
62429350|NCT00196222|EXPERIMENTAL|1|RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
62429351|NCT00196222|EXPERIMENTAL|2|cryo energy ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
62815023|NCT06593171|ACTIVE_COMPARATOR|Control group|No intervention group
62238820|NCT05317754|EXPERIMENTAL|Prostrations, according to Tibetan Buddhist tradition|
62238821|NCT05317754|EXPERIMENTAL|The Koan Mu, according to Zen Buddhist tradition|
62238822|NCT05317754|EXPERIMENTAL|The mirror exercise, according to Toltec tradition|
62238823|NCT06335992|EXPERIMENTAL|Exercise|"The exercise training protocol to be used in this study:~Supervised exercise training (aerobic- and muscle strengthening exercise): 2 times a week for 12 weeks.~* Aerobic exercise with ergometer cycling for 30 min, at moderate intensity (60% Wpeak) individually adjusted to level 4-6 on the Borg category ratio-10 scale.~* Muscle strengthening exercise will consist of 8-12 strength exercises of the major upper and lower body muscle groups. Each exercise includes three sets with 8-12 repetitions.~Exercise training at home: once a week for 12 weeks."
62238824|NCT02153372|EXPERIMENTAL|BMC2012|The large bone defect was then be bridged as per clinical standard, filled with a clinically established scaffold (ß-TCP), and 1.3 x106/ml BMC were loaded per 1 ml ß-TCP in situ.
62238825|NCT00279630|EXPERIMENTAL|type of exericse|type of exercise
62429352|NCT04317963||Cases|Patients who have received bezlotoxumab 10 mg/kg intravenously in addition to standard CDI treatment.
62429353|NCT04317963||Controls|Patients who have received only standard CDI treatment.
62429354|NCT05449327|EXPERIMENTAL|Rivaroxaban|The participants are provided with Rivaroxaban 10mg
62429355|NCT05449327|NO_INTERVENTION|Control|The participants are provided without antithrombotics
62429356|NCT01241162|EXPERIMENTAL|Single arm study|Biological/Vaccine: Autologous dendritic cell vaccine with adjuvant
62429357|NCT03911089|OTHER|Open label|UCD Anamix Infant
62429358|NCT04610073|EXPERIMENTAL|Interactive multimedia training|the intervention group 1 completed the pretest knowledge, attitude, and behavior questionnaire. Then, interactive multimedia was made available to this group. The questionnaire was completed again by the group, one week after completion of training, and then one month afterward.
62429359|NCT04610073|EXPERIMENTAL|illustrated booklet|First, the intervention group 2 completed the pretest knowledge, attitude, and behavior questionnaire. Then, illustrated booklet was made available to this group. The questionnaire was completed again by the group one week after completion of training, and then one month afterward.
62429360|NCT04610073|EXPERIMENTAL|No Intervention|In the control group, no intervention was performed. Only before the intervention, one week and one month after the intervention, they completed the knowledge, attitude and behavior questionnaires.
62238826|NCT02853721|EXPERIMENTAL|Experimental group|iPTH at 6 hours after surgery
62238827|NCT02853721|OTHER|Control group|no dosage of iPTH
62238828|NCT04930224||Proliferative Diabetic retinopathy|40 patients with proliferative diabetic retinopathy
62238829|NCT04930224||Non-Proliferative Diabetic retinopathy|40 patients with non-proliferative diabetic retinopathy
62238830|NCT04930224||Healthy individuals|40 healthy persons
62238831|NCT00881218|EXPERIMENTAL|Regadenoson CMR|Images in the cardiac short axis will be obtained using a gradient recalled echo sequence, TR 2.3 msec/TE 1.1 msec, 80\*256 matrix, slice thickness 10 mm. Images will be obtained during power injection of 0.075 mmol/Kg of a conventional gadolinium based MR contrast agent at a rate of 5 mL/sec followed by a 15 mL saline flush into an antecubital vein. Perfusion imaging will be performed at stress and rest. Stress: Regadenoson 400 mcg will be administered IV bolus via an antecubital cannula. Immediately after injection, MR scanning will begin and contrast will be given. Rest: After 10 minutes, rest imaging will be performed identically, but without regadenoson injection. To identify late enhancement of myocardial tissue inversion recovery prepared images will be obtained.
62238832|NCT05671913|ACTIVE_COMPARATOR|Treatment|Intranasal Ketamine
62238833|NCT05671913|PLACEBO_COMPARATOR|Control|Normal Saline
62815024|NCT06593171|EXPERIMENTAL|Experimental group|"Intervention group. In detail, the intervention has a total of 3 participatory sessions via videoconference, with an average duration of 90 minutes per session, with a maximum number of 3 to 4 students per mentor. Each session is accompanied by a reflective log of the activities and observations made by the students of an evaluated nature, as well as reading prior to session n°1 and n°2. In addition, the anonymous evaluation of the level of stigma before and after the implementation, both in the group of students and mentors, is included, as well as a follow-up of the measurements regarding these evaluations.~At the professional level, a 6-hour pedagogical intervention focused on stigma reduction for the training of health students towards people with psychiatric illnesses will be provided to all health professionals involved, with a certificate of participation delivered at the end of the sessions.~The sessions must have minimum material implements such as an equipped classroom, proj"
62815025|NCT05955911|EXPERIMENTAL|Exercise|Moderate intensity treadmill walking (40%-59% of heartrate reserve).
62815026|NCT05955911|OTHER|Coloring|Coloring in an adult coloring book as a distraction activity
62815027|NCT04289181|EXPERIMENTAL|Medically Tailored Meals (MTM)|Participants randomized to the MTM arm will receive MTM for 4 weeks. Meals will be prepared and delivered by Meals on Wheels, a non-profit organization that has been delivering meals to seniors nationwide for decades. Meals on Wheels will deliver 21 complete meals to the patient's home each week. They can accommodate a wide range of patient needs and preferences (e.g., low sodium, gluten-free, no pork products, cultural preferences). Meals on Wheels will contact the patient directly to set up an initial assessment phone call to collect relevant data (e.g., specific patient goals for their HF) and to set up a delivery schedule. Nearing the 4-week mark when meal delivery ends, investigators will check-in with each participant to track progress, assess treatment fidelity and answer any questions. All patients will receive information on community resources (e.g., food pantries, food banks) in the area.
62815028|NCT04289181|NO_INTERVENTION|Usual Care|Patients in this arm will receive usual services offered at Jefferson for patients with HF. This includes regular visits with a HF provider (primary care or cardiology), standard nutrition teaching, medication optimization and post discharge support. During routine office visits, providers reinforce messages about self-management and provide lists of local and national resources related to nutrition and HF self-management. These services follow guideline directed medical therapy. All patients will receive information on community resources (e.g., food pantries, food banks) in the area.
62815029|NCT06005051|EXPERIMENTAL|mitigator|Test different foods to see their mitigating effect on blood sugars after a rice meal.
62238834|NCT04011254||Healthy Control|Healthy control
62238835|NCT04011254||Haemodialysis %IDWG >4%|Patient on regular haemodialysis with average IDWG \>4%
62238836|NCT04011254||Haemodialysis %IDWG <4%|Patient on regular haemodialysis with average IDWG \<4%
62238837|NCT02736136|EXPERIMENTAL|Intervention|Joint observation and video feedback plus usual care in the neonatology (plus completion of self-report questionnaires and 15 min filmed mother-infant interaction)
62238838|NCT02736136|NO_INTERVENTION|Control|Usual care in the neonatology (plus completion of self-report questionnaires and 15 min filmed mother-infant interaction)
62238839|NCT01669304|EXPERIMENTAL|Verapamil|Verapamil extended release oral tablets administered in a flexible dose format ranging from 120 mg to 360 mg daily, as determined by severity of headache and dizziness.
62238840|NCT01669304|EXPERIMENTAL|Sertraline|Sertraline oral tablets administered in a flexible dose format ranging from 25 mg to 150 mg daily depending on severity of headache and dizziness.
62238841|NCT03643120|OTHER|Development of diagnostic typology|One main goal is to Development a typology of sub-types of gender dysphoria.
62429361|NCT02005146||Patients with chronic hepatitis B treated with nRTI|Patients with chronic hepatitis B with HBsAg loss treated with nucleoside/nucleotide analogues (Lamivudine, Adefovir, Tenofovir, Telbivudine, Entecavir, Emtricitabine)
62429362|NCT02718976|EXPERIMENTAL|Shamrock guided by US/MR image fusion|Use of US/MR image fusion guided Shamrock technique to place lumbar plexus block (20 ml 2% lidocaine with epinephrine added gadoterate meglumine).
62238842|NCT01615380|ACTIVE_COMPARATOR|CBT+ Contact|In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
62238843|NCT01615380|EXPERIMENTAL|CBT+ Exercise|Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
62238844|NCT01243541|EXPERIMENTAL|Arm I|Patients wear an Elasto-Gel cold glove and sock on their dominant hand and foot every two weeks on days the patient is scheduled for paclitaxel.The glove and sock is worn for 15 minutes prior to paclitaxel infusion, 3 hours during treatment, and for 15 minutes after completion of chemotherapy for a total of 210 minutes.
62238845|NCT01243541|EXPERIMENTAL|Arm II|Patients wear an Elasto-Gel cold glove and sock on their non-dominant hand and foot every two weeks on days the patient is scheduled for paclitaxel. The glove and sock is worn for 15 minutes prior to paclitaxel infusion, 3 hours during treatment, and for 15 minutes after completion of chemotherapy for a total of 210 minutes.
62429363|NCT02718976|OTHER|Shamrock guided by US|Use of US guided Shamrock technique to place lumbar plexus block (20 ml 2% lidocaine with epinephrine added gadoterate meglumine).
62429364|NCT03335943|EXPERIMENTAL|CDA-2 (Cell Differentiation Agent 2)|Patients will be given CDA-2 therapy.
62815030|NCT04877626|ACTIVE_COMPARATOR|AQ+AS|Group 1 received the combination AQ+AS (COARSUCAM®) which was administered orally at an initial dose of 2 tablets (200 mg AQ/540 mg AS) followed by 2 additional doses of 2 tablets at 24 and 48 hours (6 tablets in 48 hours).
62815031|NCT04877626|ACTIVE_COMPARATOR|AM+L|Group 2 received the combination Artemeter+lumefantrina (COARTEM®) administered orally at an initial dose of 4 tablets (80 mg artemeter/480 mg lumefantrina) followed by 5 additional doses of 4 tablets at 8, 24, 36, 48, and 60 hours (24 tablets in 60 hours)
62815032|NCT05808686|SHAM_COMPARATOR|Ischemic Conditioning-Low|We will use a randomized block design to randomize individuals into either Ischemic Conditioning-Low or Ischemic Conditioning-High group using an online randomizer. A handheld sphygmomanometer and blood pressure cuff will be given to study participants. For the Ischemic Conditioning-Low group participants, while sitting, the cuff will be placed around the non-dominant upper arm and inflated to 10 mmHg for 5 min, then released for a 5-min recovery period. A 5-min inflation period is most used. Five cycles of inflation/recovery will be performed. All participants will perform the intervention daily for 2 weeks. Participants will complete daily log sheets documenting the time and pressure of each cuff inflation.
62238846|NCT02645513|EXPERIMENTAL|Malaria-only text messages|Health workers at facilities in this arm receive twice-daily text message reminders for six months on key reminders related to malaria diagnosis and treatment.
62429365|NCT05103267||Tauropace in high risk participants|"TauroPace™ is a CE marked (certified) medical device defined as a Disinfecting Solution to Eradicate Airborne Microbial Contamination on the Surface of Cardiac Impiantable Electronic Devices (CIED).~TauroPace™ is to eradicate environmental microbial contamination on the surface of any CIED during implantation or revision procedure.~TauroPace™ is intended to be used during CIED surgery procedure in any adult participant at high risk of CIED infections"
62429366|NCT03312582|EXPERIMENTAL|Manual debridement and 1% metformin gel|
62429367|NCT03312582|PLACEBO_COMPARATOR|Manual debridement and placebo|
62429368|NCT02197169|EXPERIMENTAL|DNX-2401 alone|Single intratumoral injection of DNX-2401
62429369|NCT02197169|EXPERIMENTAL|DNX-2401 + Interferon gamma (IFN-γ)|Interferon gamma (IFN-γ) beginning at Day 14
62429370|NCT05957107|EXPERIMENTAL|Injection of recombinant humanized monoclonal antibody against interleukin-6 receptor4mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg as the low dose group.
62429371|NCT05957107|EXPERIMENTAL|Injection of recombinant humanized monoclonal antibody against interleukin-6 receptor6mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg as the middle dose group.
62429372|NCT05957107|EXPERIMENTAL|placebo control|placebo control
62429373|NCT05957107|EXPERIMENTAL|Tocilizumab Injection8mg/kg|Tocilizumab Injection8mg/kg
62429374|NCT01822015|EXPERIMENTAL|Treatment (sirolimus, idarubicin, cytarabine)|Patients receive sirolimus PO QD on days 1-10, idarubicin IV over 3-5 minutes on days 4-6, and cytarabine IV continuously over 24 hours on days 4-10.
62429375|NCT00965913|EXPERIMENTAL|Three Interventions on Lower Back|Three treatments were applied on the lower back, according to treatment sequence, daily for 21 days
62429376|NCT03187080|EXPERIMENTAL|Group 1 Arm A|Breast reduction with Paravertebral block using local anesthetic.
62429377|NCT03187080|SHAM_COMPARATOR|Group 1 Arm B|Breast reduction with Sham paravertebral block using saline.
62429378|NCT03187080|EXPERIMENTAL|Group 2 Arm A|Breast augmentation with Paravertebral block using local anesthetic.
62429379|NCT03187080|SHAM_COMPARATOR|Group 2 Arm B|Breast augmentation with Sham paravertebral block using saline.
62429380|NCT03187080|EXPERIMENTAL|Group 3 Arm A|Breast reduction with Enhanced recovery after breast surgery (ERABS) strategies.
62429381|NCT03187080|NO_INTERVENTION|Group 3 Arm B|Breast reduction, standard perioperative management.
62238847|NCT02645513|EXPERIMENTAL|Malaria, pneumonia, and diarrhea messages|Health workers at facilities in this arm receive twice-daily text message reminders for six months on key reminders related to diagnosis and treatment of malaria, pneumonia, and diarrhea
62238848|NCT02645513|PLACEBO_COMPARATOR|Control|No text message reminders to health workers, just the usual health system supports.
62238849|NCT04009850|EXPERIMENTAL|Menthol e-cigarette|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes and a menthol flavored e-cigarette
62238850|NCT04009850|EXPERIMENTAL|Tobacco e-cigarette|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes and a tobacco flavored e-cigarette
62429382|NCT03187080|EXPERIMENTAL|Group 4 Arm A|Breast augmentation with Enhanced recovery after breast surgery (ERABS) strategies.
62429383|NCT03187080|NO_INTERVENTION|Group 4 Arm B|Breast augmentation, standard perioperative management.
62429384|NCT06174519||Study group|For this clinical investigation, the clinical data for 325 subjects were used to demonstrate the non-inferiority of iAST® application in comparison with physician prescription. In any case, the data retrospectively analyzed for these 325 subjects were simulated using the iAST® application, in such a way that the same subjects were considered case and control at the same time.
62429385|NCT03213054|EXPERIMENTAL|OBP-301 + Radiation|OBP-301 administration on the Day 1, Day 18 and Day 32 with standard course of radiation(total 60 Gy) for 6 weeks.
62429386|NCT03044431||Cell therapy treated|All patients/participants enrolled will undergo cell therapy
62429387|NCT03841721|EXPERIMENTAL|linezolid 300 mg|
62429388|NCT02490566|EXPERIMENTAL|Technology Arm|Tablet computer with chronic disease apps will be given to patients. This tablet will also be used for follow-up visits done via video conferencing. Intervention: Telehealth.
62238851|NCT06064656||Sub-Cohort 1|All patients with active enrollment (closed claims) during part or all the study period.
62238852|NCT06064656||Sub-Cohort 2|All patients with active enrollment (closed claims) augmented with open claims
62429389|NCT03039582||Probable grad 2|Perineal laceration Probable grad 2
62429390|NCT03039582||Suspected grade 3|Perineal laceration Suspected grade 3
62429391|NCT03039582||Probable grad 3|Perineal laceration Probable grad 3
62429392|NCT00496106|EXPERIMENTAL|Control Arm|6 telephone counseling sessions
62429393|NCT00496106|ACTIVE_COMPARATOR|Usual Care Arm|6 telephone counseling sessions
62429394|NCT03966469||Support Person Present|Participants who bring a support person with them to their preoperative appointment.
62429395|NCT03966469||Patient Present Only|Participants who present by themselves to their preoperative appointment.
62429396|NCT04347161|EXPERIMENTAL|Intervention Arm|Participants in the intervention arm will be tracked and able to engage with the intervention (conversational agent) on their mobile telephone for 12 weeks.
62429397|NCT04347161|ACTIVE_COMPARATOR|Control Arm|Patients in the control arm will receive usual care, which includes clinician-driven education on medication management and self-monitoring of symptoms.
62429398|NCT04549909||preimplantation genetic testing for aneuploidy (PGT-A) Group|Patients who have undergone preimplantation genetic testing for aneuploidy (PGT-A) (transfer of own frozen embryo)
62596868|NCT06621628|EXPERIMENTAL|study group C|This group included 20 patients who had CREST syndrome with scleroderma in the dorsum of hands and who received combination of (bipotron light therapy and resisted exercise) with traditional physical therapy program (stretching, strengthening and active exercise) exercise program (stretching, strengthening and active exercise).patients received 3 sessions per week for 12weeks (3 months), time of session is 15 minutes
62238853|NCT01940354|EXPERIMENTAL|Vascular access via study device|AccuCath IV Catheter System will be used for IV therapy during interventional radiology procedure. Intervention includes vascular access, fluid infusion, and blood sample removal.
62429399|NCT04549909||endometrial receptivity array (ERA) Group|Patients who have undergone frozen embryo transfer (FET) with endometrial receptivity array (ERA) test (embryos from own or donated oocytes)
62596869|NCT01875627|PLACEBO_COMPARATOR|Carbohydrate Noodles|0g Konjac Noodles
62238854|NCT01940354|ACTIVE_COMPARATOR|Vascular access via control device|Conventional IV Catheter System (current catheter) will be used for IV therapy during interventional radiology procedure. Interventions include vascular access, administration of fluids, and blood sample removal.
62238855|NCT03794908|EXPERIMENTAL|Light therapy A (Bright) via the Re-Timer®|"* 60 minutes/day~* For the first hour after waking"
62429400|NCT04549909||CONTROL OWN (CO) Group|Control group of FET from own oocytes (without ERA or PGT-A)
62429401|NCT04549909||CONTROL DONATED(CD) Group|Control group of FET from donated oocytes (without ERA or PGT-A)
62596870|NCT01875627|EXPERIMENTAL|Carbohydrate and Konjac Noodles|Half Carbohydrate and Half Non-Caloric Konjac Noodles - 122.5g Konjac
62596871|NCT01875627|EXPERIMENTAL|Konjac Noodles|Non-Caloric Konjac Noodles (viscous gel meal) - 240g Konjac
62596872|NCT01120080|PLACEBO_COMPARATOR|Practical Counseling|
62429402|NCT01189578||Recreational cocaine users|Individuals who have used cocaine in the past 3 months, but do not meet DSM-IV-TR diagnostic criteria for Cocaine Dependence.
62429403|NCT01615302|ACTIVE_COMPARATOR|Mucosa advancement flap|
62429404|NCT01615302|EXPERIMENTAL|Mucosa advancement flap + PRP|Platelet rich plasma added to the mucosa advancement flap
62596873|NCT01120080|ACTIVE_COMPARATOR|Alcohol Intervention Counseling|
62596874|NCT04954742|OTHER|Riociguat|Riociguat (1 mg, 1.5 mg, 2 mg and 2.5 mg three times daily) starting at 1.0 mg three times daily at the beginning of the study. Dosage will be individually up-titrated up to a maximum dosage of 2.5 mg three times daily after 8 weeks. Study medication will be provided orally with or without food. Tablets should be taken three times daily approximately 6 to 8 hours apart.
62596875|NCT01219894||RUTTS Score <30%|Patients with evidence of complete healing of stent at 3 months
62429405|NCT01998516||Schizophrenia Patients|
62429406|NCT01998516||Bipolar I Patients|
62429407|NCT01998516||Siblings of Schizophrenia Patients|
62429408|NCT01998516||Siblings of Bipolar I Patients|
62429409|NCT01998516||Healthy Controls|
62429410|NCT03148288|EXPERIMENTAL|Vitamin D supplementation|4000IU Vitamin D qd
62429411|NCT03148288|PLACEBO_COMPARATOR|placebo|
62429412|NCT01027637|EXPERIMENTAL|Alloderm reconstruction|All patients recieving the intervention Alloderm for breast reconstruction
62429413|NCT02290028|OTHER|Sentus QP left ventricular lead|Subjects consented and implanted with a Sentus QP left ventricular lead.
62429414|NCT00762983||Group 1|Pediatric patients who are treated with Claritin for any of the following reasons: allergic rhinitis, urticaria, itching due to skin disease (eczema, dermatitis, or pruritus cutaneous)
62429415|NCT02170428||growth and development|Growth and development of a random sample of healthy Danish infants
62429416|NCT00056459|EXPERIMENTAL|1|Oxaliplatin/5-FU/LV and PTK787/ZK 222584
62815033|NCT05808686|EXPERIMENTAL|Ischemic Conditioning-High|We will use a randomized block design to randomize individuals into either Ischemic Conditioning-Low or Ischemic Conditioning-High group using an online randomizer. A handheld sphygmomanometer and blood pressure cuff will be given to study participants. For the Ischemic Conditioning-High group participants, while sitting, the cuff will be placed around the non-dominant upper arm and inflated to 225 mmHg for 5 min, then released for a 5-min recovery period. A 5-min inflation period is most used. Five cycles of inflation/recovery will be performed. All participants will perform the intervention daily for 2 weeks. Participants will complete daily log sheets documenting the time and pressure of each cuff inflation.
62815034|NCT01349426|EXPERIMENTAL|LigaSure|"* Arm 1~* Patients undergoing lung surgery"
62815035|NCT01349426|ACTIVE_COMPARATOR|Automatic Staplers|"* Arm 2~* Patients undergoing lung surgery"
62815036|NCT04785222|EXPERIMENTAL|DB|Group DB: Bilateral infraorbital nerve block with dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine, in total volume of 2 ml per side
62429417|NCT00056459|PLACEBO_COMPARATOR|2|Oxaliplatin/5-FU/LV and placebo
62815037|NCT04785222|ACTIVE_COMPARATOR|BP|Group BP: Bilateral infraorbital nerve block with 0.5% plain bupivacaine, a volume of 2 ml per side
62815038|NCT04785222|PLACEBO_COMPARATOR|NS|Group NS (control): Bilateral infraorbital nerve block with normal saline 2 ml per side
62429418|NCT02477007|EXPERIMENTAL|Ibuprofen+placebo of paracetamol|Patients will receive in addition to morphine (usual care) ibuprofen and placebo of paracetamol
62429419|NCT02477007|EXPERIMENTAL|Paracetamol + placebo of ibuprofen|Patients will receive in addition to morphine (usual care) paracetamol and placebo of ibuprofen
62429420|NCT02477007|EXPERIMENTAL|Paracetamol + ibuprofen|Patients will receive in addition to morphine (usual care) paracetamol and ibuprofen
62429421|NCT02477007|PLACEBO_COMPARATOR|Placebo of paracetamol + placebo of ibuprofen|Patients will receive morphine alone(usual care).
62429422|NCT01595074||Ancillary-Correlative (laboratory biomarkre analysis)|Archived RNA and DNA samples are analyzed for gene expression, mutations, and variations by RT-qPCR, MassARRAY, molecular inversion probe assay, and microarray assays. Results are then compared with patients' clinical outcomes.
62429423|NCT02602964|EXPERIMENTAL|Deep neuromsucular block|Deep neuromuscular block and low pressure pneumoperitoneum
62429424|NCT02602964|NO_INTERVENTION|Standard neuromuscular block|Standard neuromuscular block and low pressure pneumoperitoneum
62429425|NCT03360656|EXPERIMENTAL|Transnasal Thermal Regulating Device|Consented subjects will undergo cooling via transnasal thermal regulating device for a period of 8 to 24 hours
62429426|NCT06542276|OTHER|Lipiflow treatment results|A single thermal vectored pulsation treatment of MGD with 3 month results review of treatment to evaluate objective and subjective response.
62429427|NCT00704717||All Treated Patients|All patients participating in the study.
62429428|NCT06247293||Surgical resection combined with intraperitoneal hyperthermic perfusion chemotherapy|Surgical resection combined with intraperitoneal hyperthermic perfusion chemotherapy
62429429|NCT06247293||simple surgical resection|Control group: simple surgical resection
62429430|NCT06247293||other|imple interventional hemostasis group
62429431|NCT01754090|ACTIVE_COMPARATOR|Usual care|"Receives two interventions:~1. Online screening and feedback.~2. Online booklet."
62429432|NCT01754090|EXPERIMENTAL|Extended follow-up|"Receives two interventions:~1. Online screening and feedback.~2. Online multi session follow-up."
62429433|NCT06543017|EXPERIMENTAL|Experimental group|A total of three tests were conducted on all participants, each time between 6:00 and 9:00 in the morning. The first test (first day of slow weight reduction, T1) was on 26th March, the second test (first day of rapid weight reduction, T2) was on 26th April, and the third test (the day before the competition, T3) was on 3rd May.
62429434|NCT04727346||Study Group|CBCT and DISE
62429435|NCT04727346||Control Group|DISE only
62429436|NCT00420849|EXPERIMENTAL|Lenalidomide plus Dexamethasone|Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
62596876|NCT01219894||RUTTS<30%|Group with evidence of incomplete healing of the stent
62815039|NCT04554784|ACTIVE_COMPARATOR|Conventional|Conventional pain treatment.
62429437|NCT02688816||Women undergoing cervical cancer screening|"HIV-infected women will undergo a cervical cancer screening examination using the VIA method. A digital photograph of the cervix will also be taken to aide visual screening. This is known as digital cervicography, and it is currently standard of care within cervical cancer screening clinics in Zambia.~Cervical samples will be collected for molecular testing using Xpert HPV, and OncoE6. Cervical biopsy samples will also be obtained for confirmatory histopathologic diagnosis."
62596877|NCT06621901|EXPERIMENTAL|High Protein Diet|The energy composition of the high protein diet will be calculated as 40% carbohydrate, 30% protein and 30% fat. It will be stated that individuals should not eat anything other than the foods to be sent during the weeks of the diet.
62596878|NCT06621901|EXPERIMENTAL|Normal Protein Diet|The energy composition of the high protein diet will be calculated as 55% carbohydrate, 15% protein and 30% fat. It will be stated that individuals should not eat anything other than the foods to be sent during the weeks of the diet.
62596879|NCT06333574|OTHER|Control group|received routine outpatient management. Specific methods: The dialysis doctor registered the information of the patient's weight and blood pressure at the end of dialysis, and informed the patient of the purpose, role and importance of weight management.
62596880|NCT06333574|OTHER|Intervention group|On the basis of routine outpatient management, patients or their family members were subjected to remote follow-up management based on wechat, and the follow-up time was 6 months. Specific methods: Same as the control group, the information of weight and blood pressure of the patients was registered at the end of dialysis, and the purpose, role and importance of weight management were informed to the patients. On this basis, a special wechat signal is set up to add patients or patients' family members as wechat friends and establish a wechat interaction platform with patients. In the interdialysis period, remind patients to weigh themselves through wechat (the time of each weighing is fixed, preferably consistent with the time of weighing in the hemodialysis center), control the weight gain during the interdialysis period not to exceed 4.5% of dry weight, and inform patients again about the purpose, role and importance of weight management.
62596881|NCT05521334|EXPERIMENTAL|Adult Glaucomatous patients with refractory glaucoma|Adult glaucomatous patients with uncontrolled intraocular pressure despite maximal tolerated medical treatment
62596882|NCT05756790|NO_INTERVENTION|Enhanced Usual Care|Couples in this condition will receive the standard of care for alcohol use in addition to a brief alcohol counseling session modeled after WHO guidelines and Dr. Conroy's intervention in Malawi, which uses participants' baseline AUDIT scores for messaging around alcohol reduction and lasts 5-10 minutes.
62815040|NCT04554784|ACTIVE_COMPARATOR|Bowen|Patients will be referred to Occupational Therapist for Bowen therapy.
62815041|NCT00982293|ACTIVE_COMPARATOR|Active fields|
62815042|NCT00982293|SHAM_COMPARATOR|Inactive device|"Placebo treated group, will receive the 3 times weekly for 13 weeks (39) sessions, however, the device will not be on."
62815043|NCT03486821|EXPERIMENTAL|Hypofrac Radiation Therapy|"All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.~Radiation treatment will start approximately 1-2 weeks after the simulation scan. Prior to each treatment, you will be asked to have a full bladder and empty rectum. You will be asked to take a liquid diet starting the afternoon prior to each treatment, and a laxative (such as Miralax) in the evening prior to each treatment. You will also be asked to take a Fleet's enema about 1 hours prior to the treatment time to ensure that the rectum is empty. To ensure full bladder, you will be asked to drink about 32 oz of water after the enema. This is the same procedure as above for the prep before the simulation scan.~Each treatment should take about 10-20 minutes."
62815044|NCT03994874|EXPERIMENTAL|PolyCore PUF|PolyCore peritoneal ultrafiltration (PUF) (over the top of patient's prescribed heart failure medications), for 6 months.
62815045|NCT03994874|NO_INTERVENTION|Control|Patients in the control arm (receiving no PUF therapy) will remain on their prescribed heart failure medications.
62429438|NCT06496906|EXPERIMENTAL|Benex tooth extraction|This is the first study group where patients undergo extractions with presumably the vertical tooth extraction system Benex.
62429439|NCT06496906|EXPERIMENTAL|Physics forceps extraction|This is the second study group where patients undergo extractions with the presumably minimally invasive Physics forceps.
62429440|NCT06496906|ACTIVE_COMPARATOR|Convetional extraction|This is the control group where patients undergo tooth extractions with conventional extraction forceps and elevators.
62429441|NCT04934111|EXPERIMENTAL|LNP-nCOV saRNA-02 Vaccine arm|Participants that have evidence of previous infection with SARS-CoV-2 and those with no evidence of previous infection will all receive receive LNP-nCOV saRNA-02 Vaccine. Both groups will be given a dose of 5.0ug at 0 weeks and 4 weeks.
62429442|NCT01433198|ACTIVE_COMPARATOR|Aquatic exercise group|
62429443|NCT01433198|NO_INTERVENTION|Control group|
62429444|NCT03113825|EXPERIMENTAL|AVB-620 & Investigational Imaging Device|Eligible subjects will receive a single dose of AVB-620 as intravenous infusion before the surgical procedure. During the surgical procedure, fluorescent imaging will be undertaken to distinguish between malignant and nonmalignant tissues.
62429445|NCT05824156|EXPERIMENTAL|5 mg/kg CM-101|Subcutaneous injection CM-101 every 2 weeks
62429446|NCT05824156|PLACEBO_COMPARATOR|Placebo|Subcutaneous Injection Placebo every 2 weeks
62429447|NCT02971345|EXPERIMENTAL|Endovascular Brachytherapy&Stent&TACE|"Transarterial chemoembolization (TACE) is performed immediately following Iodine-125 seed strand and stent implantation.~Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE."
62596883|NCT05756790|EXPERIMENTAL|Motivational Interviewing (MI)|Couples will have three MI sessions over a 60-day period. These sessions will focus on communication between the couple, alcohol consumption patterns, and setting goals for alcohol-use reduction.
62815046|NCT06572865||Parents reported to the child welfare services|Adults who are into contact with the Swedish CWS due to a child welfare report. The adults have a parental role in relation to a child 0-17 years old (referred to as 'parents').
62238856|NCT03794908|ACTIVE_COMPARATOR|Light therapy B (Dim) via the Re-Timer®|"* 60 minutes/day~* For the first hour after waking"
62429448|NCT02971345|ACTIVE_COMPARATOR|TACE alone|Only TACE is performed. Epirubicin, ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
62596884|NCT05756790|EXPERIMENTAL|Motivational Interviewing Plus Breathalyzer (MI Plus)|In addition to three MI sessions, drinkers in this condition will be prompted via SMS message twice per day to use a mobile app and a breathalyzer to test their blood alcohol levels (BAC). Both the drinker and their partner will receive real-time feedback about alcohol use.
62815047|NCT05034497|EXPERIMENTAL|Dose Escalation|"Each participant will receive a single 5cc administration of 186RNL.~At each dose level, a minimum of three to a maximum of six participants will be enrolled.~If no dose limiting toxicity is observed in the initial three participants, then the next higher dose level cohort will open for enrollment.~The dose escalation scheme will follow a modified Fibonacci dose escalation scheme."
62815048|NCT03323892|ACTIVE_COMPARATOR|'normal' abstinence duration|Patients follow the normal abstinence duration as asked by the physician (2-7 days). This sperm will be used to inject half of the oocytes Intervention = second sperm sample
62815049|NCT03323892|EXPERIMENTAL|short abstinence duration|"Patients will be asked to produce a second sperm sample, 2 hours after the first. This sperm will be used to inject the other half of the oocytes.~Intervention = second sperm sample"
62815050|NCT01463969||PCOS patients|
62815051|NCT01463969||Control group|
62815052|NCT06289751|EXPERIMENTAL|Neoadjuvant chemoimmunotherapy for ⅠB2 cervical cancer|neoadjuvant chemotherapy + Cadonilimab + Radical hysterectomy/Extrafascial hysterectomy
62238857|NCT02538003|EXPERIMENTAL|Group 1(RT):LCB01-0371 Tablet 800mg|"1. Period:LCB01-0371 Tablet 800mg(Reference: Taken drug before meal)~2. Period: LCB01-0371 Tablet 800 mg(Test: Taken drug after meal)"
62238858|NCT02538003|EXPERIMENTAL|Group 2(TR):LCB01-0371 Tablet 800mg|"1. Period:LCB01-0371 Tablet 800mg(Test:taken drug after meal)~2. Period: LCB01-0371 Tablet 800 mg(Reference:taken drug before meal)"
62429449|NCT06161740|ACTIVE_COMPARATOR|Muscle strengthening group MSG|It was based on exercises for strengthening the hip adductor muscles associated with a bridge using a small exercise ball (two sets of 15 repetitions with seven seconds in isometry), strengthening the hamstrings with ankle weights in prone position, bilateral hip flexor strengthening in supine position with ankle weights, bilateral shoulder flexor strengthening with dumbbells, bilateral shoulder extensor strengthening with dumbbells, bilateral shoulder abductor strengthening with dumbbells, and bilateral serratus anterior muscle strengthening with dumbbells (all exercises, except the first, performed in three sets of 10 repetitions). Considering a 15-second interval between repetitions and a one-minute break between sets, totaling 30 minutes. The progression of each patient occurred through load progression.
62429450|NCT06161740|EXPERIMENTAL|Muscle strengthening associated with aerobic training group (MSGA)|It initially consisted of a five-minute warm-up, divided into two minutes of stationary marching and three minutes of jumping jacks. Subsequently, patients were instructed to climb up and down ramps, ascend and descend stairs, walk on a flat surface, and use a cycle ergometer (each task performed for five minutes). For the recovery phase, bilateral stretching of the hamstrings, rectus femoris, triceps brachii, pectoralis major, sternocleidomastoid, and scalene muscles was performed, each lasting 30 seconds per muscle. The proposed protocol was associated with the anaerobic training described in the GF (muscle strengthening group).
62429451|NCT01096706|EXPERIMENTAL|Nitric Oxide Clamp|Forearm blood flow response to Urocortins 2, 3 and Substance P in the presence of Nitric Oxide clamp
62429452|NCT01096706|PLACEBO_COMPARATOR|Saline Placebo|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of saline placebo.
62429453|NCT01096706|EXPERIMENTAL|Fluconazole|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of intra-arterial Fluconazole.
62429454|NCT01096706|EXPERIMENTAL|Aspirin|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of cyclooxygenase inhibition with Aspirin.
62429455|NCT01096706|EXPERIMENTAL|Combined|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of inhibition of cycloxygenase, EDHF and NO pathways with Aspirin, Fluconazole and NO clamp.
62596885|NCT01092819||acute ischemic stroke|Patients presenting with symptoms of acute ischemic stroke within 8 hours from symptom onset and with an imaging-defined large cerebral vessel occlusion.
62815053|NCT04949191|EXPERIMENTAL|Study Treatment 1: Pemigatinib (INCB054828)|Pemigatinib will be taken orally once daily
62815054|NCT04949191|EXPERIMENTAL|Study Treatment 2: Pemigatininb+ Retifanlimab|Participants rolling over from study INCB 54828-101 only will receive pemigatinib once daily and retifanlimab will be administered once every 4 weeks
62815055|NCT04949191|EXPERIMENTAL|Study Treatment 3: Pemigatininb + Pembrolizumab|Participants rolling over from study INCB 54828-101 only will receive pemigatinib once daily and pembroluzimab as per dosage instructions.
62815056|NCT00837434|EXPERIMENTAL|Etanercept|Participants receive a subcutaneous injection of etanercept once every week for 24 weeks
62596886|NCT00970632|PLACEBO_COMPARATOR|Placebo|Placebo tablet with tamsulosin dose orally (po) once daily (QD) and placebo capsule with tadalafil dose po QD for 12 weeks
62596887|NCT00970632|EXPERIMENTAL|Tadalafil 5 milligram (mg)|Tadalafil 5 mg tablet po QD and placebo capsule po QD for 12 weeks
62815057|NCT00837434|EXPERIMENTAL|Adalimumab|Participants receive a subcutaneous injection of adalimumab once every 2 weeks for 24 weeks
62238859|NCT06044844|EXPERIMENTAL|efficacy of tofacitinib in early diffuse cutaneous systemic sclerosis|tab tofacitinib 5mg twice daily will be given by oral route for 6month
62238860|NCT06044844|EXPERIMENTAL|efficacy of Cyclophosphamide in early diffuse cutaneous systemic sclerosis|injection cyclophosphamide 500mg/m2 body surface area/monthly by intravenous infusion.total 6cycle will be given
62238861|NCT03456531|ACTIVE_COMPARATOR|group 1|20 patients will receive pulsed radiofrequency for 6 minutes to suprascapular nerve
62238862|NCT03456531|PLACEBO_COMPARATOR|group 2|"20 patients will receive their medical treatment in the form of NSAIDs ibubrofen,Aspirin"
62596888|NCT00970632|ACTIVE_COMPARATOR|Tamsulosin 0.4 mg|Tamsulosin 0.4 mg capsule po QD and placebo tablet po QD for 12 weeks
62596889|NCT05803447||G1K-women|The G1K group consisted of women experiencing suicidal thoughts without a tendency of implementation, in whom the result of M.I.N.I. 7.0.2 test was 1 to 8 points (n=14)
62596890|NCT05803447||G1M-men|The G1M group consisted of men experiencing suicidal thoughts without a tendency of implementation, in whom the result of M.I.N.I. 7.0.2 test was 1 to 8 points (n=16)
62815058|NCT04917172||Pancreaticoduodenectomy patients|Patients scheduled to receive elective Pancreaticoduodenectomy (PD) (according to Kausch-Whipple or Longmire-Traverso) for all kinds of pancreatic disease (benign, malignant or premalignant) will be enrolled, after having signed a proper informed consent. Each patient will undergo PD once checked the presence of a resectable mass as provided by the normal clinical practice through high-quality cross-sectional imaging. Pre-operative management will follow institutional standards, serum pancreatic amylase and lipase activity will be measured as a part of the standard pre-operative evaluation.
62815059|NCT02958995||Full KPNC Cohort|Participants who were members of the KPNC registry (with or without diabetes) were followed up to 15 years (1997-2011) in this epidemiological study.
62815060|NCT02958995||Survey Responders|A subset of KPNC members who completed the Kaiser Diabetes Registry Survey in 1994-1996 and among a random sample of KPNC members who completed the Member Health Survey (MHS), in 1996, 1999, 2002, or 2005 were followed up to 15 years (1997-2011) in this epidemiological study.
62815061|NCT02082496|EXPERIMENTAL|Control Group|4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection
62815062|NCT02082496|EXPERIMENTAL|Case Group|4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection
62596891|NCT05803447||G2K-women|The G2K group consisted of women experiencing suicidal thoughts with a tendency of implementation, in whom the result of M.I.N.I. 7.0.2 test was 9 to 16 points (n=19)
62596892|NCT05803447||G2M-men|The G2M group consisted of men experiencing suicidal thoughts with a tendency of implementation, in whom the result of M.I.N.I. 7.0.2 test was 9 to 16 points (n=9)
62596893|NCT05803447||G3K-women|The G3K group consisted of women after a suicide attempt, in whom the result of M.I.N.I. 7.0.2 test was equal to or greater than 17 points (n=15)
62596894|NCT05803447||G3M-men|The G3M group consisted of men after a suicide attempt, in whom the result of M.I.N.I. 7.0.2 test was equal to or greater than 17 points (n=17)
62815063|NCT04871906|EXPERIMENTAL|Stretching exercises|Interventions are home-based stretching exercises. The experimental group will receive 6 stretching exercises which stretch 20-30 seconds, relax for 10 seconds, and repeat 5 times for each side. It will take 25-30 minutes every day for continuous 8 weeks.
62815064|NCT04871906|NO_INTERVENTION|Control group|Maintain their daily activity level in the 8 weeks. We use the study desigh-''waiting list control'' in this group.
62815065|NCT04212416|EXPERIMENTAL|Treatment (leflunomide)|Patients receive leflunomide PO QD for days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may optionally continue leflunomide for an additional 6 cycles as long as response or stable disease is maintained.
62238863|NCT05975957|EXPERIMENTAL|FBM|volunteers who will receive adjuvant photobiomodulation therapy (n=119)
62815066|NCT06043024|EXPERIMENTAL|TMD pain group|The arm includes patients with TMP pain screening scores ≥ 3 and with diagnosis of myalgia, arthralgia, headache attributed to TMP and painful disc displacement (with and without reduction) according to Axis I diagnostic criteria for temporomandibular disorders (DK/TMP). Patients will be treated with a stabilizing occlusal splint made of hard acrylate resin, about 1.5 mm thick in the posterior teeth area with an incisal plateau for canine guidance.
62815067|NCT06296849|NO_INTERVENTION|No-FIT Treatment-as-Usual (TAU) Condition|Participants in the no-FIT control condition will not receive incentives.
62238864|NCT05975957|PLACEBO_COMPARATOR|Control|volunteers who will receive placebo treatment with inert light (n=119)
62238865|NCT01361295|ACTIVE_COMPARATOR|PVI with PVAC gold|Patient for pulmonal vein isolation using the PVAC Gold Catheter. Intervention.
62238866|NCT01361295|ACTIVE_COMPARATOR|PVI with Cooled-RF|Patient for pulmonal vein isolation using the Cooled-RF catheter.
62238867|NCT02536573|NO_INTERVENTION|Control|Intraoperative fluoroscopy of the hip is used to visually estimate the acetabular cup angle and make any necessary adjustments.
62596895|NCT05803447||G0K-women|The G0K group consisted of women displaying no suicidal behaviour, in whom the result of M.I.N.I. 7.0.2 test was zero points (n=10)
62815068|NCT06296849|EXPERIMENTAL|Single-Target FIT (SFIT)|One couple member offered incentives. Targets in the SFIT condition will be offered financial incentives for biochemically verified abstinence ($200 at each of three follow-ups \[1, 3, and 6 Month\]).
62815069|NCT06296849|EXPERIMENTAL|Dyadic-FIT condition (DFIT)|Both couple members offered incentives and tracked across 12 months. Both targets and partners will be offered financial incentives for abstinence. Thus, in this condition, the total financial incentives offered to the dyad are twice the amount as offered to participants in the SFIT condition.
62238868|NCT02536573|EXPERIMENTAL|Radlink Surgical Positioning System|Fluoroscopic image of the hip joint is imported into the Radlink Surgical Positioning software. The software calculates a target cup position using bony landmarks, and the surgeon matches the cup to the target.
62238869|NCT01810692||Group 1|
62238870|NCT01810692||Group 2|
62238871|NCT05182996|OTHER|smoking education|smoking education
62596896|NCT05803447||G0M-men|The G0M group consisted of men displaying no suicidal behaviour, in whom the result of M.I.N.I. 7.0.2 test was zero points (n=20)
62596897|NCT06647901|EXPERIMENTAL|ICG group|
62037355|NCT01903473|EXPERIMENTAL|Donor Treg infusion arm|Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be first treated with Rapamycin while CNI (if any) will be discontinued and infused whith Treg cells 60-90 days after.
62037356|NCT01903473|ACTIVE_COMPARATOR|Control|Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be treated with Rapamycin which is an alternative immunosupression strategy allowing to fight againt GVHD and CNI (if any) will be discontinued.
62037357|NCT03883633||Enrolled Participants|All participants enrolled will be tracked from initial assessment to study completion.
62238872|NCT01158651|EXPERIMENTAL|RAD001 (Everolimus) Active Therapy|"If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment course lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).~You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection."
62815070|NCT05758116|EXPERIMENTAL|Consolidation Tislelizumab|Patients completed radiotherapy alone or sequential chemoradiation with 42 days received consolidation Tislelizumab 200mg every 3 weeks for 12 months.
62815071|NCT01368588|ACTIVE_COMPARATOR|Arm I|Patients undergo high-dose radiotherapy of the prostate and seminal vesicles using intensity-modulated radiotherapy (IMRT)\* or 3D-conformal radiation therapy (3D-CRT)\* once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo permanent prostate implant (PPI) brachytherapy or high-dose rate brachytherapy (I 125 or Pd 103 may be used as the radioisotope).
62037358|NCT04847869|EXPERIMENTAL|NIR laser treatment 200mW/cm2 dose|"Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period."
62238873|NCT01728220|ACTIVE_COMPARATOR|Inhaled NO @ 0.003 mg/kg/ ideal body weight (IBW)/hr (Part A)|Inhaled NO using 3.0 mg/L \[2440 ppm\] NO minicylinder delivered via INOpulse® DS-C device
62238874|NCT01728220|ACTIVE_COMPARATOR|Inhaled NO @ 0.010 mg/kg/IBW/hr (Part A)|Inhaled NO using 3.0 mg/L \[2440 ppm\] NO minicylinder delivered via INOpulse® DS-C device
62815072|NCT01368588|EXPERIMENTAL|Arm II|Patients undergo whole-pelvic radiotherapy (WPRT)\* (3D-CRT or IMRT) once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo brachytherapy as in arm I.
62238875|NCT01728220|ACTIVE_COMPARATOR|Inhaled NO @ 0.015 mg/kg/IBW/hr (Part A)|Inhaled NO using 6.0 mg/L \[4880 ppm\] NO minicylinder delivered via INOpulse® DS-C device
62238876|NCT01728220|PLACEBO_COMPARATOR|Placebo random @ 0.003, 0.010 or 0.015 mg/kg/IBW/hr (Part A)|Placebo using 99.999% N2 minicylinder delivered via INOpulse® DS-C device
62238877|NCT01728220|ACTIVE_COMPARATOR|Inhaled NO @ 0.030 mg/kg IBW/hr (Part B)|Inhaled NO using 6.0 mg/L \[4880 ppm\] NO minicylinder delivered via INOpulse® DS-C device
62815073|NCT05480995|EXPERIMENTAL|18F-fluorofuranylnorprogesterone PET / MRI|All enrolled subjects will receive the tracer and then have a PET/MRI scan.
62815074|NCT06095986|ACTIVE_COMPARATOR|PSC patients administered with Aramchol meglumine|Adult subjects with clinically diagnosed PSC that are administered with Aramchol meglumine
62815075|NCT06095986|PLACEBO_COMPARATOR|PSC patients administered with placebo|Adult subjects with clinically diagnosed PSC that are administered with matching placebo
62238878|NCT01728220|ACTIVE_COMPARATOR|Inhaled NO @ 0.075 mg/kg IBW/hr (Part B)|Inhaled NO using 6.0 mg/L \[4880 ppm\] NO minicylinder delivered via INOpulse® DS-C device
62735578|NCT02046837|EXPERIMENTAL|Home-based exercise|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as supervised groups). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
62238879|NCT01728220|ACTIVE_COMPARATOR|Placebo random @ 0.030 or 0.075 mg/kg/IBW (Part B)|Placebo using 99.999% N2 minicylinder delivered via INOpulse® DS-C device
62238880|NCT03304353|EXPERIMENTAL|Self-managed protocol|
62238881|NCT03304353|ACTIVE_COMPARATOR|Predetermined protocol|
62238882|NCT02467348|EXPERIMENTAL|Albumin|MVP (Modest Volume Paracentesis) of less than 5 litres with intravenous albumin at a dose 8 gms/l of ascitic fluid.
62238883|NCT02467348|ACTIVE_COMPARATOR|No Albumin|MVP (Modest Volume Paracentesis) of less than 5 litres without albumin.
62238884|NCT01287065|EXPERIMENTAL|FF(100mcg)/Vilanterol(25mcg) - AM dosing|FF(100mcg)/Vilanterol(25mcg) in the morning (approx 09.00) for 14 days (± 2 days).; placebo in evening (approx 21.00) for 14 days (± 2 days).
62238885|NCT01287065|EXPERIMENTAL|FF(100mcg)/Vilanterol(25mcg) - PM dosing|Placebo in morning (approx 09.00) for 14 days (± 2 days); FF(100mcg)/Vilanterol(25mcg) in evening (approx 21.00) for 14 days (± 2 days).
62238886|NCT01287065|PLACEBO_COMPARATOR|Placebo|Placebo given in morning (approx 09.00) and in evening (approx (21.00) for 14 days (± 2 days).
62238887|NCT00078754|EXPERIMENTAL|A|Participants will to receive treatment with fluoxetine for 12 weeks
62238888|NCT00078754|EXPERIMENTAL|B|Participants will to receive treatment with divalproex for 12 weeks
62238889|NCT00078754|PLACEBO_COMPARATOR|C|Participants will to receive treatment with placebo for 12 weeks
62596898|NCT05093959|ACTIVE_COMPARATOR|Metformin|20 weeks of metformin 1500 mg daily. Metformin is a widely used medication with an excellent safety profile. Dosing will be escalated during the first 3 weeks of treatment. Dosing will be initiated with 500 mg taken orally once daily in the evening for 1 week. After one week, the participant will be called to assess tolerance and will be asked to increase dose to two capsules per day for a total 1000 mg per day for one week. At the end of the second week, participants will be called again and if they tolerated the increased dose will be instructed to increase to three capsules (1500 mg/day) per day for the remainder of the 20 weeks. An extended release formulation will be used which improves compliance and reduces GI side effects.
62596899|NCT05093959|PLACEBO_COMPARATOR|Placebo|20 weeks of placebo 1500 mg daily. Placebo is a biologically inert substance placed in capsules to match appearance of active intervention (metformin). Dosing will be escalated during the first 3 weeks of treatment. Dosing will be initiated with 500 mg taken orally once daily in the evening for 1 week. After one week, the participant will be called to assess tolerance and will be asked to increase dose to two capsules per day for a total 1000 mg per day for one week. At the end of the second week, participants will be called again and if they tolerated the increased dose will be instructed to increase to three capsules (1500 mg/day) per day for the remainder of the 20 weeks.
62596900|NCT06620029|EXPERIMENTAL|BMX-001 + PTX|All patients will be administered BMX-001 + PTX weekly on Days 1, 8, 15, and 22 of each 28 day cycle. BMX-001 is a SC injection while PTX is IV.
62596901|NCT02275780|EXPERIMENTAL|Doravirine 100 mg|Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o. q.d. for 96 weeks in the Base Study. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o. q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the Doravirine regimen in Study Extension 2 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first. Eligible participants may continue to receive the Doravirine regimen in Study Extension 3 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
62596902|NCT02275780|ACTIVE_COMPARATOR|Darunavir 800 mg and Ritonavir 100 mg|Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o. q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o. q.d. for 96 weeks. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o. q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o. q.d. for an additional 96 weeks. Eligible participants may continue to receive the Doravirine regimen in Study Extension 2 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first. Eligible participants may continue to receive the Doravirine regimen in Study Extension 3 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
62735579|NCT00819000||Treated MS Subjects|Subjects who are treated with Glatiramer Acetate or Interferon (IFN)-β and receive their therapy from one of the participating Specialty Pharmacies
62735580|NCT04314700|OTHER|OCT imaging and review of excised breast lumpectomy tissue|
62815076|NCT05484102|EXPERIMENTAL|lactobacillus paracasei CBA L74|100 enrolled children will receive milk fermented with lactobacillus paracasei CBA L74 daily for 3 months.
62815077|NCT05484102|PLACEBO_COMPARATOR|placebo|100 enrolled children will receive placebo milk formula containing maltodextrins daily for 3 months.
62815078|NCT02854072|EXPERIMENTAL|GV1001 + gemcitabine/capecitabine|
62815079|NCT02854072|ACTIVE_COMPARATOR|gemcitabine/capecitabine|
62815080|NCT05524493||Healthy participants|
62815081|NCT05524493||Patients with migraine|
62815082|NCT05524493||Patients with drug resistent epilepsy|
62815083|NCT05524493||Patients with visual snow syndrome|
62815084|NCT02107417|EXPERIMENTAL|Experimental Group (EG) - TENS active|Experimental Group (EG) - TENS active: who will receive the application of active TENS. The participants of these group will receive TENS active within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.
62238890|NCT01524341|EXPERIMENTAL|Cohort 1|10 subjects with Plasmodium vivax malaria will receive 30 mg KAE609 once a day for three days
62238891|NCT01524341|EXPERIMENTAL|Cohort 2|10 subjects with Plasmodium falciparum malaria will receive 30 mg KAE609 once a day for three days
62238892|NCT02241239||participants|healthy adults without stroke and coronary heart disease
62238893|NCT02676661||no peri-implant disease|The subjects who did not suffer from peri-implant disease.
62238894|NCT02676661||peri-implant disease|The subjects who suffered from peri-implant disease.
62238895|NCT01301651|EXPERIMENTAL|virtual reality balance training|balance board training with virtual reality intervention
62238896|NCT01301651|EXPERIMENTAL|conventional balance training|physical therapy conventional balance training
62238897|NCT01301651|NO_INTERVENTION|control group|No physical therapy
62238898|NCT03047551|ACTIVE_COMPARATOR|Transabdominal Sonography|"Subjects will receive transabdominal sonography using a standard ultrasound device to determine medical abortion eligibility.~A transabdominal ultrasound is used to look at the pelvic organs. Gel is placed on your abdomen. Then a small, handheld unit called a transducer is gently moved around to view the pelvic organs. The transducer sound waves make a picture on the TV screen."
62238899|NCT03047551|ACTIVE_COMPARATOR|Transvaginal Sonography|"Subjects will receive transvaginal sonography using a standard ultrasound device to determine medical abortion eligibility.~Transvaginal ultrasound is an examination of the female pelvis and urogenital tract (kidneys and bladder). It differs from an abdominal ultrasound as it looks at the pelvic organs from inside the vagina."
62238900|NCT02047643|EXPERIMENTAL|On-algorithm first, then Off-algorithm|Users will participate in two sports camp sessions while wearing an insulin pump, continuous glucose monitor, and accelerometer/heart rate monitor (to detect exercise), which can communicate electronically to a pump shutoff algorithm that insulin delivery should be shut off. On one sports day, the algorithm is turned on; on the other day, the algorithm is turned off.
62238901|NCT02047643|EXPERIMENTAL|Off-algorithm first, then On-algorithm|Users will participate in two sports camp sessions while wearing an insulin pump, continuous glucose monitor, and accelerometer/heart rate monitor (to detect exercise), which can communicate electronically to a pump shutoff algorithm that insulin delivery should be shut off. On one sports day, the algorithm is turned on; on the other day, the algorithm is turned off.
62238902|NCT05995639|NO_INTERVENTION|Control Group|Patients who will undergo an exercise treatment for the UT. The exercise therapy will focus on stretching exercises for the UT. Exercise therapy will undergo 2 weeks.
62238903|NCT05995639|ACTIVE_COMPARATOR|Dry Needling Group|Patients who will undergo DN treatment for the UT. A clinician with 5 years of DN experience will assess patients and apply DN treatment. The active trigger points will be diagnosed by the criteria described by Simons and Travell. 0.25x25mm acupuncture needles will be used. DN will be performed with fast in fast out technique and needling will continue until a local twitch response is elicited. Treatment will be applied 3 times, one week apart.
62238904|NCT05995639|ACTIVE_COMPARATOR|Ozone Group|Patients who will undergo ozone treatment for the UT. A clinician with 10 years of ozone experience will assess patients and apply ozone treatment. 12 gamma ozone will be used. Patients will be injected with ozone in UT with most sensitive parts. Treatment will be applied 3 times, one week apart.
62815085|NCT02107417|SHAM_COMPARATOR|Control Group (CG)- Placebo TENS|Control Group (CG) who will be administering the placebo TENS.The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, . It has an application time of 60 minutes The TENS-placebo will be applied where no current will be emitted.
62238905|NCT04423354|EXPERIMENTAL|Research group|Patients diagnosed with Siewert Ⅱ adenocarcinoma of esophagogastric junction and met the inclusion criteria will be assigned to the research group and carry out transthoracic single-hole assisted laparoscopic radical gastrectomy.
62238906|NCT05938244||case/ diseased patients|ultra sound anterior chest wall echocardiogram pulmonary function test diaphragmatic ultra sound lipid profile Rheumatoid factor Anti-ccp
62238907|NCT05938244||control/ normal population|ultra sound anterior chest wall echocardiogram pulmonary function test diaphragmatic ultra sound lipid profile Rheumatoid factor Anti-ccp
62238908|NCT03935503||Total Extraperitoneal Repair|Laparoscopic Total Extraperitoneal (TEP) method was performed to repair inguinal hernia . Patients were evaluated preoperatively, at 1 month and 6 months postoperatively, International Sexual Function Index (IFIF), International Prostatic Symptom Score, SF-36 Quality of Life Scale, Visual Analog Pain Scale, Beck Depression Scale, Inguinal Region Discrimination Test ( DT), DN4 Neuropathic Pain Survey, Uroflowmetry and FSH, LH, Total Testosterone levels were evaluated.
62815086|NCT03969485|EXPERIMENTAL|Hybrid Fractional Laser|Hybrid Fractional Laser Treatment
62815087|NCT05672654|ACTIVE_COMPARATOR|Control group|
62815088|NCT05672654|ACTIVE_COMPARATOR|HIV positive CD4<350 cells/mm^3|
62815089|NCT05672654|ACTIVE_COMPARATOR|Immune-compromised patients- department rheumatology|
62815090|NCT05672654|ACTIVE_COMPARATOR|Immune-compromised patients- department nephrology|
62815091|NCT05672654|ACTIVE_COMPARATOR|Immune-compromised patients- department neurology|
62815092|NCT05672654|ACTIVE_COMPARATOR|Primary immune deficiency en common variable immunodeficiency|
62037359|NCT05545553|EXPERIMENTAL|Piezosurgery group|In the experimental group, a piezosurgery device was used to remove the bone surrounding the impacted third molar.
62815093|NCT02008396|PLACEBO_COMPARATOR|Inactive Placebo with Therapy|Participants will receive inactive placebo during two psychotherapy sessions lasting approximately 7 hours.
62815094|NCT02008396|EXPERIMENTAL|Group 1: MDMA-assisted therapy 75 mg/100mg|Participants will receive 75 mg and 100 mg midomafetamine HCl during two sessions of MDMA-assisted therapy, respectively, lasting approximately 7 hours.
62815095|NCT02008396|EXPERIMENTAL|Group 2: MDMA-assisted therapy 100 mg/125 mg|Participants will receive 100 mg and 125 mg midomafetamine HCl during two sessions of MDMA-assisted therapy, respectively, lasting approximately 7 hours.
62815096|NCT02720393|PLACEBO_COMPARATOR|Regular diet|Meals and snacks will contain carrageenan in the amount consumed in the typical daily diet and will be selected by the study dietician and distributed to study subjects randomized to the regular diet study arm.
62815097|NCT02720393|EXPERIMENTAL|No-carrageenan diet|No-carrageenan diet will be composed of meals and snacks selected by the study dietician and distributed to study participants who are randomized to the no-carrageenan diet study arm.
62815098|NCT05301959|EXPERIMENTAL|Experimental group|A single weekly intervention of low intensity galvanic currents will be applied in an ultrasound-guided manner.
62238909|NCT03935503||Lichtenstein repair|Lichtenstein method was performed to repair inguinal hernia . Patients were evaluated preoperatively, at 1 month and 6 months postoperatively, International Sexual Function Index (IFIF), International Prostatic Symptom Score, SF-36 Quality of Life Scale, Visual Analog Pain Scale, Beck Depression Scale, Inguinal Region Discrimination Test ( DT), DN4 Neuropathic Pain Survey, Uroflowmetry and FSH, LH, Total Testosterone levels were evaluated.
62815099|NCT05301959|SHAM_COMPARATOR|Simulated group.|The application of a single weekly intervention of low intensity galvanic currents will be simulated in an echogenic way, with the equipment turned off.
62815100|NCT01575444||Home Based Vaginal Collection|Somali women who are randomized for Home based Vaginal Collection will be given a kit to perform the vaginal sample collection for HPV analysis, with detailed written instructions.
62815101|NCT01575444||Clinic Based Pap Test Collection|30 Somali women who are randomized for Standard Clinic Pap Group will be given a list of clinics that they can attend for cervical cancer screening using pap test. Follow-up will be done on test completion with the clinic at 3 months after enrollment.
62815102|NCT05202808|EXPERIMENTAL|Light adjustable lens (LAL) and Light Delivery Device (LDD)|
62815103|NCT05202808|ACTIVE_COMPARATOR|Control IOL|
62815104|NCT04564417|EXPERIMENTAL|Monotherapy dose escalation: W0180|Participants will receive W0180 in a 21-day cycle until the maximum tolerated dose (MTD)/ recommended dose for expansion (RDE) for the single-agent identified.
62815105|NCT04564417|EXPERIMENTAL|Combination dose escalation: W0180+Pembrolizumab|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion every three weeks (Q3W) followed by W0180 in a 21-day Cycle until the MTD in combination is identified or an RDE in combination is established.
62815106|NCT04564417|EXPERIMENTAL|Dose expansion|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion Q3W followed by an RDE dose of W0180 in a 21-day cycle.
62815107|NCT04235140|EXPERIMENTAL|LUM/IVA|Participants weighing 7 to less than (\<) 9 kilograms (kg) received LUM 75 milligrams (mg)/IVA 94 mg fixed-dose combination (FDC) every 12 hours (q12h) and those weighing 9 to \<14 kg received LUM 100 mg/IVA 125 mg q12h in the treatment period of 96 weeks. Participants weighing greater than or equal to (\>=)14 kg received LUM 150 mg/IVA 188 mg FDC q12h in the treatment period of 96 weeks.
62815108|NCT04938960||Biological Heart Valve|Participants receiving a biological heart valve
62815109|NCT04938960||Mechanical Heart Valve|Participants receiving a mechanical heart valve
62815110|NCT02787564|EXPERIMENTAL|Free Fruit and Vegetables|After baseline assessment of food intake patterns, the intervention will consist of providing free fruits and vegetables of their choice for a period of four weeks which will be provided fresh each week. At baseline and at the end of the 4-week period, a FFQ, two 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered.
62815111|NCT02787564|NO_INTERVENTION|Control Goup|At baseline and at the end of the 4-week period, a FFQ, four 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered. At the end of the intervention period they receive once a basket of free fruits and vegetables.
62238910|NCT00916630|OTHER|Single-arm treatment|Dose finding study
62815112|NCT05777408|ACTIVE_COMPARATOR|Control Group|"Participants of this group will receive the conventional physical therapy protocol mentioned above. In addition to this, they will receive Natural apophyseal glides 3 sets of 10 repetitions.~* Frequency: 3 times a week for 2 weeks. 6 sessions in total.~* Mobilizations will be performed in Grade 1 initially and then progressed to Grade 2 and 3 depending on the patients pain status and compliance."
62238911|NCT05700201|EXPERIMENTAL|Intervention|Healthy lifestyle intervention
62238912|NCT05700201|EXPERIMENTAL|Control|Standard care (psychotherapy)
62238913|NCT01264367|EXPERIMENTAL|1|Clevudine 30mg
62238914|NCT01264367|ACTIVE_COMPARATOR|2|Clevudine 30mg + peg-interferon 180mcg
62238915|NCT01285466|EXPERIMENTAL|BEZ235 + paclitaxel|
62238916|NCT01285466|EXPERIMENTAL|BKM120 + paclitaxel|
62238917|NCT01285466|EXPERIMENTAL|BEZ235 + paclitaxel + trastuzumab|
62815113|NCT05777408|EXPERIMENTAL|Experimental Group|"* Participants of this Group will receive the conventional physical therapy protocol mentioned above. In addition to this, they will receive Natural apophyseal glides and cranial base release.~* Frequency: 3 times a week for 2 weeks. 6 sessions in total.~* Cranial base release would be given for around 1-4minutes until the tissues relax and would be given once daily"
62815114|NCT05361395|EXPERIMENTAL|Part 1: Dose Exploration Combination Regimen 1|Tarlatamab+Atezolizumab+Carboplatin+Etoposide
62815115|NCT05361395|EXPERIMENTAL|Part 2: Dose Exploration Combination Regimen 2|Tarlatamab+Atezolizumab+Carboplatin+Etoposide
62815116|NCT05361395|EXPERIMENTAL|Part 3: Dose Exploration Combination Regimen 3|Tarlatamab+Atezolizumab+Carboplatin+Etoposide
62815117|NCT05361395|EXPERIMENTAL|Part 4: Dose Expansion|Expansion of Part 1, Part 2, or Part 3 with Atezolizumab
62815118|NCT05361395|EXPERIMENTAL|Part 5: Dose Exploration Maintenance|Tarlatamab+Atezolizumab
62815119|NCT05361395|EXPERIMENTAL|Part 6: Dose Expansion Maintenance|Expansion of Part 5 with Atezolizumab
62238918|NCT01285466|EXPERIMENTAL|BKM120 + paclitaxel + trastuzumab|
62429456|NCT05759169|EXPERIMENTAL|Intervention|In line with the literature and expert opinions, each dialysis application has been applied to individuals for 30 minutes for the first 30 minutes of 4 weeks, with a 40-43°C hot water-filled foot wash tub, placing both feet of the individual (Afrasiabifar et al., 2022; Kim et al., 2021 Shafeik et al., 2018). The researcher implemented the voluntary consent Form, Patient Demonstration Form, foot Bath Application Monitoring Chart, fatigue VAS Scale Form, dialysis Symptom Index and Hemodialysis Comfort Scale in person. At the end of the fourth week, the researcher refilled the foot Bath Application Monitoring Chart, the fatigue VAS Scale Form, the dialysis Symptom Index, and the Hemodialysis Comfort Scale. A total of 12 sessions have been performed in the foot bath, including during each dialysis treatment for 4 weeks.
62429457|NCT05759169|NO_INTERVENTION|Control|Patients in the control group have been informed about the voluntary Form, Patient Demonstration Form, fatigue VAS Scale Form, dialysis Symptom Index, and Hemodialysis Comfort Scale performed by the researcher in person. At this stage, no attempt was made to the control group at the end of the fourth week; during the last hemodialysis session, the researcher, with the fatigue VAS Scale Form, the dialysis Symptom Index and the Hemodialysis Comfort Scale face-to-face, treated the patients.
62429458|NCT05990647|ACTIVE_COMPARATOR|Group I|32 patients who underwent classic abdominal wall anterior components separation and bridged hernia repair.
62815120|NCT05361395|EXPERIMENTAL|Part 7: Dose Expansion|Expansion of Part 1, 2, or 3 with Durvalumab
62815121|NCT05361395|EXPERIMENTAL|Part 8: Dose Expansion Maintenance|Expansion of Part 5 with Durvalumab
62815122|NCT05361395|EXPERIMENTAL|Part 9: Dose Expansion Maintenance|Expansion with Tarlatamab+Durvalumab
62815123|NCT03962062|EXPERIMENTAL|Cohort 1: 12-17 years|Moxidectin 8mg per oral, single dose
62815124|NCT03962062|EXPERIMENTAL|Cohort 2: 8-11 years|Moxidectin 8mg (or lower dose) per oral, single dose
62815125|NCT03962062|EXPERIMENTAL|Cohort 3: 4-7 years|Moxidectin single dose, determined by population pharmacokinetic modelling including data from Cohorts 1 and 2
62238919|NCT03205215|EXPERIMENTAL|Immediate Treatment|This arm will receive hyperbaric oxygen therapy once consented.
62238920|NCT03205215|EXPERIMENTAL|Waitlist - to be treated|This arm will receive a hyperbaric oxygen therapy after waiting two months.
62238921|NCT05467254|EXPERIMENTAL|CLL1+CD33 CAR-T|"Dose Escalation:After enrollment ,Participants complete the PBMC apheresis,then complete the Lymphocyte clearance,and then receive the dose climning test: 3×10e6/kg，6 ×10e6/kg，9×10e6/kg.~Dose Expansion:Participants receive a single dose (at the MTD determined)."
62429459|NCT05990647|ACTIVE_COMPARATOR|Group II|34 patients who underwent posterior components separation with the internal oblique myofascial release by Rives-Stoppa
62429460|NCT05990647|ACTIVE_COMPARATOR|Group III|29 patients who underwent posterior components separation with transversus abdominis release (TAR).
62429461|NCT00986154|EXPERIMENTAL|heparin/edoxaban tosylate|
62735581|NCT02517255|EXPERIMENTAL|Cardiac Magnetic Resonance Imaging|Cardiac MRI will be performed within 7 days of rescue percutaneous coronary intervention (PCI) and after 3 and 6 months.
62815126|NCT06549998|NO_INTERVENTION|Control|This group will not receive any simulation intervention
62815127|NCT06549998|EXPERIMENTAL|Experimental Group|This group will receive 2 simulations
62815128|NCT06475352|ACTIVE_COMPARATOR|Uracilemia <16|Patient with uracilemia \<16 ng/mL will receive a full standard fluoropyrimidine dose
62815129|NCT06475352|EXPERIMENTAL|Uracilemia [16-20[|Patients with uracilemia between \[16-20\[ ng/mL will receive a full standard fluoropyrimidine dose -dose
62815130|NCT06475352|EXPERIMENTAL|Uracilemia [20-50[ - 25%|Patients with uracilemia between \[20-50\[ ng/mL will be randomized to receive a 25% fluoropyrimidine dose reduction
62815131|NCT06475352|EXPERIMENTAL|Uracilemia [20-50[ - 50%|Patients with uracilemia between \[20-50\[ ng/mL will be randomized to receive a 50% fluoropyrimidine dose reduction
62429462|NCT00986154|ACTIVE_COMPARATOR|heparin/warfarin|
62735582|NCT01116466|EXPERIMENTAL|ActiGait|Receiving ActiGait - implantable drop foot stimulator
62735583|NCT00479570|EXPERIMENTAL|Study period 1, 2 or 3|
62735584|NCT00479570|PLACEBO_COMPARATOR|Placebo Study period 1, 2 or 3|
62815132|NCT06475352|EXPERIMENTAL|Uracilemia [50-100[|Patients with uracilemia between \[50-100\[ ng/mL will receive a 50% fluoropyrimidine dose reduction
62815133|NCT06475352|EXPERIMENTAL|Uracilemia [100-150[|Patients with uracilemia between \[100-150\[ ng/mL will receive a 75% fluoropyrimidine dose reduction
62815134|NCT00918281|EXPERIMENTAL|Fluciclatide Injection|Fluciclatide Injection
62815135|NCT02488577|ACTIVE_COMPARATOR|TAMIS TME|T2 N0 Cases which undergo transanal minimally invasive total mesorectal excision.
62815136|NCT02488577|ACTIVE_COMPARATOR|TAMIS-Local|T2 N0 Cases which will undergo transanal minimally invasive locoregional resection.
62596903|NCT03358771|NO_INTERVENTION|Usual Care|"During the initial stepped wedge phase, all sites will receive usual care. There is currently no standardized discharge care bundle for COPD in Alberta. Some electronic patient information sheets do exist; however, their content is general and use is limited. It is expected that a vast majority of patients will transition to the community on a sub-optimal medication regimen, with limited referral to additional outpatient programs and no formal follow-up organized with a primary care provider (e.g., F/U prn or F/U with Fam MD)."
62596904|NCT03358771|ACTIVE_COMPARATOR|COPD discharge care bundle|"COPD discharge care bundle:~1. Ensure patient has demonstrated adequate inhaler technique~2. Send discharge summary to family physician office and arrange follow-up~3. Optimize and reconcile prescription of respiratory medications~4. Provide a written discharge management plan, and assess patient's and care giver's comprehension of discharge instructions~5. Refer to pulmonary rehabilitation~6. Screen for frailty and comorbid condition(s)~7. Assess smoking status, provide counseling and refer to smoking cessation program, where appropriate"
62596905|NCT03358771|EXPERIMENTAL|COPD discharge care bundle & coordinator|COPD discharge care bundle as listed for active comparator arm enhanced with care coordinator support.
62596906|NCT06295991|EXPERIMENTAL|study group|wearing lycra garment
62596907|NCT06295991|PLACEBO_COMPARATOR|control group|wearing non-lycra garment
62596908|NCT00157248|EXPERIMENTAL|dabigatran etexilate, 150 mg once daily|dosage used at study start
62596909|NCT00157248|EXPERIMENTAL|dabigatran etexilate, 150 mg twice daily|dosage used at study start
62596910|NCT00157248|EXPERIMENTAL|dabigatran etexilate, 300 mg once daily|dosage used at study start
62596911|NCT00157248|EXPERIMENTAL|dabigatran etexilate, 300 mg twice daily|dosage used at study start
62596912|NCT05511207|EXPERIMENTAL|RECOM - hBCI training|Patients in the RECOM group will receive treatment in add-on to standard rehabilitation as follows. The RECOM device is a h-BCI system that controls FES of upper limb muscles: the patient is asked to attempt simple upper limb movements (eg extension of fingers); the device recognizes (in correct trials) close-to-normal EEG-EMG activation and initiates FES of extensor muscles in the forearm. RECOM training consists in a set of trial repetition for a total duration per session of approximately 20-30 minutes (excluding set up time and calibration). FES parameters will be set specifically for each patients according to standard guidelines to achieve full movement and so as to avoid any kind of discomfort for the patients. The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
62429463|NCT02980562|ACTIVE_COMPARATOR|2L Polyethylene glycols-Asc|1 L of PEG containing ascorbic acid (PEG A) was taken at 8:00 pm on the day before the colonoscopy, followed by an extra 500 mL of water. The second 1-L of PEG containing ascorbic acid was taken 4 h before the colonoscopy examination, with an additional 500 mL of water. Each liter of preparation and the extra 500 mL water had to be consumed within 2 h of the procedure. All colonoscopies were performed between 9 am and 1 pm.
62596913|NCT05511207|ACTIVE_COMPARATOR|CTRL - upper limb training with FES|Patients in the CTRL group will receive treatment in add-on to standard rehabilitation as follows. An expert physiotherapist will define a set of active exercises focused on upper limb function; the exercises will be combined with FES of forearm muscles. FES parameters will be set specifically for each patients according to standard guidelines to achieve the full required movement and so as to avoid any kind of discomfort for the patients. Session duration will be approximately 20-30 minutes (excluding FES calibration time). The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
62429464|NCT02980562|ACTIVE_COMPARATOR|1L PEG-Asc plus bisacodyl|10 mg bisacodyl at 9:00 pm on the day before the colonoscopy. Four hours before the colonoscopy examination, 1 L of PEG containing ascorbic acid was taken, followed by an additional 1 L of water. The preparation was completed 2 h before the examination. All colonoscopies were performed between 9 am and 1 pm.
62596914|NCT05835362|EXPERIMENTAL|Question prompt list only group|"In the question prompt list group youth will be handed the youth ADHD prompt list, and the parent will be handed the parent ADHD prompt list, and will be told, Your provider wants you to ask any questions that you have about ADHD. Here are lists of questions that you may want to ask. Please spend some time reading through this and marking any questions you want to ask your provider during the visit. You can also write other questions you want to ask on the bottom."
62429465|NCT05974345||Virtual Patient with ASCVD|Virtual Patient with ASCVD and LDL-C ≥ 70 mg/dL despite receiving a well-tolerated high-intensity statin with or without ezetimibe. Each virtual patient is his own control.
62429466|NCT01248611|EXPERIMENTAL|fentanyl|cancer patients with pain
62815137|NCT05016479|EXPERIMENTAL|Active arTMS (15 Hz)|The treatment involves 15 Repetitive Transcranial Magnetic Stimlation sessions (3/daily for 5 consecutive days, each session lasts 13 min with an interval of 50 min). Coil is placed on the left dorsolateral prefrontal cortex (LDLPFC).The stimulation has a frequency of 15 Hz and a intensity of 120% of the individual resting motor threshold.
62815138|NCT05016479|SHAM_COMPARATOR|Sham arTMS|Sham group receives the same Repetitive Transcranial Magnetic Stimlation sessions of active compactors. However the interventions in the place group are with a superficial stimulation of scalp muscles only, in order to induce a sensation close to the one experienced with the real rTMS stimulation.
62815139|NCT05858541|EXPERIMENTAL|Music Listening|Music Intervention - Music selection by LUCID The AI-based system for song selection responds to the collected measurement data (video and HRV) and music preference information (like/dislike button, music taste profile) to recommend the playlist for the listener. The songs are selected using 76 different musical features and raw audio information. The system uses these features to recommend and optimize recommendations for the listener. The video is only temporarily streamed from the device to extract a series of facial features to assist in music selection. This data stream is sent to the LUCID cloud platform via encrypted data in transit protocol; the facial features are extracted, and the video is deleted. The facial feature data, even when reconstructed, is not identifiable. No personally identifiable biometric measures are stored in LUCID servers at any time
62815140|NCT05858541|ACTIVE_COMPARATOR|Audiobooks|Audiobook selection A selection of 40 audiobooks spanning 4 genres (10 each from Literary Classics, Fantasy, Mystery, Non-fiction) will be available. For each session, the participant and their caregiver will be given a prompt to make a genre selection. After making the genre selection, one of the ten stories associated with that genre will be selected at random. All stories were sampled from the Audible audiobook database. Stories had to be 30 minutes in length to align with the length of the music interventions and the selected stories had to have had a 4- or 5-star rating to ensure quality.
62815141|NCT03521349|PLACEBO_COMPARATOR|Egg White Snacks|Egg white-based snacks
62815142|NCT03521349|EXPERIMENTAL|Whole Egg Snacks|Whole egg-based snacks
62815143|NCT04985929|EXPERIMENTAL|Healthy, Untrained|Untrained participants will be defined as having a V̇O2peak of 30-45 ml.kg-1.min-1 and will be between 18-40 years of age.
62815144|NCT04985929|EXPERIMENTAL|Healthy, Trained|Trained participants will be defined as having a V̇O2peak above 55 ml.kg-1.min-1 (females) and 60 ml.kg-1.min-1 (males) and will be between 18-40 years of age.
62815145|NCT03466658|EXPERIMENTAL|JumpStart group|This group will have the JumpStart dressing pre-operatively. Intervention: JumpStart dressing
62815146|NCT03466658|NO_INTERVENTION|Control group|This group will have no intervention pre-operatively. Intervention: none
62815147|NCT03228446|EXPERIMENTAL|Young subjects|Working memory training \& attentional filter training for participants (18-30 years)
62429467|NCT01339078|ACTIVE_COMPARATOR|Plastic stenting|Patients will be randomized towards plastic stenting.
62815148|NCT03228446|EXPERIMENTAL|Old subjects|Working memory training, attentional filter training and no training (control) for participants (60-80 years)
62815149|NCT05219825|EXPERIMENTAL|Breathwork group|Treatment-seeking individuals with cannabis use disorder who will participate in the 1-week breathwork workshop.
62815150|NCT02262936|ACTIVE_COMPARATOR|Desmopressin|Patients randomized to receive Desmopressin will be given 0.1mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 0.2mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.
62815151|NCT02262936|ACTIVE_COMPARATOR|Fesoterodine|Patients randomized to receive Fesoterodine will be given 4mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 8mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.
62429468|NCT01339078|EXPERIMENTAL|Kaffes stenting|Patients will be randomized towards Kaffes stenting.
62596915|NCT05835362|EXPERIMENTAL|Pre-visit video only group|Parents and youth in the pre-visit video only group will watch together a short educational video with six themes on an iPad encouraging families to ask questions and to be engaged during ADHD visits.
62815152|NCT02251015|ACTIVE_COMPARATOR|therapeutic exercises|13 as control group - The control group got only orientation related to therapeutic exercises.The orientation for therapeutic exercises seek to correctly position the jaw in the resting position. Maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
62815153|NCT02251015|EXPERIMENTAL|occlusal plate group|36 getting occlusal splints - the splinted group was subjects that used occlusal plate under the occlusal stability criteria. The patients also received therapeutic exercises too. The plate group arm, the patients used the occlusal splints for all night plus 4 hours during the day and they made therapeutic exercises 15 repetitions 3 times a day.
62238922|NCT01446016|EXPERIMENTAL|Chloroquine with Taxane or Taxane-Like (Paclitaxel, Docetaxel, Abraxane, Ixabepilone) Chemotherapy|Chloroquine (250 mg) was given daily orally with either Paclitaxel or Docetaxel or Abraxane or Ixabepilone chemotherapy every 3 weeks (1 cycle) fro a maximum of 6 cycles.
62238923|NCT02499081|EXPERIMENTAL|Ixazomib|Ixazomib 4.0 mg given on days 1, 8 15, 22 of a 28 day cycle maximum of 6 cycles.
62238924|NCT04398641||Nerve and vessel sparing segmental resection (NVSSR)|Women undergoing surgery for deep endometriosis of the lower rectum using the surgical technique of nerve and vessel sparing segmental resection (NVSSR)
62238925|NCT04398641||Transanal disc excision (TADE)|Women undergoing surgery for deep endometriosis of the lower rectum using the surgical technique of transanal disc excision (TADE)
62238926|NCT04247009|ACTIVE_COMPARATOR|Meat|Patients with RA served a meal of meat
62238927|NCT04247009|ACTIVE_COMPARATOR|Fish|Patients with RA served a meal of fish
62238928|NCT04247009|ACTIVE_COMPARATOR|Vegan|Patients with RA served a vegan meal
62429469|NCT03798522|EXPERIMENTAL|erector spinae plane block group (ESPB) n=14|Bilateral ultrasound guided erector spinae plane block will be performed in the lateral position at T7 vertebrae and before induction of GA. 20 ml of local anesthetic solution (20 ml bupivacaine (Sunnypivacaine, Sunny pharmaceutical, Egypt) 0.25%) will be injected in-plane into the ESP. This procedure will be repeated on the other side taking care not to exceed the maximum recommended doses (2 mg/kg of IBW for bupivacaine) and then GA will be conducted .
62429470|NCT03798522|ACTIVE_COMPARATOR|general anesthesia group (GA) n= 14|these patients will receive iv nalbuphine in dose of 2mg /kg according to ideal body weight after induction of GA
62429471|NCT01796041|EXPERIMENTAL|IV Injection of ICG|
62429472|NCT00659581||Patients with hypertension|
62429473|NCT05025982||Group of partecipants|we combined two surgical techniques in the same group of patients
62429474|NCT01611168|NO_INTERVENTION|Usual Care|
62037360|NCT05545553|ACTIVE_COMPARATOR|Conventional group|In the control group, conventional burs were used to remove the bone surrounding the impacted third molar.
62037361|NCT01318226|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
62238929|NCT04247009|ACTIVE_COMPARATOR|Meat controls|Matched controls served a meal of meat
62238930|NCT01377077|EXPERIMENTAL|epidermal 1mm grafting|Epidermal skin biopsies of 1mm diameter
62238931|NCT01377077|EXPERIMENTAL|dermal 1mm grafting|dermal skinbiopsies of 1mm diameter
62238932|NCT01377077|EXPERIMENTAL|dermal 1,5mm grafting|dermal skinbiopsies of 1,5mm diameter
62238933|NCT01377077|ACTIVE_COMPARATOR|epidermal 1,5mm grafting|epidermal skinbiopsies of 1,5mm diameter
62238934|NCT00567268||Gabapentin|Patients taking Gabapentin
62238935|NCT03450798|ACTIVE_COMPARATOR|SOFT block group|needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected
62238936|NCT03450798|SHAM_COMPARATOR|spinal anesthesia group|patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.
62429475|NCT01611168|EXPERIMENTAL|Intervention Group, treatment algorithms|
62429476|NCT00918632|OTHER|Sequence 1 (ABC)|"The following treatments will be administered in the following order A -\> B-\> C~1. Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~2. Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~3. Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
62429477|NCT00918632|OTHER|Sequence 2 (ACB)|"The following treatments will be administered in the following order A -\> C -\> B~1. Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~2. Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~3. Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
62735585|NCT01762774|EXPERIMENTAL|Cohort 1|Healthy male subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 2 mg GSK2256294 capsules, Treatment B = 6 mg GSK2256294 capsules, Treatment C = 18 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
62238937|NCT02506478||ED patients|All ED patients who are able to drink water/juice, and be able to communicate juice preference.
62238938|NCT01322048|EXPERIMENTAL|Adrenergic Blockade|Propranolol and Clonidine
62238939|NCT01322048|PLACEBO_COMPARATOR|Placebo|Placebo
62238940|NCT03330457|EXPERIMENTAL|Cohort 1 Bertrixaban/Andexanet|Andexanet 800 mg, administered as a slow IV bolus after having been dosed to steady-state with betrixaban 80 mg PO once daily (QD) for 7 days
62429478|NCT00918632|OTHER|Sequence 3 (BCA)|"The following treatments will be administered in the following order B -\> C -\> A~1. Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~2. Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~3. Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
62429479|NCT00918632|OTHER|Sequence 4 (BAC)|"The following treatments will be administered in the following order B -\> A -\> C~1. Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~2. Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~3. Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
62429480|NCT00918632|OTHER|Sequence 5 (CAB)|"The following treatments will be administered in the following order C -\> A -\> B~1. Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~2. Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~3. Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
62429481|NCT00918632|OTHER|Sequence 6 (CBA)|"The following treatments will be administered in the following order C -\> B -\> A~1. Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~2. Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~3. Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
62429482|NCT05491213|EXPERIMENTAL|TELESCOPE intervention|Participants will be surveyed at baseline and at one-week after the scheduled primary care office visit. If a participant is a current smoker then they are offered and navigated to evidence-based smoking cessation. If the participant is interested in screening, an LDCT is ordered. Support for screening, diagnostic testing and oncology care will be provided as needed from the Nurse Navigators.
62429483|NCT05491213|NO_INTERVENTION|Enhanced usual care (EUC)|Participants will be surveyed at baseline and at one-week after the scheduled primary care office visit. Primary and secondary outcome data related to the office visit will be collected.
62429484|NCT02165566|EXPERIMENTAL|Regular-insulin,|regular-insulin or lispro-insulin at 0.04 units/kg/hour continuous infusion crossover and random assignement
62429485|NCT02165566|EXPERIMENTAL|Lispro insulin|patients randomly assigned in a crossover way to one of the 2 treatments
62429486|NCT05842811||Disease Cohort|Observational
62238941|NCT03330457|EXPERIMENTAL|Cohort 1 Bertrixaban/Placebo|Placebo, administered as a slow IV bolus after having been dosed to steady-state with betrixaban 80 mg PO once daily (QD) for 7 days
62429487|NCT05842811||Engaged Cohort|Observational
62429488|NCT04916886|EXPERIMENTAL|50L Scale (Age 18-59)|Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
62429489|NCT04916886|EXPERIMENTAL|500L Scale (Age 18-59)|Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
62596916|NCT05835362|EXPERIMENTAL|Combined question prompt list/video intervention group|"In the combined pre-visit video/question prompt list group youth will watch the video with the parent. Then, youth will be handed the youth ADHD prompt list, and the parent will be handed the parent ADHD prompt list, and will be told, Your provider wants you to ask any questions that you have about ADHD. Here are lists of questions that you may want to ask. Please spend some time reading through this and marking any questions you want to ask your provider during the visit. You can also write other questions you want to ask on the bottom."
62815154|NCT03866122|EXPERIMENTAL|Neonatal Temperature Monitor|One or more test devices (NTM, Bempu, Thermospot) will be attached to the infant in the neonatal intensive care unit (NICU) or KMC ward along with the Philips Intellivue patient monitor. Temperature will be monitored continuously using each device for up to 72 hours.
62429490|NCT04916886|EXPERIMENTAL|800L Scale (Age 18-59)|Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
62238942|NCT03330457|EXPERIMENTAL|Cohort 2 Bertrixaban/Andexanet|andexanet 800 mg administered as a slow IV bolus at a target rate of approximately 30 mg/min followed by a continuous infusion of up to 8 mg/min for 120 min (960 mg) starting 4 h after the last dose of betrixaban
62238943|NCT03330457|EXPERIMENTAL|Cohort 2 Bertrixaban/Placebo|Placebo administered as a slow IV bolus at a target rate of approximately 30 mg/min followed by a continuous infusion of up to 8 mg/min for 120 min (960 mg) starting 4 h after the last dose of betrixaban
62238944|NCT05918172||manual group|The cuff pressure of the tracheal tube will be monitored every 8 hours in the manual group using a portable manometer. The target endotracheal tube cuff pressure will be 20 cm H2O throughout the follow-up of the patients.
62238945|NCT05918172||automatic group|The cuff pressure of the tracheal tube will be monitored continuously using a pneumatic device in the automatic group. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients.
62429491|NCT04916886|EXPERIMENTAL|800L Scale Lot 1 (Age 13-17)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
62429492|NCT04916886|EXPERIMENTAL|800L Scale Lot 2 (Age 13-17)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
62429493|NCT04916886|EXPERIMENTAL|800L Scale Lot 3 (Age 13-17)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
62429494|NCT04916886|EXPERIMENTAL|800L Scale Lot 1 (Age 6-12)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
62429495|NCT04916886|EXPERIMENTAL|800L Scale Lot 2 (Age 6-12)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
62429496|NCT04916886|EXPERIMENTAL|800L Scale Lot 3 (Age 6-12)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
62596917|NCT05835362|NO_INTERVENTION|Control group|The control group will receive usual care.
62815155|NCT02568969|EXPERIMENTAL|Lactate monitoring|The patients in the group will be subjected to the continuous perioperative monitoring of the venous blood lactate
62429497|NCT02677675|EXPERIMENTAL|Intervention (reminder module)|"A reminder module which included standardized weekly SMS medication reminders (sent at 9am every Monday); SMS reminder 3 days prior to scheduled clinic appointments (individualized and sent at lunch time), and an average of 90sec lunch hour telephone call reminders a day prior to scheduled clinic appointment (in addition to standard care - routine adherence counselling) was delivered consistently for 24 weeks to respondents in the intervention group by two trained PLHIV (research assistants)"
62429498|NCT02677675|NO_INTERVENTION|Control (standard care)|Control group received standard care only (routine adherence counselling and paper-based appointment scheduling)
62429499|NCT05839860|PLACEBO_COMPARATOR|3 g salt|Tomatoes with 3 g salt
62596918|NCT00759785|EXPERIMENTAL|ER-positive Luminal B|Single dose of dalotuzumab 20 mg/kg infused intravenously over 60-120 minutes.
62238946|NCT05211154|EXPERIMENTAL|Diclofenac Potassium (soluble)|50 mg diclofenac potassium taken orally once
62596919|NCT00759785|EXPERIMENTAL|Triple Negative|Single dose of dalotuzumab 20 mg/kg infused intravenously over 60-120 minutes.
62238947|NCT05211154|ACTIVE_COMPARATOR|Rimegepant|75 mg rimegepant taken orally once
62815156|NCT00693407|EXPERIMENTAL|1, FD patients|Eighty male and female FD patients according to Rome III criteria (Drossman, 2006), aged 18 to 70 years, will be recruited from primary and secondary care via advertisements and our referral networks
62596920|NCT04393064|OTHER|full term and preterm|75 preterm and 75 fullterm will be recruited in this study; all will be hemodynamically stable on discharge doing FEES
62596921|NCT00979589|ACTIVE_COMPARATOR|Combination Clopidogrel and asprin|
62596922|NCT00979589|PLACEBO_COMPARATOR|Asprin and placebo|
62596923|NCT05043012|EXPERIMENTAL|Group 1|will have an mpMRI scan with a flexible AIR coil.
62815157|NCT00693407|EXPERIMENTAL|2,Healthy controls|Forty male and female healthy volunteers, aged 18 to 70 years without any gastrointestinal pathology or history of significant abdominal pain, bowel disorders, bloating or discomfort during the last 3 months will be recruited.
62238948|NCT02944994|EXPERIMENTAL|Unified Protocol|Unified Protocol-psychotherapy
62238949|NCT02944994|EXPERIMENTAL|Routine Care|Routine Care psychotherapy comparison
62238950|NCT06393790|EXPERIMENTAL|Strength training group with fibromyalgia diagnosis|"The sample will be composed of 15 subjects (women), aged between 18 and 70 years. Participants must have been diagnosed with fibromyalgia (FM) and/or chronic fatigue syndrome (CFS) at least three months before the start of the study.~Study participants must not have any other illness and/or injury at the time of the assessments that would prevent them from performing the activity. Likewise, those following pharmacological treatments or any type of cardiorespiratory disease will be excluded from the research."
62429500|NCT05839860|EXPERIMENTAL|6 g salt|Tomatoes with 6 g salt and 1 L of water
62429501|NCT05839860|EXPERIMENTAL|9 g salt|Tomatoes with 9 g salt and 1 L of water
62429502|NCT02130895|EXPERIMENTAL|Intervention|STOPP Criteria Decision Support Content Intervention arm will receive CDS suggestions based on the STOPP criteria.
62429503|NCT02130895|NO_INTERVENTION|Control|Control arm will provide care as usual during the intervention period.
62429504|NCT02486471|OTHER|Observational approach|Wait and see
62429505|NCT02486471|ACTIVE_COMPARATOR|Use of Monsel´s Paste|cervical coagulation using a hemostatic agents, ie monsel´s paste
62429506|NCT00454311|ACTIVE_COMPARATOR|One cell biopsy|
62596924|NCT05043012|EXPERIMENTAL|Group 2|will have an mpMRI scan with an endorectal coil
62815158|NCT04932395|EXPERIMENTAL|Anshen Buxin Liuwei Pills|15 pills/time, 2 times/day, orally，for 8 weeks
62815159|NCT04932395|PLACEBO_COMPARATOR|Placebo|15 pills/time, 2 times/day, orally. for 8 weeks
62429507|NCT00454311|OTHER|Two cell biopsy|
62596925|NCT06621212|EXPERIMENTAL|MAV regimen|mitoxantrone hydrochloride liposome injection, cytarabine combined with venetoclax
62596926|NCT03203408|EXPERIMENTAL|OSTENIL PLUS|A single intra-articular injection of sodium hyaluronate 40 mg/2.0 ml at Day 2, i.e. 2 days post Baseline (Day 0 = Week 0)
62596927|NCT03203408|ACTIVE_COMPARATOR|SYNVISC-ONE|A single intra-articular injection of hylan G-F 20 48 mg/6 ml at Day 2, i.e. 2 days post Baseline (Day 0 = Week 0)
62596928|NCT03177434|ACTIVE_COMPARATOR|Dicopeg Junior|"Polyethylene glycols (PEG) - 3350 Dosage form: oral solution sachets Frequency: 2 doses~Dosage:~* weight up to 8 kg - 1 sachet per day~* weight 8 - 12 kg - 2 sachets a day~* weight 12 - 20 kg - 3 sachets a day~* weight\> 20 kg - 4 sachets per day, Duration: 12 weeks vs Lactulose Dosage form: oral solution Dosage: 2 ml / kg / day Frequency: 2 doses Duration: 12 weeks"
62596929|NCT03177434|ACTIVE_COMPARATOR|Lactulose|Lactulose Dosage form: oral solution Dosage: 2 ml / kg / day Frequency: 2 doses Duration: 12 weeks
62596930|NCT00569647|EXPERIMENTAL|v|Use of VRH headset
62596931|NCT00569647|PLACEBO_COMPARATOR|c|
62596932|NCT02624245|EXPERIMENTAL|Experimental: Conventional Physical Therapy|Strength, this arm will receive hip and knee muscle strengthening with and without weight bearing.
62596933|NCT02624245|ACTIVE_COMPARATOR|Movement control training|Movement control training, this arm will receive movement control training associated to muscle strengthening.
62238951|NCT06393790|ACTIVE_COMPARATOR|Strength training group in no fibromyalgia women|"The sample will be composed of 15 subjects (women), aged between 45 and 70 years. Participants must have not been diagnosed with fibromyalgia. These participants must be healthy individuals.~Study participants must not have any other illness and/or injury at the time of the assessments that would prevent them from performing the activity. Likewise, those following pharmacological treatments or any type of cardiorespiratory disease will be excluded from the research."
62815160|NCT06126614|EXPERIMENTAL|Povidone-Iodine 0.35% Lavage Solution|"The study lavage solution (povidone-iodine) is the final lavage and is to be poured in and left for 3 minutes then removed by suction.~The study lavage solution will be a total volume of 1 litre, made with sterile isotonic saline."
62815161|NCT06126614|EXPERIMENTAL|Povidone-Iodine 0.35% Lavage Solution and Vancomycin|"The study lavage solution (povidone-iodine) is the final lavage and is to be poured in and left for 3 minutes then removed by suction. Two grams of vancomycin is applied to the deep joint (to arthrotomy in knee and deep to fascia in hip) following removal of the study lavage solution and immediately prior to closure.~The study lavage solution will be a total volume of 1 litre, made with sterile isotonic saline."
62238952|NCT00172107|PLACEBO_COMPARATOR|1|Placebo drug injectable subcutaneously
62238953|NCT00172107|EXPERIMENTAL|2|50 mcg PTH(1-84)
62238954|NCT00172107|EXPERIMENTAL|3|75mcg PTH(1-84)
62238955|NCT00172107|EXPERIMENTAL|4|100 mcg PTH(1-84)
62238956|NCT02977208|ACTIVE_COMPARATOR|Homozygous for the wild type allele|"Patients with 18 years old or older with epilepsy, neuropathic pain or any chronic pain undergoing chronic treatment with gabapentin are being recruited.~Sparse blood sampling are being collected up to 4 h after administration of the drug for pharmacokinetic study. Urine sampling are being collected during the dosing interval, only in patients hospitalized at the Hospital Estadual de Américo Brasiliense (HEAB). Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G\>T and SLC22A4 c.1507C\>T polymorphisms."
62815162|NCT06126614|EXPERIMENTAL|Chlorhexidine Gluconate 0.05% Lavage Solution|"The study lavage solution (chlorhexidine-gluconate) is the final lavage and is to be poured in and left for 3 minutes then removed by suction.~The study lavage solution will be a total volume of 1 litre, made with sterile isotonic saline."
62238957|NCT02977208|ACTIVE_COMPARATOR|Homo- or heterozygous for rare alleles|"Patients with 18 years old or older with epilepsy, neuropathic pain or any chronic pain undergoing chronic treatment with gabapentin are being recruited.~Sparse blood sampling are being collected up to 4 h after administration of the drug for pharmacokinetic study. Urine sampling are being collected during the dosing interval, only in patients hospitalized at the Hospital Estadual de Américo Brasiliense (HEAB). Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G\>T and SLC22A4 c.1507C\>T polymorphisms."
62429508|NCT02122471|EXPERIMENTAL|Plecanatide 3.0 mg|Plecanatide tablets 3.0 mg QD for 12 weeks
62429509|NCT02122471|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets QD for 12 weeks
62429510|NCT02122471|EXPERIMENTAL|Plecanatide 6.0 mg|Plecanatide tablets 6.0 mg QD for 12 weeks
62429511|NCT01890330|EXPERIMENTAL|Canola Oil 25 g/d|Participants randomized to this arm will be provided with food items including entrées, side dishes, salad dressing, baked goods, and desserts prepared with traditional canola oil to incorporate into their usual eating pattern. They will consume one or two food items per day containing a total of 25 g/d of Canola oil.
62429512|NCT01890330|ACTIVE_COMPARATOR|Non-Canola Oil Mixture 25 g/d|Participants randomized to this arm will be provided with food items including entrées, side dishes, salad dressing, baked goods, and desserts prepared with an oil mixture representing the typical Western diet to incorporate into their usual eating pattern. They will consume one or two food items per day containing a total of 25 g/d of the non-canola oil mixture.
62596934|NCT04958681||Covid-19 history positive|
62429513|NCT06542627|EXPERIMENTAL|CGM arm|Glycemic control was monitored using CGM data for two weeks, followed by individualized dietary education.
62429514|NCT04089280|EXPERIMENTAL|Sanprobi Barrier-multispecies probiotic|A randomized placebo-controlled, parallel-group study, crossover-design. Intervention: Sanprobi Barrier-multispecies probiotic product, 2,5 x10 9 cfu/gram or placebo, cross-over design
62429515|NCT04089280|PLACEBO_COMPARATOR|carrier material of Sanprobi Barrier-multispecies probiotic|A randomized placebo-controlled, parallel-group study, crossover-design. Intervention: placebo comparator (carrier material of Sanprobi Barrier-multispecies probiotic product , not containing bacterial strains,similar appearance as the probiotic, cross-over design
62429516|NCT05130866|EXPERIMENTAL|Cohort A Adults, Dose 40 mg|
62429517|NCT05130866|EXPERIMENTAL|Cohort A Adults, Dose 60 mg|
62429518|NCT05130866|EXPERIMENTAL|Cohort A Adolescents|Starting dose of 30 mg followed by dose escalation to 40 mg and 60 mg.
62429519|NCT05130866|EXPERIMENTAL|Cohort B Active|Dose TBD
62429520|NCT05130866|PLACEBO_COMPARATOR|Cohort B Placebo|
62037362|NCT01318226|EXPERIMENTAL|ATx08-001 2.5 mg bid|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg, twice a day approximately every 12 hours over an 8 day period.
62429521|NCT02584205|EXPERIMENTAL|Powerbreathe|We will use the powerbreathe Classic light resistance in this intervention (inspiratory muscle training). Both groups will receive the equipment, but the intervention group will do the training with a load 40% of the maximum inspiratory pressure.
62429522|NCT02584205|PLACEBO_COMPARATOR|Control|"This group will also receive the equipment (powerbreathe classic light) but will do the training with a load less than 10% of the maximum inspiratory pressure (insufficient charge to train the muscles)."
62429523|NCT00149669|NO_INTERVENTION|Work Plus Naltrexone Prescription|Participants were prescribed naltrexone, but were not be required to ingest it to work. Participants could work and earn money, independent of whether or not they continued to take naltrexone.
62429524|NCT00149669|EXPERIMENTAL|Work Plus Naltrexone Contingency|Participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose (employment-based reinforcement of naltrexone ingestion).
62429525|NCT01289938|ACTIVE_COMPARATOR|Metoclopramide|Metoclopramide treatment
62429526|NCT01289938|ACTIVE_COMPARATOR|Diphenhydramine|Diphenhydramine treatment
62429527|NCT02965469|NO_INTERVENTION|Usual care|Participants randomized to this arm will have no change to their usual care
62429528|NCT02965469|EXPERIMENTAL|Cell phone app|"Participants randomized to this arm will use a stress reduction cell phone app called Breathe2Relax to assess feasibility and acceptability"
62429529|NCT00665717|ACTIVE_COMPARATOR|A|Pravastatin 40 mg QD for 4 days
62429530|NCT00665717|ACTIVE_COMPARATOR|B|Raltegravir 400mg BD for 4 days
62596935|NCT04958681||Covid-19 history negative|
62596936|NCT03175692||critical illness in infants and children|Those infants and children who has congenital metabolism disorder or acute disorder.
62037363|NCT01318226|EXPERIMENTAL|ATx08-001 7.5 mg bid|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
62037364|NCT00605280|SHAM_COMPARATOR|Sham Control|
62037365|NCT00605280|EXPERIMENTAL|Macugen|
62037366|NCT05712590||Vegans|In this group women aged 30-45 years that follow vegan diet for at least 3 years will be included.
62037367|NCT05712590||Vegetarians|In this group women aged 30-45 years that follow vegetarian (lacto-ovo/lacto/ovo) diet for at least 3 years will be included.
62037368|NCT05712590||Omnivores|In this group women aged 30-45 years that follow omnivorous diet for at least 3 years will be included.
62429531|NCT00665717|EXPERIMENTAL|C|Interaction between pravastatin and raltegravir
62429532|NCT02195960|PLACEBO_COMPARATOR|placebo|intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins
62429533|NCT02195960|ACTIVE_COMPARATOR|intake anthocyanin-rich corn extract|intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
62429534|NCT01531868|OTHER|Auditory qualitative|
62429535|NCT01531868|OTHER|Auditory absolute risk|
62596937|NCT05212701|EXPERIMENTAL|Reparixin|Reparixin will be administered orally at the dose of 1200 mg (2 x 600 mg tablets) three times daily (total dose of 3600 mg/day) with no interruptions during each cycle.
62596938|NCT05212701|PLACEBO_COMPARATOR|Placebo|Masked placebo will be administered orally (2 tablets) three times daily with no interruptions during each cycle.
62037369|NCT00546585|EXPERIMENTAL|90 mcg of Influenza A/H7N7|25 subjects to receive 90 mcg of Influenza A/H7N7.
62429536|NCT01531868|OTHER|Auditory relative risk|
62429537|NCT01531868|OTHER|Visual qualitative|
62238958|NCT06470802|EXPERIMENTAL|Familiar voice (FV)|"The recording features pleasant, optimistic, and normal voices in style of daily verbal communication between the patient and their family members (storytellers). The recording begins with the storytellers calling patient by their own name, repeated at least three times throughout the recording. The storytellers introduce themselves by name and their relationship to the patient. They will provide information about the patient's surroundings, the time and the current situation.~The recording includes words of love and affection, encouragement, stories, meaning and familiar memories shared by both the patient and the storytellers. These stories should hold a special meaning and evoke fond memories to the patient. The storytellers also discuss about the patient's recovery prospects and plans after their discharge from the hospital. These storytellers must have a close relationship with the patient and have interacted with them for at least one year prior to their current condition"
62238959|NCT06470802|ACTIVE_COMPARATOR|Nature sounds (NS)|The audio is a compilation of pleasant sounds that capture the essence of a pristine natural environment with the soft rustling of wind through leaves, the gentle rustle of wind, the melodic chirping of birds and the bubbling of a flowing stream
62238960|NCT06470802|SHAM_COMPARATOR|Control|Patients receive a recording of silence only
62238961|NCT02183285|EXPERIMENTAL|PHL 00747 capsules|
62238962|NCT02183285|EXPERIMENTAL|PHL 00747 tablets|
62238963|NCT02183285|PLACEBO_COMPARATOR|Placebo|
62429538|NCT01531868|OTHER|Visual relative risk|
62429539|NCT01531868|OTHER|Visual absolute risk|
62429540|NCT03210441||Group 1|Patients affected by breast cancer and potentially treated with taxane chemotherapy
62429541|NCT03210441||Group 2|Patients affected by breast cancer and not potentially treated without taxane chemotherapy
62429542|NCT05771116|ACTIVE_COMPARATOR|Erecto Spinae Plane Block group|a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T7 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The skin will be anaesthetized using 3ml of 2% Lidocaine. A 20-gauge block needle will be inserted in-plane in a cephalad-to-caudad direction to place the tip into the fascial plane on the deep (anterior) aspect of erector spinaemuscle;20ml bupivacaine 0.25% will be injected. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process The needle will be removed and the catheter secured with adhesive.
62429543|NCT05771116|ACTIVE_COMPARATOR|the paravertebral group|"After identification of the transverse process, internal intercostal membrane (IIM), and pleura at the T3 and T6 levels, an out-of-plane needle guidance technique was used to perform the PVB.The success of both blocks will be confirmed by loss of pinprick sensation on the dermatomal site of the block~•blocks will be activated ,After negative aspiration, 0.5 ml/kg 0.25% bupivacaine (max 20 ml) will be injected. Afterwards, a 20 gauge peripheral nerve catheter will be easily threaded into the space. The needle will be removed and the catheter secured with adhesive."
62429544|NCT02219295|EXPERIMENTAL|sweet -block|application of different sugars, artificial sweeteners and sweet-taste antagonists in a single dose in 300 ml tap water every week up to 7 times and collection of blood samples over 3 hours
62429545|NCT02219295|EXPERIMENTAL|bitter block|application of purified bitter tasting ingredients of vegetables and hop in 300 ml tap water , collection of blood samples for 3h (-15,0,15,30,60,120,180 min)
62429546|NCT02219295|EXPERIMENTAL|umami-block|"application of glutamate and glutamate +IMP~same procedure as above"
62429547|NCT02219295|OTHER|gastroscopy|gastroscopy with and without oral intervention with artificial sweetener saccharin to take tissue samples from the upper bowel for the investigation of taste receptor cells in the upper bowel in human beings
62596939|NCT06621992|EXPERIMENTAL|Skills to Enhance Positivity|Participants received 4 group sessions, session 1 focused on positive affect psychoeducation, session 2 on mindfulness, 3 on savoring and 4 on gratitude. Once completing the group sessions participants received text messages for 1 month before tapering off.
62037370|NCT00546585|EXPERIMENTAL|15 mcg of Influenza A/H7N7|25 subjects to receive 15 mcg of Influenza A/H7N7.
62429548|NCT00868582||FDG-PET|F-18 fluorodeoxyglucose (FDG-PET)
62429549|NCT00868582||NaF-18 PET|F-18 sodum-fluoride (NaF-18 PET)
62429550|NCT01862718|EXPERIMENTAL|1|Ablation plus radiation
62429551|NCT03985033|EXPERIMENTAL|L-PRF|Post-extraction sockets will be filled with autologous leucocyte and platelet-rich fibrin (L-PRF) clot.
62596940|NCT06621992|ACTIVE_COMPARATOR|Treatment as Usual|Participants received their standard treatment as usual
62037371|NCT00546585|EXPERIMENTAL|7.5 mcg of Influenza A/H7N7|25 subjects to receive 7.5 mcg of Influenza A/H7N7.
62238964|NCT01980654|EXPERIMENTAL|Main Study Arm 1|Subjects enrolled into this arm will receive ibrutinib continuously until disease progression or unacceptable toxicity. In addition, subjects will receive rituximab once weekly for four doses for the first four weeks of study treatment.
62238965|NCT01980654|EXPERIMENTAL|Exploratory Study Arm 2|Subjects enrolled into this arm will receive ibrutinib continuously as a single agent for the first eight weeks, then ibrutinib concurrently with rituximab once weekly for four doses. After the rituximab treatment, subjects will receive ibrutinib continuously until disease progression or unacceptable toxicity.
62238966|NCT03397849|ACTIVE_COMPARATOR|intervention using mobile technology (IMT) plus usual care|Each study patients that are randomized to IMT plus usual care group will receive a group of smart devices including mobile phone (Vestel Venus e2) (Vestel, Manisa, Turkey), wristband (Xiaomi band 2) (Beijing Xiaomi Technology Co., Beijing, China), weight scale (Bluecat, Yongkang Tiansheng Electronic Co., Zhejiang, China) and blood pressure monitor (Clever Chek TD-3250) (TaiDoc Technology Co., Taipei County, Taiwan).
62429552|NCT03985033|NO_INTERVENTION|Control|Post-extraction sockets will be left to heal spontaneously with natural blood clot.
62429553|NCT03513978|EXPERIMENTAL|IAI Protocol|A progressive exercises with transference to sport protocol, oriented to improve the proprioception.
62429554|NCT03513978|ACTIVE_COMPARATOR|FIFA 11+ Protocol|A typical exercises protocol to soccer
62238967|NCT03397849|NO_INTERVENTION|Only usual care|Patients that are randomized to only usual care group will receive guideline-standardized medications and lifestyle recommendations. Cardiovascular risk management and compliance to medication and lifestyle recommendation will be assessed and controlled by three cardiologists in clinical visits performed at 6 and 12 months. For the necessary cases counseling to other specialities will be performed for smoke cessation and weight management.
62238968|NCT05777473|EXPERIMENTAL|Kulawa|This arm will receive the standard Kulawa intervention. Kulawa is a USAID-funded program that seeks to change FP-related behaviors among young, low parity women at scale in Niger. Kulawa, implemented by Save the Children U.S. aims to increase use of quality FP services of all WRA, including young women ages 15-24 years, in 15 districts of Niger across 3 regions (Tillaberi, Maradi, and Zinder), covering a population of 12.5 million. Kulawa will address individual, social, and health system constraints to FP use through interventions to change behavior and influence social norms that govern FP use and related gender outcomes as well as interventions to improve FP service availability and quality. Kulawa SBC programming at the community-level will include small groups for young, low parity women and girls (ages 15-24) and community dialogues.
62238969|NCT05777473|EXPERIMENTAL|Kulawa SN (Tipping Point)|This arm will receive the Kulawa intervention, with a social network-informed intervention (KulawaSN) layered on top. In this arm 50% of eligible women will be paired with an alter to receive the adapted intervention. The social network intervention will involve pairing up young married adolescents and women with someone identified as influential in their social networks and enrolling them in the Kulawa FP programming together.
62238970|NCT05777473|NO_INTERVENTION|Control|This arm will serve as the control condition. Individuals in these villages will receive neither intervention (including any other FP-relevant SBC program)
62037372|NCT00546585|EXPERIMENTAL|45 mcg of Influenza A/H7N7|25 subjects to receive 45 mcg of Influenza A/H7N7.
62429555|NCT01757236|ACTIVE_COMPARATOR|Treatment A|"IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained).~Patients with only a confirmed Gram-positive infection will continue the study and will receive standard of care antibiotic therapy including oral rifampin (10-15mg/kg every 12 hours) combined with either oral clindamycin (600 mg every 8 hours) or oral sulfamethoxazole and trimethoprim (800/160 mg every 8 hours) or oral fluoroquinolone (Ofloxacin 200 mg every 12 hours). The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks."
62429556|NCT01757236|EXPERIMENTAL|Treatment B|"IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained).~Patients with only a confirmed Gram-positive infection will continue the study and will receive oral linezolid (600mg every 12 hours) combined with oral rifampin (10-15mg/kg every 12 hours).~The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks."
62429557|NCT01757236|EXPERIMENTAL|Treatment C|IV linezolid (600 mg every 12 hours)and IV ceftriaxone (2g daily) until Day 2. Oral or IV rifampin (10-15 mg/kg every 12 hours) will be added 48 hours after initiating the study treatment. Treatment with the study drug will continue until Day 2 to 7 (until the susceptibility test results are obtained). Patients with only a confirmed Gram-positive infection will continue the study. Treatment with ceftriaxone will be discontinued and the patient will switch to oral linezolid and oral rifampin. The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 4 weeks.
62429558|NCT00379184||A|Osteoarthritis patients scheduled for Total Knee Arthroplasty.
62429559|NCT00379184||B|Osteoarthritis patients not scheduled for Total Knee Arthroplasty.
62429560|NCT00379184||C|Healthy volunteers
62429561|NCT01674179||ACR diagnosis of Fibromyalgia|
62429562|NCT01674179||Patients without Fibromyalgia|
62815163|NCT06126614|EXPERIMENTAL|Chlorhexidine Gluconate 0.05% Lavage Solution and Vancomycin|"The study lavage solution (chlorhexidine gluconate) is the final lavage and is to be poured in and left for 3 minutes then removed by suction. Two grams of vancomycin is applied to the deep joint (to arthrotomy in knee and deep to fascia in hip) following removal of the study lavage solution and immediately prior to closure.~The study lavage solution will be a total volume of 1 litre, made with sterile isotonic saline."
62238971|NCT00561496|OTHER|Twice daily|Tenofovir gel intravaginal twice daily for 14 days
62238972|NCT00561496|OTHER|Once daily|Tenofovir gel intravaginal once daily for 14 days
62238973|NCT06421896|EXPERIMENTAL|experimental group: geriatric who receive motivational Enhancement Therapy|COPD geriatric patients who receive motivational Enhancement Therapy
62238974|NCT06421896|NO_INTERVENTION|non- experimental group|COPD geriatric patients who don't receive motivational Enhancement Therapy
62238975|NCT00901030||Patients with PCI on blood thinners|Patients have a coronary stent and are taking anti-clotting (anti-platelet) drug and are having non-cardiac surgery.
62238976|NCT01215175|ACTIVE_COMPARATOR|Prevnar™ - Adult Cohort|Healthy adult participants received a single 0.5 mL intramuscular injection of Prevnar™ on Day 1.
62238977|NCT01215175|EXPERIMENTAL|V114 Adjuvanted -Toddler Cohort|Healthy toddler (12-15 months of age) participants who had completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
62238978|NCT01215175|EXPERIMENTAL|V114 Nonadjuvanted-Toddler Cohort|Healthy toddlers (12-15 months of age) participants who completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of non-adjuvanted V114 on Day 1.
62238979|NCT01215175|ACTIVE_COMPARATOR|Prevnar™- Toddler Cohort|Healthy toddlers (12-15 months of age) participants who had previously completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of Prevnar™ on Day 1.
62815164|NCT06126614|ACTIVE_COMPARATOR|Saline Lavage Solution|"The study lavage solution (saline) is the final lavage and is to be poured in and left for 3 minutes then removed by suction.~The study lavage solution will be a total volume of 1 litre."
62037373|NCT00546585|PLACEBO_COMPARATOR|Saline placebo|25 subjects to receive placebo.
62238980|NCT01215175|EXPERIMENTAL|V114 Adjuvanted -Adult Cohort|Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
62238981|NCT03985345|EXPERIMENTAL|EMY Probe|
62815165|NCT06126614|EXPERIMENTAL|Saline Lavage Solution and Vancomycin|"The study lavage solution (saline) is the final lavage and is to be poured in and left for 3 minutes then removed by suction.~Two grams of vancomycin is applied to the deep joint (to arthrotomy in knee and deep to fascia in hip) following removal of the study lavage solution and immediately prior to closure."
62815166|NCT06165809|EXPERIMENTAL|TQB3015 tablets|TQB3015 tables is administered as a single dose or multiple dose, 2-40mg once a day; Oral administration on fast condition, 21 days as a cycle.
62815167|NCT06582212|EXPERIMENTAL|MyMovesMatter mobile application|
62815168|NCT02735863|EXPERIMENTAL|ABX464|Fixed dose of ABX464 50mg once daily given during 28 days in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)
62238982|NCT02939872|EXPERIMENTAL|DAPT|Dual antiplatelet therapy : aspirin and clopidogrel
62238983|NCT02939872|ACTIVE_COMPARATOR|Clopidogrel only|Clopidogrel monotherapy
62238984|NCT02482766|EXPERIMENTAL|INRECSURE|Infants in the INRECSURE arm will undergo the following approach: as soon as possible after the recruitment manoeuver (at CDP-Optimal) a dose of poractant alfa (Curosurf \[Chiesi Farmaceutici, Parma, Italy\]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. A temporary reduction of frequency may be necessary to increase the VT up to 2.5 ml/kg for improving the surfactant spreading.
62238985|NCT02482766|ACTIVE_COMPARATOR|INSURE|Infants in the INSURE arm will undergo the following approach: after intubation, a dose of poractant alfa (Curosurf \[Chiesi Farmaceutici, Parma, Italy\]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. During surfactant administration, infants will be manually ventilated to facilitate surfactant distribution.
62429563|NCT04858074|EXPERIMENTAL|Active medication- PECKO-D|Participants will be randomly allocated to experimental drug
62429564|NCT04858074|PLACEBO_COMPARATOR|Placebo|Corn-Starch will be administered as placebo agent
62429565|NCT04953481||Amyotrophic lateral sclerosis group|Patients with amyotrophic lateral sclerosis undergoing home care.
62815169|NCT02735863|PLACEBO_COMPARATOR|ABX464 Matching placebo|Matching placebo of ABX464 given at 50mg once daily in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)
62815170|NCT02529852|EXPERIMENTAL|Lenalidomide + Obinutuzumab + CHOP|"Phase I: Participants take Lenalidomide by mouth on Days 1 - 14 of each cycle. Participants receive Obinutuzumab by vein over 3 - 4 hours on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6. Participants receive Cyclophosphamide by vein over about 1 hour on Day 1 of all cycles. Participants receive Doxorubicin and Vincristine by vein over about 15 minutes each on Day 1 of all cycles.~Phase II: Participants treated at the recommended phase II dosing (RP2D) of Lenalidomide determined in the Phase Ib portion for 6 cycles of therapy. Dose of Obinutuzumab, Cyclophosphamide, Doxorubicin and Vincristine remain the same as in Phase I.~Each study cycle is 21 days."
62815171|NCT04961710|EXPERIMENTAL|Hetrombopag Olamine|
62815172|NCT04961710|PLACEBO_COMPARATOR|Placebo|
62815173|NCT03021057|EXPERIMENTAL|pembrolizumab|200mg i.v. once every 3 weeks Number of Cycles: until progression or unacceptable toxicity develops
62815174|NCT06390397|EXPERIMENTAL|Produce prescription program|
62238986|NCT02748837|EXPERIMENTAL|Dose escalation cohort of ERY974|Dose escalation (DE) will proceed with the dose level increment and the dose cohort size being guided by a safety evaluations during and at the end of each cohort. DE initially utilizes an accelerated titration design (ATD) and once the first dose limiting toxicity (DLT) is observed, DE will continue using a modified continual reassessment method (mCRM) until MTD.
62815175|NCT06390397|ACTIVE_COMPARATOR|Standard of Care|
62238987|NCT02748837|EXPERIMENTAL|Cohort expansion in gastric cancer|Patients with GPC3 positive advanced gastric cancer or gastroesophageal junction cancer will receive ERY974 at recommended dose until disease progression.
62238988|NCT02748837|EXPERIMENTAL|Cohort expansion in esophageal carcinoma|Patients with GPC3 positive advanced squamous cell esophageal carcinoma will receive ERY974 at recommended dose until disease progression.
62815176|NCT05945784||Minimal to moderate upper extremity deficits|"* Individuals aged 18 years to 55 years.~* Minimal to moderate upper extremity deficits, including but not limited to limited mobility or dexterity impairments.~* Regular users of beauty products.~* Able to understand and communicate in the language of the study."
62238989|NCT02748837|EXPERIMENTAL|Cohort expansion in other solid tumors|Patients with other GPC3 positive advanced solid tumors will receive ERY974 at recommended dose until disease progression
62238990|NCT01002456|OTHER|Level 1: site-specific information|provide site-specific information on nonadherence
62238991|NCT01002456|OTHER|Level 2: site-, patient-specific info|provide site- and patient-specific information on nonadherence
62238992|NCT04836663|EXPERIMENTAL|TQ-B3525 tablet|
62238993|NCT02020863|EXPERIMENTAL|Closed Loop|Study patients will receive a baseline crystalloid infusion of 3 cc/kg/hr and all additional fluid management will be performed via a closed loop (automated) system that will determine rate, amount, and timing of fluid administration.
62429566|NCT04953481||Caregiver group|Caregivers
62238994|NCT03082703|EXPERIMENTAL|Text Messaging|
62238995|NCT03082703|NO_INTERVENTION|Control|
62429567|NCT01249391|ACTIVE_COMPARATOR|Intervention (splinting)|Splinting of nominated joint in this group
62429568|NCT01249391|NO_INTERVENTION|Control|Observation and usual treatment only.
62815177|NCT05305443|EXPERIMENTAL|Navigation/tested/navigation services|After initial randomization, some participants will be assigned to receive navigation services(NS). Those who complete the COVID-19 testing will again be randomized and some will continue receiving NS.
62815178|NCT05305443|EXPERIMENTAL|Navigation/tested/brief counseling|After initial randomization, some participants will be assigned to receive navigation services (NS). Those who complete the COVID-19 testing will again be randomized and some will be assigned to receive Brief Counseling (BC)
62815179|NCT05305443|EXPERIMENTAL|Navigation/not tested/navigation services|After initial randomization, some participants will be assigned to receive navigation services (NS). Those who do not complete the COVID-19 testing will again be randomized and some will continue receiving NS.
62815180|NCT05305443|EXPERIMENTAL|Navigation/not tested/critical dialogue|After initial randomization, some participants will be assigned to receive navigation services(NS). Those who do not complete the COVID-19 testing will again be randomized and some will be assigned to Critical Dialogue (CD)
62815181|NCT05305443|EXPERIMENTAL|Referral/tested/brochure|After initial randomization, some participants will be assigned to receive standard referral services. Those who complete the COVID-19 testing will again be randomized and some will receive a digital brochure.
62238996|NCT00764751|EXPERIMENTAL|1|
62815182|NCT05305443|EXPERIMENTAL|Referral/tested/brief counseling|After initial randomization, some participants will be assigned to receive standard referral services. Those who complete the COVID-19 testing will again be randomized and some will be assigned to receive Brief Counseling (BC).
62238997|NCT00764751|ACTIVE_COMPARATOR|2|
62238998|NCT00764751|PLACEBO_COMPARATOR|3|
62238999|NCT04294069|ACTIVE_COMPARATOR|Azithromycin 500mg|500mg azithromycin PO daily for seven days
62429569|NCT06381505||custom device- radiolucent retractor|Custom device-radiolucent retractor used during staging endoscopy.
62429570|NCT00739687|EXPERIMENTAL|ALT-711|Alagebrium 200 mg BID
62429571|NCT00739687|EXPERIMENTAL|Placebo|Placebo
62429572|NCT01017458|EXPERIMENTAL|1|MK0773 + placebo injection
62429573|NCT01017458|ACTIVE_COMPARATOR|2|placebo to MK0773 + testosterone injection
62429574|NCT01017458|PLACEBO_COMPARATOR|3|placebo to MK0773 + placebo injection
62429575|NCT03687021|NO_INTERVENTION|endometriosis|tissue biopsy from patients (n=10) with endometriosis
62429576|NCT03687021|NO_INTERVENTION|without endometriosis|tissue biopsy from patients (n=10) without endometriosis
62239000|NCT04294069|ACTIVE_COMPARATOR|Azithromycin 1000mg|1000mg azithromycin PO once at admission
62239001|NCT03231943|EXPERIMENTAL|Subjects in cohort 1-2: Part 1|Eligible subjects will participate in cohort 1 or 2 and each of these two cohorts will contain up to four escalating doses of GSK3640254. In each cohort, 6 subjects will be randomized to receive single oral dose of GSK3640254 and 2 subjects will be randomized to receive placebo. Hence, each subject in cohort 1 and 2 will receive up to 3 escalating doses of GSK3640254 and one placebo in crossover manner.
62239002|NCT03231943|EXPERIMENTAL|GSK3640254 receivers (cohort 3-6 and expansion): Part 2|Eligible subjects will participate in one of the 4 cohorts (3,4,5,6). In each cohort, 6 subjects will be randomized to receive a once-daily oral dose of GSK3640254 for 14 days. After the safety data of cohort 3-6 is available, 18 eligible subjects will be randomized to receive once daily oral dose of GSK3640254 for 14 days in expansion cohort.
62239003|NCT03231943|PLACEBO_COMPARATOR|Subjects receiving placebo (cohort 3-6): Part 2|Eligible subjects will participate in one of the 4 cohorts (3,4,5,6). In each cohort, 2 subjects will be randomized to receive a once-daily oral dose of placebo for 14 days. After the safety data of cohort 3-6 is available, 6 eligible subjects will be randomized to receive once daily oral dose of placebo for 14 days in expansion cohort.
62239004|NCT04158596|EXPERIMENTAL|Treatment|The applied therapeutic vibrations generated by an acoustic coil have a defined sweeping frequency range.
62239005|NCT04158596|ACTIVE_COMPARATOR|Control|A control device with a different vibration pattern will be used as comparator intervention
62239006|NCT04506307|EXPERIMENTAL|Fat Reduction|The treatments are designed to see if the fat can be reduced in the torso area with a new applicator design.
62429577|NCT03687021|EXPERIMENTAL|Intramuscular progesterone|Intramuscular progestin(20mg)
62429578|NCT03687021|EXPERIMENTAL|vaginal progesterone|vaginal progestin (90mg)
62429579|NCT03687021|EXPERIMENTAL|oral progesterone|oral progestin(40mg)
62429580|NCT01340274|ACTIVE_COMPARATOR|Treatment as Usual|"Clients will receive 12 sessions of Treatment as usual , delivered 1 session per week for 12 consecutive weeks."
62429581|NCT01340274|EXPERIMENTAL|CRAFT Treatment|"Clients will receive 12 sessions of CRAFT, delivered 1 session per week for 12 consecutive weeks."
62429582|NCT03829033|ACTIVE_COMPARATOR|Radiotherapy delivered with photons|
62429583|NCT03829033|EXPERIMENTAL|Radiotherapy delivered with protons|
62429584|NCT00956683|EXPERIMENTAL|Ultrasound|Ultrasound guided infraclavicular block
62429585|NCT00956683|ACTIVE_COMPARATOR|Dual Endpoint Nerve Stimulator|Nerve stimulator guided dual endpoint infraclavicular block
62429586|NCT00031837|EXPERIMENTAL|Dalteparin|5,000 anti-Xa units of dalteparin subcutaneously once daily for six months in addition to gemcitabine at 1,000 mg/m2 as a 30-minute infusion weekly for 7 weeks followed by a week of rest for the first cycle and weekly for three weeks followed by a week of rest for each subsequent cycle.
62429587|NCT01591031|ACTIVE_COMPARATOR|sevoflurane|anesthesia induction with propofol, remifentanil and sevoflurane
62429588|NCT01591031|ACTIVE_COMPARATOR|rocuronium|anesthesia induction with propofol, remifentanil and rocuronium
62429589|NCT03802188||SLE Cohort|Investigators will use existing data collected on adult SLE patients enrolled into respective study cohorts from participating centers.
62815183|NCT05305443|EXPERIMENTAL|Referral/not tested/brochure|After initial randomization, some participants will be assigned to receive standard referral services. Those who do not complete the COVID-19 testing will again be randomized and some will receive a digital brochure.
62815184|NCT05305443|EXPERIMENTAL|Referral/not tested/critical dialogue|After initial randomization, some participants will be assigned to receive standard referral services. Those who do not complete the COVID-19 testing will again be randomized and some will be assigned to Critical Dialogue (CD).
62815185|NCT03290937|EXPERIMENTAL|Treatment (irinotecan hydrochloride, cetuximab, utomilumab)|Patients receive irinotecan hydrochloride IV over 90 minutes and cetuximab IV over 1-2 hours on days 1 and 15, and utomilumab IV over 1 hour on day 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62429590|NCT03802188||Qualitative group|For the interviews, patients with SLE who are currently or have taken Hydroxychloroquine will be recruited from rheumatology clinics in Calgary and Montreal to participate in an interview and/or participate in a brief survey.
62239007|NCT02467218|EXPERIMENTAL|Immediate Hyperbaric Oxygen Treatment|If a participant is randomized to the group receiving the intervention, the participant will be receiving a baseline assessment functional magnetic resonance imaging (fMRI) and subsequently receiving hyperbaric oxygen treatment for 90 minutes, once daily, five times a week for 8 consecutive weeks (40 treatments with 100% oxygen at 2.0 ATA). A follow-up fMRI will be performed after the last day of treatment.
62429591|NCT06386471|EXPERIMENTAL|Whole grain rye bread|4.3 ounces of whole grain rye bread, consumed after an overnight fast (12+ hours)
62429592|NCT06386471|PLACEBO_COMPARATOR|Refined grain rye bread|4.3 ounces of white rye bread, consumed after an overnight fast (12+ hours)
62429593|NCT01873079|ACTIVE_COMPARATOR|Esomeprazole|esomeprazole 40mg bd for 10 days
62429594|NCT01873079|SHAM_COMPARATOR|Standard care|No other study drug or placebo will be given
62429595|NCT03459833|EXPERIMENTAL|group 1|15 patients They will receive a topical anesthetic agent for 30 minutes (Emla cream; lidocaine 25 mg, prilocaine 25 mg, Astra Xeneca, Mississauga, Canada) followed by injection of two prefilled 1 ml syringes with 30 G needle of hyaluronic acid (HA; Teosyal® PureSense Global Action, Teoxane Laboratories, Geneva, Switzerland). After 18 months from the HA injection, cross-over to placebo arm will be done.
62239008|NCT02467218|EXPERIMENTAL|Delayed Hyperbaric Oxygen Treatment|If the participant is assigned to the cross group, the participant will also receive a baseline assessment functional magnetic resonance imaging (fMRI). However, it will be followed-up in a controlled manner for 3 months. After 3 months, the participant will be receiving hyperbaric oxygen treatment identical to Group A and a follow-up fMRI will be performed after the last treatment.
62239009|NCT05880277|EXPERIMENTAL|Jumping|Female jumping collegiate athletes
62239010|NCT03475017|ACTIVE_COMPARATOR|Supplement A|Administration of 3 capsules with 500mg of curcumin and piperine per day, for 12 weeks
62239011|NCT03475017|PLACEBO_COMPARATOR|Supplement B|Administration of 3 capsules with 500mg of placebo (maize starch) per day, for 12 weeks
62239012|NCT00154336|ACTIVE_COMPARATOR|Imatinib 400mmg OD +MTX|
62239013|NCT00154336|PLACEBO_COMPARATOR|Imatinib Placebo + MTX|
62429596|NCT03459833|PLACEBO_COMPARATOR|group 2|They receive by the same method 2 ml saline as a placebo. After one month of the injection, cross-over to HA arm will be done.
62239014|NCT04206592|ACTIVE_COMPARATOR|i Gel LMA|The sealing pressure of the igel laryngeal mask will be measured during pneumoperitoneum in elective laparoscopic cholecystectomy
62239015|NCT04206592|ACTIVE_COMPARATOR|Ambu Aura Gain|It will be compared the Ambu Aura Gain LMA vs iGel in elective laparoscopic cholecystectomy
62239016|NCT01023854|EXPERIMENTAL|Continuous Paravertebral block|Continuous Paravertebral block
62239017|NCT01023854|PLACEBO_COMPARATOR|Placebo|Placebo
62429597|NCT00811265|EXPERIMENTAL|Simulated ExAblate MRgFUS|Patients undergoing simulated ExAblate MRgFUS device use
62429598|NCT00185328|EXPERIMENTAL|Arm 1|
62429599|NCT00871728|EXPERIMENTAL|Itraconazole|
62429600|NCT00357474|ACTIVE_COMPARATOR|chemotherapy|Transarterial chemoembolization (TACE)
62429601|NCT00357474|ACTIVE_COMPARATOR|ethanol|Percutaneous ethanol injection therapy (PEIT)
62429602|NCT00798785|EXPERIMENTAL|group I ATG-MMF-TAC|"Two clinical implants in the liver:~First implant: ATG-fresenium Maintained immunosuppression: MMF-TAC n=30"
62429603|NCT00798785|EXPERIMENTAL|group II ATG-Rituximab-MMF-TAC|"Two clinical implants in the liver:~First Implant: ATG fresenium + Rituximab Maintained immunosuppression: MMF-TAC n=5"
62429604|NCT00798785|EXPERIMENTAL|group III ATG-Basilixumab-MMF-TAC|"Two clinical implants in the liver:~First implant: ATG-fresenium Second implant: basilixumab Maintained immunosuppression: MMF-TAC n=5"
62429605|NCT00798785|EXPERIMENTAL|group IV omentum|"Two clinical implants: first in the omentum followed by a clinical implant in the liver:~First implant: ATG-fresenium Maintained immunosuppression: MMF-TAC n=10"
62239018|NCT04010513|EXPERIMENTAL|Hypnosis|
62239019|NCT04010513|ACTIVE_COMPARATOR|Standard of Care|
62429606|NCT02197754|EXPERIMENTAL|Polyphenol Diet|After 2 weeks of adaptation to a controlled diet, polyphenol-rich fruits (berries and apple) and beverages (tea) will be fed (8 wks) as part of a controlled diet (10 wks total).
62429607|NCT01667965||pts receiving palliative radiation therapy|The design of the study will be a prospective non-randomized cohort study with structured questionnaires administered to all enrolled patients at two or three time-points.
62429608|NCT06394778||Delirium group|If the patient develops delirium after surgery, he/she is in the delirium group
62429609|NCT06394778||Non delirium group|If the patient does not experience delirium after surgery, it is considered as the non-delirium group
62429610|NCT00597207|EXPERIMENTAL|1|Mechanical CPR with AutoPulse
62239020|NCT05794646|OTHER|Intervention|Community-based intervention with screening and treatment initiation for HCV elimination among PWUD
62429611|NCT00597207|OTHER|2|Manual CPR
62429612|NCT01879982||Wellness Wearable System & Smartphone|
62429613|NCT05329090|EXPERIMENTAL|experimental group|Experimental therapeutic strategy based on the use of rituximab in combination with glucocorticoids
62429614|NCT05329090|PLACEBO_COMPARATOR|control group|Control therapeutic strategy based on glucocorticoids plus placebo
62429615|NCT05839093|ACTIVE_COMPARATOR|Inferior Alveolar Nerve Block Group|A standard Inferior Alveolar Nerve Block (IANB) injection with a conventional dental injector and a 27-G needle to achieve pulpal anesthesia in mandibular molar teeth.
62596941|NCT06622837|ACTIVE_COMPARATOR|group I conventional maxillary implant overdenture|Conventional MaxIOD: After relieving the conventional maxillary denture, direct pick-up technique was used to incorporate the attachments housing into the fitting surface of the conventional maxillary denture.
62596942|NCT06622837|ACTIVE_COMPARATOR|group II palatless maxillary implant overdenture|Palateless MaxIOD: The conventional maxillary denture was duplicated and the palatal part was cut out, finished, and polished. The fitting surface was relived and direct pick-up technique was used to incorporate the attachments housing into the fitting surface of the palateless maxillary denture.
62596943|NCT02131818|EXPERIMENTAL|Amoxicillin|The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days
62239021|NCT04580589||Adverse Drug Reaction on DOAC|Participants on Direct Oral Anti-coagulants (DOACs) who experience major bleeding or clinically relevant non-major bleeding per International Society of Thrombosis and Haemostasis criteria. This is an observational study, so there will be no intervention.
62239022|NCT04580589||Treatment Failure on DOAC|Participants on Direct Oral Anti-coagulants (DOACs) who experience treatment failure (e.g., recurrent MI, systemic embolism, ischemic stroke, etc.). This is an observational study, so there will be no intervention.
62596944|NCT02131818|PLACEBO_COMPARATOR|Placebo|The patient will be received placebo 2 capsules orally bid pc for 5 days
62239023|NCT04580589||Case Control|Participants on Direct Oral Anti-coagulants (DOACs) who experience neither major bleeding or treatment failure.
62239024|NCT02891551||Patients receiving Azacitidine per daily clinical practice|
62429616|NCT05839093|EXPERIMENTAL|Intraligamentary Injection Group|An intraligamentary injection that performed with a special pressure injection syringe (Sopira Citoject, Kulzer, Hanau, Germany) and a 30-G needle.
62429617|NCT00812435|EXPERIMENTAL|Eptifibatide|PCI with administration of eptifibatide
62429618|NCT01495169|EXPERIMENTAL|Iloperidone|Part A (dose-escalation and fixed dose): Eligible patients receive iloperidone 2mg/day (1 mg BID) on day 1, then escalated every day for up to 12days utilizing a forced titration regimen to achieve a maximum dose of 12, 16, 20 or 24 mg/day given BID. Part B (optional extension phase): Patients who successfully complete Part A of the study are eligible to continue treatment with iloperidone for an additional 26 weeks
62429619|NCT05742399|ACTIVE_COMPARATOR|Hyaluronic acid nanoparticles (2%)|patients with tear trough will receive hyaluronic acid nano-gel (2%) 2 applications / day (morning and evening) on tear troughs for 1 month
62239025|NCT06494917|ACTIVE_COMPARATOR|pelvic floor exercises|Diaphragmatic breathing training and Pelvic Floor Exercises will be applied.Participants will receive exercise training 5 days a week for 6 weeks.
62239026|NCT06494917|ACTIVE_COMPARATOR|Pelvic floor exercises and manual therapy techniques|In addition to diaphragmatic breathing training and pelvic floor exercises, manual therapy methods will be applied. Participants will receive exercise training 5 days a week for 6 weeks. Manual therapy methods will be used 2 days a week for the first 2 weeks and then 1 day a week.
62429620|NCT05742399|PLACEBO_COMPARATOR|Placebo|patients with tear trough will receive placebo conventional gel having the same color, form and packaging for 1 month
62429621|NCT01255722|EXPERIMENTAL|Iobitridol|Patients were IV injected with a single dose of iobitridol before a coronary CT angiography
62596945|NCT04258254|EXPERIMENTAL|Multimodal|Each child will receive 16 training sessions (8 weeks of training @ 2 sessions per week, approximately 30-45 minutes of interaction time per session) from an expert trainer and parent guidance using telehealth or face-to-face interactions. Within each session, the child will engage in tasks requiring interpersonal synchrony, multilimb coordination (asymmetrical and ipsi/contralateral motions), and balance. Based on feasibility, parents will be given appropriate supplies and trained to promote similar activities at home 1-2 days/week.
62596946|NCT04258254|ACTIVE_COMPARATOR|General Movement|Each child will receive 16 training sessions (8 weeks of training @ 2 sessions per week, approximately 30-45 minutes of interaction time per session) from an expert trainer and parent guidance using telehealth or face-to-face interactions. Within each session, the child will engage in structured physical activity focused on flexibility, strength, and endurance. Based on feasibility, parents will be given appropriate supplies and trained to promote similar activities at home 1-2 days/week.
62596947|NCT04258254|ACTIVE_COMPARATOR|Standard of Care|Each child will receive 16 training sessions (8 weeks of training @ 2 sessions per week, approximately 30-45 minutes of interaction time per session) from an expert trainer and parent guidance using telehealth or face-to-face interactions. Within each session, the child will engage in seated play focused on reading, building, and art-craft activities. Based on feasibility, parents will be given appropriate supplies and trained to promote similar activities at home 1-2 days/week.
62596948|NCT04117672|PLACEBO_COMPARATOR|Placebo|Egg yolk powder not enriched for antisecretory powder
62239027|NCT01649570|EXPERIMENTAL|Insulin aspart|
62239028|NCT05140733||Fusion|1 or 2 levels fusion surgery
62429622|NCT01255722|ACTIVE_COMPARATOR|Iopromide|Patients were IV injected with a single dose of iopromide before a coronary CT angiography
62429623|NCT01255722|ACTIVE_COMPARATOR|Iomeprol|Patients were IV injected with a single dose of iomeprol before a coronary CT angiography
62429624|NCT00013182|OTHER|Arm 1|
62429625|NCT04449640||Uterine rupture|Women who had uterine rupture during pregnancy.
62429626|NCT05443217||patients with response to systemic therapies|
62429627|NCT05443217||patients with no response to systemic therapies|
62429628|NCT02131337|OTHER|Contact force lesions|
62429629|NCT03153059||group 1|a large number of defecation group (≥ 2-3 times/day) - 20 subjects
62429630|NCT03153059||group 2|normal defecation group (1 time/day or 1 time/2 days) - 20 subjects
62596949|NCT04117672|EXPERIMENTAL|Salovum|Egg yolk powder enriched for antisecretory powder
62596950|NCT05469269|EXPERIMENTAL|Education and Passive Navigation|This arm receives barber-led education and access to a resource website. Barbers will encourage clients to access the screening website. Other study materials will also be located within the shop. The resource website will be accessible via QR code that will encourage potential participants to complete a Prostate Cancer Knowledge and Risk Assessment questionnaire.
62429631|NCT03153059||group 3|a small number of defecation group (≤ 2 times/week) - 20 subjects
62429632|NCT03708861|EXPERIMENTAL|MVC + ATV/r|maraviroc (300 mg tablet, 300 mg per day every 24 hours) + atazanavir/ritonavir (300 and 200 mg capsule, 300 and 200 mg per day every 24 hours / 100 mg capsule, 100 mg per day every 24 hours)
62429633|NCT05233800|EXPERIMENTAL|Voice-Activated Smart Speaker Program|Faster Asleep
62815186|NCT06704568|EXPERIMENTAL|core exercise and early pospartum|Unlike the control group; core exercises for 20-30 minutes, 3 days a week for 8 weeks, and respiratory exercises combined with core exercises for the respiratory exercises group
62815187|NCT06704568|EXPERIMENTAL|breathing exercise|Slow and controlled breathing exercises will be performed starting with 5 seconds of inhalation and 5 seconds of exhalation twice a day for 10 minutes, 5 days a week for eight weeks, with a 10-second diaphragmatic breathing cycle (6 breaths/minute). The finger counting method will be recommended so that participants can easily follow the 5-second inhalation and 5-second exhalation cycles. The exercises can be done sitting or lying down. The individuals will be taught the differences between the two by switching between normal and deep breathing a few times. The respiratory exercises will be finished with relaxation exercises.
62815188|NCT06704568|EXPERIMENTAL|control|No application will be made to the control group.
62815189|NCT04850105||TEGSEDI-exposed cohort|This cohort consist of patients diagnosed with hATTR-PN who are receiving any dose of commercial TEGSEDI and who have provided written informed consent to be included into the study.
62815190|NCT04850105||TEGSEDI-unexposed cohort|This cohort which will consist of patients diagnosed with hATTR-PN who have not taken any dose of TEGSEDI within 25 weeks prior to enrollment and are eligible for TEGSEDI treatment per applicable product label and who have provided written informed consent to be included into the study.
62239029|NCT05140733||Foraminotomy|1 or 2 levels lumbar foraminotomy
62429634|NCT05233800|ACTIVE_COMPARATOR|Website|Faster Asleep Website
62429635|NCT03787173|NO_INTERVENTION|Manual standard ventilator settings|Inspiratory trigger set at 2 l/min, Expiratory trigger set at 25% of peak inspiratory flow
62429636|NCT03787173|ACTIVE_COMPARATOR|Manual optimized ventilator settings|Inspiratory trigger and Expiratory trigger settings optimized by investigator
62429637|NCT03787173|EXPERIMENTAL|Automated ventilator settings|Inspiratory trigger and Expiratory trigger settings automatized
62596951|NCT05469269|EXPERIMENTAL|Education and Active Navigation|This arm includes all interventions of the first arm plus the addition of a community navigator. The community navigator will be onsite to assist in information delivery and navigation to resources and encourage the completion of the Screener through the QR code. The community navigator will help participants connect with a primary care provider to continue with all preventive healthcare recommendations.
62429638|NCT00659854|PLACEBO_COMPARATOR|Non milk or soy based formula|25 infants , non milk or soy based formula .
62429639|NCT00659854|ACTIVE_COMPARATOR|2|Intervention with milk based formula will be given to 25 infants.
62596952|NCT05469269|EXPERIMENTAL|Education and Active Navigation with Community Based Outreach|This arm adds the community navigator and a community outreach screening event. Case Comprehensive Cancer Center Community Outreach and Engagement will offer barber shops an onsite PSA screening event.
62596953|NCT02086084|ACTIVE_COMPARATOR|NIV|Standard application of NIV in hypercapnic respiratory failure as per usual standard of care
62596954|NCT02086084|EXPERIMENTAL|ECCO2R|Addition of ECCO2R to NIV in AECOPD
62596955|NCT03380702|ACTIVE_COMPARATOR|whitening photoactivation gel|exposure to hydrogen gel and photoactivation for teeth whitening
62596956|NCT03380702|PLACEBO_COMPARATOR|placebo|exposure to gel without active whitening substance and the same photoactivation source as active comparator
62596957|NCT02809105|EXPERIMENTAL|Part I ASP0456|ASP0456 will be administered orally for 4 weeks.
62596958|NCT02809105|PLACEBO_COMPARATOR|Part I Placebo|Placebo will be administered orally for 4 weeks.
62596959|NCT02809105|EXPERIMENTAL|Part II ASP0456|ASP0456 will be administered orally.
62596960|NCT06452199|ACTIVE_COMPARATOR|B. infantis|"The investigational product to be tested is a Probio-Tec® I Stick-0.16 IF, containing 1.0 g of a standardized fine powder consisting of a food constituent, the freeze-dried culture of Bifidobacterium longum subsp. infantis Bifin02 (DSM33361).~The infant dietary supplement is supposed to be mixed with a little human milk or clean water."
62815191|NCT04857255|ACTIVE_COMPARATOR|Technology Assisted Language Intervention (TALI)|Augmentative and alternative communication software incorporated into active speech-language therapy
62815192|NCT04857255|ACTIVE_COMPARATOR|Treatment as Usual|Speech language therapy child is typically receiving (no change to current care)
62596961|NCT06452199|PLACEBO_COMPARATOR|Placebo|Identical looking placebo.
62815193|NCT02849808||Keratoplasty patients|All patients who underwent one or more keratoplasties since january 1983.
62815194|NCT03346434|EXPERIMENTAL|Part A (Open label Dupilumab): Age cohorts 1 & 2|"Age cohort 1: ≥2 years old to \<6 years old~Age cohort 2: ≥6 months to \<2 years old"
62596962|NCT03129191|ACTIVE_COMPARATOR|AB arm|"Sequence:~1. Aided with non-invasive bone conduction hearing aid A~2. Aided with non-invasive bone conduction hearing aid B"
62596963|NCT03129191|ACTIVE_COMPARATOR|BA arm|"Sequence:~1. Aided with non-invasive bone conduction hearing aid B~2. Aided with non-invasive bone conduction hearing aid A"
62596964|NCT06523907|NO_INTERVENTION|"Control  Present Knowledge about the Basic Nursing skills"|
62596965|NCT06523907|EXPERIMENTAL|"Intervention  Educational Intervention from Registered Nurse"|
62596966|NCT06613854|ACTIVE_COMPARATOR|Oral Semaglutide Arm|Participants will receive oral semaglutide in addition to metformin (in a steady daily dose of ≥1500 mg), starting with an initial dose of 3 mg. The dose of semaglutide will be increased to 7 mg after 30 days, and then to a maintenance dose of 14 mg once daily after another 30 days that will be continued to week 26. In the case of inadequately controlled glycemia (HbA1c \>8.0 % or symptomatic hyperglycemia), rescue treatment with gliclazide will be initiated.
62815195|NCT03346434|EXPERIMENTAL|Part B (Double-blind): Dupilumab dose 1|The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.
62815196|NCT03346434|EXPERIMENTAL|Part B (Double-blind): Dupilumab dose 2|The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.
62815197|NCT03346434|EXPERIMENTAL|Part B (Double-Blind): Placebo|
62815198|NCT03567564||Mechanically ventilated patients|Abdominal muscles ultrasound
62815199|NCT03826706|ACTIVE_COMPARATOR|C-MAC Videolaryngoscope D blade|Patients was intubated with C-MAC videolaryngoscope D blade.
62815200|NCT03826706|ACTIVE_COMPARATOR|McGrath MAC Videolaryngoscope X3 blade|Patients was intubated with McGrath MAC Videolaryngoscope X3 blade
62429640|NCT04128696|EXPERIMENTAL|Participants receiving feladilimab and pembrolizumab|Participants were administered feladilimab (humanized anti-ICOS immunoglobulin G4 \[IgG4\] monoclonal antibody \[mAb\]) and pembrolizumab (humanized anti-PD-1 IgG4 mAb) as an intravenous (IV) infusion once every three weeks.
62429641|NCT04128696|ACTIVE_COMPARATOR|Participants receiving placebo and pembrolizumab|Participants were administered placebo and pembrolizumab (humanized anti-PD-1 IgG4 mAb) as an IV infusion once every three weeks.
62429642|NCT01799642||Cystic Fibrosis Patients|Participants with Cystic Fibrosis
62429643|NCT01799642||Healthy Controls|Participants who do not have cystic fibrosis and are otherwise healthy.
62429644|NCT03614871||No arms|There are no interventions
62429645|NCT00280501|ACTIVE_COMPARATOR|1|Quetiapine
62815201|NCT01893996|EXPERIMENTAL|Adalimumab|Active Study Drug is Adalimumab (Humira) which is FDA approved to treat rheumatoid arthritis since 2003.
62429646|NCT00280501|ACTIVE_COMPARATOR|2|Sulpiride
62429647|NCT00280501|PLACEBO_COMPARATOR|3|Placebo
62429648|NCT01019005|EXPERIMENTAL|Tibial|
62429649|NCT01019005|EXPERIMENTAL|Wound|
62429650|NCT01019005|NO_INTERVENTION|Sham|
62596967|NCT06613854|ACTIVE_COMPARATOR|Empagliflozin Arm|Participants will receive oral empagliflozin in a once daily dose of 10 mg in addition to metformin (in a steady daily dose of ≥1500 mg). The dose of empagliflozin will not be subsequently changed during the duration of the study. In the case of inadequately controlled glycemia (HbA1c \>8.0 % or symptomatic hyperglycemia), rescue treatment with gliclazide will be initiated.
62239030|NCT06434389||The patients undergoing routine coagulation tests|"Part1 Phase I-Laboratory calibration. Phase II-Assay performance using clinical samples. using human biological samples already collected for routine coagulation analysis.~Part2 Subject underwent surgery for acute type A aortic dissection and requires routine TEG test， residual blood samples collected for fibrinogen detection by the Clauss method and electrochemical method."
62239031|NCT04898413|EXPERIMENTAL|Group-based acceptance and commitment therapy (ACT)|Participants assigned to the group-based ACT intervention will receive eight sessions through face-to-face or Zoom video conferencing over the course of four months. Participants will also receive individualized support between sessions to help them better understand the program using phone or Zoom video conferencing. If participants' care recipient hopes to receive psychological treatment, they will be invited to participate in a group-based reminiscence therapy held once or twice a month, each lasting about 60-90 minutes, over the course of about three months.
62596968|NCT06613854|NO_INTERVENTION|Control Arm|Participants will receive metformin in a steady daily dose of ≥1500 mg. In the case of inadequately controlled glycemia (HbA1c \>8.0 % or symptomatic hyperglycemia), rescue treatment with gliclazide will be initiated.
62596969|NCT06350461|EXPERIMENTAL|HS-Discontinue|Discontinuation of current hypertonic saline (HS) therapy
62596970|NCT06350461|ACTIVE_COMPARATOR|HS-Continue|Continuation of current hypertonic saline (HS) therapy
62596971|NCT05729399|EXPERIMENTAL|GT201 treatment group|Autologous tumor infiltrating lymphocyte injection
62596972|NCT03535454||Factory workers|
62815202|NCT01893996|PLACEBO_COMPARATOR|Placebo|Placebo is inert and matches study drug, including the pre-filled syringe, and is supplied by Abbvie, the study drug manufacturer.
62239032|NCT04898413|ACTIVE_COMPARATOR|Group-based cognitive behavior therapy (CBT)|Participants assigned to the group-based CBT intervention will receive eight sessions through face-to-face or Zoom video conferencing over the course of four months. Participants will also receive individualized support between sessions to help them better understand the program using phone or Zoom video conferencing. If participants' care recipient hopes to receive psychological treatment, they will be invited to participate in a group-based reminiscence therapy held once or twice a month, each lasting about 60-90 minutes, over the course of about three months.
62239033|NCT04026841|EXPERIMENTAL|PD-1 Antibody Sintilimab|Patients receive the treatment of PD-1 antibody Sintilimab
62239034|NCT03732508|EXPERIMENTAL|Irinotecan liposome plus SHR1316 plus fluorouracil|
62239035|NCT04572022|EXPERIMENTAL|Intervention group rehabilitation teaching video instructions|Intervention group receive proximal humerus fracture standard care with additional mobile health shared step-wise rehabilitation teaching video instructions module.
62239036|NCT04572022|NO_INTERVENTION|Control group|Control group receive proximal humerus fracture standard care only.
62239037|NCT05261971|NO_INTERVENTION|Medical therapy|One non-steroidal anti-inflammatory drug (400mg etodolac) and one muscle relaxant drug (4 mg thiocolchicoside) were prescribed to the patients in this group.
62239038|NCT05261971|ACTIVE_COMPARATOR|Hard Splint Therapy|The patients in this group were asked to use a hard splint delivered to them to use at night.
62429651|NCT04004273|EXPERIMENTAL|Exercise|Participants randomised to the exercise training intervention will complete 24 moderate-intensity exercise training sessions over the subsequent six weeks (four times per week; \~50 min per session). Each week, one exercise training session will be supervised by the research team, whilst three sessions will be unsupervised but monitored objectively using a heart rate monitor.
62429652|NCT04004273|NO_INTERVENTION|Control|Participants randomised to control will receive no interventions and will be requested to maintain their habitual lifestyle during the six week intervention phase
62429653|NCT06171217|EXPERIMENTAL|Original Cohort|The original REACH cohort continuing study treatment per the protocol schedule of evaluations.
62429654|NCT06171217|EXPERIMENTAL|New Cohort|Newly enrolled REACH participants consent, 3 months screening, and treatment per the protocol schedule of evaluations
62429655|NCT02505711|EXPERIMENTAL|Homestead Food Production|Enrolled in Homestead Food Production program from 2015 to 2019, 48 clusters, approx. 1350 women and 750 children
62596973|NCT03535454||Nurses|
62596974|NCT03535454||Janitors|
62815203|NCT06205992||Experimental group|Experimental group was set to develop the novel non-invasive model for virtual HVPG using 3d-MRE
62596975|NCT03535454||Data automation employees|
62735586|NCT01762774|EXPERIMENTAL|Cohort 2|Obese adult male smoker subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 15 mg GSK2256294 capsules, Treatment B = 40 mg GSK2256294 capsules, Treatment C = 100 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
62815204|NCT06205992||Control group|Control group was set to develop the novel non-invasive model for virtual HVPG using 2d-MRE
62815205|NCT03489863|ACTIVE_COMPARATOR|Prasugrel|Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).
62239039|NCT05261971|ACTIVE_COMPARATOR|Soft Splint Therapy|The patients in this group were asked to use a soft splint delivered to them to use at night.
62429656|NCT02505711|NO_INTERVENTION|Control|(Health system strengthening in the study area), 48 clusters, approx. 1350 women and 750 children
62429657|NCT05793788|EXPERIMENTAL|Arm 1: Specific|Eligible, randomized participant will receive a brief, specific SMS message informing patients that they should obtain screenings and tests they are due for.
62429658|NCT05793788|EXPERIMENTAL|Arm 2: General|Eligible, randomized participant will receive a brief, generic SMS message informing patients that they have a health gap to be closed.
62239040|NCT01862302|ACTIVE_COMPARATOR|Haloperidol|Haloperidol 1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
62239041|NCT01862302|PLACEBO_COMPARATOR|Placebo|1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
62429659|NCT05793788|EXPERIMENTAL|Arm 3: Intention-oriented; General|Eligible, randomized participant will receive an intention-oriented, generic SMS message informing patients that they have a health gap to be closed and highlighting the importance of doing so.
62815206|NCT03489863|ACTIVE_COMPARATOR|Ticagrelor|Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).
62429660|NCT05793788|EXPERIMENTAL|Arm 4: Action-oriented; General|Eligible, randomized participant will receive an action-oriented, generic SMS-message informing patients that they have a health gap to be closed and prompting them to act soon before they forget.
62815207|NCT05766683|EXPERIMENTAL|2mm depth|Subjects will be randomized using computer generated randomization list provided by PHS to receive onabotulinumtoxinA neurotoxin injections in the glabellar complex at depth of 2mm
62815208|NCT05766683|EXPERIMENTAL|4mm depth|Subjects will be randomized using computer generated randomization list provided by PHS to receive onabotulinumtoxinA neurotoxin injections in the glabellar complex at depth of 4mm
62815209|NCT05062174||mifepristone + surgery|Mifepristone is taken orally as a one-time only dose between 48 and 56 hours before your planned prophylactic mastectomy surgery
62815210|NCT06508411||cancer patients and survivors|Individuals who self-identify as cancer patients or cancer survivors
62239042|NCT04549519||Stable group|Participants display knee valgus less or equal to 15° at 45° knee flexion in the descending phase of the squat on both legs
62239043|NCT04549519||Unstable group|Participants display knee valgus greater than 15° at 45° knee flexion in the descending phase of the squat on one leg or both legs
62239044|NCT00635726|EXPERIMENTAL|1|MVAC -\> GEM+CDDP
62239045|NCT05241509|EXPERIMENTAL|Group I (test)|included twenty patients treated with SRP and intrapocket application of 2% lemongrass oil gel.
62239046|NCT05241509|PLACEBO_COMPARATOR|Group II (control)|included twenty treated with SRP and intrapocket application of placebo gel.
62239047|NCT05628116|EXPERIMENTAL|XC243 50 mg single|Cohort 1 - 7 subjects will be randomized in a 5:2 ratio to be treated either XC243 50 mg (5 subjects) or placebo (2 subjects, see placebo single arm)
62239048|NCT05628116|EXPERIMENTAL|XC243 100 mg single|Cohort 2 - 7 subjects will be randomized in a 5:2 ratio to be treated either XC243 100 mg (5 subjects) or placebo (2 subjects, see placebo single arm)
62239049|NCT05628116|PLACEBO_COMPARATOR|Placebo single|Placebo comparator arm will consist of 4 subjects (1 subject each from Сohorts 1 and 2)
62239050|NCT05628116|EXPERIMENTAL|XC243 200 mg single-dose food effect|Cohort 3 - 14 subjects will be randomized in a 12:2 ratio to be treated either XC243 200 mg (12 subjects) or placebo (2 subjects, see placebo single arm) first on an empty stomach, and after the washing period after eating
62239051|NCT05628116|PLACEBO_COMPARATOR|Placebo single-dose food effect|Placebo comparator arm will consist of 2 subjects from Cohort 3
62239052|NCT05628116|EXPERIMENTAL|XC243 200 mg multiple|Cohort 4 - 10 subjects will be randomized in a 8:2 ratio to be treated either XC243 200 mg (8 subjects) or placebo (2 subjects, see placebo multiple arm)
62239053|NCT05628116|PLACEBO_COMPARATOR|Placebo multiple|Placebo comparator arm will consist of 2 subjects from cohort 4
62239054|NCT01210989|ACTIVE_COMPARATOR|Hepaguard|
62239055|NCT01210989|PLACEBO_COMPARATOR|Placebo|
62239056|NCT02754713||Patients with acute pericarditis|300 patients with a first episode of acute pericarditis
62239057|NCT03066752||7 pediatric-onset multiple sclerosis|
62239058|NCT03066752||7 non-patient healthy volunteers|
62239059|NCT00875095||IUI patients|Patients undergoing routine semen analysis as part of their infertility treatment pertaining to success or failure with intrauterine insemination, based upon their sperm DNA integrity
62239060|NCT00875095||IVF patients|Couples undergoing routine screening prior to IVF retrievals to assess their reproductive treatment outcomes as compared to the sperm DNA integrity
62239061|NCT04936841|EXPERIMENTAL|NKTR-214, anti-PD therapy plus Palliative Radiation|"Cycle 1 consists of anti-PD-1 therapy (200mg) and NKTR-214 (0.006 mg/kg3 administered intravenously), followed by palliative radiation (8 Gy x 3 or 4 Gy x 5 fractions) combined with anti-PD-1 therapy and NKTR-214 in cycle 2.~In subsequent cycles participants will receive NKTR-214 and anti-PD-1."
62239062|NCT01721603|EXPERIMENTAL|Dabrafenib + Trametinib + gamma knife radiosurgery|
62239063|NCT02729389|EXPERIMENTAL|High Social Status Condition|Participants will be provided with a high degree of privilege in a game of Monopoly.
62239064|NCT02729389|EXPERIMENTAL|Low Social Status Condition|Participants will be provided with a low degree of privilege in a game of Monopoly.
62429661|NCT00944385|EXPERIMENTAL|ulinastatin|Administer with 30,000U /ulinastatin
62239065|NCT00165633|EXPERIMENTAL|1|
62429662|NCT00944385|PLACEBO_COMPARATOR|C group|administer normal saline
62815211|NCT06541938|EXPERIMENTAL|Case - Inflammatory Bowel Disease|Patients with IBD, under clinical remission since more than 3 months, having at least one symptom
62596976|NCT02908672|EXPERIMENTAL|Atezolizumab + Cobimetinib + Vemurafenib + Vemurafenib Placebo|Run-In Period (Cycle 1=28 days): Participants will receive vemurafenib 960 mg (four, 240 mg tablets) PO BID along with cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21 followed by vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 22 to 28 and vemurafenib placebo (1 tablet) PO BID on Days 22 to 28. Triple Combination Period (Cycle 1 onwards): Participants will receive atezolizumab 840 mg IV infusion on Day 1 and 15, cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21, vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 1 to 28, and vemurafenib placebo (1 tablet) PO BID on Days 1 to 28 of each 28-day cycle. Study treatment will continue until investigator-determined disease progression, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurs first.
62735587|NCT01762774|EXPERIMENTAL|Cohort 3|Obese adult male smoker subjects in Cohort 3 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 3 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2.
62735588|NCT01762774|EXPERIMENTAL|Cohort 4|Obese adult male smoker subjects in Cohort 4 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 4 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2 as well as safety and PK profile obtained in cohort 3.
62735589|NCT04934696|EXPERIMENTAL|BMS-986166 + Oral contraceptive|
62815212|NCT06541938|ACTIVE_COMPARATOR|Control - Healthy household member|Family member of IBD patients who lives in the same house, shares similar diet and has no active GI disease or symptom
62815213|NCT06026046|EXPERIMENTAL|Patients benefiting from the adapted sport program based on fencing|
62815214|NCT00261690|EXPERIMENTAL|1|Virtual Reality distraction
62239066|NCT00165633|EXPERIMENTAL|2|
62239067|NCT00165633|PLACEBO_COMPARATOR|3|
62239068|NCT01248702|EXPERIMENTAL|Critical Pathway|
62239069|NCT01248702|NO_INTERVENTION|Standard Practice|
62239070|NCT00928564|ACTIVE_COMPARATOR|Pudendal Block|8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
62429663|NCT05052515|PLACEBO_COMPARATOR|Placebo|Oral treatment Two tablets twice a day for one year
62429664|NCT05052515|EXPERIMENTAL|Nutritional Supplementation|Oral treatment Two tablets twice a day for one year
62429665|NCT02409537|ACTIVE_COMPARATOR|non cholesterolemic individuals|Individuals with normal cholesterol levels will consume red wine for 1 month. There will be 1 month of wash out period. After 1 month of wash out period resveratrol will be consumed for 1 month and finally after 1 month wash out period placebo will be administered for 1 month.
62429666|NCT02409537|ACTIVE_COMPARATOR|Asymptomatic Hypercholesterolemics|individuals with high levels of cholesterol with no cardiovascular disease Those individuals will consume red wine for 1 month. There will be 1 month of wash out period. After 1 month of wash out period resveratrol will be consumed for 1 month and finally after 1 month wash out period placebo will be administered for 1 month.
62239071|NCT00928564|PLACEBO_COMPARATOR|Placebo|5ml of saline at each block site
62239072|NCT04586998|EXPERIMENTAL|"Exhaled drug monitor Edmon"|Comparison between propofol in exhaled breath and blood plasma
62239073|NCT00153361|EXPERIMENTAL|Intervention|Behavioral discussion sessions focused on reducing substance use and sexual risk behavior
62239074|NCT00153361|ACTIVE_COMPARATOR|Comparison|Video discussion on health issues unrelated to HIV prevention and substance use
62239075|NCT00153361|NO_INTERVENTION|Control|Waitlist control
62239076|NCT03270332|EXPERIMENTAL|Albuterol followed by placebo|Participants in this group will receive albuterol first followed by Placebo on the next visit
62239077|NCT03270332|EXPERIMENTAL|Placebo followed by albuterol|Participants in this group will receive placebo first followed by albuterol on the next visit
62239078|NCT02535663|EXPERIMENTAL|test group|Dietary Supplement: RG consumed one pack (150ml) of dairy yogurt containing RG (100mg Korean citrus Hallabong peel polysaccharide) per day for 8 weeks
62239079|NCT02535663|PLACEBO_COMPARATOR|placebo|Dietary Supplement: placebo consumed one pack (150ml) of dairy yogurt without RG per day for 8 weeks
62239080|NCT03706950||Elpida® + 2 NRTIs|Elpida® 20mg qd in the first line of therapy for HIV-1 infected patients with a background standard ART.
62239081|NCT05490979|EXPERIMENTAL|Contemplative dyad meditation|
62239082|NCT05490979|ACTIVE_COMPARATOR|Fast friends|
62239083|NCT05490979|NO_INTERVENTION|No intervention|
62239084|NCT00827762||Phenylketonuria|Individuals with mild phenylketonuria/hyperphenylalanemia who are beginning treatment with Kuvan.
62239085|NCT00565942|ACTIVE_COMPARATOR|Usual care|Treatment as usual coordinated by general practitioners in primary care.
62429667|NCT05674994|EXPERIMENTAL|MethylPrednisone/Prednisone|"* Day 1, 2 and 3: Intravenous Methylprednisolone 10 mg/kg/d (without exceeding 1000 mg/d) Vials of injectable solution of methylprednisolone® are diluted in 100 ml of NaCl 0.9% or G5%. Perfusion duration is between 20 to 30 minutes. The commercialized form for methylprednisolone injectable solution is not imposed and is taken from the stock of each pharmacy of the participating centers.~* From day 4 to Day 30: Oral Prednisone slow tappering~  * 1 mg/kg/d for 7 days~ * 0.5 mg/kg/d for 7 days~ * 0.25 mg/kg/d for 7 days,~ * 10 mg/d until Day 30. For 10mg/kg, 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg; rounding to 5 decimal lower if decimal ≤ 7 and the top ten if decimal ≥ 8."
62429668|NCT05674994|PLACEBO_COMPARATOR|Placebo|"* Day 1, 2 and 3: Intravenous Methylprednisolone-Placebo~* From Day 4 to Day 30: Oral Prednisone-Placebo"
62429669|NCT02964897|EXPERIMENTAL|Intervention Arm with Peer Support|Veterans in this arm will receive the peer-support intervention, in addition to the usual care from the Health Care for Reentry Veterans Program.
62429670|NCT02964897|OTHER|Comparison Arm with Usual Care|Veterans in this arm will be receiving usual care from the Health Care for Reentry Veterans program (but they will not receive the peer-support intervention). They will be selected to be frequency-matched to veterans in the intervention arm by date of release from incarceration.
62429671|NCT01340365|OTHER|Usual Care|
62429672|NCT01340365|EXPERIMENTAL|Tai Chi|Individuals will take part in community-based Tai Chi classes twice a week for 6 months as well as practice Tai Chi outside of class twice a week for the same 6 month period.
62596977|NCT02908672|EXPERIMENTAL|Atezolizumab Placebo + Cobimetinib + Vemurafenib|Run-In Period (Cycle1=28 days): Participants will receive vemurafenib 960 milligrams (mg) (four, 240 mg tablets) orally (PO) twice a day (BID) along with cobimetinib 60 mg (three, 20 mg tablets) PO once a day (QD) on Days 1 to 21 followed by vemurafenib 960 mg (four, 240 mg tablets) PO BID on Days 22 to 28. Triple Combination Period (Cycle 1 onwards): Participants will receive ATZ placebo by intravenous (IV) infusion on Day 1 and 15, cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21, and vemurafenib 960 mg (four, 240 mg tablets) PO BID on Days 1 to 28 of each 28-day cycle. Study treatment will continue until investigator-determined disease progression, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurs first.
62596978|NCT06623513|EXPERIMENTAL|Parecoxib Group|
62596979|NCT06623513|ACTIVE_COMPARATOR|Indomethacin Group|
62596980|NCT01858779||Study-cohort|"Patients after ischemic stroke without a history of atrial fibrillation will perform measurements of peripheral pulse three times daily and in case of symptomatic arrhythmic episodes. Results will be entered into a diary which will be send to the center every month. In parallel to the measurements, patients will transmit ECGs via a mobile ECG recorder to the study center.~At 3 and 6 months after inclusion patients will be evaluated using 72h holter ECG. During the whole study period AEs as well as SAEs and changes in medications are recorded."
62596981|NCT06581809|ACTIVE_COMPARATOR|Algosteril|control arm (Algostéril® hemostatic dressing): dressing used on the day of the bleeding episode in hospital
62596982|NCT06581809|EXPERIMENTAL|Other dressings|experimental arm (non-haemostatic dressing): dressing used on the day of the bleeding episode in hospital
62596983|NCT00712881|EXPERIMENTAL|Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)|Participants will receive MCH (liposomal doxorubicin hydrochloride \[60 milligrams {mg}/square meter {m\^2}\], cyclophosphamide (600 mg/m\^2), and trastuzumab (8 or 6 mg/kilogram {kg}), administered as intravenous (IV) infusion on Day 1 of each of 4 consecutive 21-day cycles. For the first cycle, the loading dose of trastuzumab will be 8 mg/kg; 6 mg/kg will be used for the remaining cycles. After 4 cycles of MCH, the treatment will be changed to 4 consecutive 21-day cycles of TH (docetaxel \[100 mg/m\^2\] and trastuzumab \[6 mg/kg\]).
62596984|NCT00712881|ACTIVE_COMPARATOR|Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)|Participants will receive AC (free doxorubicin hydrochloride \[60 mg/m\^2\] and cyclophosphamide \[600 mg/m\^2\]), administered as IV infusion on Day 1 of each of 4 consecutive 21-day cycles. After 4 cycles of AC, the treatment will be changed to 4 consecutive 21-day cycles of TH (docetaxel \[100 mg/m\^2\] and trastuzumab \[8 or 6 mg/kg\]). For the first cycle, the loading dose of trastuzumab will be 8 mg/kg; 6 mg/kg will be used for the remaining cycles.
62596985|NCT06624215||Robotic-assisted appendectomy subjects|Approximately 500 subjects will be enrolled in this group who have undergone an emergent or urgent robotic-assisted appendectomy for acute appendicitis in a reverse chronological order from 30 days prior to IRB approval going back to 2018.
62815215|NCT05196828|ACTIVE_COMPARATOR|Arm 1 - Direct Roll-Over Extension|24-wks of Active neurostimulation - Noninvasive peripheral nerve stimulation device programmed to deliver active stimulation; followed by 8-wks of No Intervention
62596986|NCT06624215||Laparoscopic appendectomy subjects|Approximately 500 subjects will be enrolled in this group who have undergone an emergent or urgent laparoscopic appendectomy for acute appendicitis in a reverse chronological order from 30 days prior to IRB approval going back to 2018.
62596987|NCT03164473|EXPERIMENTAL|Rituximab|"* pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)~* plus orally placebo-azathioprine for 24 months"
62596988|NCT03164473|ACTIVE_COMPARATOR|Azathioprine|"* standard maintenance oral azathioprine therapy (2 mg/kg/day) for 24 months~* plus 4 placebo-rituximab infusions given every 6 months for 18 months"
62596989|NCT05960227|EXPERIMENTAL|Iron dextran IV|In patients with acute renal damage, they will be aleatorized to receive the administration of intravenous iron dextran 1200mg in 1 single exhibition compared to placebo.
62815216|NCT05196828|NO_INTERVENTION|Arm 2 - Control Group|24-wks of No Intervention
62815217|NCT05680714||FALLERS IN THE INTERVENTION BOROUGHS|"Fallers 65+ years from the borough of Nordstrand from January 1. 2015 Fallers 65+ years from the borough of Østensjø from September 1. 2016~Fall injury will be included as a time-varying exposure variable. The individuals are all registered as non-fallers until they are registered with a fall injury in the NPR database, when they shift status to fallers."
62815218|NCT05680714||FALLERS IN THE CONTROL BOROUGHS|"Fallers 65+ years from all the 13 other boroughs of Oslo.~Fall injury will be included as a time-varying exposure variable. The individuals are all registered as non-fallers until they are registered with a fall injury in the NPR database, when they shift status to fallers."
62815219|NCT05680714||NON-FALLERS|All non-fallers 65+ years from all Oslo boroughs.
62815220|NCT00939549|EXPERIMENTAL|High-dose cyclohosphamide|
62239086|NCT00565942|ACTIVE_COMPARATOR|Integrative care|Selected complementary therapies (Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong) added to usual care.
62239087|NCT00752531|EXPERIMENTAL|HAT|
62239088|NCT00752531|NO_INTERVENTION|Control|
62239089|NCT00160355|OTHER|1|
62239090|NCT02896504||Chemotherapy|Breast Cancer patients undergoing conventional postsurgical adjuvant chemotherapy treatment
62239091|NCT02896504||Hormonal Therapy|Breast Cancer patients undergoing conventional postsurgical adjuvant hormonal therapy treatment (with no Chemotherapy)
62239092|NCT02896504||Healthy Control|Healthy age, height and body-mass matched healthy controls
62239093|NCT01034293|EXPERIMENTAL|low feeding frequency (3x)|
62239094|NCT01034293|EXPERIMENTAL|High feeding frequency (14x)|
62239095|NCT02306382|EXPERIMENTAL|ultrasonography, abscess|The experimental group will be treated after examination with 3D ultrasonography. Follow up after two months and one year.
62239096|NCT02306382|OTHER|Control group with clincial inscision|The control group will have drainage of their perianal abscess in the OR without ultrasound. Follow-up after two months and one year.
62239097|NCT00601250|EXPERIMENTAL|Linagliptin|Patients receive linagliptin 5 mg tablets once daily
62239098|NCT00601250|PLACEBO_COMPARATOR|Placebo|Patients receive placebo tablets matching linagliptin 5 mg tablets once daily
62239099|NCT00882453||Group 1|
62239100|NCT04013516|NO_INTERVENTION|Pure Control|Respondents received New Incentives' normal program.
62596990|NCT05960227|PLACEBO_COMPARATOR|Placebo|In patients with acute renal damage, they will be aleatorized to receive the administration of placebo.
62596991|NCT02809859|EXPERIMENTAL|Investigational CPAP device|Fisher \& Paykel Healthcare CPAP Device
62596992|NCT03726203|EXPERIMENTAL|trocars of type MiniLap|Patients benefiting from the use of trocars of type MiniLap of Teleflex during the realization of their coelioscopy scheduled in ambulatory
62815221|NCT03604367||GAITRite assessment|Subjects will undergo the GAITRite assessment of functional walking and then complete the Functional MRI Bipedal paradigm followed by questionnaires and assessments regarding the virtual environment.
62239101|NCT04013516|PLACEBO_COMPARATOR|Reminder Call|Respondents received a call from a New Incentives' staff member similar to the treatment arms, but weren't offered additional incentives.
62815222|NCT02197312|OTHER|NobelProcera Bridge Shaded Zirconia|posterior region
62815223|NCT05206747|EXPERIMENTAL|Blue-blocking glasses|Participants will wear orange/amber colored lenses that filter wavelengths of light in the blue spectrum while awake from 6 p.m. to 8 a.m.
62815224|NCT05206747|SHAM_COMPARATOR|Lightly-tinted glasses|This control will involve glasses that selectively filter short wavelength (e.g., ultraviolet), but not visible blue light during the same time window. Participants will wear these glasses while awake from 6 p.m. to 8 a.m.
62815225|NCT01991808|EXPERIMENTAL|DCE-MRI|
62815226|NCT05766397|OTHER|Health volunteer|Health volunteers will follow a standard protocol for inhalation of methoxyflurane while the off-gassing will be captured.
62815227|NCT05323695|OTHER|Depression Screening Intervention|All eligible participants will be screened using the Patient Health Questionnaire-2 (PHQ-2) for depression. If screened positive, participants will be further screened with Patient Health Questionnaire-9 (PHQ-9).
62815228|NCT05992675||AONDA contact lenses|Lotrafilcon A contact lenses worn in a 30-day, continuous wear modality (lenses worn continuously including overnight) over a period of approximately 3 years
62815229|NCT05992675||PV2 contact lenses|Balafilcon A contact lenses worn in a 30-day, continuous wear modality (lenses worn continuously including overnight) over a period of approximately 3 years
62429673|NCT00685022|EXPERIMENTAL|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses).~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. All study drug will be administered directly without using a spacer for the entire study."
62815230|NCT04362839|EXPERIMENTAL|Treatment (regorafenib, nivolumab, ipilimumab)|Patients receive regorafenib PO QD on days 1-21, nivolumab IV over 30 minutes Q2W, and ipilimumab IV over 30 minutes Q6W. Cycles repeat every 28 day for up to 2 years in the absence of disease progression or unacceptable toxicity.
62815231|NCT05930938|PLACEBO_COMPARATOR|Placebo-RT-cetuximab|3 cycles of placebo (matching oral solution from Day 1 to 14, per 3-week cycle) + IMRT (69.96 Gy in 33 fractions, 2.12 Gy/fraction) + cetuximab (loading dose of 400 mg/m² IV on Day -7, followed by weekly dose of 250 mg/m² IV until the end of the RT), followed
62239102|NCT04013516|EXPERIMENTAL|Small Additional Incentive|Respondents were told they would receive 1000 NGN more than originally promised by New Incentives' (either 2000 or 3000 NGN) when they brought their child for measles immunization.
62429674|NCT00685022|ACTIVE_COMPARATOR|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. All study drug will be administered directly without using a spacer for the entire study.
62429675|NCT02100527|EXPERIMENTAL|PF-05175157|
62429676|NCT02100527|PLACEBO_COMPARATOR|Placebo|
62429677|NCT01890785|EXPERIMENTAL|Lisdexamfetamine Dimesylate Fasting|lisdexamfetamine dimesylate 70 mg capsule administered under fasted conditions
62429678|NCT01890785|EXPERIMENTAL|Lisdexamfetamine Dimesylate Vanilla Yogurt|Lisdexamfetamine Dimesylate 70mg capsule mixed into vanilla yogurt
62596993|NCT03726203|ACTIVE_COMPARATOR|trocars classics|Patients benefiting from the use of trocats classics during the realization of their coelioscopy scheduled(programmed) in ambulatory.
62815232|NCT05930938|EXPERIMENTAL|Xevinapant-RT-cetuximab|3 cycles of xevinapant (oral solution 200 mg/day from Day 1 to 14, per 3-week cycle) + IMRT (69.96 Gy in 33 fractions, 2.12 Gy/fraction) + cetuximab (loading dose of 400 mg/m² IV on Day -7, followed by weekly dose of 250 mg/m² IV until the end of the RT), followed by 3 cycles of monotherapy of xevinapant (200 mg/day from Day 1 to 14, per 3-week cycle)
62815233|NCT01926223|EXPERIMENTAL|Home visiting Group|
62815234|NCT01926223|NO_INTERVENTION|Control Group|
62239103|NCT04013516|EXPERIMENTAL|Large Additional Incentive|Respondents were told they would receive 3000 NGN more than originally promised by New Incentives' (either 2000 or 3000 NGN) when they brought their child for measles immunization.
62239104|NCT01979835|EXPERIMENTAL|GF|Women who have a GyneFix Viz inserted
62429679|NCT01890785|EXPERIMENTAL|Lisdexamfetamine Dimesylate Orange Juice|Lisdexamfetamine Dimesylate 70mg capsule mixed into orange juice
62429680|NCT03373266|ACTIVE_COMPARATOR|Sevoflurane|anesthesia was maintained with Sevoflurane 1-2%.
62429681|NCT03373266|ACTIVE_COMPARATOR|isoflurane|anesthesia was maintained with isoflurane 1-2%.
62429682|NCT00056082|EXPERIMENTAL|Celecoxib 400 mg bid|Celecoxib 400 mg bid
62429683|NCT03744806||treated with intravitreal bevacizumab.|
62815235|NCT00246519|EXPERIMENTAL|Atenolol|atenolol 50 mg, then 100 mg if BP \< 120/70, then add HCTZ 12.5 mg if BP \< 120/70, then HCTZ 25 mg if BP \< 120/70
62815236|NCT00246519|EXPERIMENTAL|Hydrochlorothiazide (HCTZ)|HCTZ 12.5 mg then HCTZ 25 mg if BP \< 120/70, then add atenolol 50 mg if BP \< 120/70, then atenolol 100 mg if BP \< 120/70.
62239105|NCT04110119|ACTIVE_COMPARATOR|Control: Drug-Only Group|Patients with acute lower-back pain who have undergone routine conventional drug treatment at the first visit to the emergency department (49 patients). The drug treatment consists of analgesic-anti-inflammatory (diclophenac sodium 75 mg IM) and myorelaxant (thiocolchicoside 4 mg IM), administered only once.
62239106|NCT04110119|EXPERIMENTAL|Case: Drug and Chiropractic Group|Patients, who received chiropractic treatment immediately after the conventional drug treatment as in the control group (49 patients). The chiropractic treatment consists of high speed and low amplitude spinal manipulation techniques, applied only once.
62239107|NCT02422485|EXPERIMENTAL|Salsalate|All participants will be administered 2,250 mg daily \[1,500 mg every day before noon (every AM) and 750 mg every night at bedtime (every HS)\] for 6 months.
62239108|NCT01131403||BW= using baby wipes and CW= using cotton wool|
62239109|NCT01131403||wet wipe, cotton wool|Group 1 (BW),(n= 01-19):Using of wet wipe during the diaper changes Group 2 (CW),(n=20-40):Using a cotton wool cloth, moistened with clear water during the diaper changes.
62239110|NCT01859286||regular sign out process|
62239111|NCT01337804|EXPERIMENTAL|Zegerid-Prilosec|Participants receive Zegerid in Period 1 and Prilosec in Period 2, with a 10- to 21-day washout between study drug administrations.
62239112|NCT01337804|EXPERIMENTAL|Prilosec-Zegerid|Participants receive Prilosec in Period 1 and Zegerid in Period 2, with a 10- to 21-day washout between study drug administrations.
62239113|NCT01684904|EXPERIMENTAL|Proton radiation|Proton radiation
62239114|NCT00833911|EXPERIMENTAL|Tramadol Contramid® OAD|
62429684|NCT03744806||control group|
62596994|NCT00707278|EXPERIMENTAL|All patients|All participants enrolled.
62815237|NCT03386981||1|Professional athletes: Professional athletes belonging to different discipline
62815238|NCT04013386|ACTIVE_COMPARATOR|Aprepitant/Dexamethasone Group|
62815239|NCT04013386|ACTIVE_COMPARATOR|Mertazepine /Dexamethasone Group|
62815240|NCT04013386|ACTIVE_COMPARATOR|Dexamethasone Group|
62815241|NCT04364477|ACTIVE_COMPARATOR|Tap block Group|Tap Block group :(Group 1) After General anestehesia At the end of the operation, TAP blocks were placed to the 1st group patients.
62239115|NCT06012968||GAS|
62239116|NCT06012968||Control|
62239117|NCT04869280||Cohort-1: Pregnant Women Exposed to Prucalopride Prior to Enrollment|Pregnant women diagnosed with chronic idiopathic constipation (CIC) or irritable bowel syndrome-constipation (IBS-C) who have been exposed to prucalopride during pregnancy and prior to enrollment will be observed.
62429685|NCT04799470|EXPERIMENTAL|PD with DBS|Patients with Parkinson's Disease who were implanted with Medtronic Percept PC for DBS and consent to participate in the study.
62429686|NCT05798871|ACTIVE_COMPARATOR|Subgingival erythritol air polishing|"The treatment will include the following therapy steps:~1. Supragingival debridement.~2. Subgingival erythritol air polishing by perioflow."
62429687|NCT05798871|ACTIVE_COMPARATOR|Conventional root planing|"The treatment will include the following therapy steps:~1. Supragingival debridement.~2. Subgingival root planing by curette."
62596995|NCT03273465|EXPERIMENTAL|Fecal transplantation|Fecal transplantation of feces from healthy donor via capsules. Oral application.
62596996|NCT03273465|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62815242|NCT04364477|PLACEBO_COMPARATOR|Control Group|No block applied. only General anesthesia was applied.
62815243|NCT05830552|EXPERIMENTAL|Intervention Group|In the intervention group, the researcher gave feedback on the subjects' exercise amount through telephone contact every 2 weeks during the 12-week study period. Through phone consultations, they answered questions about exercise or discussed problems, encouraged to continue exercising, answered questions or discussed problems related to wearable devices and encouraged continuous data transmission.
62239118|NCT04869280||Cohort-2: Pregnant Women Not Exposed to Prucalopride|Pregnant women diagnosed with CIC or IBS-C who have not been exposed to prucalopride will be observed.
62429688|NCT00003299|ACTIVE_COMPARATOR|Cisplatin + Etoposide|
62429689|NCT00003299|EXPERIMENTAL|Cisplatin + Etoposide + Paclitaxel|
62596997|NCT02417922|EXPERIMENTAL|Autologous conditioned plasma (ACP)|"Whole blood was drawn from the patients using arthrex system (total of 10 mls whole blood). After that whole blood spinning is conducted for 5 minutes and ACP with platelets and growth factors is separated from the red and white blood cells (around 4 mls).~ACP is injected at baseline, 2 weeks, 4 weeks and after 6 weeks from injury date."
62596998|NCT02417922|PLACEBO_COMPARATOR|Saline|Saline (4 mls) is injected around the ruptured achilles tendon at baseline, 2 weeks, 4 weeks and after 6 weeks from injury date.
62596999|NCT04892628|OTHER|Aerobic training group|"The control group will be administered a standard physical therapy intervention program which will consist of active muscle stretching and aerobic exercises.~Exercises will include:~* Flexion, extension and abduction at the shoulder joint for anterior, middle and posterior fibers of deltoid~* Flexion and extension at the elbow for biceps and triceps trachii~* Flexion and extension at the knee joint for quadriceps and hamstring muscles~* Plantar flexion at the ankle joint for gastrocnemius and soleus~Three sets of ten repetitions of each exercise will be done."
62815244|NCT05830552|PLACEBO_COMPARATOR|Control Group|In the case of the control group, physical activity is monitored by itself through wearable devices and smartphone apps without phone counseling.
62815245|NCT05301660|EXPERIMENTAL|Experimental group|People with schizophrenic disorders: receiving nicotine transdermal patches.
62429690|NCT00924183||Treatment-as-usual|All patients will receive treatment as usual: antidepressant medication and/or cognitive behavioral therapy (CBT). Patients' results will be compare to their own baseline measurements.
62429691|NCT05580549||Essential Hypertension|A representative sample of adult patients, with hypertension (ICD-10 diagnose code I10.9) from 2-3 PHCC in Stockholm Region, Sweden. Age 30-85 years old.
62429692|NCT02498899|EXPERIMENTAL|Video 1 + Questionnaires|Participants complete 4 questionnaires at baseline. Participants then watch a short video. At end of video, 3 questionnaires completed. Participants then read a small story about the patient in the video. Afterwards, another set of questionnaires completed.
62429693|NCT02498899|EXPERIMENTAL|Video 2 + Questionnaires|Participants complete 4 questionnaires at baseline. Participants then watch a short video. At end of video, 3 questionnaires completed. Participants then read a small story about the patient in the video. Afterwards, another set of questionnaires completed.
62429694|NCT04068571|ACTIVE_COMPARATOR|I-PUSH intervention sites|Clusters with I-PUSH intervention
62429695|NCT04068571|NO_INTERVENTION|No I-PUSH intervention sites|Clusters with no I-PUSH intervention
62429696|NCT03779100|EXPERIMENTAL|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62429697|NCT03412019|NO_INTERVENTION|Control group|baseline hemodynamics and anxiety screen; no music. Satisfaction will be measured.
62815246|NCT05301660|PLACEBO_COMPARATOR|Control group|People with schizophrenic disorders: receive placebo treatment.
62815247|NCT03392896|EXPERIMENTAL|Group A Active (DCR-PHXC)|HVs, single ascending doses of DCR-PHXC.
62239119|NCT01238289|PLACEBO_COMPARATOR|Control group|This arm continues with standard care at community clinic
62239120|NCT01238289|EXPERIMENTAL|Peer Education|This group receives 8 weeks of peer led self management education classes and subsequent monthly support groups for a total of 10 months
62239121|NCT02838147|EXPERIMENTAL|Normal OGTT (Oral Glucose Tolerance Test)|Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.
62815248|NCT03392896|PLACEBO_COMPARATOR|Group A Placebo|HVs, normal saline 0.9% injection to match active doses.
62815249|NCT03392896|EXPERIMENTAL|Group B Active (DCR-PHXC)|PH1 and PH2 patients, open label, single ascending doses of DCR-PHXC.
62815250|NCT06479590|EXPERIMENTAL|tDCS Group|
62815251|NCT06479590|SHAM_COMPARATOR|Sham Group|
62815252|NCT01184586|ACTIVE_COMPARATOR|Intervention arm - ESWT Storz Duolith high energy|Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (STORZ DUOLITH, 1000 impulses, 0.55-0,8mJ/mm2)
62815253|NCT01184586|SHAM_COMPARATOR|Control - SHAM ESWT STORZ DUOLITH [0.01mJ/mm2]|Three weekly sessions of sham extracorporeal shock wave with modified probe without shockwave transduction (1000 impulses)
62815254|NCT01962935|EXPERIMENTAL|Part A AZD4721|Part A of the study, multiple ascending doses of AZD4721 will be administrated once daily for 10 days
62815255|NCT01962935|PLACEBO_COMPARATOR|Placebo|Part A of the study, multiple ascending doses of matching Placebo will be administrated once a daily for 14 days
62815256|NCT01962935|ACTIVE_COMPARATOR|AZD5069, then AZD4721|Part B of the study, subject will participate in two treatment periods (one with AZD5069 administrated for 3 days and the second period with AZD4721 administrated for 14 days) separated by a wash-out period of 6-10 days between the two periods.
62815257|NCT03549923|EXPERIMENTAL|Simultaneous CRRT group|CRRT is initiated simultaneously (not late than 24 hours from the initiation of ECMO treatment), regardless of presentation of conventional indication of CRRT. CRRT lasts for 12 hours or more is recommended.The physician can decide when to withdraw CRRT based on the patient's condition.
62429698|NCT03412019|EXPERIMENTAL|Intervention group - Mozart|A study investigator will turn on a playlist of pre-selected Mozart music. Hemodynamics and anxiety screen. Satisfaction will be measured.
62429699|NCT00786019|EXPERIMENTAL|Ascorbic acid|All study subjects have ascorbic acid infusion during one exercise visit as well as a three month exercise training intervention.
62239122|NCT02838147|EXPERIMENTAL|Pathological OGTT - 1 abnormal value|Patients will pathological OGTT (either one or more abnormal values) will be randomly allocated to the antenatal care plus FreeStyle group or the SMBG group by a computer generated random number table
62429700|NCT00802633|ACTIVE_COMPARATOR|Stapling device|Efficacy of stapling device during radical cystectomy
62429701|NCT00802633|ACTIVE_COMPARATOR|Ligasure Device|Efficacy of ligasure tissue sealing device during radical cystectomy
62239123|NCT02838147|EXPERIMENTAL|Pathological OGTT - 2 abnormal value|Patients will pathological OGTT (either one or more abnormal values) will be randomly allocated to the antenatal care plus FreeStyle group or the SMBG group by a computer generated random number table
62429702|NCT06515340|EXPERIMENTAL|Allulose Dose 1|Treatment
62429703|NCT06515340|EXPERIMENTAL|Allulose Dose 2|Treatment
62429704|NCT06515340|EXPERIMENTAL|Allulose Dose 3|Treatment
62735590|NCT04381052|EXPERIMENTAL|Clazakizumab 25 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum C-reactive protein (CRP) will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
62815258|NCT03549923|EXPERIMENTAL|Conventional-indication CRRT group|CRRT is not initiated unless conventional indication of CRRT is presented. The conventional indication of CRRT is as follow: KDIGO stage 3 AKI and one of the following criteria is met: severe hyperkalemia (\> 6.5 mmol/L), metabolic acidosis (pH \< 7.2), pulmonary edema, blood urea nitrogen level \>112 mg/dL, or oliguria (urine output \< 200 mL/12 h) for more than 72 hours.
62815259|NCT03549923|EXPERIMENTAL|Esmolol group|Patients will receive a continuous esmolol infusion in addition to routine management. The esmolol infusion commences at 25 mg/h and increases by 25 mg/h every 20-minute until the maximal tolerate dosage is reached or the heart rate reduced to 75±5 bpm, or an upper dose limit of 2000 mg/h is reached. Continue infusing esmolol to maintain the heart rate threshold or at the discretion of the physician until either ICU discharge or death. Oral beta-blockers should be considered before the withdrawal of esmolol.
62815260|NCT03549923|EXPERIMENTAL|Control group|All beta-blockers, including esmolol, should not be used during ICU treatment, unless the doctor thinks there's a strong indication.
62239124|NCT01704820|EXPERIMENTAL|Retroflexion arm|Retroflexion arm: retroflexion in the cecum or proximal ascending colon and slow withdrawal to the hepatic flexure with removal of all visible colon polyps
62239125|NCT01704820|PLACEBO_COMPARATOR|Forward view arm|Colonoscope is slowly withdrawn from the proximal colon to the hepatic flexure and all visible colon polyps are removed.
62239126|NCT03270904|EXPERIMENTAL|Group 1 - Interventional Treatment|Participants in this group have been randomised to receive application of violet blue light administered by the hand held Microlight i:X device in addition to routine care of their foot ulcer. This intervention will be administered four times during the study.
62239127|NCT03270904|NO_INTERVENTION|Group 2 - Usual care|This group receive routine care and no additional intervention.
62239128|NCT04005651|EXPERIMENTAL|POD L GF|Approximately 50 subjects who are scheduled for multifocal IOL implantation and enrolled in the study will be randomized into the POD L GF arm. Subjects will be implanted bilaterally with the European Conformity (CE) marked POD L GF trifocal IOL and assessed according to the study visit schedule.
62239129|NCT04005651|ACTIVE_COMPARATOR|Symfony®|Approximately 50 subjects who are scheduled for multifocal IOL implantation and enrolled in the study will be randomized into the Symfony arm. Subjects will be implanted bilaterally with the CE marked TECNIS Symfony® IOL and assessed according to the study visit schedule.
62429705|NCT03503019||Diabetic|
62429706|NCT03503019||Non-diabetic|
62429707|NCT02359734||Brigham and Women's Hospital.|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Brigham and Women's Hospital. In these unit, the intervention bundle was implemented.
62429708|NCT02359734||Johns Hopkins University Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Johns Hopkins University Hospital. In these unit, the intervention bundle was implemented.
62429709|NCT02359734||Winchester Medical Center|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Winchester Medical Center. In these unit, the intervention bundle was implemented.
62429710|NCT02359734||Central DuPage Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Central DuPage Hospital. In these unit, the intervention bundle was implemented.
62429711|NCT02359734||Vanderbilt University|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Vanderbilt University Medical Center. In these unit, the intervention bundle was implemented.
62239130|NCT04005651|ACTIVE_COMPARATOR|AcrySof®|Approximately 50 subjects who are scheduled for monofocal IOL implantation and enrolled in the study will be placed in the AcrySof® arm. Subjects will be implanted bilaterally with the CE marked AcrySof® IQ monofocal IOL and assessed according to the study visit schedule.
62239131|NCT06068660|EXPERIMENTAL|The experimental group|The experimental group during hospitalization additionally received 40 minutes of one-on-one education three times a week for three weeks, as the Goal-Oriented Care program for 6 hours in total, followed by telephone sessions of 20 minutes every month for six months post-discharge.
62239132|NCT06068660|ACTIVE_COMPARATOR|The control group|The control group received routine health education
62429712|NCT02359734||Massachusetts General Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Massachusetts General Hospital. In these unit, the intervention bundle was implemented.
62429713|NCT02359734||University of California, San Diego|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at University of California, San Diego. In these unit, the intervention bundle was implemented.
62429714|NCT02359734||Maricopa Integrated Health System|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Maricopa Integrated Health System. In these unit, the intervention bundle was implemented.
62429715|NCT02359734||Danbury Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Danbury Hospital. In these unit, the intervention bundle was implemented.
62239133|NCT02494466|ACTIVE_COMPARATOR|Group E (n=10)|Patients with high Ig E levels
62239134|NCT02494466|ACTIVE_COMPARATOR|Group C (n=10)|Patients with normal Ig E levels
62239135|NCT02494466|ACTIVE_COMPARATOR|Group M (n=10)|Patients who would be administered with 4mg PO MS 10 days before surgery because of high IgE
62429716|NCT02359734||Candler Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Candler Hospital. In these unit, the intervention bundle was implemented.
62429717|NCT03608410|EXPERIMENTAL|PRO intervention|Weekly PRO questionnaires Quality of life every 2 months
62429718|NCT03608410|NO_INTERVENTION|Standard of care|Quality of life every 2 months
62429719|NCT05459051||Patients with stable angina|"* Symptomatic~* Anatomically severe single-vessel coronary artery disease~* Physiological evidence of myocardial ischaemia"
62429720|NCT02521831|ACTIVE_COMPARATOR|General Anesthesia|"Inhalational anesthesia with Isoflurane 1-2% in 50%/50% oxygen/air mixture.~This arm will receive the General Anesthesia (isoflurane) intervention exclusively."
62429721|NCT02521831|ACTIVE_COMPARATOR|Spinal Anesthesia|"These infants will not receive any anesthetic gas prior to the spinal. These infants will be conscious for this procedure.~Spinal will be administered, containing 0.25% isobaric bupivacaine, 1 mg/kg (maximum 5mg), Clonidine, 1 µg/kg, and Epinephrine, 1:200,000.~This arm will receive the Spinal Anesthesia (bupivacaine) intervention exclusively."
62429722|NCT02586688|ACTIVE_COMPARATOR|Phase I TMS Active|Blinded Active TMS coil (Phase I). Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
62815261|NCT05588336|ACTIVE_COMPARATOR|10 mcg/kg intrathecal morphine|For postoperative analgesia, before surgical incision, 10 mcg/ideal body weight morphine HCl (in 2 ml volume) was administered intrathecally at L4-5 interspace in the lateral decubitis position.
62815262|NCT05588336|ACTIVE_COMPARATOR|7 mcg/kg intrathecal morphine|For postoperative analgesia, before surgical incision 7 mcg/ideal body weight morphine HCl (in 2 ml volume) was administered intrathecally at L4-5 interspace in the lateral decubitis position.
62815263|NCT06173830|ACTIVE_COMPARATOR|Ultrasound-guided radiofrequency ablation of the genicular nerve in chronic knee osteoarthritis|A total of 34 patients with chronic knee osteoarthritis meeting the criteria will undergo ultrasound-guided radiofrequency ablation of the genicular nerve.
62815264|NCT06173830|ACTIVE_COMPARATOR|physical therapy for chronic knee osteoarthritis|Thirty-four patients with chronic knee osteoarthritis meeting the criteria will receive 10 sessions of physical therapy.
62815265|NCT02946086|EXPERIMENTAL|prismatic adaptation|Including 8 hours of therapy with prismatic adaptation wearing prismatic goggles during bimanual intensive and locomotor intensive intervention (HABIT-ILE).
62815266|NCT02946086|ACTIVE_COMPARATOR|sham goggles|"Including 8 hours of therapy wearing sham goggles during bimanual intensive and locomotor intensive intervention (HABIT-ILE)."
62815267|NCT04180930||Cohort 1|Individuals randomized to Cohort 1 will be assigned to the CAPS-5 and will complete between two and seven research visits. Participants will be administered the CAPS-5 during visit 2, and then will be randomized a second time into groups 1-A and 1-B. Group 1-A will end participation after visit 2. Group 1-B will complete visits 3-7 and will be administered the CAPS-5 at each of these visits along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
62815268|NCT04180930||Cohort 2|Individuals randomized to Cohort 2 will be assigned to the PSSI-5 and will complete between two and seven research visits. Participants will be administered the PSSI-5 during visit 2, and then will be randomized a second time into groups 2-A and 2-B. Group 2-A will end participation after visit 2. Group 2-B will complete visits 3-7 and will be administered the PSSI-5 at each of these visits along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
62239136|NCT05781568||Control Group|"The control group will be composed of patients who will be candidates for HCC surveillance, i.e. those with liver cirrhosis or chronic hepatitis of any aetiology without HCC seen at our institution.~Included in this group are:~1. Patients newly enrolled and who will be tested for α-FP, α-FP-L3%, and DCP as part of their regular follow-up;~2. Patients who had previously given consent for the storage of a serum sample in the Biobank and who had authorized the dosage of α-FP, α-FP-L3% and DCP."
62429723|NCT02586688|SHAM_COMPARATOR|Phase I TMS Sham|Blinded Sham TMS coil (Phase I) Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)
62429724|NCT02586688|OTHER|Phase II Open Label Active TMS|Open label active TMS coil. Open label active NeuroStar® TMS.
62597000|NCT04892628|EXPERIMENTAL|Resistance training group|"The intervention group will undergo a progressive resistance training program consisting of active muscle stretching and resistance training. Exercise for intervention group will consist of:~* Resisted flexion, extension and abduction at the shoulder joint for anterior, middle and posterior deltoid, using dumbbells~* Resisted flexion and extension at the elbow for biceps and triceps trachii, using dumbbells~* Resisted flexion and extension of knee joint for quadriceps and hamstring muscles, using therabands~* Resisted dorsiflexion and plantar flexion of gastrocnemius and soleus, using therabands~Resistance will be increased on basis of progressive overload principle. Three sets of ten repetitions will be performed per muscle group. Initial weight of the dumbbells will be 1kg and will be increased by 0.5kg per week."
62815269|NCT04180930||Cohort 3|Individuals randomized to Cohort 3 will have three office visits and will complete the CAPS-5 and the PSSI-5 in a counter-balanced order during visits 2 and 3, along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
62815270|NCT04180930||Cohort 4|Individuals randomized to Cohort 4 will have three office visits and will complete the CAPS-IV and the CAPS-5 in a counter-balanced order during visits 2 and 3, along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
62815271|NCT05979493|EXPERIMENTAL|QL Block with Bupivacaine|Participants will get a QL block using 30cc Bupivacaine bilaterally in quadratus lumborum muscle (60cc total).
62815272|NCT05979493|SHAM_COMPARATOR|Control|Participants will get a sham injection of 30cc saline bilaterally in quadratus lumborum muscle (60cc total).
62429725|NCT02586688|OTHER|Phase III Long-Term Follow up TMS Active|Long term follow up with open label active TMS for retreatment as needed. Open label active NeuroStar® TMS.
62429726|NCT06432205||surgery group|metastatic gastric cancer patients who are assessed as having the opportunity for surgery finally choose to undergo surgery after MDT plus SDM.
62429727|NCT06432205||non-surgery group|metastatic gastric cancer patients who are assessed as having the opportunity for surgery finally choose not to undergo surgery after MDT plus SDM.
62429728|NCT00736099|EXPERIMENTAL|linagliptin 5 mg|open label
62429729|NCT00736099|EXPERIMENTAL|linagliptin 5 mg and pioglitazone 30 mg|open label
62815273|NCT05292794|EXPERIMENTAL|PD Patients treated with CereGate Software|This singular arm contains participants diagnosed with Parkinson's Disease (PD) and previously implanted with a subthalamic nucleus deep brain stimulation (STN-DBS) System. Participants will use the CereGate software for 60(+/-8) days on demand.
62815274|NCT05134935|ACTIVE_COMPARATOR|OKL|
62815275|NCT05134935|EXPERIMENTAL|DIMS|
62815276|NCT06596174|EXPERIMENTAL|Stage 1: Healthy people|Identify optimal tSCS parameters for non-invasive spinal stimulation.
62239137|NCT05781568||Case Group|"The case group will be composed of patients with newly diagnosed HCC in the context of cirrhosis or any other aetiology during the same study period. This group will include:~1. Patients newly enrolled and who will be tested for α-FP, α-FP-L3%, and DCP as part of their regular follow-up;~2. Patients who had previously given consent for the storage of a serum sample in the Biobank and who had authorized the dosage of α-FP, α-FP-L3% and DCP at the time of tumor diagnosis."
62597001|NCT00895128|EXPERIMENTAL|Erlotinib + Dasatinib|Erlotinib starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients. Dasatinib starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
62815277|NCT06596174|EXPERIMENTAL|Stage 2: SCI Patients|Assess the priming effect of tSCS on spinal circuitry during machine-assisted ankle movement training.
62815278|NCT06596174|EXPERIMENTAL|Stage 3:SCI Patients|Long-term clinical effects of combined tSCS and ankle movement training
62815279|NCT06596174|NO_INTERVENTION|Stage 3:SCI Patients(Control)|Control Group
62815280|NCT04913272|EXPERIMENTAL|KT-301 (formerly US-APR2020)|Patients in this group will be administered KT-301 (formerly US-APR2020) orally at 2 capsules per day for six months. The frequency will be one capsule in the morning and one capsule in the evening, after meals, (for a total daily dose of 90 Billion CFUs).
62815281|NCT04913272|PLACEBO_COMPARATOR|Placebo|Patients in this group will be administered placebo orally at 2 capsules per day for six months. The frequency will be one capsule in the morning and one capsule in the evening, after meals.
62815282|NCT06335641|EXPERIMENTAL|Treatment arm|Head cooling
62815283|NCT06272799||Retrospective cohort|80 patients will form the retrospective cohort, considering consecutively all patients treated according to clinical practice outside of studies randomized
62037374|NCT02829853||sporadic cases (SP)|Sporadic cases are defined as patients diagnosed for sarcoidosis, for which the familial history did not reveal any other cases, whatever the relative degree is: 1, 2, 3 or 4. The clinical follow-up and the genetic studies performed in the frame of this project are the same as for the familial group. During the regular follow-up, patients are regularly questioned about the putative occurrence of the disease in their family, and if such a situation occurred, the patient (and his relative) may change from the SP to the familial (FAM) group. In blood samples, genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING will be done.
62037375|NCT02829853||familial cases (FAM)|Familial cases are defined as patients diagnosed for sarcoidosis with a first and/or second degree relative parent also affected by a well-proven sarcoidosis syndrome. More than 70% of SARCFAM families included two first-degree affected individuals, with both a vertical or horizontal transmission. The Mendelian trait seems to be autosomal dominant. 20 to 30% of the families consists of 3, 4 or more cases, with a subset of families including more than 5 cases. Patients are managed as for the sporadic one, and in such families, an informed consent was also provided with a clear explanation on the complexity of the genetic background of the disease. In blood samples, genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING will be done.
62239138|NCT05245409|EXPERIMENTAL|Stress|Individuals under various degrees of stress
62815284|NCT06272799||Prospectively cohort|Additional 80 patients who meet the inclusion criteria will be enrolled prospectively
62815285|NCT05401162|EXPERIMENTAL|Experimental group|transfusion of autologous blood containing haematopoietic stem cells after conventional chemotherapy
62037376|NCT04591522|EXPERIMENTAL|FMT group|Patients were carried by fecal microbiota transplantation which described in detail that fecal bacteria are extracted from the faeces of healthy people and poured into the intestines of patients.
62597002|NCT05177354|EXPERIMENTAL|Treatment|
62815286|NCT05401162|NO_INTERVENTION|Control group|enrolled ovarian cancer patients receive conventional chemotherapy
62037377|NCT04591522|NO_INTERVENTION|control group|
62037378|NCT00959933|EXPERIMENTAL|1|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)
62239139|NCT01306890||sipuleucel-T|
62239140|NCT05145062||BIVV003 Cohort|All participants treated in parent and future studies with BIVV003
62239141|NCT05145062||ST-400 Cohort|All participants treated in parent studies with ST-400
62597003|NCT00690196|EXPERIMENTAL|1|Tai Chi Chih
62597004|NCT00690196|ACTIVE_COMPARATOR|2|Cognitive Behavioral Therapy
62815287|NCT06693570|EXPERIMENTAL|Intact Fish Skin Graft (IFSG) + Standard of Care|Up to 12 visits with Intact Fish Skin Graft (IFSG) + Standard of Care.
62815288|NCT06693570|ACTIVE_COMPARATOR|Standard of Care|Standard of care will be cleaning, debridement, ulcer moisture balance, and offloading.
62815289|NCT01788852||Perinatally HIV-infected adolescents|Perinatally HIV-infected adolescents
62815290|NCT01788852||behaviorally HIV-infected adolescents|behaviorally HIV-infected adolescents
62815291|NCT01788852||HIV negative adolescents|HIV negative adolescents
62815292|NCT04710901|ACTIVE_COMPARATOR|uTECH + Young Men's Health Project (YMHP)|Approximately 165 participants will be randomly assigned to this arm and will receive the uTECH intervention over the course of 12 months and YMHP intervention over the course of 3 months.
62815293|NCT04710901|ACTIVE_COMPARATOR|Young Men's Health Project (YMHP)|Approximately 165 participants will be randomly assigned to this arm and will receive the YMHP intervention over the course of the first 3 months. Months 3-12 will be inactive, and they will be followed for a total of 12 months.
62815294|NCT04710901|ACTIVE_COMPARATOR|uTECH|Approximately 60 participants will be randomly assigned to this arm and will receive the uTECH intervention over the course of 12 months.
62815295|NCT05976360|ACTIVE_COMPARATOR|Dupilumab drug product 1|A single subcutaneous injection on Day 1
62815296|NCT05976360|EXPERIMENTAL|Dupilumab drug product 2|A single subcutaneous injection on Day 1
62815297|NCT04444817||Tacrolimus-based immunosuppression|Similar to the clinical routine, as soon as a patient is able to swallow and has a sufficient gastrointestinal activity, Tacrolimus-based immunosuppression using Prograf®, Advagraf® or Envarsus® will be started.
62815298|NCT04297865|EXPERIMENTAL|A dose as CJ-15314 or placebo|Oral administration of A as CJ-15314 or placebo once a day
62239142|NCT04691999|EXPERIMENTAL|Intermittent Fasting|All participants will either delay their first meal of the day or advance their last meal to achieve an approximate 16-18 hour fasting period four times per week.
62815299|NCT04297865|EXPERIMENTAL|B dose as CJ-15314 or placebo|Oral administration of B as CJ-15314 or placebo once a day
62815300|NCT04297865|EXPERIMENTAL|C dose as CJ-15314 or placebo|Oral administration of C as CJ-15314 or placebo once a day and once daily for 7 days
62815301|NCT04297865|EXPERIMENTAL|D dose as CJ-15314 or placebo|Oral administration of D as CJ-15314 or placebo once a day and once daily for 7 days
62815302|NCT04297865|EXPERIMENTAL|E dose as CJ-15314 or placebo|Oral administration of E as CJ-15314 or placebo once a day and once daily for 7 days
62037379|NCT00959933|ACTIVE_COMPARATOR|2|Rebetol 200 Capsules (Schering Corporation, U.S.A.)
62037380|NCT03986112||hypertensive group|Evaluation of the ability of carotid sonography and inferior vena cava sonography for the post-induction hypotension in hypertensive patients undergoing general anesthesia
62037381|NCT04091074|ACTIVE_COMPARATOR|aspirin + ticagrelor before carotid stenting|patients undergoing carotid stenting take aspirin 150 mg + ticagrelor 90mg for 15 days before carotid stenting
62239143|NCT01549782|ACTIVE_COMPARATOR|Fiber supplement|6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
62239144|NCT01549782|PLACEBO_COMPARATOR|Maltodextrine|6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
62037382|NCT04091074|ACTIVE_COMPARATOR|aspirin + clopidogrel before carotid stenting|patients undergoing carotid stenting take aspirin 150 mg + clopidogrel 75 mg for 15 days before carotid stenting
62239145|NCT02120625||Lumbar MB RFN|Patients undergoing lumbar medial branch radiofrequency ablation using the Nimbus MEE Probe who undergo MRI and EMG validation testing of efficacy of intended lesion production.
62815303|NCT04297865|EXPERIMENTAL|F dose as CJ-15314 or placebo|Oral administration of F as CJ-15314 or placebo once a day and once daily for 7 days
62815304|NCT06211920|EXPERIMENTAL|Non-invasive ventilation (NIV) + standard medical treatment|"The intervention will consist of application of NIV through a facemask. This will happen as soon as possible after the patient has been randomized by opening the opaque envelope. All patients will receive the same standardized ventilator settings at initiation. The IPAP will be set at 12 cm H2O and the PEEP at 5 cm H2O. These settings are preset on the ventilator used in the physician manned mobile emergency care unit (MECU) in the Central Denmark Region. Oxygen delivery will be adjusted to an arterial oxygen saturation of 88-92%. Further adjustment of ventilator settings and evaluation of treatment effect will be at the discretion of the prehospital physician.~NIV will be administered together with standard medical treatment described below."
62815305|NCT06211920|NO_INTERVENTION|Standard medical treatment alone|"The standard treatment may include inhaled bronchodilators, intravenous corticosteroids, and titrated oxygen supplementation. Although this treatment is based on regional standard operating procedures (SOP), it may differ from patient to patient because it is based on the clinical judgement by the emergency physician in the MECU.~Inhaled bronchodilators can be given in the form of Fenoterol and Ipratropium as a combination drug and/or Salbutamol. Both as a nebulizer solution. One dose (4 ml) of the combination drug contains 1,25 mg Fenoterol and 0,5 mg Ipratropium. Salbutamol will be administered in a concentration of 1 mg/ml. Five mg will be given initially, which can be repeated if necessary.~Corticosteroids can be given in the form of Methylprednisolone 40-80 mg administered intravenously after establishing an intravenous access.~Oxygen therapy will be delivered through a nasal cannula if possible or a non-rebreather mask to maintain an arterial saturation of 88-92%."
62815306|NCT04915846|EXPERIMENTAL|Drug: ApoTamox 10mg|Drug: Tamoxifen (tamoxifen citrate); ApoTamox 10 mg tablets orally twice daily for 6 months
62815307|NCT04915846|PLACEBO_COMPARATOR|Placebo|Placebo (no active ingredients) tablets orally twice daily for 6 months
62815308|NCT04823585|PLACEBO_COMPARATOR|subcutaneous injections of placebo|Subcutaneous injections of placebo (physiological sodium chloride solution) once per month for 16 weeks. A total of 4 injections.
62815309|NCT04823585|EXPERIMENTAL|subcutaneous injections of Mepolizumab 100 mg|Subcutaneous injections of Mepolizumab 100 mg once per month for 16 weeks. A total of 4 injections.
62815310|NCT04162249||Conventional ablation (CONTROL GROUP)|"Pulmonary veins ablation.~* Anterior aspect: power 30 W, catheter dragging (30 s per point).~* Posterior aspect: point-by-point ablation using 30 W/30 s applications. If esophageal temperature measured with two independent esophageal probes exceeded 49 ºC radiofrequency settings were modified to 20 W/ 60 s and the number of radiofrequency applications minimized in areas with esophageal temperature rise.~Al procedures were performed with continuos intracardiac echo image and esophageal temperature monitoring."
62239146|NCT01009554|EXPERIMENTAL|Potassium Oxylate|1.5% potassium oxalate sensitive mouthwash
62239147|NCT01009554|ACTIVE_COMPARATOR|Sodium Fluoride|Sodium Fluoride Dentifrice
62239148|NCT03154762|EXPERIMENTAL|NIPPV|Patients will receive NIPPV with an S bilevel device during 4 nights, the equipment will be placed ad libitum, a 12 cmH2O inspiratory pressure and a 4 cmH2O expiratory pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after intervention.
62815311|NCT04162249||High-power and short-duration ablation|"Pulmonary veins ablation.~* Subgroup 50W: power 50 W, application duration ≤ 30 s, target lesion index: LSI ≥ 5 or Ablation Index ≥ 350 (posterior wall) or ≥400 (anterior wall).~* Subgroup 60W: power 60 W, application duration 7-10 s, contact force ≥5 g.~* Subgroup 70W: power 70 W, application duration 9 s, contact force ≥5 g.~Intracardiac echo was not used. Esophageal temperature probes were used only in 6 patients in the subgroup 50W."
62239149|NCT03154762|SHAM_COMPARATOR|CPAP|Patients will receive a 4 cmH2O continuous positive airway pressure device during 4 nights; this is the minimum pressure necessary to avoid death space with no effect on minute ventilation. The equipment will be placed ad libitum. Pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after sham intervention.
62239150|NCT01677351|ACTIVE_COMPARATOR|group 2: clonidine 4mcg.kg|this group (group 2) will receive 4mcg.kg-1 of clonidine 20 minutes before surgery.
62239151|NCT01677351|PLACEBO_COMPARATOR|Group 1: sterile saline solution|this group (Group 1) will receive a sample injection of sterile saline solution 20 minutes before surgery
62239152|NCT00786396|EXPERIMENTAL|DAART|Group that will be observed daily taking their medications for a period of six months. Followed by the remaining six months of the intervention in which the subject will take medications on their own.
62239153|NCT00786396|NO_INTERVENTION|2|SAT (standard of care) group will take their medications as directed by their physicians for the period of one year.
62239154|NCT00809081|OTHER|1|1. Enteral Feeding
62597005|NCT00039494|EXPERIMENTAL|Treatment (erlotinib hydrochloride, radiation, temozolomide)|Patients receive oral erlotinib once daily. After 1 week of erlotinib alone, patients also receive oral temozolomide once daily for 6 weeks and undergo concurrent radiotherapy 5 days a week for 6 weeks. After completion of radiotherapy, patients continue to receive erlotinib once daily alone in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of radiotherapy, patients also receive oral temozolomide once daily for 5 days. Temozolomide treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62597006|NCT03441971|EXPERIMENTAL|Single Arm|Participants will receive the device on Day 1.
62597007|NCT06622135|OTHER|Blood draw using IV and at home device|
62597008|NCT01202370|EXPERIMENTAL|AR-67|Phase 1 study
62597009|NCT04569747|EXPERIMENTAL|PERTUZUMAB + TRASTUZUMAB + ADJUVANT ENDOCRINE THERAPY|"Study treatment will be administered in 21-day (3- week, +/- 3 days) cycles for one year (18 cycles).~* Trastuzumab + Pertuzumab SC fixed dose combination~* Hormonal therapy- oral, daily per cycle (may add LHRH agonist per investigator discretion)"
62597010|NCT06623318|EXPERIMENTAL|Determine adherence rate for IV medications administered in the home.|Patients will be assigned IV Ensure's remote therapeutic monitoring device to determine their adherence rate with administration of IV medications administered in the home in comparison to their provider's orders.
62597011|NCT06623318|EXPERIMENTAL|Assess re-admission against adherence rates.|Assess correlation of patients hospital re-admission rates for infection related disease progression associated with adherence rates of IV medications administered in the home.
62239155|NCT00809081|NO_INTERVENTION|2|Total Parental support
62239156|NCT01398293|EXPERIMENTAL|A|
62239157|NCT01398293|EXPERIMENTAL|B|
62239158|NCT01398293|ACTIVE_COMPARATOR|C|
62239159|NCT01398293|PLACEBO_COMPARATOR|D|
62239160|NCT04005417||Stannous fluoride dentifrice|Twice daily brushing
62239161|NCT04005417||Positive control dentifrice|Twice daily brushing
62597012|NCT05996107|EXPERIMENTAL|RT + Ribociclib|All patients will be treated with Ribociclib and standard of care radiation therapy
62597013|NCT05763875|EXPERIMENTAL|Inclisiran|Inclisiran s.c and Placebo p.o
62597014|NCT05763875|ACTIVE_COMPARATOR|Ezetimibe|Placebo s.c. and Ezetimibe p.o.
62597015|NCT05763875|PLACEBO_COMPARATOR|Placebo|Placebo s.c. and Placebo p.o.
62597016|NCT06299904|SHAM_COMPARATOR|control group|Based on receiving personalized swallowing rehabilitation training, the control group received traditional air-pulse stimulation therapy.
62239162|NCT04005417||Negative control dentifrice|Twice daily brushing
62239163|NCT03241212|NO_INTERVENTION|Control|"At baseline enrollment: participants will be asked to fill out a demographic survey, the MWIKAD survey and the SMOD-A survey. HbA1c, frequency of Blood Glucose (BG) checks and percent of glucose values above, within and below the target range will be extracted from chart review.~Surveys (with the exception of demographics) and chart extraction will be repeated at 3 months and 6 months post enrollment."
62597017|NCT06299904|EXPERIMENTAL|trial group|The trial group received modified air-pulse stimulation therapy mediated by flexible endoscopy.
62597018|NCT01921244|NO_INTERVENTION|Usual Care|"Approximately 120 families will be asked to participate as usual care subjects and will complete surveys before and immediately after their visit, and approximately 3 months after the visit. These families will not receive the decision aid nor will their provider have been trained how to use the decision aid. All participating providers will have up to 10 usual care patients enrolled at baseline prior to allocation. During the trial, the control group \[usual care providers\] will have up to 10 additional patients enrolled for ongoing usual care data collection. After the trial is complete, the control group providers will cross over to the intervention arm."
62815312|NCT03985930|EXPERIMENTAL|Distraction Group|Children between the ages of 3 and 5 years will be distracted using virtual reality content delivered through goggles.
62239164|NCT03241212|EXPERIMENTAL|Texting|"Participants will be asked to complete the same surveys on the same timeline as above. The texting group will be asked to provide their cell phone number to the texting software.~From baseline appointment to 26 weeks post enrollment, participants will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen."
62815313|NCT03985930|ACTIVE_COMPARATOR|Treatment as Usual|Children randomized to this group will receive the usual medical care.
62815314|NCT04156841||performed SLNB using a single mapping agent|
62815315|NCT04156841||performed SLNB by combination of blue dye and radiotracer|
62815316|NCT04156841||underwent SLN surgery receiving neoadjuvant chemotherapy|
62815317|NCT04156841||underwent SLN surgery not receiving neoadjuvant chemotherapy|
62815318|NCT02397798|EXPERIMENTAL|Intervention|Person-centered high-intense training three times a week under supervision (supervision two times a week) during 5 months
62815319|NCT02397798|ACTIVE_COMPARATOR|Control|Introduction to health-enhancing physical activity, personalized exercise program to perform at home three times a week during 5 months
62815320|NCT04099563|EXPERIMENTAL|PF-04965842|Following an overnight fast for at least 10 hours, participants will receive PF-04965842 oral single dose of 200 mg (2 × 100 mg tablets) on Day 1, at approximately 08:00 am plus or minus 2 hours in the morning. On Days 3 to 8, participants will receive PF-04965842 oral dose of 200 mg (2 × 100 mg tablets) QD in the morning at approximately similar clock hour as on Day 1. On Day 3 and Day 6-8, the dosing of PF-04965842 will be after collection of pre-dose blood samples (under fasted condition for at least 10 hours). On Day 8, the dosing will be under fasted condition at approximately 8:00 am plus or minus 2 hours in the morning.
62815321|NCT02374697||Before tele-expertise|Usual second opinion with pathological slides sent by mailing
62815322|NCT02374697||During Tele-expertise|Second opinion with tele-expertise
62815323|NCT04715113|EXPERIMENTAL|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
62815324|NCT04715113|SHAM_COMPARATOR|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
62239165|NCT06396793||Cardio-respiratory|Inpatients affected by cardiac or pulmonary diseases undergoing a rehabilitative program
62815325|NCT04715113|EXPERIMENTAL|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
62815326|NCT04715113|ACTIVE_COMPARATOR|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
62239166|NCT05142020||GDM group|Specimen collection and clinical follow-up
62239167|NCT05142020||Control group|Specimen collection and clinical follow-up
62815327|NCT03164668|OTHER|Usual cigs; menthol e-cig then tobacco e-cigs|Participants can continue to smoke their usual cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes
62815328|NCT03164668|OTHER|Usual cigs; tobacco e-cig then menthol e-cigs|Participants can continue to smoke their usual cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes
62815329|NCT03164668|OTHER|avoid menthol cigs; menthol e-cig then tobacco e-cigs|Participants avoid smoking menthol cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes
62815330|NCT03164668|OTHER|avoid menthol cigs; tobacco e-cig then menthol e-cigs|Participants avoid smoking menthol cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes
62429730|NCT01788059|EXPERIMENTAL|mesenchymal stem cell|stem cells drived from iliac bone marrow with centrifuge and ficoll method then inject to non union site 2-3 ml with approximately 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion site of the bone fracture under fluoroscopic gide and general or spinal anesthesia as deemed appropriate by the anesthetist.
62597019|NCT01921244|EXPERIMENTAL|Intervention|Approximately 80 families/patients with regularly scheduled clinic follow-up visits in the Division of Developmental and Behavioral Pediatrics (DDBP) at Cincinnati Childrens with providers trained on shared decision making will receive the decision aid prior to their index visit and complete surveys before and immediately after their visit, and approximately 3 months later.
62597020|NCT00868725||possible oral cancer|Patients reporting for oral cavity examination with the possibility or certainty of oral lesions
62597021|NCT06363838||study group|women aged between 40 and 75 years who had not undergone any vaginal surgery and had not undergone any abdominal prolapse surgery were included. Thirty-one women diagnosed with rectocele on examination were included in the study group.Biopsy material was obtained from the epithelium of the posterior wall of the vagina, including the fascia that fits the Ap point. Immunohistochemical staining with Protein Gene Product 9.5 and smooth muscle α-actin was performed in the pathology laboratory. The epithelial thickness measurement and smooth muscle density parameters obtained
62597022|NCT06363838||control group|Thirty-one patients who underwent vaginal intervention and hysterectomy for reasons other than rectocele (colposcopy, conization, etc.) without anterior or posterior wall prolapse were included in the control group.Biopsy material was obtained from the epithelium of the posterior wall of the vagina, including the fascia that fits the Ap point. Immunohistochemical staining with Protein Gene Product 9.5 and smooth muscle α-actin was performed in the pathology laboratory. The epithelial thickness measurement and smooth muscle density parameters obtained
62597023|NCT01916603|EXPERIMENTAL|Normative intervention|Normative intervention on diet \& physical \& breastfeeding: diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
62597024|NCT01916603|NO_INTERVENTION|Routine care|Routine antenatal care according to national guidelines
62597025|NCT06054243|EXPERIMENTAL|CBT-I|
62597026|NCT06054243|ACTIVE_COMPARATOR|CBT-A|
62597027|NCT06054243|NO_INTERVENTION|Waiting-list control|
62597028|NCT06648590|EXPERIMENTAL|Probiotic grouptics|30B CFU/strip/day PA53, before meals; Storage:Store in a cool, dry place without sun exposure.
62429731|NCT03803085|EXPERIMENTAL|Control Condition|Participants only saw their own daily walking steps using the WeRun function in WeChat. They did not use WeChat to see other group members' daily steps and did not engage in social contact with their group members.
62429732|NCT03803085|EXPERIMENTAL|Treatment condition|Participants saw their own and other group member's daily walking steps using the WeRun function in WeChat and they were able to contact the other members of their group using We Chat.
62429733|NCT00263796|EXPERIMENTAL|Pitocin|
62429734|NCT00263796|PLACEBO_COMPARATOR|Placebo|
62429735|NCT05772234|EXPERIMENTAL|Aggressive hydration group|Periprocedural hydration with intravenous 20 mL/kg lactated Ringer's solution within 60 min from the start of ESWL (first shockwave delivered), directly followed by 3 mL/kg per h for 8 h.
62429736|NCT05772234|ACTIVE_COMPARATOR|Restricted hydration group|Periprocedural hydration with normal saline (maximum of 1.5mL/kg per h or 3L per 24h).
62429737|NCT01660490||Proximal femur fractures with ORIF|Proximal femur fractures treated with ORIF
62429738|NCT00895583|EXPERIMENTAL|Group I - Planned transition to sirolimus from tacrolimus|
62429739|NCT00895583|ACTIVE_COMPARATOR|Group II - Continuation of tacrolimus|
62429740|NCT06530043|EXPERIMENTAL|Senobi exercises|"* Group A had undergone Senobi exercises training, scheduled three times weekly over 8 weeks, for individuals with COPD the duration and time interval time for Senobi exercises can vary depending on their overall health, fitness level, and tolerance.~* The session began with the comfortable sitting of participants with slow inhalation, filling the lungs for a count of 4-5 seconds and holding the breath for 2-3 seconds.~* In the second step exhale slowly through the mouth, emptying the lungs for a count of 4-5 seconds, and hold the breath for 2-3 seconds.~* The session started with a shorter session (3-5 minutes) and increased gradually as participants built up endurance with a breathing rate of 4-6 breaths per minute.~* The cycle of Senobi exercises was repeated for 5-10 minutes and 2-3 times a day."
62429741|NCT06530043|EXPERIMENTAL|Jacobsons Muscular relaxation exercises|"* Group B engaged in a Jacobsons Muscular relaxation exercises plan, following the same frequency and duration as the Senobi exercise program-three sessions per week for 8 weeks.~* The session started by tensing the muscles in the toes and then moving up the body tensing and relaxing each muscle group in turn (feet and toes, calves, thighs, hips, lower back, upper back, shoulders, arms, hands, neck, and head) and hold it for 5-7 seconds and released it for 5-7 seconds.~* Repeat the cycle 2-3 times per day with deep breaths between each cycle.~* The session started with a shorter session (3-5 minutes) and increased gradually as participants built up endurance with a breathing rate of 4-6 breaths per minute."
62429742|NCT06536920||Sohag university students|Who diagnosed as migraine among sohag university students
62429743|NCT01460121|EXPERIMENTAL|SpotOn's corrective elements|
62429744|NCT01460121|PLACEBO_COMPARATOR|Placebo corrective elements|
62429745|NCT01453920|ACTIVE_COMPARATOR|Treat-and-extend|Ranibizumab injection every 3 months, with follow-up assessments at each visit (every 3 months)
62239168|NCT02274636|NO_INTERVENTION|Data collection|This first phase will involve having you report to the research coordinator through email the presence or absence of several symptoms associated with GERD that can occur during sleep. Phase 1 will occur over 14 days (and nights).
62239169|NCT02274636|ACTIVE_COMPARATOR|Intervention|In the second phase of the study, each subject will be given either a gel containing xylitol or discs containing xylitol to use for 14 days (the duration of the second phase of the study). If given the gel, a small amount (specified in the directions) is to be applied to the mouth lining just before bed. If given the discs, one will be placed on the gums beside a molar in each cheek each night just before bed (specified in the directions). Each subject will be asked to continue to provide daily email communication with the research coordinator detailing symptoms suggesting reflux experienced the prior night during product use as was provided during phase 1 of the study.
62239170|NCT01835197|EXPERIMENTAL|SAD Cohorts 1-8 Experimental Arm|
62239171|NCT01835197|PLACEBO_COMPARATOR|SAD Cohorts 1-8 Placebo Arm|
62239172|NCT01835197|EXPERIMENTAL|MAD Cohorts 3 through 5 Experimental Arm|
62429746|NCT01453920|EXPERIMENTAL|Treat-and-observe'|No injection, follow-up assessments every month
62429747|NCT02496221|EXPERIMENTAL|Albiglutide / Placebo or Placebo / Albiglutide|In treatment period 1, subjects will receive Albiglutide 50 mg or Placebo subcutaneously (SC) after fasting overnight for at least 10 hours according to randomization schedule on Day 1. Subject will also receive CCK (Kinevac) infusion intravenously for a period of 50 minutes after fasting overnight for at least 10 hours on Day 4. After washout period of a minimum of 42 days in treatment period 2, subjects will receive same treatment according to randomization schedule in a cross-over fashion
62815331|NCT02335619|ACTIVE_COMPARATOR|Early Palliative Care|During their first oncology appointment, the intervention arm patients will self-report any symptoms related to their cancer or treatment to the study team; scores at or above a defined benchmark will be seen by Pain and Symptom Management/Palliative Care team members during or immediately after their oncology appointment. Patients will be asked to self-report symptoms once a month following recruitment, for 4 months.
62815332|NCT02335619|NO_INTERVENTION|Standard Care|During their first oncology appointment, the control arm patients will self-report any symptoms related to their cancer or treatment to the study team; self-reports will be collected but not shared with the Pain and Symptom Management/Palliative Care team, and patients will continue with their oncology appointment as per standard procedure. Patients will be asked to self-report symptoms once a month following recruitment, for 4 months.
62815333|NCT02997631|EXPERIMENTAL|MEDi Distraction|The intervention will be the use of the MEDi robot. The robot will be at the child's eye level, and will be programmed to introduce itself, interact with the child, and make encouraging comments about how brave he/she was. The duration of its actions will coincide with the length of the procedure (approximately 5-8 minutes).
62239173|NCT01835197|PLACEBO_COMPARATOR|MAD Cohorts 3 through 5 Placebo Arm|
62239174|NCT01835197|EXPERIMENTAL|MAD Cohorts 6 and 7 Experimental Arm|
62429748|NCT01946282|ACTIVE_COMPARATOR|FIT Invitation Only|"Fecal Immunochemical Test (FIT) mailed to patient homes free of charge.~Intervention: Fecal Immunochemical Test (FIT) kits and an invitation letter to complete colorectal cancer screening are mailed to the homes of study eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3 consistent with guideline recommended annual FIT for colorectal cancer screening. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
62239175|NCT01835197|PLACEBO_COMPARATOR|MAD Cohorts 6 and 7 Placebo Arm|
62429749|NCT01946282|ACTIVE_COMPARATOR|FIT plus $5 Incentive|"Fecal Immunochemical Test (FIT) mailed to patient homes, plus an incentive to complete the test.~Intervention: FIT kits and invitation letter with a $5 gift card incentive to complete screening are mailed to the homes of 1000 randomly assigned eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
62597029|NCT06648590|PLACEBO_COMPARATOR|Placebo group|Maltodextrin, one strip/day, before meals; Storage:Store in a cool, dry place without sun exposure.
62037383|NCT02019160|EXPERIMENTAL|Silver nitrate|Biannual application of 25% AgNO3 solution followed by 5% NaF varnish.
62037384|NCT02019160|ACTIVE_COMPARATOR|Silver diamine fluoride|Biannual application of 38% SDF solution followed by placebo varnish.
62815334|NCT02997631|NO_INTERVENTION|Standard Care|The control group will receive standard care, which generally includes the use of topical anesthetic cream. This comparison is based on the pragmatic preferences of physicians at the Stollery Children's Hospital as well as precedent in the literature. Overall, it is felt that any new intervention (e.g., the MEDi robot) should be compared to what is currently in practice (i.e., standard care), as no single distraction therapy is consistently and routinely employed in EDs at this time.
62037385|NCT05920629|NO_INTERVENTION|Moderate alcohol consumption|1 standard unit a day for 12 months
62239176|NCT01835197|EXPERIMENTAL|MAD Cohort 8 Experimental Arm|
62239177|NCT01835197|PLACEBO_COMPARATOR|MAD Cohort 8 Placebo Arm|
62239178|NCT01835197|EXPERIMENTAL|MAD Cohort 9 Experimental Arm|
62239179|NCT01835197|PLACEBO_COMPARATOR|MAD Cohort 9 Placebo Arm|
62239180|NCT00462865|EXPERIMENTAL|Gemcitabine and Capecitabine and Avastin|Avastin administered concurrently with chemotherapy (Gemcitabine + Capecitabine) for six cycles followed by single agent Avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
62815335|NCT00315926|EXPERIMENTAL|Melatonin|
62815336|NCT00315926|PLACEBO_COMPARATOR|Placebo|
62815337|NCT03002441|ACTIVE_COMPARATOR|Same-day Dilators|Participants will have Dilapan-S cervical dilators placed 4-6 hours prior to D\&E and will receive 400 mcg buccal misoprostol pills 3 hours prior to D\&E.
62037386|NCT05920629|OTHER|Abstinence|No alcohol beverages for 12 months
62239181|NCT00821431|EXPERIMENTAL|Compression device|The electrical compression device is operated from battery or a main adaptor. It is based upon the use of inflatable pneumatic cuffs that apply controlled compression to the foot, ankle and calf.
62239182|NCT00821431|ACTIVE_COMPARATOR|Profore, 4-layer bandage|A high compression 4-layer bandage (Profore, Trademark of Smith and Nephew). This is a four-layer system that can be purchased either separately or as a package: a wound contact layer (Knitted viscose), a sub-compression wadding bandage, two layers of elastane bandage plus a top cohesive layer.
62239183|NCT05409833||Group 1|Patients aged ≥ 60 years old with symptomatic carpal tunnel syndrome submitted to surgery
62815338|NCT03002441|ACTIVE_COMPARATOR|Overnight dilators|Participants will have Dilapan-S cervical dilators placed the day prior to their D\&E procedure and will receive buccal placebo pills (vitamin B12) 3 hours prior to D\&E.
62815339|NCT05121766|EXPERIMENTAL|Study arm - Omega 3 supplement|Omega-3 (EPA+DHA) - Dose is 2,100mg per day via 3 mini-capsules, 2x/day (a total of 6 mini-capsules per day). Each capsule has 252mg of EPA and 102mg of DHA.
62239184|NCT05409833||Group 2|Patients aged ≥ 60 years old without symptomatic carpal tunnel syndrome submitted to hand surgery
62239185|NCT02685553|EXPERIMENTAL|1|Use of NIR
62239186|NCT02608879|EXPERIMENTAL|OMDP Group|Subjects randomized to this group will attend weekly visits and receive a full dental cleaning, as well as have their gums/tongue cleaned by a dental professional. Subjects will also receive standard of care oral hygiene instructions.
62429750|NCT01946282|ACTIVE_COMPARATOR|FIT plus $10 Incentive|"Fecal Immunochemical Test (FIT) mailed to patient homes, plus an incentive to complete the test.~Intervention: FIT kits and invitation letter with a $10 gift card incentive to complete screening are mailed to the homes of 1000 randomly assigned eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
62597030|NCT03272659|EXPERIMENTAL|Blue Light Cystoscopy with Cysview®|"The enema will be administered to participant. Fluorescence sigmoidoscopy will be performed with white light then blue excitation light after retention of the enema for 60 minutes, followed by a rest time of up to 30 minutes before rectoscopy.~Post-operative surgical specimens will be collected for further fluorescence microscopy studies and pathological correlation of fluoresce with malignant pathology/histology as the gold standard."
62815340|NCT05121766|PLACEBO_COMPARATOR|Control arm - placebo|3 Soybean Oil Placebo capsules 2x/day (a total of 6 mini-capsules per day).
62037387|NCT04368429|EXPERIMENTAL|Group 1: MenACYW Conjugate Vaccine|Participants received a single intramuscular (IM) dose of MenACYW Conjugate vaccine on Day 0.
62037388|NCT04368429|ACTIVE_COMPARATOR|Group 2: Menactra® vaccine|Participants received a single IM dose of Menactra® vaccine on Day 0.
62037389|NCT05028218|EXPERIMENTAL|TQB3824 tablets|TQB3824 tablets orally administrated orally on Days 1-21 of each 21-day treatment cycle. Dose escalation of TQB3824 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data
62037390|NCT04184791|EXPERIMENTAL|Deep Brain Stimulation(DBS) OFF Medication|Subthalamic-DBS in the Levodopa OFF state.
62239187|NCT02608879|OTHER|Control Group|Subjects assigned to the control group will receive standard of care oral health instructions and will come for bi-weekly treatment visits where they will have their teeth cleaned (brushed) by a dental professional.
62239188|NCT01836042||Randomized iStent|Implantation of one iStent in conjunction with cataract surgery, patients randomized to group
62239189|NCT01836042||Randomized cataract surgery|Cataract surgery alone, patients randomized to group
62037391|NCT04184791|EXPERIMENTAL|Deep Brain Stimulation(DBS) ON Medication|Subthalamic-DBS in the Levodopa ON state.
62239190|NCT01836042||Non-randomized iStent|Implantation of one iStent in conjunction with cataract surgery, patients not randomized to group
62239191|NCT05886582|EXPERIMENTAL|Active Rotigotine (RTG)|Participants who are randomized to the active RTG arm will receive Neupro® RTG patches
62429751|NCT02856815|EXPERIMENTAL|Immuncell-LC group|Adjuvant adoptive immune therapy using a CIK cell agent(Immuncell-LC) 12 times(5 treatments at a frequency of once per week, followed by 5 treatments every 2 weeks, and finally 2 treatments every 4 weeks.
62429752|NCT02856815|NO_INTERVENTION|Non-treatment group|Non-treatment
62815341|NCT06199570|EXPERIMENTAL|Adapted Stress Management Program|The behavioral intervention consists of 3 brief coaching sessions delivered by a trained research interventionist (at baseline/orientation, pre-scan, and post-scan time points) and program modules consisting of psychoeducation and stress management skill activities/practice. They will also be provided with a list of mental health resources and crisis line information for use if needed.
62815342|NCT06199570|ACTIVE_COMPARATOR|Enhanced Usual Care|Those randomized to enhanced usual care in the pilot RCT (n=25) will receive a resource list, tablet for study assessments, and reminder calls, but will not receive the program modules. They will also be provided with a list of mental health resources and crisis line information for use if needed.
62815343|NCT05128669|EXPERIMENTAL|CPIP+ECS|"CPIP is an innovative Child-Parent Individualized Psychotherapy, consisting of 25 sessions, designed by the PI and his clinical collaborators for children with internalizing disorders in the aftermath of childhood neglect. It is informed by Short-term Psychoanalytic Child Therapy (PaCT), elements of psychoanalytic parent work, videofeedback and Child-Parent Psychotherapy (CPP) and. CPIP supports the child-caregiver relationship and helps the child to resolve rigid conflictual internal representations/working models and improve interpretative and mentalizing techniques.~ECS (Enhanced Caregiving Support) is described in other arm."
62037392|NCT05653999||Normal Hearing|Group 1 will consist of approximately 20 infants with normal hearing. This cohort will have passed their newborn hearing screenings and will pass audiologic measurements on the day of testing. Audiologic measurements include tympanometry to determine middle ear function and otoacoustic emissions testing to determine cochlear integrity.
62037393|NCT05653999||Hearing Loss|Group 2 will consist of approximately 20 infants with diagnosed bilateral sensorineural hearing loss ranging from mild to severe. These infants will also pass audiologic measures on the day of testing (tympanometry as described in group 1), currently use bilateral air-conduction hearing aids, and are enrolled in early intervention services.
62037394|NCT04427202|OTHER|Referral to harm reduction services|Participants will be taken through the study survey and interview, blood and urine toxicology testing and given a referral to a harm reduction organization.
62037395|NCT05614349|EXPERIMENTAL|Paxlovid|Nirmatrelvir/ritonavir (Paxlovid™) BD x 5 days (this arm has been closed of Sept 30th 2024)
62037396|NCT05614349|NO_INTERVENTION|Control group|Usual care (i.e., supportive care and symptom relief)
62037397|NCT05614349|EXPERIMENTAL|Antioxidant Therapy - Intervention (arm 3)|Antioxidant therapy (comprising of selenium, zinc, lycopene, and vitamin C)
62037398|NCT05614349|EXPERIMENTAL|Other Emerging Interventions (arm 4)|Additional treatment regimens will be decided by the Canadian COVID-19 Out-Patient Therapeutics Committee based on doses and durations studied in past trials and the latest evidence
62037399|NCT01744522||Leech therapy|Patients receiving leech therapy in the outpatient clinic
62037400|NCT06265597|NO_INTERVENTION|Control group|It includes obese children who are not given a Healthy Nutrition and Yoga Programs.
62037401|NCT06265597|EXPERIMENTAL|İntervention group|It includes obese children who are given Healthy Nutrition and Yoga Programs.
62037402|NCT01792063|ACTIVE_COMPARATOR|Sevoflurane A|Generic sevoflurane
62037403|NCT01792063|ACTIVE_COMPARATOR|Sevoflurane B|Orginal sevoflurane
62037404|NCT03662204||Breast|Subjects with clinically confirmed breast cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
62037405|NCT03662204||Lung|Subjects with clinically confirmed lung cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
62037406|NCT03662204||Colorectal|Subjects with clinically confirmed colorectal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
62239192|NCT05886582|PLACEBO_COMPARATOR|Placebo|Participants who are randomized to placebo will receive transdermal patches that match the size and color of active Neupro®.
62429753|NCT00000512|EXPERIMENTAL|Niacin-Colestipol Group|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation. Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
62597031|NCT02558621|EXPERIMENTAL|Device: AQrate Robotic Assistance System|Precise positioning of surgical instruments and spinal implants during general spinal surgery.
62597032|NCT00656487|EXPERIMENTAL|Cannabis-dependent rimonabant|Cannabis dependent young adults administered rimonabant 90 mg at Day 0 and followed for 28 days post.
62037407|NCT03662204||Prostate|Subjects with clinically confirmed prostate cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
62037408|NCT03662204||Bladder|Subjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
62037409|NCT03662204||Uterine|Subjects with clinically confirmed uterine cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
62037410|NCT03662204||Kidney & Renal Pelvis|Subjects with clinically confirmed or suspicion of kidney or renal pelvis cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
62037411|NCT03662204||Pancreatic|Subjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
62037412|NCT03662204||Liver|Subjects with clinically confirmed liver cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
62037413|NCT03662204||Stomach|Subjects with clinically confirmed stomach cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
62037414|NCT03662204||Ovarian|Subjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
62037415|NCT03662204||Esophageal|Subjects with clinically confirmed esophageal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
62239193|NCT06072443||CAB-LA PrEP Cohort|Prescribed CAB-LA PrEP as standard of care or current user of CAB-LA PrEP
62597033|NCT00656487|PLACEBO_COMPARATOR|Cannabis-dependent placebo|Cannabis dependent young adults administered matched placebo at Day 0 and followed for 28 days post.
62037416|NCT05071157||anorexia nervosa|girls between 12 and 18 years old with behavioral eating disorder characterized by a drastic reduction in intakes resulting in weight loss and a BMI ≤ 17.5 kg / m2. Anorexia can be restrictive pure or associated with bulimia
62239194|NCT06072443||Oral PrEP Cohort|Prescribed oral PrEP as standard of care or current user of oral PrEP
62239195|NCT04184960||Gastric cancer cohort|Cohort of patients with gastric cancer
62239196|NCT04184960||Non-gastric cancer cohort|Cohort of patients without gastric cancer
62239197|NCT01596907|ACTIVE_COMPARATOR|Ephedrine and caffiene|"Drug treatment:~ephedrine sulfate 25-mg with caffeine 200-mg per capsule to be given three times per day 4 hours apart for 6 months after gastric bypass surgery. Weight loss rate, resting energy expenditure, fat free mass will be measured during the treatment."
62239198|NCT01596907|PLACEBO_COMPARATOR|placebo|one placebo capsule will be taken three times per day 4 hours apart, identical to the instructions for the active drug for approximately 6 months following gastric bypass surgery. Weight loss rate, resting energy expenditure and fat free mass will be measured during the treatment.
62239199|NCT01877863|EXPERIMENTAL|intradialytic exercise|baseline data prior to starting exercise program will be obtained and then compared to the data after 12 weeks of an intradialtyic biking program
62597034|NCT00656487|NO_INTERVENTION|Non-cannabis using control|Non-cannabis using demographically similar young adults followed for 28 days.
62597035|NCT06157801||Interview Study|In the interview study, participants will watch the video, then complete an interview. This will take about 50 minutes.
62597036|NCT06157801||Survey Study|In the survey study, participants will complete a survey about your education and complete a quick test about your knowledge of hereditary cancer. Participants will then watch the video. complete another survey similar to the one before the video. This should take about 30 minutes.
62597037|NCT06618209||Children with primary ciliary dyskinesia group|It is a group of patients between the ages of 6 and 17 who have recently been diagnosed with primary ciliary dyskinesia
62597038|NCT06618209||healthy patient group|Healthy children aged between 6 and 17 years, with no systemic diseases and not taking any regular medications.
62597039|NCT06618209||Parents of children with Primary Ciliary Dyskinesia group|Parents of children aged 6-17 with Primary Ciliary Dyskinesia
62597040|NCT06618209||Parents of healthy children group|Parents of children aged 6-17 healthy children
62597041|NCT06154395|EXPERIMENTAL|OCT-guided group|
62037417|NCT05071157||obesity|girls between 12 and 18 years old with a BMI projecting ≥ 30 kg / m2 at the age of 18 (IOTF C30).
62037418|NCT05071157||normal weight|girls between 12 and 18 years old without BMI abnormality, without eating disorders, without serious medical pathology
62037419|NCT02369094|EXPERIMENTAL|Acupressure Group|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
62239200|NCT02129153|EXPERIMENTAL|LIFT (Parent information)|"LIFT (Parent information): during their child's 7th and 8th grade years research staff will 1. communicate with parents about their child's academic and behavioral performance in school, roughly twice-monthly 2. invite parents to participate in a 2-hour parent support session to help teach parents to communicate better with their child and support better academic and behavioral performance in school~* students take a baseline survey then 3 surveys (one/year)~* parents take a baseline survey then 2 surveys (one/year)"
62239201|NCT02129153|NO_INTERVENTION|Usual care group|"Usual care control group/No Intervention consists of neither communication of academic information to parents nor invitation to parent support sessions.~* students take a baseline survey then 3 surveys (one/year)~* parents take a baseline survey then 2 surveys (one/year)"
62429754|NCT00000512|EXPERIMENTAL|Lovastatin-Colestipol Group|Colestipol was given as described above. Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
62597042|NCT06154395|EXPERIMENTAL|60 MHz HD-IVUS-guided group|
62597043|NCT06154395|ACTIVE_COMPARATOR|Angiography-guided group|
62239202|NCT04561804||LISESTYLE INTERVENTION|LOW CARB LOW GLYCEMIC LOAS DIET
62239203|NCT04561804||WEGHT LOSS SURGERY|SLEEVE OR MINBYPASS SURGERY
62239204|NCT00593749|ACTIVE_COMPARATOR|HCS|Intervention group
62239205|NCT00593749|PLACEBO_COMPARATOR|Control|Control
62429755|NCT00000512|PLACEBO_COMPARATOR|Conventional-Therapy Group|Patients assigned to conventional therapy (the control regimen) received placebos for colestipol and for lovastatin, given as described above, unless their base-line LDL cholesterol level exceeded the 90th percentile for age. We felt obliged to provide such patients (43 percent of the group) with colestipol instead of its placebo. For purposes of blinding, the lovastatin placebo dose for a patient assigned to conventional therapy was doubled each time the lovastatin dose was doubled for a patient assigned to receive lovastatin and colestipol.
62429756|NCT02581761|EXPERIMENTAL|Cytotec treatment group|patient with pregnancy of unkown location will receive cytotec 800 mcg per vaginal
62429757|NCT02581761|PLACEBO_COMPARATOR|Placebo treatment group|patient with pregnancy of unkown location will receive suppository which contain Whitepsol H-15 with no active material (Cytotec).
62429758|NCT01614925|EXPERIMENTAL|Emdogain|Periodontal surgery with the additional use of Straumann® Emdogain
62429759|NCT01614925|ACTIVE_COMPARATOR|Periodontal Surgery|Periodontal surgery alone
62239206|NCT05001282|EXPERIMENTAL|ELU001|Dose Escalation: Escalating doses of ELU001 Dose Expansion: Recommended Dose for Expansion (or RP2D)
62597044|NCT02113995|ACTIVE_COMPARATOR|ACERTO|"Patients received 400 ml of a beverage containing water and 50 g of maltodextrin 6 hours before the operation. They received orally extra 200 ml of this beverage containing water and 25 g of maltodextrin 3 hours before the operation. Regarding the intravenous fluids, they received 1 to 1.5 liter of crystalloid fluids (ringer lactate) in the intraoperative. In the immediate postoperative they were programmed to receive 2 liters of crystalloid fluids (ringer lactate) and 1 to 2 liters in the first day of the postoperative period. The venous hydration was suspended as soon as they started to drink liquids.~Prophylaxis of nausea and vomiting with dexamethasone 8 mg at the beginning of the anesthesia and ondansetron 4-8 mg after the surgery. In the postoperative period we utilized analgesics such as dipyrone and ketorolac and, if necessary, low doses of morphine and antiemetics like ondansetron."
62597045|NCT02113995|ACTIVE_COMPARATOR|Traditional care|"The analgesia in the postoperative period of the group control was performed with dipyrone, tramadol hydrochloride, and morphine. The prophylaxis of nausea and vomiting with dexamethasone 8 mg in the beginning of the anesthesia and the metoclopramide at the end of the surgery. During the anesthetic induction antibiotic prophylaxis (cefazolin 3 grams/day for 2 days) was administrated.~The control group were submitted to the protocol of traditional fasting with at least 8 hours. Patients in this group received 1 to 2 liters of crystalloid fluid (ringer lactate) in the intraoperative, and they received 3 to 4 liters of crystalloid fluids (ringer lactate, saline 0.9% and/or dextrose 5%). In the immediate postoperative, 2 to 3 liters in the first day of postoperative and, finally, 1 to 2 liters in the second day of the postoperative."
62597046|NCT01735344|EXPERIMENTAL|Lisinopril Tablets 40 mg|Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India
62597047|NCT01735344|ACTIVE_COMPARATOR|Zestril® (Lisinopril) 40 mg Tablets|Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA
62597048|NCT01932736|EXPERIMENTAL|healthy volunteers|healthy volunteers undergo pressure changes in ear canal
62597049|NCT03573960|EXPERIMENTAL|Lenvatinib 24 mg|Participants will receive 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily with or without food in 28-day cycles until disease progression or until unacceptable toxicity occurs.
62597050|NCT02212990|ACTIVE_COMPARATOR|Acetaminophen Arm|Acetaminophen Suspension 160mg / 5mL Oral dose immediately following IIV and every 4 to 6 hours up to 24 hours (Maximum 5 oral doses)
62597051|NCT02212990|PLACEBO_COMPARATOR|Placebo Arm|Placebo Suspension Oral dose immediately following IIV and every 4 to 6 hours up to 24 hours (Maximum 5 oral doses)
62815344|NCT05128669|ACTIVE_COMPARATOR|ECS only|"Enhanced Caregiving Support (ECS) will serve as the control condition provided by the Allgemeine Sozialdienst (ASD - Community Social Services) of the two participating cities. According to German law (§ 27 SGB VIII), caregivers are entitled to receive caregiving support (CS; Hilfe zur Erziehung) in cases where the child's wellbeing is jeopardized. CS generally includes supportive work across all child-relevant systems (family, neighborhood, (pre-)school, peer group etc.). Appointed social workers and educators provide parenting counseling, family support, and intensive child support according to an individualized helping plan (Hilfeplan). In more severe cases, children are placed in (temporary) day-care centers, children's homes, foster families etc. Within the context of the trial, we will appoint an additional multi-systemic case manager to each case to enhance the quality of case coordination (enhanced CS; ECS). All children and families will receive ECS."
62815345|NCT00074711|ACTIVE_COMPARATOR|Calcium Phosphate Treatment Group|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
62815346|NCT00074711|ACTIVE_COMPARATOR|Calcium Carbonate Treatment Group|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.
62815347|NCT04357743|EXPERIMENTAL|Chin supported Arm ergometry with pursed lip breathing|Chin supported along with Arm ergometry with pursed lip breathing
62239207|NCT00723879||Patients with hepatitis C|Patients receiving a patient assistance program during therapy for hepatitis C will be enrolled into this study. All patients will receive PegIntron plus Rebetol (according to the label) and the patient assistance program.
62429760|NCT00491673|ACTIVE_COMPARATOR|Uncemented|Uncemented primary bipolar hemiarthroplasty of the hip
62429761|NCT00491673|ACTIVE_COMPARATOR|Cemented|Cemented primary bipolar hemiarthroplasty of the hip
62239208|NCT01578967|OTHER|ABVD followed by Brentuximab vedotin|Single arm trial
62239209|NCT05980910||Major abdominal surgery|Patients undergoing elective major abdominal surgery. The definition of major surgery is the estimated surgery time \>= 2 hours.
62239210|NCT02014155|EXPERIMENTAL|Group Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard desinsuflativo (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
62239211|NCT02014155|EXPERIMENTAL|Group TMI + Pulmonary Rehabilitation|Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects. Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
62429762|NCT06201910||Controll|Pregnant women without uterine dilation due to a twin pregnancy or a macrosomic singleton
62429763|NCT06201910||Gemini|Pregnant women with uterine dilation due to a twin pregnancy
62429764|NCT06201910||Makrosome|Pregnant women with uterine dilation due to a macrosomic singleton
62429765|NCT06521671|EXPERIMENTAL|Dynaloc|
62429766|NCT06521671|ACTIVE_COMPARATOR|Cannulated cancellous screws|
62429767|NCT03909568|EXPERIMENTAL|Third molar surgery|Split mouth comparison of effect of complete third molar removal vs coronectomy of contralateral third molar
62429768|NCT00683332||A|
62429769|NCT00505505|EXPERIMENTAL|A|Insulin infusion rate titrated to maintain glycemia between 80 and 100 mg/dl
62429770|NCT00505505|ACTIVE_COMPARATOR|B|Insulin infusion rate titrated to maintain glycemia between 80 and 220 mg/dl
62597052|NCT02212990|ACTIVE_COMPARATOR|Ibuprofen Arm|Ibuprofen Suspension 100mg / 5mL Oral dose immediately following IIV and every 6 to 8 hours up to 24 hours (Maximum 4 oral doses)
62597053|NCT05923775|ACTIVE_COMPARATOR|Intrafen group|Each patient in this group will be administered intravenous Ibuprofen (400 mg/8 ml i.v. infusion) for pre-emptive analgesic effect 60 minutes before surgical third molar extraction. Before the procedure, each patient in this group will be given 2 ml of local anesthesia.
62239212|NCT02014155|EXPERIMENTAL|Control Group|Inspiratory muscle training will be held three times a week for eight weeks
62239213|NCT02014155|EXPERIMENTAL|COPD group not rehabilitation|
62239214|NCT01868451|EXPERIMENTAL|Cohort 1 (completed accrual)|Patients received 4 cycles of brentuximab vedotin \& AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, \& Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. This may be followed by 30 Gy involved site radiotherapy. Involved site radiotherapy should be initiated from 12 days to 42 days after completion of chemotherapy. It is mandatory to administer prophylactic growth factor support starting with cycle 1. Choice of growth factor and dosing can be determined at the discretion of the treating physican.
62239215|NCT01868451|EXPERIMENTAL|Cohort 2|Patients with early stage, unfavorable risk Hodgkin lymphoma. The definition of disease bulk, one of the unfavorable risk features, has been updated, and is defined as the presence of any lymph node mass with transverse maximal diameter \> 7.0 cm OR coronal maximal diameter \> 7.0 cm. Patients will receive 4 cycles of brentuximab vedotin \& AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 \& 15 of each 28 day cycle. This may be followed by 20 Gy involved site radiotherapy.
62239216|NCT01868451|EXPERIMENTAL|Cohort 3|Patients will have early stage, unfavorable risk classical Hodgkin lymphoma with disease bulk defined as the presence of any lymph node mass with transverse maximal diameter \> 7.0 cm or coronal maximal diameter \> 7.0 cm. Patients will receive 4 cycles of brentuximab vedotin and AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. This may be followed by 30.6 Gy CVRT.
62239217|NCT01868451|EXPERIMENTAL|Cohort 4|Patients will have early stage, unfavorable risk classical Hodgkin lymphoma with disease bulk defined as the presence of any lymph node mass with transverse maximal diameter \> 7.0 cm or coronal maximal diameter \> 7.0 cm. In this cohort. Pts will receive 4 cycles of brentuximab vedotin \& AVD chemo. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 \& 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, \& Dacarbazine 375 mg/m2 will be administered on days 1 \& 15 of each 28 day cycle. Pts whose PET scan is negative after 4 cycles of brentuximab vedotin \& AVD chemotherapy will not receive RT. Pts whose PET scan is positive after 4 cycles of brentuximab vedotin \& AVD chemo, but subsequent biopsy is neg, will also receive no RT. Upon MSK PI approval, if the simulation can't be covered by the institution or the pts insurance, a diagnostic IV contrast CT neck \& diagnostic IV contrast CT CAP scan will be done in addition to the FDG-PET done after 4 cycles of chemo.
62239218|NCT04370977|ACTIVE_COMPARATOR|Artemether-Lumefantrine|4 sites, namely Massinga, Mopeia, Moatize and Montepuez
62239219|NCT04370977|ACTIVE_COMPARATOR|Amodiaquine-Artesunate|3 sites, namely Massinga, Mopeia and Montepuez
62239220|NCT04367532|EXPERIMENTAL|Foam rolling|Foam rolling of cuff muscles.
62239221|NCT04367532|EXPERIMENTAL|Tissue flossing|Tissue flossing of cuff muscles.
62239222|NCT04367532|NO_INTERVENTION|Control group|Without any intervention.
62239223|NCT05437198||Chronic Obstructive Pulmonary Disease (COPD)|Patients with chronic obstructive pulmonary disease will be recruited from the pulmonology or occupational pathology department. They are either active smokers or ex-smokers. They are over 18 years old
62429771|NCT05110950|ACTIVE_COMPARATOR|No suction EBUS-TBNA|In this technique the stylet is slowly removed without any kind of device in order to avoid active suction.
62429772|NCT05110950|ACTIVE_COMPARATOR|Passive suction through dedicated EBUS-TBNA syringe|After rapid stylet removal, suction is applied through a vacuteiner syringe, without active aspiration.
62597054|NCT05923775|ACTIVE_COMPARATOR|Ketamine group|Each patient in this group will be administered intravenous 100 ml saline (Poliflex 0.9% isotonic 100 ml solution) for a placebo effect 60 minutes before surgical third molar extraction. Before the procedure, each patient in this group will be given 0.3 mg/kg of ketamine (Ketalar 500 mg) in addition to 2 ml of local anesthesia.
62429773|NCT05110950|ACTIVE_COMPARATOR|Manual applied suction EBUS-TBNA through a pistol-grip syringe holder|After rapid stylet removal, suction is applied through Cameco syringe pistol, that can apply active suction manually.
62597055|NCT05923775|ACTIVE_COMPARATOR|Combined group (Intrafen+Ketamine)|Each patient in this group will be administered intravenous Ibuprofen (400 mg/8 ml i.v. infusion) for pre-emptive analgesic effect 60 minutes before surgical third molar extraction. Before the surgery, each patient in this group will be given 0.3 mg/kg of ketamine (Ketalar 500 mg) in addition to 2 ml of local anesthesia.
62597056|NCT05923775|PLACEBO_COMPARATOR|Control|Each patient in this group will be administered intravenous 100 ml saline (Poliflex 0.9% isotonic 100 ml solution) for a placebo effect 60 minutes before surgical third molar extraction. Before the procedure, each patient in this group will be given 2 ml of local anesthesia.
62597057|NCT05277142|EXPERIMENTAL|Group (A)|they received oral motor training for 40 minutes 3 times/week for twelve successive weeks.
62597058|NCT05277142|EXPERIMENTAL|Group (B)|They received the same Oral motor training program of Group A for 20 minutes in addition to Neuromuscular Electrical Stimulation (NMES) at intensity ranged from (3-5mA) duration for 20 minutes and frequency of 80 HZ 3 times/week for twelve successive weeks.
62597059|NCT05382793|EXPERIMENTAL|Lactating women with assumed adequate habitual iodine intake|Women who consumed iodine-containing dietary supplements during pregnancy (≥150 μg/day). Women in this group will receive a daily oral iodine supplement providing 150 μg iodine as potassium iodide for 14 days before the study start.
62815348|NCT04357743|ACTIVE_COMPARATOR|Arm ergometry with pursed lip breathing|Arm ergometry with pursed lip breathing
62815349|NCT06236906|EXPERIMENTAL|Intervention|Child and parent in digi-physical family treatment
62429774|NCT02460965||Patients with schizophrenia|
62429775|NCT02460965||Patients with borderline personality disorder|
62815350|NCT06272994|NO_INTERVENTION|No MRSA Nasal Swab|Subjects will not have a nasal swab collected.
62239224|NCT05437198||NO-Chronic Obstructive Pulmonary Disease|"The no-COPD are controls followed in chi créteil for another pathology. They are between 18 and 30 years old and 45 and 70 years old.~They are either:~* Ex-smoker~* Active smoker~* Non-smoker"
62037420|NCT02369094|OTHER|Waiting Control Group|"No acupressure therapy will be provided during the 1st 12 weeks' of study.The enrolled elderly will join a group activity, resembling the other group activities that held in that particular center, their caregivers will be requested to spend two 20 minutes sessions per week with the elderly doing homework assigned by the activity group and log down the timing in the log book.This arrangement is to account for the placebo effect of additional social interaction time and attention that the treatment group will receive during this period.~After completing the 1st 12 weeks' participation in the Waiting Control Group, the subject dyads in the waiting control group will receive the same training and treatment as the treatment group."
62815351|NCT06272994|ACTIVE_COMPARATOR|MRSA Nasal Swab|Subjects will have a nasal swab collected and sent to the clinical laboratory for the MRSA nasal swab PCR test to be run. For the subjects assigned to the intervention group who have a negative MRSA nasal swab PCR result, providers will receive a pager alert which inform them of the negative result and will direct clinicians to clinical guidance recommending clinicians to discontinue vancomycin, if clinically appropriate.
62037421|NCT03683485|EXPERIMENTAL|long duration EPBD group|Balloon dilation was performed using wire-guided hydrostatic balloon catheters. An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy. Stones were removed by standard techniques, including balloon or basket catheters.
62037422|NCT03683485|ACTIVE_COMPARATOR|endoscopic sphincterotomy (EST) group|After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold. A complete sphincterotomy was defined by the free passage of a fully bowed sphincterotome and the presence of spontaneous bile drainage. A complete sphincterotomy was defined by the free passage of a fully bowed sphincterotome and the presence of spontaneous bile drainage.
62037423|NCT05865106|EXPERIMENTAL|Smartphone-based speech therapy|Smartphone-based speech therapy: Participants will be instructed to use smartphone-based speech therapy (application), including oro-motor exercises, phonation, articulation, resonance, syllable repetition, and reading exercises.
62037424|NCT05865106|OTHER|Traditional speech therapy|Traditional speech therapy: Traditional speech therapy methods, such as face-to-face sessions, oro-motor exercises for the tongue, lips, chin, and jaw, reading aloud slowly and clearly, and practicing proper breathing and sustained speech, will be employed.
62239225|NCT01794585|EXPERIMENTAL|Virtual Reality Based Exercise|
62239226|NCT01794585|ACTIVE_COMPARATOR|Standard Exercise|
62239227|NCT04388540||Jamaica|School aged children 6 - 12 years living in Jamaica
62239228|NCT04388540||Trinidad and Tobago|School aged children 6 - 12 years living in Trinidad and Tobago
62239229|NCT04388540||Belize|School aged children 6 - 12 years living in Belize
62239230|NCT04388540||Barbados|School aged children 6 - 12 years living in Barbados
62239231|NCT04388540||St. Lucia|School aged children 6 - 12 years living in St. Lucia
62429776|NCT02460965||Patients with hearing impairment|
62429777|NCT02460965||Patients with visual loss|
62429778|NCT02460965||Patients with Parkinson's Disease|
62037425|NCT00114868|ACTIVE_COMPARATOR|Vitamin A|48,000 IU vitamin A oral dose spread over 2 days as soon as possible after birth.
62429779|NCT02460965||Patients with Alzheimer's Disease|
62597060|NCT05382793|EXPERIMENTAL|Lactating mothers with assumed inadequate habitual iodine intake|Women who did not consume iodine-containing dietary supplements during pregnancy (≥150 μg/day).
62239232|NCT04388540||Grenada|School aged children 6 - 12 years living in Grenada
62239233|NCT04388540||St. Vincent & the Grenadines|School aged children 6 - 12 years living in St. Vincent \& the Grenadines
62239234|NCT04388540||Antigua|School aged children 6 - 12 years living in Antigua
62239235|NCT04388540||Dominica|School aged children 6 - 12 years living in Dominica
62239236|NCT04388540||St. Kitts and Nevis|School aged children 6 - 12 years living in St. Kitts and Nevis
62429780|NCT02460965||Patients with dementia with Lewy Bodies|
62815352|NCT02425410||Isis-Virus|T1D patients of the Isis-Diab cohort with genetic data (GWAS) and specific environmental data on viral events during childhood
62239237|NCT03236051|EXPERIMENTAL|multimodal analgesia|Patients received multimodal analgesia after laparoscopic gastrectomy .
62239238|NCT03236051|ACTIVE_COMPARATOR|PCIA analgesia|Patients received PCIA analgesia after laparoscopic gastrectomy.
62429781|NCT02460965||Healthy participants|
62429782|NCT04609865|EXPERIMENTAL|Lidocaine 2%|The lidocaine infusion protocol is a bolus of 1 mg/kg (ideal weight), followed by 3mg/kg/h for the first hour, 1.5 mg/kg/h for the second hour, 0.72 mg/kg/h for the next 22 hours,and then 0.6mg/kg/h for 14 days or until extubation.
62429783|NCT04609865|PLACEBO_COMPARATOR|Control|The NaCl 0,9% infusion protocol is a bolus of 0.05 ml/kg (ideal weight), followed by 0.15 ml/kg/h for the first hour, 0.075 ml/kg/h for the second hour, 0.36 ml/kg/h for the next 22 hours, and then 0.03 ml/kg/h for 14 days or until extubation.
62429784|NCT02059577|EXPERIMENTAL|Treatment Group|This group received a combination of nutritional treatments, added sequentially, including vitamins/minerals, essential fatty acids, Epsom salt baths, carnitine, digestive enzymes, and healthy, gluten-free, casein-free diets.
62429785|NCT02059577|NO_INTERVENTION|Non-Treatment Group|This group did not have any significant changes in their treatments for 12 months
62597061|NCT04988022|EXPERIMENTAL|Dupilumab|dupilumab 600mg loading dose at Baseline (given as two 300 mg injections) followed by one 300mg weekly subcutaneous injection through Week 52.
62597062|NCT04988022|PLACEBO_COMPARATOR|Placebo|matching placebo loading dose at Baseline (given as two injections) followed by one weekly subcutaneous injection through Week 24. Starting at Week 24, dupilumab 600mg loading dose (given as two 300 mg injections) followed by one 300mg weekly subcutaneous injection through Week 52.
62815353|NCT05362487||Patients switching from Spiriva® HandiHaler® to Spiriva® Respimat®|
62037426|NCT00114868|PLACEBO_COMPARATOR|Placebo|placebo
62037427|NCT02944136|ACTIVE_COMPARATOR|Enhanced Usual Care|Referred to a therapist and/or psychiatrist in their home town depending on the type of treatment they prefer (e.g., behavioral and/or medication)
62037428|NCT02944136|EXPERIMENTAL|stepped collaborative care|At least biweekly contact from a care coordinator by phone and face-to- face visits occurring approximately every 2 months during the patients outpatient visits or treatment, and 24/7 access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
62037429|NCT01603264|EXPERIMENTAL|A|PF-05280014
62037430|NCT01603264|ACTIVE_COMPARATOR|B|Trastuzumab-EU
62037431|NCT01603264|ACTIVE_COMPARATOR|C|Trastuzumab-US
62429786|NCT06306794|EXPERIMENTAL|experimental group|During the endotracheal aspiration procedure, the octopus will be given to experimental group 10 minutes before the procedure. Babies will be allowed to touch the octopus for 10 minutes during and after the procedure. Physiologic parameters of the infants before, during and after the procedure will be reported and recorded by camera. According to the video recordings, PIPP-R and PICS scale evaluations of the infants will be made by two research nurses other than the main researcher conducting the study.
62429787|NCT06306794|NO_INTERVENTION|control group|The routine aspiration application steps of the unit will be applied to the control group without any intervention. Physiologic parameters of the infants before, during and after the procedure will be reported and recorded by camera. According to the video recordings, PIPP-R and PICS scale evaluations of the infants will be made by two research nurses other than the main researcher conducting the study.
62429788|NCT00532454|OTHER|tamoxifen|observation for clinical efficacy on tamoxifen according to CYP2D6 genotype
62429789|NCT04146454|EXPERIMENTAL|Smartphone-based balance exercises|This group will complete in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises) with a smartphone-based wearable telerehabilitation system.
62429790|NCT04146454|NO_INTERVENTION|Paper-based balance exercises|This group will complete in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises) with typical paper-based instructions.
62429791|NCT01691599||Tibia fractures|Patients with open and closed tibia fracture treated with internal fixation in India
62037432|NCT06359938|EXPERIMENTAL|Atrial pacing with respiratory sinus arrhythmia (RSA) variability|"The experimental arm is atrial pacing with additional respiratory sinus arrhythmia (RSA) modulation following coronary artery bypass graft (CABG) surgery. Pacing impulses will be grouped together during inspiration, such that heart rate (HR) will increase by approximately 6 bpm above median during inspiration, and decrease by around 6 bpm below median during expiration. Five pacing rates will be used to accommodate a range of patients' intrinsic HR.~Pacing will be initiated after randomisation, after the patient is removed from ventilator support (Pacing Day 1, PD1). This is usually the day after surgery. Pacing will continue until the patient is ready for discharge or there is a clinical decision to stop pacing and remove the leads (whichever is soonest).~Pacing is delivered by a PACE204 pacemaker (Osypka Medical AG) modulated to respiratory phase by a Ceryx device (intervention)"
62429792|NCT02857374|EXPERIMENTAL|Diagnostic (intravital microscopy)|Patients receive indocyanine green and fluorescein sodium injection IV and then undergo intravital microscopic observation over 15-20 minutes during standard of care sentinel node biopsy.
62429793|NCT01011907|EXPERIMENTAL|varenicline|Drug: varenicline (Chantix) 12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
62429794|NCT01011907|PLACEBO_COMPARATOR|placebo|Drug: placebo for varenicline 12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
62429795|NCT02543268|EXPERIMENTAL|Group 1|Ad26.ZEBOV -Batch #1, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
62429796|NCT02543268|EXPERIMENTAL|Group 2|Ad26.ZEBOV -Batch #2, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
62429797|NCT02543268|EXPERIMENTAL|Group 3|Ad26.ZEBOV -Batch #3, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
62429798|NCT02543268|EXPERIMENTAL|Group 4|Placebo (0.9% saline)- single dose IM injection on Day 1 and Day 57
62429799|NCT01619085|EXPERIMENTAL|All subjects|patient to receive a capsule containing Nintedanib twice a day
62429800|NCT02903316||Fluid Therapy|Systematisation of fluids during CABG surgery
62429801|NCT02343562|ACTIVE_COMPARATOR|Probiotics Group|Will receive Sachet-form probiotics
62429802|NCT02343562|PLACEBO_COMPARATOR|Placebo Group|Will receive off-the-shelf oral multivitamin
62429803|NCT02153931||Volunteers|Parents of children with NF1
62429804|NCT02197182|EXPERIMENTAL|LUXSOL Cream|LUXSOL Cream is a copper containing cream to be administered intravaginally before bedtime for 10 consecutive nights.
62429805|NCT02197182|ACTIVE_COMPARATOR|Metronidazole cream|Metronidazole cream is the active comparator drug to be self-administered intravaginally each night before bedtime for 10 consecutive nights. Dosage is per package insert.
62429806|NCT06339021|EXPERIMENTAL|OCT-guided PCI and DAPT De-escalation|OCT-guided PCI follwed by DAPT de-escalation (aspirin and clopidogrel) 30 days after the DES implantation in STEMI patients
62037433|NCT06359938|ACTIVE_COMPARATOR|Monotonic atrial pacing|"The control arm is standard monotonic right atrial pacing at the relevant median rate following coronary artery bypass graft (CABG) surgery. Pacing will be initiated after randomisation, after the patient is removed from ventilator support (Pacing Day 1, PD1). This is usually the day after surgery. Pacing will continue until the patient is ready for discharge or there is a clinical decision to stop pacing and remove the leads (whichever is soonest).~Pacing is delivered by a PACE204 pacemaker (Osypka Medical AG) delivering standard monotonic right atrial pacing."
62597063|NCT04074746|EXPERIMENTAL|Treatment (AFM13-NK, AFM13)|Patients receive standard of care fludarabine IV over 1 hour and standard of care cyclophosphamide IV over 30-60 minutes on days -5 to -3, AFM13-NK IV over 4 hours on day 0, and then AFM13 IV over 4 hours on days 7, 14, and 21.
62037434|NCT05441072||Diabetic Retinopathy (DR)|Patients suffering from DR of both genders above 18 years of age with different disease degree. Each patient will be measured with BulbiCam device 6 times within three days
62037435|NCT05441072||Healthy controls DR|Gender- and age-matched healthy controls without any eye disease to the DR patients
62037436|NCT05441072||Age related macular degeneration (AMD)|Patients suffering from AMD of both genders above 18 years of age with different disease degree.
62429807|NCT06339021|EXPERIMENTAL|OCT-guided PCI and default DAPT regimen|OCT-guided PCI follwed by default DAPT regimen (aspirin and ticagrelor) 30 days after the DES implantation in STEMI patients
62597064|NCT01795092|NO_INTERVENTION|Control|Those in the control group do not obtain a dermatology evaluation and will be assessed and treated by their primary care provider. We will perform a chart review two weeks after presentation to assess for admission versus discharge home from clinic and outcome.
62037437|NCT05441072||Healthy controls AMD|Gender- and age-matched healthy controls without any eye disease to the AMD patients
62429808|NCT06339021|EXPERIMENTAL|Conventional angiography-based PCI and DAPT De-escalation|Conventional angiography-based PCI follwed by DAPT de-escalation (aspirin and clopidogrel) 30 days after the DES implantation in STEMI patients
62429809|NCT06339021|ACTIVE_COMPARATOR|Conventional angiography-based PCI and default DAPT regimen|Conventional angiography-based PCI follwed by default DAPT regimen (aspirin and ticagrelor) 30 days after the DES implantation in STEMI patients
62597065|NCT01795092|EXPERIMENTAL|Dermatology consultation|Patients randomized to the treatment group will obtain a dermatology evaluation at the primary care physician's office and will be sent to the Emergency Department (ED) or discharged home with outpatient dermatology follow-up in 2-3 days to assess their condition. Patients who are evaluated by a dermatologist and require hospitalization will have their transition to the ED managed by the dermatologist. Patients who are admitted after the initial outpatient discharge or at the follow-up visit will be considered treatment failures. A medical record review will be performed for patients in the treatment group two weeks after initial evaluation at the internal medicine clinic.
62815354|NCT05587270||Rock Climbers|The whole eligible population of Swedish climbers on elite- or sub-elite levels of competition will be invited to participate in the study. Participants will be both male and female, 13 years and older. There are approximately 40 climbers eligible at elite level and a minimum of 80 climbers at sub-elite level of competition.
62815355|NCT05587270||Controls|A non-athlete control group (n matched to the study group) from the general population, will be invited to participate in the study.
62037438|NCT01016938||Group I|This is a pilot study and there is only one group.
62037439|NCT00863174|EXPERIMENTAL|1|SPARC147709
62037440|NCT00863174|ACTIVE_COMPARATOR|2|Reference147709
62037441|NCT04414267|EXPERIMENTAL|BCG vaccine|One intradermal injection of 0.1ml of BCG (BCG vaccine Moscow strain 361-1; Serum Institute of India Pvt. Ltd)
62037442|NCT04414267|PLACEBO_COMPARATOR|Placebo|One intradermal injection of 0.1ml of sodium chloride 0.9%
62429810|NCT02420899|EXPERIMENTAL|Statins,lipid-lowering drugs|rosuvastatin 10mg or 20mg per day，pro
62429811|NCT01436019||anti-TNF treatment|Children or young adolescents with juvenile idiopathic arthritis receiving either infliximab, adalimumab or etanercept.
62429812|NCT05302284|EXPERIMENTAL|RC48-ADC + JS001|Participants will receive RC48-ADC + JS001 every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
62429813|NCT05302284|ACTIVE_COMPARATOR|Gemcitabine + cisplatin/carboplatin|Participants will receive Gemcitabine + cisplatin or carboplatin every 3 weeks (Q3W) for maximum 6 weeks or until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
62239239|NCT03595592|ACTIVE_COMPARATOR|HPCT|Patients will receive a combination of trastuzumab, pertuzumab, carboplatin and paclitaxel as neoadjuvant therapy for 6 cycles every 3 weeks. Trastuzumab (H) will be delivered on day 1 at the dose of 8 mg/kg loading dose i.v., then 6 mg/kg i.v. Pertuzumab (P) will be delivered on day 1 at the dose of 840 mg loading dose i.v., then 420 mg i.v. Carboplatin (C) will be administered at AUC 2 i.v. on day 1 and day 8. Paclitaxel (T) will be given at 90 mg/m2 i.v. on day 1 and day 8. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab and pertuzumab will then be delivered for 12 additional cycles as adjuvant therapy.
62429814|NCT05138393|EXPERIMENTAL|Active self-corrective exercises|An active self-correction tailored to the individual type of curve and clinical presentation will be applied with the aim to correct the scoliosis in all three planes. Patients will also be informed and educated in task oriented activities of daily living. Training goals are directed towards postural control, spinal stability, muscular stabilization and endurance in corrective postures. Patients will have outpatient sessions once every two weeks the first 3 months and perform the exercises at home in 30-minutes sessions three times per week. Patients are encouraged to continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily. Compliance will be monitored through a mobile application (Physitrack) where the patients record their sessions and can have contact with the research personnel. A cognitive behavioral therapy approach to reinforce physical activity will be performed every 6 months.
62429815|NCT05138393|ACTIVE_COMPARATOR|Observation|Patients are encouraged to continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. A cognitive behavioral therapy approach to reinforce physical activity will be performed every 6 months.
62597066|NCT01785225|EXPERIMENTAL|modified commercial drape Tegaderm (R)|
62597067|NCT06648343|EXPERIMENTAL|Intervention|Intensive cognitive and physical training
62597068|NCT06416787|EXPERIMENTAL|IBI355 dose-3|IBI355 15mg/kg and placebo will be given to the subjects every 4 weeks (6:2)
62597069|NCT06416787|EXPERIMENTAL|IBI355 dose-1|IBI355 1mg/kg and placebo will be given to the subjects every 4 weeks (6:2)
62597070|NCT06416787|EXPERIMENTAL|IBI355 dose-4|IBI355 30mg/kg and placebo will be given to the subjects every 4 weeks (6:2)
62597071|NCT06416787|EXPERIMENTAL|IBI355 dose-2|IBI355 7.5mg/kg and placebo will be given to the subjects every 4 weeks (6:2)
62597072|NCT06649136|ACTIVE_COMPARATOR|methotrexate 25mg s.c.|methotrexate 25mg s.c. weekly dose
62597073|NCT06649136|ACTIVE_COMPARATOR|methotrexate 25mg p.o.|methotrexate 25mg p.o. weekly dose
62597074|NCT05066282||Participants with past PTSD who received IMP in the main study|Non-interventional follow-up study
62597075|NCT05209126|EXPERIMENTAL|Beetroot supplementation|One serving 140 mL of beetroot juice (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
62597076|NCT05209126|PLACEBO_COMPARATOR|Placebo supplementation|One serving 140 mL of beetroot juice placebo (0.08 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
62037443|NCT04150679|ACTIVE_COMPARATOR|group I retrospective non access loop|patients with iatrogenic bile duct injuries, cases treated with hepaticojejunostomy without access loop
62037444|NCT04150679|ACTIVE_COMPARATOR|GROUP II access loop group|patients with iatrogenic bile duct injuries, cases treated with hepaticojejunostomy with duodenojejunostomy access loop
62597077|NCT03788746||Patients diagnosed with advanced urothelial carcinoma|Patients with a confirmed diagnosis of advanced urothelial carcinoma, prior to or during first line therapy, who have available tumor tissue samples collected as part of standard of care
62037445|NCT05154682|ACTIVE_COMPARATOR|Oxycodone Group (Control Group)|Patients will receive oxycodone as needed after surgery
62597078|NCT03565029|EXPERIMENTAL|Medium/low locally advanced rectal cancer|Patients with Stage II (cT3-4 N0) or Stage III (cT1-4, N1-3) locally advanced rectal cancer amenable to Total Mesorectal Excision (TME)/Abdominal-Perineal Amputation
62597079|NCT03885180|EXPERIMENTAL|Extend anticoagulation group|Extended the duration anticoauglation to 12 months
62597080|NCT03885180|NO_INTERVENTION|Stop anticoagulation group|Just stop oral anticoagulation like routine
62597081|NCT00670293||Subjects with anorexia nervosa|Underweight participants with anorexia nervosa who will restore normal weight levels after inpatient treatment will undergo Positron Emission Tomography (PET) using \[11C\]raclopride as well as MRI
62597082|NCT00670293||Healthy weight controls|Participants who are healthy controls will undergo Positron Emission Tomography (PET) using \[11C\]raclopride as well as MRI
62597083|NCT05887570|EXPERIMENTAL|Intervention|"Specific intervention:~Modules for each of the above comprising:~1. didactic lecture on indications and contraindications of procedure, surgical anatomy, patient positioning in the OR, anesthesia type, suture materials and suturing techniques;~2. practical component with hands-on surgical skill training in basic and advanced techniques relevant to each procedure~3. immediate feedback from dedicated educator on technical aspects~4. post-test"
62597084|NCT05887570|PLACEBO_COMPARATOR|Control -|This group receives regular instruction.
62597085|NCT03074435|NO_INTERVENTION|Control arm (LLIN-alone)|The baseline and control intervention (LLIN-alone) correspond to what is implemented in each country by their respective National Malaria Control Programs (NMCP). This include universal coverage with Long-Lasting insecticidal Nets (LLIN). This arm is common to both countries (Burkina Faso and Côte d'Ivoire)
62815356|NCT02845297|EXPERIMENTAL|Safety Run In Phase (only Cohort 1):|The treatment of relapsed and refractory AML patients.
62037446|NCT05154682|ACTIVE_COMPARATOR|Oxycodone+ Naproxen/Acetaminophen (Study Group)|each patient will receive oxycodone plus acetaminophen and naproxen for 2 weeks after surgery
62037447|NCT05787639|EXPERIMENTAL|Treatment|Stereotactic radiation therapy (SBRT (8GyX3)) will be delivered to gross tumor volume (GTV) +3mm, followed by Pembrolizumab 200 mg IV and Evorpacept 45 mg/kg IV every three weeks x 2 cycles followed by surgical resection of primary tumor and neck dissection.
62037448|NCT02947126|EXPERIMENTAL|Cystic Fibrosis (HS, IS)|"CF subjects: ages 12 or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator. Subjects receive HS dose on first imaging day and IS dose on the second imaging day,~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml), Inhaled Hypertonic Saline (4ml)"
62037449|NCT02947126|EXPERIMENTAL|Cystic Fibrosis (IS, HS)|"CF subjects: ages 12 or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator. Subjects receive IS dose on first imaging day and HS dose on the second imaging day.~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml), Inhaled Hypertonic Saline (4ml)"
62037450|NCT02947126|EXPERIMENTAL|Parents of CF subjects|"Ages 18 and older, biological parent of a CF patient who is also enrolled in the study~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml)"
62037451|NCT02947126|EXPERIMENTAL|non CF controls|"Ages 18 and older with no history of lung disease~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml)."
62037452|NCT03221387|OTHER|Nasal high flow with oxygen|While in the clinic High Flow Nasal Cannula oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep arterial oxygen saturation (SaO2) \> 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience. The subject will be discharged to home and instructed to use the high flow nasal cannula system at night and during the daytime while at home and resting.
62037453|NCT02375620|EXPERIMENTAL|PEG-somatropin: Low dose|0.1 mg/(kg.w), once per week for 52 weeks.
62239240|NCT03595592|EXPERIMENTAL|ACy followed by HPCT and atezolizumab|Patients will receive a combination of doxorubicin (A, 60 mg/m2 i.v.), cyclophosphamide (C, 600 mg/m2 i.v.) and atezolizumab (1200 mg i.v.) on day 1 every 3 week for 3 cycles. Subsequently they will be given trastuzumab on day 1 (H, at the loading dose of 8 mg/kg i.v. then 6 mg/kg i.v.), pertuzumab on day 1 (P, at the loading dose of 840 mg .v., then 420 mg i.v.), carboplatin (C) at AUC 2 i.v. on day 1 and day 8, paclitaxel (T) at 90 mg/m2 i.v. on day 1 and day 8, and atezolizumab 1200 mg i.v. on day 1 for 3 cycles every 3 weeks. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab and pertuzumab will then be delivered for 15 additional cycles and atezolizumab for 12 additional cycles as adjuvant therapy.
62429816|NCT05105711|EXPERIMENTAL|Primary care providers|Providers who treat 11-12 year old adolescent patients in participating Kaiser Permanente Washington pediatric and family medicine practices.
62429817|NCT01838161|ACTIVE_COMPARATOR|Part I|Interview questions will focus on reticence to vaccinate children.
62429818|NCT01838161|EXPERIMENTAL|Part II|"We will pilot the vaccination vignettes in a health department (clinical) setting with eligible parents of adolescents.~* a pretest survey~* the video vignette~* and a post-test survey measuring intention to receive appropriate adolescent vaccines"
62597086|NCT03074435|EXPERIMENTAL|LLIN + indoor residual sprayings|LLIN+IRS arm consisted in applying, in addition to LLINs, IRS with Actellic® 300CS (Syngenta AG, Basel, Switzerland) at a target dosage of 1 g. of active ingredient (pirimiphos-methyl) per m² in every houses of the selected villages. This arm is common to both countries (Burkina Faso and Côte d'Ivoire)
62815357|NCT02845297|EXPERIMENTAL|Cohort 2|The treatment of newly diagnosed AML patients (≥ 65 years) who are not candidates for intensive induction chemotherapy.
62815358|NCT01352117|ACTIVE_COMPARATOR|Arm A: ART alone or with delayed ET|Participants were prescribed ART (co-formulated efavirenz/emtricitabine/tenofovir disoproxil fumarate, EFV/FTC/TDF) for 96 weeks. Arm A participants who experienced KS progression on ART alone could receive ET in addition to EFV/FTC/TDF in Step 2 of the study.
62037454|NCT02375620|EXPERIMENTAL|PEG-somatropin: High dose|0.2 mg/(kg.w), once per week for 52 weeks.
62037455|NCT02293044|EXPERIMENTAL|Crest® Sensi-Stop™ Strips|Self Applied
62037456|NCT00617344|EXPERIMENTAL|CYD Dengue Vaccine 5555 Formulation|Participants received 3 doses of CYD dengue vaccine (5555 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
62037457|NCT00617344|EXPERIMENTAL|CYD Dengue Vaccine 5553 Formulation|Participants received 3 doses of CYD dengue vaccine (5553 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
62037458|NCT00617344|EXPERIMENTAL|CYD Dengue Vaccine 4444 Formulation|Participants received 3 doses of CYD dengue vaccine (4444 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
62037459|NCT02339831|ACTIVE_COMPARATOR|active motion device|An active motion device (CAM) known as a CAMOPED was given after surgery. The device was used for 3 sessions of 20 minutes for 3 weeks.
62429819|NCT01838161|EXPERIMENTAL|Part III|"* enhanced video educational intervention (video vignettes + standard of care vaccine event)~* standard of care vaccination event"
62429820|NCT04981626||Control|"* Females~* Age : matched for the AN group~* No present or past eating disorders~* No past or current psychotic disorders~* No current substance abuse or dependence.~* No current psychiatric medication"
62429821|NCT04981626||AN group|"* Females~* 16 years ≤ Age ≤ 25 years~* Diagnostic of AN according to DSM-5 criteria~* No past or current psychotic disorders~* No current substance abuse or dependence (excluding tobacco).~* No current psychiatric medication"
62429822|NCT00475111|EXPERIMENTAL|1|People in Group 1 will participate in CBT for Pain (CBT-P), which will focus on altering thought processes as a way to cope more effectively with pain.
62429823|NCT00475111|EXPERIMENTAL|2|People in Group 2 will participate in Mindfulness Medication for Emotion Regulation (MM-ER), a type of CBT that focuses on being more aware of one's emotions and regulating them.
62429824|NCT00475111|EXPERIMENTAL|3|Group 3 participants will serve as controls and receive educational information on the causes of, course of, and treatment for RA.
62429825|NCT02528630|EXPERIMENTAL|Exercise group|Performed a session regarding joint protection and energy conservation and a progressive resistance strength training program for intrinsic muscles of the hand for 12 weeks.
62429826|NCT02528630|ACTIVE_COMPARATOR|Control group|Performed a session regarding joint protection and energy conservation
62597087|NCT03074435|EXPERIMENTAL|LLIN + Larvicide|The intervention consists in treating Anopheles breeding sites with BTI biological larvicide, in addition to LLINs. This arm was implemented in Côte d'Ivoire only.
62815359|NCT01352117|EXPERIMENTAL|Arm B: ART with immediate ET|Participants were prescribed ART (co-formulated efavirenz/emtricitabine/tenofovir disoproxil fumarate, EFV/FTC/TDF) for 96 weeks with immediate ET for up to 16 weeks.
62815360|NCT00965601|ACTIVE_COMPARATOR|CTB Group|Subjects will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
62239241|NCT03595592|EXPERIMENTAL|HPCT and atezolizumab|Patients will receive a combination of trastuzumab, pertuzumab, carboplatin, paclitaxel and atezolizumab as neoadjuvant therapy for 6 cycles every 3 weeks. Trastuzumab (H) will be delivered on day 1 at the dose of 8 mg/kg loading dose i.v., then 6 mg/kg i.v. Pertuzumab (P) will be delivered on day 1 at the dose of 840 mg loading dose i.v., then 420 mg i.v. Carboplatin (C) will be administered at AUC 2 i.v. on day 1 and day 8; paclitaxel (T) will be given at 90 mg/m2 i.v. on day 1 and day 8; atezolizumab at the dose of 1200 mg i.v. on day 1. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab, pertuzumab and atezolizumab will then be delivered for 12 additional cycles as adjuvant therapy.
62239242|NCT03641053|EXPERIMENTAL|Honey|0.05 cc of honey (Madu Nusantara®) per 1 cm of laceration, given every predetermined wound care schedule
62239243|NCT03641053|ACTIVE_COMPARATOR|Povidone-iodine|0.05 cc of povidone-iodine per 1 cm of laceration, given every predetermined wound care schedule
62815361|NCT00965601|NO_INTERVENTION|Usual Care|Subjects will not receive any type of intervention
62815362|NCT05594550||28-day survival|Alive 28 days after intensive care admission
62239244|NCT03641053|ACTIVE_COMPARATOR|Paraffin gauze|1 layer of paraffin gauze, given every predetermined wound care schedule
62239245|NCT02378454||Cystic fibrosis adults (CF)|No treatment, comparison of LCI values obtained with two devices
62239246|NCT02378454||Healthy adults (HC)|No treatment, comparison of LCI values obtained with two devices Free of respiratory disease or others diseases likely to disturb respiratory system.
62037460|NCT02339831|ACTIVE_COMPARATOR|CPM passive motion device|A continuous passive motion device (CPM) given after surgery. The device bends and moved the knee passively. It was used for 4 hours daily for 3 weeks.
62037461|NCT02046330|EXPERIMENTAL|Deep Brain Stimulation|Device implantation (Deep Brain Stimulation Model 3387 Model 3389)
62239247|NCT03952806|EXPERIMENTAL|Verdiperstat|"Participants received verdiperstat 300 mg tablet orally once daily for 1 week, followed by 300 mg twice daily for 1 week, and then 600 mg twice daily for the remaining 46 weeks of the double-blind phase.~Participants who completed the double-blind phase were offered the opportunity to enroll in an open-label extension (OLE) phase to continue verdiperstat 600 mg twice daily for 48 weeks."
62239248|NCT03952806|PLACEBO_COMPARATOR|Placebo|Participants received placebo matching with verdiperstat for 48 weeks. Participants who completed the double-blind phase were offered the opportunity to enroll in an OLE phase to receive verdiperstat 600 mg tablet orally twice daily for 48 weeks.
62239249|NCT02442713|EXPERIMENTAL|fluvoxamine|fluvoxamine: 50-300mg/day
62239250|NCT04566627|EXPERIMENTAL|YSLQQ group|"Schools in this group implemented Yo Sé Lo Que Quiero program. This is the cultural adaptation of the Unplugged program. This is a preventive intervention to reduce tobacco, alcohol, and marihuana use among adolescents. It consists of 12 sessions, delivered by a trained facilitator on a weekly basis."
62239251|NCT04566627|NO_INTERVENTION|Control Group|Schools in this group implemented the usual preventive actions to reduce substance use. Usually, these actions are not manualized.
62239252|NCT05134090||Percutaneous laparoscopy|Laparoscopy with percutaneous grasp (2.9 mm).
62239253|NCT05134090||Conventional laparoscopy|Conventional laparoscopy with conventional laparoscopic trocars (10 or 5 mm).
62239254|NCT05196672|EXPERIMENTAL|Virtual reality|Participants will receive virtual reality for 30 minutes before bedtime and then will be placed on an eye mask for a whole night's sleep for consecutive two days or until discharge from ICU. A total treatment dosage of 60 minutes is required.
62239255|NCT05196672|EXPERIMENTAL|Eye masks|Participants will receive eye masks during their sleep for consecutive two days or until discharge from ICU.
62239256|NCT05196672|NO_INTERVENTION|Control group|The control group only receive routine care.
62239257|NCT02926469|NO_INTERVENTION|Standard Care|For patients presenting in labor and desiring standard care (natural childbirth without pain medications, systematic distraction, or alternative therapies) the patient will experience their contractions. Afterwards they will answer pain and anxiety questionnaires.
62239258|NCT02926469|EXPERIMENTAL|Virtual Reality|For patients presenting in labor and desiring standard care (natural childbirth without pain medications, systematic distraction, or alternative therapies) the patient will experience their contractions while using immersive Virtual Reality.Afterwards they will answer pain and anxiety questionnaires.
62239259|NCT05511896|EXPERIMENTAL|Intermittent trunk flexion|60-min intermittent trunk flexion protocol.
62239260|NCT01522482|EXPERIMENTAL|High saturated fat meal|
62239261|NCT01522482|EXPERIMENTAL|Saturated fatty acid and fish oils meal|Equivalent to two portions of oily fish
62815363|NCT05594550||28-day death|Deceased 28 days after intensive care admission
62239262|NCT01522482|ACTIVE_COMPARATOR|High unsaturated fat meal|Provided a fatty acid profile representative of a typical UK diet
62239263|NCT02833480|EXPERIMENTAL|Fluticasone group|Advair (fluticasone) 250 mcg to be administered twice daily via Diskus for 12 weeks
62239264|NCT02833480|EXPERIMENTAL|Budesonide group|Symbicort (budesonide) 400 mcg to be administered twice daily via Turbuhaler for 12 weeks
62239265|NCT02833480|ACTIVE_COMPARATOR|Formoterol group|Oxeze (formoterol) 12 microg to be administered twice daily via Turbuhaler for 12 weeks
62239266|NCT03872453|EXPERIMENTAL|Zavegepant 5 mg|Participants administered a single intranasal dose of zavegepant 5 mg on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization. The dose was administered using Aptar Unidose System (UDS) liquid spray device.
62815364|NCT06630598|EXPERIMENTAL|VEGA Family Violence Education Resources|Students in this arm will receive access to the online VEGA Family Violence Education Resources and will be asked to complete modules covering information about family violence in Canada, creating safety for survivors in clinical settings, recognizing and responding to child maltreatment and intimate partner violence, three interactive learning scenarios, and voices of those with lived experiences of family violence.
62815365|NCT06630598|NO_INTERVENTION|No Training|Students in this arm will not receive access to the training until the end of the pre- and post-training data collection for the Arm 1 group.
62815366|NCT04175249|EXPERIMENTAL|Pizza meal challenge|Vegetarian pizza containing 10 grams of salt
62239267|NCT03872453|EXPERIMENTAL|Zavegepant 10 mg|Participants administered a single intranasal dose of zavegepant 10 mg on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization. The dose was administered using Aptar UDS liquid spray device.
62239268|NCT03872453|EXPERIMENTAL|Zavegepant 20 mg|Participants administered a single intranasal dose of zavegepant 20 mg on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization. The dose was administered using Aptar UDS liquid spray device.
62239269|NCT03872453|PLACEBO_COMPARATOR|Placebo|Participants administered a single intranasal dose of zavegepant-matching placebo on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization. The dose was administered using Aptar UDS liquid spray device.
62239270|NCT00238667|ACTIVE_COMPARATOR|Anti-platelet therapy|Aspirin, Dipyridamole, clopidogrel alone or in dual therapy
62239271|NCT00238667|ACTIVE_COMPARATOR|Anti-coagulant|Warfarin, unfractionated heparin, enoxaparin, dalteparin, tinzaparin aiming for an INR in range of 2-3. Local protocols for Heparin can be used
62239272|NCT04548414||Sepsis group|The patients in this group are diagnosed sepsis with the sepsis 3.0 definition.
62239273|NCT04548414||Control group|The recruited volunteers in this group are healthy.
62239274|NCT05741346|EXPERIMENTAL|BCX9930|All subjects receive BCX9930 for 96 weeks
62239275|NCT04460677|EXPERIMENTAL|Emotional Support Plan (ESP) + Weekly Monitoring|This will involve weekly assessments without prompting to use the plan.
62239276|NCT04460677|EXPERIMENTAL|Emotional Support Plan (ESP) + 4x Daily Monitoring|Participants in this arm will be prompted on their phones 4x/day randomly, to report on activities, mood, suicidal ideation, distress level and ESP use since the last prompt
62239277|NCT05118555||Type 1|"Patients scheduled to undergo a routine clinical MR examination of the relevant anatomical regions and/or disease type will be identified from MRI department schedules.~The new MR technique will be used to acquire additional data in patients undergoing a routine MR examination. The routine MR examination will be conducted according to the standard protocol."
62597088|NCT03074435|EXPERIMENTAL|LLIN+ One-health Ivermectin|This arm consists in monthly injections of ivermectin to peri-domestic farm animals (mammals) during 4 consecutive months, oin addition to LLINs. This arm was implemented in Burkina Faso only.
62815367|NCT00805350|EXPERIMENTAL|Eplivanserin|Eplivanserin 5 mg/day
62815368|NCT00805350|PLACEBO_COMPARATOR|Placebo|Placebo of Eplivanserin 5 mg/day
62815369|NCT06435936|EXPERIMENTAL|SAB-176 1 mL|1 mL (\~75 mg) SAB-176 dose
62037462|NCT01954979|EXPERIMENTAL|Abatacept|Abatacept will be administered for a total of 6 doses. Doses 1-3 will be administered at two week intervals (+/-2 days). One month following Dose 3, abatacept will be administered, and given at four-week intervals (+/-2 days) for three doses (Doses 4-6.) Patients will be followed for toxicity for 28 days following last dose of Abatacept. Patients will then be seen monthly for six months.
62815370|NCT06435936|PLACEBO_COMPARATOR|Placebo 1mL|Normal Saline
62815371|NCT06435936|EXPERIMENTAL|SAB-176 3mL|3 mL (\~225 mg) SAB-176 dose
62239278|NCT05118555||Type 2|"Patients with the relevant disease type and no contraindications to MRI will be identified by delegated radiologists in clinics.~An additional MR examination will be scheduled; this examination is in addition to any examinations that the patient may undergo as part of their clinical care. The MR examination will be conducted using the new MR technique; standard MR techniques may also be used for comparison."
62239279|NCT05118555||Type 3|"Normal volunteers who are members of staff or students at RMH/ICR will be invited to participate using a mailing list. Exceptionally employees of other NHS Trusts and Academic Institutions will be allowed to participate if they are in collaboration with RMH/ICR.~An MR examination will be conducted using the new MR technique; standard MR techniques may also be used for comparison."
62239280|NCT01068925|EXPERIMENTAL|ARM 1|"Arm 1:~GSK1349572 QD for 5 days (Treatment A)."
62239281|NCT01068925|EXPERIMENTAL|ARM 2|ARM 2: TPV/RTV 500/200mg BID (Treatment B).
62239282|NCT01068925|EXPERIMENTAL|ARM 3|ARM 3: GSK1349572 50mg QD and TPV/RTV 500/200mg BID (Treatment C).
62239283|NCT01535014|EXPERIMENTAL|Dietressa (2 tablets 3 times daily) for 24 weeks|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Dietressa (2 tablets 3 times daily) for 24 weeks.
62815372|NCT06435936|PLACEBO_COMPARATOR|Placebo 3mL|Normal Saline
62815373|NCT06435936|EXPERIMENTAL|SAB-176 5mL|5 mL (\~375 mg) SAB-176 dose
62815374|NCT06435936|PLACEBO_COMPARATOR|Placebo 5mL|Normal Saline
62815375|NCT06435936|EXPERIMENTAL|SAB-176 20mL|20 mL (\~1500 mg) SAB-176 dose
62815376|NCT06435936|PLACEBO_COMPARATOR|Placebo 20mL|Normal Saline
62815377|NCT05183178|ACTIVE_COMPARATOR|Ticagrelor|Current standard of care
62815378|NCT05183178|EXPERIMENTAL|Prasugrel|New standard of care
62597089|NCT03074435|EXPERIMENTAL|LLIN + Behaviour Change Communication|BCC complementary intervention (LLIN+BCC arm) was designed to target the following behaviors in the human population: (i) everyone sleep under an LLIN every night, (ii) every household and community member cleans up its environment to limits mosquito proliferation, (iii) every pregnant woman asks for, and takes the intermittent preventive treatment of malaria during pregnancy (ITP) and, (iv) people in charge of \<5 y/o children come to see an health worker within 24h in case of fever. The intervention involve one health worker from the community per 35 households. Every health worker has the objective to perform 15 home visits (15-20 min), 20 interpersonal talks (15-20 min) and 4 group talks (15-30 min) per months.
62597090|NCT01806961||clearance at end of trial SP848-AK-1101|no trial medication during this follow-up trial
62597091|NCT03664310|EXPERIMENTAL|FSET Anxiety and Sleep Treatment|The FSET Anxiety and Sleep Treatment (FAST) is a brief, 45-minute computerized intervention that can be accessed by any device connected to the Internet. The majority of the information is delivered via text. The program contains some interactive features such as quizzes, which direct participants to content, personalized to the individual user (for example screenshots, see Figure 2). FAST contains four modules: motivation, psychoeducation, behavioral tools, and behavior change.
62597092|NCT03664310|ACTIVE_COMPARATOR|Control|The control condition is the Physical Health Education Treatment (PHET) used in several of our laboratory's prior studies (Schmidt, Capron, Raines, \& Allan, 2014). PHET is also a 45-minute computerized intervention, including audio and visual features as well as comprehension quizzes.
62597093|NCT00915486|EXPERIMENTAL|Good Standard of Care (GSoC)|Twice per week
62597094|NCT00915486|EXPERIMENTAL|GSoC + vehicle|Twice per week
62597095|NCT00915486|EXPERIMENTAL|GSoC + I-020201 (33microg)|Twice per week
62597096|NCT00915486|EXPERIMENTAL|GSoC + I-020201 (100microg)|Twice per week
62597097|NCT00915486|EXPERIMENTAL|GSoC + I-020201 (300microg)|Twice per week
62815379|NCT04310540|EXPERIMENTAL|Diagnostic (gallium Ga 68 gozetotide PET/MRI, PET/CT, biopsy)|Patients receive gallium Ga 68 gozetotide IV, and undergo PET/MRI over 60 minutes or PET/CT over 30 minutes at baseline and 12 weeks after completion of hepatic locoregional therapy or 8-12 weeks after completion of systemic therapy. Patients undergoing hepatic locoregional therapy may also undergo a liver biopsy.
62429827|NCT03906149|EXPERIMENTAL|Whole-body hyperthermia + standard medical care|Whole-body hyperthermia will be applied 2 times during 4 weeks in addition to guideline-based standard medical care for depression (anti-depressive drug treatment in combination with psychotherapy). At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.
62429828|NCT03906149|ACTIVE_COMPARATOR|Standard medical care|Participants will maintain standard medical care for depression (anti-depressive drug treatment in combination with psychotherapy). At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after randomization.
62597098|NCT05814094|ACTIVE_COMPARATOR|Restrictive Transfusion Trigger Group|if a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L.
62597099|NCT05814094|ACTIVE_COMPARATOR|Liberal Transfusion Trigger Group|if a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused. Additional units can be prescribed to raise the Hb concentration to greater than 90g/L
62597100|NCT05566873|ACTIVE_COMPARATOR|PA Education plus human and planetary health information|"Participants will continue to receive the remote light touch physical activity education program that they have been receiving for the past several years along with additional remote health education information to control for nonspecific factors (staff attention, participant time)."
62597101|NCT05566873|EXPERIMENTAL|PA Education plus Our Voice citizen science|"Participants will receive the remote light touch physical activity education program in combination with the remote Our Voice citizen science program aimed at identifying and addressing physical and social environmental barriers to and enablers of regular physical activity."
62597102|NCT06060613|EXPERIMENTAL|Participants with advanced solid tumors|Participants will receive conditioning therapy prior to administration of OBX-115 regimen.
62597103|NCT04212208|EXPERIMENTAL|Intervention group|EMLA cream + High-frequency USG probe kept for 15minutes.After 15 minutes IV cannulation will be done and Pain intensity assessment will be done using Faces Pain Scale-Revised (FPS-R)
62597104|NCT04212208|ACTIVE_COMPARATOR|Control group|EMLA cream+Low frequency USG probe kept over the cream for 15 minutes. IV cannulation will be done and Pain intensity assessment will be done using Faces Pain Scale-Revised (FPS-R)
62597105|NCT04792463||Patients with personal and/or family history suggestive of hereditary BAP1|Personal history of one cancer reported in BAP1 cancer predisposition syndrome and family history of at least two 1st or 2nd degree relatives with cancer reported in hereditary BAP1 cancer predisposition syndrome such as UM, CM, mesothelioma, RCC, cholangiocarcinoma, hepatocellular carcinoma and meningioma
62815380|NCT01275352|ACTIVE_COMPARATOR|Arm 1|Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele
62239284|NCT01535014|EXPERIMENTAL|Dietressa (1 tablet 6 times daily) for 24 weeks|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Dietressa (1 tablet 6 times daily) for 24 weeks.
62597106|NCT04792463||Pathogenic, likely pathogenic variants in BAP1 and variants of uncertain significance|"Affected and unaffected individuals with pathogenic or likely pathogenic variant in BAP1 and their family members~Patients with personal family history of any of the BAP1 associated cancer and a variant of uncertain significance of BAP1"
62597107|NCT02767492|EXPERIMENTAL|BioDRestore™|BioDRestore™ Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from amniotic tissues. 2cc will be injected in the knee joint.
62597108|NCT02767492|ACTIVE_COMPARATOR|Corticosteroid|Kenalog (40 mg of 40 mg/ml) will be the steroid utilized as the active comparator to be injected in the knee joint.
62597109|NCT06148428||Normal group|"Based on the Hospital Anxiety and Depression scale anxiety sub-score (HADS anxiety sub-score, the seven-item anxiety sub-score for scaling a patient's anxiety levels before LASIK)~Patients who had a sub-score of ≤7 denotes no anxiety scale (normal)."
62597110|NCT06148428||Borderline anxiety group|"Based on the Hospital Anxiety and Depression scale anxiety sub-score (HADS anxiety sub-score, the seven-item anxiety sub-score for scaling a patient's anxiety levels before LASIK)~Patients who had a sub-score of 8-10 denotes doubtful anxiety scale (borderline)."
62239285|NCT01535014|PLACEBO_COMPARATOR|Placebo (2 tablets 3 times daily)|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Placebo (2 tablets 3 times daily) for 24 weeks.
62239286|NCT01535014|PLACEBO_COMPARATOR|Placebo (1 tablet 6 times daily)|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Placebo (1 tablet 6 times daily) for 24 weeks.
62239287|NCT02178553|ACTIVE_COMPARATOR|Epidural|In the epidural catheter (TEC) group, a thoracic epidural catheter will be placed at the level of T6-T8 and advanced 5 cm into the epidural space and a 3 ml test dose of lidocaine 1.5% will be administered before the induction of general anesthesia. Patients will be excluded from the study if the catheter cannot be placed. A bolus dose of 0.5 mg hydromorphone plus 4.5 ml 0.125% bupivacaine will be administered before surgical incision. An epidural infusion of 0.075% bupivacaine and 10 mcg/ml hydromorphone, prepared by the hospital pharmacy, will be started intraoperatively at a rate of 5 ml/hr.
62239288|NCT02178553|ACTIVE_COMPARATOR|Intercostal bupivicaine (Exparel)|In the intercostal block (ICB) group, liposomal bupivacaine 1.3% (4 ml) will injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and one interspace above and below. In addition, liposomal bupivacaine 1.3 % (4 ml) will be injected at each of the chest tube exit sites. Thus, a total of 20 ml liposomal bupivacaine 1.3% (260 mg) will be administered.
62239289|NCT00973154|ACTIVE_COMPARATOR|Prednisone|Drug
62239290|NCT00973154|PLACEBO_COMPARATOR|Placebo|
62429829|NCT02834065|ACTIVE_COMPARATOR|Deep Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature ≤20 degrees Celsius
62429830|NCT02834065|ACTIVE_COMPARATOR|Low Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature 20.1 - 24.0 degrees Celsius
62815381|NCT01275352|ACTIVE_COMPARATOR|Arm 2|Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele
62815382|NCT01275352|PLACEBO_COMPARATOR|Arm 3|Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele
62815383|NCT01275352|PLACEBO_COMPARATOR|Arm 4|Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele
62815384|NCT01109264|EXPERIMENTAL|Bendamustine Hydrochloride|
62815385|NCT01109264|ACTIVE_COMPARATOR|Chlorambucil|
62815386|NCT00236223|EXPERIMENTAL|1|
62815387|NCT00236223|PLACEBO_COMPARATOR|2|
62815388|NCT06241742|ACTIVE_COMPARATOR|HT-6184 Treatment Arm|
62815389|NCT06241742|PLACEBO_COMPARATOR|HT-6184 Placebo|
62239291|NCT00770237|EXPERIMENTAL|Cues|Outcome Measures During cue trials, primary measures include craving (TCQ-SF, VAS), mood (mood form, VAS), and autonomic (heart rate, blood pressure, skin conductance and temperature) responsivity. During self-administration trials, primary measures include breakpoint (final ratio completed), total number of responses, and number of cigarette puffs earned and taken. Secondary measures include baseline smoking history, mood form, TCQ-SF, CO, FTND, and urinary cotinine and 3-hydroxycotinine (3-HC).
62597111|NCT06148428||Anxious group|"Based on the Hospital Anxiety and Depression scale anxiety sub-score (HADS anxiety sub-score, the seven-item anxiety sub-score for scaling a patient's anxiety levels before LASIK)~Patients who had a sub-score of 11-21 is abnormal and denotes a definite anxiety scale (case)."
62597112|NCT00792246|EXPERIMENTAL|graft versus host disease|Patients receiving oral voriconazole will be switched to intravenous voriconazole. Pharmacokinetics will be determined after each formulation.
62597113|NCT00792246|EXPERIMENTAL|No graft versus host disease|Patients receiving oral voriconazole will be switched to intravenous voriconazole. Pharmacokinetics will be determined after each formulation.
62597114|NCT04271319|EXPERIMENTAL|BEST™ Pro-Sport Ultra® microcurrent device|Participants will receive treatment with an active electrical stimulation device for 7 in-clinic treatments over 2 weeks.
62597115|NCT04271319|SHAM_COMPARATOR|Electrical Stimulation - Sham Comparator|Participants will receive treatment with a sham electrical stimulation device for 7 in-clinic treatments over 2 weeks.
62815390|NCT03803293|OTHER|Primary cohort|All eligible Biobank participants that receive the majority of their care at Mayo Clinic based on EHR length and depth had pharmacogenomic testing done.
62815391|NCT01359488|EXPERIMENTAL|VRS-317 Safety Arm 1|"VRS-317 Single injection SC of dose level 1 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume"
62815392|NCT01359488|EXPERIMENTAL|VRS-317 Safety Arm 2|"VRS-317 Single injection SC of dose level 2 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume"
62815393|NCT01359488|EXPERIMENTAL|VRS-317 Safety Arm 3|"VRS-317 Single injection SC of dose level 3 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume"
62815394|NCT01359488|EXPERIMENTAL|VRS-317 Safety Arm 4|"VRS-317 Two injections SC of dose level 4 (based on 90 kg patient)~Placebo Two SC injection Dose matched to treatment volume"
62815395|NCT01359488|EXPERIMENTAL|VRS-317 Safety Arm 5|"VRS-317 Two injections SC of dose level 5 (based on 90 kg patient)~Placebo Two SC injections Dose Volume matched to active treatment volume"
62815396|NCT05123872|EXPERIMENTAL|prefrontal tDCS at home|trancranial direct current stimulation 30 sessions within 6 weeks (treatment on working days) 2mA with cathode on the right and anode an the left side
62815397|NCT04040764|EXPERIMENTAL|Uncemented Tritanium Knee Replacement|30 participants will be randomly allocated to receive an uncemented Tritanium total knee replacement.
62815398|NCT04040764|ACTIVE_COMPARATOR|Cemented Triathlon Knee Replacement|30 participants will be randomly allocated to receive standard Triathlon cemented total knee replacements.
62815399|NCT04324034|EXPERIMENTAL|vNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is vaginal surgery with a natural approach. The GelPOINT V-path transvaginal access platform is used. It is a device designed to be placed transvaginally to establish a pathway for the insertion of minimally invasive instruments while maintaining insufflation to perform diagnostic or operative procedures. This device also allows a passage for the extraction of operating parts.
62815400|NCT04324034|ACTIVE_COMPARATOR|laparoscopy|conventional laparoscopy
62815401|NCT04605601|EXPERIMENTAL|Study Group|
62815402|NCT04605601|OTHER|Control Group|
62815403|NCT06525428|EXPERIMENTAL|a first-line cohort A and a second-line cohort B|
62815404|NCT01493323|EXPERIMENTAL|Control|
62239292|NCT03040310|EXPERIMENTAL|Back Rx program|Study patients will use their smartphone apps to view their Back Rx program content, exercises, and videos.
62815405|NCT01493323|EXPERIMENTAL|Depressive attempters|
62815406|NCT03817164|ACTIVE_COMPARATOR|Active Treatment|Active stimulation pulsed current delivered over 15 minutes.
62815407|NCT03817164|SHAM_COMPARATOR|Control Treatment|Active stimulation pulsed current (alternative frequency) delivered over 15 minutes.
62815408|NCT02412306|EXPERIMENTAL|Blinatumomab 9-28 µg/day Phase 1b Adult Population|Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
62815409|NCT02412306|EXPERIMENTAL|Blinatumomab 5-15 µg/m^2/day Phase 1b Pediatric Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
62815410|NCT02412306|EXPERIMENTAL|Blinatumomab 9-28 µg/day Phase 2 Adult Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
62815411|NCT02412306|EXPERIMENTAL|Blinatumomab 9-28 µg/day Adult Expansion Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
62815412|NCT02412306|EXPERIMENTAL|Blinatumomab 5-15 µg/m^2/day Pediatric Expansion Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
62815413|NCT05697770|EXPERIMENTAL|Sodium bicarbonate|Sodium bicarbonate 8.4% (1000 mEq/L) will be diluted in a D5W solution (500 mL bag). For preparation, 300 mL of D5W will be removed and 300 mL of sodium bicarbonate 8.4% added to prepare the bicarbonate solution in a total volume of 500 mL (final concentration: 600 mEq/L).
62239293|NCT03057171||Gastric ulcer|patients who will undergo EGD for gastric ulcer
62815414|NCT05697770|ACTIVE_COMPARATOR|5% dextrose|Standard 500 mL bag of D5W.
62815415|NCT03045744|EXPERIMENTAL|incomplete SCI patients|
62037463|NCT01072461|ACTIVE_COMPARATOR|Train Paretic Hand and Arm Separate|Eight three hour training sessions of robotically facilitated hand and arm training in complex virtual environments, using activities that train the fingers in isolation and other activities that train the arm in isolation.
62037464|NCT01072461|EXPERIMENTAL|Train Paretic Hand and Arm Together|
62037465|NCT01072461|EXPERIMENTAL|Train Both Hands Together in VE|
62239294|NCT03057171||Duodenal ulcer|patients who will undergo EGD for duodenal ulcer
62239295|NCT03057171||Stomach cancer|patients who will undergo EGD for stomach cance
62239296|NCT03057171||health individuals|patients who will undergo screening EGD
62239297|NCT06459323|EXPERIMENTAL|Laparoscopic cholecystectomy within first 72hours|
62239298|NCT06459323|EXPERIMENTAL|Laparoscopic cholecystectomy beyond first 72hours|
62239299|NCT02795416|EXPERIMENTAL|"Secukinumab Cosentyx TM"|"Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month"
62239300|NCT01746680|EXPERIMENTAL|Tacrolimus with Methotrexate|Subjects have tacrolimus per oral once daily with methotrexate for 24weeks. Tacrolimus increased dosing regimen: 1mg for 0\~4 weeks, 2mg for 4 weeks\~8 weeks, 3mg for 8 weeks\~24 weeks
62239301|NCT06528652||Hip-Hop (Cohort)|The hip-hop dancer group will be assigned to core stability and balance performance tests as well as injury surveillance for three months.
62239302|NCT06528652||Non-dancer (Control)|This control group will be assigned to core stability and balance performance tests only for comparison with the hip-hop dancer group and will not be subject to any injury monitoring.
62239303|NCT04174547||Clonal hematopoiesis (AIM 1)|"The investigators will analyze the genomic features of clonal dominance and ineffective hematopoiesis in elderly subjects enrolled in two population-based studies: Health and Anemia study \[Haematologica 2010;95:1849\], and Monzino 80-plus study \[BMC Neurol.2011;11:54, validation cohort\]. Overall in 5000 subjects aged \>65y peripheral blood samples (in some cases collected at different time points) will be available for biological investigations."
62239304|NCT04174547||Innovative predictive models in MDS (AIM2)|"The investigators will base on large retrospectove adult MDS population with comprehensive genomic and clinical data available within EuroBloodNet network (data on 3000 patients will be available), to accurately predict clinical outcomes in MDS at individual-patient level.~The investigators plan to define 2 homogenous clinical cohorts (learning and testing cohort at 2:1 ratio) in order to define distinct patterns and genetic groups within MDS and to independently validate their predictive value."
62239305|NCT04174547||Predictive biomarkers in MDS (AIM3)|The investigators will analyze MDS patients enrolled in prospective clinical trials conducted within the EuroBloodNet network. Overall 350 patients treated with azacitidine from prospective studies (VidazaAllotrial, RELAZA02 trial, AZA-Ida study, intensive AZA study) will be available for biological investigations to define biomarkers associated with clinical response. Validation of biomarkers will then be performed in an independent cohort including 320 patients (AZA-PLUS trial). In all these studies, biobanking of bone marrow (BM) and peripheral blood (PB) samples has been systematically performed, providing a unique resource to be investigated within this proposal.
62037466|NCT02901015|OTHER|Schizophrenic patients group 1|80 patients evaluated in the Fondamental Expertise Center for schizophrenia Network (8 centers in France).
62037467|NCT02901015|OTHER|Schizophrenic patients group 2|80 patients evaluated in the Fondamental Expertise Center for schizophrenia Network (8 centers in France).
62037468|NCT05356858|EXPERIMENTAL|zanubrutinib|zanubrutinib orally, 80mg bid for 1 year
62037469|NCT05607095|EXPERIMENTAL|Participants with Metastatic Uveal Melanoma|Participants have metastatic uveal melanoma who will undergo surgical excision to generate LN-144/LN-145
62037470|NCT05607095|EXPERIMENTAL|Participants with Metastatic Sarcoma|Participants have metastatic sarcoma who will undergo surgical excision to generate LN-144/LN-145
62239306|NCT01251120|EXPERIMENTAL|1|
62239307|NCT01251120|ACTIVE_COMPARATOR|2|
62239308|NCT03362879||Participants with advanced Parkinson's disease|Participants with advanced Parkinson's disease on current treatment with levodopa-carbidopa intestinal gel (LCIG) for at least 12 months.
62239309|NCT00704002|EXPERIMENTAL|A|antegrade intramedullary splinting
62239310|NCT00704002|ACTIVE_COMPARATOR|B|conservative treatment
62239311|NCT00922103|EXPERIMENTAL|INRA|Patients treated for medical refractory Ulcerative Colitis
62239312|NCT00922103|ACTIVE_COMPARATOR|IPAA|Patients treated for medical refractory Ulcerative Colitis
62239313|NCT01153802|EXPERIMENTAL|Healthy Male Volunteers|All the 12 subjects enrolled in the study were exposed to at least one dose of GSK1360707 15 mg, 30 mg, 60 mg, 90 mg, 120 mg and 150 mg. All the subjects completed the study. The initial dose, given in the study as a single-dose was 15 mg GSK1360707. The remaining subjects were dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose did not exceed 150 mg per day, the maximum total dose given in the FTIH study.
62239314|NCT04288895|EXPERIMENTAL|Vortioxetine|flexible-dose
62815416|NCT03064529|EXPERIMENTAL|Accelerometer Participants|All participants receive an accelerometer to wear around their wrist to measure physical activity continuously beginning 1 week before surgery (when the accelerometer is put on the wrist) and ending 2 weeks after surgery (when the accelerometer is removed from the wrist).
62239315|NCT06200298|EXPERIMENTAL|Erector spinae plane block with naropeine [3,75 mg/mL]|Experimental group: Erector spinae plane block with naropeine \[3,75 mg/mL\]
62239316|NCT06200298|ACTIVE_COMPARATOR|Control group : ESPB with saline 0,9%|
62815417|NCT04906499|EXPERIMENTAL|Physical Activity Promotion Group|Participants will receive a text message each morning with a personalized, daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day.
62815418|NCT06039839|ACTIVE_COMPARATOR|first group|Healing of the donor area will be accomplished without the use of collagen matrix
62239317|NCT06348368||Group 1 (control group)|Children with normal Pentacam and with no refractive errors
62239318|NCT06348368||Group 2 (children with high cylinder and no corneal topographic abnormalities)|Children with high cylinder without corneal topographic ectasia.
62239319|NCT06348368||Group 3 (Children with high cylinder and corneal ectatic changes).|Children with high cylinder and corneal ectatic changes
62239320|NCT01768650|EXPERIMENTAL|Self-Management #2|Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
62239321|NCT01768650|EXPERIMENTAL|Self-Management #1|Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
62239322|NCT05425706|EXPERIMENTAL|experiment group|Number of participant is 16. In addition to the conventional therapy, SNAGs technique was applied.
62239323|NCT05425706|NO_INTERVENTION|control group|Number of participant is 16. Only the conventional therapy was applied.
62239324|NCT03459144|EXPERIMENTAL|photodynamic therapy|Participants will be given the standard verteporfin photodynamic therapy at baseline followed by additional standard verteporfin PDT as needed (every three months)(namely 1+PRN regimen).
62815419|NCT06039839|EXPERIMENTAL|second group|Closure of the wound defect in the donor area in the region of the maxillary tuberosity will be carried out after CTG harvesting with the use of collagen matrix
62815420|NCT00272493|ACTIVE_COMPARATOR|A|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
62239325|NCT03459144|EXPERIMENTAL|intravitreal ranibizumab|Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab will be given to the participants when necessary (every month) (namely 1+PRN regimen).
62239326|NCT03459144|EXPERIMENTAL|combination therapy of PDT and IVR|Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the standard verteporfin PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary (every month)(namely 1+PRN regimen).
62239327|NCT05802758|ACTIVE_COMPARATOR|Youngsters who get CFT + VR|yougsters, who get compassion-focused short intervention together with training in virtual reality together with general psychosocial rehabilitation offered by prisons and state residential schools
62239328|NCT05802758|NO_INTERVENTION|Treatment as usual|youngsters, who get only general psychosocial rehabilitation offered by prisons and state residential schools
62815421|NCT00272493|EXPERIMENTAL|B|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
62239329|NCT06064513|EXPERIMENTAL|control group|It consists of nurses working in Intensive Care, Emergency Service, Internal - Surgical Services and Polyclinic units in the public hospital in Kayseri. Individuals who volunteer to participate in the research will be included.
62239330|NCT06064513|EXPERIMENTAL|Video group|It consists of nurses working in Intensive Care, Emergency Service, Internal - Surgical Services and Polyclinic units in the public hospital in Kayseri. Individuals who volunteer to participate in the research will be included.
62239331|NCT01296035|EXPERIMENTAL|Panitumumab and Gemcitabine|Panitumumab and Gemcitabine
62239332|NCT06104202||Care professionals suffering from burn out|The group of care professionals suffering from burnout will be made up of care professionals who have been admitted to an outpatient facility at the Clinique Mon Repos. Attached to the clinic, this facility is specifically dedicated to them (day care unit). Around 100 care professionals suffering from burnout have already been assessed using the Maslach Burnout Inventory, Young Schema Questionnaire Short form, Montgomery-Asberg depression rating Scale and White Bear Suppression Inventory, with a view to adapting therapeutic interventions as part of their day-to-day care. These participants will be contacted by telephone by the investigator, who will inform them about the study if they meet the eligibility criteria.
62239333|NCT06104202||Care professionals without burn out|The study will also include a group of healthcare professionals not suffering from burnout, who will be informed about the study by investigating physicians from the occupational medicine department. During a regular occupational medicine consultation, the investigator will check the eligibility criteria, collect Maslach Burnout Inventory and Montgomery-Asberg depression rating Scale data as in normal practice, and inform eligible patients about the study.
62239334|NCT06104202||Non-care professionals in a state of burn out|Lastly, the study will include a group of non-medical professionals in a state of burnout who will be seen in consultation by an occupational medicine investigator, or who will consult and be monitored by an investigator at the Clinic. For those who are seen by an occupational health physician, the investigator will check the eligibility criteria, collect the Maslach Burnout Inventory and Montgomery-Asberg depression rating Scale data as in normal practice, and inform the eligible patients about the study.
62239335|NCT02600455||Patients who are treated with ORENCIA|Patients who are treated with ORENCIA according to the approved indications, and dosage and administration
62239336|NCT02636153|EXPERIMENTAL|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
62239337|NCT02636153|EXPERIMENTAL|Restricted Phosphorus Diet|Diet containing 500mg of phosphorus per day
62239338|NCT06280326|EXPERIMENTAL|Sunflower Oil Group|In the experimental group, patch removal will be performed using sunflower oil instead of silicone-based spray remover, which is the routine of the clinic. In children in the experimental group, the patch that has stuck to the baby's skin and needs to be changed is planned to be removed by applying sunflower oil on the patch.
62239339|NCT06280326|ACTIVE_COMPARATOR|Control group|"In the clinic, the orogastric catheter is fixed above the lip (mustache area) with a hypoallergenic patch. In cases where the oral gastric catheter needs to be replaced or the adhesive patch needs to be renewed, hypoallergenic patches attached to the skin may cause tape abrasions and scratches on the newborn's skin when removed.Silicone-based spray removers are used to avoid causing injuries.~In the control group in the study, a silicone-based spray remover was used, which is the routine of the clinic, during the removal of hypoallergenic patches attached to the lip (moustache area) to fix the oragastric catheter."
62239340|NCT02884726|EXPERIMENTAL|BMS-986148 intravenous infusion|
62239341|NCT01364363|OTHER|Total Body Irradiation/VP16|Acute Leukemias, Myelodysplastic syndromes
62239342|NCT01364363|OTHER|Cytoxan/Total Body Irradiation|Chronic Leukemias, Bone Marrow Failure States, Lymphomas, Hodgkin's Disease
62239343|NCT01364363|OTHER|Busulfan/Cytoxan|Acute Leukemia, Myelodysplastic syndromes, Chronic Leukemias, Bone Marrow Failure states
62239344|NCT01364363|OTHER|BEAM (BCNU, etoposide, Ara-C, melphalan)|Lymphomas, Hodgkin's Disease
62239345|NCT01364363|OTHER|Total Lymphoid Irradiation|For patients with Multiple Myeloma, or prior autologous transplantation, or age in excess of 55
62429831|NCT02834065|ACTIVE_COMPARATOR|Moderate Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature 24.1 - 28 degrees Celsius
62429832|NCT04049890||Parents of children with a chronic disease with no siblings|Parents of children suffering from a chronic disease who has no brother or sister over 3 years of age
62429833|NCT04049890||Parents of children with a chronic disease with siblings|Parents of children suffering from a chronic disease who one or more sibling over the age of 3 years old
62429834|NCT01201356|EXPERIMENTAL|Fingolimod 0.5 mg/day|Open-label fingolimod 0.5 mg, taken orally once daily
62239346|NCT01364363|OTHER|Cladribine/Melphalan|For patients with Multiple Myeloma, or prior autologous transplantation, or age in excess of 55
62239347|NCT01364363|OTHER|FLAG (fludarabine, Ara-C, G-CSF)|For patients undergoing a second allogeneic transplant
62239348|NCT06466863||Our study will be conducted as a single-group design|"This study will be conducted with healthy young people aged 12-17 years who voluntarily agree to participate in the study. Individuals will be included in the study after obtaining consent from the participants and their parents.~This questionnaire will be filled in at the convenience of the participants during the academic year. Then the questions of the Youth Activity Profile (YAP) will be asked. The time required to complete the questionnaires is approximately 20 minutes in total."
62239349|NCT03136419|PLACEBO_COMPARATOR|Control|Placebo capsules bis in die for 8 weeks
62239350|NCT03136419|EXPERIMENTAL|Experimental|Lactobacillus casei DG capsules bis in die for 8 weeks
62239351|NCT04543604|EXPERIMENTAL|Test group1 - Leaflet with visual aid|Information concerning etiology, prevalence, risk indicators and preventive measures of peri-implantitis were included. Relevant scientific bibliography supported the statements. Along, pictograms were supplemented to display the prevalence of disease with and without the known indicator.
62239352|NCT04543604|EXPERIMENTAL|Test group2 - Leaflet with visual aid (L-NVA)|Information concerning etiology, prevalence, risk indicators and preventive measures of peri-implantitis were included. Relevant scientific bibliography supported the statements. No pictograms were supplemented.
62429835|NCT03433118|EXPERIMENTAL|Acupuncture|Acupuncture administered by specially-trained therapeutic radiographers to patients attending the UCH radiotherapy department for radiotherapy intended to be curative of their cancer
62037471|NCT03612791|ACTIVE_COMPARATOR|Standard Treatment Arm|"Radiotherapy (RT):~* Pelvic +/- para-aortic EBRT (IMRT): 45 Gy in 25 fractions over 5 weeks (Weeks 1-5, with simultaneously integrated boosts to macroscopically involved lymph nodes, if any, in order to deliver a total dose of 60 Gy to macroscopic lymph nodes (including the dose delivered by brachytherapy).~* Uterovaginal brachytherapy (Week 7; maximum interval between EBRT and brachytherapy: 14 days). If appropriate and feasible, dose escalation will be assumed, particularly for advanced disease, with the objective to deliver a minimal total dose of 85 Gy (equivalent dose in 2-Gy fractions with α/β=10 Gy) to 80% of the High Risk-Clinical Target Volume (HR-CTV), including 45 Gy through EBRT. The total dose might be lower in case of close proximity to organs at risk (OARs).~* Total duration of RT (including brachytherapy) should be ≤ 55 days.~Chemotherapy:~- Cisplatin infused 40 mg/m2 (maximum 70 mg) weekly IV during EBRT (Weeks 1-5)."
62239353|NCT04543604|NO_INTERVENTION|• Control group - No leaflet (NL)|Only verbal information was provided to the patient during initial interview.
62239354|NCT05506501|ACTIVE_COMPARATOR|Unilateral epidural anesthesia group|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia using unilateral epidural anesthesia.
62037472|NCT03612791|EXPERIMENTAL|Experimental Treatment Arm|"* Same treatment as described above (CRT, followed by uterovaginal brachytherapy), plus~* atezolizumab administered IV 1200 mg Q3W, starting on the same week as EBRT (Week 1) and continued as an adjuvant for a total maximum of 20 cycles (approximately 14 months total of treatment)."
62037473|NCT05355974|EXPERIMENTAL|Norepinephrine plus Isotonic Fluids|The treatment group will receive a continuous infusion of norepinephrine at 0.10 mcg/kg/min started 2-5 minutes prior to Rapid Sequence Intubation (assuming normal systolic blood pressure 90-140mmHg) in addition to a standard fluid bolus of Lactated Ringers or Normal Saline or Plasmalyte at 999 mL/hr.
62037474|NCT05355974|ACTIVE_COMPARATOR|Isotonic Fluids|The control group will receive an infusion of Lactated Ringers or Normal Saline or Plasma-Lyte with at least 500 mL at 999 ml/hr 2-5 minutes prior to Rapid Sequence Intubation.
62037475|NCT05101239||A: Acute mTBI|Consists of up to 80 patients with acute mTBI. All acute mTBI subjects will be scanned per the HHI study design at 3 to 5 timepoints relative to their time of injury ( Visit 1 within 72 hours; Visit 2, 7 +/- 4 days; Visit 3, 30 +/- 7 days; Visit 4, 90 +/- 14 days; Visit 5, 180 +/- 30 days from injury). Even though for practicality Visits 1 and 5 are optional, every effort will be made to image as close to the time of acute injury as possible and to complete imaging for all time points.
62239355|NCT05506501|ACTIVE_COMPARATOR|Ultrasound guided femoro/ sciatic nerve block group|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia by femoral/sciatic nerve block using ultrasound guidance.
62239356|NCT00640016|PLACEBO_COMPARATOR|Placebo|Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
62239357|NCT00640016|EXPERIMENTAL|CAT-354 1 mg/kg|CAT-354 1 milligram per kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
62239358|NCT00640016|EXPERIMENTAL|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
62239359|NCT00640016|EXPERIMENTAL|CAT-354 10 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56
62239360|NCT05203523|EXPERIMENTAL|Group 1 (G1)|Participants will receive active tACS simultaneously with cognitive exercises.
62239361|NCT05203523|SHAM_COMPARATOR|Group 2 (G2)|Participants will receive sham tACS simultaneously with cognitive exercises.
62239362|NCT06249503|ACTIVE_COMPARATOR|Activated PRP|PRP is activated by adding 200μl of 0.025 calcium chloride and used in hydrodissection.
62239363|NCT06249503|ACTIVE_COMPARATOR|Non-Activated PRP|PRP is used directly in hydrodissection.
62429836|NCT03433118|NO_INTERVENTION|Standard care|Standard care for patients attending the UCH radiotherapy department for radiotherapy intended to be curative of their cancer
62429837|NCT06446947||Septic shock|Patients with sepsis admitted to intensive care who developed septic shock.
62429838|NCT06446947||No septic shock|Patients with sepsis admitted to critical care with a favorable outcome (no septic shock)
62239364|NCT06249503|ACTIVE_COMPARATOR|Steroid group|Hydro dissection using a combination of steroid (Triamcinolone 40mg), local anesthetics and dextrose.
62239365|NCT04540848|EXPERIMENTAL|Exparel plus supraclavicular block|
62815422|NCT03703700|EXPERIMENTAL|Zishen Yutai pill group|Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
62815423|NCT03703700|PLACEBO_COMPARATOR|Placebo group|Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
62239366|NCT04540848|ACTIVE_COMPARATOR|Bupivacaine HCL plus supraclavicular block|
62239367|NCT04540848|ACTIVE_COMPARATOR|supraclavicular block only|
62239368|NCT03513172|ACTIVE_COMPARATOR|Brimonidine Pre-Administration During First Visit|
62239369|NCT03513172|ACTIVE_COMPARATOR|Brimonidine Pre-Administration During Second Visit|
62239370|NCT00300781|EXPERIMENTAL|Neratinib 240 mg, with prior trastuzumab|Neratinib administered with 80 mg capsules and 40 mg coated tablets taken orally in prescribed dose of 240 mg daily, as long as tolerated and disease does not worsen.
62239371|NCT00300781|EXPERIMENTAL|Neratinib 240 mg, no prior trastuzumab|Neratinib administered with 80 mg capsules and 40 mg coated tablets taken orally in prescribed dose of 240 mg daily, as long as tolerated and disease does not worsen.
62239372|NCT03840850|EXPERIMENTAL|Intervention and usual care|Risk communication intervention and usual care including personalized lifestyle advice
62239373|NCT03840850|NO_INTERVENTION|Usual care only|Usual care including personalized lifestyle advice
62239374|NCT03786939|OTHER|On-pump CABG.|On-pump CABG.
62429839|NCT06541535|ACTIVE_COMPARATOR|Isotonic saline|
62429840|NCT06541535|EXPERIMENTAL|Ringer Lactate|
62429841|NCT05394558|EXPERIMENTAL|Radiotherapy + AsiDNA|"Patients will receive the IMP which is the AsiDNA (etidaligide). AsiDNA will be administered intravenously as a 1-hour infusion. All patients will receive a loading dose for three consecutive days, with Day 1 being the start day of radiotherapy, followed by once weekly administrations during 11 weeks.~The infusion of AsiDNA should be administered between 4 and 6 hours before the planned start of radiotherapy.~After the administration of AsiDNA, Patients with DIBG will receive a total dose of 18 Gy, delivered in 10 fractions of 1.8 Gy, i.e. 5 fractions per week for 2 weeks, starting on Day 1. Patients with supratentorial non-DMG or DMG will receive a total dose of 36 Gy, delivered in 20 fractions of 1.8 Gy, i.e. 5 fractions per week for 4 weeks, starting on Day 1."
62429842|NCT05394558|ACTIVE_COMPARATOR|Radiotherapy|Patients with DIBG will receive a total dose of 18 Gy, delivered in 10 fractions of 1.8 Gy, i.e. 5 fractions per week for 2 weeks, starting on Day 1. Patients with supratentorial non-DMG or DMG will receive a total dose of 36 Gy, delivered in 20 fractions of 1.8 Gy, i.e. 5 fractions per week for 4 weeks, starting on Day 1.
62429843|NCT04861090||Participants With Hereditary Angioedema|Participants with HAE type I or type II who had initiated long-term prophylaxis (LTP) treatment with lanadelumab which was administered every two weeks (Q2W) or every four weeks (Q4W) or every six weeks (Q6W) or every eight weeks (Q8W) in accordance to Summary of Product Characteristics (SmPC), during a routine clinical setting will be followed up to 38 months.
62429844|NCT03076671|NO_INTERVENTION|Standard of Care|Patients to get usual care from their established neurology care team that is enrolled in the study.
62429845|NCT03076671|EXPERIMENTAL|Standard of Care plus Palliative Care|Patients to get usual care, augmented by palliative care, provided by their established neurology care team that is affiliated with the study, with additional support provided by the University of Colorado Denver Neurology Palliative Care team.
62429846|NCT03076671|EXPERIMENTAL|Clinicians|Clinicians enrolled in the study will receive an 8-hour supportive and palliative care training, followed by monthly coaching and the availability of telemedicine visits for enrolled patients with the university neuro-palliative care team. The unit of randomization is the time when they receive training. Four to five clinical practices will receive training every 6 months during years 2 and 3, at which time all of their enrolled patients will be switched from usual care to the intervention arm.
62239375|NCT03786939|OTHER|Off-pump CABG.|Off-pump CABG.
62239376|NCT03786939|OTHER|Pump-assisted CABG.|Pump-assisted CABG.
62239377|NCT02640820|EXPERIMENTAL|Sensitization Phase|Up to two doses of Sensitizing DPCP Ointment will be applied and subjects who exhibit a sensitization response will enter the Treatment Phase. Pharmacokinetics (PK) of Sensitizing DPCP Ointment will be measured in a subset of subjects. For PK, blood will be collected prior to application of the Sensitizing DPCP Ointment and again at 1, 2, and 24 hours after application.
62239378|NCT02640820|EXPERIMENTAL|Treatment Phase|In the Treatment Phase, subjects will receive doses of Treatment DPCP Ointment weekly for 10 weeks. Subjects who at the end of the Treatment Phase have exhibited partial clearance of warts may be given the option to continue with an additional 10 weekly treatments.
62239379|NCT00408603|EXPERIMENTAL|All study patients|All patients will receive voreloxin injection
62239380|NCT03576703|EXPERIMENTAL|EX+H2O|Exercise and diet that did not include SSB
62239381|NCT03576703|EXPERIMENTAL|EX+SSB|Exercise and diet that includes SSB
62239382|NCT03576703|NO_INTERVENTION|CONTROL|No exercise and diet that did not include SSB
62239383|NCT01256658|EXPERIMENTAL|Intervention|Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.
62239384|NCT01256658|EXPERIMENTAL|Control|Participants received COA566 treatment for symptomatic malaria episodes only.
62239385|NCT03712189|NO_INTERVENTION|Alaris Pump|Participants will receive IV fluids delivered by the Alaris IV Pump (standard of care) until their bladder is full.
62239386|NCT03712189|EXPERIMENTAL|LifeFlow|Participants will receive IV fluids delivered by the LifeFlow Fluid Device until their bladder is full.
62239387|NCT02300051|EXPERIMENTAL|STPGP and RPGT|16 weekly sessions of 90 minutes of Short-Term Psychodynamic Group Psychotherapy (STPGP) followed by 8 weekly sessions of 90 minutes of Relapse Prevention Group Therapy (RPGT)
62239388|NCT02300051|ACTIVE_COMPARATOR|TAU|Treatment as usual (TAU) will be introduced through psychiatric follow up, in which the three first visits will occur at intervals of 30 days and the followings will occur with an interval of 60 days. The medication protocol includes serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day) or mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).
62239389|NCT02300051|EXPERIMENTAL|STPGP and RPGT + TAU|Participants undergo both interventions: 1) 16 weekly sessions of 90 minutes of Short-Term Psychodynamic Group Psychotherapy (STPGP) followed by 8 weekly sessions of 90 minutes of Relapse Prevention Group Therapy (RPGT); 2)Treatment as usual (TAU) will be introduced through psychiatric follow up, in which the three first visits will occur at intervals of 30 days and the followings will occur with an interval of 60 days. The medication protocol includes serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day) or mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).
62239390|NCT03411954||HP-RT|Hippocampus avoidance: decrease the dose to hippocampus as low as possible without affecting the target volumes and other normal tissues
62239391|NCT00577850|EXPERIMENTAL|1|0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks
62239392|NCT00577850|ACTIVE_COMPARATOR|2|0.45 mg 14C-labeled alendronate, followed 7 days later with oral 70 mg of alendronate once a week for 52 weeks
62239393|NCT02171650|EXPERIMENTAL|BIBW 2992|
62239394|NCT00125879|EXPERIMENTAL|1|
62239395|NCT05635916|EXPERIMENTAL|Liposomal Bupivacaine|Adductor canal block using liposomal bupivacaine and conventional bupivacaine
62239396|NCT05635916|ACTIVE_COMPARATOR|Standard of Care|Adductor canal block using conventional bupivacaine
62239397|NCT03486288||Delirium|
62239398|NCT03486288||No Delirium|
62239399|NCT05987566|EXPERIMENTAL|Morning Meal Challenge|
62239400|NCT05987566|EXPERIMENTAL|Late Night Meal Challenge|
62239401|NCT02291302|ACTIVE_COMPARATOR|Environmental Intervention|Active Classroom air purifiers and school integrated pest management environmental intervention
62239402|NCT02291302|PLACEBO_COMPARATOR|Sham and Control (control)|Sham air purifiers and no school integrated pest management environmental intervention
62429847|NCT05014347||Health Care Professionals|Health Care Professionals (HCP) working in PancreatoBiliary Endoscopy and EUS Division of IRCCS San Raffaele (both endoscopists and nurses)
62429848|NCT05014347||"Expert patients"|a set of at least 30 outpatients undergoing EUS, who already underwent this procedure at least once
62429849|NCT05014347||Patients|100 consecutive patients undergoing EUS
62429850|NCT01060631||patients with frontal or frontotemporal brain tumor.|
62239403|NCT02291302|PLACEBO_COMPARATOR|Active Air Purifier and Control|Active air purifiers and no school integrated pest management environmental intervention
62239404|NCT02291302|SHAM_COMPARATOR|Sham and Inegrated Pest|Sham air purifiers and active school integrated pest management
62239405|NCT02855671||Healthy volunteers|
62239406|NCT02855671||Sepsis|
62239407|NCT02855671||Severe sepsis/septic shock|
62429851|NCT01060631||patients without supratentorial brain tumor.|
62429852|NCT06286410|EXPERIMENTAL|Aniso-A|"Aniso-A~Those found to have anisometropic accommodation response do not focus effectively in their amblyopic eye when looking at the 0.33m (near) targets. Aniso-A response will be determined by their interocular difference in measurements at near (0.33m).~They will be given a prescription for D-28 segment bifocal glasses. The distance section of the glasses will match their current glasses, and the bifocal add will be equivalent to the mean amount they are under accommodating by at 0.33m in their amblyopic eye during the cue conditions with glasses. Bifocals will only be worn during patching. They will wear their own current glasses for all other times. This will be made very clear to parents/caregivers, and written instructions will be given.~The participant will act as their own controls: visual acuity at recruitment will be used to compare to visual acuity during and after the intervention."
62597116|NCT03196427|EXPERIMENTAL|Vedolizumab High Dose Group|Participants with UC or CD having baseline weight of greater than or equal to (\>=) 30 kilogram (kg) will receive vedolizumab 300 mg and participants with UC or CD having baseline weight of less than (\<) 30 kg will receive vedolizumab 200 mg, IV infusion, every 8 weeks until vedolizumab IV is commercially available for pediatric indication(s) in the participant's country or until other drug access programs become available (whichever comes first), the participant turns 18 years of age and can be transitioned to commercial drug (up to approximately 8 years).
62239408|NCT04712825|ACTIVE_COMPARATOR|Cognitive-behavioural therapy|Cognitive-behavioural therapy sessions
62239409|NCT04712825|EXPERIMENTAL|Virtual Reality Hypnosis|Virtual Reality Hypnosis sessions
62239410|NCT02924298|EXPERIMENTAL|Stage 1-2 Chronic Kidney Disease|Individuals with estimated glomerular filtration rate \> 60 mL/min/1.73m\^2, to undergo SLIMM intervention
62239411|NCT02924298|EXPERIMENTAL|Stage 3-4 Chronic Kidney Disease|Individuals with estimated glomerular filtration rate 15 to \< 60 mL/min/1.73m\^2, to undergo SLIMM intervention
62239412|NCT06075238|EXPERIMENTAL|blinatumomab|Participants will take intravenous blinatumomab after allo-HSCT. The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
62239413|NCT06323200||Lymphedema duration > 3.6 years|
62239414|NCT06323200||Lymphedema duration ≤ 3.6 years|
62037476|NCT05101239||B: Control|Consists of 40 age-matched participants described above who will undergo imaging twice on the MAGNUS 3.0T MRI scanner at two distinct time points. The 2 MRI imaging sessions will be at least 2 weeks apart. One of the 2 visits will include a clinical MRI scan using the same MRI acquisition protocols used for Group A. Because age-matched Controls are not expected to exhibit structural and functional changes during the study period, it was not deemed necessary for the interval between scan-visit time points to be identical for all participants in Group B.
62037477|NCT05101239||C: Chronic mTBI|Consists of 40 age-matched participants with chronic mTBI (≥6 months and \<5 years from mTBI injury to enrollment). Participants in this group will have 1 set of procedures at the Baseline Visit. This cohort will be used to understand functional and structural changes in chronic mTBI patients to identify indications of progression of patients from the acute to chronic phase
62037478|NCT03516448|ACTIVE_COMPARATOR|the Tyroserleutide for injection|the Tyroserleutide for injection at the dosage of 6mg/d Gan Fu Le Tablets，6 tablets,po,tid
62037479|NCT03516448|PLACEBO_COMPARATOR|the placebo group|the placebo Gan Fu Le Tablets，6 tablets,po,tid
62037480|NCT02938351|EXPERIMENTAL|collaborative care|To test the efficacy of a collaborative care intervention with patients treated with dialysis to reduce depression, pain, fatigue, and improve quality of life
62239415|NCT03533621|EXPERIMENTAL|Probiotic|1 Probiotic pill, twice a day, for 12 weeks + 20 min weekly support to increase fruit and vegetable consumption
62239416|NCT03533621|PLACEBO_COMPARATOR|Placebo|1 placebo pill (soy protein powder), twice a day, for 12 weeks + 20 min weekly support to increase fruit and vegetable consumption
62239417|NCT02927587|EXPERIMENTAL|The induction Cet of propofol 1|The induction Cet of propofol was targeted at 1 ug/ml.
62239418|NCT02927587|OTHER|The induction Cet of propofol 2|The induction Cet of propofol was targeted at 2 ug/ml.
62239419|NCT05779592||Cohort 1|Muscle-invasive Urothelial Carcinoma Participants who received nivolumab as adjuvant treatment at least once from March 28, 2022 to December 31, 2023
62239420|NCT01369901|EXPERIMENTAL|Group A|Functional exercise
62429853|NCT06286410|EXPERIMENTAL|Anti-A|"Anti-A~Those found to have anti-accommodation over-accommodate in their amblyopic eye for the 2m (distance) target. Aniso-A response will be determined by their interocular difference in measurement in the distance (2m).~They will be given a prescription for single vision distance glasses. The distance prescription in their non-amblyopic eye will be the same as their current glasses. The distance prescription in their amblyopic eye will be reduced by the same amount they are over-accommodating by during the cue conditions with glasses. This amended distance prescription will only be worn during patching. They will wear their own current glasses for all other times. This will be made very clear to parents/caregivers, and written instructions will be given.~The participant will act as their own controls: visual acuity at recruitment will be used to compare to visual acuity during and after the intervention."
62037481|NCT04298593|OTHER|ECG monitoring|All patient will be under telemetry
62037482|NCT02696655|EXPERIMENTAL|liver transplant patients|Patients will use a behavioural intervention to assess its usability
62037483|NCT04294966|PLACEBO_COMPARATOR|Placebo|
62037484|NCT04294966|ACTIVE_COMPARATOR|7.5 mg THC|
62037485|NCT04294966|ACTIVE_COMPARATOR|15 mg THC|
62037486|NCT02852551|EXPERIMENTAL|PAT-1251 Single Dose|Oral solution of PAT-1251, 150 - 4000 mg administered once
62037487|NCT02852551|PLACEBO_COMPARATOR|Placebo Single Dose|Matching placebo solution administered once
62037488|NCT02852551|EXPERIMENTAL|PAT-1251 Multiple Dose|Oral tablet(s) of PAT-1251 up to 2000 mg administered daily for 7 days
62037489|NCT02852551|EXPERIMENTAL|Placebo Multiple Dose|Matching placebo tablets administered daily for 7 days
62037490|NCT02063126|ACTIVE_COMPARATOR|ReConnect|CFS patients who were randomized to measure the effect of oral ReConnect supplementation (NADH: 20 mg/day, Coenzyme Q10: 200 mg/day; 4 tablets/day) on the maximum HR during 8-weeks in term.
62239421|NCT01369901|ACTIVE_COMPARATOR|Group B|Stretching exercise
62239422|NCT00681954||1, 2, 3|
62239423|NCT03354442|EXPERIMENTAL|Modified Fixed Mandibular Retractor|All patients in this group will be treated using Modified Fixed Mandibular Retractor Appliance. This appliance will be used full-time.
62597117|NCT03196427|EXPERIMENTAL|Vedolizumab Low Dose Group|Participants with UC or CD having baseline weight of \>= 30 kg will receive vedolizumab 150 mg and participants with UC or CD having baseline weight of \< 30 kg will receive vedolizumab 100 mg IV infusion, every 8 weeks until vedolizumab IV is commercially available for pediatric indication(s) in the participant's country or until other drug access programs become available (whichever comes first), the participant turns 18 years of age and can be transitioned to commercial drug (up to approximately 8 years).
62429854|NCT02832076|EXPERIMENTAL|group a|This arm will receive subcutaneous negative suction drain for the midline wound for 10 days.
62429855|NCT02832076|ACTIVE_COMPARATOR|group b|This arm will receive closure of the midline wound without a subcutaneous drain.
62429856|NCT01375010|PLACEBO_COMPARATOR|Group A|Placebo vitamin D3 capsule daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 1000 IU.
62037491|NCT02063126|PLACEBO_COMPARATOR|Placebo|CFS patients who were randomized to measure the effect of oral Placebo supplementation ( phosphoserine and vitamin C, 4 tablets/day) on the maximum HR during 8-weeks in term.
62037492|NCT01830127|EXPERIMENTAL|cohort A CPA|Cohort A CPA BI 207127/QD Faldaprevir Ribavirin
62239424|NCT03354442|NO_INTERVENTION|Untreated control group|All patients in this group will be observed during the period of treating the patients in the other group to assess the growth changes.
62429857|NCT01375010|EXPERIMENTAL|Group B|2000 IU vitamin D3 daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 3000 IU.
62597118|NCT03140332|OTHER|Patient with CHC|
62597119|NCT02836964||Group A Early Loading|Crown placement will occur at 4 weeks post implant
62597120|NCT02836964||Group B Conventional Loading|Crown placement will occur at 3 months post implant
62597121|NCT04711330||Patients treated with maintenance immunotherapy after concurrent chemo/RT|"Observation of response and response. The microbiome of the patients throat and stool will be analyzed before the standard treatment with IO is initiated after completion of the chemoradiation therapy.~No intervention is planned."
62597122|NCT04500106||Participants With Nurse Support, Using Video Devices|Participants treated with Levodopa Carbidopa Intestinal Gel (LCIG) in accordance with approved label who are provided AbbVie Duodopa Specialist (ADS) nurse support, using video devices.
62597123|NCT04500106||Participants With Nurse Support, Not Using Video Devices|Participants treated with Levodopa Carbidopa Intestinal Gel (LCIG) in accordance with approved label who are provided AbbVie Duodopa Specialist (ADS) nurse support, not using video devices.
62597124|NCT01601327|OTHER|hypogonadism, treatment|77 patients with idiopathic hypogonadotropic hypogonadism were treated with testosterone gel, testosterone enanthate or human chorionic gonadotropin
62597125|NCT01601327|NO_INTERVENTION|Control group|42 healthy controls
62037493|NCT01830127|EXPERIMENTAL|cohort A CPB|Cohort B CPB BI 207127/QD Faldaprevir Ribavirin
62239425|NCT01708239||Pregnant women|Pregnant women with suspected DVT assessed by the LEFt rule, D-dimer measurement and complete ultrasonography.
62239426|NCT04536454|EXPERIMENTAL|[18F]FPyGal|"Cancer patients will first be treated with a tumor type-specific neo-adjuvant chemotherapy regimen (standard-of-care); subsequently, they will undergo surgical resection of their primary tumors in a curative intention.~After the end of the neo-adjuvant therapy a tracer injection with \[18F\]FPyGal solution will be administered (study intervention). Immediately after the injection a dynamic PET/MR imaging of the tumor sites including heart or large arterial blood pools will be conducted over 90 minutes."
62239427|NCT05827211|EXPERIMENTAL|Test group|Participants in this group will receive Doxycycline 200 mg 1 h pre-op and 100 mg for 9 days post-op in combination with dental implant therapy.
62239428|NCT05827211|PLACEBO_COMPARATOR|Control group|Participants in this group will receive a placebo 200 mg 1 h pre-op and 100 mg for 9 days post-op in combination with dental implant therapy.
62239429|NCT04645771|EXPERIMENTAL|Microwave ablations|A total of 50 patients with varicose veins of lower extremities treated with microwave ablation catheter were selected to observe their annual venous closure rate and postoperative adverse reactions.
62597126|NCT05108532||Patients after revisional bariatric surgery.|This cohort will include patients, who underwent revisional bariatric surgery.
62597127|NCT01277653||PIVKA-II and AFP 6 months|PIVKA-II and AFP measurement every 6 months
62597128|NCT01277653||tumor maker interval every 6 month|tumor maker interval every 6 month
62597129|NCT06519344|EXPERIMENTAL|anti-CD20/CD30-CAR-T Cells|"anti-CD20/CD30-CAR-T cell infusion.Infusion doses:The planned infusion doses are follows：the first dose group at 3E5 cells/kg; the second dose group at 1E6 cells/kg; the third dose group at 3E6 cells/kg. Infusion doses refer to the number of CAR-positive cells.~Administration method: anti-CD20/CD30-CAR-T cells are administered intravenously via an infusion pump at approximately 2-5 mL/minute, with a recommended infusion duration of less than 30 minutes."
62597130|NCT02946073|PLACEBO_COMPARATOR|Placebo|CAM2038 placebo injections
62597131|NCT02946073|EXPERIMENTAL|CAM2038|CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, 16 mg, 24 mg, or 32 mg. CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.
62597132|NCT04245215|PLACEBO_COMPARATOR|1. Subcutaneous ustekinumab every 8 weeks|re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 8 weeks (Q8W) for 48 weeks - receiving Q8W placebo to mimic Q4W injections
62239430|NCT04213014|EXPERIMENTAL|Guys/Girls Opt for Activities for Life Intervention (GOAL)|Receives the 4 month (16-wk) GOAL intervention, which has 3 components: (1) After-school GOAL Club: 26 events (2 d/wk; 120 min/event/day; 13 wks due to no club during 3 school break wks) for boys and girls to engage in physical activity and healthy eating and cooking activities; (2) Three parent-adolescent meetings (1st meeting at each school with parents and adolescents \[Zoom option if needed\]; 2nd and 3rd meetings delivered virtually for parents): to empower parents to assist adolescents with physical activity and healthy eating and cooking; and (3) GOAL social networking website: private website for parents to share with each other how they helped their adolescent increase physical activity and diet quality each week.
62429858|NCT01656954||Anticipated volume/blood administration|Patients who may receive IV fluid boluses or blood products for restoration of vascular volume. Prior to receiving IV fluid boluses or blood products, the patient will undergo a passive leg raise. (PLR)
62429859|NCT01920074|EXPERIMENTAL|Rectiv|
62597133|NCT04245215|ACTIVE_COMPARATOR|2. Subcutaneous ustekinumab every 4 weeks|re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 4 weeks (Q4W) for 48 weeks
62597134|NCT05568615|EXPERIMENTAL|MT-1186 orally|Subjects receive the edaravone oral suspension orally once daily for 10 days out of a 14-day period, followed by a 14-day drug-free period.
62597135|NCT05691608|EXPERIMENTAL|Patient with solid tumor or leukemia (no treatment)|Patient with solid tumor or leukemia (no treatment)
62239431|NCT04213014|NO_INTERVENTION|Control|Received usual school activities.
62597136|NCT05326308||Waldenström's Macroglobulinemia|75 patients (excluding screening failures, patients with off-label use or with violation of inclusion/exclusion criteria identified after treatment start) receiving zanubrutinib (Brukinsa®)
62597137|NCT05326308||Chronic Lymphocytic Leukemia|450 patients (excluding screening failures, patients with off-label use or with violation of inclusion/exclusion criteria identified after treatment start) receiving zanubrutinib (Brukinsa®)
62597138|NCT05326308||Marginal Zone Lymphoma|40 patients (excluding screening failures, patients with off-label use or with violation of inclusion/exclusion criteria identified after treatment start) receiving zanubrutinib (Brukinsa®)
62597139|NCT05326308||Follicular Lymphoma|40 patients (excluding screening failures, patients with off-label use or with violation of inclusion/exclusion criteria identified after treatment start) receiving zanubrutinib (Brukinsa®) in combination with obinutuzumab (Gazyvaro®)
62597140|NCT03289325|EXPERIMENTAL|DEX group|The active drug (dexmedetomidine hydrochloride for injection) will be administered during a period from before anesthesia induction until the end of mechanical ventilation after surgery.
62239432|NCT02982187|EXPERIMENTAL|Sub-study 1 : ELLIPTA followed by DISKUS+ HANDIHALER +PQ1|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then DISKUS + HANDIHALER in period 2. At the end of Visit 1, subjects will complete version 1 of the PQ (PQ1)
62239433|NCT02982187|EXPERIMENTAL|Sub-study 1 : DISKUS + HANDIHALER followed by ELLIPTA+PQ2|In this sequence, subjects will be randomized to use DISKUS + HANDIHALER in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete version 2 of the PQ (PQ2)
62239434|NCT02982187|EXPERIMENTAL|Sub-study 1 : ELLIPTA followed by DISKUS+ HANDIHALER +PQ2|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then DISKUS + HANDIHALER in period 2. At the end of Visit 1, subjects will complete PQ2
62239435|NCT02982187|EXPERIMENTAL|Sub-study 1 : DISKUS + HANDIHALER followed by ELLIPTA+PQ1|In this sequence, subjects will be randomized to use DISKUS + HANDIHALER in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete PQ1
62239436|NCT02982187|EXPERIMENTAL|Substudy 2: ELLIPTA followed by TURBUHALER + HANDIHALER +PQ3|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then TURBUHALER + HANDIHALER in period 2. At the end of Visit 1, subjects will complete version 3 of the PQ (PQ3)
62239437|NCT02982187|EXPERIMENTAL|Substudy 2: TURBUHALER + HANDIHALER followed by ELLIPTA+PQ4|In this sequence, subjects will be randomized to use TURBUHALER + HANDIHALER inhaler in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete version 4 of the PQ (PQ4)
62239438|NCT02982187|EXPERIMENTAL|Substudy 2: ELLIPTA followed by TURBUHALER + HANDIHALER +PQ4|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then TURBUHALER + HANDIHALER in period 2. At the end of Visit 1, subjects will complete PQ4
62239439|NCT02982187|EXPERIMENTAL|Substudy 2: TURBUHALER + HANDIHALER followed by ELLIPTA+PQ3|In this sequence, subjects will be randomized to use TURBUHALER + HANDIHALER inhaler in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete PQ3
62239440|NCT03054207|EXPERIMENTAL|HIV clopidogrel|clopidogrel 300 mg single dose oral route
62239441|NCT03054207|EXPERIMENTAL|HIV prasugrel|prasugrel 60 mg single dose oral route
62239442|NCT03054207|ACTIVE_COMPARATOR|Control clopidogrel|clopidogrel 300 mg single dose oral route
62239443|NCT03054207|ACTIVE_COMPARATOR|Control prasugrel|prasugrel 60 mg single dose oral route
62239444|NCT03654313|EXPERIMENTAL|Part A MEDI6570 Cohort 1|Part A MEDI6570 Cohort 1 dose level
62239445|NCT03654313|EXPERIMENTAL|Part A MEDI6570 Cohort 2|Part A MEDI6570 Cohort 2 dose level
62239446|NCT03654313|EXPERIMENTAL|Part A MEDI6570 Cohort 3|Part A MEDI6570 Cohort 3 dose level
62239447|NCT03654313|EXPERIMENTAL|Part A MEDI6570 Cohort 4|Part A MEDI6570 Cohort 4 dose level
62239448|NCT03654313|PLACEBO_COMPARATOR|Part A Placebo|Part A Placebo
62239449|NCT03654313|EXPERIMENTAL|Part B MEDI6570 Cohort 1|Part B MEDI6570 Cohort 1 dose level
62597141|NCT03289325|PLACEBO_COMPARATOR|CTRL group|The placebo drug (normal saline, or 0.9% sodium chloride for injection) will be administered in the same rate and volume for a same duration as that in the DEX group.
62239450|NCT03654313|EXPERIMENTAL|Part B MEDI6570 Cohort 2|Part B MEDI6570 Cohort 2 dose level
62239451|NCT03654313|EXPERIMENTAL|Part B MEDI6570 Cohort 3|Part B MEDI6570 Cohort 3 dose level
62239452|NCT03654313|PLACEBO_COMPARATOR|Part B Placebo|Part B Placebo
62239453|NCT03654313|EXPERIMENTAL|Part A MEDI6570 Cohort 5|Part A MEDI6570 Cohort 5 Dose level
62239454|NCT03654313|EXPERIMENTAL|Part A MEDI6570 Cohort 6|Part A MEDI6570 Cohort 6 dose level
62239455|NCT03644251|EXPERIMENTAL|AMUC Dosage 1|25mg amniotic and umbilical cord matrix
62239456|NCT03644251|EXPERIMENTAL|AMUC Dosage 2|50mg amniotic and umbilical cord matrix
62239457|NCT03644251|EXPERIMENTAL|AMUC Dosage 3|100mg amniotic and umbilical cord matrix
62239458|NCT03198598|EXPERIMENTAL|MS patients with EDSS from 0 to 5.5 for yoga|Three months of Iyengar Yoga practice.
62597142|NCT05477212|EXPERIMENTAL|intervention arm with VLCKD|all patients will receive a very low calorie Ketogenic diet (VLCKD) and will be followed for all the time of the study, monitoring gut permeability, liver steatosis and microbiome composition
62597143|NCT01437917|EXPERIMENTAL|Bread with 20% amylose content|Bread with 20% amylose content
62597144|NCT01437917|EXPERIMENTAL|Bread with 10% amylose content|Bread with 10% amylose content
62597145|NCT01437917|EXPERIMENTAL|carbohydrates|50g of carbohydrates ingested with 400 ml of water
62037494|NCT00003954|EXPERIMENTAL|Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)|"CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 15-20 minutes on day -2.~TRANSPLANTATION: Patients undergo autologous bone marrow or PBSCT on day 0.~NON-MYELOABLATIVE CONDITIONING REGIMEN: Beginning 40-120 days after autologous transplant, patients undergo TBI on day 0.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV BID on days -1 and 0 and PO BID on days 1-80 with taper based on evaluation of disease response and GVHD. Patients also receive mycophenolate mofetil PO BID on days 0-27.~POST TRANSPLANT DLI: Beginning 4 weeks after immunosuppression, patients achieving persistent or progressive disease may undergo DLI over 30 minutes every 4 weeks for up to 3 treatments."
62037495|NCT00598429|ACTIVE_COMPARATOR|High dose|PGE1 300 ng/kg/min via nebulizer over a 72-hour period
62037496|NCT00598429|ACTIVE_COMPARATOR|Low dose|PGE1 150 ng/kg/min via nebulizer over a 72-hour period
62429860|NCT04514770|ACTIVE_COMPARATOR|early amniotomy|"Group A:~1. Pregnant women had taken misoprostol (vagiprost vaginal tablet; Adwia Pharmaceutical Company) vaginally as 25 micro gram of misoprostol. It was repeated every 6 hours until three or more uterine contractions of 40 second duration occur over 10 minutes, or when reaching four doses maximum (i.e. 100 micro gram) is reached.~2. Early amniotomy was performed for the participant of the first group at 3 cementer cervical dilatation with Kocher's forceps provided the head is well fitted to the cervix."
62037497|NCT00598429|PLACEBO_COMPARATOR|Placebo|Normal saline, the diluent for the drug, via nebulizer over a 72-hour period
62037498|NCT06091865|EXPERIMENTAL|Odronextamab + CHOP|Part 1, includes dose escalation (Part 1A), and randomized exploration of 2 regimens of odronextamab -cyclophosphamide, doxorubicin, vincristine, prednisone (Odro-CHOP) dose optimization (Part 1B).
62037499|NCT06091865|ACTIVE_COMPARATOR|Rituximab + CHOP|Part 2 is the randomized controlled portion, participants will receive either Odro-CHOP or R-CHOP.
62037500|NCT05774366|EXPERIMENTAL|Remimazolam group|receives remimazolam for the maintenance of general anesthesia. At the end of surgery, flumazenil is administered as an antagonist of remimazolam.
62037501|NCT05774366|ACTIVE_COMPARATOR|Desflurane group|receives desflurane for the maintenance of general anesthesia.
62037502|NCT01735773||Hemodialysis group|Patients on chronic hemodialysis program
62037503|NCT01735773||Peritoneal dialysis group|Patients on chronic peritoneal dialysis program
62597146|NCT04546529|ACTIVE_COMPARATOR|TsMS active|Patients undergoing real Trans-spinal Magnetic Stimulation (TsMS) for 8 weeks
62239459|NCT03198598|NO_INTERVENTION|MS patients with EDSS from 0 to 5.5 for control|
62239460|NCT03198598|EXPERIMENTAL|MS patients with EDSS from 6 to 8 for yoga|Receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips
62037504|NCT01735773||Pre-dialysis group|Patients with chronic kidney disease stage-4
62239461|NCT03198598|NO_INTERVENTION|MS patients with EDSS from 6 to 8 for control|
62037505|NCT01735773||Control group|Healthy volunteers
62037506|NCT04223518|ACTIVE_COMPARATOR|Serum Bovine Immunoglobulin|Study product: Serum bovine immunoglobulin, also known by the trade name of Enteragam Dosage form: powdered packet Dosage: Each packet (10 g net weight) consists of 5 g of serum-derived bovine immunoglobulin/protein isolate (SBI) which is the active ingredient Frequency: one packet a day Duration: 60 days
62037507|NCT04223518|PLACEBO_COMPARATOR|Hydrolyzed Collagen|Placebo: hydrolyzed collagen Dosage form: powdered packet Dosage: 10 g of hydrolyzed collagen per packet Frequency: one packet a day Duration: 60 days
62037508|NCT06058650|EXPERIMENTAL|Part I (technetium Tc-99m sestamibi, MBI)|Patients receive technetium Tc-99m sestamibi IV and undergo MBI on study.
62037509|NCT06058650|EXPERIMENTAL|Part II (technetium Tc-99m sestamibi, MBI, biopsy)|Patients receive technetium Tc-99m sestamibi IV and undergo MBI. Patients whose breast lesions of interest are visualized on MBI then undergo breast biopsy using the Stereo Navigator accessory.
62037510|NCT06088264|EXPERIMENTAL|Administration of BMS-986322|
62239462|NCT03198598|NO_INTERVENTION|Healthy subjects|
62239463|NCT05461482|NO_INTERVENTION|Control group|The physician requesting the intervention will be responsible for informing the patient, explaining the purpose of the intervention, its risks and benefits, and possible alternatives and doubts related to the intervention.
62597147|NCT04546529|SHAM_COMPARATOR|TsMS sham|Patients undergoing placebo Trans-spinal Magnetic Stimulation (TsMS) for 8 weeks
62597148|NCT05249127|EXPERIMENTAL|64Cu-SAR-bisPSMA|Patients will receive a single administration of 200 megabecquerels (MBq) of 64Cu-SAR-bisPSMA.
62597149|NCT00832442||Beta blocker|
62597150|NCT00832442||Placebo|
62597151|NCT05856539|EXPERIMENTAL|ESP Block|"Patients assigned to the ESP Block arm will receive an ESP block prior to the surgery."
62037511|NCT06624137||Serotonergic Psychedelic Arm|Group (healthy or with psychological or neurological disorder) administered serotonergic psychedelic (psilocybin, DMT, LSD, 5-MeO-DMT, Ayahuasca, etc.) regardless of administration route.
62037512|NCT06624137||Placebo Arm|Group (healthy or with psychological or neurological disorder) administered placebo (diphenydramine, saline, niacin, etc.) regardless of administration route.
62037513|NCT03784339|PLACEBO_COMPARATOR|Physiotherapy|Participants will receive standard physiotherapy care, which will involve strength exercises and taping.
62037514|NCT03784339|EXPERIMENTAL|Physiotherapy + education|Physiotherapy + education Standard physiotherapy care plus 30 minute education session addressing fear of movement and catastrophizing thoughts.
62037515|NCT06235736||MRI-confirmed ACL tear group|This group will have had a complete ACL tear confirmed by MRI scan
62037516|NCT06235736||Normative group|This group will provide normative data for the study. They will have no previous history of significant knee injury and no current symptomatic lower limb injuries.
62037517|NCT01737372||Secondary Progressive MS (SPMS)|Secondary Progressive MS participants
62037518|NCT01737372||Clinically Isolated Syndrome (CIS)|Clinically isolated syndrome participants
62037519|NCT01737372||Healthy participants|No immunological or neurological illnesses.
62597152|NCT05856539|NO_INTERVENTION|Control|"Patients assigned to the Control group will not receive an ESP block prior to the surgery."
62037520|NCT04575636|OTHER|Lymphedema patients|MRL examination in lymphedema patients
62037521|NCT04575636|OTHER|Healthy volunteers|MRL examination in healthy volunteers
62815424|NCT04068025|NO_INTERVENTION|No Intervention: Control group|Patients in the control group were given usual care by a health professional who was not involved in the study and who worked in the Department of Urology. After the end of the study, the patients in the control group were also given structured bladder training similar to the patients in the intervention group.
62815425|NCT04068025|ACTIVE_COMPARATOR|the IMB model|Structured bladder training was applied to the patients in the intervention group via the IMB model.
62037522|NCT05964140|EXPERIMENTAL|Group A|Group A: One induction IV dose
62239464|NCT05461482|EXPERIMENTAL|Experimental group|In addition to the information provided by the referring physician, an interventional radiologist will assist the patient in a consultation before the intervention to inform him, explaining the objective of the intervention, its risks and benefits, and possible alternatives and doubts related to the intervention. In this group, educational videos will be used, one for each type of intervention, which will complement the explanations of the physician. The videos will aim to present in an understandable way the preparation for the intervention, its objective, the benefits and risks that derive from it and what you can expect once it has been carried out. Patients will have access to the videos before attending the consultation and will view them before being seen by the interventional radiologist.
62239465|NCT05686187|EXPERIMENTAL|AR's platform for gender empowerment|The experimental group's intervention consists of a course that embraces AR's platform for gender empowerment. The intervention course will require 50-60 minutes for preliminary planning, and participants in the experimental group can design at least three course modules to suit their learning needs.
62239466|NCT05686187|NO_INTERVENTION|control group|The control group will adopt the classroom narration method.
62239467|NCT01584154|EXPERIMENTAL|cryoablation|
62037523|NCT05964140|EXPERIMENTAL|Group B|Group B: One induction IV dose and 2 further postoperative IV doses
62037524|NCT05964140|ACTIVE_COMPARATOR|Group C|Group C: One IV dose of antibiotics on induction and 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy
62037525|NCT04857268|EXPERIMENTAL|ATP-C120 application|ATP-C120 will be applied to the high patients for new-onset atrial fibrillation
62239468|NCT01584154|ACTIVE_COMPARATOR|radiofrequency ablation|radiofrequency ablation with a 4mm-tip catheter
62815426|NCT06403787|EXPERIMENTAL|Ginkgo biloba group|This group will assess the effects of aerobic exercise combined with ginkgo biloba extract
62815427|NCT06403787|PLACEBO_COMPARATOR|Placebo group|Participants in this group will serve as a control to evaluate the effects of aerobic exercise when administered a placebo of calcined magnesia
62815428|NCT06403787|ACTIVE_COMPARATOR|Statins group|In this group, the effects of aerobic exercise along with the administration of atorvastatin will be investigated
62815429|NCT05120713||Young Adults|Young Adults aged 18-35
62815430|NCT05120713||Older Adults|Older Adults aged 50-80
62815431|NCT00217984|EXPERIMENTAL|Intensive intervention|Extended cognitive behavior therapy (16 sessions) plus nicotine patches and lozenges
62815432|NCT00217984|OTHER|Usual care|Referral to the smoking cessation clinic
62815433|NCT02366494||Androgen blockade|Androgen DeprivationTherapy or Complete Androgen Blockade
62815434|NCT02366494||Hormonal Therapy and Chemotherapy|Hormonal therapy, novel oral hormonal therapy (abiraterone/apalutamide/enzalutamide) and chemotherapy (docetaxel)
62037526|NCT04166409|ACTIVE_COMPARATOR|Arm I (vincristine sulfate, carboplatin)|"INDUCTION: Patients receive vincristine sulfate IV over 1 minute on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64, and carboplatin IV over 60 minutes on days 1, 8, 15, 22, 43, 50, 57, and 64 in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and magnetic resonance imaging (MRI) at baseline and end of induction.~MAINTENANCE: Patients receive vincristine sulfate IV over 1 minute on days 1, 8, and 15, and carboplatin IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 42 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and undergo MRI at baseline, throughout the trial, and during follow up."
62037527|NCT04166409|EXPERIMENTAL|Arm II (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and undergo MRI at baseline, throughout the trial, and during follow up.
62037528|NCT06732765|EXPERIMENTAL|Pilates exercise program|Pilates exercise program Will be treated with WBV with Pilate Exercises. Before applying exercise, hot pack will be applied for 15-20minutes
62239469|NCT02089841|EXPERIMENTAL|Artemether/lumefantrine|In this single-arm study, patients will be treated with Artemether/lumefantrine, and the first, third and fifth doses of the drug will be given under the direct observation of the health workers. The patients will be followed-up for 42 days, on day 1, 2, 3, 7, 14, 21, 28 and 42 to assess the efficacy of the drug.
62239470|NCT03157141||Control group, CG|For the purpose of the study, forty subjects for each group will be recruited. The control group (CG group) (so-called healthy subjects) CG will be recruited following the recruitment of the AA group and of the TAR group, as a sex, age and BMI matched design will be pursued. Inclusion criteria for the CG group are no history of orthopaedic lower limb surgery and absence of any known neurological or systematic disease.
62239471|NCT03157141||Total ankle replacement group (TAR group)|The number of AA and TAR subjects used in a majority of studies to analyze the functional repercussion of an ankle arthrodesis or a total ankle replacement varied between 10 and 35 subjects.
62239472|NCT03157141||Ankle arthrodesis group (AA group)|The number of AA and TAR subjects used in a majority of studies to analyze the functional repercussion of an ankle arthrodesis or a total ankle replacement varied between 10 and 35 subjects
62239473|NCT04283266|ACTIVE_COMPARATOR|Synbiotic group|The synbiotic was composed of fructo-oligosaccharides (FOS): 4.95 g/ sachet and Bifidobacterium animalis lactis: 5 billion / sachet (n=13)
62239474|NCT04283266|PLACEBO_COMPARATOR|Placebo group|A placebo was composed of maltodextrin (60%) and sucrose (40%) : 5 g /sachet (n =14)
62239475|NCT03282487|NO_INTERVENTION|Conventional immediate release hydrocortisone|
62239476|NCT03282487|ACTIVE_COMPARATOR|Modified release Hydrocortisone|12 weeks of modified release hydrocortisone (Plenadren)
62239477|NCT03282487|NO_INTERVENTION|Healthy control group|Same research laboratory measurements performed in a healthy control group for comparison to patient group
62239478|NCT01898689|EXPERIMENTAL|RIGHT side Ropivacaine 0.1% and LEFT side Ropivacaine 0.4%|Bilateral sciatic perineural catheters were inserted and ropivacaine administered as a basal infusion concurrently. For the right catheter, ropivacaine 0.1% was infused at 8 mL/h basal for 6 hours. For the left catheter, ropivacaine 0.4% was infused at 2 mL/h for 6 hours.
62239479|NCT01898689|ACTIVE_COMPARATOR|RIGHT side Ropivacaine 0.4% and LEFT side Ropivacaine 0.1%|Bilateral sciatic perineural catheters were inserted and ropivacaine administered as a basal infusion concurrently. For the right catheter, ropivacaine 0.4% was infused at 8 mL/h basal for 6 hours. For the left catheter, ropivacaine 0.1% was infused at 2 mL/h for 6 hours.
62429861|NCT04514770|ACTIVE_COMPARATOR|Late amniotomy|"Group B:~1. Pregnant women had taken misoprostol (vagiprost vaginal tablet; Adwia Pharmaceutical Company) vaginally as 25 micro gram of misoprostol. It was repeated every 6 hours until three or more uterine contractions of 40 second duration occur over 10 minutes, or when reaching four doses maximum (i.e. 100 micro gram) is reached.~2. late amniotomy was performed for the participant of the second group at 7 cementer cervical dilatation."
62429862|NCT03271463||Reliability/Validity of SCALE Assessment|Reliability + validity of the Selective Control Assessment of Lower Extremity (SCALE) in people with chronic stroke.
62597153|NCT05685004|ACTIVE_COMPARATOR|Standard of Care|Subjects will have standard surgery which will be followed approximately 5 weeks later by combined radiotherapy and chemotherapy consisting of temozolomide 75 mg/m2 dosed once daily beginning on the first day of radiotherapy and continuing until the final day of radiotherapy. Subjects will receive adjuvant temozolomide, and proceed with post therapy surveillance.
62037529|NCT06732765|ACTIVE_COMPARATOR|Traditional physical therapy program|traditional physical therapy program in form of stretching, strengthening and postural correction exercises
62239480|NCT02598557|EXPERIMENTAL|Arm I: Exemestane 25 mg QD|Patients receive exemestane PO QD on days 1-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
62429863|NCT01585311||Subarachnoid Hemorrhage patients|SAH patients with hourly eMR values of Heart Rate
62429864|NCT04852692||Part A: Retrospective Phase|Retrospective collection of data for eligible participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) who initiated salvage treatments from initiation point (administration starting point of the salvage treatment) of the identified last-line of conventional salvage therapy for cGVHD treatment as their second-forth line therapy and will be collected for up to 24 weeks from the initiation point.
62429865|NCT04852692||Part B: Prospective Phase|Prospectively enroll participants with steroid dependent/refractory cGVHD that are decided to be treated with ibrutinib in second-fourth line therapy for the treatment of cGVHD. Participants will continue to receive corticosteroids as a standard of care.
62239481|NCT02598557|EXPERIMENTAL|Arm II: Exemestane 25 TIW (exemestane, placebo)|Patients receive exemestane PO QD on days 1, 3, and 5. Patients also receive placebo PO QD on days 2, 4, 6, and 7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
62239482|NCT02598557|EXPERIMENTAL|Arm III: Exemestane 25 mg QW (exemestane, placebo)|Patients receive exemestane PO QD on day 1 and placebo PO QD on days 2-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
62239483|NCT01969825|EXPERIMENTAL|Massage|Professional Swedish massage less than 15 minutes prior to semen collection for intrauterine insemination.
62239484|NCT01969825|NO_INTERVENTION|No massage|Normal protocol for semen collection prior to intrauterine insemination.
62239485|NCT05748353||Patients with BRCA pathological variants with breast or ovarian cancers|Patient with pathogenetic mutation of BRCA 1 or 2 gene who have developed breast or ovarian neoplasm
62239486|NCT05748353||Patients with BRCA pathological variants without diagnosis of cancer|Patient with pathogenetic mutation of BRCA 1 or 2 gene without diagnosis of malignancy and without prophylactic surgery
62239487|NCT04423861|EXPERIMENTAL|nitazoxanide BID|Patients will receive nitazoxanide 600 mg BID for 7 days.
62239488|NCT04423861|PLACEBO_COMPARATOR|Placebo|Patients will receive matching placebo BID for 7 days.
62239489|NCT05232253|EXPERIMENTAL|Neurogenic Bladder Patient|Patients with neurogenic bladder
62239490|NCT06296134|EXPERIMENTAL|perineal massage|participants randomized to this arm are asked to perform themselves the perineal massage once daily from 34 gestational weeks until delivery.
62239491|NCT06296134|NO_INTERVENTION|standard care|participants randomized to this arm are asked to care for their pelvic floor according to the standard practice, which includes healthy diet, weight gain control, physical activity and voiding training therapy.
62239492|NCT05452590|EXPERIMENTAL|Ultrasound-guided wire-in-needle technique|The guidewire will be connected to the needle. The IJV will be punctured in a long-axis in-plane approach. When the needle tip enters the IJV, the guidewire will be advanced through the needle into the IJV under continuous ultrasound visualization. The needle will then be removed. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view. Afterwards, the second guidewire will be placed in the same IJV approximately 1-2 centimeters distal to the fist guidewire using the same technique. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view again.
62239493|NCT05452590|NO_INTERVENTION|Traditional technique|A syringe will be connected to the needle. The IJV will be punctured in a long-axis in-plane or short-axis out-of-plane approach (as preferred by the anesthesiologist). When the needle tip enters the IJV, blood is aspirated using the syringe. The operator will then discontinue US-guidance, disconnect the syringe and advance the guidewire through the needle into the IJV. The needle will then be removed. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view. Afterwards, the second guidewire will be placed in the same IJV approximately 1-2 centimeters distal to the fist guidewire using the same technique. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view again.
62239494|NCT02953366|EXPERIMENTAL|EMS Mometasone gel|The patient should administer 1 spray in each nostril once daily.
62429866|NCT02387788|EXPERIMENTAL|15 mg AKB-9778 BID for 84 days|Subcutaneous AKB-9778 15 mg BID (total dose of 30 mg/day) for 84 days
62429867|NCT02236754|OTHER|Healthy Controls|Pancreatic 18 F-FP-DTBZ uptake will be measured with PET scanning in healthy controls: subjects with predicted normal BCM (healthy, normal weight, non-diabetic individuals who have stimulated insulin and c-peptide levels within the normal range).
62597154|NCT05685004|EXPERIMENTAL|Interventional TVI-Brain-1 Autologous Vaccine and activated autologous blood-derived t cells|TVI-Brain-1 immunotherapy is integrated with radiation and temozolomide in the test group in the following manner: 1) Subjects undergo surgical resection of their cancer and are tapered off steroids. 2) Subjects receive the first vaccination of TVI-Brain-1 as soon as the laboratory prepared vaccine is available for use (approximately 7 - 14 days following surgery). 3) Subjects receive a second vaccination 7-10 days later. 4) Subjects are leukapheresed to obtain immune T cells for ex vivo-activation. 5) Subjects' T cells are stored frozen until after chemoradiotherapy is completed. 6) Following chemoradiotherapy Subjects are infused with activated effector T cells followed by a 10-day course of low-dose interleukin 2 (IL-2). 7) Subjects then proceed with post therapy surveillance.
62597155|NCT05466994|OTHER|Group 1(Spellbound)|Participants will play the game using the iPad's standard camera, which will show you your hospital room and the decals as they appear in the real world.
62597156|NCT05466994|OTHER|Group 2 (Spellbound)|Participants will play the game using augmented reality
62239495|NCT02953366|ACTIVE_COMPARATOR|Mometasone spray nasal|The patient should administer 1 spray in each nostril once daily.
62597157|NCT06350526||1|patient admitted with hematological disease and pulmonary manifestations
62735591|NCT04381052|PLACEBO_COMPARATOR|Placebo|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
62735592|NCT04892524|EXPERIMENTAL|Virtual multidisciplinary review|Participants in this arm will be reviewed in a virtual clinic by a multidisciplinary team
62429868|NCT02236754|OTHER|Patients with T1D|Pancreatic 18 F-FP-DTBZ uptake will be measured with PET scanning in patients with longstanding T1D: subjects with predicted reduced beta cell mass (subjects with established T1DM who have low or no measurable stimulated insulin and c-peptide levels).
62429869|NCT01343628|PLACEBO_COMPARATOR|Placebo, Atomoxetine|
62429870|NCT01343628|ACTIVE_COMPARATOR|Atomoxetine, Placebo|
62429871|NCT00678379|PLACEBO_COMPARATOR|Normal Saline|1.5 ml injection of Normal Saline into each tonsillar fossa pre-tonsillectomy
62429872|NCT00678379|ACTIVE_COMPARATOR|Lidocaine (1%) + Bupivacaine 0.5%|Submucosal injection of 1.5 mL Lidocaine (1%) + Bupivacaine 0.5% into the tonsillar fossa, pre-tonsillectomy
62429873|NCT00678379|EXPERIMENTAL|Lidocaine + Bupivacaine + Clondine|Submucosal injection of 1.5 mL Lidocaine 1% + Bupivacaine 0.5% + Clondine 25mcg into the tonsillar fossa, pre-tonsillectomy
62429874|NCT06496113||Robotic liver resections|
62239496|NCT04820777|EXPERIMENTAL|perturbation based training|External perturbations occur by forces outside the patient' control (e.g., a push or pull from the physiotherapist). Internal perturbations caused when the patient is unable to control the centre of mass and the base of support relationship during voluntary movement; 'agility' tasks, such as kicking a soccer ball,
62239497|NCT04820777|ACTIVE_COMPARATOR|Conventional' balance training|"Starting from a situated position, expand your left leg until it's corresponding to the floor. Try not to bolt your knee. At that point, gradually bring your foot down to the floor.~Rehash with your correct leg, exchanging to and fro between legs for a sum of 20 repitions (10 on every leg).~Situated Marching Starting with a situated position, lift your effected leg towards your chest, making an honest effort to keep up controlled development."
62239498|NCT03597412|EXPERIMENTAL|Rosuvamibe Tab|Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks
62239499|NCT03597412|ACTIVE_COMPARATOR|Monorova Tab|Rosuvastatin 20mg qd for 24 weeks
62239500|NCT04431050||Suspected influenza or other respiratory viral infection.|"Any adult presenting to the Accident \& Emergency department with influenza like illness or a febrile illness associated with symptoms such as cough, sore throat or rhinorrhoea, and for whom a respiratory viral screen is clinically indicated.~For the purposes of this study one nasal swab will be taken from consenting adults."
62239501|NCT01008696|EXPERIMENTAL|Rabeprazole|Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
62239502|NCT01008696|ACTIVE_COMPARATOR|Lansoprazole|Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
62239503|NCT05356468|EXPERIMENTAL|Structured pain neuroscience education|Pain neuroscience education will be given to both groups. Group A will receive Structured Pain Neuroscience Education along with therapeutic , balance exercises and Postural training.
62239504|NCT05356468|ACTIVE_COMPARATOR|Conventional treatment|"Group B will receive Pain Neuroscience Education along with therapeutic, balance exercises. The treatment will continue for 6 weeks. Three sessions will be given in a week. Assessment would be done on baseline and at the end of every third week.~Each session will be of 45 minutes. 15min electrotherapy, 15 min conventional treatment, 15 min PNE education."
62429875|NCT06496113||Laparoscopic liver resection|
62239505|NCT04914143|EXPERIMENTAL|Experimental group|
62735593|NCT04892524|NO_INTERVENTION|Face-to-face review|Participants in this group will be reviewed in a face-to-face clinic
62815435|NCT04072783|OTHER|Patients with craniosynostosis|Patients with craniosynostosis will undergo pre - and post-operative imaging studies. The surgery will be performed for these patients as standard of care. They will also be tested fro neurodevelopment.
62815436|NCT03449017|EXPERIMENTAL|E-cig use condition|Participants self-administer their own electronic cigarette device
62815437|NCT03839940|EXPERIMENTAL|Group I (dexamethasone)|Patients receive 10mg oral everolimus daily as standard of care and 10ml dexamethasone oral mouthwash, swished for 2-minutes daily, for 8 weeks.
62815438|NCT03839940|PLACEBO_COMPARATOR|Group II (placebo)|Patients receive 10mg oral everolimus daily as standard of care and 10ml placebo oral mouthwash, swished for 2-minutes daily, for 8 weeks.
62815439|NCT04571749|EXPERIMENTAL|Customized Or to ICU handoff protocol|Tailored implementation strategies will be used in 12 ICUs to facilitate the uptake and sustained use of a customized handoff protocol to be used by clinicians at the time of patient care transition from the operating room to the intensive care unit.
62815440|NCT04517123|NO_INTERVENTION|Control - Usual Care|Usual Care
62815441|NCT04517123|EXPERIMENTAL|Intervention - Prone Positioning|Prone Positioning
62239506|NCT04914143|PLACEBO_COMPARATOR|placebo comparator group|
62239507|NCT04281589|EXPERIMENTAL|Group 1|tidal volüm is 4 ml/kg
62239508|NCT04281589|EXPERIMENTAL|Group 2|tidal volüm is 6 ml/kg
62239509|NCT04281589|EXPERIMENTAL|Group 3|tidal volüm is 8 ml/kg
62239510|NCT04281589|EXPERIMENTAL|Group 4|tidal volüm is 10 ml/kg
62239511|NCT01272154|EXPERIMENTAL|Primary cervical dystonia Patients|
62429876|NCT05260983|ACTIVE_COMPARATOR|Diabetes Prevention Education Only|A brief standard diabetes prevention education engagement facilitation intervention modeled from the Center for Diseases Control and Prevention's National Diabetes Prevention Program.
62735594|NCT01734798|EXPERIMENTAL|Arm 1|post-operative radiotherapy will be done in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy Dose of Radiotherapy: 45 Gray Gy/30 fractions/3 weeks
62239512|NCT01272154|EXPERIMENTAL|Primary upperlimb Dystonia Patients|
62239513|NCT01272154|EXPERIMENTAL|Secondary Cervical or Upperlimb Dystonia due to cerebral palsy|
62239514|NCT01272154|OTHER|Healthy volunteers|
62239515|NCT04144751||Subjects Enrolled in 2019-01 BLUE-C|Subjects will be men and women, 40 years of age or older, who enroll in Exact Sciences Protocol 2019-01 BLUE-C. Subjects will provide a blood sample at time of enrollment.
62239516|NCT03595605|EXPERIMENTAL|FitBit Group|Will receive a wearable device (FitBit) designed to track number of steps for the duration of their hospital stay. They will receive nudges twice/day to ambulate
62239517|NCT03595605|ACTIVE_COMPARATOR|Control Group-Standard of Care|300 subjects who will receive usual standard of care on a general inpatient medicine unit with the addition of a wearable device (FitBit) to track usual mobility in this setting. will complete their admission without push for increased activity (although having the device may influence their steps taken).
62239518|NCT01891435|ACTIVE_COMPARATOR|oral paracetamol|patients in this arm will receive 1000mg of oral paracetamol
62239519|NCT01891435|ACTIVE_COMPARATOR|Intravenous paracetamol|patients in this arm will receive 1000 mg of intravenous paracetamol
62239520|NCT01891435|ACTIVE_COMPARATOR|Intramuscular Diclofenac|patients in this arm will receive 75 mg of intramuscular diclofenac sodium
62239521|NCT01998126|EXPERIMENTAL|EGFR patients with ipilimumab|ipilimumab and erlotinib in EGFR mutated patients
62239522|NCT01998126|EXPERIMENTAL|ALK patients plus ipilimumab|ipilimumab and crizotinib in ALK mutated patients
62239523|NCT01998126|EXPERIMENTAL|EGFR patients with nivolumab|nivolumab and erlotinib in EGFR mutated patients
62239524|NCT01998126|EXPERIMENTAL|ALK patients plus nivolumab|nivolumab and crizotinib in ALK mutated patients
62239525|NCT03991091|EXPERIMENTAL|discontinuation of oxytocin administration|Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm
62239526|NCT03991091|ACTIVE_COMPARATOR|continuation of oxytocin administration|Standard care in France, i.e. when oxytocin is started during the latent phase of the 1st stage, administration of oxytocin is continued during the active 1st stage and during the 2nd stage if the fetal heart rate is reassuring.
62239527|NCT00705432|PLACEBO_COMPARATOR|1. Placebo + PEG + RBV|PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing \[WBD\]) for 4 weeks (lead in treatment) followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
62239528|NCT00705432|EXPERIMENTAL|2. Boceprevir + PEG + RBV - 24 Weeks (RGT)|"PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.~* At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable from Treatment Weeks 8 to Treatment Week 24, will proceed to the 44-week follow-up.~* At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up."
62239529|NCT00705432|EXPERIMENTAL|3. Boceprevir + PEG + RBV - 44 Weeks|PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
62239530|NCT05169125|ACTIVE_COMPARATOR|Group A: standard hemodialysis.|patients who will undergo standard hemodialysis (dialysate sodium concentration 143 mmoL/L)
62239531|NCT05169125|ACTIVE_COMPARATOR|Group B: lower dialysate sodium hemodialysis.|patients who will undergo hemodialysis with lower dialysate sodium concentration (140 mmoL/L).
62239532|NCT02429297|EXPERIMENTAL|Patient Only - HITCM-only|Patients enrolling without a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team.
62239533|NCT02429297|EXPERIMENTAL|Patient & CarePartner - HITCM-only|Patients enrolling with a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team.
62239534|NCT02429297|EXPERIMENTAL|Patient & CarePartner - HITCM+CP|Patients enrolling with a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team plus updates to their CarePartner via phone or email.
62735595|NCT01734798|EXPERIMENTAL|Arm 2|adjuvant chemotherapy (gemcitabine and cisplatin) in addition to post operative radiotherapy in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
62239535|NCT04392453|EXPERIMENTAL|Robotic therapy|Upper limb robotic rehabilitation by means of the portable robot Icone.
62239536|NCT00148954|ACTIVE_COMPARATOR|Implantable Cardioverter Defibrillator - Boston Scientific|VITALITY 2 ICD
62239537|NCT00148954|ACTIVE_COMPARATOR|Implantable Cardioverter Defibrillator - Medtronic|Selected Medtronic family ICD
62239538|NCT03807674|OTHER|Control group - Healthy teeth|Patients with clinically healthy third molar or premolar teeth with indications for extraction; no clinical signs of pulpitis, no caries, no indications for the replacement of an old filling that is 1 mm from the pulp space as determined on the radiograph; a normal response to the cold test, and no apical radiolucency on the radiograph. For teeth of this group coronal pulpotomy was applied.
62239539|NCT03807674|EXPERIMENTAL|Test group - Teeth with pulpitis|Patients with symptomatic pulpitis resulting from caries; tooth pain defined as sharp, dull, localized or diffuse; pain at night; a symptomatic tooth with a positive response to the cold test and lingering pain; intermittent or continuous episodes of spontaneous pain (with no external stimulus) that could last from a few minutes up to a few hours; no apical radiolucency on the radiograph. For teeth of this group coronal pulpotomy was applied.
62735596|NCT01734798|EXPERIMENTAL|Arm 3|Adjuvant chemotherapy alone in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
62735597|NCT02069821|EXPERIMENTAL|Group A|single administration : amlodipine/valsartan 10/160mg, qd, 10days(oral)
62735598|NCT02069821|EXPERIMENTAL|Group B|single administration : atorvastatin 40mg, qd, 7days(oral)
62037530|NCT03717961|EXPERIMENTAL|" BTX-A group"|"* BOTOX® solution~* Saline serum~* lidocaine/prilocaine cream~* Nitrous oxide/oxygen (50%/50%)~Intervention Description :~* BOTOX 100 UNITES (Allergan, Courbevoie, France, and São Paulo, Brazil) Single injection schedule of BOTOX® in both hands, diluted in 2 ml of sterile serum saline, with a dosage of 50 UI (1 ml) by hand. Injections will be performed at the level of the distal palmar crease, targeting the neurovascular bundles in the 4 web spaces (0.25 ml/injection site)~* between 2 to 3 hours before the procedure, application of lidocaine/prilocaine cream under an occlusive dressing (polyurethane film) in each palmar crease of the patients (1/2 tube/hand), according to the recommendations of the manufacturer~* inhaled nitrous oxide/oxygen (50% / 50%) may be used, if needed"
62037531|NCT03717961|PLACEBO_COMPARATOR|Placebo group|"* Saline serum~* lidocaine/prilocaine cream~* Nitrous oxide/oxygen (50%/50%)~Intervention Description :~* Sterile saline solution Single injection schedule of 2 ml (1 ml by hand) of serum saline, in both hands. Injections will be performed at the level of the distal palmar crease, targeting the neurovascular bundles in the 4 web spaces (0.25 ml/injection site).~* between 2 to 3 hours before the procedure, application of lidocaine/prilocaine cream under an occlusive dressing (polyurethane film) in each palmar crease of the patients (1/2 tube/hand), according to the recommendations of the manufacturer of the lidocaine cream.~* inhaled nitrous oxide/oxygen (50% / 50%) may be used, if needed"
62037532|NCT04163705||Gram negative|"The presence of one or more positive samples will be considered positive blood cultures.~Patients with severe sepsis will be enrolled prospectively and consecutively. Some of the blood used for blood culture samples will be processed for the study (sample 0). The plasma will be stored at -80 ° for later analysis. A routine clinical and laboratory database will be completed.~Only patients who have positive blood cultures will be randomized according to their result in: sepsis by Gram positive or Gram negative."
62037533|NCT04163705||Gram positive|"The presence of one or more positive samples will be considered positive blood cultures.~Patients with severe sepsis will be enrolled prospectively and consecutively. Some of the blood used for blood culture samples will be processed for the study (sample 0). The plasma will be stored at -80 ° for later analysis. A routine clinical and laboratory database will be completed.~Only patients who have positive blood cultures will be randomized according to their result in: sepsis by Gram positive or Gram negative."
62037534|NCT02223923|EXPERIMENTAL|Dose Escalation|AZD6738 PO 20 to 380mg BD increasing
62037535|NCT02223923|EXPERIMENTAL|AZD6738 - Expansion Phase|AZD6738 starting dose and regimen to be determined in dose escalation phase
62037536|NCT02223923|EXPERIMENTAL|AZD6738 + Radiotherapy (Head and Neck)|AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)
62037537|NCT02223923|EXPERIMENTAL|AZD6738 + Radiotherapy (Abdomen / Pelvis)|AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)
62037538|NCT00859391||1 - Active|This group received gluten pre-treated with ALV003
62239540|NCT03037619|EXPERIMENTAL|Fitbit|Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months.
62239541|NCT03037619|EXPERIMENTAL|Fitbit+Support|"Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months."
62037539|NCT00859391||2 - Placebo|This group received Gluten pre-treated with placebo.
62037540|NCT02085408|ACTIVE_COMPARATOR|A (Induction:daunorubicin/cytarabine; consolidation:cytarabine; maintenance:observation/transplant)|See Detailed Description
62037541|NCT02085408|EXPERIMENTAL|B (Induction: clofarabine; Consolidation: clofarabine; Maintenance: decitabine or transplant)|See Detailed Description
62037542|NCT04066348|EXPERIMENTAL|Etanercept Injection Group|Subjects will receive 2 X 25mg/ 1ml etanercept injection (experimental) weekly for 12 weeks.
62037543|NCT04066348|PLACEBO_COMPARATOR|Placebo Injection Group|Subjects will receive 2 X 1ml saline injection (placebo) weekly for 12 weeks.
62239542|NCT01126151|EXPERIMENTAL|parent handbook|parent handbook to increase the quantity and quality of communications about alcohol
62239543|NCT01126151|EXPERIMENTAL|parent handbook with boosters|boosters are given to parents at three times (move in, visit weekend; student visits home)
62239544|NCT01126151|EXPERIMENTAL|parent handbook delay|parent handbook is delayed and given after semester has begun
62239545|NCT06153238|EXPERIMENTAL|GME751|Subjects will receive GME751 via intravenous (IV) infusion.
62239546|NCT06153238|ACTIVE_COMPARATOR|Keytruda - EU|Subjects will receive Keytruda-EU via intravenous (IV) infusion.
62239547|NCT06153238|ACTIVE_COMPARATOR|Keytruda - US|Subjects will receive Keytruda-US via intravenous (IV) infusion.
62239548|NCT03552796|EXPERIMENTAL|sEphB4-HSA|Cohorts of at least 3 participants each will be treated with escalating doses of sEphB4-HAS at 25mg, 50 mg, 75mg, 100 mg, and 125 mg administered intravesically over 2 hours once a week for 6 consecutive weeks to determine the maximum tolerated dose (MTD) and recommended phase II dosing (RP2D). Cycle repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
62239549|NCT04678323|ACTIVE_COMPARATOR|Phentermine Plus Lifestyle Therapy|Participants in this arm will receive 15 mg p.o.q.day of phentermine plus lifestyle therapy for 52 weeks.
62239550|NCT04678323|PLACEBO_COMPARATOR|Placebo Plus Lifestyle Therapy|Participants in this arm will receive a matching placebo plus lifestyle therapy for 52 weeks.
62239551|NCT03532646|OTHER|group 1: RYGB|All patients who underwent RYGB and were readmitted to upper endoscopy are getting observed
62239552|NCT03532646|OTHER|group 2:MGB/OAGB|All patients who underwent MGB/OAGB and were readmitted to upper endoscopy are getting observed
62239553|NCT01230853|ACTIVE_COMPARATOR|Active Comparator: A|
62735599|NCT02455336|EXPERIMENTAL|Fenofibrate|Subjects with adverse TG concentrations (i.e., paraplegia: \>/=135 mg/dl; tetraplegia \>/=115 mg/dl) will be randomized to receive once daily fenofibrate therapy (i.e., 145 mg) for 4 months
62239554|NCT01230853|PLACEBO_COMPARATOR|Placebo Comparator A|
62239555|NCT01230853|ACTIVE_COMPARATOR|Active Comparator: B|
62815442|NCT06528288|EXPERIMENTAL|Erector Spinae Plane Block|An erector spinae plane block (ESPB) will be administered prior to the surgical procedure, but after the patient receives general anesthesia. The injection will consist of 10 mL of saline, 20 mL of liposomal bupivacaine, and 30 mL of bupivacaine. This will be injected along the erector spinae fascial plane at the surgical levels. Fluoroscopy will be used for guidance during the injection.
62037544|NCT02189551|ACTIVE_COMPARATOR|Lokomat Pro|gait robot established on the market
62037545|NCT02189551|EXPERIMENTAL|Lokomat Pro FreeD|gait robot based on the Lokomat Pro with changes in guidance of the hip, approved for the Swiss market
62815443|NCT06528288|ACTIVE_COMPARATOR|Subcutaneous Anesthesia|A subcutaneous anesthesia injection will be administered after the surgery has been completed, but while the patient is under general anesthesia. The injection will consist of 10 mL of saline, 20 mL of liposomal bupivacaine, and 30 mL of bupivacaine. This will be injected around the surgical incision, subcutaneously.
62815444|NCT06704789||Hemorrhage stroke patients|
62239556|NCT01230853|PLACEBO_COMPARATOR|Placebo Comparator B|
62239557|NCT03868969|EXPERIMENTAL|Fosfomycin|Fosomycin tromethamine, one sachet for 21 days
62239558|NCT05373524|ACTIVE_COMPARATOR|the rheopheresis group|Rheopheresis is performed using an automated monitor in a double-filtration cascade. Plasma purify from of high molecular weight proteins through a secondary filter is then returned to the patient. This technique is performed in tandem with a hemodialysis monitor.
62239559|NCT05373524|PLACEBO_COMPARATOR|the shamapheresis group|Shamapheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient. This technique is performed in tandem with a hemodialysis monitor.
62037546|NCT05579418|ACTIVE_COMPARATOR|Interventional Arm|Patient that qualify for the trial will be randomized for receiving the PCSK9i injection in addition to the standard medical therapy.
62037547|NCT05579418|NO_INTERVENTION|Control Arm|Patient will only receive the standard medical therapy, No PCSK9i
62037548|NCT01214772|EXPERIMENTAL|heparin,pregnancy,IVF failure|Women in the heparin arm are administered 5000 IU twice a day on the day of embryo transfer
62037549|NCT01254058||Glaucoma Group|
62239560|NCT05109676|EXPERIMENTAL|Patients having embryo transfert|Patients benefit from the usual treatment for frozen embryo transfer with a preparatory cycle of the artificial endometrium: 150 µg of percutaneous estradiol for approximately 11 days and 200 mg of progesterone morning and evening to be taken vaginally for 2 days in case of embryo transfer at day 2 stage, 3 days in case of embryo transfer at day 3 stage, 5 days in case of day 5 embryo transfer or 6 days in case of day 6 embryo transfer.
62815445|NCT06704789||Ischemic stroke patients|
62815446|NCT06704789||Healthy adults|
62037550|NCT01254058||Age-Matched Controls|
62037551|NCT00636610|EXPERIMENTAL|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily starting on Day 3 of each 2-week treatment cycle. In addition, patients received either Modified FOLFOX (FOL=leucovorin calcium \[folinic acid\], F=fluorouracil, OX=oxaliplatin) + bevacizumab or FOLFIRI (FOL=leucovorin calcium \[folinic acid\] F=fluorouracil, IRI=irinotecan hydrochloride) + bevacizumab on Days 1-3 of each 2-week treatment cycle. The decision of which regimen (FOLFOX or FOLFIRI) to use was made by the treating physician and patient.
62037552|NCT00636610|PLACEBO_COMPARATOR|Placebo to vismodegib|Patients received placebo to vismodegib orally once daily starting on Day 3 of each 2-week treatment. In addition, patients received either Modified FOLFOX (FOL=leucovorin calcium \[folinic acid\], F=fluorouracil, OX=oxaliplatin) + bevacizumab or FOLFIRI (FOL=leucovorin calcium \[folinic acid\] F=fluorouracil, IRI=irinotecan hydrochloride) + bevacizumab on Days 1-3 of each 2-week treatment cycle. The decision of which regimen (FOLFOX or FOLFIRI) to use was made by the treating physician and patient.
62239561|NCT06196983|EXPERIMENTAL|Experimental group, Rhythmic aerobic exercises|Rhythmic aerobic exercises were used in experimental group.
62239562|NCT06196983|ACTIVE_COMPARATOR|control group, strength and balance exercises|only strength and balance exercises were given to control group.
62735600|NCT02455336|OTHER|No Intervention|Subjects with adverse TG concentrations (i.e., paraplegia: \>/=135 mg/dl; tetraplegia \>/=115 mg/dl) will be randomized to receive no therapy for 4 months
62815447|NCT02779439|EXPERIMENTAL|3rd party CTL infusion|Virus specific CTLs
62815448|NCT03260946||Palliative/Supportive care|Individuals with cancer receiving palliative or supportive care
62815449|NCT03772249|EXPERIMENTAL|Cohort A1 DCR-HBVS|Single dose, Subcutaneous injection of 0.1mg/kg of DCR-HBVS (HV)
62815450|NCT03772249|PLACEBO_COMPARATOR|Cohort A1 Placebo|Single dose, Subcutaneous injection of 0.1mg/kg of Placebo for DCR-HBVS (HV)
62815451|NCT03772249|EXPERIMENTAL|Cohort A2 DCR-HBVS|Single dose, Subcutaneous injection of 1.5mg/kg of DCR-HBVS (HV)
62815452|NCT03772249|PLACEBO_COMPARATOR|Cohort A2 Placebo|Single dose, Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS (HV)
62815453|NCT03772249|EXPERIMENTAL|Cohort A3 DCR-HBVS|Single dose, Subcutaneous injection of 3mg/kg of DCR-HBVS (HV)
62815454|NCT03772249|PLACEBO_COMPARATOR|Cohort A3 Placebo|Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (HV)
62815455|NCT03772249|EXPERIMENTAL|Cohort A4 DCR-HBVS|Single dose, Subcutaneous injection of 6mg/kg of DCR-HBVS (HV)
62815456|NCT03772249|PLACEBO_COMPARATOR|Cohort A4 Placebo|Single dose, Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS (HV)
62037553|NCT04678492|EXPERIMENTAL|High-dose esomeprazole and amoxicillin dual therapy|Esomeprazole 40 mg and amoxicillin 1000 mg by mouth，three time daily for 14 days
62037554|NCT04678492|ACTIVE_COMPARATOR|Bismuth-containing quadruple therapy|Tetracycline 500mg three time daily for 14 days，furazolidone 100 mg, esomeprazole 40 mg, and Bismuth 220mg by mouth, twice daily for 14 days.
62037555|NCT00439868|EXPERIMENTAL|Treatment Group 1|Subjects in Period 1 of treatment group 1 will receive oral doses of extended release WELLBUTRIN XL tablets for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD. In Period 2 subject will receive placebo for 2 weeks.
62037556|NCT00439868|EXPERIMENTAL|Treatment Group 2|Subjects in Period 1 of Treatment group 2 will receive Placebo for 2 weeks and in Period 2 subject will receive oral doses of extended release WELLBUTRIN XL for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD.
62037557|NCT03461003|EXPERIMENTAL|NICHE method|In the NICHE method, antihypertensive therapy will be chosen using an n-of-1 trial to identify the preferred therapy. Preferred therapy is defined a priori as that which produces the greatest reduction in ambulatory BP without intolerable side effects. Tested drugs will include amlodipine or losartan, lisinopril, and hydrochlorothiazide.
62037558|NCT03461003|ACTIVE_COMPARATOR|Usual Care|No protocol will be introduced to standardize BP management in the control arm.
62037559|NCT01835951|OTHER|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
62037560|NCT01835951|OTHER|Grouped Debriefing|Grouped debriefing consists in the analysis of the management of the anaesthesia crisis simulated in the presence of all the subject included in the Grouped Debriefing group.
62037561|NCT03977038||TRD sample|Individuals in the treatment resistant depression (TRD) sample suffer from the condition called TRD. The intervention that will be administered to this group is the standardized rTMS treatment using High Frequency dTMS (HF-dTMS) stimulation over L-DLPFC, at the frequency of 18Hz, at 120% value of the individual's motor threshold, in 5 daily sessions per week, taking place each weekday, over the course of 6 weeks.
62815457|NCT03772249|EXPERIMENTAL|Cohort A5 DCR-HBVS|Single dose, Subcutaneous injection of 12mg/kg of DCR-HBVS (HV)
62037562|NCT03977038||Healthy Controls (HC) sample|Individuals in the HC sample are age-, sex-, education-matched to the individuals in the TRD sample. HC sample does not receive any therapeutic treatment and are solely examined as a comparative measure of normal cognitive capabilities.
62037563|NCT05265611|EXPERIMENTAL|Young Adult Community Mental Health Worker|Syrian refugee young adults will be trained to implement Problem Management Plus (PM+): a WHO evidence-based low intensity mental health intervention to Syrian refugee adults in their community. They will complete 4 surveys to measure outcomes and mechanisms.
62239563|NCT02955576|PLACEBO_COMPARATOR|Control group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.
62815458|NCT03772249|PLACEBO_COMPARATOR|Cohort A5 Placebo|Single dose, Subcutaneous injection of 12mg/kg of Placebo for DCR-HBVS (HV)
62815459|NCT03772249|EXPERIMENTAL|Cohort B DCR-HBVS|Single dose, Subcutaneous injection of 3mg/kg of for DCR-HBVS (NUC naïve, CHB)
62037564|NCT05265611|ACTIVE_COMPARATOR|Young Adult Tutors|Syrian refugee young adults will be trained to tutor elementary school students in their community.They will complete 4 surveys to measure outcomes and mechanisms.
62037565|NCT05265611|NO_INTERVENTION|Young Adut Control Group|Syrian refugee young adults in the control group will only complete the surveys. They will complete 4 surveys to measure outcomes and mechanisms.
62037566|NCT03528538|PLACEBO_COMPARATOR|Placebo|
62037567|NCT03528538|ACTIVE_COMPARATOR|AlphaFen fenugreek 400 mg|This group received 400 mg of fenugreek to be ingested daily for 60 days.
62037568|NCT03528538|ACTIVE_COMPARATOR|AlphaFen fenugreek 500 mg|This group received 500 mg of fenugreek to be ingested daily.
62037569|NCT03919422|ACTIVE_COMPARATOR|IC group|Interscalene brachial plexus-Cervical plexus
62239564|NCT02955576|ACTIVE_COMPARATOR|Patch group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.
62037570|NCT03919422|EXPERIMENTAL|ICTP group|Interscalene brachial plexus-Cervical plexus combined with T2 Paravertebral blockade
62037571|NCT06443775||NGE-UD|Participants will receive one drop of Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Day 1, after Day 1 participants will administer 1-2 eye drops in each eye at least twice a day but as much as needed through Day 15.
62037572|NCT00689767|EXPERIMENTAL|A|This arm will receive the coated stent
62239565|NCT02955576|EXPERIMENTAL|Microneedle patch group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.
62239566|NCT02018757|EXPERIMENTAL|As2O3|Subjects will be treated with TACE containing As2O3
62239567|NCT02018757|PLACEBO_COMPARATOR|placebo|Subjects will be treated with TACE containing placebo which mimics the arsenic trioxide
62815460|NCT03772249|PLACEBO_COMPARATOR|Cohort B Placebo|Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (NUC naïve, CHB)
62815461|NCT03772249|EXPERIMENTAL|Cohort C1 DCR-HBVS|4 doses- Subcutaneous injection of 1.5mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
62815462|NCT03772249|PLACEBO_COMPARATOR|Cohort C1 Placebo|4 doses- Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
62815463|NCT03772249|EXPERIMENTAL|Cohort C2 DCR-HBVS|4 doses- Subcutaneous injection of 3mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
62815464|NCT03772249|PLACEBO_COMPARATOR|Cohort C2 Placebo|4 doses- Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
62815465|NCT03772249|EXPERIMENTAL|Cohort C3 DCR-HBVS|4 doses- Subcutaneous injection of 6mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
62815466|NCT03772249|PLACEBO_COMPARATOR|Cohort C3 Placebo|4 doses- Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
62037573|NCT00689767|ACTIVE_COMPARATOR|B|This arm will receive a bare metal stent
62037574|NCT00908154|OTHER|Cohort 1|
62239568|NCT01550913|EXPERIMENTAL|Sober Network IPT|Participants are assigned to Sober Network Interpersonal Psychotherapy (IPT)
62735601|NCT02452957||Device: Simpliciti™ System|"The Simpliciti™ nucleus is a humeral prosthesis intended for total and hemi shoulder arthroplasty in patients with a severely painful and/or disabled joint resulting from osteoarthritis or traumatic arthritis.~The implant is sized to match and replicate the anatomy of the proximal humerus, while maintaining a bone conserving approach. It does not extend beyond the metaphysis, leaving the humeral canal untouched. Fixation is enhanced through a porous coating with a high coefficient of friction; resulting in a solid initial fit and long term fixation.~The Simpliciti™ nucleus is designed to receive a humeral head. The Simpliciti™ system is authorized to bear the CE mark and will be investigated within this clinical study in accordance with its intended use."
62239569|NCT01550913|OTHER|Treatment as Usual|Participants are assigned to have Treatment as Usual
62239570|NCT03503513|EXPERIMENTAL|Gentamicin sulfate|Participants initiate Gentamicin instillations every night for a treatment period of 6 months. Instillations are stopped if they developed a UTI. After receiving treatment for this UTI, they resume the Gentamicin instillations. After baseline screening and being consented, they are instructed on how to do the instillations through a catheter, once they receive the drug and aid equipment (i.e. syringes) to do installations. Remaining drug from syringes are to be disposed after each use. Participants use their own catheters. In-dwelling catheters are not allowed.
62037575|NCT00908154|OTHER|Cohort 4|
62037576|NCT00908154|OTHER|Cohort 3|
62037577|NCT00908154|OTHER|Cohort 2|
62037578|NCT05261633||Healthy Volunteers|
62037579|NCT05261633||Known Liver Metastases|
62037580|NCT05476328|EXPERIMENTAL|OPAL Sound Processing Strategy|OPAL Sound Processing Strategy with programming being performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool).
62037581|NCT05476328|EXPERIMENTAL|OPAL-EM|OPAL-Enhanced Modulation with programming being performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool).
62037582|NCT05476328|EXPERIMENTAL|SPACE|Spread Precompensation Advanced Combination Encoder (SPACE) with programming being performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool).
62239571|NCT05019157|EXPERIMENTAL|Telerehabilitation group|Participants will undertake the first three training sessions in the outpatient clinic under the supervision of the specialized staff for familiarization with the intervention. and then the participants will proceed with the telerehabilitation program at their homes. Participants will undergo an exercise - based program 3 times/week, comprised of 10' warm up exercises, 40' aerobic, resistance and balance exercises and 10' cool down, with the use of wearable sensors.
62037583|NCT05476328|EXPERIMENTAL|FAST|Fundamental Asynchronous Stimulus Timing (FAST) with programming being performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool).
62037584|NCT05476328|EXPERIMENTAL|OPAL-SPACE|OPAL-SPACE (combined OPAL and SPACE strategy) with programming being performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool).
62239572|NCT05019157|ACTIVE_COMPARATOR|Centre - based rehabilitation group|Participants will attend an exercise - based cardiac rehabilitation program at the outpatient clinic's facilities under the supervision of cardiac rehabilitation specialized staff. The participants will receive an individually tailored training program on a treadmill or a cycle ergometer 3 times/week, comprised of 10' warm up exercises, 40' aerobic, resistance and balance exercises and 10' cool down.
62429877|NCT05260983|EXPERIMENTAL|Diabetes Prevention Education and Acceptance and Commitment Therapy|A brief diabetes prevention education and acceptance and commitment therapy engagement facilitation intervention. Acceptance and Commitment Therapy-informed materials (i.e. video, workbook, and activities) will retain facts about the condition, but will modify health messaging to clarify common inaccurate illness perceptions, reduce body size discrimination, and encourage psychological flexibility through framing illness perceptions, controllability awareness (i.e. ability to distinguish modifiable from unmodifiable components), non-judgmental awareness of what is occurring, willingness to allow experiences to occur, and the ability to step back from cognitions, acting according to personal values.
62429878|NCT01493726|EXPERIMENTAL|ALKS 9072, Low dose|
62597158|NCT06590389|EXPERIMENTAL|Intervention group (Mandala activity)|Mandala activity is painting with different pictures or shapes by creating a harmony of figures in different or the same colors. The entire intervention group was given a booklet consisting of 10 simple mandala drawings prepared by the researchers. Mandala activity: During the hospital stay on the zeroth, first and second postoperative days, the patient was asked to color the mandala drawing of his choice from the booklet as many times as he wanted. However, they were asked to practice at least one mandala activity every day. For painting in the mandala activity, a set of 12 colored crayons was given to the patients by the researcher and no color guidance was given for painting. The research was continued by following up within 3 days, namely the zeroth, first and second postoperative days. VAS and STAI-I forms were applied before and after the mandala activity.
62597159|NCT06590389|NO_INTERVENTION|Control group|"After the patient was mobilized on the zero postoperative day, STAI-I and VAS were applied 1 hour apart. VAS was repeated every 4 hours until the patient was discharged.~* On the first day after surgery, VAS with STAI-I was applied to the patient every 1 hour after breakfast, and VAS was repeated every 4 hours during the day.~* On the second day after the surgery, STAI-I and VAS were applied to the patient 1 hour apart after breakfast.~* On the second postoperative day, the Postoperative Period Patient Evaluation form was applied to the patient before discharge."
62597160|NCT06497764|EXPERIMENTAL|Control (PRP Alone), then Intervention (PRP with VA)|Participants in this study arm will receive treatment with PRP alone first, then PRP+VA second. The first half of the scalp of each patient will be randomized to receive standard-of-care PRP alone. The second half of the scalp of each patient will receive VA via a device during the standard-of-care PRP treatment.
62597161|NCT06497764|EXPERIMENTAL|Intervention (PRP with VA), then Control (PRP Alone)|Participants in this study arm will receive treatment with PRP+VA first, then PRP alone second. The first half of the scalp of each patient will be randomized to receive VA via a device during the standard-of-care PRP treatment.. The second half of the scalp of each patient will receive standard-of-care PRP treatment alone.
62597162|NCT06643364|ACTIVE_COMPARATOR|Control Group|The karate athletes in the control group continued their routine training planned by the national team during the study.
62597163|NCT06643364|EXPERIMENTAL|Vision Training Group|The karate athletes in the vision training group participated in a vision training programme that included eye movements and was applied by one of the researcher physiotherapists in addition to their routine training planned by the national team. The application was applied for 10 minutes in 3 sessions per week for 4 weeks.
62597164|NCT05383092|EXPERIMENTAL|Adapted physical activity Strong|
62597165|NCT05383092|ACTIVE_COMPARATOR|Adapted physical activity Soft|
62597166|NCT05002998|OTHER|Teprotumumab 4 Infusions|"• 4 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 3 infusions) (Cohort 1) followed by 4 infusions of:~* Placebo if a participant is a treatment responder at Week 12 or~* Teprotumumab 20 mg/kg if a participant is a treatment non-responder at Week 12"
62597167|NCT05002998|OTHER|Teprotumumab 8 Infusions|8 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions) (Cohort 2)
62815467|NCT03772249|EXPERIMENTAL|Cohort 4C DCR-HBVS|"1 dose- Subcutaneous injection of 100mg (NUC experienced, CHB)~1 dose- Subcutaneous injection of 200mg (NUC experienced, CHB)~1 dose- Subcutaneous injection of 400mg (NUC experienced, CHB)"
62815468|NCT03772249|EXPERIMENTAL|Cohort 5C1 DCR-HBVS|4 doses- Subcutaneous injection of 200mg administered every 4 weeks (NUC experienced, CHB)
62815469|NCT03772249|EXPERIMENTAL|Cohort 5C2 DCR-HBVS|2 doses- Subcutaneous injection of 200mg administered every 8 weeks (NUC experienced, CHB)
62815470|NCT03772249|EXPERIMENTAL|Cohort 5C3 DCR-HBVS|2 doses- Subcutaneous injection of 400mg administered every 12 weeks (NUC experienced, CHB)
62815471|NCT06523335|EXPERIMENTAL|Neuromuscular coordination-guided rehabilitative training|Post-stroke participants will perform a center-out task by generating isometric contractions of multiple muscles to move the cursor on a screen while electromyographic (EMG) responses are recorded. Activation of each muscle (or muscle group) will be mapped to 1 of 4 directions within the multi-dimensional cursor space. We will derive the cursor position in real time using EMGs recorded from multiple arm muscles.
62239573|NCT05019157|NO_INTERVENTION|Usual care group|Patients will not undertake any exercise based intervention and will only follow their usual medication treatment .The patients will wear the accelerometer for the 12 week study duration and visit the corresponding outpatient cardiac clinic every 4 weeks to upload the recorded data. The patients will also receive educational phone videoconference sessions every week for physical activity, diet/nutritional and smoking cessation counseling.
62429879|NCT01493726|EXPERIMENTAL|ALKS 9072, Med dose|
62429880|NCT01493726|EXPERIMENTAL|ALKS 9072, High dose|
62429881|NCT01493726|PLACEBO_COMPARATOR|Placebo|
62429882|NCT02542150|EXPERIMENTAL|acetate arm|IV acetate given during magnetic resonance scan
62037585|NCT05476328|EXPERIMENTAL|FAST-OPAL|FAST-OPAL (combined FAST and OPAL strategy) with programming being performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool).
62597168|NCT05002998|OTHER|Teprotumumab 16 Infusions|16 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 15 infusions) (Cohort 3)
62429883|NCT02542150|EXPERIMENTAL|alcohol arm|jello shots given before magnetic resonance scan
62429884|NCT04989621|EXPERIMENTAL|Orelabrutinib plus Rituximab followed by Maintenance with Orelabrutinib|"Induction therapy: Patients receive Orelabrutinib at a dose of 25 mg once daily on days 1-28 and rituximab at a dose of 375mg/m2 on day 1. Treatment cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~If patients achieve CR or PR or SD, they will be treated with maintenance therapy Maintenance therapy: Patients receive Orelabrutinib every day at a dose of 150mg for up to two years in the absence of disease progression or unacceptable toxicity."
62815472|NCT06523335|ACTIVE_COMPARATOR|Force strengthening-guided rehabilitative training|Post-stroke participants will perform a center-out task by generating isometric force to move the cursor on a screen. Participants will generate isometric force, which will move their cursor on the monitor. They will be trained to match one of the four force targets on display. We will derive the cursor position in real time using three forces (Fx, Fy, and Fz) measured at the load cell.
62815473|NCT05626738|EXPERIMENTAL|Long-lasting Colonoscopy With Endorail|In case of long-lasting colonoscopy, Endorail is used to facilitate the completion of the procedure.
62815474|NCT05840198|EXPERIMENTAL|Active intervention|Half of youth will be assigned to the active Recovery \& Care Canine-Assisted Therapy intervention arm.
62597169|NCT00477750|EXPERIMENTAL|Treatment (Lenalidomide, Melphalan, Prednisone)|"Intervention: Drug: lenalidomide Dose determined by Phase I treatment schedule. Taken orally days 1-21 every 28 days until progression~Intervention: Drug: melphalan Dose determined by Phase I treatment schedule. Taken orally days 1-4 every 28 days until progression~Intervention: Drug: prednisone 60mg/m\^2, orally days 1-4 every 28 days until progression"
62597170|NCT01447446||Dual Therapy: Peg-IFN Alfa-2a + Ribavirin|Participants with chronic hepatitis C (CHC) receiving dual therapy (pegylated interferon alfa-2a \[peg-IFN Alfa-2a\] along with ribavirin according to standard of care and in line with local labeling) were followed up for the duration of their treatment and for up to 24 weeks after therapy.
62597171|NCT01447446||Dual Therapy: Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving dual therapy (pegylated interferon alfa-2b \[peg-IFN Alfa-2b\] along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
62815475|NCT05840198|OTHER|Waitlist control|Half of youth will receive treatment as usual.
62037586|NCT06670625|EXPERIMENTAL|Intervention Group (IDAC+)|Participants randomized to the IDAC+ will regularly receive dietary and physical activity advice with focus on continuing breastfeeding up until the age of 12 months, limit the protein intake in the child´s diet (maximum 15E%), limit milk \& milk products (max 150 ml/day), support daily vitamin D supplementation. Specific age-appropriate advice on physical activity will be given to participants.
62239574|NCT02150525|EXPERIMENTAL|Arm I (oral omega-3 fatty acid)|Patients received 3.5g oral omega-3 fatty acid daily for 6 months. Questionnaire administration, pills counts, and medication diaries were collected at monthly intervals.
62429885|NCT03319901|EXPERIMENTAL|Venetoclax + Chemotherapy|"* Venetoclax is administered orally once daily for 21 days in each cycle~* Standard Chemotherapy will be administered every 28 days"
62429886|NCT03046537|ACTIVE_COMPARATOR|ovulatory|Comparison in metabolic state between ovulatory and PCOS women by collecting breath test from participant.
62429887|NCT03046537|ACTIVE_COMPARATOR|PCOS|Comparison in metabolic state between ovulatory and PCOS women by collecting breath test from participant
62597172|NCT01447446||Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
62597173|NCT01447446||Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
62597174|NCT01447446||Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
62735602|NCT03957668|EXPERIMENTAL|PEG 3350|The content of each sachet of PEG 3350 (17 g powder) is dissolved in 240 mL of water, drink it once daily at bedtime, for a duration of 14 days.
62815476|NCT05023733||1-2 contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1|One to two contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1 whose condition requires the use of interbody fusion.
62815477|NCT02231112|EXPERIMENTAL|Prone position whole breast RT|
62815478|NCT06313892|EXPERIMENTAL|Exercise group|The participants in the study group will be given an online personalized exercise program at home in non dialysis days. Each session will be 40 to 45 min in duration for 3 days per week over 12 weeks, 36 sessions in total.
62239575|NCT02150525|PLACEBO_COMPARATOR|Arm II (placebo)|Patients received equivalent, matched oral placebo (seven capsules) daily for 6 months. Questionnaire administration, pills counts, and medication diaries were collected at monthly intervals.
62239576|NCT06065501|EXPERIMENTAL|PACE intervention|The intervention group (PACE intervention) utilizes mobile social network support, employing a LINE group to implement a personalized plan based on the TTM model for establishing a care program.
62429888|NCT01947387||Integra|
62429889|NCT01947387||Integra + NPWT (short-inpatient use only)|
62429890|NCT01947387||Integra + NPWT (long-all other durations)|
62429891|NCT01947387||Integra + STSG|
62429892|NCT01947387||Integra + Dermoinductive Agent|
62429893|NCT01947387||Free Flap|
62429894|NCT01947387||Local Tissue Flap|
62037587|NCT06670625|NO_INTERVENTION|Control Group|No specific advice will be given to this group other than national guidelines similar to those given by the childcare centers.
62429895|NCT01947387||NPWT|
62429896|NCT01947387||NPWT then Integra (on same admission)|
62037588|NCT02291887||Neovascular ARMD Patients|Patients with Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab but Resistant to Aflibercept Treatment
62037589|NCT02045238|PLACEBO_COMPARATOR|Normal Saline|Patients will receive inhaled normal saline, initially with a 2 hour interval, and clinical evaluation prior to each inhalation. When they attain sat\>94% AND respiratory rate \<60 AND RDAI score \<4, the interval between inhalations will be changed to 4 hours. If they maintain these criteria for a whole 4 hour interval, they are discharged. If they do not improve enough to be discharged in 24 hours from the first inhalation, they are considered as admitted to hospital.
62429897|NCT05068206|EXPERIMENTAL|AK105+Anlotinib+CapeOx|"Treatment period (6 cycles):~AK105 injection: intravenous drip on Day 1; Anlotinib hydrochloride capsule: oral administration, once daily(QD) ; Oxaliplatin for injection: intravenous infusion on Day 1; Capecitabine tablet:oral administration, twice daily (BID) .~Maintenance period:~AK105 injection: intravenous drip on Day 1; Anlotinib hydrochloride capsule: oral administration, once daily(QD) ; Capecitabine tablet:oral administration, twice daily (BID) . Every 3 weeks is as one cycle.Oxaliplatin is administered for 6 cycles, and AK105 can be administered continuously for 1 year but at most for 2 years. Other cases continue to be administered until the treatment termination event specified in the plan occurs."
62597175|NCT01447446||Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
62597176|NCT06620510||No intervention|Patients who were in non-treatment group in phase 3 clinical trial IIC-I01(NCT00699816).
62597177|NCT06620510||Immuncell-LC Group|Patients who were in Immuncell-LC group in phase 3 clinical trial IIC-I01(NCT00699816).
62429898|NCT05068206|EXPERIMENTAL|Anlotinib+CapeOx|"Treatment period (6 cycles) Anlotinib hydrochloride capsule: QD orally; Oxaliplatin for injection: D1 intravenous infusion on Day 1; Capecitabine tablet: BID oral administration.~Maintenance period:~Anlotinib hydrochloride capsule: QD orally; Capecitabine tablet: BID oral administration. Every 3 weeks is as one cycle, and Oxaliplatin is administered for 6 cycles. Other cases continue to be administered until the treatment termination event specified in the plan occurs."
62597178|NCT00065637|EXPERIMENTAL|1|Women will self-administer PTH injections daily for 4 weeks, then once weekly for 48 weeks
62597179|NCT00065637|PLACEBO_COMPARATOR|2|Women will self-administer placebo injections daily for 4 weeks, then once weekly for 48 weeks
62597180|NCT06581003|EXPERIMENTAL|HBOT Group|HBOT chamber pressurized to 2.0 ATA with 100% oxygen
62815479|NCT06313892|NO_INTERVENTION|Control group|Patients allocated to the control group will receive their standard nephrological care. Through the 12-week period, all control participants will be instructed to maintain the standard treatment regimen and to maintain their customary dietary and physical activity patterns.
62815480|NCT06514157|EXPERIMENTAL|BDA MDI|Each randomized participant will receive a single dose of BDA MDI 160 μg/180 μg (administered as 2 actuations of 80 μg/90 μg) on Day 1 in the morning.
62815481|NCT06706674|EXPERIMENTAL|Lumateperone high dose|Lumateperone 42 mg for patients ages 13-17 years old
62815482|NCT06706674|EXPERIMENTAL|Lumateperone low dose|Lumateperone 21 mg for patients ages 13-17 years old
62037590|NCT02045238|EXPERIMENTAL|Hypertonic Saline|Patients will receive inhaled Hypertonic Saline 3%, initially with a 2 hour interval, and clinical evaluation prior to each inhalation. When they attain sat\>94% AND respiratory rate \<60 AND RDAI score \<4, the interval between inhalations will be changed to 4 hours. If they maintain these criteria for a whole 4 hour interval, they are discharged. If they do not improve enough to be discharged in 24 hours from the first inhalation, they are considered as admitted to hospital.
62037591|NCT05616988|EXPERIMENTAL|Experimental Group|The experimental group will consist of 20 patients with an indication for reconstruction using autologous tissues (DIEP, FALD) and 20 patients with an indication for reconstruction using the immediate prosthesis technique who will carry out the psychological-clinical intervention focusing on expressive writing about their experience of the surgical treatment.
62037592|NCT05616988|NO_INTERVENTION|Control Group|The control group will consist of 20 patients with an indication for reconstruction using autologous tissues (DIEP, FALD) and 20 patients with an indication for reconstruction using the immediate prosthesis technique who will not undergo any kind of psychological-clinical intervention and will be able to apply for the latter at the end of the research.
62037593|NCT03204279|EXPERIMENTAL|Netupitant 1.33 mg/kg plus Palonosetron|Single oral dose of Netupitant 1.33 mg/kg up to a maximum of 100 mg (for patients \< 3 months of age the netupitant dose will be 0.8 mg/kg) administered with single oral dose of 20 μg/kg palonosetron up to a maximum of 1.5 mg.
62597181|NCT06581003|SHAM_COMPARATOR|Placebo/Sham Group|HBOT chamber that remains unpressurized and has 21% oxygen
62037594|NCT03204279|EXPERIMENTAL|Netupitant 4 mg/kg plus Palonosetron|Single oral dose of Netupitant 4 mg/kg up to a maximum of 300 mg (for patients \< 3 months of age the netupitant dose will be 2.4 mg/kg) administered with single oral dose 20 μg/kg palonosetron up to a maximum of 1.5 mg.
62597182|NCT05966506|EXPERIMENTAL|Health coaching|
62597183|NCT02351908|EXPERIMENTAL|Arm 1|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat150mg/150mg/200mg/245mg) tablet 1 once daily for 48 weeks
62597184|NCT02351908|EXPERIMENTAL|Arm 2|Isentress® (Raltegravir 400 mg) 1 tablet twice a day + Truvada® (FTC \& Tenofovir) 1 tablet once a day for 48 weeks
62597185|NCT02351908|EXPERIMENTAL|Arm 3|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC \& Tenofovir) 1 tablet once a day for 48 weeks
62597186|NCT02557204|ACTIVE_COMPARATOR|conventional technique|the nasogastric tube will be inserted gently through a selected nostril with the head being maintained in the neutral position.
62815483|NCT06706674|PLACEBO_COMPARATOR|Placebo|Placebo
62037595|NCT02739581|EXPERIMENTAL|Endoscopic variceal ligation with Non-selective B-blockers|
62037596|NCT02739581|ACTIVE_COMPARATOR|Endoscopic variceal ligation with Placebo|
62037597|NCT01495429|EXPERIMENTAL|PICC line (Peripherally)|placement of a picc line
62037598|NCT01495429|ACTIVE_COMPARATOR|CICVC (central insertion)|placement of a centrally inserted central venous catheter
62037599|NCT03553810|EXPERIMENTAL|Treatment Arm|Entresto (valsartan/sacubitril) 100mg once a day
62037600|NCT03553810|ACTIVE_COMPARATOR|Controlled Arm|Valsartan 40mg once a day
62037601|NCT01914094|NO_INTERVENTION|Standard care|Received current standard care.
62037602|NCT01914094|EXPERIMENTAL|Prehab|Received pre-operative exercise therapy plus education classes concerning management of their risk factors for coronary artery disease at a local medical fitness facility.
62037603|NCT05156918|EXPERIMENTAL|Exercise Group|Exercise group participants will perform supervised high intensity exercise three times per week at the LLU department of physical therapy laboratory utilizing treadmills, stationary bicycles, and rowing machines.
62037604|NCT05156918|ACTIVE_COMPARATOR|Control Group|Control group participants will make no modifications to regular diet or exercise habits for 30 days.
62037605|NCT02726451|PLACEBO_COMPARATOR|Basic Skin Care|Subjects use a basic skin care regimen.
62037606|NCT02726451|ACTIVE_COMPARATOR|Active Skin Care|Subjects use the Sensi Peel®, Rejuvenating Serum, and C\&E Strength Max skin care products in additional to a basic skin care regiment.
62037607|NCT01854099|ACTIVE_COMPARATOR|5 Day TMZ with PEP-CMV on Day 6-8|Standard TMZ (200 mg/m2/day x 5 days) with PEP-CMV vaccination on Day 6-8 of each monthly TMZ cycle
62597187|NCT02557204|EXPERIMENTAL|head in the lateral position technique|the patient's head will be turned to the right lateral position. Nasogastric tube will be inserted through the right nostril without any maneuvers of the neck.
62037608|NCT01854099|ACTIVE_COMPARATOR|5 day TMZ with vaccine on day 22-24|Standard TMZ (200 mg/m2/day x 5 days) with vaccination on Day 22-24 of each monthly TMZ cycle
62037609|NCT01854099|ACTIVE_COMPARATOR|21 day TMZ wtih vaccine on day 22-24|Dose-intensified TMZ (100 mg/m2/day x 21 days) with vaccination on day 22-24 of each monthly TMZ cycle
62815484|NCT04780867|NO_INTERVENTION|Routine vaccination (Control)|
62037610|NCT05652062|EXPERIMENTAL|Treatment|
62429899|NCT05068206|ACTIVE_COMPARATOR|Bevacizumab+CapeOx|"Treatment period (6 cycles):~Bevacizumab D1 intravenous infusion; Oxaliplatin D1 intravenous infusion; Capecitabine BID oral administration.~Maintenance period:~Bevacizumab D1 intravenous infusion; Capecitabine BID oral administration. Every 3 weeks is as one cycle, and Oxaliplatin is administered for 6 cycles. Other cases continue to be administered until the treatment termination event specified in the plan occurs."
62815485|NCT04780867|EXPERIMENTAL|Delay vaccination (Experimental)|
62037611|NCT06634368|EXPERIMENTAL|Hospital GamePlan4care|Tailored caregiver skills training and support for caregiving for a person with dementia
62037612|NCT06634368|ACTIVE_COMPARATOR|Health Education|Education on general caregiving topics.
62037613|NCT06669169|PLACEBO_COMPARATOR|Placebo group|
62037614|NCT06669169|EXPERIMENTAL|Low dose group|
62037615|NCT06669169|EXPERIMENTAL|High dose group|
62037616|NCT04780334||Positive diagnosis of SARS-CoV-2|100 patients with a positive diagnosis of SARS-CoV-2
62037617|NCT04780334||Negative diagnosis of SARS-CoV-2|100 patients with a negative diagnosis of SARS-CoV-2 defined by the gold standard by the medical team
62037618|NCT02833168||1|Patients with proven neuromuscular disorders known to be potentially associated with significant diaphragmatic weakness, e. g. ALS, myotonic dystrophy type 1, limb-girdle muscular dystrophy, Duchenne and Becker muscular dystrophy. Patients already receiving home ventilatory support will not be included in the study.
62429900|NCT05616611|ACTIVE_COMPARATOR|Control group|control group received medication and traditional physiotherapy programs for stroke patients (strengthening, stretching, and balance exercise)
62815486|NCT04723511|EXPERIMENTAL|GPR|participants in this group receive global postural reeducation technique+ Kendall exercises
62815487|NCT04723511|ACTIVE_COMPARATOR|Kendall|Kendall exercises
62815488|NCT05286554|EXPERIMENTAL|Group 1|Will receive routine LPS and additional single GnRH-a bolus, triptorelin 0.1 mg subcutaneous injection on the 6th day after oocyte retrieval.
62037619|NCT02833168||2|Patient with proven obstructive sleep apnea syndrome prior to CPAP initiation.
62037620|NCT02833168||3|Patients with sleep disorders other than sleep-related breathing disorders, e. g. narcolepsy, hypersomnia, parasomnia or sleep-related movement disorders.
62037621|NCT06701994|EXPERIMENTAL|Kinesiotaping Bandage Group|A bandage using kinesiotape will be applied to the participant's ankle directly on the skin and covered with an opaque stocking.
62037622|NCT06701994|ACTIVE_COMPARATOR|Traditional Tape Bandage Group|A bandage will be applied to the participant's ankle using kinesiotape directly on the skin and covered with an opaque stocking.
62037623|NCT06701994|PLACEBO_COMPARATOR|Placebo Group|An opaque stocking is placed on the participant's ankle.
62037624|NCT05956119|EXPERIMENTAL|dry needling|The intervention group will have a single session of dry nedling application in the medial gastrocnemius + usual care (physiotherapy)
62037625|NCT05956119|SHAM_COMPARATOR|placebo|The control group will have a single session of sham dry nedling in the medial gastrocnemius + usual care (physiotherapy)
62037626|NCT02660827|EXPERIMENTAL|Hybrid closed loop|All subjects will be wearing the MMT-670G insulin pump, using it with the closed loop algorithm
62037627|NCT04432597|EXPERIMENTAL|1/Arm 1A|Human Papillomavirus Vaccine (HPV) vaccine at 1x10(11) Viral Particles (VP) Dose Level 1 (DL1) and at 5x10(11) VP Dose Level 2 (DL2)
62037628|NCT04432597|EXPERIMENTAL|2/Arm 1B|Human Papillomavirus Vaccine (HPV) vaccine at recommended phase 2 dose (RP2D) plus M7824 at 1200 mg.
62815489|NCT05286554|EXPERIMENTAL|Group 2|Will receive routine LPS and additional multiple mid-luteal GnRH-a, triptorelin 0.1 mg subcutaneous injection on the 5th, 7th and 9th days after oocyte retrieval.
62815490|NCT05286554|ACTIVE_COMPARATOR|Group 3 (Control)|Will receive the routine LPS without GnRH-a
62597188|NCT02557204|EXPERIMENTAL|endotracheal tube assisted technique|Nasogastric tube will be inserted the trimmed 7.5 mm internal diameter endotracheal tube what cut proximal end with sterile scissors and endotracheal tube will be advanced blindly into the oral cavity to a depth of approximately 18 cm without laryngoscope together the nasogastric tube.
62815491|NCT03808116|EXPERIMENTAL|SmartBx biopsy collection|"* Biopsy cores will be collected from the breast during US guided biopsy procedure.~* The number of cores taken will be decided per the physician discretion according to the clinical demand.~* Additional two biopsy core will be taken the SmartBx cassette"
62429901|NCT05616611|EXPERIMENTAL|high-intensity laser group|The high-intensity laser (HIL) group received the same intervention as the control group in addition to high-intensity laser therapy.
62429902|NCT05616611|EXPERIMENTAL|shock wave group|shock wave (SW) group received the same intervention as the control group in addition to shock wave therapy.
62429903|NCT05149287|EXPERIMENTAL|Experimental|The experimental group will receive a single intravenous dose of 1 g of ceftriaxone immediately postoperative in the operating room.
62429904|NCT05149287|PLACEBO_COMPARATOR|Placebo|The placebo group will receive a single intravenous dose of 1% lidocaine and saline immediately postoperative in the operating room.
62429905|NCT02593890|ACTIVE_COMPARATOR|Intervention|Arm A: Participants will be fitted with the THEYA Recovery bra
62429906|NCT02593890|NO_INTERVENTION|Control|Arm B: Participants will be recommended or fitted with current recommended bra used in each hospital by the Breast Care Nurse Specialist
62429907|NCT06536842|ACTIVE_COMPARATOR|Group 1: Postoperative Drain Group|Participants will undergo their primary lumbar fusion spine surgery as planned and will have a drain placed postoperatively
62429908|NCT06536842|ACTIVE_COMPARATOR|Group 2: No Postoperative Drain Group|Participants will undergo their primary lumbar fusion spine surgery as planned and will not have a drain placed postoperatively
62597189|NCT02557204|EXPERIMENTAL|videolaryngoscope technique|Nasogastric tube was inserted transnasally and advanced into esophagus under direct vision.
62815492|NCT04205240|EXPERIMENTAL|Treatment (conditioning regimen, stem cell transplant)|Patients receive fludarabine IV on days -5 to -2 and melphalan IV on days -3 to -2, then undergo stem cell transplantation on day 0. Patients receive cyclophosphamide on days 3 and 4, tacrolimus PO BID or IV starting on day 5, and mycophenolate mofetil IV or PO TID on days 5 to 35. Patients also receive daratumumab IV starting between days 90-150 for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
62815493|NCT01941485|EXPERIMENTAL|WaveLight Refractive Suite|LASIK surgery (laser in situ keratomileusis) per standard of care
62815494|NCT02670317|EXPERIMENTAL|G CHOP 21 + Ibrutinib|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
62815495|NCT05231226|EXPERIMENTAL|Immediately CR group|Immediately open non-IRA after successful emergency PCI of IRA in STEMI patients with MVD
62815496|NCT05231226|ACTIVE_COMPARATOR|Staged (within 45 days) CR group|Strategy of opening non-IRA by stages after emergency PCI of IRA in STEMI patients with MVD
62037629|NCT04432597|EXPERIMENTAL|3/Arm 2A|Human Papillomavirus Vaccine (HPV) vaccine at recommended phase 2 dose (RP2D) given as neoadjuvant or induction therapy.
62429909|NCT04582409|EXPERIMENTAL|HSY244|HSY244 150 mg concentrate solution for injection via intravenous infusion
62429910|NCT04582409|PLACEBO_COMPARATOR|Placebo|Placebo concentrate solution for injection via intravenous infusion
62429911|NCT06206109||with common extensor tendon tears|the participants who have common extensor tendon tears demonstrated with ultrasonography.
62429912|NCT06206109||without common extensor tendon tears|the participants who do not have common extensor tendon tears demonstrated with ultrasonography.
62429913|NCT04198350|EXPERIMENTAL|Islet implantation|
62429914|NCT05183100|EXPERIMENTAL|Experimental Condition (Neurodynamics Treatment)|Neurodynamic treatment for about 13 minutes in supine position. It will be comprised of three stages, and the tensioner technique of the tibial nerve will be used.
62597190|NCT02437331||advanced heart failure|the patients was diagnostic on Chronic heart failure with NYHA class 3 and 4, AHA stage D, or LVEF\<40%.
62815497|NCT00704210|SHAM_COMPARATOR|B|Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
62037630|NCT04432597|EXPERIMENTAL|4/Arm 2B|Human Papillomavirus Vaccine (HPV) vaccine at recommended phase 2 dose (RP2D) plus M7824 at 1200 mg given as neoadjuvant or induction therapy.
62037631|NCT06302101|EXPERIMENTAL|İntervention|chair-based exercises and cognitive exercises
62037632|NCT06302101|ACTIVE_COMPARATOR|Control group|chair-based exercises
62429915|NCT05183100|ACTIVE_COMPARATOR|Control Condition|Lying in supine.
62429916|NCT00389649|ACTIVE_COMPARATOR|HR=60|Pacemaker set at 60
62429917|NCT00389649|ACTIVE_COMPARATOR|HR=75|Pacemaker set at 75
62597191|NCT00725790|EXPERIMENTAL|A|Vardenafil treatment group
62815498|NCT00704210|EXPERIMENTAL|A|For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.
62815499|NCT00762359|EXPERIMENTAL|Lansoprazole 15 mg QD|
62815500|NCT00762359|ACTIVE_COMPARATOR|Gefarnate 50 mg BID|
62815501|NCT02164253|EXPERIMENTAL|Deferiprone|Deferiprone, 25 to 30 mg/kg per day, oral use
62815502|NCT05955612|EXPERIMENTAL|Daily measurement of serum procalcitonin concentrations|
62815503|NCT05955612|NO_INTERVENTION|Standard of practice (routine clinical care)|
62815504|NCT05251714|EXPERIMENTAL|Part A: Monotherapy Escalation and Expansion|Dose selection and expansion of CFI-402257
62815505|NCT05251714|EXPERIMENTAL|Part B: Combination Escalation and Expansion|Dose selection and expansion of CFI-402257 with Fulvestrant
62815506|NCT04588246|EXPERIMENTAL|Arm I (salvage SRS, memantine, HA-WBRT)|Patients undergo HA-WBRT daily (5 times weekly) for 2 weeks for a total of 10 fractions in the absence of disease progression or unacceptable toxicity. Within 1 week prior to or following HA-WBRT, patients undergo salvage SRS. Prior to HA-WBRT or no later than the 4th treatment, patients also receive memantine PO QD or BID for 24 weeks in the absence of disease progression or unacceptable toxicity.
62239577|NCT06065501|ACTIVE_COMPARATOR|Control group|The control group receives usual care, which involves standard CKD education and consultation.
62815507|NCT04588246|ACTIVE_COMPARATOR|Arm II (salvage SRS)|Patients undergo salvage SRS.
62815508|NCT04714840|OTHER|Personalized exercise group (INTGroup)|Participants in this group have individually tailored exercise program with supervision, 20 weeks,clinic 3 times during the course of this study: at baseline (this appointment), at 4 months and 10 months from now for follow-up.
62815509|NCT04714840|OTHER|Generalized exercise group, Attention Control (AC Group)|Study participants in this group receive generalized exercise recommendations, 20 weeks,clinic 3 times during the course of this study: at baseline (this appointment), at 4 months and 10 months from now for follow-up.
62815510|NCT00778154||Alendronate 3 to < 5 years|Alendronate (any combination of 10 mg daily or 70 mg once weekly) 3- 5 years.
62815511|NCT00778154||Risedronate 3 to < 5 Years|Risedronate (any combination of 5 mg daily or 35 mg once weekly) 3-5 years.
62815512|NCT00778154||Alendronate ≥ 5 Years|Alendronate (any combination of 10 mg daily or 70 mg once weekly) for greater than or equal to 5 years.
62815513|NCT00778154||Risedronate ≥ 5 Years|Risedronate (any combination of 5 mg daily or 35 mg once weekly) for greater than or equal to 5 years.
62815514|NCT02049775|EXPERIMENTAL|NBI|
62815515|NCT05560425|ACTIVE_COMPARATOR|Navigating College (NC) Training|Control Group
62815516|NCT05560425|EXPERIMENTAL|Koru Mindfulness (KM) Training|Study Group
62815517|NCT02654886|EXPERIMENTAL|Resistance Exercise Training|Participants will be given a regimen of resistance training after a 2 month observation period. Participants will be trained for 6 months (total= 72 training sessions). Two muscle groups (limbs) would be included in the resistance-training program. Participants will also be initiated with Respiratory muscle strength training using pressure-threshold respiratory trainers.
62815518|NCT06705686|EXPERIMENTAL|Dose Escalation: (R)-9bMS|Patient will take the assigned dose of (R)-9bMS twice daily by mouth for up to 6 months. Each cycle is 28 days.
62815519|NCT06705686|EXPERIMENTAL|Expansion: (R)-9bMS|Patient will take (R)-9bMS twice daily by mouth for up to 6 months. Each cycle is 28 days. The assigned dose will be determined in the Dose Escalation portion of the trial.
62815520|NCT05406674|ACTIVE_COMPARATOR|Arm A|Patients in Arm A are treated with interval cytoreductive surgery (with no more than 1 cm residual disease) and cispaltin-based HIPEC with a dosage of 100 mg/m2
62815521|NCT05406674|EXPERIMENTAL|Arm B|Patients in Arm B are treated with interval cytoreductive surgery (with no more than 1 cm residual disease) and cisplatin- based HIPEC with a dosage of 40 mg/L perfusate.
62815522|NCT04051996|EXPERIMENTAL|DAC5|Glasdegib will be administered at the starting dose of 100 mg orally once daily and continuously in combination with either DAC5 (decitabine 20 mg/m2 IV on a 5-day schedule) or DAC10 (decitabine 20 mg/m2 IV on a 10-day schedule) as per randomization. Treatment will be administered in 28-day cycles.
62239578|NCT02401412|OTHER|Test Ostomy Barrier|The test product is a new Hollister ostomy barrier.
62239579|NCT02401412|OTHER|Control Ostomy Barrier|The control product is a currently marketed Hollister ostomy barrier.
62239580|NCT02772523|OTHER|Intervention|
62597192|NCT00725790|PLACEBO_COMPARATOR|B|Placebo treatment group
62597193|NCT02977611|EXPERIMENTAL|High Dose, Rapid Infusion Iron Sucrose|Patients will receive an infusion of 500 mg of iron sucrose over one hour and will be monitored for four hours.
62815523|NCT04051996|EXPERIMENTAL|DAC10|Glasdegib will be administered at the starting dose of 100 mg orally once daily and continuously in combination with either DAC5 (decitabine 20 mg/m2 IV on a 5-day schedule) or DAC10 (decitabine 20 mg/m2 IV on a 10-day schedule) as per randomization. Treatment will be administered in 28-day cycles.
62815524|NCT00537134|NO_INTERVENTION|Conservative|Conservative management (watchful observation)
62815525|NCT00537134|ACTIVE_COMPARATOR|Endovascular|Endovascular treatment
62815526|NCT04612335|EXPERIMENTAL|Watchful waiting|the watchful-waiting approach consists of administration of rate control medication to obtain relief of symptoms and a heart rate \<110 beats per minute, followed by a telemetric rhythm monitoring period of four weeks to guide rate control therapy.
62239581|NCT00839943|ACTIVE_COMPARATOR|ozone|obese vs non-obese women
62597194|NCT03946878|EXPERIMENTAL|Treatment (acalabrutinib, venetoclax)|Patients receive acalabrutinib PO BID on days 1-28. Starting cycle 2 day 1, patients also receive venetoclax PO daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62239582|NCT00839943|ACTIVE_COMPARATOR|air|obese vs non obese women
62815527|NCT04612335|OTHER|Routine care|Routine care consists of the standard treatment for an acute episode of recent-onset symptomatic atrial fibrillation, namely acute or delayed cardioversion, followed by a telemetric rhythm monitoring period of four weeks to guide rate control therapy.
62239583|NCT00407589|EXPERIMENTAL|BOL-303224-A|Systemic exposure of BOL-303224-A following single and multiple topical doses
62429918|NCT00389649|ACTIVE_COMPARATOR|HR=90|Pacemaker set at 90
62429919|NCT06066307|EXPERIMENTAL|Olfactory training - Culinary arts students|Students in culinary skill training program will perform olfactory training by sniffing four specific essential oils twice daily, over the entire semester (4-month period). The odors will comprise four major odor categories: flowery (phenyl ethyl alcohol/rose), aromatic (eucalyptol), fruity (citronellal/lemon), and resinous (eugenol). They will be assessed before and after the school semester.
62429920|NCT06066307|NO_INTERVENTION|Control group - Culinary arts students|Students in culinary skill training program will be assessed before and after the school semester, without any intervention throughout this period.
62429921|NCT06066307|EXPERIMENTAL|Olfactory training - Information Technology students|Students in Information Technology program will perform olfactory training by sniffing four specific essential oils twice daily, over the entire semester (4-month period). The odors will comprise four major odor categories: flowery (phenyl ethyl alcohol/rose), aromatic (eucalyptol), fruity (citronellal/lemon), and resinous (eugenol). They will be assessed before and after the school semester.
62429922|NCT06066307|NO_INTERVENTION|Control group - Information Technology students|Students in Information Technology program will be assessed before and after the school semester, without any intervention throughout this period.
62429923|NCT05436496|EXPERIMENTAL|bi-4SCAR-CD19/70 T Cell Therapy for CD19 and/or CD70 positive B cell malignancies|
62429924|NCT04071626|EXPERIMENTAL|Ertugliflozin Treatment Arm|Ertugliflozin 5 mg tablet once a day for 12 weeks
62429925|NCT04071626|PLACEBO_COMPARATOR|Placebo|Placebo tablet once a day for 12 weeks
62597195|NCT06482125|ACTIVE_COMPARATOR|Inhalation Sevoflurane|Participants in this group will receive inhalation anesthesia Sevoflurane at 2-2.5 Vol% as their sole anesthetic maintenance agent throughout the surgical procedure.
62815528|NCT01466608|EXPERIMENTAL|Rosuvastatin|Rosuvastatin 20 mg will be administered once a day for 8 weeks (open-label, one-arm, single-sequence design)
62815529|NCT01691534|EXPERIMENTAL|TMC207, PA-824, pyrazinamide and clofazimine (J-PA-Z-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus pyrazinamide 1500mg Days 1-14 plus clofazimine 300mg Days 1-3 and Clofazamine 100mg Days 4-14
62815530|NCT01691534|EXPERIMENTAL|TMC207, PA-824 and pyrazinamide (J-PA-Z)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus pyrazinamide 1500mg Days 1-14
62239584|NCT00583570|EXPERIMENTAL|A|
62239585|NCT00065325|ACTIVE_COMPARATOR|1|Exemestane
62239586|NCT00065325|EXPERIMENTAL|2|Fulvestrant
62239587|NCT03277326|ACTIVE_COMPARATOR|ISB|Interscalene brachial plexus block
62239588|NCT03277326|ACTIVE_COMPARATOR|aSSB|Anterior Suprascapular Block
62239589|NCT03277326|ACTIVE_COMPARATOR|pSSB|Posterior Suprascapular Block
62239590|NCT03537599|EXPERIMENTAL|Treatment (DLI, daratumumab)|Participants receive daratumumab intravenously once a week for 8 weeks and donor lymphocyte infusion in weeks 3 or 4 in the absence of disease progression or unacceptable toxicity.
62239591|NCT02686021|EXPERIMENTAL|Metamizole and Ibuprofen|all patients (n=42) will receive metamizol and ibuprofen in one session. In the other session half will receive metamizol and placebo (n=21) and the other half will receive ibuprofen and placebo. The order will be randomized (balanced).
62239592|NCT02686021|ACTIVE_COMPARATOR|Metamizole and Placebo|"This is one of the two comparators for the Arm Metamizol and Ibuprofen. n=21"
62239593|NCT02686021|ACTIVE_COMPARATOR|Ibuprofen and Placebo|"This is the second of the two comparators for the Arm Metamizol and Ibuprofen. n=21"
62239594|NCT02622880|ACTIVE_COMPARATOR|: IMPACT|along 10 days before surgery
62239595|NCT02622880|EXPERIMENTAL|immunomodulatory supplement|along 10 days before surgery
62239596|NCT03689647|EXPERIMENTAL|Single Group Experimental|Each participant will act as their own control with variables of interest measured while walking without the assistive device and while walking with the assistive device.
62429926|NCT00567528|OTHER|1|Active ibuprofen liposomal transdermal gel with placebo ibuprofen capsule
62429927|NCT00567528|OTHER|2|Placebo ibuprofen liposomal transdermal gel with active ibuprofen capsules
62429928|NCT04741685||SAP with LGS|Type 1 diabetes adults patients treated with sensor-augmented insulin pump with low glucose predictive suspension function
62429929|NCT02717286|SHAM_COMPARATOR|Control|"20 first permanent molars from children aged between 6 to 12 years old presenting MIH will be included. A calibrated pediatric dentist examined the selected teeth to classify MIH according to the European Academy of Pediatric Dentistry (EADP) criteria.~Intervention of Control: The restorative treatment using a total-etching adhesive system, which was performed according to the following operative sequence: prophylaxis, infiltrative anesthesia, rubber dam, application of 37.5% phosphoric acid to enamel (30 s) and dentine (15 s), extensive washing, drying with cotton and air jet (5 s), priming (5 s), light curing (20 s), restoration with composite resin (Filtek XT350), examination of occlusal contact, and final polishing."
62815531|NCT01691534|EXPERIMENTAL|TMC207, PA-824 and clofazimine (J-PA-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14
62815532|NCT01691534|EXPERIMENTAL|TMC207, pyrazinamide and clofazimine (J-Z-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus pyrazinamide 1500mg Days 1-14 plus clofazimine 300mg Days 1-3 and Clofazimine 100mg Days 4-14
62815533|NCT01691534|EXPERIMENTAL|pyrazinamide (Z)|pyrazinamide 1500mg Days 1-14
62815534|NCT01691534|EXPERIMENTAL|clofazimine (C)|Clofazimine 300mg Days 1-3 and Clofazimine 100mg Days 4-14
62815535|NCT01691534|ACTIVE_COMPARATOR|Rifafour|Rifafour e-275 mg dosed by weight
62815536|NCT06230575|ACTIVE_COMPARATOR|erector spinae block|
62815537|NCT06230575|EXPERIMENTAL|retrolaminar block|
62815538|NCT06230575|EXPERIMENTAL|serratus anterior block|
62815539|NCT06230575|EXPERIMENTAL|pectoral nerve block|
62815540|NCT06547554|EXPERIMENTAL|Single Dose Cohorts|"Administered single fixed dose of Xeruborbactam~Administered single fixed dose of Cefiderocol~Administered single fixed dose of a combination of Xeruborbactam and Cefiderocol."
62815541|NCT06547554|PLACEBO_COMPARATOR|Single Dose Cohorts Placebo|5% Dextrose in water
62815542|NCT04079361|OTHER|Pregnancy complication|Intervention: blood samples
62815543|NCT02192658||People with Disability (PWD) (N= 850)|"PWD will be identified thanks to the disability screening tool developped by the Washington Group (WG). This tool is based on the WHO International Classification of Functionning (ICF).~A stratified cluster sampling in 2 steps will be used in both, Yaounde and Ouagadougou. Each city will be divided in enumeration areas (EAs). First step : EAs will be drawn randomly with probability proportional to their size in number of households. Second step: in each EA, 30 households will be randomly drawn and each person living in these households will be screened for disability with the WG tool, according to the inclusion and exclusion criteria."
62429930|NCT02717286|EXPERIMENTAL|Test|"20 first permanent molars from children aged between 6 to 12 years old presenting Molar Incisor Hypomineralization will be included. A calibrated pediatric dentist examined the selected teeth to classify MIH according to the EAPD criteria.~Intervention of test: the restorative treatment using a self-etching adhesive system, which was performed according to the following operative sequence: prophylaxis, infiltrative anesthesia, rubber dam, application of 37.5% phosphoric acid to enamel (30 s) and dentine (15 s), extensive washing, drying with cotton and air jet (5 s), priming (5 s), air jet (5 s), adhesive application (5 s), light curing (20 s), restoration with composite resin (Filtek XT350), examination of occlusal contact, and final polishing."
62239597|NCT01504256|EXPERIMENTAL|catumaxomab|"this arm was stopped. the antibody previously used as a study drug is not available at this time. patients will be randomized only into the standard arm~\[Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10) and 7 days after the last catumaxomab infusion FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1))"
62815544|NCT02192658||Non-Disabled People (control group) (N= 850)|For each PWD, 1 non-disabled control person will be randomly chosen from the census list of the same enumeration area. Control will also be matched on age and sex.
62239598|NCT01504256|ACTIVE_COMPARATOR|standard therapy|"FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)"
62815545|NCT06583941|EXPERIMENTAL|Low Dose Virtiva Plus|One dose (1 capsule) of Virtiva Plus will be consumed twice daily for up to 5 weeks. A single dose contains: 120mg Ginkgo biloba extract (leaf), a minimum of 14.4mg phosphatidylserine, and a minimum of 6mg ginkgo flavonglycosides.
62815546|NCT06583941|EXPERIMENTAL|High Dose Virtiva Plus|One dose (1 capsule) of Virtiva Plus will be consumed twice daily for up to 5 weeks. A single dose contains: 240mg Ginkgo biloba extract (leaf), a minimum of 28.8mg phosphatidylserine, and a minimum of 12mg ginkgo flavonglycosides.
62815547|NCT04614311|ACTIVE_COMPARATOR|Intervention|Intra-articular corticosteroid injections into active joints
62815548|NCT04614311|NO_INTERVENTION|Comparator|No intra-articular injections
62815549|NCT03799146|EXPERIMENTAL|Intervention group|Participants will receive the e- and mHealth intervention 'MyPlan 2.0'.
62815550|NCT03799146|EXPERIMENTAL|Waiting List control group|Participants will not receive the e- and mHealth intervention 'MyPlan 2.0', but will be given access to the intervention after all testing phases.
62815551|NCT03104881|EXPERIMENTAL|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
62815552|NCT03104881|EXPERIMENTAL|2D end-effector type robot|2 dimension end-effector type upper extremity robot
62815553|NCT04896866|EXPERIMENTAL|Antimicrobial stewardship|Antimicrobial stewardship prospective audit and feedback on physicians attending to patients admitted with community-acquired COVID-19 pneumonia to beds randomized to antimicrobial stewardship intervention.
62239599|NCT03461874|ACTIVE_COMPARATOR|Treatment as usual|Education of patients followed by Pharmacological Prophylaxis, prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Calcium channel blockers
62239600|NCT03461874|EXPERIMENTAL|Treatment as usual + ACT|"Education of patients, Pharmacological Prophylaxis prescribed based on patients' profile, and eight group sessions of 90 minutes of ACT.~The ACT consists in 6 weekly sessions, 90 minutes each, and 2 supplementary booster sessions, at two and four weeks after the conclusion of the weekly session. The main focus of the six ACT session will be the following: 1) Creative helplessness: the problem of control; 2) Indentifying values: introduction to Mindfulness; 3) Actions guided by values: working with thought; 4) Working with Acceptance and Willingness; 5) Committed Actions: self-as-context; 6) Integration: working with obstacles - wrap-up. The booster session starts with a mindfulness exercise, followed by a review of the contents covered across the ACT program."
62239601|NCT02017041||buprenorphine/naloxone|Opioid substitution therapy patient taking buprenorphine/naloxone, MedSignals and smartphone app.
62429931|NCT02135367|EXPERIMENTAL|PRP|This group of patients will be treated by three weekly Platelet rich Plasma intra-articular injections in the knee.
62429932|NCT02135367|ACTIVE_COMPARATOR|HA|"This group of patients will be treated by three weekly hyaluronic acid (HA) intra-articular injections in the knee.~The HA used is Hyalubrix 30 mg/2ml (Fidia Farmaceutici Spa, Padova, Italy)"
62429933|NCT03786874|ACTIVE_COMPARATOR|20 teams the first year (G1)|control group
62815554|NCT04896866|NO_INTERVENTION|No antimicrobial stewardship|No antimicrobial stewardship prospective audit and feedback.
62815555|NCT04860830|EXPERIMENTAL|Iclepertin treatment group|
62429934|NCT03786874|EXPERIMENTAL|20 teams second year (G2)|case group with implementation of the multi-unit team accompaniment intervention.
62429935|NCT01677442|EXPERIMENTAL|no-intubated group|Experimental: no-intubated thoracic epidural anesthesia Thoracic epidural anesthesia at the T5/T6 thoracic interspace
62429936|NCT01677442|ACTIVE_COMPARATOR|intubated group|Active Comparator:double-lumen endotracheal intubated anesthesia
62429937|NCT02115737|EXPERIMENTAL|Dialectical Behavior Therapy Skills Group|Twelve week skills based group therapy include four modules: mindfulness, emotion regulation, distress tolerance, and walking the middle path
62429938|NCT02115737|EXPERIMENTAL|Psychoeducation group treatment|The comparison group used in the present study is based on a publicly available treatment manual from the Services for Teens At Risk (STAR) Center at the University of Pittsburgh
62429939|NCT03775148|EXPERIMENTAL|TranS-C Group|Transdiagnostic Sleep and Circadian Treatment
62815556|NCT04860830|PLACEBO_COMPARATOR|Placebo group|
62815557|NCT06705478|EXPERIMENTAL|Arm 1: Pramipexole ER|
62429940|NCT03775148|NO_INTERVENTION|CAU Group|Care-As-Usual group
62429941|NCT02980328|EXPERIMENTAL|LLLT group|Low-level light therapy (LLLT) was self-performed for 12 weeks, 3 times a day for 20 minutes each
62815558|NCT06705478|EXPERIMENTAL|Arm 2: Escitalopram|
62815559|NCT05343754|ACTIVE_COMPARATOR|Hyperbaric Oxygen Therapy|Hyperbaric treatment will consist of 30 daily treatments in the first 6 weeks of the study, except during the weekends. After compression for 10 minutes patients will receive 80 minutes (4 times 20 minutes) 100% O2 with 3 airbrakes (21% O2) of 5 minutes at 2.4-2.5 ATA, and then 10 minutes decompression with the first part of decompression till 0.3 ATA with 100% oxygen (this will usually take seven minutes). The last 0.3 ATA will be decompressed with air. In total one hyperbaric session will be 110 minutes. Treatment will start directly at the beginning of the study.
62597196|NCT06482125|EXPERIMENTAL|Total Intravenous Dexmedetomidine|Participants in this group will receive Total Intravenous Dexmedetomidine as their sole anesthetic maintenance agent. Intravenous Dexmedetomidine 1.5ug/kg will be administered within 10 minutes and maintenance dose of 1.5ug/kg/hour will be given throughout the surgical procedure.
62597197|NCT02550392|EXPERIMENTAL|Group psychoeducation|The intervention group will receive a group psychoeducational intervention (designed in Phase 1: Qualitative study) and usual care.
62429942|NCT02980328|PLACEBO_COMPARATOR|Placebo-controlled group|Placebo low-level light therapy (LLLT) was self-performed for 12 weeks, 3 times a day for 20 minutes each. The placebo LLLT device was identical to the active device but did not radiate light as the hole was blocked.
62429943|NCT03812679|EXPERIMENTAL|AMIA APD Solution Generation System|A simulated treatment will take place before the patient receives study treatment, during week 1 and after 4, 8 and 12 weeks of study treatment period. The dialysis solution generated by the simulated treatment will be collected from the system in the heater bag and used to evaluate the chemical composition of the final dialysis solution produced by patients using the AMIA APD Solution Generation System. Also, product water from the Water Device (pre-sterilizing filters) will be collected and tested at each visit.
62815560|NCT05343754|ACTIVE_COMPARATOR|Control group|In order to compare efficacy, patients that do not wish to undergo hyperbaric treatment, will serve as a control group. At baseline they will be asked for the reason they do not wish to undergo hyperbaric treatment. All patients and controls will be asked to report pain scores using a numeric pain rating scale (NRS) and quality of life (Wound-Q) questionnaires. They will continue to receive standard care as deemed necessary by their primary physician.
62815561|NCT06582433|EXPERIMENTAL|İntervention group|"Pre-Procedure: Women who meet the inclusion criteria will be divided into experimental and control groups using simple randomization method. Before the procedure, both groups will fill out the Personal Information Form (PIF), Psychological Well-being Scale (PWS), Menopausal Symptoms Assessment Scale (MSAS), and Menopause Attitude Assessment Scale(MASS) (1st Measurement).~During the Procedure: Women in the experimental group will receive Solution-Focused Counseling (SFC) by the researcher. SFC will be conducted individually once a week, in a total of 6 sessions, with each session lasting 60 minutes.~Post-Procedure: One week after the completion of SFC sessions, both groups will fill out PWS, MSAS, and MAAS again (2nd Measurement).~Follow-Up Two Months Later: Two months later, both groups will fill out PWS, MSAS, and MAAS again to evaluate whether the effects of SFC are still present (Follow-Up Measurement)."
62815562|NCT06582433|NO_INTERVENTION|Control group|Before the procedure, women will be asked to fill out a Personal Information Form (PIF), Psychological Well-being Scale (PWS), Menopause Symptoms Assessment Scale (MSAS), and Menopause Attitude Assessment Scale (MAAS) (1st Measurement). Women in the control group will be provided with information about routine menopausal symptoms. 2 months later, the 2nd Measurement will be taken. After the follow-up measurement is taken for the control group, counseling will be provided to women according to their needs (addressing problems, answering questions, providing information as needed).
62815563|NCT04748861|EXPERIMENTAL|Indoor Cycling (IC)|Participants will engage in high-intensity interval training (HIIT; 60-90% of heart rate reserve) in their home via the commercially available Peloton® cycling system or 2) 3x/week (minimum 90 minutes/week) for 18 months.
62037633|NCT06672471|ACTIVE_COMPARATOR|Control Group Post operative Antibiotics|"A Single dose of Peri-Operative Antibiotic at the time of induction of Anaesthesia before incision for surgery is made and additional Post Operative Antibiotics for one day.~Antibiotic to be used: Cefazolin 2 Gram IV Once followed by Cefazolin 1 Gram TID"
62429944|NCT01375569|EXPERIMENTAL|TRC105 in Liver Cancer|TRC105 is an experimental cancer drug designed to slow or stop the growth of tumors. It does this by preventing the growth of new blood vessels that feed these tumors. This drug is being used to test the safety and effectiveness to treat liver cancer that has not responded to standard therapy. TRC105 will be given as an intravenous infusion every two weeks.
62429945|NCT03855124||healthy participants|Participants will be ask to perform a repetitive upper limb task while posture and muscle activity is being monitored.This will be done while wearing a posture shirt or without a shirt
62597198|NCT02550392|NO_INTERVENTION|Control group|Participants in the usual care control group will continue to receive all other services routinely available to them as is usual practice.
62597199|NCT04010929|EXPERIMENTAL|Laser+MTA group|before the MTA condensation, Er, Cr: YSGG laser was applied to the exposure area
62597200|NCT04010929|ACTIVE_COMPARATOR|MTA group|MTA was applied to the exposed area
62815564|NCT04748861|NO_INTERVENTION|Usual and Customary Care (UCC)|Participants engage in their habitual level of physical activity.
62815565|NCT00095693|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib tosylate twice daily for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 8 additional weeks of therapy beyond CR.
62597201|NCT05980923||GROUP 1: Acute illness and abnormal thyroid function|Patients admitted to the hospital with acute illness and found to have thyroid function abnormalities.
62597202|NCT05980923||GROUP 2: Acute illness and normal thyroid function|Patients admitted to the hospital with acute illness and found to have normal thyroid function.
62597203|NCT03465501||Low Dose Rate|Patients treated with brachytherapy at low dose rate of the anal canal with aim of boost
62597204|NCT03465501||High Dose Rate|Patients treated by brachytherapy with a high dose rate of the anal canal aiming for boost
62597205|NCT04083469|EXPERIMENTAL|Peer-Led Peer-Elected Intervention|The e-cigarette intervention program will be administered to students by an elected peer leader. The audience will consist of students that nominated the peer-leader.
62597206|NCT04083469|OTHER|Adult-Led Intervention|The e-cigarette intervention program will be administered to students by an adult educator.
62597207|NCT04083469|OTHER|Peer-Led Non-Elected Intervention|The e-cigarette intervention program will be administered to students by an elected peer leader. The audience will consist of students that nominated a different peer-leader.
62597208|NCT02010658|NO_INTERVENTION|Memory|
62597209|NCT02010658|EXPERIMENTAL|Cognitive Aid|
62597210|NCT06623760|EXPERIMENTAL|Desk and chair adaptation interventions|Adjustment of the height of desks and chairs according to the height of each student, intervention lasting one year
62037634|NCT06672471|EXPERIMENTAL|Intervention Group No Post Operative Antibiotics|"A Single dose of Peri-Operative Antibiotic at the time of induction of Anaesthesia before incision for surgery is made, the time of Antibiotics will be recorded in time-out form as a part of the surgical safety checklist.~Antibiotic to be used: Cefazolin 2 Gram IV Once"
62037635|NCT01018394|ACTIVE_COMPARATOR|nicotine lozenges|40 subjects will be assigned to receive nicotine lozenges for 8 weeks. They will use the nicotine lozenges ad lib, up to 8 lozenges per day.
62037636|NCT01018394|ACTIVE_COMPARATOR|tobacco free snuff|41 subjects will receive tobacco free snuff for 8 -12 weeks. The tobacco-free snuff will be used ad lib - as needed.
62037637|NCT02301312|EXPERIMENTAL|POSS-PCU graft|POSS-PCU vascular graft will be used to create vascular access for dialysis.
62037638|NCT01825538||COPD, pulmonary fibrosis|observational study, no interventions to be administered
62037639|NCT04996758|EXPERIMENTAL|Toripalimab and Anlotinib Combination Treatment|Patients receive toripalimab at a dose of 240 mg on day 1 and anlotinib at a dose of 12 mg before breakfast for once-daily on days 1-14. Treatment cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity
62037640|NCT05920551|EXPERIMENTAL|Gastrocnemius Stretching Group|Patients will receive ultrasound therapy, fascia strengthening exercises, and gastrocnemius stretching exercises.
62037641|NCT05920551|ACTIVE_COMPARATOR|Control Group|Patients will receive ultrasound therapy and fascia strengthening exercises without gastrocnemius stretching exercises.
62037642|NCT06369389||Patients eligible for CAR-T treatment|Patients eligible for CAR-T treatment for their hemopathy at TOULOUSE University Hospital under early access or marketing authorization or as part of a clinical trial between 01/01/2019 and 31/12/2028
62037643|NCT01952327|OTHER|plueurapump|Implantation of pleurapump system
62037644|NCT05725317|OTHER|LID220365 (OD) / LID006961 (OS)|LID220365 contact lens worn in the right eye (OD), with LID006961 contact lens worn in the left eye (OS), as randomized, for four days. A fresh pair of lenses will be worn each day.
62037645|NCT05725317|OTHER|LID006961 (OD) / LID220365 (OS)|LID006961 contact lens worn in the right eye (OD), with LID220365 contact lens worn in the left eye (OS), as randomized, for four days. A fresh pair of lenses will be worn each day.
62037646|NCT06059495|EXPERIMENTAL|Dostarlimab-based treatment|After inclusion patients will receive dostarlimab at 500 mg q3w (± 2-3 days) for 4 cycles (C1-C4). Then, an adaptive treatment strategy will be determined based on clinical assessment of the patient.
62037647|NCT03547089|EXPERIMENTAL|Viveve treatment|Group of women who receive Viveve treatment
62037648|NCT04437654|EXPERIMENTAL|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
62037649|NCT04437654|NO_INTERVENTION|Nonanticoagulation group|Standard treatment except anticoagulant for 2 years
62037650|NCT06213532|OTHER|Beta testing (CONNECTing to LungCare, feedback)|Participants interact with the CONNECTing to LungCare intervention and provide feedback in support of intervention refinement.
62597211|NCT06623760|NO_INTERVENTION|Continued use of original desks and chairs|No change in height of desks and chairs, use as usual
62037651|NCT06213532|EXPERIMENTAL|Feasibility trial, Group I (CONNECTing to LungCare)|Participants receive the CONNECTing to LungCare intervention, including education about the benefits and risks of LCS and the importance of shared decision making, computerized assessments of the participant's smoking status, readiness to quit and concerns about quitting, and video segments tailored to the participant's responses to assessment questions, prior to their primary care appointment. Participants and their providers receive a tailored summary of the participant's concerns and barriers to quitting to enhance motivation for smoking cessation and shared decision-making discussions. Participants then receive up to 3 follow-up phone calls over 10-15 minutes each encouraging them to follow up with their provider, to complete the shared decision-making conversation, obtain LCS if appropriate, and access smoking cessation resources. Participants may also receive brief, tailored follow-up text messages that include links to video segments or cessation resources 1-3 times weekly.
62037652|NCT06213532|ACTIVE_COMPARATOR|Feasibility trial, Group II (usual care)|Participants receive usual care from their provider at their primary care appointment.
62037653|NCT03595644|EXPERIMENTAL|SBRT plus TKI group|SBRT with photon and dose is 40-50Gy/5F after three months after EGFR-TKI treatment
62037654|NCT03595644|ACTIVE_COMPARATOR|TKI treatment group|Standard EGFR-TKI(Gefitinib, erlotinib or icotinib) Gefitinib: 250mg po Qd Erlotinib: 150mg po Qd Icotinib: 125mg po tid
62037655|NCT06143826|EXPERIMENTAL|Dementia caregiver|Caregivers will be asked to perform progressive muscle relaxation exercises 3 days a week for 3 months.
62037656|NCT06047626|EXPERIMENTAL|Fatigue Reduction Diet- FRD|3 months of individualized counseling of the FRD delivered by registered dietitians, over 8 sessions by phone/video conferencing on fatigue, quality of life, and associated symptoms in persistently fatigued lymphoma cancer survivors
62429946|NCT01273922|PLACEBO_COMPARATOR|Low Dose NDV-3 investigational vaccine|15 subjects will receive vaccine and 5 subjects will receive placebo.
62597212|NCT02781857||100 patients with lung cancer|"* Group A: 70 patients with any type of lung cancer eligible for lung cancer surgery~* Group B: 30 patients with any type of lung cancer not eligible to surgery (small-cell carcinoma, squamous cell carcinoma, adenocarcinoma, large-cell carcinoma)."
62815566|NCT06424366|EXPERIMENTAL|Immediate Ballet Program|12 weeks of ballet classes immediately after recruitment and randomization concludes.
62815567|NCT06424366|PLACEBO_COMPARATOR|Deferred Ballet Program|12 weeks of ballet classes after the first arm completes the intervention. Participants in this arm will continue to complete self-reports while they wait to begin the intervention.
62815568|NCT00688896|EXPERIMENTAL|1|JTT-705 600 mg and pravastatin 40 mg
62815569|NCT00688896|EXPERIMENTAL|2|JTT-705 300 mg and pravastatin 40 mg
62815570|NCT00688896|PLACEBO_COMPARATOR|3|Placebo and pravastatin 40 mg
62815571|NCT01088568|EXPERIMENTAL|TICL group|
62815572|NCT01088568|ACTIVE_COMPARATOR|LASIK group|
62815573|NCT03665636|EXPERIMENTAL|Triheptanoin|Open Label Study
62815574|NCT06179407|EXPERIMENTAL|MK-6552|In Part 1, participants will receive single oral doses of MK-6552 in ascending fashion approximately 6 hours apart for a single day, based on safety and tolerability of the previous dose. In Part 2, participants will receive multiple days of MK-6552 dosing (7 consecutive days) at the highest safe and well tolerated MK-6552 dose determined on an individual basis from Part 1.
62815575|NCT06179407|PLACEBO_COMPARATOR|Placebo|In Part 2, participants will receive multiple days of placebo dosing (7 consecutive days).
62815576|NCT05945420|ACTIVE_COMPARATOR|Desmopressin arm|This arm will receive tamsulosin and desmopressin
62815577|NCT05945420|PLACEBO_COMPARATOR|Placebo arm|This arm will receive tamsulosin and placepo
62815578|NCT05891600||Rheumatoid arthritis patients in Colombia|
62815579|NCT03935984|EXPERIMENTAL|Treatment Group|All subjects in this arm will be treated with calcitonin 200IU 2x per day for 2 days, then 1x on day of SPECT-CT imaging
62815580|NCT06615206|EXPERIMENTAL|HG204|Once intracerebroventricular injection; The duration of the study is about 60 weeks for each subject, including a 8 weeks screening period, enrollment visit, treatment visit and 52 weeks follow-up period.
62815581|NCT02226367|ACTIVE_COMPARATOR|prazosin hydrochloride|Prazosin hydrochloride taken orally. Titrated to a maximum dose 4 mg in the morning, 6 mg in the afternoon, and 10 mg at bedtime. (20 mg total daily at maximum dose) Dose increase will occur if the participant does not have unacceptable side effects.
62815582|NCT02226367|PLACEBO_COMPARATOR|placebo|Placebo. Oral capsule with comparable appearance to active treatment. Titrated in same manner as active treatment.
62815583|NCT00641771|EXPERIMENTAL|1|MK0217A
62815584|NCT00641771|PLACEBO_COMPARATOR|2|Placebo
62815585|NCT05826912|ACTIVE_COMPARATOR|Intervention 1: Atorvastatin calcium (ATOR)|By Mouth (PO) Twice a day (BID) 80 mg/day, with no loading dose, for 28 days
62815586|NCT05826912|ACTIVE_COMPARATOR|Intervention 2: Minocycline hydrochloride (MINO)|By Mouth (PO) Twice a day (BID) 200 mg loading dose on Day 1, then 100 mg twice daily for 6 days, then placebo twice daily for 21 days
62815587|NCT05826912|ACTIVE_COMPARATOR|Intervention 3: Candesartan cilexetil (CAND)|By Mouth (PO) Twice a day (BID) 8 mg once on Day 1, then 16 mg daily for 27 days
62815588|NCT05826912|PLACEBO_COMPARATOR|Matching Placebo|By Mouth (PO) Twice a day (BID) 2 capsules 2x/day
62815589|NCT06399406|EXPERIMENTAL|Medi1-TBS|This arm will receive a multimodal treatment with a digital mindfulness training focused on attention to breathing for up to 10 min session dose for up to 20 sessions combined with neuro-navigated iTBS type of rTMS (for 20 treatments over 4 weeks) targeting the left dorsolateral prefrontal cortex (DLPFC) brain region.
62815590|NCT06399406|EXPERIMENTAL|Medi2-TBS|This arm will receive a multimodal treatment with a digital mindfulness training focused on attention to breathing for up to 20 min session dose for up to 20 sessions combined with neuro-navigated iTBS type of rTMS (for 20 treatments over 4 weeks) targeting the left dorsolateral prefrontal cortex (DLPFC) brain region.
62815591|NCT06399406|ACTIVE_COMPARATOR|Medi3-TBS|This arm will receive a multimodal treatment with a digital mindfulness training focused on intermittent deep breathing for up to 10 min session dose for up to 20 sessions combined with neuro-navigated iTBS type of rTMS (for 20 treatments over 4 weeks) targeting the left dorsolateral prefrontal cortex (DLPFC) brain region.
62597213|NCT02781857||60 controls|60 controls (group C) matched for age, gender, smoking history.
62815592|NCT01052792|EXPERIMENTAL|Naproxen Sodium 550 mg Tablets|Naproxen Sodium 550 mg Tablets of Dr. Reddy's Laboratories Limited
62815593|NCT01052792|ACTIVE_COMPARATOR|Anaprox DS 550mg Tablets|Anaprox DS 550mg Tablets of Roche Pharmaceuticals Inc
62429947|NCT01273922|PLACEBO_COMPARATOR|High Dose NDV-3 investigational vaccine|15 subjects will receive vaccine and 5 subjects will receive placebo
62597214|NCT05069142|EXPERIMENTAL|Intervention group|15 participants will be randomly selected to the intervention group. These individuals will receive six weeks of pre-operative exercise instruction and education, as well as six weeks of graduated post-operative exercise instruction, beginning at three weeks post-op with the surgeons clearance.
62815594|NCT00323323|EXPERIMENTAL|Alemtuzumab/CHOP|For all patients enrolled, the study will begin with a stepped-up schedule of single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5. Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose
62815595|NCT05098028|EXPERIMENTAL|Low Dose Rifaximin ER|twice daily
62815596|NCT05098028|EXPERIMENTAL|Low Dose Rifaximin DER|twice daily
62429948|NCT01496690|ACTIVE_COMPARATOR|pregabalin|The pregabalin dose is 75 mg daily the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response.
62815597|NCT05098028|EXPERIMENTAL|High Dose Rifaximin ER|twice daily
62815598|NCT05098028|EXPERIMENTAL|High Dose Rifaximin DER|twice daily
62815599|NCT05098028|PLACEBO_COMPARATOR|Placebo|twice daily
62815600|NCT05539066|EXPERIMENTAL|AI health assistant|An AI health assistant suitable for diabetes patients has been developed. It has the functions of automatically uploading blood pressure, blood glucose data, intelligent reminder, automatic analysis of reports inside and outside the hospital, intelligent question and answer, etc. it is simple to operate, highly interactive, and maximizes the management level of diabetes patients outside the hospital.
62429949|NCT01496690|PLACEBO_COMPARATOR|Pregabalin Placebo Capsules|
62815601|NCT05539066|NO_INTERVENTION|Routine treatment group|Perform routine management and follow-up without using AI health assistant
62815602|NCT05512403|EXPERIMENTAL|Patients with Low Grade Glioma (LGG) without any MRI contrast enhancement|"Patients presenting with brain lesions that lack contrast enhancement on MRI, that are suspected to be LGGs and that are referred for biopsy or surgery within the following 6 months will be eligible for the study. The initial MRI should be performed a maximum of 3 weeks before patient inclusion and should at least include the conventional morphological sequences (T1, T1 sequences with injection of contrast product and T2 FLAIR).~Patients will be selected in a neuro-oncological multidisciplinary consultation meeting."
62815603|NCT05057611|ACTIVE_COMPARATOR|Usual Care Group (UC)|- Patients allocated to the usual care group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP \>65 mmHg, HR (heart rate) \<120 beats per minute (BPM), arterial oxygen saturation (SaO2) \>94%, Hb \> 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
62429950|NCT02629237|EXPERIMENTAL|Multifaceted education group|Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
62597215|NCT05069142|NO_INTERVENTION|Control group|15 participants will be randomly selected to the control group. This group will receive pre-operative education in the form of videos regarding the procedure and pain. They will not receive exercise instruction.
62819413|NCT05650606|EXPERIMENTAL|High Intensity Gait Training|"HIGT will be performed 4-6 times per week in place of conventional physical therapy. The patient's heart rate(HR)and blood pressure(BP) will be measured throughout each session. If the HR or BP is out of the acceptable range, patients will undergo standard physical therapy for that session, and the medical team will be contacted.~Target HR zones will be calculated with the Karvonen formula. The first session goal is to reach a target HR range that is 50-60% of heart rate reserve. The goal for subsequent sessions is to reach 70-80% of heart rate reserve. Rate of perceived exertion (RPE) will also be utilized.~The primary therapist will design an individualized HIGT treatment program with a combination of speed dependent treadmill activities, activity-based treadmill activities, stair training, and over ground activities.~The patient will be reminded during each session to ask for a rest as needed. Standing rests are preferred over sitting rests, but either may be utilized."
62239602|NCT03859713|EXPERIMENTAL|PT followed by Switching to CBT in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of evidence-based physical therapy (PT). At the 10-week follow-up participants who are non-responders to Phase I PT will switch to 8 weekly sessions of cognitive behavioral therapy (CBT) as Phase II treatment. If participant is a responder to Phase I PT, he or she will receive up to 2 more PT sessions in Phase II of treatment.
62429951|NCT02629237|NO_INTERVENTION|control group|Subjects will not be asked to watch education film and not participate in counseling session before and after surgery.
62429952|NCT03468374|ACTIVE_COMPARATOR|Lymphoscintigraphy|Nuclear Medicine diagnostic device using radioactive material
62429953|NCT03468374|ACTIVE_COMPARATOR|Single Photon Emission Tomography|Nuclear Medicine diagnostic device using fusion technique between SPECT and CT
62429954|NCT01964105|EXPERIMENTAL|3D Imaging Simulation|Intervention Group: 3D Image Simulation + Standard Preoperative Evaluation Goal: 50 patients
62429955|NCT01964105|NO_INTERVENTION|Standard Preoperative Evaluation|"Control Group: Patients will receive standard preoperative evaluation (2D imaging).~Goal: 50 patients"
62429956|NCT01964105|OTHER|Non-Randomized Cohort: 3D Imaging|"Patients who refuse the option of randomization but otherwise meet the inclusion and exclusion criteria will be offered participation in this study as part of a non-randomized cohort.~Goal: 50 Patients"
62429957|NCT05991245||MATRIX|Thrombotic microangiopathy with kidney biopsy
62429958|NCT02380378||Myeloproliferative Neoplasms|Patients diagnosed with Myeloproliferative Neoplasms based on WHO 2008 criteria.
62429959|NCT00087399|EXPERIMENTAL|gabapentin + antidepressant|"Patients continue to receive the same antidepressant (as before study entry) on weeks 1-5. During weeks 2-5, patients also receive oral gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity.~Patients complete a hot flash diary at baseline and then daily during study treatment."
62429960|NCT00087399|EXPERIMENTAL|gabapentin|"Patients receive gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity. Patients are tapered off their antidepressant over 7-10 days and remain on gabapentin alone.~Patients complete a hot flash diary at baseline and then daily during study treatment."
62429961|NCT02837367|EXPERIMENTAL|Adult intervention|"The intervention will consist Administration of supplements containing methyl-donors (as capsules) containing: 2 g betaine, 800 ug (micrograms) 5-MTHF (L-5-methyltetrahydrofolate) + 1000 ug (micrograms) Vitamin B12, 500 mg choline bitartrate, 1 g ALA (alfa-linolenic acid), 700 mg EPA (eicosapentaenoic acid), 280 mg DHA (docosahexaenoic acid).~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
62239603|NCT03859713|EXPERIMENTAL|PT followed by Mindfulness in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of evidence-based physical therapy (PT). At the 10-week follow-up participants who are non-responders to Phase I PT will receive 8 weekly sessions of mindfulness using a mindfulness-oriented recovery enhancement protocol as Phase II treatment. If participant is a responder to Phase I PT, he or she will receive up to 2 more PT sessions in Phase II of treatment.
62239604|NCT03859713|EXPERIMENTAL|CBT followed by Switching to PT in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of cognitive behavioral therapy (CBT). At the 10-week follow-up participants who are non-responders to Phase I CBT will switch to 8 weekly sessions of evidence-based physical therapy (PT) as Phase II treatment. If participant is a responder to Phase I CBT, he or she will receive up to 2 more CBT sessions in Phase II of treatment.
62735603|NCT03957668|ACTIVE_COMPARATOR|Lactulax|15 ml of Lactulax syrup (containing 10 g of lactulose) is drunk with 240 ml of water once daily at bedtime, for a duration of 14 days
62735604|NCT06554704||Chronic neck pain|Individuals with non-specific chronic neck pain
62735605|NCT06554704||Healthy control|Individuals without non-specific chronic neck pain
62815604|NCT05057611|EXPERIMENTAL|Capillary-refill time and phenotyping group|"Patients w/normal baseline CRT will be periodically monitored. Patients with abnormal CRT and septic shock will be categorized according to pulse pressure (PP). If \<40 mmHg, will go to fluid responsiveness (FR) assessment. FR (-) patients will undergo cardiac echo to rule out significant dysfunction. Fluid boluses will be administered in 30 min intervals and repeated as needed if CRT is still abnormal. Patients with PP ≥40 mmHg will proceed according to diastolic pressure (DAP). If ≥50 mmHg will move to FR assessment. If \<50 mmHg NE will be increased for MAP \>65 mmHg and DAP ≥50 mmHg w/CRT assessed 1 h after. NE will be increased in 0.1 mcg/k/m increments up to 0.5 mcg/k/m.~If CRT is normal, patients will proceed to periodic monitoring. Patients with persistent abnormal CRT or that reached NE safety limit will proceed directly to echo.~Patients that correct CRT with first tier interventions will not be subjected to obligatory echo but will just proceed to periodic monitoring."
62815605|NCT02411630||Interactive Questionnaire System (iQS)|An Interactive Questionnaire System (iQS) will be administered twice. First at study entry (ATN 110/113 week 24 visit) and second at week 24 (ATN 110/113 week 48 visit). The questionnaire will assess adherence as well as how structural (physical settings) and partnership factors affect adherence of YMSM to PrEP with FTC/TDF (Truvada®).
62815606|NCT01897025|ACTIVE_COMPARATOR|real-tDCS with MI-BCI|"10 sessions of the following: 20 minutes of tDCS prior to each session of motor training with the MI-BCI system.~Direct current at an intensity of 1mA with anode placed over the M1 motor cortex of the affected hemisphere and the cathode placed over the unaffected M1.~After initial calibration, MI-BCI training will involve motor imagery of reaching tasks using the clock game interface of the MIT-Manus robotic system to perform multi-directional reaching movements. Upon detection of the intention to move towards the target on BCI, the robotic arm will complete the reaching movement towards the target. Each training session will last for 40 minutes excluding set-up time."
62239605|NCT03859713|EXPERIMENTAL|CBT followed by Mindfulness in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of cognitive behavioral therapy (CBT). At the 10-week follow-up participants who are non-responders to Phase I CBT will switch to 8 weekly sessions of mindfulness using a mindfulness-oriented recovery enhancement protocol as Phase II treatment. If participant is a responder to Phase I CBT, he or she will receive up to 2 more CBT sessions in Phase II of treatment.
62239606|NCT04492345|EXPERIMENTAL|Experimental|Patient with conventional rehabilitation session and isokinetic reeducation during 7 weeks
62597216|NCT05137847||Remitoro|Participants with recurrent or refractory peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) will be administered with Remitoro 9 microgram per kilogram (mcg/kg), intravenous (IV) infusion, over 1 hour once daily for 5 consecutive days followed by 16 days withdrawal period in a 21 day cycle (up to maximum of 8 cycles). The dosage will be adjusted depending on the condition of the participant. All the participants will be observed for up to 24 weeks prospectively.
62037657|NCT06047626|ACTIVE_COMPARATOR|General Health Curriculum- GHC|3 months of individualized counseling of the attention control (matched for time and frequency of interactions with the FRD) the General Health Curriculum (GHC)
62037658|NCT03180060||SPECT|SPECT compared versus four reference standards (two anatomic cutoffs: angiographic lesions \>50% and \>70% and two functional cutoffs: FFRi \<0.80 and \<0.75).
62037659|NCT03180060||Stress Echo|Stress Echo compared versus four reference standards (two anatomic cutoffs: angiographic lesions \>50% and \>70% and two functional cutoffs: FFRi \<0.80 and \<0.75).
62239607|NCT04492345|OTHER|Control|Patient with conventional rehabilitation session during 7 weeks
62239608|NCT00747630|EXPERIMENTAL|Intervention|The group selected to watch the video.
62597217|NCT06519643|EXPERIMENTAL|the effectiveness of a career planning mobile application for male nurses|This study aims to evaluate a career planning mobile app specifically tailored for male nurses. The investigators will compare the pre- and post-test differences between the experimental group and the control group. The experimental group will receive the full career planning mobile application intervention, while the control group will receive a sham treatment.
62597218|NCT06519643|SHAM_COMPARATOR|control|This study aims to evaluate a career planning mobile app specifically tailored for male nurses. The investigators will compare the pre- and post-test differences between the experimental group and the control group. The experimental group will receive the full career planning mobile application intervention, while the control group will receive a sham treatment.
62597219|NCT05564026||Ancillary-Correlative|Children and adolescents with a germ cell tumor, previously enrolled on APEC14B1 or AEPI10N1 who allow access to medical records (including audiograms), grant permission to: evaluate of all of their DNA, place their genetic and health information in scientific databanks, and collect a blood sample at a routine clinic/home visit, as well as complete a questionnaire about your health and quality of life since treatment.
62239609|NCT03478150|EXPERIMENTAL|zinc oxide nano-particles|The zinc oxide nano-powder will be mixed with ethanol and applied in the cavity, where the ethanol evaporates, while the zinc oxide nano-particles infiltrate into the carious floor of the cavity.
62429962|NCT02837367|PLACEBO_COMPARATOR|Adult placebo|"The intervention will consist of the Administration of supplements containing methyl-donors (as capsules) containing inactive ingredients with low glycemic index (usually starch-based), and one capsule containing corn oil (1 g).~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
62815607|NCT01897025|SHAM_COMPARATOR|sham-tDCS with MI-BCI|"10 sessions of sham tDCS with BCI motor training, each session of which will be conducted as follows:~The same electrode placement and stimulation parameters will be employed for sham tDCS as for real tDCS. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation. This method of sham stimulation has also been validated (Gandiga et al., 2006). Current intensity will be increased and decreased gradually to decrease perception.~MI-BCI training will be the same as the real-tDCS group and will similarly last for 40 minutes."
62239610|NCT03478150|EXPERIMENTAL|laser diode|Each cavity will be irradiated in contact mode with continuous wave of radiation. The laser light is transferred through a 600µm flexible fiber optic tip by a special hand piece. The fiber optic will be disinfected for each use by 70% ethyl alcohol and inserted inside the cavity to 1mm with a spiral continuous movement clockwise from the top to the floor and anti-clockwise in the reverse direction. This procedure improves the distribution of the laser light inside the cavity and to avoid excessive heat generation in the internal cavity surface. Irradiation time will be 15 seconds and repeated 5 times with 15 second intervals with contact, according to manufacture instructions. During this study the output power will be adjusted at 1.5W.
62239611|NCT04193878|PLACEBO_COMPARATOR|Placebo|4 ml aerosolized 0.9% saline every 12 hours x 10 doses
62037660|NCT03180060||CMR perfusion|CMR perfusion compared versus four reference standards (two anatomic cutoffs: angiographic lesions \>50% and \>70% and two functional cutoffs: FFRi \<0.80 and \<0.75).
62239612|NCT04193878|ACTIVE_COMPARATOR|Intervention|aerosolized formoterol (20 mcg/2 ml) and budesonide (1.0 mg/2 ml) every 12 hours x 10 doses
62239613|NCT06357351|EXPERIMENTAL|VISTA technique and collagen membrane|Participants undergo periodontal surgery using the vestibular incision sub-periosteal tunnel access technique (VISTA) and collagen membrane.
62239614|NCT06357351|EXPERIMENTAL|VISTA technique and advanced platelet rich fibrin|Participants undergo periodontal surgery using the vestibular incision sub-periosteal tunnel access technique (VISTA) and advanced platelet-rich fibrin (A-PRF).
62239615|NCT02580396|OTHER|Patients eligible for CanADVICE+® (smart phone app)|
62239616|NCT01309230|EXPERIMENTAL|Group A (Vigil™)|Vigil immunotherapy was administered at a concentration of at 1 x 10e7 cells/injection via intradermal injection for a minimum of 4 doses and a maximum of 12 doses starting ≥3 weeks following completion of chemotherapy (no longer than 2.5 months post chemotherapy). Participants were treated monthly for up to 12 months as long as sufficient Vigil was available and the participant was clinically stable.
62239617|NCT01309230|NO_INTERVENTION|Group B (Observational - Standard of Care)|Participants received standard of care without maintenance therapy.
62429963|NCT02837367|EXPERIMENTAL|Children intervention|"The intervention will consist of the Administration of supplements containing methyl-donors (as syrup) containing: 1 g betaine, 400 ug (micrograms) 5-MTHF (L-5-methyltetrahydrofolate) + 500 ug (micrograms) Vitamin B12, 250 mg choline bitartrate, 0.5 g ALA (alfa-linolenic acid), 700 mg EPA (eicosapentaenoic acid), 140 mg DHA (docosahexaenoic acid).~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
62429964|NCT02837367|PLACEBO_COMPARATOR|Children Placebo|"The intervention will consist of Administration of supplements containing methyl-donors (as syrup) containing inactive ingredients with low glycemic index (usually starch-based), and one capsule containing corn oil (1 g).~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
62597220|NCT01679067||HIV-GALT|
62597221|NCT04325698|EXPERIMENTAL|Arm A|PF-06439535 (CN) + paclitaxel + carboplatin
62597222|NCT04325698|ACTIVE_COMPARATOR|Arm B|Bevacizumab-EU + paclitaxel + carboplatin
62597223|NCT05546723|EXPERIMENTAL|LMY-920 dose escalation|Open label, dose escalation study with up to four dose levels of LMY-920. The maximum tolerated dose (MTD) of LMY-920 will be determined using dose-escalation 3+3 design.
62735606|NCT00500565|EXPERIMENTAL|On-Q pump with Saline|On-Q Pump with Saline
62037661|NCT03180060||CT perfusion|CT perfusion compared versus four reference standards (two anatomic cutoffs: angiographic lesions \>50% and \>70% and two functional cutoffs: FFRi \<0.80 and \<0.75).
62597224|NCT05149352|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Participants will receive an evidence-based psychotherapeutic intervention combined with/or pharmacotherapy (TAU)
62597225|NCT05149352|EXPERIMENTAL|Treatment as usual (TAU) + Trauma-focused therapy (TFT)|Participants will receive 6 to 10, 60-90 minute TFT sessions delivered over a period of 12 weeks, in addition to TAU.
62597226|NCT02920138||Group 5PEEP|Administered 5 cmH2O positive end expiratory pressure group( Group 5PEEP n=30).
62597227|NCT02920138||Group ZEEP|no positive end expiratory pressure group (Group ZEEP n=30)
62597228|NCT04669964||High-Risk For Dehydration|Patients with an Ileostomy output of \>1L at discharge.
62597229|NCT05189093|EXPERIMENTAL|phase I dose escalation part,Phase II efficacy exploratory part and the efficacy confirmation part|"Phase Ib/II efficacy exploration and confirmation phase:~Four cohorts will be conducted in parallel to initially evaluate the recombinant humanized anti-CD47/PD-1 bifunctional anti HX009 injection.~The four cohorts in the efficacy exploration phase are:~Cohort 1: Relapsed/refractory diffuse large B-cell lymphoma; Cohort 2: relapsed/refractory peripheral T-cell lymphoma (except angioimmunoblastic T-cell lymphoma). (except angioimmunoblastic T-cell lymphoma); Cohort 3: relapsed/refractory follicular lymphoma and relapsed/refractory marginal zone lymphoma; Cohort 4: relapsed/refractory EBV-positive non-Hodgkin's lymphoma."
62597230|NCT01154088|EXPERIMENTAL|Group A|
62815608|NCT06357481|EXPERIMENTAL|MICRO MEGA ONE RECI FILES in Group 1|During the non-surgical retreatments, the rotary file systems used in our treatment consist of One Reci system 25.04, 25.06, 35.04, and 45.04 files in symptomatic teeth.
62815609|NCT06357481|EXPERIMENTAL|MICRO MEGA ONE CURVE MINI FILES in Group 2|During the non-surgical retreatments, the rotary file systems used in our treatment consist of One Curve mini system 25.04, 25.06, 35.04, and 45.04 files in symptomatic teeth.
62037662|NCT03180060||Positron Emission Tomography|PET compared versus four reference standards (two anatomic cutoffs: angiographic lesions \>50% and \>70% and two functional cutoffs: FFRi \<0.80 and \<0.75).
62037663|NCT03166761|EXPERIMENTAL|Dexamethasone|dexamethasone injected into the sacroiliac joint
62815610|NCT06357481|EXPERIMENTAL|MICRO MEGA ONE RECI FILES in Group 3|During the non-surgical retreatments, the rotary file systems used in our treatment consist of One Reci system 25.04, 25.06, 35.04, and 45.04 files in asymptomatic teeth.
62037664|NCT03166761|ACTIVE_COMPARATOR|Triamcinolone|triamcinolone injected into the sacroiliac joint
62037665|NCT02187991|ACTIVE_COMPARATOR|ER+/HER2- Paclitaxel Alone|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle
62037666|NCT02187991|EXPERIMENTAL|ER+/HER2- Paclitaxel plus Alisertib|Paclitaxel 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle; Alisertib 40 mg twice a day (BID) on days 1-3, 8-10, and 15-17 of a 28-day cycle
62037667|NCT02187991|ACTIVE_COMPARATOR|Triple Negative Paclitaxel Alone|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle
62429965|NCT02837367|NO_INTERVENTION|Adults genetic assessment|Establishing a genetic signature model in the 1-carbon and omega-6/3 fatty acids metabolic pathways, with high predictive value for dyslipidemia and insulin resistance classification in adult people with obesity.
62429966|NCT02837367|NO_INTERVENTION|Children genetic assessment|Establishing a genetic signature model in the 1-carbon and omega-6/3 fatty acids metabolic pathways, with high predictive value for dyslipidemia and insulin resistance classification in children with obesity.
62429967|NCT02579785|EXPERIMENTAL|mhealth intervention|Receives standard care which includes face to face post-MR family counselling and provision of existing hotline phone number. Also receives Mobile phone based intervention for post-abortion contraceptive uptake.
62429968|NCT02579785|NO_INTERVENTION|Standard Care|Receives standard care which includes face to face post-MR family counselling and provision of existing hotline phone number.
62815611|NCT06357481|EXPERIMENTAL|MICRO MEGA ONE CURVE MINI FILES in Group 4|During the non-surgical retreatments, the rotary file systems used in our treatment consist of One Curve mini system 25.04, 25.06, 35.04, and 45.04 files in asymptomatic teeth.
62815612|NCT02191462|EXPERIMENTAL|Niagen 100mg|1 Niagen capsule (1 x 100 mg capsule) and 9 Placebo capsules
62815613|NCT02191462|EXPERIMENTAL|Niagen 300mg|3 Niagen capsules (3 x 100mg capsule) and 7 Placebo capsules
62815614|NCT02191462|EXPERIMENTAL|1000mg Niagen|10 Niagen capsules (10 x 100mg capsule)
62815615|NCT01259063|EXPERIMENTAL|Pts who failed or relapsed after intravesical BCG|Phase I: Everolimus will be administered as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be administered at the dose determined in Phase .Everolimus will be continued for 12 months in the patients who achieve a CR or a Partial Response. Patients demonstrating a CR (by cystoscopy and cytology) or a Partial Response at their Cycle 12 cystoscopy will be observed with serial cystoscopies every 3 months.
62037668|NCT02187991|EXPERIMENTAL|Triple Negative Paclitaxel plus Alisertib|Paclitaxel 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle; Alisertib 40 mg BID on days 1-3, 8-10, and 15-17 of a 28-day cycle
62037669|NCT02161133|EXPERIMENTAL|Problem-Solving Therapy|Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
62037670|NCT02161133|ACTIVE_COMPARATOR|Health Education|Health education provides didactic information about Gulf War Illness
62037671|NCT06128109|OTHER|Group THIODERM LEFT|Split Face Design: Test Device left midface and Comparator Device right midface
62037672|NCT06128109|OTHER|Group JUVÈDERM LEFT|Split Face Design: Test Device right midface and Comparator Device left midface
62037673|NCT06269770|ACTIVE_COMPARATOR|Tramadol|Tramadol will be administered in a multimodal analgesic approach to manage postoperative pain.
62037674|NCT06269770|ACTIVE_COMPARATOR|Tapentadol|Tapentadol will be administered in a multimodal analgesic approach to manage postoperative pain.
62037675|NCT03711773|EXPERIMENTAL|Group Physical Therapy Class|Group Physical Therapy Classes. Three times weekly, these subjects will have one hour group physical therapy sessions with either a physical therapist, physical therapy assistant, or personal trainer. These sessions will be aimed to improve strength and function in a low-impact setting designed specifically for those with joint pain.
62037676|NCT05669339|EXPERIMENTAL|Irinotecan, Sonidegib, and Sorafenib|Subjects will be assigned to a dose of each drug following a 3 + 3 design
62597231|NCT01154088|EXPERIMENTAL|Group B|
62597232|NCT01154088|ACTIVE_COMPARATOR|Group C|
62597233|NCT05795140|EXPERIMENTAL|Iptacopan 200 mg|Open label , single arm
62597234|NCT03535740|EXPERIMENTAL|Brigatinib 90 mg/180 mg with Optional Dose Escalation to 240 mg|Brigatinib 90 mg, tablets, orally, once daily for 7 days, followed by Brigatinib 180 mg, tablets, orally, once daily for until objective disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by the investigator, or intolerable toxicity. Participants who experienced progression on the 180 mg dose and had not experienced toxicities greater than Grade 2 had the option to receive brigatinib 240 mg QD based on investigator's discretion, up to 20 months until data cut-off: 30 September 2020. Participants who experienced progression on any doses but judged as still benefiting from the study treatment by the investigator may continue to use the current dose, up to study end.
62597235|NCT04506905|EXPERIMENTAL|Part 1 (Panel A) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated from 16 mg to 24 mg once daily (QD), orally, over a course of 7-day treatment.
62597236|NCT04506905|EXPERIMENTAL|Part 1 (Panel B) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated up to 24 mg QD, orally, over a course of 7-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panel.
62597237|NCT04506905|EXPERIMENTAL|Part 1 (Panel C) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over a course of 7-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
62239618|NCT05434962|EXPERIMENTAL|Cardiac resynchronization therapy (CRT) obtained by stimulating the left branch area|"The CRT-P/CRT-D device and leads should be implanted according to the physician's standard practice. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. It is strongly encouraged the designation of a single and experienced implanting physician at each center for the LBBAP implant procedures.~During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA).~For LBBAP, the Medtronic 3830 lead will be used. Acceptable LBBAP threshold should be \<2,5V@0,5ms."
62429969|NCT03970668||Linagliptin plus insulin|Patients that presented hyperglycemia immediately after renal transplantation and received treatment with linagliptin plus insulin
62597238|NCT04506905|EXPERIMENTAL|Part 2 (Panel D) MK-8189|Elderly adult participants with schizophrenia receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over the course of a 13-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
62597239|NCT04506905|EXPERIMENTAL|Part 2 (Panel E) MK-8189|Elderly adult participants with schizophrenia receive MK-8189 titrated from 16 mg to 24 mg QD, orally, over the course of 10-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
62597240|NCT04506905|EXPERIMENTAL|Part 2 (Panel F) MK-8189|Healthy elderly adult participants receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over the course of a 13-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
62735607|NCT00500565|EXPERIMENTAL|On-Q Pump with Bupivicaine|On-Q Pump with bupivicaine
62735608|NCT03520686|EXPERIMENTAL|Cohort A (Experimental)|
62037677|NCT01443481|EXPERIMENTAL|TKI258 normal hepatic function|TKI258 Capsule, @ 500 mg p.o. o.d. 5 days on/2 days off
62429970|NCT03970668||Insulin|Patients that presented hyperglycemia immediately after renal transplantation and received treatment only with insulin
62429971|NCT02462382|ACTIVE_COMPARATOR|Ropivacaine infusion|270cc of Ropivacaine infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
62429972|NCT02462382|PLACEBO_COMPARATOR|Saline infusion|270cc of Normal Saline infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
62429973|NCT02971332||Treatment Group|Patients candidated to STARR after the failure of medical and dietary therapy and after a complete radiological and functional study.
62429974|NCT04575974||Adolescents 13-19 years|All adolescents between 13-19 years of age in North Trøndelag county were invited to participate in HUNT 3 and followed up after 11 years.
62429975|NCT06538272|EXPERIMENTAL|ONO-2910|
62429976|NCT06538272|PLACEBO_COMPARATOR|Placebo|
62429977|NCT06265688|EXPERIMENTAL|CX-2051|
62429978|NCT02192216|EXPERIMENTAL|Exercise & Chemotherapy|Following a control period during active chemotherapy the patients undergo ten weeks of supervised exercise comprised of resistance and aerobic training in combination with protein supplementation during ongoing chemotherapy.
62815616|NCT04982731|EXPERIMENTAL|ED/Urgent Care Positive Assurance Discharge Video Educational Intervention (EDUC).|The video intervention will be administered to participants that are randomly assigned to the EDUC group. In addition, current standard of care discharge instructions will also be provided to the participant. This EDUC intervention will consist of a brief, three to five-minute informative video message from the clinical neuropsychologist at the Inova Sports Medicine Concussion Program. In addition to the viewing of the video after ED/Urgent Care discharge, all participants will be instructed to view the video at least once every 24 - 48 hours prior to their visit to the concussion clinic.
62037678|NCT01443481|EXPERIMENTAL|TKI258 mild hepatic impairment|TKI258 capsule @ 500 or 400 mg p.o. o.d. 5 days on/2 days off
62597241|NCT04506905|EXPERIMENTAL|Part 2 (Panel G) MK-8189|Healthy elderly adult participants receive MK-8189 titrated from 16 mg to 24 mg QD, orally, over the course of 10-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
62597242|NCT04506905|PLACEBO_COMPARATOR|Part 1 (Panels A, B, C) Placebo|Oral tablets of dose-matched placebo to total daily dose of MK-8189.
62037679|NCT01443481|EXPERIMENTAL|TKI258 moderate hepatic impairment|TKI258 capsule @ starting dose at 400 mg p.o. o.d. 5 days on/2 days off
62037680|NCT01443481|EXPERIMENTAL|TKI258 severe hepatic impairment|TKI258 capsule Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
62037681|NCT00720889||Reduced sleep|Habitual sleep duration of less than 6 hours per night on most days of the week and total sleep of less than 43 hours per week.
62037682|NCT00720889||Reference sleep|Habitual sleep duration between 7 and 8.5 hours per night on most days of the week and total sleep of at least 53 hours per week.
62037683|NCT06473896|ACTIVE_COMPARATOR|Ketalar|"All patients will undergo general anesthesia using Fentanyl at a dose of 2 mcg/kg, Rocuronium at a dose of 0.6 mg/kg, Isoflurane during surgery and Remifentanil at a dose of 0.2-0.25 mcg/kg/min, 30 Minutes before the end of the operation, Morphine will be given at a dose of 0.1 mg/kg. Each patient will receive paracetamol during surgery.~In addition to the general anesthesia, the patients in the Ketalar group will also receive a bolus of Ketalar at a dose of 0.3 mg/kg in induction + Propofol and Fentanyl and during the operation, continuous Ketalar at a dose of 5 mcg/kg/minute."
62037684|NCT06473896|ACTIVE_COMPARATOR|Dexmedetomidine|"In addition to the general anesthesia, the patients in the Dexmedetomidine group will also receive a bolus of Ketalar at a dose of 0.3 mg/kg in induction + Propofol and Fentanyl and during the operation, continuous Ketalar at a dose of 5 mcg/kg/minute.~In addition to the general anesthesia, the patients in the Dexmedetomidine group will also receive a bolus of Dexmedetomidine at a dose of 0.5 mg/kg for fifteen minutes + Propofol and Fentanyl, and during the operation, continuous Dexmedetomidine at a dose of 0.3 mcg/kg/hour."
62037685|NCT03717896|EXPERIMENTAL|Thiamine|200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
62597243|NCT04506905|PLACEBO_COMPARATOR|Part 2 (Panels D, E, F, G) Placebo|Oral tablets of dose-matched placebo to total daily dose of MK-8189.
62597244|NCT04738422|EXPERIMENTAL|Alkaline glycine Inhalation|Subjects inhale alkaline glycine
62597245|NCT06621550|EXPERIMENTAL|HIIT Arm|Participants will receive a single session of HIIT, which lasts for 19 minutes
62597246|NCT06621550|NO_INTERVENTION|Control Arm|Participants will be arranged to rest quietly on a chair for 19 minutes.
62597247|NCT04486027||Healthy|Healthy individuals not smoking, not using Disease-Modifying Anti-Rheumatic Drugs (DMARD) and/or anti-inflammatory drugs other than cortisol and methotrexate, not receiving chemotherapy, not being hypothyroidic
62037686|NCT03717896|PLACEBO_COMPARATOR|Placebo|100mL 0.9% saline twice daily for two days
62037687|NCT04528836|EXPERIMENTAL|Dose Escalation|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).
62037688|NCT04528836|EXPERIMENTAL|Dose Expansion|"Oral capsules administered at MTD/RP2D defined dose. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)~* Cohort A: Advanced or metastatic KRAS mutant solid tumor~* Cohort B: Advanced solid tumor with NF1 loss-of-function (LOF) or metastatic BRAF class II/III mutant solid tumor"
62037689|NCT01983748|EXPERIMENTAL|A|Biological/Vaccine; Autologous Dendritic Cells loaded with autologous Tumor RNA
62037690|NCT01983748|NO_INTERVENTION|B|Control, Standard of care, which is clinical control every 3 months
62037691|NCT03923348|EXPERIMENTAL|Leva Users|Subjects with pure urge urinary incontinence (UUI) or urge-predominant mixed urinary incontinence (U-MUI) who are candidates for pelvic floor physical therapy or other first line treatments for UUI/U-MUI use the leva® system twice-daily at home in addition to behavioral therapies for 8 weeks.
62735609|NCT03520686|EXPERIMENTAL|Cohort B (Experimental)|
62815617|NCT04982731|NO_INTERVENTION|Standard of Care ED/Urgent Care Discharge Instructions (Treatment as Usual: TAU )|The Acute Concussion Evaluation (ACE) Care plan in place at the Inova PED/GoHealth Urgent Care sites is the standard-of-care discharge instruction for individuals with mTBI. This care plan provides patient and caregiver education about mTBI and emphasizes the monitoring of symptoms, signs of deterioration that may warrant urgent medical attention, and encourages the patient to follow up with their physician for follow up. Participants who are randomized into the TAU group will receive this standard of care treatment in video format as well, however these participants will not be given a QR code to watch the intervention video.
62239619|NCT05434962|ACTIVE_COMPARATOR|Cardiac resynchronization therapy (CRT) obtained by biventricular pacing|"The CRT-P/CRT-D device and leads should be implanted according to the physician's manual provided with the devices. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study.~Investigators may use any market approved right atrial (RA) pace/sense lead, right ventricular (RV) pacing/defibrillator lead with pace/sense capabilities and any market approved unipolar/bipolar/quadripolar LV pacing lead.~During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA).~The LV lead should be implanted at a lateral or posterolateral CS branch in a basal or mid ventricular position confirmed by ortogonal fluoroscopic views (RAO and LAO 40º).~Acceptable LV pacing threshold should be \<3V@0,5ms and phrenic nerve stimulation (PNS) margin should be \>1V with respect to the pacing threshold"
62597248|NCT04486027||Active Rheumatoid Arthritis|Active Rheumatoid Arthritis meeting American College of Rheumatology (ACR) RA remission criteria
62597249|NCT04486027||Rheumatoid Arthritis in remission|Rheumatoid Arthritis in remission meeting American College of Rheumatology (ACR) RA remission criteria
62815618|NCT05101590|EXPERIMENTAL|Monitored with HDA|Participants undergoing elective major surgery and have an arterial line as part of their standard care with HDA included as part of their care
62819414|NCT05650606|ACTIVE_COMPARATOR|Conventional|The conventional physical therapy sessions are what a patient would normally receive during their rehabilitation. Physical therapy sessions are usually 60-90 minutes per day for 5 days each week, and possibly one 30-minute session on a 6th day. Physical therapy sessions are focused on gait, balance, and strengthening activities to address goals related to functional mobility. Clinicians administering therapy to patients in this arm will not be given instructions on the types of therapies they administer; however, they will not be permitted to do HIGT with patients. Therapists will be permitted to use other devices such as Ekso exoskeleton, Lite Gait, Rifton Tram Body Weight Support Devices, and Electrical Stimulation devices including the XCITE and RT300.
62037692|NCT04877522|EXPERIMENTAL|Asciminib single agent group|Participants with CML or ALL, from Novartis sponsored asciminib studies, including but not limited to CABL001A2301, CABL001A2302, CABL001X2101, CABL001A2202, CABL001AUS04 and CABL001AUS08 studies, that were receiving asciminib
62429979|NCT02400073|EXPERIMENTAL|AutoSet for Her PAP device|Patients in this study will use the AutoSet for Her: A new AutoSetting Positive Airway Pressure (PAP) device designed specifically to treat female OSA
62429980|NCT04562298|EXPERIMENTAL|LCAR-M23 Chimeric Antigen Receptor T cell|
62429981|NCT02692352|EXPERIMENTAL|Experimental|8 sessions of Goal Management Training
62429982|NCT02692352|ACTIVE_COMPARATOR|Active control group|8 sessions of Brain Health Workshop
62429983|NCT03235531|EXPERIMENTAL|CIWA Protocol/BZD and Valproate|"1. Interventions to decrease symptoms of AWS will be made based on the CIWA tool.~   * CIWA Score 9-14: 1 mg IV push lorazepam~  * CIWA Score \>15: 2 mg IV push lorazepam~2. Patients who have a known history of alcohol withdrawal seizures or who have received greater than 4 mg IV lorazepam per CIWA protocol will be placed on a scheduled lorazepam regimen, 1 mg every 6 hours. The primary managing service may increase the scheduled lorazepam regimen above 1mg every 6 hours if needed to control withdrawal symptoms. Scheduled lorazepam will be discontinued or de-escalated following a 24-hour period in which no additional lorazepam was received per CIWA protocol.~3. The treatment group will also receive scheduled valproate (VPA), 15 mg/kg divided over 4 doses, rounded up to the nearest increment of 50mg (i.e. a 70 kg person would be administered 300 mg IV VPA every 6 hours) for 96 hours."
62597250|NCT04430842|EXPERIMENTAL|Dose escalation of QBS10072S|Intravenous administration of QBS10072S once every 4 weeks starting at 3mg/m2 and increasing dose levels in subsequent cohorts.
62597251|NCT05514587||Suicidal act|Patients who has committed a suicidal act
62597252|NCT05514587||Suicidal thoughts without acting on them|Patients with suicidal thoughts without acting on them
62597253|NCT05514587||No suicidal ideation or acting out|Patients without suicidal ideation or acting out of patients in crisis admitted to the Crisis Center
62597254|NCT06341543|EXPERIMENTAL|Qantiferon CMV result communicated to the clinician in charge|In this arm, the result of the CMV-QF will be communicated to the clinician in charge. If QF-CMV is positive, the clinician will be advised not to treat the patient. If QF-CMV is negative, he/she will be advised to use or not antiviral therapy, according to the guidelines and the local practice.
62597255|NCT06341543|OTHER|Qantiferon CMV result NOT communicated to the clinician in charge|In this arm, the result of the CMV-QF will NOT be communicated to the clinician in charge. He/she will be advised to use or not antiviral therapy, according to the guidelines and the local practice.
62597256|NCT04446195|NO_INTERVENTION|Control group|The control group received routine intestinal preparation education.
62597257|NCT04446195|ACTIVE_COMPARATOR|Experimental group|The experimental group was treated with routine intestinal preparation education and individualized intervention.
62597258|NCT00984139|EXPERIMENTAL|Engerix-B Group|Subjects who were vaccinated with 3 doses of Engerix-B in infancy and who received a single challenge dose of Engerix-B , intramuscularly in the deltoid region of the non-dominant arm, at 12-13 years of age (Day 0).
62597259|NCT02658734|EXPERIMENTAL|Trastuzumab emtansine|
62597260|NCT06617988||Normal prognosis group (control group)|Participants included in this group should have normal ovarian reserve: number of antral follicle count ≥5, level of anti-Mullerian hormone ≥1.2 ng/ml, and number of oocytes retrieved in the present IVF-ET cycles\>9. All participants in this group receive the standard operation protocol for In vitro fertilization and embryo transfer.
62597261|NCT06617988||Unexpected poor prognosis group|Participants included in this group should have normal ovarian reserve but a poor ovarian response, defined as: number of antral follicle count ≥5, level of anti-Müllerian hormone ≥1.2ng/ml, and number of oocytes retrieved in the present IVF-ET cycles ≤ 9. All participants in this group will receive the standard operation for in vitro fertilization and embryo transfer.
62597262|NCT06617988||Poor prognosis of advanced maternal age group|Participants included in this group are characterized by advanced age (≥35 years) and meet at least one of the following criteria: 1. Number of oocytes retrieved in the current IVF cycle ≤9; 2. Diminished ovarian reserve: level of anti-Mullerian hormone\<1.2 ng/ml or number of antral follicle count \<5. All participants in this group receive the standard operation protocol for In vitro fertilization and embryo transfer.
62597263|NCT06617988||Expected poor prognosis group|Participants included in this group should have diminished ovarian reserve: number of antral follicle count\<5 and level of anti-Mullerian hormone\<1.2 ng/ml. All participants in this group receive the standard operation protocol for In vitro fertilization and embryo transfer.
62597264|NCT02662400|EXPERIMENTAL|MNCs GROUP|Patients with Type 2 Diabetes mellitus
62597265|NCT06620380|EXPERIMENTAL|Arm 1: experimental arm, Pharmacoscopy-guided treatment|Arm 1 (experimental arm): Pharmacoscopy-guided treatment will be prescribed by the investigator according to the results of the analysis (relevant on-target effect) and per drug prescription guidelines.
62597266|NCT06620380|ACTIVE_COMPARATOR|Arm 2: control arm|For patients randomized to the control arm, no pharmacoscopy analysis will be performed.
62819415|NCT03630354|EXPERIMENTAL|Arm I (supervised exercise together)|Couples perform partnered exercise over 1 hour, 2 days per week in a supervised, group setting remotely for 6 months.
62819416|NCT03630354|EXPERIMENTAL|Arm II (supervised exercise separately)|Survivors and partners perform exercise routines over 1 hour, 2 days per week separately in a supervised group setting remotely for 6 months.
62037693|NCT04877522|OTHER|Bosutinib single agent group|Participants with CML-CP, from Novartis sponsored asciminib study CABL001A2301, that were receiving bosutinib
62429984|NCT03235531|ACTIVE_COMPARATOR|CIWA Protocol Only|"1. Interventions to decrease symptoms of AWS will be made based on the CIWA tool~   * CIWA Score 9-14: 1 mg IV push lorazepam~  * CIWA Score \>15: 2 mg IV push lorazepam~2. Patients who have a known history of alcohol withdrawal seizures or who have received greater than 4 mg IV lorazepam per CIWA protocol will be placed on a scheduled lorazepam regimen, 1 mg every 6 hours. The primary managing service may increase the scheduled lorazepam regimen above 1mg every 6 hours if needed to control withdrawal symptoms. Scheduled lorazepam will be discontinued or de-escalated following a 24-hour period in which no additional lorazepam was received per CIWA protocol."
62819417|NCT03630354|EXPERIMENTAL|Arm III (unsupervised exercise separately)|Survivors and partners undergo 2 training sessions remotely over 1 hour with an exercise trainer and then perform exercise routines over 1 hour, 2 days per week unsupervised at home or a facility following an instructional DVD.
62037694|NCT04877522|EXPERIMENTAL|Bosutinib-Asciminib switch group|Participants with CML-CP, from Novartis sponsored asciminib study CABL001A2301 that were receiving bosutinib treatment and switched to asciminib when entering this study or during the course of this study
62429985|NCT03996707|OTHER|Immediate protected weight-bearing|Immediate protected weight-bearing
62429986|NCT03996707|OTHER|Traditional non weight bearing|Strict non-weight-bearing
62429987|NCT05938335|EXPERIMENTAL|severe obese children|children with severe obesity with BMI \> 3sds
62429988|NCT03443219|EXPERIMENTAL|Spritztube®|The patients were randomly allocated to two groups by using computer-generated numbers.In Spritztube® group, Spritztube® was inserted into each patient after anesthesia induction.
62429989|NCT03443219|ACTIVE_COMPARATOR|LMA Supreme™|The patients were randomly allocated to two groups by using computer-generated numbers.In vgroup, LMA Supreme™was inserted into each patient after anesthesia induction.
62597267|NCT03740529|EXPERIMENTAL|Phase I Dose Escalation (Pirtobrutinib Monotherapy)|Dose Escalation and determination of MTD; multiple dose levels of pirtobrutinib to be evaluated
62429990|NCT04987671|EXPERIMENTAL|Treatment with AMX0035|Two sequential study period. In Period 1, subject receive AMX0035 daily for approximately 14 days. In Period 2, subjects receive AMX0035 twice a day, morning and evening, for up to 25 days.
62429991|NCT00279799|EXPERIMENTAL|Afiya group intervention + HIV prevention phone sessions|Afiya group-based intervention plus individually tailored HIV prevention phone sessions
62597268|NCT03740529|EXPERIMENTAL|Phase 2 (Pirtobrutinib Monotherapy) Cohort 3|CLL/SLL patients with no prior therapy.
62597269|NCT03740529|EXPERIMENTAL|Phase 2 (Pirtobrutinib Monotherapy) Cohort 1|Non-blastoid MCL patients treated with a prior BTK-inhibitor containing regimen.
62597270|NCT03740529|EXPERIMENTAL|Phase 2 (Pirtobrutinib Monotherapy) Cohort 4|CLL/SLL patients treated with prior therapy, BTK inhibitor naïve.
62597271|NCT03740529|EXPERIMENTAL|Phase 2 (Pirtobrutinib Monotherapy) Cohort 2|CLL/SLL patients treated with 2 or more prior regimens, including a BTK inhibitor-containing regimen.
62597272|NCT03740529|EXPERIMENTAL|Phase 2 (Pirtobrutinib Monotherapy) Cohort 5|WM patients treated with a prior BTK inhibitor-containing regimen.
62597273|NCT03740529|EXPERIMENTAL|Phase 2 (Pirtobrutinib Monotherapy) Cohort 6|MZL patients treated with a prior BTK inhibitor-containing regimen.
62597274|NCT03740529|EXPERIMENTAL|Phase 2 (Pirtobrutinib Monotherapy) Cohort 7|Defined as CLL/SLL or NHL not otherwise specified in Cohorts 1 through 6, inclusive of CLL/SLL, Richter's transformation, or low grade NHL with transformation, blastoid MCL, and patients with history of CNS involvement or primary CNS lymphoma. In the event the Sponsor electively closes Cohorts 2-4 prior to completion, patients with CLL/SLL who are ineligible to participate in or unable to access late phase studies of pirtobrutinib may be eligible to enroll in this cohort Diffuse large B-cell lymphoma (DLBCL) is excluded. MCL without prior BTK inhibitor treatment is excluded. Patients enrolling to Cohort 7 must have received one or more prior therapies or have no available approved therapy with demonstrated clinical benefit with the exception of untreated Richter's transformation, which is allowed.
62597275|NCT03740529|EXPERIMENTAL|Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm A|Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax
62597276|NCT03740529|EXPERIMENTAL|Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm B|Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax and rituximab
62819418|NCT05124925|EXPERIMENTAL|Treatment Arm|Ianalumab 300 mg subcutaneous monthly
62037695|NCT04877522|EXPERIMENTAL|Asciminib in combination with imatinib group|Participants with CML from Novartis sponsored asciminib studies CABL001E2201 or CABL001X2101 that were receiving asciminib combined with imatinib
62239620|NCT01458704||fresh frozen tumor tissue|patients providing fresh frozen tumor tissue
62429992|NCT00279799|ACTIVE_COMPARATOR|Afiya group session + nutrition phone sessions|Afiya group-based intervention plus individually tailored nutrition phone sessions
62429993|NCT05889026|ACTIVE_COMPARATOR|Botulinum toxin treatment with extracorporeal shock wave therapy|"Nabota® (Daewoong Pharmaceutical Co. Ltd., Seoul, Korea) was used. It was diluted with 0.9% sodium chloride solution and injected into the bellies of the upper-extremity muscles.~ESWT was performed immediately after botulinum toxin injection and was performed once a day for 5 days. Three weeks and 3 months after ESWT, spasticity was evaluated."
62429994|NCT05889026|SHAM_COMPARATOR|Botulinum toxin treatment only|Nabota® (Daewoong Pharmaceutical Co. Ltd., Seoul, Korea) was used. It was diluted with 0.9% sodium chloride solution and injected into the bellies of the upper-extremity muscles. Three weeks and 3 months after Botox treatment, spasticity was evaluated.
62429995|NCT02684383|EXPERIMENTAL|rDEN3∆30 vaccine|Participants will receive the rDEN3∆30 vaccine at Day 0.
62597277|NCT03740529|EXPERIMENTAL|Phase 1 Dose Expansion (Pirtobrutinib Monotherapy)|Patients to receive the recommended Phase 2 dose of pirtobrutinib
62597278|NCT03624543|EXPERIMENTAL|Cohort 1: TNBC|N=9 to 24 patients
62597279|NCT03624543|EXPERIMENTAL|Cohort 2: PTEN-null, ER+ and/or PR+, HER2-|N=9 to 24 patients
62597280|NCT03624543|EXPERIMENTAL|Cohort 3: Not PTEN-null, ER+ and/or PR+, HER2-|N=9 to 24 patients
62597281|NCT01759810|EXPERIMENTAL|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
62735610|NCT03520686|EXPERIMENTAL|Cohort C (Experimental)|
62735611|NCT03520686|ACTIVE_COMPARATOR|Cohort A (Control)|
62819419|NCT00392327|ACTIVE_COMPARATOR|Arm A (chemoradiotherapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy QD five days a week for 6 weeks. Patients also receive vincristine sulfate IV over 1 minute once weekly for 6 weeks. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive cisplatin IV over 6 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 8, and cyclophosphamide IV over 1 hour on days 2 and 3. Patients also receive filgrastim SC or IV beginning on day 4 and continuing until blood counts recover (at least 10 days).~Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity.~Patients also undergo blood sample collection, lumbar puncture and MRI throughout the study."
62597282|NCT01759810|ACTIVE_COMPARATOR|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
62239621|NCT04687761|EXPERIMENTAL|AZA-Based|"Azacitidine 75 mg/m2/daily SC on a 5-on/2-off \[weekend\]/2-on schedule in 28-day cycle plus Venetoclax (ramp-up) 400 mg/daily oral, days 1 to 28 plus Quizartinib phase I/RP2D mg/daily oral, days 8 to 14-28.~If 1 DLT is observed among these 3 patients, additional 3 subjects will receive the level 2 dose, and it will be recommended in the absence of DLT between them. If \>1 DLT occurs in these 6 level 2 patients, the dose administered in the level 1 will be the RP2D of the AZA-based schedule.~AZA and Venetoclax doses will remain the same in all levels and only the dose of Quizartinib will be modificated according to the following table:~Escalation-Quizartinib dose-Quizartinib duration; Level-2 -30 mg/daily-Days 8 to 14; Level-1 -30 mg/daily-Days 8 to 21; Level1-40 mg/daily Days 8 to 28; Level2-60 mg/daily-Days 8 to 28.~In phase II, patients randomized to this arm, will receive the recommended phase 2 dose (RP2D) regimen of AZA + Venetoclax + Quizartinib regimen (30 patients)."
62597283|NCT00550134||1, Non Cancer group|A noncancer control group (N=35), frequency matched on age (\< 50 and ≥ 50) and education (less than college or some college and above) will also be recruited and evaluated with the same neuropsychological test battery on a schedule that matches the inter-test interval of the patients.
62597284|NCT00550134||2 Breast Cancer Patients Scheduled for chemotherapy|We will recruit patients with localized breast cancer undergoing adjuvant chemotherapy for the first time and will test the effects of chemotherapy will be given a battery of neuropsychological tests and an MRI evaluation prior to beginning chemotherapy and approximately one month (plus/minus 4 weeks) following completion of treatment.
62815619|NCT05616286|EXPERIMENTAL|Mindfulness-SOS|Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile health adaptation of MBTR-R, mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. Mid-intervention, 3-weeks following randomization, all participants will be re-assessed. Participants initially randomized to MG-Mindfulness-SOS will be identified as either responders or non-responders. Responders will be assigned to continue MG-Mindfulness-SOS. Non-responders will be re-randomized to either Intensified-Guidance Mindfulness-SOS (IG-Mindfulness-SOS), an adaptive intervention sequence condition, or to continue with the MG-Mindfulness-SOS, a non-adaptive intervention sequence condition.
62815620|NCT05616286|NO_INTERVENTION|Waitlist-Control|Following the 7-week waitlist period and another assessment, participants randomized to waitlist-control will be assigned to Minimally-Guided Mindfulness-SOS (MG-Mindfulness-SOS) and then re-assessed following 3-weeks and, as described above, assigned to either continue in the MG-Mindfulness-SOS group or to move to the Intensified-Guidance Mindfulness-SOS (IG-Mindfulness-SOS).
62815621|NCT00672698||I|VASCULAR SURGERY
62815622|NCT00672698||II|DIGESTIVE SURGERY
62815623|NCT00672698||III|BILIARY TRACT SURGERY
62597285|NCT00550134||3 Breast Cancer Patients Not Scheduled for Chemotherapy|We will recruit patients with localized breast cancer not undergoing adjuvant chemotherapy.
62597286|NCT03898362|ACTIVE_COMPARATOR|pneumatically powered wheelchair or scooter|participants will use pneumatic powered wheelchair or scooter
62815624|NCT04530123|EXPERIMENTAL|Cohort 1, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE|Following a single-day 3 gram (g) oral run-in gluten challenge, participants will receive TAK-101 placebo-matching intravenous (IV) infusion dose, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 25 microgram per kilogram (µg/kg) GE will be given 23 weeks after the second dose at approximately Week 24.
62815625|NCT04530123|EXPERIMENTAL|Cohort 1, Group B: TAK-101 25 µg/kg GE + Placebo + TAK-101 25 µg/kg GE|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 25 µg/kg, IV infusion once on Day 1 followed by TAK-101 placebo-matching IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 25 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24.
62597287|NCT03898362|ACTIVE_COMPARATOR|battery powered wheelchair or scooter|participants will use battery powered wheelchair or scooter
62815626|NCT04530123|EXPERIMENTAL|Cohort 1, Group C: TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE + TAK-101 25 µg/kg GE|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 25 µg/kg GE IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 25 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24.
62597288|NCT06477068|EXPERIMENTAL|IVF Patients|Patients undergoes ovarian stimulation for IVF treatment at Hung Vuong Hospital
62597289|NCT06621316|EXPERIMENTAL|Treatment group A|HRS-7535 Tablet at dose level 1
62597290|NCT06621316|EXPERIMENTAL|Treatment group B|HRS-7535 Tablet at dose level 2
62597291|NCT06621316|EXPERIMENTAL|Treatment group C|HRS-7535 Tablet at dose level 3
62597292|NCT06621316|EXPERIMENTAL|Treatment group D|HRS-7535 Tablet at dose level 4
62597293|NCT06621316|PLACEBO_COMPARATOR|Treatment group E|Placebo at dose level 1
62597294|NCT06621316|PLACEBO_COMPARATOR|Treatment group F|Placebo at dose level 2
62735612|NCT03520686|ACTIVE_COMPARATOR|Cohort B (Control)|
62815627|NCT04530123|EXPERIMENTAL|Cohort 2, Group A: Placebo + Placebo + TAK-101 25 µg/kg GE|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 placebo-matching IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 25 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.
62815628|NCT04530123|EXPERIMENTAL|Cohort 2, Group D: TAK-101 50 µg/kg GE + TAK-101 50 µg/kg GE+ TAK-101 50 µg/kg GE|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 50 µg/kg GE IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 50 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.
62597295|NCT06621316|PLACEBO_COMPARATOR|Treatment group G|Placebo at dose level 3
62597296|NCT06621316|PLACEBO_COMPARATOR|Treatment group H|Placebo at dose level 4
62597297|NCT02744664|EXPERIMENTAL|Experimental|The subject receive Cryotherapy and than receive Icotinib 125mg, 3 times a day, orally administered until disease progression or intolerable toxicity reaction.
62597298|NCT02455817||Cypher|Access rate of angina including degree, post PCI up to 1 year for the Cypher stent.
62037696|NCT04877522|EXPERIMENTAL|Asciminib in combination with nilotinib group|Participants with CML or ALL from Novartis sponsored asciminib studies CABL001E2201or CABL001X2101 that were receiving asciminib combined with nilotinib
62243455|NCT06735690|EXPERIMENTAL|Part 2 (allo CMV-specific CD19-CAR T cells, CMV-MVA vaccine)|Patients receive HSCT conditioning regimen followed by alloHSCT per standard of care. Starting 28-49 days after alloHSCT, patients receive allo CMV-specific CD19-CAR T cells IV over 10-15 minutes on day 0. Patients receive CMV-MVA triplex vaccine IM on day 28 in the absence of DLTs and may receive an additional CMV-MVA triplex vaccine IM on day 56 in the absence of DLTs during the second evaluation period. Patients undergo ECHO or MUGA, blood and optional CSF sample collection and bone marrow biopsy and aspiration throughout the study. Patient may also undergo chest x-ray and lumbar puncture as needed per PI discretion and PET/CT or CT as clinically indicated throughout the study. Additionally, patients with neurological abnormalities at baseline may undergo MRI of brain throughout the study.
62597299|NCT02455817||Taxus Express|Access rate of angina including degree, post PCI up to 1 year for the Taxus Express stent.
62815629|NCT04530123|EXPERIMENTAL|Cohort 2, Group E: Placebo + Placebo + TAK-101 12.5 µg/kg GE|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 placebo-matching IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 12.5 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1. This group would be opened only if it is decided not to open Cohort 2 at the 50 µg/kg GE dose level.
62597300|NCT02455817||Xience V|Access rate of angina including degree, post PCI up to 1 year for the Xience V stent.
62815630|NCT04530123|EXPERIMENTAL|Cohort 2, Group F: TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE + TAK-101 12.5 µg/kg GE|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 12.5 µg/kg GE IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 12.5 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.
62815631|NCT06266481|ACTIVE_COMPARATOR|dexamethasone group|An endotracheal tube was soaked in 8mg of dexamethasone for group I intubation
62597301|NCT02455817||Promus Element|Access rate of angina including degree, post PCI up to 1 year for the Promus stent.
62815632|NCT06266481|ACTIVE_COMPARATOR|lidocaine group|10% lidocaine was sprayed over the tube
62815633|NCT03758781|EXPERIMENTAL|IRX-2 Regimen combined with Nivolumab|IRX-2 Regimen (4 ml) combined with Nivolumab (240 mg)
62597302|NCT02455817||Resolute|Access rate of angina including degree, post PCI up to 1 year for the Resolute stent.
62815634|NCT06151405|EXPERIMENTAL|Dietary Guidelines for Americans|7 days of a diet consistent with the Dietary Guidelines for Americans (DGA).
62815635|NCT06151405|EXPERIMENTAL|Medium Chain Triglyceride Supplemented DGA|7 days of a diet consistent with the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
62815636|NCT06151405|EXPERIMENTAL|Ketogenic Diet|7 days of a ketogenic diet (KETO).
62815637|NCT05133297|EXPERIMENTAL|Sequence 1|TLL018 tablets, 1piece,BID
62597303|NCT02455817||Bare metal stents|Access rate of angina including degree, post PCI up to 1 year for bare metal stents.
62597304|NCT06035861|EXPERIMENTAL|XBD173|6 weeks exposure to XBD173
62597305|NCT04142320|EXPERIMENTAL|Closed-loop rTMS|Closed-loop rTMS will be delivered to determine the target engagement compared to open-loop rTMS. Closed loop rTMS will be applied for two consecutive days for 30 minutes to determine dose response. Closed- loop rTMS will be delivered using neuro-navigation based on participants' own MRI images. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
62037697|NCT04877522|OTHER|Imatinib single agent group|Participants with CML-CP, from Novartis sponsored asciminib study CABL001E2201 that were receiving imatinib
62037698|NCT04877522|OTHER|Nilotinib single agent group|Participants with CML-CP, from Novartis sponsored asciminib study CABL001E2201 and CABL001J12302 that were receiving nilotinib
62037699|NCT04877522|EXPERIMENTAL|Asciminib in combination with dasatinib group|Participants with CML from Novartis sponsored study CABL001X2101 that were receiving asciminib with dasatinib
62037700|NCT04877522|OTHER|Dasatinib single agent group|Participant with CML-CP , from Novartis sponsored asciminib study CABL001A2202, CABL001J12301, that were receiving Dasatinib.
62735613|NCT03520686|ACTIVE_COMPARATOR|Cohort C (Control)|
62735614|NCT03520686|EXPERIMENTAL|Cohort D (Experimental)|
62735615|NCT02029456|EXPERIMENTAL|Low dose prolonged infusion arm|Low dose prolonged infusion of tPA arm (25mg Actilyse in 6 hours)
62597306|NCT04142320|ACTIVE_COMPARATOR|Open-loop rTMS|A series of open-loop rTMS protocols will be delivered to determine the most effective standard and individualized rTMS. Active rTMS will be delivered using neuro-navigation based on participants' own MRI images. For each clinically-utilized rTMS protocol (1Hz, 5Hz, 10Hz, 20Hz), 3000 pulses will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
62037701|NCT04877522|EXPERIMENTAL|Dasatinib-Asciminib switch group|Participants with CML-CP, from Novartis sponsored asciminib study CABL001A2202 that were receiving best available therapy (dasatinib) and switched to asciminib when entering this study or during the course of this study
62815638|NCT05133297|EXPERIMENTAL|Sequence 2|TLL018 tablets, 2pieces, BID
62597307|NCT04142320|PLACEBO_COMPARATOR|Sham rTMS|Sham rTMS will be delivered for two consecutive sessions to mimic active rTMS conditions. To maximize sham validity, both 1) a direction- sensor TMS coil will alert the operators to flip the coil if the wrong side is being used, and 2) low-intensity electrical stimulation to match the active rTMS frequency will be applied to scalp electrodes under the coil for sham and placed but not activated in the active arm. The rTMS coil will be positioned using neuro-navigation based on participants' own MRI images, mimicking active rTMS. Sham rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the sham rTMS session for adverse events and/or side effects.
62037702|NCT06171191|EXPERIMENTAL|Intervention group|Intervention group receives intervention between prétest and posttest. Three months after posttest they undergo a follow-up test
62037703|NCT06171191|OTHER|Control group|Waiting group. Control group receives intervention after all test (prétest, posttest and follow-up test)
62815639|NCT05133297|EXPERIMENTAL|Sequence 3|TLL018 tablets, 3pieces, BID
62429996|NCT02684383|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo at Day 0.
62429997|NCT06157333|ACTIVE_COMPARATOR|Active rTMS group|We determined the motor threshold (MT) of the contralateral abductor pollicis brevis muscle as the target muscle by stimulating the left motor cortex. The MT was defined as the stimulus intensity required to produce motor evoked potentials of\> 50 mV peak-to-peak amplitude in five out of ten consecutive trials in the right abductor pollicis brevis. The rTMS was performed over the left F3 on the scalp according to the 10/20 electroencephalography system with an 8-shaped 70-mm coil. The protocol included high frequency (10 Hz) rTMS applied over the left DLPFC at 110% RMT for two sessions per day, over two weeks for a total of 20 sessions. In each session, a total of 2000 pulses were stimulated for 5 seconds, applied at 25-second intervals, and each rTMS session lasted 20 minutes. Patients were given the opportunity to rest for 1-3 hours in between sessions. A total of 4000 pulses were applied to the patients in one day.
62597308|NCT06649396|EXPERIMENTAL|Capillary Blood on DBS|A total of 100µL of capillary blood will be deposited onto DBS
62597309|NCT06649396|EXPERIMENTAL|Plasma from EDTA whole blood|Plasma from peripheral blood
62815640|NCT05133297|ACTIVE_COMPARATOR|Sequence 4|TOFA tablets, 1pieces, BID
62815641|NCT04908423|EXPERIMENTAL|Xeomin®|Participants will be injected via electromyographic guidance with a total of 200 units of Xeomin® into the pectoralis major, biceps brachii, brachioradialis, and latissimus dorsi muscles of the hemiparetic side using a standardized injection protocol (16). An additional 100 units of Xeomin® will be available at the discretion of the investigator for injection into additional affected upper extremity muscles
62037704|NCT05707533||Patients underwent TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique|Patients with pelvic organ prolapse who underwent TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique between June 2008 and December 2020
62037705|NCT06095726|NO_INTERVENTION|Control group|Children with leukemia received routine nursing and hospital care for management of chemotherapy induced nausea and vomiting (antiemetic medications only).
62429998|NCT06157333|PLACEBO_COMPARATOR|Sham group|Similar protocol was applied and sham rTMS treatment was given with a sham coil to the sham group.
62815642|NCT05671107||PTEN - with NDD|Patients diagnosed with PTEN Hamartoma Tumor Syndrome and a neurodevelopmental disorder including but not limited to autism spectrum disorder, attention-deficit disorder / attention-deficit hyperactivity disorder, speech language disorder(s), intellectual disability, global developmental delay, oppositional defiant disorder, and / or motor or developmental disorders.
62815643|NCT05671107||PTEN - without NDD|Patients diagnosed with PTEN Hamartoma Tumor Syndrome
62815644|NCT05671107||Sibling Controls|Siblings related to patients with diagnosis of PTEN Hamartoma Tumor Syndrome
62815645|NCT05671107||Unrelated Controls|Unrelated participants with no known genetic or neurodevelopmental disorder
62815646|NCT00377520|EXPERIMENTAL|Pemetrexed|
62815647|NCT02254603|OTHER|Acupuncture controls|Acupuncture group will receive 30-minutes treatment three times a week for 3 months.
62815648|NCT02254603|EXPERIMENTAL|acupuncture and yoga exercise|Subject will receive a combination of acupuncture and yoga exercise three times a week for 3 months.
62815649|NCT02620839|EXPERIMENTAL|Cohort 1A|Alpelisib: 200 mg/day, orally, days 1-21 Cisplatin: 30 mg/m\^2, intravenously, days 1, 8, 15
62815650|NCT02620839|EXPERIMENTAL|Cohort 2A|Alpelisib: 250 mg/day, orally, days 1-21 Cisplatin: 30 mg/m\^2, intravenously, days 1, 8, 15
62815651|NCT02620839|EXPERIMENTAL|Cohort 2B|Alpelisib: 250 mg/day, orally, days 1-21 Cisplatin: 35 mg/m\^2, intravenously, days 1, 8, 15
62037706|NCT06095726|EXPERIMENTAL|Peppermint Inhalation Group|Children with leukemia received the inhalation of essential oil of peppermint 2% in addition to routine nursing and hospital care for management of chemotherapy induced nausea and vomiting.
62037707|NCT06095726|EXPERIMENTAL|Swedish Massage Group:|Children with leukemia received the Swedish massage therapy in addition to routine nursing and hospital care for management of chemotherapy induced nausea and vomiting.
62037708|NCT06733584|EXPERIMENTAL|Culturally and Linguistically Responsive Pathways with a Mutual Gaze Protocol|16 90-minute sessions (or 18 weeks, whichever comes first) of a Culturally and Linguistically Responsive adaptation of the Pathways manualized Naturalistic Developmental Behavioral Intervention (NDBI; research version). Pathways is parent-mediated and uses a coaching model.
62815652|NCT02620839|EXPERIMENTAL|Cohort 3A|Alpelisib: 300 mg/day, orally, days 1-21 Cisplatin: 30 mg/m\^2, intravenously, days 1, 8, 15
62815653|NCT02620839|EXPERIMENTAL|Cohort 3B|Alpelisib: 300 mg/day, orally, days 1-21 Cisplatin: 35 mg/m\^2, intravenously, days 1, 8, 15
62815654|NCT02620839|EXPERIMENTAL|Cohort 4A|Alpelisib: 350 mg/day, orally, days 1-21 Cisplatin: 30 mg/m\^2, intravenously, days 1, 8, 15
62815655|NCT02620839|EXPERIMENTAL|Cohort 4B|Alpelisib: 350 mg/day, orally, days 1-21 Cisplatin: 35 mg/m\^2, intravenously, days 1, 8, 15
62815656|NCT06195709|SHAM_COMPARATOR|Arm A: Endocrine therapy|"1. Patients in whom all tumor sites display a FES SUVmax ≥2 AND who have low levels of circulating tumor biomarkers will be treated with endocrine therapy.~2. Patients in whom 18F-FES PET shows an heterogenous uptake, with one or maximum two tumor sites with low FES uptake (SUVmax \<2) that represent less than 20% of all tumor sites and are deemed accessible to local treatment (e.g. stereotactic radiation therapy or another equivalent local therapy) will be treated, if they have low levels of circulating tumor biomarkers, by 2nd line endocrine therapy in Arm A, combined with the local treatment of FES-negative lesions."
62239622|NCT04687761|EXPERIMENTAL|LDAC-Based|"Low-dose subcutaneous cytarabine 20 mg/m2/daily SC, days 1 to 10 plus Venetoclax (ramp-up) 600 mg/daily oral, days 1 to 28 plus Quizartinib phase I/RP2D mg/daily oral, days 8 to 14-28.~If 1 DLT is observed among these 3 patients, additional 3 subjects will receive the level 2 dose, and it will be recommended in the absence of DLT between them. If \>1 DLT occurs in these 6 level 2 patients, the dose administered in the level 1 will be the RP2D of the LDAC-based schedule.~LDAC and Venetoclax doses will remain the same in all levels and only the dose of Quizartinib will be modificated according to the following table:~Escalation-Quizartinib dose-Quizartinib duration; Level-2 -30 mg/daily-Days 8 to 14; Level-1 -30 mg/daily-Days 8 to 21; Level1-40 mg/daily-Days 8 to 28; Level2-60 mg/daily-Days 8 to 28.~In phase II, patients randomized to this arm, will receive the recommended phase 2 dose (RP2D) regimen of LDAC + Venetoclax + Quizartinib regimen (30 patients)."
62239623|NCT00201838|EXPERIMENTAL|Arm I|Patients received entanercept 25 mg subcutaneously twice weekly with gemcitabine.
62239624|NCT00201838|ACTIVE_COMPARATOR|Arm II|Patients with pancreatic cancer for which treatment with gemcitabine as a single agent is planned will be asked to participate in this trial as a control group.
62239625|NCT01171352||ICU Dialysis Patients|Any patient 18 years and older who is admitted to the OHSU Hospitals ICUs with ARF, or End Stage Renal Disease (ESRD) for a diagnosis other than hyperkalemia, as the sole determinant for that level of care, will be invited to participate. The patient must have acute or chronic needs for dialytic support during their ICU stay.
62239626|NCT00794443|EXPERIMENTAL|1. Monthly - Dose 1|Monthly intermittent administration, dose 1
62815657|NCT06195709|ACTIVE_COMPARATOR|Arm B: Chemotherapy|All other patients, i.e. (i) patients in whom most or ≥3 lesions display a FES SUVmax \<2 that are not amenable to local treatment, (ii) patients with high levels of circulating tumor biomarkers, will be randomized between chemotherapy in Arm B and endocrine therapy in Arm C.
62239627|NCT00794443|EXPERIMENTAL|2. Monthly - Dose 2|Monthly intermittent administration, dose 2
62429999|NCT03757052|EXPERIMENTAL|Skin testing and Graded Oral Challenge|Penicillin skin testing as described in the intervention section, followed by amoxicillin graded oral challenge as described in the intervention section
62430000|NCT03038282|EXPERIMENTAL|Chromium Chloride|Participants transdermal chromium chloride 50 to 600 mcg/day.
62239628|NCT00794443|ACTIVE_COMPARATOR|3. Daily|Daily administration
62239629|NCT04308824|ACTIVE_COMPARATOR|Clipping|Prophylactic endoscopic clip will be placed after polypectomy
62239630|NCT04308824|EXPERIMENTAL|Cyanoacrilate|A solution of Cyanoacrilate will be nebulized after the placement of prophylactic clip
62430001|NCT03038282|EXPERIMENTAL|Individual Exercise|Exercise 150 minutes per week (over 3 to 5 days) for 12 weeks.
62597310|NCT06243952|EXPERIMENTAL|All participants|All participants receive the same intervention.
62597311|NCT05589155|NO_INTERVENTION|Control|
62430002|NCT03038282|NO_INTERVENTION|Control Group|Participants or participant's caregiver will be provided educational materials on starting an exercise program and instructions for the application of transdermal chromium chloride, but will receive no formal support for their exercise program.
62597312|NCT05589155|EXPERIMENTAL|Healthi|
62815658|NCT06195709|ACTIVE_COMPARATOR|Arm C: Endocrine therapy|All other patients, i.e. (i) patients in whom most or ≥3 lesions display a FES SUVmax \<2 that are not amenable to local treatment, (ii) patients with high levels of circulating tumor biomarkers, will be randomized between chemotherapy in Arm B and endocrine therapy in Arm C.
62815659|NCT04960046|ACTIVE_COMPARATOR|Infraclavicular nerve block using a costoclavicular approach|The costoclavicular approach, more recently described, proposes an insertion of the needle under the lower edge of the clavicle but in a lateral way to the axillary artery which makes it possible to reach the nerves at a place where the 3 main nerve bundles are still joined together. The clustering of nerve structures at the injection site may facilitate the spread of local anesthetics.
62815660|NCT04960046|PLACEBO_COMPARATOR|Infraclavicular nerve block using a paracoracoid approach|The paracoracoid approach involves inserting a needle under the lower rim of the clavicle below the coracoid process. This approach makes it possible to reach the 3 different nerve bundles, located around the axillary artery, which are involved in the sensitivity of the hand.
62239631|NCT05839756|PLACEBO_COMPARATOR|control (C) group|normal saline will be nebulized
62239632|NCT05839756|ACTIVE_COMPARATOR|Budesonide (B) group|budesonide will be nebulized
62239633|NCT02067182|EXPERIMENTAL|Oral Anticoagulation with Dabigatran|"The recommended daily dose of Pradaxa is 300 mg taken as one 150 mg capsule twice daily.~For the following patients the recommended daily dose of Pradaxa is 220 mg taken as one 110 mg capsule twice daily:~* Patients aged 75 years or above~* Cr-Cl 30-50 ml/min~* Patients who receive concomitant verapamil~For the following groups, the daily dose of Pradaxa of 300 mg or 220 mg should be selected based on an individual assessment of the thromboembolic risk and the risk of bleeding:~* Patients with moderate renal impairment~* Patients with gastritis, esophagitis or gastroesophageal reflux~* Other patients at increased risk of bleeding"
62430003|NCT01671735|EXPERIMENTAL|VA DPP|Pre-Diabetic Participants eligible for VA DPP receive a curriculum based life-style intervention program tailored off of the original DPP but in a group format
62430004|NCT01671735|NO_INTERVENTION|VA DPP-eligible MOVE!|Pre-Diabetic participants who screen and are eligible for VA DPP but bc of class being filled - have been assigned to MOVE!
62430005|NCT04230954|EXPERIMENTAL|Cabozantinib (XL 184) Plus Pembrolizumab|A Phase II Study of Cabozantinib (XL 184)Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
62430006|NCT04264559|OTHER|Healthy control group|This group will include 40 healthy adults.
62430007|NCT04264559|OTHER|CSAP group|This study will include 40 patients with chronic stable angina pectoris (CSAP).
62430008|NCT04264559|EXPERIMENTAL|Healthy intervention group|This group will include 40 healthy adults. They will receive moxibustion intervention.
62430009|NCT04259879|EXPERIMENTAL|Fasting|The participants will follow a short-term fasting period for 36 hours
62430010|NCT03095482|ACTIVE_COMPARATOR|Active tDCS + In Vivo Exposure|Participants assigned to this condition will receive excitatory transcranial direct current stimulation (tDCS) of the left medial prefrontal cortex (lmPFC) and inhibitory tDCS of right dorsolateral prefrontal cortex (rdlPFC). tDCS will be administered for 20 minutes at 1.7 mA, followed by 30 minutes of in vivo exposure therapy.
62735205|NCT04583436|ACTIVE_COMPARATOR|Open surgery|"Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.~n=45"
62815661|NCT03028766|EXPERIMENTAL|Group A - Pre-operative|Patients will receive the cohort specified dose of AZD1775 by mouth, twice a day for 3 days, commencing on days 1 and 8. Cisplatin 40mg/m2 IV delivered over 1 hour on day 8. Patients in this group will commence surgery within 42 days of commencing pre-operative chemotherapy.
62239634|NCT02067182|NO_INTERVENTION|No Oral Anticoagulation|
62239635|NCT00816309|EXPERIMENTAL|Acapella Physiotherapy|Physiotherapy with acapella versus no physiotherapy
62239636|NCT00816309|NO_INTERVENTION|No physiotherapy|Physiotherapy with acapella versus no physiotherapy
62239637|NCT01990534|EXPERIMENTAL|Brentuximab Vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 in every 3-week cycle, until there is evidence of disease progression or unacceptable toxicity occurs (Up to 16 cycles). The dose could be decreased or delayed or discontinued in participants who develop treatment-associated non-hematologic, hematologic toxicity or peripheral neuropathy to brentuximab vedotin.
62239638|NCT04586504|EXPERIMENTAL|0.2 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.2 mg/kg.
62239639|NCT04586504|EXPERIMENTAL|0.3 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.3 mg/kg.
62239640|NCT04586504|EXPERIMENTAL|0.4 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.4 mg/kg.
62239641|NCT04586504|EXPERIMENTAL|0.5 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.5 mg/kg.
62239642|NCT01526551|EXPERIMENTAL|Intervention Schools|High school students attending Wayne County and Monticello Ind. schools will be given opportunity to receive HPV Vaccine and HPV-related Health Education and Reduction of barriers to being vaccinated.
62239643|NCT01810016|EXPERIMENTAL|Arm A|Ipilimumab (IV) followed by NY-ESO-1 recombinant protein mixed with Poly-ICLC and Montanide (SC) every 3 weeks for 4 doses.
62239644|NCT01810016|EXPERIMENTAL|Arm B|Ipilimumab (IV) followed by NY-ESO-1 OLP4 mixed with Poly-ICLC and Montanide (SC) every 3 weeks for 4 doses.
62239645|NCT01810016|EXPERIMENTAL|Arm C|Ipilimumab (IV) followed by NY-ESO-1 OLP4 mixed with Poly-ICLC (SC) every 3 weeks for 4 doses.
62239646|NCT03877250||Non Small Cell Lung Cancer (NSCLC)|Participants with pathologically confirmed newly diagnosed or recurrent advanced NSCLC that is PD-L1 high by immunohistochemistry
62239647|NCT04176965|EXPERIMENTAL|FINEVISION HP|Trifocal FINEVISION HP. Cataractous lens will be removed in the study eyes and the FINEVISION HP will be implanted in the capsular bag.
62239648|NCT04176965|ACTIVE_COMPARATOR|Control Product|Cataractous lens will be removed in the study eyes and the Alcon AcrySof® SN60AT IOL will be implanted in the capsular bag.
62239649|NCT03455192|EXPERIMENTAL|Synbiotic supplements|One synbiotic tablet, per day, during 30 days
62430011|NCT03095482|SHAM_COMPARATOR|sham tDCS + In Vivo Exposure|Participants assigned to this condition will receive sham transcranial direct current stimulation (tDCS), which will consist of 30 seconds of stimulation at the beginning and end of tDCS administration. Electrode positioning will be counterbalanced across participants (i.e., either mPFC+ or mPFC-, with same electrode positioning as the active comparators). Sham tDCS will be administered for 20 minutes, followed by 30 minutes of in vivo exposure therapy.
62430012|NCT05547100|EXPERIMENTAL|5mg OLZAPINE /10mg SAMIDORPHAN|Open label, single dose 5mg OLZ/10 mg SAM
62815662|NCT03028766|EXPERIMENTAL|Group B - Post-operative:|Patients will received the cohort specified dose of AZD1775 by mouth, twice a day for 3 days on days 2, 9, 23 and 30. Cisplatin 40mg/m2 IV delivered over 1 hour on days 2, 9, 16, 23 and 30. Intensity Modulated Radiotherapy will be delivered 5 days a week (once daily, Monday to Friday) for 6 weeks commencing within 3 months of surgery.
62815663|NCT05686239|EXPERIMENTAL|RL-007 20 mg|oral dosing three times per day (TID)
62815664|NCT05686239|EXPERIMENTAL|RL-007 40 mg|oral dosing three times per day (TID)
62815665|NCT05686239|PLACEBO_COMPARATOR|Placebo|oral dosing three times per day (TID)
62239650|NCT03455192|PLACEBO_COMPARATOR|Placebo Oral Tablet|One placebo tablet , per day, during 30 days
62239651|NCT04398511|EXPERIMENTAL|L brevis|Lactobacillus brevis CD2 in lozenges containing 4 billion CFU. Patients used a lozenge 15 min after breakfast, lunch and dinner, during 21 days, starting in the day of installation of the orthodontic appliance.
62239652|NCT04398511|PLACEBO_COMPARATOR|Placebo|Placebo in lozenges, identical to those of L brevis. Patients used a lozenge 15 min after breakfast, lunch and dinner, during 21 days, starting in the day of installation of the orthodontic appliance.
62239653|NCT05532436|EXPERIMENTAL|Grup 1|One day before the operation, the participants in the experimental group were given breathing exercise training, and they were applied 5 times a day for 10 repetitions until the 30th day after the operation. Introductory Information Form, State-Trait Anxiety Scale, Visual Comparative Sleep Scale and Recovery Quality-40 Questionnaire were used to collect data 1 day before surgery, on the day of surgery, on the 1st day, 15th and 30th days after surgery.
62243456|NCT00729781|EXPERIMENTAL|Polyester Implants|There is one arm for this study. All subjects in this study will receive the investigational nasal implants. See the detailed description for procedure information.
62243457|NCT03139825|OTHER|Adolescent with suicidal behavior and personality disorder|
62430013|NCT03060031|EXPERIMENTAL|Oxytocin|Each participant will undergo pain tasks after self-administration of oxytocin
62430014|NCT03060031|PLACEBO_COMPARATOR|Placebo|Each participant will undergo pain tasks after self-administration of placebo
62430015|NCT01414361||intermediate lesion|intermediate lesions evaluated by both IVUS and FFR
62815666|NCT03868215||Patients with endoscopically removed malignant polyps|Patients with endoscopically removed malignant polyps
62815667|NCT04435925|ACTIVE_COMPARATOR|Remifentanil|Patients assigned to this group will receive IV Remifentanil as an opioid for general anesthesia.
62815668|NCT04435925|PLACEBO_COMPARATOR|Fentanyl|Patients assigned to this group will receive IV Fentanyl as an opioid for general anesthesia.
62815669|NCT02161770|OTHER|Normal hepatic function|Patients without a history or presence of hepatic disease
62815670|NCT02161770|OTHER|Mild hepatic impairment|Patients defined by the Child-Pugh classification system to be Child-Pugh A
62815671|NCT02161770|OTHER|Moderate hepatic impairment|Patients defined by the Child-Pugh classification system to be Child-Pugh B
62815672|NCT05322707|EXPERIMENTAL|Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg|Inhalation Aerosol, 2 actuations orally inhaled twice daily
62815673|NCT05322707|ACTIVE_COMPARATOR|Symbicort®|Inhalation Aerosol, 2 actuations orally inhaled twice daily
62815674|NCT05322707|PLACEBO_COMPARATOR|Placebo for Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg|Inhalation Aerosol, 2 actuations orally inhaled twice daily
62815675|NCT00966836|EXPERIMENTAL|Pre-emptive everolimus|
62815676|NCT00966836|EXPERIMENTAL|Prophylaxis mycophenolate|
62815677|NCT00966836|EXPERIMENTAL|Prophylaxis Everolimus|
62430016|NCT00405483|ACTIVE_COMPARATOR|Minimally invasive exposure|Surgical technique, minimal incision
62597313|NCT06618768|EXPERIMENTAL|Consumption of an aronia-mixture|Participants will daily consume 1 dL aronia-mixture for 6 months. The mixture may be consumed in smaller portions throughout the day, but according to results from a non-clinical pilot-study (https://pubmed.ncbi.nlm.nih.gov/25026919/), the mixture should be consumed with a meal in order to avoid nausea. The aronia-mixture has been developed by the research group and produced for free by Ronia AS, Randaberg, Norway. The mixture is produced from aronia-berries (50%) and apples (50%), and 1 dL (one serving) consists of 600 mg proanthocyanidins, 300 mg anthocyanins and 100 mg chlorogenic acids with pH 3.6. Urine samples (25 mL) will be delivered at general practices for chemical analysis of metabolites from the intervention drink at day 0, 60, 120, and 180 (spot urine). In addition, an urine sample will be collected at day 0 for microbiological analysis (urine culture). The intervention will not replace any medical treatment during the project period.
62037709|NCT06733584|ACTIVE_COMPARATOR|Culturally and Linguistically Responsive Pathways without Mutual Gaze Protocol|16 90-minute sessions (or 18 weeks, whichever comes first) of a Culturally and Linguistically Responsive adaptation of the Pathways manualized Naturalistic Developmental Behavioral Intervention (NDBI; research version) without the Mutual Gaze Protocol. Pathways is parent-mediated and uses a coaching model.
62239654|NCT05532436|NO_INTERVENTION|Grup 2|Each data collection tool was collected as in the experimental group patients, but without breathing exercises. Only routine nursing care was given to the patients in the control group. The patients in the control group were given a breathing exercise brochure/booklet when they came to the control after the postoperative 30th day, and they were shown how the breathing exercises would be done correctly.
62430017|NCT00405483|ACTIVE_COMPARATOR|Standard exposure|Standard Incision
62430018|NCT00690924|EXPERIMENTAL|Calcitriol|
62430019|NCT01241565|EXPERIMENTAL|ENDO GIA™ Stapler with TRI-STAPLE™ Technology|Single arm study, all patients will receive the study device.
62430020|NCT01341522|ACTIVE_COMPARATOR|Control|Control
62430021|NCT01341522|EXPERIMENTAL|MRI|experimental
62597314|NCT05160038|EXPERIMENTAL|Bodily illusions|Participants in the experimental group see a bodily illusion applied to their embodied virtual avatar.
62815678|NCT00966836|ACTIVE_COMPARATOR|Pre-emptive mycophenolate|
62815679|NCT01707342|EXPERIMENTAL|Simeprevir (TMC435)|Treatment A: single oral dose of simeprevir (TMC435) 50 mg; and Treatment B: single oral dose of simeprevir (TMC435) 150 mg. A single 10 minute intravenous infusion of \[3H\]-TMC435 (100 microcurie) 100 microgram will be followed 5 hours later after administration of Treatment A and Treatment B in Period 1 and Period 2, respectively.
62815680|NCT02848131|NO_INTERVENTION|Group 1: Observational|Observational Only
62815681|NCT02848131|ACTIVE_COMPARATOR|Group 2: Dasatinib & Quercetin|The drugs dasatinib and quercetin will be used in this arm
62815682|NCT04623346||Weber B-type Ankle fractures in prepandemic period|Patients with AO Weber B-type ankle fracture in prepandemic period
62239655|NCT05508750|EXPERIMENTAL|New Infant Formula|New infant formula for healthy term infants
62815683|NCT04623346||Weber B-type Ankle fractures in pandemic period|Patients with AO Weber B-type ankle fracture in pandemic period
62037710|NCT05888636||MGUS|
62037711|NCT05888636||MM smouldering|
62037712|NCT05888636||Syntomatic MM|
62037713|NCT01339754|EXPERIMENTAL|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
62239656|NCT05508750|ACTIVE_COMPARATOR|Commercial Infant Formula|Standard, commercially available infant formula for healthy term infants
62239657|NCT05508750|NO_INTERVENTION|Human Milk|Breastfed infants serve as a reference group
62239658|NCT00002951|EXPERIMENTAL|Arm A (Hyper-FHX)|Concomitant chemoradiotherapy consisting of hydroxyurea (PO, BID, x 6days), continuous infusion 5-fluorouracil (IV, x 5days), hyperfractionated radiotherapy (150 cGy twice daily for 5 days every 14 days, 5 cycles)
62239659|NCT00907257|EXPERIMENTAL|Same time of day|5% benzoyl peroxide wash and 0.04% tretinoin gel used at same time of day
62239660|NCT00907257|ACTIVE_COMPARATOR|Different times of day|5% benzoyl peroxide wash used in the morning and 0.04% tretinoin gel used in the evening
62430022|NCT00830388|EXPERIMENTAL|Ketoconazole 2% Foam|Open-label study
62430023|NCT04554407|EXPERIMENTAL|Treatment Group|All participants receive the SOMAVAC® 100 Sustained Vacuum System
62597315|NCT05160038|NO_INTERVENTION|No bodily illusions|Participants in the control group embody a virtual avatar, but without bodily illusions
62597316|NCT02584127|EXPERIMENTAL|High reinforcement cessation program|The High Reinforcement (HR) condition included five monthly, online interim surveys with financial incentives for these assessments and also for program completion. All participants completed an eligibility survey and a baseline survey. All participants were offered a financial incentive to complete the six-monh followup survey. All participants were provided access to a six step, cognitive-behavioral smoking cessation program self-administered online.
62597317|NCT02584127|EXPERIMENTAL|Low reinforcement cessation program|Participants in the Low Reinforcement (LR) condition participants completed an eligibility survey and a baseline survey. All participants were offered a financial incentive to complete the six-monh followup survey. All participants were provided access to a six step, cognitive-behavioral smoking cessation program self-administered online.
62597318|NCT05028777||Patients diagnosed with left ventricular thrombus|All patients diagnosed with left ventricular thrombus through different imaging modalities (echocardiography, CT or MRI) and who have been diagnosed and/or treated at the Inselspital or another site of the Insel Gruppe.
62430024|NCT05035485|ACTIVE_COMPARATOR|Phenylephrine group|Rescue phenylephrine (75μg) was given when postspinal anesthesia hypotension occurred
62815684|NCT04623346||Wrist fractures in prepandemic period|Patients with extraarticular distal radius fracture in prepandemic period
62815685|NCT04623346||Wrist fractures in pandemic period|Patients with extraarticular distal radius fracture in pandemic period
62815686|NCT04623346||Proximal humerus fractures in prepandemic period|Patients with 2-part,3-part and 4-part fractures in prepandemic period
62037714|NCT04617639|EXPERIMENTAL|Physical exercise|Supervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion \[RPE\] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week.
62430025|NCT05035485|EXPERIMENTAL|Norepinephrine group|Rescue norepinephrine (6μg) was given when postspinal anesthesia hypotension occurred
62815687|NCT04623346||Proximal humerus fractures in pandemic period|Patients with 2-part,3-part and 4-part fractures in pandemic period
62815688|NCT06456567|EXPERIMENTAL|Telitacicept|Telitacicept + Standard of Care (SOC)
62430026|NCT01677403|ACTIVE_COMPARATOR|Nebulised Tobramycin|Nebulised Tobramycin
62430027|NCT01677403|PLACEBO_COMPARATOR|Nebulised 0.9% Saline|Nebulised 0.9% Saline
62430028|NCT05974020|EXPERIMENTAL|Group 1- Aerobic Exercise|Group 1 participants will receive general foot care instructions and education on appropriate footwear selection, foot intrinsic muscle training, and in addition, an aerobic exercise protocol.
62815689|NCT06456567|PLACEBO_COMPARATOR|Placebo|Placebo + Standard of Care (SOC)
62815690|NCT04888624|EXPERIMENTAL|DrySee® dressing with moisture detection|DrySee® dressing with moisture detection
62815691|NCT04888624|ACTIVE_COMPARATOR|Tegaderm® + Pad transparent film dressing|Tegaderm® + Pad transparent film dressing
62815692|NCT05574686|EXPERIMENTAL|Telehealth Hypertension and Food Insecurity Intervention|Telehealth Hypertension and Food Insecurity Intervention Established clinical telehealth services will be provided to monitor and give behavioral and educational management advice to women with breast cancer to better control their hypertension. Resources for food insecurity will be provided to participants.
62239661|NCT02708017|ACTIVE_COMPARATOR|S-TAP block|ultrasound guided bilateral subcostal TAP block
62239662|NCT02708017|ACTIVE_COMPARATOR|P-TAP block|ultrasound guided bilateral Posterior TAP block
62239663|NCT02206165|EXPERIMENTAL|Candesartan 8mg + Amlodipine 5mg|Candesartan 8mg + Amlodipine 5mg, po, q.d.
62239664|NCT02206165|EXPERIMENTAL|Candesartan 8mg + Amlodipine 10mg|Candesartan 8mg + Amlodipine 10mg, po, q.d.
62239665|NCT02206165|EXPERIMENTAL|Candesartan 16mg + Amlodipine 5mg|Candesartan 16mg + Amlodipine 5mg, po, q.d.
62239666|NCT02206165|EXPERIMENTAL|Candesartan 16mg + Amlodipine 10mg|Candesartan 16mg + Amlodipine 10mg, po, q.d.
62239667|NCT02206165|ACTIVE_COMPARATOR|Candesartan 8mg|Candesartan 8mg, po, q.d.
62239668|NCT02206165|ACTIVE_COMPARATOR|Candesartan 16mg|Candesartan 16mg, po, q.d.
62239669|NCT02206165|ACTIVE_COMPARATOR|Amlodipine 5mg|Amlodipine 5mg, po, q.d.
62239670|NCT02206165|ACTIVE_COMPARATOR|Amlodipine 10mg|Amlodipine 10mg, po, q.d.
62239671|NCT01050686|ACTIVE_COMPARATOR|subcutaneous wound drain|subcutaneous wound drain inserted
62239672|NCT01050686|EXPERIMENTAL|no subcutaneous wound drain|no subcutaneous wound drain inserted
62239673|NCT00536809|EXPERIMENTAL|Phase I|Dose escalation of lapatinib along with capecitabine and oxaliplatin until the maximum tolerated dose is reached.
62239674|NCT00536809|EXPERIMENTAL|Phase II|Treatinng subjects at the maximum tolerated dose of lapatinib, capecitabine, and oxaliplatin
62239675|NCT05929560|ACTIVE_COMPARATOR|Conventional impression|
62239676|NCT05929560|EXPERIMENTAL|Digital impression|
62239677|NCT02715661|ACTIVE_COMPARATOR|Coronary artery disease|those with a diagnosis of coronary artery disease having been hospitalized for a cardiac event. The intervention is six-month interval of exercise .
62239678|NCT02715661|ACTIVE_COMPARATOR|Metabolic Syndrome|Metabolic Syndrome patients are defined by having Systolic Blood Pressure (SBP)\>130 and/or Diastolic Blood Pressure (DBP)\>85 mmHg and any two of the following criteria: Abdominal obesity (waist circumference \>102cm in males;\>88cm in females), Fasting triglycerides \> 1.695 mmol/L, Low HDL cholesterol: Males \< 1.04 mmol/L; Females \< 1.29 mmol/L, Fasting glucose \>5.60 mmol/L. Participants will be assigned randomly into an exercise and a delayed exercise intervention, 6 months.
62239679|NCT02715661|ACTIVE_COMPARATOR|Health Control|Control individuals will have no diagnosis of cardiac, vascular, metabolic, inflammatory or neurological disease, and have not been on any medication for such conditions in the past 12 months. Participants will be assigned randomly into an exercise and a delayed exercise intervention, 6 months.
62239680|NCT02805049|EXPERIMENTAL|The study population|The study population consisted of patients admitted to the ICU for septic shock associated with secondary peritonitis and requiring antifungal therapy via echinocandins (micafungin or caspofungin).
62239681|NCT03457883|EXPERIMENTAL|group A|accepted herniamesh mesh
62815693|NCT05037240|ACTIVE_COMPARATOR|Intervention Group|
62815694|NCT05037240|PLACEBO_COMPARATOR|Placebo|
62815695|NCT02602769||Cases of ROHHAD syndrome|"Children diagnosed with ROHHAD syndrome during the course of their clinical care by their physicians.~The investigators will perform transcriptome profiling in this group."
62815696|NCT02602769||Control cohort|Unaffected first degree family members. The investigators will perform transcriptome profiling in this group.
62815697|NCT04819464|EXPERIMENTAL|Group A: Participants with mild hepatic impairment|Participants with mild hepatic impairment (Child-Pugh Score of 5 to 6).
62239682|NCT03457883|EXPERIMENTAL|group B|accepted biological graft of cook
62239683|NCT03042078|EXPERIMENTAL|Zero-fluoroscopic ablation|Paroxysmal supraventricular tachycardia will be ablated under the guidance of Ensite NavX and without the use of fluoroscopy.
62239684|NCT03042078|ACTIVE_COMPARATOR|Conventional fluoroscopic ablation|Paroxysmal supraventricular tachycardia will be ablated under the guidance of Ensite NavX plus fluoroscopy.
62239685|NCT02352766||Routine FNA for thyroid nodules|Patients that undergo a clinically diagnostic thyroid FNA will be asked by their clinician, who is a study co-investigator, if they are interested in participating in the research study. A small part of FNA material will be collected for molecular analysis.
62239686|NCT01957605||prone position|Patient scheduled for surgery in the prone position
62239687|NCT04092972|EXPERIMENTAL|Atherectomy|Atherectomy and drug-coated balloon (DCB)
62037715|NCT04617639|ACTIVE_COMPARATOR|Control group I|Standard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel.
62037716|NCT04617639|OTHER|Control group II (observation group)|Follow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel.
62239688|NCT04092972|ACTIVE_COMPARATOR|Standard care|Standard care with predilation (POBA) and DCB
62239689|NCT00261846|EXPERIMENTAL|SKI-606|
62239690|NCT01032382|ACTIVE_COMPARATOR|Paromomycin Alone Treatment|
62239691|NCT01032382|ACTIVE_COMPARATOR|WR 279,396|
62239692|NCT03030235|ACTIVE_COMPARATOR|Dapagliflozin|Dapagliflozin 10 mg oral tablet, once daily, for 12 weeks
62239693|NCT03030235|PLACEBO_COMPARATOR|Placebo|Dapagliflozin matching placebo oral tablet, once daily, for 12 weeks
62735206|NCT00864175|EXPERIMENTAL|Treatment A - INCB007839 and Trastuzumab|"INCB007839 100 mg BID and trastuzumab~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
62037717|NCT03948568|ACTIVE_COMPARATOR|Concurrent Endocrine Therapy and Radiotherapy|Concurrent endocrine therapy and radiotherapy. Concurrent endocrine therapy will be defined as, the commencement of endocrine therapy around 2 weeks before (a minimum of 1 week before to a maximum of 4 weeks) commencement of radiotherapy and continued throughout radiotherapy.
62037718|NCT03948568|ACTIVE_COMPARATOR|Sequential Endocrine Therapy after Radiotherapy|Sequential endocrine therapy after radiotherapy. Using the pragmatic definition sequential endocrine therapy should commence around 2 weeks (minimum 1 week, maximum 4 weeks) after the last fraction of radiotherapy.
62037719|NCT04301778|EXPERIMENTAL|Durvalumab and SNDX-6352|Participants will receive Durvalumab and SNDX-6352.
62815698|NCT04819464|EXPERIMENTAL|Group B: Participants with moderate hepatic impairment|Participants with moderate hepatic impairment (Child-Pugh Score of 7 to 9).
62815699|NCT04819464|EXPERIMENTAL|Group C:Healthy participants|Healthy participants will be matched to the participants with hepatic impairment based on age and body weight.
62815700|NCT02031575|EXPERIMENTAL|Basic Treatment|Sends messages to participants about reproductive health.
62037720|NCT00146575|EXPERIMENTAL|1|randomized patients get sirolimus stent
62037721|NCT00146575|EXPERIMENTAL|2|randomized patients get paclitaxel stent
62037722|NCT04442074||Stroke Patients|These patients were hospitalized in the neurology / neurovascular department of the Paris Saint-Joseph Hospital Group, for the management of a transient ischemic infarction or accident for which the diagnosis of ipsilateral carotid diaphragm was accepted, between April 2017 and April 2020.
62239694|NCT04646070|ACTIVE_COMPARATOR|Wise pattern reduction mammaplasty using Inferior pedicle|Wise pattern reduction mammaplasty using Inferior pedicle
62239695|NCT04646070|ACTIVE_COMPARATOR|Wise pattern reduction mammaplasty using superomedial pedicle|
62239696|NCT02340728|EXPERIMENTAL|ERCP with SEMS plus radiofrequency ablation|Endoscopic retrograde cholangiopancreatogram (ERCP) is performed under standard conditions with cannulation of the bile duct, and demonstration on a cholangiogram the location, diameter and length of the biliary stricture. The HabibTM EndoHBP probe (EMcision, London, United Kingdom) is advanced through the working channel of a side viewing endoscope over a 0.035in guidewire, and positioned across the occluded SEMS under fluoroscopy. 7-10W are usually delivered for 90 seconds with a standard high frequency generator, followed by a 1 minute resting period. Sequential applications of RFA are applied along the entire length of the stricture with an overlap of 1cm.
62239697|NCT02340728|ACTIVE_COMPARATOR|ERCP with SEMS alone (standard of care)|Endoscopic retrograde cholangiopancreatogram (ERCP) is performed under standard conditions with cannulation of the bile duct, and demonstration on a cholangiogram the location, diameter and length of the biliary stricture. The HabibTM EndoHBP probe (EMcision, London, United Kingdom) is advanced through the working channel of a side viewing endoscope over a 0.035in guidewire, and positioned across the occluded SEMS under fluoroscopy. 7-10W are usually delivered for 90 seconds with a standard high frequency generator, followed by a 1 minute resting period.
62239698|NCT06465888|NO_INTERVENTION|No-Egg Control Group|The No-Egg Control group will not eat eggs or foods with eggs being one of the primary components of the food for 30 days.
62815701|NCT02031575|EXPERIMENTAL|Interactive Treatment|Sends multiple choice questions and receives texts message responses from participants with incentive for responding correctly
62815702|NCT02031575|PLACEBO_COMPARATOR|Control|Sends messages to students about malaria prevention and control.
62815703|NCT00647764|EXPERIMENTAL|Single Arm|
62815704|NCT00566436|ACTIVE_COMPARATOR|REA|Patients presenting with a long occlusion of the superficial femoral artery enrolled in REA arm will undergo remote endarterectomy of the occluded superficial femoral artery
62037723|NCT03681158|EXPERIMENTAL|sodium valproate|Single oral dose of sodium valproate containing \[14C\]-sodium VPA
62037724|NCT02196649|EXPERIMENTAL|Endoscopic Clipping|Participants randomised to the arm will receive endoscopic clips to their defect following EMR.
62815705|NCT00566436|ACTIVE_COMPARATOR|Bypass|Patients presenting with a long occlusion of the superficial femoral artery enrolled in Bypass arm will undergo suprageniculate femoropopliteal bypass surgery to bypass the occluded superficial femoral artery
62815706|NCT01126749|EXPERIMENTAL|E7389 in combination with gemcitabine plus cisplatin|
62815707|NCT01126749|EXPERIMENTAL|gemcitabine plus cisplatin|
62815708|NCT01914003||CSID Mutations|Individual has one or more known CSID mutations.
62815709|NCT01914003||Control|Individual does not have any known CSID mutations.
62815710|NCT03092583|EXPERIMENTAL|Patient group|Subjects must meet the modified New York criteria for AS, or the ASAS criteria for Ax-SpA, and must be naïve of biologic therapy (anti-TNF-α agents) at the time of inclusion, or have received but subsequently discontinued anti-TNF-α therapy at least 3 months before inclusion. A blood sample will be drawn (35 mL) to these patients.
62815711|NCT03092583|OTHER|Control group|Subjects must be free from any inflammatory or auto-immune disease. A blood sample will be drawn (35 mL) to these controls subjects.
62815712|NCT02989493|EXPERIMENTAL|Doxazosin|Participants receive 8 weeks of doxazosin (8mg target dose).
62815713|NCT02989493|PLACEBO_COMPARATOR|Placebo|Participants will receive 8 weeks of matched placebo.
62430029|NCT05974020|EXPERIMENTAL|Group 2- Intrinsic Muscle Training|Group 2 participants will receive general foot care instructions and education on appropriate footwear selection, along with an exercise protocol focusing on foot intrinsic muscle training.
62430030|NCT05974020|EXPERIMENTAL|Group 3- Control Group|Group 3 will receive only general foot care instructions and education on appropriate footwear selection.
62430031|NCT00947245|EXPERIMENTAL|BMS-791325 - Part A, Dose 1|
62430032|NCT00947245|EXPERIMENTAL|BMS-791325 - Part A, Dose 2|
62430033|NCT00947245|EXPERIMENTAL|BMS-791325 - Part A, Dose 3|
62815714|NCT04564846|PLACEBO_COMPARATOR|Placebo|Subjects will be administered a single capsule of placebo( fish oil); placebo will be dispensed and subjects will dose twice a day, once in the morning prior to breakfast and once at night prior to bedtime.
62815715|NCT04564846|ACTIVE_COMPARATOR|ORMD-0801|Subjects will be administered a single 8mg capsule of ORMD-0801; study medication will be dispensed and subjects will dose twice a day, once in the morning prior to breakfast and once at night prior to bedtime.
62815716|NCT03744312|EXPERIMENTAL|Cognitive impairment|Alzheimer's disease (mild cognitive impairment or mild stage Alzheimer's disease dementia)
62815717|NCT03744312|ACTIVE_COMPARATOR|No cognitive impairment|Healthy Controls
62815718|NCT03010917|EXPERIMENTAL|Fish Oil with ethanol and placebo ethanol infusions|Between days 30-40 subjects will participate in 2 test days at least 2 days apart and during the test day will receive an IV infusion of ethanol (placebo vs. targeted Breath Alcohol Concentration ((BrAC) of 100mg%) in a clamped fashion. Test days will be in a randomized order.
62239699|NCT06465888|ACTIVE_COMPARATOR|Egg White Group|Participants will eat four egg whites/day for 30 days. Participants will be given a specified number of Kieke eggs to last them until their next appointment. They will be asked to eat no other eggs than whites from the eggs given to them and to return cartons with any leftover eggs.
62815719|NCT03010917|PLACEBO_COMPARATOR|Placebo with ethanol and placebo ethanol infusions|Between days 30-40 subjects will participate in 2 test days at least 2 days apart and during the test day will receive an IV infusion of ethanol (placebo vs. targeted Breath Alcohol Concentration ((BrAC) of 100mg%) in a clamped fashion. Test days will be in a randomized order.
62815720|NCT02870738|ACTIVE_COMPARATOR|Pelvic Floor Physical Therapy|One hour of pelvic floor physical therapy twice weekly for 8 weeks
62815721|NCT02870738|ACTIVE_COMPARATOR|Bladder Instillations|Bladder instillation of lidocaine, kenalog, heparin sulphate, and bicarbonate twice weekly for 8 weeks
62239700|NCT06465888|ACTIVE_COMPARATOR|Whole Egg Group|Participants will eat two whole eggs/day for 30 days. Participants will be given a specified number of Kieke eggs to last them until their next appointment. They will be asked to eat no other eggs than the eggs given to them and to return cartons with any leftover eggs.
62239701|NCT06465888|ACTIVE_COMPARATOR|Whole Omega-3 Egg Group|Participants will eat two Christopher Farms whole omega-3 eggs/day for 30 days. Participants will be given a specified number of Christopher Farm eggs that will last them until their next appointment. They will be asked to eat no other eggs than the two from the eggs given to them and to return cartons with any leftover eggs.
62430034|NCT00947245|EXPERIMENTAL|BMS-791325 - Part B, Dose 1|
62430035|NCT00947245|EXPERIMENTAL|BMS-791325 - Part B, Dose 2|
62430036|NCT00947245|EXPERIMENTAL|BMS-791325 - Part B, Dose 3|
62735207|NCT00864175|EXPERIMENTAL|Treatment B - INCB007839 and Trastuzumab|"INCB007839 200 mg BID and trastuzumab~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
62815722|NCT03040999|EXPERIMENTAL|Pembrolizumab + Cisplatin + CRT|Participants receive a priming dose of pembrolizumab before initiation of CRT (either accelerated or standard fractionation radiotherapy regimen). During CRT, participants receive 2 doses of pembrolizumab and up to 3 cycles of Cisplatin (2 cycles during accelerated and 3 cycles during standard fractionation radiotherapy). Participants also receive up to an additional 14 cycles of pembrolizumab alone as maintenance therapy for a total of 17 cycles of pembrolizumab. If cisplatin and/or radiation therapy is discontinued, the participant may continue on treatment with pembrolizumab.
62037725|NCT02196649|NO_INTERVENTION|No Endoscopic Clipping|These participants will receive standard of care practice only.
62037726|NCT05427461|OTHER|Patient with leiomyosarcoma|
62239702|NCT06465888|ACTIVE_COMPARATOR|Egg Yolk Group|Participants will eat four egg yolks/day for 30 days. Participants will be given a specified number of Kieke eggs to last them until their next appointment. They will be asked to eat no other eggs than the yolks from the eggs given to them and to return cartons with any leftover eggs.
62239703|NCT05885880|NO_INTERVENTION|Standard of Care|Subjects in this arm will receive the standard of care, either routine screening for clinical trials or no screening, according to standard institutional protocol. Potential clinical trials, if identified, will be offered to subjects according to the usual institutional process.
62239704|NCT05885880|EXPERIMENTAL|Blue-button screening|Subjects assigned to this arm will have deidentified data elements transferred from their EHR to the Blue-button tool for identification of clinical trials for which they may be eligible. After review by clinical research staff, appropriate trials will be offered to subjects.
62239705|NCT02700243|EXPERIMENTAL|Fitbit|Participants receive a Fitbit and are followed over the course of one year, completing surveys and exercise tests.
62239706|NCT02700243|NO_INTERVENTION|Usual Care|Participants receive usual care over the course of one year and are offered a Fitbit in the second year. Followed to assess use of Fitbit and health outcomes.
62239707|NCT00936845||Females with Hemophilia|Females with severe or moderate Hemophilia A or B.
62239708|NCT01130974|EXPERIMENTAL|Bausch & Lomb contact lens|Bausch \& Lomb daily disposable cosmetic tint contact lens
62239709|NCT01130974|ACTIVE_COMPARATOR|Marketed daily disposable contact lens|Marketed daily disposable cosmetic tint contact lens
62239710|NCT01974596|EXPERIMENTAL|Probiotic Lactobacillus reuteri Vs Placebo|patients with full arch with dental implant received a tablet of Lactobacillus reuteri every day during 28 days, and after a wash-up, the same patients receive a tablet of placebo every day during 28 days
62239711|NCT02221986|EXPERIMENTAL|Interdisciplinary rehabilitation|"The intervention consists of 6 weeks intensive outpatient physiotherapy in conjunction with 0-6 weeks of occupational therapy if need is indicated. The physical intervention contains supervised group exercise of 90 minutes three times a week in groups up to four patients included continuously.~The occupational therapy intervention consists of individual training 60 minutes twice a week for patients having deficits in activity or participation levels measured by the Assessment of Motor and Process Skills (AMPS)."
62239712|NCT02221986|NO_INTERVENTION|Care as usual|The control group receives usual standard of care (e.g. no training, individual training or group training in the municipality). The amount of training in this group is based on a questionnaire at the follow-up trials.
62239713|NCT01947452|EXPERIMENTAL|Jobs Only|Youth will be offered a 5-hour per day, 5-day per week employment opportunity over 7 weeks. They will be paid the Illinois minimum wage of $8.25 per hour.
62239714|NCT01947452|EXPERIMENTAL|Jobs plus Social-Emotional Learning|Youth will be offered a 3-hour per day, 5-day per week employment opportunity over 7 weeks. They will also be offered 2-hour per day, 5-day per week social-emotional learning programming, for which they will be paid the same hourly wage as their job ($8.25/hour).
62239715|NCT02670681|ACTIVE_COMPARATOR|Aerobic Exercise Mild Intensity|The subjects engage in aerobic exercise training (8 weeks) of mild intensity (continuous). The intensity is controlled by a corresponding heart rate at anaerobic threshold.
62239716|NCT02670681|ACTIVE_COMPARATOR|Aerobic Exercise Moderate Intensity|The subjects engage in aerobic exercise training (8 weeks) of moderate intensity (continuous). The intensity is controlled by a corresponding heart rate between anaerobic threshold and respiratory compensation point.
62239717|NCT02670681|ACTIVE_COMPARATOR|Aerobic Exercise High Intensity|The subjects engage in aerobic exercise (8 weeks) of high intensity interval training. The intensity is controlled by a corresponding heart rate above respiratory compensation point.
62239718|NCT04540133|EXPERIMENTAL|dexamethasone 0.5mg/5ml solution in Mucolox™ (group A)|Dexamethasone solution (0.5mg/5ml) in Mucolox™ three times a day (TID) swish and spit for 4 weeks
62239719|NCT04540133|ACTIVE_COMPARATOR|dexamethasone 0.5mg/5ml solution (Arm B)|Dexamethasone solution (0.5mg/5ml) TID swish and spit for 4 weeks
62243458|NCT05179642||Control group|"This is a randomized, cluster stepped wedge study. The cluster will be made up of coordinating physicians grouped together according to the geographical area of their EHPAD.~Residents entering EHPAD during the pre-interventional inclusion period will be treated as usual in EHPAD. They will constitute the control group."
62815723|NCT03040999|PLACEBO_COMPARATOR|Placebo + Cisplatin + CRT|Participants receive placebo before initiation of CRT (either accelerated or standard fractionation radiotherapy regimen). During CRT, participants receive 2 doses of placebo and up to 3 cycles of Cisplatin (2 cycles during accelerated and 3 cycles during standard fractionation radiotherapy). Participants also receive up to an additional 14 cycles of placebo alone for a total of 17 cycles of placebo. If cisplatin and/or radiation therapy is discontinued, the participant may continue on treatment with placebo.
62815724|NCT03610256|EXPERIMENTAL|SADI-S|"This corresponds to obese patients (BMI ≥40 kg/m2 or BMI ≥35 kg/m2 +/- co-morbidities (high blood pressure, dyslipidemia, obstructive sleep apnea, type 2 diabetes mellitus, arthrosis)) benefiting from a laparoscopic SADI-S (laparoscopic Single-anastomosis duodeno ileal bypass with Sleeve gastrectomy).~SADI-S will be performed as a primary procedure or after failure of sleeve gastrectomy, defined as insufficient weight loss at 18 months after surgery (EWL% \<50), or as weight regain (+ 20% of nadir weight)."
62037727|NCT03249519|EXPERIMENTAL|Standard Arm|Radiation therapy: 50.4 Gy Brachytherapy: 35-40 Gy Chemotherapy: Cisplatin weekly 40mg/m\^2 (6 cycles) Hyperthermia: 10 times
62037728|NCT06025565||LET|Patients with tennis elbow.
62037729|NCT02541708|EXPERIMENTAL|IV ferric carboxymaltose|IV Ferric carboxymaltose is given at a dose calculated according to the severity of anemia and patients weight. The maximal weekly dose is 1000mg. If total dose exceeds 1000mg the dose is split in 1-3 infusions with one infusion per week.
62597319|NCT06617936|EXPERIMENTAL|Participant Group/Arm A|"Participants receive 2-4 cycles of Tislelizumab With Recombinant human endostatin combined with Chemotherapy treatment during preoperative period, every 3 weeks once for 4 cycles at most.~After neoadjuvant therapy, Patients evaluated for MDT who can be surgically resected will be placed in the surgical group for surgical excision.~Surgery will be performed within 4 to 6 weeks after completion of preoperative therapy.~After surgery, participants will receive adjuvant therapy with tislelizumab combined with recombinant human endostatin injection every 3 weeks until disease progression or postoperative adjuvant therapy for 1 year."
62239720|NCT02466438|EXPERIMENTAL|Piperacillin-tazobactam|"Piperacillin-tazobactam administration (fixed combination, ratio piperacillin:tazobactam = 8:1).~Recruitment stratified by age group and pediatric populations to ensure good representation of those subgroups. Maximum dose: 16g/day. Treatment duration: up to 14 days depending to the treating physician.~Patients with Normal Renal function:~* Pediatric and surgery units: 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)~* Pediatric intensive care unit (PICU): 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)~* Haematology-oncology unit: 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)~Patients with Acute Kidney injury:~* Pediatric and surgery units: 2 months-6 years (10)~* PICU: 2 months-6 years (10)~* Haematology-oncology unit: 2 months-6 years (10)"
62430037|NCT03820973|EXPERIMENTAL|Brief CBT for Anxiety|Participants will receive Brief Cognitive Behavioral Therapy for Anxiety (bCBT). Sessions with clinicians will be provided via VA Video Connect to Home (VVC-H). Participants will have the option to select from a list of skills to tailor to his/her preferences. Participants will be able to receive up to 9 total sessions and generally last 30 to 40 minutes. For the purpose of this study, treatment duration will be limited to 3 months to ensure standardization of study outcome measures.
62430038|NCT01950806|ACTIVE_COMPARATOR|Pecan-containing diet|Test diet containing 1.5 oz pecans/2000 kcal/day for 28 days
62239721|NCT06071403||60-70% group|We classified subjects into 3 groups by ((enteral feeding volume/total fluid volume)\*100%).
62239722|NCT06071403||71-80% group|We classified subjects into 3 groups by ((enteral feeding volume/total fluid volume)\*100%).
62815725|NCT03610256|ACTIVE_COMPARATOR|RYGB|"This corresponds to obese patients (BMI ≥40 kg/m2 or BMI ≥35 kg/m2 +/- co-morbidities (high blood pressure, dyslipidemia, obstructive sleep apnea, type 2 diabetes mellitus, arthrosis)) benefiting from a laparoscopic RYGB (laparoscopic Roux-en-Y Gastric ByPass).~Similarly to the experimental group, RYGB will be performed as a primary procedure or after failure of sleeve gastrectomy, which is defined as insufficient weight loss at 18 months after surgery (EWL% \<50), or as weight regain (+ 20% of nadir weight)."
62815726|NCT02973386|EXPERIMENTAL|Concurrent chemoradiation + adjuvant chemotherapy|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
62815727|NCT02973386|ACTIVE_COMPARATOR|Concurrent chemoradiation|IMRT combine with cisplatin concurrent chemotherapy
62239723|NCT06071403||81-90% group|We classified subjects into 3 groups by ((enteral feeding volume/total fluid volume)\*100%).
62430039|NCT01950806|PLACEBO_COMPARATOR|Nut-free diet|Placebo diet containing no nuts or nut products, and identical in total fat and fiber as the test diet, for 28 days
62597320|NCT06617936|EXPERIMENTAL|Participant Group/Arm B|Participants receive 2-4 cycles of Tislelizumab With Recombinant human endostatin combined with Chemotherapy treatment , every 3 weeks once for 4 cycles at most. After neoadjuvant therapy, Patients evaluated by MDT as unresectable will be placed in the standard treatment group, where the investigator will select the standard treatment regimen determined by the MDT discussion.
62597321|NCT01867294|EXPERIMENTAL|Arm I (Study I)|Patients apply spironolactone topically to face BID for 4 weeks.
62597322|NCT01867294|EXPERIMENTAL|Arm I (Study II)|Patients apply spironolactone topically to face and body BID for 4 weeks.
62815728|NCT05789524|EXPERIMENTAL|Part 1 - Cohort 1: SerpinPC|Participants will receive SerpinPC 1.2 mg/kg SC Injection QW for 24 weeks after a minimum of 12 weeks of a prospective observation period.
62597323|NCT01867294|PLACEBO_COMPARATOR|Arm II (Study I)|Patients apply placebo topically to face BID for 4 weeks.
62597324|NCT01867294|ACTIVE_COMPARATOR|Arm II (Study II)|Patients receive modified preemptive therapy regimen consisting of skin moisturizer topically BID, sunscreen topically as needed, hydrocortisone topically QD, and doxycycline PO BID for 4 weeks.
62735208|NCT00864175|EXPERIMENTAL|Treatment C - INCB007839 and Trastuzumab|"INCB007839 300 mg BID and trastuzumab~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
62815729|NCT05789524|EXPERIMENTAL|Part 1 - Cohort 2: SerpinPC|Participants will receive SerpinPC 1.2 mg/kg SC Injection Q2W for 24 weeks after a minimum of 12 weeks of a prospective observation period.
62815730|NCT05789524|EXPERIMENTAL|Part 1 - Cohort 3: SerpinPC|Participants will receive SerpinPC 1.2 mg/kg SC Injection Q4W for 24 weeks after a minimum of 12 weeks of a prospective observation period.
62430040|NCT00524875|EXPERIMENTAL|1|Intravitreal bevacizumab injection 1-2 weeks before surgery
62430041|NCT00524875|SHAM_COMPARATOR|2|Sham injection (needleless syringe pressed against conjunctiva)
62735209|NCT00864175|EXPERIMENTAL|Treatment D - INCB007839 and Docetaxel|INCB007839 300mg BID with docetaxel
62735210|NCT01995526|EXPERIMENTAL|Insulin Peglispro|Single subcutaneous dose of 1.3 Units per kilogram (U/kg) insulin peglispro on Day 1.
62735211|NCT01740921|ACTIVE_COMPARATOR|Liraglutide|Liraglutide (Victoza) daily injections
62815731|NCT05789524|EXPERIMENTAL|Part 2 - SerpinPC (Dose-confirmatory phase)|After a minimum of 24 weeks of prospective observation, participants will receive SerpinPC at dose of 1.2 mg/kg Q2W for 24 weeks in Part 2, unless the Interim Analysis (IA) shows a greater benefit-risk profile with either the 1.2 mg/kg QW or Q4W treatment regimens.
62815732|NCT05789524|EXPERIMENTAL|Part 3 - SerpinPC (Extension phase)|After completion of dosing in Part 1 or Part 2, participants will continue treatment with SerpinPC at the dose of SerpinPC selected for Part 2 in a 24-week extension phase (Part 3).
62819420|NCT00392327|EXPERIMENTAL|Arm B (chemoradiotherapy)|"CHEMORADIOTHERAPY: Patients receive vincristine sulfate and undergo radiation therapy as in Arm A. Patients also receive carboplatin IV over 15 minutes on each day of radiation therapy. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive maintenance therapy as in Arm A.~Patients also undergo blood sample collection, lumbar puncture and MRI throughout the study."
62597325|NCT02036658|ACTIVE_COMPARATOR|Cognitive Behavioral Group Therapy|Cognitive behavioral group therapy (CBGT) will be delivered by two Ph.D. clinical psychologists trained by Dr. Richard Heimberg to implement his CBGT for SAD (Heimberg \& Becker, 2002). Groups of six individuals will meet for 12 sessions of 2.5 hours each. The participants will also use selected portions of the client workbook developed by (Hope, Heimberg, \& Turk, 2010) to supplement relevant portions of the protocol. The treatment will be comprised of four major components: (1) psychoeducation and orientation to CBGT; (2) cognitive restructuring skills; (3) graduated exposure to feared social situations, within session and as homework; and (4) relapse prevention and termination. Further details of the treatment are available elsewhere (Heimberg \& Becker, 2002).
62735212|NCT01740921|PLACEBO_COMPARATOR|diet|reduction in calorie intake
62735213|NCT01740921|PLACEBO_COMPARATOR|Aspirin|Aspirin 300mg once daily
62815733|NCT04424537|PLACEBO_COMPARATOR|Control|"A control group will consume 2 meal replacement beverages(MRBs) made with whey protein~The control diet group will be provided with a protein powder which will provide all Amino Acids. Diets will be provided in unmarked containers, to ensure subjects will be blinded to the dietary group assignment.~No overall calorie reduction will be implemented for any group.~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
62239724|NCT04900922||Healthy tennis players|Participants in this group need to perform arm elevation in the scapular plane three times and successful flat tennis serve three times before and after a fatigue protocol. Surface electromyography on infraspinatus, pectoralis major, anterior deltoid ,and latissimus dorsi will be used to detect muscle activity related to fatigue.
62239725|NCT04575103|ACTIVE_COMPARATOR|Antipsychotics|Patients treated with antipsychotics as provided by their psychiatrist in order to treat disease best possible and in accordance with guidelines.
62430042|NCT05913388|EXPERIMENTAL|GB1211 + Pembrolizumab|GB1211 will be administered orally twice a day at 400mg in combination with standard pembrolizumab treatment.
62239726|NCT04575103|NO_INTERVENTION|Control|Healthy controls, not treated with antipsychotics.
62239727|NCT02590263|EXPERIMENTAL|Arm A of Phase 1 portion|ABT-414 administered every other weeks monotherapy
62430043|NCT05913388|PLACEBO_COMPARATOR|Pembrolizumab Monotherapy|Placebo will have the same appearance as GB1211 and administered orally twice a day in combination with standard pembrolizumab treatment.
62735214|NCT00960791|EXPERIMENTAL|1|14C-labelled AZD1656
62239728|NCT02590263|EXPERIMENTAL|Phase 2 portion|ABT-414 administered every other weeks in combination with temozolomide
62430044|NCT04953585||Normal D-dimer group|preoperative plasma D-dimer levels less than or equal to 1mg/L
62239729|NCT02590263|EXPERIMENTAL|Arm C of Phase 1 portion|ABT-414 administered every other weeks in combination with radiation and temozolomide
62430045|NCT04953585||Elevated D-dimer group|preoperative plasma D-dimer levels greater than 1mg/L
62430046|NCT01866488|EXPERIMENTAL|Cook Catheter, Oral Misoprostol|Cook Catheter is placed and a 50mcg misoprostol tablet is given orally. A repeat dose is administered in 3 hours.
62430047|NCT01866488|PLACEBO_COMPARATOR|Cook Catheter, Oral Placebo|Cook Catheter is placed and a placebo tablet is given orally. A repeat dose is administered in 3 hours.
62430048|NCT04371419|EXPERIMENTAL|Control - CDC - Mask (Control) - Concordant|Control Intro, CDC Social Distancing, Mask Control version delivered by minority doctor of same background as the recipient - other definitions are similar
62239730|NCT02590263|EXPERIMENTAL|Arm B of Phase 1 portion|ABT-414 administered every other weeks in combination with radiation and temozolomide
62239731|NCT02581293|EXPERIMENTAL|Only visceral peritoneum will be closed|Group1: Only visceral peritoneum will be closed
62430049|NCT04371419|EXPERIMENTAL|Control - CDC - Mask (Control) - Discordant|Control Intro, CDC Social Distancing, Mask Control version delivered by majority doctor of different background as the recipient - other definitions are similar
62430050|NCT04371419|EXPERIMENTAL|Control - MGH - Mask (Control) - Concordant|Control Intro, MGH Social Distancing, Mask Control version delivered by concordant doctor
62037730|NCT02541708|ACTIVE_COMPARATOR|Ferrous sulphate 60mg+Folic acid 0.25mg|Three dried ferrous sulphate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia.
62037731|NCT02858895|EXPERIMENTAL|MDNA55|"Single infusion of MDNA55 via convection enhanced delivery (CED).\*~\*Subjects may be eligible to receive a second administration of MDNA55."
62037732|NCT03712891|EXPERIMENTAL|Patients receiving coffee postoperatively|Patients who self-identify as coffee drinkers and receive coffee postoperatively
62815734|NCT04424537|ACTIVE_COMPARATOR|Low protein(LP) diet|"This group will consume 2 meal replacement beverages(MRBs) containing low protein (goal to reduce total protein by 2/3rds).~LP diet group will be provided with a protein powder which will provide all Amino Acids. Diets will be provided in unmarked containers, to ensure subjects will be blinded to the dietary group assignment.~No overall calorie reduction will be implemented for any group.~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
62815735|NCT04424537|EXPERIMENTAL|Low branched-chain amino acids (BCAA)|"The group on low-BCAA diet will consume 2 meal replacement beverages (MRBs) per day made with BCAD2 (branched chain amino acid) powder (lacking BCAAs).~BCAD2 powder(Mead Johnson) is a fortified medical food powder that does not contain the BCAAs isoleucine, leucine, or valine, but provides all other essential and nonessential AAs, carbohydrates, fat, vitamins, and minerals.~No overall calorie reduction will be implemented for any group.~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
62815736|NCT05773846|EXPERIMENTAL|PRF-110|PRF-110 3.6% ropivacaine, to be applied into the surgical wound
62815737|NCT05773846|PLACEBO_COMPARATOR|Saline .9%|Saline .9%, to b be applied into the surgical wound
62037733|NCT03712891|NO_INTERVENTION|Patients not receiving coffee postoperatively|Patients who self-identify as coffee drinkers and do not receive coffee postoperatively
62037734|NCT03584451|ACTIVE_COMPARATOR|with rehabilitation sport|rehabilitation sport over 52 weeks after THA, start 6 weeks postoperatively
62037735|NCT03584451|NO_INTERVENTION|without rehabilitation sport|no further rehabilitation program after THA
62037736|NCT01900938|ACTIVE_COMPARATOR|Intermittent bolus injection of propofol|A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
62037737|NCT01900938|ACTIVE_COMPARATOR|Continuous infusion of propofol|Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
62037738|NCT01190592|EXPERIMENTAL|Milk|
62037739|NCT01190592|EXPERIMENTAL|Juice|
62037740|NCT01190592|PLACEBO_COMPARATOR|Water|
62239732|NCT02581293|EXPERIMENTAL|Only parietal peritoneum will be closed|Group 2: Only parietal peritoneum will be closed
62037741|NCT05065866|EXPERIMENTAL|Dose Escalation|Dose escalation to determine the maximum tolerated dose (MTD) of BMS-986345 in combination with Duvelisib in patients with lymphoid malignancy. Patients will be treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable. A total of 6 dose levels will be used.
62239733|NCT02581293|EXPERIMENTAL|Both of them will be closed|Group 3: Both of them will be closed
62239734|NCT02581293|EXPERIMENTAL|None of them will be closed|Group 4: None of them will be closed
62430051|NCT04371419|EXPERIMENTAL|Control - MGH - Mask (Control) - Discordant|Control Intro, MGH Social Distancing, Mask Control version delivered by discordant doctor
62597326|NCT02036658|ACTIVE_COMPARATOR|Mindfulness-Based Stress Reduction|MBSR will follow the standard curriculum outline compiled in 1993 by Jon Kabat-Zinn except that the one-day meditation retreat will be converted to four additional weekly group sessions between the standard class 6 and 7 so that there will be 12 weekly 2.5 hour sessions. This will be done to match the CBGT protocol in duration and time. The MBSR intervention will be delivered by a University of Massachusetts Center for Mindfulness certified MBSR instructor with more than 30 years of teaching experience. To support the practice, each participant will be given A Mindfulness-Based Stress Reduction Workbook (Stahl \& Goldstein, 2010), which includes descriptions of mindfulness exercises together with pre-recorded audio files to support ongoing practice.
62597327|NCT02036658|NO_INTERVENTION|Waitlist Control|This will be a delayed treatment arm. Participants randomized to the waitlist control group will be re-randomized after completing the no treatment period of 12 weeks to CBGT or MBSR with equal probability.
62239735|NCT03075423|EXPERIMENTAL|Ipilimumab plus nivolumab|Ipilimumab 1mg/kg plus nivolumab 3mg/kg, both, will be administered i.v. every 3 weeks for 4 times as an induction therapy followed by a maintenance therapy with a fixed dose of 240 mg nivolumab every two weeks or 480 mg every four weeks until progression.
62239736|NCT03075423|ACTIVE_COMPARATOR|Standard of Care therapy|Standard of Care therapy is administered according to the physician´s decision.
62597328|NCT02517242|EXPERIMENTAL|Pens Device|All patients will receive pens device, insulin, blood glucose monitor, lancet tapes, capillary blood glucose tests (3 tests/day). All will be evaluated monthly for six months
62037742|NCT03818672|EXPERIMENTAL|Rifaximin|Rifaximin 550 mg BID
62239737|NCT04092062|EXPERIMENTAL|Treatment - ToothWave brush|Subjects using the Silk'n ToothWave, Radio frequency (RF)-utilizing toothbrush.
62239738|NCT04092062|SHAM_COMPARATOR|Control - powered toothbrush|Subjects using a regular ADA-Accepted Powered Toothbrush, no RF
62239739|NCT00805662|EXPERIMENTAL|Oxytocin|Intranasal oxytocin during IUI
62239740|NCT03607123||Baseline|After implantation of pacemaker, the pacing mode and the lower rate of pacemaker will be set as VDD and 50/45 bpm respectively, to get the baseline burden of atrial fibrillation without atrial pacing. Except for beta-blockers digoxin, and CCB to control heart rate, anti-arrhythmic drugs (AAD) will not be prescribed. Patients who can not tolerate will drop out. After follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group / stage (Atrial Pacing, Step1).
62430052|NCT04371419|EXPERIMENTAL|Ack. Discrimination- MGH - Mask (Control) - Concordant|Introduction Acknowledges past discrimination, MGH doctor talks about Social Distancing, Mask Control all by concordant MD
62597329|NCT02517242|ACTIVE_COMPARATOR|Syringe|All patients will receive syringe to insulin, insulin, blood glucose monitor, lancet tapes, capillary blood glucose tests (3 tests/day). All will be evaluated monthly for six months
62597330|NCT03961386|EXPERIMENTAL|FallsTalk-C|FallsTalk CG intervention
62239741|NCT03607123||Atrial Pacing (Step 1)|After Baseline and after follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group /stage (Atrial Pacing). At this stage, the pacing mode and the lower rate of pacemaker will be set as DDD and 70/60 bpm respectively, to perform relatively high-rate atrial pacing. Except for beta-blockers digoxin, and CCB to control heart rate, anti-arrhythmic drugs (AAD) will not be prescribed. After follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group/stage (AAD, Step1).
62239742|NCT03607123||AAD (Step 2)|After Step 1, and after follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group/stage. Anti-arrhythmic drugs including propafenone, amiodarone and dronedarone will be prescribed. After follow-up of at least 6 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group/stage (RFCA, Step3).
62239743|NCT03607123||RFCA (Step 3)|After Step 2, and after follow-up of at least 6 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group/stage (RFCA, Step3). Patients will receive catheter ablation of AF, up to patients' willingness. After follow-up of at least 12 month, patients without AF lasting longer than one minute detected by pacemaker will go to next group/stage (SAFE PAF-SND II).
62239744|NCT03607123||SAFE PAF-SND II|After RFCA, and after follow-up of at least 12 month, patients without AF lasting longer than one minute detected by pacemaker will come to this group/stage (SAFE PAF-SND II). At this stage, the pacing mode and the lower rate of pacemaker will be set as VDD and 40 bpm respectively. If the patient can not tolerate, the the pacing mode and the lower rate of pacemaker will be set as DDD/DDDR and 60 bpm. If the patient has no symptom related to bradycardia, he/she will be followed up until the end of this study.
62239745|NCT03970551|NO_INTERVENTION|No Physical Intervention|The participant will actively stand up from a seated position without performing any physical counter-maneuvers either prior to or following the stand.
62430053|NCT04371419|EXPERIMENTAL|Ack. Discrimination- MGH - Mask (Control) - Discordant|Introduction Acknowledges past discrimination, MGH doctor talks about Social Distancing, Mask Control all by discordant MD
62597331|NCT03961386|ACTIVE_COMPARATOR|FallsTalk|FallsTalk intervention
62597332|NCT03961386|NO_INTERVENTION|PostCardOnly|Postcard only- Control group
62239746|NCT03970551|EXPERIMENTAL|Supine Knee Raises|The participant will perform 30 seconds of raising their knees to their chest while sitting down before actively standing.
62239747|NCT03970551|EXPERIMENTAL|Leg Crossing|The participant will actively stand and then immediately cross their legs and tense their leg muscles for 60 seconds.
62597333|NCT02339129|EXPERIMENTAL|SST-0225|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
62597334|NCT02339129|PLACEBO_COMPARATOR|Placebo|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
62239748|NCT03970551|EXPERIMENTAL|Cold Pressor Test|The participant will submerge their hands in ice water for approximately 45 seconds.
62239749|NCT03970551|EXPERIMENTAL|Serial 7's Stress Test|The participant will perform a mental arithmetic stress test for 30 seconds prior to standing.
62239750|NCT03970551|EXPERIMENTAL|Functional Electrical Stimulation|The participant will have their quadriceps passively contracted using mild electrical stimulation for approximately 30 seconds prior to standing.
62239751|NCT00235326||2|Unexposed to gastroenteritis
62597335|NCT02027597|EXPERIMENTAL|Video Game Treatment|This group received the AOTSM game experience followed by additional oral health information. They did not receive any follow-up treatment after the exhibit.
62597336|NCT02027597|ACTIVE_COMPARATOR|Control|Instead of playing Attack of the S. Mutans!, children in the control group attended a 90 minute classroom session about virtual reality applications for relieving pain and for therapy. This content was unrelated to oral health.
62815738|NCT05773846|ACTIVE_COMPARATOR|Ropivacaine|Ropivacaine Hydrochloride 0.5%, up to 10 mL, to be applied into the surgical site
62597337|NCT02027597|EXPERIMENTAL|Video Game Treatment Plus Follow-Up|Children assigned to the Treatment-Plus conditions not only had the Attack of the S. Mutans video game experience, but also gained access to an educational website that reinforced the exhibit's teachings two months later. These students received a special login and password in the mail and were instructed to visit the site before completing their next questionnaire.
62815739|NCT04206540|EXPERIMENTAL|Healthy Subjects|Healthy volunteers aged 18-80 years old who will undergo vagus nerve stimulation.
62815740|NCT01590030|EXPERIMENTAL|Laparoscopic mesial incision|
62239752|NCT00235326||1|Exposed to gastroenteritis
62239753|NCT05538273||Minimal invasive surgery|removal of urinary catheter postoperatively
62239754|NCT05538273||Laparotomy|removal of urinary catheter postoperatively
62239755|NCT05538273||Simple surgery|removal of urinary catheter postoperatively
62430054|NCT04371419|EXPERIMENTAL|Ack. econ. circumstance- MGH - Mask (Control ) Concordant|Intro econ. circumstance -MGH - Mask (Control ) Concordant
62815741|NCT01590030|ACTIVE_COMPARATOR|Laparoscopic antimesial incision|
62815742|NCT05767515|ACTIVE_COMPARATOR|Metformin Group|Metformin will be used in dose of 500mg BD daily for 30 infertile female PCOS patients
62430055|NCT04371419|EXPERIMENTAL|Ack. econ. circumstance - MGH - Mask (Control ) Discordant|
62430056|NCT04371419|EXPERIMENTAL|Control Intro - CDC - Mask (antiStigma) Concordant|Control Intro - CDC - Mask (antiStigma) Concordant messenger
62430057|NCT04371419|EXPERIMENTAL|Control Intro - CDC - Mask (antiStigma) Discordant|Control Intro - CDC - Mask (antiStigma) discordant messenger
62239756|NCT05538273||Radical surgery|removal of urinary catheter postoperatively
62239757|NCT03919981||nephropathic cystinosis patients receiving cysteamine|nephropathic cystinosis patients receiving cysteamine. The blood samples of the group will be used to evaluate the action of cysteamine on osteoclastic differentiation and resorption activity of NC patients, depending on the underlying genotype.
62430058|NCT04371419|EXPERIMENTAL|Control - MGH - MaskS (antiStigma) Concordant messenger|Control - MGH - MaskS (antiStigma) Concordant sender
62430059|NCT04371419|EXPERIMENTAL|Control- MGH-MaskS (antiStigma) Discordant messenger|Control - MGH - MaskS (antiStigma) Discordant sender
62430060|NCT04371419|EXPERIMENTAL|Ack. Discrimination - MGH - MaskS (antiStigma) Concordant|Acknowledge Discrimination - MGH - MaskS (antiStigma) Concordant sender
62430061|NCT04371419|EXPERIMENTAL|Ack. Discrimination - MGH - MaskS (antiStigma) Discordant|Acknowledge Discrimination - MGH - MaskS (antiStigma) Discordant sender
62430062|NCT04371419|EXPERIMENTAL|Ack. Econ Hardship- MGH - Mask (antiStigma) Concordant|Acknowledge Econ Hardship- MGH - Mask (antiStigma) Concordant sender
62430063|NCT04371419|EXPERIMENTAL|Ack. Econ Hardship- MGH - Mask (antiStigma) Discordant|Acknowledge Econ Hardship- MGH - Mask (antiStigma) discordant sender
62597338|NCT06260943|EXPERIMENTAL|Aim 3: Targeted Navigation Pilot Program|Participants in this group will be enrolled in a Targeted Navigation Pilot Program for up to 12 months.
62239758|NCT01187069|EXPERIMENTAL|Training course for practice nurses in autonomy support|
62239759|NCT01187069|NO_INTERVENTION|Control|Control practices were randomly drawn from among intervention practice applicants and were informed by mail about their status as control practice.
62239760|NCT02326714|EXPERIMENTAL|Auricular acupressure|The magnetic beads will be taped to the seven pressing points: Hunger point, Ovary, Uterus, Endocrine point, liver, kidney and spleen.
62239761|NCT02326714|PLACEBO_COMPARATOR|Placebo auricular acupressure|The magnetic beads will be taped to the three pressing points:Tonsil, eye and elbow.
62239762|NCT01449318|NO_INTERVENTION|Patients undergoing hysterectomy|
62597339|NCT06117709|EXPERIMENTAL|I-STAMP Testing|"Study procedures will be conducted as follows:~Activities 1-3: Data Collection for application development~Activity 4: To be added with future amendment"
62239763|NCT00966823|EXPERIMENTAL|Detachable balloon|Intervention: Fetuses treated with endoscopic tracheal occlusion
62239764|NCT05079412||NIV-NAVA group|Premature infants (22 0/7 to 29 6/7 weeks gestation) with respiratory distress syndrome who are admitted to Mount Sinai NICU and are supported by NIV-NAVA for at least 24 hours are enrolled in this arm after obtaining parents' consent.
62597340|NCT06438133||Patients with chronic edema of the lower limbs|Patients with chronic edema of the lower limbs referred to compression bandaging in a hospital setting.
62239765|NCT05079412||NIPPV group|Premature infants (22 0/7 to 29 6/7 weeks gestation) with respiratory distress syndrome who are admitted to Mount Sinai NICU and are supported by NIPPV for at least 24 hours are enrolled in this arm after obtaining parents' consent.
62239766|NCT04641507|ACTIVE_COMPARATOR|Tamsulosin treated group|83 patient with lower ureteric stone will take tamsulosin 0.4 mg once daily .Therapy will be given for a maximum of 4 weeks.
62597341|NCT04668638|OTHER|Control group|Group 1 (Control Group) will not immediately receive respiratory rehabilitation but between the 2nd and 4th months postdiagnosis.
62597342|NCT04668638|OTHER|Intervention group|Group 2 (Intervention Group) will immediately receive rehabilitation between the diagnosis and the 2nd month postdiagnosis.
62597343|NCT06624202|EXPERIMENTAL|practice intervention|head impact outcomes will be monitored from athletes enrolled on teams participating in the COmmunities Aligned to reduce Concussion and Head impact exposure (COACH) intervention
62597344|NCT01676922||Cohort|
62735616|NCT02597452|OTHER|intelligent Breast Exam, iBE|Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for participation.
62430064|NCT04371419|PLACEBO_COMPARATOR|Info later - Pure Control|This group will not receive the videos but will receive information later.
62430065|NCT04632693|EXPERIMENTAL|CAF with SCTG and vitamin C|Coronally advanced flap with subepithelial connective tissue graft and vitamin C.
62430066|NCT04632693|ACTIVE_COMPARATOR|CAF with SCTG|Coronally advanced flap with subepithelial connective tissue graft.
62430067|NCT02631044|EXPERIMENTAL|JCAR017 1-dose schedule|Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 1 intravenous (IV) injection
62430068|NCT02631044|EXPERIMENTAL|JCAR017 2-dose schedule (no longer accruing)|Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 2 intravenous (IV) injections
62430069|NCT01645228||significant coronary artery stenosis|anyone coronary segment \> 50% diameter stenosis
62430070|NCT00811070|EXPERIMENTAL|1|
62815743|NCT05767515|EXPERIMENTAL|Inositol isomers Group|Inositols isomers (Myo inositol and D- Chiro Inositol in its physiological ratio) will be used 2000mg BD Daily for 30 infertile female PCOS patients
62815744|NCT05767515|EXPERIMENTAL|Acetyl-L- Carnitine Group|Acetyl-L-Carnitine will be given in dose of 1000mgBD Daily for 30 infertile female PCOS patients
62815745|NCT05767515|EXPERIMENTAL|Combine Group|Inositol isomers and Acetyl-L-Carnitine will be given in dose of 2000mg and 1000mg respectively BD daily for 30 infertile female PCOS patients
62037743|NCT04110769|EXPERIMENTAL|Responders|"The investigator will administer neoadjuvant chemotherapy After neoadjuvant chemotherapy, multidisciplinary team will decide to surgery or continuing chemotherapy based on following imaging studies and tumor markers.~The patients who undergo surgery after neoadjuvant chemotherapy will be included responders."
62037744|NCT04110769|ACTIVE_COMPARATOR|Non-responders|The patients who show cancer progression even after neoadjuvant chemotherapy will be classify with non-responder. And the investigator will change palliative chemotherapy.
62037745|NCT02210364|EXPERIMENTAL|lurbinectedin (PM01183) and capecitabine|
62037746|NCT00574587|EXPERIMENTAL|Vorinostat Plus Paclitaxel|Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks (and trastuzumab if HER2-positive), followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery
62037747|NCT03232970|EXPERIMENTAL|FPD group|This group will undergo three months of weekly lectures to incorporate more fiber in their diet.
62037748|NCT03232970|NO_INTERVENTION|FPD Control group|This group will receive all the assessments before, during and after the three months program period but will not attend the weekly lectures.
62239767|NCT04641507|ACTIVE_COMPARATOR|Tadalafil treated group|83 patients with lower ureteric stone will take tadalafil 10 mg once daily. Therapy will be given for a maximum of 4 weeks.
62239768|NCT05335148|NO_INTERVENTION|Standard of care arm - placebo colchicine pill|The standard of care arm will receive a placebo colchicine pill once a day
62239769|NCT05335148|EXPERIMENTAL|Experimental arm - oral colchicine once a day|The experimental arm will receive 0.6 mg of oral colchicine once a day
62239770|NCT02329665|EXPERIMENTAL|NeedleWays™ System|A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
62239771|NCT05626049|ACTIVE_COMPARATOR|Usual Medical Care|This group will consist of patients who contact clinics that have been randomized to usual medical care (no change to medical care).Usual care is defined as any care designated by a primary care physician (PCP).
62239772|NCT05626049|EXPERIMENTAL|Primary Spine Provider Model|This group will consist of patients who contact clinics that have been randomized to the primary spine provider (PSP) model (intervention clinics). Patients seeking care at intervention clinics will be given the option of seeing either a DC or a PT as their first contact clinician for an initial trial of PSP care.
62239773|NCT03606837|EXPERIMENTAL|PET/CT Imaging|
62239774|NCT03146468|EXPERIMENTAL|Nivolumab treatment arm|Nivolumab injection 3mg/kg intravenously every 2 weeks
62239775|NCT04864483|EXPERIMENTAL|Early sahoor with predawn snack|"To take the Sahoor meal 1:30-2 hours before dawn with insulin dose then a pre-dawn snack with no insulin~(Sahoor is the latest meal before starting the fast at dawn during the month of Ramadan. The intervention is meal timing in relation to start of fast and does not involve any medications)."
62037749|NCT05622669||Myeloma|Individuals experiencing fatigue related to myeloma or its treatment
62239776|NCT04864483|EXPERIMENTAL|Late Sahoor meal (within 30 minjted of dawn) with insulin dose|"To take sahoor meal as late as possi le with usual insulin dose~(Sahoor is the latest meal before starting the fast at dawn during the month of Ramadan. The intervention is meal timing in relation to start of fast and does not involve any medications)."
62239777|NCT04140383||Group 1, patients aged 85 years and older|75 eyes of 75 patients (39 female, 36 male) Mean age: 86,8 ± 1,8 years
62239778|NCT04140383||Group 2, patients aged 65 and 85 years|77 eyes of 77 patients (34 female, 43 male) Mean age:73,3 ± 5,2 years
62815746|NCT04045860|EXPERIMENTAL|CDT for head and neck lymphedema|Complete Decongestive Therapy
62037750|NCT05622669||Long COVID|Individuals experiencing fatigue related to Long COVID
62037751|NCT05622669||Heart failure|Individuals experiencing fatigue related to heart failure or its treatment
62037752|NCT05622669||Controls|Individuals who are not experiencing problematic fatigue and who do not have myeloma, long COVID, or heart failure
62239779|NCT00887250|PLACEBO_COMPARATOR|1|Placebo
62239780|NCT00887250|EXPERIMENTAL|2|Losartan 50 mg for 12 weeks
62239781|NCT00887250|EXPERIMENTAL|3|Losartan 50 mg titrated to 100 mg after 6 weeks
62239782|NCT03873493|EXPERIMENTAL|Venetoclax + Ibrutinib|Participants received 400 mg venetoclax orally once a day after a 5-day ramp-up and 420 mg ibrutinib orally once a day for up to 2 years or until progressive disease, intolerability, or they became eligible for stem cell transplantation after achieving complete remission.
62815747|NCT04045860|OTHER|Standard of Care for head and neck lymphedema|Observation
62815748|NCT03403803||Control Group|
62815749|NCT03403803||Optune Only|
62815750|NCT03403803||Optune and TMZ|
62815751|NCT06313255||PegIFNα2b|
62815752|NCT06313255||PegIFNα2b+probiotics|
62815753|NCT06313255||Nucleoside analog|
62815754|NCT06313255||Nucleoside analog+probiotics|
62815755|NCT03439280|EXPERIMENTAL|Phase 1 Dose Escalation Cohort: Mezagitamab 45 mg|Mezagitamab 45 mg, subcutaneously (SC), once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until progressive disease (PD), unacceptable toxicities or withdrawal due to other reasons.
62815756|NCT03439280|EXPERIMENTAL|Phase 1 Dose Escalation Cohort: Mezagitamab 135 mg|Mezagitamab 135 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.
62815757|NCT03439280|EXPERIMENTAL|Phase 1 Dose Escalation Cohort: Mezagitamab 300 mg|Mezagitamab 300 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.
62815758|NCT03439280|EXPERIMENTAL|Phase 1 Dose Escalation Cohort: Mezagitamab 600 mg|Mezagitamab 600 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.
62815759|NCT03439280|EXPERIMENTAL|Phase 1 Dose Escalation Cohort: Mezagitamab 1200 mg|Mezagitamab 1200 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.
62815760|NCT03439280|EXPERIMENTAL|Phase 1 Combination Cohort: Mezagitamab 300 mg + PomDex|Mezagitamab 300 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter along with pomalidomide, at product-labelled dose, orally, once daily on Days 1 to 21 and dexamethasone, at product-labelled dose, orally, once on Days 1, 8, 15, and 22 in a 28-day treatment cycle until PD.
62815761|NCT03439280|EXPERIMENTAL|Phase 2a: Mezagitamab|Mezagitamab, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons. TAK-079 dose for this phase was to be determined based on review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data obtained from the Phase 1 portion of the study. However, Phase 2a of the study was not opened for enrollment due to changes in the Sponsor's overall clinical development plan.
62815762|NCT02217839|EXPERIMENTAL|DG3173|
62815763|NCT02217839|EXPERIMENTAL|DG3173+Octreotide|
62815764|NCT00966186|ACTIVE_COMPARATOR|Standard technique|Proseal laryngeal mask airway was inserted according to the manufacture's instruction manual (insertion with help of index finger insertion)
62815765|NCT00966186|EXPERIMENTAL|Rotational technique|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was fel
62815766|NCT03459287|EXPERIMENTAL|INTERCEPT (test)|The INTERCEPT treatment process uses amustaline and glutathione together with a processing solution in a single-use disposable set and results in pathogen and leukocyte inactivated RBCs suspended in SAG-M additive solution (INTERCEPT RBCs). The INTERCEPT treatment will be performed on leukocyte reduced RBC components prepared from whole blood collections and suspended in AS-5 additive solution within 24 hours of collection. The test component is allogeneic INTERCEPT RBCs suspended in SAG-M and stored at 1°C to 6 for up to 35 days post-donation and administered intravenously. Dose and schedule of RBC transfusions will be determined by the treating physician.
62037753|NCT02756767||Completed subjects|Subjects will complete patient-reported outcomes assessments during and after radiation therapy.
62815767|NCT03459287|ACTIVE_COMPARATOR|Conventional (Control)|The control transfusion component is a conventional leukocyte-reduced RBC component in an FDA approved additive solution (AS-1, AS-3 or AS-5) stored at 1°C to 6°C for up to 35 days post-donation and administered intravenously. The Control RBC components will be handled and labeled in a manner so as to maintain blinding. Dose and schedule of RBC transfusions will be determined by the treating physician.
62815768|NCT04565067||1|COVID-19 recovered adult patients
62815769|NCT05020821|ACTIVE_COMPARATOR|Single-shot superior trunk block with intravenous dexmedetomidine|participants receiving single-shot superior trunk block with intravenous dexmedetomidine
62037754|NCT00754026|ACTIVE_COMPARATOR|1|
62037755|NCT00754026|ACTIVE_COMPARATOR|2|
62597345|NCT05015140|EXPERIMENTAL|experiment group|"The first day before the application of music to each of the 15 patients in the experimental group (D-1) 'Patient Identification First evaluation will be made by filling the form and then the Richard Campbell Sleep Questionnaire . The day before transplant (D-1) Starting from 10 days, calm music including nature sounds determined by the music therapist will be played using mp3 player. The Richard Campbell Sleep questionnaire will be filled again on the 10th day (D + 10) after the transplant."
62815770|NCT05020821|EXPERIMENTAL|Continuous superior trunk block|participants receiving continuous superior trunk block
62815771|NCT06048133|EXPERIMENTAL|Arm A|Quemliclustat (AB680), zimberelimab (AB122), gemcitabine, and cisplatin in subjects with untreated advanced BTC. Quemliclustat IV: Day 1, 15, and 29 of each cycle; Zimberelimab IV: Day 1 and 22 of each cycle; Gemcitabine IV: Day 1, 8, 22 and 29 of each cycle; Cisplatin IV: Day 1, 8, 22 and 29 of Cycles 1-4 only.
62815772|NCT06105502||Psychotherapy students|The participating psychotherapy students will come from the following courses at the Center for Psychotherapy Education and Research: the psychotherapist program (six semesters), the specialist training for psychologists in adult psychiatry (six semesters), the basic training in evidence-based psychotherapeutic methods (three semesters), and the basic training in psychotherapy for residents in child, adolescent, and adult psychiatry (two semesters).
62815773|NCT01434017|ACTIVE_COMPARATOR|Dexamethasone|Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
62037756|NCT01431625|ACTIVE_COMPARATOR|COPD with emphysema-predominant|The degree of involvement of the lung parenchyma and the airway are assessed by computed tomography. The HRCT is performed using 2-mm collimation, scan time 1.0 s, 120 kVp, and 200 mA. Images at three different levels (a cranial section is obtained 1 cm above the superior margin of the aortic arch, a middle section is taken at 1 cm below the carina, and a caudal section is taken approximately 3 cm above the top of the diaphragm) are selected and LAA% is then automatically calculated. The identification threshold of normal lung density and LAA is set at -960 HU. The cut-off level between high or low LAA% is the mean + 2SD of LAA% of the asymptomatic non-COPD smokers.
62239783|NCT03258125||severe EOPE|EOPE: PE starting before 34 weeks gestation Severe PE (Blood pressure more than 160/ 110 mm Hg on 2 occasions 2 hours to 2 weeks apart and proteinuria ( 24-hour urine protein \>2000 mg/d).
62430071|NCT06412237|EXPERIMENTAL|RELab tenoexo|3 weeks in clinic training (9 training sessions, two clinical assessment and 2 usability evaluations) followed by 2 weeks home training (1-hour daily training and to the extent participants desire). Lastly 1-month follow up clinical assessment and IMU data collection.
62430072|NCT04627870|EXPERIMENTAL|DCB group|use drug (paclitaxel) coated balloon to treat intracranial in-stent restenosis
62430073|NCT04627870|ACTIVE_COMPARATOR|PTA group|use PTA balloon to treat intracranial in-stent restenosis
62815774|NCT01434017|ACTIVE_COMPARATOR|Dexamethasone and Droperidol|Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
62815775|NCT01434017|ACTIVE_COMPARATOR|Dexamethasone and Ondansetron|Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
62815776|NCT06651749|ACTIVE_COMPARATOR|high dose propofol during induction of anesthesia.|this group will be given high dose propofol 2.5mg/kg during induction of anesthesia.
62239784|NCT03258125||control|Healthy Pregnant women who come for termination of pregnancy by vaginal delivery or CS between 28-34 weeks gestational age.
62239785|NCT01513525|EXPERIMENTAL|Abdomen|
62239786|NCT01513525|EXPERIMENTAL|Thigh|
62239787|NCT01513525|EXPERIMENTAL|Upper arm|
62239788|NCT04157504|EXPERIMENTAL|Experimental Group: Physical Function|Forty patients with burn injury will be evaluated in this study. Lower extremity function, functional capacity, functional mobility, quality of life an scar tissue will be evaluated.
62815777|NCT06651749|ACTIVE_COMPARATOR|low dose propofol during induction of anesthesia.|this group will be given low dose propofol 1.5mg/kg during induction of anesthesia.
62239789|NCT05549778|EXPERIMENTAL|Polaprezinc group|Patients will be on abiraterone plus polaprezinc (75 mg b.i.d. for 6 months)
62239790|NCT05549778|ACTIVE_COMPARATOR|Control group|Patients will be on abiraterone, radiotherapy or chemotherapy for 6 months
62239791|NCT03698890|NO_INTERVENTION|Control|Usual care of 3 to 6-monthly clinic visit
62239792|NCT03698890|EXPERIMENTAL|Intervention|Network-based home blood pressure monitor (Fora P20b Blood Pressure Monitor) and telephone consult with care team
62430074|NCT02832791|ACTIVE_COMPARATOR|QUADRICEPS TENDON|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION USING QUADRICEPS TENDON
62430075|NCT02832791|ACTIVE_COMPARATOR|HAMSTRING TENDON|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION USING HAMSTRING TENDON
62430076|NCT04428502||Patients with psoriatic arthritis|Iraqi patients diagnosed with psoriatic arthritis that receive Enbrel as treatment for disease
62239793|NCT00229554||Group 1|Male and female veterans age 50-75 who have had one or more primary care visits at a VA Medical facility in the past two years.
62239794|NCT05827250||Neonatal Profile|"LUSS will be obtained twice a week on the following schedule for the duration of each subject's NICU stay.~Day of life (DOL): 7+/-1, 10+/-1, and 14+/-1 Depending on length of stay, within +/-2 days of: DOL 17, 21, 24, 28, 31, 35, 38, 41, 44, 48, 51, 56, and 60."
62430077|NCT06543316|ACTIVE_COMPARATOR|Low Thermal Plasma (LTP)|Patients randomized to this group will receive LTP treatment of the ulcer in addition to SOC (PPI administration).
62430078|NCT06543316|ACTIVE_COMPARATOR|Standard of Care (SOC) PPI Administration|Patients randomized to this group will receive only the SOC treatment (PPI administration).
62430079|NCT02642107|EXPERIMENTAL|Elective neck irradiation|Whole neck irradiation is given in the involved neck. Elective neck irradiation of Level II,III and Va lymph node area is given in the uninvolved neck, and Level IV and Vb lymph node area were not irradiated in the uninvolved neck.
62430080|NCT02642107|ACTIVE_COMPARATOR|Whole neck irradiation|Whole neck irradiation is given regardless of the involved or uninvolved neck.
62430081|NCT04729218||Familial Mediterranean Fever group|30 participants
62430082|NCT04729218||Healthy group|30 participants
62597346|NCT05015140|NO_INTERVENTION|control group|"- The day before the transplant (D-1) for each of the 15 patients in the control group, first 'Patient Identification Form' and then 'Richard The first evaluations will be made by filling the Campbell Sleep Questionnaire, and standard treatment and care interventions will be given to the patients in this group.~The sleep questionnaire was filled out again on the tenth day (D + 10) after the transplant without any intervention."
62239795|NCT01317225|EXPERIMENTAL|17 α hydroxyprogesterone caproate|17α-Hydroxyprogesterone caproate.
62239796|NCT01317225|PLACEBO_COMPARATOR|Placebo|Saline solution.
62597347|NCT00402532|ACTIVE_COMPARATOR|Everolimus|
62430083|NCT04945161|EXPERIMENTAL|Arm A: N = 6 ON101 plus SoC|"Twelve (12) eligible subjects with DFUs will be enrolled. These 12 subjects will be randomly assigned to receive either ON101 treatment plus SoC (Arm A) or Placebo plus SoC (Arm B) for six weeks. Treatment arm allocation will be done through randomization in a double-blind fashion.~SoC will be provided from screening to the end of treatment. The SoC includes evaluation to ensure adequate arterial flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of moist wound environment via regular changing of dressings, and management of infection through oral antibiotics, if necessary."
62430084|NCT04945161|PLACEBO_COMPARATOR|Arm B: N = 6 Placebo plus SoC|"Twelve (12) eligible subjects with DFUs will be enrolled. These 12 subjects will be randomly assigned to receive either ON101 treatment plus SoC (Arm A) or Placebo plus SoC (Arm B) for six weeks. Treatment arm allocation will be done through randomization in a double-blind fashion.~SoC will be provided from screening to the end of treatment. The SoC includes evaluation to ensure adequate arterial flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of moist wound environment via regular changing of dressings, and management of infection through oral antibiotics, if necessary."
62430085|NCT04448691|OTHER|CCTA|Suspected coronary disease patients enrolled in EVINCI trial with CCTA where recalled for follow up CCTA and blood sampling
62597348|NCT00402532|ACTIVE_COMPARATOR|Mycophenolatmofetil|
62597349|NCT04887935|EXPERIMENTAL|Dapagliflozin|"* Dapagliflozin will be initiated once daily approximately 6 weeks prior to planned prostatectomy~* Dapagliflozin will be given at 10 mg by mouth once daily for 4 weeks (days 1-28) prior to prostatectomy."
62597350|NCT06648239|ACTIVE_COMPARATOR|Usual Care|Patients will proceed directly to ICA as originally referred.
62597351|NCT06648239|EXPERIMENTAL|Centralized triage with risk score-based screening for obstructive CAD|Patients originally referred for ICA will be screened for obstructive CAD with a decision support tool that uses data from their referral forms. Patients will receive either CCTA or ICA based on their predicted probability of obstructive CAD.
62597352|NCT06622382|EXPERIMENTAL|Bariatric endoscopic antral myotomy|Bariatric endoscopic antral myotomy (BEAM) is a novel endoscopic technique which is performed using a gastroscope under general anesthesia. It involves cutting the muscle fibers at the gastric antrum, thereby weakening the antral pump, delaying gastric emptying and inducing satiety.
62597353|NCT03578458|OTHER|US Healthy diet|Subjects will install a mobile app for use and will be randomly assigned to a healthy diet.
62597354|NCT03578458|OTHER|Vegetarian diet|Subjects will install a mobile app for use and will be randomly assigned to a vegetarian diet.
62815778|NCT02752022||Heavy smokers|Heavy smokers (continuous smoking of \>10 cigarettes per day) for at least 6 months who will give up smoking and switch to nicotine containing e-cigarettes for 28 days to help them quit smoking.
62239797|NCT06414915|EXPERIMENTAL|Surufatinib + tislelizumab|
62430086|NCT06527391|EXPERIMENTAL|study group|participants assigned to receive study drug
62430087|NCT06527391|PLACEBO_COMPARATOR|control group|participants assigned to receive placebo drug
62430088|NCT00529568|EXPERIMENTAL|eltrombopag|active treatment arm
62430089|NCT00529568|PLACEBO_COMPARATOR|placebo|placebo control arm
62597355|NCT03578458|OTHER|Mediterranean diet|Subjects will install a mobile app for use and will be randomly assigned to a Mediterranean diet.
62597356|NCT06618482|EXPERIMENTAL|Low back kinesiotaping|
62597357|NCT06618482|EXPERIMENTAL|Transversus abdominis Kinesiotaping|
62815779|NCT05666323|EXPERIMENTAL|Phase 1: TM1|Patients in the TM1 condition will be randomized to receive either an autonomy supportive message, or a directive motivational message.
62815780|NCT05666323|EXPERIMENTAL|Phase 1: TM+|Patients in the TM+ condition will be randomized to receive 5 text messages in scheduled succession. These messages will be either an autonomy supportive message, or a directive motivational message.
62430090|NCT06516497|EXPERIMENTAL|Group using traditional method in long bone deformity correction|20 people between the ages of 2-18. Pediatric patients with long bone deformities and surgical indications. When correcting the deformity in these patients, the current method in deformity surgery all over the world is roughly corrected and the decision is made according to clinical experience.
62430091|NCT06516497|EXPERIMENTAL|Group using computer-aided sensors in long bone deformity correction|20 people between the ages of 2-18. Pediatric patients with long bone deformities and surgical indications. A sensor designed together with engineers will be used to correct the deformity in these patients.
62430092|NCT06536790|EXPERIMENTAL|Hang clean training|Group A will perform hang clean training. Three sessions per week for twelve weeks.
62430093|NCT06536790|EXPERIMENTAL|Half squat training|Group B will perform half squat training. Three sessions per week for twelve weeks.
62597358|NCT04391738||BMI SARS-CoV-2|Patients admitted to Intensive Care Unit with SARS-CoV-2
62815781|NCT05666323|EXPERIMENTAL|Phase 2: TM1 and PN|Patients in the TM1 and PN condition will be randomized to receive either an autonomy supportive message, or a directive motivational message. Additionally, they will receive the option to talk with a Patient Navigator to receive MAPS coaching
62815782|NCT05666323|EXPERIMENTAL|Phase 2: TM1 continued|"Patients in the TM1 continued arm have the continued option to reply to the first text message in Phase 1: TM1. They do not receive any additional intervention."
62815783|NCT05666323|EXPERIMENTAL|Phase 2: TM+ and PN|Patients in the TM+ and PN condition will be randomized to receive 3 additional either autonomy supportive messages, or directive motivational messages. Additionally, they will receive the option to talk with a Patient Navigator to receive MAPS coaching
62815784|NCT05666323|EXPERIMENTAL|Phase 2: TM+ continued|Patients in TM+ continued will receive 3 additional either autonomy supportive messages, or directive motivational messages.
62815785|NCT06704425||Chronic non-specific low back pain group|"Participants with chronic non-specific low back pain (CNSLBP) should have: (1) CNSLBP that has lasted for at least 3 months, typically occurs in the area between the 12th rib to the iliac crest with and without leg pain and without a known pathoanatomical cause; (2) an average pain intensity of ≥ 5 out of 10 on an 11-point numerical rating scale (NRS) in the last 7 days, where 0 means no painand 10 means worst pain imaginable; and (3) pain occurring more than 3 days per week."
62815786|NCT06704425||Healthy group|Healthy controls should not have CNSLBP in the last 36 months.
62815787|NCT03405883||RIF (women with repeated implantation failure)|Transfer of at least 5 good quality embryos in IVF or ICSI cycles, without achieving pregnancy
62815788|NCT03405883||NF (normal fertile women)|Spontaneous conception or conception after max 9 IUI cycles
62815789|NCT00712751||1|usual care (UC) which is the standard care that patients receive
62815790|NCT00712751||2|Cancer Survivorship Intervention-Sexual Health (CSI-SH)plus Usual Care (US)
62815791|NCT05624580|EXPERIMENTAL|Single Dose 1: NNC0582-0001 10 milligram (mg)|Participants will receive a single dose of NNC0582-0001 10 mg or matching placebo injection subcutaneously.
62815792|NCT05624580|EXPERIMENTAL|Single Dose 2: NNC0582-0001 30 mg|Participants will receive a single dose of NNC0582-0001 30 mg or matching placebo injection subcutaneously.
62815793|NCT05624580|EXPERIMENTAL|Single Dose 3: NNC0582-0001 90 mg|Participants will receive a single dose of NNC0582-0001 90 mg or matching placebo injection subcutaneously.
62815794|NCT05624580|EXPERIMENTAL|Single Dose 4: NNC0582-0001 250 mg|Participants will receive a single dose of NNC0582-0001 250 mg or matching placebo injection subcutaneously.
62815795|NCT05624580|EXPERIMENTAL|Single Dose 5: NNC0582-0001 600 mg|Participants will receive a single dose of NNC0582-0001 600 mg or matching placebo injection subcutaneously.
62815796|NCT05624580|EXPERIMENTAL|Single Dose 6: NNC0582-0001 1000 mg|Participants will receive a single dose of NNC0582-0001 1000 mg or matching placebo injection subcutaneously.
62815797|NCT04734639|EXPERIMENTAL|Obese adolescents|20 adolescents with obesity are involved and will perform the three conditions.
62597359|NCT06648577||Comprehensive 2D/3D echocardiography|This an observational non interventional study. All patients will have both comprehensive 2D/3D echocardiography (including MWV imaging) and cardiac CMR.
62430094|NCT01303874|EXPERIMENTAL|Combination Therapy|Methotrexate \& Etanercept
62430095|NCT01303874|PLACEBO_COMPARATOR|Single-agent therapy|Methotrexate (MTX)
62430096|NCT04636801|EXPERIMENTAL|CHF6001 1600µg|
62597360|NCT00654875|EXPERIMENTAL|Aliskiren 300 mg (Once a Day)|Participants received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening for a total of 10 weeks.
62597361|NCT00654875|EXPERIMENTAL|Aliskiren 150 mg (Twice a Day)|Participants received Aliskiren 150 mg tablet + Placebo to Aliskiren matching 300 mg tablet daily in the morning and Aliskiren 150 mg tablet daily in the evening for the first 6 weeks then for the next 4 weeks received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening.
62815798|NCT03580512||Group 1|- 800 existing clients who already received PrEP
62815799|NCT03580512||Group 2|"* 800 new clients who present for HIV testing and are HIV-negative. All will be offered PrEP~* 600 clients who will refuse PrEP~* 200 clients who will receive PrEP"
62815800|NCT03580512||Group 3|- 400 new clients who are HIV-positive or new clients who present for HIV testing and are HIV-positive
62815801|NCT00005780|EXPERIMENTAL|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) followed by idiotype vaccine and granulocyte-macrophage colony-stimulating factor (GM-CSF).
62815802|NCT04180397|ACTIVE_COMPARATOR|Furosemide|Bolus of 5-40 mg (0.5 - 4 ml) of furosemide iv at physicians discretion followed by infusion of furosemide. Infusion rate: 0-40 mg/hour. Starting rate: 20 mg/hour. The infusion is adjusted according effect. Target is a negative fluid balance of 1 ml/kg/hour. The fluid balance is calculated 3 times a dag at 6:00 am, 2:00 pm and 10:00 pm. Goal directed fluid removal is stopped when the fluid balance is assessed neutral.
62037757|NCT01431625|ACTIVE_COMPARATOR|COPD with airway-predominant|The degree of involvement of the lung parenchyma and the airway are assessed by computed tomography. The HRCT is performed using 2-mm collimation, scan time 1.0 s, 120 kVp, and 200 mA. Images at three different levels (a cranial section is obtained 1 cm above the superior margin of the aortic arch, a middle section is taken at 1 cm below the carina, and a caudal section is taken approximately 3 cm above the top of the diaphragm) are selected and LAA% is then automatically calculated. The helical scan is performed using 120 kVp, 50 mA, 3-mm collimation, and pith 1.0. The dimensions of the right apical segmental bronchus are measured and WA% is calculated. The cut-off level between high or low WA% is the mean + 2SD of WA% of the asymptomatic non-COPD smokers.
62243459|NCT05179642||Tool OPTIM-EHPAD|"This is a randomized, cluster stepped wedge study. The cluster will be made up of coordinating physicians grouped together according to the geographical area of their EHPAD.~Residents entering EHPAD during the post-intervention inclusion period will have the optimization of their diagnostic and drug management, following a consultation between their referring physician and the coordinating physician based on the OPTIM-EHPAD method. They will constitute the intervention group.~The intervention is based on the utilization of the OPTIM-EHPAD method. It consists in training for coordinating physician and, optionally, for referring physician. It's a pedagogic tool proposing a rigorous methodology for reviewing prescriptions in chronological stages, associated with memos, constituting a form of clinical path for improving the quality and safety of prescriptions for EHPAD residents."
62597362|NCT06212271|EXPERIMENTAL|Colchicine|Colchicine (0.6 mg oral daily for 4-weeks) will be the drug administered in this study.
62815803|NCT04180397|PLACEBO_COMPARATOR|Placebo|Isotonic saline dosed the same way and by the same algorithm as for furosemide. Start bolus of 0.5-4 ml at physicians discretion. Infusion rate: 0 - 4 ml/hour. Infusion is started at 2 ml/hour and adjusted according to effect. Target is a negative fluid balance of 1 ml/kg/hour. The fluid balance is calculated 3 times a dag at 6:00 am, 2:00 pm and 10:00 pm. Goal directed fluid removal is stopped when the fluid balance is assessed neutral.
62037758|NCT03282318|EXPERIMENTAL|ASP6294|Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
62037759|NCT03282318|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
62430097|NCT04636801|EXPERIMENTAL|CHF6001 3200µg|
62430098|NCT04636801|PLACEBO_COMPARATOR|CHF6001 Placebo|
62597363|NCT06212271|PLACEBO_COMPARATOR|Placebo|This arm is a matching placebo that will be administered in the same fashion as the experimental arm.
62597364|NCT04558567|OTHER|Open-Label|
62430099|NCT03805178|EXPERIMENTAL|Rejection post-transplant|Treatment with Belatacept and Carfilzomib for subjects who show evidence of antibody-mediated rejection (AMR) following lung transplantation.
62430100|NCT03805178|EXPERIMENTAL|Pre-transplant desensitization|Treatment with Belatacept and Carfilzomib for subjects with elevated human leukocyte antigen (HLA) antibodies prior to lung transplantation.
62430101|NCT04618679||18F-FDOPA PET|Patients with HCV infection receive 18F-FDOPA PET to investigate preclinical Parkinson's disease.
62430102|NCT03956667|EXPERIMENTAL|Experimental: Live Music|Live Music will be played during the required Emergency Department procedure.
62597365|NCT04606485|PLACEBO_COMPARATOR|Placebo group|"Since acupressure administration was reported to have placebo effects, a placebo group was used to investigate the true effect of acupressure use. The application of placebo may consist of moderate pressure on an incorrect acupuncture point or a light touch on a real acupuncture point. This will allow us to determine the contribution of the placebo effect resulting from direct human contact and interaction in the light touch group.~At postoperative 0, 4, and 8 hours, a light touch was applied to the ST25 (Stomach Meridian 25th point), CV12 (Conception Vessel Meridian 12th point), TH6 (Triple Heater Meridian 6th point) and HT7 (Shenmen point points) for one second. No patients experienced pain or a feeling of pressure."
62597366|NCT04606485|EXPERIMENTAL|Experimental group|"As invasive acupuncture may cause hematoma and the wristband method of non-invasive acupressure may cause patient discomfort, itching, swelling of the wrist, and skin destruction, manual acupressure was applied in this study to reduce the risk of complications to a minimum.~The frequency and duration of the application of acupressure was decided from a scan of literature and expert opinion. The first acupressure session was applied in the first postoperative hour immediately after routine treatment and care of the patients who came to the ward from the recovery unit. Acupressure by applying pressure with the thumbs for a total of 12 mins, as 3 mins at each of the ST25, CV12, TH6 and HT7 acupuncture points, was performed at 0, 4 and 8 hours postoperatively. The acupuncture points were determined using the measurements of the patient's own fingers."
62815804|NCT04327206|EXPERIMENTAL|BCG vaccine|Participants will receive a single dose of BCG vaccine (BCG-Denmark). The adult dose of BCG vaccine is 0.1 mL injected intradermally over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the upper arm).
62037760|NCT04075500|NO_INTERVENTION|Arm 1|Control arm, 24-h Holter monitoring
62430103|NCT03956667|NO_INTERVENTION|Control: No Live Music|There will be no music played during the required Emergency Department procedure.
62430104|NCT01081483|ACTIVE_COMPARATOR|ABT-072 Tablet|ABT-072 50 mg Tablet, every day (QD), single ascending doses, groups 1-3
62430105|NCT01081483|PLACEBO_COMPARATOR|Placebo|Placebo Tablet, QD, single doses, groups 1-3
62243460|NCT06100718||Study group|Acute ischemic stroke patients at high-risk for underlying occult cancer (elevated D-dimer and suspicion of ESUS at admission)
62243461|NCT02991105||Solid organ transplant recipients|National cohort = 85,410 solid organ transplant recipients receiving their transplant between January 1st 1985 to December 31st 2015
62243462|NCT04693260|OTHER|Hand-held Device Supported by Mobile Application|Insight device ETDRS measurement compared to a standard ETDRS chart
62597367|NCT06401915||Platform tester|Participants in this group tested the proposed platform over 6 months, and their feedback were collected 8 times.
62815805|NCT04327206|PLACEBO_COMPARATOR|0.9% Saline|Participants will receive a single 0.1 mL dose of 0.9%NaCl injected intradermally over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the upper arm).
62430106|NCT01113294|EXPERIMENTAL|ablation|
62815806|NCT05414526|EXPERIMENTAL|InterCARE package|The type 2 hybrid effectiveness-implementation study will be cluster randomized trial with 1:1 paired randomization (Intervention arm vs Control arm )Using the coin flip randomization method, one clinic will be randomized to the intervention condition, and one to the control condition.
62815807|NCT03853473|NO_INTERVENTION|Standard of Care|Study participants will receive standard of care.
62815808|NCT03853473|EXPERIMENTAL|Remote Ischemic Preconditioning|Study participants will perform remote ischemic preconditioning daily, at home, from study enrollment to their date of surgery.
62815809|NCT03676842|EXPERIMENTAL|FLEX Scoring Catheter plus DCB|This is a single-arm study. All patients will be treated with the FLEX Scoring Catheter followed by an IN.PACT Admiral Drug-Coated Balloon (Medtronic Vascular; Galway, Ireland).
62815810|NCT02719535|EXPERIMENTAL|Corneal reshaping therapy|Subjects will be wearing corneal reshaping lenses for the correction of their myopia
62815811|NCT03173885|EXPERIMENTAL|PGS (genetic screening)|Intent to transfer single cryopreserved embryo, selection based on euploid status (after preimplantation genetic screening) and standard morphological assessment
62815812|NCT03173885|NO_INTERVENTION|no PGS (no genetic screening)|Intent to transfer single cryopreserved embryo, selection based on standard morphological assessment
62815813|NCT03581942|EXPERIMENTAL|Copanlisib in combination with Ibrutinib|Participants will be assigned to the following dose levels: Dose level 1: Ibrutinib 560 mg daily + Copanlisib 60 mg weekly (3w on/1w off) Dose level 2: Ibrutinib 840 mg daily + Copanlisib 60 mg weekly (3w on/1w off) Dose level -1: Ibrutinib 560 mg daily + Copanlisib 45 mg weekly (3w on/1w off). Phase II: (Simon two-stage design: 14 patients will be treated at the MTD (including 6 patients from the phaseIb portion) If at least 11 patients respond then an additional 19 patients will be accrued to the second stage. Patients in the phase II portion of the trial will receive sequential drug dosing. Patient will be treated in 28-day cycles. During one cycle, only one drug will be administered with a ibrutinib/copanlisib ratio of 1:2. Patients will receive Ibrutinib at 840 mg daily during cycle 1 (day 1 through day 28) (28-day cycles), then copanlisib 60mg weekly on day 1, 8, and 15 during cycle 2 and 3. Patients will then repeat the sequence.
62430107|NCT01452113|OTHER|neuropathy|patients with autonomic neuropathy
62430108|NCT01452113|OTHER|control|patients without autonomic neuropathy (ewing score \<= 0.5)
62597368|NCT01758107|EXPERIMENTAL|Sirolimus with Prednisolone|Sirolimus with Prednisolone, and withdraw cyclosporine
62597369|NCT01758107|NO_INTERVENTION|Sirolimus with Cyclosporine with Prednisolone|
62037761|NCT04075500|OTHER|Arm 2|Interventional arms, prolonged cardiac monitoring
62037762|NCT04016090|PLACEBO_COMPARATOR|Placebo treatment|Participant will be asked to ingest a placebo capsule.
62037763|NCT04016090|EXPERIMENTAL|Folic Acid|Participant will be asked to ingest a capsule containing 5 mg of folic acid.
62037764|NCT02043496|EXPERIMENTAL|CBT-Guided Self Help|Integrative Cognitive-Affective Therapy CBT-Guided Self Help
62243463|NCT06726928|OTHER|Intervention|Novel medical device
62430109|NCT03548207|EXPERIMENTAL|JNJ-68284528|After lymphodepletion JNJ-68284528 will be administered as a single infusion.
62430110|NCT01001871|EXPERIMENTAL|Vitamin/mineral fortificant with iron|
62430111|NCT01001871|PLACEBO_COMPARATOR|Vitamin/mineral fortificant without iron|
62430112|NCT04946422||sports injury-related injuries|"Patients who are discharged from the hospital and diagnosed in accordance with sports injury-related injuries, and those whose service item names in the detailed database contain the keyword arthroscope. Any one of the above will be included in this topic."
62430113|NCT00845754|PLACEBO_COMPARATOR|1|Placebo
62430114|NCT00845754|ACTIVE_COMPARATOR|2|Ketorolac
62430115|NCT04504929|SHAM_COMPARATOR|Sham tape|participants received sham taping during pitching, and removed after pitching
62430116|NCT04504929|EXPERIMENTAL|Dynamic tape|participants received dynamic taping during pitching, and removed after pitching
62430117|NCT00966082|ACTIVE_COMPARATOR|Endoscopic band ligation|Perform endoscopic band ligation (EBL) until eradication of esophageal varices, and then follow-up endoscopy with 3-6 months interval
62597370|NCT02290834|ACTIVE_COMPARATOR|ARM 1|"Breast cancer patients treated with chemotherapy~* Cognitive, functional and subjective assessments (Pre and Post Treatment)~* Imaging (Pre and Post Treatment)~  * Magnetic Resonance Imaging (MRI) Scan~ * Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
62430118|NCT00966082|ACTIVE_COMPARATOR|endoscopic band ligation+Propranolol|Perform endoscopic band ligation (EBL) until eradication of esophageal varices, and then follow-up endoscopy with 3-6 months interval, with propranolol
62430119|NCT00861055||Infants|Infants less than 7 days of age with clinical signs of sepsis
62430120|NCT00861055||Mothers|Mothers following antenatal care at SMRU antenatal clinic, Maela camp who are 28 - 30 weeks gestation
62597371|NCT02290834|ACTIVE_COMPARATOR|ARM 2|"Non-treated breast cancer patient control~* Cognitive, functional and subjective assessments (Post enrollment and 6-14 months later~* Imaging (Post Enrollment and at 8-14 months later)~  * Magnetic Resonance Imaging (MRI) Scan~ * Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
62597372|NCT02290834|ACTIVE_COMPARATOR|ARM 3|"Healthy control subjects~* Cognitive, functional and subjective assessments (Post enrollment and 6-14 months later~* Imaging (Post Enrollment and at 8-14 months later)~  * Magnetic Resonance Imaging (MRI) Scan~ * Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
62597373|NCT06540651|EXPERIMENTAL|Experimental group (group 1)|Luminette® with active light emission in the 400 \< X \< 750 nm spectrum
62815814|NCT05497180|EXPERIMENTAL|Passive Myofunctional Appliance|provision of passive myofunctional appliance
62815815|NCT05497180|ACTIVE_COMPARATOR|Oral Appliance Therapy|provision of mandibular advancement device
62037765|NCT02043496|EXPERIMENTAL|Integrative Cognitive-Affective Therapy|Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships
62037766|NCT02268201|EXPERIMENTAL|ADV group|Once daily
62430121|NCT04137991|EXPERIMENTAL|Nol-Guided Analgesia Group|In the Nol-Guided Analgesia Group remifentanil effect site concentration will be adapted to maintain the NOL-index between 10 and 25 throughout the anesthetic.
62430122|NCT04137991|ACTIVE_COMPARATOR|Standard Analgesia Group|Remifentanil titration in the Standard Analgesia Group will be left at the anesthesiologists discretion (i.e., guided by heart rate, blood pressure, and experience).
62430123|NCT05148130||the gestational diabetes pregnant women group|The diagnosis of GDM was established following the International Association of Diabetes and Pregnancy Study Groups (IADPSG) diagnostic criteria. GDM should be diagnosed at any time in pregnancy if one or more of the listed criteria are met following a 75-gram glucose load: fasting plasma glucose ≥5.1 mmol/l, 1-hour plasma glucose ≥10.0 mmol/l, and 2-hour plasma glucose of 8.5-11.0 mmol/l. Women diagnosed with DM or prediabetes (impaired fasting glucose or impaired glucose tolerance) before pregnancy were excluded from the study.
62430124|NCT05148130||the healthy pregnant control group|the control group was pregnant women who delivered a single fetus at full term without complications and complications during pregnancy
62430125|NCT05927805|EXPERIMENTAL|Intervention group|Eight weekly sessions of e-bibliotherapy. Participants in the intervention group will use the e-bibliotherapy app we develop, and accept e-bibliotherapy via the app.
62430126|NCT05927805|SHAM_COMPARATOR|Control group|Eight weekly sessions of self-learning of general daily living knowledge that this different from the intervention contents from the same e-bibliotherapy app.
62430127|NCT00328042|EXPERIMENTAL|Self-Management Workshop|
62597374|NCT06540651|PLACEBO_COMPARATOR|Control group (group 2)|Luminette ® with modified spectral parameters for wavelengths covered, with light emission in a spectrum of 560 \< X \< 650 nm assumed to have no therapeutic effect (placebo effect)
62430128|NCT00328042|ACTIVE_COMPARATOR|Information Only|
62597375|NCT02853669|EXPERIMENTAL|group (A) lumber plexus block|Ultrasound-guided Lumber plexus Block (30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation.
62597376|NCT02853669|EXPERIMENTAL|Group (B) adductor canal block|ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
62597377|NCT03692325|EXPERIMENTAL|Nivolumab|"* Nivolumab will be administered by IV infusion on Day 1 of each 28-day cycle~* Treatment with the study drug will continue for a maximum of 4 cycles or until unacceptable toxicity or withdrawal of consent"
62597378|NCT06455319|EXPERIMENTAL|Anti-thymocyte globulin (ATG) intravenous infusion|ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. It will be given at low doses (0.5 mg/kg Day 1 then 2 mg/kg Day 2).
62597379|NCT06455319|PLACEBO_COMPARATOR|Placebo-ATG|Saline placebo
62815816|NCT02324881|EXPERIMENTAL|Health Services Research (PMSA)|"Patients/caregivers are instructed to download the PMSA and are demonstrated how to properly use the application. Beginning on the first day of radiation therapy (day 1), patients are instructed to use the PMSA for the duration of their radiation therapy (up to day 50). The patient will fill out a satisfaction questionnaire at the completion of their treatment (Questionnaire administration). The timing of use may change depending on the availability of the app. The use of the app is classified as the telephone-based intervention per NCI."
62037767|NCT02268201|EXPERIMENTAL|PRG group|Twice daily
62037768|NCT00535730|PLACEBO_COMPARATOR|1|Placebo Comparator
62037769|NCT00535730|EXPERIMENTAL|2|vaccine
62037770|NCT03120962|EXPERIMENTAL|oxycodone|Oxycodone 20mg/day, for 4 weeks and famciclovir 500mg three-times daily for 7 days.
62597380|NCT06455319|EXPERIMENTAL|verapamil extended release capsule|Open label administration at 120, 240 or 360 mg daily based on weight and ECG findings
62597381|NCT06084715||Nutritional support group|Participants in this group will be enrolled in Benin and will receive nutritional support from the hospital where they receive care. They will be followed for 12 months.
62430129|NCT04188496|EXPERIMENTAL|PULMONARY FUNCTION TEST (PFT) GROUP|"Thoracic joint Mobilization was applied on Experimental group.~Thoracic Flexion:~Patient sits on the treatment table with arms across the chest and hands on opposite shoulders. Stand facing the patient's left side.~Thoracic Extension:~Performed by asking sits on a treatment chair with arms folded across the chest and hands on opposite shoulders.~Thoracic Segment Rotation:~Performed by asking the patient to lie on left side. Place a pillow under patient's waist to assist left side bending. Position the patient's arms are folded across the chest with hands on opposite shoulders to stabilize the shoulder girdle and minimize movement there."
62597382|NCT06084715||Standard of care group|Participants in this group will be enrolled in Togo and will not receive nutritional support from the hospital where they receive care. They will be followed for 12 months.
62597383|NCT04101916|EXPERIMENTAL|Paired Associative Stimulation|
62597384|NCT04101916|SHAM_COMPARATOR|Sham|
62815817|NCT05088564|EXPERIMENTAL|I (Hand-sewn group)|Doudenojejunal anastomosis by hand-swen method
62815818|NCT05088564|ACTIVE_COMPARATOR|II (Stapling group)|Doudenojejunal anastomosis by hemi-double-stapling method
62815819|NCT05623124||Dementia|Participants have cognitive impairment and difficulty in daily activity.
62243464|NCT05560581|EXPERIMENTAL|Intervention group|Participants will receive an one-week digital self-efficacy training (3x/day) and an one-week Ecological Momentary Assessment (3x/day questions on mood, social and virtual contacts).
62430130|NCT04188496|OTHER|Control Group|received conventional Chest physiotherapy Techniques for 30 minutes (including deep breathing, diaphragmatic breathing exercises, Self-stretching exercises for accessory respiratory muscles, Respiratory Resistance training by incentive spirometer) followed by 10 min rest.
62430131|NCT02657356|PLACEBO_COMPARATOR|Placebo capsules|Placebo capsules will be administered orally once a day for 24 weeks.
62597385|NCT02410421|EXPERIMENTAL|Individualized rTMS protocol|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 80). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The therapeutic protocol will be design to correct the rCBF anomaly first by defining each point where to deliver the stimulation than the stimulation protocol for each point (180% of active motor threshold, 4-second 10 Hz train duration, with 26-second intertrain interval for a total of 3000 pulses). The whole target will be homogeneously stimulated.~The active motor threshold will be assessed. The programmed protocol will be delivered while a figure of eight coil will be positioned by a robotic device (Axilum Robotics).~The procedure will be repeated twice a day for 10 days over 2 weeks."
62735617|NCT04860869||symptomatic post-acute sequelae SARS-CoV-2 (PASC)|Patients with post-acute sequelae SARS-CoV-2 (PASC) after COVID-19 infection
62735618|NCT04860869||non-symptomatic post-COVID|Patients with that recovered without lingering symptoms after being infected with COVID
62815820|NCT05623124||Mild cognitive impairment|Participants have cognitive impairment, but no difficulty in daily activity.
62815821|NCT05623124||cognitively normal|Participants do not have cognitive impairment.
62815822|NCT06077656|EXPERIMENTAL|Group A|Participants will receive a single 0.5mL dose of IVT PCV-25 Formulation A administered by intramuscular injection on Day 1
62815823|NCT06077656|EXPERIMENTAL|Group B|Participants will receive a single 0.5mL dose of IVT PCV-25 Formulation B administered by intramuscular injection on Day 1
62815824|NCT06077656|EXPERIMENTAL|Group C|Participants will receive a single 0.5mL dose of IVT PCV-25 Formulation C administered by intramuscular injection on Day 1
62243465|NCT05560581|ACTIVE_COMPARATOR|Control group|Participants will receive an one-week Ecological Momentary Assessment (3x/day questions on mood, social and virtual contacts).
62430132|NCT02657356|EXPERIMENTAL|Bardoxolone methyl capsules|Each patient will receive bardoxolone methyl capsules administered orally once a day for 24 weeks. Starting dosage for each patient is 5 mg and will dose-escalate to 10 mg at Week 4, unless contraindicated clinically.
62430133|NCT03178019||Euglycemia group|Normoglycemic/normotolerant subjects
62815825|NCT06077656|ACTIVE_COMPARATOR|Group D|Participants will receive a single 0.5mL dose of PCV 20 administered by intramuscular injection on Day 1
62815826|NCT01616966|ACTIVE_COMPARATOR|Sevoflurane|Anesthesia was maintained with sevoflurane during surgery.
62815827|NCT01616966|ACTIVE_COMPARATOR|Anesthesia with propofol|Anesthesia was maintained with propofol during surgery.
62815828|NCT02592031|EXPERIMENTAL|XM17|XM17 will be administered by 1 mL syringes in graduated steps of 0.01 mL.
62815829|NCT02592031|EXPERIMENTAL|Gonal-f®|Gonal-f® will be provided in pens with integrated vials of 0.5 mL
62815830|NCT02592031|ACTIVE_COMPARATOR|Zoladex®|Zoladex® 3.6 mg will be administered by subcutaneous injection
62815831|NCT06526494|EXPERIMENTAL|Metformin|Participants will receive metformin 850 mg PO once a day for 2 weeks. After 2 weeks, participants will receive metformin 1700 mg PO once a day for the remaining 10 weeks.
62430134|NCT03178019||Prediabetes group|Subjects with prediabetes
62815832|NCT06526494|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
62815833|NCT04912583|ACTIVE_COMPARATOR|High tidal volume|A high tidal volume (14-16 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
62430135|NCT03178019||Diabetes group|Subjects with type 2 diabetes mellitus
62430136|NCT03570580||Main Group - OSA Scoring|All patients include in this study for whom the four OSA scoring will be evaluated
62430137|NCT01807962|ACTIVE_COMPARATOR|rapidocain and bethametsaone|"Rapidocain and Bethametsaone :~Lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine Bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de bétaméthasone and 2mg/ml phosphate disodique de bétaméthasone)"
62430138|NCT01807962|PLACEBO_COMPARATOR|sterile saline|Placebo arm with 5ml of sterile saline (NaCl) solution
62430139|NCT00950599|EXPERIMENTAL|Saxagliptin (2.5 mg)|
62430140|NCT00950599|EXPERIMENTAL|Saxagliptin (5 mg)|
62430141|NCT00950599|EXPERIMENTAL|Saxagliptin (10 mg)|
62430142|NCT00950599|EXPERIMENTAL|Saxagliptin (20 mg)|
62430143|NCT00950599|EXPERIMENTAL|Saxagliptin (40 mg)|
62815834|NCT04912583|ACTIVE_COMPARATOR|Low tidal volume|A low tidal volume (8-10 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
62815835|NCT02988297|EXPERIMENTAL|RNS60|Nebulized RNS60 will be administered by daily inhalation for 24 weeks.
62815836|NCT02988297|PLACEBO_COMPARATOR|Placebo|Nebulized Placebo will be administered by daily inhalation for 24 weeks.
62815837|NCT02182895|EXPERIMENTAL|Saxagliptin group|DPP4 inhibitor therapy group will receive saxagliptin 2.5 to 5 mg daily in addition to correctional sliding scale insulin therapy before each meal and bedtime.
62430144|NCT00950599|EXPERIMENTAL|Saxagliptin (100 mg)|
62735619|NCT06004713||Cohort A|Patients will initially receive monotherapy PD1/PDL1 monoclonal antibody therapy.
62815838|NCT02182895|NO_INTERVENTION|Standard therapy group|Standard therapy group will receive basal-bolus insulin starting at a dose of 0.5 units/kg/day; given half as insulin glargine and half as insulin aspart. In addition, the standard therapy group will receive the correctional sliding scale insulin therapy before each meal and bedtime.
62815839|NCT06560203|EXPERIMENTAL|mechanical thrombectomy group|Researchers can choose to deal with the stenosis or occlusion of blood vessels according to their own judgment, including stent thrombectomy, thrombus aspiration, balloon angioplasty, stent replacement, intra-arterial thrombolysis or various combinations of these methods.
62815840|NCT06560203|NO_INTERVENTION|best medical management agroup|Best Medical Treatment and maximum supportive care according to local guidelines, not including mechanical thrombectomy, no intra-arterial treatment.
62815841|NCT05795179|EXPERIMENTAL|Physiological Stress|Healthy dieters will undergo a single-visit neuroimaging study where they will first complete demographic and self-report measures followed by a self-control decision task in an fMRI scanner. Prior to scanning, participants will be assigned to a physiological stress group and complete the corresponding stress task. For the physiological stress group, this task is the Cold-Pressor Task (CPT), a physiological stress task in which participants continuously submerge their hand and forearm in ice-water (0-4°C) for 3 minutes. After the scan, participants will wait for 1 hour in an adjacent study room where they will play out one trial of the decision-making task completed in the scanner.
62815842|NCT05795179|EXPERIMENTAL|Social Stress|Healthy dieters will undergo a single-visit neuroimaging study where they will first complete demographic and self-report measures followed by a self-control decision task in an fMRI scanner. Prior to scanning, participants will be assigned to the social stress group and complete the corresponding stress task. For the social stress group, this task is the Trier Social Stress Test (TSST), a psychosocial stressor that requires participants perform a short speech and solve math problems in front of 2 evaluative judges. After the scan, participants will wait for 1 hour in an adjacent study room where they will play out one trial of the decision-making task completed in the scanner.
62815843|NCT05795179|ACTIVE_COMPARATOR|Physiological Non-Stress|Healthy dieters will undergo a single-visit neuroimaging study where they will first complete demographic and self-report measures followed by a self-control decision task in an fMRI scanner. Prior to scanning, participants will be assigned to the physiological non-stress group and complete the corresponding stress task. For the physiological non-stress group, participants will continuously submerge their hand and forearm in warm water for 3 minutes. After the scan, participants will wait for 1 hour in an adjacent study room where they will play out one trial of the decision-making task completed in the scanner.
62037771|NCT03120962|ACTIVE_COMPARATOR|standard treatment|Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day (whichever is lower), for 4-12 weeks and famciclovir 500mg three-times daily for 7 days.
62735620|NCT06004713||Cohort B|Patients will initially receive dual blockade of both PD1/PDL1 and CTLA4
62735621|NCT06004713||Cohort C|Patients will initially receive PD1/PDL1 monoclonal antibody combined with chemotherapy or targeted therapy.
62037772|NCT01843426|EXPERIMENTAL|Low-volume, Low-concentration contrast (Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
62037773|NCT03876080|EXPERIMENTAL|Dry needling|Dry needling intervention to the gastrocnemius muscle trigger point
62430145|NCT00950599|PLACEBO_COMPARATOR|Placebo|
62430146|NCT05485688||Sleep apnea|60 moderate-to-severe OSA patients (AHI≧15/hour, 30 obese \[BMI\>=27\] \& 30 non-obese \[BMI\<27\])
62430147|NCT05485688||Control|40 age-, gender-, BMI-matched controls without OSA.
62430148|NCT01448265|EXPERIMENTAL|Paroxysmal atrial fibrillation.|
62430149|NCT05424107|EXPERIMENTAL|Non-nutritional intervention|Children with a prediabetic status that followed up the sessions without nutritional intervention by a health care professional
62430150|NCT00945152|EXPERIMENTAL|Drug Vancogel,Treatment,Kill MRSA,Heal|Treatment of open wounds with Vancogel(R) 1.25-1.50% to eliminate MRSA. End point is: a negative culture report after 1-3 topical applications. The infected wounds with MRSA will be treated with the Vancomycin 1.25 to 1.50% complex gel formulation and will have conventional management in order to heal the wound. Vancogel is anticipated to accelerate wound healing by eliminating MRSA. A randomized, double blind study protocol approved by FDA.
62430151|NCT00945152|PLACEBO_COMPARATOR|Placebo|Half of the patients in the study will be given a placebo consisting of all ingredients in Vancogel except the active principal Vancomycin in order to compare their clinical efficacy in rate of wound healingafter 1-3 applications
62430152|NCT04596930|EXPERIMENTAL|LITT arm|Patients will be randomized to receive biopsy and LITT (n=10)
62430153|NCT02301780|PLACEBO_COMPARATOR|Control Group|Placebo
62430154|NCT02301780|ACTIVE_COMPARATOR|Intervention Group|Aspirin
62597386|NCT02410421|ACTIVE_COMPARATOR|High frequency rTMS as usual|"rTMS will be performed as usual using a figure-eight coil: Defining the active motor threshold. For each session positioning the coil 5 cm ahead of the abductor pollicis brevis muscle, stimulating at 180% of active motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session), twice a day for 10 days over 2 weeks.~Coil and stimulator will remain the same between individualized and as usual proceedures."
62597387|NCT02410421|ACTIVE_COMPARATOR|Trans-cranial direct current stimulation (tDCS)|tDCS will be performed as usual: After controlling for skin healthiness, the anode and the cathode will be respectively placed over F3 and F4. A commercial devices (MagStim), will deliver a constant current of 2 mA through 25 cm2 saline-soaked rubber sponges for 20 min per session. The procedure will be repeated twice a day for 10 days over 2 weeks.
62597388|NCT01639066|EXPERIMENTAL|Tenofovir plus Entecavir combination|Tenofovir 300 mg/day orally and Entecavir 1 mg/day orally
62597389|NCT01639066|ACTIVE_COMPARATOR|Tenofovir monotherapy|Tenofovir 300 mg/day orally
62597390|NCT04277650|ACTIVE_COMPARATOR|Once weekly clinical evaluation|Outpatient participants evaluated as high risk by the machine learning algorithm and provided once weekly clinical evaluations
62239798|NCT06267157|EXPERIMENTAL|virtual reality training|Data Collection Forms will be administered face to face to nursing students before training. LactaVerse will be introduced to the students in the experimental group. After the introduction and information are given, virtual reality glasses, lenses and pupil distances will be adjusted and placed on their heads. Each student will be given a disposable goggle mask. Students will then be asked to use their devices in a virtual environment; In the first breastfeeding room, the patient will be asked to touch the entire anatomy, including the breast tissue, ductus, and areola, and examine every angle with the finger. In the next stage; The patient will be asked to go to the second breastfeeding room and assist the mother and baby there. In this room, the student will be expected to complete the skill steps without skipping. He/she will not be able to proceed to the next application without making the correct application.
62239799|NCT06267157|OTHER|theoretical breastfeeding training|This group will receive 2 hours of theoretical breastfeeding training. Model dolls and breasts will be used in theoretical education by applying the classical education model. Entrance Data Collection Form, Breastfeeding Information Form, Basic Empathy Level Scale, Nursing Counseling Skills Scale and Presence Scale will be applied to the students whose informed consent form has been obtained.
62597391|NCT04277650|EXPERIMENTAL|Twice weekly clinical evaluation|Outpatient participants evaluated as high risk by the machine learning algorithm and provided twice weekly clinical evaluations
62597392|NCT05883293|EXPERIMENTAL|Experimental group|"Case Inclusion Criteria:~1. Patients who sign the informed consent form.~2. Age 30\~80 years old, gender is not limited.~3. Patients with pulmonary fibrosis who have obvious pulmonary fibrosis symptoms, signs, and HRCT abnormalities, and are diagnosed as pulmonary fibrosis patients specified in this protocol, and have poor effect of existing treatment regimens or do not accept existing treatment regimens~Clinical basis for diagnosis of pulmonary fibrosis:~1. Abnormal pulmonary function, including restrictive ventilatory dysfunction and gas exchange disorder;~2. Typical fibrotic manifestations on HRCT: such as interstitial changes, grid-like changes or honeycomb lungs;"
62597393|NCT05913206|NO_INTERVENTION|Control|No new communication approaches received.
62597394|NCT05913206|EXPERIMENTAL|Ambiguity only|Receive information about ambiguity related to the clinical decision.
62815844|NCT05795179|ACTIVE_COMPARATOR|Social Non-Stress|Healthy dieters will undergo a single-visit neuroimaging study where they will first complete demographic and self-report measures followed by a self-control decision task in an fMRI scanner. Prior to scanning, participants will be assigned to the social stress group and complete the corresponding stress task. For the social non-stress group, participants will be asked to prepare for a speech that they will practice alone to themselves and complete math problems alone on a piece of scrap paper. After the scan, participants will wait for 1 hour in an adjacent study room where they will play out one trial of the decision-making task completed in the scanner.
62239800|NCT04118296|EXPERIMENTAL|Intervention|Intervention will be given in the form of the use of anti-acne combination creams that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%
62430155|NCT03473470|NO_INTERVENTION|not warmed|Not warming system
62430156|NCT03473470|ACTIVE_COMPARATOR|warmed group 1|forced air warming and warmed intravenous fluids
62430157|NCT03473470|ACTIVE_COMPARATOR|warmed group 2|warmed intravenous fluids
62430158|NCT04097119|OTHER|Dietary supplement arm|Subjects to receive a specific dietary supplement
62430159|NCT02001870|EXPERIMENTAL|In Vitro Fecundation (IVF)|Couples will be treated by In Vitro Fecundation (IVF)
62597395|NCT05913206|EXPERIMENTAL|Ambiguity and complexity only|Receive information about ambiguity and complexity related to the clinical decision.
62597396|NCT05913206|EXPERIMENTAL|Ambiguity and normalizing only|Receive information about ambiguity and normalizing language related to the clinical decision.
62597397|NCT05913206|EXPERIMENTAL|Ambiguity, complexity, and normalizing only|Receive information about ambiguity, complexity, and normalizing language related to the clinical decision.
62597398|NCT05913206|EXPERIMENTAL|Complexity only|Receive information about complexity related to the clinical decision.
62597399|NCT05913206|EXPERIMENTAL|Complexity and normalizing only|Receive information about complexity and normalizing language related to the clinical decision.
62597400|NCT05913206|EXPERIMENTAL|Normalizing only|Receive information about normalizing language related to the clinical decision.
62597401|NCT05913206|EXPERIMENTAL|Narratives only|Receive narratives in addition to the control condition.
62037774|NCT03876080|SHAM_COMPARATOR|Sham needling|Sham dry needling intervention to the gastrocnemius muscle trigger point
62037775|NCT03254680|EXPERIMENTAL|Turmeric Oil|stable dose of orally administered turmeric oil
62430160|NCT02001870|ACTIVE_COMPARATOR|Intra Uterine Insemination (IUI)|Couples will be treated by Intra Uterine Insemination (IUI)
62430161|NCT00606801|ACTIVE_COMPARATOR|Galantamine 8 mg/day|Galantamine 8 mg/day
62430162|NCT00606801|PLACEBO_COMPARATOR|Placebo|placebo
62430163|NCT01037101|ACTIVE_COMPARATOR|IVET+DCS|
62430164|NCT01037101|EXPERIMENTAL|VRET+DCS|
62430165|NCT01037101|EXPERIMENTAL|VRET+Placebo|
62430166|NCT01037101|ACTIVE_COMPARATOR|IVET+Placebo|
62430167|NCT01037101|NO_INTERVENTION|Wait-List|3 weeks Wait-List
62239801|NCT04042558|EXPERIMENTAL|Cohort with Bevacizumab|"4 cycles of induction every 3 weeks with :~* Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route~* Pemetrexed 500 mg/m² per IV route~* Atezolizumab 1200 mg per IV route~* Bevacizumab 15 mg/kg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed and Bevacizumab administered at the same dosage on 3-week cycles"
62239802|NCT04042558|EXPERIMENTAL|Cohort without Bevacizumab|"4 cycles of induction every 3 weeks with :~* Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route~* Pemetrexed 500 mg/m² per IV route~* Atezolizumab 1200 mg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed administered at the same dosage on 3-week cycles"
62239803|NCT01039025|EXPERIMENTAL|TMC|Topotecan, Melphalan, and Cyclophosphamide
62239804|NCT01277770||Kidney Transplant Recipients|Kidney Transplant Recipients at the University of Minnesota since 1984. The study looks at a 10 year followup of steroid-free maintenance immunosuppression, post-transplant infections and evaluation of the DGF nomogram in Thymoglobulin on patients at the University of Minnesota.
62239805|NCT03478163|NO_INTERVENTION|Control|The patient will not receive antibiotics as part of the study, though if at any time her provider chooses to administer antibiotics either prophylactically or for treatment she will not prohibited in any way from this or any other treatment as appropriate.
62239806|NCT03478163|EXPERIMENTAL|Antibiotics|The patient will receive a 24-hour course of antibiotics. The primary antibiotic of choice will be cefazolin 1 gm iv q8 hours. If the patient has contraindications to the use of cefazolin including cefazolin allergy, hypersensitivity, or severe beta lactam allergy, then clindamycin 900 mg iv q8 hours will be used instead.
62239807|NCT01615653|ACTIVE_COMPARATOR|EUS 1|
62815845|NCT05953545|EXPERIMENTAL|Peginterferon Lambda|A weekly subcutaneous injection of peginterferon lambda at a dose of 180 mcg and an oral twice daily dosing of Lonafarnib at 50mg boosted with twice daily Ritonavir at 100mg for 48 weeks. Following 48 weeks of treatment the subjects will be monitored for outcomes during an additional 6-month time period.
62815846|NCT01258543||Non-specific back pain|
62815847|NCT03732573|EXPERIMENTAL|Intervention Group|This group will receive 9 text messages over 3 weeks. Messages will be based on goal-setting in the first week, goal-operating in the second week, and self-monitoring in the third week.
62037776|NCT06724757||Caregiver|Caregivers aged 50 years old and older living in Quebec
62239808|NCT01615653|ACTIVE_COMPARATOR|EUS 2|
62239809|NCT04830956|EXPERIMENTAL|Sequence 1|FID123238 in 4 specification levels (minimum, moderate, moderate plus, maximum) and Systane hydration applied to the ocular surface in 1 of 5 randomized sequences. 1 application per product.
62239810|NCT04830956|EXPERIMENTAL|Sequence 2|FID123238 in 4 specification levels (minimum, moderate, moderate plus, maximum) and Systane hydration applied to the ocular surface in 1 of 5 randomized sequences. 1 application per product.
62239811|NCT04830956|EXPERIMENTAL|Sequence 3|FID123238 in 4 specification levels (minimum, moderate, moderate plus, maximum) and Systane hydration applied to the ocular surface in 1 of 5 randomized sequences. 1 application per product.
62815848|NCT03732573|NO_INTERVENTION|Control Group|Participants in this group will receive no messages during the intervention period.
62815849|NCT04827368||Crohns Disease|Potential participants will be identified based on their planned/scheduled endoscopy visit.
62239812|NCT04830956|EXPERIMENTAL|Sequence 4|FID123238 in 4 specification levels (minimum, moderate, moderate plus, maximum) and Systane hydration applied to the ocular surface in 1 of 5 randomized sequences. 1 application per product.
62815850|NCT04827368||Ulcerative Colitis|Potential participants will be identified based on their planned/scheduled endoscopy visit.
62815851|NCT04827368||Non-IBD|Healthy subjects with no bowel disorders will be included as controls.
62815852|NCT02060721|EXPERIMENTAL|Macitentan|Macitentan 10mg, oral tablet, once daily
62815853|NCT01097668|EXPERIMENTAL|Intradermal injection|Injections will be given by the intradermal route
62815854|NCT01097668|EXPERIMENTAL|Subcutaneous injection|Injections will be given by the subcutaneous route
62815855|NCT05443191||Semaglutide|Participants with type 2 diabetes and naive to injectable glucose-lowering treatment.
62037777|NCT02423512||Anti-TNF Exposure|Inflammatory Bowel Disease (IBD) patients scheduled to start vedolizumab therapy who have been previously exposed to anti-TNF therapy
62037778|NCT02423512||anti-TNF Naive|IBD patients scheduled to start vedolizumab therapy who have not been previously exposed to anti-TNF therapy
62597402|NCT05913206|EXPERIMENTAL|Ambiguity and narratives only|Receive information about ambiguity and narratives related to the clinical decision.
62037779|NCT01099904|EXPERIMENTAL|1|Normal Renal Function
62037780|NCT01099904|EXPERIMENTAL|2|Mild Renal Impairment
62037781|NCT01099904|EXPERIMENTAL|3|Moderate Renal Impairment
62239813|NCT04830956|EXPERIMENTAL|Sequence 5|FID123238 in 4 specification levels (minimum, moderate, moderate plus, maximum) and Systane hydration applied to the ocular surface in 1 of 5 randomized sequences. 1 application per product.
62239814|NCT05356117|EXPERIMENTAL|Resistance Training (RT) and Protein Supplementation (PS)|"Participants will be randomly assigned to the Resistance Training (RT) and Protein Supplementation (PS) group and receive virtually (Zoom) supervised home-based exercise program 3-days a week with daily protein supplementation for the duration of their chemotherapy with a maximum of 16-weeks of exercise. Exercises will be tailored to the participants' fitness levels.~Sessions will last \~60 minutes including 5-minute warm-up and 5-minute cool-down.~Participants will also have two body composition scans using CT over the span of chemotherapy treatment (maximum 16 weeks) and approximately 3 hours of evaluation of testing on 3 occasions."
62239815|NCT05356117|EXPERIMENTAL|Resistance Training (RT)|"Participants will be randomly assigned to the Resistance Training (RT) group and receive virtually (Zoom) supervised home-based exercise program 3-days a week. Exercises will be tailored to the participants' fitness levels.~Participants will also have two body composition scans using CT over the span of chemotherapy treatment (maximum 16 weeks) and approximately 3 hours of evaluation of testing on 3 occasions."
62597403|NCT05913206|EXPERIMENTAL|Ambiguity, complexity, and narratives only|Receive information about ambiguity, complexity, and narratives related to the clinical decision.
62597404|NCT05913206|EXPERIMENTAL|Ambiguity, normalizing, and narratives only|Receive information about ambiguity, normalizing language, and narratives related to the clinical decision.
62597405|NCT05913206|EXPERIMENTAL|All|Receive all new communication approaches
62815856|NCT01809938|ACTIVE_COMPARATOR|Black Tea|
62815857|NCT01809938|ACTIVE_COMPARATOR|Tea with Milk|
62815858|NCT06114238|EXPERIMENTAL|Cohort 1|Itepekimab administered via AI
62815859|NCT06114238|ACTIVE_COMPARATOR|Cohort 2|Itepekimab administered via PFS
62815860|NCT00287898|EXPERIMENTAL|Telephone Genetic Counseling|Participants randomized to this arm will receive all genetic counseling via telephone.
62815861|NCT00287898|ACTIVE_COMPARATOR|Usual Care|Participants randomized to usual care will receive standard in-person genetic counseling.
62815862|NCT00654667|PLACEBO_COMPARATOR|2|Placebo
62815863|NCT00654667|EXPERIMENTAL|Experimental 1|Resveratrol
62597406|NCT05913206|EXPERIMENTAL|Complexity and narratives only|Receive information about complexity and narratives related to the clinical decision.
62239816|NCT05356117|ACTIVE_COMPARATOR|Attention Control (AC)|"Participants will be randomly assigned to the Attention Control (AC) group and receive instruction on a home-based, 3 days a week stretching program.~Participants will also have two body composition scans using CT over the span of chemotherapy treatment (maximum 16 weeks) and approximately 3 hours of evaluation of testing on 3 occasions.~The attention control group will be given the option to participate in the exercise intervention after their treatment is completed, with a cap of a 16-week period."
62239817|NCT05989607|EXPERIMENTAL|Low Sugar Flavored Water|A commercially available low sugar flavored water (2.88kcal/100ml; 0.57(sugar) +0.03 (stevia)=0.60g/100ml; sodium 7.9mg/100ml).
62239818|NCT05989607|ACTIVE_COMPARATOR|Plain Water|Plain water (bottled, spring).
62239819|NCT02407522|EXPERIMENTAL|black rice group|Each subject in the experimental group will be provided with black rice (50 g/day).According to the clinical requirements, no specific rules are needed for other treatments of the two groups.
62815864|NCT05334732|EXPERIMENTAL|Sisters Informing Sisters Sessions|The intervention is peer-based and in concert with our theoretical model, builds upon positive role-modeling of the survivor coach to the patient, addresses behavioral expectations/capacities, and uses Motivational Interviewing (MI) techniques. The intervention includes a culturally relevant coach's manual and a patient workbook that will be used to facilitate the coaching sessions.
62815865|NCT05334732|NO_INTERVENTION|Enhanced Usual Care|Women in the EUC arm will receive usual care that includes standardized information in the public domain (NCI treatment information booklet). This booklet was chosen to provide women with national-level recommendations regarding treatment recommendations.
62239820|NCT02407522|PLACEBO_COMPARATOR|white rice group|individuals in the control group will be subjected to follow-up. According to the clinical requirements, no specific rules are needed for other treatments of the two groups.
62239821|NCT06140212||Decline ICOPE group|The elderly individuals who have at least one impairment in ICOPE screening domains.
62239822|NCT06140212||Non-decline ICOPE group|The elderly individuals who do not have any impairment in ICOPE screening domains.
62239823|NCT04793269||Long COVID|Patients with long COVID syndrome
62430168|NCT03598452|EXPERIMENTAL|High dose of ganciclovir group|IVG was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
62430169|NCT02593734|NO_INTERVENTION|Control|No intervention
62239824|NCT00781820|PLACEBO_COMPARATOR|Arm 2|
62239825|NCT00781820|EXPERIMENTAL|Arm 1|
62239826|NCT01910233||adult patients with acute dyspnea in ED|
62239827|NCT05055414|EXPERIMENTAL|UI030|UI030 (Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days) or placebo for 2 weeks.
62239828|NCT05055414|PLACEBO_COMPARATOR|Placebo|UI030 (Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days) or placebo for 2 weeks.
62430170|NCT02593734|EXPERIMENTAL|Experimental|The intervention is prescription and dispensing by a nurse of oral antipsychotic or antidepressant medication as clinically indicated. The mediations to be selected from include oral olanzapine, risperidone, amitryptaline or fluoxetine at doses prescribed by the treating psychiatrist.
62597407|NCT05913206|EXPERIMENTAL|Complexity, normalizing, and narratives only|Receive information about complexity, normalizing language, and narratives related to the clinical decision.
62597408|NCT05913206|EXPERIMENTAL|Normalizing and narratives only|Receive information about normalizing language and narratives related to the clinical decision.
62597409|NCT02289547|NO_INTERVENTION|Group A|observational arm
62430171|NCT06327477|EXPERIMENTAL|Treatment (P-SFRT, IG-IMRT)|Patients undergo P-SFRT over 1 fraction and then undergo IG-IMRT over 25-28 fractions for 35 to 42 days. Patients undergo surgical resection 21 to 35 days after radiation therapy. Patients undergo blood sample collection during screening and on study. Patients also undergo biopsy during screening and CT on study and on follow up.
62815866|NCT05036252||Participants with HER2-positive breast cancer|Participants with HER2-positive breast cancer who have developed mild cardiotoxicity during HER2-targeted therapy, defined by a decline in LVEF \> 10% to \< 53% without symptoms of clinical heart failure (NYHA class III or IV), will be eligible for participation in this study.
62815867|NCT06244433||SUDI cases|Sudden unexpected death in infant (SUDI) cases registered within the French National Registry of SUDI
62239829|NCT04433351|EXPERIMENTAL|SE cohort|Patients in the SE cohort will carry out first the simple rehabilitation protocol (S, 4 weeks) followed by enriched rehabilitation (E, 4 weeks).
62037782|NCT04729322|EXPERIMENTAL|Arm I (FMT, pembrolizumab)|"Patients receive metronidazole PO Q8H on days -14 to -8 and then vancomycin PO Q6H and neomycin PO Q6H on days -8 to -6. Patients then undergo colonoscopic FMT on day -5.~POST-COLONOSCOPIC FMT: Patients receive standard of care pembrolizumab IV over 30 minutes on day 1. Patients also receive fecal microbiota transplantation capsule PO on days 1, 8, and 15 of cycle 1. Beginning in cycle 2, patients receive fecal microbiota transplantation capsule PO on day 1. Cycles repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity."
62239830|NCT04433351|EXPERIMENTAL|ES cohort|Patients in the ES cohort will carry out first the enriched rehabilitation protocol (E, 4 weeks) followed by simple rehabilitation (S, 4 weeks).
62430172|NCT04682431|EXPERIMENTAL|Part A: PY159 Single agent dose level 1|PY159 dose level 1 IV administration, Q3 weekly until consent withdrawal, intolerable toxicity or investigator decision.
62430173|NCT04682431|EXPERIMENTAL|Part A: PY159 Single agent dose level 2|PY159 dose level 2
62430174|NCT04682431|EXPERIMENTAL|Part A: PY159 single agent dose level 3|PY159 dose level 3
62430175|NCT04682431|EXPERIMENTAL|Part A: PY159 single agent dose level 4|PY159 dose level 4
62430176|NCT04682431|EXPERIMENTAL|Part A: PY159 single agent dose level 5|PY159 dose level 5
62430177|NCT04682431|EXPERIMENTAL|Part A: PY159 single agent dose level 6|PY159 dose level 6
62430178|NCT04682431|EXPERIMENTAL|Part A: PY159 single agent dose level 7|PY159 dose level 7
62430179|NCT04682431|EXPERIMENTAL|Part A: PY159/Pembrolizumab Combination dose level 1|PY159 dose level 1 in combination with pembrolizumab
62430180|NCT04682431|EXPERIMENTAL|Part A: PY159/Pembrolizumab Combination dose level 2|PY159 dose level 2 in combination with pembrolizumab
62430181|NCT04682431|EXPERIMENTAL|Part A: PY159/Pembrolizumab Combination dose level 3|PY159 dose level 3 in combination with pembrolizumab
62430182|NCT04682431|EXPERIMENTAL|Part A: PY159/Pembrolizumab Combination dose level 4|PY159 dose level 4 in combination with pembrolizumab
62239831|NCT01685190|ACTIVE_COMPARATOR|Prostate Alone IMRT|Participants will receive standard prostate Intensity Modulated Radiotherapy (IMRT) of 74Gy in 37 fractions delivered over 7.5 weeks.
62239832|NCT01685190|EXPERIMENTAL|Prostate & Pelvis IMRT|Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
62430183|NCT04682431|EXPERIMENTAL|PY159 Part B: Single agent dose expansion cohort(s)|PY159 Single agent dose expansion cohort(s)
62430184|NCT04682431|EXPERIMENTAL|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 1|PY159 in combination with pembrolizumab dose expansion cohort 1 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
62430185|NCT04682431|EXPERIMENTAL|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 2|PY159 in combination with pembrolizumab dose expansion cohort 2 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
62430186|NCT04682431|EXPERIMENTAL|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 3|PY159 in combination with pembrolizumab dose expansion cohort 3 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
62430187|NCT04682431|EXPERIMENTAL|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 4|PY159 in combination with pembrolizumab dose expansion cohort 4 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
62597410|NCT02289547|EXPERIMENTAL|Group B|arm of capecitabine maintenance treatment
62735622|NCT06004713||Cohort D|Patients will receive other standard treatments for this tumor other than ICIs.
62239833|NCT05231486|EXPERIMENTAL|Cognitive Orientation to daily Occupational Performance 1|"This arm is the first group composed of four childrens who will do the CO-OP. CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas.~The four patients will begin the sessions one week apart each."
62239834|NCT05231486|EXPERIMENTAL|Cognitive Orientation to daily Occupational Performance 2|"This arm is the second group composed of four others childrens who will do the CO-OP.~CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas The four patients will begin the sessions one week apart each."
62430188|NCT04682431|EXPERIMENTAL|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 5|PY159 in combination with pembrolizumab dose expansion cohort 5 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
62430189|NCT04682431|EXPERIMENTAL|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 6|PY159 in combination with pembrolizumab dose expansion cohort 6 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
62430190|NCT00595387|ACTIVE_COMPARATOR|1|Participants receiving supportive psychotherapy
62430191|NCT00595387|EXPERIMENTAL|2|Participants receiving cognitive behavioral therapy
62430192|NCT04725565|EXPERIMENTAL|Genetics ADviSER Decision Aid Plus Standard Genetic Counselling|Participants in the intervention arm will use the Genetics ADviSER to learn about genomic sequencing and to select which results they would like to receive from genomics sequencing results. After using the Genetics ADviSER decision aid they will speak with genetic counselor to discuss their choices and to finalized their selection.
62597411|NCT03721835|OTHER|Control femoral neck fracture system|This is a single arm study of subjects who are to be implanted with the CONQUEST FN™Femoral Neck Fracture System for treatment of a trauma related femoral neck fracture
62597412|NCT03087422|EXPERIMENTAL|intervention|"The patients in this group will receive daily a text message (SMS) with some orientation about Homecare as an attempt to minimize the side effects of chemotherapy.~The text messages are based on oncology guidelines.The text messages contain information about water intake, emotional support, hygiene, immunity, nutrition, and physical activity. In addition, text messages about prevention and management of symptoms were also developed: nausea and vomiting, diarrhea, constipation, gas, changes in the skin and taste.~Also, the patients allocated in this group will receive the standard care."
62597413|NCT03087422|NO_INTERVENTION|control|The patients allocated in this group will receive the standard care.
62735623|NCT05260138|EXPERIMENTAL|The intervention group|received all basic routine care in addition to regular position change and gentle body massage
62815868|NCT06244433||Parents|Both parents of identified SUDI
62815869|NCT03662867|EXPERIMENTAL|Family-based mindfulness intervention|Family-based mindfulness intervention is a parallel-group intervention containing one parent program and one child program. The parent mindfulness program lasts for 6 weeks, one session per week, and each session lasts for 1.5 hours. The child mindfulness program lasts for 8 weeks, one session per week, and each session lasts for 1 hour. In the fourth and sixth sessions of the parent program, 30-minute joint practice of parents and children is incorporated. All sessions are implemented by qualified instructors.
62815870|NCT03662867|OTHER|Wait-list control|Intervention group participants were assessed at baseline (T1) and after the intervention (T2). Control group participants were assessed at the same time with the intervention group, and would receive the same program after posttest of intervention groups.
62815871|NCT06510374|EXPERIMENTAL|Arm 1 Nadofaragene Firadenovec|Participants in the nadofaragene firadenovec arm will receive quarterly instillations with nadofaragene firadenovec for 24 months. For these subjects, the disease evaluation visits will occur within 2 weeks prior to the investigation medicinal products instillation visits.
62815872|NCT06510374|NO_INTERVENTION|Arm 2 - Observation|"Subjects will be followed based on the surveillance schedule of the AUA/SUO guideline (quarterly) over the 24 months treatment period.~."
62815873|NCT05200143|EXPERIMENTAL|Cabozantinib + Ipilimumab + Nivolumab|Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg IV every 3 weeks + Cabozantinib 40 mg PO daily for 4 cycles followed by Nivolumab 480 mg IV every 4 weeks + Cabozantinib 40 mg PO daily for up to 24 months.
62815874|NCT05509595|EXPERIMENTAL|Treatment|Patients receiving treatment
62815875|NCT03859024|ACTIVE_COMPARATOR|Standard Protocol|Patients will receive the historical standard for pain management, which may include narcotics during and after surgery. Postoperative prescriptions ibuprofen 800 mg, and acetaminophen 1000 mg to be taken on a scheduled basis then as needed. Another prescription for oxycodone will be given to be used only if needed.
62239835|NCT05231486|EXPERIMENTAL|Cognitive Orientation to daily Occupational Performance 3|"This arm is the third group composed of four others childrens who will do the CO-OP.~CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas The four patients will begin the sessions one week apart each."
62430193|NCT04725565|ACTIVE_COMPARATOR|Standard Genetic Counselling Only|Participants will speak with a genetic counsellor over the phone to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing.
62430194|NCT03521544|EXPERIMENTAL|Plantar Fascia|Self-myofascial release in the plantar fascia.
62430195|NCT03521544|EXPERIMENTAL|Tricep surae fascia|Self-myofascial release in the triceps surae fascia.
62430196|NCT03521544|EXPERIMENTAL|Hamstrings fascia|Self-myofascial release in the hamstrings fascia.
62430197|NCT03521544|EXPERIMENTAL|Spine erectors and lumbar fascia|Self-myofascial release in the spine erectors and lumbar fascia.
62037783|NCT04729322|EXPERIMENTAL|Arm II (FMT, nivolumab)|"Patients receive metronidazole PO Q8H on days -14 to -8 and then vancomycin PO Q6H and neomycin PO Q6H on days -8 to -6. Patients then undergo colonoscopic FMT on day -5.~POST-COLONOSCOPIC FMT: Patients receive standard of care nivolumab IV over 30 minutes on day 1. Patients also receive fecal microbiota transplantation capsule PO on days 1 and 8 of cycles 1-2. Beginning in cycle 4, patients receive fecal microbiota transplantation capsule PO on day 1 of every other cycle. Cycles repeat every 14 days for up to 6 months in the absence of disease progression or unacceptable toxicity."
62037784|NCT00999375|EXPERIMENTAL|Group A|
62239836|NCT05231486|EXPERIMENTAL|Cognitive Orientation to daily Occupational Performance 4|"This arm is the fourth group composed of four others childrens who will do the CO-OP.~CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas The four patients will begin the sessions one week apart each."
62430198|NCT03521544|EXPERIMENTAL|Occipital and suboccipital fascia|Self-myofascial release in the occipital and suboccipital fascia.
62430199|NCT03521544|NO_INTERVENTION|Control group|Lay on a stretcher.
62430200|NCT00783978||1|Children with chronic lung disease
62037785|NCT00999375|ACTIVE_COMPARATOR|Group B|
62037786|NCT02002481|NO_INTERVENTION|Control|10 minutes ALS-CPR in a normal environment
62037787|NCT02002481|EXPERIMENTAL|Transport|10 minutes ALS-CPR during a transport
62239837|NCT05231486|EXPERIMENTAL|Cognitive Orientation to daily Occupational Performance 5|"This arm is the fifth group composed of four others childrens who will do the CO-OP.~CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas The four patients will begin the sessions one week apart each."
62239838|NCT04574479|PLACEBO_COMPARATOR|Placebo|Placebo group: patients have multimodal analgesia without fascia-iliaca compartment block
62430201|NCT05865665||Patients hospitalized for acute heart failure|Patients admitted for acute heart failure for at least 72 hours who are not treated with optimal doses of oral medications for HF including renin-angiotensin system inhibitors (RASI), beta-blockers (BB), and mineralocorticoid receptor antagonists (MRA) meeting all eligibility criteria including elevated NT-proBNP.
62597414|NCT03825835|ACTIVE_COMPARATOR|30% group|"Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
62735624|NCT05260138|ACTIVE_COMPARATOR|The control group|received the conventional NICU care
62735625|NCT00845468||No treatment|
62735626|NCT03531164|EXPERIMENTAL|Kayak ergometer group|Intervention: Training in kayak ergometer: 3 minutes of warming (pre-charge) , 3-5 intervals of training with moderate to high intensity and pauses of 2-4 minutes (charge) and 2 minutes of cooling down (post-charge) to complete 30 minutes.
62815876|NCT03859024|EXPERIMENTAL|Enhanced Recovery Protocol|A combination regimen of acetaminophen, Celebrex and gabapentin pre-op, with 30 mL of 0.5% bupivacaine and 4 mg of dexamethasone given as a perineal nerve block at the time of urethroplasty surgery. Narcotics will be administered judiciously and ass seen fit by the anesthesia and/or surgical teams. Postoperative prescriptions ibuprofen 800 mg, and acetaminophen 1000 mg to be taken on a scheduled basis then as needed. Another prescription for oxycodone will be given to be used only if needed.
62815877|NCT05412901|OTHER|Visual spatial discrimination task|exp 1.1
62815878|NCT05412901|OTHER|Visual spatial discrimination task with temporal manipulation|exp 1.2
62815879|NCT05412901|OTHER|Crossmodal discrimination task|exp 3.1
62037788|NCT03788837|EXPERIMENTAL|intravenous ILOPROST|a first dose of ILOPROST of 0.5ng/kg/ min with increments every 30 minutes up to a maximum of 1,5 ng/kg/min for 48h
62037789|NCT03788837|PLACEBO_COMPARATOR|Intravenous Placebo|Treatment with intravenous NaCl 0.9% therapy with incremental infusion rate every 30 minutes for 48h
62239839|NCT04574479|EXPERIMENTAL|Fascia iliaca block|Patients in this arm have multimodal analgesia with supra-inguinal fascia iliaca compartment block before surgery
62239840|NCT01617850|EXPERIMENTAL|optimized physical exercise training|Intervention: Supervised physical exercise training x3 weekly for 12 weeks
62239841|NCT01617850|ACTIVE_COMPARATOR|conventional group|Intervention: Supervised physical exercise training x2 weekly for 8 weeks
62239842|NCT02249754|ACTIVE_COMPARATOR|Routine health education|Routine health education alone
62430202|NCT02701816||K-INNOVA|Patients with femoropopliteal artery disease undergoing endovascular therapy using Innova stent (Boston Scientific).
62430203|NCT04336488|EXPERIMENTAL|Orochem (Test)|fifteen patients with lichen planus will be treated with MMPs neutralizing agent 3 times daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.
62815880|NCT05412901|OTHER|Visual rule-switching discrimination task [gratings]|exp 3.2
62597415|NCT03825835|EXPERIMENTAL|60% group|"Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
62597416|NCT04514744|EXPERIMENTAL|Unilateral Immobilization|One leg will undergo 14 days of single-leg immobilization, by means of a removable knee brace.
62815881|NCT05412901|OTHER|Visual rule-switching discrimination task [images]|exp 3.3
62597417|NCT04514744|EXPERIMENTAL|Unilateral Resistance Exercise|One leg will undergo 4 sessions of unilateral resistance exercise, over the course of 8 days. Specifically, participants will be asked to perform leg press and leg extension.
62597418|NCT05100953|EXPERIMENTAL|Experimental Group|After informing about the benefits of physical activity at the beginning of the study, physical activity counseling will be applied once a week for two months via videoconference.
62597419|NCT05100953|NO_INTERVENTION|Control Group|At the beginning of the study, a one-session briefing will be given on the benefits of physical activity.
62597420|NCT06624033|EXPERIMENTAL|Chocolate cake with peas|the subjects will consume the test meals (arm title)
62597421|NCT06624033|EXPERIMENTAL|Biscuit with peas|the subjects will consume the test meals (arm title).
62597422|NCT06624033|EXPERIMENTAL|chopped steack with peas|the subjects will consume the test meals (arm title).
62815882|NCT05968274|OTHER|"Arm A"|"1. First stimulation period: real stimulation, total 8 sessions, session frequency: weekdays every other day (i.e. duration 2.5 weeks)~2. Washout period: no stimulation, duration: 1 week~3. Second stimulation period: sham stimulation, total 8 sessions, session frequency: weekdays every other day (i.e. duration 2.5 weeks)"
62815883|NCT05968274|OTHER|"Arm B"|"1. First stimulation period: sham stimulation, total 8 sessions, weekdays every other day (i.e. 2.5 weeks)~2. Washout period: no stimulation, 1 week~3. Second stimulation period: real stimulation, total 8 sessions, weekdays every other day (i.e. 2.5 weeks)"
62815884|NCT00972413|EXPERIMENTAL|Group I|
62815885|NCT00972413|EXPERIMENTAL|Group II|
62815886|NCT00972413|EXPERIMENTAL|Group III|
62815887|NCT05584059|EXPERIMENTAL|FACT Group|4-6 weeks of 45-60 minute individual-based Focused Acceptance and Commitment Therapy (FACT) counselling sessions delivered via video-conferencing format or face-to-face
62815888|NCT06406764|EXPERIMENTAL|Plyometric training|Plyometric training program for 12 weeks.
62239843|NCT02249754|EXPERIMENTAL|Nutrition education package|Nutrition education package and routine health education
62239844|NCT00760396|EXPERIMENTAL|Group 1|40mg QD dose group
62239845|NCT00760396|EXPERIMENTAL|Group 2|100mg QD dose group
62597423|NCT06624033|PLACEBO_COMPARATOR|Chocolate cake with gluten|the subjects will consume the test meals (arm title)
62597424|NCT06624033|PLACEBO_COMPARATOR|biscuit with gluten|the subjects will consume the test meals (arm title).
62815889|NCT06406764|ACTIVE_COMPARATOR|Control training|Regular training program for 12 weeks.
62815890|NCT04924062|EXPERIMENTAL|Arm A (Pembrolizumab+Gemcitabine+Cisplatin)|Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
62815891|NCT04924062|PLACEBO_COMPARATOR|Arm B (Placebo+Gemcitabine+Cisplatin)|Placebo to Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
62815892|NCT02246530|ACTIVE_COMPARATOR|PRP injection into PTRCT|Treatment - PRP injection
62815893|NCT02246530|ACTIVE_COMPARATOR|Subacromial steroid bursal injection|Current standard of care for treatment of resistant partial thickness rotator cuff tears
62239846|NCT00760396|EXPERIMENTAL|Group 3|200mg QD dose group
62815894|NCT03796273|EXPERIMENTAL|Arm I (ketoconazole)|Patients receive ketoconazole PO QD on days 1-4 before standard surgery in the absence of disease progression or unacceptable toxicity.
62815895|NCT03796273|ACTIVE_COMPARATOR|Arm II (standard surgery)|Patients undergo standard surgery.
62815896|NCT06430853|PLACEBO_COMPARATOR|Usual step count|Participants will wear an Actigraph accelerometer watch, but not be given a step count goal, between 20 and 36 weeks of gestation.
62815897|NCT06430853|EXPERIMENTAL|Step count goal|Participants will be given a daily step count goal of 8,000 steps per day based on the Actigraph watch, between 20 and 36 weeks of gestation. If they are not at goal, a step-up protocol will be designed for each participant and reviewed with a study team member every 2 weeks.
62815898|NCT01782898|ACTIVE_COMPARATOR|Esmolol|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
62037790|NCT04984148||Trial cohort：Chemoradiotherapy followed by immunotherapy|"Contrast-enhanced thoracic CT: before, during and after radiotherapy~Radiomics~PD-L1 testing (Histological analysis of biopsy)~Molecular Markers (Histological analysis of biopsy)"
62239847|NCT00760396|EXPERIMENTAL|Group 4|200mg BID dose group
62597425|NCT06624033|PLACEBO_COMPARATOR|chopped steack|the subjects will consume the test meals (arm title).
62597426|NCT06292858|EXPERIMENTAL|Experimental|"Part A: Dose escalation phase~Six dose levels of IMB071703 injection are planned in Part A, 1 subject in the first dose level (accelerated titration design), 3 subjects in the 2nd through 6th dose levels separately (conventional Fibonacci 3+3 design). 19 to 33 subjects are expected to enroll.~Part B: Dose/cohort expansion phase~1 to 2 dose levels of subjects with 1 to 2 tumor types are tentatively planned; a total of up to 15 subjects are included in each dose level for each tumor type, 15 to 60 subjects are expected to enroll."
62597427|NCT05190211|EXPERIMENTAL|Telerehabilitation Group (TG)|
62597428|NCT05190211|EXPERIMENTAL|Video Group (VGr)|
62815899|NCT01782898|PLACEBO_COMPARATOR|.9 normal saline|.9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
62815900|NCT03173924|EXPERIMENTAL|1/Experimental intervention|18F-DCFPyL is administered to cohorts
62815901|NCT02898818||symptomless|vaginal and oral swab sample, questionnaire
62815902|NCT02898818||vaginal discharge|vaginal and oral swab sample, questionnaire
62815903|NCT02898818||atypical papa smear|vaginal and oral swab sample, questionnaire, papa smear
62239848|NCT03785678|EXPERIMENTAL|Tenecteplase|Patients in this arm will receive Tenecteplase (0.25 mg/kg, maximum 25 mg) administered as a single bolus injection over 5 seconds.
62239849|NCT03785678|PLACEBO_COMPARATOR|Placebo|Patients in this arm will receive placebo administered as a single bolus injection over 5 seconds.
62239850|NCT00786123|EXPERIMENTAL|VSL#3|Patients taking probiotics (VSL#3)
62239851|NCT00786123|PLACEBO_COMPARATOR|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
62239852|NCT02973425|ACTIVE_COMPARATOR|NRT and mHealth assessment tool without feedback|"For the comparison group, implementation will be balanced in all variables except the Take a Break Intervention. The investigators will balance the two groups further by having the comparison (NRT-Sampling group) complete mHealth assessments (without feedback or goal-setting) as an attention control.~Participants randomized to the comparison group will only have access to a mHealth assessment tool similar to the Challenge Quizzes but without feedback."
62239853|NCT02973425|EXPERIMENTAL|Take a Break as an augmentation to NRT in Motivation|"The Intervention: Take a Break as an augmentation to NRT-sampling in Motivation Phase. Take a Break is an intervention in which smokers are encouraged to engage in smoking abstinence. The main element, the Break, is a two-week challenge where smokers report days they are smoke-free. The Break is preceded by a 1-week training challenge where Challenge Quizzes (ecological momentary assessments) collect information to guide the smokers during the Break. At baseline, all smokers will be provided NRT lozenges for sampling. At weeks 1 and 3 of the Marathon, our Tobacco Treatment Specialist will call all smokers, assess their experiences and collect data.Participants in the intervention will receive the full tool suite."
62239854|NCT03496324|ACTIVE_COMPARATOR|Test (fed): Nurofen for Children|"Nurofen for Children® 400 mg/10 ml by mouth under fed condition~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
62239855|NCT03496324|ACTIVE_COMPARATOR|Test (fasted): Nurofen for Children|"Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
62239856|NCT03496324|EXPERIMENTAL|Reference (fed): Algifor Junior|"Algifor® Junior 400 mg/20 ml by mouth under fed condition.~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
62239857|NCT03496324|EXPERIMENTAL|Reference (fasted): Algifor Junior|"Algifor® Junior 400 mg/20 ml by mouth under fasted condition.~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
62239858|NCT00531882|EXPERIMENTAL|1-pioglitazone|Pioglitazone
62815904|NCT02898818||no atypical papa smear|vaginal and oral swab sample, questionnaire, papa smear
62815905|NCT02898818||lichen planus|vaginal and oral swab sample, questionnaire, papa smear
62815906|NCT05883969|ACTIVE_COMPARATOR|Early intervention for infants|Early family-centered, individualized, goal-directed, intensive, and carried out within the home environment in a cross sectorial setting fortnightly contact shifting between at home visits and virtual meetings for 6 months after an interim diagnosis of CP or high risk of CP
62239859|NCT00531882|EXPERIMENTAL|2-simvasatin|Simvastatin
62239860|NCT00531882|ACTIVE_COMPARATOR|3-Ibuprofen 1000-1600 mg/day|Ibuprofen 1000-16-- mg/day, maximum 3200 mg/day
62239861|NCT05169216|EXPERIMENTAL|Cognitive-Behavioral Therapy Group|"A mental training program was carried out with the following objectives: (a) to learn to manage their level of activation; (b) to train their ability to concentrate; (c) to optimize their self-confidence; (d) to learn to compete by improving their racing routines; and (d) to integrate mental training into their day-to-day life.~The athletes worked in small groups of four athletes. In addition, the days that the psychologist attended the concentration, he was also present in the training sessions, with the aim of giving them feedback on the strategies acquired. The psychologist was present in various phases throughout the concentration and there was also a constant online monitoring. Each week, a sheet of tasks to be executed and a diary were provided to verify compliance with the guidelines."
62430204|NCT04336488|ACTIVE_COMPARATOR|Conventional (Control)|fifteen patients with oral lichen planus confirmed with a biopsy will be treated with topical corticosteroids, topical antifungal 3 timed daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.
62430205|NCT01861119|EXPERIMENTAL|Silicone gel|Silicone gel (Kelo-cort™; Advanced Bio-Technologies, Silverdale, WA, USA) From the day of suture removal, the treatment was applied three times daily for 3 months.
62430206|NCT01861119|ACTIVE_COMPARATOR|Onion extract gel|Onion extract gel (Contractubex™; Merz Pharma, Frankfurt, Germany) From the day of suture removal, the treatment was applied three times daily for 3 months.
62430207|NCT01861119|NO_INTERVENTION|No treatment|Subjects who assigned In the no treatment group did not receive any topical scar emollients.
62430208|NCT01411670|EXPERIMENTAL|Human protein C concentrate|
62430209|NCT01411670|ACTIVE_COMPARATOR|activated protein C|Continuous infusion of Activated Protein C
62815907|NCT05883969|OTHER|Usual care|Standard care consists rehabilitation offered by the local hospital/community or other private initiatives when diagnosed with CP or high risk of CP. The approach, frequency, and location (at home or rehabilitation centers) is varied
62037791|NCT06489743|ACTIVE_COMPARATOR|Ambient air|Highlanders with HAPH will perform the 6 MWT on ambient air at 3200 m
62430210|NCT01411670|PLACEBO_COMPARATOR|Placebo|Standard treatment
62430211|NCT01559870||patients with elective cardiac surgery|adult patients who had undergone elective cardiac surgery with CPB
62430212|NCT01311310|EXPERIMENTAL|remote ischemic preconditioning|
62430213|NCT03110393|EXPERIMENTAL|Ambu® AuraGain™|Intervention with Ambu® AuraGain™Laryngeal Mask
62430214|NCT03110393|ACTIVE_COMPARATOR|Intersurgical i-gel®|Intervention with Intersurgical i-gel® Laryngeal Mask
62597429|NCT04183140|ACTIVE_COMPARATOR|Transradial|Transradial intervention
62815908|NCT06437301|OTHER|Baseline ETCO2 without mask|Subjects will have their baseline end tidal carbon dioxide measured while at rest and without a mask.
62815909|NCT06437301|OTHER|Baseline ETCO2 with mask|The second measurement will also occur at rest, but while subjects are wearing a mask.
62597430|NCT04183140|ACTIVE_COMPARATOR|Transulnar|Transulnar intervention
62597431|NCT03676296|EXPERIMENTAL|Puerarin|Puerarin (90.2 mg daily) in granules
62597432|NCT03676296|PLACEBO_COMPARATOR|Placebo|Placebo in granules
62597433|NCT03811288||Participants with type 2 diabetes mellitus (T2DM)|T2DM patients being managed in both primary and specialist care in 10 selected countries.
62597434|NCT00968136||a short-term trial of the ketogenic diet|
62597435|NCT00968136||long-term trial of the ketogenic diet.|
62815910|NCT06437301|OTHER|ETCO2 after 200 meter walk with mask|Lastly, end tidal carbon dioxide will be measured after each participant walks 200 meters, with a surgical mask.
62815911|NCT06437301|OTHER|ETCO2 after 200 meter walk without mask|Lastly, end tidal carbon dioxide will be measured after each participant walks 200 meters, without a surgical mask.
62815912|NCT05811442|EXPERIMENTAL|50561 256mg|50561 at a dose of 256mg n=20 group
62239862|NCT01749540|EXPERIMENTAL|Luspatercept 0.2 mg/kg|Participants receive luspatercept 0.2 mg/kg as a subcutaneous (SC) injection every 3 weeks (Q3W) on Day 1 of each cycle for up to 5 cycles (each cycle length = 21 days).
62815913|NCT05811442|EXPERIMENTAL|50561 128mg|50561 at a dose of 128mg n=20 group
62239863|NCT01749540|EXPERIMENTAL|Luspatercept 0.4 mg/kg|Participants receive luspatercept 0.4 mg/kg as an SC injection Q3W on Day 1 of each cycle for up to 5 cycles (each cycle length = 21 days).
62239864|NCT01749540|EXPERIMENTAL|Luspatercept 0.6 mg/kg|Participants receive luspatercept 0.6 mg/kg as an SC injection Q3W on Day 1 of each cycle for up to 5 cycles (each cycle length = 21 days).
62430215|NCT06204432|PLACEBO_COMPARATOR|Normal Saline|The Normal Saline arm will use normal saline nasal spray and olfactory training twice a day for 12 weeks.
62430216|NCT06204432|EXPERIMENTAL|Sodium Citrate|The Sodium Citrate arm will use sodium citrate nasal spray and olfactory training twice a day for 12 weeks.
62430217|NCT04817098|EXPERIMENTAL|Journey of Life Intervention Group|Community members (caregivers, teachers, and community leaders) will participate in group workshops for a period of 6 weeks.
62815914|NCT05811442|PLACEBO_COMPARATOR|placebo|Placebo n=20 group
62239865|NCT01749540|EXPERIMENTAL|Luspatercept 0.8 mg/kg|Participants receive luspatercept 0.8 mg/kg as an SC injection Q3W on Day 1 of each cycle for up to 5 cycles (each cycle length = 21 days).
62239866|NCT01749540|EXPERIMENTAL|Luspatercept 1.0 mg/kg|Participants receive luspatercept 1.0 mg/kg as an SC injection Q3W on Day 1 of each cycle for up to 5 cycles (each cycle length = 21 days).
62239867|NCT01749540|EXPERIMENTAL|Luspatercept 1.25 mg/kg|Participants receive luspatercept 1.25 mg/kg as an SC injection Q3W on Day 1 of each cycle for up to 5 cycles (each cycle length = 21 days).
62430218|NCT04817098|OTHER|Waitlist Control Group|The waitlist control group will not receive the intervention during the first 6 months of implementation in order to assess the effects of the intervention compared to the control group. However, following intervention completion in the experimental group, the control group will receive 6 months of the intervention.
62430219|NCT04242381|EXPERIMENTAL|Group 1: Cold application, Kinesiotaping treatment|"Cold application: At the beginning of each treatment session, gel ice packs were wrapped in a damp towel and applied to the patients' shoulder joints for 20 minutes.~Kinesiotaping application: KT was applied to the deltoid muscle using the inhibition and mechanical correction technique and to the supraspinatus muscle using the inhibition technique (2 sessions with a 5-day interval)."
62597436|NCT06577519|EXPERIMENTAL|Experimental group|Vicagrel loading followed by Maintenance dose
62597437|NCT06577519|ACTIVE_COMPARATOR|Control group|Clopidogrel loading followed by Maintenance dose
62597438|NCT01438294|ACTIVE_COMPARATOR|Aerobic exercise|The aerobic training will be done on the treadmill with heart monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.
62597439|NCT01438294|EXPERIMENTAL|Video game|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( reflex ridge- Adventure).
62597440|NCT00546117|EXPERIMENTAL|Lansoprazole (Prevacid)|Prevacid SoluTab (15 or 30 mg tab) once daily for 2 months
62597441|NCT00546117|PLACEBO_COMPARATOR|Placebo|Placebo SoluTab once daily for 2 months
62597442|NCT06622421|OTHER|G1 - control group|Patients with MRONJ diagnosis who will undergo to conventional surgery using rotary burns instruments
62597443|NCT06622421|EXPERIMENTAL|G2 - study group|Patients with MRONJ diagnosed who will undergo to piezoelectric surgery
62597444|NCT06619249|EXPERIMENTAL|CoQ10-treated participants|The participants will be treated with CoQ10 supplements
62597445|NCT06619249|PLACEBO_COMPARATOR|Placebo-treated participants|The participants will be treated with placebo
62597446|NCT01798407|EXPERIMENTAL|Activa Tremor Control Sys (DBS Implant)|all subjects will receive bilateral surgical implantation of DBS system. Those who respond at 12 months will enter a randomized, staggered withdrawal phase.
62735627|NCT03531164|ACTIVE_COMPARATOR|Control group|Intervention: 30 minutes of proprioceptive neurofacilitation focused on trunk control
62735628|NCT03018535|EXPERIMENTAL|RITUXIMAB|1 g. IV of Rituximab on days 1 and 15
62735629|NCT03018535|ACTIVE_COMPARATOR|Corticosteroids and Cyclophosphamide|Month 1, 3 and 5: 1g IV methylprednisolone daily for 3 doses; oral methylprednisolone (0.4mg/kg/day) or prednisone (0.5/mg/kg/day); Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day)
62597447|NCT01798407|EXPERIMENTAL|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
62597448|NCT05575752|EXPERIMENTAL|high temperature (32℃) group|Subjects in exposure group will be exposed to high temperature (32℃) for about 2 hours in a chamber.
62597449|NCT05575752|SHAM_COMPARATOR|moderate temperature (22℃) group|Subjects in exposure group will be exposed to moderate temperature (22℃) for about 2 hours in a chamber.
62239868|NCT01749540|EXPERIMENTAL|Expansion Cohort|Participants receive an initial dose of luspatercept 0.8 mg/kg as an SC injection on Day 1 of Cycle 1 (Cycle length = 21 days). For each subsequent cycle (up to 5 cycles), the dose was titrated up to a maximum dose of 1.25 mg/kg based on the safety review team (SRT) recommendations.
62239869|NCT00818181|EXPERIMENTAL|Solution of birch pollen allergen extract|In total up to 4 drops (dose for maintainace therapy)are administered under the tongue.
62430220|NCT04242381|EXPERIMENTAL|Group 2: Cold application, EX treatment|EX treatment was administered for 10 days with 3 sessions/day. A triphasic exercise program was administered to the patients. Exercise was administered twice a week under supervision; however, the patients were advised to exercise at home on the other days with 20 repetitions of each exercise. The patients were followed up via telephone to make sure they were adhering to their exercise programs.
62430221|NCT04242381|SHAM_COMPARATOR|Group 3: Cold application, sham-KT treatment|Sham-KT was applied in 10 cm I-shaped stripes on the sagittal plane over the acromioclavicular joint without stretching and on the transverse plane distal to the deltoid area. The kinesiotape was applied twice for five days with 2-day intervals
62430222|NCT00543439|EXPERIMENTAL|1|On-Demand therapy for 6 months, followed by Routine Prophylaxis treatment for 1 year.
62430223|NCT00543439|EXPERIMENTAL|2|Routine Prophylaxis Crossover
62430224|NCT03984383||Lung-derived endothelial cells|Every patient of more than 18 years undergoing lung cancer surgery in the department of thoracic surgery of the University Hospital of Lille.
62430225|NCT03984383||Umbilical cord-derived endothelial cells|Every patient of more than 18 years giving birth in the University Hospital of Lille in the absence of significant materno-foetal disorder (for example: meconium-stained amniotic fluid, chorioamnionitis, placental thrombosis, eclampsia etc.) or of infection for HIV, VHB, VHC or if unknown status for HIV, VHB, VHC the day of the childbirth.
62430226|NCT02868905|OTHER|Control group|Control group
62430227|NCT02868905|OTHER|Obese group|Obese group
62430228|NCT02868905|OTHER|Non-obese AD group|Non-obese AD groups
62430229|NCT02868905|OTHER|Obese AD group|Obese AD group
62239870|NCT03393715|EXPERIMENTAL|Perindopril morning|10 mg of perindopril oral tablet once daily in the morning for 56 days
62430230|NCT01593150|EXPERIMENTAL|Conventional|Conventional treatment Pradaxa prior to DC cardioversion
62430231|NCT01593150|EXPERIMENTAL|TEE|Transesophageal echo prior to DC cardioversion (early DC)
62430232|NCT01593150|ACTIVE_COMPARATOR|Early versus Late DC cardioversion|Comparing early versus late DC cardioversion. Patients randomized to either early or late DC cardioversion, follow-up time after intervention 12 month.
62430233|NCT06250400|EXPERIMENTAL|Treatment|"Treatment arm will receive a dose of Histamine Human Immunoglobulin 12mg (2ml) s.c. which consists of one injection of Histamine Human Immunoglobulin 12mg(2ml) vial every week for 4 times.~Treatment arm will also receive a dose of loratadine p.o. which consists of one pill of loratadine 10mg every day for 4 weeks."
62239871|NCT03393715|ACTIVE_COMPARATOR|Perindopril evening|10 mg of perindopril oral tablet once daily in the evening for 56 days
62430234|NCT06250400|PLACEBO_COMPARATOR|Placebo|"Placebo arm will receive placebo which consists of one injection of placebo 12mg(2ml) vial every week for 4 times.~Placebo arm will also receive a dose of loratadine p.o. which consists of one pill of loratadine 10mg every day for 4 weeks."
62430235|NCT01169987||Participants Treated with Adalimumab|Participants with chronic plaque psoriasis in whom adalimumab (Humira) treatment is initiated. All medications will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.
62430236|NCT01071109|EXPERIMENTAL|Therapeutic Massage|
62430237|NCT01071109|NO_INTERVENTION|No therapeutic massage|
62430238|NCT01701778|EXPERIMENTAL|Caudal Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
62430239|NCT01701778|EXPERIMENTAL|Intravenous Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg~Anesthesia was induced and maintained with sevoflurane"
62597450|NCT06649097||IRRAflow device|All patients enrolled into the study will undergo treatment with the IRRAflow device
62597451|NCT06124521|EXPERIMENTAL|Eye concern|Those with a diagnosis of glaucoma or glaucoma suspect (or other concerning eye disease, such as diabetic retinopathy or macular degeneration) will be invited to participate in the ComBaT Glaucoma.
62597452|NCT00887523|EXPERIMENTAL|1|prone intensity-modulated radiotherapy
62430240|NCT01701778|PLACEBO_COMPARATOR|Placebo|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
62430241|NCT04249752||Group 1 with GBS patients|GBS patients
62430242|NCT04249752||Group 2 with CIDP patients|with CIDP patients
62430243|NCT01726478|ACTIVE_COMPARATOR|2.5 units oxytocin|Administration of 2.5 units of oxytocin intravenously after clamping of umbilical cord
62430244|NCT01726478|PLACEBO_COMPARATOR|10 units oxytocin|Administration of 10 units of oxytocin after clamping of umbilical cord
62037792|NCT06489743|EXPERIMENTAL|SOT via nasal canula|Portable pulsed supplemental oxygen therapy (SOT) will be provided via a nasal cannula from a regular portable oxygen concentrator carried on the back according to standard care
62037793|NCT01049048|PLACEBO_COMPARATOR|Control|This group receives placebo chocolate cookies with no vitamin D3 added.
62597453|NCT00887523|ACTIVE_COMPARATOR|2|supine intensity-modulated radiotherapy
62597454|NCT00474786|EXPERIMENTAL|1|
62597455|NCT00474786|EXPERIMENTAL|2|
62597456|NCT06622993|EXPERIMENTAL|Programm SKILLS|
62239872|NCT05227157||1: intensity of perception of metallic taste|"For this study, there is only one arm: swab with iron sulfate solution at a concentration of 10g/l.~Each subject complete visual scale"
62430245|NCT03780569|EXPERIMENTAL|NovoTTF-200A/Radiotherapy/Temozolomide|Patients will receive multiple 1 month courses of continuous NovoTTF-200A treatment together with standard Radiotherapy/Temozolomide followed by maintenance Temozolomide.
62430246|NCT06394531|ACTIVE_COMPARATOR|Intervention|Jaboticaba peel extract. Patients will ingest 4 capsules/day of jaboticaba (Plinia Cauliflora) peel extract, providing 3.3g of jabuticaba peel extract daily, containing 600mg of phenolic compounds, for one month.
62430247|NCT06394531|PLACEBO_COMPARATOR|Placebo|Placebo. Patients will ingest 4 capsules/day of placebo (corn starch), providing 3.3g of placebo, for one month.
62597457|NCT06622993|NO_INTERVENTION|Waiting list|
62597458|NCT06452849|EXPERIMENTAL|Amygdala TI|Right amygdala Temporal Interference (TI) stimulation with 100 frequency difference, 20 minutes per day for 5 days.
62597459|NCT06452849|EXPERIMENTAL|dLPFC TI|L_dLPFC TI Temporal Interference (TI) stimulation with 10 frequency difference, 20 minutes per day for 5 days.
62597460|NCT05172869|ACTIVE_COMPARATOR|Group S: Suprainguinal Performed FICB|Suprainguinal Performed FICB
62597461|NCT05172869|ACTIVE_COMPARATOR|Group I: Infrainguinal Performed FICB|Infrainguinal Performed FICB
62597462|NCT05028075|NO_INTERVENTION|Usual Care|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity, hours of direct patient care, percent of time providing care for patients with COVID-19) at enrollment; 0 months, 6 months, and 9 months.
62430248|NCT03508362|EXPERIMENTAL|Drug user|Regular use of cocaine
62597463|NCT05028075|EXPERIMENTAL|Intervention|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity) at enrollment; 0 months and then again at 6 months and 9 months. The intervention group receives usual Cobalt plus: 1) monthly automated text messaging reminders and links to Cobalt resources 2) intermittent mental health assessments which triage individuals to an appointment based on their results.
62597464|NCT06618573|ACTIVE_COMPARATOR|Treatment Group|"SLE patient at the Hasan Sadikin Rheumatology Outpatient Clinic and registered as Lupus Registry with remission or mild SLE disease activity. The diagnosis of SLE is based on ACR 1997 criteria or SLE SLICC 2012 criteria. Screening will include history review, physical examinations, chest X-Ray, laboratory test such as CBC, ALT/AST, HbsAg, total anti-HCV, complement (C3), dsDNA, creatinine serum, urinalysis (proteinuria, ACR, RBC, WBC, casts), IGRA, to assess if any subject has no active TB and no chronic liver disease.~Treatment group receiving Isoniazid 5 mg/kg/day (maximum 300 mg/day) with pyridoxine 10 mg/day.~Monitor ALT/AST and SLE disease activity after two weeks, continued monthly for the first three months (1st, 2nd, 3rd) then every three months for up to a year (6th, 9th, 12th months). Routine SLE medication is continued and routinely recorded at every visit."
62597465|NCT06618573|PLACEBO_COMPARATOR|Control Group|"SLE patient at the Hasan Sadikin Rheumatology Outpatient Clinic and registered as Lupus Registry with remission or mild SLE disease activity. The diagnosis of SLE is based on ACR 1997 criteria or SLE SLICC 2012 criteria. Screening will include history review, physical examinations, chest X-ray, laboratory test such as CBC, ALT/AST, HbsAg, total anti-HCV, complement (C3), dsDNA, creatinine serum, urinalysis (proteinuria, ACR, RBC, WBC, casts) IGRA, to assess if any subject has no active TB and no chronic liver disease.~Control group receiving placebo.~Monitor ALT/AST and SLE disease activity after two weeks, continued monthly for the first three months (1st, 2nd, 3rd) then every three months for up to a year (6th, 9th, 12th months). Routine SLE medication is continued and routinely recorded at every visit."
62597466|NCT02860000|EXPERIMENTAL|Arm I (alisertib)|Patients receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression, may cross-over to Arm II.
62239873|NCT02218190|EXPERIMENTAL|Alvimopan|Alvimopan 12mg once orally two hours prior to surgery and then 2 mg orally twice a day until post-operative day (POD) seven.
62430249|NCT03508362|ACTIVE_COMPARATOR|Healthy volunteers|non-drug user
62430250|NCT04386668|EXPERIMENTAL|LIO-C|Participants receive LIO-C writing intervention
62239874|NCT02218190|PLACEBO_COMPARATOR|Placebo - Sugar Pill|Placebo Sugar Pill orally two hours prior to surgery and then one sugar pill orally twice a day until post-operative day (POD) seven
62430251|NCT04386668|PLACEBO_COMPARATOR|Neutral writing control|Participants receive neutral writing control intervention
62430252|NCT04608084|EXPERIMENTAL|Treatment group|Participant with moderate to sever ocular surface disease will be treated with autologous platelet rich plasma eye drops
62430253|NCT04032275||Untreated chronic HBV infected person group|Enrolled in the Department of Hepatology, Beijing Ditan Hospital, Capital Medical University, Department of Liver Histology, Department of Hepatology, Chronic HBV HBV infection.
62430254|NCT05747833|EXPERIMENTAL|Toy IV Catheter Before Peripheral Cannula application|Intervention Group: Child Fear Scale will be applied to the children who will meet the inclusion criteria. The data collection form will be filled in by the researcher according to the information received from the patient file and parents. Children in the intervention group will be shown the procedure on the doll with the IV Catheter developed by the researchers, and then it will be applied to it.
62430255|NCT05747833|NO_INTERVENTION|Standard of care|Control group will not be aplied other than the normal procedure of the hospital. In both groups, at the end of the procedure, the child's reactions will be observed during the procedure and the Wong-Baker Faces Pain Scale, the Child Anxiety Scale and the Child Emotional Indicators Scale will be filled independently by the researcher and the parent in line with the child's reactions.
62597467|NCT02860000|EXPERIMENTAL|Arm II (alisertib, fulvestrant)|Patients receive fulvestrant IM over 1-2 minutes on days 1 and 15 of course 1 and on day 1 of all subsequent courses. Patients also receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62815915|NCT05989009||Women < 32 weeks of gestational age|Women that delivered before 32 weeks of gestational age
62239875|NCT00617604|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered intra-operatively as an intravenous (IV) bolus on Day 0, another IV bolus on Day 3 and weekly subcutaneous injections thereafter for 12 weeks. Participants also received tacrolimus, mycophenolate mofetil (MMF) and steroid treatment.
62239876|NCT00617604|EXPERIMENTAL|Alefacept|Participants received 7.5 mg alefacept administered intra-operatively as an IV bolus on Day 0, another 7.5 mg IV bolus on Day 3, and weekly subcutaneous injections of 15 mg alefacept thereafter for 12 weeks. Participants also received tacrolimus, MMF and steroid treatment.
62239877|NCT01168739|EXPERIMENTAL|Quercetin|not necessary, contained in protocol
62239878|NCT01168739|PLACEBO_COMPARATOR|Placebo|not necessary, contained in protocol
62239879|NCT05089409|EXPERIMENTAL|A (ATB1651, 2 mg/mL)|"The planned ATB1651 dose level of 2 mg/mL.~Six participants are expected to be enrolled in each arm."
62239880|NCT05089409|EXPERIMENTAL|B (ATB1651, 5 mg/mL)|"The planned ATB1651 dose level of 5 mg/mL.~Six participants are expected to be enrolled in each arm."
62239881|NCT05089409|EXPERIMENTAL|C (ATB1651, 10 mg/mL)|"The planned ATB1651 dose level of 10 mg/mL.~Six participants are expected to be enrolled in each arm."
62239882|NCT05089409|EXPERIMENTAL|D (ATB1651, 20 mg/mL)|"The planned ATB1651 dose level of 20 mg/mL.~Six participants are expected to be enrolled in each arm."
62239883|NCT05089409|PLACEBO_COMPARATOR|E (ATB1651, 30 mg/mL)|"The planned ATB1651 dose level of 30 mg/mL.~Six participants are expected to be enrolled in each arm."
62430256|NCT06147700||Healthy fertile male|No intervention for this study.
62430257|NCT06147700||Healthy infertile male|No intervention for this study.
62430258|NCT03398928|EXPERIMENTAL|Acupuncture|Acupuncture for delirium treatment
62430259|NCT03398928|NO_INTERVENTION|Standard care|Standard conventional delirium care at the discretion of the department medical staff
62430260|NCT02079428||Systolic heart failure, Diastolic heart failure|
62430261|NCT02499185|EXPERIMENTAL|Nephro Check Test|We take urine samples and analyse the level of \[TIMP-2\]●\[IGFBP-7\] using the NephroCheck Test to diagnose AKI
62430262|NCT02499185|ACTIVE_COMPARATOR|serum creatinine measurement|"This is the Golden standard to diagnose AKI"
62430263|NCT04965649||Chronic Myeloid Leukemia|There will be approximately 10 patients with Chronic Myeloid Leukemia in this group
62430264|NCT04965649||Philadelphia+ Acute Lymphoblastic Leukemia|There will be approximately 20 patients with Philadelphia chromosome-positive Acute lymphocytic leukemia in this group
62430265|NCT06495749||Pancreatic Cancer|The patient is diagnosed with pancreatic cancer for the first time and has not received any tumor treatment.
62430266|NCT06495749||Benign Pancreatic Diseases|The patient is diagnosed with a benign pancreatic disease ，such as SCN、MCN、IPMN.and has not undergone any treatment.
62430267|NCT06495749||Healthy controls|A healthy population without any pancreatic-related diseases or other cancers.
62430268|NCT00903591||1|All women will be interviewed by telephone using the a similar questionnaire as used in the parent study. DNA samples will be obtained either via blood samples drawn during a home or clinic visits, or an Oragene Saliva DNA Self-Collection Kit sent to the participant's home.
62430269|NCT02751632|EXPERIMENTAL|Step 1-Regular SPS Therapy|Support and Problem Solving Therapy delivered to all study participants over a six-week period with a minimum of three sessions.
62597468|NCT05116202|ACTIVE_COMPARATOR|Cohort 1: Nivolumab + Ipilimumab|Cohort 1 participants in the nivolumab plus ipilimumab arm will receive treatment for 2 cycles (6 weeks) on Day 1 of each cycle (cycle length 21 days) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
62430270|NCT02751632|EXPERIMENTAL|Responders- Monthly SPS Therapy|Participants are randomised to receive monthly Support and Problem Solving Therapy for up to 12 months.
62430271|NCT02751632|EXPERIMENTAL|Responders- 3-monthly monitoring|Participants are randomised to be monitored for risk every 3 months for up to 12 months.
62430272|NCT02751632|EXPERIMENTAL|Step 2- Regular SPS Therapy|Participants are randomised to receive regular sessions of Support and Problem Solving Therapy, with a minimum of six sessions delivered over an 18-week period.
62037794|NCT01049048|EXPERIMENTAL|Vitamin D3|This group receives 2500 IU of Vitamin D3 added to a chocolate cookie daily.
62239884|NCT05089409|PLACEBO_COMPARATOR|F (placebo)|"The participants will apply placebo for 28 days.~Six participants are expected to be enrolled in each arm."
62239885|NCT04448756|EXPERIMENTAL|M5049 50 mg|
62430273|NCT02751632|EXPERIMENTAL|Step 2- Regular CBCM|Participants are randomised to receive regular sessions of Cognitive Behavioural Case Management, with a minimum of six sessions delivered over an 18-week period.
62430274|NCT02751632|EXPERIMENTAL|Step 3- Regular CBCM + Fluoxetine|Participants are randomised to receive either Cognitive Behavioural Case Management plus an antidepressant medication for six months .
62239886|NCT04448756|EXPERIMENTAL|M5049 100 mg|
62239887|NCT04448756|PLACEBO_COMPARATOR|Placebo|
62239888|NCT01798992|NO_INTERVENTION|Non-failing control|Patients with normal ejection fraction who underwent a single myocardial biopsy and received no β-blocker therapy
62239889|NCT01798992|ACTIVE_COMPARATOR|Metoprolol succinate|Idiopathic dilated cardiomyopathy patients randomized to metoprolol succinate titrated to a goal of 200 mg by mouth daily for 18 months
62430275|NCT02751632|PLACEBO_COMPARATOR|Step 3- Regular CBCM+ placebo|Participants are randomised to receive Cognitive Behavioural Case Management plus placebo medication for six months.
62597469|NCT05116202|EXPERIMENTAL|Cohort 1: RO7247669 2100 mg|Cohort 1 participants in the RO7247669 arm will receive treatment for 2 cycles (6 weeks) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
62239890|NCT01798992|ACTIVE_COMPARATOR|Metoprolol succinate + doxazosin|Idiopathic dilated cardiomyopathy patients who were randomized to receive metoprolol succinate and doxazosin titrated to a goal of 200 mg and 8 mg by mouth daily for 18 months
62239891|NCT01798992|ACTIVE_COMPARATOR|Carvedilol|Idiopathic dilated cardiomyopathy patients who were randomized to receive carvedilol titrated to a goal of 25 mg by mouth twice daily for 18 months
62239892|NCT04444622|EXPERIMENTAL|AlloStim|"AlloStim is administered in three cycles:~Cycle 1 Day 0: 0.5ml ID AlloStim® Day 7: 0.5ml ID AlloStim® Day 14: 0.5ml ID AlloStim® Day 21: 0.5ml ID AlloStim® Day 28: 0.5ml ID AlloStim®~Cycle 2 Day 42: 0.5ml ID AlloStim® Day 49: 0.5ml ID AlloStim® Day 56: 0.5ml ID AlloStim® Day 63: 0.5ml ID AlloStim® Day 70: 0.5ml ID AlloStim® + 3ml IV AlloStim®~Cycle 3 Day 84: 0.5ml ID AlloStim® Day 91: 0.5ml ID AlloStim® Day 98: 0.5ml ID AlloStim® Day 105: 0.5ml ID AlloStim® Day 112: 0.5ml ID AlloStim® + 3ml IV AlloStim®"
62239893|NCT05576922|ACTIVE_COMPARATOR|Connective tissue graft|Autogenous connective tissue graft harvested from the palate as a free gingival graft and then de-epithelialized
62239894|NCT05576922|EXPERIMENTAL|Collagen matrix + rhPDGF-BB|Xenogeneic cross-linked collagen matrix + recombinant human platelet-derived growth factor-BB
62239895|NCT00355056|SHAM_COMPARATOR|Medical Management|Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure).
62239896|NCT00355056|EXPERIMENTAL|PFO Closure|Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and undergo PFO device closure procedure with the AMPLATZER PFO Occluder.
62239897|NCT03938038|ACTIVE_COMPARATOR|Serial ultrasound assessments for GDT, then Usual Care|
62239898|NCT03938038|ACTIVE_COMPARATOR|Usual care, then Serial ultrasound assessments for GDT|
62239899|NCT01028456|PLACEBO_COMPARATOR|100 lux|100 lux / 30 minutes day
62239900|NCT01028456|EXPERIMENTAL|Light Therapy 10,000 lux|10,000 lux / 30 minutes a day for 3 months
62239901|NCT04663750|EXPERIMENTAL|Arm A - Surgery with aflibercept|Surgery with aflibercept at the end of surgery, with post-operative review day 1 and week 1 (day 7)
62239902|NCT04663750|ACTIVE_COMPARATOR|Arm B - Aflibercept monotherapy|Aflibercept monotherapy commencing at baseline.
62239903|NCT03971656|NO_INTERVENTION|Control|Standard care
62239904|NCT03971656|EXPERIMENTAL|Intervention|Three-Fold Nutritional Intervention
62239905|NCT05713773|ACTIVE_COMPARATOR|Test product 1 (T1)|Aphaia Pharma (APH)-001A: glucose coated beads containing 8 g glucose and caffeine anhydrous
62430276|NCT02440932|EXPERIMENTAL|Phenylketonuria-type diet|"Breakfast: one pouch of amino acid supplement (174 mls supplemented drink PKU cooler 20, Vitaflo®; 20 g protein, 9.4 g carbohydrates, 0.7 g Fat) Lunch: cheese sandwich \[low protein bread (Juvela, UK), no protein vegan cheese (Viotros, UK)\], low protein crackers (Vitaflo, UK), and low protein cookies (Juvela, UK).~Dinner: ad libitum buffet meal"
62815916|NCT05989009||Women between 32 and 36,6 weeks of gestational age|Women that delivered between 32 and 36,6 weeks of gestational age
62597470|NCT05116202|EXPERIMENTAL|Cohort 1: + Atezolizumab + Tiragolumab|Cohort 1 participants in the atezolizumab plus tiragolumab arm will receive treatment for 2 cycles (6 weeks) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
62815917|NCT05989009||Women > 37 weeks of gestational age|Women that delivered after 37 weeks of gestational age
62815918|NCT03472625||Acute stroke patients|All acute stroke patients will be screened for aphasia, dysarthria or dysphagia. When one of the symptoms is present, standardized assessments will follow to evaluate the severity. Recovery in time will be measured +/- 1 week following stroke.
62815919|NCT03519269|NO_INTERVENTION|Non robotics-assisted Surgical System|Conventional, non-robotics-assisted total knee surgical system
62815920|NCT03519269|EXPERIMENTAL|Navio™ Robotics-assisted Surgical System|Navio™ Robotics-assisted Surgical System
62815921|NCT04101630||Participants with Pulmonary Hypertension|Participants will undergo activity monitoring for 12 weeks, at baseline and once a year for 3 years. Patient reported outcomes will be collected including Quality of Life questionnaires \[emphasis-10, Minnesota Living with Heart Failure (MLHF), and SF-36 surveys\], medication changes, hospitalization, and death.
62239906|NCT05713773|ACTIVE_COMPARATOR|Test product 2 (T2)|APH-001B: glucose coated beads containing 8 g glucose and caffeine anhydrous
62239907|NCT05713773|ACTIVE_COMPARATOR|Test product 3 (T3)|APH-001C: glucose coated beads containing 8 g glucose and caffeine anhydrous
62239908|NCT05713773|ACTIVE_COMPARATOR|Test product 4 (T4)|APH-001D: glucose coated beads containing 8 g glucose
62239909|NCT05713773|ACTIVE_COMPARATOR|Test product 5 (T5)|APH-001E: uncoated beads containing 8 g glucose and caffeine anhydrous
62239910|NCT01622179|EXPERIMENTAL|Indirectly|The epitenon was repaired and sewed indirectly.
62239911|NCT01622179|PLACEBO_COMPARATOR|Directly|The epitenon was unrepaired and sewed directly.
62239912|NCT02301650||group A|The one year old children born in Beijing Ditan hospital and whose mothers had taken Lamivudine in late pregnancy
62239913|NCT02301650||group B|The one year old children born in Beijing Ditan hospital and whose mothers had taken Telbivudine in late pregnancy
62239914|NCT02301650||group C|The one year old children born in Beijing Ditan hospital and whose mothers had taken Tenofovir in late pregnancy
62239915|NCT02301650||group D|The one year old children born in Beijing Ditan hospital and whose mothers untreated in late pregnancy
62239916|NCT00501527|EXPERIMENTAL|A: Biological vaccine|The first active arm will receive a dose that is 10x less than the dose of the other arm
62239917|NCT00501527|EXPERIMENTAL|B: biological vaccine|The first active arm will receive a dose that is 10x more than the dose of the other arm
62239918|NCT00501527|PLACEBO_COMPARATOR|C|
62239919|NCT00701207|NO_INTERVENTION|2.|control group-no intervention
62239920|NCT00701207|NO_INTERVENTION|3|Healthy control group-blood and sputum samples
62239921|NCT00701207|EXPERIMENTAL|1.|nicotine patch; transdermal patch 7mg, 14 mg., 21 mg. 3 months
62239922|NCT01209845|EXPERIMENTAL|Ketamine|Patients were administered a single sub-anaesthetic i.v. bolus of ketamine (0.2 mg/kg over 1-2 min) in the ED, with continuous monitoring of vital signs, adverse events and psychotomimetic side-effects for 4 h post-administration.
62239923|NCT02885298||Supine intubations (0-10 degrees)|Intubations performed with patient positioned 0-10 degrees. Patient supine.
62239924|NCT02885298||Inclined (11-44 degrees)|Intubations performed with 11-44 degrees of elevation.
62239925|NCT02885298||Upright (45 degrees or greater)|intubations performed with patient elevated to 45 degrees or greater
62239926|NCT00146679|PLACEBO_COMPARATOR|Usual Care (UC)|Usual Care provided by providers
62239927|NCT00146679|ACTIVE_COMPARATOR|Psychoeducational Telephone CounselingTC|Education and Counseling for ICD patients provided through Telephone Contact
62597471|NCT05116202|EXPERIMENTAL|Cohort 1: RO7247669 2100 mg + Tiragolumab|Cohort 1 participants in the RO7247669 plus tiragolumab arm will receive treatment for 2 cycles (6 weeks) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
62430277|NCT02440932|OTHER|Normal diet|Breakfast: 174 ml of milk (20 g protein, 9.4 g carbohydrates, 0.7 g Fat) Lunch: cheese sandwich, crackers, and cookies (regular foods) Dinner: ad libitum buffet meal
62239928|NCT00146679|ACTIVE_COMPARATOR|Psychoeducation through Groups (SG)|Education and Counseling for ICD patients provided in a group setting with other ICD Patients
62239929|NCT02627755|ACTIVE_COMPARATOR|Glide group|Device: Glidescope® use
62239930|NCT02627755|EXPERIMENTAL|Glide+aScope group|Device: combined use of two airway devices Glidescope® + aScope®
62239931|NCT04894162|OTHER|Sequential recruitment of all inpatients|"Consecutive, eligible inpatients in a participating specialist palliative care unit will be invited to participate in the research: those who wish to participate will complete a questionnaire about research preferences.~This is not part of standard care and results do not contribute to usual care - thus is an 'interventional' study."
62597472|NCT05116202|EXPERIMENTAL|Cohort 2: RO7247669 2100 mg + Tiragolumab|Cohort 2 participants in RO7247669 plus tiragolumab arm will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
62239932|NCT01372553||Family history risk stratification|primary care patients who receive risk stratification and clinical decision support based upon the family health history they entered in to MeTree
62239933|NCT05653323|EXPERIMENTAL|Part A: Single Ascending Dose (SAD)|Participants will be randomized to receive a single dose of different dose levels of VX-993.
62239934|NCT05653323|EXPERIMENTAL|Part B: Multiple Ascending Dose (MAD)|Participants will be randomized to receive multiple doses of different dose levels of VX-993. The dose levels will be determined based on the data from Part A.
62239935|NCT05653323|PLACEBO_COMPARATOR|Placebo Part A|Participants will be randomized to receive placebo matched to VX-993.
62430278|NCT01476345|EXPERIMENTAL|LY2963016|A single 0.5 units/kilogram (U/kg) dose of LY2963016 administered subcutaneously followed by minimum washout interval of 7 days.
62430279|NCT01476345|EXPERIMENTAL|Lantus|A single 0.5 U/kg dose of Lantus administered subcutaneously followed by minimum washout interval of 7 days.
62430280|NCT01872468|NO_INTERVENTION|Control|There is not intervention in this group.
62239936|NCT05653323|PLACEBO_COMPARATOR|Placebo Part B|Participants will be randomized to receive multiple doses of placebo matched to VX-993.
62239937|NCT05212896|EXPERIMENTAL|Dose Escalation: Phase Ia|Participants will receive escalating doses of BC006 at assigned dose (0.08, 0.3, 1.0, 3.0, 10, 20 mg/kg) via intravenous (IV) infusion every 2 weeks until disease progression, unacceptable toxicity, withdrawal of informed consent, or up to 48 weeks of treatment, whichever occurs first.
62239938|NCT05212896|EXPERIMENTAL|Dose Expansion: Phase Ib Cohort 1|Participants with GCTTS will receive BC006 at recommended dose for expansion (RDE) IV every 2 weeks until disease progression, unacceptable toxicity, withdrawal of informed consent, or up to 24 weeks of treatment, whichever occurs first.
62239939|NCT05212896|EXPERIMENTAL|Dose Expansion: Phase Ib Cohort 2~4|Participants with other solid tumors will receive BC006 at RDE IV every 2 weeks until disease progression, unacceptable toxicity, withdrawal of informed consent, or up to 48 weeks of treatment, whichever occurs first.
62239940|NCT00463268|ACTIVE_COMPARATOR|1|Alendronate 70 mg every 2 weeks
62597473|NCT05116202|EXPERIMENTAL|Cohort 1: RO7247669 600 mg|Cohort 1 participants in the RO7247669 arm will receive treatment for 2 cycles (6 weeks) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
62597474|NCT05116202|EXPERIMENTAL|Cohort 1: RO7247669 600 mg + Tiragolumab|Cohort 1 participants in the RO7247669 plus tiragolumab arm will receive treatment for 2 cycles (6 weeks) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
62597475|NCT05613608|ACTIVE_COMPARATOR|Full-Spectrum Cannabidiol|210mg/day of full-spectrum cannabidiol, containing less than 0.3% THC.
62239941|NCT00463268|PLACEBO_COMPARATOR|2|Alendronate 70 mg placebo tablet every 2 weeks
62597476|NCT05613608|ACTIVE_COMPARATOR|Broad-Spectrum Cannabidiol|210mg/day of full-spectrum cannabidiol, containing 0.0% THC.
62597477|NCT05613608|PLACEBO_COMPARATOR|Placebo|210mg/day of hemp seed oil with no cannabinoids present.
62597478|NCT02183805|EXPERIMENTAL|Metastatic triple negative breast cancer|Abraxane,Cyclophosphamide,Carboplatin
62239942|NCT05226754|ACTIVE_COMPARATOR|GROUP A|diacerein 50 mg (capsules) every 12 hours for 10 days
62597479|NCT04220021|EXPERIMENTAL|C9orf72 positive ALS|"Subjects with C9orf72 positive ALS will be instructed in the use of Metformin and receive the first dose of Metformin under supervision of the investigator during Visit 1, Day 2.~Subjects will then continue on Metformin per the dose escalation schedule twice daily for 24 weeks."
62597480|NCT02215551||Study Group|"Younger than 90 years old. no communication barriers (e.g., English speaking, household telephone) Affirmative response to each of the three following questions: a) Do patients have pain, weakness, numbness, or tingling in their legs when walking standing? b) Does this pain, weakness, numbness or tingling in their legs interfere with their daily activities? c) Have patients tried at least one non-surgical treatment for their leg symptoms (e.g., physical therapy, pain medications, spinal injection)? Have been scheduled for surgery on lower back for a condition called lumbar spinal stenosis.~Whom have non degenerative causes of LSS such as tumor, infection, trauma, hemorrhage, or epidural lipomatosis, Prior lumbar spinal surgery, spondylolisthesis with spinal instability, significant cognitive impairment."
62597481|NCT01022294|EXPERIMENTAL|Arm 1|Inhalation of nitrousoxide-oxygen during the first experimental session; inhalation of atmospheric air during the second session
62597482|NCT01022294|EXPERIMENTAL|Arm 2|Inhalation of atmospheric air during the first experimental session; inhalation of nitrousoxide-oxygen during the second session
62597483|NCT03248310||vascularized lymph node transfer (VLNT)|This is an observational study to assess QOL in patients who have elected to undergo or considered undergoing VLNT. There is no therapeutic intervention involved during the follow-up study period.
62597484|NCT03248310||non-surgical treatment|This is an observational study to assess QOL in patients who have elected to undergo or considered undergoing VLNT. There is no therapeutic intervention involved during the follow-up study period.
62597485|NCT03443310|OTHER|Ultrasound assessment of DVT|DVT ultrasound vs Clinical assessment in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
62597486|NCT00989456|EXPERIMENTAL|exercise and education|Supervised physical exercise in groups, plus a self management education programme (patient education).
62597487|NCT00989456|ACTIVE_COMPARATOR|exercise only|Supervised physical exercise in groups.
62597488|NCT04114357|EXPERIMENTAL|Supplement Intervention and Control Diet, then Control Diet Alone|This group will first consume the supplement daily for 4 weeks in addition to the diabetic diet then cross-over to follow the diabetic diet for 4 weeks.
62815922|NCT04101630||Healthy Volunteers|Participants will undergo activity monitoring for 12 weeks, at baseline and once a year for 3 years. Patient reported outcomes will be collected including Quality of Life questionnaires \[emphasis-10, Minnesota Living with Heart Failure (MLHF), and SF-36 surveys\], medication changes, hospitalization, and death.
62239943|NCT05226754|PLACEBO_COMPARATOR|GROUP B|placebo capsules (lactose and magnesium stearate)
62430281|NCT01872468|ACTIVE_COMPARATOR|Structured intervention|Initial training session based on significant learning and follow up visits every four months at physicians and nurses´ offices over a two-year period
62430282|NCT05872074|NO_INTERVENTION|Conventional balloon|patients Who will undergo conventional provisional stenting using standard technique with plain balloon angioplasty wire both branches, MV and SB, with two coronary guide wires. Main branch pre-dilation Side branch pre-dilation using ordinary balloon for the side branch) Main vessel stenting Proximal optimization technique (POT) of the main vessel stent
62430283|NCT05872074|EXPERIMENTAL|Drug coated balloon|"patients Who will undergo provisional stenting using Drug coated balloon (paclitaxel-coated balloon (PCB)) wire both branches, main vessel and side branch, with two coronary guide wires.~Main branch pre-dilation Side branch pre-dilation using Drug coated balloon (paclitaxel-coated balloon for the side branch Main vessel stenting Proximal optimization technique (POT) of the main vessel stent"
62430284|NCT05706428|ACTIVE_COMPARATOR|Group I|Nasal high-frequency ventilation (NHFV) group (case group):
62239944|NCT04225468|NO_INTERVENTION|Treatment As Usual (TAU)|No intervention will be administered.
62239945|NCT04225468|EXPERIMENTAL|Opioid Exposure Reduction Program 1 (OERP1)|Participants will engage in a brief, educational intervention at their pre-surgery appointment approximately 2-3 weeks before ACL reconstruction surgery.
62430285|NCT05706428|PLACEBO_COMPARATOR|Group II|Nasal CPAP group (control group):
62430286|NCT02841605|OTHER|AD group|AD group: rectosigmoidospcopy with biopsies of colon
62430287|NCT02841605|OTHER|PD group|PD group: rectosigmoidospcopy with biopsies of colon
62430288|NCT02841605|OTHER|PSP group|PSP group: rectosigmoidospcopy with biopsies of colon
62430289|NCT02841605|OTHER|Patient eligible for colorectal cancer screening|Patient eligible for colorectal cancer screening: colonoscopy with biopsies of colon
62597489|NCT04114357|NO_INTERVENTION|Control Diet Alone, then Supplement Intervention and Control Diet|This group will follow the control diet for 4 weeks first then cross-over to receive the supplement for 4 weeks in addition to the diabetic diet.
62597490|NCT02719912|EXPERIMENTAL|Valve Replacement|Mitral valve replacement
62597491|NCT03256240|ACTIVE_COMPARATOR|side-to-side functional end anastomosis|side-to-side functional end anastomosis creation
62597492|NCT03256240|ACTIVE_COMPARATOR|Kono-S|antimesenteric functional side-to-side handsewn anastomosis, known as the Kono-S anastomosis
62597493|NCT04972968|EXPERIMENTAL|ABBV-154 Dose A|Participants in this group will receive dose A of ABBV-154 subcutaneously (SC) every other week (eow) for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.
62815923|NCT05413590|ACTIVE_COMPARATOR|Young, Active group|"From 18 to 35 years old.~The subjects will be considered as active if after completion of the Global Physical Activity Questionnaire (GPAQ), the subjects count:~* at least 20 minutes of vigorous physical activity per day for 3 or more days per week OR~* at least 30 minutes of moderate physical activity or walking per day for 5 or more days per week OR~* At least 5 days of walking and moderate or vigorous physical activity, reaching a minimum of 600 Metabolic Equivalent of Task (MET)-minutes per week"
62239946|NCT04225468|EXPERIMENTAL|Opioid Exposure Reduction Program 2 (OERP2)|"Participants will engage in the same intervention as OERP1, but those in OERP2 will also receive a 5-minute booster intervention session 3 days after surgery."
62430290|NCT04643782|OTHER|Single Arm Study|After consent, subjects will wear the ANNE sleep system during an attended PSG study for 1 night.
62430291|NCT03667625|EXPERIMENTAL|Aquatic group|Aquatic multidimensional mobility exercises were given in the treatment pool at Balcova Thermal Centre, Izmir, Turkey. Group of 6-7 patients was instructed by a specialized physiotherapist twice in a week for eight weeks. The water temperature was 33-340C and the depth was between 110-140 cm, patients were asked to keep T11 level submersion during vertical exercises. Exercise span was kept 30-40 min in first 4 weeks then increased to 45-50 min with additional exercises.
62430292|NCT03667625|EXPERIMENTAL|Land group|Multidimensional mobility exercises were given at exercise unit of Dokuz Eylul University School of Physical Therapy, Izmir, Turkey. Group of 6-7 patients were instructed by a specialized physiotherapist twice in a week for eight weeks. The room temperature was 23-240C. Exercise span was kept 30-40 min in first 4 weeks then increased to 45-50 min with additional exercises.
62430293|NCT03667625|ACTIVE_COMPARATOR|Control group|A conventional home exercise programme was given by a specialized physiotherapist to control group. Patients were checked and encouraged to continue their programs by weekly phone calls for eight weeks.
62430294|NCT03242382|EXPERIMENTAL|Palbocilib|Palbociclib will be administered orally at a dose of 125 mg once a day for 21 consecutive days followed by 7 rest days to comprise a complete cycle of 28 days.
62430295|NCT01433133|EXPERIMENTAL|1|• Genotype 3 chronic HCV with detectable serum HCV RNA
62430296|NCT04597554|EXPERIMENTAL|Cranberry|4 oz. cranberry beverage (breakfast) and 2 chewable cranberry gummies (lunch) per day for 8 weeks.
62430297|NCT04597554|PLACEBO_COMPARATOR|Placebo|4 oz. placebo beverage (breakfast) and 2 chewable placebo gummies (lunch) per day for 8 weeks.
62430298|NCT00961051|EXPERIMENTAL|Investigational MPS|Investigational multipurpose disinfecting solution (study MPS)
62430299|NCT00961051|ACTIVE_COMPARATOR|Predicate MPS|Opti-Free RepleniSH multipurpose disinfecting solution (predicate MPS)
62430300|NCT01407575|EXPERIMENTAL|Buprenorphine|0.2 to 1.6mg of buprenorphine sublingual over the course of 8 weeks
62430301|NCT01407575|PLACEBO_COMPARATOR|Placebo|matching placebo- sublingual- over the course of 8 weeks
62430302|NCT05926336|EXPERIMENTAL|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
62430303|NCT05926336|EXPERIMENTAL|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
62430304|NCT04300777||Treated with Non-Cervical Pedicle Screw Systems|50 patients who have been implanted with SeaSpine Non-Cervical Pedicle Screw Systems
62430305|NCT03364920||normal level of serum maresin-1|
62597494|NCT04972968|EXPERIMENTAL|ABBV-154 Dose B|Participants in this group will receive dose B of ABBV-154 SC eow for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.
62597495|NCT04972968|EXPERIMENTAL|ABBV-154 Dose C|Participants in this group will receive dose C of ABBV-154 SC eow for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.
62815924|NCT05413590|ACTIVE_COMPARATOR|Young, sedentary group|From 18 to 35 years old. Subjects who are below these thresholds will be considered as sedentary. To avoid including a subject who recently changed his lifestyle (sedentary becoming active or vice versa), the investigator will ensure the subject kept this physical activity level (expressed using the GPAQ) constant for the last 5 years.
62239947|NCT05887817|EXPERIMENTAL|Finerenone|Kerendia® tablets
62239948|NCT05887817|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62239949|NCT00682565|EXPERIMENTAL|Mid Dose CK-1827452 or Placebo|CK-1827452 I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr or placebo, followed by 6 days three times a day oral dose and a final single oral dose
62239950|NCT00682565|EXPERIMENTAL|High Dose CK-1827452 or Placebo|CK-1827452 I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr or placebo, followed by 6 days three times a day oral dose and a final single oral dose
62239951|NCT04339114|SHAM_COMPARATOR|Control meal|Pancake
62239952|NCT04339114|ACTIVE_COMPARATOR|Control meal + Cinnamon|Pancake seasoned with cinnamon
62239953|NCT04339114|ACTIVE_COMPARATOR|Control meal + Italian herb mix|Pancake seasoned with Italian herb mix
62239954|NCT04339114|ACTIVE_COMPARATOR|Control meal + Active-Herbs/Spice mix|Pancake seasoned with pumpkin spice
62239955|NCT04334733|EXPERIMENTAL|Cartoon group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography.
62239956|NCT04334733|EXPERIMENTAL|Kaleidoscope group|The children in the groups were distracted by kaleidoscope during the echocardiography process, until the process was over.
62239957|NCT04334733|EXPERIMENTAL|Cartoon+Kaleidoscope group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography and the children in the groups were distracted by kaleidoscope during the echocardiography process, until the process was over.
62239958|NCT04334733|EXPERIMENTAL|Control group|No intervention was made to children in the control group
62239959|NCT02673203|ACTIVE_COMPARATOR|Lean Healthy Control|(BMI \<25 kg/m2)
62239960|NCT02673203|ACTIVE_COMPARATOR|Obese non-diabetic subject|BMI \> 30 kg/m2
62430306|NCT03364920||abnormal level of serum maresin-1|
62430307|NCT02823873||Normotensive|Normotensive pregnant and postpartum women will have blood pressure measurements administered with standard clinical equipment and the Pulsewave oscillometric wrist cuff blood pressure monitor.
62597496|NCT04972968|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo SC eow for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.
62597497|NCT01317121||Subjects at risk for psychosis|Identification and clinical characterization of subjects with prodromal symptoms will be done in the early diagnosis outpatient center of the University Department of Psychiatry in Hamburg, Germany. Subjects At Risk Mental State (ARMS) for psychosis will be identified if they meet the criteria of the Structured Interview for Prodromal Syndromes (SIPS) (McGlashan et al 2001).
62597498|NCT01317121||Patients with a first episode of schizophrenia|Patients with a first episode of schizophrenia will be recruited from inpatients at the Clinic for Psychiatry and Psychotherapy at the University Hospital (UKE) in Hamburg, Germany. All patients have to meet criteria for DSM-IV and ICD-10 diagnosis for schizophrenia.
62597499|NCT01317121||Healthy control subjects|Healthy control subjects will be recruited from the hospital staff and students at the University Hospital Hamburg-Eppendorf (UKE), Hamburg, Germany. They have to be free from any neurological or psychiatric disorder, according to DSM-IV and ICD-10 criteria.
62597500|NCT06443398||Control Group|Primary caregivers with healthy children between the ages of 0-18 were included.
62597501|NCT06443398||Study Group|Primary caregivers who had a child diagnosed with Cerebral Palsy between the ages of 0-18 and met the inclusion criteria were included.
62239961|NCT00066742|EXPERIMENTAL|Treatment (tirapazamine, cisplatin, etoposide)|"CHEMORADIOTHERAPY: Patients receive tirapazamine IV over 1 hour on days 1, 8, 10, 12, 29, 36, 38, and 40; cisplatin IV over 1 hour on days 1, 8, 29, and 36; and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning on day 1 of chemotherapy, patients undergo thoracic radiotherapy once daily 5 days a week for 7 weeks.~CONSOLIDATION CHEMOTHERAPY: Within 28 days after completion of radiotherapy, patients with stable or responding disease receive cisplatin IV over 1 hour on days 1 and 22 and etoposide IV over 1 hour on days 1-3 and 22-24.~Treatment continues in the absence of disease progression or unacceptable toxicity."
62239962|NCT01119326|PLACEBO_COMPARATOR|Placebo|Placebo procedure
62597502|NCT06316739|EXPERIMENTAL|Immediate intervention neighborhood|According to the trial's wait-list controlled design, the Ganchero intervention will be implemented sequentially in two geographically and socially distinct Bronx neighborhoods with large migrant Puerto Rican populations. In Cycle I, the intervention will be implemented with Gancheros and their clients in neighborhood A, while participants in neighborhood B receive standard access to harm reduction through a local Syringe Services Program (SSP).
62597503|NCT06316739|EXPERIMENTAL|Delayed intervention neighborhood|In Cycle II, the Ganchero intervention will be implemented with Gancheros and their clients in neighborhood B, while participants in neighborhood A receive standard access to harm reduction through a local Syringe Services Program (SSP).
62597504|NCT05282446|EXPERIMENTAL|INV-202|INV-202 25mg by mouth once daily
62597505|NCT05282446|PLACEBO_COMPARATOR|Placebo|Matching placebo by mouth once daily
62597506|NCT05847257|SHAM_COMPARATOR|Group A|group A (29) patients received letrozole 2.5mg twice weekly for 3 months
62239963|NCT01119326|EXPERIMENTAL|Autologous Fat Transfer (AFT) group|Subjects will be registered in the context of either the Early AFT subgroup, or the Delayed AFT subgroup based on the timing of their wound closure: early AFT subgroup will contain subjects who are medically stable such that study sites are amenable to AFT within 2-4 weeks of definitive closure (STSG) or healing (secondary closure) and the delayed AFT subgroup will contain subjects who are medically stable such that study sites are amenable to AFT within 6 months or more of definitive closure (STSG) or healing (secondary closure
62597507|NCT05847257|EXPERIMENTAL|Group B|Group B (38) patients receive letrozole 2.5mg twice a week plus Co Q10 400 mg per day for 3 months
62597508|NCT06563544|EXPERIMENTAL|FCV-VCV|90 minutes of FCV followed by 90 minutes of VCV
62597509|NCT06563544|EXPERIMENTAL|VCV-FCV|90 minutes of VCV followed by 90 minutes of FCV
62597510|NCT02589522|EXPERIMENTAL|Group I (VX-970, whole-brain radiation therapy)|Patients undergo whole-brain radiation therapy QD 5 days a week for 15 fractions. Patients also receive berzosertib IV over 60-90 minutes twice a week, 18-30 hours after first radiation therapy. Treatment continues for 3 weeks in the absence of disease progression or unacceptable toxicity.
62597511|NCT02589522|EXPERIMENTAL|Group II (VX-970, surgery, whole-brain radiation therapy)|Patients receive berzosertib IV over 60-90 minutes 2-4 hours prior to surgery. After surgery, patients undergo whole-brain radiation therapy and receive berzosertib as in Group I.
62597512|NCT03944759|ACTIVE_COMPARATOR|GBM:( bupivacaine/magnesium sulphate)|"serratus plane block will performed in the supine position under strict aseptic conditions before induction of anesthesia.~GBM:( bupivacaine/magnesium sulphate): will receive bupivacaine 30 ml 0.25 and 500 mg magnesium sulphate"
62815925|NCT05413590|ACTIVE_COMPARATOR|Old, Active group|"From 65 to 80 years old.~The subjects will be considered as active if after completion of the Global Physical Activity Questionnaire (GPAQ), the subjects count:~* at least 20 minutes of vigorous physical activity per day for 3 or more days per week OR~* at least 30 minutes of moderate physical activity or walking per day for 5 or more days per week OR~* At least 5 days of walking and moderate or vigorous physical activity, reaching a minimum of 600 MET-minutes per week"
62239964|NCT03882710|EXPERIMENTAL|metoprolol XR capsule|
62239965|NCT03882710|PLACEBO_COMPARATOR|placebo capsule|
62239966|NCT05511623|EXPERIMENTAL|tislelizumab|The external radiation is administered at 45-50Gy/25f and brachytherapy is performed sequentially at 6Gy/time to a total doses of 30 Gy. The concomitant chemotherapy regimen is cisplatin 40mg/m2 on day 1 once every week for 5 weeks. In addition, patients also receive tislelizumab (200 mg, day 1) once every 3 weeks until disease progression or intolerable toxicity occurs or one year.
62239967|NCT05511623|ACTIVE_COMPARATOR|concurrent chemoradiotherapy|The external radiation is administered at 45-50Gy/25f and brachytherapy is performed sequentially at 6Gy/time to a total doses of 30 Gy. The concomitant chemotherapy regimen is cisplatin 40mg/m2 on day 1 once every week for 5 weeks.
62597513|NCT03944759|ACTIVE_COMPARATOR|GBN: ( bupivacaine/nalpuphin)|serratus plane block will performed in the supine position under strict aseptic conditions before induction of anesthesia.. ( bupivacaine/nalpuphin):received bupivacaine 30 ml 0.25 % and nalpuphine 0.2mg/kg.
62815926|NCT05413590|ACTIVE_COMPARATOR|Old sedentary group|From 65 to 80 years old. Subjects who are below these thresholds will be considered as sedentary. To avoid including a subject who recently changed his lifestyle (sedentary becoming active or vice versa), the investigator will ensure the subject kept this physical activity level (expressed using the GPAQ) constant for the last 5 years.
62815927|NCT05413590|ACTIVE_COMPARATOR|Very old, Active group|"From 81 years old.~The subjects will be considered as active if after completion of the Global Physical Activity Questionnaire (GPAQ), the subjects count:~* at least 20 minutes of vigorous physical activity per day for 3 or more days per week OR~* at least 30 minutes of moderate physical activity or walking per day for 5 or more days per week OR~* At least 5 days of walking and moderate or vigorous physical activity, reaching a minimum of 600 MET-minutes per week"
62815928|NCT05413590|ACTIVE_COMPARATOR|Very old sedentary group|From 81 years old. Subjects who are below these thresholds will be considered as sedentary. To avoid including a subject who recently changed his lifestyle (sedentary becoming active or vice versa), the investigator will ensure the subject kept this physical activity level (expressed using the GPAQ) constant for the last 5 years.
62815929|NCT06702319|NO_INTERVENTION|home exercise program|A total of at least 23 Participants will receive the home exercise program for 6 weeks.
62815930|NCT06702319|EXPERIMENTAL|internal focus exercise program|A total of at least 23 Participants will receive the internal focus exercise program for 6 weeks.
62815931|NCT06702319|EXPERIMENTAL|external focus exercise program|A total of at least 23 Participants will receive the external focus exercise program for 6 weeks.
62239968|NCT02072434|EXPERIMENTAL|Edoxaban|Edoxaban oral tablet, 60 mg-once daily (QD), reduced to 30 mg based on protocol-defined parameters, for up to 49 days
62239969|NCT02072434|ACTIVE_COMPARATOR|Warfarin|"Participants naïve to anticoagulation, taking anticoagulants other than a Vitamin K antagonist (VKA) or taking a VKA but with a prothrombin time (PT) international normalized ratio (INR) of less than 2.0 receive enoxaparin until they reach a PT INR of at least 2.0, before taking warfarin.~All participants in this arm receive warfarin oral tablet QD at their doctor's prescribed dose, for up to 49 days."
62239970|NCT02959567|EXPERIMENTAL|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
62430308|NCT02823873||Hypertensive|Hypertensive pregnant and postpartum women will have blood pressure measurements administered with standard clinical equipment and the Pulsewave oscillometric wrist cuff blood pressure monitor.
62430309|NCT01760694|EXPERIMENTAL|Resectable Patients|Surgery with Intraoperative Radiation Therapy (IORT). Radiation Therapy within 6-8 weeks after surgery followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery
62430310|NCT01760694|EXPERIMENTAL|Marginally Resectable Patients|2-3 cycles of neoadjuvant FOLFIRINOX then restaged, then undergo surgery with Intraoperative Radiation Therapy (IORT) within 2-4 weeks following chemotherapy. Then Radiation Therapy within 6-8 weeks followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery for a total of 2-4 cycles
62430311|NCT02597283|EXPERIMENTAL|Biguard stent system|PCI with Biguard sirolimus-eluting bifurcation stent system
62430312|NCT02597283|ACTIVE_COMPARATOR|Sirolimus-eluting stent system|PCI with regular sirolimus-eluting stent system
62597514|NCT02396303|EXPERIMENTAL|Patient receiving carbetocin|Experimental group subjects will receive intravenous Carbetocin during third stage of labour.
62597515|NCT02396303|ACTIVE_COMPARATOR|Patient receiving oxytocin|Comparator group subjects will receive intramascular Oxytocin during third stage of labour.
62815932|NCT02973971||Healthy subjects|
62815933|NCT02973971||Alzheimer patients|
62815934|NCT04875325|EXPERIMENTAL|Standardized surveillance|Standardized surveillance strategy with routine imaging and serum tumor marker testing.
62239971|NCT05128721|ACTIVE_COMPARATOR|NRC-VACC-101 vaccine 3 microgram|Volunteers will receive two IM doses of the vaccine, concentrations of 3 mcg, 28 days apart.
62430313|NCT01134588|ACTIVE_COMPARATOR|Reference group|This group will fill out paper questionnaires.
62430314|NCT01134588|EXPERIMENTAL|Experimental group|This group will fill out touch-screen questionnaires.
62430315|NCT02047058||high-risk|high-risk is determined by the evaluation of the biomarkers of Q cell.
62430316|NCT01138566||ESBL- and/or AmpC-(+) or (-)|
62430317|NCT05897762|OTHER|Clinic Grup|the same exercises were performed in the clinical setting, accompanied by a physiotherapist. The evaluations were made before and after the treatment.
62430318|NCT01265888|EXPERIMENTAL|Dosing Group 1|1 Liter per Minute (LPM)of inhaled nitric oxide via nasal cannula: approximately 5 parts per million (ppm)
62430319|NCT01265888|EXPERIMENTAL|Dosing Group 2|2 LPM of inhaled nitric oxide via nasal cannula: approximately 15 ppm
62430320|NCT01265888|EXPERIMENTAL|Dosing Group 3|4 LPM of inhaled nitric oxide via nasal cannula: approximately 20 ppm
62430321|NCT01767545|ACTIVE_COMPARATOR|Dexamethasone-implant (Group 1)|Group 1 included 38 patients (22 with CRVO and 16 with BRVO) and was treated with a dexamethasone-implant injection from the beginning.
62430322|NCT01767545|ACTIVE_COMPARATOR|Bevacizumab/Dexamethasone-implant (Group 2)|Group 2 included 26 patients (14 CRVO, 12 BRVO) and was treated with three consecutive injections of bevacizumab at a monthly interval, followed by a dexamethasone-implant injection four weeks after the last bevacizumab injection.
62430323|NCT03318237||Patients with focal epilepsy|Patients undergoing ultra high field MRI of the brain
62430324|NCT03091894|ACTIVE_COMPARATOR|propofol|patients will receive only propofol intravenous infusion for sedation
62430325|NCT03091894|ACTIVE_COMPARATOR|propofol-dex.|patients will receive dexmedetomidine in addition to propofol intravenous infusion for sedation
62597516|NCT04889196|ACTIVE_COMPARATOR|control group|The group that have caries in primary molars and treat them with hall technique
62597517|NCT04889196|EXPERIMENTAL|experimental group|the group that have caries in primary molars and treat them with silver diamine fluoride (SDF) solution would exert a prevention result in managing early childhood caries ECC
62597518|NCT05341336|EXPERIMENTAL|Surgical excision|complete surgical excision of the scalp AVMs after identifying feeding arteries, vein and high flew shunts to perform a complete devascularization of the AVM.
62815935|NCT04875325|NO_INTERVENTION|Non-standardized surveillance|Non-standardized surveillance strategy according to current clinical practice.
62815936|NCT01533792|EXPERIMENTAL|Supra/subgingival therapy|The experimental group received supra and subgingival scaling associated with oral hygiene orientation (OHO)
62815937|NCT01533792|ACTIVE_COMPARATOR|Control group|Control group received only supragingival scaling with OHO too.
62815938|NCT00525720|EXPERIMENTAL|Brachytherapy - Participants with < 35% biopsy core|Brachytherapy implant procedure lasting 1-2 hours. Questionnaires taking 30 total minutes.
62815939|NCT00525720|EXPERIMENTAL|Brachytherapy - Participants with > 35% biopsy core|Brachytherapy implant procedure lasting 1-2 hours. Questionnaires taking 30 total minutes.
62239972|NCT05128721|ACTIVE_COMPARATOR|NRC-VACC-101 vaccine 6 microgram|Volunteers will receive two IM doses of the vaccine, concentrations of 6 mcg, 28 days apart.
62815940|NCT02873858|ACTIVE_COMPARATOR|1.independent patients|
62239973|NCT05128721|PLACEBO_COMPARATOR|Control arm|Volunteers will receive two IM doses of the placebo (excipients only), 28 days apart.
62239974|NCT01603732||Moms w HLHS or variant|Mom's fetal diagnosis Hypoplastic Left Heart Syndrome/variant
62239975|NCT01603732||Moms w/ Other congential heart defect)|Moms fetal diagnosis -other congenital heart defects
62239976|NCT01603732||Moms-fetal - echo normal|Moms echo fetal diagnosis is normal.
62430326|NCT05504616|EXPERIMENTAL|Intervention Group|"Participants randomized to the intervention group will receive an initial electronic communication (i.e. email) that includes:~* Link to physical activity education. This will be an educational module based on Phase 1 results and evidence-based literature regarding the benefits of physical activity in the general population and specific to axSpA.~* One week after receiving the physical activity educational module, participants will receive access to the ADAS application and an .ics file for each 3-week cycle of electronic calendar reminders to engage in physical activity."
62430327|NCT05504616|NO_INTERVENTION|Control Group|Participants randomized to the control group will receive usual care, which includes standard rheumatology care and access to educational materials on the importance of exercise and physical activity available through the TWH Spondylitis Program and through the public domain. They will receive a link to the physical activity educational module at baseline. They also have access to the program physiotherapist for a single one-hour individualized exercise consultation as requested by either the patient or the treating rheumatologist.
62430328|NCT02465307||Delirium group|ICU patients with a positive Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).
62430329|NCT02465307||Control group|ICU patients with a negative Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).
62430330|NCT02465307||Healthy control group|Healthy subjects that sleep in their home environment; observational using accelerometers, cortisol swabs, and Internet Pod (iPod)
62430331|NCT04832165|EXPERIMENTAL|Muscle inspiratory strength training|An 8-week muscle inspiratory muscle strength training
62430332|NCT04832165|NO_INTERVENTION|No training program|No intervention
62430333|NCT04916860|EXPERIMENTAL|CD7 CAR-T|
62430334|NCT00204932|ACTIVE_COMPARATOR|CLA treatment|The group randomized to Conjugated Linoleic Acid (CLA) treatment at 4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA; and 22% safflower oil for 6 months
62815941|NCT02873858|EXPERIMENTAL|2. less mobile patients|
62815942|NCT02873858|EXPERIMENTAL|patient in a residence|
62815943|NCT02873858|EXPERIMENTAL|patients in a home for the elderly (EHPAD)|
62815944|NCT02299596|EXPERIMENTAL|Pre and postoperative exercise|"The intervention is prehabilitation preoperatively and physical training postoperatively. During the hospital stay both groups will be treated in the same manner.~Preoperative intervention:~One half hour of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Inspiratory muscle training. Thirty breaths x two twice daily. Postoperative intervention is mainly the same as preoperatively."
62430335|NCT00204932|PLACEBO_COMPARATOR|Placebo|The group randomized to control received 4 g/d of safflower oil.
62430336|NCT02948478||Precarious patients|Precarious patients - exposed - will be those identified as precarious by at least one of the three scores (EPICES, Pascal, European Deprivation Index)
62430337|NCT02948478||Non precarious patients|Non precarious patient - non exposed - will be all the patients identified as non-precarious by the three scores (EPICES, Pascal, European Deprivation Index)
62430338|NCT06379022||Implant unit|Newly restored single implant that is closely followed for plaque control
62430339|NCT06379022||Tooth unit|A contralateral tooth that is closely followed for plaque control
62815945|NCT02299596|NO_INTERVENTION|Control|Standard treatment with one exception, patients will fill in a physical activity diary
62239977|NCT01603732||Random Healthy Moms|Mom with healthy pregnancy.
62815946|NCT06522906|EXPERIMENTAL|Intervention|Treatments include educational sessions about OA, a muscle strengthening program, and a program that will aim to promote regular physical activity involving dyads
62815947|NCT06522906|ACTIVE_COMPARATOR|Control|Treatment only includes live video educational sessions about OA
62815948|NCT05425784|EXPERIMENTAL|Lumoral Treatment (Study group)|"Subjects will receive detailed instructions for the use of Lumoral treatment -device and Lumorinse -tablets. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol five to seven (5-7) times a week. Regular use shall be defined as frequency of a minimum of twice a week.~Standard oral hygiene instructions will be provided verbally and in writing. In addition, an electric toothbrush will be provided to all subjects."
62815949|NCT05425784|ACTIVE_COMPARATOR|Standard of care (Control group)|Standard oral hygiene instructions will be provided verbally and in writing. In addition, an electric toothbrush will be provided to all subjects.
62815950|NCT06526260|EXPERIMENTAL|Image Exposure Arm|Participants will see various images of facial expressions on a computer screen and provide various rating scores about them.
62815951|NCT06303960|ACTIVE_COMPARATOR|Bilateral Cerebellar deep brain stimulation|Following enrollment, participants underwent 1 month of upper-extremity rehabilitation twice per week to rule out potential for recovery with rehabilitation therapy alone. Thereafter, each participant underwent surgical implantation of the DBS system, with the lead implanted in the DN contralateral to the stroke-affected cerebral hemisphere. 1 months later, DBS was activated bilaterally.
62815952|NCT06303960|ACTIVE_COMPARATOR|Unilateral Cerebellar deep brain stimulation|Following enrollment, participants underwent 1 month of upper-extremity rehabilitation twice per week to rule out potential for recovery with rehabilitation therapy alone. Thereafter, each participant underwent surgical implantation of the DBS system, with the lead implanted in the DN contralateral to the stroke-affected cerebral hemisphere. 1 months later, DBS was activated unilaterally.
62815953|NCT06303960|EXPERIMENTAL|Vagus Nerve Stimulation|Following enrollment, participants underwent 1 month of upper-extremity rehabilitation twice per week to rule out potential for recovery with rehabilitation therapy alone. Thereafter, each participant underwent surgical implantation of the VNS system. 1 months later, VNS was activated unilaterally.
62815954|NCT01293903|EXPERIMENTAL|Qiliqiangxin capsule|
62815955|NCT01293903|PLACEBO_COMPARATOR|Placebo|
62815956|NCT06589531|EXPERIMENTAL|6-mm shunt TIPS group|The diameter of TIPS covered stent is 6mm.
62815957|NCT06589531|ACTIVE_COMPARATOR|8-mm shunt TIPS|The diameter of TIPS covered stent is 8mm.
62815958|NCT02921035||Relapsing Multiple Sclerosis (RMS) group|Subjects diagnosed with RMS who are prescribed Rebif (Interferon beta-1a)
62815959|NCT00764699|EXPERIMENTAL|rhIGF|Treatment with rhIGF (Increlex)
62815960|NCT05647135||Group A|Group A - enteral formula with 6.3 g/100 ml protein
62815961|NCT05647135||Group B|enteral formula with 10 g/100 ml protein
62815962|NCT05816252|EXPERIMENTAL|Cohort 1 1L NSCLC, EGFR/ALK negative and PD-L1 TPS ≥ 1%|SKB264 (Dose Level 1) + Pembrolizumab
62430340|NCT04498052|EXPERIMENTAL|Patients eligible for LDCT lung cancer screening|"This population will consist of patients eligible for, or potentially eligible for, LDCT lung cancer screening according to USPSTF guidelines, who are seen by a pilot user of the intervention. The inclusion criteria are (i) \>= 55 years and \<= 80 years old at the time of the visit; (ii) does not already have lung cancer; and (iii) meets USPSTF smoking criteria for LDCT screening (30+ pack-year smoking history and current smoker or quit in the past 15 years) or may meet the criteria if a complete smoking history were taken.~USPSTF guidelines may change during the study. In particular, it is anticipated that the guidelines may update during the study whereby the minimum age is reduced to 50 (from 55) and the minimum smoking history is reduced to 20 years (from 30). In the event that the USPSTF guidelines change, the intervention will be updated to match the change to the guidelines. We may also update the study evaluation to match the updated USPSTF guidelines."
62430341|NCT02969733|EXPERIMENTAL|Xylocaine|intravenous administration
62430342|NCT02969733|EXPERIMENTAL|Ketamine|intravenous administration
62430343|NCT02969733|PLACEBO_COMPARATOR|isotonic saline serum|isotonic saline serum intravenous administration
62430344|NCT00065065|EXPERIMENTAL|Rosiglitazone|4 mg of rosiglitazone taken twice daily for 12 weeks.
62430345|NCT00065065|PLACEBO_COMPARATOR|placebo|Identical in appearance to study drug taken twice daily for 12 weeks.
62430346|NCT01838083|EXPERIMENTAL|Insulin glargine new formulation (test T formulation)|Once daily for 6 days
62430347|NCT01838083|EXPERIMENTAL|Insulin glargine new formulation (reference R formulation)|Once daily for 6 days
62430348|NCT03630718|NO_INTERVENTION|Control Group (CG)|Patients assigned to no intervention
62430349|NCT03630718|ACTIVE_COMPARATOR|Psychoeducational Intervention Group (EG-EDU)|Patients assigned to psychoeducational intervention
62430350|NCT03630718|ACTIVE_COMPARATOR|Hypnosis intervention Group (EG-HYP)|Patients assigned to hypnosis intervention
62430351|NCT03579147|EXPERIMENTAL|Treatment Group|Treatment with the investigational device BTL EMSCULPT.
62815963|NCT05816252|EXPERIMENTAL|Cohort 3 1L NSCLC, EGFR/ALK negative, regardless of PD-L1 expression level|SKB264 (Dose Level 1') + Pembrolizumab + Carboplatin
62815964|NCT05816252|EXPERIMENTAL|Cohort 4 1L NSCLC, EGFR/ALK negative, regardless of PD-L1 expression level|SKB264 (Dose Level 1'') + Pembrolizumab + Carboplatin
62815965|NCT05816252|EXPERIMENTAL|Cohort 5 NSCLC with EGFR mutation and after failure of EGFR TKI therapy|SKB264 (Dose Level 1') + Carboplatin
62815966|NCT05816252|EXPERIMENTAL|Cohort 6 NSCLC with EGFR mutation and after failure of EGFR TKI therapy|SKB264 (Dose Level 1'') + Carboplatin
62815967|NCT05816252|EXPERIMENTAL|Cohort 7 1L NSCLC with EGFR mutation|SKB264 (Dose Level 1) + Osimertinib
62815968|NCT05816252|EXPERIMENTAL|Cohort 7-1 1L NSCLC with EGFR mutation|SKB264 (Dose Level 2) + Osimertinib
62430352|NCT03319381||w/o SOP|Time period 1: 2000-2006, without new SOPs
62430353|NCT03319381||SOP|Time period 2: 2010-2012, after implementation of the new SOPs
62815969|NCT05816252|EXPERIMENTAL|Cohort 9 2/3L NSCLC EGFR/ALK negative|SKB264 (Dose Level 1)
62815970|NCT05064735|EXPERIMENTAL|semaglutide 2.4 mg|Participants will receive semaglutide subcutaneous (s.c) 2.4 mg once-weekly as adjunct to a reduced-calorie diet and increased physical activity
62815971|NCT05064735|PLACEBO_COMPARATOR|semaglutide 2.4 mg (placebo)|Participants will receive semaglutide subcutaneous (s.c) placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
62430354|NCT00667433|OTHER|Single Arm|Single arm where subjects will receive Raltegravir 400 mg BID along with Truvada once a day for 104 weeks
62815972|NCT04727970|EXPERIMENTAL|Tricaprilin|Tricaprilin will be administered for 5-21 days. The total daily dose (individual per subject up to a maximum of 10g/kg/day) will be split into 4 doses administered orally, approximately every 6 hours.
62815973|NCT04079296|EXPERIMENTAL|Dose Escalation (Phase 1): ASP7517 1x10^6 cells/mL|Participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) and R/R higher risk Myelodysplastic Syndrome (MDS) received intravenous (IV) infusion of ASP7517 (human embryonic kidney cell \[HEK293\] transfected with encoding target WT-1) at a dose of 1x10\^6 cells/milliliters (mL) at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days).
62430355|NCT05789680||Parathyroid carcinoma among patients undergoing surgical treatment of primary hyperparathyroidism|All adult (18 years old and older) patients registered in EUROCRINE® database that underwent surgery for primary hyperparathyroidism and received histopathologic diagnosis of parathyroid carcinoma from 2015 till 2021 will be included
62430356|NCT00420290|ACTIVE_COMPARATOR|Kineret|Interleukin-1 receptor antagonist
62430357|NCT00420290|PLACEBO_COMPARATOR|Placebo|
62815974|NCT04079296|EXPERIMENTAL|Dose Escalation (Phase 1): ASP7517 1x10^7 cells/mL|Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10\^7 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days).
62815975|NCT04079296|EXPERIMENTAL|Dose Escalation (Phase 1): ASP7517 1x10^8 cells/mL|Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10\^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days).
62430358|NCT04317729|EXPERIMENTAL|Diagnostic|Collection of whole blood via fingerstick and venipuncture
62430359|NCT04124978|EXPERIMENTAL|Intervention group|prospective, single armed, single centre trial study using the MyTAP device on a daily basis for a period of 3 months
62430360|NCT01497574|EXPERIMENTAL|Insulin detemir|
62430361|NCT01497574|ACTIVE_COMPARATOR|Insulin glargine|
62430362|NCT02616679||Cognitively Normal|Participants will be deemed cognitively normal based on criteria set forth by the National Alzheimer's Disease Coordinating Center/Alzheimer's Disease Centers (ADCC/ADC).
62430363|NCT02616679||Amnestic Mild Cognitive Impairment (aMCI)|Participants will be deemed aMCI based on criteria set forth by the National Alzheimer's Disease Coordinating Center/Alzheimer's Disease Centers (ADCC/ADC).
62430364|NCT04867967|EXPERIMENTAL|Iyengar Yoga Intervention|"8-week yoga class; once weekly; 90 minutes~Note: First administered face-to-face, due to Covid-restrictions changed to online classes"
62430365|NCT04867967|ACTIVE_COMPARATOR|Mindfulness-based stress reduction|"8-week MBSR class; once weekly; 90 minutes~Note: First administered face-to-face, due to Covid-restrictions changed to online classes"
62430366|NCT04867967|NO_INTERVENTION|Waitlist control|Waitlist control, ususal care
62430367|NCT02063698|EXPERIMENTAL|Arm I (auranofin)|Patients receive auranofin PO on day 2.
62430368|NCT02063698|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO on day 2.
62815976|NCT04079296|EXPERIMENTAL|Dose Expansion (Phase 2: AML): ASP7517 1x10^8 cells/mL|Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10\^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days).
62430369|NCT04613895|EXPERIMENTAL|fed state group|just after a meal
62430370|NCT04613895|EXPERIMENTAL|fasted state group|before a meal
62430371|NCT05332080|EXPERIMENTAL|Telerehabilitation via application on cell phone|The patients in this group had application installed on their cell phones to access the online content, where they received advice on self-care and the type of exercises to be performed. The program consisted of hydrotherapy, mobility exercises, muscle strengthening, and activities to improve wrist and hand function, with planned 4-week objectives. Participants in both groups were provided with written exercise material, training, and advice on how to return to work and leisure activities. Each patient made a weekly record of the therapy he/she performed, including the day, type, and time of development of his/her exercises
62430372|NCT05332080|NO_INTERVENTION|In-person rehabilitation|The patients in this group received an in-person rehabilitation program and was considered the control group, this group received for two weeks a 10-session program for two weeks that included external heat application, stretching, mobilization, strengthening, and occupational therapy. Moreover, it was complemented with occupational therapy focused on improving essential functions and strengthening extrinsic and intrinsic hand musculature, effectiveness in wrist mobility, and simulation of specific activities for reincorporation to work
62430373|NCT01284244|EXPERIMENTAL|Uresta|
62430374|NCT01284244|SHAM_COMPARATOR|Silastic vaginal ring|
62430375|NCT03262233|EXPERIMENTAL|Active Deprived|"21 mg nicotine patches and 2 mg nicotine lozenges~+ First NPU task takes place 24 hours after start of quit attempt"
62430376|NCT03262233|EXPERIMENTAL|Active Non-deprived|"21 mg nicotine patches and 2 mg nicotine lozenges~+ First NPU task takes place during normal smoking prior to quit attempt"
62430377|NCT03262233|ACTIVE_COMPARATOR|Placebo Deprived|"Placebo patches and placebo lozenges~+ First NPU task takes place 24 hours after start of quit attempt"
62430378|NCT03262233|ACTIVE_COMPARATOR|Placebo Non-deprived|"Placebo patches and placebo lozenges~+ First NPU task takes place during normal smoking prior to quit attempt"
62430379|NCT01779531||pCR，XT|
62430380|NCT03603431|EXPERIMENTAL|Single Ascending Dose - MRG-110|Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites
62430381|NCT03603431|PLACEBO_COMPARATOR|Single Ascending Dose - Placebo|Intradermal injection of placebo at four wound sites
62430382|NCT03603431|EXPERIMENTAL|Multiple Ascending Dose - MRG-110|Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites
62430383|NCT03603431|PLACEBO_COMPARATOR|Multiple Ascending Dose - Placebo|Intradermal injection of placebo at four wound sites
62430384|NCT03374137||obinutuzumab|Participants with follicular lymphoma or previously untreated chronic lymphocytic leukemia will be treated with obinutuzumab.
62239978|NCT04888520|EXPERIMENTAL|Tensioning protocol of the elastic bandage (WT)|The group will have progressive tension throughout the week - based on the reduction of the tape in relation to the size of the applied area (which will always be the same), which generates a longitudinal tension of the tape in relation to the participant's skin. The Therapy Tex® brand has the elastic deformation capability of up to 40%. The tensioning protocol of the elastic bandage will work with 20% of the elastic deformation capacity of the bandage. The tension will be given from point A to point B in order to generate excitatory stimuli. The percentage of 20% reduction in tension will be distributed over the 7 weeks of intervention, and the first week of the protocol included application without tension. The tape reduction will be controlled by the formula: (size of the application area on the skin\*20% /7 weeks= size of the tape to be cut in each of the 7 applications starting from the second week. Tape size and tape application area will be calculated in centimeters (cm).
62239979|NCT04888520|PLACEBO_COMPARATOR|Free tension|The group will have no tension in any of its tape applications; that way the size of the tape over the applied area will always be the same.
62430385|NCT01725074|EXPERIMENTAL|"Case Management CM CHD"|The intervention consists of a biweekly telephone or personal contact by trained case managers over the first 6-months and monthly contact over the second 6-months to assess well-being, everyday life (positive, neutral and negative daily events), and to inquire after health and personal problems on which basis the case manager offers practical or emotional support or a referral to the general practitioner if deemed necessary. During the contacts also medical control measures like blood pressure or weight are taken, and other study outcome measures like need for medical treatment.
62430386|NCT01725074|EXPERIMENTAL|Social Interaction|Identical as the CM CHD group, but with exclusion of medical control measures.
62430387|NCT01725074|NO_INTERVENTION|Control Group|Patients assigned to the control group received usual care (no additional contact/support) and therefore stays under the standard supervision of the general practitioner i.e. as participant in the normal disease management program for CHD (quarterly check-ups).
62815977|NCT04079296|EXPERIMENTAL|Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 cells/mL|Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10\^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days).
62815978|NCT04053036|EXPERIMENTAL|Placebo Then MDMA|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive MDMA (1.5 mg/kg)
62815979|NCT04053036|EXPERIMENTAL|MDMA Then Placebo|Participants first receive MDMA (1.5 mg/kg) at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive placebo.
62815980|NCT02553213|EXPERIMENTAL|LSG group|Laparoscopic sleeve gastrectomy
62815981|NCT02553213|EXPERIMENTAL|LRYGB group|Laparoscopic Roux-en-Y gastric bypass
62815982|NCT02553213|OTHER|Control group|Caloric restriction
62815983|NCT06029426|EXPERIMENTAL|NMRA-335140 80 milligrams (mg) once daily (QD)|Participants will receive a NMRA-335140 tablet at a dose of 80 mg once daily (QD)
62430388|NCT03268031||Glaucoma patients|Glaucoma patients will take visual field test and OCT imaging of optic nerve area. All of these data will be collected as source of machine learning.
62430389|NCT03268031||Non-glaucoma participants|Non-glaucoma participants will take visual field test and OCT imaging of optic nerve area. All of these data will be collected as source of machine learning.
62735630|NCT03335904|PLACEBO_COMPARATOR|Placebo|Participants will ingest microcrystalline cellulose by mouth on two consecutive days. The first tablet will be consumed on day 1 at 0700 hrs. The second tablet will be consumed at 1900 hrs and the final tablet will be consumed at 0700hrs on day 2. Participants will undergo a Hyperoxic Hypercapnic Ventilatory Response Test, a Hypoxic Hypercapnic Ventilatory Response Test, and Repeated Hypoxic Apneas before and after a Hypoxic Sleep Study.
62815984|NCT06029426|PLACEBO_COMPARATOR|Placebo|Placebo participants will receive matching placebo tablet orally, once daily. Participants who complete the study may be eligible to participate in a separate 52-week open-label long term study.
62815985|NCT03807986|EXPERIMENTAL|Nanofat grafting and PRP injection|Striae diatensae will be treated by nanofat grafting once every three months for 2 times combined with PRP injection once a month for 6 times.
62815986|NCT03807986|EXPERIMENTAL|Microfat grafting and PRP injection|Striae diatensae will be treated by microfat grafting once every three months for 2 times combined with PRP injection once a month for 6 times.
62815987|NCT03973229|EXPERIMENTAL|Cohort 1: PTSD Receiving Estradiol then Placebo|Participants with PTSD will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
62815988|NCT03973229|EXPERIMENTAL|Cohort 1: PTSD Receiving Placebo then Estradiol|Participants with PTSD will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
62815989|NCT03973229|ACTIVE_COMPARATOR|Cohort 1: Trauma without PTSD Receiving Estradiol then Placebo|Participants with trauma exposure will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
62815990|NCT03973229|ACTIVE_COMPARATOR|Cohort 1: Trauma without PTSD Receiving Placebo then Estradiol|Participants with trauma exposure will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
62597519|NCT06511596|EXPERIMENTAL|BR-AC plus Standard Care|"All subjects in the treatment group will receive sponsor-approved standard of care. Standard of care is defined as:~* Debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer, a foam pad, alginate or hydrofiber dressing for moderately draining wounds, a secondary retention bandage, and~* An off-loading device.~Using an appropriate size to cover the entire wound area, BR-AC should be applied directly to the wound surface following sharp debridement w. It is recommended that the product be trimmed to fit the area of the wound with sterile scissors before application."
62815991|NCT03973229|ACTIVE_COMPARATOR|Cohort 1: Healthy Controls Receiving Estradiol then Placebo|Participants without trauma history or psychiatric disorder will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
62815992|NCT03973229|ACTIVE_COMPARATOR|Cohort 1: Healthy Controls Receiving Placebo then Estradiol|Participants without trauma history or psychiatric disorder will will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
62430390|NCT03064633|ACTIVE_COMPARATOR|Dexamethasone arm (group A)|The local anesthetic solution mixture consists of dexamethasone 8 mg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 2 ml dexamethasone = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
62430391|NCT03064633|ACTIVE_COMPARATOR|Dexmedetomidine arm (group B)|The local anesthetic solution mixture consists of dexmedetomidine 80 µg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 80 µg dexmedetomidine in 2 ml = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
62430392|NCT06305637|EXPERIMENTAL|Ketoconazole Shampoo, 2%|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
62430393|NCT06305637|ACTIVE_COMPARATOR|Ketoconazole Shampoo, 2% (Reference Standard)|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
62430394|NCT06305637|PLACEBO_COMPARATOR|Placebo Control|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
62430395|NCT04537702|ACTIVE_COMPARATOR|Tradition Counseling Group (TG)|After completion of baseline surveys, the TG subjects will be referred to a formal pre-test consultation with a genetic counselor. TG subjects will complete an electronic family history questionnaire (FHQ) within one week of the primary visit. A member of the genetics team will curate the results by contacting the subject to review errors and clarify any ambiguities in the pedigree. The TG subjects will then meet with the genetic counselor. After counseling, participants will be given the option to undergo a multi-gene panel genetic test. Those who agree to testing will also complete the standard genetic testing consent form. As per standard practice, patients will also be asked to provide consent for somatic tumor testing of surgical (non-cytologic) specimen. Subjects will complete a post-education distress and anxiety survey (IES) either via an email link to a confidential REDCap survey link 1-2 weeks after formal consultation.
62433673|NCT04331119|EXPERIMENTAL|Duvelisib Maintenance|"* Duvelisib maintenance at 25 mg PO BID after count recovery (approximately 30 days after transplant) for one year. If the patient is in a complete remission at day +100, with no evidence of disease on PET/CT, then the dosing schedule of duvelisib may be changed to 25 mg BID for 14 days, then 14 days off in 28 day cycles (at the treating physician's discretion). If the patient has residual disease, duvelisib will continue at 25 mg BID until they have a negative PET CT. PET CTs will be completed every 3 months for patients with residual disease. Duvelisib maintenance will be continued for one year post-transplant.~* Starting on 06/10/2021, all new participants will be enrolled to take 25 mg BID of duvelisib on days 1-14 of a 28 day cycle."
62815993|NCT03973229|EXPERIMENTAL|Cohort 2: PTSD Receiving Estradiol then Placebo|Participants with PTSD will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
62815994|NCT03973229|EXPERIMENTAL|Cohort 2: PTSD Receiving Placebo then Estradiol|Participants with PTSD will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
62597520|NCT06511596|PLACEBO_COMPARATOR|Standard Care|"All subjects in the control group will receive sponsor-approved standard of care. Standard of care is defined as:~* Debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer, a foam pad, alginate or hydrofiber dressing for moderately draining wounds, a secondary retention bandage, and~* An off-loading device."
62597521|NCT01565226||Open|open, observational study
62597522|NCT05798741|EXPERIMENTAL|Hardware removal|hardware removal
62597523|NCT05798741|NO_INTERVENTION|hardware retaining|Patients that retain their hardware
62597524|NCT06329960|EXPERIMENTAL|Experimental group|Ultrasound-guided dorsal scapular nerve injection combined with needle release of major and minor rhomboideus
62597525|NCT06320431|NO_INTERVENTION|Standard-dose intravenous tenecteplase (0.25 mg/kg body weight)|The intervention group will receive intravenous tenecteplase as a single bolus as per the standard manufacturers' instructions for use. The dose administered will be 0.25 mg/kg body weight (maximum dose 25 mg) over 10-20 seconds as soon as possible after randomization.
62597526|NCT06320431|ACTIVE_COMPARATOR|2) IVT with tenecteplase at low-dose: 0.18 mg/kg|The intervention group will receive intravenous tenecteplase as a single bolus as per the standard manufacturers' instructions for use. The dose administered will be 0.18 mg/kg body weight (maximum dose 18 mg) over 10-20 seconds as soon as possible after randomization.
62597527|NCT06320431|ACTIVE_COMPARATOR|3) No IV thrombolysis [(only in those undergoing EVT or those on DOACs)|No intravenous tenecteplase only applied to subjects on DOACs over the last 24 hours or those planned for emergency EVT
62597528|NCT04514640|EXPERIMENTAL|General Meditation|"Participants will be asked to meditate every day during the daytime for at least 10 min/session. Participants can use any general meditation including the Daily Calm which can be found on the homepage or by clicking on the meditate tab in the app. Participants will be asked to not choose any sleep meditations or Sleep Stories."
62597529|NCT04514640|EXPERIMENTAL|Sleep Meditation|"Participants will be asked to meditate every day just before going to bed for at least 10 min/session. Participants can use any sleep meditations which can be found by clicking on the meditate tab and then sleep. Particpiants will be asked to not choose any general meditations including the Daily Calm or Sleep Stories."
62597530|NCT04514640|EXPERIMENTAL|Sleep Stories|"Participants will be asked to listen to a Sleep Story every day just before going to bed for at least 10 min/session. Participants can listen to any Sleep Story which can be found by clicking on the sleep tab. Participants will be asked to not choose any general meditations including the Daily Calm or sleep meditations."
62597531|NCT04150484|OTHER|interventional group|dietary intervention, physical exercise and mindfulness
62597532|NCT04150484|NO_INTERVENTION|control group|Group without any intervention.
62597533|NCT00704444||Zetia monotherapy|Patients to be treated with Zetia alone (10-mg tablets,) for hypercholesterolemia
62597534|NCT00704444||Zetia combination therapy|Patients to be treated with Zetia (10-mg tablets,) in combination with other lipid-lowering drugs for hypercholesterolemia
62239980|NCT04393051|EXPERIMENTAL|BAR group|"Patients who will be assigned (after a computerized randomization) to the BAR group will. receive baricitinib as adjunctive therapy.~Baricitinib will be administered at 4 mg daily via oral route for 14 days as add-on therapy or 2 mg daily via oral route (eGFR between 30 and 60 ml/min and for patients with age \>75 years old) for 14 days as add-on therapy"
62239981|NCT04393051|NO_INTERVENTION|Control group|Patients in the control group will continue to receive standard therapy.
62239982|NCT04376970|ACTIVE_COMPARATOR|Fluorometholone group|This group included 38 patients treated with topical fluorometholone 0.1% (FLUCON®) 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
62239983|NCT04376970|ACTIVE_COMPARATOR|Cyclosporine A group|This group included 34 patients treated with cyclosporine A 0.5% eye drops prepared in Ricin oil by the pharmacy of Tunis Military Hospital and prescribed 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
62597535|NCT06620978|ACTIVE_COMPARATOR|Low pressure|Low pressure (100 mmHg) Saline medium during hysteroscopy.
62597536|NCT06620978|ACTIVE_COMPARATOR|High pressure|High pressure (150 mmHg) Saline medium during hysteroscopy.
62239984|NCT05679284||Cases: Intravenous drug users with drug needle fragment retentions|All intravenous drug users from the service units will be asked to participate. X-ray imaging has the goal to identify patients with needle fragment retentions in subcutaneous tissue.
62597537|NCT03841968|ACTIVE_COMPARATOR|Dynamic needle tip positioning|Dynamic needle tip positioning
62597538|NCT03841968|ACTIVE_COMPARATOR|Conventional long-axis|Conventional long-axis
62597539|NCT01000350|EXPERIMENTAL|Exercise Post Saline|Saline infusion 1L hours before exercise test
62597540|NCT01000350|PLACEBO_COMPARATOR|Placebo|Placebo given prior to exercise test
62597541|NCT06078709|EXPERIMENTAL|Treatment (FLOT and Radiation and FOLFOX)|Patients received Induction Chemotherapy \[FLOT (5-FU/leucovorin/oxaliplatin/docetaxel)\] following by radiation therapy daily for 3 weeks with 2 concurrent cycles of FOLFOX per protocol. See detailed description for more information.
62597542|NCT03602391|EXPERIMENTAL|SCP Plus|
62597543|NCT03602391|NO_INTERVENTION|Services as usual|
62597544|NCT06580600|ACTIVE_COMPARATOR|OCS|To receive OCS (this is standard of care as the children will be recruited if their is clinicial uncertainty over the benefit of OCS, i.e. this is not a CTIMP). The local policy is to prescribe Dexamethasone suspension 300mcg/kg in a single dose.
62597545|NCT06580600|NO_INTERVENTION|No OCS|The child will not recieve any cortisteroid medications (this is standard of care as the children will be recruited if their is clinicial uncertainty over the benefit of OCS, i.e. this is not a CTIMP).
62430396|NCT04537702|EXPERIMENTAL|Streamlined Group (SG)|"After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video. All subjects will then have the option to opt out and receive formal genetic counseling prior to making a decision about testing. If the subject elects to undergo genetic testing, she will fill out the standard genetic testing consent form. As per standard practice of the clinical genetic service at Duke Cancer Institute (DCI), patients will also be asked to provide consent for somatic tumor testing of surgical (non-cytologic) specimen. SG subjects will complete an FHQ within one week of the primary visit. A member of the genetics team will curate the results by contacting the subject to review common errors and clarify any ambiguities in the pedigree. Subjects will complete a post-education distress and anxiety survey (IES) via either an email link to a confidential REDCap survey link or over the phone 1-2 weeks after education."
62430397|NCT05394142|PLACEBO_COMPARATOR|Arm 1 - Placebo|Placebo
62430398|NCT05394142|EXPERIMENTAL|Arm 1 - PIO|Pioglitazone
62430399|NCT05394142|EXPERIMENTAL|Arm 1 - SPIO|Spironolactone and Pioglitazone
62597546|NCT05002894|EXPERIMENTAL|exercise group|This group included twenty six post-menopausal women. They will participate in Pilates exercise, medical standard care for fatigue and advices to deal with fatigue. The Pilates exercises consisted of a set of 10 movements: bridging; hundred; roll up; one leg circle (both ways); single straight leg stretch; single leg kick; side kick up and down; side kick circles; rest position (stretch and relaxation); and curling ,women were instructed to perform 30 min per session, 3 sessions per week, for 8 weeks.
62597547|NCT05002894|EXPERIMENTAL|standard care group|Each post-menopausal woman in both groups will receive a medical standard care for post-menopausal fatigue.
62815995|NCT03973229|ACTIVE_COMPARATOR|Cohort 2: Trauma Control Receiving Estradiol, then Placebo|Participants with trauma exposure will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
62815996|NCT03973229|ACTIVE_COMPARATOR|Cohort 2: Trauma Control Receiving Placebo then Estradiol|Participants with trauma exposure will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
62815997|NCT03973229|ACTIVE_COMPARATOR|Cohort 2: Healthy Control Receiving Estradiol then Placebo|Participants without trauma history or psychiatric disorder will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
62037795|NCT00454051|ACTIVE_COMPARATOR|Omalizumab|Omalizumab was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level.
62239985|NCT05679284||Controls: Intravenous drug users without drug needle fragment retentions|All intravenous drug users from the service units will be asked to participate. Control group consists of those with no radiologically confirmed subcutaneous needle fragment retentions.
62430400|NCT05394142|EXPERIMENTAL|Arm 1 - SPIOMET|Spironolactone, Pioglitazone and Metformin
62597548|NCT06516055|EXPERIMENTAL|S1B-408|One dose of S1B-408 with up-titration of one of its components after one week as needed and tolerated
62597549|NCT05071040|EXPERIMENTAL|Exercise group|Participants will follow a strength exercise program monitored through the use of a specifically designed smartphone application.
62815998|NCT03973229|ACTIVE_COMPARATOR|Cohort 2: Healthy Control Receiving Placebo then Estradiol|Participants without trauma history or psychiatric disorder will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
62815999|NCT05675059|ACTIVE_COMPARATOR|Group 1: STRONG Intervention|The STRONG program includes consultation with a Moffit dietician, logging intake of food daily into a food diary with a Fitbit smartphone app, and completing questionnaires.
62816000|NCT05675059|ACTIVE_COMPARATOR|Group 2: Usual Care|Participants will be referred to dieticians based on clinical discretion. Participants will also be asked to wear a Fitbit for 12 weeks to passively collect data on activity level.
62816001|NCT06591949|ACTIVE_COMPARATOR|BETY session group|Childhood rheumatic diseases participating in BETY sessions.
62816002|NCT06591949|ACTIVE_COMPARATOR|Control Group|Childhood rheumatic diseases followed up with a home exercise program.
62816003|NCT01286675|EXPERIMENTAL|Eltrombopag|0 mg Eltrombopag
62430401|NCT05338554|EXPERIMENTAL|pcTBS|The protocol is same as the previous study: pcTBS was administered to the left M1 at 80% resting motor threshold (RMT), consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz using repetitive transcranial magnetic stimulation device . A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline.
62430402|NCT05338554|EXPERIMENTAL|10HZ rTMS|The protocol is same as the previous study: 10HZ rTMS included 15 trains of 10-second stimulation given at 10 Hz to the left M1 at 80% resting motor threshold (RMT) using repetitive transcranial magnetic stimulation device , with the inter-train interval being set to 50 seconds (1500 pulses)
62430403|NCT02836340|EXPERIMENTAL|2-Iminobiotin|Increasing dosage of study drug
62430404|NCT00938600|EXPERIMENTAL|A1 - non-pregnant single-dose|
62597550|NCT05071040|NO_INTERVENTION|Control group|Continue their daily routine without exercise prescription.
62816004|NCT05730725|EXPERIMENTAL|BMS-986322 Dose 1|
62037796|NCT00454051|PLACEBO_COMPARATOR|Placebo|Placebo was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks.
62430405|NCT00938600|EXPERIMENTAL|A2 - non-pregnant; weekly dose|
62430406|NCT00938600|EXPERIMENTAL|B1 - pregnant; single-dose|
62597551|NCT01921192|ACTIVE_COMPARATOR|Folic Acid, vit B6 and B12|
62597552|NCT01921192|PLACEBO_COMPARATOR|Sugar pill|
62597553|NCT03001349|EXPERIMENTAL|Diagnostic (gallium Ga 68-edotreotide, PET/CT)|Participants receive gallium Ga 68-edotreotide intravenously. After 1 hour, participants undergo PET/CT scan over 60 minutes.
62597554|NCT03698838||McDESPOT Study Group|Patients aged 0-19 who have an MRI ordered clinically and have one of the following conditions: epilepsy, hydrocephalus, craniosynostosis or mild traumatic brain injury. Epilepsy, hydrocephalus and craniosynostosis patients will be both newly diagnosed and chronic. MTBI patients will be acute and chronic and defined as a glascow coma score (GCS) of 13-15.These patients will have a 10 minute MRI sequence (McDESPOT) added to their standard of care T1 and T2 scans.
62597555|NCT03698838||Control Model|Control model derived from a linear mixed-effects model (Spader et al 2013)
62597556|NCT01624857|PLACEBO_COMPARATOR|control group|Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
62597557|NCT01624857|ACTIVE_COMPARATOR|statin group|Rosuvastatin 20mg/d for at least 5 days before the CABG surgery, then continue to take for a month
62430407|NCT00938600|EXPERIMENTAL|B2 - pregnant; weekly dose|
62597558|NCT06619327|EXPERIMENTAL|Resilient Together for Dementia|The research team will compare two programs to reduce emotional distress among couples after dementia diagnosis.
62597559|NCT04188431|EXPERIMENTAL|Dexamethasone|Single intraoperative administration of 0.15 mg/kg of Dexamethasone intravenously with a maximum dose of 5 mg
62597560|NCT04188431|PLACEBO_COMPARATOR|Sodium chloride|Single intraoperative administration of Sodium Chloride (NaCl) 0.9% intravenously
62597561|NCT04919122||Patients with metastatic renal cell cancer (mRCC) with no prior systemic therapy for mRCC|This is an observational cohort.
62597562|NCT03335423|EXPERIMENTAL|Oral Metformin|Oral metformin 1000mg will be given as a single dosis
62597563|NCT03335423|EXPERIMENTAL|Intravenous metformin|Intravenous metformin 500mg will be injected as a single dosis
62597564|NCT03335423|EXPERIMENTAL|Oral codeine and oral metformin|Codeine 25 mg will be given at 5 occasions with approximately 6 hours between each dosing. The fifth and last dose will be given together with 1000 mg oral metformin
62597565|NCT03335423|EXPERIMENTAL|Oral codeine and intravenous metformin|Codeine 25 mg will be given at 5 occasions with approximately 6 hours between each dosing. The fifth and last dose will be given together with 500 mg metformin administrated as an injection.
62597566|NCT06579183|EXPERIMENTAL|ES/VJ+ES/VC|Participants will be instructed to orally take ES/VJ and ES/VC capsules each day, and will continue their current medications as usual, including prescribed sleep pills, anxiolytics, and antidepressants, for 12 weeks.
62597567|NCT06579183|PLACEBO_COMPARATOR|Placebo|Participants will be instructed to orally take placebo capsules each day, and will continue their current medications as usual, including prescribed sleep pills, anxiolytics, and antidepressants, for 12 weeks.
62597568|NCT01730534|EXPERIMENTAL|Dapagliflozin|Dapagliflozin + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
62597569|NCT01730534|PLACEBO_COMPARATOR|Placebo|Placebo + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
62597570|NCT06316869||CSPH group|HVPG≥10 mmHg
62037797|NCT03519854|PLACEBO_COMPARATOR|Arm A. Placebo; given 3 minutes after Esmeron®|Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62430408|NCT00938600|ACTIVE_COMPARATOR|C1 - active control; pregnant women|
62430409|NCT03725787|EXPERIMENTAL|CuroCell S.A.M. ® pro mattress|Mattresses of eligible participants will be replaced by a static air pressure redistribution mattress (CuroCell S.A.M. ® Pro).
62597571|NCT06316869||Non-CSPH group|HVPG\<10 mmHg
62597572|NCT00602290|ACTIVE_COMPARATOR|1 - Citalopram and placebo|Participants will take a combination of citalopram and placebo for 16 weeks
62597573|NCT00602290|ACTIVE_COMPARATOR|2 - Methylphenidate and placebo|Participants will take a combination of methylphenidate and placebo for 16 weeks
62597574|NCT00602290|ACTIVE_COMPARATOR|3 - Methylphenidate and Citalopram|Participants will take a combination of methylphenidate and citalopram for 16 weeks
62597575|NCT05545631||Conception positive|serum human chorionic gonadotropin ≥10 mIU/mL
62037798|NCT03519854|EXPERIMENTAL|Arm B. 1 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62037799|NCT03519854|EXPERIMENTAL|Arm C. 2 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62037800|NCT03519854|EXPERIMENTAL|Arm D. 4 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62037801|NCT03519854|EXPERIMENTAL|Arm E. 6 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62037802|NCT03519854|EXPERIMENTAL|Arm F. 8 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62430410|NCT02177747|EXPERIMENTAL|Diabet patients|Smartphone ophthalmoscopy followed by traditional slit-lamp dilated ophthalmoscopy
62430411|NCT04311138|EXPERIMENTAL|Experimental group|Experimental group receive a 10-wk diversified community-based reablement service.
62430412|NCT04311138|ACTIVE_COMPARATOR|Control group|Control group receive a 10-wk multicomponent training.
62597576|NCT05545631||Conception negative|serum human chorionic gonadotropin \<10 mIU/mL
62597577|NCT03998163|EXPERIMENTAL|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
62597578|NCT06514716|EXPERIMENTAL|GAE with IACI|Participants in this arm will undergo geniculate artery embolization (GAE) followed by an intraoperative intra-articular corticosteroid injection (IACI). The procedure aims to alleviate post-procedural pain and improve early functional outcomes in patients with knee osteoarthritis (OA).
62597579|NCT06514716|ACTIVE_COMPARATOR|GAE alone|Participants in this arm will undergo geniculate artery embolization (GAE) without the additional intraoperative intra-articular corticosteroid injection. This group will serve as the control to evaluate the effectiveness and safety of GAE with IACI in comparison.
62597580|NCT01104246|EXPERIMENTAL|Testosterone Transdermal Systems|Testosterone
62816005|NCT05730725|EXPERIMENTAL|BMS-986322 Dose 2|
62816006|NCT05730725|EXPERIMENTAL|BMS-986322 Dose 3|
62239986|NCT02234323|EXPERIMENTAL|rFVIIIFc|Participants were to receive rFVIIIFc as follows- Prophylaxis regimen (PR): rFVIIIFc 25-80 international units per kilogram (IU/kg), at 3- to 5-day intervals until participant reached greater than or equal to (\>=) 50 exposure days (ED: 24-hour period in which \>=1 injection/dose of rFVIIIFc was given), or study withdrawal/end of study. Adjustments to dose/dosing interval was done as needed by investigator; Treatment with an optional ER (Episodic regimen) can be initiated before PR at investigators discretion; ITI: rFVIIIFc 200 IU/kg, daily for participants who, after exposure to rFVIIIFc, had positive high titer inhibitor (\>=5.00 Bethesda Units per milliliter \[BU/mL\]) or positive low titer inhibitor (\>=0.60 and \<5.00 BU/mL) and had poorly controlled bleeding despite increased rFVIIIFc doses, or required bypassing agent to treat bleeding.
62239987|NCT02544217|EXPERIMENTAL|Single Escalating|2 alternating groups receiving escalating single doses of active/placebo
62239988|NCT02544217|EXPERIMENTAL|Multiple Escalating|3 multiple escalating groups, receiving active/placebo
62597581|NCT01264237|EXPERIMENTAL|Etoricoxib|The study will use an Enriched Enrollment Randomized Withdrawal (EERW) design consisting of a 2-week open-label enrichment phase, during which subjects will receive etoricoxib. Patients who experience at least a 30% reduction in pain intensity will be randomized to either continued treatment with etoricoxib 90 mg qd or matching placebo (at a 1:1 ratio) for 4 weeks.
62597582|NCT01264237|PLACEBO_COMPARATOR|Placebo|The study will use an Enriched Enrollment Randomized Withdrawal (EERW) design consisting of a 2-week open-label enrichment phase, during which subjects will receive etoricoxib, followed by a 4-week randomized, double-blind, placebo-controlled treatment phase, during which subjects will receive either etoricoxib or placebo.
62597583|NCT06259695|EXPERIMENTAL|Adjustable Aquatic Therapy Prosthesis|The prosthesis will be designed to be adjustable in circumference, residual limb length, and overall height. This will allow adjustability to accommodate most limb shapes. The design will also provide secure suspension, on both land and in the water. This will maximize safety for the patient and translate motion from the residual limb to the prosthesis. Additionally, the prosthesis design will include a comfortable fit and interface, protecting the participant's skin. Skin will be assessed prior to use, during initial fitting, and after each therapy session. Finally, the prosthesis will be test fit and used with maximum assistance from clinical staff, minimizing risk.
62597584|NCT01550705|EXPERIMENTAL|Isoniazid|Subjects will receive isoniazid daily for 2 months. Subjects will be seen every 2 weeks to obtain lab samples and health check.
62597585|NCT05895890||Cohorte|The study will include a population of patients with excessive alcohol consumption seen in consultation or hospitalized for alcohol addiction problems and/or exploration of alcohol-related liver damage
62597586|NCT05397171|EXPERIMENTAL|Substudy 1 - Parts A, B, and C|"* Part A: AZD8853 monotherapy dose escalation~* Part B1 and Part B2: AZD8853 monotherapy safety expansion at dose levels and indications determined to be safe in Part A~* Part C1 and Part C2: AZD8853 monotherapy safety and preliminary efficacy expansion at dose levels and indications determined to be safe in Parts A and B"
62597587|NCT05397171|EXPERIMENTAL|Substudy 1 - Parts B1 and B2 with CD8+ PET|Sub-set of participants from Parts B1 and B2 will also receive investigational CD8+ T cell targeted radioactive tracer, Zirconium-89 crefmirlimab berdoxam with PET scans
62597588|NCT06621615|EXPERIMENTAL|CVL006 monotherapy group|"This study is divided into three stages. Ia. Dose escalation stage: Accelerated titration combined with a 3+3 design was used for dose escalation, with a maximum enrollment of 42 subjects.~Ib. Dose extension stage: Based on the data from dose escalation, in dose groups where a certain therapeutic effect is observed, each dose group will be extended by no more than 10 subjects, and RP2D will be determined based on the data from dose escalation and extension stages.~Ic. Efficacy expansion stage: RP2D was selected for expansion, with each tumor type expanded to 10-30 cases.~The above three stages involve intravenous infusion of CVL006, administered every 2 weeks and every 28 days as a treatment cycle. The first treatment cycle (28 days) serves as the DLT observation period, during which DLT is collected and its MTD and RP2D are determined."
62597589|NCT06275711|EXPERIMENTAL|Therapeutic communication|Therapeutic communication methods were applied. Pre-test and post-test measurements were made
62037803|NCT03519854|PLACEBO_COMPARATOR|Arm G. Placebo; given 5 minutes after Esmeron®|Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62239989|NCT03065023|EXPERIMENTAL|Group A: Cutaenous lesions|Participants with transdermally/transmucosally injectable tumors including cutaneous, subcutaneous or lymph node injectable tumors received escalating doses of MK-4621 via intratumoral (IT)/intralesional (IL) injection twice each week (Q2W) over a period of 4 weeks. Participants may have continued to receive study treatment beyond Cycle 1 for the remaining duration of the study as long as clinical benefit (no overt clinical progression or toxicity considered to be intolerable as per Investigator's assessment) was present (up to approximately 2 years).
62597590|NCT02573558||DEX|patients who received dexmedetomidine during the operation
62597591|NCT02573558||PPF|patients who received propofol during the operation
62597592|NCT02521558|EXPERIMENTAL|Intervention Group|In the Intervention Group, patients will receive an iPad with the Constant Therapy cognitive rehabilitation application. Patients in the Intervention Group will practice the memory tasks developed for the Constant Therapy application for a total of six months. On a weekly basis, a clinician and/or research assistant will check in with the patient to answer any questions or address any concerns the patient has with using the Constant Therapy application, or how to perform any of the memory tasks. At the end of six months, each individual in the Intervention Group is assessed with standard cognitive testing to determine if there was any change on overall cognition.
62597593|NCT02521558|ACTIVE_COMPARATOR|Control Group|The Control Group will not receive any intervention. The Control Group will be given simple sets of puzzle booklets to practice over the 6 month period (e.g., word search puzzles, number and/or math puzzles). The Control Group will also receive standardized cognitive testing at the end of 6 months. Weekly check-ins by a clinician and/or research assistant will also occur in the Control Group. Every 4th patient recruited for the study will be assigned to the Control Group.
62597594|NCT06315478|ACTIVE_COMPARATOR|Triple regimen(Group A)|
62597595|NCT06315478|ACTIVE_COMPARATOR|Quadruple regimen (Group B)|
62597596|NCT06315478|ACTIVE_COMPARATOR|Hybrid regimen (Group C)|
62037804|NCT03519854|EXPERIMENTAL|Arm H. 1 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62597597|NCT01300299|EXPERIMENTAL|All subjects|Subjects will receive chemotherapy after stereotactic body radiation therapy.
62597598|NCT00519233|EXPERIMENTAL|1.AGS-1C4D4|
62597599|NCT05630521|EXPERIMENTAL|Telehealth Intervention Group|"The intervention components are: 1) educational modules and 2) bi-weekly telehealth visits for managed problem solving for 12 weeks.~All intervention participants will be provided four educational modules, electronically and in print form. The modules are adapted from evidence-based materials developed by the American Heart Association, American College of Cardiology, and Centers for Disease Control and Prevention and cover (1) the causes of HTN, (2) how HTN raises risks for other chronic conditions, (3) medications for effectively managing high BP, and (4) how to manage barriers to medication adherence.~Telehealth visits will supplement and reinforce the educational modules, addressing participants' specific knowledge needs and enhancing self-efficacy."
62597600|NCT05630521|NO_INTERVENTION|Control|The study will use a usual-care control group. The standard of care for this patient population does not involve any type of medication adherence intervention or monitoring beyond regular clinic follow-up visits with their health care provider. Control group participants will be given printed handouts on the American Heart Association's Life's Simple 7 lifestyle changes for reducing cardiovascular risk, along with the instructions for using the MEMS cap. If control group participants ask about their antihypertensive medications during the study, they will be referred to their prescribing provider or pharmacist for any information that could not be obtained from the medication label or pharmacy packaging.
62597601|NCT04722991|EXPERIMENTAL|Runcaciguat (BAY1101042)|
62597602|NCT04722991|PLACEBO_COMPARATOR|Placebo|
62430413|NCT04844996|EXPERIMENTAL|Ezetimibe group|The endometriosis model was developed surgically in all 18 rats and pretreatment sizes of the endometriotic explants were measured. After randomization Ezetimibe (1 mg/kg/day (Ezetrol®, Merck Sharp Dohme, Istanbul, Turkey) was administered orally with gavage methodology to the 9 rats in the ezetimibe group for 28 days postoperatively.
62597603|NCT03544931|EXPERIMENTAL|Root Instrumentation + EMD Application|"Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one-stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.~In this group, at the end of the instrumentation enamel matrix derivatives is placed in all sites with a periodontal pocket depth deeper than 5mm."
62597604|NCT03544931|ACTIVE_COMPARATOR|Root Instrumentation|Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one-stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.
62816007|NCT05730725|PLACEBO_COMPARATOR|Placebo|
62816008|NCT06601608|EXPERIMENTAL|Rosemary extract gel|rosemary extract gel will be applied in deep periodontal pockets with a concentration 5%.
62816009|NCT06601608|PLACEBO_COMPARATOR|placebo gel|a placebo gel will be applied in deep periodontal pockets in stage III periodontitis patients as an adjunct to non-surgical periodontal therapy.
62816010|NCT06600867|EXPERIMENTAL|Tooth Mobility Assessment|Tooth Mobility and Applied Force Assessment
62816011|NCT04675567|ACTIVE_COMPARATOR|Safety-Net Intervention|
62816012|NCT04675567|NO_INTERVENTION|Treatment as Usual|
62816013|NCT06100900|EXPERIMENTAL|BCX10013|Participants with PNH will receive BCX10013 daily for 4 weeks before dose escalation may occur.
62597605|NCT02499146|EXPERIMENTAL|Cohort 1|Combination therapy of palbociclib and letrozole
62597606|NCT02728583|ACTIVE_COMPARATOR|Margarine enriched with plant sterols and fish oil|Low-fat margarine (25 g per day) with added plant sterols and Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) from fish oil
62816014|NCT06068933|EXPERIMENTAL|Phase 2A -MCI Pilot Trial Immediate Treatment Group|Immediate treatment with K-HEARS intervention
62816015|NCT06068933|PLACEBO_COMPARATOR|Phase 2A -MCI Pilot Trial Delayed Treatment Group|6-month delayed treatment with K-HEARS intervention
62816016|NCT06068933|OTHER|Phase 2B -KA Older Adult Focused Trial (non-randomized)|Immediate treatment with K-HEARS intervention
62816017|NCT06296290||All participants|The participants are the swimmers engaged in the 6-hour cold water swim during the Channel Swim Camp who volunteered to participate in the study.
62037805|NCT03519854|EXPERIMENTAL|Arm I. 2 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62816018|NCT02329444|EXPERIMENTAL|Remote Ischemic Preconditioning|Patients treated with Remote Ischemic Preconditioning
62816019|NCT02329444|ACTIVE_COMPARATOR|Sham ischemic preconditioning|Patients treated with sham ischemic preconditioning
62597607|NCT02728583|PLACEBO_COMPARATOR|Placebo margarine|Low-fat margarine (25 g per day) without added plant sterols and EPA + DHA
62597608|NCT03144843|EXPERIMENTAL|Experimental group|Apatinib: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
62597609|NCT03144843|PLACEBO_COMPARATOR|Placebo group|Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
62597610|NCT00867828|EXPERIMENTAL|1|Neptune Krill Oil(TM)softgels (1g QD). Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
62597611|NCT00867828|ACTIVE_COMPARATOR|2|Fish oil softgels (1g QD). Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
62597612|NCT00867828|PLACEBO_COMPARATOR|3|Placebo (soy oil) softgels (1g QD. The soy oil placebo will provide neither EPA nor DHA.
62597613|NCT03994770|OTHER|STR|Older people who have suffered a stroke
62597614|NCT04450134|PLACEBO_COMPARATOR|Placebo|6 weeks high-intensity interval training + placebo intake
62597615|NCT04450134|EXPERIMENTAL|Blockade|6 weeks high-intensity interval training + histamine H1/H2 receptor blockade
62816020|NCT06285435||pemphigus vulgaris patients|
62816021|NCT06285435||control group|
62816022|NCT03802578|EXPERIMENTAL|EXERCISE GROUP|Patients in the exercise group performed a program of strengthening, stretching and resistance upper limbs exercises (Hand exercise), of 30 minutes duration daily, for 12 weeks in addition to medical care.
62816023|NCT03802578|NO_INTERVENTION|CONTROL GROUP|Patients in the control group continued their usual medical care.
62816024|NCT02893293|ACTIVE_COMPARATOR|Ferumoxytol-enhanced MRI|Patients receive a ferumoxytol injection (Feraheme, AMAG, 5mg Fe/kg, single administration) prior to routine decompression surgery and autologous stem cell transplant. Follow-up imaging with magnetic resonance imaging will be conducted in regular intervals for evaluation of the response to treatment.
62816025|NCT02893293|SHAM_COMPARATOR|Non-ferumoxytol enhanced MRI|Patients scheduled for routine decompression surgery and autologous stem cell transplant will receive follow-up magnetic resonance imaging in regular intervals for evaluation of the response to treatment.
62037806|NCT03519854|EXPERIMENTAL|Arm J. 4 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62239990|NCT03065023|EXPERIMENTAL|Group B: Liver lesions|Participants with injectable liver tumors or liver metastases were to receive escalating doses of MK-4621 via intratumoral (IT)/intralesional (IL) injection once each week over a period of 4 weeks. Participants were to have been able to continue to receive study treatment beyond Cycle 1 for the remaining duration of the study as long as clinical benefit (no overt clinical progression or toxicity considered to be intolerable as per Investigator's assessment) was present (up to approximately 2 years). (Group B was not started. Development will continue with new protocol.)
62597616|NCT06483048|EXPERIMENTAL|Treatment (MUC1-activated T cells, lymphodepletion)|Patients undergo leukapheresis over 4 hours within 14 days after registration. Patients receive cyclophosphamide IV over 60 minutes on days -5 to -3 or bendamustine IV over 10 minutes on days -5 and -4 or -4 and -3. Patients receive MUC1-activated T cells IV over 10-60 minutes on day 0 or days 0 and 21. Patients also undergo ECHO or MUGA during screening, and blood sample collection throughout the trial. In addition, patients may undergo CT, MRI, or PET/CT as clinically indicated throughout the trial. Patients may also undergo collection of ascites on study and during follow up.
62597617|NCT02266290|EXPERIMENTAL|Kinesio-Tape group|In this study, Sport tex® kinesiotape over lateral ankle (6cm\*2.5m) is used.
62597618|NCT02266290|PLACEBO_COMPARATOR|Placebo Tape Group|In the placebo group, Pretape Cramer® (100% cotton, 1.25cm\*10m) was used. With patient in the same position described above, horizontal strips were placed covering the sural region with no defined direction.
62597619|NCT02375555|EXPERIMENTAL|Elotuzumab, lenalidomide, bortezomib, and dexamethasone|"Participants will receive therapy with the combination of lenalidomide, bortezomib, and dexamethasone and elotuzumab (E-RVD). Induction cycles (1 to 8) are 21-day cycles.~* Elotuzumab will be administered by intravenous (IV) infusion~* Bortezomib as a subcutaneous injection~* Lenalidomide single daily oral dose~* Dexamethasone as oral tablets and IV infusion~* Stem cell mobilization will be performed for all subjects at the end of Cycle 4.~Subjects may elect to stop E-RVD at the end of Induction Cycle 4 and proceed to autologous SCT. Subjects who do not proceed to SCT may receive a full 8 cycles of induction therapy.~The maintenance schedule (28 days) will start after 8 cycles of induction regimen for subjects not proceeding with SCT, or after recovery from SCT for subjects proceeding with it.~Maintenance therapy with E-RVD will be administered to all patients, with the specific maintenance regimen determined by risk category."
62816026|NCT06573996|EXPERIMENTAL|Upper Right Side - Active TENS Device|Participants will receive the active TENS device on the upper right side of their mouth. This arm is designed to evaluate the effectiveness of the TENS device in reducing pain during orthodontic alignment on this specific side of the upper arch.
62816027|NCT06573996|SHAM_COMPARATOR|Arm 2: Upper Left Side - Placebo/Sham Device|Participants will receive a placebo (non-functioning) device on the upper left side of their mouth. This arm serves as a control to compare pain levels with the side receiving the active TENS device.
62816028|NCT06573996|EXPERIMENTAL|Arm 3: Lower Right Side - Active TENS Device|Participants will receive the active TENS device on the lower right side of their mouth. This arm is intended to assess the effectiveness of the TENS device in reducing pain during orthodontic alignment on this specific side of the lower arch.
62816029|NCT06573996|SHAM_COMPARATOR|Arm 4: Lower Left Side - Placebo/Sham Device|Participants will receive a placebo (non-functioning) device on the lower left side of their mouth. This arm also serves as a control, providing a basis for comparison with the side receiving the active TENS device.
62816030|NCT02358473|EXPERIMENTAL|mogamulizumab + docetaxel|"Mogamulizumab will be given as monotherapy in a 4-week run-in period. Subjects will then receive up to 6 cycles of mogamulizumab in combination with docetaxel at appropriate intervals.~Subjects may then continue to receive mogamulizumab, at the same dose administered in Cycle 1, once every 3 weeks as monotherapy."
62816031|NCT04252547|EXPERIMENTAL|Grup 1|"-During the Procedure Group 1 The preprocedural measurements(weight, heart rate and oxygen saturation ) will be applied to the infants in Group 1 before the first feeding hour when they are included in the study and then they will be held on their mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother.~During the second feeding hour, his/her heart rate and oxygen saturation will begin to be recorded ten minutes before the feeding hour. The data will be recorded for ten minutes and then the infant will be taken out of the incubator and weight is measured only in his/her clean diaper. He/she will be handed over to the mother to breastfeed."
62037807|NCT03519854|EXPERIMENTAL|Arm K. 6 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62037808|NCT03519854|EXPERIMENTAL|Arm L. 8 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62239991|NCT04140279|EXPERIMENTAL|Latanoprostene Bunod|Participants will receive LBN ophthalmic solution 0.024% in the applicable eye identified during randomization. The first dose will be instilled in the morning (AM) at approximately 11 AM on Day 1 and the remaining 6 doses will be instilled once per day in the evening at approximately 8 PM.
62037809|NCT03519854|PLACEBO_COMPARATOR|Arm M. Placebo; given 15 minutes after Esmeron®|Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62037810|NCT03519854|EXPERIMENTAL|Arm N. 1 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62037811|NCT03519854|EXPERIMENTAL|Arm O. 2 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62037812|NCT03519854|EXPERIMENTAL|Arm P. 4 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62037813|NCT03519854|EXPERIMENTAL|Arm Q. 6 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62037814|NCT03519854|EXPERIMENTAL|Arm R. 8 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
62239992|NCT04140279|PLACEBO_COMPARATOR|Placebo|Participants will receive Renu MultiPlus Lubricating and Rewetting Drops (placebo) in the applicable eye identified during randomization. The first dose will be instilled in the morning (AM) at approximately 11 AM on Day 1 and the remaining 6 doses will be instilled once per day in the evening at approximately 8 PM.
62430414|NCT04844996|PLACEBO_COMPARATOR|Control groups|The endometriosis model was developed surgically in all 18 rats and pretreatment sizes of the endometriotic explants were measured. After randomization saline (1 ml/kg/day) was administered orally with gavage methodology to the 9 rats in the control group for 28 days postoperatively.
62430415|NCT05703555|EXPERIMENTAL|Tusamitamab ravtansine 100mg/m2|Tusamitamab ravtansine 100 mg/m2 IV Q2W
62430416|NCT02868307|EXPERIMENTAL|Patient prsenting schizophrenia|
62430417|NCT03342326|OTHER|patient with Alzheimer's Disease|"1. Exposure to familiar songs : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.~2. Music Experience Questionnaire : questions about the past music training~3. Implicit tasks memory : a) Completion of trigrams : freely complete the first 3 letters of a word. b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not."
62430418|NCT03342326|OTHER|healthy volunteer|"1. Exposure to familiar songs : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.~2. Music Experience Questionnaire : questions about the past music training~3. Implicit tasks memory : a) Completion of trigrams : freely complete the first 3 letters of a word. b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not.~4. For volunteer over 65 years : Mini Mental State Examination, 5 words by Dubois and fluence verbal test"
62430419|NCT05066074|EXPERIMENTAL|Distal Radial Access|Distal Radial (Anatomical Snuffbox) Vascular Access prior to catheterization
62430420|NCT05066074|ACTIVE_COMPARATOR|Proximal Radial Access|Proximal Radial Vascular Access prior to catheterization
62430421|NCT05966870|EXPERIMENTAL|Replacement of SSB with Unsweetened Sparkling Beverage|To encourage participants to substitute sparkling water flavored water for SSB intake, we will provide enough supplies of the drinks to adolescents (and their families) each month. We will also provide iPhones with the TADA app to the adolescent participants. Study staff will remind participants to consume the sparkling water through iMessages sent through the TADA app.
62430422|NCT01893983|EXPERIMENTAL|Motivational Coaching|Telephone based Motivational Coaching sessions
62430423|NCT01893983|NO_INTERVENTION|Referral alone|This is the current standard of care
62430424|NCT03456726|EXPERIMENTAL|FL with EZH2 gene mutation|Participants with follicular lymphoma (FL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 milligrams (mg) twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.
62430425|NCT03456726|EXPERIMENTAL|DLBCL with EZH2 gene mutation|Participants with diffuse large B-cell lymphoma (DLBCL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 mg twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.
62430426|NCT01499342||Rutherford category 2 - 5|
62430427|NCT04009954||Delayed transit|CRC patients with delayed gut transit recovery( first time defecation \>3 day )
62239993|NCT03551964|EXPERIMENTAL|Cangrelor therapy|Initiation of iv Cangrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study.
62239994|NCT03551964|ACTIVE_COMPARATOR|Ticagrelor therapy|Initial dose Ticagrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study. In patients with a disorder of consciousness, initial dose of Ticagrelor will be administered immediately after nasogastric tube insertion.
62239995|NCT04703478|EXPERIMENTAL|Single group|Implementation of a mobile application for the rehabilitation of patients with respiratory sequelae of COVID-19
62597620|NCT05644821|EXPERIMENTAL|Intervention group|Patients who are not fully continent 6-weeks post-surgery (i.e., do not use pads in 24 hours) are randomized into the intervention or control group. In the intervention group, when the respective questionnaire thresholds are exceeded in the ePROM survey, an alarm is triggered at the treating prostate cancer center and contact is made by the center, as well as subsequent actions, if necessary.
62239996|NCT04628299|PLACEBO_COMPARATOR|Sham Laser|A non-emission laser will be applied in plantar fascia
62239997|NCT04628299|EXPERIMENTAL|Experimental group Myofascial Induction|Myofascial Induction in plantar fascia
62037815|NCT00862160|ACTIVE_COMPARATOR|1|using minimized cardiopulmonary bypass circuit ROCsafeTM
62037816|NCT00862160|NO_INTERVENTION|2|using standard cardiopulmonary bypass circuit
62037817|NCT01082536||One ventricle pts, bypass, perfusion|1. Single ventricle patients who undergo cardiopulmonary bypass and selective cerebral perfusion.
62037818|NCT01082536||One ventricle pts, bypass only|Single ventricle patients who undergo cardiopulmonary bypass but not selective cerebral perfusion
62239998|NCT00702845|EXPERIMENTAL|corifollitropin alfa 100 µg|Participants received a single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of the menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day by intramuscular \[IM\] injection), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
62430428|NCT04009954||Normal transit|CRC patients with normal gut transit recovery( first time defecation \<=3 day )
62430429|NCT01362959|EXPERIMENTAL|Nicotine patch|
62430430|NCT01362959|PLACEBO_COMPARATOR|Control patch|The control product is a look-alike patch compared to the test product, containing no nicotine or other active substances.
62430431|NCT03126851|EXPERIMENTAL|No age range / no explicit warning|Label: No age range and no explicit warning on front display panel of medication box.
62430432|NCT03126851|EXPERIMENTAL|age range / no explicit warning|Label: Age range present but no explicit warning on front display panel of medication box.
62430433|NCT03126851|EXPERIMENTAL|age range / explicit warning in words|Label: Age range present with explicit warning in words on front display panel of medication box.
62430434|NCT03126851|EXPERIMENTAL|age range / explicit warning+pictogram|Label: Age range present with explicit warning in words plus pictographic warning on front display panel of medication box.
62430435|NCT02934386|EXPERIMENTAL|WinMedical WinPack device|50 volunteers undergoing experimental protocol according to IEEE 1708:2014 standard
62430436|NCT03395574|EXPERIMENTAL|terlipressin group|group will receive terlipressin infusion one mg in 50 ml normal saline will be given over 30 minute as loading dose then will be maintained as infusion of 160 μg per hour (8 ml/h).
62430437|NCT03395574|PLACEBO_COMPARATOR|saline (control) group|group will receive normal saline infusion 50 ml normal saline will be given over 30 minute as loading dose then will be maintained as infusion of (8 ml/h).
62430438|NCT02649608|EXPERIMENTAL|0.04 mg Lu AE04621|Patients having received a dose of 0.04 mg, independent of which Cohort they belong to.
62430439|NCT02649608|EXPERIMENTAL|0.08 mg Lu AE04621|Patients having received a dose of 0.08 mg, independent of which Cohort they belong to.
62597621|NCT05644821|NO_INTERVENTION|Control group|Patients who are not fully continent 6-weeks post-surgery (i.e., do not use pads in 24 hours) are randomized into the intervention or control group. In the control group, ePROMs will be collected 24 and 52 weeks after radical prostatectomy, but without triggering an alarm with subsequent measures - the control group will therefore receive treatment according to the current clinical routine.
62037819|NCT01082536||One ventricle pts, no bypass/perfusion|Single ventricle patients who undergo surgery, but do not undergo cardiopulmonary bypass or selective cerebral perfusion.
62037820|NCT01082536||Two ventricle pts, bypass, perfusion|Two ventricle patients who undergo cardiopulmonary bypass and selective cerebral perfusion.
62816032|NCT04252547|EXPERIMENTAL|Grup 2|"- During the Procedure Group 2 The preprocedural measurements will be applied to the infants in Group 2 before the first feeding hour when they are included in the study and then they will be breastfed by their mothers.~The preprocedural measurements (weight, heart rate and oxygen saturation) will be applied to the infant during the second feeding hour and then he/she will be held on his/her mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother."
62816033|NCT06521086|EXPERIMENTAL|Enhanced Protein Supplementation|Oral nutrition supplements (ONS) will be given, at maximum, three times per day throughout hospitalization. Upon discharge, participants will be given 4-weeks' worth of oral supplements to take. Adjustments may be made based on indirect calorimetry (IC) measurements.
62037821|NCT01082536||Two ventricle pts, bypass only|Two ventricle patients who undergo cardiopulmonary bypass but not selective cerebral perfusion.
62816034|NCT06521086|NO_INTERVENTION|Control Pathway|Standard of care nutrition delivery throughout hospitalization. Upon discharge participants will be sent home with standard nutrition information without Indirect Calorimetry (IC) guidance.
62037822|NCT01082536||Two ventricle pts, no bypass/perfusion|Two ventricle patients who do not undergo cardiopulmonary bypass or selective cerebral perfusion.
62037823|NCT04149405|ACTIVE_COMPARATOR|Group A|"* Subjects with chronic periodontitis and osteoporosis.~* Phase 1 periodontal therapy and bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects."
62430440|NCT02649608|EXPERIMENTAL|0.2 mg Lu AE04621|Patients having received a dose of 0.2 mg, independent of which Cohort they belong to.
62430441|NCT02649608|EXPERIMENTAL|0.4 mg Lu AE04621|Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.
62430442|NCT02649608|EXPERIMENTAL|0.6 mg Lu AE04621|Patients having received a dose of 0.6 mg, independent of which Cohort they belong to.
62430443|NCT02649608|EXPERIMENTAL|0.8 mg Lu AE04621|Patients having received a dose of 0.8 mg, independent of which Cohort they belong to.
62816035|NCT05022550|EXPERIMENTAL|DEEP VR Experiment Group|Participants identified from the Dane County Juvenile Court Program will be asked to experience up to 6 VR-B sessions. Participants will wear a lightweight, ultra-high-resolution, wireless, head-mounted display (Oculus Quest 2 Enterprise VR Headset). Each session will proceed through a series of four stages. First, participants will begin with a 5 minute acclimation period inside a demo VR environment. Second, baseline levels of physiological arousal will be captured over a 5 minute resting period where participants will be asked to sit quietly in a serene virtual environment. Third, participants will progress through the DEEP VR experience for 15 minutes. Finally, participants will complete a short series of online questionnaires.
62816036|NCT00262860|EXPERIMENTAL|Bortezomib, Gemcitabine Hdrochloride|
62816037|NCT06704958|OTHER|Use of AMPERE EMA prototype|An EMA risk monitoring system using a smartphone EMA app to collect self-reported data from participating patients experiencing suicidal ideation.
62816038|NCT05135702|EXPERIMENTAL|Sodium Propionate First|Subjects in this arm will consume 500mg sodium propionate powder twice daily for four weeks, mixed into their food/drink. This is followed by four weeks of placebo twice daily.
62816039|NCT05135702|PLACEBO_COMPARATOR|Placebo First|Subjects in this arm will consume a placebo twice daily for four weeks, mixed into their food/drink. This is followed by four weeks of 500mg sodium propionate powder, twice daily.
62037824|NCT04149405|ACTIVE_COMPARATOR|Group B|"* Subjects with chronic periodontitis and systemically healthy.~* Phase 1 periodontal theraphy was administered to the subjects."
62037825|NCT04149405|ACTIVE_COMPARATOR|Group C|"* Subjects with periodontally healthy and osteoporosis.~* Bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects."
62037826|NCT04149405|NO_INTERVENTION|Group D|"* Systemically and periodontally healthy controls~* No intervention has been made."
62037827|NCT03651089|ACTIVE_COMPARATOR|SP16 0.0125|0.0125 mg/kg of SP16 will be administered by subcutaneous injection once
62037828|NCT03651089|ACTIVE_COMPARATOR|SP16 0.050|0.050 mg/kg of SP16 will be administered by subcutaneous injection once
62037829|NCT03651089|ACTIVE_COMPARATOR|SP16 0.20|0.20 mg/kg of SP16 will be administered by subcutaneous injection once
62037830|NCT03651089|PLACEBO_COMPARATOR|placebo|Placebo (sterile saline) will be administered by subcutaneous injection once
62037831|NCT05794542|EXPERIMENTAL|Intervention|Use of Cue X intervention
62037832|NCT04178733|EXPERIMENTAL|LY3493269 - Subcutaneous (SC)|LY3493269 administered SC.
62037833|NCT04178733|PLACEBO_COMPARATOR|Placebo - SC|Placebo administered SC.
62037834|NCT04178733|EXPERIMENTAL|LY3493269 - Intravenous (IV)|LY3493269 administered IV.
62037835|NCT02693743|ACTIVE_COMPARATOR|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) will be delivered to the left PFC, deﬁned as a location 6 cm (cm) anterior to the right hand motor thumb area. A research nurse will deliver the treatments. rTMS will be delivered with a ﬁgure-eight coil at 120% motor threshold, 10 Hertz (Hz), 5 s (s) train duration, 20 s intertrain interval for 50 min (6000 pulses) 3 times daily for 3 days (total 9 sessions, 54,000 stimuli).
62430444|NCT02649608|EXPERIMENTAL|1.0 mg Lu AE04621|Patients having received a dose of 1.0 mg, independent of which Cohort they belong to.
62430445|NCT02649608|EXPERIMENTAL|1.2 mg Lu AE04621|Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.
62239999|NCT00702845|ACTIVE_COMPARATOR|recFSH 150 IU|Participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including the day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
62240000|NCT02936934|ACTIVE_COMPARATOR|Morphine|Multimodal analgesia to morphine
62240001|NCT02936934|EXPERIMENTAL|Oxycodone|Multimodal analgesia to oxycodone
62430446|NCT06119646|EXPERIMENTAL|Warm Pads Applied to the Breast|When repairing the episiotomy of a pregnant woman who has given birth, a pad heated in a microwave oven at 180 W for 1 minute is applied to each breast for 20 minutes. The application is made when the temperature of the pad, measured with a thermometer, reaches a maximum of 40.5 C.
62430447|NCT06119646|NO_INTERVENTION|Control|A routine care was performed.
62597622|NCT05644821|OTHER|Comparison group|In patients who are fully continent 6-weeks post-surgery (i.e., do not use pads in 24 hours), ePROMs are collected at 24 and 52 weeks, but no alarms or further actions are derived from them. Thus, treatment is provided according to routine clinical practice. Patients are not randomized.
62597623|NCT06620094|EXPERIMENTAL|Intervention Group|This group, used mobile application and underwent routine controls.
62597624|NCT06620094|NO_INTERVENTION|Control Group|This group, underwent only routine controls.
62597625|NCT04653753|EXPERIMENTAL|Orthosis Group|Use of kneeSOFT500 device
62597626|NCT04653753|NO_INTERVENTION|Control Group|No use of the device
62597627|NCT05570851|ACTIVE_COMPARATOR|Control|Usual Care
62597628|NCT05570851|EXPERIMENTAL|Intervention|Text Message Based Program
62597629|NCT06629298|EXPERIMENTAL|5 Hertz Whole-Body Vibration Intervention|Three 1-minute sessions of stochastic whole-body vibration (SR-WBV) training with 1-minute breaks at 5 Hz
62597630|NCT06629298|SHAM_COMPARATOR|2 Hertz Whole-Body Vibration Intervention|Three 1-minute sessions of stochastic whole-body vibration (SR-WBV) training with 1-minute breaks at 2 Hz
62816040|NCT05011188|EXPERIMENTAL|Does Escalation|Approximately 3 dose levels of FOR46 will be evaluated. Participants will receive a lead-in treatment period of enzalutamide monotherapy for 14 days (day -14 to day -1), followed by addition of FOR46 on Cycle 1 Day 1. If participants are on enzalutamide at the time of study entry, and remain on continuous dosing at 160 mg daily, the lead-in treatment period will not be required. Prophylactic Pegfilgrastim (G-CSF) 6mg, subcutaneously (SQ) will also be administered on Day 2 during all treatment cycles. Pegfilgrastim could be modified to a lower dose of 3 mg with treating investigator approval.
62816041|NCT05011188|EXPERIMENTAL|Dose Expansion|Participants will receive a lead-in treatment period of enzalutamide monotherapy for 14 days (day -14 to day -1), followed by addition of FOR46 on Cycle 1 Day 1, at the maximum tolerated dose (MTD) as determined in Phase 1b. If participants are on enzalutamide at the time of study entry, and remain on continuous dosing at 160 mg daily, the lead-in treatment period will not be required. Prophylactic Pegfilgrastim (G-CSF) 6mg, subcutaneously (SQ) will also be administered on Day 2 during all treatment cycles. Pegfilgrastim could be modified to a lower dose of 3 mg with treating investigator approval.
62816042|NCT04464863||Cases|Acute stroke patients during the first week of evolution
62816043|NCT04464863||Control|Age and sex 1:1 healthy participants
62240002|NCT00551109|PLACEBO_COMPARATOR|P|Placebo
62240003|NCT00551109|EXPERIMENTAL|A1|SA4503
62240004|NCT00551109|EXPERIMENTAL|A2|SA4503
62240005|NCT01353625|EXPERIMENTAL|CC-115|
62240006|NCT04908176|EXPERIMENTAL|Participants with metastatic, unresectable GIST, non-CNS solid tumors, or CNS tumors|Participants will receive 5 mg of midazolam orally on Day 1 and Day 17. Participants will receive avapritinib 300 mg daily, orally on starting on Day 3. Participants with CNS tumors will receive avapritinib 300 mg daily orally, until Day 56.
62240007|NCT01967303||Patients with stroke or transient ischemic attack|Interview regarding restless legs syndrome
62240008|NCT01967303||Subjects without stroke or transient ischemic attack|Interview regarding restless legs syndrome
62430448|NCT02139605|ACTIVE_COMPARATOR|D2 Lymphadenectomy|Intervention D3 Lymphadenectomy
62430449|NCT02139605|EXPERIMENTAL|D3 Lymphadenectomy|Comparator D2 Lymphadenectomy
62430450|NCT03644602|ACTIVE_COMPARATOR|IBD patients|"All subjects with Crohn's disease in clinical remission (defined in the presence of a Crohn's Disease Activity Index, CDAI \<150), and with Ulcerative colitis in clinical remission (defined in the presence of \<3 evacuations / day without blood, in the absence of endoscopic alterations) received a low FODMAPs diet.~The low FODMAPs diet was administered for 3 months."
62597631|NCT02340442||Low risk group|40 subjects: Healthy, pregnant women
62597632|NCT02340442||High risk group|"40 pregnant women:~* 20 Pregnant women with preeclampsia~* 20 Obese pregnant women"
62597633|NCT02340442||Healthy control subjects|40 subjects
62597634|NCT02407457|ACTIVE_COMPARATOR|AFX EVAR AAA Graft System|Subjects randomized to receive the Endologix AFX Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
62597635|NCT02407457|ACTIVE_COMPARATOR|FDA Approved EVAR AAA Graft Systems|Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
62597636|NCT04598451|EXPERIMENTAL|efgartigimod PH20 SC|patients receiving efgartigimod PH20 SC on top of prednisone
62597637|NCT04598451|EXPERIMENTAL|placebo|patients receiving placebo on top of prednisone
62597638|NCT05306782|EXPERIMENTAL|Transcranial Random Noise Stimulation|Transcranial Random Noise Stimulation (1.5 mA, High Frequency) administered by using surface scalp electrodes (20 minutes, initial part of the session) in correspondence of associative motor regions, during speech therapy sessions (45 minutes).
62816044|NCT04024865||Treated with domperidone|Women who received a prescription for domperidone during the six months following delivery.
62816045|NCT04024865||Unexposed group (reference)|Women with no prescription for domperidone during the six months following delivery.
62816046|NCT05389293|EXPERIMENTAL|Single Agent Mosunetuzumab|Participants with newly diagnosed FL in need of systemic therapy
62240009|NCT01821378|EXPERIMENTAL|Lurasidone 20 mg|Lurasidone 20 mg once daily
62240010|NCT01821378|EXPERIMENTAL|Lurasidone 80 mg|Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2
62240011|NCT01821378|PLACEBO_COMPARATOR|Placebo|Placebo Comparator 20 or 80 mg once daily
62816047|NCT05389293|EXPERIMENTAL|Mosunetuzumab + Zanubrutinib|Participants with newly diagnosed FL in need of systemic therapy
62240012|NCT03267953|EXPERIMENTAL|First stage: Self-directed My Health CheckUp|Participants randomized to this group will be sent an e-mail invitation by the research team to register to the website. Once registered, participants will receive a second e-mail that will provide brief instructions on getting started and invite them to use the website for 12 weeks ad libitum. No additional contact will be provided thereafter by research team.
62240013|NCT03267953|EXPERIMENTAL|First stage: Minimally guided My Health CheckUp.|This group will also be invited to use the 12-week Internet-based stress management program, but they will additionally receive support via weekly telephone calls from a lay coach.
62240014|NCT03267953|EXPERIMENTAL|Second stage: High intensity Motivational Interviewing (MI)|After 6 weeks, response to the first stage programs will be assessed and only the non-responders will be randomized a second time to (a) continue with the first stage programs or (b) High-intensity MI. In addition to continued access to My Health CheckUp, participants in this group will also be supported with 6 weekly, telephone-based MI sessions.
62430451|NCT03644602|ACTIVE_COMPARATOR|Coeliac patients|Celiac patients on a gluten free diet for at least one year received a low FODMAPs diet. The low FODMAPs diet was administered for 3 months.
62430452|NCT03644602|ACTIVE_COMPARATOR|IBS patients|Patients with Irritable Bowel Syndrome received a low FODMAPs diet. The low FODMAPs diet was administered for 3 months.
62816048|NCT06444516|EXPERIMENTAL|FID123300|One drop of FID123300 ocular lubricant in each eye on Day 1 in the morning, followed by at least one drop in each eye 4 times a day on Days 2-30.
62240015|NCT01479829|EXPERIMENTAL|Intervention cohort|Participants assigned to the intervention cohort receive 10mg escitalopram twice daily plus 200mg celecoxib twice daily.
62240016|NCT01479829|PLACEBO_COMPARATOR|Control cohort|Participants assigned to the control cohort receive 10mg escitalopram twice daily plus placebo administered twice daily.
62240017|NCT00584168|PLACEBO_COMPARATOR|2|Patient will receive a placebo.
62240018|NCT00584168|EXPERIMENTAL|1|Patient will receive dexamethasone.
62240019|NCT05175651|EXPERIMENTAL|Subjects identified by Optum Health|10,000 individuals identified by Optum Health as likely meeting inclusion criteria by claims analysis.
62240020|NCT04872881|ACTIVE_COMPARATOR|ETT Group|"ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords). The Reposition Time will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a Failed Airway and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords)"
62240021|NCT04872881|ACTIVE_COMPARATOR|LMA Group|"After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted. The LMA Insertion Time will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a Failed Airway and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords)"
62240022|NCT00145925|PLACEBO_COMPARATOR|Blood pressure|Perindopril indapamide vs placebo
62240023|NCT00145925|OTHER|Glucose control|Standard versus intensive glucose control
62240024|NCT05374304|EXPERIMENTAL|Lead-In (BC/WC-GeriOnc)|Lead-in phase oncologists will complete the BC/WC-GeriOnc communication tool training. Cancer treatment decision-making discussions will be recorded with 2 patients per oncologist and ask patients and oncologists to complete study questionnaires over one-month follow-up and one semi-structured interview about the decision-making process and communication.
62430453|NCT00821041|NO_INTERVENTION|Waiting list control|
62430454|NCT00821041|EXPERIMENTAL|CBT|A 6 weeks online course. Each week participants log on to view videos and read information that focus on a variety of intervention techniques. These include relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training. Participants also monitor their sleep using an online sleep diary and respond to questions regarding their adherence to the program.
62816049|NCT05104853|EXPERIMENTAL|4 mg/Kg CNP-104|200 mL intravenous infusion on Day 1 and Day 8: 4 mg/Kg CNP-104
62816050|NCT05104853|EXPERIMENTAL|8 mg/Kg CNP-104|200 mL intravenous infusion on Day 1 and Day 8: 8 mg/Kg CNP-104
62816051|NCT05104853|PLACEBO_COMPARATOR|Placebo|200 mL intravenous infusion on Day 1 and Day 8: Placebo
62816052|NCT01026844|EXPERIMENTAL|Erlotinib plus hydroxychloroquine|erltoinib 150mg per day plus HCQ in esclating doses of 400mg, 600mg, 800mg and 1000mg per day
62816053|NCT01026844|EXPERIMENTAL|Hydroxychloroqine|hydroxychloroquine given at escalating doses of 400mg, 600mg, 800mg and 1000mg per day
62240025|NCT05374304|EXPERIMENTAL|Intervention (BC/WC-GeriOnc)|Intervention group oncologists will complete the BC/WC-GeriOnc communication tool training. Cancer treatment decision-making discussions will be recorded with 2 patients per oncologist to understand baseline oncologist practices and communication. Patients and oncologists will be asked to complete study questionnaires over a 2 month follow-up and 1 semi-structured interview. For each randomized oncologist, cancer treatment decision-making discussions will be recorded with 5 patients per oncologist. Both patients and oncologists will also be asked to complete study questionnaires over a 2 month follow-up and 1 semi-structured interview about the decision-making process and communication. Each patient will be given the option to select 1 caregiver to participate. Caregivers will be asked to complete study questionnaires and a semi-structured interview about their decision-making experience.
62240026|NCT05374304|NO_INTERVENTION|Waitlist Control|Usual care will be provided to the patients, with optional training for the oncologists at study completion.
62816054|NCT04418791|EXPERIMENTAL|MIF-regular|MIF-regular will start with modified intermittent fasting. After 12 weeks, this arm will return to regular diet with no fasting intervention.
62816055|NCT04418791|EXPERIMENTAL|Regular-MIF|Regular-MIF will start with regular diet with no fasting. After 12 weeks, this arm will start with modified intermittent fasting.
62816056|NCT06207786|EXPERIMENTAL|Povidone Iodine nasal swab|Patients undergoing Mohs micrographic surgery (MMS) for malignant cutaneous neoplasms will receive nasal povidone-iodine swabs prior to skin reconstruction.
62816057|NCT06207786|OTHER|Oral antibiotic prophylaxis protocol (usual care)|Patients undergoing Mohs micrographic surgery (MMS) for malignant cutaneous neoplasms will receive standard of care, including the provision of an oral anti-staphylococcal antibiotic per the standardized Antibiotic Prophylaxis protocol currently used for clinical decision making in Dermatologic Surgery at Mayo Clinic Rochester.
62240027|NCT02121496|EXPERIMENTAL|Resources for Postpartum Parenting|Behavioral intervention will include techniques to help mothers get their infants to cry/fuss less and sleep more to determine if this has an effect on prevalence of postpartum depression in low SES women and if it improves the quality of mother-infant interaction and subsequent child development.
62816058|NCT05314868||Primary cohort|Pediatrics or adults who underwent cardiac repair surgery that nessecitated the use of a PhotoFix patch.
62816059|NCT03473678|ACTIVE_COMPARATOR|Nitrate-rich beetroot juice|2 x 70mL concentrated juice per day for 10 days
62816060|NCT03473678|PLACEBO_COMPARATOR|Nitrate-depleted beetroot juice|2 x 70mL concentrated juice per day for 10 days
62816061|NCT04752618|EXPERIMENTAL|P-STAIR|Participants will receive 23 weekly individual treatment sessions. Each session will last one hour. P-STAIR is a combination of STAIR and PCIT. STAIR focuses on reduction of PTSD symptoms through enhancement of emotion regulation skills. PCIT focuses on the reduction of negative parenting skills and the increase of positive parenting skills.
62240028|NCT02121496|NO_INTERVENTION|Control Group|This group will not receive the coaching tips to help babies cry less and sleep more.
62240029|NCT04680403|EXPERIMENTAL|supervised exercise plan|patients will receive a tailored exercise regimen and behavior change techniques focused on adherence to the exercise program. These will be delivered by using a video platform, much liker telehealth clinic appointments. These telehealth visits will be over a 12-week period, occur 3 times a week, and last for 1 hour each.
62240030|NCT04147325||Prospective Cohort|Participants newly diagnosed with Human Immunodeficiency Virus (HIV)-1, will receive Antiretroviral Therapy (ART) in accordance with clinical practice and will be included in a Test and Treat model of care at the outpatient clinic of the center.
62240031|NCT04147325||Historical Cohort|Naive HIV-1 infected participants who had their first care visit at the outpatient clinic of the center through 2017 will be included in this cohort.
62240032|NCT01786239|EXPERIMENTAL|Omega-3 capsules & Risperidone|Subjects will take 1 capsule in the morning and 1 capsule in the evening. Each capsule contains 370 mg EPA and 200 mg DHA as well as 2 mg/g tocopherol. The study dose will start on day 1 and remain the same throughout the study.
62240033|NCT01786239|OTHER|Placebo & Risperidone|Subjects will take 1 capsule in the morning and 1 capsule in the evening.The placebo is a soybean/corn blend (each capsule contains 1000 mg). The study dose will start on day 1 and remain the same throughout the study.
62240034|NCT05318222|OTHER|WGS arm|All 200 patients recruited will undergo WGS
62816062|NCT04752618|ACTIVE_COMPARATOR|Supportive Counseling|Participants will receive 23 weekly individual treatment sessions. Each session will last one hour. Supportive counseling has been modified to permit non-trauma discussion of parenting problems. Each session is client-directed and clinicians take an unconditionally supportive role.
62816063|NCT02659163|EXPERIMENTAL|intervention|Intervention subjects will receive feedback on their health behaviors along with clinical recommendations.
62816064|NCT02659163|ACTIVE_COMPARATOR|control|Control subjects will receive feedback on their health behaviors for self-guided care.
62816065|NCT01169103|EXPERIMENTAL|recombinant human growth hormone|Forty subjects will be randomized to receive either recombinant human growth hormone or placebo.
62816066|NCT01169103|PLACEBO_COMPARATOR|Placebo|Forty subjects will be randomized to receive either recombinant human growth hormone or placebo.
62816067|NCT01615146|EXPERIMENTAL|Therapeutic Platelet Transfusion Arm|Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions.
62816068|NCT01615146|ACTIVE_COMPARATOR|Prophylactic Platelet Transfusion Group|Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion (a single dose of random donor platelets (4 unit pool or random donor platelets or one apheresis unit) when the measured platelet count is \< 10 x 109/L.
62816069|NCT04931940|ACTIVE_COMPARATOR|Usual Care|Patients will receive a usual protein/amino acid dose (≤1.2 g/kg/d)
62816070|NCT04931940|ACTIVE_COMPARATOR|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
62816071|NCT04854135|EXPERIMENTAL|CGM Intervention|All eligible patients will receive a Continuous Glucose Monitor (CGM) prior to hospital discharge after signing an informed consent.
62037836|NCT02693743|SHAM_COMPARATOR|Sham rTMS|Parameters for sham Repetitive Transcranial Magnetic Stimulation (rTMS) are identical to those for active stimulation except that aluminum plate blocks the propagation of a magnetic field. The sound and physical sensation is the same as with the active coil while been biologically inactive.
62037837|NCT04958018|EXPERIMENTAL|Almond|57 g almonds each day in split doses (half in the morning, half in the afternoon)
62037838|NCT04958018|ACTIVE_COMPARATOR|Snack Bar|snack bar group will ingest a matched calorie, common snack bar in split doses (324 calories/day, Nutri-Grain cereal bars, 120 kcal each)
62433674|NCT06198985|EXPERIMENTAL|Dynamic balance exercise with tecnobody prokin 252 balance device added to current medical treatment|Dynamic balance exercises: The treatment will be performed in 3 days a week for 6 weeks. Each exercise will last 30 minutes. It will take 18 sessions in total. These exercises include 14 balance exercise movements performed on tecnobody prokin 252 balance device.
62816072|NCT04065139|ACTIVE_COMPARATOR|Control Arm|
62816073|NCT04065139|EXPERIMENTAL|Experimental Arm : PIPAC|
62816074|NCT06046040|EXPERIMENTAL|Dose Level -1|After lymphodepleting chemotherapy subjects to receive 1x10(7) TmPSMA-02 CAR T Cells
62037839|NCT01164358||study arm I|"patients who have been enrolled in the previous study Intrastromal Correction of Ametropia by Femtosecond Laser (study ISCAF), study arm 1, Presbyopia sub-group: treatment pattern 5-Rings"
62240035|NCT00528567|EXPERIMENTAL|Bevacizumab and Chemotherapy|Participants randomized to receive bevacizumab in combination with chemotherapy as prescribed.
62816075|NCT06046040|EXPERIMENTAL|Dose Level 1|After lymphodepleting chemotherapy subjects to receive 5 x10(7) TmPSMA-02 CAR T Cells
62816076|NCT06046040|EXPERIMENTAL|Dose Level 2|After lymphodepleting chemotherapy subjects to receive 1x10(8) TmPSMA-02 CAR T Cells
62816077|NCT06046040|EXPERIMENTAL|Dose Level 3|After lymphodepleting chemotherapy subjects to receive 3x10(8) TmPSMA-02 CAR T Cells
62816078|NCT05127044|OTHER|Qualified Preterm Infants|Preterm infants will receive non-invasive optical spectroscopy and transcutaneous bilirubin testing for baseline comparison
62816079|NCT06706258|EXPERIMENTAL|Pantoprazole Group|"Pantoprazole (Protonix) will be given at 4 different timepoints:~1. After anesthesia induction, before surgical incision.~2. At chest closure. 3 \& 4. Every 12 hrs in post operative day 1."
62816080|NCT06706258|ACTIVE_COMPARATOR|Famotidine Group|"Famotidine (Pepcid) will be given at 4 different timepoints:~1. After anesthesia induction, before surgical incision.~2. At chest closure. 3 \& 4. Every 12 hrs in post operative day 1."
62816081|NCT05361551|EXPERIMENTAL|Liver ablation|The ablation procedure will be performed in 1 day
62816082|NCT06120712|EXPERIMENTAL|Participants with advanced malignant melanoma using cryopreserved GC101 TIL|A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed Pembrolizumab.
62816083|NCT06500390|EXPERIMENTAL|Group of patients using levonorgestrel intrauterine system|The levonorgestrel intrauterine system use patients group consisted of 50 women who had previously a mirena implanted by a gynecologist at least 3 months ago due to menstrual bleeding and pelvic pain.
62816084|NCT06500390|EXPERIMENTAL|Control group of healthy patients|The control group included 50 randomized health women who had regular menstrual cycles and were not taking any medication.
62816085|NCT03672331|OTHER|Standard arm|Participants will be screened for breast cancer according to current national/regional guidelines and procedures: with a mammogram and/or tomosynthesis (TS) every 1-3 years starting at age 40-50 years, up to age 69-74 years, with or without ultrasound and MRI depending on breast mammographic density and current recommendations. The national/regional guidelines in use in the including center may be subjected to changes during the study. Guidelines and procedures in the standard arm will be updated accordingly.
62037840|NCT01164358||study arm II|"patients who have been enrolled in the previous study Intrastromal Presbyopia Correction by Means of Femtosecond Laser (study # 0905)"
62240036|NCT00528567|ACTIVE_COMPARATOR|Chemotherapy|Participants randomized to receive standard adjuvant chemotherapy as prescribed.
62240037|NCT01956656|PLACEBO_COMPARATOR|lotus leaf mouthwash|10 ml mouthwash to be used for 4days twice daily
62240038|NCT01956656|PLACEBO_COMPARATOR|placebo mouthwash|10 ml mouthwash to be used for 4 days twice daily
62240039|NCT00931333|EXPERIMENTAL|1|
62240040|NCT04873414|EXPERIMENTAL|Treatment group|Subjects in the Treatment Group are given 200 ml of Plasma collected from Convalescent Patients recovered from COVID-19 at two-day intervals in addition to standard supportive treatment
62240041|NCT04873414|NO_INTERVENTION|Control group|Subjects in the Control Group are given standard supportive treatment
62240042|NCT03250832|EXPERIMENTAL|Part 1a: TSR-033 monotherapy dose escalation|Part 1a will evaluate TSR-033 at ascending doses (20 milligrams \[mg\], 80 mg and 240 mg) every 2 weeks. Cohorts will be enrolled sequentially and will initially follow a 3+3 design at a starting dose of 20 mg.
62037841|NCT03707977|EXPERIMENTAL|Group PK-A: ART + VRC01LS|In the PK Step, participants will continue ART and receive VRC01LS at Weeks 0, 4, and 8 as a single intravenous (IV) dose (30 mg/kg load then 10 mg/kg maintenance).
62037842|NCT03707977|EXPERIMENTAL|Group PK-B: ART + 10-1074|In the PK Step, participants will continue ART and receive 10-1074 at Weeks 0, 4, and 8 as a single IV dose (30 mg/kg).
62037843|NCT03707977|EXPERIMENTAL|Steps 1-3 Participants (ART + 10-1074 + VRC01LS)|In Step 1, eligible participants will continue to receive ART and will receive both 10-1074 and VRC01LS at Weeks 0, 4, and 8. Following a recommendation from the study team and Safety Monitoring Committee (SMC) to increase the maintenance dosing based on the PK Step, a VRC01LS loading dose of 30 mg/kg will be given at the start of Step 1, followed by 15 mg/kg dosing at each 4-weekly visit, and 10-1074 dosing will be at 30 mg/kg at each 4-weekly visit. In Step 2, participants with ongoing viral suppression throughout Step 1 will undergo withdrawal of ART and will continue maintenance 10-1074 (30 mg/kg) and VRC01LS (15 mg/kg) treatment for up to 24 weeks. In Step 3, both 10-1074 and VRC01LS will be discontinued and ART will be re-started.
62037844|NCT02541552|EXPERIMENTAL|Knee arthroscopic patient|"1) Male and females 2) Age 16-60 years 3) Scheduled surgery 4) Knee arthroscopy 5) ASA Class I - III~Volume finding study to follow up-and-down design using a single cohort of patients. Intervention of patient will be dependent on effect of previous patients dose of and response to Ropivacaine 0.5% injectate."
62037845|NCT03036358|OTHER|Teledermatology consult|To determine the benefit of teledermatology to differentiate cellulitis from pseudocellulitis in emergency departments through the analysis of time spent in the emergency department (ED), admission to the inpatient hospital, antibiotic use, time to improvement, and 30-day remission rate. This arm will undergo imaging, a dermatologic assessment will be performed, AND this assessment will be entered into the patients chart.
62240043|NCT03250832|EXPERIMENTAL|Part 1b: TSR-033 monotherapy PK/PDy characterization|Part 1b will evaluate the PK profile and assess PDy data from blood and tumor tissue samples following TSR-033 treatment. The participants will begin treatment with TSR-033 on Day 1 followed by 28 days observation for collection of blood sampling for PK/PDy. Participants will receive their second dose of TSR-033 on Day 29 and every 14 days thereafter.
62240044|NCT03250832|EXPERIMENTAL|Part 1c: TSR-033+dostarlimab combination dose escalation|Participants will be administered ascending doses of TSR-033 in combination with dostarlimab 500 mg every 3 weeks. Planned dose levels of TSR-033 include 80 and 240 mg.
62816086|NCT03672331|EXPERIMENTAL|Risk-based arm|Participants will be screened according to a personalised timetable based on their estimated 5-year risk of developing breast cancer: with a mammography and/or tomosynthesis every 1-4 years with or without ultrasound depending on breast density. Risk estimation will be performed using the following variables: age, family history, previous history of benign breast biopsy, personal hormone and reproductive history, breast mammographic density and genotyping (polygenic risk score). Risk assessment will be conducted using Mammorisk™ for women with at most one first-degree relative with breast or ovarian cancer and using Tyrer-Cuzick™ risk score for those women with more than one first-line first degree relative with breast or ovarian cancer.
62816087|NCT05263934|EXPERIMENTAL|Participants receiving depemokimab+placebo matching mepolizumab|
62816088|NCT05263934|ACTIVE_COMPARATOR|Participants receiving mepolizumab+placebo matching depemokimab|
62816089|NCT06308952|PLACEBO_COMPARATOR|placebo group|placebo 20mg qd
62816090|NCT06308952|ACTIVE_COMPARATOR|atorvastatin group|atorvastatin 20mg qd
62037846|NCT03036358|OTHER|Routine Care|To determine the benefit of teledermatology to differentiate cellulitis from pseudocellulitis in emergency departments through the analysis of time spent in the emergency department (ED), admission to the inpatient hospital, antibiotic use, time to improvement, and 30-day remission rate. This arm will undergo imaging, a dermatologic assessment will be performed, AND this assessment WILL NOT be entered into the patients chart
62240045|NCT03250832|EXPERIMENTAL|Part 2 Cohort A: TSR-033+dostarlimab combination|Part 2 Cohort A will evaluate the preliminary activity of TSR-033 in combination with dostarlimab in anti-PD-1 naive participants with third and fourth line MSS-CRC. TSR-033 will be administered every 2 weeks and dostarlimab every 6 weeks.
62430455|NCT01368679|EXPERIMENTAL|Endoprothesis Scitech|"The endoprothesis of SCITECH is a self-expandable stent mixed (laser cut and wire plotted) covered with polyester fabric. The delivery system has lower profile than the existing market and this approach allows the passage of the delivery system through the femoral artery with ease and without dissection. Fixation has proximal and distal securing lower rates of leakage and displacement.~The delivery system is done by linear drive or screw diameters greater than 30mm"
62430456|NCT03233737|EXPERIMENTAL|Stage II: One spray CTY-5339-A, then one spray CTY-5339-CB|A single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session. Used in Stage II of the study only.
62240046|NCT03250832|EXPERIMENTAL|Part 2 Cohort B1: TSR-033+dostarlimab with mFOLFOX6|Part 2 Cohort B1 will evaluate the preliminary activity of TSR-033 administered every 2 weeks (Q2W) in combination with dostarlimab administered every 6 weeks (Q6W) along with mFOLFOX6 and bevacizumab (standard of care \[SOC\]) in anti-PD-1 naive second line MSS-CRC participants who have progressed on frontline treatment with FOLFIRI, with or without biologics.
62240047|NCT03250832|EXPERIMENTAL|Part 2 Cohort B2: TSR-033+dostarlimab with FOLFIRI|Part 2 Cohort B2 will evaluate the preliminary activity of TSR-033 in combination with FOLFIRI and bevacizumab (SOC) in anti-PD-1 naive second line MSS-CRC participants who have progressed on frontline treatment with FOLFOX, with or without biologics.
62240048|NCT04035850|EXPERIMENTAL|Participants|Vortioxetine PO tablets, 5-20mg Daily
62816091|NCT03535922|EXPERIMENTAL|The disease-specific PROM group|Hemodialysis (HD) units randomized to this PROMs assessment group will administer a disease-specific PROM every 2 months to all patients able to complete the instrument independently or with assistance for a period of 12 months. Patients will receive a copy of their PROM results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the PROM. The disease-specific PROM report will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROM report will be accompanied by treatment aids for all symptoms. The proposed disease-specific PROM is the ESAS-r:Renal or the IPOS-Renal.
62816092|NCT03535922|EXPERIMENTAL|The generic PROM group|HD units randomized to this PROMs assessment group will administer a generic PROM every 2 months to all patients able to complete the instrument independently or with assistance for a period of 12 months. Patients will receive a copy of their PROM results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the PROM. The generic PROM report will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROM report will be accompanied by treatment aids for all symptoms. The proposed generic PROM is the EQ-5D-5L.
62430457|NCT03233737|ACTIVE_COMPARATOR|Stage II: One spray of CTY-5339-CB, then one spray CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session. Used in Stage II of the study only.
62430458|NCT03233737|EXPERIMENTAL|Stage I: One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
62430459|NCT03233737|ACTIVE_COMPARATOR|Stage I: One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
62816093|NCT03535922|EXPERIMENTAL|Disease-specific and generic PROMs group|HD units randomized to this PROMs assessment group will administer a disease-specific and generic PROM every 2 months to all patients able to complete the instrument for a period of 12 months. Patients will receive a copy of both their PROMs results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the two PROMs. The disease-specific and generic PROMs reports will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROMs reports will be accompanied by treatment aids for all symptoms.
62816094|NCT03535922|NO_INTERVENTION|The control or 'usual care' group|HD units randomized to this group will follow usual care and patients will not have any PROMs assessment; however, all the treatment aids will be made available for clinicians in this study group during the 12 months trial period.
62430460|NCT03233737|PLACEBO_COMPARATOR|Stage I: One spray CTY-5339-P|Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (placebo: vehicle control). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
62430461|NCT02082262|EXPERIMENTAL|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
62430462|NCT01416142|ACTIVE_COMPARATOR|Spectacles|The subject's habitual spectacles (updated or confirmed as correct within the last 2 years)
62816095|NCT05252546|EXPERIMENTAL|pyrotinib alone, then pyrotinib + Montmorillonite Power or Loperamide|Sequential treatments of pyrotinib alone followed by pyrotinib + Montmorillonite Power or Loperamide, with a washout period in between.
62816096|NCT03314103|EXPERIMENTAL|Vaccine|live attenuated varicella-zoster virus vaccine (with live virus \>=4.3 LgPFU per dose)
62816097|NCT03314103|PLACEBO_COMPARATOR|Placebo|Placebo with no live virus
62240049|NCT02914691|ACTIVE_COMPARATOR|Active|Dapagliflozin 10 mg once daily tablet treatment
62240050|NCT02914691|PLACEBO_COMPARATOR|Placebo|Identical once daily tablet treatment
62240051|NCT00959972|EXPERIMENTAL|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
62240052|NCT00959972|EXPERIMENTAL|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
62240053|NCT02673619|EXPERIMENTAL|Umeclidinium once daily (QD) 1.85%|Subjects will apply UMEC topically once daily (2microliter \[µL\]/centimeter \[cm\]\^2) to both the hands (palm and fingers) using graduated syringe at night before bedtime for 28 days. Randomization will be 4:1 (UMEC 1.85%: vehicle)
62597639|NCT05306782|EXPERIMENTAL|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (1.5 mA, anodal) administered by using surface scalp electrodes (20 minutes, initial part of the session) in correspondence of associative motor regions, during speech therapy sessions (45 minutes).
62597640|NCT05306782|SHAM_COMPARATOR|Sham Direct Current/Random Noise Stimulation|Sham stimulation administered by using surface scalp electrodes (20 minutes, initial part of the session) in correspondence of associative motor regions, during speech therapy sessions (45 minutes).
62597641|NCT04955665||Bone block procedure|patients with recurrent peroneal tendon dislocation underwent the bone block procedure
62597642|NCT04955665||Reattachment of the superior peroneal retinaculum|patients with recurrent peroneal tendon dislocation underwent reattachment of the superior peroneal retinaculum
62816098|NCT06329440|ACTIVE_COMPARATOR|Costoclavicular block|Patients who will receive costoclavicular brachial plexus block for hand surgery. Costoclavicular block is performed via depositing local anesthetic in the costoclavicular space which is placed in the posterior of middle part of the clavicle. The diaphragma thickness will be evaluated after the surgery in postanesthesia care unit.
62816099|NCT06329440|ACTIVE_COMPARATOR|Supraclavicular block|Patients who will receive supraclavicular brachial plexus block for hand surgery. Supraclavicular is performed via depositing local anesthetic using corner pocket technique which is described as injecting the drugs to the inferolateral side of axillary artery above the 1st rib. The diaphragma thickness will be evaluated after the surgery in postanesthesia care unit.
62816100|NCT04739982|EXPERIMENTAL|Treatment|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
62816101|NCT04739982|NO_INTERVENTION|Treatment as Usual|Participants in control group will continue their treatment as usual.
62816102|NCT02307890||Liver transplantation group|Participants will include all deceased adult liver transplant donors (\>16 years of age) whose livers are being utilised for transplantation in the Scottish Liver Transplant Unit in the Royal Infirmary of Edinburgh. Exclusion criteria will include paediatric liver transplant donors (\<16 years of age).
62816103|NCT04790188|EXPERIMENTAL|Experimental intervention first.|Participants randomized to receive the nootropic first.
62816104|NCT04790188|PLACEBO_COMPARATOR|Experimental intervention second.|Participants randomized to receive the placebo first
62816105|NCT06299683|EXPERIMENTAL|Psychosocial Treatment|The psychosocial self-management intervention consists of 8 weekly 50-minute individual visits with an assigned trained therapist. Sessions follow a structured protocol that has been developed with the patient population and tested in a prior study. Treatment modules are individualized and include topics such as pain coping strategies, relaxation training, education on IC/BPS, and communication strategies.
62816106|NCT06299683|ACTIVE_COMPARATOR|Pelvic Floor Physical Therapy|The pelvic floor physical therapy condition consists of 10 weekly 45-minute individual visits with an assigned trained physical therapist. In IC/BPS, pelvic floor physical therapy (PT) uses manual manipulation to release localized muscle tension, trigger points, and correct other scars and restrictions to reduce pain and urgency symptoms. Specific techniques will include external connective tissue manipulation to the abdominal wall, back, buttocks and thighs, myofascial trigger point release, and internal transvaginal/transrectal treatment of the soft tissues of the pelvic floor with connective tissue and myofascial manipulation to pelvic floor musculature
62816107|NCT05782868|EXPERIMENTAL|TNB Identity Affirmation (IA) Condition|Participants in the IA only intervention condition will receive the same prompt for all four days of writing, a design used in expressive writing interventions to allow for deeper and continued reflection into specific thoughts and emotions.
62816108|NCT05782868|EXPERIMENTAL|IA + Strengthening Social Connections (SSC) Condition|For participants in the IA+SSC condition, participants will complete the IA intervention on the first three days. On the fourth day, participants will be directed to compose a brief letter.
62816109|NCT05782868|EXPERIMENTAL|Control Condition|Expressive writing assignment, without prompts.
62816110|NCT04696484|EXPERIMENTAL|Intervention|coopeRATE Prompt
62430463|NCT01416142|EXPERIMENTAL|PureVision2 HD contact lenses|Currently marketed Bausch + Lomb PureVision2 HD contact lenses
62597643|NCT03942068|EXPERIMENTAL|albumin-bound paclitaxel+apatinib|albumin-bound paclitaxel:260mg/m2，q3w，d1 apatinib:500mg，qd，po
62597644|NCT05622929|EXPERIMENTAL|Intervention group|Real-world evidence (RWE) platform to provide data on their clinical practice + usual care + Digitally-enabled Multifaceted Quality Improvement Intervention
62597645|NCT05622929|ACTIVE_COMPARATOR|Control group|RWE platform to provide data on their clinical practice + usual care
62037847|NCT04949373|EXPERIMENTAL|HILT+nerve/tendon gliding exercise+rest splint|Patients will receive pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for three weeks (one session per day for a total of 15 sessions). A 3-phase treatment program will be performed in each session, and a physiotherapist will then apply nerve/tendon gliding exercises program to the patients once daily. The patients will use rest splint at night.
62037848|NCT04949373|SHAM_COMPARATOR|Sham HILT+nerve/tendon gliding exercise+rest splint|Patients will receive sham laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for three weeks (one session per day for a total of 15 sessions). A 3-phase treatment program will be performed in each session, and a physiotherapist will then apply nerve/tendon gliding exercises program to the patients once daily . The patients will use rest splint at night.
62037849|NCT02275676||Inflammatory bowel disease|Patients with active and inactive inflammatory bowel disease
62037850|NCT06450132|NO_INTERVENTION|Observation|Participants randomized to the observation arm will receive no intervention.
62037851|NCT06450132|EXPERIMENTAL|Low-dose atropine|Participants randomized to low-dose atropine will instill one drop of 0.05% atropine in each eye at bedtime for 12 months.
62037852|NCT06450132|EXPERIMENTAL|Soft multifocal contact lenses|Participants randomized to soft multifocal contact lenses will wear MiSight 1-day disposable contact lenses for 5-7 days per week for 12 months.
62037853|NCT05703568|EXPERIMENTAL|Group- based virtual reality training|Individuals in this arm will be received intervention protocol of group- based virtual reality training program in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
62037854|NCT05703568|EXPERIMENTAL|Individual virtual reality training|Individuals in this arm will be received intervention protocol of individual virtual reality training program in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
62037855|NCT05703568|NO_INTERVENTION|Control group|Individuals in this arm will continue their routine daily activities.
62037856|NCT01592318|ACTIVE_COMPARATOR|DNV + r reference|
62037857|NCT01592318|EXPERIMENTAL|DNV/r fixed dose combination|
62037858|NCT06579222|EXPERIMENTAL|Comprehensive Comorbidity Clinic|"The following investigations and treatments will be offered as associated with a comprehensive comorbidity clinic appointment with the primary care rheumatology family physician: Blood pressure, heart rate, height and weight measurement. Blood work (standard lipid panel, fasting plasma glucose or glycated hemoglobin (A1C), eGFR, and Lipoprotein a, Bone densitometry (if applicable to the patient/participant).~Vaccinations will be offered if applicable to the patient/participant according to Health Canada guidelines (Vaccination with Pneu-P-23, Pneu-C-13, herpes zoster and COVID-19 vaccine)."
62037859|NCT01045746|EXPERIMENTAL|Group 1|T0, Stochastic resonance whole-body vibration A intervention over four weeks, three time a week;T1, 16 days wash-out period; T2, Stochastic resonance whole-body vibration B intervention over four weeks, three times week, T3
62430464|NCT02501031|EXPERIMENTAL|Flaxseed (ground)|
62430465|NCT02501031|NO_INTERVENTION|Usual diet|
62430466|NCT05482087|EXPERIMENTAL|XZP-3621|XZP-3621 single agent,500 mg oral tables，QD，continuously
62816111|NCT05602493|EXPERIMENTAL|test group (n=30) Soludronate® 0.7 mg/ml|"It will be applied on the fresh extraction socket for 15 min and then rinsed with sterile saline 3 time, 1 minute each rinse. After the extraction will be required a CBCT scan. The medication that will be prescribed for the patient will be Enantyum 25 mg (2-3 days) and in case of allergic patient Paracetamol 650 mg (2-3 days).~15 days later (-/+ 2 days), during the follow-up 1 the suture will be removed, the cicatrization of the surgical site evaluated and intraoral photos will be taken. The last follow-up (2) visit, 91 days later (-/+ 2 day) the follow-up 2 will take place. A CBCT scan and intraoral photos will be required."
62037860|NCT01045746|EXPERIMENTAL|Group 2|T0, Stochastic resonance whole-body vibration B intervention over four weeks, three time a week;T1, 16 days wash-out period;T2, Stochastic resonance whole-body vibration A intervention over four weeks, three times week, T3
62037861|NCT06448754|EXPERIMENTAL|Arm 1A: Volrustomig dose regimen 1 + Carboplatin and Pemetrexed|Volrustomig priming dose followed by volrustomig dosing regimen 1 in combination with carboplatin and pemetrexed.
62037862|NCT06448754|EXPERIMENTAL|Arm 1 B Volrustomig dose regimen 2 + Carboplatin and Pemetrexed|Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with carboplatin and pemetrexed.
62037863|NCT06303050|EXPERIMENTAL|Mental Imagery with task Oriented training group|Participants will perform warm-up exercise for 5 minutes to prepare the body for functional task and to improve overall performance.
62240054|NCT02673619|PLACEBO_COMPARATOR|Vehicle QD|subjects will apply vehicle topical once daily (2µL/cm\^2) to both the hands (palm and fingers) using graduated syringe at night before bedtime for 28 days.
62240055|NCT00352885|EXPERIMENTAL|Escitalopram|Participants will receive escitalopram and IL-2 treatment
62240056|NCT00352885|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo and IL-2 treatment
62240057|NCT00434551||1|Patients with suspected Crohn's disease
62240058|NCT04706754||Prospective|Confirmed ALK, EGFR, ROS1, ERBB2 (HER2), exon 20 EGFR mutation, MET and BRAF cancer patients from across participating sites/cancer centers across Canada.
62430467|NCT01562431|OTHER|Control|Participants complete the Signal-checklist BUT counselors do not obtain the results of the checklist
62430468|NCT01562431|OTHER|Intervention|Participants complete the Signal-checklist AND the counselor will get the results of the questionnaire
62430469|NCT00944437|ACTIVE_COMPARATOR|Helmet|Patients in this group will receive continuous positive airway pressure delivered through a helmet connected to a high-flow reservoir system.
62430470|NCT00944437|EXPERIMENTAL|Mask|Patients in this group will receive continuous positive-airway pressure delivered through a novel full-face mask connected to a high-flow system. Expiratory pressure will be maintained using an expiratory valve connected to a T-tube.
62037864|NCT06303050|ACTIVE_COMPARATOR|Task Oriented training group|Task oriented training In standing, forward stepping and sideward stepping, reaching in standing, Transition from sit to stand, Walk then back to sit, Walk with even steps, Walk with carrying objects.
62816112|NCT05602493|PLACEBO_COMPARATOR|control group (n=30) sterile saline|"It will be applied on the fresh extraction socket for 15 min and then rinsed with sterile saline 3 time, 1 minute each rinse. After the extraction will be required a CBCT scan. The medication that will be prescribed for the patient will be Enantyum 25 mg (2-3 days) and in case of allergic patient Paracetamol 650 mg (2-3 days).~15 days later (-/+ 2 days), during the follow-up 1 the suture will be removed, the cicatrization of the surgical site evaluated and intraoral photos will be taken. The last follow-up (2) visit will be 1,5 months after the intervention and will be optional for those cases showing redness, swelling or pain during the first follow up, 3,5 months later (-/+ 1 week) the end visit will take place. A CBCT scan and intraoral photos will be required at the end visit."
62816113|NCT04066062||Retrospective|A total of 700 vessel from 700 patients clinically indicated CCTA and IVUS or OCT performed within 3 months.
62816114|NCT04066062||Prospective|A total of 1,000 subjects will be enrolled in this Registry. This number of subject is expected to provide a maximum of 1,300 vessels. All CCTA and IVUS/OCT will be performed within 3 months
62430471|NCT02828748|EXPERIMENTAL|active UC|patients with clinically active ulcerative colitis undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
62037865|NCT03691467|EXPERIMENTAL|immediate implant with hyaluronic acid.|immediate dental implant with topical application of hyaluronic acid.
62037866|NCT03691467|ACTIVE_COMPARATOR|immediate implant.|immediate dental implant placement with placebo gel
62430472|NCT02828748|EXPERIMENTAL|remission UC|patients with clinically non active ulcerative colitis undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
62816115|NCT06593431|EXPERIMENTAL|MDT (Metastasis-Directed Therapy)|Patients will be randomized 1:1 to (a) MDT or (b) systemic therapy alone (no MDT).
62037867|NCT01461876||HIV-infected cohort|
62037868|NCT01461876||HIV-uninfected control group|
62037869|NCT06249932|EXPERIMENTAL|empagliflozin|Jardiance, 25 mg, QD, for 6 months
62037870|NCT06249932|PLACEBO_COMPARATOR|placebo|QD, for 6 months
62430473|NCT02828748|EXPERIMENTAL|active CD|patients with clinically active crohns disease undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
62430474|NCT02828748|EXPERIMENTAL|remission CD|patients with clinically non active crohns disease undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
62430475|NCT04399096||General population|The general public attending exhibitions of the artworks who wish to complete the on-line questionnaire and feedback
62430476|NCT04856579|OTHER|Varicocelectomy|Subinguinal varicocelectomy under general anesthesia and complete aseptic condition
62430477|NCT04238468|EXPERIMENTAL|Intradermal injection of stromal vascular fraction|Most lateral 5 cm of abdominal donor site will be injected with stromal vascular fraction just after the wound is closed.
62430478|NCT04238468|NO_INTERVENTION|control|Most contralateral 5 cm of abdominal donor site will serve as control.
62430479|NCT01580020|EXPERIMENTAL|Ranibizumab (Arm A)|"The PRN injection scheme applied in the core study will also be followed during this extension study:~Patients should be monitored monthly (starting at V1E) for VA and treatment is to be resumed when monitoring indicates loss of VA due to disease activity. Monthly injections should then be administered until stable VA is reached again for 3 consecutive monthly assessments (implying a minimum of 2 injections during stable VA). The interval between 2 doses should not be shorter than 1 month"
62816116|NCT06593431|EXPERIMENTAL|System Therapy (control)|Patients will be randomized 1:1 to (a) MDT or (b) systemic therapy alone (no MDT).
62433675|NCT06198985|NO_INTERVENTION|Group receiving current medical treatment|Participants in this group will receive only current medical treatment.
62430480|NCT01580020|SHAM_COMPARATOR|Dexamethasone (Arm B)|A PRN re-treatment scheme will be applied for the Ozurdex arm during this extension study, i.e. patients may receive an implant at V1E or later as needed: Patients should be monitored monthly and if there is a decline from stable VA stability due to macular edema patients will receive another intravitreal implant. (700 µg; long acting release (LAR)) given that in the opinion of the investigator the patient would benefit from the re-treatment. However, a minimum period of 5 months in between implantations is required.
62430481|NCT05439759|EXPERIMENTAL|Condition 1: Training visual sensitivity|A standard Perceptual Learning approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold- level contrast. Preliminary data, using this method, in normally seeing and MD participants show both feasibility and preliminary evidence that this training gives rise to improvements in acuity.
62430482|NCT05439759|EXPERIMENTAL|Condition 2: Training spatial integration|Most visual tasks involve integrating features to discriminate objects, therefore requiring brain areas that can integrate features from multiple receptive fields from early visual areas. Thus spatial integration involves what investigators refer to as mid-level vision. Spatial integration is a particular concern in developing a PRL since an area of the visual periphery that is best suited to discriminate a simple visual feature may not be appropriate to integrate information across objects, such as in reading or recognizing facial identity or expression. Investigators address this issue with a targeted spatial integration training approach developed by MPI Seitz and based on contour integration tasks used in previous PL studies to train mid-level visual processes. Target stimuli consist of contours formed by spaced Gabors. Difficulty of detecting the target is manipulated by varying orientation jitter of Gabors making up the target.
62597646|NCT06413056|EXPERIMENTAL|micafungin group|Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups. Will receive micafungin at a dose of 8 mg/kg/day for 14 day (Auriti et al., 2016).
62597647|NCT06413056|ACTIVE_COMPARATOR|amphotericin B group|Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups. Will receive amphotericin B at a dose of 1 mg /kg/day for 14 days (chen et al.,2019).
62597648|NCT06620913||Patients with CV2 Abs|Patients harboring CV2 Abs and a paraneoplastic neurological syndromes.
62597649|NCT06260267|EXPERIMENTAL|FE 999322|Microbiota suspension
62816117|NCT03770234|EXPERIMENTAL|Treatment A: Transtec patch application for 96 hours|Transtec 35 µg/hour transdermal patch wearing period of 96 hours, with application of patch on Study Day 1 and removal on Study Day 5.
62816118|NCT03770234|EXPERIMENTAL|Treatment B: Transtec patch application for 72 hours|Transtec 35 µg/hour transdermal patch wearing period of 72 hours, with application of patch on Study Day 1 and removal on Study Day 4.
62597650|NCT06260267|EXPERIMENTAL|FE 999324|Microbiota capsule
62597651|NCT06260267|PLACEBO_COMPARATOR|Placebo FE 999322|Placebo suspension
62597652|NCT06260267|PLACEBO_COMPARATOR|Placebo FE 999324|Placebo capsule
62597653|NCT04766957|EXPERIMENTAL|Idracare|The treatment will be applied 2 times a week, preferably at night before going to bed.
62597654|NCT05860439||Telangiectasias Group - Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)|Previously treated with PDHG, no new interventions were performed.
62597655|NCT05860439||Telangiectasias Group - Hypertonic Glucose 75% (HG)|Previously treated with HG, no new interventions were performed.
62597656|NCT05860439||Reticular Veins Group (PG3T) - Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)|Previously treated with PDHG, no new interventions were performed.
62597657|NCT05860439||Reticular Veins Group (PG3T) - Hypertonic Glucose 75% (HG)|Previously treated with HG, no new interventions were performed.
62597658|NCT06424275||Manresa, Spain|The pilot is run by the Althaia Foundation, driven by the director of primary care.
62597659|NCT06424275||Region Galicia, Spain|The pilot is run by the Galician Healthcare Service (SERGAS), publicly funded healthcare system of Galicia, Spain.
62597660|NCT06424275||Ireland|The pilot is run by the Health Service Executive, with University College Dublin as the academic institutional partner, in full support of the National Cancer Control programme (NCCP) and the National Screening Service (NSS) in Ireland
62597661|NCT06424275||Poland|The pilot is run by the Lower Silesian Oncology, Pulmonology and Haematology Center. Subdivision of Urology with support from the National Institute of Public Health.
62597662|NCT06424275||Lithuania|The pilot is run by the National Cancer Institute, where residents of the capital Vilnius region are served.
62816119|NCT02718079|EXPERIMENTAL|Standard medical therapy with Plasma Exchange|Plasma Exchange will be performed for consecutive days. Standard medical therapy included as per requirement,management of cerebral edema/intracranial hypertension: transfer to ICU,prophylactic antibiotics, intubation of trachea (as required),administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure,volume replacement and pressor support (norepinephrine, vasopressin) as needed, NAC, correction of metabolic parameters and nutrition.
62597663|NCT06618430||Healthy older women|Older women who do not have sarcopenia, obesity or sarcopenic obesity.
62597664|NCT06618430||Older women with sarcopenia|Older women with sarcopenia, i.e. low handgrip strength and low muscle mass index.
62430483|NCT05439759|EXPERIMENTAL|Condition 3: Training spatial attention|A key attribute of most real-world visual tasks is that individuals alternate shifting and holding attention and eye movements to different objects in the visual field while searching for and discriminating possible sources of visual information. To train this, investigators will implement a task structure that requires participants to alternate between holding and switching attention and making targeted eye movements. The basic task is to press a key whenever a red circle appears in a series of other colored circles, with a target presented every 2 to 4s. Participants must maintain vigilance for relatively long periods, detect objects in the near periphery, switch attention based upon exogenous and endogenous cues, and make eye- movements to move areas of spared vision to those locations. These are aspects of attention and eye movements not incorporated in Conditions 1 and 2.
62430484|NCT05439759|EXPERIMENTAL|Condition 4: Combination training|In Condition 4, investigators combine the elements of Conditions 1-3. The investigators test the extent to which a combined training gives rise to the joint benefits of each training individually, or integrative benefits potentially surpass the benefits of the individual training alone. The visual sensitivity task from Condition 1 will alternate across blocks with the spatial integration task from Condition 2, using the timing of targets and location switches from Condition 3; Gabors or contours are used as targets instead of the red- circle in Condition 3 and a fixation point is presented instead of distractors to maintain a similar stimulus configuration as Conditions 1 and 2.
62597665|NCT06618430||Older women with obesity|Older women with obesity
62816120|NCT02718079|ACTIVE_COMPARATOR|Standard medical therapy alone|Standard medical therapy included as per requirement,management of cerebral edema/intracranial hypertension: transfer to ICU,prophylactic antibiotics, intubation of trachea (as required),administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure,volume replacement and pressor support (norepinephrine, vasopressin) as needed, NAC, correction of metabolic parameters and nutrition.
62597666|NCT06618430||Older women with sarcopenic obesity|Older women with sarcopenic obesity, i.e. low handgrip strength, low muscle mass index and high body mass index.
62597667|NCT01752881|EXPERIMENTAL|AdimFlu-S|
62597668|NCT00036491|EXPERIMENTAL|rituximab|375 mg/m\^2 administered intravenously
62597669|NCT03783130|EXPERIMENTAL|Group 1: Trimer 4571 (100 mcg) IM with alum|Trimer 4571 injections (100 mcg), with 500 mcg of alum field mixed, administered intramuscularly (IM) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
62597670|NCT03783130|EXPERIMENTAL|Group 2: Trimer 4571 (100 mcg) SC with alum|Trimer 4571 injections (100 mcg), with 500 mcg of alum field mixed, administered subcutaneously (SC) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
62597671|NCT03783130|EXPERIMENTAL|Group 3: Trimer 4571 (500 mcg) IM with alum|Trimer 4571 injections (500 mcg), with 500 mcg of alum field mixed, administered intramuscularly (IM) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
62597672|NCT03783130|EXPERIMENTAL|Group 4: Trimer 4571 (500 mcg) SC with alum|Trimer 4571 injections (500 mcg), with 500 mcg of alum field mixed, administered subcutaneously (SC) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
62597673|NCT05139459||Participants with sepsis|
62597674|NCT06342011|NO_INTERVENTION|Regular diet group|Explain disease related knowledge; According to the patient's situation, give personalized dietary guidance, establish regular eating habits, carefully evaluate the types of food in the food, and avoid spicy stimulation, gas production, high fat and other foods that are easy to cause intestinal discomfort. SMS follow-up was conducted 3 days after discharge, and weekly phone follow-up was conducted to see if patients needed to solve problems and help them solve them in time.
62816121|NCT04756310|PLACEBO_COMPARATOR|Control|"Patients receiving Theavit food supplement considered as a placebo treatment for AMD condition.~Two capsules/day before breakfast each day for 2 years"
62816122|NCT04756310|EXPERIMENTAL|Retilut|Patients receiving Retilut food supplement. Two capsules/day before breakfast each day for 2 years
62816123|NCT03316781|EXPERIMENTAL|HLX03 group|
62816124|NCT03316781|ACTIVE_COMPARATOR|adalimumab group|
62816125|NCT02640274|EXPERIMENTAL|Intervention group|The intervention is an individual nurse-led counselling programme in addition to usual care.
62816126|NCT02640274|OTHER|Control group|usual care
62037871|NCT06150547||Central Nervous System Malignant Tumor|Subjects may receive up to two CEST MRI's tests and/or up to two FDG PET. The physician will determine which test is appropriate based on your tumor type, past treatment history and research question. Tests will be completed at initial baseline visit and at least one other MRI/PET after the initial baseline, up to a maximum of four scans. Additionally, patients undergo finger-poke blood collection prior to receiving FDG on study.
62037872|NCT04292626|EXPERIMENTAL|Lymphoma|At least five (5) evaluable subjects with Hodgkin Lymphoma or Non Hodgkin Lymphoma. The tested injected dose of 500 MBq.
62037873|NCT01936584||TAPP repair|TAPP repair for inguinal hernia
62037874|NCT01936584||TEP repair|TEP repair for inguinal hernia
62037875|NCT02806375|EXPERIMENTAL|PTCy and ruxolitinib|
62037876|NCT01296451|EXPERIMENTAL|Arm A, group1|Intervention: MVA-NSmut. Administration schedule: 1 dose MVA-NSmut 2 x 10\^8 pfu. Subjects: 4 healthy volunteers
62597675|NCT06342011|EXPERIMENTAL|Anti-inflammatory diet group|"AID knowledge education was given to patients in the intervention group after admission. At the same time, patients are asked to pay attention to the anti-inflammatory diet wechat mini program developed by researchers, and teach patients how to use it, including the choice of anti-inflammatory diet, inappropriate anti-inflammatory diet, diet alarm clock, diet notes and other related functions. Missionary patients persisted with AID until re-examination 8 weeks later.~The researchers conducted weekly telephone follow-up to urge the patients to adhere to the AID diet, answer the questions raised by the patients during the implementation process, and understand the patients' knowledge acceptance and diet implementation. Follow-up is carried out by qualified members of the training research team. Follow-up can take the form of face-to-face visit to the community or direct telephone follow-up, and make follow-up records."
62597676|NCT00514904|EXPERIMENTAL|Nimenrix Group|Subjects received 1 dose of Nimenrix vaccine at Month 0. Nimenrix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62430485|NCT03723928|ACTIVE_COMPARATOR|Arm I (usual care)|Patients will have imaging studies (modality and frequency per treating physician, however at a minimum frequency of every 12 weeks) alone or in conjunction with STMs (frequency determined by treating physician). Patients will continue with usual care disease monitoring for up to 312 weeks in the absence of disease progression.
62816127|NCT05503030||Nintedanib for CTD-associated PF-ILD patients in Greece|Connective Tissue Disease (CTD)-associated Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
62037877|NCT01296451|EXPERIMENTAL|Arm A, group 2|"Interventions: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 0 and 1 dose MVA-NSmut 2 x 10\^8 pfu at week 8.~Subjects: 10 healthy volunteers"
62037878|NCT01296451|EXPERIMENTAL|Arm B, group 1|"Interventions: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 14 and 1 dose MVA-NSmut 2 x 10\^8pfu at week 22, after starting PEG-IFN and ribavirin therapy.~Subjects: 5 patients"
62037879|NCT01296451|EXPERIMENTAL|Arm B, group 2|"Interventions: AdCh3NSmut; MVA-NSmut.. Administration schedule: 1 dose AdCh3NSmut 2.5 x 1010vp at week 2 and 1 dose MVA-NSmut 2 x 108pfu at week 10, after starting PEG-IFN and ribavirin therapy.~Subjects: 5 patients"
62430486|NCT03723928|EXPERIMENTAL|Arm II (serum tumor directed disease monitoring)|Patients undergo disease specific serum tumor marker evaluation (CEA and either CA 15-3 or CA 27.29, whichever were tested at Step 1 Registration and Step 2 Registration) every 4-8 weeks (starting from randomization) without imaging until an elevation of at least one disease specific STM. In the event of an elevated STM, the patient will have imaging within 4 weeks to evaluate for disease progression. Patients continue with STMDDM for up to 312 weeks in the absence of disease progression.
62816128|NCT04922086|EXPERIMENTAL|Test group|Patients will be submitted to ACL planned using cone beam computed tomography (CBCT), digital planning and guided dual technique.
62816129|NCT04922086|ACTIVE_COMPARATOR|Control group|Patients will be submitted to the conventional ACL planned using clinical examination.
62816130|NCT06209658|EXPERIMENTAL|experimental group|breastfeeding education with Teach Back
62816131|NCT06209658|OTHER|Control Group|breastfeeding education simple explanation
62037880|NCT01296451|EXPERIMENTAL|Arm C, group 1|"Interventions: AdCh3NSmut; MVA-NSmut Administration schedule: 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 0 and 1 dose MVA-NSmut 2 x 10\^8pfu at week 8.~Subjects: 4 patients"
62037881|NCT01296451|EXPERIMENTAL|Arm A, group 3|"Interventions: AdCh3NSmut; MVA-NSmut Administration schedule: 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 0, 1 dose MVA-NSmut 2 x 10\^8pfu at week 8, 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 16 and 1 dose MVA-NSmut 2 x 10\^8 pfu at week 24.~Subjects: 5 healthy volunteers"
62037882|NCT01296451|EXPERIMENTAL|Arm A, group 4|"Intervention: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10\^10vp (at least 6 months after they were initially enrolled) and 1 dose MVA-NSmut 2 x 10\^8 pfu 8 weeks later.~Subjects: up to 5 healthy volunteers who were previously in group A2"
62037883|NCT01296451|EXPERIMENTAL|Experimental: Arm A, group5|"Intervention: AdCh3NSmut1. MVA-NSmut. Administration schedule:1 dose AdCh3NSmut1 2.5 x 10\^10vp at week 0, 1 dose MVA-NSmut 2 x 10\^8 pfu at week 8 and 1 dose MVA-NSmut 2 x 10\^8 pfu at week 40.~Subjects: 5 healthy volunteers"
62037884|NCT01296451|EXPERIMENTAL|Arm A, group 6|"Interventions: AdCh3NSmut1. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10\^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10\^7 pfu at week 8.~Subjects: 5 healthy volunteers"
62037885|NCT01296451|EXPERIMENTAL|Arm A, group 7|"Interventions: AdCh3NSmut1; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10\^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10\^6 pfu at week 8.~Subjects: 5 healthy volunteers"
62816132|NCT03193840|EXPERIMENTAL|old acetabular fracture|posterior wall osteotomy would be conducted for thr patient with displaced acetabular fracture without surgical treatment over three weeks.
62037886|NCT01764737|EXPERIMENTAL|VX15/2503|
62037887|NCT01764737|EXPERIMENTAL|Placebo|
62037888|NCT04822038|ACTIVE_COMPARATOR|Scleroderma patients with hypovitaminosis D and dietary recommendations|Patients with scleroderma and hypovitaminosis D who receive dietary recommendations
62430487|NCT03876158|ACTIVE_COMPARATOR|Prometra® Programmable Pump|Pain scores and drug doses will be prospectively collected for valve-gated Prometra® Programmable Pump system(Flowonix Medical)' at (refill #1, refill #2, refill #3) and will be compared to retrospectively collected pain (VAS) scores and drug doses from the last refill prior to peristaltic pump explant.
62037889|NCT04822038|ACTIVE_COMPARATOR|Scleroderma patients with hypovitaminosis D and Vitamin D supplementation|Patients with scleroderma and hypovitaminosis D who receive Vitamin D supplementation
62037890|NCT03626597|ACTIVE_COMPARATOR|CHV-provided post-test counseling & referral|The CHV will provide the woman with the urine pregnancy test and collect baseline information. If the woman desires enrollment in Arm 1 (CHV-provided post-test counseling and referral), the CHV will provide all post-test counseling and referral based on training provided. This may occur at the time of enrollment or at a later time, as preferred by the woman.
62430488|NCT03876158|OTHER|Prior records for peristaltic pump|Prior pain scores and drug doses from the patients who need a new valve gated pump will be recorded and used for comparison after it is changed.
62430489|NCT06133088|EXPERIMENTAL|single arm|This is a single-arm, Phase II clinical study to explore the efficacy and safety of dalpiciclib combined with fluvestrant and compound gossypol acetate tablets in advanced HR-positive and HER2-negative breast cancer after CDK4/6 treatment failed.
62430490|NCT02955992|NO_INTERVENTION|standard of care|
62430491|NCT02955992|EXPERIMENTAL|Intervention|"All caregivers will receive a leaflet about the importance of end of life (EOL) communication: key elements and recommendations regarding verbal and non-verbal communication.~A local champion (opinion leader) will be designated by each team in order to help implement the strategy. These physicians will help colleagues to connect external knowledge and requirements of the study to the local context.~Development of a 3-step physician-driven support strategy starting after a decision to withhold or withdraw life-sustaining therapies is implemented:~1. Preparation for the death : Prepare the relative for the patient's imminent death~2. During the dying and death process: The physician enters the patient's room at least once to check on the relatives~3. After the patient's death: the physician and the nurse meet the relative"
62430492|NCT01776619|EXPERIMENTAL|Multiple Dose: Cohort 1|
62430493|NCT01776619|EXPERIMENTAL|Multiple Dose: Cohort 2|
62430494|NCT01776619|EXPERIMENTAL|Multiple Dose: Cohort 3|
62430495|NCT01776619|EXPERIMENTAL|Multiple Dose: Cohort 4|
62430496|NCT01776619|EXPERIMENTAL|Relative Bioavilability: Cohort 1|
62430497|NCT02247583||mRCC patients|Patients with metastatic renal cell carcinoma
62430498|NCT05668715|EXPERIMENTAL|Group 1: Antimuscarinic Naive (AM-N)|None of the women had previously taken anti-muscarinic agents and oral ß3 adrenoreceptor agonist (mirabegron) in this group.
62430499|NCT05668715|ACTIVE_COMPARATOR|Group 2: Antimuscarinic Refractory (AM-R)|Women with idiopathic OAB refractory to anti-muscarinic agents and oral ß3 adrenoreceptor agonist (mirabegron) when 2 or more were administered for at least 6 weeks each and failure was due to lack of efficacy with or without side effects were included in this group.
62430500|NCT03284073|EXPERIMENTAL|Uterus Transplantation|Patients undergo transplantation of the uterus from a live donor
62430501|NCT03933319|EXPERIMENTAL|PLD in combination with trastuzumab|"Trastuzumab: administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.~pegylated liposomal doxorubicin(PLD):administered at dose of 35mg/m2 IV once every 21 days."
62430502|NCT00921479||Females|Norwegian females Caucasian origin, between the age of 18 and 45, who are candidates for surgical removal of one mandibular 3. molar.
62430503|NCT00921479||Males|Norwegian males of Caucasian origin, between the age of 18 and 45, who are candidates for surgical removal of one mandibular 3. molar
62430504|NCT02353429|EXPERIMENTAL|Toremifene treatment|Patients will receive 60 mg daily of Toremifene and the dose will be escalated to 180 mg daily in case of progression
62816133|NCT04268459|ACTIVE_COMPARATOR|Regular exchange|Patients will be appointed each 3 months for regular exchange of voice prosthesis.
62816134|NCT04268459|ACTIVE_COMPARATOR|Leakage exchange|Patients will have voice prosthesis exchange when leakage occurs.
62816135|NCT06150612|EXPERIMENTAL|Unwinding Anxiety|
62037891|NCT03626597|ACTIVE_COMPARATOR|Phone-based post-test counseling & referral|The CHV will provide the woman with the urine pregnancy test and collect baseline information. If the woman desires enrollment in Arm 2 (phone-based post-test counseling and referral), the CHV will provide the woman with a phone number which she may call or short message service (SMS) to receive post-test counseling and referral. If the study team does not receive a call or SMS from the woman within one week, our research assistant will phone and/or SMS the participant to provide phone-based post-test counseling and referral.
62037892|NCT03436394|EXPERIMENTAL|Evobrutinib: Normal Renal Function|Subjects with estimated glomerular filtration rate (eGFR) greater than or equal to (\>=) 90 milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2) will receive a single oral dose of evobrutinib under fasting conditions.
62430505|NCT00644605|ACTIVE_COMPARATOR|Arm 1|
62430506|NCT00644605|ACTIVE_COMPARATOR|Arm 2|
62430507|NCT00644605|ACTIVE_COMPARATOR|Arm 3|
62430508|NCT00644605|PLACEBO_COMPARATOR|Arm 4|
62430509|NCT03835975|ACTIVE_COMPARATOR|13vPnC|Pneumococcal conjugate vaccine
62430510|NCT03835975|ACTIVE_COMPARATOR|PPSV23|Pneumococcal polysaccharide vaccine
62430511|NCT03835975|EXPERIMENTAL|20vPnC|Pneumococcal conjugate vaccine
62597677|NCT00514904|ACTIVE_COMPARATOR|Mencevax ACWY Group|Subjects received 1 dose of Mencevax ACWY vaccine at Month 0. Mencevax ACWY vaccine was administered subcutaneously into the upper region of the non-dominant arm.
62816136|NCT03796728|EXPERIMENTAL|Juvéderm® VOLIFT™ with Lidocaine|Initial treatment with Juvéderm® VOLIFT™ with Lidocaine injectable gel to augment the lips on Day 1, with an optional touch-up treatment 14 days later, if applicable. Volume was determined by the Investigator not to exceed 3.0 milliliters (mL).
62816137|NCT05381948|EXPERIMENTAL|EYP-1901 2060 ug|EYP-1901 2060 ug, single dose
62816138|NCT05381948|EXPERIMENTAL|EYP-1901 3090 ug|EYP-1901 3090 ug, single dose
62430512|NCT01187160|EXPERIMENTAL|Transoral robotic surgery (TORS)|da Vinci® Robotic Surgical System
62430513|NCT05587478|EXPERIMENTAL|EDP-323 SAD Cohorts|EDP-323 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6, orally, once daily in one single administration
62430514|NCT05587478|EXPERIMENTAL|EDP-323 MAD Cohorts|EDP-323 Dose 1, Dose 2, Dose 3 and Dose 4 orally, once daily for 7 days
62597678|NCT02193139|EXPERIMENTAL|WL8713, 6 mg|6 mg WL8713 administered daily
62597679|NCT02193139|EXPERIMENTAL|WL8713, 12 mg|12 mg WL8713 administered daily
62597680|NCT02193139|EXPERIMENTAL|WL8713, 18 mg|18 mg WL8713 administered daily
62816139|NCT05381948|ACTIVE_COMPARATOR|Aflibercept|Aflibercept 2 mg \[0.05mL\] every 8 weeks
62816140|NCT05101317|ACTIVE_COMPARATOR|HMI-115 60mg|Once Every 2 weeks, subcutaneously injection
62816141|NCT05101317|ACTIVE_COMPARATOR|HMI-115 120mg|Once Every 2 weeks, subcutaneously injection
62816142|NCT05101317|ACTIVE_COMPARATOR|HMI-115 240mg|Once Every 2 weeks, subcutaneously injection
62816143|NCT05101317|PLACEBO_COMPARATOR|Placebo|Once Every 2 weeks, subcutaneously injection
62816144|NCT02438163|EXPERIMENTAL|Patients with MDD|the group of depressed patients undergo 2 Theta Burst Stimulations : iTBS and cTBS. There is one session per stimulation. Cerebral Plasticity is measured after each stimulation for each session
62816145|NCT02438163|EXPERIMENTAL|healthy Controls|the group of healthy controls undergo 2 Theta Burst Stimulations : iTBS and cTBS. There is one session per stimulation. Cerebral Plasticity is measured after each stimulation for each session
62816146|NCT02731638|EXPERIMENTAL|Intrastromal voriconazole plus natamycin|Intrastromal voriconazole plus standard of care topical treatment for fungal keratitis
62816147|NCT02731638|ACTIVE_COMPARATOR|Natamycin alone|Standard of care topical treatment for fungal keratitis
62430515|NCT05587478|PLACEBO_COMPARATOR|EDP-323 SAD Placebo Cohorts|Matching placebo, orally, once daily in one single administration
62430516|NCT05587478|PLACEBO_COMPARATOR|EDP-323 MAD Placebo Cohorts|Matching placebo, orally, once daily for 7 days
62430517|NCT01683552|OTHER|Aprepitant|Aprepitant is administered in patients ,affected by solid tumors treated with biological therapy, who did not receive any treatment for severe pruritus
62430518|NCT01683552|OTHER|Aprepitant after anti-itch standard therapy|Aprepitant will be administered in patient affected by severe itch resistant to standard treatment (steroids and/or antihistamines) administered for at least one week
62430519|NCT00362856|PLACEBO_COMPARATOR|Placebo + Gluten|placebo TID + gluten 800 mg TID administered orally in capsules
62597681|NCT02193139|EXPERIMENTAL|WL8713, 24 mg|24 mg WL8713 administered daily
62597682|NCT02193139|PLACEBO_COMPARATOR|Placebo|placebo administered daily
62430520|NCT00362856|PLACEBO_COMPARATOR|Placebo + Gluten placebo|placebo TID + gluten placebo TID administered orally in capsules
62597683|NCT06620770||Patients participating in the therapeutic education program|"Patients treated with subcutaneous biotherapy who wish to participate in the therapeutic education program will be included in the intervention group. This program will begin within 3 months of inclusion.~An initial meeting with a nurse allows for a shared educational assessment. The other days are planned monthly with groups of up to 6 people. A discussion around biotherapies is established by a doctor-nurse pair on theoretical and practical questions. In a second step, questions around nutrition are addressed with the dietician. Mealtime is also a time for discussion with professionals and the group of patients. The third workshop is led by a physical activity teacher. A nurse and a patient partner lead a time dedicated to fatigue management in the form of practical exercises that can be easily reproduced at home."
62597684|NCT06620770||Patients who do not wish to participate in the therapeutic education program|"Patients treated with subcutaneous biotherapy who do not wish to participate in the therapeutic education program will be included in the control group.~Patients will be followed by their physicians as usual."
62597685|NCT01138592||Primary Care Patients|Any patient undergoing a telemedicine evaluation involving auscultation of the heart and lungs.
62037893|NCT03436394|EXPERIMENTAL|Evobrutinib: Severe Renal Impairment|Subjects with eGFR less than (\<) 30 mL/min/1.73 m\^2 will receive a single oral dose of evobrutinib under fasting conditions.
62430521|NCT00362856|OTHER|Larazotide acetate 8 mg + Gluten placebo|Safety Control Arm. Larazotide acetate 8 mg TID + gluten placebo TID administered orally in capsules
62037894|NCT03436394|EXPERIMENTAL|Evobrutinib: Moderate Renal Impairment|Subjects with eGFR \>= to 30 mL/min/1.73 m\^2 and \< 60 mL/min/1.73 m\^2 will receive a single oral dose of evobrutinib under fasting conditions.
62037895|NCT03436394|EXPERIMENTAL|Evobrutinib: Mild Renal Impairment|Subjects with eGFR \>= to 60 mL/min/1.73 m\^2 and \< 90 mL/min/1.73 m\^2 will receive a single oral dose of evobrutinib under fasting conditions.
62430522|NCT00362856|ACTIVE_COMPARATOR|Larazotide acetate 0.25 mg + Gluten|Larazotide acetate 0.25 mg TID + gluten 800 mg TID administered orally in capsules
62430523|NCT00362856|ACTIVE_COMPARATOR|Larazotide acetate 1 mg + Gluten|Larazotide acetate 1 mg TID + gluten 800 mg TID administered orally in capsules
62430524|NCT00362856|ACTIVE_COMPARATOR|Larazotide acetate 4 mg + Gluten|Larazotide acetate 4 mg TID + gluten 800 mg TID administered orally in capsules
62597686|NCT00878150|EXPERIMENTAL|Telephone-based CBT|- 12 counseling sessions over 16 weeks over the telephone
62597687|NCT00878150|EXPERIMENTAL|In-person CBT|- 12 counseling sessions over 16 weeks at either Harborview Medical Center or the University of Washington Medical Center in Seattle, WA
62597688|NCT00878150|NO_INTERVENTION|3: Usual care|- No counseling sessions as part of this study, however you are free to pursue regular medical care and counseling outside of this study
62240059|NCT04657757|EXPERIMENTAL|Intraoral apparatus|intraoral apparatus in which two platelets of each of the 8 materials (Esteticor Lumina PF; Esteticor Lumina PF - after Lactic acid storage; Pagalinor 2; Esteticor Economic; Pekkton ivory - untreated; Pekkton ivory - rough; Oralloy; Machined Titan Zirconia (TiZr) alloy) are to be examined. Examination is a crystal violet OD595 staining (10 minutes). The color absorbed by the bacteria is then dissolved with a 30% acetic acid and measured spectrophotometrically at 595 nm. The plaque formed on the material surface is removed immediately after removal from the oral cavity and analyzed by determination of Colony Forming Unit (CFU) number.
62597689|NCT00510016|EXPERIMENTAL|Clonidine treatment|Infants intrauterine exposed to opioids (heroin or methadone) that demonstrate signs and symptoms of withdrawal with withdrawal scores (modified Finnegan score) greater than 9 on to consecutive scores taken 4 hours apart.
62597690|NCT06623617|OTHER|Intervention Group：three-dimensional breathing training group|Engage in app-based three-dimensional breathing training and learn to use a biofeedback pressure device at home for proper and effective training. They will also be guided to log their daily training, manually inputting data such as duration and frequency. A virtual assistant will provide real-time feedback based on this data, including encouragement and adjustments to training intensity.
62240060|NCT00525889|EXPERIMENTAL|Rapamycin/IL-2 combination therapy|IL-2 (Proleukin) was administered at 4.5 3 106 IU s.c., three times per week for 4 weeks for a total of 12 doses. Rapamycin (Rapamune or Sirolimus) was administered without a loading dose at 2 mg/day, with adjustments to maintain trough blood levels of 5-10 ng/mL for 3 months.
62240061|NCT03655379|EXPERIMENTAL|Nasal Doppler|Pregnant patients who present with preterm labor will be evaluated with ultrasonography and fetal nasal Doppler will be used to detect specific fetal breathing patterns
62240062|NCT06449950|EXPERIMENTAL|Verbal Oral Hygiene Instruction Group|Verbal oral hygiene instructions were given to the pediatric patients by the instructor using the Bass brushing technique without any training model or visual aids, only with the verbal instructions.
62430525|NCT00362856|ACTIVE_COMPARATOR|Larazotide acetate 8 mg + Gluten|Larazotide acetate 8 mg TID + gluten 800 mg TID administered orally in capsules
62430526|NCT03571854|EXPERIMENTAL|Group PCV-VG|Pressure controlled ventilation-volume guaranteed
62430527|NCT03571854|ACTIVE_COMPARATOR|Group VCV|Volume controlled ventilation
62597691|NCT06623617|OTHER|Control group：Health education|The control group received health education, which was conducted one-on-one by researchers during the recruitment of mothers. The content included the etiology and risk factors of PPSUI (Prolapse of Pelvic Organs during Straining), the benefits and precautions of pelvic floor muscle exercises and breathing, as well as the implementation methods.
62816148|NCT05142787|OTHER|axillary lymph nodes requiring localisation prior to surgical excision|"The Magseed Pro® marker is intended to be placed percutaneously in suspicious/biopsy proven positive axillary lymph nodes under imaging guidance to mark tissue intended for selective surgical removal.~The Magseed Pro® marker is localised using the Sentimag® Gen3 system handheld probes and surgically removed within/from the target tissue."
62430528|NCT03343977|EXPERIMENTAL|Every two weeks docetaxel|50 mg/m2 of docetaxel will be given on day 1 every 14 days over one hour IV infusion for up to 9 cycles (1 cycle = 14 days)
62430529|NCT03343977|ACTIVE_COMPARATOR|Every three weeks docetaxel|75 mg/m2 of docetaxel will be given on day 1 every 21 days over one hour IV infusion for up to 6 cycles (1 cycle = 21 days)
62037896|NCT00930293|EXPERIMENTAL|Personalized Depression Care|Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication (citalopram) treatment.
62037897|NCT00930293|ACTIVE_COMPARATOR|Standard Depression Care|Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication (citalopram) treatment.
62430530|NCT04272736|EXPERIMENTAL|Low calorie protein substitute|Single arm designed, 3 day baseline, 28 day on the lower calorie amino acid based liquid protein substitute.
62430531|NCT06013761|ACTIVE_COMPARATOR|IF 16:8|12 weeks intermittent fasting according to the 16:8 method (IF 16:8)
62430532|NCT06013761|EXPERIMENTAL|IF MCT 16:8|12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8)
62816149|NCT05142787|OTHER|breast lesions requiring localisation|"The Magseed Pro® marker is intended to be placed percutaneously in breast lesions under imaging guidance to mark tissue intended for selective surgical removal.~The Magseed Pro® marker is localised using the Sentimag® Gen3 system handheld probes and surgically removed within/from the target tissue."
62240063|NCT06449950|EXPERIMENTAL|Video-Based Oral Hygiene Instruction Group|The video-based oral hygiene instructions to be delivered to the paediatric dental participants were given by watching a pre-prepared video tape on a tooth and jaw model, using the instructions specified in the verbal education.
62240064|NCT06290063|EXPERIMENTAL|Full-Spectrum Hemp-Derived CBD (fsCBD)|8 weeks of use of a daily dose of cannabis (200mg CBD/4mg THC)
62240065|NCT06290063|EXPERIMENTAL|Broad-Spectrum Hemp-Derived CBD (bsCBD)|8 weeks of use of a daily dose of cannabis (200mg CBD)
62240066|NCT06290063|PLACEBO_COMPARATOR|Placebo|
62430533|NCT01303588|NO_INTERVENTION|Waiting Group|
62430534|NCT01303588|ACTIVE_COMPARATOR|Qigong|
62430535|NCT01303588|ACTIVE_COMPARATOR|Yoga|
62430536|NCT01931891||prreclampsia|
62430537|NCT01566669|PLACEBO_COMPARATOR|Normal Saline|Before incision, patients in controlled Group received NS
62430538|NCT01566669|EXPERIMENTAL|parecoxib sodium|Before incision, parecoxib patients received 40mg of parecoxib IV
62430539|NCT04716400|EXPERIMENTAL|Intervention group|"Stop sexual harassment"
62430540|NCT04716400|NO_INTERVENTION|Control group|No intervention
62430541|NCT01215682|ACTIVE_COMPARATOR|vit D|
62597692|NCT05670223|EXPERIMENTAL|Open Pilot Group|Participants (N=30) will be recruited across two churches, MorningStar Baptist Church and People's Baptist Church, to examine the feasibility and acceptability of the HAIL Online platform. Participants will complete the 8-week F\&S! exercise program (with access to the adjunct HAIL online platform), which will be delivered in-person as well as remote, and then continue to use the HAIL online platform during the 3-mo follow-up.
62597693|NCT00550979||1|Black women with history of pregnancy/ies complicated by gestational diabetes mellitus
62037898|NCT02597400|EXPERIMENTAL|HMS5552 and Metformin|"All subjects will receive the following:~* Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;~* Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;~* HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals."
62037899|NCT06402734||Celiac Disease|Adult patients who were diagnosed with celiac disease were enrolled in the study.
62240067|NCT05208801|SHAM_COMPARATOR|Control|a sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle
62430542|NCT01215682|PLACEBO_COMPARATOR|placebo|
62430543|NCT04921046|ACTIVE_COMPARATOR|Group Lignocaine|Group of 112 patients ASA-I and II (American Society of Anesthesiology)ages from 25-44 undergoing elective surgical procedure.
62816150|NCT05317104|EXPERIMENTAL|Aerobic Exercise Group|"Intervention group will be included in a program consisting of warm-up, loading and cool-down periods. Maximum Heart Rate (MHR) method will be used to determine the intensity of aerobic exercise training. Since moderate aerobic exercise training was aimed, exercise training will be given in 55-74% of MHRs. Exercise training will be started at mild-moderate intensity. Afterwards, within the limits that the person can tolerate and does not cause complications, with 5-10 minute increments every 1-2 weeks, the person will progress without muscle pain, injury, respiratory distress or fatigue due to overload. Polar H9 Heart Rate Sensor, which will be worn on the chest, will be used to monitor heart rate during exercise training.~Aerobic exercise training will be given in accordance with the procedures determined on the treadmill in the laboratory environment, with a program consisting of 6-week."
62816151|NCT05317104|NO_INTERVENTION|Control Group|No intervention will be made other than evaluations. However, in order for the participants in this group to achieve the same health gains, they will remain under follow-up and control to apply the same aerobic exercise training program after the study is completed.
62816152|NCT06670001|NO_INTERVENTION|Control|In addition to using a wearable device, participants in the control arm will receive a daily notification of their step count from the previous day.
62037900|NCT06402734||Healthy Subjects|Healthy subjects with matching demographical characteristics to the celiac group were enrolled in the study.
62037901|NCT05775614|EXPERIMENTAL|Uro-Tainer® catheter flushing|Uro-Tainer® catheter flushing two times weekly for 6 months.
62037902|NCT05775614|PLACEBO_COMPARATOR|Saline catheter flushing|Saline solution catheter flushing two times weekly for 6 months.
62037903|NCT03757000|EXPERIMENTAL|YY-20394|"YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3- kinase (PI3Kδ).~YY-20394 for clinical use is presented as a sterile tablets at 20 mg, or 100 mg doses. The drug product is intended for oral administration.Preset cohorts of 3-6 subjects will be enrolled sequentially at doses of 20, 40, 80, 140, 200, 260 and 320 mg/day."
62037904|NCT02895087||Cohort 1: Diurnal Variation Group|Cohort recruitment - open to recruitment
62037905|NCT02895087||Cohort 2: External Stress Group|Cohort recruitment - closed to recruitment
62037906|NCT04026776|EXPERIMENTAL|Preterm Group|Subjects with very low birth weight (\<37 completed weeks' gestation and birth weight \<1500 g) will receive a dietary intervention (high/low salt diet) and FDA approved drug, Allopurinol
62240068|NCT05208801|ACTIVE_COMPARATOR|Morphine|
62240069|NCT05208801|EXPERIMENTAL|Morphine+bupivicaine|
62240070|NCT02847351|PLACEBO_COMPARATOR|Control Diet (CD)|Period 1(the first 4 weeks): 10 subjects were randomly assigned to Control Diet: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with a normal white grain flour. After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with Arabinoxylan-enriched flour.
62240071|NCT02847351|EXPERIMENTAL|Arabinoxylan Diet (AXD)|Period 1(the first 4 weeks): 9 subjects were randomly assigned to Arabinoxylan-Diet: they replaced for 4 weeks all the carbohydrates consumed in day with crackers baked with an Arabinoxylan-enriched flour. After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day with crackers produced with a normal white grain flour
62430544|NCT04921046|ACTIVE_COMPARATOR|Group Midazolam|Group of 112 patients ASA-I and II ages from 25-44 undergoing elective surgical procedure.
62430545|NCT04171388|PLACEBO_COMPARATOR|Routine care: Placebo|"In all pregnancies presenting at all centers, routine antenatal care will be strengthened:~* Provision of iron-folic acid and tetanus toxoid vaccine~* Screening for anemia and blood pressure~* Screening/treatment of HIV, syphilis, malaria, tuberculosis~Placebo tablets will be administered twice in pregnancy: at enrollment (\<=24 weeks) and a follow up ANC visit at least 4 weeks later."
62597694|NCT00550979||2|Black women with history of normal, uncomplicated pregnancy/ies
62597695|NCT00550979||3|White women with a history of pregnancy/ies complicated by gestational diabetes.
62816153|NCT06670001|EXPERIMENTAL|Gamification plus social incentive|"Participants will receive daily text messages on whether or not they hit their step goal.~Participants will be entered into a game, that runs for 6 months. Each week they receive 70 points. If the step goal was met they keep their points. If not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level. If not, they drop a level.~They will receive twice-weekly motivational or educational text messages that highlight the effect of exercise on functional capacity in patients with HFpEF.~Participants will select a family member or friend who will serve as a support partner. We hold a 3-way phone call with the participant and partner to discuss ways they can help the participant meet their goal. The support partner will receive a weekly email reminding him/her of these approaches and updating him/her on the participant's progress including accumulated points, level in the game, and average step count."
62597696|NCT00550979||4|White women with a history of normal, uncomplicated pregnancy/ies.
62816154|NCT06670001|EXPERIMENTAL|Gamification plus competition|"Participants will receive daily text messages on whether or not they hit their step goal.~Participants will be entered into a game, that runs for 6 months. Each week they receive 70 points. If the step goal was met they keep their points. If not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level. If not, they drop a level.~They will receive twice-weekly motivational or educational text messages that highlight the effect of exercise on functional capacity in patients with HFpEF. Participants will have access to a leaderboard that will include four other participants, identified by pseudonyms. Participants will be ranked on the leaderboard by total points over the course of the study. They will receive a weekly text message with their position on the leaderboard."
62816155|NCT00980954|ACTIVE_COMPARATOR|Arm I: Cisplatin/Radiation Therapy|Standard external beam radiation therapy (EBRT) or intensity-modulated radiation therapy (IMRT) to the pelvis once daily 5 days a week for 5-6 weeks as 45 Gy in 25 fractions or 50.4 Gy in 28 fractions (1.8 Gy/fraction). Concurrent cisplatin IV over one hour once weekly for 6 weeks as 40 mg/m\^2, maximum dose 70 mg. A brachytherapy boost following radiation therapy is optional.
62816156|NCT00980954|EXPERIMENTAL|Arm II: Cisplatin/Radiation Therapy + Carboplatin/Paclitaxel|Chemoradiotherapy as in arm I, followed 4-6 weeks later by paclitaxel IV \[135 mg/m2, with maximum body surface area (BSA) of 2.0 m\^2 over 3 hours\] and carboplatin IV \[area under the curve (AUC) 5 over 30 minutes\] on day 1 of 21-day cycle for 4 cycles in the absence of disease progression or unacceptable toxicity.
62816157|NCT02365155|EXPERIMENTAL|Intervention group.|Multicomponent training intervention; Nutrition intervention; Cognitive intervention; D-vitamin intervention; Occupational intervention; Heart failure follow up.
62816158|NCT02365155|ACTIVE_COMPARATOR|Control group.|Nutrition intervention; Cognitive intervention; D-vitamin intervention; Occupational intervention; Heart failure follow up.
62816159|NCT05924022|EXPERIMENTAL|Full treatment|Participants are administered 100% oxygen in the HBOT chamber at 2.0 ATA
62816160|NCT05924022|ACTIVE_COMPARATOR|Partial pressure treatment|Participants are administered 100% oxygen in the HBOT chamber at 1.3 ATA
62816161|NCT05924022|SHAM_COMPARATOR|Sham|Participants are administered 21% oxygen n the HBOT chamber at 1.3 ATA.
62816162|NCT04097678|EXPERIMENTAL|Retained Sponge Group|Just prior to imaging, the surgeon will purposely place a sponge in the wound. Two radiographs will be taken of the spine (AP and Lateral views).
62816163|NCT04097678|NO_INTERVENTION|No Retained Sponge Group|No sponge will be placed in the wound. Two radiographs will be taken of the spine (AP and Lateral views).
62816164|NCT04592874|EXPERIMENTAL|AL002 Dose 1|AL002 every 4 weeks
62816165|NCT04592874|EXPERIMENTAL|AL002 Dose 2|AL002 every 4 weeks
62037907|NCT04026776|ACTIVE_COMPARATOR|Term-born control group|Subjects with birth weight ≥2500 g will receive a dietary intervention (high/low salt diet)
62240072|NCT01875822|EXPERIMENTAL|Supercurcumin|The study protocol stipulates that subjects diagnosed as DSM IV-TR (Diagnostic Statistical Manual IV-Transitional Revised) would be receiving either 1 gm Super-Curcumin@ capsule once daily or 4 gm Super-Curcumin@ once daily for a total of 16 weeks. Super-Curcumin@ in capsule form is a patented formulation of curcumin certified by Sabinsa Corp.NJ USA and produced by America's Finest Inc. 1 gm-capsule Super-Curcumin@ consist of 1 gm Curcumin C-3 complex and 5 mg of Bioperine.
62430546|NCT04171388|EXPERIMENTAL|Routine care: Azithromycin|Azithromycin will be provided twice in pregnancy: at enrollment (\<=24 weeks) and a follow up ANC visit at least 4 weeks later.
62816166|NCT04592874|EXPERIMENTAL|AL002 Dose 3|AL002 every 4 weeks
62816167|NCT04592874|PLACEBO_COMPARATOR|Placebo|Placebo every 4 weeks
62597697|NCT01129349|EXPERIMENTAL|Oprozomib|Phase I, Dose Escalation, Single Arm, Open Label
62597698|NCT02027662|EXPERIMENTAL|Osvaren Granules|Osvaren Granules
62816168|NCT06705517|EXPERIMENTAL|Intervention group (standard of care + MD)|The intervention group will participate in a six-month program aimed at promoting adherence to the MD. At the start, participants will be given a physical booklet outlining foods to prioritize and avoid. They will also receive monthly recipes featuring seasonal ingredients. In addition, cooking classes will be offered, with caregiver involvement encouraged.
62037908|NCT06530862|ACTIVE_COMPARATOR|ESWT group|Patients in this group received three sessions of ESWT at an energy density of 4 bars and a frequency of 2,000 shocks/min at 5 Hz for three weeks, each session once a week.
62037909|NCT06530862|ACTIVE_COMPARATOR|Dry needling|The piriformis muscle of the patients in the group will be dry needled with 0.6\*80 mm acupuncture needles under ultrasound guidance for 3 sessions at one week intervals.
62597699|NCT02027662|ACTIVE_COMPARATOR|Osvaren film-coated tablets|Osvaren film-coated tablets
62597700|NCT02545361|EXPERIMENTAL|KAHR002|premedication (20mg Dexamethasone (IV), 10mg Loratadine (P.O), and 1gr Paracetamol (P.O), 1 hour before treatment) with 2µg/kg KAHR-102 subcutaneous (SC) injection
62597701|NCT06622057|EXPERIMENTAL|D07001-Softgel Capsules 60 mg + Capecitabine|"* D07001-softgel capsules, 60 mg/day, orally 3 times per week before lunch (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle)~* Capecitabine tablets (1000 mg/m2 bid) for 14 days (on Days 1 through 14 of a 21 day cycle) followed by a 7-day rest period. Capecitabine will be taken after breakfast and after dinner."
62597702|NCT06622057|EXPERIMENTAL|D07001-Softgel Capsules 100 mg + Capecitabine|"* D07001-softgel capsules, 100 mg/day, orally 3 times per week before lunch (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle)~* Capecitabine tablets (1000 mg/m2 bid) for 14 days (on Days 1 through 14 of a 21 day cycle) followed by a 7-day rest period. Capecitabine will be taken after breakfast and after dinner."
62037910|NCT03009045|EXPERIMENTAL|Drug: 200mg oral Tedizolid|200mg oral tablet of tedizolid to be taken once daily
62240073|NCT01381354|EXPERIMENTAL|Combined intervention|Combination intervention consisting of the following: structured modified paleolithic diet, Progressive Exercise, Neuromuscular Electrical Stimulation designed to facilitate the adoption of multiple therapeutic lifestyle behaviors associated with superior health outcomes.
62240074|NCT01869075|EXPERIMENTAL|AMI - Knowledge Translation toolkit|AMI - Knowledge Translation (KT) toolkit includes use of pre-printed orders, audit and feedback, pharmacist as a reminder and education of staff
62240075|NCT01869075|NO_INTERVENTION|AMI - Usual Care|Usual care
62430547|NCT04171388|EXPERIMENTAL|Routine care: Enhanced Infection Management Package (EIMP)|At the study enrollment visit, pregnant women will receive presumptive deworming (albendazole) and screening for urinary tract infection and sexually transmitted infections (chlamydia and gonorrhea). Women with identified infections will be treated with appropriate antibiotics. A second dose of albendazole will be given at a follow up ANC visit at least 4 weeks after enrollment.
62430548|NCT04171388|EXPERIMENTAL|Enhanced Nutrition Package (ENP): Placebo|"Pregnant women will receive a daily multiple micronutrient. Women with undernutrition, identified with mid-upper arm circumference \<23 cm, will receive a daily fortified balanced energy protein supplement.~Placebo tablets will be administered twice in pregnancy: at enrollment (\<=24 weeks) and a follow up ANC visit at least 4 weeks later."
62430549|NCT04171388|EXPERIMENTAL|ENP: Azithromycin|"Pregnant women will receive a daily multiple micronutrient. Women with undernutrition, identified with mid-upper arm circumference \<23 cm, will receive a daily fortified balanced energy protein supplement.~Azithromycin will be provided twice in pregnancy: at enrollment (\<=24 weeks) and a follow up ANC visit at least 4 weeks later."
62430550|NCT04171388|EXPERIMENTAL|ENP: EIMP|"Pregnant women will receive a daily multiple micronutrient. Women with undernutrition, identified with mid-upper arm circumference \<23 cm, will receive a daily fortified balanced energy protein supplement.~At the study enrollment visit, pregnant women will receive presumptive deworming (albendazole) and screening for urinary tract infection and sexually transmitted infections (chlamydia and gonorrohea). Women with identified infections will be treated with appropriate antibiotics. A second dose of albendazole will be given at a follow up ANC visit at least 4 weeks after enrollment."
62597703|NCT06622057|PLACEBO_COMPARATOR|Placebo + Capecitabine|"* Placebo, orally 3 times per week before lunch (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle)~* Capecitabine tablets (1000 mg/m2 bid) for 14 days (on Days 1 through 14 of a 21 day cycle) followed by a 7-day rest period. Capecitabine will be taken after breakfast and after dinner."
62597704|NCT05854303||Opioid Cessation|Subjects able to complete opioid cessation.
62597705|NCT05854303||Non-Opioid Cessation|Subjects unable to complete opioid cessation.
62597706|NCT02757937|EXPERIMENTAL|Health & Wellness Website|Subjects will receive access to an interactive health \& wellness website for 6 months. The site aims to provide patients with information, tools, and resources to manage their chronic condition (e.g., Type 2 diabetes). The website will send subjects emails with tips to help them take better care of their diabetes, such as how to track diet and exercise habits and how to cook healthy meals. The study researchers will keep track of how many times subjects access the website and which parts of the site are most commonly viewed. Intervention subjects will receive questionnaires assessing engagement and satisfaction with the website. Subjects will also complete questionnaires at baseline and 2, 4, and 6 months post-baseline.
62037911|NCT03655769|SHAM_COMPARATOR|sham tDCS|tDCS delivered for only 30 sec to replicate tingling sensation and blind subject
62037912|NCT03655769|EXPERIMENTAL|cathodal tDCS|cathodal tDCS, 2 milliamps (mA), delivered to right parietal region
62240076|NCT01869075|EXPERIMENTAL|MGS - Knowledge Translation Toolkit|Knowledge Translation toolkit involves use of pre-printed orders, audit and feedback, pharmacist as reminder and education of staff
62240077|NCT01869075|NO_INTERVENTION|MGS - Usual Care|Usual Care
62240078|NCT01869075|EXPERIMENTAL|HFS - Knowledge Translation Toolkit|Knowledge Translation Toolkit consists of pre-printed orders, audit and feedback, pharmacist as a reminder and education of staff
62037913|NCT00760929|PLACEBO_COMPARATOR|Placebo for R1507 (16mg/kg iv)|
62037914|NCT00760929|PLACEBO_COMPARATOR|Placebo for R1507 (9mg/kg iv)|
62037915|NCT00760929|EXPERIMENTAL|R1507 (16mg/kg iv)|
62037916|NCT00760929|EXPERIMENTAL|R1507 (9mg/kg iv)|
62240079|NCT01869075|NO_INTERVENTION|HFS - Usual Care|Usual Care
62240080|NCT02877927|EXPERIMENTAL|Omadacycline|Omadacycline tablets
62240081|NCT02877927|ACTIVE_COMPARATOR|Linezolid|Linezolid tablets
62240082|NCT05116046|EXPERIMENTAL|Low Dose|Low Dose
62240083|NCT05116046|EXPERIMENTAL|Medium Dose|Medium Dose
62240084|NCT05116046|EXPERIMENTAL|High Dose|High Dose
62240085|NCT02435589|EXPERIMENTAL|Intervention group|"Intervention:~1. systematic pain assessment~2. Notification of results of assessments to nurses and physicians. Pain Assessments will be done with the use of 2 different behavioral pain tools by independent assessors and the results of the assessments will be notified to the nurses and physicians and their respond will be observed and documented"
62240086|NCT02435589|ACTIVE_COMPARATOR|Control Group|Intervention. Systematic pain assessments. Assessments of pain will be done by independent assessors but results will not be notified to nurses or physicians
62240087|NCT00795951|EXPERIMENTAL|TRUE Test panels 1.1, 2.1, 3.1|All subjects were patched with 3 T.R.U.E. Test panels containing 28 allergens and 1 negative control.
62430551|NCT02991833|EXPERIMENTAL|Of A New Incontinence Care Product|Patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 days. The visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD. Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased. To evaluate skin integrity, the perineal skin of the patients was observed every day by researcher and was recorded to the Perineal Skin Integrity Assesment Form. The number of defecation, stool consistency, and the number of care product ( the novel incontinent care product) was observed daily and was recorded to the Patient Observation Form. The main study outcomes was IAD.
62597707|NCT02757937|OTHER|Control Arm|Subjects in the control arm will continue with standard diabetes care without getting access to the intervention website. Subjects will also complete questionnaires at baseline and 2, 4, and 6 months post-baseline. Control subjects will be granted access to the health \& wellness website after the study is completed.
62597708|NCT06620276|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT)|20 consecutive participants who will receive 8 sessions of Acceptance and Commitment Therapy (ACT) at our research site or virtually.
62597709|NCT06620887||Pregnancies before HEMAGO|Pregnancies follow-up before HEMAGO : complications and outcomes of pregnancies in sickle cell patients which had a classical follow-up.
62597710|NCT06620887||Pregnancies HEMAGO following-up|Pregnancies in sickle cell patients follow-up by HEMAGO : complications and outcomes of pregnancies in sickle cell disease patients which were monitored by HEMAGO program.
62597711|NCT05840315|EXPERIMENTAL|Phase 1|"First subtrial (participants 1-10):~Sit-to-stand-to-sit training"
62597712|NCT05840315|EXPERIMENTAL|Phase 2|"Second subtrial (participants 11-20):~Sit-to-stand and leg press training."
62597713|NCT05840315|EXPERIMENTAL|Phase 3|"Third subtrial (participants 21-30):~Sit-to-stand, leg press training and hip abduction training."
62597714|NCT00166257|ACTIVE_COMPARATOR|Medical antitrhombotic treatment|
62597715|NCT00166257|EXPERIMENTAL|Device Implant|Percutaneous closure of patent foramen ovale
62597716|NCT06597565|EXPERIMENTAL|Cohort A (p16/HPV-neg)|Participants with p16/HPV-negative recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) will be assigned to Cohort A. Participants will be administered lead-in low dose gemcitabine (LDG) 10 mg/m2 IV Day -7 (+/- 3 days, before Cycle 1 only) followed by ACR-368 105 mg/m2 IV every 2 weeks and LDG 10 mg/m2 every 2 weeks until discontinuation due to disease progression, intolerability, or consent withdrawal. When delay or discontinuation of the treatment is necessary, both ACR-368 and LDG will be delayed or discontinued together.
62597717|NCT06597565|EXPERIMENTAL|Cohort B (p16/HPV-pos)|Participants with p16/HPV-positive R/M HNSCC will be assigned to Cohort B. Participants will be administered lead-in low dose gemcitabine (LDG) 10 mg/m2 IV Day -7 (+/- 3 days, before Cycle 1 only) followed by ACR-368 105 mg/m2 IV every 2 weeks and LDG 10 mg/m2 every 2 weeks until discontinuation due to disease progression, intolerability, or consent withdrawal. When delay or discontinuation of the treatment is necessary, both ACR-368 and LDG will be delayed or discontinued together.
62597718|NCT06545656|EXPERIMENTAL|Doxycycline|Study participants taking 7 consecutive, daily doses of 100mg of Doxycycline.
62240088|NCT02884427|EXPERIMENTAL|Cathode Stimulation|Group that is involved with the (black) negative electrode seeking the polar effect of nervous increased excitability and conductivity with the current application.
62240089|NCT02884427|EXPERIMENTAL|Anode Stimulation|Group that is involved with the (red) positive electrode seeking the polar effect of nervous excitability and conductivity decreased with the current application.
62597719|NCT06616025|EXPERIMENTAL|NTX-001|NTX-001 used during the surgical repair of an upper extremity peripheral nerve injury in conjunction with standard suture neurorrhaphy.
62597720|NCT06616025|NO_INTERVENTION|Standard Suture Neurorrhaphy|Standard of Care
62597721|NCT03912714|EXPERIMENTAL|Laparoscopic appendectomy|Laparoscopic appendectomy in therapy refractory ulcerative colitis patients after pre-operative endoscopic biopsies of the appendix
62597722|NCT03912714|ACTIVE_COMPARATOR|Non-active UC|Patients with non-active ulcerative colitis planned for surveillance colonoscopy will have additional endoscopic appendix biopsies to evaluate the histological characteristics of the appendix.
62597723|NCT03912714|ACTIVE_COMPARATOR|Healthy control|'Healthy control' patients (i.e. patients planned for colonoscopy for polyps) will have additional endoscopic appendix biopsies to evaluate the histological characteristics of the appendix.
62597724|NCT03912714|ACTIVE_COMPARATOR|JAK-inhibitor|JAK-inhibitor in therapy-refractory ulcerative colitis patients
62037917|NCT04758637|NO_INTERVENTION|Control Group|Physicians in the control group will receive no notification of their patient's fatal or nonfatal overdose.
62597725|NCT06194747|NO_INTERVENTION|Baseline phase|During this arm, sites will provide routine care.
62240090|NCT02884427|PLACEBO_COMPARATOR|Control|Group that will be placed electrotherapy without operation, but only installation. Patients in this group will see the team work but it will not be delivering current.
62597726|NCT06194747|EXPERIMENTAL|Adoption phase|Following the dissemination visit, sites will actively work to implement the bundle of interventions.
62597727|NCT06194747|EXPERIMENTAL|Sustain phase|During this arm, sites will actively work to sustain the implemented interventions and will be allowed to develop site-specific plan-do-study-act cycles in order to address site-specific key drivers with central data and methodological support.
62037918|NCT04758637|EXPERIMENTAL|Overdose Notification Group|The overdose notifications will alert prescribers to the patient's opioid-related overdose, recommend the use of the state-level PDMP, and list evidence-based interventions to lower opioid-related overdoses.
62037919|NCT01147224||ATEM|A prospective one-arm non-interventional study with asthma patients treated with Alvesco.
62037920|NCT03453268|OTHER|1: Interventional (drug reduction)|"STEP DOWN strategy.~Proposition of reduction of the number of antihypertensive medication according to:~* the systolic blood pressure levels,~* co-morbidities"
62037921|NCT03453268|OTHER|2: Control|Usual treatment
62037922|NCT01509898|EXPERIMENTAL|water-Jet|use of water jet for 1 month
62037923|NCT05071118|ACTIVE_COMPARATOR|pregabalin group|Two hours before surgery, the pregabalin patients (group P) received capsules containing 150mg of pregabalin in the ward then transferred to OR to receive spinal anesthesia before surgery.
62816169|NCT06705517|NO_INTERVENTION|Control group (standard of care)|The control group will be asked to maintain their current dietary habits and usual standard care. They will undergo the same routine examinations and check-ups as the intervention group.
62037924|NCT05071118|ACTIVE_COMPARATOR|placebo group|The patients received placebo capsules in the ward Then transferred to OR to receive spinal anesthesia before surgery .
62037925|NCT02077257|OTHER|Rosuvastatin 20mg|Rosuvastatin 20 mg/d
62037926|NCT02077257|OTHER|Rosuvastatin 10mg|Rosuvastatin 10 mg/d
62037927|NCT01773070|OTHER|All Participants|Participants who received ABT-450, ABT-333 or ABT-267 at any dose level in an eligible prior AbbVie Phase 2 or 3 study for the treatment of chronic HCV, followed for up to 3 years post-treatment.
62597728|NCT06194747|EXPERIMENTAL|Independent phase|During this arm, sites will continue to sustain the implemented interventions and develop site-specific plan-do-study-act cycles in order to address site-specific key drivers without central data and methodological support.
62816170|NCT06538896|EXPERIMENTAL|Tislelizumab + Nab-Paclitaxel|Tislelizumab, 200mg,intravenous, every 3 weeks; nab-paclitaxel, 125mg/m2 on day 1 and day 8, followed by once every three weeks; RANKL inhibitor chosen by investigator is administered at a dose of 120 mg every 4 weeks, with dosing on Days 1, 8, and 15 during the first cycle.
62816171|NCT06603038|EXPERIMENTAL|Intervention|Supplementation with Daily Performance Greens daily for 28 days
62816172|NCT06603038|NO_INTERVENTION|Control|Control group, no supplementation
62240091|NCT02847741|OTHER|Major depressive episode|Depressive patients will be assessed by interview (psychiatrists), questionnaires and blood sampling, as the inpatients's routine care
62240092|NCT06257992|EXPERIMENTAL|Dry Needling Group|
62240093|NCT06257992|ACTIVE_COMPARATOR|Stretch Group|
62597729|NCT06295627||Infected group|The infection group consisted of patients with urinary tract infection (13 cases)
62816173|NCT02014688||American Indian or Alaskan Native Descent|
62816174|NCT02014688||Black or African American Descent|
62037928|NCT03905889|EXPERIMENTAL|Experimental Abemaciclib and Sunitinib|For the dose escalation phase, Subjects will receive a 21-day cycle of continuous oral daily Sunitinib in combination with Abemaciclib every 12 hours for 14 days followed by 7 days off. Using a traditional 3 x 3 study design assessing dose limiting toxicity, if the initial prescribed dosing of these 2 medications (Dose Level 1) is tolerated by the first 3 subjects, the study will pause for a 30 day time period between cohorts to assess toxicity. If no dose limiting toxicity is identified, the next cohort of 3 new subjects will be treated at the next higher dose level (Dose Level 2). If the original cohort treated at Dose Level 1 do not tolerate the combination of medications, the medication regimen will be modified to a lower dose (Dose Level - 1). A dose expansion phase is included which will evaluate the combination of Abemaciclib in combination with Sunitinib when given at the maximum tolerated dose as determined from the from dose escalation phase.
62037929|NCT01201590|EXPERIMENTAL|High Flavanol Cocoa|609mg cocoa flavanols per 24g serving
62037930|NCT01201590|PLACEBO_COMPARATOR|Low flavanol cocoa|13mg cocoa flavanols per 24g serving
62037931|NCT02742948|ACTIVE_COMPARATOR|preoperative antibiotic group|200 women will receive IV ceftriaxone (2g) 60 minutes before skin incision
62037932|NCT02742948|ACTIVE_COMPARATOR|early intraoperative antibiotic group|200 women will receive IV ceftriaxone (2g) immediately with skin incision
62037933|NCT02742948|ACTIVE_COMPARATOR|post cord clamping antibiotic group|200 women will receive IV ceftriaxone (2g) immediately after umbilical cord clamping
62240094|NCT01554488|EXPERIMENTAL|Arm 1|High dose inhaled fluticasone (1760mcg/day)
62240095|NCT01554488|ACTIVE_COMPARATOR|Arm 2|Low dose inhaled fluticasone (88mcg/day)
62240096|NCT01875536|EXPERIMENTAL|rTMS|The experimental group received rTMS to the primary motor cortex of the unaffected side in 10 sessions, 3 days per week, and conventional physical therapy
62240097|NCT01875536|SHAM_COMPARATOR|control|The control group received sham stimulation (same area as the experimental group) in 10 sessions, 3 days per week, and conventional physical therapy
62240098|NCT01442116|EXPERIMENTAL|Hypertensives|
62816175|NCT02014688||Asian Descent|
62816176|NCT02014688||Hispanic Descent|
62816177|NCT02327546|EXPERIMENTAL|AKB-6548|AKB-6548
62816178|NCT02327546|EXPERIMENTAL|AKB-6548 plus Ferrous Sulfate|AKB-6548 plus ferrous sulfate
62816179|NCT02546167|EXPERIMENTAL|Cohort 1|will receive 1-5x10\^7 CART-BCMA cells given as a split dose infusion over 3 days.
62816180|NCT02546167|EXPERIMENTAL|Cohort 2|Cyclophosphamide infusion prior to 1-5x10\^7 CART BCMA cells given as a split dose infusion over 3 days.
62816181|NCT02546167|EXPERIMENTAL|Cohort 3|Cyclophosphamide infusion prior to 1-5x10\^8 CART BCMA cells given as a split dose infusion over 3 days.
62816182|NCT01034826||life style modification|everyone in this study was advised about their life style, diet, exercise habits.
62816183|NCT05951114||Patients with diaphragm weakness|Diaphragm weakness will be defined as thickening fraction \<=20 % at the time of extubation
62816184|NCT05951114||Patients without diaphragm weakness|Diaphragm thickening fraction \>20 % at the time of extubation
62816185|NCT04133883|OTHER|Haemophilia A patients|Treated on-demand or prophylaxis with any Factor VIII (FVIII) product, plasma derived or recombinant (conventional or extended-half life) FVIII, according to routine clinical practice.
62816186|NCT06601257|ACTIVE_COMPARATOR|Control|Weight-stratified dosing as the current standard of care
62816187|NCT06601257|EXPERIMENTAL|Test|Kidney function stratified dosing
62240099|NCT01678209|ACTIVE_COMPARATOR|fMRI scans|Healthy Control Group: will receive initial evaluation, and 2 fMRI (functional magnetic resonance imaging) scans each 6-8 weeks apart
62240100|NCT01678209|EXPERIMENTAL|Atomoxetine arm|These subjects will receive initial evaluation and baseline fMRI scan, flexible dose titration with atomoxetine for 6-8 weeks, and fMRI postscan, with optional post study stabilization visits.
62816188|NCT03261648||hospitalized patient|100 patients will completed the 'State-Trait-Anxiety Inventory (Forme Y) questionnaire Patients will evaluated here pain answering to a pain level scale
62240101|NCT01678209|EXPERIMENTAL|Methylphenidate arm|Subjects will receive initial evaluation, baseline fMRI scan, flexible dose titration with methylphenidate (Concerta) for 6-8 weeks, and fMRI scan post treatment.
62430552|NCT02991833|ACTIVE_COMPARATOR|Diaper|Patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 days. The visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD. Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased. To evaluate skin integrity, the perineal skin of the patients was observed every day by researcher and was recorded to the Perineal Skin Integrity Assesment Form. The number of defecation, stool consistency, and the number of care product (diaper ) was observed daily and was recorded to the Patient Observation Form. The main study outcomes was IAD.
62430553|NCT05617859|OTHER|Lenvatinib mesylate capsule|Eligible subjects with bone and soft tissue sarcoma were selected and treated with the following treatment regimens:Subjects will receive Lenvatinib mesylate capsules, 8mg (body weight ≤60kg) or 12mg (body weight \>60kg) orally once daily. Take the medicine about half an hour after meals (the time of taking the medicine should be the same as possible every day) and take it with warm water.
62816189|NCT03261648||partner of the hospitalized patient|100 partners will completed the State-Trait-Anxiety Inventory (Forme Y) questionnaire
62816190|NCT04523688|EXPERIMENTAL|Experimental treatment|"Induction phase: 4 weekly doses of dendritic cell vaccine (10x10exp6 cells) intradermally administered (weeks 1-4).~Maintenance phase: 28 days cycles with vaccine administration (start on week 7) and adjuvant temozolomide (150-200mg/m2/day) assumed orally from day 1 to 5 q28 (start on week 5). The combined maintenance treatment will continue until disease progression, unacceptable toxicity or withdrawal of consent by the patient, or up to a maximum of 1 year of treatments.~After disease progression or the end of maintenance phase, is foreseen a one-year follow-up phase for each subject."
62816191|NCT04690829||control|control with non-inflammatory related eye disease
62240102|NCT00154076|EXPERIMENTAL|1|
62240103|NCT00154076|ACTIVE_COMPARATOR|2|
62240104|NCT04608669|OTHER|Temperature comparison|
62430554|NCT03670407|NO_INTERVENTION|Control group|Participants who opt not to go ahead with ovarian fragmentation.
62430555|NCT03670407|EXPERIMENTAL|Study group|Participants who opt for ovarian fragmentation.
62430556|NCT02407028|EXPERIMENTAL|Hyperbaric oxygen (1.5 ATA, no NBH)|Hyperbaric oxygen at 1.5 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.
62430557|NCT02407028|EXPERIMENTAL|Hyperbaric oxygen (2.0 ATA, no NBH)|Hyperbaric oxygen at 2.0 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.
62240105|NCT04608669|ACTIVE_COMPARATOR|No change|
62240106|NCT03248934|EXPERIMENTAL|Patient Self-Administered Exam Group|Participants with hip pain presenting in the hip preservation clinics will be asked to complete two diagnostic exams. Participants with hip pain will first complete a patient self-administered diagnostic exam.
62430558|NCT02407028|EXPERIMENTAL|Hyperbaric oxygen (2.5 ATA, no NBH)|Hyperbaric oxygen at 2.5 ATA for 1 hour, without NBH. This treatment is administered twice a day for 5 days.
62430559|NCT02407028|EXPERIMENTAL|Hyperbaric oxygen (1.5 ATA + NBH)|Hyperbaric oxygen at 1.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
62816192|NCT04690829||control (healthy participant)|healthy volunteer
62240107|NCT03248934|ACTIVE_COMPARATOR|Clinician-Performed Exam Group|Participants with hip pain presenting in the hip preservation clinics will be asked to complete two diagnostic exams. Participants with hip pain will next complete a clinician-performed diagnostic exam.
62240108|NCT03228758|ACTIVE_COMPARATOR|Anterior Orientation|"The anterior endoscopic myotomy of the lower esophageal sphincter will be performed between the 11 o'clock to 3 o'clock position in the esophagus determined by the usual endoscopic convention of 12 o'clock representing the most anterior aspect of the esophagus on endoluminal view.~Intervention is the endoscopic myotomy of the lower esophageal sphincter."
62430560|NCT02407028|EXPERIMENTAL|Hyperbaric oxygen (2.0 ATA + NBH)|Hyperbaric oxygen at 2.0 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
62430561|NCT02407028|EXPERIMENTAL|Hyperbaric oxygen (2.5 ATA + NBH)|Hyperbaric oxygen at 2.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
62037934|NCT05597969|EXPERIMENTAL|FoodCoach|"The experimental group uses the FutureMe app for 9 weeks and continue to voluntarily use it. The app has the following functionality:~* Dashboard: show the Nutri-Score changes over the last 10 baskets and comparisons between the specific user and all FoodCoach app users.~* Recommendations: show three recommendations regarding their food purchases and healthier product recommendations to help them achieve these recommendations.~* Nutrition Analysis: show the monthly energy contribution of 7 food categories in the past 6 months.~* Spending Analysis: show the monthly expense contribution of 7 food categories and 1 not categorized category in the past 6 months.~* Shopping history: show their purchase history in the past 6 months, together with monthly average Nutri-Score and basket Nutri-Score if applicable~* Q \& A: show answers to the commonly asked questions. E.g., how is the Nutri-Score calculated?"
62037935|NCT05597969|NO_INTERVENTION|Control|The control group receives no application for use. They need to finish the onboarding survey, donate their food purchase data and finish the post-study survey (voluntary). They receive no intervention while the experimental group should be actively using the FoodCoach app. The investigators will send them an analysis report of their food purchase data via email in 3 months after the intervention phase is gone. Note the intervention lasts for 9 weeks.
62816193|NCT04690829||uveitis|patients with a diagnosis of uveitis or ocular inflammation
62816194|NCT04175223|EXPERIMENTAL|probiotics|probiotic administration
62037936|NCT00127101|EXPERIMENTAL|Cohort 1|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter\[2\] daily x 7 days per week
62816195|NCT04175223|NO_INTERVENTION|without probiotic|no change from the usual care
62816196|NCT06705803||Prostate Cancer Patients Undergoing Prostate Ablation|Patients with prostate cancer undergoing prostate ablation for the management of prostate cancer.
62430562|NCT02407028|EXPERIMENTAL|Normobaric Hyperoxia (NBH)|Normobaric Hyperoxia (NBH meaning 100% O2 at 1.0 ATA) for 4.5 hours twice a day for 5 days.
62816197|NCT06255275|EXPERIMENTAL|pedestrian crossing - virtual reality|
62816198|NCT04565158||Women with bilateral salpingo-oophorectomy (BSO)|
62037937|NCT00127101|EXPERIMENTAL|Cohort 2|Vorinostat 300 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter\[2\] daily x 7 days per week
62037938|NCT00127101|EXPERIMENTAL|Cohort 2a|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 225 milligrams/meter\[2\] daily x 7 days per week
62037939|NCT00127101|EXPERIMENTAL|Cohort 2b|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 300 milligrams/meter\[2\] daily x 7 days per week
62430563|NCT02407028|ACTIVE_COMPARATOR|Usual care|Usual care for severe TBI
62430564|NCT01222715|EXPERIMENTAL|Arm I (vinorelbine tartrate, cyclophosphamide, bevacizumab)|Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1 and 8 and cyclophosphamide IV over 30-60 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1.
62430565|NCT01222715|EXPERIMENTAL|Arm II (vinorelbine tartrate, cyclophosphamide, temsirolimus)|Patients receive vinorelbine tartrate and cyclophosphamide as in arm I. Patients also receive temsirolimus IV over 30-60 minutes on days 1, 8, and 15.
62430566|NCT03461315|NO_INTERVENTION|Traditional Mode|Traditional Model: Team That Cares for the Rest of the Community
62430567|NCT03461315|EXPERIMENTAL|Study Model|Study Model:Team Dedicated Exclusively to the Home Patient
62597730|NCT06295627||Non-infected group|Non-infection group The first group consisted of patients without urinary tract infection (278 cases)
62816199|NCT04565158||Women without bilateral salpingo-oophorectomy (BSO)|
62816200|NCT00435409|EXPERIMENTAL|A|
62816201|NCT00435409|ACTIVE_COMPARATOR|B|
62816202|NCT05988645|EXPERIMENTAL|MiWEndo + colonoscope|All patients will be explored with MiWEndo as an accessory to colonoscopy
62816203|NCT06697717|EXPERIMENTAL|Transpulmonary Pressure-Guided PEEP Titration|
62816204|NCT06697717|EXPERIMENTAL|EIT-Guided PEEP Titration|
62816205|NCT05531786|EXPERIMENTAL|Arm 2 - Low-dose|Expansion dosing to evaluate the efficacy of pacritinib 100 mg PO BID
62816206|NCT05531786|EXPERIMENTAL|Arm 3 - High-dose|Expansion dosing to evaluate the efficacy of pacritinib 200 mg PO BID
62816207|NCT05531786|EXPERIMENTAL|Escalating doses of treatment|Escalating doses of pacritinib to confirm safety in cGVHD
62816208|NCT02769923|ACTIVE_COMPARATOR|Arm A|Westpharma ID Adapter
62816209|NCT02769923|ACTIVE_COMPARATOR|Arm B|Star ID syringe
62816210|NCT02769923|ACTIVE_COMPARATOR|Arm C|BCG NS
62816211|NCT04844814|EXPERIMENTAL|Anakinra|Anakinra 100 mg/d+Placebo of Prednisone
62816212|NCT04844814|ACTIVE_COMPARATOR|Prednisone|Prednisone 30 mg/d+Placebo of Anakinra
62816213|NCT04721860|EXPERIMENTAL|Backward Locomotion Treadmill Training (BLTT)|Participants train on a reverse treadmill (no bodyweight support), three times per week x 4 weeks.
62816214|NCT04721860|SHAM_COMPARATOR|Forward Locomotion Treadmill Training (FLTT)|Participants train on a treadmill (no bodyweight support), three times per week x 4 weeks.
62816215|NCT05334368|EXPERIMENTAL|Depemokimab|All participants in this arm will receive depemokimab.
62816216|NCT05334368|PLACEBO_COMPARATOR|Placebo|All participants in this arm will receive placebo.
62816217|NCT01723241|EXPERIMENTAL|XAF5|
62816218|NCT01723241|PLACEBO_COMPARATOR|Placebo|
62816219|NCT05959044|ACTIVE_COMPARATOR|Folic acid|30 patinets will receive Orally 5mg tablet two times daily for 8 weeks
62816220|NCT05959044|PLACEBO_COMPARATOR|Control|30 patinets will receive Orally 5mg tablet two times daily for 8 weeks
62816221|NCT03977792|EXPERIMENTAL|Experimental treatment|"Subjects treated with BOR15001L7.~All subjects will be randomized 1:1 (BOR15001L7:docosanol 10%) to receive either BOR15001L7 or docosanol 10%."
62240109|NCT03228758|ACTIVE_COMPARATOR|Posterior Orientation|"The posterior endoscopic myotomy of the lower esophageal sphincter will be performed between the 5 o'clock to 6 o'clock position in the esophagus determined by the usual endoscopic convention of 12 o'clock representing the most anterior aspect of the esophagus on endoluminal view.~Intervention is the endoscopic myotomy of the lower esophageal sphincter."
62037940|NCT00127101|EXPERIMENTAL|Cohort 6|Vorinostat 400 milligrams daily for 7 days per week + Bexarotene 150 milligrams daily for 7 days per week
62037941|NCT00127101|EXPERIMENTAL|Cohort 7|Vorinostat 400 milligrams daily for 7 days per week + Bexarotene daily for 7 days per week \[150 milligrams (Cycle 1) 225 milligrams (Cycle 2-6)
62037942|NCT05278910|PLACEBO_COMPARATOR|Soybean oil + Roasted wheat flour|Assign soybean oil capsule and roasted wheat flour.
62430568|NCT04449679|EXPERIMENTAL|Health Services Research (RT-CAMSS)|Patients receive RT-CAMSS over 2 months or until chemotherapy is discontinued, whichever is earlier. RT-CAMSS consists of text messages addressing knowledge about specific cancer type and chemotherapy, side-effect prevention, suggestions of lifestyle behavioral changes and emotional support, and preparation for surgery. Patients then record their symptoms through answering a series of questionnaires and receive tailored feedback according to their answers, including a consultation with a nurse.
62430569|NCT06338683|EXPERIMENTAL|Arm I (ONS group)|Patients receive olanzapine 2.5mg PO until disease progression. Intervention: Patients received olanzapine and nutritional advice and standard antitumor treatment.
62037943|NCT05278910|EXPERIMENTAL|Fish oil + Roasted wheat flour|Assign fish oil capsule and roasted wheat flour.
62037944|NCT05278910|EXPERIMENTAL|Soybean oil + Vegetable and fruit extracts|Assign soybean oil capsule and Vegetable and fruit extracts.
62037945|NCT05278910|EXPERIMENTAL|Fish oil + Vegetable and fruit extracts|Assign fish oil capsule and Vegetable and fruit extracts.
62430570|NCT06338683|PLACEBO_COMPARATOR|Arm II (NS group)|No Intervention: Patients received nutritional advice and standard anti-tumor treatment.
62430571|NCT00490737|EXPERIMENTAL|Hemodialysis (HD) Participants|Participants will receive daptomycin 6 mg/kg by intravenous infusion (i.v.) at 48-hours intervals (with dialysis) for a total of 3 doses.
62430572|NCT00490737|EXPERIMENTAL|Continuous Ambulatory Peritoneal Dialysis (CAPD) Participants|Participants will receive daptomycin 6 mg/kg, i.v., at 48-hours intervals for a total of 3 doses.
62430573|NCT04871178|NO_INTERVENTION|Control Group|Care as usual: (i.e. best medical treatment)
62430574|NCT04871178|EXPERIMENTAL|Mindfulness-Based Intervention|Care as usual (i.e. best medical treatment) in combination with an eight-week mindfulness-based educational and training program.
62430575|NCT03932747|PLACEBO_COMPARATOR|Placebo Creams|Measuring the skin before the application of the cream without urea (placebo), wait 3 hours and re-measure the hydration
62816222|NCT03977792|ACTIVE_COMPARATOR|Comparator treatment|"Subjects treated with Docosanol 10%.~All subjects will be randomized 1:1 (BOR15001L7:docosanol 10%) to receive either BOR15001L7 or docosanol 10%."
62816223|NCT04392960|EXPERIMENTAL|18F-florbetaben PET-CT scans|
62816224|NCT06282432||Subjects that received RP-L201 on the RP-L201-0318 Parent Study|Subjects that received RP-L201 on the RP-L201-0318 Parent Study and either completed the study or discontinued early.
62816225|NCT06164951|EXPERIMENTAL|Infigratinib 0.25 mg/kg/day|Infigratinib at 2, 3.5, 5, 7, 10 mg
62816226|NCT06164951|PLACEBO_COMPARATOR|Placebo 0.25 mg/kg/day|Placebo Comparator at 2, 3.5, 5, 7, 10 mg
62816227|NCT06389396|EXPERIMENTAL|Investigational device - newly developed TAI catheter.|
62816228|NCT06389396|NO_INTERVENTION|Peristeen Plus|
62816229|NCT03827434|ACTIVE_COMPARATOR|Continuous glucose Monitoring and Clarity|Patients with DM2 and abnormal glycemic control followed by Continuous glucose Monitoring, using Clarity software
62816230|NCT03827434|PLACEBO_COMPARATOR|Point of Care Fingerstick Glucose values|Patients with DM2 and abnormal glycemic control followed by Point of Care Fingerstick Glucose values
62037946|NCT04118153|EXPERIMENTAL|Abatacept|Abatacept will be given by a subcutaneous (SC) formulation weekly for three months.
62037947|NCT05856448|EXPERIMENTAL|GLPG3667 - Treatment A|Participant will receive a dose A of GLPG3667 capsules orally once daily (q.d.) for 48 weeks.
62240110|NCT03027557|EXPERIMENTAL|Combined treatment.|20 subjects will be treated with combined 60mg denosumab bi-annually , 30 mg cinacalcet daily and 50 micrograms vitamin-D daily.
62240111|NCT03027557|ACTIVE_COMPARATOR|Monotherapy|20 subjects will receive 60mg denosumab bi-annually, placebo and 50 micrograms vitamin-D daily.
62037948|NCT05856448|EXPERIMENTAL|GLPG3667 - Treatment B|Participant will receive a dose B of GLPG3667 capsules orally (q.d.) for 48 weeks.
62037949|NCT05856448|PLACEBO_COMPARATOR|Placebo|Participant will receive placebo matched to GLPG3667 capsules orally q.d for 48 weeks.
62816231|NCT06455228|EXPERIMENTAL|upper arm|①Evaluation: The puncture site was determined by senior nurses based on group assignment before placement. The depth and diameter of the pre-punctured vein were measured using ultrasound assessment, and the intima of the pre-punctured vein was examined without applying a tourniquet. ②Catheterization: A 3 Fr, 8 cm tip-opened long PIVC was used. Catheters were placed according to the designated sites for each group using ultrasound-guided and accelerated Seidinger techniques. After confirming catheter placement, needleless connectors and extension were attached, and the catheter was secured without tension using a sterile transparent dressing. ③Maintenance: Specialized nurses were trained to monitor and evaluate catheter function daily. Clinical nurses conducted routine maintenance until the study completion. Daily data were recorded and updated in computerized records.
62240112|NCT03027557|PLACEBO_COMPARATOR|Placebo|20 subjects will receive a saline injection bi-annually (blinded), placebo-tablets and 50 micrograms vitamin-D daily.
62240113|NCT00596934|EXPERIMENTAL|Metreleptin treatment group|Treatment group
62816232|NCT06455228|OTHER|forearm|①Evaluation: The puncture site was determined by senior nurses based on group assignment before placement. The depth and diameter of the pre-punctured vein were measured using ultrasound assessment, and the intima of the pre-punctured vein was examined without applying a tourniquet. ②Catheterization: A 3 Fr, 8 cm tip-opened long PIVC was used. Catheters were placed according to the designated sites for each group using ultrasound-guided and accelerated Seidinger techniques. After confirming catheter placement, needleless connectors and extension were attached, and the catheter was secured without tension using a sterile transparent dressing. ③Maintenance: Specialized nurses were trained to monitor and evaluate catheter function daily. Clinical nurses conducted routine maintenance until the study completion. Daily data were recorded and updated in computerized records.
62816233|NCT04733768|EXPERIMENTAL|18F-PSMA-1007 PET/CT scan|Single Arm study - all enrolled patients will undergo an experimental 18F-PSMA-1007 PET/CT scan
62816234|NCT06577896||Aged 75 or more|Elderly patients aged 75 years or older
62816235|NCT06577896||Eligible for interventional procedures|"Patients requiring PCI (Percutaneous Coronary Intervention) procedure"
62816236|NCT06577896||Evidence of myocardial ischemia or coronary artery stenosis ≥ 50%|Patients with evidence of myocardial ischemia or coronary artery stenosis ≥ 50% on coronary angiography
62816237|NCT06577896||Able to take antiplatelets for at least 1 months after the procedure|Patients able to take antiplatelets after the procedure
62816238|NCT06577896||Patients who underwent coronary artery procedures with ZES stent|Patients who underwent coronary artery procedures with Onyx™ family stent
62816239|NCT06525298|EXPERIMENTAL|EIS-12656 Dose Escalation|
62240114|NCT06141044|NO_INTERVENTION|Drainage|Patients undergoing distal pancreatectomy with surgical drainage.
62816240|NCT06525298|EXPERIMENTAL|Dose Expansion Module 1 (EIS-12656 Monotherapy)|
62816241|NCT06525298|EXPERIMENTAL|Dose Expansion Module 2 (EIS-12656 + Olaparib)|EIS-12656 will be given in combination with Olaparib
62816242|NCT06525298|EXPERIMENTAL|Dose Expansion Module 3 (EIS-12656 + T-DXd)|EIS-12656 will be given in combination with Trastuzumab deruxtecan
62816243|NCT03207126|OTHER|Women needing endometrial biopsy|All women who would be offered hysteroscopy guided biopsy as standard of care will be offered ultrasound guided biopsy first.
62816244|NCT00241384|ACTIVE_COMPARATOR|Pd-103 with 20Gy External Beam|Pd-103 with 20Gy External Beam
62816245|NCT00241384|ACTIVE_COMPARATOR|Pd-103 alone|Pd-103 alone
62816246|NCT03939546|NO_INTERVENTION|Control|The Control Arm will not receive any study intervention or placebo. The infants in this arm will receive standard NICU care.
62816247|NCT03939546|ACTIVE_COMPARATOR|B. infantis EVC001|Infants in the B. infantis arm will receive a once daily enteral feed of Evivo with MCT oil (8B CFU B. infantis EVC001) from Study Day 0 (by Day 10 of life) to hospital discharge, except on days when the infant is NPO.
62240115|NCT06141044|EXPERIMENTAL|No drainage|Patients undergoing distal pancreatectomy without surgical drainage.
62240116|NCT02929745|EXPERIMENTAL|10 HLA-Cw6+|HLA-Cw6+ patients will donate blood and skin samples
62240117|NCT02929745|EXPERIMENTAL|10 HLA Cw6-|HLA-Cw6- patients will donate blood and skin samples
62240118|NCT02929745|EXPERIMENTAL|Healthy Skin|Healthy patients will donate blood and skin samples
62240119|NCT03343951||Shoulder patients|Shoulder patients referred to examination at the shoulder clinic, Silkeborg Regional Hospital.
62240120|NCT06093789||Group PT-PADC|patients who will receive sedoanalgesia for the oocyte retrieval procedure.
62240121|NCT01856166|ACTIVE_COMPARATOR|CEI-PCEA|Continuous Epidural Infusion coupled with Patient Controlled Epidural Analgesia
62240122|NCT01856166|EXPERIMENTAL|PIEB-PCEA|Programmed Intermittent Epidural Bolus coupled with Patient Controlled Epidural Analgesia
62240123|NCT00786825|EXPERIMENTAL|somatostatin|Type 1 diabetes and Hypoglycemia unawareness
62240124|NCT00786825|NO_INTERVENTION|2|Healthy control subjects
62240125|NCT01920594|EXPERIMENTAL|GSK1278863|Subject will receive GSK1278863 300mg on Day-1 (12 +/- 4 hours prior to planned surgery) as a loading dose followed by GSK1278863 100mg once daily for 4 days starting from Day 0.
62240126|NCT01920594|PLACEBO_COMPARATOR|Placebo|Subject will receive GSK1278863 matching placebo on Day-1 (12 +/- 4 hours prior to planned surgery) as a loading dose followed by GSK1278863 matching placebo once daily for 4 days starting from Day 0.
62430576|NCT03932747|ACTIVE_COMPARATOR|Urea 5%|Measuring the skin before the application of the cream with urea (5%), wait 3 hours and re-measure the hydration
62037950|NCT05564234|ACTIVE_COMPARATOR|Neoadjuvant chemotherapy|cases with predictive index value score 8 or greater in which primary cytoreductive surgery was not feasible were were referred for neoadjuvant chemotherapy then interval cytoreductive surgery was done
62816248|NCT03363373|EXPERIMENTAL|GM-CSF + Naxitamab|Each investigational cycle is started with 5 days of GM-CSF administered at 250 µg/m2/day in advance of the start of Naxitamab administration. GM-CSF is thereafter administered at 500 µg/m2/day on days 1 to 5. As standard treatment, Naxitamab is administered at 3 mg/kg/day on days 1, 3, and 5 totalling 9 mg/kg per cycle. Treatment cycles are repeated every 4 weeks until CR or PR followed by 5 additional cycles every 4 weeks (±1 week). Subsequent cycles are repeated every 8 weeks (±2 weeks) through 101 weeks from first infusion at the discretion of the investigator. After end of treatment patients will enter a long-term follow up for up to 3 years after end of treatment visit.
62430577|NCT03932747|ACTIVE_COMPARATOR|Urea 20%|Measuring the skin before the application of the cream with urea (20%), wait 3 hours and re-measure the hydration
62430578|NCT05849909||Stable Carotid Atherosclerotic Plaques|
62816249|NCT03633396|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo administered by subcutaneous injection on Day 1 followed by monthly doses of placebo by subcutaneous injection on Days 29, 57, and 85.
62816250|NCT03633396|EXPERIMENTAL|imsidolimab|Participants will receive 200 mg imsidolimab by subcutaneous injection on Day 1 followed by monthly doses of 100 mg imsidolimab by subcutaneous injection on Days 29, 57, and 85.
62240127|NCT06188169|EXPERIMENTAL|Group A = C-PCV received conventional pressure-controlled ventilation|Inspiratory pressure will be adjusted to achieve an expired tidal volume of 7 ml/Kg; the respiratory rate will be adjusted to achieve an end ETCO2 at 32-35 mmHg, inspiratory to expiratory ratio at 1:2, PEEP at 4 cm H2O, and FiO2 at 0.5. No further adjustment in IP will be made throughout the surgery. LUS will be performed at the same fixed four-time interval as Group-B. Anesthesiologist will not do any interventions to the atelectatic areas in this group.
62240128|NCT06188169|ACTIVE_COMPARATOR|Group B = US-PCV: received ultrasound-guided pressure-controlled ventilation|Initial IP will be ten cmH2O, PEEP 4 cmH2O with a 0.5 inspired oxygen fraction, and RR 12 breaths/min. Then under ultrasound guidance, a stepwise increase in inspiratory pressure from 10 cmH2O by 2 cmH2O increments every 5 min until the atelectasis disappeared on ultrasound (progression from lung collapse to B lines to normal lung image). The IP will be fixed at this level, and RR will be adjusted to maintain an EtCO2 at 32-35 mmHg. The maximum airway pressure will be limited to 35 cmH2O.
62240129|NCT00695617|EXPERIMENTAL|A|citrate first
62240130|NCT00695617|EXPERIMENTAL|B|no anticoagulation first
62430579|NCT05849909||Unstable Carotid Atherosclerotic Plaques|
62430580|NCT05765045|EXPERIMENTAL|Nursing triage group|Using a triage protocol for medical imaging conducted by a triage nurse in the emergency department
62430581|NCT05765045|NO_INTERVENTION|Regular care group|Regular triage in the emergency department
62430582|NCT02777853|EXPERIMENTAL|Active (green) tea|Tea to be ingested 3 times per day for 7 days.
62816251|NCT01378364|EXPERIMENTAL|AbGn-168H very low dose i.v.|subject to receive a single very low dose of AbGn-168H intravenously (i.v.) or placebo
62816252|NCT01378364|EXPERIMENTAL|AbGn-168H low dose i.v.|subject to receive a single low dose of AbGn-168H intravenously (i.v.) or placebo
62816253|NCT01378364|EXPERIMENTAL|AbGn-168H medium dose i.v.|subject to receive a single medium dose of AbGn-168H intravenously (i.v.) or placebo
62816254|NCT01378364|EXPERIMENTAL|AbGn-168H high dose i.v.|subject to receive a single high dose of AbGn-168H intravenously (i.v.) or placebo
62816255|NCT01378364|EXPERIMENTAL|AbGn-168H very low dose s.c.|subject to receive a single very low dose of AbGn-168H subcutaneously (s.c.) or placebo
62816256|NCT01378364|EXPERIMENTAL|AbGn-168H medium dose s.c.|subject to receive a single medium dose dose of AbGn-168H subcutaneously (s.c.) or placebo
62816257|NCT00976274|PLACEBO_COMPARATOR|starch capsule|
62037951|NCT05564234|ACTIVE_COMPARATOR|primary cytoreductive surgery|cases with predictive index value score less than 8 were offered primary cytoreductive surgery.
62037952|NCT05537220|EXPERIMENTAL|Group 1 - N-acetylcysteine|This is the intervention group. Patients in this group will be receiving 1800 mg of N-acetylcysteine in the form of 3 effervescent 600 mg tablets dissolved in water twice a day for 45 months.
62037953|NCT05537220|PLACEBO_COMPARATOR|Group 2 - Placebo|Patients in the placebo group will receive identical effervescent tablets lacking active drug.
62037954|NCT03273634|EXPERIMENTAL|Active treatment|The treatment will consist of lanzoprazole 30 mg once daily at night time
62816258|NCT00976274|EXPERIMENTAL|Korea red ginseng|
62430583|NCT02777853|PLACEBO_COMPARATOR|Placebo tea|Tea to be ingested 3 times per day for 7 days.
62430584|NCT05875766|EXPERIMENTAL|Patient with osteopathy session|Patients after their DIDT surgery have 4 osteopathy sessions in addition to physiotherapy
62430585|NCT05875766|PLACEBO_COMPARATOR|Patient without osteopathy session|Patients after their DIDT surgery have only physiotherapy
62430586|NCT01987661|ACTIVE_COMPARATOR|bilevel ventilation BIPAP ST|one night, BIPAP ST ventilation with individually optimised pressure parameters and supplemental oxygen if necessary.
62430587|NCT01987661|EXPERIMENTAL|BIPAP ST plus Airtrap|"one night, BIPAP ST ventilation with Airtrap control, same pressure parameters and oxygen."
62430588|NCT01127386|EXPERIMENTAL|fix dose lenalidomide 25mg, basic cachexia management|dose reduction according to toxicity possible
62430589|NCT01127386|EXPERIMENTAL|CRP-response guided lenalidomide, basic cachexia management|start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
62430590|NCT01127386|EXPERIMENTAL|placebo|to generate data about basic cachexia management, no direct comparator for treatment arms efficacy
62430591|NCT04329650|EXPERIMENTAL|Siltuximab 11mg/Kg|
62240131|NCT06119009||Non- Heart blocks|The number of patients who did not suffered the heart blocks in the postoperative 1-year period
62240132|NCT06119009||Heart blocks|The number of patients who suffered the heart blocks in the postoperative 1-year period
62240133|NCT04624490|EXPERIMENTAL|Hyperpolarized 129Xe|Administration of hyperpolarized xenon during MRI (up to 1L doses) to develop imaging methods and assess pulmonary function in adults.
62816259|NCT06700733|EXPERIMENTAL|study group|The first 9 patients will receive the PEEK prosthesis (PP) first. After 3 months, chewing efficiency, maximum bite force, patient satisfaction, and OHRQoL will be measured, and PP will be replaced by a Titanium prosthesis (TP). After another 3 months, the measurements will be repeated.
62816260|NCT06700733|EXPERIMENTAL|study group 1|The second 9 patients will receive TP first, and after 3 months, measurements will be made. Then, TP was replaced by PP, and measurements will be repeated after another 3 months. This randomization will be made to reduce the effect of prosthesis type and bias
62816261|NCT00716677||1|
62816262|NCT00716677||2|
62430592|NCT04329650|ACTIVE_COMPARATOR|Dexamethasone 6mg/24h|
62816263|NCT06546163|EXPERIMENTAL|Baseline and HRVB group|In-person baseline surveys (using paper and pen survey) before the random assignment to HRVB arm. This group will receive a standardized HeartMath© Inner balance device and HRV biofeedback training session at the start of the two-week intervention period. They will be asked to attend one-on-one 30-minute HRVB training session and asked to practice their HRV biofeedback skills at home for 10 minutes each day for a two-week period. Participants will receive a weekly email notification and reminder phone call to complete their at-home practice of HRVB.
62816264|NCT06546163|OTHER|Baseline and HRVB waitlist|In-person baseline surveys (using paper and pen surveys) before the random assignment to HRVB waitlist group. After the baseline data collection, for two weeks, they will be provided educational material regarding education materials and coping with stress and they will be encouraged to read them during the two weeks. At the end of the two-week period, participants will be scheduled for a final in-person session including T2 survey and HRV assessment. They will be also provided HRVB training session at T2.
62816265|NCT01612338|EXPERIMENTAL|Targeted|Targeted letter and booklet
62240134|NCT02357823||Group 1|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 2 PCV13 doses received from more than 3 years that have prescription for a single booster dose of PCV13.
62240135|NCT02357823||Group 2|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 1 PPV23 dose received from more than 3 years that have prescription to receive 2 doses (priming + boost) of PCV13.
62816266|NCT01612338|EXPERIMENTAL|Tailored|Tailored letter and booklet, enhanced family communication and support brochure
62816267|NCT04609098|ACTIVE_COMPARATOR|Dihydroartemisinin-Piperaquine (DP)|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a low dose of 1.66mg/kg, 0.83mg/kg, or 0.415mg/kg. Tafenoquine (TQ) on the first date of DP treatment.
62816268|NCT04609098|EXPERIMENTAL|DP with 0.415mg/kg Tafenoquine (TQ)|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a single dose of 0.415mg/kg Tafenoquine (TQ) on the first date of DP treatment.
62816269|NCT04609098|EXPERIMENTAL|DP with 0.83 mg/kg TQ|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a single dose of 0.83mg/kg Tafenoquine (TQ) on the first date of DP treatment.
62816270|NCT04609098|EXPERIMENTAL|DP with 1.66mg/kg TQ|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and single dose of 1.66mg/kg Tafenoquine (TQ) on the first date of DP treatment.
62240136|NCT02357823||Group 3|HIV- positive adults that have never received a pneumococcal vaccine (naive) and have a CD4+ cell count \< 200 cells/ul that have prescription to be primed with a single dose of PCV13 then boosted with a single dose of PPV23.
62430593|NCT05879900|EXPERIMENTAL|Intervention Group - IG|The intervention group will have in their Physical Education classes the inclusion of functional physical exercises lasting approximately 15 minutes at the beginning of the classes. After the intervention, the classes will continue according their previously planned contents. Classes take place twice a week, on non-consecutive days. In this way, the intervention program will take place over 12 weeks, totaling 24 sessions distributed in 24 classes. The exercises will be performed with natural body movements such as running, jumping, jumping, pulling, crouching, turning and pushing in order to develop Physical Fitness. During the intervention program period there will be an increase in intensities and complexity going through processes that follow the initial, intermediate and final preparation and progression.
62430594|NCT05879900|ACTIVE_COMPARATOR|Comparator Group - CG|The comparator group wil keep performing the Physical Education classes according their previously planned contents.
62430595|NCT00267293|ACTIVE_COMPARATOR|A|At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg)
62597731|NCT03625635|EXPERIMENTAL|Nutrition diagnosis and intervention|At baseline and 6-mo after, a nutrition diagnosis will be done by measuring body composition components with DXA and basic anthropometric measurements. Based on the results, an individualized food-based intervention will be prescribed for each patient according to her diagnosis, food preferences, cultural and socioeconomic status. Follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed and initial measurements are repeated.
62597732|NCT00562289|ACTIVE_COMPARATOR|aspirin|aspirin use like antiplatelet
62037955|NCT03273634|PLACEBO_COMPARATOR|Placebo|A Placebo pill to be given with similar looking to experimental drug but contains inactive ingredient
62037956|NCT06237205|EXPERIMENTAL|Niraparib|
62430596|NCT00267293|EXPERIMENTAL|B|At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) and an appropriate dose of Acetaminophen (15 mg/kg)
62430597|NCT00267293|EXPERIMENTAL|C|At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) and at time 3 hours is given an appropriate dose of Acetaminophen (15 mg/kg)
62430598|NCT02479932|ACTIVE_COMPARATOR|Extraperitoneal cesarean|
62430599|NCT02479932|ACTIVE_COMPARATOR|Transperitoneal cesarean|
62430600|NCT01276028|EXPERIMENTAL|Acupuncture|This group will start acupuncture treatments within 3 weeks of consent and continue to receive up to 20 treatments over a six month period. The number of treatments will be jointly determined by the participant and the acupuncturist.
62597733|NCT00562289|EXPERIMENTAL|anticoagulant|Antivitamins K or rivaroxaban or dabigatran or apixaban
62597734|NCT00562289|EXPERIMENTAL|Devices for PFO closure|Devices for PFO closure
62597735|NCT00632684|ACTIVE_COMPARATOR|1|Participants in Phase 1 will undergo four interviews, including a single treatment planning session.
62597736|NCT00632684|EXPERIMENTAL|2|Participants in Phase 2 will receive the adaptive treatment model.
62597737|NCT02453217|EXPERIMENTAL|Chinese CHIP|Chinese Health Improvement Profile (CHIP) screening and intervention
62597738|NCT02453217|NO_INTERVENTION|Treatment as usual|Routine community mental health care and medical outpatient appointments
62816271|NCT03590444|ACTIVE_COMPARATOR|Prompt laser group|"Eyes of eligible patients will be randomized (ratio 1:1) and receive ranibizumab and focal/grid laser on the same day (prompt' group, 25 eyes, 50%).~Interventions: ranibizumab and focal/grid laser on the same day \[Ranibizumab (Ranibizumab 0.5 MG/0.05 ML Intraocular Solution\]"
62816272|NCT03590444|ACTIVE_COMPARATOR|Deferred laser group|"Eyes of eligible patients will be randomized (ratio 1:1) and receive ranibizumab and focal/grid laser on one week prior to laser treatment (deferred' group, 25 eyes, 50%).~Interventions: ranibizumab and focal/grid laser on one week prior to laser treatment \[Ranibizumab 0.5 MG/0.05 ML Intraocular Solution\]"
62816273|NCT01026545|EXPERIMENTAL|Cohort 1|
62597739|NCT01917812|PLACEBO_COMPARATOR|Blinded Digital Activity Tracker|Blinded Digital Activity Tracker = Group wears the tracker but is blinded to the numeric physical activity feedback information provided by the tracker.
62597740|NCT01917812|EXPERIMENTAL|Unblinded Digital Activity Tracker / No Smart Text Messaging|"Unblinded Digital Activity Tracker = Group unblinded to the numeric physical activity feedback information provided by the digital activity tracker.~No Smart Text Messaging = Group does not receive personalized, health coaching via smart text messages.~Note that the study occurred over two study phases after the 1-week blinded run-in. In the first 2-week phase, participants were randomized to unblinded or blinded tracking. In the second 2-week phase, the unblinded participants were randomized to receive smart texts or no texts."
62816274|NCT01026545|EXPERIMENTAL|Cohort 2|
62816275|NCT01026545|EXPERIMENTAL|Cohort 3|
62816276|NCT01026545|EXPERIMENTAL|Cohort 4 (optional)|If intermediate or repeat dose level is needed; dose will not exceed 1100 mg.
62816277|NCT01026545|EXPERIMENTAL|Cohort 5 (Japanese)|
62816278|NCT01026545|EXPERIMENTAL|Cohort 6 (Japanese)|
62816279|NCT05975723|EXPERIMENTAL|MIND diet intervention|Participants in the MIND diet group will receive an education program on a localized MIND diet for 1-year, and will be routinely followed up and given advice on other healthy lifestyles.
62816280|NCT05975723|ACTIVE_COMPARATOR|Control group|Participants in the control group will be routinely followed up and given general advice on healthy lifestyle.
62816281|NCT05899257|EXPERIMENTAL|Immersive Training using EYME-Explore Your Meanings|Immersive training based on the RGT and EYME to improve the metacognitive abilities and self-knowledge of young people.
62816282|NCT04179552|EXPERIMENTAL|PAAG-OA|All subjects receive treatment with PAAG-OA
62819421|NCT00392327|EXPERIMENTAL|Arm C (chemoradiotherapy, isotretinoin-CLOSED TO ACCRUAL)|"CHEMORADIOTHERAPY: Patients undergo chemoradiotherapy as in Arm A. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive isotretinoin PO BID on day 1 and days 16-28 and cisplatin, vincristine sulfate, cyclophosphamide, and filgrastim as in Arm A maintenance therapy. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive isotretinoin PO BID on days 15-28 every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
62037957|NCT03422250|EXPERIMENTAL|Arm 1|Alzheimer's disease (AD): anodal tDCS of the default mode network (DMN)
62430601|NCT01276028|OTHER|Waitlist|This group of participants will be asked to wait 6 months and will then be allowed to receive acupuncture.
62037958|NCT03422250|EXPERIMENTAL|Arm 2|Alzheimer's disease (AD): cathodal tDCS of the salience network (SN)
62037959|NCT03422250|EXPERIMENTAL|Arm 3|Behavioral-variant frontotemporal dementia (bvFTD): anodal tDCS of the salience network (SN)
62037960|NCT03422250|EXPERIMENTAL|Arm 4|Behavioral-variant frontotemporal dementia (bvFTD): cathodal tDCS of the default mode network (DMN)
62430602|NCT03768219|EXPERIMENTAL|Stage 1 (SAD) Cohort 1|6 subjects will receive 2 mcg/kg of APVO210 2 subjects will receive placebo
62430603|NCT03768219|EXPERIMENTAL|Stage 1 (SAD) Cohort 2|6 subjects will receive 5 mcg/kg of APVO210 2 subjects will receive placebo
62597741|NCT01917812|EXPERIMENTAL|Unblinded Digital Activity Tracker / Smart Text Messaging|"Unblinded Digital Activity Tracker = Group unblinded to the numeric physical activity feedback information provided by the digital activity tracker.~Smart Text Messaging = Group receives personalized, health coaching via smart text messages.~Note that the study occurred over two study phases after the 1-week blinded run-in. In the first 2-week phase, participants were randomized to unblinded or blinded tracking. In the second 2-week phase, the unblinded participants were randomized to receive smart texts or no texts."
62597742|NCT06293118|EXPERIMENTAL|Ischemic conditioning group|Therapy will be performed bilaterally on the upper limbs. The ischemic conditioning group will perform 4 times, 8 cycles with 30 seconds of ischemia (80 - 200 mmHg) with 5 seconds of reperfusion in each cycle. Ischemia cycles are controlled by a device (KAATSU C3 - KAATSU GLOBAL / USA) In the first cycle, participants will be subjected to pressures of 80 to 150 mmHg. In the 3 subsequent cycles, pressures from 130 to 200 mmHg will be applied.
62597743|NCT06293118|SHAM_COMPARATOR|Sham group|Participants in the control group (Sham) will perform 4 cycles of 5 minutes of ischemia (30 mmHg) with 4 subsequent cycles of reperfusion (rest) bilaterally in the arms with a sphygmomanometer (Welch Allyn DS44-11BR Durashock).
62597744|NCT05504486|EXPERIMENTAL|Arm 1|Brexpiprazole
62430604|NCT03768219|EXPERIMENTAL|Stage 1 (SAD) Cohort 3|6 subjects will receive 10 mcg/kg of APVO210 2 subjects will receive placebo
62819422|NCT00392327|EXPERIMENTAL|Arm D (chemoradiotherapy, isotretinoin-CLOSED TO ACCRUAL)|"CHEMORADIOTHERAPY: Patients undergo chemoradiotherapy as in Arm B. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive maintenance therapy as in Arm C. Patients then proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive continuation therapy as in Arm C."
62819423|NCT02403505|EXPERIMENTAL|Assess for CEA Antigen Presentation Therapeutic Biological Product Mix activity|CEA protein antigen 0.05 mg add into BCG Organism 50 MG
62430605|NCT03768219|EXPERIMENTAL|Stage 1 (SAD) Cohort 4|6 subjects will receive 20 mcg/kg of APVO210 2 subjects will receive placebo
62430606|NCT03768219|EXPERIMENTAL|Stage 1 (SAD) Cohort 5|6 subjects will receive 40 mcg/kg of APVO210 2 subjects will receive placebo
62430607|NCT03768219|EXPERIMENTAL|Stage 1 (SAD) Cohort 6|6 subjects will receive 80 mcg/kg of APVO210 2 subjects will receive placebo
62819424|NCT05605574|EXPERIMENTAL|1 / Assessments and Conversation|Baseline and follow-up assessments and conversations at three timepoints
62037961|NCT06497166||Research Group|12-18 year old adolescents diagnosed with internet gaming disorder
62037962|NCT06497166||Control Group|12-18 year old healthy adolescents
62037963|NCT00990691|EXPERIMENTAL|Desipramine high dose|"12 patients with Rett syndrome receiving a daily dose of desipramine correlated with the weight :~* From 15 to 25 kg : 50 mg ;~* From 26 to 35 kg : 75 mg ;~* From 36 to 45 kg : 100 mg ;~* \> 46 kg : 150 mg."
62037964|NCT00990691|EXPERIMENTAL|Desipramine low dose|"12 patients with Rett syndrome receiving a daily dose of desipramine correlated with the weight :~* From 15 to 25 kg : 25 mg ;~* From 26 to 35 kg : 50 mg ;~* From 36 to 45 kg : 75 mg ;~* \> 46 kg : 100 mg."
62037965|NCT00990691|PLACEBO_COMPARATOR|Placebo|12 patients with Rett syndrome receiving a daily dose of placebo.
62037966|NCT05195645|EXPERIMENTAL|A-10mg/kg|Patients in arm A will receive doses of 10 mg/kg of Abatacept
62037967|NCT05195645|EXPERIMENTAL|B-20mg/kg|Patients in arm B will receive doses of 20 mg/kg of Abatacept
62037968|NCT05195645|EXPERIMENTAL|C-25mg/kg|Patients in arm C will receive doses of 25 mg/kg of Abatacept
62037969|NCT06205602|ACTIVE_COMPARATOR|Broadly neutralizing antibodies (bNAbs) infusions with antiretroviral therapy (ART)|
62430608|NCT03768219|EXPERIMENTAL|Stage 1 (SAD) Cohort 7|6 subjects will receive 160 mcg/kg of APVO210 2 subjects will receive placebo
62430609|NCT03768219|EXPERIMENTAL|Stage 1 (SAD) Cohort 8|6 subjects will receive 320 mcg/kg of APVO210 2 subjects will receive placebo
62430610|NCT03768219|EXPERIMENTAL|Stage 2 (MAD) Cohort 9|8 subjects will receive 40 mcg/kg of APVO210 2 subjects will receive placebo
62037970|NCT06205602|PLACEBO_COMPARATOR|Placebo infusions with ART|
62430611|NCT03768219|EXPERIMENTAL|Stage 2 (MAD) Cohort 10|8 subjects will receive 80 mcg/kg of APVO210 2 subjects will receive placebo
62430612|NCT03768219|EXPERIMENTAL|Stage 2 (MAD) Cohort 11|8 subjects will receive 160 mcg/kg of APVO210 2 subjects will receive placebo
62430613|NCT03768219|EXPERIMENTAL|Stage 2 (MAD) Cohort 12|8 subjects will receive 360 mcg/kg of APVO210 2 subjects will receive placebo
62430614|NCT03768219|EXPERIMENTAL|Expansion Cohort (Psoriasis)|"12 subjects will receive the starting dose for the Psoriasis Patients Expansion Cohort portion of the study will be the recommended dose from Stage 2 of the study of APVO210. It will be a dose that has been demonstrated to be safe and well tolerated by the Safety Monitoring Committee.~8 subjects will receive placebo"
62597745|NCT04390672|EXPERIMENTAL|SUPRAFLEX Cruz|Percutaneous Coronary Intervention with the SUPRAFLEX Cruz Sirolimus Eluting Bioabsorbable Polymer Coronary Stent System. It is a balloon expandable sirolimus eluting stent with an bioabsorbable polymer coating.
62597746|NCT04390672|ACTIVE_COMPARATOR|SYNERGY|Percutaneous Coronary Intervention with the SYNERGY EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with an bioabsorbable polymer coating.
62597747|NCT03091881|ACTIVE_COMPARATOR|Granisetron group|patients in this group will receive intravenous Granisetron 0.1 MG/ML 10 minutes before spinal anesthesia
62597748|NCT03091881|PLACEBO_COMPARATOR|Placebo group|Patients in this group will receive 10 ml normal saline as placebos considering the same timing and color of solution
62597749|NCT00792376|EXPERIMENTAL|etoricoxib|etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
62816283|NCT06690658|OTHER|Thirty people with lower limb orthopedic injury or lower limb amputation|"Participants will be asked to fill pre-experiments questionnaires. Each patient will be assigned a unique number before the first session, which they will use to log into the system.~The patient together with the physical therapist will schedule the time for the patient to self-practice with the system, 3 times per week for 3 weeks, 30 min each session. A training session begins with the robot introducing itself, and the participant sits in front of the robot. The robot will demonstrate upper body exercises and will provide verbal instructions and feedback. The participant will be asked to follow the robot's demonstration and simultaneously perform the exercise. When completing the training program, the users will be asked to fill in questionnaires. After each session, the participant will be asked to rate his perceived rate of exertion using the Borg scale (0 to 10 scale) on the robot's screen and will be offered to start the training session from the beginning."
62597750|NCT00792376|ACTIVE_COMPARATOR|diclofenac|diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
62597751|NCT02703272|EXPERIMENTAL|Part 1: Ibrutinib|The first 2 participants enrolled in each age group (1-5 years, 6-11 years and 12-17 years) will receive starting dose of Ibrutinib 240 milligram per square meter (mg/m\^2) for the first cycle, followed by dose escalation at the start of Cycle 2 as long as all pharmacokinetic assessments are within the expected range and there are no safety concerns. For participants being treated at 240 mg/m\^2 dose level during the first cycle, the maximum dose should not exceed a total of 420 mg/day. All participants will receive rituximab, ifosfamide, carboplatin, etoposide and dexamethasone (RICE) or ituximab, vincristine, ifosfamide, carboplatin, idarubicin and dexamethasone (RVICI) background therapy (investigator's choice), during treatment phase. Participants with PR or better only will receive Ibrutinib for 3 cycles or until PD, unacceptable toxicity or until initiating antilymphoma therapy or a conditioning regimen for stem cell transplantation during post-treatment phase.
62240137|NCT02357823||Group 4|Immunological and microbiological status of HIV- positive adults that have never received a pneumococcal vaccine (naive) and have a CD4+ cell count \> 200 cells/ul that have prescription to be primed with a single dose of PCV13 then boosted with a single dose of PPV23.
62430615|NCT03768219|EXPERIMENTAL|Expansion Cohort (Ulcerative Colitis)|"12 Subjects will receive the starting dose for the Ulcerative Colitis Patients Expansion Cohort portion of the study will be the recommended dose from Stage 2 of the study of APVO210. It will be a dose that has been demonstrated to be safe and well tolerated by the Safety Monitoring Committee.~8 subjects will receive placebo"
62816284|NCT01853020|ACTIVE_COMPARATOR|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
62816285|NCT01853020|PLACEBO_COMPARATOR|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
62816286|NCT01395797|PLACEBO_COMPARATOR|Placebo - Heroin|Participants will be maintained on 0 mg of Pioglitazone (PIO) prior to sessions assessing the abuse liability of heroin.
62816287|NCT01395797|EXPERIMENTAL|PIO low dose - Heroin|Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of heroin.
62816288|NCT01395797|EXPERIMENTAL|PIO high dose - Heroin|Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of heroin.
62816289|NCT01395797|PLACEBO_COMPARATOR|Placebo - Nicotine|Participants will be maintained on 0 mg of PIO prior to sessions assessing the abuse liability of nicotine.
62816290|NCT01395797|EXPERIMENTAL|PIO Low Dose - Nicotine|Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of nicotine
62816291|NCT01395797|EXPERIMENTAL|PIO High Dose - Nicotine|Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of nicotine
62037971|NCT05876546|EXPERIMENTAL|Liquid bandage|liquid bandage - The liquid bandage will be distributed on a contact test filter paper disc, appropriately identified, in the letter of the alphabet corresponding to the experimental product.
62037972|NCT05876546|SHAM_COMPARATOR|Saline Solution|saline solution - The sterile saline solution (NaCl 0.9%) will be used as control in another contact test filter paper disc, appropriately identified, in the letter of the alphabet corresponding to the control.
62240138|NCT02357823||Group 5|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 1 PPV23 dose received from more than 3 years and that that have prescription to receive a single dose of PCV13.
62240139|NCT02160704|EXPERIMENTAL|Arm 1(IP)|Enclomiphene citrate capsules 25 mg 1x daily for 16 weeks
62240140|NCT02160704|PLACEBO_COMPARATOR|Arm 2 (Placebo)|Placebo capsule 1x daily for 16 weeks
62240141|NCT02157350|EXPERIMENTAL|Panretinal Laser Photocoagulation|See interventional description.
62240142|NCT02849301|EXPERIMENTAL|Cervical pessary|Arabin cervical pessary
62240143|NCT02849301|NO_INTERVENTION|Standard care|No treatment
62240144|NCT06094426|EXPERIMENTAL|GT316 treatment group|
62430616|NCT02598622|EXPERIMENTAL|Acetyl-L-Carnitine only|The first 15 subjects participating in this study will receive Acetyl-L-Carnitine and pharmacokinetic testing will be done.
62816292|NCT05690841|NO_INTERVENTION|Control: Standard Interventions|Standard interventions for the control cluster will include providing participants with long-lasting insecticide-treated bednets, management of known and possible mosquito breeding sites, passive case detection through detection and diagnosis of symptomatic cases of malaria in health facilities and through community health workers (conducted in villagers with fever), microscopy testing in households of recent index cases to detect asymptomatic malaria cases, and treatment of active cases of malaria (artesunate-mefloquine (AS-MQ) for Plasmodium falciparum and Chloroquine (CQ) (10 mg/kg on days 1 and 2, followed by 5 mg/kg on day 3) + PQ (0.5mg/kg x 7 days).
62430617|NCT02598622|EXPERIMENTAL|Acetyl-L-Carnitine or Placebo|Subjects 16-30 will be randomized to receive drug or placebo.
62430618|NCT06389474|EXPERIMENTAL|INM004|Two doses of Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab´)2 fragment at a dosage of 4 mg/kg of body weight, 24 hours apart.
62816293|NCT05690841|EXPERIMENTAL|Focal Mass Drug Administration (fMDA)|Standard interventions in addition to focal mass drug administration. Focal mass drug administration will include using primaquine, chloroquine, and tafenoquine, for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax (Pv) index case households from the prior 2 years (including individuals in the index case household). Pv index cases include symptomatic cases detected at health facilities or in fever screenings, and asymptomatic cases identified during routine active case detection by health facilities. Households will then be notified regarding their potential to receive two rounds fMDA that cycle. Eligibility to receive medications as part of fMDA will be assessed prior to each administration and include glucose 6 phosphate dehydrogenase (G6PD) testing and counseling if not previously conducted or result is not available on the participant's identification card.
62816294|NCT03188094|EXPERIMENTAL|Alert + CHW-Led Coaching|Participants will receive an alert and registry-driven CHW-led coaching during either the first or second round.
62816295|NCT03188094|NO_INTERVENTION|Usual Care - Wait-List Control|All participants waitlisted during the first round will be randomized to the control group. Control group participants will be offered the full CHW group education sessions during the second round. The control participants will receive usual care during the first round.
62240145|NCT05294354|EXPERIMENTAL|aerobic exercise group (AE)|35-min cycling at moderate intensity (50-60% heart rate reserve).
62816296|NCT05062655|EXPERIMENTAL|Drug reconciliation|Drug reconciliation and transmission to pharmacist
62816297|NCT05062655|NO_INTERVENTION|standard|
62816298|NCT03985761|EXPERIMENTAL|Home Telerehabilitation_Motivation Enhanced HTme|The Home Telerehabilitation Motivation Enhanced (HTme) group will use the NJIT-HoVRS system to play a series of three games to train movement of their shoulder, elbow, wrist and fingers. The study team will set up the apparatus in their home at the initial visit and train them to use the system. After this, subjects will practice in their homes with on-line or in-person support as needed (once a week in person for the first month, and then an average of two times per month in person and two times per month on line). Subjects will be instructed to perform three of the simulations assigned to them as much as possible, but at least twenty minutes, daily for twelve weeks. The HTme group will use three simulations that will provide the user with eight to twelve levels of gradually increasing difficulty and complexity. A screen announces each level change and the graphics for each new level change substantially. Scoring opportunities increase at each new level.
62819425|NCT05605574|NO_INTERVENTION|2 / Survey|Following each AYA/caregiver dyad s completion of timepoint 3, a one-time survey will be sent to a primary clinical attending and APPs who cared for the AYA during the study period
62819426|NCT03596502||Direct oral anticoagulants (DOACs)|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with a DOAC (apixaban, dabigatran or rivaroxaban) at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
62819427|NCT03596502||Warfarin|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with warfarin at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
62819428|NCT06548230|EXPERIMENTAL|ARM 1: All Patients Cycle 1|
62819429|NCT06548230|EXPERIMENTAL|ARM 1A: Cycle 2-24 for responder after Cycle 1 Mono|
62037973|NCT02464449|EXPERIMENTAL|AI CBT|AI CBT engine will make recommendations to step-down or step-up intensity of CBT FU based on what patient reports and what other similar patients report. Stepped care model.
62240146|NCT05294354|EXPERIMENTAL|aerobic exercise with virtual reality group (AE-VR)|35-min cycling at moderate intensity (50-60% heart rate reserve) with 3D virtual reality.
62240147|NCT05294354|EXPERIMENTAL|combined exercise group (CE)|This 35-min exercise combines aerobic, bodyweight exercise, and meditation.
62240148|NCT05294354|ACTIVE_COMPARATOR|control group|It has a 35-minute video about exercise science.
62240149|NCT03889431|EXPERIMENTAL|Capsule group|Group one received iodine capsule
62240150|NCT03889431|EXPERIMENTAL|Iodized salt group|Group two received iodized salt
62240151|NCT01241552|EXPERIMENTAL|MK-3415 + SOC|Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI
62240152|NCT01241552|EXPERIMENTAL|MK-6072 + SOC|Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI
62430619|NCT06389474|PLACEBO_COMPARATOR|Placebo|Two doses of saline solution, 24 hours apart.
62430620|NCT00265083|EXPERIMENTAL|003|golimumab 100 mg sc injections every 4 wks from wk 0 up to 5 yrs
62430621|NCT00265083|PLACEBO_COMPARATOR|001|Golimumab (CNTO 148); placebo SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
62240153|NCT01241552|EXPERIMENTAL|MK-3415A + SOC|Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI
62240154|NCT01241552|PLACEBO_COMPARATOR|Placebo + SOC|Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI
62240155|NCT06397807||NALDEBAIN|Patients injected with dinalbuphine sebacate intramuscularly will be allocated to NALDEBAIN group.
62037974|NCT02464449|ACTIVE_COMPARATOR|Standard telephone CBT|Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
62240156|NCT06397807||CONTROL|Patients receiving postoperative pain management without dinalbuphine sebacate will be allocated to CONTROL group.
62430622|NCT00265083|EXPERIMENTAL|002|golimumab 50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
62430623|NCT00117585|OTHER|Treatment Phase 1|Stepped intervention consisting of treatment phase 1, 2 and 3. Subjects whose orthostatic hypotension is resolved after treatment phase 1 will not receive new treatments (phase 2 and 3)
62037975|NCT02625896|EXPERIMENTAL|Intervention|A sequence of free fall manoeuvres performed using the human body: A free fall velocity reduction prior to main parachute deployment followed by a head high body attitude prior to main parachute extraction.
62037976|NCT02625896|NO_INTERVENTION|Control|Normal main parachute extraction performed in a manner that is typical for the study participant.
62037977|NCT04166994|EXPERIMENTAL|IMPACT Intervention|Incorporate a rehabilitation approach to slowly increasing KT recipients' physical activity in addition to individualized dietary intervention at every post-transplant appointment through six months post-transplant, with follow-up at 12 months post-transplant.
62037978|NCT04166994|OTHER|Usual Care|No exercise or diet specialization.
62240157|NCT04699734|ACTIVE_COMPARATOR|Xylocaine|Nerve block
62240158|NCT04699734|PLACEBO_COMPARATOR|Isotonic saline|Nerve block
62240159|NCT00652392|EXPERIMENTAL|1|
62240160|NCT00652392|PLACEBO_COMPARATOR|2|
62240161|NCT05564871|EXPERIMENTAL|Occupation-based teleintervention|20 children and their parents will be participate in Occupation-based teleintervention.
62240162|NCT05564871|EXPERIMENTAL|Occupation-based in person intervention|20 children and their parents will be participate in Occupation-based in person intervention.
62816299|NCT03985761|ACTIVE_COMPARATOR|Home Telerehabilitation_Unenhanced (HTu)|The Home Telerehabilitation Motivation Enhanced (HTu) group will use the NJIT-HoVRS system to play a series of three games to train movement of their shoulder, elbow, wrist and fingers. The study team will set up the apparatus in their home at the initial visit and train them to use the system. After this, subjects will practice in their homes with on-line or in-person support as needed (once a week in person for the first month, and then an average of two times per month in person and two times per month on line). Subjects will be instructed to perform three of the simulations assigned to them as much as possible, but at least twenty minutes, daily for twelve weeks. The HTu group will use three simulations. Difficulty will be increased utilizing an adaptive control algorithm that increases difficulty based on performance. Difficulty changes are extremely incremental making them imperceptible for most subjects. Graphics and scoring do not change as difficulty level changes.
62816300|NCT01489540|ACTIVE_COMPARATOR|new diagnostic strategy|Combination of laser Doppler imaging and clinical assessment of burn depth
62240163|NCT02746666|EXPERIMENTAL|Intervention|Under pharmacist's behavioral intervention
62240164|NCT02746666|NO_INTERVENTION|Control|No pharmacist's behavioral intervention
62240165|NCT06062225|EXPERIMENTAL|Kamikawa reconstruction|Patients will be administered Kamikawa reconstruction after proximal gastrectomy.
62430624|NCT01726335|EXPERIMENTAL|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
62816301|NCT01489540|NO_INTERVENTION|current diagnostic strategy|Clinical assessment of burn depth
62816302|NCT05716958||Cancer group|Interpreted as BI-RADS 0 (Assessment Incomplete), BI-RADS 3 (Probably Benign), 4 (Suspicious) or 5 (Highly Suggestive of Malignancy) with a visible suspicious lesion for breast cancer on the DBT exam and confirmed as a cancer (malignant) through the subsequent biopsy conducted within following 1 year of the DBT exam.
62816303|NCT05716958||Non-Cancer group|"Negative Cases~▪ Interpreted as BI-RADS 0 (Assessment Incomplete) or BI-RADS 1 (Negative) with no cancers on the DBT exam and confirmed as BI-RADS 1 (Negative) on the further diagnostic imaging (e.g., MMG, DBT, MRI, CT and Ultrasound) taken at least after 1 year of the DBT exam.~Benign Cases~* Interpreted as BI-RADS 0 (Assessment Incomplete) or BI-RADS 2 (Benign) with a visible lesion on the DBT exam and confirmed as BI-RADS 2 (Benign) on the further diagnostic imaging (e.g., MMG, DBT, MRI, CT and Ultrasound) taken at least after 1 year of the DBT exam without a further breast biopsy.~* Or for the biopsy-proven benign exams, interpreted as BI-RADS 0 (Assessment Incomplete), BI-RADS 3 (Probably Benign), 4 (Suspicious) or 5 (Highly Suggestive of Malignancy) with a visible suspicious lesion for breast cancer on the DBT exam but confirmed as benign through subsequent biopsy conducted within following 1 year of the DBT exam."
62816304|NCT06594393|EXPERIMENTAL|TCP-25|Topical gel
62816305|NCT06594393|PLACEBO_COMPARATOR|Vehicle|Placebo gel
62816306|NCT02135861|EXPERIMENTAL|Healthy volunteers|All subjects will undergo MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.
62816307|NCT02135861|EXPERIMENTAL|Heart failure patients|All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system.
62816308|NCT02135861|EXPERIMENTAL|Acute decompensated heart failure|All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system
62819430|NCT06548230|EXPERIMENTAL|ARM 1B: Cycle 2-24 for non responder after Cycle 1 Combo|
62819431|NCT06548230|EXPERIMENTAL|ARM 2: Relapsed/refractory AML|
62819432|NCT06541990|EXPERIMENTAL|HARMONY|HARMONY is a psychoeducational intervention that consists of five one-on-one coaching sessions and a structured session workbook.
62037979|NCT06385457|EXPERIMENTAL|Intervention group|The intervention group will receive information about Mindhelper.dk and inspiration on how to use Mindhelper through text-messages during the study period.
62430625|NCT02383537||Pregnant women with diabetes|Pregnant women with diabetes type 1, type 2 or gestational diabetes
62430626|NCT02383537||Healthy pregnant women|Healthy pregnant women with no underlying illness
62816309|NCT02686372|EXPERIMENTAL|HBV/TCR-T cell infusion|Subjects enrolled in the experimental (treatment) group will receive escalating doses of HBV/ TCR expressing autologous T cells. The interval between the first two doses is 14 days, followed by one month of safety monitoring, before subsequent two doses of 1 month interval in between. Thereafter, subjects would enter into observation period of the safety and tolerability of the treatment and will be followed up until disease relapse.
62816310|NCT02686372|OTHER|No intervention and TCR-T (at crossover)|No intervention and to be crossover to experimental arm upon confirmation of disease recurrence.
62816311|NCT06487572|EXPERIMENTAL|Risankizumab Dose A for Intravenous (IV) Infusion|Participants will receive IV infusion of risankizumab at dose A and then followed for 140 days.
62816312|NCT06487572|EXPERIMENTAL|Risankizumab Dose B for Subcutaneous (SC) Injection|Participants will receive SC injections of risankizumab at dose B and then followed for 140 days.
62816313|NCT02647125|EXPERIMENTAL|Huachansu Arm|Patients in this arm will receive a treatment of Huachansu combined with thoracic radiotherapy.
62816314|NCT02647125|ACTIVE_COMPARATOR|Control Arm|Patients in this arm will receive thoracic radiotherapy alone.
62816315|NCT05555290|EXPERIMENTAL|Treatment A (PT027) [experimental], then Treatment B (PT007) [active comparator] Part 1 & 2|At Visit 2, participants will receive repeated oral inhalations of PT027 to treat acute airway obstruction induced by a repeated airway challenge, followed by a washout period of 10-14 days. At Visit 3, participants will receive repeated oral inhalations of PT007 to treat acute airway obstruction induced by a repeated airway challenge.
62816316|NCT05555290|EXPERIMENTAL|Treatment B (PT007) [active comparator], then Treatment A (PT027) [experimental] Part 1 & 2|At Visit 2, participants will receive repeated oral inhalations of PT007 to treat acute airway obstruction induced by a repeated airway challenge, followed by a washout period of 10 to 14 days. At Visit 3, participants will receive repeated oral inhalations of PT027 to treat acute airway obstruction induced by a repeated airway challenge.
62037980|NCT06385457|NO_INTERVENTION|Control group|The control group does not receive information about Mindhelper.dk, until after completion of the last follow-up questionnaire.
62037981|NCT02102087|EXPERIMENTAL|Initial Specimen Diversion Device (ISDD)|The ISDD will be used in conjunction with standard blood culture bottles.
62037982|NCT02102087|ACTIVE_COMPARATOR|Lab standard practice (LSP)|A standard blood culture kit will be used.
62037983|NCT02160587|ACTIVE_COMPARATOR|ZuraPrep|Irritation scores of the following applied to test sites will be compared: ZuraPrep, ZuraPrep without IPA, ChloraPrep, and 0.9% Physiological Saline.
62430627|NCT05578755|EXPERIMENTAL|Smartphone-based intervention|
62430628|NCT05578755|EXPERIMENTAL|Virtual reality intervention|
62037984|NCT03993769|EXPERIMENTAL|A19010-F, B19010-F Use Group|Use of product A19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
62430629|NCT05578755|ACTIVE_COMPARATOR|Goal-setting control condition|
62037985|NCT03993769|EXPERIMENTAL|B19010-F, A19010-F Use Group|Use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
62037986|NCT01384994|EXPERIMENTAL|FOLFOX + Panitumumab|
62037987|NCT01384994|ACTIVE_COMPARATOR|FOLFOX|
62430630|NCT06133699|EXPERIMENTAL|SLNB|
62430631|NCT04976049||Orthopedic infection|Subjects who have undergone previous trauma surgeries and have developed an infection will be assessed for protocol inclusion criteria. Patients will be administered a single, oral, 20mg/kg dose of 5-Aminolevulinic Acid (ALA) by a qualified member of their care team. This dose will be administered ideally 3 hours prior to surgery. Fluorescent imaging will be obtained pre and post irrigation and debridement.
62430632|NCT03165643||NGT-normal birth weight|
62430633|NCT03165643||NGT-macrosomia|
62816317|NCT01650506|EXPERIMENTAL|Erlotinib + Metformin|This is a single arm phase 1 study. All patients will receive erlotinib and metformin.
62816318|NCT05286814|EXPERIMENTAL|1/ HAIP +PDS01ADC+FOLFOX or FOLFORI|PDS01ADC+HAIP FUDR and Dexamethasone chemotherapy in combination with FOLFOX or FOLFIRI
62816319|NCT05286814|EXPERIMENTAL|2/HAIP +PDS01ADC+GemOx|PDS01ADC+HAIP FUDR and Dexamethasone chemotherapy in combination with GemOx
62816320|NCT06156020|OTHER|Endoscopic endonasal surgery|Patients who received endoscopic endonasal resection of pituitary adenomas
62819433|NCT06541990|ACTIVE_COMPARATOR|Enhanced usual care|The enhanced usual care condition consists of a curated list of supportive care services for patients with HCC.
62037988|NCT03568864|PLACEBO_COMPARATOR|Low nucleotide meal|Mixed meal containing mycoprotein with a reduced nucleotide content (\~ 2% nucleotides)
62240166|NCT06062225|ACTIVE_COMPARATOR|STJI reconstruction|Patients will be administered Single-Tract Jejunal Interposition(STJI) reconstruction after proximal gastrectomy.
62816321|NCT05950464|EXPERIMENTAL|Treatment (tuvusertib, BET bromodomain inhibitor ZEN-3694)|Patients receive tuvusertib and BET bromodomain inhibitor ZEN-3694 PO on study. Patients in the dose-escalation phase of the trial also undergo ECG during screening, collection of blood samples on study, and x-ray, CT, or MRI throughout the trial. Patients in the dose-expansion phase of the trial also undergo ECG during screening, biopsies during screening and on study, and x-ray, CT, or MRI, and collection of blood samples throughout the trial.
62816322|NCT04377100||Adults 18 and over|Adults 18 and over
62816323|NCT00500617||segment 1|Gene discovery blood draw
62816324|NCT00500617||sement 2|Assay development blood draw
62816325|NCT00500617||segment 3|Assay validation blood draw
62240167|NCT06062225|ACTIVE_COMPARATOR|SOFY reconstruction|Patients will be administered SOFY reconstruction after proximal gastrectomy.
62240168|NCT01386658|EXPERIMENTAL|Icatibant|Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
62816326|NCT00500617||segment 4|Additional assay testing blood draw (Note: post discovery diabetic subjects assigned to this group)
62816327|NCT02803788|ACTIVE_COMPARATOR|Group O|this group will receive inj. ondansetron 4mg iv stat and inj. dexamethasone 8mg iv stat just before extubation.
62816328|NCT02803788|EXPERIMENTAL|Group R|this group will receive inj. ramosetron 0.3mg iv stat just before extubation.
62037989|NCT03568864|EXPERIMENTAL|High nucleotide meal|Mixed meal containing mycoprotein with a high nucleotide content (\~ 10% nucleotides)
62240169|NCT01270087|OTHER|Adalimumab|
62240170|NCT02119325|EXPERIMENTAL|Test|Fibre rich Health Food Drink packed as 30g individual sachet, administered as a single serve in 200 mL of luke warm water
62240171|NCT02119325|PLACEBO_COMPARATOR|Placebo|No Fibre Health Food Drink packed as 25g individual sachet, administered as single serve in 200 mL of luke warm water
62816329|NCT00627393|EXPERIMENTAL|1|Participants will receive granulocyte transfusions in addition to standard antimicrobial therapy
62816330|NCT00627393|ACTIVE_COMPARATOR|2|Participants will receive standard antimicrobial therapy alone
62816331|NCT00627393|OTHER|3|Participants will donate granulocytes after receiving a combination of two drugs, G-CSF and dexamethasone
62816332|NCT06485635||Patients with a reimbursement of AF treatment|
62816333|NCT04719390|NO_INTERVENTION|No Message|Randomized at daily time point to NOT receive a text messaging intervention. Randomization probability for this arm is .20.
62037990|NCT04954118|ACTIVE_COMPARATOR|Group P|The clinicians performed an internal jugular vein cannulation using only personal protective equipment.
62037991|NCT04954118|ACTIVE_COMPARATOR|Group P&A|The clinicians performed an internal jugular vein cannulation using personal protective equipment and aerosol box.
62240172|NCT05257408|EXPERIMENTAL|Nab-paclitaxel 80 mg/m^2 with Relacorilant 150 mg|Patients receive nab-paclitaxel 80 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle in combination with intermittent relacorilant (150 mg relacorilant once daily on the day before, the day of, and the day after nab-paclitaxel), administered orally under fed conditions. Relacorilant will not be administered on Cycle 1 Day -1.
62240173|NCT05257408|ACTIVE_COMPARATOR|Nab-paclitaxel 100 mg/m^2|Patients receive nab-paclitaxel 100 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle.
62240174|NCT04410250|ACTIVE_COMPARATOR|Oral hygiene before tooth eruption|"The mothers of the newborns allocated to Group 1 will be instructed to clean the child's oral cavity by massaging the gingival rods with gauze and filtered water once a day at night.~Following the eruption of the child's first tooth, mothers will be instructed to brush twice a day with fluoride toothpaste (1100 ppm fluoride) in a minimum amount, equivalent to one grain of raw rice, using the Fones technique. circular movements in the buccal and lingual faces of all teeth (FONES, 1934)."
62430634|NCT03165643||GDM-normal birth weight|
62430635|NCT03165643||GDM-macrosomia|
62430636|NCT04714684|EXPERIMENTAL|fitostimoline proctogel|
62816334|NCT04719390|ACTIVE_COMPARATOR|Maternal Message|Randomized at daily time point to receive a maternal-focused message. Randomization probability for this arm is .40.
62816335|NCT04719390|ACTIVE_COMPARATOR|Drinking Message|Randomized at daily time point to receive a drinking-focused message. Randomization probability for this arm is .40.
62816336|NCT06705595|EXPERIMENTAL|Group T (Inhaled Lidocaine)|Participants will receive 2 ml of 10% lidocaine via a Tracheo-Spray device before anesthesia induction.
62816337|NCT06705595|EXPERIMENTAL|Group X (Lidocaine Applied to the Double-Lumen Tube):|Participants will receive 10% lidocaine sprayed directly onto the distal surface and cuffs of the double-lumen tube.
62816338|NCT06705595|SHAM_COMPARATOR|Group C (Control)|Participants will receive 1 ml of 0.9% saline as a placebo.
62816339|NCT01874639|EXPERIMENTAL|hepatectomy ( conventional hemostasis )|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~- Control group: hepatectomy with conventional hemostasis using standard bipolar coagulation"
62816340|NCT01874639|OTHER|hepatectomy with Aquamantys|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~- Test group: hepatectomy with Aquamantys®"
62816341|NCT06598969|EXPERIMENTAL|Single arm|This trial is designed to evaluate the antileukemic activity of an Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide conditioning regimen for allogeneic hematopoietic stem cell transplantation, in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia, as assessed by 2-year progression-free survival. The first 6-18 patients enrolled/treated in this study will be part of a safety sub-analysis, so patients will be assigned to the dose level that is currently open once they are verified to be eligible; up to three dose levels can be studied.
62816342|NCT05081882|EXPERIMENTAL|Kava Intervention|
62816343|NCT05081882|PLACEBO_COMPARATOR|Placebo Control|
62816344|NCT04333914|EXPERIMENTAL|Autophagy inhibitor (GNS651)|
62816345|NCT04333914|OTHER|Standard of care|
62037992|NCT01692782|EXPERIMENTAL|SEP-225289 4mg|SEP-225289 4mg once daily taken as a combination of SEP-225289 2mg and placebo capsules to achieve 4mg QD doses
62816346|NCT04333914|EXPERIMENTAL|anti-NKG2A (Monalizumab)|
62816347|NCT04333914|EXPERIMENTAL|anti-C5aR (Avdoralimab)|
62816348|NCT03858049|EXPERIMENTAL|Crinone|Participants received Crinone 8% (90 milligrams \[mg\] an intravaginal progesterone gel contained in a single use, one piece applicator) once daily in morning from the day of endometrial transformation (Day -5) until ongoing pregnancy was confirmed up to Day 63.
62816349|NCT03858049|EXPERIMENTAL|Crinone plus Duphaston|Participants received Crinone 8% (90 mg an intravaginal progesterone gel contained in a single use, one piece applicator) once daily in morning followed by 10 mg of Duphaston tablet orally twice a day from the day of endometrial transformation (Day -5) until ongoing pregnancy was confirmed up to Day 63.
62816350|NCT06491030|EXPERIMENTAL|Thoracolumosacral Orthosis|"Patients randomized to this arm will be fitted with an Aspen Medical Products Align PJK™ TLSO brace. This is a 3-point, rigid hyperextension TLSO brace which is currently FDA approved under a 510k exemption but not commercially available. With this brace, the sternal pad height/width and belt component will be adjusted to optimize patient position and comfort. The brace will also be fitted with an external temperature sensing probe. Patients will be instructed to wear the brace at all times, including when in bed for 6-weeks post-operatively. At the 6-week visit patients will be asked to self-report compliance with the brace"
62816351|NCT06491030|PLACEBO_COMPARATOR|No brace|"Patients in the control arm will be treated without a brace but will have no other differences in their post-operative treatment protocol. This will be considered usual care for the purposes of this study."
62240175|NCT04410250|EXPERIMENTAL|Absence of oral hygiene before tooth eruption|"The mothers of the newborns allocated to Group 2 will be advised not to perform any type of oral cavity cleaning of the newborn.~Following the eruption of the child's first tooth, mothers will be instructed to brush twice a day with fluoride toothpaste (1100 ppm fluoride) in a minimum amount, equivalent to one grain of raw rice, using the Fones technique. circular movements in the buccal and lingual faces of all teeth (FONES, 1934)."
62240176|NCT02512198|EXPERIMENTAL|Bronchodilators|"Prescription Data Feedback to GP Practices - practices will be fed back data for people with presumed asthma who have either been dispensed more than 12 short-acting beta-agonist bronchodilators in the last 12 months who are not concurrently prescribed inhaled corticosteroids (poor asthma control with inadequate prevention) or been dispensed a long-acting beta-agonist bronchodilator as a single agent in the last 12 months who are not or are only infrequently concurrently prescribed inhaled corticosteroids (potentially harmful prescribing). To minimise inclusion of people with COPD, patient aged 35 years and older prescribed long-acting antimuscarinic bronchodilators will be excluded.~Practices in the bronchodilator arm are controls for the antibiotic experimental arm (below)."
62240177|NCT02512198|EXPERIMENTAL|Antibiotics|"Prescription Data Feedback to GP Practices - number of women in the GP practice aged 12 years and older dispensed more than 6 courses of urinary tract infection (UTI) antibiotics in the last year. UTI antibiotics are defined as trimethoprim, nitrofurantoin, co-trimoxazole, quinolones and cefalexin.~Practices in the antibiotic arm are controls for the bronchodilator experimental arm (above)."
62240178|NCT02493894|EXPERIMENTAL|PEG & Cefazolin|patients firstly get liquid diet for 24 hours. After that they get PEG solution (80gr/1Litr) each 8 hours for 24 hours. After 48 hours, cefazolin 1gram, every 6hours for 2 days
62240179|NCT02493894|SHAM_COMPARATOR|placebo & cefazolin|placebo for PEG and cefazolin 1gram, every 6hours for 2 days
62240180|NCT02047825|EXPERIMENTAL|Experimental group|The patients included in this group will receive an intensive intervention based on upper limbs intervention with exercises added to the usual treatment they receive.
62430637|NCT04714684|EXPERIMENTAL|fitostimoline proctogel + muscle relaxants|
62430638|NCT04714684|EXPERIMENTAL|muscle relaxants|
62816352|NCT01102686|EXPERIMENTAL|Pyrimethamine|
62816353|NCT04684719|EXPERIMENTAL|Whole Blood|Subjects will receive up to two units of whole blood as collected by local blood bank procedures and stored at 1-6 degrees Celsius initiated in the prehospital phase of care.
62816354|NCT04684719|ACTIVE_COMPARATOR|Standard Care|Subjects will receive prehospital crystalloid infusion or blood component transfusion resuscitation per site standard care for the respective Emergency Medical unit/service.
62816355|NCT06655220|EXPERIMENTAL|Metformin hydrochloride alone (reference) followed by metformin hydrochloride + BI 1815368 (Test)|
62816356|NCT06655220|EXPERIMENTAL|Metformin hydrochloride + BI 1815368 (Test) followed by metformin hydrochloride alone (reference)|
62816357|NCT05014776|EXPERIMENTAL|Arm A - Tadalafil, Pembrolizumab, Ipilimumab, CRS-207|
62816358|NCT03467958|EXPERIMENTAL|Administration of oral Ozanimod|
62816359|NCT03157830||Ocrelizumab, OCREVUS|Patients eligible for this study will be receiving OCREVUS as part of their routine care for MS treatment, and undergo the standard monitoring tests and procedures for MS patients receiving treatment. In addition, they will complete the EDSS scale on 6 occasions over a 12-month period, and the MSIS-29 on three occasions during the 12 month period for research.
62816360|NCT05979064|EXPERIMENTAL|Laparoscopically harvested omental tissue autograft|Use of laparoscopically harvested omental autografts into the resection cavity of recurrent glioblastoma multiforme (rGBM) patients.
62037993|NCT01692782|EXPERIMENTAL|SEP-225289 8mg|SEP-225289 8mg once daily taken as a combination of SEP-225289 2mg and placebo to achieve 8mg QD doses
62037994|NCT01692782|PLACEBO_COMPARATOR|Placebo|4 capsules of placebo
62037995|NCT03686852|ACTIVE_COMPARATOR|group A|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A).
62597752|NCT02703272|EXPERIMENTAL|Part 2: Ibrutinib|Participants will either receive ibrutinib and RICE/RVICI background therapy or RICE/RVICI background therapy alone, until 3 cycles are completed or until PD or unacceptable toxicity during the treatment phase. Participants who received ibrutinib and RICE/RVICI background therapy and with PR or better only will receive ibrutinib alone for 3 cycles during post-treatment phase.
62597753|NCT02863107||Observational (questionnaire, biospecimen collection)|"PATIENTS: Patients complete questionnaires over 30-50 minutes about work, family history, medical history, health habits, and experience as a cancer survivor (quality of life, well-being, concerns, types of health care, and follow-up care received). Patients also undergo collection of blood or saliva samples. Active patients, who have undergone treatment at MD Anderson Cancer Center within the past year, complete additional questionnaires at enrollment, 6 months, 12 months after treatment completion, and then every years for up to 6 years. Also, active patients who are consented to the study more than 5 years from surgery, they may complete the survivorship questionnaire once. Patients medical records are also reviewed.~FAMILY MEMBERS: Participants complete questionnaires over 10-15 minutes. Participants also undergo collection of blood or saliva samples once."
62597754|NCT06124248|EXPERIMENTAL|Experimental group|RISE intervention and usual care
62240181|NCT02047825|ACTIVE_COMPARATOR|Control group|Patients with multiple sclerosis not included in the intensive intervention. They receive the usual treatment of occupational and physical therapy.
62240182|NCT01318720|EXPERIMENTAL|Manipulation|The experimental group is receiving thoracic spine thrust manipulation and cervical spine non-thrust manipulation.
62240183|NCT01047696|NO_INTERVENTION|Open fire|Households continuing to use an open fire for cooking and heating
62240184|NCT01047696|EXPERIMENTAL|Chimney stove|Households randomized to receive a chimney stove (plancha) for cooking and heating
62240185|NCT01116141|ACTIVE_COMPARATOR|Methotrexate (MTX) + Folic Acid|20 mg MTX weekly + 1 mg folic acid daily
62240186|NCT01116141|EXPERIMENTAL|0.3 mg CH-4051|0.3 mg CH-4051 daily
62430639|NCT01864473|OTHER|Kshar Sutra|
62430640|NCT02902380|EXPERIMENTAL|Dexmedetomidine Group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
62430641|NCT02902380|PLACEBO_COMPARATOR|Control Group|0.9% saline infusion
62430642|NCT04784845|EXPERIMENTAL|N. lactamica Y92-1009|Nasal inoculation with 10\^5 CFU N. lactamica in 1ml phosphate-buffered saline via pipette to both nostrils; single inoculation at 36+0 to 37+6 weeks gestation
62430643|NCT01318265|EXPERIMENTAL|Arm1|
62430644|NCT00751569||A1|A group of 3 to 5 pregnant women as donors for umbilical cord blood
62430645|NCT04496778|ACTIVE_COMPARATOR|low level laser plus exercise|acupuncture low level laser combined with nasal laser irradiation in addition to aerobic exercise 3 times per week for 3 months
62240187|NCT01116141|EXPERIMENTAL|1.0 mg CH-4051|1.0 mg CH-4051 daily
62240188|NCT01116141|EXPERIMENTAL|3.0 mg CH-4051|3.0 mg CH-4051 daily
62240189|NCT01116141|EXPERIMENTAL|3.0 mg CH-4051 + folic acid|3.0 mg CH-4051 + 1.0 mg folic acid daily
62240190|NCT04586595|EXPERIMENTAL|Intervention arm|GP trainees in this arm will receive the REVISiT intervention which will involve having their prescribing reviewed and feedback provided, at two time points (approximately 100 prescriptions at each time point) separated by approximately a 3-month time period.
62240191|NCT04586595|NO_INTERVENTION|Control arm|GP trainees in this arm will continue with training as usual and will have their prescribing (approximately 200 prescriptions) reviewed once but representing two time points - separated by an approximate 3-month time period. Feedback will occur at one time point, to cover the review for the 200 prescriptions.
62240192|NCT06010069||pre-frail patients|That patient group have clinical frailty scale scores 1,2 or 3 which is accepted as non-frail.
62597755|NCT06124248|NO_INTERVENTION|Control group|Usual care
62597756|NCT04774861||CCTA Group|This is an all-comers group, of all ages and ethnicities who have been evaluated with a CCTA from 2017-2020.
62816361|NCT06706024|EXPERIMENTAL|respiratory exercise program|A practical explanation was given about how to use the flow-oriented Intensive Spirometry Device (ICC) (Triflow) after the 3rd hour of the treatment in the HD unit. Each of the patients was given the same brand and model flow-focused intensive spirometer (Triflow) device for breathing exercise.
62816362|NCT02558894|EXPERIMENTAL|MEDI4736 monotherapy|MEDI4736 via IV infusion.
62816363|NCT02558894|EXPERIMENTAL|tremelimumab+MEDI4736|MEDI4736+tremelimumab via IV infusion.
62240193|NCT06010069||frail patients|That patient group have clinical frailty scale scores 4 or 5 which is accepted as frail.
62240194|NCT06010069||very frail patients|That patient group have clinical frailty scale scores 6,7,8 or 9 which is accepted as severly frail.
62240195|NCT05033808|PLACEBO_COMPARATOR|Placebo|Administration of NaCl i.v. as placebo once.
62430646|NCT04496778|PLACEBO_COMPARATOR|sham laser plus exercise|placebo acupuncture low level laser combined with nasal laser irradiation in addition to aerobic exercise 3 times per week for 3 months
62430647|NCT01205529|OTHER|AF with ST changes on ECG|Those patients with ST segment or J Point elevation on electrocardiogram. Can be on initial screening electrocardiogram or on electrocardiograms during procainamide infusion. These subjects will harbor cardiac sodium channel gene variants.
62037996|NCT03686852|ACTIVE_COMPARATOR|groppo B|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 150IU (Group B)
62240196|NCT05033808|EXPERIMENTAL|Epirubicin Phase I|Administration of epirubicin i.v. 3.75 mg/m2 once.
62430648|NCT03698318|EXPERIMENTAL|Subject sequence 1|Subject allocation sequence 1. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
62430649|NCT03698318|EXPERIMENTAL|Subject sequence 2|Subject allocation sequence 2. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
62430650|NCT03698318|EXPERIMENTAL|Subject sequence 3|Subject allocation sequence 3. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
62430651|NCT03698318|EXPERIMENTAL|Subject sequence 4|Subject allocation sequence 4. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
62597757|NCT05923242|EXPERIMENTAL|Computerized Intervention Authoring Software (CIAS)|Participants will be provided with a link to begin the study following consent, and the link will direct the participants to a baseline survey. At the end of the survey, participants will be automatically redirected to Computerized Intervention Authoring Software (CIAS). Participants will be encouraged to complete 2 sessions in CIAS, approximately 1 week apart. After completing the second session, CIAS will automatically redirect the participants to a post-test survey. Approximately 30 days after completing the second session, participants will be invited to complete a 30 day follow-up survey.
62597758|NCT00199797|EXPERIMENTAL|huA33 antibody plus chemotherapy|"huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2 for 12 weeks.~Starting on day 15 and continuing every second week, oxaliplatin, 5-fluorouracil (5-FU) and leucovorin were also administered.~Oxaliplatin and leucovorin were given as infusions over 2 hours. Afterwards, patients received a bolus infusion of 5-FU intravenously followed by an infusion of 5-FU over 22 hours.~The doses of oxaliplatin were 85mg/m2, leucovorin 200mg/m2, 400mg/m2 of 5-FU as a bolus infusion and 600mg/m2 as a continuous infusion.~A complete treatment cycle consisted of 12 weeks. Patients were eligible to receive an additional cycle in the absence of dose-limiting toxicity (DLT), immunogenicity (huA33 human anti-human antibodies {HAHA}) and disease progression."
62597759|NCT04962724|EXPERIMENTAL|Radiolabeled Xevinapant Oral Solution|"Participants will receive:~• single oral dose of \[14C\]-xevinapant, as an oral solution"
62597760|NCT04962724|EXPERIMENTAL|Radiolabeled Xevinapant Intravenous Solution + Xevinapant Oral Solution|"Participants will receive:~• single oral dose of xevinapant, as an oral solution followed by an IV bolus of \[14C\]-xevinapant, solution for infusion"
62240197|NCT05033808|EXPERIMENTAL|Epirubicin Phase II|Administration of epirubicin i.v. 7.5 mg/m2 once.
62430652|NCT03698318|EXPERIMENTAL|Subject sequence 5|Subject allocation sequence 5. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
62240198|NCT05033808|EXPERIMENTAL|Epirubicin Phase III|Administration of epirubicin i.v. 15 mg/m2 once.
62240199|NCT06118125||2019|patients diagnosed in 2019
62240200|NCT06118125||2020|patients diagnosed in 2020
62240201|NCT06379308||Patient with Anterior Cruciate Ligament (ACL) revision|Patient with Anterior Cruciate Ligament (ACL) revision will be included. Questionary will be administrated and datas will be collected by medical record.
62430653|NCT03698318|EXPERIMENTAL|Subject sequence 6|Subject allocation sequence 6. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
62240202|NCT05061563|EXPERIMENTAL|Period 1|A single dose of elinzanetant and an additional IV (microtracer dose) of \[13C5\]BAY 3427080 will be administered.
62430654|NCT03698318|EXPERIMENTAL|Subject sequence 7|Subject allocation sequence 7. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
62430655|NCT03698318|EXPERIMENTAL|Subject sequence 8|Subject allocation sequence 8. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
62597761|NCT00534079|EXPERIMENTAL|Dornase alfa|28 days of sinonasal inhalation (Pari Sinus)
62597762|NCT00534079|PLACEBO_COMPARATOR|isotonic saline|28 days of sinonasal inhalation (Pari Sinus)
62597763|NCT06591884|EXPERIMENTAL|0.08% tacrolimus nanoencapsulated aqueous solution spray|tacrolimus modified-release
62597764|NCT06591884|ACTIVE_COMPARATOR|0.1% free tacrolimus commercial ointment|
62240203|NCT05061563|EXPERIMENTAL|Period 2|Once daily oral dose of esomeprazole and a single oral dose of elinzanetant will be administered.
62240204|NCT05229926||Patient Group|Patients who previously were hospitalized during the COVID-19 pandemic, receiving mock care inside the CareCube
62597765|NCT00006024|EXPERIMENTAL|Pre and Post radiation Chemotherapy|
62816364|NCT04855552|EXPERIMENTAL|Single-Arms Longitudinal Group|Behavioral weight-loss program via telehealth (video conferencing). Participants will receive weekly group sessions of lifestyle counseling for the first 20-weeks, followed by every other week sessions in weeks 22 and 24, for a total of 6-months of intervention.
62816365|NCT05250505|EXPERIMENTAL|Treatment Arm|The Treatment Arm receives the eShunt Implant.
62240205|NCT05229926||Patient Caregiver Group|Caregivers/family/friends of patients previously hospitalized during the COVID-19 pandemic, communicating with the patient inside the CareCube
62240206|NCT05229926||Heathcare Provider Group|Physicians, Certified Registered Nurse Anesthetists, RNs, Certified Nursing Assistants who will perform routine clinical care tasks, including passing food and medicines, drawing blood, inserting an IV. To simulate intubation, a mannequin will be used.
62240207|NCT00711256|ACTIVE_COMPARATOR|1|No sunscreen applied
62430656|NCT03698318|EXPERIMENTAL|Subject sequence 9|Subject allocation sequence 9. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
62430657|NCT03698318|EXPERIMENTAL|Subject sequence 10|Subject allocation sequence 10. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
62430658|NCT05089240|OTHER|20-29 years (+0.40D extra power)|
62430659|NCT05089240|OTHER|30-35 years (+0.40D extra power)|
62816366|NCT00882440|PLACEBO_COMPARATOR|1|Placebo
62816367|NCT00882440|EXPERIMENTAL|2|Losartan 10 mg
62816368|NCT00882440|EXPERIMENTAL|3|Losartan 25 mg
62240208|NCT00711256|ACTIVE_COMPARATOR|2|Sunscreen applied 0.5 mg/cm2
62240209|NCT00711256|ACTIVE_COMPARATOR|3|Sunscreen applied 1mg/cm2
62240210|NCT00711256|ACTIVE_COMPARATOR|4|Sunscreen applied 2mg/cm2
62240211|NCT04273698|EXPERIMENTAL|Clinical intervention|The project involved recruiting families, with children under the age of five years old, who were experiencing one or more difficulties, and these families were offered five therapeutic sessions, based on a psychodynamic parent-infant psychotherapy approach.
62240212|NCT01121978|NO_INTERVENTION|Conservative treatment group|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole or vision deterioration occurs
62430660|NCT05089240|OTHER|20-29 years (+0.40D extra power with blue cut)|
62430661|NCT04463277|EXPERIMENTAL|Calorie Restriction|
62430662|NCT04463277|EXPERIMENTAL|Time Restricted Feeding|
62816369|NCT00882440|EXPERIMENTAL|4|Losartan 50 mg
62816370|NCT00882440|EXPERIMENTAL|5|Losartan 100 mg
62816371|NCT00882440|EXPERIMENTAL|6|Losartan 150 mg
62816372|NCT00882440|ACTIVE_COMPARATOR|7|Enalapril 20 mg
62816373|NCT04698343|EXPERIMENTAL|Noninvasive Peripheral Nerve Stimulation (NPNS)|NPNS device programmed to deliver active stimulation.
62816374|NCT06190093|EXPERIMENTAL|ONS-5010 bevacizumab|
62816375|NCT06190093|ACTIVE_COMPARATOR|ranibizumab|
62816376|NCT05317403|OTHER|AML without Down Syndrome|The subject receives 2 courses of therapy approximately 35 days each. Venetoclax: Days 1-14 Azacitidine and Vorinostat: Days 1-5 Filgrastim Days: 5 start and continue until post-nadir ANC \> 500 cells/mm3 Fludarabine and Cytarabine Days 6 - 10 IT Cytarabine Day 0 or 1, optional between day 35 and 42
62816377|NCT05317403|OTHER|AML with Down Syndrome|The subject receives 2 courses of therapy approximately 35 days each. Venetoclax: Days 1-14 Azacitidine and Vorinostat: Days 1-5 Filgrastim Days: 5 start and continue until post-nadir ANC \> 500 cells/mm3 Fludarabine and Cytarabine Days 6 - 10 IT Cytarabine Day 0 or 1, optional between day 35 and 42
62240213|NCT01121978|EXPERIMENTAL|Early vitrectomy|Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine green dye assisted internal limiting membrane peeling
62816378|NCT05615818|EXPERIMENTAL|Experimental|Molecular targeted therapy matched to genetic alteration carried by the tumour
62816379|NCT05615818|ACTIVE_COMPARATOR|Control|Continued standard of care treatment for first-line biliary tract cancer
62816380|NCT04974671|EXPERIMENTAL|Stereotactic Body Radiation Therapy|
62816381|NCT01598935|PLACEBO_COMPARATOR|Control|placebo
62816382|NCT01598935|ACTIVE_COMPARATOR|High protein intake|Nutrition - High protein
62240214|NCT03956368|EXPERIMENTAL|Treatment Group|Randomised on the day of admission to receive oral Atorvastatin 20mg daily for 8 weeks.
62240215|NCT03956368|PLACEBO_COMPARATOR|Control Group|Randomised on the day of admission to receive placebo 20mg daily for 8 weeks.
62597766|NCT02726438|EXPERIMENTAL|Debio 1450|"Participants will receive 3 oral administrations of Debio 1450 at a dose of 240 mg approximately 12 hours apart. The last dose should be given approximately 2, 4, 6 or 12 hours prior to surgery with 3 patients each to be dosed at each of these time points.~If the surgery is delayed by more than 12 hours postdose, the patients could receive up to 2 additional administrations (approximately 12 hours apart) to ensure that the last dose is administered between 2 and 12 hours before the surgery."
62240216|NCT03598322|ACTIVE_COMPARATOR|Dextrose 1mL|Dextrose injection, Dextrose 1mL, active comparator
62240217|NCT03598322|EXPERIMENTAL|Dextrose 2mL|Dextrose injection, Dextrose 2mL
62597767|NCT02726438|NO_INTERVENTION|Calibration|A single participant will not receive the study drug, providing data to be used as calibration.
62597768|NCT06622811|EXPERIMENTAL|Nursing students group|Nursing students will be scheduled to apply educational program of virtual reality to improve their critical thinking disposition.
62597769|NCT03815591|EXPERIMENTAL|adolescents between ages of 10-16|Adolescents given a pre-post survey to measure the effect of the game and building that into the smokeSCREEN video game to anonymously collect information on players' perspectives, beliefs, attitudes, intentions, social norms, and behaviors around tobacco use, and collaborating with youth programs to pilot test how the game can be implemented in real world settings.
62816383|NCT01598935|ACTIVE_COMPARATOR|Low protein intake|Nutrition - Low protein
62240218|NCT03598322|EXPERIMENTAL|Dextrose 4mL|'Dextrose injection, Dextrose 4mL
62240219|NCT03619538|PLACEBO_COMPARATOR|control group|
62240220|NCT03619538|EXPERIMENTAL|Nefopam group|
62240221|NCT02921269|EXPERIMENTAL|Treatment (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62240222|NCT05783102|EXPERIMENTAL|KINDER Intervention|KINDER is a 9-week psychoeducational intervention.
62240223|NCT01480453||Trabecular Metal Humeral Stem|Patients requiring primary, total or hemi shoulder arthroplasty who receive the Trabecular Metal Humeral Stem.
62430663|NCT04463277|EXPERIMENTAL|Time Restricted Feeding with Calorie Restriction|
62597770|NCT06619158|EXPERIMENTAL|Group A|Crown modification with glaze removal and polish of implant crown
62816384|NCT01598935|ACTIVE_COMPARATOR|Medium protein intake|Nutrition - Medium protein
62816385|NCT03924622|EXPERIMENTAL|Group 1: Mepilex on Litter + AE Mattress + 30 degree backrest|Intervention: Mepilex
62240224|NCT04638582|EXPERIMENTAL|Neoadjuvant pembrolizumab + adjuvant pembrolizumab +/- adjuvant chemotherapy|"Neoadjuvant: Participants receive pembrolizumab \[200 mg, intravenous (IV)\] every 3 weeks for 3 cycles.~Adjuvant: Participants receive pembrolizumab \[400 mg IV\] every 6 weeks for 6 cycles, and may receive histology-specific adjuvant chemotherapy \[consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2\] every 3 weeks for 4 cycles, if indicated."
62430664|NCT04463277|NO_INTERVENTION|Control|
62430665|NCT02775461||Hereditary Pancreas Cancer Syndrome|Patients that have a diagnosis or any family history of a hereditary pancreas cancer syndrome, such as, but not limited to, Familial Pancreatic Cancer, hereditary pancreatitis, FAMMM syndrome, FAP and its variants, HNPCC (Lynch syndrome), Peutz-Jeghers syndrome, or BRCA1 and/or BRCA2 germline mutations.
62430666|NCT02775461||Personal or FHx of Pancreas Cancer or Pancreas Cysts|Patients that have personal or family history of pancreatic cancer or pancreatic cysts.
62430667|NCT02775461||Inflammatory Pancreatic Diseases|Patients that have a personal or family history of pancreatic dysplasia or inflammatory pancreatic diseases.
62816386|NCT03924622|NO_INTERVENTION|Group 2: Without Mepilex on Litter + AE mattress + backrest|Intervention: Control (no Mepilex)
62816387|NCT03924622|EXPERIMENTAL|Group 3: Mepilex on VSB on AE mattress|Intervention: Mepilex
62430668|NCT04192617|EXPERIMENTAL|SM03 600 mg*2|SM03: 600 mg intravenous (IV) on week 0,2, and week 12,14; placebo: 600 mg intravenous (IV) on week 4 and16; Methotrexate: 7.5-20 mg/wk oral.
62816388|NCT03924622|NO_INTERVENTION|Group 4: Without Mepilex on VSB on AE mattress|Intervention: Control (no Mepilex)
62816389|NCT03924622|EXPERIMENTAL|Group 5 Prolonged Field Care (PFC) - LiquiCell on Talon litter|Intervention: LiquiCell mat
62816390|NCT03924622|NO_INTERVENTION|Group 6: PFC Without LiquiCell on Talon Litter|Intervention: Control (no LiquiCell)
62816391|NCT06580496|EXPERIMENTAL|Mightier|Ad lib use of child biofeedback video game play and CBT-based offscreen program materials in home
62816392|NCT05292326|EXPERIMENTAL|PacePress|the patients will be dressed with PacePress medical device instead of a standard compression device
62816393|NCT05292326|ACTIVE_COMPARATOR|standard compression band/tourniquet|standard treatment with respect to preventing hemorrhagic complications and implantation site inflammation, the patients will be dressed with a standard compression device/sand bag
62816394|NCT05272683|EXPERIMENTAL|GLPG3667 + itraconazole|
62816395|NCT06005688|EXPERIMENTAL|Vepdegestrant with and without Carbamazepine|Vepdegestrant administered as a single dose in Period 1 and Period 2. Carbamazepine administered once a day for 19 days in Period 2.
62037997|NCT03686852|ACTIVE_COMPARATOR|Group C|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 250IU (Group C) of recFSH (Puregon®, MSD).
62037998|NCT06530940||Group 1|consisting of 90 patients with SS and confirmed xerostomia by SF measurement (\<0.1 ml/minute).
62037999|NCT06530940||Group 2|consisting of 90 patients with SS and normal SF (≥0.1 ml/minute).
62038000|NCT06540066|EXPERIMENTAL|Phase 1a Part A: Dose Escalation (BGB-B3227 Monotherapy)|Sequential cohorts of increasing dose levels of BGB-B3227 will be evaluated as monotherapy.
62038001|NCT06540066|EXPERIMENTAL|Phase 1a Part B: Dose Escalation (BGB-B3227 + tislelizumab)|Sequential cohorts of increasing dose levels of BGB-B3227 will be evaluated in combination with tislelizumab.
62038002|NCT06540066|EXPERIMENTAL|Phase 1b: Dose Expansion|Sequential cohorts of increasing dose levels of BGB-B3227 will be evaluated in combination with tislelizumab and chemotherapy.
62038003|NCT04681612||MINOCA|Patients hospitalised with MINOCA according to the recently published consensus document of ESC after cardiac MRI confirmation.
62038004|NCT02261493|EXPERIMENTAL|OnabotulinumtoxinA Dose A|OnabotulinumtoxinA Dose A injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
62240225|NCT04638582|EXPERIMENTAL|Neoadjuvant pembrolizumab and chemotherapy + adjuvant pembrolizumab +/- adjuvant chemotherapy|"Neoadjuvant: Participants receive pembrolizumab \[200 mg, intravenous (IV)\] every 3 weeks for 3 cycles in combination with standard of care histology-specific chemotherapy \[consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2\] every 3 weeks for 3 cycles.~Adjuvant: Participants receive pembrolizumab \[400 mg IV\] every 6 weeks for 6 cycles, and may receive histology-specific adjuvant chemotherapy \[consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2\] every 3 weeks for 4 cycles, if indicated."
62240226|NCT00947778|ACTIVE_COMPARATOR|session of training 1|Arm from which members will perform their training session after the first session of evaluation
62240227|NCT00947778|ACTIVE_COMPARATOR|Session of training 2|Arm from which members will perform their training session after the second session of evaluation
62240228|NCT01635465||Observation group:vinorelbine plus capecitabine|
62240229|NCT01635465||Control group:docetaxel plus capecitabine|
62240230|NCT05193240|EXPERIMENTAL|preliminary swallowing test|compared as nasofibroscopy and ultrasound examination of vocal cords
62430669|NCT04192617|EXPERIMENTAL|SM03 600 mg*3|SM03: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16; Methotrexate: 7.5-20 mg/wk oral.
62430670|NCT04192617|PLACEBO_COMPARATOR|placebo*3|placebo: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16; Methotrexate: 7.5-20 mg/wk oral.
62597771|NCT06619158|NO_INTERVENTION|Group B|No intervention will be applied. The crown will be removed and superficially cleaned
62240231|NCT03106181|ACTIVE_COMPARATOR|Cataract surgery|Conventional phacoemulsification cataract surgery and intraocular lens implantation
62038005|NCT02261493|EXPERIMENTAL|OnabotulinumtoxinA Dose B|OnabotulinumtoxinA Dose B injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
62430671|NCT02230085||CPAP therapy|
62430672|NCT06337630|EXPERIMENTAL|Single arm: treatment with PLX038 and Tuvusertib|"Dose escalation step Dose escalation will be conducted on the grid defined by the 4 doses of PLX038 (800 mg/m², 1000 mg/m², 1300 mg/m² and 1700 mg/m² IV every 21 days D1=D22) and 3 doses of Tuvusertib (90 mg, 130 mg and 180 mg QD for 10 days from D3, D3-12). Premedication with anti-emetic agents is not required prior to the initial infusion, but may be used for an individual patient, as needed.~Expansion cohorts Two expansion cohorts are planned, investigating the efficacy and safety in pre-specified populations of interest.~Patients will be treated at the RP2D; 25 evaluable patients are needed in each cohort, to account for possible non evaluable patients, up to 28 patients will be enrolled in each cohort.~Patients enrolled in the phase I part at the RP2D and fulfilling the eligibility criteria of one of the expansion cohorts will be counted in those 25 evaluable patients."
62430673|NCT06381427|NO_INTERVENTION|Standard group|In this group, the anesthesiological risk evaluation is generally conducted in accordance with the current guidelines. Possible additional (instrumental) examinations, intraoperative anesthesiological management, and postoperative inpatient therapy are carried out according to current guidelines and are unaffected by study participation. If services are provided in the control group within the local standards that are also part of the new care model, these will be documented to ensure comparability.
62597772|NCT01179841|EXPERIMENTAL|Playgroup and Parent Training|"1. One to two-hour individual therapeutic sessions with parent training in the home or clinic, 1x every week over six months;~2. parent training/enrichment once a week in our clinic for 20 sessions at 1-2 hours;~3. a playgroup session for 1-2 hours 2x week for 6 months in our clinic and~4. Community treatment as usual."
62597773|NCT01179841|ACTIVE_COMPARATOR|Parent Training|"1. Parent enrichment sessions once a week for 20 sessions (for 1-2 hours)~2. Community treatment as usual."
62597774|NCT01125670|EXPERIMENTAL|fast-fed sequence group|
62038006|NCT02261493|PLACEBO_COMPARATOR|Placebo followed by OnabotulinumtoxinA Dose A|Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria, the subject will receive up to 2 treatments with onabotulinumtoxinA Dose A into the protocol-specified areas.
62038007|NCT03432975|EXPERIMENTAL|Povidone Iodine 10%|The side of the mouth receiving the subgingival irrigations of povidone iodine.
62038008|NCT03432975|PLACEBO_COMPARATOR|Sterile saline solution|The other side of the mouth will be irrigated with a sterile saline solution.
62038009|NCT00508066|EXPERIMENTAL|Arm 1|Subjects in arm 1 will intraoperatively have a continuous infusion catheter placed in the paraspinal musculature of the posterior spinal wound. Post-operatively, the catheter will infuse 0.25 - 0.5% (according to patient's weight) Bupivacaine at a rate of 4ml/hr for 72 hours. This is in addition to the standardized PCA pain management.
62240232|NCT03106181|EXPERIMENTAL|Cataract surgery plus iStent inject®|Conventional phacoemulsification cataract surgery and lens implantation plus insertion of iStent inject®
62240233|NCT04095078|EXPERIMENTAL|SIMEOX|Use the device for 3 months in addition to usual care
62240234|NCT04095078|NO_INTERVENTION|Control|Usual care
62430674|NCT06381427|ACTIVE_COMPARATOR|Intervention group|A cardiology consultation is conducted, which includes a standardized evaluation. This includes, medical history and physical examination:ECG, Echocardiography, Determination of cardiac troponins and natriuretic peptides in the local central laboratory. The echocardiography aims to qualitatively and quantitatively describe the left and right ventricular systolic and diastolic dimensions and function, as well as the valvular apparatus, the collected findings are presented at the interdisciplinary and intersectoral preoperative medical (POM) conference. Bedside visits with the patient are also possible.During this conference, structured preoperative interdisciplinary and intersectoral case discussions take place, involving the attending outpatient physicians. The POM conference consists of Anesthesiology, Cardiologist, Treating surgeon and optimize preoperative therapy and plan further pre-, intra-, and postoperative as well as outpatient care.
62816396|NCT06220032|EXPERIMENTAL|Arm A|"Standard R-CHOP 21 treatment regimen:~6 cycles R-CHOP 21 (rituximab\*, cyclophosphamide, doxorubicin, vincristine, prednisolone)~\*The use of a biosimilar is allowed."
62038010|NCT00508066|PLACEBO_COMPARATOR|Arm 2|Subjects in arm 2 will intraoperatively have a continuous infusion catheter placed in the paraspinal musculature of the posterior spinal wound. Post-operatively, the catheter will infuse normal saline at a rate of 4ml/hr for 72 hours. This is in addition to the standardized PCA pain management.
62038011|NCT04899830|EXPERIMENTAL|Installation of a telepresence robot in the home of a disabled person hospitalized in a PRM center|From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,...)
62038012|NCT01247142||Invasive pulmonary aspergillosis (IPA)|Patients with proven or probable invasive pulmonary aspergillosis (IPA) (EORTC/MSG criteria) or putative IPA (Blot et al. Am J Respir Crit Care Med 2012)
62816397|NCT06220032|EXPERIMENTAL|Arm B -|"Addition of the cardioprotectant dexrazoxane to the R-CHOP 21 regimen:~R-CHOP21 (rituximab\*, cyclophosphamide, doxorubicin, vincristine, prednisolone plus dexrazoxane).~\*The use of a biosimilar is allowed."
62816398|NCT04390880|EXPERIMENTAL|PEt/CT arm|Subjects receive a PET/CT scan.
62816399|NCT05493891||Group A|40 participants have been exposed to cesarean delivery
62816400|NCT05493891||Group B|15 participants have been exposed to vaginal delivery
62038013|NCT01247142||Controls|Patients without signs of infection.
62038014|NCT04468438||50 patients with LN with regular menstrual cycle|1- First group of50 patients with regular menstrual cycle
62038015|NCT04468438||50 patients with LN with amenorrhea|2- Second group of 50 patients with amenorrhea.
62038016|NCT04943198|EXPERIMENTAL|R1 time of vemurafenib treatment|vemurafenib will be given to 6 months after BRAF negativization
62240235|NCT04436237|EXPERIMENTAL|Non-visual exproprioception training|The training requires the participant to place the foot at a target without visual cues of the foot in virtual environment.
62240236|NCT04436237|ACTIVE_COMPARATOR|Visual exproprioception group|The training requires the participant to place the foot at a target with visual cues of the foot in virtual environment.
62240237|NCT03656978|ACTIVE_COMPARATOR|Dynamic|Keep moving the probe for needle tip visualization during the puncture procedure.
62240238|NCT03656978|PLACEBO_COMPARATOR|Regular-triangle|Needle access along the hypotenuse of the regular triangle formed by the vascular depth and puncture point.
62240239|NCT05528250||İndividuals with do regular physical activity|International Physical Activity Questionnaire (IPAQ)-Short Form ,Anthropometric Measurements and Evaluation Body Weight and Height, Electromyogram (EMG), Digital Dynamometer measurement ,Static Balance Measurements ,Dynamic Balance Measurements ,Tecnobody Balance Measurement , Mini-Balance Evaluation (MiniBESTest) Systems Test ,Y Balance Test ,Flamingo Balance Test ,Modified Borg Scale will be applied to individuals with do regular physical activity is declared.
62240240|NCT05528250||Sedentary individuals with do not have regular physical activity|International Physical Activity Questionnaire (IPAQ)-Short Form ,Anthropometric Measurements and Evaluation Body Weight and Height, Electromyogram (EMG), Digital Dynamometer measurement ,Static Balance Measurements ,Dynamic Balance Measurements ,Tecnobody Balance Measurement , Mini-Balance Evaluation (MiniBESTest) Systems Test ,Y Balance Test ,Flamingo Balance Test ,Modified Borg Scale will be applied to sedentary individuals with do not have regular physical activity is declared.
62240241|NCT01297413|EXPERIMENTAL|Stem cells|All subjects will receive allogeneic adult mesenchymal bone marrow stem cells
62240242|NCT01556035|EXPERIMENTAL|Lenalidomide treatment|
62240243|NCT03516851|ACTIVE_COMPARATOR|Precision bypass group|Using ICG with Flow800 software and multimodal neuronavigation to choose the recipient vessel
62240244|NCT03516851|NO_INTERVENTION|Empirical group|choosing the recipient vessel by the surgeon's own experience
62240245|NCT03434353|EXPERIMENTAL|Group 1: Inarigivir Soproxil 50 mg + TAF|Viremic participants will be administered inarigivir soproxil 50 mg (2 x 25 mg capsules) once daily orally 1 hour before or 1 hour after a meal plus TAF 25 mg tablet once daily orally with food for 12 weeks followed by TAF 25 mg tablet once daily orally with food for 36 weeks.
62240246|NCT03434353|EXPERIMENTAL|Group 2: TAF|Viremic participants will be administered TAF 25 mg tablet once daily orally with food for 48 weeks.
62038017|NCT04943198|EXPERIMENTAL|R2 time of vemurafenib treatment|vemurafenib will be given to 12 months after BRAF negativization
62240247|NCT03434353|EXPERIMENTAL|Group 3: Inarigivir Soproxil 200 mg + TAF|Viremic participants will be administered inarigivir soproxil 200 mg (2 x 100 mg tablets) once daily orally 1 hour before or 1 hour after a meal plus TAF 25 mg tablet once daily orally with food for 12 weeks followed by TAF 25 mg tablet once daily orally with food for 36 weeks
62240248|NCT03434353|EXPERIMENTAL|Group 4: Inarigivir Soproxil 100 mg + commercially available NUCs|Virally suppressed participants receiving commercially available nucleoside/nucleotide (NUC) will be administered inarigivir soproxil 100 mg tablet once daily orally 1 hour before or 1 hour after a meal for 12 weeks. Participants will continue commercially available NUCs for 48 weeks.
62240249|NCT03434353|EXPERIMENTAL|Group 5: Inarigivir Soproxil 400 mg + TAF|Viremic participants will be administered inarigivir soproxil 400 mg (2 x 200 mg tablets) once daily orally 1 hour before or 1 hour after a meal plus TAF 25 mg tablet once daily orally with food for 12 weeks followed TAF 25 mg tablet once daily orally with food for 36 weeks.
62240250|NCT03259594|EXPERIMENTAL|endophytic group|participants are with endophytic renal cyst and undergo laparoscopic deroofing.2 day before laparoscopic deroofing, they were given intravenous 100 g of amino acids supplementation.
62240251|NCT03259594|SHAM_COMPARATOR|exophytic group|participants are with exophytic renal cyst and undergo laparoscopic deroofing.2 day before laparoscopic deroofing, they were given intravenous 100 g of amino acids supplementation.
62430675|NCT03816800|PLACEBO_COMPARATOR|Placebo-Allergic|Over the course of 6 months allergic participants receive twice daily a placebo tablets.
62038018|NCT03491761|EXPERIMENTAL|PRP Treatment|PRP is injected using 22 gauge needles through the classic approach (lateral midpatellar) in a sterile setting. The PRP is obtained from a maximum 16 cc sample of the patients' blood drawn at the time of treatment. Using sterile technique, the venous blood is transferred to a centrifuge and prepared by the centrifugation process for 5 minutes. 4-7 mL of PRP is transferred from the large outer syringe into the small inner syringe and injected within 30 minutes of being spun to negate the need of anticoagulants. The procedure will take approximately 20-30 minutes.
62240252|NCT01118325|EXPERIMENTAL|AZD6140 45 mg bd|
62240253|NCT01118325|EXPERIMENTAL|AZD6140 90 mg bd|
62240254|NCT01118325|ACTIVE_COMPARATOR|Clopidogrel 75 mg od|
62240255|NCT00523718|EXPERIMENTAL|riluzole|Patients randomized to this arm will receive riluzole augmentation, at a standard, fixed dose (50 mg bid), in addition to the medication regimen they are on at enrollment
62240256|NCT00523718|PLACEBO_COMPARATOR|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from riluzole, in addition to the medication regimen they are on at study enrollment.
62240257|NCT02087748|ACTIVE_COMPARATOR|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
62240258|NCT02087748|PLACEBO_COMPARATOR|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
62430676|NCT03816800|ACTIVE_COMPARATOR|Active-Allergic|Over the course of 6 months allergic participants receive twice daily a dietary supplement containing whey protein-bound, chelated iron.
62430677|NCT02444156|EXPERIMENTAL|Exercise training|All participants will receive usual care, including standard advice about diet and physical activity. In addition to usual care, participants will be asked to take part in a 12-week exercise programme. Participants will use an indoor rower (Concept 2, Model E) three times per week at Leicester Diabetes Centre. Each session will be supervised and the investigators will liaise with the participants to arrange convenient times to exercise, including mornings and evenings. The supervisors will teach the participants how to row correctly.
62430678|NCT06176859|EXPERIMENTAL|Home-based PrEP|In the home-based PrEP arm, participants will complete the HIV self-test at home with support received through telemedicine or over the phone. Confirmation of HIV test result will be shared with the provider through a photograph of the test. PrEP refills will be delivered to participants at home by courier.
62816401|NCT05493891||Group C|40 participants who were in the control negative group (no previous pregnancy),
62038019|NCT03491761|ACTIVE_COMPARATOR|HA Treatment|HA is injected using 22 gauge needles through the classic approach (lateral midpatellar) in a sterile setting. Euflexxa will be prepared according to the package insert.
62038020|NCT01855776|OTHER|Control Group|"The control group will receive a usual care educational programme at baseline created by the Singapore Health Promotion Board. This guide describes the importance of physical activity and illustrates one possible physical activity programme. It also discusses strategies for adopting a healthy lifestyle. They will not receive the Fitbit Zip wireless pedometer from the study team. However, they will receive $4 per week, regardless of physical activity levels."
62240259|NCT04097522|ACTIVE_COMPARATOR|real neurofeedback|Participants receive neurofeedback from a region of the brain thought to be associated with increasing pain resilience
62240260|NCT04097522|SHAM_COMPARATOR|sham neurofeedback|Participants receive neurofeedback from a region of the brain thought to be unrelated with increasing pain resilience
62240261|NCT01521819|EXPERIMENTAL|Iray plus Lucentis|open label arm in which all subjects receive a single 16 gy dose of radiation plus an injection of Lucentis.
62597775|NCT01125670|EXPERIMENTAL|fed-fast sequence group|
62816402|NCT05457790|ACTIVE_COMPARATOR|1/Immediate Intervention Group|1-week baseline data collection period followed by an 8-week ACT intervention period focusing on acceptance, cognition defusion (i.e., not letting thoughts about sleep control behavior), present moment awareness, perspective taking, values, and committed actions.
62816403|NCT05457790|ACTIVE_COMPARATOR|2/Waitlist Control Group|1-week baseline data collection period followed by 8 weeks of maintaining usual routine followed by an 8-week intervention focusing on acceptance, cognition defusion (i.e., not letting thoughts about sleep control behavior), present moment awareness, perspective taking, values, and committed actions.
62816404|NCT04986007|EXPERIMENTAL|digital Cognitive Behavioral Therapy for Insomnia|Following baseline evaluation, participants in this group will receive 8 weeks of digital Cognitive Behavioral Therapy for Insomnia delivered using Sleep Healthy Using the Internet (SHUTi). After the interim assessment, participants will then crossover to 8 weeks of active monitoring.
62240262|NCT05678322|EXPERIMENTAL|Patients with PSA > 0.2 ng/ml following Radical Prostatectomy|Men will be eligible for the study when their post-prostatectomy PSA level is initially observed to be PSA \>0.2ng/ml. All participants will receive a baseline rhPSMA-7.3 (18F) MRI scan within a month of enrollment, and the second rhPSMA-7.3 (18F) scan will be performed within a year of the initial scan. Only those participants with rhPSMA-7.3 (18F) identifiable disease during the initial scan will be offered salvage intervention per standard of care. All participants with a negative initial rhPSMA-7.3 (18F) scan will undergo a second scan when the PSA\> 0.5 ng/ml or one year after the initial PET scan. The salvage intervention will be at the discretion of the investigator.
62240263|NCT01770912|PLACEBO_COMPARATOR|Lactated Ringers|1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.
62597776|NCT03360006|EXPERIMENTAL|ABBV-744 Dose Escalation|ABBV-744 will be administered at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
62816405|NCT04986007|NO_INTERVENTION|Waitlist Control|Following baseline evaluation, participants in this group will undergo weekly monitoring of insomnia and suicidal ideation for 8 weeks. Participants will continue whatever treatments they are currently receiving, but will receive no specific instructions or behavioral interventions for insomnia. After the interim assessment, participants will then crossover to receive digital Cognitive Behavioral Therapy for Insomnia.
62816406|NCT04866810|EXPERIMENTAL|1|Intervention
62816407|NCT04866810|OTHER|2|Control- Standard diet and Exercise
62816408|NCT04058938|ACTIVE_COMPARATOR|Control|The control group received standard of care, including standard patient counseling from the surgical teams.
62816409|NCT04058938|EXPERIMENTAL|Intervention|In conjunction with oncologic psychology and plastic surgery, an instrument was developed to be provided as a single-paged paper handout to the intervention group. The instrument included information about expectations for pain control, information about the pain scale, and examples of opioid and adjunct medications which may be used as part of a multi-modal approach to pain control during the perioperative period.
62816410|NCT06092749|ACTIVE_COMPARATOR|Transgrade technique (TG)|
62816411|NCT06092749|ACTIVE_COMPARATOR|Interlaminar technique (IL)|
62816412|NCT06594757|ACTIVE_COMPARATOR|Standart Manual Toothbrush (SMB)|Conventional toothbrushing with standart manual toothbrush
62240264|NCT01770912|ACTIVE_COMPARATOR|Triamcinolone acetonide|1 cc of triamcinolone acetonide (20 mg) injected once after the TMJ rinsing procedure.
62240265|NCT03174990||Aspirin responsive|The participant is shown to be responsive to platelet activity inhibition by aspirin, as determined by testing with VerifyNow
62430679|NCT06176859|ACTIVE_COMPARATOR|Community-based PrEP|In the community-based PrEP arm, participants will be tested using rapid diagnostic tests (RDT) in person (at a community venue) or through telemedicine (at a community venue) where they will be linked by counsellor telephonically to nurse or clinician. PrEP refills will be collected by participants at a community venue.
62430680|NCT02615379|EXPERIMENTAL|Transdermal Continuous Oxygen Therapy|EPIFLO® working study unit, all day, every day for 2 weeks + standard wound care
62430681|NCT02615379|NO_INTERVENTION|Standard of care|standard wound care for 2 weeks
62430682|NCT00958815||HIV-seronegative with no CVD risk factors|Healthy, 35-60 yr old HIV-seronegative men and women with no CVD risk factors (normal fasting glucose tolerance, normal fasting lipid/lipoprotein levels, normotensive, waist circumference \<102cm (men) and \<88cm (women).
62597777|NCT03360006|EXPERIMENTAL|ABBV-744 Dose Expansion|ABBV-744 will be administered at the recommended Phase 2 dose determined during the Dose Escalation phase.
62597778|NCT04484636|OTHER|Hepatocellular Cancer|molecular profiling - hepatocellular cancer (HCC)
62597779|NCT04484636|OTHER|Cholangiocarcinoma|molecular profiling - intra- and extrahepatic cholangiocellular carcinoma (CCA)
62597780|NCT04484636|OTHER|Gallbladder Cancer|molecular profiling - gallbladder carcinoma (GBCA)
62816413|NCT06594757|EXPERIMENTAL|Triple-Headed Manual Toothbrush (3HB)|Toothbrushing with triple-headed manual toothbrush
62816414|NCT03111303||HAP patients|Mechanical ventilation, patients fulfilled HAP criteria
62816415|NCT03111303||non HAP patients|Mechanical ventilation, patients without HAP
62816416|NCT03310138|ACTIVE_COMPARATOR|Dorsolateral Prefrontal Cortex|"Intervention: Real Transcranial Magnetic Stimulation~Real Transcranial Magnetic Stimulation will be delivered to the left dorsolateral prefrontal cortex (10Hz, 110% of resting motor threshold) using a MagVenture MagPro B60 coil."
62430683|NCT00958815||HIV+ with CVD risk factors|35-60 yr old HIV-infected men and women with insulin resistance, dyslipidemia, hypertension, and central adiposity.
62430684|NCT03150030||Patients with type 2 diabetes|Insulin-treated type 2 diabetes with diabetic complications
62816417|NCT03310138|ACTIVE_COMPARATOR|Motor Cortex|"Intervention: Real Transcranial Magnetic Stimulation~Real Transcranial Magnetic Stimulation will be delivered to the left primary motor cortex (10Hz, 80% of resting motor threshold) using a MagVenture MagPro B60 coil."
62430685|NCT03150030||Healthy controls|Healthy control subjects
62597781|NCT04484636|OTHER|Pancreatic Cancer|molecular profiling - pancreatic cancer (PanCa)
62597782|NCT04484636|OTHER|Oesophageal Cancer + Stomach Cancer|molecular profiling - esophagogastric cancer (EC/GC)
62430686|NCT01174641|EXPERIMENTAL|TMS intervention|Trans-cranial magnetic stimulation will be applied at a 1Hz rate for 20min over the ipsilesional posterior parietal cortex of patients showing left neglect after a right hemisphere stroke
62430687|NCT01174641|PLACEBO_COMPARATOR|Placebo TMS|1 Hz trans-cranial magnetic stimulation will be applied over the vertex
62597783|NCT01961895|ACTIVE_COMPARATOR|Intravenous patient-controlled analgesia|Intravenous morphine solution 0.2 mg / ml in PCA mode without basal infusion, 1mg bolus demand and lockout of 8 minutes.
62816418|NCT03310138|PLACEBO_COMPARATOR|Sham stimulation|"Intervention: Sham Transcranial Magnetic Stimulation~Sham Transcranial Magnetic Stimulation will be delivered to the prefrontal cortex (10Hz, 110% of resting motor threshold) using the integrated sham system on the MagVenture MagPro B60 coil."
62816419|NCT01704027|EXPERIMENTAL|Radiotherapy|Patient will receive a pelvic and prostatic simultaneous integrated boost intensity-modulated arctherapy (SIB-IMAT) in combination with three years of androgen deprivation
62816420|NCT04657679|ACTIVE_COMPARATOR|African American/Black|Subject who self identify as African American or Black with metastatic HR+/HER2- advanced breast cancer (estimate 3 participants who are CYP3A5 poor metabolizers and approximately 15 participants who are CYP3A5 intermediate or normal metabolizers)
62430688|NCT02343016||Near-InfraRed Spectroscopy (NIRS)|The NIRS Group will be monitored with the interventional system (NIRS) and with the standard one (ecodoppler)
62430689|NCT06537518|ACTIVE_COMPARATOR|IV anesthetic Group|
62816421|NCT04657679|ACTIVE_COMPARATOR|Non-Hispanic White|Subjects who self-identify as non-Hispanic White with metastatic HR+/HER2- advanced breast cancer (estimate 3 participants who are CYP3A5 poor metabolizers and approximately 15 participants who are CYP3A5 intermediate or normal metabolizers)
62816422|NCT05845385|ACTIVE_COMPARATOR|lumbar epidural analgesia with bupivacaine|For postoperative analgesia; Lumbar epidural catheter inserted at L3-4 or L4-5 epidural space before anesthesia induction in the sitting position. After the end of surgery but approximately 20 minutes before extubation, 0.125% bupivacaine 20 ml administered through epidural catheter and the catheter was removed.
62430690|NCT06537518|ACTIVE_COMPARATOR|Local anesthetic Group|
62430691|NCT06537518|ACTIVE_COMPARATOR|Control Group|
62430692|NCT05329415||Diabetic Group (Cases)|"1. Subject aged 18 years of age or over~2. Written, informed consent obtained.~3. New diagnosis of tuberculosis and starting on anti-tuberculosis treatment~4. Known diagnosis of diabetes or a raised IFCC HbA1c level (\>= 48 mmol/mol) at the time of TB diagnosis"
62430693|NCT05329415||Non-Diabetic Group (Controls)|"1. Subject aged 18 years of age or over~2. Written, informed consent obtained.~3. New diagnosis of tuberculosis and starting on anti-tuberculosis treatment~4. IFCC HbA1c level \< 48mmol/mol and no known diagnosis of diabetes"
62597784|NCT01961895|EXPERIMENTAL|Continuous lumbar plexus (LP) block analgesia|"Continuous lumbar plexus (LP) block analgesia. Continuous infusion of a solution of 0.1% bupivacaine in PCA mode, programmed at 8 ml / h.~Rescue bolus 5 ml and 30 minutes lockout"
62816423|NCT05845385|ACTIVE_COMPARATOR|transversus abdominis plane block with bupivacaine|For postoperative analgesia; After the end of surgery but before extubation, USD-guided TAP block was performed with 0.125% bupivacaine 20 ml to the anatomic neurofacial space between the internal oblique and transersus abdominis muscles, bilaterally (10 ml for each side).
62816424|NCT05845385|ACTIVE_COMPARATOR|wound infiltration with bupivacaine|For postoperative analgesia; After the end of surgery but before extubation, 0.125% bupivacaine 20 ml administered to the surgical incision site.
62816425|NCT04467983|ACTIVE_COMPARATOR|Denosumab alone|3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.
62240266|NCT03174990||Aspirin non-responsive|The participant is shown to be non-responsive to platelet activity inhibition by aspirin, as determined by testing with VerifyNow
62430694|NCT05003583|EXPERIMENTAL|Experimental Condition|Speaking while viewing images with negative and neutral valence
62430695|NCT04060654|EXPERIMENTAL|SUBLOCADE|All subjects will receive SUBLOCADE 300mg on Day 1, followed by injections every 4 weeks at a dose determined by the Investigator (either 100 mg or 300 mg) for up to 5 total injections
62597785|NCT06618950|NO_INTERVENTION|Control Group|
62597786|NCT06618950|EXPERIMENTAL|Intervention|
62597787|NCT02175134|NO_INTERVENTION|conventional diagnostic flow arm|Perform the laparoscopic biopsy as a discretion of attending physician's decision
62816426|NCT04467983|ACTIVE_COMPARATOR|Combination therapy|3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.
62038021|NCT01855776|EXPERIMENTAL|Programme Only Group|This group receives the Fitbit Zip, and access to the Fitbit website. Fitbit Zip counts the number of steps walked, calories burned, and distance travelled. Participants can set goals for their physical activity levels, and will have access to personalised feedback from Fitbit. This group will also receive $4 per week, regardless of physical activity levels.
62038022|NCT01855776|EXPERIMENTAL|Cash Incentive Group|"This group receives the Fitbit Zip and the opportunity to earn money each week based on the number of steps logged on the pedometer during that week. We will offer the following incentive schedule:~* $0 SGD for less than 50,000 steps during the week~* $15 SGD for 50,000 - 69,999 steps during the week (max of 20,000 steps per day)~* $30 SGD for 70,000 or more steps during the week (max of 20,000 steps per day) Participants will receive monthly payments in cash after their physical activity is confirmed. The incentive will be calculated separately for each week of the 6-month incentive programme."
62038023|NCT01855776|EXPERIMENTAL|Charitable Incentive Group|This group is identical to the cash incentive group except that incentive payments will be donated directly to a tax-exempt nonprofit charity of the participant's choice. The charity will be selected at the start of the programme but will be limited to the most common tax-exempt nonprofit charities operating in Singapore. As a motivational feedback component of the programme, participants will receive a thank-you email or letter from the charity.
62430696|NCT02373735|ACTIVE_COMPARATOR|Group A (SVV <10% group)|"* infuse crystalloid (Hartmann's solution) 6-10 ml/kg/hr continuously during surgery~* infuse colloid (Volulyte) 200 ml if SVV is ≥ 10% during the surgery~Interventions: crystalloid (Hartmann's solution), colloid (Volulyte)"
62038024|NCT06487455|EXPERIMENTAL|SPH7485|
62038025|NCT06664918|EXPERIMENTAL|4-step milk ladder|
62038026|NCT06664918|ACTIVE_COMPARATOR|6-step milk ladder|
62038027|NCT02031887|EXPERIMENTAL|Infant starter formula with synbiotics|Infant starter formula with synbiotics
62038028|NCT02031887|ACTIVE_COMPARATOR|Infant formula without synbiotics|Infant formula without synbiotics
62430697|NCT02373735|EXPERIMENTAL|Group B (SVV 10-20% group)|"* infuse crystalloid (Hartmann's solution) 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy~* infuse colloid (Volulyte) 200 ml if SVV is \> 20%~* infuse mannitol 0.5 g/kg or lasix 5 mg if SVV \< 10%~Interventions: crystalloid (Hartmann's solution), colloid (Volulyte), mannitol, lasix"
62430698|NCT00363129|EXPERIMENTAL|Arm I|Patients receive oral vitamin E twice daily beginning within 4 days of the start of chemotherapy course 1 and continuing until 1 month after completion of chemotherapy.
62430699|NCT00363129|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo twice daily beginning within 4 days of the start of chemotherapy course 1 and continuing until 1 month after completion of chemotherapy.
62430700|NCT02277795|EXPERIMENTAL|AccuCirc|"The AccuCirc procedure is performed according to manufacturer instructions: http://www.clinicalinnovations.com/site_files/files/AccuCirc_IFUs.pdf~Before the surgery, the mother (and father, if available) will be counseled on benefits and risks of EIMC in their language of choice (English, Kiswahili, DhoLuo). At least one parent/guardian will provide documented informed consent using IRB-approved Consent Form. Providers will record demographic and locator information and EIMC eligibility criteria. If the infant is eligible for EIMC, the provider will perform the procedure and document the outcome of the surgery on a post-operative form. Information recorded will include: amount and type of anesthesia provided, intra-operative adverse event and outcome, and procedure start and end time."
62038029|NCT05799755|PLACEBO_COMPARATOR|Placebo plus Standard of Care, then Nintedanib plus Standard of Care|Placebo twice a day (BID) plus standard of care (SOC) Immunosuppressive Therapy for 12 weeks followed by open-label Nintedanib 150 mg BID + SOC Immunosuppressive Therapy for additional 12 weeks.
62430701|NCT02379832||Cases|Nulliparous women recruited at diagnosis of preeclampsia No intervention, only observation of biochemical and ultrasonographic markers at recruitment and at delivery N= 45
62240267|NCT03174990||Clopidogrel responsive|The participant is shown to be responsive to platelet activity inhibition by clopidogrel, as determined by testing with VerifyNow
62240268|NCT03174990||Clopidogrel non-responsive|The participant is shown to be responsive to platelet activity inhibition by clopidogrel, as determined by testing with VerifyNow
62240269|NCT01019291|EXPERIMENTAL|NO2|NO2 400 µg/m3
62430702|NCT02379832||Control|Nulliparous women recruited at the beginning of pregnancy. No intervention, only observation of biochemical and ultrasonographic markers at recruitment (1st trimester), 3 other times during pregnancy (2nd and 3rd trimester) and at delivery N= 45
62597788|NCT02175134|EXPERIMENTAL|two-step algorithm-based approach|"Perform the laparoscopic biopsy as a discretion of attending physician's decision, but if the below conditions are met, do not perform the laparoscopic biopsy.~1. Blood ELISPOT \>= 6 spots or ascites adenosine deaminase \> 20 IU/L, and~2. Ascites ELISPOT/Blood ELISPOT rato \> 3"
62240270|NCT01019291|EXPERIMENTAL|Formaldehyde|Formaldehyde 100 µg/m3
62597789|NCT02018172||Zomacton® treatment with Zomajet® Vision X device|
62597790|NCT04889157|EXPERIMENTAL|PF-06882961|Participants will be titrated up to 6 weeks of the 8-week dosing duration to reach desired dose level 120 mg
62597791|NCT04889157|PLACEBO_COMPARATOR|Placebo|Placebo
62038030|NCT05799755|ACTIVE_COMPARATOR|Nintedanib plus Standard of Care|Nintedanib 150 mg BID + SOC Immunosuppressive Therapy for 12 weeks followed by open-label Nintedanib 150mg BID + SOC Immunosuppressive Therapy for additional 12 weeks.
62038031|NCT05836493||Ring annuloplasty|
62240271|NCT01019291|EXPERIMENTAL|NO2 + Formaldehyde|mixture of Formaldehyde and NO2
62240272|NCT01019291|PLACEBO_COMPARATOR|Placebo|
62038032|NCT05836493||Suture procedure|
62240273|NCT04379648|OTHER|Posttraumatic stress disorder|cohort of patients with Posttraumatic stress disorder PTSD
62240274|NCT03872232|EXPERIMENTAL|Ezetimibe/Rosuvastatin and Telmisartan|"60 subjects will be assigned and the subjects will be administered Ezetimibe/Rosuvastatin and Telmisartan for 8 weeks."
62240275|NCT03872232|ACTIVE_COMPARATOR|Ezetimibe/Rosuvastatin|"60 subjects will be assigned and the subjects will be administered Ezetimibe/Rosuvastatin for 8 weeks."
62240276|NCT03872232|ACTIVE_COMPARATOR|Telmisartan|"60 subjects will be assigned and the subjects will be administered Telmisartan for 8 weeks."
62240277|NCT02870699|EXPERIMENTAL|ARM A|"* Evonail film forming solution : 1 daily application on the left hand~* Placebo excipient : 1 daily application on the right hand"
62240278|NCT02870699|ACTIVE_COMPARATOR|ARM B|"* Evonail film forming solution : 1 daily application on the right hand~* Placebo excipient : 1 daily application on the left hand"
62597792|NCT00346047|PLACEBO_COMPARATOR|0|
62597793|NCT00346047|EXPERIMENTAL|1|
62240279|NCT03073226|EXPERIMENTAL|Barrett's surveillance Olympus Spectrum|Barrett's surveillance with Olympus Spectrum.
62240280|NCT03073226|EXPERIMENTAL|Barrett's Surveillance Olympus Elite|Barrett's surveillance with Olympus ELITE.
62240281|NCT03073226|EXPERIMENTAL|Polyp Surveillance Olympus Spectrum|Colonic polyp surveillance/screening with Olympus Spectrum.
62240282|NCT03073226|EXPERIMENTAL|Polyp Surveillancewith Olympus ELITE.|Colonic polyp surveillance/screening with Olympus ELITE.
62430703|NCT02639819|EXPERIMENTAL|Treatment|Study drug
62430704|NCT02537067|EXPERIMENTAL|Autologous cultured Chondrocyte|Subjects who give consent will be screened and those who meet trial criteria will receive CHONDRON (Autologous cultured Chondrocyte) by transplant.
62430705|NCT00738010|EXPERIMENTAL|KH|Kneehab is a garment integrated NMES device with multipath technology.
62430706|NCT00738010|ACTIVE_COMPARATOR|PS|Poli-Stim, a standard NMES device, used for 3 times per day, five days per week for 12 weeks.
62597794|NCT01490606|EXPERIMENTAL|knee OA project|12 sessions of PT, 6 INDIVIDUAL AND 6 GROUP TREATMENTS
62597795|NCT01490606|NO_INTERVENTION|conventional PT|
62430707|NCT00738010|ACTIVE_COMPARATOR|CO|Control group performed voluntary muscle contractions for 20 minutes 3 times per day, 5 days per week for 12 weeks.
62597796|NCT01864876|EXPERIMENTAL|GLA-AF|5 mcg GLA-AF given as one subcutaneous injection.
62597797|NCT01864876|EXPERIMENTAL|GLA-SE|5 mcg GLA-SE given as one intramuscular injection.
62816427|NCT04861597|EXPERIMENTAL|Internet-based cognitive behavioral therapy|The iCBT platform selected for use in this study (Sanvello™) is an evidence-based mobile app created by clinical experts that has been shown to decrease depression, anxiety, and stress and to increase self-efficacy in a non-IBD population.15 App features include: daily mood tracking; guided journeys (e.g. psychoeducational content providing background information about cognitive behavioral therapy and instructing users on how to use app tools to maintain motivation and interest); coping tools (e.g. meditation, goal setting, and negative thought redirecting activities); weekly progress assessments; community support board.
62240283|NCT02577952||People with Lipodystrophy & family|People currently living with lipodystrophy and their family members.
62240284|NCT05932004|OTHER|Reformer pilates group|Reformer pilates
62240285|NCT05932004|OTHER|Control group|intervention waiting group
62816428|NCT04861597|ACTIVE_COMPARATOR|Digital mood tracking|The digital mood tracking application (app) selected for this study (PixelTM) allows participants to log their mood each day by way of a facial expression emoji and a free-text box. This app is commercially available free of charge through iOS and Android app stores with English and Spanish language options.
62240286|NCT01630434|EXPERIMENTAL|OCS Lung (Treatment Group)|The OCS Lung, which is a portable, integrated platform designed to maintain adult donor lungs in a normothermic state through continuous normothermic perfusion and ventilation, will be used to preserve and transport donor lungs.
62240287|NCT01630434|ACTIVE_COMPARATOR|Cold flush and storage (Control Group)|Donor lungs will be preserved using cold flush and storage (control group)
62240288|NCT02281279|EXPERIMENTAL|Treatment (rituximab, romidepsin, lenalidomide)|Patients receive rituximab IV over 90 minutes on day 1; romidepsin IV over 4 hours on either day 1, days 1 and 8, or days 1, 8, and 15; and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62240289|NCT03370471|EXPERIMENTAL|Healthy Older Adults|"Participants complete all four interventions~Retrieval Practice + Moderate Intensity Exercise: Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)~Retrieval Practice + Gentle Stretching: Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)~Study Only + Moderate Intensity Exercise: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)~Study Only + Gentle Stretching: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)"
62240290|NCT03370471|EXPERIMENTAL|Individuals with Aphasia|"Participants complete all four interventions~Retrieval Practice + Moderate Intensity Exercise: Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)~Retrieval Practice + Gentle Stretching: Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)~Study Only + Moderate Intensity Exercise: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)~Study Only + Gentle Stretching: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)"
62240291|NCT01409863|NO_INTERVENTION|laser and standard diamond fraise dermabrasion|laser and standard diamond fraise dermabrasion
62240292|NCT01708122|EXPERIMENTAL|Fentanyl|Subjects will receive either 0.5mL or 1 mL of intranasal fentanyl (50mcg or 100mcg)
62430708|NCT01145703|ACTIVE_COMPARATOR|RDA Vitamin D|
62430709|NCT01145703|EXPERIMENTAL|Vit D repletion + 6M Supplementation|
62430710|NCT01145703|EXPERIMENTAL|Vit D repletion + 6M Supplementation +AEX|
62430711|NCT01145703|EXPERIMENTAL|Vit D repletion + 6M Supplementation +RT|
62816429|NCT06338774|EXPERIMENTAL|Cognitive Control: Neutral (CC-N)|Game-like cognitive training program that they will run themselves at home up to 5 times per week. A game-like experience begins, where the participant is encouraged to earn points and in-game rewards to advance. In this condition, all the stimuli presented are neutral (not emotionally valenced). After each session, the difficulty of the next session is updated.
62430712|NCT02170701|EXPERIMENTAL|BIBR 1048|Ascending doses (in mg) given twice daily
62430713|NCT04168047|OTHER|Healthy volunteers|
62597798|NCT01864876|EXPERIMENTAL|EM060G (SE)|EM060G (SE) given as one intramuscular injection.
62597799|NCT04505722|EXPERIMENTAL|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S at a dose level of 5\*10\^10 virus particles (vp) as single dose vaccine on Day 1. At Year 1 (booster visit), participants who previously received any coronavirus disease-2019 (COVID-19) vaccination (as primary regimen or additional dose) will be offered a single booster dose of Ad26.COV2.S at the 5\*10\^10 vp dose level.
62816430|NCT06338774|EXPERIMENTAL|Cognitive Control: Emotionally Valenced (CC-E)|Game-like cognitive training program that they will run themselves at home up to 5 times per week. A game-like experience begins, where the participant is encouraged to earn points and in-game rewards to advance. In this condition, all the stimuli presented within the tasks are emotionally valenced.
62816431|NCT06338774|ACTIVE_COMPARATOR|Casual Games|Composed of 6 commercially available computer games. It matches the experimental treatment program in overall program use intensity, time-spent attending, delivered rewards, and overall engagement.
62430714|NCT04168047|OTHER|Patients with insomnia|
62430715|NCT04168047|OTHER|Patients with irritable bowel syndrome|
62430716|NCT04168047|EXPERIMENTAL|Patients with irritable bowel syndrome and insomnia|
62430717|NCT06536491|EXPERIMENTAL|EC-104 high dose|Intravitreal implant of fluocinolone acetonide
62597800|NCT04505722|EXPERIMENTAL|Placebo|Participants will receive IM injection of placebo on Day 1. At Month 6/unblinding visit, post Emergency Use Authorization (EUA), conditional licensure, or approval for the single dose regimen, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S vaccine IM at a dose level of 5\*10\^10 vp. At Year 1 (booster visit), participants who previously received any COVID-19 vaccination (as primary regimen or additional dose) will be offered a single booster dose of Ad26.COV2.S at the 5\*10\^10 vp dose level.
62816432|NCT06560385|ACTIVE_COMPARATOR|Active arm|Subjects will receive 1 sachet of BLHK03 daily from the start of the chemotherapy cycle to 2 months after the final dose of chemotherapy.
62816433|NCT06560385|PLACEBO_COMPARATOR|Placebo arm|Subjects will receive 1 sachet of active placebo daily from the start of the chemotherapy cycle to 2 months after the final dose of chemotherapy.
62240293|NCT01708122|PLACEBO_COMPARATOR|Placebo|Subjects will receive either 0.5mL or 1 mL of intranasal saline as placebo.
62240294|NCT04710888|EXPERIMENTAL|basil extract mucoadhesive gel|10 patients treated with mucoadhesive gel containing 2% of basil extract 4 times per day (test group) for 20 min after every meal and before going to bed.
62240295|NCT04710888|PLACEBO_COMPARATOR|mucoadhesive placebo gel|10 patients treated by mucoadhesive gel without drug which was used as placebo (contains tragacanth gum, alcohol, sodium benzoate, and distilled water) 4 times per day
62240296|NCT04710888|SHAM_COMPARATOR|healthy patients|10 healthy patients will be selected to participate in the study to test the salivary level of endocan in the healthy individuals (negative control group)
62240297|NCT02936063|EXPERIMENTAL|Surgical staples|Skin closure with surgical staples
62240298|NCT02936063|EXPERIMENTAL|Sutures|Skin closure with subcuticular sutures
62430718|NCT06536491|EXPERIMENTAL|EC-104 low dose|Intravitreal implant of fluocinolone acetonide
62430719|NCT06536491|ACTIVE_COMPARATOR|Dexamethasone intravitreal implant|Marketed product
62430720|NCT00613678|ACTIVE_COMPARATOR|1|Exercise + Education: Eight group sessions (8-15 people) during which participants engage in muscular strength and flexibility exercises. In addition, weekly educational lectures on topics germane to osteoarthritis management are included.
62430721|NCT00613678|EXPERIMENTAL|2|Exercise + Activity Strategy Training: 7/8 sessions will be in a group format in which participants engage in muscular strength \& flexibility exercises and listen to education lessons on management strategies for osteoarthritis. The remaining session includes a home assessment by an occupational therapist to facilitate adequate participation in daily living and leisure activities.
62430722|NCT02930109|EXPERIMENTAL|PTX-200 and cytarabine|"PTX-200 administered intravenously over 1 hour~Phase I: 4 dose levels: 25 to 55 mg/m2 (with reduction to 15 mg/m2 if needed.~Phase II: maximum tolerated dose. given as a 1 hour infusion~Cytarabine administered by continuous infusion at a dose of 400 mg/m2/day for 4 days."
62430723|NCT00507182|EXPERIMENTAL|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
62597801|NCT05919472|EXPERIMENTAL|Pre-treatment group|Participants assigned to this group will receive 200 mg oral iron on alternate days on study days 1-56.
62597802|NCT05919472|EXPERIMENTAL|Simultaneous treatment group|Participants assigned to this group will receive placebo on alternate days on study days 1-28 and 200 mg oral iron on alternate days on study days 29-56.
62819434|NCT03397966|EXPERIMENTAL|BNP, then placebo|At Study Visit 1, subjects will receive an IV infusion of recombinant human b-type natriuretic peptide (BNP (1-32), nesiritide) for 240 minutes. After a washout period of at least 2 weeks, subjects then present for Study Visit 2, where they will receive an IV infusion of placebo (control, normal saline) for 240 minutes.
62240299|NCT01794364|EXPERIMENTAL|Experimental: Cohort A|Each subjects in Cohort A will receive 2 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-06291874 will be administered in Period 4 in the fed state.
62240300|NCT04897269|NO_INTERVENTION|Control group|In the control group, the patients will be indicated with standard protocol, micronized progesterone (Cyclogest pessary) 400mg two times per day for 14 days, without any progesterone supplementation. If the beta-hcg test is positive, the patients will be treated with the same protocol and followed till 7 weeks of pregnancy when the fetal heart can be confirmed
62430724|NCT04603937|EXPERIMENTAL|KSI-301 (Arm A)|Intravitreal injection of KSI-301 (5 mg) once every 4 weeks for 3 monthly doses followed by an individualized dosing regimen (every 8 to 24 weeks) via intravitreal injection from Week 16 to Week 100.
62430725|NCT04603937|ACTIVE_COMPARATOR|Aflibercept (Arm B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 5 monthly doses followed by aflibercept (2 mg) once every 8 weeks via intravitreal injection from Week 24 to 100.
62430726|NCT02467088|EXPERIMENTAL|Individualised Homoeopathic Remedy|Each participant will receive an individualised homoeopathic remedy, in a vehicle of sucrose pillules, according to the symptoms of their PMS. Although different individualised remedies may be dispensed, each remedy will be homoeopathic. Each individualised homoeopathic remedy will have an individualised dosage, frequency and duration based on the laws of individualised homoeopathic prescribing as outlined by De Schepper.
62597803|NCT05919472|PLACEBO_COMPARATOR|Control group|Participants assigned to this group will receive placebo on alternate days on study days 1-56.
62597804|NCT02202044|EXPERIMENTAL|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks of Intravesical Intravesical BCG and EMDA/MMC
62597805|NCT00169715|OTHER|A|
62597806|NCT03101826|EXPERIMENTAL|Filtered Music Intervention|All participants will participate in pre-intervention assessments (6 months, 1 week prior) and post-intervention assessments (1 week, 1 month post). The Filtered Music Intervention (i.e., Listening Project Protocol) will last for 1 hour per day, for 5 consecutive days.
62597807|NCT06499610|EXPERIMENTAL|experimental group|therapeutic measure： Irinotecan hydrochloride for liposome injection 70mg/m2，intravenous drip，d1 Sintilimab Injection 200mg，intravenous drip，d1 Lenvatinib Mesilate Capsules ，8mg (weight\<60kg) or 12mg (weight≥60kg) ,po, qd
62597808|NCT06267560|EXPERIMENTAL|TQJ230|TQJ230 80mg QM s.c.
62597809|NCT06267560|PLACEBO_COMPARATOR|Placebo|Matching placebo.
62597810|NCT05838339|EXPERIMENTAL|Co-creation School|An existing healthy sleep intervention will be scaled up using a shortened co-creation process. An effect- and process evaluation will be performed.
62597811|NCT05838339|ACTIVE_COMPARATOR|Standard Implementation School|The existing healthy sleep intervention will be implemented without using a co-creation approach. An effect- and process evaluation will be performed.
62597812|NCT05838339|NO_INTERVENTION|Control School|No intervention will be implemented. An effect evaluation will be performed.
62597813|NCT01084317||asthmatic children|patients under 18 age, with newly diagnosed asthma
62597814|NCT04754438|EXPERIMENTAL|e-CBT|12 weekly sessions of approximately 30 slides and interactive content, delivered through OPTT. The e-CBT module content mirrors in-person standard CBT content, including different weekly topics, general information, skill overviews, and homework. Participants are instructed to go through the content and complete homework at the end of the session which helps them practice skills they learned through that session. Homework is submitted through OPTT and reviewed by the therapist assigned to the participant, who will provide personalized feedback within three days of submission. Therapists have access to pre-designed session-specific feedback templates to use as a basic structure to write their feedback. By doing so, the time needed to respond to each patient is reduced and therefore the number of patients each therapist can handle increases.
62597815|NCT04754438|EXPERIMENTAL|Mental Health Coaching|"Weekly interactions with the therapist using general questions on the following topics:~Week 1 (Mood) Week 2 (Sleep) Week 3 (Activity) Week 4 (Hobbies) Week 5 (Friendship) Week 6 (New Events) Week 7 (Job/Study) Week 8 (Diet/Food) Week 9 (Books/Movies/Shows) Week 10 (Phone/Apps/Games) Week 11 (Habits) Week 12 (Accomplishments)"
62597816|NCT06216535|PLACEBO_COMPARATOR|Placebo|Participants will receive an inactive placebo by mouth using the same administration schedule as for escitalopram.
62597817|NCT06216535|ACTIVE_COMPARATOR|Escitalopram|Participants will take oral escitalopram 10 mg per day for two weeks, followed by oral escitalopram 20 mg per day for 22 weeks.
62816434|NCT04251130||Cognitively Normal Older Adults|Subjects will receive an IV bolus injection of approximately 5 mCi ± 20% of \[18F\]PI-2620. All subjects will undergo a 30-minute brain PET/CT scan performed starting at approximately 45 minutes' post injection of \[18F\]PI-2620. A low-dose CT scan will be acquired according to standard PET/CT imaging procedures to be used for attenuation correction. All images will be reconstructed using standard reconstruction techniques
62430727|NCT01430104|EXPERIMENTAL|Teriparatide + Aspara-CA + Alfarol|Aspara-CA 600 milligrams (mg) and Alfarol 1.0 microgram (µg) administered orally once daily throughout the study. Teriparatide 20 µg administered subcutaneously once daily for 28 days during the Treatment Period.
62430728|NCT00459589|EXPERIMENTAL|1|nutritional intervention with dietician at each cycle of chemotherapy in 6 first cycles to maintain 30 kcal/kg/d and 1.2 protein/kg/d
62430729|NCT00459589|ACTIVE_COMPARATOR|2|
62430730|NCT01693276|EXPERIMENTAL|Gemzar/Abraxane and Radiation Therapy|Patients will receive 2 cycles of gemcitabine and abraxane prior to the start of chemoradiation. Chemoradiation will commence 2 week after the completion of second cycle of gemcitabine/abraxane. Patients will receive an additional 2 cycles of gemcitabine and abraxane to start 2-4 weeks after the completion of chemoradiation. After the last two cycles of chemotherapy, if well tolerated with continued tumor response additional cycles of chemotherapy may be given.
62430731|NCT01488266|EXPERIMENTAL|aripiprazole augmentation|
62430732|NCT01488266|ACTIVE_COMPARATOR|different class of antidepressant|
62816435|NCT04251130||Mild Cognitively Impaired Older Adults or Older Adults with Alzheimer's Disease|Subjects will receive an IV bolus injection of approximately 5 mCi ± 20% of \[18F\]PI-2620. All subjects will undergo a 30-minute brain PET/CT scan performed starting at approximately 45 minutes' post injection of \[18F\]PI-2620. A low-dose CT scan will be acquired according to standard PET/CT imaging procedures to be used for attenuation correction. All images will be reconstructed using standard reconstruction techniques
62816436|NCT04921436|EXPERIMENTAL|cardiac surgery patients with preventive treatment|"In addition to standard antibiotic prophylaxis (cefazolin 2 g 60 minutes before skin incision and 2 g 3 times a day after surgery), the following antibiotic regimens will be used perioperatively:~Doxycycline (the day before surgery 200 mg and 100 mg on days 1 and 2 after surgery) or Rimfampicin (150 mg 2 times a day before and after surgery) + Gentamicin (240 mg 3 times a day before and 2 days after surgery) or Clarithromycin (500 mg once daily for up to 2 days after surgery).~The route of administration (oral / intravenous) will depend on the condition of the patient."
62240301|NCT04897269|EXPERIMENTAL|Study group|In the interventional group,the patients will be indicated with standard protocol, micronized progesterone (Cyclogest pessary) 400mg x 2 per day for 14 days, supplemented with intramuscular progesterone (Progesterone 25mg/ml) 25 mg x 2 at one time per day for 14 days. If the beta-hcg test is positive, the patients will be treated with the same protocol and followed till 7 weeks of pregnancy when the fetal heart can be confirmed
62240302|NCT01233453|ACTIVE_COMPARATOR|the everolimus eluting ® stent|the everolimus eluting XIENCE-V®, XIENCE-Prime® or PROMUS® stent
62240303|NCT01233453|ACTIVE_COMPARATOR|Biolimus A9 stent|the Biolimus A9 eluting NOBORI® stent
62240304|NCT01349335|EXPERIMENTAL|1. tolvaptan|15 mg, P.O., Qd, for 7 days,
62816437|NCT04921436|NO_INTERVENTION|cardiac surgery patients without preventive treatment|standard antibiotic prophylaxis (cefazolin 2 g 60 minutes before skin incision and 2 g 3 times a day after surgery)
62816438|NCT05687058|EXPERIMENTAL|Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing|All participants undergoing thrice-weekly hemodialysis (HD) on the Monday-Wednesday-Friday (MWF) schedule will be assigned to the empagliflozin 25 mg thrice-weekly post-hemodialysis dosing arm (Group I).
62816439|NCT05687058|EXPERIMENTAL|Empagliflozin 10 mg daily dosing|Patients undergoing thrice-weekly hemodialysis (HD) on the Tuesday-Thursday-Saturday (TTS) schedule, patients on twice-weekly HD, or patients on peritoneal dialysis will receive empagliflozin 10 mg daily (Group II).
62816440|NCT06285591|PLACEBO_COMPARATOR|Control group|Placebo-containing tablets
62816441|NCT06285591|EXPERIMENTAL|Experimental group|Lactobacillus Reuteri tablets
62816442|NCT02739230|ACTIVE_COMPARATOR|Exparel Injection|
62816443|NCT02739230|ACTIVE_COMPARATOR|On-Q intraarthicual catheter placement|
62816444|NCT05978622||Dexamethasone Intravitreal Implant (DEX-I)|Dexamethasone 700 μg intravitreal implant (DEX-I) administered according to general clinical practice.
62240305|NCT01349335|EXPERIMENTAL|2 tolvaptan|30 mg, P.O., Qd, for 7 days,
62240306|NCT01349335|EXPERIMENTAL|3. Placebo|30mg,P.O.,Qd, for 7 days.
62240307|NCT04721821||Patients with Rheumatoid Arthritis (RA)|
62240308|NCT00433342|EXPERIMENTAL|I|Flucloxacillin
62240309|NCT00433342|NO_INTERVENTION|II|
62240310|NCT03691090|EXPERIMENTAL|SHR-1210 + paclitaxel + cisplatin|Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，SHR-1210 200mg，Day 2，every 3 weeks, maximum 6 cycles, then SHR-1210 maintenance
62240311|NCT03691090|ACTIVE_COMPARATOR|placebo+paclitaxel + cisplatin|Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，placebo，Day 2，every 3 weeks, maximum 6 cycles, then placebo maintenance
62430733|NCT02453919||RECOVIH|"Complete cardiac examination including echocardiography, ischemia tests, and ambulatory blood pressure monitoring.~Collection of clinical information and biochemical laboratory results."
62430734|NCT01990898|EXPERIMENTAL|Cyclosporine|Drug: Cyclosporine, Pill form, dosage calculated upon patient study visit, frequency - twice daily, duration - 3 months.
62240312|NCT02420132||Main Study|Decentralized participant recruitment, participant and local ophthalmologist compliance, and use of the mVT mobile medical application in a more geographically diverse, decentralized cohort of participants with DME or nAMD receiving intravitreal ranibizumab therapy as part of standard-of-care treatment.
62240313|NCT02420132||Traditional Substudy|"Subset of participants enrolled through a single investigator who will determine visual acuity and anatomical markers of disease status using clinical gold standard assessments (certified ETDRS protocol visual acuity and macula OCT)."
62240314|NCT06087679|EXPERIMENTAL|Selfcare program|6-month intervention period with a PPS guided selfcare based intervention program
62430735|NCT03575182|EXPERIMENTAL|Gait retraining program|
62430736|NCT03575182|NO_INTERVENTION|Physical therapy standard care|
62430737|NCT00293826|EXPERIMENTAL|1|196 subjects
62597818|NCT02638571|SHAM_COMPARATOR|Usual education|Households in the control clusters (kebeles) will receive usual nutrition education from Health extension workers, about complementary foods, over 9 months.
62430738|NCT00293826|EXPERIMENTAL|3|196 subjects
62430739|NCT00293826|EXPERIMENTAL|2|196 subjects
62430740|NCT00293826|PLACEBO_COMPARATOR|4|196 subjects
62816445|NCT03770260|EXPERIMENTAL|Treatment (ixazomib citrate, pevonedistat)|Patients receive ixazomib citrate PO QD on days 1, 8, and 15 of each cycle and pevonedistat IV over 60 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62816446|NCT06555068|EXPERIMENTAL|Treatment group A: HRS-6209 in Combination with Fulvestrant|
62816447|NCT06555068|EXPERIMENTAL|Treatment group E: HRS-6209 in Combination with HRS-1358|
62816448|NCT06555068|EXPERIMENTAL|Treatment group B：HRS-6209 in Combination with Letrozole|
62816449|NCT06555068|EXPERIMENTAL|Treatment group C：HRS-6209 in Combination with HRS-8080|
62816450|NCT06555068|EXPERIMENTAL|Treatment group D：HRS-6209 in Combination with HRS-1358|
62816451|NCT03655340||Prophylactic patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
62597819|NCT02638571|EXPERIMENTAL|Enhanced Education|Additional education sessions from Health extension workers (HEWs) trained on use of pulses for complementary foods (CF). HEWs provide nutrition education programs and counseling about pulse-cereal mix complementary foods, over 9 months.
62816452|NCT03655340||On demand patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for on-demand treatment
62816453|NCT06520787||Cohort|40 families with children already receiving pharmacological therapy as per clinical indication will be asked to use the ACDP® for obesity. We will track their progress with the digital intervention for ten months, and there will be a 2-month follow-up (total 12 months)
62816454|NCT04737512|EXPERIMENTAL|Mindfulness-Based ADHD Treatment for Children|
62597820|NCT00251082|EXPERIMENTAL|A|
62597821|NCT00251082|ACTIVE_COMPARATOR|B|
62597822|NCT00251082|PLACEBO_COMPARATOR|C|
62597823|NCT03886961|EXPERIMENTAL|Lung Transplant Patients|For the first four weeks, lung transplant patients will not wear the Reflux Band. Use of the Reflux Band will subsequently commence in the next four weeks.
62597824|NCT01046279||Glioma Patient receiving Bevacizumab|Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV)assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
62597825|NCT06016569|EXPERIMENTAL|LDCT and collection of breath condensate and blood sample|Each participant of the study will provide exhaled breath condensate sample and blood sample for further laboratory analyses. Each participant will have LDCT (low dose computer tomography) performed. A pulmonologist examines the patient for any concomitant diseases and performs spirometry. Vital signs will be measured.
62597826|NCT04393220|EXPERIMENTAL|Bevacizumab and anti-PD-1 therapy|
62597827|NCT04393220|ACTIVE_COMPARATOR|Bevacizumab|
62597828|NCT04393220|ACTIVE_COMPARATOR|anti-PD-1|
62597829|NCT02852200||SEGAm|Elderly community-dwelling people
62816455|NCT04737512|ACTIVE_COMPARATOR|Medication|
62816456|NCT04737512|ACTIVE_COMPARATOR|Combined (MBAT-C + medication)|
62816457|NCT00006359|EXPERIMENTAL|Androgen suppression + EBRT + Brachytherapy|Androgen suppression with external beam radiation therapy followed by brachytherapy boost
62816458|NCT01033981||Central America and Caribbean|Dominican Republic, Guatemala, Panama, Costa Rica, Honduras, Trinidad \& Tobago
62816459|NCT04648033|EXPERIMENTAL|Dose level 1 - 450 mg BD atovaquone + concurrent CRT|"Atovaquone:~* Taken during an initial run in period (2 weeks +/- 7 days), then continued during standard of care chemoradiotherapy.~* One of 4 dose levels is allocated to each patient by a TiTE-CRM statistical model which takes into account all toxicity data to date.~* Dose levels - 450 mg, 600 mg, 675 mg or 750 mg (all doses PO BD).~* Last dose atovaquone taken on the last day of radiotherapy.~* Total duration of atovaquone treatment is 59 days (+/- 7 days), unless stopped earlier for toxicity or any other reason.~Chemotherapy:~* 2 x 21-day cycles.~* 80 mg/m2 cisplatin on day 1 and 22 of chemoradiotherapy.~* 15 mg/m2 vinorelbine on days 1,8, 22 and 29 of chemoradiotherapy.~Radiotherapy:~* 66 Gy in 33 fractions.~* Delivered once daily, 5 days a week (Monday-Friday) for 6.5 weeks."
62240315|NCT06087679|NO_INTERVENTION|Control group|Treatment as usual
62240316|NCT00042406|PLACEBO_COMPARATOR|Placebo|
62240317|NCT00042406|EXPERIMENTAL|HuMax-CD4 80 milligrams (mg)|
62816460|NCT04648033|EXPERIMENTAL|Dose level 2 - 600 mg BD atovaquone + concurrent CRT|"Atovaquone:~* Taken during an initial run in period (2 weeks +/- 7 days), then continued during standard of care chemoradiotherapy.~* One of 4 dose levels is allocated to each patient by a TiTE-CRM statistical model which takes into account all toxicity data to date.~* Dose levels - 450 mg, 600 mg, 675 mg or 750 mg (all doses PO BD).~* Last dose atovaquone taken on the last day of radiotherapy.~* Total duration of atovaquone treatment is 59 days (+/- 7 days), unless stopped earlier for toxicity or any other reason.~Chemotherapy:~* 2 x 21-day cycles.~* 80 mg/m2 cisplatin on day 1 and 22 of chemoradiotherapy.~* 15 mg/m2 vinorelbine on days 1,8, 22 and 29 of chemoradiotherapy.~Radiotherapy:~* 66 Gy in 33 fractions.~* Delivered once daily, 5 days a week (Monday-Friday) for 6.5 weeks."
62038033|NCT06071962|EXPERIMENTAL|Treatment group|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
62038034|NCT06071962|EXPERIMENTAL|Control group|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
62240318|NCT00042406|EXPERIMENTAL|HuMax-CD4 160 mg|
62430741|NCT02204215|EXPERIMENTAL|electric acupuncture & conservative|Electric acupuncture therapy on four limbs 30 min each time, twice per day; or conservative treatment without electric acupuncture.
62430742|NCT02762877||A|Patients with non-squamous NSCLC either newly diagnosed or progressing on any therapy (except erlotinib, gefitinib, or afatinib)
62430743|NCT02762877||B|Patients with non-squamous NSCLC who are progressing on erlotinib, gefitinib, or afatinib
62430744|NCT02087228|EXPERIMENTAL|Hydrothermal ablation|Uterine ablation performed with a device that circulates heated water inside the uterus
62430745|NCT02087228|ACTIVE_COMPARATOR|radiofrequency energy|ablation performed with a device that uses radiofrequency energy.
62430746|NCT06526858|EXPERIMENTAL|Extravsacular(Laparoscopic) Renal Denervation|"Intervention:~Device: HyperQureTM Renal Denervation (RDN) System:~* HyperQureTM RDN Generator~* HyperQureTM RDN Laparoscopic Instrument"
62430747|NCT00184431|EXPERIMENTAL|A|Intensive task specific balance training
62430748|NCT00184431|ACTIVE_COMPARATOR|B|Traditional physical therapy
62430749|NCT05516420||Patients with first abdominal surgery in Scotland between 2009 and 2011|Patients with first abdominal surgery in Scotland between 2009 and 2011
62430750|NCT02755545|ACTIVE_COMPARATOR|Product A (adapalene)|Product A applied topically to the entire face or other affected area of the skin once daily
62430751|NCT02755545|ACTIVE_COMPARATOR|Product B (salicylic acid)|Product B applied topically to the affected area of the skin 1 to 3 times daily.
62430752|NCT04063384|ACTIVE_COMPARATOR|Alcohol|Participants will be dosed to a 0.08g% blood alcohol concentration.
62430753|NCT04063384|PLACEBO_COMPARATOR|Placebo|Participants will receive a low dose of alcohol (placebo condition).
62430754|NCT04466774|EXPERIMENTAL|Dip Home-Based Dipstick Analyzer|Each participant will test their urine sample using the HBDA. device
62597830|NCT04115917|EXPERIMENTAL|Schocket Scleral Depressor|Scleral Depression with Schocket Scleral Depressor
62816461|NCT04648033|EXPERIMENTAL|Dose level 3 - 675 mg BD atovaquone + concurrent CRT|"Atovaquone:~* Taken during an initial run in period (2 weeks +/- 7 days), then continued during standard of care chemoradiotherapy.~* One of 4 dose levels is allocated to each patient by a TiTE-CRM statistical model which takes into account all toxicity data to date.~* Dose levels - 450 mg, 600 mg, 675 mg or 750 mg (all doses PO BD).~* Last dose atovaquone taken on the last day of radiotherapy.~* Total duration of atovaquone treatment is 59 days (+/- 7 days), unless stopped earlier for toxicity or any other reason.~Chemotherapy:~* 2 x 21-day cycles.~* 80 mg/m2 cisplatin on day 1 and 22 of chemoradiotherapy.~* 15 mg/m2 vinorelbine on days 1,8, 22 and 29 of chemoradiotherapy.~Radiotherapy:~* 66 Gy in 33 fractions.~* Delivered once daily, 5 days a week (Monday-Friday) for 6.5 weeks."
62816462|NCT04648033|EXPERIMENTAL|Dose level 4 - 750 mg BD atovaquone + concurrent CRT|"Atovaquone:~* Taken during an initial run in period (2 weeks +/- 7 days), then continued during standard of care chemoradiotherapy.~* One of 4 dose levels is allocated to each patient by a TiTE-CRM statistical model which takes into account all toxicity data to date.~* Dose levels - 450 mg, 600 mg, 675 mg or 750 mg (all doses PO BD).~* Last dose atovaquone taken on the last day of radiotherapy.~* Total duration of atovaquone treatment is 59 days (+/- 7 days), unless stopped earlier for toxicity or any other reason.~Chemotherapy:~* 2 x 21-day cycles.~* 80 mg/m2 cisplatin on day 1 and 22 of chemoradiotherapy.~* 15 mg/m2 vinorelbine on days 1,8, 22 and 29 of chemoradiotherapy.~Radiotherapy:~* 66 Gy in 33 fractions.~* Delivered once daily, 5 days a week (Monday-Friday) for 6.5 weeks."
62816463|NCT03611738|EXPERIMENTAL|Phase I Dose Escalation|"The design will recruit participants in cohorts of three patients each and will not allow for dose-skipping during escalation. A maximum of 18 participants will be enrolled for the phase I dose escalation. Three ceritinib dose levels have been identified for dose escalation (150 mg, 300 mg, and 450 mg), plus docetaxel at 75 mg. A backup dose (ceritinib 150 mg with docetaxel at 60 mg) is also prepared in case the three dose levels are too toxic. Therefore, four potential dose levels will be used for determination of maximum tolerated dose (MTD). The first cohort will start at dose level 1 (ceritinib 150 mg with docetaxel at 75 mg).~Level -1 Backup Cohort: 150 mg ceritinib; 60 mg/m\^2 docetaxel Level 1 Starting Cohort: 150 mg ceritinib; 75 mg/m\^2 docetaxel Level 2 Cohort: 300 mg ceritinib; 75 mg/m\^2 docetaxel Level 3 Cohort: 450 mg ceritinib; 75 mg/m\^2 docetaxel"
62816464|NCT03611738|EXPERIMENTAL|Phase Ib Dose Expansion|Treatment at recommended dose. Investigators plan to have 30 patients for the expansion cohort. This will include participants from the dose escalation portion receiving the recommended dose.
62816465|NCT05961553|EXPERIMENTAL|Physical Activity Counseling + Pulmonary Rehabilitation|The counseling session on physical activity was carried out individually, six weeks after starting the respiratory rehabilitation program, with an average duration of 30 minutes, based on the guidelines of the Living Well with COPD program. The main objective of the session was: to help the participant and family members to increase physical activity levels and their integration in the long term and as secondary objectives; reinforce the importance and benefits of physical activity in the management of the health condition/symptoms; plan daily/weekly moments of physical activity; define daily goals (physical activity time/sitting time) attainable for each participant; integrate family members/companions into the user's physical activity plan; clarify doubts of the user/relative about the theme.
62597831|NCT04115917|ACTIVE_COMPARATOR|Cotton Tipped Applicator|Scleral Depression with Cotton Tipped Applicator
62816466|NCT05961553|ACTIVE_COMPARATOR|Pulmonary Rehabilitation|The program comprises a hospital group exercise program, twice a week, on alternate days, for 1h30 to 2h, each session, which included: monitoring of vital signs, peripheral oxygen saturation (SpO2), subjective perception of exertion (RPE), dyspnea and body mass; warm-up phase (10min), with ventilatory control and low-intensity upper and lower limb exercises; continuous aerobic training phase, performed on a treadmill, static cycle ergometer and/or arm ergometer (30-45min), at 60-80% of the maximum Cardiopulmonary Exercise Test load; strength training phase, with free weights, machines (10-20min), at 50-80% of the Maximum Repetition (RM), (8-12 repetitions), 1-2 sets, 8-10 exercises ( upper limbs, trunk and lower limbs); cooling phase (5-10min), with 5 to 8 relaxation, stretching and ventilatory control exercises. The progression of training loads is carried out according to RPE and dyspnea, safeguarding SpO2 values above 88-90% and Heart Rate below the maximum defined for training.
62597832|NCT05798013|EXPERIMENTAL|Digital health management intervention Group|Patients in the trial group receives intervention management from the digital health management platform, including reminding patients to take medication on time, monitoring and managing risk factors, reminding patients to have regular checkups and regular follow-ups, and pushing personalized science based on patients' risk factors, etc. Meanwhile, the platform's customer service staff regularly follows up with patients and reminds them of health management, and regularly invites experts to conduct formal medical science conferences for patients.
62597833|NCT05798013|NO_INTERVENTION|Control group|The group doesn't not receive intervention reminders and customer service supervision from the platform, but receives the same follow-up visits.
62597834|NCT02405169|EXPERIMENTAL|Test -4 implants-|Evaluate marginal bone level (MBL) changes at implants that are placed in total edentulous patient when they are treated with four with titanium Cad/Cam framework.
62816467|NCT06453148||Heart Transplantation|Adults heart transplantation
62816468|NCT04242355|ACTIVE_COMPARATOR|Transcranial Magnetic Stimulation - real|Participants will receive active TMS during their study visit
62597835|NCT02405169|ACTIVE_COMPARATOR|Control -6 implants-|Evaluate marginal bone level (MBL) changes at implants that are placed in total edentulous patient when they are treated with six with titanium Cad/Cam framework
62597836|NCT01940315|ACTIVE_COMPARATOR|rBV A/B|0.5 mL dose of rBV A/B (40 µg) will be administered intramuscularly (IM) in a three-dose dosing schedule given at Days 0, 28 ± 5 days, and 182 ± 9 days
62240319|NCT05832008|EXPERIMENTAL|Clinician Nudge + Patient Nudge|"An EHR-prompt (pended order) will prompt clinicians in this arm when a patient is due for lung cancer screening or diagnostic follow-up.~Patients in this arm will receive messaging designed to increase awareness about the importance of annual screening and recommended follow-up"
62240320|NCT05832008|EXPERIMENTAL|Clinician Nudge Only|"Clinicians in this arm will not be prompted by a pended order when a patient is due for lung cancer screening or diagnostic follow-up.~Patients will receive usual care."
62240321|NCT05832008|EXPERIMENTAL|Patient Nudge Only|"Patients in this arm will receive messaging designed to increase awareness about the importance of annual screening and recommended follow-up.~Clinicians will receive usual care."
62597837|NCT01940315|PLACEBO_COMPARATOR|Placebo|0.5 mL dose of placebo will be administered intramuscularly (IM) given at Days 0, 28 ± 5 days, and 182 ± 9 days
62597838|NCT03603951|EXPERIMENTAL|SHR2554 treated group|Part I：treated with escalated doses of EZH2 inhibitor SHR2554 respectively； Part II：treated with fixed dose (RP2D) SHR2554 respectively
62597839|NCT06501820|SHAM_COMPARATOR|Sham stimulation|The tDCS electrodes are applied and the current ramps up and then down, resulting in a very effective sham condition.
62597840|NCT06501820|EXPERIMENTAL|Active stimulation|Transcranial direct current stimulation, bilateral, 2 mA, applied to the vestibular cortex.
62597841|NCT05659862|EXPERIMENTAL|Digitally assisted behavioral physical activity intervention+Education|"An activity diary and a pedometer will be given to write down the number of steps per day.~After one week, the patient will be asked to send the activity diary as a photo via WhatsApp.~Afterwards, a 20-minute phone call will be made to provide patient education.~After the patient education, the patient will be consulted about the average number of steps he wants to take at the end of the intervention, and the daily average number of steps will be determined for the first week of the intervention, taking into account the patient's number of steps in the last week and the goal of the number of steps she wants to reach.~The person will be added to the WhatsApp patient support group. Patients will receive messages from this group by the researcher twice a week.~The target for the number of steps will be renewed every next week and an average of 20 minutes of phone calls including motivational interviews will be held in the light of Social Cognitive Theory."
62816469|NCT04242355|PLACEBO_COMPARATOR|Transcranial Magnetic Stimulation - sham|Participants will receive sham stimulation during their study visit simulating TMS
62816470|NCT05762679|OTHER|Latent PSSP|Latent PSSP defined as focal palpable nodules that may be tender on palpation with pain rating of \< 5/10 when combined with the hand-behind-neck (HBN) maneuver.
62816471|NCT05762679|OTHER|Active PSSP|Active PSSP is defined as focal palpable nodules that are tender on palpation, reproducing the pain, and eliciting a pain rating of \>= 5/10 when combined with the hand-behind-neck (HBN) maneuver.
62816472|NCT04728958|EXPERIMENTAL|Gratitude Journal|Participants will be given instructions and asked to write a gratitude journal about their week, focusing upon what they are grateful for. Over the course of the 4-week intervention they will be asked to do this weekly (a total of four times).
62816473|NCT04728958|PLACEBO_COMPARATOR|Weekly Diary|Participants will be given instructions and asked to write a diary about their week, focusing upon both the good and the bad they have experienced that week. Over the course of the 4-week intervention they will be asked to do this weekly (a total of four times).
62816474|NCT02647281|EXPERIMENTAL|Part 1: GSK3389404 10 mg|Subjects will receive a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.
62816475|NCT02647281|PLACEBO_COMPARATOR|Part 1: Placebo|Subjects will receive a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.
62240322|NCT05832008|NO_INTERVENTION|Usual care (no nudges)|Patients and clinicians in this arm will receive usual care.
62240323|NCT01681810|EXPERIMENTAL|14Nitrogen sodium nitrite|sodium nitrite 40 mg three times a day for 12 weeks
62816476|NCT02647281|EXPERIMENTAL|Part 1: GSK3389404 30 mg|Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.
62816477|NCT02647281|EXPERIMENTAL|Part 1: GSK3389404 60 mg|Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.
62816478|NCT02647281|EXPERIMENTAL|Part 1: GSK3389404 120 mg|Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.
62816479|NCT02647281|EXPERIMENTAL|Part 2: GSK3389404 30 mg|Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.
62816480|NCT02647281|PLACEBO_COMPARATOR|Part 2: Placebo|Subjects will receive a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.
62240324|NCT02570893|EXPERIMENTAL|adjuvant chemoradiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.
62240325|NCT02570893|EXPERIMENTAL|adjuvant radiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.
62597842|NCT05659862|ACTIVE_COMPARATOR|Education|"An activity diary and a pedometer will be given to write down the number of steps per day.~After one week, the patient will be asked to send the activity diary as a photo via WhatsApp.~Afterwards, a 20-minute phone call will be made to provide patient education.~A reminder call will be made to the patient in the 4th week after the training and any questions will be answered.~Individuals in the patient education group will be asked to record their steps for one week with a pedometer in the 8th week after the training."
62597843|NCT05168332|EXPERIMENTAL|Experimental(Group A): patellar taping combined with isometric strength training|The experimental group (Group A): patellar taping with isometric strength training for six weeks.
62597844|NCT05168332|SHAM_COMPARATOR|Control group (Group B): sham patellar taping combined with isometric strength training.|Control group (Group B): sham patellar taping combined with isometric strength training for six weeks.
62597845|NCT01845168|ACTIVE_COMPARATOR|Computer-alert|2 arm study active group: 'A computer alert which pops up when the GP prescribes NSAID/ASA to a patient with risk-factors
62597846|NCT01845168|NO_INTERVENTION|controlgroup, normal procedures|The control-group: GP working in normal procedures
62816481|NCT02647281|EXPERIMENTAL|Part 2: GSK3389404 60 mg|Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.
62816482|NCT02647281|EXPERIMENTAL|Part 2: GSK3389404 120 mg|Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.
62816483|NCT04489316|NO_INTERVENTION|Control|Subjects in the Control group will proceed through the standard pediatric oncology curriculum. They will not receive any sessions in narrative medicine. They will take the pretest and the post-test.
62240326|NCT00672061|EXPERIMENTAL|Ramelteon 16 mg QD or Placebo QD|
62240327|NCT00186862|OTHER|1|
62816484|NCT04489316|EXPERIMENTAL|Intervention|Subjects in the Intervention group will receive 2-3 sessions in narrative medicine. They will also take the pretest and the postest.
62816485|NCT03158844||HIV+ patients (Standard of care)|300 HIV-infected and hospitalized adult patients at the University Teaching Hospital (UTH) will be recruited.
62816486|NCT03158844||Health systems informants|15 key Zambian health systems informants and leaders who can discuss inpatient care and the process of linking hospitalized patients to HIV care.
62430755|NCT04154566|EXPERIMENTAL|the study group|Group (A) the study group received aerobic exercise in addition to selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and gait training exercises in open environment.
62430756|NCT04154566|NO_INTERVENTION|the control group|group (B) the control group received the same selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and gait training exercises in open environment only.
62597847|NCT05143268||A|In the experimental arm (arm A), a total of 11 sessions of acupuncture will be performed on a weekly basis, spanning from 2 weeks before Radiotherapy start throughout 7 weeks of treatment, to 2 weeks after its completion. Patients randomized to the experimental arm will receive acupuncture in addition to standard of care treatment, chosen by the treating multidisciplinary team in accordance with international guidelines.
62597848|NCT05143268||B|In the standard arm (arm B), patients will be treated with standard of care treatment.
62597849|NCT01607229||otherwise healthy with various BMI|
62597850|NCT06621381|EXPERIMENTAL|Concentrated exposure and response prevention|The intervention consists of: Psychoducation for the patients (1 session, 2-3h in group format), psychoeducation for the legal guardians (1 session, 3h in group format), exposure and response prevention (3-4 sessions, 9-12h over the course of one week, individual format), group reunions for sharing experiences, motivational work and relapse prevention ( 2 sessions, 3h)
62597851|NCT05565040|EXPERIMENTAL|Phallopexy group|phallopexy only
62597852|NCT05565040|EXPERIMENTAL|Dartos excision group|complete circumferential dissection and excision of dartos fascia only
62038035|NCT05671848|EXPERIMENTAL|experimental arm|Patient with ET and Receiving deep brain stimulation treatment with implantation of the PERCEPT™ device
62430757|NCT03108391|EXPERIMENTAL|Ambu AuraGain|Subjects will receive the Ambu AuraGain size 3 to size 5 based on manufacturer guidelines
62430758|NCT03108391|ACTIVE_COMPARATOR|LMA Supreme|Subjects will receive the LMA Supreme size 3 to size 5 based on manufacturer guidelines
62430759|NCT05409131|ACTIVE_COMPARATOR|Intervention Arm|Omnipod 5 System with Dexcom G6 continuous glucose monitoring system
62430760|NCT05409131|NO_INTERVENTION|Control Arm|Participant's current insulin pump with Dexcom G6 continuous glucose monitoring system
62597853|NCT05565040|EXPERIMENTAL|Combined phallopexy and dartos excision group|phallopexy as in patients of group A but after complete dissection and excision of dartos fascia
62597854|NCT04641260|EXPERIMENTAL|Fezolinetant: Fed State then Fasted State|Participants will receive a single oral dose of fezolinetant in fed state on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant in fasted state on day 1 of study period 2.
62597855|NCT04641260|EXPERIMENTAL|Fezolinetant: Fasted State then Fed State|Participants will receive a single oral dose of fezolinetant in fasted state on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant in fed state on day 1 of study period 2.
62816487|NCT06703307||Healthy subjects|Healthy subjects without history of stroke or cognitive impairment.
62816488|NCT06703307||PSCI|Stroke patients with post-stroke cognitive impairment.
62816489|NCT06703307||NPSCI|Stroke patients without post-stroke cognitive impairment.
62816490|NCT06704841|EXPERIMENTAL|Music in combination with mindfulness group|Participants in this group will receive music in combination with mindfulness group for up to two weeks.
62038036|NCT04850846|EXPERIMENTAL|Metformin|"Randomly assigned participants receive a stepped dose escalation until target daily dose of 1500mg Metformin XR is reached (3 x 500mg pills/day). The intervention duration will last an additional 6 months.~Metformin Extension:~Participants will have the option of unblinding at the end of their 6months treatment and those who were randomly assigned to the metformin experimental arm can continue taking metformin if they opt in. The extended intervention duration will last an additional 6 months. (1500mg Metformin XR or highest tolerated dose )"
62038037|NCT04850846|EXPERIMENTAL|Placebo|Randomly assigned participants receive a stepped dose escalation until target daily dose of 3 pills/day is reached. The intervention duration will last 6 months.
62038038|NCT02519348|EXPERIMENTAL|Part 1: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg|Participants in Part 1A (safety run-in cohort) and Part 1 B (efficacy-gating cohort) will receive tremelimumab 1 mg/kg every 4 weeks (Q4W) 4 doses and durvalumab 20 mg/kg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
62430761|NCT01289431|EXPERIMENTAL|Mapracorat|
62430762|NCT01289431|PLACEBO_COMPARATOR|Mapracorat Vehicle|
62597856|NCT01362244|EXPERIMENTAL|Treatment Periods 1-8|Part A comprises eight outpatient visits (Visits 1 - 8). For six of these visits, subjects will receive a dose of either 750 mg mepolizumab or placebo. Dosing occurs in four week intervals. Assessment for entry into Part B will take place at the last visit in Part A (Visit 8). Subjects not eligible for Part B will have study exit procedures performed and be discontinued.
62597857|NCT01362244|OTHER|Run In period|10-14 day run in period to assess the patients suitability for entry into Part A of the trial.
62038039|NCT02519348|EXPERIMENTAL|Parts 2 and 3: Durvalumab 1500 mg|Participants will receive durvalumab 1500 mg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
62816491|NCT05216016|NO_INTERVENTION|Control Group|Individuals will receive a handout with additional job related services; e.g. Job Accommodation Network.
62038040|NCT02519348|EXPERIMENTAL|Parts 2 and 3: Tremelimumab 300 mg + Durvalumab 1500 mg|Participants will receive tremelimumab 300 mg 1 dose and durvalumab 1500 mg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow, or development of other reason for treatment discontinuation, whichever occurs first.
62038041|NCT02519348|EXPERIMENTAL|Parts 2 and 3: Tremelimumab 750 mg|Participants will receive tremelimumab 750 mg Q4W 7 doses followed by every 12 weeks (Q12W) until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
62430763|NCT02535052||Chronic Kidney Disease (CKD) patients|Any gender, aged 65 years and over. Chronic kidney disease with eGFR between 15 and 60 ml/min. No immunological cause of kidney disease. Not immunosuppressed. To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
62038042|NCT02519348|EXPERIMENTAL|Parts 2 and 3: Tremelimumab 75 mg + Durvalumab 1500 mg|Participants will receive tremelimumab 75 mg Q4W 4 doses and durvalumab 1500 mg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first. Participant recruitment to this arm was closed following protocol amendment 5.
62430764|NCT02535052||Healthy Control subjects|Any gender, aged 65 years and over. No known renal disease and eGFR 60ml/min or greater. Not immunosuppressed. To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
62597858|NCT01362244|NO_INTERVENTION|Treatment periods 9-13|Subjects eligible for Part B will attend the clinic for up to 5 more outpatient visits (Visits 9 - 13) for assessments. Visits occur every four weeks. There is no dosing in Part B. At the point when each subject meets Study Exit criteria, study exit procedures will be performed and the subject will exit the study.
62597859|NCT01844180|EXPERIMENTAL|Experimental Arm 1|ONO-2952 low dose every day for 4 weeks
62597860|NCT01844180|EXPERIMENTAL|Experimental Arm 2|ONO-2952 high dose every day for 4 weeks
62597861|NCT01844180|PLACEBO_COMPARATOR|Placebo Arm|ONO-2952 Matching Placebo every day for 4 weeks
62816492|NCT05216016|EXPERIMENTAL|Intervention Group|Individuals will be assigned a dedicated Minnesota RETAIN Return-to-Work Case Manager. Intervention group participants will be referred for additional career and workforce development resources when needed.
62816493|NCT05216016|EXPERIMENTAL|Sub Study Group|Individuals will be assigned a dedicated Minnesota RETAIN Return-to-Work Case Manager. Intervention group participants will be referred for additional career and workforce development resources when needed.
62816494|NCT02588690||Women participating in screening|Community screening project targets women of color and/or low income women over 21 years of age in economically and ethnically diverse greater Los Angeles community. Women will be risk stratified based on ASCVD risk calculation and if labeled high risk will be referred to physician services. In 1 year, women will have their ASCVD re-risk stratify to see if seeing a physician/ health care provider reduced overall ASCVD risk scores.
62597862|NCT06114875|NO_INTERVENTION|Control|Half of RallyPoint's active users will comprise the control group. The control group will not be shown the intervention flags and will see posts displayed as usual.
62735215|NCT05734911||patients with ovarian cancer (OC) received niraparib as first-line (1st-L) maintenance therapy|This multi-center, observational, retrospective study collected real-world medical record data of patients with advanced ovarian cancer treated with niraparib as first-line maintenance therapy from fourteen hospitals in China. In reality, these patients received different oral doses of niraparib until disease progression, severe toxicity occurred, or death. A total of 199 patients were included in a centralized database ultimately with a median age of 57.0 years (range, 51.0-63.5 years).
62816495|NCT06706180|EXPERIMENTAL|Exercise for Mood video|The Exercise for Mood intervention is an approximately 11-minute video shown to participants which presents a mood-based motivational frame for exercise and physical activity. Video content focuses on discussions related to the immediate mood benefits from exercise, longer-term cognitive and mental health benefits of exercise, effects of positive affect during exercise, and mood-centered strategies for engaging in regular physical activity, including exercising in diverse locations, exercising with friends, and exercising with music or audiobooks.
62816496|NCT06706180|ACTIVE_COMPARATOR|Exercise for Fitness video|The Exercise for Fitness intervention is an approximately 11-minute video shown to participants which presents a fitness-based motivational frame for exercise and physical activity. Video content focuses on discussions related to the physical health effects of exercise, including cardiovascular health, increased calorie burning, and overall physical wellbeing. The video also includes recommendations for diversity of exercise, balancing cardiovascular and strength-training activities.
62816497|NCT05992883|EXPERIMENTAL|Non-steroidal anti-inflammatory drug (NSAID)|Patients will proceed to their injection appointment within 4 weeks of their initial evaluation. At the injection appointment, patients will receive an injection containing 1.0 mL of ketorolac 15 mg/mL (15 mg total of ketorolac).
62816498|NCT05992883|ACTIVE_COMPARATOR|Corticosteroid|Patients will proceed to their injection appointment within 4 weeks of their initial evaluation. At the injection appointment, patients will receive an injection containing 0.5 mL of triamcinolone 40 mg/mL (20 mg total of triamcinolone).
62816499|NCT05325125||Children who have completed treatment for Tuberculosis|Children 19 years and below who had drug-sensitive pulmonary tuberculosis, either bacteriologically confirmed or not and who have completed treatment within the preceding 6 weeks before enrolment
62816500|NCT03858985|ACTIVE_COMPARATOR|Transcutaneous Vagus Nerve Stimulation|Cervical Transcutaneous vagus nerve stimulation. Participants will undergo once daily cervical transcutaneous vagus nerve stimulation.
62816501|NCT03858985|SHAM_COMPARATOR|Sham Vagus Nerve Stimulation|Sham Cervical Transcutaneous Vagus Nerve Stimulation. Participants will undergo once daily sham cervical transcutaneous vagus nerve stimulation.
62038043|NCT02519348|EXPERIMENTAL|Part 4: Durvalumab 1120 mg + Bevacizumab 15 mg/kg|Participants will receive durvalumab 1120 mg and bevacizumab 15 mg/kg every 3 weeks (Q3W) until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first
62240328|NCT02614534|EXPERIMENTAL|Proactive cytoreductive surgery + HIPEC|Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women) plus HIPEC (Mytomicin C - 60 minutes).
62240329|NCT02614534|ACTIVE_COMPARATOR|Proactive cytoreductive surgery|Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women).
62240330|NCT00445068|EXPERIMENTAL|Panobinostat|Participants received panobinostat 20 milligrams (mg) orally once daily (OD), three times a week on days: 1, 3 and 5, then 8, 10 and 12, then 15, 17 and 19 of each cycle, as part of a 3-week (21 days) treatment cycle. Participants could continue treatment until disease progression or unacceptable toxicity.
62240331|NCT05298982||Intervention arm: TEAM protocol|Based on TEAM (III) protocol patients will be assessed daily by an ICU physiotherapist using the ICU Mobility Scale (IMS) to determine the dosage and type of active exercises the patient will receive, using the early activity and mobilisation protocol. This protocol is hierarchical, with the objective of each intervention session beginning with the highest level of activity possible for the longest time possible, which then steps down to lower levels of activity if the patient fatigues. The intervention will be administered on all days in which the patient is admitted to ICU during the index hospitalisation, censored at 28days after.
62430765|NCT06538324|EXPERIMENTAL|Marine Omega-3 fatty acid supplement|Participants will be randomized to either star to receive a capsule/day with omega-3 fatty acid from 1g Nannochloropsis sp. microalga (250 mg of EPA) for 6 weeks. Followed by a wash-out period of 10 weeks.
62430766|NCT06538324|PLACEBO_COMPARATOR|High-oleic sunflower oil (HOSO) containing no EPA or other omega-3 fatty acid|Participants will be randomized to either star to receive a placebo capsule/day with the same weight of high oleic sunflower oil -HOSO (with no EPA or other omega-3 fatty acid content), for 6 weeks. Followed by a wash-out period of 10 weeks.
62430767|NCT04539509|ACTIVE_COMPARATOR|Monitoring|Participants will be given a heart rate monitor to wear on their wrist for the duration of the study (i.e. until recovered, or 8 weeks post-injury, whatever comes first).
62430768|NCT04539509|PLACEBO_COMPARATOR|Monitoring + Treadmill Test|In addition to wearing the heart rate monitor, participants will undergo a treadmill test at each appointment.
62430769|NCT04539509|EXPERIMENTAL|Monitoring + Treadmill Test + Specific Exercise Prescription|In addition to wearing the heart rate monitor, and completing a treadmill test at each appointment, participants will receive an exercise prescription based on the results of the treadmill test. They will be prescribed 30 minutes of structured aerobic exercise, 5 times per week, at a heart rate determined by their treadmill test.
62735216|NCT05494463|NO_INTERVENTION|Macintosh blade|laryngoscopy with Macintosh blade
62816502|NCT05684536|ACTIVE_COMPARATOR|ligasure throidectomy|the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall, with dissection around ligament of berry and inferior thyroidal artery
62816503|NCT05684536|NO_INTERVENTION|conventional thyroidectomy|with dissection around ligament of berry and inferior thyroidal artery through ligation with vicryl and hemoclips
62597863|NCT06114875|EXPERIMENTAL|Intervention|Participants will not be actively recruited for this intervention. Rather, about half of active RallyPoint users (approximately 40,000 users; 80,000 users total) will be randomized to see the Intervention #1 psychoeducational pop-ups. The investigators will work with RallyPoint collaborators who will only display the distress flags to participants in the intervention group. RallyPoint users will not see flags appear on their own concerning posts, if they make any. The intervention will last up to six months (i.e., flags will be visible on concerning posts made over a six month period).
62597864|NCT01389570|EXPERIMENTAL|Acupressure wrist band|The group receiving acupressure wrist band
62597865|NCT00336024|ACTIVE_COMPARATOR|Arm I (induction+consolidation chemotherapy, autologous PBSC)|"Patients receive vincristine IV over 1 minute on days 1, 8, and 15; etoposide IV over 1 hour on days 1-3; cyclophosphamide IV over 1 hour on days 1 and 2; cisplatin IV over 6 hours on day 3. Treatment repeats every 3 weeks for 3 courses.~Within 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and G-CSF IV or SC beginning on day 5 and continuing until blood counts recover. Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity."
62597866|NCT00336024|EXPERIMENTAL|Arm II (induction+consolidation chemotherapy, autologous PBSC)|"Patients receive vincristine IV over 1 minute on days 1, 8, and 15; high-dose methotrexate IV over 4 hours on day 1; and leucovorin calcium IV or PO every 6 hours beginning on day 2 and continuing until methotrexate levels are in a safe range. Patients then receive etoposide IV over 1 hour on approximately days 4, 5, and 6, cyclophosphamide IV over 1 hour on approximately days 4 and 5, and cisplatin IV over 6 hours on approximately day 6. Treatment repeats every 3 weeks for 3 courses.~Within 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and G-CSF IV or SC beginning on day 5 and continuing until blood counts recover. Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity."
62816504|NCT02019966||TDF monotherapy|"TDF monotherapy - treated by tenofovir alone~patients with CHB receiving rescue TDF (300mg once daily) monotherapy"
62816505|NCT02019966||TDF-based combination therapy|"TDF-based combination therapy - treated by tenofovir based combination therapy.~patients with CHB receiving rescue TDF-based combination therapy (TDF 300mg once daily with any other nucleoside analogue such as lamivudine 100mg, telbivudine 600mg, or entecavir 1.0 mg once daily)."
62816506|NCT04335656|EXPERIMENTAL|Treatment Group|Subjects will be randomized to the treatment or placebo group. The treatment is a capsule taken by mouth once a day for 6 months.
62816507|NCT04335656|PLACEBO_COMPARATOR|Placebo Group|Subjects will be randomized to the treatment or placebo group. The placebo is a capsule taken by mouth once a day for 6 months.
62816508|NCT06704438||Control Group|The control group consisted of healthy individuals without any disease who voluntarily participated in the study.
62816509|NCT06704438||Patients Group|Patients over the age of 18 who were diagnosed as critically ill by the emergency department physician and who gave informed consent were included in the study.
62240332|NCT05298982||Standard of Care arm: TEAM protocol|Based on TEAM (III) protocol the control group will receive standard care from physiotherapy staff not involved in delivering the intervention. We have previously established that standard care in Australia for a patient receiving prolonged IMV (control group intervention) frequently involves no active exercise out of bed.
62240333|NCT05627206|NO_INTERVENTION|Usual care|
62240334|NCT05627206|EXPERIMENTAL|Intervention|
62240335|NCT02366728|EXPERIMENTAL|Group I: Unpulsed DC pre-conditioning|0.4 mLs of 1 x 10\^6 autologous unpulsed DCs in saline will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the 4th human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies.
62597867|NCT03761758|EXPERIMENTAL|Lens Design 1|Spectacle lenses design 1, fitted into spectacle frames
62597868|NCT03761758|EXPERIMENTAL|Lens Design 2|Spectacle lenses design 2, fitted into spectacle frames
62597869|NCT03761758|EXPERIMENTAL|Lens Design 3|Spectacle lenses design 3, fitted into spectacle frames
62597870|NCT05132712|EXPERIMENTAL|Use of ACE inhibitor|losartan potassium will be administered 25 mg daily
62816510|NCT04448964|EXPERIMENTAL|Part 1: Treatment Sequence ABC|Participants will receive a single dose of JNJ-70033093 spray-dried dispersion (SDD) tablet under fasted conditions (Treatment A) in Treatment Period 1, followed by JNJ-70033093 SDD tablet in fed conditions (Treatment B) in Treatment Period 2, and then JNJ-70033093 SDD granule capsule under fasted conditions (Treatment C) in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
62816511|NCT04448964|EXPERIMENTAL|Part 1: Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
62816512|NCT04448964|EXPERIMENTAL|Part 1: Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
62240336|NCT02366728|EXPERIMENTAL|Group II: Tetanus pre-conditioning|Tetanus diptheria toxoid (Td) (1 flocculation unit) will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the 4th human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies.
62240337|NCT02366728|EXPERIMENTAL|Group III: Basiliximab and Tetanus pre-conditioning|Basiliximab infusions prior to human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccines #1 and #2 with Td pre-conditioning (1 flocculation unit) will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the 4th human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine.
62240338|NCT02939755|EXPERIMENTAL|Stepped collaborative care intervention|The 'Stepped Collaborative Care Intervention' includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
62240339|NCT02939755|ACTIVE_COMPARATOR|Enhanced Usual Care|Patients randomized to the 'Enhanced Usual Care' arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed.
62816513|NCT04448964|EXPERIMENTAL|Part 1: Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
62816514|NCT04448964|EXPERIMENTAL|Part 1: Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, and then Treatment C in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
62816515|NCT04448964|EXPERIMENTAL|Part 1: Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
62240340|NCT05729568|EXPERIMENTAL|Randomized Phase: Lenacapavir (LEN) + Teropavimab Dose A + Zinlirvimab Dose B|Participants will receive oral LEN 600mg, subcutaneous (SC) LEN 927 mg, teropavimab Dose A, and zinlirvimab Dose B on Day 1. Participants will self-administer oral LEN 600 mg on Day 2. The last treatment regimen will include SC LEN + teropavimab Dose A + zinlirvimab Dose B.
62240341|NCT05729568|EXPERIMENTAL|Randomized Phase: Antiretroviral Therapy (ART)|Participants will continue their baseline oral ART through Week 52.
62240342|NCT05729568|EXPERIMENTAL|Extension Phase: LEN + Teropavimab Dose A + Zinlirvimab Dose B|At Week 52, participants who receive the study drug of LEN, teropavimab, zinlirvimab, and complete study through Week 52 with human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) \< 50 copies/mL will be given the option to participate in the study extension phase, where they will continue to receive their randomized study drugs treatment regimen until after completion of the primary analysis (unless modified based on the data monitoring committee (DMC) analysis), up to approximately 5 years.
62597871|NCT05132712|PLACEBO_COMPARATOR|placebo group|matched for age and gender
62597872|NCT04475926||LGMD2E/R4 Cohort|Participants with LGMD2E/R4 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.
62816516|NCT04448964|EXPERIMENTAL|Part 2: Treatment Sequence DE|Participants will receive Treatment D (single dose of JNJ-70033093 SDD tablet in fed conditions) in Treatment Period 1, and then Treatment E (single dose of JNJ-70033093 SDD granule capsule under fasted conditions) in Treatment Period 2 on Day 1 of each Period during Part 2. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
62816517|NCT04448964|EXPERIMENTAL|Part 2: Treatment Sequence ED|Participants will receive Treatment E in Treatment Period 1, and then Treatment D in Treatment Period 2 on Day 1 of each Period during Part 2. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
62816518|NCT03027427||Patients|Patients with confirmation of, or suspicion of, a heritable gastric malignancy disorder
62816519|NCT03965130|EXPERIMENTAL|Glucagon|Participants will receive glucagon during the PINTA study
62816520|NCT03965130|EXPERIMENTAL|Control|The same participants will not receive glucagon during the PINTA study
62816521|NCT02188264|EXPERIMENTAL|Treatment (selumetinib and cyclosporine)|Patients receive selumetinib PO BID on day -7 of course 1 and then on days 1-28 (one dose on day 1 only). Patients also receive cyclosporine PO BID on day -3 of course 1 and then on days 1-28 (one dose on day 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62816522|NCT06159361|EXPERIMENTAL|Balance targeted exercises group|participants in this group will receive the balance targeted exercises for up to 6 weeks
62816523|NCT04482179|ACTIVE_COMPARATOR|Active TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 30 two-second stimulation trains of 10 Hz TMS will be delivered every 30 seconds to the left inferior pars triangularis and to the left posterior superior left temporal gyrus. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
62597873|NCT04475926||LGMD2D/R3 Cohort|Participants with LGMD2D/R3 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.
62038044|NCT02519348|EXPERIMENTAL|China Cohort: Durvalumab 20 mg/kg|Participants will receive durvalumab 20 mg/kg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
62038045|NCT02519348|EXPERIMENTAL|China Cohort: Tremelimumab 10 mg/kg|Participants will receive tremelimumab 10 mg/kg Q4W 7 doses followed by Q12W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
62038046|NCT02519348|EXPERIMENTAL|China Cohort: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg|Participants will receive tremelimumab 1 mg/kg Q4W 4 doses and durvalumab 20 mg/kg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
62240343|NCT05729568|EXPERIMENTAL|Extension Phase: ART|Participants who complete study through Week 52 with HIV-1 RNA \< 50 copies/mL and in the absence of confirmed virologic rebound (VR) throughout the randomized phase of the study will be given the option to participate in the extension phase and receive the study drugs of LEN, teropavimab, and zinlirvimab at the dose specified for randomized phase until after completion of the primary analysis (unless modified based on the data monitoring committee (DMC) analysis), up to approximately 5 years. Treatment with study drug will begin at Week 52 and at that time the baseline oral ART will be discontinued.
62240344|NCT04066803|EXPERIMENTAL|MTX group with folic acid|the group with optimal MTX dose (gradually increased from 0 to 12weeks，appropriate folic acid，and stable original other DMARDs
62597874|NCT04475926||LGMD2C/R5 Cohort|Participants with LGMD2C/R5 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.
62597875|NCT04475926||LGMD2A/R1 Cohort|Participants with LGMD2A/R1 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.
62597876|NCT06006494|ACTIVE_COMPARATOR|aerobic group|only a separate aerobic exercise will be given
62597877|NCT06006494|EXPERIMENTAL|resistant group|aerobic and resistance exercises will be given
62816524|NCT04482179|SHAM_COMPARATOR|Sham TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 30 two-second stimulation trains of 10 Hz sham TMS will be delivered every 30 seconds to the left inferior pars triangularis and to the left posterior superior left temporal gyrus. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
62038047|NCT03536806|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. After drug administration the patient will be observed for 2 hours after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient will depend on clinical condition and will follow appropriate clinical guidelines.
62597878|NCT06006494|EXPERIMENTAL|yoga group|aerobic exercises will be given and yoga will be done
62240345|NCT04066803|ACTIVE_COMPARATOR|control group without folic acid|the group with stable MTX 10mg/w dose and maximum DMARDs doses（graduallly increased from 0 to 12 weeks）without folic acid
62240346|NCT00858520||Smoking controls|Smokers without lung cancer and without COPD
62597879|NCT02464761|EXPERIMENTAL|Dose escalating PDT|
62597880|NCT05081700||Patients with relapsing MS|Patients with relapsing remitting MS who are intending to receive ocrelizumab.
62597881|NCT06649058|EXPERIMENTAL|cSRS PR or SD|Patients with a CR will be observed with ongoing standard of care MRI. Patients with SD or PR will be randomized to receive cSRS or ongoing observation.
62597882|NCT06649058|EXPERIMENTAL|a-pdSR CNS PD|At the time of CNS PD, patients will also be randomized to pdSRS versus pdSRS + cSRS.
62597883|NCT06649058|EXPERIMENTAL|b-PDC CNS PD|At the time of CNS PD, patients will also be randomized to pdSRS versus pdSRS + cSRS.
62240347|NCT00858520||COPD patients|Smokers with COPD but without lung cancer
62240348|NCT00858520||Lung cancer patients|smokers - never smokers with lung cancer
62597884|NCT06649058|EXPERIMENTAL|SST treated SD or PR patients to receive cSRS/ ongoing observation|Patients with a CR will be observed with ongoing standard of care MRI. Patients with SD or PR will be randomized to receive cSRS or ongoing observation.
62597885|NCT06649058|EXPERIMENTAL|SST treated PD patients to pdSRS / pdSRS+cSRS|At the time of CNS PD, patients will also be randomized to pdSRS versus pdSRS + cSRS.
62597886|NCT06630078|EXPERIMENTAL|Case group|children with bronchiolits, controlled asthma and asthmatic re-exacerbations and adults with primary upper aero-digestive tract affections or secondary to radiotherapy
62597887|NCT04760288|EXPERIMENTAL|Arm A (Pralsetinib)|Participants will receive pralsetinib at a dose of 400 milligrams (mg) orally once daily (PO QD) in 28-day cycles.
62597888|NCT04760288|ACTIVE_COMPARATOR|Arm B (SOC: Cabozantinib/Vandetanib)|Adult participants will receive investigator's choice of SOC MKI therapy with either 140 mg cabozantinib PO QD or 300 mg vandetanib PO QD in 28-day cycles. Adolescents participants (≥ 12 and \< 18 years of age) will receive vandetanib, PO QD or every other day, in 28-day cycles depending on the body surface area (BSA), at a dose determined according to the dosing nomogram available in the E.U. Vandetanib SmPC.
62038048|NCT03536806|EXPERIMENTAL|Experimental: canrenone|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After administration of canrenone: dose 200 mg (1 ampule a 10 ml) within 2-3 minutes the patient will be observed for 2 hours after the dose with exit ECG and BP measure taken at the end of observation.
62240349|NCT01410578||systemic inflammatory response syndrome|(1) temperature \> 38oC or \< 36oC; (2) pulse rate \> 90 beats/min; (3) ventilation rate \> 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) \< 32 mmHg; (4) white blood cell (WBC) count \>1 2,000μL-1 or \< 4000 μL-1 , or \> 10% immature cells.
62240350|NCT01410578||sepsis|SIRS + infection
62240351|NCT01410578||bacteremia|(1) The blood culture tested positive at least for the same pathogen;(2) The patient had at least one of the following symptoms: fever, shivering, or low blood pressure and showed signs of at least one of the following conditions: the blood culture tested positive at least twice for common skin flora from different sites; the blood culture tested positive only once for the skin flora listed above, the intravascular catheter culture tested positive for the same pathogen and the correct antibiotic treatment had been initiated for the patient; or a positive serology test consistent with other clinical laboratory test results and unrelated to infections at different sites.
62240352|NCT05945966|EXPERIMENTAL|experimental group|In this group stroke patients will be undergone task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) for the hemi-paretic side
62597889|NCT05918991|EXPERIMENTAL|Language Intervention|The language intervention will include 18 weeks of 20-25 minutes of intervention approximately 4 days per week. The language intervention is delivered via shared book reading and focuses on English language vocabulary development as well as development of syntax knowledge and expressive language.
62597890|NCT05918991|EXPERIMENTAL|Daily Report Card|The Daily Report Card group will receive the Daily Report Card intervention for 18 weeks.
62597891|NCT05918991|EXPERIMENTAL|Combined Language and Daily Report Card|Participants in this arm will receive a combination of the language intervention and the behavioral intervention. The interventions will be implemented simultaneously for 18 weeks.
62597892|NCT05918991|NO_INTERVENTION|School As Usual|Participants in the School as Usual Arm will receive neither the Behavioral Intervention nor the Language Intervention. There will be no restrictions, however, on interventions or supports that students may receive outside of the study either implemented through standard school protocol or accessed by parents. Thus, the School as Usual Arm provides a real-world practice comparison for the three active treatment groups.
62597893|NCT04852276||Control participants|Control participants will be healthy volunteers, and may include unaffected relatives of immunodeficient/dysregulated participants
62597894|NCT04852276||Patients with immunodeficiencies and immune dysregulations|Affected patients with evidence of a primary or secondary immune deficiency or dysregulation
62597895|NCT03150992|EXPERIMENTAL|Elemental 028 Extra Liquid|All patients will be assessed and given an individual plan for Elemental Diet (ED) introduction. The actual amount of ED prescribed will depend on the tolerance and palatability and not nutritional status. The recommendation of a minimum of 2 cartons of ED will be drunk orally by patients, along with other clear fluids only. Following introduction of ED, patients will be discharged from hospital (if applicable) and followed up for 2 weeks. They will have a telephone follow-up assessment once a week for 2 weeks. All other assessments will follow the standard of care. During the follow-up patients will be assessed using the Memorial Symptom Assessment Scale (MSAS) and will be asked to complete a nutritional diary every day and a quality of life questionnaire at several time points.
62240353|NCT05945966|ACTIVE_COMPARATOR|control group|In this group stroke patients will be undergone strength training using frequency, intensity, type, time (FITT) principle to non-hemi-paretic side and task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) to hemi-paretic side
62240354|NCT06211465||Cases|Patients with end-stage osteoarthritis (OA), who were eligible for total joint arthroplasty in Tartu University Hospital. Exclusion criteria: posttraumatic OA, infectious or endocrine arthropathy, acute or chronic inflammatory disease, malignancies, end-stage renal impairment (eGFR \< 60ml/min/1.73m2), dysrhythmias, clinically relevant heart failure, heart valve-disease, diabetes.
62597896|NCT00515359|ACTIVE_COMPARATOR|Continuous Dosing|continuous dosing
62038049|NCT03750552|EXPERIMENTAL|ampreloxetine|Participants randomized to ampreloxetine will receive a single, oral, daily dose of active drug for 4 weeks.
62038050|NCT03750552|PLACEBO_COMPARATOR|Placebo|Participants randomized to Placebo will receive a single, oral, daily dose of placebo for 4 weeks.
62038051|NCT01037348|EXPERIMENTAL|ranibizumab 0.5mg|
62597897|NCT00515359|ACTIVE_COMPARATOR|Intermittent Dosing|Intermittent Dosing
62735217|NCT05494463|ACTIVE_COMPARATOR|Miller blade|laryngoscopy with Miller blade in the same patient
62038052|NCT03934398||ReNEW Clinical Cohort|Individuals evaluated in the ReNEW Clinic at Johns Hopkins University who join the ReNEW Clinic Cohort Study are eligible for this cross-sectional study. Tests will be done for all participants which includes Cardiovascular Assessments, Actigraphy and Laboratory assessments.
62038053|NCT03877094|ACTIVE_COMPARATOR|Nature Virtual Reality Video|After signing the Informed Consent Form, the patient will receive a head-set dispositive to watch a nature virtual reality video during the whole procedure of breast biopsy. In the end of the procedure, the patient you will receive a Ipad (specific to the study and blocked for other functions) to respond a demographic questionnaire to characterize the sample and the likerts questionnaire to measure their pain, comfort, well-being, stress and anxiety during the procedure.
62038054|NCT03877094|NO_INTERVENTION|Control group|This control group will not receive an intervention.
62038055|NCT03385928|ACTIVE_COMPARATOR|Tranexamic acid|Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl (or in 50ml syringe with 0.9% NaCl) over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
62038056|NCT03385928|PLACEBO_COMPARATOR|Normal Saline (0.9% NaCl)|100 mls (or in 50ml syringe) intravenous 0.9%NaCl over 10 minutes followed by 500 ml intravenous 0.9% NaCl infusion over 8 hours.
62038057|NCT01440491|OTHER|physiotherapy orientated|"G1 patients were orientated by the physiotherapist during the performance of physiotherapy exercises, using the booklet~G2 received the booklet to self perform the physiotherapy exercises"
62038058|NCT01387139|ACTIVE_COMPARATOR|Ketamine Alone|1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
62038059|NCT01387139|EXPERIMENTAL|Ketamine Co-Administered with Propofol|0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
62597898|NCT03813186|EXPERIMENTAL|ASTX727 + Day 2 Food|Subjects will receive ASTX727 on Days 1-5 of Cycle 1 and a high-calorie, high-fat breakfast meal of 800-1000 calories pre-dose on Day 2 of Cycle 1.
62038060|NCT01187251||Group 1 - mp3 users|Subjects who have been using mp3 players for at least 1 hour per day for at least 1 year
62038061|NCT01187251||Group 2 - mp3 non-users|Subjects who does not listen regularly to mp3 music
62038062|NCT05777226|EXPERIMENTAL|Epalrestat treatment group|Epalrestat;Tablet; 50mg; three times a day; 36 months
62038063|NCT05777226|NO_INTERVENTION|control group|No Intervention
62038064|NCT05118685|ACTIVE_COMPARATOR|the first group estrogen group|they will receive estrogen conjugate vaginal cream one tube every night for 14 nights; then, one tube 2 nights in 1 week (two tubes every week) for 10 weeks.
62038065|NCT05118685|EXPERIMENTAL|the second group PRP group|they will receive a Platelet-rich plasma injection every 3 weeks for 4 times. PRP will be administered to the anterior vaginal wall using 27-G needles o and it is mainly injected into the anterior wall of the vagina to increase the tactile sensitivity of the injection site.
62038066|NCT05929950||patients with PCOS|
62038067|NCT05929950||control group|
62240355|NCT06211465||Controls|Gender and age matched control group, who is recruited from the general practitioner (GP) list and who are from the same geographical regions as the cases. Excluding criteria: acute or chronic inflammatory disease, GP visitation due to hip or knee problems, persistent knee or hip pain, diabetes, symptomatic coronary disease, dysrhythmias, cerebrovascular or peripheral artery disease, malignancy or renal impairment.
62240356|NCT03305068|PLACEBO_COMPARATOR|the use of a COX-II inhibitor in shoulder surgery.|Arm 1 shoulder replacement, both primary and reverse
62038068|NCT00605293|EXPERIMENTAL|C.E.R.A|Participants received starting dose of 120, 200 or 360 mcg of C.E.R.A IV once monthly for 6 months. The starting dose was based on the dose of epoetin alfa administered in Week -1.
62038069|NCT00605293|ACTIVE_COMPARATOR|Epoetin Alfa|Participants received IV injection of 6000 International Units (IU) of epoetin alfa every 3 weeks (q3wk) during the Stability Verification Period (SVP; Week -4 to -1), and 7443 IU of epoetin alfa q3wk during Dose Titration Period (DTP; Week 0 to 15), 7363 IU of epoetin alfa q3wk during Efficacy Evaluation Period (EEP; Week 16 to 23) up to 23 weeks.
62038070|NCT05890599|EXPERIMENTAL|Yoga Therapy|12 week yoga program, one weekly session of 90 minutes each, plus 2 times weekly 30 minutes of self practice.
62038071|NCT05890599|ACTIVE_COMPARATOR|Health Education|12 week health education program, one weekly session of 90 minutes each, plus 2 times weekly 30 minutes of self practice.
62038072|NCT03217110|EXPERIMENTAL|patient active rTMS|Subjects will receive 5 days of 2x daily rTMS targeted over the cerebellum.
62038073|NCT03217110|SHAM_COMPARATOR|patient sham rTMS|Subjects will receive 5 days of 2x daily sham stimulation of the cerebellum.
62038074|NCT03217110|ACTIVE_COMPARATOR|Control active rTMS|
62038075|NCT03217110|SHAM_COMPARATOR|Control sham rTMS|
62038076|NCT05190991|EXPERIMENTAL|RPH-104 q2w|RPH-104 80 mg once every 2 weeks subcutaneously or RPH-104 160 mg once every 2 weeks subcutaneously
62240357|NCT03305068|PLACEBO_COMPARATOR|the use of a COX-II inhibitor in arhroscopic shoulder surgery.|Arm 2 arthroscopic rotator cuff repair
62597899|NCT03813186|EXPERIMENTAL|ASTX727 + Day 4 Food|Subjects will receive ASTX727 on Days 1-5 of Cycle 1 and a high-calorie, high-fat breakfast meal of 800-1000 calories pre-dose on Day 4 of Cycle 1.
62735218|NCT04648488|EXPERIMENTAL|Early mobilisation|Patients will start unloaded exercise treatment 3 days after surgery. They will remove the plaster 5 times every day to perform range of motion exercises.
62735219|NCT04648488|ACTIVE_COMPARATOR|Standard treatment|Patients will have a plaster 3 weeks after surgery and after that start with exercise treatment.
62597900|NCT06145581|EXPERIMENTAL|Supportive Care (home-based physical activity)|Patients participate in remote monitored home-based physical activity sessions including flexibility practice, slow walking and breathing exercises daily on 6 out of 7 days a week and receive telephone health coaching over 5-20 minutes once a week for 12 weeks. Patients also participate in a brief telephone interview at the end of 12 weeks. Additionally, patients wear a monitor on the wrist to monitor physical activity for 7 days during enrollment and at 3 months.
62240358|NCT03805009|EXPERIMENTAL|Robotic Group (RG)|Robotic Group (RG) will perform, in addition to conventional therapy, gait training using an end-effector robotic device for Robot-Assisted Gait Training (RAGT), 3 times/week for 20 sessions. During the training, patients will be asked to walk, at a varying speed, for 45 minutes and a partial Body Weight Support (BWS). Participants will start with 30-40% of BWS and an initial speed of 1.5 km/h; increasing to a maximum of between 2.2 and 2.5 km/h and reducing the initial BWS to 15%. The therapist will provide any help during sessions if required. Over 45 minutes, the patient simulates a minimum of 300 steps; patients could rest during the session, though they will be asked to walk continuously for a minimum of 5 minutes during each session.
62038077|NCT03195933|EXPERIMENTAL|Cortisol first, Placebo second|Single oral administration of 20 mg cortisol capsule to pharmacologically elevate cortisol levels during first functional magnetic resonance imaging (fMRI) session; Identically appearing placebo capsule during second fMRI session.
62240359|NCT03805009|NO_INTERVENTION|Conventional Group (CG)|Conventional Group (CG) will perform conventional gait rehabilitation program. The treatment will include: muscle strengthening exercises and stretching of the lower limb, and static and dynamic exercises for the recovery of balance in the supine and standing positions using assistive devices; training gait exercises with parallel bars or in open spaces performed both with and without assistive devices; training to climb up and down stairs; exercises to improve proprioception in the supine, sitting and standing positions, using a proprioceptive footboard; exercises to improve trunk control.
62240360|NCT01857778||Lactating Women|
62240361|NCT02576236|EXPERIMENTAL|Triple therapy guided by result of the molecular resistance|"* If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.~* If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days."
62240362|NCT02576236|ACTIVE_COMPARATOR|Quadruple concomitant therapy|high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days
62240363|NCT03732079||Research group|Women with early postpartum hemorrhage.
62240364|NCT03732079||Control group|Postpartum women without abnormal bleeding.
62240365|NCT03839407|EXPERIMENTAL|MUSE device Class 21|Participants will utilize the MUSE device for 12 weeks during the intervention period.
62240366|NCT03839407|NO_INTERVENTION|No MUSE device Class 21|Participants will not utilize the MUSE device for 12 weeks during the non-intervention period.
62597901|NCT06624098|EXPERIMENTAL|Early transjugular intrahepatic portosystemic shunt (TIPS)|TIPS was performed within 72 hours after the endoscopic hemostasis.
62240367|NCT03839407|EXPERIMENTAL|MUSE device Class 22|Participants will utilize the MUSE device for 12 weeks during the intervention period.
62240368|NCT03839407|NO_INTERVENTION|No MUSE device Class 22|Participants will not utilize the MUSE device for 12 weeks during the non-intervention period.
62240369|NCT06350851|OTHER|Group1: Control subjects (non-infected with filariasis)|Blood drawing + feces sample collection
62240370|NCT06350851|OTHER|Group 2: Subjects mono-infected with Onchocerca volvulus|Blood drawing + feces sample collection
62240371|NCT06350851|OTHER|Group 3: Subjects mono-infected with Loa loa|Blood drawing + feces sample collection
62597902|NCT00538044|EXPERIMENTAL|1simvastatin group|before the operation, the patient start the simvastatin medication on the dosage of 40mg per day
62597903|NCT00538044|NO_INTERVENTION|2contral group|just do routin operation with no use of simvastatin, other medication is exact the same as the simvastatin group
62597904|NCT02632240|ACTIVE_COMPARATOR|Control group|Surgery:The tunnel technique for covering gingival recession. Graft: connective tissue.
62597905|NCT02632240|ACTIVE_COMPARATOR|Study group|Surgery:The tunnel technique for covering gingival recession.Graft: xenogenic collagen matrix (Mucoderm).
62038078|NCT03195933|EXPERIMENTAL|Placebo first, Cortisol second|Placebo capsule during first fMRI session; Single oral administration of 20 mg cortisol capsule to pharmacologically elevate cortisol levels during second fMRI session.
62038079|NCT04099108|EXPERIMENTAL|Intervention|Combined cycle ergometry and bolus amino acid supplementation, along with standard of care
62597906|NCT04878432|EXPERIMENTAL|MBG453 (sabatolimab) + HMA|MBG453 + HMA (azacitidine, decitabine, or INQOVI (oral decitabine))
62597907|NCT02085616|EXPERIMENTAL|Proactive service|Intervention: Tobacco cessation by telephone support. The structured treatment protocol is a mixture of motivational interviewing (MI), cognitive behaviour therapy, and pharmacological consultation. In the proactive service the callers to the quitline are offered a number of callbacks.
62430770|NCT04624061|EXPERIMENTAL|Intervention|"The integrated HIV/HTN care model with the following components;~1. Training and capacity building on the INTEGRATED HIV/HTN model and NCD care~2. Integrated HIV/HTN care delivery model by promoting HTN screening and care in HIV clinics.~3. HMIS enhancements through mentorship and coaching on the use of NCD registers and NCD patient cards and HTN data capture in the (Electronic Medical Record) EMR system.~4. SMS and/or WhatsApp for data coordination and communication among providers, District Health officers (DHOs) and study team (Mentors) to strengthen feedback."
62597908|NCT02085616|ACTIVE_COMPARATOR|Reactive service|Intervention: Tobacco cessation by telephone support. The structured treatment protocol is a mixture of motivational interviewing (MI), cognitive behaviour therapy, and pharmacological consultation. In the reactive service the callers to the quitline are informed that they can themselves call back whenever they like.
62597909|NCT04919824|EXPERIMENTAL|Bipolar Knife|ESD procedure performed with a novel bipolar knife.
62597910|NCT04919824|ACTIVE_COMPARATOR|Monopolar Knife|ESD procedure performed with monopolar knives.
62240372|NCT06350851|OTHER|Group 4: Subjects mono-infected with Mansonella perstans (alternatively co-infected with Loa loa)|Blood drawing + feces sample collection
62430771|NCT04624061|NO_INTERVENTION|Control|Standard of care maintained. These are procedures conducted during the routine HIV and Hypertension care visits at the health facilities include;a) Provision of BP machines b)Provision of NCD register and NCD patient card and ; c) Following MOH treatment guidelines
62430772|NCT04937751||Invasive fusariosis|
62597911|NCT06643767|EXPERIMENTAL|Participants|Participants scheduled for screening mammography.
62597912|NCT06624280||SEMLS group|The study population will include patients who attended the Children Rehabilitation Unit of Local Health Authority of Reggio Emilia from 2011 to 2021. The study will focus on patients diagnosed with cerebral palsy who underwent lower limb SEMLS (single-event multilevel surgery) and 3D Gait Analysis before and after surgery.
62240373|NCT02927743|ACTIVE_COMPARATOR|evidence-based online feedback|During three months GPs will receive weekly feedback about evidence-based management of respiratory tract infections. In order to control that they read the material, there is a questionnaire, they have to fill in every week
62430773|NCT04937751||Fusarium keratitis|
62430774|NCT01150513|ACTIVE_COMPARATOR|EC-T|
62430775|NCT01150513|EXPERIMENTAL|TP|
62240374|NCT02927743|NO_INTERVENTION|control|GPs will register data without receiving online feed-back
62430776|NCT04005105|ACTIVE_COMPARATOR|Intensive management|"Baseline mean blood pressure (MAP) and central venous pressure (CVP) will be measured to calculate baseline mean perfusion pressure. Intra-surgical values of ± 25% basal MAP will be maintained and once in the ICU an algorithm corresponding to group~1 based on cardiac index and MPP will be followed for 24 hours."
62430777|NCT04005105|NO_INTERVENTION|Standard management|MAP during surgery will be maintained \> 60 mmHg according to usual protocol. Once in ICU, during the first 24 hours an algorithm corresponding to group 2 based on cardiac index, MAP and CVP will be followed.
62597913|NCT03475199|EXPERIMENTAL|FabLife group|Fablife personnalised support and telephone follow-up with a dietician.
62597914|NCT03475199|NO_INTERVENTION|Control group|General dietary recommendations.
62597915|NCT01330277||Participants with Hunter syndrome|Participants diagnosed with Hunter syndrome (Mucopolisaccharidosis type 2) aged between 2 months to 50 years
62597916|NCT01748617|EXPERIMENTAL|Pomegranate Juice|Acute ingestion of pomegranate juice with high fat meal.
62597917|NCT01748617|PLACEBO_COMPARATOR|Control|Acute ingestion of juice-free sweetened beverage with high fat meal.
62597918|NCT03722745|EXPERIMENTAL|Study group 1|Juvenile offenders will attend 4-session Trauma Affect Regulation: Guide for Education \& Treatment (TARGET) groups led by one or two juvenile staff members
62597919|NCT03722745|ACTIVE_COMPARATOR|study group 2|Juvenile offenders will receive treatment-as-usual (TAU).
62597920|NCT04987099|EXPERIMENTAL|Experimental Dose|Participants will consume a 15 mL grape juice cocktail solution that contains 550 mg of choline once daily for the duration of their pregnancy.
62597921|NCT04987099|PLACEBO_COMPARATOR|Control Dose|Participants will consume a 15 mL grape juice cocktail solution that contains 25 mg of choline once daily for the duration of their pregnancy.
62597922|NCT06620419|EXPERIMENTAL|Treatment group|Self-applied electrical stimulation for 6 weeks.
62597923|NCT06078449|EXPERIMENTAL|Injection group|Group (1) the study group, they will receive HA intra-articular injection in addition to 12 sessions of therapeutic ultrasound.
62816525|NCT01612351|EXPERIMENTAL|Non-Randomized Single-Arm|All participants will receive induction chemotherapy and transoral surgery. Following surgery, participants will be stratified into a risk category (low, medium, or high). Subjects in the low risk category will receive no further treatment after their transoral surgery. Subjects in the medium risk category will receive ipsilateral radiation concurrent with weekly cisplatin, and subjects in the high risk category will receive cisplatin every three weeks with concurrent bilateral radiation.
62816526|NCT05614492|EXPERIMENTAL|Individual Arm (IDM)|Self-administration of the intervention
62816527|NCT05614492|EXPERIMENTAL|Shared Arm (SDM)|Advocate-administration of the intervention
62240375|NCT02461030|EXPERIMENTAL|CSPR + NS treatment|"In-office and at home Colgate sensitive pro-relief - CSPR~Intervention: Non-surgical periodontal treatment (full-mouth debridement, scaling and root planing with ultrasonic/hand instruments) associated with In-office application of Colgate Sensitive Pro-Relief (CSPR) + tooth brushing with at home CSPR toothpaste during 8 weeks."
62240376|NCT02461030|PLACEBO_COMPARATOR|Villevie® + NS treatment|"In-office Villevie® prophy paste + Colgate Toothpaste~Treatment: In-office application of a Villevie® (fluoride-free) prophy paste + tooth brushing with a Colgate Cavity Protection Toothpaste during 8 weeks, after non-surgical periodontal treatment. (Full-mouth debridment/ Scaling and root planing with ultrasonic/hand instruments)"
62240377|NCT01839253|EXPERIMENTAL|Atenolol|In each group, premedication with either b-blocker (Atenolol) or ACE inhibitor (enalapril) or nothing (control group) in the preparation room.
62240378|NCT01839253|ACTIVE_COMPARATOR|Enalapril|In each group, premedication with either b-blocker (Atenolol) or ACE inhibitor (enalapril) or nothing (control group) in the preparation room.
62430778|NCT02551003|EXPERIMENTAL|Cord blood with hypothermia|Autologous cord blood will be collected after birth and stored in Cord Blood Bank of hospital. All cord blood samples are routinely performed by dedicated, trained UCB collection staff and is restricted to deliveries of mothers who have given prior written informed consent for collection. If the mother delivered a baby with signs of HIE or cerebral infarction, Bank staff collected UCB utilizing standard procedures. Collected UCB was transported at roomtemperature in validated shippers to the NICU. Infusions were started when cells and study staff were available for administration and monitoring. Infants received up to 3 infusions, with the first dose as soon as possible after birth, and at, 48, and 72 postnatal hours. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
62430779|NCT02551003|ACTIVE_COMPARATOR|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
62430780|NCT03156517|ACTIVE_COMPARATOR|Deep Brain Stimulation in VIM|Patients receive stimulation in the VIM-nucleus of the thalamus
62430781|NCT03156517|ACTIVE_COMPARATOR|Deep Brain Stimulation in PSA|Patients receive stimulation in the posterior subthalamic area
62430782|NCT05358561|NO_INTERVENTION|Nutritional analyzes applied to four cakes|The study is two-fold. In the preliminary study, the standard and test cakes (chia added cake, flax seed added cake, and chia+flax seed added cake) were developed and the amount of cake containing 50 g carbohydrate and the amount of moisture, ash, pulp, protein, fat, and digestible carbohydrate will be determined via analyses that will be carried at Toros University Food Chemistry Laboratory. Based on the results obtained, the amount of cakes containing 50 g digestible carbohydrate will be calculated and produced.
62430783|NCT05358561|EXPERIMENTAL|Flaxseed cake|Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of flaxseed cake
62816528|NCT05614492|ACTIVE_COMPARATOR|Control Arm (Time and Attention Matched Control)|Self-administration of standard PrEP information from Centers for Disease Control (CDC).
62816529|NCT04677647|EXPERIMENTAL|OurChild|
62240379|NCT01839253|PLACEBO_COMPARATOR|control|none of antihypertensive agents
62597924|NCT06078449|OTHER|Ultrasound group|Group (2) served as the control group, will receive only HA intra-articular knee injection.
62597925|NCT05115422|EXPERIMENTAL|"Coping with Brain Fog intervention"|
62597926|NCT02688998|ACTIVE_COMPARATOR|Venous access PORT or PICC|Participants will receive a central line placement either a PORT or a PICC prior to the initiation of chemotherapy.
62597927|NCT02688998|NO_INTERVENTION|No intervention|Participants will only receive a central line if required once chemotherapy has been initiated.
62816530|NCT04494256|EXPERIMENTAL|Part 1: Cohort A|Participants with ALS will receive BIIB105 Dose 1, intrathecally (IT), as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
62816531|NCT04494256|EXPERIMENTAL|Part 1: Cohort B|Participants with ALS will receive BIIB105 Dose 2, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
62816532|NCT04494256|EXPERIMENTAL|Part 1: Cohort C1|Participants with ALS will receive BIIB105 Dose 3, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
62816533|NCT04494256|EXPERIMENTAL|Part 1: Cohort D1|Participants with ALS will receive BIIB105 Dose 4, IT, as 3 loading doses on Day 1 and two later days, followed by five maintenance doses on five later days.
62816534|NCT04494256|EXPERIMENTAL|Part 1: Cohort C2|Participants with polyQ-ALS will receive BIIB105 Dose 3, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
62038080|NCT04099108|NO_INTERVENTION|Control|Standard of care only
62038081|NCT01483924|EXPERIMENTAL|10 mg Apo805K1, or placebo|
62240380|NCT02992483|EXPERIMENTAL|MIK665|
62240381|NCT03659279|EXPERIMENTAL|Let's Get Organized|Group intervention with 10 weekly sessions, each lasting 1.5 hours.
62240382|NCT04603586|EXPERIMENTAL|Arm A|SBRT with BED 60-70Gy combined with Gemcitabine + albumin-bound paclitaxel
62597928|NCT05839652|EXPERIMENTAL|Study 1|Twenty-five participants will be asked to visit the laboratory on 6 occasions, for an open-label, dose escalation trial to determine the effect of midodrine and droxidopa on supine and seated blood pressure and on symptoms of autonomic dysreflexia and orthostatic hypotension.
62597929|NCT05839652|EXPERIMENTAL|Study 2|Determine the effects of compression garments, midodrine, and droxidopa, compared to placebo, on orthostatic hemodynamics, symptoms of AD and OH and reporting of fatigue and thermal comfort.
62597930|NCT04775342||1 group|1 group will be assessed then will be given smartphone to use and assessed
62597931|NCT01506765|ACTIVE_COMPARATOR|patients who receive NAC first|this group will receive 2g/day of NAC (2 caps of 0.5g twice day)for a duration of 8 weeks first, and after this 8 weeks their receive placebo for 8 weeks.
62597932|NCT01506765|PLACEBO_COMPARATOR|patients who receive placebo first|this patients will receive first placebo for a duration of 8 weeks, and after this 8 weeks their receive NAC for 8 weeks
62597933|NCT06459505|ACTIVE_COMPARATOR|Routine or standard Physical Therapy Group|This group will receive routine or conventional physical therapy.
62597934|NCT06459505|EXPERIMENTAL|Adapted Physical Activity Group|This group will receive Adapted Physical Activities.
62597935|NCT03091192|EXPERIMENTAL|Savolitinib|See: intervention description
62597936|NCT03091192|ACTIVE_COMPARATOR|Sunitinib|See: intervention description
62597937|NCT05234879|EXPERIMENTAL|Frame Running intervention|Participants will be invited to 12 Frame Running training sessions
62597938|NCT02686242||spinal anesthesia|patients receive spinal anesthesia before general anesthesia
62597939|NCT02686242||general anesthesia|patients receive general anesthesia
62597940|NCT02459847|EXPERIMENTAL|Mindfulness|Two sessions, each lasting 60-minutes total. The first session involves standard hand therapy care for the entire session. The second session begins with the participant listening to a 19-minute audio-recorded body scan (i.e., mindfulness training), followed by standard care.
62597941|NCT02459847|EXPERIMENTAL|Biofeedback|Two sessions, each lasting 60-minutes total. The first session involves standard hand therapy care for the entire session. The second session begins with the participant receiving 20 minutes of visual biofeedback training using sonographic imaging (i.e., sonographic biofeedback), followed by standard care.
62240383|NCT04603586|EXPERIMENTAL|Arm B|SBRT with BED \>70Gy combined with Gemcitabine + albumin-bound paclitaxel
62597942|NCT02553499|EXPERIMENTAL|MK-1248|Participants received escalating doses of MK-1248 at assigned dose (dose range: 0.12 mg to 170 mg MK-1248) via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 4 cycles (up to \~3 months).
62597943|NCT02553499|EXPERIMENTAL|MK-1248 + Pembrolizumab|Participants received escalating doses of MK-1248 at assigned dose (dose range: 0.12 mg to 60 mg MK-1248) via IV infusion on Day 1 of each 21-day cycle for a maximum of 4 cycles (up to \~3 months) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to \~24 months).
62597944|NCT05425043|EXPERIMENTAL|Granulocytes|Patient to receive pooled granulocytes for 7 days concurrently. 20 participants will be approached for this arm.
62240384|NCT00527254|NO_INTERVENTION|Control group|
62240385|NCT00527254|ACTIVE_COMPARATOR|Telemedicine group|
62240386|NCT04396314|EXPERIMENTAL|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), a health oriented, multi-perspective and person-centred approach with a focus on the patient's resources, is a movement awareness training approach in physiotherapy, aiming to promote movement quality in daily life through self-exploration and self-experience enabling the learning of new movement habits. BBAT consists of a broad scope of movements in the following positions: lying, sitting, standing and walking. Relational movements are practiced in therapy with components such as rhythm, form, elasticity, flow, intention and voice
62430784|NCT05358561|EXPERIMENTAL|Chia cake|Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of chia cake
62430785|NCT05358561|EXPERIMENTAL|Flaxseed and chia cake|Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of flaxseed and chia cake
62430786|NCT05358561|EXPERIMENTAL|Standart|Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of standart cake
62430787|NCT06024902||childhood asthma|Subjects with confirmed diagnosis of asthma without other lung disease followed for collection of demographic and clinical data.
62430788|NCT01882231|OTHER|DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI|Patients will have dynamic contrast-enhanced (DCE), diffusion-weighted (DW), magnetization transfer (MT), and chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) performed before and after 1 cycle of chemotherapy.
62430789|NCT04670029|NO_INTERVENTION|Standard|
62430790|NCT04670029|EXPERIMENTAL|APA|"* During the first 3 cures, 3 APA sessions will be offered per week:~  * 2 sessions of anaerobic type of 1 hour with muscle strengthening, stretching, flexibility and balance, supervised in the room,~ * 1 aerobic type exercise session of 1.5 hours (Nordic walking: outdoors) or a 3rd indoor session if not possible,~ * + home exercise book if the patient so wishes with record the time in minutes per session and the intensity felt and the modalities of the exercises carried out.~* During the 5 remaining cycles, 3 APA sessions will be offered per week:~  * 1 session of 1 hour in an anaerobic exercise room (muscle strengthening, stretching, flexibility, balance) supervised,~ * 1 session of anaerobic exercise per week in autonomy at home (with exercise book),~ * 1 or more session per week of one hour of walking or cycling independently at home (aerobic effort) with declaration in the logbook of the intensity of exertion felt and the time in minutes per session."
62430791|NCT05697484|ACTIVE_COMPARATOR|intervention group|
62430792|NCT05697484|NO_INTERVENTION|control group|
62430793|NCT03501199|EXPERIMENTAL|PRF Group|PRF is will be used in immediate dental implant placement.
62430794|NCT03501199|EXPERIMENTAL|Graft Group|The xenogenic graft is will be used in immediate dental implant placement.
62430795|NCT03501199|EXPERIMENTAL|Control Group|No extra material is will be used in immediate dental implant placement.
62430796|NCT01230866|OTHER|Proton Radiation Hypofractionation|5 fractions (7.6 Gy(RBE) x 5)
62240387|NCT04396314|ACTIVE_COMPARATOR|Control|The control group will be treatment for usual for PTSD. Pharmacological treatment is based in fluoxetine, paroxetine, sertraline and venlafaxine. Regarding non-pharmacological treatment the strongly recommendations are cognitive-behavioural therapy, cognitive processing therapy, cognitive therapy and prolonged exposure therapy
62597945|NCT05425043|NO_INTERVENTION|Control|Non-randomised control arm, where patients who are receiving a stem cell transplant, as described in the eligibility criteria, are asked for a blood sample. This is to establish a baseline versus the experimental arm. 20 participants will be approached for this arm.
62597946|NCT03212092|EXPERIMENTAL|Multivitamin, mineral & n-3 FA|The daily supplementation of multivitamin- and mineral in 2 capsules and n-3 fatty acids in 2 softgel capsules.
62597947|NCT03212092|PLACEBO_COMPARATOR|Placebo|The placebo consists of daily supplementation of 2 capsules with rice bran extract, hypromellose and 1.6 mg riboflavin. And 2 softgel capsules with a vegetable oil.
62816535|NCT04494256|EXPERIMENTAL|Part 1: Cohort D2|Participants with polyQ-ALS will receive BIIB105 Dose 4, IT, as 3 loading doses on Day 1 and two later days, followed by five maintenance doses on five later days.
62816536|NCT04494256|PLACEBO_COMPARATOR|Part 1: Cohorts A-D2: Placebo|Participants with ALS and polyQ-ALS for Cohorts A, B, C1 and C2 will receive matching placebo to BIIB105 as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days, and participants with ALS and polyQ-ALS for Cohorts D1 and D2 will receive matching placebo to BIIB105 as 3 loading doses on Day 1 and two later days, followed by five maintenance doses on five later days.
62038082|NCT01483924|EXPERIMENTAL|30 mg Apo805K1, or placebo|
62240388|NCT05573321|EXPERIMENTAL|BFR-RE|In the BFR-RE intervention, the exercise will be done as a set of 30 repetitions with a loading of 30% of 1 RM and an additional 3 sets x 15 repetitions, with 30 seconds rest between sets.
62430797|NCT01230866|ACTIVE_COMPARATOR|Proton Radiation Standard Fractionation|44 fractions (1.8 Gy(RBE) x 44)
62430798|NCT01837420|OTHER|Placebo with crossover to VB-201 160mg|Subjects on placebo will crossover to VB-201 160 at week 16.
62430799|NCT01837420|EXPERIMENTAL|VB-201 80mg|Subjects will receive VB-201 80mg/day for 24 weeks
62430800|NCT01837420|EXPERIMENTAL|VB-201 160mg|Subjects will received 80mg twice daily for 24 weeks
62430801|NCT05620680|EXPERIMENTAL|Treatment group|CD7 CAR-T treatment group
62430802|NCT04862104|EXPERIMENTAL|Intervention group (Discharge Training)|In addition to the general care provided by health professionals, the study group received discharge training created according to the Nursing Interventions Classification.
62240389|NCT05573321|ACTIVE_COMPARATOR|HL-RE|In the HL-RE intervention, the exercise will be performed with a loading of 80% of 1 RM, with 4 sets x 7 repetitions, with 60 seconds of rest between sets.
62430803|NCT04862104|NO_INTERVENTION|Control group (Usual Care)|The control group continued to receive the routine care
62430804|NCT02946502|EXPERIMENTAL|Handheld dynamometry (handgrip strength)|All included patients will have a blinded evaluation of handgrip strength before weaning process.
62597948|NCT05958771|ACTIVE_COMPARATOR|Children who receive the IP|"The Test Article/placebo will be co-administered with the childhood vaccines that are scheduled at the regular National Program of Immunization vaccination visits around 2 months, 4 months and 6 months of age.~Test article: ROTAVAC 5D, 3 doses. Each dose of 0.5 mL. Administered orally."
62816537|NCT04494256|EXPERIMENTAL|Part 2: Cohorts A-C2: Open-Label|Participants who complete Cohorts A, B, C1, and C2 will receive BIIB105 Dose 3, IT, as 3 loading doses on Day 1 and two later days, followed up to thirty-eight maintenance doses, on up to thirty-eight later days.
62430805|NCT02444182|EXPERIMENTAL|Probiotics|participants will receive a lozenge containing mixture of probiotic bacteria BB-12 and LGG
62430806|NCT02444182|PLACEBO_COMPARATOR|Control - No probiotics|Participants will receive a control lozenge containing no probiotics. all lozenges are sugar-free; sweetened by xylitol (0.5 g xylitol per piece)
62597949|NCT05958771|PLACEBO_COMPARATOR|Children who receive placebo|"The Test Article/placebo will be co-administered with the childhood vaccines that are scheduled at the regular National Program of Immunization vaccination visits around 2 months, 4 months and 6 months of age.~Placebo: 3 doses. Each dose of 0.5 mL. Administered orally."
62597950|NCT03991013|ACTIVE_COMPARATOR|Supplementary dose|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later for the first 14 days.
62430807|NCT04290806||ESCC|250 patients with esophageal squamous cell carcinoma
62430808|NCT04290806||GAC|250 patients with gastric adenocarcinoma
62038083|NCT01483924|EXPERIMENTAL|60 mg Apo805K1, or placebo|
62038084|NCT01483924|EXPERIMENTAL|100 mg Apo805K1, or placebo|
62038085|NCT05865431|EXPERIMENTAL|Zinc Oxide, Avobenzone, No Product|Participants have zinc oxide, avobenzone, and no product applied to 3 different spots on the forearm and singlet oxygen is measured after UV exposure.
62038086|NCT00103246|EXPERIMENTAL|Topical silicon phthalocyanine 4 (Pc 4) + photodynamic therapy|Topical silicon phthalocyanine 4 (Pc 4) followed by photodynamic therapy.
62430809|NCT04290806||GEJAC|250 patients with gastroesophageal junction adenocarcinoma
62430810|NCT04290806||EAC|150 patients with esophageal adenocarcinoma
62430811|NCT02282111|ACTIVE_COMPARATOR|EUS-CNB|Using a linear EUS with color and pulsed Doppler to scan the area for vessels, the lesion was then sampled with a 22-gauge beveled needle (using the slow capillary suction and fanning techniques with 5 to 15 to-and-fro movements with each pass). A total of 4 passes were performed and after that the procedure terminated.
62430812|NCT02282111|ACTIVE_COMPARATOR|SINK|Using a conventional needle-knife sphincterotome connected to an electrosurgical unit, and under direct endoscopic vision, a 6-12mm linear incision was made from the periphery of the lesion to its highest convexity zone. A conventional biopsy forceps was then deeply introduced through the hole, and 2 bites were obtained per pass. A total of 4 passes were performed by passing the biopsy forceps through the incision on each occasion. The mucosal incision was then closed with endoclips whenever possible.
62430813|NCT05356351|EXPERIMENTAL|test group|RC48-ADC 2.0 mg/kg）D1,Triplizumab 3mg/kg D2，Q2W
62597951|NCT03991013|PLACEBO_COMPARATOR|Placebo dose|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet daily with a matching placebo taken 12 hours later for the first 14 days.
62597952|NCT03580434|EXPERIMENTAL|V-STRUT|V-STRUT implantation
62597953|NCT03081806|EXPERIMENTAL|Group A|High dose group: X0002, BID (approximately every 12 hours; n=102); Placebo, BID(approximately every 12 hours; n=102)
62597954|NCT03081806|PLACEBO_COMPARATOR|Group B|Low dose group: X0002, BID (approximately every 12 hours; n=102); Placebo, BID(approximately every 12 hours; n=102)
62597955|NCT03163056|OTHER|Cognitive-behavioral treatment (CBT)|The CBT treatment condition is implemented in group-based sessions carried out during 8 weeks. Components included: information about tobacco, behavioral contract whereby patients committed to attend sessions, self-monitoring and graphical representation of cigarette smoking, nicotine fading (a weekly reduction of 30% of nicotine intake from the first to the four week, and abstinence from the fifth week onwards), physiological feedback (CO in expired air and cotinine analyses) on cigarette intake, stimulus control, strategies for managing nicotine withdrawal symptoms, training in alternative behaviors, and relapse prevention strategies (e.g., problem solving techniques).
62240390|NCT02271074|NO_INTERVENTION|Standard of Care|The role of this arm is to provide a baseline measure that can be used to assess the effectiveness of the combination interventions in improving the proportion of individuals entering care within 3 months. Participants in this arm only receive standard post-test counselling after they are issued with a positive HIV result. They are counselled on possible emotional resources, and given information on how to reduce risk of HIV transmission, ongoing positive living, nutrition and healthy lifestyles. These clients are given referral letters and referred to health facilities of their choice that offer HIV care/treatment. They are then followed up at the designated study time points to ascertain entry into care.
62240391|NCT02271074|EXPERIMENTAL|Point of care CD4 testing|Participants in this arm will receive point of care (POC) cluster differentiation 4 (CD4) testing using the PIMA™ CD4 test system.
62240392|NCT02271074|EXPERIMENTAL|Care facilitation|Participants receive a combination of POC CD4 testing and care facilitation.
62240393|NCT02271074|EXPERIMENTAL|Transport support|Participants receive a combination of POC CD4 testing and transport support.
62430814|NCT02372682||Test|"Any pediatric patient (0-18 years of age) with known liver disease in whom a liver biopsy is to be performed as standard of care to assess the degree of fibrosis will also undergo an abdominal ultrasound to evaluate the liver.~Underlying diagnoses include but are not limited to biliary atresia, congenital fibrosis-cholestasis, Alagille syndrome, Caroli's disease, choledochal cyst, alpha-1-antitrypsin deficiency, progressive familial intrahepatic cholestasis (PFIC), viral hepatitis, glycogenosis, fructosemia, Wilson disease, cystic fibrosis, autosomal recessive polycystic kidney disease (ARPCKD), mesenterico-caval shunt, post liver transplant, and nonalcoholic steatohepatitis (NASH)."
62430815|NCT02372682||Control|Any pediatric patient (0-18 years of age) undergoing evaluation with an abdominal ultrasound as standard of care for evaluation for a diagnosis other than liver disease and in whom the US shows a normal liver, gallbladder, pancreas, spleen, and biliary tree will then be asked to enroll in the research study by undergoing shear wave elastography.
62430816|NCT00817466|EXPERIMENTAL|Racemic adrenaline, fixed intervals|Active drug with fixed intervals of inhalation, adjusted at least every 24h.
62430817|NCT00817466|EXPERIMENTAL|Racemic adrenalin, on demand|Racemic adrenaline, inhalations on demand (max every 2 hrs)
62430818|NCT00817466|ACTIVE_COMPARATOR|Saline, fixed intervals|Saline inhalation fixed intervals, adjusted at least every 24 hrs
62430819|NCT00817466|ACTIVE_COMPARATOR|saline on demand|Saline inhalations on demand, max every 2 hrs, adjusted every 12 hrs
62430820|NCT06381596|EXPERIMENTAL|Fundus autofluorescence (FAF) imaging|
62430821|NCT01873638|OTHER|Minilaparotomy|Minilaparotomy cholecystectomy as a day surgery
62430822|NCT01873638|OTHER|Laparoscopy|Laparoscopic cholecystectomy as a day surgery
62430823|NCT03836729|EXPERIMENTAL|TAF/FTC followed by TAF/FTC + GSK3640254|Subjects will receive TAF/FTC 25/200 mg QD on Days 1 through 14 in Treatment Period 1. Subjects will be co-administered TAF/FTC 25/200 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Treatment Period 2.
62430824|NCT00657397|EXPERIMENTAL|A|Methadone inducted by a primary care physician
62430825|NCT00657397|ACTIVE_COMPARATOR|B|Methadone inducted (in CSAPA)
62430826|NCT03152227|EXPERIMENTAL|ACGG & ATONU|ACGG high-producing chicks to households along with provision of technical input on production and ATONU Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
62430827|NCT03152227|ACTIVE_COMPARATOR|ACGG only|ACGG high-producing chicks to households along with provision of technical input on production
62430828|NCT03152227|NO_INTERVENTION|Control|ACGG eligible households in non-ACGG villages receiving standard of care agricultural and health services as provided in Ethiopia
62430829|NCT04178317||Venetoclax Participants|Participants receiving venetoclax for chronic lymphocytic leukemia according to the approved local label, and the decision to prescribe Venetoclax is independent from the enrollment into the study.
62597956|NCT03163056|ACTIVE_COMPARATOR|CBT+Behavioral Activation (BA)|This intervention includes both CBT and BA strategies for smoking cessation and depression management. Participants allocated to this condition received 8 therapy sessions. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
62430830|NCT03066635|EXPERIMENTAL|Botulinum Toxin 25 IU|5 patients will be injected with 25 IU of Botulinum Toxin Type A towards the otic ganglion in the symptomatic side (ipsilateral to the pain)
62430831|NCT03066635|EXPERIMENTAL|Botulinum Toxin 12.5 IU|5 patients will be injected with 12.5 IU of Botulinum Toxin Type A towards the otic ganglion in the symptomatic side (ipsilateral to the pain)
62430832|NCT03143088||Medical clown|Medical clown will be present in the pediatric emergency department while assessing blood pressure during triage of patients.
62430833|NCT03143088||Blood pressure assessment|Blood pressure will be measured by the medical center protocols.
62430834|NCT06263465|EXPERIMENTAL|Lactobacillus cispatus|10\^9 cfu,5 days
62430835|NCT06263465|PLACEBO_COMPARATOR|Placebo|0 cfu,5 days
62430836|NCT02795130|EXPERIMENTAL|8-0 polyglactin 910|
62430837|NCT02795130|EXPERIMENTAL|6-0 plain gut suture|
62430838|NCT05099328|EXPERIMENTAL|Recast Therapy Provided By Clinician|Children will be exposed to recasts at a rate of 1/minute. Treatment will be provided 2x/week for 8 weeks for a total of 16 visits (960 recasts). 2 additional weeks are allocated for make up visits. Treatment will be provided by a trained, certified, licensed Speech Language Pathologist (SLP).
62430839|NCT05099328|EXPERIMENTAL|Illustrated Syntax Stories Provided by Clinician|Children will be listen to books that are specially scripted to promote the use of a particular syntax target. Treatment will be provided 2x/week for 8 weeks for a total of 16 visits (960 exposures), with 2 books read at each visit. 2 additional weeks are allocated for make up visits. Treatment will be provided by a trained, certified, licensed SLP.
62597957|NCT03163056|ACTIVE_COMPARATOR|CBT+BA+ Contingency Management (CM)|This intervention is provided in the same manner as the above treatment protocols but with the addition of a CM procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
62816538|NCT04494256|EXPERIMENTAL|Part 2: Cohorts D1, D2: Open-Label|Participants who complete Cohorts D1 and D2 will have a blinded Loading Dose Period, during which those who received placebo in Part 1 will receive BIIB105 Dose 4, IT, as 3 loading doses on Day 1 and two later days, while those who received BIIB105 in Part 1 will receive 2 loading doses of BIIB105 Dose 4, IT, on Days 1 and one later day, and placebo on Day 15. After the blinded Loading Dose Period, participants will receive BIIB105 Dose 4 up to thirty-eight maintenance doses, on up to thirty-eight later days.
62816539|NCT06009653|ACTIVE_COMPARATOR|Standard Care|In this arm, participants will receive the standard care intervention from community health workers.
62816540|NCT06009653|EXPERIMENTAL|Intensive lifestyle intervention plus placebo|In this arm, participants will receive a culturally-tailored dietary and behavioral intensive lifestyle intervention from community health workers, and will receive placebo subcutaneous injections weekly during the 52-week intervention.
62816541|NCT06009653|EXPERIMENTAL|Intensive lifestyle intervention plus tirzepatide|In this arm, participants will receive the behavioral plant-based intervention from community health workers, and will receive subcutaneous injections of tirzepatide weekly during the 52-week intervention
62430840|NCT05099328|EXPERIMENTAL|Recast Therapy Provided by a Caregiver|Caregivers will receive two training sessions on how to provide recast therapy and demonstrate their skill at providing recast therapy with support from the clinician. Caregivers will then provide recast therapy at a rate of 1 recast per minute to their children for a minimum of 16 hrs (960 exposures) scheduled at their own convenience.
62816542|NCT02317328||Affected participants|Participants with ocular conditions
62816543|NCT02317328||Healthy Volunteers|Healthy volunteers
62816544|NCT06699979||Non-small cell lung cancer|Early-stage lung cancer exhibiting distinct phenotypes including lung cancer associated with cystic airspaces, multiple primary lung cancers, and so on.
62816545|NCT03685760|EXPERIMENTAL|Reiki|Reiki will be administered for 5 consecutive days even if the subject is transferred to the floor from the ICU. Thirty minutes before and after the daily Reiki, session, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data.
62816546|NCT03685760|SHAM_COMPARATOR|Sham Reiki|Sham Reiki will be administered for 5 consecutive days even if the subject is transferred to the floor from the ICU. Thirty minutes before and after the daily sham Reiki, session, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data.
62816547|NCT03685760|NO_INTERVENTION|Usual Care|Twice per day, 30 minutes apart, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data. Usual care will also involve a 5-day period.
62430841|NCT05099328|EXPERIMENTAL|Illustrated Syntax Stories Provided by a Caregiver|Caregivers will receive two training sessions on how to provide read illustrated syntax stories to their children and demonstrate their skill at reading these stories with support from the clinician. Caregivers will then read these stories to their children for a minimum of 32 book readings (960 exposures)
62597958|NCT02664467|EXPERIMENTAL|Bright light therapy (BLT)|Bright light therapy (10'000 lux) for 30 minutes after wake-up using Philips EnergyUp EnergyLight HF3419/01
62597959|NCT02664467|PLACEBO_COMPARATOR|Placebo dim light|Placebo dim light (50 lux) for 30 minutes after wake-up using Philips EnergyUp EnergyLight HF3419/01
62597960|NCT00846677|EXPERIMENTAL|1|Vitamin D quick dissolve strip
62597961|NCT00846677|ACTIVE_COMPARATOR|2|Vitamin D syrup
62597962|NCT02091596|PLACEBO_COMPARATOR|PluroGel|PluroGel
62597963|NCT02091596|EXPERIMENTAL|PluroGel N|PluroGel N
62816548|NCT05506540|EXPERIMENTAL|Single Ascending Dose, ENN0403 1 mg|Single oral use of ENN0403 at dose level 1 mg, in fasted state.
62597964|NCT03198832|SHAM_COMPARATOR|Type 2 diabetes mellitus and periodontitis|periodontal debridement in a single session.
62597965|NCT03198832|NO_INTERVENTION|Type 2 diabetes mellitus and without periodontitis|maintained every three months.
62816549|NCT05506540|EXPERIMENTAL|Single Ascending Dose, ENN0403 4 mg|Single oral use of ENN0403 at dose level 4 mg, in fasted state.
62816550|NCT05506540|EXPERIMENTAL|Single Ascending Dose, ENN0403 10 mg|Single oral use of ENN0403 at dose level 10 mg, in fasted state.
62816551|NCT05506540|EXPERIMENTAL|Single Ascending Dose, ENN0403 20 mg|Single oral use of ENN0403 at dose level 20 mg, in fasted state.
62816552|NCT05506540|EXPERIMENTAL|Single Ascending Dose, ENN0403 30 mg|Single oral use of ENN0403 at dose level 30 mg, in fasted state.
62816553|NCT05506540|EXPERIMENTAL|Single Ascending Dose, ENN0403 20 mg (Fed)|Single oral use of ENN0403 at dose level 30 mg, after high calorie and high-fat breakfast meal.
62816554|NCT05506540|EXPERIMENTAL|Multiple Ascending Dose, ENN0403 6 mg|ENN0403 capsules for oral administration, 6 mg QD X 14 Days
62816555|NCT05506540|EXPERIMENTAL|Multiple Ascending Dose, ENN0403 12 mg|ENN0403 capsules for oral administration, 12 mg QD X 14 Days
62816556|NCT05506540|EXPERIMENTAL|Multiple Ascending Dose, ENN0403 20 mg|ENN0403 capsules for oral administration, 20 mg QD X 14 Days
62816557|NCT05506540|PLACEBO_COMPARATOR|Single/Multiple Ascending Dose, placebo capsules for oral adminstration|Placebo capsules for oral administration
62816558|NCT06097221|EXPERIMENTAL|Advance-group|The group will recieve 8 hours of psychotherapy with focus on advancing sleep timing, besides their treatment as usual.
62816559|NCT06097221|ACTIVE_COMPARATOR|Control-group|Treatment as usual at the outpaitent unit.
62430842|NCT06529081|NO_INTERVENTION|Standard Treatment|PDL1/PD1 immunotherapy (durvalumab or atezolozumab - according to the SmPC) after chemo-immunotherapy based on platinum compounds.
62430843|NCT06529081|EXPERIMENTAL|Standard Treatment with Palliative Radiotherapy|
62430844|NCT06529081|EXPERIMENTAL|Standard Treatment with Radical/Ablative Radiotherapy|
62430845|NCT01004484|ACTIVE_COMPARATOR|Yogurt with probiotics and inulin|A probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10\^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10\^7 cfu/g; 5x10\^9 cfu/serving) and Inulin (3gr/serving).
62816560|NCT06586593||Operable metastatic melanoma|Operable metastatic melanoma
62816561|NCT04943744|OTHER|String Test-cohort A|"Participants in the COMBINE study will have an EST performed at pre- specified timepoints (screening, week 8, and week 32) and as needed depending on GI symptoms.~A. Omalizumab for 8 weeks followed by mOIT with placebo for dupilumab for 24 weeks (Cohort A: Omalizumab-facilitated mOIT)"
62816562|NCT04943744|OTHER|String Test-cohort B|"Participants in the COMBINE study will have an EST performed at pre- specified timepoints (screening, week 8, and week 32) and as needed depending on GI symptoms.~B. Omalizumab for 8 weeks followed by mOIT with dupilumab for 24 weeks (Cohort B: Omalizumab-facilitated mOIT with concurrent dupilumab)"
62816563|NCT04943744|OTHER|String Test-cohort C|"Participants in the COMBINE study will have an EST performed at pre- specified timepoints (screening, week 8, and week 32) and as needed depending on GI symptoms.~C. Placebo for omalizumab for 8 weeks followed by mOIT with dupilumab for 24 weeks (Cohort C: mOIT with concurrent dupilumab)"
62430846|NCT01004484|PLACEBO_COMPARATOR|Placebo|Acidified dairy snack without yogurt cultures, probiotic or inulin.
62430847|NCT06406985|EXPERIMENTAL|EMPOWER Weight-Loss Participants|All weight-loss participants will receive the same protocol and weight-loss education materials. Nutrition coaching is individualized to participant needs, but emphasizes the program's core themes throughout.
62430848|NCT03210233|EXPERIMENTAL|Naive controls|Never received teicoplanin. Blood test, skin testing and challenge testing.
62430849|NCT03210233|EXPERIMENTAL|High Risk|Received teicoplanin and suffered suspected IgE mediated anaphylaxis. Blood test, skin testing and challenge testing.
62430850|NCT03210233|EXPERIMENTAL|Low Risk|Received teicoplanin previously with no adverse reaction Blood test, skin testing and challenge testing.
62430851|NCT00294320|EXPERIMENTAL|1|250mg of Imiquimod cream application once daily 3 times per week.
62430852|NCT00294320|PLACEBO_COMPARATOR|2|250mg vehicle cream for application once daily 3 times per week.
62430853|NCT02122510|ACTIVE_COMPARATOR|dexmetomedine group|dexmetomedine group will receive pre-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe labeled G 2.
62430854|NCT02122510|ACTIVE_COMPARATOR|Bupivacaine group|Bupivacaine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline in 20 ml syringe labeled G 2.
62430855|NCT01377649||Control|Age matched control subjects without PAD
62430856|NCT01377649||Patients with PAD|
62430857|NCT04857827|EXPERIMENTAL|QLS-101 ophthalmic solution 1.0%|Ophthalmic solution once daily (QD) dosing in both eyes (OU) for 14 days followed by 14 days of twice daily (BID) dosing.
62430858|NCT04857827|ACTIVE_COMPARATOR|Timolol maleate PF 0.5% ophthalmic solution|Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
62430859|NCT04857827|EXPERIMENTAL|QLS-101 ophthalmic solution 2.0%|Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
62816564|NCT06220721|EXPERIMENTAL|REPAIR ARM|Intensive postpartum blood pressure control with nifedipine ER initiation at systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg and maintaining blood pressure \<140/90 mmHg during the first 6 weeks postpartum.
62816565|NCT06220721|ACTIVE_COMPARATOR|CONTROL ARM|Usual care with nifedipine ER initiation at SBP ≥150 mmHg or DBP ≥100 mmHg and maintaining blood pressure \<150/100 mmHg during the first 6 weeks postpartum.
62816566|NCT06706037|EXPERIMENTAL|reformer exercise grup|Reformer exercise group will receive a 6-week reformer pilates exercise.
62430860|NCT02209454|OTHER|Enantyum® oral solution|25mg DKP.TRIS oral solution
62430861|NCT02209454|OTHER|Keral® tablet|25mg DKP.TRIS tablet
62430862|NCT06375031|EXPERIMENTAL|Arm 1: Medication regimen A-B-C|
62430863|NCT06375031|EXPERIMENTAL|Arm 2: Medication regimen B-C-A|
62430864|NCT06375031|EXPERIMENTAL|Arm 3: Medication regimen C-A-B|
62430865|NCT00962182|EXPERIMENTAL|Enzyme treatment|Enzyme for 12 weeks
62816567|NCT06706037|NO_INTERVENTION|control group|The control group will consist of patients with chronic musculoskeletal pain waiting in the treatment list. No intervention method will be applied to the patients in the control group.
62430866|NCT00962182|PLACEBO_COMPARATOR|Placebo control|Placebo enzyme for 12 weeks
62430867|NCT00962182|EXPERIMENTAL|Enzyme + gluten|Enzyme and 500 mg gluten b.i.d. for 12 weeks
62430868|NCT03333681|EXPERIMENTAL|Refractory rheumatoid arthritis patients|Autologous mesenchymal stem cells
62430869|NCT05117086|EXPERIMENTAL|Dietary Intervention Arm|Subjects will receive the active intervention of nutrition education and medical nutrition therapy counseling for dietary and behavioral lifestyle changes. The focus will be on DASH diet implementation and adherence for management of heart failure. The subjects will have 4 study visits with a Registered Dietitian over 6 months (visits at 1, 2, 3, and 6 months). Outcome measures will be assessed at baseline, 3 and 6 months.
62430870|NCT00447187|EXPERIMENTAL|LX201 0.50 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.50 inch in length
62430871|NCT00447187|EXPERIMENTAL|LX201 0.75 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.75 inch by length
62430872|NCT00447187|PLACEBO_COMPARATOR|Placebo 0.75 inch implant|Silicone implant not containing cyclosporine A, 0.75 inch in length
62430873|NCT04266678|EXPERIMENTAL|Elastic band resistance training|Resistance training with elastic resistance bands two days per week for 6-weeks.
62430874|NCT04266678|ACTIVE_COMPARATOR|Dumbbell resistance training|Resistance training with dumbbell weights two days per week for 6-weeks.
62430875|NCT04266678|NO_INTERVENTION|Non-exercise Control|Education and guidance for exercise recommendations in older adults but no active training sessions.
62430876|NCT03884595||No SIRS|Children without clinical signs of SIRS, according to Goldstein criteria.
62430877|NCT03884595||SIRS|Children with clinical signs of SIRS, according to Goldstein criteria.
62430878|NCT03884595||Sepsis|Children with clinical signs of sepsis, according to Goldstein criteria.
62816568|NCT06706713|EXPERIMENTAL|BEBT-109 Capsule Treatment|BEBT-109 Capsule: Administration and dosage: Oral administration, 120mg; Frequency and duration of administration: Twice a day,and 28 days as a treatment cycle.
62430879|NCT03884595||Severe sepsis|Children with clinical signs of severe sepsis, according to Goldstein criteria.
62430880|NCT03884595||Septic Shock|Children with clinical signs of septic shock, according to Goldstein criteria.
62430881|NCT01330615|ACTIVE_COMPARATOR|Cryotherapy with EMLA|EMLA applied before cryotherapy
62430882|NCT01330615|PLACEBO_COMPARATOR|Cryotherapy with placebo analgesia|Placebo cream applied instead of EMLA
62430883|NCT03264079|EXPERIMENTAL|Bardoxolone methyl 10 mg and Itraconazole 200 mg|Period 1: Bardoxolone methyl capsules 10 mg Period 2: two Itraconazole capsules 100 mg
62430884|NCT03096574||Pregnant women|"* Over the age of 16~* Under the care of staff working in: University Hospital Southampton NHS Foundation Trust, St Georges Healthcare NHS Trust, Oxford University Hospitals NHS Foundation Trust or University Hospitals Bristol NHS Foundation Trust~* Able to read and write in English and give fully informed consent"
62816569|NCT01711554|EXPERIMENTAL|Treatment (lenalidomide, dinutuximab, isotretinoin)|Patients receive lenalidomide PO QD on days 1-21, dinutuximab IV over 10 hours on days 8-11, and isotretinoin PO BID on days 15-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62816570|NCT03679247|EXPERIMENTAL|Intervention|Providers overseeing patients in the intervention arm will receive guidance within electronic health record from clinical decision support system.
62816571|NCT03679247|EXPERIMENTAL|Control|Providers overseeing patients in the control arm will continue to provide usual care.
62816572|NCT05876689||DREAM OCT|All 50 patients will have both eyes (if able) imaged, 3 times, on the same day during their clinic visit.
62816573|NCT05499832|NO_INTERVENTION|Best Medical Treatment (standard of care)|Patients will receive standard of care as per current ESO guidelines.
62816574|NCT05499832|EXPERIMENTAL|Intra-arterial Tenecteplase|Patients will receive intra-arterial administration of Tenecteplase using a standard approved microcatheter.
62816575|NCT06704308|EXPERIMENTAL|Parents' Stories Web Application + Provider Elaborated Prompts|Participating parents will be asked to navigate a web application that consists of (a) brief, 90-second narrative videos that encourage parent-provider communication about the vaccine and (b) personalized feedback to parents that is tailored to provide educational content in response to their concerns and be motivational in nature. Providers will provide elaborated prompts related to the vaccine when meeting with parents tailored to their concerns.
62816576|NCT04652973||1/Prostate cancer dataset|Biopsy-proven prostate cancer patients who have abdomen CT studies that were available in the clinical PACS (picture archiving system) in the Clinical Center.
62816577|NCT04652973||2/Multiphase CT dataset|Men or women of all age and race, who have Multiphase abdomen-pelvic CT studies that were available in the PACS.
62597966|NCT01318590|EXPERIMENTAL|Celiac bloc|The experimental arm will consist of the fractional injection on both sides of the celiac trunk, via EUS, of a local anesthetic (10 ml of Bupivacaine 0.5% (gr / ml)) and an injection of steroids (Triamcinolone 40 mg). In this group antibiotic prophylaxis will be administered after administration of sedation (Cephazolin 1gr IV or Gentamycin).
62597967|NCT01318590|SHAM_COMPARATOR|Conservative treatment|Subject will undergo standard EUS without any additional interventions.
62816578|NCT04838171||Specimen collection to support development of engineering Treg|
62816579|NCT05816395|EXPERIMENTAL|RHH646|RHH646
62816580|NCT05816395|PLACEBO_COMPARATOR|Placebo|RHH646 placebo
62816581|NCT03078114|EXPERIMENTAL|Spinal Manipulation|Subjects with subacute low back pain. Subjects will receive 6 treatments of Spinal Manipulation (SM) over 2 consecutive weeks
62816582|NCT03078114|PLACEBO_COMPARATOR|Placebo Spinal Manipulation|Subjects with subacute low back pain. Subjects will be asked to visit the clinic for 6 times. The clinician will go through SM motions but the spine will not actually be manipulated.
62816583|NCT05656859||Study group|Descriptive study
62816584|NCT05083351|EXPERIMENTAL|MightySat|All subjects who are enrolled into the test group and participate in data collection have the noninvasive MightySat pulse oximeter applied on their finger(s).
62597968|NCT03369067|EXPERIMENTAL|Artificial Pancreas Therapy|Subjects will use the Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
62735220|NCT01144416|EXPERIMENTAL|Single injection of 150 µg SCH 900962 (MK-8962)|Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7
62735221|NCT01144416|ACTIVE_COMPARATOR|Daily 300 IU recFSH|Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of recFSH from Stimulation Days 1-7
62735222|NCT04734483|ACTIVE_COMPARATOR|functional findings|Participants with laryngeal stenosis
62735223|NCT04734483|ACTIVE_COMPARATOR|to find anatomic feathers of larynx|Participants with laryngeal stenosis
62735224|NCT04734483|ACTIVE_COMPARATOR|to determine the type of stenosis of larynx and method of surgical treatment|Participants with laryngeal stenosis
62735225|NCT04734483|ACTIVE_COMPARATOR|determining the motor abilities of the muscles of the larynx|Participants with laryngeal stenosis
62735226|NCT00742131|EXPERIMENTAL|Subjects receiving GSK1363089|Eligible subjects will receive GSK1363089 administered orally as a cinnamon-flavored liquid or as solid capsules with the starting dose for cohort 1 as 0.1 milligram/kilogram. Subjects in cohorts 1, 2, and 3A will receive GSK1363089 in the liquid formulation, while Cohorts 3B, 4, 5, 6, 7, and 8 will receive GSK1363089 in the solid capsule formulation.
62735227|NCT02282072|ACTIVE_COMPARATOR|Deep Brain Stimulation|Stimulator is ON
62735228|NCT02282072|SHAM_COMPARATOR|Placebo|Stimulator is OFF
62735229|NCT01977729|EXPERIMENTAL|CBT with SRT|CBT (Cognitive Behavioral Therapy)+SRT (Sertraline) will be scheduled at weeks 9-12, 14, 16, 18, 20 with telephone visits at weeks 15, 17, and 19. The same therapist as in Phase I will deliver CBT in Phase II, which will occur in conjunction with the psychiatrist visits. Phase II CBT will emphasize continued therapist prescribed in-session and out-of-session exposure tasks (developed with patient) and continued patient cognitive-affective processing of exposure sessions with therapist, with no instruction on new skills or therapeutic strategies. Therapists will be encouraged to discuss clinical status with patients, psychiatrists, and PIs to allow for treatment integration (e.g., psychiatrist could increase the dose of SRT, or not, depending on whether the patient Is making sufficient progress in CBT).
62816585|NCT06705725|EXPERIMENTAL|CBG002 CAR-T Cell Suspension|"Single dose of CAR+ T cells will be infused, and classic 3+3 dose escalation will be applied."
62816586|NCT04813588|EXPERIMENTAL|Pantomimng|In experimental group pantomiming treatment will be administered
62816587|NCT04813588|ACTIVE_COMPARATOR|Easy onset|In active comparator group easy onset method will be administered
62240394|NCT02545322|EXPERIMENTAL|Adaptive Radiotherapy|"Follow-up CT scans during week 3 and week 5 of Treatment~Image-guided adaptive Radiotherapy arm:~Follow-up CT scans are performed on a conventional CT-simulator. Deformable Image Registration between the planning-CT and the follow-up CT (fCT) is done using a dedicated Software package. Delineations for target volumes and organs at risk are transferred to the fCT based on the Deformation vector fields calculated during deformable Image registration. Volumetric changes in target volumes and organs-at-risk are assessed. The initial treatment plan is transferred to the fCT scan. Dosimetric consequences of morphologic changes are analysed with the Focus on target dose coverage for the planning target volume. Adaption and plan re-optimisation are performed."
62240395|NCT02797067|EXPERIMENTAL|Indomethacin|Subjects will be randomized to receive a 100-mg indomethacin suppository 30 min before ESWL.
62240396|NCT02797067|PLACEBO_COMPARATOR|Glycerin|Subjects will be randomized to receive either a 100-mg identical-appearing placebo (glycerin suppository) 30 min before ESWL.
62240397|NCT02003014||Pioglitazone 15 mg to 30 mg|administered orally once daily
62240398|NCT03702803|EXPERIMENTAL|Galphimia glauca standardized extract|Patients with a clinical diagnosis of GAD (with a score of 18 points or more on the Hamilton anxiety scale) that will be included in the experimental group and will be assigned the treatment consisting of hard gelatin capsules with a pharmaceutical formulation prepared with a standardized extract from G. glauca, which will be administered once a day.
62816588|NCT03661723|EXPERIMENTAL|Pembrolizumab + Radiation (lead-in)|"* Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks. (De-escalation dosing frequencies = once every 4 weeks and once every 6 weeks.)~* Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
62816589|NCT03661723|EXPERIMENTAL|Pembrolizumab + Bevacizumab + Radiation (lead-in)|"* Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks. (De-escalation dosing frequencies = once every 4 weeks and once every 6 weeks.)~* Bevacizumab (15 mg/kg) will be administered intravenously (IV) once every 3 weeks~* Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
62816590|NCT03661723|EXPERIMENTAL|Pembrolizumab + Radiation|"* Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks~* Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
62816591|NCT03661723|EXPERIMENTAL|Pembrolizumab + Bevacizumab + Radiation|"* Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks~* Bevacizumab (15 mg/kg) will be administered intravenously (IV) once every 3 weeks~* Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
62038087|NCT04216316|EXPERIMENTAL|Arm A (pembrolizumab, gemcitabine, carboplatin, M6620)|Patients receive pembrolizumab IV over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and berzosertib IV over 60 minutes on days 2 and 9. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pembrolizumab IV over 30 minutes on day 1 and berzosertib IV over 60 minutes on days 2 and 9. Cycles repeat every 21 days for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients then receive pembrolizumab alone IV over 30 minutes on day 1. Cycles repeat every 6 weeks for up to 1 more year in the absence of disease progression or unacceptable toxicity. Patients undergo MRI scans and/or CT scans, and undergo blood specimen collection on study.
62240399|NCT03702803|ACTIVE_COMPARATOR|alprazolam 1mg|Patients with a clinical diagnosis of GAD (with a score of 18 points or more on the Hamilton anxiety scale) that will be included in the control group and will be assigned the treatment consisting of hard gelatin capsules with the drug Alprazolam (1 mg ), which will be administered once a day.
62240400|NCT05097014|ACTIVE_COMPARATOR|CHF5993|pMDI fixed combination product of beclometasone dipropionate (BDP) 100 µg plus 6 µg of formoterol fumarate (FF) and 10 µg of glycopyrronium (G)
62240401|NCT05097014|ACTIVE_COMPARATOR|CHF1535|pMDI fixed combination product beclometasone dipropionate (BDP) 100 µg plus 6 µg of formoterol fumarate (FF)
62240402|NCT05097014|PLACEBO_COMPARATOR|Matched placebo|Matched placebo pMDI
62240403|NCT00557388|EXPERIMENTAL|1|Young men 18-30 years, BMI \< 27 kg/m2
62240404|NCT00557388|EXPERIMENTAL|2|Young men 18-30 years, BMI \< 27 kg/m2
62240405|NCT00557388|EXPERIMENTAL|3|Old men 70-85 years, BMI \< 27 kg/m2
62240406|NCT00557388|EXPERIMENTAL|4|Old men 70-85 years, BMI \< 27 kg/m2
62240407|NCT00557388|EXPERIMENTAL|5|Old men 70-85 years, BMI \< 27 kg/m2
62240408|NCT00557388|EXPERIMENTAL|6|Old men 70-85 years, BMI \< 27 kg/m2
62816592|NCT03096834|PLACEBO_COMPARATOR|Placebo DB|Matching placebo subcutaneous injections administered every 4 weeks during Double-Blind Epoch
62240409|NCT00557388|EXPERIMENTAL|7|Old men 70-85 years, BMI \< 27 kg/m2
62240410|NCT00557388|EXPERIMENTAL|8|Old men 70-85 years, BMI \< 27 kg/m2
62240411|NCT00557388|EXPERIMENTAL|9|Old men 70-85 years, BMI \< 27 kg/m2
62240412|NCT00557388|EXPERIMENTAL|10|Old men 70-85 years, BMI \< 27 kg/m2
62240413|NCT02790957|EXPERIMENTAL|Plerixafor|Single subcutaneous injection of Plerixafor (0.24 mg/kg)
62240414|NCT02790957|PLACEBO_COMPARATOR|Placebo|Single injection of an equal volume of NaCl solution
62240415|NCT02887690|EXPERIMENTAL|Modular Prosthetic Limb|The Defense Advanced Research Projects Agency's (DARPA) advanced upper limb prosthesis, the Modular Prosthetic Limb (MPL)
62816593|NCT03096834|EXPERIMENTAL|AMG334 140 mg DB|AMG334 70 mg subcutaneous injections (2) administered every 4 weeks during Double-Blind Epoch
62038088|NCT04216316|ACTIVE_COMPARATOR|Arm B (pembrolizumab, gemcitabine, carboplatin)|Patients receive pembrolizumab, gemcitabine, and carboplatin as in Arm A. Patients undergo MRI scans and/or CT scans, and undergo blood specimen collection on study.
62038089|NCT04572048|OTHER|Single-day NRP training|This group will follow the single-day NRP training course that is currently the standard. It usually takes 8 hours to complete this training course and the nurses are released from their clinical duty to attend the training course.
62038090|NCT04572048|EXPERIMENTAL|Longitudinal one year NRP Training|This group will follow the longitudinal NRP training course. The longitudinal NRP training course will consist of nine 30-minute modules that will be taught every 6-8 weeks over a period of one year. The nurses will attend the different modules of the training course at their work place and during their work shift so they will have to be released from their clinical duty only 30 minutes at a time.
62038091|NCT01628029|EXPERIMENTAL|Arm I (methylphenidate, melatonin, light therapy, CBT)|Patients undergo CBT comprising 3 30-minute counseling sessions between baseline and day 14. Patients also receive methylphenidate hydrochloride PO BID and therapeutic melatonin PO QD, and undergo light therapy over 30 minutes for 15 days.
62038092|NCT01628029|EXPERIMENTAL|Arm II (placebo, placebo, sham light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and melatonin placebo PO QD, and undergo sham light therapy over 30 minutes for 15 days.
62038093|NCT01628029|EXPERIMENTAL|Arm III (methylphenidate, melatonin, sham light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and therapeutic melatonin PO QD, and undergo sham light therapy over 30 minutes for 15 days.
62038094|NCT01628029|EXPERIMENTAL|Arm IV (methylphenidate, placebo, light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and melatonin placebo PO QD, and undergo light therapy over 30 minutes for 15 days.
62240416|NCT04369222||Controls|Children born from mothers with no consumption of mild analgesics 3 months before or during pregnancy
62240417|NCT04369222||Exposed|Children born from mothers with consumption of mild analgesics 3 months before or during pregnancy
62240418|NCT04071795|EXPERIMENTAL|Opt Out|Training and Academic Detailing
62240419|NCT04071795|EXPERIMENTAL|Opt In|Training and Academic Detailing
62240420|NCT02233283|ACTIVE_COMPARATOR|Hypercaloric diet and basal|Volunteers fed a hypercaloric diet for one month will be submitted to a fasting period of ten hours duration
62240421|NCT02233283|EXPERIMENTAL|Hypercaloric diet and clamp|Volunteers fed a hypercaloric diet for one month will be submitted to a hyperinsulinemic and euglycemic clamp of ten hours duration
62240422|NCT02233283|ACTIVE_COMPARATOR|Isocaloric diet and basal|Volunteers fed a isocaloric diet for one month will be submitted to a fasting period of ten hours duration
62240423|NCT02233283|EXPERIMENTAL|Isocaloric diet and clamp|Volunteers fed a isocaloric diet for one month will be submitted to a hyperinsulinemic and euglycemic clamp of ten hours duration
62240424|NCT01681134|EXPERIMENTAL|Advagraf followed by Prograf|
62240425|NCT01681134|EXPERIMENTAL|Prograf followed by Advagraf|
62240426|NCT00974090|PLACEBO_COMPARATOR|Placebo / Teneli + SU|
62816594|NCT03096834|EXPERIMENTAL|AMG334 140 mg DB cont on AMG334 140 mg|AMG334 70 mg subcutaneous injections (2) during DB continued on AMG334 140 mg in Open-Label Epoch
62816595|NCT03096834|EXPERIMENTAL|Placebo in DB to AMG334 140 mg|Placebo in Double-Blind Epoch (DB) switched to AMG334 140 mg in Open-Label Epoch
62816596|NCT04151940|EXPERIMENTAL|Research (PET/CT scan)|Patients undergo PET/CT scan within 4 weeks before starting standard of care chemoimmunotherapy and a second PET/CT scan within 5 days of the second chemoimmunotherapy cycle. Patients receiving standard of care radiation treatment undergo additional PET/CT scans within 4 weeks prior to radiation treatment and 1 month post-radiation treatment.
62816597|NCT04002141|EXPERIMENTAL|Endometriosis Letrozole|Participants will be asked to take 5mg letrozole daily throughout their ovarian stimulation and for 2 weeks following retrieval. Participants will be blinded to their randomization to letrozole. Participants will be asked to complete surveys during their stimulation and up to 12 weeks following retrieval to evaluate endometriosis associated symptoms. Specifically, surveys will be administered at baseline ultrasound appointment for controlled ovarian hyperstimulation cycle, the day of trigger shot, 3 weeks following egg retrieval, 6 weeks following egg retrieval and 12 weeks following egg retrieval. There will be a total of 20 participants in this arm.
62816598|NCT04002141|PLACEBO_COMPARATOR|Endometriosis Placebo|Participants will be asked to take one tablet placebo daily throughout their ovarian stimulation and for 2 weeks following retrieval. Participants will be blinded to their randomization to placebo. Participants will be asked to complete surveys during their stimulation and up to 12 weeks following retrieval to evaluate endometriosis associated symptoms. Specifically, surveys will be administered at baseline ultrasound appointment for controlled ovarian hyperstimulation cycle, the day of trigger shot, 3 weeks following egg retrieval, 6 weeks following egg retrieval and 12 weeks following egg retrieval. There will be a total of 20 participants in this arm.
62816599|NCT04002141|NO_INTERVENTION|No Endometriosis Control|Participants will be asked to complete surveys during their ovarian stimulation and up to 12 weeks following retrieval to evaluate symptoms of pelvic pain. Specifically, surveys will be administered at baseline ultrasound appointment for controlled ovarian hyperstimulation cycle, the day of trigger shot, 3 weeks following egg retrieval, 6 weeks following egg retrieval and 12 weeks following egg retrieval. There will be a total of 20 participants in this arm.
62816600|NCT05821985|OTHER|The Study group|The patients within the study group will receive intraarticular TMJ and masseteric Trigger point injection of a solution that contains (0.75 ml. 12.5% Dextrose solution, 0.75 ml. Saline solution, and 1.5 ml. Lidocaine).
62816601|NCT05821985|OTHER|The Control group|Patients in the control group will receive intraarticular TMJ and masseteric Trigger point dry needle insertion without injecting any solution.
62816602|NCT06705114|ACTIVE_COMPARATOR|group I: complete dentures|Each patient received a newly constructed conventional complete denture.
62816603|NCT06705114|ACTIVE_COMPARATOR|group II: mandibular implant overdenture|Two dental implants were inserted in the patient's mandibular arch at the canine region using guided surgery and a delayed loading protocol.
62816604|NCT03184064|EXPERIMENTAL|Treatment arm 1|Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), citrus extract (low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
62816605|NCT03184064|EXPERIMENTAL|Treatment arm 2|Participants will receive the placebo, citrus extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
62240427|NCT00974090|EXPERIMENTAL|Teneli / Teneli + SU|
62597969|NCT03369067|PLACEBO_COMPARATOR|Sensor Augmented Pump Therapy|Subjects will use a Dexcom CGM G5 and their Continuous Subcutaneous Insulin Infusion devices (insulin pumps) to modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
62240428|NCT06242054|EXPERIMENTAL|Patients with cervical spine myelopathy|
62597970|NCT03657524|EXPERIMENTAL|Resuscitation patients|
62597971|NCT03657524|ACTIVE_COMPARATOR|healthy volunteers|
62597972|NCT05709444|EXPERIMENTAL|Subcutaneous Bremelanotide|BMT sterile aqueous solution for injection provided as a prefilled syringe, administered by subcutaneous (SQ) injection into the abdomen.
62597973|NCT04696861|EXPERIMENTAL|IDEAS for Hope Intervention|Participants will receive three counseling sessions at two week intervals, delivered by telehealth by a trained psychiatric nurse, focused on managing suicidal ideation and enhancing HIV care engagement.
62597974|NCT04696861|ACTIVE_COMPARATOR|Enhanced Standard of Care with Safety Planning|Participants will receive a brief, 10-15 minute counseling session, delivered by telehealth by a trained psychiatric nurse, focused on safety planning.
62597975|NCT04228757|EXPERIMENTAL|Investigational Herbal Blend|A phytoestrogen herbal blend
62597976|NCT04228757|PLACEBO_COMPARATOR|Placebo|Tablet without active ingredients
62597977|NCT01953432|EXPERIMENTAL|Doxazosin|Doxazosin is a long-acting and selective alpha 1-NE blocker, which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system.
62816606|NCT03184064|EXPERIMENTAL|Treatment arm 3|Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
62816607|NCT03184064|EXPERIMENTAL|Treatment arm 4|Participants will receive the placebo, blackcurrant extract (low dose), citrus extract (low dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
62816608|NCT00139152|PLACEBO_COMPARATOR|Placebo|Saline placebo
62240429|NCT06242054|OTHER|Healthy people|
62240430|NCT06059651||Cohort 1|Cohort #1 (within-subject) will enroll up to 10 women with class III obesity who plan to undergo Roux-en-Y metabolic and bariatric surgery as a standard of obesity care. Subjects will complete study measures preoperatively and one year postoperatively.
62240431|NCT06059651||Cohort 2|Cohort #2 (between-subject) will enroll up to 10 women with a history of class III obesity who underwent Roux-en-Y metabolic and bariatric surgery as a standard of obesity care approximately one year before enrollment. Subjects in this cohort will be matched on demographic and clinical variables to those in Cohort #1.
62597978|NCT01953432|PLACEBO_COMPARATOR|Placebo|Matched placebo daily dosing.
62597979|NCT06434220|NO_INTERVENTION|Physician assessment before intervention|No intervention. Physician is surveyed to provide their assessment of patient disposition.
62597980|NCT06434220|ACTIVE_COMPARATOR|Physician assessment after baseline model intervention|Physician is shown a baseline model recommendation for patient disposition including description of factors driving the model prediction.
62597981|NCT06434220|ACTIVE_COMPARATOR|Physician assessment after fairness-aware model intervention|Physician is shown a model recommendation form a model tuned for subgroup performance for patient disposition including description of factors driving the model prediction.
62597982|NCT06475729|EXPERIMENTAL|Citrate-Free Mirikizumab Autoinjector (Single Injection - Test)|Citrate-Free Mirikizumab administered subcutaneously (SC) by autoinjector.
62597983|NCT06475729|EXPERIMENTAL|Citrate-Free Mirikizumab Autoinjector (Two Injections - Reference)|Citrate-Free Mirikizumab administered SC by autoinjector.
62816609|NCT00139152|EXPERIMENTAL|Xolair|Xolair treatment
62240432|NCT03435003|EXPERIMENTAL|Intervention Arm|"A) Pre-operatively: aprepitant 80 mg oral capsule and scopolamine transdermal patch.~B) Intra-operatively: total intravenous anesthesia (TIVA) will be maintained with IV infusions of propofol, and dexmedetomidine infusion or intermittent bolus dosing of fentanyl after induction. Sugammadex (2-4 mg/Kg IV) will be used for reversal of neuromuscular blockade in both groups. A single dose of dexamethasone 8 mg IV will be administered after induction, and a single dose of ondansetron 4 mg IV will be administered approximately 20 minutes prior to the end of operation.~C) Post-operatively: Scheduled ondansetron and Raglan every 6 hours, using Compazine as a rescue medication."
62240433|NCT03435003|ACTIVE_COMPARATOR|Control Arm|"A) Pre-operatively: No intervention~B) Intra-operatively: inhalation anesthetics (sevoflurane or desflurane) and intermittent opioid boluses will be used for maintenance of anesthesia, as standard practice in the institution of the investigators and across the country. PONV prevention measures in the control group will be limited to dexamethasone 8 mg and ondansetron 4 mg.~C) Post-operatively: Scheduled ondansetron and Raglan every 6 hours, using Compazine as a rescue medication."
62240434|NCT06177249|ACTIVE_COMPARATOR|Experimental vaccines and vaccine|A total of 1956 subjects were randomly divided into three groups at a ratio of 1:1:1, 652 subjects in each group were vaccinated with the test vaccine or the control vaccine on a schedule of 0, 3, 7, 14, 28 days (a total of 5 doses). Blood samples were collected from the subjects for antibody detection on 0, 7/14, 35/42 days, respectively.
62240435|NCT06177249|ACTIVE_COMPARATOR|experimental vaccines|An additional group of 652 people received the trial vaccine in a 0 -, 7 -, and 21-day schedule (two first doses for a total of four doses). Blood samples were collected at 0, 7/14 and 35/42 days for antibody detection, and all subjects were systematically observed for safety.
62240436|NCT05496751|EXPERIMENTAL|Low amount, low intensity exercise|exercise dose (amount and intensity) will be controlled.
62240437|NCT05496751|EXPERIMENTAL|Low amount, high intensity exercise|exercise dose (amount and intensity) will be controlled.
62240438|NCT05496751|NO_INTERVENTION|Control|no exercise intervention
62240439|NCT05496751|EXPERIMENTAL|High amount, high intensity exercise|exercise dose (amount and intensity) will be controlled.
62240440|NCT03015792|EXPERIMENTAL|Treatment (ibrutinib, lenalidomide, dexamethasone)|"PHASE I: Patients receive ibrutinib PO on days 1-28, lenalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Beginning course 25, patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 84 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive ibrutinib and dexamethasone as in phase I and lenalidomide PO on days 1-21 beginning course 2. Beginning course 25, patients receive lenalidomide and dexamethasone as in phase I."
62240441|NCT06168136|OTHER|Intervention|Group A: included (42) patients who will receive high protein intake (target: 1.8 g protein/kg body weight /d).
62240442|NCT06168136|OTHER|Control|Group B: included (42) patients who will receive Standard of nutrition Care: (target: 1.2 g protein/kg body weight /d)
62597984|NCT06617975|EXPERIMENTAL|Balneotherapy|18-day balneotherapy program with Mineral Water of Santenay in addition to standard of care for knee osteoarthritis
62597985|NCT06604234|ACTIVE_COMPARATOR|Probiotic|Probiotic formulation comprising Levilactobacillus brevis KABP-052, Lactiplantibacillus plantarum KABP-051 and Pediococcus acidilactici KABP-021
62816610|NCT03525444|PLACEBO_COMPARATOR|Placebo|Participants who received placebo matched to VX-445/TEZ/IVA for 24 weeks in the TC treatment period.
62816611|NCT03525444|EXPERIMENTAL|VX-445/TEZ/IVA TC|Participants who received VX-445 200 mg/TEZ 100 mg/IVA150 mg as fixed-dose combination (FDC) tablets in the morning and IVA 150 mg as mono tablet in the evening for 24 weeks in the TC treatment period.
62816612|NCT05027321|NO_INTERVENTION|Control|control
62816613|NCT05027321|EXPERIMENTAL|Preparation in Self-Hypnosis by anchoring|1-hour consultation with a hypnopractor just before the examination
62038095|NCT01628029|EXPERIMENTAL|Arm V (placebo, melatonin, light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and therapeutic melatonin PO QD, and undergo light therapy over 30 minutes for 15 days.
62240443|NCT03600623|EXPERIMENTAL|Folfirinox + SBRT|Folfirinox comprises the following: Fluorouracil 2,400 mg/m2 intravenously over 48 hours Days 1-3 and 15-17 every 4 weeks; Folinic acid 400 mg intravenously on Days 1 and 15 every 4 weeks; Oxaliplatin 85 mg/m2 intravenously on Days 1 and 15 every 4 weeks; and Irinotecan 180 mg/m2 intravenously on Days 1 and 15 every 4 weeks. Radiation will begin at the completion of cycle 2 if chemotherapy toxicity permits and will last over a period of 5 days.
62240444|NCT03600623|EXPERIMENTAL|Gemcitabine-nab Paclitaxel + SBRT|Gemcitabine-nab Paclitaxel comprises the following: Gemcitabine 1000 mg/m2 on Days 1, 8, and 15 every 4 weeks; nab Paclitaxel 125 mg/m2 on Days 1, 8, and 15 every 4 weeks. Radiation will begin at the completion of cycle 2 if chemotherapy toxicity permits and will last over a period of 5 days.
62240445|NCT04214314||Control|The control group will continue to receive the integral rehabilitation provided by the center.
62240446|NCT04214314||Experimental|The participants of the experimental group, in addition to the integral rehabilitation of the center will receive the training of the attention through NeuronUp APT. There will be 3 rehabilitation sessions of one hour a week for about a month and a half or two.
62240447|NCT06495450|EXPERIMENTAL|Omni-VR group|20 participants will undergo 45-minute training sessions 3 times per week for 12 weeks using omnidirectional virtual reality and treadmill training.
62240448|NCT06495450|ACTIVE_COMPARATOR|Control group|10 participants will undergo 45-minute traditional physiotherapy training sessions including lower limb strengthening and unidirectional treadmill training 3 times per week for 12 weeks.
62240449|NCT01437696|EXPERIMENTAL|Vitamin D fortified food 500 IU|One portion of a specific food item will be provided each day. 500 IU Vitamin D added.
62240450|NCT01437696|EXPERIMENTAL|Vitamin D fortified food 1000 IU|One portion of a specific food item will be provided each day. 1000 IU Vitamin D added.
62240451|NCT01437696|PLACEBO_COMPARATOR|Placebo|One portion of a specific food item will be provided each day. No vitamin D added.
62240452|NCT03948360|EXPERIMENTAL|LIMB Phototherapy with SOC|Arm I: The first 3 participants enrolled will receive standard of care therapy under the Low-Irradiance Monochromatic Biostimulation (LIMB) phototherapy device.
62816614|NCT05027321|EXPERIMENTAL|Conversational Hypnosis|conversational hypnosis support during the examination by a radiology technician and a radiologist specifically trained
62816615|NCT05027321|EXPERIMENTAL|Preparation in Self-Hypnosis by anchoring + Conversational Hypnosis|1-hour consultation with a hypnopractor just before the examination and conversational hypnosis support during the examination by a radiology technician and a radiologist specifically trained
62240453|NCT03948360|EXPERIMENTAL|LIMB Phototherapy without SOC|Arm II: The subsequent participants will receive only the Low-Irradiance Monochromatic Biostimulation (LIMB) phototherapy device without standard of care.
62240454|NCT01399190||Bevacizumab|Participants will receive bevacizumab in combination with capecitabine and oxaliplatin.
62240455|NCT03787225|EXPERIMENTAL|NNC0174-0833 (0.3 mg)|Participants will receive single dose of NNC0174-0833
62240456|NCT03787225|EXPERIMENTAL|NNC0174-0833 (0.9 mg)|Participants will receive single dose of NNC0174-0833
62240457|NCT03787225|EXPERIMENTAL|NNC0174-0833 (1.8 mg)|Participants will receive single dose of NNC0174-0833
62240458|NCT03787225|PLACEBO_COMPARATOR|Placebo (NNC0174-0833)|Participants will receive placebo (NNC0174-0833)
62240459|NCT01736085|NO_INTERVENTION|Material Group|Subjects will receive self-help materials
62240460|NCT01736085|ACTIVE_COMPARATOR|Materials plus Voucher|Subjects will receive self-help materials and a voucher for 2 week's worth of nicotine patches
62240461|NCT01736085|ACTIVE_COMPARATOR|Materials plus Patches|Subjects will receive self-help materials and a 2 week's worth of nicotine patches
62240462|NCT01736085|ACTIVE_COMPARATOR|Counseling|Subjects will receive up to 5 sessions of telephone counseling
62240463|NCT01736085|ACTIVE_COMPARATOR|Counseling plus Voucher|Subjects will receive up to 5 sessions of telephone counseling plus a voucher for 2 week's worth of nicotine patches.
62240464|NCT01736085|ACTIVE_COMPARATOR|Counseling plus Patches|Subjects will receive up to 5 sessions of telephone counseling plus 2 week's worth of nicotine patches.
62240465|NCT04553068|EXPERIMENTAL|EVO100 gel|EVO100 vaginal gel, 5 g
62597986|NCT06604234|PLACEBO_COMPARATOR|Placebo|Placebo comparator arm with identical pharmaceutical form and aspect
62597987|NCT03627416|EXPERIMENTAL|active rTMS|10 hertz (Hz) rTMS will be administered over bilateral primary motor areas for the muscles of lower extremities. Therapy will include five daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
62816616|NCT05346120|EXPERIMENTAL|Intervention|Single IV infusion of 6 million cells/kg allogeneic marrow stromal cells (MSCs) lasting approximately 30 minutes
62240466|NCT04553068|PLACEBO_COMPARATOR|Placebo gel|Placebo vaginal gel, 5 g
62240467|NCT00889226|EXPERIMENTAL|Pitavastatin Group|
62240468|NCT00889226|ACTIVE_COMPARATOR|Atorvastatin Group|
62240469|NCT04772950||Healthy adults|
62240470|NCT04772950||Patients with non-specific low back pain|
62240471|NCT05742503||Depo-Provera group|This group will receive150 mg of injectable progesterone every 90 days or 3 months
62240472|NCT05742503||Implanon group|This group will receive 68 mg of etonogestrel implant formerly known as Implanon.
62240473|NCT05742503||Norgestrel group|This group will receive 0.075 mg of norgestrel (Ovrette®) once daily.
62240474|NCT05742503||Mirena group|This group will receive IUD (Mirena) containing 52 mg of levonorgestrel.
62240475|NCT01685424||Etoricoxib Prescription (Period 1)|First Etoricoxib Prescription, Apr. 1, 2002 to Feb. 17, 2005
62240476|NCT01685424||Etoricoxib Prescription (Period 2)|First Etoricoxib Prescription, Feb. 18, 2005 to Dec. 31, 2015
62240477|NCT01685424||Repeat Etoricoxib Prescription|One prescription during the Period 1 and, at least, one etoricoxib prescription during Period 2.
62240478|NCT06099210||Moderate traumatic brain injury|Intervention: Glasgow coma scale
62240479|NCT06099210||Healthy control group|
62240480|NCT00893282|EXPERIMENTAL|BackStop|Intracorporeal lithotripsy with the use of an anti-retropulsion device.
62816617|NCT05346120|PLACEBO_COMPARATOR|Placebo controlled|PlasmaLyte A supplemented with 5% HSA
62816618|NCT06584188|EXPERIMENTAL|Intra-radicular saline at room temperature|"* Final flush with 20 mL of saline solution~* At room temperature for 5 minutes.~* Three samples will be collected from periapical fluid ."
62816619|NCT04875286||Observational (medical record review, questionnaires))|Patients' medical records are reviewed and then complete questionnaires over 27 minutes.
62819435|NCT03397966|EXPERIMENTAL|Placebo, then BNP|At Study Visit 1, subjects will receive an IV infusion of placebo (control, normal saline) for 240 minutes. After a washout period of at least 2 weeks, subjects then present for Study Visit 2, where they will receive an IV infusion of recombinant human b-type natriuretic peptide (BNP (1-32), nesiritide) for 240 minutes.
62597988|NCT03627416|SHAM_COMPARATOR|Sham rTMS|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
62597989|NCT02609100|ACTIVE_COMPARATOR|Video Capsule Endoscopy|Randomization arm one is to video capsule endoscopy (VCE) a non-invasive procedure in which a patient swallows a disposable 1.0 X 2.5 cm 'pill' containing a camera electronically linked to equipment outside the patient which records images as it passes from the esophagus through the entire tract and is excreted in feces. It images the small intestine in areas beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. Its greatest use is in identifying points of bleeding and ulcers.
62430885|NCT03096574||Maternity healthcare professionals|"* Over the age of 18~* Working in obstetrics or midwifery who regularly care for women in pregnancy at University Hospital Southampton NHS Foundation Trust, St Georges Healthcare NHS Trust, Oxford University Hospitals NHS Foundation Trust or University Hospitals Bristol NHS Foundation Trust~* Able to read and write in English and give fully informed consent"
62430886|NCT03096574||UK General Practitioners|"* Fully-qualified general practitioners practicing in the UK~* Able to read and write in English and give fully informed consent"
62430887|NCT01271933|EXPERIMENTAL|Pregabalin|
62430888|NCT01271933|PLACEBO_COMPARATOR|Placebo|
62430889|NCT00108901|NO_INTERVENTION|Control|Children were not provided with an after-school exercise intervention. They were free to do their usual activities. Families were offered a monthly healthy lifestyle class.
62430890|NCT00108901|EXPERIMENTAL|Low Dose|This group was assigned to receive a 20 min/day aerobic exercise program offered 5 days/week after school. Families were offered a monthly healthy lifestyle class.
62430891|NCT00108901|EXPERIMENTAL|High dose|This group was assigned to receive a 40 min/day aerobic exercise program offered 5 days/week after school. Families were offered a monthly healthy lifestyle class.
62430892|NCT01217528|ACTIVE_COMPARATOR|Group A|"Group A:~* VT zone: 350ms~* VF zone: 280ms"
62430893|NCT01217528|EXPERIMENTAL|Group B|"Group B:~* VT zone: 320ms~* VF zone: 250ms"
62597990|NCT02609100|ACTIVE_COMPARATOR|Next Day Colonoscopy|Randomization arm two is to colonoscopy, a test that allows the doctor to look at the inner lining of the large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.
62597991|NCT02599597|EXPERIMENTAL|Therapist-assisted iCBT|Internet-delivered cognitive behavioral therapy (iCBT), containing physical activity and sleep management for preventing depressive relapse. Monthly depression screening with therapist feedback.
62597992|NCT02599597|ACTIVE_COMPARATOR|Monthly screening with feedback|Monthly depression screening with therapist feedback.
62597993|NCT02599597|NO_INTERVENTION|Control|No intervention, follow-up along with all participants at 6 and 12-months.
62597994|NCT01187498|EXPERIMENTAL|Behavioral Training|Behavioral training using delayed voiding, urge suppression techniques, and pelvic floor muscle training
62597995|NCT01187498|ACTIVE_COMPARATOR|Drug Therapy|Oxybutynin chloride, extended-release, individually-titrated, 5-30 mg
62038096|NCT01628029|EXPERIMENTAL|Arm VI (placebo, placebo, light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and melatonin placebo PO QD, and undergo light therapy over 30 minutes for 15 days.
62430894|NCT00443131|EXPERIMENTAL|Group A|
62430895|NCT00443131|EXPERIMENTAL|Group B|
62430896|NCT00443131|EXPERIMENTAL|Group C|
62430897|NCT05191225|EXPERIMENTAL|Rapid infusion group|After the administration of intravenous premedication (usually dexchlorpheniramine 5 mg IV and paracetamol 1 g IV), rituximab will be administered at standard dose (375 mg/m2 diluted in 250 ml of saline) administered in one hour, divided into: 10 first minutes at 450 mg/hour, and 50 minutes later at 720 mg/hour.
62430898|NCT05191225|EXPERIMENTAL|Ultrarapid infusion group|After the administration of intravenous premedication, the dose of rituximab will be administered at standard dose administered in half an hour, divided into: 10 first minutes at 450 mg/hour, and 20 minutes later at 1800mg/hour.
62430899|NCT05191225|EXPERIMENTAL|Ultrarapid plus infusion group|After the administration of oral premedication, the dose of rituximab will be administered at the standard dose administered in half an hour, divided into: 10 first minutes at 450 mg/hour, and 20 minutes later at 1800mg/hour.
62430900|NCT02856451||Patients Treated with Nivolumab followed by Encephalitis Event|Case series reported to the sponsor from various health care facilities
62430901|NCT01318941||Ranibizumab|
62430902|NCT03374150|EXPERIMENTAL|high protein|High protein (HP) group were given counseling about weight loss program by applying low calorie-high protein diet with diet menu composition of 22-30% protein, along with instructions for allowed cooking method.
62430903|NCT03374150|ACTIVE_COMPARATOR|standard protein|Active comparator receiving standard protein (SP) proportion were counseled about weight loss program by means of low calorie-balanced composition diet with menu comprised of 12-20% protein.
62430904|NCT03866837|ACTIVE_COMPARATOR|Study group A: GOS|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA \[2.5 mg\] and ferrous fumarate \[2.5 mg\]) and galacto-oligosaccharides (GOS), 7.5 mg.
62597996|NCT01044290|EXPERIMENTAL|Outlook Intervention|"Subjects in the first group (Life Completion) completed a psychosocial intervention which consisted of meeting with the facilitator three times for 45-60 minutes each. In the first session, subjects were asked to discuss issues related to life review. In session two, participants spoke about issues of regret and forgiveness. In the final session, subjects focused on heritage and legacy."
62240481|NCT00893282|ACTIVE_COMPARATOR|Control|No anti-retropulsion device will be used during lithotripsy.
62597997|NCT01044290|ACTIVE_COMPARATOR|Attention Control|"The subjects in the second group (attention control) met with a facilitator three times for 45 minutes and listened to a non-guided relaxation CD."
62816620|NCT02640586|EXPERIMENTAL|Assessing response with MRI|"Preoperative chemo-radiotherapy as standard treatment. Neoadjuvant therapy (long course intensity modulated radio-chemotherapy, GTV 50.6Gy, totally 22 fractions; Capecitabine 825mg/m2 /bid by oral administration).~Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.~All patients are scheduled to receive total mesorectal excision surgery 12-14 weeks after the completion of preoperative chemo-radiotherapy."
62240482|NCT05044026||Arm A: JAK inhibitor naive|JAK-inhibitor-naive patients, treatment start with ruxolitinib less than 14 days prior to the baseline visit
62240483|NCT05044026||Arm B: Pretreated patients|Patients pretreated with a JAK-inhibitor for more than 14 days prior to the baseline visit
62240484|NCT00475618|EXPERIMENTAL|Fluoride Varnish|Professional cleaning + education + fluoride vanish
62240485|NCT00475618|ACTIVE_COMPARATOR|Fluoride Toothpaste 500 ppm|Professional cleaning + education + fluoride toothpaste 500 ppm
62240486|NCT00475618|ACTIVE_COMPARATOR|No fluoride toothpaste|Professional cleaning + education + no fluoride toothpaste
62240487|NCT05591820|EXPERIMENTAL|Brief behavioral parent training with optional booster sessions|A brief, individualized, three-session parent training that exists of two (bi)weekly individually tailored training sessions of two hours and a third session of one hour in which the training will be evaluated, and maintenance training will be provided. After that, parents wishing to receive additional support can receive single booster sessions maximum once every four weeks and/or receive care as usual.
62430905|NCT03866837|ACTIVE_COMPARATOR|Study group B: bLF|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA \[2.5 mg\] and ferrous fumarate \[2.5 mg\]), bovine lactoferrin (bLF), 1.0 g.
62430906|NCT03866837|ACTIVE_COMPARATOR|Study group C: GOS + bLF|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA \[2.5 mg\] and ferrous fumarate \[2.5 mg\]), galacto-oligosaccharides (GOS), 7.5 mg, and bovine lactoferrin (bLF), 1.0 g.
62430907|NCT03866837|PLACEBO_COMPARATOR|Study group D|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA \[2.5 mg\] and ferrous fumarate \[2.5 mg\]) alone, with no galacto-oligosaccharides (GOS), and no bovine lactoferrin (bLF).
62430908|NCT01535846|EXPERIMENTAL|Conscious food tasting intervention|Instead of focusing on dieting rules to restrict food intake, paying attention to sensory stimulation allow the recognition of internal cues of hunger and satiety which can be helpful to facilitate a more internalized regulation of food intake among restrained eaters. In the experimental group, the conscious food tasting intervention will be conducted by a registered dietitian into small groups of ten to twelve women during six weekly 2-hour workshops. Workshops will be taking place in a well-ventilated room to insure that there are no extraneous odours or noises that may hamper the activities involving senses.
62816621|NCT02340026|EXPERIMENTAL|Conventional Therapy|"The conventional treatment group will receive traditional, therapist-directed pediatric physical therapy. Therapy will focus on early gait training strategies and encouragement of normal movement patterns for walking and other age-appropriate movements, with manual guidance or correction of atypical movements from the therapist. This group may use assistive devices, orthoses, and may receive static body weight support for gait training. Therapy activities will be performed in blocks of practice, with the specific activities and level of therapist assistance tailored to each child."
62819436|NCT03016156|EXPERIMENTAL|Stratum I: Initial Evaluation Group|Initially, a small group of patients diagnosed with congenital or infantile cataracts, congenital glaucoma or retinoblastoma and who meet the eligibility criteria will undergo testing with CRADLE on Day 1.
62819437|NCT03016156|EXPERIMENTAL|Stratum II: Leukocoria Evaluation Group|A separate group of participants who are referred for evaluation of leukocoria or any other eye condition will undergo red reflex testing testing with CRADLE on Day 1.
62430909|NCT01535846|NO_INTERVENTION|Control|
62430910|NCT00054119|EXPERIMENTAL|Treatment|Patients receive karenitecin IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62430911|NCT02219269||Medically complex contraception users|Cohort includes women of reproductive age with diverse medical conditions (listed in inclusion criteria) who are referred to Family Planning felowship-trained physicians, seeking contraception counseling and administration.
62597998|NCT01044290|NO_INTERVENTION|Treatment as Usual|"Subjects in the third group (treatment as usual) were exposed to no intervention or attention control during the intervention window."
62597999|NCT05022524|EXPERIMENTAL|Transition-Age Adults|16-25 year old patients on stable dose of antipsychotic medication for treatment of depression or anxiety.
62240488|NCT05591820|ACTIVE_COMPARATOR|Care as usual (CAU)|The care that is usually provided by the clinical institutions to treat children's disruptive behaviors. There will be no restrictions regarding type or duration of CAU (only the brief parent training will not be allowed) which may for example include psychoeducation, (long) parent training, child treatment (e.g., pharmacotherapy, cognitive behavioral therapy) or family therapy.
62240489|NCT03061461|ACTIVE_COMPARATOR|rESWT|"Treatment of chronic wounds with the Swiss DolorClast (Electro Medical Systems S.A., Nyon, Switzerland) and the EvoBlue handpiece as follows:~* Use of the 15-mm applicator or the 36-mm applicator of the Swiss DolorClast according to the individual wound size.~* Six treatment sessions, two treatment sessions per week.~* 1000 radial shock waves per cm\^2 wound and treatment session.~* Energy flux density 0.07 mJ/mm\^2 (i.e., setting of the air pressure of the Swiss DolorClast at 2 bar when using the 15-mm applicator, and at 4 bar when using the 36-mm applicator).~* Frequency of the radial shock waves set at 15 Hz."
62240490|NCT03061461|SHAM_COMPARATOR|Sham rESWT|"Treatment of chronic wounds with the Swiss DolorClast (Electro Medical Systems S.A., Nyon, Switzerland) and the placebo EvoBlue handpiece of the Swiss DolorClast (that looks and sounds like the EvoBlue handpiece of the Swiss DolorClast, but does not generate radial shock waves) as follows:~* Use of the 15-mm applicator or the 36-mm applicator of the Swiss DolorClast according to the individual wound size.~* Six treatment sessions, two treatment sessions per week.~* 1000 sham radial shock waves per cm\^2 wound and treatment session.~* Energy flux density 0.00 mJ/mm\^2 (setting of the air pressure of the Swiss DolorClast at 2 bar when using the 15-mm applicator, and at 4 bar when using the 36-mm applicator).~* Frequency of the sham radial shock waves set at 15 Hz."
62430912|NCT03255031|ACTIVE_COMPARATOR|Ketogenic diet (KD)|Subjects with alcohol use disorder receive ketogenic diet (KD) which consists of food, snacks, and shakes three times per day (high in fat) for up to four weeks while inpatient.
62816622|NCT02340026|EXPERIMENTAL|Dynamic Supported Mobility|Children will receive dynamic weight support during all DSM treatment time. The environment will be arranged to encourage active motor exploration, somewhat similar to a play gym for toddlers, to promote the motor variability, engagement, and error experiences that characterize the typical development of upright motor skills and walking. The floor area within 3 feet below either side of the overhead track for a distance of 20 feet (approximately 120 ft2 total) will be defined with colorful thin rubber interlocking mats and arranged with pediatric toys and activities, tailored to the child's interests and to encourage motor skills just beyond his/her current ability. The therapist will minimally assist the child as needed to perform the movements he/she initiates.
62816623|NCT01680341|EXPERIMENTAL|IDegAsp Simple|
62816624|NCT01680341|EXPERIMENTAL|IDegAsp Step wise|
62816625|NCT03589859||Normal Volunteers|Testing motor learning
62816626|NCT03589859||Vestibular hypofunction|Testing feasibility of rehabilitation game
62240491|NCT02166866||Experimental arm|
62430913|NCT03255031|PLACEBO_COMPARATOR|Standard American (SA) diet|Subjects with alcohol use disorder receive Standard American (SA) diet which consists of ketogenic diet (KD) food, snacks, and shakes three times per day (high in fat) in the proportions of carbohydrates, protein and fat of traditional western diet for up to four weeks while inpatient.
62430914|NCT03810664|EXPERIMENTAL|Somatrogon pre-filled PEN|
62816627|NCT01149993|EXPERIMENTAL|pre-transplant immunosuppression|subjects in this arm will receive Myfortic 720mg twice daily for 7 days prior to transplantation. Intra-operatively, the donor kidney will receive an infusion of Thymoglobulin, prior to the transplantation.
62816628|NCT01149993|EXPERIMENTAL|pre-transplant induction|subjects in this arm will not receive any pre-transplant immunosuppression. However, the donor kidney will receive an infusion of Thymoglobulin prior to transplantation.
62816629|NCT01149993|ACTIVE_COMPARATOR|standard of care|subjects in this arm will not receive any pre-transplant immunosuppression, and the donor kidney will not receive an additional dose of Thymoglobulin prior to transplantation. This is the standard of care protocol for Georgetown University Hospital
62816630|NCT03497936|EXPERIMENTAL|Women's Stories|Participants in this group will be randomly assigned to use the Women's Stories intervention.
62816631|NCT03497936|NO_INTERVENTION|Programming as usual|Participants in this group will be randomly assigned participate in their usual programming.
62816632|NCT03267277|EXPERIMENTAL|Treatment|Participants received intravenous sodium thiosulfate 16 g/m\^2 three times weekly for 10 weeks
62816633|NCT02535312|EXPERIMENTAL|Arm A (methoxyamine, pemetrexed disodium, cisplatin)|Patients receive methoxyamine PO QD on days 1-4, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.
62240492|NCT04733781|ACTIVE_COMPARATOR|Subcutaneous injection of 125ml by a physician and self-injection of 125ml by a volunteer (Arm I):|A volunteer layperson (research subject), at least 16 years of age, will first receive 125ml of TLE injected subcutaneously into the left anterior thigh by a physician. Then the subject will self-inject a second 125ml of TLE into his/her right anterior thigh.
62430915|NCT03810664|ACTIVE_COMPARATOR|Somatrogon frozen liquid formulation|
62816634|NCT02535312|EXPERIMENTAL|Arm B (methoxyamine, pemetrexed disodium)|Patients receive methoxyamine PO QD on days 1-4 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.
62816635|NCT03694158|EXPERIMENTAL|Treatment group|Dupilumab (Dupixent®) administered subcutaneously every two weeks. An initial dose of 600 mg (two 300 mg injections) followed by 300 mg given every other week.
62816636|NCT03694158|PLACEBO_COMPARATOR|Placebo group|Placebo (preparation, administration, packaging, and labeling all equivalent to the treatment) administered subcutaneously every two weeks.
62816637|NCT01935934|EXPERIMENTAL|Treatment (cabozantinib s-malate)|Patients receive 60 mg cabozantinib s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62816638|NCT04803318|EXPERIMENTAL|Combination treatment of 3 inhibitors|Oral administration of 3 signaling pathways inhibitors: Mek inhibitor Trametinib, mTOR inhibitor Everolimus, and angiogenesis inhibitor Lenvatinib on refractory advanced solid tumors.
62430916|NCT01990066|EXPERIMENTAL|Intervention|Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
62430917|NCT01990066|NO_INTERVENTION|Observation|Subjects randomized to observation will only have physical therapy assessment using the Berg Balance Test and 6min Walk Test at baseline and end point. These subjects will not receive any exercise teaching.
62816639|NCT06173687|EXPERIMENTAL|All participants|
62598000|NCT04285424|EXPERIMENTAL|HSCT patients with acute steroid-resistant GI-related GVHD|Patients will receive 500ml fecal microbiota which were sprayed evenly on the entire colon through colonscopy or duodenal nutrition tube injection which collected from one unrelated healthy donors. Patients receiving FMT treatment will be followed for at least 1,3,5,7 days.Stool, blood and colonic mucosa samples will be serially collected and tested (before pre-treatment, 1,3,5,7 days after FMT).
62598001|NCT04946032|ACTIVE_COMPARATOR|4 cm epidural catheter|The epidural catheter will be thread into the epidural space at a length of 4 cm.
62598002|NCT04946032|ACTIVE_COMPARATOR|5 cm epidural catheter|The epidural catheter will be thread into the epidural space at a length of 5 cm.
62598003|NCT06444763|EXPERIMENTAL|Maolactin|2 capsules containing a total of 500 mg/day active proteins taken once daily before the morning meal
62240493|NCT04733781|ACTIVE_COMPARATOR|Subcutaneous injection of 125ml by a physician and 125ml by another volunteer (Arm II):|A volunteer layperson (primary research subject), at least 16 years of age, will first receive 125ml of TLE injected subcutaneously into the left anterior thigh by a physician. The primary research subject will then receive a second 125ml of TLE injected into his/her right anterior thigh by a second adult volunteer who is at least 16 years old and not a medical professional.
62240494|NCT04733781|ACTIVE_COMPARATOR|Subcutaneous injection of 250ml by a physician into a volunteer (Arm III)|A volunteer layperson (research subject), at least 16 years old, will receive 250ml of TLE injected subcutaneously into the one anterior thigh by a physician.
62240495|NCT04617756|EXPERIMENTAL|Durvalumab+Gemcitabine/Cisplatin or with Gemcitabine/Carboplatin|This is a single arm including 2 different cohorts : Cohort 1 includes patients on 40mg/ML Gemcitabine/50mg Cisplatin used in combination with 50 mg/mL of intravenous Durvalumab (laboratory code MEDI 4736) every 3 weeks for a total of 4 cycles and Cohort 2 includes patients on 40mg/ML Gemcitabine/450mg Carboplatin used in combination with 50 mg/mL of intravenous Durvalumab (laboratory code MEDI 4736) every 3 weeks for a total of 4 cycles..
62240496|NCT03575286||Pregnant female|Patient has been determined pregnant with a urine pregnancy test and, if applicable, a serum pregnancy test performed at Northwestern University.
62240497|NCT03575286||Non-pregnant female|Patient has been determined not pregnant with a urine pregnancy test and, if applicable, a serum pregnancy test performed at Northwestern University.
62816640|NCT05147220|EXPERIMENTAL|Remibrutinib - Core|Remibrutinib tablet and matching placebo of teriflunomide capsule
62816641|NCT05147220|ACTIVE_COMPARATOR|Teriflunomide - Core|Teriflunomide capsule and matching placebo remibrutinib tablet
62816642|NCT05147220|EXPERIMENTAL|Remibrutinib - Extension|Participants on remibrutinib in Core will continue on remibrutinib tablet
62240498|NCT02637115|PLACEBO_COMPARATOR|Placebo|Placebo corresponds to a solution of Phosphate buffer saline (PBS) and glycerol, that is the carrier used in the 3 other groups receiving the bacteria (active arms)
62240499|NCT02637115|EXPERIMENTAL|Live Akk 9|Live Akkermansia muciniphila (Akk) at the dose of 10exp9 live bacteria (one billion of live bacteria) per day
62240500|NCT02637115|EXPERIMENTAL|Live Akk 10|Live Akkermansia muciniphila (Akk) at the dose of 10exp10 live bacteria (ten billion of live bacteria) per day
62240501|NCT02637115|EXPERIMENTAL|Killed Akk|This group corresponds to Akkermansia muciniphila that have been heat-killed. The initial quantity of bacteria before the heating procedure was of 10exp10 bacteria.
62240502|NCT01102803|PLACEBO_COMPARATOR|Sugar Pill|Participants will receive placebo augmented cognitive behavioral therapy
62240503|NCT01102803|EXPERIMENTAL|D-Cycloserine|Participants will receive D-Cycloserine augmented cognitive behavioral therapy
62240504|NCT01695577|EXPERIMENTAL|Multidisciplinary evaluation and VR|Vestibular rehabilitation and balance training. Twice a week for eight weeks.Outcome measures and tests at baseline, after 8 weeks and 6 months after the injury.
62240505|NCT01695577|ACTIVE_COMPARATOR|Multidisciplinary evaluation and no VR|Multidisciplinary evaluation. Outcome measures and tests at baseline, after 8 weeks and 6 months after the injury.
62430918|NCT01673165|ACTIVE_COMPARATOR|Specialized Formula|25 infants of mothers who do not have breast milk or do not want to use the skimming technique. These infants will receive our standard of care - specialized formula for the treatment of chylothorax
62430919|NCT01673165|EXPERIMENTAL|Skimmed mother's milk|25 infants of mothers who have breast milk and who also want to learn the skimming technique will be taught the technique. The infants will then receive the skimmed breast milk for the treatment of chylothorax
62598004|NCT06444763|PLACEBO_COMPARATOR|Maltodextrin|2 capsules containing maltodextrin (0mg/day active proteins) taken once daily before the morning meal
62598005|NCT04994912|EXPERIMENTAL|EI-001|IV infusion
62816643|NCT05147220|EXPERIMENTAL|Remibrutinib - Extension (on teriflunomide in Core)|Participants on teriflunomide in Core will switch to remibrutinib tablet
62816644|NCT05137041|EXPERIMENTAL|ITP FIRTECH|The ITP FIRTECH patch was applied on the lower back region of the body on Day 1 and intended to be worn for 5 Days (Day 5).
62430920|NCT04891367|EXPERIMENTAL|Group CBT|Group cognitive behavioral therapy for obsessive compulsive disorder in youth
62430921|NCT01309828|EXPERIMENTAL|Azilsartan Medoxomil + Chlorthalidone|United States and Europe: Azilsartan medoxomil 20 mg plus chlorthalidone 12.5 mg fixed dose combination tablets, titrated up to azilsartan medoxomil 40 mg plus chlorthalidone 25 mg orally, once daily for up to 52 weeks.
62598006|NCT04994912|PLACEBO_COMPARATOR|Placebo|IV infusion
62598007|NCT04983667|EXPERIMENTAL|Orange|Zinc-AA, Tablet, 30 mg. PO, Once Daily for up to one year
62598008|NCT04983667|PLACEBO_COMPARATOR|Green|Placebo, Tablet, 30 mg. PO, Once Daily for up to one year.
62598009|NCT06473025|EXPERIMENTAL|Treatment Arm 1: Relative Nutritional Status|Provide information on the true height-for-age and weight-for-age percentiles of the child relative to a reference group of healthy children based on WHO standards
62598010|NCT06473025|EXPERIMENTAL|Treatment Arm 2: Relative Nutritional Status and Returns|Provide information on the true height-for-age and weight-for-age percentiles of the child relative to a reference group of healthy children based on WHO standards AND provide information on the impacts of child undernutrition on health (risk of chronic and infectious diseases, mortality), education (high school test scores, years of education), and labor market (earnings) outcomes, synthesized from existing literature
62598011|NCT06473025|NO_INTERVENTION|Control Arm|Status-quo, no intervention
62598012|NCT05948566|PLACEBO_COMPARATOR|Placebo|Placebo
62816645|NCT05137041|NO_INTERVENTION|No Patch Control Arm|No patch application.
62240506|NCT03342248|EXPERIMENTAL|access to the social network|This group is made up of carers who have access to the social network via a digital platform developed during step 1. This network will offer features from step 1 (sharing experiences on a forum, monitoring health status )
62430922|NCT01309828|ACTIVE_COMPARATOR|Olmesartan Medoxomil + Hydrochlorothiazide|United States: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 40 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks. Europe: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 20 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks.
62430923|NCT05599204|EXPERIMENTAL|schroth exercise|the patients will receive Schroth exercise twice a week for four weeks
62430924|NCT05599204|ACTIVE_COMPARATOR|postural correction exercise|the patients will receive postural correction exercise twice a week for four weeks
62430925|NCT02496871|ACTIVE_COMPARATOR|KWMP-GP|Weekly group phone calls for 6 months. Group phone calls will last about 45 minutes each. Phone calls will include groups of 12-18 participants.
62430926|NCT02496871|EXPERIMENTAL|KWMP-SM|Participants interact through a private Facebook group. New activities for participants to complete each week for 6 months.
62430927|NCT02620319|EXPERIMENTAL|biodegradable stent|endoscopic implantation of biodegradable airway stent, the SX-ELLA Stent DV Tracheal (DV Stent)
62430928|NCT03229395||patients with Cushing's syndrome|Patients were selected by the PI at the diagnosis.
62430929|NCT03229395||control patients|Selected patients are matched for age and sex.
62430930|NCT01586767|ACTIVE_COMPARATOR|Proton beam therapy|Subjects treated at Massachusetts General Hospital with proton beam therapy
62430931|NCT01586767|ACTIVE_COMPARATOR|IMRT|Intensity-modulated radiation therapy at institutions other than Massachusetts General Hospital
62430932|NCT05363852|EXPERIMENTAL|Emotional reaction|Physiological responses (cerebral blood flow, brain electrical activity, heart rate variability, and skin conduct-ance response) to visual word and picture stimuli
62430933|NCT00304954|ACTIVE_COMPARATOR|Intravenous Daclizumab|Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
62430934|NCT00304954|ACTIVE_COMPARATOR|Intravenous Infliximab|Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
62430935|NCT00304954|ACTIVE_COMPARATOR|Oral Rapamycin|Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
62430936|NCT00304954|OTHER|Observation|Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
62430937|NCT04972136|ACTIVE_COMPARATOR|Active bilateral theta burst stimulation|An X100 stimulator with a B65 A/P type coil (Magventure Inc.) will be used. The coil is positioned under MRI guidance using real-time neuronavigation using Brainsight \[x,y,z= -38, 44, 26(left), +38, 44, 26 (right). BL-TBS will be delivered at 90% RMT, corrected for scalp to cortex distance, to targeted left and right DLPFC sites, differing only in stimulation pattern and total number of pulses (triplet 50 Hz bursts, repeated at 200 msec (i.e., 5 Hz); right DLPFC (continuous TBS, cTBS): 120 seconds uninterrupted bursts (total of 600 pulses); left DLPFC (intermittent TBS, iTBS: 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 9 seconds/hemisphere).
62430938|NCT04972136|SHAM_COMPARATOR|Sham bilateral theta burst stimulation|"An X100 stimulator with a B65 A/P type coil (Magventure Inc.) will be used with the active coil facing away from the scalp, for sham stimulation. The coil is positioned under MRI guidance using real-time neuronavigation using Brainsight \[x,y,z= -38, 44, 26(left), +38, 44, 26 (right). To reproduce the nociceptive qualities of the stimulation, the B65-type stimulation coil - sham side - includes a built in electrical stimulator in the coil connector which fires a synchronous electrical pulse along with the TMS stimulus through electrodes mounted on the forehead or near the area of stimulation, to generate auditory and somatosensory (vibration) stimuli."
62430939|NCT05085197|EXPERIMENTAL|Cohort 1:1mg/kg|All participants (fasted) received either 1mg/kg of STSA-1005 as a single dose or dose-matched placebo.
62430940|NCT05085197|EXPERIMENTAL|Cohort 2:2.5mg/kg|All participants (fasted) received either 2.5mg/kg of STSA-1005 as a single dose or dose-matched placebo.
62430941|NCT05085197|EXPERIMENTAL|Cohort 3:5mg/kg|All participants (fasted) received either 5 mg/kg of STSA-1005 as a single dose or dose-matched placebo.
62430942|NCT05085197|EXPERIMENTAL|Cohort 4:10mg/kg|All participants (fasted) received either 10 mg/kg of STSA-1005 as a single dose or dose-matched placebo.
62816646|NCT05622734|EXPERIMENTAL|VOCALE LBD+|
62816647|NCT05543603|EXPERIMENTAL|Chlorhexidine 0,12%|15 ml 0,12% Chlorhexidine, one minute rinse.
62240507|NCT03342248|NO_INTERVENTION|no access to the network|"This group consists of caregivers who do not have access to the social network via a digital platform developed during step 1.~Access to the social network will be offered to all carers at the end of the study, especially those assigned in the control group to limit their refusal to participate."
62240508|NCT01865565||Imatinib treat|"• Locally advanced unresectable GIST without metastasis at~* EC junction requiring total gastrectomy,~* Duodenum requiring Whipple operation;~* Large GIST requiring multiviceral resection;~* Rectum: requiring APR."
62430943|NCT02084979|EXPERIMENTAL|Asynchronous telepsychiatry|Experimental Arm: Asynchronous telepsychiatry evaluation and consultation
62430944|NCT02084979|ACTIVE_COMPARATOR|Synchronous telepsychiatry|Control Arm: Synchronous telepsychiatry evaluation and consultation
62430945|NCT05085860|EXPERIMENTAL|Moderate Intensity Continuous Training (MICT)|Participants will do 3 sessions of moderate-intensity continous exercise training over 7 days
62430946|NCT05085860|EXPERIMENTAL|High Intensity Interval Training (HIIT)|Participants will do 3 sessions of high-intensity interval training over 7 days
62430947|NCT05085860|NO_INTERVENTION|Rest|Participants will abstain from doing moderate- to high-intensity interval training over 7 days
62430948|NCT02182960|EXPERIMENTAL|Ibuprofen|
62816648|NCT05543603|EXPERIMENTAL|Chlorhexidine 0,20%|15 ml 0,20% Chlorhexidine, one minute rinse.
62816649|NCT05543603|EXPERIMENTAL|Gingilacer Encias Delicadas|15 ml 0,10% cymenol + 0,10% zinc chloride, one minute rinse.
62816650|NCT05543603|PLACEBO_COMPARATOR|Distilled Water|15 ml Distilled Water, one minute rinse.
62240509|NCT05045326|EXPERIMENTAL|Experimental: Intervention Group|Participants in the intervention group will receive an intensive motivational intervention with individual and group treatment for smoking cessation. The treatment, provided by trained professionals, will include psychological, psycho-educational support and pharmacological treatment advice.
62240510|NCT05045326|PLACEBO_COMPARATOR|Placebo Comparator: Brief Counselling|Participants in the placebo group will receive a brief intervention for smoking cessation.
62240511|NCT05184686|ACTIVE_COMPARATOR|noise(low-level) and RF(low-level)|
62240512|NCT05184686|ACTIVE_COMPARATOR|noise(high-level) and RF(low-level)|
62240513|NCT05184686|ACTIVE_COMPARATOR|noise(high-level) and RF(high-level)|
62430949|NCT02182960|ACTIVE_COMPARATOR|Brufen|
62430950|NCT04583488|EXPERIMENTAL|Intraperitoneal docetaxel|Participants will receive intraperitoneal docetaxel combined with the standard of care. A standard 3 + 3 dose escalation design will be used according to the dose escalation plan.
62430951|NCT04296461|EXPERIMENTAL|Welgenaleucel (UWC19)|Part I The safety and efficacy of Welgenaleucel (UWC19) will be evaluated in a standard 3+3 dose escalation approach.The planned dose escalation cohort levels for Welgenaleucel (UWC19) are 4, 8, 12, 16 and 20 x10\^6 CAR-T cells/kg administered intravenously once.
62430952|NCT03171506|EXPERIMENTAL|Usual care plus ketogenic diet|
62430953|NCT03171506|PLACEBO_COMPARATOR|Usual care plus AND diet|
62430954|NCT01736137||Chronic Heart failure group|All chronic heart failure group participants will perform two walk tests at the same day, with a heart rate monitor, and answer questionnaires about their perception of quality of life. Tests will be conducted on a single day, without follow up of patients. The six minute walk test will be performed according the American Thoracic Society Statement (2002).
62430955|NCT01736137||Control Group|All control group participants will perform two walk tests at the same day, with a heart rate monitor, and answer questionnaires about their perception of quality of life. Tests will be conducted on a single day, without follow up of patients. The six minute walk test will be performed according the American Thoracic Society Statement (2002).
62430956|NCT06121349||OCR|Patients under treatment with Ocrelizumab (OCR) for at least 1 year prior to study start.
62430957|NCT06121349||OMB|Patients under treatment with ofatumumab (OMB) for at least 6 months prior to study start
62430958|NCT03724916|PLACEBO_COMPARATOR|Pooled Placebo|TAK-079 placebo-matching injection, subcutaneously, once every 3 weeks in combination with principal investigator-directed background therapy for SLE for up to 12 weeks. Placebo data will be pooled across all the dose levels.
62430959|NCT03724916|EXPERIMENTAL|TAK-079 45 mg|TAK-079 45 mg injection subcutaneously, once every 3 weeks in combination with principal investigator-directed background therapy for SLE for up to 12 weeks.
62430960|NCT03724916|EXPERIMENTAL|TAK-079 90 mg|TAK-079 90 mg injection subcutaneously, once every 3 weeks in combination with principal investigator-directed background therapy for SLE for up to 12 weeks.
62430961|NCT03724916|EXPERIMENTAL|TAK-079 135 mg|TAK-079 135 mg injection subcutaneously, once every 3 weeks in combination with principal investigator-directed background therapy for SLE for up to 12 weeks.
62430962|NCT01928654|EXPERIMENTAL|Micropulse laser treatment|Sub-threshold laser treatment covering the area of retinal thickening with a dense pattern
62430963|NCT01928654|ACTIVE_COMPARATOR|Laser modified ETDRS|Macular treatment using the modified ETDRS protocol, with barely visible laser burns to close microaneurysms, or with a grid pattern in the area of retinal thickening.
62598013|NCT05948566|EXPERIMENTAL|Dose 1 TS23|low dose
62598014|NCT05948566|EXPERIMENTAL|Dose 2 TS23|next higher dose
62240514|NCT05184686|ACTIVE_COMPARATOR|noise(low-level) and RF(high-level)|
62240515|NCT06005389||50 patients with common or planter cutaneous warts|"Every patient had a cryotherapy session every 2 weeks until complete clearance for a maximum of six sessions and follow-up was done at 3 months after treatment completion to detect any recurrence. The therapeutic efficacy was evaluated by a decrease in the size (measured by a ruler) and the number of warts with photographic documentation at (the baseline, each visit, 2 weeks after the final session, and the 3 months follow-up period). The response of the treated wart was considered: complete; if there was a disappearance of the wart and appearance of normal skin markings, partial; if the warts had regressed in size or decreased in number and no response; if no decrease in wart size or number.~From each patient 3 ml venous blood was withdrawn under complete aseptic conditions before treatment and 2 weeks after the last treatment session by a disposable plastic syringe. Serum Gal-3 was measured using human Galectin-3 enzyme-linked immunosorbent assay (ELISA) kits."
62430964|NCT02492295|EXPERIMENTAL|Propofol|"Propofol is administered intravenously as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 (light sedation - awakens to voice \<10 seconds) to RASS target of -3 (moderate sedation - movement or eye opening without eye contact) for 15 minutes."
62430965|NCT03496532|EXPERIMENTAL|Pulse generator change under sedation|"The efficacy of every set will be measured on induced changes in LFP recorded from the STN electrodes.LFP will be compared between before, during and right after each stimulation conditions. The stimulation order will be randomized. All other stimulation parameters will be the same (macrocontact with most beta-oscillations, 1 minute, 1.5mA) .~Hence 4 sets of 1 minutes of STN stimulation will be performed, for:~Symmetrical biphasic pulses versus standard pseudo monophasic pulses (study I; 2 sets).~Pseudorandom uniform distribution stimulation paradigms versus pseudorandom Poisson distribution stimulation paradigms (study II: 2 sets)."
62430966|NCT03496532|EXPERIMENTAL|First pulse generator implantation under general an|The depth of anesthesia will be documented, recording the BIS spectral analysis index. The difference in spectral amplitude density of LFP, in particular in beta band oscillations will be correlated with the depth of anesthesia as measured with the BIS index.
62430967|NCT01491490|ACTIVE_COMPARATOR|GWP42003 : GWP42004 (40:1)|
62430968|NCT01491490|PLACEBO_COMPARATOR|Placebo|
62598015|NCT05948566|EXPERIMENTAL|Dose 3 TS23|next higher dose
62598016|NCT05948566|EXPERIMENTAL|Dose 4 TS23|highest dose
62598017|NCT06621069||patients with over 5-year BP history|patients who took bisphosphonates over 5 years
62598018|NCT06621069||control patients without BP usage|patients who do not receive bisphosphonates therapy
62598019|NCT02345889|ACTIVE_COMPARATOR|FUSE® Colonoscopy|A FUSE® system with 3 HD (high-definition) monitors will be used to perform the colonoscopy
62240516|NCT06005389||50 healthy age-and sex-matched control subjects.|From each control subject, 3 ml venous blood was withdrawn under complete aseptic conditions before treatment and 2 weeks after the last treatment session by a disposable plastic syringe. Serum Gal-3 was measured using human Galectin-3 enzyme-linked immunosorbent assay (ELISA) kits.
62240517|NCT04880447||COMIRNATY|COVID-19 mRNA vaccine
62240518|NCT04116424|EXPERIMENTAL|nurse training of the patient|
62430969|NCT01420835|ACTIVE_COMPARATOR|Without Protocol Group|"The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.~Five points will be chosen to treat stress according to the symptoms and Chinese diagnosis."
62430970|NCT01420835|ACTIVE_COMPARATOR|Auriculotherapy with protocol|Auriculotherapy with stress protocol points. Five points are indicated for stress (Liver yang1, Liver yang2, Shenmen, Brainstem and Kidney).
62430971|NCT01420835|NO_INTERVENTION|Control Group|Control Group won't receive any treatment and will be evaluated at the same time and the same way of interventions group
62816651|NCT02370329|EXPERIMENTAL|Treatment (PEG-proline-interferon alpha-2b)|Patients receive PEG-proline-interferon alpha-2b SC on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62816652|NCT01052493|EXPERIMENTAL|2mg PP 1420|PP 1420 single dose, subcutaneous
62240519|NCT04116424|ACTIVE_COMPARATOR|simple information of the patient by neurologist|
62240520|NCT00584883|EXPERIMENTAL|ABT 510|The only arm will receive the ABT 510 following standard therapy with radiation and temozolomide chemotherapy concurrent.
62816653|NCT01052493|EXPERIMENTAL|4mg PP 420|PP 1420 single dose, subcutaneous
62816654|NCT01052493|EXPERIMENTAL|8mg PP 1420|PP 1420 single dose, subcutaneous
62816655|NCT01052493|PLACEBO_COMPARATOR|Placebo|0.9% saline
62240521|NCT00583024|EXPERIMENTAL|Adenovirus/PSA Vaccine|Participants will receive three injections of 0.16 ml. (0.125 ml. vaccine + 0.035 ml. Gelfoam) of the Ad/PSA subcutaneously
62240522|NCT03019471||Lung cancer|Isolate Tumor DNA from the patients blood.
62240523|NCT03019471||Breast cancer|Isolate Tumor DNA from the patients blood.
62430972|NCT02698631|ACTIVE_COMPARATOR|Conventional AF ablation.|A standard radiofrequency AF ablation procedure will be carried out without LGE information.
62816656|NCT05470504|OTHER|1|open label pegvisomant
62816657|NCT00179621|PLACEBO_COMPARATOR|Placebo|Placebo matching to active study arms.
62816658|NCT00179621|EXPERIMENTAL|Lenalidomide 5 mg|Lenalidomide 5 mg daily 28/28 days
62816659|NCT00179621|EXPERIMENTAL|Lenalidomide 10 mg|Lenalidomide 10 mg daily 21/28 days
62816660|NCT05222984|EXPERIMENTAL|Treatment (navitoclax, venetoclax, decitabine)|Patients receive venetoclax PO QD and navitoclax PO QD on days 1-35, and decitabine IV over 1 hour on days 8-12 of cycle 1. Starting on cycle 2, patients receive venetoclax PO QD and navitoclax PO QD on days 1-28, and decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62240524|NCT03019471||Colorectal cancer|Isolate Tumor DNA from the patients blood.
62240525|NCT03019471||Glioma|Isolate Tumor DNA from the patients blood.
62240526|NCT03367715|EXPERIMENTAL|Nivolumab + Ipilimumab + Short-course radiation therapy|within 6 weeks of the first diagnostic surgery for glioblastoma, all subjects will initiate study treatment on Day 1
62240527|NCT03910712|EXPERIMENTAL|Pyrotinib and trastuzumab plus aromatase inhibitor|Participants will receive pyrotinib in combination with trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
62240528|NCT03910712|ACTIVE_COMPARATOR|Trastuzumab plus aromatase inhibitor|Participants will receive trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
62240529|NCT03436706||Participants|The cohort will consist of male and female children ages 11-12 accompanied by a participating parent over the age of 18 years. The family income of participants in this cohort cannot exceed 200% of the federal poverty level established in 2018.
62240530|NCT00770835|EXPERIMENTAL|Pioglitazone and Metformin QD|(along with lifestyle modification)
62430973|NCT02698631|EXPERIMENTAL|LGE-MRI guided AF ablation.|Fibrosis information obtained from post-processed LGE-MRI will be used to guide AF ablation procedures.
62430974|NCT02358954|EXPERIMENTAL|Vestibular Pain interactions|
62430975|NCT00829101||1 One-stage repair|A consecutive group of children born with unilateral cleft lip and palate from the south region of Sweden, in all 10 children, who have had a primary palatal surgery at 12 months of age.
62598020|NCT02345889|ACTIVE_COMPARATOR|Colonoscopy with EndoCuff™|An EndoCuff™ distal attachment will be placed at the distal end of a standard colonoscope
62598021|NCT02345889|ACTIVE_COMPARATOR|Colonoscopy with EndoRings™|An EndoRings™ distal attachment will be placed at the distal end of a standard colonoscope
62598022|NCT02345889|ACTIVE_COMPARATOR|Standard Colonoscopy|A standard colonoscope will be used to complete the procedure
62598023|NCT04768127|EXPERIMENTAL|Early aftercare (intervention group 1)|Patients in this group will begin the ACHT program immediately after their bariatric metabolic operation. 3 weeks post surgery, they will attend the initial examination and meet their case manager. The obesity guide will then set up an electronic case file for the patient and introduce the patient to the obesity app. Through the next 18 months the obesity guide will monitor the patient's therapeutic success and adherence to the therapeutic goals. In month 2 patients visit a sports physician who assesses their mobility and physical capacity to compile a personal training plan, which will be uploaded onto the patient's case file and thus be available to the patient via the app. In months 3,6,9.12 and 18, patients will attend their aftercare appointments at specially trained ACHT physicians, where they will be physically examined by a physician and receive tailored dietary advice from a nutritional advisor. In month 18 patients revisit the surgical centre for the follow-up examination
62735230|NCT01977729|EXPERIMENTAL|Switch to SRT alone|Sertraline is a selective serotonin reuptake inhibitor. Sertraline is FDA approved for the treatment of major depressive disorder, obsessive compulsive disorder, posttraumatic stress disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder in adults. Sertraline is also approved for the treatment of obsessive compulsive disorder in children and adolescents. Pharmacotherapy visits will be scheduled at weeks 9-12, 14, 16, 18, 20 with phone visits at weeks 15, 17, and 19. The psychiatrist will meet for \~30 min. with the youth and parents. Efforts will be made to use the most effective and tolerated SRT dose.
62038097|NCT01628029|EXPERIMENTAL|Arm VII (methylphenidate, placebo, sham light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and melatonin placebo PO QD, and undergo sham light therapy over 30 minutes for 15 days.
62038098|NCT01628029|EXPERIMENTAL|Arm VIII (placebo, melatonin, sham light intervention, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and therapeutic melatonin PO QD, and undergo sham light therapy over 30 minutes for 15 days.
62240531|NCT00770835|ACTIVE_COMPARATOR|Glibenclamide and Metformin QD|(along with lifestyle modification)
62240532|NCT01326195|EXPERIMENTAL|Skills|Cognitive-Behavioral Dating Violence and HIV Prevention Group
62240533|NCT01326195|ACTIVE_COMPARATOR|Health Promotion|Psycho-educational Dating Violence and HIV Prevention group
62240534|NCT06331780|EXPERIMENTAL|Closed-field Aberrometer|Objective refraction at different distances with Shack-Hartmann Aberrometer
62240535|NCT04304781|EXPERIMENTAL|Dimer Application with SFE imaging|Subjects having a standard-of-care ERCP will have the dimer sprayed on an area of interest in the bile duct and images taken with the SFE.
62240536|NCT04141254|EXPERIMENTAL|Debriefing|"a standardized follow-up visit at one month associated with debriefing and enhanced educative component"
62240537|NCT04141254|OTHER|Without debriefing|"a standardized follow-up visit at one month alone (i.e.; without debriefing and educative component)"
62240538|NCT04758299|NO_INTERVENTION|Standard care|information from an FDA authorized home test kit for what actions to take for a negative or positive COVID-19 test
62240539|NCT04758299|EXPERIMENTAL|Decision science-based design|Information from a decision science-based design (of similar length to the FDA authorized home test kit information) for what actions to take for a negative or positive COVID-19 test
62240540|NCT05683587|EXPERIMENTAL|experimental group|intervention
62240541|NCT02228187|ACTIVE_COMPARATOR|BCI Intervention|Subjects will undergo the Brain-Computer Interface Intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the intervention in the first 8 weeks of the trial.
62240542|NCT02228187|NO_INTERVENTION|Waitlist Control Group|The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards. They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.
62240543|NCT05334537|EXPERIMENTAL|the aromatherapy group|"After the birth of the baby, two drops of 100% pure medical lavender oil (Lavandula angustifolia) was inhaled for 5 min through an oxygen mask by groups A and C, respectively. After 5 min, 2 mg intravenous midazolam for sedation was administred to the patients who gained 1 point from the Ramsey Sedation Scale (RSS). Complications, such as nausea, vomiting, hypotension (mean arterial pressure\<60 mmHg), and allergies that developed after aromatherapy, were recorded. At the end of the operation, the dose added to the initial midazolam dose for all patients and the total surgical time were recorded. VAS pain and STAI-I scores were re-evaluated at the third postoperative hour, and the satisfaction levels of each patient after aromatherapy were recorded according to the Likert scale as very satisfied, satisfied, moderate, and not at all satisfied."
62240544|NCT05334537|PLACEBO_COMPARATOR|the control group|"Then, after the birth of the baby two drops of odorless baby oil (jojoba and almond oil) was inhaled for 5 min through an oxygen mask by groups A and C, respectively. After 5 min, 2 mg intravenous midazolam for sedation was administred to the patients who gained 1 point from the Ramsey Sedation Scale (RSS). Complications, such as nausea, vomiting, hypotension (mean arterial pressure\<60 mmHg), and allergies that developed after aromatherapy, were recorded. At the end of the operation, the dose added to the initial midazolam dose for all patients and the total surgical time were recorded. VAS pain and STAI-I scores were re-evaluated at the third postoperative hour, and the satisfaction levels of each patient after aromatherapy were recorded according to the Likert scale as very satisfied, satisfied, moderate, and not at all satisfied."
62240545|NCT01135680|PLACEBO_COMPARATOR|Arm 1|"Cohort A: 9 mL HPN-100 or placebo~Cohort B: 12 mL HPN-100 placebo"
62430976|NCT00829101||2 Two-stage repair, early closure|A consecutive group of children born with unilateral cleft lip and palate from the western region of Sweden, in all 10 children, who have had a two-stage palatal surgery, with soft palate closure at 4-6 months and repair of the hard palate at 12 months of age.
62430977|NCT00829101||3 Two-stage repair, delayed closure|A consecutive group of children born with unilateral cleft lip and palate from the western region of Sweden, in all 10 children, who have have had a two-stage palatal surgery, with soft palate closure at 4-6 months and repair of the hard palate at 36 months of age.
62430978|NCT00736333||Pegylated Liposomal Doxorubicin|Subjects with metastatic breast cancer
62430979|NCT02226939|EXPERIMENTAL|BILN 2061 ZW|
62430980|NCT02226939|PLACEBO_COMPARATOR|Placebo|
62430981|NCT05131490|EXPERIMENTAL|Experimental|Experimental group intervention consists two months a mobile application intervention developed for gynecological cancer patients receiving chemotherapy
62430982|NCT05131490|NO_INTERVENTION|No intervention|Control group receive routine care.
62430983|NCT01920373|ACTIVE_COMPARATOR|Group A (corticosteroid injection group)|Group A will receive one intra-articular injection of 2 ml of solution containing 1ml of 10mg/ml Triamcinolone suspended in 1 ml of 0.5% Bupivacaine solution per affected joint
62430984|NCT01920373|EXPERIMENTAL|Group B (platelet rich plasma injection)|Group B will receive a 2 ml intra-articular injection of a platelet rich plasma preparation per affected joint
62430985|NCT05837598|EXPERIMENTAL|Tumor Board Arm|"This intervention has three parts:~Part 1: Proactive identification and assessment of patient needs, values, psychiatric symptoms, and illness understanding~Part 2: Virtual tumor board discussion~o Bring together expertise in mental illness and cancer, the interdisciplinary team will co-design an integrated cancer and mental health treatment plan. Key strategies include: addressing resource-related barriers to care, framing next steps in terms of patient values, and identifying action steps to address barriers to psycho-oncology/specialty oncology expertise~Part 3: Closed Loop Communication~o Tumor board recommendations shared with treating oncologist, documented in medical record, and shared with patient. Team tracks steps taken to address barriers to care and follows up with patient at 12 weeks."
62430986|NCT02044276|EXPERIMENTAL|lipegfilgrastim.|subcutaneous (SC) injection of 6 mg lipegfilgrastim
62430987|NCT02044276|ACTIVE_COMPARATOR|pegfilgrastim|SC injection of 6 mg pegfilgrastim
62430988|NCT03351127||18-29 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 18-29 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
62430989|NCT03351127||30-39 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 30-39 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
62430990|NCT03351127||40-49 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 40-49 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
62430991|NCT03351127||50-59 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 50-59 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
62598024|NCT04768127|EXPERIMENTAL|Mid-term to long-term aftercare (intervention group 2)|Patients in this group first visit the study center 18 months after their bariatric surgery for the initial examination and start the program in month 19 post-op. At the center, they will meet their obesity guide who will set up an electronic case file for the patient and introduce the patient to the obesity app. Throughout the next 18 months, the obesity guide will monitor the patient's therapeutic success and adherence to the therapeutic goals. In month 19 post-surgery, patients visit a sports physician who assesses their mobility and devises a personal training plan. This plan will be uploaded onto the patient's case file and made available to the patient via the app. In months 19,21,24, 30 and 36, patients attend their aftercare appointments at specially trained ACHT physicians, where they will be physically examined and receive tailored dietary advice. In month 36, patients will be reexamined at the study center.
62816661|NCT02138617|EXPERIMENTAL|*1/*1 Genotype|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 310 mg/m2,(IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
62038099|NCT01508039|EXPERIMENTAL|Treatment with chitin micro-particles|The study will involve 14-healthy subjects confirming to the inclusion criteria randomised to the treatments.
62430992|NCT03351127||60-69 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 60-69 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
62735231|NCT04474197|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to VX-864 in the treatment period for 28 days.
62816662|NCT02138617|EXPERIMENTAL|*1/*28 Genotype|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 260 mg/m2, FOLFIRI (IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
62038100|NCT01516047|EXPERIMENTAL|Cohort 1|Patients with severe hepatic impairment.
62038101|NCT01516047|EXPERIMENTAL|Cohort 2|Healthy individuals with normal hepatic function.
62430993|NCT03351127||70-79 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 70-79 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
62430994|NCT04106466|EXPERIMENTAL|Deep Brain Stimulation (DBS)|Open label active Deep Brain Stimulation (DBS)
62430995|NCT00124566|EXPERIMENTAL|1|Irofulven + prednisone
62430996|NCT00124566|EXPERIMENTAL|2|Irofulven + capecitabine + prednisone
62430997|NCT00124566|ACTIVE_COMPARATOR|3|Mitoxantrone + prednisone
62598025|NCT04768127|NO_INTERVENTION|control group 1 (early aftercare)|"Analogous to intervention group I, patients in this group are invited to the study center after verbal and written information. These patients will attend the one-off evaluation examination (18 months after the operation) at the obesity centre.~If interested, patients in this group can be included in intervention group II until the required number of cases (140 patients) has been reached."
62598026|NCT04768127|NO_INTERVENTION|control group 2 (mid-term to long-term aftercare)|Analogous to intervention group II, patients in this group are invited to the study center after verbal and written information. These patients will attend the one-off evaluation examination at the study center 36 months after the operation.
62598027|NCT06623136|EXPERIMENTAL|ES102 in combination with Toripalimab|
62816663|NCT02138617|EXPERIMENTAL|*28/*28|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 180 mg/m2, FOLFIRI (IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
62816664|NCT06706401|ACTIVE_COMPARATOR|Standard radiotherapy|"Patient will receive 6 to 8 weeks of standard (chemo)radiotherapy then will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).~In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments)."
62240546|NCT01135680|PLACEBO_COMPARATOR|Arm 2|"This study requires 4 periods. In each of the periods you will receive one of the dose groups listed below. At the completion of the study you will have participated in all 4 dose groups. The order in which you participate in each dose group will be randomly assigned.~Dose Group A: 9 mL placebo via oral syringe 3 times daily for 3 days~Dose Group B: single oral dose of 400 mg moxifloxacin on study Day 3~Dose Group C: 6 mL HPN-100 and 3 mL placebo via oral syringe 3 times daily for 3 days~Dose Group D: 9 mL HPN-100 via oral syringe 3 times daily for 3 days"
62240547|NCT06227884||Patients with APN intervention|Participants with a schedule of a MD consultation (within approximately 2 to 12 months) + an APN intervention halfway between day hospitalization et MD consultation
62240548|NCT06227884||Patients without APN intervention|Participants with a MD consultation only, within approximately 2 to 12 months
62240549|NCT06008886|EXPERIMENTAL|Vegan diet|Vegan diet all foods included were of plant sources. During the vegan diet, the participants took 1000 µg of cyanocobalamin twice a week (Harrison Sport Nutrition, Granada, Spain)
62240550|NCT06008886|ACTIVE_COMPARATOR|Mediterranean diet|In the case of the mediterranean diet, foods of animal sources were also included (animal protein accounted for 60% of total protein intake). In this diet there was a predominance of plant foods; moderate to low consumption of fish, white meat, low-fat dairy and eggs; and very low consumption of red and processed meats, butter, full-fat dairy and sweets.
62240551|NCT01217151|SHAM_COMPARATOR|Usual treatment|The hemodynamic management will be performed according to the institution's standard of care, using fluids at the discretion of the anesthesiologist and the ICU specialist.
62240552|NCT01217151|ACTIVE_COMPARATOR|NICOM|"For volume replacement, crystalloids will be used following the standard procedure according to the anesthesiologist or ICU specialist. Mean arterial pressure and cardiac index will be assessed every 5 minutes, and a volume bolus (250 mL colloid in 10 minutes) will be used to achieve a:~* Mean arterial pressure ≥ 65 mmHg (intra and postoperatively), AND~* Cardiac index ≥ 2.5 L/min/m2 (intra and postoperatively).~If these cardiovascular parameters are not met after the first colloid infusion, a supplementary bolus will be added. In case of not achieving the target, additional colloid boluses and/or pharmacologic support (norepinephrine in case of persistent hypotension, dobutamine in case of low cardiac output) will be provided according to the protocol"
62240553|NCT01306422|PLACEBO_COMPARATOR|Stage 2: Placebo|Placebo product, twice-daily, 65 minutes before breakfast and dinner
62038102|NCT05261399|ACTIVE_COMPARATOR|Chemotherapy|Pemetrexed (500 mg/m2) with either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles (Q3W) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) Q3W
62038103|NCT05261399|EXPERIMENTAL|Savolitinib + Osimertinib|300 mg savolitinib BID plus 80 mg osimertinib QD
62240554|NCT01306422|ACTIVE_COMPARATOR|Stage 2: H.g.PE 1110 mg b.d.|Hoodia gordonii Purified Extract (H.g.PE) formulated product (1110 mg), twice-daily, 65 minutes before breakfast and dinner
62240555|NCT01306422|PLACEBO_COMPARATOR|Stage 1: placebo, breakfast & dinner|Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
62240556|NCT01306422|ACTIVE_COMPARATOR|Stage 1: H.g.PE 1110 mg breakfast/dinner|Hoodia gordonii purified extract (H.g.PE) formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
62240557|NCT01306422|PLACEBO_COMPARATOR|stage 1: Placebo breakfast/lunch|Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
62240558|NCT01306422|ACTIVE_COMPARATOR|Stage 1: H.g.PE 1110 mg breakfast/lunch|Hoodia gordonii purified extract (H.g.PE) formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
62240559|NCT01771068|NO_INTERVENTION|Waiting list|
62598028|NCT02347215|OTHER|All patients|All patients undergo quality of life assessment at 2-3 time points and stress imaging at two time points
62598029|NCT03551951||Patients having surgery|Cancer patients undergoing surgery will have test for circulating tumor cells, DNA alterations
62598030|NCT03551951||Patients not having surgery|"Cancer patients not undergoing surgery (but potentially other treatments) will have test for circulating tumor cells, DNA alterations.~Lung cancer screening subjects"
62598031|NCT03551951||Healthy subjects|Healthy control subjects will have test for circulating tumor cells, DNA alterations
62598032|NCT05640297|EXPERIMENTAL|KMC with Massage therapy|Preterm low birth weight babies who will get KMC will also receive massage therapy
62598033|NCT05640297|NO_INTERVENTION|KMC only|Preterm low birth weight babies who will get KMC only
62735232|NCT04474197|EXPERIMENTAL|VX-864 100 mg|Participants received VX-864 100 milligrams (mg) every 12 hours (q12h) in the treatment period for 28 days.
62816665|NCT06706401|EXPERIMENTAL|Tailored radiotherapy and ATRA (Vesanoid)|ATRA will be administered per os 1 week before the start of (chemo)radiotherapy (daily administration for 3 days). Then, patient will receive 6 to 8 weeks of tailored (chemo)radiotherapy. In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments). Subsequently, ATRA will be administered per os for 3 days every 3 weeks for a total of 4 courses starting 2 to 3 weeks after the end of (chemo)radiotherapy. Finally, the patient will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).
62816666|NCT06706401|EXPERIMENTAL|Standard radiotherapy and ATRA (Vesanoid)|ATRA will be administered per os 1 week before the start of (chemo)radiotherapy (daily administration for 3 days). In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments).Then, patient will receive 6 to 8 weeks of standard (chemo)radiotherapy. Subsequently, ATRA will be administered per os for 3 days every 3 weeks for a total of 4 courses starting 2 to 3 weeks after the end of (chemo)radiotherapy. Finally, the patient will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).
62816667|NCT06706401|EXPERIMENTAL|Tailored radiotherapy|"Patient will receive 6 to 8 weeks of tailored (chemo)radiotherapy then will be followed until document progression disease, death, withdrawal of consent or end of trial (whichever occurs first).~In addition of radiotherapy, patient will receive cisplatin or cetuximab (standard of care treatments)."
62816668|NCT05914766|EXPERIMENTAL|Study Phase I: PATHWAYS Intervention|Participants assigned to the PATHWAYS Intervention will receive: 1) four coaching sessions, 2) a comprehensive patient education guidebook, and 3) a coaching session workbook.
62816669|NCT05914766|ACTIVE_COMPARATOR|Study Phase I: Enhanced Usual Care|Participants assigned to the enhanced usual care will receive: 1) an information resource guide for navigating information online.
62816670|NCT05914766|EXPERIMENTAL|Study Phase II: PATHWAYS Intervention|Participants assigned to the PATHWAYS Intervention will receive: 1) four coaching sessions, 2) a comprehensive patient education guidebook, and 3) a coaching session workbook.
62038104|NCT04315077|EXPERIMENTAL|Experimental Group|Subjects will consume one serving per day (25mg) of the treatment condition (Oceanix ®) for 21 days following baseline testing. Days 1 through 14 subjects will consume the supplement with the first meal of the day and refrain from resistance training. Days 15 through 19, subjects will complete one supervised resistance training each day and consume the supplement approximately 30 minutes prior to the training session. On days 20 and 21, subjects will complete follow-up testing in a manner identical to baseline and consume the supplement approximately 30 minutes prior to their arrival at the laboratory.
62038105|NCT04315077|PLACEBO_COMPARATOR|Placebo Group|Subjects will consume one serving per day (25mg) of the microcrystalline cellulose-based placebo condition for 21 days following baseline testing. Days 1 through 14 subjects will consume the supplement with the first meal of the day and refrain from resistance training. Days 15 through 19, subjects will complete one supervised resistance training each day and consume the supplement approximately 30 minutes prior to the training session. On days 20 and 21, subjects will complete follow-up testing in a manner identical to baseline and consume the supplement approximately 30 minutes prior to their arrival at the laboratory.
62038106|NCT04193800||Rotational paramedic pilot group|
62038107|NCT04193800||Paramedic control group|
62240560|NCT01771068|EXPERIMENTAL|Parenting Discussion Group|Two-hour discussion group on child noncompliance. Groups were composed by a maximum of 10 parents and were facilitated by the principal researcher, who is an accredited practitioner. The groups were interactive and discussion based, and a power point presentation with embedded-video clips was used to aid the facilitator. The key points covered in the discussion group included reasons for disobedience, parenting traps, encouraging good behaviour, and managing disobedience. Parents also received a workbook that included the content covered in the discussion group and 2 follow up telephone calls to check how they were doing after the discussion groups.
62240561|NCT06450756|EXPERIMENTAL|Couples arm .|The Couples Arm intervention addressed gaps identified from baseline findings. It involved comprehensive family planning education delivered to married women and men by community agents, Health Extension Workers, and FP experts using flyers, booklets, and face-to-face discussions. Health Extension Workers supported community agents in delivering health education messages about family planning twice a month for 6 months, with each session lasting 2 hours. Note: The group size for the Couples Arm was 748 couples (374 women and 374 men).
62430998|NCT06189352|EXPERIMENTAL|Intervention group|The infants will follow a feeding protocol with detailed nutritional needs, and individual supportive care interventions for enhancing oral feeding development. Parents will get counseling sessions for supporting this strategy. The protocol will follow the infant until discharge.
62430999|NCT04063618|EXPERIMENTAL|Osteopathic Manipulative Therapy (OMT) Treatment Group|Initial concussion treatment will involve OMT in addition to standard of care treatment. The OMT practitioner, using a strong anatomic knowledge base, applies specific genital forces in the dysfunctional area, thus providing aid to the body's innate mechanisms of healing. During OMT, a patient's muscles and joints are moved using techniques that include stretching, gentle pressure, and resistance.
62431000|NCT04063618|ACTIVE_COMPARATOR|Standard of care concussion treatment group|Standard of care concussion treatment without OMT
62431001|NCT02530879|EXPERIMENTAL|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
62431002|NCT02530879|ACTIVE_COMPARATOR|Antireflux medication|"Intervention includes treatment with one of the following:~1. Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day~2. Lansoprazole-Dose range 15mg per day- 30mg twice a day~3. Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day~4. Rantidine-Dose range: 150 mg twice a day or 300 mg once a day.~5. Rantidine may be used in combination with any of the above"
62431003|NCT02530879|EXPERIMENTAL|Voice therapy and Anti-reflux therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
62816671|NCT05914766|ACTIVE_COMPARATOR|Study Phase II: Enhanced Usual Care|Participants assigned to the enhanced usual care will receive: 1) an information resource guide for navigating information online.
62816672|NCT06327100|EXPERIMENTAL|Group 1|Participants have already been receiving ruxolitinib for at least 3 months and are not responding well to ruxolitinib or have low blood cell counts, participants will be assigned to Group 1. In Group 1, participants will receive tasquinimod alone daily each 28 day cycle.
62816673|NCT06327100|EXPERIMENTAL|Group 2|Participants who are already on a stable dose of ruxolitinib for at least 8 weeks who have achieved a sub-optimal response will be assigned to Group 2. In Group 2, participants will receive tasquinimod daily on days 1-28 and ruxolitinib dose will be continued.
62816674|NCT04398771||Treatment|Rovatitan 5/80mg (Rosuvastatin 5mg/Valsartan 80mg) Rovatitan 5/160mg (Rosuvastatin 5mg/Valsartan 160mg) Rovatitan 10/80mg (Rosuvastatin 10mg/Valsartan 80mg) Rovatitan 10/160mg (Rosuvastatin 10mg/Valsartan 160mg) Rovatitan 20/80mg (Rosuvastatin 20mg/Valsartan 80mg) Rovatitan 20/160mg (Rosuvastatin 20mg/Valsartan 160mg)
62816675|NCT06706089|NO_INTERVENTION|No intervention: Control Group: Group A (N=156)|This group did not receive this study's intervention, and were only used for comparisons with the experimental group.
62816676|NCT06706089|EXPERIMENTAL|Experimental: Group B: Intervention Group (N=156)|This group received the described intervention of this study.
62816677|NCT05607446|EXPERIMENTAL|TQC3564 tablets|Orally administer TQC3564 tablets for 14 days.
62816678|NCT05607446|PLACEBO_COMPARATOR|placebo tablets|Orally administer placebo tablets for 14 days.
62816679|NCT05607446|EXPERIMENTAL|TQC3564 tablets + montelukast sodium tablets|Orally administer TQC3546 tablets combined with Montelukast sodium tablets for 14 days.
62816680|NCT05607446|PLACEBO_COMPARATOR|placebo tablets + montelukast sodium tablets|Orally administer placebo tablets combined with Montelukast sodium tablets for 14 days.
62431004|NCT05153291|EXPERIMENTAL|Bachmann's bundle area pacing|Lead placement in Bachmann's bundle area
62431005|NCT05153291|ACTIVE_COMPARATOR|Right atrial appendage pacing|Lead placement in the right atrial appendage
62431006|NCT01986790|EXPERIMENTAL|Plain Language|This intervention group will receive a plain-language table describing the features and costs of health insurance plans, with definitions of health insurance terms incorporated into the table.
62431007|NCT01986790|EXPERIMENTAL|Plain Language + Visuals|This intervention group will receive the plain-language table plus visuals that focus on specific features of the plans. Participants will be able to view the information about each health insurance feature one feature at a time, in the order they prefer.
62431008|NCT01986790|EXPERIMENTAL|Plain Language + Narratives|This intervention group will receive the plain language table plus narratives about how others might use and rate the insurance plans.
62431009|NCT06334978|EXPERIMENTAL|Intervention Group|Techniques used: the dog technique in flexion, scalene muscle energy technique, Jones' first rib adjustment, first rib trust in posterior subluxation, occipitomastoid thrust, Sutherland's posterior needle-scratch, SBS decompression, semi-direct thrust for the sacrum, Sutherland's sacrum, posterior occipital condyle thrust, SBS equilibration.
62431010|NCT06334978|NO_INTERVENTION|Control Group|Conventional treatment
62431011|NCT06496594|EXPERIMENTAL|Erythritol group|
62431012|NCT06496594|ACTIVE_COMPARATOR|Ultrasonic scaler|
62431013|NCT01783730||Participants with high rheumatoid arthritis disease activity|Participants who received adalimumab treatment
62431014|NCT05512715|ACTIVE_COMPARATOR|Lithium|Tablet Lithium Carbonate 300mg daily for 2 months
62431015|NCT05512715|ACTIVE_COMPARATOR|Carbimazole|Tablet Carbimazole 10mg daily for 2 months
62431016|NCT05020054|ACTIVE_COMPARATOR|Intervention Tecartherapy|"The procedures will be performed with Tecartherapy equipment, with the equipment Nèartek®- IBRAMED- Industria Brasileira de Equipamentos Eletromédicos.~The treatment will be carried out once a week, totaling 10 sessions, by two dermato-functional physiotherapists. During the sessions, all volunteers will be positioned in dorsal decubitus and the applicator positioned in the abdominal region, the therapy will be dynamic and simultaneously the professional must assess the local temperature.~The parameters used will be:~Area of 300cm², 1MHz, Capacitive Mode: 60mm Disc: Default 100W Time of 10 minutes, keeping temperature at 42°C Resistive Mode: 60mm Disc: Default 110W Time of 10 minutes, keeping temperature at 42ºC. The total treatment time is 20 minutes."
62431017|NCT05020054|PLACEBO_COMPARATOR|Placebo Tecartherapy|the therapy took place with the equipment turned off
62431018|NCT00305110|EXPERIMENTAL|2 mg IV hydromorphone|2 mg IV hydromorphone administered over 2-3 minutes
62431019|NCT01796431|EXPERIMENTAL|Eviplera®|Participants will take Eviplera every day for 14 days. Levels of the active ingredients, Tenofovir disoproxil fumarate, emtricitabine, rilpivirine hydrochloride will be measured in in blood after the drug intake has been stopped in order to understand how long these drugs persist in the blood.
62431020|NCT01236053||UK GPRD 1993-2008|The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993. Subjects are excluded from the GPRD cohort if they have a cancer diagnosis or a history of cancer prior to the cohort entry date.
62431021|NCT06217952|ACTIVE_COMPARATOR|SPL84|
62598034|NCT06621641|NO_INTERVENTION|Standard Protocol Group|"Control Arm (Pre-Protocol Implementation):~This group includes patients aged 1-24 months receiving HFNC (High-Flow Nasal Cannula) therapy for bronchiolitis based on the conventional, non-standardized approach. HFNC weaning decisions in this group are made at the treating clinicians' discretion, without following a formal protocol. Decisions are influenced by clinical presentation, respiratory effort, and clinician experience. This group serves as the control arm, representing the current standard of care."
62816681|NCT01414634|EXPERIMENTAL|ETIMS 1x10^3|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10\^3 cells.
62816682|NCT01414634|EXPERIMENTAL|ETIMS 1x10^5|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10\^5 cells.
62816683|NCT01414634|EXPERIMENTAL|ETIMS 1x10^7|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10\^7 cells.
62431022|NCT06217952|PLACEBO_COMPARATOR|Placebo|
62431023|NCT04349176|EXPERIMENTAL|Group A 100U|
62431024|NCT04349176|EXPERIMENTAL|Group A 155U|
62431025|NCT04349176|EXPERIMENTAL|Group B 100U|
62431026|NCT04349176|EXPERIMENTAL|Group B 155|
62735233|NCT04474197|EXPERIMENTAL|VX-864 300 mg|Participants received VX-864 300 mg q12h in the treatment period for 28 days.
62240562|NCT06450756|EXPERIMENTAL|Male arm|"The intervention in the married male arm provided health education based on baseline findings to address gaps. Community agents and videos featuring men involved in family planning (FP), a male model supporting his wife's FP use, and a supportive husband sharing information with his wife were used. Clan leaders Abbaa Gada (Indigenous Oromo), religious leaders, and district FP experts also played key roles. Monthly 1-hour sessions over 6 months delivered health education messages about FP. The 374 men selected were the husbands in the intervention group, participating in household and individual-level interventions alongside their wives and attending community gatherings twice. Note: The group size for the male arm (Male Involvement group) was 374 men."
62240563|NCT06450756|NO_INTERVENTION|Control arm|This arm of the Couples-based intervention involves observing the community without providing male education or couples' education at the household/individual level. There is no active intervention by the researchers, but government family planning activities continue. Couples in the control arm are not exposed to the comprehensive interventions of the intervention arms. They only receive the standard intervention as per national guidelines, involving routine reproductive health care. 748 couples (374 women and 374 men) were assigned to the control group, with routine healthcare access or no specific intervention. Note: The group size for the control arm was 748 couples (374 women and 374 men).
62240564|NCT02323633|ACTIVE_COMPARATOR|tPCS group|Arm in which random noise oscillating frequencies will be produced for the duration of 20 minutes.
62240565|NCT02323633|SHAM_COMPARATOR|Sham group|Arm in which no random noise oscillating frequencies will be produced for the duration of 20 minutes
62240566|NCT00615238|EXPERIMENTAL|Diet plus continuous bouts|diet-plus-continuous bouts of vigorous aerobic exercise
62240567|NCT00615238|EXPERIMENTAL|Diet plus short bouts|diet-plus-short bouts of vigorous aerobic exercise accumulated throughout the day
62240568|NCT00615238|EXPERIMENTAL|Diet plus moderate lifestyle activity|diet-plus-moderate intensity lifestyle activity accumulated throughout the day
62240569|NCT00849719|EXPERIMENTAL|1|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient.
62240570|NCT00849719|ACTIVE_COMPARATOR|2|Patients in this arm will be administered with only boluses of 1.5 mg/bolus of MO, by request.
62240571|NCT02257216|ACTIVE_COMPARATOR|Sequence 1: Treatment/Treatment|Treatment/Treatment- consists of Vayarin® for 8 weeks followed by 8 weeks of additional treatment with Vayarin®
62240572|NCT02257216|ACTIVE_COMPARATOR|Sequence 2: Placebo/Treatment|Placebo/Treatment- consists of Placebo for 8 weeks followed by 8 weeks of treatment with Vayarin®
62240573|NCT02257216|PLACEBO_COMPARATOR|Sequence 3: Placebo/Placebo|Placebo/Placebo- consists of Placebo for 8 weeks followed by 8 weeks of additional treatment with Placebo
62431027|NCT02693600|ACTIVE_COMPARATOR|Partial Trapeziectomy (PT)|Patients with Osteoarthritis of the trapeziometacarpal joint determined by the classification of Eaton-Littler (stages II-III) treated with with ligamentoplasty and partial trapeziectomy.
62598035|NCT06621641|ACTIVE_COMPARATOR|New Protocol Group|This group includes patients aged 1-24 months who are randomized to receive HFNC therapy under a newly implemented standardized weaning protocol, developed using Quality Improvement (QI) methodology. The protocol involves a structured, criteria-based weaning approach with clear steps for reducing HFNC support, focusing on clinical indicators like respiratory rate, work of breathing, and oxygen saturation. A multidisciplinary team, including pediatricians, nurses, and respiratory therapists, created this protocol, and staff received training before implementation.
62598036|NCT05720494|EXPERIMENTAL|JZP441|Healthy participants who will be randomized to receive an oral dose of JZP441.
62598037|NCT05720494|PLACEBO_COMPARATOR|Placebo|Healthy participants who will be randomized to receive placebo.
62598038|NCT05885295||Patient|Patient with stroke
62598039|NCT05885295||Controls|Age-matched controls
62598040|NCT02375490|EXPERIMENTAL|Intervention arm|The intervention arm will participate in Healthy Start.
62816684|NCT01414634|EXPERIMENTAL|ETIMS 1x10^8|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10\^8 cells.
62240574|NCT05459285|EXPERIMENTAL|14028 injection|Subjects receive 14028 injection in the study, 0.75mg, once
62240575|NCT05459285|ACTIVE_COMPARATOR|dulaglutide injection (TRULICITY®)|Subjects receive dulaglutide injection (TRULICITY®) in the study, 0.75mg, once
62240576|NCT04058379|EXPERIMENTAL|CT scan|During this study each patient will have 3 CT scans : D0, D1 and D3. A daily follow up during first seven days in ICU, then a follow up at D28 if still in hospital, and a phone call at M6 for neurological outcome
62240577|NCT00603655|EXPERIMENTAL|A|This group will receive a low glycemic load
62240578|NCT00603655|ACTIVE_COMPARATOR|B|This group will receive a high glycemic load
62240579|NCT06360809|EXPERIMENTAL|PEP group|Breast cancer patients involved in a prehabilitation physical exercise program
62240580|NCT06360809|NO_INTERVENTION|CON group|Breast cancer patients not involved in a prehabilitation physical exercise program
62240581|NCT03836807|EXPERIMENTAL|OKITASK®|Single oral administration of Ketoprofen lysine salt 40 mg granules
62240582|NCT03836807|PLACEBO_COMPARATOR|Placebo|Single oral administration of placebo matching granules.
62240583|NCT02018367|EXPERIMENTAL|Proflavine, high resolution imaging|Proflavine hemisulfate will be used as a topical contrast agent in conjunction with the high resolution imaging device to visualize and image areas suspicious for neoplasia. Biopsies will be taken per Seattle biopsy protocol for Barrett's Esophagus surveillance.
62240584|NCT02018367|NO_INTERVENTION|Standard of care|Standard of care examination of the upper GI tract using the standard high resolution endoscope with bipsies taken per Seattle biopsy protocol for Barrett's Esophagus surveillance.
62431028|NCT02693600|ACTIVE_COMPARATOR|Total Trapeziectomy (TT)|Patients with Osteoarthritis of the trapeziometacarpal joint determined by the classification of Eaton-Littler (stages II-III) treated with ligamentoplasty and total trapeziectomy.
62431029|NCT00522327|EXPERIMENTAL|1|remote simult med interpret
62431030|NCT00522327|ACTIVE_COMPARATOR|2|Usual \& Customary
62431031|NCT00522327|OTHER|3|comparison group
62598041|NCT02375490|NO_INTERVENTION|Control arm|Control arm will pursue daily activities at early childcare center as usual.
62598042|NCT01444729||xiapex|Subject treated with Xiapex
62816685|NCT01414634|EXPERIMENTAL|ETIMS 5x10^8|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 5x10\^8 cells.
62816686|NCT01414634|EXPERIMENTAL|ETIMS 1x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10\^9 cells.
62816687|NCT01414634|EXPERIMENTAL|ETIMS 2.5x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 2.5x10\^9 cells.
62816688|NCT01414634|EXPERIMENTAL|ETIMS 3x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 3x10\^9 cells.
62816689|NCT06602986|EXPERIMENTAL|International study|"Hepatocellular carcinoma (HCC) is associated with considerable morbidity and mortality with a high prevalence in developing countries including Pakistan1. Statistics from Pakistan indicate that the cancer is among the top five causes of cancer deaths nationally and the commonest cancer in adult males with respect to frequency of diagnosis2. Risk factors implicated in our population are chronic hepatitis B and C infection, alcohol consumption, autoimmune hepatitis, Wilson disease and alpha-1 anti-trypsin deficiency as the commonest causes3. It is projected that lifestyle modifications including eating habits and increase in the frequency of hepatitis B and C infections would increase the incidence of the disease by threefold in the next decade4.~The treatment options for the disease are diverse depending on the tumor size, location, time of diagnosis and associated co-morbidities. Small tumor with local restriction are offered surgical options including resection and/or tr"
62816690|NCT02774759|EXPERIMENTAL|NEXT-Steps- Aerobic Exercise and Resistance Training (NS-ART)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.~Participants placed into an exercise plan focused on physical activity and resistance training. Physical activity guidelines workbook distributed along with activity monitor. Participants receive phone calls and text messages for support in reaching exercise and diet goals.~Participants receive resistance bands to perform resistance exercises. Exercise handouts and an iPad mini with training videos used to video chat with a research team member.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
62816691|NCT02774759|EXPERIMENTAL|NEXT-Steps- Aerobic Exercise (NS-A)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.~Participants placed into an exercise plan focused on physical activity only. Physical activity guidelines workbook distributed along with activity monitor. Participants receive phone calls and text messages for support in reaching exercise and diet goals.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
62816692|NCT02774759|ACTIVE_COMPARATOR|Standard Care Control Group (CG)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.~Participants receive standard of care consisting of phone calls asking about their health and self-help materials.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
62816693|NCT01779830|EXPERIMENTAL|0.3 mg LY2624803|Single dose of 0.3 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
62240585|NCT03575390|PLACEBO_COMPARATOR|control group|Control group will receive placebo medication therapy
62240586|NCT03575390|EXPERIMENTAL|test group|pomegranate group will receive oral pomegranate (500 mg, twice per day)
62240587|NCT02960373|ACTIVE_COMPARATOR|White Bread (Control)|Participants will consume a test meal containing white bread (dose: 50g available carbohydrate) at three study visits.
62240588|NCT02960373|EXPERIMENTAL|Dried Fruit - Glycemic Index|Participants will consume a test meal containing one variety of dried fruit (dose: 50g available carbohydrate) per visit for four visits. Varieties include raisins, sultanas, dates, and apricots.
62240589|NCT02960373|EXPERIMENTAL|Catalytic Fructose Dose Effect|Participants will consume a test meal containing white bread (dose: 50g available carbohydrate) and one variety of dried fruit (dose: 7g fructose) per visit for four visits. Varieties of dried fruit include: raisins, sultanas, dates, and apricots.
62240590|NCT02960373|EXPERIMENTAL|High GI Displacement Effect|Participants will consume a test meal containing white bread (dose: 25g available carbohydrate) and one variety of dried fruit (dose: 25g available carbohydrate) per visit for four visits. Varieties of dried fruit include: raisins, sultanas, dates, and apricots.
62240591|NCT01612143|ACTIVE_COMPARATOR|A: STV capsule (after high fat meal)|
62598043|NCT01444729||Surgery|Fasciotomy or fasciectomy
62598044|NCT05170100|EXPERIMENTAL|NUIG OAB App|Digital behaviour change intervention. Software-delivered intervention including best-practice behavioural therapy, and evidence-based dietetics, physiotherapy and psychology treatments to reduce the symptoms of overactive bladder.
62598045|NCT04547218||Elderly patients|"Above 65 year old patients undergoing elective surgery Inclusion criteria I. Geriatric patients ( age more than 65 y/o) II. All elective surgeries under GA~Exclusion criteria I. Refuse to participate in the study II. Patients with cognitive disorders such as dementia and Alzheimer's disease"
62598046|NCT06166043|EXPERIMENTAL|NURSE FOLLOW-UP PROGRAM SUPPORTED WITH WEB-BASED EDUCATION IN|An online training consisting of 10 sessions in total for 5 weeks will be given to the patients in order to improve their fatigue management skills. In addition to this training, they will receive a nurse support program.
62816694|NCT01779830|EXPERIMENTAL|3.0 mg LY2624803|Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
62816695|NCT01779830|EXPERIMENTAL|6.0 mg LY2624803|Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
62816696|NCT01779830|ACTIVE_COMPARATOR|10 mg Zolpidem|Single dose of 10 mg zolpidem administered orally in up to 1 of 4 treatment periods.
62816697|NCT01779830|PLACEBO_COMPARATOR|Placebo|Single dose of placebo administered orally in up to 1 of 4 treatment periods.
62240592|NCT01612143|ACTIVE_COMPARATOR|B: STV capsule (fasted state)|
62598047|NCT01757912|EXPERIMENTAL|Cuff pressure after positioning|The patient will be positioned in 16 distinct body positions. Immediately after correct positioning, the cuff pressure is measured.
62598048|NCT05565443|EXPERIMENTAL|Idiopathic PD Patients|Idiopathic PD patients receiving 3 cycles of BBBO. There is option to include simultaneous GCase delivery after safety profile review by Data and Safety Monitoring Board (DSMB).
62598049|NCT05565443|EXPERIMENTAL|GBA PD Patients|GBA PD patients receiving 3 cycles of BBBO. There is option to include simultaneous GCase delivery after safety profile review by Data and Safety Monitoring Board (DSMB).
62816698|NCT04965142|EXPERIMENTAL|Home Exercise Group|The home-based exercise group will be asked to exercise 3 to 5 times per week (≥ 150 minutes of aerobic exercises (i.e. walking, cycling, or treadmill) of at least moderate intensity) and to also complete resistance training (resistance bands or free weights) at least twice weekly over a 12-week period supervised by an exercise professional. The resistance training will be personalized, aiming for 6 to 10 exercises targeting the major muscle groups, progressing to 3 sets of 8 to 12 repetitions. Exercise prescriptions will be developed and monitored by an exercise professional with weekly follow-up meetings and supported with a web application (Physiotec) that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials. Participants will receive one counselling session on healthy eating and physical activity at the start of the study along with an exercise manual.
62598050|NCT05177926|OTHER|antiviral prophylaxis with Tenofovir Alafenamide Fumarate (TAF)|All participants will receive oral Tenofovir Alafenamide Fumarate 25mg, daily, at gestational 27-29 week until delivery.
62816699|NCT04965142|NO_INTERVENTION|Control Group|Participants will receive one counselling session on healthy eating and physical activity at the start of the study.
62816700|NCT02360579|EXPERIMENTAL|Cohort 1|Lifileucel (LN-144) without cryopreservation (Gen 1 infusion product) (Closed)
62816701|NCT02360579|EXPERIMENTAL|Cohort 2|Cryopreserved lifileucel (LN-144) (Gen 2 infusion product) (Closed)
62816702|NCT02360579|EXPERIMENTAL|Cohort 3|Retreatment cohort: patients from Cohort 1, Cohort 2 or Cohort 4 may rescreen for a second TIL regimen therapy if they meet all Inclusion and Exclusion Criteria (except exclusion criterion b).
62816703|NCT02360579|EXPERIMENTAL|Cohort 4|Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)
62816704|NCT06706232|EXPERIMENTAL|Psilocybin with therapeutic support|Up to two sequential administrations of 25 mg psilocybin with additional therapeutic support.
62816705|NCT06397781|EXPERIMENTAL|Skin Cleansing Regimen|"1. Mupirocin 2% nasal ointment to the anterior nares to be applied twice daily~2. Chlorhexidine 4% topical soap (Hibiclens) to be used every other day in the shower or bath from the neck down and then completely rinsed.~3. Sulfamethoxazole/trimethoprim (Bactrim): one double strength (DS) tablet (800 mg/160 mg) twice per day for adolescents and adults"
62816706|NCT05126563|ACTIVE_COMPARATOR|Treatment|HB-ad MSC's allogeneic
62816707|NCT05126563|PLACEBO_COMPARATOR|Placebo|Sterile Normal Saline
62816708|NCT02726503|EXPERIMENTAL|Treatment Arm|
62816709|NCT06374550|EXPERIMENTAL|Jump Start on the Go Group|Participants will be in this group for a total of up to 12 months. These participants will receive the intervention via a mobile app.
62816710|NCT06374550|ACTIVE_COMPARATOR|Jump Start plus Coronavirus Support Group|Participants will be in this group for a total of up to 12 months.
62816711|NCT00667628|PLACEBO_COMPARATOR|Placebo|Participants were administered with placebo tablets matching to TAC-101 orally, every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) treatment recovery period. Repeated every 21 days cycle up to new lesions were observed or the participant met a treatment discontinuation criterion.
62240593|NCT01612143|EXPERIMENTAL|C: STV tablet (after high fat meal)|
62816712|NCT00667628|EXPERIMENTAL|TAC-101|Participants were administered with TAC-101 tablets, 20 milligram per day (mg/day) orally for every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) recovery period (21-day Cycle). Repeated every 21 days cycle up to new lesions were observed or the participant met a treatment discontinuation criterion.
62816713|NCT05907759|EXPERIMENTAL|Arm 1|Treatment with daratumumab SC
62816714|NCT05741424||Before innovative diagnostic technologies|
62816715|NCT05741424||After innovative diagnostic technologies|
62816716|NCT00060528|EXPERIMENTAL|no GM|No granulocyte macrophage colony stimulating factor (GM-CSF) was given
62038108|NCT04866212||Children with Type 1 Diabetes Group|"Children with type 1 diabetes were evaluated in terms of their hand skills, visual motor integration, participation in daily life activities and academic success.~Hand skills were evaluated using the Jebsen Taylor Hand Function Test. Participation was evaluated with Participation and Environment Measurement-Children and Youth. Visual motor integration was evaluated with Beery-Buktenica Developmental Test of Visual Motor Integration. Academic success was evaluated with the course success score."
62816717|NCT00060528|EXPERIMENTAL|Rec-hGM|Recombinant human GM-CSF (Sargramostim) was administered at 100mcg/day on days 1-4 following each vaccine. Given subcutaneously (s.c.) at site of vaccine.
62240594|NCT01612143|EXPERIMENTAL|D: STV tablet (fasted state)|
62240595|NCT03050151|EXPERIMENTAL|1 - Dupilumab (Part A)|Dose (dose 1) as per protocol delivered by auto-injector device
62240596|NCT03050151|EXPERIMENTAL|2 - Dupilumab (Part A)|Dose (dose 1) as per protocol delivered by prefilled syringe
62240597|NCT03050151|EXPERIMENTAL|3 - Dupilumab (Part B)|Dose (dose 2) as per protocol delivered by auto-injector device
62240598|NCT03050151|EXPERIMENTAL|4 - Dupilumab (Part B)|Dose (dose 2) as per protocol delivered by prefilled syringe
62431032|NCT00722111|EXPERIMENTAL|Arm 1|lingual press (high-intensity, oral, non-swallowing)
62431033|NCT00722111|EXPERIMENTAL|Arm 2|effortful swallowing (high-intensity swallowing)
62431034|NCT00722111|EXPERIMENTAL|Arm 3|natural swallowing (high frequency, low intensity swallowing)
62431035|NCT00722111|SHAM_COMPARATOR|Arm 4|non-oral sham (control) exercise
62431036|NCT03367286||Computed Tomography Perfusion (CTP)|
62816718|NCT00060528|EXPERIMENTAL|rF-GM (10^7pfu)|recombinant fowlpox GM-CSF was given on day one at 10\^7 in last two arms. Given subcutaneously (s.c.) at site of vaccine.
62816719|NCT00060528|EXPERIMENTAL|rF-GM (10^8)|recombinant fowlpox GM-CSF was given on day one at 10\^8 in last two arms. Given subcutaneously (s.c.) at site of vaccine.
62816720|NCT04387448|EXPERIMENTAL|GFB-887 multiple ascending dose (MAD) active|GFB-887 active once-daily dosing
62816721|NCT04387448|PLACEBO_COMPARATOR|GFB-887 MAD placebo|GFB-887 placebo once-daily dosing
62816722|NCT06602934|OTHER|Group A : Patients with acute major cardiovascular event|Comparator
62816723|NCT06602934|OTHER|Group B: Patients with severe chronic cardiovascular disease|Comparator
62816724|NCT06602934|OTHER|Group C: Patients with a high risk of CVD, yet no known history of CVRD or HA|Comparator
62816725|NCT06602934|EXPERIMENTAL|Group D: Patients cured of HAP|
62816726|NCT05214534||Experimental|Retrospective analysis of the correlation between SuPAR measurement and patient outcome after hospitalization
62816727|NCT01568177|OTHER|abnormal CRT|"40 subjects with microvascular coronary dysfunction (MCD) defined as abnormal CRT.~Visits 1, 2, and 3"
62816728|NCT01568177|OTHER|Cardiac Syndrome X|20 subjects with symptoms and normal stress tests, no MCD. Visits 1 and 2
62816729|NCT01568177|OTHER|normal reference controls|40 normal reference controls subjects Visits 1 and 2
62816730|NCT01942928|ACTIVE_COMPARATOR|Usual NHS care|
62816731|NCT01942928|ACTIVE_COMPARATOR|Usual NHS Care plus Osteopathic Manipulative Therapy|
62816732|NCT00119847|EXPERIMENTAL|PCI+MED|Percutaneous Coronary Intervention (PCI) with angioplasty and stenting of the infarct-related artery and optimal medical therapy
62816733|NCT00119847|EXPERIMENTAL|MED|Optimal medical therapy alone
62240599|NCT05807880|EXPERIMENTAL|Intervention arm|"First, patients will receive the combination treatment of anlotinib, penpulimab and capecitabine every three weeks for 4-6 cycles. For each cycle, patients receive anlotinib 10mg, po, qd from day 1 to day 14, penpulimab 200mg, iv in day 1, and capecitabine 650mg/m2, po, bid from day 1 to day 21. Then a maintenance treatment will be run with penpulimab and capecitabine(the dose and the medication method remain the same) for every 3 weeks until PD or intolerance to drug toxicity.~Note: After using the penpulimab for 2 years, it is dependent on the researcher's judgement of the benefit evaluation whether to continue using it."
62816734|NCT06600477|ACTIVE_COMPARATOR|7.5 mg olanzapine per 100 µL with 0.25% Intravail A3|7.5 mg olanzapine per 100 µL with 0.25% Intravail A3
62816735|NCT06600477|ACTIVE_COMPARATOR|7.5 mg olanzapine per 100 µL with 0.50% Intravail A3|7.5 mg olanzapine per 100 µL with 0.50% Intravail A3
62816736|NCT06600477|ACTIVE_COMPARATOR|olanzapine intramuscular injection|7.5 mg olanzapine per 1.5 ml of reconstituted 5.0 mg/ml solution intramuscular injection
62240600|NCT04636866||Gastric ulcer|
62240601|NCT04636866||Duodenal ulcer|
62431037|NCT03367286||Magnetic Resonance Perfusion (MRP)|
62598051|NCT05616117||High-dose intrauterine D3-vitamin|Children of mothers who received 90 µg vitamin D3 daily during pregnancy from 12 weeks to delivery.
62598052|NCT05616117||Low-dose intrauterine D3-vitamin|Children of mothers who received 10 µg vitamin D3 daily during pregnancy from 12 weeks to delivery
62598053|NCT01217385|EXPERIMENTAL|DOSI Pre-Surgery|Participants undergo approximately four assessments of breast health using the DOSI technology during treatment and prior to surgery for breast cancer.
62816737|NCT05208476|EXPERIMENTAL|Participants|All subjects will be observed for one menstrual cycle then given Osteopathic manipulative treatment during the second menstrual cycle. During the third menstrual cycle, participants will continue to be observed.
62816738|NCT06071845|EXPERIMENTAL|Known or Suspected Barrett's Esophagus (Case Arm)|Investigators will follow Cytosponge Cell Collection Kit Instructions for Use to administer and retrieve the Cytosponge device.c. After the sponge is retrieved, it will then be placed in a vial of cell preservative solution (PN DD-13631, Exact Sciences, Madison, WI) and shipped to the Exact Sciences laboratory for further processing and subsequent analysis.
62816739|NCT06071845|ACTIVE_COMPARATOR|No Known Barrett's Esophagus (Control Arm)|Participants will undergo a diagnostic clinically indicated sedated endoscopy with standard endoscopic equipment.
62240602|NCT01372670|EXPERIMENTAL|Hydroxyzine|Hydroxyzine given TID
62240603|NCT01372670|PLACEBO_COMPARATOR|Sugar Pill|Placebo given 3 times per day
62240604|NCT04985890|EXPERIMENTAL|UB-421 monotherapy|Subjects will receive 10 mg/kg UB-421 weekly infusion for 8 weeks.
62431038|NCT01480908|EXPERIMENTAL|VSD, +Right bundle branch block|Patients undergone surgical closure of ventricular septal defect and have a postoperative right bundle branch block, about 20 patients
62431039|NCT01480908|EXPERIMENTAL|VSD, -Right bundle branch block|Patients undergone surgical closure of ventricular septal defect and does not have a postoperative right bundle branch block, about 20 patients
62431040|NCT01480908|EXPERIMENTAL|Control|Healthy control subjects, about 20 patients
62598054|NCT03195647|EXPERIMENTAL|Relaxed control|Those randomised to the 'Relaxed' Group will receive potassium supplementation only if their serum potassium drops below or equals 3.6 mEq/L.
62816740|NCT01881191||Aubagio MRI|Patients with relapsing-remitting multiple sclerosis who take Aubagio will have an MRI, eye test, blood drawn, and complete a questionnaire.
62816741|NCT01881191||Healthy controls|Subjects who are otherwise healthy, without neurological disorders will have an MRI, eye test, blood drawn, and complete a questionnaire.
62816742|NCT05544240|EXPERIMENTAL|Treatment Arm|Treatment Arm
62816743|NCT04586374||Control Group|Transported patients with full monitoring (including an arterial line), without inotropic/vasoactive support.
62816744|NCT04586374||Study Group|Transported patients with full monitoring and vasoactive/inotropic support being delivered by a syringe driver.
62816745|NCT00644423|ACTIVE_COMPARATOR|1|Omega-3 Fatty Acid
62816746|NCT00644423|PLACEBO_COMPARATOR|2|Placebo
62816747|NCT05939414|EXPERIMENTAL|Investigational Arm: lutetium (177Lu) vipivotide tetraxetan (AAA617)|All participants will be treated with Stereotactic Body Radiation Therapy (SBRT) to all metastatic lesions followed by a dose of 7.4 GBq (200 mCi) +/- 10% of AAA617 which will be administered once every 6 weeks (1 cycle) for a planned 4 cycles.
62816748|NCT05939414|NO_INTERVENTION|Control arm: observation (watchful waiting)|All participants will be treated with Stereotactic Body Radiation Therapy (SBRT) to all metastatic lesions followed by observation only.
62038109|NCT04866212||Children without Type 1 Diabetes Group|"Children without type 1 diabetes were evaluated in terms of their hand skills, visual motor integration, participation in daily life activities and academic success.~Hand skills were evaluated using the Jebsen Taylor Hand Function Test. Participation was evaluated with Participation and Environment Measurement-Children and Youth. Visual motor integration was evaluated with Beery-Buktenica Developmental Test of Visual Motor Integration. Academic success was evaluated with the course success score."
62431041|NCT03829449|EXPERIMENTAL|rVA576 Coversin|The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin) for up to 4 years.
62431042|NCT02657083|EXPERIMENTAL|Glucose control using DreaMed MD-AID|In this group the subjects use a closed loop system (DreaMed Substance Administration Device) that combines glucose monitoring system (S.C wired sensor, named Sof® Sensor™ or Enlite® Sensor™), which provides real-time interstitial glucose values, with a modern insulin pump (MiniMed® Paradigm® Veo™, Medtronic) and computer algorithm, which directs insulin delivery in response to glucose sensor data.
62431043|NCT02657083|ACTIVE_COMPARATOR|Glucose control using SAP|In this group the subjects use a standard treatment (Sensor Augmented Pump), characterised by glucose monitoring system (S.C wired sensor, named Sof® Sensor™ or Enlite® Sensor™) which provides real-time interstitial glucose values and a modern insulin pump (MiniMed® Paradigm® Veo™, Medtronic) without computer algorithm decisions.
62598055|NCT03195647|ACTIVE_COMPARATOR|Tight Control|Patients randomised to the 'Tight' group will receive potassium supplementation if their serum potassium falls below 4.5 mEq/L (current practice).
62598056|NCT02814227|EXPERIMENTAL|Zansors® sleep screening device|Zansors device compared to overnight polysomnography
62598057|NCT03862430|EXPERIMENTAL|NanO2TM|NanO2TM infusion in conjunction with Radiation Treatment and temozolomide
62598058|NCT03862430|PLACEBO_COMPARATOR|Placebo|Placebo Saline infusion in conjunction with Radiation Treatment and temozolomide
62598059|NCT03706859|EXPERIMENTAL|Tourniquet inflation pressure method 1|the pneumatic tourniquet inflation pressure at 20 mmHg above the arterial occlusion pressure which will be estimated using the equation of Unver B. et al.,: (AOP=\[SBP+10\]/KTP)
62598060|NCT03706859|ACTIVE_COMPARATOR|Tourniquet inflation pressure method 2|the pneumatic tourniquet inflateion pressure at 20 mmHg above the arterial occlusion pressure which will be estimated using the equation of Hong-yun Liu et al.,: (AOP = 17.986 + 3.158X1 + 0.408X2)
62598061|NCT01222754|EXPERIMENTAL|1|Radiation with Lenalidomide
62816749|NCT01383928|EXPERIMENTAL|Phase 1: Ixazomib 3 mg or 3.7 mg|Ixazomib (MLN9708), orally, twice-weekly in combination with lenalidomide orally and dexamethasone orally as prescribed, in 21-day treatment cycles for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 1. Participants with stable or responding disease continued receiving ixazomib (MLN9708) orally, twice weekly in 21-day treatment cycles as maintenance therapy until progressive disease or unacceptable toxicity.
62816750|NCT01383928|EXPERIMENTAL|Phase 2: Ixazomib 3 mg|Ixazomib (MLN9708), orally, twice-weekly in combination with lenalidomide orally and dexamethasone orally as prescribed, in 21-day treatment cycles for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 2. Participants with stable or responding disease continued receiving ixazomib (MLN9708) orally, twice weekly in 21-day treatment cycles as maintenance therapy until progressive disease or unacceptable toxicity.
62038110|NCT02247609|EXPERIMENTAL|CAR T cells|Autologous 4th generation anti-CD19-CAR T cells
62038111|NCT03280758|EXPERIMENTAL|Muscle strengthening group|Participants will be required to perform muscle strengthening exercises 3 hours per week. Close kinetic chain exercises will be performed progressively according to the ACSM guidelines over the 4-month intervention period. The exercise intervention will be conducted by an experienced sports trainer.
62038112|NCT03280758|NO_INTERVENTION|Control group|No exercise training.
62038113|NCT05011851|EXPERIMENTAL|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
62431044|NCT00158327|EXPERIMENTAL|1|Participants will receive telephone-based collaborative care
62431045|NCT00158327|ACTIVE_COMPARATOR|2|Participants will receive usual care
62598062|NCT04930042|EXPERIMENTAL|AVT04 45 mg SC|Test Product: AVT04 (ustekinumab) Initial loading dose of 45 mg followed by 45 mg SC once every 12 weeks starting 4 weeks after the initial loading dose administered SC. Injected as subcutaneous in thigh and abdomen.
62038114|NCT03278418|EXPERIMENTAL|Tricuspid Valve Repair|Concomitant tricuspid valve repair in patients undergoing left-sided valve surgery
62038115|NCT03278418|ACTIVE_COMPARATOR|left-sided valve surgery|No concomitant tricuspid valve repair in patients in pts undergoing left-sided valve surgery
62038116|NCT03015402|EXPERIMENTAL|Sodium Nitrite|Study
62038117|NCT03015402|PLACEBO_COMPARATOR|Placebo|Control
62038118|NCT04750746|ACTIVE_COMPARATOR|Control Group|Control group will get conventional treatment.
62431046|NCT03352817||Patients in cardiac rehabilitation|Eligible patients must have reached the age of majority, participate in a CR program at one of the centers cited, and agreed to respond to the study questionnaire voluntarily
62431047|NCT02881073|NO_INTERVENTION|Control|"Eligible women at participating centres prior to roll-out of PlGF testing (as per stepped wedge trial design) will be managed according to HSE/Institute of Obstetrician and Gynaecologists' National Guidelines for 'The management of hypertensive disorders during pregnancy' \& The management of Pre-eclampsia or by NICE guidelines for Management of Hypertension in Pregnancy for those in Northern Ireland."
62598063|NCT04930042|ACTIVE_COMPARATOR|EU Stelara 45 mg SC|Comparator ref product: EU Stelara (ustekinumab) Initial loading dose of 45 mg followed by 45 mg SC once every 12 weeks starting 4 weeks after the initial loading dose administered SC. Injected as subcutaneous in thigh and abdomen.
62598064|NCT05745207|EXPERIMENTAL|Part A, Cohort 1: E2086 1 mg or Placebo|Participants will receive 1 milligram (mg) (2\*0.5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
62598065|NCT05745207|EXPERIMENTAL|Part A, Cohort 2: E2086 2.5 mg or Placebo|Participants will receive 2.5 mg (5\*0.5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
62598066|NCT05745207|EXPERIMENTAL|Part A, Cohort 3: E2086 5 mg or Placebo|Participants will receive 5 mg (1\*5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
62240605|NCT04985890|EXPERIMENTAL|UB-421 + chidamide combination therapy|Subjects will receive 10 mg/kg UB-421 weekly infusion and 10 mg chidamide twice a week administration for 8weeks.
62240606|NCT06024681|EXPERIMENTAL|NAFLD patients|Patients receiving capsulised FMT
62240607|NCT00716053|EXPERIMENTAL|BLVR|
62240608|NCT00716053|SHAM_COMPARATOR|Saline|
62240609|NCT05974592|EXPERIMENTAL|Intervention Group|"To the participants in the intervention group; the Diabetic Foot Self-Management Training Program (DFSMTP) will be implemented. Printed, visual, and audio training materials will be used within this training program's scope. Training will be held in the Diabetes Education Room in line with the content of DFSMTP prepared by the researcher after determining the appropriate day and time with the participants. Written (training booklet) and visual (computer and PowerPoint presentation) training materials will be used during this training. The printed training booklet will be delivered to the participants at the end of the training. DFSMTP will be held in three sessions on the same day. In order to reinforce the learning of the participants in the intervention group, DFSMTP will also be video recorded with the presentation of the researcher and this recording will be transferred to the DFSMTP YouTube channel to be created by the researcher."
62240610|NCT05974592|NO_INTERVENTION|Control Group|To the participants in the control group; General information about the anatomy and physiology of the pancreas will be explained with the verbal lecture technique. Participants in this group will receive the training only once. Following the completion of the research, the printed training booklet and YouTube channel link information will be shared with the participants.
62240611|NCT04356248|EXPERIMENTAL|High-intensity interval training + energy management education|"* High-intensity interval training (HIIT): physiologically defined heart rate-controlled cycling with 80-100 rounds per minute (rpm) at 95-100% of maximum heart rate (HRmax). Participants will perform 5 × 1.5-min high-intensive exercise bouts at 95-100% of their HRmax followed by active breaks of unloaded pedalling over 2 min with the aim to achieve 60% of HRmax.~* Energy management education (IEME): face-to-face education sessions of 6.5 h in duration over a 3-week period, all conducted by a trained occupational therapist. Participants acquire knowledge and understanding about factors that influence energy and the consequences of fatigue on their habits and lifestyle. Six weeks after returning home, the participants will receive a reinforcement letter in the form of information material to remember the content of the IEME and to reinforce the implementation of the behaviour change in managing energy."
62240612|NCT04356248|ACTIVE_COMPARATOR|Low-intensity training + progressive muscle relaxation|"* Low-intensity training (ST): participants will exercise for 24 min continuously at 65% of participants' HRmax (60-70 rpm).~* Progressive muscle relaxation (PMR): The aim of PMR is to achieve enhanced mental relaxation by reducing muscle tension. Participants will attend six 1-h group sessions over the 3-week intervention period, instructed by a trained physical therapist. Six weeks after returning home, the participants will receive a reinforcement letter with information material for remembering the content of the PMR techniques and to reinforce the implementation of the exercises at home."
62240613|NCT00105950|EXPERIMENTAL|Lapatinib|Single arm study of lapatinib with no comparator arm.
62816751|NCT06593132||single port endoscopic breast conserving surgery|Endoscopic breast conserving surgery, which uses breast endoscope for breast conserving surgery, can not only preserve the breast completely, but also meet the appearance needs of patients with breast preservation, and has more advantages than traditional surgery.
62240614|NCT03355313|EXPERIMENTAL|Low level light therapy 1|
62240615|NCT03355313|EXPERIMENTAL|Low level light therapy 2|
62240616|NCT03355313|EXPERIMENTAL|Low level light therapy 3|
62240617|NCT01349023|EXPERIMENTAL|Standard Energy content/Standard ED|
62240618|NCT01349023|EXPERIMENTAL|Standard Energy content/Reduced ED|
62240619|NCT01349023|EXPERIMENTAL|Reduced Energy content/Standard ED|
62240620|NCT01349023|EXPERIMENTAL|Reduced Energy content/Reduced ED|
62240621|NCT01351012|PLACEBO_COMPARATOR|Corn and safflower oil|
62240622|NCT01351012|ACTIVE_COMPARATOR|Canola oil|
62240623|NCT01351012|ACTIVE_COMPARATOR|High oleic acid canola oil|
62240624|NCT01351012|ACTIVE_COMPARATOR|DHA enriched high oleic acid canola oil|
62240625|NCT01351012|ACTIVE_COMPARATOR|Flax and safflower oil|
62240626|NCT06412484||Low Back Pain (LBP) Patients|"LBP patients will undergo three study visits, at moments at which their pain status is different: a) pain-free, b) low back pain (clinically relevant), c) experimental pain (clinically irrelevant). Measures will be repeated in each visit, to understand the influence / relationship of pain state on possible mechanistic alterations observed in LBP compared to HCs."
62816752|NCT06593132||open breast conserving surgery|On the surface of the breast tumor centered, is apart from the 2 cm do arc, radial incision tumor, tags in the cut edge around the joints and removing tissue inspection, to ensure the cut edge negative.
62816753|NCT05356702|EXPERIMENTAL|Brain Health Intervention|"* Calculate eRADAR scores using EHR data to identify eligible individuals~* Invite eligible individuals for brain health assessment visit~* Enter results of brain health assessment visit into EHR~* Provide summary of results and recommended next steps to the Primary Care Physician and participant"
62816754|NCT05356702|NO_INTERVENTION|Usual care|Individuals who meet eligibility criteria will receive usual care.
62816755|NCT05940402|EXPERIMENTAL|Mild Renal Impairment|Participants will receive a single oral dose of 10 milligrams (mg) emraclidine on Day 1.
62816756|NCT05940402|EXPERIMENTAL|Moderate Renal Impairment|Participants will receive a single oral dose of 10 mg emraclidine on Day 1.
62816757|NCT05940402|EXPERIMENTAL|Severe Renal Impairment|Participants will receive a single oral dose of 10 mg emraclidine on Day 1.
62240627|NCT06412484||Healthy Controls (HCs)|"HCs will undergo one single visit, equivalent to patients' pain-free visit."
62240628|NCT03180749||Patients implanted with vendor B anchor|
62240629|NCT03388255|EXPERIMENTAL|Polydeoxyribonucleotides|"PLACENTEX: Polydeoxyribonucleotides 5.625 mg/3 ml for parenteral use i.m.~The study period consists of the following phases:~* Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).~* Follow up period: 3 months after end of active treatment, without study medication."
62240630|NCT03354741|OTHER|Laser then Sham therapy|2nd cycle of chemotherapy : administration of laser therapy 3th cycle of chemotherapy : administration of a sham laser according to the same modalities
62240631|NCT03354741|OTHER|Sham therapy then laser|2nd cycle of chemotherapy : administration of a sham laser 3th cycle of chemotherapy : administration of laser therapy according to the same modalities
62240632|NCT05069896|EXPERIMENTAL|Mirikizumab - Prefilled Syringe|Mirikizumab administered by subcutaneous injection (SC) via a prefilled syringe (PFS) at 3 different injection sites (arm, thigh, and abdomen).
62240633|NCT05069896|EXPERIMENTAL|Mirikizumab - Autoinjector|Mirikizumab administered by SC via an autoinjector (AI) at 3 different injection sites (arm, thigh, and abdomen).
62816758|NCT05940402|EXPERIMENTAL|Normal Renal Function|Participants will receive a single oral dose of 10 mg emraclidine on Day 1.
62598067|NCT05745207|EXPERIMENTAL|Part A, Cohort 4: E2086 10 mg or Placebo|Participants will receive 10 mg (2\*5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
62598068|NCT05745207|EXPERIMENTAL|Part A, Cohort 5: E2086 25 mg or Placebo|Participants will receive 25 mg (1\*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
62240634|NCT00620568|EXPERIMENTAL|1|
62240635|NCT00620568|EXPERIMENTAL|2|
62431048|NCT02881073|ACTIVE_COMPARATOR|Maternal plasma PlGF quantification|"Women in the interventional arm will have an additional point of care test performed at the time of enrolment for immediate PlGF quantification. The PlGF measurement will be reported as the absolute value in pg/ml with the following ranges given:~* PlGF \<12 pg/ml: Very low~* PlGF ≥12 and \<100 pg/ml: Low~* PlGF ≥100 pg/ml: Normal~All hospitals will follow National Guidelines for 'The management of hypertensive disorders during pregnancy' \& The management of Pre-eclampsia with the additional integration of PlGF results as indicated in the algorithm."
62431049|NCT06416137||Migrants|A group of 1,500 migrants with cognitive impairment will be enrolled at CCDDs.
62431050|NCT06416137||Natives|A group of 1,500 natives with cognitive impairment will be enrolled at CCDDs.
62431051|NCT04740112|PLACEBO_COMPARATOR|Control breakfast bar with low dietary fiber without product claims|
62431052|NCT04740112|EXPERIMENTAL|Test breakfast bar with high dietary fiber without product claims|
62598069|NCT05745207|EXPERIMENTAL|Part A, Cohort 6: E2086 50 mg or Placebo|Participants will receive 50 mg (2\*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
62816759|NCT05895786|EXPERIMENTAL|PF-06823859|Participants will receive PF-06823859 via intravenous infusion every 4 weeks.
62816760|NCT05895786|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo via intravenous infusion every 4 weeks.
62816761|NCT05632640|ACTIVE_COMPARATOR|Standard of Care|
62431053|NCT04740112|EXPERIMENTAL|Test breakfast bar with high dietary fiber with product claims|
62431054|NCT03075657|ACTIVE_COMPARATOR|Risperidone group|Schizophrenia patients with predominant negative symptoms on Risperidone monotherapy
62431055|NCT03075657|EXPERIMENTAL|Risperidone with Ramelteon group|Schizophrenia patients with predominant negative symptoms on Risperidone with add-on Ramelteon therapy
62598070|NCT05745207|EXPERIMENTAL|Part A, Cohort 7: E2086 100 mg or Placebo|Participants will receive 100 mg (4\*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
62598071|NCT05745207|EXPERIMENTAL|Part B, Cohort 8: E2086 25 mg or Placebo|Participants will receive 25 mg (1\*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
62598072|NCT06514755|EXPERIMENTAL|Sequential GNA Followed by GAE|Participants in this group will undergo genicular nerve ablation (GNA), followed by geniculate artery embolization (GAE) one month later. The GNA procedure will target the genicular nerves responsible for knee pain, and the GAE procedure will target the geniculate arteries to reduce inflammation and pain. The sequence is designed to optimize pain relief and functional outcomes.
62735234|NCT04474197|EXPERIMENTAL|VX-864 500 mg|Participants received VX-864 500 mg q12h in the treatment period for 28 days.
62816762|NCT05632640|EXPERIMENTAL|Weighted blanket|
62816763|NCT05552027|EXPERIMENTAL|Intervention|Participants will harness the car seat in 3 separate scenarios with the sensor system enabled to provide feedback.
62240636|NCT00620568|EXPERIMENTAL|3|
62240637|NCT00620568|EXPERIMENTAL|4|
62240638|NCT03986866|NO_INTERVENTION|No Video|Patients are not shown the informational video on the safe usage of opioids.
62735235|NCT01294111|EXPERIMENTAL|Tai Chi training|Participation in a group of 15 patients, completing a 60 minutes tai chi training programme twice-weekly for 16 weeks.
62735236|NCT01294111|NO_INTERVENTION|Control|Living as usual, following ordinary care plans and personal activities. Participants will be called to hospital for data collection. Participants are asked not to start any of the activities Tai Chi, Qui Gong or Yoga during the study period.
62735237|NCT04311970|OTHER|EoE patients|Patients will all be administered the EsoCheck device as a diagnostic test
62240639|NCT03986866|EXPERIMENTAL|Video|Patients are shown an informational video on the safe usage of opioids.
62240640|NCT03049735|EXPERIMENTAL|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
62240641|NCT03049735|EXPERIMENTAL|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
62240642|NCT03049735|PLACEBO_COMPARATOR|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
62431056|NCT03075657|ACTIVE_COMPARATOR|Haloperidol group|Schizophrenia patients with predominant positive symptoms on Haloperidol monotherapy
62431057|NCT03075657|EXPERIMENTAL|Haloperidol with Ramelteon group|Schizophrenia patients with predominant positive symptoms on Haloperidol with add-on Ramelteon therapy
62431058|NCT06085482|EXPERIMENTAL|LY3502970 + [14C]-LY3502970|Single dose of LY3502970 administered orally followed by single dose of \[¹⁴C\]-LY3502970 administered intravenously (IV)
62431059|NCT02981602|EXPERIMENTAL|IONIS-HBVRx|Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
62431060|NCT02981602|PLACEBO_COMPARATOR|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
62735238|NCT04054206|ACTIVE_COMPARATOR|Sequence 1|"Two participants will be randomly assigned to sequence 1 comprising 3 treatments (ER fasted, ER fed, and IR fasted) in a crossover design, administered one week apart:~Day 1-7: ER fasted; Day 8-15: ER fed Day 15-22: IR fasted"
62735239|NCT04054206|ACTIVE_COMPARATOR|Sequence 2|Two participants will be randomly assigned to sequence 2 comprising 3 treatments in a crossover design, administered one week apart: Day 1-7: ER fed; Day 8-15: IR fasted; Day 15-22: ER fasted
62816764|NCT05552027|OTHER|Control|Participants will harness the car seat in 3 separate scenarios with the sensor system disabled in order to not provide feedback.
62598073|NCT06514755|ACTIVE_COMPARATOR|GAE Alone|Participants in this group will receive geniculate artery embolization (GAE) alone, without prior genicular nerve ablation (GNA). The GAE procedure will target the geniculate arteries to reduce inflammation and pain. This arm serves as the control to compare the effectiveness and safety of the sequential GNA followed by GAE intervention.
62598074|NCT03737500|ACTIVE_COMPARATOR|Standard silicone-based breast implant|Participants candidated to total mastectomy and radiotherapy will receive immediate or delayed breast reconstruction by the use of standard silicone-based breast implant (i.e. the breast implant commonly used in our institution)
62598075|NCT03737500|EXPERIMENTAL|B-Lite® light weight breast implant|Participants candidated to total mastectomy and radiotherapy will receive immediate or delayed breast reconstruction by the use of B-Lite® light weight breast implant
62598076|NCT06607835|EXPERIMENTAL|Online mindful-compassion weekly for four weeks|Mindful compassion exercises
62598077|NCT06607835|EXPERIMENTAL|Cannabis suppositories and online mindful-compassion for vaginal pain|Cannabis suppositories and online mindful-compassion for vaginal pain
62598078|NCT03916367||Early Stage Lung Cancer|The patients with early stage non-small cell lung cancer who were treated with CT-guided radioactive iodine-125 seeds implantation during December 2010 to December 2018.
62598079|NCT06509750|EXPERIMENTAL|Meal_1|Bread, butter and carob-beverage
62598080|NCT06509750|EXPERIMENTAL|Meal_2|bread, butter and beverage with sugar (orange beverage)
62598081|NCT03796819|EXPERIMENTAL|lymphadenectomy|This group of patients would undergo routine hepatoduodenal lymphadenectomy combined with ICC resection
62598082|NCT03796819|NO_INTERVENTION|No lymphadenectomy|This group of patients would not undergo hepatoduodenal lymphadenectomy when preoperative imaging and intraoperative exploration found no lymph node enlargement.
62240643|NCT02809573|EXPERIMENTAL|study drugs|Lead-in period is 4 days. Patients take a single dose of Chidamide tablet, then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle. Cyclophosphamide, adriacin and vincristine are given in intravenous infusion on Day 1. On Day 1 to 5, prednisone is given orally. Treatment cycles are repeated every 3 weeks .The combination therapy lasts for at most 6 cycles. Patients enter the single agent therapy if attained complete response after 6-cycle combination therapy. In this stage, patients take chidamide orally on Day 1, 4, 8 and 11 of each cycle.
62431061|NCT01089049|EXPERIMENTAL|Pre-Menopausal|
62431062|NCT01089049|EXPERIMENTAL|Post-Menopausal|
62431063|NCT03621020||Healthy controls|Subjects not taking medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
62598083|NCT05212688|ACTIVE_COMPARATOR|Acupuncture|"* Weekly treatment of 15 minutes for 6 weeks using Seirin 36 g 30 mm needles applied to two upper midline sternal points, thoracic paravertebral points, 5 pairs, 2 bilateral Trapezius trigger points, LI4, TE5, ST36, GB34, SP6, LR3 bilaterally, GV20 \& GV24 midline~* A maximum of two upper sternal indwelling studs \[Seirin Pyonex semi-permanent studs\] may be used after the second treatment if dyspnoea is present~* Instructions will be given to massage the studs for 1 minute prior to exercise, if dyspnoeic or if very anxious, as often as necessary up to 12 times/day~* Patients will be asked to rest for 15 minutes after each acupuncture treatment.~* Clear instructions about self-needling for ongoing maintenance will be given to each patient~The acupuncture will be given in 6 sessions at weekly intervals. Delays of up to 2 weeks in delivery of acupuncture are allowed within the protocol. The timing of the study questionnaires at weeks 2, 6 and 12 will remain unchanged."
62735240|NCT04054206|ACTIVE_COMPARATOR|Sequence 3|"Two participants will be randomly assigned to sequence 3 comprising 3 treatments in a crossover design, administered one week apart:~Day 1-7: IR fasted; Day 8-15: ER fasted; Day 15-22: ER fed"
62735241|NCT04054206|ACTIVE_COMPARATOR|Sequence 4|"Two participants will be randomly assigned to sequence 4 comprising 3 treatments in a crossover design, administered one week apart:~Day 1-7: IR fasted; Day 8-15: ER fed; Day 15-22: ER fasted"
62735242|NCT04054206|ACTIVE_COMPARATOR|Sequence 5|"Two participants will be randomly assigned to sequence 5 comprising 3 treatments in a crossover design, administered one week apart:~Day 1-7: ER fasted; Day 8-15: IR fasted; Day 15-22: ER fed"
62735243|NCT04054206|ACTIVE_COMPARATOR|Sequence 6|"Two participants will be randomly assigned to sequence 6 comprising 3 treatments in a crossover design, administered one week apart:~Day 1-7: ER fed; Day 8-15: ER fasted; Day 15-22: IR fasted"
62735244|NCT06085716|EXPERIMENTAL|Psychoeducational Intervention|Participants will be randomly assigned to 1 of 3 study groups. The study treatment participants get will be chosen by chance, like rolling the dice. Both participants and the study staff will know which treatment you were assigned:
62240644|NCT04556136|EXPERIMENTAL|Standing Phototherapy Kiosk (SPK)|Volunteers assigned to this group were administered phototherapy treatments in a standing phototherapy kiosk once every other week, for 10 weeks. The treatment usually lasts no more than 10 minutes and is based on the Fitzpatrick skin type classification tool, which is self-reported via the computer touch screen in the kiosk.
62240645|NCT04556136|ACTIVE_COMPARATOR|Oral Supplement|Volunteers assigned to this group were provided with a 10-week supply (70 pills) of a vitamin D3 supplement. Consented subjects were instructed to take one 600 IU pill by mouth each day for ten weeks. They were instructed to take this with a meal. This dose is the RDA for adults between 18 and 70 years old according to the Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D and Calcium.
62240646|NCT01540383|EXPERIMENTAL|Intensive aphasia therapy group|Group starts intensive integrative aphasia therapy within 3 workdays (or as soon as possible) after baseline exam
62240647|NCT01540383|OTHER|Waiting list control group|Group starts intensive integrative aphasia therapy after a waiting period of at least three weeks
62240648|NCT03249077||Digital DPP enrolled|The DPP online program is a CDC-certified translation of the DPP lifestyle intervention delivered in an online small group format of 10-15 participants.
62431064|NCT03621020||Aspirin monotherapy|Subjects taking 81+ mg daily aspirin and no additional medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
62431065|NCT03621020||von Willebrand Disease|Subjects diagnosed with vWD (all types except Type 2N), not taking medications with antiplatelet effects, and history of clinically significant bleeding.
62598084|NCT05212688|ACTIVE_COMPARATOR|Active Control|Patients randomised to the Active Control will be contacted once per week for 6 weeks for a semi-structured telephone consultation. Delays of up to 2 weeks in delivery of the Active Control session are allowed within the protocol. Patients will be asked during the telephone call to complete the study questionnaires at week 0, 2, 6. Participants will also be asked after the telephone call to rest for 15 minutes if they are able. The patients will also be telephoned on week 12 to complete the study assessments. Patients in Arm B will be required to attend RM in person for the baseline visit and at week 6 to perform the 1 Minute Sit to Stand Test (1-MSTS). The 1-MSTS can be performed virtually rather than in person. Other visits will be telephone calls and completion of questionnaires (paper or via patient portal) Once patients in the Active Control group have completed the 12 week study assessments, they will be offered crossover to receive acupuncture.
62240649|NCT03249077||In-person DPP enrolled|In-person DPP participants will attend group sessions of \~20 participants in size at KPNW clinics. The group facilitator will use the CDC National DPP curriculum,
62240650|NCT03249077||DPP not enrolled (usual care)|Access to usual care services without restrictions.
62598085|NCT06619925||after-school extended sports service|Impact of voluntary participation in different types (e.g. outdoor physical activities, indoor physical activities, ball games, calisthenics, etc.), intensity and duration of after-school extended physical education services on children's myopia and other physical and psychological well-being
62598086|NCT06619925||non-after school extended sports service|Students in the same grade as the exposure group but participating in after-school non-physical education extended services (e.g., homework help, static activities such as calligraphy, chess, etc.) served as a control group, aiming to maximise the control of the influence of potential factors other than physical activity on the results of the study.
62598087|NCT05930028|EXPERIMENTAL|Fimasartan/Ezetimibe/Atorvastatin|BR1017A+BR1017B(Experimental Group)
62240651|NCT05009186|OTHER|Covid-19 group|We will measure the PSA value during and after Covid-19 infection in the same group via paired simple t test
62240652|NCT00529451|EXPERIMENTAL|Aliskiren 300 mg|Aliskiren 300 mg once daily
62240653|NCT00529451|EXPERIMENTAL|Aliskiren 150 mg|Aliskiren 150 mg once daily
62240654|NCT00529451|EXPERIMENTAL|Aliskiren 75 mg|Aliskiren 75 mg once daily
62240655|NCT00529451|ACTIVE_COMPARATOR|Ramipril 5 mg|Ramipril 5 mg once daily
62598088|NCT05930028|ACTIVE_COMPARATOR|Fimasartan|BR1017A(Control Group 2)
62598089|NCT05930028|ACTIVE_COMPARATOR|Ezetimibe/Atorvastatin|BR1017B(Control Group 1)
62240656|NCT01638091|EXPERIMENTAL|All participating endoscopists|All endoscopists will undergo ex vivo training and will participate in in vivo practice-based learning.
62240657|NCT05784987|EXPERIMENTAL|R-MINE+X|"R-MINE: Rituximab, Isophosphamide, Mitoxantrone hydrochloride liposome, Etoposide~X: Orelabrutinib, Chidamide, Penpulimab, Lenalidomide"
62240658|NCT01605981|EXPERIMENTAL|Nilotinib oral|Nilotinib oral dose of 400 mg BID (800 mg/day) continuous dosing for up to 24 months. Nilotinib oral dose of 300 mg BID (600 mg/day) continuous dosing in case of intolerance. Nilotinib oral dose of 400 mg QD (400 mg/day) continuous dosing in case of intolerance
62240659|NCT00708175|EXPERIMENTAL|Pioglitazone|
62240660|NCT00708175|PLACEBO_COMPARATOR|Placebo|
62240661|NCT04058951|PLACEBO_COMPARATOR|High Animal Protein Diet (HAPD)|Consuming a diet high in protein primarily from animal origin.
62431066|NCT03621020||Glanzmann's Thrombasthenia|Subjects diagnosed with Glanzmann's Thrombasthenia, not taking medications with antiplatelet effects, and history of clinically significant bleeding.
62431067|NCT03621020||Dual antiplatelet therapy (DAPT)|Subjects taking 81 mg daily aspirin and either 75 mg daily clopidogrel, 10 mg daily prasugrel, or 180 mg daily ticagrelor
62431068|NCT00773981|ACTIVE_COMPARATOR|1|Endoluminal vacuum therapy.
62431069|NCT00773981|NO_INTERVENTION|2|Patients not receiving vacuum therapy should be treated with a catheter with daily rinsing for a minimum of 7 days.
62598090|NCT06424990|EXPERIMENTAL|study group|
62598091|NCT06424990|PLACEBO_COMPARATOR|control group|
62735245|NCT06085716|EXPERIMENTAL|Open Label Placebo|Participants will be randomly assigned to 1 of 3 study groups. The study treatment participants get will be chosen by chance, like rolling the dice. Both participants and the study staff will know which treatment you were assigned:
62240662|NCT04058951|EXPERIMENTAL|High Plant Protein Diet (HPPD)|Consuming a diet high in protein exclusive from plant origin.
62431070|NCT01886170|NO_INTERVENTION|Hemoglobin A1C|The arms apply to the second phase of the study. This is the control arm. Participants will receive information regarding their diabetes control using the hemoglobin A1C value (standard medical information)
62598092|NCT05540041|EXPERIMENTAL|Bubble breathing play therapy|Children in intervention group 2 will be given a bubble breathing play therapy intervention. With this intervention, it is aimed to teach the child and parent to breathe correctly and deeply, to relax them, to reduce their anxiety and fears, to relax, to direct their attention to something other than pain. In the intervention pediatric surgery service, investigative coaching will be applied 30 minutes before premedication. The procedure time is planned to be at least 5-10 minutes. The intervention will be implemented with a ready-made foam bubble toy. The toy will be provided by the researcher and given to the children as a gift.
62598093|NCT05540041|EXPERIMENTAL|Tell-show-do play therapy|Tell-show-do play therapy initiative will be applied to children included in intervention group 1. The initiative will be applied to children without disturbing the parent-child relationship. The intervention will be applied for 10-15 minutes. The tell-show-do play therapy initiative will be implemented using the directed play therapy method and therapeutic play tools. Amigurumi dolls, medical toys (surgical shirt, movable toy bed) and real medical materials such as stethoscope, patient armband, bone, mask, degree will be used as therapeutic play tools.
62598094|NCT05540041|OTHER|No intervention|The participants in the control group will be given routine nursing care.
62598095|NCT02224027|ACTIVE_COMPARATOR|i-gel|Each novice performs i-gel insertion in difficult laryngoscopy scenario.
62598096|NCT02224027|ACTIVE_COMPARATOR|proceal laryngeal mask airway|Each novice performs proceal laryngeal mask airway insertion in difficult laryngoscopy scenario.
62598097|NCT02224027|ACTIVE_COMPARATOR|tracheal tube|Each novice performs tracheal intubation in difficult laryngoscopy scenario.
62598098|NCT06401226||Primary Dysmenorrhea|Women with primary dysmenorrhea according to the Primary Dysmenorrhea Consensus Guide and those with pain \> 5 according to visual analog scale
62816765|NCT03696160|EXPERIMENTAL|Biktarvy|"Bictegravir is an inhibitor of HIV-1 integrase that is being evaluated for the treatment of HIV-1 infection.~Biktarvy® received marketing authorisation valid throughout the European Union (EU) in June 2018.~Biktarvy is a combination of bictegravir, emtricitabine, and tenofovir (B/F/TAF).~Method of administration: One combined B 50mg/F 200mg/TAF 25mg tablet taken orally once daily for up to 48 weeks without regard to food."
62816766|NCT03696160|EXPERIMENTAL|Symtuza|"Symtuza® is a boosted PI indicated for the treatment of HIV-1 infection.~Symtuza® received marketing authorisation valid throughout the EU in September 2017.~Symtuza is a combination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide (D/C/F/TAF)~Method of administration: One combined D 800mg/C 150mg/F 200mg/TAF 10mg tablet taken orally once daily for up to 48 weeks with the addition of food."
62431071|NCT01886170|EXPERIMENTAL|Experimental Format #1|In phase II of the study, participants in this arm will receive information about their current diabetes control conveyed using experimental format #1. The experimental formats will be determined based on the results from Phase I of the study.
62598099|NCT06401226||Control Group|Women who do not experience painful cramps during their menstrual period or who have a visual analog scale score \< 5
62598100|NCT06620718|OTHER|Evaluation of root migration at sixth month after coronectomy|Seventy three patients were divided into two age groups: The first group, consisting of patients aged 18-30, included 17 males and 23 females. The second group, consisting of patients aged 31-55, included 17 males and 16 females
62431072|NCT01886170|EXPERIMENTAL|Experimental Format #2|In phase II of the study, participants in this arm will receive information about their current diabetes control conveyed using experimental format #2. The experimental formats will be determined based on the results from Phase I of the study.
62598101|NCT00288600|EXPERIMENTAL|Experimental group|Intravenous Immunoglobulin
62598102|NCT00288600|PLACEBO_COMPARATOR|CONTROL GROUP|Normal Saline solution
62598103|NCT05637775|EXPERIMENTAL|EXP - BCI|(EEG-)BCI- assisted MI training delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
62598104|NCT05637775|ACTIVE_COMPARATOR|CTRL - MI|MI training delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
62816767|NCT06705985|EXPERIMENTAL|Lateral Meniscus Prosthesis|Implantation of the Lateral Meniscus Prosthesis, intended to replace the function of the natural meniscus to provide unicompartmental pain relief in the meniscus-deficient knee.
62431073|NCT04455594|EXPERIMENTAL|Almonertinib|Almonertinib 110mg QD
62816768|NCT04952779||Xultophy®|Korean adults with type 2 diabetes mellitus (T2DM) initiating Xultophy® under routine clinical practice and according to approved label in Korea.
62816769|NCT05889156|PLACEBO_COMPARATOR|Matched Placebo|
62038119|NCT04750746|EXPERIMENTAL|Experimental Group|This group will get base line treatment with exer gaming.
62816770|NCT05889156|ACTIVE_COMPARATOR|NST-1024|NST-1024 400 mg BID
62816771|NCT05993689|EXPERIMENTAL|BUNDLE Intervention|Proposed components of the intervention will include: 1) attendance at two visits in the 2nd trimester and two visits in the 3rd trimester by a doula; 2) exchange of contact information between the clinic and the doula; 3) exchange of social needs and social-structural risk factors complicating patient's prenatal care from doula and exchange of clinical risk factors complicating prenatal care from obstetric provider; 4) communication between the doula and provider; 5) educating the obstetric team on benefits of doula support; 6) preparing labor and delivery team for presence of doula during labor ; and 7) enhancing doula support postpartum for cardiovascular risk reduction.
62816772|NCT05993689|ACTIVE_COMPARATOR|Usual Care|Standard of care for pregnancy and pregnancy-related issues will be provided by the obstetric provider as per routine.
62598105|NCT06514703|EXPERIMENTAL|CT-Guided Genicular Nerve Ablation|Participants in this arm will undergo genicular nerve ablation using computed tomography (CT) guidance. The procedure involves precise needle placement based on CT imaging to effectively target the genicular nerves responsible for transmitting pain signals from the knee.
62598106|NCT06514703|ACTIVE_COMPARATOR|Fluoroscopic-Guided Genicular Nerve Ablation|Participants in this arm will receive genicular nerve ablation using fluoroscopic guidance. The procedure utilizes real-time fluoroscopy to guide needle placement for the ablation of the genicular nerves.
62598107|NCT06665217|EXPERIMENTAL|Induction Therapy|Patients were treated by G-Pola-ZLP as Induction Therapy
62598108|NCT06648044|OTHER|Patients with nephronophthisis/renal associated ciliopathies|"Affected patients:~Suffering from nephronophthisis or renal associated ciliopathies with known genetic diagnosis or not, Having obtained the signature of the informed consent form of patient, parent~Intervention : blood and urine sample collection Collection of urines from patients will be followed by multiomics analyses including proteome and miRNAome profiling on EVs purified from urines by ultracentrifugation and metabolomics on unfractionated urine. Biomarkers identification for ciliopathy-induced chronic kidney disease will allow to monitor the drug response in treated urine-derived renal epithelial cells."
62598109|NCT06648044|OTHER|Healthy relatives of Patients|"Healthy relatives:~Being the healthy relative (father / mother / brother / sister) of an included patient Having signed the informed consent form (patient or parent in case of minor subject) No age limit is requested for these subjects, who can be recruited from birth.~Intervention : blood and urine sample collection Collection of urines from patients will be followed by multiomics analyses including proteome and miRNAome profiling on EVs purified from urines by ultracentrifugation and metabolomics on unfractionated urine. Biomarkers identification for ciliopathy-induced chronic kidney disease will allow to monitor the drug response in treated urine-derived renal epithelial cells"
62598110|NCT06648044|OTHER|Negative control|"Being unscathed of any chronic renal disease, with or without ciliopathies Having obtained the signature of the informed consent form No age limit is requested for these patients, who can be recruited from birth.~Intervention : blood and urine sample collection Collection of urines from patients will be followed by multiomics analyses including proteome and miRNAome profiling on EVs purified from urines by ultracentrifugation and metabolomics on unfractionated urine. Biomarkers identification for ciliopathy-induced chronic kidney disease will allow to monitor the drug response in treated urine-derived renal epithelial cells"
62598111|NCT06648044|OTHER|Positive control|"Suffering from Chronic Kidney Disease unrelated to ciliary dysfunction (such as glomerulopathy, tubulopathy...) Having obtained the signature of the informed consent form No age limit is requested for these patients, who can be recruited from birth.~Intervention : blood and urine sample collection Collection of urines from patients will be followed by multiomics analyses including proteome and miRNAome profiling on EVs purified from urines by ultracentrifugation and metabolomics on unfractionated urine. Biomarkers identification for ciliopathy-induced chronic kidney disease will allow to monitor the drug response in treated urine-derived renal epithelial cells"
62598112|NCT05769868|EXPERIMENTAL|Single Arm|1 conventional echocardiography without esmolol administration followed by 1 echocardiography with esmolol administration at Baseline and other study visits.
62598113|NCT06405789|EXPERIMENTAL|intervention|The intervention group participated in 15 weeks of yoga/awareness activities led by the researcher. The yoga curriculum for the use of yoga in the classroom had been previously studied with nursing students and permission was obtained for its use in this study. The course content consists of 1.5 hours/per week (theoretical: 30 minutes; practical: 60 minutes) Each yoga session includes 5 minutes of breathing (pranayama) and warming up, 40 minutes of postures (asanas), 5 minutes of breathing (pranayama), 5 minutes of corpse pose (shavasana).In addition, to develop mindfulness, after the class, students were offered daily practices that enable a mindfulness-based approach to life events. The students participated in activities such as yoga practice, breathing and relaxation exercises, meditation practices with instructor notes and resources.
62598114|NCT06405789|NO_INTERVENTION|control|No intervention
62816773|NCT03237624|EXPERIMENTAL|Functional chewing gum|Subjects given as intervention functional chewing gum device to supplement oral hygiene practices. Functional gum contains chitosan which is a food additive or generally recognized as safe food product. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
62816774|NCT03237624|PLACEBO_COMPARATOR|Control chewing gum|Subjects given control gum to supplement oral hygiene practices. Placebo gum does not contain any active ingredients. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
62431074|NCT04455594|ACTIVE_COMPARATOR|Investigator-choice therapy (Erlotinib or Chemotherapy)|Erlotinib 150mg QD or Cisplatin(75mg/m2) or Carboplatin (AUC=5) to be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
62431075|NCT02411656|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab 200mg IV over approximately 30 minutes on day 1. Cycles repeat every 21 days for 8 cycles and then pembrolizumab 400mg IV every 42 days for total up to 24 months in the absence of disease progression or unacceptable toxicity
62240663|NCT02307864|EXPERIMENTAL|Treatment Sequence 1|Participants will receive treatment A (2\*50 milligram \[mg\] tramadol hydrochloride \[HCl\] immediate release \[IR\] tablet + 1 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 2\*50 mg tramadol HCl IR tablet + 1 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4); treatment B (3\*50 mg tramadol HCl IR tablet every 6 hours on Days 1, 2, and 3, along with single dose of 3\*50 mg tramadol HCl IR tablet + 1 moxifloxacin placebo on Day 4); treatment C (3 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 3 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4); and treatment D (3 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 3 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4) in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
62598115|NCT06506019|EXPERIMENTAL|Single Dose Psilocybin|Single dose of orally administered 25 mg of psilocybin taken in conjunction with supportive therapy
62598116|NCT04319627|EXPERIMENTAL|Rosuvastatin|Participants randomized to the experimental arm will take one rosuvastatin 20 mg tablet by mouth every day for the duration of their participation in the study.
62598117|NCT04319627|PLACEBO_COMPARATOR|Placebo|Participants randomized to the control arm will take one placebo tablet by mouth every day for the duration of their participation in the study.
62598118|NCT02888392|EXPERIMENTAL|Kiwifruit intervention|4 week intervention treatment with 2 fresh, whole green kiwifruit per day
62598119|NCT02888392|ACTIVE_COMPARATOR|Psyllium intervention|4 week intervention treatment with psyllium, matched for fibre content of 2 green kiwifruit / day for 4 weeks
62598120|NCT06538740|NO_INTERVENTION|Control group|Ventilating the patient with 100% oxygen concentration during the wash out phase, before extubation
62598121|NCT06538740|ACTIVE_COMPARATOR|Intervention group|Ventilating the patient with 70% oxygen concentration during the wash out phase, before extubation
62598122|NCT01311518|PLACEBO_COMPARATOR|Placebo|
62598123|NCT01311518|ACTIVE_COMPARATOR|Drug: Thymosin Beta 4 injectable|
62598124|NCT05923866|EXPERIMENTAL|ONO-2808 Arm|
62816775|NCT05695950|EXPERIMENTAL|GLPG3667 During DB + During OLE|Participants will receive GLPG3667 dose A orally once daily for 24 weeks in the double-blind (DB) treatment period. Eligible participants will roll-over to an open-label extension (OLE) period to receive the same dose for another 24 weeks.
62816776|NCT05695950|PLACEBO_COMPARATOR|Placebo During DB + GLPG3667 During OLE|Participants will receive placebo matching to GLPG3667 orally once daily for 24 weeks in the DB treatment period. Eligible participants will roll-over to an OLE period to receive GLPG3667 dose A orally once daily for another 24 weeks.
62431076|NCT02194166|EXPERIMENTAL|Pre-Randomization (Trastuzumab IV)|Trastuzumab IV will be given during the first 4 cycles for all participants before randomization for SC administration. A dose of 6 milligrams per kilogram (mg/kg) will be given every 3 weeks. All the participants will require a loading dose on Day 1 of Cycle 1, so they will receive 8 mg/kg followed by 6 mg/kg, 3 weeks later and then 3-weekly. Concurrent administration during the first 4 cycles of trastuzumab IV with paclitaxel/docetaxel will have to be performed in accordance with local hospital practice.
62431077|NCT02194166|EXPERIMENTAL|Group A: Trastuzumab SC (First Vial Formulation, then SID)|Participants will receive 7 cycles of SC trastuzumab 600 mg with assisted administration using a conventional syringe and needle (SC vial formulation) followed by 7 cycles of SC trastuzumab 600 mg SID administration after cross-over.
62598125|NCT05923866|PLACEBO_COMPARATOR|Placebo Arm|
62598126|NCT05874375|OTHER|Group A (Urge and Time limited)|The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) using UCon with a stimulation mode that is activated for 60 seconds by the participant when he experience urgency (urge stimulation).The urge stimulation can be activated repeatedly during the day as the participant wears the device from morning to evening at home for 14 days. Following a stimulation wash-out period (14 days), the participants then stimulates with UCon for another 14 days using the time limited stimulation mode.
62598127|NCT05874375|OTHER|Group B (Time limited and Urge)|The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) using UCon with a stimulation mode that is activated for 30 minutes once a day, at a time that is convenient for the participant. The participant uses the device at home for 14 days. Following a stimulation wash-out period (14 days), the participant then stimulates with UCon for another 14 days using the urge stimulation mode.
62598128|NCT06624124|EXPERIMENTAL|Training using AI-powered SimuVersity Training Platform|Students and faculty will receive training on diversity considerations in pain and opioid management via an online gamified platform with AI-powered virtual patients to apply knowledge.
62598129|NCT06624124|ACTIVE_COMPARATOR|Training using traditional text-base methods|Students and faculty will receive training on diversity considerations in pain and opioid management via written materials and text-base case studies to apply knowledge.
62735246|NCT06085716|EXPERIMENTAL|Psychoeducational Intervention+Placebo|Participants will be randomly assigned to 1 of 3 study groups. The study treatment participants get will be chosen by chance, like rolling the dice. Both participants and the study staff will know which treatment you were assigned:
62816777|NCT06005194|PLACEBO_COMPARATOR|Wait List Control (WLC) Condition|The WLC control condition entails following usual care and includes the ability to participate in the intervention at the 12 week-end point for the intervention group. The WLC condition is based on equity considerations; the investigators want all participants to have access to treatment. Equity is especially important given our plans to over-enroll African American persons given statistically increased barriers to access care.
62819438|NCT03016156|EXPERIMENTAL|Stratum III: Retinoblastoma Group|A separate group of participants with known retinoblastoma and who are undergoing ocular salvage treatments will be screened with red reflex testing using direct ophthalmoscopy on Day 1. They will also undergo testing with the CRADLE software application defined as the most effect in Stratum I on Day 1 then for three additional consecutive visits which typically occur every 3 to 4 weeks.
62038120|NCT01624038|ACTIVE_COMPARATOR|Hydroxyurea,blood transfusion|Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.
62240664|NCT02307864|EXPERIMENTAL|Treatment Sequence 2|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
62240665|NCT02307864|EXPERIMENTAL|Treatment Sequence 3|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
62240666|NCT02307864|EXPERIMENTAL|Treatment Sequence 4|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
62598130|NCT03729570|EXPERIMENTAL|ePrEP|Participants will receive the ePrEP home care system for telemedicine PrEP, permitting initiation and persistence in PrEP care. The ePrEP home care system consists of: a smartphone application (app) for video-based telemedicine PrEP consultations with a clinician; secure messaging; a system to track shipments to \& from participants; and behavioral risk surveys that are complemented by home specimen kits. Self-collected specimens will be mailed to laboratories for routine, guideline-based testing for PrEP care. Home specimen collection will be used to determine the primary study outcome of tenofovir-diphosphate levels.
62816778|NCT06005194|ACTIVE_COMPARATOR|InMotion Intervention Condition|"The intervention consists of a manualized physical activity counseling program and includes motivational interviewing over a HIPAA-compliant telehealth delivery model. There will be 8 counseling sessions over 12 weeks. Sessions will be 30-90 minutes long and scheduled during weeks 1-4, 6, 8, 10, and 12. The Fitbit Charge 5 will be set up to sync with the participants' internet-connected device to share activity data with the physical activity coach /interventionist to monitor progress and tailor treatment goals.~Given the InMotion intervention was designed to treat Major Depressive Disorder (MDD) in Traumatic Brain Injury (TBI), the intervention will be delivered by a mental health provider (licensed masters level social worker/MSW) with training and supervision in behavioral aspects of exercise promotion and supervised by a psychologist (who is also the study Principal Investigator) and a physical therapist."
62240667|NCT05374720|EXPERIMENTAL|Salpingectomy for Extra-Uterine Pregnancy|patients with salpingectomy for Ectopic Pregnancy
62240668|NCT05374720|SHAM_COMPARATOR|hysterectomies|patients with hysterectomy for prolapsus, adenomyosis or myomectomy
62240669|NCT06312748|EXPERIMENTAL|L-Citrulline, Then Placebo|Participants will receive a 90-day supply of L-Citrulline and perform baseline assessments of resting arterial blood pressure, ECT, arterial elasticity/pulse contour analysis, flow-mediated vasodilation and passive limb movement procedures. Participants will return to the laboratory for up to 5 additional study visits (days 10, 20, 30, 60, and 90) and repeat the experimental protocol. After a two-week washout period, participants will receive a 90-day supply of Placebo and perform baseline and follow-up assessments as above.
62431078|NCT02194166|EXPERIMENTAL|Group B: Trastuzumab SC (First SID, then Vial Formulation)|Participants will start with 7 cycles of SC trastuzumab 600 mg administration via SID and after cross-over will receive 7 injections of trastuzumab 600 mg with assisted administration using a conventional syringe and needle (SC vial formulation).
62816779|NCT06474286|EXPERIMENTAL|Tab. Prucalopride|The study drug Tab. Prucalopride 1 mg (30 tablets) will be dispensed to the participant. They will be explained to take one tablet of 1 mg Prucalopride per oral in the morning.
62816780|NCT06410248|EXPERIMENTAL|Group 3 (triapine, surgical resection, temozolomide)|Patients receive triapine PO QD for 5 days prior to surgical resection. After surgical resection, patients receive temozolomide PO QD and triapine PO QD on days 1-5 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI at screening and on study and undergo collection of blood samples on study.
62431079|NCT02740933|EXPERIMENTAL|Demeclocycline|"All subjects will take Demeclocycline 300 mg po bid. Patients will be advised to take demeclocycline on an empty stomach, at least 1-2 hours before meals, and they will be warned that it can reduce the efficacy of oral contraceptives.~The investigators will begin by treating subjects with 2 days of demeclocycline. The investigators will increase the numbers of days that subjects are exposed to demeclocycline in increments of 1 day until at least 80% of patients at a given dose have detectably fluorescent tumors, or participants reach 5 days of drug, whichever comes first."
62431080|NCT00580333|EXPERIMENTAL|Cisplatin/Avastin|Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide , adjuvant (optional) paclitaxel, adjuvant (optional)
62431081|NCT01292460|ACTIVE_COMPARATOR|Preservative-free timolol|
62431082|NCT01292460|EXPERIMENTAL|Preservative-free FDC and placebo|
62431083|NCT01292460|ACTIVE_COMPARATOR|Preservative-free tafluprost|
62431084|NCT01292460|EXPERIMENTAL|Preservative-free FDC|
62431085|NCT00002484|EXPERIMENTAL|external beam radiotherapy|Patients undergo 3-dimensional conformal external beam radiotherapy 5 days a week for 8-10 weeks.
62431086|NCT03376984|ACTIVE_COMPARATOR|Gutta Percha|Subjects in both arms of the study will be receiving standard of care RCT and routine follow-up examinations/assessments at 6 months, 1 year, and 2 years post RCT. For all the patients into the control arm of the study, the root canals will be filled with gutta percha (current standard of care), using the vertical condensation obturation technique (standard of care RCT technique).
62598131|NCT03729570|NO_INTERVENTION|Standard of care|Participants will be referred to a publicly available website that geolocates the nearest PrEP provider. They will receive standard of care, defined as what a member of the general public would be able to access for PrEP services. Home specimen self-collection will be used to determine the primary study outcome of tenofovir-diphosphate levels. Additional research assessments will include quarterly surveys.
62816781|NCT06410248|EXPERIMENTAL|Groups 1 and 2 (temozolomide, triapine)|Patients receive temozolomide PO QD and triapine PO QD on days 1-5 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI at screening and on study and undergo collection of blood samples on study.
62431087|NCT03376984|EXPERIMENTAL|ND and Amox modified Gutta Percha|Subjects in both arms of the study will be receiving standard of care RCT and routine follow-up examinations/assessments at 6 months, 1 year, and 2 years post RCT. The difference between the two arms will be the root canal filler material used. The root canals for the treatment arm of the study will be filled with gutta percha at the apical third, gutta percha modified with nanodiamonds and amoxicillin (NDGX) will be used for the middle and coronal thirds.
62240670|NCT06312748|EXPERIMENTAL|BH4, Then Placebo|Participants will receive a 90-day supply of BH4 and perform baseline assessments of resting arterial blood pressure, ECT, arterial elasticity/pulse contour analysis, flow-mediated vasodilation and passive limb movement procedures. Participants will return to the laboratory for up to 5 additional study visits (days 10, 20, 30, 60, and 90) and repeat the experimental protocol. After a two-week washout period, participants will receive a 90-day supply of Placebo and perform baseline and follow-up assessments as above.
62598132|NCT04553640|EXPERIMENTAL|Group A/Intervention Curriculum|Virtual patient (VP) cases and feedback available through solving VP cases and participants' self-report on the diagnosis of dizzy patients in the emergency department.
62240671|NCT06312748|EXPERIMENTAL|Atorvastatin, Then Placebo|Participants will receive a 90-day supply of Atorvastatin and perform baseline assessments of resting arterial blood pressure, ECT, arterial elasticity/pulse contour analysis, flow-mediated vasodilation and passive limb movement procedures. Participants will return to the laboratory for up to 5 additional study visits (days 10, 20, 30, 60, and 90) and repeat the experimental protocol. After a two-week washout period, participants will receive a 90-day supply of Placebo and perform baseline and follow-up assessments as above.
62240672|NCT06312748|EXPERIMENTAL|Placebo, Then L-Citrulline|Participants will receive a 90-day supply of Placebo and perform baseline assessments of resting arterial blood pressure, ECT, arterial elasticity/pulse contour analysis, flow-mediated vasodilation and passive limb movement procedures. Participants will return to the laboratory for up to 5 additional study visits (days 10, 20, 30, 60, and 90) and repeat the experimental protocol. After a two-week washout period, participants will receive a 90-day supply of L-Citrulline and perform baseline and follow-up assessments as above.
62598133|NCT04553640|ACTIVE_COMPARATOR|Group B/Control curriculum|Online articles on dizziness AND regular emergency department clinical rotations
62816782|NCT05625737|EXPERIMENTAL|Fruquintinib plus Sintilimab|Fruquintinib combined with sintilimab. Fruquintinib: 4 mg/d, qd, po, d1-14, q3w; Sintilimab: 200 mg/d, ivgtt, d1, q3w.
62816783|NCT00706368|EXPERIMENTAL|1|Participants in this group will perform self-tests for the first half of the study and will have clinical examinations for the second half of the study
62816784|NCT00706368|EXPERIMENTAL|2|Participants in this group will have clinical examinations for the first half of the study and will perform self-tests for the second half of the study
62240673|NCT06312748|EXPERIMENTAL|Placebo, Then BH4|Participants will receive a 90-day supply of Placebo and perform baseline assessments of resting arterial blood pressure, ECT, arterial elasticity/pulse contour analysis, flow-mediated vasodilation and passive limb movement procedures. Participants will return to the laboratory for up to 5 additional study visits (days 10, 20, 30, 60, and 90) and repeat the experimental protocol. After a two-week washout period, participants will receive a 90-day supply of BH4 and perform baseline and follow-up assessments as above.
62240674|NCT06312748|EXPERIMENTAL|Placebo, Then Atorvastatin|Participants will receive a 90-day supply of Placebo and perform baseline assessments of resting arterial blood pressure, ECT, arterial elasticity/pulse contour analysis, flow-mediated vasodilation and passive limb movement procedures. Participants will return to the laboratory for up to 5 additional study visits (days 10, 20, 30, 60, and 90) and repeat the experimental protocol. After a two-week washout period, participants will receive a 90-day supply of Atorvastatin and perform baseline and follow-up assessments as above.
62240675|NCT06509178|EXPERIMENTAL|Peyton group|"The experimental group students attended the course in accordance with the routine procedures but in the laboratory practice, sterile urinary catheter application was taught to the students according to Peyton's 4-step approach.~In the first stage of the method, students were only asked to watch the researcher demonstrate the application.~In the second step, the sterile urinary catheterization process was demonstrated a second time by the researcher, with each step explained in detail.~In the third step, the students were asked to give guidance and repeat the steps while the researcher applied the application for the third time.~In the fourth step, each student was asked to perform the application individually without any help."
62240676|NCT06509178|OTHER|Halsed group|The control group students attended the course in accordance with the routine procedures, students were taught how to apply sterile urinary catheter using the Halsted method (see one and do it), which is traditionally used in laboratory practice.
62240677|NCT01955122|OTHER|Group A|"Tandem Colonoscopy- Each patient will undergo 2 colonoscopy procedures:~a Standard view colonoscopy followed immediately by an EndoRings™ colonoscopy."
62240678|NCT01955122|OTHER|Group B|"Tandem Colonoscopy- Each patient will undergo 2 colonoscopy procedures:~an EndoRings™ colonoscopy followed immediately by a Standard view colonoscopy."
62240679|NCT00619905|EXPERIMENTAL|1|
62598134|NCT06649513||Preterm patients|Former patients who were born prematurely (GA \< 37 weeks)
62735247|NCT02890745|EXPERIMENTAL|Empagliflozin|One tablet 25 mg empagliflozin every morning for 14 days
62735248|NCT02890745|PLACEBO_COMPARATOR|Placebo|One tablet placebo every morning for 14 days
62735249|NCT00812396|ACTIVE_COMPARATOR|1|Low dose testosterone
62735250|NCT00812396|ACTIVE_COMPARATOR|2|High dose testosterone
62735251|NCT00812396|PLACEBO_COMPARATOR|3|Placebo
62735252|NCT05211674||COPD patients|
62735253|NCT05211674||Healthy controls|
62735254|NCT06318247|SHAM_COMPARATOR|Control group|Tooth extraction of third molars
62735255|NCT06318247|EXPERIMENTAL|GBR group|Tooth extraction of third molars with site preservation using bio-oss (0.5g, Small granule) and bio-guide (25\*25mm size). The bone graft material used in the surgical procedure was provided by Geistlich Pharma AG.
62735256|NCT00714077||adjuvant capecitabine|To compare different adjuvant concurrent chemoradiotherapy regimen (Oxaliplatin with capecitabine vs capecitabine) for patients with II/III rectal cancer
62735257|NCT00714077||adjuvant oxaliplatin and capecitabine|To compare different adjuvant concurrent chemoradiotherapy regimen (Oxaliplatin with capecitabine vs capecitabine) for patients with II/III rectal cancer
62735258|NCT04393038|EXPERIMENTAL|ABX464|ABX464 - Capsules + Standard of Care (SOC)
62735259|NCT04393038|PLACEBO_COMPARATOR|Placebo|Placebo - Capsules + Standard of Care (SOC)
62735260|NCT03685474|EXPERIMENTAL|Facing Your Fears-School Based (FYF-SB)|This group will receive the Facing Your Fears - School Based intervention during the fall semester
62735261|NCT03685474|ACTIVE_COMPARATOR|Usual Care (UC)|This group will receive usual care of anxiety treatment during the fall semester, but will be in the FYF-SB arm the following spring semester.
62240680|NCT00619905|PLACEBO_COMPARATOR|2|
62240681|NCT03920813|EXPERIMENTAL|Antitumor drugs|Mercaptopurine administered at standard dose for children with hematological neoplasms.
62240682|NCT00930514|ACTIVE_COMPARATOR|Rituximab IV 375 mg/m^2 (Stage 1: Cohort A)|
62240683|NCT00930514|ACTIVE_COMPARATOR|Rituximab IV 375 mg/m^2 (Stage 2: Cohort E)|
62816785|NCT04805502|EXPERIMENTAL|Aerobic Exercise (AE)|"All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data.~The AE group will exercise on aerobic machines (i.e. treadmill, elliptical, bicycle) for all of their sessions."
62816786|NCT04805502|EXPERIMENTAL|Resistance Exercise (RE)|"All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data.~The RE group will perform 12-15 repetitions of 10-12 resistance exercises in a circuit, for 3 sets with rest period of 30-60 seconds between sets as needed.\[100\] Seated isokinetic exercise using Cybex machines will target all major muscle groups. Light dumbbells and resistance bands will be used if the participant is unable to lift the minimal load on Cybex machines. Core exercises will be performed at the end of the session (i.e. seated side bends)."
62816787|NCT04805502|EXPERIMENTAL|Combination Exercise (AERE)|"All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data.~The AERE group will switch between AE exercise and RE; for this group, RE exercises will consist of 1 set of 12-15 repetitions of 4 resistance exercises, then 5 minutes of AE, then repeated repeat with different exercises.\[106-108\] The investigators will also calculate the metabolic minutes per week (METmin/wk) of all participants in order to account for potential differences in energy expenditure based on activity, though the dose of 150 min/wk at moderate intensity is held constant between exercise groups."
62816788|NCT04805502|NO_INTERVENTION|Control (no exercise)|The Control group will participate in weekly sessions that focus on stretching, breathing, and healthy lifestyle.
62816789|NCT06299098|PLACEBO_COMPARATOR|Placebo|Part A Randomized 1:1
62816790|NCT06299098|EXPERIMENTAL|Trevogrumab|Part A Randomized 1:1
62240684|NCT00930514|EXPERIMENTAL|Rituximab SC 1400 mg (Stage 2: Cohort F)|
62240685|NCT00930514|EXPERIMENTAL|Rituximab SC 375 mg/m^2 (Stage 1: Cohort B)|
62240686|NCT00930514|EXPERIMENTAL|Rituximab SC 625 mg/m^2 (Stage 1: Cohort C)|
62240687|NCT00930514|EXPERIMENTAL|Rituximab SC 800 mg/m^2 (Stage 1: Cohort D)|
62240688|NCT01571765|EXPERIMENTAL|MNCH programming|protocols and training for data collection, referrals, and management for health district. Training in obstetrics, newborn care and management of sick children for health workers, Increased community health promotion such as training of CHWs, health centre management teams and bednet distribution
62431088|NCT03997331|EXPERIMENTAL|Intervention|"Subjects in the Intervention arm will receive the following:~1. Automated in-app messages containing behavioral and educational content that is tailored to each subject based on an assessment of their entry survey results and on their adherence and glucose data. (Behavioral Support Engine).~2. Targeted in-app messages and phone calls from clinicians or as designated by the Investigator (through the CRx Care app) based on the subject's adherence and glucose data.~3. Push notifications that alert the subject that it is time to complete a regimen event (ie take medication or take a fasting blood glucose reading).~4. Push notifications that alert the subject that they have missed a scheduled regimen event.~5. In-app messages containing adjustments to the subject's insulin glargine dose when the Investigator(s) approves an adjustment in the CRx Care App. (Treatment Support Engine)."
62431089|NCT03997331|ACTIVE_COMPARATOR|Control|Subjects in the Control arm will receive the CRx Health solution for self-management of chronic conditions.
62431090|NCT03012815|EXPERIMENTAL|Gabapentin|Patients will receive gabapentin taper over 9 days with the option to add divalproex for patients who have a history of seizures or severe withdrawal. Will still undergo CIWA-Ar scoring but will not be administered a benzodiazepine.
62431091|NCT03012815|ACTIVE_COMPARATOR|Benzodiazepine|Patients will receive a benzodiazepine if scoring greater than 9 on the CIWA-Ar scale.
62816791|NCT06299098|EXPERIMENTAL|Arm A0|Part B Semaglutide (sema) and subcutaneous (SC) placebo and intravenous (IV) placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1
62816792|NCT06299098|EXPERIMENTAL|Arm A1|Part B Sema and SC placebo and IV placebo followed by high dose trevogrumab (trevo) Randomized 1:1:1:1:1:1:1:1
62240689|NCT01571765|NO_INTERVENTION|no added MNCH activities|
62240690|NCT02600962||STEMI|Patients discharged with STEMI
62240691|NCT02600962||NSTEMI|Patients discharged with NSTEMI
62240692|NCT00294385|ACTIVE_COMPARATOR|Gemcitabine, Docetaxel|Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
62240693|NCT00294385|ACTIVE_COMPARATOR|Docetaxel|Arm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
62240694|NCT06277908||Patients with morbidity|Patients who suffered from any type of morbidity after surgery
62240695|NCT06277908||Patients without morbidity|Patients who did not suffer from any type of morbidity after surgery
62240696|NCT03142308||Surgeons|Young surgeons in all surgical specialities
62240697|NCT01170039|ACTIVE_COMPARATOR|Lubiprostone|
62240698|NCT01170039|PLACEBO_COMPARATOR|Placebo|
62240699|NCT06214871|EXPERIMENTAL|Single Arm|
62240700|NCT03653221|EXPERIMENTAL|standardized patients with VRNET|The medical students examine the standardized patients who have neurological deficits which presented by VRNET.
62598135|NCT03768440|EXPERIMENTAL|continuous erector spinae block|An erector spinae block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
62598136|NCT03768440|ACTIVE_COMPARATOR|continuous paravertebral block|A paravertebral block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
62816793|NCT06299098|EXPERIMENTAL|Arm B0|Part B Sema, moderate-high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1
62816794|NCT06299098|EXPERIMENTAL|Arm B1|Part B Sema, moderate-high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1
62816795|NCT06299098|EXPERIMENTAL|Arm C0|Part B Sema, high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1
62598137|NCT06648187|EXPERIMENTAL|Early motor-cognitive integrative training (e-MCIT)|Evaluation will be conducted at three assessment time points including baseline assessment (following initial medical intervention), assessment at the time of discharge from the intensive care center (an average of 2 weeks), and discharge from the hospital (an average of 4 weeks). After recruiting in this study, participants all receive the intervention of e-MCIT.
62598138|NCT05245721|ACTIVE_COMPARATOR|Nalbuphine|
62598139|NCT05245721|ACTIVE_COMPARATOR|Bupivacaine|
62598140|NCT06179017|EXPERIMENTAL|Intervention Group:Endovascular treatment|Interventionist choose the optimal EVT strategy and device based on the patient's condition and local guidelines. This may include, but not limited to, stent-retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation and so on. The EVT regimen and relevant time points will be accurately recorded. The patient will receive the best medical treatment according to the local guidelines.
62735262|NCT01057693|EXPERIMENTAL|pregabalin (Lyrica)|
62735263|NCT01057693|PLACEBO_COMPARATOR|Placebo|
62735264|NCT02317198|EXPERIMENTAL|Intervention|Clopidogrel
62735265|NCT02317198|ACTIVE_COMPARATOR|Control|Ticagrelor/Prasugrel
62735266|NCT03962907|EXPERIMENTAL|Carrier group - intervention|BACTROBAN® Nasal ong, 3g, GSK Lifo-Scrub sol 4%®, 500ml, B. Braun
62735267|NCT03962907|NO_INTERVENTION|Carrier group - control|
62816796|NCT06299098|EXPERIMENTAL|Arm C1|Part B Sema, high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1
62816797|NCT06299098|EXPERIMENTAL|Arm D0|Part B Sema, high dose trevo, and garetosmab (gareto) followed by SC placebo Randomized 1:1:1:1:1:1:1:1
62816798|NCT06299098|EXPERIMENTAL|Arm D1|Part B Sema, high dose trevo, and gareto followed by high dose trevo Randomized 1:1:1:1:1:1:1:1
62816799|NCT06299098|EXPERIMENTAL|Arm 1|Part C Sema and SC placebo Randomized 1:2:2
62038121|NCT01624038|EXPERIMENTAL|Hydroxyurea, Epiao|"* Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued. White cell count and platelet count were determined on a monthly basis. Side effects such as nausea, vomiting, diarrhea, rashes, and malaise, experienced during the first 6 h after taking the HU will be considered as clinical toxicity.~* Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week."
62598141|NCT06179017|PLACEBO_COMPARATOR|Control group: Best medical treatment|Patients will receive the best medical treatment according to local guidelines, including antiplatelet agents, anticoagulants, thrombolysis, etc., but not any EVT. In the control arm, rescue EVT is allowed in patients with disease progression leading to an increase in NIHSS≥4 and excluding the impact of non-stroke factors, and the onset-to-treatment time is within 24 hours.This may include, but not limited to, stent-retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation and so on.
62598142|NCT04943302|EXPERIMENTAL|Isatuximab + bendamustine|Bendamustine will be administered by IV at a dose of 70mg/m2 on cycle days 1 and 8 for up to 6 cycles. Isatuximab will be administered by IV at a dose of 10mg/kg on cycle 1 days 1, 8, 15, and 22; cycle 2-6 days 1,8; and cycle 7-12 day 1.
62038122|NCT04948099|EXPERIMENTAL|VIB1116|"Single dose of VIB1116, SC or IV administration.~Multiple doses of VIB1116, SC administration."
62038123|NCT04948099|PLACEBO_COMPARATOR|Placebo|"Single dose of Placebo, SC or IV administration.~Multiple doses of Placebo, SC administration."
62038124|NCT00262821|ACTIVE_COMPARATOR|Arm I (cisplatin)|Patients receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6).
62038125|NCT00262821|EXPERIMENTAL|Arm II (cisplatin, tirapazamine)|Patients receive tirapazamine IV over 2 hours on days 1, 8, 10, 12, 15, 22, 24, 26, and 29 and cisplatin IV over 1 hour on days 1, 15, and 29.
62598143|NCT04511962||Fast track group|Participants randomised to the fast track group will receive the pulmonary rehabilitation intervention 14 ± 7 days after randomisation.
62598144|NCT04511962||Wait list group|Participants randomised to the wait-list group will receive the pulmonary rehabilitation intervention 56 ± 7 days after randomisation.
62598145|NCT06619054|EXPERIMENTAL|Cohort1 (Normal)|Child-Pugh Score: N/A
62598146|NCT06619054|EXPERIMENTAL|Cohort2 (Mild Impairment)|Child-Pugh Score: A (5 to 6 points)
62598147|NCT06619054|EXPERIMENTAL|Cohort3 (Moderate Impairment)|Child-Pugh Score: B (7 to 9 points)
62598148|NCT06619054|EXPERIMENTAL|Cohort4 (Severe Impairment)|Child-Pugh Score: C (10 to 15 points)
62598149|NCT05963516|ACTIVE_COMPARATOR|Real-time Guidance|The LIVEBORN app will provide audio-visual guidance to the birth attendant during a resuscitation based on the data inputted by an observer as well as heart rate data from NeoBeat (if used).
62598150|NCT05963516|ACTIVE_COMPARATOR|Debriefing|The LIVEBORN app will support birth attendants in debriefing following a resuscitation based on the data inputted by an observer as well as heart rate data from NeoBeat (if used).
62598151|NCT06630585|NO_INTERVENTION|Standard of Care|Participants in this arm will use their standard of care (SoC)
62598152|NCT06630585|EXPERIMENTAL|Standard of Care + Drug|Participants in this arm will use their standard of care (SoC) plus tirzepatide (titrated to reach a minimum accepted dose.
62598153|NCT06263153|EXPERIMENTAL|Treatment (futibatinib, durvalumab, radical cystectomy)|Patients receive futibatinib PO QD on days 1-28 and durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo radical cystectomy within 4-12 weeks. Patients also undergo CT and MRI during screening and on the trial and also undergo blood sample collection on the trial.
62038126|NCT01625221|EXPERIMENTAL|Magnetic anal sphincter augmentation|The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
62038127|NCT04696666|EXPERIMENTAL|Patients assigned in a single group and treated with 6 instillations of INSTYLAN for 6 weeks|Single Group Assignment
62038128|NCT06276868|EXPERIMENTAL|Dalcilib+letrozole+HP|"All subjects received Dalcilib 150mg qd, stopped for 1 week after 3 weeks，and letrozole (2.5mg qd) (premenopausal combined with OFS). The subjects received 2 cycles of preoperative treatment with darcilib combined with letrozole, trastuzumab, and patstuzumab.~Then, MRI efficacy evaluation will be conducted, and patients who achieved PR continue to receive the original treatment regimen for 6 cycles, while those who did not achieve PR switched to the TCHP chemotherapy regimen for 6 cycles."
62598154|NCT03420807|EXPERIMENTAL|MHRC camera|Subjects will undergo a retina imaging session with the MHRC camera.
62598155|NCT01942044|EXPERIMENTAL|Promus element|Promus element is a thin struts, 2-link design, evelolimus-eluting stents.
62598156|NCT01942044|ACTIVE_COMPARATOR|Xience Prime|Xience Prime is a thin struts, 3-link design, evelolimus-eluting stents.
62598157|NCT01942044|ACTIVE_COMPARATOR|Nobori|Nobori is a thick struts, 2-link design, biolimus-eluting stents.
62598158|NCT01118624|EXPERIMENTAL|Pralatrexate, (RS)-10-propargyl-10-deazaaminopterin (Folotyn)|"Intravenous (IV) push administration over 3-5 minutes. Initial dose: 190 mg/m2 Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
62598159|NCT05977127|EXPERIMENTAL|Intradermal vaccination with 20 mcg mRNA vaccine|Participants will receive a single dose of 20 mcg COVID-19 mRNA vaccine (Comirnaty; Pfizer/BioNTech) through the intradermal route using microneedles.
62735268|NCT03962907|EXPERIMENTAL|Non - carrier group - intervention|Lifo-Scrub sol 4%®, 500ml, B. Braun
62816800|NCT06299098|EXPERIMENTAL|Arm 2|Part C Sema and SC low dose trevo Randomized 1:2:2
62816801|NCT06299098|EXPERIMENTAL|Arm 3|Part C Sema and SC moderate dose trevo Randomized 1:2:2
62816802|NCT04146181|EXPERIMENTAL|SCT-I10A|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
62816803|NCT03968679|EXPERIMENTAL|Unilateral elective nodal irradiation|Exclusion of contralateral neck from elective nodal irradiation, based on results of SPECT/CT and (in case of contralateral drainage) contralateral sentinel node procedure.
62038129|NCT04648150|EXPERIMENTAL|VERUM|An active wave emission bracelet for a period of 2 months. Then delivery of a second active medical device for a period of 4 months
62431092|NCT05084534|EXPERIMENTAL|Midodrine hydrochloride plus standard medical treatment|"* Standard Medical Treatment will be continued in all, which includes,~* To continue restriction of sodium to \< 2meq/kg/day~* To continue maximum tolerable dose of diuretics~* Repeat LVP with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~* Albumin infusion for serum albumin \<2.5g/dl - dose 1g/kg/day (maximum 20g/day)~* Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% (maximum dose - 15mg/day)~* Midodrine dosage will be decreased by 25% in case of arterial hypertension (\>95th centile BP for the age)"
62598160|NCT05977127|ACTIVE_COMPARATOR|Intramuscular vaccination with 30 mcg mRNA vaccine|Participants will receive a single dose of 30 mcg COVID-19 mRNA vaccine (Comirnaty; Pfizer/BioNTech) through the intramuscular route.
62816804|NCT06383858||Screening based on maternal factors|Pregnant women with low risk of pre-eclampsia assessment and no suspected pre-eclampsia symptoms in the later period are only followed up at delivery to register the outcome indicators. For pregnant women with high risk of preeclampsia evaluation, it is necessary to register the history of drug use (whether or not to use and the dosage), and follow up to register the outcome index at delivery.
62598161|NCT05977127|ACTIVE_COMPARATOR|Intramuscular vaccination with 20 mcg mRNA vaccine|Participants will receive a single dose of 20 mcg COVID-19 mRNA vaccine (Comirnaty; Pfizer/BioNTech) through the intramuscular route.
62598162|NCT02086682||General Care Cohort|The group included adult hospitalized patients requiring hemodialysis at the inpatient dialysis unit. This was an observational study, with no interventions.
62598163|NCT02086682||Critical Care Cohort|The group included adult hospitalized patients requiring hemodialysis at the intensive care unit. This was an observational study, with no interventions.
62816805|NCT06383858||Screening based on FMF model|Preeclampsia risk assessment should be carried out at 11-13+6 weeks and 20-36+6 weeks of pregnancy. For low-risk pregnant women (PlGF≥100pg/ml or sFlt-1 /PlGF \<38), it is suggested to closely monitor maternal blood pressure and conduct routine prenatal examination. The basic information of pregnant women, medical and obstetric history, physical examination information, ultrasonic examination data, serum markers (PlGF, sFlt-1) test results, pre-eclampsia risk assessment results, medication history and so on were registered in the study. For high-risk pregnant women (PlGF\<100pg/ml or sFlt-1/PlGF ≥ 38), we should pay close attention to the changes of maternal blood pressure and proteinuria. Dynamic monitoring of PlGF or sFlt-1/PlGF should be carried out when necessary, and baseline information should also be registered after joining the group.
62598164|NCT03205761|EXPERIMENTAL|Olaparib|Patients with a positive methylation status on at least one of the two genes and lacking of known deleterious or suspected deleterious mutations in both genes could be included in the study to receive olaparib tablet formulation at 600 mg total daily dose (given in two oral administrations of 300 mg every 12 hours approximately). Patients will continue to receive their treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
62598165|NCT03426865||Axumin PET scan|Only one arm is being evaluated--the arm receiving PET scan
62816806|NCT05601219|EXPERIMENTAL|ADA-011 Monotherapy Dose Escalation|ADA-011 monotherapy will be administered intravenously (IV), every 3 weeks (Q3W) at escalating doses starting with Cycle 1, Day 1, until participant withdrawal. Participants enroll with histologically or cytologically confirmed solid tumors.
62816807|NCT05601219|EXPERIMENTAL|ADA-011 Monotherapy Dose Expansion|ADA-011 monotherapy with the preliminary recommended phase 2 dose (RP2D) of ADA-011, in participants with histologically or cytologically confirmed solid tumors.
62038130|NCT04648150|SHAM_COMPARATOR|SHAM|An inactive wave emission bracelet for a period of 2 months of use then delivery of an active medical device from M2 to M6 after inclusion.
62038131|NCT01039701|EXPERIMENTAL|1|AZD1446 60mg once daily + donepezil 10mg
62038132|NCT01039701|EXPERIMENTAL|2|AZD1446 60mg three times daily + donepezil 10mg
62598166|NCT05994118|PLACEBO_COMPARATOR|Normal Saline|0.5 milliliter of NACL 0.9% subcutaneous saline injection
62598167|NCT05994118|ACTIVE_COMPARATOR|Magnetized Normal Saline|0.5 milliliter of magnetized NACL 0.9% subcutaneous saline injection
62598168|NCT02835651|EXPERIMENTAL|Palmitic acid|Diet rich in palmitic acid
62038133|NCT01039701|EXPERIMENTAL|3|AZD1446 30mg three times daily + donepezil 10mg
62038134|NCT01039701|PLACEBO_COMPARATOR|4|placebo + donepezil 10mg
62598169|NCT02835651|EXPERIMENTAL|Stearic acid|Diet rich in stearic acid
62735269|NCT03962907|NO_INTERVENTION|Non - carrier group - control|
62816808|NCT05601219|EXPERIMENTAL|Combination Therapy Dose Escalation|Combination therapy with ADA-011 and PD(L)-1 inhibitor (at escalating ADA-011 doses) will be administered IV Q3W, starting with Cycle 1, Day 1 in participants with histologically or cytologically confirmed solid tumors.
62816809|NCT04484961|NO_INTERVENTION|Control - Routine Rehab|Participants in this group received standard ACL rehab with no blood flow restriction therapy.
62816810|NCT04484961|EXPERIMENTAL|Experimental - BFR|Participants in this group received standard ACL rehab with the addition of blood flow restriction therapy.
62038135|NCT02332590|ACTIVE_COMPARATOR|Adalimumab 40 mg/Sarilumab 200 mg|Adalimumab 40 milligrams (mg) subcutaneous (SC) injection in combination with placebo for sarilumab every 2 weeks (q2w) for 24 weeks during the double-blind (DB) period. The dosing frequency of adalimumab was adjusted to 40 mg every week (qw) dosing in case of participants with inadequate response (less than \[\<\] 20% improvement from baseline in tender joint count \[TJC\] and swollen joint count \[SJC\] for 2 consecutive visits) at or after Week 16 until Week 23. Participants who completed 24 weeks in the DB period had the option to continue in open label extension (OLE) period and received sarilumab 200 mg q2w until commercial availability of sarilumab in their country or up to a maximum of an additional 276 weeks (i.e. up to Week 300).
62038136|NCT02332590|EXPERIMENTAL|Sarilumab 200 mg/Sarilumab 200 mg|Sarilumab 200 mg SC injection in combination with placebo for adalimumab q2w for 24 weeks during the DB period. The dosing frequency of placebo for adalimumab was adjusted to 40 mg qw dosing in case of participants with inadequate response (\<20% improvement from baseline in TJC and SJC for 2 consecutive visits) at or after Week 16 until Week 23. Participants who completed 24 weeks in the DB period had the option to continue in OLE period and received sarilumab 200 mg q2w until commercial availability of sarilumab in their country or up to a maximum of an additional 276 weeks (i.e. up to Week 300).
62038137|NCT01618162|EXPERIMENTAL|Insulin degludec/liraglutide|
62240701|NCT03653221|PLACEBO_COMPARATOR|standardized patients|The medical students examine the standardized patients who have neurological deficits which presented by words or pictures.
62240702|NCT05867953|EXPERIMENTAL|Biopsy Arm|Patients undergoing biopsy with the Ion Endoluminal System
62431093|NCT05084534|OTHER|Standard medical treatment|"* Standard Medical Treatment will be continued in all, which includes,~* To continue restriction of sodium to \< 2meq/kg/day~* To continue maximum tolerable dose of diuretics~* Repeat LVP with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~* Albumin infusion for serum albumin \<2.5g/dl - dose 1g/kg/day (maximum 20g/day)"
62431094|NCT00769678|ACTIVE_COMPARATOR|Stimulation of diaphragm|
62431095|NCT05368233|EXPERIMENTAL|ERAS protocol without the use of of abdominal drain in the perforated peptic ulcer patient|"Tracheal intubation. Short acting anesthetic agents,avoid opioid agents . Omental patch repair without placement of sub hepatic drain. Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~Abdominal drain will not be placed Post operative nausea and vomiting prophylaxis. Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~Initiation of feeding-Oral sips on day 1, step up day 2 onward. Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~Removal of urinary catheter-after weaning from the effect of general anesthesia.~Avoid opioid analgesics."
62431096|NCT05368233|ACTIVE_COMPARATOR|ERAS protocol with the use of of abdominal drain in the perforated peptic ulcer patient|"Tracheal intubation. Short acting anesthetic agents, avoid opioid agents. Omental patch repair with placement of sub hepatic drain. Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~Abdominal Drains will be placed and removed at anytime within 24 hrs and to not remove if the output is bilious or pus.~Post operative nausea and vomiting prophylaxis. Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~Initiation of feeding-Oral sips on day 1, step up day 2 onward. Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~Removal of urinary catheter-after weaning from the effect of general anesthesia.~Placing Sub hepatic drain intraoperatively. Avoid opioid analgesics."
62816811|NCT05930678|ACTIVE_COMPARATOR|Without ventilation|No ventilation sequence during the intubation period and without face mask ventilation during the apnea period
62816812|NCT05930678|EXPERIMENTAL|With ventilation|"Sequence with ventilation during the apnea period with face mask ventilation"
62816813|NCT06633562|ACTIVE_COMPARATOR|Nezavist Cohort 1|Nezavist 500 mg in a volume of 60 mL NPO 8 hrs AM bib.
62816814|NCT06633562|ACTIVE_COMPARATOR|Nezavist Cohort 2|Nezavist 1500 mg in a volume of 60 mL NPO 8 hrs AM bib.
62038138|NCT01618162|PLACEBO_COMPARATOR|Placebo|
62038139|NCT03322969|EXPERIMENTAL|receiving modified chemotherapy|Paclitaxel/DDP
62038140|NCT03322969|ACTIVE_COMPARATOR|receiving the original chemotherapy|XELOX/SOX
62038141|NCT03907124|EXPERIMENTAL|Genetically-guided treatment arm|The active arm - where patients will receive genetically-guided treatment
62816815|NCT06633562|EXPERIMENTAL|Nezavist Cohort 3|Nezavist 4500 mg in a volume of 60 mL NPO 8 hrs AM bib.
62816816|NCT06633562|EXPERIMENTAL|Nezavist Cohort 4|Nezavist 13500 mg in a volume of 60 mL NPO 8 hrs AM bib.
62038142|NCT03907124|NO_INTERVENTION|Treatment as usual (TAU) control arm|TAU is the control arm - where patients will continue to receive their usual treatment as before.
62038143|NCT01575366|EXPERIMENTAL|Slow tracking training|
62038144|NCT01575366|EXPERIMENTAL|Fast tracking training|
62240703|NCT01106820|ACTIVE_COMPARATOR|Resistance training|
62240704|NCT01106820|ACTIVE_COMPARATOR|Relaxation training|
62240705|NCT01481389|ACTIVE_COMPARATOR|Theobromine drink|
62240706|NCT01481389|ACTIVE_COMPARATOR|Cocoa drink|
62240707|NCT01481389|PLACEBO_COMPARATOR|Placebo drink|
62240708|NCT01481389|ACTIVE_COMPARATOR|Cocoa and theobromine drink|
62816817|NCT06633562|PLACEBO_COMPARATOR|Placebo|Placebo to match 5.4 g of Avicel in a volume of 60 mL NPO 8 hrs AM bib.
62038145|NCT06533228||Crohn's Disease Patients|Children and adults, who are scheduled for a clinical magnetic resonance enterography (MRE) to evaluate staging/ restaging of Crohn's disease, will be approached to undergo our novel abbreviated MRE. No intervention, observation only, perform MRE, and complete trade-off tolerance survey.
62038146|NCT03265600|ACTIVE_COMPARATOR|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
62038147|NCT03265600|OTHER|Low-dose Comparator|Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group and allowed to receive behavioral and medical referrals and treatment as usual. All participants complete an action planning protocol during Week 7.
62038148|NCT04823884|ACTIVE_COMPARATOR|open distal chevron osteotomy|Hallux valgus correction is provided by using the traditional open distal v-shaped chevron osteotomy.
62038149|NCT04823884|ACTIVE_COMPARATOR|minimally invasive distal chevron osteotomy|Hallux valgus correction is provided by using a minimally invasive distal v-shaped chevron osteotomy.
62038150|NCT00381940|EXPERIMENTAL|Treatment (enzyme inhibitor therapy, chemotherapy)|"Patients receive ifosfamide IV continuously over days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, bortezomib IV on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy."
62038151|NCT03059550||cardiac rehabilitation|Patients reffered to cardiac Rehabilitation after an acute coronary syndrome
62240709|NCT00860821|EXPERIMENTAL|1|AZD8309
62431097|NCT03639961|EXPERIMENTAL|Staff of facilities for intervention|Intervention: Participants have been trained two times in six months period with integrated leading, managing and governing for results model.
62431098|NCT03639961|ACTIVE_COMPARATOR|Staff of facilities for control|Intervention: Participants have been trained two times in six months period with traditional model.
62598170|NCT03247491|EXPERIMENTAL|Experimental|TAU + mindfulness applied face to face 8 sessions of 120 minutes/session Mindfulness and Compassion based intervention applied in groups of 12-15 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
62431099|NCT01352559|EXPERIMENTAL|responders|50 ≤ Decrease rate(%) of HAM-D score
62038152|NCT03059550||Whole French population post-ACS|The whole French population who presented an acute coronary syndrome (ACS) in the years 2013 and 2014.
62038153|NCT04319510|EXPERIMENTAL|Craniosacral therapy|24 CST units à 45 minutes over 12 weeks. Follow-up assessment 6 months after randomization.
62038154|NCT04319510|EXPERIMENTAL|Craniosacral self-help group training|24 CST units à 45 minutes over 12 weeks. Follow-up assessment 6 months after randomization.
62038155|NCT04319510|OTHER|Treatment as usual / wait list control|Waiting period of six months.
62240710|NCT00860821|PLACEBO_COMPARATOR|2|Placebo
62240711|NCT03445988|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|A trained psychologist delivers pain-CBT to individual patients or groups of patients with chronic pain. Group treatment is delivered across 8 weekly sessions that last for 2 hours each. Pain-CBT incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session. Pain-CBT is effective for reducing pain intensity, pain catastrophizing, depression and social impacts.
62431100|NCT01352559|ACTIVE_COMPARATOR|non-responders|nonresponders is a patients having 50 \> Decrease rate(%) of HAM-D score
62431101|NCT01235858|OTHER|Gown group|Anesthesiologists wearing sterile gown for epidural insertion
62431102|NCT01235858|OTHER|No Gown group|Anesthesiologists not wearing gown for epidural insertion
62240712|NCT03445988|ACTIVE_COMPARATOR|Chronic Pain Self Management Program|The CPSMP is similar to pain-CBT in format and content but is peer-led, and is effective across pain conditions (e.g., back pain, arthritis) for improving pain and pain self-efficacy. The CPSMP consists of six weekly 2-hour group sessions in which two peer co-leaders provide patient education about pain, effective self-management, pain impacts, and other symptoms from a highly structured manual. Peers are people with chronic pain who live in the communities in which they teach. For this project, at least one peer facilitator per workshop will have had experience with prescription opioid use. Intervention fidelity is determined by having a trained observer with a checklist attend random workshop sessions. Similar to pain-CBT, CPSMP incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session.
62240713|NCT03445988|PLACEBO_COMPARATOR|Taper Only (Usual Care)|Participants allocated to 'Taper Only' will engage in a physician-guided, patient-centered opioid tapering program without additional behavioral intervention.
62240714|NCT03445988|NO_INTERVENTION|Observational Arm|Participants that do not wish to reduce their opioid medications but are otherwise eligible and interested in the research study will be offered participation in the observational arm. The observational arm of the study will not include interventions of any kind and will only collect survey data for the year following consent.
62240715|NCT06510647||Group A|Patients with endometriosis who are non-responsive to medical therapy after 12 months
62240716|NCT06510647||Group B|Patients with endometriosis who are responsive to medical therapy after 12 months
62240717|NCT02323763||Bipolar I or II Disorder|30 currently depressed patients with DSM-IV bipolar I and II disorder who are currently or previously suicidal will receive fMRI.
62598171|NCT03247491|NO_INTERVENTION|No intervention|Usual medical treatment (TAU) In this group the midwife will apply the usual treatment (childbirth education class in the third trimester of pregnancy).
62819439|NCT05720182|EXPERIMENTAL|Healthy Volunteers|"Healthy subjects are not subjected to any type of treatment besides non-invasive lower leg muscle compressibility measurements in rest and after exercise.~All 35 healthy subjects will undergo four times four measurements in rest (m. tibialis anterior of both legs, using two different internal landmarks). These four times four measurements in rest will each be done by three observers.~To measure the effect of exercise, compressibility will be measured immediately, one minute, and five minutes after a standard treadmill exercise at just one leg. The treadmill exercise and the corresponding measurements will be performed twice to address for measurements of both legs."
62240718|NCT00958620|ACTIVE_COMPARATOR|Active ESWT|
62240719|NCT00958620|SHAM_COMPARATOR|Sham ESWT|
62240720|NCT04629716||Intervention|The intervention group will be comprised of adults 50 and older who report severe or chronic pain, are newly registered for the Medical Marijuana Registry in the State of Florida, have no prior history of medical marijuana use, can communicate in English, and are willing and able to complete study procedures. The control group will be age, sex, and race matched. The primary study outcome is simulated driving performance (i.e. errors in response time, attention, and executive functioning tasks that predict on-road performance). Secondary outcomes include adverse effects.
62240721|NCT04629716||Control|The control group will be comprised of adults 50 and older who report severe or chronic pain, have no prior history of medical marijuana use, can communicate in English, and are willing and able to complete study procedures. The control group will be age, sex, and race matched. The primary study outcome is simulated driving performance (i.e. errors in response time, attention, and executive functioning tasks that predict on-road performance). Secondary outcomes include adverse effects.
62598172|NCT05728853||Trans gender males|Trans gender males in hormonal therapy
62598173|NCT05773651||Rare tumor disease|Prospective epidemiological and clinical data collection of subjects with diagnosis of a rare solid tumor.
62240722|NCT03759977|EXPERIMENTAL|Adapted Physical Activity group|This group will receive 3 sessions per week of specific physical activity.
62240723|NCT03759977|NO_INTERVENTION|Usual accompaniment group|This group will continue to follow the usual accompaniment of the nursing home.
62240724|NCT04129918|EXPERIMENTAL|experimental group|ear plugs and eye mask for 3 successive nights
62240725|NCT04129918|NO_INTERVENTION|control group|without ear plugs and eye mask
62240726|NCT01643954|NO_INTERVENTION|Arm A|Patients with prostate cancer who have undergone robotic radical prostatectomy at The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University Medical Center.
62240727|NCT01643954|OTHER|Arm B|Patients with prostate cancer that will undergo robotic radical prostatectomy at The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University Medical Center .
62598174|NCT01899716|EXPERIMENTAL|Exercise|Aerobic Exercise, 3 times peer week, A dose of 16.5 kcal/kg weight peer week.
62598175|NCT01899716|NO_INTERVENTION|Control|
62598176|NCT00810446||rifabutin|Patients administered Rifabutin.
62240728|NCT03318809|EXPERIMENTAL|Group 1: Severely Renal Impaired Participants|Participants with severely impaired renal function (estimated glomerular filtration rate \[eGFR\] 15 to 29 mL/min/1.73 m\^2) receive a single oral dose of 200 mg AMG 986.
62598177|NCT01828541|OTHER|Standard Care|Subjects in this condition will receive our standard care for itch, which includes a stepped based algorithm of medications.
62598178|NCT01828541|EXPERIMENTAL|Hypnosis Condition|Subjects in this condition will receive standard care plus the addition of 4 sessions of hypnosis delivered over a two month period.
62038156|NCT00162370|EXPERIMENTAL|Definity|All patients will undergo a gray scale baseline unenhanced imaging session (apical 2- or 4 chamber view), as well as a DEFINITY (Perflutren Lipid Microsphere Injectable Suspension)-enhanced rest and a DEFINITY enhanced exercise or dobutamine stress echocardiography imaging session. The unenhanced and DEFINITY-enhanced rest and stress echocardiography imaging sessions will be performed on the same day. For the DEFINITY-enhanced imaging sessions all patients will receive diluted DEFINITY intravenously (IV). Diluted DEFINITY will be prepared by mixing 1 mL of activated DEFINITY® with 9 mL of normal saline in a 10 mL syringe.
62598179|NCT06008197|EXPERIMENTAL|Finerenone|
62038157|NCT02190539|EXPERIMENTAL|Homeopathic treatment|A feasibility study examining whether patients with advanced breast cancer would follow a homeopathic protocol for three to six months.
62240729|NCT03318809|ACTIVE_COMPARATOR|Group 2: Healthy Participants|Participants with normal renal function (eGFR \>= 90 mL/min/1.73 m\^2 or above) receive a single oral dose of 200 mg AMG 986.
62240730|NCT02429622|EXPERIMENTAL|Radical 2.14|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
62240731|NCT02429622|EXPERIMENTAL|Radical 2.17|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.17Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
62240732|NCT02429622|EXPERIMENTAL|Radical 2.21|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.21Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
62431103|NCT02272582|EXPERIMENTAL|SOMVC001 Vascular Conduit Solution|Each patient will serve as his/her own control because each patient will have two graft segments with one segment immersed in SOMVC001 and the other in heparin dosed saline (Standard solution). Patients will be randomized using a simple random sample allocation scheme. At the time of randomization, patients will be assigned an allocation number. Each randomized patient will be implanted with two SVGs, alternating Target Region A (Circumflex or Diagonal) and Target Region B (Right Coronary System or Diagonal) and alternating (proximal vs. distal) segments of the harvested SV. A randomization schedule will be developed to ensure appropriate randomization allocation of the harvested vein segment being grafted to the targeted regions.
62598180|NCT06008197|PLACEBO_COMPARATOR|Placebo|
62598181|NCT06641349||Children born to mothers who received a multiple micronutrient supplement|From preconception to 6-months postpartum, mothers received a multiple micronutrient supplement (oral tablet at UNIMMAP composition \[30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine\])
62598182|NCT06641349||Children born to mothers who received the standard of care|From preconception to 6-months postpartum, mothers received the standard of care
62598183|NCT01461720|OTHER|Standard medical care|This is the control arm, which is given the best evidence-based standard treatment for the management of acute stroke
62598184|NCT01461720|EXPERIMENTAL|BM-MSCs|Autologous bone marrow-derived mesenchymal stem cells(BM-MSCs)
62598185|NCT05497388|NO_INTERVENTION|Web for HCV education|
62038158|NCT04654780|EXPERIMENTAL|tax on purchases|"exposed to high-price purchases of high in foods, including sugary drinks."
62038159|NCT04654780|EXPERIMENTAL|subsidies on purchases|exposed to purchases with prices that consider subsidies in fruits and vegetables.
62038160|NCT04654780|PLACEBO_COMPARATOR|Control|It will not be subjected to any intervention and therefore will buy with current or market prices.
62038161|NCT05698810|OTHER|Healthy Volunteers|tests
62038162|NCT05698810|OTHER|Parkinson's Disease patients|tests
62038163|NCT05698810|OTHER|Para/tetraplegic Patients|tests
62038164|NCT05917795|EXPERIMENTAL|kidney transplant candidates with obesity (BMI > 35 kg/m2)|Subjects with an indication to kidney transplantation that are not listed because of a high BMI according to the policy of the transplant Centre (cut-off 35 kg/m2)
62038165|NCT02621931|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62598186|NCT05497388|EXPERIMENTAL|Serious Game for HCV education|
62598187|NCT01993589|NO_INTERVENTION|Control group|Control group
62598188|NCT01993589|ACTIVE_COMPARATOR|Pain reliever|1000 mg paracetamol (Parol 1 g Atabay ilaç Turkey)
62819440|NCT06134180|EXPERIMENTAL|CONFIDENCE AI|Participants will attend the 4-week CONFIDENCE-AI Program. This program will include attending 4 group-based sessions delivered by videoconference. Each session will last approximately 1.5 hours each and will cover topics such as how to budget, accessing community resources to displace the out-of-pocket costs of caregiving, asking for help, and more. Participation will be supplemented by access to a digital app to support engagement, such as through text messaging and resources navigation support.
62240733|NCT02429622|EXPERIMENTAL|Neoadjuvant 2.14|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 4 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity. Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
62598189|NCT01993589|ACTIVE_COMPARATOR|Dexketoprofen trometamol|25 mg oral Dexofen Atabay ilaç Turkey
62240734|NCT04911088||Analgesic calibration|Participants will receive calibration of electromyography at state entropy of 90.
62240735|NCT04911088||Sedated calibration|Calibration will be started at state entropy of 70.
62598190|NCT01993589|ACTIVE_COMPARATOR|Lidocaine spray|2 puff on cervical mucosa (Xylocain Pump 100 Mg 50 Ml Sprey Astra Zeneca)
62598191|NCT01993589|ACTIVE_COMPARATOR|pethidine|Aldolan 100 mg Liba Laboratuarı İstanbul Turkey
62598192|NCT01993589|ACTIVE_COMPARATOR|diclofenac sodium|Dicloron amp 75 mg Deva İlaç Levent İstanbul/Turkey
62240736|NCT04911088||No calibration|Participants will not receive calibration of electromyography. Measurements will start simultaneously to the standard electromyography with a default current of 60mA at state entropy of 50.
62240737|NCT06038825|ACTIVE_COMPARATOR|topical vibration|For all patients one half of the scalp was injected with vibration device.
62240738|NCT06038825|NO_INTERVENTION|control|Same patient's other side of the scalp was injected without vibration device.
62598193|NCT03912532|EXPERIMENTAL|NGM282 Dose 1|Administered by subcutaneous injection
62598194|NCT03912532|EXPERIMENTAL|NGM282 Dose 2|Administered by subcutaneous injection
62598195|NCT03912532|EXPERIMENTAL|NGM282 Dose 3|Administered by subcutaneous injection
62598196|NCT03912532|PLACEBO_COMPARATOR|Placebo|Administered by subcutaneous injection
62598197|NCT04103827||old patients|"During the first 24 hours of the hospitalisation in the equiped room and before the presentation of the device, A first series of questions will be asked a priori to the patients. Patient will freely use Le Qoos during all his hospitalisation. After this use, a survey concerning the usability of Le Qoos will be administered to the patient, during the 48 hours before his discharge from hospital."
62819441|NCT04170153|EXPERIMENTAL|Part A1: Monotherapy Dose Escalation|Participants will initially receive Tuvusertib (M1774) once daily under fasting conditions. Additional schedules may be evaluated if needed.
62038166|NCT02621931|EXPERIMENTAL|Fremanezumab 675 mg/placebo/placebo|Participants randomized to the fremanezumab 675 mg/placebo/placebo treatment arm received 675 mg of fremanezumab as 3 active injections (225 mg/1.5 mL) on Day 0, and placebo as a single 1.5-mL injection on Days 28 and 56.
62240739|NCT05406388|ACTIVE_COMPARATOR|Erector Spinae Plane Block|Erector Spinae Plane Block for Postoperative Analgesia
62240740|NCT05406388|ACTIVE_COMPARATOR|Control group|No regional anesthesia technique will be applied to the control group.
62598198|NCT04103827||relatives / unformal caregivers|"Before the presentation of the device, a first series of questions will be asked a priori to the unformal caregiver. Unformal caregiver will freely use Le Qoos during the hospitalization of his relative. After this use, a survey concerning the usability of Le Qoos will be administered to the unformal caregivers, 48 hours before the discharge of his hospitalized relative from hospital."
62598199|NCT04103827||profesional caregivers|"After the inclusion of all expected patients and relatives, a survey concerning the usability of Le Qoos will be administered to professional caregivers."
62598200|NCT03770416|EXPERIMENTAL|Cohort A|Patients receive ibrutinib PO daily on days 1-28. Beginning course 1, patients also receive nivolumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response after 6 courses may continue therapy for up to 2 years.
62240741|NCT02593669|EXPERIMENTAL|Neutral IOL|Phacoemulsification cataract surgery is performed with neutral IOL implantation.
62240742|NCT02593669|EXPERIMENTAL|Blue-blocking IOL|Phacoemulsification cataract surgery is performed with blue-blocking IOL implantation.
62240743|NCT02762825|EXPERIMENTAL|Higher Intensity Interval Training (HIIT)|
62240744|NCT02762825|ACTIVE_COMPARATOR|Moderate Continuous Training (MCT)|
62240745|NCT05226026|EXPERIMENTAL|NiteCAPP HELPS|4 weeks of online CBT-I (1 session/week for 1 hour), followed by tapered withdrawal and motivational interviewing and check-ins.
62431104|NCT02272582|ACTIVE_COMPARATOR|Standard of Care Heparin-dosed saline|Each patient will serve as his/her own control because each patient will have two graft segments with one segment immersed in SOMVC001 and the other in heparin dosed saline (Standard solution). Patients will be randomized using a simple random sample allocation scheme. At the time of randomization, patients will be assigned an allocation number. Each randomized patient will be implanted with two SVGs, alternating Target Region A (Circumflex or Diagonal) and Target Region B (Right Coronary System or Diagonal) and alternating (proximal vs. distal) segments of the harvested SV. A randomization schedule will be developed to ensure appropriate randomization allocation of the harvested vein segment being grafted to the targeted regions.
62240746|NCT05226026|OTHER|Treatment as Usual|Continuation of standard treatment for sleep and pain for 4 weeks, followed by tapered withdrawal and motivational interviewing and check-ins.
62431105|NCT01073683|EXPERIMENTAL|larynx preservation|Decision between surgery and Chemo-rt according to response to initial induction chemotherapy
62431106|NCT04188769|SHAM_COMPARATOR|uninflated - rest|splint around the arm is not inflated both arms are in rest during the entire trial
62431107|NCT04188769|SHAM_COMPARATOR|uninflated - triggered|splint around the arm is not inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
62598201|NCT03770416|EXPERIMENTAL|Cohort B|Patients receive ibrutinib PO daily on days 1-28 and nivolumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response after 6 courses may continue therapy for up to 2 years.
62598202|NCT03350061|EXPERIMENTAL|SENSY benefit|Sensory feedback elicited by intraneural stimulation will be provided by SENSY with and without the leg prosthesis to improve walking ability, increase embodiment, and reduce metabolic cost, cognitive load and phantom pain.
62598203|NCT02149823|ACTIVE_COMPARATOR|Intranasal Oxytocin Group 1|Placebo on visit 1, oxytocin 24IU on visit 2, then 40 IU on visit 3
62240747|NCT01303965|EXPERIMENTAL|Open Label, Single Arm|Use sirolimus and tacrolimus as GvHD prophylaxis with sirolimus and lenalidomide as post-transplant maintenance
62240748|NCT02091895|EXPERIMENTAL|endo group|colon polyp, early colon cancer, colorectal submucosal tumor, ileocecal ulcers
62240749|NCT03231696||Patients receiving Regional Anesthesia|All patients 18 years or older with a peripheral nerve block at Charité - Universitätsmedizin Berlin Campus Charite Mitte from 2012 to 2016.
62240750|NCT00771004|EXPERIMENTAL|Pioglitazone 30 mg to 45 mg QD|
62240751|NCT00771004|PLACEBO_COMPARATOR|Placebo QD|
62240752|NCT03133806|EXPERIMENTAL|Ultrasept LAA Closure System|Interventional percutaneous transcatheter device.
62240753|NCT04978142|EXPERIMENTAL|Active|Active tDCS stimulation at 2 mA for 20 minutes, with a 10 seconds of ramp-up and 10 seconds of ramp-down time as used in previous tinnitus studies. The stimulation will be delivered via two rubber electrodes attached using a layer of conductive paste (35 cm2). The anode will be placed over the right dlPFC and cathode over the left dlPFC).
62431108|NCT04188769|ACTIVE_COMPARATOR|constantly inflated - rest|splint around the arm is constantly inflated both arms are in rest during the entire trial
62431109|NCT04188769|ACTIVE_COMPARATOR|constantly inflated - triggered|splint around the arm is constantly inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
62431110|NCT04188769|EXPERIMENTAL|intermittently inflated - rest|splint around the arm is intermittently inflated both arms are in rest during the entire trial
62431111|NCT04188769|EXPERIMENTAL|intermittently inflated - triggered|splint around the arm is intermittently inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
62431112|NCT05787977|EXPERIMENTAL|Interventional Group|Treadmil Training with visual feedback and rhythmic Auditory Cue
62240754|NCT04978142|SHAM_COMPARATOR|Sham|Placebo stimulation is performed using the same current intensity, but only applied for 45 seconds in addition to the 10 second ramp-up and 10 second ramp-down periods. The electrode configuration and placement will be identical to the active stimulation.
62816818|NCT05806645|EXPERIMENTAL|Intervention|The proposed experimental intervention will incorporate our risk prediction model which will be used to guide the hospital to home transition of care for medium and high-risk groups of patients. Patients will receive transition of care plans that are tailored to their risk and embedded within standardized discharge pathways within the EHR- Education and self-management guidance about AKI for patients, Medication guidance based on evidence-based indications for reducing risk of cardiac and kidney outcomes, Recommendations for subsequent laboratory testing of kidney function and electrolytes according to clinical characteristics and risks, Recommendations for timing and nature of PCP follow-up, Information about the patient's AKI and subsequent management provided to PCPs through discharge summary, Recommendations for outpatient Pharmacy follow-up for medication reconciliation and review according to patient risk and medication management gaps, Recommendations for Nephrology referral
62816819|NCT05806645|NO_INTERVENTION|Usual Care|The usual care group will not receive the risk-guided transition of intervention and will receive standard hospital discharge care in accordance with local health system standards (Alberta Health Services), and additional requisitions for kidney function testing at 90 days.
62038167|NCT02621931|EXPERIMENTAL|Fremanezumab 675/225/225 mg|Participants randomized to the fremanezumab 675/225/225 mg treatment arm received 675 mg of fremanezumab as 3 active injections (225 mg/1.5 mL) on Day 0 and 225 mg of fremanezumab as 1 active injection (225 mg/1.5 mL) on Days 28 and 56.
62816820|NCT01000090||Acromegaly patients, somatostain analogues|
62816821|NCT01000090||Acromegaly patients, surgery|
62038168|NCT03150472|EXPERIMENTAL|Ivory Dentin Graft (Ivory Graft Ltd.)|"Ivory Dentin Graft is a bone graft material for the repair or augmentation of bone defects in dental procedures. It consists of sterile 300 - 1200 μm porous particles or granules of hydroxyapatite which retain the natural form of the source porcine dentin and also the natural protein matrix which consists largely of porcine collagen.~This type of Graft Matrix will be administered as the intervention."
62240755|NCT01448213|ACTIVE_COMPARATOR|Fluorometholone 0.1% Solution|Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
62240756|NCT01448213|ACTIVE_COMPARATOR|Prednisolone acetate 1% Solution|Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
62240757|NCT06502249||control|Healthy volunteers not suffering from any disease or not taking any Medications
62816822|NCT05000398|ACTIVE_COMPARATOR|exercise with a physiotherapist|Participants will exercise with a physiotherapist. 4 times a week for 8 weeks
62816823|NCT05000398|EXPERIMENTAL|home program|The same exercises will be given to the participants as brochures. 4 times a week for 8 weeks
62038169|NCT03150472|ACTIVE_COMPARATOR|OsteoBiol Gen-Os ® (Tecnoss)|"A natural replicate of autologous bone, Gen-Os® conserves the same intimate structures (matrix and porous form) and presents a highly osteoconductive properties.~It is biocompatible and bioavailable, as recognized by tests made according to the ISO 10993 method conducted at Eurofins Biolab.~This type of Graft Matrix will be administered as the intervention."
62431113|NCT05787977|NO_INTERVENTION|Control Group|No intervention
62431114|NCT02954120||(PCOS-CP-)|systemically and periodontally healthy participants
62431115|NCT02954120||(PCOS-CP+)|systemically healthy participants with CP
62431116|NCT02954120||(PCOS+CP-)|PCOS participants with periodontally healthy
62431117|NCT02954120||(PCOS+CP+)|PCOS participants with CP
62431118|NCT03221439|EXPERIMENTAL|Cognitive Functional Therapy|Cognitive Functional Therapy (CFT) is a behavioral intervention that addresses multiple aspects of low back pain. This approach focuses on changing the patient's beliefs, confronting their fears, educating them about pain mechanisms, increasing mental strength, and control of their body. This is done with functional tasks performed by individuals training them to reduce excessive muscle activity in the trunk and generate behavioral changes related to pain, from postures and provocative movements.
62431119|NCT03221439|ACTIVE_COMPARATOR|Manual Therapy and Exercise|The active comparator will be the combination of manual therapy and motor control exercises.
62431120|NCT02997956|EXPERIMENTAL|Tocilizumab|"Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.~The first part of the trial will be Phase Ib and will enroll 18 participants. Participants will receive TACE on day 1 and Tocilizumab at dose level 1, 2, or 3 on days 1, 29 and 57. Maximum tolerated dose (MTD) of Tocilizumab will be determined.~The second part of the trial will be a Phase II and will enroll 50 subjects. Participants will receive TACE on day 1 and Tocilizumab at the MTD on days 1, 29 and 57."
62598204|NCT02149823|ACTIVE_COMPARATOR|Intranasal Oxytocin Group 2|oxytocin 24IU on visit 1, placebo on visit 2, then oxytocin 40IU on visit 3
62816824|NCT05387083|EXPERIMENTAL|Low Dose of TP-05 (lotilaner)|Single Oral Low Dose of TP-05 tablet.
62816825|NCT05387083|EXPERIMENTAL|High Dose of TP-05 (lotilaner)|Single Oral High Dose of TP-05 tablet.
62038170|NCT03399695|ACTIVE_COMPARATOR|control|spontaneous breathing through a face mask connected to the anaesthesia machine delivering 100% oxygen gas flow (15l/min)
62038171|NCT03399695|EXPERIMENTAL|ohd|spontaneous breathing through a nasal cannula connected to an humidifier device delivering warm (37°C) high flow oxygen(60l/min)
62038172|NCT00478348|OTHER|Drain|
62038173|NCT00478348|OTHER|No drain|
62038174|NCT05488392|EXPERIMENTAL|Intrajugular cooling group|The safety and tolerability of hypothermia with intrajugular cooling will be investigated using 3+3 dose-escalation trial design.
62240758|NCT06502249||Diseased|NSCLC patients
62431121|NCT00766506|EXPERIMENTAL|Fentanyl IONSYS|Participants will receive 40 microgram (mcg) of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
62598205|NCT02149823|ACTIVE_COMPARATOR|Intranasal Oxytocin Group 3|oxytocin 40IU on visit 1, oxytocin 24IU on visit 2, then placebo on visit 3.
62598206|NCT02149823|ACTIVE_COMPARATOR|Intranasal Oxytocin Group 4|after visit 4, placebo on subsequent visit , then oxytocin 40IU at following visit
62598207|NCT02149823|ACTIVE_COMPARATOR|Intranasal Oxytocin Group 5|after visit 4, oxytocin 40IU on subsequent visit, then placebo at following visit
62598208|NCT06622369|EXPERIMENTAL|Experimental;:Virtual Reality-Game group|Virtual Reality-Game group Before the circumcision procedure, patients in the VR group will be given a 5-minute training including instructions for the use of the virtual reality. Children in the game group will be allowed to choose a game of their choice compatible with virtual reality. Children in this group will be allowed to play the game of their choice for 10-15 minutes before the procedure. VR will be disinfected before and after each use in terms of infection risk.
62598209|NCT06622369|EXPERIMENTAL|Experimental: Virtual Reality-Cartoon group|Virtual Reality-Cartoon group Before the circumcision procedure, patients in the VR group will be given a 5-minute training including instructions for the use of the virtual reality. Children in the cartoon-video group will be allowed to choose a cartoon of their choice compatible with virtual reality. Children in this group will be allowed to watch the cartoon of their choice for 10-15 minutes before the procedure. VR will be disinfected before and after each use in terms of infection risk.
62431122|NCT00766506|ACTIVE_COMPARATOR|Morphine IV PCA|Morphine sulphate solution will be administered intravenously (directly into the vein, IV) by a patient-controlled analgesia (PCA) pump using set bolus (a large amount) doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
62431123|NCT05578417||HAE nC1-INH|Participants with HAE nC1-INH will be observed retrospectively for the treatments they receive and their outcomes in the real-world setting from January 1, 2012, to January 1, 2022.
62431124|NCT05578417||NHAE nC1-INH|Participants with NHAE nC1-INH will be observed retrospectively for the treatments they receive and their outcomes in the real-world setting from January 1, 2012, to January 1, 2022.
62598210|NCT06622369|NO_INTERVENTION|No Intervention|Children in the control group will not be subjected to any distraction method. The routine procedure of the clinic will be applied.
62598211|NCT01945801|ACTIVE_COMPARATOR|Lasilactone|Dosage form: One capsule taking in the morning Dosage: furosemide, 20mg, and spironolactone, 100 mg. Frequency and duration: One capsule daily for 7 days.
62598212|NCT01945801|PLACEBO_COMPARATOR|placebo pill|One capsule taking in the morning. Frequency and duration: One capsule daily for 7 days.
62598213|NCT01945801|ACTIVE_COMPARATOR|Sodium-Restricted Diet|The diet group will receive a regimen with a prescribed intake of three grams of sodium per day
62598214|NCT04604275|EXPERIMENTAL|Sucrase intervention followed by placebo|Participants in this arm will receive sucrase for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of placebo.
62598215|NCT04604275|EXPERIMENTAL|Placebo followed by sucrase intervention|Participants in this arm will receive placebo for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of sucrase.
62598216|NCT05314140||Coronary artery calcium score evaluation|Patients with diabetes and having a CT scan for evaluation of their coronary artery calcium score will be consecutively include. The indication of the scanner is at the choice of the clinician (usually cardiologist and/or diabetologist), in compliance with the recommendations
62598217|NCT05930145|EXPERIMENTAL|Double stentriever technique|Patients treated with thrombectomy with a proximal balloon guiding catheter using two stentrievers simultaneously (one of 6 mm x 50 mm and another of 6 mm x 50 mm or 4 mm x 35 mm)
62598218|NCT05930145|ACTIVE_COMPARATOR|Single stentriever technique|Patients treated with thrombectomy with a proximal balloon guiding catheter using one stentriever (6 mm x 50 mm).
62598219|NCT04153890|EXPERIMENTAL|FamPALcare|Standard Care plus FamPALcare
62598220|NCT04153890|NO_INTERVENTION|Standard Care|The standard care group will receive routine HF care and instruction at university hospital or at clinic appointments. All patients can be referred for supportive care and heart failure care per national HF guidelines.
62598221|NCT01424514|EXPERIMENTAL|SB-705498|
62598222|NCT01424514|PLACEBO_COMPARATOR|Placebo|
62598223|NCT06602349|EXPERIMENTAL|experimental ARMS|treated with lidocaine 10 mg/ml
62598224|NCT06602349|PLACEBO_COMPARATOR|placebo arm|treated with placebo;salin solution
62598225|NCT02889835|ACTIVE_COMPARATOR|Universal Composite|Supreme Universal Restorative
62598226|NCT02889835|EXPERIMENTAL|Flowable Composite|Supreme Flowable Restorative
62598227|NCT02889835|EXPERIMENTAL|Bulk Fill Flowable Composite|Bulk Fill Flowable Restorative
62598228|NCT06511570|EXPERIMENTAL|Arm 1|12 participants receive sabirnetug by intravenous infusion
62038175|NCT05803226|EXPERIMENTAL|Intervention|The first 10-minute of Slow Art Plus involves a brief psychoeducation on slow looking, mindfulness, and self-compassion practices. This is followed by a 10-minute participants self-introduction and sharing of one act of self-kindness; a 10-minute facilitator led mindfulness meditation on affectionate breathing to foster greater somatic and emotional clarity for slow-looking. This is followed by a set of 30-minute slow looking activity with 1 selected art-piece, including: (a) creating an Artwork Title with one sentence description, (b) imaging music that resonates with the viewers' emotional response to artwork, and (c) sketching a Response Art that facilitates a dialogue between the viewer and the art piece for perspective widening. A 10-minute dyadic sharing follows with a 5-minute large group sharing of joint collective experience. Artwork reveal and sharing of its self-care implications is offered. Finally, a closure self-compassion activity of Supportive Healing Touch.
62240759|NCT02805725|EXPERIMENTAL|Cohort 1: Trabectedin 0.30 mg/m2 IV + CP|"Trabectedin 0.30 mg/m2 will be administered intravenously (IV), 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks, in cohort 1 of dose escalation.~Cyclophosphamide (CP) will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.~1 cycle = 28 days"
62816826|NCT05387083|PLACEBO_COMPARATOR|Placebo|Single Oral Dose of placebo tablet.
62240760|NCT02805725|EXPERIMENTAL|Cohort 2: Trabectedin 0.40 mg/m2 IV + CP|"Trabectedin 0.40 mg/m2 will be administered intravenously (IV), 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks, in cohort 2 of dose escalation.~Cyclophosphamide (CP) will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.~1 cycle = 28 days"
62598229|NCT06511570|EXPERIMENTAL|Arm 2|16 participants receive sabirnetug + rHuPH20 by subcutaneous injection
62598230|NCT01984892|EXPERIMENTAL|IT and IM injections Poly-ICLC|Enrolled patients will receive two cycles of Poly-ICLC treatment. Each priming (intratumoral injections - IT) and boosting (intramuscular injections - IM) treatment course will constitute one cycle.
62598231|NCT04933084|NO_INTERVENTION|Usual Care|During their pre-operative visit, the usual care group will undergo usual pre-surgery patient education care dependent on their provider.
62598232|NCT04933084|EXPERIMENTAL|Text Handout|This group will receive limited opioid analgesia in conjunction with pre-operative education in the form of a text handout.
62598233|NCT04933084|EXPERIMENTAL|Text handout and Pre-recorded Video|This group will receive limited opioid analgesia in conjunction with pre-operative education in the form of a text handout AND pre-recorded video.
62038176|NCT05803226|NO_INTERVENTION|Control|Wait-list Control Arm who will receive the Slow Art Plus after the Experimental Arm completes the Intervention.
62240761|NCT02805725|EXPERIMENTAL|Cohort 3: Trabectedin 0.50 mg/m2 IV + CP|"Trabectedin 0.50 mg/m2 will be administered intravenously (IV), 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks, in cohort 3 of dose escalation.~Cyclophosphamide (CP) will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.~1 cycle = 28 days"
62431125|NCT04379440||" Acute Ward Patients  care setting cohort"|Acute Ward Hospitalised patients with suspected or known SARS-CoV-2 infection
62431126|NCT04379440||" Nursing Homes (RSA)  care setting cohort"|Nursing Home Resident Older Adult suffering from Suspected or known SARS-CoV-2 infection
62431127|NCT04379440||" Home and Outpatients' Care  cohort"|Outpatients at risk of SARS-CoV-2 infection
62431128|NCT04379440||" Dementia Outpatients  cohort"|Outpatients suffering from Dementia according to NIA-AA criteria, at risk of SARS-CoV-2 infection and on Treatment with anti-cholinesterase- dugs and/or anti-psychotics
62598234|NCT05288595|EXPERIMENTAL|Pediatric patients with malignant or non-malignant hematologic condition|The infusion of the final TCRαβ/CD19 depleted product will be given through the recipient's central venous catheter and will be administered fresh, without cryopreservation whenever possible. If the product must be cryopreserved and then thawed, this will be done according to institutional standards.
62598235|NCT02137109||natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab per the local label specifications.
62598236|NCT05918419|EXPERIMENTAL|Neoadjuvant Chemoradiation|neoadjuvant chemoradiation plus PD-1 antibody (Serplulimab) Intervention: Drug: Neoadjuvant chemoradiation plus PD-1 antibody(Serpluimab)
62598237|NCT00855205|EXPERIMENTAL|Treatment|Treatment with rituximab
62598238|NCT05806567|EXPERIMENTAL|Part 1|Belumosudil + UGT1A1 victim drug administered in the fed state
62598239|NCT05806567|EXPERIMENTAL|Part 2|Belumosudil + P-gp victim drug administered in the fed state
62598240|NCT05806567|EXPERIMENTAL|Part 3|Belumosudil + OATP1B1/BCRP victim drug administered in the fed state
62598241|NCT03933644|OTHER|Ambu Aura Gain TM with gastric tube|
62598242|NCT03933644|OTHER|Ambu Aura Gain TM without gastric tube|
62735270|NCT02068677|OTHER|sympathetic response|This group will be composed of subjects who experience a heart rate and/or Blood Pressure change during injection.
62735271|NCT02068677|OTHER|no sympathetic response|This group will be made up of subjects that do not experience a vital sign change with injection for CPN.
62816827|NCT05498883|OTHER|patient requiring NIV|Clinical examination, completion of the ALS-FRS score, completion of the SRI score.
62816828|NCT06404814|OTHER|Transcutaneous electrical nerve stimulation (TENS)|
62816829|NCT06404814|EXPERIMENTAL|Muscle Energt Techinique (METs)|
62816830|NCT05099770|SHAM_COMPARATOR|Sham Procedure|Participants randomized to the Sham Comparator arm will have 2 sham procedures.
62431129|NCT04379440||" At home  cohort"|Outpatients at risk of SARS-CoV-2 infection
62816831|NCT05099770|EXPERIMENTAL|Experimental (REACT injections)|Participants randomized to the experimental arm will receive 2 injections of REACT.
62038177|NCT02234674|ACTIVE_COMPARATOR|Standard intensive CDP|This arm is the controlled group ; patients in that group will undergo a current practice performed in the lymphology unit.
62038178|NCT02234674|EXPERIMENTAL|Stendo group|This arm contitutes the group where the Stendo pulsating suit sessions are investigated in the frame of the CDP in replacement of the pressotherapy sessions.
62038179|NCT02089880|EXPERIMENTAL|C-brace then stance control orthosis|
62038180|NCT02089880|EXPERIMENTAL|Stance control orthosis then C-brace|
62038181|NCT03326375|EXPERIMENTAL|SBRT (Stereotatic body radiotherapy)|Treatment of SBRT in HCC patients who have incomplete response after first TACE
62240762|NCT02805725|EXPERIMENTAL|Cohort 4: Trabectedin 0.60 mg/m2 IV + CP|"Trabectedin 0.60 mg/m2 will be administered intravenously (IV), 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks, in cohort 4 of dose escalation.~Cyclophosphamide (CP) will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.~1 cycle = 28 days"
62431130|NCT04379440||" Outcomes  cohort"|Age≥65 years as target population Hospitalised patients diagnosed with SARS-CoV-2 infection
62431131|NCT05057234|EXPERIMENTAL|Simultaneous - FoundationOne liquid CDx|Patients undergoing FoundationOne liquid CDx while tissued-based NGS panel is in progress or reported within 4 weeks of enrollment
62816832|NCT05551299|EXPERIMENTAL|Photodynamic therapy (PDT)|The index procedure in all patients at baseline includes stenting, using an endoscopic retrograde cholangio-pancreatography (ERCP) procedure. The Intervention is at least one PDT at baseline according to the clinical routine of the trial site.
62431132|NCT05057234|EXPERIMENTAL|Simultaneous - no additional testing|Patients undergoing no additional testing while tissue-based NGS panel is in progress or reported within 4 weeks of enrolment
62816833|NCT05551299|EXPERIMENTAL|Radiofrequency ablation (RFA)|The index procedure in all patients at baseline includes stenting, using an endoscopic retrograde cholangio-pancreatography (ERCP) procedure. The Intervention is at least one RFA at baseline according to the clinical routine of the trial site.
62816834|NCT06368050|NO_INTERVENTION|No Intervention|Unexposed practice group
62431133|NCT05057234|EXPERIMENTAL|Sequential - FoundationOne liquid CDx|Patients undergoing FoundationOne liquid CDx if standard tissue based NGS oncopanel testing identifies no somatic tier 1 variant of strong clinical significance
62431134|NCT03230968|NO_INTERVENTION|Phase 1 without intervention|In selected heath centers we interviewed all consenting patients older than 15 years. Before the physician consultation, we investigated sociodemographic, epidemiologic, clinical characteristics and reason for seeking health services. Immediately after consultation, we asked the patient his/her diagnoses. We confirmed all diagnoses with treating physicians. If the patient had been diagnosed with respiratory disease, we collected information on prescribed treatment, and classified the type of respiratory disease and comorbidities based on the 10th International Classification of Diseases (ICD-10). Patients were given follow up one month later.
62431135|NCT03230968|ACTIVE_COMPARATOR|Phase 2 with intervention|"We trained health personnel from the participating health centers on implementation of the proposed model based on the AIRE guidelines previously approved by the AIRE committee of the National Institute for Respiratory Diseases. The AIRE guidelines have been adapted from WHO Practical Approach to Lung Health. Once the model was in action we interviewed all consenting patients older than 15 years as in phase 1."
62816835|NCT06368050|EXPERIMENTAL|Experimental - practice structure intervention|Athletes of teams at the 12U and 13U level pilot testing the intervention program. On-field activity will be monitored with head impact sensors and video to evaluate the effectiveness of the intervention program.
62816836|NCT05615376|EXPERIMENTAL|ECG App arm|Participants will be provided with a wearable device on Day 1 and Day 4 whilst admitted in hospital.
62816837|NCT02210572|EXPERIMENTAL|Bimuno Galacto-oligosaccharide|Dietary intervention
62038182|NCT03326375|NO_INTERVENTION|TACE (Transarterial chemoembolization)|Treatment of repeated TACE in HCC patients who have incomplete response after first TACE
62038183|NCT01508468|ACTIVE_COMPARATOR|active comparator|"Non Immunosuppressive Symptomatic Treatment (NIST). No specific treatment Converting Enzyme Inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin."
62038184|NCT01508468|EXPERIMENTAL|experimental|NIST and Rituximab: 500 Mg and 100Mg in solution to be diluted for IV infusion (Mabthera®)
62038185|NCT04552964|OTHER|Single arm|This will be a single centre, single-arm, prospective pilot study.
62038186|NCT02828722|EXPERIMENTAL|Controlled light, noise and nutrition|Simultaneously with the standard treatment performed at the clinical trial site environmental simulation of night time and daytime alternation as well as the nutrition protocol corresponding to the daily rhythm will be applied.
62038187|NCT02828722|EXPERIMENTAL|Controlled light and noise|Simultaneously with the standard treatment performed at the clinical trial site environmental simulation of night time and daytime alternation as well as the continuous nutrition (in accordance with the clinical trial site's standard practice) will be applied.
62038188|NCT02828722|NO_INTERVENTION|Control|The treatment of the study subject will be performed based on the clinical trial site's standard practice without environmental simulation or changes in the nutrition protocol.
62038189|NCT03468010|ACTIVE_COMPARATOR|The control group (Group A)|In Group A, observation is given after chemoradiation
62598243|NCT06138002|EXPERIMENTAL|Test Intervention arm|"The LumbaCure® is a robotic system which provide active, specific and controlled mobilization of the low back. The device is to be used by the Physiotherapist at the rehabilitation centre. The duration of a session for the patient is 15 minutes.~Patients follow a serie of 12 consecutive LumbaCure® sessions at a frequency of 3 sessions / week for 4 weeks."
62598244|NCT06138002|ACTIVE_COMPARATOR|Control Intervention arm|"A set of core stability exercises/active qualitative mobilization has been defined with principal investigator according to the standard of care at Investigator site. At each session, 5 exercises will be selected by the investigator depending on the evolution and pathology of the patient. Five minutes of warm-up will be performed before starting the exercises session.~The program will last 15 to 30 min depending on the time required for the patient to complete the prescribed exercises.~Patients follow a serie of 12 consecutive physical exercises sessions at a frequency of 3 sessions / week for 4 weeks."
62240763|NCT02805725|EXPERIMENTAL|Phase II: Trabectedin 0.50 mg/m2 IV + CP|"Trabectedin 0.50 mg/m2 will be administered intravenously (IV), 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks, in the phase II part of the study.~Cyclophosphamide (CP) will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.~1 cycle = 28 days"
62240764|NCT04195581|EXPERIMENTAL|comfilcon A with Hy-Care Multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
62598245|NCT01136889|ACTIVE_COMPARATOR|PFMT plus routine pessary management|"Women allocated to the intervention group will be invited to attend 5 out-patient appointments over a 16 week period with a trained specialist women's health physiotherapist at the study centre. Women will be taught how to contract the muscles, and also how to contract and hold prior to an event that increases intra-abdominal pressure (the Knack). Tailored advice will be given on ways of reducing intra-abdominal pressure, e.g. advice on weight loss, chronic cough, heavy lifting and general exercise. A prolapse specific Lifestyle Advice sheet will also be given to the women by the physiotherapist."
62240765|NCT04195581|EXPERIMENTAL|comfilcon A with All in One Light Multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
62816838|NCT02210572|PLACEBO_COMPARATOR|Low- FODMAPs diet|Dietary intervention
62240766|NCT04195581|EXPERIMENTAL|comfilcon A with Refine One Step Hydrogen Peroxide Solution|Subjects were randomized to wear each lens and solution combination for a month.
62735272|NCT00828802|EXPERIMENTAL|Cohort 1|Lenalidomide (5mg) and Decitabine
62816839|NCT05003401|EXPERIMENTAL|HabitAware Keen 2|Participants will receive the wrist device device that alerts the participant when the participant is engaging in hair pulling behavior.
62240767|NCT04195581|ACTIVE_COMPARATOR|fanfilcon A with Hy-Care Multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
62240768|NCT04195581|ACTIVE_COMPARATOR|fanfilcon A with All in One Light multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
62240769|NCT04195581|ACTIVE_COMPARATOR|fanfilcon A with Refine One Step Hydrogen Peroxide Solution|Subjects were randomized to wear each lens and solution combination for a month.
62240770|NCT02970734|EXPERIMENTAL|Breathe|6 sessions of Internet-based cognitive behavioural therapy (CBT) with limited telephone and e-mail support
62735273|NCT00828802|EXPERIMENTAL|Cohort 2|Lenalidomide (10 mg) and Decitabine
62735274|NCT00828802|EXPERIMENTAL|Cohort 3|Lenalidomide (15 mg) and Decitabine
62816840|NCT04505059|EXPERIMENTAL|Precision cardiac anesthesia|Remifentanil (TCI) for intra-operative analgesia Propofol (TCI) for intra-operative sedation
62816841|NCT04505059|ACTIVE_COMPARATOR|Conventional cardiac anesthesia|Institutional standard of care.
62240771|NCT02970734|ACTIVE_COMPARATOR|Resource webpage|Webpage that provides general resources on anxiety
62240772|NCT00691886|NO_INTERVENTION|1|Subjects randomized to arm 1 of the study will recieve standard of care conscious sedation for EBUS; midasolam and or fentanyl.
62240773|NCT00691886|ACTIVE_COMPARATOR|2|Subjects undergoing EBUS randomized to arm 2 of the study will recieve demedetomadine hydrochloride plus standard of care conscious sedation
62240774|NCT00800423|EXPERIMENTAL|brimonidine|"50 patients receiving Brimonidine Tartrate drops in the operated eye: 1 drop X2 a day for 1 month.~they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)"
62240775|NCT00800423|ACTIVE_COMPARATOR|2 tmolol|"50 patients receiving timolol maleate 0.5% drops in the operated eye~1 drop X2 a day for 1 month. they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)"
62240776|NCT00800423|NO_INTERVENTION|3|50 patients will not receive any additional drug to the usual medications after cataract surgery (corticosteroids and antibiotics drops)
62240777|NCT02183922|PLACEBO_COMPARATOR|light fruit jam|The placebo group received light fruit jam (15 g/day) during 12 weeks.
62240778|NCT02183922|EXPERIMENTAL|microencapsulated fish oil|The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.
62431136|NCT04663269|OTHER|Control|Standard Care Protocol - peritubal block standard local analgesic administration in the form of a peritubal block
62735275|NCT00828802|EXPERIMENTAL|Cohort 4|Lenalidomide (20 mg) and Decitabine
62816842|NCT05943964|EXPERIMENTAL|Virtual exercise and rehabilitation program|Trial of exercise and rehabilitation program delivered via a virtual platform for patients undergoing HCT at Children's Healthcare of Atlanta.
62816843|NCT00704015|EXPERIMENTAL|A|Smoking cessation
62816844|NCT00704015|NO_INTERVENTION|B|
62240779|NCT02183922|EXPERIMENTAL|microencapsulated conjugated linoleic acid|The microencapsulated conjugated linoleic acid group received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.
62240780|NCT06470412|ACTIVE_COMPARATOR|Control Group|
62240781|NCT06470412|EXPERIMENTAL|AI-Guided Group|
62240782|NCT02536755|EXPERIMENTAL|Eliglustat|Participants who completed one of the Phase 2 (GZGD00304 \[NCT00358150\]) or Phase 3 studies (GZGD02507 \[NCT00891202\], GZGD02607 \[NCT00943111\], or GZGD03109 \[NCT01074944\]) were enrolled in this current (EFC13781) study. Participants who were cytochrome P450 (CYP) 2D6 intermediate metabolizer (IM), extensive metabolizer (EM) and ultra-rapid metabolizers (URM) received eliglustat 84 milligrams (mg) twice daily and participants who were CYP2D6 poor metabolizer (PM) received eliglustat 84 mg once daily, for duration of minimum 2 years (unless early discontinuation occurred) and up to 4 years, or until commercial eliglustat was available to participants through reimbursement or through the compassionate use (expanded access) program.
62240783|NCT02962544|ACTIVE_COMPARATOR|Visumax device for FS-SMILE group|(FS-SMILE )femtosecond small incision lenticule extraction procedure using Visumax laser device as a surgical intervention for correction of myopia and myopic astigmatism will be done for 30 eyes of patients with myopia or myopic astigmatism.
62598246|NCT01136889|ACTIVE_COMPARATOR|Lifestyle|Women allocated to the control group will be sent a Lifestyle Advice Leaflet only. They will have no planned intervention after their pessary is fitted, other than routine pessary management according to local protocols. The Lifestyle Advice Leaflet gives instructions on seeking advice, where appropriate, about weight loss, constipation, and avoidance of heavy lifting, coughing and high impact exercise, with a view to minimising increases in intra-abdominal pressure which may cause the prolapse to worsen.
62598247|NCT01276522|EXPERIMENTAL|Canakinumab|A 6-month open-label, single treatment arm study of canakinumab 150 or 300 mg (in case of insufficient response to 150 mg) subcutaneous injection once per month.
62598248|NCT06385340|OTHER|Lipikar Baume AP+M|Application of Lipikar Baume AP+M at least twice daily for 4 weeks on one of the two arms according to a randomization scheme
62598249|NCT06385340|NO_INTERVENTION|no intervention|Application of Lipikar Baume AP+M at least twice daily for 4 weeks on one of the two arms according to a randomization scheme
62598250|NCT05814536|EXPERIMENTAL|AB-218|AB-218 for the treatment of adult patients with advanced cholangiocarcinoma, chondrosarcoma and other solid tumors with IDH1 mutation.
62240784|NCT02962544|ACTIVE_COMPARATOR|FS 200 device for FS-LASIK group|(FS-LASIK)femtosecond assisted LASIK procedure using Fs200 laser device as a surgical intervention for correction of myopia and myopic astigmatism will be done for 30 eyes of patients with myopia or myopic astigmatism.
62240785|NCT02354313|EXPERIMENTAL|Lenalidomide|lenalidomide 10-15 mg once daily on days 1-21, every 28 day, for two years
62598251|NCT04867993|ACTIVE_COMPARATOR|asphyxiated neonates treated with amikacin and hypothermia|Amikacin (Likacin®; 500 mg/2mL vial; Lisapharma S.p.A., Erba, Italy) is given to the neonate, as an IV infusion via umbilical vein over 20 min by use of a syringe-pump (Braun; B. Braun Medical Inc., Bethlehem, PA USA). Infusion is followed by slow 0.5 mL Sodium chloride 0.9% flush.
62598252|NCT04867993|PLACEBO_COMPARATOR|asphyxiated neonates treated with amikacin|Amikacin (Likacin®; 500m g/2mL vial; Lisapharma S.p.A., Erba, Italy) is given to the neonate, as an IV infusion via umbilical vein over 20 min by use of a syringe-pump (Braun; B. Braun Medical Inc., Bethlehem, PA USA). Infusion is followed by slow 0.5 mL Sodium chloride 0.9% flush.
62240786|NCT02354313|NO_INTERVENTION|Observation|no therapy is planned but only observation
62431137|NCT04663269|EXPERIMENTAL|ANES Block|Patients randomized to the erector spinae block (Group 2) will have the block placed in the preoperative area by the anesthesia team. 0-4 mg midazolam and/or 0-100 mcg of fentanyl may be provided prior to and in order to place the block itself. The local anesthetic will diffuse to involve the dorsal and ventral rami of the spinal nerves, achieving a sensory block of the affected area. The erector spinae block analgesic will be administered by the anesthesia team. The analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone.
62431138|NCT02717338|EXPERIMENTAL|Competence|Participants will be assigned to review our donor coping website.
62598253|NCT02893553|EXPERIMENTAL|Study 1|Study 1: is a dose escalation to determine the individualized dose of each of 3 medications (midodrine, pyridostigmine, mirabegron) that increases SBP into the normal range (111-139 mmHg). The investigator will be using midodrine hydrochloride, pyridostigmine bromide and mirabegron.
62598254|NCT02893553|EXPERIMENTAL|Study 2|Study2: is a randomized placebo-controlled double-blinded investigation to determine the effect of the normalization of SBP on cerebral blood flow, cognitive function (memory and attention processing) and quality of life. The investigator will be using midodrine hydrochloride, pyridostigmine bromide, mirabegron and placebo.
62598255|NCT02838836||Study sample collection|Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery
62598256|NCT03937401|EXPERIMENTAL|Patients treated with oxytocin during MRI-HIFU|
62038190|NCT03468010|EXPERIMENTAL|The experiment group (Group B)|in Group B, three cycles of Paclitaxel, Cisplatin are administered after radiation with concurrent cisplatin. The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel 135mg/m2 plus Cisplatin 60mg/m2 once 3 weeks.
62038191|NCT04986176|EXPERIMENTAL|HC-1119 + Usual Care|4 (40mg) soft gel capsule, 160 mg total
62038192|NCT04986176|PLACEBO_COMPARATOR|Placebo + Usual Care|4 soft gel capsule
62598257|NCT00664859|EXPERIMENTAL|Single|Open-label LCP-AtorFen
62038193|NCT01967732|ACTIVE_COMPARATOR|THS 2.2 then CC|"Each subject will follow the below study design:~* Day 0 = Wash-out (1 day)~* Day 1 = 1st intervention (single product use of THS 2.2)~* Day 2 = wash-out~* Day 3 = 2nd intervention (single product use of CC)."
62038194|NCT01967732|ACTIVE_COMPARATOR|CC then THS 2.2|"Each subject will follow the below study design:~* Day 0 = Wash-out (1 day)~* Day 1 = 1st intervention (single product use of CC)~* Day 2 = wash-out~* Day 3 = 2nd intervention (single product use of THS 2.2)."
62038195|NCT01967732|ACTIVE_COMPARATOR|THS 2.2 then NNS|"Each subject will follow the below study design:~* Day 0 = Wash-out (1 day)~* Day 1 = 1st intervention (single product use of THS 2.2)~* Day 2 = wash-out~* Day 3 = 2nd intervention (single administration of NNS)"
62038196|NCT01967732|ACTIVE_COMPARATOR|NNS then THS 2.2|"Each subject will follow the below study design:~* Day 0 = Wash-out (1 day)~* Day 1 = 1st intervention (single administration of NNS)~* Day 2 = wash-out~* Day 3 = 2nd intervention (single product use of THS 2.2)."
62431139|NCT02717338|EXPERIMENTAL|Autonomy|Participants will be assigned to receive a brief telephone interview.
62431140|NCT02717338|EXPERIMENTAL|Relatedness|Participants will be asked to join a closed Facebook group for one month.
62816845|NCT05640830|EXPERIMENTAL|TREAZURE|This is a single arm study. Trastuzumab has been administered at 6 mg/kg every 3 weeks after initial loading of 8 mg/kg during the first anticancer treatment, so in the second anticancer treatment, 4 mg/kg is administered every 2 weeks to maintain the same concentration. Bevacizumab is administered at 5 mg/kg at 2-weekly intervals used in metastatic colorectal cancer. Paclitaxel is administered on a standard schedule of 80 mg/m2 for 3 consecutive weeks followed by a 1-week break as an existing weekly regimen, and when side effects occur, the weekly dose is reduced by 25% to 60 mg/m2 for 3 weeks or administered every 2 weeks. Administer 80 mg/m2. Administration of this drug is set as one cycle of 4 weeks.
62038197|NCT05366777|EXPERIMENTAL|Maxigesic group|At the end of induction, the Maxigesic group will receive intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) for 15 min, every 6 hours, a total of 4 times.
62431141|NCT02717338|EXPERIMENTAL|Competence + Autonomy|Participants will be assigned to the web site review, followed by the brief telephone interview.
62431142|NCT02717338|EXPERIMENTAL|Competence + Relatedness|Participants will be assigned to the web site review, followed by the one-month Facebook group membership.
62598258|NCT03687372|EXPERIMENTAL|A-101|topical solution
62598259|NCT03687372|OTHER|Vehicle|topical solution
62240787|NCT04956042|EXPERIMENTAL|Cohort 1 - Fosciclopirox only|An initial 14 study participants will be enrolled in Cohort 1a and will be treated with fosciclopirox. If there is a disease response, an additional 14 study participants will be enrolled into Cohort 1 (Cohort 1b).
62240788|NCT04956042|EXPERIMENTAL|Cohort 2 - Fosciclopirox + Cytarabine|To be implemented if a disease response is not seen in Cohort 1a. Cohort 2a will have an initial 14 study participants treated with fosciclopirox and cytarabine. If a disease response is seen, an additional 14 study participants will be enrolled (Cohort 2b).
62240789|NCT00170612|EXPERIMENTAL|A|PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 18 months
62240790|NCT00170612|EXPERIMENTAL|B|PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 12 months and 18 months
62240791|NCT00170612|EXPERIMENTAL|C|PCV at 6 weeks and 14 weeks; PPS at 18 months
62240792|NCT00170612|EXPERIMENTAL|D|PCV at 6 weeks and 14 weeks; PPS at 12 months and 18 months
62598260|NCT02536118||Patients implanted with Micra System|Patients implanted with a Micra Transcatheter Pacing System are eligible for enrollment into the Micra PA Registry.
62598261|NCT06043479|EXPERIMENTAL|Intervention group|The mothers were provided with a three-day training consisting of six sessions. Two sessions were held each day, with each session lasting for 30 minutes.
62816846|NCT06639594|EXPERIMENTAL|Intermittent theta burst stimulation|Participants undergo rTMS once a week for 2 weeks. In week 1 participants receive continuous theta burst stimulation (cTBS) for 3 sessions; in week 2 participants receive intermittent theta burst stimulation (iTBS) for 3 sessions. Additionally, participants complete cued food delivery task assessment and undergo saliva sample collection on study.
62240793|NCT00170612|EXPERIMENTAL|E|PCV at 14 weeks; PPS at 18 months
62240794|NCT00170612|EXPERIMENTAL|F|PCV at 14 weeks; PPS at 12 months and 18 months
62240795|NCT00170612|EXPERIMENTAL|G|No PCV; PPS at 12 months and 18 months
62240796|NCT00170612|ACTIVE_COMPARATOR|H|No PCV; PPS at 18 months
62240797|NCT04604678|EXPERIMENTAL|Treatment with Metformin and LDN|Patients will be treated with 1500 mg/day of metformin and 4.5 mg/day of LDN for a total of 4 weeks.
62431143|NCT02717338|EXPERIMENTAL|Autonomy + Relatedness|Participants will be assigned to the brief telephone interview, followed by the one-month Facebook group membership.
62240798|NCT04604678|NO_INTERVENTION|Regular health care comparison group|Patients will receive regular health care and will serve as a control group.
62240799|NCT02220309||Anxiety and mood disorders|
62240800|NCT04273256|EXPERIMENTAL|Myo-inositol arm|Patients will be supplemented with 2 grams of Myo-inositol + at least 400 μg of folic acid (received from routinely prescribed multivitamins) every day for 3 months before the IVF cycle.
62431144|NCT02717338|EXPERIMENTAL|Competence + Autonomy + Relatedness|Participants will be assigned to the web site review, brief telephone interview, and one-month Facebook group membership.
62816847|NCT06639594|EXPERIMENTAL|Continuous theta burst stimulation|Participants undergo rTMS once a week for 2 weeks. In week 1 participants receive continuous theta burst stimulation (cTBS) for 3 sessions; in week 2 participants receive intermittent theta burst stimulation (iTBS) for 3 sessions. Additionally, participants complete cued food delivery task assessment and undergo saliva sample collection on study.
62240801|NCT04273256|NO_INTERVENTION|Control arm|Patients will receive at least 400 μg of folic acid from routinely prescribed multivitamins every day for 3 months before the IVF cycle.
62240802|NCT01245634|EXPERIMENTAL|A|
62240803|NCT01245634|PLACEBO_COMPARATOR|B|
62240804|NCT01176968|EXPERIMENTAL|Eplerenone plus standard of care|
62240805|NCT01176968|PLACEBO_COMPARATOR|Placebo plus standard of care|Matching placebo for eplerenone 25mg film coated tablets.
62240806|NCT00438321|PLACEBO_COMPARATOR|Placebo|Placebo injection, gel and pill
62240807|NCT00438321|ACTIVE_COMPARATOR|Testosterone only|Zoladex 3.6 mg IM injection Testosterone 7.5 g gel (AndroGel) transdermally daily Anastrozole 10 mg (Arimidex) orally daily
62240808|NCT00438321|ACTIVE_COMPARATOR|Testosterone and Estrogen|Zoladex 3.6 mg IM injection Testosterone 7.5 g gel (AndroGel) transdermally Placebo pill orally daily
62431145|NCT02717338|NO_INTERVENTION|Treatment-as-Usual Control|Participants will receive the standard communications that New York Blood Center has with all first-time donors.
62240809|NCT03909204|OTHER|LAPEC|Patients with cecal percutaneous catheter placement.
62240810|NCT04746378||extracorporeal shockwave lithotripsy|Patients that are included in the study and undergo a shockwave lithotripsy. The pre- and postoperative assessment remains the same across groups
62240811|NCT04746378||uretero(reno)scopy|Patients that are included in the study and undergo a semirigid or flexible uretero(reno)scopy. The pre- and postoperative assessment remains the same across groups
62598262|NCT06043479|NO_INTERVENTION|Control group|Routine practices continued for the mothers for three days without providing any training.
62598263|NCT04482660|EXPERIMENTAL|PET|
62598264|NCT03576755|EXPERIMENTAL|spironolactone|spironolactone, 100 mg capsule administered orally once daily for 6 or 12 months
62598265|NCT03576755|PLACEBO_COMPARATOR|placebo|matching placebo capsule administered orally once daily for 6 or 12 months
62598266|NCT02715700|EXPERIMENTAL|Maintenance Methadone and MK-1439|Participants maintained on a stable methadone regimen (20 to 200 mg once daily) for ≥14 days prior to Day 1 will continue to receive methadone maintenance once per day on Days 1 to 7. From Day 2 to 6, participants will also receive doravirine 100 mg once daily.
62598267|NCT06648733|EXPERIMENTAL|Prospective patients|Current palliative care patients who are discharged from the University Hospital to outpatient palliative care.
62598268|NCT06648733|NO_INTERVENTION|Retrospective patients|Former palliative care patients who were discharged from the university hospital to outpatient palliative care.
62735276|NCT00828802|EXPERIMENTAL|Cohort 5|Lenalidomide (25 mg) and Decitabine
62735277|NCT01505478||Patients admitted with infection|All consecutive ED patients during the study period that have been admitted and identified to have a suspected infection at ED disposition using a data collection tool
62598269|NCT03887507|EXPERIMENTAL|Experimental|There will be 3 Vojta therapy sessions conducted on 2 consecutive weeks with an interval of 7 dayssessions, on 1st, 7th and 14th days. Each session will consist of a 45-minute Vojta thera between py protocol based on three exercises, 15 minutes per exercise: Crawling Réflex, and 1st phase and 2nd phase Rolling reflex. The relative or close person will be instructed to carry out an exercise protocol to do at home every day for 20 minutes during the 2-week study. All interventions will be made by the principal investigator.
62038198|NCT05366777|PLACEBO_COMPARATOR|Control group|At the end of induction, the control group will receive intravenous normal saline with the same volume and same time points as the intervention group receives.
62038199|NCT06200766|EXPERIMENTAL|Momethasone furoate nasal spray (trade name: Yiqing®/ Yiqing®)|Dosage form: nasal spray Specification: 60 press per bottle, 50 µ g of mometasone furoate, drug concentration: 0.05% (g / g) Route of administration: nasal injection Storage: 2℃ \~25℃ storage Manufacturer: Zhejiang Xianju Pharmaceutical Co., Ltd Specific administration method: 2 snap (50 µ g per snap), total 4 snap (total 200 µ g), 1 time / day.
62598270|NCT03887507|ACTIVE_COMPARATOR|Standard Therapy|The standard group shall perform 4 sessions of physiotherapy in the same period for two consecutive weeks, with one hour per session in its specialized MS association, on 1st, 3rd, 8th, 10th and 15th days. This will be applied by experienced physiotherapists during the treatment of people with MS. The program will consist in balance exercises targeting core stability, exercises of coordination and Pilates as well as individual sessions using the Bobath concept. Patients in this group will walk at least for 20 minutes per day during the study period.
62598271|NCT03376451|OTHER|Patients in EndoSearch|EndoSearch will conduct on only one cohort divided in two groups : patients affected by endometriosis and patient unaffected (controls). All of these patients need a laparoscopic surgery for endometriosis indication (endometriosis group) or another indication which is not endometriosis (controls). However, nothing in the surgery or the patient medical care will be different between the two groups : patients will be treated exactly the same.
62038200|NCT06200766|ACTIVE_COMPARATOR|Momethasone furoate nasal spray (trade name: Nasonex ®/ Nasonex ®)|Dosage form: nasal spray Specification: 60 press per bottle, 50 µ g of mometasone furoate, drug concentration: 0.05% (g / g) Route of administration: nasal injection Storage: 2℃ \~25℃ storage Holder manufacturer: MSD Belgium BVBA / SPRL Specific administration method: 2 presses (50 per side nostril µ g per snap), total 4 presses (total 200 µ g), One time / day
62038201|NCT06200766|PLACEBO_COMPARATOR|placebo|Dosage form: nasal spray Specification: 60 press per bottle Route of administration: nasal injection Storage: 2℃ \~25℃ storage Manufacturer: Zhejiang Xianju Pharmaceutical Co., Ltd Specific administration method: 2 presses (50 per side nostril µ g per snap), total 4 presses (total 200 µ g), One time / day
62038202|NCT02137161|ACTIVE_COMPARATOR|Dexamethasone+Tobramycin eye drop|An antibiotic and steroid eye drop association will be given starting the day after the surgery for two weeks, dosed QID for the first week and BID for the second week, to 31 patients.
62240812|NCT04746378||percutaneous nephrolithotomy|Patients that are included in the study and undergo a percutaneous nephrolithotomy. The pre- and postoperative assessment remains the same across groups
62240813|NCT06425276|EXPERIMENTAL|High-dose Melphalan HCl for Injection treatment arm|Patients will receive Melphalan HCl for Injection dosed at 100 mg/m2 on Day -3 and Day -2. Following 1 day of rest after the myeloablative conditioning (Day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (Day 0).
62240814|NCT04825769|EXPERIMENTAL|Intervention|Red light irradiation was conducted at school from Monday to Friday and at home everyday in summer and winter holiday twice a day for 3 minutes per time, with an interval of 4 hours
62240815|NCT04825769|NO_INTERVENTION|Control|No intervention
62240816|NCT04603664||study group|blood sampling and measduring of serum NGAL and cystatin c on admission and after 48 hours and creatinine every day
62240817|NCT03982342|ACTIVE_COMPARATOR|Catheter-closure of PDA|Infants randomized to this group will undergo a catheter procedure to close hemodynamically-significant patent ductus arteriosus (HSPDA).
62598272|NCT03476174|EXPERIMENTAL|Pembrolizumab and HD Interleukin 2|Pembrolizumab 200 mg IV over 30 minutes; Day 1 of each cycle 3 weeks (21 days) for 2 cycles. IL-2 600,000 IU/kg2 IV over 15 minutes every 8 hours for up to 14 doses over 5 days; Days 1-5 = Cycle 1; 9 days of rest in between; Days 15-19 = Cycle 2
62598273|NCT06421675|EXPERIMENTAL|Elranatamab injection|The administration of two step-up elranatamab doses (12 mg and 32 mg) and full dose 76 mg. The dosing interval for the first 6 cycles (each cycle q28 days) is every week, cycles 7-12 are bi-weekly. The dosing interval will increase to q4 weeks (cycle 13+) according to IMWG dose-response criteria of \>= VGPR. Further dosing interval increase to q8weeks (cycles 19+) will be done among participants based on response criteria IMWG of \>= CR.
62598274|NCT06623929||Group E|Group E, Etofenamate spray 100 mg/ml (Flexo 100 mg/ml-Kocaeli) is applied to the painful area from a distance of approximately 10-15 cm in a maximum of 7 puffs. Each puff contains 18 mg etofenamate.
62598275|NCT06623929||Group D|Group D Diclofenac diethylammonium 1% spray (Painout Ice 1%-Ankara) was applied to the painful area from a distance of approximately 10-15 cm in a maximum of 6 puffs. Each puff contained 5.8 mg diclofenac diethylammonium.
62240818|NCT03982342|ACTIVE_COMPARATOR|Conservative management of PDA|"Infants randomized to this group will be treated to reduce the symptoms of a hemodynamically-significant patent ductus arteriosus (HSPDA), in the hopes that over time the HSPDA will become reduced in size (to the point of no longer meeting criteria for being hemodynamically significant) or close naturally. Infants in this group with declining health status attributable to a PDA which meet qualifying criteria may receive catheter closure (intervention) if deemed medically necessary."
62240819|NCT00565383|ACTIVE_COMPARATOR|Intravenous fentanyl analgesia|Intravenous fentanyl (50 mcg) analgesia
62240820|NCT00565383|EXPERIMENTAL|Combined spinal-epidural analgesia|Combined spinal-epidural analgesia (intrathecal fentanyl 2.5 mg plus bupivacaine 2.5 mg) single administration
62240821|NCT04923048|EXPERIMENTAL|GB261|Participants will receive GB261 via intravenous (IV) infusion as a single agent on Day 1, Day 8 and Day 15 of Cycle 1 and 2 followed by Day 1 of each cycle（21 days per cycle） afterwards until disease progression or other situations specified in the protocol, whichever comes earlier.
62240822|NCT06219070|EXPERIMENTAL|Experimental group|The experimental group will undergo 60 minutes of Core Training.
62240823|NCT06219070|NO_INTERVENTION|Control group|The control group will follow the curriculum standards set by the Sports University.
62240824|NCT00665743|EXPERIMENTAL|A|PN400 (naproxen/esomeprazole)
62240825|NCT00665743|ACTIVE_COMPARATOR|B|naproxen 500 mg
62240826|NCT00665743|ACTIVE_COMPARATOR|C|naproxen 500 mg
62240827|NCT05757115|EXPERIMENTAL|Intervention Group|It is the group to which individualized training will be applied to develop play skills.
62240828|NCT03696615|EXPERIMENTAL|Tabata Kettlebell Swings|"Participants in this group performed:~1. A brief dynamic warm-up (10 clockwise and counterclockwise arm circles, 10 horizontal arm swings, and 15 air squats)~2. Receive instruction on the kettlebell swing~3. Performed a high-intensity workout in a Tabata Kettlebell Swings format, which involves 20 seconds of all out effort followed by 10 seconds of rest, repeated for a total of 8 times."
62816848|NCT02300207|NO_INTERVENTION|Control group|Subjects were in a resting, flat, head-down position -6° from the horizontal. The entire bed rest period was composed of the 4-day head-down bed rest and 2-day period of data collection (before and after the bed rest period). During all of these periods, there was intensive care monitoring. All dining, washing, urination, and defecation were carried out in the bedridden state. Changing position around the body axis was permitted. Dietary intake was 2300-2500 kcal/day, and water intake was 1.0-1.5 L/day. Urine samples (24 h) were collected every day throughout the study. Body weight, heart rate (HR), and blood pressure (BP) were measured in the morning before breakfast.
62240829|NCT03696615|ACTIVE_COMPARATOR|Control Group|"Participants in this group performed:~1. A brief dynamic warm-up (10 clockwise and counterclockwise arm circles, 10 horizontal arm swings, and 15 air squats)"
62240830|NCT04469166|ACTIVE_COMPARATOR|Tourniquet|Group of tourniquet
62240831|NCT04469166|ACTIVE_COMPARATOR|No tourniquet|Group of no tourniquet
62240832|NCT01557348||Rituximab|Eligible participants will receive rituximab as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
62240833|NCT01557348||Alternative TNFi|Eligible participants will receive alternative TNFi treatment as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
62240834|NCT04637698|EXPERIMENTAL|Dose expansion|OH2 injection will be administered at 1E+07 CCID50/mL .
62240835|NCT05638750|EXPERIMENTAL|Intervention|Participants will participate in the rehabilitation intervention.
62240836|NCT05619978||3L+ Cohort|Patients who initiated third-line treatment (3L) therapy. Treatments received in 3L were dasatinib, nilotinib, imatinib, ponatinib, bosutinib, and allo-SCT
62240837|NCT05619978||T315I cohort|Patients with chronic myeloid leukemia with T315I mutation
62240838|NCT05761223|EXPERIMENTAL|Phase Ia dose-escalation part of FB849 Monotherapy|Participations will receive FB849 orally once a day.
62240839|NCT05761223|EXPERIMENTAL|Phase Ib dose-expansion of FB849 monotherapy|Participations will receive FB849 orally once a day.
62240840|NCT05761223|EXPERIMENTAL|Phase IIa dose-escalation part of FB849 in Combination with Pembrolizumab|Participations will receive FB849 orally once a day in combination with pembrolizumab.
62240841|NCT05761223|EXPERIMENTAL|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)|Participations will receive FB849 orally once a day in combination with pembrolizumab.
62240842|NCT05761223|EXPERIMENTAL|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)|Participations will receive FB849 orally once a day in combination with pembrolizumab.
62240843|NCT05761223|EXPERIMENTAL|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)|Participations will receive FB849 orally once a day in combination with pembrolizumab.
62240844|NCT02336763|EXPERIMENTAL|Treatment (external beam radiation therapy)|Patients undergo external beam radiation therapy daily over 20 minutes on Monday-Friday for up to 10 fractions over approximately 2 weeks.
62240845|NCT05867459||CKD PREGNANT PATIENT|The Group of pregnant CKD PT as mentioned in introduction and according to KIDOG definition of CKD regardless cause of CKD
62240846|NCT03937284||Parkinson's patients|Patients with Parkinson disease evaluated in agreement with UK Brain Bank criteria
62240847|NCT03937284||Control group|Subject matched for sex, age and BMI
62240848|NCT04437160|EXPERIMENTAL|Adjuvant chemotherapy|"Adjuvant chemotherapy for triple negative breast cancer with residual invasive disease (invasive breast tumor size≥1cm and/or positive axillary lymph nodes) after taxanes and platinum based neoadjuvant chemotherapy.~Adjuvant chemotherapy regiments: Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV + Cyclophosphamide 600mg/m2 IV, q21d\*4cycles."
62240849|NCT04437160|NO_INTERVENTION|Observation|No adjuvant chemotherapy for triple negative breast cancer with residual invasive disease (invasive breast tumor size≥1cm and/or positive axillary lymph nodes) after taxanes and platinum based neoadjuvant chemotherapy.
62240850|NCT05282277|EXPERIMENTAL|Perimenopausal women with mild-to-moderate anhedonia + absent-to-mild psychosis, active group|Participants will be randomly assigned to take 100 μg/day of transdermal estradiol for 3 weeks followed by 1 week of combined 100 μg/day of transdermal estradiol and 200 mg/day progesterone.
62240851|NCT05282277|EXPERIMENTAL|Perimenopausal women with mild-to-moderate anhedonia + absent-to-mild psychosis, placebo group|Participants will be randomly assigned to receive a matching placebo patch for 3 weeks.
62598276|NCT01292421|PLACEBO_COMPARATOR|Arm I|Participants consume placebo HBV-EPV on days 0, 14, 28, and 56.
62598277|NCT01292421|EXPERIMENTAL|Arm II|Participants consume HBV-EPV expressing HBsAg on days 0 and 28 and placebo HBV-EPV on days 14 and 56.
62598278|NCT01292421|EXPERIMENTAL|Arm III|Participants consume HBV-EPV expressing HBsAg on days 0, 28, and 56 and placebo HBV-EPV on day 14.
62598279|NCT01292421|EXPERIMENTAL|Arm IV|Participants consume HBV-EPV expressing HBsAg on days 0, 14, 28, and 56.
62816849|NCT02300207|EXPERIMENTAL|Electroacupuncture group|During the bed rest phase, subjects in the Electroacupuncture(EA) groups received 30 min of EA treatment, while subjects in the Con group did not receive any treatment.EA was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms. The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
62816850|NCT04880980|ACTIVE_COMPARATOR|Efficacy of double dose oral terbinafine in treatment of dermatophytic infections of skin|This group of participants will be given double than usual dose of oral terbinafine for the treatment of dermatophyte skin infections.
62816851|NCT04880980|ACTIVE_COMPARATOR|Efficacy of double dose oral itraconazole in treatment of dermatophytic infections of skin|This group of participants will be given double than usual dose of oral itraconazole for the treatment of dermatophyte skin infections
62038203|NCT02137161|EXPERIMENTAL|Bromfenac|Bromfenac eye drops (BID for two weeks starting the day after surgery) plus an antibiotic and steroid eye drop association (QID for the first week and BID for the second week) will be given concurrently to 31 patients.
62038204|NCT01435083|EXPERIMENTAL|nocturnal polyuria patient with desmopressin MELT|
62038205|NCT03832595|ACTIVE_COMPARATOR|Usual care|Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).
62240852|NCT05282277|EXPERIMENTAL|Perimenopausal women with mild-to-moderate anhedonia + moderate psychosis, active group|Participants will be randomly assigned to take 100 μg/day of transdermal estradiol for 3 weeks followed by 1 week of combined 100 μg/day of transdermal estradiol and 200 mg/day progesterone.
62240853|NCT05282277|EXPERIMENTAL|Perimenopausal women with mild-to-moderate anhedonia + moderate psychosis, placebo group|Participants will be randomly assigned to receive a matching placebo patch for 3 weeks.
62240854|NCT05282277|EXPERIMENTAL|Perimenopausal women with high anhedonia + absent-to-mild psychosis, active group|Participants will be randomly assigned to take 100 μg/day of transdermal estradiol for 3 weeks followed by 1 week of combined 100 μg/day of transdermal estradiol and 200 mg/day progesterone.
62240855|NCT05282277|EXPERIMENTAL|Perimenopausal women with high anhedonia + absent-to-mild psychosis, placebo group|Participants will be randomly assigned to receive a matching placebo patch for 3 weeks.
62038206|NCT03832595|EXPERIMENTAL|Intervention Arm|Patients will receive a care bundle
62240856|NCT05282277|EXPERIMENTAL|Perimenopausal women with high anhedonia + moderate psychosis, active group|Participants will be randomly assigned to take 100 μg/day of transdermal estradiol for 3 weeks followed by 1 week of combined 100 μg/day of transdermal estradiol and 200 mg/day progesterone.
62240857|NCT05282277|EXPERIMENTAL|Perimenopausal women with high anhedonia + moderate psychosis, placebo group|Participants will be randomly assigned to receive a matching placebo patch for 3 weeks.
62598280|NCT04761549|OTHER|Adolescent Idiopathic Scoliosis|Questionnaires, Radiological EOS scan, 3D Dynamic Motion analysis
62598281|NCT02581475|ACTIVE_COMPARATOR|Group A|"Extending withdrawal time in the proximal colon: After cecal intubation, the colonoscopy is withdrawn to the hepatic flexure and then to the splenic flexure with an extended withdrawal time during colonoscopy.~From cecum to hepatic flexure, 1.5-2 min is required and 2.5-3 min is required from heptic flexure to splenic flexure."
62598282|NCT02581475|EXPERIMENTAL|Group B|Segmental examination twice of the proximal colon: After cecal intubation, the colonoscopy is withdrawn to the hepatic flexure and then the colonoscopy is intubated to the cecum again. The same procedure is performed in the colonic segment from hepatic flexure to splenic flexure. The withdrawal time in each colonic segment is similar to the group A.
62598283|NCT06528535||Group 1 - intervention|Pregant women living in French Guiana who benefited from a health promotion intervention
62598284|NCT06528535||Group 2 - control|Pregant women living in French Guiana who did not benefit from a health promotion intervention
62598285|NCT01007136|EXPERIMENTAL|tDCS and occupational therapy|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
62598286|NCT01007136|SHAM_COMPARATOR|Sham and occupational therapy|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
62598287|NCT06622213|EXPERIMENTAL|mucoadhesive film with Acmella oleracea extract|Participants received mucoadhesive film with Acmella oleracea extract.
62598288|NCT06622213|ACTIVE_COMPARATOR|Triamcinolone acetonide|Participants received 0.1% Triamcinolone acetonide.
62598289|NCT06622213|PLACEBO_COMPARATOR|mucoadhesive film without Acmella oleracea extract|Participants received mucoadhesive film without Acmella oleracea extract.
62598290|NCT02043951||Single Arm: Lutonix Drug Coated Balloon|
62598291|NCT03655678|EXPERIMENTAL|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Subjects will receive a single infusion of CTX001 through a central venous catheter.
62598292|NCT05870449|EXPERIMENTAL|trial group|
62598293|NCT05870449|ACTIVE_COMPARATOR|control group|
62598294|NCT00800306|EXPERIMENTAL|levosimendan|
62598295|NCT00800306|ACTIVE_COMPARATOR|Control|
62598296|NCT02620384|PLACEBO_COMPARATOR|Experimental: Placebo|This group will receive all standard heart failure therapy and placebo pill.
62598297|NCT02620384|ACTIVE_COMPARATOR|Experimental: Metolazone|This group will receive all standard heart failure therapy with addition of metolazone.
62598298|NCT04096443|EXPERIMENTAL|Intervention|Fecal microbial transplant capsules
62598299|NCT02864927|EXPERIMENTAL|Menactra Group 1|Participants aged 9 to 23 months will receive 2 doses of Menactra
62598300|NCT02864927|EXPERIMENTAL|Menactra Group 2|Participants aged 2 to 55 years will receive 1 dose of Menactra
62816852|NCT03987035|EXPERIMENTAL|BGP Stent Graft System|BGP Stent Graft System as bridging stent in Fenestrated Endovascular Repair (FEVAR) for complex aortic aneurysms
62240858|NCT05421962|EXPERIMENTAL|Midazolam and Fentanyl|Patients were premedicated with 0.05 mg kg-1 of midazolam (PanPharma), 5 minutes before the starting of the procedure. Afterwards, sedation induction was performed with 1 mcg kg-1 of fentanyl (Panpharma; SanMed) and 0.5 mg kg-1 of propofol (Fresenius Kabi; Amicus Pharma).
62431146|NCT06542549|EXPERIMENTAL|AK104 combined with chemotherapy|10mg/kg, administered every three weeks. The drug was administered by intravenous infusion for 60 minutes (±10 minutes). For subjects who cannot tolerate a 60-minute infusion, the infusion time can be extended up to 120 minutes. Dose adjustment is not allowed during treatment; Delayed dosing is allowed.
62816853|NCT03646604|EXPERIMENTAL|Part 1; Cohort 1|Participants, 6 to \<12 years of age, will receive low dose of upadacitinib.
62816854|NCT03646604|EXPERIMENTAL|Part 1; Cohort 2|Participants, 6 to \<12 years of age, will receive high dose of upadacitinib.
62431147|NCT06542549|NO_INTERVENTION|chemotherapy only|Conventional chemotherapy regimen can be selected: ① Paclitaxel: 175mg/㎡, intravenous infusion d1+ carboplatin AUC5, intravenous infusion d1, Q3W; ② Paclitaxel (albumin-bound type) 260mg/m2 d1+ carboplatin AUC 5, d1, Q3W; (Limited to patients who are allergic to solvent-based paclitaxel solute (polyoxyethylene castor oil) or to paclitaxel/docetaxel, paclitaxel (albumin-bound type) can be substituted in the combination regimen), ③ paclitaxel (albumin-bound type) 260mg/m2 d1+ cisplatin: 75mg/m2 d1, Q3W. (Limited to patients who are allergic to solvent-based paclitaxel solutes (polyoxyethylene castor oil) or to paclitaxel/docetaxel, paclitaxel (albumin-bound) can be substituted in the combination regimen)
62816855|NCT03646604|EXPERIMENTAL|Part 1; Cohort 3|Participants, 2 to \<6 years of age, will receive low dose of upadacitinib.
62816856|NCT03646604|EXPERIMENTAL|Part 1; Cohort 4|Participants, 2 to \<6 years of age, will receive high dose of upadacitinib.
62816857|NCT03646604|EXPERIMENTAL|Part 2|Eligible participants who completed Part 1 will receive weight-dependant low dose of upadacitinib.
62431148|NCT00676026|EXPERIMENTAL|Zolpidem 1|Zolpidem will be administered twice to each participant; once in the follicular and luteal phases of the menstrual cycle.
62431149|NCT00676026|EXPERIMENTAL|Progesterone 2|Progesterone will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.
62816858|NCT06595602||Invasively mechanically ventilated patients expected to stay ventilated for more than 24 h.|
62038207|NCT01089426|OTHER|Historical controls|A subset of patients previously seen, who have had at least 2 consecutive direct bilirubin levels \> 2 mg/dL, who depended on parenteral nutrition for at least 90 days after surgical therapy for congenital or acquired intestinal diseases
62431150|NCT00676026|EXPERIMENTAL|Fluoxetine 3|Fluoxetine will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.
62431151|NCT01571635|EXPERIMENTAL|Sotatercept dose level 0.1mg/kg|Experimental 0.1 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
62816859|NCT06178419|EXPERIMENTAL|RIC group|The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
62816860|NCT06178419|SHAM_COMPARATOR|sham RIC group|The sham RIC protocol includes five cycles of 5-min inflation to 60mmHg and 5-min deflation.
62816861|NCT04962776|ACTIVE_COMPARATOR|Low-concentration carbohydrate and nitrates group (CHON group )|
62816862|NCT04962776|ACTIVE_COMPARATOR|Low-concentration carbohydrate group (CHO group)|
62816863|NCT04962776|PLACEBO_COMPARATOR|W group|
62816864|NCT06169540||ADHF|Patients with ADHF (during admission and discharge).
62816865|NCT06169540||CHF|Patients with CHF.
62816866|NCT06169540||Control|Patients with SVT and no other cardiovascular diseases.
62240859|NCT05421962|EXPERIMENTAL|Midazolam and Ketamine|Patients were premedicated with 0.05 mg kg-1 of midazolam (PanPharma), 5 minutes before the starting of the procedure. Afterwards, sedation induction was performed with ketamine (Inresa Arzneimittel) 0.5 mg kg-1 and 0.5 mg kg-1 of propofol.
62240860|NCT05421962|NO_INTERVENTION|Midazolam and Propofol|Patients were premedicated with 0.05 mg kg-1 of midazolam (PanPharma), 5 minutes before the starting of the procedure. Afterwards, sedation induction was performed with 1 mg kg-1 of propofol.
62819442|NCT04170153|EXPERIMENTAL|Part A2 - Preliminary Food Effect Assessment|Participants in the food effect assessment will receive Tuvusertib (M1774) at the dose and schedule determined as recommended dose for expansion (RDE) in Part A1. A single dose of Tuvusertib (M1774) will be administered on Day -7 under a fed (low-fat meal) or fasted condition, followed by a 1-week washout period. After completion of the scheduled food effect assessments, participants will follow the same schedule as participants in Part A1.
62240861|NCT05474586|EXPERIMENTAL|Collavant n2 40 mg/day|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
62431152|NCT01571635|EXPERIMENTAL|Sotatercept dose level 0.3mg/ kg|Experimental 0.3 mg/kg - Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
62431153|NCT01571635|EXPERIMENTAL|Sotatercept dose level 0.5mg/kg|Experimental 0.5 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
62431154|NCT01571635|EXPERIMENTAL|Sotatercept dose level 0.75mg/kg|Experimental 0.75 mg/kg - Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
62431155|NCT01571635|EXPERIMENTAL|Sotatercept dose level 1.0mg/kg|Experimental 1.0 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
62431156|NCT01571635|EXPERIMENTAL|Sotatercept dose level 1.5mg/kg|Experimental 1.5 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
62431157|NCT02964052||Acute ischemic stroke patients|Acute ischemic stroke patients who received intravenous (IV) thrombolysis and/or intra-arterial (IA) recanalization treatment
62431158|NCT03630588|PLACEBO_COMPARATOR|Placebo|
62431159|NCT03630588|EXPERIMENTAL|Surimi intervention|
62431160|NCT05774873|EXPERIMENTAL|IBI334 E|
62038208|NCT01089426|EXPERIMENTAL|Omegaven™|
62240862|NCT05474586|ACTIVE_COMPARATOR|Glucosamine hydrochloride & Chondroitin sulfate|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
62240863|NCT05474586|PLACEBO_COMPARATOR|Microcrystalline cellulose|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
62431161|NCT05774873|EXPERIMENTAL|IBI334 D|
62431162|NCT05774873|EXPERIMENTAL|IBI334 C|
62431163|NCT05774873|EXPERIMENTAL|IBI334 A|
62431164|NCT05774873|EXPERIMENTAL|IBI334 F|
62431165|NCT05774873|EXPERIMENTAL|IBI334 B|
62819443|NCT04170153|EXPERIMENTAL|Part A3 - Monotherapy Expansion|Part A3 is an expansion of Part A1 where Tuvusertib (M1774) will be administered as a single agent at the RDE established in Part A1. Participants with defined loss-of-function mutation in ARID1A, ATRX and/or DAXX, and ATM will be enrolled.
62819444|NCT04170153|EXPERIMENTAL|Part B1: Combination Therapy Dose Finding|"B1a: Participants with baseline body weight less than (\<) 77 kilogram (kg) or platelets \<150,000 cubic per millimeter (mm\^3) will receive Niraparib once daily combined with different doses of Tuvusertib (M1774).~B1b: Participants with baseline body weight greater than or equal to (\>=) 77 kg and or platelets \>= 150,000 mm\^3 will receive Niraparib once daily combined with different doses of Tuvusertib (M1774) and schedule determined as recommended dose for expansion (RDE) in Part B1a."
62819445|NCT04170153|EXPERIMENTAL|Part A4: Japan Dose Confirmation Monotherapy|Starting at global RDE from Part A1, in Japan. Participants will initially receive Tuvusertib (M1774) once daily under fasting conditions. Additional schedules may be evaluated if needed.
62819446|NCT04170153|EXPERIMENTAL|Part A5: China Dose Confirmation Monotherapy|Starting at global RDE from Part A1, in China. Participants will initially receive Tuvusertib (M1774) once daily under fasting conditions. Additional schedules may be evaluated if needed.
62819447|NCT06704230|EXPERIMENTAL|Intervention group (+ video googles)|Patients undergoging surgery, video googles are used during surgery to reduce patient distress
62038209|NCT06540339||Patients with high-energy pelvic ring injuries|
62816867|NCT06704412|EXPERIMENTAL|floss band group|"The floss band intervention used the standard floss band technique, wrapping a floss band (lime green Sanctband Comprefloss™, 2 × 3.5 m; PENTEL, Shah Alam, Malaysia) made of natural rubber tightly around the ankle on the affected side. It was started at the fifth metatarsal and wrapped horizontally around the metatarsals twice, in a figure eight to the medial malleolus, over the Achilles tendon and the lateral malleolus three times, and around the medial malleolus again, before being passed twice from the medial mal-leolus over the Achilles tendon to the lateral malleolus, forming an end knot"
62816868|NCT06704412|SHAM_COMPARATOR|sham group|The wrap used in the sham group lacked the elasticity of a floss band; the ankle was wrapped in the same manner, but loosely to facilitate blood circulation. Similarly, the participants were instructed to perform low-intensity active exercise involving ankle DF and plantar flexion for 2 minutes after applying the sham floss band. Finally, the sham floss band was removed, and the patient was asked to walk lightly on level ground for about 1 minute under the same conditions as in the floss band group.
62816869|NCT03379818|EXPERIMENTAL|Specific word training intervention|This training programme will be similar to a typical word learning intervention. Infants will be introduced to 28 real objects and their names (e.g. biscuit, trousers). These objects will be divided into 7 sets of four words, and during each session, infants will be presented with one of this sets. Each session will consist of a 15 min play session in which each object will be presented at least 10 times and each object name will be mentioned at least 10 times. Additionally, techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used.
62038210|NCT06540339||Patients with complex pelvic trauma|
62038211|NCT06540339||Pratients with fragility fractures of the pelvis|
62240864|NCT01460186|EXPERIMENTAL|Blood samples|
62598301|NCT04892212|EXPERIMENTAL|Sirolimus group|"1. The initial dose of sirolimus is 1mg/day. And the serum trough level of sirolimus is monitored at Week 2, Week 4, Week 8, and Week 12，respectively. The target serum trough level of sirolimus is 5-8 ng/mL. The dose of sirolimus is titrated according to therapeutic drug level monitoring.~2. The previous immunosuppressive medication is not allowed to be changed during the 3-month follow-up, unless premature discontinuation from study."
62816870|NCT03379818|EXPERIMENTAL|Shape training intervention|In the shape training intervention, infants will be presented with four novel words paired with four novel sets of objects. Each set consists of two exemplars with the same shape but with different colors and textures, and a contrasting object. Each set will be presented in a play session, and the name of the objects will be mentioned at least 10 times. The other three sets of exemplars will be presented in the same way. Each session will last 15 minutes. This intervention is based on a study conducted by Smith and colleagues (2002), where they found that typically developing infants that are taught to attend to shape at 17 months old, can enhance significantly their word learning.
62816871|NCT05292586|EXPERIMENTAL|CHF 1535 pMDI|CHF 1535 pMDI 800/24µg TDD
62816872|NCT05292586|ACTIVE_COMPARATOR|CHF 718 pMDI|CHF 718 pMDI 800µg TDD
62816873|NCT05089019|EXPERIMENTAL|Selpercatinib (Test)|Selpercatinib given orally on days 1 and 15.
62816874|NCT05089019|ACTIVE_COMPARATOR|Selpercatinib (Reference)|Selpercatinib given orally on days 1 and 15.
62038212|NCT03932604|NO_INTERVENTION|Atrial sensing OFF mode|VDD-ICD programmed as atrial sensing Off mode
62038213|NCT03932604|ACTIVE_COMPARATOR|Atrial sensing ON mode|VDD-ICD programmed as atrial sensing ON mode
62038214|NCT00636649|EXPERIMENTAL|A|Escitalopram
62038215|NCT00636649|PLACEBO_COMPARATOR|B|Placebo
62038216|NCT04656535|EXPERIMENTAL|Zimberelimab (AB 122) + Domvanalimab (AB 154) Safety Cohort (Cohort A)|Eligible patients will be sequentially enrolled to receive intravenous domvanalimab (AB 154) combined with zimberelimab (AB 122) (N=6). domvanalimab (AB 154) will be given at a dose of 10 mg/kg and zimberelimab (AB 122) will be given at a dose of 240 mg (flat).
62038217|NCT04656535|EXPERIMENTAL|Domvanalimab (AB 154) Surgical Cohort (Cohort B1)|"Candidates for surgical resection will be enrolled and initiate study treatment approximately two weeks prior to the resection. The pre-surgical dose (neoadjuvant treatment) will be double-blinded.~B1 (N=10): domvanalimab (AB 154) single agent (10 mg/kg) + placebo~Following surgery, all patients will initiate treatment with the combination of domvanalimab (AB 154) and zimberelimab (AB 122). Domvanalimab (AB 154) will be given at a dose of 10 mg/kg and zimberelimab (AB 122) will be given at a dose of 240 mg (flat)."
62431166|NCT03100253|EXPERIMENTAL|"Switching strategy"|Tocilizumab \[RoActemra®\] \[ATC: L04AC07\] 8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days
62431167|NCT03100253|ACTIVE_COMPARATOR|"Cycling strategy"|"1. Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab OR~2. Infliximab, adalimumab, golimumab or certolizumab if initial failure to the receptor fusion protein, etanercept."
62816875|NCT05259566|NO_INTERVENTION|no menthol ban|usual menthol cigarettes and menthol flavored e-cigarette available
62038218|NCT04656535|EXPERIMENTAL|Zimberelimab (AB 122) Surgical Cohort (Cohort B2)|"Candidates for surgical resection will be enrolled and initiate study treatment approximately two weeks prior to the resection. The pre-surgical dose (neoadjuvant treatment) will be double-blinded.~B2 (N=10): zimberelimab (AB 122) single agent (240 mg) + placebo~Following surgery, all patients will initiate treatment with the combination of domvanalimab (AB 154) and zimberelimab (AB 122). Domvanalimab (AB 154) will be given at a dose of 10 mg/kg and zimberelimab (AB 122) will be given at a dose of 240 mg (flat)."
62240865|NCT05039398|ACTIVE_COMPARATOR|Comparison group|
62240866|NCT05039398|EXPERIMENTAL|Telephone D&G|
62240867|NCT05039398|EXPERIMENTAL|Physical meeting D&G|
62431168|NCT04324398|NO_INTERVENTION|group I (control )|irrigation with 5% sodium hypochlorite at room temperature from the beginning of cleaning and shaping, between each file and till the final rinse
62598302|NCT02224820|EXPERIMENTAL|Intravenous IdeS|One or two doses of IdeS in ascending doses
62598303|NCT02796859|ACTIVE_COMPARATOR|Treatment Group|Subjects in the siltuximab group will receive an 11 mg/kg infusion at baseline, and weeks 3 and 6, as per the recommended dosing for multicentric Castleman's disease
62598304|NCT02796859|PLACEBO_COMPARATOR|Control Group|Subjects in the placebo group will receive an infusion of normal saline (with the same packaging and volume as the siltuximab group) at baseline, and weeks 3 and 6.
62598305|NCT06623851|EXPERIMENTAL|Digital dental Impression|
62598306|NCT06623851|ACTIVE_COMPARATOR|Conventional dental impression|
62240868|NCT04669977|EXPERIMENTAL|Auxiliary|One bottle (600ml/bottle) of sanitized mulberry juice would be sent to participants of the auxiliary group with instructions to consume 50ml of juice diluted with drinking water at room temperature. They are expected to finish the mulberry juice in 10 to 11 days. Measurements of clinical symptoms and blood sampling are conducted on day 1 of every other week for 5 weeks. If clinical measurements or blood extractions fail or miss, a substitute assessment or blood sample will be obtained on day 2 or day 3. The research period for these participants is 29 days (4 weeks). The checkpoints are arranged because patients with oxaliplatin treatment visit the clinic every two weeks, and patients with paclitaxel treatment visit the clinic every week. For patients having docetaxel therapy, the research period is 43 days (6 weeks) because docetaxel is administered every three weeks.
62240869|NCT04669977|NO_INTERVENTION|Non-auxiliary|For the non-auxiliary group (control group), patients are informed of their allocation results and they will not consume mulberry juice during the research period but will receive the mulberry juice after the research period.
62240870|NCT00690625|EXPERIMENTAL|A|MyoRx cream
62816876|NCT05259566|EXPERIMENTAL|menthol ban in cigarettes only|non-menthol cigarettes and menthol flavored e-cigarette available
62816877|NCT05259566|EXPERIMENTAL|menthol ban in both cigarettes and e-cigarettes|non-menthol cigarettes and tobacco flavored e-cigarette available,
62816878|NCT03633370|NO_INTERVENTION|Control Group|Usual management of patients according to international guidelines. Protocols of call acceptance, phone advice and sending of emergency services are not modified
62816879|NCT03633370|OTHER|Test Group|"Multifaceted intervention~1. Training using distance learning for medical regulation assistants to recognise cardiac arrest on phone~2. Activation of the location-software application to send bystanders on cardiac arrest location before the arrival of emergency medical services (EMS)~3. Motivation feed-back Volunteers will received feed-back regarding CPR initiated before EMS arrival and survival"
62816880|NCT05366335|EXPERIMENTAL|Live Combined Bifidobacterium and Lactobacillus|The experimental group receive basic treatment and a single infusion of Live Combined Bifidobacterium and Lactobacillus solution through colonoscopy.
62240871|NCT00690625|PLACEBO_COMPARATOR|B|Placebo cream, same composition as experimental cream, without Omega 3 fatty acid
62240872|NCT04118517|EXPERIMENTAL|test meal|The study comprises one arm of 12 healthy Jamaican male and female adults with normal body mass inex, aged 20 to 45 years, receiving a test meal containing the common bean that was intrinsically labelled with deuterium .
62240873|NCT00398970|ACTIVE_COMPARATOR|Traditional flouroscopy guided sampling|
62240874|NCT00398970|EXPERIMENTAL|Ultrasound guide sampling|
62431169|NCT04324398|EXPERIMENTAL|Group II|irrigation with 5% cold sodium hypochlorite (2-5°C) from the beginning of cleaning and shaping and between each file. Final rinse was done by 20 mL of 5% cold sodium hypochlorite (2-5°C) for 5 minutes
62431170|NCT04324398|EXPERIMENTAL|Group III|irrigation with 5% sodium hypochlorite at room temperature from the beginning of cleaning and shaping and between each file. Then final rinse with 20 mL of 5% cold sodium hypochlorite (2-5°C) for 5 minutes
62431171|NCT04324398|EXPERIMENTAL|Group IV|irrigation with 5% sodium hypochlorite at room temperature from the beginning of cleaning and shaping and between each file. Then final rinse with 20 mL of cold saline (2-5°C) for 5 minutes
62431172|NCT02783742|EXPERIMENTAL|Intervention|Providers in this arm will receive a communication coaching intervention immediately post-randomization.
62431173|NCT02783742|OTHER|Waitlist Control|Providers assigned to this arm will be offered the option of receiving the communication coaching intervention after follow up data collection is complete.
62431174|NCT05607810||No Intervention - Subjects who received ADVM-022 in prior clinical study|
62431175|NCT02572180|ACTIVE_COMPARATOR|NIRS-based NF in 3D|A near-infrared spectroscopy (NIRS)-based neurofeedback training in which participants learn to increase the BOLD signal in prefrontal cortical regions will take place in a 3D virtual reality classroom environment.
62431176|NCT02572180|ACTIVE_COMPARATOR|NIRS-based NF in 2D|A near-infrared spectroscopy (NIRS)-based neurofeedback training in which participants learn to increase the BOLD signal in prefrontal cortical regions will take place in a 2D (normal computer screen) classroom environment.
62431177|NCT02572180|ACTIVE_COMPARATOR|EMG-based BF in 3D|An electromyogram (EMG)-based biofeedback training in which participants learn to self-regulate activity of the musculi supraspinatus will take place in a 3D virtual reality classroom environment.
62598307|NCT00620334||1|"ASTHMA:~PREVOUSLY DIAGNOSED MILD ASTHMA PATIENTS"
62598308|NCT00620334||2|"CONTROL:~PATIENTS WHO HAVE NEVER BEEN DIAGNOSED WITH ASTHMA"
62598309|NCT06444464|ACTIVE_COMPARATOR|Aerobic Exercise|After baseline 24-hour blood pressure measurements are taken at visit 2, participants will attend a final study visit where they will engage in a single session of aerobic exercise. The exercise routines will include 5 to 10-minute warm-up and cool-down periods, along with a 30-minute workout. Twenty-four hour blood pressure measurements will be taken after the exercise bout.
62816881|NCT05366335|PLACEBO_COMPARATOR|Control|The control group receive basic treatment and a single injection of normal saline through colonoscopy.
62816882|NCT05020951||Laboratory Data|Electronic transfer of laboratory data from participating institutions' local electronic health records to the Medidata/RAVE
62816883|NCT04694534|EXPERIMENTAL|"Remediation program via a serious game"|"Classic care (recommended by the French Haute Autorité de Santé) accompanied by cognitive remediation by serious game"
62816884|NCT04694534|PLACEBO_COMPARATOR|Classic care (French Haute Autorité de Santé)|Classic care (recommended by French Haute Autorité de Santé)
62816885|NCT06365879|EXPERIMENTAL|CMAB007|patients received a dose of Omalizumab alpha (CMAB007) 300mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks(Day 1, Week 4 and Week 8) in the treatment period
62816886|NCT06365879|ACTIVE_COMPARATOR|Xolair®|patients received a dose of Xolair® 300mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks(Day 1, Week 4 and Week 8) in the treatment period
62816887|NCT00868634|ACTIVE_COMPARATOR|A|Capecitabine / Bevacizumab
62431178|NCT03677778|PLACEBO_COMPARATOR|Placebo group|After surgery, in the post-operative recovery room, patients randomized to both the intervention and control groups will have 10cc 0.5% ropivacaine bolused via their nerve catheters. After 30 minutes, the following will be measured/assessed: spirometry data, pain scores (using the Numeric Rating Scale), and, if time is sufficient, bilateral diaphragmatic excursion via ultrasonography and brachial plexus motor and sensory exams. This control group will have no normal saline injected into their nerve catheter (no intervention). Then, both the control and treatment groups will have the following measured/assessed after 5, 15 and 30 minutes: spirometry data, pain scores (using the Numeric Rating Scale), and, if time is sufficient, bilateral diaphragmatic excursion via ultrasonography and brachial plexus motor and sensory exams. Investigators will be blinded to whether the patient is in the intervention or treatment group.
62431179|NCT03677778|ACTIVE_COMPARATOR|Treatment group|After surgery, in the post-operative recovery room, patients randomized to both the intervention and control groups will have 10cc 0.5% ropivacaine bolused via their nerve catheters. After 30 minutes, the following will be measured/assessed: spirometry data, pain scores (using the Numeric Rating Scale), and, if time is sufficient, bilateral diaphragmatic excursion via ultrasonography and brachial plexus motor and sensory exams. This group will then have 30ml of normal saline injected into their nerve catheter. Then, both the control and treatment groups will have the following measured/assessed after 5, 15 and 30 minutes: spirometry data, pain scores (using the Numeric Rating Scale), and, if time is sufficient, bilateral diaphragmatic excursion via ultrasonography and brachial plexus motor and sensory exams. Investigators will be blinded to whether the patient is in the intervention or treatment group.
62431180|NCT04368325||Study group|Total of 46 patients with low serum creatinine levels whose values were obtained from the central laboratory with inclusion criteria (\< 40mmol/L)
62431181|NCT04368325||Control group|A total of 61 consecutive patients were obtained who were treated in ICU CHC Osijek, according to the date of admission.
62431182|NCT06517849|NO_INTERVENTION|No Incentive|"The No Incentive arm will participate in two surveys-including questions about beliefs about therapy and willingness to pay for therapy, gambling behavior, and well-being-at the baseline and at the end (four months after the first survey). The arm will have access to free cognitive behavioral therapy through Kindbridge Behavioral Health, but will not receive a monetary incentive to undergo therapy."
62431183|NCT06517849|EXPERIMENTAL|Fixed Incentive|"The Fixed Incentive arm will participate in two surveys-including questions about beliefs about therapy and willingness to pay for therapy, gambling behavior, and well-being-at the baseline and at the end (four months after the first survey). The arm will have access to free cognitive behavioral therapy through Kindbridge Behavioral Health and will be offered a modest monetary incentive to undergo therapy. The incentive will be in form of an electronic gift card. The amount of money offered as an incentive will not depend on the participants' survey replies."
62431184|NCT06517849|EXPERIMENTAL|Payment According to Multiple Price List Choices|"The Multiple Price List arm will participate in two surveys-including questions about beliefs about therapy and willingness to pay for therapy, gambling behavior, and well-being-at the baseline and at the end. The arm will have access to free cognitive behavioral therapy through Kindbridge Behavioral Health and might be offered a modest monetary incentive to undergo therapy. More specifically, for all arms, the surveys will include a multiple price list to gauge willingness to pay for CBT. For this multiple price list arm, one of the rows from the multiple price list will be (randomly) picked and implemented. Depending on what the participant answered in the randomly picked row, they will either receive an unconditional payment or a payment conditional on undergoing CBT. In either case, the payment will be in form of an electronic gift card."
62431185|NCT04331652|EXPERIMENTAL|Polypectomy without anesthesia or analgo-sedation|Patient will undergo polypectomy without anesthesia.
62431186|NCT01406873|ACTIVE_COMPARATOR|Mexiletine|20 subjects will be randomized (assigned) to receive Mexiletine. Mexiletine is available on the market for the treatment of cardiac arrhythmias, but it is not currently approved for the treatment of myotonia or myotonic dystrophy.
62431187|NCT01406873|PLACEBO_COMPARATOR|Sugar pill|20 subjects will be randomized (assigned) to receive placebo (sugar pill). This control group is necessary to definitely establish the antimyotonic efficacy and safety of mexiletine.
62431188|NCT01050166||Labeled islets|Type 1 diabetic recipients after islet transplantation with islets labeled by iron contrast agent
62431189|NCT00894465|EXPERIMENTAL|Versed|Both patients who are VCUG naive and patients who have had a previous VCUG are given oral midazolam prior to undergoing the VCUG.
62816888|NCT00868634|EXPERIMENTAL|B|Capecitabine / Bevacizumab / Vinorelbine
62816889|NCT02642601|EXPERIMENTAL|indomethacin|one dose of indomethacin 100 mg rectal suppository;will be adminstrated1-2 hours before embryo transfer
62816890|NCT02642601|NO_INTERVENTION|no medication|no indomethacine before embryo transfer
62816891|NCT01751061|EXPERIMENTAL|Decision aid|Web-based decision aid (decision support tool) provided to surrogate decision maker
62816892|NCT01751061|ACTIVE_COMPARATOR|Usual care|usual care in an intensive care unit setting
62816893|NCT06609174|EXPERIMENTAL|First degree relatives|Subjects who are first-degree relatives of patients with DCM
62816894|NCT06609174|EXPERIMENTAL|DCM (Dilated Cardiomyopathy) Patients|Subjects who are diagnosed with DCM (dilated cardiomyopathy).
62816895|NCT01917500||Cardiac ward 10 patients|10 patients from the cardiac ward.
62240875|NCT03082950||1|human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions
62240876|NCT03082950||2|non-human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions
62240877|NCT05295316||Fibromyalgia|FM group was recruited at AMaR (rheumatic patients association of Piedmont) and the diagnosis of primary fibromyalgia was confirmed by the referring rheumatologist of the AMaR association.
62240878|NCT05295316||Control|The control group was recruited in the same geographic area as the FM participant. The general practitioner of each individual patient certified the subject's state of good health.
62240879|NCT00510250|EXPERIMENTAL|Cisplatin and Radiation in Combination with Sorafenib|
62240880|NCT02213432|EXPERIMENTAL|Day 1 vaccination|"Different timing of influenza vaccination: Day 1~Day 1 vaccination group: patients will be vaccinated against influenza at the day (Day 1) when chemotherapy starts."
62816896|NCT03379675|EXPERIMENTAL|Treatment A: JNJ-53718678 500 mg|Participants will receive 500 mg dose of JNJ-53718678 once daily for 7 days.
62240881|NCT02213432|ACTIVE_COMPARATOR|Day 11 vaccination|"Different timing of influenza vaccination: Day 11~Day 11 vaccination group: patients will be vaccinated against influenza at the 11th days after chemotherapy starts"
62240882|NCT02342756|EXPERIMENTAL|Group 1: CMV - HFOV|"Patients in group 1 will start with conventional mechanical ventilation with different values of PEEP (A-PEEP so that PLEEO = 0 cmH2O, B- PEEP so that PLEIO = 15 cmH2O, C- PEEP so that PLEEO = 0 cmH2O) and then will be ventilated with high frequency oscillatory ventilation (D- mPaw so that PL = 0 cmH2O, E- mPaw so that PL = 15 cmH2O, F- mPaw so that PL = 0 cmH2O)~Intervention: Device: Targeting transpulmonary pressure to avoid VILI"
62816897|NCT03379675|EXPERIMENTAL|Treatment B: JNJ-53718678 80 mg + Placebo|Participants will receive 80 mg dose of JNJ-53718678 along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
62598310|NCT06444464|EXPERIMENTAL|Isometric Exercise|After baseline 24-hour blood pressure measurements are taken at visit 2, participants will attend a final study visit where they will engage in a single session of isometric exercise. The exercise routines will include 5 to 10-minute warm-up and cool-down periods, along with a 30-minute workout. Twenty-four hour blood pressure measurements will be taken after the exercise bout.
62816898|NCT03379675|PLACEBO_COMPARATOR|Treatment C: Placebo|Participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
62431190|NCT00894465|PLACEBO_COMPARATOR|Placebo|Both patients who are VCUG naive and patients who have had a previous VCUG are given an oral placebo prior to undergoing the VCUG.
62816899|NCT04531410|EXPERIMENTAL|Linoleic|Linoleic acid 13 g and 600 mg algal docosahexaenoic acid (DHA)
62816900|NCT04531410|ACTIVE_COMPARATOR|Oleic|Oleic acid 13 g and 600 algal DHA
62816901|NCT06204679|EXPERIMENTAL|FDC Fasting|Day 1, Day 7, Day 13
62816902|NCT06204679|EXPERIMENTAL|FDC Fed|Day 1, Day 7, Day 13
62816903|NCT06204679|EXPERIMENTAL|Reference Fasting|Day 1, Day 7, Day 13
62816904|NCT06247917|EXPERIMENTAL|FBM group|undergoing FBM regiment
62816905|NCT05380973|EXPERIMENTAL|fiber reinforced resin composite|"Short fiber resin composite (SFRC) (Ever X Posterior, GC, Japan) The material will be applied according to manufacturer instructions. A thin layer of flowable resin composite will be applied prior placing the short fiber reinforced composite, then SFRC (Ever X Posterior, GC, Tokyo, Japan) will be injected in bulk, and light cured for 20 seconds, nanohybrid resin composite will be placed to the rest of the cavity incrementally.~Polyethylene ribbon fiber (Ribbond Inc., Seattle, WA, USA) The material will be applied according to manufacturer instructions. After application of a thin layer of the flowable resin composite to the cavity, a layer of Polyethylene ribbon fiber on the unpolymerized flowable composite will be condensed with a plugger and polymerized for 20 seconds then, nanohybrid resin composite will be placed to the rest of the cavity incrementally."
62816906|NCT05380973|ACTIVE_COMPARATOR|Nanohybrid resin composite|A thin layer of flowable composite will be applied then nanohybrid resin composite will be applied to the rest of the cavity using the conventional incremental technique according to manufacturer instructions.
62816907|NCT05177510|EXPERIMENTAL|Mifepristone and standard of care|Mifepristone 300mg once only and standard of care
62240883|NCT02342756|EXPERIMENTAL|Group 2: HFOV - CMV|"Patients in group 2 will start with high frequency oscillatory ventilation (D- mPaw so that PL = 0 cmH2O, E- mPaw so that PL = 15 cmH2O, F- mPaw so that PL = 0 cmH2O) and then will be ventilated with conventional mechanical ventilation with different values of PEEP (A-PEEP so that PLEEO = 0 cmH2O, B- PEEP so that PLEIO = 15 cmH2O, C- PEEP so that PLEEO = 0 cmH2O).~Intervention: Device: Targeting transpulmonary pressure to avoid VILI"
62240884|NCT02290522|EXPERIMENTAL|tumor biopsy|Tumor biopsy for targeted treatment according to molecular profile
62240885|NCT06132854|EXPERIMENTAL|VR|"Participants in the VR group are immersed in a unique 360° VR experience specifically designed for this study.~The custom made VR experience consists of two parts. In the first part, children find themselves in a simulated MRI room which resembles to the one they will be scanned.~The second half of the VR experience introduces a mindfulness-ACT based meditation segment within the context of a space travel."
62431191|NCT00821522|ACTIVE_COMPARATOR|Preconditioning|
62431192|NCT00821522|NO_INTERVENTION|Control|Standard clinical management during cardiac surgery.
62431193|NCT02046473|OTHER|Volumetric Flow in TIPS|Subjects who have TIPS (transjugular intrahepatic porto-systemic shunts) have measurements taken to determine if someone has increased blood pressure in the portal vein of the liver (portal hypertension). Subjects who have a TIPS receive clinical ultrasounds every 3 months to determine if the TIPS is working properly.
62431194|NCT05541601||Pearl Cohort|All 3000 patients recruited to the Pearl study
62598311|NCT04537117||Pediatric dentists|Pediatric dentists following Facebook groups for pediatric dentists and practicing dentistry nowadays
62598312|NCT06328244|EXPERIMENTAL|Systematic simple swallowing training|The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of systematic simple swallowing training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 15-30 minutes. Each training session will be conducted approximately one hour prior to meals. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
62598313|NCT06328244|NO_INTERVENTION|Blank group|No intervention will be applied to this group. It is a blank group.
62598314|NCT06621225|EXPERIMENTAL|Primary Intervention Arm|In this arm, colonoscopy was performed using Computer Aided detection in combination with a Mucosal Exposure Device, which is FDA approved.
62816908|NCT05177510|PLACEBO_COMPARATOR|Placebo|Placebo 300mg once only and standard of care
62816909|NCT02331056||thoracoscopic pulmonary lobectomy|to observe a fluid responsiveness in patients who receives scheduled thoracoscopic pulmonary lobectomy
62038219|NCT04656535|EXPERIMENTAL|Domvanalimab (AB 154) + Zimberelimab (AB 122) Surgical Cohort (Cohort B3)|"Candidates for surgical resection will be enrolled and initiate study treatment approximately two weeks prior to the resection. The pre-surgical dose (neoadjuvant treatment) will be double-blinded.~B3 (N=10): domvanalimab (AB 154, 10 mg/kg) + zimberelimab (AB 122, 240 mg)~Following surgery, all patients will initiate treatment with the combination of domvanalimab (AB 154) and zimberelimab (AB 122). Domvanalimab (AB 154) will be given at a dose of 10 mg/kg and zimberelimab (AB 122) will be given at a dose of 240 mg (flat)."
62038220|NCT04656535|EXPERIMENTAL|Placebo Surgical Cohort (Cohort B4)|"Candidates for surgical resection will be enrolled and initiate study treatment approximately two weeks prior to the resection. The pre-surgical dose (neoadjuvant treatment) will be double-blinded.~B4 (N=10): Two placebo infusions~Following surgery, all patients will initiate treatment with the combination of domvanalimab (AB 154) and zimberelimab (AB 122). Domvanalimab (AB 154) will be given at a dose of 10 mg/kg and zimberelimab (AB 122) will be given at a dose of 240 mg (flat)."
62816910|NCT02331056||open pulmonary lobectomy(thoracotomy)|to observe a fluid responsiveness in patients who receives scheduled open pulmonary lobectomy(thoracotomy)
62038221|NCT02605486|EXPERIMENTAL|Palbociclib in Combination with Bicalutamide|This is a non-randomized, open-label, phase I/II trial for patients with AR(+) MBC . There will be a dose finding phase I portion of the study to establish the recommended phase II dose (R2PD). This will be followed by a phase II where efficacy is evaluated. Patients with AR(+)ER(-) breast cancer treated on the phase I at the recommended phase II dose will be counted towards the primary endpoint analysis for the phase II study.
62038222|NCT01611701|ACTIVE_COMPARATOR|Cryoballoon group|
62038223|NCT01611701|ACTIVE_COMPARATOR|RF group|
62816911|NCT06512064|EXPERIMENTAL|Asthma|Physician diagnosis plus at least one of the following in the past year: asthma symptoms that improve with albuterol; prescribed asthma controller medication(s); an acute asthma exacerbation requiring systemic steroids; or an emergency department visit or hospitalization for asthma. Alternatively, report of current asthma symptoms per US NAEPP or Global Initiative for Asthma (GINA) guidelines, plus documentation of bronchodilator response or airway hyperresponsiveness.
62816912|NCT06512064|EXPERIMENTAL|Chronic Obstructive Pulmonary Disease (COPD)|Physician diagnosis, plus symptoms of COPD per GOLD guidelines, plus post-bronchodilator FEV1/FVC \<0.70 or below the lower limit of normal (LLN) using GLI reference equations.
62816913|NCT06512064|EXPERIMENTAL|Cystic Fibrosis (CF)|Physician diagnosis based on U.S. CF Foundation guidelines, including signs/symptoms of CF and either a positive sweat chloride test (\>60 mmol/L), or an indeterminate sweat chloride test (30-59 mmol/L) plus two CF-causing CFTR mutations. The study may include subjects with different CFTR mutation classes as well as both on and off CFTR modulators.
62038224|NCT01163370|PLACEBO_COMPARATOR|control and exercise|this is trained and receives placebo
62038225|NCT01163370|EXPERIMENTAL|creatine|this is non-exercise trained and receives creatine supplementation
62038226|NCT01163370|EXPERIMENTAL|exercise and creatine|this is exercised trained and receives creatine supplementation
62038227|NCT01163370|PLACEBO_COMPARATOR|placebo|this only receives placebo (dextrose)
62431195|NCT05828433|EXPERIMENTAL|Epley-Canalith Repositioning|"Step 1: The patient was brought down with the head tilted 45 degrees towards the af-fected canal as in Hallpike test. The neck was extended.~Step 2: The head was rotated 90 degrees towards the unaffected side. The neck was extended.~Step 3: The head and body were rotated by further 90 degrees from the previous positions (now face down). The neck was in neutral position.~Step 4: The patient was brought into a sitting position while having their head turned constantly in the direction of the unaffected side.~Step 5: The head was turn forward and the chin was kept 20° down for a minute"
62038228|NCT06683508|EXPERIMENTAL|LY3549492 Dose 1|Participants will receive LY3549492 orally
62431196|NCT05828433|EXPERIMENTAL|Vestibular Rehabilitation Therapy|Habituation exercises Gaze stability exercises and balance training
62431197|NCT01826318|EXPERIMENTAL|intervention|"Participants received a 10 minute instruction to cope with stress by loudly posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention group)"
62431198|NCT01826318|NO_INTERVENTION|Control|Students in the control group did not receive any further instructions.
62431199|NCT05066087|EXPERIMENTAL|DAHLIA treatment|6 weeks of online behavioural treatment; mainly self-guided and weekly contact with their therapist
62431200|NCT05066087|OTHER|Treatment as usual|receive usual treatment at their rehabilitation centre; detailed information will be collected to define what treatment as usual means in clinical settings.
62431201|NCT04737668|OTHER|Usual care|Pump refill will be performed as usual.
62431202|NCT04737668|OTHER|Virtual Reality|Children will play a commercially available VR game during pump refill
62431203|NCT04737668|OTHER|Distraction|Children will watch a commercial 360° music video on YouTube during pump refill
62431204|NCT00838500|ACTIVE_COMPARATOR|Immediate SPA treatment|Immediate spa treatment during 18 days soon after randomization (1 year)
62431205|NCT00838500|SHAM_COMPARATOR|Late SPA treatment|Late spa treatment during 18 days soon after 12 months visit (2nd year)
62431206|NCT01354262|EXPERIMENTAL|Lower dose vitamin D|Fixed daily doses of 600 IU vitamin D oral supplementation.
62431207|NCT01354262|EXPERIMENTAL|Higher dose vitamin D|50,000 IU supplementation bi-monthly.
62431208|NCT01354262|NO_INTERVENTION|Control Group|Patients will be followed from baseline to 12 and 24 week follow up. Patients do not receive any research treatment or intervention beyond the standard care of their diabetes. This group are patients with normal levels of Vitamin D.
62431209|NCT06537882|ACTIVE_COMPARATOR|Active arm|Subjects will take 1 sachet of G-NiiB synbiotics formula (SLP07) daily for 3 months
62431210|NCT06537882|PLACEBO_COMPARATOR|Placebo arm|Subjects will take 1 sachet of active vitamin daily for 3 months
62038229|NCT06683508|EXPERIMENTAL|LY3549492 Dose 2|Participants will receive LY3549492 orally
62038230|NCT06683508|EXPERIMENTAL|LY3549492 Dose 3|Participants will receive LY3549492 orally
62816914|NCT06512064|EXPERIMENTAL|Other Airway Diseases|This group will include subjects with airway ciliary motility disorders, bronchiectasis, and airway malaria. Given variability in the clinical presentation and diagnosis of these conditions, they will be ascertained by physician diagnosis and reviewed by study physician investigators.
62038231|NCT06683508|EXPERIMENTAL|LY3549492 Dose 4|Participants will receive LY3549492 orally
62038232|NCT06683508|EXPERIMENTAL|LY3549492 Dose 5|Participants will receive LY3549492 orally
62038233|NCT06683508|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo orally
62038234|NCT03792126|NO_INTERVENTION|Standard Care|Standard care, as per usual working practice for the stroke unit. Control stroke units will have minimal contact with the research team, other than for data collection. They will be aware of the broad aims of the study, but not the specific detail of the intervention.
62038235|NCT03792126|EXPERIMENTAL|Implicit Learning Approach|All mobility focussed rehabilitation sessions will utilise the Implicit Learning approach (ILA), as usual care. This includes rehabilitation (delivered by a physiotherapist, occupational therapist or therapy assistant) that focusses on sitting, sit to stand, standing, stepping, transfers and walking. The content of therapy will be based on the treatment guidelines and intervention manual, which have been developed by an international expert group (using Delhi methodology). As this is a clinically grounded, pragmatic trial, therapists will have freedom to tailor the specific content of each treatment session to patient need, whilst remaining true to the ILA. Other therapy interventions, such as upper limb rehabilitation, will be provided as usual.
62038236|NCT02930733|ACTIVE_COMPARATOR|ultrasound guided serratus plane block|Bilateral ultrasound guided serratus plane block with 30 ml %0,25 bupivacaine
62038237|NCT02930733|PLACEBO_COMPARATOR|ultrasound guided sham block|Bilateral ultrasound guided sham block with 2 ml saline subcutaneously
62038238|NCT06649292|EXPERIMENTAL|Treatment group A: SHR-A1904|
62431211|NCT04812704|EXPERIMENTAL|Nutritional complement|"A prospective study will be carried out including adult patients with neoplasia who should benefit in their therapeutic strategy from oncological surgery. About fifty patients will be recruited in the oncology / surgery department at the Saint-Luc University Clinics in Brussels. Patients will be assessed at the initial consultation and after the pre-habilitation period, ie the day before the operation.~Dietary monitoring will be carried out in parallel with a physical and respiratory preparation program (prehabilitation) and the intake of protein nutritional supplements in the form of powder to be diluted will be carried out after each exercise session."
62431212|NCT03900845|EXPERIMENTAL|Environmental Chamber|All participants will wear all three study prostheses in an environmental chamber set at 35 degrees Celsius and 50% relative humidity.
62431213|NCT03900845|EXPERIMENTAL|Field Measurements|All participants will wear all three study prostheses in their home, work, and community environments for two weeks.
62431214|NCT04822961|EXPERIMENTAL|Senaparib (IMP4297) 20 mg|During the treatment period, eligible patients will receive single agent of Senaparib at a dose of 100 mg once daily (QD), continuously on a 4-week cycle
62431215|NCT04822961|PLACEBO_COMPARATOR|Placebo|During the treatment period, eligible patients will receive placebo QD, continuously on a 4-week cycle
62431216|NCT03008629|EXPERIMENTAL|Podofix nail brace|for mild ingrown toenails
62816915|NCT06512064|EXPERIMENTAL|Healthy Controls|This will include generally healthy subjects who do not have any of the airway diseases included in the study, nor other chronic cardiorespiratory or other diseases that may alter lung function or the ability to participate in the study.
62816916|NCT06704880|EXPERIMENTAL|CIMT GROUP|
62816917|NCT06704880|EXPERIMENTAL|STRENGHTH TRAINING GROUP (cross education)|
62816918|NCT03932903|EXPERIMENTAL|Contextually-tailored Mobile Messages for Adherence|AYA participants will be micro-randomized to receive contextually-tailored mobile messages designed to promote their oral chemotherapy adherence, with a 60% probability of receiving a contextually-tailored message each day.
62816919|NCT03932903|NO_INTERVENTION|No messages|All participants will also be micro-randomized to not receive messages on some days of the intervention (\~40% of the time).
62816920|NCT03924661||Single Arm|Surgical treatment of a diseased, damaged, or malfunctioning aortic valve using SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve surgical replacement device
62819448|NCT06704230|NO_INTERVENTION|Control group (- video googles)|Patients undergo surgery in the same way, no video googles or other devices for the reduction of distress is used
62819449|NCT03697304|EXPERIMENTAL|Cohort 1 - Module A|
62819450|NCT03697304|EXPERIMENTAL|Cohort 2 - Module A|
62819451|NCT03697304|EXPERIMENTAL|Cohort 3 - Module A|
62038239|NCT06649292|ACTIVE_COMPARATOR|Treatment group B: Paclitaxel, Docetaxel, Irinotecan.|
62038240|NCT03816774|NO_INTERVENTION|PEG split-dose|Group A: PEG split dose ending 3 hours before colonoscopy
62038241|NCT03816774|ACTIVE_COMPARATOR|PEG split-dose and simethicone|Group B: 250mg simethicone pill 15 minutes before PEG dose on the previous evening plus 250mg simethicone pill 15 minutes before PEG dose ending 3 hours before colonoscopy
62038242|NCT06398327|ACTIVE_COMPARATOR|Zinc oxide eugenol cement|During pulpotomy treatment, a blood sample was taken from the coronal pulp and stored. The remaining pulp tissue was covered with ZOE, randomly selected from among four material groups. The teeth treated with ZOE were monitored for 12 months. Subsequently, the levels of IL-6, IL-8, and Presepsin in the blood were measured using the ELISA method and noted in ng/ml. Thus, the effect of the material used on the success of the treatment was determined based on the level of pulpal inflammation before treatment.
62038243|NCT06398327|ACTIVE_COMPARATOR|Mineral Trioxide Aggregate (MTA)|During pulpotomy treatment, a blood sample was taken from the coronal pulp and stored. The remaining pulp tissue was covered with MTA, randomly selected from among four material groups. The teeth treated with MTA were monitored for 12 months. Subsequently, the levels of IL-6, IL-8, and Presepsin in the blood were measured using the ELISA method and noted in ng/ml. Thus, the effect of the material used on the success of the treatment was determined based on the level of pulpal inflammation before treatment.
62819452|NCT03697304|EXPERIMENTAL|Cohort 1 - Module C|
62819453|NCT03697304|EXPERIMENTAL|Cohort 2 - Module C|
62816921|NCT06474195|EXPERIMENTAL|Intervention|. The intervention arm will receive the cues in the form of daily repeating reminders for a time period of 30 days. The reminders will be set on participants' mobile phones to receive at least 1 hour prior to the prescribed oral antipsychotic medication. The same reminder will be repeated after 10 minutes duration to ensure that the participant does not miss the cue and the uniformity of the cue will be ensured by setting the same emoji or the same phrase on the participant's own mobile phone. The participant will also be asked a task of daily routine during the same time of medication.
62038244|NCT06398327|ACTIVE_COMPARATOR|NeoMTA (newly developed mta)|During pulpotomy treatment, a blood sample was taken from the coronal pulp and stored. The remaining pulp tissue was covered with NeoMTA, randomly selected from among four material groups. The teeth treated with NeoMTA were monitored for 12 months. Subsequently, the levels of IL-6, IL-8, and Presepsin in the blood were measured using the ELISA method and noted in ng/ml. Thus, the effect of the material used on the success of the treatment was determined based on the level of pulpal inflammation before treatment.
62038245|NCT06398327|ACTIVE_COMPARATOR|Biodentine (biomaterial)|During pulpotomy treatment, a blood sample was taken from the coronal pulp and stored. The remaining pulp tissue was covered with Biodentine, randomly selected from among four material groups. The teeth treated with Biodentine were monitored for 12 months. Subsequently, the levels of IL-6, IL-8, and Presepsin in the blood were measured using the ELISA method and noted in ng/ml. Thus, the effect of the material used on the success of the treatment was determined based on the level of pulpal inflammation before treatment.
62431217|NCT03008629|EXPERIMENTAL|Combiped nail brace|for Severe dystrophic ingrown toenails
62431218|NCT03008629|EXPERIMENTAL|Podofix and then Combiped nail brace|for Ingrown toenails with pyogenic granuloma
62431219|NCT01245595|ACTIVE_COMPARATOR|Aminophylline|Patients to receive aminophylline 5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
62816922|NCT06474195|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as Usual (TAU) Arm will not get any reminders but the baseline assessment will be similar to the intervention arm.
62431220|NCT01245595|PLACEBO_COMPARATOR|Placebo|Normal Saline Placebo
62431221|NCT00771901|PLACEBO_COMPARATOR|Placebo|Subjects will be given a placebo rather than tauroursodeoxycholic acid.
62816923|NCT00825292|ACTIVE_COMPARATOR|2|HDNBI colonoscopy followed by standard white light colonoscopy
62038246|NCT00599612|EXPERIMENTAL|Healthy male volunteers|Six healthy male volunteers aged between 30-60 years old will be recruited for this study,
62038247|NCT02246127|ACTIVE_COMPARATOR|Sequence A, drug: everolimus first|Everolimus (10mg/daily, oral) followed by STZ-5FU (injection/infusion; Moertel or Uppsala regime).
62431222|NCT00771901|EXPERIMENTAL|tauroursodeoxycholic acid|Subjects will receive tauroursodeoxycholic acid for four weeks.
62431223|NCT00771901|EXPERIMENTAL|PBA|Subjects will receive sodium phenylbutyrate for four weeks.
62431224|NCT01198119|EXPERIMENTAL|Patient with oral cavity cancer|Patient treated by surgery for the oral cavity cancer
62431225|NCT04537325|ACTIVE_COMPARATOR|RenalGuard group|
62431226|NCT04537325|NO_INTERVENTION|Control group|
62431227|NCT04748094||Free-breathing versus Compression|This cohort of volunteers and patients will undergo imaging on the MR-Linac investigating free-breathing motion, and comparing it to motion using an abdominal compression device.
62431228|NCT04748094||Free-breathing versus Breath-holding|This cohort of volunteers and patients will undergo imaging on the MRSim investigating free-breathing motion and comparing it to visually-guided breath-hold motion (and reproducibility).
62431229|NCT06538974|EXPERIMENTAL|Hands-free exoskeleton|
62431230|NCT05801354|ACTIVE_COMPARATOR|Formocresol (Control-Gold standard-Group A)|Premade Formocresol (Tricresol \& Formalin) was used composed of Tricresol 35%, Formaldehyde (40%) 19%, excipient additive 100% (PD, Switzerland, ISO9001/ISO9001_2000/ ISO13485/CE_MARK), (Universal Dental Pvt, Ltd).
62431231|NCT05801354|EXPERIMENTAL|Turmeric gel (Experimental-Group B)|Turmeric gel will be self-prepared at the Institute of Microbiology and Molecular Genetics, Punjab University, Lahore. 2kgs of Turmeric rhizomes were purchased from a local market in Lahore and verified by a taxonomist, Botany Department, Government College University, Lahore (voucher number: GC.Herb.Bot.3693). Approximately 170g powder along with 550ml distilled water will be taken in a Soxhlet extractor for 96 hours and then filtered repeatedly through Whatman No.1 filter paper. The obtained filtrate will then be mixed with 6% Sodium Carboxy-Methyl Cellulose (NaCMC) (Genevex Chem, Hyderabad, India) to form gel. Four Vitamin C grounded tablets (Wilson's Vitamin C, Wilson's Healthcare, Islamabad, Pakistan) and twelve Vitamin E capsules (Evion, Martin Dow pharmaceuticals, Ltd. Karachi, Pak) will then be added in 100g of gel as antioxidants.
62431232|NCT04571957||Donors with NASH|Donors with NASH underwent donor optimization protocol
62431233|NCT04571957||Donors without NASH|Donors without NASH
62431234|NCT02942173|NO_INTERVENTION|CD45RA-|
62431235|NCT02942173|EXPERIMENTAL|CD45RA+|
62431236|NCT02814669|EXPERIMENTAL|Cohort 1: ATZ + R-223-D (Concurrent)|Participants will receive concurrent radium-223 dichloride and atezolizumab for a single-cycle, 28-day dose limiting toxicity (DLT) assessment. If the combination is initially found to be safe and tolerable, additional participants will be randomized to Arms A, B, and C.
62038248|NCT02246127|EXPERIMENTAL|Sequence B, drug: STZ - 5FU first|STZ-5FU (injection/infusion; Moertel or Uppsala regime) followed by Everolimus (10 mg/ daily, oral)
62038249|NCT05245669|EXPERIMENTAL|ENZ215|ENZ215 Injection:- 60 mg Denosumab (ENZ215) will be administered subcutaneously on day 1.
62038250|NCT05245669|ACTIVE_COMPARATOR|EU Sourced Prolia|EU sourced Prolia Injection:- 60 mg Denosumab (EU sourced Prolia) will be administered subcutaneously on day 1.
62038251|NCT05245669|ACTIVE_COMPARATOR|US Sourced Prolia|US sourced Prolia Injection:- 60 mg Denosumab (US sourced Prolia) will be administered subcutaneously on day 1.
62038252|NCT01022762|ACTIVE_COMPARATOR|repaglinide|1 mg repaglinide twice daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 4 mg three times daily
62038253|NCT01022762|ACTIVE_COMPARATOR|gliclazide|80 mg gliclazide once daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 160 mg twice daily
62038254|NCT06393348|EXPERIMENTAL|Group A|Subjects will receive escalated dose of HRS-7535 administered orally
62240886|NCT06132854|ACTIVE_COMPARATOR|Booklet|Children in the booklet condition will be prepared by using an educational booklet containing colorful illustrations of the MRI examination room and about the procedure. This serves as a resource to familiarize them with the MRI procedure, address common concerns, and provide information about what to expect during the exam. The role of the booklet condition is to serve as an active control for our experimental condition. This condition also contains an interaction with the experimenter and increases familiarity through explanation and illustrations. However, it does not involve the immersive effect of the VR.
62431237|NCT02814669|EXPERIMENTAL|RT Arm A: ATZ + R-223-D (Concurrent)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm (randomized treatment \[RT\]) to receive concurrent radium-223 dichloride and atezolizumab.
62431238|NCT02814669|EXPERIMENTAL|RT Arm B: ATZ + R-223-D (Staggered, 28-Day R-223-D Run-In)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm to receive radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward.
62431239|NCT02814669|EXPERIMENTAL|RT Arm C: ATZ + R-223-D (Staggered, 28-Day ATZ Run-In)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm to receive atezolizumab in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward.
62431240|NCT02814669|EXPERIMENTAL|Cohort 2: ATZ + R-223-D (Staggered, 28-Day R-223-D Run-In)|If Cohort 1 regimen is not tolerable, Arms A, B, and C will not be introduced and additional participants will be enrolled in this cohort to receive radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab in Cycle 2. If the regimen is found to be safe, additional participants will be enrolled to receive this same treatment (radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward). If, at Cycle 2, Cohort 2 regiment is not tolerable, additional participants will be enrolled in Cohort 3.
62431241|NCT02814669|EXPERIMENTAL|Cohort 3: ATZ + R-223-D (Staggered, 56-Day R-223-D Run-In)|If Cohort 2 regimen is not tolerable, additional participants will be enrolled in this cohort to receive radium-223 dichloride in Cycles 1, 2 and radium-223 dichloride and atezolizumab in Cycle 3. If the regimen is found to be safe, additional participants will be enrolled to receive this same treatment (radium-223 dichloride in Cycles 1, 2 and radium-223 dichloride and atezolizumab from Cycle 3 onward). If, at Cycle 3, Cohort 3 regiment is not tolerable, no additional participants will be enrolled in this study.
62431242|NCT03086668|EXPERIMENTAL|Conventional Jaw thrust Group|an assembly of video-stylet and double curve endotracheal tube with conventional jaw thrust technique to facilitate nasotracheal intubation
62431243|NCT03086668|EXPERIMENTAL|Fingers hook Group|an assembly of video-stylet and double curve endotracheal tube with fingers-hook technique to facilitate nasotracheal intubation
62431244|NCT03078842|ACTIVE_COMPARATOR|Zinc-20|Zinc tablets, 20 mg per day
62431245|NCT03078842|EXPERIMENTAL|Zinc-10|Zinc tablets, 10 mg per day
62431246|NCT03078842|EXPERIMENTAL|Zinc-05|Zinc tablets, 5 mg per day
62431247|NCT06542848|EXPERIMENTAL|Experimental Group|This group consists of patients with post-stroke hemiplegia who will undergo a physiotherapy and rehabilitation program to assess its effects on spasticity levels, upper extremity functions, activities of daily living, and kinesiophobia.
62816924|NCT00825292|ACTIVE_COMPARATOR|1|standard white light colonoscopy followed by HDNBI colonoscopy
62816925|NCT02825498|EXPERIMENTAL|Operator guided by contact force|Operator has full access to contact force parameters including force time integral (FTI).
62816926|NCT02825498|NO_INTERVENTION|Operator blinded to contact force|Operator is blinded to contact force with ablation guided by standard markers of effective ablation.
62816927|NCT03485924|ACTIVE_COMPARATOR|EUS-FNA with ROSE|EUS/FNA with ROSE will be performed using standard techniques via 22-g FNA needle (Cook Medical EchoTip Ultra or Boston Scientific Expect or Medtronic Beacon). Lesions will be identified using EUS and punctured with the FNA needle (10-15 back and forth movements per needle pass, fanning as appropriate). After the lesion is punctured, the stylet will be removed and 10cc suction will be applied. FNA specimens will be processed for ROSE using standard techniques with bedside smear slide evaluation and liquid-based cytology and cell-block preparation.
62819454|NCT03697304|EXPERIMENTAL|Cohort 3 - Module C|
62819455|NCT03697304|EXPERIMENTAL|Cohort 4 - Module C|
62819456|NCT03697304|EXPERIMENTAL|Cohort 5 - Module C|
62819457|NCT04609956|EXPERIMENTAL|virtual reality|Experimental arm is a virtual reality headphones
62038255|NCT06393348|EXPERIMENTAL|Group B|Subjects will receive dose of HRS-7535 administered orally
62038256|NCT06393348|PLACEBO_COMPARATOR|Group C|Subjects will receive Placebo administered orally
62240887|NCT06132854|NO_INTERVENTION|Usual care|In the usual care condition children are prepared by the healthcare staff through explanations, reframing, playing as per personal preference which is currently the standard of care in our departments.
62431248|NCT04612205|EXPERIMENTAL|group A|females complain from SUI treated by TECAR and pelvic floor exercises
62240888|NCT01306188||Breast cancer|Metastatic breast cancer
62816928|NCT03485924|ACTIVE_COMPARATOR|EUS-FNB without ROSE|EUS/FNB without ROSE will be performed using similar techniques for tissue acquisition as FNA using 22-g FNB needle (Medtronic SharkCore or Boston Scientific Acquire). Lesions will be identified using EUS and punctured with the 22-g FNB needle (10-15 back and forth movements per needle pass, fanning as appropriate). After the lesion is punctured, the stylet will be removed and 10cc suction will be applied. FNB samples will be placed directly into formalin containers and sent to be processed by surgical pathology.
62816929|NCT05351749|EXPERIMENTAL|New-prescription Alert / Existing-prescription notification to prescriber|
62816930|NCT05351749|EXPERIMENTAL|New-prescription Alert w/ referral option/ Existing-prescription notification to prescriber|
62240889|NCT01306188||Lung cancer|Metastatic lung cancer
62240890|NCT03042780|EXPERIMENTAL|FOLFIRINOX Treatment|Participants will receive modified FOLFIRINOX which consists of 85 mg/m\^2 of oxaliplatin, 400 mg/m\^2 of leucovorin over the first 2 hours, 165 mg/m\^2 of irinotecan in a 90-minute infusion on day 1, followed by a continuous, 46-hour infusion of 5-FU at a dosage of 2,400 mg/m\^2. A cycle will be repeated every 14 days. Granulocyte colony-stimulating factor (G-CSF) prophylaxis will be allowed after each cycle. Participants will undergo re-staging studies every 8 weeks. Participants will receive up to 12 cycles during the study. Additional cycles will be determined per investigators' discretion.
62240891|NCT05400642|EXPERIMENTAL|High Flow Oxygen Therapy|Surgery conducted under High Flow Oxygen Therapy
62240892|NCT05400642|ACTIVE_COMPARATOR|Mechanical ventilation|Surgery conducted under orotracheal intubation and mechanical ventilation
62240893|NCT05915897||CGD with p47phox phenotype|
62240894|NCT05915897||X-Linked CGD|
62240895|NCT03831425|EXPERIMENTAL|Coenzyme Q|Each patient will be asked to take part in a 6 wk trial of pharmaceutical grade CoQ10 and will be randomly assigned to a start time. There will be a 6 wk washout period between treatment and placebo arms. At baseline, if this is the first arm, testing will include determination of muscle function based on our 3 min step test, muscle power (maximal jump, handgrip), strength (Queens' Square), endurance (6MWT), fatigue (PedsQL fatigue scale), physical activity level (3DPAR), attention (ADHDT scale), cognition (MoCA), physical function (CHAQ).and quality of life (PedQL). Following the 6 wk CoQ10 trial, testing will include repeat determination of all of the above as well as determination of total aerobic capacity (maximum cycle ergometry) and muscle metabolism (31P-MRS ergometry).
62240896|NCT03831425|PLACEBO_COMPARATOR|Placebo|Each patient will be asked to take part in a 6 wk trial of placebo and will be randomly assigned to a start time. There will be a 6 wk washout period between treatment and placebo arms. At baseline, if this is the first arm, testing will include determination of muscle function based on our 3 min step test, muscle power (maximal jump, handgrip), strength (Queens' Square), endurance (6MWT), fatigue (PedsQL fatigue scale), physical activity level (3DPAR), attention (ADHDT scale), cognition (MoCA), physical function (CHAQ).and quality of life (PedQL). Following the 6 wk placebo trial, testing will include repeat determination of all of the above as well as determination of total aerobic capacity (maximum cycle ergometry) and muscle metabolism (31P-MRS ergometry).
62240897|NCT04850157|EXPERIMENTAL|Tislelizumab+IMRT|
62240898|NCT01544699|ACTIVE_COMPARATOR|Real stimulation|real tDCS (well, that's the way it is I am not gonna change it)
62240899|NCT01544699|SHAM_COMPARATOR|Sham|sham tDCS
62240900|NCT00325039|ACTIVE_COMPARATOR|1|retropubic mid-urethral sling (TVT) The specific TVT used was the Tension-free Vaginal Tape (Gynecare)
62240901|NCT00325039|ACTIVE_COMPARATOR|2|"transobturator mid-urethral sling (TVT-O and the Monarc) Two transobturator slings were used: the Tension-free Vaginal Tape Obturator (Gynecare), which is placed starting inside the vagina and coming out through the obturator foramen (in-to-out) or the Monarc (American Medical System), which is placed starting in the groin area, passing through the obturator foramen, and then into the vagina (out-to-in)."
62240902|NCT03156127|EXPERIMENTAL|BR-UPS 5 mg tablet|
62240903|NCT03156127|ACTIVE_COMPARATOR|Inisia 5 mg tablet|
62240904|NCT03954574||Retrospective patient cohort|
62240905|NCT03954574||Prospective patient cohort|
62431249|NCT04612205|ACTIVE_COMPARATOR|group B|females treated by pelvic floor exercises only
62431250|NCT04222322|EXPERIMENTAL|Epitomee Capsule|Epitomee Capsule combined with moderate intensity lifestyle counseling
62431251|NCT04222322|PLACEBO_COMPARATOR|Control-Placebo|Visually matching (to Epitomee capsule) placebo capsule combined with moderate intensity lifestyle counseling
62431252|NCT05543070|EXPERIMENTAL|Low-dose Radiotherapy|Involved-site radiotherapy (3 Gy\*4f) in one week
62598315|NCT06621225|EXPERIMENTAL|Secondary Intervention Arm|In this arm, participants underwent colonoscopy solely with an FDA approved Mucosal Exposure Device
62816931|NCT05351749|EXPERIMENTAL|New-prescription Alert/ Existing-prescription notification to pharmacist|
62816932|NCT05351749|EXPERIMENTAL|New-prescription Alert w/ referral option/ Existing-prescription notification to pharmacist|
62816933|NCT04575194|ACTIVE_COMPARATOR|Liraglutide 3 mg|Patients will be prescribed sc liraglutide 3 mg/day along with a dietary and physical activity intervention.
62816934|NCT04575194|ACTIVE_COMPARATOR|Naltrexone/bupropion 32/360 mg|Patients will be prescribed oral naltrexone/bupropion 32/360 mg/day along with a dietary and physical activity intervention.
62816935|NCT00003994|EXPERIMENTAL|Arm I (cisplatin, vincristine sulfate, fluorouracil)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive cisplatin IV over 4 hours on day 1, vincristine sulfate IV on days 3, 10, and 17, and fluorouracil on day 3.
62816936|NCT00003994|EXPERIMENTAL|Arm II (cisplatin, vincristine, fluorouracil, amifostine)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive treatment as in arm I with the addition of amifostine trihydrate IV over 15 minutes prior to cisplatin on day 1.
62816937|NCT00003994|EXPERIMENTAL|Arm III (carboplatin, cisplatin)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive carboplatin IV over 1 hour on day 1 and cisplatin IV over 4 hours on day 15.
62431253|NCT02926183|EXPERIMENTAL|Gemcitabine plus nab-paclitaxel|Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel: Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
62598316|NCT06621225|NO_INTERVENTION|Control group|In this arm, the participants underwent standard white light endoscopy without any intervention.
62598317|NCT05567432|ACTIVE_COMPARATOR|Patients will do throidectomy using diathermy|In these patients the investigators will control bleeding and cut tissues and blood vessels using the diathermy .
62598318|NCT05567432|ACTIVE_COMPARATOR|Patients will do thyroidectomy using ligasure .|In these patients the investigators will control bleeding and cut tissues and blood vessels using the liagasure.
62598319|NCT05420857|EXPERIMENTAL|Hip Biofeedback|Training: Participants will complete three training bouts in a session. For these training bouts, participants will be instructed to walk around the perimeter of the 9m x 15m laboratory while wearing the custom gait biofeedback device and visual display glasses. The training bouts will each be 6 minutes in duration with a 5-minute break in between bouts. The biofeedback will be intermittent, with one minute on and one minute off, in order for the individual to not become dependent on the feedback and to promote motor learning. Participants will be told that the device measures the angle their paretic leg is at, and as they move their leg, the line on the screen will move. They will be shown as they move their leg farther back, the line moves up, closer to the target. Participants will not be given specific feedback on what walking strategies to use to increase hip extension angle. If the participant surpasses the target hip extension angle, the target will blink green.
62598320|NCT02947256|ACTIVE_COMPARATOR|standard laparoscopic cholecystectomy|This included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery.
62598321|NCT02947256|EXPERIMENTAL|RI approach|"Retroinfundibular laparoscopic cholecystectomy: This included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.~Operative procedure of by RI approach:"
62598322|NCT06622863|ACTIVE_COMPARATOR|Control group (C): Standard oral hygiene instructions will be given verbally by the periodontics res|
62816938|NCT00003994|EXPERIMENTAL|Arm IV (carboplain, cisplatin, amifostine)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive treatment as in arm III with the addition of amifostine trihydrate IV over 15 minutes prior to carboplatin on day 1.
62816939|NCT05748873|EXPERIMENTAL|Step 1 : SPVN06 dose 1|Participants will receive a single subretinal injection of SPVN06 Dose 1 on Day 0.
62431254|NCT06047366|EXPERIMENTAL|Buffered|Buffered 2% lidocaine with 1:100,000 epinephrine Buffered 4% articaine with 1:100,000 epinephrine Buffered 3% mepivacaine Buffered local anesthetic (addition of sodium bicarbonate to make a 10% buffered solution)
62598323|NCT06622863|EXPERIMENTAL|Test group (T): Avatar-based group will receive oral hygiene instructions from a digital avatar of t|
62816940|NCT05748873|EXPERIMENTAL|Step 1 : SPVN06 dose 2|Participants will receive a single subretinal injection of SPVN06 Dose 2 on Day 0
62816941|NCT05748873|EXPERIMENTAL|Step 1 : SPVN06 dose 3|Participants will receive a single subretinal injection of SPVN06 Dose 3 on Day 0
62431255|NCT06047366|ACTIVE_COMPARATOR|Unbuffered|Unbuffered 2% lidocaine with 1:100,000 epinephrine Unbuffered 4% articaine with 1:100,000 epinephrine Unbuffered 3% mepivacaine Standard local anesthetics
62816942|NCT05748873|EXPERIMENTAL|Step 2 : SPVN06 Dose Recommended 1|Participants will receive a single subretinal injection of SPVN06 recommended dose 1 on Day 0
62816943|NCT05748873|EXPERIMENTAL|Step 2 : SPVN06 Dose Recommended 2|Participants will receive a single subretinal injection of SPVN06 recommended dose 2 on Day 0
62816944|NCT05748873|NO_INTERVENTION|Step 2 : Control group|
62819458|NCT04609956|OTHER|standard|Control arm is a usual practice (hydroxyzine + patient music with headphones)
62038257|NCT01839110|ACTIVE_COMPARATOR|Ranolazine|Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day
62038258|NCT01839110|PLACEBO_COMPARATOR|Placebo|Placebo by mouth twice per day
62038259|NCT01839110|NO_INTERVENTION|Observational|Patients with pulmonary hypertension who have normal RV function (RVEF \>=45%) will undergo same procedures in the observational arm but will not receive an intervention.
62038260|NCT03430674|EXPERIMENTAL|Exercise Intervention|Clinic and at home exercise sessions.
62038261|NCT01280279||group with nocturnal polyuria and nocturia|Patients were enrolled when they had the urine volume at nighttime more than one third of total daily urine volume (NPU) and voided more than two times at nighttime (nocturia)
62038262|NCT01085851|EXPERIMENTAL|Dexchlorpheniramine 1% lotion|
62038263|NCT01085851|ACTIVE_COMPARATOR|Dexchlorpheniramine 1% cream|
62240906|NCT02525861|EXPERIMENTAL|Cohort I: GLASSIA (High-end)|Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the high end within) at 60 milligrams per kilogram (mg/kg) BW active A1PI protein administered at a rate of 0.2 milliliters per kilogram of body weight per minute (ml/kg/min) for 25 weeks (25 planned infusions) via an IV administration.
62240907|NCT02525861|EXPERIMENTAL|Cohort II: GLASSIA (Low-end)|Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the low end within the normal range) at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 ml/kg/min for 25 weeks (25 planned infusions) via an IV administration.
62240908|NCT02216487|EXPERIMENTAL|HA-Irinotecan|HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan.
62240909|NCT02761746|EXPERIMENTAL|Intervention Condition (MESA)|MESA involves two sessions (ACASI assessment and intervention), one at study entry (prior to beginning ART) and one a month later. Then, participants will complete ACASI assessments only at 3, 6, 9, and 12 months. The first MESA session is tailored based on how important and how confident the person feels about taking medications as prescribed. The participant is also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, the participant may engage in goal setting. The second MESA session focuses on adherence behavior over the previous month and the consequences (good or bad) of that behavior.
62240910|NCT02761746|NO_INTERVENTION|Control Condition (SH)|The SH control condition involves two sessions (ACASI assessment and control condition), one at study entry (prior to beginning ART) and one a month later. Then, participants will complete ACASI assessments only at 3, 6, 9, and 12 months. The first SH session targets healthy eating and physical activity and is matched for dose and length of time of the intervention session. Feedback and education are provided, if desired. Finally, the participants may engage in goal setting for healthy eating and physical activity. The second SH session focuses on the goals set during the first session and behavior over the previous month.
62240911|NCT05136365|EXPERIMENTAL|Xiongdan Wan group|Xiongdan Wan is used in patients diagnosed with Major Depressive Disorder. The daily dose (1350mg per day) should be strictly controlled according to the experimental design.
62240912|NCT01782079|EXPERIMENTAL|L. brevis|
62431256|NCT05400837|EXPERIMENTAL|Corrie Virtual Atrial Fibrillation Management Program|Multicomponent virtual atrial fibrillation management program
62431257|NCT05400837|NO_INTERVENTION|Usual Care|Receives usual care. Usual care is defined as care according to the patients care team's standard practice
62038264|NCT06372769||Healthy young adults with individual normal occlusion|Healthy subjects who fulfilled the following criteria: centred midline and no marked restriction and deviation of mouth opening and closing; overjet and overbite of 1-3 mm, bilateral molar support with molar and cusp relation of Angle's class I, and presence of complete permanent dentition, except third molars.
62038265|NCT06372769||Temporomandibular disorder patients with disc displacement|Patients with unilateral or bilateral temporomandibular joint (TMJ) disc displacement symptoms, such as TMJ clicking, TMJ locking, and limitation in opening mouth were included in the study. The study did not cover the patients with muscle disorders (myofascial pain), with arthralgia, osteoarthritis, and osteoarthrosis, with TMJ fracture, with dentofacial deformity, with systemic disease affecting TMJ, and undergone TMD treatments.
62038266|NCT06668376|PLACEBO_COMPARATOR|Placebo Product|Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear products and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.
62431258|NCT04938401||epistaxis|Postoperative pituitary tumor group with epistaxis
62431259|NCT04938401||no epistaxis|Postoperative pituitary tumor group without epistaxis
62431260|NCT03823365|EXPERIMENTAL|Indolent NHL or CLL patients|Adults diagnosed with indolent non-Hodgkin lymphomas (iNHL) or chronic lymphocytic leukemia (CLL) in need of first line treatment consisting of either FCR or BR as per investigator assessment
62431261|NCT00969059|PLACEBO_COMPARATOR|PLACEBO|Eligible participant with at least moderate intensity of pain (an average daily pain score of ≥ 4 on the 11 point PI-NRS at baseline) will receive placebo for 28 days.
62038267|NCT06668376|ACTIVE_COMPARATOR|Incrediwear Product|Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear products and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.
62038268|NCT05822115|EXPERIMENTAL|treated group|Breast reduction
62240913|NCT02030405|EXPERIMENTAL|Ixazomib (MLN9708)|Participants receive ixazomib PO (orally) on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62598324|NCT06621797|EXPERIMENTAL|Caffeine Only Arm|Participants receive a caffeine supplement only.
62598325|NCT06621797|EXPERIMENTAL|Caffeine + L-Theanine Arm|Participants receive a combination of caffeine and L-theanine supplements.
62240914|NCT00937833|EXPERIMENTAL|Urethrovesical Sling|Surgisis Male Sling placed at the time of prostatectomy
62431262|NCT00969059|EXPERIMENTAL|Active|Eligible participant with at least moderate intensity of pain (an average daily pain score of ≥ 4 on the 11 point PI-NRS at baseline) will receive 7.5 mg twice daily (bid) GW856553 for 28 days.
62598326|NCT06621797|EXPERIMENTAL|Caffeine + Diaphragmatic Breathing Exercises Arm|Participants receive a caffeine supplement and perform diaphragmatic breathing exercises.
62038269|NCT01581827||Study population|People at high risk of heart failure (from SCREEN-HF study)
62598327|NCT03813147|EXPERIMENTAL|Treatment (cytarabine, azacitidine, pevonedistat, fludarabine)|Patients receive cytarabine intrathecally on day 0 at least 24 hours prior to the start of each cycle. Patients then receive azacitidine IV over 15 minutes QD on days 1-5, pevonedistat IV over 60 minutes on days 1, 3, and 5, and fludarabine phosphate IV over 30 minutes QD and cytarabine IV over 1-3 hours QD on days 6-10. Patients with CNS2 or CNS3 receive cytarabine intrathecally or methotrexate intrathecally, hydrocortisone intrathecally, and cytarabine intrathecally on days 8 and 11-34. Cycles continue for 35 days in the absence of disease progression or unacceptable toxicity. Patients with stable or greater with non-hematologic toxicities probably or definitely related to pevonedistat may receive an additional cycle of treatment.
62598328|NCT06136481|EXPERIMENTAL|Intervention group|CPT intervention: participants will attend the 12 consecutive sessions administered by a psychologist in twice a week.
62038270|NCT06270966|EXPERIMENTAL|Virtual Reality Cognitive Remediation + treatment as usual|15 Participants with more than 65 years and with MCI diagnosis will undergo a cognitive remediation program using fully immersive VR. Participants will continue with standard care during the experimental intervention
62038271|NCT06270966|NO_INTERVENTION|Treatment as usual|The control group, 15 participants with more than 65 years and with MCI diagnosis, will continue with standard care.
62816945|NCT04373902|EXPERIMENTAL|Physiological-based cord clamping|In PBCC, the Concord will be placed next to the bed of the mother and all equipment will be checked before the second stage of labour has started. The infant will be placed on the platform of the Concord immediately after birth, avoiding any traction or pressure on the cord and avoiding heat loss by radiation heating. The umbilical cord will not be clamped until the infant is considered respiratory stable, which is defined as the presence of a heart rate \>100 bpm and preductal oxygen saturation \>85%, while using an fraction of inspired oxygen (FiO2) of \<0.5. The minimum and maximum times of cord clamping are three and ten minutes after birth, respectively. Oxytocin administration will be postponed until after cord clamping if there are no obstetric concerns. At any time, the attending neonatologist and obstetrician can decide that PBCC should not be performed or be interrupted. In that case, the infant can be placed on the standard resuscitation table for (further) stabilisation.
62038272|NCT03583216||Diabetic pregnancy|Pregnant patients with a diagnosis of Type I, Type II or gestational diabetes will be included in this arm. Blood will be drawn from each patient when they are hospitalized and before they deliver either vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will contain 4 ml blood.
62816946|NCT04373902|NO_INTERVENTION|Immediate cord clamping|In the immediate cord clamping group, the cord will be clamped immediately after birth. The infant will then be transferred to the standard neonatal resuscitation table. After cord clamping, all infants will be managed according to the standardised neonatal management protocol for infants with a CDH, which is a consensus of current clinical guidelines by the CDH EURO consortium.
62038273|NCT03583216||Non-diabetic pregnancy|Healthy non-diabetic pregnant patients will be included in this arm. Blood will be drawn from each patient when they are hospitalized and before they deliver either vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will contain 4 ml blood.
62431263|NCT00896883|EXPERIMENTAL|Middle Turbinate Implant|Subjects to receive Middle Turbinate Implant
62431264|NCT03068910|EXPERIMENTAL|Spironolactone|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with spironolactone (50 mg twice daily).
62431265|NCT03068910|PLACEBO_COMPARATOR|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
62240915|NCT00937833|ACTIVE_COMPARATOR|Control|Prostatectomy
62240916|NCT03326895|EXPERIMENTAL|Group 1|Powered circular stapler used to complete anastomosis of colon
62240917|NCT01212250|EXPERIMENTAL|Carvedilol|Tablet 6.25 mg BD
62240918|NCT01212250|PLACEBO_COMPARATOR|placebo|Placebo tablets 2 BD
62240919|NCT04849182|ACTIVE_COMPARATOR|Vertistop D|Patients with deficiency (\<20 ng/mL, \<50 nmol/L) or insufficiency (20-30 ng/mL, 50-75 nmol/L) of Vitamin D
62240920|NCT04849182|ACTIVE_COMPARATOR|Vertistop L|Patients with normal vitamin D levels (\>30 ng/mL, \>75 nmol/L)
62240921|NCT04849182|NO_INTERVENTION|Control group|Patients meeting the inclusion criteria with normal levels of vitamin D (\>30 ng/mL, \>75 nmol/L)
62240922|NCT04633707|EXPERIMENTAL|Adjunctive morning BLT group|treat participants with adjunctive BLT in the morning
62240923|NCT04633707|EXPERIMENTAL|Adjunctive afternoon BLT group|treat participants with adjunctive BLT in the afternoon
62240924|NCT04633707|PLACEBO_COMPARATOR|Adjunctive placebo therapy group|treat participants with adjunctive dim red light in the afternoon
62816947|NCT02943174|EXPERIMENTAL|MIND Programme for cancer|"MIND programme for cancer is a manualized acceptance, mindfulness and compassionate-based group intervention for cancer patients. It included 8 weekly group sessions, 2h hours each, run in small groups (ranging from 6 to 12 participants).~Participants in this group also receive cancer treatment as usually performed at the Coimbra University Hospital."
62240925|NCT03152279||Celiac Disease|Patients with suspected Celiac Disease who plan to undergo duodenal biopsy as part of routine clinical care
62240926|NCT03152279||Control|Patients scheduled for an upper endoscopy for indication other than evaluation of Celiac Disease or concern for CeD as part of routine clinical care
62816948|NCT02943174|OTHER|Treatment as Usual (TAU)|Cancer treatment as usually performed at the Coimbra University Hospital.
62431266|NCT04056507||ITP group|On frozen spleens of already splenectomized adult ITP patients.
62431267|NCT04056507||Control group|On frozen control spleens from patients who had a splenectomy at the Bordeaux University Hospital following a road accident.
62431268|NCT06020105|EXPERIMENTAL|Intervention Group|The intervention will be a combination of consultations and face-to-face follow-ups, with teleconsultations, based on other observational and experimental studies. The intervention program includes monitoring for one year of patients enrolled in the bariatric surgery consultation, with criteria for surgeries.
62816949|NCT00548665|EXPERIMENTAL|1|Carotid plaque screening and brief advice for smoking cessation: Smokers with at least one carotid plaque will receive pictures of their own plaques with a structured explanation on the general significance of plaques.
62038274|NCT05446168|EXPERIMENTAL|Parkinson's Disease Tributyrin Intervention|Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
62240927|NCT01283698|EXPERIMENTAL|LAS 41004 dosage 1|dosage 1, once daily
62240928|NCT01283698|EXPERIMENTAL|LAS 41004 dosage 2|dosage 2, once daily
62431269|NCT06020105|NO_INTERVENTION|Control Group|The control group will only carry out the assessments and will be offered the same intervention as the intervention group at the end of the intervention.
62816950|NCT00548665|ACTIVE_COMPARATOR|2|Brief advice for smoking cessation (without carotid ultrasound for plaque screening): to ensure equal contact conditions, smokers not undergoing ultrasound will receive a relevant explanation on the risks associated with tobacco smoking.
62816951|NCT05915806|EXPERIMENTAL|High-dose DHA|Enteral supplementation with high-dose DHA in the neonatal period.
62816952|NCT05915806|PLACEBO_COMPARATOR|Control|Control.
62816953|NCT04026113|EXPERIMENTAL|FC Participants: Placebo|Placebo single dose, once daily at approximately the same time each day, 30 minutes before any meal.
62038275|NCT05446168|EXPERIMENTAL|Healthy Control Tributyrin Intervention|Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
62240929|NCT01283698|EXPERIMENTAL|LAS 41004 dosage 3|dosage 3, once daily
62240930|NCT01283698|PLACEBO_COMPARATOR|placebo|once daily
62431270|NCT01200394|EXPERIMENTAL|PF-00489791|
62431271|NCT01200394|PLACEBO_COMPARATOR|Placebo|
62431272|NCT04451382||OnabotulinumtoxinA (BoNTA)|DRUG: OnabotulinumtoxinA (BoNTA) is an injection into the bladder which blocks the presynaptic release of acetylcholine. BoNTA was approved for the treatment of OAB by the FDA in 2013.
62431273|NCT04451382||Percutaneous tibial nerve stimulation (PTNS)|DEVICE: PTNS involves needle stimulation of the posterior tibial nerve and is typically performed with weekly 30 minute sessions for a 12 week treatment course.
62431274|NCT04661566|EXPERIMENTAL|Education+Narratives+Skills+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, Scenarios, Future, and Risk"
62816954|NCT04026113|EXPERIMENTAL|FC Participants: Linaclotide 72 μg|Linaclotide 72 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.
62816955|NCT04026113|EXPERIMENTAL|IBS-C Participants: Linaclotide 145 μg|Linaclotide 145 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal.
62816956|NCT04026113|EXPERIMENTAL|IBS-C Participants: Linaclotide 290 μg|Linaclotide 290 μg single dose, once daily at approximately the same time each day, 30 minutes before any meal
62816957|NCT06705790|EXPERIMENTAL|Pelvic Floor Muscle Training Group|
62431275|NCT04661566|EXPERIMENTAL|Education+Narratives+Skills+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, Scenarios, and Future"
62240931|NCT01283698|ACTIVE_COMPARATOR|Reference|once daily
62240932|NCT02092350|EXPERIMENTAL|Immediate Treatment|Participants receive grazoprevir 100 mg tablet, orally, once per day (QD) + elbasvir 50 mg tablet, orally, QD, for 12 weeks.
62240933|NCT02092350|EXPERIMENTAL|Deferred Treatment|Participants receive placebos to both grazoprevir and elbasvir for 12 weeks, and after a 4-week break, grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks.
62240934|NCT02092350|EXPERIMENTAL|Intensive PK|Participants receive grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks with intensive PK testing.
62240935|NCT01647750|OTHER|Lower dose of levothyroxine|Participants may be randomised to receive a lower dose of levothyroxine (lower than their usual dose) to achieve a target TSH level of 4.1 - 8.0 mU/L
62816958|NCT06705322|EXPERIMENTAL|Treatment (Cnidium Monnieri Detoxification Formula)|Take Cnidium Monnieri Detoxification Formula orally for at least 3 months. Baseline HPV clearance, improvement in clinical symptoms and quality of life, and drug safety were assessed at 3 months, 6 months, and 12 months after initiation of treatment.
62038276|NCT00313404|EXPERIMENTAL|Norovirus in groundwater|We dosed volunteers with safety tested infectious norovirus in groundwater (that met EPA standards for drinking water). The length of time norovirus remained in groundwater varied by volunteer.
62431276|NCT04661566|EXPERIMENTAL|Education+Narratives+Skills+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, Scenarios, and Risk"
62431277|NCT04661566|EXPERIMENTAL|Education+Narratives+Skills+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, and Scenarios"
62816959|NCT01660971|EXPERIMENTAL|Treatment (gemcitabine, dasatinib, erlotinib)|Patients receive gemcitabine hydrochloride IV over 30-60 minutes on days 1, 8, and 15, and dasatinib PO QD and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62816960|NCT03071120|EXPERIMENTAL|Parent-Mediated Intervention with ASD|In-home intervention (1-2x/week) will occur with families with children with ASD, including direct intervention, parent coaching, and parent training.
62038277|NCT04435665|EXPERIMENTAL|NFX-179 Gel Low|NFX-179 Gel for topical administration, once daily for 28 days
62038278|NCT04435665|EXPERIMENTAL|NFX-179 Gel Mid|NFX-179 Gel for topical administration, once daily for 28 days
62431278|NCT04661566|EXPERIMENTAL|Education+Narratives+Skills+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, Future, and Risk"
62431279|NCT04661566|EXPERIMENTAL|Education+Narratives+Skills+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, and Future"
62816961|NCT03892200|EXPERIMENTAL|Daily Mouth Care|The intervention being tested is a standardized educational and skill-building program for use in assisted living communities, which highlights that mouth care is infection control (e.g., can reduce pneumonia); includes techniques and products to clean and protect the teeth, tongue, gums, and dentures (e.g., the jiggle-sweep approach to remove plaque, use of an interdental brush instead of floss); provides strategies for care provision in special situations (e.g., broken teeth); and includes a toolkit of dementia-sensitive approaches for people who are resistant (e.g., refuse to open the mouth). It also includes information about potential dental emergencies and issues that merit assessment.
62816962|NCT03892200|NO_INTERVENTION|Standard Mouth Care|Assisted living communities will continue to provide standard mouth care to all residents. Assisted living staff will not receive training or supplies in the control condition.
62816963|NCT05523765|EXPERIMENTAL|Brepocitinib Dose Level 1 PO QD|
62816964|NCT05523765|EXPERIMENTAL|Brepocitinib Dose Level 2 PO QD|
62038279|NCT04435665|EXPERIMENTAL|NFX-179 Gel High|NFX-179 Gel for topical administration, once daily for 28 days
62038280|NCT04435665|PLACEBO_COMPARATOR|Vehicle Arm|Vehicle Gel, for topical administration, once daily for 28 days
62038281|NCT04789538||Monofocal IOL|
62038282|NCT06723951||Children with spina bifida|• Male or female aged 8 -12 years with spina bifida
62038283|NCT06723951||Control group children|• Male or females aged 8 -12 years without spina bifida
62038284|NCT06723951||Teenagers with spina bifida|• Males or female aged 13 - 17 years with spina bifida
62038285|NCT06723951||Control group teenagers|• Males or females aged 13 - 17 years without spina bifida
62038286|NCT06723951||Adults with spina bifida|Adults with spina bifida
62038287|NCT06723951||Control group adults|Adults without spina bifida
62431280|NCT04661566|EXPERIMENTAL|Education+Narratives+Skills+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, and Risk"
62038288|NCT01915615||Hypertrophic cardiomyopathy|"None - this is an observational study.~Patients with hypertrophic cardiomyopathy will be observed for up to 5 years after index cardiac magnetic resonance imaging and blood draw for genetics and biomarkers"
62038289|NCT06442150|ACTIVE_COMPARATOR|LCD Group|Participants will receive a Low-Calorie Diet (815-835 kcal/day; approximately 43% carbohydrate, 29% protein, and 29% fat) meals for 12 weeks, followed by a gradual food reintroduction phase combined with physical activity support for 12 weeks.
62038290|NCT06442150|EXPERIMENTAL|LCMD Group|Participants will receive a Low-Calorie Medicine Diet (815-835 kcal/day; approximately 43% carbohydrate, 29% protein, and 29% fat) meals product for 12 weeks, followed by a gradual food reintroduction phase combined with physical activity support for 12 weeks.
62038291|NCT03529474|EXPERIMENTAL|Psychology and Physiotherapy group|The psychological program consists of 4 sessions (2 hours each) comprising psychoeducation, training techniques of psychological management of pain and kinesiophobia resources The physiotherapy program consists of 3 domiciliary sessions per week, including physical exercise and stretching
62038292|NCT03529474|PLACEBO_COMPARATOR|Placebo Comparator: Control group|Usual daily activities
62038293|NCT03345238|EXPERIMENTAL|Active MTP|
62038294|NCT03345238|EXPERIMENTAL|Latent MTP|
62038295|NCT03345238|EXPERIMENTAL|Out of MTP|
62431281|NCT04661566|EXPERIMENTAL|Education+Narratives+Skills|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives and Skills"
62816965|NCT06253351||Group1|Patients between 15 and 25 years old with type 1 diabetes and treated by hybrid closed loop
62240936|NCT01647750|OTHER|Standard dose of levothyroxine|Patients may be randomised to receive their usual dose of levothyroxine (target TSH level 0.4 - 4.0 mU/L)
62240937|NCT05522816|EXPERIMENTAL|KX01 0.01% in stage I|Six patients in the stage 1 will receive KX01 0.01% (0.1 mg/g) for 2 weeks, followed by 1-week wash-out, another 2-week treatment, and then 2-week follow-up.
62240938|NCT05522816|PLACEBO_COMPARATOR|Placebo in stage 1|Two patients in the stage 1 will receive placebo treatment for 2 weeks, followed by 1-week wash-out, another 2-week treatment, and then 2-week follow-up.
62240939|NCT05522816|EXPERIMENTAL|KX01 0.1% in stage 2|Six patients in the stage 2 will receive KX01 0.1% (1.0 mg/g) for 4 weeks, followed by 2-week follow-up.
62240940|NCT05522816|PLACEBO_COMPARATOR|Placebo in stage 2|Two patients in the stage 2 will receive placebo treatment for 4 weeks, followed by 2-week follow-up.
62240941|NCT05522816|EXPERIMENTAL|KX01 1% for 5 days in stage 3|Six patients in stage 3 will receive 1% KX01 (10 mg/g) once daily for consecutive 5 days and then receive post-treatment follow-up on Day 6, 15 and 29.
62240942|NCT05522816|EXPERIMENTAL|KX01 1% for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles in stage 4|Six patients in stage 4 will be treated with daily KX01 1% (10 mg/g) ointment for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles. And post-treatment follow-up visits will be conducted 14 days (Follow-up visit 1) and 28 days (Follow-up visit 2) after the end of cycle 4 treatment.
62240943|NCT04228809|EXPERIMENTAL|anodal tDCS|anodal tDCS stimulation
62431282|NCT04661566|EXPERIMENTAL|Education+Narratives+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives. Scenarios, Future, and Risk"
62431283|NCT04661566|EXPERIMENTAL|Education+Narratives+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Scenarios, and Future"
62431284|NCT04661566|EXPERIMENTAL|Education+Narratives+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Scenarios, and Risk"
62240944|NCT04228809|ACTIVE_COMPARATOR|cathodal tDCS|cathodal tDCS stimulation
62240945|NCT04228809|PLACEBO_COMPARATOR|sham tDCS|sham tDCS stimulation (stopped after 30 seconds)
62240946|NCT04978311|EXPERIMENTAL|Mirror therapy (MT) priming with task-specific training|In the regimen, participants will perform MT first followed by task-specific training. After completion of MT, participants will practice task-specific training that emphasizes on restoration of essential skills for daily activities. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
62240947|NCT04978311|ACTIVE_COMPARATOR|Mirror therapy priming with impairment-oriented training|In the regimen, participants will perform MT first followed by impairment-oriented training. After completion of MT, participants will practice impairment-oriented training that emphasizes on restoration of movement. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
62240948|NCT04978311|ACTIVE_COMPARATOR|Control therapy|The control group will receive therapeutic training equivalent in duration to the two experimental groups. The control intervention will include practice of gross/fine motor activities, training of activities of daily living, practice to increase range of motions, muscle strengthening, as well as use of adaptive or compensatory technique to alleviate functional deficits. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
62240949|NCT01184053|EXPERIMENTAL|Trisenox treatment|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
62431285|NCT04661566|EXPERIMENTAL|Education+Narratives+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives and Scenarios"
62816966|NCT06131255||Women with Post-Partum Depression|15 women with PPD referred to the S.C. Psychiatry of IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation and referred to the S.C. Neonatology and Neonatal Intensive Care Unit of the same institution for enrollment.
62598329|NCT06136481|NO_INTERVENTION|Control group|The control (enhanced care as usual) group will receive the information about freely available psychological support options. E-CAU ranges from standard community care which may include any existing mental health support services available to earthquake survivors in container cities. The participants will be given flyers which include information about the services provided by the government and by non-governmental organizations. After completion of the post and follow-up assessment of experimental group, those in the E-CAU condition will be offered with CPT
62598330|NCT02261662|EXPERIMENTAL|Ribavirin and Betamethasone|"A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.~It will be used along with Topical steroids; Betamethasone"
62038296|NCT01895972|EXPERIMENTAL|Latanoprostene Bunod|Latanoprostene bunod 0.024% instilled into the eye once daily (QD) over a 1-year treatment period.
62038297|NCT03131557|EXPERIMENTAL|Line extension of the Phonak Audéo B hearing aid|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
62598331|NCT02261662|EXPERIMENTAL|Betamethasone alone|Topical steroids alone will be used; Betamethasone.
62598332|NCT05871398|PLACEBO_COMPARATOR|placebo group|
62240950|NCT03947125||knee applied group|the patients with buprenorphine patch applied to painful knee joint in knee osteoarthritic patients
62431286|NCT04661566|EXPERIMENTAL|Education+Narratives+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Future, and Risk"
62598333|NCT05871398|ACTIVE_COMPARATOR|tegoprazan group|
62598334|NCT05817383|EXPERIMENTAL|Freeze-dried Blueberry Powder|Randomized participants will be asked to consume 48 grams of freeze-dried blueberry powder each day for 12 weeks.
62598335|NCT05817383|PLACEBO_COMPARATOR|Placebo Powder|Randomized participants will be asked to consume 48 grams of a nutritionally matched placebo powder devoid of fiber and anthocyanins each day for 12 weeks.
62598336|NCT06618261|EXPERIMENTAL|Caffeine - Males|
62598337|NCT06618261|PLACEBO_COMPARATOR|Placebo - Males|
62598338|NCT06618261|EXPERIMENTAL|Caffeine - Females|
62598339|NCT06618261|PLACEBO_COMPARATOR|Placebo - Females|
62598340|NCT06153186|EXPERIMENTAL|Flunarizine|Flunarizine 5 mg capsules will be administered once a day at night. If the 5mg/day dose is tolerated by any given participant, the dose will be escalated to 10mg/day taken as two 5mg capsules at night
62038298|NCT03131557|ACTIVE_COMPARATOR|Phonak Audéo B hearing aid|Phonak Audéo B will be fitted to the participants individual hearing loss.
62598341|NCT06606574|OTHER|Titration protocol|This is a single arm study where each subject will be started with a standardized ITB protocol. The dosing will be increased or decreased stepwise based on parameters that have been described in detail in the intervention section.
62598342|NCT03500458|NO_INTERVENTION|Typical Sleep|All participants will sleep for 6 nights (Sunday - Thursday) in the home environment per their usual school schedule.
62598343|NCT03500458|EXPERIMENTAL|Sleep Extension|Participants will be prescribed a sleep schedule that allows them to obtain 1 hour more time in bed compared to Typical Sleep. For participants completing the study September 2021 and later, they will also be instructed to take exogenous melatonin (500mcg) and maintain dim light conditions 2 hours before bedtime, and use light glasses for 30 minutes in an upright position after waking in the morning (Sleep Extension + Circadian Manipulation).
62598344|NCT01367496|EXPERIMENTAL|Arm 1|
62598345|NCT01367496|EXPERIMENTAL|Arm 2|
62598346|NCT01367496|EXPERIMENTAL|Arm 3|
62598347|NCT01367496|EXPERIMENTAL|Arm 4|
62598348|NCT05418894|NO_INTERVENTION|EMU|Patient's behavioral and neural activity via computer tasks and questionnaires are monitored in the Epilepsy Monitoring Unit
62598349|NCT05418894|EXPERIMENTAL|TRD|
62598350|NCT03760367|EXPERIMENTAL|Blue Covarine Toothpaste|After a short video introduction to the bass technique, participants brush their teeth once with a silica toothpaste containing blue covarine (Pepsodent White Now Gold, 1 g) for 2 min, starting with the upper front teeth. Thereafter, participants rinse their mouth with of tap water.
62038299|NCT05618795|OTHER|aggresive gap arthoplasty|control group- aggressive gap arthroplasty(15 to 20 mm) for management of TMJ ankyosis
62598351|NCT03760367|ACTIVE_COMPARATOR|Control Toothpaste|After a short video introduction to the bass technique, participants brush their teeth once with a silica toothpaste (Colgate Advanced Whitening, 1 g) for 2 min, starting with the upper front teeth. Thereafter, participants rinse their mouth with of tap water.
62038300|NCT05618795|ACTIVE_COMPARATOR|minimal gap arthoplasty|experimental group-minimal gap arthroplasty(5 to 8mm) for management of TMJ ankylosis
62038301|NCT03235167|EXPERIMENTAL|CpG DNA|CpG DNA concentrate
62038302|NCT03235167|PLACEBO_COMPARATOR|placebo|placebo concentrate
62038303|NCT05582720|ACTIVE_COMPARATOR|Conventional burger group|This arm will consume 2 portions (each 120 g cooked) of conventional burger per week for a 4-week period.
62038304|NCT05582720|EXPERIMENTAL|Vegan burger group|This arm will consume 2 portions (each 120 g cooked) of vegan burger per week for a 4-week period.
62038305|NCT05403866|EXPERIMENTAL|LT3001 Drug Product|Administered by intravenous infusion
62240951|NCT03947125||chest applied group|the patients with buprenorphine patch applied to anterior chest wall in knee osteoarthritic patients
62240952|NCT02750098|EXPERIMENTAL|Diabetic patients|Diabetic patients planned to undergo elective cataract surgery
62240953|NCT02706301|EXPERIMENTAL|Telephone-Based Coping Skills Training (CST)|The CST condition will receive 5 sessions of a cognitive behavior theory-based protocol that teaches coping skills (e.g., relaxation, activity pacing/planning, cognitive restructuring) relevant to managing pain as well as psychological distress.
62240954|NCT02706301|NO_INTERVENTION|Standard care control|The standard care control condition will receive resources and referrals related to survivorship health. This information will be provided to the participant during their initial survivorship care consult.
62431287|NCT04661566|EXPERIMENTAL|Education+Narratives+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives and Future"
62431288|NCT04661566|EXPERIMENTAL|Education+Narratives+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives and Risk"
62598352|NCT03410472|EXPERIMENTAL|Web based diet application|This arm entails the subject to record their diet into an online web program to monitor calories. The calorie goal will be given to the subjects in this group prior to the study based on dual x-ray absorptiometry test that will test resting metabolic rate.
62598353|NCT03410472|NO_INTERVENTION|Control|This group will have body composition tested at week 1 and then repeat this test at 8 weeks having no intervention.
62598354|NCT06620562|EXPERIMENTAL|Naltrexone/Bupropion|Patients will be started one month after sleeve gastrectomie on a progressive dose of Naltrexone/Bupropion extended-release 8mg/90mg, up to 2 tabs twice a day (32mg/360mg) adjusted according to tolerance and side-effects.
62598355|NCT06620562|PLACEBO_COMPARATOR|Placebo|Patients will be started one month after sleeve gastrectomie on a progressive numbers of matched placebo tablets up to 2 tabs twice a day
62240955|NCT02679950||Initial diagnosis|The initial diagnosis only cohort will include 3 patients with germ cell tumor (GCT) who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department. One prospective blood and one tissue sample will be collected from each patient in this cohort. Tissue samples will come from the orchiectomy or virgin retro-peritoneal lymph node dissection (RPLND) that was done at initial diagnosis.
62431289|NCT04661566|EXPERIMENTAL|Education+Narratives|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives"
62431290|NCT04661566|EXPERIMENTAL|Education+Skills+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills, Scenarios, Future, and Risk"
62431291|NCT04661566|EXPERIMENTAL|Education+Skills+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills, Scenarios, and Future"
62431292|NCT04661566|EXPERIMENTAL|Education+Skills+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills, Scenarios, and Risk"
62038306|NCT05403866|PLACEBO_COMPARATOR|Placebo|Administered by intravenous infusion
62038307|NCT03239119|EXPERIMENTAL|rE-4 5 mcg|Placebo, then rE-4 5 mcg, then rE-4 5 mcg
62598356|NCT02128425|EXPERIMENTAL|FOLFOXIRI|FOLFOXIRI
62598357|NCT02128425|ACTIVE_COMPARATOR|FOLFOX|FOLFOX
62598358|NCT02961322|EXPERIMENTAL|lobo isthmectomy|
62598359|NCT04865549|EXPERIMENTAL|TAD arm|Sentinel Node Biopsy + Targetted Axillary Dissection (Clipped cN1 node) extraction + lymphadenectomy.
62038308|NCT03239119|EXPERIMENTAL|rE-4 10 mcg|Placebo, then rE-4 5 mcg, then rE-4 10 mcg
62598360|NCT04884113||Experimental: Motorized Spiral Enteroscopy|"Procedure: Motorized Spiral Enteroscopy:~PowerSpiral enteroscope will be inserted and advanced with the assistance of motorized spiral rotation, After reaching the point of maximum insertion, cecum or if no further advancement of the enteroscope can be achieved, the enteroscope will be withdrawn using motorized counter-clockwise spiral rotation. When no total enteroscopy is reached, submucosal ink dye injection is performed as an endoscopically visible marker of the maximum insertion depth. A retrograde enteroscopy is then performed in the same session or at second session"
62598361|NCT06648863||A/6 months|Measures of child development (GSED), nutrition, medical history and anthropometrics, followed by MRI
62598362|NCT06648863||B/12 months|Measures of child development (GSED), nutrition, medical history and anthropometrics, followed by MRI
62816967|NCT05182086|EXPERIMENTAL|Intervention group|Patients that are allocated to the intervention group will participate in a 12 week lifestyle intervention program consisting of group exercise therapy and dietary advice combined with dietary supplementation. The group exercise therapy will be guided by trained physical therapists. Patients will participate in this part of the intervention twice a week for one hour. The exercise therapy will combine cardiorespiratory with strength training. At the start of the intervention, patients will have an appointment with a nutritional scientist or doctor in which they will receive dietary advise and dietary supplements (ProSource®) to reach the advised caloric and protein intake as composed by the Dutch Centre for Nutrition (Voedingscentrum). Dietary supplements like ProSource® are extensively tested and often used as part of general practice to patients after ICU- or hospital-discharge following critical illness.
62598363|NCT06648863||C/18 months|Measures of child development (GSED), nutrition, medical history and anthropometrics, followed by MRI
62816968|NCT05182086|NO_INTERVENTION|Standard care|Standard care outpatient post-ICU clinic
62431293|NCT04661566|EXPERIMENTAL|Education+Skills+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills and Scenarios"
62431294|NCT04661566|EXPERIMENTAL|Education+Skills+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills, Future, and Risk"
62431295|NCT04661566|EXPERIMENTAL|Education+Skills+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills Future"
62431296|NCT04661566|EXPERIMENTAL|Education+Skills+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills and Risk"
62431297|NCT04661566|EXPERIMENTAL|Education+Skills|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills"
62431298|NCT04661566|EXPERIMENTAL|Education+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Scenarios, Future, and Risk"
62431299|NCT04661566|EXPERIMENTAL|Education+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Scenarios and Future"
62431300|NCT04661566|EXPERIMENTAL|Education+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Scenarios and Risk"
62431301|NCT04661566|EXPERIMENTAL|Education+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Scenarios"
62431302|NCT04661566|EXPERIMENTAL|Education+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Future and Risk"
62431303|NCT04661566|EXPERIMENTAL|Education+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Future"
62431304|NCT04661566|EXPERIMENTAL|Education+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Risk"
62431305|NCT04661566|EXPERIMENTAL|Education|Participants will receive a version of the Mission Wellness app (intervention) that only includes the static educational component.
62598364|NCT06648863||D/24 months|Measures of child development (GSED), nutrition, medical history and anthropometrics, followed by MRI
62598365|NCT06648863||E/30 months|Measures of child development (GSED), nutrition, medical history and anthropometrics, followed by MRI
62431306|NCT02816554|EXPERIMENTAL|JECEVAX-1|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1.0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12days
62598366|NCT06648863||F/36 months|Measures of child development (GSED), nutrition, medical history and anthropometrics, followed by MRI
62598367|NCT06648863||G/48 months|Measures of child neurocognitive development and school readiness, nutrition, medical history, and anthropometrics followed by MRI
62038309|NCT03239119|PLACEBO_COMPARATOR|Placebo 5 mcg|Placebo 5 mcg, then Placebo 5 mcg, then Placebo 5 mcg
62038310|NCT03239119|PLACEBO_COMPARATOR|Placebo 10 mcg|Placebo 5 mcg, then Placebo 5 mcg, then Placebo 10 mcg
62038311|NCT02371954|EXPERIMENTAL|Health Promotion|Happy Older Latinos are Active (HOLA) is multicomponent health promotion intervention led by a community health worker (CHW). First component is a social and physical activation session. Participants meet individually with CHW for 30 minutes once at week 1, then again at week 8 (the midway point). Second component is a moderate intensity group walk. Groups will consist of 6 participants and will meet for one hour, 3 times a week, for 16 weeks. Third component is pleasant events scheduling during cool down phase of the group walk.
62240956|NCT02679950||Late relapse|"The late relapse cohort will include 3 patients with late relapse germ cell tumor (GCT) who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department. One prospective blood and two tissue samples will be collected from each patient in this cohort. Tissue samples will come from the orchiectomy or virgin retro-peritoneal lymph node dissection (RPLND) that was done at initial diagnosis and the other will come from the site of late relapse.~Patients in this cohort will have biopsies at the site of late relapse as part of their routine cancer treatment. No biopsies will be performed specifically for the purposes of this study. Tissue from the site of late relapse will also be requested from the Pathology Department."
62816969|NCT06704373|EXPERIMENTAL|Manipulation group|"Thoracic spinal manipulation will be performed between the T1-T12 vertebral levels, based on the segment with movement limitations. The manipulation will be applied to the area of back pain using a high-velocity, low-amplitude thrust with a short-lever technique.~Also, the same postural exercises that were given to the control group will be given."
62816970|NCT06704373|ACTIVE_COMPARATOR|Control Group|The postural exercises program will be given.
62431307|NCT02816554|EXPERIMENTAL|JECEVAX-0.8|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
62598368|NCT06648863||H/60 months|Measures of child neurocognitive development and school readiness, nutrition, medical history, and anthropometrics followed by MRI
62598369|NCT06374225|NO_INTERVENTION|Usual Care (Manual Titration)|Patients randomized to the usual care arm will receive usual care, manual oxygen titration, removal of supplemental oxygen, and escalation per hospital protocol, based on the site's usual SpO2 assessments. The SpO2 monitor for the O2matic PRO100 will also be connected to the patient in observation mode for data collection purposes only (not used for titration decisions).
62816971|NCT06706154||Kidney transplant recipients|
62816972|NCT00698854||Vanguard™ Complete Knee System|Vanguard Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
62431308|NCT02816554|EXPERIMENTAL|JECEVAX-0.5|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
62598370|NCT06374225|EXPERIMENTAL|Intervention (Automated Titration)|Patients randomized to the intervention arm will receive supplemental oxygen via nasal cannula (recommended up to 6 lpm) or face mask (recommended up to 15 lpm) and will have supplemental oxygen titrated using an autonomous oxygen titration system for the first 72 hours after randomization, or hospital discharge (whichever sooner).
62816973|NCT00698854||Vanguard™ Patient-Specific Femur|Vanguard Total Knee System used in combination with Signature technique to provide a patient-specific femur
62816974|NCT04165070|EXPERIMENTAL|Part A: Pembrolizumab+Vibostolimab+Carboplatin + Paclitaxel|On Day 1 of each 3-week cycle, participants with squamous NSCLC receive pembrolizumab 200 mg intravenously (IV) PLUS vibostolimab IV PLUS carboplatin Area Under the Concentration-Time Curve (AUC) 6 IV PLUS paclitaxel 200 mg/m\^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS vibostolimab IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).
62038312|NCT02371954|ACTIVE_COMPARATOR|Psychoeducation|Participants will be given a fotonovela and will meet once a month after they receive the fotonovela to discuss their thoughts on the materials they received. These discussion groups will last one hour and will consist of 10 participants.
62240957|NCT06176170|EXPERIMENTAL|VividWhite Glaucoma Implant (VW-51)|Surgical implantation of VW-51.
62240958|NCT05003713|EXPERIMENTAL|Part 1: SAD Cohorts A through F CORT125236|Cohorts will receive a single dose of CORT125236 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. Cohort A will receive a 20-mg dose in a fasted state. Cohort B will receive a ≤3-fold increase in dose from Cohort A in a fasted state; the dose level and dose regimen (whether to split the dose) will be determined after evaluation of safety and PK data for Cohort A. Subsequent cohorts will receive a ≤3-fold increase in CORT125236 dose from the previous cohort in a fasted or fed state; the dose level, dose regimen, and prandial state will be determined after evaluation of safety and PK data from previous cohorts.
62431309|NCT02816554|ACTIVE_COMPARATOR|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
62431310|NCT02626182|EXPERIMENTAL|Sildenafil|Subjects will be randomized in a 3:1 (sildenafil:placebo) fashion. Subjects randomized to the treatment arm will receive sildenafil 20 mg p.o. t.i.d for 1 week followed by 40 mg p.o. t.i.d. for 11 weeks.
62431311|NCT02626182|PLACEBO_COMPARATOR|Placebo|Subjects randomized to the placebo arm will receive placebo p.o. t.i.d for 1 week followed by 2 placebo tablets p.o. t.i.d. for 11 weeks.
62598371|NCT06302296|EXPERIMENTAL|injectable form of PRF|A group of patients in which participants will be undergo to orthodontic treatment will be received a 0.9 ml injection of PRF after 1st premolar extraction.
62598372|NCT06302296|EXPERIMENTAL|traditional orthodontic treatment|A group of patients in which participants will be undergo to traditional orthodontic treatment will be received a Placebo injection after 1st premolar extraction.
62598373|NCT00138073|EXPERIMENTAL|Web-based waveform interpretation guide|The arm has access to the Web-based waveform interpretation guide.
62598374|NCT03616444|EXPERIMENTAL|TCM-Shenbai Granules|"Shenbai Granules: Hedyotis diffusa 10g, Sophorae flavescentis radix 4.5g, Codonopsis radix 7.5g, Atractylodis macrocephalae rhizoma 6g, Mume fructus 4.5g, Coptidis rhizoma 1.5g, Zingiberis rhizome praeparatum 3g, Coicis semen 10g.~Orally, 1 sachet once, diluted in 150-200 ml of boiling water, 2 times a day."
62816975|NCT04165070|EXPERIMENTAL|Part A: Pembrolizumab+Vibostolimab+Carboplatin + Pemetrexed|On Day 1 of each 3-week cycle, participants with nonsquamous NSCLC receive pembrolizumab 200 mg IV PLUS vibostolimab IV PLUS carboplatin AUC 5 IV PLUS pemetrexed 500 mg/m\^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS vibostolimab IV PLUS pemetrexed 500 mg/m\^2 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).
62816976|NCT04165070|EXPERIMENTAL|Part A: Pembrolizumab+Boserolimab+Carboplatin+Paclitaxel|On Day 1 of each 3-week cycle, participants with squamous NSCLC receive pembrolizumab 200 mg IV PLUS carboplatin AUC 6 IV PLUS paclitaxel 200 mg/m\^2 IV PLUS boserolimab IV on Day 1 every 6 weeks (every other 3-week cycle) (Q6W) in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV Q3W PLUS boserolimab IV Q6W from Cycles 5 up to Cycle 35 (total treatment duration: up to approximately 2 years).
62816977|NCT04165070|EXPERIMENTAL|Part A: Pembrolizumab+Boserolimab+Carboplatin+Pemetrexed|On Day 1 of each 3-week cycle, participants with nonsquamous NSCLC receive pembrolizumab 200 mg IV PLUS carboplatin AUC 5 IV PLUS pemetrexed 500 mg/m\^2 IV PLUS boserolimab IV on Day 1 every 6 weeks (every other 3-week cycle) (Q6W) in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV Q3W PLUS pemetrexed 500 mg/m\^2 IV Q3W PLUS boserolimab IV Q6W from Cycles 5 up to Cycle 35 (total treatment duration: up to approximately 2 years).
62431312|NCT05478005|EXPERIMENTAL|Femoral nerve block|Patients undergoing total knee arthroplasty received a single-shot femoral nerve block during the surgical procedure.
62598375|NCT03616444|PLACEBO_COMPARATOR|TCM-Placebo|"It contains 5% SBG content, and the remaining ingredients are flavoring agents, starch and coloring agents. It is the same with SBG in appearance, smell and dosage form.~Orally, 1 sachet once, diluted in 150-200 ml of boiling water, 2 times a day."
62816978|NCT04165070|EXPERIMENTAL|Part A: Pembrolizumab+MK-4830+Carboplatin+Paclitaxel|On Day 1 of each 3-week cycle, participants with squamous NSCLC receive pembrolizumab 200 mg IV PLUS MK-4830 IV PLUS carboplatin AUC 6 IV PLUS paclitaxel 200 mg/m\^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS MK-4830 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).
62598376|NCT06648434|EXPERIMENTAL|Dose escalation phase (zunsemetinib + mFOLFIRNOX)|The dose of zunsemetinib will be determined by the dose level assigned and will be taken by mouth either once or twice daily depending on assigned dose level. mFOLFIRINOX will be 85 mg/m\^2 of oxaliplatin intravenous (IV) on day 1 of each cycle, 150 mg/m\^2 of irinotecan IV on day 1 of each cycle, 400 mg/m\^2 of leucovorin IV on day 1 of each cycle, and 2400 mg/m\^2 continuous infusion starting on day 1 of each cycle and continuing for 46 hours. Each cycle is 2 weeks in length.
62816979|NCT04165070|EXPERIMENTAL|Part A: Pembrolizumab+MK-4830+Carboplatin+Pemetrexed|On Day 1 of each 3-week cycle, participants with nonsquamous NSCLC receive pembrolizumab 200 mg IV PLUS MK-4830 IV PLUS carboplatin AUC 5 IV PLUS pemetrexed 500 mg/m\^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS MK-4830 IV PLUS pemetrexed 500 mg/m\^2 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).
62816980|NCT04165070|EXPERIMENTAL|Part A: Pembrolizumab+MK-0482+Carboplatin+Paclitaxel|On Day 1 of each 3-week cycle, participants with squamous NSCLC receive pembrolizumab 200 mg IV PLUS MK-0482 IV PLUS carboplatin AUC 6 IV PLUS paclitaxel 200 mg/m\^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS MK-0482 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).
62816981|NCT04165070|EXPERIMENTAL|Part A: Pembrolizumab+MK-0482+Carboplatin+Pemetrexed|On Day 1 of each 3-week cycle, participants with nonsquamous NSCLC receive pembrolizumab 200 mg IV PLUS MK-0482 IV PLUS carboplatin AUC 5 IV PLUS pemetrexed 500 mg/m\^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS MK-0482 IV PLUS pemetrexed 500 mg/m\^2 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).
62816982|NCT04165070|EXPERIMENTAL|Part B: Pembrolizumab + I-DXd|On Day 1 of each 3-week cycle, participants with squamous and nonsquamous NSCLC will receive pembrolizumab 200 mg IV for up to 2 years, PLUS I-DXd in escalating doses until progressive disease or toxicity.
62816983|NCT04165070|EXPERIMENTAL|Part B: Pembrolizumab + Carboplatin + I-DXd|On Day 1 of each 3-week cycle, participants will receive pembrolizumab 200 mg IV for up to 2 years, PLUS carboplatin AUC 5-6 up to 4 cycles PLUS I-DXd IV in escalating doses until PD or toxicity.
62816984|NCT04165070|EXPERIMENTAL|Part B: Pembrolizumab + Carboplatin + HER3-DXd|On Day 1 of each 3-week cycle, participants will receive pembrolizumab 200 mg IV for up to 2 years, PLUS carboplatin AUC 5-6 up to 4 cycles PLUS HER3-DXd IV in escalating doses until PD or toxicity.
62816985|NCT06245941|EXPERIMENTAL|TQB3909 Tablets|TQB3909 Tablets, orally administered. 28 days as a treatment cycle.
62816986|NCT06245941|EXPERIMENTAL|TQ05105 Tablets combined with TQB3909 Tablets|TQ05105 Tablets combined with TQB3909 Tablets, orally administered. 28 days as a treatment cycle.
62816987|NCT05206734||Cases|All incident cases of Inflammatory Bowel Disease (IBD); comprising of Ulcerative Colitis, Crohn's Disease and IBD Unclassified in children, adolescents and young adults up to their 25th birthday. Cases will be defined based on an algorithm using diagnostic codes from the electronic medical record (EMR).
62816988|NCT05206734||Controls|People without a diagnosis in their electronic medical record (ERM) of Inflammatory Bowel Disease, matched on age group, sex, ethnicity (consistent with UK census categories: White, Asian, Black, Mixed, Other), index of multiple deprivation based on postcode, and by practice where numbers allow.
62816989|NCT03735303|EXPERIMENTAL|VD3 group|dietary supplement : VD3 group treated with 50000 IU VD3/ week for 8 weeks
62816990|NCT03735303|EXPERIMENTAL|omega 3- FA group|dietary supplement : omega 3- FA group 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
62431313|NCT05478005|EXPERIMENTAL|Intra-articular block|Patients undergoing total knee arthroplasty received a intra-articular block during the surgical procedure.
62431314|NCT05478005|NO_INTERVENTION|Control group|Patients undergoing total knee arthroplasty and didn't receive pain block.
62431315|NCT04126733|EXPERIMENTAL|Regorafenib + Nivolumab|
62240959|NCT05003713|PLACEBO_COMPARATOR|Part 1: SAD Cohorts A through F Placebo|Cohorts will receive a single dose of placebo matching CORT125236 lipid capsule formulation by mouth on Day 1. The dose regimen and prandial state will be the same as those for the cohort members receiving CORT125236.
62240960|NCT05003713|EXPERIMENTAL|Part 2: MAD Cohorts A through D CORT125236|Cohorts will receive once- or twice-daily doses of CORT125236 lipid capsule formulation by mouth for 14 days. The anticipated exposure will not exceed the highest exposure considered safe and well-tolerated during Part 1. The dose level, dose schedule, and prandial state for each cohort will be determined after evaluation of safety and PK data from Part 1 and preceding Part 2 cohorts.
62598377|NCT06648434|EXPERIMENTAL|Dose expansion phase (zunsemetinib + mFOLFIRNOX)|The dose of zunsemetinib will be determined during the dose escalation phase of the trial. mFOLFIRINOX will be 85 mg/m\^2 of oxaliplatin intravenous (IV) on day 1 of each cycle, 150 mg/m\^2 of irinotecan IV on day 1 of each cycle, 400 mg/m\^2 of leucovorin IV on day 1 of each cycle, and 2400 mg/m\^2 continuous infusion starting on day 1 of each cycle and continuing for 46 hours. Each cycle is 2 weeks in length.
62431316|NCT03360526|ACTIVE_COMPARATOR|PICSI|Physiological ICSI
62431317|NCT03360526|EXPERIMENTAL|TESA|Testicular sperm aspiration
62431318|NCT02957682|EXPERIMENTAL|Group 1|Praluent Regimen - Administration through subcutaneous injection
62431319|NCT02957682|EXPERIMENTAL|Group 2|Placebo matching Praluent - Administration through subcutaneous injection
62431320|NCT01218737|EXPERIMENTAL|Association|0.3% gatifloxacin and 1.0% prednisolone acetate association in eye drops plus placebo
62431321|NCT01218737|ACTIVE_COMPARATOR|Isolated ingredients|0.3% gatifloxacin and 1.0% prednisolone acetate isolated eye drops formulations
62598378|NCT06237244||coronary artery disease|patients with coronary angiography of at least one vessel with more than 50% stenosis
62598379|NCT06237244||no coronary artery disease|patient with no stenosis in coronary angiography
62598380|NCT06622915|ACTIVE_COMPARATOR|group A,|steroid dependent nephrotic syndrome
62598381|NCT06622915|ACTIVE_COMPARATOR|Group B|steroid resistant nephrotic syndrome
62598382|NCT06618963|ACTIVE_COMPARATOR|Participants with Food Allergy|This group will receive 4 months of Omalizumab treatment, and undergo regular skin barrier assessments.
62598383|NCT06618963|NO_INTERVENTION|Participants without Food Allergy|This group will undergo skin barrier assessment.
62598384|NCT01013844|ACTIVE_COMPARATOR|Solo Learning|Participant learning alone (without partner).
62598385|NCT01013844|ACTIVE_COMPARATOR|Dyadic Learning|Participant and partner learning together.
62598386|NCT06618365|EXPERIMENTAL|Group 1: Vitamin D2 50000 units per tablet|They will take one tablet weekly.
62816991|NCT03735303|EXPERIMENTAL|VD3 and omega 3 FA group|dietary supplement : VD3 and omega-3FA 50000 IU VD3/week for 8 weeks and 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
62816992|NCT03735303|EXPERIMENTAL|control group|no intervention was given
62816993|NCT05351944|EXPERIMENTAL|The intervention group (group A) DBT skills|"Will attend Dialectical Behavioral Therapy skills group for both the children and their parents, DBT is an evidence based comprehensive cognitive behavioral treatment for complex mental disorders and have been adapted for intractable behavioral disorders involving emotion dysregulation, skills will be provided in group therapy as fixed weekly sessions over 9-month duration for all the children and the parents in group A including:~1. Emotion regulation skills module over 8 weeks.~2. Mindfulness skills module over 3 weeks~3. Interpersonal effectiveness skills module over 7 weeks.~4. Distress tolerance skills module over 8 weeks.~5. Walking the middle path skills module over 3 weeks."
62816994|NCT05351944|ACTIVE_COMPARATOR|the control group (group B)|Will receive psychoeducation and medications targeting ADHD symptoms (stimulants or atomoxetine according to FDA approved dose per age and weight) according to the international guidelines for management of ADHD according to symptom severity, given that assessment before and after intervention will be done by different medical personnel than those providing the intervention for the two groups.
62816995|NCT05892432|PLACEBO_COMPARATOR|Placebo|Participants in this Arm will take a medically inert placebo. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the capsule orally each morning.
62816996|NCT05892432|ACTIVE_COMPARATOR|Semaglutide 3 milligrams and 7 milligrams|Participants in this Arm will study medication for a total of 8 weeks - on semaglutide 3 milligrams per day for 4 weeks, then 7 milligrams per day for 4 weeks. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the capsule orally each morning.
62816997|NCT05363267|EXPERIMENTAL|Curcumin with high phenolic extra virgin olive oil (HP-EVOO)|Identical for all participants with the exception of the curcumin dose level, which is assigned at study enrollment.
62816998|NCT06579768||spiral CT|
62816999|NCT06579768||cone beam CT|
62817000|NCT05829694||Parents|Individuals diagnosed with cystic fibrosis who became a first-time parent between January 1, 2012 and December 31, 2022.
62817001|NCT05829694||Non-parents|Individuals diagnosed with cystic fibrosis who have never been a parent.
62431322|NCT02516631|ACTIVE_COMPARATOR|Oral (A)|One tablet of Angusta™ (25 µg) or 1/8 of a tablet of Cytotec® (25 µg).
62431323|NCT02516631|ACTIVE_COMPARATOR|Oral (B)|Two tablets of Angusta™ 25 µg or ¼ of a tablet of Cytotec®.
62431324|NCT02516631|ACTIVE_COMPARATOR|Sublingual (C)|Two tablets of Angusta™ (total dose of 50 µg) or ¼ of a tablet of Cytotec® (50 µg.
62431325|NCT01440595|EXPERIMENTAL|Grazoprevir 200 mg + Peg-IFN + RBV|Grazoprevir 200 mg in combination with Peg-IFN and RBV for 12 weeks.
62598387|NCT06618365|EXPERIMENTAL|Group 2: Vitamin D2 300000 units Intramuscular injection|They will have one injection every 6 weeks initially.
62598388|NCT06618365|EXPERIMENTAL|Group 3: Vitamin D3 50000 units tablet|They will take one tablet weekly.
62598389|NCT06618365|EXPERIMENTAL|Group 4: Vitamin D3 300000 units Intramuscular injection|They will have one injection every 6 weeks initially.
62598390|NCT02999529|EXPERIMENTAL|Education Group|Participants offered a consent for chemotherapy treatment will watch an educational video.
62598391|NCT01310556||coronary artery disease|patients with coronary artery disease
62431326|NCT01440595|EXPERIMENTAL|Grazoprevir 400 mg + Peg-IFN + RBV|Grazoprevir 400 mg in combination with Peg-IFN and RBV for 12 weeks.
62598392|NCT05573490|EXPERIMENTAL|Experimental Cognitive Training and Tai Chi- Qi Gong Arm|Participants receiving 14 weeks of Cognitive Training (BrainHQ) and Tai Chi- Qi Gong exercise training
62598393|NCT05573490|ACTIVE_COMPARATOR|Active Control Arm|Participants receiving 14 weeks of Brain Games (BrainHQ) and stretching
62598394|NCT03359486|EXPERIMENTAL|Group problem management plus|Five sessions of group low intensity psychological intervention
62598395|NCT03359486|ACTIVE_COMPARATOR|Enhanced treatment as usual|Referral to primary health care workers trained in mental health Gap Action Programme.
62038313|NCT04973865||Disease Population|50 Patients who have chronic diseases, such as cardiovascular, will consider as high risk, those who have more than two number of CAD risk factor will categorize as mild and patients have less than two risk factor of CAD will consider as low risk factor. (ACSM risk stratification guide lines)
62038314|NCT04973865||Healthy|30 Healthy individual with no cardiac diseased.
62240961|NCT05003713|PLACEBO_COMPARATOR|Part 2: MAD Cohorts A through D Placebo|Cohorts will receive once- or twice-daily doses of placebo matching CORT125236 lipid capsule formulation by mouth for 14 days. The dose regimen and prandial state will be the same as those for the cohort members receiving CORT125236.
62431327|NCT01440595|PLACEBO_COMPARATOR|Placebo + Peg-IFN + RBV|Placebo to grazoprevir in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.
62431328|NCT01440595|EXPERIMENTAL|Grazoprevir 800 mg + Peg-IFN + RBV|Grazoprevir 800 mg in combination with Peg-IFN and RBV for 12 weeks.
62431329|NCT03451331|EXPERIMENTAL|Arm A|Gemcitabine plus carboplatin plus nivolumab
62431330|NCT03451331|EXPERIMENTAL|Arm B|Gemcitabine plus oxaliplatin plus nivolumab
62431331|NCT04608149||Subjects treated with Carpediem system|All patients who receive CRRT with the Carpediem™ system, as prescribed by the investigator, will be offered participation in the post market surveillance study after obtaining parental consent.
62598396|NCT01039922||1|Patients with a histologically confirmed diagnosis of a neuroendocrine tumor irrespective of primary tumor location
62598397|NCT03185806|EXPERIMENTAL|Puncture and Drainage|The enrolled SAP patients are administered puncture and drainage use 8-F or 10-F pigtail tube under guidance of B ultrasound or CT scan.
62598398|NCT03185806|NO_INTERVENTION|Conservative therapy|The enrolled SAP patients are administered conservative therapy and without puncture and prolonged drainage.
62598399|NCT06588907|ACTIVE_COMPARATOR|Group P|Reduction will be performed under procedural sedation analgesia (PSA)
62598400|NCT06588907|ACTIVE_COMPARATOR|Group B|Reduction will be performed under ultrasound-guided infraclavicular nerve block (ICB).
62598401|NCT04101929|EXPERIMENTAL|Experimental: Apatinib + S-1+ Irinotecan|Apatinib: 250mg po qd； S-1 capsule: According to the body surface area \<1.25m2 60mg/d, 1.25 \~ 1.5 m2 80 mg/d, \> 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle; Irinotecan: According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks.
62598402|NCT03839771|PLACEBO_COMPARATOR|Arm A: Placebo|"Cycle 1: day 1-start cycle 2 \| Cycle 2: day 1 - start consolidation treatment \| Consolidation treatment: day 1 - start maintenance \| Maintenance treatment: day 1- day 730 (2 years) \|~The dosage for Placebo for AG-120 (IDH1): 500 mg dose/day~The dosage for Placebo for AG-221 (IDH2): 100mg dose/day"
62817002|NCT05558696|EXPERIMENTAL|Bomedemstat|Participants will receive bomedemstat daily for 36 weeks and may qualify for additional treatment through Week 52 if deriving clinical benefit.
62817003|NCT05672784|ACTIVE_COMPARATOR|C group|the patients will take standard analgesia ( meloxicam (15 mg) once a day + paracetamol 1gm /3 times a day). ,with no nerve block
62817004|NCT05672784|ACTIVE_COMPARATOR|G group|the patients will take standard analgesia plus GNB
62817005|NCT05672784|ACTIVE_COMPARATOR|GI group|the patients will take standard analgesia plus GNB plus IPACK
62240962|NCT05003713|EXPERIMENTAL|Part 3: Single Dose Pharmacodynamic Effect|In Period 1, participants will receive a single dose of prednisone 25 mg (20 mg + 5 mg) tablet by mouth on Day 1 in a fasted or fed state. After a 7-day washout, in Period 2, participants will receive a single dose of prednisone as in Period 1 plus a single dose of CORT125236 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. The dose of CORT125236 and the prandial state will be determined after evaluation of safety and PK data from Part 1. Part 3 of the study is optional.
62240963|NCT05036616||Separation technique|
62240964|NCT05036616||Integration technique|
62240965|NCT05922176||patient group of House dust mist allergic rhinitis|"1. Adult male and female patients aged 19 to 60 with allergic rhinitis caused by the antigen of the American house dust mite (It is judged that the positive for the house dust mite is MAST ≥ Class 3 or ImmunoCAP® ≥3.5 kUA/L)~2. Moderate-severe persistent rhinitis when evaluated according to ARIA (Allergic rhinitis and its impact on asthma)~3. A person who has signed a written consent to participate in this clinical trial at his/her own discretion after fully explaining the purpose, contents, characteristics of the test drug, and expected adverse reactions prior to participation in the clinical trial"
62240966|NCT05922176||control group|"1. Adults 19 years of age or older who are judged to be free from skin diseases or allergic diseases through medical examination and visual observation by a specialist~2. A person who agrees to provide samples derived from the human body~3. A person who voluntarily agreed to this study and prepared a consent form after approval of the IRB"
62240967|NCT03220087||Group A - Uncontrolled CS|Patients who have had at least one episode of uncontrolled CS, according to medical criteria, since the start of their treatment for NET.
62240968|NCT03220087||Group B - Controlled CS|Patients who have not had any episode of uncontrolled CS, according to medical criteria, in the last 12 months.
62240969|NCT04286425|PLACEBO_COMPARATOR|Placebo|"500 µl of saline solution applied in the vaginal volt twice :~1. one month before the IVF procedure during the ovulation period~2. Same month of the IVF procedure after ovum pick up"
62817006|NCT04448002|EXPERIMENTAL|AIM2ACT|AIM2ACT is the experimental arm for the trial. AIM2ACT is a dyadic mHealth intervention designed to sustain caregiver involvement and monitoring as well as guide dyads through collaborative asthma management.
62240970|NCT04286425|ACTIVE_COMPARATOR|seminal plasma|"500 µl of seminal plasma applied in the vaginal volt twice :~1. one month before the IVF procedure during the ovulation period~2. Same month of the IVF procedure after ovum pick up"
62240971|NCT02900534|EXPERIMENTAL|Internet-based self-help|The self-help programme consists of 10 text-based sessions and one supportive E-Mail a week. The programme employs cognitive-behavioural interventions. The theoretical background is the Dual Process Model by Stroebe and Schutt (1999).
62240972|NCT02900534|NO_INTERVENTION|Waiting control group|
62431332|NCT00032370|OTHER|1|Elective vascular surgery
62431333|NCT00032370|OTHER|2|Cardiac revascularization prior to vascular surgery.
62431334|NCT03705884|OTHER|Cardiac Sarcoidosis|Patients with an established diagnosis of cardiac sarcoidosis.
62431335|NCT03705884|OTHER|Healthy volunteers|Healthy volunteer subjects of similar age and gender to patient cohort.
62431336|NCT06156228|EXPERIMENTAL|Multilevel Intervention|The Multilevel Intervention condition will receive tailored and targeted messages about vaccination. Health educators will also deliver motivational interview sessions to patients eligible to receive the vaccines during the first 6 months of the study. To supplement these encounters, health educators will also send patients mail, emails and/or text message-based informational materials (including videos, testimonials, and resources) that reinforce the benfits of vaccines.
62598403|NCT03839771|EXPERIMENTAL|Arm B: Ivosidenib (IDH1) or Enasidenib (IDH2)|"Cycle 1: day 1-start cycle 2 \| Cycle 2: day 1 - start consolidation treatment \| Consolidation treatment: day 1 - start maintenance \| Maintenance treatment: day 1- day 730 (2 years) \|~The dosage for AG-120 (IDH1): 500 mg dose/day~The dosage for AG-221 (IDH2): 100mg dose/day"
62817007|NCT04448002|ACTIVE_COMPARATOR|mHealth Attention Control Condition|The mHealth attention control condition is the active comparator arm in the trial that accounts for staff attention and novelty of technology based asthma management intervention.
62817008|NCT06231381|ACTIVE_COMPARATOR|HB0034|Subjects will be given a single intravenous infusion of HB0034 on D1.
62817009|NCT06231381|PLACEBO_COMPARATOR|Placebo|Subjects will be given a single intravenous infusion of placebo on D1.
62817010|NCT05609565|ACTIVE_COMPARATOR|Group 1|
62817011|NCT05609565|ACTIVE_COMPARATOR|Group 2|
62817012|NCT06663670|EXPERIMENTAL|GROUP A Intraneural Facilitation Therapy along with Home care plan|Group A will receive 24 sessions of Intraneural Facilitation therapy, delivered three times weekly for eight weeks, each session lasting 60 minutes. Effects will be measured at baseline, post-intervention (after 8 weeks), and at a 2-months follow-up.
62817013|NCT06663670|EXPERIMENTAL|Group B Nerve Flossing Technique along with Home care plan|Group B will receive the nerve flossing technique for about 3 sets of 10 repetitions with an interval of 1 minutes between sets. A total of 24 sessions (3x/week for 8 weeks) will be conducted, lasting 50-60 minutes each. The effects will be measured at baseline (pre-treatment), after week 8 (post-intervention), and at 2-month follow-up.
62240973|NCT05788822|EXPERIMENTAL|MVA treated group|Oocytes in this groups will be cultured with MVA
62240974|NCT05788822|NO_INTERVENTION|Control group|Oocytes in this groups will be culture without MVA
62431337|NCT06156228|NO_INTERVENTION|Standard Clinical Practice|Standard clinical practice consisting of generic patient outreach to promote vaccine uptake among Latino patients.
62431338|NCT01559831|OTHER|IXIARO|IXIARO, applied according to licensed dose, intramuscular
62431339|NCT05288673|EXPERIMENTAL|ALXN1210 400 mg|Participants received ALXN1210 every 28 days.
62431340|NCT05288673|EXPERIMENTAL|ALXN1210: 800 mg|Participants received ALXN1210 every 28 days.
62431341|NCT05288673|PLACEBO_COMPARATOR|Placebo|Participants received placebo every 28 days.
62817014|NCT06551272|EXPERIMENTAL|EXL01 arm|Patients treated with atezolizumab-bevacizumab with the addition of the experimental treatment exl01, 1 capsule per day for a maximum of 12 months.
62817015|NCT04232319|EXPERIMENTAL|Sleep Hygiene Training|The intervention will be delivered online by an occupational therapist. The intervention consists of 3 weekly sessions; each session will be 30-45 minutes long. The focus of the intervention is to teach breast cancer survivors sleep hygiene strategies to improve their sleep.
62038315|NCT05066724|EXPERIMENTAL|Centanafadine|Participants will receive centanafadine sustained release (SR) tablets, orally at a TDD of 400 milligrams (mg), administered as 200 mg doses, BID, approximately 4 to 6 hours apart, for a total of 7 weeks.
62038316|NCT05521516|ACTIVE_COMPARATOR|Active Percutaneous Auricular Neuromodulation with NSS-2 Bridge|Application of 5 days of percutaneous auricular Neuromodulation with NSS-2 Bridge device
62038317|NCT05521516|SHAM_COMPARATOR|Sham Treatment|Application of 5 days of a nonfunctional sham device
62038318|NCT02738866|EXPERIMENTAL|Palbociclib and Fulvestrant|Participants will receive fulvestrant with palbociclib until disease progression or unacceptable toxicity.
62038319|NCT05646667|EXPERIMENTAL|Interscalene with erector spinae plane block group|Patients will receive interscalene brachial plexus block using 10 ml of bupivacaine 0.5% and ultrasound guided erector spinae plane block at thoracic (T2) using 10 ml of bupivacaine 0.5%.
62038320|NCT05646667|EXPERIMENTAL|Interscalene group|Patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5%.
62038321|NCT06166927||Cuffed Endotracheal tube.|Patients will be intubated using a high-volume low-pressure cuffed ETT with its OD determined by US measurement of the epiphyseal diameter of the distal radius.
62038322|NCT06166927||Uncuffed Endotracheal tube.|Patients will be intubated using an uncuffed ETT with its OD determined by US measurement of the epiphyseal diameter of the distal radius.
62240975|NCT04628884|ACTIVE_COMPARATOR|Protamine dosing according the total heparin administrated|The protamine dose will be calculated according to the total heparin administered including the heparin dose add during the pump purge, 1 mg of protamine for each 100 IU of heparin
62240976|NCT04628884|EXPERIMENTAL|Protamine dosing according the residual heparin determined by a pharmacokinetic model|The protamine dose will be calculated according to the residual heparin estimated before the separation of the cardiopulmonary bypass using a pharmacokinetic model, 1 mg of protamine for each 100 IU of residual heparin
62240977|NCT02624466||CKD - no dialysis|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
62240978|NCT02624466||Patients on PD|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, urine and PD fluid, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
62598404|NCT05721846|EXPERIMENTAL|Experimental|"SBRT: 15 Gy x 1 on a single site of disease on day 1 cycle 1~Immunotherapy:~Nivolumab 3 mg/kg (up to 240 mg maximum) as i.v. infusion on day 1 (± 3 days) of each 14-day treatment cycle Ipilimumab 1 mg/kg as i.v. infusion on day 1 cycle 1 and subsequently every 6 weeks (± 3 days).~Vaccine (500 μl aqueous solution of 200 μg TGFβ-B-15 peptide mixed to an emulsion with 500μl Montanide ISA-51) as s.c. injection on day 1 of the first 6 cycles and subsequently every 4 weeks (± 3 days)"
62240979|NCT02624466||Patients on HD|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, urine and spent dialysate, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
62817016|NCT04474470|EXPERIMENTAL|Dose escalation of NT219 as a single agent|
62817017|NCT04474470|EXPERIMENTAL|Dose escalation of NT219 in combination with ERBITUX®|
62817018|NCT04474470|EXPERIMENTAL|Expansion cohort of NT219 in combination with ERBITUX®|
62038323|NCT05842408|EXPERIMENTAL|DA-5212|administered once daily for 4weeks
62240980|NCT02257957|EXPERIMENTAL|Platelet -Rich Plasma (PRP)|15 patients with diagnosis of severe dry eye will receive PRP injection at day 0, 30,60 and 90
62240981|NCT02257957|ACTIVE_COMPARATOR|Standard Care|15 patients with diagnosis of severe dry eye will receive standard of care treatment and will be revised at day 0, 30,60,90
62240982|NCT00820976|NO_INTERVENTION|control|remission induction with cytosine arabinoside amd idarubicine
62240983|NCT00820976|EXPERIMENTAL|G-CSF|G-CSF was administered starting on Day 8 until neutrophil recovery
62240984|NCT02696772|EXPERIMENTAL|Energy balance|Intervention day diet containing 100% of estimated energy requirements
62240985|NCT02696772|EXPERIMENTAL|Energy restriction|Intervention day diet containing 25% of estimated energy requirements
62431342|NCT02601911|ACTIVE_COMPARATOR|Ketorolac tromethanine|This group will receive a caplet including10 mg Ketorolac tromethamine 45 minutes before applying infra alveolar nerve block injection.
62431343|NCT02601911|ACTIVE_COMPARATOR|Acetaminophen|This group receive a caplet including10 mg Ketorolac tromethamine/ 1000 mg Acetaminophen, before applying the injection.
62431344|NCT02601911|PLACEBO_COMPARATOR|Placebo|This group receive a caplet including placebo, before applying the injection.
62431345|NCT03346031|NO_INTERVENTION|Group 1|Group 1 is control group that does not listen to music
62431346|NCT03346031|ACTIVE_COMPARATOR|Music Therapy Group 2|Group 2 is the group listening to preoperative music
62038324|NCT05842408|OTHER|DA-5212-R|administered once daily for 4weeks
62038325|NCT05844813|EXPERIMENTAL|The Neoadjuvant Therapy Group|Neoadjuvant chemotherapy + Target therapy+ Radical resectional Surgery Drugs: Doxorubicin（PLD） 40mg/㎡ d1, Ifosfamide 1g/㎡ d1-5, Anlotinib10mg d1-14 Q3weeks \* 3 Circles, Watch-Wait 4-6 weeks
62038326|NCT05844813|ACTIVE_COMPARATOR|The Surgery only Group|Procedure: Radical resectional surgery
62038327|NCT00771810|PLACEBO_COMPARATOR|Placebo|Combination gemcitabine and platinum-based chemotherapy with concurrent placebo
62038328|NCT00771810|EXPERIMENTAL|TXA127 100 ug/kg|Combination gemcitabine and platinum-based chemotherapy with concurrent 100 ug/kg/day TXA127
62038329|NCT00771810|EXPERIMENTAL|TXA127 300 ug/kg|Combination gemcitabine and platinum-based chemotherapy with concurrent 300 ug/kg/day TXA127
62038330|NCT03732183|EXPERIMENTAL|Podcast SMART-3RP|"The mind body intervention is delivered by podcast and material posted online. All session content will be audio recorded into 15-min audio-recordings that will be delivered on a podcast platform. During the course of the 4-week program, one new podcast session will be delivered every day."
62038331|NCT02212756|EXPERIMENTAL|B Group|1st oral administration of Metformin 1000mg and 2nd oral administration of Metformin 1000mg and DW1029M 1200mg
62038332|NCT02212756|EXPERIMENTAL|A Group|1st oral administration of DW1029M 1200mg and Metformin 1000mg and 2nd oral administration of Metformin 1000mg
62431347|NCT03346031|ACTIVE_COMPARATOR|Music Therapy Group 3|Group 3 is the preoperative and peroperative music listening group (continuous)
62598405|NCT03415789||80 patients non ischemic DCM|"A cohort of 80 patients with nonischemic dilated cardiomyopathy in sinus rhythm with left ventricle ejection fraction (EF) less than 45%.~In the first 24 hours after enrollment a coagulation blood test, an electrocardiogram, a Doppler echocardiogram exam and a clinical examination (including neuropsiquiatric evaluation) will be performed.~A cardiac magnetic resonance and a brain magnetic resonance will be performed within 10 days after the enrollment."
62598406|NCT03698994|EXPERIMENTAL|Treatment (ulixertinib)|Patients receive ulixertinib PO BID. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62598407|NCT06488209|EXPERIMENTAL|Part 1: LAD191 (Cohort 1)|Participants will receive single ascending dose of LAD191 subcutaneous (SC) injection on Day 1.
62038333|NCT04068337||Hemiarch|Patients with Freestyle aortic root implantation receiving a hemiarch replacement by open anastomosis technique with axillary cannulation and antegrade cerebral perfusion
62598408|NCT06488209|EXPERIMENTAL|Part 1: LAD191 (Cohort 2)|Participants will receive single ascending dose of LAD191 SC injection on Day 1.
62598409|NCT06488209|EXPERIMENTAL|Part 1: LAD191 (Cohort 3)|Participants will receive single ascending dose of LAD191 SC injection on Day 1.
62598410|NCT06488209|EXPERIMENTAL|Part 1: LAD191 (Cohort 4)|Participants will receive single ascending dose of LAD191 SC injection on Day 1.
62598411|NCT06488209|EXPERIMENTAL|Part 1: LAD191 (Cohort 5)|Participants will receive single ascending dose of LAD191 SC injection on Day 1.
62598412|NCT06488209|PLACEBO_COMPARATOR|Part 1: Placebo|Participants will receive single dose of matching placebo SC injection on Day 1 (Cohort 1 to Cohort 5).
62598413|NCT06488209|EXPERIMENTAL|Part 2: LAD191 (Cohort 6)|Participants will receive multiple ascending doses of LAD191 SC injection on Days 1, 8, 15, 22, 29 and 36.
62598414|NCT06488209|EXPERIMENTAL|Part 2: LAD191 (Cohort 7)|Participants will receive multiple ascending doses of LAD191 SC injection on Days 1, 8, 15, 22, 29 and 36.
62598415|NCT06488209|EXPERIMENTAL|Part 2: LAD191 (Cohort 8)|Participants will receive multiple ascending doses of LAD191 SC injection on Days 1, 8, 15, 22, 29 and 36.
62598416|NCT06488209|PLACEBO_COMPARATOR|Part 2: Placebo|Participants will receive multiple doses of matching placebo SC injection on Days 1, 8, 15, 22, 29 and 36 (Cohort 6 to Cohort 8).
62598417|NCT06488209|EXPERIMENTAL|Part 3: LAD191 (Cohort 9)|Participants will receive repeat doses of LAD191 SC injection on Days 1, 8, 15, 22, 29 and 36.
62598418|NCT06488209|PLACEBO_COMPARATOR|Part 3: Placebo|Participants will receive repeat doses of matching placebo SC injection on Days 1, 8, 15, 22, 29 and 36 (Cohort 9).
62817019|NCT01950897||subjects dx'd clinically w/ muscular dystrophy|subjects with muscular dystrophy from whom muscle samples are obtained for clinical diagnosis or for any other medical purpose
62817020|NCT01950897||normal controls|subjects who do not have muscular dystrophy and from whom muscle samples are obtained for any medical purpose
62817021|NCT05871541|EXPERIMENTAL|Investigational Product|Participants randomized to this arm will be given the investigational product (JCXH-105).
62817022|NCT05871541|ACTIVE_COMPARATOR|Active Control|Participants randomized to this arm will be given the FDA approved Shingrix.
62819459|NCT06704711|EXPERIMENTAL|Caffeine Mouth Rinse with incremental exercise|They will rinse a solution containing a total of 400 mg caffeine (20 mL, 2% concentration) in the mouth for 20 seconds and try to continue the exercise against increasing resistance until exhaustion. The exercise test will be performed on a bicycle ergometer (Ergometer Exercise Bike SANA 500, Germany) (where the pedaling speed is kept constant at 60 rpm, with an initial load of 50 Watts and a load increase of 25 watts per minute, gradually increasing until the participants become exhausted. To be able to determine the degree of difficulty perceived during the test and The Borg Scale will be used to end the test when the athlete reaches the point of exhaustion.
62038334|NCT04068337||Non-Hemiarch|Patients with Freestyle aortic root implantation without hemiarch replacement with normal systemic perfusion
62038335|NCT06034587||good response group of treated keloids|"The Vancouver Scar Scale (VSS) is the most established questionnaire used for the evaluation of pathological scarring. This scale evaluates aspects of scar vascularity, pigmentation, pliability, and height, with the scoring system ranging from 0 to 15, where 0 is the least severe and 15 is the most severe.All the keloids in the study were classified into three categories based on the VSS score: mild (0-5), moderate (6-9), and severe (10-15).~For treatment assessment, investigators further divided the treated participants into two groups: a good response group (showing an improvement of 5 or more points in the VSS score) and a poor response group (less than 5 points improvement in the VSS score)"
62038336|NCT06034587||poor response group of treated keloids|"The Vancouver Scar Scale (VSS) is the most established questionnaire used for the evaluation of pathological scarring. This scale evaluates aspects of scar vascularity, pigmentation, pliability, and height, with the scoring system ranging from 0 to 15, where 0 is the least severe and 15 is the most severe. All the keloids in the study keloids were classified into three categories based on the VSS score: mild (0-5), moderate (6-9), and severe(10-15).~For treatment assessment, investigators further divided the treated participants into two groups: a good response group (showing an improvement of 5 or more points in the VSS score) and a poor response group (less than 5 points improvement in the VSS score)"
62038337|NCT04777500|EXPERIMENTAL|taVNS Group1|This group will receive taVNS for 4 weeks.
62240986|NCT02693613|EXPERIMENTAL|Group 1|Treatment arm includes 4 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® without a time lag, single dose of ASP1517 + Kremezin® with a time lag (1 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (1 h after ASP1517 administration)
62038338|NCT04777500|EXPERIMENTAL|taVNS Group 2|This group will receive taVNS for 4 weeks.
62431348|NCT04938609|EXPERIMENTAL|Pembrolizumab + SBRT + Surgery|Pembrolizumab administration (3 dose) every 3 weeks and 1 dose before radiation (5 days) therapy followed by an additional administration of Pembrolizumab (2 doses) prior to restaging and surgical resection followed by risk-adapted adjuvant therapy, per standard of care. Patient will then be treated with adjuvant pembrolizumab every 3 weeks for 14 additional doses (17 doses total)
62431349|NCT01208259|EXPERIMENTAL|Binge Eating Disorder/Therapy|
62431350|NCT01400672|EXPERIMENTAL|DIPG Patients Receiving Vaccine|Patients with diffuse intrinsic pontine glioma (DIPG) receiving radiation therapy, Tumor Lysate Vaccine (dose of 4 x 10\^6 cells divided into 2 doses then every 4 weeks for up to 1 year) and Imiquimod (5% Aldara cream at a total dose of 12.5 mg) topically at each site prior to and 24 hours after vaccination.
62431351|NCT01424371||Adjuvanted Vaccine Group|
62431352|NCT01424371||Unadjuvanted Vaccine Group|
62598419|NCT02326922|EXPERIMENTAL|Metraplant-E First prototype|Metraplant-E (first prototype) levonorgestrel-releasing intrauterine device
62598420|NCT02326922|EXPERIMENTAL|Metraplant-E second prototype|Metraplant-E (second prototype) levonorgestrel-releasing intrauterine device
62817023|NCT05154773|EXPERIMENTAL|KidneyTIME|KidneyTIME is a self-directed digital intervention. It contains 26 animated videos, each 1-3 minutes in length, designed to address knowledge gaps and concerns about kidney transplantation and living donation that were identified in literature reviews, formative research, and video development studies as critical for optimal prospective kidney recipient and donor participation in LDKT. We chose 6 videos from the entire series to be delivered sequentially for a total duration of 13 minutes. After completing the proscribed videos and an immediate-post exposure survey, everyone then received a link to access all 26 videos centralized on a website where the videos were activated for sharing through various modalities, including text, email, Facebook, and Twitter. The website could be accessed using this link from any electronic device throughout the study. Prompts to use the intervention were sent once a week for 3 weeks and then monthly for 12 months.
62598421|NCT04476342|EXPERIMENTAL|MICPB group|The experimental group is minimal invasive cardiopulmonary bypass (MICPB) group, with built-in micro-thrombotic oxygenator and mini cardioplegia (MP) formula (15ML15% KCl+10ml compound potassium, calcium and magnesium +25ml normal saline).
62598422|NCT04476342|NO_INTERVENTION|CCPB group|The control group was conventional cardiopulmonary bypass (CCPB) group, using ordinary oxygenator, microemboli filter, and 4:1 cardioplegia solution.
62598423|NCT06649409|EXPERIMENTAL|Study arm 1 vamorolone|"single oral dose of vamorolone 20 mg/kg on day 2~Fludrocortisone Day 1: 1 mg single dose at 9 h predose vamorolone dosing. Day 2: 0.1 mg and 0.5 mg multiple doses. For detailed timepoints, see protocol Section 4.1. Day 3: 0.1 mg single dose at 24 h postdose vamorolone dosing."
62817024|NCT05154773|NO_INTERVENTION|Usual Care|Routine educational materials from non-study sources through usual Transplant Center protocols including booklets, nurse communications, and the usual care video, a nurse-narrated power-point presentation outlining recipient and donor evaluation, surgery, and recovery processes and outcomes.
62817025|NCT01451606|PLACEBO_COMPARATOR|Placebo pill|A pill that looks like the active drug, but does not contain any active ingredients.
62817026|NCT01451606|ACTIVE_COMPARATOR|Duloxetine|The drug, Duloxetine, is marketed under the trade name Cymbalta. It is a serotonergic and noradrenergic reuptake inhibitor (SNRI).
62817027|NCT05025787|EXPERIMENTAL|300mg BID|The higher dose (i.e., 300mg BID) demonstrated good tolerability and safety, as well as over 90% inhibition of the binding of monocyte chemoattractant protein-1 to its CCR-2 receptor. Moreover, this dose produced nearly 90% binding inhibition at the CCR-5 receptor as well.
62817028|NCT05025787|PLACEBO_COMPARATOR|Placebo|Placebo
62817029|NCT02373709||Cases: Perinatal depression|Cases will be defined as those with a depressive episode with onset during the antenatal or postnatal period.
62240987|NCT02693613|EXPERIMENTAL|Group 2|Treatment arm includes 3 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® with a time lag (2 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (2 h after ASP1517 administration)
62240988|NCT02987179||ESRD Patients|"The following inclusion criteria must be met for each subject.~* Age ≥18 years and able to give written informed consent to the study~* On chronic hemodialysis for ≥ 90 days at time of enrollment~* Ability to read~* Consent to have video recording taken during study visit"
62431353|NCT01424371||Unvaccinated Elderly|
62431354|NCT01092299|EXPERIMENTAL|Cohort 1 (2 arms)|Period 1: randomized to either fasting IR or ER1. Period 2: Cross-over to either IR or ER1. Period 3: ER1 in fed conditions.
62431355|NCT01092299|EXPERIMENTAL|Cohort 2 (2 arms)|Period 1: randomized to either fasting IR or ER2. Period 2: Cross-over to either IR or ER2. Period 3: ER2 in fed conditions.
62431356|NCT01092299|EXPERIMENTAL|Cohort 3( 2 arms)|Period 1: randomized to either fasting IR or ER3. Period 2: Cross-over to either IR or ER3. Period 3: ER3 in fed conditions.
62431357|NCT01092299|EXPERIMENTAL|Cohort 4 (2 arms)|Period 1: randomized to either fasting IR or MR4. Period 2: Cross-over to either IR or MR4. Period 3: MR4 in fed conditions.
62431358|NCT01092299|EXPERIMENTAL|Part 2: Extended/Modified release|Extended/Modified release capsule to be determined
62431359|NCT01092299|PLACEBO_COMPARATOR|Part 2: Placebo|
62431360|NCT03559010|EXPERIMENTAL|Use Phase Norgestrel 0.075 mg|Norgestrel 0.075 mg tablets to be taken orally, one tablet daily at the same time everyday for up to 16 weeks
62431361|NCT06545682|EXPERIMENTAL|Dose Escalation|Study treatment will be administered on an outpatient basis.
62598424|NCT06649409|ACTIVE_COMPARATOR|Study arm 2 (positive control arm): eplerenone|"single oral dose of eplerenone 200 mg on day 2~Fludrocortisone Day 1: 1 mg single dose at 9 h predose eplerenone dosing. Day 2: 0.1 mg and 0.5 mg multiple doses. For detailed timepoints, see protocol Section 4.1. Day 3: 0.1 mg single dose at 24 h postdose eplerenone dosing."
62598425|NCT06649409|OTHER|"Study arm 3 (negative control arm): no active treatment"|"Fludrocortisone challenge only, no active treatment:~Day 1: 1 mg single dose at 9 h predose vamorolone/eplerenone\* dosing. Day 2: 0.1 mg and 0.5 mg multiple doses. For detailed timepoints, see protocol Section 4.1. Day 3: 0.1 mg single dose at 24 h postdose vamorolone/eplerenone\* dosing.~\*or corresponding timepoint for negative control arm"
62431362|NCT06545682|EXPERIMENTAL|Dose Expansion|Study treatment will be administered on an outpatient basis.
62598426|NCT04682652|EXPERIMENTAL|GAE Treatment|Subjects will be treated with a genicular artery embolization (GAE) procedure performed with Embozene Microspheres. The microspheres will be delivered in a saline-contrast medium solution and will be delivered to the arteries supplying the areas of the subject's pain.
62817030|NCT02373709||Controls: No perinatal depression|Controls will be defined as those who score \< 7 on Edinburgh Postnatal Depression Scale and/or no episode of clinical depression from pregnancy until 6 months postnatal.
62431363|NCT00902291|ACTIVE_COMPARATOR|1. Gemcitabine monotherapy|
62431364|NCT00902291|EXPERIMENTAL|2. Gemcitabine plus AGS-1C4D4|
62431365|NCT04559165|EXPERIMENTAL|sericin and chitosan cream|Apply sericin and chitosan cream on pressure ulcer 2 times/day for 21 days.
62431366|NCT04559165|ACTIVE_COMPARATOR|Cavilon cream|Apply cavilon cream on pressure ulcer 2 times/day for 21 days.
62431367|NCT02134691|EXPERIMENTAL|Prolonged Exposure|Behavioral: Prolonged Exposure (PE) PE is a 16 week, 90 minute culturally informed treatment program.
62431368|NCT02134691|ACTIVE_COMPARATOR|Applied Relaxation|Behavioral: Applied Relaxation (AR) AR is a 16 week, 90 minute treatment program.
62038339|NCT00840853|EXPERIMENTAL|Group A with disease|"CD19+ B-ALL undergoing allogeneic HSCT, with minimal residual disease or relapse post-HSCT~Patients will receive one of the following dose levels of CD19CAR/virus specific T cells:~Dose Level 1: 1.5 x 10\^7/m2~Dose Level 2: 4.5 x 10\^7/m2~Dose Level 3: 1.2 x 10\^8/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.~If patients with relapse have a partial response or have stable disease they will be eligible to receive up to 6 further doses of CTLs, each of which will consist of the same number or less than as their first injection."
62038340|NCT00840853|EXPERIMENTAL|Group A without disease|"CD19+ B-ALL undergoing allogeneic HSCT, without detectable disease post-HSCT.~Patients will receive CD19CAR/virus specific T cells - Dose Level 1: 1.5 x 10\^7/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells."
62038341|NCT00840853|EXPERIMENTAL|Group B with disease|"CD19+ B cell CLL or NHL undergoing allogeneic HSCT, with minimal residual disease or relapse post-HSCT~Patients will receive one of the following dose levels of CD19CAR/virus specific T cells:~Dose Level 1: 1.5 x 10\^7/m2~Dose Level 2: 4.5 x 10\^7/m2~Dose Level 3: 1.2 x 10\^8/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.~If patients with relapse have a partial response or have stable disease they will be eligible to receive up to 6 further doses of CTLs, each of which will consist of the same number or less than as their first injection."
62240989|NCT04845360|EXPERIMENTAL|pregnancy and differences in gender can be found in the radial arterial pulse|Establishing the meridian through harmonics of blood pressure waves could be a powerful tool to qualitatively and quantitatively indicate physiologic and pathologic factors.
62240990|NCT05805566||Post-Covid Syndrome Patients|
62431369|NCT02148783|EXPERIMENTAL|methylphenidate administration|All participants will receive oral methylphenidate 60 mg before the second TMS study. The participants will receive oral methylphenidate 60 mg before the second PET scan. Subjects will then be treated with oral methylphenidate, using a forced titration. Dose titration will be incremental within 6 days (dose-escalation phase) , starting at 5 mg orally twice daily for 3 days, and 10 mg twice daily for the next 3 days. Then the dose will be increased to 30 mg twice daily starting from day 7 given twice daily for additional 3 weeks.
62598427|NCT04682652|NO_INTERVENTION|Observational|"Subjects randomized to the observational group will not undergo the experimental GAE Treatment.~PI will offer subjects enrolled into the observational group to crossover to the experimental GAE Treatment group after they have completed their 6-month follow-up assessments."
62598428|NCT01649648|EXPERIMENTAL|Intervention|Autologous cord blood cells arm
62598429|NCT06217783|EXPERIMENTAL|Group A|Participants will receive a catheter that is up to 1.75 inches long based on what the nurse thinks is best for you.
62240991|NCT05166135||Acute Myeloid Leukemia|Patients ≥18 years old at diagnosis, with de novo AML diagnosed between 01 January 2015 and 31 December 2019, as documented in the medical chart and according to the physician's notes, and with at least 1 line of treatment for AML within the study period.
62817031|NCT05961839|EXPERIMENTAL|Dose Escalation in the Absence of Specific Azole Antifungal Treatments|Up to 9 dose levels will be evaluated in subjects not receiving specific azole antifungal treatment.
62817032|NCT05961839|EXPERIMENTAL|Dose Escalation in the Presence of Specific Azole Antifungal Treatments|Up to 9 dose levels will be evaluated in subjects receiving specific azole antifungal treatment.
62240992|NCT05166135||Relapsed/Refractory Acute Lymphoid Leukemia|Patients ≥18 years old at diagnosis, with R/R ALL diagnosed between 01 January 2015 and 31 December 2019, as documented in the medical chart and according to the physician's notes, and with at least 1 line of treatment for R/R ALL within the study period.
62240993|NCT02169817|EXPERIMENTAL|Enterogermina + Enterolyte|2 vials of Enterogermina per day for 5 days and Enterolyte according to investigator´s recommendation
62240994|NCT00151554|NO_INTERVENTION|Control group|
62431370|NCT02664766|NO_INTERVENTION|Control condition|Control condition with no intervention. Participants will be recording their daily alcohol consumption. No lifestyle modification during this period.
62817033|NCT00780195|EXPERIMENTAL|1|Single 2 hour hyperinsulinemic euglycemic clamp study at \~90 mg/dl.
62817034|NCT00780195|EXPERIMENTAL|2|Single 2 hour hyperinsulinemic hypoglycemic clamp study at \~70 mg/dl.
62598430|NCT06217783|EXPERIMENTAL|Group B|Participants will receive a catheter that is either 1.75 or 2.5 inches long based on what the nurse thinks is best for you.
62598431|NCT01294007|EXPERIMENTAL|Study Graft Composite|"AlphaGraft ProFuse Demineralized Bone Scaffold are soaked in PureGen according to Preparation for Use and handling technique. The graft composite is placed on the randomized study side contralateral to the autograft bone graft per surgeon's standard technique for PLF. The wound is closed according to surgeon's standard technique.~Post operative care will be according to the site specific standard of care. An avoidance of heavy physical activity and limitations on working, lifting, bending etc. are common precautions post procedure. The decision to use a post operative orthosis is left to the discretion of the Investigator."
62817035|NCT00780195|EXPERIMENTAL|3|Single 2 hour hyperinsulinemic hypoglycemic clamp at \~60 mg/dl.
62817036|NCT00780195|EXPERIMENTAL|4|Single, 2 hour hyperinsulinemic hypoglycemic clamp at \~50 mg/dl.
62817037|NCT05682625||Participants|Adults who are receiving a COVID-19 vaccine
62817038|NCT00322855||Chart Review|patients diagnosed with soft tissue sarcoma
62598432|NCT01294007|ACTIVE_COMPARATOR|Control Graft Composite|"Contralateral to the study graft composite, placement of posterolateral fusion graft composite containing iliac crest bone (5 cc/level/side) and local autograft composite (equal volume split with study side). Supplemental posterior pedicle screw fixation utilizing Zodiac, Illico or Xenon Spinal Fixation system.~* A defined volume of iliac crest bone graft (indicated in table 2) is harvested and combined with 50% of the previously harvest morselized local bone~* The graft composite is placed on the randomized control side using standard technique for PLF"
62598433|NCT00370981|EXPERIMENTAL|0.15 mg|
62431371|NCT02664766|EXPERIMENTAL|Exercise training program|Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week.
62431372|NCT01802840|PLACEBO_COMPARATOR|biscuits without soy fiber|biscuits without soy fiber
62431373|NCT01802840|EXPERIMENTAL|biscuits supplemented with soy fiber|biscuits supplemented with soy fiber
62598434|NCT00370981|EXPERIMENTAL|0.30 mg|
62598435|NCT00370981|EXPERIMENTAL|0.60 mg|
62598436|NCT00370981|PLACEBO_COMPARATOR|PBO|
62598437|NCT02396017|ACTIVE_COMPARATOR|Single-dose Polyethylene Glycol regimen|Drug: Polyethylene Glycol Intervention: 2 liters of Polyethylene Glycol will be given in the day before Capsule Endoscopy ingestion.
62431374|NCT02683187|ACTIVE_COMPARATOR|Sitagliptin|The infusion procedures performed during study visits 2 and 3 are identical except that the oral medicine Sitagliptin will only be administered at one of the two visits, with order of Sitagliptin administration determined at random by study staff. In this arm, Sitagliptin will be administered.
62240995|NCT00151554|EXPERIMENTAL|Intervention group|
62240996|NCT06270433|EXPERIMENTAL|Toludesvenlafaxine hydrochloride sustained-release tablets treatment group|
62240997|NCT06270433|ACTIVE_COMPARATOR|Desvenlafaxine succinate sustained-release tablets treatment group|
62240998|NCT02997488||McGrath|McGrath Videolaryngoscope
62240999|NCT02997488||Pentax|Pentax Airwayscope
62241000|NCT01641211|EXPERIMENTAL|Video intervention|Group that will watch the Meducation inhaler device technique videos.
62241001|NCT01641211|OTHER|Control|This group will watch a nutrition video.
62431375|NCT02683187|PLACEBO_COMPARATOR|Non-Sitagliptin|The infusion procedures performed during study visits 2 and 3 are identical except that the oral medicine Sitagliptin will only be administered at one of the two visits, with order of Sitagliptin administration determined at random by study staff. In this arm, placebo will be administered
62431376|NCT03970720|EXPERIMENTAL|T1DM - Unaware: Metoclopramide|T1DM participants with hypoglycemia unawareness determined by a hypoglycemic clamp study will receive 10 mg metoclopramide four times a day during the four-week intervention period.
62431377|NCT03970720|PLACEBO_COMPARATOR|T1DM - Unaware: Placebo|T1DM participants with hypoglycemia unawareness determined by a hypoglycemic clamp study will receive 10 mg matching placebo capsules four times a day during the four-week intervention period.
62431378|NCT03970720|PLACEBO_COMPARATOR|T1DM - Aware: Placebo|T1DM participants with hypoglycemia awareness determined by a hypoglycemic clamp study will receive 10 mg matching placebo capsules four times a day during the four-week intervention period.
62431379|NCT01814995|EXPERIMENTAL|Nutrition/Physical Activity Intervention|There will be four in-person group sessions (1/month), two including the participants' partners, and all with on-site child care. Sessions will include preparation of a healthy meal (hands-on) and discussions of mindful eating, balanced meals, portion sizes, and preparing food at home, under a dietitian's supervision. Sessions will also include a one-hour physical activity information/practice session with a kinesiologist. Participants will track daily step counts with a pedometer and aim to eventually reach more than 10,000 steps/day. They will also receive instruction and demonstration from a kinesiologist of some simple resistance exercises they may perform at home. Between sessions, participants will receive advice and support through a study-specific website and telephone calls.
62598438|NCT02396017|EXPERIMENTAL|Split-dose Polyethylene Glycol regimen|Drug: Polyethylene Glycol Intervention: 1 liter of Polyethylene Glycol will be given in the day before Capsule Endoscopy ingestion and another 1 liter Polyethylene Glycol will be given in the same day of Capsule Endoscopy ingestion.
62598439|NCT06620874|EXPERIMENTAL|STABHA Injection|Participants will receive two ultrasound-guided STABHA injections into the medial collateral ligament of the knee at a 2-week interval.
62241002|NCT02849340|EXPERIMENTAL|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62241003|NCT02849340|ACTIVE_COMPARATOR|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62598440|NCT06620874|EXPERIMENTAL|High-Concentration Glucose Water Injection|Participants will receive two ultrasound-guided high-concentration glucose water injections into the medial collateral ligament of the knee at a 2-week interval.
62598441|NCT06620874|PLACEBO_COMPARATOR|Saline Injection|Participants will receive two ultrasound-guided saline injections into the medial collateral ligament of the knee at a 2-week interval.
62598442|NCT05100368||Patients|Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis
62241004|NCT05717426|ACTIVE_COMPARATOR|Open chain exercises group|Group A(Open chain exercises group) received open kinetic exercises 3 times a week for 3-4 weeks.
62431380|NCT00769015|EXPERIMENTAL|BA-LVR|In BA-LVR, a low vision occupational therapist (OT) will deliver Behavior Activation (BA), a psychological treatment to prevent depression. This will be administered in the context of the standard of low vision care for OTs as defined by the American Occupational Therapy Association (AOTA). The OTs will collaborate with low vision optometrists, who will deliver the standard of low vision care as defined by the American Optometric Association. The optometrists will evaluate remaining vision and magnification needs, prescribe optical devices, and provide the OTs with initial care plans. The OTs will subsequently meet with subjects in their homes 6 times over 12 weeks to enhance device use, home modifications, and compensatory strategies.
62038342|NCT00840853|EXPERIMENTAL|Group B without disease|"CD19+ B cell CLL or NHL undergoing allogeneic HSCT, without detectable disease post-HSCT~Patients will receive CD19CAR/virus specific T cells -~Dose Level 1: 1.5 x 10\^7/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells."
62038343|NCT05099042|EXPERIMENTAL|Group intervention - questionnaire and recommendations|The intervention group will take the ESOGER questionnaire at month 0 and month 3 ( beginning and end) and receive recommendations following their needs.
62241005|NCT05717426|ACTIVE_COMPARATOR|Closed kinetic chain exercises group|Group B(Closed kinetic chain exercises group) received close kinetic exercises 3 times a week for 3-4 weeks.
62241006|NCT05319028|EXPERIMENTAL|Continuous Dosing Schedule|Mivavotinib 100 mg once daily (QD)
62241007|NCT05319028|EXPERIMENTAL|Induction Dosing Schedule|Mivavotinib 120 mg QD for 14 days, then 80 mg QD starting Day 15
62241008|NCT02945150|EXPERIMENTAL|Elbasvir/grazoprevir for HCV+ kidney transplant recipients|"Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those \<75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV)."
62431381|NCT00769015|PLACEBO_COMPARATOR|ST-LVR|Subjects randomized to ST-LVR will receive clinic-based low vision optometry, in addition to 6 in-home Supportive Therapy (ST) sessions. ST is a placebo condition that controls for the attention that subjects in the active treatment arm will receive.
62431382|NCT02279576|EXPERIMENTAL|Pazopanib plus weekly paclitaxel|Pazopanib 800mg /day continuously administered plus paclitaxel 65 mg/m2 in weekly administration, 3 administrations (D1, D8 and D15) every 4 weeks period.
62431383|NCT04271683|EXPERIMENTAL|Pressure controlled ventilation with PEEP|In this group, ventilation after apnoea during induction of general anesthesia starts with pressure controlled ventilation with PEEP.
62431384|NCT04271683|ACTIVE_COMPARATOR|Manual ventilation without PEEP|In this group, ventilation after apnoea during induction of general anesthesia starts with manual ventilation without PEEP.
62431385|NCT01463683|EXPERIMENTAL|V232-2XP SC|2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6
62598443|NCT01740128|EXPERIMENTAL|Multimodal then Treadmill training|Participants will undergo harness-supported multimodal balance training exercises while simultaneously performing skilled hand exercises. Following a washout period of at least 6 weeks, Participants will undergo body weight supported treadmill training using the Lokomat apparatus.
62598444|NCT01740128|ACTIVE_COMPARATOR|Treadmill then Multimodal training|Robotic body weight supported treadmill training will be applied using the Lokomat apparatus. Following a washout period of at least 6 weeks, Participants will undergo harness-supported balance training exercises while simultaneously performing skilled hand exercises.
62598445|NCT06161831|EXPERIMENTAL|Text message/automated phone reminders|Text message or automated phone reminders
62038344|NCT05099042|NO_INTERVENTION|Group control - questionnaire without recommendations|The participants will only take the ESOGER questionnaire at month 0 and month 3 without recommendations.
62038345|NCT01211925|EXPERIMENTAL|critical ischemia|
62598446|NCT06161831|NO_INTERVENTION|Usual Care|No reminders
62817039|NCT02944110|ACTIVE_COMPARATOR|Pancreatectomised + LY2409021|During the experimental day the patient will undergo a 75gr-OGTT. On the evening before the experimental day, the patient will ingest a dose of 300mg of LY2409021.
62817040|NCT02944110|PLACEBO_COMPARATOR|Pancreatectomised + placebo|During the experimental day the patient will undergo a 75gr-OGTT. On the evening before the experimental day, the patient will ingest placebo tablets.
62038346|NCT01211925|NO_INTERVENTION|Control|Best medical treatment
62038347|NCT00233077|EXPERIMENTAL|Behavioral: Patient Assistance|Patient assistance programs
62038348|NCT00233077|OTHER|Control: Information only|Control patients will be sent a pamphlet about breast cancer \& its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
62038349|NCT06733038|ACTIVE_COMPARATOR|Arm A - FOLFOXIRI plus bevacizumab|"Every 2 weeks for a maximum of 8 cycles:~* Bevacizumab 5 mg/kg iv 90 minutes at cycle 1 (if well tolerated, it is administered over 60 minutes at cycle 2, and over 30 minutes at cycle 3) day 1, followed by~* Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by~* Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with~* L-Leucovorin 200 mg/sqm iv over 2 hours day 1, followed by~* 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1.~If no progression occurs during FOLFOXIRI plus bev, patients will receive maintenance 5-FU/LV plus bev at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
62241009|NCT01975818|EXPERIMENTAL|Molidustat (BAY 85-3934)(25mg)|Starting dose of 25 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.
62241010|NCT01975818|EXPERIMENTAL|Molidustat (BAY 85-3934)(50mg)|Starting dose of 50 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.
62241011|NCT01975818|EXPERIMENTAL|Molidustat (BAY 85-3934) (75mg)|Starting dose of 75 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.,
62431386|NCT01463683|ACTIVE_COMPARATOR|V232-1XP SC|1XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6
62598447|NCT02893176|PLACEBO_COMPARATOR|Placebo|10mg will be administered one time daily
62431387|NCT01463683|EXPERIMENTAL|V232-2XP IM|2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6
62598448|NCT02893176|ACTIVE_COMPARATOR|Active|10mg macitentan will be administered one time daily
62598449|NCT06620081|EXPERIMENTAL|Oxygen therapyHigh flow nasal cannula|High-Flow Nasal Cannula Therapy (HFNC Therapy).
62241012|NCT01975818|EXPERIMENTAL|Molidustat (BAY 85-3934) (150mg)|Starting dose of 150 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, 150 and 200 mg once daily
62431388|NCT02593188||HYQVIA- Epoch 1|Participants receiving HYQVIA
62431389|NCT02593188||HYQVIA- Epoch 2|Participants with rHuPH antibody titers ≥160 (tested in Epoch 1)
62431390|NCT03774927|EXPERIMENTAL|10 Hz treatment group|In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
62598450|NCT06620081|ACTIVE_COMPARATOR|Conventional oxygen therapy|Conventional Oxygen Therapy with Venturi Mask or Non-Rebreather Mask.
62431391|NCT03774927|EXPERIMENTAL|20 Hz treatment group|In active rTMS, 20 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 20 intervals with 28s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
62431392|NCT03774927|SHAM_COMPARATOR|Control Group|In sham rTMS, all procedures were identical to 10Hz group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
62431393|NCT00968396|EXPERIMENTAL|Stem Cell Collection + Transplantation|Apheresis: On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation. Co-culture Stem Cell Infusion on Day 0. Melphalan 100 mg/m\^2 IV over 30 minutes daily on Days -2 and -1.
62598451|NCT04664946|EXPERIMENTAL|Intra-arterial administration of 3-n-butylphthalide|Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.
62598452|NCT04504266|NO_INTERVENTION|Control Arm|Recommendations to follow Mediterranean diet and exercise regularly before surgery.
62598453|NCT04504266|EXPERIMENTAL|Prehab|This intervention consists of a motivational interview and a mobile-app based coaching program to encourage patients to exercise and adopt a Mediterranean diet in the 3+ weeks prior to surgery.
62598454|NCT04982692|EXPERIMENTAL|Intravaginal prasterone|6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
62598455|NCT04982692|PLACEBO_COMPARATOR|Placebo ovules|Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
62598456|NCT01308112|EXPERIMENTAL|Supplemental iron|
62598457|NCT01308112|PLACEBO_COMPARATOR|Placebo|
62817041|NCT02944110|ACTIVE_COMPARATOR|Healthy + LLY2409021|During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest a dose of 300mg of LY2409021.
62817042|NCT02944110|PLACEBO_COMPARATOR|Healthy + placebo|During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest placebo tablets.
62817043|NCT03190928||1|Patients with grades 1-2 or 3a follicular lymphoma (FL)
62598458|NCT04378959|EXPERIMENTAL|Lidocaine patch first|This group will receive up to 3 lidocaine patches for 4 weeks, followed by placebo patches after a 1-3 week washout period.
62598459|NCT04378959|PLACEBO_COMPARATOR|Placebo patch first|This group will receive up to 3 placebo patches for 4 weeks, followed by lidocaine patches after a 1-3 week washout period.
62817044|NCT06311864||daridorexant|Patients who have been newly prescribed oral tablets of daridorexant 50 mg to treat their insomnia
62817045|NCT05466422|EXPERIMENTAL|MK-2214|Participants will receive MK-2214 administered in escalating doses as an intravenous (IV) infusion on Days 1, 29, and 57.
62817046|NCT05466422|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo as an IV infusion on Days 1, 29, and 57.
62598460|NCT02123836|EXPERIMENTAL|NK cells|Peripheral blood cell will be collected by apheresis from donors. Peripheral blood mononucleated cells will be cultured with irradiated K562-mb15-41BBL cells and low dose (10 IU/mL) IL-2 for 10 days. After T-cell depletion, expanded activated NK cells will be infused. Before infusion, patients will receive immunosuppressive therapy to promote temporary engraftment of NK cells. After infusion, they will receive IL-2 to support NK cell viability and expansion in vivo. The effects of NK cell infusion will be determine by comparing MRD levels before and after treatment.
62598461|NCT03673748|EXPERIMENTAL|Mesenchymal stem cells (MSC)|Participants will receive a single Intravenous infusion of Mesenchymal Stem Cells (MSV) 2 million cells per kg wt suspended in 100 ml of physiological saline solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial. GMP-compliant MSV will be prepared by IBGM-University of Valladolid-Citospin.
62598462|NCT03673748|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo infusion (100 ml of physiological saline solution) that does not contain any mesenchymal stem cells.
62598463|NCT02168374|EXPERIMENTAL|Chlorhexidine - CHX|Deciduous teeth were filled with GIC containing 1.25% chlorhexidine.
62038350|NCT06733038|EXPERIMENTAL|Arm B - FOLFOXIRI plus bevacizumab plus atezolizumab|"Every 2 weeks for a maximum of 8 cycles:~* Atezolizumab 840 mg iv over 30 minutes (60 minutes at first infusion) day 1 followed by~* Bevacizumab 5 mg/kg iv over 90 minutes at cycle 1 (if well tolerated, it is administered over 60 minutes at cycle 2, and over 30 minutes at cycle 3) day 1 followed by~* Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by~* Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with~* L-Leucovorin 200 mg/sqm iv over 2 hours day 1, followed by~* 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1.~If no progression occurs during FOLFOXIRI plus bev plus atezolizumab, patients will receive maintenance 5-FU/LV plus bev plus atezolizumab at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev plus atezolizumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
62038351|NCT06128668|EXPERIMENTAL|Yoga|Yoga will be aplicated
62038352|NCT06128668|NO_INTERVENTION|Control|Yoga will not be aplicated
62038353|NCT01785966|EXPERIMENTAL|Daily checklist and clinician prompting|Checklist during multidisciplinary daily visits + clinician prompting + audit \& feedback
62038354|NCT01785966|NO_INTERVENTION|Usual care|Usual care
62431394|NCT06439615|SHAM_COMPARATOR|Control group|Participants will receive standard treatment and care according to the current management guidelines for SAH.
62431395|NCT06439615|EXPERIMENTAL|Baricitinib group|In addition to receiving standard treatment and care, baricitinib will be administrated orally (or crushed for nasogastric tube delivery) at a daily dosage of 4mg for three consecutive days following SAH.
62431396|NCT01497873|EXPERIMENTAL|Belotecan|Camtobell Injection
62431397|NCT01497873|ACTIVE_COMPARATOR|Topotecan|Hycamtin Injection
62431398|NCT04516694|NO_INTERVENTION|Control|Usual care reflects the standard treatment currently provided to T1D patients. All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits.
62598464|NCT02168374|EXPERIMENTAL|Doxycycline - DOX|Deciduous teeth were filled with GIC containing 4.5% doxycycline.
62038355|NCT05601102|EXPERIMENTAL|Intervention group|The programme was a digital movement and music programme with resources from danceSing Care (https://dancesingcare.uk/) and consisted of two movement sessions and one music session each week, each lasting about 20 minutes. Also, the danceSing care resources were designed to suit older adults with physical and cognitive impairments (residents with mobility aids and/or dementia). Movement sessions included chair and standing fitness, which started with a warm-up and finished with stretching exercises. Sessions were managed and supervised by care home activity coordinators.
62038356|NCT05601102|NO_INTERVENTION|Waitlist control group|Waitlist for 12 weeks before participating in the digital movement and music programme with resources from danceSing Care (https://dancesingcare.uk/).
62038357|NCT04310995|EXPERIMENTAL|Nicorandil|
62038358|NCT04310995|EXPERIMENTAL|Diltiazem|
62038359|NCT04310995|EXPERIMENTAL|Isosorbide Mononitrate|
62038360|NCT00322348|EXPERIMENTAL|ZOLADEX 10.8 mg|ZOLADEX (goserelin acetate) 10.8 mg intramuscular depot for injection every 12 weeks
62038361|NCT00322348|EXPERIMENTAL|ZOLADEX 3.6 mg|ZOLADEX (goserelin acetate) 3.6 mg intramuscular depot for injection every 4 weeks
62038362|NCT01261338|EXPERIMENTAL|olestra|Non-absorbable fat administered in the form of 24 potato crisps per day (12 each with mid-day and evening meal) providing approximately 15g/day of olestra.
62038363|NCT01261338|PLACEBO_COMPARATOR|Vegetable oil|Absorbable fat administered in the form of 12 potato crisps per day (6 each with mid-day and evening meal) in order to match the caloric intake provided by the crisps with Olestra.
62598465|NCT02168374|PLACEBO_COMPARATOR|Glass ionomer cement - GIC|Deciduous teeth were filled with GIC without chlorhexidine or doxycycline.
62038364|NCT05717868|EXPERIMENTAL|Kinesio-taping group|Kinesio-tape will be applied from the dorsal region (T1-T2) to the upper cervical region (C1-C2), two times weekly in a period of four weeks.
62241013|NCT01975818|ACTIVE_COMPARATOR|Epoetin alfa/beta|Starting dose at the subject's current weekly dose. Administered IV or SC 3 times per week. Doses will be titrated at the scheduled dose control visits according to the local label. Titration will be based on the subject's Hb response and tolerability of the prior dose. Epoetin alfa may be administered in either the United States (US) or Japan; epoetin beta will only be administered in Japan.
62241014|NCT04696991|EXPERIMENTAL|Experimental Group|The mothers in the experimental group (70) were given the postpartum discharge education with PechaKucha Method.
62241015|NCT04696991|NO_INTERVENTION|Control Group|The mothers in the control group (70) were given the routine postpartum discharge education.
62241016|NCT04725383|ACTIVE_COMPARATOR|amitriptyline|Subjects will receive active amitriptyline compounded into look-alike capsules to resemble placebo capsules. Dosing will be as tolerated, up to tid and maximum of 100mg/day or 1.5mg/kg/day, for 10 weeks.
62241017|NCT04725383|PLACEBO_COMPARATOR|placebo|Subjects in this arm will receive placebo compounded into capsules that resemble the compounded amitriptyline capsules, up to 4 capsules a day (1 qam, 1 q4pm and 2 capsules qhs), for 10 weeks.
62241018|NCT00592761|EXPERIMENTAL|Within subjects treatment, no-treatment|Within subject, treatment and no-treatment periods. Each participant served as his/her own control in this AABB/BBAA alternating treatment conditions design. Results were also compared across groups (treatment v. no-treatment).
62241019|NCT01685710|EXPERIMENTAL|GTN patch|GTN patch 5mg, in situ 24hrs
62241020|NCT01685710|PLACEBO_COMPARATOR|Placebo patch|Placebo patch, in situ for 24hrs
62241021|NCT04052568|EXPERIMENTAL|Experimental psilocybin|Participants will have up to four doses of psilocybin.
62241022|NCT01674335|NO_INTERVENTION|Delayed-Intervention|A total of 120 participants with fibromyalgia will be randomly assigned to one of four intervention groups (Operant Learning (OL), Energy Conservation (EC), delayed-OL and delayed-EC). The delayed groups will receive the AP intervention 3 months later and will serve as a Usual Care control group. All groups will continue to receive any concomitant interventions that they are receiving (pharmacological and non-pharmacological) at the time of enrollment.
62241023|NCT01674335|ACTIVE_COMPARATOR|Operant Learning|
62241024|NCT01674335|ACTIVE_COMPARATOR|Energy Conservation|
62241025|NCT06046911|EXPERIMENTAL|Tai Chi group|The intervention was 12 weeks of Yang-style Tai Chi, three times a week.
62431399|NCT04516694|EXPERIMENTAL|Gain-framed incentive|"Participants will start off with nothing at the beginning of the treatment period. For each day that participants' meet goals, value will be added to their incentive balance.~All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits."
62431400|NCT04516694|EXPERIMENTAL|Loss-framed incentive|"Participants will start off at the maximum incentive balance at the beginning of the treatment period and for each day that participants' fail to meet goals, value will be subtracted from their incentive balance over the 12-week.~All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits."
62431401|NCT06274216|EXPERIMENTAL|Group A|Patients in group A received 5000 IU of vitamin D3 orally every day for 12 weeks
62431402|NCT06274216|ACTIVE_COMPARATOR|Group B|Patients in group B received 400mg of vitamin E orally every day for 12 weeks
62241026|NCT06046911|EXPERIMENTAL|Daily activity group|The daily activity group mainly maintained daily activities, such as walking and stretching, three times a week for 12 weeks.
62241027|NCT02802930|EXPERIMENTAL|SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104|All test products (SPF 50 Y65 110,SPF 50 Y51 002, and SPF 15 V27 l 04 compared to that of a negative control \[0.9% NaCl\]) were tested simultaneously on each subject.
62241028|NCT02423018|ACTIVE_COMPARATOR|Pregabalin|Pregabalin titrated up to, and tapered from, 225mg/day in divided doses for 10 days
62431403|NCT04856995||working in the operating|operating room workers exposed to surgical smoke
62431404|NCT04856995||working in internal units|Internal unit workers not exposed to surgical smoke
62241029|NCT02423018|PLACEBO_COMPARATOR|Placebo|Placebo for 10 days
62431405|NCT04677582|EXPERIMENTAL|Intervention Group|The intervention group will receive weekly education sessions about nutrition, exercise, and behavioral health.
62431406|NCT04379388|EXPERIMENTAL|Web + text smoking cessation intervention|Participants will receive referral to a quit smoking hotline and 12-week web and text-based smoking cessation intervention
62431407|NCT04379388|NO_INTERVENTION|Usual care control|Participants will receive referral to a quit smoking hotline
62431408|NCT01954329||Patients suspected of TIA by the GP|
62817047|NCT06591169|EXPERIMENTAL|study|this group will contain twenty obese females with a complaint of NAFLD, PCOS and OSA. for eight weeks, these obese females will receive metformin tablet (thrice daily), program of low diet intake, and daily walking for 30 minutes
62038365|NCT05717868|EXPERIMENTAL|Self-mobilization group|Self-SNAG technique will be applied by the participants with the help of a towel, and performed for a four week period.
62598466|NCT05856344|EXPERIMENTAL|Spherical tip noncompliant balloon|Enrolled patients who were randomly assigned to this group underwent stent postdilation using the spherical tip non compliant balloon(APT Medical Inc，CONQUEROR NC Pro). The selection of balloon size is based on the expected target lesion stent diameter, and the length range is restricted among 8-12mm. It will be defined as balloon passage failure if it fails to pass the target lesion after three attempts. After that, based on the purpose of completing the surgery, alternative options can be selected based on the surgeon's experience, including double-guide wire assistance, 5in6 support, the use of regular noncompliant balloon and so on.
62598467|NCT05856344|ACTIVE_COMPARATOR|Regular noncompliant balloon|Enrolled patients who were randomly assigned to this group underwent stent postdilation using the regular noncompliant balloon(tapered-tip). The selection of balloon size is also based on the expected target lesion stent diameter, and the length range is restricted among 8-12mm. It will be defined as balloon passage failure if it fails to pass the target lesion after three attempts. After that, based on the purpose of completing the surgery, alternative options can be selected based on the surgeon's experience, including tip modification, double-guide wire assistance, 5in6 support, the use of spherical tip non compliant balloon(APT Medical Inc，CONQUEROR NC Pro) and so on.
62817048|NCT06591169|ACTIVE_COMPARATOR|control group|this group will contain twenty obese females with a complaint of NAFLD, PCOS and OSA. for eight weeks, these obese females will receive metformin tablet (thrice daily) and program of low diet intake
62038366|NCT05091710|EXPERIMENTAL|Follow up care program for HF patients|Discharged HF patients in rural Haiti will be receive a follow-up care program delivered by trained community health workers (CHWs).
62038367|NCT05091710|OTHER|Standard of care|Historical reference group who received standard of care for HF identified prior to CHW training.
62735631|NCT03335904|EXPERIMENTAL|Losartan|Participants will ingest 50 mg of losartan, an angiotensin receptor blocker, by mouth on two consecutive days. The first tablet will be consumed on day 1 at 0700 hrs. The second tablet will be consumed at 1900 hrs and the final tablet will be consumed at 0700hrs on day 2. Participants will undergo a Hyperoxic Hypercapnic Ventilatory Response Test, a Hypoxic Hypercapnic Ventilatory Response Test, and Repeated Hypoxic Apneas before and after a Hypoxic Sleep Study.
62038368|NCT01639885|NO_INTERVENTION|Group 1|Patients will receive standard care (gemcitabine)
62038369|NCT01639885|EXPERIMENTAL|Group 2|Patients will receive standard care (gemcitabine) combined with interferon-alpha 2b (Peg-Intron)
62038370|NCT01639885|EXPERIMENTAL|Group 3|Patients will receive standard care (gemcitabine) combined with interferon-alpha 2b (Peg-Intron) and p53 SLP vaccin
62038371|NCT04203693||Cohort 1: Tildrakizumab Treated Participants|Participants will be treated with tildrakizumab who have participated in prior tildrakizumab studies
62038372|NCT04203693||Cohort 2: Newly Tildrakizumab Prescribed Participants|Participants will be newly prescribed tildrakizumab (a prescription has occurred independently of the enrolment in the study)
62038373|NCT06733064|EXPERIMENTAL|Vitamin D3 supplementation|Group receiving vitamin D3 at a dose of 4000 IU / day
62038374|NCT06733064|PLACEBO_COMPARATOR|Placebo supplementation|Vegetable oil as a placebo.
62038375|NCT06462508|EXPERIMENTAL|[18F]F-PSMA-N5 and [68Ga]Ga-PSMA-11 PET/ CT scan|Subjects PET/CT imaging: On any two days for two consecutive weeks, each subject underwent a PET/ CT scan after intravenous injection of \[18F\]F-PSMA-N5 and \[68Ga\]Ga-PSMA-11.
62038376|NCT05261152|EXPERIMENTAL|Probiotic group|Capsules are containing S. boulardii and were administered twice daily (250 mg). The administration of investigated product started within 30 min before the first dose of the antibiotic and continued for 21 days.
62038377|NCT05261152|PLACEBO_COMPARATOR|Placebo group|Capsules are containing placebo and were administered twice daily. The administration of investigated product started within 30 min before the first dose of the antibiotic and continued for 21 days.
62038378|NCT02405520|EXPERIMENTAL|low dosage HPV Vaccine|Participants in this arm would receive low dosage of HPV vaccines.
62038379|NCT02405520|EXPERIMENTAL|medium dosage HPV Vaccine|Participants in this arm would receive medium dosage of HPV vaccines.
62038380|NCT02405520|EXPERIMENTAL|high dosage HPV Vaccine|Participants in this arm would receive high dosage of HPV vaccines.
62038381|NCT02405520|PLACEBO_COMPARATOR|Placebo|Participants in this arm would receive placebo (Aluminium Adjuvant).
62038382|NCT03724643|EXPERIMENTAL|Protocolized Wean|Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 \< 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI \< 105 breaths/min/L). Respiratory distress signs included RR \> 30 breaths/min, SaO2\< 90%, HR \> 140 beats/min, or a sustained change in HR of \>20%, systolic BP \>200 mmHg or \<80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
62038383|NCT03724643|NO_INTERVENTION|Usual Care|In the UC group, the SBT type and extubation decision was determined by the attending intensivist on service based upon neurologic status, airway competence (gag, cough, suction requirements), and negative inspiratory force (NIF) or RSBI measurements.
62038384|NCT00990834|EXPERIMENTAL|Statin exposure|Subjects' endpoints will be measured before and after one to eight months of statin exposure.
62038385|NCT06268574|EXPERIMENTAL|RVU120 single agent|RVU120 oral capsules administered at dose of 250 mg every other day on Days 1-13 of each 21-day cycle of treatment.
62038386|NCT05311657||Test Group|Severe COPD (GOLD 3 and 4).
62038387|NCT05311657||Control Group|Matched to Test Group regarding age, sex, smoking history and number of systemic diseases.
62038388|NCT01229761|ACTIVE_COMPARATOR|infant cotrimoxazole|
62038389|NCT01229761|PLACEBO_COMPARATOR|infant placebo|
62038390|NCT01229761|ACTIVE_COMPARATOR|exclusive breastfeeding for 6 months|
62038391|NCT01229761|ACTIVE_COMPARATOR|exclusive breastfeeding for 12 months|
62038392|NCT06731959|EXPERIMENTAL|Fexlamose|Fexlamose solution once daily via nebulizer for 28 days
62038393|NCT06731959|PLACEBO_COMPARATOR|Placebo|Placebo solution once daily via nebulizer for 28 days
62038394|NCT00436657|EXPERIMENTAL|Surgery + CHPP of Escalating Cisplatin|Abdominal Surgery + CHPP of Escalating Cisplatin (Starting dose of 100 mg/m\^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.)
62038395|NCT05095818|NO_INTERVENTION|Standard of Care with EMR Enhancements|Participants in this arm will receive Standard of Care with EMR Enhancements.
62038396|NCT05095818|EXPERIMENTAL|Standard of Care with EMR Enhancements and PrEP-RN|Participants in this arm will receive Standard of Care with EMR Enhancements and PrEP-RN.
62038397|NCT01992003||Patients undergoing spine surgery|
62038398|NCT06579716|EXPERIMENTAL|Traditional balance exercise + Resistance exercise + Whole-body vibration|It consisted of 30 participants diagnosed as having diabetic peripheral neuropathy. Each received traditional balance exercise, resistance exercise, and whole-body vibration, for 6 weeks.
62038399|NCT06579716|EXPERIMENTAL|Traditional balance exercise + Resistance exercise + Kineso tape|It consisted of 30 participants diagnosed as having diabetic peripheral neuropathy. Each received traditional balance exercise, resistance exercise, and kineso tape, for 6 weeks.
62038400|NCT01311960|EXPERIMENTAL|bevacizumab eye drop|
62038401|NCT01311960|EXPERIMENTAL|placebo normal saline eye drop|
62038402|NCT05918068|OTHER|Control group|Newly diagnosed patients with T2DM, treated with non-pharmacological therapy (lifestyle modification).
62038403|NCT05918068|ACTIVE_COMPARATOR|Metformin only group|T2DM patients treated with metformin 500 mg/day in addition to non-pharmacological therapy (lifestyle modification)
62735632|NCT04404790|EXPERIMENTAL|Anfibatide 5 IU/60kg|Ten subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes.
62735633|NCT04404790|EXPERIMENTAL|Anfibatide 5 IU/60kg+0.002 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours.
62038404|NCT05918068|EXPERIMENTAL|Combination group|T2DM patients treated with metformin 500 mg/day plus vitamin B6 300 mg/day in addition to non-pharmacological therapy (lifestyle modification)
62038405|NCT05940532|EXPERIMENTAL|Interventional arm|Patients will receive 3 cycles of induction therapy with sugemalimab and chemotherapy before curative local therapy.
62038406|NCT06288906||Symptomatic deep vein thrombosis (DVT) patients|
62038407|NCT03475550|ACTIVE_COMPARATOR|Standard of care 1|"Patients will receive one of 2 different descriptions of the medication's risks and benefits. Both descriptions meet ethical standards of transparency and respect for person and are commonly used but have never been compared. Standard of Care 1 includes more details than Standard of Care 2."
62241030|NCT02169180|EXPERIMENTAL|Ibrutinib|Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response \[CR\]), unacceptable toxicity, or end of treatment, whichever occurs first.
62241031|NCT00992511|EXPERIMENTAL|GSK2340272A New 1D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
62241032|NCT00992511|EXPERIMENTAL|GSK2340272A New 2D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
62241033|NCT00992511|EXPERIMENTAL|GSK2340272A INI 1D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the Initial process-manufactured (INI 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
62241034|NCT00992511|EXPERIMENTAL|GSK2340272A INI 2D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the Initial process-manufactured (INI 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
62241035|NCT01672788|EXPERIMENTAL|Test 1|fixed dose combination tablet
62241036|NCT01672788|ACTIVE_COMPARATOR|Reference 1|empagliflozin tablets and metformin tablet
62241037|NCT01672788|EXPERIMENTAL|Test 2|fixed dose combination tablet
62241038|NCT01672788|ACTIVE_COMPARATOR|Reference 2|empagliflozin tablet and metformin tablet
62241039|NCT01418820|EXPERIMENTAL|Verum stimulation|repetitive transorbital alternating current stimulation (rtACS)
62241040|NCT01418820|SHAM_COMPARATOR|Placebo stimulation|compared to verum stimulation the same electrode montage set-up is used during placebo stimulation, except that placebo patients receive a minimal stimulation
62431409|NCT04130919|EXPERIMENTAL|Tilpisertib 300 mg|Participants will receive blinded tilpisertib 300 mg for up to 10 weeks. An efficacy assessment will be performed at Week 10. Participants who achieve MCS response will continue on the blinded treatment for up to 50 weeks.
62431410|NCT04130919|EXPERIMENTAL|Tilpisertib 100 mg|Participants will receive blinded tilpisertib 100 mg for up to 10 weeks. An efficacy assessment will be performed at Week 10. Participants who achieve MCS response will continue on the blinded treatment for up to 50 weeks.
62038408|NCT03475550|ACTIVE_COMPARATOR|Standard of care 2|"Patients will receive one of 2 different descriptions of the medication's risks and benefits. Both descriptions meet ethical standards of transparency and respect for person and are commonly used but have never been compared. Standard of Care 2 includes fewer details than Standard of Care 1."
62038409|NCT01928719|EXPERIMENTAL|Reduced Nicotine Content Cigarettes|the experimental group will smoke cigarettes with Gradually Reduced Nicotine Content (RNC) (11.6, 7.4, 3.3, 1.4, 0.7, and 0.2 mg per cigarette) cigarettes, each smoked for 3 weeks, except for the last period which will last 6 weeks to evaluate a longer-term adherence to the lowest nicotine content cigarette.
62241041|NCT04980950|EXPERIMENTAL|gastric cancer patients (immunonutrition)|Experimental gastric cancer group will receive Impact Oral Nestlé Health Science/ Cubitan® Nutricia for 10 days.
62241042|NCT04980950|ACTIVE_COMPARATOR|gastric cancer patients (standard nutrition)|These patients will receive Nutridrink® Nutricia/ Resource 2.0 Nestlé Health Science for 10 days.
62241043|NCT04980950|EXPERIMENTAL|colorectal cancer patients (immunonutrition)|Experimental colorectal cancer group will receive Impact Oral Nestlé Health Science/ Cubitan® Nutricia for 10 days.
62241044|NCT04980950|ACTIVE_COMPARATOR|colorectal cancer patients (standard nutrition)|These patients will receive Nutridrink® Nutricia/ Resource 2.0 Nestlé Health Science for 10 days.
62431411|NCT04130919|PLACEBO_COMPARATOR|Placebo|Participants will receive blinded tilpisertib matching placebo for up to 10 weeks. An efficacy assessment will be performed at Week 10. Participants who achieve MCS response will continue on the blinded treatment for up to 50 weeks.
62735634|NCT04404790|EXPERIMENTAL|Anfibatide 5 IU/60kg+0.004 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours.
62735635|NCT04404790|EXPERIMENTAL|Anfibatide 5 IU/60kg+0.008 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours.
62735636|NCT04404790|EXPERIMENTAL|Anfibatide 7 IU/60kg|Ten subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes.
62241045|NCT04111965|EXPERIMENTAL|Nanodrop® (PRO-176)|- Nanodrop®. 0.6% propylene glycol. Ophthalmic emulsion Laboratorios Sophia, S.A. from C.V. Route of administration: Ophthalmic.
62241046|NCT04111965|ACTIVE_COMPARATOR|Systane® Balance|"* Systane® Balance. 0.6% propylene glycol. Ophthalmic emulsion Alcon Laboratories, Inc.~* Route of administration: Ophthalmic."
62241047|NCT01790126|ACTIVE_COMPARATOR|ARN-509|ARN-509 Tablets, 240 mg/day administered orally
62241048|NCT01790126|ACTIVE_COMPARATOR|LHRH agonist + ARN-509|Choice of LHRHa per investigator discretion/site practice guidelines (e.g, Eligard®, Zoladex®, Lupron Depot®, Trelstar®) and ARN-509 Tablets, 240 mg/day administered orally
62241049|NCT01790126|ACTIVE_COMPARATOR|LHRH agonist|Choice of LHRHa per investigator discretion/site practice guidelines (e.g., Eligard®, Zoladex®, Lupron Depot®, Trelstar®).
62038410|NCT01928719|PLACEBO_COMPARATOR|Same Nicotine Content Cigarettes|The Same Nicotine Control Group (SNC) will continue to smoke research cigarettes with a usual nicotine content (about 11.6 mg per cigarette)
62038411|NCT05086133|EXPERIMENTAL|cTBS stimulation|The participants randomized into experimental group will receive cTBS stimulation of left M1 area for 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.
62038412|NCT05086133|SHAM_COMPARATOR|Sham stimulation|The participants randomized into experimental group will receive sham stimulation of left M1 area for 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.
62038413|NCT00728390|EXPERIMENTAL|1|
62038414|NCT06657937||Study population|"The study population must correspond to the research inclusion criteria:~Adult patients admitted to the emergency department, presenting with an ankle sprain"
62038415|NCT06139887|EXPERIMENTAL|BESST|Patients randomized to the BESST intervention arm will receive the BESST intervention combined with standard mental health care.
62038416|NCT06139887|OTHER|Control|Patients randomized to the control arm will receive standard mental health care alone.
62038417|NCT03392714|EXPERIMENTAL|R-B(O)AD|Intravenous R-B(O)AD every 4 weeks for up to 4 cycles
62038418|NCT05357612|EXPERIMENTAL|Pimavanserin|
62038419|NCT05858996|EXPERIMENTAL|Pain-CPG-EIT|The four components of the PAIN-CPG-EIT are provided by a research nurse facilitator working with the champion(s) and stakeholder team. Following the first stakeholder team meeting, the research nurse facilitator works 8 hours weekly during months one and two and then for four hours weekly months three to 12 to implement: Component I: Stakeholder team meeting and goal setting; Component II: Education of the staff; Component III: Mentoring and motivating the staff to address pain using the Pain Management CPG ; and Component IV: Ongoing monitoring of pain management in the community based on the Pain Management CPG.
62735637|NCT04404790|EXPERIMENTAL|Anfibatide 7 IU/60kg+0.002 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours.
62735638|NCT04404790|EXPERIMENTAL|Anfibatide 7 IU/60kg+0.004 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours.
62735639|NCT04404790|EXPERIMENTAL|Anfibatide 7 IU/60kg+0.008 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours.
62038420|NCT05858996|ACTIVE_COMPARATOR|Pain-CPG-Education Only|Communities randomized to education only will be provided with staff education using our developed Powerpoint for Component II of the PAIN-CPG-EIT intervention in 30 minute sessions as is currently done in usual practice. They will also be given access to an online copy of the Pain Management CPG. The education will be provided in the preferred format (e.g., face-to-face; webinar).
62038421|NCT03958370||Fitbit|
62038422|NCT06073821|EXPERIMENTAL|Sonrotoclax Plus Zanubrutinib|Participants will receive from start of Cycle 1 a standard dose of zanubrutinib once or twice daily orally and in combination with sonrotoclax starting from Cycle 4 onwards at increasing doses until target dose is reached and continuing until end of Cycle 15 (each cycle is 28 days)
62038423|NCT06073821|ACTIVE_COMPARATOR|Venetoclax Plus Obinutuzumab|Participants will receive obinutuzumab 100mg intravenously on Day 1 Cycle 1, followed by 900 mg on Day 2 Cycle 1 (or alternatively receive 1000 mg intravenously on Day 1), followed by 1000 mg on Days 8 and 15 of Cycle 1 and thereafter on Day 1 of Cycles 2 through 6 (each cycle is 28 days) in combination with venetoclax at increasing doses until target dose is reached from Day 22 Cycle 1 until end of Cycle 12 (each cycles is 28 days)
62038424|NCT03152526|OTHER|Single-arm trial|Multi-center, open-label, single-arm, phase I/II clinical trial
62038425|NCT03876405|EXPERIMENTAL|sensory feedback|"A non-invasive air-mediated sensory feedback system embedded in the prosthesis socket.~Group description: Individuals with acquired forearm amputation."
62038426|NCT04137042|ACTIVE_COMPARATOR|Saline|intraoperative fluid therapy by using 0.9% saline
62038427|NCT04137042|EXPERIMENTAL|Balanced crystalloid|intraoperative fluid therapy by using balanced crystalloid
62038428|NCT05349344|EXPERIMENTAL|Aerobic Circuit Training|Each session consists of 5 minutes of warming up,20 minutes of aerobic exercises with brief resting periods, followed by 5 minutes to cool down.
62038429|NCT05349344|ACTIVE_COMPARATOR|outdoor walk|30minutes Walking outside below 40% of HR max for 2 months.(3 times per week for 8 weeks).
62038430|NCT06603220|EXPERIMENTAL|EVO756|
62038431|NCT03285139|EXPERIMENTAL|Immediate Intervention|Group CBT for PPD. Women in the treatment group will attend a 9-week group Cognitive Behavioural Therapy intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton and designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. The CBT intervention will be delivered by lay-peers.
62038432|NCT03285139|EXPERIMENTAL|Wait List Controls|Group CBT for PPD 9 weeks after enrollment. The women in this arm of the study will receive the same Cognitive Behavioural Therapy intervention as in the immediate intervention arm, however they will begin the CBT group 9 weeks after enrolling in the study.
62038433|NCT03285139|NO_INTERVENTION|Healthy Controls|No treatment. The participants in this arm of the study will not be suffering from postpartum depression and will not receive the Cognitive Behavioural Therapy treatment. Healthy controls will complete study measures upon enrollment in the study, 9 weeks later as well as 6 months later.
62431412|NCT04130919|EXPERIMENTAL|Open-label Tilpisertib 300 mg|Based on the efficacy assessment results at Week 10, participants who do not achieve MCS response will have the option to receive open-label tilpisertib 300 mg for up to 50 weeks.
62598468|NCT05288387|EXPERIMENTAL|Spinal cord stimulation in heart failure patients with hypotension|"Adhesive patches are applied to subjects' back skin. Single stimuli are delivered in order to define the stimulation threshold under the guidance of neuromyography. Vascular access is performed (jugular or subclavian) according to conventional preparation to right heart catheterization. Invasive hemodynamic measures are performed as usual.~High-frequency spinal cord stimulation at T5 level is initiated, and repeated hemodynamic measures performed within 2 minutes. Stimulation lasts for 5-10 minutes, and then ceased. Following a 5-minutes waiting period, repeat hemodynamic measures are performed. The same sequence of steps applies for stimulation levels T7-8 and a combination of T5 and T7-8.~Then the procedure is completed and data are analysed."
62598469|NCT05563012|EXPERIMENTAL|Patients with untreated, operable locally advanced gastric adenocarcinoma|"Drug: Sintilimal Injection Sintilimal (200mg) will be given i.v. on day 1 of each 3-week cycle.~Drug: Capecitabine Capecitabine (1000mg/m2) will be administered orally twice daily on days 1-14 of each 3-week cycle.~Drug: Oxaliplatin Oxaliplatin (130mg/m2) will be given i.v. on day 1 of each 3-week cycle."
62598470|NCT05319743||Medicaid expansion states|Eight Medicaid expansion states: (experimental group): Arizona, California, Illinois, Massachusetts, New Jersey, Ohio, Washington
62598471|NCT05319743||Non-Medicaid expansion states|Five states that did not expand Medicaid (control group): Florida, Georgia, North Carolina, Texas, Virginia
62598472|NCT06617910||Sinonasal malignancy patients received post-operative cyberknife|Sinonasal malignancy patients in our hospital receive curative surgery. These patients received post-operative radiotheray of SBRT by cyberknife.
62598473|NCT06461143|EXPERIMENTAL|Intraosseous anesthesia|Computerized intraosseous anesthesia will be applied to the mandibular first molars of 40 patients.
62598474|NCT06461143|ACTIVE_COMPARATOR|Inferior alveolar nerve block|Conventional inferior alveolar block anesthesia will be applied to the mandibular first molars of 40 patients.
62598475|NCT05958316|EXPERIMENTAL|Computerized Symptom Assessment Tool C-SCAT|Participants will be asked to complete the C-SCAT at three of their clinic visits for cancer treatment in addition to usual care for assessing symptoms. This intervention period will last up to about 12 weeks, depending on cancer treatment schedule (for example, every 2, 3 or 4 weeks).
62598476|NCT05958316|ACTIVE_COMPARATOR|Usual Care Control Group|Participants will follow usual care for cancer symptoms for up to 12 weeks, depending on how cancer treatment schedule (for example, every 2, 3 or 4 weeks).
62598477|NCT06624150|EXPERIMENTAL|Active tDCS|10 Active tDCS sessions: 10 active sessions of transcranial direct current stimulation paired with cognitive training tasks. Device used is StarStim.
62598478|NCT06624150|SHAM_COMPARATOR|Sham (fake) tDCS|10 Sham (fake) tDCS sessions: 10 fake sessions of transcranial direct current stimulation paired with cognitive training tasks. The device will be on the participants head, but the current will not be active.
62598479|NCT05789784|EXPERIMENTAL|mymobility Physical Therapy|The mymobility Physical Therapy cohort will complete an identical protocol to the Standard Office-based Physical Therapy cohort with one exception: the mymobility cohort's therapy for the entire duration of the protocol is administered at home through the mymobility application. This cohort initiates use of the mymobilty application one postoperative day 1. Exercises and restrictions are described in-depth in the Study Protocol document.
62598480|NCT05789784|ACTIVE_COMPARATOR|Standard Office-based Physical Therapy|The Standard Office-based Physical Therapy cohort completes an identical protocol to the mymobility Physical Therapy cohort with one exception: rather than through use of the mymobility application, the Standard Office-based Physical Therapy cohort's protocol is administered through the traditional means of an exercise handout for postoperative day 1 through 2 weeks followed by formal office-based physical therapy for the duration of the protocol. Exercises and restrictions are described in-depth in the Study Protocol document.
62038434|NCT02119507|EXPERIMENTAL|Curodont Repair|Single application on Day 0.
62038435|NCT02119507|OTHER|No treatment - control|"No treatment as control - wait and see."
62038436|NCT05757219|EXPERIMENTAL|Pre-Modulation Treatment|Participants will receive itacitinib 200 mg PO QD beginning at time of apheresis approximately 4-6 weeks prior to CAR-T-cell therapy and will continue until Day 30 (30 Days Post-CAR-T-cell therapy)
62038437|NCT00498719||CTP Group|One-on-one cognitive training
62241050|NCT01822522|EXPERIMENTAL|Stratum A Treatment (cabozantinib s-malate): 20 mg/day|"Patients receive cabozantinib s-malate 20 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~This arm includes patients who are on ritonavir-boosted or cobicistat-boosted antiretroviral regimens"
62038438|NCT00498719||Control Group|Standard educational support.
62038439|NCT02859792|PLACEBO_COMPARATOR|Placebo|
62038440|NCT02859792|EXPERIMENTAL|Experimental|
62241051|NCT01822522|EXPERIMENTAL|Stratum A Treatment (cabozantinib s-malate): 40 mg/day|"Patients receive cabozantinib s-malate 40 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~This arm includes patients who are on ritonavir-boosted or cobicistat-boosted antiretroviral regimens"
62431413|NCT01880645|OTHER|Ultrasound + Breast Surgery + Lymph Node Removal|Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s). If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected. Standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction) performed.
62598481|NCT02433925|ACTIVE_COMPARATOR|Supplement B|Administration of 500mg of trans-resveratrol per day, for 4 weeks
62038441|NCT03971682|EXPERIMENTAL|Experimental - PSYCHOPATHY.COMP program.|"The PSYCHOPATHY.COMP is a structured individual program for detained youth. This program is based on Compassion Focused Therapy (CFT), which conceptualizes antisocial behavior and psychopathic traits as evolutionary rooted responses to deal with harsh rearing scenarios. The ultimate goal of the PSYCHOPATHY.COMP is to develop a compassionate motivation in these youth.~PSYCHOPATHY.COMP consists of 20 individual sessions, each lasting about 60 minutes, which run on a weekly basis. Sessions must be carried out by therapists skillful in CFT. Sessions are grouped into four modules: (1) The basics of our mind; (2) Our mind according to CFT; (3) Compassionate Mind Training; and (4) Recovery, relapse prevention, and finalization.~The treatment group attended the PSYCHOPATHY.COMP program in addition to the Treatment As Usual (TAU) delivered at Portuguese juvenile detention facilities."
62038442|NCT03971682|ACTIVE_COMPARATOR|Treatment As Usual - TAU|"Treatment As Usual:~Subjects in this group received Treatment As Usual in Portuguese juvenile detention facilities (school frequency, token economy system for behavior control, frequency of a structured cognitive-behavioral group program, as well as individualized counseling sessions delivered by psychologists from the juvenile justice system) and did not attend the PSYCHOPATHY.COMP program."
62598482|NCT02433925|PLACEBO_COMPARATOR|Supplement A|Administration of 500mg of placebo per day, for 4 weeks
62598483|NCT04630249|EXPERIMENTAL|Listening to Women and Pregnant and Postpartum People|Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, home-based telemedicine mental health and substance use disorder treatment services. The text screenings contain the SBIRT which is a survey with 9 questions related to depression, anxiety, substance abuse (alcohol, cigarettes, other drugs including prescription medication), and domestic violence.
62431414|NCT05834257|EXPERIMENTAL|Normal Saline|5 Cardiac surgery patients admitted to the intensive care units will receive, following consent and randomisation, Normal Saline as resuscitation fluid. 50mL of blood will be withdrawn before surgery and 24 hours after for each patient in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.
62038443|NCT03932851||HBsAg(+) pregnant woman|Data from pregnant women during pregnancy (including age, maternal history, liver function during pregnancy, HBV DNA in early pregnancy and before delivery, comorbidities and complications during pregnancy, antiviral use before and during pregnancy, and HBV infection status in fathers) Newborn birth data (including body length, weight, Apgar score, feeding status, hepatitis B vaccination, hepatitis B immunoglobulin use, HBsAg at birth and 7 months after birth, HBV DNA). The newborns born to HBV-infected pregnant women were divided into HBV DNA-negative group, low-viral group, and high-viral group according to HBV DNA status. The HBV infection status of these newborns was counted in July, and the different viral loads were tested. The impact of HBV mother-to-child transmission.
62038444|NCT03932851||HBsAg(-) pregnant woman|Data from pregnant women during pregnancy (including age, maternal history, liver function during pregnancy, HBV DNA in early pregnancy and before delivery, comorbidities and complications during pregnancy, antiviral use before and during pregnancy, and HBV infection status in fathers) Newborn birth data (including body length, weight, Apgar score, feeding status, hepatitis B vaccination, hepatitis B immunoglobulin use, HBsAg at birth and 7 months after birth, HBV DNA).
62598484|NCT04630249|NO_INTERVENTION|Usual Care|This group will receive in-person screening and referral to treatment by a nurse or physician per usual prenatal care. The in person screenings contain the SBIRT which is a survey with 9 questions related to depression, anxiety, substance abuse (alcohol, cigarettes, other drugs including prescription medication), and domestic violence.
62038445|NCT05298735||Healthy volunteers|Healthy volunteers with no known significant medical conditions
62598485|NCT05965635|EXPERIMENTAL|Experimental|
62038446|NCT05298735||Patients with type 1 diabetes|Patients with a diagnosis of type 1 diabetes (with or without detectable C-peptide)
62038447|NCT00265889|EXPERIMENTAL|Poor Risk|Primary progressive, recurrent, or resistant relapse patients
62038448|NCT00265889|EXPERIMENTAL|Good Risk|First recurrence patients
62038449|NCT01990027||SKSC Patients group|"A group a 1000 subjects affected by kidney stone as described in the eligibility criteria will be recruited in the period 2014-2024 and the same exams will be repeated for each participants for a period of 3 years.~No intervention will be undertaken."
62598486|NCT02585817|EXPERIMENTAL|Remote CIED Management|Patients with a CIED will undergo remote monitoring with information technology.
62598487|NCT03470012|EXPERIMENTAL|Treatment Arm|Investigational tape
62598488|NCT03760406|EXPERIMENTAL|Severe essential tremor treated by DBS|
62598489|NCT03250091||Gastric cancer|Gastric adenocarcinoma and other gastric malignancies
62431415|NCT05834257|EXPERIMENTAL|PlasmaLyte|5 Cardiac surgery patients admitted to the intensive care units will receive, following consent and randomisation, PlasmaLyte as resuscitation fluid. 50mL of blood will be withdrawn before surgery and 24 hours after for each patient in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.
62598490|NCT03250091||Gastric mucosal dysplasia|Includes: a. High-grade dysplasia; b. Low-grade dysplasia; c. Indefinite for dysplasia
62598491|NCT03250091||High-risk IM gastritis stages|High-risk stages according to OLGIM classification: OLGIM Stage IV and OLGIM Stage III.
62598492|NCT03250091||High-risk atrophic gastritis stages|High-risk stages according to OLGA classification: OLGA Stage IV and OLGA Stage III.
62598493|NCT03250091||Extensive gastric intestinal metaplasia|Intestinal metaplasia of any grade both in gastric corpus and antrum/incisura (other than OLGIM III-IV).
62598494|NCT03250091||Extensive atrophy|Moderate to severe (++ or +++) atrophy both in corpus and antrum/incisura, other than OLGA III-IV.
62598495|NCT03250091||Isolated corpus atrophy|Isolated moderate-to-severe atrophy or IM in the corpus.
62598496|NCT04066296|ACTIVE_COMPARATOR|Liposomal Bupivicaine|Treatment with liposomal bupivicaine
62598497|NCT04066296|ACTIVE_COMPARATOR|Standard Local Anesthestic|Treatment with Standard Local Anesthestic
62598498|NCT02344290|EXPERIMENTAL|Pitavastatin|Participants received pitavastatin once a day for the entire time they were in study follow-up.
62598499|NCT02344290|PLACEBO_COMPARATOR|Placebo|Participants received placebo for pitavastatin once a day for the entire time they were in study follow-up.
62431416|NCT05834257|EXPERIMENTAL|Ringer's Lactate|5 Cardiac surgery patients admitted to the intensive care units will receive, following consent and randomisation, Ringer's lactate as resuscitation fluid. 50mL of blood will be withdrawn before surgery and 24 hours after for each patient in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.
62598500|NCT02235051|EXPERIMENTAL|Arm I (exercise intervention)|Patients participate in a supervised Curves exercise program three days a week for 16 weeks. The circuit-style workout consists of 14 exercises constructed with pneumatic or hydraulic resistance that target opposing muscle groups in a concentric-only fashion. Each session at Curves will include two complete circuits which correspond to exercising for approximately 30 minutes followed by a standardized stretching routine.
62598501|NCT02235051|NO_INTERVENTION|Arm II (no formal exercise intervention)|Patients do not participate in a formal exercise program for 16 weeks. Patients are then offered the Curves exercise intervention.
62598502|NCT02062424|ACTIVE_COMPARATOR|DIPI: Danish national dietary guidelines|The subjects will receive dietary advice according to the current national dietary guidelines
62598503|NCT02062424|ACTIVE_COMPARATOR|DIPI: Specific IHD dietary guideline|The subjects will receive dietary advice, according to the specific ischemic heart disease dietary guidelines.
62038450|NCT01990027||SKSC Control group|"A group of 250 stone-free participants will be recruited and analysed with the same protocol as the patients but in a single visit. This group will be used for comparison with the patients group in future studies.~No intervention will be undertaken."
62431417|NCT01922531||Mild Traumatic Brain Injury|These were patients who presented to the ER within 6 hours of a witnessed head injury. Patients were also eligible if the patient had a self-reported head injury with evidence of head trauma.
62598504|NCT02062424|NO_INTERVENTION|Normal dietary habits|The Subjects will be instructed to follow their normal dietary habits
62598505|NCT02085668|EXPERIMENTAL|Treatment Group|Renal denervation and maintenance of heart failure medications
62817049|NCT02145143|EXPERIMENTAL|thyroid cancer patients|Patients will have lesional dosimetry with 124I PET/CT performed to quantify the baseline iodine avidity of index metastatic lesion(s). Patients will then receive vemurafenib (960 mg orally BID) for about 4 weeks, after which a second 124I PET/CT will be performed. For patients in whom the second 124I PET/CT demonstrates that \> or = 2000 cGy can be achieved in at least one tumor with \< 300 mCi of 131I, Thyrogen-stimulated standard dosimetry \& therapeutic 131I will be performed/administered concurrently with vemurafenib. The drug will then be discontinued \& tumor assessments will be conducted with serial radiologic scan(s) \& thyroglobulins (scans will be performed at baseline, before 131I, 3-4 months following 131I, \& 6 months after 131I). Patients whose tumors fail to demonstrate adequate iodine incorporation following vemurafenib to warrant 131I therapy, the study drug will be discontinued, a final tumor assessment will be performed, \& the patient will be taken off the study.
62817050|NCT04930445||Oxbryta Product Registry|
62817051|NCT06296953|EXPERIMENTAL|Patient Group|Patient will be examined with the new device, PERIsign.
62817052|NCT06296953|ACTIVE_COMPARATOR|Healthy Volunteers|The group will also be examined with the device, PERIsign
62817053|NCT04737616|EXPERIMENTAL|CO2 Laser +OCT|Postmenopausal women with genitourinary syndrome of menopause who will receive CO2 vaginal laser treatment
62817054|NCT04737616|EXPERIMENTAL|OCT only|Premenopausal, peri-menopausal and postmenopausal women who will only get one time OCT scan
62598506|NCT02085668|NO_INTERVENTION|Control Group|Maintenance of heart failure medications with option for cross-over renal denervation treatment after 6-months
62598507|NCT00834639|EXPERIMENTAL|1|
62598508|NCT00834639|ACTIVE_COMPARATOR|2|
62598509|NCT06648252|EXPERIMENTAL|Healing Minds|Ten weekly treatments of Heart Math Biofeedback and Breathing Practices
62598510|NCT06648252|NO_INTERVENTION|Control|Waiting List Delayed Intervention
62598511|NCT06056882||Study group|
62598512|NCT01370824||Basal cell carcinoma|"- Population: Eligible are patients (men and women) ≥18 years of age who visit the outpatient department of dermatology of the Maastricht University Medical Centre because of a clinically suspected BCC.~- Inclusion criteria: All patients aged 18 years or older, otherwise healthy, with ≤ three primary (no previous treatment) clinically determined BCC.~- Exclusion criteria: Patients using immunosuppressive drugs. Genetic skin cancer disorders. Earlier treatments at the same site. Age under 18 years. More than 3 clinical suspected BCCs. Not capable of informed consent."
62735640|NCT04230265|EXPERIMENTAL|UniCAR02-T-CD123 (4 mg/day TM123)|Preconditioning (lymphodepletion) with cyclophosphamide and fludarabine, followed by combination treatment of genetically modified T-cells carrying universal chimeric antigen receptors (UniCAR02-T) with 4 mg/day of the recombinant antibody derivative TM123.
62735641|NCT04230265|EXPERIMENTAL|UniCAR02-T-CD123 (8 mg/day TM123)|Preconditioning (lymphodepletion) with cyclophosphamide and fludarabine, followed by combination treatment of genetically modified T-cells carrying universal chimeric antigen receptors (UniCAR02-T) with 8 mg/day of the recombinant antibody derivative TM123.
62735642|NCT02052661|EXPERIMENTAL|Engerix-B Kinder Group|Subjects who were previously primed and boosted with four doses of Infanrix™ hexa in the first two years of life, received a single dose of Engerix™-B Kinder vaccine. The vaccine was administered intramuscularly into the deltoid of the non-dominant arm.
62735643|NCT02622295|EXPERIMENTAL|Acute gene regulation|Adaptations in gene regulation in response to single-session electrically induced exercise
62038451|NCT06511141|OTHER|Single Arm|Clinical outcomes with use of Axonics SNM system for the male OAB population.
62735644|NCT02622295|EXPERIMENTAL|Training Study|Adaptations in gene regulation, metabolic markers, and subject-report metrics in response to up to 3 years of electrically induced exercise
62735645|NCT03435120||Breakthrough Cancer Pain|No intervention (Non Interventional Study)
62735646|NCT03272386||Observational study|Observational study with patients over 18 years old, consulting for lower urinary tract symptoms in a tertiary center are included.
62735647|NCT02259725|EXPERIMENTAL|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62431418|NCT01922531||Orthopedic Injury|Patients were eligible as an orthopedic injured control who presented to the ER within 6 hours of an isolated extremity trauma that radiography and an Abbreviated Injury Scale (AIS) of less than or equal to 3.
62598513|NCT05718427|EXPERIMENTAL|Ayres Sensory Integration Therapy Group|Ayres Sensory Integration (ASI) therapy will be applied to children in the intervention group. In the intervention group, Ayres Sensory Integration Therapy will be performed 3 days a week for a total of 10 weeks, 60 minutes each session, in accordance with the Ayres Sensory Integration Fidelity Measure (ASI-FM). A manualized protocol will be followed based on the principles of ASI-FM, Ayres sensory integration.
62598514|NCT05718427|NO_INTERVENTION|Waiting Group|The children in the control group will be wait just 10 weeks. The second evaluation will be repeated 10 weeks after the first evaluation. In order for the children in the control group to benefit from sensory integration therapy, after a 10-week waiting period, after the result measurements are applied again, Ayres sensory integration therapy will be applied 3 days a week with 60 minutes each session in accordance with the Ayres Sensory Integration Fidelity Measure (ASI-FM).
62817055|NCT03041038|EXPERIMENTAL|Secukinumab|Secukinumab 300mg (liquid formation) administered subcutaneously weekly for 5 weeks then monthly until end of trial
62431419|NCT02996370|ACTIVE_COMPARATOR|Test group- ı shape incision|Second stage surgery was made I shape incision technique .
62431420|NCT02996370|ACTIVE_COMPARATOR|Control group- midcrestal incision|In the control group second stage surgery was made using the conventional method, midcrestal technique.
62598515|NCT05592561|EXPERIMENTAL|Caffeine group|Subjects will receive 200 mg of caffeine powder which was obtained from a 200 mg capsule (Hard Eight Nutrition, LLC, dba, Bulk Supplements, Henderson, Nevada). Researchers will break open the capsule and mix with water and 5/8 tsp of crystal light immediately before subjects ingest the randomly assigned treatment.
62598516|NCT05592561|PLACEBO_COMPARATOR|Placebo|flavored water (sweetened with crystal light powder, 0.5 tsp) will be provided to subjects without any caffeine powder added.
62817056|NCT03041038|PLACEBO_COMPARATOR|Placebo|Placebo (sterile saline) 2ml administered subcutaneously weekly for 5 weeks then monthly until end of trial
62817057|NCT04231773|EXPERIMENTAL|12.1% Oxygen and Inhaled Nitric Oxide|Moderate level of hypoxia (12.1% Oxygen) and Inhaled Nitric Oxide (40 ppm)
62038452|NCT06731933|ACTIVE_COMPARATOR|Treatment with BVEC|
62038453|NCT06731933|NO_INTERVENTION|No treatment with BVEC|
62431421|NCT03768882|EXPERIMENTAL|Paracetamol|Experimental: Paracetamol 1000 mg of paracetamol (parol 10mg/ml solution Mefar,Turkey ) intravenous (IV) was given 102 patients
62431422|NCT03768882|EXPERIMENTAL|dexketoprofen|Dexketoprofen Second group: dexketoprofen 50 MG (Arveles ampoule -İE Ulagay-Menarini,Turkey) intravenous (IV) was given 98 patients
62431423|NCT05472285|ACTIVE_COMPARATOR|Verum|2 capsules per day during 8 weeks
62431424|NCT05472285|PLACEBO_COMPARATOR|Placebo|2 capsules per day during 8 weeks
62431425|NCT06157489|ACTIVE_COMPARATOR|Hamza|
62431426|NCT06157489|SHAM_COMPARATOR|Noor mohamed|
62431427|NCT06157489|ACTIVE_COMPARATOR|Janna ahmed|
62817058|NCT04231773|PLACEBO_COMPARATOR|12.1 % Oxygen Placebo|Moderate level of hypoxia (12.1 % Oxygen) and Placebo (0 ppm Nitric Oxide)
62817059|NCT04231773|EXPERIMENTAL|13.6 % Oxygen and Inhaled Nitric Oxide|Severe level of hypoxia (13.6% Oxygen) and Inhaled Nitric Oxide (40 ppm)
62817060|NCT04231773|PLACEBO_COMPARATOR|13.6 % Oxygen and Placebo|Severe level of hypoxia (13.6% Oxygen) and Placebo (0 ppm Nitric Oxide)
62817061|NCT05323253|EXPERIMENTAL|DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. Objective Response Rate (ORR) will be determined based on confirmed BOR following DaRT insertion.
62817062|NCT04529083|EXPERIMENTAL|Intervention|Mixed Reality System for virtual mirror therapy
62817063|NCT05428501||Person Living with Obesity (PLwO)|PLwO recruited via online platforms or face-to-face channels
62817064|NCT05428501||Health Care Professionals (HCPs)|HCPs treating people who have obesity
62817065|NCT03559114|ACTIVE_COMPARATOR|Anticoagulant|Dalteparin sodium (at a dose of 5000 IU once daily by subcutaneous injection) for 7 days upon randomization after hospital admission.
62817066|NCT03559114|PLACEBO_COMPARATOR|Saline|Saline (0.2 mL) once daily by subcutaneous injection for 7 days upon randomization after hospital admission.
62431428|NCT06157489|ACTIVE_COMPARATOR|Hamza salah|
62431429|NCT06157489|SHAM_COMPARATOR|Mohammed asel|
62431430|NCT06157489|ACTIVE_COMPARATOR|Ali ahmed|
62431431|NCT06157489|SHAM_COMPARATOR|Malek Mohamed|
62598517|NCT05592561|EXPERIMENTAL|Theanine group|200mg pure theanine powder (Hard Eight Nutrition, LLC, dba, Bulk Supplements, Henderson, Nevada) + 8 oz water+ 0.55 tsp crystal light will be ingested.
62598518|NCT05592561|EXPERIMENTAL|Tyrosine group|2000 mg pure tyrosine powder (Hard Eight Nutrition, LLC, dba, Bulk Supplements, Henderson, Nevada) +8 oz water + 0.5 tsp crystal light will be ingested.
62598519|NCT01014897|EXPERIMENTAL|subcortical|Subcortical stroke patients will receive tDCS stimulation and sham in random order
62598520|NCT01014897|EXPERIMENTAL|cortical|subjects will receive active and sham tDCS in random order
62817067|NCT06074835|EXPERIMENTAL|Test group (Robot-assisted gamete preparation, ICSI, embryo culture and vitrification)|
62817068|NCT06074835|ACTIVE_COMPARATOR|Control group (routine manual ICSI workflow)|
62817069|NCT03840317|EXPERIMENTAL|Senl_1904A CD19 CAR-T|Autologous CD19-targeting CAR T cells, dosage 3\*10\^5/kg, intravenous injection once
62817070|NCT03840317|EXPERIMENTAL|Senl_1904B CD19 CAR-T|Autologous CD19-targeting CAR T cells,dosage 3\*10\^5/kg, intravenous injection once
62817071|NCT04887558|ACTIVE_COMPARATOR|NCI QuitGuide and NRT|The National Cancer Institute's QuitGuide app is a free smartphone app and is one of few apps that includes many of the recommendations detailed in the Clinical Practice Guideline. The QuitGuide app aims to help smokers understand their smoking patterns and develop the skills needed to quit smoking. QuitGuide provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. All participants will receive free NRT.
62431432|NCT06157489|ACTIVE_COMPARATOR|Sayed Mohamed|
62431433|NCT06157489|ACTIVE_COMPARATOR|Omar ahmed|
62431434|NCT06157489|SHAM_COMPARATOR|Ahmed Mohamed|
62431435|NCT06157489|SHAM_COMPARATOR|Yousef salah|
62431436|NCT06157489|ACTIVE_COMPARATOR|Rofan ahmed|
62431437|NCT06157489|SHAM_COMPARATOR|Kinesio tape hasnot assigned to arm group Exercise only|
62431438|NCT06157489|ACTIVE_COMPARATOR|Fareda salah|
62431439|NCT06157489|ACTIVE_COMPARATOR|Abd elrahman ahmed|
62431440|NCT01253876|EXPERIMENTAL|Soy milk|
62431441|NCT01253876|EXPERIMENTAL|Caw's milk|
62431442|NCT06370195|EXPERIMENTAL|Comprehensive rehabilitation+Stellate ganglion block|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 10 days.
62598521|NCT04439019|EXPERIMENTAL|All patients referred to the Alberta Hip and Knee Clinic|All patients who are diagnosed with severe osteoarthritis undergoing total hip/knee replacement surgery and show interest to be part of the study.
62598522|NCT01093326|EXPERIMENTAL|Ponesimod 10 mg|Ponesimod 10 mg oral use
62598523|NCT01093326|EXPERIMENTAL|Ponesimod 20 mg|Ponesimod 20 mg oral use
62598524|NCT01093326|EXPERIMENTAL|Ponesimod 40 mg|Ponesimod 40 mg oral use
62598525|NCT04501783|EXPERIMENTAL|TL-FVP-t (favipiravir) Treatment Arm|Day 1: favipiravir 1800 mg BID plus Standard of Care (SOC); Days 2-10: 800 mg BID plus SOC.
62817072|NCT04887558|EXPERIMENTAL|Smart-T Mental Health and NRT|Smart-T Mental Health provides smoking cessation and mental health content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive NRT.
62817073|NCT04887558|EXPERIMENTAL|Smart-T Mental Health+ and NRT|Smart-T Mental Health provides smoking cessation and mental health content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. During the pre-quit and post-quit period, the app will also send messages that encourage the use of the nicotine patch and lozenges according to recommended practices. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive free NRT.
62817074|NCT06550934||Isolated posterior surgical fracture stabilization|
62817075|NCT06550934||Combined anterior-posterior surgical fracture stabilization|
62817076|NCT06554574|EXPERIMENTAL|LTG-305|
62241052|NCT01822522|EXPERIMENTAL|Stratum A Treatment (cabozantinib s-malate): 60 mg/day|"Patients receive cabozantinib s-malate 60 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~This arm includes patients who are on ritonavir-boosted or cobicistat-boosted antiretroviral regimens"
62431443|NCT06370195|PLACEBO_COMPARATOR|Comparator: Comprehensive rehabilitation+placebo|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 10 days.
62431444|NCT01595490|EXPERIMENTAL|Mind-Body Skills Groups|
62431445|NCT01595490|NO_INTERVENTION|Control Group|
62431446|NCT01268137|ACTIVE_COMPARATOR|stimulation on|At first stage, electrodes will be implanted in all patients, who will be continuously stimulated for several months. After this stage, the random-crossed part of the study will start, and patients who responded to DBS will be randomly distributed in two groups: on stimulation or off stimulation group, for the next three months. Subsequently, patients will be allocated in the other group (on or off, crossed part) for three months
62431447|NCT01268137|PLACEBO_COMPARATOR|Stimulation off|At first stage, electrodes will be implanted in all patients, who will be continuously stimulated for several months. After this stage, the random-crossed part of the study will start, and patients who responded to DBS will be randomly distributed in two groups: on stimulation or off stimulation group, for the next three months. Subsequently, patients will be allocated in the other group (on or off, crossed part) for three months
62431448|NCT02666365|ACTIVE_COMPARATOR|Bolus infusion of Cefazolin|Subjects undergoing a ventral hernia repair in this arm of the study will receive the surgical prophylactic, cefazolin, in a bolus infusion
62431449|NCT02666365|ACTIVE_COMPARATOR|Continuous Infusion of Cefazolin|Subjects undergoing a ventral hernia repair in this arm of the study will receive the surgical prophylactic, cefazolin, in a continuous infusion
62431450|NCT02149550|ACTIVE_COMPARATOR|NF135 n=5|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes
62431451|NCT02149550|EXPERIMENTAL|NF135 n=2|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes
62431452|NCT02149550|EXPERIMENTAL|NF135 n=1|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito
62431453|NCT02149550|ACTIVE_COMPARATOR|NF166 n=5|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes
62431454|NCT02149550|EXPERIMENTAL|NF166 n=2|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes
62431455|NCT02149550|EXPERIMENTAL|NF166 n=1|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito
62817077|NCT06554574|PLACEBO_COMPARATOR|Placebo|
62817078|NCT03497676|EXPERIMENTAL|Cohort 1C: CAB|"Step 1: CAB administered orally as one 30 mg tablet once daily, beginning at the Entry visit, for 4-6 weeks.~Step 2 (Q4W dosing): CAB LA administered as three single intramuscular (IM) injections four weeks apart (600 mg injection at Week 4b, 400 mg injection at Week 8, and 400 mg injection at Week 12).~Step 2 (Q8W dosing): CAB LA administered as two single IM injections four weeks apart (600 mg injection at Week 4b and 600 mg injection at Week 8)."
62817079|NCT03497676|EXPERIMENTAL|Cohort 1R: RPV|"Step 1: RPV administered orally as one 25 mg tablet once daily, beginning at the Entry visit, for 4-6 weeks.~Step 2 (Q4W dosing): RPV LA administered as three single IM injections four weeks apart (900 mg injection at Week 4b, 600 mg injection at Week 8, 600 mg injection at and Week 12).~Step 2 (Q8W dosing): RPV LA administered as two single IM injections four weeks apart (900 mg injection at Week 4b and 900 mg injection at Week 8)."
62038454|NCT01877538||[11C]donepezil PET|\[11C\]donepezil is a radiopharmaceutical. It is evaluated whether the binding of \[11C\]donepezil in various peripheral tissues is in accordance with known distribution of the parasympathetic nervous system.
62038455|NCT02738268|SHAM_COMPARATOR|Control group|Control group: receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
62241053|NCT01822522|EXPERIMENTAL|Stratum B Treatment (cabozantinib s-malate): 60 mg/day|"Patients receive cabozantinib s-malate 60 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~This arm includes patients who are on efavirenz or etravirine-based antiretroviral regimens"
62241054|NCT01822522|EXPERIMENTAL|Stratum B Treatment (cabozantinib s-malate): 100 mg/day|"Patients receive cabozantinib s-malate 100 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~This arm includes patients who are on efavirenz or etravirine-based antiretroviral regimens"
62241055|NCT01822522|EXPERIMENTAL|Stratum C Treatment (cabozantinib s-malate): 60 mg/day|"Patients receive cabozantinib s-malate 60 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~This arm includes patients who are on antiretroviral regimens that do not include the agents specified on stratum A or B, or who are not on antiretroviral therapy"
62241056|NCT04803799|EXPERIMENTAL|Experimental Arm|Training programme using Exergame as a support over a 12 week period
62241057|NCT06494527|EXPERIMENTAL|RG002C0106|Randomly enrolled subjects receiving the investigational drug will receive subcutaneous injection for administration
62598526|NCT04501783|ACTIVE_COMPARATOR|Standard of Care Arm|Standard of Care including etiotropic therapy according to MoH of Russian Federation Recomendations for COVID-19 (umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine, or mefloquine in recomended regimen) up to10 days
62598527|NCT01037127|EXPERIMENTAL|Cohort A|Subjects who have had previous treatment with a BRAF inhibitor.
62241058|NCT06494527|PLACEBO_COMPARATOR|placebo|Randomly enrolled subjects receiving placebo will receive subcutaneous injection for administration
62241059|NCT00906919|ACTIVE_COMPARATOR|Regular diabetes patient education|Regular professionally-led diabetes patient education
62241060|NCT00906919|EXPERIMENTAL|Augmented Diabetes Patient Education|Regular professionally-led diabetes patient education augmented by participation in the Stanford Chronic Disease Self-Management Program
62241061|NCT01693081|ACTIVE_COMPARATOR|VR040/Aspirair® inhaler|VR040 was administered as an inhaled dry powder, in a dosage of 1.5, 2.3, 3.0 and 4.0mg, single dose given at each dose level.
62241062|NCT01693081|PLACEBO_COMPARATOR|Placebo|Placebo was administered as an inhaled dry powder, matching to active comparator at dosages of 1.5, 2.3, 3.0 and 4.0mg, single dose given at each dose level.
62241063|NCT02488187|OTHER|ABUS vs MRI (ultrasound when indicated)|To compare the overall sensitivity and specificity of ABUS versus MRI (and hand-held breast ultrasound when clinically indicated) for the ipsilateral and contralateral breast in newly diagnosed breast cancer patients.
62241064|NCT02488187|OTHER|ABUS vs mammography (ultrasound when indicated)|To compare the sensitivity and specificity of ABUS versus mammography (and hand-held breast ultrasound when clinically indicated) for the ipsilateral and contralateral breast in newly diagnosed breast cancer patients when MRI is not performed.
62241065|NCT06402981||liver damage group|Lung cancer patients using PD-1/PD-L1 inhibitors with hepatic injury as determined by the hepatic index criteria set by the Common Terminology Criteria for Adverse Events (CTCAE 5.0)
62241066|NCT06402981||No liver damage group|Lung cancer patients with PD-1/PD-L1 inhibitors who are judged not to have liver injury according to the liver index criteria set by the Common Terminology Criteria for Adverse Events (CTCAE 5.0)
62241067|NCT04921007|ACTIVE_COMPARATOR|Group (A) Sacral ESP block|Ultrasound guided sacral erector spinae plane (ESP) block will be performed in the lateral position under sterile conditions, and bupivacaine will be administered.
62241068|NCT04921007|ACTIVE_COMPARATOR|Group (B) Caudal block|Ultrasound guided caudal block will be performed in the lateral position under sterile conditions, and bupivacaine will be administered.
62241069|NCT05364268||Trial Population|The trial population will be enrolled from adults presenting for elective, outpatient COVID-19 testing at a single center, potentially with multiple testing locations (subject to local needs at the time of the trial). The investigational device will be provided to Participants via a cell phone preloaded with Common off-the-shelf original equipment manufacturer (COTS OEM) software and the investigational Dx SaMD. The investigational device will be evaluated during a single encounter in which an FCV-SDS will be collected. No follow-up visits or participant contacts will be involved in this trial.
62241070|NCT04403750|EXPERIMENTAL|Combined laser-surgical technology|"Combined laser-surgical technology includes 3 steps:~1. Nd-YAG laser excision of the vitreoretinal traction zone~2. Pneumatic retinopexy (10% C3F8)~3. Barrier laser photocoagulation around retinal break after retinal attachment."
62431456|NCT06056700|EXPERIMENTAL|Intervention Group|Women were informed of the study, and their participation was requested. Those who offered their willingness to participate signed the informed consent and were randomly assigned to the intervention group (IG) or the control group (CG). Randomization was performed using Microsoft Excel spreadsheet software. All study follow-up information was collected through this app. The information offered to all the mothers through the mobile application contained a welcome message, contact data, sociodemographic and clinical variables, and access to the TMM-24 questionnaire. However, the GI through the app had access to complementary information content regarding the CG. The mothers of the IG had additional training material related to the first two prenatal face-to-face training sessions and new information during the postnatal period throughout consecutive weeks 1 to 8.
62598528|NCT01037127|EXPERIMENTAL|Cohort B|Subjects who have had previous chemotherapy or immunotherapy without a BRAF inhibitor.
62038456|NCT02738268|EXPERIMENTAL|Treatment Group|Treatment Group: receives low-level laser therapy (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
62241071|NCT06226831||MS with LUTS|Patients with multiple sclerosis with LUTS symptoms.
62241072|NCT06226831||MS without LUTS|Patients with multiple sclerosis without LUTS symptoms.
62241073|NCT00809211|EXPERIMENTAL|Nilotinib|
62241074|NCT06046625||Head-neck cutaneous Squamous cell carcinomas|Patients with high risk cutaneous squamous cell carcinoma in the head neck region, receiving regular multidisciplinary care.
62241075|NCT05385133|EXPERIMENTAL|Computer guided condylar position|post-osteotomy condylar position was performed using patient specific surgical guides and pre-bent plates
62598529|NCT06620848|EXPERIMENTAL|HRS-4642 monotherapy arm|Patients will receive HRS-4642 monotherapy at a fixed dose.
62598530|NCT06620848|EXPERIMENTAL|combination therapy arm|Patients will receive HRS-4642 and adebrelimab combination therapy.
62598531|NCT03249246||Infection only|The patients have only infection
62598532|NCT03249246||Infection + SIRS|Patients have infection plus systemic inflammatory response syndrome (SIRS)
62598533|NCT03249246||Severe sepsis|Septic patients with newly developed organ dysfunctions
62598534|NCT03249246||Septic shock|Sepsis plus sepsis related hypotension
62241076|NCT05385133|EXPERIMENTAL|Manual condylar position|post-osteotomy condylar position was performed using the conventional free hand approach
62598535|NCT05735262|EXPERIMENTAL|DLPFC group|Active iTBS will be delivered to the left DLPFC.
62431457|NCT06056700|NO_INTERVENTION|Control Group|Women were informed of the study, and their participation was requested. Those who offered their willingness to participate signed the informed consent and were randomly assigned to the intervention group (IG) or the control group (CG). Randomization was performed using Microsoft Excel spreadsheet software. All study follow-up information was collected through this app. The information offered to all the mothers through the mobile application contained a welcome message, contact data, sociodemographic and clinical variables, and access to the TMM-24 questionnaire. However, the GI through the app had access to complementary information content regarding the CG. The mothers of the IG had additional training material related to the first two prenatal face-to-face training sessions and new information during the postnatal period throughout consecutive weeks 1 to 8.
62598536|NCT05735262|EXPERIMENTAL|DMPFC group|Active iTBS will be delivered to the left DMPFC.
62817080|NCT03497676|EXPERIMENTAL|Cohort 2A: Oral CAB + Oral RPV and CAB LA + RPV LA|"Step 3: CAB administered orally as one 30 mg tablet once daily AND RPV administered orally as one 25 mg tablet once daily, beginning at the Entry visit for 4-6 weeks.~Step 4: First and second injections: CAB LA administered as a 600 mg IM injection AND RPV LA administered as a 900 mg IM injection at Week 4b and at Week 8. Subsequent injections: starting at Week 16, CAB LA administered as a 600 mg IM injection AND RPV LA administered as a 900 mg IM injection every eight weeks through Week 96 or final safety extension visit."
62817081|NCT03497676|EXPERIMENTAL|Cohort 2B: CAB LA + RPV LA|Step 5: First and second injections: CAB LA administered as a 600 mg IM injection AND RPV LA administered as a 900 mg IM injection at Entry and at Week 4. Subsequent injections: starting at Week 12, CAB LA administered as a 600 mg IM injection AND RPV LA administered as 900 mg IM injection every eight weeks through Week 92 or final safety extension visit.
62817082|NCT03960827|NO_INTERVENTION|Sedentary control|The control group does not engage in any acute exercise testing protocol, but biospecimens are collected prior to and following a period of rest.
62817083|NCT03960827|ACTIVE_COMPARATOR|Sedentary EE|Participants randomized to EE first engage in a single acute exercise test of Endurance Exerciser (on a cycle ergometer) consistent with their random assignment.
62817084|NCT03960827|ACTIVE_COMPARATOR|Sedentary RE|Participants randomized to RE first engage in a single acute exercise test of Resistance Exerciser, consistent with their random assignment.
62817085|NCT03960827|NO_INTERVENTION|Highly Active EE|A comparison group of highly active EE participants are recruited and engage only in the initial round of acute exercise testing. Highly Active Endurance Exerciser (HAEE) participants are tested on a cycle ergometer.
62817086|NCT03960827|NO_INTERVENTION|Highly Active RE|A comparison group of highly active RE participants are recruited and engage only in the initial round of acute exercise testing. Highly Active Resistance Exerciser (HARE) participants are tested via a bout of resistance exercise.
62038457|NCT00430768|EXPERIMENTAL|Group 1 Low Dose|"rAAV1-CB-hAAT 6.9 x10e12 vector genomes (vg) administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
62598537|NCT05735262|SHAM_COMPARATOR|Sham to DLPFC group|Sham iTBS will be delivered to left DLPFC.
62598538|NCT05735262|SHAM_COMPARATOR|Sham to DMPFC group|Sham iTBS will be delivered to left DMPFC.
62598539|NCT01852552||Transcatheter aortic valve implantation|All consecutive patients undergoing TAVI at participating centres during study period
62598540|NCT01852552||Aortic Valve Replacement|All consecutive patients aged ≥ 80 years or with Logistic Euroscore≥ 15% undergoing AVR for AS at participating centers during the period of enrollment
62598541|NCT06603961|ACTIVE_COMPARATOR|CPG-EB group|Customized-pressure guided elastic bandage group is the interventional group in order to compare with standard of care in post operative CABG surgery patients.
62817087|NCT06705387|ACTIVE_COMPARATOR|dupilumab (also known as Dupixent)|
62817088|NCT06705387|ACTIVE_COMPARATOR|fluticasone (also known as Flovent)|
62817089|NCT03825120||Women from original OVA cohort|
62817090|NCT04965623|EXPERIMENTAL|Edwards Transcatheter Atrial Shunt System|Edwards Transcatheter Atrial Shunt System
62817091|NCT05616624|EXPERIMENTAL|Phase I: ADI-PEG + gemcitabine + docetaxel|"* ADI-PEG 20 is given as an intramuscular injection on a weekly basis (Day 1, 8 and 15) at a dose of 36 mg/m\^2. ADI-PEG 20 dosing will start one week prior to the initiation of gemcitabine + docetaxel on Day -7 prior to the initiation of Cycle 1.~* Gemcitabine is given intravenously at the assigned dose level on Day 2 of each cycle.~* Docetaxel is given intravenously at the assigned dose level on Day 1 of each cycle.~* A cycle is defined as 21 days.~* After Cycle 8, patients may continue on ADI-PEG 20 alone (without gemcitabine and docetaxel) per physician discretion or patient request.~* Treatment may continue for up to 34 cycles."
62038458|NCT00430768|EXPERIMENTAL|Group 2 Middle Dose|"rAAV1-CB-hAAT 2.2 x 10e13 vg administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
62038459|NCT00430768|EXPERIMENTAL|Group 3 High Dose|"rAAV1-CB-hAAT 6.0 x10e13 vg administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
62241077|NCT01195545|EXPERIMENTAL|Veritas Mesh in Hernia Repair|Subjects undergoing laparoscopic paraesophageal hiatal hernia repair using a bovine pericardium mesh (BP) (Veritas® Collagen Matrix, Synovis ®, St. Paul MN) as a reinforcing material during repair.
62598542|NCT06603961|NO_INTERVENTION|Standard group|Standard group is the standard of care in post operative CABG surgery patients. This group used elastic bandage for 24 hours or overnight after surgery.
62598543|NCT00904202|PLACEBO_COMPARATOR|placebo capsules + placebo patch|Placebo to match lidocaine patch; up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing
62598544|NCT00904202|EXPERIMENTAL|placebo capsules + Lidoderm patch (Lidocaine Group)|Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing
62241078|NCT02646748|EXPERIMENTAL|pembrolizumab + itacitinib|"Part 1a Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.~Part 1b Group A-1 and Group A-2 will evaluate the MTD or PAD of itacitinib in combination with pembrolizumab in subjects with select solid tumors."
62431458|NCT03157310|EXPERIMENTAL|Gefitinib|Gefitinib is an selective small molecule epidermal growth factor receptors (EGFRs) tyrosine kinase inhibitors (EGFR-TKI) for non-small cell lung cancer.
62431459|NCT05285332|EXPERIMENTAL|1 Primary and metastatic lesions PCR|surgery 1 Mastectomy OR Breast conserving surgery
62431460|NCT05285332|EXPERIMENTAL|2 Primary lesions NPCR and metastatic lesions PCR|surgery 1 Mastectomy OR Breast conserving surgery
62431461|NCT05285332|EXPERIMENTAL|3 Primary lesions PCR and metastatic lesions NPCR|surgery 2 Resection of metastasis
62431462|NCT05285332|EXPERIMENTAL|4 Primary lesions NPCR and metastatic lesions NPCR|Systemic therapy Endocrine therapy or chemotherapy or targeted therapy
62431463|NCT05203588|EXPERIMENTAL|Experimental group|Patients in this group are received denosumab (60 mg) subcutaneously at one week and 26 weeks after the lumbar fusion surgery, combined with receiving daily calcium (≥1·0 g) and vitamin D (≥400 IU).
62431464|NCT05203588|SHAM_COMPARATOR|Control group|Patients in this group are only received daily calcium (≥1·0 g) and vitamin D (≥400 IU) after the lumbar fusion surgery.
62431465|NCT02113969|EXPERIMENTAL|Vaginal Pessary|Pessary users for at least 12 months
62598545|NCT00904202|ACTIVE_COMPARATOR|Gabapentin capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules for oral dosing at a dose of 1800 mg/day AND Placebo patch to match lidocaine patch; up to four patches applied topically daily (q24h) to the area of maximal peripheral pain
62598546|NCT00904202|OTHER|Gabapentin capsules 1800 mg/day + Lidoderm patch|Gabapentin 1800 mg/day AND Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain
62598547|NCT02434172||Screening|There are no arms to the study. All participants will undergo screening. Preemptive treatment will only be provided to those who are CrAg positive.
62431466|NCT05935319|EXPERIMENTAL|experimental group|Vivifrail
62598548|NCT06623942||Group 1 (Control)|This group consists of uncomplicated pregnancies (who do not have pre-eclampsia or severe pre-eclampsia). These participants will be matched to the case group based on relevant characteristics such as age, gestational age, and other demographic factors.
62598549|NCT06623942||Group 2 (Case - Pre-eclampsia)|This group consists of pregnant women diagnosed with pre-eclampsia and severe preeclampsia.
62598550|NCT00504491|EXPERIMENTAL|1|"Four Rituximab - CHOP courses will be given The courses will be given every 21 days Drug Dose Day Rituximab (Mabthera) 500mg/m2 1(\*) (\*\*) Cyclophosphamide 750mg/m2 1 Adriamycin 50mg/m2 1 Vincristine 1,4 mg/m2 1 Prednisone 60mg/m2 1 to 5~(\*\*) 1st course, 375 mg/m2 (\*) If lymphocyte count is \> 30 X 10 9/l, dose will be split up in two, which will be given in days 0 and 1"
62038460|NCT05903417|ACTIVE_COMPARATOR|Pleural Irrigation Arm|subjects were administered 250 ml of 0.9% sodium chloride via chest tube a three way tap from a drip stand which were allowed drainage freely over 1 hour. Pleural irrigation will be performed minimum of 3 installations and maximum of 9 installation (3 times per day).
62241079|NCT02646748|EXPERIMENTAL|pembrolizumab + INCB050465|"Part 1a Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.~Part 1b Group B-1 and Group B-2 will evaluate the MTD or PAD of INCB050465 in combination with pembrolizumab in subjects with select solid tumors.~Part 2 will evaluate the combination of INCB050465 in combination with pembrolizumab in subjects with small cell lung cancer, non-small lung cancer and urothelial cancer."
62241080|NCT03088722|EXPERIMENTAL|Community health extension workers|Community health extension workers providing contraceptive implants
62431467|NCT05935319|NO_INTERVENTION|control group|Traditional Sports Health Leaflet
62431468|NCT06159439|EXPERIMENTAL|Participants with CKD having MRI and CEUS|10 participants with CKD will have an MRI scan and a contrast enhanced ultrasound scan. The two scans will be done within 7 days of each other.
62431469|NCT06045975|EXPERIMENTAL|Durvalumab/Tremelimumab|Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting
62431470|NCT02541435||conventional radiotherapy|450 breast cancer patients treated with conventional radiotherapy with or without anthracyclines and/or trastuzumab during 2007-2012
62431471|NCT02541435||breath controlled radiotherapy|350 breast cancer patients treated with laser assisted breath controlled radiotherapy with or without anthracyclines and/or trastuzumab during 2015-2017
62431472|NCT02541435||controls|per participating patient 2 age-matched female controls from the HUNT-3 population (total 800)
62431473|NCT04461652|EXPERIMENTAL|New method|One thoracic tube (28fr drainage tube) was inserted through intercostal incision, and one microtubule (7fr × 20cm) was punctured through the middle line of clavicle
62598551|NCT05432947|EXPERIMENTAL|68Ga-P16-093 and 18F-FDG PET/ CT scan|Within 1 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-P16-093 and 18F-FDG, respectively.
62241081|NCT03088722|NO_INTERVENTION|Nurses and midwives|Nurses and midwives providing contraceptive implants (existing care)
62241082|NCT02665065|EXPERIMENTAL|Iomab-B|Iomab-B in conjunction with a Reduced Intensity Conditioning (RIC) regimen containing Fludarabine and low-dose Total Body Irradiation (TBI) prior to allogeneic HCT
62241083|NCT02665065|ACTIVE_COMPARATOR|Conventional Care|Defined as Investigator's choice of salvage chemotherapy with any combination of the following agents: Azacitidine (not allowed as a single agent), Carboplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Daunorubicin, Decitabine (not allowed as a single agent with the exception of patients with documented TP53 mutations who have not previously received 10-day regimens of single agent decitabine), Doxorubicin, Enasidenib, Etoposide, Fludarabine, Gemtuzumab ozogamicin, Idarubicin, Ivosidenib (for subjects with IDH1 mutation), L-Asparaginase, Midostaurin (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Mitoxantrone, Sorafenib (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Thioguanine, Topotecan, Venetoclax (in combination with a hypomethylating agent). Chemotherapy agents not listed above may be administered after providing clinical justification and receiving medical monitor approval prior to initiation of treatment.
62598552|NCT04023552|EXPERIMENTAL|TQJ230|TQJ230 80 mg injected monthly administered subcutaneously
62241084|NCT04408261|EXPERIMENTAL|Buqitongluo Granule|Subjects will receive orally administered Buqitongluo Granules, combined with guidelines-based standard care.
62431474|NCT04461652|PLACEBO_COMPARATOR|Traditional method|Two conventional chest tubes (28fr or 24fr) were placed through intercostal incision
62598553|NCT04023552|PLACEBO_COMPARATOR|Placebo|Monthly subcutaneous injections.
62241085|NCT04408261|PLACEBO_COMPARATOR|Placebo|Subjects will receive orally administered Buqitongluo Granule placeboes, combined with guidelines-based standard care.
62241086|NCT03366493|EXPERIMENTAL|FRD, Cyctology, HPV testing|Subjects will be asked to have the FRD, Cytology, and HPV test performed on them by the study doctor or staff.
62598554|NCT02691936|EXPERIMENTAL|CO2 fractionated vaginal laser|Postmenopausal women will undergo treatment intravaginally with the fractional microablative CO2 laser system MonaLisa Touch vaginal laser protocol x 3 time points at baseline, 6 weeks and 3 months.
62241087|NCT03366493|EXPERIMENTAL|Colposcopy Examination (and ECC if necessary)|Subjects with abnormal cytology (≥ ASCUS/AGC), positive FRD test in either the cervix or cervical canal, and/or positive HPV test will be referred to colposcopy. Subjects with a positive FRD test for the cervical canal, unsatisfied colposcopy (type II-III), and/or detection of AGC during cytology will also have to complete an ECC procedure. In addition, 10% of the subjects who tested negative for all three tests and are ≥ 25 years old will be randomly selected to complete a colposcopy as well.
62431475|NCT01218906||Cohort Population (Case )|Participants will be examined for febrile illness to diagnose dengue and to identify common causes of fever.
62598555|NCT02691936|ACTIVE_COMPARATOR|Estrogens, Conjugated (USP)|The women in the vaginal estrogen group will be prescribed and asked to administer the conjugated estrogen cream 0.5 g of cream equivalent to 0.625 mg of conjugated estrogen.
62598556|NCT02447497|EXPERIMENTAL|3M CHG/IPA - Abdominal Region|Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.
62598557|NCT02447497|PLACEBO_COMPARATOR|Normal Saline - Abdominal Region|Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.
62598558|NCT02447497|EXPERIMENTAL|3M CHG/IPA - Inguinal Region|Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.
62598559|NCT02447497|PLACEBO_COMPARATOR|Normal Saline - Inguinal Region|Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.
62598560|NCT06228924|EXPERIMENTAL|Cohort 1|Dose for Cohort 1 will be 3E13 vg/kg
62598561|NCT06228924|EXPERIMENTAL|Cohort 2|Dose for Cohort 2 will be 6E13 vg/kg
62735648|NCT04678362|EXPERIMENTAL|Talazoparib+avelumab|"* Talazoparib will be administered at the daily dose of 1 mg given orally in a 28-day cycle, except for patients with mild renal impairment (Creatinine clearance 30-59 mL/min) who will receive 0.75 mg per day.~* Avelumab will be administered by intravenous (I.V.) route over 60 minutes at the dose of 800 mg on D1 and D15, in a 28-day cycle."
62431476|NCT05944770|ACTIVE_COMPARATOR|Intervention arm|Subjects in the treatment arm will use a DIY portable air cleaner made by attaching a highly effective furnace filter (MERV 13) and carbon absorbent to a box fan.
62431477|NCT05944770|SHAM_COMPARATOR|Control arm|Subjects in the control arm will use a DIY portable air cleaner with a sham filter. All subjects will receive education on air quality, wildfire smoke, and health.
62431478|NCT05251415||patients suffering from autoimmune disease|Biological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity.
62431479|NCT05756088||Low MFR (less than or equal to 1.5)|Subjects who are found to have a low MFR of less than or equal to 1.5.
62431480|NCT05756088||Normal MFR (greater than 1.5)|Subjects who are found to have normal MFR of greater than 1.5.
62735649|NCT05237505|EXPERIMENTAL|Oxygen|OVS subjects will receive treatment with oxygen during night time for 6 months
62735650|NCT05237505|EXPERIMENTAL|Bi-level positive pressure non invasive ventilation|OVS subjects will receive treatment with bi-level PAP therapy during night time for 6 months
62735651|NCT05130385||Diabetic Retinopathy|Patients with various degree of diabetic retinopathy
62735652|NCT05130385||Artery and vein occlusion|Patients with history of artery or vein occlusion (central or branch artery)
62735653|NCT05130385||Glaucoma|Patients with history of glaucoma (open-angle glaucoma, chronic angle closure glaucoma)
62735654|NCT05130385||Optic nerve neuropathy|Patients with history of various optic nerve neuropathies
62735655|NCT05130385||Hereditary retinal diseases|Patients with history of various retinal dystrophies
62735656|NCT05130385||Retinal detachment|Patients history of retinal detachment
62735657|NCT05130385||Age related macular degeneration|Patients with history of age related macular degeneration
62735658|NCT05130385||Retinal changes from arterial hypertension|Patients with history of arterial hypertension
62241088|NCT03366493|EXPERIMENTAL|Biospy|According to the colposcopy assessment, if the results show satisfied (type I) then a biopsy will be taken. Finally, a histopathological examination will be done and used as the gold standard. Subjects with a histopathological examination result of \< CIN2 will be asked to come back for a follow up visit within 6 months or 1 year, according to the investigator's discretion.
62241089|NCT02431650|EXPERIMENTAL|OZ439|"Each participant in the cohort will be inoculated on Day 0 with \~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants is ≥ 5,000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood stage parasitemia. When gametocytemia is at the peak (approximately 15 days after administration of piperaquine), participants will be randomised to receive either OZ439 or a control group (primaquine treatment).~In the first cohort 500 mg OZ439 will be administered as a single dose. Doses used in subsequent cohort(s) will be determined following a review of observed safety and pharmacodynamic drug effects."
62241090|NCT02431650|ACTIVE_COMPARATOR|Primaquine|"Each participant in the cohort will be inoculated on Day 0 with \~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants is ≥ 5,000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood stage parasitemia. When gametocytemia is at the peak (approximately 15 days after administration of piperaquine), participants will be randomised to receive either OZ439 or a control group (primaquine treatment).~Primaquine is a positive control for OZ439, to be administered 15 mg as a single dose."
62241091|NCT03879850||Propofol group|This is a prospective, observational study in surgical patients undergoing elective surgery under general anesthesia stratified for the anesthetic agent used intraoperatively - i.v. Propofol - focusing on pre-, intra- and postoperative EEG spectral parameters in elderly patients.
62241092|NCT03879850||Volatile group|This is a prospective, observational study in surgical patients undergoing elective surgery under general anesthesia stratified for the anesthetic agent used intraoperatively - volatile anesthetic agent as Sevoflurane or Desflurane - focusing on pre-, intra- and postoperative EEG spectral parameters in elderly patients.
62241093|NCT01729156|OTHER|Healthy controls|Healthy controls receiving 1000 mg metformin twice daily for 3 months
62241094|NCT01729156|PLACEBO_COMPARATOR|Placebo|Placebo
62241095|NCT01729156|ACTIVE_COMPARATOR|Metformin|"Metformin Sandoz, 1000 mg twice daily for 3 months"
62598562|NCT06648005|EXPERIMENTAL|SMTB group|"subjects in SMTB group and Brace group were all prescribed a brace with reference to the 2016 SOSORT guidelines and received preliminary assessment for brace design and fabrication at their first visit . Subjects were requested to wear orthosis 23 hrs/d and 1 hr for personal hygiene and exercise activities . The subjects were treated for 12 months . In addition, interview for compliance was launched when the subjects came to the scoliosis clinic for follow-up visits.~Besides bracing, the SMTB group was treated with spinal manipulative therapy . If discomfort occurs, we will stop the treatment immediately. Spinal manipulation is performed twice a week. Two doctors with 10 years of clinical experience will perform all examinations and manipulations. Intensive training was given to the physiotherapists in spinal manipulation. The doctors took the medical history of all participants and performed a clinical examination."
62241096|NCT04063254|EXPERIMENTAL|High-Dose Stereotactic Radiotherapy|
62241097|NCT04063254|ACTIVE_COMPARATOR|Standard-Dose Stereotactic Radiotherapy|
62241098|NCT05092633|EXPERIMENTAL|Control|Will have miniscrew only without laser application
62241099|NCT05092633|EXPERIMENTAL|Experimental|Will have miniscrew and laser application
62241100|NCT00400309|EXPERIMENTAL|REPEVAX® after REVAXIS®|REVAXIS® at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28).
62241101|NCT00400309|ACTIVE_COMPARATOR|REPEVAX® after Placebo|Placebo at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28).
62241102|NCT03559920|EXPERIMENTAL|Sevoflurane group|Patients who are sedated using sevoflurane
62431481|NCT04874766|EXPERIMENTAL|Surgical face mask|Simulated hockey period with 2x20s Wingate tests; progressive-intensity on-ice sprint test while wearing a surgical mask
62431482|NCT04874766|SHAM_COMPARATOR|Sham face mask|Simulated hockey period with 2x20s Wingate tests; progressive-intensity on-ice sprint test while wearing a sham mask
62431483|NCT04153201|EXPERIMENTAL|Hydroxychloroquine|Patients with primary antiphospholipid syndrome started on hydroxychloroquine while continuing standard care (vitamin K antagonists or direct oral anticoagulants, and/or antiplatelet agents, depending on primary APS subgroup)
62431484|NCT04153201|NO_INTERVENTION|Standard care|Patients with primary antiphospholipid syndrome continuing standard care only (vitamin K antagonists or direct oral anticoagulants, and/or antiplatelet agents
62431485|NCT03963999|EXPERIMENTAL|Patients Undergoing HCT|All patients enrolled will undergo grayscale US, Doppler US, US SWE and CEUS at specific time points as outlined in the protocol based on disease course.
62241103|NCT03559920|ACTIVE_COMPARATOR|Intravenous sedation group|Patients who are sedated using propofol
62241104|NCT05912387|EXPERIMENTAL|Rosuvastatin therapy|Participants will receive rosuvastatin for 12 weeks followed by a 2 week washout period prior to the final follow-up visit. All patients will receive the study drug, and will serve as their own control. No participants will receive placebo. Rosuvastatin is FDA approved for treatment of high cholesterol, but its use in this trial is off label.
62431486|NCT01469988|EXPERIMENTAL|Testosterone|
62431487|NCT01469988|PLACEBO_COMPARATOR|Placebo|
62735659|NCT05130385||Uveitis|Patients with history of uveitis intermedia and/or posterior and/or pan-uveitis
62735660|NCT05130385||Healthy|Healthy age matched control subjects
62241105|NCT02390817|ACTIVE_COMPARATOR|Sugammadex|At the wakeup status Sugammadex 2 mg/kg single dose will perform.
62241106|NCT02390817|PLACEBO_COMPARATOR|Neostigmine|At the wakeup status Neostigmine 0,04 mg/kg single dose will perform.
62598563|NCT06648005|ACTIVE_COMPARATOR|Brace group|Upon enrollment, subjects in SMTB group and Brace group were all prescribed a brace with reference to the 2016 SOSORT guidelines and received preliminary assessment for brace design and fabrication at their first visit. Subjects were requested to wear orthosis 23 hrs/d and 1 hr for personal hygiene and exercise activities. The subjects were treated for 12 months. In addition, interview for compliance was launched when the subjects came to the scoliosis clinic for follow-up visits.
62598564|NCT06503406|EXPERIMENTAL|SupraSDRM®|Once randomization is completed and the site is adequately debrided the assigned treatment dressing will be applied according to their respective instructions for use. Supplemental supportive dressings including negative pressure treatment may be used in conjunction with the study dressings.
62598565|NCT06503406|ACTIVE_COMPARATOR|SOC Skin Substitute|Once randomization is completed and the site is adequately debrided the assigned treatment dressing will be applied according to their respective instructions for use. Supplemental supportive dressings including negative pressure treatment may be used in conjunction with the study dressings.
62241107|NCT01854645|EXPERIMENTAL|GFF MDI|Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) (PT003)
62598566|NCT06599099|EXPERIMENTAL|Medtronic Percept RC System Implantation for TRBD|All subjects will receive surgical implantation of Percept RC DBS system
62598567|NCT06599099|EXPERIMENTAL|One Month Blinded Discontinuation Period|The investigators will use blinded discontinuation at 12 months rather than sham control to establish evidence that response is dependent on ongoing DBS.
62598568|NCT01869621|EXPERIMENTAL|Metformin|6 days treatment with metformin
62598569|NCT05669898|ACTIVE_COMPARATOR|Single-injection ACB combined with IV-PCA morphine|Allocation of which participant is to receive single-injection adductor canal block combined with intravenous morphine patient-controlled analgesia (IV-morphine PCA) is determined by randomization, using a computer-generated random sequence and opaque sealed envelopes. After completion of the TKA surgery and surgical suturing, adductor canal block will be performed by an anesthesiologist. Under ultrasound guidance, the femoral artery and the saphenous nerve are identified in the middle one-third of the thigh, deep to the sartorious muscle in the adductor canal. The sartorious and adductor muscles form the roof and the floor of the canal, respectively. Following skin infiltration, 20 mL of 0.25% bupivacaine with 1:400000 epinephrine is injected through a 3-inch, 23-gauge, short bevel block needle. Finally, the IV-morphine PCA will be connected to the intravenous catheter of the patient for postoperative pain management.
62241108|NCT01854645|EXPERIMENTAL|GP MDI|Glycopyrronium (GP) MDI (PT001)
62241109|NCT01854645|EXPERIMENTAL|FF MDI|Formoterol Fumarate (FF) MDI (PT005)
62241110|NCT01854645|ACTIVE_COMPARATOR|Open-label tiotropium bromide inhalation powder|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
62431488|NCT05270694|EXPERIMENTAL|COVID-19 Testing|The cohort participants will attend an in-person training on how to take an at-home COVID-19 test and also be provided with five at-home test kits at the training and every other month for a total of 35 kits over the course of a year.
62431489|NCT06321666|OTHER|WB-MRI and CT Scan|CT scan (neck/thorax/abdomen/pelvis) and WB-MRI
62431490|NCT02626065|EXPERIMENTAL|Nivolumab, patients with BRAF mutation|"Nivolumab (dose equal to 3mg/kg), 10 mg/ml solution for infusion. injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.~Blood sampling at different time"
62431491|NCT02626065|EXPERIMENTAL|Nivolumab, patients with BRAF wild type|"Nivolumab (dose equal to 3mg/kg), 10 mg/ml solution for infusion. injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.~Blood sampling at different time"
62431492|NCT02316678||anti-TNF - no intervention|Patients who are new users of anti-TNF therapy
62431493|NCT02316678||Corticosteroids - no intervention|Patients initiating corticosteroids
62735661|NCT04242628|EXPERIMENTAL|Facebook course|T1 study members attended a three week course (two classes per week) on smartphones and SNS use. Specifically, the course covers the following topics: smartphone use; Facebook use; WhatsApp use, privacy rules and fraud risk prevention using Facebook. Throughout the duration of the intervention, a tutor was available every Tuesday and Thursday to assist T1 participants in using SNSs.
62241111|NCT01854645|PLACEBO_COMPARATOR|Placebo|Placebo MDI
62241112|NCT01772004|EXPERIMENTAL|Dose Escalation Cohort: Avelumab 1.0 mg/kg|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 1.0 milligrams per kilogram (mg/kg) once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or investigational medicinal product (IMP) occurs.
62241113|NCT01772004|EXPERIMENTAL|Dose Escalation Cohort: Avelumab 3.0 mg/kg|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 3.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241114|NCT01772004|EXPERIMENTAL|Dose Escalation Cohort: Avelumab 10.0 mg/kg|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62431494|NCT04384926||Cohort 1|Adult patients (aged ≥18 years), planned for curative cancer surgery, that have surgery completed during the COVID-19 pandemic
62431495|NCT04384926||Cohort 2|Adult patients (aged ≥18 years), planned for curative cancer surgery, that have surgery delayed or cancelled during the COVID-19 pandemic
62431496|NCT01818895||Withdrawal of mechanical ventilation|
62431497|NCT01354600|OTHER|Energy Balance|
62431498|NCT01354600|OTHER|Positive Energy Balance|
62431499|NCT04683887|EXPERIMENTAL|Tape application|
62431500|NCT04683887|NO_INTERVENTION|No tape application|
62431501|NCT05374772||Patient with COVID-19|Mild to moderate COVID-19 patient with at least one risk factor for serve COVID-19 illness or death.
62431502|NCT03398655|EXPERIMENTAL|Arm 1|VB-111 + Paclitaxel
62431503|NCT03398655|ACTIVE_COMPARATOR|Arm 2|Placebo + Paclitaxel
62241115|NCT01772004|EXPERIMENTAL|Dose Escalation Cohort: Avelumab 20.0 mg/kg|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 20.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241116|NCT01772004|EXPERIMENTAL|Dose Escalation Cohort: Avelumab 10.0 mg/kg Weekly|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once weekly for the first 12 weeks and once every 2 weeks starting Week 13 in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241117|NCT01772004|EXPERIMENTAL|Primary Expansion Cohort: NSCLC, Post-platinum Doublet|Participants with non-small cell lung cancer (NSCLC), who had progressed after 1 line of platinum-containing doublet chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241118|NCT01772004|EXPERIMENTAL|Primary Expansion Cohort: NSCLC, First Line|Participants with non-small cell lung cancer (NSCLC), first line received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241119|NCT01772004|EXPERIMENTAL|Primary Expansion Cohort: Metastatic Breast Cancer|Participants with metastatic breast cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241120|NCT01772004|EXPERIMENTAL|Primary Expansion Cohort: GC/GEJC Progressed|Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who progressed on or after first line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241121|NCT01772004|EXPERIMENTAL|Primary Expansion Cohort: GC/GEJC Non Progressed|Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who non-progressed on or after first-line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241122|NCT01772004|EXPERIMENTAL|Secondary Expansion Cohort: Colorectal Cancer|Participants with colorectal cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241123|NCT01772004|EXPERIMENTAL|Secondary Expansion Cohort: Castrate-resistant Prostate Cancer|Participants with castrate-resistant prostate cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241124|NCT01772004|EXPERIMENTAL|Secondary Expansion Cohort: Adrenocortical Carcinoma|Participants with adrenocortical carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241125|NCT01772004|EXPERIMENTAL|Secondary Expansion Cohort: Melanoma|Participants with melanoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241126|NCT01772004|EXPERIMENTAL|Secondary Expansion Cohort: Mesothelioma|Participants with mesothelioma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62431504|NCT02008331|EXPERIMENTAL|SYNBIOTIC|Patients of this group assumed Probinul-Neutro® po 5g three times a day for 30 days
62431505|NCT02008331|PLACEBO_COMPARATOR|PLACEBO|patients of this group received 5g of placebo 3 times a day for 30 days
62431506|NCT06074419|EXPERIMENTAL|Experimental group|Virtual reality glasses will be applied 3 days a week for 6 weeks. A sleep quality scale and a mental well-being scale will be applied before and after the procedure.
62431507|NCT06074419|NO_INTERVENTION|Control group|There will be no virtual reality application. Sleep quality and mental well-being scale will be applied every 6 weeks.
62431508|NCT05972070||Cardiac patients|Adult patients who have undergone surgical or percutaneous coronary revascularization due to atherosclerotic coronary artery disease.
62817092|NCT05616624|EXPERIMENTAL|Phase II Non-small cell lung cancer: ADI-PEG + gemcitabine + docetaxel|"* ADI-PEG 20 is given as an intramuscular injection on a weekly basis (Day 1, 8 and 15) at a dose of 36 mg/m\^2. ADI-PEG 20 dosing will start one week prior to the initiation of gemcitabine + docetaxel on Day -7 prior to the initiation of Cycle 1.~* Gemcitabine is given intravenously at the assigned dose level on Day 2 of each cycle.~* Docetaxel is given intravenously at the assigned dose level on Day 1 of each cycle.~* A cycle is defined as 21 days.~* After Cycle 8, patients may continue on ADI-PEG 20 alone (without gemcitabine and docetaxel) per physician discretion or patient request.~* Treatment may continue for up to 34 cycles."
62241127|NCT01772004|EXPERIMENTAL|Secondary Expansion Cohort: Urothelial Carcinoma|Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241128|NCT01772004|EXPERIMENTAL|Secondary Expansion Cohort: Ovarian Cancer|Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241129|NCT01772004|EXPERIMENTAL|Secondary Expansion Cohort: Renal Cell Carcinoma (First Line)|Participants with Renal cell carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a first-line therapy in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241130|NCT01772004|EXPERIMENTAL|Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line)|Participants with Renal cell carcinoma who failed 1 prior systemic first-line regimen received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a second line treatment in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62598570|NCT05669898|ACTIVE_COMPARATOR|Continuous adductor canal infusion combined with intravenous NSAID|Allocation of which participant is to receive continuous adductor canal infusion in combination with intermittent intravenous non-steroidal anti-inflammatory drug (NSAID) is determined by randomization, using a computer-generated random sequence and opaque sealed envelopes. After completion of the TKA surgery and surgical suturing, a peripheral nerve catheter will be implanted into adductor canal by an anesthesiologist. Under ultrasound guidance, the femoral artery and the saphenous nerve are identified in the middle one-third of the thigh, deep to the sartorious muscle in the adductor canal. The sartorious and adductor muscles form the roof and the floor of the canal, respectively. Following the peripheral nerve catheter is implanted, 20 mL of 0.25% bupivacaine with 1:400000 epinephrine is injected through the catheter. Intravenous tenoxicam 20 mg for a total amount of 3 doses at 24-hour interval after surgery will be added in the postoperative pain management.
62598571|NCT00522535|ACTIVE_COMPARATOR|Open Surgical Repair|Open surgical repair of abdominal aortic aneurysm. All patient enrollment and 2-year follow-ups completed.
62817093|NCT05616624|EXPERIMENTAL|Phase II Small cell lung cancer: ADI-PEG + gemcitabine + docetaxel|"* ADI-PEG 20 is given as an intramuscular injection on a weekly basis (Day 1, 8 and 15) at a dose of 36 mg/m\^2. ADI-PEG 20 dosing will start one week prior to the initiation of gemcitabine + docetaxel on Day -7 prior to the initiation of Cycle 1.~* Gemcitabine is given intravenously at the assigned dose level on Day 2 of each cycle.~* Docetaxel is given intravenously at the assigned dose level on Day 1 of each cycle.~* A cycle is defined as 21 days.~* After Cycle 8, patients may continue on ADI-PEG 20 alone (without gemcitabine and docetaxel) per physician discretion or patient request.~* Treatment may continue for up to 34 cycles."
62817094|NCT03291535|PLACEBO_COMPARATOR|Control|This arm will consist of the usual care of management of hypertension by a clinical pharmacist.
62431509|NCT03202511|ACTIVE_COMPARATOR|Control|The control phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) on day 1 (2 tablets) followed by 300/200 mg (1 tablet) doses on days 2 and 3.
62598572|NCT00522535|EXPERIMENTAL|Endovascular Repair|"Endovascular treatment arm of 160 patients having suitable anatomy for the Aorfix™ AAA Flexible Stent Graft System. Use of stent grafts in aortic angles greater than 60° has not been approved for other devices available in the US. As a result, a minimum of 120 patients in this arm will have an aortic angle between 60° and 90°.~Patient recruitment completed; 5-year follow-up evaluations continue."
62817095|NCT03291535|ACTIVE_COMPARATOR|Intervention|This arm will consistent of usual care plus the addition of a blood pressure cuff that will allow patients to upload data to the electronic health record via a secure portal.
62431510|NCT03202511|EXPERIMENTAL|Treatment|The treatment phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (2 tablets) along with a 2 gram oral probenecid (PRO) dose (4 tablets, 500 mg each) on day 1.
62431511|NCT00877266|ACTIVE_COMPARATOR|1. Ultrasound|Ultrasound is randomly chosen by use of a computer program. The time for catheter placement will begin with the ultrasound probe touches the patient. Patients will be asked their discomfort on a 0-10 scale (0=no discomfort and 10=worst discomfort imaginable) and will be called the next day by the research staff.
62431512|NCT00877266|ACTIVE_COMPARATOR|2. Electrical Stimulation|Nerve Stimulation (electrical stimulation) is randomly chosen using a computer program. Time of placement begins when the catheter-placement first touches the patient. After catheter placement patient is asked their discomfort on a 0-10 scale (0=no discomfort and 10=worst discomfort imaginable) and called the day after surgery by the research staff.
62817096|NCT06586073||Diagnosed cancer patients receiving different therapies with hand-foot syndrome skin side effects|Participants were diagnosed cancer patients receiving chemotherapy and targeted or hormonal treatments. Recruitment was performed by the medical oncologists based on the presence of Hand-foot syndrome (HFS) grade 1 symptoms. The severity of HFS was graded according to the The National Cancer Institute-Common Terminology Criteria for Adverse Events Criteria (NCI-CTCAE) version 5.0. All patients enrolled were provided with a kit of four cosmetic products formulated explicitly for cancer skincare
62817097|NCT04672239|EXPERIMENTAL|Smiling Instead of Smoking (SiS) app|"Participants will be onboarded (remotely) to the smartphone app Smiling instead of Smoking (SiS), and will be asked to use it for 7 weeks while they quit smoking."
62817098|NCT04672239|ACTIVE_COMPARATOR|QuitGuide (QG) app|"Participants will be onboarded (remotely) to the smartphone app QuitGuide (QG), and will be asked to use it for 7 weeks while they quit smoking."
62817099|NCT04672239|OTHER|Clearing the Air (CTA) brochure|"Participants will be onboarded (remotely) to the NCI brochure Clearing the Air (CTA), and will be asked to use it for 7 weeks while they quit smoking."
62817100|NCT04265963|EXPERIMENTAL|CD123 CAR-T cells treat|Patients will be be treated with CD123 CAR-T cells
62431513|NCT03053622|EXPERIMENTAL|Mirikizumab Test Subcutaneous (SC) 1|250 mg mirikizumab test formulation given as a single injection SC in healthy participants
62817101|NCT06652243|EXPERIMENTAL|SN301A CAR NK cell therapy|"Using the modified 3 + 3 design principle, a total of 3 dose groups are planned,.There were 1 case in the first group and 3 to 6 cases in each of the last two groups ： Dose level 1 (Initial safe dose): 0.5e9 CAR+ NK cells, Dose level 2 (Target effective dose): 1e9 CAR+ NK cells, Dose level 3（Maximum dose）: 2e9 CAR+ NK cells Which are administered once on Days 0, 7, and 14 of each 28 day cycle."
62817102|NCT02010892||Watchful Waiting|Patients with aneurysms considered to be at low risk of rupture will remain under surveillance with annual CT / MRI scans and multi-disciplinary team review (as per local practice). These patients' data will contribute to the natural history component of the study.
62817103|NCT02010892||Best Medical Therapy|This refers to lifestyle modification (smoking cessation and dietary management) as well as medical management of hypercholesterolaemia and hypertension for patients who are considered unsuitable for, or who refuse, OSR / ESG.
62817104|NCT02010892||Open Surgery (OSR)|Replacement of the aneurysmal aorta with prosthetic conduit via a sternotomy or thoracotomy with circulatory support.
62817105|NCT02010892||Stenting (ESR)|Endovascular repair of the aneurysm via transluminal introduction of a stent-graft under X-ray guidance. Hybrid procedures that comprise a combination of a conventional surgical component and a transluminal repair are to be included in this group.
62817106|NCT05739981|EXPERIMENTAL|Chemotherapy + BEV + IMNN-001 (Experimental)|"Chemotherapy (neoadjuvant and adjuvant): Paclitaxel 175 mg/m2 IV followed by carboplatin AUC 5-6 IV starting on C1D1. During the neoadjuvant period, there will be from 4 to 6 cycles repeated every 21 days.~BEV 15 mg/kg IV administration will be included with each cycle except during the cycles around time of surgery. During maintenance, BEV will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.~IMNN-001 80 mg/m2 IP will be administered weekly beginning C1D15 and continue weekly through the last cycle of adjuvant therapy. At the conclusion of chemotherapy, GEN-1 will be administered every 21 days with BEV in subjects who are BRCA-/HRP until disease progression or unacceptable toxicity for up to an additional 18 cycles."
62817107|NCT05739981|OTHER|Chemotherapy + BEV (Control)|"Chemotherapy (neoadjuvant and adjuvant): Paclitaxel 175 mg/m2 IV followed by carboplatin AUC 5-6 IV starting on C1D1. During the neoadjuvant period, there will be from 4 to 6 cycles (at the Investigator's discretion, having an additional C4+1 and C4+2) repeated every 21 days.~BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: \[1\] Cycle 1, \[2\] the last cycle of neoadjuvant therapy immediately preceding ICS, and \[3\] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV."
62817108|NCT04405791|EXPERIMENTAL|Active stimulation group|"low intensity transcranial focused ultrasound (tFUS) stimulationThe acoustic intensity output of the FUS transducer was validated at the maximum intensity area using a calibrated needle hydrophone (HNR-500, Onda). The incident acoustic intensity and pressure at the FUS focus were 3W/cm2 spatial-peak pulse-average acoustic intensity (Isppa) and a peak negative pressure (Pr) of 300 kPa. The incident acoustic intensity and pressure at the FUS focus were 3W/cm2, and tone burst duration was 1 ms at 50 % duty cycle (thus, pulse repletion frequency was 500 Hz) for the duration of 300 ms, according to the studies in humans. Each sonication was delivered every 6 s for the duration of 20 min (a total FUS stimulation per each session was therefore 200 times). With a derating factor of 55% reduction in pressure transmission by the human skull, estimated in situ Pr was \~135 kPa with an in situ acoustic intensity of 600 mW/cm2 Isppa ."
62817109|NCT04405791|SHAM_COMPARATOR|Sham stimluation group|"sham stimulation In case of sham stimulation, the same procedure was repeated without providing actual sonication. No subjects in FUS condition hear/feel any tangible somatosensory phenomena; therefore, the sham condition was indistinguishable."
62817110|NCT02333435|EXPERIMENTAL|Purified EPA group|3g per day of purified EPA, capsules, to be taken once a day, for 14 months.
62817111|NCT02333435|EXPERIMENTAL|Placebo group|3 g per day of high-oleic sunflower oil capsules, to be taken once a day, for 14 months.
62817112|NCT04721223|EXPERIMENTAL|JAB-3068+PD1 inhibitor Part1|JAB-3068+JS001 dose escalation
62817113|NCT04721223|EXPERIMENTAL|JAB-3068+PD1 inhibitor Part2|JAB-3068+JS001 dose expansion
62817114|NCT06705166||Normal weight|Patients 60-85 years old whom Suffered a femoral neck fracture in the last year with normal BMI
62431514|NCT03053622|EXPERIMENTAL|Mirikizumab Test SC 2|250 mg mirikizumab test formulation given as two injections given SC in healthy participants
62431515|NCT03053622|EXPERIMENTAL|Mirikizumab Test Intravenous (IV)|250 mg mirikizumab test formulation given as an infusion into the vein in healthy participants
62598573|NCT00522535|EXPERIMENTAL|Continued Access|"Endovascular treatment arm of 50 patients maximum having suitable anatomy for the Aorfix™ AAA Flexible Stent Graft System. This Arm will provide active sites with ongoing device access while FDA reviews the PMA.~Patient recruitment completed; 5-year patient follow-ups continue."
62598574|NCT00662662||Oropharyngeal Cancer|
62598575|NCT00662662||Non-Oropharyngeal Cancer|
62598576|NCT01972451|PLACEBO_COMPARATOR|Colonoscopy without enhanced dye|no enhanced dye
62598577|NCT01972451|ACTIVE_COMPARATOR|Colonoscopy with enhanced dye|enhanced dye
62598578|NCT06648629|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT)|Participants randomized to the ACT arm will receive six, weekly, 30-45-minute ACT intervention sessions delivered via telephone.
62598579|NCT06648629|ACTIVE_COMPARATOR|Brief Alcohol Intervention (BI)|Participants randomized to BI will receive two 30-60 minute sessions of a brief alcohol intervention delivered via telephone, two 5-10-minute booster calls, and two 5-minute reminder phone calls.
62598580|NCT04525079|EXPERIMENTAL|Cohort 1|Cohort 1 will receive a dose of CT-P59 or matching placebo
62598581|NCT04525079|EXPERIMENTAL|Cohort 2|Cohort 2 will receive a dose of CT-P59 or matching placebo
62598582|NCT04525079|EXPERIMENTAL|Cohort 3|Cohort 3 will receive a dose of CT-P59 or matching placebo
62598583|NCT04525079|EXPERIMENTAL|Cohort 4|Cohort 4 will receive a dose of CT-P59 or matching placebo
62817115|NCT06705166||Obese|Patients 60-85 years old whom Suffered a femoral neck fracture in the last year with normal BMI
62817116|NCT06456320||Suspected Genetic Predisposition or Multi-Omics Contribution|Patients with a diagnosis or phenotype with the potential for association with a genetic predisposition or Multi-Omics Contribution.
62431516|NCT03053622|ACTIVE_COMPARATOR|Mirikizumab Reference|250 mg mirikizumab reference formulation given as three injections subcutaneous (SC) in healthy participants
62431517|NCT03171675||Preterm/Chronic Periodontitis|Included ten female patients who underwent spontaneous preterm birth and were diagnosed with chronic periodontitis upon clinical examination
62431518|NCT03171675||Preterm/Healthy Periodontium|Included ten female patients who underwent spontaneous preterm birth and who had a healthy periodontium upon clinical examination
62431519|NCT03171675||Term/Chronic Periodontitis|Included ten female patients who underwent spontaneous normal term birth and were diagnosed with chronic periodontitis upon clinical examination
62431520|NCT03171675||Term/Healthy Periodontium|Included ten female patients who underwent spontaneous normal term birth and who had a healthy periodontium upon clinical examination (Armitage1999)
62431521|NCT04354337|EXPERIMENTAL|Intervention Group|8-weeks online program with weekly modules for parents to learn about specific sleep topics and implement behavioral changes to improve their child's sleep.
62431522|NCT02866019|EXPERIMENTAL|CLS2702C/CLS2702D|
62598584|NCT03673345|EXPERIMENTAL|Cohort 1A|0.25 mL dose of IIV-4 administered intramuscularly on days 0 and 28 of study year 1 and on day 0 of study year 2 in children 6-12 months of age who have not previously had an influenza infection or vaccination, n=20
62598585|NCT03673345|EXPERIMENTAL|Cohort 1B|0.25 mL dose of IIV-4 administered intramuscularly on day 0 of study year 2 after primary influenza infection in study year 1 in children 3-12 months of age, who have not previously had an influenza vaccination, n=20
62598586|NCT03673345|EXPERIMENTAL|Cohort 2A|0.25 mL (less than 36 months of age) or 0.5 mL (36 months of age or older) dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children greater than 12 months of age and born after 2009, who have previously received 2 doses of influenza vaccine prior to the study, n=60
62598587|NCT03673345|EXPERIMENTAL|Cohort 2B|0.25 mL (less than 36 months of age) or 0.5 mL (36 months of age or older) dose of IIV-4 administered intramuscularly on day 0 of study year 2 in children greater than 12 months of age and born after 2009, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
62598588|NCT03673345|EXPERIMENTAL|Cohort 3A|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children born between 2006 and 2009, who have previously received 2 doses of influenza vaccine prior to the study, n=30
62598589|NCT03673345|EXPERIMENTAL|Cohort 3B|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 2 in children born between 2006 and 2009, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
62598590|NCT03673345|EXPERIMENTAL|Cohort 4A|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children born between 2003 and 2006, who have previously received 2 doses of influenza vaccine prior to the study, n=30
62598591|NCT03673345|EXPERIMENTAL|Cohort 4B|0.5 mL does of IIV-4 administered intramuscularly on day 0 of study year 2 in children born between 2003 and 2006, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
62598592|NCT06421545|EXPERIMENTAL|Open Pilot RT-D Dyads|Persons living with dementia (PWDs) and their spousal care-partners
62431523|NCT04013022||Young|Healthy young subjects (age 18 - 30 )
62431524|NCT04013022||Old Sedentary|Healthy and sedentary old subjects (age 65 - 75)
62431525|NCT04013022||Old Endurance Trained|Healthy old subjects ( age 65 - 75) who participated in endurance sports for ≥30 years, ≥5 hours per week and ≥4 sessions per week
62431526|NCT04013022||Old Strength Trained|Healthy old subjects ( age 65 - 75) who participated in resistance training/sports for ≥30 years, ≥5 hours per week and ≥4 sessions per week
62431527|NCT02662608|EXPERIMENTAL|Brontictuzumab|1.5 mg/Kg of Brontictuzumab single agent intravenously every three weeks.
62598593|NCT02491372|EXPERIMENTAL|Intervention|Acceptance and commitment therapy group
62431528|NCT01328054|EXPERIMENTAL|lapatinib/placebo|This is a crossover study where subjects will receive placebo that mimics lapatinib for 2 days and lapatinib for 2 days. Subjects will not know when they are receiving placebo vs. lapatinib.
62598594|NCT02491372|NO_INTERVENTION|Comparison|Treatment as usual
62817117|NCT06456320||Healthy Control|Patients with no diagnosis associated with a genetic predisposition or Multi-Omics Contribution.
62817118|NCT06453044|EXPERIMENTAL|Treatment (mosunetuzumab, polatuzumab vedotin)|Patients receive polatuzumab vedotin IV over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive mosunetuzumab SC on days 1, 8 and 15 of cycle 1 and day 1 of remaining cycles. Cycles repeat every 21 days for up to 8-17 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and CT, PET/CT, or MRI throughout the study.
62817119|NCT04014829||Control group for CPHP|Preoperative assessment with questionnaires, Mechanical Temporal Summation, Pain-Pressure Threshold, and heart rate variability. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if no significant pain is noted during the follow up evaluations at 4 and 6 months.
62817120|NCT04014829||Chronic Post-Hysterectomy Pain (CPHP)|Preoperative assessment with questionnaires, Mechanical Temporal Summation, Pain-Pressure Threshold, and heart rate variability. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if significant pain is noted during the follow up evaluations at 4 and 6 months.
62817121|NCT04014829||Control group for significant postoperative pain|Preoperative assessment with questionnaires, Mechanical Temporal Summation, Pain-Pressure Threshold, and heart rate variability. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if no significant pain is noted during the follow up evaluations at 24 and 48 hours.
62817122|NCT04014829||Significant postoperative pain|Preoperative assessment with questionnaires, Mechanical Temporal Summation, Pain-Pressure Threshold, and heart rate variability. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if significant pain is noted during the follow up evaluations at 24 and 48 hours.
62817123|NCT01351909|EXPERIMENTAL|Treatment (veliparib, cyclophosphamide)|Patients receive veliparib orally PO QD and cyclophosphamide PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62817124|NCT03020667||IQOS Users|"The criteria defining an IQOS user are listed in the section Eligibility."
62817125|NCT03020667||Cigarette (CC) Smokers|"The criteria defining a CC smoker are listed in the section Eligibility."
62817126|NCT01212055||Cohort 1|Patients with DOCK8 deficiency, LAD-1, or GATA2 Deficiency
62817127|NCT06392165|OTHER|Self-adhesive wound care devices|test devices with adhesive material to be attached to skin
62817128|NCT05863052||American Indian population|
62817129|NCT05863052||Caucasians treated with immunotherapy|
62817130|NCT05595148|ACTIVE_COMPARATOR|Immediate WBAT|Recent studies have highlighted that early WBAT is may be safe following fixation of lower extremity, pelvis, and acetabulum fractures where the standard of care has been delayed WBAT, but high-quality prospective studies on this topic are needed.
62817131|NCT05595148|ACTIVE_COMPARATOR|Delayed WBAT|Though immediate postoperative WBAT has become the standard of care following fixation of pertrochanteric, femoral shaft, and tibial shaft fractures, most surgeons restrict patient weight bearing following fixation of other lower extremity and pelvis/acetabulum fractures. Progression to full weight bearing varies greatly by type of fracture, fixation method, and surgeon. Weight bearing restrictions following fracture fixation have been shown to be associated with various poor outcomes (increased complications, prolonged hospital length of stay, etc.), particularly in geriatric patients. Thus, it is important for us to understand if it is safe to allow early weight bearing following lower extremity and pelvis/acetabulum fracture fixation, as this could help expedite patient mobility and return to function, and potentially reduce complications.
62817132|NCT04114123||Longitudinal|The researchers will be evaluating baseline indicators of wanting salience and liking between 2 and 6 month olds, with the goal of following up with these families at 24 months and beyond by reviewing the dyads' medical charts. The researchers will also examine direct and indirect associations between reward-driven eating, and maternal and infant characteristics and infant weight-for-length.
62431529|NCT04087083|EXPERIMENTAL|technological intervention arm|Twenty technological treatment sessions divided into 3 training sessions per week for 7 weeks.
62431530|NCT04087083|ACTIVE_COMPARATOR|Control arm|Twenty traditional treatment sessions divided into 3 training sessions per week for 7 weeks.
62431531|NCT06327321|EXPERIMENTAL|Drug group|Following central randomization, patients will be assigned to receive either deucravacitinib 12mg daily (QD) or a placebo daily (QD) for a duration of 24 weeks. At the end of this period, patients will be re-randomized to receive either deucravacitinib 12mg QD alone or deucravacitinib 12mg QD + twice weekly narrowband UVB treatment twice weekly for an additional 24 weeks.
62241131|NCT01772004|EXPERIMENTAL|Efficacy Expansion Cohort: Ovarian Cancer|Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241132|NCT01772004|EXPERIMENTAL|Efficacy Expansion Cohort: Urothelial Carcinoma|Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241133|NCT01772004|EXPERIMENTAL|Efficacy Expansion Cohort: GC/ GEJC, Third Line|Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who have failed both a first-line chemotherapy regimen and subsequent ramucirumab therapy, received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a third-line treatment in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62817133|NCT04114123||Cross-sectional|The researchers will as the mother to answer questionnaires and participate in up to two video taped behavioral protocols when the infant is 6 months old.
62817134|NCT01715181|NO_INTERVENTION|Usual care|Individuals will receive usual care
62241134|NCT01772004|EXPERIMENTAL|Efficacy Expansion Cohort: HNSCC|Participants with head and neck squamous cell carcinoma (HNSCC) received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
62241135|NCT04722926||PJI|Patients having had a PJI
62431532|NCT06327321|PLACEBO_COMPARATOR|Placebo group|Following central randomization, patients will be assigned to receive either deucravacitinib 12mg daily (QD) or a placebo daily (QD) for a duration of 24 weeks. At the end of this period, patients will be re-randomized to receive either deucravacitinib 12mg QD alone or deucravacitinib 12mg QD + twice weekly narrowband UVB treatment twice weekly for an additional 24 weeks.
62431533|NCT02459639||Anthroposophic integrative care|"Inclusion criteria are: Pain patients with a primary diagnosis corresponding to ICD-10 M79, or long-term pain for a period of over 3 months in neck/shoulders and/or low back, or generalised pain, fluency in Swedish and allowing for co-morbidity/ multiple secondary diagnoses.~The exclusion criteria are: psychotic illness, schizophrenia, bipolar disorder, substance dependency problems, and cancer."
62431534|NCT02459639||Multimodal pain rehabilitation|"Inclusion criteria are: Pain patients with a primary diagnosis corresponding to ICD-10 M79, or long-term pain for a period of over 3 months in neck/shoulders and/or low back, or generalised pain, fluency in Swedish and allowing for co-morbidity/ multiple secondary diagnoses.~The exclusion criteria are: psychotic illness, schizophrenia, bipolar disorder, substance dependency problems, and cancer."
62431535|NCT01644578|OTHER|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
62431536|NCT01681043|NO_INTERVENTION|24 hour PSG under ordinary conditions|24 hour PSG in 46 patients under ordinary (routine) conditions
62431537|NCT01681043|ACTIVE_COMPARATOR|24 hours PSG under protocol 'Quiet in the room'|24 hour PSG in the same 46 patients with protocol 'Quiet in the room' from 10 p.m. til 6 a.m.
62431538|NCT03039374||OASI patients|All patients older than 18 and a 3rd or 4th degree perineal tear during birth meet the inclusion criteria. All women who have obtained such a injury during birth in the Vaasa or Seinäjoki Central hospitals will be evaluated for eligibility.
62817135|NCT01715181|EXPERIMENTAL|Volunteer visits|Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
62241136|NCT03519958||EGFR NSCLC Progressed on EGFR TKI|Patients with EGFR NSCLC who have progressed following EGFR TKI therapy will undergo plasma-tissue testing
62241137|NCT05020288|EXPERIMENTAL|Orelabrutinib|Orelabrutinib 50mg po qd
62241138|NCT04622033|EXPERIMENTAL|Brodalumab 210mg|
62431539|NCT04918537|EXPERIMENTAL|Intervention walnuts|During the 3 last weeks of the study, the participants will eat a 30g daily walnut serving
62431540|NCT01195389|ACTIVE_COMPARATOR|Resonator|Treatment with active Resonator device using low level magnetic fields
62431541|NCT01195389|PLACEBO_COMPARATOR|Placebo treatment|
62598595|NCT05307016||MAP patients|All pregnancies complicated with any degree of Placenta previa anterior, posterior or centralis undergoing pre-labor CS at gestational age (36+0 to 40+0)
62817136|NCT04371432||Sample Group 1 (NIHCC)|Existing NIH Clinical Center patients/participants tested positive for SARS-CoV-2 invited to participate by their NIH study team
62817137|NCT04371432||Sample Group 2 (OMS &amp; Field)|Recruited through NIH OMS, referred by collaborators or who self-refer, tested positive for SARS-CoV-2 (and selected relatives of participants irrespective of infection status)
62817138|NCT05696236|EXPERIMENTAL|Monitor (TEWL) and stopping rules|Wears the monitor, and the food challenge will be done using the new stopping rules to end the test.
62817139|NCT05696236|ACTIVE_COMPARATOR|Monitor (TWLG) without stopping rules|Wears the monitor, but the stopping rules will not be used to end the food challenge. The food challenge will be done following standard oral food challenge procedures.
62817140|NCT06517082|EXPERIMENTAL|Ambient Listening Group 1|Participants randomized to this arm will start using Ambient AI at week 7.
62817141|NCT06517082|EXPERIMENTAL|Ambient Listening Group 2|Participants randomized to this arm will start using Ambient AI at week 13.
62241139|NCT04350216|EXPERIMENTAL|Sarilumab therapy|Patients will be treated every two weeks with 200 mg of the anti-IL human monoclonal antibody-6Rα Sarilumab (Kevzara) with or without conventional DMARDs. Sarilumab administration will be subcutaneous (abdomen, thigh, or upper arm). The dose will be reduced to 150 mg in the event of neutropenia, thrombocytopenia, and elevated liver enzymes.
62241140|NCT02405923|EXPERIMENTAL|HRF (Rice formula)|Hydrolyzed Rice Protein Formula (HRF)
62241141|NCT02405923|PLACEBO_COMPARATOR|eHF (Extensive Hydrolysed Formula)|Extensive Hydrolysed Cow's Milk Protein Formula (eHF)
62241142|NCT00960960|EXPERIMENTAL|Part 1 (Cohort 1-2): Pictilisib 60 mg +Paclitaxel +Bevacizumab|Pictilisib 60 mg will be administered orally (PO) once daily (QD) for 21 consecutive days of each 28-day cycle (21+7 schedule) with paclitaxel 90 milligrams per meter square (mg/m\^2) intravenously (IV) on Days 1, 8, and 15 and bevacizumab 10 milligrams per kilogram (mg/kg) IV on Days 1 and 15 of each 28-day cycle. In Cohort 1 (Part 1), pictilisib will be evaluated with paclitaxel only; participants in Cohort 1 (Part 1) will be eligible to receive bevacizumab starting at Cycle 2. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
62241143|NCT00960960|EXPERIMENTAL|Part 1 (Cohort 3): Pictilisib 100 mg+ Paclitaxel + Bevacizumab|Pictilisib 100 mg will be administered PO QD for 21 consecutive days of each 28-day cycle (21+7 schedule) with paclitaxel 90 mg/m\^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
62241144|NCT00960960|EXPERIMENTAL|Part 2 (Arm A: Cohort 1a): Pictilisib 165 mg + Paclitaxel|Pictilisib 165 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m\^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity
62241145|NCT00960960|EXPERIMENTAL|Part 2 (Arm A: Cohort 2a): Pictilisib 250 mg + Paclitaxel|Pictilisib 250 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m\^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
62817142|NCT06517082|EXPERIMENTAL|Ambient Listening Group 3|Participants randomized to this arm will start using Ambient AI at week 19.
62817143|NCT02538510|EXPERIMENTAL|Treatment (vorinostat, pembrolizumab)|Patients receive vorinostat PO QD or via PEG on days 1-5 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62241146|NCT00960960|EXPERIMENTAL|Part 2 (Arm A: Cohort 3a): Pictilisib 330 mg + Paclitaxel|Pictilisib 330 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m\^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
62241147|NCT00960960|EXPERIMENTAL|Part2(Arm B:Cohort 1b):Pictilisib 200mg+Paclitaxel+Bevacizumab|Pictilisib 200 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m\^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
62241148|NCT00960960|EXPERIMENTAL|Part2(Arm B:Cohort 2b):Pictilisib 250mg+Paclitaxel+Bevacizumab|Pictilisib 250 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m\^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
62431542|NCT02535676|ACTIVE_COMPARATOR|Active tDCS|Sham Comparator: Sham Stimulation In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the temporo-parietal cortex with the Transcranial Direct Current Stimulation. The device will deliver a charge of 2mA for 20 minutes.
62431543|NCT02535676|SHAM_COMPARATOR|Sham tDCS|Sham Comparator: Sham Stimulation In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the temporo-parietal cortex with the Transcranial Direct Current Stimulation. The device will deliver a charge of 2mA for 1 minute, after that the device will be automatically turned off for 19 minutes.
62431544|NCT01131702|EXPERIMENTAL|Ranitidine Tablets, 300 mg|Ranitidine Tablets, 300 mg of Dr. Reddy's Laboratories Limited
62431545|NCT01131702|ACTIVE_COMPARATOR|Zantac Tablets, 300 mg|
62598596|NCT00636194|EXPERIMENTAL|B&L Multipurpose solution|Bausch \& Lomb Multipurpose Contact Lens Solution
62817144|NCT06706076|EXPERIMENTAL|Phase 1 Dose Escalation and Expansion|"* BH-30643 monotherapy for dose escalation~* BH-30643 monotherapy for dose expansion/optimization at doses determined from dose escalation data~* BH-30643 twice daily oral dosing"
62817145|NCT06706076|EXPERIMENTAL|Phase 2|BH-30643 administered at the RP2D dose determined in Phase 1
62817146|NCT03011008|EXPERIMENTAL|Liraglutide + insulin|Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.
62817147|NCT03011008|ACTIVE_COMPARATOR|Insulin|Patients will receive insulin injection as a routine therapy.
62817148|NCT05157386||Participants in Braining, years 2017-2020|"Braining was primarily open for patients with a main or secondary diagnosis within affective disorder or anxiety syndromes, sleep disturbance or stress.~Participants in Braining (n≈600), who have participated in three or more training sessions 2017-2020 (n≈250), and who agree to contribute to this study, will be included."
62241149|NCT00960960|EXPERIMENTAL|Part2(Arm B:Cohort 3b):Pictilisib 260mg+Paclitaxel+Bevacizumab|Pictilisib 260 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m\^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
62598597|NCT00636194|ACTIVE_COMPARATOR|Alcon Multipurpose Solution|Alcon OptiFree Replenish Multipurpose Contact Lens Solution
62598598|NCT00707876|EXPERIMENTAL|1|Dose 1 versus non-contrast MRA
62431546|NCT05578300||Patient with ischemic stroke with suspected large vessel occlusion|"The investigators shall recruit patients that meet the following inclusion criteria:~1. Patient who are over 18 years of age.~2. Patient with ischemic stroke with suspected large vessel occlusion (LVO), defined as occlusion of the internal carotid artery (ICA), M1 or M2 segment of the middle cerebral artery (MCA), or basilar artery (BA)."
62431547|NCT01883999|EXPERIMENTAL|GORE® EXCLUDER® Iliac Branch Endoprosthesis|GORE® EXCLUDER® Iliac Branch Endoprosthesis
62431548|NCT05217056||1/Measurement|All of the infants with high risk of cerebral palsy
62431549|NCT00616928|EXPERIMENTAL|Influenza A (H5N1) 18-64Y Group|Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
62431550|NCT00616928|PLACEBO_COMPARATOR|Placebo 18-64Y Group|Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
62598599|NCT00707876|EXPERIMENTAL|2|Dose 2 versus non-contrast MRA
62598600|NCT00707876|EXPERIMENTAL|3|Dose 3 versus non-contrast MRA
62598601|NCT01088243|EXPERIMENTAL|Mesalamine|Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
62598602|NCT01088243|PLACEBO_COMPARATOR|Placebo|Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
62598603|NCT04108494|EXPERIMENTAL|Experimental group|D2 radical gastrectomy with partial omentectomy
62598604|NCT04108494|NO_INTERVENTION|Control group|D2 radical gastrectomy with total omentectom
62598605|NCT03808350|PLACEBO_COMPARATOR|Families Excluded From Presence at Procedures|Families not invited to remain for ICU procedures
62598606|NCT03808350|ACTIVE_COMPARATOR|Families Invited to Be Present at Procedures|Families invited to remain for ICU procedures
62598607|NCT04346212||Patients infected by SARS-CoV-2|Patients infected by SARS-CoV-2 at the Hospital de Mataró, Hospital de St. Jaume i Sta. Magdalena and other medicalized facilities in Mataró.
62598608|NCT04546321||HIE group (I)|All fullterm newborn admitted to the NICU with Hypoxic Ischemic Encephalopathy during the study period
62598609|NCT04546321||TTN group(II)|All fullterm babies with Transient Tachypnea of the Newborn admitted to the NICU during the study period
62598610|NCT03338803||Patients with a written prescription for linagliptin|
62817149|NCT00379015|EXPERIMENTAL|HER2 over-expressing primary breast cancer group|"Patients receive epirubicin hydrochloride and cyclophosphamide in week 1-3. Treatment with epirubicin hydrochloride and cyclophosphamide repeats every 3 weeks for 4 courses. Patients then receive docetaxel in week 13 and trastuzumab (Herceptin®) in weeks 13-15. Treatment with docetaxel and trastuzumab repeats every 3 weeks for 4 courses.~Patients then undergo appropriate surgery. After surgery, patients with hormone receptor-positive disease receive trastuzumab once weekly and either tamoxifen with or without a luteinizing hormone-releasing hormone agonist or an aromatase inhibitor. Treatment continues for 40 weeks."
62431551|NCT00616928|EXPERIMENTAL|Influenza A (H5N1) >64Y Group|Subjects aged \> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
62431552|NCT00616928|PLACEBO_COMPARATOR|Placebo >64Y Group|Subjects aged \> 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
62598611|NCT03439215|EXPERIMENTAL|Lorlatinb Arm|Eligible patients will be treated with Lorlatinib at the dose of 100 mg QD p.o.
62598612|NCT03852368|EXPERIMENTAL|The Effects of Light Exercise in Executive Functions|The effects of light exercise in executive functions of adolescents
62598613|NCT03852368|EXPERIMENTAL|The Effects of Moderate Exercise in Executive Functions|The effects of moderate exercise in executive functions of adolescents
62598614|NCT03852368|EXPERIMENTAL|The Effects of Heavy Exercise in Executive Functions|The effects of heavy exercise in executive functions of adolescents
62598615|NCT04202913|EXPERIMENTAL|Health Coaching|1:1 Health coaching with student
62598616|NCT03068819|EXPERIMENTAL|CIML NK cell after T cell DLT (Pilot Pediatric/Young Adult Cohort)|"* The recipient will receive standard of care salvage chemotherapy consisting of fludarabine (or cladribine if shortage), cytarabine, and G-CSF (FLAG) to be started 2 to 4 weeks prior to the CIML NK cell infusion. 5-day decitabine is an acceptable alternative for FLAG, and another standard of care salvage chemotherapy regimen, if clinically appropriate and approved by the study PI, may be used.~* The donor will undergo non-mobilized leukapheresis on Day -2 or -1. Standard of care DLI (1 x 10\^6 CD3+ cells/kg) will be given fresh on day -1.~* A second cycle of therapy may be administered \> 30 days after the administration of the first course of protocol therapy to maintain response or to treat persistent/relapsed AML, if a patient continues to meet the inclusion/exclusion criteria. Chemotherapy may be omitted before a second infusion of DLI and CIML NK cells. In the setting of GVHD following the first cycle of therapy, the T cell DLI may be omitted, and ML NK cells administered."
62241150|NCT00960960|EXPERIMENTAL|Part2(Arm C:Cohort 1c):Pictilisib 180mg+Paclitaxel+Trastuzumab|Pictilisib 180 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m\^2 IV on Days 1, 8, and 15 and trastuzumab 2-4 mg/kg IV on Days 1, 8, 15, and 22 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
62431553|NCT00616928|EXPERIMENTAL|Influenza A (H5N1) Group|Pooled group of subjects aged \>18 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
62431554|NCT00616928|PLACEBO_COMPARATOR|Placebo Group|Pooled group of subjects aged \>18 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
62431555|NCT00616928|EXPERIMENTAL|Influenza A (H5N1) 18-60Y Group|Subjects aged 18-60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
62431556|NCT00616928|PLACEBO_COMPARATOR|Placebo 18-60Y Group|Subjects aged 18-60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
62431557|NCT00616928|EXPERIMENTAL|Influenza A (H5N1) >60Y Group|Subjects aged \>60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
62431558|NCT00616928|PLACEBO_COMPARATOR|Placebo >60Y Group|Subjects aged \> 60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
62431559|NCT03218410|ACTIVE_COMPARATOR|surgical pulmonary embolectomy|
62598617|NCT03068819|EXPERIMENTAL|CIML NK cell after T cell DLT (Phase 2 Adult Cohort)|"* The recipient will receive lymphodepleting chemotherapy with fludarabine (or cladribine if shortage) and cyclophosphamide beginning on day -7.~* The donor will undergo non-mobilized leukapheresis on Day -2 or -1. T cell dose per standard of care institutional practices and physician discretion will be given frozen for administration on day 30.~* A second cycle of therapy may be administered \> 30 days after the administration of the first course of protocol therapy to maintain response or to treat persistent/relapsed AML, if a patient continues to meet the inclusion/exclusion criteria. Chemotherapy may be omitted before a second infusion of DLI and CIML NK cells. In the setting of GVHD following the first cycle of therapy, the T cell DLI may be omitted, and ML NK cells administered. The date of the second NK cell infusion will be considered a second Day 0."
62598618|NCT05836974|EXPERIMENTAL|Ex-utero cord blood collection|Ex-utero cord blood collection
62598619|NCT05836974|ACTIVE_COMPARATOR|In-utero cord blood collection|In-utero cord blood collection
62817150|NCT06518954||Athlete with eating disorder|Athletes with/with a history of eating disorder while competing in sport
62241151|NCT00960960|EXPERIMENTAL|Part2(Arm C:Cohort 2c):Pictilisib 260mg+Paclitaxel+Trastuzumab|Pictilisib 260 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m\^2 IV on Days 1, 8, and 15 and trastuzumab 2-4 mg/kg IV on Days 1, 8, 15, and 22 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
62241152|NCT00960960|EXPERIMENTAL|Part 3: Pictilisib 260 mg + Letrozole|Pictilisib 260 mg will be administered PO QD continuously with letrozole 2.5 mg PO QD for each 28-day cycle. Study treatment will continue until disease progression or unacceptable toxicity.
62241153|NCT04081454||Children with chronic pain|
62431560|NCT03218410|ACTIVE_COMPARATOR|catheter-directed thrombolysis|
62431561|NCT00626587|PLACEBO_COMPARATOR|A|Conventional diagnostic procedures (transbronchial biopsy and bronchial washing) for peripheral pulmonary lesions
62598620|NCT05526807|EXPERIMENTAL|Ursodeoxycholic acid|Only one arm - subjects receiving ursodeoxycholic acid
62598621|NCT02156895||Patients who are using Axitinib|
62598622|NCT04530266|ACTIVE_COMPARATOR|Persons with knee osteoarthritis|
62241154|NCT04081454||Caregivers of children with chronic pain|
62241155|NCT03730974|EXPERIMENTAL|Experimental arm AB (Ball blanket + TAU)|"Participants will be randomized into either sequence AB or BA each lasting four weeks.~Patients that are randomized to the AB sequence receive intervention A (Protac Ball BlanketTM 7 kg Flexible) in the first two weeks and treatment B treatment as usual (TAU) in the second period."
62598623|NCT04530266|PLACEBO_COMPARATOR|Healthy controls|
62598624|NCT01608815|EXPERIMENTAL|Study Group|All participants will receive single dose of typhoid Vi polysaccharide vaccine on Day 0.
62598625|NCT00775840|EXPERIMENTAL|Candesartan QD + Heart Failure Therapy|(with angiotensin-converting enzyme-inhibitors/beta-blockers)
62598626|NCT00775840|PLACEBO_COMPARATOR|Placebo QD + Heart Failure Therapy|(with angiotensin-converting enzyme-inhibitors/beta-blockers)
62817151|NCT06518954||Athlete without eating disorder|Athletes without any history of eating disorder and originating from the same club or team as the athlete with an eating disorder
62819460|NCT06704711|PLACEBO_COMPARATOR|Placebo Rinse with incremental exercise|They will rinse 20 mL of distilled water in the mouth for 20 s and try to continue the exercise against increasing resistance until exhaustion.The exercise test will be performed on a bicycle ergometer (Ergometer Exercise Bike SANA 500, Germany) (where the pedaling speed is kept constant at 60 rpm, with an initial load of 50 Watts and a load increase of 25 watts per minute, gradually increasing until the participants become exhausted. To be able to determine the degree of difficulty perceived during the test and The Borg Scale will be used to end the test when the athlete reaches the point of exhaustion.
62817152|NCT06506253|EXPERIMENTAL|Swedish Massage Therapy|"The therapist uses non-aromatic cream to facilitate making long strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then re-draped before moving to another part. The primary techniques used in the research protocol therapy are effleurage, petrissage, kneading, tapotement and thumb friction. These techniques are performed in a very precise, carefully elaborated manner. The session starts with the subject fully draped in a prone position on the massage table and after approximately 22 minutes the subject is instructed to turn to the supine position. Finally, the therapist moves to the head area of the subject, begins working on the shoulders, neck and head using effleurage and thumb friction, and concludes by using light tapotement on the head. The total time for the entire massage is 45 minutes. Subjects randomized to SMT will undergo 2/week for a total of 6 weeks."
62817153|NCT06506253|ACTIVE_COMPARATOR|Light Touch Control|The Light Touch Control protocol entails the same duration and sequence of procedures as the massage protocol, except that the therapist employs only light-touch hand placement on the subject's body. This condition isolates the effect of the mechanical intervention of SMT. Subjects randomized to LT will undergo 2/week for a total of 6 weeks.
62817154|NCT00771758|EXPERIMENTAL|001|tapentadol IR 50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days maximum daily dose 450 mg
62817155|NCT00771758|EXPERIMENTAL|002|oxycodone IR 5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days maximum daily dose 60 mg
62817156|NCT00771758|PLACEBO_COMPARATOR|003|placebo 1 capsule every 4 - 6 hr as needed for up to 10 days
62817157|NCT05163041|EXPERIMENTAL|BT7480 monotherapy dose escalation|Participants will receive increasing doses of BT7480. It is expected that approximately 80 patients will participate in this dose escalation arm.
62817158|NCT05163041|EXPERIMENTAL|BT7480 and nivolumab dose escalation|Participants will receive increasing doses of BT7480 and standard dose of nivolumab. It is expected that approximately 12 patients will participate in this dose escalation arm.
62817159|NCT05163041|EXPERIMENTAL|BT7480 monotherapy dose expansion|Participants will receive a selected dose of BT7480. It is expected that approximately 45 patients will participate in this dose expansion arm in Phase 2.
62817160|NCT05163041|EXPERIMENTAL|BT7480 and nivolumab dose expansion|Participants will receive a selected dose of BT7480 and standard dose of nivolumab. It is expected that approximately 45 patients will participate in this dose expansion arm in Phase 2.
62817161|NCT05163041|EXPERIMENTAL|BT7480 monotherapy in patients with renal insufficiency|Participants will receive a selected dose of BT7480. It is expected that approximately 12 patients will participate in this dose confirmation arm.
62817162|NCT02859922|ACTIVE_COMPARATOR|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
62817163|NCT02859922|ACTIVE_COMPARATOR|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
62817164|NCT00383786|EXPERIMENTAL|GR205171|selective neurokinin-1 receptor antagonist, fixed 5 mg dose every day, for 8 weeks.
62817165|NCT00383786|PLACEBO_COMPARATOR|placebo|sugar pill
62817166|NCT02375854||Preterm infants|Less than 32 weeks' gestation
62431562|NCT05016076|ACTIVE_COMPARATOR|Dexamethasone|In the designated patients, 8 mg of dexamethasone or placebo will be given intravenously within 10 minutes after the induction of anesthesia. Anesthesia will be maintained with 2-3 vol% sevoflurane and 60% oxygen in nitrogen, whereas the fraction of inspired oxygen (FiO2) 0.8-1.0 will be used during pneumoperitoneum to ensure oxygen saturation higher than 92%.
62431563|NCT05016076|PLACEBO_COMPARATOR|Placebo (0.9% sodium chloride)|In the designated patients, 8 mg of dexamethasone or placebo will be given intravenously within 10 minutes after the induction of anesthesia. Anesthesia will be maintained with 2-3 vol% sevoflurane and 60% oxygen in nitrogen, whereas the fraction of inspired oxygen (FiO2) 0.8-1.0 will be used during pneumoperitoneum to ensure oxygen saturation higher than 92%.
62598627|NCT00359736|EXPERIMENTAL|Sildenafil|Sildenafil 20 mg tid orally
62598628|NCT00359736|PLACEBO_COMPARATOR|Placebo|Identical Placebo 20 mg tid orally
62598629|NCT03560726|EXPERIMENTAL|Telehealth|Participants randomized into the telehealth arm will receive up to 7 one-hour telehealth visits with the study psychologist. The first six sessions will focus on cognitive behavioral stress management topics and the seventh session is optional, focusing on lung transplant readiness. Participants will fill out questionnaires every other week (baseline, week 2, week 4, week 6, week 8) and during a 3-month follow-up (week 20). Participants will wear an actigraphy watch to track sleep and movement for one week at a time during baseline, week 8, and week 20.
62598630|NCT03560726|NO_INTERVENTION|Treatment-As-Usual (TAU)|"Participants randomized into the TAU arm will not receive any telehealth visits during the 8-week intervention phase. Participants will fill out questionnaires every other week (baseline, week 2, week 4, week 6, week 8) and during a 3-month follow-up (week 20).~Participants will wear an actigraphy watch to track sleep and movement for one week at a time during baseline, week 8, and week 20."
62817167|NCT02910817|EXPERIMENTAL|Metformin-treated group|51 overweight and obese women (BMI\>24) with PCOS underwent their first fresh autologous IVF-embryo transfer cycle
62817168|NCT02910817|PLACEBO_COMPARATOR|Placebo|A cohort of fifty-one cross matched PCOS women
62817169|NCT05862766|EXPERIMENTAL|Peri-transplant desensitization group|Listed and will receive a lung transplant or multi-organ transplant involving a lung at NYU Langone Health that is deemed to require peri-transplant desensitization. Participants will be treated with standard-of-care consisting of plasmaspheresis, IVIG, rituximab and the experimental agent, isatuximab. Patients will be followed with standard-of-care immunologic assessment consisting of weekly DSA assessment and flow cytometry crossmatch (only in the desensitization arm). Additionally, participants will have a bone marrow biopsy with pathologic examination and cell counts performed at the time of transplant and repeated at the 30-day bronchoscopy to assess for plasma cell elimination
62817170|NCT05862766|EXPERIMENTAL|Treatment of antibody-mediated rejection|Received a lung transplant or multi-organ transplant involving a lung at NYU Langone Health. Participants will be treated with standard-of-care consisting of plasmaspheresis, IVIG, rituximab and the experimental agent, isatuximab.
62817171|NCT03317860|SHAM_COMPARATOR|Sham tDCS plus RTP|Single session of bilateral sham parietal cortex tDCS (for 30 minutes) paired with repetitive task-specific practice (RTP)
62241156|NCT03730974|EXPERIMENTAL|Experimental arm BA (TAU + Ball blanket)|Patients that are randomized to the BA sequence receive treatment B (TAU) in the first period and intervention A in the second period (Protac Ball BlanketTM 7kg Flexible).
62241157|NCT05558176|ACTIVE_COMPARATOR|Sildenafil citrate arm|"The same brand of sildenafil citrate (VIAGRA, manufactured by Fareva Amboise Zone Industrielle, 29 route des Industries, 37530 Poce Sur Cisse, France, under authority of Pfizer Inc, NewYork, NAFDAC Reg NO: 04 - 1509, Batch No: 477209; Exp date: 11 - 2024) will be used in the course of the study.~Women will receive the first dose of trial medication after transfer to the birth suite once diagnosed to be in labour with cervical dilatation \< 8 cm. Sildenafil citrate will be given orally as a 50-mg dose 6 hourly to a maximum of 3 doses (150mg). Blood pressure will be monitored 15-30 minutes after each dose. Labour will be monitored with the aid of partograph, appropriate analgesic given in labour. Foetal heart rate monitoring will be performed in all cases by cardiotocograph or intermittent auscultation every fifteen minutes"
62817172|NCT03317860|ACTIVE_COMPARATOR|Active tDCS plus RTP|Single session of bilateral active parietal cortex tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP)
62817173|NCT06706635|EXPERIMENTAL|Full access to a mobile App|Study patients will receive full access to a mobile App
62241158|NCT05558176|PLACEBO_COMPARATOR|Placebo|The placebo will be a vitamin C of the same size, colour and shape with sildenafil (Viagra).
62241159|NCT01581944|NO_INTERVENTION|No Treatment (Control)|Women were randomised to receive no gonadotropin-releasing hormone agonist prior to myomectomy.
62241160|NCT01581944|EXPERIMENTAL|2 Doses Goserelin|Women were randomised to receive 2 doses of 3.6mg of gonadotropin releasing hormone agonist prior to the myomectomy.
62817174|NCT06706635|OTHER|Restricted access to a mobile App|Study patients will receive restricted access to a mobile App
62817175|NCT03084211|NO_INTERVENTION|Control Group|The control group will be instructed to gradually return to activities.
62817176|NCT03084211|EXPERIMENTAL|Prescribed Light Exercise Group|Intervention: Prescribed Light Exercise Group will receive discharge instructions prescribing 30 minutes of light exercise (ie: walking).
62817177|NCT06256185|EXPERIMENTAL|Arm used for predicting lymph node metastasis|
62817178|NCT06706648|NO_INTERVENTION|control group|
62817179|NCT06706648|EXPERIMENTAL|Study Group|Study group who recived Nursing-Led Psychological Capital Interventions
62817180|NCT05531656|ACTIVE_COMPARATOR|CT1812 100 mg|CT1812 at a dose of 100 n=180 group
62817181|NCT05531656|ACTIVE_COMPARATOR|CT1812 200 mg|CT1812 at a dose of 300mg, n=180 group
62241161|NCT01581944|EXPERIMENTAL|3 Doses Goserelin|Women were randomised to receive 3 doses of the gonadotropin-releasing agonist (3.6mg monthly injections).
62241162|NCT05539859|EXPERIMENTAL|Experimental Arm|Endoscopic surgery
62817182|NCT05531656|PLACEBO_COMPARATOR|Placebo|Placebo, n=180 group
62817183|NCT05600543|EXPERIMENTAL|Arm 1: Lumbar belt Lombastab® (Thuasne, Levallois Perret, France)|Low back pain patients wear Lumbar belt Lombastab® during 4 weeks according to the instructions given by the investigator of the study.
62241163|NCT05539859|ACTIVE_COMPARATOR|Control Arm|Medical management
62241164|NCT02298296||No treatment|
62241165|NCT05737290|ACTIVE_COMPARATOR|Group A|
62241166|NCT05737290|ACTIVE_COMPARATOR|Group B|
62241167|NCT01118689|EXPERIMENTAL|MLN0128|
62817184|NCT06031727|EXPERIMENTAL|HG202|
62817185|NCT03433651|EXPERIMENTAL|creatine monohydrate|Experimental will take by mouth 5 grams a day of creatine monohydrate powder. Subjects will be given a 30 day supply of the study powder. They will be reminded to take the powder as instructed.
62817186|NCT03433651|PLACEBO_COMPARATOR|Placebo|Placebo will take by mouth 5 grams a day of placebo powder. Subjects will be given a 30 day supply of the study powder. They will be reminded to take the powder as instructed.
62817187|NCT05414500|EXPERIMENTAL|Cohort|Fixed dose of Mogamulizumab and dose de-escalation with Brentuximab Vedotin
62241168|NCT01054651|EXPERIMENTAL|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
62241169|NCT01054651|ACTIVE_COMPARATOR|Praziquantel|
62241170|NCT04027231||Ahlback I|
62241171|NCT04027231||Ahlback II|
62241172|NCT04027231||Ahlback III|
62241173|NCT04027231||1 year following TKA|
62241174|NCT04027231||TKA revision|
62241175|NCT00654342|OTHER|1|In vivo injection group
62241176|NCT00654342|OTHER|2|Ex vivo injection group
62241177|NCT05104008|ACTIVE_COMPARATOR|Lateral wedge insoles with home exercises group(Group 1)|In this group, participants were advised to use lateral wedge insole during walking and long-standing. Non customized full-length lateral wedge insoles of 7mm made of silicon material with 5 degrees angulation (because greater wedging is associated with foot discomfort) was used. Full-length wedge extends under the lesser metatarsal heads which increases the lever arm for rearfoot eversion and thus can prevent subtalar joint rotation. The evaluations were performed every week till fourth week.
62817188|NCT06124807|EXPERIMENTAL|LY3305677 Dose 1|Participants will receive LY3305677 subcutaneously (SC).
62817189|NCT06124807|EXPERIMENTAL|LY3305677 Dose 2|Participants will receive LY3305677 SC.
62817190|NCT06124807|EXPERIMENTAL|LY3305677 Dose 3|Participants will receive LY3305677 SC.
62817191|NCT06124807|PLACEBO_COMPARATOR|Placebo|Participants will receive LY3305677 matching placebo.
62817192|NCT05198869|OTHER|Spectral scan (All participants)|"1. Fitzpatrick skin assessment.~2. Fingertip scanned using the SpotLight-19 device. The scan is approximately 10-20 seconds. Participants will not feel any sensation from the device, i.e., no heat, no pain, no cold, no vibration or pressure.~3. Information collected from the medical record regarding participant age, COVID-19 vaccination status, presence of COVID-19 symptoms, and PCR test result."
62817193|NCT01277016|NO_INTERVENTION|MDex:|"MDex:~Administration of oral melphalan (M) at 0.22 mg/kg and dexamethasone (Dex) at 40 mg daily for 4 consecutive days every 28 days (MDex) until end of therapy"
62817194|NCT01277016|EXPERIMENTAL|BMDex|"BMDex:~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle."
62817195|NCT04798183||Healthy participants|A healthy person with no history of facial surgery or paralysis.
62817196|NCT04798183||Amyotrophic Lateral Sclerosis with bulbar involvement patients|Amyotrophic lateral sclerosis with no history of facial surgery or paralysis
62817197|NCT03550027|EXPERIMENTAL|PleurX|Positioning of Pleurx drainage during surgical exploration if lung does not reinflate
62817198|NCT03550027|EXPERIMENTAL|Pleurocath|Positioning of Pleur o cath drainage during surgical exploration if lung does not reinflate
62241178|NCT05104008|ACTIVE_COMPARATOR|Traditional physiotherapy with home exercises group (Group 2)|Each participant received 40-45 minutes long session, started in lying position. The therapeutic low-intensity pulsed ultrasound (US) was used for 7 minutes with the frequency of 1 MHz, Spatial Average Intensity was 0.2 W /cm2, pulsed duty cycle 20%, therapeutic dose was 112.5 J/cm2 with fixed application on the medial side of the knee joint. The model of US was Unit Intelect Mobile, (Chattanooga Inc). After US therapy passive stretching of calf, hamstring, quadriceps, hip flexors, adductors \& abductor s was done, which was followed by the manual strengthening exercises and strengthening with quadriceps bench. The session was repeated thrice a week and 12 sessions per month. The home program was guided in both groups including avoiding low sitting, cross leg sitting along with Isometrics of quadriceps atleast 3 times a day, with 5-10 seconds hold of each contraction.
62431564|NCT05016076|ACTIVE_COMPARATOR|Inspiratory pressure (10 cmH2O)|After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
62431565|NCT05016076|ACTIVE_COMPARATOR|Inspiratory pressure (15 cmH2O)|After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
62598631|NCT05960448|EXPERIMENTAL|Transcutaneous Spinal Cord Stimulation|The transcutaneous spinal cord stimulation used in this experiment is specific to each participant as determined in a previous study. Possible parameters include biphasic or monophasic, Russian or Nonrussian, a variety of pulse widths, and location of stimulation (T7-8, T9-10,- T11-12, L1-2). The amplitude of the stimulation also depends on the results of the mapping study. This stimulation will be delivered 30 minutes at a time.
62598632|NCT05960448|SHAM_COMPARATOR|Sham Transcutaneous Spinal Cord Stimulation|The sham stimulation will follow the above parameters but will only be delivered for a minute rather than the full 30 minutes.
62598633|NCT00003829|EXPERIMENTAL|fludarabine + cyclophosphamide|Patients receive alternating courses of fludarabine and cyclophosphamide. Fludarabine is administered IV over 10-30 minutes on days 1-5 of courses 1, 3, and 5. Cyclophosphamide is administered IV over 30-60 minutes on day 1 of courses 2, 4, and 6. Treatment repeats every 4 weeks. Patients achieving clinical complete remission (CCR) after 6 courses of chemotherapy receive 2 additional courses (one course of each drug). Patients achieving partial remission after 6 courses of chemotherapy also receive 2 additional courses. If these patients then achieve CCR, they receive another 2 courses. Patients are followed every 3 months.
62817199|NCT06537817|EXPERIMENTAL|HT-4253|Subjects will participate in 1 of 10 groups and receive single or multiple doses of HT-4253 or matching placebo. In each group 6 subjects will receive HT-4253.
62817200|NCT06537817|PLACEBO_COMPARATOR|Placebo to match HT-4253|Subjects will participate in 1 of 10 groups and receive single or multiple doses of HT-4253 or matching placebo. In each group 2 subjects will receive matching placebo.
62817201|NCT01436149|EXPERIMENTAL|Antidepressant + SPD489|
62817202|NCT01436149|PLACEBO_COMPARATOR|Antidepressant + Placebo|
62817203|NCT01634477||HIV-infected patients group|HIV positive
62241179|NCT03620019|EXPERIMENTAL|Single Arm: Denosumab+ PD-1 Inhibitor|Subjects in this trial will be given denosumab every 4 weeks, starting on day 1 of study treatment. An additional loading dose of denosumab will be administered on day 8. Subjects who started Pembrolizumab (initiated 21 days after the first dose of denosumab is given) will continue to have it administered intravenously (IV) every 3 weeks. New subjects will receive Nivolumab administered intravenously (IV) every 4 weeks (initiated 21 days after the first dose of denosumab is given). Combination therapy will continue as long as subjects benefit from therapy for up to 1 year.
62817204|NCT01634477||HIV-uninfected patients group|HIV negative
62817205|NCT04829292|EXPERIMENTAL|Open treatment|Supportive therapy followed by CBT
62817206|NCT01024517|EXPERIMENTAL|Single oral dose, solution|
62817207|NCT01024517|EXPERIMENTAL|Single oral dose, solid, fasted|
62817208|NCT01024517|EXPERIMENTAL|Single oral dose, solid, fed.|
62817209|NCT02365649|ACTIVE_COMPARATOR|Induction Period ABT-494 Twice Daily Medium/High Dose|Induction Period ABT-494 Twice Daily Medium/High Dose orally dosed twice a day
62817210|NCT02365649|ACTIVE_COMPARATOR|Extension Phase ABT-494 High Dose|Extension Phase ABT-494 High Dose orally dosed twice a day
62817211|NCT02365649|PLACEBO_COMPARATOR|Induction Period Placebo|Induction Period Placebo orally dosed twice a day
62817212|NCT02365649|ACTIVE_COMPARATOR|Induction Period ABT-494 Low Dose|Induction Period ABT-494 Low Dose orally dosed twice a day
62817213|NCT02365649|ACTIVE_COMPARATOR|Induction Period ABT-494 Once Daily Medium/High Dose|Induction Period ABT-494 Once Daily Medium/High Dose orally dosed once a day
62817214|NCT02365649|ACTIVE_COMPARATOR|Extension Phase ABT-494 Low Dose|Extension Phase ABT-494 Low Dose orally dosed twice a day
62817215|NCT02365649|ACTIVE_COMPARATOR|Induction Period ABT-494 High Dose|Induction Period ABT-494 High Dose orally dosed twice a day
62817216|NCT02365649|ACTIVE_COMPARATOR|Induction Period ABT-494 Low/Medium Dose|Induction Period ABT-494 Low/Medium Dose orally dosed twice a day
62817217|NCT02365649|ACTIVE_COMPARATOR|Extension Phase ABT-494 Medium Dose|Extension Phase ABT-494 Medium Dose orally dosed twice a day
62817218|NCT05099302|EXPERIMENTAL|cartoon group|In the research, the group whose fear was tried to be reduced by watching cartoons
62817219|NCT05099302|NO_INTERVENTION|control group|The group whose change in the process was monitored without any intervention in the research
62817220|NCT06705205|EXPERIMENTAL|SAS video full intervention group|Participants view the full SAS video intervention with sound on Day 1.
62598634|NCT00591617|ACTIVE_COMPARATOR|1: MM|Medical Management: group receives medical management from study physician and Suboxone pharmacotherapy
62241180|NCT05699135||Canadian Patients with Advanced Urothelial Carcinoma|Patients with LA/mUC who following 4-6 cycles of platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight intravenously administered over 60 minutes every 2 weeks
62598635|NCT00591617|ACTIVE_COMPARATOR|2: CBT|Cognitive Behavioral Therapy (CBT) group receives CBT, medical management and Suboxone pharmacotherapy
62598636|NCT00591617|ACTIVE_COMPARATOR|3: CM|Contingency Management (CM) group receives CM, medical management, and Suboxone pharmacotherapy
62598637|NCT00591617|ACTIVE_COMPARATOR|4: CBT + CM|Cognitive Behavioral Therapy (CBT) and Contingency Management (CM) group receives CBT, CM, medical management, and Suboxone pharmacotherapy
62598638|NCT03780465|ACTIVE_COMPARATOR|Oral idronoxil|10 male and female subjects randomised to 400 mg active Oral idronoxil suspension or oral placebo suspension (n=8 active; n= 2 placebo).
62598639|NCT03780465|EXPERIMENTAL|NOX66 400 mg|10 male and female subjects randomised to 400 mg active NOX66 (A) suppository or 400 mg active NOX66 (B) suppository or suppository placebo (n=8 active; n= 2 placebo).
62241181|NCT04441112|EXPERIMENTAL|Ketorolac Intraarticular Hip Injection|Patients will receive an intraarticular hip injection with ketorolac.
62241182|NCT04441112|ACTIVE_COMPARATOR|Triamcinolone Intraarticular Hip Injection|Patients will receive an intraarticular hip injection with triamcinolone.
62241183|NCT04441112|EXPERIMENTAL|Ketorolac Intraarticular Knee Injection|Patients will receive an intraarticular knee injection with ketorolac.
62241184|NCT04441112|ACTIVE_COMPARATOR|Triamcinolone Intraarticular Knee Injection|Patients will receive an intraarticular knee injection with triamcinolone.
62241185|NCT01723813|EXPERIMENTAL|Group 1 : peptides + GM-CT-01 IV|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2 plus Galectin-3 inhibitor: GM-CT-01 systemic injections
62241186|NCT01723813|EXPERIMENTAL|Group 2 : peptides + GM-CT-01 IV+PT|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2 plus Galectin-3 inhibitor: GM-CT-01 systemic injections and Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration
62241187|NCT01831830|NO_INTERVENTION|control condition|The control group receives two attention-control calls.
62241188|NCT01831830|EXPERIMENTAL|The Veterans' in-home program|The VIP intervention consists of 8 sessions (up to 6 in the home and 2 phone calls) from an occupational therapist. This is delivered to Veterans and their family members.
62241189|NCT01499953|EXPERIMENTAL|Rivaroxaban|Rivaroxaban for 45 days oral dose: 10 mg OD
62431566|NCT05016076|ACTIVE_COMPARATOR|Inspiratory pressure (20 cmH2O)|After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
62431567|NCT05016076|ACTIVE_COMPARATOR|Inspiratory pressure (25 cmH2O)|After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
62431568|NCT05016076|ACTIVE_COMPARATOR|Video intubating stylet|A tracheal tube (ConvaTec, Berkshire, England, UK) in appropriate sizes is preloaded over the Trachway® video intubating stylet (TVI-4050, Markstein Sichtec Medical Corp, Taichung, Taiwan), which is introduced into oral cavity to visualize the epiglottis and guided to glottis via a monitor after full neuromuscular blockade is achieved.
62431569|NCT05016076|ACTIVE_COMPARATOR|Video laryngoscopy|A tracheal tube is preloaded over a GlideRite® stylet, which is specifically designed to work with GlideScope® video laryngoscope (Verathon Medical, Bothell, WA, USA). GlideScope® blade size 3 (GS-3) or 4 (GS-4) is used in all patients.
62431570|NCT05016076|ACTIVE_COMPARATOR|Direct laryngoscopy|Tracheal tubes are prepared with a hockey stick-shaped stylet, and direct laryngoscopy is performed using a size-3 or -4 Macintosh blade (Rüsch Inc., Duluth, GA, USA).
62431571|NCT05016076|ACTIVE_COMPARATOR|Goal-directed hemodynamic therapy|Subjects of the GDHT group will be managed according to the ERAS algorithm utilizing ProAQT® parameters to maintain the cardiac index ≥ 2.5 l·min-1·m-2.61 In brief, if cardiac index \< 2.5 l·min-1·m-2, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is \< 10%. If cardiac index \< 2.5 l·min-1·m-2 despite the stroke volume variation of ≥ 10% following fluid challenge, continuous intravenous infusion of dopamine 5-10 μg·kg-1·min-1 will be administered. If mean arterial pressure is \< 70 mmHg despite cardiac index ≥ 2.5 l·min-1·m-2, intravenous infusion of norepinephrine 2-10 μg·min-1 will be used.
62431572|NCT05016076|NO_INTERVENTION|Usual care (control)|Subjects allocated to the control group are hemodynamically managed as per anesthesiologist preference. Typically, isolated hypotension (20% decrease in mean arterial pressure below baseline or \< 60 mmHg) is treated by single or consecutive boluses of norepinephrine 5 or 10 μg. If hypotension persists, repeat boluses of ephedrine 4 mg will be administered until mean arterial pressure is above 60 mmHg. If hypotension is accompanied by signs of hypovolemia (urine output \< 0.5 ml·kg-1·hr-1 and/or an increase in heart rate \> 20% above baseline), crystalloid or colloid fluids will be given until urine output and/or heart rate are normalized. If hypotension persists despite volume challenge, norepinephrine will be used.
62431573|NCT06191510||Experimental Group|The aim of this study is to assess the effectiveness of usage of xenogeneic bone intentionally left exposed to the oral environment after immediate implant placement in preserving keratinized mucosa and the alveolar ridge height and width preservation, without compromising the healing process.
62431574|NCT06191510||Control group|The aim of this study is to evaluate whether the use of collagen matrix has benefits when compared to xenogeneic bone intentionally left exposed to the oral environment after immediate implant placement.
62817221|NCT06705205|EXPERIMENTAL|SAS video partial intervention (without sound)|Participants view the partial SAS video intervention without sound on Day 1.
62241190|NCT01499953|ACTIVE_COMPARATOR|Fondaparinux|Fondaparinux for 45 days subcutaneous application: 2,5 mg OD
62241191|NCT01641809|EXPERIMENTAL|Arm 1 GSK1265744 10 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 10 mg + matching placebo + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 10 mg + matching placebo + Rilpivirine 25 mg once daily from Week 24 to Week 96.
62817222|NCT06705205|NO_INTERVENTION|Active Control Group|Participants read written information about addiction prevalence
62817223|NCT06705582|EXPERIMENTAL|Fortified bread|Intervention group will be supplied with fortified bread
62817224|NCT06705582|PLACEBO_COMPARATOR|Unfortified bread|Control arm will receive unfortified bread and dietary advice to incorporate fortified foods that are commonly available on the market in their diet.
62817225|NCT02190526|EXPERIMENTAL|Mesalazine(asacol 800 mg)|patients receive asacol (800 mg/TDS) and a placebo agent similar to amitriptyline (10 mg/HS) for 8 weeks
62817226|NCT02190526|EXPERIMENTAL|Amitriptyline|patients receive amitriptyline (10 mg/HS) and a placebo like asacol (800 mg/ TDS) for 8 weeks
62241192|NCT01641809|EXPERIMENTAL|Arm 2 GSK1265744 30 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 30 mg + matching placebo + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 30 mg + matching placebo + Rilpivirine 25 mg once daily from Week 24 to Week 96.
62241193|NCT01641809|EXPERIMENTAL|Arm 3 GSK1265744 60 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 60 mg + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 60 mg + Rilpivirine 25 mg once daily from Week 24 to Week 96.
62431575|NCT01664494||Capecitabine|Participants will receive capecitabine according to the label text as monotherapy (1250 mg/m\^2 twice daily) or combination therapy (800 to 1000 mg/m\^2 or 1250 mg/m\^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
62241194|NCT01641809|ACTIVE_COMPARATOR|Arm 4 Efavirenz 600 mg|In the Induction Phase and Maintenance Phase subjects will receive oral tablets of Efavirenz 600 mg + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine).
62241195|NCT04399122|ACTIVE_COMPARATOR|Acetaminophen with codeine|codeine 30mg/acetaminophen 325mg Take one to two tablets every 4 to 6 hours as needed for pain for up to 4 days following surgery.
62241196|NCT04399122|ACTIVE_COMPARATOR|Acetaminophen with oxycodone|oxycodone 5mg/acetaminophen 325mg Take one tablet every 4 to 6 hours as needed for pain for up to 4 days following surgery.
62431576|NCT00882986||1|Men with high fitness (above VO2max of 60)
62431577|NCT00882986||2|Men with average fitness (below VO2max of 50)
62241197|NCT03552861|ACTIVE_COMPARATOR|left and right DLPFC active treatment|Intervention: repetitive transcranial stimulation (rTMS) Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface.
62431578|NCT04470622|EXPERIMENTAL|Treatment Group 1|Aprepitant injectable emulsion.
62431579|NCT04470622|PLACEBO_COMPARATOR|Treatment Group 2|Saline placebo.
62431580|NCT05086081||Prasugrel|Reference group
62431581|NCT05086081||Ticagrelor|Exposure group
62431582|NCT00590291||Cases|premature CAD and MI, AVM
62431583|NCT00590291||Controls|No CAD, MI, AVM
62431584|NCT04036383|ACTIVE_COMPARATOR|vestibüler|vestibular exercise training
62431585|NCT04036383|EXPERIMENTAL|balance training|vestibular exercise training+ balance training with computerized balance system
62431586|NCT04036383|EXPERIMENTAL|square-step|vestibular exercise training+ square step exercise
62431587|NCT03341598|ACTIVE_COMPARATOR|CAF+R|First of all, a sterile rubber dam will be placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M- St. Paul, Minnesota, USA), following the manufacturer's instructions. CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures will be placed to stabilize the flap in a coronal position 2 mm above the cementoenamel junction (CEJ), followed by interrupted sutures to close the releasing incisions.
62817227|NCT02190526|PLACEBO_COMPARATOR|placebo group|patients receive placebo like asacol (800 mg/TDS) and placebo similar to amitriptyline (10 mg/HS) for 8 weeks
62817228|NCT05972278|PLACEBO_COMPARATOR|Obicetrapib placebo|identical matching placebo
62817229|NCT05972278|EXPERIMENTAL|Obicetrapib 10 mg|10 mg tablets
62817230|NCT06705127|EXPERIMENTAL|Toripalimab treatment group|"Local radiotherapy: Subjects received stereotactic radiotherapy for the primary breast cancer lesion at 8Gy each time for 3 consecutive days, once a day, 2 weeks before the start of systemic therapy.~Drug A: 240mg intravenous infusion of Toripalimab, once every 3 weeks, the first dosing date was C1D1,followed by the first day of each course for 18 cycles, a total of 1 year.~Drugs B and C: Epirubicin was administered intravenously after the dosage was calculated at 90mg/m2 body surface area, cyclophosphamide was calculated at 600mg/m2 body surface area by intravenous micropump, both drugs were administered every 3 weeks, the first administration date was C1D1, and then the first day of each course was administered for 4 cycles.~Drug D: albumin paclitaxel was given intravenatically at a dose of 125mg/m2 body surface area, once a week, with the first administration date of C5D1, and then on the first day of each course for 12 cycles."
62817231|NCT05823116|ACTIVE_COMPARATOR|Vancomycin continuous infusion|Continuous infusion of Vancomycin
62817232|NCT05823116|ACTIVE_COMPARATOR|Vancomycin intermittent infusion|Intermittent infusion of vancomycin
62819461|NCT06704711|EXPERIMENTAL|Control Group|Only rinse a solution containing a total of 400 caffeine (20 mL, 2% concentration) in the mouth for 20 seconds and receive no exercise treatment.
62038461|NCT05903417|ACTIVE_COMPARATOR|Intrapleural fibrinolytic arm|"t-PA (Alteplase) 5mg and DNase (Pulmozyme)5mg t-PA (Alteplase) that is available in our pharmacy is 50mg ampoule and DNase (Pulmozyme) is 2.5mg per ampoule The number of installation of intrapleural t-PA/DNase depends on the discretion of the treating physician (at least 6 hours apart between each dose). 5mg of Alteplase (t-PA) and 5mg DNase are diluted in each 50ml of 0.9% sodium.~Both medication are administered sequentially which t-PA is first instilled intrapleurally and the chest tube is then clamped for 45 minutes, then unclamped to allow free drainage for 45 minutes. The same procedure is then repeated for DNase. Selection of the timing of treatment and removal of chest tube are depending on the chest physician's judgement."
62241198|NCT03552861|ACTIVE_COMPARATOR|left DLPFC active and right DLPFC sham treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
62038462|NCT03078348|ACTIVE_COMPARATOR|Targeted Psychoeducational Photo Novella|"Fecal Immunochemical Test (FIT) Kit + Culturally targeted Photo Novella Booklet + culturally targeted reminders. This study involves participation at distinct time points:~1. Baseline~2. 6 month follow-up"
62038463|NCT03078348|ACTIVE_COMPARATOR|Standard Brochure Intervention|"FIT Kit + Screen for Life Brochure + standard reminders. This study involves participation at distinct time points:~1. Baseline~2. Post 6 month follow-up"
62038464|NCT06580262||Patients suspected of severe trauma treated in the emergency departments|Patients suspected of severe trauma defined as trauma likely to have caused multiple injuries and/or threatening the vital or functional prognosis.
62038465|NCT03902704|EXPERIMENTAL|Cleverscope|Cleverscope is a new videolaryngoscope used for tracheal intubation. in this group we use this device to intubate participants.
62038466|NCT03902704|ACTIVE_COMPARATOR|Laryngoscope / Videolaryngoscope C-MAC® Storz|in this group we use a standart comercial device for intubation (laryngoscope or C-MAC) to intubate participants
62038467|NCT04204629|EXPERIMENTAL|Sequence 1|Period 1: Fasted state + HIP1601 Period 2: Fed state + HIP1601
62038468|NCT04204629|EXPERIMENTAL|Sequence 2|Period 1: Fed state + HIP1601 Period 2: Fasted state + HIP1601
62038469|NCT06598306|EXPERIMENTAL|Part 1 Dose Exploration|Tarlatamab will be administered as a SC injection in Part 1.
62038470|NCT06598306|EXPERIMENTAL|Part 2 Dose Expansion|Following the selection of a SC dosing regimen in Part 1, tarlatamab will be administered in Part 2 at the dose deemed safe and tolerable in Part 1.
62038471|NCT00695669|EXPERIMENTAL|Influenza A (H5N1) 1 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm.
62038472|NCT00695669|EXPERIMENTAL|Influenza A (H5N1) 2 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 14. The vaccine was administered intramuscularly in the deltoid region of the arm.
62038473|NCT00695669|EXPERIMENTAL|Influenza A (H5N1) 3 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 7. The vaccine was administered intramuscularly in the deltoid region of the arm.
62038474|NCT00695669|EXPERIMENTAL|Influenza A (H5N1) 4 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0. The vaccine was administered intramuscularly in the deltoid region of the arm.
62241199|NCT03552861|ACTIVE_COMPARATOR|left DLPFC sham and right DLPFC active treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
62431588|NCT03341598|EXPERIMENTAL|CAF+R+MC|First of all, a sterile rubber dam will be placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M - St. Paul, Minnesota, USA), following the manufacturer's instructions. CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous collagen matrix graft (Geistlich) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
62431589|NCT02869932|OTHER|Atypical and classic cystic fibrosis|Lung CT scan without injection
62431590|NCT00700869|EXPERIMENTAL|1|Tracheal tube withdrawal governs by respiratory behaviour status
62817233|NCT06204965|EXPERIMENTAL|Time-restricted eating group (TRE group)|Participants assigned to the TRE group will be instructed to continue eating their usual diet during the experiment (without any qualitative or quantitative restrictions), but to eat it within a limited time frame - from 9:00 a.m. to 5:00 p.m., and then fast until the next day ( protocol 8/16).
62817234|NCT06204965|NO_INTERVENTION|Non-fasting group|Participants assigned to the control group will receive only dietary recommendations consistent with the healthy eating plate. Additionally, the recommended energy intake will be individually determined for each patient using the PPM (calculated using the Harris-Benedict formula) multiplied by the physical activity factor.
62817235|NCT03710187|EXPERIMENTAL|Combination|Hydrocortisone 50 mg IV Q6h plus Fludrocortisone 50 mcg PO/PFT Q24h
62817236|NCT03710187|ACTIVE_COMPARATOR|Hydrocortisone only|Hydrocortisone 50 mg IV Q6h
62817237|NCT02991469|EXPERIMENTAL|Sarilumab|Participants will receive one of two ascending doses (or an additional intermediate dose based on available data) of sarilumab by subcutaneous (SC) injection based on body weight. All the participants will receive the selected dose once the selected dose is identified. Sarilumab will be given during 12-week core treatment phase followed by a 144- week extension treatment phase.
62817238|NCT05975827|EXPERIMENTAL|Sterile Wound Care Liquid Dressing|
62817239|NCT05975827|NO_INTERVENTION|Control|
62817240|NCT06108232|EXPERIMENTAL|Obinutuzumab+CC-99282|"Participants will receive obinutuzumab and CC-99282 together for up to 12 study cycles. Each study cycle is 28 days.~Participants will first receive the study drugs for Cycles 1-6. Then after participants complete Cycle 6, the study doctor will decide based on the status of the disease if participant will continue to receive the study drugs for Cycles 7-12 or if participant will stop receiving them."
62817241|NCT02064803|ACTIVE_COMPARATOR|Control group: A|Gastro-entero anastomosis only
62817242|NCT02064803|EXPERIMENTAL|Experimental: B|Gastric partitioning Plus Gastro-entero anastomosis
62431591|NCT05725707|ACTIVE_COMPARATOR|Face to face Friendship Group|8-week face-to-face peer-led intervention to support their mental health
62598640|NCT03780465|EXPERIMENTAL|NOX66 600 mg|10 male and female subjects randomised to 600 mg active NOX66 (A) suppository or 600 mg active NOX66 (B) suppository or suppository placebo (n=8 active; n= 2 placebo).
62431592|NCT05725707|ACTIVE_COMPARATOR|Online Friendship Group|8 week online peer-led intervention to support their mental health
62817243|NCT04223115|EXPERIMENTAL|Digitalized CBT intervention with phone coaching|Participants receive weekly sessions of internet-based CBT, including telephone coaching
62817244|NCT04223115|ACTIVE_COMPARATOR|Psychoeducation about depression|Participants receive psychoeducative material about depression in digitalized form.
62817245|NCT00279318||General Population, First Degree Relative|Newborns with high risk HLA in the general population or having a first-degree relative affected with T1DM.
62817246|NCT05906953|EXPERIMENTAL|HG004|
62817247|NCT05681546||Observational Group|The investigators are going to observe the risk factors about inferior alveolar nerve block anesthesia.
62817248|NCT05894369||Neoadjuvant chemotherapy combi|
62817249|NCT04590274|EXPERIMENTAL|Regimen|0-400 mg Hydroxychloroquine 0-500 mg Azithromycin 0-50 mg elemental Zinc 0-3,000 mg Vitamin C 0-5,000 IU Vitamin D3 0-1200 mg N-acetylcysteine 0-600 mg Elderberry 0-600 mg Quercetin
62817250|NCT04419025|ACTIVE_COMPARATOR|NAC|Patients receiving N-acetylcysteine (NAC)
62817251|NCT04419025|NO_INTERVENTION|Control|Patients not receiving N-acetylcysteine (NAC)
62817252|NCT03305614|ACTIVE_COMPARATOR|Aphasia therapy and tDCS|combined tDCS and aphasia therapy and the effect of conventional intensive aphasia
62817253|NCT03305614|SHAM_COMPARATOR|Aphasia therapy and sham-tDCS|computer-based intensive aphasia therapy as measured by specific linguistic tests
62817254|NCT06413576||normal pregnancy|Normotensive age- matched pregnant controls
62817255|NCT06413576||preeclampsia|pre-eclampsia patients who are managed in ward (not critical)
62431593|NCT00932958||All comers >18 yrs old|This study is observational, studying patients who are already scheduled to undergo CCTA. Minors and those unable to consent to the study are excluded.
62431594|NCT03334916|EXPERIMENTAL|YMC026|108 subjects will be assigned in this group. They will be administered 20mL of YMC026 three times a day for 6 days.
62431595|NCT03334916|PLACEBO_COMPARATOR|Placebo|108 subjects will be assigned in this group. They will be administered 20mL of placebo three times a day for 6 days.
62817256|NCT06413576||critically ill preeclampsia|pre-eclampsia patients who are admitted to intensive care unit due to severity or complications
62817257|NCT00317980|EXPERIMENTAL|Low dose|Meglumine antimoniate 5 mg/kg/d for 20 days
62817258|NCT00317980|ACTIVE_COMPARATOR|Standard dose|Meglumine antimoniate 15 mg/kg/d for 20 days
62817259|NCT05673928|EXPERIMENTAL|Tucatinib and Adotrastuzumab Emtansine (T-DM1)|"Each study cycle is 21 days (3 weeks)~Participants will take tablets of tucatinib two (2) times a day, about 8-12 hours apart. Participants will receive T-DM1 by vein over about 30 minutes on Day 1 of each cycle"
62598641|NCT02533557|EXPERIMENTAL|2P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced at the behind site of the initial puncture site. And the needle is penetrated the nerve sheath with a direction of upward, and then the same process is performed and LA 15 mL is injected.
62598642|NCT02533557|ACTIVE_COMPARATOR|1P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced with a direction of upward at the same puncture site and penetrated the nerve sheath. If hand muscle twitching is observed at 0.3 mA, LA 15 mL is injected.
62817260|NCT06399900|EXPERIMENTAL|Far red light therapy + home-based walking exercise|Subgroup of participants receiving home-based walking exercise and the 670 nm far red light device
62817261|NCT06399900|SHAM_COMPARATOR|Sham therapy + home-based walking exercise|Subgroup of participants receiving home-based walking exercise and the sham light device, far red light device covered with blue filter paper to block 670 nm light, resulting in mean power generated of 0.24 mW/cm2, compared to 26.3 mW/cm2 for the intervention, a 100-fold difference.
62817262|NCT04337177|EXPERIMENTAL|90 mg/m2/day VAL-413 (Orotecan®)|Orotecan® at 90 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as Orotecan® for during Cycle 1.
62431596|NCT05530642|EXPERIMENTAL|Emotional Resilience Skills Training (ERST)|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) is an evidence-based cognitive-behavioral intervention designed to cultivate constructive approach-oriented emotional engagement. The 13-week Emotional Resilience Training (ERST) is an adaptation of the UP designed for use as a proactive training course. The ERST frames emotional experiences as natural responses to threat, rather than pathological occurrences to avoid; as such, the ERST is well-suited for mitigating health challenges and the skills may also help PSP to support persons in distress, including other PSP and the community members they all serve. The ERST training materials include an instructor guide, didactic PowerPoints, and a trainee workbook.
62431597|NCT00371488|EXPERIMENTAL|GW572016 in combination with trastuzumab|"Lapatinib:~A specified dose of lapatinib will be orally taken once daily, at least one hour before or one hour after the morning meal. Lapatinib should be taken at the same time of day wherever possible.~The starting dose of lapatinib should be 750 mg/day, which will be increased to 1000 mg/day (dose escalation group) according to the dose escalation criteria.~Trastuzumab:~Trastuzumab (4 mg/kg/day in the first week and 2 mg/kg/day for the 2nd and subsequent weeks) will be administered by intravenous infusion over at least 90 minutes immediately after administration of lapatinib. The fifth (Day 36) and subsequent doses may be administered up to 3 days after the scheduled date. In this case, however, the all following doses should be administered at one-week intervals."
62431598|NCT02556632|EXPERIMENTAL|Arm I (curcumin-based gel)|Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
62431599|NCT02556632|EXPERIMENTAL|Arm II (HPR Plus)|Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
62431600|NCT02556632|PLACEBO_COMPARATOR|Arm III (placebo gel)|Patients apply placebo gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
62431601|NCT04412876|EXPERIMENTAL|Duloxetine|Receive Duloxetine 30 mg treatment per day
62431602|NCT04412876|ACTIVE_COMPARATOR|Imipramine|Receive Imipramine 25 mg treatment per day
62598643|NCT04448067|EXPERIMENTAL|LOW Lentil Intake|Consumption of meals containing 60 g of lentils 5 out of 7 days per week for 8 weeks.
62598644|NCT04448067|EXPERIMENTAL|HIGH Lentil Intake|Consumption of meals containing 120 g of lentils 5 out of 7 days per week for 8 weeks
62598645|NCT04448067|SHAM_COMPARATOR|CONTROL|Consumption of meals matched in total energy and protein to the lentil meals but containing 0 g of lentils 5 out 7 days per week for 8 weeks
62598646|NCT06362018|ACTIVE_COMPARATOR|Formulation A|
62598647|NCT06362018|EXPERIMENTAL|Formulation B|
62598648|NCT06362018|EXPERIMENTAL|Formulation C|
62598649|NCT04001894|EXPERIMENTAL|Ticagrelor|To observe the safety and efficacy of standard-dose ticagrelor in Chinese patients with Stable Coronary Artery Disease
62598650|NCT04001894|ACTIVE_COMPARATOR|Clopidogrel|To observe the safety and efficacy of standard-dose clopidogrel in Chinese patients with Stable Coronary Artery Disease
62598651|NCT05617638|NO_INTERVENTION|Control Group|The control group will not have access to VR.
62598652|NCT05617638|ACTIVE_COMPARATOR|Intervention Group|Participants in the intervention group will use VR for 20 minutes for 2 consecutive days.
62817263|NCT04337177|EXPERIMENTAL|110 mg/m2/day VAL-413 (Orotecan®)|Orotecan® at 110 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as Orotecan® for during Cycle 1.
62817264|NCT04337177|EXPERIMENTAL|75 mg/m2/day VAL-413 (Orotecan®)|In the event the 90 mg/m2/day starting dose is not tolerable due to toxicity, a lower starting dose of 75 mg/m2/day may be implemented. Orotecan® at 75 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as Orotecan® for during Cycle 1.
62598653|NCT03543098|EXPERIMENTAL|Early Surgery & Early Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to early surgery and early rehabilitation.
62598654|NCT03543098|EXPERIMENTAL|Early Surgery & Delayed Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to early surgery and delayed rehabilitation.
62038475|NCT05847426|EXPERIMENTAL|Provision of standard audiological + fNIRS test results|"The treatment arm involves the provision of additional fNIRS sound detection and speech discrimination test results to the audiologists, in addition to standard audiology information. Standard information includes:~1. At diagnosis: unaided Auditory Brainstem Response results;~2. After initial hearing aid provision: as a) above plus aided Cortical Evoked Potentials;~3. After hearing aid program is adjusted to satisfaction: as b) above plus parent observational report, PEACH (2);~4. After initial cochlear implant programming: behavioural observations."
62038476|NCT05847426|ACTIVE_COMPARATOR|Provision of standard audiological test results only|"The standard audiology information available to the audiologists includes:~1. At diagnosis: unaided Auditory Brainstem Response results;~2. After initial hearing aid provision: as a) above plus aided Cortical Evoked Potentials;~3. After hearing aid program is adjusted to satisfaction: as b) above plus parent observational report, PEACH (2);~4. After initial cochlear implant programming: behavioural observations."
62598655|NCT03543098|EXPERIMENTAL|Delayed Surgery & Early Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to delayed surgery and early rehabilitation.
62598656|NCT03543098|EXPERIMENTAL|Delayed Surgery & Delayed Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to delayed surgery and delayed rehabilitation.
62598657|NCT03543098|EXPERIMENTAL|Early Rehab Only|Individuals not eligible for randomization to timing of surgery will be randomized to only early rehabilitation.
62598658|NCT03543098|EXPERIMENTAL|Delayed Rehab Only|Individuals not eligible for randomization to timing of surgery will be randomized to only delayed rehabilitation.
62598659|NCT06619548|EXPERIMENTAL|Group A|The participants will have auricular magnets with a strength of 1800 Gauss applied to specific acupoints in the first treatment phase. This is followed by a 14-day washout period. In the second treatment phase, the participants will have auricular magnets with no magnetic strength applied to the same acupoints.
62598660|NCT06619548|PLACEBO_COMPARATOR|Group B|The participants will have auricular magnets with no magnetic strength applied to specific acupoints in the first treatment phase. This is followed by a 14-day washout period. In the second treatment phase, the participants will have auricular magnets with a strength of 1800 Gauss applied to the same acupoints.
62598661|NCT04571970|EXPERIMENTAL|Single Arm|6.5 × 10\^10 GC/g brain mass of RGX-121
62038477|NCT00726726|OTHER|A|
62598662|NCT00916968|ACTIVE_COMPARATOR|Standard CR-Flex|
62038478|NCT00726726|EXPERIMENTAL|B|
62038479|NCT00726726|EXPERIMENTAL|C|+ Other
62598663|NCT00916968|EXPERIMENTAL|Gender specific CR-Flex|
62598664|NCT04291664|EXPERIMENTAL|Prostate Cancer|
62038480|NCT03606330||VP-SG 01|Study subjects that present MACE at the 36 months follow-up
62038481|NCT03606330||VP-SG 02|Study subjects that do not present MACE at the 36 months follow-up
62598665|NCT05294159||Clinic-based PLH on CAB+RPV LA|All PWH participants will begin injections in the clinic setting in Phase 1. During Phase 1, PWH participants are screened and consented to participate in the study. During the screening phase, potential participants will be asked to identify their preferred location for phase 2 (decentralised site) and the reason for their preference. At the time of consent, patients will select their injection setting for Phase 2. Patients can select their preferred choice of setting until the 50 in-clinic numbers and 100 decentralised site places have been reached. After this, PWH participants will be allocated to the setting yet to reach its cap. In Phase 2, PWH participants will either continue to receive injection in clinic or receive injections from community nurses or clinic nurses at decentralised sites.
62817265|NCT06699927|ACTIVE_COMPARATOR|Non-gamified First|Training type 1 will be administered in the first part of the crossover trial and Training type 2 will be administered in the second part of the trial. Each training part consists of 20 twenty-minute long sessions with the recommended frequency of 2 sessions per work day. Thus each training part can be completed in 10 work days (2 weeks).
62038482|NCT05029765|PLACEBO_COMPARATOR|Healthy diet Arm|Healthy diet (WHO recommendations) + placebo
62038483|NCT05029765|PLACEBO_COMPARATOR|Mediterranean diet Arm|Mediterranean diet + placebo
62038484|NCT05029765|ACTIVE_COMPARATOR|"Mediterranean diet plus Arm"|Mediterranean diet + Biopolis-MIX42 (1 capsule per day containing 10\^9 colony forming units of Lactobacillus rhamnosus and Bifidobacterium long).
62038485|NCT02156583||Older, left ventricular assist device|Older heart failure patients undergoing left ventricular assist device implantation
62038486|NCT03873948||Control|Healthy patients
62038487|NCT03873948||Periodontitis|Patients with periodontal disease
62038488|NCT03873948||Cardiovascular|Patients with cardiovascular disease
62038489|NCT03873948||Periodontitis+Cardiovascular|Patients with both periodontal and cardiovascular disease
62038490|NCT06141811||ALLO-ASC-DFU|Subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial of ALLO-ASC-DFU-302
62038491|NCT06141811||Vehicle sheet|Subjects with Vehicle sheet treatment in phase 3 clinical trial of ALLO-ASC-DFU-302
62038492|NCT02274714||Case (with IBD)|Women aged 18-48 years with regular menstrual cycles AND with an established diagnosis of CD or UC involving the small bowel, colon or both
62598666|NCT05294159||Community-based PLH on CAB+RPV LA|All PWH participants will begin injections in the clinic setting in Phase 1. During Phase 1, PWH participants are screened and consented to participate in the study. During the screening phase, potential participants will be asked to identify their preferred location for phase 2 (decentralised site) and the reason for their preference. At the time of consent, patients will select their injection setting for Phase 2. Patients can select their preferred choice of setting until the 50 in-clinic numbers and 100 decentralised site places have been reached. After this, PWH participants will be allocated to the setting yet to reach its cap. In Phase 2, PWH participants will either continue to receive injection in clinic or receive injections from community nurses or clinic nurses at decentralised sites.
62598667|NCT03756727|EXPERIMENTAL|Ascorbic acid group|the patients received 2g of intravenous Ascorbic acid at the night before surgery, during the surgery and five days after surgery.
62241200|NCT03552861|SHAM_COMPARATOR|left DLPFC sham and right DLPFC sham treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks,the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
62598668|NCT03756727|PLACEBO_COMPARATOR|Control comparator group|the patients received 10ml saline at the night before surgery, during the surgery and five days after surgery.
62598669|NCT04432090|EXPERIMENTAL|MBX-2982 first then placebo- Volunteers with Type 1 diabetes|Participants with type 1 diabetes (T1D) will be randomized to either study medication or placebo group. In this arm, participants will receive a pill that contains the study medication (MBX-2982). This will be followed by a wash-out period and a cross over to the second study period in which they will receive a pill that does not contain the medication (placebo).
62598670|NCT04432090|ACTIVE_COMPARATOR|Healthy Volunteers|This group will not receive any medication. It will be studied to establish the norm of the measurement that will be performed to obtain the study outcomes.
62598671|NCT04432090|EXPERIMENTAL|Placebo first then MBX-2982- Volunteers with Type 1 diabetes|Participants with type 1 diabetes (T1D) will be randomized to either study medication or placebo group. In this arm, participants will receive a pill that does not contain the medication (placebo). This will be followed by a wash-out period and a cross over to the second study period in which they will receive a pill that contains the study medication (MBX-2982).
62598672|NCT00591058|EXPERIMENTAL|Cohort 1|0.04 mg/kg TM-601 dose per administration
62598673|NCT00591058|EXPERIMENTAL|Cohort 2|0.08 mg/kg TM-601 dose per administration
62598674|NCT00591058|EXPERIMENTAL|Cohort 3|0.16 mg/kg TM-601 dose per administration
62598675|NCT00591058|EXPERIMENTAL|Cohort 4|0.3 mg/kg TM-601 dose per administration
62598676|NCT00591058|EXPERIMENTAL|Cohort 5|0.6 mg/kg TM-601 dose per administration
62598677|NCT00591058|EXPERIMENTAL|Cohort 6|1.2 mg/kg TM-601 dose per administration
62598678|NCT06619145|NO_INTERVENTION|Remifentanil|
62598679|NCT06619145|EXPERIMENTAL|High dose Oliceridine|High dose Oliceridine
62598680|NCT06619145|EXPERIMENTAL|Low dose Oliceridine|Low dose Oliceridine
62817266|NCT06699927|ACTIVE_COMPARATOR|Gamified First|Training type 2 will be administered in the first part of the crossover trial and Training type 1 will be administered in the second part of the trial. Each training part consists of 20 twenty-minute long sessions with the recommended frequency of 2 sessions per work day. Thus each training part can be completed in 10 work days (2 weeks).
62817267|NCT00754663|ACTIVE_COMPARATOR|1|exercise training
62598681|NCT04535050|EXPERIMENTAL|DENEX Renal denervation|Subjects are treated with the renal denervation procedure after randomization
62598682|NCT04535050|SHAM_COMPARATOR|Sham control|Subjects are treated with renal angiography
62598683|NCT03363451||Infection Group|Patients with end stage liver disease with infection
62598684|NCT03363451||Non-infection Group|Patients with end stage liver disease without infection
62817268|NCT00754663|PLACEBO_COMPARATOR|2|control arm: normal behavior, no additional exercise will be advised
62817269|NCT06705660|ACTIVE_COMPARATOR|WEB-based lifestyle interventions|The web-based lifestyle interventions will be administered to women by monitoring their menstrual cycles for 8 weeks, with sessions held twice a week for 30-45 minutes each (totaling 16 sessions). Measurements will be taken both before the intervention and after its completion. An additional measurement will be conducted during the following menstrual cycle, 4 weeks later, to ensure follow-up.In this study, telehealth and counseling services will be provided. Through telehealth and counseling, women will have the opportunity to communicate online with healthcare professionals and receive guidance on health goals, nutrition, exercise, and stress management
62817270|NCT06705660|NO_INTERVENTION|Control Group|The third group will serve as the control group and will not receive any training.
62598685|NCT05957536|EXPERIMENTAL|D3L-001|"Part 1 Dose Escalation in subjects with HER2-positive advanced solid tumors~* Cohort 1 (starting dose)~* Cohort 2~* Cohort 3~* Cohort 4~* Cohort 5~Part 2 Dose Expansion~* Cohort A for subjects with HER2-positive advanced breast cancer~* Cohort B for subjects with HER2-positive advanced gastric cancer/gastroesophageal junction cancer"
62598686|NCT04999306|EXPERIMENTAL|Hypnosis group|"the sessions will be conducted following the same dynamics and the same exercises (safe place, reification, anchoring): introduction of the session (conversational hypnosis in order to probe the patient's perceptions of his or her illness and fatigue, discussion of myths and realities); induction with the creation of a safe place that will be used for each session; visualization; deepening of the trance with work on metaphors (reification technique); making specific suggestions on sensations of fatigue, on regaining energy; then instruction for self-hypnosis or anchoring."
62735662|NCT04242628|EXPERIMENTAL|Lifestyle course|T2 study members attended 5 interactive 90-min meetings on lifestyle education and brain functioning in older people. These meetings covered the following topics regarding good habits for wellbeing at older age: nutrition, brain ageing, physical activity, leisure activities, resources of the city for older people. A goodbye tea was offered after the meetings.
62241201|NCT00028821|EXPERIMENTAL|Treatment (2-methoxyestradiol)|Patients receive oral 2-methoxyestradiol (2-ME) once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62598687|NCT04999306|EXPERIMENTAL|CBT group|"This program will work specifically on the psychosocial determinants of fatigue.~The first session will be patient education on cancer-related fatigue. S2 will address the concept of perceived control and allow the patient to understand what factors accentuate this condition. S3 will allow the patient to work on the emotions associated with cancer and will be complemented by a hypnosis audio. S4 will address the notion of social support and how the patient can learn to delegate or ask for help. S5 will address the notion of coping strategies, the patient will then be able to identify what he/she puts in place, what is productive and what is not. Finally, the S6 will be a synthesis session that will allow to come back to the points that deserve to be deepened."
62598688|NCT04694950||Group feasibility|Adults undergoing elective urologic laparoscopic robotic surgery.
62241202|NCT05047783|EXPERIMENTAL|Masitinib 3.0 mg/kg/day|Masitinib 3.0 mg/kg/day for 10 days versus corresponding placebo (all patients will receive Best Supportive Care)
62241203|NCT05047783|EXPERIMENTAL|Masitinib 4.5 mg/kg/day|Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 8 days versus corresponding placebo (all patients will receive Best Supportive Care)
62241204|NCT05047783|EXPERIMENTAL|Masitinib 6.0 mg/kg/day|Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 2 days then 6.0 mg/kg/day for 6 days versus corresponding placebo (all patients will receive Best Supportive Care)
62241205|NCT05047783|PLACEBO_COMPARATOR|Placebo|Placebo arms associated with the three Experimental arms (all patients will receive Best Supportive Care) which will be pooled for analysis
62241206|NCT06274671||Clinically Isolated Syndrome|Patients with a diagnosis of Clinically Isolated Syndrome
62241207|NCT06274671||Healthy Controls|Age- and gender-matched healthy controls.
62241208|NCT04769453|ACTIVE_COMPARATOR|iTrack canaloplasty microcatheter with Healon GV Pro|Patients will be randomized to the iTrack microcatheter (canaloplasty) with Healon GV Pro (ophthalmic viscoelastic device)
62431603|NCT03287479|EXPERIMENTAL|Gavi®|surplus or all fertilized oocytes will be cryoperserved by utilizing the closed, semi-automated Gavi® vitrification system
62431604|NCT03287479|ACTIVE_COMPARATOR|Cryotop®|surplus or all fertilized oocytes will be cryoperserved by utilizing the open, manual Cryotop® vitrification system
62431605|NCT00700310|ACTIVE_COMPARATOR|1|
62431606|NCT00700310|ACTIVE_COMPARATOR|2|
62598689|NCT05093530|EXPERIMENTAL|Neumifil|"Neumifil will be administered intranasally using an Aptar delivery system. Each dose will consist of 0.5ml to each nostril, with adjusted concentrations of solution to enable dose ranging. Participants in Part A will receive a single dose of Neumifil and participants in Part B will receive once daily doses of Neumifil for 7 days according to the randomization.~Ascending single doses for Part A are anticipated to be 0.028mg (group A1), 0.085mg (group A2), 0.28mg (group A3), 0.885mg (group A4) and 2.8mg (group A5). Two further groups of up to 9 subjects may be investigated. The planned dose levels may change following review of the safety and tolerability of previous doses. The maximum dose will not exceed 2.8mg.~The starting dose level (dose and dose regimen) in Part B will be determined following review of the safety and tolerability of at least 3 dose levels in part A and subsequent dose levels will be determined following review of the safety and tolerability of previous doses."
62735663|NCT04242628|NO_INTERVENTION|Waiting list|Throughout the duration of the intervention, we put C study members on a waiting list; at the end of the intervention, in June 2019, interested group C study members attended the SNSs course (held on June 2019).
62431607|NCT00700310|ACTIVE_COMPARATOR|3|
62819462|NCT00492999|EXPERIMENTAL|Group 1|Patients receive hepatic arterial infusion (HAI) therapy comprising floxuridine and dexamethasone continuously on days 1-14. Patients also receive oxaliplatin IV over 2 hours and irinotecan hydrochloride IV over 30 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62819463|NCT00492999|EXPERIMENTAL|Group 2|Patients receive HAI therapy as in group 1. Patients also receive irinotecan hydrochloride IV over 30 minutes and leucovorin calcium IV over 30 minutes on days 1 and 15 and fluorouracil IV continuously over 48 hours on days 1, 2, 15, and 16. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62819464|NCT06704178|EXPERIMENTAL|Intervention Arm|Participants in this arm will take NuBest Tall Growth Protein Powder daily for 6 months.
62431608|NCT00700310|PLACEBO_COMPARATOR|4|
62431609|NCT03235583|OTHER|MotionPod Validation|Medical device validation
62431610|NCT04401787|ACTIVE_COMPARATOR|laparoscopic anterior resection (LAR)|LAR group included 88 patients, 17 patients converted to open
62431611|NCT04401787|ACTIVE_COMPARATOR|open anterior resection|Open anterior resection for 56 patients
62431612|NCT02205866|ACTIVE_COMPARATOR|Group A|Non Obese patients
62038493|NCT02274714||Control (without IBD)|Women aged 18-48 years with regular menstrual cycles and without a diagnosis of CD will qualify for the study
62241209|NCT04769453|ACTIVE_COMPARATOR|OMNI surgical system with Healon GV Pro|Patients will be randomized to the OMNI surgical system (canaloplasty) with Healon GV Pro (ophthalmic viscoelastic device)
62241210|NCT04769453|ACTIVE_COMPARATOR|iTrack canaloplasty microcatheter with Healon Pro|Patients will be randomized to the iTrack microcatheter (canaloplasty) with Healon Pro (ophthalmic viscoelastic device)
62241211|NCT04769453|ACTIVE_COMPARATOR|OMNI surgical system with Healon Pro|Patients will be randomized to the OMNI surgical system (canaloplasty) with Healon Pro (ophthalmic viscoelastic device)
62241212|NCT00737919|ACTIVE_COMPARATOR|1|A group of subjects consuming daily 2 grams of plant stanols 4-6 weeks before the operation
62241213|NCT00737919|ACTIVE_COMPARATOR|2|A group of patients consuming daily 2 grams of plant sterols 4-6 weeks before the operation
62241214|NCT02838069|EXPERIMENTAL|2x106 ASC intra-articular injection|Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
62431613|NCT02205866|EXPERIMENTAL|Group B|Obese patients
62431614|NCT05998733||sepsis group|diagnostic sepsis；age\>18；Time from clinical symptoms to admission ≤ 7 days； It also meets the following two criteria: ① clinical infection② Sequential Organ Failure Assessment (SOFA) score ≥ 2 points at admission
62598690|NCT05093530|PLACEBO_COMPARATOR|Placebo|Placebo will be administered intranasally using an Aptar deliver system. Each dose will consist of 0.5ml to each nostril. Participants in Part A will receive a single dose of placebo according to the randomization and participants in Part B will receive once daily doses of placebo for 7 days according to the randomization schedule.
62598691|NCT02223650|EXPERIMENTAL|Overminus Treatment|2.50D overminus spectacles
62819465|NCT06704178|PLACEBO_COMPARATOR|Placebo Arm|Participants in this arm will take a placebo product daily for 6 months.
62038494|NCT05614102|EXPERIMENTAL|Dose escalation of BAY2965501|For escalation part, different dose levels of BAY2965501 are planned.
62241215|NCT02838069|EXPERIMENTAL|10x106 ASC intra-articular injection|Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
62241216|NCT02838069|PLACEBO_COMPARATOR|Placebo|0.5% glucose in saline with 4.5% albumin
62241217|NCT05276557|EXPERIMENTAL|Indication for H. pylori testing|Walk in basis: Symptomatic patients of H. pylori infection will be enrolled for this study if all acceptance criteria are met. Patients will undergo C13 Urea Breath Test (a single dose of 13C urea at 75mg in powder form, to be dissolved in potable water as the kit indicates) in addition to stool antigen test comparison.
62241218|NCT03580772||Persona TKR|Patients will have undergone a medial congruent Persona total knee replacement
62241219|NCT03580772||Attune TKR|Patients will have undergone a Attune total knee replacement
62241220|NCT03580772||Control participants|Patients will not have recieved a primary TKR
62431615|NCT05998733||non-sepsis group|diagnostic sepsis；age\>18；Time from clinical symptoms to admission ≤ 7 days； It also meets the following two criteria: ① clinical infection②Systemic inflammatory response syndrome(SIRS)，SIRS was defined as the presence of 2 or more of the following: (1) temperature \<36℃or \>38℃, (2) heart rate \>90 beats per minute, (3) respiratory rate \>20 breaths per minute or PaCO2 \< 32 mm Hg, or (4) white blood cell count ≥12 000 cells/mm3 or≤4000 cells/mm
62431616|NCT02807324||Controls|Controls are women (18 years or older) with an uncomplicated pregnancy (i.e no foetal or maternal placental complications, such as pregnancy induced hypertension, preeclampsia or HELLP-syndrome, or small for gestational birth infancies)
62431617|NCT02807324||Early PE with IUGR|These cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE \< 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
62598692|NCT02223650|ACTIVE_COMPARATOR|Non-overminus Treatment|spectacles without overminus or no spectacles
62598693|NCT06512935|EXPERIMENTAL|cardiac hemodynamics and respiratory status assessment with increasing PEEP|"Infants will be randomized to the order of changes in PEEP levels during mechanical ventilation - increase followed by decrease in PEEP.~Baseline parameters looking into cardiac hemodynamics as well as compliance and respiratory mechanics will be assessed using EIT"
62598694|NCT06512935|ACTIVE_COMPARATOR|cardiac hemodynamics and respiratory status assessment with decreasing PEEP|"Infants will be randomized to the order of changes in PEEP levels during mechanical ventilation - decrease followed by increase in PEEP.~Baseline parameters looking into cardiac hemodynamics as well as compliance and respiratory mechanics will be assessed using EIT"
62598695|NCT05001295|EXPERIMENTAL|Physical Activity|
62598696|NCT05001295|PLACEBO_COMPARATOR|Daily Live|
62598697|NCT03126006|EXPERIMENTAL|NSPT plus oral hygiene|It includes pregnant women (with periodontal disease) who will be subjected to one episode of non-surgical periodontal therapy under local anesthesia during pregnancy. they will receive oral hygiene instruction also.
62819466|NCT01969344||Smokers without COPD|Current or former smokers with at least a 20 pack-year history with normal lung function based on post-bronchodilator spirometry (n=944).
62038495|NCT05614102|EXPERIMENTAL|Dose expansion of BAY2965501|For expansion part, specific tumor types are recruited (non-small cell lung cancer (NSCLC) and gastric/gastroesophageal junction (GEJ) adenocarcinoma).
62241221|NCT02540538|ACTIVE_COMPARATOR|HB vaccine naive - HBVaxPro|Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBVaxPro-10ug at day 0, 30, and 180.
62241222|NCT02540538|EXPERIMENTAL|HB vaccine naive - HBAI20|Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.
62241223|NCT02540538|EXPERIMENTAL|Non-responders - HBAI20|"Subjects have been vaccinated 6 times with a Hepatitis B vaccine without developing a protective immune response, measured as anti Hepatitis B surface antigen antibodies, superior to 10mIU/ml.~Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180."
62241224|NCT01331265||no treatment|
62241225|NCT05432128||Low-risk group|Combined with AI calculation of malignant probability and ctDNA methylation results, patients were divided into three groups. The high probability of malignancy calculated by AI was defined as positive, and vice versa. The methylation markers detected in specific peripheral blood of lung cancer were defined as positive, and vice versa. Negative for both items was considered as low risk group. Follow-up was conducted according to The Chinese Expert Consensus on the Diagnosis and Treatment of Pulmonary Nodules (2018 edition). 10ml peripheral blood was collected from each follow-up and stored for testing until the end of the study.
62241226|NCT05432128||medium-risk group|As above, one positive patient was considered to be in the medium-risk group and was reexamined every 6 months, with a total of 3 reexaminations expected
62241227|NCT05432128||High-risk group|Same as above, both positive are considered high-risk group.Part of high-risk nodules (5-10mm) will be reviewed every 3 months for the above two examinations, which is expected to be reviewed 6 times in total. Biopsy or surgical resection of high-risk nodules over 10mm will be performed after evaluation by the expert group and the patient's knowledge, and histopathological diagnosis will be made and compared with ctDNA methylation results. To analyze the sensitivity and specificity of ctDNA methylation markers in lung cancer.
62241228|NCT03334409|EXPERIMENTAL|Arm A (pazopanib hydrochloride, ascorbic acid)|Patients receive pazopanib hydrochloride PO QD on days 1-28 and ascorbic acid IV three times per week. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
62817271|NCT06705660|ACTIVE_COMPARATOR|The WEB-based progressive relaxation training|"WEB-based progressive relaxation training will be given for 8 weeks, 2 days a week for 30-45 minutes (16 sessions), following the menstrual cycles of women. Measurements will be taken before and after (at the end of) the intervention. Measurements will be taken 4 weeks after the next menstrual cycle to ensure follow-up.~Progressive relaxation training is an easy-to-learn, non-invasive and side-effect free method. PGE beginners will be trained for at least 30 minutes and practitioners who have learned the basics of the method will be trained to introduce PGE for 15 minutes. Prior to the PGE, individuals will be informed that they should not come overly hungry or overly full (eating should be finished 2 hours before), wear loose and comfortable clothes, avoid clothes that tightly wrap the abdomen (pants, dresses, belts), remove contact lenses, glasses, jewelry and tight shoes. PGE will be administered in a quiet, comfortable and dimly lit place. Women will perform PCI in the supine posi"
62431618|NCT02807324||Early PE without IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE \< 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
62431619|NCT02807324||Late PE with IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE \< 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
62431620|NCT02807324||Late PE without IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE \< 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
62431621|NCT02807324||HELLP syndrome|Cases consist of women (18 years or older) with HELLP syndrome in the current pregnancy (defined as (1) the presence of microangiopathic hemolytic anemia with abnormal blood smear, low serum haptoglobin and elevated lactate dehydrogenase (LDH) levels, (2) aspartate transaminase (ASAT) above 70 IU/L and lactate dehydrogenase (LD) above 600 IU/L or bilirubin more than 1.2 mg/dL, (3) platelet count below 100 x 10\^9 L-1 )
62431622|NCT02175654|EXPERIMENTAL|Regorafenib|Regorafenib will be administered orally at the initial dosage of 160 mg per day for 3 weeks, followed by one week of rest, according to the 3/1 regimen
62431623|NCT06427330|EXPERIMENTAL|Inotuzumab ozogamicin|
62817272|NCT06704802||Diamicron® MR 60 (originator product) plus educational program|uncontrolled patients with T2D who will be initiated to Diamicron® MR 60 (originator product) plus an educational program
62817273|NCT06704802||other OAD except Diamicron®|uncontrolled patients with T2D who will be initiated other OAD except Diamicron®
62817274|NCT01968447|EXPERIMENTAL|hypocapnia|arterial pCO2 of 3.5 kPa
62817275|NCT01968447|ACTIVE_COMPARATOR|normocapnia|arterial PCO2 of 6.5-7.0 kPa
62431624|NCT04495387||patients with colon cancer|
62431625|NCT04495387||patients with breast cancer|
62431626|NCT05719610|EXPERIMENTAL|Cawthorne Cooksey Exercises|
62819467|NCT01969344||Severe COPD|Current and former smokers with at least a 20 pack-year history with severe COPD based on post-bronchodilator spirometry (n=625).
62431627|NCT05719610|EXPERIMENTAL|Swiss Ball Exercises|
62598698|NCT03126006|OTHER|Oral hygiene alone|It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
62598699|NCT01196689|EXPERIMENTAL|1|AZD1981 100 mg twice daily for 6 ½ days
62598700|NCT05170503|EXPERIMENTAL|Neoadjuvant chemo-immunotherapy|Neoadjuvant Immunotherapy (Sintilimab, PD-1 inhibitor) Combined With Chemotherapy (Tegafur+Oxaliplatin) Each patient will complete 3 cycles of neoadjuvant therapy. After evaluating the radiographical response, operation with curative extent (Ivor-lewis or Mckeown procedure with two-field lymph node dissection) will be performed after 6 to 8 weeks from the last cycle of neoadjuvant treatment. Patients with and without surgery enter the survival follow-up period.
62598701|NCT01032421||GNRH|Observational (IVF is not done as part of the study)
62598702|NCT02819245|OTHER|Age before and after 18 years old|Surgical treatment before and after skeletal maturity
62241229|NCT03334409|ACTIVE_COMPARATOR|Arm B (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
62241230|NCT00859950|ACTIVE_COMPARATOR|Sleep Apnea|Subjects found to have Obstructive Sleep Apnea (OSA) with Intermittent Hypoxemia (IH). This arm will undergo a pre-treatment blood draw, one month of Continuous Positive Airway Pressure (CPAP) to treat OSA, and a post-treatment blood draw.
62241231|NCT00859950|NO_INTERVENTION|Normal Control|Subject found to have no evidence of Obstructive Sleep Apnea (OSA) after Nocturnal Polysomnography (NPSG). These subjects will only undergo a blood draw and will not have the Continuous Positive Airway Pressure (CPAP) treatment.
62431628|NCT04888741|ACTIVE_COMPARATOR|Control Arm Thymoglobulin + Cyclosporine + MMF|"Thymoglobulin is given as an intravenous infusion of 2.5 mg/kg/day over 2 days (days -2 and -1; total dose 5 mg/kg) via a central line through a 0.2 micron inline filter. Each dose will be infused over 6-8 hours. No test dose will be given. 30 minutes before Thymoglobulin, the patient should receive methylprednisolone 1mg/kg intravenously, 1g paracetamol PO and 10mg chlorphenamine IV. Patients should be monitored carefully and receive appropriate therapy for any infusion-related or anaphylactic reactions as per local policy.~Patients will receive IV/PO cyclosporine according to local policy to begin on day -1 maintaining a trough level of 100-200 µg/L until day 90 before a subsequent taper in the absence of any active GvHD.~MMF will be given IV/PO according to local policy at a dose of 1g TDS to begin on day -1 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing \<55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS."
62598703|NCT03126019|EXPERIMENTAL|Treatment A: Parsaclisib 20 mg QD for 8 Weeks Followed by 20 mg QW|Participants received parsaclisib 20 mg once daily (QD) for 8 weeks followed by 20 mg once weekly (QW) for up to approximately 52 weeks.
62598704|NCT03126019|EXPERIMENTAL|Treatment B: Parsaclisib 20 mg QD for 8 Weeks Followed by 2.5 mg QD|Participants received parsaclisib 20 mg QD for 8 weeks followed by 2.5 mg QD for up to approximately 52 weeks.
62817276|NCT06018350|EXPERIMENTAL|Intervention|"Clinicians in this arm will be trained to conduct the adherence intervention in general rheumatology clinic with all follow up patients with a chronic rheumatic disease.~Patients seen by these clinicians will contribute to the outcome data collection."
62817277|NCT02101775|EXPERIMENTAL|Arm I (WEE1 inhibitor MK-1775, gemcitabine hydrochloride)|Patients receive WEE1 inhibitor MK-1775 PO on days 1, 2, 8, 9, 15, and 16 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62817278|NCT02101775|ACTIVE_COMPARATOR|Arm II (placebo, gemcitabine hydrochloride)|Patients receive placebo PO on days 1, 2, 8, 9, 15, and 16 and gemcitabine hydrochloride as patients in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62817279|NCT00684866|EXPERIMENTAL|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (8 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (8 cumulative doses).~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. Treatment will be administered with an AeroChamber Plus ™ spacer for the first cohort (spacer cohort) of subjects and without the AeroChamber Plus ™ spacer (non-spacer cohort) for the second cohort of subjects."
62817280|NCT00684866|ACTIVE_COMPARATOR|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. Treatment will be administered with an AeroChamber Plus ™ spacer for the first cohort (spacer cohort) of subjects and without the AeroChamber Plus ™ spacer (non-spacer cohort) for the second cohort of subjects.
62817281|NCT05856422|EXPERIMENTAL|Pediatrics population|
62817282|NCT04462640||regurgitation|45 infants aged 0 to 5 months suffering from regurgitation
62241232|NCT01557023|EXPERIMENTAL|dienogest 2 mg/ethynilestradiol 30 mcg;|
62598705|NCT05220566|EXPERIMENTAL|'Reserved Therapeutic Space'|Participants will receive 'Reserved Therapeutic Space' Nursing Intervention
62598706|NCT05220566|NO_INTERVENTION|Control|Participants will receive usual care
62817283|NCT04462640||colic|45 infants aged 0 to 5 months suffering from colic
62817284|NCT05676203|ACTIVE_COMPARATOR|Arm 1|6 x Docetaxel 75 mg/m2 every 3 weeks of a 3 week cycle Co-administration of docetaxel, darolutamide and standard ADT
62817285|NCT05676203|EXPERIMENTAL|Arm 2|6 x Docetaxel 50 mg/ m2 every 2 weeks of a 4 week cycle Co-administration of docetaxel, darolutamide and standard ADT
62241233|NCT01557023|ACTIVE_COMPARATOR|Yasmin®|
62241234|NCT02941926|EXPERIMENTAL|Ribociclib + letrozole+goserelin/leuprolide|Participants received ribociclib (orally taken, 3 weeks on/1 week off) in combination with letrozole (orally taken once daily). For men and premenopausal women, either goserelin was given as an injectable subcutaneous implant or leuprolide was given as an intramuscular injection.
62241235|NCT06059066|ACTIVE_COMPARATOR|Standard Injection Sites|Standard number of injections
62241236|NCT06059066|EXPERIMENTAL|Reduced Injection Sites|Reduced number of injections
62241237|NCT03049787|EXPERIMENTAL|home exercise|For the home exercise protocol alone arm, subjects will be given an experimental home exercise program and study team will demonstrate the exercises in the clinic and will direct the subjects to perform the exercises 1-2 times daily until symptom resolution.
62241238|NCT03049787|ACTIVE_COMPARATOR|physical therapy|Patients will be prescribed routine physical therapy protocol where they will see a physical therapist twice a week and will be instructed by the physical therapist to perform physical therapy exercises at home daily until symptom resolution, as is the routine practice.
62038496|NCT05614102|EXPERIMENTAL|Dose escalation of BAY2965501+pembrolizumab|For escalation part different dose levels of BAY2965501 are planned in combination with 200mg pembrolizumab. BAY2965501 will be taken in combination with 200mg pembrolizumab every 3 weeks.
62241239|NCT02141542|EXPERIMENTAL|Tremelimumab and MEDI3617|"* Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~* Tremelimumab-Fixed doses of Tremelimumab are given once per cycle~* MEDI3617-MEDI3617 is administered twice per cycle"
62241240|NCT04877717|EXPERIMENTAL|SHR-A1904|
62241241|NCT03227055||CKD|Children and adolescents with stage G1-G4 CKD, age 3 to 18 yr
62241242|NCT01109173|EXPERIMENTAL|Nepafenac 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional dose was administered between 30-120 minutes prior to surgery.
62431629|NCT04888741|EXPERIMENTAL|Experimental arm (PTCy + Cyclosporine + MMF)|"Cyclophosphamide is given as an IV infusion of 50 mg/kg/day over 2 days (days 3 and 4; total dose 100 mg/kg) together with IV hydration and Mesna, as per local policy.~Patients will receive IV/PO cyclosporine according to local policy to begin on day 5 maintaining a trough level of 100-200 µg/L until day 90 before a subsequent taper in the absence of active GvHD.~MMF will be given IV/PO according to local policy at a dose of 1g TDS to begin on day 5 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing \<55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS."
62817286|NCT06435663|ACTIVE_COMPARATOR|experimental group|In HIFUA treatment, SMI technology was used to evaluate the therapeutic effect. The SMI technology used Toshiba Aplio 800 color ultrasound diagnostic instrument, equipped with SMI imaging software, convex array probe, frequency 1-6 MHz, and color mode ultra fine vessel imaging (eSMI). After the target lesion is determined by abdominal scanning, adjust the depth and gain, and record the number, location, size, shape and boundary of the lesion. CDFI and eSMI models were used to observe the blood supply within the lesion, which were divided into four levels according to Adler grading criteria. Hemodynamic parameters were measured, including peak systolic velocity (PSV) and resistance index (RD). Hemodynamic data were compared to calculate the effectiveness of changes in uterine benign tumor examination after treatment.
62241243|NCT01109173|ACTIVE_COMPARATOR|NEVANAC|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery.
62431630|NCT04888741|EXPERIMENTAL|Experimental arm (PTCy + Sirolimus + MMF)|"Cyclophosphamide is given as an IV infusion of 50 mg/kg/day over 2 days (days 3 and 4; total dose 100 mg/kg) together with IV hydration and Mesna, as per local policy.~Sirolimus will be initially given PO as a loading dose of 6 mg on day 5 followed by 2 mg daily; doses will be adjusted to maintain a trough level (in whole blood) of 8 to 14 ng/mL until day 60, thereafter 5-8 ng/mL until day 90. In the absence of active GvHD, the dose of sirolimus will be tapered from day 90. We recommend that the daily maintenance dose of sirolimus is reduced empirically to 0.5-1mg daily with concomitant treatment with a triazole anti-fungal agent.~MMF will be given IV/O according to local policy at a dose of 1g TDS to begin on day 5 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing \<55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS."
62598707|NCT06621355||LCA1|Patients with ACL involvement (with less than 6 months of evolution since the surgical intervention (IQ)) and are in a phase in which they can perform the incremental intervallic test either on a cycloergometer or treadmill.
62431631|NCT03573115|EXPERIMENTAL|Acne patients|
62038497|NCT05614102|EXPERIMENTAL|Dose expansion of BAY2965501 +pembrolizumab|For expansion part, specific tumor types are recruited (non-small cell lung cancer (NSCLC) and gastric/gastroesophageal junction (GEJ) adenocarcinoma). BAY2965501 will be taken in combination with 200mg pembrolizumab every 3 weeks.
62241244|NCT01109173|PLACEBO_COMPARATOR|Nepafenac Vehicle 0.3%|Nepafenac Ophthalmic Suspension 0.3% Vehicle, one drop in affected eye once daily for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional dose was administered between 30-120 minutes prior to surgery.
62241245|NCT01109173|PLACEBO_COMPARATOR|NEVANAC Vehicle|Nepafenac 0.1% vehicle, one drop in affected eye three times daily, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery.
62241246|NCT04987892|ACTIVE_COMPARATOR|Prostatic Lift|Treatment with the UroLift System
62241247|NCT04987892|ACTIVE_COMPARATOR|Medication|Treatment with Tamsulosin HCl 0.4mg
62241248|NCT00120406|EXPERIMENTAL|1|Zilver® PTX™ Drug Eluting Vascular Stent
62241249|NCT00120406|ACTIVE_COMPARATOR|2|Angioplasty
62241250|NCT03504514|NO_INTERVENTION|Conventional mechanical ventilation|Conventional mechanical ventilation, with patient ventilator usual parameters
62241251|NCT03504514|EXPERIMENTAL|Adapted mechanical ventilation|Mechanical ventilation with parameters specifically modified to improve speech the effect is evaluated with speech trials during different ventilation conditions
62431632|NCT04212182|EXPERIMENTAL|HFNC group|AECOPD patients receive ventilation support via HFNC.
62431633|NCT04212182|ACTIVE_COMPARATOR|NPPV group|AECOPD patients receive ventilation support via NPPV.
62431634|NCT03223285|EXPERIMENTAL|Real Treatment Group|Patients included in this group will receive 3 multifaced physiotherapy/osteopathic treatments + experimental manoeuvres, 1 treatment/week. Each session will last about 30 minutes.
62431635|NCT03223285|SHAM_COMPARATOR|Sham Treatment Group|Patients included in this group will receive 3 multifaced physiotherapy/osteopathic treatments + sham manoeuvres, 1 treatment/week. Each session will last about 30 minutes.
62431636|NCT00527397|EXPERIMENTAL|B|Type 2 Diabetes Mellitus (DM) who has not yet treated by Insulin
62431637|NCT00527397|EXPERIMENTAL|C|Type 2 DM who has already treated by Insulin
62431638|NCT00527397|EXPERIMENTAL|A|Type 1 DM
62431639|NCT03533530|ACTIVE_COMPARATOR|No electrical source imaging (ESI)|In all patients, the multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, except for ESI.
62817287|NCT06435663|OTHER|control group|In HIFUA treatment, organ ultrasound contrast evaluation technology is used for efficacy evaluation. Sono Vue (Bracco company) is used as the contrast agent. Before use, 5 ml of physiological saline is injected into the bottle, vigorously shaken until the freeze-dried powder is completely dispersed. 1.5 ml of contrast agent is extracted and rapidly injected through the anterior elbow vein, followed by 5 ml of physiological saline injection. After injecting contrast agent, start the timer at the same time, observe under ultrasound imaging, keep the probe stationary during examination, observe continuously for 2 minutes, and store dynamic images. Calculate the effective rate of physical examination changes in benign uterine tumors after treatment by displaying ablation volume through contrast-enhanced ultrasound before and after treatment.
62598708|NCT06621355||LCA2|Patients who have recovered from an ACL injury for more than 2 years. And can perform the incremental intervallic test either on a cycloergometer or treadmill.
62598709|NCT06621355||CON|Patients who have never suffered an ACL injury or involvement to date. And can also perform the test.
62817288|NCT04963166||12-17 years of age|12-17 years of age
62817289|NCT04963166||2-6 years of age|2-6 years of age
62817290|NCT04963166||7-11 years of age|7-11 years of age
62431640|NCT03533530|EXPERIMENTAL|Low-density ESI (LD ESI)|The multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, including ESI using LD EEG recordings.
62817291|NCT04291547|EXPERIMENTAL|Computerised Behavioural Activation Programme|All recruited young people will be given the BALM (Behavioural Activation for Low Mood) programme to work through
62817292|NCT05537883|ACTIVE_COMPARATOR|Bupivacaine only|Active control group patients receive Transversus Abdominis Plane (TAP) block with a Bupivacaine only mixture, containing 50 mL 0.5% Bupivacaine, and 100 mL normal saline solution.
62817293|NCT05537883|EXPERIMENTAL|Liposomal Bupivacaine|Study group patients will receive Transversus Abdominis Plane (TAP) block with a Liposomal Bupivacaine mixture, containing 20 mL Liposomal Bupivacaine, 30 mL 0.5% Bupivacaine, and 100 mL normal saline solution.
62817294|NCT05635344|NO_INTERVENTION|Second evacuation only|Patients that are randomised onto this arm of the study will be treated by second evacuation ALONE.
62817295|NCT05635344|EXPERIMENTAL|Pembrolizumab and second evacuation|Patients that are randomised onto this arm will be given a single dose of Pembrolizumab in a neoadjuvant setting followed by second evacuation
62817296|NCT06601413|ACTIVE_COMPARATOR|M-TAPA Group|At the end of the surgery, without waking the patient, a linear transducer will be placed on the costochondral angle in the sagittal plane under ultrasound guidance, and a total of 40 mL of LA (0.25% Bupivacaine) will be applied bilaterally to the lower surface of the chondrium, giving a deep angle to see the lower side of the chondrium centrally.
62817297|NCT06601413|PLACEBO_COMPARATOR|Trochar-site Group|At the end of surgery, infiltration analgesia will be applied by the surgeon to all trocar entry sites (4 port entries) with 10 ml of 0.25% bupivacaine (40 mL in total) without waking the patient.
62817298|NCT01901445|EXPERIMENTAL|Educational action group|
62817299|NCT01901445|NO_INTERVENTION|Control group|
62431641|NCT03533530|EXPERIMENTAL|High-density ESI (HD ESI)|The multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, including ESI using HD EEG recordings.
62431642|NCT01347879|EXPERIMENTAL|Visonac cream with PDT|active treatment with light dose of 37 Joule/cm2
62598710|NCT00170313|EXPERIMENTAL|Conducted AF-Response Algorithm (CAFR) On|"CAFR: On~* Level medium~* Max. Rate: 110ppm VSR: Off"
62598711|NCT00170313|ACTIVE_COMPARATOR|Conducted AF-Response Algorithm (CAFR) Off|CAFR: Off VSR: Off
62817300|NCT06555406|EXPERIMENTAL|Time Restricted Eating (TRE) for 8 weeks|Participants will receive an intro to TRE and then throughout 8 weeks they will receive brief online psychoeducation several times per week with optional weekly coaching sessions. TRE involves restricting the window of eating to 10 hours/ day, most typically by avoiding eating in the first 1-2 hours after awakening and in the 2-4 before sleep. Those with an eating window \> 14 hours will be asked to restrict their eating to 12 hours in the first week, then 10 hours in week 2. To select the period, investigators will ask Ss to review baseline logs to consider sleep, eating, family meals and social commitment schedules, and any special energy demands, such as exercise. During the eating window, no restrictions are placed on the type or quantity of food consumed. The investigators will instruct participants to follow their habitual diet within their 10-hour eating window and to aim to consume the same number of calories per day as they did at baseline.
62431643|NCT01347879|PLACEBO_COMPARATOR|Vehicle cream with PDT|Placebo treatment, Light dose 37 Joule/cm2
62431644|NCT00069160|EXPERIMENTAL|Pts who received docetaxel on day 1, 8, & tariquidar day 8,22|Patients receive 40 mg/m\^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m\^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.
62431645|NCT00069160|EXPERIMENTAL|Pts who received docetaxel on days 1, 8, & tariquidar day 1,22|Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8 and tariquidar intravenous (IV) over 30 minutes on days 1 and 22.
62431646|NCT02309918|OTHER|LDV/SOF FDC|Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
62431647|NCT03438305||Group D|
62431648|NCT03438305||Group N|
62431649|NCT01220089|ACTIVE_COMPARATOR|Standard maintenance|During months 7 to 18, individuals in the Standard Maintenance condition will receive informational handouts by mail (or e-mail) regarding weight maintenance.
62431650|NCT01220089|ACTIVE_COMPARATOR|Intensified Maintenance|"During months 7 to 18, individuals in the Intensified Maintenance condition will continue to have monthly in-person visits with the weight loss counselor (Weight Coach)."
62431651|NCT02289027|EXPERIMENTAL|Deployed volunteers - Group 1|Low dose cAd3-EBOZ (2.5x10e10 vp)
62598712|NCT04689048|OTHER|PET/CT, MRI|In total, three 18F-fluciclovine PET/CT brain scans (pre-, interim-, and post-treatment) will be performed according to the study calendar. Generic name is Axumin and will be administered as an intravenous bolus. May administer diluted or undiluted. The maximum volume of undiluted 18F-fluciclovine is 5 mL. After administration, flush with normal saline to ensure full delivery of the dose.
62817301|NCT06706700||Cohort A|"A retrospective study of a cohort of 350 resected patients with a histologically-confirmed IPMN, diagnosed from the 1st January 2009 to the 31st May 2018 following these inclusion criteria:~* histologically proven IPMNs with full pathological data (type of IPMNs, grade of dysplasia; for invasive IPMNs: grading, pTNM classification, presence of perineural (microvascular infiltration)~* availability of clinical and imaging criteria for surgical resections defined by International and European guidelines (worrisome features and high-risk stigmata according to International Guidelines and absolute/relative criteria for surgery according to European guidelines~* age ≥18 years and exclusion criteria:~* lack of preoperative clinical and radiological data according the two guidelines"
62817302|NCT06706700||Cohort B|"A prospective observational study whose aim is to identify EMI profiles and radiological/endosonographical biomarker(s) associated to surgically removed IPMNs with HGD/IC.~Patients diagnosed with IPMN and candidates for resection with following inclusion criteria will be enrolled:~* Age \>= 18 years~* Charlson comorbidity index \<7 \[26\] The patients' cohort will be selected following the best criteria for surgery identified in the retrospective study (Cohort A).~At the admission, patients will be informed by PI, or his delegates about the study, and they will be asked to sign the specific informed consents (see par. 5.1) In the course of standard pre-operative evaluation, all patients will undergo MRI and EUS, within no more than 3 months between exams."
62817303|NCT06706700||Cohort C|"A prospective study with the aim to validate potential biomarker(s) identified in the Cohort B.~Patients with a diagnosis of IPMN candidate for resection with the following inclusion criteria will be enrolled:~* Age \>= 18 years~* Charlson comorbidity index \<7 \[26\] The patients' cohort will be selected following the best criteria for surgery identified in the retrospective study (Cohort A).~At the admission patients will be informed by PI or his delegates about the study and they will be asked to sign specific informed consents"
62817304|NCT00915954|ACTIVE_COMPARATOR|Active Acromegaly|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
62598713|NCT05275868|EXPERIMENTAL|Dose escalation|Patients with advanced NSCLC harboring NFE2L2/KEAP1/CUL3 mutations enrolled based on locally available test results of mutation status
62038498|NCT05614102|EXPERIMENTAL|Dose escalation of BAY 2965501 + pembrolizumab + platinum-based regimen|The starting dose of BAY 2965501 with pembrolizumab for this combination will be no higher than one dose level below that shown to be safe in BAY 2965501 and pembrolizumab dose escalation. The doses of platinum-based regimen will be as per standard of care and given for a maximum of 6 cycles, in line with the current labeled dose. The dose of pembrolizumab will be 200 mg every 3 weeks, in line with the current labeled dose.
62038499|NCT05614102|EXPERIMENTAL|Dose expansion of BAY 2965501 + pembrolizumab + platinum-based regimen|Participants with selected (to be decided by the sponsor) advanced solid tumors will be recruited in a dose expansion cohort of BAY 2965501 with pembrolizumab and platinum-based regimen.
62038500|NCT05881759|NO_INTERVENTION|Usual Practice - ESBA|The control group sites will receive the existing ESBA curriculum which is their usual practice.
62038501|NCT05881759|EXPERIMENTAL|ESBA + Feeding Practices|The intervention site staff will implement the ESBA-FFYF feeding curriculum in classes using standardized implementation protocols.
62038502|NCT04575051|ACTIVE_COMPARATOR|HearCARE (Consult+Engage)|Residents will be exposed to the Consult Model and the Engage Model.
62038503|NCT04575051|OTHER|Consult Model|The Consult Model (i.e., usual care) is an acute care strategy, relying on a monthly Audiologist visit to the facility.
62038504|NCT02019368|PLACEBO_COMPARATOR|Placebo|Smoker subjects take 6 capsules once a day for 4 weeks.
62038505|NCT02019368|EXPERIMENTAL|Aged garlic extract|Smoker subjects take 1.5 g of aged garlic extract in 6 capsules once a day for 4 weeks.
62038506|NCT02019368|NO_INTERVENTION|Non-smoker|Oxidative status in non-smoker
62038507|NCT06279325|EXPERIMENTAL|Cognitive Stimulation program|
62038508|NCT06279325|ACTIVE_COMPARATOR|Control Group|
62038509|NCT01064232|EXPERIMENTAL|Risperidone|Risperidone Tablets 1 mg of Dr Reddys Laboratories Limited
62038510|NCT01064232|ACTIVE_COMPARATOR|Risperdal|Risperdal® Tablets, 1 mg of Janssen Pharmaceutica Products, L.P
62038511|NCT00673972|ACTIVE_COMPARATOR|EPS|Patients with functional dyspepsia will be classified into EPS or PDS two subgroups according to Rome III diagnostic criteria.
62598714|NCT05275868|EXPERIMENTAL|Dose expansion group 1|Patients with advanced NSCLC harboring NFE2L2/KEAP1/CUL3 mutations enrolled based on locally available test results of mutation status
62598715|NCT05275868|EXPERIMENTAL|Dose expansion group 2|Patients with advanced NSCLC irrespective of prior knowledge of NFE2L2/KEAP1/CUL3 mutational status.
62598716|NCT02953587|EXPERIMENTAL|Vertical Sleeve Gastrectomy (VSG) NJ/PO|Patients that are undergoing routine VSG will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed by administering glucose through a nasojejunal (NJ) feeding tube preoperatively and orally (PO) postoperatively.
62038512|NCT00673972|ACTIVE_COMPARATOR|PDS|Patients with functional dyspepsia will be classified into EPS or PDS two subgroups according to Rome III diagnostic criteria.
62038513|NCT06433908|EXPERIMENTAL|Cohort 1: Salbutamol 200 μg|Participants will receive single 200 μg doses given as 2x100 μg (ex-valve) at 20-second intervals. The intervention period will be 10 days with dosing with either HFA-152a or HFA-134a on Day 1, Day 4, Day 7, and Day 10.
62038514|NCT06433908|EXPERIMENTAL|Cohort 2: Salbutamol 800 μg|Participants will receive single 800 μg doses given as 8x100 μg (ex-valve) at 20-second intervals. The intervention period will be 10 days with dosing with either HFA-152a or HFA-134a on Day 1, Day 4, Day 7, and Day 10.
62431652|NCT02289027|EXPERIMENTAL|Deployed volunteers - Group 2|High dose cAd3-EBOZ (5x10e10 vp)
62431653|NCT02289027|EXPERIMENTAL|Not deployed volunteers - Group 3|Low dose cAd3-EBOZ (2.5x10e10 vp)
62817305|NCT00915954|ACTIVE_COMPARATOR|Type 2 Diabetes Mellitus(DM)|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
62817306|NCT00915954|ACTIVE_COMPARATOR|Heathy Controls|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
62817307|NCT00352768|EXPERIMENTAL|F|
62817308|NCT00352768|PLACEBO_COMPARATOR|P|
62817309|NCT02918370|EXPERIMENTAL|Aripiprazole|Aripiprazole will be given to the participant beginning at 2 mg per day(QD) then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.
62817310|NCT02918370|PLACEBO_COMPARATOR|Placebo|Matching placebo will be given to the participant beginning at 2mg QD then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.
62817311|NCT05764525|EXPERIMENTAL|VVZ-149 Injections|
62817312|NCT05764525|PLACEBO_COMPARATOR|Placebo|
62817313|NCT02539823|PLACEBO_COMPARATOR|Control|Subjects will receive a solution that resemble the Cannabidiol solution but do not have have its properties
62817314|NCT02539823|EXPERIMENTAL|CBD 400mg|Subjects will receive 400mg of cannabidiol
62817315|NCT02539823|EXPERIMENTAL|CBD 800mg|Subjects will receive 800 mg of cannabidiol
62817316|NCT04078841|ACTIVE_COMPARATOR|ReaLife+ (RLP)|Dietary Supplement: ReaLife+ (RLP) RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids
62817317|NCT04078841|PLACEBO_COMPARATOR|Inert Brown Powder|"Brown powder~Inert brown powder to look similar to RLP"
62817318|NCT04078841|NO_INTERVENTION|Control|Control
62817319|NCT02202122||Study Group|OSA Scoring
62817320|NCT02133495|EXPERIMENTAL|open label|Non Cadaveric human BellaDerm Acellular dermal tissue
62598717|NCT02953587|EXPERIMENTAL|Roux-en-Y Gastric Bypass (RYGB) NJ/PO|Patients that are undergoing routine RYGB will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed by administering glucose through a nasojejunal (NJ) feeding tube preoperatively and orally (PO) postoperatively.
62817321|NCT02673372|ACTIVE_COMPARATOR|Morphine Group|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg.
62817322|NCT02673372|EXPERIMENTAL|Ketamine Group|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min)
62817323|NCT05876078|EXPERIMENTAL|ADHF patients|ADHF patients with insufficient response to diuretics treated with the Doraya catheter
62038515|NCT00338065|EXPERIMENTAL|Subjects with autonomic dysfunction|"Subjects with known autonomic dysfunction diagnoses as defined by the General Clinical Research Center (GCRC) such as pure autonomic failure, Postural orthostatic tachycardia syndrome (POTS), and Multiple System Atrophy( MSA).~1. Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~2. Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
62038516|NCT00338065|EXPERIMENTAL|Primary open-angle glaucoma subjects|"Subjects diagnosed with primary open-angle glaucoma following a glaucoma specialist's examination.~1. Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~2. Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
62241252|NCT04943003|EXPERIMENTAL|Active tDCS|"SimNIBS will be used for modeling. It is a free and open source software package for the simulation of electric field induced by tDCS in the individual brain.~Modeling will be done using T1-weighted anatomical images of each subject to reconstruct a high-resolution head model of each individual. For electrode placement, we will simulate areas F5 and F6, according to the EEG 10-20 system, for the anode and cathode, respectively, targeting the left and right Dorsolateral Prefrontal Cortex (DLPFC). This group will receive active tDCS, for 30 minutes and for 5 consecutive days, in two weeks, with an anode positioned on the left DLPFC and a cathode electrode placed on the right supraorbital area."
62598718|NCT02953587|EXPERIMENTAL|Vertical Sleeve Gastrectomy (VSG) PO/PO|Patients that are undergoing routine VSG will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed.
62735664|NCT03201575|EXPERIMENTAL|Remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient. The remote ischemic conditioning consists in alternative inflations and deflations of the brachial cuff.
62817324|NCT00002682|EXPERIMENTAL|Antibiotic Treatment|
62241253|NCT04943003|SHAM_COMPARATOR|Sham tDCS|The electrodes will be placed in the same way as in the Active tDCS group. However, individuals in this group will receive a stimulation that will last only 20-30 seconds. Afterwards, the device will be turned off, no longer emitting current.
62241254|NCT05713188|EXPERIMENTAL|Treatment|All volunteers will receive the same treatment
62431654|NCT02289027|EXPERIMENTAL|Not deployed volunteers - Group 4|High dose cAd3-EBOZ (5x10e10 vp)
62431655|NCT02289027|PLACEBO_COMPARATOR|Not deployed volunteers - Group 5|
62735665|NCT03201575|OTHER|Control group|A brachial cuff is positioned around the arm of the patient. No inflation or deflation is made.
62817325|NCT06147843|OTHER|ALL participants|"ALS patients will be stratified in 4 groups according to the weight loss percentage: a) no weight loss; b) \<5% of weight loss; c) 5-10% of weight loss; d) \>10% of weight loss.~In order to identify the genomic, metabolomic, metabolic, neurofilaments, and inflammation markers associated to weight loss."
62817326|NCT04197934|EXPERIMENTAL|Dose escalation (WSD0922-FU)|Patients receive WSD0922-FU PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and blood sample collection on study. Patients with NSCLC with LM also undergo collection of CSF samples on study.
62819468|NCT01969344||Mild/Moderate COPD|Current and former smokers with at least a 20 pack-year history with mild to moderate COPD based on post-bronchodilator spirometry (n=1210).
62817327|NCT04197934|EXPERIMENTAL|Dose expansion Cohort I (WSD0922-FU)|Patients with GBM/AA receive WSD0922-FU PO on days 1 and 4 of cycle 0. Patients then receive WSD0922-FU PO BID on days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI during screening and on study, as well as blood sample collection on study. Patients may undergo additional optional blood sample collection on study.
62817328|NCT04197934|EXPERIMENTAL|Dose expansion Cohort II (WSD0922-FU, surgery)|Patients with BTP receive a single dose of WSD0922-FU prior to surgery. Patients then undergo surgical resection of brain tumor. After surgery, patients receive WSD0922-FU PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI during screening and on study, as well as blood sample collection on study.
62817329|NCT04197934|EXPERIMENTAL|Dose expansion Cohort III (WSD0922-FU)|Patients with NSCLC receive WSD0922-FU PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI and CT during screening and on study, as well as blood sample collection on study. Patients with LM also undergo collection of CSF samples on study. Patients may also undergo optional blood sample collection on study.
62817330|NCT03210558|ACTIVE_COMPARATOR|Group A|Testosterone cream 1% (Andro-Feme® )
62817331|NCT03210558|PLACEBO_COMPARATOR|Group B|Placebo cream
62817332|NCT06499844|EXPERIMENTAL|assessment of microvascular endothelial function|The investigators use intradermal microdialysis to deliver acetylcholine, L-NAME, and acetylcholine + L-NAME to the cutaneous microvasculature.
62817333|NCT01149850|EXPERIMENTAL|Arm I|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks and oral temozolomide on days 1-5. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
62817334|NCT04696757|EXPERIMENTAL|Cape|Capecitabine without surgery
62431656|NCT02194803||Cohort with routine OCT monitoring|
62431657|NCT02194803||Cohort without routine OCT monitoring|
62431658|NCT01308983|OTHER|Amiloride|
62431659|NCT01058382||Progesterone Vaginal Suppositories|
62431660|NCT01058382||Intramuscular Progesterone-in-Oil|
62431661|NCT02309554|ACTIVE_COMPARATOR|SILCS Diaphragm alone|Participants will complete a post-coital test cycle with SILCS diaphragm alone.
62431662|NCT02309554|ACTIVE_COMPARATOR|SILCS Diaphragm with 3% Nonoxynol-9 Gel|Participants will complete a post-coital test cycle with SILCS diaphragm used with 3% nonoxynol-9 gel.
62431663|NCT02309554|EXPERIMENTAL|SILCS Diarphragm with ContraGel|Participants will complete a post-coital test cycle with SILCS diaphragm used with ContraGel.
62431664|NCT01133444|EXPERIMENTAL|Finasteride|Finasteride tablets 1 mg of Dr. Reddy's
62431665|NCT01133444|ACTIVE_COMPARATOR|Propecia|Propecia 1 mgTablets of Merck \& Co.,
62431666|NCT03978169||General anaesthesia with orotracheal intubation|surgery patients under general anaesthesia with orotracheal intubation
62431667|NCT03978169||General anaesthesia with laryngeal mask|surgery patient under general anaesthesia with laryngeal mask
62431668|NCT03978169||Spinal anaesthesia|surgery's patients under Spinal anaesthesia
62431669|NCT01591486||Hp-negative cohort|"Hp-negative cohort~The second cohort consists of ASA users with ulcer bleeding but no current or past Hp infection, as evidenced by:~1. negative rapid urease test~2. negative histology for Hp infection on both initial and follow-up endoscopy~3. negative serology test~4. absence of intestinal metaplasia and atrophy on 4 random biopsies of the antrum and corpus~After ulcer healing, the Hp-negative cohort will receive enteric-coated ASA (\<160 mg daily) without regular co-prescription of anti-ulcer drugs."
62431670|NCT01591486||Hp-eradicated cohort|Hp-eradicated cohort This cohort consists of ASA users with ulcer bleeding and Hp infection who have healed ulcers and successful eradication of Hp on follow-up endoscopy. They will receive plain ASA (\<160 mg daily) without co-prescription of anti-ulcer drugs.
62431671|NCT01591486||Average-risk cohort|Average-risk cohort The third cohort consists of ASA-naive patients without a history of ulcer who attend the general outpatient clinic. They require long-term ASA for established cardiothrombotic diseases. They receive plain ASA (\<160 mg daily) without co-prescription of anti-ulcer drugs. Hp status will not be determined in this cohort because Hp testing is not justified in average-risk asymptomatic patients.
62598719|NCT02953587|EXPERIMENTAL|Roux-en-Y Gastric Bypass (RYGB) PO/PO|Patients that are undergoing routine RYGB will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed.
62817335|NCT06396039|EXPERIMENTAL|Administration of BMS-986374|
62817336|NCT05176899||Prospective cohort|Patients who are at least 50 years of age during their primary care exam will undergo SENSORA™ screening if they provide consent.
62817337|NCT05176899||Retrospective cohort|Patients who saw participating providers in the 6 months prior to study start date, and who were referred to echocardiogram and/or cardiology, will be included as provider self-control for patient outcomes and referral rates.
62431672|NCT06536634|EXPERIMENTAL|SAES|"Treatment group (SAES)~Interventions: Sensory afferent electrical stimulation (SAES)"
62431673|NCT06536634|OTHER|Control group|The control intervention (treatment as usual, TAU) consists of the prescribed conventional occupational therapy and/or physiotherapy.
62431674|NCT03355859|EXPERIMENTAL|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 4 CAR T dosage will be tested in this study: 1×10\^7, 2.5×10\^7, 5×10\^7, 1×10\^8 CAR+ T cells.
62431675|NCT05078710|EXPERIMENTAL|Telitacicept arm|Telitacicept 160mg once a week for 24 week as an add-on treatment regimen.
62431676|NCT03760107|EXPERIMENTAL|Incentive Level High, Call|
62431677|NCT03760107|EXPERIMENTAL|Incentive Level High, No Call|
62431678|NCT03760107|EXPERIMENTAL|Incentive Level Medium, Call|
62431679|NCT03760107|EXPERIMENTAL|Incentive Level Medium, No Call|
62431680|NCT03760107|EXPERIMENTAL|No Incentive, Call|
62431681|NCT03760107|EXPERIMENTAL|No Incentive, No Call|
62431682|NCT01956682|ACTIVE_COMPARATOR|Infant formula|HA formula + starch + L. reuteri
62431683|NCT01956682|PLACEBO_COMPARATOR|Standard Formula|Standard Infant Formula
62431684|NCT02122159|EXPERIMENTAL|MA09-hRPE Cellular Therapy|MA09-hRPE cells for transplantation will be provided by Ocata Therapeutics as a suspension frozen to the temperature of liquid nitrogen (approximately -196 °C). They will be processed at UCLA under GMPs according to protocol. Following vitrectomy performed under general anesthesia or waking sedation at the surgeon's discretion, hRPE cells will be introduced into a subretinal bleb formed by the injection of balanced salt solution (BSS). Direct viewing will guide the implantation of thawed and washed MA09-hRPE cells, resuspended in BSS, into the created bleb over a period of one minute. To avoid cell reflux, the cannula used to introduce the cells will be held in position for an additional minute. A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.
62431685|NCT03712228|PLACEBO_COMPARATOR|Placebo|Subjects with C1-INH HAE receiving buffer only
62431686|NCT03712228|ACTIVE_COMPARATOR|CSL312 (low)|Subjects with C1-INH HAE receiving low dose CSL312
62431687|NCT03712228|ACTIVE_COMPARATOR|CSL312 (med)|Subjects with C1-INH HAE receiving medium dose CSL312
62431688|NCT03712228|ACTIVE_COMPARATOR|CSL312 (high)|Subjects with C1-INH HAE receiving high dose CSL312
62431689|NCT03712228|ACTIVE_COMPARATOR|CSL312 (med/high)|Subjects with C1-INH HAE receiving medium/high dose CSL312
62431690|NCT02267850|EXPERIMENTAL|OrthoPulse™|Subjects assigned to this group receive fixed orthodontic appliance treatment in conjunction with receiving daily OrthoPulse™ treatments.
62598720|NCT05948124|EXPERIMENTAL|L-Carnitine Group|Enrolled patients in this group who are on regular hemodialysis fulfilling our study's inclusion criteria with secondary carnitine deficiency(based on clinical manifestations and decreased serum level of L-carnitine ;serum free carnitine level less than 20 μmol/L) will receive intravenous L-carnitine (20 mg/kg dry body weight) after each dialysis session three times weekly for 6 months.
62598721|NCT05948124|PLACEBO_COMPARATOR|Placebo Group|enrolled patients in this group who will receive 5 ml intravenous isotonic saline after each dialysis session three times weekly for 6 months.
62598722|NCT01230424|EXPERIMENTAL|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
62598723|NCT01230424|PLACEBO_COMPARATOR|Sodium Chloride|0.9% Sodium chloride injection as Placebo will be given into the study knee once every 12 weeks for a total of 8 injections.
62598724|NCT06648278|EXPERIMENTAL|Health services research (Patient COUNTS2)|Participants attend focus groups to help further develop the patient portal and navigation program to expand to other groups. Patients use in-person navigation program. Patients also complete data collection and surveys over 15 minutes via web portal at baseline and 6 months and user experience survey at end of program participation.
62598725|NCT04723953|EXPERIMENTAL|Acute myocardial infarction patient group|
62241255|NCT02540863|EXPERIMENTAL|myofascial release protocol and Rocabado exercise therapy|"Myofascial Release Protocol:~* Suboccipital release.~* Compression - decompression of temporomandibular joint.~* Horizontal release of temporomandibular joint.~* Deep fascia release in temporal region.~* Masseter deep fascia release.~* Pterygoiddeep fascia release.~* Intraoral pterygoid deep fascia release."
62241256|NCT02540863|ACTIVE_COMPARATOR|exercise therapy|Rocabado´s 6 x 6 exercises program utilizes six exercises six times by day. The patient is in supine position with a loop of 6 cm in the cervical area, and the therapist sits at the head of the bed.
62598726|NCT03764540|EXPERIMENTAL|Cabazitaxel plus prednisone|"Cabazitaxel: Single-dose vial, containing a total of 60 mg of cabazitaxel expressed as anhydrous and solvent-free basis, per 1.5 mL of solution. Cabazitaxel will be administered by IV route Prednisone will be administered orally, 5 mg twice daily (10 mg per day total dose).~Prednisone will be administered by oral route"
62598727|NCT03764540|ACTIVE_COMPARATOR|Docetaxel plus prednisone|"Docetaxel is formulated in polysorbate 80 and commercially available as 80 mg/2.0 mL single-dose vials with accompanying diluent (13% ethanol in water for injection) for IV use.~Prednisone will be administered orally, 5 mg twice daily (10 mg per day total dose).~Prednisone will be administered by oral route"
62817338|NCT06470308|EXPERIMENTAL|Intervention Arm|An educational intervention and training in deprescribing algorithms and deprescribing tools ( Beers Criteria, STOPP/START) will be provided to the general practitioners caring for the patients selected in the intervention arm.
62817339|NCT06470308|NO_INTERVENTION|Control Arm|No educational intervention will be provided to the general practitioners of the selected patients.
62241257|NCT01326728||Allogeneic Stem Cell Transplant|Allogeneic hematopoietic stem cell transplantation (or allotransplant; donor blood stem cells)
62241258|NCT03786978|EXPERIMENTAL|Structured pharmaceutical care|Patients receive a structured pharmaceutical care until one year after hospital discharge
62241259|NCT03786978|ACTIVE_COMPARATOR|Comparator group|Patient received a single phone call 30 days after basal hospital discharge.
62241260|NCT03878004|EXPERIMENTAL|Primary Group|135 people who will receive the vaccine in the therapeutic scheme
62241261|NCT03878004|PLACEBO_COMPARATOR|Placebo Group|45 people who will receive placebo in the therapeutic scheme
62241262|NCT06493877|EXPERIMENTAL|Aerobic exercice on a treadmill with a negative slope|The aerobic exercise will be developed in interval mode, on a treadmill with a negative slope of up to -6% for the intervention group, performing a 2-minute interval with the workload estimated in METS, followed by another 4-minute interval with half the work intensity. It will last between 20 and 30 minutes. The intensity or workload will be individualized (between low and medium), according to the functional status of each participant and will be gradually increased depending on their tolerance. The working heart rate will be between 60% and 80% of the theoretical maximum HR, the oxygen saturation. It should never go below 90% and the subjective perception of effort according to the modified Borg scale will have its objective between 4 and 6 maximum. The treadmill used is the Commercial X22i model from Nordictrack, with a maximum slope of -6º.
62431691|NCT02267850|SHAM_COMPARATOR|Sham-Control OrthoPulse™|Subjects assigned to this group receive fixed orthodontic appliance treatment in conjunction with carrying out daily non-functional OrthoPulse™ treatments (untreated control).
62431692|NCT03066154|EXPERIMENTAL|N15DOP|Chemoradiation with ModraDoc/r and radiotherapy of the prostate in dose escalation design, followed by maintenance treatment.
62431693|NCT03530033|NO_INTERVENTION|Conventional surgery group|Induction of anesthesia according to conventional neuromuscular blockade dose, no neuromuscular blockade drug maintenance during lateral neck dissection.
62598728|NCT02994459||Metabolically Normal Obese (likely insulin sensitive)|i) BMI ≥30.0 but \<45.0 kg/m2; maximum body circumference \<165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) fasting blood glucose: \<100 mg/dl; iv) blood glucose 2 h after an OGTT: \<140 mg/dl; v) HbA1c \<5.7 %; vi) fasting insulin: \<20 µU/mL.
62817340|NCT04768504|EXPERIMENTAL|Treatment Arm|Tofacitinib 10 mg PO BID for 30 days
62817341|NCT03534804|EXPERIMENTAL|Cabozantinib and Pembrolizumab, all patients|
62817342|NCT02196896|EXPERIMENTAL|deprexis®|Patients in this arm use deprexis® as an additional treatment during their inpatient stay and as an aftercare intervention.
62241263|NCT06493877|ACTIVE_COMPARATOR|Aerobic exercice on a treadmill with a positive slope|The aerobic exercise will be carried out in interval mode, on a treadmill with a positive slope, performing a 2-minute interval with the workload estimated in METS, followed by another 4-minute interval with half the work intensity. It will last between 20 and 30 minutes. The intensity or workload will be individualized (between low and medium), according to the functional status of each participant and will be gradually increased depending on their tolerance. The working heart rate will be between 60% and 80% of the theoretical maximum HR, the oxygen saturation It should never go below 90% and the subjective perception of effort according to the modified Borg scale will have its objective between 4 and 6 maximum. The treadmill used is the Commercial X22i model from Nordictrack, with a maximum slope of 40º
62241264|NCT06493877|ACTIVE_COMPARATOR|Aerobic exercice on a cycle ergometer|The aerobic exercise will be carried out in interval mode, on a cycle ergometer, performing a 2-minute interval with the estimated workload in watts, followed by another 4-minute interval with half the work intensity. It will last between 20 and 30 minutes. The intensity or workload will be individualized (between low and medium), according to the functional status of each patient and will be gradually increased depending on her tolerance. The working heart rate will be between 60% and 80% of the theoretical maximum HR, the oxygen saturation should never drop below 90% and the subjective perception of effort according to the modified Borg scale will have its objective between 4 and 6. maximum.
62241265|NCT02859961|EXPERIMENTAL|PRO 140 SC 350 mg weekly injection (Group A)|PRO 140 350 mg (175 mg/mL) SC injections per week
62241266|NCT02859961|EXPERIMENTAL|PRO 140 SC 525 mg weekly injections (Group B)|PRO 140 525 mg (175 mg/mL) SC injections per week
62241267|NCT02859961|EXPERIMENTAL|PRO 140 SC 700 mg weekly injections (Group C)|PRO 140 700 mg (175 mg/mL) SC injections per week
62241268|NCT04866888|EXPERIMENTAL|pregnant women with placenta accreta spectrum|"Bladder will be dissected and mobilized down to the vagina after skeletonization and securing of bridging vessels either by electro-coagulation or ligation. Uterus will be incised 5mm above the placenta bulge, delivering the fetus followed by Carbetocin 100 microgram /1 ml intravascular. Repair of the uterine wall defect will be done. If extrauterine bleeding is excessive we may revert to internal iliac artery ligation followed by insertion of intra-peritoneal drain and regular abdominal wall closure.~After 3 months from delivery, ultrasound with different modalities will be done to all patients and outpatient hysteroscopy if symptomatic patients or with abnormal sonography."
62241269|NCT04834687|EXPERIMENTAL|Rope-skipping group|Participants would be required to take part in an exercise plan, under the instruction and guidance of professional sports teachers.
62241270|NCT04834687|EXPERIMENTAL|Diet intervention group|Participants would be required to take part in a diet plan , including a high-fiber diet and time-restricted eating.
62241271|NCT04834687|EXPERIMENTAL|Combined intervention group|Participants will receive both rope-skipping and diet interventions at the same time.
62241272|NCT04834687|NO_INTERVENTION|Control group|Participants would be required to maintain existing diet patterns and physical activity levels.
62241273|NCT04047693|EXPERIMENTAL|ddMVAC|4 cycles of neoadjuvant chemotherapy using dose dense MVAC with G-CSF
62817343|NCT02196896|PLACEBO_COMPARATOR|Information|Patients in this arm receive online information about depression as a placebo comparator in addition to their treatment during their inpatient stay and as an aftercare intervention.
62241274|NCT01609465||Stable angina|
62241275|NCT00953719|ACTIVE_COMPARATOR|36 mm|36 mm ceramic head on ceramic acetabular liner
62241276|NCT00953719|OTHER|28 mm ceramic-on-polyethylene|28 mm ceramic-on-polyethylene historical control
62241277|NCT03067155|EXPERIMENTAL|Treatment group|The patients for which a suitable donor product can be obtained will be included in the treatment arm of the protocol. Treatment consists of the administration of CMV-specific T-cells, administered through intravenous transfusion. Depending on response in viral load and GVHD status, a second and/or third administration is possible.
62241278|NCT03067155|ACTIVE_COMPARATOR|Control group|Patients for which the investigator can't obtain a suitable donor product, will be included in the control group consisting of standard anti-viral treatment.
62241279|NCT02809742||Epidural group|Epidural : automatic intermittent boluses ( 8-12 mL per hour) + patient controlled bolus (4 mL evrey 20 min) using ropivacaine
62241280|NCT02610153||Cohort 1|Adult patients, diagnosed with no-valvular atrial fibrillation and who have recently initiated or are going to initiate VKA treatment, that attend the Cardiology Units
62598729|NCT02994459||Metabolically Abnormal Obese (likely insulin resistant)|i) BMI ≥30.0 but \<45.0 kg/m2; maximum body circumference \<165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) fasting blood glucose: ≥100 mg/dl or blood glucose 2 h after an OGTT: ≥140 or fasting insulin: \>20 µU/mL.
62598730|NCT02994459||Metabolically Normal Lean|i) BMI ≥18.5 but \<25.0 kg/m2; ii) maximum body circumference \<165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) fasting blood glucose: \<100 mg/dl; iv) blood glucose 2 h after an OGTT: \<140 mg/dl; v) HbA1c \<5.7 %; vi) fasting insulin: \<20 µU/mL.
62817344|NCT02913339|EXPERIMENTAL|Intervention|Community health workers (CHWs) will conduct screening for CVD risk using a mobile phone application to assess risk and to schedule appointments at primary care centers (PCCs). The screening process will be non-invasive and no surgical, pharmaceutical, or other testing procedures will be utilized for screening of CVD risk by CHWs. If the CHW calculates the risk of CVD to be \> 10%, s/he will schedule a clinical visit with a health professional at one of the PCCs for further assessment and/or appropriate treatment. An automatic reminder messaging system will send reminder messages about upcoming appointments to the participants.
62819469|NCT01969344||Non-smokers|Never-smokers with normal lung function on spirometry without use of bronchodilators (n=201).
62038517|NCT00338065|EXPERIMENTAL|Subjects with normal-pressure glaucoma|"Subjects with open-angle glaucoma damage following a glaucoma specialist's examination without ever an intraocular pressure recording greater than 21 mm Hg.~.1. Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~2. Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
62431694|NCT03530033|EXPERIMENTAL|Lidocaine group|Anesthesia induction was performed according to conventional nerve monitoring neuromuscular blockade doses and lateral neck dissection was performed. When local muscle tremors occur, lidocaine is injected locally to eliminate muscle tremors.
62431695|NCT02751086||Robotic Gastrectomy|Patients who will be treated for gastric cancer with the assistance of the robotic surgical system
62431696|NCT02751086||Laparoscopic Gastrectomy|Patients who will be treated for gastric cancer through laparoscopic devices.
62241281|NCT04288830|EXPERIMENTAL|TCMMMRT First|Participants will perform an instructor-led mind-body exercise regimen 1 day per week during this arm of the study for a total of 8 weeks. Home practice will be logged. At the completion of the TCMMMRT Condition, participants will perform an instructor-led low impact aerobic exercise regimen 1 day per week for a total of 8 weeks. Home exercise will be logged.
62431697|NCT02751086||Open Gastrectomy|Patients who will be treated for gastric cancer with traditional open surgery.
62431698|NCT03778359||Gonadotropin-releasing hormone agonist treatment|Endometriosis post-operative Gonadotropin-releasing hormone agonist treatment
62598731|NCT02994459||Metabolically Abnormal Lean|i) BMI ≥18.5 but \<25.0 kg/m2; ii) maximum body circumference \<165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) iii) fasting blood glucose: ≥100 mg/dl or blood glucose 2 h after an OGTT: ≥140 or fasting insulin: \>20 µU/mL.
62817345|NCT02913339|ACTIVE_COMPARATOR|Control|"The protocol will be identical to that implemented in the intervention arm with the following difference:~If the CHW calculates the risk of CVD to be \> 10%, s/he will verbally advise the study participant of her/his increased risk and recommend that s/he schedule a clinical visit with a health professional at one of the PCCs for further assessment and/or appropriate treatment."
62817346|NCT01095185|EXPERIMENTAL|Standard therapy + Simvastatin|"* Standard therapy: Endoscopic variceal ligation (EVL)+ B Blockers (Propanolol titrated until achieve maximum tolerated dose)~* Simvastatin (20 mg for 15 days and after 40 mg/day until the end of the study)"
62431699|NCT03778359||Intrauterine device treatment|Endometriosis post-operative intrauterine device treatment
62817347|NCT01095185|PLACEBO_COMPARATOR|Standard therapy + placebo|"* Standard therapy: Endoscopic variceal ligation (EVL)+ B Blockers (Propanolol titrated maximum tolerated dose).~* Placebo"
62431700|NCT03778359||Hormone therapy|Endometriosis post-operative hormone therapy
62431701|NCT03778359||Oral contraceptive|Endometriosis post-operative oral contraceptive
62431702|NCT01684449|EXPERIMENTAL|Phase 2: Experimental Arm|Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).
62431703|NCT03101579|EXPERIMENTAL|Intra-pemetrexed|Patients were treated with intrathecal pemetrexed at dose escalation. The regimen of intrathecal pemetrexed is 10/15/20 mg, plus dexamethasone 5 mg, twice per week for 2 weeks, followed by once per week for 2-4 weeks. Pemetrexed is administrated by intrathecal injection via lumbar puncture. Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed. A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed，once per 3 weeks. To detect the pharmacokinetics of intrathecal pemetrexed, the serum and cerebrospinal fluid samples are collected. These samples would be analyzed by spectrometer for drug concentration.
62431704|NCT00751972|EXPERIMENTAL|HeartWare® VAS|Ventricular Assist Device (HeartWare® VAS)
62431705|NCT05409599|ACTIVE_COMPARATOR|Vestibular Exercises|Cawthorne-Cooksey Exercises applied to 1st group for 3 days/week for 12 weeks
62431706|NCT05409599|ACTIVE_COMPARATOR|Cervical Stabilization Exercises|cervical stabilization Exercises applied to 1st group for 3 days/week for 12 weeks
62431707|NCT05409599|ACTIVE_COMPARATOR|Balance Exercises|classical balance Exercises applied to 1st group for 3 days/week for 12 weeks
62598732|NCT03180658|EXPERIMENTAL|experimental|GTR+CGF+bone graft, CGF
62598733|NCT03180658|ACTIVE_COMPARATOR|controlled|CGF+bone graft
62598734|NCT03622398|EXPERIMENTAL|HXLPE|"This side of knee implanted with HXLPE(highly crosslinked polyethylene) liner while undergoing total knee arthroplasty. This group will receive the intervention, Total knee arthroplasty with HXLPE liner."
62598735|NCT03622398|ACTIVE_COMPARATOR|Conventional|"This side of knee implanted with conventional polyethylene while undergoing standard total knee arthroplasty. This group will receive the intervention, Total knee arthroplasty with conventional polyethylene liner."
62817348|NCT01740167|EXPERIMENTAL|Lifestyle program|health promotion lifestyle program : individual counseling, once a month, total 3 times.
62817349|NCT01964651|EXPERIMENTAL|Cohort A (Part 1)|Healthy male participants, 18 to 55 years of age.
62038518|NCT00338065|ACTIVE_COMPARATOR|Normal subjects|"Subjects without evidence of glaucoma or autonomic dysfunction.~..1. Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~2. Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
62817350|NCT01964651|EXPERIMENTAL|Cohort B (Part 1)|Healthy male participants, 18 to 55 years of age.
62038519|NCT05945433||Patients undergoing gynecological surgical procedure with the anovo Surgical System|
62038520|NCT05257096|EXPERIMENTAL|Medical clown EEG|50 Children performing the EEG at the days that the medical clown is available will be included in the study group.
62038521|NCT05257096|NO_INTERVENTION|Regular EEG|50 Children performing the EEG at the days that the medical clown is unavailable will be included in the control group. The EEG will be performed in the traditional way without medical clowns.
62038522|NCT03900468|EXPERIMENTAL|Active Deep Brain Stimulation (DBS)|
62817351|NCT01964651|EXPERIMENTAL|Cohort C (Part 2)|Healthy female participants of nonchildbearing potential (surgically sterile or postmenopausal), 18 to 58 years of age.
62598736|NCT00520481|EXPERIMENTAL|IMC-A12|Thirty-one participants will receive IMC-A12 at 10 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). An additional 10 participants will receive IMC-A12 at a dose of 20 mg/kg every three weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Radiographic evaluation of response will be performed every 8 weeks for the participants treated with intravenous (i.v.) IMC-A12 at 10 mg/kg and every 9 weeks for the participants treated with i.v. IMC-A12 at 20 mg/kg.
62598737|NCT01783639|EXPERIMENTAL|Arm 1|"Device: WIRION™ Embolic Protection System~Interventions: Carotid Artery Stent"
62598738|NCT05081180|EXPERIMENTAL|Avelumab + Lenvatinib|
62598739|NCT02226705|EXPERIMENTAL|Multiple Surgeries|Patients undergoing transnasal endoscopic surgery
62598740|NCT02559791|EXPERIMENTAL|Study participants|All study participants will receive 2 monthly doses of placebo followed by 4 monthly doses of IV reslizumab 3mg/kg
62817352|NCT01964651|EXPERIMENTAL|Cohort D (Part 2)|Healthy elderly male or female participants, from 65 to 85 years of age.
62817353|NCT05924984|EXPERIMENTAL|perforator localization|CT and color Doppler ultrasound were used to locate the perforating branch of the descending branch of the lateral circumflex femoral artery, and the position of the perforator was compared with real perforator respectively during the operation.
62817354|NCT00642200|ACTIVE_COMPARATOR|1|Patients receive Lichtenstein hernioplasty as a treatment for recurrent inguinal hernia.
62817355|NCT00642200|ACTIVE_COMPARATOR|2|Patients receive laparoscopic TEP as a treatment for recurrent inguinal hernia.
62817356|NCT02443467||HER2-positive early breast cancer|Human Epidermal Growth Factor Receptor 2 (HER2)-positive early breast cancer treated with loading dose of Herceptin (trastuzumab) administered as 6 mg/kg followed by once in 3 weeks administration at 4 mg/kg up to 12 months of treatment
62598741|NCT01770366|PLACEBO_COMPARATOR|Usual Care|Patients will receive usual care from the post-surgical clinic team.
62598742|NCT01770366|EXPERIMENTAL|Intervention Condition|Intervention participants will receive the Weight and Exercise Lifestyle Support (WELS) intervention, which involves use of a wireless activity monitor and weight scale, as well as access to a patient portal website displaying data from these devices.
62817357|NCT01611714|EXPERIMENTAL|Audit-feedback|Arm 1: Audit-feedback only
62817358|NCT01611714|EXPERIMENTAL|CDS message|Arm 2: CDS message only
62241282|NCT04288830|ACTIVE_COMPARATOR|Aerobic Exercise First|Participants will perform an instructor-led low impact aerobic exercise regimen 1 day per week during this arm of the study for a total of 8 weeks. Home exercise will be logged. At the completion of the aerobic exercise condition, participants will perform an instructor-led mind-body exercise regimen 1 day per week for a total of 8 weeks. Home practice will be logged.
62817359|NCT01611714|EXPERIMENTAL|Both Interventions|Arm 3: Audit-feedback and CDS message
62817360|NCT01611714|NO_INTERVENTION|Control|Arm 4: Control
62038523|NCT01270347|EXPERIMENTAL|Aeroquin|Aeroquin, Inhaled Levofloxacin (MP-376)
62038524|NCT01270347|ACTIVE_COMPARATOR|TIS|Tobramycin Inhalation solution (TIS) \[TOBI® Novartis Pharmaceuticals\]
62038525|NCT04728321|EXPERIMENTAL|AK104|AK104 15mg/kg IV every 3weeks (Q3W)
62241283|NCT01580280|EXPERIMENTAL|Thrust manipulation|
62241284|NCT01580280|ACTIVE_COMPARATOR|Non-thrust mobilization and exercise|
62241285|NCT04820374|NO_INTERVENTION|traditional extubation indications and traditional restoration indoor requirements|
62241286|NCT04820374|EXPERIMENTAL|Extubate the tube according to the pupil index and leave the recovery room|
62241287|NCT04194281|EXPERIMENTAL|Action Observation Therapy [AOT]|
62241288|NCT02915471|EXPERIMENTAL|Virtual Peer-to-Peer Support Mentoring|n addition to standard medical care, adolescents in the experimental group will receive the iP2P support program, a manualized peer-mentorship program that will provide mentoring and reinforcement by peers (young adults with cancer aged 16-25 years who have learned to function successfully with their cancer to the mentored participants).
62241289|NCT02915471|NO_INTERVENTION|Wait-list Control|The control group will receive usual care but without the mentorship intervention. They will be offered the iP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
62241290|NCT05522049|EXPERIMENTAL|Intervention group|Tracheal intubation facilitated by a hyperangulated videolaryngoscope (C-MAC D-Blade)
62241291|NCT05522049|ACTIVE_COMPARATOR|Control group|Tracheal intubation facilitated by a videolaryngoscope with a Macintosh type blade (C-MAC)
62598743|NCT06505135|ACTIVE_COMPARATOR|Standard Care|ROTATOR CUFF SURGERY Rotator cuff tendon suture is carried out at Hospital Sønderjylland according to inclusion criteria. Standard treatment also includes intravenous injection preoperatively of 2 g of Cloxacillin In case of allergy 1.5 g of Cefuroxim is chosen. Tendon suture is performed arthroscopically under regional anaesthetic blockage and light sedation with standard double row technique using suture anchors.
62735666|NCT01389453|ACTIVE_COMPARATOR|stem cell transplatation|All experimental group patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7-14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
62817361|NCT06114615|ACTIVE_COMPARATOR|Discharged with LiveCare and Text Message Intervention|Patients receive blood pressure monitoring and text messages reminders for enrollment in cardiac rehab, follow up appointment, diet and exercise counseling.
62817362|NCT06114615|SHAM_COMPARATOR|Discharged with Conventional Care|Patients do not receive blood pressure monitoring and text messages reminders for enrollment in cardiac rehab, follow up appointment, diet and exercise counseling.
62817363|NCT05005260|ACTIVE_COMPARATOR|liposomal bupivacaine single-shot interscalene blockade|Subjects will receive a preoperative single-injection interscalene nerve block with long-acting numbing medicine, liposomal bupivacaine
62038526|NCT04728321|EXPERIMENTAL|AK104 and Lenvatinib|AK104 15 mg/kg IV every 3 weeks (Q3W) Lenvatinib 12mg weight≥60kg or 8mg weight\<60kg,PO QD
62038527|NCT01693757||BPTB group|Bone-patellar tendon-bone
62038528|NCT01693757||STG group|Semitendinosus and gracilis tendon
62038529|NCT01693757||Control|Healthy
62038530|NCT01952535|EXPERIMENTAL|HMS5552 dose 1|A single dose of HMS5552 tablets (5\~50mg) taken orally.
62817364|NCT05005260|ACTIVE_COMPARATOR|continuous interscalene nerve blockade|Subjects will receive a preoperative interscalene nerve block with a continuous catheter device which provides local anesthetic, bupivacaine, for up to 3 days.
62817365|NCT06538480|EXPERIMENTAL|All participants|
62817366|NCT04426422|EXPERIMENTAL|metformin group|all the patients were treated with metformin 1500-2000mg daily for 3 months.
62817367|NCT00836368|EXPERIMENTAL|MaxiGamma|
62817368|NCT06356922|EXPERIMENTAL|[177Lu]Lu-PentixaTher|Injection of \[177Lu\]Lu-PentixaTher
62817369|NCT04904692||COVID-19 positive|"Peripheral blood draw:~* Day 1 of admission: blood draw.~* Day 7-10 of hospitalization: blood draw.~* Follow-up consultation: blood draw (selected patients).~Bronchoscopic sampling:~Material from bronchoscopic sampling (lavage fluid) will be collected only in those subjects in whom there is a diagnostic or therapeutic need for this procedure.~Swabs for SARS-CoV-2 PCR:~* Day 1 of admission: Extra oropharyngeal, nasal and nasopharyngeal (NP) swabs will be collected after the result of the initial diagnostic swab is known. In case of shortage of swabs, sputum samples will be collected as an alternative.~* Day 7-14 of hospitalization: NP swab or clinically available alternative will be executed on day 7 repeated weekly."
62817370|NCT04904692||COVID-19 negative|"Peripheral blood draw:~* Day 1 of admission: blood draw.~* Follow-up consultation: blood draw (selected patients).~Bronchoscopic sampling:~Material from bronchoscopic sampling (lavage fluid) will be collected only in those subjects in whom there is a diagnostic or therapeutic need for this procedure.~Swabs for SARS-CoV-2 PCR:~o Day 1 of admission: Extra oropharyngeal, nasal and nasopharyngeal (NP) swabs will be collected after the result of the initial diagnostic swab is known. In case of shortage of swabs, sputum samples will be collected as an alternative."
62817371|NCT05941793|EXPERIMENTAL|Cohort 1|low dosage of IP
62817372|NCT05941793|EXPERIMENTAL|Cohort 2|high dosage of IP
62817373|NCT05941793|PLACEBO_COMPARATOR|Cohort 3|Placebo
62817374|NCT04372017|EXPERIMENTAL|Cohort A: Healthcare worker (hydroxychloroquine)|
62817375|NCT04372017|PLACEBO_COMPARATOR|Cohort A: Healthcare worker (placebo)|
62817376|NCT04372017|EXPERIMENTAL|Cohort B: High-Risk participant (hydroxychloroqine)|
62817377|NCT04372017|PLACEBO_COMPARATOR|Cohort B: High-Risk participant (placebo)|
62817378|NCT03183453|EXPERIMENTAL|Neuropsychological treatment|The tested treatment is a combination of neuropsychological rehabilitation procedures: learning, episodic memory recall after a delay, selective attention, inhibition of predominant responses and awareness of deficits.
62817379|NCT03183453|NO_INTERVENTION|Non-confabulators control group|Non-confabulators (brain injured patients but without confabulations) in this control group only performed the pre- and post-measurements without treatment.
62038531|NCT01952535|EXPERIMENTAL|HMS5552 dose 2|A single dose of HMS5552 tablets (5\~50mg) taken orally.
62038532|NCT01952535|EXPERIMENTAL|HMS5552 dose 3|A single dose of HMS5552 tablets (5\~50mg) taken orally.
62241292|NCT04311567|EXPERIMENTAL|Tofacitinib|Oral tablet tofacitinib 5 mg BID for 48 weeks
62817380|NCT03183453|NO_INTERVENTION|Healthy control group|Healthy participants in this control group only performed the pre- and post-measurements without treatment.
62817381|NCT04441307|ACTIVE_COMPARATOR|Healthy Foundations|A community-based parenting education program with individual family check ins will be implemented to all participants assigned to this arm.
62817382|NCT04441307|EXPERIMENTAL|Family Foundations|An adapted Family Foundations parenting program for expecting first time parents with individual family check ins will be implemented to all participants assigned to this arm.
62817383|NCT02018562|EXPERIMENTAL|Intervention|"1. The talking tracheostomy trial involves placement of a talking tracheostomy tube (Portex Blueline Ultra Suctionaid Tracheostomy Tube) by respiratory therapist after obtaining an order from an authorized prescriber (Physician or Nurse Practitioner). The Speech-Language Pathologist (SLP) sets up the tracheostomy tube for speech and then determines the optimal air flow required for voicing. This amount of air flow is communicated to the ICU staff for further use.~2. We will ensure that the SLP meets with the patient for a minimum of 3 sessions within a week to optimize the use of a talking tracheostomy tube.~i. SLP will also assess the duration of successful speech during each session~ii. Sentence intelligibility will also be assessed during the 3rd session. This session will be audio-taped and reviewed by a second rater for sentence intelligibility.~iii. SLP will determine the level of independence with talking tracheostomy during the 3rd session."
62817384|NCT02018562|NO_INTERVENTION|Control|This group will also receive talking tracheostomy tube trial as standard of care but a week later after the pre and post assessments have been completed
62817385|NCT03074409|EXPERIMENTAL|oxytocin|intranasal administration of oxytocin
62817386|NCT03074409|PLACEBO_COMPARATOR|placebo|intranasal administration of the same ingredient except oxytocin
62038533|NCT01952535|EXPERIMENTAL|HMS5552 dose 4|A single dose of HMS5552 tablets (5\~50mg) taken orally.
62038534|NCT01952535|EXPERIMENTAL|HMS5552 dose 5|A single dose of HMS5552 tablets (5\~50mg) taken orally.
62038535|NCT01952535|EXPERIMENTAL|HMS5552 dose 6|A single dose of HMS5552 tablets (5\~50mg) taken orally.
62038536|NCT04588350|EXPERIMENTAL|i-SEP autotransfusion system|Use of i-SEP autotransfusion system during the surgery
62038537|NCT06496633||cohort :Hypertrophic Cardiomyopathy patients with residual obstruction after Alcohol Septal Ablation|All patients performed procedure of Percutaneous Intramyocardial Septal Radiofrequency Ablation
62038538|NCT03599648|EXPERIMENTAL|BPT-E|"Behavioral parent training (BPT) plus a psychoeducation program.~Includes a 10-week standard BPT, plus a 6-week psychoeducation program delivered prior to the standard BPT."
62241293|NCT04311567|ACTIVE_COMPARATOR|Methotrexate|Oral tablet methotrexate 2.5 mg: 8 tablets in one dose (=20 mg) once weekly for 48 weeks
62241294|NCT05881889|EXPERIMENTAL|repetitive transcranial magnetic stimulation|For patients in the rTMS group, we will first determine the intensity of the rTMS protocol by assessing the individual resting motor threshold (rMT). After determination of each individual's rMT, we will set rTMS intensity at 100% of the rMT and apply a single train of low-frequency rTMS over the DLPFS at 1 Hz for a total duration of 30 min (2000 pulses). receive 4 week rTMS treatment.
62241295|NCT05881889|SHAM_COMPARATOR|sham stimulation|For patients in the sham group, we will apply rTMS over the DLPFS in sham modality.
62241296|NCT04626817|ACTIVE_COMPARATOR|Isotretinoin receiving group|Isotretinoin receiving group for acne vulgaris
62241297|NCT04626817|PLACEBO_COMPARATOR|Local treatment receiving group|Local treatment receiving group for acne vulgaris
62598744|NCT06505135|EXPERIMENTAL|Stem-cell treatment|"HARVEST OF ADIPOSE TISSUE Harvest of adipose tissue from abdominal subcutis and the cell preparation will be performed in the approved lipoplasty system.This lipoaspirate will be processed in the dedicated adipose tissue-processing device. Cell clusters collected at the top of the adipose tissue-processing device undergo a second size reduction by being passed through a size reduction filter. The final product (approximately 60-100 mL) is then concentrated and collected into a 10-mL syringe for subsequent use.~HARVEST OF MUSCLE BIOPSY FROM THE SUPRASPINATUS MUSCLE A biopsy of 0.1-0.2 g muscle is obtained from the supraspinatus muscle to estimate preoperative muscle fiber atrophy, intracellular lipid accumulation, mitochondrial dysfunction, inflammation and reduced regenerative capacity. The muscle biopsy specimens will be taken near the muscular tendinous junction during routine exposure or arthroscopy of the glenohumeral region."
62038539|NCT03599648|EXPERIMENTAL|BPT-M|"Behavioral parent training (BPT) plus mindfulness-based stress reduction (MBSR).~Includes a 10-week standard BPT, plus a 6-week MBSR delivered prior to the standard BPT."
62241298|NCT02785497|EXPERIMENTAL|Treatment group|"Chronic ulcer patients will be treated with 50 minutes of the high-voltage current or 10 minutes of the diadynamic current. To burn patients 50 minutes high voltage current in the donor area. For both group the metal electrodes will be sterilized and the negative polarity in the active electrode.~50 min, 100Hz, intensity according to the sensitivity patient - High Voltage; 10 min, intensity according to the sensitivity patient - Diadynamic"
62817387|NCT05955898|EXPERIMENTAL|Parents THRIVE Group|Participants in this group will receive the Parents THRIVE intervention. Participants will be in this group for up to two hours.
62817388|NCT05955898|ACTIVE_COMPARATOR|Sharing Feelings Project Group|Participants in this group will receive the Sharing Feelings Group intervention. Participants will be in this group for up to two hours.
62241299|NCT02785497|SHAM_COMPARATOR|Control group|"For the control group the unit is turned on, the time will pass but will not be given intensity~50min, 100Hz, Intensity according to the sensitivity patient"
62241300|NCT05570474|EXPERIMENTAL|Protein|Daily protein shake during 6 months after surgery
62241301|NCT05570474|PLACEBO_COMPARATOR|Control|Daily placebo shake during 6 months after surgery
62241302|NCT06159192|EXPERIMENTAL|Monitoring Effect Of Shock Wave On Microcirculation Changes In Type2 Diabetes Mellitus|Energy intensity of (0.09 mJ/mm2) for 12 treatment sessions, two per week, for six weeks
62241303|NCT06159192|EXPERIMENTAL|Effect Of Shock Wave On Microcirculation Changes In Type2 Diabetes Mellitus|low intensity extracorporeal shock wave with the following parameters: - 3000 SWs (energy intensity of (0.09 mJ/mm2).
62241304|NCT03096925|EXPERIMENTAL|Intervention group|The intervention group will receive guided self-help comprising six web-based sessions, comprising information, exposure to physical activity, how worry can excess pain, physical reactions to pain and worry, consequences of avoidance, and specific panic treatment. The first session will be done at the hospital before discharge, the others at home. Between sessions there will be a brief telephone contact with a project worker.
62241305|NCT03096925|NO_INTERVENTION|Control group|This group will receive treatment as usual, which is no specific treatment. They can however use the general health system as they like.
62431708|NCT04567199||Cytosorb recipients|"Patients receiving Cytosorb due to septic shock.~SOFA score, Changes in catecholamine support after CytoSorb initiation Survival to discharge ICU Survival \>28d Thromboembolic events~General data:~Need of catecholamines Type of extra-corporal treatments Anticoagulation medication Concomitant allogenic blood products Concomitant factor concentrates Bleeding events Vital signs Underlying Disease SAPSII, SAPSIII, SOFA Scores (on 1st day of treatment) Type of Pathogen (gram+, gram-, fungi) Sepsis Multi Organ Failure~Data records:~Myoglobin, CK (creatine kinase), CK-MB, Fibrinogen D-dimers, Antithrombin III, Procalcitonin Creatinin, urea, Natrium, Potassium, Bilirubin, GOT (glutamate-oxalacetate transaminase), GPT, GGT (glutamate-pyruvate transaminase), PT (prothrombin time) aPTT (activated partial thromboplastin time) CRP (C reactive protein) Blood count Further parameters if of interest"
62817389|NCT05198921|EXPERIMENTAL|rTMS + neurorehabilitation|
62817390|NCT05198921|SHAM_COMPARATOR|sham rTMS + neurorehabilitation|
62817391|NCT04583280|EXPERIMENTAL|Rilematovir|Participants will receive rilematovir orally based on body weight and age group.
62817392|NCT04583280|EXPERIMENTAL|Placebo|Participants will receive matching placebo of rilematovir based on body weight and age group.
62817393|NCT06705088|EXPERIMENTAL|Single Ascending Dose|single ascending doses administered orally
62038540|NCT04221997|EXPERIMENTAL|sertraline|90 patients will be randomized to sertraline
62431709|NCT04567199||Non Cytosorb recipients|"Patients not receiving Cytosorb due to septic shock.~Patients not treated with CytoSorb under suspicion for inflammation, septic shock or SIRS will be searched for same characteristics as the first group.~These groups will be matched when parameters like epidemiology, infectious parameters, prognostic scores, age, gender amount of catecholamines fit best.~Parameters as in Group of Cytosorb recipients"
62817394|NCT06705088|EXPERIMENTAL|Multiple Ascending Dose|multiple ascending doses administered orally for 14 days.
62038541|NCT04221997|PLACEBO_COMPARATOR|Placebo|30 patient will be randomized to placebo
62038542|NCT04221997|NO_INTERVENTION|Healthy Control|30 healthy comparison subjects will be followed over the course of 12 weeks
62241306|NCT00866749|EXPERIMENTAL|Augmented BFM Therapy|Induction + Maintenance: Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Doxorubicin, Thioguanine
62241307|NCT05881980|EXPERIMENTAL|Group T1|Terbinafine 250 mg/day will be given in this group
62431710|NCT03777787|EXPERIMENTAL|Bitter|A single intragastric administration of denatonium benzoate (1 µmol/kg)
62038543|NCT02570126|EXPERIMENTAL|VAR_HSA_F Group|2 doses of Varilrix HSA-free vaccine, one at Visit 1 (Day 0) and the other at Visit 2 (Day 42), will be given to the subjects in this group. The vaccine will be administered subcutaneously in the triceps region of the left arm
62241308|NCT05881980|EXPERIMENTAL|Group I1|Itraconazole 200 mg/day will be given in this group
62241309|NCT05881980|EXPERIMENTAL|Group T+I|Terbinafine 250 mg + Itraconazole 200 mg/day will be given in this group
62241310|NCT05881980|EXPERIMENTAL|Group T2|Terbinafine 500 mg/day in two divided doses will be given in this group
62431711|NCT03777787|PLACEBO_COMPARATOR|Placebo|A single intragastric administration of placebo (water)
62431712|NCT04133480|EXPERIMENTAL|GWP42003-P|For the first 7 days of the treatment period, participants are to take GWP42003-P at a dose of 5 milligrams per kilogram per day (mg/kg/day), administered as 2 equally divided doses (i.e., 2.5 mg/kg in the morning and 2.5 mg/kg in the evening). On Day 8, participants are to increase the dose to 10 mg/kg/day, administered as 2 equally divided doses (i.e., 5 mg/kg in the morning and 5 mg/kg in the evening). The 10 mg/kg/day dose should be maintained for the remainder of the treatment period; however, per labeling, investigators may increase the dose to a maximum of 20 mg/kg/day if clinically warranted by titrating an additional 5 mg/kg/day each week until reaching the maximum dose. GWP42003-P will be taken b.i.d. (morning and evening).
62431713|NCT06058468|EXPERIMENTAL|Cardioneuroablation of right anterior ganglionated plexus|
62431714|NCT06058468|ACTIVE_COMPARATOR|Pulmonary vein isolation|
62431715|NCT01111630|EXPERIMENTAL|once weekly|
62431716|NCT01111630|ACTIVE_COMPARATOR|three times weekly|
62431717|NCT02627365|EXPERIMENTAL|Individualized, interactive SMS|Individualized, interactive SMS intervention plus Standard care. Messages sent automatically using the Text-IT system.
62817395|NCT06002620|EXPERIMENTAL|Control arm (CA)|A positive control group using an existing nutritional intervention with the known effect will be adopted, so as to meet ethical practice and be able to determine the effect of our new intervention response on the experimental group. The study will use double blinded approach with the control group receiving standard known flour of the supercereal CSB+ adjusted for ages as follows:6-8 months infants receiving 31g daily,9-11 months receiving 47g and 12-24 months receiving 86g to supply 200,300 and 550KCal daily respectively, with both the caregiver and person administering the food will be blinded from the content of the flour.
62817396|NCT06002620|EXPERIMENTAL|Enriched nutrition arm (ENA)|The study will use a Cricket Enriched flour(CEF) - with 20% cricket (, maize, millet, mineral and vitamin premix with amounts served adjusted to ages as:6-8 months infants receiving 29g daily,9-11 months receiving 44g and 12-24 months receiving 80g to supply 200,300 and 550KCal daily respectively, with both the caregiver and person administering the food will be blinded from the content of the flour.
62817397|NCT06002620|EXPERIMENTAL|Nutrition education arm (NEdA)|Combines the control and nutrition education where nutrition education comprises of a video, face to face session and SMS reminder in predetermined regular sessions
62817398|NCT06002620|EXPERIMENTAL|Combined Nutrition Education and enriched nutrition (CEdNA)|Combines the Cricket Enriched flour(CEF) and Nutrition education
62817399|NCT02044354|OTHER|Do/Ca|Arm Do/Ca : Taxotere 75mg/m2/3w x 4 cycles, followed by Jevtana 25mg/m2/3w x 4 cycles
62817400|NCT02044354|OTHER|Ca/Do|Arm Ca/Do : Jevtana 25mg/m2/3w x 4 cycles, followed by Taxotere 75mg/m2/3w x 4 cycles
62038544|NCT02570126|ACTIVE_COMPARATOR|VAR Group|2 doses of Varilrix™ vaccine, one at Visit 1 (Day 0) and the other at Visit 2 (Day 42), will be given to the subjects in this group. The vaccine will be administered subcutaneously in the triceps region of the left arm
62038545|NCT00925613|NO_INTERVENTION|Control|The double lumen tube is kept until extubation; there is no exchange with any tracheal tube or LMA.
62038546|NCT00925613|ACTIVE_COMPARATOR|Proseal|The double lumen tube is exchanged with a Proseal (LMA) before emergence according to the study protocol.
62241311|NCT05881980|EXPERIMENTAL|Group I2|Itraconazole 400 mg/day in two divided doses will be given in this group
62241312|NCT05187156|EXPERIMENTAL|Intervention|Veterans will participate in a novel intervention to improve PTSD and social support
62241313|NCT05187156|ACTIVE_COMPARATOR|Treatment as usual|Veterans will participate in usual care in PCMHI
62241314|NCT03940547|EXPERIMENTAL|Experimental - provision of flour|This arm will receive infant and young child feeding education performed by community health workers and very-low aflatoxin (AF) pre-blended porridge flour, ratio 4:1 maize to groundnut. Provision of this pre-blended flour will be 50 grams/day for 6-8 month olds, 60/day grams for 9-11 months and 75 grams/day for 12-18 month olds (with 10-15 grams added per day to account for any loss). Participants will also receive 1 kg of low-AF groundnut flour each month for 6-18 month olds. Finally, participants will receive a thermos flask to hygienically store porridge and a plastic scoop to measure appropriate amount of porridge flour each day.
62241315|NCT03940547|ACTIVE_COMPARATOR|Control - promotion of flour|This arm will receive infant and young child feeding education performed by community health workers and promotion of porridge made from maize and groundnut to match what is provided to the intervention arm. Participants will also receive a thermos flask to hygienically store porridge and a plastic scoop to measure appropriate amount of porridge flour each day.
62241316|NCT05987397|EXPERIMENTAL|Group A: Idebenone short-term treatment group|The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).
62241317|NCT05987397|EXPERIMENTAL|Group B: Idebenone long-term treatment group|The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.
62241318|NCT01219647|EXPERIMENTAL|aerobic exercise|Subjects will train on a recumbent cross trainer 20-30 minutes/session for three times/week for six months under supervision of a fitness specialist
62241319|NCT01219647|ACTIVE_COMPARATOR|stretching|Subjects will particiate in supervised stretching at same frauency, duration and intensity of aerobic exericse arm
62241320|NCT05296525|OTHER|GDA-201|"Phase 1 dose escalation with up to 4 dose levels to reach MTD and determine recommended phase 2 dose (RP2D).~Phase 2 RP2D will be administered to all patients."
62241321|NCT01423812|EXPERIMENTAL|Once-daily Darunavir and ritonavir|Subjects switched from Darunavir 600mg plus Ritonavir 100mg twice-daily to Darunavir 800mg plus Ritonavir 100mg once-daily
62431718|NCT02627365|NO_INTERVENTION|Standard care|Standard care according to Kenyan guidelines, including clinic-based adherence education and counseling.
62431719|NCT06464237|ACTIVE_COMPARATOR|Training group|Training with Mio-App for 5 weeks, three times per week.
62038547|NCT00925613|ACTIVE_COMPARATOR|Tracheal tube|The double lumen tube is exchanged with a tracheal tube before emergence according to the study protocol.
62038548|NCT01798329|ACTIVE_COMPARATOR|Probiotic|Probiotic VSL#3 for 15 weeks, dosage variations according to the weight
62038549|NCT01798329|PLACEBO_COMPARATOR|Placebo|subjects treated with placebo for 15 weeks
62038550|NCT06733363|EXPERIMENTAL|Adaptation|CAB members participate in maintenance phase development discussion over an hour up to 3 times per week.
62038551|NCT06733363|EXPERIMENTAL|Arm II - POW-R Health Only/Core + Maintenance|Patients receive study materials and phone calls during life of study
62038552|NCT02303184|EXPERIMENTAL|4 mg CLS-TA + IVT aflibercept|Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA following a 2 mg intravitreal injection of aflibercept
62038553|NCT02303184|ACTIVE_COMPARATOR|sham + IVT aflibercept|Single unilateral, suprachoroidal sham procedure following a 2 mg intravitreal injection of aflibercept
62038554|NCT00501176|ACTIVE_COMPARATOR|plastic stent|Stent insertion
62038555|NCT00501176|ACTIVE_COMPARATOR|metalic stent|Stent inserttion
62038556|NCT02192502|EXPERIMENTAL|HES 130/0.4 (Voluven)|6% HES 130/0.4 during surgery
62038557|NCT02192502|ACTIVE_COMPARATOR|human albumin 5%|human albumin 5% during surgery
62038558|NCT06185764|EXPERIMENTAL|Part A: Single Ascending Dose|Participants will be randomized to receive a single dose of different dose levels of VX-670.
62038559|NCT06185764|PLACEBO_COMPARATOR|Part A: Placebo|Participants will be randomized to receive single dose of placebo matched to VX-670.
62038560|NCT06185764|EXPERIMENTAL|Part B: Single and Multiple Ascending Dose|Participants will be randomized to receive single and multiple doses of different dose levels of VX-670. The dose levels will be determined based on the data from Part A.
62038561|NCT06185764|PLACEBO_COMPARATOR|Part B: Placebo|Participants will be randomized to receive single or multiple doses of placebo matched to VX-670.
62038562|NCT01302847|EXPERIMENTAL|Cohort I|Adolescents 12 to younger than 18 years of age who received DTG film-coated tablets
62431720|NCT06464237|NO_INTERVENTION|Control group|Waiting control group. Participants may use the Mio-App after completion of the last follow-up assessment.
62431721|NCT06206499|EXPERIMENTAL|Laterally Rotated Flap|LRF, Moreno and Caffesse, 2016
62817401|NCT05975671|OTHER|PICU Clinicians and Sepsis stakeholders|"Clinicians and sepsis stakeholders in the participating sites will be primarily recruited via email. During the course of this multifaceted intervention:~* All the PICU (Pediatric Intensive Care Unit) prescribing clinicians and sepsis stakeholders in the participating sites will receive clinical guidelines, unit-level feedback reports, and education on Vancomycin use during the intervention.~* Investigators will perform semi-structured interviews with 90 PICU clinicians and sepsis stakeholders.~* Surveys will be sent to all eligible clinicians, estimated to be up to 2500 individuals across the 4 sites. These structured surveys will be done at baseline and at 9 months post-implementation."
62038563|NCT01302847|EXPERIMENTAL|Cohort IIA|Children 6 to younger than 12 years of age who received DTG film-coated tablets
62038564|NCT01302847|EXPERIMENTAL|Cohort IIB|Children 6 to younger than 12 years of age who received DTG granules for suspension
62038565|NCT01302847|EXPERIMENTAL|Cohort III|Children 2 to younger than 6 years of age who received DTG granules for suspension
62038566|NCT01302847|EXPERIMENTAL|Cohort IV|Children 6 months to younger than 2 years of age who received DTG granules for suspension
62038567|NCT01302847|EXPERIMENTAL|Cohort III-DT|Children 2 to younger than 6 years of age who received DTG dispersible tablets
62038568|NCT01302847|EXPERIMENTAL|Cohort IV-DT|Children 6 months to younger than 2 years of age who received DTG dispersible tablets
62038569|NCT01302847|EXPERIMENTAL|Cohort V-DT|Infants 4 weeks to younger than 6 months of age who received DTG dispersible tablets
62038570|NCT02543034|EXPERIMENTAL|Betafoam Wound Dressing|This contains 3% povidone iodine. Dressing will be routinely changed on day 3 and day 7, and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
62038571|NCT02543034|ACTIVE_COMPARATOR|Petrolatum Gauze|Dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
62038572|NCT02543034|ACTIVE_COMPARATOR|Allevyn Wound Dressing|Allevyn adhesive wound dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
62038573|NCT03484975|OTHER|Observation group|Patients undergoing coronary angiography and intravascular imaging for either diagnostic purposes or for PCI following a presentation with either stable angina or an acute coronary syndrome.
62431722|NCT06206499|ACTIVE_COMPARATOR|Free gingival graft|FGG, Sullivan and Atkins, 1968, Langer and Sullivan, 1989
62735667|NCT01389453|NO_INTERVENTION|control|The control group gives injection through intravenous and lumbar puncture ways separately in the corresponding time, but the transplantation matter is physiological saline not the stem cell.
62038574|NCT04089033||Primary Retinal Detachment 1|Patients presenting with primary macula-off rhegmatogenous retinal detachment being treated with Pneumatic Retinopexy
62241322|NCT01423812|ACTIVE_COMPARATOR|Twice-daily Darunavir and ritonavir|Subjects remain on regimens containing Darunavir 600mg plus Ritonavir 100mg twice-daily
62241323|NCT05933486|EXPERIMENTAL|Tongluo-Kaibi tablet plus placebo of pregabalin|
62241324|NCT05933486|ACTIVE_COMPARATOR|placebo of Tongluo-Kaibi tablet plus pregabalin|
62241325|NCT05216900|EXPERIMENTAL|Neoadjuvant radiotherapy group|Twenty breast cancer patients will be included after they have given informed consent. Patients are eligible if they have an indication for mastectomy and RT, and a wish for an immediate reconstruction, either implant-based or autologous, in UMCU, Alexander Monro hospital, St Antonius Hospital, ZiekenhuisGroep Twente, Haagladen Medical Center and Amsterdam UMC.
62241326|NCT00588510||Blood draw|Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible.
62241327|NCT01464125|EXPERIMENTAL|Fos-Azi|Open label single arm concurrent administration of fosmidomycin and azithromycin.
62241328|NCT04806698|EXPERIMENTAL|Menicon Z Night|The experimental arm includes a group of children wearing Menicon Z Night orthokeratology contact lenses for 7 years
62241329|NCT04806698|ACTIVE_COMPARATOR|Control|The active comparator arm includes a control group of children wearing distance, single-vision glasses or soft contact lenses
62241330|NCT04202952|EXPERIMENTAL|600 mg multiple doses|Subjects receiving 600 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days
62241331|NCT04202952|EXPERIMENTAL|800 mg multiple doses|Subjects receiving 800 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days
62241332|NCT04202952|EXPERIMENTAL|1200 mg multiple doses|Subjects receiving 1200 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days
62241333|NCT04254744||Acyanotic children|Acyanotic children undergoing cardiac surgery due to congenital heart disease
62241334|NCT04254744||Cyanotic children|Cyanotic children undergoing cardiac surgery due to congenital heart disease
62241335|NCT03738969||Laparotomy group|Patients in this group accepted laparotomic radical hysterectomy for cervical cancer.
62241336|NCT03738969||Laparoscopy group|Patients in this group accepted laparoscopic or robotic radical hysterectomy for cervical cancer.
62241337|NCT01499472|ACTIVE_COMPARATOR|shock wave therapy, shortened wound healing time|
62241338|NCT01499472|OTHER|normal wound care|standard of care intervention
62241339|NCT02082236|ACTIVE_COMPARATOR|Treatment A|Sufenta® IV (50 mcg/mL) 30 mcg infused over 1 minute
62241340|NCT02082236|EXPERIMENTAL|Treatment B|Single dose of SSM 30 mcg
62241341|NCT02082236|EXPERIMENTAL|Treatment C|2 consecutive doses of SSM 15 mcg administered 20 minute apart
62241342|NCT02082236|EXPERIMENTAL|Treatment D|12 consecutive doses of SSM 30 mcg administered 1 hour apart
62241343|NCT04997928||Group 1 (n=20; with mild symptoms)|"Group 1 (n=20; with mild symptoms)~* Covid positive patients with mild symptoms who required to be hospitalized,~* Symptomatic (fever, cough, weakness, joint pain, etc.) new patients who apply to the Covid clinic for the first time,~* Patients with stable vital signs and/or SpO2 ≥92% in room air, no radiological signs of lung involvement or mild pneumonia,~* Patients who have not been started on steroid therapy and who have not yet received anticoagulant therapy."
62241344|NCT04997928||Group 2 (n=20; with moderate symptoms)|"Group 2 (n=20; with moderate symptoms)~* Patients who are positive for Covid 19 and admitted to the covid clinic for the first time;~* Radiologically moderate pneumonia findings and/or SpO2=88-92% in room air,~* Patients who have not been started antiviral, steroid, and anticoagulant treatment."
62241345|NCT04997928||Group 3 (n=20; with severe symptoms)|"Group 3 (n=20; with severe symptoms)~* Patients who are currently hospitalized in the Covid clinic,~* Patients with radiological findings of severe pneumonia or ARDS and/or high FiO2 requirement due to respiratory failure.~* Patients of this group may have received antiviral, anticoagulant, and/or steroid and/or biologic agent treatment."
62241346|NCT04997928||Group 4 (n=20; Control group)|"Group 4 (n=20; Control group)~* The control group will be composed of healthy adult individuals applying to adult allergy outpatient clinics on a voluntary basis.~* Patients who have not been previously diagnosed with Covid-19 and have not vaccinated against Covid-19,~* The control patients will be matched with the study groups according to age, gender, and BMI."
62038575|NCT04089033||Primary Retinal Detachment 2|Patients presenting with primary macula-off rhegmatogenous retinal detachment being treated with Pars Plana Vitrectomy
62241347|NCT00597753|EXPERIMENTAL|Peginesatide|
62241348|NCT00597753|ACTIVE_COMPARATOR|Epoetin alfa|
62241349|NCT05545033|EXPERIMENTAL|Virtual reality intervention|Comparison of pain and anxiety levels before and after VR intervention within the same patient.
62241350|NCT01033617|PLACEBO_COMPARATOR|Placebo|Saline solution with autologous plasma.
62241351|NCT01033617|EXPERIMENTAL|CD133+ stem cells|Autologous CD133+ intramyocardial injection at time of coronary artery bypass grafting.
62241352|NCT04160143|EXPERIMENTAL|SBRT followed by pulmonary metastasectomy|SBRT+Surgery
62241353|NCT04537273||Localy advanced Cervical Cancer|Patients with Localy advanced Cervical Cancer confirmed by pathology, clinical exams and computed tomography scan, treated with concurrent chemoradiotherapy.
62241354|NCT03948217|ACTIVE_COMPARATOR|L1|regimen L1 has overall higher intensity, higher color temperature and less light fluctuations
62241355|NCT03948217|ACTIVE_COMPARATOR|L2|regimen L2 has lower intensity, lower color temperature and more light fluctuations.
62241356|NCT05117697|EXPERIMENTAL|main group|Patients of the main group are treated with a crack by performing a lateral subcutaneous sphincterotomy.
62817402|NCT05975671|NO_INTERVENTION|PICU Patients with suspected sepsis|Research procedures involving patients will be limited to medical record review. This medical record review will help inform the intervention directed at PICU clinicians/stakeholders and the assessment of study outcomes. Approximately 50,000 patients will participate in the study. Data elements will be collected at each site and stored as password-protected Comma-separated values (CSV) files. These files will not contain any direct Protected Health Information (PHI) but will contain elements of date (e.g., date of admission, date of suspected sepsis episode). The study Identification (ID) number will be used to identify each unique patient. Each site will collect and store data in compliance with the Children's Hospital of Philadelphia (CHOP) and local Institutional Review Board (IRB) policies.
62241357|NCT05117697|EXPERIMENTAL|control group|In the control group, the fissure is excised in combination with a lateral subcutaneous sphincterotomy.
62241358|NCT02734823||Ancillary-Correlative (ovary imaging, hormonal analysis)|Patients undergo transvaginal ultrasound for antral follicles analysis and collection of serum for ovarian reserve markers and hormonal analysis before TKI therapy and at 12, 24, and 48 weeks.
62241359|NCT04370288|NO_INTERVENTION|Control group|Covid-19 patients treated with standard medical therapy (supportive therapy).
62241360|NCT04370288|EXPERIMENTAL|Intervention group|Covid-19 patients treated with mixture of MCN (Methylene blue, vitamin C, N-acetyl cysteine).
62241361|NCT00555555|EXPERIMENTAL|Coagulation FVIII/VWF|Anti-Hemophilic/von Willebrand Factor VIII (Human) Alphanate SD/HT
62431723|NCT00860574|EXPERIMENTAL|Treatment (allogeneic transplantation)|CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.
62431724|NCT04039165|EXPERIMENTAL|Intervention Group|Participants will complete an 8-week group physical activity and positive psychology program, in which they will complete exercises related to increasing positive emotions and physical activity during and between the group sessions. They will track their activity (steps) and set personalized physical activity goals each week, and complete a group walk or indoor exercise during the group sessions. The investigators will ask questions about participants' health and health behaviors, and ask them to wear a physical activity monitor at the beginning and end of the program. During times when in-person visits cannot happen (e.g., COVID-19), we will do virtual group sessions instead of meeting at the clinics, conducted via videoconference platform (i.e., Zoom), the group walks will not happen, and all exercise will be done individually to comply with social distancing measures.
62431725|NCT04039165|NO_INTERVENTION|Wait-list Control Comparison Group|Participants in the waitlist control group will not receive any active intervention during the initial study period (weeks 1-9). At Week 10, this group will receive the same intervention and assessments as described in the active treatment group above.
62431726|NCT01676259|EXPERIMENTAL|siG12D-LODER + chemotherapy|Eight siG12D-LODER+Gemcitabine+nab-Paclitaxel or Eight siG12D-LODER+Folfirinox or Eight siG12D-LODER+modifide Folfirinox
62431727|NCT01408576|EXPERIMENTAL|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles
62431728|NCT01408576|EXPERIMENTAL|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles
62431729|NCT00459381|EXPERIMENTAL|Treatment (pazopanib hydrochloride)|"Patients receive oral pazopanib hydrochloride daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Other: laboratory biomarker analysis"
62431730|NCT04540120|EXPERIMENTAL|dapansutrile capsules|Subjects will receive 4 x 250mg dapansutrile capsules BID for 14 days with an initial (first) dose of 8 x 250mg (2000 mg) administered at the study site on Day 1 (Day 1 dose may be 3000 mg).
62431731|NCT04540120|PLACEBO_COMPARATOR|placebo capsules|Subjects will receive 4 placebo capsules BID for 14 days with an initial (first) dose of 8 capsules administered at the study site on Day 1.
62241362|NCT01717963|EXPERIMENTAL|Naltrexone intramuscular suspension|Extended release naltrexone injections 380mg
62241363|NCT01717963|ACTIVE_COMPARATOR|Buprenorphine-naloxone|Flexible oral dose 4-24 mg daily
62241364|NCT02722174||BED|Binge Eating Disorder
62241365|NCT02722174||ADHD|Attention Deficit Hyperactivity Disorder
62241366|NCT02722174||SUD, cocaine subtype|Stimulant Use Disorder, cocaine subtype
62241367|NCT02722174||BPD|Borderline Personality Disorder
62241368|NCT02722174||BPD, Cohort 2|Borderline Personality Disorder, Cohort 2
62241369|NCT02722174||HC|Healthy Controls
62241370|NCT02486809|EXPERIMENTAL|Treatment 1: Needle and Syringe|Healthy volunteers will receive a single SC injection of lebrikizumab, withdrawn from a vial and administered by a needle and syringe.
62241371|NCT02486809|EXPERIMENTAL|Treatment 2: PFS-NSD|Healthy volunteers will receive a single SC injection of lebrikizumab, administered by PFS-NSD.
62241372|NCT01436071|EXPERIMENTAL|Fluticasone furoate 50mcg|Inhalation powder delivered by Novel Dry Powder Inhaler
62241373|NCT01436071|PLACEBO_COMPARATOR|Placebo|Inhalation powder delivered by Novel Dry Powder Inhaler
62241374|NCT05592067|ACTIVE_COMPARATOR|I tape technique|I tape technique described by Dr Kenzo Kase will be applied once a week, a total of 3 times, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
62817403|NCT04244448|OTHER|BIKTARVY® ADMINISTRATION DISSOLVED IN WATER|BIKTARVY® route in healthy volunteers: dissolved in water in Pharmacokinetics study protocol Compare the pharmacokinetic (PK) of dissolved in water versus crushed and solid form of BIKTARVY® in the same healthy volunteer, to determine if there is a PK equivalence between these three modes of administration of BIKTARVY®.
62817404|NCT04244448|OTHER|BIKTARVY® ADMINISTRATION CRUSHED|BIKTARVY® route in healthy volunteers: crushed in Pharmacokinetics study protocol Compare the pharmacokinetic (PK) of crushed versus dissolved in water and solid form of BIKTARVY® in the same healthy volunteer, to determine if there is a PK equivalence between these three modes of administration of BIKTARVY®.
62038576|NCT05467891|EXPERIMENTAL|Investigational Group|"The drug ribociclib will be taken orally at a dose of 400 mg daily for 21 days out of a 28-day cycle. Ribociclib will be used in combination with ET per physician choice.~All new subjects enrolled under the 08JUL2024 protocol or after will receive ribociclib 400mg daily for 21 days out of a 28-day cycle. Subjects receiving 600mg ribociclib under a prior protocol version will be switched to 400mg.~Physician's choice of endocrine therapy includes:~* 500 mg of fulvestrant received intramuscularly. This will be taken on Day 1 and Day 15 of Cycle 1 and on Day 1 of Cycle 2 and beyond.~* 1 mg of anastrozole taken orally daily of the 28 day cycle.~* 2.5 mg of letrozole taken orally daily of the 28 day cycle.~* 25 mg of exemestane taken orally daily of the 28 day cycle.~* Concomitant use with tamoxifen is not allowed.~Premenopausal subjects must also be treated with ovarian suppression according to institutional standards or have undergone bilateral oophorectomy."
62038577|NCT00223834|OTHER|1|Single session orientation to available services
62038578|NCT03886532||Medical Marijuana|Those subject taking only medical marijuana as standard of care. Will collect registry data and collect blood samples.
62038579|NCT03886532||CBD only products|Those subjects taking only CBD products as standard of care. Will collect registry data and collect blood samples.
62038580|NCT02133534|EXPERIMENTAL|Atorvastatin|Subjects will be treated with atorvastatin 10 mg/day for 30 days. The study team will obtain one blood and urine sample at baseline prior to starting atorvastatin therapy, and again after 30 days of drug therapy. The study team will do ultrasound imaging of the arm in which a probe will be placed over the blood vessels to measure the diameter of the artery and how this changes after a blood pressure cuff is inflated and then deflated. Subjects will take one nitroglycerine tablet during the ultrasound imaging.
62038581|NCT02738567||local anesthesia with adrenaline|patients undergoing surgery or medical procedure with the use of local anesthesia with adrenaline
62038582|NCT02738567||local anesthesia without adrenaline|patients undergoing surgery or medical procedure with the use of local anesthesia without adrenaline
62038583|NCT06732310|EXPERIMENTAL|PMEP + ECM|"In pregnancy: PMEP~In early childhood: enhanced case management"
62431732|NCT03344380||Prospective cohort|Adult patients undergoing liver transplantation will be included and followed up during the first 72 hours post-liver transplantation in order to confirm the development of acute kidney injury. The patients will be divided into two groups (AKI group vs. non-AKI group) according to the development of acute kidney injury. The GWAS will be performed with the blood obtained from enrolled patients.
62431733|NCT03344380||Retrospective cohort|In previous study performed in adult patients undergoing liver transplantation (NCT02489474, 4-2015-0411), we enrolled patients and collected data regarding the development of acute kidney injury during the first 72 hours post-liver transplantation. Among these patients enrolled in this previous study, only patients who agreed to additional use of the blood sample for research purposes will be included in the present study. The GWAS will be performed with the blood obtained from enrolled patients.
62431734|NCT02864680|OTHER|Cannabis users|
62431735|NCT02864680|OTHER|Healthy volunteers, not cannabis/tobacco users|
62817405|NCT04244448|OTHER|BIKTARVY® ADMINISTRATION SOLID|BIKTARVY® route in healthy volunteers: solid tablet in Pharmacokinetics study protocol Compare the pharmacokinetic (PK) of solid form of BIKTARVY® versus dissolved in water and crushed in the same healthy volunteer, to determine if there is a PK equivalence between these three modes of administration of BIKTARVY®.
62817406|NCT04160182|EXPERIMENTAL|Energy Conservation Work Simplification Education|The intervention will be delivered online by an occupational therapist. The intervention consists of 6 weekly sessions; each session will be 45 minutes long. The focus of the intervention is to teach breast cancer survivors strategies to manage their fatigue.
62038584|NCT06732310|EXPERIMENTAL|Pregnancy - Active Control + RET|"In pregnancy: Women who are not randomized to PMEP participate in a contact-equivalent, non-directive social support group.~In early-childhood: Women participant in the RET."
62431736|NCT02864680|OTHER|Healthy volunteers, tobacco users|
62241375|NCT05592067|ACTIVE_COMPARATOR|Button hole technique|Button hole technique defined by Dr Kenzo Kase will be applied once a week, 3 times in total, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
62241376|NCT05592067|OTHER|exercises|exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
62241377|NCT05908955|ACTIVE_COMPARATOR|PVI|Participants in this group will receive pulmonary vein isolation.
62431737|NCT02864680|OTHER|Schizophrenia patients|
62431738|NCT05074563|ACTIVE_COMPARATOR|Online REsOluTioN training|The active comparator arm will receive access to online REsOluTioN training to enhance resilience.
62598745|NCT05164640|OTHER|assessment of coronary physiology|"This is a prospective, multicentric, non-randomized , single-arm , open label clinical study.~Included patients will be studied with invasive functional tests performed during index coronary angiography. These will include FFR, instantaneous Wave-Free Ratio (iFR), Resting Ful-Cycle Ra-tio (RFR), CFR, IMR and provocative Acetylcholine test.~After the diagnosis of vasospastic angina (VSA) or coronary microvascular dysfunction (CMD) is made, a stratified medical therapy will then be initiated according to the results of physiological assessment according to ESC guidelines and recent EAPCI expert consensus document ."
62241378|NCT05908955|EXPERIMENTAL|PVI+SVCI|Participants in this group will receive superior vena cava isolation in addition to pulmonary vein isolation.
62241379|NCT00227188||1|Children from 0-5 years of age evaluated for IPD
62598746|NCT03499691|EXPERIMENTAL|Expanded Hemodialysis (HDx) Therapy|Patients will undergo 3 dialysis sessions per week with Theranova 500 for up to 24 weeks.
62598747|NCT03499691|ACTIVE_COMPARATOR|Hemodiafiltration (HDF) Therapy|Patients will undergo 3 dialysis sessions per week with on-line HDF for up to 24 weeks.
62817407|NCT03181022|NO_INTERVENTION|Phase 1a|To develop a measure of MI fidelity to ensure methodological rigor, acceptability and feasibility of administration, and clinical usefulness (Phase 1a). Ratings of 200 recordings of full patient-provider interactions with ratings of thin slices (recording 1 minute every 5 minutes) will be compared.
62241380|NCT05535634||Children referred for tympanostomy tube insertion|Study Sound Ear Check (SEC) hearing test among 3-10 years old otherwise healthy children referred to tympanostomy tube placement. SEC test prior surgery (with middle ear fluid) and at 1 month control visit (dry middle ear with ventilation tube). Otitis media 6 questionnaire prior surgery and at the 1 month control visit.
62241381|NCT05103696|EXPERIMENTAL|Remimazolam group|Patients received remimazolam to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure. And patients were injected remifentanil 0.3μg/kg (infusion time \> 1min) at the first time，When the analgesia was insufficient, Remifentanil can be added according to the situation.
62241382|NCT05103696|ACTIVE_COMPARATOR|EP group|Patients received Etomidate combined with propofol to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure. And patients were injected remifentanil 0.3μg/kg (infusion time \> 1min) at the first time.When the analgesia was insufficient,Remifentanil can be added according to the situation
62241383|NCT01753154|EXPERIMENTAL|Solution B (balance PD solution)|Treatment 8 weeks with solution B (balance PD solution), next 8 weeks with solution A (conventional PD solution)
62431739|NCT05074563|OTHER|Control|The control arm will have no access to the online training.
62817408|NCT03181022|NO_INTERVENTION|Phase 1b|To conduct evidence-based tailoring of MI training for adolescent HIV care settings (Phase 1b). Coding via sequential analysis will be conducted of the 200 recordings to identify those specific provider communication behaviors that predict subsequent youth motivational statements.
62431740|NCT03877237|EXPERIMENTAL|Dapagliflozin|Green, diamond shaped, film coated tablets 10 mg administered orally, once daily
62431741|NCT03877237|PLACEBO_COMPARATOR|Placebo|Green, diamond shaped, film coated tablets placebo administered orally, once daily
62431742|NCT02169583|EXPERIMENTAL|Part A (Cohort 1)|Approximately 8 subjects (6 Active, 2 Placebo) will be randomized to receive single escalating IV doses i.e.10 milligrams (mg), 25 mg and 100 mg, plus one oral 100 mg dose (on the last occasion) of GSK1325756 or matching placebo, with a 7-days washout between doses. Dose escalations will be based on review of PK and safety data from preceding dose level. The projected doses for each group are subject to modification based upon PK and safety data from preceding cohorts. Pharmacokinetic parameters will be reviewed from at least 4 active subjects from preceding dose before dose escalating to the next dose level. The maximum dose administered will be 100 mg. Additional subjects/Cohorts may be enrolled.
62598748|NCT06512454||Cohort 1: AATD-Pi*ZZ Genotype/Phenotype|Participants who have been diagnosed with Alpha-1 Antitrypsin Deficiency homozygote ZZ (AATD-Pi\*ZZ) genotype/phenotype with mild or without liver disease manifestations will be enrolled and data will be prospectively collected per routine care throughout the follow-up period (up to 5 years).
62598749|NCT06512454||Cohort 2: AATD-Pi*SZ Genotype/Phenotype|Participants who have been diagnosed with alpha-1 antitrypsin deficiency heterozygous SZ (AATD-Pi\*SZ) genotype/phenotype with moderate-advanced or severe liver disease manifestations will be enrolled and data will be prospectively collected per routine care throughout the follow-up period (up to 5 years).
62598750|NCT01271816||Presymptomatic ARVC gene carriers|ARVC gene positive patients without manifest ARVC after standard screening clinical testing.
62598751|NCT06579937|EXPERIMENTAL|Esketamine group|During anesthesia induction, 0.2 mg/kg esketamine was administered intravenously.
62598752|NCT06579937|PLACEBO_COMPARATOR|Control group|During anesthesia induction, an equal volume of 0.9% saline was administered intravenously.
62598753|NCT00427206|ACTIVE_COMPARATOR|1|acetaminophen 4 g/day
62598754|NCT00427206|PLACEBO_COMPARATOR|2|placebo undistinguishable from active drug
62241384|NCT01753154|ACTIVE_COMPARATOR|Solution A (conventional PD solution)|Treatment 8 weeks with solution A (conventional PD solution), next 8 weeks with solution B (balance PD solution)
62241385|NCT03383549|EXPERIMENTAL|Tele-rehabilitation|Tele-rehabilitation arm undergo a home-based rehabilitation combined protocol, made up of cognitive and physical exercises
62241386|NCT03383549|NO_INTERVENTION|Control group|Control group receives only verbal instructions to train cognitive and physical conditions. Instructions will aim to promote daily and leisure activities.
62241387|NCT05279209|EXPERIMENTAL|Sclerotherapy|Patients who receive uterine artery embolization for symptomatic fibroids
62241388|NCT05279209|ACTIVE_COMPARATOR|Surgery|Patients who receive uterine artery embolization for symptomatic fibroids
62241389|NCT02261038|OTHER|Kanekasu radiographs|No drugs or devices are used in this study. Commonly available radiological techniques such as radiographs and CT are used. All patients undergo a CT of the knee and a special radiograph (Kanekasu technique).
62241390|NCT01920386|ACTIVE_COMPARATOR|Tramadol hydrochloride/Acetaminophen Tab.|1tab PO within 5hours from teeth extraction
62241391|NCT01920386|EXPERIMENTAL|Tramadol hydrochloride/Acetaminophen SR Tab.|1tab PO within 5hours from teeth extraction and then 1tab more after 6hours
62431743|NCT02169583|EXPERIMENTAL|Part B (Cohorts 2 and 3)|Approximately 8 subjects (6 Active, 2 Placebo) per cohort will be randomized to receive escalating repeated IV doses of GSK1325756 or matching placebo (Cohort 2: 25 mg, Cohort 3: 50 mg) for 5 days. Repeated (BID) doses of GSK1325756 will begin the morning of Day 1 and continue through the morning of Day 5 (9 total doses). Dose escalations will be based on review of PK and safety data from preceding dose level. The projected doses for each group are subject to modification based upon PK and safety data from preceding cohorts. Pharmacokinetic parameters will be reviewed from at least 4 active subjects from preceding dose before dose escalating to the next dose level. The maximum dose administered will be 50 mg BID. Additional subjects/Cohorts may be enrolled.
62431744|NCT05162885|ACTIVE_COMPARATOR|implant placement in defective Sockets preserved with alendronic acid sponge|"anesthesia according the site of implant placement were administered using mepivacaine HCl (2%) with levonordefrin 1:20 000 (Scandonest 2%; Septodont, Saint- Maur-des-Fossés, France). Injection to control pain and bleeding for hemostasis. Crestal incision with a full thickness mucoperiosteal flap was reflected .A pilot drill will be used to start the osteotomy preparation, then different drilling sizes will be used to attain the final drill size and the planed implant height and width according to Cone Beam CT. Implants were screwed directly into the osteotomy site, primarily the screwing was done mechanically by Fixture Mount Connection attached to the implant carrier.~The created gap sutured passively to allow tension-free interrupted closure using 3-0 coated undyed braided polyglactin 910 suture material."
62598755|NCT01983072|ACTIVE_COMPARATOR|Infant starter formula|standard infant formula
62241392|NCT01866397|EXPERIMENTAL|Cidofovir pharmacokinetics|Patient received cidofovir due to clinical necessity (therapy resistant HCMV retinitis) while being on continuous hemofiltration. Pre- and postfilter plasma samples were taken at multiple timepoints during 24 hours.
62241393|NCT03849443|PLACEBO_COMPARATOR|Group 1 PLACEBO|
62241394|NCT03849443|EXPERIMENTAL|Group 2 IV TXA|
62241395|NCT03849443|EXPERIMENTAL|Group 3 Pre-Oral TXA|
62241396|NCT03849443|EXPERIMENTAL|Group 4 Full Oral TXA|
62598756|NCT01983072|EXPERIMENTAL|Infant starter formula + prebiotics + probiotics|infant formula
62598757|NCT01983072|OTHER|Breastfeeding group|reference group
62598758|NCT05482321||Group 1|SOP (healthy) subjects. Part I of study (optimizing protocol).
62598759|NCT05482321||Group 2|Control (healthy and autoantibody positive) subjects. Part II of study (cross-sectional study)
62598760|NCT05482321||Group 3|T1D subjects. Part II of study (cross-sectional study)
62598761|NCT01968356|EXPERIMENTAL|3M CHG/IPA Prep Colorless|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
62598762|NCT01968356|EXPERIMENTAL|3M CHG/IPA Prep Tint|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
62598763|NCT01968356|ACTIVE_COMPARATOR|ChloraPrep Hi-Lite Orange|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
62241397|NCT02367326||Patients with Inflammatory Bowel Disease|patients with Crohn's Disease or Ulcerative Colitis meeting clinical, endoscopic and histological criteria and on thiopurines at stable doses for at least 3 months, monotherapy or combined with corticotherapy
62241398|NCT06054412|OTHER|Neurofeedback Training|Mothers in the Neurofeedback Training group will complete pre and post-training self-report surveys assessing trauma symptoms, mental health, parenting attitudes and behaviors, and infant crying patterns and socioemotional development. Mothers in this group will all be receiving in-person psychotherapy outside of the study, and they will all demonstrate clinically significant symptoms aligned with post-traumatic stress disorder and/or it's dissociative subtype.
62241399|NCT01109836|EXPERIMENTAL|Motivation and lifestyle intervention|Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
62817409|NCT03181022|NO_INTERVENTION|Phase 2|To collaboratively develop the implementation intervention with 2 clinic teams associated with the ATN (Phase 2). A formative evaluation will be done to provide local diagnostic data regarding barriers and facilitators to adoption and create development panels - local development teams made up of clinicians and administrators from the site, and study staff to address barriers and facilitators from formative evaluation and draft locally-customized clinical care and multi-level implementation strategies with initial sustainability plans.
62817410|NCT03181022|EXPERIMENTAL|Phase 3|To pilot test the implementation intervention and process/outcome evaluation protocols at two ATN sites in preparation for a full-scale trial.
62817411|NCT06600555|EXPERIMENTAL|metabolic surgery with SLEEVE technique|
62817412|NCT06600555|EXPERIMENTAL|metabolic surgery with BY-PASS technique|
62817413|NCT02706652||all patients|all eligible patients
62817414|NCT06705075|EXPERIMENTAL|Uterine fibroids|
62598764|NCT01968356|PLACEBO_COMPARATOR|Normal Saline|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
62598765|NCT06475885|EXPERIMENTAL|Group Receiving Infant Massage Training|The experimental group received a 5-week International Association of Infant Massage (IAIM) Infant Massage Program starting from the 14th day postpartum.
62817415|NCT01860339||Gene-expanded (GE)|Children at risk for HD who have a CAG repeat length of 40 and above.
62817416|NCT01860339||Gene Non-Expanded (GNE)|Children at risk for HD who have a CAG repeat length of 39 or less
62817417|NCT04844827||malignant pleural effusion|Patients with malignant pleural effusion who underwent pleural biopsies and blood tests under general anesthesia
62817418|NCT06159335|EXPERIMENTAL|PET-MRI|Participants will undergo F-Fluciclovine PET radiotracer and MRI
62817419|NCT03742076|ACTIVE_COMPARATOR|High-dose prebiotic|10 gm gum arabic (powder) with 2 gm fiber powder daily for at least 6 weeks
62817420|NCT03742076|ACTIVE_COMPARATOR|Low-dose prebiotic|5 gm gum arabic (powder) with 2 gm fiber powder daily for at least 6 weeks
62817421|NCT03742076|PLACEBO_COMPARATOR|Placebo|2 gm powdered fiber daily for at least 6 weeks
62817422|NCT05041413|EXPERIMENTAL|Moms Quit Intervention|12 weeks of the Moms Quit text message intervention
62817423|NCT05041413|ACTIVE_COMPARATOR|Text4Baby|12 weeks of Text4Baby messages
62817424|NCT06705257|EXPERIMENTAL|Single arm with increasing and decreasing PEEP levels|
62431745|NCT05162885|ACTIVE_COMPARATOR|Implant placement in Defective sockets preserved with sticky bone|"anesthesia according the site of implant placement were administered using mepivacaine HCl (2%) with levonordefrin 1:20 000 (Scandonest 2%; Septodont, Saint- Maur-des-Fossés, France). Injection to control pain and bleeding for hemostasis. Crestal incision with a full thickness mucoperiosteal flap was reflected .A pilot drill will be used to start the osteotomy preparation, then different drilling sizes will be used to attain the final drill size and the planed implant height and width according to Cone Beam CT. Implants were screwed directly into the osteotomy site, primarily the screwing was done mechanically by Fixture Mount Connection attached to the implant carrier.~The created gap sutured passively to allow tension-free interrupted closure using 3-0 coated undyed braided polyglactin 910 suture material."
62817425|NCT06334432|OTHER|Phase 1: Schedule A|Schedule A evaluating escalating dose levels of NUV-1511
62431746|NCT02651896||HypoIGRT|"1. Low Risk (T1-T2a, Gleason score 6, and PSA \< 10 ng/mL)~2. Intermediate Risk (T1-T2c, Gleason 7, and PSA 10-20 ng/mL)~3. High Risk (T3 - 4 , Gleason 8-10, and/or PSA \> 20 ng/mL) Neoadjuvant hormone therapy is allowed on groups 2 and 3"
62817426|NCT06334432|OTHER|Phase 1: Schedule B|Schedule B evaluating escalating dose levels of NUV-1511
62817427|NCT06334432|EXPERIMENTAL|Phase 2: Tumor Type 1|Tumor type to be selected after Phase 1. Dose Schedules A and B to be further evaluated.
62817428|NCT06334432|EXPERIMENTAL|Phase 2: Tumor Type 2|Tumor type to be selected after Phase 1. Dose level and schedule to be selected after identification of the recommended phase 2 dose (RP2D) in Phase 1.
62817429|NCT06334432|EXPERIMENTAL|Phase 2: All comers|All tumor types allowed per protocol. Dose level and schedule to be selected after identification of the recommended phase 2 dose (RP2D) in Phase 1.
62817430|NCT02730858|EXPERIMENTAL|Palliative and oncology care model|"After the screening procedure confirm eligibility to participate in the research study. Participants will be randomized into one of two study groups;~-- Standard oncology care with palliative care."
62817431|NCT02730858|ACTIVE_COMPARATOR|Standard oncology care|"After the screening procedure confirm eligibility to participate in the research study. Participants will be randomized into one of two study groups;~-- Standard oncology care"
62817432|NCT03954639|EXPERIMENTAL|Cohort 1, Group 1|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with EXPAREL.~EXPAREL will be mixed with Bupivacaine~Subjects enrolled in Cohort 1 will provide blood samples and measures for efficacy and safety."
62817433|NCT03954639|ACTIVE_COMPARATOR|Cohort 1, Group 2|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with bupivacaine.~Subjects enrolled in Cohort 1 will provide blood samples and measures for efficacy and safety."
62817434|NCT03954639|EXPERIMENTAL|Cohort 2, Group 1|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with EXPAREL.~EXPAREL will be mixed with Bupivacaine~Subjects enrolled in Cohort 2 will provide measures for efficacy and safety."
62817435|NCT03954639|ACTIVE_COMPARATOR|Cohort 2, Group 2|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with bupivacaine.~Subjects enrolled in Cohort 2 will provide measures for efficacy and safety."
62817436|NCT04829136|EXPERIMENTAL|Arm I (enteral nutrition) [Discontinued in January 2024]|Patients receive enteral nutrition via nasoenteric feeding tube starting on day 1 until hospital discharge.
62817437|NCT04829136|ACTIVE_COMPARATOR|Arm II (standard of care) [Discontinued in January 2024]|Patients receive standard of care nutritional support.
62817438|NCT04829136|EXPERIMENTAL|Supportive care (Fiber) [Current study activity]|Patients receive fiber supplementation PO or enterally starting 14 to 5 days prior to standard of care conditioning chemotherapy and continuing until discharge from the hospital. Stool will be collected at different time points throughout the study. Patients may also undergo blood sample collection throughout the study.
62817439|NCT04388592|EXPERIMENTAL|Nurse practitioner (NP)-led care arm|The patient randomized to the NP intervention arm will be contacted by the NP to be scheduled for an NP appointment within 4 to 6 weeks from the date of the referral. The NP consultation will include patient history, physical examination, symptomatic management strategies as appropriate (eg: bladder and bowel management strategies, fatigue management, depression, anxiety, spasticity etc), discussion of mental and physical health resources for symptomatic treatment, support, physical and mental health resources to optimize functioning (eg: home care, physical/occupational therapy referral) and quality of life. There will be NP followup, in person or by phone or videoconferencing at 3 months, and 6 months. The NP will be using the electronic medical record offered by Alberta Health Services.
62817440|NCT04388592|NO_INTERVENTION|Usual Care Arm|Those patients randomized to the usual care arm (community neurologist and registered nurses) will be contacted by the NP to be scheduled for an NP appointment in 6 months, so that every participant is given the opportunity to meet with the NP, after their involvement in the study has concluded. During the six-month period, patients randomized to the control group will receive usual care from community neurologists and MS registered nurses or family physicians. The care will be delivered according to standard practices, and follow-up visits will be conducted according to the various neurologists' or family physicians' practices.
62817441|NCT04525755|EXPERIMENTAL|Varenicline (.5mg BID)|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline (.5 mg, 60 tablets total), NRT, or not, with outcomes assessed through 12 weeks of follow-up. 324 participants will be enrolled in this group. Participants in the varenicline sampling group will be given standard instructions on titration but ultimately will decide on their own as to if and how it is used. Dosing is lower than most industry trials of varenicline (1mg BID) but consistent with two trials of lower dosing that showed efficacy and with fewer side effects. Varenicline participants can choose to titrate 2mg if they wish, with shorter duration of sampling experience.
62817442|NCT04525755|ACTIVE_COMPARATOR|Nicotine Replacement Therapy (NRT)|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline, NRT, or not, with outcomes assessed through 12 weeks of follow-up. 162 participants will be enrolled in this group. Participants in NRT group will receive 28 day supply of nicotine patch (1patch x 28 days @ 14mg) and lozenge (14 per day x 28 days @4mg) with instructions to use based on number of cigarettes smoked per day. Like varenicline participants, smokers in NRT group can use as much or as little of the NRT as they wish.
62817443|NCT04525755|NO_INTERVENTION|Control Group|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline, NRT, or not, with outcomes assessed through 12 weeks of follow-up. 162 participants will be enrolled in this group.
62817444|NCT06228625|ACTIVE_COMPARATOR|Control Group|Conventional exercise training will be given to the control group for 6 weeks, 5 days a week, for 45 minutes. Conventional exercises will be applied to this group under the supervision of a physiotherapist for 5 days in our unit.
62817445|NCT06228625|EXPERIMENTAL|Body Awareness Training Group|After the first evaluation, the training group will be given basic body awareness exercise training for 6 weeks, 2 days a week, for 45 minutes. This group will be given to basic body awareness exercises under the supervision of a physiotherapist for 2 days in our unit. Individuals in this group will be applied basic body awareness exercisea program in addition to conventional exercises.
62431747|NCT01291719|EXPERIMENTAL|insulin and glucose infusion|trial of experimental technique in outpatient setting; the group under study will be comprised of type 1 and type 2 diabetic individuals ; they will have automated treatment using algorithm which regulates balancing infusions of glucose and/or insulin intravenously without manual intervention; blood glucose target of 80-180 mg/dl will be guide for the automated system
62241400|NCT01109836|NO_INTERVENTION|Control|Standard stroke care
62431748|NCT06485037|EXPERIMENTAL|Time-restricted eating|Participants in the TRE group must restrict their eating to a time window of 10 hours per day, with mandatory fasting from 11 p.m. to 6 a.m.
62431749|NCT06485037|NO_INTERVENTION|Control|Participants in the Control group must follow their usual diet routine, without any time restriction
62431750|NCT00391937|EXPERIMENTAL|1|ASR prosthesis placed using CAS
62431751|NCT00391937|ACTIVE_COMPARATOR|2|ASR prosthesis placed by conventional method
62598766|NCT06475885|NO_INTERVENTION|Infant massage training not provided group|The control group received no training or intervention.
62598767|NCT02580474|EXPERIMENTAL|Daclatasvir plus Asunaprevir|
62598768|NCT06618586|EXPERIMENTAL|New low touch (LT) hospital implementation strategy|This will occur during either the first or second 6-month intervention time period (order randomly assigned). For the period of time hospitals are randomized into this arm mothers will be attracted to TodaysBaby through direct-to-consumer marketing and sign themselves up using a QR code. These mothers will also receive standard postpartum care.
62598769|NCT06618586|ACTIVE_COMPARATOR|Original high touch (HT) hospital implementation strategy|This will occur during either the first or second 6-month intervention time period (order randomly assigned). For the period of time hospitals are randomized into this arm hospital staff will help mothers sign up and view the first 2 TodaysBaby in a one-on-one conversation format. These mothers will also receive standard postpartum care.
62241401|NCT01193881|EXPERIMENTAL|Treatment (erlotinib, RO4929097)|Patients receive erlotinib hydrochloride PO QD on days 1-21 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62241402|NCT04852263|OTHER|Group I|Fiberoptic intubation was carried out without nasopharyngeal airway
62241403|NCT04852263|OTHER|Group II (NPA group)|Fiberoptic intubation was performed with a modified nasopharyngeal airway.
62241404|NCT04817384|EXPERIMENTAL|Graston technique group|For Graston practice, instruments made of stainless steel material of a type suitable for the body structures and sizes of the children will be preferred. The treatment time takes approximately 20-25 minutes depending on the area being treated. The instant effects of the people will be looked at.
62241405|NCT04817384|EXPERIMENTAL|Classical massage group|The trapezius, erector spina and levator scapula muscles will be applied with one hand or both hands, starting with general stroking. The intermediate to be used is baby oil or natural oils. The application time will be approximately 20 minutes.
62817446|NCT06228625|EXPERIMENTAL|Rehabilitative Game Exercise Group|Individuals in this group will be applied a video-based rehabilitative game exercise program in addition to conventional exercises. A digital game network called 'Active Arcade Game' will be used for rehabilitative game exercises. Rehabilitative Game Exercise Group for 6 weeks, 2 days a week, for 45 minutes. This group will be given to basic body awareness exercises under the supervision of a physiotherapist for 2 days in our unit.
62241406|NCT05158933|EXPERIMENTAL|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
62241407|NCT02676856|EXPERIMENTAL|CR group|For the patients in CR group(CR status of AML at microtransplantation), the conditioning regimen is high-dose (HD) Ara-C. Hematopoietic stem cell microtransplantation will be given to these patients with long-term course.
62241408|NCT02676856|EXPERIMENTAL|Non-CR group|For the patients in Non-CR group (PR or NR status of AML at microtransplantation), the conditioning regimens include: IAC or HD Ara-C. Hematopoietic stem cell microtransplantation will be given to these patients with short-term course.
62241409|NCT05571046|ACTIVE_COMPARATOR|Glucocorticoid injection|Intramuscular glucocorticoid (5 mg betamethasone dipropionate and 2 mg betamethasone sodium phosphate)
62598770|NCT06618586|NO_INTERVENTION|Control- Standard of Care|During the 3 months immediately prior to the first intervention time period, hospitals will recruit approximately 100 mothers to complete surveys regarding infant care practices. These mothers will also receive postpartum standard of care.
62817447|NCT05194124|EXPERIMENTAL|Run-in Period: Setmelanotide 2 mg QD|Participants received subcutaneous (SC) injection of 2 mg setmelanotide once daily (QD) for 1 week in the run-in period.
62817448|NCT05194124|EXPERIMENTAL|Run-in Period: Setmelanotide 2.5 mg QD|Participants received SC injection of 2.5 mg setmelanotide QD for 1 week in the run-in period.
62817449|NCT05194124|EXPERIMENTAL|Run-in Period: Setmelanotide 3 mg QD|Participants received SC injection of 3 mg setmelanotide QD for 1 week in the run-in period.
62817450|NCT05194124|EXPERIMENTAL|DB Period: Setmelanotide 20 mg QW|Participants who received 2 mg setmelanotide QD in the run-in period, received SC injection of 20 mg setmelanotide once weekly (QW) and placebo matched to setmelanotide QD for 13 weeks in the DB period.
62817451|NCT05194124|EXPERIMENTAL|DB Period: Setmelanotide 25 mg QW|Participants who received 2.5 mg setmelanotide QD in the run-in period, received SC injection of 25 mg setmelanotide QW and placebo matched to setmelanotide QD for 13 weeks in the DB period.
62241410|NCT05571046|PLACEBO_COMPARATOR|Placebo injection|Intramuscular saline (%0.9 isotonic sodium chloride)
62241411|NCT03187171|ACTIVE_COMPARATOR|Allograft Fusion Group|The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft.
62241412|NCT03187171|ACTIVE_COMPARATOR|Cohere PEEK Fusion Group|The anterior approach to the cervical spine for discectomy and fusion by the insertion of a Cohere porous PEEK fusion device.
62241413|NCT02653300|EXPERIMENTAL|Oral Insulin|treatment
62241414|NCT01775839|EXPERIMENTAL|Aspirin+Clopidogrel/Digoxin(oral)|Aspirin: Day 1 \~ Day 59(\~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55
62817452|NCT05194124|EXPERIMENTAL|DB Period: Setmelanotide 3 mg QD|Participants who received 3 mg setmelanotide QD in the run-in period, received SC injection of 3 mg setmelanotide QD and placebo matched to setmelanotide QW for 13 weeks in the DB period.
62241415|NCT01775839|EXPERIMENTAL|Aspirin+Clopidogrel/Digoxin(IV)|Aspirin: Day 1 \~ Day 59(\~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55
62241416|NCT02030756|ACTIVE_COMPARATOR|Vibrating capsule|patients will receive vibrating capsule for 8 weeks of treatment \[1 every 3 days (+/- 1 day)\].
62735668|NCT03067519|EXPERIMENTAL|Fast track surgery|Intervention: Fast track surgery patients underwent early feeding and mobilization after surgery
62817453|NCT05194124|EXPERIMENTAL|DB Period: Setmelanotide 30 mg QW|Participants who received 3 mg setmelanotide QD in the run-in period, received SC injection of 30 mg setmelanotide QW and placebo matched to setmelanotide QD for 13 weeks in the DB period.
62817454|NCT05194124|EXPERIMENTAL|OL Period: Setmelanotide 20 mg QW|Participants who received 2 mg setmelanotide QD in the run-in period and 20 mg setmelanotide QW in the DB period, received SC injection of 20 mg setmelanotide QW for 13 weeks in the OL period.
62817455|NCT05194124|EXPERIMENTAL|OL Period: Setmelanotide 25 mg QW|Participants who received 2.5 mg setmelanotide QD in the run-in period and 25 mg setmelanotide QW in the DB period, received SC injection of 25 mg setmelanotide QW for 13 weeks in the OL period.
62817456|NCT05194124|EXPERIMENTAL|OL Period: Setmelanotide 30 mg QW|Participants who received 3 setmelanotide QD in the run-in period and 3 mg setmelanotide QD or 30 mg setmelanotide QW in the DB period, received SC injection of 30 mg setmelanotide QW for 13 weeks in the OL period.
62817457|NCT00755664|ACTIVE_COMPARATOR|Low-dose complex B-vitamins|Intervention group receives Low-dose complex B-vitamins every day. Low-dose complex B-vitamins contain 400µg of folic acid, 2mg of vitamin B6, 10µg of vitamin B12 and 50mg vitamin C. Daily supplementation lasts for 12 months
62817458|NCT00755664|PLACEBO_COMPARATOR|Vitamin C|Control group receives Vitamin C (50mg)every day. Daily supplementation lasts for 12 months.
62241417|NCT02030756|SHAM_COMPARATOR|sham non-vibrating capsule|patients will receive sham non-vibrating capsule for 8 weeks of treatment \[1 every 3 days (+/- 1 day)\].
62817459|NCT04523194||Acute Coronary Syndrome|Patients diagnosed with acute coronary syndrome.
62817460|NCT04523194||Stable Angina|Patients diagnosed with stable angina.
62038585|NCT06732310|EXPERIMENTAL|PMEP + RET|"In pregnancy: PMEP~In early childhood: Reminiscing and Emotion Training Program"
62817461|NCT04736888|SHAM_COMPARATOR|Conventional group|Conventional CPR training consists of a BLS video and a manikin equipped with a feedback device.
62817462|NCT04736888|ACTIVE_COMPARATOR|XR group|The XR group participants will be provided training via the XR BLS module and are allotted an additional 2 minutes that is needed to adapt to the XR equipment.
62817463|NCT01584869|EXPERIMENTAL|capsule endoscopy|
62241418|NCT06085911|EXPERIMENTAL|individual follow-ups|tailored individual follow-up rehabilitation program with home-based exercises
62817464|NCT00739921|EXPERIMENTAL|1|"Patients with sinusitis compared to patients without.~To find out if any specific type of fungus or mold is correlated with chronic sinus disease. The study will add new information about the different types of fungus and mold found in the human nose."
62817465|NCT03028233|EXPERIMENTAL|Healthy Lifestyles|The study will test the impact of a community health worker (CHW)-delivered intervention aimed at helping families overcome barriers to childhood obesity prevention. Barriers include social, environmental, and family issues.
62817466|NCT03028233|ACTIVE_COMPARATOR|Positive Parenting|The control condition consists of a community health worker (CHW)-delivered intervention aimed at helping families improve positive parenting skills.
62241419|NCT06085911|ACTIVE_COMPARATOR|a one-day course.|a one-day course.
62598771|NCT05755607|OTHER|laparoscopic pancreaticoduodenectomy group|The laparoscopic group will perform the surgical procedure using laparoscopic instruments, with three surgeons involved throughout the procedure.
62598772|NCT05755607|OTHER|Robot Pancreaticoduodenectomy|The robotic team will perform the surgery using the latest generation Da Vinci robotic surgical system, with an additional surgeon assisting in the procedure.
62598773|NCT03270475|EXPERIMENTAL|Exercise|12-15 training sessions of 30 min over 4-5 weeks
62817467|NCT06705881|ACTIVE_COMPARATOR|Control Group|
62817468|NCT06705881|EXPERIMENTAL|Intervantion Group|
62817469|NCT03773978|EXPERIMENTAL|Baricitinib|Baricitinib was administered QD (once daily) as a 4-mg oral tablet for adolescent participants (12 to \<18 years of age) and children ≥9 years of age; and 2 mg for children \<9 years of age. Participants \<6 years of age received an oral suspension. Participants ≥6 to \<12 years old had the option of receiving an oral suspension. Participants \>12 years old were supplied tablets. The oral suspension dose was administered as 4-mg, 2-mg, 1-mg, and 0.5-mg as needed.
62817470|NCT03773978|PLACEBO_COMPARATOR|Placebo|Placebo matched to baricitinib was administered to participants during the DBW period.
62817471|NCT02470897|EXPERIMENTAL|Arm A (moderate dose SBRT with SIB)|"Patients undergo 5 fractions of moderate dose SBRT with SIB every other day for 10 days following urethral-sparing IMRT planning.~SBRT: 8.0Gy escalated dose"
62817472|NCT02470897|ACTIVE_COMPARATOR|Arm B (uniform dose SBRT)|"Patients undergo 5 fractions of uniform dose SBRT every other day for 10 days following urethral-sparing IMRT planning.~SBRT: 7.5Gy conventional dose"
62038586|NCT06732310|ACTIVE_COMPARATOR|Pregnancy - Active Control + ECM|"In pregnancy: Women not randomized to PMEP will participate in a contact-equivalent, nondirective social support group.~In early childhood: Families who are not randomized to the RET condition will be mailed a kit containing 5 packets to be opened weekly. Each packet includes a family activity and a newsletter with parenting materials."
62038587|NCT03540914|ACTIVE_COMPARATOR|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
62241420|NCT06456450||Omalizumab|Severe asthma patients who are treated with omalizumab after January 1, 2020.
62817473|NCT03542487|NO_INTERVENTION|1: Control|A randomly selected half of primary care practices in the study sample at Inova Health Care Services will not receive any intervention and patients/physicians located at these practices will continue with business as usual.
62817474|NCT03542487|EXPERIMENTAL|2a: Practice Orientation- No Reminder|In the other randomly selected half of primary care practices in the study sample at Inova Health Care Services, practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2a will receive no additional reminder messaging to enter glucose measurements in the electronic flowsheets.
62241421|NCT06456450||Mepolizumab|Severe asthma patients who are treated with mepolizumab after January 1, 2020.
62241422|NCT06456450||Benralizumab|Severe asthma patients who are treated with benralizumab after January 1, 2020.
62241423|NCT06456450||Dupilzumab|Severe asthma patients who are treated with dupilzumab after January 1, 2020.
62241424|NCT06456450||Tezepelumab|Severe asthma patients who are treated with Tezepelumab after January 1, 2020.
62241425|NCT00931944|EXPERIMENTAL|KNS-760704 300 mg/day|Open-label KNS-760704 (150 mg Q12H)
62431752|NCT05950633|ACTIVE_COMPARATOR|Standard of Care|Participants will receive standard postoperative instructions only
62431753|NCT05950633|ACTIVE_COMPARATOR|Active Recovery|Participants will receive active recovery instructions with specific walking goals, abdominal strengthening exercises, and pelvic floor exercises
62431754|NCT01909505||Normal Males|Males with normal levels of serum testosterone
62431755|NCT01909505||Hypogonadal males|Males known to have low levels of serum testosterone
62431756|NCT00591487|ACTIVE_COMPARATOR|I|Infiltration with 0.9% saline+1:1,000,000 epinephrine+0.06% Lidocaine
62431757|NCT00591487|PLACEBO_COMPARATOR|II|Infiltration with 0.9% saline+1:1,000,000 epinephrine
62817475|NCT03542487|EXPERIMENTAL|2b: Practice Orientation- Standard Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2b will receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets.
62817476|NCT03542487|EXPERIMENTAL|2c: Practice Orientation- Gift Card Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2c will receive generic biweekly reminders to enter data, addressed from Inova Medical Group, that will also notify that the patient will be entered to win a $50 gift card for each day entering data.
62241426|NCT02445196|EXPERIMENTAL|PTSD Coach|Subjects assigned to this condition receive information about how to download the research app, PTSD Explorer. This research version of PTSD Coach functions exactly the same, however we have the ability to track individual usage of the app. The app contains contains psycho-education about PTSD and the management of symptoms of PTSD along with activities and techniques to address symptoms. Subjects are told to use the app as much or as little as they want over the next three months.
62817477|NCT03542487|EXPERIMENTAL|2d: Practice Orientation- Physician Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2d will receive biweekly reminders, addressed from their physician, encouraging them to enter glucose measurements in the electronic flowsheets (Note that though messages will be addressed from physician, they will be sent by Inova IT).
62817478|NCT02670447||First episode of psychosis patients|Patients with schizophrenia will be studied in this clinical trial, and that have never received anti-psychotic treatment. They will perform an MRI.
62038588|NCT03540914|PLACEBO_COMPARATOR|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.
62038589|NCT00686881|EXPERIMENTAL|PegIFN-2b|Participants receiving PegIFN-2b at 0.5 ug/kg subcutaneously (SC) once a week for up to 156 weeks.
62038590|NCT00686881|ACTIVE_COMPARATOR|SNMC|Participants receiving SNMC 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for up to 156 weeks.
62241427|NCT02445196|ACTIVE_COMPARATOR|Waitlist Control|"Subjects assigned to this condition are told: You have been randomly assigned to Group 2, the group that does not use the app.~Following their completion of the post-intervention assessment at 3 months, they are told how to access to the publicly available PTSD Coach app in the Apple App Store or Android Play Store, just so that they are made aware of the resources available to them."
62241428|NCT04970043|EXPERIMENTAL|Camrelizumab+ pemetrexed + platinum|
62431758|NCT00345683|EXPERIMENTAL|Menhibrix Group|Subjects received 3 doses of Menhibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course in the study NCT00345579 and a fourth dose of Menhibrix vaccine at 12-15 months of age in this study (study Month 10-13). Menhibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
62431759|NCT00345683|ACTIVE_COMPARATOR|ActHIB Group|Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course in the study NCT00345579 and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in this study (study Month 10-13). ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
62431760|NCT02191956|ACTIVE_COMPARATOR|Behavioral Parent Training|Standard of care intervention
62431761|NCT02191956|EXPERIMENTAL|Behavioral Parent Training - Enhanced|Standard of Care Behavioral Parent Training plus new delivery methods
62598774|NCT05310500|EXPERIMENTAL|ProTaper Gold (F2) - NaOCL|ProTaper Files without NaOCL
62598775|NCT05310500|EXPERIMENTAL|ProTaper Gold (F2) + NaOCL|ProTaper Files with NaOCL
62598776|NCT05310500|EXPERIMENTAL|Dia-X ProTaper (D4) - NaOCL|Dia-X ProTaper (D4) without NaOCL
62598777|NCT05310500|EXPERIMENTAL|Dia-X ProTaper (D4) + NaOCL|Dia-X ProTaper (D4) with NaOCL
62598778|NCT01670734|EXPERIMENTAL|alirocumab SAR236553 (REGN727) - mild hepatic function|Injection through subcutaneous (SC) administration in patients with mild hepatic function
62241429|NCT01569360|ACTIVE_COMPARATOR|Corset|the patients are assigned the use of a custome made corset during daytime
62241430|NCT01569360|NO_INTERVENTION|No corset|the patients do not use a corset during daytime
62038591|NCT01752673|EXPERIMENTAL|Visualized pulmonary embolism computer task model|This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.
62038592|NCT01752673|ACTIVE_COMPARATOR|Didactic review pulmonary embolism lecture|This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
62241431|NCT00993915||Main group|Newly diagnosed or known coronary artery disease and known dislipidemia and high risk of cardiovascular complications
62241432|NCT00324701|EXPERIMENTAL|Telepsychology|therapy done at patients house
62817479|NCT06378541|EXPERIMENTAL|Virtual Hope Box Enhanced Facilitation (VHB-EF)|The VHB-EF intervention has two phases: (1) The in-person inpatient phase involves a single, one-on-one, 60-minute session delivered by the study interventionist prior to hospital discharge. During this session, the interventionist will obtain access to the participant's personal phone and assist them in downloading the VHB app. The interventionist will provide education about the app and personalized behavioral practice for each component of the app. They will also address strategies to enhance app use. In addition, participants will review a list of Veteran mental health resources, community services, Veteran service organizations, and other Veteran social support services available to Veterans in the area. (2) The remote-delivery phase builds on the work begun in the hospital via 2 follow-up phone contacts within 14 days following discharge, during which the study interventionist will monitor risk, review/revise VHB content, and support app use and outpatient treatment engagement.
62817480|NCT06378541|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|The EUC condition will involve a one-on-one, 30-minute session delivered by the study interventionist prior to hospital discharge, during which the interventionist will review Veteran mental health resources, community services, Veteran service organizations, and other Veteran social support services available to Veterans in the area. The EUC session will remain focused only on reviewing the standardized list of Veteran and community services; no counseling will be provided, and the list provided by the study interventionist does not include non-services (i.e., does not list any smartphone applications, including the VHB app).
62817481|NCT03576885|ACTIVE_COMPARATOR|Treatment group - active|inhaled nitric oxide treatment will start at 20 ppm and continue for 2 weeks or until resolution of pulmonary hypertension, whichever comes first.
62817482|NCT03576885|PLACEBO_COMPARATOR|Treatment group - placebo|Placebo treatment will start at 20 ppm and continue for 2 weeks or until resolution of pulmonary hypertension, whichever comes first.
62241433|NCT00324701|ACTIVE_COMPARATOR|Face-to-face therapy|therapy delivered at the VAMC
62817483|NCT03576885|NO_INTERVENTION|Control group|Enrolled infants with no evidence of pulmonary hypertension will serve as the control group for incidence of death or bronchopulmonary hypertension
62241434|NCT06052150||Cirrhosis|"Outpatients with cirrhosis with the following criteria~Inclusion criteria A. Age\>18 years B. Cirrhosis confirmed (liver biopsy, signs of current or prior decompensation, varices in patients with chronic liver disease, nodular liver on imaging, AST\>ALT and platelet count \>150K in patients with chronic liver disease, ultrasound, or MR elastography suggestive of cirrhosis).~C. Willing and able to give consent Exclusion criteria A. Unclear diagnosis of cirrhosis B. Unable or unwilling to consent C. Edentulous D. Prior organ transplant E. On anticoagulant therapy"
62241435|NCT05745454|EXPERIMENTAL|HER2-E-CART cells|HER2-E-CART cells were intravenously transfused and followed up to 2 years after the last cell transfusion
62241436|NCT00980681|EXPERIMENTAL|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg.
62241437|NCT00980681|OTHER|Time Of Flight|Each subject will undergo a TOF Magnetic Resonance Angiography
62431762|NCT04009473|EXPERIMENTAL|SEGOVA Intervention Group|Intervention group of 50-100 patients with ovarian failure would be subjected to a three-day procedure named SEGOVA: bone marrow derived StEm cell treatment, Growth factor incubation and Ovarian In Vitro Activation. After the procedure, one year follow up of hormones measurements (follicle stimulating hormone (FSH), luteinizing hormone (LH),estradiol (E2), progesterone (PG) and anti-mullerian hormone (AMH)) and follicle counts would be established. In patients with oocytes retrieved after SEGOVA procedure, standard In Vitro Fertilization protocol would be performed. The fertilization, cleavage and clinical pregnancy rate will be monitored.
62431763|NCT03893409||pulmonary function|
62431764|NCT03893409||biological sample detection outcome|
62598779|NCT01670734|EXPERIMENTAL|alirocumab SAR236553 (REGN727) - moderate hepatic function|Injection through subcutaneous (SC) administration in patients with moderate hepatic function
62598780|NCT01670734|EXPERIMENTAL|alirocumab SAR236553 (REGN727) - normal hepatic function|Injection through subcutaneous (SC) administration in patients with normal hepatic function
62598781|NCT04482595|EXPERIMENTAL|BIO 300 Oral Suspension (genistein 1500 mg)|BIO 300 Oral Suspension (genistein 1500 mg) will be self-administered daily for 7 days each week for 12 weeks.
62038593|NCT02053818|ACTIVE_COMPARATOR|Remifentanil|Remifentanil the basic opioid drug in anesthesia
62038594|NCT02053818|ACTIVE_COMPARATOR|Sufentanil|Sufentanil the basic opioid drug in anesthesia
62598782|NCT04482595|PLACEBO_COMPARATOR|Placebo|BIO 300 Oral Suspension matched placebo will be self-administered daily for 7 days each week for 12 weeks.
62598783|NCT02784626|EXPERIMENTAL|Dexmedetomidine|Patients who received dexmedetomidine during the operation
62598784|NCT02784626|EXPERIMENTAL|Propofol|Patients who received propofol during the operation
62241438|NCT00667355|EXPERIMENTAL|Adalimumab|Adalimumab 40 mg or 80 mg subcutaneously (SC) administered every other week (eow) until approval of adalimumab for Ankylosing Spondylitis (AS) in Japan. All subjects received 40 mg of adalimumab SC eow at Baseline. The subjects who completed 16 weeks of therapy and who failed to achieve Assessments in Ankylosing Spondylitis 20 (ASAS 20) response on or after Week 16, could increase the dose of adalimumab to 80 mg eow. When the dose was increased, the higher dose was to be continued during the rest of the study.
62241439|NCT05780411||Myloid group|Patients diagnosed as Multiple Myeloma, treated, and not in relapse
62431765|NCT05633537|EXPERIMENTAL|group 1: zinc oxide-ozonated olive oil|"Group I: 30 primary molars were filled with fresh mix of zinc oxide powder with ozonated olive oil~A single-visit pulpectomy procedure was performed . Standardized preoperative periapical radiograph was obtained to assess tooth condition \& proper selection. Teeth were anesthetized \& Rubber dam isolation was done, then all caries was removed \& access opening was gained. Working length was determined by apex locator. All canals were prepared using Kidzo file system in a lateral brushing motion with an Endo-Mate DT endodontic motor at 350 RPM and 2.5 N/cm torque. EDTA gel 17% will be used before instrumentation \& irrigation was done with normal saline. Dryness with paper points size 30 . placement of the root canal filling material (zinc oxide-ozonated olive oil) was applied . Intermediate restorative material was placed, then tooth was restored with stainless-steel crown"
62431766|NCT05633537|EXPERIMENTAL|group 2: zinc oxide- olive oil|"Group 2: 30 primary molars were filled with fresh mix of zinc oxide powder with olive oil~A single-visit pulpectomy procedure was performed . Standardized preoperative periapical radiograph was obtained to assess tooth condition \& proper selection. Teeth were anesthetized \& Rubber dam isolation was done, then all caries was removed \& access opening was gained. Working length was determined by apex locator. All canals were prepared using Kidzo file system in a lateral brushing motion with an Endo-Mate DT endodontic motor at 350 RPM and 2.5 N/cm torque. EDTA gel 17% will be used before instrumentation \& irrigation was done with normal saline. Dryness with paper points size 30 . placement of the root canal filling material (zinc oxide- olive oil) was applied . Intermediate restorative material was placed, then tooth was restored with stainless-steel crown"
62431767|NCT05633537|ACTIVE_COMPARATOR|group 3:zinc oxide- eugenol|"Group 3: 30 primary molars were filled with zinc oxide- eugenol~A single-visit pulpectomy procedure was performed . Standardized preoperative periapical radiograph was obtained to assess tooth condition \& proper selection. Teeth were anesthetized \& Rubber dam isolation was done, then all caries was removed \& access opening was gained. Working length was determined by apex locator. All canals were prepared using Kidzo file system in a lateral brushing motion with an Endo-Mate DT endodontic motor at 350 RPM and 2.5 N/cm torque. EDTA gel 17% will be used before instrumentation \& irrigation was done with normal saline. Dryness with paper points size 30 . placement of the root canal filling material (zinc oxide- eugenol) was applied . Intermediate restorative material was placed, then tooth was restored with stainless-steel crown"
62431768|NCT00240864|EXPERIMENTAL|001|acetaminophen
62431769|NCT00240864|EXPERIMENTAL|002|ibuprofen
62431770|NCT00240864|PLACEBO_COMPARATOR|003|placebo
62431771|NCT06529224||Health professionals|General practitioner, gynecologist or midwife
62431772|NCT00769080||1|Standard Treatment plus PSP
62431773|NCT00769080||2|Standard Treatment
62598785|NCT03430661|EXPERIMENTAL|Part A: Group 1|Clopidogrel will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax
62241440|NCT05780411||Lymphoid group|Patients diagnosed as having lymphoma, treated, and not in relapse
62241441|NCT06171412|EXPERIMENTAL|Glu-COACH|The experimental group will receive ESOC plus peer-mentoring support from a peer of the same cultural identity (Glu-COACH) and access to a private social media group for all Black and Latinx teens to improve the initiation and maintenance of CGM (Dexcom)
62241442|NCT06171412|ACTIVE_COMPARATOR|Enhanced standard-of-care (ESOC)|This group will receive ESOC including additional training and support on CGM beyond routine clinical practice.
62241443|NCT04679779|EXPERIMENTAL|control group|receive occupational therapy program
62241444|NCT04679779|EXPERIMENTAL|study group|receive wii virtual reality
62598786|NCT03430661|EXPERIMENTAL|Part A: Group 2|Clopidogrel will be administered 12 h after ACT-246475 or placebo
62598787|NCT03430661|EXPERIMENTAL|Part A: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and clopidogrel may be studied
62598788|NCT03430661|EXPERIMENTAL|Part B: Group 1|Prasugrel will be administered 12 h after ACT-246475 or placebo
62598789|NCT03430661|EXPERIMENTAL|Part B: Group 2|Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied
62598790|NCT03430661|EXPERIMENTAL|Part B: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied
62598791|NCT03430661|EXPERIMENTAL|Part C: Group 1|Ticagrelor will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax
62598792|NCT03430661|EXPERIMENTAL|Part C: Group 2|Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied
62598793|NCT03430661|EXPERIMENTAL|Part C: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied
62598794|NCT02017912|ACTIVE_COMPARATOR|Nurown MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
62817484|NCT06704698|EXPERIMENTAL|Thoracic paravertebral block|Ultrasound guided paravertebral block (TPVB) with liposomal bupivacaine is performed in this group. 40ml of liposomal bupivacaine and saline mixture was injected to the right T4-T5, T7-T8, and bilateral T10-T11 paravertebral spaces, with 10 ml for each space. Patient-controlled intravenous analgesia (PCIA) is used for postoperative pain management.
62817485|NCT06704698|OTHER|Epidural block|For the standard control group, a T6-T8 epidural block is administered. Postoperative analgesia is managed with patient-controlled epidural analgesia (PCEA).
62817486|NCT02157818|ACTIVE_COMPARATOR|midazolam|midazolam IV bolus 0.05ml/kg bolus in 1minute. rescue drug(Midazolam) 1 mg, IV boluses for double blinding setting, we use saline, 0.4 mcg/kg IV bolus in 10 minutes and 0.5 mcg/kg/h, as placebo.
62817487|NCT02157818|EXPERIMENTAL|Dexmedetomidine|"Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.25-0.75 mcg/kg/h for RSS 3-5. Midazolam 1mg bolus IV pro re nata (PRN).~for double blinding setting, IV bolus 0.05ml/kg bolus in 1minute."
62817488|NCT06705673||Juvenile Idiopathic Arthritis|Patients diagnosed with JIA who are being followed at the Istanbul Medical Faculty Pediatric Rheumatology Clinic will be included in the study.
62817489|NCT06705673||Familial Mediterranean Fever|Patients diagnosed with FMF who are being followed at the Istanbul Medical Faculty Pediatric Rheumatology Clinic will be included in the study.
62598795|NCT02017912|PLACEBO_COMPARATOR|Excipient|Combined intramuscular and intrathecal placebo administration
62598796|NCT05047731|EXPERIMENTAL|Deprescribing group|The facility pharmacist will actively deprescribe antihypertensive medication of residents in this group.
62598797|NCT05047731|NO_INTERVENTION|Usual care group|The facility pharmacist and the attending physician will provide usual care to residents in this group, and this includes quarterly medication reviews.
62817490|NCT06705673||Healthy control|For the healthy control group, healthy children and adolescents without any illnesses who volunteer to participate in the study will be included.
62817491|NCT05816811|EXPERIMENTAL|Power Training|The program is intentionally designed with 3 progressive phases: Phase 1 Familiarization (Week 1) will allow participants to begin with a low-intensity version of the training program (body weight resisted or light weights at RPE 2-3 for 8 repetitions) to acclimate participants to the movements. Phase 2 Strength (Weeks 2-5) will progress in loads to achieve volitional fatigue between 5-8 repetitions (RPE 7-9). Phase 3 Power (Weeks 6-10) will use intensities between RPE 4-6 (15-20 repetitions) and execute each exercise at the highest possible velocity to focus on muscle power. The exercises, selected to emphasize functional movements relevant to daily activities.
62817492|NCT04649541|ACTIVE_COMPARATOR|Single intravenous doses of MRX-8|Single escalating doses of MRX-8
62817493|NCT04649541|PLACEBO_COMPARATOR|Single intravenous doses of placebo|Single intravenous doses of placebo to match MRX-8
62817494|NCT04649541|ACTIVE_COMPARATOR|Multiple intravenous doses of MRX-8 for 7 days|Multiple ascending intravenous doses of MRX-8 every 12 hours for 7 days.
62817495|NCT04649541|PLACEBO_COMPARATOR|Multiple intravenous doses of placebo for 7 days|Multiple intravenous doses of placebo every 12 hours for 7 days to match MRX-8.
62817496|NCT04649541|ACTIVE_COMPARATOR|Multiple intravenous doses of MRX-8 for 14 days|Multiple ascending intravenous doses of MRX-8 every 12 hours for 14 days.
62817497|NCT04649541|PLACEBO_COMPARATOR|Multiple intravenous doses of placebo for 14 days|Multiple intravenous doses of placebo every 12 hours for 14 days to match MRX-8.
62817498|NCT05635786||Alteplase (ALT)|Patients with distal vessel occlusion stroke treated with alteplase (from March 2016 to February 2018)
62598798|NCT05109637|EXPERIMENTAL|Participants with SMA (PwSMA)|Participants with SMA will have their motor functions assessed using the Konectom NMD smartphone-based application up to Day 28.
62598799|NCT05109637|EXPERIMENTAL|Participants with ALS (PwALS)|"Participants with ALS will have their cognitive and motor functions assessed using the Konectom NMD smartphone-based application up to Day 28.~As per protocol version 4.0, enrolment of ALS participants is stopped, and the data of the already enrolled ALS participants would not be analyzed."
62817499|NCT05635786||Tenecteplase (TNK)|Patients with distal vessel occlusion stroke treated with tenecteplase (from March 2018 to February 2020)
62598800|NCT05109637|EXPERIMENTAL|Healthy Participants|Healthy participants will have their cognitive and motor functions assessed using the Konectom NMD smartphone-based application for 28 days.
62598801|NCT02049840|EXPERIMENTAL|Altis Single Incision Sling System|Altis Single Incision Sling System
62817500|NCT04039087|ACTIVE_COMPARATOR|Sildenafil|active sildenafil 40 mg p.o. three times per day
62817501|NCT04039087|PLACEBO_COMPARATOR|Placebo Arm|placebo three times per day
62817502|NCT05294588|EXPERIMENTAL|Experimental arm|"All participants receive two immunizations prior to the bacterial challenge phase and two immunizations after the challenge phase. Individuals assigned to the experimental arm receive the recommended two doses of BEXSERO™ prior to bacterial challenge and control vaccines (FLULAVAL™ and TDVAX™) in the post-challenge vaccination phase.~For bacterial challenge, all participants receive a suspension containing 10\^6 colony-forming units of N. gonorrhoeae strain FA1090 delivered to the anterior urethra. Participants receive 100% effective antibiotic treatment for N. gonorrhoeae strain FA1090 infection when (1) requested by the participant regardless of signs, symptoms or positive cultures, (2) urethral discharge is observed by the examining clinician or reported by the participant, or (3) 10 days afterurethral inoculation with bacterial product, regardless of infection status."
62241445|NCT02410941|EXPERIMENTAL|Decision-support for MTBI|Clinical decision support will be provided on ordering CT scans for patients suspected to have Minor Traumatic Brain Injury (MTBI) to treating physicians randomized into this group. This arm will also serve as a control for the PE group.
62598802|NCT05524818||Test-retest reliability group|All the participants received conventional rehabilitation (e.g., occupational therapy, physical therapy, or speech therapy) or other interventions (e.g., acupuncture) as usual during the research period.
62598803|NCT05524818||Responsiveness group|All the participants received conventional rehabilitation (e.g., occupational therapy, physical therapy, or speech therapy) or other interventions (e.g., acupuncture) as usual during the research period.
62735669|NCT03067519|ACTIVE_COMPARATOR|Conventional management|usual postoperative care per surgeon
62038595|NCT04510805|EXPERIMENTAL|Intervention Arm|"NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles.~Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose."
62038596|NCT04510805|NO_INTERVENTION|Control Arm|Usual standard of care. Clinical experience of the treating physician taking into account the covariates, dosing and INR history of each patient, to determine the initial, and subsequent maintenance doses.
62038597|NCT06682299|EXPERIMENTAL|TMS|Patients who have achieved remission of treatment resistant depression through an initial course of ECT (8 to 12 sessions) at the University of Kentucky will be identified by the ECT attending physician as a candidate for this study. They will receive TMS in this arm of study for maintenance treatment of their depression and monitored with depressive scales.
62817503|NCT05294588|OTHER|Control arm|"All participants receive two immunizations prior to the bacterial challenge phase and two immunizations after the challenge phase. Individuals assigned to the control arm receive control vaccines that have no relevance to N. gonorrhoeae infection (FLULAVAL™ and TDVAX™) prior to bacterial challenge and then receive two doses of BEXSERO™ in the post-challenge vaccination phase.~For bacterial challenge, all participants receive a suspension containing 10\^6 colony-forming units of N. gonorrhoeae strain FA1090 delivered to the anterior urethra. Participants receive 100% effective antibiotic treatment for N. gonorrhoeae strain FA1090 infection when (1) requested by the participant regardless of signs, symptoms or positive cultures, (2) urethral discharge is observed by the examining clinician or reported by the participant, or (3) 10 days afterurethral inoculation with bacterial product, regardless of infection status."
62598804|NCT03042169|ACTIVE_COMPARATOR|continuation of chemotherapy|"Patients assigned to arm A will continue to receive the same chemotherapy regimen they received before randomization. Chemotherapy should be restarted between D1 and D30 after randomization.~In case of poor tolerance to the induction chemotherapy, alternative chemotherapy regimen might be discussed, according to local standards and national guidelines (www.tncd.org)."
62817504|NCT06420960|EXPERIMENTAL|connected watch|All patients will be equipped by HOLTER for 48-hour monitoring, with an event form to be filled in, at the same time as receiving a connected watch for a 6 -months period. They will be asked to record an ECG with the watch only when they experience symptoms that have included them in the study
62817505|NCT06420960|ACTIVE_COMPARATOR|HOLTER ECG 48 hours|All patients will be equipped by HOLTER for 48-hour monitoring, with an event form to be filled in, at the same time as receiving a connected watch for a 6 -months period. They will be asked to record an ECG with the watch only when they experience symptoms that have included them in the study
62817506|NCT05267262|EXPERIMENTAL|Cohort 2 (Alport Syndrome Patients)|R3R01 administered orally as 200 mg tablets twice daily for 84 days.
62817507|NCT05267262|EXPERIMENTAL|Cohort 3 (Focal Segmental Glomerulosclerosis Patients)|R3R01 administered orally as 200 mg tablets twice daily for the 84 days.
62817508|NCT05963880|EXPERIMENTAL|Advanced CKD group|Patients with eGFR \< 30 ml/min/1.73m2 not on dialysis
62817509|NCT05963880|EXPERIMENTAL|Dialysis groups|Patients on hemodialysis or peritoneal dialysis
62817510|NCT05963880|EXPERIMENTAL|Hypertension group|Patients with BP \> 135/85 mmHg or taking any antihypertensive medication with normal kidney function (eGFR \> 60 ml/min/1.73m2)
62038598|NCT06682299|ACTIVE_COMPARATOR|ECT|Patients who have achieved remission of treatment resistant depression through an initial course of ECT (8 to 12 sessions) at the University of Kentucky will be identified by the ECT attending physician as a candidate for this study. If they elect to continue with maintenance ECT treatments which is the current standard of care, their depressive symptoms and cognitive functioning will be monitored accordingly.
62241446|NCT02410941|EXPERIMENTAL|Decision-support for PE|Clinical decision support will be provided on ordering CT scans for patients suspected to have Pulmonary Embolism (PE) to treating physicians randomized into this group. This arm will also serve as a control for the MTBI group.
62241447|NCT05955404|EXPERIMENTAL|Kangaroo mother care|This study uses the Kangaroo mother care as a non-pharmacological strategy to alleviate the pain that preterm infants experience in the NICU.
62598805|NCT03042169|EXPERIMENTAL|surgical removal of the primary tumour and treatment of the metastatic site followed by chemotherapy|"Patients assigned to arm B will undergo gastrectomy (subtotal or total according to the location of the primary tumour) between D1 and D30 after randomization.~Subtotal gastrectomy is recommended if it allows a complete resection of the primary tumour to limit postoperative morbidity in such metastatic situations, based on the results of REGATTA"
62598806|NCT04902703|EXPERIMENTAL|Sargramostim|250 mcg/m2/day subcutaneously 5 days/week for 24 weeks
62598807|NCT04902703|PLACEBO_COMPARATOR|Placebo Control - Saline|Placebo comparator (saline) subcutaneously 5days/week for 24 weeks
62598808|NCT04766489|EXPERIMENTAL|Complete Deongestive Therapy|Patients will be given complete decongestive therapy for 5 days a week and for a mean of 20 sessions. Each session will be of approximately 2 hours and 15 minutes in duration, although short stretch bandaging will be left on for 23 hours a day.
62598809|NCT01117233|EXPERIMENTAL|Single IV Dose 1|
62598810|NCT01117233|EXPERIMENTAL|Single IV Dose 2|
62598811|NCT01117233|EXPERIMENTAL|Single IV Dose 3|
62598812|NCT01117233|EXPERIMENTAL|Single IV Dose 4|
62598813|NCT01117233|EXPERIMENTAL|Single IV Dose 5|
62735670|NCT02202915|EXPERIMENTAL|Fidelity Checklist Arm|Therapists are receiving training using the fidelity Checklist
62735671|NCT02688829|EXPERIMENTAL|treatment group|Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
62735672|NCT00349349|EXPERIMENTAL|ofatumumab|Anti-CD20 antibody therapy
62735673|NCT06180499|EXPERIMENTAL|T-reg depleted DLI|
62817511|NCT05963880|ACTIVE_COMPARATOR|Control group|Normotensive patients without any antihypertensive drugs or chronic kidney disease
62817512|NCT03322956|EXPERIMENTAL|experimental group (EGR)|"Physical therapy intervention.~In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises)."
62817513|NCT03322956|SHAM_COMPARATOR|Sham group (SGR)|"Physical therapy intervention.~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze and Evidence Based Practice Therapy. The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
62817514|NCT05390372|EXPERIMENTAL|humanmilk|For skin damage care of preterm newborns randomly assigned to the breast milk group, their own breast milk will be applied topically once every 60 minutes until complete healing. Skin damage in newborns will be evaluated by an independent nurse and specialist doctor for 60 minutes during the treatment, and the score will be given and recorded. A minimum decrease of 1 point in the skin condition assessment scale score will be considered to indicate 'improvement'. The decision that the skin integrity of the newborn is completely healed will be made by the neonatal doctor independent of the trial. Areas between 0-3 on the newborn skin condition assessment scale will be considered healed. Breastfeeding does not have any side effects in preterm newborns.
62431774|NCT04583839|EXPERIMENTAL|Navigation Group|Women who are randomized into SWEET will be assigned to a patient navigator. The navigator will meet women during hospitalization, at postpartum appointments, during primary care appointments, and as needed. At these face-to-face meetings, the navigator will perform education about the postpartum OGTT, post-GDM management plan, diabetes mellitus risks, lifestyle modification, and primary care transition. The navigator will facilitate the development of an individualized GDM Care Plan in conjunction with the patient and the medical team. The navigator will assess individual barriers to T2DM screening and prevention. At appointments, the navigator will also ensure a woman understands her diabetes-related care plan and will perform health education and barrier-reducing tasks as needed.
62817515|NCT05390372|EXPERIMENTAL|routine care group|cream applied as part of hospital routine practice
62817516|NCT06257303|ACTIVE_COMPARATOR|Valgus Group|If there is an increase of 10 degrees or more in the frontal plane projection angle while squatting on one leg, the participant will be included in this group.
62431775|NCT04583839|NO_INTERVENTION|Non-navigation cohort|No navigation will be provided; women will receive usual care.
62431776|NCT01335464|EXPERIMENTAL|BIBF 1120|patient receives capsules containing BIBF 1120 twice a day
62431777|NCT01335464|PLACEBO_COMPARATOR|placebo|patient receives capsules identical to those containing active drug
62431778|NCT01588587||DPP-IV inhibitors|
62431779|NCT00512356|EXPERIMENTAL|Investigational product group|"Anti-Adhesion Product was applied to the rectal stump and the incision line.~Like in the control group, surgical measures to prevent adhesions were also taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves."
62817517|NCT06257303|ACTIVE_COMPARATOR|Control Group|If the frontal plane projection angle is in the normal values while squatting on one leg, the participant will be included in this group.
62817518|NCT02707627||Laser Therapy|Participants will receive laser therapy for the treatment of their hypertrophic burn scars. Laser treatment decisions will be tailored to meet the needs of the patient.
62817519|NCT06706115|EXPERIMENTAL|Intranasal Breast Milk Group|Preterm infants (28-37 gestation week) in the intervention group will receive 0.2 ml of breast milk intranasally three times a day for three days.
62817520|NCT06706115|NO_INTERVENTION|Control Group|Preterm newborns in the control group will not receive any intervention.
62817521|NCT05856500|PLACEBO_COMPARATOR|basic nutrition|basic nutrition treatment, energy 30-35 kcal/kg, protein 1.0-2.0 g/kg, total nutrition and/or whey protein oral nutrition supplement or tube feeding enteral nutrition supplement if diet deficiency;
62817522|NCT05856500|EXPERIMENTAL|oral supplement of creatine and curcumin|On the basis of basic nutrition in group A, creatine 5g/d and curcumin 4g/d are orally added, and the intervention time is 1 month.
62817523|NCT04732520|EXPERIMENTAL|Treatment|Patients participating in the treatment group will undergo pulsed electric field (PEF) treatment of a single NSCLC nodule measuring 1 to 4 cm by CT, using the Aliya System. The treatment may be performed endoluminally in conjunction with a diagnostic bronchoscopy, or percutaneously.
62817524|NCT04732520|NO_INTERVENTION|Control|Patients declining to participate in the treatment arm may self-select to participate in an observational control arm.
62431780|NCT00512356|NO_INTERVENTION|Control group|Only surgical measures to prevent adhesions were taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves. No specific additional treatment was applied.
62431781|NCT01501201|EXPERIMENTAL|Gastric By-Pass|group treated with Gastric By-Pass
62431782|NCT01501201|ACTIVE_COMPARATOR|optimized medical management|group receiving an optimized medical management
62431783|NCT05640882|EXPERIMENTAL|VRET|VRET - 10 week protocol using VR
62431784|NCT05640882|ACTIVE_COMPARATOR|VRET Olfaction|VRET olfaction - 10 week protocol using VR with olfaction
62735674|NCT04075747|EXPERIMENTAL|Arm A|
62735675|NCT04075747|EXPERIMENTAL|Arm B|
62817525|NCT06704529||baseball players with GIRD|
62817526|NCT06704529||baseball players without GIRD|
62817527|NCT00756106|EXPERIMENTAL|Temozolomide and Radiation Therapy|
62817528|NCT06127784|EXPERIMENTAL|MI Counselling|An individualized treatment summary and survivorship care plan (TSSP) will be prepared within a one-hour motivational interviewing (MI) counseling session with a clinical nurse specialist. Participants will be asked to identify their top three symptom/survivorship concerns. The intervention will address symptoms/survivorship care specifically tailored to the needs of head and neck cancer patients based on the best available evidence and consultation with patients and a multidisciplinary team of head and neck cancer specialists. Patient participants will engage in role play to empower them to follow-up with their healthcare provider regarding their survivorship care needs.
62241448|NCT05149703|EXPERIMENTAL|Mezieres Group|This intervention includes a total of three postures of the Mézières therapy. Specifically, the postures maintained for 12 weeks consist of: supine dancer; in supine position with the upper extremities abducted 120 °; and dancer in a sitting position.
62431785|NCT05888207|EXPERIMENTAL|Savolitinib/Savolitinib+Fluvoxamine|In period 1, subjects will receive a single oral dose of savolitinib on Day 1 after overnight fasting. Following minimum 10 days of washout after the last dose of savolitinib, in period 2 subjects will take oral doses of fluvoxamine alone, twice daily from Days 1 to 4. On Day 5 subject will receive a single oral dose of savolitinib and a twice daily oral dose of fluvoxamine. On Day 6, subjects will receive a twice daily oral dose of fluvoxamine alone.
62431786|NCT05151094||Remdesivir exposure|Patients treated with remdesivir due to the COVID-19 infection
62431787|NCT04551807|ACTIVE_COMPARATOR|Modified natural cycle|corpus luteum present
62431788|NCT04551807|ACTIVE_COMPARATOR|Programmed cycle|corpus luteum absent
62431789|NCT04821440|ACTIVE_COMPARATOR|Lower Limb Lymphedema|Patients suffering from unilateral lower-limb lymphedema will receive volume measurements of their limb three times, once with the water displacement method, twice with the 3D sensor method
62598814|NCT06298474|EXPERIMENTAL|Experimental, BRAIN Programming|PLWD in the Experimental Group will be invited to use the BRAIN intervention twice per week for 3 months. Each session is expected to last 20-30 minutes. The BRAIN app will initially recommend activities for each PLWD based upon his/her background/interests/preferences, which will be collected when the PLWD first enrolls in the study. After the initial sessions, the BRAIN app will use AI to recommend new activities for subsequent sessions. These recommendations will be based upon the AI's rating of the relative success or failure of the activities initially provided to the PLWD.
62431790|NCT04821440|ACTIVE_COMPARATOR|Upper Limb Lymphedema|Patients suffering from unilateral upper-limb lymphedema will receive volume measurements of their limb three times, once with the water displacement method, twice with the 3D sensor method
62431791|NCT06243081|EXPERIMENTAL|intervention group (Flipped Teaching Method Group)|Intervention group students will be given skill training with the Flipped Teaching method.
62431792|NCT06243081|NO_INTERVENTION|Control group (Traditional Method Group)|Control group students will receive skill training with the traditional method. No intervention will be made.
62431793|NCT01440647|EXPERIMENTAL|NIPPV|Extubation to NIPPV (nasal intermittent positive pressure ventilation)
62038599|NCT06733662|EXPERIMENTAL|Education-based motivational interviewing Group|Patients in the intervention group will be given COPD education lasting approximately 45-50 minutes in a single session in line with the education booklet and by evaluating the pre-test data. On the 3rd day, the first session of motivational interview will be held. On the 5th day and 7th day and 15th day, motivational interview sessions will continue with the patients.
62038600|NCT06733662|NO_INTERVENTION|Control group|There will be no intervention for individuals in this group.
62431794|NCT01440647|ACTIVE_COMPARATOR|CPAP|After extubation this arm was placed on CPAP (continuous positive airway pressure) and was not offered NIPPV in the first month on life
62431795|NCT04052074|EXPERIMENTAL|Intervention group. Music in palliative patient|Listening to pre-recorded and selected music preferred by the patient, half an hour for 7 days.
62241449|NCT05149703|ACTIVE_COMPARATOR|Isostretching Group|This study aims to follow a total of 6 isostretching postures, the most similar to the Mezieres method. In each of the isostretching positions, if it is symmetric, 3, 6 or 9 repetitions will be performed and if it is asymmetric, 2, 4, or 8 repetitions.
62598815|NCT06298474|NO_INTERVENTION|Control: Standard Programming / Care|PLWD in the Control Group will participate in standard care / programming for 3 months.
62598816|NCT05136313|EXPERIMENTAL|MHO|metabolically healthy obese subjects undergoing TRE
62598817|NCT05136313|EXPERIMENTAL|MUO|metabolically unhealthy obese subjects undergoing TRE
62817529|NCT06127784|NO_INTERVENTION|Standard care|The standard care group will receive no intervention (no TSSP or MI counselling session).
62241450|NCT05662410|EXPERIMENTAL|Aflibercept treatment group|Patients receiving three monthly aflibercept injections
62431796|NCT04052074|SHAM_COMPARATOR|Palliative patient.|Basic therapeutic education repetition performed to all patients through earphones, half, an hour for 7 days.
62431797|NCT04052074|EXPERIMENTAL|Carer music.|Listening to pre-recorded and selected music preferred by the carer, half an hour for 7 days.
62431798|NCT04052074|SHAM_COMPARATOR|Carer.|Basic therapeutic education repetition performed to all carer through earphones, half an hour for 7 days.
62598818|NCT06618495|EXPERIMENTAL|Intervention group|Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + Xuesaitong soft capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 4 weeks
62817530|NCT01225874|EXPERIMENTAL|Stratum 3|Patients receive oral dexamethasone twice daily on days 1-28; vincristine sulfate IV on days 1, 8, 15, and 22; pegaspargase intramuscularly (IM) on day 4, 5, or 6; cytarabine intrathecally (IT) on day 1; and methotrexate IT on day 8 (some patients also receive methotrexate IT on days 15 and 22).
62817531|NCT01225874|EXPERIMENTAL|Stratum 4|Patients receive oral prednisone twice daily on days 1-28; vincristine sulfate IV on days 1, 8, 15, and 22; IM SC-PEG E. coli asparaginase on days 2, 5, 8, 12, 15, and 19; daunorubicin hydrochloride IV over 15-20 minutes on days 8, 15, and 22; and methotrexate IT on days 1 and 8 (some patients also receive methotrexate IT on days 15 and 22).
62817532|NCT06399666||Prospective cohort|Prospective cohort measuring the previously described biomarkers.
62817533|NCT06219889|ACTIVE_COMPARATOR|Hourly Neurochecks|Patients will be awakened hourly for their examinations
62817534|NCT06219889|EXPERIMENTAL|Every-Other-Hour Neurochecks|Patients will be awakened every other hour for their examinations
62817535|NCT05831228|EXPERIMENTAL|Experimental: Ketogenic food products|Dietary Supplement: Ketogenic food products Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
62817536|NCT05831228|PLACEBO_COMPARATOR|Control: Placebo|Dietary Supplement comparator
62598819|NCT00536224|ACTIVE_COMPARATOR|2|Minimal counseling
62598820|NCT00536224|EXPERIMENTAL|1|Full counseling
62431799|NCT06536829|EXPERIMENTAL|MYOFACIAL RELEASE TECHNIQUE, SCIATIC NERVE SLIDER TECHNIQUE|Group A (18) and Group B(18). Both groups will be given a patient evaluation sheet. Group A will receive myofacial release technique and sciatic nerve slider technique with routine physiotherapy. simple myoficial release technique by applying gentle sustained pressure to the myoficial layer for 30-50 seconds. The myofacial release technique will apply on lumber region and calf musle. Group A will receive both techniques
62431800|NCT06536829|EXPERIMENTAL|MYOFACIAL RELEASE TECHNIQUE|Group B will receive just myofacial release technique and routine physiotherapy. Pain, range of motion and functional disability will be measured before session, immediate effect after first session, then after 06 weeks (18 session) and after weeks 12 (18 session) (3 sessions a week with 7-10 repetitions). with simple myoficial release technique by applying gentle sustained pressure to the myoficial layer for 30-50 seconds. The myofacial release technique will apply on lumber region and calf musle. Group B will receive myofacial release techniqe and routine physiotherapy.
62431801|NCT01695798|NO_INTERVENTION|Chronic malnourished bOPV|This arm will receive only bOPV
62431802|NCT01695798|EXPERIMENTAL|Malnourished IPV+bOPV|This arm will receive IPV and bOPV
62431803|NCT01695798|NO_INTERVENTION|Normally nourished bOPV|This arm will receive only bOPV
62431804|NCT01695798|EXPERIMENTAL|Normally nourished IPV+bOPV|This arm will receive both IPV and bOPV
62817537|NCT04576507|EXPERIMENTAL|Dose A, followed by Dose B|On the first full inpatient day (Day 1), participants will smoke one specified strength (Dose A) of cannabis. Days 2-8 will comprise Phase 1, in which a second strength (Dose B) of cannabis will be administered 3x/day. The next 7 days (Day 9-15) will be Phase 2, in which cannabis Dose A will be administered once again, at the same 3 daily time points.
62817538|NCT00537394|EXPERIMENTAL|A|Regimen with higher predicted activity assigned by the study plus at least 2 NRTIs (personalized choice from expert recommendation) for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
62598821|NCT03932149|EXPERIMENTAL|Experimental Group|Real stimulation
62598822|NCT03932149|SHAM_COMPARATOR|Control Group|Sham stimulation
62598823|NCT06618248|EXPERIMENTAL|Sirolimus-coated spiral balloon (SuperFlow®)|A PTCA spiral balloon catheter with sirolimus coating (3ug/mm\^2) on balloon surface
62598824|NCT06618248|ACTIVE_COMPARATOR|Paclitaxel-coated balloon (Bingo™）|A PTCA balloon catheter with paclitaxel coating (3ug/mm\^2) on balloon surface
62598825|NCT02362776||breast cancer patients|
62598826|NCT02362776||lung cancer patients|
62598827|NCT02362776||control subjects|
62598828|NCT05499260|EXPERIMENTAL|CB03-154 SAD 5mg|Participants will receive CB03-154 5mg orally once daily in a fasted state.
62038601|NCT02200718|EXPERIMENTAL|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA V Beta Peptides BV5S2, BV6S5 and BV13S1 emulsified in incomplete Freund's adjuvant
62431805|NCT03941171|EXPERIMENTAL|Group 1|PAO+usual+PRT
62431806|NCT03941171|ACTIVE_COMPARATOR|Group 2|PRT
62431807|NCT05402761|EXPERIMENTAL|Nurse-guided BBTi group|Participants will experience 4-week treatment period (2 in person and 2 via telephone).
62431808|NCT05402761|EXPERIMENTAL|Mobile-delivered BBTi group|Participants will be shown how to download and use the app in their own mobile device after the baseline assessment.
62598829|NCT05499260|PLACEBO_COMPARATOR|Placebo SAD 5mg|Participants will receive placebo 5mg orally once daily in a fasted state.
62598830|NCT05499260|EXPERIMENTAL|CB03-154 SAD 10mg|Participants will receive CB03-154 10mg orally once daily in a fasted state.
62598831|NCT05499260|PLACEBO_COMPARATOR|Placebo SAD 10mg|Participants will receive placebo 10mg orally once daily in a fasted state.
62735676|NCT04075747|EXPERIMENTAL|Arm C|
62817539|NCT00537394|EXPERIMENTAL|B|Regimen with higher predicted activity assigned by the study without NRTIs for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
62817540|NCT00537394|OTHER|C|Regimen with lower predicted activity assigned plus at least 2 NRTIs (personalized choice from expert recommendation) for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
62817541|NCT03856060|EXPERIMENTAL|Group I (questionnaires, videos)|Patients complete questionnaires and watch a video portraying a physician using a standard EHR and then another portraying a physician using an integrated model of EHR during communication over 35 minutes.
62817542|NCT03856060|EXPERIMENTAL|Group II (video, questionnaire)|Patients complete questionnaires and watch a video portraying a physician using an integrated model of EHR and then another portraying a physician using a standard EHR during communication over 35 minutes.
62817543|NCT05890833||Neuromuscular disorders|
62038602|NCT02200718|PLACEBO_COMPARATOR|IFA Incomplete Freund's Adjuvant|IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil a surfactant system designed to make a water-in-oil emulsion
62038603|NCT00447057|EXPERIMENTAL|Pemetrexed (Nonsquamous)|Group of participants with non-small cell lung cancer (NSCLC) of nonsquamous histology who were assigned to Pemetrexed arm
62038604|NCT00447057|EXPERIMENTAL|Pemetrexed + Erlotinib (Nonsquamous)|Group of participants with NSCLC of nonsquamous histology who were assigned to Pemetrexed + Erlotinib arm
62038605|NCT00447057|EXPERIMENTAL|Pemetrexed (Squamous)|Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed arm
62038606|NCT00447057|EXPERIMENTAL|Pemetrexed + Erlotinib (Squamous)|Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed + Erlotinib arm
62038607|NCT04609033|ACTIVE_COMPARATOR|bupivacaine group|
62817544|NCT03409796|OTHER|Group A: Gluten 3 gm|Gluten 3 gram (gm), powder, orally, once daily up to 14 days.
62817545|NCT03409796|OTHER|Group B: Gluten 10 gm|Gluten 10 gm, powder, orally, once daily up to 14 days.
62817546|NCT06703164||Group 1 will be followed up by conservative management|This group will be followed up by close observation of GCS ,ct brain ,fundus examination \&may need Csf flowmetry
62038608|NCT04609033|ACTIVE_COMPARATOR|bupivacaine + morphine|
62038609|NCT04609033|ACTIVE_COMPARATOR|bupivacaine + morphine + ketamine|
62817547|NCT06703164||Group 2 will undergo csf diversion|Csf diversion is either vp shunt or evd
62817548|NCT06334003||FET-group|Children conceived by frozen embryo transfer
62817549|NCT06334003||Fresh ET-group|Children conceived by fresh embryo transfer
62817550|NCT06334003||NC group|Naturally conceived children
62817551|NCT00374140|EXPERIMENTAL|RAD001 (Everolimus)|RAD001 (Everolimus)10 mg by mouth daily without interruption
62817552|NCT06229626|EXPERIMENTAL|the reeducation group|"The population included in the reeducation group will benefit, in addition to their usual physiotherapy care (at least 1 session per week), from :~* 1 group physiotherapy session per week at the ICM or by videoconference from home for 6 weeks~* 2 sessions per week at home with video support sent by e-mail for 6 weeks~These 3 additional video or group sessions will last 30 min. These sessions will be created and adjusted by a physiotherapist and a Physical and Rehabilitation Medicine doctor. They will include exercises such as :~* Stretching~* posture~* Muscle strengthening~* Proprioception~And will be performed in standing, sitting and lying positions."
62431809|NCT05402761|NO_INTERVENTION|Sleep hygiene control group|Participants will receive sleep hygiene at the enrollment of the study and be required to maintain their usual lifestyle and medical treatment for 4 weeks.
62431810|NCT02677610|EXPERIMENTAL|MSRD-100|MSRD-100 is a topical gel with an active ingredient in a vehicle. Excipients are purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. Application is twice daily for 28 days.
62817553|NCT06229626|NO_INTERVENTION|The control group|usual physiotherapy care (at least 1 session per week)
62817554|NCT05160337|OTHER|Healthy Volunteers|Healthy Volunteers will be recruited into the study
62817555|NCT03156101|EXPERIMENTAL|BinD19|BinD19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity. Minimum/maximum dose: 1x10\^6/kg / 1x10\^7/kg administered to patients with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma.
62817556|NCT04475081|EXPERIMENTAL|MMR vaccination|Subjects will be randomized to receive the MMR Vaccine subcutaneously
62817557|NCT04475081|PLACEBO_COMPARATOR|Placebo control|Subjects will be randomized to receive sterile saline given subcutaneously
62817558|NCT04841122|ACTIVE_COMPARATOR|Camera observation|Camera observation
62817559|NCT04841122|NO_INTERVENTION|No camera observation|No intervention
62817560|NCT01702207|ACTIVE_COMPARATOR|Once Daily Tacrolimus|Treatment Arm - Subjects are switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
62817561|NCT01702207|ACTIVE_COMPARATOR|Twice Daily Tacrolimus|Control Arm - Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
62038610|NCT04609033|PLACEBO_COMPARATOR|isotonic saline|
62038611|NCT04329039|ACTIVE_COMPARATOR|Group 1|Active somatostatin analogue combined with perioperative antibiotics
62038612|NCT04329039|PLACEBO_COMPARATOR|Group 2|Placebo combined with perioperative antibiotics
62038613|NCT01795833|EXPERIMENTAL|Text Messages|Short text messages related to healthy lifestyle will be sent to half the subjects three times per week, in addition to one off 'one-to-one structured education' during the study period.
62038614|NCT01795833|NO_INTERVENTION|Control|Half of the subjects who has received only one off 'one-to-one structured education about healthy lifestyle during the study period
62038615|NCT04196179|EXPERIMENTAL|SAD|"A1 Day 1 ANG-3070 50 mg (n=6) / Placebo (n=2) Oral~A2 Day 1 ANG-3070 100 mg (n=6) / Placebo (n=2) Oral~A3 Day 1 ANG-3070 200 mg (n=6) / Placebo (n=2) Oral~Day 15 ANG-3070 200mg (n=6) / Placebo (n=2) Oral~A4 Day 1 ANG-3070 400 mg (n=6) / Placebo (n=2) Oral~A5 Day 1 ANG-3070 600 mg (n=6) / Placebo (n=2) Oral~D1 Single Dose Food Effect: Day 1 ANG 3070 600 mg \*with and without food\* (n=6)/ Placebo (n=2) Oral"
62038616|NCT04196179|EXPERIMENTAL|MAD|"B1 ANG-3070 50 mg BID (n=6) / Placebo (n=2)~B2 ANG-3070 100 mg BID (n=6) / Placebo (n=2)~B3 ANG-3070 250 mg BID (n=6) / Placebo (n=2)~B4 ANG-3070 500 mg, BID (n=6)/ Placebo (n=2)~C1 ANG-3070 400 mg, QD(n=6)/ Placebo (n=2)~C2 ANG-3070 600 mg, QD (n=6)/ Placebo (n=2)"
62038617|NCT05885022|EXPERIMENTAL|Investigational Device Arm|Subjects will receive a Calibreye glaucoma device (permanent implant)
62038618|NCT06083207|EXPERIMENTAL|IBI3003|
62038619|NCT03598413|NO_INTERVENTION|Control|Patients undergoing standard laparoscopic colorectal resection with no omega-3 enriched peri-operative nutritional support
62038620|NCT03598413|EXPERIMENTAL|Omega-3|Patients in this group will receive 7 days pre and 7 days post surgery of a nutritional supplement enriched with 1.42g/dose of the fish oils EPA and DHA. The supplement is pre-mixed and will be taken twice daily for a total of 14 days.
62038621|NCT00067015|EXPERIMENTAL|IMRT alone to 86.4 Gy|External radiotherapy is given for 10 weeks, Monday through Friday for a total of 48 sessions. The total dose of radiotherapy delivered during these 10 weeks is 86.4 Gy. The radiation treatments are delivered with a high precision technique called intensity modulated radiotherapy or IMRT. For this treatment, no hormonal therapy is required.
62038622|NCT00067015|EXPERIMENTAL|IMRT TO 75.6 Gy plus Adjuvant Androgen Deprivation|Prior to a planned course of radiotherapy, which will last for eight and a half weeks, 10 weeks of hormonal therapy are given. The hormonal therapy will start with a daily pill called Casodex. Three to seven days after starting this pill, a Zoladex injection will be administered in addition to the Casodex pill. Zoladex hormonal therapy is given in the form of a monthly injection. After 10 weeks from the initiation of hormone therapy, you will begin external radiotherapy. For these treatments only 42 treatment sessions are given. The total dose of radiotherapy delivered during these 8.5 weeks is 75.6 Gy. The hormone injections continue during the radiation treatments and for 2 years after the radiation treatments. The pills are only taken for the 10 weeks before and also during the radiation treatments, however afterwards the pills are discontinued.
62038623|NCT03213158|EXPERIMENTAL|Highly sensitized kidney transplant candidates|The study population will include all highly sensitized kidney transplant candidates on the waitlist for more than 24 months at University of Wisconsin.
62038624|NCT03677713|ACTIVE_COMPARATOR|Nasal Packing|Nasal packing will be placed at the end of surgery.
62038625|NCT03677713|EXPERIMENTAL|No Nasal Packing|No nasal packing will be placed during or after the surgery.
62038626|NCT05143827|EXPERIMENTAL|Senatore Cappelli pasta|
62038627|NCT05143827|EXPERIMENTAL|Korasan pasta|
62038628|NCT05143827|ACTIVE_COMPARATOR|Claudio pasta|
62038629|NCT03731468|ACTIVE_COMPARATOR|dexmethasone group|8 mg dexamethasone will be added to local anaesthetics
62038630|NCT03731468|SHAM_COMPARATOR|control group|isobaric bupivacaine will be given on each side
62038631|NCT05045625|EXPERIMENTAL|Study Group|Twelve patients offered SCS for standard of care were also invited to participate in this study, in which a study electrode was temporarily placed intraoperatively and neuromonitoring was done per our routine standard-of-care
62038632|NCT05151302|OTHER|completion of the computer vision symptom scale questionnaire, italian version|video display terminal (VDT) workers completed the questionnaire
62038633|NCT03178266||Zip Closure Device|Patients will receive the Zip Closure Device for final skin closure after knee arthroplasty.
62241451|NCT00878852|ACTIVE_COMPARATOR|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of a 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001)
62241452|NCT00878852|EXPERIMENTAL|Experimental|Participants randomly assigned to this group will received standard treatment (including 12 session therapy program) supplemented with an intervention with a contingency management program, designed to improve adherence and efficacy of the treatment program.
62038634|NCT03178266||Metal Staples|Patients will receive Metal Staples for final skin closure after knee arthroplasty.
62038635|NCT03141359|EXPERIMENTAL|Single Arm|SBRT + Concurrent Mediastinal Chemoradiation +/- Consolidation Chemotherapy/Adjuvant Immunotherapy
62038636|NCT04085328|EXPERIMENTAL|LID015385|LID015385 soft contact lenses worn in both eyes for up to 6 nights/7 days continuously (awake and asleep). Must sleep 1 night per week without lenses. Lenses will be replaced as specified in the study protocol.
62038637|NCT04085328|ACTIVE_COMPARATOR|Biofinity|Comfilcon A soft contact lenses worn in both eyes for up to 6 nights/7 days continuously (awake and asleep). Must sleep 1 night per week without lenses. Lenses will be replaced as specified in the study protocol.
62038638|NCT05870748|EXPERIMENTAL|Luveltamab tazevibulin dose Cohort A|5.2 mg/kg q3w with prophylactic pegfilgrastim for 2 cycles followed by 4.3 mg/kg q3w for Cycle 3 onwards
62241453|NCT05053477|ACTIVE_COMPARATOR|Control Group|Patients will receive median nerve perineural injection of bupivacaine with mehylprednisolone under ultrasound guidance
62038639|NCT05870748|EXPERIMENTAL|Luveltamab tazevibulin dose Cohort B|4.3 mg/kg q3w
62038640|NCT05870748|ACTIVE_COMPARATOR|Part 2: IC Chemotherapy|"* Gemcitabine 1000 mg/m2 on Days 1, 8, and 15 q4w or 1000mg/m2 on Days 1 and 8 q3w~* Paclitaxel 80 mg/m2 on Days 1, 8, and 15 q4w~* Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 q4w~* Topotecan 4.0 mg/m2on Day 1, 8, and 15 q4w or 1.25 mg/m2 on Days 1 - 5 q3w"
62038641|NCT04197843|EXPERIMENTAL|NaviCam (ANKON)|NaviCam (ANKON)
62038642|NCT00726206|OTHER|1|Recording of the movements Recording of the electroencephalogram
62241454|NCT05053477|ACTIVE_COMPARATOR|PRF Group|Patients will receive median nerve pulsed radiofrequency (PRF) and median nerve perineural injection of bupivacaine under ultrasound guidance
62241455|NCT05053477|ACTIVE_COMPARATOR|PRP Group|Patients will receive median nerve perineural injection of platelet-rich plasma (PRP) under ultrasound guidance
62241456|NCT04537169||Mild congenital ptosis|children with mild congenital ptosis
62241457|NCT04537169||Moderate congenital ptosis|children with moderate congenital ptosis
62598832|NCT05499260|EXPERIMENTAL|CB03-154 SAD 20mg|Participants will receive CB03-154 20mg orally once daily in a fasted state.
62038643|NCT06498765|EXPERIMENTAL|Experimental group|The newborns in the experimental group were given a pacifier.
62038644|NCT06498765|NO_INTERVENTION|Control group|The newborns in the control group were not given a pacifier.
62241458|NCT04537169||Severe congenital ptosis|children with severe congenital ptosis
62241459|NCT02075411|ACTIVE_COMPARATOR|Males Single shot peripheral nerve block|a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
62038645|NCT00950469||patients with acute coronary syndrome|"94 consecutive patients without ST-segment elevation admitted to the Chest Pain Unit of the University of Heidelberg were enrolled with symptoms suggestive of ACS.~Unstable angina and non-ST-segment elevation myocardial infarction were diagnosed using the joint European Society of Cardiology/American College of Cardiology/American Heart Association/World Heart Federation Task Force redefinition of myocardial infarction guidelines. Patients with ST-segment elevation were excluded."
62241460|NCT02075411|ACTIVE_COMPARATOR|Females Single shot peripheral nerve block|a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
62241461|NCT02075411|ACTIVE_COMPARATOR|Males Continuous peripheral neural infusion|The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
62241462|NCT02075411|ACTIVE_COMPARATOR|Females Continuous peripheral neural infusion|The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
62241463|NCT04536584|EXPERIMENTAL|Arm A: personalized coaching for physical activities|This arm consists of providing patients with a personalized coaching focused on exercise and physical activity, with or without connected watch.
62241464|NCT04536584|ACTIVE_COMPARATOR|Arm B: standard supportive approach|The standard supportive approach will consist in recommendations made during visits with the oncologist. The delivery of post-treatment care by oncologists and their team systematically provide exercise advice patients including recommendations for strength training and aerobic activity.
62241465|NCT01407172||Symptomatic PAD|Patient with symptomatic PAD as defined by the presence of typical or atypical claudication symptoms or critical limb ischemia in conjunction with ABI \<0.9.
62241466|NCT01407172||Patients without PAD|Patients without PAD as defined by ABI\>0.9 and \<1.3.
62241467|NCT01407172||Asymptomatic PAD|Patients with asymptomatic PAD as defined by ABI\<0.9 but no symptoms.
62241468|NCT04640844|EXPERIMENTAL|patients hospitalized|for surgery of the aorta and / or arteries of the lower limbs.
62241469|NCT02367235|EXPERIMENTAL|Traditional vaginal positioning device|Patients will undergo their robotic-assisted sacrocolpopexy using a vaginally placed endo anal sizer.
62431811|NCT02677610|PLACEBO_COMPARATOR|Vehicle|The vehicle is a topical gel and contains excipients of the formulation: purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. It does not contain the active ingredient MSRD-100. Application is twice daily for 28 days.
62431812|NCT06189183|EXPERIMENTAL|Adjuvant Hypofractionation Radiotherapy|Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
62431813|NCT01331083|EXPERIMENTAL|PX-866|
62817562|NCT04745559|EXPERIMENTAL|Treatment|Pneumococcal conjugate vaccine (PCV13) .5 ml will be administered intramuscularly three times: 7 days (range 4 to 21 days) before apheresis collection and on day +30 (range +21 to +37) and day +90 (range +75 to +115) after CAR T cell infusion.
62817563|NCT05897541|EXPERIMENTAL|S-217622|S-217622 will be administered orally for 5 days.
62817564|NCT05897541|PLACEBO_COMPARATOR|Placebo|Placebo matching to S-217622 will be administered orally for 5 days.
62817565|NCT03264586|ACTIVE_COMPARATOR|Lidocaine-prilocaine cream|"Women who were assigned randomly to receive EMLA cream had a 5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate pemetration thrug stratum corneum~* EMLA cream was applied, 1 hour before the expected time of birth.~* With the assistance at birth, the residue of cream was removed to prevent contact with the fetus, because sodium hydroxide, which is a component of the cream, can cause fetal eye irritation.~* No additional anesthetic was applied if episiotomy was necessary.~* Before commancement of perineal repair any residual cream was wiped off."
62038646|NCT01992380|EXPERIMENTAL|Healthy Volunteer Subjects|Healthy males or females 50 years or older with no evidence of cognitive impairment
62038647|NCT01992380|EXPERIMENTAL|MCI subjects|Subjects 50 years or older with mild cognitive impairment (MCI)
62431814|NCT00947765|EXPERIMENTAL|Autologous blood injection group|This is the study group in whom autologous blood injection was injected at lateral epicondylitis site.
62817566|NCT03264586|ACTIVE_COMPARATOR|mepivacaine infiltration group|"* In the mepivacaine group, 10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.~* In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.~* The suture procedure was delayed 10 minutes after the injection of the aneathetic"
62817567|NCT04682197|ACTIVE_COMPARATOR|Cereset Research|For this single arm, open label, exploratory trial this will be the intervention arm using 4 CR sessions.
62817568|NCT04682197|OTHER|Continued Current Care|Participants will continue their current care.
62817569|NCT05699642|EXPERIMENTAL|Tai chi + wearable|48 virtual tai chi classes on Zoom over 6 months plus assigned home practice of tai chi 3x a week plus daily use of a Fitbit fitness tracker will be required for this group.
62038648|NCT01992380|EXPERIMENTAL|Probable AD Subjects|Subjects 50 years or older with probable Alzheimer's Disease (AD)
62038649|NCT05549973|EXPERIMENTAL|Anlotinib Hydrochloride Capsule|Anlotinib Hydrochloride Capsule, 21 days as a treatment cycle.
62817570|NCT05699642|NO_INTERVENTION|Enhanced usual care|Printed educational materials based on existing resources (e.g., AHA; Centers for Disease Control and Prevention) will be shared with subjects in this group.
62241470|NCT02367235|EXPERIMENTAL|Colpassist vaginal positioning device|Patients will undergo their robotic-assisted sacrocolpopexy using a vaginally placed Colpassist vaginal manipulator.
62241471|NCT01859078|EXPERIMENTAL|Baricitinib + Digoxin|"Digoxin - 0.5 milligrams (mg) administered orally, twice daily (BID), 12 hours apart on Day 1. Then, 0.25 mg administered orally, once daily (QD) on Days 2 through 16.~Baricitinib - 10 mg administered orally, QD, on Days 8 through 16."
62817571|NCT06473233||Before TEG6S|Patients managed in a period of 12 months before the implementation of TEG6S®
62038650|NCT01420055|EXPERIMENTAL|fingolimod|
62038651|NCT03386279|OTHER|Sequence 1|Sequential allocation to PF-04965842 600 mg (oral, single dose), placebo (oral, single dose), and moxifloxacin 400 mg (oral, single dose)
62038652|NCT03386279|OTHER|Sequence 2|Sequential allocation to PF-04965842 600 mg (oral, single dose), moxifloxacin 400 mg (oral, single dose), and placebo (oral, single dose)
62038653|NCT03386279|OTHER|Sequence 3|Sequential allocation to placebo (oral, single dose), PF-04965842 600 mg (oral, single dose), and moxifloxacin 400 mg (oral, single dose).
62241472|NCT06138964|EXPERIMENTAL|siSPARC microneedle patch|siSPARC microneedle patch
62431815|NCT00947765|ACTIVE_COMPARATOR|Local corticosteroid injection group|This is the control group in whom the commonly used treatment modality-local corticosteroid injection was given at lateral epicondyle site.
62038654|NCT03386279|OTHER|Sequence 4|Sequential allocation to placebo (oral, single dose), moxifloxacin 400 mg (oral, single dose), and PF-04965842 600 mg (oral, single dose)
62038655|NCT03386279|OTHER|Sequence 5|Sequential allocation to moxifloxacin 400 mg (oral, single dose), PF-04965842 600 mg (oral, single dose), and placebo (oral, single dose)
62038656|NCT03386279|OTHER|Sequence 6|Sequential allocation to moxifloxacin 400 mg (oral, single dose), placebo (oral, single dose) and PF-04965842 600 mg (oral, single dose)
62038657|NCT00853814|EXPERIMENTAL|Reduced access to sedentary behaviors, High park access|
62431816|NCT04768829|ACTIVE_COMPARATOR|Placebo group|Nystatin ear drops formulations prepared as intervention except for the addition of Moringa prepared using biodegradable polymers in aseptic condition and tested for sensitivity
62431817|NCT04768829|EXPERIMENTAL|Moringa group|Moringa ear drops prepared using biodegradable polymers in aseptic condition and tested for sensitivity
62431818|NCT01190826|EXPERIMENTAL|ASM-024 10 mg|ASM-024 administered once by inhalation at a target dose of 10 mg
62038658|NCT00853814|EXPERIMENTAL|Usual access to sedentary behaviors, High park access|
62038659|NCT00853814|EXPERIMENTAL|Reduced access to sedentary behaviors, Low park access|
62038660|NCT00853814|EXPERIMENTAL|Usual access to sedentary behaviors, Low park access|
62038661|NCT02877043||patients undergoing lung resection|
62038662|NCT06486467|OTHER|Minimally-trained operators|Group A: Minimally trained operators for LVOT VTI measurement will be intensive care residents and medical students having done less than 20 transthoracic echocardiography (TTE). All untrained operators will benefit from a standardized preliminary minimal training to teach them how to obtain apical 5-chamber view and acquire LVOT VTI using pulsed-wave Doppler according to the guidelines of the American Society of Echocardiography.
62038663|NCT06486467|OTHER|Expert operators|Group B: Experts are ICU attending physicians considered experienced and competent in TTE (either board certified or considered as experts locally). Experts will also be trained in using the same ultrasound platform equipped with the Ultrasight AI software. All operators will be trained on the same ultrasound platform: Philips Lumify® equipped with the Ultrasight AI software to optimize the quality of the 5-chamber views.
62038664|NCT05845138|EXPERIMENTAL|SHR-A1811 combined with capecitabine|
62038665|NCT01846182|ACTIVE_COMPARATOR|Group 1|60 mg of duloxetine in the AM for 20 weeks and placebo in PM
62038666|NCT01846182|ACTIVE_COMPARATOR|Group 2|300 mg of pregabalin in the PM for 20 weeks and placebo in AM
62038667|NCT01846182|PLACEBO_COMPARATOR|Group 3|placebo in the AM \& PM for 20 weeks
62241473|NCT06138964|EXPERIMENTAL|siSPARC + siLR4A microneedle patch|siSPARC + siLR4A microneedle patch
62241474|NCT05806125||the postoperative group|All patients in the postoperative group will undergo computed tomography angiography (CTA) to evaluate the status of the preserved ascending branch and the residual uterine blood supply pattern after surgery.
62241475|NCT05806125||the preoperative group|Patients in the preoperative group will undergo CTA before RT to determine the uterine blood supply pattern in healthy individuals.
62431819|NCT01190826|EXPERIMENTAL|ASM-024 100 mg|ASM-024 administered once at a target dose of 100 mg
62431820|NCT01190826|PLACEBO_COMPARATOR|Placebo|Placebo administered once by inhalation
62431821|NCT05755594|OTHER|Robot-assisted Pancreaticoduodenectomy|By performing pancreaticoduodenectomy on the subject using the latest generation Da Vinci robotic surgical system and assisted by another surgeon for the entire procedure
62817572|NCT06473233||After TEG6S|Patients managed in a period of 12 months after the implementation of TEG6S®
62817573|NCT06230900|EXPERIMENTAL|Experimental group|14C (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one ingestion (test period)
62817574|NCT05927818|EXPERIMENTAL|Sentinel Lymph Node Biopsy and Systematic Lymph Node Dissection (Single Arm)|This is a single arm interventional study in which the interventional and control arms are the same participant (each participant becomes its own control since the sentinel node biopsy- interventional arm - results are to be compared to systematic lymphadenectomy results-control arm). Intervention is injection of 2-4 mL sterile charcoal to the infundibulopelvic ligament or mesovarium of the suspicious adnexal mass followed by collection of stained sentinel lymph nodes and lymph nodes by systematic lymphadenectomy.
62038668|NCT06133400|EXPERIMENTAL|Subjects representative of the adult population (18-69 y) of French Polynesia|Population sample composed of people aged 18 to 69. These people must have been living in French Polynesia for more than two years at the time of the 2017 census
62817575|NCT04120285|NO_INTERVENTION|Primary Care Treatment|The participant will receive treatment as usual as prescribed by the primary care physician for MDD.
62817576|NCT04120285|ACTIVE_COMPARATOR|Primary care treatment with eCBT|The participant will receive treatment as usual as prescribed by the primary care physician with the addition of eCBT for MDD.
62817577|NCT04120285|ACTIVE_COMPARATOR|Primary care treatment with guided eCBT|The participant will receive treatment as usual as prescribed by the primary care physician with the addition of guided eCBT for MDD.
62817578|NCT06595173|EXPERIMENTAL|Theraputic Artistic activities group|The group receiving therapeutic artistic activities
62817579|NCT06595173|NO_INTERVENTION|Standardized Control Group|the group that did not receive any training
62817580|NCT06011759|EXPERIMENTAL|Intervention|A multi-faceted implementation intervention including qualitative interviews and feedback and optional delivery of Academic Detailing and/or LEAP.
62817581|NCT06026384|EXPERIMENTAL|Non-Narrative Text|A short text (480 words) that deals with the preventability of cancer cases. It shows that lifestyle factors such as smoking, unhealthy diet, obesity and physical inactivity are responsible for about 40% of cancer cases. It also suggests ways to reduce the risk of cancer through behavioural changes in these areas. A special focus is on nutrition and physical activity. The text was developed on the basis of the Protection Motivation Theory.
62817582|NCT06026384|EXPERIMENTAL|Narrative Text|The narrative text contains the same information as the non-narrative text, except that it is built into a story. This makes the text slightly longer at 725 words. The text is about a main character and two work colleagues who share their personal experiences about nutrition and exercise.
62817583|NCT06026384|EXPERIMENTAL|Non-Narrative Animation|The animation with a total duration of 3:12 min is based on the text in non-narrative form and aims to be as fully comparable as possible.
62817584|NCT06026384|EXPERIMENTAL|Narrative Animation|The animaion (3:45 min) is based on the text in narrative form and aims to be as fully comparable as possible.
62817585|NCT06057753|NO_INTERVENTION|Standard Education|Standard stroke patient education as per the medical providers
62038669|NCT03118583|EXPERIMENTAL|Dietary supplement with carrageenan|300 mg/day of dietary supplement containing carrageenan
62038670|NCT05574569|EXPERIMENTAL|Group 1: Play Therapy|Play therapy will be given to the participants.
62817586|NCT06057753|EXPERIMENTAL|MyStroke|Access to a personalized video-based stroke educational platform
62817587|NCT06552273|EXPERIMENTAL|Emotional Reasoning bias correction training|The experimental arm will receive an Emotional Reasoning bias correction training. The training consists of 12 self-administrated sessions, delivered online.
62817588|NCT06552273|ACTIVE_COMPARATOR|Intervention based on mindfulness|The control group refers to an intervention based on mindfulness skills. This treatment is part of a Transdiagnostic treatment developed in our laboratory, for the treatment of patients with emotional disorders (Díaz-García et al., 2017).
62817589|NCT04634097|EXPERIMENTAL|Experimental group|"Clusters will be proposed LE DECLIC EPRI intervention, which is a complex intervention, associating 3 components,:~A. DECLIC program set up in the centers, open to concerned patients.~B. 3 training sessions :~* one public of primary care physicians in order to give them the opportunity to be involved in the medical care in charge of the patient suffering from cancer pain.~* one public of cancer physicians, leaders of opinions in each cancer centers participating to the study and one public of health professionals in order to train them to be educators (team building).~* for healthcare professionals in order to train them as educators in this program.~C. The collaboration of one primary care network, specialized in pain management, in order to reinforce the patient care pathway."
62817590|NCT04634097|OTHER|Standard group|Standard follow-up patient related to pain. Specific to each center : with or without existing local ETP program (standard care).
62817591|NCT04144569|EXPERIMENTAL|PD-1 Combined With Pyrotinib|PD-1 combined With pyrotinib used fo first-line chemotherapy failedr HER2 Insertion mutation positive advanced NSCLC
62038671|NCT05574569|EXPERIMENTAL|Group 2: Mindful Parenting|Mindful parenting worksheets will be given to the parents.
62598833|NCT05499260|PLACEBO_COMPARATOR|Placebo SAD 20mg|Participants will receive placebo 20mg orally once daily in a fasted state.
62038672|NCT05574569|EXPERIMENTAL|Group 3: (Combined Interventions of both Group 1 & 2)|Play therapy will be given to children and in addition, culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
62038673|NCT05574569|NO_INTERVENTION|Group 4: Treatment as usual|No intervention will be given to the participants
62038674|NCT03722186|EXPERIMENTAL|SHR-1603|Multiple escalating doses of SHR-1603
62038675|NCT05646875|EXPERIMENTAL|post-ROSC|patients directly post-ROSC receiving HBOT
62038676|NCT05646875|ACTIVE_COMPARATOR|cardiac arrest survivors discharged home receiving HBOT|cardiac arrest survivors discharged home
62038677|NCT05646875|ACTIVE_COMPARATOR|healthy volunteers receiving HBOT|healthy volunteers receiving HBOT
62038678|NCT03333850|EXPERIMENTAL|Visual feedback of physical activity|Participants in the exposure cohort will receive usual hospital care and continuous measurement of physical activity by sensors collecting physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level, in terms of time spent bedridden, sitting, standing and walking. This information will be visible to the health personnel, the patients and their relatives.
62038679|NCT03333850|ACTIVE_COMPARATOR|No feedback of physical activity|The participants in the non-exposure cohort will receive usual hospital care and continuous measurement of physical activity by sensors collecting physical activity level during hospitalisation. No visual feedback is provided.
62038680|NCT03201939|ACTIVE_COMPARATOR|Active Medication (Intervention arm)|ACE-inhibitor lisinopril
62817592|NCT06581835||Observational|Healthy, non-smoking volunteers ages 18-50 years who meet inclusion criteria
62038681|NCT03201939|PLACEBO_COMPARATOR|Placebo comparator (Control arm)|Matched placebo
62038682|NCT05214833|EXPERIMENTAL|Real neurofeedback|The first arm will receive real neurofeedback.
62817593|NCT00579774|EXPERIMENTAL|1 - Low AGE Diet|Low Age Diet
62817594|NCT00579774|ACTIVE_COMPARATOR|2 - Regular Diet|Regular Diet
62241476|NCT04828694|EXPERIMENTAL|BICX104|BICX104 is an eroding implantable pellet that contains 1 g naltrexone and 11 mg magnesium stearate that will be inserted subcutaneously. It will be administered once for 84 days.
62241477|NCT04828694|ACTIVE_COMPARATOR|Vivitrol|Vivitrol intramuscular injection containing 380 mg of naltrexone. Three consecutive doses will be administered once every 28 days for 84 days.
62817595|NCT02050438||Knee Osteoarthritis patients with prostesis treatment|Patients operated previously of Knee Osteoarthritis with different prostesis designs according the Hospital guide
62038683|NCT05214833|SHAM_COMPARATOR|Sham neurofeedback|The second arm will receive sham neurofeedback.
62241478|NCT02383589|ACTIVE_COMPARATOR|Mycophenolate Mofetil (MMF)|Participants will receive MMF orally twice daily (every 12 hours, Q12H) from Day 1 to Week 52. Participants will also receive rituximab matching placebo by intravenous (IV) infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria have been met.
62735677|NCT03292640|EXPERIMENTAL|DFD-03 Lotion (0.1% tazarotene)|DFD-03 Lotion (0.1% tazarotene)
62735678|NCT03292640|PLACEBO_COMPARATOR|DFD-03 Vehicle (0% tazarotene)|DFD-03 Vehicle Lotion (0% tazarotene)
62735679|NCT03377816|EXPERIMENTAL|Art Therapy|The AT intervention is an 8-week group intervention comprised of 8 1.5 hour weekly sessions conducted by an experienced Art Therapist who received special training in conducting the treatment protocol as designed.
62735680|NCT03377816|SHAM_COMPARATOR|Mandala group|The comparison group will color prefabricated shapes. The same art materials as in the intervention group will be on the table as will the same instrumental music.
62735681|NCT03548896|EXPERIMENTAL|Dental Implants|Dental implants Titanium SLA treated surface of different dimensions according to the specific needs of the patient
62735682|NCT03548896|EXPERIMENTAL|Resorbable membrane|Resorbable membrane Cross link collagen membrane from porcine animal with a measure of 15 x 25 mm
62735683|NCT03548896|EXPERIMENTAL|Allograft|Allograft Bone from human source that is administered in a dosage of 1 cc per patient
62735684|NCT05441605|EXPERIMENTAL|First group|1% chlorhexidine, n=24 patients.
62735685|NCT05441605|EXPERIMENTAL|Second group|2% chlorhexidine, n=24 patients.
62735686|NCT05441605|EXPERIMENTAL|Third group|4% chlorhexidine, n=24 patients.
62735687|NCT05441605|OTHER|Fourth group|control group, 70% iso-propyl alcohol, n=24 patients.
62735688|NCT04491435|EXPERIMENTAL|Interventional|4 weeks use of mucin-based saliva substitute
62735689|NCT04491435|PLACEBO_COMPARATOR|Control|4 weeks use of xylitol-based mouthwash
62735690|NCT02841579|EXPERIMENTAL|Osimertinib|The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.
62735691|NCT00861757|PLACEBO_COMPARATOR|Placebo|
62735692|NCT00861757|EXPERIMENTAL|2.5 mg Tadalafil|
62598834|NCT05499260|EXPERIMENTAL|CB03-154 SAD 40mg|Participants will receive CB03-154 40mg orally once daily in a fasted state.
62598835|NCT05499260|PLACEBO_COMPARATOR|Placebo SAD 40mg|Participants will receive placebo 40mg orally once daily in a fasted state
62598836|NCT05499260|EXPERIMENTAL|CB03-154 SAD 60mg|Participants will receive CB03-154 60mg orally once daily in a fasted state.
62598837|NCT05499260|PLACEBO_COMPARATOR|Placebo SAD 60mg|Participants will receive placebo 60mg orally once daily in a fasted state.
62598838|NCT05499260|EXPERIMENTAL|CB03-154 FE|Participants will receive CB03-154 orally once daily in a fed state.
62598839|NCT05499260|EXPERIMENTAL|CB03-154 MAD 10mg|Participants will receive CB03-154 10mg orally once daily in a fasted state, for 14 consecutive days.
62598840|NCT05499260|PLACEBO_COMPARATOR|Placebo MAD 10mg|Participants will receive placebo 10mg orally once daily in a fasted state, for 14 consecutive days.
62598841|NCT05499260|EXPERIMENTAL|CB03-154 MAD 20mg|Participants will receive CB03-154 20mg orally once daily in a fasted state, for 14 consecutive days.
62598842|NCT05499260|PLACEBO_COMPARATOR|Placebo MAD 20mg|Participants will receive placebo 20mg orally once daily in a fasted state, for 14 consecutive days.
62598843|NCT05499260|EXPERIMENTAL|CB03-154 MAD 40mg|Participants will receive CB03-154 40mg orally once daily in a fasted state, for 14 consecutive days.
62598844|NCT05499260|PLACEBO_COMPARATOR|Placebo MAD 40mg|Participants will receive placebo 40mg orally once daily in a fasted state, for 14 consecutive days.
62598845|NCT02897726|EXPERIMENTAL|NVP-1402|NVP-1402 was administered once a day for 24 hours
62598846|NCT02897726|ACTIVE_COMPARATOR|NVP-1402R|Active comparator was administered twice a day for 24 hours
62598847|NCT05019846|EXPERIMENTAL|SRT+ADT|Patients in ARM A will be treated with SRT on the prostate (consecutive days or at alternate days to a total dose of 36.25 Gy administered in 5 fraction (7.25 Gy/fraction) + LHRH analogue (Triptoreline 22.5 mg). An anti-androgen drug (es. Bicalutamide 50 mg) must be administered daily starting from 7 days before LHRH analogue administration to 10 days after to prevent the flare effect
62598848|NCT05019846|NO_INTERVENTION|SRT alone|Patients in ARM B will be treated with SRT on prostate alone at a total dose of 36.25 Gy administered daily or on alternate days in 5 fraction (7.25 Gy/fraction).
62598849|NCT03344575|ACTIVE_COMPARATOR|Conventional defect closure|The defect is sutured with continuous PDS 2-0.
62598850|NCT03344575|EXPERIMENTAL|Peritoneal bridging|The peritoneum is dissected beginning 2-3 cm from the edge of the defect. The sac is dissected all the way to the opposite edge of the defect. The peritoneal flap is pulled to the opposite side and fixated with Optifix
62598851|NCT01215058||1|
62598852|NCT02410083|EXPERIMENTAL|Clopirin 1|Clopirin single-administration. Before this clinical trial Clopidogrel/Aspirin co-administration.
62598853|NCT02410083|ACTIVE_COMPARATOR|Clopidogrel/Aspirin co-administration 1|Clopidogrel-aspirin co-administration. Before this clinical trialClopidogrel/Aspirin co-administration.
62598854|NCT02410083|EXPERIMENTAL|Clopirin 2|Clopirin single-administration. Before this clinical trial Aspirin single-administration.
62598855|NCT02410083|ACTIVE_COMPARATOR|Clopidogrel/Aspirin co-administration 2|Clopidogrel-aspirin-co-administration. Before this clinical trial Aspirin single-administration.
62598856|NCT06619717|ACTIVE_COMPARATOR|Single HBO treatment|"The exact parameters of each dive will be left to individual clinicians. Commonly used treatments would be:~1 treatment: 100% oxygen at 2.8 atmospheres for 30 minutes followed by a 10-minute air break, then 100% oxygen at 2 atmospheres for 60 minutes with one 10-minute air break after 30 minutes"
62598857|NCT06619717|EXPERIMENTAL|Three HBO treatments|"The exact parameters of each dive will be left to individual clinicians. Commonly used treatments would be:~3 treatments: Weaver protocol or similar variation (i.e. 100% oxygen at 3 atmospheres for 90 minutes with two 10-minute air breaks every 30 minutes. This will be repeated every 8 hours until 3 treatments are complete.)"
62598858|NCT03710070|EXPERIMENTAL|Intervention|In the presence of a significant coronary artery stenosis and randomization to the intervention group: Catheter-based permanent occlusion of the ipsilateral (to the culprit coronary lesion) IMA will be performed at the projected height of inferior vena cava confluence and right atrium using a dedicated occlusion device (Amplatzer vascular plug 4, CE0086).
62735693|NCT00861757|EXPERIMENTAL|5.0 mg Tadalafil|
62735694|NCT00861757|ACTIVE_COMPARATOR|0.2 mg Tamsulosin|
62735695|NCT01564849||chronic rhinitis,|
62817596|NCT02814916|EXPERIMENTAL|Dalbavancin single-dose|Participants received dalbavancin administered intravenously as follows: birth to \< 3 months old and 3 months to \< 6 years old: 22.5 mg/kg (maximum 1500 mg) on Day 1; ≥6 years to 17 years old (inclusive): 18 mg/kg (maximum 1500 mg) on Day 1. Participants aged birth to \< 3 months were not randomized; all received dalbavancin single-dose.
62817597|NCT02814916|EXPERIMENTAL|Dalbavancin two-dose|Participants received dalbavancin administered intravenously as follows: 3 months to \< 6 years old: 15 mg/kg (maximum 1000 mg) on Day 1, and 7.5 mg/kg (maximum 500 mg) on Day 8; ≥6 years to 17 years old (inclusive): 12 mg/kg (maximum 1000 mg) on Day 1, and 6 mg/kg (maximum 500 mg) on Day 8.
62241479|NCT02383589|EXPERIMENTAL|Rituximab (RTX)|Participants will receive rituximab by IV infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria have been met. Participants will also receive MMF matching placebo orally twice daily Q12H from Day 1 to Week 52.
62241480|NCT05453019|EXPERIMENTAL|tinnitus group|Patients who have tinnitus got cochlear implant
62241481|NCT05453019|ACTIVE_COMPARATOR|without tinnitus group|Patients who have no tinnitus got cochlear implant
62241482|NCT04009317|EXPERIMENTAL|TQ-B3139|TQ-B3139 tablet 600mg administered orally , twice daily in 28-day cycle.
62241483|NCT04009317|ACTIVE_COMPARATOR|Crizotinib|Crizotinib tablet 250mg administered orally, twice daily in 28-day cycle.
62241484|NCT00908063|EXPERIMENTAL|Oxycyte|"Single intravenous infusion of Oxycyte (Perfluoro(t-butylcyclohexane) Intravenous Emulsion 60% w/v)~One of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury."
62431822|NCT03565666|ACTIVE_COMPARATOR|Adult RCT: Usual care|Participants randomized to usual care first started the usual care arm (UC) managing their diabetes with either multiple daily injections or continuous subcutaneous insulin infusion (pump therapy) for 7 days. All subjects wore a Dexcom G5 continuous glucose monitor (CGM) and half of all subjects also were a senseonics CGM. The usual care period was followed by the other 2 arms according to each subject's randomization schedule
62735696|NCT01564849||chronic sinusitis|
62241485|NCT00908063|PLACEBO_COMPARATOR|Normal Saline|"Single intravenous infusion of Normal Saline~One of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury."
62241486|NCT05042518|EXPERIMENTAL|Intervention group|The participant in the intervention group will practice breathing control and self-talk with objectives for relaxation. The duration of training is 4-5 minutes in each session, 4 sessions per week for 1 month.
62241487|NCT05042518|PLACEBO_COMPARATOR|Control group|The participant in the control group will receive consultations by a sport psychologist for goal setting and positive thinking. The duration is similar to the training group (4-5 minutes in each session, 4 sessions per week for 1 month).
62241488|NCT04257565|ACTIVE_COMPARATOR|Control group|The Control Group will receive usual and customary care from their vascular specialist.
62241489|NCT04257565|EXPERIMENTAL|Intervention Group|The Intervention Group will receive usual and customary care from their vascular specialist and they will be provided and trained to use the wheeled knee walker.
62735697|NCT01564849||nasal polyps|
62735698|NCT01564849||control rhinitis|
62735699|NCT01564849||control sinusitis|
62735700|NCT01564849||control polyps|
62735701|NCT04010656|EXPERIMENTAL|PVR-based home self-catheterization|Patients will learn to self-catheterize preoperatively prior to urogynecology surgery requiring trial of void. First post-operative void will be used to collect basic information about voiding function. All participants will leave the hospital and self-catheterize until they achieve two sequential voids with post-void residual (PVR) less than half the volume voided. The cases of urinary retention captured with abnormal PVR will be used to compare the diagnostic accuracy of several commonly-used, pre-defined parameters for trial of void.
62735702|NCT01551654|PLACEBO_COMPARATOR|Placebo Acu-TENS|No Electrical output was coming out from the TENS unit
62735703|NCT01551654|EXPERIMENTAL|TENS over acupuncture points|A constant mode of electrical stimulation at 2 pulses per second and pulse width at 200µs for 45 minutes. Intensity was set to just initiate muscle contraction.
62817598|NCT02814916|ACTIVE_COMPARATOR|Comparator|Participants 3 mos to \< 6 yrs old and ≥6 yrs to 17 yrs old received a 10-14 day course of either vancomycin 10 to 15 mg/kg/dose, not to exceed a 4000 mg total daily dose; or oxacillin 30 mg/kg/dose, infused over 60 (± 10) mins every 6 (± 1) hrs; or flucloxacillin 50 mg/kg/dose, infused over 60 (± 10) mins every 6 (± 1) hrs, not to exceed a 2000 mg total daily dose. Vancomycin was to be taken for methicillin-resistant Gram-positive infections. Based on local practice patterns/approvals for clinical use in the pediatric population, oxacillin or flucloxacillin were supplied as an IV comparator. At investigator's discretion, after 72 hrs of IV therapy, those on oxacillin or flucloxacillin could switch to oral cefadroxil (dose for infants/children: 15 mg/kg/dose every 12 hrs, max 2 g/day; dose for adolescents: 500-1000 mg every 12 hrs), and if infection with methicillin-resistant S. aureus was confirmed, those on vancomycin were allowed to switch to oral clindamycin 10 mg/kg every 8 hrs.
62817599|NCT06704763|EXPERIMENTAL|Orforglipron|Orforglipron administered orally either alone or with another investigational agent
62817600|NCT06706414|EXPERIMENTAL|Denosumab|Subcutaneous injection with 60 mg Denosumab once
62817601|NCT06702631|EXPERIMENTAL|Nitrous Oxide + Pain|Single-arm study. All subjects receive nitrous oxide and painful electric nerve stimulation, as described in the interventions.
62817602|NCT05375669|EXPERIMENTAL|ISIS IOM System|Total intravenous anesthesia (TIVA), surgery and TES MEP monitoring will proceed routinely without modification and normally involves acquiring many MEPs over several hours. The only departure from standard care will be the placement of two small accelerometers and a brief MEP sequence before skin incision to determine chronaxie and compare the effect of an equivalent increase of I or D on MEP amplitude and movement.
62817603|NCT04272294|EXPERIMENTAL|Use of Optical Spectroscopy|Optical spectroscopy used to characterize treatment response
62817604|NCT03626727|EXPERIMENTAL|Sodium Oxybate Oral Solution (Xyrem®)|4.5g of oral solution Xyrem will be given as a starting dose. This will be titrated up weekly to the final treatment dose of 9.0g. Participants will be on this final dose for 8 weeks.
62817605|NCT02168868||Control Group of Young Children|2-12 years old age \& sex-matched controls - typically developing (TD) children
62817606|NCT02168868||Young Children-Autism Spectrum Disorder|2-12 years old children diagnosed with ASD according to DSM-IV (299.00) or DSM-V (299.00)
62817607|NCT02168868||Young Children-Autism Spectrum Disorder+SCT|2-12 years old children diagnosed with ASD according to DSM-IV (299.00) or DSM-V (299.00) due to undergo stem cell transplantation therapy
62817608|NCT02168868||High-risk infants|Infants aged 10-19 months not diagnosed with ASD but with a sibling diagnosed with ASD
62817609|NCT02168868||Mothers of high-risk infants|Mothers of recruited infants aged 10-19 months not diagnosed with ASD but with a sibling diagnosed with ASD
62241490|NCT03998293|OTHER|proinsulin clearance|all participants will be studied once where somatostatin will be used to block endogenous insulin secretion
62241491|NCT01725048|ACTIVE_COMPARATOR|Mirtazapine|Treatment with oral mirtazapine, dosed once daily, for 9 weeks, with starting dose of 7.5 milligrams (mg) daily up to 30mg daily.
62431823|NCT03565666|EXPERIMENTAL|Adult RCT: closed-loop control with iLet Humalog or Novolog|Participants randomized to the iLet with humalog/novolog first started the insulin-only iLet arm using the insulin analog that they use for their usual care (either Humalog or Novolog). All subjects wore a Dexcom G5 CGM and half of all subjects also wore a Senseonics Eversense CGM. The iLet period was followed by the other 2 arms according to each subject's randomization schedule
62817610|NCT02168868||Adolescent-Autism Spectrum Disorder+SCT|12-18 years old children diagnosed with ASD according to DSM-IV (299.00) or DSM-V (299.00) due to undergo stem cell transplantation therapy
62817611|NCT06705738|EXPERIMENTAL|1st group|50 participants will follow the MeDi pattern and will receive SUPOL for 12 months.
62817612|NCT06705738|PLACEBO_COMPARATOR|2nd group|50 participants will follow the MeDi pattern and will receive Placebo capsules for 12 months.
62817613|NCT06705738|ACTIVE_COMPARATOR|3rd group|50 participants will follow the Western diet pattern and will receive SUPOL for 12 months.
62817614|NCT06705738|NO_INTERVENTION|4th group|50 participants will follow the Western diet pattern and will receive Placebo capsules for 12 months.
62817615|NCT06651593|EXPERIMENTAL|Treatment with SAR444881 and Cemiplimab|SAR444881 will be given by vein over about 60 minutes on Day 1 of each cycle. Cemiplimab will be administered by vein over about 30 minutes on Day 1 of each cycle, starting with Cycle 2. During Cycle 1, you will only receive SAR444881. Starting on Day 1 of Cycle 2 and for all other cycles, you will receive both SAR444881 and cemiplimab.
62817616|NCT06360302|ACTIVE_COMPARATOR|Healthy volunters|Voluntary participants with no chronic diseases aged 40 to 75 wishing to take part in the study and benefit from an exercise test.
62817617|NCT06360302|ACTIVE_COMPARATOR|Metabolic syndrome patients|Patients aged 40 to 75 with metabolic syndrome undergoing functional assessment in the physiology department.
62817618|NCT06360302|EXPERIMENTAL|CKD dialysis patients|Chronic renal failure patients on dialysis, stable hemodialysis for more than 3 months
62598859|NCT03710070|SHAM_COMPARATOR|Sham-Control|In the presence of a significant coronary artery stenosis, and randomization to the sham-procedure: IMA will be selectively intubated using an appropriate catheter. Angiography of the IMA and the pericardiacophrenic branch will be performed.
62038684|NCT06579118|EXPERIMENTAL|Experimental Group|"In order to have laughter yoga as a nursing intervention, a laughter yoga leadership certificate was obtained by the researcher. Mobile phone numbers were taken to contact the women.Laughter sessions were held in an empty room in the Gynecology outpatient clinic, away from the other rooms indicated by the nurse.A total of 8 sessions of laughter yoga were applied for 4 weeks,2 sessions per week.Before starting laughter yoga, 8 separate WhatsApp groups consisting of approximately 8 people were established to ensure faster and easier communication with women, and information was provided about the sessions and communication was provided. In consultation with the women, the appropriate day, time and program for the session were determined.Sessions will be held twice a week;It was done between 13.00-13.45 on Mondays and Fridays.The sessions were performed in an empty room in the outpatient clinic.A warning sign was hung on the door to avoid being disturbed during the application."
62241492|NCT01725048|ACTIVE_COMPARATOR|Citalopram|Treatment with Citalopram, once daily, for 9 weeks, with dosages starting at 10mg once daily to 40mg once daily.
62431824|NCT03565666|EXPERIMENTAL|Adult RCT: closed-loop control with iLet using Fiasp|Participants randomized to the iLet with Fiasp first started the insulin-only iLet arm using faster insulin aspart (Fiasp) in PumpCart, where the pharmacokinetic (PK) parameter for tmax used by the insulin-dosing algorithm was set to the same value as is used for Humalog and Novolog (65 minutes). All subjects wore a Dexcom G5 CGM and half of all subjects also wore a Senseonics Eversense CGM. The iLet period was followed by the other 2 arms according to each subject's randomization schedule
62598860|NCT06620601|EXPERIMENTAL|Diagnosis|"Description:~A portable polysomnography device to assess sleep apnea in individuals at risk of sleep apnea. The Prodigy 2 has Health Canada Approval for home sleep study. The system is small, easy to use, and can be setup by a research technician at the shelter. Prodigy measures thoraco-abdominal motion, nasal airflow, oxyhemoglobin saturation (SpO2), cardiac function with electrocardiogram and leg movement. The main advantage of Prodigy 2 to other portable devices is that it has a simple headband to record forehead electroencephalogram to detect rapid eye movement (REM) and non-REM sleep stages. After processing Prodigy 2 signals, an apnea-hypopnea index (AHI) will be calculated for each participant based on the number of respiratory events (apneas or hypopneas) per hour of sleep. The investigators will measure AHI, REM AHI, non-REM AHI, AHI in different body postures, snoring duration, arousal index, sleep time with SpO2\<90%, oxygen desaturation index (ODI), and sleep efficiency."
62598861|NCT06620601|EXPERIMENTAL|Treatment|"Description:~Individuals who are diagnosed with sleep apnea, and are deemed eligible for treatment, will receive a treatment option based on Canadian Agency for Drugs and Technologies in Health (CADTH), physician recommendations, and the participant's preferences. In this study, auto-titrating positive airway pressure (Auto-CPAP) and Mandibular advancement device (MAD) will be the main modalities of treatment."
62598862|NCT06620601|OTHER|Screening|"Also, the participants are asked to complete the following questionnaires with the help of a research assistant. The result of the application will be combined with the questionnaires for the final risk assessment.~* Participant Demographics questionnaire~* STOP-Bang~* Insomnia severity index~* Epworth sleepiness score (ESS)~* Functional outcome of Sleep Questionnaire (FOSQ-10)~* Beck Depression Inventory (BDI)~* Chalder Fatigue Scale (CFQ)~* Health Information Technology Usability Evaluation Scale (Health-ITUES) Questionnaire~* Oral Health Impact Profile - 14 (OHIP-14)~* Asthma Control Test (ACT)~* Primary care post-traumatic stress disorder (PTSD) screen (PC-PTSD-5)~* A survey to help identify barriers to treatment in the people experiencing homelessness (General Survey)"
62598863|NCT01483482|OTHER|Conservative treatment|"The group allocated to conservative treatment is treated with a simple sling. The sling is removed when the patient is pain free.~The first 6 weeks max 1 kg of weight-bearing is allowed and the patient is instructed to restrict movement of the arm to the level of the shoulder."
62598864|NCT01483482|OTHER|Surgical treatment|"Patients allocated to surgical treatment are operated with a superior locking plate.~The first 6 weeks max 1 kg of weight-bearing is allowed and the patient is instructed to restrict movement of the arm to the level of the shoulder."
62598865|NCT01250132|OTHER|Moderate to severe Traumatic Brain Injury|"Assessment of hypopituitarism. Blood tests at different moments:~* day 0~* when leaving intensive care unit~* month 3~* month 12"
62241493|NCT00611195|OTHER|1|Larynx assessment under stimulation
62431825|NCT00492388|EXPERIMENTAL|A|PMI-150 (intranasal ketamine)
62431826|NCT00492388|PLACEBO_COMPARATOR|B|placebo
62431827|NCT00406432|EXPERIMENTAL|Subjects receiving paroxetine|Eligible subjects will receive single dose of paroxetine 25 milligrams controlled release formulation followed by wash-out period of 5 days. Subjects will receive multiple doses of paroxetine 25 milligrams for further 14 days.
62431828|NCT02058771||Ischaemic cardiomyopathy|Patients with ischaemic cardiomyopathy attending for ICD implantation
62431829|NCT00821990|ACTIVE_COMPARATOR|Chemotherapy|Eligible patients will be first offered randomization. If willing to participate RCT, the patient will be randomized to chemotherapy or best supportive care. If patients refuse to participate in RCT, but nevertheless agree to receive treatment of their preferences, they are offered their treatment of choice (chemotherapy or supportive care).
62431830|NCT00821990|ACTIVE_COMPARATOR|Supportive care|Eligible patients will be first offered randomization. If willing to participate RCT, the patient will be randomized to chemotherapy or best supportive care. If patients refuse to participate in RCT, but nevertheless agree to receive treatment of their preferences, they are offered their treatment of choice (chemotherapy or supportive care).
62431831|NCT02323295|EXPERIMENTAL|Non Surgical-Radiation Only|Non-surgical candidates receive 72 up to 77.l4 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma
62431832|NCT02323295|EXPERIMENTAL|Malignant Tumor Surgery And Radiation|The standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor. After approximately 6 weeks of recovery, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease). If the wound is not healed or there is another medical reason to delay adjuvant radiation, then radiation may begin later.
62598866|NCT02106416|EXPERIMENTAL|PET/MRI|Patient receives PET/MRI
62817619|NCT03117751|EXPERIMENTAL|B-ALL and B-LLy, Low-risk|"Patients with low-risk B ALL and LLy will have Induction (6 weeks), Consolidation (8 weeks), and Continuation (120 weeks). During Remission Induction therapy, prednisone dose is 40mg/m\^2 and 1-2 doses of daunorubicin (based on day 8 peripheral blood MRD in patients with ETV6-RUNX1 or hyperdiploid) are given. Dasatinib is given for patients with ABL-class fusion. Blinatumomab will be given to patients with certain genetic subtypes and those with Down syndrome.~Interventions: Prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®, Rylaze™ or Calaspargase pegol), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, thioguanine, methotrexate, dexamethasone, blinatumomab."
62817620|NCT03117751|EXPERIMENTAL|B-ALL and B-LLy, Standard-risk|"Induction (6wks), Early Intensification (4wks), Consolidation (8wks) and Continuation (120 wks). Remission Induction: Prednisone dose is 40mg/m\^2 and 2 doses daunorubicin are given. Dasatinib: given for patients with Ph+ and those with ABL-class fusion. Ruxolitinib: given for patients with activation of JAK-STAT signaling; ALL patients with Day 15 or Day 22 MRD ≥5%, LLy patients who don't qualify for complete response at end of Remission Induction and all patients with ETP and T/M MPAL. Bortezomib is given to patients without targetable lesions and Day 15 or Day 22 MRD \>5%. Blinatumomab will be given to patients with residual disease at the end of induction (≥0.01% and \<1%), certain genetic subtypes and Down syndrome.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®, Rylaze™ or Calaspargase pegol), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, blinatumomab, thioguanine, methotrexate, dexamethasone, doxorubicin"
62431833|NCT01560091|PLACEBO_COMPARATOR|Group A|Patients will receive ESWL and no medication
62817621|NCT03117751|EXPERIMENTAL|B-ALL and B-LLy, High-risk|"Induction (6 weeks), Early Intensification (4 weeks), Consolidation (8 weeks), and Immunotherapy (chimeric antigen receptor \[CAR\] T cells). Patients who do not respond to Immunotherapy will receive Reintensification therapy. During Remission Induction therapy, prednisone dose is 40mg/m\^2 and 2 doses of daunorubicin are given. Dasatinib, ruxolitinib, and bortezomib are given as done for patients with standard-risk B-ALL but are discontinued in Immunotherapy and Reintensification therapy. Blinatumomab will be given to patients who are not able to receive CAR T cell therapy and patients with certain genetic subtypes and those with Down syndrome.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®, Rylaze™ or Calaspargase pegol), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, blinatumomab, etoposide, dexamethasone, clofarabine, thioguanine, methotrexate."
62431834|NCT01560091|ACTIVE_COMPARATOR|Group B|Patients will receive Flomax after ESWL
62431835|NCT01560091|ACTIVE_COMPARATOR|Group C|Patients will receive silodosin after ESWL
62431836|NCT06445556|ACTIVE_COMPARATOR|NatureUplift|Parent-child dyads randomized to NatureUplift group
62431837|NCT06445556|EXPERIMENTAL|NatureUplift+Active|Parent-child dyads randomized to NatureUplift+Active group
62431838|NCT04656093|EXPERIMENTAL|Intervention|"Intervention group - Cognitive Restructuring, Motivational Interviewing, and Multi-Medication Adherence.~The pilot intervention is comprised of three educational sessions for individual study patients, conducted by interventionist with a master's degree in psychology with cognitive behavioral therapy training. The topics addressed in the sessions are as follows:~Review of COPD medication inhaler technique, psychoeducation on maladaptive beliefs and emotional response."
62431839|NCT04656093|ACTIVE_COMPARATOR|Control|Control group - Supportive counseling for comorbidity management
62431840|NCT01226875|ACTIVE_COMPARATOR|A (Narrow focus, LP)|A (Narrow focus): stone is in lower pole of kidney and SWL using narrow focus on lithotripter
62598867|NCT00236158|OTHER|AAIR|
62598868|NCT00236158|OTHER|DDDR|
62598869|NCT04291482|EXPERIMENTAL|Intervention arm|The intervention group participants will be assessed with EMA and they will provide daily data regarding their predictors of weight loss outcomes and their adherence to the personal weight loss plan (phase I, month 0-3). Then participants will receive tailored information regarding the most predictive factors relevant to their weight loss trajectories (phase II, month 3-6). The information will be tailored and delivered through emails and text messages.
62817622|NCT03117751|EXPERIMENTAL|T-ALL and T-LLy, Standard-risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Continuation (120 wks). During Remission Induction therapy, prednisone dose is 60mg/m\^2 and 3 doses daunorubicin are given. Dasatinib is given for patients with Ph+ and those with ABL-class fusion. Ruxolitinib is given for patients with activation of JAK-STAT signaling; ALL patients with Day 15 or Day 22 MRD ≥5% and all patients with ETP and T/M MPAL and LLy patients who don't qualify for complete response at end of Remission Induction. Bortezomib is given to patients without targetable lesions and Day 15 or Day 22 MRD ≥ 5%.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®, Rylaze™ or Calaspargase pegol), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, methotrexate, dexamethasone, doxorubicin, nelarabine, thioguanine."
62817623|NCT03117751|EXPERIMENTAL|T-ALL and T-LLy, High-risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Reintensification. During Remission Induction therapy, prednisone dose is 60mg/m\^2 and 3 doses daunorubicin are given. Dasatinib, ruxolitinib, and bortezomib given as done for patients with standard-risk T-ALL but are discontinued in Reintensification therapy.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®, Rylaze™ or Calaspargase pegol), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, methotrexate, etoposide, dexamethasone, clofarabine, vorinostat, idarubicin, nelarabine, thioguanine.."
62817624|NCT03117751|EXPERIMENTAL|ALL, CEP72 T/T, Vincristine|"Patients with the CEP72 rs904627T/T genotype (\~16% of patients) will be randomized (unblinded design, only those who evaluate neuropathy are blinded) to receive either 1.5 mg/m\^2 or 1 mg/m\^2 of vincristine after Continuation Week 1. Patients in low- risk will complete vincristine in Week 49 and those in standard/high-risk will complete in Week 101.~Intervention: vincristine."
62038685|NCT06579118|NO_INTERVENTION|Control group|"* Written consent was obtained from pregnant women who agreed to participate in the study.~* In order to determine the descriptive characteristics of menopausal women, they were asked to fill out the Personal Information Form, Menopause Rating Scale and Menopause-Specific Quality of Life Scale.~* After 4 weeks, the process was completed by having women in menopause fill out the Menopause Symptoms Assessment Scale/MSDS and Menopause-Specific Quality of Life Scale/MSDS."
62431841|NCT01226875|ACTIVE_COMPARATOR|B (Wide focus, LP)|B: stone is in lower pole of kidney and SWL using wide focus on lithotripter
62431842|NCT01226875|ACTIVE_COMPARATOR|C (Narrow focus, no LP)|C: stone is in no-lower pole of kidney and SWL using narrow focus on lithotripter
62431843|NCT01226875|ACTIVE_COMPARATOR|D (Wide focus, no LP)|D: stone is in no-lower pole of kidney and SWL using wide focus on lithotripter
62038686|NCT05517317|EXPERIMENTAL|Autologous BMMC infusion|One administration of autologous bone marrow mononuclear cells via the hepatic artery
62038687|NCT03597568|EXPERIMENTAL|Resveratrol first, then placebo|Patients will receive resveratrol 400 mg PO per day in divided doses of 200 mg in the morning and 200 mg in the evening. After a minimum of 2 week washout period, subjects then took placebo for 6 weeks.
62038688|NCT03597568|PLACEBO_COMPARATOR|Placebo first, then resveratrol|Patients will receive placebo pill identical in appearance and taste to the supplement. Subjects took this placebo twice daily, once in the morning and once in the evening. After a minimum of 2 week washout period, subjects then took resveratrol for 6 weeks.
62038689|NCT03882333|EXPERIMENTAL|Acute exercise|Acute exercise (bicycle at stationary cycle).
62241494|NCT02217189|EXPERIMENTAL|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
62431844|NCT03952936|OTHER|Mobility|Self comparison of data from pre-post intervention.
62431845|NCT03104088||SPG4 patients|
62431846|NCT03104088||Healthy controls|
62431847|NCT03049137|EXPERIMENTAL|Computer Guided Stent Augmentation|Patients with defective maxillary anterior alveolar ridges requiring implant insertion will have simultaneous implant placement with ridge augmentation using autogenous bone ring graft covering them with Platelet-rich fibrin (PRF) using computer guided stent.
62431848|NCT03049137|ACTIVE_COMPARATOR|Free Hand Augmentation|Patients with defective maxillary anterior alveolar ridges requiring implant insertion will have simultaneous implant placement with ridge augmentation using Free hand simultaneous implant placement with ridge augmentation and covering them with Platelet-rich fibrin (PRF).
62431849|NCT01632683|ACTIVE_COMPARATOR|C-MAC|Providers will utilize the C-MAC video laryngoscope equipped with a D-blade to facilitate intubation
62431850|NCT01632683|ACTIVE_COMPARATOR|Glidescope|Providers will utilize the Glidescope video laryngoscope equipped with the #4 blade to facilitate intubation
62241495|NCT02217189|NO_INTERVENTION|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment.
62431851|NCT05113901|ACTIVE_COMPARATOR|Methylprednisolone taper|21 x 4mg tablets at 6 weeks, qualifying for MUA if ROM \<90° at 8 weeks
62431852|NCT05113901|PLACEBO_COMPARATOR|Placebo taper|21 sugar tablets at 6 weeks with standard management, qualifying for MUA if ROM \<90° at 8 weeks
62431853|NCT05033015|EXPERIMENTAL|Test|Mouth rinse containing enzymes
62431854|NCT05033015|ACTIVE_COMPARATOR|Placebo|Control, same content as test, without enzymes
62431855|NCT04208191|NO_INTERVENTION|Control - Women|Participants who delivered or received family planning services at a facility that was not implementing a QI project on PCC
62431856|NCT04208191|EXPERIMENTAL|Intervention - Women|Participants who delivered or received family planning services at a facility that was implementing a QI project on PCC
62431857|NCT04208191|NO_INTERVENTION|Control - Provider|Provider working in a facility that is not implementing a QI project on PCC
62431858|NCT04208191|EXPERIMENTAL|Intervention - Provider|Provider working in a facility that is implementing a QI project on PCC
62431859|NCT04881591|EXPERIMENTAL|APP+Usual Treatment|Participants at this condition will receive the usual medical treatment for their scoliosis but also they will be monitored daily using the Scoliosis Pain Monitor APP. Alarms will be generated in the face of certain preestablished undesired events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
62817625|NCT03117751|EXPERIMENTAL|ALL, CEP72 C/T or C/C, Vincristine|"Patients with either a CEP72 rs904627 C/T or C/C genotype (\~84% of patients) will be randomized (unblinded design, only those who evaluate neuropathy are blinded) to receive vincristine (2 mg/m\^2 per dose except during Reinduction I and Reinduction II when 3 weekly doses of 1.5 mg/m\^2 will be given) and dexamethasone pulses through Week 49 of Continuation Treatment or through Week 101 of Continuation Treatment. Patients at low-risk will complete vincristine in Week 49.~Interventions: vincristine, dexamethasone, methotrexate, mercaptopurine."
62817626|NCT05192889|EXPERIMENTAL|Block 1|"All eligible patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Navitoclax, Dexamethasone, Vincristine, Calaspargase Pegol, Pegaspargase, Erwinia asparaginase, Dasatinib, Leucovorin, Intrathecal (IT) MHA (methotrexate/hydrocortisone/cytarabine)"
62038690|NCT03882333|NO_INTERVENTION|Rest|Rest (lying down or sitting in a chair) for 30 minutes, i.e. same time duration as in experimental arm.
62431860|NCT03232749|OTHER|symptomatic primary osteoarthritis of the shoulder|Subjects enrolled into the study will be those who have failed previous treatment including over-the-counter analgesics and activity modification, and have elected to receive a medically-indicated, ultrasound-guided IACSI in the shoulder
62817627|NCT05192889|EXPERIMENTAL|Block 2|"Block 2a Therapy:~Patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Navitoclax, Dexamethasone, Cytarabine, Calaspargase Pegol, Pegaspargase, Erwinia asparaginase, Dasatinib, IT MHA, Radiation~Block 2b Therapy:~Patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Blinatumomab, Dexamethasone, Dasatinib, IT MHA~Following Block 2 of therapy, late (≥36 months from diagnosis) first relapse B-ALL who are MRD negative after Block 1 will continue chemotherapy using adapted R3 intensification, interim, and continuation therapies.~Patients receive intervention according to the Detailed Description section with the following:~Methotrexate, Mercaptopurine, IT MHA, Leucovorin, Dexamethasone, Vincristine, Cyclophosphamide, Etoposide, Cytarabine, Dasatinib, Calaspargase Pegol, Pegaspargase, Erwinia asparaginase, Radiation"
62817628|NCT04146376||Non-Corrector|Patients with gestational week 34-38 von Willebrand factor activity, or von Willebrand factor ristocetin cofactor, or Factor VIII procoagulant activity less than 100 percent will be termed non-correctors. When laboratory monitoring can be performed, patients with an isolated von Willebrand factor collagen binding type 2 defect, von Willebrand factor collagen binding less than 100 percent can also be enrolled and determined as a non-corrector.
62817629|NCT04146376||Corrector|Patients with von Willebrand factor parameter levels greater than or equal to 100 percent self-corrected at gestational weeks 34-38 will be termed correctors.
62038691|NCT00126412|EXPERIMENTAL|123I-mIBG (Meta-iobenzylguanidine)|"All subjects received 123I-mIBG injection over at least 1 to 2 minutes through a cannula (or indwelling catheter in the vein). After the injection of 123I-mIBG was complete, the cannula was flushed with at least 5 mL of 0.9% sodium chloride solution over a maximum of 10 seconds.~All subjects ≥18 years of age and children with a weight of ≥70 kg were to receive an intravenous injection of 370 ±10% MBq (333 to 407 MBq \[9.0 to 11 mCi\] of 123I-mIBG). Doses of 123I-mIBG for children \<18 years of age (with a weight of 8-70 kg) were to be calculated on the basis of a reference activity for an adult scaled to body weight according to the schedule proposed by the European Association of Nuclear Medicine (EANM) Paediatric Task Group; for children \<8 kg, a scaled activity or a fixed minimum activity of 80 ±10% MBq (72 to 88 MBq \[1.9 to 2.2 mCi\]) was permissible."
62038692|NCT01632748|EXPERIMENTAL|Modified Neurotech Vital Device|Checking to observe stimulation delivered using this device
62038693|NCT01632748|ACTIVE_COMPARATOR|Neurotech Vital Device|Checking to see if stimulation observed using this device
62038694|NCT00408213|EXPERIMENTAL|1|
62038695|NCT00408213|PLACEBO_COMPARATOR|2|
62431861|NCT02456051||High AM|Newly diagnosed diabetic patients with high Adrenomedullin serum levels
62431862|NCT02456051||Low AM|Newly diagnosed diabetic patients with low Adrenomedullin serum levels
62431863|NCT02425865|OTHER|open-label, uncontrolled trial|All patients will receive Standard regimen with golimumab 50 mg Q4W, or 100 mg Q4W if \> 80 kg
62431864|NCT06190782|EXPERIMENTAL|PD-1 inhibitor+/- chemotherapy combined with local therapy|Patients randomized to this arm will receive local treatment combined with systemic treatment (immunotherapy or chemo-immunotherapy)
62431865|NCT06190782|ACTIVE_COMPARATOR|PD-1 inhibitor +/- chemotherapy alone|Patients randomized to this arm will receive only systemic treatment (immunotherapy or chemo-immunotherapy)
62431866|NCT02941237|OTHER|Healthcare worker measurement of SpO2|Measurement of SpO2 using the Lifebox pulse oximeter probe in children of different ages, stratified by age: 0-1 months, 2-11 months, 12-23 months and 24-59 months
62431867|NCT02941237|OTHER|Expert measurement of SpO2|Measurement of SpO2 using the Lifebox pulse oximeter probe and Masimo oximeter probe in children of different ages, stratified by age: 0-1 months, 2-11 months, 12-23 months and 24-59 months
62431868|NCT04249063|EXPERIMENTAL|Treatment Group|NovaSure EA with an injection of local anaesthetic into the fundus. Paracervical block and procedural sedation as per usual.
62431869|NCT04249063|PLACEBO_COMPARATOR|Control Group|NovaSure EA with an injection of normal saline into the fundus. Paracervical block and procedural sedation as per usual.
62431870|NCT02077751|EXPERIMENTAL|Biotin labelled RBCs|Subjects receive biotin labelled autologous red blood cells.
62431871|NCT02431884||body fluids/tissues & history|collect body fluids/tissues \& med history from subjects with polycystic ovary syndrome(PCOS), congenital uterine malformations, endocrine malfunctions, endometriosis, and infertility;
62431872|NCT05429853|EXPERIMENTAL|Sondalis® HP 2 kcal (with or without fibre)|
62431873|NCT04926961|EXPERIMENTAL|Sham stimulation first, then real stimulation|Participants will first be delivered sham TMS stimulation. Then on a separate day, participants will be delivered real TMS stimulation.
62038696|NCT05386888|EXPERIMENTAL|treatment|GFH018 80mg 7-Day on/ 7-Day off and 4 doses of Toripalimab 240mg Q3W concurrently with standard chemo-radiotherapy, followed by GFH018 80mg 14-Day on/ 14-Day off and Toripalimab 3mg/kg Q2W for up to 48 weeks
62038697|NCT01894295|EXPERIMENTAL|Vitamin D analogue|1-α hydroxyvitamin D3; dose 0.25, 0.5 and 1 microgram.
62038698|NCT01894295|PLACEBO_COMPARATOR|Placebo|Corn oil pearl Capsules 1 gram
62038699|NCT01911403|ACTIVE_COMPARATOR|Angio-Seal|Closure procedure by Angio-Seal
62038700|NCT01911403|ACTIVE_COMPARATOR|Manual compression|Closure procedure by manual compression
62038701|NCT05530213|EXPERIMENTAL|Healthy adults UZ Gent|A group of 30 healthy adults aged 18-65years old will carry out a 3D gait analysis at UZ Gent within a week of the 3D gait analysis at UHasselt and/or UMaastricht.
62038702|NCT05530213|EXPERIMENTAL|Healthy adults UHasselt|The same group of 30 healthy adults aged 18-65years old will carry out a 3D gait analysis at UHasset within a week of the 3D gait analysis at UZGent and/or UMaastricht.
62038703|NCT05530213|EXPERIMENTAL|Healthy adults UMaastricht|The same group of 30 healthy adults aged 18-65years old will carry out a 3D gait analysis at UHasset within a week of the 3D gait analysis at UZGent and/or UZGent.
62038704|NCT06006546|EXPERIMENTAL|Group 1 (ATI)|"Group 1 will receive 2 doses of the vaccine at Week 0 and 12. Group 1 will transition to Schedule 2 at the Week 14 visit. The Schedule 2 ATI with Monitoring phase can last for 24 weeks OR until any antiretroviral therapy (ART) re-initiation criteria are met, OR the ATI can continue longer with the approval of the Protocol Safety Review Team (PSRT) and the participant's primary HIV healthcare provider. Group 1 will transition to Schedule 3, the Follow-up on ART restart phase that lasts until study week 64, regardless of the point where it begins."
62038705|NCT06006546|EXPERIMENTAL|Group 2 (No ATI) Control|"Group 2 transitions from Schedule 1 into Schedule 4, Follow-up on ART, at the Week 14 visit, and remains on Schedule 4 through study week 64."
62431874|NCT04926961|EXPERIMENTAL|Real stimulation first, then sham stimulation|Participants will first be delivered real TMS stimulation. Then on a separate day, participants will be delivered sham TMS stimulation.
62431875|NCT03032588|EXPERIMENTAL|Group 1: sIPV|Participants will receive single intramuscular injection of the trivalent inactivated poliovirus vaccine based on Sabin strains produced on PER.C6 cells (sIPV) on Day 1.
62431876|NCT03032588|ACTIVE_COMPARATOR|Group 2: cIPV|Participants will receive single intramuscular injection of the currently used trivalent inactivated poliovirus vaccine IMOVAX POLIO, based on the conventional Salk poliovirus strains produced on Vero cells (cIPV) on Day 1.
62431877|NCT01757366|EXPERIMENTAL|experimental|Ginsenoside Rg3 plus First-line Chemotherapy
62431878|NCT01757366|ACTIVE_COMPARATOR|Active Comparator|First-line Chemotherapy
62431879|NCT06129487|EXPERIMENTAL|Narrative Pictorial Warning Labels|Participants in this arm will be presented with three narrative pictorial warning labels for alcoholic beverages.
62431880|NCT06129487|EXPERIMENTAL|Non-Narrative Pictorial Warning Labels|Participants in this arm will be presented with three non-narrative pictorial warning labels for alcoholic beverages.
62431881|NCT05274399||Hemodialysis Patients|Receiving hemodialysis treatment for at least three months
62431882|NCT00796211|EXPERIMENTAL|1|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
62431883|NCT00796211|EXPERIMENTAL|2|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
62431884|NCT00796211|ACTIVE_COMPARATOR|3|0.1% nortriptyline HCl topical cream
62431885|NCT00796211|ACTIVE_COMPARATOR|4|0.005% calcipotriol topical cream
62431886|NCT00796211|PLACEBO_COMPARATOR|5|Vehicle of CRx-197 topical cream (placebo)
62038706|NCT01461668|EXPERIMENTAL|Retapamulin|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of retapamulin with follow up bilateral nares swab one week following completion of therapy (\~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (retapamulin) to begin one week following swab collection (\~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (\~D47).
62038707|NCT01461668|PLACEBO_COMPARATOR|Placebo|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of a placebo with follow up bilateral nares swab one week following completion of therapy (\~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (placebo) to begin one week following swab collection (\~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (\~D47).
62431887|NCT04407195||Healthcare Providers|Healthcare workers (physicians and nurses) who have interacted with patients with known or suspected COVID-19.
62431888|NCT04472182|EXPERIMENTAL|Fluoride varnish with xylitol coated calcium and phosphate|
62431889|NCT04472182|ACTIVE_COMPARATOR|Conventional Fluoride varnish|
62431890|NCT02796898|EXPERIMENTAL|Treated Group|"SM88 is a combination therapy consisting of 4 agents. One agent, the tyrosine isomer will be increased in each of 2 dose cohorts as follows:~Cohort 1:~* Tyrosine isomers - 230 mg qd~* Phenytoin - 50 mg qd.~* Methoxsalen - 10 mg qd~* Sirolimus - 0.5 mg qd~Cohort 2:~Cohort 2 has increasing tyrosine isomer from q.d. to b.i.d.~Expansion Cohort:~The optimum dose will be expanded in 2nd stage of the study to 30 subjects."
62431891|NCT05589610|EXPERIMENTAL|EQ101|EQ101 weekly
62431892|NCT05488652|NO_INTERVENTION|Control|no intervention
62431893|NCT05488652|EXPERIMENTAL|Time restricted eating|not more than 10 hrs. eating window daily goal for 6 months
62598870|NCT04291482|OTHER|Control arm|Control group participants will receive basic educational weight loss information in a form of educational factual emails and text messages.
62598871|NCT06369519||Synchronous BRCC patients|Synchronous BRCC is defined as the second primary RCC emerges within 6 months from the diagnosis of the first primary RCC.
62817630|NCT05131308||Detachable embolization coils group|Patients who have an intervention for leak closure with detachable embolization coils
62598872|NCT06369519||Metachronous BRCC patients|Metachronous BRCC develops beyond 6 months from the diagnosis of the first primary RCC.
62598873|NCT05940493|EXPERIMENTAL|Active Treatment (Abemaciclib)|Administered twice daily on days 1-28 of each 28-day cycle.
62817631|NCT05131308||Vascular plugs/septal occluders group|Patients who have an intervention for leak closure with vascular plugs/CSO
62817632|NCT05131308||RF Ablation group|Patients who have an intervention for leak closure with Radio Frequency Ablation (RFA)
62817633|NCT05090696||One group only|Participants recruited from patients hospitalized in intensive care units and pulmonary unit of the University Hospital of Clermont-Ferrand, France.
62817634|NCT06582225|EXPERIMENTAL|Internet-delivered exposure and response prevention (I-ERP)|A therapist-guided, internet-delivered exposure and response prevention (I-ERP) programme for children and adolescents with OCD and autism.
62817635|NCT06582225|ACTIVE_COMPARATOR|Internet-delivered stress management (I-SM)|A therapist-guided, internet-delivered stress management (I-SM) programme for children and adolescents with OCD and autism.
62817636|NCT06018441||Severe asthma|Participants with severe asthma starting treatment with dupilumab
62817637|NCT04105036||45-54 years of age|Divided into two subgroups: individuals who are and are not socially deprived
62817638|NCT04105036||54-64 years of age|Divided into two subgroups: individuals who are and are not socially deprived
62817639|NCT04105036||65-74 years of age|Divided into two subgroups: individuals who are and are not socially deprived
62817640|NCT04105036||75-85 years of age|Divided into two subgroups: individuals who are and are not socially deprived
62817641|NCT05604040|EXPERIMENTAL|Self-monitoring and education program for lifestyle changes|Participants will send self-reports of their home BPs, diet, physical activity and emotions while attending a 6-week education program of lifestyle changes and coping skills. Participants will get summary reports of their home BP and lifestyle monitoring. Participants primary care physicians will be notified of persisting high BPs and final average home BP levels. Researchers will monitor home BP levels and change in hypertension control state
62598874|NCT05940493|PLACEBO_COMPARATOR|Placebo|Administered twice daily on days 1-28 of each 28-day cycle.
62598875|NCT01317797|EXPERIMENTAL|Namilumab 150 mg|Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.
62598876|NCT01317797|EXPERIMENTAL|Namilumab 300 mg|Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.
62598877|NCT01317797|PLACEBO_COMPARATOR|Placebo|Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.
62598878|NCT00396552|EXPERIMENTAL|1|
62598879|NCT00396552|SHAM_COMPARATOR|2|
62598880|NCT01451138|EXPERIMENTAL|Treated|
62598881|NCT04056273|EXPERIMENTAL|Guide sheath group|Transbronchial biopsy with a guide sheath
62598882|NCT04056273|ACTIVE_COMPARATOR|Conventional group|Transbronchial biopsy without a guide sheath
62817642|NCT06705699|EXPERIMENTAL|Urethral Mobilization Technique|• Description: Involves mobilizing the urethral tube proximally and advancing it distally to the glans. The urethra is repositioned and sutured at the neomeatal position.
62817643|NCT06705699|EXPERIMENTAL|Mathieu Technique|• Description: Utilizes a perimeatal-based flap, which is flipped up to create the neourethra.
62817644|NCT06702644|ACTIVE_COMPARATOR|RIC|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily for 6 consecutive days after enrollment.
62817645|NCT06702644|PLACEBO_COMPARATOR|Sham RIC|Sham remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. Sham RIC will be conducted twice daily for 6 consecutive days after enrollment.
62817646|NCT03479814|EXPERIMENTAL|IMRT-SIB plus sequential IG-RT boost|45 Gy plus 5 Gy concomitant boost are delivered to rectum and locoregional lymphnodes (25 fractions); sequential IG-RT (imaging guided-radiotherapy) boost of 5 Gy in 2 fractions is planned with 18-FDG-PET
62817647|NCT06150040|EXPERIMENTAL|Refractory Acute Myeloid Leukemia|Patients who meet primary refractory disease definition according to ELN criteria after 2 cycles of standard \[AZACITIDINE +VENETOCLAX\] (i.e: patients who have failed to have a complete remission (with complete (CR) or incomplete hematologic recovery (CRi))
62817648|NCT02236026|EXPERIMENTAL|Supratherapeutic dose of Nestorone|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
62817649|NCT02236026|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
62817650|NCT02236026|EXPERIMENTAL|Moxifloxacin|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
62817651|NCT03244878|EXPERIMENTAL|Intervention - Thrive program|Participants will receive access to the Thrive program for 8 weeks
62598883|NCT05030909|EXPERIMENTAL|transdiagnostic group protocol|The study will run two gender-specific treatment groups (8 participants each) recruited from the community, with one individual session (for information, consent and initial data collection) and 6 group sessions. Both groups will receive the same intervention. A second round of recruitment will run later with anticipated n of 32 in the experimental arm.
62817652|NCT03244878|NO_INTERVENTION|Wait-list Control|Participants will have no access to the Thrive program for 8 weeks upon enrollment. They will receive a link to the NIMH website to read about information on depression.
62817653|NCT05913882|EXPERIMENTAL|Lung Volume Recruitment +Expiratory Muscle Strength Training|All enrolled participants will commence a combined lung volume recruitment and expiratory muscle strength training exercise regimen following a 5-week no-intervention lead-in period.
62241496|NCT03165318|ACTIVE_COMPARATOR|Pulsed Electromagnetic Field Therapy|Active Pulsed Electromagnetic Field therapy device; exposed once weekly for 10 minutes.
62817654|NCT04965987|ACTIVE_COMPARATOR|Oxaloacetate|"Oxaloacetate (OAA) is a four-carbon molecule involved in many metabolic pathways, including gluconeogenesis, citric acid cycle, glyoxylate cycle, urea cycle, and amino acid metabolism. In the glyoxylate and citric acid cycles, oxaloacetate is formed as the result of the catalysis by malate dehydrogenase.~Subjects will take 1000mg OAA BID for 8 weeks."
62241497|NCT03165318|SHAM_COMPARATOR|Sham Therapy|Inactive Pulsed Electromagnetic Field therapy device; exposed once weekly for 10 minutes.
62241498|NCT06012383||NanoAlvand Bortezomib|1.3 mg/m2 Bortezomib, IV infusion
62241499|NCT06445309||Group 1|"Between 80-100 healthy volunteers between 60-75 years old are needed to carry out this sensory tasting study in untrained tasters.~Additionally, the participant will be given a form to assess the Geriatric Oral Health Assessment Index (GOHAI) and a form for the assessment of dysphagia (EAT-10) to assess the participant's sensory perceptions, as well as any oral health problems. oral health that could interfere with the results of the sensory tasting."
62241500|NCT02427152||Lean|body mass index: 18-25 kg/m²
62241501|NCT02427152||Overweight/Obese|body mass index: \>25 kg/m²
62241502|NCT02202551|EXPERIMENTAL|ADS-5102|amantadine HCl extended release
62241503|NCT06090526||cases group|. first group (case group) will include 40 patients who will be suspected to have urinary septicemia at intensive care units of Ain Shams university.
62241504|NCT06090526||control group|Second group (control group) will include 40 nonhospitalized, healthy age and sex matched adults.
62241505|NCT05236933||Neuropathic|Individuals who report pain that is categorized as neuropathic will be assigned to this group.
62241506|NCT05236933||Nociceptive|Individuals who report pain that is categorized as nociceptive will be assigned to this group.
62241507|NCT04638517|ACTIVE_COMPARATOR|Danazol|800mg daily in two divided doses orally for 12 months. In subjects who have difficulty tolerating danazol / placebo, the dose will be reduced by 200mg/day and side effects will be reassessed. If symptoms related to the study drug persist, subsequent 200mg/day dose reductions will be allowed until a tolerated dose is achieved. Background antifibrotic therapy is allowed.
62241508|NCT04638517|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules.
62241509|NCT06371287|EXPERIMENTAL|Study Group - Musical Auditory Training|"For musical training, the protocol proposed by Freire, et al. (2009). This protocol was created for elderly users of hearing aids and in this study it will be used as an instrument for intervention in tinnitus, aiming at auditory training through the hierarchization of auditory skills associated with musicality (FREIRE, 2009).~Eight sessions will be held over four weeks, two sessions per week. Sessions will last a minimum of 40 minutes and a maximum of 50 minutes. Victory supra-aural headphones will be used, connected to the computer. There will be calibration, with adjustment of the volume of sounds to the most comfortable level for the individual at the beginning of all sessions."
62241510|NCT06371287|PLACEBO_COMPARATOR|Control Group - Placebo|"Placebo sessions will also be held twice a week for four weeks, totaling eight sessions.~To ensure the same conditions for performing musical auditory training, in the placebo treatment, instrumental music will be used concomitantly with the exposure of films without sound, in which patients will be exposed to visual and auditory stimulation during the same time of EG intervention, at least 40 minutes and a maximum of 50 minutes."
62241511|NCT03716050|OTHER|Group 1|Breast skin after mastectomy will be clinically examined by the surgeon to determine if there is adequate blood flow to the skin to allow safe coverage of the breast implant. No treatment, including dye study, ointment, or vacuum dressing will be applied to the breast after implant placement.
62241512|NCT03716050|ACTIVE_COMPARATOR|Group 2|Breast skin after mastectomy will be clinically examined by the surgeon, and nitroglycerin (NTG) cream will be applied to the breast skin after implant placement. This cream does not have systemic effects but may improve blood flow to the remnant breast skin after mastectomy.
62241513|NCT03716050|ACTIVE_COMPARATOR|Group 3|Breast skin after mastectomy will be clinically examined by the surgeon, and an incisional vacuum-assisted dressing (iVAC) will be placed over the breast incisions after implant placement, which may improve blood flow to the skin and help wound healing.
62241514|NCT03716050|ACTIVE_COMPARATOR|Group 4|Breast skin after mastectomy will be clinically examined by the surgeon, and both NTG cream will be applied to the breast skin and an iVAC will be placed over the incisions after implant placement.
62241515|NCT03716050|ACTIVE_COMPARATOR|Group 5|Blood flow to breast skin after mastectomy will be examined using a fluorescent dye study called fluorescent angiography (FA) to determine if there is adequate blood flow to the skin to allow safe coverage of the breast implant. No further intervention will be used after implant placement.
62241516|NCT03716050|ACTIVE_COMPARATOR|Group 6|Blood flow to breast skin breast skin will be examined using FA, and NTG cream will be applied to the skin after the implant is placed.
62735704|NCT03377595|EXPERIMENTAL|TAP (Transversus Abdominis Plane) block|20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL m.A 2-point classic TAP block will be performed under ultrasound guidance within 1 hour (± 30 minutes) following skin incision closure of the C-section.
62817655|NCT04965987|PLACEBO_COMPARATOR|Placebo|Subjects will take 1000mg Placebo BID for 8 weeks.
62817656|NCT04435704|EXPERIMENTAL|Oxytocin|Oxytocin will be administered at increasing and decreasing rates
62817657|NCT04927546|EXPERIMENTAL|IL-6 blockade|RA patients under pharmacological treatment with interleukin-6 blockade.
62431894|NCT02116491|NO_INTERVENTION|Closed suction system|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Cloesd suction system was performed which the patient remained connected to the ventilator. The catheter was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
62598884|NCT05030909|OTHER|Waitlist control|At both recruitment rounds, we will recruit 16 young people to receive the same intervention at a later stage. We will ask them to complete data collection at the same timepoints as the experimental arm participants to compare intervention effect size but will offer them the intervention afterwards so they still have access to the group. Data collected from them in the group will be used to assess feasibility and acceptability but not treatment effect size comparison.
62598885|NCT00756392|OTHER|1|
62817658|NCT04927546|EXPERIMENTAL|Anti-TNF-alpha|RA patients under pharmacological treatment with anti-TNF-alpha.
62817659|NCT04927546|EXPERIMENTAL|Healthy controls|Healthy participants.
62817660|NCT06706323||Training group|From the final cohort of 300 participants, 200 will be recruited at Hospital I (University Hospital Zurich) to form the training group for developing the optimal statistical model.
62817661|NCT06706323||Test group|From the final cohort of 300 participants, the remaining 100 will be recruited at Hospital II (Stadtspital Zurich Triemli) to form the test group for validating the final model.
62817662|NCT05370495|EXPERIMENTAL|SY-201 Ophthalmic Solution 2.0%|SY-201 Ophthalmic Solution 2.0%
62817663|NCT05370495|EXPERIMENTAL|SY-201 Ophthalmic Solution 1.0%|SY-201 Ophthalmic Solution 1.0%
62817664|NCT05370495|EXPERIMENTAL|SY-201 Ophthalmic Solution 0.5%|SY-201 Ophthalmic Solution 0.5%
62817665|NCT05370495|PLACEBO_COMPARATOR|SY-201 Ophthalmic Solution Vehicle|SY-201 Ophthalmic Solution Vehicle
62817666|NCT03497637|ACTIVE_COMPARATOR|Pd/Pa guided Therapy|use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
62241517|NCT03716050|ACTIVE_COMPARATOR|Group 7|Blood flow to breast skin breast skin will be examined using FA, and an iVAC will be placed over breast skin incisions after the implant is placed.
62817667|NCT03497637|ACTIVE_COMPARATOR|FFR guided therapy|use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
62817668|NCT05985954|EXPERIMENTAL|BRAF Expansion Cohort|1 of these 2 doses will be selected as the recommended dose of ulixertinib that can be given in combination with cetuximab and encorafenib.
62817669|NCT05985954|EXPERIMENTAL|Cohort A|1 of these 2 doses will be selected as the recommended dose of ulixertinib that can be given in combination with cetuximab alone.
62817670|NCT05291520|EXPERIMENTAL|Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]|Participants in this group received a single subcutaneous (SC) dose of VH3810109 20 mg/kg co-administered with rHuPH20 at Day 1 and were followed up to 24 weeks.
62817671|NCT05291520|EXPERIMENTAL|Part 2 Group: VH3810109 60 mg/kg [IV]|Participants in this group received a single intravenous (IV) dose of VH3810109 60 mg/kg at Day 1 and were followed up to 24 weeks.
62817672|NCT05291520|EXPERIMENTAL|Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]|Participants in this group received a single subcutaneous (SC) dose of VH3810109 3000 mg co-administered with rHuPH20 at Day 1 and were followed up to 24 weeks.
62817673|NCT05725395|EXPERIMENTAL|Virtual Reality then Standard of Care|Participants will be randomized to receive the virtual reality intervention on the first day and receive standard of care on the second day of in-patient care.
62817674|NCT05725395|EXPERIMENTAL|Standard of Care then Virtual Reality|Participants will be randomized to receive the standard of care on the first day and receive virtual reality intervention on the second day of in-patient care.
62817675|NCT06029296|ACTIVE_COMPARATOR|Diclofenac|Participants will take a single 100mg dose of diclofenac.
62817676|NCT06029296|PLACEBO_COMPARATOR|Placebo|Participants will take a single dose of placebo.
62817677|NCT05216250|EXPERIMENTAL|BOTOX/BOTOX Unilateral|Participants will receive BOTOX in Cycle 1 and Cycle 2 and unilateral BOTOX in Cycle 3
62598886|NCT05161520|ACTIVE_COMPARATOR|IOL plus CTR Patients will undergo phacoemulsification combined with IOL and CTR implantation.|
62598887|NCT05161520|PLACEBO_COMPARATOR|single IOL Patients will undergo phacoemulsification combined with IOL implantation.|
62598888|NCT03281187|EXPERIMENTAL|Nasotestt 5 mg|Participants randomized to this arm must administer one packet of Nasotestt 5 mg in each nostril (3 times a day - T.I.D) for 60 days.
62817678|NCT05216250|EXPERIMENTAL|BOTOX/BOTOX Bilateral|Participants will receive BOTOX in Cycle 1 and Cycle 2 and bilateral BOTOX in Cycle 3
62817679|NCT05216250|EXPERIMENTAL|Placebo/BOTOX Unilateral|Participants will receive placebo in Cycle 1 and Cycle 2 followed by unilateral BOTOX in Cycle 3.
62598889|NCT03281187|ACTIVE_COMPARATOR|Androgel 50 mg|Participants randomized to this arm must administer one packet of Androgel 50 mg applied once daily to skin of shoulder for 60 days.
62817680|NCT05216250|EXPERIMENTAL|Placebo/BOTOX Bilateral|Participants will receive placebo in Cycle 1 and Cycle 2 followed by bilateral BOTOX in Cycle 3.
62817681|NCT05021354|EXPERIMENTAL|Dry needling+eccentric exercises|It is established a plan of treatment base on the evidence for dry needling, eccentric exercise in the patient with lateral epicondylalgia. This is done in two sessions, one session every 10 days and with a duration of about 45 minutes.
62817682|NCT05021354|ACTIVE_COMPARATOR|topical gel|application of topical gel to the area of pain
62817683|NCT05021354|ACTIVE_COMPARATOR|NSAIDs|oral intake of NSAIDs
62817684|NCT06416306|EXPERIMENTAL|Spanish Language Intervention|Treatment will be conducted entirely in Spanish, targeting Spanish speech sounds. Treatment will follow a drill-play format.
62817685|NCT06416306|EXPERIMENTAL|English Language Intervention|Treatment will be conducted entirely in English, targeting English speech sounds. Treatment will follow a drill-play format.
62817686|NCT06211114|EXPERIMENTAL|PD-(L)1 inhibitor + Axitinib|Immune Checkpoint Inhibitors in Combination With Axitinib
62817687|NCT06572631|EXPERIMENTAL|Treatment (NEXI-001, decitabine, chemotherapy)|"DONOR: Donors undergo leukapheresis on study.~PATIENTS: Patients may receive bridging therapy per standard of care ≥ 14 days prior to the start of cycle 1. Patients receive decitabine IV over 1 hour QD on day -3, -5 or -10 to day -1, lymphodepletion chemotherapy with fludarabine IV over 30 minutes QD and cyclophosphamide IV over 60 minutes QD on day -5 to -3 and then receive NEXI-001 IV over 30 minutes QD on days 1, 8 and 15 of cycle 1. Cycles repeat every 33 or 38 days in the absence of disease progression or unacceptable toxicity. If NEXI-001 cells remain and treatment criteria are met, patients may receive and additional cycle of decitabine IV over 1 hour QD on day -5 to -1 and NEXI-001 IV QD on days 1, 8 and 15 in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening, bone marrow aspirate and/or bone marrow biopsy, PET/ CT scan or MRI and blood sample collection throughout the study."
62817688|NCT03631043|EXPERIMENTAL|Stage I (personalized vaccine)|Patients undergo collection of blood and bone marrow for making the vaccine. Patients then receive personalized vaccine SC on days 1 and 15 of cycles 1-2 and on day 1 of cycles 3-6. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62817689|NCT03631043|EXPERIMENTAL|Stage II (personalized vaccine, lenalidomide)|Patients undergo collection of blood and bone marrow for making the vaccine. Patients then receive personalized vaccine SC on days 1 and 15 of cycles 1-2 and on day 1 of cycles 3-6. Patients also receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62817690|NCT05499910|EXPERIMENTAL|NSBAA|The Neuro Strengths-Base Approach to Autism is an approach developed from various research on how the autistic brain works, the approaches that work best to motivate autistic individuals, and how others can understand as well as support behaviors that may occur with autistic individuals.
62817691|NCT06345066|EXPERIMENTAL|LY3841136 + Tirzepatide|LY3841136 administered subcutaneously (SC) in combination with tirzepatide given SC.
62598890|NCT03281187|PLACEBO_COMPARATOR|Androgel Placebo|Participants must administer one packet of Androgel placebo applied once daily to skin of shoulder in addition to an experimental drug for 60 days.
62598891|NCT03281187|PLACEBO_COMPARATOR|Nasotestt Placebo|Participants must administer one packet of Nasotestt Placebo in each nostril (3 times a day - T.I.D) in addition to an experimental drug for 60 days.
62817692|NCT06345066|PLACEBO_COMPARATOR|Placebo + Tirzepatide|Placebo administered SC in combination with tirzepatide given SC.
62038708|NCT06477575|EXPERIMENTAL|neurocognitive therapy based on new technologies|
62038709|NCT06477575|ACTIVE_COMPARATOR|conventional neurocognitive therapy|
62598892|NCT06387667|EXPERIMENTAL|Immunocompromised ICU patients|Immunocompromised ICU Patients with Respiratory tract infections
62598893|NCT05225415|ACTIVE_COMPARATOR|CT1812 300 mg|CT1812 300 mg
62598894|NCT05225415|ACTIVE_COMPARATOR|CT1812 100 mg|CT1812 100 mg
62598895|NCT05225415|PLACEBO_COMPARATOR|Placebo|Placebo
62598896|NCT01539954||Youth 9-18 years of age|
62241518|NCT03716050|ACTIVE_COMPARATOR|Group 8|Blood flow to breast skin breast skin will be examined using FA, and both NTG cream and iVAC will be used as interventions after the implant is placed.
62598897|NCT03748576|EXPERIMENTAL|Mobile technologies group|m-health group (Intervention Group) participants were managed continuously through WeChat group chat during prenatal clinic interval.
62598898|NCT03748576|NO_INTERVENTION|control group|Standard Clinic Prenatal Care (Control Group): regular routine prenatal care following Chinese standard.
62598899|NCT04891406|OTHER|ABCDE|"Subjects use product A (ZoneX #2, white tobacco-free nicotine pouch, 5.8 mg nicotine/pouch) for 20 minutes on Day 1, then switch to use product B (ZoneX #3, white tobacco-free nicotine pouch, 10.1 mg nicotine/pouch) for 20 min on Day 2, then product C (Skruf snus fresh slim white, 10.9 mg nicotine/pouch) for 20 min on Day 3, then D (nicotine pouch, 10.6 mg/pouch) on Day 4 and finally E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette), smoked in approximately 5 minutes with puffs taken at regular intervals approximately 30 seconds apart, on Day 5.~Subjects can use their assigned product ad libitum on each study day, after all study assessments are performed, until 10pm. A washout period of product abstinence is observed between products, overnight."
62598900|NCT04891406|OTHER|BCDEA|Same as previous arm but in a different randomization order.
62817693|NCT06374992||Patient|Hospitalized older adults with cognitive impairment/dementia
62038710|NCT01881126|ACTIVE_COMPARATOR|bimatoprost 0.01% and hypromellose 0.3%|Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
62038711|NCT01881126|ACTIVE_COMPARATOR|travatan 0.004% and timolol 0.5%|Travatan 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
62241519|NCT02743416||ECG screening|Will be screened for AF using only one-stop protocol
62241520|NCT02743416||Control group|as per regular standard as of today
62241521|NCT06260189||Lichen Planus Cases|40 cases with lichen planus from who skin biopsies and blood samples will be taken to assess cold inducible RNA binding protein levels in both tissues and serum.
62241522|NCT06260189||Healthy control group|40 healthy controls from who skin biopsies and blood samples will be taken to assess serum and tissue levels of cold-inducible RNA binding protein and compare them to active cases.
62241523|NCT05128825|OTHER|Open-label with ZN-c3 (also known as azenosertib)|ZN-c3 (azenosertib) taken orally with food
62038712|NCT01380340|EXPERIMENTAL|Seniors early intervention driving group|The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
62241524|NCT00288977|EXPERIMENTAL|islet cell transplant|
62431895|NCT02116491|EXPERIMENTAL|Visual Sputum Suctioning System|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Closed suction system was performed which the patient remained connected to the ventilator. The double-lumen catheter of the Visual Sputum Suctioning System integrated with a 0.9-mm micro-imaging fiber was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
62431896|NCT02178449|EXPERIMENTAL|Verum|Dexamethasone and Ropivacaine
62431897|NCT02178449|ACTIVE_COMPARATOR|Placebo|Ropivacaine and Saline
62241525|NCT02052063|EXPERIMENTAL|Surgery|Patient who undergone stapled transanal rectal resection for rectocele. Anal compliance will be evaluated before and starting the surgery using endoflip system
62241526|NCT04910503|ACTIVE_COMPARATOR|Usual strategy|
62241527|NCT04910503|EXPERIMENTAL|Innovative strategy|
62241528|NCT05761730|NO_INTERVENTION|Control group|Patients suffering from acute pain due to symptomatic irreversible pulpitis on a lower mandibular molar . Conventional emergency treatment is performed . Pulpotomy is performed after inferior alveolar nerve block injection ( IANB )
62241529|NCT05761730|EXPERIMENTAL|Intervention Group|Patients suffering from acute pain due to symptomatic irreversible pulpitis on a lower mandibular molar . Short course orally administered dexamethasone after inferior alveolar nerve block injection without performing conventional pulpotomy
62431898|NCT03636542|EXPERIMENTAL|liposomal bupivacaine|These patients receive an interscalene block with liposomal bupivacaine.
62431899|NCT03636542|ACTIVE_COMPARATOR|bupivacaine|These patients receive an interscalene block with bupivacaine.
62431900|NCT05397600|EXPERIMENTAL|T4032|
62431901|NCT05397600|ACTIVE_COMPARATOR|Lumigan|
62431902|NCT02971865|EXPERIMENTAL|CBT/CMT|The CBT/CMT program does not focus specifically on a particular condition such as diabetes. All treatment included patient education on nutrition content and mindfulness practice (emotions, and sensations in the present moment without trying to change them, awareness of breathing, and social economic problems) with manual therapy.
62598901|NCT04891406|OTHER|CDEAB|Same as previous arm but in a different randomization order.
62038713|NCT01380340|NO_INTERVENTION|Matched comparison group|The subjects will be recruited from a parallel service and will be paired with similar subjects in the experimental group.
62038714|NCT06542874|PLACEBO_COMPARATOR|Placebo subcutaneous|Placebo for subcutaneous treatment
62241530|NCT04553510|EXPERIMENTAL|Bevacizumab and steroid|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.
62241531|NCT04553510|ACTIVE_COMPARATOR|Bevacizumab and placebo|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.
62241532|NCT04907110|EXPERIMENTAL|Exercise + NR|Participants will be asked to take two pills of NR (250mg/pill) twice daily (a total of 4 pills/day; 1000mg/day), for 40 days. During days 17-38 of the NR intervention, participants will perform a 3-weeks supervised exercise training program with four \~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions. To assess the outcomes, participants will undergo three test days before the start of the NR supplementation and repeat these three test days at the end (day 38-40) of NR supplementation.
62431903|NCT02971865|ACTIVE_COMPARATOR|traditional primary care visit|Provide high quality primary care for men, women, and children of all ages. Our providers work together to ensure that you receive the most comprehensive care possible. Primary care is described as the medical setting in which patients receive most of their medical care and, therefore, is typically their first source for treatment
62431904|NCT06156410|EXPERIMENTAL|Treatment|Cabozantinib
62431905|NCT06314984|ACTIVE_COMPARATOR|Group I A (Conventional neddle syringe)|The injection was done in the mandible by the conventional needle syringe \[Inferior Alveolar Nerve Block\].
62431906|NCT06314984|ACTIVE_COMPARATOR|Group I B (Conventional needle syringe)|The injection was done in the maxilla by the conventional needle syringe \[Infiltration\].
62598902|NCT04891406|OTHER|DEABC|Same as previous arm but in a different randomization order.
62431907|NCT06314984|EXPERIMENTAL|Group II A (Comfort-in Jet Injector)|The injection was done in the mandible by the needleless Comfort-in jet injector \[Inferior Alveolar Nerve Block\].
62431908|NCT06314984|EXPERIMENTAL|Group II B (Comfort-in Jet Injector)|The injection was done in the maxilla by the needleless Comfort-in jet injector \[Infiltration\].
62431909|NCT02621827|EXPERIMENTAL|Non-pregnant, non-lactating (NPNL)|"NPNL women are age and parity matched to pregnant women. Each NPNL women is studied twice, approximately 3 months apart.~At each study period the participant receives (as the intervention) a single oral dose of stable isotope labeled 25(OH)D3."
62598903|NCT04891406|OTHER|EABCD|Same as previous arm but in a different randomization order.
62817694|NCT06374992||Family|Family member, friend, or neighbor involved in a hospitalization of an older adult motivated by a personal relationship rather than financial remuneration
62817695|NCT06374992||Healthcare Worker|Physicians, APPs, or nurses involved in the care of the patient with cognitive impairment/dementia
62817696|NCT06374992||Health system leader|Hospital executives, department chairs, division chiefs, nurse managers, medical directors, and other leaders within the health system.
62817697|NCT06592417|EXPERIMENTAL|Dose escalation/expansion|The subjects at dose escalation stage will be administered with investigational product (JSKN016) starting at 0.5 mg/kg, followed by1 mg/kg，2 mg/kg，4 mg/kg，6 mg/kg，7 mg/kg，8 mg/kgmg/kg, IV ,Q3W The subjects at dose expansion stage will be adiministered with JSKN016 at 6mg/kg or more(anticipated response dose)
62431910|NCT02621827|EXPERIMENTAL|Pregnant/Lactating|Pregnant women receive (as the intervention) a single oral dose of stable isotope labeled 25(OH)D3. The same women are followed-up in lactation to repeat the same protocol.
62598904|NCT02952625|OTHER|Single arm imaging study|Single arm study: all patients have 2 PET/MR scans in the radiotherapy treatment position
62598905|NCT04803422|ACTIVE_COMPARATOR|Arm 1- Postoperative Course|"Pre-or intraoperative antibiotics (both uncomplicated and complicated) appendicits: Single-dose inj. Metronidazole and Pipperacillin/Tazobactam. In case of allergy to penicillin: Single-dose inj. Metronidazole and intravenous inj. Cefuroxim.~First 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.In case of allergy to Penicillin: Tablet Metronidazole and Tablet Ciprofloxacillin.~Last 6 month: Intravenous Metronidazole and Intravenous Pipperacillin / Tazobactam. In case of allergy to penicillin: Intravenous Metronidazole and Intravenous Cefuroxim."
62598906|NCT04803422|ACTIVE_COMPARATOR|Arm 2 - Postoperative Course|"Pre-or intraoperative antibiotics (both uncomplicated and complicated) appendicits: Single-dose inj. Metronidazole and Pipperacillin/Tazobactam. In case of allergy to penicillin: Single-dose inj. Metronidazole and intravenous inj. Cefuroxim.~First 6 month: Intravenous Metronidazole and Intravenous Pipperacillin / Tazobactam. In case of allergy to penicillin: Intravenous Metronidazole and Intravenous Cefuroxim.~Last 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.In case of allergy to Penicillin: Tablet Metronidazole and Tablet Ciprofloxacillin."
62817698|NCT05007405||Osteoarticular infections|Retrospective study on medical file of patients with osteoarticular infections diagnose (date of the positive bacteriological sample) between January 1, 2010 and December 31, 2020
62817699|NCT01827137|EXPERIMENTAL|Galinpepimut-S + Montanide + GM-CSF|Galinpepimut-S (GPS) vaccinations are started 12-22 days following autologous stem cell transplantation (ASCT). GPS and Montanide (in a 1 mL emulsion) are administered subcutaneously (s.c.) Q2W on weeks 0, 2, 4, 6, 8, and 10. GM-CSF (70 μg) are administered s.c. one to two days before and on the day of GPS/Montanide administration. Participants whose disease has not progressed and who are clinically stable (no active infection with fevers and no cardiovascular/respiratory compromise) may receive up to 6 additional monthly vaccinations. The use of post-ASCT maintenance therapy is allowed starting 3 months after ASCT.
62241533|NCT04907110|PLACEBO_COMPARATOR|Exercise + Placebo|Participants will be asked to take two pills of placebo, twice daily (a total of 4 pills/day), for 40 days. During days 17-38 of the intervention, participants will perform a 3-weeks supervised exercise training program with four \~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions. To assess the outcomes, participants will undergo three test days before the start of the NR supplementation and repeat these three test days at the end (day 38-40) of the placebo supplementation.
62817700|NCT04525586||It's just an observational study, no interventions|children with recurrent wheezing
62817701|NCT00558584|ACTIVE_COMPARATOR|IA/IgG group|immunoadsorption using IA columns and subsequent IgG substitution
62431911|NCT01492712|EXPERIMENTAL|Low-high-low blood target concentration|Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
62817702|NCT00558584|PLACEBO_COMPARATOR|control group|pseudo-immunoadsorption followed by an intravenous infusion without IgG
62817703|NCT06706427|EXPERIMENTAL|NGGT001|Single Arm: This study is a single-arm design in which all participants receive the NGGT001 gene therapy administered via subretinal injection. Participants are divided into three dose-escalation groups to evaluate safety and efficacy.
62817704|NCT06245889|EXPERIMENTAL|Neoadjuvant therapy|4 cycles of paclitaxel/carboplatin/pembrolizumab
62817705|NCT01950624||Down syndrome cohort|Individuals who have a diagnosis of complete trisomy 21, translocation down syndrome and Mosaic Down syndrome
62817706|NCT05876754|EXPERIMENTAL|Ivosidenib|Ivosidenib 500 mg, taken orally as two 250 mg tablets once daily for an unlimited amount of continuous 28-day cycles
62817707|NCT03284710|ACTIVE_COMPARATOR|Group 1: ALVAC-HIV + gp120/MF59|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120/MF59 in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
62817708|NCT03284710|ACTIVE_COMPARATOR|Group 2: ALVAC-HIV + gp120/Al(OH)3|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
62431912|NCT01492712|EXPERIMENTAL|High-low-high target blood concentration|Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
62817709|NCT03284710|ACTIVE_COMPARATOR|Group 3: ALVAC-HIV + gp120/MF59|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid and Bivalent Subtype C gp120/MF59 in the right deltoid at months 0, 1, 6, and 12. All injections are via needle and syringe.
62038715|NCT06542874|EXPERIMENTAL|NNC0487-0111 subcutaneous dose 1|NNC0487-0111 subcutaneous dose 1 treatment
62038716|NCT06542874|EXPERIMENTAL|NNC0487-0111 subcutaneous dose 2|NNC0487-0111 subcutaneous dose 2 treatment
62038717|NCT06542874|EXPERIMENTAL|NNC0487-0111 subcutaneous dose 3|NNC0487-0111 subcutaneous dose 3 treatment
62817710|NCT03284710|ACTIVE_COMPARATOR|Group 4: ALVAC-HIV + gp120|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
62817711|NCT04706364||Autism Spectrum Disorder (ASD)|Individuals diagnosed with an Autism Spectrum Disorder
62817712|NCT04706364||Healthy Control|Typically developing individuals without a history of autism
62038718|NCT06542874|EXPERIMENTAL|NNC0487-0111 subcutaneous dose 4|NNC0487-0111 subcutaneous dose 4 treatment
62038719|NCT06542874|EXPERIMENTAL|NNC0487-0111 subcutaneous dose 5|NNC0487-0111 subcutaneous dose 5 treatment
62038720|NCT06542874|EXPERIMENTAL|NNC0487-0111 subcutaneous dose 6|NNC0487-0111 subcutaneous dose 6 treatment
62038721|NCT06542874|PLACEBO_COMPARATOR|Placebo oral|Placebo for oral treatment
62431913|NCT06526689||Group A|Adult volunteers who are recent contacts of Mycobacterium tuberculosis sputum smear positive cases with positive IGRA
62431914|NCT06526689||Group B|Adult volunteers who are recent contacts of Mycobacterium tuberculosis sputum smear positive cases with negative IGRA
62598907|NCT03962543|EXPERIMENTAL|Mirdametinib (PD-0325901)|Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\^2 (maximum dose of 4 mg) by mouth twice daily
62038722|NCT06542874|EXPERIMENTAL|NNC0487-0111 oral dose 1|NNC0487-0111 oral dose 1 treatment
62038723|NCT06542874|EXPERIMENTAL|NNC0487-0111 oral dose 2|NNC0487-0111 oral dose 2 treatment
62038724|NCT06542874|EXPERIMENTAL|NNC0487-0111 oral dose 3|NNC0487-0111 oral dose 3 treatment
62431915|NCT06526689||Group C|Healthy adult volunteers with no previous exposure to Mycobacterium tuberculosis.
62598908|NCT04349865||Idiopathic PD|PD patients without the LRRK2 G2385R mutation
62817713|NCT06704542||Case Group|patients who underwent allogeneic hematopoietic stem cell transplantation from March 2019 to March 2024; donor fasting blood glucose and/or HbA1c data available; fasting blood glucose ≥6.1 mmol/L or HbA1c ≥5.7%
62817714|NCT06704542||Control Group|patients who underwent allogeneic hematopoietic stem cell transplantation from March 2019 to March 2024; donor fasting blood glucose and/or HbA1c data available; fasting blood glucose \<6.1 mmol/L; HbA1c \<5.7% (if available)
62817715|NCT04675931|EXPERIMENTAL|IV KAE609 Dose regimen 1|Intravenous KAE609 (cipargamin) 20 mg
62817716|NCT04675931|EXPERIMENTAL|IV KAE609 Dose regimen 2|Intravenous KAE609 (cipargamin) 40 mg
62817717|NCT04675931|EXPERIMENTAL|IV KAE609 Dose regimen 3|Intravenous KAE609 (cipargamin) Dose regimen 3 (dose will be evaluated post Interim analysis from Cohort 1 and Cohort 2.
62817718|NCT04675931|ACTIVE_COMPARATOR|IV Artesunate|IV Artesunate 2.4 mg/kg (for participants weighing at least 20 kg) IV Artesunate 3 mg/kg (for participants weighing less than 20 kg)
62817719|NCT04675931|OTHER|Coartem|Standard of care (Coartem) will be given to all participants for 3 days as part of treatment.
62817720|NCT06531395|EXPERIMENTAL|Abiprubart 400mg SC q2wk|"Part A: Loading dose of abiprubart 800 mg subcutaneous (SC) followed by abiprubart 400 mg SC every 2 weeks (q2wk) through Week 22.~Part B: Abiprubart 400 mg SC q2wk: abiprubart 400 mg SC q2wk up to and including Week 46."
62817721|NCT06531395|EXPERIMENTAL|Abiprubart 400mg SC q4wk|"Part A: Loading dose of abiprubart 800 mg SC followed by abiprubart 400 mg SC q2wk through Week 22 which will alternately administer placebo or abiprubart to provide active drug every 4 weeks (q4wk) while maintaining treatment concealment.~Part B: Abiprubart 400 mg SC q4wk: abiprubart 400 mg SC q2wk up to and including Week 46 which will alternately administer placebo or abiprubart to provide active drug q4wk while maintaining treatment concealment."
62817722|NCT06531395|PLACEBO_COMPARATOR|Placebo|"Part A: A matched volume placebo loading dose followed by placebo SC injections q2wk through Week 22.~Part B: Participants assigned to placebo in Part A will transition to active abiprubart treatment, according to randomized assignment, with either abiprubart 400 mg SC q2wk or abiprubart 400 mg SC q4wk."
62817723|NCT05989230|EXPERIMENTAL|Emotional Awareness and Expression Therapy|Emotional Awareness and Expression Therapy (EAET) is a non-pharmacological intervention designed to address persistent pain.
62817724|NCT05986240|EXPERIMENTAL|Danvatirsen Monotherapy|"Patients will be enrolled in cohorts of 3 for the Danvatirsen dose escalation substudy. Based on the DLT of the first cohort of participants, subsequent cohorts will either be administered doses at the next higher dose level, de-escalated to the next lower dose level, or remain the same. Dose escalation discontinuations and MTD will be determined as described in the 'Detailed Study Description.' The total duration of 1 cycle is approximately 4 weeks (28 days). Proposed dose levels and treatment schedule are as follows:~Dose Level 1 (DL1): Danvatirsen Day 1 - Day 28 (1mg/kg loading dose on Cycle 1/Day 1 (C1D1), Cycle 1/Day 3 (C1D3); and Cycle 1/Day 5 (C1D5) followed by weekly 1mg/kg infusion for 3 weeks) Dose Level 2 (DL2): Danvatirsen Day 1 - Day 28 (2mg/kg loading dose on C1D1, C1D3, and C1D5 followed by weekly 2mg/kg infusion for 3 weeks) Dose Level 3 (DL3): Danvatirsen Day 1 - Day 28 (3mg/kg loading dose on C1D1, C1D3, and C1D5 followed by weekly 3mg/kg infusion for 3 weeks)"
62817725|NCT05986240|EXPERIMENTAL|Danvatirsen + Venetoclax Combination Therapy|"Patients will be enrolled in cohorts of 3 for the Danvatirsen + Venetoclax dose escalation substudy. Dose escalation administration will be as described in the Danvatirsen monotherapy substudy arm and dose escalation discontinuations and MTD will be determined as described in the 'Detailed Study Description.'~Up to 2 dose levels of Danvatirsen will be evaluated based on data from the Danvatirsen monotherapy arm. Dose 1 will be one level lower than the dose with expected target activity.~Venetoclax: 400 mg (or equivalent) administered as fixed dose daily (except for specific dose modifications described in the protocol) orally for 28 days per cycle. To mitigate risk of tumor lysis syndrome, during Cycle 1 Venetoclax will be dose escalated daily to the goal dose of 400mg daily (100mg on Day 1, 200mg on Day 2 and 400mg on Day 3, and onwards, or adjusted dose ramp-up per Venetoclax label if on concomitant azoles).~The three cycles are approximately 28 days each in duration."
62431916|NCT02661282|EXPERIMENTAL|Arm I (temozolomide, CMV-specific T cells, surgery)|Patients receive temozolomide PO QD on days 1-21 and CMV-specific T cell transfer IV over 1-5 minutes on day 22. Patients undergo surgery on day 30 of cycle 1. Treatment repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-21. Treatment repeats every 42 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62038725|NCT02210117|EXPERIMENTAL|Arm A (nivolumab, surgery)|"Patients receive nivolumab IV over 60 minutes on day 1 every 2 weeks for 6 weeks. Approximately 4 weeks later, patients undergo nephrectomy, metastasectomy or biopsy.~Beginning 4-6 weeks after surgery, patients in all arms who have clinical response, stable disease, or even slight progression of disease to therapy preoperatively, receive maintenance nivolumab IV over 60 minutes on day 1. Cycles repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
62038726|NCT02210117|EXPERIMENTAL|Arm B (nivolumab, bevacizumab, surgery)|"Patients receive nivolumab IV over 60 minutes and bevacizumab IV over 90 minutes on day 1 every 2 weeks for 6 weeks. Patients also undergo nephrectomy, metastasectomy or biopsy as in Arm A.~Beginning 4-6 weeks after surgery, patients in all arms who have clinical response, stable disease, or even slight progression of disease to therapy preoperatively, receive maintenance nivolumab IV over 60 minutes on day 1. Cycles repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
62038727|NCT02210117|EXPERIMENTAL|Arm C (nivolumab, ipilimumab, surgery)|"Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes on day 1 every 3 weeks for 6 weeks. Patients also undergo nephrectomy, metastasectomy or biopsy as in Arm A.~Beginning 4-6 weeks after surgery, patients in all arms who have clinical response, stable disease, or even slight progression of disease to therapy preoperatively, receive maintenance nivolumab IV over 60 minutes on day 1. Cycles repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
62038728|NCT06140524|EXPERIMENTAL|Safety Run-In (Part 1)|Sequential groups of participants will be enrolled to assess the initial safety and tolerability of the step-up regimen leading up to the start of different full doses of linvoseltamab.
62817726|NCT06216925|EXPERIMENTAL|#BabyLetsMove|For 24 weeks, participants will wear a Fitbit activity tracker (continually) and receive interactive self-monitoring and tailored feedback text messages (twice per week), tailored skills training texts and materials (once per week), and peer health coaching (once every other week). In addition, the participants will receive ancillary healthy food to allay food insecurity, nutritional counseling, and clinical care referrals once every three months.
62817727|NCT06216925|ACTIVE_COMPARATOR|WIC Antenatal Care|The participants will receive ancillary healthy food to allay food insecurity, nutritional counseling, and clinical care referrals once every three months.
62817728|NCT04822675|EXPERIMENTAL|Percutaneous mitral repair|Percutaneous mitral repair +/- coronary artery bypass grafting within 14 days of mitral repair.
62817729|NCT04822675|ACTIVE_COMPARATOR|Mitral valve surgery|Surgical mitral valve surgery +/- coronary artery bypass grafting
62817730|NCT04638088||robot-assisted laparoscopy|radical prostatectomy performed by robot-assisted laparoscopy
62817731|NCT04638088||conventional laparoscopy|radical prostatectomy performed by conventional laparoscopy
62817732|NCT04638088||laparotomy|radical prostatectomy performed by laparotomy
62038729|NCT06140524|EXPERIMENTAL|Expansion (Part 2) - Dose regimen 1|Participants will be randomized in a 1:1:1:1 ratio across 4 dosing regimens
62431917|NCT02661282|ACTIVE_COMPARATOR|Arm II (temozolomide, CMV-specific T cells)|Patients receive temozolomide PO QD on days 1-21 and CMV-specific T cell transfer intravenously IV over 1-5 minutes on day 22. Treatment repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62431918|NCT01319071||Top-level athletes|
62431919|NCT01319071||Control group|
62431920|NCT03931057|EXPERIMENTAL|ADV6209|ADV6209 (= gamma-cyclodextrin-Midazolam) 0.25 mg/kg p.o. once 30 min. before anesthesia
62431921|NCT03931057|ACTIVE_COMPARATOR|Midazolam|Midazolam (in orange flavored syrup) 0.25 mg/kg p.o. once 30 min. before anesthesia
62431922|NCT02916160|EXPERIMENTAL|SACUBITRIL - VALSARTAN|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.
62431923|NCT05840666|ACTIVE_COMPARATOR|Conventional Physical Therapy (CPT) Group|Conventional Physical Therapy will consist of Therapeutic Ultrasound, Moist Heat-pack, TENS and standard exercises. Participants will receive 15 sessions of Conventional Physical Therapy (CPT) at a frequency of 5 sessions per week.
62431924|NCT05840666|EXPERIMENTAL|Conventional Physical Therapy (CPT) plus Mulligan SNAGs Group|Besides Conventional Physical Therapy, Mulligan Mobilizations will be provided in this group. It consist of Extension SNAGS in prone, and Lumbar flexion SNAGS in sitting. The techniques will be applied in 3 sets with 10 repetitions and 60 seconds rest between sets.
62598909|NCT04349865||LRRK2 G2385R PD|PD patients with the LRRK2 G2385R mutation
62598910|NCT04349865||LRRK2 G2385R carriers|Subjects without PD who screen positive for the LRRK2 G2385R mutation
62817733|NCT05148286|ACTIVE_COMPARATOR|Treatment|For the treatment group, 200cc of 20% human albumin with 15 cc per kg of crystalloid will be administered over 1\~2h for initial fluid resuscitation.
62431925|NCT05840666|EXPERIMENTAL|Conventional Physical Therapy plus McKenzie MDT Group|Along with Conventional Physical Therapy, McKenzie MDT will be be given in this group. It consist of Prone lying, Prone lying Elbow popups, Prone elbow Extension. Standing Extension, supine Both Knee to Chest, Sitting on chair with forward flexion. The techniques will be applied in 3 sets with 8-10 repetitions and 60 seconds rest between sets.
62817734|NCT05148286|PLACEBO_COMPARATOR|Control|For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice.
62817735|NCT05823948|EXPERIMENTAL|Insulin Icodec|Participants will receive 70 Units (U) insulin icodec subcutaneously once-weekly for 26 weeks.
62431926|NCT01890018|ACTIVE_COMPARATOR|Control|"This arm will use GlowCaps to have their adherence tracked with no additional modifications:~Arm 1. Control group no modifications~Electronic Pill Bottle tracking"
62431927|NCT01890018|EXPERIMENTAL|Feedback group|"This arm will use GlowCaps to have their adherence tracked with the following modifications:~Arm 2. Feedback group participants will receive an adherence message after 48 hours of not using the GlowCaps~Electronic Pill Bottle tracking; Adherence Messaging"
62598911|NCT04349865||Controls|Subjects without PD who screen negative for the LRRK2 G2385R mutation
62598912|NCT06636084|EXPERIMENTAL|Customized CAD/CAM Titanium Mesh|A customized CAD/CAM Titanium Mesh will be used to cover the bone graft
62598913|NCT06636084|ACTIVE_COMPARATOR|Reinforced Perforated PTFE Mesh (RPM)|A Reinforced Perforated PTFE Mesh membrane will be used to cover the bone graft
62038730|NCT06140524|EXPERIMENTAL|Expansion (Part 2) - Dose regimen 2|Participants will be randomized in a 1:1:1:1 ratio across 4 dosing regimens
62598914|NCT02129790|EXPERIMENTAL|Mentalization-Based Therapy|Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A will include psychoeducation and coping strategies.
62598915|NCT05994274||HTx|Patients after heart transplantation.
62817736|NCT03366610||Patients Previously Treated with Daclatasvir-Based Regimens|Patients in China Previously Treated with Daclatasvir-Based Regimens
62817737|NCT01824238|EXPERIMENTAL|Anacetrapib|Participants will receive 100-mg anacetrapib tablet, orally, once-daily for 12 weeks.
62817738|NCT01824238|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo tablet, orally, once daily for 12 weeks.
62817739|NCT04195646|EXPERIMENTAL|EndoVigilant CAD Software assisted Colonoscopy Procedure|The gastroenterologist performing the colonoscopy procedure will be able to observe a standard colonoscopy video on the primary monitor and video augmented by EndoVigilant CAD software on the second monitor. The gastroenterologist will primarily rely on the second monitor but the standard procedure monitor will be always operational and available for maneuvers such as fast insertion, polypectomy etc.
62817740|NCT06596083|PLACEBO_COMPARATOR|Placebo Comparator|Training intervention: 5 weeks of live high, train low followed by an additional 1 week of reduced training (to simulate preparation for an upcoming event or race) Dietary intervention: placebo supplement
62817741|NCT06596083|EXPERIMENTAL|Experimental group|Training intervention: 5 weeks of live high, train low followed by an additional 1 week of reduced training (to simulate preparation for an upcoming event or race) Dietary intervention: Ketone ester supplement
62817742|NCT03986970|NO_INTERVENTION|Arm 1: Control|No PrEP.
62817743|NCT03986970|EXPERIMENTAL|Arm 2: FTC-TDF|FTC-TDF one day, 5 hours before circumcision.
62817744|NCT03986970|EXPERIMENTAL|Arm 3: FTC-TDF|FTC-TDF one day, 21 hours before circumcision.
62817745|NCT03986970|EXPERIMENTAL|Arm 4: FTC-TDF|FTC-TDF two days, 5 hours before circumcision.
62817746|NCT03986970|EXPERIMENTAL|Arm 5: FTC-TDF|FTC-TDF two days, 21 hours before circumcision.
62817747|NCT03986970|EXPERIMENTAL|Arm 6: FTC-TAF|FTC-TAF one day, 5 hours before circumcision.
62817748|NCT03986970|EXPERIMENTAL|Arm 7: FTC-TAF|FTC-TAF one day, 21 hours before circumcision.
62038731|NCT06140524|EXPERIMENTAL|Expansion (Part 2) - Dose regimen 3|Participants will be randomized in a 1:1:1:1 ratio across 4 dosing regimens
62431928|NCT01890018|EXPERIMENTAL|Adherence partner group|"This arm will use GlowCaps to have their adherence tracked with the following modifications:~Arm 3. Adherence partner group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient~Electronic Pill Bottle tracking; Social Influence"
62431929|NCT01890018|EXPERIMENTAL|Adherence partner along with feedback|"This arm will use GlowCaps to have their adherence tracked with the following modifications:~Arm 4. Adherence partner along with feedback group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient, both the patient and partner will receive a message after 48 hours of not using the GlowCaps~Electronic Pill Bottle tracking; Adherence Messaging; Social Influence"
62431930|NCT02872545|EXPERIMENTAL|forward tilted|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in forward tilted position
62431931|NCT02872545|OTHER|semi sitting|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in semi sitting
62431932|NCT02872545|OTHER|dorsal decubitus|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in dorsal decubitus
62431933|NCT06017765|EXPERIMENTAL|Immediate Meditation Training group|The Immediate Meditation Training group will immediately receive 8 weekly sessions of Mindfulness Training within 4 weeks after the Baseline visit (V0, during which participants are randomized).
62431934|NCT06017765|OTHER|Waitlist Control group|The Waitlist Control group will receive the Mindfulness Training after a waiting time of 12 weeks. Participants in this group will not receive any type of intervention before this and will wait till the Immediate Meditation Training group finished all assessment visits (including the follow-up visit in week 12 (V3)).
62431935|NCT01666925|EXPERIMENTAL|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
62431936|NCT01666925|ACTIVE_COMPARATOR|Rabies vaccine|2 x 2.5IU Verorab
62431937|NCT03856671|EXPERIMENTAL|oral antibiotics+mechanical bowel preparation|Liquid diet and polyethylene glycol with 2L water was administrated orally 1 day before surgery. A combination of neomycin 1g and metronidazole 0.2g every 6 hours was also administrated. Enteroclysis was conduted for patients on surgical morning.
62431938|NCT03856671|NO_INTERVENTION|simple mechanical bowel preparation|Only liquid diet and polyethylene glycol with 2L water was administrated orally 1 day before surgery. Enteroclysis was conduted for patients on surgical morning.
62431939|NCT05415982|EXPERIMENTAL|Ketogenic Diet|Ketogenic Diet every day for 4 weeks
62431940|NCT00505128|OTHER|1|to test the interest of early bile duct decompression by endoscopic sphincterotomy after early non invasive diagnosis by endosonography or MR cholangiography
62431941|NCT04221087|PLACEBO_COMPARATOR|Placebo Arm|Participants will be given a placebo of sugar water (0.6ml/kg/dose) in a single oral dose and standard of care for bronchiolitis (supplemental oxygen, antipyretics, suctioning etc.)
62431942|NCT04221087|EXPERIMENTAL|Dexamethasone Arm|Participants will be given dexamethasone (0.6mg/kg/dose) in a single oral dose in addition to the standard of care for bronchiolitis (supplemental oxygen, antipyretics, suctioning etc.)
62431943|NCT05155631|EXPERIMENTAL|Cognitive Behavioral Treatment Arm|"Subjects in the Cognitive Behavioral Treatment Arm will undergo 8-10 weeks of remote cognitive behavioral therapy. Subjects will complete modules on their phones and will be monitored by study coordinators for support and treatment completion."
62431944|NCT05155631|NO_INTERVENTION|Usual Care Arm|"Subjects in the Usual Care Arm will undergo 8-10 weeks of continued lifestyle. Subjects will be asked to report any new medications or lifestyle changes to study coordinators throughout the 8-10 weeks."
62431945|NCT04157634|EXPERIMENTAL|Prognostication model|In a prospective cohort of children hospitalized in a PICU, development of a model based on biomarkers, HRV, and a computerized classifier output, to predict long-term neurological outcome after a moderate or severe TBI in children aged 0 to 18 years.
62431946|NCT01637961|EXPERIMENTAL|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62038732|NCT06140524|EXPERIMENTAL|Expansion (Part 2) - Dose regimen 4|Participants will be randomized in a 1:1:1:1 ratio across 4 dosing regimens
62817749|NCT03986970|EXPERIMENTAL|Arm 8: FTC-TAF|FTC-TAF two days, 5 hours before circumcision.
62817750|NCT03986970|EXPERIMENTAL|Arm 9: FTC-TAF|FTC-TAF two days, 21 hours before circumcision.
62817751|NCT04968990|ACTIVE_COMPARATOR|Favorable Histology Stage I & II and FH Stage III/IV|Favorable Histology Stage I \& II and FH Stage III/IV Delayed Local Control with clear surgical margins and pathologically negative lymph nodes. Participants will undergo complete surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy.
62817752|NCT04968990|ACTIVE_COMPARATOR|Stage III & IV Adjuvant RT and Stage V|Participants will undergo surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy. Those with evidence of LN involvement, surgical margin involvement, local or diffuse spill, gross disease in the renal bed or peritoneal implants, will receive adjuvant PBRT.
62431947|NCT04825509||Successful weaning group|Patients will be in this group according to primary outcome, if they will succeed spontaneous breathing trial for 120 minutes and will be extubated successfully without need for invasive or non-invasive ventilation for 48 hours
62431948|NCT04825509||Weaning failure group|"Patients will be in this group according to primary outcome, if they will fail spontaneous breathing trial or extubation within 48 hours~Weaning failure will be considered if:~* Patients will need MV during spontaneous breathing trial within 120 minutes, or~* patients will need invasive or non-invasive ventilation within 48 hours"
62817753|NCT04968990|ACTIVE_COMPARATOR|Stage V Adjuvant RT:|Participants will undergo partial nephrectomy after 6-12 weeks of induction chemotherapy. Those with evidence of LN involvement, surgical margin involvement, local or diffuse spill, gross disease in the renal bed or peritoneal implants, will receive adjuvant PBRT
62817754|NCT05537753|EXPERIMENTAL|Encore PFO closure device|
62817755|NCT05537753|ACTIVE_COMPARATOR|Any FDA-approved PFO closure device chosen by the investigator|
62817756|NCT04607668|EXPERIMENTAL|trilaciclib + FOLFOXIRI/bevacizumab|"During Induction the following study drugs are administered on Day 1:~Irinotecan - IV, Oxaliplatin - IV, Leucovorin- IV, Fluorouracil - continuous infusion (CI) over 46 to 48 hours beginning on Day 1, Bevacizumab - IV~Following completion of Induction, patients will continue in Maintenance, where they will continue to receive trilaciclib per randomization allocation at study entry. Trilaciclib will be administered prior to infusional- 5FU/leucovorin/bevacizumab at the same dose and schedule used during Induction."
62817757|NCT04607668|PLACEBO_COMPARATOR|placebo + FOLFOXIRI/bevacizumab|The subjects in the placebo arm will follow the same schedule as the trilaciclib arm, but will receive placebo instead of trilaciclib.
62817758|NCT02953652|EXPERIMENTAL|HBI-8000|Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.
62817759|NCT01327625|EXPERIMENTAL|Azithromycin|Patient who are diagnosed as bronchiolitis obliterans according to the WHO criteria
62817760|NCT04495218||Patient with a diagnosis of incomplete form of albinism|
62817761|NCT05985161|EXPERIMENTAL|Cohort A.1 Wilms Tumor|Participants will have any type of Wilms tumor or nephroblastoma
62431949|NCT01535157|EXPERIMENTAL|Fenretinide/LXS + Ketoconozale|One course is defined as 7 days of Fenretinide/LXS + Ketoconazole followed by 14 days of rest. A course is repeated every 21 days if no evidence of disease progression for six courses.
62598916|NCT06620692|EXPERIMENTAL|5 % GM-XANTHO [GM-XAN003] group|Patients will take the test product, 5 % GM-XANTHO \[GM-XAN003\].
62817762|NCT05985161|EXPERIMENTAL|Cohort B.1 Rhabdoid Tumor|Participants will have any Rhabdoid tumor
62817763|NCT05985161|EXPERIMENTAL|Cohort C.1 MPNST|Participants will have progressive, relapsed, unresectable or metastatic MPNST
62817764|NCT05985161|EXPERIMENTAL|Cohort D.1 Other Solid Tumor|Participants must not qualify for Cohorts A, B, or C but have a solid tumor (no hematologic malignancies including lymphoma) for which there is specific evidence that this particular patient's tumor may benefit from selinexor.
62817765|NCT04864210|EXPERIMENTAL|Liposomal bupivacaine|The patient will receive an intercostal nerve block by the surgeon in the operating room after anesthetic has been administered. The surgeon will use thoracoscopic guidance to administer the intercostal nerve block. The medication used in this block will liposomal bupivacaine (Exparel).
62817766|NCT04864210|ACTIVE_COMPARATOR|Bupivacaine|The patient will receive a paravertebral block by the anesthesiologist staffing the pain service area within the hospital prior to surgery. This regional anesthesia will be done using ultrasound guidance. The medication used in this block will be plain bupivacaine with epinephrine.
62038733|NCT06733480|EXPERIMENTAL|Group 1|Patients in group 1 will be set up with the Band Connect platform and build their treatment plan at the first in-clinic visit.
62817767|NCT02543684|EXPERIMENTAL|ready to eat mixed meal 1|
62817768|NCT02543684|EXPERIMENTAL|ready to eat mixed meal 2|
62817769|NCT02543684|EXPERIMENTAL|ready to eat mixed meal 3|
62817770|NCT02543684|EXPERIMENTAL|oral glucose load|
62817771|NCT04647227|OTHER|Hemophilia A and B Cases|SEVENFACT® has been approved for the treatment of bleeding events in individuals with hemophilia A or B with inhibitors. This study is intended to further investigate the safety and tolerability of SEVENFACT in participants with hemophilia A or B with inhibitors in the presence or absence of prophylactic therapies. Dosing will be at the discretion of the attending physician, and each participant will be supplied with the equivalent of nine 75 µg/kg doses, which aligns with the recommended dosing schedule as provided in SEVENFACT's United States Prescribing Information (USPI). In the event of a bleeding episode (BE), the participant will either self-administer the correct dose under the guidance of the treating investigator or the dose will be administered at a treatment facility.
62817772|NCT03547518|EXPERIMENTAL|Active PTNS treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
62817773|NCT03547518|SHAM_COMPARATOR|Sham treatment|One-week induction consisting of three sham treatments, each 2 hours long
62817774|NCT04141748|ACTIVE_COMPARATOR|Hand Casting|hand cast will be taken using a circumferential plaster of Paris or fiber glass wrap of the residual limb with the subject in a seated position
62598917|NCT06620692|PLACEBO_COMPARATOR|Placebo group|Patients will take the placebo.
62817775|NCT04141748|ACTIVE_COMPARATOR|standing hydrostatic pressure casting with a water cylinder|hand cast will be taken using a circumferential plaster of Paris wrap of the residual limb with the subject in a seated position. The residual limb is then placed into the Symphonie Aqua System while in a weight bearing standing position.
62038734|NCT06733480|NO_INTERVENTION|Group 2|Group 2 will consist of retrospective chart review to as act a control group. Charts will be pulled from 1/1/2019-12/31/2023.
62817776|NCT04204447|EXPERIMENTAL|Brochure intervention|Subjects will be asked to read an educational brochure about Hepatitis C
62817777|NCT04204447|EXPERIMENTAL|Video intervention|Subjects will be asked to watch an educational video about Hepatitis C
62817778|NCT01810471|EXPERIMENTAL|ankle supports|
62817779|NCT06704893|EXPERIMENTAL|ASA injection 40 mg group|AMNIOGEN® 40mg (HCT Regenerative, New Taipei, Taiwan) was diluted in 3.0 mL of sterile normal saline.
62817780|NCT06704893|EXPERIMENTAL|ASA injection 20 mg group|AMNIOGEN® 20mg (HCT Regenerative, New Taipei, Taiwan) was diluted in 3.0 mL of sterile normal saline.
62817781|NCT06704893|ACTIVE_COMPARATOR|HA injection group|3 ml of HyLink (SEIKAGAKU CORPORATION, Tokyo, Japan)
62817782|NCT06704893|PLACEBO_COMPARATOR|Normal saline injection group|3 ml of sterile normal saline
62817783|NCT05324293|EXPERIMENTAL|HMI-115 240mg|
62817784|NCT06329830|EXPERIMENTAL|177Lu-PSMA-617 in Combination with Niraparib/Abiraterone Acetate plus Prednisone|177Lu-PSMA-617 will be administered per standard of care at 7.4 gigabecquerel (GBq) (200 mCi) via intravenous (IV) infusion once every cycle (6 weeks) for 6 cycles. Niraparib/Abiraterone Acetate (Nira/AA) will be taken orally by the participant daily until disease progression or unacceptable toxicity. The starting dose level is 150 mg/1000 mg Nira/AA. Other dose levels include 200 mg/1000 mg, 100 mg/1000 mg, or 50 mg/500 mg Nira/AA once daily. Prednisone (5 mg) will be taken orally by the participant twice daily each day that Nira/AA is taken.
62817785|NCT03019406|EXPERIMENTAL|Cohort 1: Avalglucosidase Alfa 20 mg/kg|Avalglucosidase alfa, 20 mg/kg intravenous (IV) infusion every other week (qow) for 25 weeks in the Primary Analysis Period (PAP), followed by same treatment from Week 26 up to Week 371 in extension treatment period (ETP).
62817786|NCT03019406|EXPERIMENTAL|Cohort 2: Avalglucosidase Alfa 40 mg/kg|Avalglucosidase alfa 40 mg/kg IV infusion qow for 25 weeks in the PAP, followed by same treatment from Week 26 up to Week 371 in ETP.
62817787|NCT03019406|EXPERIMENTAL|Cohort 3a: Avalglucosidase Alfa 40 mg//kg|After determination of the highest tolerated avalglucosidase alfa dose in Cohort 1 and Cohort 2 (after at least 5 participants in each Cohort 1 and Cohort 2 had received the 7th dose of avalglucosidase alfa or completed Week 13 with a minimum of 6 infusions), participants received avalglucosidase alfa 40 mg/kg (the highest tolerated dose) IV infusion qow for 25 weeks in PAP, followed by same treatment from Week 26 up to Week 371 in ETP.
62817788|NCT03019406|EXPERIMENTAL|Cohort 3b: Alglucosidase Alfa in PAP|After determination of the highest tolerated avalglucosidase alfa dose in Cohort 1 and Cohort 2 (after at least 5 participants in each Cohort 1 and Cohort 2 had received the 7th dose of avalglucosidase alfa or completed Week 13 with a minimum of 6 infusions), participants received alglucosidase alfa at their current stable dose (defined as dose \[between 20 mg/kg qow and 40 mg/kg weekly as per physician\] administered regularly for a minimum of 6 months immediately prior to entry in this study) IV infusion for 25 weeks in PAP. After PAP, participants received avalglucosidase alfa 40mg/kg IV infusion qow from Week 26 up to Week 371 in ETP.
62817789|NCT03355976|EXPERIMENTAL|Arm 1 Nivolumab Ovarian|Nivolumab 240 mg Day 1 Cycle = 2 weeks
62817790|NCT03355976|EXPERIMENTAL|Arm 2 Nivolumab and Ipilimumab Ovarian|Nivolumab 240 mg every 2 weeks Ipilimumab 1mg/kg day 1 Cycle=6 weeks
62817791|NCT03355976|EXPERIMENTAL|Arm 1 Nivolumab Extra-renal|Nivolumab 240 mg Day 1 Cycle = 2 weeks
62817792|NCT03355976|EXPERIMENTAL|Arm 2 Nivolumab and Ipilimumab Extra-renal|Nivolumab 240 mg every 2 weeks Ipilimumab 1mg/kg day 1 Cycle=6 weeks
62038735|NCT03129828|EXPERIMENTAL|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals \< 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
62038736|NCT04105231|EXPERIMENTAL|Cannabidiol|"Cannabidiol (Epidiolex®) (oral suspension)100 mg/ml dosed as 3 ml in the morning for 4 days, then increased to 3 ml in the morning and 3 ml in the evening, equivalent to CBD 300 mg BID, with a total treatment duration of 7 weeks.~AND Risperione placebo, encapsulated tablet."
62038737|NCT04105231|ACTIVE_COMPARATOR|Risperidone|"Risperidone (encapsulated tablet) dosed as 2 mg in the morning for 4 days, then increased with 2 mg in the morning and 2 mg in the evening, with a total treatment duration of 7 weeks~AND Cannabidiol placebo, oral suspension"
62038738|NCT00797654|EXPERIMENTAL|1|Participants will receive pre and post HIV-test counseling and an information-motivation-behavior skills training combined with cognitive processing therapy
62038739|NCT00797654|ACTIVE_COMPARATOR|2|Participants will receive pre and post HIV-test counseling
62038740|NCT06282809|EXPERIMENTAL|HistoSonics System|
62431950|NCT04512027|EXPERIMENTAL|Prolectin-M; a (1-6)-alpha-D-Mannopyranose class+Stand of care|Tablet chewed for 5 days along and given alongside standard of care
62817793|NCT01384981|ACTIVE_COMPARATOR|pulmonary rehabilitation with NIV|Patients receiving nocturnal non-invasiv Ventilation during a 3-week pulmonary Rehabilitation program.
62817794|NCT01384981|SHAM_COMPARATOR|pulmonary rehabilitation without NIV|Patients receiving no nocturnal non-invasiv Ventilation during a 3-week pulmonary Rehabilitation program.
62817795|NCT05544162|EXPERIMENTAL|SeND Home precision nutrition pathway|Oral nutrition supplements (ONS) will be given, at maximum, three times per day throughout hospitalization. Upon discharge, participants will be given 4-weeks' worth of oral supplements to take. Adjustments may be made based on indirect calorimetry (IC) measurements by the clinical dietitian.
62038741|NCT00421551|EXPERIMENTAL|1|
62038742|NCT00421551|ACTIVE_COMPARATOR|2|
62431951|NCT04512027|NO_INTERVENTION|Standard of Care|All patients will receive currently practiced standard of care medicines
62431952|NCT01325857|EXPERIMENTAL|Group B|Group B = Nerve block group
62431953|NCT01325857|PLACEBO_COMPARATOR|Group L|Group L = Local wound infiltration group
62431954|NCT01325857|ACTIVE_COMPARATOR|Group C|Group C = Control group
62817796|NCT05544162|NO_INTERVENTION|Control pathway|Standard of care nutrition delivery throughout hospitalization. Upon discharge they will be sent home with standard nutrition information without Indirect Calorimetry (IC) guidance.
62817797|NCT01925885|ACTIVE_COMPARATOR|PVI Ablation|Standard of care arm-pulmonary vein isolation (PVI)-involving moving the ablation catheter from point to point in a continuous line to surround the the orifices of the pulmonary veins in order to eliminate electrical conduction between the veins and left atrium.
62817798|NCT01925885|EXPERIMENTAL|FIRM Ablation|FIRM ablation for paroxysmal atrial fibrillation at sites of rotors or focal impulse formation as designated by using the mapping algorithm of RhythmView
62817799|NCT03851458|EXPERIMENTAL|Consumo de Opciones Mas Ideales De Alimento (COMIDA)|Participants will be placed in either individual or group interventions by convenience. Recruitment will be consecutive and participants will be placed in either intervention depending on what resource is available on a given day at the VDS, individual counselor or a group educator.
62817800|NCT03851458|EXPERIMENTAL|SANOS|Conducting SANOS Focus Groups. We will conduct 3-5 focus groups (in Spanish) with 6-10 participants each, until saturation. Bilingual study staff will approach individuals visiting the VDS and VDS Mobile for potential participation. A brief screening questionnaire will be administered, and a BMI assessment conducted, to ascertain eligibility. Focus groups will be scheduled at the VDS Mobile unit at times convenient to participants. Participants will be verbally consented in Spanish, and will be apprised that their participation is purely voluntary and that their names will not be included in the final narrative. The 6-month follow-up and my plate dietary surveys can be done over phone. Study staff will access step counts (or obtain it through phone via the pedometer manual provided to the participant) and upload data onto the REDCap tracking tool. Staff may ask participants to report step counts captured by their personal devices (i.e., phone or smartwatch).
62598918|NCT06647732|EXPERIMENTAL|Zanubrutinib in combination with Rituximab|"Eligible patients will receive:~1. Rituximab: 375 mg/m², administered once a week during Cycle 1 (C1), and on Day 1 (D1) of Cycles 2-6 (C2-C6).~2. Zanubrutinib: 160 mg, administered twice daily from Day 1 to Day 28 (D1-D28). Each cycle lasts 28 days. After 6 cycles of treatment, patients who achieve complete remission (CR) will end treatment and enter observation follow-up, while patients with partial remission (PR) or stable disease (SD) will receive an additional 2 cycles."
62598919|NCT04557462|EXPERIMENTAL|LNP023|All participants are receiving 200 mg b.i.d
62598920|NCT03108599|EXPERIMENTAL|Intervention|All participants in the intervention arm will receive two interventions: an enhanced cab intervention alone, and then the enhanced cab conditions combined with a behavioral sleep intervention.
62598921|NCT03108599|NO_INTERVENTION|Control|Usual practices with regards to cab conditions and access to workplace programs for preventing sleep and fatigue problems.
62038743|NCT06733909|ACTIVE_COMPARATOR|NuSmile Zirconia crowns|Prefabricated pediatric Zirconia crowns offer an excellent alternative to full-coverage crowns when restoring deciduous teeth with a sizeable carious defect
62431955|NCT04042974|EXPERIMENTAL|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
62598922|NCT04006262|EXPERIMENTAL|Experimental arm|"* Neo-adjuvant treatment (6 cycles - 12 weeks)~* Surgery~* Adjuvant treatment (9 cycles - 9 months)"
62598923|NCT02985073|EXPERIMENTAL|Veritas® mesh|Use of Veritas mesh in conjunction with immediate breast reconstruction on one side
62598924|NCT02985073|EXPERIMENTAL|TIGR® mesh|Use of TIGR® mesh in conjunction with immediate breast reconstruction on one side
62598925|NCT01849068|EXPERIMENTAL|Ezetimibe|
62598926|NCT01849068|PLACEBO_COMPARATOR|Placebo|
62735705|NCT03377595|EXPERIMENTAL|Wound infiltration|20 mL of EXPAREL 266 mg expanded in volume with 40 mL normal saline for a total volume of 60 mL, infiltrated in the fascia prior to skin closure with attention to infiltrate the angles of the incision.
62431956|NCT04042974|PLACEBO_COMPARATOR|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
62431957|NCT05994443||Pregnant women exposed to threatened preterm labor and exposed to antenatal corticosteroids|Pregnant women with threatened preterm labor (TPTL) who received antenatal corticosteroids (ACS) between 22 and 34 weeks and 6 days of gestation at our hospital.
62431958|NCT05994443||Non-exposed pregnant women|Pregnant women with normal pregnancies.
62431959|NCT00558519|EXPERIMENTAL|Treatment (chemotherapy, radiotherapy)|"Patients are given a series of leukemia treatments that are divided into several sequential courses and different chemotherapy combinations of treatment. Please see the Detailed Description section for more information."
62431960|NCT04809038|EXPERIMENTAL|dry needling|dry needling will be received twice a week for four weeks
62431961|NCT04809038|EXPERIMENTAL|magnesium sulphate iontophoresis|magnesium sulphate iontophoresis will be received twice a week for four weeks
62431962|NCT04809038|ACTIVE_COMPARATOR|stretching exercise|stretching will be received twice a week for four weeks
62431963|NCT05140018||Kidney Transplant Recipients with an immunological high risk for ABMR|"* Kidney transplant recipients ≥18 years old~* About to receive a post mortal or living donor renal transplant~* Immunological high risk for rejection~  1. Luminex positive DSAs ; or~ 2. Retransplantation with repeated mismatch ; or~ 3. Husband to wife donation (after fathering children); or~ 4. Offspring to mother donation"
62431964|NCT05140018||Living Kidney Donors|Participants who are about to donate their kidney to a Recipient with a high immunological risk (as described above)
62431965|NCT02451969|EXPERIMENTAL|Experimental Group|"* Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~* Intervention: investigational 23-valent PPV"
62431966|NCT02451969|ACTIVE_COMPARATOR|Control Group|"* Single intramuscular injection of the control vaccine (0.5 ml) on Day 0~* Intervention: control 23-valent PPV"
62431967|NCT04698057|ACTIVE_COMPARATOR|Amoxicillin clavulanate + ciprofloxacin|Treatment with amoxicillin-clavulanate 1g tib and ciprofloxacine 750mg bid for 5 days
62598927|NCT04175782|EXPERIMENTAL|ERAS group|A standardized ERAS protocol is applied to the ERAS group based on the latest guidelines. Smoking and alcohol consumption is stopped 4 weeks before the surgery. Preoperative anemia is corrected with intravenous iron supplementation. Prolonged fasting, bowel preparation, and premedication are avoided in this group. Clear fluids are allowed up to 2 h and solids rich in carbohydrate up to 6 h hours prior to induction of anesthesia. Warmed up intravenous fluids are administered to maintain normothermia intraoperatively. This group of subjects receives general anesthesia. Volume and salt overload and drain usage are avoided to the utmost. Intravenous paracetamol is administered for postoperative analgesia before the completion of the surgical procedure. Nasogastric tube placement is avoided and catheters are removed as soon as possible. Nonopioid oral analgesics and NSAIDs are utilized for postoperative pain medication.
62817801|NCT03851458|EXPERIMENTAL|ROADmAP schema|Participants will be randomly assigned to one of eight study groups which will be one or a combination of 4 conditions: (1) in person individualized diet and exercise counseling (2) diet and exercise text messages (3) weekly telephone support and (4) self-monitoring tools for diet and weight. For the first part of the study, Survey, approximately 64 drivers and 36 management staff will take pate in the feedback questionnaire. For the second part of the study, Interview, approximately 8 drivers and 12 management staff may be invited to take part in an interview via phone, in person, or teleconference (Zoom).
62598928|NCT04175782|NO_INTERVENTION|Control|This group will receive conventional pre-and postoperative care.
62598929|NCT00230022|EXPERIMENTAL|Brief computer-delivered intervention|A 20-minute interaction with software designed to partially replicate the experience of a brief motivational intervention with a therapist or health care professional. Included decisional balance, normed feedback, and optional goal-setting.
62817802|NCT06384066|OTHER|Standard of Care|Standard Care
62817803|NCT06384066|OTHER|Standard Care + GetWell App|
62038744|NCT06733909|EXPERIMENTAL|BioFlx crowns|The Bioflex crown has been introduced in pediatric practice as a synthetic crown that will provide better adaptation, durability, and ease of handling with improved aesthetic properties compared to conventional crowns
62038745|NCT06733909|EXPERIMENTAL|Digital VITA ENAMIC crowns|is a hybrid ceramic with a dual network structure that combines the best characteristics of ceramic and composite. Fast and efficient CAM fabrication; for minimally invasive reconstructions, tooth-like material properties.
62598930|NCT00230022|NO_INTERVENTION|Assessment only|Participants in this arm only completed assessment section, same as intervention group, but then was done.
62598931|NCT01430780||control group|placebo
62038746|NCT06733753||ultrasound-guided thermal ablation|ultrasound-guided thermal ablation
62038747|NCT04887454|EXPERIMENTAL|Once-Weekly HIIT|Once-weekly HIIT for 16 weeks, led by certified athletic coaches
62038748|NCT04887454|EXPERIMENTAL|Thrice-Weekly HIIT|Thrice-weekly HIIT for 16 weeks, led by certified athletic coaches
62598932|NCT01430780||nitrate group|Isosorbide Mononitrate orally 20mg twice per day.
62598933|NCT03018366|ACTIVE_COMPARATOR|17Beta Estradiol, Progesterone|17Beta Estradiol (0.1mg/day) , Progesterone (100mg) or Medroxyprogesterone (10mg) for patient with a peanut allergy because progesterone 100mg is a peanut based product
62598934|NCT03018366|PLACEBO_COMPARATOR|Transdermal Placebo Patch, Placebo Pill|Placebo Transdermal Patch, Placebo Pill
62598935|NCT02930746|EXPERIMENTAL|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62598936|NCT02284659|SHAM_COMPARATOR|FES-sham|Functional Electro Stimulation (FES-sham)
62598937|NCT02284659|ACTIVE_COMPARATOR|Intervention (FES)|functional electro stimulation
62598938|NCT04938219|EXPERIMENTAL|Shivering Treatment Group|Participants will be observed, and intervention will begin when a shivering score of 2 or higher is reached. The participants in the treatment group will receive one glove filled with warm water into each hand.
62598939|NCT04938219|NO_INTERVENTION|Control Group|Participants in the control group will only be observed, and not given additional treatment for the shivering.
62598940|NCT06647615|EXPERIMENTAL|VR Headset|
62598941|NCT03110861|EXPERIMENTAL|Pulsta® Transcatheter Pulmonary Valve|Pulsta® Transcatheter Pulmonary Valve (TaeWoong Medical Co., Ltd. Korea)
62598942|NCT06260033|EXPERIMENTAL|Treatment (SBRT, FES PET/CT)|Patients currently taking SERMs/ SERDs immediately undergo 3 or 5 treatment fractions of SBRT within 3 weeks in the absence of unacceptable toxicity or evidence of \> 4 sites of disease progression. Patients not currently taking SERMs/SERDs first receive F-FES IV and undergo PET/CT scans at baseline. After baseline FES PET/CT, patients with ≤ 4 sites of progressive disease then undergo 3 or 5 treatment fractions of SBRT within 3 weeks in the absence of unacceptable toxicity or evidence of \> 4 sites of disease progression. All patients undergo FES PET/CT at 12 and 24 weeks. Patients with SD after 12 or 24 week FES PET/CT may continue standard systemic therapy. Patients with ≤ 4 sites of progressive disease after 12 or 24 week FES PET/CT may receive SBRT to additional sites in the absence of unacceptable toxicity or evidence of \> 4 sites of disease progression. All patients also undergo CT, PET/CT, or bone scans, and blood samples collection during screening and on study.
62817804|NCT06704581|EXPERIMENTAL|5 mg BGM0504 injection|
62817805|NCT06704581|EXPERIMENTAL|10 mg BGM0504 injection|
62817806|NCT06704581|EXPERIMENTAL|15 mg BGM0504 injection|
62817807|NCT06704581|PLACEBO_COMPARATOR|BGM0504 placebo|
62817808|NCT04806386|EXPERIMENTAL|Psyllium fiber supplement treatment|All patients will receive psyllium fiber in the form of edible bars, 7g, twice a day to total 14g per day.
62038749|NCT04887454|OTHER|Usual Care|Bi-weekly health education, led by research personnel
62431968|NCT04698057|EXPERIMENTAL|Amoxicillin clavulanate + Placebo|Treatment with amoxicillin-clavulanate 1g tib for 5 days
62431969|NCT01700751|EXPERIMENTAL|Dose Level 0 (starting dose)|brentuximab vedotin 0.3mg/kg, given IV on Days 7, 28, 49 \& 70
62431970|NCT01700751|EXPERIMENTAL|Dose Level 1|brentuximab vedotin 0.6mg/kg, given IV on Days 7, 28, 49 \& 70
62431971|NCT01700751|EXPERIMENTAL|Dose Level 2|brentuximab vedotin 1.2mg/kg, given IV on Days 7, 28, 49 \& 70
62817809|NCT03189368||Heart failure patients eligible for CRT|"Adult, consenting patients with any cardiomyopathy type and an existing I/IIa indication for a CRT-D device will receive a device with multi-site pacing capability. Initially, for 6 months, optimal, conventional, resynchronization therapy will be delivered. Following this, all patients will crossover to optimized multi-site pacing, and receive this therapy for 6 more months. Optimization of therapy will be determined based on maximization of cardiac output, i.e. maximization of left ventricular outflow tract velocity-time integral.~Baseline measurements of serum creatinine and ventriculoarterial coupling will also be acquired."
62598943|NCT06648109|EXPERIMENTAL|Mild-heat group|Participants will be randomized into groups A and B. When the subject's group cohort undergoes the intervention phase (as opposed to the control phase), they will receive a 7-day, 8-hour intervention with an electric blanket set at +5±1°C above room temperature.
62598944|NCT06648109|NO_INTERVENTION|Non-mild-heat group|Participants will be randomized into groups A and B. There will be no additional sleep temperature intervention while the group is in the control period.
62598945|NCT01091545|OTHER|FFDM+DBT|Single-armed study. Women are their own controls with paired images of digital mammography and breast tomosynthesis.
62598946|NCT02026817|EXPERIMENTAL|HCP1201|Participants received a single oral dose of the HCP1201 750/10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
62598947|NCT02026817|ACTIVE_COMPARATOR|Metformin and Rosuvastatin|Participants received a single oral dose of coadministration of Metformin SR 750 mg and Rosuvastatin 10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
62598948|NCT06072677|EXPERIMENTAL|Healthy Minds Program|Participants in this group will begin the Healthy Minds Program immediately following the 4-week baseline period.
62598949|NCT06072677|OTHER|Waitlist Control|After the 4-week baseline period, participants in the waitlist control condition will wait an additional 4 weeks before starting the Healthy Minds Program.
62598950|NCT00595517|EXPERIMENTAL|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
62431972|NCT01700751|EXPERIMENTAL|Dose Level 3|brentuximab vedotin 1.8mg/kg, given IV on Days 7, 28, 49 \& 70
62431973|NCT01700751|NO_INTERVENTION|Control Dose Level|The first 3 patients will not receive brentuximab vedotin.
62431974|NCT01935531|EXPERIMENTAL|Diclofenac|3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is applied twice daily in the treatment area. 3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is to be applied 1cm beyond the single AK.
62431975|NCT04026295|EXPERIMENTAL|Short burst Interval Treadmill Training (SBLTT)|SBLTT will consist of short-bursts (30 seconds) of high speed walking alternating with 30 seconds of low/moderate speed walking. Participant will receive 40 home-based sessions (5x/week for 8 weeks) of SBLTT
62598951|NCT03672123||APE with RVD|RVD (right ventricle disfunction) defined according to ESC (European Society of Cardiology) criteria
62598952|NCT03672123||APE without RVD|RVD defined according to ESC criteria
62038750|NCT02110641|ACTIVE_COMPARATOR|In-Person or Telephone-Based Counseling|The exact same information, content, schedule, and 30 minute sessions will be provided to telephone-based participants as offered to participants who receive in-person counseling. Participants will be taught diet, exercise and behavior change strategies via the telephone (weekly calls for month 1, every other week for months 2-3, and monthly for months 4-6). All lessons and diet and physical activity logs will be mailed to them at the beginning of the program. Participants will record their daily diet and exercise in the logs.
62431976|NCT04026295|ACTIVE_COMPARATOR|Traditional Locomotor Treadmill Training (TLTT)|TLTT will consist of walking at steady-state speeds. Participant will receive 40 home-based sessions (5x/week for 8 weeks) of TLTT
62431977|NCT01068873|EXPERIMENTAL|open label single arm|Drug: lopinavir/ritonavir plus maraviroc
62598953|NCT03809377||Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points during and after radiotherapy
62817810|NCT04985604|EXPERIMENTAL|Arm #1 (Closed to Enrollment)|Tovorafenib monotherapy
62431978|NCT04380324|EXPERIMENTAL|LY3471851|Healthy participants in each cohort will receive single subcutaneous (SC) doses of LY3471851.
62431979|NCT04380324|PLACEBO_COMPARATOR|Placebo|Healthy participants in each cohort will receive the placebo comparator.
62431980|NCT04892940|EXPERIMENTAL|Virtual Reality group|Adolescents aged 13 to 18 years who have undergone scoliosis surgery
62431981|NCT04892940|ACTIVE_COMPARATOR|Control group|Adolescents aged 13 to 18 years who have undergone scoliosis surgery
62431982|NCT06203691|EXPERIMENTAL|Supplement Group|50 of the 100 participants will be given supplements (Prepare \& Recover) for pre \& post operation.
62431983|NCT06203691|PLACEBO_COMPARATOR|Non-Supplement Group|No supplements will be given to the non-supplement group.
62598954|NCT02892513|EXPERIMENTAL|Active Stimulation|Participants will have active percutaneous auricular neurostimulation for 5 days during and after elective surgery.
62598955|NCT02892513|SHAM_COMPARATOR|Sham Percutaneous Neurostimulation|Participants will have inactive device worn for 5 days during and after elective surgery.
62598956|NCT03530787|ACTIVE_COMPARATOR|Acetyl Zingerone Group|This group was given the topical with the active acetyl zingerone agent.
62431984|NCT06518941|EXPERIMENTAL|Open Label|Donepezil
62431985|NCT01016821|OTHER|Oxycodone, labour pain|
62431986|NCT05105477|EXPERIMENTAL|HPI Arm|AcumenTM HPI Software Feature to guide hemodynamic management in moderate-to-high-risk noncardiac surgery.
62431987|NCT05105477|PLACEBO_COMPARATOR|Non-HPI arm|Non-protocolized standard of care management per clinician and provider judgement
62598957|NCT03530787|PLACEBO_COMPARATOR|Control Group|This group was given the topical without the active acetyl zingerone agent and just the carrier lotion.
62598958|NCT05666128|EXPERIMENTAL|HD-6277 100mg|
62598959|NCT05666128|EXPERIMENTAL|HD-6277 50mg|
62598960|NCT05666128|PLACEBO_COMPARATOR|Placebo|
62598961|NCT00862342|EXPERIMENTAL|Bevacizumab|Bevacizumab continuation plus chemotherapy in patients who have failed previous bevacizumab plus other chemotherapy
62241534|NCT05218681|OTHER|"Control: Unit-based Person First Anti-stigma Awareness Rounds"|"The Person First Initiative was developed independent of this study by bedside nurses (including McFadden) in collaboration with HUP Nursing Executive Leadership. The objective of this initiative is to provide (1) unit-based huddles on person-first language as a mechanism to reduce the stigma around substance use; (2) socialize best practices and resources for patients with substance use disorder; and (3) provide overdose reversal training and kits, including Narcan nasal spray, to nurses. The planning and implementation of these activities fall under the purview of Nursing Shared Governance (NOT the research team), and oversight for these activities will be provided by HUP Nursing Executive Leadership."
62241535|NCT05218681|OTHER|"Unit-based Person First stigma rounds + Text-based Messaging"|Participating nurses will be randomized to receive weekly short text messages that employ evidence-based strategies to reduce stigma towards individuals with substance use disorder over the course of 6-months.
62241536|NCT05606887|EXPERIMENTAL|Intervention|In addition to completing 3 surveys over the course of 6 months, participants in the intervention arm will be asked to wear a wearable device (FitBit Charge 5), complete texting-based ecological momentary assessments to gauge real-time feelings of stress, and receive bi-weekly personalized data dashboards to report back their data.
62241537|NCT05606887|NO_INTERVENTION|Control|Participants randomized to this arm will receive digital surveys over the course of 6 months (one at baseline, one at 3 months, and one at 6 months). These surveys will be the same as the intervention arm and will ask questions related to burnout, anxiety, depression, PTSD, and stress.
62241538|NCT01840891|EXPERIMENTAL|Noro virus shedder|Lactose H2 breath test (LH2BT)
62817811|NCT04985604|EXPERIMENTAL|Arm #2|Tovorafenib plus pimasertib
62817812|NCT05488678|EXPERIMENTAL|Group 1 - Control|Healthy control participants will be matched by gender, age, and BMI to participants with renal impairment
62817813|NCT05488678|EXPERIMENTAL|Group 2 - Mild Renal Impairment|Mild Renal Impairment
62817814|NCT05488678|EXPERIMENTAL|Group 3 - Moderate Renal Impairment|Moderate Renal Impairment
62817815|NCT05488678|EXPERIMENTAL|Group 4 - Severe Renal Impairment|Severe Renal Impairment
62817816|NCT05488678|EXPERIMENTAL|Group 5 - End Stage Renal Disease|End Stage Renal Disease undergoing chronic intermittent hemodialysis
62817817|NCT00629980|EXPERIMENTAL|1|
62817818|NCT00629980|NO_INTERVENTION|2|
62817819|NCT05293769||IBS - arm|
62817820|NCT05293769||healthy - arm|
62817821|NCT04107948|EXPERIMENTAL|fibromyalgia patients with physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
62038751|NCT02110641|NO_INTERVENTION|Usual Care/Wait List|At 6-months the participants in the Wait List group may choose to participate in the 11 sessions either in-person or via telephone or a combination of the two modes of delivery. They will also be offered the opportunity to return to Yale at 12-months (immediately after the end of the 6-month counseling sessions) to have weight and DEXA measured.
62817822|NCT04107948|OTHER|fibromyalgia patients with physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
62038752|NCT05835297|EXPERIMENTAL|Exercise group|Physical exercise interventions for 45 min, twice a week plus usual care provided at the nursing home.
62038753|NCT05835297|NO_INTERVENTION|Usual care|Usual care provided at the nursing home with no specific physical exercise intervention.
62817823|NCT03035032|EXPERIMENTAL|Leuprolide Acetate 22.5 milligrams (mg)|Participants received 22.5 mg of leuprolide acetate (eligard) by subcutaneous injection at baseline, month 3, 6, 9, 12 and 15.
62817824|NCT06586684|EXPERIMENTAL|inclisiran Therapy group|Patients with carotid plaques undergoing treatment with inclisiran
62817825|NCT06473246|ACTIVE_COMPARATOR|CBD Isolate (25 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
62817826|NCT06473246|ACTIVE_COMPARATOR|CBD Isolate (40 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
62038754|NCT04101305||Localised prostate cancer|Patients diagnosed with prostate cancer of moderate estimated risk suitable for and scheduled for prostatectomy with gland evacuation
62038755|NCT04101305||Stage 3 prostate cancer|Patients with diagnosed stage 3 prostate cancer
62038756|NCT04101305||Stage 4 prostate cancer|Patients with diagnosed stage 4 prostate cancer
62241539|NCT01840891|ACTIVE_COMPARATOR|No norovirus shedding|Lactose H2 breath test (LH2BT)
62241540|NCT06246617|EXPERIMENTAL|Arm 1|Subjects who have received or plan to receive pulmonary lobectomy/segmentectomy, mediastinal tumor resection (including thymectomy), radical resection of esophagus cancer or other surgeries with the SP single-port robot.
62241541|NCT03051581|EXPERIMENTAL|18F-FDG PET/CT-based prognostic model of PTCL|The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
62817827|NCT06473246|ACTIVE_COMPARATOR|CBD Isolate (50 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
62817828|NCT06473246|ACTIVE_COMPARATOR|CBD Broad Extract (50 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
62817829|NCT06473246|PLACEBO_COMPARATOR|Placebo|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
62817830|NCT06700668|EXPERIMENTAL|MIT Powered Knee|Subjects wears the MIT powered knee prosthesis.
62817831|NCT06700668|NO_INTERVENTION|Prescribed prosthesis|Subjects wears their prescribed prosthesis.
62817832|NCT05904158|EXPERIMENTAL|PRF Group|Patients in this group, received PRF application during the standard ACL reconstruction surgery
62817833|NCT05904158|ACTIVE_COMPARATOR|Control Group|Patients in this group received a standard ACL reconstruction surgery without any other intervention.
62817834|NCT06317181|EXPERIMENTAL|Elastography|Collection of ultrasound data and elastography data from patients who were clinically planned for elastography
62817835|NCT06317181|EXPERIMENTAL|Focal lesion|Collection of ultrasound data of the suspected lesion and a definitive diagnosis based on either normal ultrasound investigation or if not sufficient additional investigations like CEUS, Biopsy, MRI or CT. This further investigation should be in accordance to normal clinical routine of the centers to differentiate focal lesions.
62817836|NCT06250699|EXPERIMENTAL|no tube|no drainage tube after laparoscopic adrenalectomy
62817837|NCT06250699|EXPERIMENTAL|Drainage tube|tube drainage after laparoscopic adrenalectomy
62241542|NCT03697434|EXPERIMENTAL|Palliative Care referral|Participants with specific uncontrolled symptoms or critical events in course of their Parkinson disease will be referred to a palliative care specialist for supportive care.
62241543|NCT03750383|EXPERIMENTAL|EDP-938 and cyclosporine interaction (Part 1)|
62241544|NCT03750383|EXPERIMENTAL|EDP-938 and prednisone interaction (Part 2)|
62241545|NCT00752687|OTHER|1|Single dose of ABT-072, dose escalation ranging from 10 mg to 320 mg or placebo in healthy volunteers
62817838|NCT06175338|EXPERIMENTAL|Rituximab (manufactured by Mabscale, LLC)|Eligible subjects (104 patients) will receive Rituximab 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml) twice: on Visit 1 and 5. The following visits are the visits of safety and PK, PD and immunogenicity and also preliminary effectiveness). Patients will also receive background treatment Methotrexate+ Folic acid.
62817839|NCT06175338|ACTIVE_COMPARATOR|MabThera®|Eligible subjects (104 patients) will receive MabThera® 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml) twice: on Visit 1 and 5. The following visits are the visits of safety and PK, PD and immunogenicity and also preliminary effectiveness). Patients will also receive background treatment Methotrexate+ Folic acid.
62817840|NCT06501001|EXPERIMENTAL|High-Intensity Interval Training|High-intensity interval training for sixteen weeks. Three weekly, supervised training sessions.
62817841|NCT06501001|EXPERIMENTAL|Time-Restricted Eating|Time-restricted eating for sixteen weeks. Maximal daily eating window of 10 hours
62817842|NCT06501001|EXPERIMENTAL|High Intensity Interval Training & Time-Restricted Eating|"High-intensity interval training for sixteen weeks. Three weekly, supervised training sessions.~Time-restricted eating for sixteen weeks. Maximal daily eating window of 10 hours"
62817843|NCT06501001|NO_INTERVENTION|Control|Information about the recommended level of physical activity for health benefits and a healthy diet will be given.
62817844|NCT02400216||Group A|Patients with fibrosis levels spanning from bridging fibrosis to cirrhosis (Ishak fibrosis score 5-6)
62817845|NCT02400216||Group B|Patients with minimal fibrosis (Ishak score 0-1).
62817846|NCT04772170||Current Challenge Study Participant|Current participation in a respiratory virus challenge study at the NIH CC
62817847|NCT03617562|EXPERIMENTAL|Superior Capsular Reconstruction|Patients will be treated with the new technique of superior capsular reconstruction with dermal allograft.
62817848|NCT03617562|ACTIVE_COMPARATOR|Partial Repair|Patients will have a partial repair with residual defect as an established standard procedure.
62817849|NCT06333184|ACTIVE_COMPARATOR|Control|50 g glucose (55 g dextrose powder accounting for hydration) plus 417 mL water
62817850|NCT06333184|EXPERIMENTAL|Product|"417 mL of commercially available Mango \& Passion fruit fruit smoothie providing 50 g carbohydrate"
62038757|NCT04101305||Healthy controls|Age-matched healthy individuals free from diagnosed cancer, but with benign inflammatory prostatitis or other benign urological condition
62241546|NCT00752687|OTHER|2|HCV positive subjects administered 160mg ABT-072 or placebo, multi-dose, QD
62241547|NCT01233869|EXPERIMENTAL|Cohort A|
62817851|NCT06333184|EXPERIMENTAL|Whole|Apples (51%), Mango (16%), Banana (16%), Orange (12%), Passionfruit (3%), Peach (2%), Lime (0.4%; recipe matched to PRODUCT) eaten as whole fruit with added water as needed to match volume.
62817852|NCT06333184|EXPERIMENTAL|Blend|Apples (51%), Mango (16%), Banana (16%), Orange (12%), Passionfruit (3%), Peach (2%), Lime (0.4%; recipe matched to PRODUCT) eaten as blended fruit with added water as needed to match volume.
62817853|NCT06333184|EXPERIMENTAL|Slow|"417 mL of commercially available Mango and Passionfruit fruit smoothie providing 50 g carbohydrate ingested slowly over 25-35 mins."
62817854|NCT06333184|EXPERIMENTAL|Fibre|"417 mL of commercially available Mango and Passionfruit fruit smoothie providing 50 g carbohydrate with 6 g of added inulin."
62817855|NCT06333184|EXPERIMENTAL|Dose|"250 mL of commercially available Mango and Passionfruit fruit smoothie providing 30 g carbohydrate."
62817856|NCT05993806|EXPERIMENTAL|A (L04RD1 -> L04TD3)|Administration of 1 tablet of L04RD1, and taking 7-day wash-out period, and then administration of 1 tablet of L04TD3
62241548|NCT01233869|EXPERIMENTAL|Cohort B|
62598962|NCT05386277|OTHER|LeMaitre TufTex Single Lumen Embolectomy Catheter|The LeMaitre® Single Lumen Embolectomy Catheter is a catheter that consists of a natural latex rubber balloon secured with ligatures to a single lumen radiopaque shaft. When the balloon the emboli and/or thrombi can be removed by withdrawing the catheter tip through the arteriotomy.
62038758|NCT04749030|OTHER|Faecal microbiota transplantation (FMT)|Donor faeces is obtained from thoroughly screened healthy blood donors and processed in compliance with the European Tissue and Cells Directive.
62038759|NCT04749030|PLACEBO_COMPARATOR|Placebo|Placebo capsules will be identical in terms of visual appearance, weight, and vials and number
62241549|NCT01233869|PLACEBO_COMPARATOR|Cohort C|
62241550|NCT03548987|EXPERIMENTAL|Semaglutide|"Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.~Maintenance period: Participants will be randomized to receive semaglutide injection for 48 weeks (from week 20 to week 68).~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period."
62598963|NCT06629233|OTHER|Standard of care tumor resection|
62817857|NCT05993806|EXPERIMENTAL|B (L04TD3 -> L04RD1)|Administration of 1 tablet of L04TD3, and taking 7-day wash-out period, and then administration of 1 tablet of L04RD1
62817858|NCT06527794|EXPERIMENTAL|RHYTHM (Remote Hypertension Tracking Help Management)|home blood pressure telemonitoring with remote medication management and social support, lifestyle education and connection to community resources to address social needs
62817859|NCT06527794|EXPERIMENTAL|Enhanced usual care (UC)|standardized packet with evidence-based hypertension education material and a blood pressure monitor to complete blood pressure measurements at home
62817860|NCT00609102|PLACEBO_COMPARATOR|Placebo|
62817861|NCT00609102|ACTIVE_COMPARATOR|antioxidant drug|n-acetylcysteine
62817862|NCT04990024|EXPERIMENTAL|Mediterranean Diet|30 participants will be randomized to this arm. The intervention consists of 8 visits, over a period of 24 weeks, including 6 individual educational sessions on Mediterranean diet in patients on Semaglutide and 2 reinforcement educational sessions towards the end of the trial. Dietary assessments and adherence questionnaires will be conducted on several visits to assess adherence.
62817863|NCT04990024|EXPERIMENTAL|High Protein/Low Carbohydrate Diet|30 participants will be randomized to this arm. The intervention consists of 8 visits, over a period of 24 weeks, including 6 individual educational sessions on High Protein/Low Carbohydrate diet in patients on Semaglutide and 2 reinforcement educational sessions towards the end of the trial. Dietary assessments and adherence questionnaires will be conducted on several visits to assess adherence.
62817864|NCT05302089|EXPERIMENTAL|One-time physiotherapy instruction|One-time physiotherapy instruction and no usual rehabilitation care
62817865|NCT05302089|ACTIVE_COMPARATOR|Usual rehabilitation care|One-time physiotherapy instruction and usual rehabilitation care
62817866|NCT05345444|EXPERIMENTAL|Irreversible Electroporation and Radiotherapy|
62817867|NCT04607005|EXPERIMENTAL|Participants receiving mepolizumab + Standard of care (SoC)|Participants will receive one dose of 100 mg mepolizumab SC on top of SoC every 4 weeks during the 52-week treatment period.
62817868|NCT04607005|PLACEBO_COMPARATOR|Participants receiving placebo + SoC|Participants will receive one dose of placebo via SC route on top of SoC, every 4 weeks during the 52-week treatment period.
62817869|NCT01415271|EXPERIMENTAL|Internet Intervention|
62817870|NCT06584903|PLACEBO_COMPARATOR|Still air|still air condition with no supplemental air flow
62817871|NCT06584903|EXPERIMENTAL|Electric fan|Force air flow with a 46 cm 3-blade fan positioned 1.2 m anterior to the participants chest
62817872|NCT02595125|SHAM_COMPARATOR|Conventional technique|Intrauterine device (IUD) insertion by the conventional technique
62038760|NCT05909332|EXPERIMENTAL|Arm-A|"BP102 (10 mg/kg) iv D1 and D15 repeated administration of Q4W + Chemotherapy ddEC-P(described below). This was followed by maintenance therapy with BP102 (10 mg/kg) iv D1 and D15 repeated administration of Q4W to complete treatment with a total duration of 1 year from the first dose.~Chemotherapy: ddEC-P (dose-dense Epirubicin and Cyclophosphamide followed by Nab-paclitaxel). Epirubicin (75-100 mg/m2) iv D1 + Cyclophosphamide (600 mg/m2) iv D1 repeated administration of Q2W for a total of 4 doses, followed by Nab-paclitaxel (125 mg/m2) once weekly (QW) for 4 weeks."
62241551|NCT03548987|PLACEBO_COMPARATOR|Placebo|"Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.~Maintenance period: Participants will be randomized to receive semaglutide placebo injection for 48 weeks (from week 20 to week 68).~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period."
62598964|NCT00687349|EXPERIMENTAL|Intervention Arm|The training program will assign resident or NP student to a rotation. They will be receiving the educational intervention during 8 half-day sessions.
62817873|NCT02595125|EXPERIMENTAL|Direct technique|Intrauterine device (IUD) insertion by the direct technique
62817874|NCT01794429|PLACEBO_COMPARATOR|Placebo|Subcutaneum injection of placebo once-weekly for 3 months
62817875|NCT01794429|ACTIVE_COMPARATOR|exenatide|Subcutaneum injection of exenatide once-weekly for 3 months
62817876|NCT06481683||Pre-eclampsia Group (Case Group)|This group consists of pregnant women diagnosed with pre-eclampsia. These participants will have specific characteristics related to the pre-eclampsia condition, such as elevated blood pressure and proteinuria.
62817877|NCT06481683||Severe Pre-eclampsia Group (Case Group)|This group consists of pregnant women diagnosed with severe pre-eclampsia. These participants will have more severe symptoms and complications related to pre-eclampsia, potentially including higher blood pressure, significant proteinuria, and other related health issues.
62598965|NCT00687349|NO_INTERVENTION|Control Arm|Resident or NP student is assigned to usual education.
62817878|NCT06481683||Control Group|This group consists of pregnant women who do not have pre-eclampsia or severe pre-eclampsia. These participants will be matched to the case groups based on relevant characteristics such as age, gestational age, and other demographic factors.
62817879|NCT04839705|OTHER|WEB Aneurysm Embolization Device|WEB Aneurysm Embolization Device The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant.
62817880|NCT05940103|EXPERIMENTAL|Mixed Reality Simulation|Participants in the experimental arm will be introduced to workplace training modules through an Augmented Reality (AR) headset.
62817881|NCT06596369|EXPERIMENTAL|tSCS + Rehab|In this single arm study, individuals will receive transcutaneous spinal cord stimulation over the cervical spinal cord with upper extremity training utilizing the ReJoyce system.
62817882|NCT05851651|EXPERIMENTAL|Standard care plus an antenatal milk expression education|Participants will have one face-to-face breastfeeding education in lactation clinic at 37 weeks of gestation and telephone follow-up weekly till delivery.
62817883|NCT05851651|NO_INTERVENTION|Standard hospital antenatal care|Participants will receive standard care include prenatal breastfeeding education at gestation of 24-36 weeks same as intervention group. They will not discuss about antenatal milk expression, breastfeeding self-efficacy and the effects of breastfeeding on GDM women.
62817884|NCT06434272|EXPERIMENTAL|Early initiated Blood Flow Restriction Exercise|Receives an intervention in adjunct to usual care in weeks 1-12, and continues with usual care in weeks 13-24.
62817885|NCT06434272|EXPERIMENTAL|Late initiated Blood Flow Restriction Exercise|Receives usual care in weeks 1-12, and receives an intervention in weeks 13-24.
62817886|NCT06277739|EXPERIMENTAL|Group1 (Spinal Manipulation Therapy)|The participant was placed in a side-lying position facing the clinician with the more painful side facing upward. The clinician passively flexed the participant's hips and knees to induce lumbar spine flexion until they felt the spinous process of the affected lumbar vertebrae begin to move. Next, the clinician passively rotated the participant's torso opposite to the side they were lying on until they felt rotation in the vertebra above the suspected lesion. The clinician applied a rapid thrust to the shoulder (anterior to posterior force) and pelvis (posterior to anterior force) resulting in a rotation force couple on the hypomobile segment.
62817887|NCT06277739|PLACEBO_COMPARATOR|Group2 Sham Laser Treatment)|The laser manufacturer (MedX Health Corp) provided a MedX 1100 system that did not deliver any significant amount of light energy or heat but otherwise appeared operational to participants and clinicians. The sham laser was delivered over the painful region with the study participant positioned as described for spinal manipulation and spinal mobilization treatments.
62817888|NCT06277739|NO_INTERVENTION|Group3 (healthy controls)|
62817889|NCT04007692||Simple interrupted suture group|Participants will have a simple interrupted suturing pattern, determined by care provider, at the time of esophageal stent placement for esophageal stent fixation as part of standard care and will have an endoscopy at 3-4 weeks after the stent placement as part of a routine follow-up.
62817890|NCT04007692||Triangular suture group|Participants will have a triangular suturing pattern, determined by care provider, at the time of esophageal stent placement for esophageal stent fixation as part of standard care and will have an endoscopy at 3-4 weeks after the stent placement as part of a routine follow-up.
62431988|NCT03359928|EXPERIMENTAL|Boxing|"In each of the three sessions a different exercise modality will be conducted, in a randomised sequence. Non-contact boxing involves boxing punch pads that will be held by the one of the researchers, while wearing protective boxing gloves. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest). During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed."
62817891|NCT04997486|NO_INTERVENTION|Control|Subjects will consume all meals/snacks during a \~15-h daily eating period (\~9-h fasting). The prescribed energy intake will be monitored and adjusted as needed to achieve weight maintenance.
62817892|NCT04997486|EXPERIMENTAL|TRE isocaloric|Subjects will consume all meals/snacks during a \~9-h daily eating period (\~15-h fasting). The prescribed energy intake will be monitored and adjusted as needed to achieve weight maintenance.
62817893|NCT04997486|EXPERIMENTAL|TRE ad libitum|Subjects will consume all meals/snacks during a \~9-h daily eating period (\~15-h fasting) without any other dietary advice.
62241552|NCT01338129|EXPERIMENTAL|vitamin c|administration of vitamin c for 45 days following ankle fracture operation
62241553|NCT01338129|PLACEBO_COMPARATOR|placebo|placebo pills
62241554|NCT05355025|EXPERIMENTAL|Intervention|Participants will be provided with a personal login code for the study web portal via automated email and encouraged to complete the initial components of the intervention which seek to determine participants' current support and management strategies and help them to understand their specific antidepressants. They will then complete the third component which contains three sub-sections to assist in creating a personal plan to help them cease their ADs: i) Management strategies for withdrawal symptoms and opportunities to discuss the plan with their GP or trusted Mental health worker; ii) Selecting a start time to begin tapering; iii) Print out of the personalised action plan to keep and share with supportive family and/or friends. Participants will also be required to complete a daily check-in through the portal which will check current symptoms and highlight any negative changes in emotional wellbeing, they will also receive texts reminders to complete these tasks.
62241555|NCT05355025|EXPERIMENTAL|Usual care - Attention Control|Participants allocated to the treatment as usual group will receive usual care plus attention control which comprises a link to the AD factsheet within the BeyondBlue website. This provides education material relevant to the participants' enrolment in the study but they will not be advised to cease or continue with their medication. GPs will not be advised of the participants allocated to this treatment arm.
62241556|NCT00564005|EXPERIMENTAL|1|constraint-induced therapy
62241557|NCT00564005|EXPERIMENTAL|2|bilateral arm training
62241558|NCT00564005|EXPERIMENTAL|3|combined therapy
62241559|NCT00564005|ACTIVE_COMPARATOR|Control intervention|
62241560|NCT00279110|EXPERIMENTAL|A|
62431989|NCT03359928|EXPERIMENTAL|Stair stepping|Participants will complete 3 sessions of exercise. In each of the three sessions a different exercise modality will be conducted in a randomised sequence. Stair stepping involves stepping on to and off a 35 cm Reebok exercise bench, repeatedly. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest). During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed.
62431990|NCT03359928|EXPERIMENTAL|Stair climbing|"In each of the three sessions a different exercise modality will be conducted, in a randomised sequence. Stair climbing involves continuously ascending the stairs located in a public access staircase. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest).~During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed."
62241561|NCT00279110|NO_INTERVENTION|B|
62241562|NCT03661125|EXPERIMENTAL|Saracatinib or placebo|In the first arm of the study, participants will be randomised into either the group that receives Saracatinib (study drug) or the Placebo.
62431991|NCT00069407|ACTIVE_COMPARATOR|RUL|Right unilateral electroconvulsive therapy
62431992|NCT00069407|ACTIVE_COMPARATOR|BL|Bilateral electroconvulsive therapy
62817894|NCT03085004|ACTIVE_COMPARATOR|Control Group|Cyst will be lavaged for 3 to 5 minutes with \>/=99% ethanol. Following lavage with \>/=99% ethanol, the cyst will be infused with an admixture of (3mg/ml paclitaxel + 19mg/ml gemcitabine).
62817895|NCT03085004|EXPERIMENTAL|Study group|Cyst will be lavaged for 3 to 5 minutes with normal saline. Following lavage with normal saline, the cyst will be infused with an admixture of (3mg/ml paclitaxel + 19mg/ml gemcitabine).
62817896|NCT01511406|EXPERIMENTAL|cognitive behavioral therapy|Cognitive behavioral therapy up to 26 sessions
62817897|NCT03474588|ACTIVE_COMPARATOR|Standard Treatment (ST)|"This is the same as the treatment normally received at this clinic. This will be tailored to participants' needs, but generally includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as:~* Teaching about the treatment program~* Teaching important ideas about recovery~* Increasing knowledge about specific problems about addiction~* Demonstrating new ways of coping with skills designed to fit each participant"
62817898|NCT03474588|EXPERIMENTAL|2. Standard treatment (ST) PLUS web-based CBT4CBT|"This is the same as the treatment normally received at this clinic. This will be tailored to participants' needs, but generally includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as:~* Teaching about the treatment program~* Teaching important ideas about recovery~* Increasing knowledge about specific problems about addiction~* Demonstrating new ways of coping with skills designed to fit each participant PLUS~Participants will have access the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on."
62817899|NCT05472090|EXPERIMENTAL|TNX-102 SL Tablet, 5.6 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
62817900|NCT05472090|PLACEBO_COMPARATOR|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
62817901|NCT03982355||Breast Cancer|Anonymised MRI scans (pre-therapy) of locally advanced breast cancer sufferers.
62817902|NCT03982355||Rectal Cancer|Anonymised MRI scans (pre-therapy) of locally advanced rectal cancer sufferers.
62817903|NCT01082770|ACTIVE_COMPARATOR|TEGO|TEGO needle free access devices will be used in patients randomised to this arm
62817904|NCT01082770|PLACEBO_COMPARATOR|Control|Patients will continue to receive current standard of practice, ie a 'bung' cap at the end of the hemodialysis line
62817905|NCT06483230|EXPERIMENTAL|Hemi-spatial Neglect|Individuals with stroke with hemi-spatial neglect as identified on the star cancellation and line bisection tests.
62817906|NCT06483230|ACTIVE_COMPARATOR|No hemi-spatial neglect|Individuals with stroke without hemi-spatial neglect as identified on the star cancellation and line bisection tests.
62817907|NCT02296164||MF-CTCL Patients receiving Valchlor|Patients will undergo clinical assessments and receive standard medical care, as determined by the patients' physician, in the real world setting. With the exception of protocol-required patient completed questionnaires for symptoms and Quality Of Life.
62817908|NCT05926817|NO_INTERVENTION|Control group|Postoperative standard analgesia was administered to patients in the control group.
62817909|NCT05926817|PLACEBO_COMPARATOR|Placebo-VR group|Patients in the Placebo-VR group watched a 10-minute relaxation-based 2D film through VR headsets along with receiving conventional analgesia.
62817910|NCT05926817|EXPERIMENTAL|QTC-VR group|Patients in the QTC-VR group engaged in 10-minute interactive pain relief 3D VR programs while wearing VR headsets along with receiving conventional analgesia.
62817911|NCT04846829|PLACEBO_COMPARATOR|Placebo infusion|Placebo comparator to active study drug
62817912|NCT04846829|ACTIVE_COMPARATOR|intravenous citalopram hydrochloride (CIT)|A single 40 mg dose of CIT diluted in 60 cc normal saline will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
62817913|NCT04846829|EXPERIMENTAL|intermittent Theta Burst Stimulation|"* 10 sessions of treatment with cTBS to right DLPFC~* TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~* iTBS paradigm of a 2 s train repeated every 10 seconds"
62817914|NCT04846829|EXPERIMENTAL|continuous Theta Burst Stimulation|"* 10 sessions of treatment with iTBS to left or cTBS to right DLPFC~* TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~* 1800 pulses of cTBS will be delivered"
62817915|NCT03796559|EXPERIMENTAL|Magseed marker|Magseed marker deployed percutaneously, prior to patient undergoing neo-adjuvant chemotherapy (NAC), under ultrasound guidance to mark a lymph node intended for selective surgical removal post NAC.
62817916|NCT05502939|EXPERIMENTAL|Music|"57 Hispanic participants, aged 6-8~Participants will be enrolled in a music training program led by professional trained music instructor of the Colburn School of Music. The music curriculum follows the standard Suzuki training method. Students attend the program 3 days per week, 2 weekday afternoons and one weekend morning. Each session lasts approximately 1 hour long. Each student will be given a string instrument to take home (often a viola or a violin). Each learning day focuses on development of musical elements including rhythm and meter, form, pitch, and performance. Students will take part in annual performances intended to give them a motivational goal, sense of mastery and to share their accomplishments with their peers, family, and community."
62817917|NCT05502939|ACTIVE_COMPARATOR|After School Enrichment Group|"57 participants, aged 6-8~Participants will be enrolled in an after school program led by instructors and will include visual arts, theater, and general cultural studies. Students attend the program 3 days per week in the afternoon for 1 hour long lessons. Students will take part in an end of the year celebration to share their work with family and community members. Duration and frequency of the after-school program will be matched to the music intervention."
62817918|NCT04101955|OTHER|Incisionless Threaded Carpal Tunnel|
62817919|NCT04101955|OTHER|Standard Mini-Open Carpal Tunnel|
62431993|NCT00069407|ACTIVE_COMPARATOR|BF|Bifrontal electroconvulsive therapy
62817920|NCT06170385|EXPERIMENTAL|Intervention|"Children will participate in six PT sessions over the course of 12 weeks and will be provided with the option to choose their preferred mode of the delivery (i.e., 1:1 in-person, 1:1 virtual, group virtual, or a combination of all). The program will be tailored to the child's age, presenting symptoms, and preferred activities.~Children and parents/ caregivers will be encouraged to carry out additional tailored PT sessions through their preferred mode of delivery and to access the exercise videos provided in the additional resources section of the HEAL-ME platform."
62038761|NCT05909332|ACTIVE_COMPARATOR|Arm-B|Chemotherapy: ddEC-P (dose-dense Epirubicin and Cyclophosphamide followed by Nab-paclitaxel). Epirubicin (75-100 mg/m2) iv D1 + Cyclophosphamide (600 mg/m2) iv D1 repeated administration of Q2W for a total of 4 doses, followed by Nab-paclitaxel (125 mg/m2) once weekly (QW) for 4 weeks.
62817921|NCT06702722|EXPERIMENTAL|Enhanced Friendship Bench|Friendship Bench problem-solving therapy, social support sessions and home visits during the 3rd trimester as well as postpartum.
62241563|NCT03661125|EXPERIMENTAL|Placebo or Saracatinib (Cross-over)|The groups will now cross over i.e. the group that had the study drug in the first arm will get the placebo in the second arm and the group that had the placebo in the first arm will have the study drug in the second arm.
62241564|NCT03513510|EXPERIMENTAL|iChoose|6 biweekly family sessions, 6 biweekly telephone support calls to parents, 6 biweekly newsletters for children, and 3 supervised exercise sessions per week/3 months; delivers intervention to parents and children only
62431994|NCT03526952|EXPERIMENTAL|Intervention Group|Couples in this group will receive the Internet-Delivered Intervention for Sexual Re-Adjustment
62431995|NCT03526952|ACTIVE_COMPARATOR|Educational Comparison Group|Couples in this group will receive only written educational material about sexuality and intimacy with an ostomy.
62817922|NCT06702722|ACTIVE_COMPARATOR|Enhanced usual care|Continue with usual outpatient care, enhanced to provide a mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral for further follow-up at a mental health clinic or psychiatric unit.
62598966|NCT06624241|EXPERIMENTAL|Lipo-Curcumin gel + SRP|After SRP the pocket defect will be filled with a Lipo-Curcumin gel and sealed with cyanoacrylate.
62598967|NCT06624241|ACTIVE_COMPARATOR|Lipo gel + SRP|After SRP the pocket defect will be filled with a Lipo gel and sealed with cyanoacrylate
62598968|NCT06624241|ACTIVE_COMPARATOR|Discharged Gel + SRP|After SRP the pocket defect will be filled with a discharged gel and sealed with cyanoacrylate
62431996|NCT02545010|EXPERIMENTAL|LDWART + paclitaxel|All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices. Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.
62431997|NCT06354712|OTHER|Control arm|Standard Care
62431998|NCT06354712|ACTIVE_COMPARATOR|Interventional arm|Standard Care plus NAC
62817923|NCT06585241|EXPERIMENTAL|mRNA-1273 Variant-containing Formulation|Participants will receive an intramuscular (IM) injection of a mRNA-1273 variant-containing formulation.
62817924|NCT06612320||Acceptance|Women who accept to participate to a Randomized Controlled Trial (RCT)
62241565|NCT04226833|EXPERIMENTAL|Mild|Participants with mild hepatic impairment will receive 1x100 milligram (mg) F06 (entrectinib) capsule administered orally with approximately 240 milliliter (mL) water within 30 minutes after consumption of a standardized meal.
62431999|NCT02748538||Face Down|To posture in the face down position for the first 24 hours following surgery.
62432000|NCT02748538||Position to Support the Break|The head is positioned so that the retinal breaks (which caused the retinal detachment) are positioned at the highest point of the eye and well supported by the intra-ocular gas bubble left within the eye at the completion of surgery.
62432001|NCT02104128|EXPERIMENTAL|Depressed patient given bupropion|All depressed patients will be given open label bupropion
62432002|NCT02104128|NO_INTERVENTION|Control pts given no intervention|Control participants will be assessed at the same time points as the depressed group, but will be given no drug
62432003|NCT02414425|EXPERIMENTAL|Rectal Injection of Botulinum toxin A|"Botulinum toxin A will be injected during rectoscopy for patient with rectal incontinence.~Anorectal manometry will be performed for evaluation of efficacy of experimental drug"
62432004|NCT02414425|PLACEBO_COMPARATOR|Rectal Injection of physiologic serum|"physiologic serum will be injected during rectoscopy for patient with rectal incontinence.~Anorectal manometry will be performed for evaluation of efficacy of placebo"
62432005|NCT00619086|PLACEBO_COMPARATOR|A, 1|Placebo 45 minutes prior to surgery
62598969|NCT06624241|ACTIVE_COMPARATOR|SRP alone|SRP alone will be performed.
62598970|NCT04794205|EXPERIMENTAL|Low Dose BCP|Subjects will receive low dose of BCP.
62598971|NCT04794205|EXPERIMENTAL|Medium Dose BCP|Subjects will receive a medium dose of BCP
62598972|NCT04794205|EXPERIMENTAL|High Dose BCP|Subjects will receive high dose of BCP.
62598973|NCT04794205|EXPERIMENTAL|Placebo|Subjects will receive placebo drug.
62598974|NCT06612463|EXPERIMENTAL|Caffeine|In the caffeine trial, participants ingested a capsule containing 3 mg/kg caffeine (Wako Pure Chemical Industries, Ltd., Osaka, Japan) 60 min prior to the match.
62598975|NCT06612463|PLACEBO_COMPARATOR|Placebo|In the placebo trial, participants ingested a capsule containing starch (Chung-Yu Biotech Co LTD, Taichung, Taiwan) at the same time point.
62598976|NCT05389657|EXPERIMENTAL|Web-based training|Web-based training will provide online training primarily focused on family-based treatment and appropriate adaptations to the treatment model.
62817925|NCT06612320||Refusal|Women who refuse to participate to a Randomized Controlled Trial (RCT)
62817926|NCT03239626|EXPERIMENTAL|POHIM-RT|adjuvant hypofractionated IMRT for cervical cancer patients
62817927|NCT06587776||Normal axial length grooup|At the screening stage, the axial length of the subjects was measured by IOL master 700. If the other conditions were met, the subjects would be included in this group If the axial length is between 23mm and 24mm.
62817928|NCT06587776||Long axial group|At the screening stage, the axial length of the subjects was measured by IOL master 700. If the other conditions were met, the subjects would be included in this group if the axial length is greater than 24mm.
62817929|NCT04361396|OTHER|Collection of samples|Only in enrolled patient : different samples will be taken at different times of the surgery (3 samples of pneumoperitoneum, 1 sample of peritoneal effusion or peritoneal lavage fluid and 1 sample of bile, in case of cholecystectomy).
62817930|NCT04277975|ACTIVE_COMPARATOR|A: liberal post-discharge opioid prescribing|Standardized postoperative instructions on non-opioid pain control + liberal opioid prescription provided prior to surgery (standard prescription for opioid prescribed prior to surgery)
62817931|NCT04277975|EXPERIMENTAL|B: restricted post-discharge opioid prescribing|Standardized postoperative instructions on non-opioid pain control + opioid prescribed only 'as needed' after discharge
62817932|NCT05526716|EXPERIMENTAL|Concomitant group (V116 + QIV followed by placebo)|Participants will receive a single 0.5 mL intramuscular (IM) injection of V116 and a single 0.5 mL IM injection of QIV on Day 1 and a single 0.5 mL injection of placebo on Day 30
62817933|NCT05526716|EXPERIMENTAL|Sequential group (placebo + QIV followed by V116)|Participants will receive a single 0.5 mL IM injection of QIV and a single 0.5 mL IM injection of placebo on Day 1 and a single 0.5 mL injection of V116 on Day 30
62241566|NCT04226833|EXPERIMENTAL|Moderate|Participants with moderate hepatic impairment will receive 1x100 mg F06 (entrectinib) capsule administered orally with approximately 240 mL water within 30 minutes after consumption of a standardized meal.
62432006|NCT00619086|ACTIVE_COMPARATOR|A, 2|8 mg Dexamethasone 45 minutes prior to surgery
62432007|NCT02924103|ACTIVE_COMPARATOR|Right side|"All included participants serve as their own control. A bacterial swab (Eswab 481CE, Copan Diagnostics, Italy), will be introduced to both sides of the nose (to the middle meatus); on the RIGHT side by using the Contamination free bacterial swab introduction device.~The Contamination free bacterial swab introduction device is a prototype developed for clinical testing."
62432008|NCT02924103|ACTIVE_COMPARATOR|Left side|All included participants serve as their own control. A bacterial swab (Eswab 481CE, Copan Diagnostics, Italy) will be introduced to both sides of the nose (to the middle meatus); on the LEFT side using the present day clinical procedure (visually guided introduction).
62432009|NCT03125824|OTHER|Tattoos previously treated in Soliton 2016-001 trial|Identical tattoos treated by Laser + AWD in Soliton's previous trial
62598977|NCT05389657|ACTIVE_COMPARATOR|Live training|Live training will include two days of expert-led live training (via zoom). The content of the training will be similar to that provided in web-based training, primarily focused on family-based treatment and appropriate adaptations to the treatment model.
62432010|NCT04343911|NO_INTERVENTION|conventional positioning|positioning with shoulder braces
62598978|NCT05248295|EXPERIMENTAL|Intervention|All participants will repeat sentences under four speech conditions, in a 2x2 design
62432011|NCT04343911|ACTIVE_COMPARATOR|positioning on Pink Pad ®|
62735706|NCT01453452|EXPERIMENTAL|Exercise and Lifestyle counseling|Patients will receive behavioral dietary intervention \& counseling intervention by phone, exercise intervention at Curves(R) facility, and take a quality-of-life assessment online.
62817934|NCT06706349|EXPERIMENTAL|Managed adapted physical activity|Participants will receive 3 weekly sessions of supervised adapted physical activity (APA) starting from Visit 3.
62241567|NCT04226833|EXPERIMENTAL|Severe|Participants with severe hepatic impairment will receive 1x100 mg F06 (entrectinib) capsule administered orally with approximately 240 mL water within 30 minutes after consumption of a standardized meal.
62735707|NCT03640507|ACTIVE_COMPARATOR|Chlorhexidine-alcohol|Subjects will receive vaginal preparation with chlorhexidine-alcohol.
62735708|NCT03640507|ACTIVE_COMPARATOR|Povidine-iodine|Subjects will receive vaginal preparation with povidine-iodine.
62735709|NCT03640507|PLACEBO_COMPARATOR|Saline|Subjects will receive vaginal preparation with sterile saline.
62735710|NCT02509468|NO_INTERVENTION|Observational|"Patients will first be included in an observational period, then, at a randomized time different from one to another, will all receive the experimental treatment (i.e. sirolimus).~This design has been defined a the randomized placebo-phase design (Feldman et al. J Clin Epidemiol. 2001 Jun;54(6):550-7)"
62735711|NCT02509468|EXPERIMENTAL|Experimental|At a randomized date, patients will start treatment with sirolimus (beginning dose: 0.08mg/kg/day)
62735712|NCT05939245|EXPERIMENTAL|Administration of continuous furosemide intravenous|
62735713|NCT05939245|PLACEBO_COMPARATOR|Administration of continuous placebo intravenous|
62735714|NCT03993886|OTHER|Arm 1|Adult (≥ 18 years of age) ambulatory patients diagnosed with heart failure and/or undergoing cardiac management.
62735715|NCT03993886|OTHER|Arm 2|Adult (≥ 18 years of age) patients undergoing chronic hemodialysis.
62735716|NCT03993886|OTHER|Arm 3|Adult (≥ 18 years of age) patients (i) implanted with the CardioMEMS HF device and (ii) diagnosed with heart failure and/or undergoing cardiac management.
62735717|NCT03993886|OTHER|Arm 4|Adult (≥ 18 years of age) patients diagnosed with heart failure and/or undergoing cardiac management.
62735718|NCT03489772|EXPERIMENTAL|1 mg ITI-214|Single dose
62735719|NCT03489772|EXPERIMENTAL|10 mg ITI-214|Single dose
62817935|NCT06706349|PLACEBO_COMPARATOR|Autonomous adapted physical activity|Participants in this arm will receive a leaflet summarizing WHO recommendations on physical activity at the start of the study.
62241568|NCT04226833|EXPERIMENTAL|Normal|Participants with normal hepatic function will receive 1x100 mg F06 (entrectinib) capsule administered orally with approximately 240 mL water within 30 minutes after consumption of a standardized meal.
62241569|NCT03475810|EXPERIMENTAL|VR GROUP|Patients watches 3D documentary videos on virtual reality glasses
62241570|NCT03475810|ACTIVE_COMPARATOR|midazolam|Patients do not watch virtual reality videos but will be administered iv sedative drugs before spinal attempt.
62817936|NCT05604534||Healthy Adult|Adults 18 years of age or older, in good general health
62817937|NCT04516447|EXPERIMENTAL|Combination with carboplatin|combined with azenosertib
62817938|NCT04516447|EXPERIMENTAL|Combination with PLD|combined with azenosertib
62817939|NCT04516447|EXPERIMENTAL|Combination with paclitaxel|combined with azenosertib
62817940|NCT04516447|EXPERIMENTAL|Combination with gemcitabine|combined with azenosertib
62817941|NCT04516447|EXPERIMENTAL|Combination with bevacizumab|combined with azenosertib
62817942|NCT05375539|EXPERIMENTAL|AGN-CognI.Q|Dose level +1 (800 mg, 4 CognI.Q capsules, Fast at least 2 h before dose and 1 h after) Dose level +2 (1,200 mg, 6 CognI.Q capsules, Fast at least 2 h before dose and 1 h after) Dose level +3 (1,600 mg, 8 CognI.Q capsules, Fast at least 2 h before dose and 1 h after)
62241571|NCT00234494|EXPERIMENTAL|Single Group Assignment|Cisplatin + Gemcitabine + Bevacizumab
62241572|NCT03234062|EXPERIMENTAL|25%Cho, 50%Cho, 100%Cho|Diets containing 137.5mg (25% Cho diet), 275mg (50% Cho diet), and 550mg (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
62432012|NCT02726737|EXPERIMENTAL|sodium bicarbonate|0.7 mL of 8.4% sodium bicarbonate \& 0.3 mL of 2% lidocaine with 1:100,000 epinephrine
62432013|NCT02726737|ACTIVE_COMPARATOR|Non-sodium bicarbonate|Sterile distilled water \& 0.3 mL of 2% lidocaine with 1:100,000 epinephrine
62432014|NCT05323500|EXPERIMENTAL|Senobi breathing group|The study participants will be screened first, then trained to perform SBE (1-minute maneuver). The participants will also guided to repeat this procedure 3 times in one minute with resting period of 10 seconds. They will perform it 3 times a day for 3 months. Assessments will be taken at Baseline \& after 3 months.
62432015|NCT05139654||Shoulder pain climbers group|Subjects with shoulder pain will be included to perform scaption and pull-up, and assess shoulder kinematics and muscle activation at the same time.
62432016|NCT05139654||Healthy climbers group|Healthy subjects will be included to compare the differences in shoulder kinematics and muscle activation between healthy subjects and subjects with shoulder pain. Subjects in this group will received the same assessments as the shoulder pain climbers group.
62432017|NCT05882981||Study group|22 young adults aged 17-26 years with high femoral anteversion.
62817943|NCT06062420|EXPERIMENTAL|Dostarlimab Monotherapy|
62817944|NCT06062420|EXPERIMENTAL|Sub study 1: Dostarlimab and Belrestotug|
62817945|NCT06062420|EXPERIMENTAL|Sub study 2: Dostarlimab and nelistotug|
62817946|NCT06062420|EXPERIMENTAL|Sub study 3: Dosarlimab and Belrestotug and nelistotug|
62241573|NCT03234062|EXPERIMENTAL|25% Cho, 100% Cho, 50% Cho|Diets containing 137.5mg (25% Cho diet) , 550mg (100% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
62241574|NCT03234062|EXPERIMENTAL|50% Cho, 25% Cho, 100% Cho|Diets containing 275mg (50% Cho diet), 137.5mg (25% Cho diet), and 550mg Cho (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
62241575|NCT03234062|EXPERIMENTAL|50% Cho, 100% Cho, 25% Cho|Diets containing 275mg (50% Cho diet), 550mg (100% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
62241576|NCT03234062|EXPERIMENTAL|100% Cho, 25% Cho, 50% Cho|Diets containing 550mg (100% Cho diet), 137.5mg (25% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
62241577|NCT03234062|EXPERIMENTAL|100% Cho, 50% Cho, 25% Cho|Diets containing 550mg (100% Cho diet), 275mg (50% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
62241578|NCT00720655|EXPERIMENTAL|Fatty fish|
62432018|NCT05882981||Control group|22 young adults aged 17-26 years with normal femoral anteversion
62432019|NCT05758935|EXPERIMENTAL|Mobile application|A six weeks, rule-based chatbot intervention
62432020|NCT01153399||1|Patients with Non Small Cell Lung Cancer, visiting hospital oncology clinics
62432021|NCT04275661|PLACEBO_COMPARATOR|Group (C) (control group)|Patient will receive 10 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5 and 10 ml at level of T7.
62432022|NCT04275661|EXPERIMENTAL|Group (K) (Ketamine group)|Patient will receive 10 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5 and 10 ml at level of T7+ 1 mg / kg ketamine at each level with total dose 2mg/kg
62432023|NCT04275661|EXPERIMENTAL|Group (M) (magnesium sulphate group)|Patient will receive 10 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5 and 10 ml at level of T7+ 1 mg / kg MgSo4 at each level with total dose 2mg/kg
62817947|NCT06062420|EXPERIMENTAL|Sub study 4: Dostarlimab and GSK4381562|
62817948|NCT05391503|ACTIVE_COMPARATOR|Active treatment|Active light therapy
62817949|NCT05391503|PLACEBO_COMPARATOR|Control treatment|Placebo light therapy
62817950|NCT02379429||1/Participants|Adults with biopsy-proven or suspected urothelial cancer who require diagnostic or therapeutic intervention
62817951|NCT02379429||2/Healthy Volunteers|Healthy volunteers from whom blood, saliva and urine samples are easily obtainable.
62817952|NCT02884869|EXPERIMENTAL|Intubating laryngeal Mask|Intubating laryngeal Mask
62817953|NCT02884869|ACTIVE_COMPARATOR|Direct laryngoscopy|Intubating laryngeal Mask
62598979|NCT05399017|EXPERIMENTAL|EZVent|"* Subjects who are involved in the clinical trial are already mechanically ventilated on traditional standard commercial ventilator. Baseline measurements (T0) will be taken from each patient before being transferred to EZVent ventilator. The following measurements will be taken: Vital Signs and hemodynamics (heart rate, blood pressure, temperature, Respiratory rate), Chest X-ray, Arterial blood gases as well as the ventilator mode parameters (dependent on each mode) and lung mechanics parameters (Peak, Plateau, Mean Airway Pressure, Tidal Volume, Airway Resistance and Static Compliance).~* After taking the baseline measurements, subjects will be disconnected from their traditional standard ventilator and immediately connected to EZVent using the same previous original setting.~* After 60 \& 120 minutes of ventilation on EZVent (T1\&T2) respectively, the same measurement will be taken (Vital signs and Hemodynamics will be continuously monitored and recorded every five minutes)."
62598980|NCT03023111|ACTIVE_COMPARATOR|Sbv|"Meglumine antimoniate (Glucantime):~Dosage: 20 mg / kg / day, intravenously, during 20 days."
62038762|NCT03215797|ACTIVE_COMPARATOR|phenylephrine and norepinephrine|Phenylephrine 100ug/ml and Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of perioperative hypotension.
62432024|NCT01335152|EXPERIMENTAL|Web-based workbook|Participants will use one chapter of the web-based workbook each week for 10 weeks. The workbook consists of stress management education, cognitive behavioral interventions and relaxation training exercises.
62598981|NCT03023111|EXPERIMENTAL|Miltefosine plus placebo|Miltefosine (28 days / 2.5mg / Kg / day at a maximum dose of 150mg / day orally) + Topical placebo (gel cream, 2 times a day for 28 days)
62598982|NCT03023111|EXPERIMENTAL|Miltefosine plus GM-CSF|Miltefosine (28 days / 2.5mg / kg / day at a maximum dose of 150mg / day orally) + Topical GM-CSF (0.01% gel cream, 2 times a day for 28 days)
62241579|NCT00720655|EXPERIMENTAL|Lean Fish|
62241580|NCT00720655|PLACEBO_COMPARATOR|Control diet|
62432025|NCT01335152|NO_INTERVENTION|Waitlist control group|Participants will no intervention for the first 10 weeks of the study and then will receive the web-based intervention.
62432026|NCT01230385|EXPERIMENTAL|Lersivirine 500 mg QD fasted (wet granulated tablet)|
62432027|NCT01230385|EXPERIMENTAL|Lersivirine 500 mg QD fed (wet granulated tablet)|
62432028|NCT01230385|EXPERIMENTAL|Lersivirine 750 mg QD fasted (wet granulated tablet)|
62432029|NCT01230385|EXPERIMENTAL|Lersivirine 750 mg QD fed (wet granulated tablet)|
62432030|NCT01230385|ACTIVE_COMPARATOR|Lersivirine 500 mg QD fasted (dry granulated tablet)|
62432031|NCT05185687|EXPERIMENTAL|First Come, First Served|"Respondents will view the following description: The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:~Below this statement, respondents will view the First Come, First Served plan description."
62432032|NCT05185687|EXPERIMENTAL|Random|"Respondents will view the following description: The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:~Below this statement, respondents will view the Random plan description."
62598983|NCT05283382|EXPERIMENTAL|Cannabidiol|600 mg Cannabidiol Isolate Gel Capsules / participant. One-time dose.
62598984|NCT05283382|PLACEBO_COMPARATOR|Placebo|Same number of placebo capsules / participant. One-time dose.
62598985|NCT05051605||Vaccinated group|Fifty living donor liver transplantation recipients on maintenance immunosuppressive regimen who would receive COVID-19 vaccine at least 3 months postoperatively.
62598986|NCT05501015|NO_INTERVENTION|Group A - Standard Dysphagia Treatment|Group A will serve as the control group. This group will receive oral hygiene followed by traditional dysphagia exercises, including effortful swallow, Masako Maneuver, and Tongue Press.
62735720|NCT03489772|PLACEBO_COMPARATOR|Placebo|Single dose
62038763|NCT03215797|OTHER|Norepinephrine and phenylephrine|Phenylephrine 100ug/ml and Norepinephrine 5ug/ml IV infusion in postoperative time in case of hypotension
62038764|NCT02498483|EXPERIMENTAL|Acetaminophen Arm|Acetaminophen 15 mg/kg PO solution administered via syringe one time immediately post circumcision.
62038765|NCT02498483|NO_INTERVENTION|Non-treatment Arm|Routine circumcision without acetaminophen.
62038766|NCT06331884|PLACEBO_COMPARATOR|Placebo|
62038767|NCT06331884|ACTIVE_COMPARATOR|AK1967 3 mg/kg/body weight|
62038768|NCT06331884|ACTIVE_COMPARATOR|AK1967 6 mg/kg/body weight|
62038769|NCT06331884|ACTIVE_COMPARATOR|AK1967 12 mg/kg/body weight|
62038770|NCT04936152|ACTIVE_COMPARATOR|mime therapy using tablet PC mirror application|these individuals will receive mime therapy using tablet PC mirror application
62241581|NCT04267718|EXPERIMENTAL|Patients with the Padua and IMPROVE Bleeding scores|A number of centres will be randomized to systematically evaluate all eligible patients with the Padua and IMPROVE Bleeding scores within 48 h after hospitalization.
62241582|NCT04267718|NO_INTERVENTION|Patients will be evaluated according to clinical judgment only|A number of centres will be randomized to the Control arm of the study, in which patients will be evaluated for their thrombotic and hemorrhagic risk according to clinical judgment only.
62817954|NCT06163963|EXPERIMENTAL|Sentinel Lymph Node Mapping With Double Tracer in Endometrium Cancer (Single Arm)|Sentinel Lymph Node Mapping With Double Tracer and Double Injection Sites in Early-Stage Endometrium Cancer (Single Arm)
62817955|NCT05407441|EXPERIMENTAL|Phase I a: DOSE ESCALATION (STRATUM A, ATRT and primary CNS malignant tumor, INI/SMARCA4-deficient)|"Part 1 will be two concurrent rolling six phase 1 studies starting at a different tazemetostat dose for each stratum), with one dose escalation and one dose de-escalation planned. All subjects will receive the same nivolumab and ipilimumab doses and dosing schedule"
62817956|NCT05407441|EXPERIMENTAL|Phase I b: DOSE ESCALATION (STRATUM B, NON-ATRT, NON-CNS)|"Part 1 will be two concurrent rolling six phase 1 studies starting at a different tazemetostat dose for each stratum), with one dose escalation and one dose de-escalation planned. All subjects will receive the same nivolumab and ipilimumab doses and dosing schedule"
62817957|NCT05407441|EXPERIMENTAL|EXP A1: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA A1)|"Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2.~Part 2 will consist of 3 substrata per stratum based on their disease status"
62817958|NCT05407441|EXPERIMENTAL|EXP A2: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA A2)|"Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2.~Part 2 will consist of 3 substrata per stratum based on their disease status"
62432033|NCT05185687|EXPERIMENTAL|Disadvantaged Priority & Random|"Respondents will view the following description: The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:~Below this statement, respondents will view the Disadvantaged Priority \& Random plan description."
62432034|NCT01572831|NO_INTERVENTION|standard care|Abx will be determined by the managing physician
62241583|NCT01348386|EXPERIMENTAL|KOH 10%|Treatment consists of the application of topical 10% KOH in an aqueous solution.
62432035|NCT01572831|EXPERIMENTAL|experimental arm|Abx determined by normalization of PCT and basic clinical parameters
62432036|NCT01604382|EXPERIMENTAL|treatment|Receives General Anesthesia as described above
62432037|NCT01604382|PLACEBO_COMPARATOR|Placebo|Patients receives neuraxial anesthesia as described above
62432038|NCT02133352|EXPERIMENTAL|Ranolazine|Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.
62432039|NCT03236493|EXPERIMENTAL|PF-06700841|Multiple ascending doses of PF-06700841
62432040|NCT03236493|PLACEBO_COMPARATOR|Placebo|Multiple ascending doses of Placebo
62432041|NCT00382291|EXPERIMENTAL|Regular Titration|Regular titration of Sertraline plus cognitive behavioral therapy. The titration schedule used a flexible upward titration from 25 mg/day to 200 mg/day over 9 weeks unless higher doses were not tolerated, after which the dosage was adjusted as a function of tolerability. If tolerated, maximum dose could be achieved in 5 weeks.
62735721|NCT05754398|OTHER|Single group will receive the nurse-led intervention|A single group of community-dwelling older persons will receive a nurse-led intervention after an initial screening and eligibility checks.
62241584|NCT01348386|EXPERIMENTAL|KOH 15%|Treatment consists of the application of topical 15% KOH in an aqueous solution
62241585|NCT01348386|PLACEBO_COMPARATOR|PLACEBO|100 milliliters of saline solution
62241586|NCT04332601|EXPERIMENTAL|ENERGY intervention|"ENERGY Intervention:~* 14 sessions of 1h CBT intervention (standardized fatigue treatment comprising six modules over 14 individual therapy sessions)~* 1 session per week~* With a psychologist (different to the psychologist who will perform the assessments)~* Individual sessions~* and Treatment as usual"
62241587|NCT04332601|OTHER|Treatment as usual (TAU)|"* Comparison group~* TAU defined by antipsychotic medication coupled with day hospital care"
62241588|NCT01284062|EXPERIMENTAL|Arm 1|200 mg PF-05230917, Anrukinzumab active dose level
62241589|NCT01284062|EXPERIMENTAL|Arm 2|400 mg PF-05230917, Anrukinzumab active dose level
62241590|NCT01284062|EXPERIMENTAL|Arm 3|600 mg PF-05230917, Anrukinzumab active dose level
62735722|NCT01506635|PLACEBO_COMPARATOR|Control group|included patients who received artificial tear twice a day as control group.
62735723|NCT01506635|EXPERIMENTAL|Timolol group|included the patients with myopic regression who received timolol 0.5% eye drop twice a day
62735724|NCT02755662|ACTIVE_COMPARATOR|Narval O.R.M CC™|First mandibular retention device : Narval O.R.M CC™
62735725|NCT02755662|ACTIVE_COMPARATOR|Narval O.R.M™ trad|Second mandibular retention device : Narval O.R.M TRAD™
62735726|NCT03076489|EXPERIMENTAL|high consumption habits|high consumption habits of fatty and sugary foods
62241591|NCT01284062|PLACEBO_COMPARATOR|Arm 4|Matching placebo - administered at matching dose level 200 mg, 400 mg or 600 mg.
62241592|NCT00418951|EXPERIMENTAL|Liposomal amphotericin B: 3 mg/kg|3 mg/kg intravenously (IV) three times per week
62735727|NCT03076489|EXPERIMENTAL|low consumption habits|low consumption habits of fatty and sugary foods
62735728|NCT00690690|EXPERIMENTAL|video|
62735729|NCT00690690|ACTIVE_COMPARATOR|HCT|Offer of HIV counseling and testing
62735730|NCT03171584|EXPERIMENTAL|Terbinafine group|Arm (1) will receive Terbinafine (250mg/day for 6 weeks).
62817959|NCT05407441|EXPERIMENTAL|EXP A3: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA A3)|"Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2.~Part 2 will consist of 3 substrata per stratum based on their disease status"
62432042|NCT00382291|PLACEBO_COMPARATOR|Placebo|Placebo plus cognitive behavioral therapy
62432043|NCT00382291|EXPERIMENTAL|Slow Titration|Slow titration of Sertraline plus cognitive behavior therapy. The titration schedule utilized a slower titration schedule relative to the RegSert arm. Unless unable to tolerate higher doses, children remained on 25mg/day for the first two weeks, 50mg/day from weeks 3-4, 75mg/day for weeks 5-6, 100mg/day for week 7, 150mg/day for week 8, and 200mg/day for week 9 until the end of the study.
62817960|NCT05407441|EXPERIMENTAL|EXP B1: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA B1)|"Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2.~Part 2 will consist of 3 substrata per stratum based on their disease status"
62817961|NCT05407441|EXPERIMENTAL|EXP B2: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA B2)|"Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2.~Part 2 will consist of 3 substrata per stratum based on their disease status"
62817962|NCT05407441|EXPERIMENTAL|EXP B3: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA B3)|"Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2.~Part 2 will consist of 3 substrata per stratum based on their disease status"
62817963|NCT06533969|EXPERIMENTAL|Brain Computer Interface-Epidural Spinal Cord Stimulation (BCI-ESCS)|"Participants in this group will receive a onetime surgery to have the leads implanted temporarily for ESCS which will be triggered through the BCI system. The BCI-ESCS arms will include Upper limb (UL) therapist-guided training, with triggered through a BCI system during task practice. The BCI system will decode motor intention of Upper limb (UL) tasks from cortical signals recorded using EEG system or using their intracranially implanted devices (e.g., ECoG). Participants will perform UL daily activities (e.g., grasping, reaching) tailored to participants deficits. The therapist will facilitate task practice and progress therapy within and between session.~Subjects will be involved in the intervention for up to 2 months."
62817964|NCT04977375|EXPERIMENTAL|Pembrolizumab with stereotactic radiation therapy and surgical resection|
62817965|NCT06394024||POSTDURAL PUNCTURE HEADHECHE|We don't use drug
62817966|NCT01894139|EXPERIMENTAL|High-protein/Low-GI Diet|High-protein (25-28 E%), especially marine- and dairy-protein (8-10 E%) and low-GI (GI\<55) ad libitum Diet in accordance with the principles of palatability and sustainability of the New Nordic Diet.
62817967|NCT01894139|ACTIVE_COMPARATOR|Low-protein/High-GI Diet|Ad libitum diet based on the Danish National Guidelines (NNR) (protein 10-20 E%; no information on restricting glycaemic load (GI \~ 60)) and in accordance with the principles of palatability and sustainability of the New Nordic Diet.
62038771|NCT04936152|EXPERIMENTAL|the control intervention including the mime therapy|these individuals will receive the control intervention including the mime therapy).
62432044|NCT01204060|ACTIVE_COMPARATOR|Nasal allergen challenge|
62038772|NCT01570829|EXPERIMENTAL|Dietressa|Tablet for oral use. 1 tablet 6 times a day. The duration of Dietressa therapy is 24 weeks.
62432045|NCT01204060|PLACEBO_COMPARATOR|Nasal placebo challenge|
62432046|NCT01119976|EXPERIMENTAL|Group A|Reduced calorie diet and exercise plan that changes with phases of the menstrual cycle
62735731|NCT03171584|EXPERIMENTAL|Fluconazole group|Arm (2) will receive Fluconazole (300mg once weekly for 3monthes).
62735732|NCT03171584|EXPERIMENTAL|Itraconazole group|Arm (3) will receive Itraconazole (400mg/day for one week per month followed by 3 free weeks ,, 2 pulses for finger nail)
62735733|NCT04796272|ACTIVE_COMPARATOR|Traditional exercise|fatigued multiple sclerosis patients with a traditional training program
62735734|NCT04796272|EXPERIMENTAL|Individual exercise|tired multiple sclerosis patients with an adapted and individualized training program
62038773|NCT01570829|PLACEBO_COMPARATOR|Placebo|Tablet for oral use. 1 tablet 6 times a day. The duration of Placebo therapy is 24 weeks.
62038774|NCT06732583|EXPERIMENTAL|Experimental vaccine group, Low dose|1 doses of Ad5-105K vaccine (0.1ml) on Day 0
62038775|NCT06732583|PLACEBO_COMPARATOR|Placebo Group, Low dose|1 doses of placebo (0.1ml) on Day 0
62038776|NCT06732583|ACTIVE_COMPARATOR|Experimental vaccine group, High dose|1 doses of Ad5-105K vaccine (0.2ml) on Day 0
62038777|NCT06732583|PLACEBO_COMPARATOR|Placebo Group, High dose|1 doses of placebo (0.2ml) on Day 0
62432047|NCT01119976|ACTIVE_COMPARATOR|Group B|Different reduced calorie diet and exercise plan based on MyPyramid.gov website
62432048|NCT03654261|EXPERIMENTAL|1-Day CBT Workshop - Immediate|Women assigned to the immediate workshop group will participate in the first of two workshops (9 weeks apart).
62432049|NCT03654261|EXPERIMENTAL|1-Day CBT Workshop - Waitlist|Women assigned to the waitlist will participate in the second of two workshops (12 weeks apart).
62432050|NCT02232451|EXPERIMENTAL|ERCP with loop tip wire|ERCP with loop tip wire is an endoscopic procedure to treat biliary disease. Wire guide cannulation with loop-tip is a new procedure to improve rate of biliary cannulation and reduce complication, as post-procedure pancreatitis.
62432051|NCT02232451|ACTIVE_COMPARATOR|ERCP for cannulation|ERCP for cannulation of CBD with traditional technique
62735735|NCT02374788|EXPERIMENTAL|Group A|Participants in the intensive intervention group (A) receive a pedometer intervention and 12 group meetings over two years' time, with the majority of meetings being held in the first 6 months. The group meetings constitutes of a 30 min walk and 60 min group consulting based on techniques for behaviour change using an interactive program with positive feed-back following their steps on a website. One occasion is taking place at a gym with instruction for a home-based strength training program. Participants receive 10 individual consultations with a diabetes specialist nurse.
62735736|NCT02374788|EXPERIMENTAL|Group B|Participants in the pedometer group (B) receive a pedometer intervention. Henceforth they are left to continue by they own for two years.
62817968|NCT04258566|EXPERIMENTAL|Suspected hepatic malignancy|Malignancy determination of new onset hepatic lesion
62038778|NCT04726020|EXPERIMENTAL|Intensive monitoring|Intensive phone monitoring of drug adverse events
62817969|NCT04104243|EXPERIMENTAL|Power-Up|Participants randomized to this arm will undergo 16 classes tailored for men, that discuss food choices, physical activity, and managing stress over 6 months, which are called the core, and 6 classes over the following 6 months, which is called the maintenance phase.
62817970|NCT04104243|NO_INTERVENTION|Standard NDPP (National Diabetes Prevention Program)|Participants randomized to this arm will undergo 16 mixed gender classes that discuss food choices, physical activity, and managing stress over 6 months which are called the core and 6 classes over the following 6 months which is called the maintenance phase.
62817971|NCT04166006|EXPERIMENTAL|Experimental|"7-14×106 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1), followed by Interleukin (IL) - 2 (IL-2), at a dose of 3 Million Units (MU), given by subcutaneous injection daily for five days (days 3-7). This constitutes a treatment cycle.~Treatment cycles are repeated every 28 days up to a maximum of six cycles."
62817972|NCT06705712|NO_INTERVENTION|Control group: Usual physical activity habits|"The participants will receive a wrist-worn activity tracker (Garmin VívoSmart 5) including clear instructions on how to use the tracker and how to connect to a software (Fitrockr). We ask the participants to wear the tracker 24/7 during the period they are trying to conceive and during the first trimester of their pregnancy if they conceive within 12 months to measure physical activity. Participants in the control group will not receive any PA feedback.~Participants are advised to maintain their usual activity habits."
62817973|NCT06705712|EXPERIMENTAL|Intervention group: Changing physical activity habits|"The participants will receive a wrist-worn activity tracker (Garmin VívoSmart 5) including clear instructions on how to use it. They will be asked to wear the tracker 24/7 during the period they are trying to conceive plus the first trimester of their pregnancy. They will receive information material on the Danish national guidelines on PA, health benefits from PA, and suggestions on how to reduce sedentary behavior and increase daily activity. Based on the current PA level, they are asked to set personal goals to meet the PA recommendations and to split up sedentary behavior. They will receive a phone call two and five weeks after they received the activity tracker, to stimulate the participant's motivation to be physically active, to set goals for maintaining or increasing PA and to facilitate a revision of the goals if needed.~The conversations will be inspired by motivational interviewing and the principles of this motivational technique."
62038779|NCT04726020|PLACEBO_COMPARATOR|Standard monitoring|Standard monitoring of drug adverse events
62038780|NCT01657058|EXPERIMENTAL|Treatment # 1|Soluble viscous fibre blend powder in hydrophobic matrix
62038781|NCT01657058|EXPERIMENTAL|Treatment # 2|Soluble viscous fibre blend in pre hydrated form
62241593|NCT00418951|EXPERIMENTAL|Liposomal amphotericin B: 9 mg/kg|9 mg/kg IV once per week
62735737|NCT02374788|NO_INTERVENTION|Group C|The control group (C) receive diabetes care as usual except for the extra measurements included in the study. Diabetes care as usual is meeting a diabetes specialist nurse and a general practitioner once a year receiving lifestyle advice and physical activity on prescription.
62038782|NCT01657058|PLACEBO_COMPARATOR|Control # 1|No soluble viscous fibre blend
62038783|NCT01657058|EXPERIMENTAL|Treatment # 3|Soluble viscous fibre blend premixed with ½ carbohydrate gel
62038784|NCT01657058|PLACEBO_COMPARATOR|Control # 2|No soluble viscous fibre blend, ½ carbohydrate jello
62241594|NCT00418951|EXPERIMENTAL|Voriconazole: 400 mg|400 mg oral twice daily day 1 followed by 200 mg twice daily
62241595|NCT05292014||Coronary Artery Disease (CAD)|
62241596|NCT02724124|EXPERIMENTAL|static stretching|group of 11 volunteers (gSS)
62241597|NCT02724124|EXPERIMENTAL|warm up -|group of 11 volunteers (gWU)
62241598|NCT02724124|EXPERIMENTAL|static stretching + warm up|(group of 11 volunteers - SS+WU)
62735738|NCT01439659|OTHER|Nutritional Counseling|For 6 months control group receives dietary counseling.
62735739|NCT01439659|EXPERIMENTAL|Daily Supplements|2 capsules (Juice Plus+) twice a day (morning and evening) plus Juice Plus+ Complete drink each evening for 6 months.
62735740|NCT02526953|EXPERIMENTAL|Paclitaxel|Patients will receive intensity-modulated radiotherapy with dose based on T stage. The planned doses to the primary tumor and pelvis are 52-58 Gy and 44 Gy, respectively.The concurrent chemotherapy regimen will consist of paclitaxel 45 mg/m2 on days 3,10,17,24,31, capecitabine 625 mg/m2 bid on treatment days and mitomycin C 10 g/m2 on day 1.
62735741|NCT02526953|ACTIVE_COMPARATOR|Standard|Patients will receive intensity-modulated radiotherapy with dose based on T stage. The planned doses to the primary tumor and pelvis are 52-58 Gy and 44 Gy, respectively.The concurrent chemotherapy regimen will consist of capecitabine 825 mg/m2 bid on treatment days and mitomycin C 12 g/m2 on day 1.
62735742|NCT05159687|ACTIVE_COMPARATOR|Atomoxetine|Atomoxetine 40 mg PO BID (morning and late afternoon) Dosing will start at 40 mg daily for 3 days1 week, followed by a forced titration to 40 mg BID, as per the FDA label for atomoxetine.
62735743|NCT05159687|PLACEBO_COMPARATOR|Placebo|Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)
62735744|NCT05818540|EXPERIMENTAL|Eclipse novel mask|Human subjects will use the Eclipse CPAP interface for 60 days for a total of 6 hours per night.
62817974|NCT04867616|EXPERIMENTAL|Dose level 1 bepranemab|Participants randomized to this arm will receive pre-specified doses (Dose level 1) of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period.
62817975|NCT04867616|EXPERIMENTAL|Dose level 2 bepranemab|Participants randomized to this arm will receive pre-specified doses (Dose level 2) of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period.
62817976|NCT04867616|PLACEBO_COMPARATOR|Placebo Arm|Participants randomized to this arm will receive Placebo to maintain the blinding during the Double-blind Treatment Period and will re-randomized during the Open-label Extension Period to receive pre-specified doses of bepranemab.
62817977|NCT06369909||AIP group|Suspected AIP, pancreatic mass patients who have not initiated steroid hormone therapy
62817978|NCT06369909||Control group|Pancreatic mass patients considering malignancy and planning to undergo EUS-FNA
62817979|NCT05370651|ACTIVE_COMPARATOR|Emsella Chair Active Treatment|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will be decreased slightly and stay unchanged for the remainder of the treatment. The treatment threshold should be increased with every treatment until the subject reaches 100%.
62817980|NCT05370651|SHAM_COMPARATOR|Emsella Chair Sham Treatment|Sham treatment subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level (\<10% power).
62817981|NCT04281485|OTHER|Cohort 1|Approximately two thirds of participants will be randomized to Cohort 1.
62817982|NCT04281485|OTHER|Cohort 2|Approximately one third of participants will be randomized to Cohort 2.
62817983|NCT03740022|ACTIVE_COMPARATOR|ACL plasty|The surgical procedure consists of a ligamentoplasty of the antero crusader ligament (ACL) with the patellar tendon according to a conventional arthroscopic procedure.
62241599|NCT02724124|EXPERIMENTAL|warm up+static stretching|(group of 11 volunteers - WU+SS)
62432052|NCT06547463||Patients with prolonged weaning|Mechanically ventilated tracheotomized patients admitted for ventilation weaning.
62817984|NCT03740022|EXPERIMENTAL|ACL + ALL plasty|The surgical procedure consists of a hamstring ligamentoplasty (DIDT) of the antero crusader ligament (ACL) and anterolateral ligament (ALL) according to a published arthroscopic procedure.
62817985|NCT04942717||Aim 1|For the survey component, recruitment will focus on patients who have not participated in a semi-structured interview as part of the Aim 1 research. For Aim 1, we will seek to recruit approximately 36 patients and 12 family members for the initial key informant interviews, 20 patients for the followup survey, and 10 for the English/backtranslated-English side-by-side comparison.
62241600|NCT02724124|OTHER|Control Group|No intervention - athletes rested
62241601|NCT02819622||Control group|control (no disease)
62241602|NCT02819622||central serous retinopathy group|Central serous retinopathy (with CSCR disease) by exam and OCT
62241603|NCT04295096|OTHER|Experimental|Healthy donor
62432053|NCT02839356|EXPERIMENTAL|Drug: epinephrine|20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
62432054|NCT02839356|PLACEBO_COMPARATOR|Drug: normal saline|20-mL irrigation with physiological saline over the entire papilla
62432055|NCT05125679|EXPERIMENTAL|Guselkumab|Participants will receive guselkumab 100 milligrams (mg) by subcutaneous injection at Weeks 0, 4, 12, 20 and 28.
62432056|NCT01279590|EXPERIMENTAL|PPD10558|Dosing will be forced-titrated as follows: 40 mg orally twice daily for 4 weeks and 80 mg orally twice daily for 8 weeks
62817986|NCT04942717||Aim 2|"Patients who provide consent during Months 9-11 (i.e., first three months of Control Period of pilot trial) will be in the control group, with follow-up for outcomes data collection occurring during Months 12-14. Patients who provide consent during Months 16-18 (after implementation of the intervention at the end of Month 15) will be in the intervention group and will be followed for three more months (Months 19-21) for outcomes data collection. We will enroll a total of 130 patients (65 in control period, 65 in intervention period) during the pilot trial across the two trial sites, SBH and Jacobi, to reflect, as much as possible, the relative patient numbers and the demographic composition of the sites. During the intervention period, family who accompany patients to clinic and are included (patient option to include one family member) in the CONVO values discussions will be approached (in person or via video conferencing platform or telephone) for participation at the clinic."
62817987|NCT04683627|EXPERIMENTAL|HP-5000 Treatment|HP-5000 Topical Patch will be evaluated against placebo topical patches.
62817988|NCT04683627|PLACEBO_COMPARATOR|Placebo Treatment|Placebo patches without diclofenac sodium will be used.
62817989|NCT05497830|NO_INTERVENTION|Standard care|Routine clinical care. Physicians will actively be asked to self-report their clinical impression of each included patient and policy will be monitored.
62817990|NCT05497830|EXPERIMENTAL|RISKINDEX|Routine clinical care. Physicians will actively be asked to self-report their clinical impression of each included patient and policy will be monitored. In the intervention group, physicians will be presented with the RISKINDEX. Subsequently, self-report will again be initiated to evaluate the physicians' response to the ML score and possible policy changes due to the intervention.
62038785|NCT04940429||Roux n Y Gastric Bypass (RYGB)|"Participants in this arm will include patients who will be having a RYGB after their assessment by their bariatric surgeon. After reviewing and signing the consent form, participants will perform the paper-based standard psychometric tests (number connection test A and B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes) at their preoperative visit.~After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes at their preoperative visit.~These will also be performed at their post operative visits 2 weeks, 3, 6 and 12 months."
62038786|NCT04940429||Sleeve gastrectomy (SG)|"Participants in this arm will include patients who will be having a SG after their assessment by their bariatric surgeon. After reviewing and signing the consent form, participants will perform the paper-based standard psychometric tests (number connection test A and B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes) at their preoperative visit.~After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes at their preoperative visit:~These will also be performed at their post operative visits 2 weeks, 3, 6 and 12 months."
62038787|NCT05874063|EXPERIMENTAL|Experimental for high-risk patients|Thromboprophylaxis in addition of the standard chemotherapy
62038788|NCT05874063|NO_INTERVENTION|Control for high-risk patients|No thromboprophylaxis in addition of the standard chemotherapy
62038789|NCT05874063|NO_INTERVENTION|Low-risk patients|No thromboprophylaxis in addition of the standard chemotherapy
62241604|NCT04032730|NO_INTERVENTION|Control|Participants assigned to the control arm will undergo treatment and care for MDR/XDR-TB as per the South African Department of Health guidelines.
62241605|NCT04032730|EXPERIMENTAL|Intervention|Participants assigned to the intervention arm will undergo extensive counselling, participants will be provided with an electronic pillbox that monitors their adherence to one of their TB and one of their ART medication. Based on the recordings provided by the wisepill device we will determine if a participant is adherent to their medication and intervene with counselling, phone calls, home visits and relevant referrals.
62241606|NCT00041951||CAE participants|Both parents and a child with CAE of families without other affected members (trios) or whole families with many members affected with epilepsy.
62241607|NCT00041951||Controls|Healthy individuals without epilepsy and no family history of epilepsy.
62241608|NCT01432834|OTHER|LASIK group (LG group)|Volunteers of this group received LASIK treatment.
62432057|NCT01279590|ACTIVE_COMPARATOR|Atorvastatin|Dosing will be forced titrated as 40 mg orally once daily for 4 weeks, and 80 mg orally once daily for 8 weeks
62432058|NCT01279590|PLACEBO_COMPARATOR|Placebo|Dosing will be 2 placebo capsules twice daily for 12 weeks
62432059|NCT05742854|ACTIVE_COMPARATOR|Oxytocin|(subjects administered oxytocin as a uterotonic agent) (5 IU oxytocin diluted with 10 ml saline followed by slow injection) (for 3 minutes)
62432060|NCT05742854|ACTIVE_COMPARATOR|Carbetocin|subjects administered carbetocin as a uterotonic agent) (100µg carbetocin diluted with 10 ml saline followed by slow injection (for 3 minutes))
62432061|NCT05081076|ACTIVE_COMPARATOR|Glazed surface|One side of the zirconia crown will receive glazed surface treatment according to standard laboratory procedure and manufacturer's recommendations (Ceramill Stain \& Glaze Kit).
62432062|NCT05081076|EXPERIMENTAL|Polished surface|The contralateral side of the zirconia crown will receive polished surface treatment (polishing rubbers kit in the sequence indicated by the manufacturer - EVE DIACERA Finishing and Polishing Kit, EVE Ernst Vetter GmbH - Germany).
62432063|NCT01537549|EXPERIMENTAL|Juvenon|
62432064|NCT04551352|EXPERIMENTAL|Part I: Single Participant Cohorts (IV)|Part I is a dose escalation in single participant cohorts. RO7293583 will be administered intravenously (IV) every three weeks (Q3W). The starting dose will be 0.045mg and the maximum dose explored will be 1.5mg.
62817991|NCT06587685|EXPERIMENTAL|PG-011Gel 3%|Topically administered Pumecitinib Gel 3% to the skin twice daily for 52 or 44 weeks
62817992|NCT06587685|PLACEBO_COMPARATOR|Vehicle Gel|Topically administered the Vehicle Gel to the skin twice daily for 8 weeks
62241609|NCT01432834|OTHER|PRK group (PG group)|Volunteers of this group received PRK treatment
62241610|NCT06475391|EXPERIMENTAL|L-arginine|Participants will ingest 2 grams of L-arginine before completing three anaerobic exercise tasks (grip strength, vertical jump, and Wingate cycle ergometer test).
62241611|NCT06475391|PLACEBO_COMPARATOR|Placebo|Participants will ingest 2 grams of placebo (dextrose) before completing three anaerobic exercise tasks (grip strength, vertical jump, and Wingate cycle ergometer test).
62817993|NCT04218968|EXPERIMENTAL|carvedilol therapy|Twice daily oral doses of adrenergic blocker 12.5 mg or 25mg, according to patient tolerability.
62817994|NCT04239898|EXPERIMENTAL|Red cabbage microgreens|2 cups of fresh red cabbage microgreens per day
62038790|NCT03901326|EXPERIMENTAL|CTA/CT-FFR care group|If the subjects are randomly allocated to CT-FFR arm, they will be examined by on-site DeepFFR for three major epicardial coronary arteries. If the result of CT-FFR calculation is less than or equal to 0.8 in one or more major coronary arteries, the patient will be referred to ICA directly; if the result of CT-FFR value is more than 0.8, optimal medical therapy will be recommended. The decision on the mode of revascularization is left to the treating cardiologists and depends on local practice standard.
62038791|NCT03901326|NO_INTERVENTION|Routine clinically-indicated diagnostic care group|If the subjects are randomized to usual care arm, attending physicians will decide the next step of diagnosis and treatment, such as exercise ECG, stress cardiac echo, cardiac MR, and SPECT. According to the results of examination combined with risk factors assessment and clinical manifestations, physicians should provide recommendation whether the subjects would undergo ICA or not.
62598987|NCT05501015|EXPERIMENTAL|Group B - Ice Chip Treatment|Group B will serve as the experimental group. In place of traditional dysphagia exercises, participants in Group B will receive oral hygiene and will consume small amounts of ice chips with supervision, three times a day. The ice chip protocol is based on the same findings as the Frazier Free Water Protocol, in that small amounts of clean water or ice chips are not harmful to the lungs and relatively benign if aspirated. Ice chips provide additional advantages in rehabilitating dysphagia as they are a cohesive bolus that are easier for patients with severe dysphagia to control in their mouth and swallow.
62598988|NCT00334633|ACTIVE_COMPARATOR|control|metronidazole 500 BID for 7 days
62598989|NCT00334633|ACTIVE_COMPARATOR|tinidazole 500|tinidazole 500 BID for 7 days
62598990|NCT00334633|ACTIVE_COMPARATOR|tinidazole 1 gm|tinidazole 1 gm BID for 7 days
62038792|NCT04497168|EXPERIMENTAL|Citalopram|20mg daily
62038793|NCT04497168|PLACEBO_COMPARATOR|Placebo|matching placebo pills
62241612|NCT01978353|EXPERIMENTAL|Memory Training|Participants receive memory training to facilitate learning and memory of face-name associations
62241613|NCT01978353|ACTIVE_COMPARATOR|Psychoeducation|Participants receive information about memory functioning and aging
62432065|NCT04551352|EXPERIMENTAL|Part II: Multiple Participant Cohorts (IV/SC)|Multiple ascending dose-escalation of RO7293583 in multiple participant cohorts: The starting-dose for the initiation of the IV dose-escalation will be determined by Part I and RO7293583 will be administered IV or SC every 3 weeks. Dose-escalation will be undertaken based on safety until determination of the MTD or the highest safe dose if MTD is not reached. Fractionated, step up or subcutaneous dosing may be implemented. The maximum dose explored will be 600mg IV and 160mg SC.
62432066|NCT02682433|EXPERIMENTAL|diagnostic hysteroscopy|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, and in the same position, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
62598991|NCT01918150|EXPERIMENTAL|TITAN 2 stent - Hexacath France|Patients receiving Titan 2 stents (percutaneous coronary intervention)
62598992|NCT01918150|ACTIVE_COMPARATOR|Cobalt-Chromium BMS - Any firm|Patients receiving Cobalt-Chromium Bare Metal Stents (free of any coating)(percutaneous coronary intervention)
62598993|NCT04364802|NO_INTERVENTION|Healthcare Workers - Control|Front-line healthcare workers (FLCHW) who are negative for COVID will receive standard PPE and a pre- and post-study test for COVID-19.
62598994|NCT04364802|EXPERIMENTAL|Healthcare Workers - PVP-I|Front-line healthcare workers (FLCHW) who are negative for COVID-19 will receive standard PPE and a pre- and post-study test for COVID-19. Additionally, they will receive PVP-I spray and gargle.
62598995|NCT04364802|NO_INTERVENTION|Inpatients - Control|Inpatients who have a 7+ day hospitalization or who are set to undergo a significant surgical procedure will receive standard care and a pre- and post-study COVID-19 test.
62598996|NCT04364802|EXPERIMENTAL|Inpatients - PVP-I|Inpatients who have a 7+ day hospitalization or who are set to undergo a significant surgical procedure will receive standard care and a pre- and post-study COVID-19 test. Additionally, they will receive PVP-I gargle and nasal sprays that will be applied shortly after admission or perioperatively.
62817995|NCT04239898|EXPERIMENTAL|Red beet microgreens|2 cups of fresh red beet microgreens per day
62817996|NCT06547619|PLACEBO_COMPARATOR|local lactated Ringer's perfusion|lactated Ringer's is perfused through the microdialysis fiber to serve as the vehicle control
62598997|NCT04364802|NO_INTERVENTION|Community - Control|Community participants who are negative for COVID-19 will receive a pre- and post-study COVID-19 test.
62817997|NCT06547619|EXPERIMENTAL|local BQ-788 and BQ-123 perfusion|local ET-1 inhibitors perfused through the microdialysis fiber to serve as the experimental treatment
62817998|NCT06547619|EXPERIMENTAL|local L-NAME perfusion|local L-NAME is perfused through the microdialysis fiber to inhibit nitric oxide synthase
62817999|NCT06547619|EXPERIMENTAL|local BQ-788 + BQ-123 + L-NAME perfusion|local ET-1 inhibitors and L-NAME are perfused through the microdialysis fiber to inhibit nitric oxide synthase during the experimental treatment
62818000|NCT04752215|EXPERIMENTAL|BI 765049 single treatment group|BI 765049
62818001|NCT04752215|EXPERIMENTAL|BI 765049 + ezabenlimab combination treatment group|BI 765049 + ezabenlimab
62818002|NCT05296226|EXPERIMENTAL|dry needling group|dry needling is probably the most popular, trigger-point dry needling is an invasive procedure where a fine Needle or acupuncture needle is inserted into the skin and muscle Goniometry will be used to assess range ofmotion. Ischemic compression is one of the least invasive trigger point therapies.
62818003|NCT05296226|EXPERIMENTAL|ischemic compression group|compression is one of the least invasive trigger point therapies. Ischemic compression is a mechanical treatment of myofascial trigger points that consists of application of sustained pressure for a long enough time to inactivate the trigger points. Pressure is sustained for 10 to 20 second
62432067|NCT02682433|EXPERIMENTAL|diagnostic sonar test|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, and in the same positionabdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
62432068|NCT06053879|EXPERIMENTAL|Biofeedback electrical stimulation|Biofeedback electrical stimulation
62432069|NCT02982447|ACTIVE_COMPARATOR|Blue Laser Imaging colonoscopy|Insertion to cecum was performed under white light(WL) and once the cecum was reached, the Blue Laser Imaging mode was switched on during withdrawal of endoscope for complete colonic examination. Second colonoscopic examination was performed in a similar manner after the first complete withdrawal of the colonoscope. WL was used on insertion and WL was used on withdrawal
62432070|NCT02982447|EXPERIMENTAL|conventional white light colonoscopy|In this arm, WL was used for both insertion and withdrawal of the colonoscope during the first-pass and second-pass examinations.
62432071|NCT06527235|EXPERIMENTAL|ultrasound-guided betamethasone infiltration of the meniscal wall|patients allocated to the experimental group will receive a single betamethasone infiltration (1mL) of the meniscal wall under ultrasound guidance.
62432072|NCT06527235|PLACEBO_COMPARATOR|ultrasound-guided physiological serum infiltration of the meniscal wall|patients allocated to the control group will receive a single placebo infiltration of isotonic saline (1mL) of the meniscal wall under ultrasound guidance.
62432073|NCT04401319|SHAM_COMPARATOR|Sham Stimulation Group for Crossover Study (DLPFC + AG)|Sham stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) and on the angular cortex (AG) using a sham coil in the crossover study.
62432074|NCT04401319|ACTIVE_COMPARATOR|DLPFC Stimulation Group for Crossover Study|Real stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil in the crossover study.
62432075|NCT04401319|ACTIVE_COMPARATOR|AG Stimulation Group for Crossover Study|Real stimulation will be delivered on the left angular cortex (AG) using a real coil in the crossover study.
62598998|NCT04364802|EXPERIMENTAL|Community - PVP-I|Community participants who are negative for COVID-19 will receive a pre- and post-study COVID-19 test. Additionally, they will receive PVP-I gargle and nasal sprays.
62598999|NCT01950559||Subjects who are allergic to Soy|Subject allergy to soy is determined by an oral food challenge or history of positive soy food challenge.
62818004|NCT06552871|EXPERIMENTAL|FLAPS intervention|Participants receiving FLAPS intervention
62818005|NCT04479358|ACTIVE_COMPARATOR|Sub-study A, Tocilizumab-Free Standard of Care|Patient assigned to Sub-study A by primary treating physicians. Patient enrolled on trial sub-study A and randomized to receive no tocilizumab.
62818006|NCT04479358|EXPERIMENTAL|Sub-study A, Tocilizumab 40mg|Patient assigned to Sub-study A by primary treating physicians. Patient enrolled on trial sub-study A and randomized to receive tocilizumab 40mg.
62735745|NCT05818540|ACTIVE_COMPARATOR|Traditional CPAP mask|Human subjects will use the ResMed P-10 CPAP interface for 60 days for a total of 6 hours per night.
62818007|NCT04479358|EXPERIMENTAL|Sub-study A, Tocilizumab 120mg|Patient assigned to Sub-study A by primary treating physicians. Patient enrolled on trial sub-study A and randomized to receive tocilizumab 120mg.
62599000|NCT06615713|EXPERIMENTAL|Steerable Ureteroscopic Renal Evacuation (SURE) with CVAC System|The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).
62599001|NCT03841539|EXPERIMENTAL|Mediterranean Diet|Follow a Mediterranean eating pattern and take a study supplement for one year. Dietary education will be provided by a Registered Dietitian.
62599002|NCT03841539|ACTIVE_COMPARATOR|Low-fat Diet|Follow a low-fat eating pattern and take a study supplement for one year. Dietary education will be provided by a Registered Dietitian.
62599003|NCT04197921|OTHER|Sham/Active ExAblate Treatment Stage 1 and 2|Subject will undergo both Treatment 1 (sham) and Treatment 2 (with enhanced intensity). Subjects are blinded to the order of the sham vs active treatment.
62599004|NCT06621823|OTHER|surgical lymph nodes|Patients referred to the Gynecology Oncology Unit in Fondazione Policlinico A. Gemelli IRCCS, Italy, Rome with a diagnosis of gynecological malignancy requiring surgical lymph nodes harvest will be evaluated for the enrolment.
62599005|NCT06186817|ACTIVE_COMPARATOR|Manual Therapy based Fascial Distortion Model|All participants were given manual therapy based on the Fascial Distortion Model in addition to conventional therapy (Rocabado's 6x6 Exercises and Patient Education). Conventional therapy was implemented as a home program for 8 weeks, while Manual Therapy was conducted for forty-five minutes once a week in a clinical setting.
62599006|NCT06186817|ACTIVE_COMPARATOR|Core Stabilization Training|All participants were given manual therapy based on the Core Stabilization Training in addition to conventional therapy (Rocabado's 6x6 Exercises and Patient Education). Conventional therapy was implemented as a home program for 8 weeks, while Core Stabilization Training was conducted for forty-five minutes once a week in a clinical setting.
62599007|NCT06186817|NO_INTERVENTION|Control|No participant was given any therapy during the study.
62599008|NCT04500600||Observational (questionnaire)|Patients complete an online questionnaire over 10 minutes regarding the COVID-19 pandemic including testing, risks of exposure, whether people they know have acquired COVID-19, as well as questions on how the pandemic has impacted their quality of life.
62818008|NCT04479358|ACTIVE_COMPARATOR|Sub-study B, Tocilizumab 400mg or 8mg/kg Standard of Care|Patient assigned to Sub-study B by primary treating physicians. Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab dose (400mg or 8mgkg).
62818009|NCT04479358|EXPERIMENTAL|Sub-study B, Tocilizumab 40mg|Patient assigned to Sub-study B by primary treating physicians. Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab 40mg.
62818010|NCT04479358|EXPERIMENTAL|Sub-study B, Tocilizumab 120mg|Patient assigned to Sub-study B by primary treating physicians. Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab 120mg.
62241614|NCT02274168|OTHER|Conventional RF catheter ablation|Conventional RF ablation will be performed without using ICD-EG information
62241615|NCT02274168|OTHER|Investigational RF Catheter Ablation using ICD-EG information|RF Catheter Ablation will be performed using ICD-EG information
62599009|NCT06460844|EXPERIMENTAL|Low Dose RTx-015|Single intravitreal injection of low dose RTx-015
62241616|NCT02155036|NO_INTERVENTION|Usual care|Usual care
62599010|NCT06460844|EXPERIMENTAL|Middle Dose RTx-015|Single intravitreal injection of middle dose RTx-015
62599011|NCT06460844|EXPERIMENTAL|High Dose RTx-015|Single intravitreal injection of high dose RTx-015
62599012|NCT03097055|EXPERIMENTAL|Traditional Acupuncture|"Traditional acupoints and traditional deqi manipulation"
62599013|NCT03097055|SHAM_COMPARATOR|Minimal Acupuncture|To avoid traditional acupoints and minimal manipulation
62599014|NCT04902313|EXPERIMENTAL|Cancer patients|Youths (10-18 y) with newly diagnosed cancer, as well as their family members.
62241617|NCT02155036|ACTIVE_COMPARATOR|Exercise|exercise intervention
62241618|NCT01762670|ACTIVE_COMPARATOR|Metronidazole|Oral administration of metronidazole, 500 mg twice daily for 7 consecutive days
62241619|NCT01762670|EXPERIMENTAL|GoldenCare|GoldenCare administered intravaginally for at least 6 hours at night for 7 consecutive nights.
62241620|NCT01452854||Cancer|The study cohort will include adult women of childbearing potential with a diagnosis of low grade glioma (WHO grade II) who are being treated with low doses of Temozolomide (Temodar).
62241621|NCT05887453||Group 1: Persistent AF|
62241622|NCT05887453||Group 2 : Paroxysmal AF|
62241623|NCT05887453||Healthy controls|
62241624|NCT05398068|EXPERIMENTAL|Training (Exercises and Diet) Group|"Training (Exercises and Diet) Group; Patients will follow a regular diet program for 10 weeks.~Aerobic exercises will be planned for patients 2 days a week under the supervision of a physiotherapist, and 3 days a week as home exercises.~Strengthening exercises will be planned for patients 1 days a week under the supervision of a physiotherapist, and 2 days a week as home exercises."
62599015|NCT04902313|ACTIVE_COMPARATOR|Pediatric patients|Youths (10-18 y) with a chronic somatic disease receiving care at a pediatric outpatient facility.
62599016|NCT02587572|EXPERIMENTAL|LMSCs 10 million IV|A total of 10 subjects will receive: A single peripheral intravenous (IV) infusion of 10 x10\^6 (10 million) of LMSCs to be administered on day 1.
62599017|NCT02587572|PLACEBO_COMPARATOR|Placebo (Plasmalyte A,HSA) IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of Plasmalyte A containing human serum albumin (HSA) to be administered on day 1.
62735746|NCT02504398|EXPERIMENTAL|Fast injection|Vaccine injections will be given at a rate of approximately 2-4 ml/sec by the immunizer
62599018|NCT02587572|EXPERIMENTAL|LMSCs 20 million IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of 20x10\^6 (20 million) LMSCs to be administered on day 1.
62599019|NCT02587572|EXPERIMENTAL|LMSCs100 million IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of 100x10\^6 (100 million) LMSCs to be administered on day 1.
62818011|NCT01364051|EXPERIMENTAL|Treatment (cediranib maleate, selumetinib)|Patients receive cediranib maleate PO QD and selumetinib sulfate PO QD or BID on days 1-28 (days 8-28 of cycle 1). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cycles may be extended to 12 weeks after 1 year of study treatment.
62818012|NCT05201547|EXPERIMENTAL|Arm A: Dostarlimab 500 mg, every 3 weeks, 4 cycles and then 1000 mg every 6 weeks|
62599020|NCT03586674|ACTIVE_COMPARATOR|Ursogal|Control group : Ursogal 10-20 mg/kg/d on 2 divided dose for four months with regular follow up.
62599021|NCT03586674|EXPERIMENTAL|Lipanthyl + Ursogal|Therapy group: Ursogal 10-20 mg/kg/d by mouth, on 2 divided dose, and lipanthyl 10-20 mg/kg/d by mouth,once per day, for four months with regular follow up.
62599022|NCT02609724|EXPERIMENTAL|Fluoroscopy-guided MLD|Information, skin care, compression therapy, exercises and fluoroscopy-guided MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
62599023|NCT02609724|ACTIVE_COMPARATOR|Traditional MLD|Information, skin care, compression therapy, exercises and traditional MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
62038794|NCT02002169|EXPERIMENTAL|Shower Technique Protocol (STP)|Participants will be given a minimum 30 minute personalized educational session by the study coordinator. They will be taught safe and clean techniques for showering with their CVC. If the participant passes the Shower Technique Test, they will be provided a pamphlet on the STP, not to be shared with other participants, to be kept as a reference and placed in their bathroom/household. They will also be given the necessary supplies for the STP.
62038795|NCT02002169|ACTIVE_COMPARATOR|Standard CVC care|Standard CVC Care consists of cleansing with chlorhexidine 2% or povidone (if allergic to chlorhexidine) at the CVC exit site by trained HD nurses followed by placement of a dry gauze dressing by the HD nurse 1x/week or when clinically indicated. In order to participate in the standard CVC care arm, participating sites must have in their policy that it is trained HD nurses who will apply the Polysporin Triple Ointment after standard cleansing with chlorhexidine 2% or povidone during HD, according to guideline recommendations or as per hospital patient care standards and nursing regulations.
62818013|NCT05201547|EXPERIMENTAL|Arm B: Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2, every 3 weeks, 6 cycles.|
62038796|NCT06258590|EXPERIMENTAL|tVNS|All patients will receive at-home Transcutaneous auricular vagus nerve stimulation (taVNS) and assess the impact on multiple behavioral outcomes associated with ASD and anxiety. This is an open-label trial.
62038797|NCT02917707||normal colorectal tissues (PN)|normal colorectal tissues
62038798|NCT02917707||primary colorectal carcinoma tissues|primary colorectal carcinoma tissues
62599024|NCT02609724|PLACEBO_COMPARATOR|Placebo MLD|Information, skin care, compression therapy, exercises and placebo MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
62818014|NCT05572359|EXPERIMENTAL|Total knee arthroplasty cryo-and compression group|use of the cryo- and compression brace during the six postoperative weeks
62818015|NCT05572359|NO_INTERVENTION|Total knee arthroplasty regular care group|regular care during the six postoperative weeks
62818016|NCT05572359|EXPERIMENTAL|Unicompartmental knee arthroplasty cryo- and compression group|use of the cryo- and compression brace during the six postoperative weeks
62818017|NCT05572359|NO_INTERVENTION|Unicompartmental knee arthroplasty regular care group|regular care during the six postoperative weeks
62818018|NCT05139992||Observational Cohort|Previously unvaccinated persons with sickle cell disease who are scheduled to receive their initial COVID-19 vaccine series.
62599025|NCT06530758|EXPERIMENTAL|ASRS without shading and with grouping|"These participants will receive the ASRS form that does not have shading for the screen positive response options and has the questions grouped (ie, the headings Part A and Part B will remain on the form)."
62599026|NCT06530758|EXPERIMENTAL|ASRS with shading and without grouping|"These participants will receive the ASRS form that has the screen positive response options shaded and has the questions ungrouped (ie, the headings Part A and Part B are removed)."
62599027|NCT06530758|EXPERIMENTAL|ASRS without shading and without grouping|"These participants will receive the ASRS form that does not have shading for the screen positive response options and has the questions ungrouped (ie, the headings Part A and Part B are removed)."
62599028|NCT06530758|NO_INTERVENTION|Standard ASRS: with shading and with grouping|"These participants will receive the standard ASRS form. This form has the positive response options for each question shaded and has the questions grouped (ie, the headings Part A and Part B will remain on the form)."
62599029|NCT02454712|EXPERIMENTAL|PF614|PF614 is the drug under evaluation. Doses may range from 15 mg to 640 mg. N=6 subjects per cohort. For Cohort 7, N=16 subjects in crossover study ± naltrexone.
62599030|NCT02454712|ACTIVE_COMPARATOR|Oxycodone extended-release (OxyContin)|Initial dose (Cohort 1) will be 10 mg. Subsequent doses will be 10, 20, 40, or 80 mg. N=2 subjects per cohort. Active comparator will not be used in Cohort 7.
62599031|NCT05775003|PLACEBO_COMPARATOR|Placebo|Resistant starch
62599032|NCT05775003|EXPERIMENTAL|500 mg BAIBA supplementation|500 mg BAIBA supplementation
62599033|NCT05775003|EXPERIMENTAL|500 mg BAIBA supplementation + 40 mg Grains of Paradise|500 mg BAIBA supplementation + 40 mg Grains of Paradise
62599034|NCT04932824|NO_INTERVENTION|Subjects Without Treatment Cross-over|these subjects will not receive any vaccination during this study.
62599035|NCT04932824|EXPERIMENTAL|Subjects With Treatment Cross-over (From 1st Dose of Active Study Vaccine Onwards)|Once the treatment assignments of study CLO-SCB-2019-001 are unblinded, those subjects who have received placebo and provided there is active study vaccine available, will be given the option to receive 2 doses of active study vaccine 21 days apart (ie, treatment cross-over)
62599036|NCT04932824|EXPERIMENTAL|Subjects who will receive Booster Vaccine|For subjects out of those who received SCB-2019 CpG/Alum-adjuvanted vaccine in study CLO-SCB-2019-001: the subjects will receive a booster dose.
62599037|NCT04761120||Group 1: Primary mitral disease repair surgery with an Abbott annuloplasty ring implant|Group 1 will enroll 200 subjects undergoing surgical repair of primary mitral regurgitation that includes annuloplasty with an Abbott SJM Rigid Saddle Ring, Séguin Ring or full Tailor Ring without cut zone removal. Enrollment must include at least 50 subjects implanted with each ring model. In primary mitral regurgitation, backflow through the closed valve is caused by disease intrinsic to the mitral valve tissue itself.
62599038|NCT04761120||Group 2: Secondary mitral disease repair surgery with an Abbott annuloplasty ring implant|Group 2 will enroll 200 subjects undergoing surgical repair of secondary mitral regurgitation that includes annuloplasty with an Abbott SJM Rigid Saddle Ring, Séguin Ring or full Tailor Ring without cut zone removal. Enrollment must include at least 50 subjects implanted with each ring model. In secondary mitral regurgitation, backflow through the closed valve is secondary to diseases of the surrounding myocardium, rather than caused by disease of the valve tissue itself.
62599039|NCT04761120||Group 3: Primary tricuspid disease repair surgery with a full Tailor Ring implant|Group 3 will enroll up to 50 subjects undergoing surgical repair of primary tricuspid regurgitation that includes annuloplasty with a full Abbott SJM Tailor Ring without cut zone removal. In primary tricuspid regurgitation, backflow through the closed valve is caused by disease intrinsic to the tricuspid valve tissue itself.
62599040|NCT04761120||Group 4: Secondary tricuspid disease repair surgery with a full Tailor Ring implant|Group 4 will enroll up to 50 subjects undergoing surgical repair of secondary tricuspid regurgitation that includes annuloplasty with a full Abbott SJM Tailor Ring without cut zone removal. In secondary tricuspid regurgitation, backflow through the closed valve is secondary to diseases of the surrounding myocardium, rather than caused by disease of the valve tissue itself.
62599041|NCT04761120||Group 5: Primary tricuspid disease repair surgery with a partial Tailor Ring or Tailor Band implant|Group 4 will enroll up to 50 subjects undergoing surgical repair of secondary tricuspid regurgitation that includes posterior annuloplasty with either a partial Abbott SJM Tailor Ring with cut zone removed or an Abbott SJM Tailor Band. In primary tricuspid regurgitation, backflow through the closed valve is caused by disease intrinsic to the tricuspid valve tissue itself.
62599042|NCT02543892|EXPERIMENTAL|Adult 0.6mg PATH-wSP|Two 0.6 mg doses of PATH-wSP with a 28 day interval between doses
62599043|NCT02543892|PLACEBO_COMPARATOR|Adult Placebo Low Dose|Two injections of normal saline with a 28 day interval between injections
62599044|NCT02543892|EXPERIMENTAL|Adult 1.0 mg PATH-wSP|Two 1 mg doses of PATH-wSP with a 28 day interval between doses
62599045|NCT02543892|PLACEBO_COMPARATOR|Adult Placebo High Dose|Two injections of normal saline with a 28 day interval between injections
62599046|NCT02543892|EXPERIMENTAL|Toddler 0.6mg PATH-wSP|Two 0.6 mg doses of PATH-wSP with a 28 day interval between doses
62599047|NCT02543892|PLACEBO_COMPARATOR|Toddler Placebo Low Dose|Two injections of normal saline with a 28 day interval between injections
62599048|NCT02543892|EXPERIMENTAL|Toddler 1.0 mg PATH-wSP|Two 1 mg doses of PATH-wSP with a 28 day interval between doses
62599049|NCT02543892|PLACEBO_COMPARATOR|Toddler Placebo High Dose|Two injections of normal saline with a 28 day interval between injections
62599050|NCT05144503|EXPERIMENTAL|SpherePVI™ Catheter|Subjects treated with the SpherePVI™ Catheter
62735747|NCT02504398|ACTIVE_COMPARATOR|Slow injection|Vaccine injections will be given at a rate of approximately 10 ml/sec by the immunizer
62735748|NCT00988052|EXPERIMENTAL|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
62038799|NCT02917707||liver metastasis tissues|liver metastasis tissues
62241625|NCT05398068|ACTIVE_COMPARATOR|Control (Diet) Group|Control (Diet) Group; Patients will follow a regular diet program for 10 weeks.
62241626|NCT06006338|EXPERIMENTAL|Experimental arm|
62599051|NCT06649539|EXPERIMENTAL|Primary Cohort|"Men would receive 4 series of CCH injections:~* Administered on back-to-back days~* 0.9 mg administered with each series, diluted to 0.8 mL~* Mild in-office modeling performed on treatment day 2 of each series~* Wraps applied 2-4 full-time and 2-4 part-time days~* Sildenafil 25 mg nightly and Restorex beginning treatment day 2 (sildenafil) or 3 (Restorex - 30 min/day) until 6 weeks after final injection of the final series.~Note that men may stop sooner if they are satisfied before completing the 4 series. If the patient is not satisfied with outcomes by the end of the 4th series, they would be permitted to enter the 'salvage' phase of the treatment protocol.~* Performed 9-12 months after the 4th series of injections.~* The technique would incorporate more aggressive, in-office modeling.~* Men would receive up to two additional series per this protocol."
62599052|NCT03064100||Specimens that meet inclusion criteria|
62599053|NCT01944618||T2DM patients newly prescribed Forxiga|A post-marketing evaluation of the safety of Forxiga (10 mg tablets, orally once daily for 6 months) through an observational prescription adverse event monitoring program (registry-based monitoring program) is warranted to assess real-world incidence of adverse events in routine clinical practice.
62599054|NCT03982446||Patients with germline mutations|This group will comprise of patients with pancreatic cancer who carry pathogenic mutations in genes associated with a predisposition to cancer.
62599055|NCT03982446||Patients without germline mutations|This group will comprise of patients with pancreatic cancer who did not carry pathogenic mutations in any of the genes tested, that have been previously shown to be associated with a predisposition to cancer.
62599056|NCT01955525||Acute coronary patients|Patients aged 18 and above who have been hospitalised with an ACS during the period of 2011 to 2013.
62241627|NCT01978795|EXPERIMENTAL|Brain 101 website|Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. The website offers a school-wide approach to preventing and managing sports concussion, including a) training for educators, athletics staff, students, and parents; b) guidelines for creating a concussion management team; and c) information on strategies for supporting students in the classroom following concussion.
62241628|NCT01978795|ACTIVE_COMPARATOR|Control|
62241629|NCT00528255|EXPERIMENTAL|1|
62241630|NCT03707509|EXPERIMENTAL|Camrelizumab + Gemcitabine + Cisplatin|subject will receive camrelizumab 200mg every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, at most 6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles
62241631|NCT03707509|ACTIVE_COMPARATOR|Placebos + Gemcitabine + Cisplatin|subject will receive placebos every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, at most 6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles
62241632|NCT01088191|ACTIVE_COMPARATOR|Hyaluronan Alone|Hyaluronan Alone
62241633|NCT01088191|EXPERIMENTAL|MSB-CAR001|Single Dose of MSB-CAR001 Combined With Hyaluronan
62432076|NCT04401319|SHAM_COMPARATOR|Sham Stimulation Group for Parallel Study (DLPFC + AG)|Sham stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or on the angular cortex (AG) using a sham coil in the parallel study.
62432077|NCT04401319|ACTIVE_COMPARATOR|DLPFC Stimulation Group for Parallel Study|Real stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil in the parallel study.
62432078|NCT04401319|ACTIVE_COMPARATOR|AG Stimulation Group for Parallel Study|Real stimulation will be delivered on the left angular cortex (AG) using a real coil in the parallel study.
62432079|NCT01533272|EXPERIMENTAL|Tenofovir, emtricitabine, Maraviroc|New postexposure prophylaxis (it is a combination drug)
62432080|NCT01533272|ACTIVE_COMPARATOR|Tenofovir, emtricitabine, lopinavir/r|Standard prophylaxis (it is a combination drug)
62432081|NCT04256005|NO_INTERVENTION|Control|Participants will attend the laboratory and complete no exercise. The participants will remain seated for the 29 minutes of the session.
62432082|NCT04256005|EXPERIMENTAL|105% VO2Peak|Participants will complete ten intervals at a work rate which equates to 105% VO2peak with a 1:1 work rest ratio. The recovery period will involve free cycling against no resistance. The duration of the interval and recovery periods will vary between trials so that the total work done during each trial, excluding CON, will be the same, the duration of intervals will be determined by the 50% ∆ trial which will be set at 60 s for work and recovery intervals.
62599057|NCT06160128||Outpatient Veterans with risk factors for severe COVID-19 & tested positive during Jan-Feb 2022|"This cohort study assessed outpatient Veterans with risk factors for severe COVID-19 who tested positive for SARS-CoV-2 during January and February 2022.~The purpose is to describe factors associated with receipt of outpatient COVID-19 pharmacotherapies in the Veterans Affairs (VA) health care system."
62735749|NCT04535102|EXPERIMENTAL|Polatuzumab + BR (minimum 3 cycles)|Patients will be treated with a minimum of 3 cycles up to a maximum six cycles to optimize response prior to ASCT (stem cell transplant) per investigator discretion
62241634|NCT04439071|EXPERIMENTAL|PTC299 + Standard of Care (SOC)|"Participants will receive PTC299 at 200 milligrams (mg), administered orally, twice daily (BID) on Days 1 to 7, then at 50 mg administered orally, once daily (QD) on Days 8 to 14.~SOC will also be administered according to local, written policies or guidelines."
62241635|NCT04439071|PLACEBO_COMPARATOR|Placebo + SOC|"Participants will receive PTC299-matching placebo administered orally, BID on Days 1 to 7, then administered orally, QD on Days 8 to 14.~SOC will also be administered according to local, written policies or guidelines."
62432083|NCT04256005|EXPERIMENTAL|50% ∆ Gas Exchange Threshold|Participants will complete ten intervals at a work rate which equates to 50% ∆ GET with a 1:1 work rest ratio. The recovery period will involve free cycling against no resistance. The duration of the interval and recovery periods will vary between trials so that the total work done during each trial, excluding CON, will be the same, the duration of intervals will be determined by the 50% ∆ trial which will be set at 60 s for work and recovery intervals.
62818019|NCT03602612|EXPERIMENTAL|1/Conditioning chemotherapy plus chimeric antigen receptors (CARs) T-cells dose escalation|Patients will receive escalating doses (up to 5 planned) of CAR+ T cells infused on day 0 + Cyclophosphamide: 300 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg /m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
62818020|NCT03602612|EXPERIMENTAL|2/Conditioning chemotherapy plus chimeric antigen receptors (CARs) T-cells expansion phase|6.0x10\^6 dose (maximum feasible dose) of CAR T Cells + Cyclophosphamide: 300 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg/m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
62818021|NCT00005800|EXPERIMENTAL|Dose-Dense Chemotherapy|Patients receive doxorubicin IV on day 1 every 2 weeks for 3 courses. After 3 weeks of rest, patients receive docetaxel IV over 1 hour on day 1 every 2 weeks for 3 courses. Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each doxorubicin and docetaxel course. Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
62818022|NCT06706297|NO_INTERVENTION|control|Control group patients will not undergo any exercise and the normal clinical protocol will not be interfered with.
62818023|NCT06706297|EXPERIMENTAL|breathing exercise group|The researcher will make the application group patients perform a 30-minute pranayama exercise twice a week for 6 weeks.
62818024|NCT06024941|EXPERIMENTAL|Radiation|Radiation to one progressive lesion
62818025|NCT04838782|EXPERIMENTAL|Repeat Surgical Resection|Standard surgical operative management according to local practices.
62599058|NCT06160128||Nonhospitalized Veterans in VHA at risk for SARS-CoV-2 Jan-Jul 2022|"Three retrospective target trial emulation studies comparing matched cohorts of nirmatrelvir-ritonavir versus no treatment, molnupiravir versus no treatment, and nirmatrelvir- ritonavir versus molnupiravir.~The purpose is to measure the effectiveness of nirmatrelvir-ritonavir and molnupiravir for outpatient treatment of COVID-19."
62599059|NCT06160128||Outpatient Veterans who tested positive for SARS-CoV-2 from Jan 2022 through Jan 2023|"This cohort study evaluated nonhospitalized Veterans in VHA care who tested positive for SARS-CoV-2 from January 2022 through January 2023 using VHA and linked Community Care and Medicare databases.~The purpose is to analyze trends and factors associated with prescription of outpatient COVID-19 pharmacotherapies within the Veterans Health Administration (VHA)."
62599060|NCT06160128||Outpatient Veterans with risk factors for severe COVID-19 & tested positive during Jan-Jul 2022|"Retrospective target trial emulation study comparing matched cohorts receiving nirmatrelvir-ritonavir versus no treatment.~The purpose is to measure the effectiveness of outpatient treatment of COVID-19 with nirmatrelvir-ritonavir in preventing Post COVID conditions."
62599061|NCT00937040|EXPERIMENTAL|001|OROS MPH Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
62038800|NCT01978613|EXPERIMENTAL|Oral B (DC)|Escalation design. Planned end dose level is 5 mg alternative dosing condition (fasting for 30 minutes post-dosing)
62241636|NCT02106754|EXPERIMENTAL|Brief Intervention|Youth may receive brief intervention from their provider based on randomization.
62241637|NCT02106754|ACTIVE_COMPARATOR|Treatment As Usual|Youth may receive treatment as usual from their provider based on randomization.
62432084|NCT05740059|NO_INTERVENTION|Control|Patients assigned to the Control group will be transfused if hemoglobin (Hb) concentration is lower than 9 g/d.
62432085|NCT05740059|ACTIVE_COMPARATOR|Adjusted transfusion|Patients assigned to the SvO2 group will be transfused if Hb concentration is lower than 9 g/dL and central SvO2 ≤ 65%.
62599062|NCT00937040|PLACEBO_COMPARATOR|002|Placebo Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
62599063|NCT00598546||1|
62599064|NCT01952119|NO_INTERVENTION|Routine Care|Routine care, no intervention
62599065|NCT01952119|ACTIVE_COMPARATOR|Secure message reminder|Will receive a secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
62735750|NCT05046873|EXPERIMENTAL|NNC0480-0389 + semaglutide(co-formulation)and placebo|Sequence A: The participants will be administered a single subcutanous (s.c.) dose of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate dosing visits separated by at least 8 weeks. The two drugs will be administered as a co-formulation by a single injection and a placebo injection
62735751|NCT05046873|ACTIVE_COMPARATOR|NNC0480-0389 + semaglutide (separate injections)|Sequence B: The participants will be administered 0.5 mg semaglutide and 5 mg NNC0480 0389 as an subcutaneus injection (s.c) on two separate dosing visits separated by at least 8 weeks. The two drugs will be administered as two separate injections.
62735752|NCT03520920|EXPERIMENTAL|R/R Non-GCB DLBCL|Participants with non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance.
62735753|NCT03520920|EXPERIMENTAL|R/R FL or MZL|Participants with R/R FL or MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance.
62241638|NCT02106754|EXPERIMENTAL|Brief Intervention with Coaching|Youth may receive brief intervention with coaching from their provider based on randomization.
62241639|NCT05642182|EXPERIMENTAL|Drug (SFA002) Vitamin D, Magnesium|Drug (SFA002) 1000 mg, 80 mg Calcium, 40 mg Magnesium 3 times daily after meals and Vitamin D 1000 IU once daily
62735754|NCT01245686|ACTIVE_COMPARATOR|One-on-one counseling|Participants in this arm will receive 4 intensive one-on-one counseling sessions (either in person or on the phone) and 3 brief maintenance sessions.
62735755|NCT01245686|ACTIVE_COMPARATOR|Web counseling|Participants in this arm will receive 4 intensive counseling sessions over the web. They will also receive 3 maintenance sessions over the web.
62038801|NCT01978613|EXPERIMENTAL|Oral D|Escalation design. Planned end dose level is 20 mg standard dosing condition (fasting for 120 minutes post-dosing)
62038802|NCT01978613|EXPERIMENTAL|Oral C|Escalation design. Planned end dose level is 10 mg standard dosing condition (fasting for 120 minutes post-dosing)
62038803|NCT01978613|EXPERIMENTAL|Oral B|Escalation design. Planned end dose level is 5 mg standard dosing condition (fasting for 120 minutes post-dosing)
62038804|NCT01978613|EXPERIMENTAL|Oral A|Escalation design. Planned end dose level is 2.5 mg standard dosing condition (fasting for 120 minutes post-dosing)
62241640|NCT05642182|EXPERIMENTAL|Drug (SFA002) Vitamin D, Magnesium and Propionate|Drug (SFA002) 1000 mg, Propionate 150 mg, 80 mg Calcium, 40 mg Magnesium 3 times daily after meals and Vitamin D 1000 mg once daily
62818026|NCT04838782|ACTIVE_COMPARATOR|Management Without Re-operation|Non-surgical management with standard care according to local practices.
62818027|NCT06704243|EXPERIMENTAL|Peer Support|The intervention will be a monthly online AYA peer support group (1 hour) that will run for six months via Microsoft Teams.
62818028|NCT06139328|EXPERIMENTAL|BI 765845 very low dose group|
62818029|NCT06139328|EXPERIMENTAL|BI 765845 low dose group|
62241641|NCT03359213|EXPERIMENTAL|JR-141 1.0 mg/kg/week|
62241642|NCT03359213|EXPERIMENTAL|JR-141 2.0 mg/kg/week|
62241643|NCT03359213|EXPERIMENTAL|JR-141 4.0 mg/kg/week|
62241644|NCT03623581|EXPERIMENTAL|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
62432086|NCT01652261|EXPERIMENTAL|experimental arm|"An experimental arm (early FDG-PET/CT-response adapted), where all patients are initially treated with a single cycle of ABVD. Very early FDG-PET/CT-negative patients continue on ABVD therapy to a total of six cycles. Very early FDG-PET/CT-positive patients receive 3 cycles of BEACOPPesc followed by another 3 cycles of BEACOPPesc. Mid-treatment evaluation is performed after 4 cycles. In case of treatment failure (less than partial remission (PR)), the patient goes off protocol treatment.~Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es))."
62599066|NCT06622122|EXPERIMENTAL|MIED group|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge, and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression, and other emotional problems.
62818030|NCT06139328|EXPERIMENTAL|BI 765845 medium dose group|
62818031|NCT06139328|EXPERIMENTAL|BI 765845 high dose group|
62818032|NCT06139328|PLACEBO_COMPARATOR|Placebo group|
62241645|NCT00393328|ACTIVE_COMPARATOR|A|
62241646|NCT00393328|ACTIVE_COMPARATOR|B|
62818033|NCT04221945|EXPERIMENTAL|chemoradiotherapy + pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 5 cycles followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 15 cycles. During the Q3W dosing period of pembrolizumab, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m\^2 IV once per week (QW) for 5 or 6 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80 Gray Units (Gy) for volume-directed and 75 Gy for point-directed given with the total duration of radiation treatment not to exceed 50 days (with an extension to a maximum of 56 days for unforeseen delays).
62243466|NCT03235440|EXPERIMENTAL|Kids N Fitness|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
62818034|NCT04221945|EXPERIMENTAL|chemoradiotherapy + placebo for pembrolizumab|Participants receive placebo for pembrolizumab IV on Day 1 of each 3-week cycle (Q3W) for 5 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 15 cycles. During the Q3W dosing period of placebo, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m\^2 IV once per week (QW) for 5 or 6 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80 Gray Units (Gy) for volume-directed and 75 Gy for point-directed given with the total duration of radiation treatment not to exceed 50 days (with an extension to a maximum of 56 days for unforeseen delays).
62818035|NCT03777306|EXPERIMENTAL|ARM A EARLY INTERVENTION GROUP|In Arm A, the intervention group, the participants will start on the program immediately. The participants will receive MPI educational program, implemented in parallel with standard of care treatment. The MPI is implemented at the time of enrollment x 12 weeks
62038805|NCT05703854|EXPERIMENTAL|Chemotherapy and NK Cell Infusion|Participants will be assigned to a dose level of NK cells. A computer will decide by chance which of the dose level you will receive, and this will not be based on the doctor's or patient's decision. Up to 5 dose levels of NK cells will be tested. Each new patient will receive a different dose. If any dose shows to be not tolerable, this dose and the higher doses will not be given anymore.
62241647|NCT03938077|EXPERIMENTAL|S4E App intervention|"Youth will receive the S4E intervention via provided iPads. The intervention will last approximately 60. Content includes: (a) storytelling scenarios, (b) drug use and HIV/STI knowledge, (c) interactive activities, (d) increasing self-efficacy to prevent/reduce sexual and drug use risk behaviors and increase HIV self-testing, (e) Near Peer-youth communication, and (f) highlighting prevention principles. The youth will participate in a Near Peer-initiated prevention and risk reduction encounter which includes (a) reinforcement of HIV solutions that youth learned in the S4E app, (b) promotion of HIV self-tests, and (c) linkage to care and prevention services.~Youth have the option to take a HIV self-test. We will determine the acceptability of youth disclosing their results to their Near Peer and linkage to resources.~The research staff will also conduct in-depth qualitative interviews with both youth and Near Peer participants to assess feasibility and acceptability of S4E."
62241648|NCT00913250|EXPERIMENTAL|Sequence 1|Serum containing Avonex followed by serum free Avonex
62241649|NCT00913250|EXPERIMENTAL|Sequence 2|Serum free Avonex followed by serum containing Avonex
62241650|NCT03575455|EXPERIMENTAL|Exercise|"Concussed participants will participate in a single 20' bout of treadmill walking at either 40% or 60% of the age-predicted HRmax.~Healthy participants will participate in a single 20' bout of treadmill walking at either 40% or 60% of the age-predicted HRmax."
62241651|NCT03575455|NO_INTERVENTION|Seated Control|"Concussed participants will participate in a single 20' treatment session of seated rest.~Healthy participants will participate in a single 20' treatment session of seated rest."
62241652|NCT02749448|OTHER|mesenchymal stem cell|There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers
62241653|NCT01474863|ACTIVE_COMPARATOR|Low Dose Citrulline|Low Dose Citrulline
62241654|NCT01474863|PLACEBO_COMPARATOR|Placebo|Placebo IV infusion
62432087|NCT01652261|ACTIVE_COMPARATOR|standard arm|"A standard arm, where patients are treated with four cycles of BEACOPPesc followed by 2 cycles of BEACOPPesc. FDG-PET/CT is performed after one cycle, but with no therapeutic consequences. Mid-treatment evaluation is performed after four cycles. In case of treatment failure (less than PR), the patient goes off protocol treatment.~Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es))."
62432088|NCT01785186|EXPERIMENTAL|Arm 1 (R35)|Arm 1 (R35): HR35ZE isoniazid, rifampicin 35 mg/kg, pyrazinamide, ethambutol
62432089|NCT01785186|EXPERIMENTAL|HRZQ|Arm 2 (Q): HRZQ isoniazid, rifampicin standard, pyrazinamide, SQ109 300 mg
62818036|NCT03777306|EXPERIMENTAL|ARM B DELAYED INTERVENTION GROUP|Arm B, is a wait-list control group that will serve as the control. The wait-list control group will be observed for an initial 12 week period while receiving usual care and then have the educational intervention implemented from week 12-24 in parallel with standard of care
62432090|NCT01785186|EXPERIMENTAL|HR20ZQ|Arm 3 (R20Q): HR20ZQ isoniazid, rifampicin 20 mg/kg, pyrazinamide, SQ109 300 mg
62818037|NCT03513770|EXPERIMENTAL|Ketorolac|The Wrist-to-Elbow occlusion procedure will be performed followed by 2 ketorolac tromethamine + saline infusions into the occluded arm.
62241655|NCT01474863|ACTIVE_COMPARATOR|High Dose Citrulline|High Dose Citrulline
62241656|NCT01444651|ACTIVE_COMPARATOR|Tadalafil|20 mg Tadalafil tablet taken by mouth once a day for 3 months
62818038|NCT03513770|PLACEBO_COMPARATOR|Control|The Wrist-to-Elbow occlusion procedure will be performed followed by 2 saline only infusions into the occluded arm.
62818039|NCT06457373|EXPERIMENTAL|Group A|20 sockets will be grafted with Demineralized Dentin Allograft (DDA)
62038806|NCT06105632|EXPERIMENTAL|Arm A|PF-07220060 to be taken by mouth as a tablet in combination with fulvestrant (a solution for injection)
62038807|NCT06105632|ACTIVE_COMPARATOR|Arm B|"Investigator's choice of therapy of either:~* Fulvestrant alone (a solution for injection), or~* Everolimus in combination with exemestane, both a tablet to be taken by mouth."
62038808|NCT04677972|EXPERIMENTAL|SPI-1005 400 mg BID|Oral administration of SPI-1005 400 mg BID for 28 days, with 84-day followup
62241657|NCT01444651|PLACEBO_COMPARATOR|Placebo|Placebo tablet taken by mouth once a day for 3 months
62241658|NCT01916863|EXPERIMENTAL|LX4211|400 mg of LX4211
62432091|NCT01785186|EXPERIMENTAL|HR20ZM|Arm 4 (R20M): HR20ZM isoniazid, rifampicin 20 mg/kg, pyrazinamide, moxifloxacin 400 mg
62599067|NCT06622122|EXPERIMENTAL|MIED+CF group|The increase in cognitive flexibility dosage involves incorporating additional psychoeducational content related to cognitive flexibility and corresponding exercises to enhance cognitive flexibility within the MIED (Mindfulness Intervention for Emotional Distress) program.
62599068|NCT06622122|NO_INTERVENTION|waitlist control group|no intervention
62038809|NCT04677972|PLACEBO_COMPARATOR|Placebo|Oral administration of matching placebo BID for 28 days, with 84-day followup
62038810|NCT02690064|EXPERIMENTAL|Acute Antioxidant Treatment|Following an overnight fast, blood samples, flow-mediated dilation, lung function, and exercise capacity (VO2 peak) (post only) will be performed at baseline and 2 hours following either a single dose oral 1) antioxidant cocktail (1000 mg Vitamin C, 600 IU vitamin E, 600 mg Alpha Lipoic Acid) 2) Resveratrol (1500 mg) 3) Mitoquinol (10 mg) or placebo on two days separated by at least 72 hours.
62818040|NCT06457373|ACTIVE_COMPARATOR|Group B|20 sockets will be grafted with Demineralized Dentin Autograft (Auto-DD)
62818041|NCT00601224|EXPERIMENTAL|1|Participants will receive social cognition and interaction training plus treatment as usual
62818042|NCT00601224|ACTIVE_COMPARATOR|2|Participants will receive treatment as usual
62818043|NCT05217615|EXPERIMENTAL|ezParent+ coach|"ezParent - Program is a 6-module digital adaptation of the group-based Chicago Parent Program, 12-session program for parents of young children. A core objective of the CPP is to promote positive parenting behavior - for example, teaching parents to limit the amount of attention given to negative behaviors and reward the positive - to decrease child behavior problems and increase child prosocial behavior.~Coach - The purpose of the brief weekly telephone coaching calls is to provide parents with an opportunity to receive clarification of intervention content, encouragement and reinforcement of intervention completion, and support tailoring of intervention content for their child. The coaching calls will be guided by a semi-structured script aimed at supporting parent learning and motivation. Coaches will be trained in active and empathic listening and problem solving techniques to facilitate learning and support of parents."
62818044|NCT05217615|EXPERIMENTAL|ezParent|ezParent - Program is a 6-module digital adaptation of the group-based Chicago Parent Program, 12-session program for parents of young children. A core objective of the CPP is to promote positive parenting behavior - for example, teaching parents to limit the amount of attention given to negative behaviors and reward the positive - to decrease child behavior problems and increase child prosocial behavior.
62818045|NCT05217615|ACTIVE_COMPARATOR|Active Control+coach|"Active Control - The active control is an adaptation of a digital application used in our previous study (HS024273). The program will include general information typically provided during well-child or NICU follow up visits but unrelated to parenting or child development and behavior. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes digital handouts, websites, and resources provided to parents of children in this age group.~Coach - The purpose of the brief weekly telephone coaching calls is to provide parents with an opportunity to receive clarification of intervention content, encouragement and reinforcement of intervention completion, and support tailoring of intervention content for their child. The coaching calls will be guided by a semi-structured script aimed at supporting parent learning and motivation."
62818046|NCT05217615|PLACEBO_COMPARATOR|Active Control|The active control is an adaptation of a digital application used in our previous study (HS024273). The program will include general information typically provided during well-child or NICU follow up visits but unrelated to parenting or child development and behavior. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes digital handouts, websites, and resources provided to parents of children in this age group. Parents will be instructed to review each topic over 10-weeks (\~1 topic every 1.5 weeks) to match the dose and timing of contact that the intervention groups will receive.
62818047|NCT00878501|EXPERIMENTAL|AZD1386, 90 mg|
62818048|NCT00878501|EXPERIMENTAL|AZD1386, 30 mg|
62038811|NCT02690064|EXPERIMENTAL|Chronic Antioxidant Treatment|Following the completion of Arm 1, blood samples, flow-mediated dilation, lung function, and exercise capacity (VO2 peak) will be performed, only in patients with CF, at baseline, 4 weeks, 8 weeks, and 12 weeks following one of the following: 1) an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day, 2) 1500 mg Resveratrol once a day or 3) 10 mg Mitoquinol once a day.
62038812|NCT04712942|EXPERIMENTAL|pevonedistat + azacitidine|pevonedistat in combination with azacitidine
62038813|NCT04712942|OTHER|azacitidine monotherapy|administration of azacitidine monotherapy
62038814|NCT02868359||Pregabalin / Other analgesics|Patients will be treated for 8 weeks with pregabalin in primary care: no intervention
62599069|NCT05517824|ACTIVE_COMPARATOR|Post-treatment|After a single treatment using a microinsulated needle RF device
62038815|NCT02868359||Other analgesics|Patients will be treated for 8 weeks with other analgesics in usual care: no intervention
62241659|NCT01916863|ACTIVE_COMPARATOR|Canagliflozin|300 mg canagliflozin
62241660|NCT01916863|PLACEBO_COMPARATOR|Placebo|LX4211 placebo
62241661|NCT05292950|EXPERIMENTAL|ARO-MUC5AC|ARO-MUC5AC Inhalation
62241662|NCT05292950|PLACEBO_COMPARATOR|Placebo|(0.9% NaCl)
62241663|NCT06440057|EXPERIMENTAL|Dose Escalation|A total of six dose escalations were preset: 0.1 mg, 0.3 mg, 1 mg, 3 mg.
62241664|NCT06440057|EXPERIMENTAL|Dose Expansion|Participants will receive the RP2D identified in Dose Escalation Study .
62599070|NCT05517824|NO_INTERVENTION|Pre-treatment (Baseline)|
62818049|NCT00878501|PLACEBO_COMPARATOR|Placebo|
62818050|NCT01351103|EXPERIMENTAL|LGK974|LGK974
62818051|NCT01351103|EXPERIMENTAL|LGK974 in combination with PDR001|LGK in combination with PDR001
62818052|NCT05577754|PLACEBO_COMPARATOR|Group A|
62818053|NCT05577754|EXPERIMENTAL|Group B|
62818054|NCT06586125||VR - based training|Five children and adolescents with cerebral palsy and/or neuromuscular disease and five children and adolescents with cerebral palsy and/or neuromuscular disease with difficulties to control the VR joysticks
62818055|NCT05380466|EXPERIMENTAL|Quantum Touch|Those who are planned to be hospitalized from the emergency department and applied quantum touch
62818056|NCT05380466|NO_INTERVENTION|Control|Those who are planned to be hospitalized from the emergency department and who have not intervention
62818057|NCT02218372|EXPERIMENTAL|Fidaxomicin|Participants from birth to \< 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days. Participants aged ≥ 6 years to \< 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
62038816|NCT06481709|OTHER|Sequence DCAB|"Where the Subject receives in this order~D is 1 x 10 mg/kg dose\* of Kuvan (sapropterin dihydrochloride) 100 mg powder for oral solution dissolved in water and administered under fed conditions~C is 1 x 10 mg/kg dose\* of sapropterin dihydrochloride oral suspension 100 mg/mL administered with water under fed conditions.~A is 1 x 10 mg/kg dose\* of sapropterin dihydrochloride oral suspension 100 mg/mL administered without water under fasting conditions.~B is 1 x 10 mg/kg dose\* of sapropterin dihydrochloride oral suspension 100 mg/mL administered without water under fed conditions."
62038817|NCT06481709|OTHER|Sequence ADBC|"Where the Subject receives in this order~A is 1 x 10 mg/kg dose\* of sapropterin dihydrochloride oral suspension 100 mg/mL administered without water under fasting conditions.~D is 1 x 10 mg/kg dose\* of Kuvan (sapropterin dihydrochloride) 100 mg powder for oral solution dissolved in water and administered under fed conditions~B is 1 x 10 mg/kg dose\* of sapropterin dihydrochloride oral suspension 100 mg/mL administered without water under fed conditions.~C is 1 x 10 mg/kg dose\* of sapropterin dihydrochloride oral suspension 100 mg/mL administered with water under fed conditions."
62038818|NCT06481709|OTHER|Sequence BACD|"Where the Subject receives in this order~B is 1 x 10 mg/kg dose\* of sapropterin dihydrochloride oral suspension 100 mg/mL administered without water under fed conditions.~A is 1 x 10 mg/kg dose\* of sapropterin dihydrochloride oral suspension 100 mg/mL administered without water under fasting conditions.~C is 1 x 10 mg/kg dose\* of sapropterin dihydrochloride oral suspension 100 mg/mL administered with water under fed conditions.~D is 1 x 10 mg/kg dose\* of Kuvan (sapropterin dihydrochloride) 100 mg powder for oral solution dissolved in water and administered under fed conditions"
62818058|NCT02218372|ACTIVE_COMPARATOR|Vancomycin|Participants from birth to \< 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days. Participants aged ≥ 6 years to \< 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
62038819|NCT06481709|OTHER|Sequence CBDA|"Where the Subject receives in this order~C is 1 x 10 mg/kg dose\* of sapropterin dihydrochloride oral suspension 100 mg/mL administered with water under fed conditions.~B is 1 x 10 mg/kg dose\* of sapropterin dihydrochloride oral suspension 100 mg/mL administered without water under fed conditions.~D is 1 x 10 mg/kg dose\* of Kuvan (sapropterin dihydrochloride) 100 mg powder for oral solution dissolved in water and administered under fed conditions~A is 1 x 10 mg/kg dose\* of sapropterin dihydrochloride oral suspension 100 mg/mL administered without water under fasting conditions."
62038820|NCT04783155|EXPERIMENTAL|12-weeks pulmonary rehabilitation training plus inspiratory muscle training|To assess maximum inspiratory pressure, you will be asked to breathe through a device called POWERBreathe Plus®. This device is commercially available and will be provided to you by the study. You will be asked to use this device twice per day, 5 days per week, for 12 weeks. Each session will require you to breathe into the device 30 times. You can use the device at home.
62038821|NCT04783155|PLACEBO_COMPARATOR|12-weeks pulmonary rehabilitation plus placebo (inactive) inspiratory muscle|To assess maximum inspiratory pressure with placebo, you will be asked to breathe through a device called POWERBreathe Plus®. This device is commercially available and will be provided to you by the study. You will be asked to use this device twice per day, 5 days per week, for 12 weeks. Each session will require you to breathe into the device 30 times. You can use the device at home. The resistance will be set to about 5% throughout the study.
62599071|NCT05251948|ACTIVE_COMPARATOR|Atezo + CAPOX (capecitabine + oxaliplatin)|Participants in the atezolizumab plus capecitabine plus oxaliplatin in Stage 1 will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62599072|NCT05251948|EXPERIMENTAL|Atezo + CAPOX +Tira|Participants in the atezolizumab plus capecitabine plus oxaliplatin plus tiragolumab arm in Stage 1 will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62599073|NCT03105986|EXPERIMENTAL|Treatment sequence AB|Participants will receive Treatment A (1000 milligram (mg) oral dose of JNJ-64041575 on Day 1) in Period 1, followed by Treatment B (1000 mg oral dose of JNJ-64041575 on Day 22 along with probenecid 500 mg on Day 21 to Day 28) in Period 2. A washout Period of 21 days will be maintained between each Period.
62818059|NCT00984256|EXPERIMENTAL|Drug|"5 groups, each group receiving Malarone tablet(s) (250/100mg)prior to challenge.~Group 1 - 1 tablet 1 day before challenge Group 2 - 1 tablet 4 days before challenge Group 3 - 1 tablet 7 days before challenge Group 4 - 2 tablets 7 days before challenge Group 5 - 4 tablets 7 days before challenge"
62818060|NCT00984256|PLACEBO_COMPARATOR|Control -no prophylaxis|
62818061|NCT03670823||Healthy subjects|50 healthy subjects for a control group
62241665|NCT06368427||COPD patients who initiate treatment with BGF MDI.|Patients with COPD, who are eligible for BGF MDI triple therapy. Patients are assigned to a therapeutic strategy within current routine care and not according to a clinical trial protocol. Every medical decision including the course of treatment will reflect exclusively the decision of the treating physician in a routine clinical situation according to the Summary of Product Characteristics of the corresponding medicinal products. There are no dose regimens or diagnostic procedures pre-defined.
62241666|NCT01750541|ACTIVE_COMPARATOR|Haloperidol|Haloperidol 5mg intramuscular injection
62599074|NCT03105986|EXPERIMENTAL|Treatment sequence BA|Participants will receive Treatment B (1000 mg oral dose of JNJ-64041575 on Day 1 along with probenecid 500 mg on Day -1 to Day 7) in Period 1, followed by Treatment A (1000 mg oral dose of JNJ-64041575 on Day 22) in Period 2. A washout Period of 21 days will be maintained between each Period.
62599075|NCT02010281|EXPERIMENTAL|rTMS of the motor cortex (Magventure)|experimental : rTMS of the motor cortex : repetitive magnetic stimulation targeting the motor cortex assisted by neuronavigation
62599076|NCT02010281|PLACEBO_COMPARATOR|rTMS placebo (magventure)|sham stimulation of the motor or prefrontal cortex with the placebo face of the device
62599077|NCT02010281|EXPERIMENTAL|rTMS prefrontal cortex (magventure)|Experimental : repetitive transcranial stimulation targeting the prefrontal cortex as indicated by neuronavigation
62599078|NCT05670314|PLACEBO_COMPARATOR|Placebo arm|The participants in the placebo/control arm (N=30) will be required to take 10g of maltodextrin for the same period of 6 weeks.
62599079|NCT05670314|EXPERIMENTAL|Diet only Arm|The participants in the dietary intervention arm will be required to take 20g of inulin (N=30) for a period of 6 weeks.
62818062|NCT03670823||Patients with Major Depression|50 patients with major depression for a research group
62818063|NCT05655598|EXPERIMENTAL|Level 0 Starting Palbociclib with TAS-116|
62818064|NCT05655598|EXPERIMENTAL|Level -1 Palbociclib with TAS-116|
62818065|NCT05655598|EXPERIMENTAL|Level -2 Palbociclib with TAS-116|
62818066|NCT06587113|EXPERIMENTAL|Study Group|This study examines eye movement behavior using eye-tracking technology. Healthy participants perform three different tasks, including a visual search task, a stop-signal task, and a useful field of view task. Behavioral performance and eye movements are recorded for all tasks.
62818067|NCT05719311|EXPERIMENTAL|Adrulipase|Upon study enrolment, the patient will be switched from their commercial PERT to receive adrulipase. Patients will initially receive a low dose of adrulipase. Upon the appearance of EPI symptoms, lasting at least three days, and upon discussion with the investigator, the patient will be switched to the medium dose of adrulipase. If signs and symptoms of EPI persist for three or more days, the patient will be switched to the high dose of adrulipase.
62818068|NCT06595043|EXPERIMENTAL|the tip opening angle to the left|After fixing the position of the tracheal catheter, the opening of the tip of the blocker will be adjusted to left under the guidance of the fiber bronchoscope.
62818069|NCT06595043|PLACEBO_COMPARATOR|the tip opening angle to the right|After fixing the position of the tracheal catheter, the opening of the tip of the blocker will be adjusted to right under the guidance of the fiber bronchoscope.
62818070|NCT06320457|EXPERIMENTAL|Intervention group|Brief case management intervention group
62038822|NCT06620042|OTHER|Open-label Ketamine TRBD|Outpatients with treatment resistant bipolar depression referred by their clinical providers for intravenous ketamine treatment
62241667|NCT01750541|ACTIVE_COMPARATOR|Valproate|Valproate single Infusion; 400 mg (weigh\<60 kg), 500 mg (weight\>60 Kg)
62818071|NCT02004236|EXPERIMENTAL|tRNS Fronto-temporal cortex|This group receive 35 sessions of tRNS over fronto-temporal cortex
62818072|NCT02004236|EXPERIMENTAL|tRNS over fusiform temporal cortex|This group receive 35 sessions of tRNS over fusiform temporal cortex
62241668|NCT05477381||Asymptomatic women with a history of preterm birth|Pregnant women \>18 years of age, with a history of spontaneous PTB before 34 weeks. All women have biweekly visits for routine transvaginal cervical length measurement between 14-24 weeks of gestation. During these visits data on cervical softening will be collected as additional marker.
62818073|NCT02004236|PLACEBO_COMPARATOR|tRNS with sham|This group receive 35 sessions with sham
62818074|NCT05899634|NO_INTERVENTION|Group 1 - Recipes|Participants will receive healthy recipes (3 main meal + 1 snack/breakfast/lunch recipe per week of the two-week intervention).
62818075|NCT05899634|EXPERIMENTAL|Group 2 - Default|Participants will receive healthy recipes (3 main meal + 1 snack/breakfast/lunch recipe per week of the two-week intervention). In addition, in this group, participants' online grocery shopping carts will be pre-filled with ingredients corresponding to the provided recipes. They will be told that their cart has been filled with items that can be used to make recipes from the provided recipe cards, and that they can modify it as they like.
62818076|NCT01239199|EXPERIMENTAL|Exhaled NO|
62818077|NCT02610296|ACTIVE_COMPARATOR|QPI-1002|QPI-1002 Injection, single dose
62038823|NCT06205420|EXPERIMENTAL|Injectable composite resin restoration|The use of injectable GC Gaenial restoration in restoring hypoplastic permanent anterior teeth and the evaluation of its clinical performance using FDI criteria.
62818078|NCT02610296|PLACEBO_COMPARATOR|Placebo|isotonic saline
62818079|NCT01003808|EXPERIMENTAL|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
62818080|NCT06314711|EXPERIMENTAL|Post-operative ex vivo 3D ultrasound|3D ultrasound of surgical specimen
62818081|NCT06590636|EXPERIMENTAL|Infertile women|
62818082|NCT06590636|NO_INTERVENTION|Control group|
62818083|NCT03330925|EXPERIMENTAL|ElastiMed's SACS|Healthy Subjects which the Elastimed's SACS will be tried on
62818084|NCT06600451||Patients treated with NobelProcera Zr Implant Bridge (4-14-unit)|"Patients partially and fully edentulous in need of the implant supported dental prosthesis treated with NobelProcera Zr Implant Bridge (4-14-unit) from June 2020.~Device is CE and available on the market in May 2020."
62818085|NCT01365923|ACTIVE_COMPARATOR|Remifentanil group|Remifentanil group : remifentanil effect site-TCI 2-4ng/ml
62818086|NCT01365923|ACTIVE_COMPARATOR|Dexmedetimidine group|Dexmedetomidine group: remifentanil effect site-TCI 2-4ng/ml + dexmedetomidine 0.5mcg/kg
62818087|NCT04765722|EXPERIMENTAL|Mepolizumab arm|Mepolizumab Dosage form: 1ml pre-filled syringe Dosage: 100mg Frequency: 3 doses at days 0, 28, 56 and 84 Duration: 12 weeks
62818088|NCT04765722|PLACEBO_COMPARATOR|Placebo arm|Normal Saline (0.09% normal saline) Dosage form: 1ml pre-filled syringe Dosage: n/a Frequency: 3 doses at days 0, 28, 56 and 84 Duration: 12 weeks
62818089|NCT05831774|PLACEBO_COMPARATOR|Control - Standard IV administration of vancomycin|Patients will receive the Houston Methodist Hospital orthopedic surgeon's standard of care pre-operative antibiotic regimen for primary total shoulder arthroplasty patients. This includes IV abx (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg \[6,7\] generally 1000-1750mg in 500mL NS).
62818090|NCT05831774|EXPERIMENTAL|Intervention - Intraosseous (IO) administration of vancomycin|"* IV antibiotics (per physician's standard of care): Typically ancef or cefepime is started in pre-op within 1 hour of incision~* IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~* Injection will take place into the proximal humerus"
62038824|NCT06205420|EXPERIMENTAL|Injectable Giomer restoration|The use injectable beautiful flow giomer restoration in restoring hypoplastic permanent anterior teeth and the evaluation of its clinical performance using FDI criteria.
62241669|NCT05477381||Symptomatic women with symptoms of threatened preterm birth|Pregnant women \>18 years of age, between 24 and 34 weeks of gestation, presenting with symptoms of threatened Preterm birth (e.g. abdominal pain, blood loss, contractions, or other complaints suggestive for threatened Preterm birth).
62818091|NCT05031819|EXPERIMENTAL|Practice Facilitation to support TASSH integration (group A).|Components of the PF strategy include: (a) establishment of a steering committee of key stakeholders (ministry of health, state primary care agency, AIDS control agency, patient advocates) to provide leadership and guide integration of TASSH into HIV care platform; (b) training of the HIV nurses on TASSH protocol; and (c) training of practice facilitators, who will serve as coaches, provide support, and performance feedback to the PHC nurses on TASSH implementation.
62818092|NCT05031819|SHAM_COMPARATOR|TASSH only (group B)|HIV nurses based at Group B facilities will be trained on the 5As counseling approach strategy (Ask, Assess, Advise, Assist, and Arrange) and referral for the participants to the health center. However, they will not receive practice facilitation from the POFs. Participants attending PHC randomized to Group B will receive standard care offered by the facility.
62818093|NCT06705868|OTHER|Standard of Care (Group A-Control)|"Participants in Group A will follow a Standard of Care Intervention. They will receive guidance on a) energy restriction, b) weight reduction, c) the macronutrient composition of the diet, d) limitation of alcohol intake (below the risk threshold of 30g/d and 20g/day for men and women, respectively) and e) increase their physical activity levels. Additionally, in this study patients will be asked to consume the general recommendation of 5-a-day as part of their dietary healthier behaviour. Moreover, participants should stay well hydrated and get adequate of sleep (an average of 6 consecutive hours at night). Oral and written guidance for the management of MASLD will be administered. The duration of the intervention is 3 months."
62818094|NCT06705868|EXPERIMENTAL|Time-restricted eating (Group B-Intervention)|"Participants will have to adhere to an ad libitum TRE dietary pattern (8 hours eating, 16 hours fasting) with an additional dietary restriction regarding the 5-a-day fruit and vegetable in which they will need to be consumed between 9am-4pm. Some more restrictions regarding first and last meal will be asked. First meal of the day should take place within an hour from wake-up time and last meal if the day should be consumed earlier than 2 hours before actual bed-time. The duration of the intervention is 3 months."
62818095|NCT04471909|EXPERIMENTAL|Chronic Dissection|
62241670|NCT06437964|ACTIVE_COMPARATOR|Prophylactic antibiotics|Intravenous infusion of 2.0g ceftriaxone before endoscopic therapy
62599080|NCT05670314|EXPERIMENTAL|Exercise only arm|Joint Academy An app-based exercises platform (Joint Academy®) will be used as an intervention given to the treatment arm. The programme consists of a mixture of open and close chain exercises, a combination of concentric, eccentric and focusing on the global strength of legs including the muscles around the hips and knee joints as well as balance enhancement exercises. The intervention also includes educational sessions integrated into the programme covering the basics of OA, its treatment, self-managing symptoms of OA and the benefits of maintaining a healthy lifestyle. The exercise intervention focuses on core stability and performance, neuromuscular leg strengthening and balance enhancement.
62818096|NCT04471909|EXPERIMENTAL|Aneurysm|
62818097|NCT04471909|EXPERIMENTAL|Penetrating Aortic Ulcer and/or Intramural Hematoma|
62818098|NCT05975476|EXPERIMENTAL|Physical Activity|Individuals in this group will wheel on a paved trail within the park for 30 minutes 2 times per week for 5 weeks.
62241671|NCT06437964|EXPERIMENTAL|No prophylactic antibiotics|No use of prophylactic antibiotics before endoscopic therapy
62241672|NCT06736002|EXPERIMENTAL|Vitamin D|
62241673|NCT06736002|PLACEBO_COMPARATOR|Placebo|
62241674|NCT00347672|EXPERIMENTAL|1|Two vaccinations of H5N1 VN 2004/AA vaccine at the highest dose
62241675|NCT00347672|EXPERIMENTAL|2|One vaccination of H5N1 VN 2004/AA vaccine at a dose in-between the lowest and highest doses
62818099|NCT05975476|EXPERIMENTAL|Sensory Engagement|Individuals in this group will sit comfortably in a peaceful area of the park and enjoy the sights and sounds of nature for 30 minutes 2 times per week for 5 weeks.
62599081|NCT05670314|EXPERIMENTAL|Diet + exercise intervention arm|The participants in this arm will be required to take 20g of inulin (N=30) for a period of 6 weeks and doing exercise at the same time.
62599082|NCT05304949||Lucentis|Patients prescribed with Lucentis
62599083|NCT03203226|EXPERIMENTAL|EXPERIMENTAL GROUP|This protocol has an unique period or phase of 30 week. Experimental group will be composed by 30 volunteer who were previously randomly assigned to this group. This group will receive a intervention based on 30 1-hour session of Feldenkrais Method (1 hour per week).
62599084|NCT03203226|NO_INTERVENTION|CONTROL GROUP|This protocol has an unique period or phase of 30 week. Control group will be composed by 30 volunteer who were previously randomly assigned to this group. They will not receive any intervention.
62818100|NCT05532566|EXPERIMENTAL|Extract Q. ilex + extract Q. robur + positive control + negative control|"There is only one treatment arm. In each subject, one drop of each of the 3 concentrations of each allergenic extract (2 extracts) will be applied in addition to the positive control (histamine 10mg/mL) and the negative control, with prick test.~Quercus ilex: 2,500, 500 and 100 μg/mL Quercus robur: 2,500, 500 and 100 μg/mL"
62818101|NCT02659930|EXPERIMENTAL|1/Group I|Pomalidomide and liposomal doxorubicin given at escalating doses to patients with KS requiring systemic therapy
62818102|NCT02659930|EXPERIMENTAL|2/Group I; Antitumor Assessment Phase|Pomalidomide and liposomal doxorubicin, given at the highest tolerated dose to patients with KS requiring systemic therapy
62038825|NCT05821309|EXPERIMENTAL|PEG 3350|Patients will receive PEG 3350 (miralax or generic equivalent) for their MACE flushes.
62599085|NCT06622252|EXPERIMENTAL|Intervention Session (Corazones) Group|Caregivers in this group will be asked to participate in a 13-session program (Corazones) delivered via Zoom. Caregivers will be asked to complete study questionnaires at the beginning of the study (Baseline), after completing the 13 zoom-based sessions (T2) and 3 months after participating in the program (T3). Caregivers will also be asked to participate in an interview with members of the research team to discuss their experiences participating in the program.
62599086|NCT06622252|NO_INTERVENTION|Control Group (standard of care)|Caregivers will be asked to complete study questionnaires at the beginning of the study (Baseline), following week 2 of the intervention timeline, after week 12 of the intervention timeline (T2), and 3 months after the intervention groups completes their sessions (T3). Caregivers in this group will be offered the opportunity to participate in sessions after T3 surveys are completed. Attendance will not be compensated.
62599087|NCT03259828|EXPERIMENTAL|Adjuvant image-guided radiotherapy|Adjuvant radiotherapy with image guidance via cone beam computed tomography. Treatment is identical to the current standard of care.
62599088|NCT06620263||Pre-education period (PreEd)|In PreEd, the SUP use of patients in the ICU was observed observationally for three months.
62599089|NCT06620263||Post-education period (PostEd)|The SUP education program in the ICU was implemented for ICU physicians after examining the patient data in the first three months of the study. In the 3-month PostEd after the education program (April 3, 2024 - July 3, 2024), SUP was only used in patients in the ICU, and no intervention was observed. Throughout the study period, the appropriateness of SUP uses for the indication was evaluated according to the Sociedade Portuguesa de Cuidados (SPC) SUP guideline
62599090|NCT05264792|ACTIVE_COMPARATOR|Routine Implementation Support|All 14 health facilities will continue to receive existing routine implementation support. The facilities allocated to the control arm (n=7) will receive routine implementation support only.
62599091|NCT05264792|EXPERIMENTAL|Enhanced Implementation Support|In addition to routine support, Enhanced Implementation Support will be provided to 7 facilities allocated to the 'intervention arm'.
62599092|NCT04450407|EXPERIMENTAL|LY3209590 Algorithm 1 (Paper)|Algorithm 1 is a paper-based algorithm where dose adjustments were manually determined by the investigator based on fasting glucose and hypoglycemia data. LY3209590 was provided in a 20 milligram (mg) vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the basal insulin dose prior randomization and baseline fasting glucose by subcutaneous (SC) injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of \<=100 milligrams per deciliter (mg/dL).
62599093|NCT04450407|EXPERIMENTAL|LY3209590 Algorithm 2 (Digital)|"Algorithm 2 is a computer-based algorithm to determine dose adjustments. LY3209590 was provided in a 20 mg vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the basal insulin dose prior randomization and baseline fasting glucose by SC injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of \<=100 mg/dL.~As per protocol amendment (d) approved on 28-Oct-2020, this arm was terminated during the early enrollment phase due to technical issues with data entry."
62599094|NCT04450407|ACTIVE_COMPARATOR|Insulin Degludec|Insulin degludec was provided as 100 units/milliliter (U/mL) in a prefilled pen. Participants received individually adjusted doses once daily by SC injection with a starting dose same as basal insulin dose prior randomization, during the 26-week treatment period, to achieve target fasting blood glucose of \<=100 mg/dL.
62599095|NCT04097158||Upper Motor Neuron predominant ALS|
62599096|NCT04097158||Lower Motor Neuron predominant ALS|
62599097|NCT04097158||Bulbar predominant ALS|
62599098|NCT04097158||Generalized ALS|
62818103|NCT02659930|EXPERIMENTAL|3/Group II|Pomalidomide with liposomal doxorubicin given at escalating doses in to patients with advanced KS or KS and concurrent KSHV-associated MCD or KICS requiring systemic therapy
62818104|NCT02659930|EXPERIMENTAL|4/Group II; Antitumor Assessment Phase|Pomalidomide and liposomal doxorubicin, given at the highest tolerated dose to patients with KS or KS with concurrent KSHV-associated MCD or KICS requiring systemic therapy
62818105|NCT06512727|NO_INTERVENTION|Usual Care (Control Group)|"The control group will continue their usual pain treatment and self-management (SM) routines.~Participations will not receive in-depth culturally congruent education, prayer skills, or financial counseling. Usual care is expected to vary between participants."
62038826|NCT05821309|EXPERIMENTAL|PEG 3350 with electrolytes|Patients will receive PEG 3350 with electrolytes (Go-Lytely or generic equivalent) for their MACE flushes.
62038827|NCT04821778|PLACEBO_COMPARATOR|Definitive Chemoradiation|This arm received chemoradiation without immunotherapy/targeting agents as definitive treatment.
62038828|NCT04821778|EXPERIMENTAL|Chemoradiation Combined With Immunotherapy/targeting agents|This arm received chemoradiation with immunotherapy/targeting agents as definitive treatment.
62599099|NCT04889521||HIV and painful neuropathy|Persons living with HIV who also have painful distal sensory polyneuropathy in the feet.
62599100|NCT04889521||HIV without painful neuropathy|Persons living with HIV who do NOT have painful distal sensory polyneuropathy in the feet.
62599101|NCT06622538|ACTIVE_COMPARATOR|Videolaryngoscope King Vision|The King Vision video laryngoscope used in this study has a 45° angulation, with a disposable No. 3 blade and no channel for the orotracheal tube.
62818106|NCT06512727|EXPERIMENTAL|PROACTIVE|This is a four-session pain self-management (SM) intervention designed to reduce movement-evoked pain by providing participants with behavioral support that addresses social determinants of health: (1) culturally congruent SM education + SM resource toolkit, (3) active prayer support, and (3) financial counseling.
62432092|NCT01785186|ACTIVE_COMPARATOR|HRZE|HRZE: Isoniazid, rifampicin standard, pyrazinamide, ethambutol
62599102|NCT06622538|EXPERIMENTAL|Videolaryngoscope ORION|The ORION video laryngoscope is designed by additive manufacturing, has the same dimensions as a Macintosh No. 3 blade, with 45° angulation, is biocompatible and reusable when subjected to high-level disinfection with 2% Glutaraldehyde for 40 minutes. It has an endoscopic camera fully covered in the body of the videolaryngoscope of 8 mm diameter with 2 megapixels with a resolution of 1280x720, has a viewing angle of 70°, has 6 LEDS with adjustable intensity and the camera has an anti-fogging system and can be connected to any mobile device with Android operating system through a free application. (AN98 Version 2.2.0). It complies with ISO 7376:2020 standards for orotracheal intubation laryngoscopes because its blade withstands a stiffness of more than 60 Newtons and a resistance of more than 150 Newtons.
62599103|NCT01985438|ACTIVE_COMPARATOR|percutaneous endoscopic gastrostomy tube|Percutaneous endoscopic gastrostomy tube placement - A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion
62599104|NCT01985438|ACTIVE_COMPARATOR|nasogastric tube|Nasogastric tube placement - All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.
62599105|NCT03192995|ACTIVE_COMPARATOR|Experimental|lorcaserin, extended release, Substance use counseling, ACASI behavioral questionnaire, BART, and ecological momentary assessment
62599106|NCT03192995|PLACEBO_COMPARATOR|Control|Placebo, Substance use counseling, ACASI behavioral questionnaire, BART, and ecological momentary assessment
62599107|NCT06622590|EXPERIMENTAL|Intervention (Adults aged 18-59 years, one-dose)|QIV in adults aged 18-59 years on Day 0
62599108|NCT06622590|ACTIVE_COMPARATOR|Control (Adults aged 18-59 years, one-dose)|Control vaccine in adults aged 18-59 years on Day 0
62599109|NCT06622590|EXPERIMENTAL|Intervention (Elders aged 60 years and above, one-dose)|QIV in elders aged 60 years and above on Day 0
62599110|NCT06622590|ACTIVE_COMPARATOR|Control (Elders aged 60 years and above, one-dose)|Control vaccine in elders aged 60 years and above on Day 0
62599111|NCT06622590|EXPERIMENTAL|Intervention (Adolescents aged 9-17 years, one-dose)|QIV in adolescents aged 9-17 years on Day 0
62818107|NCT05138653|EXPERIMENTAL|Part A: Cohort 1: Sequence 1|Participants were randomized to sequence 1 to receive placebo on Day 1 of Period 1 followed by CVL-354 1.5 milligrams (mg) on Day 1 of Period 2, followed by CVL-354 5 mg on Day 1 of Period 3 \& followed by CVL-354 15 mg on Day 1 of Period 4. Each dosing period was separated by a washout period of at least 5 days.
62818108|NCT05138653|EXPERIMENTAL|Part A: Cohort 1: Sequence 2|Participants were randomized to sequence 2 to receive CVL-354 0.5 mg on Day 1 of Period 1 followed by placebo on Day 1 of Period 2, followed by CVL-354 5 mg on Day 1 of Period 3 \& followed by CVL-354 15 mg on Day 1 of Period 4. Each dosing period was separated by a washout period of at least 5 days.
62038829|NCT02998073|EXPERIMENTAL|Conduct Disorder|Participants are justice-involved youth with conduct disorder. Participants will receive Stop, Now and Plan (SNAP) psychosocial intervention.
62038830|NCT02998073|NO_INTERVENTION|Control|Participants are healthy males. Participants receive no intervention.
62432093|NCT02022371|EXPERIMENTAL|Targeted biopsy|Snap frozen targeted biopsies of the prostate for genomic analysis
62432094|NCT01532349|ACTIVE_COMPARATOR|400 IU vitamin D|Children will be randomly allocated to receive cholecalciferol supplementation 400 IU/day (2,800 IU/weekly), which is the recommended dietary allowance. Study participants will be prescribed any clinically indicated additional cholecalciferol supplementation once the 3-month laboratory measures have been obtained, based on serum 25D levels at the end of the study period.
62599112|NCT06622590|ACTIVE_COMPARATOR|Control (Adolescents aged 9-17 years, one-dose)|Control vaccine in adolescents aged 9-17 years on Day 0
62599113|NCT06622590|EXPERIMENTAL|Intervention (Children aged 3-8 years, two-dose)|QIV in children aged 3-8 years on Day 0 and Day 28
62599114|NCT06622590|EXPERIMENTAL|Intervention (Children aged 3-8 years, one-dose)|QIV in children aged 3-8 years on Day 0
62599115|NCT06622590|ACTIVE_COMPARATOR|Control (Children aged 3-8 years, one-dose)|Control vaccine n children aged 3-8 years on Day 0
62241676|NCT00347672|EXPERIMENTAL|3|One vaccination of H5N1 VN 2004/AA vaccine at the lowest dose
62818109|NCT05138653|EXPERIMENTAL|Part A: Cohort 1: Sequence 3|Participants were randomized to sequence 3 to receive CVL-354 0.5 mg on Day 1 of Period 1 followed by CVL-354 1.5 mg on Day 1 of Period 2, followed by placebo on Day 1 of Period 3 \& followed by CVL-354 15 mg on Day 1 of Period 4. Each dosing period was separated by a washout period of at least 5 days.
62818110|NCT05138653|EXPERIMENTAL|Part A: Cohort 1: Sequence 4|Participants were randomized to sequence 4 to receive CVL-354 0.5 mg on Day 1 of Period 1 followed by CVL-354 1.5 mg on Day 1 of Period 2, followed by CVL-354 5 mg on Day 1 of Period 3 \& followed by placebo on Day 1 of Period 4. Each dosing period was separated by a washout period of at least 5 days.
62241677|NCT04112446|EXPERIMENTAL|Study Treatment|4 mg \[14C\]-saroglitazar magnesium (approximately 100 μCi) oral suspension
62241678|NCT06452004|EXPERIMENTAL|AI-DSS validation Bangladesh|Women in selected intervention area in Bangladesh, who tested hrHPV-positive eligible for VIA, are included. VIA is performed. During VIA the health worker performs an assessment. With the device a picture and taken and AI-DSS generates and assessment as well. The pictures are also assessed by an expert panel.
62599116|NCT00201240|EXPERIMENTAL|CD34+ selection with CliniMACS device|T cell depletion using Miltenyi device
62599117|NCT01772186|NO_INTERVENTION|Without real-time somatosensory cue|Parkinson patients wear the somatosensory stimulation system but not receive the real-time somatosensory cue during freezing-of-gait episodes.
62818111|NCT05138653|EXPERIMENTAL|Part A: Cohort 2: Sequence 1|Participants were randomized to sequence 1 to receive placebo on Day 1 of Period 1 followed by CVL-354 90 mg on Day 1 of Period 2, followed by CVL-354 150 mg on Day 1 of Period 3 \& followed by CVL-354 200 mg on Day 1 of Period 4. Each dosing period was separated by a washout period of at least 5 days.
62818112|NCT05138653|EXPERIMENTAL|Part A: Cohort 2: Sequence 2|Participants were randomized to sequence 2 to receive CVL-354 45 mg on Day 1 of Period 1 followed by placebo on Day 1 of Period 2, followed by CVL-354 150 mg on Day 1 of Period 3 \& followed by CVL-354 200 mg on Day 1 of Period 4. Each dosing period was separated by a washout period of at least 5 days.
62818113|NCT05138653|EXPERIMENTAL|Part A: Cohort 2: Sequence 3|Participants were randomized to sequence 3 to receive CVL-354 45 mg on Day 1 of Period 1 followed by CVL-354 on 90 mg Day 1 of Period 2, followed by placebo on Day 1 of Period 3 \& followed by CVL-354 200 mg on Day 1 of Period 4. Each dosing period was separated by a washout period of at least 5 days.
62241679|NCT06452004|EXPERIMENTAL|AI-DSS validation Uganda|Women in selected intervention area in Uganda, who tested hrHPV-positive eligible for VIA, are included. VIA is performed. During VIA the health worker performs an assessment. With the device a picture and taken and AI-DSS generates and assessment as well. The pictures are also assessed by an expert panel.
62818114|NCT05138653|EXPERIMENTAL|Part A: Cohort 2: Sequence 4|Participants were randomized to sequence 4 to receive CVL-354 45 mg on Day 1 of Period 1 followed by CVL-354 90 mg on Day 1 of Period 2, followed by CVL-354 150 mg on Day 1 of Period 3 \& placebo on Day 1 of Period 4. Each dosing period was separated by a washout period of at least 5 days.
62818115|NCT05138653|EXPERIMENTAL|Part A: Cohort 3: Sequence 1: Fed/Fasted Sequence|Participants first received a single oral dose of CVL-354 50 mg, under fed state on Day 1 of Period 1 followed by a single oral dose of CVL-354 50 mg under fasted state on Day 1 of Period 2, with a washout period of 2 days between both periods.
62818116|NCT05138653|EXPERIMENTAL|Part A: Cohort 3: Sequence 2: Fasted/Fed Sequence|Participants first received a single oral dose of CVL-354 50 mg, under fasted state on Day 1 of Period 1 followed by a single oral dose of CVL-354 50 mg under fed state on Day 1 of Period 2, with a washout period of 2 days between both periods
62818117|NCT05138653|EXPERIMENTAL|Part B: Cohort 1: CVL-354 10 mg|Participants received oral dose of CVL-354 10 mg or Placebo, once daily (QD) from Day 1 up to Day 14 in Cohort 1.
62818118|NCT05138653|EXPERIMENTAL|Part B: Cohort 2: CVL-354 25 mg|Participants received oral dose of CVL-354 25 mg or Placebo, QD from Day 1 up to Day 14 in Cohort 2.
62818119|NCT05138653|EXPERIMENTAL|Part B: Cohort 3: CVL-354 50 mg|Participants received oral dose of CVL-354 50 mg or Placebo, QD from Day 1 up to Day 14 in Cohort 3.
62241680|NCT06452004|EXPERIMENTAL|AI-DSS validation India|Women in selected intervention area in India, who tested hrHPV-positive eligible for VIA, are included. VIA is performed. During VIA the health worker performs an assessment. With the device a picture and taken and AI-DSS generates and assessment as well. The pictures are also assessed by an expert panel.
62243467|NCT02514733||Young donor|Kidney transplant recipient \> 60 years of age who received organ from donor \<=40 years of age
62599118|NCT01772186|EXPERIMENTAL|With real-time somatosensory cue|Parkinson patients wear the somatosensory stimulation system and receive the real-time somatosensory cue during freezing-of-gait episodes.
62599119|NCT01870375||MPS IH, MPS IHS, MPS IS|MPS IH (Hurler syndrome) patients; MPS IHS (Hurler-Scheie syndrome) patients; and MPS IS (Scheie syndrome) patients
62599120|NCT01870375||MPS II|Hunter syndrome patients
62599121|NCT01870375||MPS IV|Morquio syndrome patients who will be considered for enrollment in the study on an individual basis
62599122|NCT01870375||MPS VI|Maroteaux-Lamy syndrome patients
62599123|NCT01870375||MPS VII|Sly syndrome patients who will be considered for enrollment in the study on an individual basis
62818120|NCT05138653|EXPERIMENTAL|Part B: Cohort 4: CVL-354 80 mg|Participants received oral dose of CVL-354 80 mg or Placebo, QD from Day 1 up to Day 14 in Cohort 4.
62038831|NCT05823259|EXPERIMENTAL|Hybrid Telehealth Inspiratory and Expiratory Muscle Training Program with Patient Education|Participants will be instructed in performing a home respiratory muscle training program using a device called the Breather that trains both inspiratory and expiratory muscle strength for 8 weeks. They will also be provided patient education on proper breathing techniques to pass a bowel movement and optimal toilet posture.
62038832|NCT05823259|ACTIVE_COMPARATOR|Standard of Care Physical Therapy With No Study Intervention|A historical control group of participants who received about 8 weeks of standard physical therapy care that includes interventions such as biofeedback treatment, manual therapy, therapeutic exercise, and education on improving bowel health.
62038833|NCT01687023||Tai Chi|Healthy Tai Chi practitioners
62038834|NCT00688818|EXPERIMENTAL|Quetiapine and existing psychotropics|
62038835|NCT00688818|PLACEBO_COMPARATOR|Placebo and existing psychotropics|
62038836|NCT03923933|PLACEBO_COMPARATOR|Placebo|This group will receive 3 milligrams of bumetanide per day for a week plus placebo (starch) that will simulate the chlorthalidone dose of the treatment group. In case the dose is well tolerated, the dose of bumetanide will be increased to 4 milligrams per day.
62038837|NCT03923933|EXPERIMENTAL|Treatment grup|This group will receive 3 milligrams of bumetanide plus 50 milligrams of chlorthalidone per day, for a week. If the dose is well tolerated, it will be increased to 4 milligrams of bumetanide and 100 milligrams of chlorthalidone per day.
62038838|NCT06719505|ACTIVE_COMPARATOR|Multicomponent exercises (ME)|The interventions for the ME group will consist of exercises for aerobic training, strengthening, resistance, balance, and flexibility. The first week of the protocol will be dedicated to familiarizing the volunteers with the exercises, during which the correct execution of the movements will be demonstrated. Resources such as dumbbells, ankle weights, elastic bands, resistance bands, sticks, obstacles, and balls will be used.
62038839|NCT06719505|EXPERIMENTAL|Pilates exercises (PE)|For the intervention of the PE group, the first week of the protocol will be used to familiarize participants with the exercises, during which the correct execution of the movements will be demonstrated and each principle of the method will be explained: concentration, centering, precision, breathing, control, and fluidity. Regarding the progression of spring resistance, it will occur according to the volunteers' progress by switching to a spring with higher resistance (changing the position of the springs on the equipment or replacing them with ones of higher resistance). The basic equipment used will include the Cadillac Trapeze, Combo Chair, Universal Reformer, Ladder Barrel, and Wall Unit.
62241681|NCT03376477|EXPERIMENTAL|Lenalidomide plus GM-CSF Vaccine plus Prevnar13|"Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment.~Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. Prevnar vaccine will be administered with the GM-CSF vaccine administration."
62241682|NCT03376477|PLACEBO_COMPARATOR|Lenalidomide Only|Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment. Patients will also get placebo GM-CSF vaccine and placebo prevnar13. Placebo will be saline.
62241683|NCT03376477|PLACEBO_COMPARATOR|Lenalidomide plus GM-CSF Vaccine|"Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment.~Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. Patients will also be administered a placebo prevnar13 vaccination. Placebo will be saline."
62241684|NCT05651932|EXPERIMENTAL|Cohort A (Single agent): KTX-1001 + dexamethasone (DEX)|Cohort A1 (single agent): KTX-1001 at RP2D1 + DEX Cohort A2 (single agent): KTX-1001 at RP2D2 + DEX
62432095|NCT01532349|ACTIVE_COMPARATOR|4000 IU vitamin D|Children will be randomly allocated to receive cholecalciferol supplementation 4000 IU/day (28,000 IU weekly) according to the KDOQI recommended supplementation for children with mild 25D deficiency. Study participants will be prescribed any clinically indicated additional cholecalciferol supplementation once the 3-month laboratory measures have been obtained, based on serum 25D levels at the end of the study period.
62432096|NCT01363401|EXPERIMENTAL|Test group|Treatment group with HYNR-CS inj.
62432097|NCT01363401|EXPERIMENTAL|Control group|No treatment with HYNR-CS inj.
62241685|NCT05651932|EXPERIMENTAL|Cohort C (carfilzomib): KTX-1001 + DEX + carfilzomib|Cohort C1 (carfilzomib): KTX-1001 at RP2D1 + DEX + carfilzomib Cohort C2 (carfilzomib): KTX-1001 at RP2D2 + DEX + carfilzomib
62241686|NCT05651932|EXPERIMENTAL|Cohort D (pomalidomide): KTX-1001 + DEX + pomalidomide|Cohort D (pomalidomide): KTX-1001 at RP2D1/2 + DEX + pomalidomide
62243468|NCT02514733||Old donor|Kidney transplant recipient \>= 60 years of age who received organ from donor \>=50 years of age
62432098|NCT06156969|EXPERIMENTAL|Robot-assisted gait training|Robot-Assisted Gait Training using the LokomatPro device. Total of 18 training sessions, over a period of approximately 6-7 weeks. Sessions will last approximately 60 minutes.
62818121|NCT05138653|EXPERIMENTAL|Part B: Cohort 5: CVL-354 85 mg|Participants received oral dose of CVL-354 85 mg or Placebo, QD from Day 1 up to Day 14 in Cohort 5.
62432099|NCT01338285||1|Workers exposed to high levels of formaldehyde and unexposed workers in Guangdong Province, China.
62432100|NCT05139407|EXPERIMENTAL|Workshop|"The workshop is to discuss methods in various fields through activities, discussions, and lectures. It is an academic way to encourage participation, innovation, and predict solutions, suitable for people from different positions and ethnic groups to think, discuss, and communicate.~Each Intervention includes information relevant to how the Intervention was administered to participants in the associated Arm.~Workshop intervention for students: basketball training plan, basketball lesson plan, energy supply in muscle exercise, exercise prescription, track, and field mapping, basketball rules. All patients were intervened according to the frequency of 3 hours/once a week."
62818122|NCT03564600|EXPERIMENTAL|ABC Group|Veterans with back pain for at least the past 6 months receive personalized care by providers trained based on a published set of algorithms that guide care for conditions that contribute to disability in older adults with chronic low back pain
62818123|NCT03564600|NO_INTERVENTION|UC Group|Veterans with back pain for at least the past 6 months who receive usual care as directed by their primary care physician.
62038840|NCT03532295|EXPERIMENTAL|Regimen A: Retifanlimab+RT+bevacizumab|"* Retifanlimab will be given intravenously over the course of 30 to 60 minutes at a dose of 500 mg on Day 1 of each 28-day cycle.~* Bevacizumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.~* Ten fractions of radiation therapy will be given at a dose of 3.5 Gy per fraction~* Retifanlimab and bevacizumab will be started approximately two weeks before the first day of radiation therapy~* Treatment may continue for up to two years."
62241687|NCT02115399||ADStaph-|Atopic Dermatitis without a history of Eczema Herpeticum and without S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group.
62241688|NCT02115399||ADStaph+|Atopic Dermatitis without a history of Eczema Herpeticum and with S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group.
62241689|NCT02115399||NAStaph-|Non-atopic healthy participants without S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group
62818124|NCT05310279|EXPERIMENTAL|Active video gaming|Participants will engage in 6 weeks of active video gaming (AVG), 2x/week
62241690|NCT02115399||NAStaph+|Non-atopic healthy participants with S. aureus skin colonization. As the NAStaph+ phenotype is expected to be rare, as many participants as possible will be enrolled in this group; however, we do not expect to enroll 45 participants in this group.
62241691|NCT01320787|EXPERIMENTAL|18F-fluoroacetate|18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.
62241692|NCT04127825|EXPERIMENTAL|Acute Normovolemic Hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a blood conservation technique that entails the removal of blood from a patient shortly after induction of anesthesia, with maintenance of normovolemia using crystalloid and/or colloid replacement.
62432101|NCT05139407|EXPERIMENTAL|Oral examination|"The oral examination is a way of examination, which requires the examination to answer questions orally. Content intervention includes the comment, teacher's question and answer, proposition explanation, and proposition debate. In addition, each Intervention provides information relevant to how the Intervention was administered to students in the associated Arm.~Specific interventions for students: basketball training plan, basketball lesson plan, energy supply system, exercise prescription formulation, track and field venue planning, basketball game rules. All oral examinations take 90 minutes/once/week."
62432102|NCT04592991|ACTIVE_COMPARATOR|AAA Group|"Participants with AAA will undergo routine clinical evaluation of AAA including ultrasound and CT and scheduling of open surgical repair as directed by the treating physician. We will record age and tobacco use of participant. If participant has not had a renal function blood test performed within the past 90 days, we will draw approximately 2 teaspoons of blood for a creatinine test. We will also ask the participant's permission to use a contrast dye for the CT portion of the PET-CT scan. If the participant agrees we will additional questions to gauge eligibility to receive the contrast dye.~If available, we would like to collect any discarded AAA tissue from the surgical procedure. This discarded tissue will be kept as part of a Washington University vascular research repository. If the participant agrees to this there will be a separate consent form to sign allowing the collection of the leftover tissue along with some information about medical history."
62432103|NCT04592991|ACTIVE_COMPARATOR|Aortoiliac Occlusive Disease Group|Participants with non-aneurysmal aortoiliac occlusive disease, will be eligible for the study based on lifestyle limiting claudication (lack of blood flow to muscles causing cramping), pain in the feet or toes at rest, and/or tissue loss (leg or foot ulcers that don't heal or gangrene) that requires aortofemoral bypass. The aortofemoral bypass is not part of this research study.
62432104|NCT02712385|NO_INTERVENTION|Control - usual care|Usual post-TIA/minor stroke care as per current healthcare system protocol will be given to patients in control group and details will be recorded.
62432105|NCT02712385|ACTIVE_COMPARATOR|Manual|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual'.
62432106|NCT02712385|ACTIVE_COMPARATOR|Manual + pedometer, 1|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual' and a pedometer with telephone follow-up from a General Practitioner.
62432107|NCT02712385|ACTIVE_COMPARATOR|Manual + pedometer, 2|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual' and a pedometer with telephone follow-up from a Stroke nurse.
62432108|NCT03605537|EXPERIMENTAL|Stent|"Subjects will undergo repair of the choanal atresia in the operating room with a drug eluting stent placed at the end of the surgical procedure. They will return to the operating room in 3-5 weeks for repeat nasal endoscopy with possible balloon dilation, which is standard of care within our institution. At this time in the operating room the intervention arm will have the stent removed. Following removal of the stent, photodocumentation of the posterior nasal cavity and nasopharynx will take place to assess the size (standard of care).~Subjects will then follow up and undergo a bedside or outpatient nasal endoscopy and nasopharyngoscopy (standard of care) at the following approximate intervals 1 month, 6 months, 12 months (these are not exact time periods as clinic scheduling can sometimes be 2-3 months on either side of these time stamps)."
62818125|NCT02521285|EXPERIMENTAL|Arm A (aspirin)|Patients receive aspirin PO QD for 12 months.
62818126|NCT02521285|PLACEBO_COMPARATOR|Arm B (placebo)|Patients receive placebo PO QD for 12 months.
62818127|NCT00988494|EXPERIMENTAL|High concentration|DE-105 high concentration
62818128|NCT00988494|EXPERIMENTAL|Low concentration|DE-105 low concentration
62818129|NCT00988494|PLACEBO_COMPARATOR|Placebo|DE-105 placebo
62818130|NCT04364386|EXPERIMENTAL|InPress|Treatment with InPress Device for Postpartum Hemorrhage
62241693|NCT04127825|NO_INTERVENTION|Standard of Care|Standard of care for blood volume maintenance during surgery
62241694|NCT05330403|EXPERIMENTAL|the lung meridian intervention group|moxibustion intervention was performed over Site 1 (LU5) of the lung meridian
62241695|NCT05330403|EXPERIMENTAL|the heart meridian intervention group|moxibustion intervention was applied over Site 4 (HT3) of the heart meridian
62241696|NCT02041754|ACTIVE_COMPARATOR|IQP-AK-102|2 capsules per dose, 3 times daily, 30-60 mins before each main meal with a full glass (250 mL) of water
62241697|NCT02041754|PLACEBO_COMPARATOR|Placebo|2 capsules per dose, 3 times daily, 30-60 mins before each main meal with a full glass (250 mL) of water
62241698|NCT03942406|EXPERIMENTAL|BPZE1 Intranasal Prime, BPZE1 Boost|Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of intramuscular (I.M.) placebo. Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator™ atomization device.
62038841|NCT03532295|EXPERIMENTAL|Regimen B: Retifanlimab+RT+bevacizumab+epacadostat|"* Retifanlimab will be given intravenously over the course of 30 to 60 minutes at a dose of 500 mg on Day 1 of each 28-day cycle.~* Bevacizumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.~* Ten fractions of radiation therapy will be given at a dose of 3.5 Gy per fraction~* Retifanlimab and bevacizumab will be started approximately two weeks before the first day of radiation therapy~* Epacadostat will be administered orally at 400 mg BID.~* Treatment may continue for up to two years."
62038842|NCT01717118|ACTIVE_COMPARATOR|Tetravalent Vaccine|"* Month 2 visit: May be scheduled on the appropriate month +/- 3 weeks.~* Month 6, 21, 60 and 61 visit (vaccination scheme 0, 2, 6): May be programmed on the appropriate month +/- 4 weeks.~* Month 7 and 61 visit (vaccination scheme 0, 6, 60): The time interval between the month 6/60 visit and the month 7/61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination"
62038843|NCT01717118|ACTIVE_COMPARATOR|Bivalent Vaccine|"* Month 1 visit: May be scheduled 21 to 62 days after the Day 0 visit.~* Month 6 visit: May be scheduled 161 to 216 days after the Day 0 visit.~* Month 6 visit: The time interval between the month 6 visit and the month 7 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination.~* Month 21, 60 and 61 visit (vaccination scheme 0, 1, 6): May be scheduled on the appropriate month +/- 4 weeks.~* Month 61 (vaccination scheme 0, 6, 60) The time interval between the month 60 visit and the month 61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination"
62038844|NCT06732115|EXPERIMENTAL|Intervention|One-step polishing system with nanohybrid resin composite restorations
62038845|NCT06732115|ACTIVE_COMPARATOR|Compartor|Multistep system polishing system with nanohybrid resin composite restorations.
62038846|NCT02207816|EXPERIMENTAL|GSK257049 Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of GSK257049 malaria vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on a 0-1-2-month schedule, and a booster dose of GSK257049 malaria vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
62038847|NCT02207816|ACTIVE_COMPARATOR|GSK257049 Comparator Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of GSK257049 malaria vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on 0-1-2-month schedule, and a booster dose of Menjugate vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: in the anterolateral left thigh (GSK257049 vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
62038848|NCT02207816|ACTIVE_COMPARATOR|VeroRab/Menjugate Comparator Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of VeroRab vaccine (children subgroup) or Menjugate vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on 0-1-2-month schedule, and a booster dose of Menjugate vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: left deltoid (VeroRab vaccine and Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
62038849|NCT05668117||Control|Historical patient data from other published studies in the literature
62038850|NCT05668117||Study participants|Adult patients with non-pathologic distal femur and femoral shaft fractures treated with the Depuy Synthes Advanced Retrograde femoral nail who had at least 6 months of follow up.
62038851|NCT05289362|EXPERIMENTAL|Treating pancreatic duct stones by using baskets|ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, Endoscopic Sphincterotomy or Endoscopic Papillary Balloon Dilatation will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. After that, the basket will be used to remove the stones first, and the balloon will replace the basket after 15 minutes to remove any remaining stones. Finally, the effect of the basket will be evaluated.
62038852|NCT05289362|ACTIVE_COMPARATOR|Treating pancreatic duct stones by using balloons|ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, Endoscopic Sphincterotomy or Endoscopic Papillary Balloon Dilatation will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. After that, the balloon will be used to remove the stones first, and the basket will replace the balloon after 15 minutes to remove any remaining stones. Finally, the effect of the balloon will be evaluated.
62432109|NCT03605537|NO_INTERVENTION|No Stent|"Subjects will undergo repair of the choanal atresia in the operating room with no stent placed at the end of the surgical procedure. They will return to the operating room in 3-5 weeks for repeat nasal endoscopy with possible balloon dilation, which is standard of care within our institution. Photodocumentation of the posterior nasal cavity and nasopharynx will take place to assess the size (standard of care).~Subjects will then follow up and undergo a bedside or outpatient nasal endoscopy and nasopharyngoscopy (standard of care) at the following approximate intervals 1 month, 6 months, 12 months (these are not exact time periods as clinic scheduling can sometimes be 2-3 months on either side of these time stamps)."
62432110|NCT00990561|ACTIVE_COMPARATOR|Twice Daily Ultravate|Patients will apply both Ultravate ointment and LacHydrin lotion twice daily
62432111|NCT00990561|ACTIVE_COMPARATOR|Once daily Ultravate|Patients will apply Ultravate ointment once daily, but will use LacHydrin lotion twice daily
62432112|NCT06290869|EXPERIMENTAL|MedStar Health System|Phone-based Tobacco Treatment, Nicotine Replacement, and Stepped Care Intervention
62241699|NCT03942406|EXPERIMENTAL|BPZE1 Intranasal Prime, Placebo Boost|Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of intramuscular (I.M.) placebo. Individuals will receive a boost dose of intranasal placebo via the VaxINator™ atomization device.
62241700|NCT03942406|EXPERIMENTAL|Boostrix IM Prime, BPZE1 Boost|Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of intramuscular (I.M.) Boostrix (aP vaccine comparator). Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator™ atomization device.
62241701|NCT03942406|ACTIVE_COMPARATOR|Boostrix IM Prime, Placebo Boost|Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of intramuscular (I.M.) Boostrix (aP vaccine comparator). Individuals will receive a boost dose of intranasal placebo via the VaxINator™ atomization device.
62432113|NCT06290869|ACTIVE_COMPARATOR|E-Referral to the Tobacco Quitline|Standard tobacco quitline protocol, including coaching, nicotine replacement, and web-, and text-based resources.
62599124|NCT05809258|ACTIVE_COMPARATOR|Supraclavicular block|In the supraclavicular group, the ultrasound probe will be positioned in the supraclavicular fossa, pointing caudad and locating the subclavian artery. The first rib is identified deep to the artery, and the hyperechoic pleura will be identified by sliding lung sign. The brachial plexus is consistently found with a characteristic ''honeycomb'' appearance lateral and superficial to the subclavian artery and superior to the first rib. The needle will be introduced through the skin from lateral to medial, in-plane with the transducer, with constant visualization, and directed toward the deep border of the nerve group. Three separate injections will be made at various sites in the bundle, tending to start deep, in the ''corner pocket'' close to the artery, and moving more superficially. The local anesthetics will be Lidocaine 2% 10 ml + Levobupivacaine 0.5% 10 ml.
62735278|NCT03279887||Post operative respiratory failure|"Patients with acute respiratory failure (ARF) less than 72 hours after a major cardiac surgery with cardiopulmonary bypass~ARF was defined as one of the following conditions:~* If mechanical ventilation, a partial pressure of oxygen/ inspired oxygen fraction ratio (PaO2/FiO2) \< 200, or failure of weaning (failure of spontaneous ventilation test, re-intubation in the first 24 hours), or need for non-invasive ventilation immediately after extubation,~* If spontaneous ventilation: clinical signs of acute respiratory distress (dyspnea at least exertion, cyanosis, polypnea\> 25/min, upper or intercostal swallowing, abdominal swing ...), pulse oximetry (SpO2) \< 90% or PaO2 \<60 mmHg despite oxygen therapy ≥ 3 L/min."
62038853|NCT04530292|EXPERIMENTAL|intervention by a pediatric nurse at the child's home|"The pediatric nurse will visit the patient's home 3 times during the first six months of the discovery of diabetes in children. These visits will be organized during the first, fourth and sixth months after the discovery of diabetes and last about 2 hours each time. An additional visit can be organized according to the needs of families.~The pediatric nurse will ensure the implementation of learning in terms of drug therapy (modality of insulin administration, adaptation of insulin doses) and diet, according to the knowledge acquired during the initial hospitalization. She will offer her help to the families to make a connection with the school and after-school activities of the child.~In addition to these visits, the child and his family will come to the hospital as part of the regular medical follow-up: consultations with the pediatric diabetologist at the 3rd and 6th month and at 1 year of the discovery of diabetes."
62241702|NCT03511404|EXPERIMENTAL|Chronical LBP|Patients with chronic low back pain to be measured with Numeric Pain Rating Scale (NPRS).
62432114|NCT01927081|ACTIVE_COMPARATOR|discussion group|Eight weekly group sessions in which participants will engage in discussions regarding issues related to coping with advanced cancer and pain
62432115|NCT01927081|ACTIVE_COMPARATOR|discussion group + exercise|Eight weekly group sessions in which participants will engage in discussions regarding issues related to coping with advanced cancer and pain and learn gentle exercise and breathing techniques
62432116|NCT02629965|EXPERIMENTAL|tiotropium + olodaterol|inhalation two puffs from the RESPIMAT inhaler, once a day, in the morning
62432117|NCT02629965|ACTIVE_COMPARATOR|tiotropium|inhalation two puffs from the RESPIMAT inhaler, once a day, in the morning
62432118|NCT06369337||group control|undeveloped dysphagia
62432119|NCT06369337||Group cohort|Developed dysphagia
62432120|NCT05943496|EXPERIMENTAL|Treatment (tafasitamab, obinutuzumab, acalabrutinib)|See Detailed DescriptionPatients receive obinutuzumab IV over a rate titrated up to 400 mg/hour on days 1, 2, 8, and 15 for cycle 1 then on day 1 for cycles 2-6 and tafasitamab IV over 1.5-2 hours on days 1, 4, 8, 15, and 22 for cycle 2, on days 1, 8, 15, and 22 for cycles 3-4, and on days 1 and 15 for cycles 5-7. Patients also receive acalabrutinib PO BID in each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and CT throughout the trial. Patients may undergo an ECHO at baseline as clinically indicated and may also undergo bone marrow biopsy and/or aspiration at baseline and/or follow-up.
62432121|NCT02617173|EXPERIMENTAL|Transcutaneous electrical nerve stimulation|Low current electrical stimulator
62432122|NCT04006847|EXPERIMENTAL|Eicosapentaenoic Acid (EPA)|"Phase I: TKI with escalating/de-escalating doses of EPA to determine MTD.~Phase I dose levels: Dose Level 1 = EPA 1500 mg orally once per day; Dose Level 2 = EPA 2000 mg orally once per day; Dose Level 3 = EPA 3000 mg orally once per day; Dose Level -1 = EPA 1000 mg orally once per day; Dose Level -2 = EPA 500 mg orally once per day.~Phase II: TKI administered in combination with the recommended Phase II dose of EPA"
62241703|NCT06717230|EXPERIMENTAL|EverX Posterior with Vita Endo-Crowns, EverX Posterior with Bulk-Fill Resin Restorations|Biomimetic dentistry leverages modern materials to replicate the biological and mechanical functions of natural teeth, presenting a distinct approach that minimizes the need for extensive tooth reduction and post-placement, particularly advantageous for endodontically treated teeth. Utilizing fiber-reinforced composites, this technique aims to strengthen the dentin-resin bond and evenly distribute occlusal forces across the restoration. By closely adhering to the intact tooth's natural contours and functionality, biomimetic restorations not only preserve more of the natural tooth structure but also reduce stress and strain within the restored tooth. This approach enhances longevity and minimizes the risk of bond failure, with any necessary repairs being straightforward and contributing to the restoration's sustainability.
62241704|NCT06717230|ACTIVE_COMPARATOR|Lithium Disilicate Endo-Crowns|conventional restoration for endodontically treated teeth
62241705|NCT02952391||Parkinson's disease patients|patients with Parkinson's disease, between the ages of 45 and 65, with a disease duration of 3 - 10 years
62241706|NCT02952391||healthy control subjects|Healthy control subjects, between the ages of 45 and 65
62241707|NCT04780490|ACTIVE_COMPARATOR|liberal fluid therapy|"Patients will be applied 2 mg midazolam for premedication. Before anesthesia induction, epidural catheter will be inserted to all patients and test dose will be made with 3 cc % 2 lidocaine (No medication from the epidural catheter will be administered during surgery).~Standard anesthesia induction will be applied (fentanyl 2 mcg/kg; propofol 2 mg/kg; rocuronium 0.6 mg/kg ), and after intubation maintenance of anesthesia will be achieved with sevoflurane with a minimum alveolar concentration (MAC) of 0.8-1.~Fluid resuscitation will be started with 10 ml / kg / hr Ringer's lactate solution.~In patients with MAP \<65 mmHg, 250 ml of Ringer's lactate solution will be given as a bolus.~If the hypotension persists, the bolus 250 ml Ringer's lactate solution will be repeated up to 10 times."
62241708|NCT04780490|ACTIVE_COMPARATOR|restrictive fluid therapy|"Patients will be applied 2 mg midazolam for premedication. Before anesthesia induction, epidural catheter will be inserted to all patients and test dose will be made with 3 cc % 2 lidocaine ( No medication from the epidural catheter will be administered during surgery. ) Standard anesthesia induction will be applied ( fentanyl 2 mcg/kg; propofol 2 mg/kg; rocuronium 0.6 mg/kg ) and after intubation maintenance of anesthesia will be achieved with sevoflurane with a minimum alveolar concentration (MAC) of 0.8-1.~Fluid resuscitation will be started with 2 ml / kg / hr Ringer's lactate solution and norepinephrine infusion at a dose of 2 mcg / kg / hr.~In patients with MAP\<65 mmHg, norepinephrine dose will be increased up to 8 mcg / kg / hr.~If the hypotension persists although the norepinephrine dose is 8 mcg / kg / hr, 250 ml bolus Ringer's lactate solution will be given."
62241709|NCT04847531||Stage 3 chronic kidney disease patients|Patients with two consecutive eGFR measurements indicating stage 3 CKD (≥30 and \<60 mL/min/1.73m2) during the observation period
62241710|NCT04289740|EXPERIMENTAL|cognitive-bahavioral therapy|Trasdiagnotic cognitive-behavioral group therapy: The psychological interventions will be manualized. Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12 week period.
62241711|NCT04289740|ACTIVE_COMPARATOR|relaxation therapy|The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. This intervention will have the same number of sessions as the experimental intervention and last anywhere from 60 to 90 minutes, depending on the session.
62241712|NCT01717768|EXPERIMENTAL|Part 1: 120 mg BID|Oral TSX-002 120 mg BID (total dose = 240 mg/day) for a duration of 15 days
62241713|NCT01717768|EXPERIMENTAL|Part 1: 240 mg BID|Oral TSX-002 240 mg BID (total dose = 480 mg/day) for a duration of 15 days
62818131|NCT06204068|EXPERIMENTAL|Hip Spica 6 weeks, Brace 6 weeks|The experimental group will be placed in a hip spica cast for a total of 6 weeks, then will transition to a brace for 6 weeks.
62818132|NCT06204068|ACTIVE_COMPARATOR|Hip Spica 12 weeks (Control)|The control group will be placed in a hip spica cast for a total of 12 weeks with a change of spica cast, under anesthesia, at the 6-week mark. This treatment is the accepted standard of care for children who undergo closed reduction of a developmentally dysplastic and dislocated hip.
62241714|NCT01717768|EXPERIMENTAL|Part 2: 120 mg BID|Single cohort, open-label, nonrandomized oral TSX 002 120 mg BID (total dose = 240 mg/day) for a duration of 15 days
62432123|NCT03818919|EXPERIMENTAL|Post-Operative Non Opioid Pain Protocol|Patients in this group will be administered a novel multimodal pain protocol post-operatively consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
62432124|NCT03818919|ACTIVE_COMPARATOR|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-Acetaminophen Cap 5-500
62432125|NCT05659706||"Arm 1: intervention group, named Group 3+"|attend at least three workshops per week
62432126|NCT05659706||"Arm 2: control group, named Group 0-1"|not participate in the activities program or will attend a maximum of one workshop per week.
62735279|NCT02466035|EXPERIMENTAL|Lactobacillus GG|Treatment with Lactobacillus rhamnosus GG
62818133|NCT04983251||U4 Women|Women in under-served, under-studied, under-represented, and under-reported (U4) populations.
62599125|NCT05809258|ACTIVE_COMPARATOR|Axillary block|Patients in the axillary group are placed in the supine position with the arm to be blocked, abducted and externally rotated. After sterilization of the axilla, the Ultrasound probe will be placed parallel to the anterior axillary fold at the axilla to identify the axillary artery and surrounding radial, ulnar, and median nerve, appearing as hypo-echoic round structures around the axillary artery. The musculocutaneous nerve will also be identified between the coracobrachialis and biceps muscle or in either of them. Lidocaine 1% was infiltrated subcutaneously 1 cm lateral to the probe, and then 0.5% bupivacaine will be injected around branches of the brachial plexus. The local anesthetics will be Lidocaine 2% 10 ml + Levobupivacaine 0.5% 15 ml. In this block, 5-7 ml of local anesthetic will block each nerve.
62818134|NCT06104228|OTHER|Idiopathic Pulmonary Arterial Hypertension|Arm 1... patients with IPAH
62818135|NCT06104228|OTHER|Pulmonary Arterial Hypertension Associated with Connective Tissue Disease|Arm 2... patients with CTD-PAH
62818136|NCT04767659|EXPERIMENTAL|Women candidate for clinical trial|Twenty adult women with a recent diagnosis of breast cancer, candidate for NAC, besides assessing the response to neoadjuvant chemotherapy using standard imaging evaluation, will undergo optical imaging at six selected time points from prior to commencement of NAC/baseline to the completion of NAC treatment (prior to surgery).
62818137|NCT04819217|OTHER|Active bamboo charcoal|Based on these previous findings, we will conduct a prospective randomized open blinded end-point (PROBE) study to see if oral uremic toxin absorbent + probiotics prevent CKD progression.
62818138|NCT04819217|OTHER|Probiotics|Based on these previous findings, we will conduct a prospective randomized open blinded end-point (PROBE) study to see if oral uremic toxin absorbent + probiotics prevent CKD progression.
62818139|NCT02167490|ACTIVE_COMPARATOR|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
62735280|NCT02466035|NO_INTERVENTION|Other formula|Children assuming other hypoallergenic formulas
62818140|NCT02167490|NO_INTERVENTION|Arm 2: observation|No axillary staging
62038854|NCT04530292|NO_INTERVENTION|Classic strategy (for retrospective group)|The child and his family benefited from a consultation with a pediatric nurse at 1 month of the discovery of T1D and had medical consultations with the pediatric diabetologist at the 3rd and 6th month and at 1 year of the discovery of diabetes. The data from this group were collected in a previous study (collection of retrospective data) for children whose parents were in a precarious social situation and whose management was traditional.
62038855|NCT06200181|EXPERIMENTAL|Arm 1|Participants will take a lower dose of olanzapine every day for Days 1-7 and then a higher dose every day for the next 3 weeks
62038856|NCT06200181|EXPERIMENTAL|Arm 2|Participants will take the lower dose of olanzapine every day for 4 weeks.
62038857|NCT06200181|PLACEBO_COMPARATOR|Arm 3|Participants will take a placebo every day for 4 weeks.
62038858|NCT05225246||Readmission group|Patients who had heart surgery and returned unplanned to the University Hospital Basel within 30 days of leaving the hospital (outpatient or inpatient)
62038859|NCT05225246||control group|Patients who had heart surgery and did not return unplanned to the University Hospital Basel within 30 days of leaving the hospital (outpatient or inpatient)
62038860|NCT04109703|ACTIVE_COMPARATOR|High level pulsed heat|Subjects randomized to this arm received a generation 5 device (Soovu Labs Inc.) that produced 30 minutes of heat. The heat was delivered as waves peaking at 45° C.
62038861|NCT04109703|PLACEBO_COMPARATOR|Low level steady heat|Subjects randomized to this arm received an identical generation 5 device (Soovu Labs Inc.) that produced 30 minutes of heat. The heat was delivered in a steady manner at 37° C.
62038862|NCT04534374|EXPERIMENTAL|Resistance exercise|The experimental intervention is a session of resistance exercise described in the intervention section.
62038863|NCT04534374|ACTIVE_COMPARATOR|Stretching exercise|The active control intervention is a session of stretching exercise described in the intervention section.
62818141|NCT04166643|ACTIVE_COMPARATOR|Education only|Education
62432127|NCT02354365||Normal lungs|Mechanically ventilated patients without pulmonary parenchymal disease or lower airway disease as measured by flow volume loops consistent with expiratory flow obstruction (e.g. seizures, apnea, upper airway obstruction).
62818142|NCT04166643|EXPERIMENTAL|WHHIP-PLUS and Function Focused Care|"Component I: Stakeholder Group Involvement:~Component II: Environment Assessment:~Component III: Organizational Changes To Reduce Job Stress:~Component IV- Worker Health Behavior Change including function focused care interventions"
62818143|NCT06028919|OTHER|Temperature controlled DiamondTemp (DT) ablation catheter|Intervention arm
62818144|NCT06028919|OTHER|Power controlled Tacticath/Tactiflex ablation catheter|Control arm
62818145|NCT03154346||General Population|An unlimited number of participants will be accepted into a Baseline registry. From the Baseline registry, approximately 10,000 participants will be selected for the Baseline Study. Participant enrollment for the Baseline Study will be stratified by age, sex and risk factors and will aim to reflect the race and ethnicity distribution within the U.S.. The population includes a broad range of participants across the health spectrum, including exceptionally healthy participants, participants at risk of disease, and participants with current disease. The study population will be enriched for participants with an elevated risk of primary cardiovascular disease, lung cancer, and/or breast/ovarian cancers.
62818146|NCT04968288||Cohort 1|Subjects with KSHV-associated MCD
62818147|NCT05161377|ACTIVE_COMPARATOR|Surgical management|
62818148|NCT05161377|ACTIVE_COMPARATOR|Endovascular management|
62818149|NCT05640271|EXPERIMENTAL|Early Tocilizumab|This arm will receive tocilizumab 80 mg at the time of acute chest syndrome diagnosis and subsequent randomization. Then, two days later, they will receive 50 mL of normal saline.
62818150|NCT05640271|ACTIVE_COMPARATOR|Delayed Tocilizumab|This arm will receive 50 mL of normal saline at the time of acute chest syndrome diagnosis and subsequent randomization. Then, two days later, they will receive tocilizumab 80 mg. Thus, this delayed arm will serve as a placebo comparator for the first 48 hours and then as an active comparator for the remaining duration on study.
62818151|NCT04918420|EXPERIMENTAL|Flow Diverter (Tonbridge)|Treatment with Flow Diverter (Tonbridge)
62818152|NCT04729907|EXPERIMENTAL|BIIB058 28 mg (Prior Maintenance Dose 28 mg)|Participants who received maintenance dose of 28 milligrams (mg) nusinersen in study 232SM203 (NCT04089566), will receive maintenance dose of 28 mg nusinersen, by intrathecal injection, on Day 1, followed by maintenance dose of 28 mg nusinersen, by intrathecal injection, every 4 months, up to Day 1921.
62818153|NCT04729907|EXPERIMENTAL|BIIB058 50/28 mg (Prior Maintenance Dose 12 mg)|Participants who received maintenance dose of 12 mg nusinersen in study 232SM203 (NCT04089566), will receive loading dose of 50 mg nusinersen, by intrathecal injection, on Day 1, followed by maintenance dose of 28 mg nusinersen, by intrathecal injection, every 4 months, up to Day 1921.
62818154|NCT06300580|EXPERIMENTAL|ABBV-932|Participants will receive ABBV-932.
62818155|NCT06672406|EXPERIMENTAL|Intervention Group|Preterm infants who receive 5 drops of probiotic Lactobacillus reuteri for 7 days
62241715|NCT01717768|EXPERIMENTAL|Part 3: A-B-C 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~* Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~* Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~* Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
62432128|NCT02354365||Acute Hypoxic Respiratory Failure|Mechanically ventilated patients with two consecutive Saturation to FiO2 (SF) ratio \< 265 or PaO2 to FiO2 (PF) ratio \< 300 (e.g. pneumonia, ARDS).
62432129|NCT02354365||Obstructive airway disease|Mechanically ventilated patients with flow volume loops consistent with expiratory flow obstruction (e.g. asthma, bronchiolitis).
62432130|NCT05178147|EXPERIMENTAL|Volunteers|Volunteers having compression bandages applied to their legs.
62432131|NCT00328783|EXPERIMENTAL|Active Breathing Coordinator|Patients breathe through the ABC device
62432132|NCT00941252|ACTIVE_COMPARATOR|Imiquimod|topical therapy for 16 weeks with imiquimod containing therapy
62432133|NCT00941252|PLACEBO_COMPARATOR|Placebo|topical therapy for 16 weeks with a placebo containing vaginal suppository
62432134|NCT01377961|ACTIVE_COMPARATOR|Arm1: Metabolic Syndrome Volunteers|
62432135|NCT01377961|ACTIVE_COMPARATOR|Arm 2:Previously Diagnosed diabetic patients|
62599126|NCT02525601|ACTIVE_COMPARATOR|Triathlon CR cemented|Triathlon Cruciate Retaining knee with cemented fixation randomised versus Triathlon Cruciated Retaining knee with uncemented fixation. The aim with this study is to evaluate the uncemented Peri-Apatite (PA) knee fixation and migration properties versus the cemented version.
62818156|NCT06672406|NO_INTERVENTION|Control Group|Preterm infants who receive standard care without probiotics
62818157|NCT03766789|ACTIVE_COMPARATOR|Intervention|They will receive the cell phone application, as reminder of medications time and dose.
62818158|NCT03766789|NO_INTERVENTION|Control|Patients will receive standard of care recommendations.
62818159|NCT03054519|ACTIVE_COMPARATOR|Metformin|Metformin daily
62818160|NCT03054519|PLACEBO_COMPARATOR|Placebo|Placebo daily for six months.
62818161|NCT03754725|EXPERIMENTAL|Deferiprone|This is the drug arm (deferiprone). Patients will receive oral deferiprone
62818162|NCT03754725|PLACEBO_COMPARATOR|Control|this group will only receive the placebo (sugar pill)
62818163|NCT06390722|EXPERIMENTAL|Upadacitinib|Participants randomized to receive upadacitinib Dose A once daily for 2 weeks during double-blind treatment period. At week 2, participants will be switched to open-label upadacitinib Dose A once daily for 22 weeks.
62818164|NCT06390722|PLACEBO_COMPARATOR|Placebo|Participants randomized to receive Placebo once daily for 2 weeks during double-blind treatment period. At week 2, participants will be switched to open-label upadacitinib Dose A once daily for 22 weeks.
62818165|NCT06673017|EXPERIMENTAL|Dose Escalation|Dose escalation will follow a modified (3+3) design to establish the preliminary RP2D and characterize the safety and pharmacokinetic profile of PTM-101, which will be taken together with all prior clinical data to establish and characterize the preliminary RP2D. A maximum of 12 subjects with treatment-naïve, borderline resectable or locally advanced PDAC will be recruited and receive PTM-101 combined with standard of care neoadjuvant chemotherapy, and be followed for a minimum of 24 months.
62818166|NCT06673017|EXPERIMENTAL|Dose Expansion|The dose of PTM-101 will be the preliminary RP2D determined from all available clinical data. Up to 20 subjects, inclusive of those already assigned to the preliminary RP2D in the dose escalation part, with treatment-naïve, borderline resectable or locally advanced PDAC will be recruited and receive PTM-101, combined with standard of care neoadjuvant chemotherapy, and be followed for a minimum of 24 months.
62818167|NCT02455791|EXPERIMENTAL|Ultrasound-Guided Biopsy of Tumor Site|Ultrasound-guided biopsy of the tumor site performed before scheduled surgery.
62818168|NCT06368700|EXPERIMENTAL|Hyalex Knee Cartilage System|Implantation of the Hyalex Knee Cartilage Implant
62818169|NCT06511973|EXPERIMENTAL|BAYHO06689|Topical application of BAYH006689 naproxen 10% topical gel on the intact skin
62818170|NCT06511973|PLACEBO_COMPARATOR|Placebo|Topical application of placebo gel which contains 0% of naproxen on the intact skin
62818171|NCT06511973|PLACEBO_COMPARATOR|Negative control|Topical application of the sterile 0.9% saline (negative control) on the intact skin
62432136|NCT01225991|EXPERIMENTAL|Milnacipran, active drug, open-label|All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day, or to their maximum tolerated dose in the course of the first week. The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day). Final efficacy assessments will be made at the termination visit, and the study medication will be tapered down following 12 weeks of drug treatment.
62818172|NCT06511973|ACTIVE_COMPARATOR|Positive control|Topical application of the 0.2% sodium lauryl sulfate (SLS) (positive control) on the intact skin
62818173|NCT04432935|EXPERIMENTAL|Bovine Lactoferrin|Intervention group will receive bovine lactoferrin supplementation daily once a day from day 0 of birth to 6 weeks of life.
62818174|NCT04432935|PLACEBO_COMPARATOR|Glucon D|Control group will receive Glucon-D supplementation daily once a day from day 0 of birth to 6 weeks of life.
62818175|NCT06369870|ACTIVE_COMPARATOR|Levobupivacaine Hydrochloride 0.25 % Injectable Solution|Unilateral (right) IPP-PSP block with 30 mL levobupivacaine 0.25%, administered after the closure of the wounds. After wound closure, the IPP-PSP block is performed at the level of the 4th rib. At the pre-axillary line, the pectoralis major, the pectoralis minor and the serratus anterior muscle are identified. At first, the needle is positioned in the fascial plane between the pectoralis minor and the serratus anterior muscle. The needle position is confirmed by hydro-dissection of this plane with 2 mL of normal saline 0.9%.The 20 ml syringe with trial drug solution is injected in this pectoserratus plane (PSP). The needle tip is repositioned in the interpectoral plane between both the pectoralis major and minor muscle. The 10 ml syringe with trial drug solution is administered in this interpectoral plane (IPP).
62818176|NCT06369870|SHAM_COMPARATOR|Sodium chloride 0.9%|Unilateral (right) IPP-PSP block with 30 mL normal saline 0.9%, administered after the closure of the wounds. Unilateral (right) IPP-PSP block with 30 mL normal saline 0.9%, administered after the closure of the wounds. The IPP-PSP block procedure will be carried out as described in the Active Comparator.
62818177|NCT06503432||high expression of programmed death-ligand 1|According to the distribution of PD-L1 concentration levels in the plasma, participants were divided into two groups: high expression of PD-L1 (PD-L1(H)) and low expression of PD-L1 (PD-L1(L)).
62432137|NCT03560505||Common fibular compression neuropathy|"Patients referred for electrophysiological assessment of common fibular compression neuropathy with subsequent confirmation of referral diagnosis.~Intervention: Ultrasound protocol."
62432138|NCT03560505||Type 2 diabetes polyneuropathy|"Patients with type 2 diabetes referred for polyneuropathy involving the common fibular nerve with subsequent confirmation of referral diagnosis.~Intervention: Ultrasound protocol."
62432139|NCT00852956|EXPERIMENTAL|Treatment|Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total)and Olanzapine (10 mg/day)
62818178|NCT06503432||low expression of programmed death-ligand 1|According to the distribution of PD-L1 concentration levels in the plasma, participants were divided into two groups: high expression of PD-L1 (PD-L1(H)) and low expression of PD-L1 (PD-L1(L)).
62818179|NCT03557749||Immune and Microbial Reconstitution|
62818180|NCT03557749||Immune Response Triggered by Severe, Systemic Viral Infection|
62818181|NCT03557749||Immune Response Triggered by Acute Graft-versus-Host Disease|
62432140|NCT00852956|ACTIVE_COMPARATOR|Control|Matching placebo TID; 08:00, 13:00 and 18:00 and Olanzapine (10 mg/day).
62818182|NCT03557749||Immune Response Triggered by Chronic Graft-versus-Host Disease|
62432141|NCT06246851|EXPERIMENTAL|Group A: 2-8 x 10^5 cfu intradermal BCG (non-type 2 diabetic group)|12 historically BCG-vaccinated volunteers without type 2 diabetes will receive 2-8 X 10\^5 cfu intradermally injected BCG. All Group A volunteers will have a bronchoscopy 14 days post challenge.
62432142|NCT06246851|EXPERIMENTAL|Group B: 2-8 x 10^6 cfu aerosol inhaled BCG (non-type 2 diabetic group)|12 historically BCG-vaccinated volunteers without type 2 diabetes will receive 2-8 X 10\^6 cfu aerosol inhaled BCG. All Group B volunteers will have a bronchoscopy 14 days post challenge.
62432143|NCT06246851|EXPERIMENTAL|Group C: 2-8 x 10^5 cfu intradermal BCG (type 2 diabetic group)|12 historically BCG-vaccinated volunteers with confirmed type 2 diabetes will receive 2-8 X 10\^5 cfu intradermally injected BCG. All Group C volunteers will not have a bronchoscopy.
62735281|NCT01779336|EXPERIMENTAL|PL225B|Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design.
62818183|NCT03557749||Immune Response Triggered by Relapse|
62818184|NCT03557749||Immune Response Triggered by Cytokine Release Syndrome|
62818185|NCT03557749||Allogeneic Related Donor Samples|
62818186|NCT03557749||Cellular Therapy Products|
62818187|NCT01468285|EXPERIMENTAL|Treatment arm 1: betahistine dihydrochloride|
62818188|NCT01468285|PLACEBO_COMPARATOR|Treatment arm 2: placebo|
62818189|NCT03507842|EXPERIMENTAL|High-dose cytarabine|High-dose cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).
62818190|NCT03507842|EXPERIMENTAL|high-dose daunorubicin|cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7) plus high-dose daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).
62818191|NCT06501534|ACTIVE_COMPARATOR|Febuxostat 40mg|Tablets, Once a day (QD), Per oral
62818192|NCT06501534|EXPERIMENTAL|IBI128 50mg|Tablets, Once a day (QD), Per oral
62818193|NCT06501534|EXPERIMENTAL|IBI128 200mg|Tablets, Once a day (QD), Per oral
62818194|NCT06501534|EXPERIMENTAL|IBI128 100mg|Tablets, Once a day (QD), Per oral
62818195|NCT04934748|ACTIVE_COMPARATOR|Tight Pressure Management with phenylephrine|Pressure maintenance with phenylephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
62818196|NCT04934748|ACTIVE_COMPARATOR|Tight Pressure Management with norepinephrine|Pressure maintenance with norepinephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
62818197|NCT04934748|ACTIVE_COMPARATOR|Routine Pressure Management with phenylephrine|Pressure maintenance with phenylephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial
62818198|NCT04934748|ACTIVE_COMPARATOR|Routine Pressure Management with norepinephrine|Pressure maintenance with norepinephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
62818199|NCT06194825|EXPERIMENTAL|Eplontersen|Eplontersen by subcutaneous injection once every 4 weeks
62818200|NCT06194825|PLACEBO_COMPARATOR|placebo|Eplontersen-matching placebo by subcutaneous injection once every 4 weeks
62818201|NCT03524612|OTHER|eltrombopag|Participants were treated with eltrombopag to induce sustained response off treatment to reach a target platelet count of \>=100×10\^9/L (CR), after 1st line steroids had failed.
62818202|NCT06079008||survival group|The patients who survived more than 1-year after amputation surgery.
62818203|NCT06079008||mortality group|The patients who were dead within 1-year after amputation surgery.
62818204|NCT00995761|NO_INTERVENTION|biweekly schedule|docetaxel 40mg/m2 on day 1,15 every 4weeks cisplatin 40mg/m2 on day 1,15 every 4weeks
62818205|NCT05331638|EXPERIMENTAL|Prostate Cancer Genius app|The Prostate Cancer Genius app includes the following components: (1) educational content that is consistent with existing evidence and recommendations for prostate cancer and prostate cancer screening but has been adapted for the African American male population and for adults who read at or below the 8th-grade level; (2) real-time messages about the risks of prostate cancer and the benefits of completing a PSA test, placing a special emphasis on screening considerations for individuals with a family history of prostate cancer and/or lower urinary tract symptoms (measured via the American Urological Association Symptom Score); (3) general trivia that also incorporates quiz questions about prostate cancer and the PSA test; (4) African American-specific testimonials and educational videos; (5) optional counseling by African American prostate cancer survivors; and (6) on-demand, automated ordering of a home-based PSA test.
62818206|NCT05331638|ACTIVE_COMPARATOR|Prevention Taskforce app|The Prevention Taskforce app provides on-demand access to evidence-based recommendations for prostate cancer for men between 55 and 69 (i.e., it can be accessed as needed).
62818207|NCT06377176|EXPERIMENTAL|Intervention group|Massage therapy for mother and infant.
62818208|NCT06377176|NO_INTERVENTION|Control group|the control group received standard care.
62818209|NCT06006208|NO_INTERVENTION|Arm 1: AMBU bag manual ventilation during transport to the ICU|
62818210|NCT06006208|EXPERIMENTAL|Arm 2: Hamilton C1 ventilator during transport to the ICU|
62818211|NCT04909710|EXPERIMENTAL|Autism Case Group|Autistic participants will receive mobile game system for 12 weeks and be asked to play a minimum of ten 90-second game sessions per week per child over 12 weeks. Research team will further require that at least three of these 10 weekly sessions with each child be with game decks displaying emotion.
62599127|NCT02525601|ACTIVE_COMPARATOR|Triathlon CR uncemented|Triathlon Cruciate Retaining knee with cemented fixation randomised versus Triathlon Cruciated Retaining knee with uncemented fixation. The aim with this study is to evaluate the uncemented PA knee fixation and migration properties versus the cemented version.
62599128|NCT03950375||cochlear implantation|"cochlear implantation group : patients undergoing cochlear implantation between December 2018 and June 2019 in the ENT service of Reims universitary hospital."
62599129|NCT02244346||Benign prostatic hyperplasia patients|
62818212|NCT04909710|OTHER|Neurotypical Sibling Control Group|Neurotypical control participants will receive the same mobile game system for 12 weeks and be asked to play a minimum of ten 90-second game sessions per week per child over 12 weeks. Research team will further require that at least three of these 10 weekly sessions with each child be with game decks displaying emotion.
62818213|NCT06569238|ACTIVE_COMPARATOR|Conventional bacterial culture|Wound tissue removed will be sent for standard of care evaluation.
62818214|NCT06569238|EXPERIMENTAL|Conventional bacterial culture plus rapid diagnostic group|Wound tissue removed will be sent for standard of care evaluation as well as rapid diagnostic with metagenomics next generation sequencing (mNGS).
62818215|NCT04065048|EXPERIMENTAL|Soy-based diet|Participants will be randomized to follow a soy-based diet for 7 days. The diet will be preceded by a 12-hr overnight fast.
62818216|NCT04065048|ACTIVE_COMPARATOR|Regular diet|Participants will be randomized to follow a diet without soy for 7 days. The diet will be preceded by a 12-hr overnight fast.
62599130|NCT05545345|ACTIVE_COMPARATOR|TT|Participants only receive tympanostomy tube placement.
62432144|NCT05824468|EXPERIMENTAL|Zimberelimab + Lenvatinib|"Safety run-in phase A dose de-escalation schedule is used in this phase. Dose Level 1: zimberelimab 240 mg administered intravenously on day 1 and lenvatinib 16 mg administered orally once daily on a 21-day treatment cycle. If ≥2/6 patients experience a DLT, we will de-escalate to Dose Level 2: zimberelimab 240 mg administered intravenously on day 1 and lenvatinib 12 mg administered orally once daily on a 21-day treatment cycle. Approximately 3-12 patients will be enrolled in the safety run-in phase.~Expansion phase The expansion stage will begin once the RP2D of lenvatinib have been determined in the safety run-in phase in order to assess antitumor activity of zimberelimab and lenvatinib combination. In expansion stage, zimberelimab 240 mg administered intravenously and lenvatinib PR2D will be administered."
62599131|NCT05545345|EXPERIMENTAL|Ad+TT|Participants will receive tympanostomy tube placement and concurrent adenoidectomy.
62818217|NCT05687604|ACTIVE_COMPARATOR|FACILITATED Program|STELLAR arm participants will receive goals related to their physical activity, smoking, and/or obesity, and will be asked to meet those goals weekly/daily. Participants will also be asked to record their weight, activity, and/or cigarette smoking daily, and will complete 16 telehealth sessions with study staff across the 12 months of the study. Will have physical measures taken or extracted from the medical record at baseline, 3 months, 6 months, and 12 months.
62038864|NCT00817362|EXPERIMENTAL|IPI-504 and Trastuzumab|"IPI-504 IV infusion 300 mg/m2 once weekly in combination with trastuzumab infusion every 3 weeks. (Continuous schedule)~Three week cycle with IPI-504 twice per week for 2 weeks and trastuzumab once per cycle followed by one week without treatment.~Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was \<4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.~IPI-504 and trastuzumab will be administered for all cycles. Until progression or unacceptable toxicity develops."
62432145|NCT04591418|ACTIVE_COMPARATOR|Rotary handpieces|
62432146|NCT04591418|EXPERIMENTAL|Er:YAG laser|
62432147|NCT01400854||Effentora®|Single group prospective treatment cohort
62432148|NCT01604954|OTHER|Non-obese|Non-obese women (BMI between 18.5 and 25 kg/m2)
62599132|NCT04046848|EXPERIMENTAL|Cohort 1|"50 IU/kg (n=4): single-period investigation with a single sc dose of 50 IU/kg OCTA101 profiled up to 72 hours after dosing in adult male patients with severe hemophilia A.~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 2, alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
62432149|NCT01604954|OTHER|Obese|Obese women (BMI between 30 and 40 kg/m2)
62432150|NCT05537337|NO_INTERVENTION|Arm 1 (Control Arm)|Participants will experience an unmodified version of NUSMart that is designed to replicate the traditional shopping experience of any online grocery shopping platform with details such as item description, brand, price, image, nutritional information etc.
62432151|NCT05537337|EXPERIMENTAL|Arm 2 (Multicomponent Intervention Arm)|Participants will experience a modified version of NUSMart with the multicomponent intervention enabled. This intervention consists of a subset of the combined interventions tested in Aim 1 namely, 1. Food labels (with the summary of healthiness of shopping baskets \& targets), 2. Ordering and 3. Within Group Healthier Substitution.
62432152|NCT04906473|EXPERIMENTAL|KY100001|KY100001; Tablet; Oral route; Dose escalation and dose extension
62432153|NCT01015911|EXPERIMENTAL|1|SGN-75
62432154|NCT03320473|EXPERIMENTAL|IC-8 IOL|IC-8 IOL implantation after removal of KAMRA ACI 7000 PDT inlay
62599133|NCT04046848|EXPERIMENTAL|Cohort 2|"100 IU/kg (n=4): single-period investigation with a single sc dose of 100 IU/kg OCTA101 profiled up to 96 hours after dosing in adult male patients with severe hemophilia A.~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 3, alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
62735282|NCT02183493|EXPERIMENTAL|Fed administration of BI 1356|
62735283|NCT02183493|ACTIVE_COMPARATOR|Fasted administration of BI 1356|
62735284|NCT06093308|EXPERIMENTAL|Elderly subjects|elderly subjects with underlying diseases.
62818218|NCT05687604|NO_INTERVENTION|SELF GUIDED Program|Patients in the EUC group will receive informational packets about their risk behaviors - obesity, physical inactivity, and/or smoking. Will have physical measures taken or extracted from the medical record at baseline, 3 months, 6 months, and 12 months
62241716|NCT01717768|EXPERIMENTAL|Part 3: B-C-A 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~* Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~* Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~* Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
62818219|NCT06296147|EXPERIMENTAL|Virtual Reality Device|The VR device used is the Flowly biofeedback virtual headset. This device uses calming immersive virtual worlds along with breathing exercises and a heart rate monitor to guide patients through meditated breathing exercises. The Flowly app is based on a smartphone which will be purchased through the department and used by all participants. The account used is a generic account for our department. No patient information or individualized accounts will be needed. No patient information or data will be collected.
62599134|NCT04046848|EXPERIMENTAL|Cohort 3|"50 IU/kg (n=8): two-period investigation of a single iv dose of 50 IU/kg Human-cl rhFVIII (Nuwiq) profiled for up to 72 hours after dosing followed by sc dose of 50 IU/kg OCTA101 profiled up to 72 hours in adult male patients with severe hemophilia A.~Treatments will be administered in fixed sequence, with Human-cl rhFVIII first.~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 4 and 5 alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
62818220|NCT06296147|EXPERIMENTAL|Aromatherapy|The aromatherapy arm will utilize one standardized patch with a peppermint/lavender scent based on prior research and experience.
62818221|NCT06296147|EXPERIMENTAL|Virtual Reality and Aromatherapy|This arm will combine both the Virtual Reality arm and the aromatherapy arm procedure.
62818222|NCT06296147|ACTIVE_COMPARATOR|Standard of Care|Participant will undergo transperineal prostate biopsy as standard of care.
62241717|NCT01717768|EXPERIMENTAL|Part 3: C-A-B 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~* Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~* Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~* Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
62818223|NCT05318131|EXPERIMENTAL|Single Arm Prospective Study|
62818224|NCT06600230|EXPERIMENTAL|Interventional group|Pelvic floor and exercise training was given by physiotherapists.
62432155|NCT02227537||Adolescence idiopathic scoliosis|Patients must be at least 10 years of age with a risser score of 0, 1, or 2
62432156|NCT05146869|EXPERIMENTAL|50 mg DBPR108 tablets|10 patients will be randomized to receive 50 mg DBPR108 tablets.
62432157|NCT05146869|EXPERIMENTAL|100 mg DBPR108 tablets|10 patients will be randomized to receive 100 mg DBPR108 tablets.
62432158|NCT05146869|EXPERIMENTAL|200 mg DBPR108 tablets|10 patients will be randomized to receive 200 mg DBPR108 tablets.
62599135|NCT04046848|EXPERIMENTAL|Cohort 5|(n=4): Three-period investigation of single sc doses of 20, 40, and 60 IU/kg OCTA101 profiled up to 72 hours after dosing. Treatments were to be administered in fixed dose-ascending sequence.
62599136|NCT04046848|EXPERIMENTAL|Cohort 6|(n≥16): Following an initial 4 to 6-week run-in period with Nuwiq iv prophylaxis, \>3-6 months daily prophylactic treatment with 12.5 IU/kg OCTA101 sc, then 25 IU/kg OCTA101 sc for a further 6-7 months (exact dosing depends on available vial sizes). In case of two spontaneous bleeding episodes, after having completed at least 3 months with 12.5 IU/kg OCTA101 daily treatment the individual treatment dose will be increased from 12.5 to 25 IU/kg. Site of administration (abdomen or thigh) to be chosen by the patient. A further treatment phase with 40 IU/kg OCTA101 will be discussed with the DMC, once results of earlier dosing phases are available.
62818225|NCT06600230|ACTIVE_COMPARATOR|Control group|Classical self-methods such as hot application were applied
62241718|NCT01717768|EXPERIMENTAL|Part 4 Cohort 1: 60 mg BID/ 60 mg TID|Oral TSX-002 60 mg BID for 15 days then 60 mg TID for 15 days
62241719|NCT01717768|EXPERIMENTAL|Part 4 Cohort 2: 90 mg BID/ 90 mg TID|Oral TSX-002 90 mg BID for 15 days then 90 mg TID for 15 days
62241720|NCT01717768|EXPERIMENTAL|Part 4 Cohort 3: 180 mg QD|Oral TSX-002 180 mg once daily (QD) for 15 days
62432159|NCT05848271||HPDL deficiency|Patients with HPDL mutations
62432160|NCT00588627||1|Post Nasal Drip and chronic cough
62432161|NCT00588627||2|Post nasal drip and no cough
62432162|NCT00732771|EXPERIMENTAL|LCI696 1mg bid|
62432163|NCT00894985|EXPERIMENTAL|1|Heparin 5.000UI
62432164|NCT00894985|ACTIVE_COMPARATOR|2|Heparin 5.000USP - APP
62432165|NCT05535517||Group 1|"KP Scoring Day Participants~Participants who attend the one-day scoring session in August 2022."
62432166|NCT05535517||Group 2|"KP Follow-up Scoring (September)~Participants who attended the scoring day in August will be invited to attend a follow-up scoring session in September - October 2022. The purpose of this scoring session is to see how stable their condition is and take baseline photographs of their skin to monitor their condition.~Four assessors will score the participants in 5-minute intervals with the proposed scoring system KPAI and the KP-IGA. Participants will be offered free samples of Cerave Salicylic Acid Smoothing Cleanser and Cream to try."
62818226|NCT06239272|EXPERIMENTAL|Low-Risk Subset A|Participants with low grade tumors of any size, or high-grade tumors \< 5 cm that have been (or are expected to be) completely removed by surgery. When the pathologist reviews the tumor specimen, the tissue around the tumor (margins) must be negative for cancer cells, meaning all of the cancer has been removed. These participants will have surgery to remove the tumor, followed by close observation. There will no further therapy after surgery, just monitoring for tumor recurrence and any side effects from surgery.
62818227|NCT06239272|EXPERIMENTAL|Low-Risk Subset B|Participants with high-grade tumors that are \< 5 cm with positive margins. This means that the pathologist finds cancer cells at the edge of the tissue, suggesting that all of the cancer has not been removed. These participants will have surgery followed by radiation therapy for about 5-6 weeks.
62599137|NCT04743804|EXPERIMENTAL|Ravulizumab|
62599138|NCT04743804|PLACEBO_COMPARATOR|Placebo|
62599139|NCT06046001|EXPERIMENTAL|AirWaze|AirWaze - easy and advanced tools for CBCT guided lung interventions
62599140|NCT04190498||NASH-related HCC|The study is focused on patients suffering from NASH-induced HCC. Each patient with NASH-related HCC will be paired with 2 patients with non NASH-related HCC (HCV-induced CHC).
62599141|NCT04190498||HCV-related HCC|HCV-related HCC has been chosen as control population for several reasons: HCV represent a common etiology of HCC; with a distinct pathophysiology distinct from that of post-NASH HCC; populations with post-NASH and post-HCV CHC share similar epidemiological characteristics.
62038865|NCT06561529|EXPERIMENTAL|Treatment group, subjects will be treated with the Gastric Bypass Stent System implanted|In total, 10 subjects will be enrolled from 2 investigational sites located in Latvia. Any subject participating in this clinical investigation will not be replaced once withdrawn or lost to follow-up. This study includes 3 phases; screening period, procedural period, and a follow-up period. Following screening, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 3; Day 0).
62038866|NCT06732817|ACTIVE_COMPARATOR|Personalized dual-target active rTMS treatment|Active rTMS was sequentially administered over the left DLPFC and left TPJ sites one hour apart, for 3 weeks.
62038867|NCT05109299|EXPERIMENTAL|Miswak toothpaste|Dabur meswak herpal toothpaste
62432167|NCT05535517||Group 3|"KP Follow-up Scoring (November)~Participants who attend the September scoring session will be invited to return for another rescoring in November - December 2022 to see if there is any improvement in their KP and if the score is responsive to change.~Participants will be given free samples of Propaira 30% Urea exfoliating emollient and Propaira 20% Lactic acid exfoliating lotion to try."
62432168|NCT05535517||Group 4|"KP Follow-up Scoring (December)~Participants who attend the November scoring session will be invited to return for another rescoring in December 2022 to monitor their progress, and see if there is any improvement in their KP and if the score is responsive to change."
62241721|NCT01717768|EXPERIMENTAL|Part 4 Cohort 4: 120 mg BID|Oral TSX-002 120 mg BID for 15 days
62241722|NCT04806139|EXPERIMENTAL|Intervention Group - Remote Enhance Fitness|Participants assigned to the intervention group will participated in a 16-week remote exercise intervention. Following a home/space environment and technology needs assessment, participants will attend a one-on-one orientation and practice class with a research assistant. Participants will join a live-streamed, instructor-led group Enhance Fitness exercise session for 1-hour, 3 days/week for 4 months (16-weeks).
62241723|NCT04806139|NO_INTERVENTION|Waitlist Control|Participants randomized to the waitlist control group will be offered the opportunity to participate in the Remote Enhance Fitness class after study measures are completed. Cuff weights will be provided along with technical orientation, support, and equipment as needed.
62241724|NCT01179672|EXPERIMENTAL|Duloxetine|
62432169|NCT01224756|EXPERIMENTAL|Tinoridine HCl 100 mg (2 capsules) TID|
62038868|NCT05109299|ACTIVE_COMPARATOR|Fluoride toothpaste|Signal fluoride toothpaste, containing 1450 ppm of fluoride
62241725|NCT01179672|PLACEBO_COMPARATOR|Placebo|
62038869|NCT04495179|EXPERIMENTAL|Arm A: AZD4635 + durvalumab|AZD4635 plus durvalumab (Arm A) will consist of participants with mCRPC previously treated with one or more approved NHAs (eg, abiraterone acetate, enzalutamide, apalutamide and/or darolutamide), and one or more taxanes, or participants who are taxane ineligible.
62241726|NCT00822354|EXPERIMENTAL|1|Subjects will receive tadalafil 20mg every other day for the first month, and then placebo for the second month.
62241727|NCT00822354|EXPERIMENTAL|2|Subjects will receive placebo for the first month, and tadalafil 20mg orally every other day for the second month.
62432170|NCT01224756|PLACEBO_COMPARATOR|Placebo TID|
62432171|NCT02053571|EXPERIMENTAL|TIPS with 3D overlay|
62241728|NCT02586220||normal pregnant women|150 normal pregnant women (28-32 weeks' gestation)
62241729|NCT02586220||pregnant women with gestational|100 pregnant women with gestational diabetes (28-32 weeks' gestation)
62432172|NCT06522516|EXPERIMENTAL|Caregiving training group|Caregiving training group will receive an evidence-based caregiving training via manual during nurse home visit.
62432173|NCT06522516|EXPERIMENTAL|Caregiving training plus family resilience group|Caregiving training plus family resilience group will receive an evidence-based caregiving training and family resilience psychological intervention via manual during nurse home visit
62432174|NCT06522516|ACTIVE_COMPARATOR|Control group|Controlled group will receive usual community service by nurse.
62432175|NCT04728737|EXPERIMENTAL|combined swallowing and IOPI group|the patients will receive swallowing therapy and IOPI biofeedback exercise program
62599142|NCT02852668|EXPERIMENTAL|Power Training Group|Physical exercises. Strength training performed quickly
62599143|NCT02852668|EXPERIMENTAL|Strength Training Group|Physical exercises. Strength training performed in moderate speed
62599144|NCT02852668|NO_INTERVENTION|Control Group|This group maintained the same physical activity level during the intervention period.
62599145|NCT01854879|EXPERIMENTAL|Nucleus 6|
62599146|NCT06041425|EXPERIMENTAL|Oxycodone|The patients were given 0.1mg/kg oxycodone 15 minutes before transcatheter arterial chemoembolization (TACE).
62599147|NCT06041425|ACTIVE_COMPARATOR|Sufentanil|The patients were given 0.1μg/kg sufentanil 15 minutes before transcatheter arterial chemoembolization (TACE).
62599148|NCT04824391|EXPERIMENTAL|3 mcg/0.5 ml Vaccine|Low dose vaccine
62599149|NCT04824391|EXPERIMENTAL|6 mcg/0.5 ml Vaccine|Medium dose vaccine
62599150|NCT04824391|PLACEBO_COMPARATOR|Placebo|Placebo
62432176|NCT04728737|ACTIVE_COMPARATOR|combined swallowing and NMES group|the patients will receive swallowing therapy and neuromuscular electrical stimulation
62432177|NCT04728737|NO_INTERVENTION|Normal group|20 normal people will receive sonography evaluations to verify the inter-rater and intra-rater reliability of sonography, and use IOPI to assess maximal muscle strength and endurance of oropharyngeal muscles.
62432178|NCT04180254|EXPERIMENTAL|Experimental: normal-hearing and hearing-impaired participants|normal and hearing-impaired participants
62599151|NCT04984473|SHAM_COMPARATOR|Sham arm|Perform inspiratory muscle training at 2% maximal inspiratory pressure for 12 weeks.
62599152|NCT04984473|ACTIVE_COMPARATOR|Non-sham arm|Perform inspiratory muscle training at 40% maximal inspiratory pressure for 12 weeks.
62038870|NCT04495179|EXPERIMENTAL|Arm B: AZD4635 + durvalumab + cabazitaxel|AZD4635 plus durvalumab plus cabazitaxel (Arm B) will consist of participants with mCRPC previously treated with docetaxel and one prior NHA (either abiraterone acetate or enzalutamide but not both (prior apalutamide is not allowed in Arm B).
62038871|NCT01374542||Respiratory endoscopy patients|Patients undergoing respiratory endoscopy at Singapore General Hospital
62038872|NCT05612490||Critically ill patients undergoing RRT|Patients admitted to participating ICU and receiving renal replacement therapy.
62038873|NCT01041638|EXPERIMENTAL|Treatment (Ch14.18, GM-CSF, IL-2, isotretinoin)|Patients receive sargramostim SC or IV over 2 hours on days 0-13 of courses 1, 3, and 5; monoclonal antibody Ch14.18 IV over 10 hours on days 3-6 of courses 1, 3, and 5 and on days 7-10 of courses 2 and 4; and isotretinoin PO BID on days 11-24 of course 1, on days 14-27 of courses 2, 4, and 6, and on days 10-23 of courses 3 and 5. Patients also receive aldesleukin IV continuously on days 0-3 and on days 7-10 of courses 2 and 4. Treatment repeats every 24-32 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62241730|NCT06725121|OTHER|Treatment|"This is a pilot, single-arm study enrolling 48 patients to evaluate the feasibility of locoregional therapy followed by immunotherapy in patients with advanced liver cancer. Patients will receive stereotactic body radiotherapy or Yttrium-90 radioembolization as per the standard-of-care (SOC) protocol, determined during Multidisciplinary Rounds.~Starting two to six weeks after radiotherapy, patients will begin treatment with Atezolizumab and Bevacizumab administered in approximately 21-day intervals, following SOC procedures, for a maximum of 9 months. Clinical follow-up will align with SOC protocols, and imaging will be performed every 2-3 months during immunotherapy.~If a patient is sufficiently responding to treatment at any follow-up, patients will be referred for transplant evaluation and added to the waitlist if no contraindications are found. Patients with disease progression or who become ineligible for LT due to other factors will be transitioned off the study."
62432179|NCT04806477|ACTIVE_COMPARATOR|Adult patients with respiratory tract symptom - telemedicine before face-to-face evaluation|We included adults (≥18 years of age) who had at least one acute symptom compatible with Respiratory Tract Infection (sore throat, nasal obstruction, coryza, new or growing cough, sputum, hoarseness, dyspnea) with or without symptoms related to the infection (fever ≥ 38oC, chills, sweating, myalgia) who have undergone telemedicine consultation before face-to-face evaluation
62241731|NCT05419375|OTHER|Non-Small Cell Lung Cancer (NSCLC)|Participants with NSCLC will be screened for biomarker eligibility for a linked Roche study.
62432180|NCT04806477|ACTIVE_COMPARATOR|Adult patients with respiratory tract symptom - only face-to-face evaluation|We included adults (≥18 years of age) who had at least one acute symptom compatible with Respiratory Tract Infection (sore throat, nasal obstruction, coryza, new or growing cough, sputum, hoarseness, dyspnea) with or without symptoms related to the infection (fever ≥ 38oC, chills, sweating, myalgia) who have undergone only face-to-face evaluation
62432181|NCT04182139|EXPERIMENTAL|30 seconds and %50 intensity stretching|The participants in this group performed an 30 seconds, %50 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
62432182|NCT04182139|EXPERIMENTAL|30 seconds and %75 intensity stretching|The participants in this group performed an 30 seconds, %75 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
62599153|NCT03652636|OTHER|One: Patient population with hepatic lesion(s)|Patient scheduled to get MRI will also be asked to receive an ultrasound of the liver
62599154|NCT06130891|EXPERIMENTAL|Cognitive sensory motor relearning Group|Cognitive, sensory, and motor training
62038874|NCT02374905|EXPERIMENTAL|Drinksmeter|Web-based application delivering Identification and Brief Advice of Alcohol Use
62038875|NCT02374905|ACTIVE_COMPARATOR|Brief Advice of Alcohol Use|Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
62241732|NCT01548924|EXPERIMENTAL|Priming Phase|The study treatment begins with the period of seven days of priming Phase, which is administered in monoterapi dovitinib
62241733|NCT01548924|EXPERIMENTAL|Treatment Phase|The phase of treatment with two drugs (paclitaxel dovitinib more fixed dose of 80 mg/m2 per week) will begin after a washout period of seven days after the priming phase.
62241734|NCT03671746|PLACEBO_COMPARATOR|Standard of Care without NSAID|Polytrauma participants will receive standard of care in addition to saline solution according to standard ATLS and standard ICU routine medical care.
62241735|NCT03671746|EXPERIMENTAL|Standard of Care with NSAID|Participants in the group will receive Ketorolac in addition to standard of care for the standard ATLS or ICU routine medical care.
62241736|NCT00801996||1. Prostate Cancer|"Inclusion Criteria:~* All study subjects should be able to provide informed consent~* Males ages 40 years or older~* Individuals from the Qatari Peninsula whose ancestors up to three generations back were natives of Qatar.~* Individuals undergoing Trans Rectal Ultrasound (TRUS) biopsy as dictated by their standard clinical care~* Ultrasound OR digital rectal examination consistent with prostate disease OR A level of PSA (Prostatic Specific Antigen) greater than 3.0~Exclusion Criteria:~• Patient refuses consent"
62241737|NCT00801996||2. Normal Healthy Controls|"Inclusion Criteria:~* All study subjects should be able to provide informed consent~* Males or females ages 40 years or older (see section A8 for the rationale for the inclusion of females)~* Individuals of Arab descent from Qatari peninsula without any personal or family history of prostate cancer~Exclusion Criteria:~* Individuals with family history of prostate cancer~* Individuals not deemed in good overall health by the investigator will not be accepted into the study"
62241738|NCT01881503|OTHER|All subjects|all qualifying subjects will receive HBOC-201 (Hemopure) to treat their life-threatening anemia
62241739|NCT02639468|EXPERIMENTAL|Tomographie par impédance électrique|Tomographie par impédance électrique
62241740|NCT01329016|ACTIVE_COMPARATOR|GDM Subjects|Women with GDM requiring treatment
62599155|NCT06130891|EXPERIMENTAL|Sensory Motor Relearning Group|Sensory and motor training
62241741|NCT01329016|NO_INTERVENTION|Non-pregnant Type 2 Diabetes Milletus Subjects|Non-pregnant women with Type 2 diabetes mellitus who plan to use metformin treatment
62818228|NCT06239272|EXPERIMENTAL|Intermediate-Risk Subset A (participants with low grade tumors):|"* If your tumor is completely removed at surgery \[meaning the tissue around the tumor (margins) is negative for tumor cells\], you will receive no further therapy and you will be closely observed for any signs of tumor recurrence.~* If your tumor cannot be completely removed at surgery \[meaning the tissue around the tumor (margins) is positive for tumor cells\] and the tumor is low-grade, you will get consolidation therapy with additional chemotherapy and radiation therapy, followed by 6 months of maintenance therapy with pazopanib."
62818229|NCT06239272|EXPERIMENTAL|Intermediate-Risk Subset B (participants with high-grade tumors between 5 and 10 cm in size|"* If your tumor is completely removed at surgery \[meaning the tissue around the tumor (margins) is negative for tumor cells\] you will continue with consolidation chemotherapy with additional chemotherapy without radiation therapy, followed by 6 months of maintenance therapy with pazopanib.~* If your tumor cannot be completely removed at surgery \[meaning the tissue around the tumor (margins) is positive for tumor cells\], you will get consolidation therapy with additional chemotherapy and radiation therapy, followed by 6 months of maintenance therapy with pazopanib."
62818230|NCT06239272|EXPERIMENTAL|Intermediate-Risk Subset C (participants with high-grade tumors > 10 cm):|"* After 3 cycles of induction chemotherapy, your doctor may decide to give an additional 4th cycle if he/she thinks it would be beneficial before surgery.~* You will get consolidation therapy with additional chemotherapy and radiation therapy, followed by 6 months of maintenance therapy with pazopanib. The dose of radiation that you receive will be higher if your tumor cannot be completely removed at surgery (positive margins)."
62241742|NCT01329016|NO_INTERVENTION|Healthy Pregnant Women|Healthy pregnant women with normal 1-hour glucose tolerance test
62818231|NCT06239272|EXPERIMENTAL|High-Risk - 2 groups|"* If you have a low-grade tumor that has spread to other parts of the body AND the surgeon was able to completely remove all tumors from all parts of your body, you will have no further therapy after surgery. You will be closely followed to monitor you for any signs of tumor recurrence.~* If you have a high-grade tumor OR a tumor that cannot be completely removed by surgery OR you have the CIC-DUX4 mutation, you will get consolidation chemotherapy and radiation therapy, followed by 6 months of maintenance therapy with pazopanib."
62241743|NCT05699018|OTHER|Diagnostic Test: e-LIFT|only one arm because diagnostic study evaluating blood test using elastometry and liver biopsy as reference
62241744|NCT04987658|EXPERIMENTAL|Group 1 Olanzapine/ 5 mg Samidorphan|Olanzapine will be gradually increased to a target dose of 10mg/samidorphan 5mg (Range: 5-20mg Olanzapine/samidorphan 5mg)
62241745|NCT04987658|EXPERIMENTAL|Group 2 Olanzapine/ 10mg Samidorphan|Olanzapine will be gradually increased to a target dose of 10mg/samidorphan 10mg (Range: 5-20mg Olanzapine/samidorphan 10mg)
62241746|NCT04752475|EXPERIMENTAL|Lasix (furosemide)|Furosemide 20 mg, oral, once daily for 5 days
62241747|NCT04752475|PLACEBO_COMPARATOR|Placebo|Identical-appearing placebo, oral, once daily for 5 days
62241748|NCT06018272|EXPERIMENTAL|Mentalization-Based Treatment (MBT)|
62432183|NCT04182139|EXPERIMENTAL|30 seconds and %100 intensity stretching|The participants in this group performed an 30 seconds, %100 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
62432184|NCT04182139|EXPERIMENTAL|60 seconds and %50 intensity stretching|The participants in this group performed an 60 seconds, %50 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
62432185|NCT04182139|EXPERIMENTAL|60 seconds and %75 intensity stretching|The participants in this group performed an 60 seconds, %75 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
62432186|NCT04182139|EXPERIMENTAL|60 seconds and %100 intensity stretching|The participants in this group performed an 60 seconds, %100 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
62432187|NCT02924571|EXPERIMENTAL|Bone Marrow Aspirate Concentrate (BMAC) + Allograft|"A total of 60, 120, or 180 mL of BMA to be aspirated. BMA is then placed into the Harvest SmartPrep® Bone Marrow Concentrate (BMAC) system and concentrated to a final volume of 10, 20, or 30 mL. The BMAC will then be combined with packed allograft cancellous bone chips using the Harvest Graft Delivery Pack. The allograft bone will be obtained routinely from the bone bank in the operating suite.~If using Harvest Graft Delivery Kit, the BMAC dosing estimate is as follows (BMAC to graft ratio will be 1:1):~* 1-level fusion: 10 cc of BMAC from 60 cc of BMA (roughly 10 cc of graft)~* 2-level fusion: 20 cc of BMAC from 120 cc of BMA~* 3-level fusion: 20 cc of BMAC from 120 cc of BMA~* 4-level fusion: 180 cc kit~* 5-level fusion: 240 cc kit~If not using Harvest Graft Delivery Kit:~* Volume of BMAC will be slightly increased (some BMAC will not get directly into hydrating the graft as the BMAC would get lost in the hydration process and left in mixing bowls)."
62432188|NCT02924571|ACTIVE_COMPARATOR|Recombinant Human Bone Morphogenetic Protein-2 (BMP)|"12 mL BMP will be applied at the surgical site of the interbody fusion using a collagen sponge following manufacturer's directions.~The BMP kit use per level is as follows:~* 1 Level Fusion: Extra small kit (1.4 cc)~* 2 Level Fusion: Small Kit (2.8cc)~* 3 Level Fusion: (4.2 cc)~* 4 Level Fusion: Medium Kit (5.6cc)~* 5 Level Fusion: (7.0 cc)"
62599156|NCT06130891|EXPERIMENTAL|Motor Relearning Group|Motor training
62599157|NCT01087840|EXPERIMENTAL|Raltegravir, NPEP|"Drug: Raltegravir Tablet 400mg taken orally, twice daily with or without food for 28 days along with Truvada 1 tablet taken orally daily for 28 days.~Arms: Raltegravir/Truvada"
62818232|NCT04934800||Cladribine|
62818233|NCT06593704|EXPERIMENTAL|PROSPERA|The PROSPERA-program
62241749|NCT06018272|ACTIVE_COMPARATOR|Bona-Fide Treatment in Germany (BFT)|
62241750|NCT03509896||Participants newly diagnosed with CML-CP|
62241751|NCT05492188|EXPERIMENTAL|Operant Conditioning of Cutaneous Reflexes|Each participant completes 6 baseline sessions and 30 conditioning sessions. In each of the 30 conditioning sessions, while the participant is standing nerves in the lower leg and ankle are stimulated to activate the reflex. The participant attempts to change the reflex activity based on visual feedback. In this way the cutaneous reflex (skin reflex) will be changed to decrease neuropathic pain resulting from spinal cord injury.
62241752|NCT05679466|ACTIVE_COMPARATOR|ReCOV|
62241753|NCT05679466|PLACEBO_COMPARATOR|ReCOV placebo|
62241754|NCT05046574|EXPERIMENTAL|Therapy dog during stroke rehabilitative therapy sessions|Participants randomized to this arm will have a therapy dog present during their stroke rehabilitative therapy sessions.
62818234|NCT06593704|NO_INTERVENTION|Control|Primary cardiovascular care-as-usual, according to national and international applicable guidelines.
62818235|NCT02955589|EXPERIMENTAL|HBI-8000|Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.
62818236|NCT02455245|ACTIVE_COMPARATOR|Carboplatine and Vincristine|"Induction: 10 weeks of Carboplatin and Vincristine therapy. Carboplatin 175 mg/m2 give an an IV infusion weeks 1, 2, 3, 4, 7, 8, 9, 10. Vincristine 1.5mg/m2 (0.05 mg/kg if child less than 12 kg) (maximum dose 2.0 mg) give as an IV bolus infusion on weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.~Maintenance: Maintenance consists of 8, 6-week cycles of chemotherapy. It begins week 12 of Induction or when peripheral counts recover with ANC \>1,000/µL and platelet count \>100,000/µL. Each cycle will consist of 4 weekly doses of carboplatin, three weekly doses of vincristine (given concomitantly with the first 3 weeks of carboplatin), followed by two weeks of rest for a total of 6 weeks. Maintenance will continue for a total of 8 cycles.~Carboplatin 175 mg/m2 as an IV continuous infusion over 60 minutes on Week 1, 2, 3, 4 of each cycle. Vincristine 1.5 mg/m2 (0.05 mg/ kg for children \<12 kg) (maximum dose 2.0 mg) IV bolus infusion on Week 1, 2, 3 of each cycle."
62818237|NCT02455245|EXPERIMENTAL|Carboplatin alone|"Carboplatin is given once every four weeks, Each 4-week period is considered a cycle. Regimen B will last for 13 cycles which is equivalent to one year (52 weeks).~Carboplatin 560 mg/m2 (or 19 mg/kg for children weighing less than 12 kg) IV over 1 hour every 4 weeks"
62241755|NCT05046574|NO_INTERVENTION|No therapy dog during stroke rehabilitative therapy sessions|Participants randomized to this arm will have stroke rehabilitative therapy sessions per standard of care with no therapy dog present.
62432189|NCT02924571|ACTIVE_COMPARATOR|Autograft|As per standard of care, the control group will receive 15cc - 45 cc of allograft with autograft and bone marrow aspirate at each level. The iliac crest is the common donor site for autograft. Using the standard technique for anterior lateral fusion, the bone graft will be laid onto the desired site of fusion.
62432190|NCT00634283|EXPERIMENTAL|antidepressant-experienced|Subjects who had previously been exposed to active antidepressant medication (venlafaxine)
62432191|NCT00634283|PLACEBO_COMPARATOR|antidepressant-naive|Subjects who had previously been exposed to placebo only (and never to active antidepressant medication)
62432192|NCT06042894|EXPERIMENTAL|BL-B01D1 + SI-B003|Participants receive SI-B003 or BL-B01D1 + SI-B003 therapy in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
62432193|NCT05737459||Group K|Those who have been administered ketamine for perioperative sedation
62432194|NCT05737459||Group D|Those who have been administered dexmedetomidine for perioperative sedation.
62241756|NCT06638671|EXPERIMENTAL|Metformin (MET)|"At the end of the screening visit, participants will be randomized to either Condition A or Condition B (MET or PL first). Participants will begin the 19-day treatment phase of study the day after screening.~During each treatment phase, participants will consume metformin as follows: 1x500 mg tablet/day for 5 days, 2x500 mg tablets/day for 5 days, and 3x500 mg tablets/day (or maximally tolerated dosage) for 9 days.~Participants will then complete a VO2peak/LT test on day 16, rest for 48 hours, then complete a time-to-exhaustion test (day 19) during the final days of the treatment phase. After the time-to-exhaustion test, participants will begin the placebo treatment phase."
62241757|NCT06638671|PLACEBO_COMPARATOR|Placebo (PL)|"At the end of the screening visit, participants will be randomized to either Condition A or Condition B (MET or PL first). Participants will begin the 19-day treatment phase of study the day after screening.~During each treatment phase, participants will consume placebo as follows: 1x500 mg tablet/day for 5 days, 2x500 mg tablets/day for 5 days, and 3x500 mg tablets/day (or maximally tolerated dosage) for 9 days.~Participants will then complete a VO2peak/LT test on day 16, rest for 48 hours, then complete a time-to-exhaustion test (day 19) during the final days of the treatment phase. After the time-to-exhaustion test, participants will begin the metformin treatment phase."
62241758|NCT02852161|EXPERIMENTAL|MACE|MACE procedure
62241759|NCT02852161|ACTIVE_COMPARATOR|OGD|Clinically indicated gastroscopy
62432195|NCT03876288||People presenting with the Sx of Gp|People presenting with the symptoms of gastroparesis. The three main interventions are GI neuromodulation, immunotherapy, and pyloric therapies.
62432196|NCT01318733|EXPERIMENTAL|CD07805/47 Gel 0.5%|
62432197|NCT00217971|ACTIVE_COMPARATOR|Dronabinol|Dronabinol: 20mg bid for a daily maximum dose of 40mg.
62432198|NCT00217971|PLACEBO_COMPARATOR|Placebo|placebo
62432199|NCT03582007|EXPERIMENTAL|Murepavadin|Murepavadin + ertapenem
62432200|NCT03582007|ACTIVE_COMPARATOR|Anti-pseudomonal antibiotic|One anti-pseudomonal-β-lactam-based antibiotic (either meropenem or piperacillin-tazobactam)
62432201|NCT01827371|EXPERIMENTAL|Arm C|88 subjects receive IMVAMUNE® 1x10\^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 22.
62432202|NCT01827371|EXPERIMENTAL|Arm B|88 subjects receive IMVAMUNE® 1x10\^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 15.
62599158|NCT02685813||Pregnant women in Denmark|Pregnant women in Denmark participating in prenatal screening. This counts for approximately 50000 pregnancies/year and covers \>95% of all pregnancies nationally.
62599159|NCT03164655|EXPERIMENTAL|HAI oxaliplatin combined with I.V. FOLFIRI + target therapy|"* HAI oxaliplatin 100 mg/m² on D1~* I.V. cetuximab 500 mg/m² or panitumumab 6 mg/kg or bevacizumab 5 mg/kg D1 according to RAS status and prior response/tolerance to systemic induction CT~* modified FOLFIRI regimen without fluorouracil bolus~* I.V. irinotecan 180 mg/m² D1~* I.V. bolus 5-Fluorouracil (5-FU): 0~* I.V. leucovorin 400 mg/m² in 2 hours D1~* I.V. continuous infusion 5-FU 2400 mg/m² in 46 hours"
62599160|NCT03164655|ACTIVE_COMPARATOR|conventional systemic CT|"* Response to systemic induction CT~* Toxicity and duration of the systemic induction CT~* RAS status~* Current guidelines/standard of care"
62241760|NCT05737134|EXPERIMENTAL|MA_PESAN APPLICATION|"The content of MA_PESAN includes an understanding of children, children's rights, sexual understanding, the definition of CSA, forms of CSA, the prevalence of CSA, the impact of CSA, risk factors for the occurrence of CSA, the importance of communication with children, who are the perpetrators/predators of CSA, efforts to prevent CSA. The material is presented in the form of text, images, stop motion videos about the prevention of CSA and videos of the jargon TANGKIS, songs about permissible and unacceptable touches, TikTok about permissible and prohibited touches, and discussion columns. The MA_PESAN intervention was carried out for 9 days."
62241761|NCT05737134|NO_INTERVENTION|common information from the school|The control group was given intervention according to the procedure at each elementary school. However, information was provided regarding preventing child sexual violence under the procedures usually carried out in each elementary school. The time spent was the same as the intervention group.
62599161|NCT03165760|NO_INTERVENTION|control group|Vt = 8 ml/kg of PBW and PEEP = 4 cm H2O
62241762|NCT00530868|EXPERIMENTAL|Letrozole + Avastin|50 evaluable patients received the combination therapy of 2.5 gm daily oral Letrozole and Avastin 15 mg/kg IV every 3 weeks for 24 weeks.
62241763|NCT00530868|EXPERIMENTAL|Letrozole alone|25 evaluable patients received daily oral 2.5 mg letrozole as a single agent
62241764|NCT04166383|EXPERIMENTAL|1/Arm 1|Vascular Biogenics (VB)-111 and nivolumab
62432203|NCT01827371|EXPERIMENTAL|Arm A|88 subjects receive IMVAMUNE® 1x10\^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 29.
62432204|NCT01827371|EXPERIMENTAL|Arm D|88 subjects receive IMVAMUNE® 1x10\^8 TCID50/0.5 mL subcutaneously (SC) via Stratis™ on Days 1 and 29.
62432205|NCT01484028|OTHER|EALE/1DM|etafilcon A with PVP for light eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
62432206|NCT01484028|OTHER|1DM/EALE|etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for light eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
62599162|NCT03165760|EXPERIMENTAL|protective ventilation group|Vt = 6ml/kg of PBW, PEEP = 10 and RM if disconnected
62599163|NCT00258349|EXPERIMENTAL|Arm I|Patients will receive vorinostat by mouth twice a day for 2 weeks. They will also receive a 90-minute infusion of trastuzumab in week 1.
62599164|NCT05463237||Pregnant women with gestational diabetes(n:87)|Visceral adipokine level will be examined in pregnant women with gestational diabetes.
62599165|NCT05463237||Control group pregnant (n:87)|Visceral adipokine level will be examined in pregnant women with normal pregnant .
62599166|NCT03966937|EXPERIMENTAL|Dry needling|The experimental group will receive dry needling over trigger points of Quadriceps muscles along with therapeutic exercises.
62038876|NCT00088231|EXPERIMENTAL|PTK 787 + Imatinib|For 1 week prior to receipt of study combination regimen, all patients will receive single agent PTK 787 at dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels. Patients should not have a grade 3 or 4 PTK 787-related adverse events in order to begin study combination therapy with a imatinib on day 8. On Day 8, PTK 787 250 mg by mouth every day and imatinib 600 mg by mouth every day (for Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia- blastic phase (CML-BP) and imatinib 400 mg by mouth every day (for Agnogenic Myeloid Metaplasia (AMM). Length of therapy is four courses; each course equals 28 days. Patients assessed for response after each course.
62241765|NCT00648089|EXPERIMENTAL|1|
62241766|NCT00648089|NO_INTERVENTION|2|
62432207|NCT01484028|OTHER|EADE/1DM|etafilcon A with PVP for dark eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
62432208|NCT01484028|OTHER|1DM/EADE|etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for dark eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
62432209|NCT03220763||Thirds of number of restaurant meals|Respondent self-reports of # of times/week restaurant prepared meals were consumed. The respondents will be categorized into approximate thirds.
62432210|NCT01558531||DEB|paclitaxel-eluting balloon angioplasty
62432211|NCT01558531||conventional PTA|historical conventional balloon angioplasty control group (patients referred to our institution between 2008 and 2009)
62432212|NCT00410852|EXPERIMENTAL|A|
62432213|NCT00410852|EXPERIMENTAL|B|
62432214|NCT00410852|ACTIVE_COMPARATOR|C|
62432215|NCT00798824|ACTIVE_COMPARATOR|Indwelling nasogastric tube placement|
62432216|NCT00798824|ACTIVE_COMPARATOR|Intermittent orogastric tube placement|
62599167|NCT03966937|ACTIVE_COMPARATOR|Control|The control group will only receive standardized therapeutic exercises for Patellofemoral pain syndrome.
62599168|NCT03784794|EXPERIMENTAL|Thromboelastometry|Decision to treat will be guided with thromboelastometry results, for fribrinogen deficiency the investigators will treat with fibrinogen concentrate (human), for correction of factor deficiency Prothrombin Complex Concentrates, Platelets with the use of platelets and Red Blood Cells for correcting hemoglobin levels
62432217|NCT04320459||ankylosing spondylitis|55 patients having Ankylosing Spondylitis (AS) for at least 1 year diagnosed according to the ASAS classification criteria who presented to our hospital's outpatient clinic
62038877|NCT00088231|EXPERIMENTAL|PTK 787 (vatalanib) Alone|For 1 week prior to receipt of study combination regimen, all patients will receive single agent PTK 787 at dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels. Patients should not have a grade 3 or 4 PTK 787-related adverse events in order to begin study combination therapy with a imatinib on day 8. PTK 787 250 mg by mouth for Days 1 - 7.
62241767|NCT03794921|NO_INTERVENTION|Usual Care|Patients referred to conventional PR or eligible for PR but declined or cannot access. Using a standardized script at the randomization phone call, study staff will deliver verbal instructions to slowly and steadily increase one's walking and exercise each week. Participants will be asked to perform exercise of moderate intensity for at least 30 minutes on most days of the week, defined as a dyspnea level of 4-5 on the Borg scale and taking 1-2 minutes to recover. Use of the Borg rating scale for dyspnea will be reviewed with each participant. Exercise is defined as planned PA, outside of activities performed as part of one's daily routine. Exercise can be walking in the community or using exercise equipment at a local gym. Adapted written materials reinforce the verbal instructions. Participants will receive this 45-page spiral-bound book with information about aerobic and strength training exercises.
62241768|NCT03794921|EXPERIMENTAL|Every Step Counts Intervention|Patients referred to conventional PR or eligible for PR but declined or cannot access. After randomization to ESC, participants will be mailed detailed instructions about the website. They will be asked to wear the lightweight, unobtrusive pedometer every day, except while asleep or showering/bathing, during the 12-week intervention period. Subjects will be instructed to upload their date and time-stamped step-count data to the study website at least weekly. Each week, the study computer will run the goal calculation algorithm and provide each participant with his/her daily step-count goal for the week. The week's step-count goal will be displayed on each subject's personal study web page. Participants will be instructed to exercise and reach their individualized step-count goals with walking of moderate intensity for at least 30 minutes on most days of the week, defined as a dyspnea level of 4-5 on the Borg scale and taking 1-2 minutes to recover.
62241769|NCT06032338|OTHER|"Control C"|"Usual care : Screening test (Fecal immunochemical test - FIT) delivery and reminders will be carried out in accordance with the Colorectal cancer population-based organised screening program (CRC-PBOSP) specifications at the time of the study.~This arm is suitable for both the first screening round in 50-51 years old population, and for the subsequent screening rounds."
62241770|NCT06032338|EXPERIMENTAL|"Intervention B1"|"FIT mailed at home within the CRC screening invitation without prior information letter.~This arm is suitable for both the first screening round in 50-51 years old population, and for the subsequent screening rounds."
62241771|NCT06032338|EXPERIMENTAL|"Intervention B2"|"FIT mailed at home within the CRC screening invitation with prior information letter.~This arm is suitable for the first screening round in 50-51 years old population only."
62241772|NCT04011228||Type 2 diabetic patients|
62241773|NCT04011228||Prediabetic patients|
62241774|NCT04011228||Women with gestational diabetes|
62241775|NCT04011228||Healthy control subjects|
62241776|NCT04011228||Pregnant women without gestational diabetes|
62038878|NCT02656433|PLACEBO_COMPARATOR|Placebo Group|Receive treatment with physiotherapy
62038879|NCT02656433|EXPERIMENTAL|Experimental or tRNS Group|Receive treatment with physiotherapy plus Transcranial Random Noise Stimulation (tRNS)
62241777|NCT04471948|EXPERIMENTAL|Fractional picosecond laser 1,064 nm laser|1 arm The subjects with enlarged pores were treated with fractional picosecond laser 1,064 nm laser
62432218|NCT04320459||healthy control|age and sex matched healthy controls
62432219|NCT05215041||Cesarean section group|
62432220|NCT05215041||Non-cesarean section group|
62599169|NCT03784794|ACTIVE_COMPARATOR|STANDARD COAGULATION TEST ALGORITHM|Decision to treat will be guided by standard cogulation lab test (Thrombine time, Active Thromboplastine time, Clauss fibrinogen, platelets count etc) for fribrinogen deficiency the investigators will treat with cryoprecipitates, for correction of factor deficiency fresh frozen plasma, Platelets with the use of platelets and Red Blood Cells for correcting hemoglobin levels
62038880|NCT02862457|EXPERIMENTAL|Part A Cohort 1: epacadostat 25 mg|Participants received 25 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years).
62432221|NCT02345928|EXPERIMENTAL|Part 1: Dose 1|Drug CNTO7160 or Placebo administered IV infusion Dose 1.
62432222|NCT02345928|EXPERIMENTAL|Part 1: Dose 2|Drug CNTO7160 or Placebo administered IV infusion Dose 2.
62818238|NCT02890329|EXPERIMENTAL|Arm A (decitabine, ipilimumab)|"PRIMING PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 out of 28 days.~INDUCTION PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 4 or 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity."
62432223|NCT02345928|EXPERIMENTAL|Part 1: Dose 3|Drug CNTO7160 or Placebo administered IV infusion Dose 3.
62599170|NCT01287091|EXPERIMENTAL|Part 1|
62038881|NCT02862457|EXPERIMENTAL|Part A Cohort 1: epacadostat 100 mg|Participants received 100 mg of epacadostat orally BID alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time IV infusion of 200 mg pembrolizumab while continuing to receive 100 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years).
62038882|NCT02862457|EXPERIMENTAL|Part A Cohort 2: epacadostat 25 mg+pembrolizumab|For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years).
62599171|NCT01287091|EXPERIMENTAL|Part 2|
62599172|NCT01287091|EXPERIMENTAL|Part 3: Group A|
62599173|NCT01287091|EXPERIMENTAL|Part 3: Group B|
62599174|NCT01130519|EXPERIMENTAL|1 - Bevacizumab and Erlotinib|All patients will be receiving fixed starting dose of bevacizumab (10 mg/kg intravenous (IV) every 2 weeks) and erlotinib (150 mg/day by mouth (PO)
62038883|NCT02862457|EXPERIMENTAL|Part A Cohort 2: epacadostat 100 mg+pembrolizumab|For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years).
62038884|NCT02862457|EXPERIMENTAL|Part B Cohort 1: pembrolizumab+cisplatin+pemetrexed|For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of 75 mg/m\^2 cisplatin and 500 mg/m\^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02.
62432224|NCT02345928|EXPERIMENTAL|Part 1: Dose 4|Drug CNTO7160 or Placebo administered IV infusion Dose 4.
62432225|NCT02345928|EXPERIMENTAL|Part 1: Dose 5|Drug CNTO7160 or Placebo administered IV infusion Dose 5.
62432226|NCT02345928|EXPERIMENTAL|Part 1: Dose 6|Drug CNTO7160 or Placebo administered IV infusion Dose 6.
62432227|NCT02345928|EXPERIMENTAL|Part 1: Dose 7|Drug CNTO7160 or Placebo administered IV infusion Dose 7.
62432228|NCT02345928|EXPERIMENTAL|Part 1: Dose 8|Drug CNTO7160 or Placebo administered IV infusion Dose 8.
62432229|NCT02345928|EXPERIMENTAL|Part 1: Dose 9|Drug CNTO7160 or Placebo administered IV infusion Dose 9.
62432230|NCT02345928|EXPERIMENTAL|Part 2 (Asthma): Dose 1|Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks).
62432231|NCT02345928|EXPERIMENTAL|Part 2 (Asthma): Dose 2|Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks).
62432232|NCT02345928|EXPERIMENTAL|Part 2 (Atopic Dermatitis): Dose 1|Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks).
62432233|NCT02345928|EXPERIMENTAL|Part 2 (Atopic Dermatitis): Dose 2|Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks).
62432234|NCT06530992||tucking|trans women who practice tucking
62432235|NCT06530992||no tucking|trans women who do not practice tucking
62432236|NCT05771311|ACTIVE_COMPARATOR|Potassium Titanyle Phosphate (KTP) Laser|split-side, 1 - 5 sessions at intervals of 6 - 8 weeks
62432237|NCT05771311|ACTIVE_COMPARATOR|Pulsed Dye Laser|split-side, 1 - 5 sessions at intervals of 6 - 8 weeks
62432238|NCT04217668|EXPERIMENTAL|Isosorbide mononitrate|Cases and controls both receive one tablet Imdur® 60 mg (isosorbide mononitrate) on the study day.
62432239|NCT06301633|EXPERIMENTAL|Intermittent Oro-esophageal Tube Feeding+comprehensive rehabilitation therapy|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation therapy. The observation group was provided the support of enteral nutrition by Intermittent Oro-esophageal Tube Feeding.
62432240|NCT06301633|ACTIVE_COMPARATOR|Nasogastric Tube Feeding+comprehensive rehabilitation therapy|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation. The observation group was provided the support of enteral nutrition by Nasogastric Tube Feeding.
62432241|NCT05058144|EXPERIMENTAL|novel alpha glucan|50g novel alpha glucan dissolved in 300ml water
62432242|NCT05058144|ACTIVE_COMPARATOR|glucose syrup|50g dissolved in 300ml water
62599175|NCT06622772|EXPERIMENTAL|VAD group|Valsalva manoeuvre with a valsalva assist device (VAD)
62599176|NCT06622772|OTHER|Control group|standard Valsalva manoeuvre
62599177|NCT04747067|EXPERIMENTAL|High-flux Hemodialysis|patients treated by conventional hemodialysis
62599178|NCT04747067|EXPERIMENTAL|Hemodiafiltration|patients treated by online post-dilution hemodialysis
62599179|NCT06373458|EXPERIMENTAL|Participants receiving keloidectomy|A total of 20 patients receiving keloidectomy (\~50% earlobe keloidectomy cap) at Day 1 as Group 1
62599180|NCT06373458|EXPERIMENTAL|Participants with no keloidectomy|A total of 10 patients with no keloidectomy during the study and with at least one keloid measuring ≥3 cm or multiple keloids, measuring ≥1 cm in length each, as Group 2
62599181|NCT04569968|EXPERIMENTAL|Expiratory muscle training group|Daily expiratory muscle training for four weeks will be applied.
62432243|NCT05058144|ACTIVE_COMPARATOR|Inulin|15g Inulin dissolved in 300ml water
62818239|NCT02890329|EXPERIMENTAL|Arm B (decitabine, ipilimumab)|"PRIMING PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 out of 28 days.~INDUCTION PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 4 or 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity."
62818240|NCT03380728|EXPERIMENTAL|Ibogaine|Ibogaine Hydrochloride 240 mg on day 1, placebo on day 4, placebo on day 7
62432244|NCT01783925||Group 1|
62432245|NCT03536819|EXPERIMENTAL|Treatment|Participants receive Votiva treatment
62818241|NCT06705933|ACTIVE_COMPARATOR|Core stability exercise and myofascial release group|The participants will receive core stability exercise and myofascial release for 20 min three times per week for 8 weeks.
62818242|NCT06705933|EXPERIMENTAL|Kinesiotaping, in addition to core stability exercise and myofascial release group|The participants will receive kinesiotaping, in addition to core stability exercise and myofascial release for 8 weeks
62818243|NCT06136169|EXPERIMENTAL|StudyArm|Participants will receive reminder-cue scanning training in a driving simulator.
62818244|NCT05253209|EXPERIMENTAL|Active|"Patients will receive:~1. an L-citrulline bolus of 150 mg/kg at the initiation of cardiopulmonary bypass~2. the addition L-citrulline to maintain a steady state target concentration of approximately 100 μmol/L of L-citrulline during cardiopulmonary bypass~3. an L-citrulline bolus of 10 mg/kg 30 minutes after decannulation from cardiopulmonary bypass, followed immediately by a 9 mg/kg/hour continuous L-citrulline infusion or placebo for up to 48 hours post-first dose. The infusion rate will be adjusted (up or down titration of drug infusion) to achieve a target steady state concentration of 100 μmol/L.~Infusion will be discontinued once invasive arterial blood pressure monitoring is discontinued or at 48 hours, whichever occurs first."
62038885|NCT02862457|EXPERIMENTAL|Part B Cohort 2: pembrolizumab+carboplatin+pemetrexed|For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of Area Under the Curve (AUC) 5 carboplatin and 500 mg/m\^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02.
62432246|NCT03438799||Cordio|Cordio R\&D database to develop the Cordio System
62432247|NCT06271421|ACTIVE_COMPARATOR|NanoTherm arm (group A)|Recurrent glioblastoma multiforme patients treated with NanoTherm therapy.
62432248|NCT06271421|PLACEBO_COMPARATOR|Stupp protocol (group B)|Glioblastoma multiforme patients treated according to Stupp protocol including surgery, chemotherapy and radiotherapy.
62432249|NCT02082912|EXPERIMENTAL|D-cycloserine|Subjects will take D-cycloserine and use the HandMentor Pro for robotic therapy
62432250|NCT02082912|ACTIVE_COMPARATOR|Placebo|Subjects will take a placebo pill and use the HandMentor Pro for robotic therapy
62432251|NCT06064981|NO_INTERVENTION|Control|Participants in the control arm receive usual care. In this case they receive naloxone training only. The training involves a 1-hour in-person overdose recognition and reversal course, which addressed the following topics: the scope and nature of the opioid overdose epidemic nationally and locally in Philadelphia, signs of opioid overdose, strategies for approaching or interacting with a person who is suspected to have overdosed, administration of naloxone in its nasal spray formulation, what to expect after administering naloxone, legal considerations and Good Samaritan protection, and how and where to acquire naloxone.
62432252|NCT06064981|EXPERIMENTAL|Text message nudges|Participants in this arm receive text message nudges with salient messaging around overdose and naloxone. They also receive naloxone training.
62432253|NCT06064981|EXPERIMENTAL|Commitment contract|Participants in this arm receive sign a commitment contract agreeing to obtain or carry naloxone. They also receive naloxone training.
62432254|NCT01207401|EXPERIMENTAL|Paracervical Block|
62432255|NCT01207401|NO_INTERVENTION|No Paracervical Block|
62432256|NCT02857725|EXPERIMENTAL|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were considered for SPF testing.
62432257|NCT02681107|EXPERIMENTAL|Single Arm|Single cohort to receive Accelerated Partial Breast Irradiation (APBI) 27Gy in 5 fractions
62432258|NCT01392859|EXPERIMENTAL|Initial Treatment: Levocetirizine(LCT)|Group 1 will begin with active Levocetirizine(LCT) 0.5 mg/ml oral solution for 5-8 days. This arm will then undergo a 3-7 day washout period at which point crossover will occur and placebo will be provided for 5-8 days.
62818245|NCT05253209|PLACEBO_COMPARATOR|Placebo|Plasmalyte A administered to the same schedule as the active treatment arm.
62432259|NCT01392859|EXPERIMENTAL|Initial Treatment: Placebo|Group 2 will begin with placebo oral solution for 5-8 days. This arm will then undergo a 3-7 day washout period at which point crossover will occur and active Levocetirizine(LCT) 0.5 mg/ml will be provided for 5-8 days.
62432260|NCT02519972|EXPERIMENTAL|Low dose computed tomography|All the Low dose computed tomography of lung was performed with 64 slices multidetectors CT in single hold breath covering entire lung. The protocol of scanning parameters (120KVp, 40-80 mA, 1.25 mm or less in thickness) was standardized. The raw data would be reconstructed to axial images (3 mm thickness and interval) and coronal images (3 mm thickness and interval). The scan should be finished in a single breath (15-20 second) from the thoracic inlet to adrenal glands.
62432261|NCT04881422|EXPERIMENTAL|Experimental group|A group of pwMS participate in a multidimensional integrate high-motivating rehabilitation program for the change of lifestyle and bad habits.
62432262|NCT01208922|EXPERIMENTAL|Group A|Rifamycin SV-MMX® 200 mg tablets
62432263|NCT01208922|ACTIVE_COMPARATOR|Group B|Ciprofloxacin 500 mg capsules
62432264|NCT00707915|EXPERIMENTAL|Dose reduction|The benzodiazepine dose will be discontinued in 4 weeks by a weekly 25% reduction. Participants will be observed for 8 weeks.
62432265|NCT05102045|EXPERIMENTAL|TMS group|In the TMS group (n=10) rTMS was applied to the bilateral dorsolateral prefrontal cortex (DLPFC) at 20 Hz, for 5 consecutive days per week for over 2 weeks (totally 10 sessions) in addition to the pharmacological treatment.
62818246|NCT06592404|EXPERIMENTAL|Cluster 1|"As explained earlier on, all clusters receive the person-oriented intervention, which involves deploying the social robot on personal goals related to selected activities.~In this study, randomization determines the duration of study periods.~For cluster 1, periods are planned as follows:~* Control: 2 weeks (week 1-2)~* Intervention: 6 weeks (week 3-8)~* Effect measurement: 5 weeks (week 9-13)~* Follow-up: 2 weeks (week 34-35)"
62818247|NCT06592404|EXPERIMENTAL|Cluster 2|"For cluster 2, periods are planned as follows:~* Control: 3 weeks (week 1-3)~* Intervention: 6 weeks (week 4-9)~* Effect measurement: 4 weeks (week 10-13)~* Follow-up: 2 weeks (week 35-36)"
62818248|NCT06592404|EXPERIMENTAL|Cluster 3|"For cluster 3, periods are planned as follows:~* Control: 4 weeks (week 1-4)~* Intervention: 6 weeks (week 5-10)~* Effect measurement: 3 weeks (week 11-13)~* Follow-up: 2 weeks (week 36-37)"
62818249|NCT06592404|EXPERIMENTAL|Cluster 4|"For cluster 4, periods are planned as follows:~* Control: 5 weeks (week 1-5)~* Intervention: 6 weeks (week 6-11)~* Effect measurement: 2 weeks (week 12-13)~* Follow-up: 2 weeks (week 37-38)"
62818250|NCT01721135|EXPERIMENTAL|GSK2190915 100mg|GSK2190915 100mg on days 1-5; moxifloxacin placebo on day 5
62818251|NCT01721135|EXPERIMENTAL|GSK2190915 1000mg|GSK2190915 1000mg on days 1-5; moxifloxacin placebo on day 5
62818252|NCT01721135|ACTIVE_COMPARATOR|moxifloxacin 400mg|placebo tablet on days 1-5; moxifloxacin 400mg on day 5
62818253|NCT01721135|PLACEBO_COMPARATOR|placebo|placebo tablet on days 1-5; moxifloxacin placebo on day 5
62818254|NCT06543953|OTHER|HearCare MED-EL App|Subjects perform system check and install audio processor configuration via the HearCare MED-EL App
62818255|NCT03991780|EXPERIMENTAL|Fostamatinib|All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib (tablet taken orally) twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.
62818256|NCT01281618||Those with barrett's esophagus|Those with barrett's esophagus: no dysplasia or low grade dysplasia
62818257|NCT05239143|EXPERIMENTAL|P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A)|"* Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 1.~* Rimiducid may be administered as indicated."
62432266|NCT05102045|EXPERIMENTAL|AE group|AE group (n=9) received a moderate- intensity aerobic exercise program lasting 50 minutes per session, 5 consecutive days per week for over 2 weeks (totally 10 sessions) in addition to the pharmacological treatment.
62432267|NCT05102045|ACTIVE_COMPARATOR|Control group|No additional intervention was given to the patients in the control group (n=8) and participants were only treated pharmacologically.
62432268|NCT01917903|EXPERIMENTAL|Identification of at risk variables|Individuals will come in for a single visit to perform all tasks / conditions. Measurements will be taken of spatial and temporal features of walking with and without a secondary task. In addition, cognitive tests of memory and attention will be performed. Outcomes will narrow measures to those most likely to show clinically significant change.
62432269|NCT01917903|EXPERIMENTAL|Gait-Cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
62432270|NCT04036448||Lenalidomide in IPSS Low-or intermediate-1-risk del population|For the IPSS Low- or intermediate-1-risk del (5q) (MDS), Lenalidomide treatment must not be started if the ANC \< 0.5 x 109/L and/or platelet counts \< 25 x 109/L. The recommended starting dose of lenalidomide is 10 mg orally once daily on days 1 to 21 of repeated 28-day cycles.
62432271|NCT04036448||Lenalidomide in Refractory/relapsed rrMC/ Follicular lymphoma population|For the Refractory/relapsed Mantle cell lymphoma (rrMCL), the recommended starting dose of lenalidomide is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles. For the Follicular lymphoma (FL), the recommended starting dose of rituximab is 375 mg/m2 intravenously (IV) every week in Cycle 1 (days 1, 8, 15, and 22) and day 1 of every 28-day cycle for Cycles 2 through 5.
62432272|NCT06520436|EXPERIMENTAL|Arthroscopic-Assisted Reduction|
62599182|NCT04569968|NO_INTERVENTION|Control group|Nothing will be applied except for the hospital conventional physiotherapy program.
62599183|NCT04748601|PLACEBO_COMPARATOR|Placebo|
62599184|NCT04748601|EXPERIMENTAL|Qudexy XR|
62818258|NCT05239143|EXPERIMENTAL|P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm B)|"* Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 1.~* Rimiducid may be administered as indicated."
62818259|NCT05239143|EXPERIMENTAL|P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm C)|"* Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 2.~* Rimiducid may be administered as indicated."
62818260|NCT05239143|EXPERIMENTAL|P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm D)|"* Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 2.~* Rimiducid may be administered as indicated."
62818261|NCT05239143|EXPERIMENTAL|P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A1)|"* Single ascending A1 dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 1.~* Rimiducid may be administered as indicated."
62818262|NCT05239143|EXPERIMENTAL|P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm E)|"* Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following assigned lymphodepletion regimen.~* Rimiducid may be administered as indicated."
62818263|NCT05239143|EXPERIMENTAL|P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm F)|"* Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following assigned lymphodepletion regimen.~* Rimiducid may be administered as indicated."
62818264|NCT05239143|EXPERIMENTAL|P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm M)|"* Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following assigned lymphodepletion regimen.~* Rimiducid may be administered as indicated."
62818265|NCT06428110||Patients taking warfarin with vascular aging group|
62818266|NCT06428110||Patients taking warfarin with normal vascular group|
62241778|NCT03531281|EXPERIMENTAL|Arm I (goat milk, transplant conditioning/prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell infusion on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
62241779|NCT03531281|ACTIVE_COMPARATOR|Arm II (transplant conditioning/prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell infusion on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
62241780|NCT00698464|EXPERIMENTAL|Pasireotide|
62432273|NCT03473847|EXPERIMENTAL|Repeatability and Reproducibility - Normal eyes|"This arm will include 20 eyes of 20 patients with no previous ocular surgery.~The research participant will be scanned a number of times using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). The scan sequence will be undertaken on a single day as follows:~1. 5 consecutive repeated scans of the cornea will be performed by the first operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set).~2. There will be a break of about 30 minutes.~3. 5 consecutive repeated scans of the cornea will be performed by the second operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set)."
62432274|NCT03473847|EXPERIMENTAL|Repeatability and Reproducibility - Post-op eyes|"This arm will include 20 eyes of 20 patients between 3 and 9 months after corneal laser refractive surgery.~The research participant will be scanned a number of times using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). The scan sequence will be undertaken on a single day as follows:~1. 5 consecutive repeated scans of the cornea will be performed by the first operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set).~2. There will be a break of about 30 minutes.~3. 5 consecutive repeated scans of the cornea will be performed by the second operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set)."
62432275|NCT03473847|EXPERIMENTAL|Comparison between devices - Normal eyes|"This arm will include 101 eyes of 101 patients with no previous ocular surgery.~The research participant will be scanned once using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). Expected total time approximately 20 minutes to complete all four scans."
62432276|NCT03473847|EXPERIMENTAL|Comparison between devices - Post-op eyes|"This arm will include 101 eyes of 101 patients between 3 and 9 months after corneal laser refractive surgery.~The research participant will be scanned once using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). Expected total time approximately 20 minutes to complete all four scans."
62432277|NCT01735877|EXPERIMENTAL|Mirror therapy|All eligible patients will be randomly allocated into 2 groups. Group 1 will be given Mirror therapy
62432278|NCT01735877|SHAM_COMPARATOR|Control group|Group 2 will be given sham mirror therapy
62432279|NCT02236156|EXPERIMENTAL|1% SPL7013 Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
62432280|NCT02236156|PLACEBO_COMPARATOR|Placebo Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
62432281|NCT00591253|EXPERIMENTAL|Azilsartan Medoxomil 40 mg QD|
62432282|NCT00591253|EXPERIMENTAL|Azilsartan Medoxomil 80 mg QD|
62432283|NCT00591253|PLACEBO_COMPARATOR|Placebo QD|
62432284|NCT06146621|ACTIVE_COMPARATOR|Information about free tax-filing support|Basic information about where to find free tax filing support in their community will be provided to all participants by email once upon enrollment.
62599185|NCT06621199|EXPERIMENTAL|Modified MAV regimen|Mitoxantrone hydrochloride liposome ×1 day, cytarabine × 5 days combined with venetoclax as induction regimen
62818267|NCT06705179|OTHER|Behavioral task battery|
62818268|NCT01760057|PLACEBO_COMPARATOR|Health promotion message|Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites
62818269|NCT01760057|EXPERIMENTAL|Combined Web-based HIV intervention|Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging
62241781|NCT05317988|EXPERIMENTAL|Intervention group|Participants receive a step-by-step demonstration video of detailed reconstitution procedures and text-based vaccine product information
62241782|NCT05317988|PLACEBO_COMPARATOR|Control group|Participants receive a generic video of similar duration on basic facts of COVID-19 (unrelated to reconstitution procedures) and text-based product information
62241783|NCT05343897|EXPERIMENTAL|2-month Ping-Shuai Gong (PSG) training|"Ping-Shuai Gong (PSG) is pioneered by Qi Gong master, Li Feng-shan. It is featured in synchronous and rhythmic arm-swinging movement, with arms straightly forward flexing to shoulder level and backward extending repeatedly, and combined with lightly squat twice while arms swing to the fifth time and continue this cycle.~They were asked to conduct and record 30 minutes of PSG in one day lasting for 2-month, and at least 3 days a week."
62241784|NCT05343897|ACTIVE_COMPARATOR|2-month Arm-Swing-Exercise (ASE) training|"Participents in Arm-Swing-Exercise (ASE) group were instructed to keep whole upper limbs pronated, and maintain their trunk straight while movement. The movement is to swing bilateral arms forward to around 30 degree and backward to around 60 degree continuously. The participants need to stabilize their trunk, pelvic, and legs while bilateral arms swinging passing through the side of the trunk. The most significant difference from PSG group is the way they pull the arm, not just swing backward and downward.~They were asked to conduct and record 30 minutes of ASE in one day lasting for 2-month, and at least 3 days a week."
62241785|NCT03613662|EXPERIMENTAL|SP-102|SP-102
62241786|NCT05821530|EXPERIMENTAL|HFIT|Participants received a HFIT device to treat their chronic pain and took part in a digital MSK program, which provided customized exercise therapy sessions, educational articles, and access to coaches and physical therapists. Participants were encouraged to use the HFIT device for at least 1 hour daily for 4 weeks.
62818270|NCT03406884|EXPERIMENTAL|Open label C-kit+ cells Group A|Group A is an open-label treatment group determining safety and feasibility. Participants enrolled in this group will be receiving previously harvested c-kit+ cells during their Stage II BDCPA operation. Harvested c-kit+ cells will be injected into the right ventricle directly intramyocardially.
62818271|NCT03406884|ACTIVE_COMPARATOR|C-kit+ cells Group B|Participants randomized to Group B Treatment Group will receive previously harvested c-kit+ cells during their Stage II BDCPA operation. Harvested c-kit+ cells will be injected into the right ventricle directly intramyocardially.
62818272|NCT03406884|NO_INTERVENTION|No Intervention Group|Participants randomized to Group B Control Group will receive only their standard of care (SOC) Stage II BDCPA operation without the injection of harvested c-kit+ cells.
62818273|NCT02906514|EXPERIMENTAL|Hydroxyethyl starch 130/0.4|
62818274|NCT02906514|PLACEBO_COMPARATOR|Sodium Chloride 0.9%|
62818275|NCT06389526|EXPERIMENTAL|Part A: Single Agent CHS-1000|
62038886|NCT02862457|EXPERIMENTAL|Part B Cohort 3: pembrolizumab+carboplatin+paclitaxel|For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of AUC 6 carboplatin and 200 mg/m\^2 paclitaxel on Day 1. Treatment with epacadostat was stopped with protocol amendment 02.
62599186|NCT02614222|EXPERIMENTAL|Peripheral Nerve Block with CAIG|The participants in this group (test group) will utilize the same procedure utilizing existing ultrasound equipment with the supplemental CAIG system.
62599187|NCT02614222|NO_INTERVENTION|Peripheral Nerve Block without CAIG|The participants in the control group will receive the procedure with traditional ultrasound methods and equipment.
62818276|NCT06389526|EXPERIMENTAL|Part B: Combination Agents CHS-1000 + Toripalimab|
62818277|NCT02079896|EXPERIMENTAL|Single dose cross-over pilot|Single dose of lexaptepid pegol (NOX-H94) cross-over with single dose of placebo
62599188|NCT02467257|EXPERIMENTAL|Intrevention arm|Patients received Gum Arabic as intervention
62818278|NCT02079896|PLACEBO_COMPARATOR|Control|Twice weekly doses of placebo, 9 total
62818279|NCT02079896|EXPERIMENTAL|Lexaptepid pegol (NOX-H94)|Twice weekly doses of lexaptepid pegol (NOX-H94), 9 total
62818280|NCT06064929|EXPERIMENTAL|Felzartamab|
62038887|NCT04941599|ACTIVE_COMPARATOR|2-Hydroxybenzylamine (2-HOBA)|2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
62038888|NCT04941599|PLACEBO_COMPARATOR|Placebo|Placebo- three tabs TID (po) for 6 weeks.
62818281|NCT01584232|EXPERIMENTAL|LY2189265 + OAM|"LY2189265: 0.75 milligrams (mg), administered subcutaneously (SC), once weekly for 26 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin)."
62818282|NCT01584232|ACTIVE_COMPARATOR|Insulin glargine + OAM|"Insulin glargine: dose based on targeting fasting blood glucose ≤110 milligrams per deciliter (mg/dL), administered subcutaneously (SC), once daily for 26 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin)."
62818283|NCT01064388|EXPERIMENTAL|1|
62818284|NCT01064388|PLACEBO_COMPARATOR|2|
62241787|NCT05821530|EXPERIMENTAL|TENS|Participants received a TENS device to treat their chronic pain and took part in a digital MSK program, which provided customized exercise therapy sessions, educational articles, and access to coaches and physical therapists. Participants were encouraged to use the TENS device for at least 1 hour daily for 4 weeks.
62241788|NCT05821530|ACTIVE_COMPARATOR|Control|Participants took part in a digital MSK program, which provided customized exercise therapy sessions, educational articles, and access to coaches and physical therapists.
62241789|NCT00288795|NO_INTERVENTION|1|Standard Care
62432285|NCT06146621|EXPERIMENTAL|Low-touch text messaging|To address families' lack of awareness of the Earned Income Tax Credit (EITC) and the ways they may benefit from filing taxes, one study arm will receive low-touch text messages. These act in part by increasing awareness of programs and eligibility rules and in part as reminders to overcome limited attention to filing. Study participants receiving this intervention will receive behavioral science-informed text messages in English or Spanish from WIC that inform them about the EITC throughout tax season (i.e., January-April) 2024. We will personalize message contents (e.g., EITC benefit size mentioned in message based on participant income, marital status, and number of dependents) due to suggestive evidence that a tailored, individualized text message has the potential to be effective
62432286|NCT06146621|EXPERIMENTAL|Personal tax filing support|Participants randomized to this intervention will be connected with a human assistor who will work with them to ensure they access resources to help them file taxes and apply for the EITC. The English- and Spanish-speaking assistors will be study team staff trained to provide personalized support to help families access resources for which they are eligible. The assistor will be available by text or phone to talk with people if they encounter barriers and will call to follow-up on a mutually agreed upon schedule.
62818285|NCT04892498|EXPERIMENTAL|RT+PD-1+GM-CSF+IL-2|
62818286|NCT06706544|EXPERIMENTAL|Ozone Group|Drug: Ozone (O3/O2). Treatment: Usual treatment + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
62818287|NCT06706544|PLACEBO_COMPARATOR|Oxygen Group (Placebo)|Drug: Oxygen (O2). Treatment: Usual treatment + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
62818288|NCT04742634|EXPERIMENTAL|Phase I Dose Level 1: DEC-C|"* Bone marrow biopsy \& MyeloSeq-HD will be obtained on Day 30 post-transplant. MRD positivity is defined as the presence of at least one somatically acquired mutation detected prior to transplant that persists at Day 30 post-transplant with a variant allele frequency of ≥ 0.5%. MRD-positive patients will receive up to 5 cycles of DEC-C prior to the Day 180 bone marrow evaluation. If the Day 180 MyeloSeq-HD shows that MRD is still detectable in the opinion of the MGI board-certified molecular pathologist but below 0.5% and patient has tolerated initial treatment without toxicity, the patient may continue treatment. If it shows a lack of MRD, the patient will be moved to the post-treatment surveillance arm. If it shows any mutation detection prior to transplant that persists with a variant allele frequency of ≥ 0.5%VAF, the patient will receive up to an additional 6 cycles of DEC-C.~* 35 mg decitabine/100 mg cedazuridine taken by mouth once daily on Days 1, 2, 3 of a 28 day cycle."
62818289|NCT04742634|EXPERIMENTAL|Phase I Dose Level 2: DEC-C|"* Bone marrow biopsy \& MyeloSeq-HD will be obtained on Day 30 post-transplant. MRD positivity is defined as the presence of at least one somatically acquired mutation detected prior to transplant that persists at Day 30 post-transplant with a variant allele frequency of ≥ 0.5%. MRD-positive patients will receive up to 5 cycles of DEC-C prior to the Day 180 bone marrow evaluation. If the Day 180 MyeloSeq-HD shows that MRD is still detectable in the opinion of the MGI board-certified molecular pathologist but below 0.5% and patient has tolerated initial treatment without toxicity, the patient may continue treatment. If it shows a lack of MRD, the patient will be moved to the post-treatment surveillance arm. If it shows any mutation detection prior to transplant that persists with a variant allele frequency of ≥ 0.5%VAF, the patient will receive up to an additional 6 cycles of DEC-C.~* 35 mg decitabine/100 mg cedazuridine taken by mouth once daily on Days 1-4 of a 28 day cycle."
62818290|NCT04742634|EXPERIMENTAL|Phase II MRD Positive: DEC-C|"* 35 mg decitabine/100 mg cedazuridine taken by mouth once daily per the schedule determined in the Phase I portion of the study. Cycle 1 Day 1 may take place between Day 42 and Day 100 post-transplant. MRD-positive patients will receive up to 5 cycles of DEC-C prior to the Day 180 bone marrow evaluation.~* Bone marrow biopsy with MyeloSeq-HD will be obtained on Day 180 post-transplant. If the Day 180 MyeloSeq-HD shows that MRD is still detectable in the opinion of the MGI board-certified molecular pathologist but below 0.5% and patient has tolerated initial treatment without toxicity, the patient may continue treatment. If it shows a lack of MRD, the patient will be moved to the post-treatment surveillance arm. If it shows any mutation detection prior to transplant that persists with a variant allele frequency of ≥ 0.5%VAF, the patient will receive up to an additional 6 cycles of DEC-C."
62818291|NCT04742634|ACTIVE_COMPARATOR|Phase II MRD Negative: Observation Arm|"* In phase II, up to 77 patients who do not have MRD positivity on Day 30 post-transplant (i.e., the absence of at least one somatically acquired mutation detected prior to transplant that persists at Day 30 post-transplant with a variant allele frequency of ≥ 0.5%) will be placed on the observation arm and treated with standard of care.~* Patients on the observation arm will be followed every 3 months for 2 years and every 6 months for 3 years for progression and survival"
62818292|NCT06597526||gastric cancer patients with peritoneal metastasis|Initial diagnosis of gastric cancer with peritoneal metastases, excluding other distant metastases
62241790|NCT00288795|OTHER|2|Massage Treatment
62432287|NCT06146621|EXPERIMENTAL|Financial assistance|Participants randomized to this intervention will receive a $100 cash incentive for tax filing, designed to offset the time, hassle, and resources spent on tax preparation and filing, as well as psychological frictions like inattention that prevent some people from filing. This will be provided to recipients as soon as they show proof of tax filing, to provide a more immediate reward relative to the delays in receiving a federal tax refund. We will test the feasibility of delivering this via gift card, check, or other modalities, in addition to evaluating the framing and incentive amount.
62241791|NCT00288795|OTHER|3|Polarity Treatment
62038889|NCT02654626|EXPERIMENTAL|KBP-7072: Cohort 1|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
62241792|NCT02592018|EXPERIMENTAL|Secukinumab|All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.
62241793|NCT03558022|EXPERIMENTAL|Salt Pills|One week on low salt diet plus salt pills
62818293|NCT06564389|EXPERIMENTAL|PF-07832837|single or multiple doses of PF-07832837 at ascending dose levels
62241794|NCT03558022|PLACEBO_COMPARATOR|Placebo Pills|One week on low salt diet plus placebo pills
62818294|NCT06564389|PLACEBO_COMPARATOR|placebo|single or multiple doses of placebo
62241795|NCT03296462|EXPERIMENTAL|Hip external rotation exercise (alone)|Standardised hip external rotation exercise training - over 12 week period
62241796|NCT03296462|EXPERIMENTAL|Hip external rotation + PFM exercises|Standardised hip external rotation plus pelvic floor muscle exercises - over 12 week period
62241797|NCT03296462|ACTIVE_COMPARATOR|pelvic floor muscle exercises (alone)|Standardised pelvic floor muscle exercises - over 12 week period (usual care)
62599189|NCT04106050|EXPERIMENTAL|Part A: BIIB095 Dose 1|Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 1 capsules from Day 1 to Day 8.
62599190|NCT04106050|EXPERIMENTAL|Part A: BIIB095 Dose 2|Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 2 capsules from Day 1 to Day 8.
62599191|NCT04106050|EXPERIMENTAL|Part A: BIIB095 Dose 3|Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 3 capsules from Day 1 to Day 8.
62818295|NCT03767933|ACTIVE_COMPARATOR|Non-Opioid Trial: Arm 1|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo, both administered once during the study at the time of recruitment.
62818296|NCT03767933|EXPERIMENTAL|Non-Opioid Trial: Arm 2|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen (15mg/kg, maximum 1000mg), both administered once during the study at the time of recruitment.
62818297|NCT03767933|ACTIVE_COMPARATOR|Opioid Trial: Arm 1|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo + Oral hydromorphone placebo, all administered once during the study at the time of recruitment.
62818298|NCT03767933|EXPERIMENTAL|Opioid Trial: Arm 2|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen (15mg/kg, maximum 1000mg) + Oral hydromorphone placebo, all administered once during the study at the time of recruitment.
62818299|NCT03767933|EXPERIMENTAL|Opioid Trial: Arm 3|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo + Oral hydromorphone (0.05mg/kg, maximum 5 mg), all administered once during the study at the time of recruitment.
62818300|NCT04610346|OTHER|Immediate|Participants in this group will begin the training protocol immediately (within 1 week) after baseline pre-training evaluation is completed.
62818301|NCT04610346|OTHER|Delayed|Participants in the delayed arm will participate in two pre-training evaluations, one immediately upon enrollment and one at the end of the delay period immediately before beginning training
62818302|NCT05954130|EXPERIMENTAL|Mobile Application Support Specific to Sexual Health in Pregnancy|The training module will consist of 3 sessions. The first session will last 1 hour, with 45 minutes of interactive lecture and 15 minutes of question and answer. The second and third sessions will last 1 hour, with 45 minutes of interactive narration and 15 minutes of qualitative interviews. Module sessions will have a dynamic structure that takes into account the needs of the pregnant woman in her trimester. The content of the training sessions will be structured on the following topics.
62818303|NCT05954130|NO_INTERVENTION|control|No training will be given to the pregnant women in the control group who accepted to participate in the study.
62818304|NCT05539625|ACTIVE_COMPARATOR|MitoQ|Once daily dosing of two capsules for 40mg/d (or one capsule for 20mg/d if weight \<30kgs)
62818305|NCT05539625|PLACEBO_COMPARATOR|Placebo|Participants will take an oral matched placebo daily
62818306|NCT04318977|EXPERIMENTAL|high-frequency repetitive transcranial magnetic stimulation|repetitive transcranial magnetic stimulation over left dorsolateral prefrontal cortex using 3000 pulses applied with 10Hz and 120% resting motor threshold
62818307|NCT04318977|EXPERIMENTAL|theta burst stimulation|intermittent theta burst stimulation over left dorsolateral prefrontal cortex using 600 pulses applied in trains of 10 triplets/bursts (50Hz) with 8s intertrain-interval and 120% resting motor threshold
62818308|NCT04318977|PLACEBO_COMPARATOR|sham rTMS|half of the patients with high-frequency repetitive transcranial magnetic stimulation and half of the patients with theta burst Stimulation with angled coil (45 degree) or sham coil
62818309|NCT03466918|EXPERIMENTAL|Patients with SAPIEN 3 THV|Patients will be treated with Edwards SAPIEN 3 Transcatheter Heart Valve and Commander delivery system
62818310|NCT03212911|ACTIVE_COMPARATOR|3-standard dose HBV vaccination group|participants will receive 3 standard doses of HBV vaccination at 0, 1, 6 months
62241798|NCT00395551|ACTIVE_COMPARATOR|ranibizumab|ranibizumab 0.5mg intravitreal injection
62038890|NCT02654626|EXPERIMENTAL|KBP-7072: Cohort 2|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
62241799|NCT04382196||Health care workers|Health care workers at university hospital
62241800|NCT03778814|EXPERIMENTAL|TCR-T cell therapy group|Appropriate lung cancer or other solid tumor patients who could benefit from immunotherapy will be treated with targeting TCR-T cells.
62241801|NCT02827240|EXPERIMENTAL|Direct Distribution|The direct distribution arm consists of peer educators directly distributing HIV self-test kits to participants. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
62241802|NCT02827240|EXPERIMENTAL|Fixed Distribution|The fixed distribution arm consists of peer educators distributing coupons to participants. The participants can then use the coupon to collect an HIV self-test kit at a participating distribution point, including drug stores, pharmacies, and health posts. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
62241803|NCT02827240|NO_INTERVENTION|Referral to Existing Services|Peer educators will not provide HIV self-tests to participants. Peer educators will only provide referral to existing services for HIV testing.
62241804|NCT02243098|EXPERIMENTAL|Semaglutide|
62599192|NCT04106050|PLACEBO_COMPARATOR|Part A: BIIB095 Placebo|Healthy participants and participants with DPN will receive oral dose of placebo matching BIIB095 capsules from Day 1 to Day 8.
62818311|NCT03212911|ACTIVE_COMPARATOR|4-standard dose HBV vaccination group|participants will receive 4 standard doses of HBV vaccination at 0, 1, 2, 6 months
62818312|NCT05398757|OTHER|Midazolam|For sedation during surgery, patients will receive i.v. midazolam in dose 0.05 - 0.07 mg/kg.
62818313|NCT05398757|ACTIVE_COMPARATOR|Propofol|For sedation during surgery, patients will receive i.v. propofol in dose 25-27 mcg/kg/min.
62818314|NCT05398757|ACTIVE_COMPARATOR|Dexmedetomidin|For sedation during surgery, patients will receive i.v. dexmedetomidin in dose 0.5 mcg/kg/h
62818315|NCT06462339|EXPERIMENTAL|Pilates training via telerehabilitation|The intervention group will be received online pilates training three times a week for 6 weeks.
62038891|NCT02654626|EXPERIMENTAL|KBP-7072: Cohort 3|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
62038892|NCT02654626|EXPERIMENTAL|KBP-7072: Cohort 4|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
62241805|NCT05491915|EXPERIMENTAL|Peripheral Nerve Stimulation|All study subjects will have up to 2 leads placed in the back of their neck, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
62241806|NCT01542268|ACTIVE_COMPARATOR|pentoxifylline|
62241807|NCT01542268|PLACEBO_COMPARATOR|pentoxifylline placebo|
62241808|NCT04226807|EXPERIMENTAL|Early Postpartum Contact|Patient receive a phone call from research staff 2-3 weeks after giving birth in addition to routine postpartum visit
62241809|NCT04226807|NO_INTERVENTION|Routine Postpartum Care|Patient receives routine postpartum visit only
62241810|NCT06050954|OTHER|Maintenance Therapy 200mg Pembrolizumab|Participants who have radiographical or ctDNA progression after 3-6 cycles of standard-of-care platinum-based chemotherapy will be offered 200mg Pembrolizumab every six weeks via IV infusion.
62432288|NCT05639569||Patients with Descending Thoracic Aneurysm (DTA) or Type B Aortic Dissection (TBAD)|"All patients who signed informed consent and are used with Ankura™ TAA Stent Graft Systems will undergo follow-up (FU) evaluations as per local hospital standards and corresponding IFU which is expected to be at the following time points post-implant:~Before discharge, 30days after the procudure, 3-6 months after the Procedure, 12 months after the procedure, 24 months after the procedure, 36 months after the procedure"
62432289|NCT05770401|EXPERIMENTAL|Internet-Behavioral Cough Suppression Therapy|Participants will watch treatment-specific educational and training videos and perform the training exercises as recommended. There are a total of five videos ranging from 2-5 minutes in length. Participants will be asked to watch the videos at least once weekly. Daily training exercises will be discussed in the videos and should take no more than a few minutes to complete every day. All exercises are non-invasive and are not physically demanding. Each week participants will complete a progress check question that will take less than one minute to answer, indicating whether they are watching the videos and completing the exercises as recommended.
62599193|NCT04106050|ACTIVE_COMPARATOR|Part A: Lidocaine|Healthy participants and participants with DPN will receive single injection of lidocaine for partial nerve conduction block and single injection of lidocaine for skin infiltration on Day 8.
62599194|NCT04106050|EXPERIMENTAL|Part B: BIIB074 Dose 1|Healthy participants and participants with DPN will receive oral dose of BIIB074 Dose 1 tablets from Day 1 to Day 8.
62599195|NCT04106050|PLACEBO_COMPARATOR|Part B: BIIB074 Placebo|Healthy participants and participants with DPN will receive oral dose of placebo matching BIIB074 tablets from Day 1 to Day 8.
62818316|NCT06462339|NO_INTERVENTION|Waitlist|The control group will be a wait-list group without any additional specific treatment.
62818317|NCT06700135|ACTIVE_COMPARATOR|control group|the control group, which comprised 15 neonates, received only traditional medical treatment.
62241811|NCT06050954|OTHER|Maintenance Therapy 400mg Pembrolizumab|Participants who have radiographical or ctDNA progression after 3-6 cycles of standard-of-care platinum-based chemotherapy will be offered 400mg Pembrolizumab every six weeks via IV infusion..
62241812|NCT06050954|OTHER|Active Surveillance|Participants who are deemed ctDNA responders (reduction in ctDNA by 50% or more) on post-chemo testing will undergo active surveillance and continued serial ctDNA testing at regular intervals as defined by the study protocol. Patients will also undergo surveillance imaging as defined in the study protocol. At the time of first radiographic or ctDNA progression (to be assessed every 12 weeks in conjunction with radiographic assessment), the patient will be offered treatment with pembrolizumab.
62241813|NCT05718570||Participants with Adult Growth Hormone Deficiency (AGHD)|Participants will be treated with commercially available Sogroya according to routine clinical practice at the discretion of the treating physician. The decision to treat a participant with Sogroya has been made prior to and independently from the decision to include the participant in this study.
62241814|NCT00146328|EXPERIMENTAL|Group 1|Patients With Varying Degrees of Tipranavir Treatment Experience
62241815|NCT00146328|EXPERIMENTAL|Group 2|Highly Tipranavir Treatment Experienced Patients
62241816|NCT00146328|EXPERIMENTAL|Group 3|Tipranavir Treatment Naive Patients
62241817|NCT06273605|OTHER|Egg Ladder|An egg ladder is a form of home-based dietary advancement therapy that aims to facilitate the development of natural tolerance through the gradual introduction of egg containing foods with increasing quantity and allergenicity through different cooking processes. This intervention involves 5 steps over a 12 month period 1.baked egg, 2.well-cooked egg as an ingredient, 3. well cooked whole egg, 4. lightly cooked whole egg and 5.then raw egg.
62818318|NCT06700135|EXPERIMENTAL|study group|The study group, consisting of 15 neonates, received traditional medical treatment along with sensorimotor stimulation program sessions. These sessions included oral stimulation protocol, Tactile/Kinesthetic (T/K) intervention, feeding position, and oral support.
62818319|NCT06071377||Individuals with sickle cell trait|
62818320|NCT06469294|EXPERIMENTAL|Test (T) - Photodynamic therapy and 2% chlorexidine and 0,005% methylene blue|After conventional periodontal treatment, photosensitization will be performed with 2% chlorhexidine gel with 0.005% methylene blue (Fórmula e Ação Farmácia, São Paulo, SP, Brasil) for 5 minutes and photodynamic therapy will be applied with a rede laser (660nm) usinf DuoⓇ laser (MMOptics, São Carlos, SP, Brazil) with the optical fiber inside the periodontal pocket in back and forth movements, according to the manufacturer's protocol, for 90s, 9 joules of energy, dose of 508.5J/cm2, irradiance of 5.65W/cm2 and power of 100mW.
62818321|NCT06469294|PLACEBO_COMPARATOR|Control (C) - Saline Gel|After conventional periodontal treatment, saline gel will be applied in the periodontal pocket and, after 5 minutes, the laser application will be simulated with the device in inactive mode, in order to maintain blinding of the patients. Application of the gel for 5 minutes and photodynamic therapy will be applied with a rede laser (660nm) usinf DuoⓇ laser (MMOptics, São Carlos, SP, Brazil) with the optical fiber inside the periodontal pocket in back and forth movements, according to the manufacturer's protocol, for 90s, 9 joules of energy, dose of 508.5J/cm2, irradiance of 5.65W/cm2 and power of 100mW
62818322|NCT05160480||Total-body PET scan|All participants will receive a dynamic PET scan for up to 90 minutes. This will be followed by two 30 minutes static PET scans at 3 hours +/-20 minutes and 6 hours +/-20 minutes post injection. Subjects injected with 18F-PSMA or 18F-FES will receive a 40 minute scan at 9 hours +/-20 minutes post injection.
62818323|NCT06047834|PLACEBO_COMPARATOR|Control|All participants will receive non pharmacologic interventions per the local standard of care (i.e. non-pharmacologic measures and morphine when indicated).
62818324|NCT06047834|EXPERIMENTAL|Dose 1|Drug: Lofexidine (LX2) All participants will receive standard of care and 32 µg/kg/day of Lofexidine, administered as 4 µg/kg/day every 3 hours. Lofexidine will be tapered to discontinuation.
62818325|NCT06047834|EXPERIMENTAL|Dose 2|Drug: Lofexidine (LX2) All participants will receive standard of care and 20 µg/kg/day of Lofexidine, administered as 5 µg/kg/day every 3 hours. Lofexidine will be tapered to discontinuation.
62818326|NCT06047834|EXPERIMENTAL|Dose 3|Drug: Lofexidine (LX2) All participants will receive standard of care and 16-24 µg/kg/day of Lofexidine, administered every 6 hours, with the final daily dose level to be decided based upon data collected in participants receiving Dose 2. Lofexidine will be tapered to discontinuation.
62241818|NCT04802564|EXPERIMENTAL|Multisensory-based music treatment|Using a multisensory-based music treatment synchronizing with vibrotactile stimulation on the finger pulps during the protection phase (week 0-4) for hand injury patients.
62241819|NCT04802564|ACTIVE_COMPARATOR|Traditional sensory reeducation intervention|Using constant and moving tactile stimulation on the finger pulps during the protection phase (week 0-4) for hand injury patients.
62241820|NCT06418854|EXPERIMENTAL|Non-endemic international travelers|
62599196|NCT01057472||Term born babies|Term born babies
62599197|NCT01057472||Preterm babies ready for discharge|Preterm babies ready for discharge
62818327|NCT05358366|EXPERIMENTAL|Infeccion de Amor (Love Infection)|"33 Latinas will view four IA intervention episodes, one per week immediately after the baseline survey and orientation.~Participants will receive an email to their preferred email address with a password to access to the episode on the IA's website: https://www.infecciondeamor.com. Each 10-minute episode can be watched more than once during the week and presents a situation with notable HIV risk and ways the characters avoided risk (e.g., condom use) or confronted consequences of poor practices (e.g., HIV infection). The one-week time frame for each episode is needed to provide time to review and reflect about IA's content and modify HIV prevention behaviors. It will also allow Latinas to obtain information and support from the team and referral if needed. This time frame was effective to improve behaviors in previous studies."
62241821|NCT04793620|EXPERIMENTAL|TQL1055|TQL1055 + acellular pertussis vaccine
62241822|NCT04793620|ACTIVE_COMPARATOR|Acellular pertussis vaccine|Acellular pertussis vaccine
62241823|NCT06396650|EXPERIMENTAL|Lab and home-based training|Conduct balance training and/or lower-limb muscle strengthening in lab and at home
62241824|NCT03382652||Patients who received the Continuum Metal on Metal System|Patients requiring total hip arthroplasty, who meet the inclusion/exclusion criteria and received the Continuum Metal on Metal System
62241825|NCT00907049||Subacute neck pain; chronic neck pain|Patients with subacute or chronic neck pain seen in the Primary Care Centers participating in the study.
62241826|NCT02818920|EXPERIMENTAL|Pembrolizumab prior to and after surgery|
62241827|NCT04307277|OTHER|Control arm|
62241828|NCT04307277|EXPERIMENTAL|Experimental arm|
62241829|NCT05503563||tetra modal bladder preservation|
62241830|NCT05302934||Pheno4U|The study will collect data for each patient receiving an Aesculap TKA implant. The data set will be analyzed for critical risk factors among implant and patient data in order to optimize patient-centered therapies.
62241831|NCT05070039|OTHER|patients with invasive and non invasive urothelial carcinoma|patients with urothelial carcinoma will be subjected to radical cystectomy or trans uretheral resection of the tumor, specimens will be sent to the pathology lab. to be examined.
62241832|NCT04521699|EXPERIMENTAL|CalmioGo + Standard of care|Use of CalmiGO stress management device once daily + standard of care during the 12 weeks of Cardiac rehabilitation
62818328|NCT05358366|OTHER|Wait-listed|"A wait-listed control group of 33 Latinas will receive IA in the same manner as the intervention group.~Latinas will start watching the telenovela episodes 4 months after their baseline survey (after T3 survey).~Latinas will be informed at recruitment of this group condition and the study randomization. During the waiting time, participants will be called on a monthly basis to encourage participation and refer to services if needed."
62038893|NCT02724943|EXPERIMENTAL|TX CORD Intervention|TX CORD Intervention. The intervention entailed: (1) BMI screening, (2) Next Steps brief counseling materials for the healthcare provider, (3) a 3-month intensive Mind Exercise Nutrition Do It! and Coordinated Approach To Child Health (MEND/CATCH) phase, which included the Mind Exercise Nutrition Do it! ( MEND) programs for preschool (ages 2-5) and school-aged (ages 6-12) children coupled with adapted CATCH activities, and (5) a 9-month transition MEND/CATCH Transition phase, which offered monthly reinforcement sessions for parents and children, and twice weekly Young Men's Christian Association (YMCA) sports for children. Community Health Workers (CHWs) serve as program liaisons and assist in delivering all intervention group sessions as well as tracking families. Electronic Health Record (EHR) changes supported the screening and Next Steps delivery.
62241833|NCT04521699|NO_INTERVENTION|Standard of Care|Stand of care alone with 12 weeks of Cardiac rehabilitation
62818329|NCT06586996||osteoporotic vertebral compression fractures|
62818330|NCT06517160|NO_INTERVENTION|Control Group|"Patients will receive standard care, where doctors review previous medical records in the home-based medical card and discharge notes if provided by the patient during their first review. Doctors cannot access the patient's discharge medication list from the MedBook Portal, and no MedBook Portal Notice is attached to the patient's home-based medical card.~The principal investigator will give a list of control group patients to the study pharmacist at the health clinic. Knowing their appointment dates, the study pharmacist will search for the first prescription after transitioning care from the hospital to the primary health clinic. The study pharmacist will then compare the discharge prescription in the MedBook Portal with the first prescription to identify medication discrepancies. Any discrepancies will be addressed by confirming with the doctor whether they are intentional or unintentional."
62818331|NCT06517160|EXPERIMENTAL|Intervention Group|MedBook Portal Notice will be attached to the patient's home-based medical card for doctors and pharmacists at health clinics to identify recruited patients during their first follow-up after hospital discharge. During the doctor's review of intervention group patients, the doctor will log in to the MedBook Portal to check the discharge medication list and review the case based on the previous medical record in the home-based medical card and the discharge note, if provided. The doctor will then conduct medication reconciliation by comparing the discharge prescription with the new prescription. Study pharmacists at health clinics will screen patients' home-based medical cards when collecting medications. Study pharmacists will retrieve the discharge prescription from the MedBook Portal and conduct medication reconciliation by comparing the discharge prescription with the new prescription. Any discrepancies will be addressed by confirming with the doctor whether they are intentional.
62818332|NCT05788510||Pneumococcal vaccine|Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy
62818333|NCT06441643|EXPERIMENTAL|AR-17043 low concentration (Stage 1)|AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.
62241834|NCT01585220|EXPERIMENTAL|Neuramis|
62241835|NCT01585220|ACTIVE_COMPARATOR|Restylane®|
62241836|NCT06415838|EXPERIMENTAL|Brief Behavioral Activation plus Care as Usual|Five-session Brief Behavioral Activation intervention. Sessions 1 - 4 are completed once a week, and session 5 is a booster-session completed four weeks after session 4.
62241837|NCT06415838|ACTIVE_COMPARATOR|Care as Usual|Care as usual as provided by primary care and/or municipal care.
62241838|NCT05773950|PLACEBO_COMPARATOR|Dual therapy group|"On the day of surgery, in the preoperative holding area, the principal investigator administers the study drug to the participants. During the study drug administration period, the principal investigator observes the presence of specific symptoms and abnormalities at the injection site of participants.~In the case of the control group, the study drug is 150 ml of normal saline, which is visually indistinguishable from the dilute solution of the fosaprepitant, administered over 30 minutes.~The subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered."
62432290|NCT05770401|SHAM_COMPARATOR|Sham Treatment|Participants will watch sham treatment-specific educational and training videos and perform the training exercises as recommended. There are a total of five videos ranging from 2-5 minutes in length. Participants will be asked to watch the videos at least once weekly. Daily training exercises will be discussed in the videos and should take no more than a few minutes to complete every day. All exercises are non-invasive and are not physically demanding. Each week participants will complete a progress check question that will take less than one minute to answer, indicating whether they are watching the videos and completing the exercises as recommended.
62432291|NCT02278731|NO_INTERVENTION|Control Group|The elderly in Control Group suffered no intervention and continued with their daily activities.
62599198|NCT01057472||Preterm stable babies 1500 grams|Preterm stable babies 1500 grams
62599199|NCT04733937|ACTIVE_COMPARATOR|a2 Group|The infant group consuming a2 Platinum® stage 1 infant formula
62599200|NCT04733937|ACTIVE_COMPARATOR|Control Group|The infant group consuming conventional, A1 and A2 β-casein containing stage 1 infant formula
62599201|NCT04733937|NO_INTERVENTION|breast feeding|
62818334|NCT06441643|EXPERIMENTAL|AR-17043 medium concentration (Stage 1)|AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.
62818335|NCT06441643|EXPERIMENTAL|AR-17043 high concentration (Stage 1)|AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.
62599202|NCT00585013|EXPERIMENTAL|Nitric Oxide Delivery Group|Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
62818336|NCT06441643|PLACEBO_COMPARATOR|AR-17043 vehicle (Stage 1)|AR-17043 Vehicle, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.
62038894|NCT02724943|ACTIVE_COMPARATOR|Brief Clinic Comparison|Next Steps brief clinical intervention. The comparison program was a 12-month clinic-based program conducted at twelve partner healthcare clinics and entailed (1) EHR changes to support childhood obesity clinical visits; (2) BMI screening, (3) Next Steps brief counseling materials for the healthcare provider, and (4) Next Steps self-paced booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity.
62038895|NCT06221566|EXPERIMENTAL|Group A|Muscle energy technique (MET)
62038896|NCT06221566|ACTIVE_COMPARATOR|Group B|Stretching exercise program
62038897|NCT03181100|EXPERIMENTAL|Cohort I (vemurafenib, cobimetinib, atezolizumab)|Patients receive vemurafenib PO BID on days 1-21, cobimetinib PO QD on days 1-21, and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity.
62038898|NCT03181100|EXPERIMENTAL|Cohort II (atezolizumab, cobimetinib)|Patients receive cobimetinib PO QD on days 1-21 and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity.
62038899|NCT03181100|EXPERIMENTAL|Cohort III (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 60-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression and unacceptable toxicity.
62038900|NCT03181100|EXPERIMENTAL|Cohort IV (nab-paclitaxel, atezolizumab, paclitaxel,)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 and atezolizumab IV on day 1 over 30-60 minutes. Patients may receive paclitaxel IV over 30 minutes on day 1 as a substitute for nab-paclitaxel. Cycles repeat every 21 days in the absence of disease progression and unacceptable toxicity.
62038901|NCT04082546||Surgical unroofing|Refractory angina to medical treatment (beta-blockers or calcium channels blockers)
62038902|NCT04082546||Medical treatment|Responders to medical treatment for angina relief
62038903|NCT01175603|EXPERIMENTAL|Cognitive behavioral intervention|Women in the intervention condition will receive 6 two-hour intervention sessions delivered weekly in a group format by the Study Clinician. Each session contains didactic instruction on core content, as well as activities and group discussion. One of the strengths of embedding the MB Course within home visiting is our ability to have home visitors reinforce the material presented by the Study Clinician. The 6-week curriculum is divided into three modules: (a) pleasant activities, (b) thoughts, and (c) relationships with others. Each module has two sessions. These sessions map onto core cognitive-behavioral concepts.
62038904|NCT01175603|NO_INTERVENTION|Usual home visiting|Women in the control group will receive usual home visiting services and information on postpartum depression.
62038905|NCT03209804|OTHER|Traditional neurosurgical techniques|Unsimultaneous endovascular interventional embolisation/radiotherapy followed by microsurgical resection, as traditional clinical routines.
62038906|NCT03209804|EXPERIMENTAL|Hybrid operating techniques|A one-stage hybrid operation combining endovascular intervention and microsurgical techniques will be conducted simultaneously
62432292|NCT02278731|ACTIVE_COMPARATOR|Pilates Group|Pilates group (PG), which underwent one-month (three times per week) training program with the Pilates method. This protocol consisted of Pilates exercises on the ground.Stretches were performed on upper trunk and lower limbs before the exercises. Subsequently, exercises that included the range of motion and strength of the upper limbs, trunk and lower limbs were performed, always associated with breathing and contraction of transversus abdominis muscles, in different positions, increasing repetitions and resistance in the weeks of the study, using the Swiss ball, thera-band and the magic circle.
62432293|NCT02278731|ACTIVE_COMPARATOR|PNF Group|PNF group that underwent one-month (three times per week) training program using the propriocptive neuromuscular facilitation method.The selected PNF diagonal patterns were chosen with all the basic procedures to the facilitation and according to three specific principles of PNF: rhythmic initiation, sustain and relax and reversal of antagonists. During the first week, one set of ten repetitions for each diagonal was performed; in the second week, two sets of ten repetitions and in the third and fourth weeks, three sets of ten repetitions were performed.
62432294|NCT00871598|PLACEBO_COMPARATOR|Placebo|
62818337|NCT06441643|ACTIVE_COMPARATOR|Rhopressa (Stage 1)|Netarsudil 0.02% Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.
62038907|NCT03725917|EXPERIMENTAL|Experimental Group|The intervention will be a progressive physiotherapy protocol formed by therapeutic exercise and manual therapy
62038908|NCT03725917|NO_INTERVENTION|Control Group|The control group will not receive physiotherapy treatment.
62038909|NCT03704766|EXPERIMENTAL|Inflamed/Infected Joint|Patients undergoing joint aspiration/debridement due to suspicion of septic joint or rheumatologic/inflammatory condition
62038910|NCT03704766|ACTIVE_COMPARATOR|Normative Control|Patient undergoing procedure unrelated to infection/inflammation
62432295|NCT00871598|EXPERIMENTAL|Single 0.3|
62432296|NCT00871598|EXPERIMENTAL|Repeat 1.0|
62432297|NCT00871598|EXPERIMENTAL|Repeat 2.0|
62432298|NCT00871598|EXPERIMENTAL|Repeat 4.0|
62818338|NCT06441643|EXPERIMENTAL|PG043 low concentration (Stage 2)|PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.
62818339|NCT06441643|EXPERIMENTAL|PG043 high concentration (Stage 2)|PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.
62241839|NCT05773950|EXPERIMENTAL|Triple therapy group|"On the day of surgery, in the preoperative holding area, the principal investigator administers the study drug to the participants. During the study drug administration period, the principal investigator observes the presence of specific symptoms and abnormalities at the injection site of participants. In the case of the experimental group, 150 ml of normal saline mixed with 150 mg of fosaprepitant is administered over 30 minutes.~The subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered."
62599203|NCT00585013|NO_INTERVENTION|Placebo|Placebo delivery of oxygen at standard dose.
62599204|NCT05896722||Study group|27 young adults aged 17-26 who scored 4 or more according to the Beighton scoring
62599205|NCT05896722||Control group|27 young adults aged 17-26 who scored less than 4 points according to the Beighton scoring
62241840|NCT05532449|NO_INTERVENTION|control|
62432299|NCT00871598|EXPERIMENTAL|Repeat 8.0|
62432300|NCT03914144||Normal Vaginal Delivery|The group of patients who achieved a normal delivery will be retrospectively assessed as to whether they had any episode of catheter insertion during their delivery.
62432301|NCT03914144||Insturmental Vaginal Delivery|The group of patients who underwent instrumental delivery (ventouse or forceps) will be retrospectively assessed as to whether they had any episode of catheter insertion during their delivery.
62432302|NCT03914144||Emergency Caesarean Section|Each patient will be recorded how many catheter episodes occurred during their labour and delivery.
62432303|NCT03914144||Elective Caesarean Section|We expect all patients in this group to have an indwelling catheter sited before their elective caesarean sections, however we will assess each patient individually to confirm whether they had a catheter for their delivery.
62432304|NCT01389024|EXPERIMENTAL|Hydroxyurea|Treatment with hydroxyurea 20 mg/kg/day increased by 5 mg/kg every 8 weeks to maximum of 35 mg/kg/day or hematologic toxicity or Absolute Neutrophil Count (ANC) \<4000
62599206|NCT05651919||No-T2D +MS / No-HF (control group)|15 patients without T2D +MS and without Heart Failure will be included in group 1.
62599207|NCT05651919||No-T2D +MS / HFpEF or HFmrEF|15 patients without T2D+MS and presenting HFpEF or HFmrEF will be included in group 2
62241841|NCT05532449|EXPERIMENTAL|Dezocine|intravenous dezocine (0.03mg/kg diluted to 5 ml)
62241842|NCT05579990|EXPERIMENTAL|Meal Delivery|Meal delivery intervention program designed to help low income postpartum women lose weight through weekly meal delivery and behavioral strategies.
62432305|NCT01389024|PLACEBO_COMPARATOR|Placebo|Sucrose placebo 0.2 ml/kg/day increased to max of 0.35 ml/kg/day
62432306|NCT01361906|NO_INTERVENTION|Untreated control|Untreated control
62432307|NCT01361906|EXPERIMENTAL|Sensomotoric training|Treatment with Sensomotoric training
62432308|NCT06307600|EXPERIMENTAL|RD06-03 cell infusion|The enrolled patients will use 1 dose RD06-03 CART cell injection
62432309|NCT05843838|EXPERIMENTAL|Hypotensive group|Patients who are hypotensive (even once) and need ephedrine under spinal anesthesia with routine doses of heavy bupivacaine (Hypotension, Mean Arterial Pressure\<65 mmHg, or Systolic arterial pressure \< 30% will be considered an initial value.)
62432310|NCT05843838|PLACEBO_COMPARATOR|Normotensive group|Patients who are not hypotensive under spinal anesthesia with routine doses of heavy bupivacaine
62599208|NCT05651919||T2D+MS / no-HF|15 patients presenting T2D +MS and without any type of HF will be included in group 3.
62818340|NCT06441643|ACTIVE_COMPARATOR|AR-17043 high concentration (Stage 2)|AR-17043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.
62818341|NCT06441643|ACTIVE_COMPARATOR|Latanoprost (Stage 2)|Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.
62038911|NCT06732544|EXPERIMENTAL|experiment group|These women will spend labor in the snoezelen room.
62038912|NCT06732544|OTHER|control group|These women will spend the duration of labor in a standard delivery room.
62241843|NCT06735885|EXPERIMENTAL|Arm 1. Home training with stock photos and no neurofeedback|Home training with stock photos and no neurofeedback
62599209|NCT05651919||T2D +MS / HFpEF or HFmrEF|15 patients presenting T2D +MS and HFpEF or HFmrEF will be included in group 4.
62599210|NCT02071706|OTHER|Single-Arm PET/MRI|Single-group evaluation of PET/MRI for diagnostic quality of image
62599211|NCT03521297|PLACEBO_COMPARATOR|Placebo group|Placebo (three times per day, one pack each time) and UDCA (13-15mg/kg/day), orally, 6 months
62599212|NCT03521297|EXPERIMENTAL|Probiotics group|Probiotics (three times per day, one pack each time) and UDCA(13-15mg/kg/day), orally, 6 months
62599213|NCT02990585|ACTIVE_COMPARATOR|One individual back school session|The 1 individual session will consist of a 60 min 1-on-1 education/exercise session with an athletic trainer. Information will be an abbreviated version of the 8-session school and fill focus on the strengthening, stretching, pain control and movement re-education most needed for the individual.
62818342|NCT06441643|ACTIVE_COMPARATOR|Rocklatan (Stage 2)|Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.
62241844|NCT06735885|EXPERIMENTAL|Arm 2. Home training with stock photos and neurofeedback|Home training with stock photos and neurofeedback
62818343|NCT05791981|EXPERIMENTAL|Harmony & Health Intervention (Group 1)|Participants randomized to the Harmony and Health intervention group will attend group-based in-person intervention sessions at FOP or COGIC. on.
62432311|NCT03335709|EXPERIMENTAL|ADL intervention|The participants are assigned to an eight-week intervention program aiming at enhancing ADL ability. The program consists of a minimum of five and a maximum of eight sessions; Session one - First meeting and occupational therapy evaluation (mandatory), Session two - Goal setting and clarifying reasons for problems related to ADL (mandatory), Session three- seven - Interventions aiming at enhancing ADL ability (Number of sessions can vary. However, a minimum of two sessions are mandatory), Session eight - Re-evaluation (Mandatory)
62432312|NCT02555618|EXPERIMENTAL|TAK-850|A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin \[HA\] antigen per strain) is injected subcutaneously into the upper arm.
62432313|NCT02555618|ACTIVE_COMPARATOR|Influenza HA Vaccine|A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.
62432314|NCT03402178|EXPERIMENTAL|E2082|E2082 will be administered as a solution (0.2 milligram \[mg\]), a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg E2082 solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, or 2.5 mg E2082 tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg E2082 under fasted conditions, and then they will receive 5 mg E2082 under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg (adult participants), 15 mg, 25 mg, 40 mg, or 10 mg (elderly participants) E2082 tablets under fasted conditions. Part B: Participants in Cohorts 1 to 4, respectively, will receive 2.5 mg, 5 mg, 10, or 15 mg tablets once daily for 10 days. E2082 will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.
62432315|NCT03402178|PLACEBO_COMPARATOR|E2082-matched placebo|Matched placebo will be administered as a solution (0.2 mg), a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg matched placebo solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, or 2.5 mg matched placebo tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg matched placebo under fasted conditions, and then they will receive 5 mg matched placebo under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg (adult participants), 15 mg, 25 mg, 40 mg, or 10 mg (elderly participants) matched placebo tablets under fasted conditions. Part B: Participants in Cohorts 1 to 4, respectively, will receive 2.5 mg, 5 mg, 10, or 15 mg matched placebo tablets once daily for 10 days. Matched placebo will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.
62599214|NCT02990585|ACTIVE_COMPARATOR|8 group session of back school|All sessions last 45-60 minutes. There will be up to 8 participants in each session which will be led by an athletic trainer or rehabilitation trainer. Pain management, prevention strategies, and active treatment will be covered in the 8 sessions. Active treatment includes strengthening, stretching, pain control, movement re-education, and walking.
62599215|NCT06618183||1|Donors randomized into the 0 mg codeine dosage block
62599216|NCT06618183||2|Donors randomized into the 30 mg codeine dosage block
62599217|NCT06618183||3|Donors randomized into the 60 mg codeine dosage block
62241845|NCT06735885|EXPERIMENTAL|Arm 3. Home training with matter photos and no neurofeedback|Home training with matter photos and no neurofeedback
62038913|NCT03602118|ACTIVE_COMPARATOR|Phenobarbital Sodium Injection 20 mg|Once participants are deemed to be eligible for participation in the study and randomized to the lower dose they will be given a loading dose of phenobarbital 20 mg/kg administered intravenously over the course of 30 minutes.
62241846|NCT06735885|EXPERIMENTAL|Arm 4. Home training with matter photos and neurofeedback|Home training with matter photos and neurofeedback
62241847|NCT06735885|EXPERIMENTAL|Arm 5. No home training no feedback|No home training no feedback
62818344|NCT05791981|EXPERIMENTAL|Attention Control (Group 2)|Participants randomized to the attention control condition will participate in in-person group-based health education sessions twice a week for 8 weeks with a trained interventionist and will receive 4 monthly newsletters (20 total contacts).
62038914|NCT03602118|ACTIVE_COMPARATOR|Phenobarbital Sodium Injection 40 mg|Once participants are deemed to be eligible for participation in the study and randomized to the higher dose they will be given a loading dose of phenobarbital 20 mg/kg administered intravenously over the course of 30 minutes. ministered intravenously over the course of 30 minutes.
62241848|NCT06735885|EXPERIMENTAL|Arm 6. No home training with Stock Photos and neurofeedback (Standard of Care)|No home training with Stock Photos and neurofeedback (Standard of Care)
62241849|NCT06735885|SHAM_COMPARATOR|Arm 7. No home training with Matter Photos and neurofeedback|No home training with Matter Photos and neurofeedback
62241850|NCT05033652|NO_INTERVENTION|Standard strategy|
62818345|NCT06340581|EXPERIMENTAL|Treatment Sequence 1: ABC|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive single-dose treatments of BGF MDI HFA with spacer (Treatment A), followed by BGF MDI HFO with spacer (Treatment B), and then BGF MDI HFO without spacer (Treatment C) in 3 treatment periods with single dose (4 puffs) on Day 1 of all treatment periods.
62038915|NCT04088409|EXPERIMENTAL|Baricitinib|"Participants ≥9 to \<18 years of age were administered 4 milligrams (mg) baricitinib once daily (QD). Participants \<9 years of age were administered 2 mg baricitinib QD.~Participants \<6 years of age received an oral suspension. Participants ≥6 to \<12 years of age had the option of receiving an oral suspension. Participants \>12 years of age were supplied tablets."
62241851|NCT05033652|EXPERIMENTAL|Warning KD strategy|
62241852|NCT01159912|EXPERIMENTAL|Fluticasone Furoate OD and Placebo BID|Fluticasone furoate inhalation powder once daily and placebo inhalation powder twice daily for 24 weeks
62241853|NCT01159912|ACTIVE_COMPARATOR|Fluticasone Propionate BID and Placebo OD|Fluticasone propionate inhalation powder twice daily and placebo inhalation powder once daily for 24 weeks
62241854|NCT01159912|PLACEBO_COMPARATOR|Placebo only BID|Placebo inhalation powder twice daily for 24 weeks
62241855|NCT01768988|EXPERIMENTAL|Group I|Conventional analgesic treatment + pregabalin.
62241856|NCT01768988|PLACEBO_COMPARATOR|Group II|Conventional analgesic treatment + placebo.
62818346|NCT06340581|EXPERIMENTAL|Treatment Sequence 2: ACB|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive single-dose treatments of BGF MDI HFA with spacer (Treatment A), followed by BGF MDI HFO without spacer (Treatment C), and then BGF MDI HFO with spacer (Treatment B) in 3 treatment periods with single dose (4 puffs) on Day 1 of all treatment periods.
62818347|NCT06340581|EXPERIMENTAL|Treatment Sequence 3: BAC|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive single-dose treatments of BGF MDI HFO with spacer (Treatment B), followed by BGF MDI HFA with spacer (Treatment A), and then BGF MDI HFO without spacer (Treatment C) in 3 treatment periods with single dose (4 puffs) on Day 1 of all treatment periods.
62038916|NCT04088409|ACTIVE_COMPARATOR|Adalimumab|Participants received adalimumab administered subcutaneously (SC) once every 2 weeks. The dose was based on body weight: 20 mg every 2 weeks for participants weighing \<30 kilograms (kg), or 40 mg every 2 weeks for participants weighing ≥30 kg.
62038917|NCT02612948|NO_INTERVENTION|Standard Care|Standard care for delerium
62241857|NCT03374085|EXPERIMENTAL|Administration of CC-92480 in combination with dexamethasone|Part 1: Escalating doses of CC-92480 plus a fixed dose of dexamethasone Part 2: RP2D of CC-92480 in combination with dexamethasone
62241858|NCT03374085|EXPERIMENTAL|Administration of CC-92480 monotherapy|Escalating doses of CC-92480 Monotherapy administered according to different dosing schedules
62241859|NCT02964858|ACTIVE_COMPARATOR|Standard Arm|45 Gy in 25 fractions of 1.8 Gy per fraction over 5 weeks Involved Field radiotherapy (IFRT)/ Involved Site Radiotherapy (ISRT)
62241860|NCT02964858|EXPERIMENTAL|Experimental Arm|36 Gy in 20 fractions of 1.8 Gy per fraction over 4 weeks Involved Field radiotherapy (IFRT)/ Involved Site Radiotherapy (ISRT)
62241861|NCT06140472|ACTIVE_COMPARATOR|Phoenix application|Specific individualized nurse follow-up using the PHOENIX application.
62241862|NCT06140472|SHAM_COMPARATOR|Journal de bord|Regular nursing follow-up, with the use of an electronic journal.
62241863|NCT05520645|EXPERIMENTAL|Eto 0.15mg/kg|Etomidate 0.15mg/kg for anesthesia induction
62241864|NCT05520645|EXPERIMENTAL|Eto 0.2mg/kg|Etomidate 0.2mg/kg for anesthesia induction
62241865|NCT05520645|EXPERIMENTAL|Eto 0.25mg/kg|Etomidate 0.25mg/kg for anesthesia induction
62241866|NCT05520645|ACTIVE_COMPARATOR|Propofol 2mg/kg|propofol 2mg/kg for anesthesia induction
62241867|NCT03591783||study group|All patients will be subjected to: Baseline investigations, end of treatment investigations and 3 months after treatment investigations.
62599218|NCT04611867|EXPERIMENTAL|Intervention Arm|"The intervention will be comprised of providing patients with supportive application with integrated PRO consisting of:~* Weekly self-reporting of PRO-CTCAE with integrated preparation questionnaire available for staff~* Daily monitoring of self-reporting by study staff~* Intervention if required based on self-reporting~* Reports to oncologists (at consultation)~* Information module about treatment, side effects and contact information"
62599219|NCT04611867|NO_INTERVENTION|Standard Arm|"Standard care for patients will be included in no-intervention arm will consist of the standard procedures at Herlev Hospital, Department of Oncology for monitoring and documenting symptoms, which will be typical of oncology practice. Symptoms will be discussed and documented in the medical record during clinical encounters between patients and their oncologists. Patients will be encouraged to initiate telephone contact between visits for concerning symptoms, i.e. call early and often."
62599220|NCT05979935||patients with high-risk of esophageal varices in liver cirrhosis|The maximum diameter of varices \>5mm or maximum diameter of varices \<5mm with positive red sign in patients with liver cirrhosis
62599221|NCT05979935||patients with low-risk of esophageal varices in liver cirrhosis|the maximum diameter of esophageal varices \<5mm without positive red sign in patients with liver cirrhosis.
62599222|NCT03080766|EXPERIMENTAL|decitabine|"Decitabine is a white to almost white powder for concentrate for solution for infusion. It is supplied as a lyophilized preparation in a clear colorless 20ml glass vial containing 50 mg decitabine.~The concentrate should be aseptically reconstituted with 10 ml of water for injections. After reconstitution, the concentrate must be diluted within 15 minutes using cooled infusion fluids and completely administered to patients within 5 hours.~The drug will then be administrated intravenously.~Dosage 20 mg/m2~28-day course, for each course, receive decitabine for 10 days"
62599223|NCT00865917|ACTIVE_COMPARATOR|1|beta-blocker
62599224|NCT00865917|EXPERIMENTAL|2|I(f)-blocker
62599225|NCT00865917|PLACEBO_COMPARATOR|3|Placebo
62735756|NCT01536561|EXPERIMENTAL|open-label, dose escalation|"Each subject will undergo two phases of study. The first phase, termed tracer Study, involves the injection of low-radioactivity doses (about 5 mCi) of 131-I anti-B1 for the purposes of determining the rate of whole body clearance of radiation so that a whole body radiation can be calculated. The calculated whole-body radiation dose per mCi administered can then be used to determined how many mCi will be required to deliver a specified whole-body radiation dose in the second phase of the study for each patient, termed radio-immunotherapy dose in a tracer-projected whole-body radiation dose will be used for dose escalation with a minimum of three subjects per dose level."
62241868|NCT04903106||Meniscal Tear|Subject requires a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
62241869|NCT04903106||Meniscal Insufficiency|Subject requires a MAT for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed.
62432316|NCT02450760|OTHER|Control|Subjects will take their blood pressure twice daily using the provided Withings blood pressure cuff. If subjects miss blood pressure readings, they will receive automated alerts reminding them to take their blood pressure. Subjects will also receive weekly emails with their blood pressure data for the week.
62432317|NCT02450760|OTHER|Social Incentive|Subjects will take their blood pressure twice daily using the provided Withings blood pressure cuff. Subjects in this arm will also identify a social supporter who may help subjects adhere to daily blood pressure readings. If the subject misses blood pressure readings, they will receive automated alerts reminding them to take their blood pressure. The identified social supporter will also receive these alerts, with the expectation that the social supporter will remind the subject to take their blood pressure. Both the subject and the social supporter will also receive weekly emails with their blood pressure data for the week.
62432318|NCT01682941|ACTIVE_COMPARATOR|Soy Bread Intervention|Arm I Soy Bread
62432319|NCT01682941|EXPERIMENTAL|Soy -Almond Bread Intervention|Arm II Soy-Almond Bread
62432320|NCT00962949|EXPERIMENTAL|Control|Healthy controls
62432321|NCT00962949|EXPERIMENTAL|Postural Tachycardia Syndrome|Patients with Postural Tachycardia Syndrome
62432322|NCT00080288|EXPERIMENTAL|1|Armodafinil 150 mg/day
62432323|NCT00080288|PLACEBO_COMPARATOR|2|Placebo
62432324|NCT04078139|EXPERIMENTAL|The MP/RP group|Participates will receive peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 40mg methylprednisolone, plus 10ml saline;
62432325|NCT04078139|ACTIVE_COMPARATOR|The RP group|Participates will receive peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10ml saline;
62432326|NCT00404586|EXPERIMENTAL|Treatment period 1|In treatment period subjects will receive once daily 100 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
62432327|NCT00404586|EXPERIMENTAL|Treatment period 2|In treatment period subjects will receive once daily 200 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
62432328|NCT00404586|EXPERIMENTAL|Treatment period 3|In treatment period subjects will receive once daily 400 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
62599226|NCT06612099|EXPERIMENTAL|Aerobic Exercise Group|Individuals in this group will perform aerobic exercise training on a treadmill/bicycle under the supervision of a physiotherapist for a period of 8 weeks, consisting of a total of 24 training sessions. Moderate intensity aerobic exercise training will be set by calculating the target heart rate range. During the training session, individuals will receive a total of 50 minutes of training, consisting of a 10-minute warm-up, 30 minutes of moderate walking/cycling and a 10-minute cool-down period. In addition to the aerobic exercise training group, on the days he does not come to the session, resistance exercises will be taught in the form of 2 sets of 8 repetitions, with weights of 60-80% of 1 maximum repetition, according to the guidelines of the American Sports Medicine Association, and will be given as home exercises.
62599227|NCT06612099|ACTIVE_COMPARATOR|Mat Pilates Exercise Group|Individuals in this group will perform mat pilates exercises under the supervision of a physiotherapist for a period of 8 weeks, consisting of a total of 24 exercise sessions. During the exercise sessions, individuals will undergo a 50-minute mat pilates exercise program. In addition to the mat pilates exercise group, on the days when he does not come to the session, resistance exercises will be taught in the form of 2 sets of 8 repetitions, 60-80% of 1 maximum repetition, according to the guidelines of the American Sports Medicine Association, and will be given as home exercises.
62599228|NCT06612099|NO_INTERVENTION|Control Group|Hypertensive individuals who meet the inclusion and exclusion criteria will note their blood pressure values 2 days a week for 8 weeks and share them with the physiotherapist. Patients in this group will be instructed to continue their normal lives.
62599229|NCT03382301|EXPERIMENTAL|Ciclosporin A preconditioning|Ciclosporin A preconditioning before renal artery stenosis dilation
62599230|NCT03382301|PLACEBO_COMPARATOR|NaCl preconditioning|
62599231|NCT03440294|OTHER|with neoprene suit and life jacket|"Realization of the following examinations WITH neoprene suit and life jacket :~* resting standard spirometry~* maximum exercise testing. No drug and no placebo will be used in this arm."
62599232|NCT03440294|OTHER|without neoprene suit and life jacket|"Realization of the following examinations WITHOUT neoprene suit and life jacket :~* resting standard spirometry~* maximum exercise testing. No drug and no placebo will be used in this arm."
62599233|NCT02429388|EXPERIMENTAL|High dose spironolactone|This arm of the study will include addition of high dose spironolactone upto 100mg twice daily in adjunct to usual care of hospitalized acute decompensated heart failure patients with loop diuretics.
62599234|NCT02429388|NO_INTERVENTION|Usual Care|This arm of the study will continue the usual care of hospitalized acute decompensated heart failure patients with loop diuretics.
62599235|NCT03785912|EXPERIMENTAL|Internet-based self-help|The self-help program consists of eight text- and video-based modules. All participants in this group receive immediate access to the self-help program. The program's self-management approach does not provide for regular support from a specialist. However, participants can contact the study team if they need or want additional help.
62599236|NCT03785912|NO_INTERVENTION|Waiting control group|Access to internet-based intervention after 12 weeks.
62599237|NCT06174376|EXPERIMENTAL|GORE Synthetic Cornea Device|Treatment with GORE Synthetic Cornea Device
62818348|NCT06340581|EXPERIMENTAL|Treatment Sequence 4: BCA|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive single-dose treatments of BGF MDI HFO with spacer (Treatment B) followed by BGF MDI HFO without spacer (Treatment C), and then BGF MDI HFA with spacer (Treatment A) in 3 treatment periods with single dose (4 puffs) on Day 1 of all treatment periods.
62038918|NCT02612948|ACTIVE_COMPARATOR|Quetiapine|Quetiapine therapy was initiated at 12.5 mg twice daily a. After thefirst dose of quetiapine 12.5 mg, the regimen could then be adjusted by the rounding surgeon. If the surgeon felt benefit from receiving a higher dose of quetiapine the dose could then be increased. Quetiapine was discontinued if adverse events (torsades de pointes or other ventricular tachycardias) occurred. All patients receiving at least one dose of quetiapine were included in the final intention-to-treat analyses. All prescribing decisions were left to the discretion of the rounding surgeon and were not mandated as part of the study.
62818349|NCT06340581|EXPERIMENTAL|Treatment Sequence 5: CAB|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive single-dose treatments of BGF MDI HFO without spacer (Treatment C), followed by BGF MDI HFA with spacer (Treatment A), and then BGF MDI HFO with spacer (Treatment B) in 3 treatment periods with single dose (4 puffs) on Day 1 of all treatment periods.
62818350|NCT06340581|EXPERIMENTAL|Treatment Sequence 6: CBA|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive single-dose treatments of BGF MDI HFO without spacer (Treatment C), followed by BGF MDI HFO with spacer (Treatment B), and then BGF MDI HFA with spacer (Treatment A) in 3 treatment periods with single dose (4 puffs) on Day 1 of all treatment periods.
62818351|NCT06700824|EXPERIMENTAL|OTR4132|OTR4132 is a new ReGeneraTing Agent (RGTA®) which is a polymer of glucose (α-1,6 bounds, i.e. dextran backbone) engineered to mimic heparan sulphate (HS) in all three mechanical functions (extracellular matrix scaffold element, protector of matrix pro-teins and cellular communication peptides storage sites) but differ from HS by their resistance to glycanases. OTR4132 allows a restoration of the matrix architecture which secondarily facilitates cell survival and recovery at the site of injury.
62818352|NCT06700824|PLACEBO_COMPARATOR|Placebo|Saline solution
62818353|NCT04527796||rehabilitation|All included patients get an pre-intervention and a post intervention analysis
62599238|NCT05284929||Patients with pemphigus|
62038919|NCT06670261||Healthy subjects|100 patients without ONC
62599239|NCT05284929||Healthy controls|
62038920|NCT06670261||Patients with CNO|200 patients with anatomical ONC
62599240|NCT00858299|EXPERIMENTAL|valsartan|
62599241|NCT06614296||Unscheduled readimission|Unscheduled readimission after CLIF
62599242|NCT06614296||Scheduled readimission|Scheduled readimission after CLIF
62735757|NCT04789954|EXPERIMENTAL|AryoSeven 10 μg/kg|Single dose, intravenously
62599243|NCT00738881|EXPERIMENTAL|Arm I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62818354|NCT05980260|OTHER|Sequence 1|This sequence will assign eligible participants to a three-week run-in period followed by a scheduled opioid taper approach for five months followed by a three-week washout period followed by symptom-based dosing approach for five months.
62818355|NCT05980260|OTHER|Sequence 2|This sequence will assign eligible participants to a three-week run-in period followed by a symptom-based dosing approach for five months followed by a three-week washout period followed by scheduled opioid taper approach for five months.
62818356|NCT06569212|EXPERIMENTAL|Metoprolol (Beta-adrenergic blockade)|Patients will receive metoprolol during the first 72-hours of hospitalization after non-traumatic SAH.
62818357|NCT06569212|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo during the first 72-hours of hospitalization after non-traumatic SAH.
62818358|NCT04539496|EXPERIMENTAL|Dose Escalation and Expansion Study|To determine the MTD and RP2D of XZP-3287
62038921|NCT01912612|EXPERIMENTAL|Arm 1 (Patients with pain, duloxetine)|Duloxetine 30 mg daily x 1 week, then 60 mg daily x 4 weeks, then 30 mg daily x 2 weeks.
62038922|NCT01912612|NO_INTERVENTION|Arm 2 (Patients without pain -- control)|Patient reported pain and symptoms assessment for comparison at baseline.
62241870|NCT02515578|ACTIVE_COMPARATOR|Standard practice transformation support|Primary care practices will receive a cardiovascular care toolkit, practice facilitation, practice assessment with feedback, health information technology assistance, academic detailing, and periodic collaborative learning sessions
62241871|NCT02515578|EXPERIMENTAL|Enhanced practice transformation support|Primary care practices will receive practice facilitation, practice assessment with feedback, health information technology assistance, academic detailing, and periodic collaborative learning sessions PLUS patient advisory council support and a modified cardiovascular care toolkit based on combined practice and patient input regarding the local context.
62241872|NCT01690897|EXPERIMENTAL|MBCT group|Women randomized into the MBCT group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the mindfulness-based treatment.
62241873|NCT01690897|ACTIVE_COMPARATOR|Support group|Women randomized into the support group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the sex therapy, education, and support treatment.
62038923|NCT05363566|ACTIVE_COMPARATOR|group I|will be inserted Single use supraglottic airway ( Baska mask® (proact Medical Ltd, Northants, UK)
62241874|NCT06734884|EXPERIMENTAL|Benralizumab|
62241875|NCT06734884|PLACEBO_COMPARATOR|Placebo|
62241876|NCT02642484|ACTIVE_COMPARATOR|Gabapentin|Gabapentin twice daily
62241877|NCT02642484|PLACEBO_COMPARATOR|PLacebo|Calcium carbonate twice daily
62241878|NCT04510688||Managed Access Program (MAP) patients|Patients with RCC treated with cabozantinib under a Managed Access Program (MAP) prior to Cabometyx® marketing authorization
62241879|NCT04510688||Real World (RW) patients|Patients with RCC treated with cabozantinib as routine clinical prescription (Real World), with treatment started after Cabometyx® marketing authorization
62241880|NCT05629650|EXPERIMENTAL|Tai Chi for memory|TCM is a standardized type of Tai Chi for health developed by Dr. Lam specifically for those who experience or want to prevent cognitive problems. TCM, consisting of 12 Sun-style and Yang-style Tai Chi movements, can be provided while sitting and while standing with five blocked movement sets so that cognitively impaired individuals (MCI vs. dementia) are able to follow them.
62241881|NCT02455934|PLACEBO_COMPARATOR|Sucrose|Sucrose 50 g
62599244|NCT00738881|EXPERIMENTAL|Arm II (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62599245|NCT00916344|EXPERIMENTAL|Pacemaker therapy|
62735758|NCT04789954|EXPERIMENTAL|AryoSeven 30 μg/kg|Single dose, intravenously
62241882|NCT02455934|ACTIVE_COMPARATOR|SAlloulose2.5|Sucrose 50 g + D-allulose (psicose) 2.5 g
62241883|NCT02455934|ACTIVE_COMPARATOR|SAllulose5|Sucrose 50 g + D-allulose (psicose) 5 g
62241884|NCT02455934|ACTIVE_COMPARATOR|SAllulose7.5|Sucrose 50 g + D-allulose (psicose) 7.5 g
62241885|NCT02455934|ACTIVE_COMPARATOR|SAllulose10|Sucrose 50 g + D-allulose (psicose) 10 g
62241886|NCT05452096|ACTIVE_COMPARATOR|Intervention group|"The intervention provided to the intervention group is based on evidence-based good standard of care and includes:~* Healthy scheduling (fast forward-rotating shift schedules adapted to chronotype, adequate resting times, napping, bright-light therapy)~* Education program for drivers (psychoeducation promoting sleep hygiene, cognitive-behavioral strategies, stress-management techniques, information on chronotherapy such as bright-light therapy and napping)"
62735759|NCT04789954|EXPERIMENTAL|AryoSeven 90 μg/kg|Single dose, intravenously
62735760|NCT04789954|EXPERIMENTAL|AryoSeven 270 μg/kg|Single dose, intravenously
62735761|NCT04789954|ACTIVE_COMPARATOR|NovoSeven 30 μg/kg|Single dose, intravenously
62735762|NCT04120844|EXPERIMENTAL|Intervention|Patients in the intervention group (n=117) received a four-session PEP in small groups over one month by trained nurses and doctors.
62818359|NCT04539496|EXPERIMENTAL|Combination Therapy Study|To determine the RP2D of XZP-3287 combined with endocrine therapy
62818360|NCT04539496|EXPERIMENTAL|A Phase 2 Study of Single-Agent XZP-3287 in Patients After Failure of Multi-Line Therapy|To determine the efficacy and safety profiles of XZP-3287 as a single- agent in hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced breast cancer
62818361|NCT06705101|EXPERIMENTAL|Gabapentin Group (Group G): Participants receiving Gabapentin 300 mg as a pre-treatment.|Gabapentin Group (Group G): Participants receiving Gabapentin 300 mg as a pre-treatment.
62818362|NCT06705101|PLACEBO_COMPARATOR|Placebo Group (Group P): Participants receiving a placebo as a pre-treatment.|Placebo Group (Group P): Participants receiving a placebo as a pre-treatment.
62818363|NCT05880199||Children with functional GI disorders|
62818364|NCT05880199||Healthy controls|
62818365|NCT02931188||Anacetrapib|Participants who received anacetrapib, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
62818366|NCT02931188||Placebo|Participants who received placebo, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
62599246|NCT06342219|EXPERIMENTAL|neurofeedback mindfulness|This group is asked to do 10 min/day practice of neurofeedback mindfulness for 8 weeks. They should sit comfortably in a quiet area and do one of ten beginner self-guided mindfulness sessions on mind-body scanning techniques from within the MUSE app. Each session includes a brief explanation for 2-3 minutes before the practice. Once the participants start their practices, they receive sounds for their real-time brain activities: thunderstorm for an active state, ocean waves for a neutral state, and birds chirping for a relaxed state. For each five seconds of consistent relaxed state, the participants are reinforced with points.
62599247|NCT06342219|ACTIVE_COMPARATOR|Attention Task|The participants in the controlled intervention group are assigned to have an attention routine in a relaxed position. They are required to sit comfortably and relax in a quiet area to put on their MUSE headband, set it up, and use the same practices on MUSE app but they will mute all the neurofeedback sounds and instructions. Instead, on their smartphone the participants will check their emails, the news, or their preferred social media platform for 10 minutes. Once the session is over, the participants receive the graphical feedback of their brain activities. The feedback includes a timeline indicating their brain states (active, or relaxed) during the 10-minute session.
62599248|NCT06342219|NO_INTERVENTION|Waitlisted Group|The participants in this group are informed about being appointed in the waitlisted group and that we will only be collecting headache data from them for 8 weeks. They will complete the questionnaires for three rounds (i.e., Week 1, Week 4, and Week 8) and information about their headaches will be collected via the headache diaries. After 8 weeks, they will receive the MUSE device and will be offered a complementary session on how to use the device for their personal use. A debriefing form will be emailed to all the participants after completion of the study.
62599249|NCT06333275||CAR T-cell recipients|Patients with B-cell malignancies receiving anti-CD19 or anti-BCMA CAR T-cell therapies
62599250|NCT03824886|EXPERIMENTAL|Implementation of skin care algorithm|In the interventional nursing homes, a structured skin care prevention package based on a newly developed evidence-based skin care algorithm will be implemented at the nursing homes and delivered by nurses.
62599251|NCT03824886|NO_INTERVENTION|Standard Care|In the control group, no additional intervention will be implemented. PU and IAD prevention and basic hygiene and skin care activities are routinely conducted in German nursing homes. This is considered as 'usual practice'.
62735763|NCT04120844|PLACEBO_COMPARATOR|Control|The control group (n=108) received the traditional lecture-style health education on Diabetes Mellitus.
62241887|NCT05452096|NO_INTERVENTION|Control group|The control group will continue working according to the default shift schedules while being assigned to a waiting list in anticipation of the education program.
62241888|NCT03920150|ACTIVE_COMPARATOR|Control|5 ml alcoholic solution containing 24'000 IU vitamin D for 3 months
62432329|NCT00404586|PLACEBO_COMPARATOR|Treatment period 4|In treatment period subjects will receive once daily Placebo and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive Placebo and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
62818367|NCT05153746|EXPERIMENTAL|3D colonoscopy|"Colonoscopy insertion under regular method. After reaching cecum, the subjects will be randomized into 3D or conventional colonoscopy.~Subjects in 3D colonoscopy arm:~Colonoscopist will switch the image to 3D imaging form and wearing special glasses to enhance the 3D imaging. The 3D mode will be maintained during the whole colonoscopy withdrawal. When encountering suspicious neoplasm, the colonoscopist can use any image-enhancing technique (such as NBI or indigo carmine dye) to assist the diagnosis and use standard resection procedure (such as polypectomy) to complete lesion resection if necessary. The procedure time, withdrawal time, adenoma detection rate will be recorded during the colonoscopy. The pathology specimen will be sent for histology examination and any adverse event after colonoscopy (such as bleeding or perforation) will be recorded after routine surveillance."
62818368|NCT05153746|ACTIVE_COMPARATOR|Conventional colonoscopy|"Colonoscopy insertion under regular method. After reaching cecum, the subjects will be randomized into 3D or conventional colonoscopy.~Subjects in conventional colonoscopy arm:~Colonoscopist will use regular colonoscopy imaging form during the whole colonoscopy withdrawal. When encountering suspicious neoplasm, the colonoscopist can use any image-enhancing technique (such as NBI or indigo carmine dye) to assist the diagnosis and use standard resection procedure (such as polypectomy) to complete lesion resection if necessary. The procedure time, withdrawal time, adenoma detection rate will be recorded during the colonoscopy. The pathology specimen will be sent for histology examination and any adverse event after colonoscopy (such as bleeding or perforation) will be recorded after routine surveillance."
62432330|NCT04312919|EXPERIMENTAL|Intervention Group|3 in-person visit group
62038924|NCT05363566|ACTIVE_COMPARATOR|group II|will be inserted Single use supraglottic airway ( I-gel® ) (Intersurgical Ltd, Wokingham, Berkshire, UK)
62241889|NCT03920150|ACTIVE_COMPARATOR|IMP|Vitamin D oily capsules containing 24'000 IU vitamin D for 3 months
62241890|NCT03920150|ACTIVE_COMPARATOR|IMP + loading dose|Vitamin D oily capsules containing 24'000 IU vitamin D for an individual number of weeks calculated with the formula: 40 x (100 - actual value \[nmol/l\] x body weight \[kg\] / 24'000 IU.
62241891|NCT06707636|EXPERIMENTAL|Black Women's Stress and Wellness (B-SWELL) arm|The B-SWELL arm consists of 8-weekly sessions. Sessions last 90 minutes and focus on stress reduction, heart disease, and healthy lifestyle changes. The American Heart Association's Life's Essential 8 metrics are leveraged and culturally tailored in the B-SWELL materials. Participants will also receive personalized health coaching.
62432331|NCT04312919|ACTIVE_COMPARATOR|Control/Crossover Group|5 in-person visit group
62432332|NCT00428194|EXPERIMENTAL|Cohort 1|Erlotinib 100 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m\^2 intravenous every 7 days during RT) and continuing daily through radiation
62432333|NCT00428194|EXPERIMENTAL|Cohort 2|Erlotinib 125 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m\^2 intravenous every 7 days during RT) and continuing daily through radiation
62432334|NCT00428194|ACTIVE_COMPARATOR|Cohort 3|Erlotinib 150 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m\^2 intravenous every 7 days during RT) and continuing daily through radiation
62432335|NCT05131997|EXPERIMENTAL|AD-221|AD-221, Placebo of AD-221A, AD-221B and AD-221C
62038925|NCT05363566|ACTIVE_COMPARATOR|group III (SP Air-Q) (n = 26)|will be inserted Single use supraglottic airway (self-pressurized Air-Q intubating laryngeal airway (Air-Q SP®)) (Mercury Medical, Clearwater, FL, USA)
62599252|NCT06620354|EXPERIMENTAL|Drug group|Patients assessed as having no indication for surgical resection were treated with smetinib bisulfate capsules. Based on individual patient body surface area (BSA), Smetinib bisulfate capsules (20-50mg bid) were taken orally daily for 30 days for 6 cycles to evaluate tumor reduction efficacy, ORR, and resection range.
62818369|NCT04983017|ACTIVE_COMPARATOR|Dietary supplements|Dietary supplements are either (1) designated as Generally Recognized As Safe (GRAS) by the Food and Drug Administration or (2) compounds at similar concentrations to those found in foods.
62818370|NCT04983017|PLACEBO_COMPARATOR|Placebo|Placebo-matched formulations
62818371|NCT05890664|EXPERIMENTAL|Experimental Group|Study participants in the active study arm will receive a daily oral dose of 0.5 mg Colchicine for 3 months without a loading dose. The dose is recommended to be taken in the morning. There is no deviation from the usual treatment intake.
62818372|NCT05890664|PLACEBO_COMPARATOR|Control Group|Study participants in the placebo group will receive a matched placebo.
62818373|NCT03359538|PLACEBO_COMPARATOR|placebo|Patients assigned to this arm will take Riluzole as usual + placebo tablets
62818374|NCT03359538|ACTIVE_COMPARATOR|Rapamycin 1 mg/m2|Patients assigned to this arm will take Riluzole as usual + tablets corresponding to a Rapamycin dose of 1 mg/m2/day
62241892|NCT06707636|ACTIVE_COMPARATOR|Wellness (WE) arm|This is an attention control group. Participants placed in his arm will receive 8-weekly sessions focused on the Life's Essential 8 metrics. Sessions will last approximately 90 minutes.
62599253|NCT04412200|EXPERIMENTAL|Hyperbaric oxygen chamber Arm|Patients will be randomized at a ratio of 2:1, to hyperbaric chamber (100% oxygen at 2 ATA)
62818375|NCT03359538|ACTIVE_COMPARATOR|Rapamycin 2 mg/m2|Patients assigned to this arm will take Riluzole as usual + tablets corresponding to a Rapamycin dose of 2 mg/m2/day
62599254|NCT04412200|NO_INTERVENTION|Control arm|control group will receive common practice management.
62241893|NCT06735287|EXPERIMENTAL|bladder sparing set|
62241894|NCT06735287|ACTIVE_COMPARATOR|radical cystectomy set|
62432336|NCT05131997|EXPERIMENTAL|AD-221A|AD-221A, Placebo of AD-221, AD-221B and AD-221C
62818376|NCT06444568|NO_INTERVENTION|Passive control group|The passive control arm will not receive any intervention and will only be evaluated for primary outcome variables at the beginning (week: 0) and at the end (week: 12) of the protocol.
62818377|NCT06444568|ACTIVE_COMPARATOR|Active control group|MIND diet will be applied to participants assigned to the active control arm for 12 weeks. This group will be evaluated at visits (week: 0-4-8-12) in terms of primary and secondary outcome variables, in parallel with the intervention group (KD).
62038926|NCT00725673||1|GOLD II COPD patients with osteoporosis
62038927|NCT00725673||2|GOLD II COPD patients with a normal bone mineral density
62241895|NCT02628314||Osteoarthritis|Study population to include adult men and women with osteoarthritis.
62432337|NCT05131997|ACTIVE_COMPARATOR|AD-221B|AD-221B, Placebo of AD-221, AD-221A and AD-221C
62432338|NCT05131997|ACTIVE_COMPARATOR|AD-221C|AD-221C, Placebo of AD-221, AD-221A and AD-221B
62241896|NCT04626583|ACTIVE_COMPARATOR|Low dose of allogeneic MSC|Escalating doses of allogeneic MSC subconjunctival injection will be assigned 1,000,000 cells/50 µL at the low dose level.
62241897|NCT04626583|ACTIVE_COMPARATOR|Medium dose of allogeneic MSC|Escalating doses of allogeneic MSC subconjunctival injection will be assigned 3,000,000 cells/150 µL at the medium dose level.
62599255|NCT00765895|ACTIVE_COMPARATOR|Nortriptyline|Nortriptyline Hydrochloride dose escalation from 10 mg to 75 mg
62432339|NCT01234090||Persons with Aphasia|
62599256|NCT00765895|PLACEBO_COMPARATOR|Placebo (for nortriptyline)|No treatment
62241898|NCT04626583|ACTIVE_COMPARATOR|High dose of allogeneic MSC|Escalating doses of allogeneic MSC subconjunctival injection will be assigned 6,000,000 cells total consisting of injection at 2 sites of 3,000,000 cells/150 µL each at the high dose level.
62241899|NCT02950402|EXPERIMENTAL|Two Dried Plums per day|Two Dried Plums per day is approximately 14 g.
62241900|NCT02950402|EXPERIMENTAL|Six Dried Plums per day|Six Dried Plums per day is approximately 42 g.
62241901|NCT04341896||Caregivers|Prior obese living kidney donors who served as the primary caregiver for their recipient
62241902|NCT04341896||Non-caregivers|Prior obese living kidney donors who were not the primary caregiver for their recipient
62241903|NCT02500381|EXPERIMENTAL|SRP-4045|Participants amenable to exon 45 skipping will receive SRP-4045 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
62432340|NCT06537986|EXPERIMENTAL|Intervention Group|Standard therapy with intervention module (Module comprised of Cognitive retraining exercise and cognitive behavioral therapy- pen and paper based) Duration - 8 weeks Frequency - once in a week for 2 hours. In person delivery of intervention in a group of 5 patients.
62432341|NCT06537986|NO_INTERVENTION|Control Group|Standard therapy without intervention module
62432342|NCT04688983|ACTIVE_COMPARATOR|Arm 1|Ponatinib plus standard induction and consolidation
62432343|NCT04688983|ACTIVE_COMPARATOR|Arm 2|Imatinib plus standard induction and consolidation (comparator arm)
62432344|NCT04688983|EXPERIMENTAL|Arm 3|Ponatinib plus Blinatumomab
62432345|NCT03185247|EXPERIMENTAL|Group Intervention|10-week parent-child multi-family group
62432346|NCT01450579|PLACEBO_COMPARATOR|Placebo|Saline
62432347|NCT01450579|EXPERIMENTAL|Dose -1|ASP7373
62432348|NCT01450579|EXPERIMENTAL|Dose -2|ASP7373
62432349|NCT01450579|EXPERIMENTAL|Dose -3|ASP7373
62599257|NCT06215924|ACTIVE_COMPARATOR|'Reverse Kegel' exercise group|In addition to the training given by the physician, patients will be taught the 'Reverse Kegel' exercise. The 'Reverse Kegel' exercise is an exercise that is used to relax the pelvic floor muscles. To practice the exercise, patients will be asked to lie in a supine position with a support under the knees. In this position, patients will be asked to relax the pelvic floor muscles while breathing through their nose, maintain this movement for 5 seconds, and tighten the pelvic floor muscles while exhaling. Patients will be advised to do this exercise for 5 sets, 10 repetitions during the day. On the day of the training, initial evaluations will be made to the patients before the exercise training is given. Evaluations will be repeated at the end of the second and fourth week.
62818378|NCT06444568|EXPERIMENTAL|Intervention group (Modified ketogenic diet)|The modified ketogenic diet (MKD) will be applied to participants assigned to the intervention arm for 12 weeks. This group will be evaluated for primary and secondary outcome variables at visits (weeks 0-4-8-12).
62038928|NCT04321538||Failed Vision Screen Cohort|This cohort represents the entire group of study participants- children who were referred to Yale New Haven Hospital and Yale Medicine for a failed vision screen by either their primary care provider or their school.
62241904|NCT02500381|EXPERIMENTAL|SRP-4053|Participants amenable to exon 53 skipping will receive SRP-4053 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
62241905|NCT02500381|PLACEBO_COMPARATOR|Placebo followed by SRP-4045 or SRP-4053|Participants amenable to exon 45 or 53 skipping will receive SRP-4045 or SRP-4053 placebo-matching IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 or SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
62241906|NCT04244487|EXPERIMENTAL|intraoperative endoscopic variceal ligation group|intraoperative endoscopic variceal ligation group Every patient of vagus nerve-preserving group will receive the synchronous vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation procedure
62818379|NCT05797246|EXPERIMENTAL|Arm 1|Bevacizumab treatment course
62818380|NCT02250846|EXPERIMENTAL|arm a|EGFR exon 19 mutation with EGFR-TKI
62818381|NCT02250846|EXPERIMENTAL|arm b|EGFR exon 21 mutation with EGFR-TKI
62241907|NCT04244487|NO_INTERVENTION|Non-intraoperative endoscopic variceal ligation group|Every patient of conventional group will receive single vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection without intraoperative endoscopic variceal ligation procedure
62241908|NCT06735989|EXPERIMENTAL|Moral|The Moral group will read a short text explaining the meaning and function of moral justification, and outlining brief descriptions of six morally relevant factors. The Moral group will then attend a 1h30 lecture on moral reasoning.
62241909|NCT06735989|ACTIVE_COMPARATOR|Non-moral|The Non-moral will read a short text explaining the meaning and function of argumentation, and outlining brief descriptions of six logical and argumentative principles. The Non-moral group will then attend a 1h30 lecture on (non-moral) logical reasoning.
62241910|NCT04628468|EXPERIMENTAL|Possibility to use the mobile application without a predefined number of physiotherapy sessions|Rehabilitation after hip or knee arthroplasty with the option to use a mobile application and no predefined traditional physiotherapy.
62241911|NCT04628468|EXPERIMENTAL|Possibility to use the mobile application with a predefined number of physiotherapy sessions|Rehabilitation after hip or knee arthroplasty with the option to use a mobile application and a predefined number of traditional physiotherapy sessions
62241912|NCT04628468|NO_INTERVENTION|Usual care|Rehabilitation after hip or knee arthroplasty without the use of a mobile application.
62241913|NCT01958190|ACTIVE_COMPARATOR|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
62241914|NCT01958190|EXPERIMENTAL|combination Tacrolimus and Sirolimus|Patients receive combination of low-dose extended release Tacrolimus and low-dose Sirolimus
62241915|NCT05320250||Parkinson's disease|"60 patients. People with Parkinson's disease (pwPD) will be recruited for the study at Fondazione Don Gnocchi.~PwPD will be assigned to a rehabilitation program that will last for 6 consecutive weeks. Two possible rehabilitation plans are included:~1. Rehabilitation treatment at the IRCCS S. Maria Nascente: 30 sessions / 5 days a week including motor rehabilitation, cognitive rehabilitation and speech therapy rehabilitation.~2. Self-treatment program consisting of stretching and active mobilization exercises at home. Before starting the program, the subjects will undergo an educational and training session with the physiotherapist to learn the correct way of carrying out the proposed exercises."
62241916|NCT05320250||Atypical Parkinsonism|Progressive supranuclear palsy: 20 patients; Corticobasal syndrome: 20 patients; Multisystemic atrophy: 20 patients.
62241917|NCT05320250||REM sleep Behavior Disorder|30 patients
62241918|NCT05320250||Healthy controls|30 patients
62241919|NCT01829425|ACTIVE_COMPARATOR|Anticholinergic medications|Either of two standard, long acting anti-cholinergic medications (Long acting Tolterodine or Extended Release Oxybutynin)will be given. Subjects receive 8 weeks of medication counseling in conjunction with the medications. Medications will be continued for 1 year.
62241920|NCT01829425|ACTIVE_COMPARATOR|Hypnotherapy|Subjects will receive approximately weekly hypnotherapy sessions over 8 weeks and will receive/download digital recordings for home practice. Subjects will be encouraged to practice self-hypnosis +/or listen to their recordings for 1 year.
62241921|NCT05553704|NO_INTERVENTION|Control Group|this group will take mesalamine 1 gm three times daily for 6 months
62241922|NCT05553704|ACTIVE_COMPARATOR|metformin group|this group will take mesalamine 1 gm three times daily plus metformin 500 mg two times daily for 6 months
62241923|NCT05555251|EXPERIMENTAL|Phase I -Dose escalation|Dose escalation study of BI-1607 combined with trastuzumab in HER2+ advanced or metastatic solid tumors.
62432350|NCT00763984|ACTIVE_COMPARATOR|1 Usual Care|This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT
62818382|NCT01402752|EXPERIMENTAL|All patients|All patients included in this study according to stated inclusion and exclusion criteria.
62818383|NCT03737695||Observational (biospecimen, clinical info collection)|Patients' archival and newly collected tissue and blood samples are collected periodically for genetic testing. Patients also undergo collection of clinical information within 30 days of biopsy procedure and every 4 months.
62038929|NCT05318794|EXPERIMENTAL|Neoadjuvant systemic and peritoneal chemotherapy|Standard neoadjuvant systemic and pressurised intraperitoneal aerosol chemotherapy
62038930|NCT03863340|EXPERIMENTAL|short interruptions of work tasks|randomly start with or without short interruptions on the first experimental day and without or with them on the second experimental day
62599258|NCT06215924|EXPERIMENTAL|'Postisometric Relaxation Technique' group|In addition to training given by the physican, internal digital Postisometric Relaxation method will be applied to the patients in this group from the anal region. Application will be made to the muscles where muscle spasm, movement restriction and pain are detected. The patient will be asked to perform a contraction against the digital resistance with maximum force and maintain this contraction for 5 seconds, actively relax after 5 seconds. During relaxation, stretching will be applied for 30 seconds by digitally supporting the movement of the pelvic floor muscles. The process will be performed with 5 repetitions. The application will be made 2 days a week for 4 weeks. On the day of the training, initial evaluations will be made to the patients before the exercise training is given.Evaluations will be repeated at the end of the second and fourth week.
62241924|NCT05555251|EXPERIMENTAL|Phase 2a - Expansion cohorts|Dose expansion study of BI-1607 combined with trastuzumab in cohort 1: HER2 positive locally advanced or metastatic HER2+ breast cancer and cohort 2: metastatic gastric or gastroesophageal junction adenocarcinoma
62432351|NCT00763984|EXPERIMENTAL|2 Bladder Health Class|Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
62599259|NCT06031935|EXPERIMENTAL|Yoga study group|This is the only arm of the study. The patients will be given yoga videos to do at home for 8 weeks as a treatment for anterior knee pain.
62599260|NCT03193801|EXPERIMENTAL|Failing mitral transcatheter valve|Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve.
62599261|NCT00705718|EXPERIMENTAL|Endurant Bifurcated arm|The Bifurcated arm includes subjects who have received a bifurcated device. The Endurant Stent Graft System Bifurcated device is administered to treat patients with an Abdominal Aortic Aneurysm.
62599262|NCT00705718|EXPERIMENTAL|Endurant AUI arm|The AUI arm includes subjects who have received an AUI device. The Endurant Stent Graft System AUI device is administered to treat patients with an Abdominal Aortic Aneurysm.
62432352|NCT04821050|EXPERIMENTAL|Treatment|Sacral nerve stimulation
62432353|NCT04821050|SHAM_COMPARATOR|Control|Sham stimulation
62432354|NCT04292171|ACTIVE_COMPARATOR|Gabapentin Arm|Gabapentin 600 mg given 1-2 hours prior to surgical abortion
62432355|NCT04292171|PLACEBO_COMPARATOR|Placebo Arm|Placebo (vit C) given 1-2 hours prior to surgical abortion
62432356|NCT03549663|EXPERIMENTAL|Tacrolimus monotherapy|
62432357|NCT03549663|ACTIVE_COMPARATOR|Tacrolimus combined with hormone therapy|
62432358|NCT06097611|EXPERIMENTAL|Efficacy of early Tranexamic Acid in Pediatric Polytraumatized Patients|
62432359|NCT06097611|ACTIVE_COMPARATOR|Efficacy of Early Tranexamic Acid in Pediatric Polytraumatized Patients|
62432360|NCT02414854|PLACEBO_COMPARATOR|Placebo (for Dupilumab 200 mg) q2w|2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection every 2 weeks (q2w) from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
62432361|NCT02414854|EXPERIMENTAL|Dupilumab 200 mg q2w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
62432362|NCT02414854|PLACEBO_COMPARATOR|Placebo (for Dupilumab 300 mg) q2w|2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
62599263|NCT03839290||Bilateral cleft lip and palate patients|Newborns with complete bilateral cleft lip and palate (cBCLP) and bilateral cleft lip and palate with tissue bridges (BCLP + B) analyzed one year after neonatal cheiloplasty
62599264|NCT03839290||Unilateral cleft lip and palate patients|Newborns with complete unilateral cleft lip and palate (cUCLP) and unilateral cleft lip and palate with tissue bridges (UCLP + B) analyzed one year after neonatal cheiloplasty
62599265|NCT04283682|NO_INTERVENTION|standard group|Feeding procedures follow clinical nursing practices
62038931|NCT06516289|EXPERIMENTAL|Safety run-in|HRS-1167 + famitinib
62241925|NCT01852604|EXPERIMENTAL|Part A: GT 1b, 4 - samatasvir 50/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 50 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
62241926|NCT01852604|EXPERIMENTAL|Part A: GT 1b, 4 - samatasvir 100/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 100 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
62241927|NCT01852604|EXPERIMENTAL|Part A: GT 1b, 4 - samatasvir 150/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 150 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
62241928|NCT01852604|EXPERIMENTAL|Part B: GT 1b, 4 - samatasvir 25/simeprevir/RBV|Part B: Participants with genotype 1b or 4 received samatasvir 25 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
62241929|NCT01852604|EXPERIMENTAL|Part B: GT 1b, 4 - samatasvir 100/simeprevir/RBV|Part B: Participants with genotype 1b or 4 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
62599266|NCT04283682|EXPERIMENTAL|intervention group|At appropriate time to invite mothers of premature infants into the NICU for skin-to-skin and breastfeeding
62241930|NCT01852604|EXPERIMENTAL|Part B: GT 6 - samatasvir 100/simeprevir/RBV|Part B: Participants with Genotype 6 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
62599267|NCT01764789|EXPERIMENTAL|Supportive care (psychosocial intervention)|Patients participate in a multi-component intervention based on cognitive and behavioral principles comprising MBSR, an intervention to promote hopefulness, and a problem solving approach which navigates around obstacles or generates alternatives when goals become blocked. Additional topics may be covered as indicated by clinical need and patients goals. Biobehavioral components include addressing social and disease-specific quality of life, and pain education. Intensive treatment sessions continue weekly for 16 weeks followed by 2 biweekly and 2 monthly maintenance sessions.
62241931|NCT01852604|EXPERIMENTAL|Part C: GT 1a, 1b - samatasvir 50/simeprevir/TCM647055/RTV|Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily plus RTV 30 mg once daily for 12 weeks
62432363|NCT02414854|EXPERIMENTAL|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines . Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
62432364|NCT05465330|EXPERIMENTAL|Desflurane Inhalational group (DR group)|
62432365|NCT05465330|ACTIVE_COMPARATOR|Desflurane propofol balanced anesthesia group (DPR group)|
62432366|NCT05528289|ACTIVE_COMPARATOR|HFNC 40 L/min with conventional symmetric nasal cannula|The patients will be asked to breathe with HFNC at flow of 40 L/min with standard interface
62432367|NCT05528289|ACTIVE_COMPARATOR|HFNC 40 L/min with new asymmetric nasal cannula|The patients will be asked to breathe with HFNC at flow of 40 L/min with the new asymmetric nasal cannula
62432368|NCT04431531|ACTIVE_COMPARATOR|yogatherapy-EMDR|one of the two groups will have yogatherapy treatment and Eye movement desensibilization reprocessing (EMDR)
62432369|NCT04431531|ACTIVE_COMPARATOR|waiting list and EMDR|The other group will have Eye movement desensibilization reprocessing
62432370|NCT01697995||Lexiscan-Echo echo subjects|No Intervention: Observational study
62432371|NCT01697995||Lexiscan-Echo control subjects|No intervention: observational study
62241932|NCT01852604|EXPERIMENTAL|Part C: GT 1a, 1b - samatasvir 50/simeprivir/TCM647055/RTV/RBV|Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily, plus RTV 30 mg once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
62241933|NCT03356171|EXPERIMENTAL|Cardiac Coherence|Patients participate to Adapted physical activity sessions and to cardiac coherence sessions
62432372|NCT04364724||Study group|"All patients referred to the Hematology clinic for diagnosis and treatment of active multiple myeloma will be asked to participate in the study and undergo 3 consecutive low-dose CT scans over a period of 12 months. For non-consenting patients only minimal demographic data will be documented.~Eligible consenting patients will sign informed consent."
62432373|NCT05649982|EXPERIMENTAL|Digital Tool for Problematic Alcohol Use|This is the base version of the intervention with no added guidance.
62432374|NCT05649982|EXPERIMENTAL|Digital Tool for Problematic Alcohol Use + Extra Telephone Interview|This is the same intervention as the base version, with an added mid-treatment telephone interview.
62432375|NCT05649982|EXPERIMENTAL|Digital Tool for Problematic Alcohol Use + Written Guidance|This is the same intervention as the base version, with added weekly written guidance.
62432376|NCT05649982|EXPERIMENTAL|Digital Tool for Problematic Alcohol Use + Extra Telephone Interview and Written Guidance|This is the same intervention as the base version, with added weekly written guidance and an added mid-treatment telephone interview.
62432377|NCT05779111||Scores greater than or equal to 3 in patients with locally advanced cervical cancer|Scores greater than or equal to 3 in patients with locally advanced cervical cancer
62432378|NCT05779111||Patients with locally advanced cervical cancer scored less than 3 points|Patients receiving radiotherapy for locally advanced cervical cancer were scored according to five factors, with a score of less than 3
62432379|NCT00206622|ACTIVE_COMPARATOR|Arm 1|
62432380|NCT00206622|ACTIVE_COMPARATOR|Arm 2|
62432381|NCT00206622|PLACEBO_COMPARATOR|Arm 3|
62432382|NCT04998253|EXPERIMENTAL|Group 1: Sevofruorane (Svofast)|"Experimental group: will receive sedation with sevoflurane with an infusion rate to maintain MAC of 0.7 and fentanyl 1mcg /kg/hour.~Inhalation sedation The AnaConda device (Sedana Medical, Ireland) is placed between the endotracheal tube and the ventilator circuit. The anesthetic infusion line is attached to a syringe, from where the anesthetic (sevoflurane) will be delivered to said device. The sample line will be taken to the anesthetic gas analyzer whit the Carescape B450 multiparametric monitors (General Electric, Finland) for MAC control. The anesthetic gas outlet port will be attached to the absorbent material container."
62432383|NCT04998253|ACTIVE_COMPARATOR|Group 2: Propofol (Diprivant)|"Control group: will receive sedation with Propofol (Diprivant) at doses of 20-50mcg/kg/min and fentanyl (Fentanest) at doses of 1 to 2mcg/kg /hour.~For both groups, the doses will be titrated to maintain a RASS score between -3 to -4 in both groups.~Both groups will receive cisatracurium (Nimbex) as a continuous infusion of 3 to 5mcg / kg/min for 48 hours. We will maintain sedation for both groups with the same scheme for 48 hours, after which the drugs used for sedation will be modified at the discretion of the intensive care physicians."
62432384|NCT02276976||cerebral white matter lesions|patients with MRI confirmed cerebral white matter lesions
62432385|NCT02276976||healthy volunteers|healthy volunteers 1:1 matched by age,sex and education years
62432386|NCT02413697|ACTIVE_COMPARATOR|Two-dimensional ultrasound|Two-dimensional ultrasound guided embryo transfer
62432387|NCT02413697|EXPERIMENTAL|Three-dimensional ultrasound|Three-dimensional ultrasound guided embryo transfer
62432388|NCT06237140|EXPERIMENTAL|PNF exercise group|proprioceptive neuromuscular facilitation (PNF) techniques will be applied to the cervical region. In the study, flexion-lateral flexion and rotation patterns will be studied together with antagonist patterns. In the antagonist movement involving cervical extension, the hand above the head is displaced diagonally and positioned to resist extension, lateral flexion and rotation. Before the exercise, the patient will be informed about the diagonal direction of the movement and made to feel it, and then the exercises will be performed in 5 sets, each set containing 10 repetitions. Participants will be given sufficient time to rest between sets.
62432389|NCT06237140|ACTIVE_COMPARATOR|biofeedback exercise group|cervical stabilization exercises will be used to stimulate cervical proprioceptors. Neck stabilization training will be applied with a low load to strengthen the longus capitis and longus colli, the deep muscles of the upper cervical vertebra. The oblique and costal muscles, which are the auxiliary respiratory muscles, will be relaxed and the neck will be flexed. A pressure biofeedback device will be placed on the upper cervical spine (below the occiput) while lying with the air pocket set at 20 mmHg to obtain visual feedback from the dial. The pressure will be gradually increased to 30 mmHg in 2 mmHg increments. While the patient was asked to retract his chin, the contraction duration was determined as 10 seconds. While the contractions are repeated 10 times, a 3-5 second rest period will be given between each contraction.
62599268|NCT00029536|EXPERIMENTAL|Catamenial Epilepsy: Progesterone Lozenges|Subjects with catamenial epilepsy received 200 mg progesterone lozenges
62599269|NCT00029536|PLACEBO_COMPARATOR|Catamenial Epilepsy: Placebo Lozenges|Subjects with catamenial epilepsy received matched placebo lozenges
62038932|NCT06516289|EXPERIMENTAL|Phase 2: Cohort A (HR+/HER2-, gBRCAm)|HRS-1167 + famitinib, RP2D
62038933|NCT06516289|EXPERIMENTAL|Phase 2: Cohort B (HR-/HER2-, gBRCAm)|HRS-1167 + famitinib, RP2D
62038934|NCT06516289|EXPERIMENTAL|Phase 2: Cohort C (HR+/HER2-, gBRCAm expansion cohort)|HRS-1167 + famitinib, (RP2D) + camrelizumab
62241934|NCT03356171|ACTIVE_COMPARATOR|Adapted Physical Activity|Patients only participate to Adapted physical activity sessions
62241935|NCT02705209|ACTIVE_COMPARATOR|Treatment|
62241936|NCT02705209|PLACEBO_COMPARATOR|Control|
62241937|NCT03417518|ACTIVE_COMPARATOR|Desflurane Inhalant Product Group|general anesthesia with desflurane
62241938|NCT03417518|EXPERIMENTAL|Propofol Group|general anesthesia with propofol
62241939|NCT06736145|ACTIVE_COMPARATOR|Traditional Physical Therapy|Cervical stretches and inspiratory muscle training
62241940|NCT06736145|EXPERIMENTAL|Mulligan Glides|Mulligan Natural Apophyseal Glides along with cervical stretches and inspiratory muscle training
62241941|NCT05604131|ACTIVE_COMPARATOR|Hemorrhagic Myocardial Infarction - Deferiprone|Enrolled patients with CMR confirmed presence of intramyocardial hemorrhage
62241942|NCT05604131|ACTIVE_COMPARATOR|Non-hemorrhagic Myocardial Infarction - Deferiprone|Enrolled patients with CMR confirmed absence of intramyocardial hemorrhage
62241943|NCT05604131|PLACEBO_COMPARATOR|Hemorrhagic Myocardial Infarction - Placebo|Enrolled patients with CMR confirmed presence of intramyocardial hemorrhage
62241944|NCT05604131|PLACEBO_COMPARATOR|Non-hemorrhagic Myocardial Infarction - Placebo|Enrolled patients with CMR confirmed absence of intramyocardial hemorrhage
62241945|NCT05555667|EXPERIMENTAL|Remimazolam besylate|Remimazolam besylate at an initial infusion rate of 0.15 mg/kg/h and adjusted (maximum of 0.3 mg/kg/h) to maintain a RASS score between - 3 and 0
62241946|NCT05555667|ACTIVE_COMPARATOR|Propofol|Propofol intravenously at an initial infusion rate of 2.0 mg/kg/h and adjusted (maximum of 4.0 mg/kg/h) to maintain a RASS score between - 3 and 0
62241947|NCT04243603|EXPERIMENTAL|Internet-based ERITA-DK|ERITA is a youth-adapted version of Emotion Regulation Group Therapy (ERGT), based on cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), and Acceptance and Commitment Therapy (ACT), which encounters emotional recognition and regulation, crisis strategies and skills training. The ERITA intervention is provided as add-on to TAU and consists of 12 weeks, manualized, therapist guided internet-based therapy. The intervention also provides six modules for the parents focusing on NSSI and other risk-taking behaviors, emotional awareness, and validation skills. The participants must complete one module every week while the parents must complete a module every second week. A mobile app is available to complement the online treatment. The app includes reminders of homework and skills and allows to report on both self-destructive behaviors and impulses daily.
62241948|NCT04243603|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Child and Adolescent Mental Health Services (CAMHS) offer specialized treatment for children and adolescents. TAU encounters a variety of clinical treatment and assessment offers, representing a highly inhomogeneous group of treatments, for instance: Pharmacological treatment, Family-Based Treatment (FBT), Cognitive Behavioral Therapy, supportive counselling and psychoeducation. Throughout the trial course the treatment responsibility is handled by clinicians providing TAU.
62241949|NCT02079012|EXPERIMENTAL|Intervention group|"Receives:~* An information session~* A 10-week walking program (with documents, pedometer and three information sessions about motivation, a healthy diet and smoking cessation)~* A physical activity diary (which also functions as a tool to check protocol-compliance)~* Measurements"
62241950|NCT02079012|NO_INTERVENTION|Control group|Only receives measurements.
62241951|NCT05467683|OTHER|Open Exposure-Based Therapy (EBT)|All participants will receive a well-established psychological treatment.
62241952|NCT02774551|EXPERIMENTAL|Physical activity intervention group|The physical activity program includes 150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week are demonstrated by the research nurse. The resistance training is progressive by increasing resistance in the band based on patient's adaptability during the intervention.
62241953|NCT02774551|NO_INTERVENTION|Standard care control group|Patients follow their routine daily physical activity.
62241954|NCT03079232|EXPERIMENTAL|OCTAV Patient|The patients who will have a biopsy of skin suspected to be a melanoma, basal cell carcinoma or squamous cell carcinoma will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
62241955|NCT03079232|EXPERIMENTAL|OCTAV Control group|Control group (patients without skin cancer) will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
62241956|NCT02215837|SHAM_COMPARATOR|Chemotherapy|After accepting chemotherapy according to NCCN guidelines, patients will just regularly follow up.
62432390|NCT03716505|ACTIVE_COMPARATOR|gammaCore Sapphire active|"Treatment 3 times per day, every day for the 12-week treatment period~Each of the 3 daily treatments comprises 2 consecutive 120-second stimulations on 1 side, ipsilateral (2 stimulations) to the side of predominate pain, upon waking, lunch time (i.e., between 11:00 AM and 2:00 PM), and prior to sleep, for a total of 6 stimulations per day"
62818384|NCT01004952||screening questionnaire|This study will involve two phases. Guided by EDTM, we will first build models of decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing)using in-home ethnographic interviews with 25 melanoma FDRs (Phase I). In Phase II, we will test the validity of each composite model. This will be completed using EMA data collection with 60 different melanoma FDRs from Phase I who will report on their sunscreen use, shade-seeking, use of hat, and use of UVR protective clothing and decision-making regarding these outcomes via interactive voice response (IVR) system and audio narrative diaries (using a digital voice recorder). We will examine the validity of each model and examine the influence of theory-driven affective and cognitive predictors of UVR protection maintenance across time.
62818385|NCT05278962|ACTIVE_COMPARATOR|SGLT2i|Participants will be asked to take an SGLT2i for 6 months. The SGLT2i and heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
62818386|NCT05278962|ACTIVE_COMPARATOR|No SGLT2i|Participants will not be asked to take an SGLT2i. Heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
62818387|NCT05506683|EXPERIMENTAL|MotoMeds users (parent/chid participant pairs)|
62818388|NCT05655351|EXPERIMENTAL|Patients vaccinated with the anti-SARS-Cov-2 vaccination|These patients will receive the anti-SARS-Cov-2 vaccination and their blood will be regularly monitored.
62818389|NCT04049032||In-Person Participants|This group received perinatal OUD treatment in-person.
62818390|NCT04049032||Telemedicine Participants|This group received perinatal OUD treatment via telemedicine.
62818391|NCT06223867|ACTIVE_COMPARATOR|Enhanced treatment as usual (ETAU) alone|Subjects in this arm will receive the usual care for patients with suicidal risk at UMass Memorial ED that may include a behavioral health evaluation by a trained clinician, and environmental safety precautions dictated by risk level (Mild, Moderate, High). Individuals deemed appropriate for discharge undergo discharge planning and offered a personalized safety plan using the Stanley-Brown Safety Planning Intervention, including lethal means safety counseling.
62432391|NCT03716505|SHAM_COMPARATOR|gammaCore Sapphire Sham|"Treatment 3 times per day, every day for the 12-week treatment period~Each of the 3 daily treatments comprises 2 consecutive 120-second stimulations on 1 side, ipsilateral (2 stimulations) to the side of predominate pain, upon waking, lunch time (i.e., between 11:00 AM and 2:00 PM), and prior to sleep, for a total of 6 stimulations per day"
62432392|NCT03456362|ACTIVE_COMPARATOR|Cerebellar iTBS|Intermittent theta burst stimulation applied immediately before the daily physical therapy session for a period of three weeks.
62432393|NCT03456362|SHAM_COMPARATOR|Sham iTBS|Sham intermittent theta burst stimulation applied immediately before the daily physical therapy session for a period of three weeks.
62432394|NCT03167814|ACTIVE_COMPARATOR|Diet group|Diet group will be on no-fat diet including MCT-oil supplement starting right after surgery according to our pancreas ERAS-protocol.
62432395|NCT03167814|NO_INTERVENTION|Normal food-group|This study group will follow normal ERAS-protocol after pancreas surgery and start normal diet after surgery. If chyle-leak is diagnosed then it will be treated with the same no-fat diet as the intervention group.
62599270|NCT00029536|EXPERIMENTAL|Noncatamenial Epilespy:Progesterone Lozenges|Subjects without catamenial epilepsy received 200 mg progesterone lozenges
62599271|NCT00029536|PLACEBO_COMPARATOR|Noncatamenial Epilespy: Placebo Lozenges|Subjects without catamenial epilepsy received matched placebo lozenges
62818392|NCT06223867|EXPERIMENTAL|Jaspr intervention with enhanced treatment as usual (ETAU)|"Subjects in this arm will receive ETAU in addition, they will complete a guided Suicide Status Interview (SSI), Safety Planning, and Lethal means counseling on the Jaspr tablet-based app before open access to the Jaspr resource library.~Subjects can sign up to receive JAH mobile app."
62818393|NCT06529536|EXPERIMENTAL|Prospective Cohort: Pre-emptive CYP3A5 genotype combined with a Bayesian dose prediction|Planned SOT recipients where initial tacrolimus dosing will be based on genotype and subsequent doses predicted using Bayesian revised dosing using NextDose. NextDose, a web-based tool is a model-informed precision dosing software tool used to optimise dosage regimens. It uses Bayesian statistics to integrate prior drug information from a population pharmacokinetic (popPK) model, individual characteristics, and drug concentrations to provide the most accurate individual pharmacokinetic (PK) estimates. The popPK model, a mathematical-statistical model developed from real patient data, captures the drug's typical pharmacokinetics, its variability among individuals and over time, and the factors influencing this variability. By leveraging prior knowledge about a drug's PK along with individual patient data and drug concentrations, the software accurately estimates individual PK parameters with minimal drug concentration data. Tacrolimus dose, form, frequency, \& duration will be assessed
62038935|NCT06516289|EXPERIMENTAL|Phase 2: Cohort D (HR-/HER2-, gBRCAm expansion cohort)|HRS-1167 + famitinib, (RP2D) + camrelizumab
62038936|NCT01088932|EXPERIMENTAL|SRX246|SRX246
62599272|NCT05462223|EXPERIMENTAL|Alucent VRS for Treatment of Atherosclerotic Lesions|"Alucent Vessel Restoration System for AVF (VRS-AVF) consists of the following components:~1. VRS 10-8-10 Dimer Coated Balloon Catheter for AVF~2. VRS Light Fiber~3. VRS Light Source"
62599273|NCT06620146|EXPERIMENTAL|intervention group provided with mechanical bathing every other day for a week|Participants in the intervention group will be provided mechanical bathing every other day for a week.
62599274|NCT06620146|NO_INTERVENTION|control group provided with routine care (mechanical bathing once a week)|control group receive routine care (using mechanical bathing once a week)
62818394|NCT03629886|NO_INTERVENTION|Vacc-039 Group|Healthy Chinese female subjects, above 26 years of age at study entry, who previously received HPV vaccine in HPV-039 study (NCT00779766), underwent cervical sample collection and didn't receive any vaccine in the current study.
62818395|NCT03629886|EXPERIMENTAL|Vacc-092 Group|Healthy Chinese female subjects, above 26 years of age at study entry, who previously received placebo (control group) in HPV-039 study (NCT00779766), were intended to receive HPV vaccine in the current study and were to provide cervical samples before HPV vaccination.
62599275|NCT00428051||All eligible patients|
62599276|NCT02737631|EXPERIMENTAL|Healthy subject|"Healthy subjects exposed to Chameleon personal lubricant via occlusive patch"
62818396|NCT03648905||Control patients (iatrogenic CAF)|Patients with iatrogenic chronic autonomic failure (CAF) (e.g., status-post cardiac transplantation, pre/post bilateral thoracic sympathectomies)
62599277|NCT03660475|EXPERIMENTAL|Naltrexone|Naltrexone Ophthalmic Solution 0.002%
62599278|NCT03660475|PLACEBO_COMPARATOR|Placebo|Placebo Ophthalmic Solution
62599279|NCT03652233|EXPERIMENTAL|Afatinib and Nivolumab|
62599280|NCT06515483|EXPERIMENTAL|Arm 1|Brushing and Flossing
62818397|NCT03648905||Control patients (PD No OH)|Patients with Parkinson's disease (PD) without orthostatic hypotension (PD no OH)
62818398|NCT03648905||Healthy Volunteers|Healthy Volunteers, includes people with genetic risk of PD or studied as concurrent controls
62818399|NCT03648905||Patients with neurodegenerative chronic autonomic failure (CAF)|Includes patients with orthostatic hypotension (OH) due to sympathetic neurocirculatory failure (nOH), and people with multiple system atrophy (MSA).
62818400|NCT05516537|EXPERIMENTAL|Guidelines for Exercise in Multiple Sclerosis (GEMS)|Participants in this condition will receive a 4-month home-based, remotely supported aerobic and resistance exercise program based on the Guidelines for Exercise in Multiple Sclerosis (GEMS).
62818401|NCT05516537|SHAM_COMPARATOR|FLEX Stretching and Toning Program|Participants in this condition will receive a 4-month home-based, remotely supported stretching program emphasizing flexibility and range of motion as important components of fitness based on Stretching for People with MS: An Illustrated Manual from the National MS Society.
62818402|NCT03523819|EXPERIMENTAL|CS1002|Participants will receive CS1002 intravenously at specified dose on specified days.
62038937|NCT01088932|PLACEBO_COMPARATOR|Placebo|placebo
62038938|NCT00657345||1|This is a tissue acquisition and collection protocol that will analyze potential cellular changes that occur after treatment with trastuzumab.
62038939|NCT04906395|EXPERIMENTAL|Active Comparator: TOL2506|TOL2506 in combinatination with standard endocrine therapy (Tamoxifen \& Aromatase Inhibitors)
62038940|NCT05648110|EXPERIMENTAL|Parent study Sentinel Safety Cohort - Subcohort 1a Gluteal - AZD5156|The Sentinel Safety Cohort of the Parent Study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
62241957|NCT02215837|EXPERIMENTAL|Ag-D-CIK|After accepting chemotherapy according to NCCN guidelines,patients will receive 3 cycles of autologous tumor lysate pulsed D-CIK treatment.
62241958|NCT00800943|EXPERIMENTAL|Campath-1H|
62599281|NCT06515483|PLACEBO_COMPARATOR|Arm 2|Brushing only
62818403|NCT03523819|EXPERIMENTAL|CS1003|Participants will receive CS1003 intravenously at fixed dose on specified days.
62818404|NCT04514185|EXPERIMENTAL|With exoskeleton|The experimental trial will be performed with exoskeleton.
62818405|NCT04514185|EXPERIMENTAL|Without exoskeleton|The experimental protocol will be performed without exoskeleton.
62818406|NCT06069128|EXPERIMENTAL|Neurotrigger device treatment arm|treatment with Neuro-trigger device for blinking stimulation for a duration of 14 days
62599282|NCT03831334|EXPERIMENTAL|Minoxidil Treatment|Low dose oral minoxidil
62599283|NCT03184337|ACTIVE_COMPARATOR|Active Control|Participants in the active control group will receive 8 group sessions of the CDC's PreventT2 program.
62599284|NCT03184337|EXPERIMENTAL|Experimental|Participants in the experimental group will receive 8 group sessions of the CDC's PreventT2 Program with Added Sleep Content designed to extend and improve sleep.
62599285|NCT01652326||Benzodiazepine-resistant|those patients with either 1) a requirement of either 200 mg of diazepam (or diazepam equivalents) in 4 hrs; 2) \>40mg of diazepam (or diazepam equivalents) in 1 hr; or 3) an individual dose of 40 mg or greater of intravenous diazepam for control of agitation
62599286|NCT01156649|SHAM_COMPARATOR|Sham PAP therapy|Sham PAP will be used with 30 children, and consists of continuous sub-therapeutic levels of air pressure (approximately 1 cm of water) that are delivered through the nasal interface device.
62599287|NCT01156649|ACTIVE_COMPARATOR|Treatment group|30 children will receive active treatment PAP, which consists of automatically adjusted air pressures that are delivered through the nasal interface device at levels which effectively treats the obstructive events.
62599288|NCT01584219||Women after cesarean section|Women after cesarean section
62599289|NCT01584219||pregnancy pathologies|pregnancy pathologies
62599290|NCT01584219||first/second trimester pregnancy|
62599291|NCT01584219||Women after vaginal delivery|Women after vaginal delivery
62818407|NCT05280496|EXPERIMENTAL|Metformin|Participants will be given a daily prescription of metformin for 12 months postpartum. At 12 months and again at 15 months (3 months off the drug), HbA1c and weight will be assessed.
62818408|NCT03567733||Coronary Artery Disease|Drug- eluting Stent
62818409|NCT06597851|EXPERIMENTAL|Non-diabetic patients with ANOCA|"* Thermodilution based assessment of coronary microcirculation with the derivation of CFR and IMR~* Hyperinsulinemic euglycemic clamp for insulin resistance assessment"
62818410|NCT03757091|ACTIVE_COMPARATOR|Arm A (flexible intubation scope)|Patients undergo flexible scope intubation up to 2 attempts following induction of general anesthesia and adequate manual ventilation. In case of failed 2 attempts, patients undergo a third attempt utilizing another technique or device.
62818411|NCT03757091|EXPERIMENTAL|Arm B (flexible intubation scope,video laryngoscope)|Patients undergo flexible scope intubation and video laryngoscopy up to 2 attempts following induction of general anesthesia and adequate manual ventilation. In case of failed 2 attempts, patients undergo a third attempt utilizing another technique or device.
62241959|NCT05813717|EXPERIMENTAL|Cohort J1|
62241960|NCT05813717|EXPERIMENTAL|Cohort J2|
62818412|NCT02749396||IFN-β / Cohort 1|Exposure to IFN-β only
62818413|NCT02749396||IFN-β + other MSDMDs / Cohort 2|Women with MS exposed to IFN-β regardless of exposure to other MSDMDs
62241961|NCT05813717|EXPERIMENTAL|Cohort J3|
62599292|NCT05351827|EXPERIMENTAL|Mild Intermittent Hypoxia|This arm of the protocol will receive mild intermittent hypoxia (8% Oxygen) with end-tidal carbon dioxide maintained 1-3 millimeters of mercury above baseline, while in the laboratory. If diagnosed with sleep apnea, participants will be treated with continuous positive airway pressure for the duration of the intervention.
62818414|NCT02749396||No MSDMDs / Cohort 3|Women with MS exposed with no exposure to any MSDMDs
62818415|NCT02749396||No IFN-β + other MSDMDs / Cohort 4|Women with MS exposed to IFN-β exposure regardless of exposure to other MSDMDs
62818416|NCT02749396||Other MSDMDs / Cohort 5|Women with MS exposed to other MSDMD only excluding IFN-β or glatiramer acetate (Copaxone) or dimethyl fumarate (Tecfidera)
62818417|NCT02749396||Control / Cohort 6|Women from the general population without MS
62818418|NCT00610870|EXPERIMENTAL|1|Atorvastatin group
62818419|NCT00610870|NO_INTERVENTION|2|Control group
62818420|NCT01339832||Cohort|
62818421|NCT05164120|EXPERIMENTAL|Interventional|900mg dose TID Administration Total: 2700mg
62818422|NCT05164120|PLACEBO_COMPARATOR|Placebo|0 mg dose TID Administration Total: 0 mg
62818423|NCT06362421||Treatment naive patients with HPV+ OPSCC|Participants will receive a pre-study visit and pre-radiation dental evaluation.
62818424|NCT06362421||Control Group - Healthy subjects without cancer|Participants will receive a pre-study visit and oral medicine consultation visit.
62818425|NCT06348927|EXPERIMENTAL|Experimental group|"Drug: Sunvozertinib combination with Anlotinib~Sunvozertinib 300 mg once daily (QD) with Anlotinib 8mg once daily （QD in Day 1-14），21 days in one cycle."
62818426|NCT04430920|ACTIVE_COMPARATOR|Intensive intraoperative blood pressure management|
62818427|NCT04430920|PLACEBO_COMPARATOR|Conventional intraoperative blood pressure management|
62038941|NCT05648110|PLACEBO_COMPARATOR|Parent study Sentinel Safety Cohort - Subcohort 1a Gluteal - Placebo|The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
62241962|NCT00420602|OTHER|Single Arm, Open Label|Single Arm, Open Label
62241963|NCT05630144|EXPERIMENTAL|All Participants|
62241964|NCT02612025|EXPERIMENTAL|Exercise group|Exercise training during intensive medical treatment
62241965|NCT02612025|NO_INTERVENTION|Control group|Usual Care
62241966|NCT04622683|EXPERIMENTAL|Control Group- Healthy, Lean Individuals|Determine whether ultrasound exposure at the porta hepatis will affect plasma glucose levels in lean, healthy control subjects.
62241967|NCT04622683|ACTIVE_COMPARATOR|Overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance|Determine whether three episodes of porta hepatic ultrasound exposure will affect plasma glucose levels as well as insulin sensitivity among overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance (as defined by OGTT.
62241968|NCT06516952|EXPERIMENTAL|Povorcitinib Dose 1|Povorcitinib at the protocol-defined dose.
62241969|NCT06516952|EXPERIMENTAL|Povorcitinib Dose 2|Povorcitinib at the protocol-defined dose.
62241970|NCT06516952|PLACEBO_COMPARATOR|Placebo|Placebo at the protocol-defined dose.
62241971|NCT01426516|NO_INTERVENTION|Treatment as usual (TAU)|Subjects will give DNA sample for genetic testing but will not receive genetic results and will therefore receive treatment as usual.
62818428|NCT03638453|EXPERIMENTAL|PediCARE|"* PediCARE Administered x6 mos~* Resource Provision: Monthly Groceries (delivery via Instacart)~* Resource Provision: Transport to/from home/hospital 8x per month (via RideHealth)"
62818429|NCT03638453|ACTIVE_COMPARATOR|Usual Care|The control group will receive usual supportive care
62818430|NCT04519008|EXPERIMENTAL|Treatment as usual plus mobile app|Those who will receive naturalistic treatment in outpatient setting and also the mobile app
62818431|NCT04519008|ACTIVE_COMPARATOR|Treatment as usual|Those who will receive naturalistic treatment in outpatient setting but not the mobile app
62818432|NCT04106297|EXPERIMENTAL|GLPG3970 SAD|Single doses of GLPG3970 at up to 6 dose levels in ascending order
62599293|NCT05351827|SHAM_COMPARATOR|Sham|This arm of the protocol will receive sham air (21 % Oxygen) while in the laboratory. No additional gases will be employed. If diagnosed with sleep apnea, participants will be treated with continuous positive airway pressure for the duration of the intervention.
62599294|NCT04236518|EXPERIMENTAL|Hypertriglyceridimic/blood sugar/HDLcholesterol/blood pressure waist phenotype/animal protein source|20 men or postmenopausal women between 25 and 55 years old with a high waist circumference and at the choice, one of the following criteria high triglyceridemia, blood sugar above standards,a lower than standard HDL-cholesterol level,slightly elevated blood pressure receiving diets with predominantly animal protein sources
62599295|NCT04236518|EXPERIMENTAL|Hypertriglyceridimic/blood sugar/HDLcholesterol/blood pressure waist phenotype/plant protein source|20 men or postmenopausal women between 25 and 55 years old with a high waist circumference and at the choice, one of the following criteria high triglyceridemia, blood sugar above standards,a lower than standard HDL-cholesterol level,slightly elevated blood pressure receiving diets with predominantly plant protein sources
62599296|NCT02070627|EXPERIMENTAL|NIRF-C and IOC|Each enrolled subject will undergo injection with indocyanine green (ICG), intraoperative near infrared fluorescence cholangiography (NIRF-C) and standard of care intraoperative cholangiography.
62599297|NCT01210677|ACTIVE_COMPARATOR|Prednisone|Prednisone 0.5 mg/Kg per day orally for 3 months
62599298|NCT01210677|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets(s) taken orally per day
62432396|NCT05301166|EXPERIMENTAL|Interventional Group|"The intervention group of the RCT consisted of 42 randomly selected students with a Body Mass Index (BMI) score of 25 and above, who were evaluated by inclusion and exclusion criteria.~Students in the intervention group will participate in the Technology-Based Motivation Education Program. This program will last 4 months.~* Students in the intervention group will conduct semi-structured individual motivational interviews, consisting of 6 sessions in total, prepared according to the components of the Health Belief Model.~* Students in the intervention group will access the web-based education and motivation program that supports motivational interviews by logging into the website prepared for the study."
62599299|NCT01099501|ACTIVE_COMPARATOR|Oxepa|Oxepa (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
62599300|NCT01099501|ACTIVE_COMPARATOR|Control group|Pulmocare or Jevity (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
62599301|NCT01446276|EXPERIMENTAL|Resveratrol|Resveratrol 500mg 3 times daily for six month
62038942|NCT05648110|EXPERIMENTAL|Parent study Sentinel Safety Cohort - Subcohort 1b Thigh - AZD5156|The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
62599302|NCT01446276|PLACEBO_COMPARATOR|Placebo|Placebo 1 tablet 3 times daily for six month
62599303|NCT01446276|NO_INTERVENTION|Control group|Men without non-alcoholic fatty liver disease
62599304|NCT02047994|EXPERIMENTAL|Group 1:Triple therapy|Among those assigned to Group 1, participants who are Helicobacter pylori positive will receive Triple therapy and/or upper endoscopy. Participants with serological evidence of atrophic gastritis will undergo upper endoscopy and further endoscopic follow-up. H. pylori positive individuals will be offered Helicobacter pylori eradication as appropriate, independently of the pepsinogen results. From subjects in this group, breath samples will also be collected for volatile markers study. In addition, fecal occult blood test (FOBT) will be offered to this group as a benefit to participate in the study.
62599305|NCT02047994|NO_INTERVENTION|Group 2:No intervention|Those who assigned to Group 2 will receive no intervention and will be offered FOBT as a benefit of study participation. Any participants who show positive FOBT will be referred to colonoscopy. This will be the benefit to this group together with initial medical evaluation at the time of inclusion. During the follow-up period this group will be offered to consult a specialist when required due to clinical symptoms.
62599306|NCT04336449|EXPERIMENTAL|Cohort 1 100 mg eptinezumab|
62599307|NCT04336449|EXPERIMENTAL|Cohort 2 300 mg eptinezumab|
62599308|NCT04336449|PLACEBO_COMPARATOR|Placebo|
62241972|NCT01426516|EXPERIMENTAL|Genecept Assay|Subjects donate DNA sample for genetic testing and treatment decisions take genetic results into account.
62599309|NCT03173846||Adult children of AD patients|
62599310|NCT05529017||non/injured players|rink hockey players participating in senior leagues
62599311|NCT03367546|EXPERIMENTAL|rATG, FLU/CY/TBI, & Thiotepa|Anti-Thymocyte Globulin - Rabbit (rATG), Fludarabine (Fludara), Cyclophosphamide (Cytoxan, Neosar), Total Body Irradiation (TBI), \& Thiotepa
62599312|NCT04062032|EXPERIMENTAL|ASA 81 mg daily|Participants will be given ASA 81 mg orally once daily for a total of 7 days
62599313|NCT04062032|EXPERIMENTAL|ASA 325 mg daily|Participants will be given ASA 325 mg orally once daily for a total of 7 days.
62599314|NCT06426862|EXPERIMENTAL|Interventional Group|The interventional group will receive both treatment routine physiotherapy and the Otago exercise program (OEP). The OEP is the exercise designed for strength and balance to improve mobility, functional balance and walking. The exercises included in this protocol are 17: strength, balance and walking. The participants will receive this protocol with 10 repetitions while the interval between exercises will not be fixed; patients will be given ample time to relax and recuperate before beginning another exercise, 3 times a week for six weeks and the time duration will be 30 to 45 minutes. The exercises will be progressively administered weekly.
62599315|NCT06426862|ACTIVE_COMPARATOR|Control group|The control group will receive routine treatment of physiotherapy for strokes like strengthening of upper and lower limb muscles (knee flexor, hip adductor and ankle dorsiflexor), stretching (hip abductors and ankle plantar flexor), postural awareness, gait and balance training like static and dynamic. The participants will be assessed through baseline assessment.
62599316|NCT03472300||Frederiksberg Citizens|All citizen in the Frederiksberg Community aged 60-69
62818433|NCT04106297|PLACEBO_COMPARATOR|Placebo SAD|Single doses of placebo
62818434|NCT04106297|EXPERIMENTAL|GLPG3970 MAD|Multiple doses of GLPG3970 at up to 4 dose levels in ascending order, daily for 14 days
62241973|NCT01920945|EXPERIMENTAL|OnabotulinumtoxinA|
62599317|NCT05398185|NO_INTERVENTION|Control|The control includes standard health services offered at each site (e.g., mental health services, case-management, referral to clinical care) and a brief adherence educational session.
62599318|NCT05398185|EXPERIMENTAL|Intervention|Participants randomized to intervention will receive the CleverCap pill bottle, an innovative technology that dispenses only the prescribed amount of medication, keeps track of medications dispensed, and communicates wirelessly with the WiseApp.
62599319|NCT02416531|ACTIVE_COMPARATOR|Corticosteroid|Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
62599320|NCT02416531|EXPERIMENTAL|Photodynamic therapy|Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks.
62599321|NCT02416531|EXPERIMENTAL|Low level laser therapy|λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks.
62599322|NCT02967913|EXPERIMENTAL|Bladder flap performed as per routine|Bladder flap surgical step performed at time of non-urgent primary cesarean delivery as per routine
62038943|NCT05648110|PLACEBO_COMPARATOR|Parent study Sentinel Safety Cohort - Subcohort 1b Thigh - Placebo|The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
62038944|NCT05648110|EXPERIMENTAL|Parent study Sentinel Safety Cohort - Subcohort 2a Gluteal- AZD5156|The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
62241974|NCT01949155|EXPERIMENTAL|OTO-201|"OTO-201: Single, intratympanic injection:~One injection of 6 mg OTO-201 (ciprofloxacin in poloxamer 407) into each ear during surgery."
62432397|NCT05301166|OTHER|Control Group|"The intervention group of the RCT consisted of 42 randomly selected students with a Body Mass Index (BMI) score of 25 and above, who were evaluated by inclusion and exclusion criteria.~* Students in the control group will only participate in the web-based education of the Technology-Based Motivation Education Program prepared according to the Health Belief Model for obesity.~* Students in the control group will be given face-to-face or online interviews once a month for 4 months, lasting 10-15 minutes, in accordance with the web-based education content."
62432398|NCT04458779|EXPERIMENTAL|CPAP group|Subjects will receive CPAP treatment in addition to optimal standard therapy for acute stroke.
62432399|NCT04458779|NO_INTERVENTION|Usual-care group|Subjects will receive optimal standard therapy for acute stroke.
62599323|NCT02967913|NO_INTERVENTION|Bladder flap is omitted|No bladder flap performed at time of non-urgent primary cesarean delivery
62241975|NCT01949155|SHAM_COMPARATOR|Sham|"Sham: Simulated single, intratympanic injection:~One sham injection into each ear during surgery."
62432400|NCT05195554|EXPERIMENTAL|Intervention group|The intervention groups will involve a psycho-educational intervention and will consist of between 10 and 12 people led by two professionals, one of whom must be a psychologist, while the other may be any professional in the center (usually social workers).
62432401|NCT05195554|NO_INTERVENTION|Control group|Participants in the control group will receive information on suicide and advice if the suicidal ideation increases.
62599324|NCT05195684|OTHER|single arm|entirely within-subject outcome variables
62599325|NCT00381238|EXPERIMENTAL|rosiglitazone|Extended Release Tablets
62599326|NCT01714843|EXPERIMENTAL|ASP0456 lowest dose group|oral
62241976|NCT02780674|ACTIVE_COMPARATOR|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
62241977|NCT02780674|PLACEBO_COMPARATOR|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
62818435|NCT04106297|PLACEBO_COMPARATOR|Placebo MAD|Multiple doses of placebo
62241978|NCT03025399|EXPERIMENTAL|Tangwang Prescription|The prescription was composed five Chinese herbal medicines,every bag has 4.87g granules, take it one bag each time, two times a day.
62241979|NCT03025399|PLACEBO_COMPARATOR|Placebo|Placebo is a simulated drug of tangwang Prescription,every bag has 4.87g granules, take it one bag each time, two times a day.
62432402|NCT03263819||POTS: Postural Tachycardia Syndrome|patients with postural orthostatic tachycardia syndrome diagnosis.
62432403|NCT03263819||Healthy controls|Patients with Postural orthostatic tachycardia syndrome who has peripheral neuropathy
62599327|NCT01714843|EXPERIMENTAL|ASP0456 low dose group|oral
62599328|NCT01714843|EXPERIMENTAL|ASP0456 middle dose group|oral
62599329|NCT01714843|EXPERIMENTAL|ASP0456 high dose group|oral
62599330|NCT01714843|PLACEBO_COMPARATOR|placebo group|oral
62599331|NCT01253668|EXPERIMENTAL|Arm 1|Patients receive oral brivanib alaninate daily in the absence of disease progression or unacceptable toxicity.
62818436|NCT04106297|EXPERIMENTAL|GLPG3970 FE-rBA|Single dose of GLPG3970 in fed and fasted state
62818437|NCT04106297|EXPERIMENTAL|GLPG3970 FE|Single dose of GLPG3970 in fed and fasted state
62818438|NCT04106297|EXPERIMENTAL|GLPG3970 in psoriasis subjects|
62818439|NCT04106297|EXPERIMENTAL|Placebo in psoriasis subjects|
62432404|NCT02359084|EXPERIMENTAL|Family Navigation|Families will work one-on-one with the navigator who provides off-site support - e.g. home visits or accompanying families to appointments. The goal of FN during the diagnostic evaluation period is to ensure timely completion of the evaluation. The focus of these interactions is to understand the structure and purpose of the evaluation, gather and complete required materials, and address logistic barriers related to the diagnostic visit. The navigator will continue to work with the family after the diagnostic evaluation to access recommended services and support the family's engagement in treatment.
62599332|NCT05526378|EXPERIMENTAL|Group 1 (mother's voice)|"The mother called her baby between 40 and 60 decibels loudness. The intervention was continued 5 minutes before the heel blood collection and continued until the 5th minute after the procedure. NIPS score was saved in 5 minutes before the heel blood collection and continued until the 5th minute after the procedure.~Benetech brand GM1352 model decibel meter was used to measure the loudness."
62599333|NCT05526378|EXPERIMENTAL|Group 2 (mother's milk)|Breast milk was dripped onto the gauze in an amount to wet the entire 2,5cm\*2,5cm sterile gauze. The gauze was then placed close to the baby's nose wings. The intervention was continued 5 minutes before the heel blood collection and continued until the 5th minute after the procedure. NIPS score was saved in 5 minutes before the heel blood collection and continued until the 5th minute after the procedure
62599334|NCT05526378|EXPERIMENTAL|Group 3 (skin to skin contact)|Skin-to-skin contact between mother and baby is provided. The intervention was continued 5 minutes before the heel blood collection and continued until the 5th minute after the procedure. NIPS score was saved in 5 minutes before the heel blood collection and continued until the 5th minute after the procedure
62818440|NCT06340685|EXPERIMENTAL|Triheptanoin|Open label study
62599335|NCT05526378|NO_INTERVENTION|Control group|
62599336|NCT02317835|OTHER|Study in healthy volunteers|Skin foot temperature measurement by DFUPS device
62599337|NCT06647979|EXPERIMENTAL|Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia|
62599338|NCT05484076|EXPERIMENTAL|breastfeeding counseling|Pregnant women will be given breastfeeding counseling, which will take place in a total of five sessions at specified intervals.
62599339|NCT05484076|NO_INTERVENTION|control group|No training will be given to the control group. They will be asked to fill in the questionnaires included in our study at specified intervals.
62599340|NCT00811317|EXPERIMENTAL|Closed-loop|Type 1 diabetic subjects under closed-loop blood glucose control
62599341|NCT02074969|ACTIVE_COMPARATOR|Gamma Nail 3|Gamma Nail 3 Stryker.
62599342|NCT02074969|ACTIVE_COMPARATOR|PFNA|PFNA Antirotation Synthes
62818441|NCT04733638||Pre-Viz ICH VOLUME|Patient data collected prior to Viz ICH VOLUME implementation, utilized as a control data set
62818442|NCT04733638||Post-Viz ICH VOLUME|Patient data collected post-Viz ICH VOLUME implementation
62818443|NCT04195945|EXPERIMENTAL|Arm I (CPX-351)|"INDUCTION: Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients who achieve a response other than an MRDneg CR receive a second course of CPX-351 intravenously IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity.~POST-REMISSION: Patients who achieve a CR/CRi receive a reduced dose of CPX-351 IV over 90 minutes on days 1, 3, and 5 for up to 4 additional courses in the absence of disease progression or unacceptable toxicity."
62432405|NCT02359084|ACTIVE_COMPARATOR|Conventional Care Management|Families will be assigned to a care manager for the diagnostic evaluation and for 100 days thereafter. Consistent with a high quality medical home, the care manager will be responsible to ensure that the referral for the diagnostic evaluation has been made. She is also available for family-initiated support. The care manager will be responsible for ensuring that referrals are made and continue to provide family-initiated, clinic-based support to families for up to 100 days after the completion of diagnostic evaluation.
62599343|NCT01173055|EXPERIMENTAL|Milnacipran|Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
62599344|NCT01173055|EXPERIMENTAL|Placebo|Placebo will be given orally twice daily in tablet form at different times during the course of the study.
62599345|NCT04913350|EXPERIMENTAL|Russian current and elbow support group|participants in the experimental group will apply elbow support and will receive Russian current on biceps and triceps muscles of the unaffected elbow three therapy sessions per week for 4 weeks.
62599346|NCT04913350|ACTIVE_COMPARATOR|elbow support group|Participants in this group will apply elbow support only.
62599347|NCT03817411|ACTIVE_COMPARATOR|Telatinib+Capecitabine+Oxaliplatin|Patients receive Telatinib orally (PO) twice daily (bid) on days 1-21 and Capecitabine PO on days 1-14, then stopped for 7 days, and Oxaliplatin by intravenous injection on day 1 of every cycle. Courses repeat every 21 days.
62599348|NCT03817411|PLACEBO_COMPARATOR|Placebos+Capecitabine+Oxaliplatin|Patients receive placebo orally (PO) twice daily (bid) on days 1-21 and Capecitabine PO on days 1-14, then stopped for 7 days, and Oxaliplatin by intravenous injection on day 1 of every cycle. Courses repeat every 21 days.
62599349|NCT02034396|OTHER|Blood draw|One blood draw at enrollment
62599350|NCT05665166|EXPERIMENTAL|Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII|
62599351|NCT04621526|ACTIVE_COMPARATOR|dexmedetomidine- ketamine|patients will receive combination of ketamine 1mg/kg and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
62599352|NCT04621526|ACTIVE_COMPARATOR|dexmedetomidine- propofol|patients will receive combination from 1 mg/kg propofol and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 1 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
62599353|NCT06098872|EXPERIMENTAL|Experimental: Oral Trametinib|Participants will receive oral Trametinib once daily for up to 60 days prior to their elective surgery
62599354|NCT05814900|EXPERIMENTAL|TPFM imaging of surgical margins|Patients will be imaged with TPFM
62599355|NCT04290988|EXPERIMENTAL|Active EEG Neurofeedback|15 sessions of active EEG neurofeedback at a frequency of 3-5 sessions per week for a duration of 3-5 weeks.
62599356|NCT04290988|SHAM_COMPARATOR|Sham Feedback|15 sessions of sham neurofeedback at a frequency of 3-5 sessions per week for a duration of 3-5 weeks.
62599357|NCT02056106|ACTIVE_COMPARATOR|Clinical acumen|Depression diagnosis and antidepressant treatment provided based on clinical acumen of primary care providers trained to provide depression care.
62599358|NCT02056106|ACTIVE_COMPARATOR|Protocolized Arm|Structured, algorithm-based protocol that guides depression diagnosis and antidepressant treatment
62599359|NCT05720026|EXPERIMENTAL|Treatment group|SYSA1901 combined with trastuzumab and docetaxel will be administrated intravenously on a 3-weekly schedule for 4 cycles (21 days per cycle).
62599360|NCT05720026|ACTIVE_COMPARATOR|Control group|Perjeta® combined with trastuzumab and docetaxel will be administrated intravenously on a 3-weekly schedule for 4 cycles (21 days per cycle).
62818444|NCT04195945|EXPERIMENTAL|Arm II (CLAG-M)|"INDUCTION: Patients receive cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, G-CSF SC on days 0-5, and mitoxantrone IV over 60 minutes on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients who achieve a response other than an MRDneg CR receive a second course of cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, G-CSF SC on days 0-5, and mitoxantrone IV over 60 minutes on days 1-3 in the absence of disease progression or unacceptable toxicity.~POST-REMISSION: Patients who achieve a CR/CRi receive an intermediate dose of cytarabine IV over 2 hours on days 1-6 for up to 4 additional courses in the absence of disease progression or unacceptable toxicity."
62818445|NCT03075787||patients with obstructive sleep apneas|
62818446|NCT05650710|OTHER|Surgical Procedure|Consented patients who meet eligibility will have a surgical procedure for management of head and neck cancer, with dissection and exposure of the relevant anatomic structures as part of regular clinical care.
62241980|NCT05207670|EXPERIMENTAL|Cohort A|Participants with high tumor burden with untreated follicular lymphoma (FL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first. Participants that achieve complete or partial metabolic response will have the option of receiving maintenance therapy with mosunetuzumab every 8 weeks for 1 year.
62432406|NCT05350254|EXPERIMENTAL|Stratified Maintenance Care|"All participating patients will receive pragmatic chiropractic care for the initial 3 weeks (6 visits) and home exercise recommendations.~Participants in the Stratified Maintenance Care group will be classified based on the MAINTAIN instrument into: not a candidate, good candidate, and very good candidate for maintenance care:~* Participants showing a good response to the initial care and classified as not a candidate or a good candidate for maintenance care will be given home exercise recommendations. Return for further manual treatment will be recommended if they have a relapse or exacerbation of symptoms (symptom-guided care).~* Participants classified as having a good response to the initial care and very good candidates for maintenance care, will have visits with tapering manual treatments and home exercise recommendations. They will then be recommended maintenance care with pre-planned visits at 4-12 week intervals (aiming at increasing the interval as soon as possible)."
62432407|NCT05350254|ACTIVE_COMPARATOR|Standard Chiropractic Care|"All participating patients will receive pragmatic chiropractic care for the initial 3 weeks (6 visits) and home exercise recommendations.~In the Standard chiropractic care group, participating patients will receive a standard (pragmatic) chiropractic care in which treatment will be provided based on the clinician's judgement and home exercise recommendations. This may or may not include maintenance care depending on the clinicians' standard operating procedures. All treatments provided will be recorded. Return for further treatment will be recommended if they have a relapse or exacerbation of symptoms (symptom-based)."
62432408|NCT04303494||Experimental1|preterm infants will be routinely immunised during primary hospitalisation
62599361|NCT05032274|EXPERIMENTAL|Single group|The study will include one group and each participant will perform home-based exercise for 8-weeks.
62599362|NCT05406505|EXPERIMENTAL|Dapagliflozine 10mg|
62599363|NCT05406505|PLACEBO_COMPARATOR|Placebo|
62599364|NCT00710684|EXPERIMENTAL|DONEPEZIL + SB-742457 15 MG|SB-742457 - 15mg added to existing donepezil treatment
62599365|NCT00710684|PLACEBO_COMPARATOR|DONEPEZIL + PLACEBO|Placebo added to existing donepezil
62599366|NCT00710684|EXPERIMENTAL|DONEPEZIL + SB-742457 35 MG|SB-742457 - 35mg added to existing donepezil
62599367|NCT05060146|NO_INTERVENTION|Standard care|
62599368|NCT05060146|EXPERIMENTAL|Structured medico-pharmaceutical collaboration|
62599369|NCT02548000|EXPERIMENTAL|Resistance training|Resistance training will be performed three times a week, for 12 weeks, composed by 12 resistance exercises for all body muscles with 2-3 series and 12-8 repetitions in each exercise.
62432409|NCT04303494||Experimental2|preterm infants discharged and readmitted for immunisation during the 3-year period
62599370|NCT02548000|ACTIVE_COMPARATOR|Stretching control|The control group will perform one stretching session a week.
62818447|NCT05992935|EXPERIMENTAL|Phase 1 Part: mRNA-1403 Dose Level 1|Participants will receive 2 intramuscular (IM) injections of mRNA-1403 at Dose Level 1.
62599371|NCT03260517|EXPERIMENTAL|Treatment arm (Mdt Drug-Coated Balloon)|Medtronic Coronary Drug-Coated Balloon Catheter used for dilatation of the target lesion.
62818448|NCT05992935|EXPERIMENTAL|Phase 1 Part: mRNA-1403 Dose Level 2|Participants will receive 2 IM injections of mRNA-1403 at Dose Level 2.
62818449|NCT05992935|EXPERIMENTAL|Phase 1 Part: mRNA-1403 Dose Level 3|Participants will receive 2 IM injections of mRNA-1403 at Dose Level 3.
62818450|NCT05992935|EXPERIMENTAL|Phase 1 Part: mRNA-1403 Dose Level 4 Regimen 1|Participants will receive 2 IM injections of mRNA-1403 at Dose Level 4.
62818451|NCT05992935|EXPERIMENTAL|Phase 1 Part: mRNA-1403 Dose Level 4 Regimen 2|Participants will receive 1 IM injection of mRNA-1403 at Dose Level 4 and 1 IM injection of study vaccine-matched placebo.
62818452|NCT05992935|EXPERIMENTAL|Phase 1 Part: mRNA-1405 Dose Level 1|Participants will receive 2 IM injections of mRNA-1405 at Dose Level 1.
62818453|NCT05992935|EXPERIMENTAL|Phase 1 Part: mRNA-1405 Dose Level 2|Participants will receive 2 IM injections of mRNA-1405 at Dose Level 2.
62038945|NCT05648110|PLACEBO_COMPARATOR|Parent study Sentinel Safety Cohort - Subcohort 2a Gluteal - Placebo|The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
62038946|NCT05648110|EXPERIMENTAL|Parent study Sentinel Safety Cohort - Subcohort 2b Thigh - AZD5156|The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
62038947|NCT05648110|PLACEBO_COMPARATOR|Parent study Sentinel Safety Cohort - Subcohort 2b Thigh - Placebo|The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
62038948|NCT05648110|EXPERIMENTAL|Parent study Main Cohort - AZD3152|The Main Cohort of the Parent study will enroll approximately 3200 participants. Dosing in the Main Cohort will be staggered, so that it starts with adult participants aged 18 years and older, with no adolescent participants dosed in the Main Cohort until safety data from Visit 2a (Day 8) and Visit 2b (Day 15) have been reviewed by the DSMB for at least 80 adult Main Cohort participants (which will include at least 40 participants who have received AZD3152). Participants in the Main Cohort will be randomized 1:1 to receive AZD3152 300 mg or comparator administered IM in the anterolateral thigh on Day 1. Participants will receive a second dose of their original randomized study intervention (ie, active treatment or comparator) 6 months after Visit 1.
62241981|NCT05207670|EXPERIMENTAL|Cohort B|Elderly participants with untreated diffuse large B-cell lymphoma (DLBCL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
62432410|NCT04303494||Control|healthy control infants
62432411|NCT05531045||Cohort|FDG PET/CT assessed after 2 cycles of chemotherapy
62432412|NCT03036995|EXPERIMENTAL|Apremilast - Group A|Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
62432413|NCT03036995|PLACEBO_COMPARATOR|Placebo - Group B|Patient will receive UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment and placebo during 24 weeks.
62599372|NCT05385952|EXPERIMENTAL|GATT-Patch|Hemostatic patch
62599373|NCT05385952|ACTIVE_COMPARATOR|TachoSil|Hemostatic patch
62599374|NCT00278148|EXPERIMENTAL|Dose Level A|"Erlotinib, Paclitaxel, and Carboplatin with Radiation~Dose Level A: 50 mg OSI-774/50 mg/m2 Paclitaxel/2 AUC Carboplatin"
62599375|NCT00278148|EXPERIMENTAL|Dose Level B|"Erlotinib, Paclitaxel, and Carboplatin with Radiation~Dose Level B: 100 mg OSI-774/50 mg/m2 Paclitaxel/2 AUC Carboplatin"
62818454|NCT05992935|EXPERIMENTAL|Phase 1 Part: mRNA-1405 Dose Level 3|Participants will receive 2 IM injections of mRNA-1405 at Dose Level 3.
62818455|NCT05992935|EXPERIMENTAL|Phase 1 Part: mRNA-1405 Dose Level 4 Regimen 1|Participants will receive 2 IM injections of mRNA-1405 at Dose Level 4.
62818456|NCT05992935|EXPERIMENTAL|Phase 1 Part: mRNA-1405 Dose Level 4 Regimen 2|Participants will receive 1 IM injections of mRNA-1405 at Dose Level 4 and 1 IM injection of study vaccine-matched placebo.
62599376|NCT00278148|EXPERIMENTAL|Dose Level C|"Erlotinib, Paclitaxel, and Carboplatin with Radiation~Dose Level C: 150 mg OSI-774/50 mg/m2 Paclitaxel/2 AUC Carboplatin"
62241982|NCT05207670|EXPERIMENTAL|Cohort C|Participants with untreated marginal zone lymphoma (MZL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
62241983|NCT05207670|EXPERIMENTAL|Cohort D|Participants with relapsed or refractory (R/R) mantle cell lymphoma (MCL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
62241984|NCT05207670|EXPERIMENTAL|Cohort E|Participants with R/R Richter's transformation (RT), or R/R transformed follicular lymphoma (tFL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
62432414|NCT04262869|EXPERIMENTAL|Arm I (squamous NSCLC)|Patients receive carboplatin IV over 15-60 minutes, paclitaxel IV over 3 hours and durvalumab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who do not progress receive durvalumab IV every 4 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
62432415|NCT04262869|EXPERIMENTAL|Arm II (non-squamous NSCLC)|Patients receive carboplatin IV over 15-60 minutes, pemetrexed IV over 10 minutes and durvalumab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who do not progress receive durvalumab IV and pemetrexed IV every 3 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
62432416|NCT00597584|EXPERIMENTAL|Peginesatide|
62432417|NCT00597584|ACTIVE_COMPARATOR|Epoetin|
62432418|NCT06290700|EXPERIMENTAL|İntervational group|Neonatal care education given to primiparous pregnant women affect their postpartum maternal function Neonatal care education given to primiparous pregnant women affect their postpartum quality of life?
62432419|NCT06290700|NO_INTERVENTION|Control group|All pregnant women, those in the control group, were provide with standard
62432420|NCT06529874|EXPERIMENTAL|Normal Healthy children|All forty normal healthy children will undergo measurement of pressure pain tolerance via digital pressure algometry, balance assessment using HUMAC balance system, and evaluation lower limb strength using Lafayette Hand Held Dynamometer.
62432421|NCT06529874|EXPERIMENTAL|Sickle cell anemia children|All forty Sickle cell anemia children will undergo measurement of pressure pain tolerance via digital pressure algometry, balance assessment using HUMAC balance system, and evaluation lower limb strength using Lafayette Hand Held Dynamometer.
62432422|NCT06129331||AS-CA without amyloid-specific treatment|Patients with no amyloid-specific treatment
62432423|NCT06129331||AS-CA with amyloid-specific treatment|Patients receiving newly available amyloid-specific drugs
62432424|NCT05926219|EXPERIMENTAL|Fatigue|Volunteers will perform one-legged knee extension exercise until fatigue while seated on an ergometer. Volunteers will then undergo bilateral skeletal muscle biopsies of the vastus lateralis muscle in their thigh.
62432425|NCT05588830||Belimumab group|
62432426|NCT05588830||Telitacicept group|
62432427|NCT04000828|OTHER|single Arm|all patients receive the measurement with Sensimed Triggerfish
62432428|NCT06539819|EXPERIMENTAL|Electrical Posterior Box Isolation and Rotor Modulation Ablation group (R&B group)|The subject's surgical procedure is electrical posterior box isolation plus rotor modulation ablation.
62432429|NCT06539819|ACTIVE_COMPARATOR|Electrical Posterior Box Isolation group (BO group)|The subject's surgical procedure is electrical posterior box isolation.
62432430|NCT06529393|ACTIVE_COMPARATOR|SHAC block group|For the SHAC block, with the patient in a beach-chair position and with the arm in extension, the subscapularis muscle is stretched posteriorly and becomes easily visible. With external rotation and abduction, the coracobrachialis and the biceps brachii muscles are displaced, allowing the visualization of the interfascial space between the deep lamina of the deltoid muscle fascia and the superficial lamina of the subscapularis fascia.Once the injection into the fascial space is achieved, the investigators can proceed towards the glenohumeral pericapsular space by crossing the subscapularis muscle with the needle. By injecting the pericapsular space, the investigators reach the terminal articular branches indistinctly from their origin. Furthermore, through the Weitbrecht foramen, a natural capsular foramen between the upper and middle glenohumeral ligaments, we also reach the intra-articular space .
62432431|NCT06529393|ACTIVE_COMPARATOR|Suprascapular nerve block group|Patients will be placed in lateral position by using A high - frequency linear ultrasound probe will be placed approximately 2 cm medial to the medial border of the acromion and about 2 cm cranial to the superior margin of the scapular spine until supraspinatus or infraspinatus muscle contractions were elicited. Following negative aspiration,A 21G 10-cm needle will be inserted using an in-plane approach .The tip of the needle will be placed at the floor of the supraspinatus fossa where the nerve has passed .A volume of 15 mL of a mixture of 2% lidocaine (5 mL) and 0.5% levobupivacaine (10 mL) was injected.
62599377|NCT05811585||Patient of a Laparoscopic Gynecologic Surgery|ADEPT administered intraperitoneally as a liquid, used for irrigation throughout the procedure and for final instillation of a suitable amount at the end of the procedure.
62818457|NCT05992935|PLACEBO_COMPARATOR|Phase 1 Part: Placebo|Participants will receive 2 IM injections of study vaccine-matching placebo.
62241985|NCT00437671|EXPERIMENTAL|Entered study|
62241986|NCT04376060|EXPERIMENTAL|Study population|Fifteen patients (1 male, 14 females) aged between 27 and 64 years old
62241987|NCT02556866|EXPERIMENTAL|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
62241988|NCT02556866|PLACEBO_COMPARATOR|placebo|Prednisone treatment plus placebo administered by slow intravenous infusion at day 1 (D1), D8, D15 and D22.
62241989|NCT02225717|EXPERIMENTAL|Non pregnant women|Healthy pregnancy : women 15-16 weeks of gestation, at 35-36 weeks of gestation, and \>37 weeks of gestation and planed cesarean prior labor
62599378|NCT03634033|EXPERIMENTAL|MiCAP with IF (Main Study)|MiCAP with Internal Facilitation will receive MiCAP (implementation strategies). Internal facilitators will be waiver site clinicians with exemplary clinical practice and/or supervisory experience, who are expected to be early adopters of CAPABLE; and will be selected by their supervisors.
62599379|NCT03634033|EXPERIMENTAL|MiCAP with IF and EF (Main Study)|MiCAP with Internal Facilitation and External Facilitation will receive MiCAP (implementation strategies) and the addition of external facilitation. The external facilitators will be Super-Champion waiver program site clinicians from prior work who were trained and early adopters of CAPABLE; and will be selected by the research team to perform external facilitation.
62599380|NCT03081559|EXPERIMENTAL|Intervention|Healthy Divas intervention
62599381|NCT03081559|NO_INTERVENTION|Control|Treatment as usual
62599382|NCT03499457|EXPERIMENTAL|treatment|penicillin chalange test, as descibed.
62599383|NCT00972816|EXPERIMENTAL|3.75_(50)MF59|3.75 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
62599384|NCT00972816|EXPERIMENTAL|7.5_(0) MF59|7.5 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
62599385|NCT00972816|EXPERIMENTAL|7.5_(50) MF59|7.5 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
62599386|NCT00972816|EXPERIMENTAL|7.5_(100) MF59|7.5 μg A/H1N1 antigen with 100% MF59 adjuvant administered on study day 1 and day 22
62599387|NCT00972816|EXPERIMENTAL|15_(0) MF59|15 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
62599388|NCT00972816|EXPERIMENTAL|15_(50)MF59|15 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
62599389|NCT00972816|EXPERIMENTAL|15_(100) MF59|15 μg A/H1N1 antigen with 100% MF59 adjuvant administered on study day 1 and day 22
62241990|NCT02225717|EXPERIMENTAL|Preterm Labor|Pregnant women admitted for preterm labor
62241991|NCT02225717|EXPERIMENTAL|Healthy pregnancy|Healthy pregnancy : women 15-16 weeks of gestation, at 35-36 weeks of gestation, and \>37 weeks of gestation and planed cesarean prior labor
62599390|NCT00972816|EXPERIMENTAL|30_(0) MF59|30 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
62599391|NCT04824235|EXPERIMENTAL|Amnoitic Chorion Membrane and xenograft|extraction sockets where ridge preservation will be performed using Chorion Membrane with Xenograft
62432432|NCT01918709|EXPERIMENTAL|Valsartan 160mg, Rosuvastatin 20mg|Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 7 days.
62432433|NCT01918709|EXPERIMENTAL|Rosuvastatin 20mg|Rosuvastatin 20mg is administered daily by mouth once a day for 7 days.
62432434|NCT01918709|EXPERIMENTAL|Valsartan 160mg|Valsartan 160mg is administered daily by mouth once a day for 7 days.
62432435|NCT04839237|EXPERIMENTAL|Liraglutide|Obese patients with HbA1C lower than 9.0%,receive Liraglutide alone for 3 months.
62432436|NCT04839237|EXPERIMENTAL|Liraglutide combined with metformin|Obese patients with HbA1C ≥9.0%, receive Liraglutide in combination with metformin for 3 months.
62432437|NCT02442752|EXPERIMENTAL|Regimen A: Dexlansoprazole 10 mg|Dexlansoprazole 10 mg, delayed-release capsules, orally, once daily for 8 weeks.
62432438|NCT02442752|EXPERIMENTAL|Regimen B: Dexlansoprazole 15 mg|Dexlansoprazole 15 mg, delayed-release capsules, orally, once daily for 8 weeks.
62599392|NCT04824235|ACTIVE_COMPARATOR|Amnoitic Chorion Membrane only|extraction sockets where ridge preservation will be performed using Chorion Membrane Alone
62818458|NCT05992935|EXPERIMENTAL|Phase 2 Part: mRNA-1403 Dose Level 1|Participants will receive 1 IM injection of mRNA-1403 at Dose Level 1.
62818459|NCT05992935|EXPERIMENTAL|Phase 2 Part: mRNA-1403 Dose Level 2|Participants will receive 1 IM injection of mRNA-1403 at Dose Level 2.
62241992|NCT01367964|EXPERIMENTAL|ACTH treatment|Infants with a Type 3 EEG (pre-hypsarhythmia) will be treated with ACTH for 2 weeks.
62241993|NCT05071495|EXPERIMENTAL|Intervention group|
62241994|NCT05071495|NO_INTERVENTION|Control group|
62241995|NCT04231136|EXPERIMENTAL|Tegoprazan 50 mg|Oral administration of Tegoprazan 50 mg tablet once a day
62241996|NCT04231136|ACTIVE_COMPARATOR|EAPA115|Oral administration of EAPA115 once a day
62599393|NCT03792529||breast cancer with HER2 overexpression|
62599394|NCT03792529||hormone receptor-positive breast cancer|
62599395|NCT03792529||triple negative breast cancer|
62599396|NCT06016088|EXPERIMENTAL|RSP-1502|"Cohorts 1-4 will receive RSP-1502 (300 mg tobramycin plus an ascending dose of CaEDTA).~Cohort 5 will receive 300 mg tobramycin + CaEDTA at the MTD."
62599397|NCT06016088|ACTIVE_COMPARATOR|Active Control|• Tobramycin Inhalation Solution 300 mg.
62241997|NCT04231136|ACTIVE_COMPARATOR|RAPA115|Oral administration of RAPA115 once a day
62241998|NCT02279823|EXPERIMENTAL|CB-03-01 solution|Topical solution applied twice daily for 26 weeks
62241999|NCT02279823|ACTIVE_COMPARATOR|Minoxidil Solution 5%|Topical solution applied twice daily for 26 weeks
62242000|NCT02279823|PLACEBO_COMPARATOR|Placebo solution|Topical solution applied twice daily for 26 weeks
62242001|NCT00001163||1|primary clinical; volunteers come from all U.S.
62242002|NCT02315599||1|Patients screening for, participating in, or have participated in a POB gene therapy clinical trial and have received/or be scheduled to receive a genetically engineered cellular therapy.
62432439|NCT02442752|EXPERIMENTAL|Regimen C: Dexlansoprazole 20 mg|Dexlansoprazole 20 mg, delayed-release capsules, orally, once daily for 8 weeks.
62432440|NCT02442752|EXPERIMENTAL|Regimen D: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release capsules, orally, once daily for 8 weeks.
62432441|NCT01462500|EXPERIMENTAL|Miltefosine|Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days
62432442|NCT01796860|OTHER|AFO|All persons in the study will be fit with the same AFO (Tamarack joint with adjustable check strap).
62432443|NCT02085707|ACTIVE_COMPARATOR|Total hip replacement arthroplasty|59 off 118 patients will be randomized to total hip replacement arthroplasty
62818460|NCT05992935|EXPERIMENTAL|Phase 2 Part: mRNA-1403 Dose Level 3|Participants will receive 1 IM injection of mRNA-1403 at Dose Level 3.
62818461|NCT05992935|PLACEBO_COMPARATOR|Phase 2 Part: Placebo|Participants will receive 1 IM injection of study vaccine-matching placebo.
62818462|NCT05219500|EXPERIMENTAL|FPI-2265|All patients will receive FPI-2265, administered at 8 ± 1-week interval, with the initial activity of 100 kBq/kg (±10%).
62242003|NCT05103943|EXPERIMENTAL|SPECT MPI (myocardial perfusion imaging) Group|the SPECT MPI protocol will be modified to evaluated MBF and MFR. This modification will result in no added radiation; the radiopharmaceutical dose will still be the same compared to a standard MPI protocol.
62242004|NCT04384913||MA (mechanical alignment)|Patients in group MA (mechanical alignment) will be operated according to mechanical implantation technique. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation.
62432444|NCT02085707|ACTIVE_COMPARATOR|Closed reduction and internal fixation|"59 off 118 patients will be randomized to closed reduction and internal fixation.~2 cancellous parallel hip pins"
62432445|NCT03227822|EXPERIMENTAL|Short spot stenting|Short spot stenting
62432446|NCT03227822|EXPERIMENTAL|Long lesion stenting|Long lesion stenting
62432447|NCT00897442||Ancillary-Correlative (biomarker sampling and analysis)|Snap frozen tumor tissue, OCT molds of tumor tissue, formalin-preserved tumor tissue, buffy coat-prepared tumor tissue, and blood samples are collected and stored in the repository. Patient information is kept confidential, and patients are not informed of any research/test results from use of their tissues.
62432448|NCT00676988||Observation|Subjects with Luminal Crohn's Disease receiving infliximab
62432449|NCT05725278|EXPERIMENTAL|Users of Tiko Platform|These participants accessed various services on Tiko platform such as buying contraceptives, visiting doctors for ANC etc. They earned Tiko Miles/Points for such health seeking behaviours which they could then redeem at network of grocery shops, pharmacies, beauty salon etc. Tiko card also enabled them to get discounts at pharmacies and at health care providers. These participants were free to access any other government or private health care facility as free economic agents. Users of Tiko platform were identified by the backend system that recorded all health seeking behaviours / actions, reward point accumulation, and use of those reward points.
62432450|NCT05725278|ACTIVE_COMPARATOR|Non-Users of Tiko Platform|These participants registered on Tiko platform on basis of recruitment drive and pitch by Pro agents, but they did not access any service and became dormant. However, These participants were free to access any other government or private health care facility and could access fame family planning and ANC products and services. They could even access Tiko network doctors and pharmacies but they would not get any Tiko Miles/Points or discounts without the use of Tiko card. Non Users were identified as those registered women who did not have any record of using services using Tiko card as per the backend system
62432451|NCT04155697|ACTIVE_COMPARATOR|Hand washing with soap for thirdhand smoke removal|
62599398|NCT06619340|EXPERIMENTAL|Experimental Group|Patients will receive an EXPAREL IPSA block intraoperatively.
62599399|NCT05448326||Work package 1 (WP1)|Patients without a diagnosis who consulted for a developmental anomaly in 2012 and 2022 and agree to resume a diagnostic approach
62599400|NCT05448326||Work package 2 (WP2)|Part 1 (Lab): Patients with developmental abnormalities with or without neurodevelopmental disorders who have had a CNV (Copy Number Variation) rendering that remained of unknown significance or classified as (probably) benign Part 2 (Clinical part): Patients who agree to resume the diagnostic process following a CNV report of unknown significance or classified as (probably) benign
62599401|NCT05448326||Work package 3 (WP3)|Patients with an established clinical diagnosis belonging to the characteristic syndromes of the AnDDI-Rares network (known gene(s) but negative molecular diagnosis)
62599402|NCT05368402|EXPERIMENTAL|Ladarixin|Ladarixin will be administered orally at the dose of 400 mg b.i.d. for 7 cycles of 14 days with an interval of 14 days off, for a total duration of 26 weeks.
62599403|NCT05368402|PLACEBO_COMPARATOR|Placebo|Matching placebo will be administered with the same treatment schedule of the IMP.
62599404|NCT00570544||1|patients with moderate to severe copd with varying extent of emphysema
62599405|NCT04157127|EXPERIMENTAL|Autologous DC Vaccine Cohort 1|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.~DC Vaccine dose evaluated in Cohort 1:~1. st vaccine - 0.5 million cells~2. nd vaccine - 1 million cells~3. rd vaccine - 2 million cells~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
62432452|NCT04155697|ACTIVE_COMPARATOR|Ethyl alcohol-based sanitizer for thirdhand smoke removal|
62432453|NCT00926289|ACTIVE_COMPARATOR|Telmisartan|Telmisartan 80 mg
62432454|NCT00926289|EXPERIMENTAL|Telmisartan/hydrochlorothiazide|Telmisartan80mg/Hydrochlorothiazide25mg
62432455|NCT02217345|EXPERIMENTAL|Growth hormone|Growth hormone (somatropin) administered by daily injection at starting dose of 0.3 mg daily for women and 0.2 mg daily for men, with dose titration for goal IGF-1 in the upper quartile of normal for age.
62242005|NCT04384913||KA (kinematic alignment)|Patients in group KA (kinematic alignment) will be operated according to kinematic implantation technique. The kinematic cutting blocks will be designed to resurface the femoral and tibial bones to restore each patient´s pre-arthritic anatomy and Joint line. Based on a available CT dat the prearthritic anatomy is reconstructed by compensating bone defects and restoring the physiological cartilage height of 1,7mm. Femoral Flexion is evaluated by the anterior Cortex of the distal femur, tibia slope is defined to 3° due to ACL (Anterior Cruciate Ligament) loss, but cab be adapted during surgery.
62038949|NCT05648110|ACTIVE_COMPARATOR|Parent study Main Cohort - EVUSHELD™|"Participants in the Main Cohort of the Parent study will be randomized 1:1 to receive AZD3152 300 mg or comparator administered IM in the anterolateral thigh on Day 1. Participants will receive a second dose of their original randomized study intervention (ie, active treatment or comparator) 6 months after Visit 1.~At the request of regulatory authorities the active comparator will be changed to placebo. As the comparator is given on two occasions, this means that a participant randomized to the comparator arm may receive (a) two doses of EVUSHELD, (b) a dose of EVUSHELD and a dose of placebo, or (c) two doses of placebo."
62038950|NCT05648110|PLACEBO_COMPARATOR|Parent study Main Cohort - Placebo|"Participants in the Main Cohort of the Parent study will be randomized 1:1 to receive AZD3152 300 mg or comparator administered IM in the anterolateral thigh on Day 1. Participants will receive a second dose of their original randomized study intervention (ie, active treatment or comparator) 6 months after Visit 1.~At the request of regulatory authorities the active comparator will be changed to placebo. As the comparator is given on two occasions, this means that a participant randomized to the comparator arm may receive (a) two doses of EVUSHELD, (b) a dose of EVUSHELD and a dose of placebo, or (c) two doses of placebo."
62432456|NCT02217345|PLACEBO_COMPARATOR|Placebo|Placebo will be administered by daily injection in this double blind study design. Sham dosing will be performed to maintain blinding.
62432457|NCT01283607|ACTIVE_COMPARATOR|Digicoach|Women randomized in the Digicoach group will be treated by the Digicoach therapy. Digicoach is an e-health cognitive behavioral therapy with 4-12 weekly sessions especially developed for in vitro fertilization (IVF) women. Digicoach is facilitated by an e-therapist. The investment for the weekly home work assignments is about one and a half hour. Digicoach consist of different modules (e.g. stress reduction, acceptance). Digicoach starts before the hormonal down regulation as the start of the IVF procedure and ends three weeks after the pregnancy test.
62432458|NCT01283607|NO_INTERVENTION|Control|Women in the control group will get the usual treatment, there will be no additional intervention.
62432459|NCT04098549|EXPERIMENTAL|Rapid-Slow|"This arm will begin with intervention rapid (rapid rate of fall in plasma glucose) for the first study visit and proceed to intervention slow (slow rate of fall in plasma glucose) for the second study visit."
62432460|NCT04098549|EXPERIMENTAL|Slow-Rapid|"This arm will begin with intervention slow (slow rate of fall in plasma glucose) for the first study visit and proceed to intervention rapid (rapid rate of fall in plasma glucose) for the second study visit."
62599406|NCT04157127|EXPERIMENTAL|Autologous DC Vaccine Cohort 2|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.~DC Vaccine dose evaluated in Cohort 2:~1. st vaccine - 2 million cells~2. nd vaccine - 4 million cells~3. rd vaccine - 8 million cells~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
62599407|NCT04157127|EXPERIMENTAL|Autologous DC Vaccine Cohort 3|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.~DC Vaccine dose evaluated in Cohort 3:~1. st vaccine - 8 million cells~2. nd vaccine - 8 million cells~3. rd vaccine - 8 million cells~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
62735764|NCT04089670|ACTIVE_COMPARATOR|Online Acceptance and Commitment Therapy Intervention|"This online Acceptance and Commitment Therapy intervention is delivered over 8 weeks, in 8 15-minute modules. Each module has a practice assignment at the end with the goal of having the participant engage in the material over the next week. Additionally, each participant will receive a weekly call for the duration of the intervention (i.e., 9 phone calls, one introduction phone call, 8 module related phone calls) from a Master's-level clinical student who will serve as the participants phone coach. During the call the clinical student will be able to help troubleshoot any technical difficulties being experienced, as well as clarify any questions about the material being taught in the intervention."
62818463|NCT03422913|EXPERIMENTAL|CLCVP Group|Controlled low central venous pressure(CLCVP) will be performed combined with intraoperative combined hilar intermittent (Pringle method)
62818464|NCT03422913|NO_INTERVENTION|Control Group|Only intraoperative combined hilar intermittent (Pringle method) will be performed
62818465|NCT06288581|EXPERIMENTAL|Traditional toothbrush group|Children in this group will use a traditional brush first to clean their teeth then will use U shaped brush later.
62432461|NCT04647461|EXPERIMENTAL|BRIDIN-T Eye drops 0.15%(Non preservative)|Brimonidine Tartrate 1.5mg : 1 drop 3 times a day for 12 weeks to target eyes
62432462|NCT04647461|ACTIVE_COMPARATOR|ALPHAGAN-P Eye drops 0.15%(Preservatives)|Brimonidine Tartrate 1.5mg : 1 drop 3 times a day for 12 weeks to target eyes
62432463|NCT03275779|EXPERIMENTAL|Low Frequency Condition|Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
62432464|NCT03275779|EXPERIMENTAL|High Frequency Condition|Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
62242006|NCT04863664|EXPERIMENTAL|Intervention/Treatment (LEADR)|Patients will be implanted with a Next Generation ICD Lead and undergo required electrical testing
62038951|NCT05648110|EXPERIMENTAL|Sub-study - AZD3152|This sub-study will enroll approximately 450 participants, ≥ 18 years of age with a minimum weight of 40 kg. An initial Sentinel Safety Cohort will include 12 healthy volunteers; all other participants in the study will be either immunocompromised or immunocompetent (including healthy participants) with all degrees of SARS-CoV-2 infection risk.
62038952|NCT05648110|ACTIVE_COMPARATOR|Sub-study - AZD7442 (EVUSHELD™)|This sub-study will enroll approximately 450 participants, ≥ 18 years of age with a minimum weight of 40 kg. An initial Sentinel Safety Cohort will include 12 healthy volunteers; all other participants in the study will be either immunocompromised or immunocompetent (including healthy participants) with all degrees of SARS-CoV-2 infection risk.
62818466|NCT06288581|EXPERIMENTAL|U shaped toothbrush group|children in this group will use a U-shaped brush first to clean their teeth then will use traditional brush later
62818467|NCT06591390|ACTIVE_COMPARATOR|Ticagrelor and aspirin arm|The ticagrelor arm will receive (a 180 mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90 mg twice daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
62818468|NCT06591390|ACTIVE_COMPARATOR|cilostazol and aspirin arm|The cilostazol arm will receive (a 200 mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
62818469|NCT03957551|EXPERIMENTAL|Cabozantinib and pembrolizumab|Cabozantinib will be administered in the tablet form, at three dose levels: 40, 20 and 60 mg per day. Pembrolizumab will be administered as an intravenous infusion at a fixed dose of 200 mg once every 3 weeks.
62818470|NCT05682170|EXPERIMENTAL|Acute Myeloid Leukemia|"Phase 1: Dose Escalation- c3 monotherapy and d5+c3 combination~Phase 2: Dose Expansion"
62818471|NCT06180135|NO_INTERVENTION|Control Group|"The patients in this group will rest their bowel movements after starting oral intake at the 6th hour postoperatively. The time of first degassing and the time of first discharge will be recorded by asking verbally.~Only evaluation will be made at 6. hours after surgery without intervention in the control group."
62038953|NCT05648110|EXPERIMENTAL|Sub-study - AZD7442 (EVUSHELD™) Immunocompromised participants offered AZD3152 1200mg IV|This sub-study will enroll approximately 450 participants, ≥ 18 years of age with a minimum weight of 40 kg. An initial Sentinel Safety Cohort will include 12 healthy volunteers; all other participants in the study will be either immunocompromised or immunocompetent (including healthy participants) with all degrees of SARS-CoV-2 infection risk.
62038954|NCT03845153|ACTIVE_COMPARATOR|Metformin|20 post-menopausal women with a bone fracture treated with metformin Retard 850 mg once daily for two weeks then 850 mg twice daily for three months.
62038955|NCT03845153|PLACEBO_COMPARATOR|Placebo|20 post-menopausal women with a bone fracture treated with placebo once daily for two weeks then twice daily for three months.
62038956|NCT03088826|ACTIVE_COMPARATOR|MSIR and Acetaminophen Group|The patients in this group will receive 1 tablet 15mg PO morphine sulfate immediate release combined with 650mg of Acetaminophen
62432465|NCT02226809||General anesthesia|Evaluation of RNMB. Application of accelerometry to patients after general anesthesia receiving at least one intermediate action nondepolarizing neuromuscular blocking agent dose
62818472|NCT06180135|ACTIVE_COMPARATOR|TURKISH COFFEE DRINKING GROUP - TURKISH COFFEE DRINK|"Turkish coffee group after the patients in start oral intake at the 6th hour after the surgery, 7 gr of Turkish coffee in 75 ml of water will be boiled with water at 50-60°C, prepared by the researcher and given to the patients to drink. Bowel movements will be rested before and after the intake of Turkish coffee. The time of first degassing and the time of first discharge will be recorded by asking verbally.~Evaluation will be made at the 0th hour after the operation without application. The application will be made at the 6th hour after the surgery and the gıs functıons and healıng qualıty will be evaluated."
62038957|NCT03088826|ACTIVE_COMPARATOR|Oxycodone and Acetaminophen Group|The patients in this group will receive 1 tablet 10mg Oxycodone combined with 650mg of Acetaminophen
62038958|NCT03678753|EXPERIMENTAL|Cenobamate|Cenobamate 12.5 mg tablet once a day for two weeks, 25 mg tablet once a day for two weeks, 50 mg tablet once a day for two weeks, 100 mg tablets once a day for two weeks, 150 mg tablets once a day for two weeks and 200 mg tablets once a day for twelve weeks. Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight.
62038959|NCT03678753|PLACEBO_COMPARATOR|Placebo|Matching placebo
62432466|NCT06155799|EXPERIMENTAL|Navigation group|Zygomatic implant placement by dynamic computer assisted surgery system.
62242007|NCT04863664|EXPERIMENTAL|Intervention/Treatment (LEADR LBBAP)|Patients will be implanted with a Next Generation ICD Lead in the LBBAP location and undergo required electrical testing
62432467|NCT06155799|ACTIVE_COMPARATOR|Freehand group|Zygomatic implant placement by Freehand, without any guidance.
62432468|NCT02964065|EXPERIMENTAL|LAIV|a single dose of Live-Attenuated influenza Vaccine;Dose: 0.2 ml; Each dose contains not less than 6.9 lg EID50 of type A live attenuated influenza virus reassortants(H1N1 and H3N2), and not less than 6.4 lg EID50 of type B live attenuated influenza virus reassortants.
62242008|NCT00007813|EXPERIMENTAL|Arm 1|
62432469|NCT02964065|PLACEBO_COMPARATOR|Placebo|a single dose of Placebo. Inactivated placebo will be identical to LAIV in appearance, ingredients and concentrations, attenuated influenza virus free.
62432470|NCT05841966|EXPERIMENTAL|Intraoperative Transoral Ultrasound|Transoral ultrasound of the tonsils and tongue base under general anesthesia.
62432471|NCT02827513|EXPERIMENTAL|Arm 1|Participants will receive sustained release (SR) Tablet Formulation 1 (SR1) containing 100 mg of Centanafadine (CTN) (2 x 100 mg tablets taken orally by mouth \[PO\] in the morning at starting at approximately 7 am and 2 x 100 mg tablets PO 5 hours later) for a total daily dose (TTD) of 400 mg on Days 1, 4, 7, and 10.
62432472|NCT02827513|EXPERIMENTAL|Arm 2|Participants will receive extended release (XR) Tablet Formulation 1 (XR1) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
62432473|NCT02827513|EXPERIMENTAL|Arm 3|Participants will receive XR Tablet Formulation 2 (XR2) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
62242009|NCT05794113|ACTIVE_COMPARATOR|Web-based notification arm|All participants randomized to the web-based notification arm received the following web-based CANVAS notifications \[4,5\]. Briefly, participants received an email notifying them of their registration in the study. Eight days following their influenza vaccine, participants received an email with the survey link asking them to complete their online influenza vaccine safety survey. Participants received a reminder email on day 11 if they did not complete their survey.
62242010|NCT05794113|EXPERIMENTAL|Mobile app arm|Participants randomized to the mobile app arm, received an email asking them to download the app and activate their account. Users who did not activate their account after 48 hours received a reminder email. Participants who activated their accounts, could spontaneously report an adverse event through the app, and were also notified of the day 8 survey through the app.
62242011|NCT01288872|EXPERIMENTAL|Praziquantel|45 women in 3 cohorts (15 early pregnancy: 12-16 weeks gestation; 15 late pregnancy: 30-36 weeks gestation; and 15 lactating nonpregnant women who are 5-7 months (inclusive) postpartum) given praziquantel (PZQ), 60 mg/kg orally in split dose (30 mg/kg each) separated by 3 hours.
62735765|NCT04089670|NO_INTERVENTION|Control|Participants in this arm of the study will complete the same sleep diaries and questionnaires at the same time points as the intervention group, but will not be administered the intervention modules and will not receive any phone coaching. When they have completed the 1-month follow-up they will be offered the intervention.
62242012|NCT02558192|EXPERIMENTAL|Probiotics|Vials containing 3 x 10\^9 Colony Forming Units of LGG, vitamins ( B and C) and zinc
62242013|NCT02558192|PLACEBO_COMPARATOR|Placebo|Vials containing water, maltodextrin, magnesium stearate, potassium sorbate, sodium benzoate, citric acid, fructose, flavor.
62242014|NCT00762749|EXPERIMENTAL|diphenhydramine HCl|diphenhydramine HCl / Children's Benadryl Allergy Liquid
62818473|NCT06180135|ACTIVE_COMPARATOR|FENNEL TEA DRINKING GROUP- FENNEL TEA DRINK|"fennal tea group after the patients in start oral intake at the 6th hour postoperatively, 150 ml of boiled water at 100˚C will be added to 2 g of fennel seeds, and then infused for 5-10 minutes, they will be given to the patients to drink. Bowel movements will be rested before and after fennel tea intake. The time of first degassing and the time of first discharge will be recorded by asking verbally.~Evaluation will be made at the 0th hour after the operation without application. The application will be made at the 6th hour after the surgery and the gıs functıons and healıng qualıty will be evaluated."
62242015|NCT06735495|EXPERIMENTAL|Effective of CD19&CD22 bispecific CAR-T cells|The infusion dose range of cells in this trial is recommended: 1 to 2 10\^6 And CAR-T cells / kg.
62242016|NCT05290051|EXPERIMENTAL|Patients referred for cytogenetic analysis|Analysis of patient DNA with Optical Genome Mapping (Bionano®) and long read Sequencing (Nanopore®) in search for chromosome abnormalities (aneuploidies and SV)
62735766|NCT03356353|EXPERIMENTAL|sildenafil citrate|Following enrolment, participants will be given an initial dose of sildenafil 20 mg. If tolerated, a schedule of 20 mg three times daily (tid) will be initiated. Dosage will be titrated over 3-4 days to the target dose of 40 mg tid. If the initial dose is not tolerated, the participant will be exited from the trial.
62818474|NCT05984121|ACTIVE_COMPARATOR|Local ozon injections|Local ozone therapy consists of 95-99% oxygen, 1-5% medical ozone mixture and is obtained from medical ozone generators. Medical ozone therapy contains at least 95% oxygen and at most 5% ozone. (Bocci, Velio Alvaro. 2006)
62038960|NCT05895461|EXPERIMENTAL|BWLI-College|BWLI-College is a multicomponent behavioral weight loss intervention to reduce weight through diet, physical activity, and behavioral modifications designed to be responsive to emerging adult preferences. It will be delivered in a hybrid format with in-person and remotely-delivered asynchronous sessions. As presently designed, the intervention will last 10 weeks, though this may change with refinement.
62038961|NCT05895461|ACTIVE_COMPARATOR|Control|The Control intervention consists of 1 in-person psychoeducational group session on general weight loss information and myths. Public web-resources about healthy eating and physical activity will be provided. Newsletters with similar content will be sent to promote retention.
62038962|NCT03817424|EXPERIMENTAL|Cohort 1: VIB7734 Dose 1|Participants will receive VIB7734 Dose 1 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
62038963|NCT03817424|EXPERIMENTAL|Cohort 2: VIB7734 Dose 2|Participants will receive VIB7734 Dose 2 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
62038964|NCT03817424|EXPERIMENTAL|Cohort 3: VIB7734 Dose 3|Participants will receive VIB7734 Dose 3 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
62038965|NCT03817424|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to VIB7734 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
62038966|NCT06053476|ACTIVE_COMPARATOR|Chest tube duration at least 3 days plus TEA|
62242017|NCT06378411|EXPERIMENTAL|Music Game Group|Use of Moniz Game with digital interface
62242018|NCT06378411|EXPERIMENTAL|Music Game Controller Group|Use of Moniz Game with piano controller
62242019|NCT06378411|ACTIVE_COMPARATOR|Music Practice Group|Use of music trainning as intervention
62242020|NCT05013853|ACTIVE_COMPARATOR|Resin Z350 of proximal posterior teeth|Restorative with Z350 composite of proximal caries lesions or restorations replacement
62242021|NCT05013853|ACTIVE_COMPARATOR|Resin Tetric N Ceram Bulkfill of proximal posterior teeth|Restorative with Tetric N Ceram Bulkfill composite of proximal caries lesions or restorations replacement
62242022|NCT05013853|EXPERIMENTAL|Resin Fill Up! of proximal posterior teeth|Restorative with Fill Up! composite of proximal caries lesions or restorations replacement
62242023|NCT04592913|PLACEBO_COMPARATOR|Arm B|placebo product and FLOT chemotherapy
62242024|NCT04592913|EXPERIMENTAL|Arm A|Durvalumab and FLOT chemotherapy
62242025|NCT04426604|EXPERIMENTAL|Light induced fluorescence intraoral camera|
62242026|NCT04426604|EXPERIMENTAL|Laser-induced fluorescence device|
62242027|NCT04426604|ACTIVE_COMPARATOR|Visual-tactile assessment method according to FDI criteria|
62242028|NCT03589690|EXPERIMENTAL|Alpha Lipoic acid|Alpha lipoic acid capsules (600 mg/day)
62242029|NCT03589690|PLACEBO_COMPARATOR|Placebo|Starch-filled capsules (600 mg/day)
62818475|NCT05984121|ACTIVE_COMPARATOR|Local dextroz prolotherapy injections|"Hypertonic dextrose prolotherapy stimulates the cells at the injection site dehydrates, causing local tissue trauma, and increases macrophage and attracts granulocytes to that area and provides tissue healing. (Hauser, Ross and et al, 2016). Kesikburun Serdar et al. in 2022 with plantar fasciitis prolotherapy injection 3 times at 2 weeks intervals in their study They used a 15% dextrose prolotherapy solution."
62038967|NCT06053476|EXPERIMENTAL|Chest tube duration at least 3 days plus single-shot PVB|
62038968|NCT06053476|EXPERIMENTAL|Early chest tube removal plus TEA|
62038969|NCT06053476|EXPERIMENTAL|Early chest tube removal plus single-shot PVB|
62038970|NCT01587508|ACTIVE_COMPARATOR|meloxicam - Movatec®|
62242030|NCT00144612|EXPERIMENTAL|1|
62432474|NCT02827513|EXPERIMENTAL|Arm 4|Participants will receive XR Tablet Formulation 3 (XR3) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
62735767|NCT03962894||Early Prehospital Systemic Corticosteroids|Children with asthma attacks who receive systemic corticosteroids in the prehospital environment by emergency medical services
62735768|NCT03962894||Usual Care|Children with asthma attacks treated by emergency medical services who receive usual care en route to emergency departments, where in the ED they then receive systemic corticosteroids
62038971|NCT01587508|ACTIVE_COMPARATOR|cyclobenzaprine - Miosan®,|
62242031|NCT05581979||68-Ga PSMA PET scan|68-Ga PSMA PET scan
62242032|NCT01777087|EXPERIMENTAL|Healthy normal volunteers|Healthy normal volunteers
62242033|NCT05958368|EXPERIMENTAL|Avocado|Participants will consume 1 Hass avocado a day.
62735769|NCT03375489|EXPERIMENTAL|Telehealth|"* Patients will meet with the PC clinician in person within four weeks of enrollment~* Subsequent visits with the PC clinician will be conducted with the patients in their home or other location using video at least every four weeks~* Patients may be scheduled to meet with the PC clinician in the clinic if requested by the patient or a clinician"
62038972|NCT01587508|EXPERIMENTAL|meloxicam/cyclobenzaprine hydrochloride|
62038973|NCT02515760|EXPERIMENTAL|Lung cancer group|Bone marrow puncture in patients with non-small cell lung cancer
62038974|NCT02515760|EXPERIMENTAL|Control group (healthy donors)|Bone marrow puncture in healthy donors
62038975|NCT06722222||tandem carotid lesions|Extracranial tandem carotid lesions (TCLs) refer to two or more severe stenoses/occlusions in two or more locations in the carotid artery. TCLs are indicated for surgical intervention but are difficult to resolve by conventional carotid endarterectomy
62038976|NCT01687816||No interventions to be administered|Only a nasal swab is collected, no therapeutic interventions
62038977|NCT01568333|EXPERIMENTAL|Decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
62038978|NCT05824026|OTHER|main arm|Non comparative - One armed - open labelled Intervention - subjects will wear the test dressing in a two weeks period with planned dressing changes once pr. week.
62242034|NCT05958368|ACTIVE_COMPARATOR|Other Fruit(s)|Participants in the other fruit arm will receive other fruits.
62242035|NCT04203862|EXPERIMENTAL|1|Single administration of low dose NPC-22
62242036|NCT04203862|EXPERIMENTAL|2|Single administration of low/middle dose NPC-22
62242037|NCT04203862|EXPERIMENTAL|3|Single administration of middle dose NPC-22
62242038|NCT04203862|EXPERIMENTAL|4|Single administration of middle/high dose NPC-22
62242039|NCT04203862|EXPERIMENTAL|5|Single administration of high dose NPC-22
62242040|NCT04203862|EXPERIMENTAL|6|Single administration of placebo dose NPC-22
62735770|NCT03375489|ACTIVE_COMPARATOR|In Person PC|"* Patients will be scheduled for their first In-person PC visit within four weeks of enrollment and then at least every four weeks thereafter until the patient is no longer coming into the clinic~* PC visits will be scheduled on the same day as an oncology visit if possible"
62735771|NCT06554054|EXPERIMENTAL|Experimental: Part A (single dose)|"Drug: GZR18 tablet Three single-dose cohorts of GZR18 tablet administered according to an ascending dose design. Progression to next dose will be based on safety evaluation. Sequential cohorts.~Active Comparator: GZR18 injection Single-dose administered s.c. (under the skin)."
62735772|NCT06554054|EXPERIMENTAL|Experimental: Part B (multiple dose)|"Drug:GZR18 tablet GZR18 tablet administered as two multiple dose cohorts, to test the different meal time effect.~Parallel assignment"
62735773|NCT03672812|NO_INTERVENTION|placebo|0,5ml
62735774|NCT03672812|EXPERIMENTAL|liraglutide|0,5ml
62735775|NCT00543270|EXPERIMENTAL|Endovascular Repair - EVAR (Powerlink System)|EVAR (Powerlink System)
62038979|NCT00149513|EXPERIMENTAL|1|Targeted nurse case management
62038980|NCT00149513|ACTIVE_COMPARATOR|2|Usual Care
62242041|NCT00486876|PLACEBO_COMPARATOR|1|Placebo
62242042|NCT00486876|EXPERIMENTAL|2|100 mg BID
62242043|NCT00486876|EXPERIMENTAL|3|200 mg BID
62242044|NCT00486876|EXPERIMENTAL|4|300 mg BID
62242045|NCT06102603|EXPERIMENTAL|the biobased polyester cast group|biobased polyester cast was applied
62242046|NCT06102603|ACTIVE_COMPARATOR|the synthetic fiberglass cast group|synthetic fiberglass cast was applied
62242047|NCT06604442|EXPERIMENTAL|piflufolastat (18F) and flotufolastat (18F) positron emission tomography (PET)|Each patient will be administered a single dose of piflufolastat (18F) on Day 1, followed by a PET scan. At least 24 hours after the piflufolastat (18F) scan, but within 10 calendar days, all patients will be administered a single dose of flotufolastat (18F) followed by a PET scan.
62242048|NCT06650995|EXPERIMENTAL|Intervention Group|This group receives exercise training
62242049|NCT06650995|NO_INTERVENTION|Control Group|This group does not receive exercise training
62432475|NCT05502068|EXPERIMENTAL|Vitamin D 25 (OH) 12000 IU, Sublingual sprayable microemulsion|Vitamin D in the form of a sublingual sprayable microemulsion (4000 IU) will be given three times daily after breakfast, lunch, and dinner (daily dose 12,000 IU) to patients with blood vitamin D levels below 30 ng/ml for 5-day intervention
62735776|NCT00543270|ACTIVE_COMPARATOR|Open Surgical Control|Open Surgical Control
62038981|NCT00898885||Bone Marrow Transplantation|
62038982|NCT05036044||With moderate or severe carotid-cerebral artery disease|moderate (stenosis 50-69%) or severe (stenosis 70-100%) carotid-cerebral artery disease
62038983|NCT05036044||Without moderate or severe carotid-cerebral artery disease|mild (stenosis 30-49%) or no (stenosis 0-29%) carotid-cerebral artery disease
62038984|NCT02264028|ACTIVE_COMPARATOR|[14C]-DK-AH 269 CL intravenous|
62038985|NCT02264028|EXPERIMENTAL|[14C]-DK-AH 269 CL oral|
62242050|NCT01123954|OTHER|Arm 1|
62242051|NCT04822168|ACTIVE_COMPARATOR|Standard Care|Standard Care through detox-based opioid treatment with B/N and weekly urine toxicology screening
62242052|NCT04822168|EXPERIMENTAL|MySafeRx™ Intervention|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of B/N medication within a secure medication storage device, and a standardized protocol for supervising self-administration of medication via videoconferencing.
62242053|NCT01970488|EXPERIMENTAL|ABP 501|"Participants received 80 mg ABP 501 subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~Participants with a PASI 50 response at week 16 continued to receive 40 mg APB 501 until week 48."
62242054|NCT01970488|ACTIVE_COMPARATOR|Adalimumab|"Participants received 80 mg adalimumab subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~At week 16 participants with a PASI 50 response were re-randomized to treatment with adalimumab or were transitioned to ABP 501 until week 48."
62242055|NCT01255852|EXPERIMENTAL|Atorvastatin group|Patients in atorvastatin group will received 40 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
62242056|NCT01255852|NO_INTERVENTION|Control group|Patients in control group will receive 20mg atorvastatin daily treatment.
62242057|NCT02150330|ACTIVE_COMPARATOR|DHEAS in DOR Group|Additional usage of DHEAS supplement in patients with DOR under ovarian hyper-stimulation protocol.
62242058|NCT02150330|ACTIVE_COMPARATOR|Normal Control|Patients under ovarian hyper-stimulation protocol. No DHEAS supplement.
62242059|NCT02150330|ACTIVE_COMPARATOR|Shame DOR Group|Patients with DOR under ovarian hyper-stimulation protocol. No DHEAS supplement.
62735777|NCT04839458|EXPERIMENTAL|Dental Prescale II used|
62735778|NCT02036710||Cecum|Food hydrolysate instilled into terminal cecum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin.
62735779|NCT02036710||Ileum|Food hydrolysate instilled into terminal ileum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin.
62735780|NCT05953597|EXPERIMENTAL|Nutrition Education Group|Participants in this study arm will receive nutrition education once a month for 12 months.
62735781|NCT06264466|EXPERIMENTAL|POEM with Speedboat Ultraslim|Participants aged 18-years and above, referred to the participating center (IECED) with a diagnosis of achalasia and indication for POEM, POEM procedures will be performed using the Speedboat UltraSlim
62038986|NCT03252392||children with autism spectrum disorder|Children aged 3-12 years diagnosed to have mild to moderate autism spectrum disorder diagnosed by childhood autism spectrum disorder(CARS 35% or less)
62038987|NCT03252392||healthy non autistic age matched volunteers|children aged 3-12 years old never diagnosed to have autism spectrum disorder
62038988|NCT01464541|EXPERIMENTAL|orbital fractures size|patients who undergo surgical repair of orbital fracture with measuring the fracture size intraoperatively and had available orbital Ct scan preoperatively.
62038989|NCT05198830|EXPERIMENTAL|Arm I (methoxyamine, usual care)|Patients receive methoxyamine PO on day 1 of each cycle, pemetrexed IV over 10 minutes on day 1 of each cycle, and cisplatin IV over 60 minutes or carboplatin IV over 30 minutes on day 3 of each cycle. Beginning day 3, patients also undergo radiation therapy daily Monday-Friday. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after cycle 2, patients receive durvalumab IV over 60 minutes every 2 weeks or monthly for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI throughout the trial and FDG-PET/CT scan during screening and optionally on study.
62038990|NCT05198830|ACTIVE_COMPARATOR|Arm II (usual care)|Patients receive pemetrexed IV over 10 minutes and cisplatin IV over 60 minutes or carboplatin IV over 30 minutes on day 1 of each cycle. Beginning day 1 of each cycle, patients also undergo radiation therapy daily Monday-Friday. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after cycle 2, patients receive durvalumab IV over 60 minutes every 2 weeks or monthly for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI throughout the trial and FDG-PET/CT scan during screening and optionally on study.
62242060|NCT04212988|EXPERIMENTAL|the trial group|The interwention process will be started once the SCO2 value below ideal levels (80% of the basic level or 50% of absolute value), by adjusting the position of extracorporeal circulation arteriovenous catheter, balancing arterial pressure, increasing oxygen supply , adjusting pump speed ,etc.
62432476|NCT05502068|PLACEBO_COMPARATOR|Placebo|Placebo will be given to the control group. It will be administrated sublingually, with one spray three times per day for 5 days of the study period
62242061|NCT04212988|PLACEBO_COMPARATOR|the control group|In control group patients, only place the probe for NIRS monitor.
62242062|NCT05010954|EXPERIMENTAL|LXI-15028 50mg group(n=200)|
62242063|NCT05010954|ACTIVE_COMPARATOR|Lansoprazole 30mg group (n=200)|
62432477|NCT03768609|EXPERIMENTAL|Group 1: Sequence AB|Participants will receive Treatment A (pimodivir 600 milligram \[mg\] orally as two tablets of 300 mg each) on Day 1 in Period 1 followed by Treatment B (pimodivir 600 mg as two tablets of 300 mg each plus cyclosporine 400 mg orally as four capsules of 100 mg each) on Day 1 in Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 14 days.
62432478|NCT03768609|EXPERIMENTAL|Group 2: Sequence BA|Participants will receive Treatment B on Day 1 in Period 1 followed by Treatment A on Day 1 in Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 14 days.
62432479|NCT03459781|EXPERIMENTAL|Cognitively-Based Compassion Training|Cancer survivors and their informal caregivers (family and close friends), one of whom has at least mild depression and/or anxiety features (determined by PROMIS Depression 4a and PROMIS Anxiety 4a, respectively) who are randomized to CBCT®.
62432480|NCT03459781|ACTIVE_COMPARATOR|CHE (Cancer Health Education)|Cancer survivors and their informal caregivers (family and close friends), one of whom has at least mild depression and/or anxiety features (determined by PROMIS Depression 4a and PROMIS Anxiety 4a, respectively) who are randomized to CHE.
62242064|NCT03818087||Elevate|Participants over the age of 70 years old with early-stage breast cancer will be recruited.
62242065|NCT05452850||Light Chain Cardiac Amyloidosis|Participants with light chain cardiac amyloidosis actively receiving chemotherapy or undergoing autologous bone marrow transplant
62242066|NCT04094896|EXPERIMENTAL|Arm A: TCHP|docetaxel/carboplatin/trastuzumab/Pertuzumab
62242067|NCT04094896|ACTIVE_COMPARATOR|Arm B: EC-THP|epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab
62242068|NCT05183048|EXPERIMENTAL|[89Zr]panitumumab-PET/MRI patients|All study patients will receive \[89Zr\]Panitumumab-PET/MRI imaging.
62242069|NCT03463733|EXPERIMENTAL|Daily hydroxyurea and temozolomide|"Hydroxyurea and temozolomide will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. Oral hydroxyurea (dose specified by the Dose Cohort below) and oral temozolomide (50 mg/m2/day) will be administered daily in 28-day cycles for 12 cycles or until unacceptable toxicity, intolerance, progressive disease, or withdrawal of consent. Patients will be treated in dose cohorts of 3 with each cohort receiving a specific daily dose assignment of hydroxyurea.~All patients in the study will receive temozolomide at 50 mg/m2/day (dose-intense schedule). The starting dose level for hydroxyurea will be 200 mg daily (QD) up to a maximum of 2000mg hydroxyurea a day."
62242070|NCT01479933|EXPERIMENTAL|Vitamin D 40|Vitamin D3 40 micrograms (1600 IU) per day
62432481|NCT04317833|EXPERIMENTAL|Dose Escalation SSS17|Escalating doses of SSS17; single dose administration; different dosage forms (redosing of the SSS17 in one cohort with food on Day15)
62432482|NCT04317833|PLACEBO_COMPARATOR|Escalation matching Placebo|Escalating doses of matching placebo; single dose administration; different dosage forms (redosing of matching placebo in one cohort with food on Day15)
62432483|NCT03634332|EXPERIMENTAL|PEGPH20 plus Pembrolizumab|All patients will receive treatment with PEGPH20 3 micrograms/kg IV weekly x 3, and pembrolizumab 200 mg IV every 3 weeks, in 3-week cycles.
62432484|NCT03078803|EXPERIMENTAL|Fecal microbiota transplant|Transfer of healthy human gut bacteria
62599408|NCT04157127|EXPERIMENTAL|Autologous DC Vaccine Cohort 4|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.~DC Vaccine dose evaluated in Cohort 4:~1. st vaccine - 8 million cells~2. nd vaccine - 12 million cells~3. rd vaccine - 16 million cells~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
62242071|NCT01479933|EXPERIMENTAL|Vitamin D 80|Vitamin D3 80 micrograms (3200 IU) per day
62242072|NCT01479933|PLACEBO_COMPARATOR|Placebo|
62242073|NCT02690779|EXPERIMENTAL|Patients watching educational video|The educational intervention will consist of a 2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration. This video will be posted on YouTube. Group 1 will consist of 30 subjects who will be instructed to view this video prior to beginning their colonoscopy preparation. Information to access the YouTube video will be provided to the patients by endoscopy nurse assessment staff when contacting the patients as per standard practice to review appointment scheduling and procedure-day logistics.
62242074|NCT02690779|SHAM_COMPARATOR|Patients not watching educational video|Group 2 will consist of 30 subjects who will not receive instructions to view the video. They will be given routine care instructions for bowel prep.
62242075|NCT04406623|EXPERIMENTAL|SL-172154|Intravenous administration
62242076|NCT06375434||Radiosensitive group|
62432485|NCT03078803|PLACEBO_COMPARATOR|Placebo|Water
62432486|NCT02926391||Cervical|30 patients who need anterior cervical corpectomy and fusion with patient-specific implants (UNiD 3D VBR)
62432487|NCT02926391||Thoraco-lumbar|30 patients who need anterior thoracolumbar corpectomy and fusion with patient-specific implants (UNiD 3D VBR)
62432488|NCT01536691|EXPERIMENTAL|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
62242077|NCT06375434||The radiotherapy-insensitive group|
62242078|NCT05845216|EXPERIMENTAL|ACTIVE tPBM|one session of 24-min tPBM with the active device (tPBM helmet with 80 Light-Emitting Diodes (LEDs) emitting red and near-infrared light at 670 - 810nm)
62242079|NCT05845216|SHAM_COMPARATOR|SHAM tPBM|one session of 24-tPBM with a sham device visually identical to the active device
62432489|NCT01536691|ACTIVE_COMPARATOR|ondansetron, aprepitant, dexamethasone|ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
62038991|NCT06005233|EXPERIMENTAL|Application of Smartwatch|Application of smartwatch in addition to an implanted event recorder. Follow-up of 6 months
62432490|NCT03292965|ACTIVE_COMPARATOR|Neostigmine|"At the end of surgery, administrating neostigmine to participants according to the protocol below:~when train-of-four (TOF) 2-3, administrating neostigmine 50mcg/kg when TOF 4 with fade, administrating neostigmine 40mcg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg"
62038992|NCT02630628|EXPERIMENTAL|Tacrolimus|route: oral duration: 96 weeks
62242080|NCT02066051|EXPERIMENTAL|IPL Treatment|Subjects who had inactive chronic graft versus host disease (GVHD) after allogeneic bone marrow transplantation and severe dry eye symptoms related to ocular rosacea unresponsive to conventional management were recruited. Subjects were treated with 4 monthly sessions of intense pulsed light (IPL) and meibomian gland expression.
62242081|NCT04357145|ACTIVE_COMPARATOR|Standard Exercise Group|Exercise training is given to patients in the form of a home exercise program.
62242082|NCT04357145|EXPERIMENTAL|High Dosage Exercise Group|The high dosage exercise training group will implement the recommended exercise program 3 times more than the standard exercise group.
62242083|NCT05432869|EXPERIMENTAL|Electrical stimulation (ES) group|ES group will be given additional external electrical stimulation to the lifestyle advices.
62432491|NCT03292965|ACTIVE_COMPARATOR|Sugammadex|"At the end of surgery, administrating sugammadex to participants according to the protocol below:~when TOF=0 and post-tetanic count (PTC)=1 or more, administrating sugammadex 4mg/kg when TOF=1 or more, administrating sugammadex 2mg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg"
62432492|NCT05992649|EXPERIMENTAL|Aquatic physiotherapy treatment in warm water|The participant is placed supine in the water, supported by the physiotherapist as well as aqua noodles. The physiotherapist supports and moves the participant in the water and adapts to the participant's reaction.
62432493|NCT03787108||Children with suspected NAFLD|Children with overweight or obesity. Both children that are and children that are not suspected of having NAFLD (based on ultrasound and laboratory findings) are included.
62432494|NCT02515357|PLACEBO_COMPARATOR|Control group|This arm will receive standard care, i.e. CPAP prescription and brief written healthy lifestyle advice.
62432495|NCT02515357|EXPERIMENTAL|Mediterranean lifestyle group|This arm will receive a hypocaloric diet and attend a comprehensive 6-month lifestyle intervention based on the Mediterranean lifestyle on top of standard care.
62432496|NCT02515357|EXPERIMENTAL|Mediterranean diet group|This arm will receive a hypocaloric diet and attend a comprehensive 6-month dietary intervention based on the Mediterranean dietary pattern on top of standard care.
62432497|NCT06043999|EXPERIMENTAL|Salvage adjuvant chemoradiotherapy group|"Patitents under local radical resection of rectal adenocarcinoma received:~1. Concurrent adjuvant chemotherapy~2. Adjuvant radiotherapy: long-course radiotherapy was planned in this study."
62432498|NCT06043999|ACTIVE_COMPARATOR|Radical TME group|"Patitents under local radical resection of rectal adenocarcinoma received:~Standard TME surgery was performed 3-4 weeks after local resection."
62432499|NCT01809795|EXPERIMENTAL|Blueberry Smoothie|Participants in this group will receive a smoothie containing 1 1/2 cups of freeze-dried whole blueberries crushed into a powder.
62432500|NCT01809795|SHAM_COMPARATOR|Sham Smoothie|Participants in this group will receive a smoothie that contains no blueberries.
62432501|NCT01512784|EXPERIMENTAL|HIV-infected adolescents and young adults|female and male HIV-infected subjects aged from 13-27 years old
62432502|NCT01512784|ACTIVE_COMPARATOR|healthy adolescents and young adults|female and male healthy adolescents and young adults aged 13-27 years
62432503|NCT01682473|EXPERIMENTAL|Arm 1: 5/2 Dosing|Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 5 days on drug and 2 days off drug.
62432504|NCT01682473|EXPERIMENTAL|Arm 2: 21/7 Dosing|Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 21 days on drug and 7 days off drug.
62432505|NCT02521454|EXPERIMENTAL|MBRT|Mindfulness-Based Resilience Training
62432506|NCT02521454|NO_INTERVENTION|WL Control|waitlist control group
62432507|NCT05487872|OTHER|Audio-guided mindfulness skills training|Participants in this group listened to a 15 mins audio track to practice mindfulness exercises
62038993|NCT02630628|ACTIVE_COMPARATOR|Mycophenolate Mofetil|route: oral duration: 96 weeks
62038994|NCT06118411|EXPERIMENTAL|Study 1, Period A: Group 1|Participants will receive upadacitinib 15 mg once daily for 48 weeks.
62038995|NCT06118411|PLACEBO_COMPARATOR|Study 1, Period A: Group 2|Participants will receive placebo once daily for 48 weeks.
62038996|NCT06118411|EXPERIMENTAL|Study 2, Period A: Group 1|Participants will receive upadacitinib 15 mg once daily for 48 weeks.
62038997|NCT06118411|PLACEBO_COMPARATOR|Study 2, Period A: Group 2|Participants will receive placebo once daily for 48 weeks.
62038998|NCT06118411|EXPERIMENTAL|Study 1, Period B: Group 1 Open-Label Extension Period|Participants that were randomized to receive upadacitinib in Period A Group 1, will continue to receive upadacitinib 15 mg once daily for 112 weeks in Period B.
62038999|NCT06118411|EXPERIMENTAL|Study 1, Period B: Group 2 Open-Label Extension Period|Participants that were randomized to receive placebo in Period A Group 2, will receive upadacitinib 15 mg once daily for 112 weeks in Period B.
62039000|NCT06118411|EXPERIMENTAL|Study 2, Period B: Group 1 Open-Label Extension Period|Participants that were randomized to receive upadacitinib in Period A Group 1, will continue to receive upadacitinib 15 mg once daily for 112 weeks in Period B.
62039001|NCT06118411|EXPERIMENTAL|Study 2, Period B: Group 2 Open-Label Extension Period|Participants that were randomized to receive placebo in Period A Group 2, will receive upadacitinib 15 mg once daily for 112 weeks in Period B.
62039002|NCT06118411|EXPERIMENTAL|(Optional) Study 3, Period B: Open Label Upadacitinib|Open Label Upadacitinib Participants will receive upadacitinib 15 mg once daily for 112 weeks
62242084|NCT05432869|EXPERIMENTAL|Control group|Control group will be given only lifestyle advices .
62432508|NCT05487872|EXPERIMENTAL|Virtual reality (VR) -based mindfulness skills training|Participants in this group completed mindfulness exercises on the VR system. The system included the same 15 mins audio track and additionally a video that displayed a 360° spherical landscape view of the sea in the afternoon
62432509|NCT04071366|EXPERIMENTAL|Part 1: Open Label Itacitinib Once Daily|During Part 1, all participants receive itacitinib 200mg once daily (open label) for 30 days. The study population will include participants receiving any approved IEC for an approved indication.
62599409|NCT03320850|EXPERIMENTAL|100U cohort - BOTOX® plus Hydrogel admixture|100U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
62599410|NCT03320850|PLACEBO_COMPARATOR|100U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
62599411|NCT03320850|EXPERIMENTAL|300U cohort - BOTOX® plus Hydrogel admixture|300U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
62599412|NCT03320850|PLACEBO_COMPARATOR|300U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
62599413|NCT03320850|EXPERIMENTAL|400U cohort - BOTOX® plus Hydrogel admixture|400U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
62599414|NCT03320850|PLACEBO_COMPARATOR|400U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
62599415|NCT03320850|EXPERIMENTAL|500U cohort - BOTOX® plus Hydrogel admixture|500U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
62599416|NCT03320850|PLACEBO_COMPARATOR|500U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
62599417|NCT05163821||Participants|Somali migrants in UK, aged over 50.
62599418|NCT03647735|EXPERIMENTAL|Group PCS|Patients in Group PCS (patient-controlled sedation) received intravenous (IV) propofol via a patient controlled analgesia (PCA) infusion pump. The machine was set to deliver a demand bolus dose of 0.25 mg/kg with 1-minute lockout interval, without basal infusion.The patient was instructed to press on a hand-held device as often as required, to achieve their desired level of comfort or sedation.
62599419|NCT03647735|ACTIVE_COMPARATOR|Group TCIS|Patients in Group TCIS (target-controlled infusion sedation) received IV propofol via a target-controlled infusion (TCI) pump, targeted at an initial effect site concentration (Cet) of 0.6 μg/ml, using the Schnider pharmacokinetic model. Upon attainment of 0.6 μg/ml Cet, the patient's sedation level was assessed. The Cet was increased or reduced accordingly by 0.2 μg/ml to attain an OAA/S score of 3.
62599420|NCT04283292|EXPERIMENTAL|Capsaicin|capsaicin 0.075% cream applied once topically
62039003|NCT06118411|EXPERIMENTAL|(Optional) Study 3:|Participants will receive 15 mg upadacitinib once daily for 112 weeks and NB-UVB for up to 28 weeks
62432510|NCT04071366|EXPERIMENTAL|Part 2: Double-Blind Itacitinib Twice Daily|During Part 2, participants will be randomized to receive itacitinib 200mg or placebo twice daily for 30 days. The study population also includes participants who are receiving Yescarta for relapsed or refractory large B-cell lymphoma or follicular lymphoma.
62432511|NCT05758779|EXPERIMENTAL|Coronary CT scan visualized for patient|The patient is allowed to see the CT image of his/hers coronary vessels, including oral describtion of the findings.
62432512|NCT05758779|NO_INTERVENTION|Coronary CT scan NOT visualized for patient|The patient is not allowed to see the CT image of his/hers coronary vessels.
62432513|NCT01073059|EXPERIMENTAL|Valproic acid|
62599421|NCT04283292|ACTIVE_COMPARATOR|Placebo|placebo cream applied once topically
62599422|NCT06620783|ACTIVE_COMPARATOR|exercise program group|Those in the exercise program group will access and undertake the exercise program on a web or mobile platform for approximately 50 minutes per session, three times a week, for a total of 12 sessions over 4 weeks.
62599423|NCT06620783|ACTIVE_COMPARATOR|yoga program group|The yoga program group will access and perform the yoga program on a web or mobile platform for approximately 50 minutes per session, three times a week, for a total of 12 sessions over 4 weeks.
62599424|NCT06620783|SHAM_COMPARATOR|self-care group|The self-care group will access materials helpful for stress management via a web or mobile platform and engage in self-study three times a week, for a total of 12 sessions over 4 weeks.
62599425|NCT00453674||Adrenocortical carcinoma|Adrenocortical carcinoma
62599426|NCT04561102||COVID-19 asymptomatic population|COVID-19 asymptomatic Rollins College community
62599427|NCT00559780|EXPERIMENTAL|1|12 weeks of resistance training
62599428|NCT00559780|EXPERIMENTAL|2|12 weeks of neuromuscular electrical stimulation
62039004|NCT06733285|EXPERIMENTAL|Test Toothpaste|Participants will dose the toothbrush with a ribbon of test toothpaste, across the full brush head and brush the entire dentition thoroughly for at least 1-timed minute, twice daily (morning and evening) for 2 weeks, making sure to brush the sensitive areas of the two 'test teeth' carefully first.
62039005|NCT06733285|ACTIVE_COMPARATOR|Regular Fluoride Toothpaste (Negative Control)|Participants will dose the toothbrush with a ribbon of regular fluoride toothpaste, across the full brush head and brush the entire dentition thoroughly for at least 1-timed minute, twice daily (morning and evening) for 2 weeks.
62039006|NCT01106105||control (Body Mass Index < 25)|
62039007|NCT01106105||Obese (Body Mass Index > 35)|
62039008|NCT06240442|EXPERIMENTAL|Fasted Exercise|Exercise followed by breakfast
62039009|NCT06240442|EXPERIMENTAL|Fed Exercise|Breakfast followed by exercise
62039010|NCT06701539|EXPERIMENTAL|Liposome bupivacaine group|
62039011|NCT06701539|ACTIVE_COMPARATOR|Ropivacaine group|
62039012|NCT01887938|EXPERIMENTAL|Cohort 1|Participants will receive 10 milligram (mg) of HGT-1110 (Recombinant human arylsulfatase A) intrathecal (IT) injection every-other-week (EOW).
62039013|NCT01887938|EXPERIMENTAL|Cohort 2|Participants will receive 30 mg of HGT-1110 IT injection EOW.
62039014|NCT01887938|EXPERIMENTAL|Cohort 3|Participants will receive 100 mg of HGT-1110 IT injection EOW.
62242085|NCT04871165||Oncohematological patient group|Patients with prior diagnosis of oncohematological disease vaccinated with SARS-CoV-2 vaccine.
62242086|NCT04871165||Healthy control group|Subjects without prior diagnosis of oncohematological disease vaccinated with SARS-CoV-2 vaccine.
62432514|NCT00320593|ACTIVE_COMPARATOR|Progressive addition lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
62599429|NCT00559780|OTHER|3|12 weeks of standard rehabilitation
62599430|NCT01765244|EXPERIMENTAL|Anterior lamellar nanostructured artificial human cornea|Anterior lamellar nanostructured artificial human cornea with allogenic from dead donor and cultured in its inside and allogeneic corneal epithelium cultured in its surface
62599431|NCT01765244|ACTIVE_COMPARATOR|Amniotic membrane transplantation|Amniotic membrane transplantation as conventional treatment of corneal trophic ulcers.
62599432|NCT02631460|EXPERIMENTAL|S1 and Carboplatin|S1 80-120 mg/d+Carboplatin AUC=5 Patients without progression received maintenance until disease progression with S1
62599433|NCT02631460|ACTIVE_COMPARATOR|pemetrexed and Carboplatin|pemetrexed 500 mg/m2+ Carboplatin AUC=5 Patients without progression received maintenance until disease progression with pemetrexed
62039015|NCT01887938|EXPERIMENTAL|Cohort 4|Participants will receive 100 mg of HGT-1110 IT injection once weekly for 12 weeks followed by 150 mg EOW.
62039016|NCT05338970|EXPERIMENTAL|Patritumab deruxtecan|Participants who will be randomized to receive patritumab deruxtecan (HER3-DXd) 5.6 mg/kg q3W.
62039017|NCT05338970|ACTIVE_COMPARATOR|Platinum-based chemotherapy|Participants who will be randomized to receive platinum-based chemotherapy for 4 cycles: pemetrexed plus either cisplatin or carboplatin. Participants without disease progression after 4 cycles of platinum plus pemetrexed therapy may continue treatment with maintenance pemetrexed with no restriction on the number of cycles.
62039018|NCT05388370||Base Cohort|The Base Cohort includes all enrolled patients aged 3 to \< 18 years.
62039019|NCT05388370||Nested Prospective Cohort|The Nested Prospective Cohort will include the subset of Base Cohort patients aged 8 to \< 18 years who have not reached Tanner Stage V on the index date
62242087|NCT00772213|EXPERIMENTAL|MIGTS treatment|controlled trial (quasi-randomized) versus controls (=conventional treatment not in the MIGTS)
62242088|NCT00772213|NO_INTERVENTION|controls (=conventional treatment not in the MIGTS)|
62242089|NCT00595023||1|All eligible subjects
62242090|NCT04165590|EXPERIMENTAL|Blood-stage infection of P.vivax|This is a single arm study that is planed to enroll 60 patients with advanced malignant solid tumor and each patient will be vaccinated with P.vivax-infected red blood cells containing approximately 0.1-1.0 × 10\^7 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 5-10 weeks from the day of successful infection and will be terminated by antimalarial drugs.
62599434|NCT02563262|OTHER|body angles measurements during weightlessness|body angles : ankle, knee, hip, shoulder, elbow, wrist, and neck.
62599435|NCT01825356|ACTIVE_COMPARATOR|Dorsal Cheilectomy no Amniotic Membrane Tissue Implantation|Dorsal cheilectomy is a surgery for hallux rigidus(degenerative arthritis and stiffness due to bone spurs that affect the joint at the base of the big toe). No amniotic membrane will be used for this group.
62735782|NCT04522882|EXPERIMENTAL|At home clinical data collection|Clinical data will be collected during 7 days: physical activity, sleep duration, chronotype, food and medication intake, glucose level and insulin administration.
62432515|NCT00320593|ACTIVE_COMPARATOR|Single vision lenses (SVLs)|Single vision lenses
62432516|NCT01481831|ACTIVE_COMPARATOR|H PALO day 1|Highly Emetogenic Arm, Palonosetron 0.25mg IV\*1 dose on day 1
62432517|NCT01481831|EXPERIMENTAL|H PALO day 1,3,5|Highly Emetogenic Arm, Palonosetron 0.25mg IV\*3 doses on days 1,3 and 5
62432518|NCT01481831|ACTIVE_COMPARATOR|M PALO day 1|Moderately Emetogenic Arm, Palonosetron 0.25mg IV\*1 dose on day 1
62432519|NCT01481831|EXPERIMENTAL|M PALO day 1,3,5|Moderately Emetogenic Arm, Palonosetron 0.25mg IV\*3 doses on days 1,3 and 5
62432520|NCT04235231|EXPERIMENTAL|Lateral tilt bed|Bed tilting (15° lateral tilt, original product brand name LINET Eleganza 5)
62242091|NCT02606461|EXPERIMENTAL|Phase 2 Double-blinded: Selinexor|Participants received a fixed blinding dose of 60 milligrams (mg) selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until progressive disease (PD).
62818476|NCT05984121|OTHER|Exercise Group (Control Group)|"Patients in the exercise group were treated as in the other groups during the treatment period.~plantar fascia stretching exercises, gastrocsoleus stretching exercises, foot intrinsic muscle strengthening exercises will be taught 2 times a day 10 times each will be asked to do so. In a systematic review by Siriphorn et al. fascia stretching exercises and gastrocsoleus stretching exercises in plantar fasciitis There is evidence that it is effective. The control group was given exercise therapy We aimed to ensure that the control group was not left untreated. in case of cold application and NSAIDs other than paracetamol will be asked not to take medication."
62818477|NCT05983965|EXPERIMENTAL|Cohort A|T-cell Lymphomas
62818478|NCT00558142|ACTIVE_COMPARATOR|1|Healthy volunteers will be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
62242092|NCT02606461|EXPERIMENTAL|Phase 3 Double-blinded: Selinexor|Participants received a fixed blinding dose of 60 mg selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD.
62242093|NCT02606461|PLACEBO_COMPARATOR|Phase 2 Double-blinded: Placebo Followed by Open Label- Selinexor|Participants received a fixed blinding dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD in double-blinded treatment period. Participants in the placebo group who had PD during the Phase 2 double-blinded treatment, will be elected to cross over to open-label selinexor.
62242094|NCT02606461|PLACEBO_COMPARATOR|Phase 3 Double-blinded: Placebo Followed by Open Label- Selinexor|Participants received a fixed blinding dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD or development of unacceptable toxicity. Participants in the placebo group who had PD during the Phase 3 double-blinded treatment, will be elected to cross over to open-label selinexor.
62242095|NCT04687150|ACTIVE_COMPARATOR|The study group|The study group with newly diagnosed active ulcerative colitis receive an FMT via colonoscopy from a tested general donor, frozen and thawed from a fecal bank at week 0 and at week 4 as an enema at the study nurse´s visit
62242096|NCT04687150|PLACEBO_COMPARATOR|The control group|The control group will be given colored water at same timepoints
62432521|NCT04235231|EXPERIMENTAL|Body positioning|Manual positioning of body by nurse.
62818479|NCT00558142|ACTIVE_COMPARATOR|2|Volunteers with CKD III will be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
62818480|NCT00558142|ACTIVE_COMPARATOR|3|Healthy volunteers will receive a single IV dose of 100mls Visipaque 320 (iodixanol, equivalent to 320 mg iodine/ml). They will then be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
62818481|NCT00558142|ACTIVE_COMPARATOR|4|Volunteers with CKD III will receive Visipaque 320 during coronary angiography. They will have been randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
62818482|NCT02197884|EXPERIMENTAL|Itraconazole + JNJ-54861911 (Part 1)|Single dose of JNJ-54861911, 25 milligram (mg) tablet orally on Day 1 and Day 9 along with itraconazole 200 mg (2\*100 mg capsule) orally once daily from Day 5 to Day 12.
62818483|NCT02197884|EXPERIMENTAL|Clarithromycin + JNJ-54861911 (Part 2)|Single dose of JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9 along with clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
62818484|NCT03600233|EXPERIMENTAL|CVM-1118|CVM-1118 200mg or 300mg Bis In Die (BID) daily/ Cycle (28 days per cycle)
62039020|NCT05289726|EXPERIMENTAL|Traditional chinese medicine TDX105|"* Experimental group Traditional chinese medicine TDX105 (Dissolve in warm water and then dilute to 600ml and soak hands and feet for 30 minutes each time, once in the morning and evening every day, until the end of the first 8 weeks of treatment with regorafenib)~* Basic care was the same in both groups, including routine care such as topical use of urea ointment"
62242097|NCT05398510|EXPERIMENTAL|Treatment for intravenously/subcutaneously|Treatment for intravenously: 6 dose groups； Treatment for subcutaneously: 3 dose groups.
62242098|NCT05398510|PLACEBO_COMPARATOR|Placebo for intravenously/subcutaneously|Treatment for intravenously: 6 dose groups； Treatment for subcutaneously: 3 dose groups.
62818485|NCT06541028|EXPERIMENTAL|PWID in Malaysia- General Population|Participants will receive the RS-START strategy (RS-START strategy will be informed and developed in Aims 1 and 2) from prescribing physicians. Participants will complete a survey to assess their experiences with stigma, health behaviors, and other related constructs at baseline, month 1, month 3 and month 6. Data from viral load that are obtained as part of participants' standard of care will be obtained through medical record review.
62242099|NCT01494350|EXPERIMENTAL|WR 279,396 topical cream|120 subjects will be enrolled to this open label study to receive WR 279,396 topical cream
62242100|NCT06026683|ACTIVE_COMPARATOR|CSP (Conduction system pacing)|Patients with pacemaker implanted with conduction system pacing.
62242101|NCT06026683|ACTIVE_COMPARATOR|RVAP (Right ventricular apical pacing)|Patients with pacemaker implanted with right ventricular apical pacing.
62432522|NCT04933669|EXPERIMENTAL|Imatinib neoadjuvant|Patients receive oral imatinib mesylate 400mg once daily for 3-12 months in the absence of disease progression or unacceptable toxicity. Within 1 week after completion of preoperative imatinib mesylate, patients with responding or stable disease undergo surgical resection. After complete resection, patients receive oral imatinib mesylate 400mg once daily for 36 months in the absence of disease progression or unacceptable toxicity, and are followed for 5 years.
62432523|NCT04568369|EXPERIMENTAL|Treatment group|Patients will engage in a four-week treatment protocol (20 treatments). This was chosen as it is the midpoint between typical depression and migraine protocol durations. A standardized atlas brain with Montreal neurologic institute (MNI) coordinates will be used for navigation. The DLPFC will be located through MNI coordinates (-50, 30, 36). The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, with a frequency of 10 Hz, 10 trains of 60 pulses/train (total of 600 pulses) and an inter-train interval of 45s.
62818486|NCT06541028|EXPERIMENTAL|PWID in Malaysia- Prisoners|Participants will receive the RS-START strategy (RS-START strategy will be informed and developed in Aims 1 and 2). Participants will complete a survey to assess their experiences with stigma, health behaviors, and other related constructs at baseline, month 1, month 3 and month 6. Data from viral load that are obtained as part of participants' standard of care will be obtained through medical record review.
62039021|NCT05289726|PLACEBO_COMPARATOR|placebo|"The control group received placebo granules mixed with dextrin and food coloring (Dissolve in warm water and then dilute to 600ml and soak hands and feet for 30 minutes each time, once in the morning and evening every day, until the end of the first 8 weeks of treatment with regorafenib)~- Basic care was the same in both groups, including routine care such as topical use of urea ointment"
62599436|NCT01825356|EXPERIMENTAL|Dorsal Cheilectomy-Amniotic Membrane Tissue Implantation|Dorsal cheilectomy procedure with the addition of the amniotic membrane. Amniotic membrane represents a biologic therapy that has the ability to actively regulate myrofibroblast formation and activity within the joint space and surgical site
62599437|NCT06648369|OTHER|Control arm (usual care)|Control group is treated according to local standard of care
62818487|NCT01614249|PLACEBO_COMPARATOR|Soybean oil soft gels|Participants on this arm will receive a dietary supplement of OmegaVia soybean oil soft gels as a placebo for 8 weeks with bi-weekly follow-up visits to monitor side effects and compliance.
62818488|NCT01614249|EXPERIMENTAL|Fish oil omega-3 EPA-rich soft gels|Participants will receive OmegaVia fish oil omega-3 EPA-rich soft gels to take orally for eight (8) weeks with bi-weekly follow-up visits for monitoring of side effects and compliance and data collection.
62818489|NCT03125928|EXPERIMENTAL|Investigational Arm|
62818490|NCT02633059|EXPERIMENTAL|Treatment (ixazomib citrate, idasanutlin, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and idasanutlin PO QD on days 1-5 every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive dexamethasone PO on days 1, 8, 15, and 22 every 28 days for 12 courses at the discretion of the treating physician.
62818491|NCT02192515|EXPERIMENTAL|APD356 10 mg|Subjects will be randomized to APD356 10 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug.
62818492|NCT02192515|EXPERIMENTAL|APD356 20 mg|Subjects will be randomized to APD356 20 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug.
62818493|NCT02192515|EXPERIMENTAL|APD356 XR-20 mg|Subjects will be randomized to APD356 XR-20 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug on Day 1 and multiple doses of study drug on Day 8-14 once daily before breakfast.
62039022|NCT02362529|EXPERIMENTAL|Minocycline|The dose of minocycline would be 50mg per day on week 1, 50mg bid on week 2 and 100mg bid weeks 3-8. For tapering, the dose will be reduced to 50mg bid for a week, and then stopped.
62039023|NCT02362529|PLACEBO_COMPARATOR|Placebo|The number and appearance of the pills would be identical to those in the minocycline arm.
62599438|NCT06648369|EXPERIMENTAL|Experimental arm (MAX-ICH care bundle)|Experimental group is treated according MAX-ICH care bundle
62818494|NCT02192515|EXPERIMENTAL|APD356 10 mg and APD356 XR-20mg (orange tablet)|"Subjects will be randomized to Sequence A (8 subjects) or Sequence B (8 subjects) to receive study drug in the sequence shown below.~Sequence A: 10 mg tablet, 2 doses (12 hours apart) =\> XR-20 mg orange tablet, single dose =\> XR-20 mg orange tablet, q. d., multiple doses (fasted) =\> XR-20 mg orange tablet, q. d., multiple dose (fed)~Sequence B: XR-20 mg orange tablet, single dose =\> 10 mg tablet, 2 doses (12 hours apart) =\> XR-20 mg orange tablet, q. d., multiple dose (fed) =\> XR-20 mg orange tablet, q. d., multiple doses (fasted)"
62818495|NCT02620774|EXPERIMENTAL|Diabetic Wound Infection|Participants with a documented history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 8 hours.
62818496|NCT02620774|ACTIVE_COMPARATOR|Healthy Volunteer|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid in the thigh by a microdialysis probe over 8 hours.
62818497|NCT04975698|OTHER|HST-NEETs|HIV+ Participants that were treated with autologous hematopoietic stem cell transplant.
62818498|NCT04182516|EXPERIMENTAL|Dose Escalation Part|Patients with histologically confirmed diagnosis of locally advanced/metastatic HER2 negative breast cancer, epithelial ovarian cancer, castration-resistant prostate cancer (CRPC) or pancreatic cancer.
62818499|NCT04182516|EXPERIMENTAL|Dose Expansion Part - Epithelial Ovarian Cancer|Patients with gBRCA mutation and epithelial ovarian cancer.
62818500|NCT04182516|EXPERIMENTAL|Dose Expansion Part - Pretreated HER 2 Neg. Breast Cancer|Patients with gBRCA mutation and HER2 negative breast cancer previously treated with a PARP inhibitor.
62818501|NCT04182516|EXPERIMENTAL|Dose Expansion Part - No Pretreated HER 2 Neg. Breast Cancer|Patients with gBRCA mutation and HER2 negative breast cancer who have not received prior therapy with a PARP inhibitor.
62818502|NCT04182516|EXPERIMENTAL|Dose Expansion Part - CRPC|Patients with gBRCA mutation and castration-resistant prostate cancer (CRPC).
62818503|NCT04182516|EXPERIMENTAL|Dose Expansion Part - Pancreatic Cancer|Patients with gBRCA mutation and pancreatic cancer who have not received prior therapy with a PARP inhibitor.
62818504|NCT05324358|EXPERIMENTAL|NTM-001 Treatment Arm|"* NTM-001 loading dose of 12.5 mg administered over approximately 60 seconds, followed by a continuous IV infusion at a rate of 3.5 mg/h for 24h, by a pre-programmed infusion pump.~* Subjects will also receive placebo to IV Morphine (injections)."
62242102|NCT01764048|EXPERIMENTAL|Fix protocol|"During 48 hours following surgery pain medications will be given as followed (listed in brackets are the generic names of each medication):~At patient arrival to the department: Intravenous Tramadol hydrochloride 100 milligrams + TAB. Paracetamol 500 milligrams + TAB. Diclofenac 100 milligrams~After 6 hours from patient arrival and every 6 hours: TAB. Zaldiar (Paracetamol 650 milligrams + Tramadol 75 milligrams).~After 12, 24 and 48 hours from patient arrival: TAB. Diclofenac 100 milligrams.~Rescue medication: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)as necessary up to 4 times per day.~The total amount of paracetamol is limited to 4 gr per day."
62242103|NCT01764048|EXPERIMENTAL|medications following demand protocol|The same combinations will be given as in the fixed protocol however only after patient request
62242104|NCT03553095|ACTIVE_COMPARATOR|Chronic Periodontitis and Depression Medications|Patients with clinically diagnosed depression taking (SSRIs, NDRIs, SNRIs, tricyclic antidepressants) and with chronic periodontitis
62242105|NCT03553095|ACTIVE_COMPARATOR|Chronic Periodontitis without Depression Medications|Patients with clinically diagnosed depression not taking any antidepressants (SSRIs NDRIs, SNRIs and Tricyclic antidepressants) and with chronic periodontitis
62242106|NCT03553095|ACTIVE_COMPARATOR|Chronic Periodontitis|Patients without depression, not taking any antidepressants and with chronic periodontitis
62242107|NCT05538598|EXPERIMENTAL|Intramuscular Dry Needling|IMDN will be performed at the sacral multifidus and fibularis longus muscles.
62818505|NCT05324358|ACTIVE_COMPARATOR|Morphine Treatment Arm|"* A single IV morphine bolus (4 mg) every 4h for up to 24h.~* Subjects will also receive placebo to NTM-001."
62818506|NCT05324358|PLACEBO_COMPARATOR|Placebo Treatment Arm|"Subjects randomized will receive placebos of both active treatments concomitantly.~* Placebo to NTM-001: Placebo loading dose applied over approximately 60 seconds, followed by a continuous IV infusion at a rate of 3.5 mL/h for 24h by a pre-programmed infusion pump.~* Placebo to IV morphine injections: A single IV placebo bolus every 4h for up to 24h."
62242108|NCT03352011|EXPERIMENTAL|Primary Care Brief Mindfulness Training|group-based mindfulness training
62242109|NCT03352011|ACTIVE_COMPARATOR|PTSD Psychoeducational Class|group-based psychoeducation class
62242110|NCT05493761|EXPERIMENTAL|"Denosumab"|35 postmenopausal women with low bone mineral density (BMD) and NAFLD will receive denosumab.
62242111|NCT05493761|ACTIVE_COMPARATOR|"Alendronate"|35 postmenopausal women with low bone mineral density (BMD) and NAFLD will receive alendronate.
62242112|NCT02072928||BOTOX®|Patients with incontinence from NDO due to spinal injury or MS prescribed BOTOX® (Botulinum toxin Type A) as standard of care in clinical practice.
62242113|NCT06044337|EXPERIMENTAL|BIIB059|Participants will receive BIIB059 subcutaneously, once every 4 weeks up to Week 100.
62818507|NCT04937036||COMISA group|Patients with diagnosed COMISA.
62818508|NCT04937036||Healthy controlls|Healthy indyviduals.
62818509|NCT06268236|EXPERIMENTAL|Electro-acupuncture group|Patients in EA group receive acupuncture at Shuigou (also known as Renzhong, GV26) and Yintang (updated number GV24+, previous number GV29). Paired electrodes from the EA apparatus are clipped to the needle handles at Shuigou and Yintang. The electroacupuncture stimulation lasts for 30 minutes with a wave of rarefaction and condensation (10 Hz / 50 Hz) and a current intensity of the maximum withstand current within 7mA. All patients receive EA at 9 am for 30 minutes once a day for consecutive 14 days.
62242114|NCT03355391||Screening participants|Individuals aged 50 to 65 years who were included in the screening program of Cancer Hospital of Barretos
62242115|NCT04162925|EXPERIMENTAL|Cancer screening cohort|"All women in this study to be evaluated for cancer screening utilization rates (breast, colon and oral cancers) and cancer screening perspectives of these hospitalized women.~The intervention will be a cancer screening education."
62242116|NCT03447951|EXPERIMENTAL|PTS100 (Para-Toluenesulfonamide): 30%TTV|Total dose = 30% total tumor volume
62242117|NCT00799279|EXPERIMENTAL|Follow-up Counseling Arm|smoking cessation training for providers,practice tools for providers, patient quit plan, and follow-up telephone counselling for smokers
62432524|NCT04568369|SHAM_COMPARATOR|Sham group|In the sham condition, a sham coil will be applied to the scalp after the resting motor threshold is determined. Patients will be able to hear the sound and feel the vibration of sham coil, but will not experience any effective stimulation. Previous sham studies have demonstrated efficacy of the blinding method.
62432525|NCT02746705|ACTIVE_COMPARATOR|Transcranial Direct Current Stimulation (tDCS)|
62432526|NCT02746705|SHAM_COMPARATOR|Sham Transcranial Direct Current Stimulation (tDCS)|
62432527|NCT04189419|EXPERIMENTAL|SCM-AGH|"* Ingredient: Allogeneic human bone marrow derived mesenchymal stem cells~* Dose: 1x10\^6 cells/Kg"
62432528|NCT04189419|PLACEBO_COMPARATOR|Placebo|IV infusion.
62432529|NCT02410070|EXPERIMENTAL|Though Volar Minimal Incision|Patients in group A were treated through a small Incision.
62432530|NCT02410070|ACTIVE_COMPARATOR|Though Convectional Incision|Patients in group B were treated through the conventional Incision
62432531|NCT03070431|EXPERIMENTAL|High-precision RT 5x5 Gy in 1 week|Patients with motor deficits of the lower extremities due to metastatic spinal cord compression (MSCC) will receive 5x5 Gy of high-precision RT in 1 week.
62432532|NCT03836274|EXPERIMENTAL|Experimental|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'MONACO' for a period of 9 days.
62432533|NCT01162395|EXPERIMENTAL|A|Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD)
62432534|NCT05911347|ACTIVE_COMPARATOR|Psyllium|Psyllium 15 g+ inulin 15 gm in 375ml water
62432535|NCT05911347|PLACEBO_COMPARATOR|maltodextrin|Maltodextrin 15 g + inulin 15 gm in 375 ml water
62599439|NCT05714046|EXPERIMENTAL|Yoga Group|In addition to routine tennis training yoga exercise training was applied to the yoga group 2 days a week for 8 weeks with the telerehabilitation method.
62039024|NCT02362529|OTHER|Celecoxib|This will be an open label trial for those with Hamilton Depression Rating Scale score ≥ 8 following the minocycline v. placebo trial or those not eligible for Phase 2. Dose of celecoxib will be 100 mg bid for the first week and 200mg bid for weeks 2-8. For tapering, the dose of celecoxib will be reduced to 100mg bid for one week, and then stopped.
62039025|NCT04416269|EXPERIMENTAL|Oral Anti-diabetes Drugs (OADs) alone|OADs will be continued at same outpatient dosage unless contraindicated
62242118|NCT00799279|ACTIVE_COMPARATOR|Practice Support Arm|smoking cessation training for providers,practice tools for providers, patient quit plan for smokers.
62242119|NCT04694872|EXPERIMENTAL|a) TELEREHABILITATION BASED LSVT BIG TREATMENT GROUP|It is planned to recruit 16 patients with Parkinson's Disease in this group. Exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week, 60 minutes a day, 4 weeks protocol respectively.
62242120|NCT04694872|ACTIVE_COMPARATOR|b) TELEREHABILITATION BASED FUNCTIONAL BALANCE AND MOBILITY EXERCISES GROUP|It is planned to recruit 16 patients with Parkinson's Disease in this group. These exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week and 60 minutes a day for 4 weeks.
62432536|NCT05911347|EXPERIMENTAL|Methylcellulose|Methylcellulose 15g + Inulin 15 g in 375 ml water
62432537|NCT01572428|ACTIVE_COMPARATOR|Narrow-Band Imaging (NBI)|Inspection with Narrow-Band Imaging(NBI) versus inspection with standard white light(usual care)
62432538|NCT01572428|ACTIVE_COMPARATOR|Standard White Light|Inspection with Standard White Light versus Narrow-Band Imaging(NBI)
62432539|NCT05765929|EXPERIMENTAL|Non-operative treatment|Non-operative treatment based on weightbearing radiographs
62432540|NCT04129034|EXPERIMENTAL|Treatment|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
62432541|NCT02953197|EXPERIMENTAL|Single arm radiotherapy dose escalation|FDG-PET guided radiation dose escalation Selective dose escalation
62432542|NCT02772913||acute mesenteric ischemia|patients with abdominal pain and acute mesenteric ischemia
62432543|NCT02772913||non-acute mesenteric ischemia|patients with abdominal pain without mesenteric ischemia
62432544|NCT03038178|EXPERIMENTAL|LAI plus multi-drug regimen|once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines
62599440|NCT05714046|EXPERIMENTAL|Control Group|Routine Tennis training and information training was given to Control group.
62599441|NCT02395640|EXPERIMENTAL|XELOX|oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
62599442|NCT02395640|ACTIVE_COMPARATOR|EOX|Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
62818510|NCT06268236|SHAM_COMPARATOR|Sham electro-acupuncture group|Patients in sham-EA group receive sham-EA at sham-Shuigou and sham-Yintang.Acupuncture needles are inserted into the adhesive pads but do not pierce the skin. Paired electrodes from the EA apparatus via sham connecting cords are clipped to the needle handles at sham-Shuigou and sham-Yintang. The sham connecting cords are similar in appearance to the normal ones, but the inner wires in sham connecting cords are cut off and cannot conduct electricity. All patients receive sham-EA at 9 am for 30 minutes once a day for consecutive 14 days.
62818511|NCT06600932|EXPERIMENTAL|TMS|TMS treatment indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.
62242121|NCT03681886|EXPERIMENTAL|Primary Implantation (Cohort 1)|Primary implantation with HMIOL through Month 1 visit, followed by study exit. 1 site followed up to Month 12.
62242122|NCT03681886|EXPERIMENTAL|Optic Exchange (Cohort 2)|Subset of Cohort 1 with optic exchange at Month 1 post primary implantation, followed up to Month 1 post optic exchange
62242123|NCT01031160||U.S. high school students|U.S. high school students who were in 10th grade in the 2009-2010 school year.
62818512|NCT06600932|SHAM_COMPARATOR|Control|The sham group will be exposed to the recorded sounds of TMS pulses but without real magnetic stimulation.
62242124|NCT05179369|NO_INTERVENTION|Standard Care|Participants randomized to standard care will be offered prenatal and postpartum care in accordance with site-specific procedures based on AAP and ACOG Guidelines for Perinatal Care. The initial intake appointment, involving a comprehensive visit with physical exam, medical and psychosocial history, laboratory testing, and education would optimally occur in the 1st trimester. Subsequent prenatal visits, per ACOG, is monthly for the first 28 weeks, biweekly for weeks 28-36, and weekly after 36 weeks. More frequent visits may be offered to women at high risk. In addition, some sites may offer supports such as nutritional counseling, childbirth education, and case management. A comprehensive postpartum care visit would typically occur within the first 6 weeks of birth, involving a physical examination, lab tests, and immunizations.
62818513|NCT06704321|EXPERIMENTAL|TOTUM-448|The experimental active arm will be supplemented with TOTUM-448 twice per day.
62818514|NCT06704321|PLACEBO_COMPARATOR|Placebo|The placebo comparator arm will be supplemented with a placebo twice per day.
62818515|NCT06705647||COPD|24 COPD participants, 12 Female and 12 Male.
62242125|NCT05179369|EXPERIMENTAL|Standard Care with Well-Mama Intervention|Participants will receive standard perinatal care plus the Well Mama intervention, including the Well Mama Checklist, assistance from a Community Doula Navigator, and virtual support groups.
62818516|NCT06705647||HC|24 HC participants, 12 Female and 12 Male.
62818517|NCT01672645|EXPERIMENTAL|PF-05402536|
62818518|NCT01672645|EXPERIMENTAL|PF-06413367|Intramuscular, multiple dose
62818519|NCT01672645|PLACEBO_COMPARATOR|Placebo|Intramuscular
62818520|NCT05861466|ACTIVE_COMPARATOR|Group A|Patients with eyes with non ischemic diffuse center involving DME will be assigned to receive IVI of ranibizumab without Anterior Chamber Paracentesis.
62818521|NCT05861466|ACTIVE_COMPARATOR|Group B|Patients with eyes with non ischemic diffuse center involving DME will be assigned to receive IVI of ranibizumab with Anterior Chamber Paracentesis.
62818522|NCT04348240||Group 1|asymptomatic or mildly symptomatic high-risk subjects with unknown SARS-CoV-2 status but with known history of close personal contact with a COVID-19 positive person.
62818523|NCT04348240||Group 2|asymptomatic or mildly symptomatic (e.g., low grade fever, mild malaise, minor sore throat, runny nose, or sneezing) subjects who are COVID-19 positive.
62242126|NCT02627352|EXPERIMENTAL|Transscleral Cyclophotocoagulation|Subjects undergo a Micropulse Transscleral Cyclophotocoagulation(TSCPC) laser surgery, where a diode laser is used to damage tissue of the ciliary body, the tissue inside the eye that produces aqueous, the clear fluid in the eye that maintains intraocular pressure. This causes it to produce less aqueous.
62242127|NCT06689449||erector spinae plan block group|The patient will be monitored with routine monitoring and ANI under operating room conditions. VAS values and vital signs before and after peripheral nerve block will be recorded. Patients will be placed in the lateral position and an erector spinae plane block will be applied under USG guidance by an experienced anesthesiologist. Surgery will be allowed 30 minutes after the block is performed.
62735783|NCT00733733|ACTIVE_COMPARATOR|ATG|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
62818524|NCT04348240||Group 3|COVID-19 positive individuals retesting negative can be enrolled to complete the electronic questionnaire(s) and allow evaluation of history of symptoms.
62818525|NCT04348240||Group 4|COVID-19 positive individuals enrolled and admitted to the NIH Clinical Center for other protocols.
62818526|NCT02183675|EXPERIMENTAL|T/A/H|Telmisartan/Amlodipine/HCTZ fixed-dose combination
62818527|NCT02183675|ACTIVE_COMPARATOR|T/A|Telmisartan/Amlodipine fixed-dose combination
62818528|NCT02183675|ACTIVE_COMPARATOR|T/H|Telmisartan/HCTZ fixed-dose combination
62818529|NCT02891174|ACTIVE_COMPARATOR|Ibuprofen followed by acetaminophen|Ibuprofen administered immediately post-partum, 600 mg (3 x 200 mg tablets) every 6 hours for 24 hours followed by acetaminophen, 650 mg (2 x 325 mg tablets) every 6 hours for 24 hours.
62818530|NCT02891174|ACTIVE_COMPARATOR|Acetaminophen followed by ibuprofen|Acetaminophen administered immediately post-partum, 650 mg (2 x 325 mg tablets) every 6 hours for 24 hours followed by ibuprofen, 600 mg (3 x 200 mg tablets) every 6 hours for 24 hours.
62818531|NCT01539824|EXPERIMENTAL|IMM-101 plus SBRT|The treatment regimen with IMM-101 (Mycobacterium obuense) will be every 2 weeks for the first three doses with the last of these doses being on the same day as the radiotherapy by CyberKnife treatment on a liver lesion targeted by the Principal Investigator. Following a rest of 4 weeks, patients will again receive IMM-101 every 2 weeks for the next 3 doses followed by a further 4 weeks rest. Thereafter, IMM-101 will be given at 4 week intervals for up to 12 months or until patient withdrawal for any reason
62818532|NCT05462145|EXPERIMENTAL|Globe Pulsed Field System|
62242128|NCT06689449||paravertebral block group|The patient will be monitored with routine monitoring and ANI under operating room conditions. VAS values and vital signs before and after peripheral nerve block will be recorded. Patients will be placed in the lateral position and a paravertebral block will be applied under USG guidance by an experienced anesthesiologist. Surgery will be allowed 30 minutes after the block is performed.
62818533|NCT05625360|EXPERIMENTAL|Arm 1 - eHealth Mindful Movement and Breathing Group (eMMB)|Participants will be given access to 20-minute eMMB videos (either saved as a local files on an iPad or via links to watch on their own devices) with written instructions for eMMB and to watch a video at least once before surgery (videos have the same content, one is taught in a bed and one in a chair). The instructor will call participants before surgery to offer guidance upon request and meet with participants individually via a synchronous videoconference or telephone session, postoperative day 1 (the day after surgery), or as soon as feasible.
62242129|NCT06689449||mid-point transverse process to pleura block group|The patient will be monitored with routine monitoring and ANI under operating room conditions. VAS values and vital signsbefore and after peripheral nerve block will be recorded. Patients will be placed in the lateral position and a mid-point transverse process to pleura block will be applied under USG guidance by an experienced anesthesiologist. Surgery will be allowed 30 minutes after the block is performed.
62242130|NCT02259998|EXPERIMENTAL|Persantin® new formulation|
62242131|NCT02259998|ACTIVE_COMPARATOR|Persantin® commercial formulation|
62242132|NCT04258371|EXPERIMENTAL|Dapagliflozin Treatment Arm|Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
62242133|NCT04258371|PLACEBO_COMPARATOR|Placebo Arm|Placebo Matching Dapagliflozin Tablet for 12 weeks
62242134|NCT01923116|EXPERIMENTAL|HPV-16 vaccine|
62432545|NCT05306080|EXPERIMENTAL|Tadekinig alfa|"* Injection #1/Day 1: As clinically indicated in accordance with Figure 1.1-1.~* Repeat Injection(s): Missed doses will not be made up.~* Injection #2/Day 3: Approximately 48 hours (+/- 5 hours) after receipt of the 1st injection.~* Injection #3/Day 5: Approximately 48 hours (+/- 5 hours) after receipt of the 2nd injection.~* Continued Dosing (Optional): Approximately q48-72 hours; If the subject is responsive to initial therapy, but has ongoing symptoms of CRS/CRHLS.~* Retreatment (Optional): May be considered"
62242135|NCT06717867|EXPERIMENTAL|PEA (Levagen)|600mg PEA each day. 1 oral capsule is taken twice per day after food, each capsule contains 300mg.
62242136|NCT06717867|PLACEBO_COMPARATOR|Placebo|600mg microcrystalline cellulose a day. 1 oral capsule is taken twice per day after food, each capsule contains 300mg.
62242137|NCT02400450|EXPERIMENTAL|Functional Ingredient Group|Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix. The food items will contain a standardized amount of functional ingredients.
62242138|NCT02400450|PLACEBO_COMPARATOR|Control Ingredient Group|The control group will receive a comparable set of food items that contain an equivalent amount of calories per portion but without the added functional ingredients.
62242139|NCT06505603||Emphysema|FEV1/FVC \<70%
62242140|NCT06493981|EXPERIMENTAL|Cases of aplastic anemia recieving Eltrombopag|Newely diagnosed bone marrow aplasia starting treatment with Eltrombopag in adose of 50-150mg / day
62242141|NCT06570044|EXPERIMENTAL|PerioMonitor|
62432546|NCT03625817|NO_INTERVENTION|Urban setting|The participants will be staying in their permanent house in an urban area in Cyprus for at least 7 days. On the 7th day, they will be wearing 2 temperature sensors, for skin and air temperature. They will also collect the urine samples of the day and note in an activity diary, the names and times of activities.
62432547|NCT03625817|EXPERIMENTAL|Mountainous setting|The intervention is the short stay in the mountainous area of Troodos for atleast 7 consecutive days. The participants will be staying in their holiday house in the mountainous-rural area of Troodos, Cyprus for at least 7 days. On the 7th day, they will wear 2 temperature sensors, for skin and personal air temperature monitoring (every minute data points). They will also collect the urine samples of the day and note in an activity diary, the names and times of activities.
62242142|NCT06512337||Participants treated with deucravacitinib|Adults with moderate plaque psoriasis who are newly initiating deucravacitinib according to the product label
62432548|NCT01190098|EXPERIMENTAL|Lacosamide|
62432549|NCT01190098|PLACEBO_COMPARATOR|Sugar pill|
62432550|NCT01951547|EXPERIMENTAL|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy given at baseline
62432551|NCT01951547|ACTIVE_COMPARATOR|Oral hygiene instructions|Oral hygiene instructions given at baseline
62039026|NCT04416269|ACTIVE_COMPARATOR|Basal bolus insulin|Basal insulin with glargine or detemir and rapid-acting insulin (lispro/aspart) will be used as per the hospital formulary. OADs and non-insulin injectable antidiabetic medication will be discontinued on admission.
62599443|NCT04258969|EXPERIMENTAL|Pedaling Group|During the first 2 hours of their chemotherapy infusions, participants will pedaling for 30 minutes using a stationary cycle ergometer. Participants will be allowed to determine their pedaling intensity and cadence, however, will be encouraged to reach the established goal intensity level. Additionally, subjects will complete both a physical activity questionnaire (International Physical Activity Questionnaire) and a quality of life questionnaire (European Organization for Research and Treatment of Cancer QLQ - CR 29) at baseline and following their last chemotherapy treatment. A questionnaire on chemotherapy side effects (Memorial Symptom Assessment Scale) will be gathered at baseline, during chemotherapy cycles 3, 6, and/or 12, and following completion of chemotherapy treatment. Lastly, muscular strength and physical performance will be measured via grip strength tests and TGUG tests within 2-4 weeks of the post-surgery and chemotherapy completion CT scans.
62599444|NCT05555225||Patients with amelia|Patients with severe hypoplasia or agenesia of at least two limbs who gave their consent for the research and for whom a DNA sample is available in our laboratory
62599445|NCT05555225||Patients with Femur-Fibula-Ulna Syndrome|Patients with anomaly of at least one femur, one fibula and with oligodactyly who gave their consent for the research and for whom a DNA sample is available in our laboratory.
62599446|NCT05555225||Healthy subjects|Healthy subjects used as controls, who gave their consent for the research and for whom a DNA sample is available in our laboratory.
62599447|NCT05866562|EXPERIMENTAL|Dupilumab|200 mg or 300 mg SC injections every 2 or 4 weeks (weight based)
62599448|NCT05866562|PLACEBO_COMPARATOR|Placebo|Injections without active ingredients
62599449|NCT06365008|EXPERIMENTAL|Sintilimab+irinotecan+leucovorin folinate+fluorouracil|sintilimab 3mg/kg for patients with body weight\<60kg or 200mg for patients with body weight ≥ 60kg, plus irinotecan 180mg/m2 intravenous infusion, leucovorin folinate 400mg/m2 intravenous infusion and fluorouracil 400mg/m2 intravenous injection followed by 2400mg/m2 intravenous infusion for 48 hours, repeated every two weeks.
62039027|NCT00734110|EXPERIMENTAL|P.F.C. Sigma Total Knee Replacement System|Primary total knee arthroplasty using the fixed bearing P.F.C. Sigma Total Knee Replacement System.
62039028|NCT02444390|OTHER|Exemestane+everolimus|Exemestane+everolimus are administered as per their approved indication
62039029|NCT06231862||Suspected/documented bacterial sepsis|Patients have evidence of an acute bacterial infection with organ dysfunction
62039030|NCT06231862||Suspected/documented viral sepsis|Patients have evidence of an acute viral infection with organ dysfunction
62039031|NCT06231862||Infection negative systemic inflammation (SIRS)|Patients have no active infection but exhibit SIRS
62039032|NCT06021301|EXPERIMENTAL|iPRF and Microneedling|First, MN will be done in the required area with insulin syringe gauge 30,The interdental papilla will vertically and horizontally measured in mm. By establishing a ratio and proportion, the number of microchannels in the region to be treated will calculated to be 250 microchannels per square cm Then, a venous blood sample will be taken for each patient using a 10-ml injector into i-PRF tube containing no anticoagulant and centrifuged at room temperature for 3 min at 700 rpm (60 g force). The 30-gauge dental injector needles will be used for injection of i-PRF. The needle will be inserted at 45° angle, 2-3-mm apical to the involved papilla and all surrounding areas will receive iPRF. Each involved papilla will be injected with an amount till blanching is visible . This method will be repeated for 4 times at 10 days intervals consecutively.
62039033|NCT04373239||Women in BC conceiving by ART|All women in BC registered in the Perinatal Services BC database having undergone Assisted Reproductive Technology. Assisted Reproductive Technology will consist of in vitro fertilization (+/-ICSI). Data from April 1, 2008 to March 31 2018 will be analyzed for live birth rate.
62039034|NCT04373239||Women in BC conceiving spontaneously|he comparison group will be all women in BC registered in the Perinatal Services BC database with spontaneously conceived pregnancies between April 1, 2008 to March 31 2018.
62039035|NCT06454747|EXPERIMENTAL|SM-030 gel 0.64%|Topical application of SM-030 gel 0.64% twice daily for 12 weeks and a 4-week additional safety follow-up period.
62039036|NCT06454747|PLACEBO_COMPARATOR|Placebo gel|Inactive comparator.
62039037|NCT06454747|EXPERIMENTAL|SM-030 gel 0.08%|Topical application of SM-030 gel 0.08% twice daily for 12 weeks and a 4-week additional safety follow-up period.
62039038|NCT03031652||Enrolled group|Patients who had senile cataract and underwent phacoemulsification with topical anesthesia.
62039039|NCT04431596|ACTIVE_COMPARATOR|Cooling|Participants will be actively cooled during rest breaks.
62039040|NCT04431596|NO_INTERVENTION|No Cooling|"Participants will participant in passive cooling where they sit in a chair during rest."
62039041|NCT04486391|EXPERIMENTAL|Tislelizumab|Tislelizumab monotherapy for up to 45 months
62242143|NCT02613351|EXPERIMENTAL|scooting|incremental test to establish the relationship between leg and breathing heaviness with increasing demand (speed) during scooting
62039042|NCT04486391|EXPERIMENTAL|Salvage chemotherapy|Salvage chemotherapy for up to 45 months
62039043|NCT04988451|EXPERIMENTAL|ASL Services - Adult ASL Development|Presence (or absence, across 6-week periods) of ASL services designed to support improvement in ASL fluency
62039044|NCT04988451|EXPERIMENTAL|ASL Services - Child Language Development|Presence (or absence, across 6-week periods) of ASL services designed to support improvement in ASL fluency
62039045|NCT05801081||Active group|Participants will be divided into two groups according to their physical activity level using the International Physical Activity Scale. Individuals with high physical activity levels will be included in this group.
62599450|NCT04030962|EXPERIMENTAL|Stage 1: AGN-242428 Cohort 1A|Administration of AGN-242428 ophthalmic solution
62599451|NCT04030962|EXPERIMENTAL|Stage 1: AGN-242428 Cohort 1B|Administration of AGN-242428 ophthalmic solution
62599452|NCT04030962|EXPERIMENTAL|Stage 1: AGN-242428 Cohort 1C|Administration of AGN-242428 ophthalmic solution
62599453|NCT04030962|EXPERIMENTAL|Stage 1: AGN-231868 Cohort 1A|Administration of AGN-231868 ophthalmic solution
62039046|NCT05801081||Inactive Group|cipants will be divided into two groups according to their physical activity level using the International Physical Activity Scale. Individuals with low physical activity levels will be included in this group.
62599454|NCT04030962|EXPERIMENTAL|Stage 1: AGN-231868 Cohort 1B|Administration of AGN-231868 ophthalmic solution
62599455|NCT04030962|EXPERIMENTAL|Stage 1: AGN-231868 Cohort 1C|Administration of AGN-231868 ophthalmic solution
62818534|NCT05625360|ACTIVE_COMPARATOR|Arm 2 Life Impacts Reflection Group (LIR)|The format for interactions with an LIR interventionist, frequency of recommended home practice (brief diary entries), and home assessments will be matched to the eMMB group. LIR will not include active ingredients of eMMB.
62039047|NCT05690386|EXPERIMENTAL|Lonapegsomatropin at 0.24 mg hGH/kg/week|Lonapegsomatropin at 0.24 mg hGH/kg/week administered once-weekly by subcutaneous injection
62039048|NCT05690386|EXPERIMENTAL|Lonapegsomatropin at 0.30 mg hGH/kg/week|Lonapegsomatropin at 0.30 mg hGH/kg/week administered once-weekly by subcutaneous injection
62039049|NCT05690386|EXPERIMENTAL|Lonapegsomatropin at 0.36 mg hGH/kg/week|Lonapegsomatropin at 0.36 mg hGH/kg/week administered once-weekly by subcutaneous injection
62039050|NCT05690386|ACTIVE_COMPARATOR|Somatropin at 0.05 mg/kg/day|Somatropin at 0.05 mg/kg/day administered once-daily by subcutaneous injection
62039051|NCT02707835|ACTIVE_COMPARATOR|control group|self massage, skin care education, manual lymph drainage exercise, compression garment
62039052|NCT02707835|ACTIVE_COMPARATOR|manual lymph drainage group|manual lymph drainage by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
62039053|NCT02707835|EXPERIMENTAL|experimental group|epidermis fascia taping by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
62039054|NCT06733922|EXPERIMENTAL|ETNATM-ProgMS|Patients with active RRMS being prescribed ofatumumab as part of routine clinical care will have their eye movements reliably and accurately tracked using ETNATM-ProgMS SaMD (v1.0.11 or later) at baseline, 3-, 6-, 12-, and 24-months following ofatumumab initiation
62039055|NCT05971719|EXPERIMENTAL|Air Leaks|Lungs from patients undergoing lung transplantation after their removal from the recipient patient with previous informed consent signed before transplantation will be obtained. To establish a standard protocol to use our system we will use a dark box to validate that our system is able to localize the air leaks and to establish the best way to use the system. A one centimeter leak will be created on the lung with a scalpel. A laparoscope will be introduced via a trocar in the dark box and the surgeon will be asked to localize the leaks. The detection will be recorded via the laparoscope. The goal will be to perform a standardized protocol to use the system smoothly and efficiently on ex-vivo human lungs.
62039056|NCT05599828|EXPERIMENTAL|AMG 510 + Omeprazole + Famotidine|Participants will receive AMG 510 on Day 1, famotidine on Day 3, AMG 510 and famotidine on Day 4, omeprazole on Days 6 through 10, and omeprazole and AMG 510 on Day 11.
62432552|NCT05627908||abdominal trauma|CEUS in detecting post-traumatic splenic, hepatic, and renal PAs
62818535|NCT06078241|ACTIVE_COMPARATOR|Intravenous lidocaine infusion|
62039057|NCT06733623||Scoliosis patients|Patients aged between 6 and 18 years old with a diagnosis of idiopathic scoliosis are asked to answer a questionnaire investigating the preferred postures adopted daily
62039058|NCT06733623||Control group|Subjects aged between 6 and 18 years old without a diagnosis of idiopathic scoliosis are asked to answer a questionnaire investigating the preferred postures adopted daily
62039059|NCT04064034|EXPERIMENTAL|Subjects with pancreas cancer|Subjects will have blood collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
62039060|NCT04064034|EXPERIMENTAL|Subjects with non-cancerous disorders|Subjects will have blood collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
62599456|NCT04030962|PLACEBO_COMPARATOR|Stage 1: AGN-242428 Vehicle|Administration of matching placebo (vehicle) ophthalmic solution
62599457|NCT04030962|PLACEBO_COMPARATOR|Stage 1: AGN-231868 Vehicle|Administration of matching placebo (vehicle) ophthalmic solution
62599458|NCT04030962|EXPERIMENTAL|Stage 2: AGN-242428 Group 1|Administration of AGN-242428 ophthalmic solution
62599459|NCT04030962|EXPERIMENTAL|Stage 2: AGN-242428 Vehicle Group 2|Administration of matching placebo (vehicle) ophthalmic solution
62599460|NCT04030962|EXPERIMENTAL|Stage 2: AGN-231868 Group 3|Administration of AGN-231868 ophthalmic solution
62599461|NCT04030962|EXPERIMENTAL|Stage 2: AGN-231868 Vehicle Group 4|Administration of matching placebo (vehicle) ophthalmic solution
62599462|NCT04030962|ACTIVE_COMPARATOR|Lifitegrast|Administration of Lifitegrast ophthalmic solution
62818536|NCT06078241|ACTIVE_COMPARATOR|Erector spinae plane block (ESPB)|
62818537|NCT06078241|PLACEBO_COMPARATOR|Intravenous infusion of normal saline and ESPB with normal saline|
62818538|NCT06599489|OTHER|sleeve gastrectomy and cruroplasty|Under a general anesthesia. Three 12-mm trocars were inserted in the upper abdomen and one 5-mm trocar was inserted laterally in the left-upper quad¬rant. Retractor was inserted through the subxyphoid 10 mm trocar site to re¬tract the liver (five to seven Trocars always used) . The hiatal hernia sac containing the proximal stomach was reduced. Distal esophagus and gastroesophageal junction were mobilized by using a laparoscopic Harmon¬ic Scalpelto get a 4-cm tension-free intra-abdominal esophagus. Pos¬terior crural repair was performed with three interrupt¬ed
62432553|NCT04534192|EXPERIMENTAL|JADE balloon|Non-compliant high pressure JADE balloon for the treatment of infrainguinal stenotic occlusive or stenotic TASC C \& D lesions in patients with chronic limb threatening ischemia.
62818539|NCT06599489|OTHER|sleeve gastrectomy and cruroplasty with ligamentum teres wrapping|"sleeve gastrectomy and cruroplasty with ligamentum teres wrapping for cardiopexy for morbidly obese patients with reflux symptomspatients will Laparoscopic sleeve gastrectomy with crural repair with ligamentum teres wrapping .the same as in group (A) in addition to ligamentum teres wrapping behind lower end of oesophagus and fixed to anterior wall of stomach with interrupted sutures .~The mean follow up period was eight months .clinical outcomes were also evaluated in term of GERD symptoms improvement or resolution .interruption of anti reflux medications and xray evidence of HH recurrence."
62818540|NCT06216613|EXPERIMENTAL|Sensory Enhanced Aquatics|Sensory Enhanced Aquatics is a specialized swimming and water safety program for autistic children.
62818541|NCT06216613|ACTIVE_COMPARATOR|Standard Swim Lessons|Standard swim lessons which are provided to the general public will be used as the comparison group.
62039061|NCT04064034|EXPERIMENTAL|Subjects with pancreas cyst|Subjects already undergoing biopsy of a pancreas cyst will have cyst fluid collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
62039062|NCT02566954|EXPERIMENTAL|3D measurement of the lower limb by EOS|"The intervention is to performed an additional radiologic exam by the EOS® system of imaging. This imaging is not usually realized for the patient.~3 dimensional study of lower limbs and feet of children in standing position will be performed using the EOS® system (EOS® Imaging, France)"
62242144|NCT04977310|NO_INTERVENTION|Control|After LVAD implantation, patients undergo cardiac rehab and pump speed will be optimized to maximize left ventricular unloading using echocardiographic imaging and other standard-of-care practices. During the Unloading phase, patients are serially evaluated with echocardiograms to assess for cardiac recovery, and LVAD explantation performed when predefined criteria are met. After explantation, patients undergo cardiac rehab and regular follow up.
62242145|NCT04977310|EXPERIMENTAL|Intervention|After LVAD and wireless monitoring system (CardioMEMS) implantation, patients undergo cardiac rehab and pump speed will be optimized to maximize left ventricular unloading using CardioMEMS. During the Unloading phase, invasive hemodynamic guidance (via CardioMEMS) will be utilized to optimize pressure and volume unloading along with serial echocardiographic evaluations to assess for cardiac recovery, and LVAD explantation will be considered. After explantation, patients will undergo cardiac rehab and regular follow up with adjustments of HF medications based on the CardioMEMS-guided hemodynamic assessment.
62818542|NCT02163538|ACTIVE_COMPARATOR|articulating Enseal|This group of women undergoing total laparoscopic hysterectomy is randomized to the the articulating Enseal energy device.
62818543|NCT02163538|ACTIVE_COMPARATOR|Ligasure device|This group of women undergoing hysterectomy is randomized to the Ligasure energy device.
62818544|NCT05443308||Alzheimer Disease|patients with presumed Alzheimer disease and no known vascular, psychiatric or other major diseases age \> 60 years
62039063|NCT05418699||Type I diabetic patient|
62039064|NCT03637205|EXPERIMENTAL|ECLS|PCI (or CABG) plus medical treatment + ECLS
62039065|NCT03637205|ACTIVE_COMPARATOR|No ECLS|PCI (or CABG) plus medical treatment
62242146|NCT06581263||Healthy Volunteer|
62432554|NCT03875430||Perimenopausal|Patients in this group will take one capsule of a dietary supplement containing Humulus lupulus L.
62432555|NCT03875430||Postmenopausal|Patients in this group will take one capsule of a dietary supplement containing Humulus lupulus L.
62432556|NCT04948255||Healthcare Workers at the Gill Medical Centre|Clinical and non-clinical staff at the Gill Medical Centre will complete a validated stress questionnaire during the Covid-19 pandemic. A baseline was established in May, 2019.
62039066|NCT06627296|EXPERIMENTAL|Neuromuscular Electrical Stimulation Group combined with Exercise Training|"The intervention group will receive neuromuscular electrical stimulation combined with exercise training. The group will also be given home exercises to continue at home.~Individuals in the NMES group will undergo NMES application accompanied by a physiotherapist for a total of 24 sessions of 15 repetitions 3 days a week for 8 weeks and then exercise programs will be performed face-to-face.~On the other days, patients will be asked to perform 3 sets of 15 repetitions every day as home exercises.~Exercise training includes intrinsic and extrinsic muscle strengthening, wrist stabilization exercises, dart exercises, wrist neuromuscular exercises using different materials, reactive muscle control, perturbation exercises."
62039067|NCT06627296|EXPERIMENTAL|Exercise Training Group (Control Group)|Patients in the control group will have face-to-face exercise programs with a physiotherapist. Exercise training includes intrinsic and extrinsic muscle strengthening, wrist stabilization exercises, dart exercises, wrist neuromuscular exercises using different materials, reactive muscle control, perturbation exercises.
62599463|NCT05392439|EXPERIMENTAL|taVNS treatment|The taVNS treatment is performed at auricular cymba concha. The stimulation parameters are set as follows: train on-time of 2 seconds and off-time of a 3-second pulse width of 0.5 ms, pulse frequency of 25 Hz, and amplitude of 0-2 milliamp (at the maximum level tolerated by the subject).
62039068|NCT03583554|PLACEBO_COMPARATOR|Placebo, then AV-101 720mg, then AV-101 1440mg|Participants first received oral placebo. After at least 3 days wash-out participants get oral AV-101 720mg (matching placebo capsules). After at least 3 days wash-out participants get oral AV-101 1440mg (matching placebo capsules).
62242147|NCT04170712||Surgical or High Risk|Patients with confirmed diagnosis of ovarian cancer or suspicious mass or who have a family history or genetic mutation that puts them at high risk fro ovarian cancer.
62432557|NCT05398575|EXPERIMENTAL|Standard treatment with tailored music playlist|Music playlist tailored for a group of 5-8 individuals.
62432558|NCT05398575|ACTIVE_COMPARATOR|Standard treatment with radio music|Listening to local radio channel with music
62432559|NCT05398575|NO_INTERVENTION|Standard treatment without music|Standard physiotherapy with no audio intervention
62599464|NCT05392439|SHAM_COMPARATOR|sham-taVNS treatment|Sham-taVNS is performed with the same parameters as taVNS except that electrical stimulation is applied at the elbow area.
62599465|NCT02433041|ACTIVE_COMPARATOR|Haloperidol|Haloperidol 0.005mg/kg at induction of anesthesia
62599466|NCT02433041|ACTIVE_COMPARATOR|Ketamine|Ketamine 1mg/kg at induction of anesthesia
62242148|NCT00800787|EXPERIMENTAL|Arm One: Nabi-HB|All subjects will be administered Nabi HB Subcutaneously
62818545|NCT05443308||Small vessel disease|"patients diagnosed with small vessel disease of the brain by MRI and presumed cognitive dysfunction and no other known psychiatric or other major diseases.~age \> 60 years"
62242149|NCT04280965|EXPERIMENTAL|Quetiapine|Flexible dosing begins at 50 mg, titrating up to 100 mg at the end of week 2 with additional doses up to 400 mg per day if needed
62242150|NCT04280965|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Standard of care medications
62242151|NCT02841228|EXPERIMENTAL|IMRT + SIB + Chemotherapy|For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction, SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
62242152|NCT02679339|EXPERIMENTAL|CNTX-2022 (lidocaine gel, 40%)|Application of 1mL CTNX-2022 (40% Anhydrous Lidocaine Gel) topically applied to 300cm squared outlined area once daily (in the morning) for 8 days at the study site.
62432560|NCT01260571|EXPERIMENTAL|Benzoyl Peroxide and Sulfur|Topical Medications containing benzoyl peroxide and sulfur
62432561|NCT00370396|EXPERIMENTAL|Synflorix-Synflorix Group|This group consisted of subjects previously vaccinated with the Synflorix™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Synflorix™ vaccine at 2, 3 and 4 months of age (injected intramuscularly \[IM\] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Synflorix™ vaccine, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
62432562|NCT00370396|ACTIVE_COMPARATOR|Prevenar-Prevenar Group|This group consisted of subjects previously vaccinated with the Prevenar™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Prevenar™ vaccine at 2, 3 and 4 months of age (injected intramuscularly \[IM\] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Prevenar™ vaccine, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
62599467|NCT02433041|ACTIVE_COMPARATOR|Haloperidol + Ketamine|Combination of Haloperidol + Ketamine in same dosage at induction of anesthesia
62599468|NCT02433041|PLACEBO_COMPARATOR|Saline solution (NaCl 0.9%)|Placebo
62599469|NCT03736330|EXPERIMENTAL|Combinations treatment|Drug: Axitinib 5mg orally twice a day Combination Treatment：Anti-PD-1 Combinations of D-CIK Immunotherapy
62599470|NCT06137703|EXPERIMENTAL|Sequence 1|Period 1 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A) followed by at least 7 days washout; Period 2 - Two zavegepant 100mg immediate release tablets (Treatment C) followed by at least 7 days washout; Period 3 - Single zavegepant 100mg immediate release tablet (Treatment B) followed by at least 7 days washout; Period 4 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D).
62735784|NCT00733733|NO_INTERVENTION|Control|Standard immunosuppressive treatment for renal transplantation including tacrolimus/MMF/prednisolone without ATG treatment.
62735785|NCT06339450|EXPERIMENTAL|Cystic fibrosis patients|cystic fibrosis patient
62818546|NCT05443308||Healthy subjects|"Age-matched subjects with no known vascular, psychiatric or other major diseases.~age \> 60 years"
62818547|NCT05764564|EXPERIMENTAL|Experimental: Patients with heart failure (Aim 1)|
62818548|NCT05764564|ACTIVE_COMPARATOR|Control: Healthy Volunteers (Aim 1)|
62039069|NCT03583554|EXPERIMENTAL|AV-101 720mg, then AV-101 1440mg, then placebo|Participants first received oral AV-101 720mg (matching placebo capsules). After at least 3 days wash-out participants get oral AV-101 1440mg (matching placebo capsules). After at least 3 days wash-out participants get oral placebo.
62039070|NCT03583554|EXPERIMENTAL|AV-101 1440mg, then placebo, then AV-101 720mg|Participants first received oral AV-101 1440mg (matching placebo capsules). After at least 3 days wash-out participants get oral placebo. After at least 3 days wash-out participants get oral AV-101 720mg (matching placebo capsules).
62432563|NCT00370396|EXPERIMENTAL|Prevenar-Synflorix Group|This group consisted of subjects previously vaccinated with the Prevenar™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Synflorix vaccine at 2, 3 and 4 months of age (injected intramuscularly \[IM\] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Synflorix™, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
62039071|NCT06517043|ACTIVE_COMPARATOR|Active tsDCS treatment|Participants will receive 30 minutes of continuous 2.5-mA tsDCS over the lumbar regions while engaging in a 30-minute complex balance task during each intervention session over a period of 2 weeks (every other day), totaling 5 intervention visits.
62432564|NCT01260480|EXPERIMENTAL|[18F]-ML-10|
62039072|NCT06517043|SHAM_COMPARATOR|Sham tsDCS control|Participants will receive 3 minutes of 2.5-mA tsDCS over the lumbar regions while engaging in a 30-minute complex balance task during each intervention session over a period of 2 weeks (every other day), totaling 5 intervention visits.
62242153|NCT02679339|PLACEBO_COMPARATOR|Placebo|Application of 1mL placebo topically applied to 300cm squared outlined area once daily (in the morning) for 8 days at the study site.
62242154|NCT03701763|EXPERIMENTAL|Administration of Apremilast (CC-10004) - 20mg|Apremilast 20mg Twice Daily (BID)
62432565|NCT01988428|NO_INTERVENTION|standard care|"* standard care~* training of ambulance personnel in recognizing sepsis and initiating pre-hospital treatment"
62432566|NCT01988428|EXPERIMENTAL|Antibiotics|"* ceftriaxone 2000 mg (after taking bloodcultures)~* training of ambulance personnel in recognizing sepsis and initiating pre-hospital treatment"
62432567|NCT01710878|OTHER|Intergard Synergy Graft|
62432568|NCT06452433|EXPERIMENTAL|Gumarontinib combined with third-generation EGFR-TKI|Patients were treated with Gumarontinib in combination with third-generation EGFR-TKI (Osmertinib,Almonertinib, Furmonertinib) oral therapy until disease progression or the onset of intolerable toxicity, treatment is expected to last 3-6 months.
62242155|NCT03701763|EXPERIMENTAL|Administration of Apremilast (CC-10004) - 30mg|Apremilast 30mg Twice Daily (BID)
62242156|NCT03701763|PLACEBO_COMPARATOR|Administration of Placebo|Placebo tablet Twice Daily (BID)
62242157|NCT03571763||acute ischemic stroke patient|acute ischemic stroke patient acute ischemic stroke patient Patient age ≥18 years .Acute ischemic stroke patient confirmed by imaging(SWI sequence) .Time of onset: within 3 months
62242158|NCT00364871|EXPERIMENTAL|1|Bupropion SR (400 mg/day) plus Naltrexone (48 mg/day)
62242159|NCT00364871|EXPERIMENTAL|2|Bupropion SR (400 mg/day) plus Naltrexone (16 mg/day)
62242160|NCT00364871|ACTIVE_COMPARATOR|3|Bupropion SR (400 mg/day)
62242161|NCT00364871|ACTIVE_COMPARATOR|4|Naltrexone (48 mg/day)
62242162|NCT00364871|PLACEBO_COMPARATOR|5|B-Placebo plus N-Placebo
62242163|NCT00364871|PLACEBO_COMPARATOR|6|B-Placebo plus N-Placebo
62242164|NCT00364871|EXPERIMENTAL|7|Bupropion SR (400 mg/day) plus Naltrexone (32 mg/day)
62242165|NCT04924504||Type A|Healthy pregnant women without pregestational or gestational diabetes
62242166|NCT04924504||Type B|Pregnant women with type 2 diabetes or gestational diabetes with a total daily insulin dose \<= 75 units/day
62242167|NCT04924504||Type C|Pregnant women with type 2 diabetes or gestational diabetes with a total daily insulin dose \>= 100 units/day
62242168|NCT04304651|ACTIVE_COMPARATOR|Limited cancer screening|Limited screening alone.
62432569|NCT02144493||Patients with recurrent CBD stone|
62432570|NCT02144493||Patients without recurrent CBD stone|
62432571|NCT04869488|EXPERIMENTAL|Fluzoparib|
62432572|NCT04869488|ACTIVE_COMPARATOR|Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets|
62432573|NCT04869488|EXPERIMENTAL|Fluzoparib Combined With Apatinib|
62432574|NCT00769730||1|Patients with hepatocellular carcinoma caused by hepatitis B virus who will be treated by transcatheter arterial chemoembolization were included.
62735786|NCT06339450|EXPERIMENTAL|Patient Control|patient without cystic fibrosis
62242169|NCT04304651|EXPERIMENTAL|Limited cancer screening + FDG PET/CT|Limited screening + FDG PET/CT
62432575|NCT00513565|PLACEBO_COMPARATOR|placebo arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
62432576|NCT00513565|EXPERIMENTAL|GSK561679 arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
62432577|NCT00513565|ACTIVE_COMPARATOR|lorazepam arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
62599471|NCT06137703|EXPERIMENTAL|Sequence 2|Period 1 - Two zavegepant 100mg immediate release tablets (Treatment C) followed by at least 7 days washout; Period 2 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D) followed by at least 7 days washout; Period 3 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A) followed by at least 7 days washout; Period 4 - Single zavegepant 100mg immediate release tablet (Treatment B).
62599472|NCT06137703|EXPERIMENTAL|Sequence 3|Period 1 - Single zavegepant 100mg immediate release tablet (Treatment B) followed by at least 7 days washout; Period 2 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A) followed by at least 7 days washout; Period 3 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D) followed by at least 7 days washout; Period 4 - Two zavegepant 100mg immediate release tablets (Treatment C).
62599473|NCT06137703|EXPERIMENTAL|Sequence 4|Period 1 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D) followed by at least 7 days washout; Period 2 - Single zavegepant 100mg immediate release tablet (Treatment B) followed by at least 7 days washout; Period 3 - Two zavegepant 100mg immediate release tablets (Treatment C) followed by at least 7 days washout; Period 4 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A).
62599474|NCT01805076|OTHER|Arm 1 (control)|Patients undergo a clinical breast examination and mammography with ultrasound of the breast and regional nodes followed by breast conserving surgery.
62599475|NCT01805076|EXPERIMENTAL|Arm 2 (experimental)|Patients undergo a clinical breast examination, mammography with ultrasound of breast and regional nodes and breast MRI followed by breast conserving surgery or mastectomy.
62432578|NCT05057429|EXPERIMENTAL|Bioelectric Dressing on the Right Armpit and Standard Gauze Dressing on the Left Armpit|Participants undergoing standard of care deroofing surgery will be randomized to receive the bioelectric dressing for up to 8 weeks on the right armpit and will receive the standard gauze dressing for up to 8 weeks on the left armpit.
62039073|NCT05920369|EXPERIMENTAL|low-energy extracorporeal shockwave and a tailored exercise program|"the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a 0.056-0.068 mJ/mm range.~in addition to the following types of exercises: Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises"
62432579|NCT05057429|EXPERIMENTAL|Bioelectric Dressing on the Left Armpit and Standard Gauze Dressing on the Right Armpit|Participants undergoing standard of care deroofing surgery will be randomized to receive the bioelectric dressing for up to 8 weeks on the left armpit and will receive the standard gauze dressing for up to 8 weeks on the right armpit.
62432580|NCT06447519|EXPERIMENTAL|Ca(OH)2 intracanal medicament|Ca(OH)2 intracanal medicament used for root canal disinfection as interapointment dressing.
62432581|NCT06447519|NO_INTERVENTION|Standard of Care|No intracanal medicament. The root canal will be left empty without any intracanal dressing between appointments.
62432582|NCT00820391|EXPERIMENTAL|KIDNET|Narrative Exposure Therapy for Children
62432583|NCT00820391|EXPERIMENTAL|Meditation/Relaxation|
62432584|NCT00566098|EXPERIMENTAL|ASCT+MILs|Autologous stem cell transplant with a conditioning regimen of melphalan 100 mg/m\^2 on each of Days -2 and -1. Infusion of activated marrow infiltrating lymphocytes (MILs) on Day 3. PCV13 vaccine will be given before and/or after Day 0 depending on when participants are enrolled.
62432585|NCT03682783||Fundus Image|Glaucomatous and Non-glaucomatous fundus images that have been taken from the last 5 years in Shanghai General hospital.
62432586|NCT02038985|OTHER|+ ICG Dye (Firefly)|Participants will receive ICG Dye
62432587|NCT00037973|EXPERIMENTAL|1|Ventilation-feedback plus exercise
62432588|NCT00037973|ACTIVE_COMPARATOR|2|Exercise
62599476|NCT01552915|EXPERIMENTAL|Lisdexamfetamine Dimesylate|
62432589|NCT00037973|ACTIVE_COMPARATOR|3|ventilation feedback only
62432590|NCT02533388|EXPERIMENTAL|Electrical acupoint stimulation|Electrical acupoint stimulation at the Hegu (LI4), Neiguan (PC6), Lieque (LU7), Chize (LU5), Futu (LI18) and Renying (ST9) acupoints, Stimulus frequency was an alternate dense-disperse frequency of 2/10 Hz ( 2 Hz for 10 s and 10 Hz for 5 s). The optimal intensity ranged from 6-15 mA, which was adjusted to maintain a slight twitching of the regional muscles according to individual maximum tolerance.
62599477|NCT01552915|ACTIVE_COMPARATOR|Methylphenidate Hydrochloride|
62818549|NCT05764564|EXPERIMENTAL|Experimental: Patients with heart failure (Aim 2)|
62432591|NCT02533388|SHAM_COMPARATOR|Sham stimulation|Sham stimulation only connected to the apparatus, but electronic stimulation was not applied.
62242170|NCT03758521||BCH Cohort|Patients enrolled at BCH will travel to BCH every 2 years at a minimum for comprehensive evaluation taking place over a 48 hour period. Visits to BCH may occur within ± 2 months of the scheduled visit date. Electronic surveys will be sent out every 6 months.Visits will consist of clinical assessments (demographics, medical history, physical examination, neurological exam, medication history, neuropsychological assessments, and clinical severity score), neurophysiological assessments (Brain Magnetic resonance imaging \[MRI/MRS/DTI\], Electroencephalogram \[EEG\], and Transcranial magnetic stimulation \[TMS\]), and yearly bio-specimen collection.
62432592|NCT06317766|EXPERIMENTAL|Part 1 Pre-Clinical Procedure|"* 1 healthy adult (male or female)~* 18-75 years of age, who are scheduled to undergo an abdominoplasty (where abdominal skin will be excised) will be recruited.~* Informed consent will be obtained by a delegated member of the study staff prior to the day of surgery.~* On the day of the scheduled procedure, the laser device will be applied to the skin that will be removed as part of the surgery. The treatment will be completed after induction and prior to prepping for the surgical procedure."
62599478|NCT01552915|PLACEBO_COMPARATOR|Placebo|
62818550|NCT04758572|EXPERIMENTAL|Manual Therapy|"Mobilization. Axial decoaptation, talar mobilization, global and specific articulatory mobilization of the foot, mobilization of the fibular head, femorotibial mobilization, hip mobilization. In addition, lumbar joint mobilization is applied. It lasted 20 minutes. Subsequently, Trigger Point Inhibition is applied. in the medial gastrocnemius, soleus, and square plantar muscles.~Plantar fascia massage. A deep friction technique was applied longitudinally and transversely to the plantar fascia and the triceps surae. The duration was 5/10 minutes Passive stretching. Stretches were applied to the plantar fascia, the gastrocnemius muscles and the soleus muscles in order to relax these muscles. The duration was 5/10 minutes."
62818551|NCT04758572|ACTIVE_COMPARATOR|Massage|Consist of gentle kneading and rubbing based on a muscle chain protocol (20 minutes), and the same trigger point Inhibition, plantar fascia massage, and passive stretching.
62818552|NCT04595071|NO_INTERVENTION|Standard Control|Use of standard two-site myoelectric control of multi-articulating hand.
62039074|NCT05920369|ACTIVE_COMPARATOR|low-energy extracorporeal shockwave|the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a 0.056-0.068 mJ/mm range.
62039075|NCT05920369|ACTIVE_COMPARATOR|tailored exercise program|Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises. a combination of all these types of exercises will be used. Repeat these exercises 5 times, with 3 repetitions done each day for four consecutive weeks.
62818553|NCT04595071|EXPERIMENTAL|Voice Recognition Control|Use of voice recognition control in addition to standard two-site myoelectric control of a multi-articulating hand.
62818554|NCT05738174|EXPERIMENTAL|intermittent theta burst stimulation (iTBS)|1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold
62818555|NCT05738174|SHAM_COMPARATOR|sham treatment|1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold with angled coil
62818556|NCT06539598|EXPERIMENTAL|Respiratory Strength Training (RST)|Participants will receive a respiratory strength training device to take home and use up to 5 times a week for 12 weeks.
62818557|NCT03473756|EXPERIMENTAL|Rogaratinib + Atezolizumab in Part A|"Part A: Part A is conducted in patients who are cisplatin-ineligible and have had no prior systemic treatment for locally advanced or metastatic disease.~Patients will receive rogaratinib plus atezolizumab combination treatment."
62818558|NCT04882735|EXPERIMENTAL|Acoramidis HCI 800 mg (two 400mg tablets)|TTR stabilizer administered orally twice daily (BID)
62818559|NCT06592092|EXPERIMENTAL|QH104 cell Injection(Allogenic B7H3 CAR-γδT cell)|Plan to enroll 3 to 6 patients with meningeal metastasis of B7H3+ solid tumor with single or multiple local injections of allogenic B7H3 CAR-γδ T cells (3\*107/ dose)
62039076|NCT00626431|EXPERIMENTAL|Leuprolide acetate - Formulation A|Leuprolide acetate 45 mg, 6-month depot
62039077|NCT00626431|EXPERIMENTAL|Leuprolide acetate - Formulation B|Leuprolide acetate, 45 mg, 6-month depot
62039078|NCT04632875|EXPERIMENTAL|Loving-Kindness Meditation|4-week guided Loving-Kindness Meditation training (administered online).
62039079|NCT04632875|EXPERIMENTAL|Relaxation Meditation|4-week guided Relaxation Meditation training (administered online).
62242171|NCT03758521||iNTD Cohort|Patients enrolled at iNTD sites will travel to their iNTD site according to standard of care requirements. Data collection includes clinical history and relevant laboratory-chemical, therapeutic, instrumental and neuropsychological parameters by the study centers. Data collection takes place within the framework of elective outpatient visits. The collected parameters are congruent with the current standard investigations. Electronic surveys will be sent out every 6 months. Imaging and neurophysiological data will be collected if performed during the clinical visit or if performed as part of the site's ongoing research. Yearly bio-specimen collection will be attempted after consent is obtained from the family.
62242172|NCT03758521||Standard of Care Cohort|Patients enrolled at other sites will attend their visit at their regular clinical site as mandated by standard of care. Data collection includes medical history, family history, medications, and all clinical and neuropsychological assessments listed. Imaging and neurophysiological data will be collected if performed during the clinical visit or if performed as part of the clinical site's ongoing research. Yearly bio-specimen collection will be attempted.
62242173|NCT06736262|EXPERIMENTAL|Briquilimab|Briquilimab via SQ injection
62818560|NCT06234059|EXPERIMENTAL|Healthy Adult Speakers|healthy adult participants across the lifespan in three groups:18-35, 36-55, and 56+
62818561|NCT03338777|EXPERIMENTAL|Suicide plus immunogene therapy|Intra and peritumoral infiltrates with multiple injections of lipoplexes carrying the HSVtk suicide gene co-administered with GCV and subcutaneous vaccine produced with formolized allogeneic tumor extracts and lipoplexes carrying hIL-2 and hGM-CSF genes.
62818562|NCT03516123|EXPERIMENTAL|CS3006|Participants will receive CS3006 orally at specified dose on specified days
62818563|NCT06705283|EXPERIMENTAL|yoga group|This is a group where yoga and home exercise (pelvic floor muscle training) will be done together.
62818564|NCT06705283|EXPERIMENTAL|whole body vibration training (WBVT) group|This is a group where whole body vibration training and home exercise (pelvic floor muscle training) will be done together.
62039080|NCT05809752|EXPERIMENTAL|Dendritic Cell (DC) Vaccine dose escalation|HER2/3 peptide-pulsed DC1 will be administered intrathecally (IT) weekly for 6 doses /cycle for a maximum of two cycles, and then re-staged. If there are sufficient DC1s this may be continued weekly thereafter. There are 1 safety cohort (1 million DCV cells) and 3 escalating doses (2 million, 10 million and 50 million DCV cells) possible.
62039081|NCT05531773||COVID-19 patients|patients recovered from an acute COVID-19 episode
62039082|NCT01751828|EXPERIMENTAL|Sertraline|Open-label sertraline, 8 week trial, dosing from 50mg to 200mg daily.
62242174|NCT00227487|OTHER|Stool collection, Carbohydrate administration, Questionnaires|"A stool sample will be obtained~A carbohydrate solution (lactulose plus rhamnose dissolved in tap water) will be administered during a clinically indicated endoscopic procedure.~Five questionnaires will be completed by parent/guardian"
62242175|NCT05191069|EXPERIMENTAL|Moringa Oleifera Mouthwash|15ml of Moringa Oleifera mouthwash will be given to be used twice daily for 6 months.
62242176|NCT05191069|PLACEBO_COMPARATOR|Placebo Mouthwash|The mouthwash will have all other ingredients other than Moringa Oleifera extract. Participants will be advised to use 15ml of Placebo mouthwash twice daily for 6 months.
62599479|NCT03875092|EXPERIMENTAL|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
62818565|NCT06705283|ACTIVE_COMPARATOR|home exercise group|This is a group where pelvic floor muscle training will be done.
62818566|NCT01781936|EXPERIMENTAL|Low dose FA-i (Fluocinolone Acetonide insert)|Each FA-i contains 180 µg FA (Fluocinolone Acetonide) designed to be released over 15 - 30 months.
62818567|NCT06705231||Decided not participate group|Children aged 5-10 years with obesity from the city of Aarhus, who decided not to participate in the lifestyle intervention in Aarhus municipality.
62039083|NCT03921515|OTHER|1|Blister Induction
62039084|NCT03921515|OTHER|2|Skin Biopsies
62039085|NCT06419322|OTHER|Treated cohort|
62039086|NCT02069444||Truview EVO2 laryngoscope|patients intubated withTruview EVO2 laryngoscope
62039087|NCT02069444||Macintosh laryngoscope|patients intubated with Macintosh laryngoscope
62818568|NCT06705231||Intervention group|Children aged 5-10 years with obesity who participated in a one-year lifestyle intervention in Aarhus municipality.
62599480|NCT03875092|ACTIVE_COMPARATOR|Chemotherapy|Participants receive normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
62599481|NCT04789291|EXPERIMENTAL|BI 1595043 fasted (Reference (R)) / BI 1595043 fed (Test (T))|"Two period crossover separated by a wash-out of at least 8 days:~Period 1: Healthy subjects received a single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet) following an overnight fast of at least 10 hours.~Period 2: Healthy subjects received a single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet) following an following a high fat/high calorie breakfast."
62599482|NCT04789291|EXPERIMENTAL|BI 1595043 fed (Test (T)) / BI 1595043 fasted (Reference (R))|"Two period crossover separated by a wash-out of at least 8 days:~Period 1: Healthy subjects received a single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet) following an following a high fat/high calorie breakfast.~Period 2: Healthy subjects received a single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet) following an overnight fast of at least 10 hours."
62599483|NCT00635453|EXPERIMENTAL|I, Intervention|"Physicians, nurses and administrative staff of all intervention health centers participated in a training of Dietary Advice in January 2008 based on the Ten Steps for Healthy Feeding for Brazilian Children from Birth to Two Years of Age guideline.13 An experienced nutritionist conducted a standardized session for the health care team to outline the Ten Steps recommendations and strategies and to provide suggestions how best to incorporate these into the consultations. Printed materials were provided to the Health Care Centers for use by these professionals and for access to the Brazilian Ministry of Healthy Nutrition Department´s website. Health staff members received a pocket guide for use during the appointments and waiting room sessions."
62818569|NCT06705231||Non-intervention group|Children aged 5-10 years with obesity from the city of Aarhus, who were never invited to participate in the intervention.
62818570|NCT05460104|EXPERIMENTAL|Expérimental|Virtual Reality Exposure Therapy will be realised.
62818571|NCT05460104|ACTIVE_COMPARATOR|Control|Standard care without VRET
62818572|NCT04028713|ACTIVE_COMPARATOR|Standard dosing group|Patients will continue to receive adalimumab according to the standard dosing schedule.
62039088|NCT06732232|EXPERIMENTAL|CD19/CD20/BCMA CAR-T cells therapy|CD19/CD20/BCMA CAR T cells Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CD19/CD20/BCMA CAR T cells. Cyclophosphamide and fludarabine will be given from day-5 to day-3 before the infusion for lymphodepletion. On day0 subjects will receive one dose treatment with CD19/CD20/BCMA CAR T cells by intravenous (IV) injection
62039089|NCT06542198|EXPERIMENTAL|Healthy adults|Part 1 of the study is conducted with healthy adults.
62039090|NCT06542198|EXPERIMENTAL|Primary polydipsia (PP) patients|Part 2 of the study is conducted with PP patients.
62242177|NCT04260451|EXPERIMENTAL|Driving pressure group|Positive end expiratory pressure is adjusted to tidal volume of 5 mL/kg of ideal body weight, inspiratory:expiratory=1:2, and minimize driving pressure (plateau pressure minus end expiratory pressure) during one-lung ventilation. Other procedures are same with the control arm.
62242178|NCT04260451|NO_INTERVENTION|Protective Ventilation|The control arm receives existing conventional protective ventilation with tidal volume of 5mL/kg of ideal body weight and positive end expiratory pressure of 5cmH2O during one-lung ventilation
62818573|NCT04028713|EXPERIMENTAL|Dose tapering group|Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.
62242179|NCT02838862||Response to Therapy|
62242180|NCT02838862||No therapy response|
62242181|NCT03733067|EXPERIMENTAL|abatacept|Adult and pediatric dosing will be based on weight per protocol
62432593|NCT06317766|EXPERIMENTAL|Part 2 Clinical Study Procedure|"* 1 healthy adult (male or female)~* 18-75 years of age, who are scheduled to undergo an abdominoplasty (where abdominal skin will be excised) will be recruited.~* Informed consent will be obtained by a delegated member of the study staff prior to the day of surgery.~* The study team will utilize the specific setting based off the results of Part 1.~* Subject will be asked to return to the site on days -30, -3, -2, -1 before their procedure.~* At each visit, subjects will receive a single pulse treatment in areas that will be marked by the study team.~* On the day of their procedure, a member of the study team will administer 1 final pulse immediately post-surgery and all 5 timepoints will be harvested for analysis."
62599484|NCT00635453|NO_INTERVENTION|II, Control|Healthcare centers randomized to the non-intervention group continued their routine medical assistance without any involvement of the research team. No materials were provided to these clinics.
62039091|NCT06542198|EXPERIMENTAL|Arginine vasopressin deficiency (AVP-D) patients|Part 2 of the study is conducted with AVP-D patients.
62039092|NCT03341793|EXPERIMENTAL|Muscle secretion|Characterize the changes in muscle secretion induced by bariatric surgery and determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by B cell responsible for the remission of diabetes mellitus.
62039093|NCT05500469|ACTIVE_COMPARATOR|GDD-tube in anterior chamber|The Paul glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal or nasal quadrant of the eye. The tube is positioned in the anterior chamber.
62039094|NCT05500469|EXPERIMENTAL|GDD-tube in posterior chamber|The Paul glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal or nasal quadrant of the eye. The tube is positioned in the posterior chamber.
62039095|NCT05127174|EXPERIMENTAL|Phase 1: Dose Level 1|Participants will take 200 mg fedratinib once daily by mouth.
62039096|NCT05127174|EXPERIMENTAL|Phase 1: Dose Level 2|Participants will take 300 mg fedratinib once daily by mouth.
62599485|NCT02625441|EXPERIMENTAL|Short anti-HER2 treatment|Pertuzumab 840 mg, i.v., then 420 mg i.v., 3-weekly for 3 cycles; Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles
62039097|NCT05127174|EXPERIMENTAL|Phase 1: Dose Level 3|Participants will take 400 mg fedratinib once daily by mouth.
62039098|NCT05127174|EXPERIMENTAL|Phase 2: Treatment at Recommended Phase 2 Dose (RP2D)|Participants will take fedratinib at the dose determined in the phase 1 portion of this study, once daily by mouth.
62039099|NCT04360733||asymptomatic Covid-19|Patients with confirmed SARS-CoV2 PCR but no clinical symptoms
62039100|NCT04360733||symptomatic Covid-19|Patients with confirmed SARS-CoV2 PCR and light clinical symptoms
62039101|NCT04360733||severe Covid-19|Patients with confirmed SARS-CoV2 PCR and severe clinical symptoms with ICU admission
62039102|NCT04360733||healthy controls|Persons with negative SARS-CoV2 PCR
62039103|NCT02427126|EXPERIMENTAL|Apixaban|Apixaban 5mg b.i.d. Study treatment: 12 months Follow-up: 30 days after last study drug intake
62039104|NCT02427126|ACTIVE_COMPARATOR|Aspirin|Acetylic Salicylic Acid 100mg o.d.; Study treatment: 12 months Follow-up: 30 days after last study drug intake
62039105|NCT01402453|NO_INTERVENTION|Control Subjects|Receive educational materials and a home BP monitor.
62039106|NCT01402453|EXPERIMENTAL|Intervention Subjects|Receive educational materials and a home BP monitor, as well as monetary incentives tied to amount of improvement in BP from baseline and a personalized intervention to internalize motivation for BP control. Monthly monetary incentives will cease after 6 months.
62242182|NCT03733067|PLACEBO_COMPARATOR|placebo|will be given as the same IV volume as abatacept
62242183|NCT01291199|EXPERIMENTAL|Vardenafil 10 mg bid|
62432594|NCT05522933|EXPERIMENTAL|Musculoskeletal Health|The intervention group will receive the 4 weekly workshops
62599486|NCT02625441|ACTIVE_COMPARATOR|Standard anti-HER2 treatment|Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles; Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
62818574|NCT04096430|EXPERIMENTAL|ENGAGE approach (child-oriented goal-setting)|Therapists will receive training on our principles-based goal setting approach and strategies in the goal setting toolbox. Training will include an overview of tools and strategies including the Perceived Efficacy and Goal Setting Tool (PEGS) and the Pediatric Activity Card Sort (PACS). In addition, we will provide training on Goal Attainment Scaling and administration of the Canadian Occupational Performance Measure (COPM). We will introduce simple strategies to assist children in identifying goals and to ensure ongoing focus on goals using principles of motivational interviewing, strategies to assess and nurture perceived competence (self-efficacy), and child-friendly feedback strategies on goal-related performance.
62818575|NCT04096430|NO_INTERVENTION|Usual care|The control group will comprise of usual care.
62818576|NCT05108870|EXPERIMENTAL|Phase 1: Dose-Finding Group 1 - Drug Combination 1|"All participants in this group will receive HB-201 combined with chemotherapy using carboplatin and paclitaxel.~- HB-201 will be administered on cycle 1 day 15, cycle 2 day 15, and cycle 3 day 15 with three 21-day cycles of carboplatin on day 1 and paclitaxel 100mg/m2 on days 1, 8, and 15"
62242184|NCT01291199|PLACEBO_COMPARATOR|Placebo|
62242185|NCT06736470||5-ALA|Patients who are prescribed 5-ALA (n=13)
62599487|NCT06113341||IDegLira + Dose Check|Participants will be treated with commercially available Xultophy® (IDegLira) used with Dose Check app according to local label and routine clinical practice at the discretion of the treating physician.
62599488|NCT06618131|ACTIVE_COMPARATOR|Exercising with Virtual Reality|12 participants will undergo a virtual reality exercise program with the X-Box 360 KinectTM game console (X-Box 360, Microsoft, United States of America) for 50 minutes a day, 2 days a week for 12 weeks.
62599489|NCT06618131|NO_INTERVENTION|Control Group|In this group of 12 people, there will be no intervention.
62599490|NCT01892085|EXPERIMENTAL|Early initiation|Initiation of breast milk expression \<1 hour following delivery.
62599491|NCT01892085|EXPERIMENTAL|Intermediate expression|Initiation of milk expression 1-\<3 hours following delivery.
62242186|NCT06736470||No 5-ALA|Patients who are not prescribed 5-ALA (n=7)
62242187|NCT02414724|EXPERIMENTAL|Treatment (ribociclib, gemcitabine hydrochloride)|Patients receive ribociclib PO on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62242188|NCT03470675|PLACEBO_COMPARATOR|Epidural saline + IV saline|Sterile saline via the epidural catheter. Sterile saline via intravenous catheter.
62242189|NCT03470675|ACTIVE_COMPARATOR|Epidural morphine 3 mg + IV saline|3 milligrams morphine via the epidural catheter. Sterile saline via intravenous catheter.
62599492|NCT01892085|OTHER|Late initiation|Initiation of milk expression \>3-6 hours following delivery.
62599493|NCT03820219|PLACEBO_COMPARATOR|Standard sterile wound dressing|Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
62599494|NCT03820219|ACTIVE_COMPARATOR|Prevena™ system|The Prevena™ System is indicated for use over clean, closed incisions that continue to drain following sutured or stapled closure. It acts by removing exudate, helping hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment, until it is removed at Post-Operative Day 7.
62599495|NCT00875433|EXPERIMENTAL|Monotherapy|BIBW 2992 high dose, once daily, continuous, monotherapy
62599496|NCT01312233|ACTIVE_COMPARATOR|Medical Care|Conventional medical care alone
62818577|NCT05108870|EXPERIMENTAL|Phase 1: Dose-Finding Group 2 - Drug Combination 2|"All participants in this group will receive alternating doses of HB-201 and HB-202 combined with chemotherapy using carboplatin and paclitaxel.~Participants will be given 3 doses of HB-201 \& HB-202 alternating two vector therapy. Patients will receive 2 doses of HB-202 and 1 dose of HB-201. HB-202 will be administered on cycle 1 day 15 and cycle 3 day 15, and HB-201 will be administered on cycle 2 day 15 with three 21-day cycles of chemotherapy with carboplatin on day 1 and paclitaxel 100mg/m2 on days 1, 8, and 15."
62039107|NCT05243758|ACTIVE_COMPARATOR|Group video fiberscope of experienced practitioner|More experienced physician: endotracheal intubation with video fiberscope Assoc. Dr. The group in which Ersin Köksal performed endotracheal intubation using a video fiberscope( Karl Storz GmbH \&Co. KG, Tuttlingen, Germany) consisted of 15 patients.Endotracheal intubation was performed by two practitioners using two different devices. Intubation times, number of attempts, failed attempts, postoperative complications and hemodynamic responses were recorded.
62818578|NCT05108870|EXPERIMENTAL|Phase 2: Efficacy Arm 1 - HB-201 + Chemotherapy|"Participants in this group will receive HB-201 combined with chemotherapy using carboplatin and paclitaxel at the dose established in the first phase of the study.~After completing treatment at the established phase 2 dose, subjects will receive surgery, radiotherapy alone, or chemotherapy with radiotherapy together based on how their tumor responds to the medications."
62818579|NCT05108870|EXPERIMENTAL|Phase 2: Efficacy Arm 2 - HB-201 and HB-202 + Chemotherapy|"Participants in this group will receive alternating doses of HB-201 and HB-202 combined with chemotherapy using carboplatin and paclitaxel at the dose established in the first phase of the study.~After completing treatment at the established phase 2 dose, subjects will receive surgery, radiotherapy alone, or chemotherapy with radiotherapy together based on how their tumor responds to the medications."
62432595|NCT03908112|ACTIVE_COMPARATOR|Standard Community Concussion Care (SC)|Standard concussion care consists of physical and cognitive rest immediately following the injury for a brief period of time to allow symptoms to abate, followed by a gradual reintroduction of academic and physical activities, restricting activities at high risk for repeat brain injury (such as contact or collision sports) until a graded return to play protocol has been completed in a symptom-free manner.
62818580|NCT03678064|EXPERIMENTAL|Lokomat|16 sessions total. Provided by study PT twice weekly for 8 weeks.
62432596|NCT03908112|EXPERIMENTAL|SC plus Simple Convergence Procedures (SC+)|In addition to the treatment described for SC, participants in this group will be asked to work with the Brock String, which is a popular and simple therapy technique designed to improve convergence. A 3-phase, graded Brock String procedure has been developed for ICONICC.
62432597|NCT03908112|EXPERIMENTAL|SC plus Office-based Vergence/Accommodative Therapy (SC+VAT)|Office-based vergence accommodative therapy (OBVAT) is administered by a study certified therapist at weekly intervals (60-minute office visits with 55 minutes of therapy time), combined with procedures to practice at home for 15 minutes, 5 times per week.
62432598|NCT01076166||Children with lower respiratory tract infection|Thai children with lower respiratory tract infections on Klacid Granules for Oral Suspension
62432599|NCT00399490|EXPERIMENTAL|1|
62432600|NCT04014101|EXPERIMENTAL|SHR-1210+ apatinib|SHR-1210 was administered intravenously (without prophylaxis) at a fixed dose of 200 mg for 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 2 years; Apatinib was taken orally after meals, once a day, for continuous medication, and 1 cycle every 4 weeks.
62432601|NCT01528878|EXPERIMENTAL|Good liver function.|Patients with good liver function as defined by no more than Child-Pugh Class A.
62599497|NCT01312233|ACTIVE_COMPARATOR|Dual Care|Unlinked co-occurrence of conventional medical care and chiropractic care
62599498|NCT01312233|ACTIVE_COMPARATOR|Shared Care|Co-management of medical care and chiropractic care
62599499|NCT05704335||Patients with headache during the course of influenza|Patients with influenza infection who experience new-onset headache during the course of the disease, or a two-fold worsening of a prior headache disorder, according to the International Classification of Headache Disorders
62039108|NCT05243758|ACTIVE_COMPARATOR|Group video laryngoscope of experienced practitioner|More experienced physician: Endotracheal intubation with DCI video laryngoscopeThe group in which Assoc. Dr. Ersin Köksal performed endotracheal intubation using a DCI video laryngoscope(Storz DCI Video Laryngoscope (Karl Storz GmbH \&Co. KG, Tuttlingen, Germany) consisted of 15 patients.Endotracheal intubation was performed by two practitioners using two different devices. Intubation times, number of attempts, failed attempts, postoperative complications and hemodynamic responses were recorded.
62039109|NCT05243758|ACTIVE_COMPARATOR|Group video fiberscope of less experienced practitioner|Endotracheal intubation with video fiberscope: The group in which DrHalil Cebeci applied endotracheal intubation using a video fiberscope( Karl Storz GmbH \&Co. KG, Tuttlingen, Germany) consisted of 15 patients. Endotracheal intubation was performed by two practitioners using two different devices. Intubation times, number of attempts, failed attempts, postoperative complications and hemodynamic responses were recorded.
62039110|NCT05243758|ACTIVE_COMPARATOR|Group video laryngoscope of less experienced practitioner|Endotracheal intubation with DCI video laryngoscope:The group in which Dr.Halil Cebeci applied endotracheal intubation using a DCI video laryngoscope(Karl Storz GmbH \&Co. KG, Tuttlingen, Germany) consisted of 15 patients.Endotracheal intubation was performed by two practitioners using two different devices. Intubation times, number of attempts, failed attempts, postoperative complications and hemodynamic responses were recorded.
62039111|NCT06052696|EXPERIMENTAL|Gardasil 9|see intervention
62039112|NCT06052696|PLACEBO_COMPARATOR|placebo|see intervention
62039113|NCT06311695|EXPERIMENTAL|Contrast Enhanced Mammography|Patients underwent Contrast Enhanced Mammography
62039114|NCT04274907|EXPERIMENTAL|Dose Escalation Phase: Venetoclax + Pembrolizumab|Participants will receive escalating doses of venetoclax in combination with pembrolizumab Dose A.
62039115|NCT04274907|EXPERIMENTAL|Randomization Phase: Venetoclax + Pembrolizumab|Participants will receive venetoclax at dose levels determined in the dose escalation phase in combination with pembrolizumab Dose A.
62039116|NCT04274907|ACTIVE_COMPARATOR|Randomization Phase: Pembrolizumab Monotherapy|Participants will receive pembrolizumab Dose A
62039117|NCT00038051|EXPERIMENTAL|HuM195/rGel|HuM195/rGel starting Dose = 3 mg/m\^2 twice weekly for 2 weeks.
62039118|NCT00916682||Cystic Fibrosis|
62039119|NCT00071617|EXPERIMENTAL|Youth-Nominated Support Team|Adolescents nominate up to 4 caring adults from family, school, community settings. These adults participate in psychoeducation sessions regarding adolescent's treatment plan and support needs. They maintain regular, supportive contact with the adolescent for 3 months -- with ongoing consultation and support check-ins from study clinical staff.
62242190|NCT03470675|ACTIVE_COMPARATOR|Epidural morphine 3 mg + IV ketamine 0.3 mg/kg|3 milligrams morphine via the epidural catheter. Ketamine 0.3 milligrams per kilogram via intravenous catheter.
62818581|NCT05668351|EXPERIMENTAL|SUPR-SABR treatment|The prescription dose of this study will be 40 Gy in 5 fractions assigned to PTV_4000 which permits sparing of the rectum, urethra and pudendal artery. There will be a secondary dose level of 36.25 Gy in 5 fractions. A minimum dose of 36.25 Gy will be given to the entire prostate PTV_3625. 36.25 Gy in five fractions is currently endorsed as a standard of care for localized prostate cancer by the National Comprehensive Cancer Network guidelines in prostate cancer. Escalating the therapeutic radiation dose above 36.25 Gy provides potential for improved biochemical control of prostate cancer and decrease in relapse free survival.
62432602|NCT01528878|EXPERIMENTAL|Compromised liver function.|Patients with compromised liver function as defined by patients with Child-Pugh Class B.
62818582|NCT06466746|ACTIVE_COMPARATOR|Faba bean-enriched bread.|100 g of bread prepared using 40% faba bean flour and 60% wheat flour will be provided in the breakfast test meal.
62818583|NCT06466746|PLACEBO_COMPARATOR|Conventional white bread|100 g of white bread prepared using 100% wheat flour will be provided in the breakfast test meal.
62599500|NCT06622018|PLACEBO_COMPARATOR|Group A (Control Group)|About 11 patients with hypersensitive teeth of no treatment materials used
62818584|NCT05856877|ACTIVE_COMPARATOR|Nasal insulin spray|
62599501|NCT06622018|ACTIVE_COMPARATOR|Group B(Seashell Nanoparticles Group)|About 11 patients with hypersensitive teeth faced treatment by sea shell nanoparticles
62818585|NCT05856877|PLACEBO_COMPARATOR|Placebo spray|
62818586|NCT05891431|EXPERIMENTAL|Untire app|"Participants will be given access to the Untire app.~Untire is a mHealth app and a registered medical device (ICD10 code R53.83 Fatigue) introduced in 2018 to treat Cancer Related Fatigue in adults."
62818587|NCT03743272||Liver condition|Participants who have a history of of liver disease
62818588|NCT03743272||Healthy volunteers|Participants who have do not have a diagnosed liver condition and are in general good health
62039120|NCT00071617|NO_INTERVENTION|Enhanced Treatment as Usual|Adolescents in this condition receive study assessments and risk management services (at time of assessments) only
62039121|NCT05202301||Darolutamide cohort (Daro)|Participants received Second Generation Androgen Receptor Inhibitor (SGARI) Darolutamide as initial treatment
62039122|NCT05202301||Enzalutamide cohort (Enza)|Participants received Second Generation Androgen Receptor Inhibitor (SGARI) Enzalutamide as initial treatment
62039123|NCT05202301||Apalutamide cohort (Apa)|Participants received Second Generation Androgen Receptor Inhibitor (SGARI) Apalutamide as initial treatment
62039124|NCT06661733|EXPERIMENTAL|Cohort 1|Participants with severe renal impairment (eGFR ≥ 15 to \< 30 mL/min/1.73 m2, not requiring dialysis).
62039125|NCT06661733|EXPERIMENTAL|Cohort 2|Participants who are healthy control (eGFR ≥ 90 mL/min/1.73 m2) matched at a group level to Cohort 1.
62039126|NCT06661733|EXPERIMENTAL|Cohort 3 (conditional)|Participants with moderate renal impairment (eGFR ≥ 30 to \< 60 mL/min/1.73 m2).
62242191|NCT00152698|ACTIVE_COMPARATOR|Irbesartan|
62599502|NCT06622018|ACTIVE_COMPARATOR|Group C (Gluma Group)|About 11 patients with hypersensitive teeth faced treatment by Gluma
62242192|NCT00152698|PLACEBO_COMPARATOR|Placebo|
62242193|NCT05082116|EXPERIMENTAL|N8-GP prophylaxis|All patients will receive prophylaxis with 50 IU/kg N8-GP every 4 days for a treatment period of at least 28 weeks (with the possibility of switching to twice-weekly dosing during the treatment period at the discretion of the investigator).
62242194|NCT04694898|OTHER|Control|Households in the control arm receive standard/national nutrition specific interventions, i.e. growth monitoring, vaccination, vitamin A supplementation and deworming
62818589|NCT00492817|EXPERIMENTAL|Single Session Stereotactic Body Radiotherapy (SBRT)|On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
62039127|NCT03937154|EXPERIMENTAL|Romiplostim|The study in a 2:1 randomization ratio(108 subjects to romiplostim). Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
62818590|NCT06031623|NO_INTERVENTION|Control|Patients allocated to this arm receives conventional resuscitative measures according to the 2020 AHA CPR Guidelines.
62039128|NCT03937154|PLACEBO_COMPARATOR|Placebo|The study in a 2:1 randomization ratio (54 subjects to placebo) Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
62039129|NCT03912558|EXPERIMENTAL|Butterfly device implantation|"Butterfly device implantation will be performed following initial cystoscopy to evaluate prostate condition and rule out other pathologies.~Following implant size selection, the Butterfly implant will be deployed and positioned through the cystoscope over-sheath. After deployment the cystoscope (with its optics) will be re-introduced into the urethra to examine the Butterfly device position."
62039130|NCT04453631|EXPERIMENTAL|active tDCS + CBT-UP|Active tDCS combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
62242195|NCT04694898|EXPERIMENTAL|SURE Intervention|"Households in the intervention group with children younger than 2 years benefit from:~1. Interpersonal contacts to provide counselling on infant and young child feeding practices (IYCF) and nutrition-sensitive agriculture advice to mothers and fathers of children under 24 months, inclusive of pregnant women and fathers-to-be, jointly delivered by the local health and agriculture extension workers during routine household visits~2. Men's and women's group dialogues targeting all men and women in a given community network, facilitated also by the local health and agriculture extension workers~3. Media campaign to reinforce IYCF and dietary diversity messages"
62818591|NCT06031623|EXPERIMENTAL|REBOA|After enrollment and randomization, patients allocated to this arm receives REBOA in addition to conventional ACLS according to the 2020 AHA CPR guidelines. The common femoral artery is accessed with ultrasound guidance. A sheath catheter is inserted, followed by a REBOA catheter. The REBOA is ballooned with 20cc of normal saline or until resistance is felt.
62039131|NCT04453631|ACTIVE_COMPARATOR|sham tDCS + CBT-UP|Sham tDCS (control for active tDCS) combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
62039132|NCT04453631|ACTIVE_COMPARATOR|active tDCS + Psychoeducation|Active tDCS combined with psychoeducation (control condition for CBT-UP).
62039133|NCT04453631|PLACEBO_COMPARATOR|sham tDCS + Psychoeducation|Sham tDCS combined with psychoeducation (control conditions for active tDCS and CBT-UP).
62039134|NCT05198466|ACTIVE_COMPARATOR|Active E-Stim|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
62039135|NCT05198466|SHAM_COMPARATOR|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
62039136|NCT01684748|EXPERIMENTAL|Olmesartan Medoxomil first, then No Drug|During the First Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects receive additional daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), no drug will be administered to the subjects.
62242196|NCT01543386|OTHER|curcumin|The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
62432603|NCT04365088|EXPERIMENTAL|Deflazacort|Deflazacort is a glucocorticoid used as an anti-inflammatory drug. We used deflazacort 30 mg tablet. Patient took a pill once preoperatively (1 hour ago) in third molar surgery.
62432604|NCT04365088|PLACEBO_COMPARATOR|Sugar pill|Placebo is an inert substance or treatment which is designed to have no therapeutic value. Patients took sugar pill for plasebo once one hour before operation.
62599503|NCT02211690|EXPERIMENTAL|dolutegravir 50mg with co-formulated emtricitabine-tenofovir|One-hundred eligible participants will receive dolutegravir (1 x 50mg tablet) with co-formulated emtricitabine-tenofovir (1 tablet) once daily for 28 days
62818592|NCT03730909|EXPERIMENTAL|Lactate infusion|Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels
62818593|NCT03730909|PLACEBO_COMPARATOR|NaCl infusion|As a control condition, subjects will receive intravenous NaCl infusion
62818594|NCT03901274|ACTIVE_COMPARATOR|Wellness Condition|Participants in this condition will receive school-based behavioral health services from clinicians who are trained in the evidence-based Wellness Framework.
62818595|NCT03901274|EXPERIMENTAL|Partnership|Participants in this condition will receive school-based behavioral health services from clinicians who are trained in the evidence-based Wellness framework. The clinicians in this condition will receive additional training on patient-centered enhancements called the Partnership intervention.
62818596|NCT05622864|EXPERIMENTAL|PartA|
62599504|NCT04457375||Healthy Adults|Healthy
62818597|NCT05622864|EXPERIMENTAL|PartB|
62818598|NCT02340793|EXPERIMENTAL|Counterweight Plus Dietary Intervention|Weight management programme including total diet replacement with soups and shakes; approximately 800 calories/day
62432605|NCT02798237|EXPERIMENTAL|Aerobic treadmill training|"Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of aerobic treadmill training at 60-80% of heart rate reserve). The training intensity progression will be individualized.~Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously during training. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program. Device: treadmill."
62599505|NCT04913337|EXPERIMENTAL|NGM707 Monotherapy Dose Escalation|Part 1a Single Agent Dose Escalation
62432606|NCT02798237|SHAM_COMPARATOR|Control (overground walking)|Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of comfortable walking below 40% of heart rate reserve). Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program.
62599506|NCT04913337|EXPERIMENTAL|NGM707 Combination Dose Finding with pembrolizumab (KEYTRUDA®)|Part 1b NGM707 plus pembrolizumab (KEYTRUDA®)
62242197|NCT00818389|ACTIVE_COMPARATOR|1|Participants randomized to lithium/riluzole (randomization is 1:1 lithium/riluzole to placebo/riluzole, i.e., participants have an equal chance of getting randomized to lithium vs. placebo).
62599507|NCT04913337|EXPERIMENTAL|NGM707 Combination Dose Expansion Arm A|NGM707 with pembrolizumab (KEYTRUDA®) in Squamous NSCLC
62599508|NCT04913337|EXPERIMENTAL|NGM707 Combination Dose Expansion Arm B|NGM707 with pembrolizumab (KEYTRUDA®) in Non-Squamous NSCLC
62599509|NCT04913337|EXPERIMENTAL|NGM707 Combination Dose Expansion Arm C|NGM707 with pembrolizumab (KEYTRUDA®) in SCCHN
62599510|NCT04913337|EXPERIMENTAL|NGM707 Monotherapy Dose Expansion Arm D|NGM707 in RCC
62599511|NCT04913337|EXPERIMENTAL|NGM707 Monotherapy Dose Expansion Arm E|NGM707 in CRC
62599512|NCT04913337|EXPERIMENTAL|NGM707 Monotherapy Dose Expansion Arm F|NGM707 in Ovarian
62242198|NCT00818389|PLACEBO_COMPARATOR|2|Participants randomized to placebo/riluzole (randomization is 1:1 lithium/riluzole to placebo/riluzole, i.e., participants have an equal chance of getting randomized to lithium vs. placebo).
62599513|NCT03268824||Children / adolescents with drug-resistant focal epilepsy|
62432607|NCT02434796|EXPERIMENTAL|Arm 1 Male Peer Groups (MPG)|Women participate in savings groups and male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. This intervention aims to improve knowledge and attitudes about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals (e.g. caring for one's family) and to challenge gender stereotypes (e.g. women are not equal to men); and the ability to formulate positive outcome expectations regarding IPV (intolerance of violence perpetrated by themselves or others) and healthy relationships with their spouses and communities.
62039137|NCT01684748|EXPERIMENTAL|No Drug first, then Olmesartan Medoxomil|During the First Intervention (8 weeks), no drug will be administered to the subjects. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects then receive daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period.
62039138|NCT05916326|EXPERIMENTAL|Experimental vaccine group|
62039139|NCT05916326|PLACEBO_COMPARATOR|placebo group|
62039140|NCT05916326|EXPERIMENTAL|Experimental vaccine group（Immunogenic subgroup ）|
62039141|NCT05916326|PLACEBO_COMPARATOR|placebo group（Immunogenic subgroup）|
62039142|NCT05156190|EXPERIMENTAL|bright classrooms with skylight or renovated artificial light|Students will study in bright classrooms with either skylight or renovated artificial light with light level of over 1000 lux on school time for three years and vision will be screened annually.
62039143|NCT05156190|NO_INTERVENTION|conventional classrooms|Students will study in conventional classrooms with normal light level for three years and vision will be screened annual.
62432608|NCT02434796|EXPERIMENTAL|Arm 2 MPG & Community Dialogues|This arm will include women participants in savings groups, male peer groups and community dialogues. Village community leaders will engage in community dialogues on gender norms, IPV and HIV prevention.
62432609|NCT00361257|EXPERIMENTAL|Arm 1: Minocycline|100 mg orally every 12 hours
62599514|NCT03268824||Children / adolescents without drug-resistant focal epilepsy|
62432610|NCT00361257|PLACEBO_COMPARATOR|Arm 2: Matching placebo|orally every 12 hours
62432611|NCT05471219|EXPERIMENTAL|Çalışma grubu|Primiparous pregnant women who will undergo vaginal examination by focusing on visual traces
62599515|NCT04154462|NO_INTERVENTION|No intervention|The VAMC sites randomized to the comparison arm will not have medical scribes introduced into emergency departments or specialty clinics.
62039144|NCT06112756|EXPERIMENTAL|Elinzanetant arm|Participants will take Elinzanetant
62039145|NCT06112756|PLACEBO_COMPARATOR|Placebo arm|Participants will take elinzanetant matching placebo
62432612|NCT05471219|NO_INTERVENTION|Kontrol grubu|Primiparous pregnant women who will undergo vaginal examination with standard care
62432613|NCT02874638|EXPERIMENTAL|BASE egg protein|0.8 g/kg/d of BASE protein provided as crystalline amino acid made after egg protein.
62432614|NCT02874638|EXPERIMENTAL|BCAA-enriched egg protein|branched-chain amino acid-enriched egg protein
62432615|NCT02874638|EXPERIMENTAL|small amount of essential amino acids|small amount of essential amino acids made after egg protein, which is equivalent to the amount of essential amino acids in BASE
62432616|NCT02874638|EXPERIMENTAL|large amount of essential amino acids|large amount of essential amino acids made after egg protein, which is equivalent to the amount of amino acids in BCAA
62432617|NCT01584726|OTHER|magnesium sulfate arm|magnesium sulfate with standard therapy
62432618|NCT01584726|NO_INTERVENTION|placebo arm|placebo with standard therapy
62039146|NCT06519968|EXPERIMENTAL|Part 1a: AZD4604 (Dose 1) SAD|Japanese participants will receive single dose of AZD4604 (Dose 1) via inhalation on Day 1.
62039147|NCT06519968|EXPERIMENTAL|Part 1a: AZD4604 (Dose 2) SAD|Japanese participants will receive single dose of AZD4604 (Dose 2) via inhalation on Day 1.
62242199|NCT03253939||Case group|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
62432619|NCT04878250|EXPERIMENTAL|Bintrafusp alfa|
62432620|NCT01001676|ACTIVE_COMPARATOR|Conventional Balloon Angioplasty|
62599516|NCT04154462|EXPERIMENTAL|Treatment|The VAMC sites randomized to the treatment arm are each expected to have four medical scribes, with two being VA employees and two being contractors, introduced into emergency departments or specialty clinics to assist providers during patient encounters.
62599517|NCT05261334|ACTIVE_COMPARATOR|socket shield technique|immediate implant placement with socket shield technique
62599518|NCT05261334|ACTIVE_COMPARATOR|contour augmentation|early implant placement with contour bone augmentation
62599519|NCT00750841|EXPERIMENTAL|1|Cediranib alone, followed by cediranib plus rifampicin, followed by cediranib alone.
62599520|NCT01756105|EXPERIMENTAL|treatment by Metformin plus insulin if needed|Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
62039148|NCT06519968|EXPERIMENTAL|Part 1a: AZD4604 (Dose 3) SAD|Japanese participants will receive single dose of AZD4604 (Dose 3) via inhalation on Day 1.
62039149|NCT06519968|PLACEBO_COMPARATOR|Part 1a: Placebo|Japanese participants will receive single dose of matching placebo to AZD4604 on Day 1.
62242200|NCT03253939||Control group|Cytoreductive surgery alone
62242201|NCT03540472|EXPERIMENTAL|efficiency of tacrolimus on PRCA|"A prospective research of the tacrolimus efficiency on refractory PRCA patients On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study.~Medication time should last at least 6 months."
62432621|NCT01001676|EXPERIMENTAL|Drug Eluting Balloon Angioplasty|
62432622|NCT03830931||Primary knee arthroplasty patients|Fasting Plasma Glucose test will be obtained the morning after surgery and the frequency of hyperglycemia in non diabetic and diabetic patients will be evaluated
62432623|NCT02360410|EXPERIMENTAL|Check Yourself App With Feedback|Adolescents complete Check Yourself, an electronic health screening app and receive personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers receive a summary report of health risk behaviors from Check Yourself prior to their adolescent patient's primary care appointment.
62818599|NCT06070766||Chronic Pain|Drug: Ketamine The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine research within the treatment plan of those with chronic conditions. A RIVER Ketamine protocol will be developed
62039150|NCT06519968|EXPERIMENTAL|Part 1b: AZD4604 (Dose 4) Multiple dose cohort|Japanese participants will receive AZD4604 (Dose 4) via inhalation twice daily (BID) from Day 1 to Day 6 and a single dose on Day 7.
62818600|NCT06070766||Anxiety|Drug: Ketamine The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine research within the treatment plan of those with chronic conditions. A RIVER Ketamine protocol will be developed
62432624|NCT02360410|NO_INTERVENTION|Usual Care|Participants are asked to complete health risk screening on a tablet computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors.
62432625|NCT03951597|EXPERIMENTAL|Combined therapy using Gemox, Lenvatinib and PD1|"1. Gemox chemotherapy Day1 oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day8 gemcitabine 1g/m2 Three weeks is a course of treatment with a total of 6 courses.~2. Lenvatinib (8mg/d), continuous use for 1 year.~3. PD-1 antibody (JS001) (240mg every 3 weeks), continuous use for 1 year."
62818601|NCT06070766||Veterans and First Responders|The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine research within the treatment plan of those with chronic conditions. A RIVER Ketamine protocol will be developed
62818602|NCT06070766||Depression|Drug: Ketamine The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine research within the treatment plan of those with chronic conditions. A RIVER Ketamine protocol will be developed
62432626|NCT02680977|EXPERIMENTAL|MP-Equivalent; MP-Low; MP+DDCI|"MP-Equivalent: Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI (for example 100mg of Madopar corresponds to 500mg of Levodopa in MP).~MP-Low: Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI (for example 100mg of Madopar corresponds to 350mg of Levodopa in MP) MP+DDCI: Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI (for example 100mg of Madopar corresponds to 100mg of Levodopa in MP plus 25mg of Benserazide)"
62432627|NCT02680977|ACTIVE_COMPARATOR|LD+DDCI; LD-DDCI|"LD+DDCI: Levodopa plus Benserazide (dispersible formulation). The dose is calculated as 3.5mg per kg of body weight.~LD-DDCI: Levodopa without any dopa decarboxylase inhibitor (galenic formulation). The dose is 5-fold than LD+DDCI."
62432628|NCT02680977|PLACEBO_COMPARATOR|Placebo|Powder of groundnuts
62432629|NCT06025396|EXPERIMENTAL|Active TMP-301|"Cohort 1= 50mg, capsules form, one capsule - two times per day - total 100mg/day;~Cohort 2= 50mg, capsule form, 1 capsules - one time per day- total 50mg/day~Cohort 3= 50mg, capsule form, 2 capsules - one time per day- total 100mg/day;~Cohort 4 = Dose Titration: 50mg, capsule form, 1 capsules - one time per day - total 50 mg/day - on Days 1-7; and 50 mg, capsule form, 2 capsules - one time per day - total 100mg/day - on Days 8-14;~Each cohort duration is 14 days of dosing"
62432630|NCT06025396|PLACEBO_COMPARATOR|Placebo|"Cohort 1= Placebo, capsules form, one capsule - two times per day;~Cohort 2= Placebo, capsule form, 1 capsules - one time per day;~Cohort 3= Placebo, capsule form, 2 capsules - one time per day;~Cohort 4 = Dose Titration: Placebo, capsule form, 1 capsules - one time per day - on Days 1-7; and Placebo, capsule form, 2 capsules - one time per day - on Days 8-14;~Each cohort duration is 14 days of dosing"
62735787|NCT05965076|ACTIVE_COMPARATOR|Standard|Patients will be professionally treated with standard dental hygiene treatment, and they will use a standard toothbrush for their domiciliary oral hygiene.
62818603|NCT06070766||Trauma|Drug: Ketamine The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine research within the treatment plan of those with chronic conditions. A RIVER Ketamine protocol will be developed
62818604|NCT06070766||Auricular Chronic Pain|"Auricular Therapy (Ear acupuncture)~1. National Acupuncture Detoxification Association~2. Battlefield Acupuncture"
62818605|NCT06070766||Auricular Anxiety|"Auricular Therapy (Ear acupuncture)~1. National Acupuncture Detoxification Association~2. Battlefield Acupuncture"
62818606|NCT06070766||Auricular Depression|"Auricular Therapy (Ear acupuncture)~1. National Acupuncture Detoxification Association~2. Battlefield Acupuncture"
62818607|NCT06070766||Auricular Trauma|"Auricular Therapy (Ear acupuncture)~1. National Acupuncture Detoxification Association~2. Battlefield Acupuncture"
62039151|NCT06519968|PLACEBO_COMPARATOR|Part 1b: Placebo|Japanese participants will receive matching placebo to AZD4604 BID from day 1 to day 6 and a single dose of placebo on Day 7.
62039152|NCT06519968|EXPERIMENTAL|Part 2a: AZD4604 (Dose 1) SAD|Chinese participants will receive single dose of AZD4604 (Dose 1) via inhalation on Day 1.
62039153|NCT06519968|EXPERIMENTAL|Part 2a: AZD4604 (Dose 3) SAD|Chinese participants will receive single dose of AZD4604 (Dose 3) via inhalation on Day 1.
62039154|NCT06519968|PLACEBO_COMPARATOR|Part 2a: Placebo|Chinese participants will receive single dose of matching placebo to AZD4604 on Day 1.
62039155|NCT06519968|EXPERIMENTAL|Part 2 b: AZD4604 (Dose 4) Multiple dose cohort|Chinese participants will receive AZD4604 (Dose 4) via inhalation BID from Day 1 to Day 6 and a single dose on Day 7.
62242202|NCT04919252|EXPERIMENTAL|Vedolizumab|"* Crohn's disease (CD): If a subject does not respond to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, an additional dose of vedolizumab 300 mg will be given at week 10. On the other hand, Maintenance therapy should be continued every 8 weeks from week 14 in responding patients, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks.~* Ulcerative colitis (UC): If a subject responds to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, maintenance therapy should be continued every 8 weeks from week 14, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks."
62242203|NCT02195258||salbutamol|
62039156|NCT06519968|PLACEBO_COMPARATOR|Part 2b: Placebo|Chinese participants will receive placebo via inhalation BID from Day 1 to Day 6 and a single dose on Day 7.
62242204|NCT01096888|NO_INTERVENTION|Standard WIC care|Patients randomized to this group will receive standard WIC care and an information packet surround healthy eating and activity topics.
62242205|NCT01096888|ACTIVE_COMPARATOR|Enhanced WIC weight loss program|Participants randomized into this condition will receive standard WIC care, but will also receive weight loss classes provided through the internet. Topics will cover behavioral weight loss topics, based off the protocols of the Look AHEAD program.
62432631|NCT02544945|ACTIVE_COMPARATOR|Standard Bolus|The radiotherapy treatment days when the standard bolus is used
62432632|NCT02544945|EXPERIMENTAL|3D printed bolus|the radiotherapy treatment days when the 3D bolus is used
62432633|NCT02499549|EXPERIMENTAL|10% Cocamide diethanolamine 8 hours|Cocamide DEA topical lotion applied 8 hours/overnight with drying
62432634|NCT02499549|EXPERIMENTAL|10% Cocamide diethanolamine 2 hours|Cocamide DEA topical lotion applied 2 hours with drying, repeated after 7 days
62432635|NCT01092702|OTHER|Varenicline|Everyone on study will receive Varenicline daily for 12 weeks
62432636|NCT05990205|ACTIVE_COMPARATOR|Life Style Intervention|Hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week)
62432637|NCT05990205|ACTIVE_COMPARATOR|Life Style Intervention + Metformin|Hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week) + (750 mg metformin twice a day).
62432638|NCT00323609|ACTIVE_COMPARATOR|Kyphoplasty|
62432639|NCT00323609|ACTIVE_COMPARATOR|Vertebroplasty|
62735788|NCT05965076|EXPERIMENTAL|Glycine|Patients will be professionally treated by adding glycine perio-flow in the treatment, and they will use a standard toothbrush for their domiciliary oral hygiene.
62039157|NCT02471196|EXPERIMENTAL|ORM-12741 low dose|ORM-12741 low dose twice a day for 12 weeks.
62039158|NCT02471196|EXPERIMENTAL|ORM-12741 high dose|ORM-12741 high dose twice a day for 12 weeks.
62039159|NCT02471196|PLACEBO_COMPARATOR|Placebo|Placebo twice a day for 12 weeks.
62242206|NCT00685685|EXPERIMENTAL|Lovastatin 40 mg tablet|A single dose of Lovastatin 40 mg administered after an overnight fast of at least 10 hours.
62242207|NCT00685685|EXPERIMENTAL|Lovastatin (Mevacor®) 40 mg Tablet|A single dose of Lovastatin (Mevacor®) 40 mg administered after an overnight fast of at least 10 hours.
62242208|NCT00307125|EXPERIMENTAL|Pilot Phase-Rituximab plus immunosuppression|"Enrollment into a Stage 2 pilot treatment study will occur after Stage 1. Adult Rituximab Dosing (Subjects \> 18 years): 1000 mg on days 0 and 14; Pediatric Rituximab Dosing (Subjects \<\\=18 years): 375 mg/m\^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
62242209|NCT00307125|PLACEBO_COMPARATOR|Pilot Phase-Placebo plus immunosuppression|"Adult Placebo Dosing (Subjects \>18 years): 1000 mg on days 0 and 14; Pediatric Placebo Dosing (Subject \<\\=18 years): 375 mg/m\^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
62432640|NCT03166306|EXPERIMENTAL|Patients with idiopathic or familial PAH|Ten patients with severe idiopathic or familial PAH will undergo PET-CT imaging with \[89Zr\]-bevacizumab.
62432641|NCT03166306|EXPERIMENTAL|Patients with exercise associated PAH|Ten patients with exercise associated PAH (EPAH) will undergo PET-CT imaging with \[89Zr\]-bevacizumab.
62432642|NCT03166306|ACTIVE_COMPARATOR|Healthy volunteers|Ten individuals with no known cardiopulmonary disease will undergo PET-CT imaging with \[89Zr\]-bevacizumab.
62039160|NCT06662227|EXPERIMENTAL|Off-the-shelf REVO-UWD-19|Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning, followed by a one-time injection of universal UWD-19 cells
62039161|NCT03969862||Patient with an allergen-mediated IgE allergy|Patients with a clinical history consistent with an allergen-mediated IgE allergy \& with a sensitization demonstrated by a positive Prick-Test for the allergen source tested
62039162|NCT03969862||Patient without an allergen-mediated IgE allergy|Patient without a clinical history compatible with an IgE allergy-mediated allergy and without PT sensitization to be allergen
62039163|NCT01016665|PLACEBO_COMPARATOR|Placebo|Placebo
62039164|NCT01016665|OTHER|Tamoxifen|Tamoxifen 20 mg day 26 days
62432643|NCT04345731|NO_INTERVENTION|Condition 1 - Control|"We note that our within subjects experimental design, in which each subject receives all treatments, is not well suited to this system of reporting. Thus we are defining arms as the label treatments we are evaluating. This label is the control label treatment which represents the current, legally required over-the-counter labeling standard."
62432644|NCT04345731|EXPERIMENTAL|Condition 2 - Highlighted|This condition will involve a novel method of presenting critical active ingredient, drug/drug, and drug/diagnosis information with highlighting.
62039165|NCT01016665|OTHER|Anastrozole|Anastrozole 1mg 26 days
62242210|NCT06734234|EXPERIMENTAL|Part A: Cohort 1: Participants receiving GSK4771261 Dose level 1|Healthy participants will be randomized to receive GSK4771261 Dose level 1.
62242211|NCT06734234|EXPERIMENTAL|Part A: Cohort 2 : Participants receiving GSK4771261 Dose level 2|Healthy participants will be randomized to receive GSK4771261 Dose level 2.
62039166|NCT06685861|EXPERIMENTAL|i-CBT group|i-CBT combined with conventional drug treatment
62242212|NCT06734234|EXPERIMENTAL|Part A: Cohort 3: Participants receiving GSK4771261 Dose level 3|Healthy participants will be randomized to receive GSK4771261 Dose level 3.
62242213|NCT06734234|EXPERIMENTAL|Part A: Cohort 4: Participants receiving GSK4771261 Dose level 4|Healthy participants will be randomized to receive GSK4771261 Dose level 4.
62242214|NCT06734234|EXPERIMENTAL|Part A: Cohort 5: Participants receiving GSK4771261 Dose level 5|Healthy participants will be randomized to receive GSK4771261 Dose level 5.
62242215|NCT06734234|EXPERIMENTAL|Part A: Cohort 6: Participants receiving GSK4771261 Dose level 6|Healthy participants will be randomized to receive GSK4771261 Dose level 6.
62242216|NCT06734234|EXPERIMENTAL|Part A: Cohort 7 (optional): Participants receiving GSK4771261 Dose level 7|Healthy participants will be randomized to receive GSK4771261 Dose level 7 as the recommendation of Dose escalation committee (DEC).
62242217|NCT06734234|EXPERIMENTAL|Part A: Cohort 8 (optional): Participants receiving GSK4771261 Dose level 8|Healthy participants will be randomized to receive GSK4771261 Dose level 8, as per the recommendation from DEC.
62432645|NCT04345731|EXPERIMENTAL|Condition 3 - FOP warning label|This condition will involve presenting critical drug/drug, and drug/diagnosis information in a novel Front-of-Pack (FOP) warning label.
62432646|NCT04345731|EXPERIMENTAL|Condition 4- FOP+Highlighting label|This condition will combine both the highlighting and FOP labeling interventions from conditions 2 and 3. Note: Across the four arms we are essentially doing a 2 (highlighting/no highlighting) by 2 (front of pack warning/ no front of pack warning) within subjects design.
62599521|NCT01756105|ACTIVE_COMPARATOR|treatment by insulin|Insulin therapy:If post meal (2 hours after meal) glycaemia is \> to 120 mg/dl introduce Insulin rapid acting analog (Humalog\*, Novorapid\*) before the meal concerned and according to the weight. If weight is \< 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is \> 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH\*, insulatard\*) before sleeping : 5U if weight is \< 80 kg - 6U if weight is \> 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
62599522|NCT05537792|EXPERIMENTAL|Smart Robotic Knee/Ankle Prothesis|This study will be conducted on a sample population of individuals with transfemoral amputation (single arm). Each participant will test with each condition of the study (repeated measures).
62599523|NCT04616560|EXPERIMENTAL|Treatment (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 35 cycles in the absence of disease progression or unacceptable toxicity.
62599524|NCT04047134|EXPERIMENTAL|Experimental Group (EG)|The Experimental Group (EG) will observe and execute/repeat Activities of Daily Living (ADL) actions.
62599525|NCT04047134|ACTIVE_COMPARATOR|Control Group (CG)|The COntrol Group (CG) will observe landscapes and perform the same actions observed by their peers but after verbal instructions.
62599526|NCT04112160|PLACEBO_COMPARATOR|control|normal saline 0.9%
62599527|NCT04112160|ACTIVE_COMPARATOR|Ketorolac|30 mg of Ketorolac
62599528|NCT04878445||Cohort A: 10 participants with no COPD|"Control patients Have no physician diagnosis of COPD Have no other significant chronic lung disease (asthma, fibrotic diseases) or ongoing lung infection other than the suspected cancer for which they have been referred for surgery.~Lifelong never-smokers or ex-smokers (\< 10 pack years). (1 pack year= 20 cigarettes/day for 1 year)."
62599529|NCT04878445||Cohort B: 10 participants with COPD - chronic bronchitis|Have a physician diagnosis of COPD with primarily a chronic bronchitis presentation (determined via CT, spirometry, histopathology, GOLD COPD classification).
62599530|NCT04878445||Cohort C: 10 participants with COPD emphysema|Have a physician diagnosis of COPD with primarily a emphysema presentation (determined via CT, spirometry, histopathology, GOLD COPD classification) .
62039167|NCT06685861|NO_INTERVENTION|control group|conventional drug treatment
62242218|NCT06734234|EXPERIMENTAL|Part B: Cohort 1: Participants receiving GSK4771261 Dose level 9|Participant with Autosomal dominant polycystic kidney disease (ADPKD) will be randomized to receive GSK4771261 Dose level 9.
62432647|NCT06242522|OTHER|Female patients with gestational trophoblastic tumour.|Female patients treated in phase II or III clinical trials: TROPHIMMUN and TROPHAMET or who have received AVELUMAB outside the trial for a gestational trophoblastic tumour.
62432648|NCT00711867|EXPERIMENTAL|VH2|Dynatherm vitalHeat2 (VH2) temperature management system.
62432649|NCT00711867|ACTIVE_COMPARATOR|Bair Hugger|Arizant Bair Hugger temperature management system.
62432650|NCT05202613||Dorage group|"* HIV-1 infected patients~* aged \> 50 years old~* naive patients receiving doravirine-based regimens~* experienced patients with persistent HIV RNA \< 50 copies/mLfor at least 6 months, who switched to doravirine-based regimens, because of toxicity, convenience or other reasons."
62432651|NCT05202613||Control group|HIV negative subjects, matched for age and Charlson Index score (to evaluate comorbidity impact)
62599531|NCT01185223|OTHER|Valganciclovir|
62039168|NCT04998357|EXPERIMENTAL|Transplantation|Endovascular infusion
62242219|NCT06734234|EXPERIMENTAL|Part B: Cohort 2: Participants receiving GSK4771261 Dose level 10|Participant with ADPKD will be randomized to receive GSK4771261 Dose level 10.
62242220|NCT06734234|EXPERIMENTAL|Part B: Cohort 3: Participants receiving GSK4771261 Dose level 11|Participant with ADPKD will be randomized to receive GSK4771261 Dose level 11.
62432652|NCT02267733|EXPERIMENTAL|Early Disease|Patients not requiring anti-tumor therapy
62432653|NCT02267733|EXPERIMENTAL|Disease Requiring Anti-tumor therapy|Patients that have disease requiring anti-tumor therapy at any time
62242221|NCT06734234|EXPERIMENTAL|Part B: Cohort 4 (optional): Participants receiving GSK4771261 Dose level 12|Participant with ADPKD will be randomized to receive GSK4771261 Dose level 12 as the recommendation from DEC.
62039169|NCT04576091|EXPERIMENTAL|Treatment (pembrolizumab, BAY 1895344, SBRT)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Starting on day 7, patients also receive BAY 1895344 PO BID on days 7-9 and 14-16 during cycle 1, and before and after each SBRT treatment during cycle 2 for a total of 9 doses. Beginning cycle 2, patients undergo SBRT starting between days 2 and 8 for 3 fractions with 2-3 days between fractions. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or PET-CT scan and collection of blood samples throughout the trial.
62818608|NCT06070766||Chronic Pain MH|4. Millennium Health The Phase 2 Protocol (P2P) has entered its 4th year of application in those with symptoms associated with all forms of traumatic brain injury (T.B.I.). Listening to any of the following Joe Rogan Experience podcasts, 1589, 1056, or 700, will provide a number of discussions on this topic. Since the 2020 pilot study with active duty Marines (U.S.M.C.), looking at the benefits of a 100% nutraceutical approach to T.B.I., precipitated changes in mental and physical health, we had the start to developing the P2P. With over 8,000 participants, we see the benefits derived from the 2023 Phase 2 Protocol.
62242222|NCT06734234|EXPERIMENTAL|Part B: Cohort 5 (optional): Participants receiving GSK4771261 Dose level 13|Participant with ADPKD will be randomized to receive GSK4771261 Dose level 13, as per the recommendation from DEC.
62242223|NCT06734234|PLACEBO_COMPARATOR|Part A: Participants receiving placebo matching GSK4771261|Participants will receive placebo matching GSK4771261
62242224|NCT06734234|PLACEBO_COMPARATOR|Part B: Participants receiving placebo matching GSK4771261|Participants will receive placebo matching GSK4771261
62242225|NCT01323621|EXPERIMENTAL|Fluticasone Furoate / GW642444 (vilanterol)|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
62432654|NCT04455074|EXPERIMENTAL|PD patients with motor fluctuations|FN scale is an autoquestionnaire consisting of 20 questions, to be answered in On-med and OFF-med condition
62432655|NCT04273152||children with allergy|children with allergies
62432656|NCT04273152||healthy control|healthy control (non allergic children)
62242226|NCT01323621|ACTIVE_COMPARATOR|Fluticasone Propionate / salmeterol|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
62432657|NCT06383377|ACTIVE_COMPARATOR|Bio-Oss®|Tooth scheduled for extraction will be removed in the least traumatic way. The socket will be filled with the comparator (Bio-Oss® Geistlich, granules 0.25 - 1mm). Two follow up visits to monitor the healing process will take place at 2 and 6 weeks after surgery. Implant placement will be performed 4 months after the regenerative procedure. Implant loading will be allowed after having waited a minimum of 3 months after the implant placement and after a control visit. The implant survival and success will be assessed at 3, 6 and 12 months after implant placement. A long-term follow-up will evaluate the implant survival and success at 3 and 5 years post implant placement.
62599532|NCT01185223|ACTIVE_COMPARATOR|Ganciclovir|
62039170|NCT06095570|EXPERIMENTAL|Group C|Ciprofol + sufentanil + rocuronium bromide
62599533|NCT02793401|ACTIVE_COMPARATOR|HILT group|71 of the patients were in the HILT group
62599534|NCT02793401|ACTIVE_COMPARATOR|US Group|70 of the patients were in the US group.
62599535|NCT04188015|EXPERIMENTAL|2.5mg ANX007|1 in every 3 subjects will be randomized to 2.5mg dose of ANX007.
62599536|NCT04188015|EXPERIMENTAL|5.0mg ANX007|1 in every 3 subjects will be randomized to 5.0mg dose of ANX007.
62242227|NCT05572684|EXPERIMENTAL|NC410 and pembrolizumab|All participants will receive NC410 (IV) and pembrolizumab (IV) according to the treatment schedule until a reason for treatment discontinuation is reached.
62242228|NCT03445260|PLACEBO_COMPARATOR|Placebo|Each placebo is composed of a collagen-based filler with exactly the same taste and texture as the intervention.
62242229|NCT03445260|EXPERIMENTAL|Nutritional Supplements|carbohydrate loading, immunonutrition (formulated liquid diet), protein supplement
62599537|NCT04188015|SHAM_COMPARATOR|Sham Procedure|1 in every 3 subjects will have a sham procedure performed instead of receiving ANX007.
62242230|NCT06569186|ACTIVE_COMPARATOR|Intervention|Cue-based feedings
62242231|NCT06569186|NO_INTERVENTION|Control|Clinician based feedings
62599538|NCT01882881|ACTIVE_COMPARATOR|Healthy American Control Diet|
62599539|NCT01882881|EXPERIMENTAL|Dark Chocolate/Cocoa Diet|
62599540|NCT01882881|EXPERIMENTAL|Almond Diet|
62599541|NCT01882881|EXPERIMENTAL|Dark Chocolate/Cocoa + Almond Diet|
62818609|NCT06070766||Anxiety MH|4. Millennium Health The Phase 2 Protocol (P2P) has entered its 4th year of application in those with symptoms associated with all forms of traumatic brain injury (T.B.I.). Listening to any of the following Joe Rogan Experience podcasts, 1589, 1056, or 700, will provide a number of discussions on this topic. Since the 2020 pilot study with active duty Marines (U.S.M.C.), looking at the benefits of a 100% nutraceutical approach to T.B.I., precipitated changes in mental and physical health, we had the start to developing the P2P. With over 8,000 participants, we see the benefits derived from the 2023 Phase 2 Protocol.
62818610|NCT06070766||Depression MH|4. Millennium Health The Phase 2 Protocol (P2P) has entered its 4th year of application in those with symptoms associated with all forms of traumatic brain injury (T.B.I.). Listening to any of the following Joe Rogan Experience podcasts, 1589, 1056, or 700, will provide a number of discussions on this topic. Since the 2020 pilot study with active duty Marines (U.S.M.C.), looking at the benefits of a 100% nutraceutical approach to T.B.I., precipitated changes in mental and physical health, we had the start to developing the P2P. With over 8,000 participants, we see the benefits derived from the 2023 Phase 2 Protocol.
62818611|NCT06070766||Tramua MH|4. Millennium Health The Phase 2 Protocol (P2P) has entered its 4th year of application in those with symptoms associated with all forms of traumatic brain injury (T.B.I.). Listening to any of the following Joe Rogan Experience podcasts, 1589, 1056, or 700, will provide a number of discussions on this topic. Since the 2020 pilot study with active duty Marines (U.S.M.C.), looking at the benefits of a 100% nutraceutical approach to T.B.I., precipitated changes in mental and physical health, we had the start to developing the P2P. With over 8,000 participants, we see the benefits derived from the 2023 Phase 2 Protocol.
62818612|NCT06571253|EXPERIMENTAL|Fiziu Digital Physiotherapy Platform Arm|Participants in this arm received a 6-week corrective exercise program delivered via the Fiziu Digital Physiotherapy Platform. The program included guided exercise videos, visual and auditory instructions, and automated reminders to ensure adherence. This arm was designed to evaluate the effectiveness of digital exercise delivery in improving forward head posture (FHP).
62818613|NCT06571253|EXPERIMENTAL|Paper-Based Exercise Program Arm|Participants in this arm followed a traditional paper-based exercise program for 6 weeks. The program included written instructions and images illustrating the exercises. This arm served as a comparison to evaluate the effectiveness of the traditional exercise delivery method against the digital platform.
62818614|NCT06047093|EXPERIMENTAL|HBsAg <100 IU/ml|Patients chronically mono-infected with HBV, whose HBsAg is less than 100 IU/ml (patients treated or not with NA)
62818615|NCT06047093|EXPERIMENTAL|HBsAg between 100 and 3000 IU/ml|Patients chronically mono-infected with HBV, with HBsAg levels \>100 and \<3000 IU/ml (patients treated or not with NA).
62818616|NCT06047093|EXPERIMENTAL|HBsAg ≥ 3000 IU/ml|Patients chronically mono-infected with HBV, with HBsAg levels ≥ 3000 IU/ml (patients treated or not with NA).
62818617|NCT06047093|EXPERIMENTAL|Loss of HBsAg (spontaneously or under NA)|"Patients with loss of HBsAg (spontaneously or under NA). This group will allow comparison of the HBsAg loss immuno-virological profile with that of patients with active infection and varying levels of HBsAg (groups 1-3 and 5) and aid in identifying of predictors of functional cure. The identification of determinants of HBV functional cure is fundamental and is comparable to investigations that have been carried out in HIV-infected elite controllers."
62818618|NCT06047093|EXPERIMENTAL|Patients co-infected with HBV and HDV|Patients co-infected with HDV (positive HDV viral load), regardless of HBsAg level (presence or absence of HBV or HDV treatment)
62818619|NCT03888612|EXPERIMENTAL|ARV-110|"Part A: Oral tablet(s), once or twice daily in 28 day cycles~Part B: Oral tablet(s), once or twice daily in 28 day cycles"
62242232|NCT06115967|EXPERIMENTAL|AZD6912 Dose 1|Participants will receive AZD6912 Dose 1.
62242233|NCT06115967|EXPERIMENTAL|AZD6912 Dose 2|Participants will receive AZD6912 Dose 2.
62242234|NCT06115967|EXPERIMENTAL|AZD6912 Dose 3|Participants will receive AZD6912 Dose 3.
62242235|NCT06115967|EXPERIMENTAL|AZD6912 Dose 4|Participants will receive AZD6912 Dose 4.
62242236|NCT06115967|EXPERIMENTAL|AZD6912 Dose 5|Participants will receive AZD6912 Dose 5.
62242237|NCT06115967|EXPERIMENTAL|AZD6912 Dose 6|Participants will receive AZD6912 Dose 6.
62242238|NCT06115967|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo.
62242239|NCT06115967|EXPERIMENTAL|AZD6912 additional Japanese cohort 1|Participants will receive AZD6912.
62242240|NCT06115967|EXPERIMENTAL|AZD6912 additional Japanese cohort 2|Participants will receive AZD6912.
62242241|NCT06735443|EXPERIMENTAL|Bupivacaine with Dexmetedomidine group|In group A, patients will be given 0.25% bupivacaine 1 mL/kg with dexmedetomidine 0.5μg/kg
62242242|NCT06735443|EXPERIMENTAL|Bupivacaine with Tramadol group|In group B, patients will be given 0.25% bupivacaine 1 mL/kg with 1 mg/kg of tramadol
62242243|NCT06734117||Participants With Signs and Symptoms of Acute Coronary Syndromes|The study population will be a consecutive all-comers cohort consisting of patients with signs and symptoms of acute coronary syndromes presenting to the emergency department. Participants will be diagnosed and treated according to the local standard of care at the study site.
62599542|NCT01258179||Sepsis Group|Patients suffering from sepsis in the postoperative course after major abdominal surgery
62242244|NCT05638087|EXPERIMENTAL|Dexamethasone Treatment|Oral Dexamethasone treatment
62242245|NCT05638087|PLACEBO_COMPARATOR|Placebo Treatment|Placebo control
62242246|NCT02830997||Conventional guidance|The conventional guidance will undergo TKA surgery with use of the Investigator's usual precision guided technique based on conventional instrumentation (mechanical and simple computer-assisted guidance techniques). For participants of the conventional guidance arm, the Investigator will employ the established technique he currently employs for all routine TKA procedures and would employ if the patient were not a participant in the study.
62242247|NCT02830997||Stereotactic guidance|The stereotactic guidance group will undergo their TKA surgery with use of a stereotactic guidance system.
62599543|NCT01258179||Control Group|Patients without suffering sepsis during postoperative follow up after major abdominal surgery
62735789|NCT05965076|EXPERIMENTAL|Angled toothbrush|Patients will be professionally treated with standard dental hygiene treatment, and they will use an angled toothbrush for their domiciliary oral hygiene.
62242248|NCT04435379|EXPERIMENTAL|VPM1002|"The active ingredient of the recombinant BCG vaccine, VPM1002, is Mycobacterium bovis rBCGΔureC::hly, freeze-dried and standardized to the number of viable mycobacteria (colony forming units; CFU) per application.~Dose: 2-8 x 10e5 CFU VPM1002 administered in 0.1 ml reconstituted suspension."
62599544|NCT02584894|PLACEBO_COMPARATOR|rTMS 1Hz|Subjects have 8 session of trauma exposure with repeated transcranial magnetic stimulation (rTMS) at 1Hz on dorsolateral prefrontal cortex (1Hz rTMS is describe in the literature to have no effect on the dorsolateral prefrontal cortex). psychoneurological assessment. Electrodermal conductance measure With conductivity meter . Heart rate measure With electrocardiogram
62599545|NCT02584894|EXPERIMENTAL|rTMS 10Hz|Subjects have 8 session of trauma exposure with repeated transcranial magnetic stimulation (rTMS) at 10Hz on dorsolateral prefrontal cortex (10Hz rTMS is describe in the literature to have effect on the dorsolateral prefrontal cortex). psychoneurological assessment. Electrodermal conductance measure With conductivity meter. Heart rate measure with electrocardiogram
62599546|NCT04040634|EXPERIMENTAL|Intensive Control of Systolic Blood Pressure (SBP)|Participants randomized into the Intensive Blood Pressure arm will have a goal of SBP \<120 mm Hg.
62818620|NCT05247372|OTHER|The effect of Iyengar yoga practice on patients with multiple sclerosis|
62242249|NCT04435379|PLACEBO_COMPARATOR|Placebo|Physiological saline 0.1ml
62242250|NCT02743819|EXPERIMENTAL|Treatment|Treatment with the combination of pembrolizumab and ipilimumab.
62242251|NCT01400581|EXPERIMENTAL|Collaborative Care [CC] Intervention|The CC intervention will consist of offering subjects: 1) an in-depth baseline assessment, 2) frequent (weekly first, then monthly) visits with a nurse care manager, 3) alcohol dependence medications prescribed by a Nurse Practitioner. An interdisciplinary CC team will supervise nurse care managers weekly.
62599547|NCT04040634|ACTIVE_COMPARATOR|Standard Control of Systolic Blood Pressure (SBP)|Participants randomized into the Standard arm will have a goal of SBP \<140 mm Hg.
62599548|NCT06645054||LLL|Rehabilitation patients with lower limb loss
62818621|NCT04519164|EXPERIMENTAL|Eplerenone|Participants will receive eplerenone, ranging from 25-100mg daily for one year.
62242252|NCT01400581|NO_INTERVENTION|Usual Care|Observational
62039171|NCT06095570|ACTIVE_COMPARATOR|Group R|Remimazolam+ sufentanil + rocuronium bromide
62039172|NCT04781374|EXPERIMENTAL|Neratinib|"The research study procedures include: screening for eligibility and study treatment including evaluations and follow up visits.~- Neratinib-once daily with 28 consecutive days defined as a treatment cycle"
62242253|NCT02231788|EXPERIMENTAL|Telminuvo®Tab. 40/2.5mg|Telminuvo®Tab.(Telmisartan/S-Amlodipine) 40/2.5mg
62432658|NCT06383377|EXPERIMENTAL|WHA|Tooth scheduled for extraction will be removed in the least traumatic way. The socket will be filled with the investigational device (WHA, granules 0.25- 1.0mm). Two follow up visits to monitor the healing process will take place at 2 and 6 weeks after surgery. Implant placement will be performed 4 months after the regenerative procedure. Implant loading will be allowed after having waited a minimum of 3 months after the implant placement and after a control visit. The implant survival and success will be assessed at 3, 6 and 12 months after implant placement. A long-term follow-up will evaluate the implant survival and success at 3 and 5 years post implant placement.
62432659|NCT02169661|EXPERIMENTAL|Burger and Beetroot Study|
62432660|NCT05238285||Healthy adult population aged 18 to 80 years|Participants will be asked to produce vocal sounds of different nature according to the non-verbal parameters of interest for the given study.
62432661|NCT01901211|EXPERIMENTAL|Exergaming|In this arm, the participants will participate in the exergaming intervention.
62432662|NCT01901211|NO_INTERVENTION|Comparison Arm|In this arm of the study, participants will engage in their typical physical activity routines for the ten week duration. Participants will receive a call from the RA each week. The RA will ask the child to report on all the physical and social activities that they engaged in for that week.
62432663|NCT04562584|EXPERIMENTAL|MyHomeDoc|Comparison of MyHomeDoc pulse oximetry readings with arterial blood saturation laboratory analysis in the same subject
62599549|NCT06645054||LLO|Rehabilitation patients fitted with a lower limb orthosis
62599550|NCT00504725|EXPERIMENTAL|Ketamine|Single bolus 0.5mg/kg ketamine IV after induction of anesthesia
62818622|NCT04519164|ACTIVE_COMPARATOR|Chlorthalidone with potassium chloride|Participants will receive chlorthalidone (6.25-25mg daily for one year) along with potassium chloride (up to 20 mEq daily for one year)
62039173|NCT05410938||Intraperitoneal group|The intraperitoneal regimen was given as 135 mg/m2 intravenous paclitaxel over a 3 or 24 hours period on day 1, followed by 75-100 mg/m2 intraperitoneal cisplatin on day 2 and 60 mg/m2 intraperitoneal paclitaxel on day 8. For women with significantly impaired renal function (i.e., estimated glomerular filtration rate\<50 mL/min/1.73 m2), carboplatin (area under the curve \[AUC\]=6) was used instead of cisplatin.
62242254|NCT02231788|ACTIVE_COMPARATOR|Telmitrend®Tab. 80mg|Telmitrend®Tab.(Telmisartan) 80mg
62242255|NCT00152139|OTHER|1|
62599551|NCT00504725|PLACEBO_COMPARATOR|Placebo|0.9 % saline bolus of equivalent volume
62242256|NCT06735716||A patient who received PCI procedure using a AVIAR.|After the subject is assigned a registration number, the robot-assisted procedure group will undergo percutaneous coronary intervention (PCI) using the clinical trial medical device 'AVIAR (MX-02)', while the conventional manual procedure group will undergo percutaneous coronary intervention (PCI) according to the standard procedure.
62242257|NCT06735716||A patient who received PCI procedure wth conventional manual techniques.|After the subject is assigned a registration number, the robot-assisted procedure group will undergo percutaneous coronary intervention (PCI) using the clinical trial medical device 'AVIAR (MX-02)', while the conventional manual procedure group will undergo percutaneous coronary intervention (PCI) according to the standard procedure.
62039174|NCT05410938||Triweekly group|The triweekly intravenous chemotherapy regimen was given as 175 mg/m2 paclitaxel and carboplatin at a dose calculated to produce an AUC of 6 mg/mL/min on day 1. Bevacizumab was given at a dose of 7.5mg/kg intravenously on day 2 since cycle 2. The treatments were repeated every 3 weeks for 6 cycles. Those women without achievement of complete response after 6 cycles of chemotherapy might be treated with an additional 1-2 cycles of chemotherapy. Bevacizumab was continued for 12 additional cycles or until disease progression, death, unacceptable toxic effects, or patient voluntary withdrawal \[5\].
62039175|NCT05113628|NO_INTERVENTION|anatomical identification|thyroidectomy was done with identification of both RLN and parathyroid gland done on anatomical basis
62039176|NCT05113628|SHAM_COMPARATOR|methylene blue identification|thyroidectomy was done with identification of both RLN and parathyroid gland done using methylene blue spray (0.5 ml methylene blue 2% was diluted by 5ml normal saline) was sprayed over the lower thyroid pole and the perilobar area
62599552|NCT06050655|EXPERIMENTAL|Adults with Angle Class I malocclusion|"* Adults older than 18 years old~* About to undergo orthodontic treatment"
62599553|NCT06025253|EXPERIMENTAL|Negative Pressure Wound Therapy.|Application of a negative wound pressure therapy dressing to the wound post major lower extremity amputation
62599554|NCT06025253|ACTIVE_COMPARATOR|Standard Wound dressing|Application of sterile standard gauze dressing to the wound post major lower extremity amputation
62599555|NCT06104761|EXPERIMENTAL|Release Group|Release of tight muscles in upper crossed syndrome
62242258|NCT05541029|EXPERIMENTAL|Live music > Recorded music > Usual Care|Order of conditions for the day
62242259|NCT05541029|EXPERIMENTAL|Recorded music > Usual care > Live music|Order of conditions for the day
62432664|NCT00066807|EXPERIMENTAL|OFS plus T or E|Ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.
62432665|NCT00066807|EXPERIMENTAL|Chemotherapy plus OFS plus T or E|Chemotherapy plus ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.
62432666|NCT01259518|EXPERIMENTAL|Once monthly administration of TRIN2755|
62432667|NCT01259518|EXPERIMENTAL|Once weekly administration of TRIN2755|
62432668|NCT00493363|EXPERIMENTAL|arm 1|
62432669|NCT00493363|ACTIVE_COMPARATOR|arm 2|
62599556|NCT06104761|OTHER|Control group|strength exercises and stretching for upper crossed syndrome
62599557|NCT00697034|EXPERIMENTAL|1|Study subjects will be patients with chronic plaque-type psoriasis
62599558|NCT03826810|EXPERIMENTAL|aPDT + ART group|In this group, both aPDT and ART were performed.
62599559|NCT03826810|EXPERIMENTAL|ART group|In this group, only ART was performed.
62599560|NCT02987517|EXPERIMENTAL|Cadence|Runners who use an increased running cadence of 7.5 percent over preferred running cadence.
62599561|NCT02987517|EXPERIMENTAL|Forefoot Strike|Runners who use a forefoot strike instead of a rear foot strike
62039177|NCT05644977|EXPERIMENTAL|Part A: Cohort 1: Emraclidine Dose 1|Participants will receive emraclidine dose 1 or emraclidine-matching placebo tablets, orally, once daily (QD) up to Day 14.
62242260|NCT05541029|EXPERIMENTAL|Usual Care > Live music > Recorded music|Order of conditions for the day
62242261|NCT05541029|EXPERIMENTAL|Live music > Usual Care > Recorded music|Order of conditions for the day
62242262|NCT05541029|EXPERIMENTAL|Recorded music > Live music > Usual care|Order of conditions for the day
62242263|NCT05541029|EXPERIMENTAL|Usual care > Recorded music > Live music|Order of conditions for the day
62432670|NCT00492466|EXPERIMENTAL|1|
62432671|NCT04976608||Group 1|The BCVA of eyes is greater than 0.6
62432672|NCT04976608||Group 2|The BCVA of eyes is from 0.1 to 0.6
62432673|NCT04976608||Group 3|The BCVA of eyes is less than 0.6
62432674|NCT04141995|EXPERIMENTAL|Treatment|Participants start FOLFIRINOX. They will also begin digoxin and take it up to 4-5 months time period in patients with resectable pancreatic cancer. Digoxin is taken at the time of neo-adjuvant chemotherapy treatment, prior to surgery. After surgery, participants will continue with post-adjuvant chemotherapy.
62599562|NCT03122613|ACTIVE_COMPARATOR|Curcumin|Dietary supplements of Curcumin capsules
62599563|NCT03122613|PLACEBO_COMPARATOR|Curcumin Placebo|Identical looking placebo of the active arm
62599564|NCT06628752|ACTIVE_COMPARATOR|Active stimulation|Deep brain stimulation - active stimulation
62432675|NCT05550558|EXPERIMENTAL|Anlotinib + Camrelizumab|Anlotinib 12 mg QD p.o for 2 weeks and then stop for 1 week plus Camrelizumab 200 mg (fixed dose) IV every 3 weeks (+/- 3 days) until progression or adverse effects prohibit therapy
62432676|NCT03552354|EXPERIMENTAL|Argatroban combined with antiplatelet|
62599565|NCT06628752|SHAM_COMPARATOR|Sham stimulation|Deep brain stimulation - no stimulation
62599566|NCT02052596|EXPERIMENTAL|GSK1437173A Group|Subjects received one injection of Boostrix vaccine and one injection of the GSK1437173A vaccine during the first visit and a second injection of the GSK1437173A vaccine during the third visit, two months later.
62599567|NCT02052596|ACTIVE_COMPARATOR|Control Group|Subjects received all vaccines separately i.e. one injection of Boostrix vaccine at the first visit, one injection of the GSK1437173A vaccine at the third visit and a second injection of the GSK1437173A vaccine at the fourth visit, all two months apart.
62599568|NCT03187067||Mozambique, cases|
62599569|NCT03187067||Mozambique, controls|
62599570|NCT03187067||Pakistan, cases|
62599571|NCT03187067||Pakistan, controls|
62039178|NCT05644977|EXPERIMENTAL|Part A: Cohort 2: Emraclidine Dose 2|Participants will receive emraclidine dose 2 or emraclidine-matching placebo tablets, orally, QD up to Day 14.
62039179|NCT05644977|EXPERIMENTAL|Part A: Cohort 3: Emraclidine Dose 3|Participants will receive emraclidine dose 3 or emraclidine-matching placebo tablets, orally, QD up to Day 14.
62599572|NCT01665846|EXPERIMENTAL|Ferumoxotyol|Brain MRI will be performed before and 48 +/- 8 hours after ferumoxytol administration.
62039180|NCT05644977|EXPERIMENTAL|Part A: Cohort 4: Emraclidine Dose 4|Participants will receive emraclidine dose 4 or emraclidine-matching placebo tablets, orally, QD up to Day 14.
62039181|NCT05644977|EXPERIMENTAL|Part A: Cohort 5: Emraclidine Dose 5|Participants will receive emraclidine dose 5 or emraclidine-matching placebo tablets, orally, QD up to Day 14.
62039182|NCT05644977|EXPERIMENTAL|Part B: Cohort 6: Emraclidine Dose 6|Participants with dementia due to AD will receive emraclidine dose 6 or emraclidine-matching placebo tablets, orally, QD up to Day 28.
62039183|NCT00783926|EXPERIMENTAL|Cohort 1|60 subjects randomized in an equal number to six different vaccine doses
62039184|NCT00783926|EXPERIMENTAL|Cohort 2|Following review of safety data of Cohort 1, approximately 360 additional subjects randomized in an equal number to the six different vaccine doses
62039185|NCT06443463|EXPERIMENTAL|BHV-7000 50 mg|
62039186|NCT06443463|EXPERIMENTAL|BHV-7000 75 mg|
62039187|NCT06732505|EXPERIMENTAL|[225Ac]Ac-DOTATATE|Investigational radiotherapeutic drug targeting somatostatin receptor-positive neuroendocrine tumors in PRRT naive patients (Cohort 1) and previous PRRT patients (Cohort 2)
62039188|NCT03332368||TCM exposure group|TCM exposure group were treated with traditional Chinese medicine while the other do not treated with that
62599573|NCT05890690|EXPERIMENTAL|Study Part 1 urea followed by placebo|Participants will undergo a diagnostic test with a single weight-adapted dose of oral urea first. After a a wash-out phase of at least 3 days and not more than 28 days participants will undergo a second diagnostic test with a single weight-adapted dose of placebo.
62039189|NCT05875181|EXPERIMENTAL|VS tFUS/Sham tFUS|VS tFUS (tFUS applied to the ventral striatum) Sham tFUS (go through the motions of applying tFUS to the VS)
62599574|NCT05890690|EXPERIMENTAL|Study Part 1 placebo followed by urea|Participants will undergo a diagnostic test with a single weight-adapted dose of placebo first. After a a wash-out phase of at least 3 days and not more than 28 days participants will undergo a second diagnostic test with a single weight-adapted dose of urea.
62599575|NCT05890690|EXPERIMENTAL|Study part 2 Urea|Participants will undergo a diagnostic test with a single weight-adapted dose of oral urea
62599576|NCT01797081|EXPERIMENTAL|Botulinum toxin Type A (24U)|24 units (U) botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
62599577|NCT01797081|EXPERIMENTAL|Botulinum toxin Type A (12U)|12U botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
62599578|NCT01797081|OTHER|Placebo/Botulinum toxin Type A (24U)|Placebo (normal saline) one treatment injected into bilateral Crow's Feet Line areas on Day 1 and subsequent treatments if applicable until day 180. Botulinum toxin Type A (24U) injected into bilateral Crow's Feet Line areas at any additional treatments from day 180 onward. Based on retreatment criteria participants were eligible for up to 5 treatment cycles (2 Placebo + 3 botulinum toxin type A).
62039190|NCT05875181|EXPERIMENTAL|Sham tFUS/VS tFUS|VS tFUS (tFUS applied to the ventral striatum) Sham tFUS (go through the motions of applying tFUS to the VS)
62599579|NCT01797081|OTHER|Placebo/Botulinum toxin Type A (12U)|Placebo (normal saline) one treatment injected into bilateral Crow's Feet Line areas on Day 1 and subsequent treatments if applicable until day 180. Botulinum toxin Type A (12U) injected into bilateral Crow's Feet Line areas at any additional treatments from day 180 onward. Based on retreatment criteria participants were eligible for up to 5 treatment cycles (2 Placebo + 3 botulinum toxin type A).
62599580|NCT06619405|OTHER|Early AMD|Study patients who have a diagnosis of early AMD
62599581|NCT06619405|OTHER|Intermediate AMD|Study patients who have a diagnosis of Intermediate AMD
62599582|NCT06619405|OTHER|Geographic Atrophy|Study patients who have a diagnosis of Geographic Atrophy
62039191|NCT06124209|EXPERIMENTAL|Tachosil® used in Vena Cava Inferior anastomosis|Tachosil® used in Vena Cava Inferior anastomosis.
62039192|NCT06124209|NO_INTERVENTION|Control|Standard haemostatic treatment in HPB surgery.
62039193|NCT05138419|ACTIVE_COMPARATOR|Case Management Model (CMM)|CMM includes 3 visits of pharmacist initiated discussion of workbook content (including AP \[action plan\] and CKD web-based sites) and AP reinforcement. Pre-testing is done on Visit 1 (V1) and Post testing and program evaluation on V3. Subjects are asked to read 1 chapter a week, write down questions and take tests at the end of chapters. On V1 pharmacist introduces the Workbook System highlighting chapters 1-4 and assist with AP goal selection. On V2, the pharmacist answers questions, provides chapter 4-8 highlights and reviews AP goal progress and food label exercise. On V3, pharmacist answers questions, expands on workbook content and reviews AP goals progress and program evaluation including modality and transplant questions from pre/posttests, identification and ranking of peer cluster leader teaching style and effectiveness, identification of AP goals selected and ranking of helpfulness is completed. Pharmacists track time spent at each visit to compare cost and outcomes.
62039194|NCT05138419|ACTIVE_COMPARATOR|Self Study (SS)|SS includes 2 visits. Subjects receive the workbook, paper copies of AP and food label exercise. Pre-testing will be done on V1 and Post testing on V2, eight weeks later. Subjects will be asked to read 1 chapter a week for the next 8 weeks. The pharmacist will provide a brief introduction of the workbook (5-10 minutes) and the AP. Only subject initiated questions will be answered. On V2, the pharmacist will answer subject initiated questions and ask about progress in the AP goal attainment and the program evaluation will be completed, as described in arm 1.Pharmacists track time spent at each visit to compare cost and outcomes.
62432677|NCT05941468|EXPERIMENTAL|AR group (EG-A)|Behavioral: AR intervention For the EG-A, the AR dental care training system will give to patients that 2 to 3 times tooth clean skill learning course (including Bass method of brushing and inter-dental toothbrush brushing technique) during non-surgical periodontal treatment period.
62599583|NCT06619405|OTHER|AMD Controls|Study patients who have healthy eyes
62599584|NCT00182728|EXPERIMENTAL|Intraoperative Radiation Arm|Intraoperative radiotherapy (radiation therapy) during surgery for tumor excision.
62818623|NCT06465524|EXPERIMENTAL|High-intensity laser therapy and stretching exercise|The BTL-6000 device, with 12W power and a wavelength of 1,064 nm, will administer laser therapy to the experimental group using the De la Barra et al. protocol. Treatment includes three phases: (Phase 1) Manual scanning 1: 12 W for 42 seconds, delivering 500 J over 100 cm2 per upper trapezius muscle (total 1,000 J). (Phase 2) Point technique: 4 W for 10 seconds per point (10 J per point), totaling 60 J per side (120 J total). (Phase 3) Manual scanning 2: 6 W for 83 seconds, delivering 500 J over 100 cm2 per upper trapezius muscle (total 1,000 J). Following the HILT treatment, we will perform three sets of 30 seconds each of passive bilateral static stretching exercises for the upper trapezius, levator scapulae, and scalene muscles.
62432678|NCT05941468|EXPERIMENTAL|AR-health consulting group (EG-B)|"Behavioral: AR intervention For the EG-B, the AR dental care training system will give to patients that 2 to 3 times tooth clean skill learning course (including Bass method of brushing and inter-dental toothbrush brushing technique) during non-surgical periodontal treatment period.~The health counseling will also provide professional oral health related courses (including oral care for diabetes and periodontal disease, etc.)"
62818624|NCT06584539|EXPERIMENTAL|Eco-labels|Participants will view a mock restaurant menu based on a popular US sit-down restaurant. They will be instructed to select the item or items they would like to order from the restaurant. The menu will display eco-labels next to more sustainable menu appetizers and entrees (i.e., appetizers and entrees that are in the bottom half of carbon footprints \[i.e., greenhouse gas emissions in CO2-equivalents associated with production of the item\] among appetizers and entrees).
62818625|NCT06584539|NO_INTERVENTION|Control|Participants will view a mock restaurant menu based on a popular US sit-down restaurant. They will be instructed to select the item or items they would like to order from the restaurant. The menus will not display eco-labels.
62432679|NCT05941468|NO_INTERVENTION|Control group (CG)|the control group(CG) only have standard oral hygiene education
62599585|NCT06356753||1-Women without deep endometriosis benefiting surgery|"Group recruited from the gynaecology/obstetrics department : Women without deep endometriosis benefiting surgery.~* Caucasian women, aged 18 to 45 years undergoing gynaecological surgery, for example: benign laparoscopy (example: tubal ligation), benign ovarian surgeries or benign uterine procedures (fibroma, ovarian cyst) or genital prolapse.~* Non-interventional access to parietal and epiploic adipose tissue as part of routine care~* No clinical-biological criteria in favour of a diagnosis of endometriotic disease, nor any radiological evidence (ultrasound or MRI) suggestive of endometriosis."
62735790|NCT05965076|EXPERIMENTAL|Glycine - Angled toothbrush|Patients will be professionally treated by adding glycine perio-flow in the treatment, and they will use an angled toothbrush for their domiciliary oral hygiene.
62818626|NCT03808974|EXPERIMENTAL|Intervention|The intervention group will be shown an educational video
62818627|NCT03808974|ACTIVE_COMPARATOR|Control|The control group will be given an educational leaflet
62818628|NCT06100588|EXPERIMENTAL|MT + DN|"4 treatment sessions of 20 minutes manual therapy will be given over 4 weeks (1session/week). The techniques will be tailored to the patients needs, and will exclude 'High Velocity Low Amplitude' manipulations.~In addition, a maximum of 4 muscles will be treated by means of dry needling in at least 3 sessions, based on the pain pattern of the patient."
62039195|NCT05138419|SHAM_COMPARATOR|Control (Ctrl)|Ctrl includes 2 visits. Subjects receive a list of web-based CKD sites, a food label exercise and a copy of the AP with no additional intervention, other than answering subject initiated questions, on V1. Pre-testing will be done on V1 and Post testing on V2 and program evaluation will be done eight weeks later. On V2, the pharmacist will ask about AP goals and answer subject initiated questions. Pharmacists track time spent at each visit to compare cost and outcomes.
62039196|NCT05926180|EXPERIMENTAL|DZD9008 + Probe Drugs|Single dose of 2 mg midazolam (oral solution), 0.25 mg digoxin (tablet) and 10mg rosuvastatin (tablet) and in combination with 300 mg DZD9008 (tablet)
62039197|NCT05979441|EXPERIMENTAL|EFG PH20 SC|participants receiving efgartigimod PH20 SC on top of background treatment
62432680|NCT06360900|EXPERIMENTAL|Active taVNS + CBT|
62432681|NCT06360900|ACTIVE_COMPARATOR|Active taVNS + Education Control|
62039198|NCT03292250|EXPERIMENTAL|Arm1: BYL719|Experimental: BYL719 BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
62039199|NCT03292250|EXPERIMENTAL|Arm2: Poziotinib|Experimental:Poziotinib Poziotinib is a pan-HER tyrosine kinase inhibitor.(oral class)
62039200|NCT03292250|EXPERIMENTAL|Arm3: Nintedanib|Nintedanib is a potent small molecule triple receptor tyrosine kinase inhibitor (PDGFR, FGFR 1-3,VEGFR 1-3 ,VEGFR- 2) is considered to be the crucial receptor involved in initiation of the formation as well as the maintenance of tumour vasculature.(oral class)
62818629|NCT06100588|ACTIVE_COMPARATOR|MT alone|4 treatment sessions of 20 minutes manual therapy will be given over 4 weeks (1session/week). The techniques will be tailored to the patients needs, and will exclude 'High Velocity Low Amplitude' manipulations.
62818630|NCT06490900|EXPERIMENTAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles (room air) to resaturation.
62818631|NCT06490900|SHAM_COMPARATOR|Intermittent normoxia|The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air).
62818632|NCT06595472|EXPERIMENTAL|plant sterol-enriched palm oil|The group given cooking oil (palm oil) which is Enriched with Plant Sterol.
62818633|NCT06595472|PLACEBO_COMPARATOR|palm oil|The group given cooking oil (palm oil) which has the same composition and physical appearance as the intervention oil, but without plant sterol.
62818634|NCT04017221||Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Current use of a SGLT2 inhibitor alone or in combination with other antidiabetic drugs, excluding DPP-4 inhibitors and insulin.
62818635|NCT04017221||Dipeptidyl peptidase-4 (DPP-4) inhibitors|Current use of a DPP-4 inhibitor alone or in combination with other antidiabetic drugs, excluding SGLT2 inhibitors and insulin.
62818636|NCT04017221||Other treatment combinations|Current use of other antidiabetic drugs, current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
62818637|NCT03404817|ACTIVE_COMPARATOR|Sequence 1|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:~Period 1: EMB-001 new formulation under fed condition Period 2: EMB-001 new formulation under fasted conditions Period 3: EMB-001 original formulation under fed conditions"
62818638|NCT03404817|ACTIVE_COMPARATOR|Sequence 2|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:~Period 1: EMB-001 original formulation under fed conditions Period 2: EMB-001 new formulation under fed conditions Period 3: EMB-001 new formulation under fasted conditions"
62818639|NCT03404817|ACTIVE_COMPARATOR|Sequence 3|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:~Period 1: EMB-001 new formulation under fasted conditions Period 2: EMB-001 original formulation under fed conditions Period 3: EMB-001 new formulation under fed conditions"
62432682|NCT06360900|ACTIVE_COMPARATOR|Sham taVNS + CBT|
62818640|NCT05881018|EXPERIMENTAL|Low glycaemic index|
62818641|NCT05881018|EXPERIMENTAL|Low glycaemic index with physical activity units|
62818642|NCT05881018|EXPERIMENTAL|High glycaemic index|
62818643|NCT05881018|EXPERIMENTAL|High glycaemic index with physical activity units|
62818644|NCT06547827|EXPERIMENTAL|Integrated Treatment with Robotic & Technological Devices (RADTs)|This intervention employs various RADTs to target the following domains: a) upper limb sensorimotor abilities; b) lower limb sensorimotor abilities and gait; c) balance; and d) cognitive abilities. For upper limb sensorimotor function, we will use planar end-effector robots, exoskeletons, or electromechanical systems for shoulder, elbow, and wrist rehabilitation; end-effector robots or exoskeletons for hand rehabilitation; and sensor-based devices for comprehensive upper limb treatment. For lower limb sensorimotor function, we will utilize end-effector robots or exoskeletons and treadmills with body-weight support systems. Balance training will involve stabilometric platforms and sensor-based systems. Cognitive functions will be addressed using digital systems, sensor-based devices, and virtual reality programs. All devices must have a CE mark for medical devices and be used according to the manufacturer's specifications.
62039201|NCT03292250|EXPERIMENTAL|Arm4: Abemaciclib|Abemaciclib represents a selective and potent small molecule CDK4 and CDK6 dual inhibitor with broad antitumor activity in preclinical pharmacology models.(oral class)
62432683|NCT06360900|SHAM_COMPARATOR|Sham taVNS + Education Control|
62432684|NCT02778763|EXPERIMENTAL|One injection of CBLB612 after Сhemo|One injection of placebo at Day -2 (48 hours prior AC chemotherapy treatment) and one injection of 4 μg CBLB612 at Day 1 (24 hours after AC chemotherapy treatment)
62432685|NCT02778763|EXPERIMENTAL|One injection of CBLB612 prior Сhemo|One injection of 4 μg CBLB612 at Day -2 (48 hours prior AC chemotherapy treatment) and one injection of placebo at Day 1 (24 hours after AC chemotherapy treatment)
62432686|NCT02778763|PLACEBO_COMPARATOR|Placebo|Two injections of placebo at Day -2 and Day 1 (48 hours prior and 24 hours after AC chemotherapy treatment)
62432687|NCT01906099|EXPERIMENTAL|legume enriched diet|legume consumption, 4 servings per week, for 6 weeks
62432688|NCT01906099|ACTIVE_COMPARATOR|healthy dietary recommendations|no nutritional intervention
62432689|NCT04528303|EXPERIMENTAL|Whole genome sequencing|
62818645|NCT06547827|ACTIVE_COMPARATOR|Traditional Treatment|In the control group, subjects will undergo a standard traditional rehabilitation program without the use of RADTs, focusing on the following domains:a) upper limb sensorimotor abilities; b) lower limb sensorimotor abilities and gait; c) balance; and d) cognitive abilities, using traditional methods of physiotherapy and cognitive rehabilitation.
62818646|NCT05058976|EXPERIMENTAL|Romosozumab, then Zoledronic Acid|Monthly dose: 210 mg Romosozumab subcutaneous injections; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements); all participants will receive 5 mg Zoledronic Acid IV infusion at the Month 12 visit.
62039202|NCT03292250|EXPERIMENTAL|Arm5: Durvalumab,Tremelimumab|"Durvalumab is a human immunoglobulin (Ig) G1 kappa (IgG1κ) monoclonal antibody (mAb) that blocks the interaction of PD-L1 with PD-1 on T-cells and CD80 on immune cells and is engineered to reduce antibody-dependent cell-mediated cytotoxicity.(IV class)~Tremelimumab is specific for human CTLA-4; cluster of differentiation a cell surface receptor that is expressed primarily on activated T cells and acts to inhibit their activation.(IV class)"
62432690|NCT04528303|ACTIVE_COMPARATOR|Whole exome sequencing|
62432691|NCT03734679|EXPERIMENTAL|Surveil drug coated balloon|
62242264|NCT03606980|EXPERIMENTAL|Iontophoresis with Dexamethasone|Iontophoresis is a non-invasive delivery mechanism for transmitting a medication to a local area of the body. The I-Bresis™ System and I-Bresis™ Patch will be the delivery system used for this study. The I-Bresis™ Patch is an adhesive patch. 1.5 ml of the dexamethasone sodium phosphate (4ml/1mL) will be placed on one side and 1.5 ml of 0.9% sodium chloride (saline) solution will be placed on the other. Duration of exposure: 123 minutes. Frequency of exposure: twice per week for a total of 12 sessions over a maximum of 8 weeks or until Return to Sport Criteria are met, whichever is sooner. Participants will also receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
62818647|NCT05058976|PLACEBO_COMPARATOR|Placebo, then Zoledronic Acid|Monthly dose: placebo saline subcutaneous injections; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements); all participants will receive 5 mg Zoledronic Acid IV infusion at the Month 12 visit.
62039203|NCT03175133|EXPERIMENTAL|Strength training|Strength exercises for ankle PF, hip abduction, and trunk muscles. Exercises will be done in three standard positions of supine, sidelying, prone, seated, and standing. Exercises during the initial 4 weeks will be completed 2x week with supervision of a physical therapist and 2x week at home, for a total of 4x week. For the final 4 weeks of the intervention will be completed 1x week with supervision and 3x week at home.
62599586|NCT06356753||2-Women with endometriosis benefiting surgery|"Group recruited from the gynaecology/obstetrics department : Women with endometriosis benefiting surgery.~* Caucasian women aged 18 to 45~* Severe and deep endometriotic pathology, with or without endometriomas, with surgical indication (clinical examination, imaging examinations, intraoperative observation),~* Access to epiploid and/or parietal adipose tissue as part of routine care."
62039204|NCT03715933|EXPERIMENTAL|Dose Escalation (Complete)|INBRX-109 will be escalated (3+3 design) in subjects with locally advanced or metastatic solid tumors including sarcomas.
62039205|NCT03715933|EXPERIMENTAL|Expansion Malignant Pleural Mesothelioma (Complete)|Subjects with malignant pleural mesothelioma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
62039206|NCT03715933|EXPERIMENTAL|Expansion Gastric Adenocarcinoma (Complete)|Subjects with gastric adenocarcinoma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
62039207|NCT03715933|EXPERIMENTAL|Expansion Colorectal Adenocarcinoma (Complete)|Subjects with colorectal (CRC) adenocarcinoma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
62039208|NCT03715933|EXPERIMENTAL|Expansion Sarcomas (Complete)|Subjects with certain sarcoma subtypes will be treated with single-agent INBRX-109 at either the MTD or RP2D.
62039209|NCT03715933|EXPERIMENTAL|Combination Expansion Malignant Pleural Mesothelioma (Complete)|Subjects with malignant pleural mesothelioma will be treated with INBRX-109 in combination with chemotherapies (carboplatin, cisplatin, carboplatin and pemetrexed, or cisplatin and pemetrexed)
62039210|NCT03715933|EXPERIMENTAL|Combination Expansion Pancreatic Adenocarcinoma (Complete)|Subjects with pancreatic adenocarcinoma will be treated with INBRX-109 in combination with 5FU/irinotecan based chemotherapy
62039211|NCT03715933|EXPERIMENTAL|Combination Expansion Ewing Sarcoma|Subjects with Ewing Sarcoma will be treated with INBRX-109 in combination with irinotecan and temozolomide
62039212|NCT03715933|EXPERIMENTAL|Combination Expansion Colorectal Adenocarcinoma|Subjects with colorectal adenocarcinoma will be treated with INBRX-109 in combination with FOLFIRI based chemotherapy
62039213|NCT03715933|EXPERIMENTAL|Expansion Solid Tumors (Complete)|Subjects with Solid tumors and high BMI will be treated with single-agent INBRX-109 at either the MTD or RP2D.
62039214|NCT03715933|EXPERIMENTAL|Combination Expansion SDH-deficient solid tumors or GIST (Complete)|Subjects with SDH-deficient solid tumors or GIST will be treated with INBRX-109 in combination with temozolomide
62039215|NCT00737165|EXPERIMENTAL|Multimodal community intervention|Multimodal suicide prevention program
62039216|NCT00737165|ACTIVE_COMPARATOR|Community intervention as usual|Suicide prevention program as usual
62039217|NCT04840589|EXPERIMENTAL|Doublet treatment (ZEN003694, nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ZEN003694 PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, a CT scan, a PET scan, and/or an x-ray as well as blood sample collection throughout the trial. Patients also undergo a biopsy during screening.
62242265|NCT03606980|PLACEBO_COMPARATOR|Iontophoresis with Sodium Chloride|Iontophoresis is a non-invasive delivery mechanism for transmitting a medication to a local area of the body. The I-Bresis™ System and I-Bresis™ Patch will be the delivery system used for this study. The I-Bresis™ Patch is an adhesive patch. 1.5 ml of 0.9% sodium chloride (saline) solution will be placed on one side and 1.5 ml of 0.9% saline solution will be placed on the other. Duration of exposure: 123 minutes. Frequency of exposure: twice per week for a total of 12 sessions over a maximum of 8 weeks or until Return to Sport Criteria are met, whichever is sooner. Participants will also receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
62242266|NCT03606980|ACTIVE_COMPARATOR|Physical Therapy alone|Participants will only receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
62432692|NCT04582097|EXPERIMENTAL|Ramipril|Ramipril, 2.5 mg daily, administered orally for 16 weeks
62432693|NCT04582097|PLACEBO_COMPARATOR|Placebo|Placebo, matched for the interventional drug, administered orally, daily for 16 weeks
62432694|NCT06085742|OTHER|CMC orally|All agents in CMC are oral and conform to a 3-week = 1 cycle regimen. All subjects will receive Cyclophosphamide 60mg/m2 PO once a day (21 continuous days) Methotrexate 10mg/m2 PO BID on days 1, 8, and 15 Capecitabine 825mg/m2 PO BID on days 1-14
62432695|NCT05906784|NO_INTERVENTION|usual care|Participants will receive care as usual provided through their primary care providers. Usual care includes medical diagnostic evaluation, analgesic drug therapies, recommendations for physical activity, and sometimes referral to specialist physicians or physical therapy. Usual care was chosen as a comparison arm for this study because it is practical and clinically relevant. Participants randomized to usual care will be put on a waitlist and can access group acupuncture or IGMV after their final study visit.
62818648|NCT00633477|EXPERIMENTAL|Resatorvid 2.4 mg/kg/day|
62818649|NCT00633477|PLACEBO_COMPARATOR|Placebo|
62039218|NCT04840589|EXPERIMENTAL|Triplet treatment (nivolumab, ZEN003694, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1, ipilimumab IV over 90 minutes on day 1, and ZEN003694 PO QD on days 1-21 of each cycle. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 5, patients are no longer treated with ipilimumab, but receive nivolumab IV over 30 minutes on day 1 and ZEN003694 PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, a CT scan, a PET scan, and/or an x-ray as well as blood sample collection throughout the trial. Patients also undergo a biopsy during screening and on study.
62039219|NCT01320046||Patients with urinary incontinence|Patients attending the urogynecological clinic for urinary incontinence-100 patients. In this group we will recruit patients with UI, and will assess co-existence of VCD
62599587|NCT06356753||3-Infertile Women with deep endometriosis benefiting from IVF|"Group recruited from the Reproductive Medicine Department : Infertile Women with deep endometriosis benefiting from IVF.~* Women with IVF or ICSI for infertility with deep endometriosis diagnosed in routine care (clinical examination, imaging examinations +/- surgical findings). They will be classified into 2 subgroups: 1) deep endometriosis without endometrioma and 2) deep endometriosis associated with endometriomas.~* Access to follicular fluid as part of routine care during oocyte retrieval and access to serum as part of routine care during gonadotropin follicular stimulation."
62818650|NCT05902169|EXPERIMENTAL|Experimental Arm: SonoCloud-9 Ultrasound + Carboplatin|The SonoCloud-9 (SC9) device will be implanted in the skull bone window upon completion of tumor resection and routine craniotomy. Carboplatin (CBDCA) will be administered intravenously prior to sonication. The CBDCA/SC9 treatment will be repeated every 3 weeks (depending on patient's tolerability) until disease progression or as clinically indicated. Administration of up to 7 cycles is planned.
62039220|NCT01320046||Patients with vulvar contact dermatitis|Patients attending the vulvovaginal clinic with vulvar contact dermatitis (100 patients). In this group we will recruit patients with VCD, and will assess co-existence of UI.
62039221|NCT01320046||Age matched control group|"Patients attending the general clinic for annual checkup, which will be matched for age with the two other groups (200 patients).~These patients will be evaluated for symptoms of UI and VCD"
62039222|NCT04347551|EXPERIMENTAL|Eye movement Fitts' task|High velocity/low amplitude cervical spine manipulation applied to chronic neck pain and asymptomatic participants.
62039223|NCT04347551|ACTIVE_COMPARATOR|Head movement Fitts' task|High velocity/low amplitude cervical spine manipulation applied to chronic neck pain and asymptomatic participants.
62242267|NCT01650285|EXPERIMENTAL|Cabazitaxel and radiation|Radiation therapy (RT) will be delivered to 64.8 Gy, using IMRT treatment Cabazitaxel will be administered IV every 21 days for 3 doses at the assigned dose level.
62039224|NCT06670235|EXPERIMENTAL|Upright Birthing Position Group|"Participants assigned to the Upright Birthing Position Arm will be encouraged to maintain an upright position during labor and delivery. The upright position includes a squatting. This arm aims to assess the potential benefits of the upright position, such as improved maternal outcomes (e.g., shorter labor duration, reduced need for interventions) and favorable newborn outcomes (e.g., higher Apgar scores, better oxygenation).~To evaluate the effects of upright positioning on both maternal and newborn outcomes compared to the traditional lithotomy position."
62242268|NCT00160381|EXPERIMENTAL|1|
62039225|NCT06670235|ACTIVE_COMPARATOR|Lithotomy Birthing Position|"Participants in the Lithotomy Position Arm will follow the standard hospital practice of delivering in the lithotomy position, where the mother is lying on her back with legs supported in stirrups. This position is widely used in clinical settings and serves as the control arm to compare with the outcomes from the upright birthing position.~To serve as a control group to provide a comparative measure of maternal and newborn outcomes against the upright birthing position. Outcomes will include maternal comfort, labor duration, intervention requirements, and newborn health indicators."
62039226|NCT01627327|EXPERIMENTAL|fluticasone furoate/vilanterol|inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)
62242269|NCT00160381|EXPERIMENTAL|2|
62039227|NCT01627327|ACTIVE_COMPARATOR|tiotropium bromide|anticholinergic
62039228|NCT03146624|EXPERIMENTAL|attachment|attachment retained obturator
62039229|NCT03146624|ACTIVE_COMPARATOR|clasp|clasp retained obturator
62242270|NCT00160381|PLACEBO_COMPARATOR|3|
62039230|NCT02525874|EXPERIMENTAL|dimethyl fumarate|120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter
62039231|NCT04930068|EXPERIMENTAL|ultra-sound|ultrasonic cavitation applied on abdominal region for 30 minutes, 2 times per week for 6 weeks.
62039232|NCT04930068|EXPERIMENTAL|aerobic exercise|aerobic exercises through treadmill (60-70% of VO2 max.) for 30 minutes, 2 times per week for 6 weeks
62242271|NCT06735456|EXPERIMENTAL|Mandala Group|The patient will undergo mandala painting during 1 session of chemotherapy.
62242272|NCT06735456|NO_INTERVENTION|Control Group|No application will be made to this group by the researcher.
62242273|NCT01260727|EXPERIMENTAL|Group 1|Participants will receive PENNVAX-G vaccine administered by intramuscular injection (IM) via Biojector 2000 needleless device in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
62242274|NCT01260727|EXPERIMENTAL|Group 2|Participants will receive PENNVAX-G vaccine administered via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
62242275|NCT01260727|EXPERIMENTAL|Group 3: Subgroup 1|Participants will receive PENNVAX-G vaccine administered IM via Biojector 2000 needleless device in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
62039233|NCT05476939|ACTIVE_COMPARATOR|everolimus|"Tablets of 2.5 mg or 10 mg. The prescribed dose is 5 mg/m²/day, orally, once daily. Dose will be capped at 10 mg once daily.~Study treatment will be continued until centrally confirmed disease progression (either radiologically or histologically), unacceptable toxicity, or consent withdrawal.~At the time of centrally confirmed progression, patients will stop treatment and will be allowed to switch to the other arm in case no better option is available after considering the results of the molecular profiling. In case of switch (everolimus to ONC201 or vice-versa), the patient will observe a wash-out period before starting:~* the second treatment,~* or a reirradiation (if applicable). No treatment is allowed during reirradiation. Then, if an additional treatment is needed, the second treatment will be started within one week after the end of the reirradiation."
62039234|NCT05476939|EXPERIMENTAL|ONC201|"Capsules of 125 mg. The prescribed dose is 375 mg/m², once daily at Day 1 and Day 2 of each week. Dose will be capped at 625 mg per dose.~Study treatment will be continued until centrally confirmed disease progression (either radiologically or histologically), unacceptable toxicity, or consent withdrawal.~At the time of centrally confirmed progression, patients will stop treatment and will be allowed to switch to the other arm in case no better option is available after considering the results of the molecular profiling. In case of switch (everolimus to ONC201 or vice-versa), the patient will observe a wash-out period before starting:~* the second treatment,~* or a reirradiation (if applicable). No treatment is allowed during reirradiation. Then, if an additional treatment is needed, the second treatment will be started within one week after the end of the reirradiation."
62039235|NCT04461002||Cohort|Retrospective cohort
62039236|NCT04719780|ACTIVE_COMPARATOR|Waitlist Control Group (CBT)|Individuals in this arm (n=44) are provided with a transdiagnostic cognitive-behavioural treatment for depression and anxiety (MoodGym) that has been empirically validated after their 15-week wait period is complete.
62039237|NCT04719780|EXPERIMENTAL|EFIT Group|Individuals in the EFIT Group (n=44) will receive 12-15 sessions of EFIT in order to treat their symptoms of depression and anxiety.
62242276|NCT01260727|PLACEBO_COMPARATOR|Group 3: Subgroup 2|Participants will receive placebo vaccine for PENNVAX-G administered IM via Biojector 2000 needless device in either deltoid on Days 0 and 28. They will then receive placebo vaccine for MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
62242277|NCT01260727|EXPERIMENTAL|Group 4: Subgroup 1|Participants will receive PENNVAX-G vaccine administered IM via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
62242278|NCT01260727|PLACEBO_COMPARATOR|Group 4: Subgroup 2|Participants will receive placebo vaccine for PENNVAX-G administered IM via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive placebo vaccine for MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
62242279|NCT05905510|ACTIVE_COMPARATOR|Control Group|Patients will receive spinal anesthesia alone (30 ml bupivacaine 0. 25%).
62242280|NCT05905510|ACTIVE_COMPARATOR|Lumbar Erector spinae plane block (L-ESPB)|Patients will receive spinal anesthesia and then ipsilateral lumbar erector spinae plane block (30 ml bupivacaine 0. 25%) at the level of the lumbar region in the operating room after the end of the surgery.
62242281|NCT05905510|ACTIVE_COMPARATOR|Fascia iliaca compartment block (FICB)|Patients will receive spinal anesthesia and then ipsilateral suprainguinal fascia iliaca compartment block (30 ml bupivacaine 0. 25%) in the operating room after the end of the surgery.
62039238|NCT05805592|EXPERIMENTAL|Intervention Group|"It is planned as 6 sessions, 1 session per week for children and parents. The program will be introduced to children and parents under the call with Screen-to-Move-Program (STEP). The symbol of the program has been created and this symbol will be hung on the classroom door. Sessions for children include story, picture, video demonstration and active playing activities. A more clear, simple and understandable language will be used for children, and reinforcements will be used. For parents; There will be 6 training sessions in the form of presentations. At the same time as the children's activities, information notes will be sent to the parents outlining the expectations. Before the intervention, after the intervention and in the 3rd month, children's screen use time, daily physical activity time, sleep time, parents' knowledge, behavior, attitude and self-efficacy about their children's screen use time will be evaluated."
62039239|NCT05805592|NO_INTERVENTION|Control Group|Screen use time, daily physical activity time, sleep time, parents' knowledge, behavior, attitude and self-efficacy about children's screen use time will be evaluated simultaneously from the control group with the intervention group. After the 3rd month follow-up test, the STEP will be applied to the children and parents in the control group.
62242282|NCT03157232|EXPERIMENTAL|Test Group|All subjects are enrolled into the test group and all subjects received both the Rainbow DCI and R1-25 sensor.
62242283|NCT05940610|EXPERIMENTAL|MSC-EV group|On the basis of standard medical treatment, an additional injection of MSC-EVs will be received by participants once a week for 4 weeks while hospitalized.
62432696|NCT05906784|EXPERIMENTAL|group acupuncture|Participants randomized to acupuncture will receive 12 weeks of acupuncture treatments delivered in a group setting, dosing similar to prior research. Acupuncture point selection and other treatment details will follow responsive manualization, a protocol developed for the largest clinical trial of group acupuncture to date. A licensed acupuncturist experienced with administering group acupuncture treatments will determine each participant's traditional Chinese medicine diagnosis and administer 8-10 acupuncture needles on distal points of participant's body (below the knees, from the elbows to the hands, and on the head). Duration of assessment, needle placement and retention will be 30-45 minutes. Details of acupuncture treatments (e.g., frequency and duration, traditional Chinese medicine diagnosis, number of needles and points used) will be documented in electronic health records.
62432697|NCT05906784|EXPERIMENTAL|Integrative Group Medical Visits (IGMV)|IGMV will consist of a 12-week program that provides education on the biopsychosocial model of pain and multimodal treatments; physical movement; mindfulness training; and peer support. Non-pharmacologic approaches are based on guidelines on chronic pain management; feedback of experts, staff, and patients; and feasibility with the greatest potential to benefit participants. Participants will receive a binder with educational materials.
62242284|NCT05940610|NO_INTERVENTION|Non-MSC-EV group|In the non-MSC-EV group, patients will receive standard medical treatment and 100ml saline as a control.
62242285|NCT01521897||7-valent vaccine injection|Infants starting to receive Prevenar at the age of more than 2 and less than 7 months
62242286|NCT02017379|EXPERIMENTAL|Erythromycin|Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure
62432698|NCT05906784|EXPERIMENTAL|group acupuncture and IGMV|Both group acupuncture and IGMV. Along with usual care, participants will be offered weekly group acupuncture treatments and integrative group medical visits as described above.
62432699|NCT04624269|EXPERIMENTAL|Hydroxychloroquine sulfate Tablets|drug:Hydroxychloroquine sulfate Tablets,0.1mg bid po
62432700|NCT04624269|PLACEBO_COMPARATOR|placebo|drug:placebo,0.1mg bid po
62599588|NCT06356753||4-Infertile Women w/o endometriosis receiving IVF+/-ICSI|"Group recruited from the Reproductive Medicine Department : Infertile women without endometriosis receiving IVF+/-ICSI.~* Women, aged 18-43 receiving IVF± ICSI for female infertility~* No history of endometriosis or suggestive clinical-biological or radiological signs.~* The etiology of infertility will be determined in reproductive medicine. Women will be divided into 2 groups of patients:~  1. PCOS (Polycystic Ovary Syndrome). PCOS will be diagnosed in routine care (interrogation, clinical examination, hormone test and pelvic ultrasound) according to the criteria of the Rotterdam Consensus Conference reviewed in 2018.~ 2. IOD (Early Ovarian Failure). IOD will be diagnosed in routine care (clinical examination, hormonal and ultrasound check-up) according to the following criteria: AMH\<0.8ng/ml and/or CFA \<6~* Access to follicular fluid as part of routine care during oocyte retrieval and access to serum as part of routine care during gonadotropin follicular stimulation"
62039240|NCT00951275|EXPERIMENTAL|1|
62039241|NCT06421012|EXPERIMENTAL|Patients without additional preoxygenation|
62818651|NCT05902169|ACTIVE_COMPARATOR|Control Arm: SoC single agent chemotherapy TMZ or CCNU|"Standard of Care (SoC) treatment with either temozolomide (TMZ) or lomustine (CCNU).~Standard TMZ chemotherapy as a single oral dose every 4 weeks for up to 6 cycles.~Standard CCNU chemotherapy as a single oral dose every 6 weeks for up to 4 cycles."
62818652|NCT04720183|EXPERIMENTAL|Sulfasalazine + GLPG3970|
62818653|NCT02878499|OTHER|ASD|
62818654|NCT06601036|EXPERIMENTAL|Sevoflurane sedation group|Patients will undergo fiberoptic intubation under sevoflurane sedation.
62818655|NCT06601036|ACTIVE_COMPARATOR|Awake fiberoptic group|Patients will undergo fiberoptic intubation with bilateral Superior Laryngeal Nerve block and Recurrent laryngeal nerve block.
62818656|NCT04197700|OTHER|Personalized Arm|"Personalized Arm: The target MAP will be defined as +/- 5% of the resting MAP. Resting MAP will be defined in priority order using one of the following MAP measurements:~* Pre-operative anesthesia or surgical consultation;~* Other physician outpatient consultation (e.g. cardiology, family physician, internist) within 30 days of surgery;~* Inpatient measurement the night before surgery;~* Pre-anesthetic MAP~The order of the measurements prioritizes outpatient MAPs given that temporary pre-operative discontinuation of anti-hypertensive agents could potentially raise, while fasting and/or fluid restriction pre-operatively could potentially lower resting blood pressure.39 The lower and upper safety limits of personalized MAP targets will be 50mmHg and \<90mmHg, respectively."
62818657|NCT04197700|OTHER|Protocolized Arm|"Protocolized Arm: The target MAP will be defined as 65 +/- 5mmHg. Pharmacologic and fluid treatment decisions will be at the discretion of the most responsible physician.~In both study arms, the blood pressure control period will extend from anesthetic induction until 12 hours after admission to the CSICU. As an additional safety metric, the anesthesiologist will be encouraged to utilize clinically-driven cerebral saturation monitoring to identify potential hypoperfusion. In cases with low bilateral saturations where the anesthesiologist feels low MAP may be the putative mechanism, the investigators will request that MAPs be raised in 5mmHg increments. Following completion of the study protocol, the MAP and/or systolic blood pressure targets will be at the discretion of the most responsible physician."
62818658|NCT04521790||Arrhythmic (A)|"Arrhythmic Group. To oversimplify, specific subgroups of patients will be considered.~1. Group 1: major ventricular arrhythmias (haemodynamically unstable VT, hu-VT; ventricular fibrillation, VF).~2. Group 2: other ventricular arrhythmias (high-burden premature ventricular complexes = hb-PVC; nonsustained VT = NSVT; haemodynamically stable VT = hs-VT).~3. Group 3: bradyarrhythmias (2nd type II or 3rd degree atrioventricular block = advanced AVB; critical sinus pauses = SND).~4. Group 4: supraventricular arrhythmias (atrial fibrillation = AF; atrial flutter = AFlu; atrial tachycardia = AT)."
62039242|NCT06421012|ACTIVE_COMPARATOR|Patients with additional preoxygenation|
62039243|NCT00712361|EXPERIMENTAL|Group A|The group A incorporates three subgroups of individuals at various ages. A.1 Age: 16 - 30 A.2 Age: 31 - 60 A.3 Age \> 60 All subgroups will be randomly distributed according to the following factors: BMI, gender, race and hematocrit.
62039244|NCT03043508||Participants With Confirmed MEN1 With PNET|"Retrospective review of a prospectively maintained MEN1 database.~Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history."
62039245|NCT03043508||Participants With Confirmed MEN1 Without PNET|"Retrospective review of a prospectively maintained MEN1 database.~Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history."
62242287|NCT02017379|EXPERIMENTAL|Metoclopromide|Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy
62242288|NCT02017379|NO_INTERVENTION|Control|no medications will be given prior to endoscopy
62242289|NCT02728882|EXPERIMENTAL|single arm|"Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days，the first day,the fourth day,the seventh day,28 days,31 days,34 days.~Duration:Total seven times."
62242290|NCT05734183|EXPERIMENTAL|MIME Group|"Stimulation with MIME will be performed in a large ad hoc room in which video images will be projected on three walls. The patient will be positioned in the center of the room, 3 meters from the front wall, with the back of the bed tilted at a 45-degree angle, so as to obtain a truly immersive view covering the entire 220-degree field of view. Audio stimulation will be achieved through two speakers located at the sides of the room, with the low frequencies reinforced by a subwoofer. The average sound intensity recorded from the patient's position will be 81 db average (maximum 87, minimum 69).~Patients will undergo treatment with MIME once a day for five consecutive days, for a total of two weeks (10 sessions), in addition to conventional treatment."
62599589|NCT06356753||5-Fertile W. w/o endometriosis receiving IVF-ICSI as oocyte|"Group recruited from the Reproductive Medicine Department : Fertile women without endometriosis receiving IVF-ICSI as oocyte donors.~* Women receiving IVF± ICSI as oocyte donors~* No history of endometriosis or clinical-biological or radiological signs suggestive of endometriosis.~* Access to follicular fluid will be part of the standard care for oocyte puncture and access to serum will be part of the standard care for gonadotropin follicular stimulation."
62818659|NCT04521790||Nonarrhythmic (NA)|"Nonarrhythmic Group. To oversimplify, specific subgroups of patients will be considered.~1. Heart failure presentation (and subtypes)~2. Chest pain presentation (and subtypes)~3. Asymptomatic presentation/screening (and subtypes)"
62599590|NCT00422344|EXPERIMENTAL|RAD001 AND SUNITINIB|RAD001 AND SUNITINIB IN METASTATIC RENAL CELL CARCINOMA PATIENTS
62599591|NCT05269420|EXPERIMENTAL|SAS-J|single anastomosis sleeve Jejunal Bypass as a revisional bariatric procedure after restrictive bariatric procedures
62818660|NCT04521790||Subgroups|"For specific study aims, different patient subgroups will be compared. The main groups are hereby reported:~A. Arrhythmic myocarditis subgroups (1-4). B. Non-arrhythmic myocarditis subgroups (i.e.: fulminant, acute coronary syndrome-like, pericarditis-like, heart failure, nonischaemic dilated /hypokinetic cardiomyopathies of unknown aetiology...).~C. Infectious vs. autoimmune vs. toxic myocarditis. D. Myocarditis treated by aetiology-based treatment vs. isolated cardiac medical treatment.~E. Myocarditis at different disease stages: acute, hyperacute, fulminant, chronic active, post-inflammatory, or active vs. previous vs. non-myocarditis.~F. Myocarditis presenting as organ-specific diseases vs. in the context of a genetic disorder or systemic disease.~G. Myocarditis vs. peri-myocarditis/myo-pericarditis. H. Other subgroups."
62818661|NCT03630289|EXPERIMENTAL|Surgical tissue autograft: TPF flap/pericranial flap|Use of a pedicled autologous piece of tissue called the temporoparietal fascial (TPF) flap or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients
62599592|NCT00854425|EXPERIMENTAL|L-asp|
62599593|NCT01796197|EXPERIMENTAL|Treatment Arm|"Run in: Trastuzumab IV 4 mg/kg, Pertuzumab IV 840 mg (Day 1 Week 1)~Pre-Op:~Trastuzumab IV 2 mg/kg weekly, Paclitaxel 80 mg/m2 IV weekly (beginning on Day 8 Week 2) x 16 doses.~Starting Day 21 (week 4) continue trastuzumab and paclitaxel as above, add Pertuzumab 420 mg IV x 3 weeks. After completing 16 doses of Paclitaxel, Trastuzumab (6 mg/kg IV) and Pertuzumab 420 mg IV may be continued x 3 weeks until surgery Modified Radical Mastectomy~Post-Op:~Option 1: Adriamycin 60 mg/m2 IV and Cyclophosphamide 600 mg/m2 IV x 2-3 weeks x 4 cycles. Followed by Trastuzumab 8 mg/kg and Pertuzumab 840 IV load; followed by Trastuzumab 6 mg/kg every and Pertuzumab 420 mg IV every 3 weeks to complete 12 months of HER2-directed therapy Option 2: Continue Trastuzumab 6 mg/kg and Pertuzumab 420 mg x 3 weeks to complete 12 months of HER2-directed therapy Post-mastectomy radiation to the chest wall / regional lymph nodes and endocrine therapy by standard of care."
62599594|NCT06042569|EXPERIMENTAL|Arm I: (Dose-reduced docetaxel, cyclophosphamide)|Patients receive dose-reduced docetaxel IV over 60 minutes and cyclophosphamide IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
62599595|NCT06042569|ACTIVE_COMPARATOR|Arm II: (Standard dose docetaxel, cyclophosphamide)|Patients receive standard dose docetaxel IV over 60 minutes and cyclophosphamide IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
62599596|NCT00962364||AMI|Patients with acute myocardial infarction treated with intracoronary administration of bone marrow derived cells
62599597|NCT00962364||ICM|Patients with ischemic cardiomyopathy treated with intracoronary administration of bone marrow derived cells
62599598|NCT00962364||DCM|Patients with dilated cardiomyopathy treated with intracoronary administration of bone marrow derived cells
62599599|NCT05853367|EXPERIMENTAL|MK-0472|Participants receive MK-0472 via oral capsule according to one of the protocol-specified dosing regimens until disease progression or withdrawal/discontinuation.
62599600|NCT05853367|EXPERIMENTAL|MK-0472 + Pembrolizumab|Participants receive MK-0472 via oral capsule according to one of the protocol-specified dosing regimens until disease progression or withdrawal/discontinuation, plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
62599601|NCT05853367|EXPERIMENTAL|MK-0472 + MK-1084|Participants receive MK-0472 via oral capsule according to one of the protocol-specified dosing regimens, plus MK-1084 via oral capsule QD until disease progression or withdrawal/discontinuation.
62599602|NCT02651415|EXPERIMENTAL|Regorafenib and Perindopril|Phase II, open label, single arm trial of patient with refractory mCRC treated with regorafenib (10 mg/day) and perindopril (4 mg/day). There will be no stratification in this study.
62599603|NCT03091049||EMLA anesthetic ointment (AO)|In AO group a layer of 2.5 gr EMLA cream (standard adult dose) is applied to both wrists, 1 cm above the styloid process of the radius 30 minutes before the puncture, by an experienced cathlab nurse
62599604|NCT03091049||Local Skin Anesthetic Injection (LA)|In LA group the radial artery is infiltrated with 1-2 mL of 2% lidocaine, using a 26 G needle, 0.5-1 cm proximal to the styloid process one minute before the puncture
62818662|NCT03940963|ACTIVE_COMPARATOR|AxoGuard® Nerve Cap|"Porcine derived extracellular matrix (ECM) based Nerve Termination Device~Implantation of appropriate diameter of AxoGuard® Nerve Cap at the time of surgery"
62599605|NCT06295640|EXPERIMENTAL|Intranasal insulin spray|160 Units of human insulin as nasal spray
62818663|NCT03940963|ACTIVE_COMPARATOR|Standard Neurectomy|Standard surgical treatment for symptomatic neuroma entailing neuroma excision.
62818664|NCT06077968||Vaccinated|Patients will be considered vaccinated if they have documented evidence of receiving ABRYSVO ≥21 days before index date (i.e., defined as the date of hospitalization or Emergency Department (ED) admission.)
62818665|NCT06077968||Unvaccinated|Patients will be considered unvaccinated if they do not have documented evidence of receiving ABRYSVO.
62818666|NCT05414461|EXPERIMENTAL|Combination treatment|PD-1 inhibitor-based combination treatment
62818667|NCT01186263|EXPERIMENTAL|99mTc- labeled albumin macroaggregates (MAA)|Diagnostic MAA- SPECT- imaging.
62039246|NCT03418766||Normal|Normal healthy individual without migraine.
62039247|NCT03418766||Magraine|Clinical history of migraine diagnosed by a neurologist according to the International Classification of Headache Disorders.
62599606|NCT06295640|PLACEBO_COMPARATOR|Placebo spray|Nasal spray containing placebo solution
62242291|NCT05734183|ACTIVE_COMPARATOR|MIME + tDCS Group|Simultaneously with MIME treatment, patients will undergo transcranial direct current stimulation (tDCS). Stimulation with tDCS will begin 5 minutes after the start of resting phase 1, and the electrodes will be placed as follows: the 5×4 anode (about 20 cm2) will be placed on the left dorsolateral prefrontal area; the reference electrode, 6x5 (about 30 cm2), will instead be placed on the upper arm, specifically at the level of the right deltoid muscle, contralateral to the active electrode. Current will be applied at an intensity of 2 mA, for 20 minutes a day for 2 weeks, five days a week, for a total of 10 sessions. The current density will be kept below the safe limits reported in the literature.
62242292|NCT06462521|EXPERIMENTAL|Cold Snare Piecemeal Resection (CSPR)|Conventional adenomas sized 10-19mm or serrated lesions 10mm or larger found during colonoscopy will be removed using CSPR technique.
62242293|NCT06462521|EXPERIMENTAL|Cold Snare Endoscopic Mucosal Resection (Cold EMR)|Conventional adenomas sized 10-19mm or serrated lesions 10mm or larger found during colonoscopy will be removed using Cold EMR technique.
62599607|NCT05315700|EXPERIMENTAL|Dose Escalation and Dose Optimization|ORIC-114 dosed orally on a continuous once daily dosing regimen in 28-day cycles.
62242294|NCT00982969||TB suspected|Soldiers who are clinically suspected with tuberculosis
62242295|NCT01012154|EXPERIMENTAL|All patients|
62599608|NCT05315700|EXPERIMENTAL|Combination Dose Escalation|ORIC-114 dosed orally on a continuous once daily dosing regimen in 21-day cycles.
62599609|NCT02831985|EXPERIMENTAL|general practice follow-up|post-surgery follow-up by general practitioner
62599610|NCT02831985|ACTIVE_COMPARATOR|ENT specialist follow-up|post-surgery follow-up by ear-nose-throat (ENT) specialist
62818668|NCT01186263|EXPERIMENTAL|99mTc- labeled albumin microspheres (B20)|Diagnostic B20- SPECT- imaging.
62599611|NCT02032381|OTHER|allogeneic hematopoietic stem cell|The eligible population for this study will consist of all children under 18 years who received allogeneic hematopoietic stem cell and evaluate of late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.
62599612|NCT02658006||Cardiac surgical patients|Adult patients having a cardiac surgery at the Montreal Heart Institute
62818669|NCT04193046|OTHER|Participants with PH and non-PH|Blood samples will be collected for biomarker analysis from new (incident) and existing (prevalent) participants who undergo right heart catheterization (RHC). Participants will be categorized into non-PH or PH based on the results of the RHC and those who are found to have PH will be further classified into the different groups of PH. A transthoracic echocardiography (TTE) will be performed if not done previously.
62818670|NCT06128382|EXPERIMENTAL|OVX033 - 100µg dose level|Recombinant sarbecovirus vaccine based on the nucleocapsid of SARS-CoV-2. One single administration intramuscularly of a 100µg (0.2mL) dose on Day 1.
62818671|NCT06128382|EXPERIMENTAL|OVX033 - 250µg dose level|Recombinant sarbecovirus vaccine based on the nucleocapsid of SARS-CoV-2. One single administration intramuscularly of a 250µg (0.5mL) dose on Day 1.
62818672|NCT06128382|EXPERIMENTAL|OVX033 - 500µg dose level|Recombinant sarbecovirus vaccine based on the nucleocapsid of SARS-CoV-2. One single administration intramuscularly of a 500µg (1.0mL) dose on Day 1.
62818673|NCT06128382|PLACEBO_COMPARATOR|Saline solution - 0.2mL|Saline solution (NaCl 0.9%), B. Braun Ecoflac® Plus 50mL. One single administration intramuscularly of a 0.2mL dose on Day 1.
62818674|NCT06128382|PLACEBO_COMPARATOR|Saline solution - 0.5mL|Saline solution (NaCl 0.9%), B. Braun Ecoflac® Plus 50mL. One single administration intramuscularly of a 0.5mL dose on Day 1.
62818675|NCT06128382|PLACEBO_COMPARATOR|Saline solution - 1.0mL|Saline solution (NaCl 0.9%), B. Braun Ecoflac® Plus 50mL. One single administration intramuscularly of a 1.0mL dose on Day 1.
62818676|NCT05874674|ACTIVE_COMPARATOR|nafamostat|Patients received dialysis through nafamostat
62242296|NCT02090153|EXPERIMENTAL|S-1 plus LV|All patients were orally treated with S-1 in doses of 40 mg (body surface area (BSA)\<1.25 m2), 50 mg (1.25≤BSA\<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-7 in combination with LV given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest. Treatment courses were repeated every 2 weeks.
62242297|NCT05172167||Early vaccinated against COVID-19|80 subjects with less than 4 months after being fully vaccinated against COVID-19
62599613|NCT02416648|EXPERIMENTAL|CCC Counseling; baseline and 2 months|Intervention group 1 received 2 CCC Counseling sessions; at baseline and at 2 months. The intervention was a 10 to 15 minute clinic based one on one counseling session between a clinician (counselor) and a HIV positive adult patient (client). Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
62599614|NCT02416648|EXPERIMENTAL|CCC Counseling; baseline|Intervention group 2 received a session CCC Counseling session at baseline only. The intervention was a 10 to 15 minute clinic based one on one counseling session between a clinician (counselor) and a HIV positive adult patient (client). Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
62242298|NCT05172167||Late vaccinated against COVID-19|80 subjects with more than 4 months after being fully vaccinated against COVID-19
62242299|NCT05172167||COVID-19 infection|40 patients diagnostic of COVID-19
62599615|NCT02416648|NO_INTERVENTION|Routine care|The control group received routine clinic care.
62242300|NCT01839721|ACTIVE_COMPARATOR|Bifilact® probiotics standard dose|concentration of 1.3 billion of Lactobacillus acidophilus LAC-361 and Bifidobacterium longum BB-536. one pill twice a day. Each capsule contained maltodextrin and magnesium stearate as excipient
62818677|NCT05874674|NO_INTERVENTION|Cnoxane|Patients received dialysis through cnoxan
62818678|NCT06585566|OTHER|Secondary alveolar bone grafting (SBAG)|A SABG technique that utilizes retromolar cortical shells and the underlying cancellous particulates to formulate a three-dimensional alveolar cleft reconstruction.
62818679|NCT02405689|ACTIVE_COMPARATOR|remifentanil|In the remifentanil group, anesthesia was maintained with 0.5-1.5% sevoflurane and 0.125-0.25 μg/kg/min remifentanil infusion during surgery
62818680|NCT02405689|ACTIVE_COMPARATOR|dexmedetomidine|In the dexmedetomidine group anesthesia was maintained with 0.5-1.5% sevoflurane and 0.5 μg/kg dexmedetomidine loading dose during 10 minute and then 0.3-0.9 μg/kg/min infusion.
62818681|NCT05917899|EXPERIMENTAL|Virtual Family-Centered Rounds|Parents/guardians of the hospitalized infants will be invited to join family-centered rounds virtually plus usual care (usual care is the ability to join family-centered rounds in person or not to join at all).
62818682|NCT05691270|OTHER|Pilot Study Participants|All adolescents who engage with the IN-Control Program will be asked if they would like to formally enroll as a study participant after interaction with the navigator. However, enrollment is not required to receive support from the navigator.
62818683|NCT06175676|EXPERIMENTAL|HBCS group|Apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap
62818684|NCT06175676|EXPERIMENTAL|HBCS+5-FU group|Inject 0.3ml of 5-FU solution (25mg/ml) into the nasal mucosa around the anastomosis, and apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap
62818685|NCT06175676|ACTIVE_COMPARATOR|Gelatin Sponge group|Apply gelatin sponge sheet covered with thrombin and tobramycin and dexamethasone ophthalmic ointment to the anastomosis of nasal mucosal flap and dacryocyst mucosal flap
62242301|NCT01839721|ACTIVE_COMPARATOR|Bifilact® probiotics high dose|containing 10 billion Lactobacillus acidophilus LAC-361 and Bifidobacterium longum BB-536. One pill three times a day. Each capsule contained maltodextrin and magnesium stearate as excipient
62242302|NCT01839721|PLACEBO_COMPARATOR|placebo|Each capsule contained maltodextrin and magnesium stearate as excipient. One pill twice a day
62599616|NCT00348595|ACTIVE_COMPARATOR|1|5mg/day Arm: one 5 mg active Revlimid capsule and one 25 mg matched placebo capsules PO QAM (every morning) (at approximately the same time) days 1-21 days (28-day cycles).
62599617|NCT00348595|ACTIVE_COMPARATOR|2|25 mg/day Arm: one 25 mg active Revlimid capsule and one 5 mg matched placebo capsule PO QAM (every morning) (at approximately the same time) days 1-21 (28 day cycles).
62818686|NCT03405220|EXPERIMENTAL|Self-affirm, No examples, Study 1|Behavioral: Self affirmation, 10 items, no examples
62818687|NCT03405220|ACTIVE_COMPARATOR|Self-affirm, Write examples, Study 1|Behavioral: Self affirmation, 10 items, written examples
62818688|NCT03405220|EXPERIMENTAL|Self-affirm, Imagine examples, Study 1|Behavioral: Self affirmation, 10 items, imagined examples
62818689|NCT03405220|NO_INTERVENTION|Opinion survey, No examples, Study 1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will not be asked to provide examples for any items they respond yes to."
62818690|NCT03405220|NO_INTERVENTION|Opinion survey, Write examples, Study 1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will be asked to provide written examples for each item they respond yes to."
62818691|NCT03405220|NO_INTERVENTION|Opinion survey, Imagine examples, Study1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will be asked to imagine examples for each item they respond yes to."
62818692|NCT03405220|EXPERIMENTAL|Self-affirm, 10-item, No ex, Study 2|Behavioral: Self affirmation, 10 items, no examples
62818693|NCT03405220|EXPERIMENTAL|Self-affirm, 5-item, No ex, Study 2|Behavioral: Self affirmation, 5 items, no examples
62818694|NCT03405220|EXPERIMENTAL|Self-affirm, 3-item, No ex, Study 2|Behavioral: Self affirmation, 3 items, no examples
62818695|NCT03405220|ACTIVE_COMPARATOR|Self-affirm, 10-item, Write ex, Study 2|Behavioral: Self affirmation, 10 items, written examples
62818696|NCT03405220|EXPERIMENTAL|Self-affirm, 5-item, Write ex, Study 2|Behavioral: Self affirmation, 5 items, written examples
62039248|NCT03162224|EXPERIMENTAL|First-line Recurrent/Metastatic (1L R/M) Platinum Non-refractory|Participants with recurrent or metastatic disease and were non-refractory to neoadjuvant/adjuvant platinum based chemotherapy, will receive MEDI0457 7 mg intramuscularly followed by electroporation on Day 1 of Weeks 1, 3, 7, 12, and then every 8 weeks (Q8W) and durvalumab 1500 mg intravenously on Day 1 of Week 4 and then every 4 weeks (Q4W) until disease progression, unacceptable toxicity, or withdrawal of consent, whichever occurs first.
62039249|NCT03162224|EXPERIMENTAL|1L R/M Platinum Refractory|Participants with R/M disease and were refractory to neoadjuvant/adjuvant platinum based chemotherapy, will receive MEDI0457 7 mg intramuscularly followed by electroporation on Day 1 of Weeks 1, 3, 7, 12, and then Q8W and durvalumab 1500 mg intravenously on Day 1 of Week 4 and then Q4W until disease progression, unacceptable toxicity, or withdrawal of consent, whichever occurs first.
62818697|NCT03405220|EXPERIMENTAL|Self-affirm, 3-item, Write ex, Study 2|Behavioral: Self affirmation, 3 items, written examples
62039250|NCT03162224|EXPERIMENTAL|Second-line (2L) + R/M|Participants with R/M disease and were treated with 1 or more lines of platinum based chemotherapy, will receive MEDI0457 7 mg intramuscularly followed by electroporation on Day 1 of Weeks 1, 3, 7, 12, and then Q8W and durvalumab 1500 mg intravenously on Day 1 of Week 4 and then Q4W until disease progression, unacceptable toxicity, or withdrawal of consent, whichever occurs first.
62039251|NCT03119467|EXPERIMENTAL|Single arm|RP4010 to be administered
62039252|NCT00527566|EXPERIMENTAL|Mepolizumab|Subjects will receive open-label mepolizumab
62039253|NCT02495272|ACTIVE_COMPARATOR|Control Group|Oxytocin 10IU im was administered after placental delivery
62242303|NCT04385888|EXPERIMENTAL|Low-calorie sweetener restriction|Participants will be instructed to avoid low-calorie sweetened beverages and other sources of low-calorie sweeteners, and to instead consume unsweetened alternatives, such as plain or sparkling water for 12 weeks.
62599618|NCT06620003|ACTIVE_COMPARATOR|cAd3-Marburg vaccine (1.0 × 10^11 PU)|Single dose of cAd3-Marburg vaccine (1x10\^11 PU) administered intramuscularly (IM) with needle and syringe in a volume of 0.56 mL.
62818698|NCT03405220|EXPERIMENTAL|Self-affirm, 10-item, Imagine ex, Study2|Behavioral: Self affirmation, 10 items, imagined examples
62818699|NCT03405220|EXPERIMENTAL|Self-affirm, 5-item, Imagine ex, Study 2|Behavioral: Self affirmation, 5 items, imagined examples
62039254|NCT02495272|EXPERIMENTAL|Study Group|Oxytocin 10IU im was administered after the anterior shoulder could be seen.
62818700|NCT03405220|EXPERIMENTAL|Self-affirm, 3-item, Imagine ex, Study 2|Behavioral: Self affirmation, 3 items, imagined examples
62818701|NCT04205227|EXPERIMENTAL|ENB003 150 ug + Pembrolizumab|150 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
62818702|NCT04205227|EXPERIMENTAL|ENB003 300 ug + Pembrolizumab|300 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
62818703|NCT04205227|EXPERIMENTAL|ENB003 500 ug + Pembrolizumab|500 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
62818704|NCT04205227|EXPERIMENTAL|ENB003 750 ug + Pembrolizumab|750 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
62818705|NCT04205227|EXPERIMENTAL|ENB003 1000 ug + Pembrolizumab|1000 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
62818706|NCT04205227|EXPERIMENTAL|ENB003 2000 ug + Pembrolizumab|2000 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg). In this treatment arm, ENB003 will be administered during each 21 day cycle, as opposed to every other cycle in early arms
62818707|NCT04205227|EXPERIMENTAL|ENB003 RP2D from dose escalation + Pembrolizumab|The recommended phase 2 dose (RP2D) of ENB003 will be selected from the dose escalation portion of the study and administered in combination with a fixed dose of pembrolizumab (200mg)
62242304|NCT04385888|NO_INTERVENTION|Usual consumption/control|Participants will continue low-calorie sweetener consumption, as usual.
62599619|NCT06620003|PLACEBO_COMPARATOR|Placebo 0.9% NaCl solution|Single dose of Placebo (0.9% NaCl solution for injection) administered intramuscularly (IM) with needle and syringe in a volume of 0.56 mL.
62599620|NCT05174858|EXPERIMENTAL|Device under investigation|intra-alveolar placement of the hemostatic dressing ETIK COLLAGENE immediately after tooth extraction.
62599621|NCT05174858|OTHER|Comparator|the alveolus is left empty after tooth extraction.
62599622|NCT03929159||Group A (biospecimen collection)|Patients undergo blood specimen collection at baseline (before surgery), the day after surgery, either the day of hospital discharge or the day of sepsis diagnosis, and 6 days after the baseline blood draw if still hospitalized.
62818708|NCT05386043||Baseline Imaging and Biopsy|Subjects will receive a PET-CT with the radiopharmaceuticals FET and O-15 Water (under RDRC approval for basic research) prior to their standard of care neurosurgery via stereotactic core biopsy. Research samples will be collected for analysis intraoperatively.
62039255|NCT05402280|NO_INTERVENTION|Qualitative study|15 nurses (direct care nurses, nurse managers) and 5 patients, to investigate experiences and compare attitudes and opinions concerning the need for and quality of sleep in hospitalized patients.
62039256|NCT05402280|NO_INTERVENTION|Prospective quantitative study|diagnosing predisposition to sleep disturbances: 400 inpatients staying in gene-ral wards: Patients will undergo a serial of structured and standardized questi-onnaires during scheduled: FIRST: on the day of admission and RCSQ during their hospital stay (record length of up to 7 days).
62039257|NCT05402280|NO_INTERVENTION|Retrospective quantitative study|subjective assessment of factors affecting sleep: 600 hospitalized patients (360 patients in general wards, 240 patients in intensive care wards). On the day of discharge, patients will retrospectively assess disruptive factors that could in-fluence the quality of their sleep during their hospital stay by standardized que-stionnaire.
62242305|NCT05772468|EXPERIMENTAL|Virtual Reality Therapy (Intervention group 1)|In addition to the standard wound care procedure, the Virtual Reality Therapy group (intervention group 1) will receive the VR system during the wound care. The VR system consists of Virtual Reality glasses, and a headphone. The application VRelax will be used, which will contain various videos for the patient those from to relax and be distracted. This group wears the VR system 10 minutes before the start of the wound care, until 1 minute after the wound care has ended.
62242306|NCT05772468|NO_INTERVENTION|Care as usual (control group/group 2)|The control group (group 2), also known as the care as usual group, receives the standard procedure during wound care without 'VRelax' VR system.
62242307|NCT03482843||Vitamin D Deficiency|25-Vitamin D level \<25 ng/ml
62242308|NCT03482843||Sufficient Vitamin D Level|25-Vitamin D Level \>=25-70 ng/ml
62242309|NCT04287842|NO_INTERVENTION|control|Induction of anesthesia: Chloralhydrat intraperitoneal 300 mg/kg. This provides complete suppression of animal responses to pain, fixation, tracheal intubation. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed.
62432701|NCT04372212|ACTIVE_COMPARATOR|Inversion and Snaring|"Vertical trans umbilical 5-mm incision \[Point A\] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
62432702|NCT04372212|ACTIVE_COMPARATOR|Inversion and Ligation|"Vertical trans umbilical 5-mm incision \[Point A\] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
62242310|NCT04287842|EXPERIMENTAL|training ischemia|Induction of anesthesia: Chloralhydrat intraperitoneal 300 mg/kg. Comparison of a total GSK-3 and phosphorytated (Ser9) GSK-3beta (pGSK3b) in brain tissuesupracardiac bundle of vessels by means of a special hook after cardiac arrest and absence of ventilation lasts 10 min.
62242311|NCT04287842|ACTIVE_COMPARATOR|desflurane|Intervention. Drug: Desflurane. Desflurane 8 vol% anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Surgery: Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
62432703|NCT00631683||MICU-1|Mechanically ventilated patients who are about to start a weaning trial at the medical intensive care unit of Memorial Hermann Hospital.
62432704|NCT05836597|EXPERIMENTAL|Experimental|Experimental VR
62432705|NCT05836597|SHAM_COMPARATOR|Sham|Sham VR
62818709|NCT05354661||Hypotension Prediction Index (HPI) group|Hemodinamic monitoring with HPI working with ClearSight
62818710|NCT05354661||Control group|Hemodinamic monitoring with classic ClearSight
62039258|NCT05402280|OTHER|Interventional study|(subjective and objective assessment of sleep, quality of sleep with respect to delirium, baseline - routine care: PRE phase) implementation of sleep protocol and assess effectiveness (POST phase: determining the effectiveness of imple-mented sleep measures): overal: 2240 patients (1480 general ward, 760 inten-sive care wards.
62039259|NCT05152680|EXPERIMENTAL|[14C]-NV-5138|\[14C\]-NV-5138 oral solution
62242312|NCT04287842|ACTIVE_COMPARATOR|sevoflurane|Sevoflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
62242313|NCT02956512|EXPERIMENTAL|Dexibuprofen 300mg - Fed|Fed condition
62242314|NCT02956512|EXPERIMENTAL|Dexibuprofen 300mg - Fasting|Fasting condition
62242315|NCT06441526|ACTIVE_COMPARATOR|Anti-TNF|Seton placement, followed by anti-TNF medication (infliximab or adalimumab) in combination with a immunomodulator after ± 2 weeks. The seton will be removed after ± 6 weeks. Continuation of anti-TNF medication for at least 1 year, after one year continuation is at the discretion of treating physician.
62242316|NCT06441526|ACTIVE_COMPARATOR|Surgical closure|Seton placement, followed by anti-TNF medication in combination with a immunomodulator after ± 2 weeks. After 8-10 weeks removal of seton and surgical closure (advancement plasty or ligation of the intersphincteric tract (LIFT) procedure). Anti-TNF in combination with a immunomodulator will be stopped after ± 4 months.
62039260|NCT05566041|EXPERIMENTAL|Arm 1|"RRx-001 + eLOOP Device 4 mg IV infusion once weekly for 3 weeks~Cisplatin/carboplatin plus etoposide (up to 4 cycles):~Cisplatin or Carboplatin:~Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR Carboplatin initially dosed at an AUC (area under the curve) of 5 on Day 1 every 3 weeks Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks"
62242317|NCT05241782|EXPERIMENTAL|Experimental group|Experimental group will receive acupressure treatment by the second week, trice daily, 3\~5minutes each session for a course of four weeks.
62242318|NCT05241782|NO_INTERVENTION|Control group|Experimental group will receive routine care for a course of four weeks.
62242319|NCT06460285|ACTIVE_COMPARATOR|Mindfulness|There will be six, one hour, treatment sessions across nine weeks of a mindfulness intervention program, a post treatment assessment, and a follow up assessment three months later. The sessions will occur over zoom with a trained member of the study staff.
62242320|NCT06460285|EXPERIMENTAL|EmRes|There will be six, one hour, treatment sessions across nine weeks of an Emotional Resolution therapy intervention program, a post treatment assessment, and a follow up assessment three months later. The sessions will occur over zoom with a trained emotional resolution coach.
62242321|NCT01647529|EXPERIMENTAL|Ganciclovir|Treatment with topical ganciclovir ointment
62242322|NCT04363073|EXPERIMENTAL|Anaabella|Milk will be expressed using Annabella breast pump.
62242323|NCT04363073|ACTIVE_COMPARATOR|Control pump|Milk will be expressed using a control breast pump.
62242324|NCT06330883||Frail|Patients will be evaluated frail if the clinical frailty score is ≥5
62242325|NCT06330883||non-fragile|Patients will be evaluated non-fragile if the clinical frailty score is \<5.
62432706|NCT00028730|EXPERIMENTAL|Pts < than or = 18 years with lymphohematopoietic disorders|This is a phase II, single-center study to evaluate a cytoreductive regimen of hyperfractionated TBI, thiotepa and cyclophosphamide (HFTBI/thio/cy) followed by infusions of SBA-E- T-cell depleted marrow in pediatric leukemia recipients of either HLA-identical or HLA-1Ag non-identical related or unrelated donors.
62242326|NCT01479114|NO_INTERVENTION|control group|
62242327|NCT01479114|EXPERIMENTAL|G-CSF group|
62242328|NCT01479114|NO_INTERVENTION|Non-GCSF group|
62242329|NCT01667107|EXPERIMENTAL|Posaconazole - CF Participants|Posaconazole 400 mg oral solution twice daily administered with Calogen® to optimize absorption for a total of 6 weeks starting within 12 hours of leaving surgery, thereafter administered in the hospital or as an outpatient; the dose could be changed to posaconazole 200 mg 4 times per day if the participant is unable to meet the conditions for optimal absorption of posaconazole.
62242330|NCT01667107|EXPERIMENTAL|Posaconazole - Non-CF Participants|Posaconazole 400 mg oral solution twice daily administered with Calogen® to optimize absorption for a total of 6 weeks starting within 12 hours of leaving surgery, thereafter administered in the hospital or as an outpatient; the dose could be changed to posaconazole 200 mg 4 times per day if the participant is unable to meet the conditions for optimal absorption of posaconazole.
62242331|NCT06735027|EXPERIMENTAL|intraarticular methylprednisolone acetate injection (IACI)|Patients with glenohumeral osteoarthritis, rheumatoid arthritis, or rotator cuff arthropathy who are poor surgical candidates or who are not interested in pursuing surgery randomized to intraarticular corticosteroid injection (IACI).
62242332|NCT06735027|EXPERIMENTAL|suprascapular nerve block (SSNB) with bupivacaine and triamcinolone|Patients with glenohumeral osteoarthritis, rheumatoid arthritis, or rotator cuff arthropathy who are poor surgical candidates or who are not interested in pursuing surgery randomized to suprascapular nerve block (SSNB)
62242333|NCT06343012|EXPERIMENTAL|Study group|The study group received the Caring Leadership Intervention program
62432707|NCT04423653|EXPERIMENTAL|Tele-coaching group|This group will receive exercises videos, 2 sessions a week to be done on participant's own and the 3rd session will be live video conference session for training, supervision, and consultation purposes.
62432708|NCT04423653|ACTIVE_COMPARATOR|Self-monitored group|This group will receive exercises videos, 3 sessions a week to be done on participant's own with out any supervision.
62432709|NCT02328807|EXPERIMENTAL|Radio-Frequency Ablation (RFA)|Focal Prostate Radio-Frequency Ablation (RFA). Focal bipolar RFA followed by clinical follow-up visits at 6 weeks, 3 months and 6 months.
62432710|NCT06526871|ACTIVE_COMPARATOR|control group|ten patients treated with removable clear aligner
62432711|NCT06526871|EXPERIMENTAL|Experimental group|ten patients treated with removable clear aligner with application of Low-Level-Laser
62432712|NCT01503242|EXPERIMENTAL|Treatment (monoclonal antibody, chemo, TBI, transplant)|Patients receive 90Y-BC8 Ab IV on day -12 and fludarabine phosphate IV on days -4 to -2. Patients undergo TBI and allogeneic peripheral blood stem cell transplant on day 0. Patients also receive graft-vs-host disease prophylaxis comprising cyclosporine PO BID on days -3 to 56 with taper to day 180 or on days -3 to 100 with taper to 180; and mycophenolate mofetil IV or PO BID on days 0-27, or 0-40 with taper to 96.
62818711|NCT05254626|EXPERIMENTAL|Diabetic Group 1|25 diabetic patients will be prescribed on dapagliflozin 10 mg - once daily (OD) - to be taken orally (PO) for 24 weeks
62818712|NCT05254626|ACTIVE_COMPARATOR|Diabetic Group 2|25 diabetic patients will be prescribed on Pioglitazone 30 mg - once daily (OD) - to be taken orally (PO) for 24 weeks
62818713|NCT05254626|EXPERIMENTAL|Non-diabetic Group 1|25 non-diabetic patients will be prescribed on dapagliflozin 10 mg - once daily (OD) - to be taken orally (PO) for 24 weeks.
62039261|NCT05566041|ACTIVE_COMPARATOR|Arm 2|"Cisplatin/carboplatin plus etoposide (up to 4 cycles):~Cisplatin or Carboplatin:~Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR Carboplatin initially dosed at an AUC of 5 on Day 1 every 3 weeks Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks"
62818714|NCT05254626|ACTIVE_COMPARATOR|Non-diabetic Group 2|25 non-diabetic patients will be prescribed on Pioglitazone 30 mg - once daily (OD) - to be taken orally (PO) for 24 weeks
62818715|NCT05590481|EXPERIMENTAL|EG (experimental group): TIBIAL TRANSCUTANEOUS ELECTROSTIMULATION + Behavioral Therapy|EG (experimental group): submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene. In addition, patients will be submitted to biphasic current and surface electrodes during 12 treatment sessions, twice a week, on non-consecutive days, with a DUALPEX 961s electrical stimulation device (Quark, Brazil).
62039262|NCT04606355||PDI Check & Conventional|Autostereoscopic, dynamic forced choice game (ie on Nintendo 3DS) and Rosenbaum or HOTV near card, Ishihara color plates, Innova Rabin color test, Titmus Stereo test
62039263|NCT06440915|OTHER|Isavuconazole group|Theraputic drug monitoring
62039264|NCT01920451|EXPERIMENTAL|Cognitive-Behavioral Therapy for Insomnia|Cognitive-Behavioral Therapy for Insomnia (CBTI) consists of an an individually-tailored sleep prescription intended to consolidate fragmented sleep; guidance on changing learned associations that are harmful to sleep using stimulus control theory; education on standard sleep hygiene and to correct unrealistic sleep expectations; and the identification and restructuring of maladaptive thoughts and beliefs about sleep.
62039265|NCT01920451|NO_INTERVENTION|Wait List|Study participants who are randomized to the wait-list condition will not receive the intervention as part of this study protocol. They will, however, be offered the opportunity to receive CBTI at the end of their participation in this study. Wait-list participants will not be restricted in terms of additional therapies/treatments which they may seek for their sleep complaint.
62039266|NCT05946811|EXPERIMENTAL|Macitentan arm|Participants allocated to this arm will receive Macitentan 10 mg daily for 3 months
62039267|NCT05946811|PLACEBO_COMPARATOR|Placebo|Participants allocated to this arm will receive placebo daily for 3 months.
62039268|NCT01187693|OTHER|Shoe lift|
62039269|NCT02065336|EXPERIMENTAL|ARC-520 Cohort 1|a single intravenous (IV) dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
62039270|NCT02065336|PLACEBO_COMPARATOR|ARC-520 Cohort 2|a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
62039271|NCT02065336|EXPERIMENTAL|ARC-520 Cohort 3|a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
62039272|NCT02065336|EXPERIMENTAL|ARC-520 Cohort 4|a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
62039273|NCT02065336|EXPERIMENTAL|ARC-520 Cohort 5|a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection
62039274|NCT02065336|EXPERIMENTAL|Placebo Normal Saline Cohorts 1-5|a single IV dose of double-blind normal saline in combination with entecavir administered to participants with HBeAg-negative or -positive immune active chronic HBV infection
62039275|NCT02065336|EXPERIMENTAL|ARC-520 Cohort 6|two IV doses of open-label ARC-520 2.0 mg/kg administered to participants with HBeAg-positive immune active chronic HBV
62039276|NCT02065336|EXPERIMENTAL|ARC-520 Cohort 7|a single IV dose of open-label ARC-520 4.0 mg/kg administered to treatment-naïve, HBeAg-negative or -positive participants with chronic hepatitis B (CHB)
62432713|NCT02174900|EXPERIMENTAL|G6PD deficient 0.25 mg/kg PQ + AL|G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
62432714|NCT02174900|ACTIVE_COMPARATOR|G6PD deficient receiving AL only|G6PD deficient males receiving Artemether-Lumefantrine (AL) combination
62818716|NCT05590481|SHAM_COMPARATOR|GS (Sham-sham group): Behavioral therapy|GS (Sham-sham group): submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene. Twelve sessions will be held, twice a week, on non-consecutive days. The electrodes of the DUALPEX 961 equipment will be positioned one immediately posterior to the lateral malleolus of the ankle and the other approximately 30 cm above it, where there is no stimulus for the tibial nerve.
62039277|NCT02065336|EXPERIMENTAL|ARC-520 Cohort 8|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg every \[Q\]4 weeks) administered to HBeAg-negative participants with CHB receiving chronic entecavir therapy who completed Cohorts 1 through 4
62242334|NCT06343012|OTHER|Control group|The control group did not receive the caring leadership intervention program
62242335|NCT06057545|EXPERIMENTAL|Group A - Envarsus followed by Prograf|4 weeks treatment sequence 1 (Envarsus) followed by 4 weeks treatment sequence 2 (Prograf)
62432715|NCT02174900|ACTIVE_COMPARATOR|G6PD normal 0.25 mg/kg PQ + AL|G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
62432716|NCT02174900|ACTIVE_COMPARATOR|G6PD normal 0.4 mg/kg PQ + AL|G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
62432717|NCT02174900|EXPERIMENTAL|G6PD-deficient 0.4 mg/kg PQ + AL|G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
62599623|NCT03929159||Group B (biospecimen collection)|Patients undergo blood specimen collection at baseline (day of sepsis diagnosis), the day after baseline, and on day 7 from baseline if still hospitalized.
62599624|NCT02350946|EXPERIMENTAL|Cross over Oxytocin and Placebo|fMRI measurement and blood examinations following 26 IU Oxytocin (Syntocinon) on day 1 and following placebo on day 14
62599625|NCT02350946|EXPERIMENTAL|Cross over Placebo and Oxytocin|fMRI measurement and blood examinations following placebo on day 1 and following 26 IU Oxytocin (Syntocinon) on day 14
62242336|NCT06057545|EXPERIMENTAL|Group B - Prograf followed by Envarsus|4 weeks treatment sequence 2 (Prograf) followed by 4 weeks treatment sequence 1 (Envarsus)
62432718|NCT05694429|EXPERIMENTAL|Product K cleanser and moisturizer|Participants will used product K cleanser and moisturizer twice daily for 8 weeks
62432719|NCT03595709|EXPERIMENTAL|combined tablet (EFV 400,TDF 300, 3TC 300)|All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.
62432720|NCT04800107|EXPERIMENTAL|Treatment Group|Subjects will be provided with a supply of capsules containing 500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl. Subjects will take 1 capsule by mouth twice daily for 30 days.
62432721|NCT04800107|PLACEBO_COMPARATOR|Placebo Group|Subjects will be provided with a placebo compound with instructions to take 1 capsule by mouth twice daily for 30 days.
62242337|NCT05930782|ACTIVE_COMPARATOR|Part 1 (fasted) : Group 1 PQP hard tablet, 320mg (N=12)|Group 1: Piperaquine hard tablet, 320mg (administered in fasting condition of at least 10 hours) (N=12)
62432722|NCT02996435|EXPERIMENTAL|Mobile Adherence Platform|Participant adherence will be monitored using a mobile application and platform which provides a real-time reminder that alerts the participant to take his or her medication. The application will also send an alert to the participant when a refill is needed based on calculated medication or pill supply. The intervention will focus only on daily adherence to rivaroxaban.
62432723|NCT02996435|OTHER|Control: Standard of Care|Participants will receive physician- or nurse-guided standard of care for their rivaroxaban adherence. No drug will be administered as part of this study.
62432724|NCT05898490|EXPERIMENTAL|Animation Therapy Group|10 sessions of Animation Therapy (2 session/week)
62242338|NCT05930782|EXPERIMENTAL|Part 1 (Fasted): Group 2: PQP dispersible granules 320mg (N=12)|Group 2: Piperaquine dispersible granules 320mg administered in fasting condition of at least 10 hours (N=12)
62242339|NCT05930782|EXPERIMENTAL|Part 2 (Fed): Group 3 - high fat: PQP dispersible granule (planned as 320 mg) (N=12)|Group 3: Piperaquine dispersible granules 320mg administered in fed conditions - High-fat meal (N=12)
62242340|NCT05930782|EXPERIMENTAL|Part 2 Fed): Group 4 - low fat: PQP dispersible granule (planned as 320 mg) (N=12)|Group 4: Piperaquine dispersible granules 320mg administered in fed conditions - Low-fat meal representative of African diet (N=12)
62599626|NCT02564640|ACTIVE_COMPARATOR|videolaryngoscope|patients intubated by using the videolaryngoscopy
62599627|NCT02564640|ACTIVE_COMPARATOR|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
62599628|NCT01815606|ACTIVE_COMPARATOR|19 Gauge needle biopsy|biopsy with 19 gauge needle
62599629|NCT01815606|ACTIVE_COMPARATOR|25 gauge needle biopsy|biopsy with 25 gauge needle
62599630|NCT05359549||Two adjacent dental implants|25 patients with two missing adjacent teeth in the maxillary aesthetic region which was treated 10 years ago with dental implant placement and an implant-supported restorations.
62039278|NCT02065336|EXPERIMENTAL|ARC-520 Cohort 9|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q6 weeks or Q8 weeks) administered to HBeAg-positive participants with CHB receiving chronic entecavir therapy who completed Cohorts 5 or 6
62242341|NCT05930782|EXPERIMENTAL|Part 2 (Fed): Group 5 - whole milk: PQP dispersible granule (planned as 320 mg) (N=12)|Group 5: Piperaquine dispersible granules 320mg administered in fed conditions - Whole milk 250 ml (N=12)
62242342|NCT03442790|EXPERIMENTAL|Agitated Saline Method|The proper placement of the central venous line will be confirmed using agitated saline under ultrasound vision
62242343|NCT03442790|ACTIVE_COMPARATOR|Chest X-Ray Confirmation|The proper placement of the central venous line will be compared with chest x-ray obtained in supine position after central line placement
62432725|NCT05898490|NO_INTERVENTION|Control Froup|No intervention
62039279|NCT02065336|EXPERIMENTAL|ARC-520 Cohort 10|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q4 weeks) administered to a mixed cohort (HBeAg-negative and -positive participants) who were naïve (within the last 6 months) to entecavir treatment and completed Cohort 7
62039280|NCT02065336|EXPERIMENTAL|ARC-520 Cohort 11|a single IV dose of open-label ARC-520 5.0 mg/kg administered to treatment-naïve, HBeAg-positive participants with CHB
62039281|NCT02065336|EXPERIMENTAL|ARC-520 Cohort 12|a single IV dose of open-label ARC-520 6.0 mg/kg administered to treatment-naïve, HBeAg-positive participants with CHB
62039282|NCT06332885||Single Group Assignment|Bronchoscopic lung volume reduction with Zephyr Valves
62242344|NCT00950430|EXPERIMENTAL|PiB PET, FDG PET, Tau PET|
62242345|NCT04644380|EXPERIMENTAL|Treatment Group|During an IVF/IVC cycle, participants will retain the INVOcell Culture Device with the Retention Device in the vaginal cavity for 5 days vaginal incubation
62242346|NCT01711151||Idiopathic Pulmonary Fibrosis|Questionnaire evaluation
62432726|NCT03413865|EXPERIMENTAL|OTN virtual clinic|Pharmacist and nurse led OTN based remote teleconference based clinic (OTN) The OTN clinic will be conducted by providing the patient with a link via email which will allow the patient to access OTN teleconferencing and meet virtually with a pharmacist and nurse during a previously scheduled appointment. Virtual clinic appointments will be 30 minutes long and will consist of a patient assessment and open ended questions about the patient health status using a modified version of the validated MOATT (MASCC Oral Agent Teaching Tool) created by the Multidisciplinary Association of Supportive Care in Cancer.
62432727|NCT03413865|NO_INTERVENTION|In person Visits|Patients are followed in person at the cancer clinic based on standard of care guidelines
62432728|NCT06530394|EXPERIMENTAL|Greek yogurt exercising group (GYEX)|Participants will be asked to consume 2 servings/day (preferably morning and night) of 175 g commercially available GY (0% MF, flavoured, 130 calories, 17 g protein, 225 g calcium (e.g., OIKOS High Protein GY) for a total of 8 weeks. For their convenience, the participants will be provided with appropriate scoops to measure out 175 g of GY per serving of the larger 650 g commercially available, pre-packaged containers. Although it is recommended to consume the two servings morning and night, to increase ecological validity and strengthen the feasibility of the intervention, the timing of the servings will be flexible to facilitate daily routines and lifestyles. For the same reasons, the participants will be able to choose the flavour of their GY.
62432729|NCT06530394|NO_INTERVENTION|Control exercising group (NYEX)|During the 8-weeks, participants will be instructed to follow their typical, habitual diet and exercise regimen.
62432730|NCT06530394|ACTIVE_COMPARATOR|Intervention non-exercising group (GYNE)|Participants will be instructed to follow their typical habitual diet. Participants will be asked to consume 2 servings/day (preferably morning and night) of 175 g commercially available GY (0% MF, flavoured, 130 calories, 17 g protein, 225 g calcium; e.g., OIKOS High Protein GY) for a total of 8 weeks. For their convenience, the participants will be provided with appropriate scoops to measure out 175 g of GY per serving of the larger 650 g commercially available, pre-packaged containers. Although it is recommended to consume the two servings morning and night, to increase ecological validity and strengthen the intervention's feasibility, the servings' timing will be flexible to facilitate daily routines and lifestyles. For the same reasons, the participants will be able to choose the flavour of their GY.
62432731|NCT00350519|EXPERIMENTAL|PROCRIT (epoetin alfa)|Participants will receive PROCRIT (epoetin alfa).
62432732|NCT00350519|EXPERIMENTAL|STANDARD THERAPY|Participants will receive standard of care.
62432733|NCT00854620|EXPERIMENTAL|Sorafenib|"* Cycle 1: 400 mg BID sorafenib~* Cycle 2: 600 mg BID sorafenib~* Cycle 3+: 800 mg BID sorafenib"
62039283|NCT05575076|EXPERIMENTAL|Simufilam 100 mg|simufilam 100 mg oral tablet, twice daily
62039284|NCT03821168|ACTIVE_COMPARATOR|intravitreal injection of bevacizumab and erythropoietin|erythropoietin:
62039285|NCT03821168|ACTIVE_COMPARATOR|intravitreal injection of bevacizumab|bevacizumab:1.25 mg
62039286|NCT05964660||VT Patients|Patients with indication for catheter ablation of ventricular arrhythmia and preprocedural contrast-enhanced cardiac computed tomography for cardiac structure characterization.
62432734|NCT00409188|EXPERIMENTAL|Tecemotide (L-BLP25)|
62242347|NCT01711151||Non Idiopathic Pulmonary Fibrosis|Questionnaire evaluation
62242348|NCT01711151||Sarciodosis|Questionnaire evaluation
62242349|NCT01711151||Healthy Controls|Questionnaire evaluation
62242350|NCT03886792|EXPERIMENTAL|Triggered Reinforcement|This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
62818717|NCT05025059|EXPERIMENTAL|Supportive care (coaching, exercise, questionnaire)|Patients participate in one-on-one coaching sessions with a health coach QW to discuss the content offered in the program, and challenges they are currently facing in achieving their exercise goals. Patients receive a copy of the WWE workbook, wear a fitness tracker and are encouraged to achieve 150 minutes of walking per week during chemotherapy and up to 1 month after chemotherapy. Patients also participate in the Growing Stronger Strength Training Program and receive instruction manuals. They perform the initial 2 exercises 2 days per week for 4 weeks, and subsequent 2 exercises 2 days per week for the remainder of the chemotherapy course. Patients maintain exercise logs and complete questionnaires over 30-45 minutes at baseline, end of chemotherapy and at 1 month after chemotherapy.
62818718|NCT04251052|EXPERIMENTAL|Group I (bilateral salpingectomy)|Patients undergo bilateral salpingectomy. Patients may then undergo oophorectomy after initial surgery. Patients also undergo a pelvic or transvaginal ultrasound during screening and blood sample collection throughout the trial.
62039287|NCT05452057|EXPERIMENTAL|Prehabilitation|"This will include an individualized, light to moderate intensity resistance training and aerobic exercise components. Each prescribed session will include: a minute warm-up, aerobic exercise, resistance training, and a cool-down, but may be modified to accommodate the participants exercise ability.~A registered dietitian will provide an individualized nutrition assessment and counselling session within the first week of prehabilitation and again in the week prior to surgery.~A staff psychologist or psychology resident will deliver a \~60-minute psychoeducation session that focuses on stress management via relaxation, mindfulness, goal setting, and strategies to overcoming barriers to practice. In the week prior to surgery, participants will be offered a second consultation with the psychology team member to review their stress management experiences and provide further support for the acute perioperative period."
62039288|NCT05452057|NO_INTERVENTION|Usual care|Usual care group will be asked to resume your typical lifestyle behaviours until the date of the surgery and will be provided with publicly available resources on physical activity, diet, and stress management.
62039289|NCT05483504|ACTIVE_COMPARATOR|F61 injection|"F61 injection, specification: 150 mg/5ml/bottle, batch number: 202202002-1, produced by Wuhan Institute of Biological Products Co., Ltd.~Validity period: 24 months; Storage conditions: 2\~8°C, protected from light and sealed."
62432735|NCT00409188|PLACEBO_COMPARATOR|Placebo|
62039290|NCT05483504|PLACEBO_COMPARATOR|F61 placebo|"F61 placebo, specification: 5 ml/bottle, produced by Wuhan Institute of Biological Products Co., Ltd.~Validity period: 24 months; Storage conditions: 2\~8°C, protected from light and sealed."
62039291|NCT05027139|EXPERIMENTAL|Zanidatamab plus evorpacept (ALX148)|
62039292|NCT00698646|ACTIVE_COMPARATOR|Valsartan|(patients initiated on valsartan)
62039293|NCT00698646|ACTIVE_COMPARATOR|HCTZ|(patients initiated on HCTZ)
62818719|NCT04251052|ACTIVE_COMPARATOR|Group II (bilateral salpingo-oophorectomy)|Patients undergo bilateral salpingo-oophorectomy. Patients also undergo a pelvic or transvaginal ultrasound during screening and blood sample collection throughout the trial.
62818720|NCT04848675|EXPERIMENTAL|Inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, six days a week, for three months.
62039294|NCT00698646|EXPERIMENTAL|Valsartan + HCTZ|(patients initiated on Valsartan+HCTZ)
62039295|NCT00810264||Data Collection Group|
62039296|NCT03306212|EXPERIMENTAL|Casting Group|Patients treated by botulinum toxin A and occupational therapy and intermittent serial casting
62039297|NCT03306212|ACTIVE_COMPARATOR|Control Group|Patients treated by botulinum toxin A and occupational therapy
62039298|NCT06335888|EXPERIMENTAL|AzaFol first, FDG second|AzaFol PET/CT imaging followed by FDG PET/CT imaging (standard of care)
62039299|NCT06335888|ACTIVE_COMPARATOR|FDG first, AzaFol second|FDG PET/CT imaging (standard of care) imaging followed by AzaFol PET/CT
62039300|NCT02645734|ACTIVE_COMPARATOR|Injection intravitreous bevacizumab|Injection intravitreous bevacizumab at a dose 1.25mg
62039301|NCT02645734|ACTIVE_COMPARATOR|Injection ziv-aflibercept at dose of 1.25 mg|Injection ziv-aflibercept at dose of 1.25 mg
62039302|NCT02645734|ACTIVE_COMPARATOR|Injection ziv-aflibercept at dose of 2.5 mg|Injection ziv-aflibercept at dose of 2.5 mg
62039303|NCT03387553|ACTIVE_COMPARATOR|Lead In Phase - Arm A|Arm A: One Dendritic Cell Vaccine (DC1) per week x 3 weeks.
62039304|NCT03387553|ACTIVE_COMPARATOR|Lead In Phase - Arm B|Arm B: Two DC1 vaccinations per week (given 3 days apart i.e., Mon and Thurs or Tues and Friday) x 3 weeks.
62039305|NCT03387553|EXPERIMENTAL|Expansion Phase|DC1 vaccinations according to optimal vaccination schedule. Participants will receive a booster intranodal study vaccine at week 25 prior to receiving surgery. Participants will then undergo definitive curative surgery following completion of the neoadjuvant therapy, additional adjuvant locoregional/systemic therapy (as deemed appropriate by their treating physicians).
62039306|NCT03733262||Hemodialysis Patients|There will be approximately 1,200 patients in the outpatient HD units from Toronto (300), Vancouver (200), Winnipeg (400) and Halifax (300). Based on a previous pilot study, it is assumed that 80% of patients have been prescribed at least one of the nine target drugs (i.e., n=960). Of those, it is assumed that 50% will be eligible for the study (i.e., n=480). Of eligible individuals, it is assumed 88% will initiate a De-prescribing Trial (Intervention Group), resulting in an anticipated cohort of n=420.
62039307|NCT06200558||For ARON-3S: Patients with metachronous or de novo metastatic hormone/castration-sensitive PCa|Patients with metachronous or de novo metastatic hormone/castration-sensitive PCa treated with ADT+ARSI or ADT+ARSI+docetaxel
62432736|NCT02577289|ACTIVE_COMPARATOR|Control group ( Hydroxyappetite)|Patients will undergo open sinus lift using nano crystalline hydroxyapatite as augmentation material and placing implants simultaneously then evaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)
62432737|NCT02577289|EXPERIMENTAL|Test group (PRF)|Patients will undergo open sinus lift using PRF as sole augmentation material and placing implants simultaneously then Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)
62432738|NCT00541294||B|M.tb unexposed HIV-infected and uninfected children \<15 years of age
62432739|NCT00541294||A|M.tb exposed HIV-infected and uninfected children \<15 years of age
62039308|NCT06200558||For ARON-3Lu: Patients receiving Lutetium-177 PSMA for castration resistant PC (CRPC)|
62039309|NCT06200558||For ARON-3GEN: Patients treated with PARP inhibitors (alone or plus ARSI) for CRPC|
62432740|NCT01454882||Behavioral effects of clothing and temperature|In this first study, we will determine how variations in clothing and ambient temperature influence the accuracy of EE determined from measurements of total heat production. 65 individuals will be studied. This will be a randomized cross-over trial with two within subject factors: 1) ambient temperature and 2) amount of clothing. There will be two temperature conditions; warm temperature \[WT, 75°F (24°C)\] and cool temperature \[CT, 60°F (16°C)\]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
62818721|NCT04848675|ACTIVE_COMPARATOR|Brisk walking|Participants will walk for 25 minutes a day, six days a week, for three months at a target heart rate of 40-60% heart rate reserve. Heart rate will be monitored with a heart rate monitor.
62818722|NCT00823511||Female Partners|Female partners of HIM Study participants
62818723|NCT03524430|EXPERIMENTAL|Single Interventional Study Arm|There will be 2 biopsy collection time points with 2 core needle biopsy specimens taken at each biopsy collection time point for RDA analysis during neoadjuvant chemotherapy.
62818724|NCT02985827|ACTIVE_COMPARATOR|Rohto (r) Hydra|Menthol containing over the counter eyedrop
62818725|NCT02985827|PLACEBO_COMPARATOR|Systane (r) Ultra|Non-Menthol containing over the counter eyedrop
62818726|NCT06136871|EXPERIMENTAL|Cognitive Orientation to daily Occupational Performance (CO-OP)|Each CO-OP session will last 45 minutes and subjects will complete one session per week over the course of 10 weeks. All sessions will be delivered remotely via the Zoom platform.
62818727|NCT06136871|OTHER|Inactive Control Group|Subjects will complete one session per week over the course of 10 weeks. All sessions will be delivered remotely via the Zoom platform.
62818728|NCT05298579|EXPERIMENTAL|Group A|"Yoga exercises applied by video-conference method accompanied by a physiotherapist.~Evaluations and yoga exercises will be applied to the participants in this group through the Zoom program. Yoga exercises were created with reference to studies in the literature. It will be applied for 8 weeks, 3 days a week and 40-45 minutes, at a time determined jointly by the physiotherapist and the participant (Table 1). Before starting the program, an informative broadcast will be made to the participants and groups of 6-8 people will be formed."
62818729|NCT05298579|ACTIVE_COMPARATOR|Group B|"Yoga exercises performed asynchronously accompanied by videos. Exercise videos will be broadcast to the participants in this group through the YouTube program. The shooting of the exercise videos will be completed in advance and uploaded to a channel opened on YouTube. All posts made in this channel will only be open to individuals participating in the research during the duration of the study. Yoga exercises were created with reference to studies in the literature. It will be applied for 8 weeks, 3 days a week and 40-45 minutes. Participants will be able to access the exercise videos at a time they want (Table 2). Participants will be encouraged to achieve weekly targeted training sessions and to keep an exercise diary."
62818730|NCT06602076|EXPERIMENTAL|Treatment|Receive standard smoking cessation treatment in the form of the NCI's QuitGuide smoking cessation smartphone app and free over-the-counter nicotine replacement therapy provided by mail, plus participate in online SGM-serving volunteer activities (≥4 sessions) and a digital hub (Facebook) to foster social support across sites.
62818731|NCT06602076|NO_INTERVENTION|Control|Receive standard smoking cessation treatment in the form of the NCI's QuitGuide smoking cessation smartphone app and free over-the-counter nicotine replacement therapy provided by mail.
62432741|NCT01454882||Behavioral effects of age, sex, and adiposity|THe aim of this study is to Determine how age, sex, and adiposity influence the accuracy of EE determined from measurements of total heat production . This will be a randomized study with two within subject conditions(high and low physical activity levels). A heterogenous sample of adult men and women in stable health will be studied. We will study subjects across a wide range of weight (up to 300 lbs) and age range (≥ 18 yrs).
62818732|NCT04742556|EXPERIMENTAL|4 mg BI 3011441|The patients were administered 4 milligram (mg) BI 3011441 soft capsule once daily during 4 weeks with water limited to a maximum of 100 milliliters (mL) per capsules, taken without food, at least 1 hour before a meal or 1 hour after a meal. Patients continued the treatment until undue drug toxicity, disease progression, or withdrawal of consent, whichever occurred first.
62818733|NCT04742556|EXPERIMENTAL|6 mg BI 3011441|The patients were administered 6 milligram (mg) BI 3011441 soft capsule once daily during 4 weeks with water limited to a maximum of 100 milliliters (mL) per capsules, taken without food, at least 1 hour before a meal or 1 hour after a meal. Patients continued the treatment until undue drug toxicity, disease progression, or withdrawal of consent, whichever occurred first.
62818734|NCT04742556|EXPERIMENTAL|8 mg BI 3011441|The patients were administered 8 milligram (mg) BI 3011441 soft capsule once daily during 4 weeks with water limited to a maximum of 100 milliliters (mL) per capsules, taken without food, at least 1 hour before a meal or 1 hour after a meal. Patients continued the treatment until undue drug toxicity, disease progression, or withdrawal of consent, whichever occurred first.
62818735|NCT03463057|OTHER|Atezolizumab|18 cycles atezolizumab followed by 12 months of observation
62818736|NCT01647789|EXPERIMENTAL|CFG920|
62818737|NCT05712460|EXPERIMENTAL|Group A: Higher dose sisunatovir|higher dose of sisunatovir dosed every 12 hours
62818738|NCT05712460|EXPERIMENTAL|Group B: Lower dose sisunatovir|Lower dose of sisunatovir dosed every 12 hours
62818739|NCT05712460|PLACEBO_COMPARATOR|Group C: Placebo|Placebo for sisunatovir dosed every 12 hours
62818740|NCT05712460|EXPERIMENTAL|Group D: Higher dose of sisunatovir|Higher dose of sisunatovir dosed every 12 hours under fasted conditions
62432742|NCT01454882||Effects of free living energy expenditure|The primary aim of this study is to compare the accuracy of measuring free-living energy expenditure in humans measured using portable direct calorimetry. This will be a comparison study; TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied. We will study subjects across a wide range of weight (up to 300 lbs) and age (\>18 yrs).
62432743|NCT04952532|OTHER|Cognitive Remediation+Bridging Intervention|This is a pilot study to collect feasibility data on this novel cognitive remediation intervention for Veterans at high risk for suicide. All patients will receive the active intervention.
62039310|NCT00344461|EXPERIMENTAL|Nevirapine, FTC, Tenofovir|Open Label Drugs- Nevirapine 200 mg twice a day, FTC 200 mg once a day and Tenofovir 300 mg once a day for 96 weeks.
62242351|NCT03886792|SHAM_COMPARATOR|Social Interaction|This group will participate in a home-based dose-equivalent control intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray. This control program will combine social interaction between infant/parent with the opportunity for self-initiated play with toys repeatedly placed on the tray. A toy will be placed in front of the infant seat and tray but it will not be connected to the SEMG unit nor will the infant have an SEMG electrode attached over the biceps. During the intervention, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
62242352|NCT03288870|EXPERIMENTAL|BCD-100 monotherapy|Patients will receive solution of BCD-100 in a dose 3 mg/kg every 3 weeks as intravenous infusion until progression of the disease or signs of intolerable toxicity
62242353|NCT03288870|ACTIVE_COMPARATOR|Docetaxel monotherapy|Patients will receive solution of docetaxel in a dose 75 mg per square meter every 3 weeks as intravenous infusion until progression of the disease or signs of intolerable toxicity, maximum 6 cycles
62242354|NCT01938807|EXPERIMENTAL|Intervention|The intervention group receives the CareCoach mobile application
62242355|NCT01938807|ACTIVE_COMPARATOR|Control|The control group receives standard care.
62242356|NCT03171727|EXPERIMENTAL|study group|After TIPS procedure was performed, low molecular weight heparin was given for three days.
62242357|NCT03171727|NO_INTERVENTION|control group|After TIPS procedure was performed, no low molecular weight heparin was given.
62242358|NCT06101823|ACTIVE_COMPARATOR|OpSCF|OpSCF, 600 mg, subcutaneously, every two weeks x 14 weeks
62242359|NCT06101823|PLACEBO_COMPARATOR|Placebo|Matched placebo, subcutaneously, every two weeks x 14 weeks
62242360|NCT06101823|ACTIVE_COMPARATOR|Open Label Extension|Subjects may choose to continue in an Open Label Extension (OLE) phase if they complete the randomized phase. All subjects regardless of treatment assignment in the randomized phase will receive OpSCF, 600 mg every 4 weeks for up to 36 weeks.
62818741|NCT05712460|EXPERIMENTAL|Group E: sisunatovir palatability|Sisunatovir in 4 vehicles (water, saline, apple juice, infant formula) to assess the palatability of sisunatovir in each vehicle. sisunatovir will not be swallowed, participants will swirl and spit to assess various aspects of the taste.
62242361|NCT04706611|EXPERIMENTAL|Irritable Bowel Syndrome|Fecal Microbiota Transplantation will be performed.
62818742|NCT04043910|EXPERIMENTAL|Single-sided deaf group|30 children will be included in this group
62242362|NCT04706611|EXPERIMENTAL|Constipation|Fecal Microbiota Transplantation will be performed.
62242363|NCT04706611|EXPERIMENTAL|Clostridium Difficile Infection|Fecal Microbiota Transplantation will be performed.
62242364|NCT04706611|EXPERIMENTAL|Functional Dyspepsia|Fecal Microbiota Transplantation will be performed.
62242365|NCT04706611|EXPERIMENTAL|Parkinson's Disease|Fecal Microbiota Transplantation will be performed.
62242366|NCT04706611|EXPERIMENTAL|Metabolic Syndrome|Fecal Microbiota Transplantation will be performed.
62242367|NCT04706611|EXPERIMENTAL|Non-Alcoholic Fatty Liver Disease|Fecal Microbiota Transplantation will be performed.
62818743|NCT04043910|ACTIVE_COMPARATOR|Normal hearing group|30 children will be included in this group
62242368|NCT04706611|EXPERIMENTAL|Autism Spectrum Disorder|Fecal Microbiota Transplantation will be performed.
62242369|NCT04706611|EXPERIMENTAL|Radiation Enteritis|Fecal Microbiota Transplantation will be performed.
62242370|NCT04706611|EXPERIMENTAL|Atopic Dermatitis|Fecal Microbiota Transplantation will be performed.
62242371|NCT04706611|EXPERIMENTAL|Food Allergic|Fecal Microbiota Transplantation will be performed.
62242372|NCT04706611|EXPERIMENTAL|Graft-versus-Host Disease|Fecal Microbiota Transplantation will be performed.
62242373|NCT04706611|EXPERIMENTAL|Obesity|Fecal Microbiota Transplantation will be performed.
62242374|NCT04706611|EXPERIMENTAL|Diabetes mellitus|Fecal Microbiota Transplantation will be performed.
62242375|NCT04706611|EXPERIMENTAL|Multi-Drug Resistant Infection|Fecal Microbiota Transplantation will be performed.
62242376|NCT04706611|EXPERIMENTAL|Hepatic Encephalopathy|Fecal Microbiota Transplantation will be performed.
62242377|NCT04706611|EXPERIMENTAL|Enteric Dysbacteriosis|Fecal Microbiota Transplantation will be performed.
62242378|NCT04706611|EXPERIMENTAL|Multiple Sclerosis|Fecal Microbiota Transplantation will be performed.
62242379|NCT04706611|EXPERIMENTAL|Pseudomembranous Enteritis|Fecal Microbiota Transplantation will be performed.
62242380|NCT04706611|EXPERIMENTAL|Acute Pancreatitis|Fecal Microbiota Transplantation will be performed.
62242381|NCT04706611|EXPERIMENTAL|Chronic Fatigue Syndrome|Fecal Microbiota Transplantation will be performed.
62242382|NCT04706611|EXPERIMENTAL|Acute-on-chronic Liver Failure with HBV Infection|Fecal Microbiota Transplantation will be performed.
62242383|NCT04706611|EXPERIMENTAL|Alcoholic Liver Disease|Fecal Microbiota Transplantation will be performed.
62242384|NCT04706611|EXPERIMENTAL|Anorexia|Fecal Microbiota Transplantation will be performed.
62242385|NCT04706611|EXPERIMENTAL|Decompensated Cirrhosis|Fecal Microbiota Transplantation will be performed.
62242386|NCT04706611|EXPERIMENTAL|Henoch-Schonlein Purpura|Fecal Microbiota Transplantation will be performed.
62242387|NCT04706611|EXPERIMENTAL|Autoimmune Liver Disease|Fecal Microbiota Transplantation will be performed.
62242388|NCT04706611|EXPERIMENTAL|Systemic Lupus Erythematosus|Fecal Microbiota Transplantation will be performed.
62242389|NCT04706611|EXPERIMENTAL|IgG4-Related Disease|Fecal Microbiota Transplantation will be performed.
62242390|NCT04706611|EXPERIMENTAL|Celiac Disease|Fecal Microbiota Transplantation will be performed.
62242391|NCT04706611|EXPERIMENTAL|Protein-losing Enteropathy|Fecal Microbiota Transplantation will be performed.
62242392|NCT04706611|EXPERIMENTAL|Asperger Syndrome|Fecal Microbiota Transplantation will be performed.
62242393|NCT04706611|EXPERIMENTAL|Rheumatoid arthritis|Fecal Microbiota Transplantation will be performed.
62818744|NCT06121102|EXPERIMENTAL|Group A (supervoltage pulsed radiofrequency glossopharyngeal nerve block)|Patients will receive supervoltage pulsed radiofrequency glossopharyngeal nerve block.
62818745|NCT06121102|ACTIVE_COMPARATOR|Group B (standard voltage pulsed radiofrequency glossopharyngeal nerve block)|Patients will receive standard voltage pulsed radiofrequency glossopharyngeal nerve block.
62818746|NCT00003127|EXPERIMENTAL|carbo, taxol, amifostine|carbo, taxol, amifostine
62242394|NCT04706611|EXPERIMENTAL|Ulcerative colitis|Fecal Microbiota Transplantation will be performed.
62242395|NCT04706611|EXPERIMENTAL|Crohn's disease|Fecal Microbiota Transplantation will be performed.
62242396|NCT04706611|EXPERIMENTAL|Psoriasis|Fecal Microbiota Transplantation will be performed.
62242397|NCT04706611|EXPERIMENTAL|Ankylosing spondylitis|Fecal Microbiota Transplantation will be performed.
62242398|NCT04706611|EXPERIMENTAL|Immune checkpoint inhibition-related colitis|Fecal Microbiota Transplantation will be performed.
62242399|NCT04706611|EXPERIMENTAL|Autoimmune enteropathy|Fecal Microbiota Transplantation will be performed.
62242400|NCT04706611|EXPERIMENTAL|Drug-induced diarrhea|Fecal Microbiota Transplantation will be performed.
62242401|NCT02311998|EXPERIMENTAL|Treatment (bosutinib, inotuzumab ozogamicin) Phase I Dose 1|Patients receive bosutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15. Patients with confirmed CR, CRi, CCyR and/or absence of MRD may receive inotuzumab ozogamicin IV on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62242402|NCT02311998|EXPERIMENTAL|Treatment (bosutinib, inotuzumab ozogamicin) Phase II|Patients receive bosutinib at the Maximum Tolerated Dose from the Phase I dose part, PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15. Patients with confirmed CR, CRi, CCyR and/or absence of MRD may receive inotuzumab ozogamicin IV on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62242403|NCT02311998|EXPERIMENTAL|Treatment (bosutinib, inotuzumab ozogamicin) Phase I Dose 2|Patients receive bosutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15. Patients with confirmed CR, CRi, CCyR and/or absence of MRD may receive inotuzumab ozogamicin IV on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62432744|NCT02069834|EXPERIMENTAL|Arm 1 (intervention)|Dolutegravir 50 mg/d + Rilpivirine 25 mg/d qd orally (intake during a meal)
62599631|NCT03275675||Patients with cancer chemotherapy|This study project is designed to evaluate the satisfaction of patients undergoing oral chemotherapy treated for a cancer and whose treatment is provided by their community pharmacies.
62599632|NCT01021475|EXPERIMENTAL|Usual drug FD therapy + Visceral Manipulation|
62599633|NCT01021475|ACTIVE_COMPARATOR|Usual drug FD therapy|
62599634|NCT00059605|EXPERIMENTAL|DOTAP:Chol-fus1|Infusion intravenous once every 3 weeks
62599635|NCT00189306|EXPERIMENTAL|Aldara|Aldara (imiquimod) cream 5% applied 7 times per week for 6 weeks
62599636|NCT06647992|EXPERIMENTAL|Intervention group- Nurse Navigation Program|The standard education and information booklet will be applied to both the experimental and control groups. Nurse navigation program will be applied to the experimental group. Within the navigation program, HPV DNA and Pap Smear Test Training and Counseling, Nurse Managed Telephone Support Line, Reminder Telephone Message, Transtheoretical Model and Motivational Interviews will be applied to individuals. Health Belief Model Scale for Cervical Cancer and Pap Smear Test: Psychometric testing is planned to be applied to both groups before and after the intervention in terms of outcome variables at 3 and 6 months.
62599637|NCT06647992|NO_INTERVENTION|control group- Standardised Education|"It was planned to give Cervical Cancer Education and Information Booklet to the women in the control group about cervical cancer. Health Belief Model Scale for Cervical Cancer and Pap Smear Test: Psychometric testing was planned to be applied before and after the standard education and booklet in terms of outcome variables at 3 and 6 months."
62599638|NCT02815124|ACTIVE_COMPARATOR|Standard of Care|Cochlear Implant programming using standard of care
62818747|NCT06088888|EXPERIMENTAL|TGRX-678|Subjects to be treated with the investigational drug TGRX-678
62432745|NCT02069834|ACTIVE_COMPARATOR|Arm 2 (control)|Continuation of existing HAART at the time of randomization
62432746|NCT03454100|EXPERIMENTAL|multi-sectoral package of activities|Villages in the experimental arm received the full multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
62432747|NCT03454100|NO_INTERVENTION|Control|Villages in the control arm did not receive teh multi-sectoral package of village level activities.
62432748|NCT06413654|EXPERIMENTAL|B001 injection|
62432749|NCT06413654|PLACEBO_COMPARATOR|Placebo|
62432750|NCT02836197|EXPERIMENTAL|Experimental group|This group of 30 physicians will immediately attend the intervention communication skills training program (experimental group).For this experimental group, the first assessment will take place before the first training session and the second recording after the last session. This assessment involves the analyses of communicational, physiological and psychological variables recorded in the context of an encounter with a simulated advanced stage cancer patient.
62432751|NCT02836197|NO_INTERVENTION|Waiting-list group|This group of 30 physicians will attend the intervention communication skills training in a delayed manner (control group). For this control group, the first and the second recording will take place with a four-month interval. This assessment involves the analyses of communicational, physiological and psychological variables recorded in the context of an encounter with a simulated advanced stage cancer patient.
62599639|NCT02815124|EXPERIMENTAL|Image-Guided Cochlear Implant Programming|Cochlear Implant programming using Image-Guided Cochlear Implant Programming
62599640|NCT03061656|EXPERIMENTAL|High risk neuroblastoma|"1. Conventional chemotherapy (9 cycles)~2. Surgery conventional chemotherapy (after 6 cycles of chemotherapy)~3. Tandem HDCT/autoSCT~   * First HDCT (cyclophosphamide, etoposide, carboplatin)~  * Second HDCT (high-dose 131I-MIBG, thiotepa, melphalan)~4. Local radiotherapy~5. Retinoic acid, interleukin-2"
62599641|NCT01424046|EXPERIMENTAL|basal insulin approach|Participants will be treated primarily with a daily basal insulin injection ( glargine) with later introduction of prandial coverage with a shortacting insulin.
62039311|NCT00538135|EXPERIMENTAL|1|"Cognitive Behaviour Therapy plus Treatment as Usual (CBT plus TAU) for borderline personality disorder.~CBT is a structured, time limited, psycho-social intervention developed to treat Cluster B personality disorder. Patients are encouraged to engage in treatment through a formulation of their problems within a cognitive framework. Interventions focus on the patient's beliefs and behaviour that impair social and adaptive functioning. Thirty sessions of CBT over one year, each lasting up to one hour, are required to work on long-standing problems and develop new ways of thinking and behaving. Priority is given to behaviours that cause harm to self or others. In addition, participants received the usual treatment they would have received if the trial had not been in place"
62039312|NCT00538135|ACTIVE_COMPARATOR|2|"Treatment as Usual.~All participants received the standard treatment (TAU) they would have received if the trial had not been in place. Although standard treatment may vary across the three sites, and depend on the specific problems of the individual participant, it was thought that all participants would be in contact with mental health services and would have some contact with Accident and Emergency services for repeated self-harm episodes. TAU will be documented carefully after each patient exits the trial."
62039313|NCT04062266|EXPERIMENTAL|Treatment (azacytidine, venetoclax)|Patients receive azacitidine SC or IV over 1 hour daily on days 1-5, and venetoclax PO daily on days 1-14. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62039314|NCT05502432|ACTIVE_COMPARATOR|Active Repetitive Transcranial Magnetic Stimulation(rTMS)|15 days with 1 Hz of repetitive transcranial magnetic stimulation (rTMS) with active mood.
62039315|NCT05502432|SHAM_COMPARATOR|Sham Repetitive Transcranial Magnetic Stimulation(rTMS)|15 days with 1 Hz of repetitive transcranial magnetic stimulation (rTMS) with sham mood.
62039316|NCT03054792|EXPERIMENTAL|BOLD- DW- MRS|Blood Oxygen Level Dependent \[BOLD\], Diffusion-Weighted \[DW\] MRI, MR Spectroscopy \[MRS\]
62039317|NCT01692340|EXPERIMENTAL|Isotopically labeled lycopene|We will administer 10 mg of isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
62039318|NCT01692340|EXPERIMENTAL|Isotopically labeled phytoene|We will administer 3.2 mg isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
62039319|NCT01692340|EXPERIMENTAL|Isotopically labeled phytofluene|We will administer 10 mg of isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
62039320|NCT03692533|ACTIVE_COMPARATOR|Group A|Group (A) \[study cases\] Adult patients who will undergo radical or partial nephrectomy.for primary renal cell carcinoma.
62039321|NCT03692533|ACTIVE_COMPARATOR|Group B|Group (B) \[control cases\] Adult patients who will undergo simple nephrectomy for benign causes
62039322|NCT03532074|OTHER|laparoscopic approach|assessment of bowel symptoms before surgery; assessment of rectosigmoid perfusion using indocyanine green; removal of rectosigmoid endometriosis nodule using a laparoscopic approach; follow up and assessment of bowel symptoms after surgery
62039323|NCT03532074|OTHER|robot-assisted approach|assessment of bowel symptoms before surgery; assessment of rectosigmoid perfusion using indocyanine green; removal of rectosigmoid endometriosis nodule using a robot-assisted approach; follow up and assessment of bowel symptoms after surgery
62039324|NCT06732739|EXPERIMENTAL|percussions with teach-back breathing exercises|The treatment will be given with the frequency of 3 times per week for 8 weeks. Treatment sessions will be 25 to 30 minutes with short resting intervals.
62242404|NCT02311998|EXPERIMENTAL|Treatment (bosutinib, inotuzumab ozogamicin) Phase I Dose 3|Patients receive bosutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15. Patients with confirmed CR, CRi, CCyR and/or absence of MRD may receive inotuzumab ozogamicin IV on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62039325|NCT06732739|ACTIVE_COMPARATOR|percussions|The treatment will be given with the frequency of 3 times per week for 8 weeks. Treatment sessions will be 25 to 30 minutes with short resting intervals.
62039326|NCT02744534|EXPERIMENTAL|Abnormalities found with FACBC PET-CT|All participants with suspected recurrence of prostate cancer will have the FACBC PET-CT scan performed. Participants with abnormal FACBC PET-CT scan results will have a PET/ultrasound fusion targeted prostate biopsy followed a standard of care prostate biopsy.
62242405|NCT04132960|EXPERIMENTAL|HER2 status|"Three cohorts of advanced breast cancer patients:~* Cohort 1: HER2 over-expressing (HER2 IHC3+ or HER2 IHC2+/ISH+)~* Cohort 2: HER2 low-expressing (IHC1+ or IHC2+/ISH-)~* Cohort 3: HER2 non-expressing (IHC0+)"
62242406|NCT02068365|OTHER|Pegyinterferon-alfa-2a|Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks
62242407|NCT02618824|ACTIVE_COMPARATOR|HTK Solution|Hearts will be arrested with HTK solution during cardiac operation
62242408|NCT02618824|ACTIVE_COMPARATOR|HTK Solution + TWBC|Hearts will be arrested with HTK solution during cardiac operation and received terminal warm blood cardioplegia before aortic cross clamp removal.
62242409|NCT06734793||Pediatric patients with asthma|The study participants will be asked to wear up to a total of 5 patches in the following locations: left upper chest for the left upper lobe, left lower back for left lower lobe, right upper chest for the right upper lobe, right middle chest for the right middle lobe, and right lower back for the right lower lobe of the lung.
62242410|NCT00841893|EXPERIMENTAL|1|Mustard
62039327|NCT02744534|ACTIVE_COMPARATOR|No abnormalities found with FACBC PET-CT|All participants with suspected recurrence of prostate cancer will have the FACBC PET-CT scan performed. Participants without abnormal FACBC PET-CT scan results will have a standard of care prostate biopsy.
62039328|NCT02446405|EXPERIMENTAL|Enzalutamide|"Enzalutamide is 160 mg daily, by mouth, until clinical disease progression or prohibitive toxicity.~All participants are to receive standard background therapy with a LHRHA or surgical castration, as per standard of care. The choice of the LHRHA or surgical castration is at the discretion of the treating clinician."
62039329|NCT02446405|ACTIVE_COMPARATOR|Conventional NSAA|"Conventional NSAA, by mouth until clinical disease progression or prohibitive toxicity.~All participants are to receive standard background therapy with a LHRHA or surgical castration, as per standard of care. The choice of the LHRHA or surgical castration is at the discretion of the treating clinician."
62039330|NCT00554970|OTHER|Treatment 1 then Treatment 2|Subjects received Treatment 1 in period 1 followed by a 7 day washout period and then Treatment 2 in period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.
62039331|NCT00554970|OTHER|Treatment 2 then Treatment 1|Subjects received Treatment 2 in period 1 followed by a 7 day washout period and then Treatment 1 period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.
62039332|NCT00554970|OTHER|Treatment 3 then Treatment 4|Subjects received Treatment 3 in period 1 followed by a 7 day washout period and then Treatment 4 period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.
62039333|NCT00554970|OTHER|Treatment 4 then Treatment 3|Subjects received Treatment 4 in period 1 followed by a 7 day washout period and then Treatment 3 in period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.
62039334|NCT04720079|ACTIVE_COMPARATOR|Intercostobrachial nerve Infiltration|Preoperative infiltration of intercostobrachial nerve with 10ml of ropivacaine 0.5%
62039335|NCT04720079|ACTIVE_COMPARATOR|Ultrasound guided T2 paravertebral block|Preoperative ultrasound guided T2 paravertebral nerve block with 10ml of ropivacaine 0.5%
62039336|NCT01567384|EXPERIMENTAL|Combination therapy with OSI and Pemetrexed|
62432752|NCT05837065||training cohort|HCC patients receiving curative hepatic resection
62039337|NCT04324944|EXPERIMENTAL|Collaborative Decision Skills Training|Collaborative Decision Skills Training (CDST) is the intervention group (experimental arm).
62039338|NCT04324944|ACTIVE_COMPARATOR|Leveling Up|Leveling Up is the active control arm.
62432753|NCT05837065||validation cohort|HCC patients receiving curative hepatic resection
62039339|NCT04956302|EXPERIMENTAL|Treatment (panobinostat, daratumumab, bortezomib, dexa)|Patients receive panobinostat PO QD on days 1, 3, 5, 15, 17, 19, daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles, bortezomib SC on days 1, 8, 15, 22 and dexamethasone PO (IV on days of daratumumab and hyaluronidase-fihj administration) QD on days 1, 8, 15, 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62039340|NCT05390840|EXPERIMENTAL|Part 1 (MG-O-1002)|Drug: MG-O-1002; Dose level: 0.8%; Dosage form: ophthalmic solution; Route of administration: topical ocular
62039341|NCT05390840|PLACEBO_COMPARATOR|Part 2 (MG-O-1002 or Placebo)|"Arm 1:~Drug: MG-O-1002; Dose level: 0.8%; Dosage form: ophthalmic solution; Route of administration: topical ocular~Arm 2:~Drug: Placebo; Dosage form: ophthalmic solution; Route of administration: topical ocular"
62242411|NCT00841893|EXPERIMENTAL|2|Placebo
62242412|NCT00588536|EXPERIMENTAL|1|MTX, 6-TG, Leucovorin
62432754|NCT01999231|EXPERIMENTAL|1μg/ml ESAT6-CFP10|The 1μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
62432755|NCT01999231|EXPERIMENTAL|5μg/ml ESAT6-CFP10|The 5μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
62432756|NCT01999231|EXPERIMENTAL|10μg/ml ESAT6-CFP10|The 10μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
62039342|NCT01273454||001|OROS Hydromorphone 8 16 32 mg once a day for 4 weeks
62039343|NCT04474236||COVID-19 patients|Adult (\> 18 years) with Proven COVID-19 (specific PCR from respiratory track sample)
62242413|NCT03517384|EXPERIMENTAL|I-CBT for Body Dysmorphic Disorder|All participants will receive our Internet-Cognitive Behavioral Therapy treatment for Body Dysmorphic Disorder.
62242414|NCT04256486|EXPERIMENTAL|Family DSMES|
62242415|NCT04256486|EXPERIMENTAL|Wait List|
62242416|NCT03374098|EXPERIMENTAL|Education|Attend an hour-long classes once per week for three weeks
62432757|NCT01999231|EXPERIMENTAL|20μg/ml ESAT6-CFP10|The 20μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
62432758|NCT01517334|EXPERIMENTAL|Treatment|Treatment (minocycline HCl microspheres, 1mg) administered at Baseline (following randomization) and Day 90 to qualifying implant sites, plus full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180.
62432759|NCT01517334|NO_INTERVENTION|Control|Full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180; no treatment
62432760|NCT03712137|EXPERIMENTAL|VOLUX XC|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with optional touch-up at day 30 and optional maintenance treatment at Month 12.
62432761|NCT03712137|EXPERIMENTAL|No-treatment control|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) at the beginning of the Post-Control period.
62432762|NCT03604354|ACTIVE_COMPARATOR|Pregabalin|Pregabalin 150mg oral tablets before one hour before undergoing unilateral total knee arthroplasty
62432763|NCT03604354|EXPERIMENTAL|Tapentadol|tapentadol 100mg oral tablets before one hour before undergoing unilateral total knee arthroplasty
62432764|NCT02118701|EXPERIMENTAL|SDM care planning|
62242417|NCT03374098|EXPERIMENTAL|Home Visitation|Receive home visits that focus on the social determinants of health and attend hour-long classes once per week for three weeks
62242418|NCT00764933|EXPERIMENTAL|1|Structured information
62242419|NCT00764933|SHAM_COMPARATOR|2|Unspecific conversation
62242420|NCT06428825|EXPERIMENTAL|Treatment scheme 1|The Participants will receive either BAY3283142 or placebo once a day. The treatment scheme consists of 3 dose steps. Treatment will start with the low dose for 7 days , followed for 14 days at the middle dose and 14 days on the high dose.
62039344|NCT06732999|EXPERIMENTAL|Starting GC-MRT training after randomized allocation of period of time after assesment|Gaze-Contingent Music Reward Therapy (GC-MRT) is a treatment method for adults with social anxiety disorder found to be effective in reducing social anxiety in various RCTs. This method includes a computerized cognitive training to redirect threat-related attention patterns. Time period between Pre assessment and start of GC-MRT is randomly assigned (1 week/ 2 weeks/ 3 weeks) to create a multiple baseline design.
62039345|NCT06495853|EXPERIMENTAL|GroupA|Patients with rectal cancer who did not receive neoadjuvant chemoradiotherapy and underwent rectal anterior resection with anastomotic reinforcement were included in Cohort A. The rectal cancer radical resection was performed in strict accordance with the principles of no-tumor technique and total mesorectal excision (TME) by experienced deputy chief physicians or higher from our research center. The procedure followed standard rectal cancer radical resection protocols. After rectal division using a linear stapler, an end-to-end anastomosis was performed using a circular stapler. For patients in the treatment group, anastomotic reinforcement was performed using absorbable Johnson \& Johnson EB403 barbed sutures laparoscopically.Unless there were clear high-risk factors for anastomotic leakage preoperatively (e.g., diabetes, narrow pelvis, unsatisfactory anastomosis, positive colonic air leak test), ileostomy was not routinely performed in this group of patients.
62242421|NCT06428825|EXPERIMENTAL|Treatment scheme 2|Participants will receive either BAY3283142 or placebo once a day. The treatment scheme consists of 3 dose steps. Treatment will start with the low dose for 7 days , followed for 14 days at the middle dose and 14 days on the very high dose.
62242422|NCT06428825|EXPERIMENTAL|Treatment scheme 3|Participants will receive either BAY3283142 or placebo twice a day. The treatment scheme consists of 3 dose steps. Treatment will start with the low dose for 7 days , followed for 14 days at the middle dose and 14 days on the very high dose.
62242423|NCT06428825|EXPERIMENTAL|Treatment scheme 4|Participants will receive either BAY3283142 or placebo twice a day. The treatment scheme consists of 3 dose steps. Treatment will start with the low dose for 7 days , followed for 14 days at the middle dose and 14 days on the high dose.
62242424|NCT06736054|EXPERIMENTAL|Prostate Adenocarcinoma with PSMA-Positive Disease on a PSMA Targeted PET/CT|TEST PRODUCT, DOSE, AND ROUTE OF ADMINISTRATION: Subjects will undergo imaging with 100-300 MBq (2.7-8.1 mCi) of 61Cu-NODAGA-PSMA intravenously (IV), followed by PET/CT imaging 60 (+/- 10) minutes post radiotracer administration.
62242425|NCT04570111|ACTIVE_COMPARATOR|Standard Care Diet|After the controlled feeding study, participants in this group will follow the standard care diet for the remainder of pregnancy with the assistance of a study dietitian. The standard care study diet will provide the standard 40% Carb/20% Pro/40% Fat as energy, distributed consistently across 3 meals and 2 snacks.
62242426|NCT04570111|EXPERIMENTAL|Macro-Optimized Diet (MOD)|After the controlled feeding study, participants in this group will follow the MOD diet for the remainder of pregnancy with the assistance of a study dietitian. The MOD diet will differ from control by macronutrient distribution at breakfast specifically, but also at each eating occasion, although the daily macronutrient distribution is equal to the control diet. At breakfast, the MOD diet will provide 10% Carb/30% Pro/60% Fat.
62242427|NCT06735105|NO_INTERVENTION|SS-EPI-DWI T-stage of gastric cancer|
62242428|NCT06735105|OTHER|TSE-DWI T-stage of gastric cancer|
62242429|NCT06735105|OTHER|ZOOM-DWI T-stage of gastric cancer|
62242430|NCT01704963|EXPERIMENTAL|PCI-32765|Patients will receive oral doses of PCI-32765 in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be given before administration of daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
62242431|NCT06115408|EXPERIMENTAL|Drug;Dienogest|2mg pills oral daily
62242432|NCT06115408|EXPERIMENTAL|Drug;N-Acetylcysteine|600 mg/day oral daily
62242433|NCT01473316|EXPERIMENTAL|A|
62242434|NCT01132066|EXPERIMENTAL|tDCS|tDCS will provide an increase in cortical excitability. Patients will be randomized to receive tDCS or sham stimulation.
62242435|NCT01132066|PLACEBO_COMPARATOR|sham|Sham stimulation will provide identical subjective sensation as anodal tDCS.
62242436|NCT06712550||Women with Preeclampsia|This group will comprise pregnant women having preeclampsia who are scheduled to undergo either vaginal or cesarean delivery. Their blood and their newborn blood will be collected and tested for a panel of inflammatory markers. This research aims to explore the potential association between maternal and neonatal inflammatory profiles and the development of preeclampsia, as well as its impact on pregnancy outcomes. By examining these markers, we hope to gain a better understanding of the underlying inflammatory mechanisms involved in preeclampsia.
62242437|NCT06712550||Normotensive pregnant women|This group will consist of normotensive pregnant women during delivery who are scheduled to have their blood and their newborn blood tested for a panel of inflammatory markers and responses to inflammatory markers. One of the aims of this research is to investigate the potential association between maternal and neonatal inflammatory profiles in normotensive pregnancy in comparison to women with preeclampsia and their newborn By examining these markers
62242438|NCT01301820|OTHER|ARM A|maintenance study treatment: azacitidine sc 75 mg/m²/d (d1- d7) in first cycle: months 1,3,5,7,9 ,11 then lenalidomide 10mg/d (d1- d21) months 2,4,6,8,10,12
62242439|NCT01301820|OTHER|ARM B|maintenance study treatment: lenalidomide 10mg/d (d1- d21)in first cycle and months 1,3,5,7,9 ,11 then azacitidine sc 75 mg/m²/d (d1- d7) months 2,4,6,8,10,12
62242440|NCT01651013||metastatic colorectal cancer|
62242441|NCT04828083|ACTIVE_COMPARATOR|Ultrasound-guided adductor canal block with local anesthetic|Single shot Ultrasound-guided adductor canal block with 0.5% ropivacaine 30 ml
62242442|NCT04828083|SHAM_COMPARATOR|Ultrasound-guided adductor canal block with saline|Single shot Ultrasound-guided adductor canal block with 30 mL of normal saline (Sodium chloride)
62242443|NCT02209155|ACTIVE_COMPARATOR|R-verapamil 75 mg tablet|375 mg/day; one in the morning, two in the afternoon and two at bedtime daily
62242444|NCT02209155|PLACEBO_COMPARATOR|Placebo|one in the morning, two in the afternoon and two at bedtime daily
62242445|NCT06736418|EXPERIMENTAL|Phase 1a Dose Escalation Group|225Ac-ABD147 administered in escalating dose cohorts
62242446|NCT06736418|EXPERIMENTAL|Phase 1b Dose Expansion Group|Expansion Dose Level selected from Phase 1a Dose Escalation
62242447|NCT00935545|EXPERIMENTAL|Open Label|
62242448|NCT06725719||Single Group Assignment|Each subject receive a single intravenous injection of 18F-DPA714/FDPA, and undergo PET/CT or MRI imaging within the specificed time.
62242449|NCT02223403|EXPERIMENTAL|submaximal steady state exercise|90 minutes after respective beetroot juice ingestion, subjects walked on treadmill at a pre-determined steady state workload for a total of 15 minutes with oxygen consumption recorded for the last 10 minutes
62242450|NCT02223403|EXPERIMENTAL|six minute walk test|subjects performed six-minute walk at self-determined pace 30 minutes after treadmill exercise was performed
62242451|NCT01383161|ACTIVE_COMPARATOR|Curcumin|Theracurmin (180mg/day)
62242452|NCT01383161|PLACEBO_COMPARATOR|Placebo|Sugar Pill
62432765|NCT05350683|NO_INTERVENTION|Control group|EVAR patients no ischemic preconditioning
62432766|NCT05350683|ACTIVE_COMPARATOR|Preconditioning Group|EVAR patients with remote ischemic preconditioning
62432767|NCT05695235||Traditional call|In the traditional overnight on-call system, each resident is on call for 4-6 nights per month (7 am - 5 pm, followed by overnight call until 8 am the next morning)
62432768|NCT05695235||Float call|In the night float system, residents work from 8 pm to 8 am for 5 - 7 consecutive nights once every month
62432769|NCT05105087|EXPERIMENTAL|Diagnostic (perflubutane microbubble, ultrasound)|Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.
62599642|NCT01424046|ACTIVE_COMPARATOR|standard therapy|Participants will continue current mixed insulin management and education
62599643|NCT01881997|PLACEBO_COMPARATOR|Normal Saline|IM normal saline
62242453|NCT04582981|EXPERIMENTAL|Arm A|Combination treatment of Fruquintinib and Raltitrexed
62242454|NCT04582981|EXPERIMENTAL|Arm B|Monotherapy of Fruquintinib
62242455|NCT05798078|EXPERIMENTAL|Cognitive Bias Modification for Interpretation (CBM-I)|Participants in this arm complete an initial introductory session of Cognitive Bias Modification for Interpretation (CBM-I) in the lab followed by 6 sessions scheduled to be completed over the subsequent week (1 per day). CBM-I will be administered via an online platform using an individual login account.
62242456|NCT05798078|SHAM_COMPARATOR|Sham Training Control Condition|Participants in this arm complete an initial introductory session of the sham training control condition in the lab followed by 6 sessions scheduled to be completed over the subsequent week (1 per day). CBM-I will be administered via an online platform using an individual login account.
62242457|NCT04662151|EXPERIMENTAL|Phase 1b open-label AT-100|Once daily AT-100 via intratracheal administration for up to 2 doses (initial Phase 1b dose-escalation portion) or 7 doses (latter Phase 1b highest tolerated \& safety dose level tested portion).
62242458|NCT04662151|SHAM_COMPARATOR|Phase 1b open-label air-sham|Once daily air-sham via intratracheal administration for up to 2 doses (initial Phase 1b dose-escalation portion) or 7 doses (latter Phase 1b highest tolerated \& safety dose level tested portion).
62242459|NCT01186939|EXPERIMENTAL|Azacitidine|Azacitidine (study drug) plus best supportive care.
62242460|NCT00564785|PLACEBO_COMPARATOR|Placebo|
62242461|NCT00564785|EXPERIMENTAL|Synera(TM)|
62242462|NCT04423913|EXPERIMENTAL|Patients undergoing transarterial embolization of the prostate|Three patients will undergo transarterial embolization of the prostate using unloaded beads.
62242463|NCT04423913|EXPERIMENTAL|Transarterial prostatic chemoembolization, 2.5 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 2.5 mg of doxorubicin.
62432770|NCT01504867|EXPERIMENTAL|Aspirin|This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.
62432771|NCT01504867|PLACEBO_COMPARATOR|Placebo|This group received matching lactose powder filled capsules on days 1-7.
62432772|NCT03016663||Breast Lipofilling Technique|Preliminary MRI breast were performed for volumetric measurement. Fat harvesting performed by same surgeon using water-assisted liposuction (WAL) and subsequent washing with buffered lactate in a standardized technique. Fat transfer performed using Berlin autologous lipotransplantation technique according to the BEAULI protocol .Patient were followed up monthly and MRI breast were repeated at 1st and 6th months after lipofilling. Clinical assessment and MRI Volumetric measurement performed using OsiriX (v7.0.3, 64 bit, Pixmeo c) software by same radiologist based on predefined operational procedure
62599644|NCT01881997|EXPERIMENTAL|Fentanyl|IM Fentanyl
62599645|NCT06618378|NO_INTERVENTION|Control Group|
62599646|NCT06618378|ACTIVE_COMPARATOR|Urotherapy educational group|
62599647|NCT06618378|EXPERIMENTAL|Biofeedback exercise group combined with breathing exercise|
62599648|NCT06395298|EXPERIMENTAL|Experimental Group PIOMI|"Participants will receive:~1. The traditional intervention Newborn Individualized Development Care and Assessment Program (NIDCAP) model of the Neonatal Intensive Care Unit (NICU) .The nurse providing direct care to the patient and family, will carry out the relevant care of the patient.~2. The Premature Oral Motor Intervention (PIOMI) .The family will apply the PIOMI , 7 activities are intraoral stimulation for 10 consecutive days, twice a day, 5 minutes.~3. Gustatory stimulation technique:the application of oropharyngeal colostrum, a 0.5 milliliter twice a day~4. Olfactory stimulation Technique:A swab is moistened in breast milk and placed near the nose for one minute, twice a day."
62242464|NCT04423913|EXPERIMENTAL|Transarterial prostatic chemoembolization, 5.0 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 5.0 mg of doxorubicin.
62818748|NCT05167851|EXPERIMENTAL|Lazertinib, a combination group of SBRT|"* Lazertinib 240mg once a day(QD) oral(PO)~  -If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year.~* Stereotactic Body Radiation Therapy (SBRT) to oligometastatic sites SBRT(Stereotactic Body Radiation Therapy) will be delivered to the primary tumour and to all metastatic sites. SBRT(Stereotactic Body Radiation Therapy) will be delivered using risk-adapted SBRT with a maximum of 5 SBRT(Stereotactic Body Radiation Therapy) fractions."
62818749|NCT05167851|ACTIVE_COMPARATOR|Lazertinib single administration group|"\* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year."
62039346|NCT06495853|EXPERIMENTAL|Group B|"Patients who did not receive neoadjuvant chemoradiotherapy and underwent rectal anterior resection with anastomotic reinforcement were included in Cohort B. The rectal cancer radical resection was performed in strict accordance with the principles of no-tumor technique and total mesorectal excision (TME) by experienced deputy chief physicians or higher from our research center. The procedure followed standard rectal cancer radical resection protocols. After rectal division using a linear stapler, an end-to-end anastomosis was performed using a circular stapler. For patients in the treatment group, anastomotic reinforcement was performed using absorbable Johnson \& Johnson EB403 barbed sutures laparoscopically.~Since neoadjuvant chemoradiotherapy is a high-risk factor for postoperative anastomotic leakage, ileostomy was routinely performed in this group of patients to prevent severe intra-abdominal infections caused by anastomotic leakage."
62039347|NCT04808401|EXPERIMENTAL|Normoxaemia First + Hyperoxia Procedure|Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second. After the image acquisition patients receive hyperoxic concentrations.
62039348|NCT04808401|EXPERIMENTAL|Normoxaemia First + Normoxia Procedure|Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second. After the image acquisition patients receive normoxic concentrations.
62039349|NCT04808401|EXPERIMENTAL|Hyperoxia First + Hyperoxia Procedure|Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second. After the image acquisition patients receive hyperoxic concentrations.
62242465|NCT04423913|EXPERIMENTAL|Transarterial prostatic chemoembolization, 10.0 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 10.0 mg of doxorubicin.
62432773|NCT04304235|ACTIVE_COMPARATOR|Control|Hospital nurses will triage participants using the Emergency Triage and Treatment (ETAT) guidelines, the triage policy that is currently in place at the study hospital sites.
62432774|NCT04304235|EXPERIMENTAL|Intervention|Hospital nurses will triage participants using the digital triage tool (mhealth intervention).
62432775|NCT03439293|EXPERIMENTAL|Ixazomib 4 mg + Daratumumab 16 mg/kg + Dexamethasone 20 mg|Ixazomib, 4 mg, capsules, orally, on Days 1, 8 and 15 of each 28-day cycle along with daratumumab, 16 mg/kg, intravenously (IV), on Days 1, 8, 15 and 22 of Cycles 1 and 2, on Days 1 and 15 (every 2 weeks) for Cycles 3 to 6 and on Day 1 (every 4 weeks) for Cycle 7 and beyond along with dexamethasone, 20 mg, tablets, orally on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle until progressive disease (PD), unacceptable toxicity, or withdrawal of consent, or up to 5 years.
62432776|NCT06466044|EXPERIMENTAL|Treatment group|Auricular point containing Vaccaria seed was attached to the auricular concha area rich in vagus nerve. According to the degree of pressure, the patient's gaseous state (acid, numbness, heaviness, swelling, etc.) shall prevail. ). Frequency: Press the auricular points three times a day within half an hour after meals for about 1-2 minutes, and press the auricular points for about 30 times. Press the auricular concha alternately. The treatment lasted for 2 weeks. Go to the hospital once a week to change the ear patch.
62432777|NCT06466044|SHAM_COMPARATOR|Control group|Auricular point with Vaccaria seed was attached to the earlobe, which is the place with the least vagal innervation. Ear pressure therapy depends on the patient's gas state (acid, numbness, heaviness, bloating, etc.). ). Frequency: Press the auricular points three times a day within half an hour after meals for about 1-2 minutes, and press the auricular points for about 30 times. Press the bilateral earlobes alternately. The treatment lasted for 2 weeks. Go to the hospital to change the ear patch once a week.
62432778|NCT01039285|EXPERIMENTAL|Surfactant instillation|2.5 ml/kg of Surfactant will be instilled in the trachea
62432779|NCT01039285|PLACEBO_COMPARATOR|Placebo instillation|2.5 ml/kg of Air will be instilled in the trachea
62432780|NCT00543582|EXPERIMENTAL|1|
62432781|NCT02605083|EXPERIMENTAL|eFT508|Escalation cohort
62432782|NCT00271999|ACTIVE_COMPARATOR|1|Three times a week conventional at home hemodialysis
62432783|NCT00271999|EXPERIMENTAL|2|Six times a week nocturnal home hemodialysis
62818750|NCT01814111|EXPERIMENTAL|renal sympathetic denervation|Perform renal angiogram immediately prior to renal sympathetic denervation procedure to confirm anatomic eligibility，The treatment catheter was introduced into each renal artery using a guiding catheter. Up to six ablations at 10 W for 1 min each were performed in both renal arteries. Treatments were delivered from the first distal main renal artery bifurcation to the ostium proximally and were spaced longitudinally and rotationally under fluoroscopic guidance. Catheter tip impedance and temperature were constantly monitored, and radio frequency energy delivery was regulated according to a predetermined algorithm. Visceral pain at the time of energy delivery was managed with intravenous analgetics and sedatives.
62039350|NCT04808401|EXPERIMENTAL|Hyperoxia First + Normoxaemia Procedure|Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second. After the image acquisition patients receive normoxic concentrations.
62818751|NCT01814111|NO_INTERVENTION|Drug Treatment Group|All the patients in this group will take their baseline antihypertensive medication at the original doses, without any changes except when medically required. AAD treatment is consistent in both arms.
62818752|NCT06154291|EXPERIMENTAL|Dose Escalation part then Expansion part|"Dose Escalation part: Six dose levels are planned: 1.5; 3; 6; 12; 16 and 20mg/kg~Expansion part: Up to 7 cohorts (1 cohort for one selected solid tumor type) could be investigated:~Cohort E1: Non-small cell lung cancer (NSCLC) Cohort E2: Gastro-esophageal adenocarcinoma Cohort E3: Colorectal cancer (CRC) Cohort E4: Pancreatic cancer Cohort E5: Sarcoma Cohort E6: Triple-negative breast cancer (TNBC) Cohort E7: Ovarian cancer"
62818753|NCT06587009|EXPERIMENTAL|ESWT group|Patients who receive shock wave technique
62818754|NCT06587009|EXPERIMENTAL|Control group|Patients who receive conventional conservative treatment
62818755|NCT04776395|EXPERIMENTAL|Arm A (iberdomide hydrochloride, dexamethasone)|Patients receive iberdomide hydrochloride PO QD on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive iberdomide hydrochloride PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62818756|NCT04776395|ACTIVE_COMPARATOR|Arm B (iberdomide hydrochloride)|Patients receive iberdomide hydrochloride PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62818757|NCT04696120|EXPERIMENTAL|Study group: apixaban|apixaban 2.5mg or 5mg bid
62818758|NCT04696120|PLACEBO_COMPARATOR|Control group: placebo|placebo bid
62818759|NCT04309734|EXPERIMENTAL|Part A - 60 mg AT-777 single dose|
62818760|NCT04309734|EXPERIMENTAL|Part A - 120 mg AT-777 single dose|
62818761|NCT04309734|PLACEBO_COMPARATOR|Part A - Placebo single dose|
62818762|NCT04309734|EXPERIMENTAL|Part B - 60 mg AT-777 + 550 mg AT-527 once daily for 8 weeks|
62818763|NCT05130788|EXPERIMENTAL|Intervention Group A|Participants will be assigned to a 6-week intervention period.
62039351|NCT04769037|ACTIVE_COMPARATOR|B. infantis|Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day
62039352|NCT04769037|PLACEBO_COMPARATOR|Placebo|Lactose identical in appearance and taste to the active supplement
62432784|NCT01001663|EXPERIMENTAL|FemoSeal®|Closure device for femoral artery access closure
62818764|NCT05130788|EXPERIMENTAL|Intervention Group B|Participants will be assigned to a 12-week intervention period.
62039353|NCT04392765|OTHER|Therapy arm|Six week use of eXciteOSA device. Once daily for 20 minutes.
62039354|NCT05090579|ACTIVE_COMPARATOR|Group I (BN10)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine , 1 mL of 10 mg of nulbuphine plus 4 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall.
62039355|NCT05090579|ACTIVE_COMPARATOR|Group II (BN20)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine ,2 mL of 20 mg of nulbuphine plus 3 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall.
62039356|NCT05090579|ACTIVE_COMPARATOR|Group lll(B)|patients will receive 20 mL of 0.25%bupivacaine plus 5 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall.
62039357|NCT05886270|EXPERIMENTAL|Participants|This arm consists of 300 homes of low-income families with children \< 7 years of age who are referred from two of GHHI's currently active programs, DSS Foster Care Homes Program, and Amerigroup Maryland Asthma Program.
62039358|NCT04326543||ADHD and typically developing controls|120 subject: 53 with an ADHD clinical diagnosis and 57 typically developing controls aged between 3 and 16 years old.
62432785|NCT01001663|ACTIVE_COMPARATOR|Manual compression|Conventional manual compression
62432786|NCT06529523|EXPERIMENTAL|Cohort 1: Stage 4 Colorectal cancer|All patients in the trial will be given Tislelizumab at a dose of 200mg IV over 30 minutes (60 minutes at the initial infusion), every 3 weeks.
62818765|NCT05130788|ACTIVE_COMPARATOR|Control Group|
62818766|NCT02086175|EXPERIMENTAL|Imprime PGG and Rituximab|The study drug, Imprime PGG, will be administered intravenously at a dose of 4mg/kg weekly for 4 weeks. Rituximab will be administered intravenously by institutional standards concurrently at a dose of 375mg/m2 weekly for 4 weeks. Response will be assessed with CT scans 10 weeks +/- 3 days following the completion of treatment
62818767|NCT06222866||Patients after cardiovascular surgery who received anticoagulation|The investigated population comprises all patients after cardiovascular surgery who received anticoagulation. Subgroup analyses based on the level of inflammation, delirium, anticoagulation, and others will be conducted.
62818768|NCT05404139|OTHER|Arm 1 - Standard of Care|Participants in this group will receive standard of care radiation treatment and ADT. Participants will start ADT first. Androgen deprivation therapy will be delivered via injection every 4 months as per standard of care (for 8 months total). At the same time, or within 3 months of starting ADT, participants will begin radiation treatment. The radiation treatment course will consist of 2-5 sessions of radiation daily or every other day (the number of sessions will be determined by the physician depending on the location of cancer, number of cancer spots, etc.).
62039359|NCT01527734|PLACEBO_COMPARATOR|Placebo|
62039360|NCT01527734|EXPERIMENTAL|Tetrodotoxin, TTX|
62242466|NCT05803616||ILD group|All patients newly diagnosed or relapsing from an ILD could be enrolled in this observational study
62818769|NCT05404139|EXPERIMENTAL|Arm 3 - Study Treatment|Participants in this group will receive standard of care radiation treatment and ADT, plus abiraterone. Participants will start ADT first. Androgen deprivation therapy will be delivered via injection every 4 months as per standard of care (for 8 months total). At the same time, or within 3 months of starting ADT, participants will begin radiation treatment. The radiation treatment course will consist of 2-5 sessions of radiation daily or every other day (the number of sessions will be determined by the physician depending on the location of cancer, number of cancer spots, etc.). In addition, participants will take abiraterone orally (by mouth) daily for 8-9 months. Participants will start the first pill within a month of enrollment. This pill can be taken around the same time of day with or without food.
62818770|NCT05516992|EXPERIMENTAL|SB-01 For Injection|Subjects receive a SB-01 For Injection intradiscal injection per treated disc.
62818771|NCT05516992|PLACEBO_COMPARATOR|Sham Needle|Subjects receive a sham needle placement for each treated disc.
62818772|NCT06704204||people with HIV (PWH) who are experiencing community re-entry|ART is highly effective in controlling HIV and can significantly reduce HIV transmission when viral suppression is achieved. ART is usually administered as a combination of antiretroviral medications taken orally daily. Despite the convenience of single pill fixed-dose ART regimens, many persons, including justice involved substance users, struggle with daily ART adherence and consequently experience disease progression, emergence of HIV resistance, and contribute to HIV transmission. Long-acting injectable (LAI) ART is a new alternative to help overcome the challenges of adhering to daily pills. LAI ART is administered by intramuscular injection every four weeks and the first LAI regimen, cabotegravir (CAB) combined with rilpivirine (RPV), was FDA-approved in January 2021 for treatment of HIV infection. While rollout of LAI ART has recently begun, using LAI ART among PWH during the challenging community re-entry period has the substantial potential to improve HIV treatment outcomes.
62818773|NCT02649166|EXPERIMENTAL|Deep brain stimulation|All participants will undergo unilateral deep brain stimulation (DBS) implantation for essential tremor. Medtronic Summit RC+S devices will be used because these are capable of recording brain signals, as well as delivering DBS. Participants will receive continuous (open-loop) and closed-loop deep brain stimulation interventions, which will be compared for efficacy.
62818774|NCT04640025|EXPERIMENTAL|itacitinib|Participants will receive treatment with itacitinib as per the treatment dose and schedule they received in the study in which they were originally enrolled. Participants who are receiving ruxolitinib under parent protocol INCB39110-209 may continue to receive it as described in that protocol.
62818775|NCT05361941|EXPERIMENTAL|Treatment Arm|The device will be placed in voids at Stage 1. This will be followed by IV therapy for about six weeks, followed by assessment of infection, with a stage 2 surgery to follow. During the stage 2 surgery, the surgeon completes the procedure with affixing the revision implants.
62818776|NCT05361941|ACTIVE_COMPARATOR|Control Arm|In the standard of care arm, voids are left empty and a bone cement spacer placed during stage 1 surgery. This is followed by IV therapy for a minimum of six weeks, followed by a pathology assessment of infection by needle aspiration, after week 8, with a stage 2 surgery scheduled after week 9. During the stage 2 surgery, the spacer is removed and procedure completed by affixing the revision implants.
62432787|NCT06529523|EXPERIMENTAL|Cohort 2: Stage 2/3 Rectal cancer|All patients in the trial will be given Tislelizumab at a dose of 200mg IV over 30 minutes (60 minutes at the initial infusion), every 3 weeks.
62818777|NCT03542812|EXPERIMENTAL|Single-dose|"Participants will be enrolled into the two groups, Group 1 (which will consist of 10 participants) and Group 2 (which will consist of 8 participants) in an alternating basis. Both Group 1 and Group 2 participants will receive a single, 150 mg/kg dose of oral L-citrulline. Population PKs will be done for both groups, at up to 3 time points.~Multiple interim time points and following completion of enrollment into Groups 1 and 2, data analysis will be done and results reviewed by the data safety monitoring board (DSMB). After the DSMB review is complete, enrollment into Group 3 will begin."
62818778|NCT03542812|EXPERIMENTAL|Steady-state|To evaluate the tolerability and ability to achieve target trough L-citrulline levels of 100-150 µM, an additional group of 18 infants (group 3) will be given oral L-citrulline doses at intervals over a total of 72 hours. If the participant is not nipple feeding, the dose will be delivered via the participant's indwelling gavage feeding tube. The dose and interval of L-citrulline will be based on results from the studies that assess pharmacokinetic parameters using a maximum daily dose of 3 g/kg/d. Blood draws for PKs will be done at baseline and prior to last dose of L-citrulline. Urine will be collected to measure nitric oxide metabolites.
62818779|NCT05141019|EXPERIMENTAL|Immediate panel-based pharmacogenetic genotyping|Subjects assigned to the immediate pharmacogenetic genotyping group will be tested and have their results both entered into their electronic health record as well as provided to them within 2-4 weeks from enrollment.
62818780|NCT05141019|OTHER|Delayed panel-based pharmacogenetic genotyping|Subjects assigned to delayed panel-based pharmacogenetic genotyping will be tested, but their results will not be released until after their participation in the study has ended (12 months after enrollment).
62818781|NCT05027230|EXPERIMENTAL|Consecutive doses of low-dose of STSP-0601|
62818782|NCT05027230|EXPERIMENTAL|Consecutive doses of high-dose of STSP-0601|
62818783|NCT06706583|EXPERIMENTAL|Enhanced education arm|Telematic educational interviews are added to standard PIRASOA training
62432788|NCT01480271|EXPERIMENTAL|Part 1 Cohort 1 GSK2445053|2ng GSK2245053
62432789|NCT01480271|PLACEBO_COMPARATOR|Part 1 Cohort 1 Placebo|Placebo
62818784|NCT06706583|ACTIVE_COMPARATOR|Standard education arm|Only standard PIRASOA training is provided
62818785|NCT06513858|EXPERIMENTAL|Drum Circle- Cohort 1|"Cohort 1 will listen together to recordings of drumming and be allowed to drum along while listening.~The facilitator will lead participants in procedures such as checking in (e.g. How are you doing today? before and after the circle) and breathing exercise."
62432790|NCT01480271|EXPERIMENTAL|Part 1 Cohort 2 GSK2445053|20ng GSK2445053
62432791|NCT01480271|PLACEBO_COMPARATOR|Part 1 Cohort 2 Placebo|Placebo
62432792|NCT01480271|EXPERIMENTAL|Part 1 Cohort 3 GSK2245053|100ng GSK2445053
62432793|NCT01480271|PLACEBO_COMPARATOR|Part 1 Cohort 3 Placebo|Placebo
62599649|NCT06395298|SHAM_COMPARATOR|Control Group NIDCAP|"Participants will receive :~1.The traditional intervention Newborn Individualized Development Care and Assessment Program (NIDCAP) model of the Neonatal Intensive Care Unit (NICU).The nurse providing direct care to the patient and family, will carry out the relevant care of the patient.~3.Gustatory stimulation technique:the application of oropharyngeal colostrum, a 0.5 milliliter twice a day~4.Olfactory stimulation Technique:A swab is moistened in breast milk and placed near the nose for one minute, twice a day."
62599650|NCT00611182||1|Patients with Pulmonary Fibrosis
62599651|NCT01553240|EXPERIMENTAL|TMS and fMRI|"* functional MRI~* single and paired pulse TMS (to identify the difference of motor excitability between patients and healthy controls)"
62599652|NCT04399408|EXPERIMENTAL|Study group|Device users
62599653|NCT06648304|EXPERIMENTAL|TTYP01 tablets|2 tablets (60 mg) of TTYP01, twice daily, administered 30\~60 minutes before breakfast and dinner
62599654|NCT06648304|PLACEBO_COMPARATOR|Placebo (Simulant TTYP01 Tablets)|2 tablets (0 mg) of placebo, twice daily, administered 30\~60 minutes before breakfast and dinner
62599655|NCT05000203|EXPERIMENTAL|Specific intervention for fear of childbirth|"Online education intervention Participants randomly assigned to the experimental group will be informed by telephone call of their inclusion in the first phase of the trial.~Participants in the intervention group will be encouraged to attend routine consultations with their midwife and obstetrician, as well as to take advantage of the group maternal education that participants usually develop in their health center.~Specific intranatal support~An experimental group will be carried out with a specific support intervention in the obstetric-gynecological emergency area that will supplement the one usually provided to all pregnant women.~At the end of the participant's stay within the emergency area due to hospital discharge, admission to the ward, or the end of the pregnancy, the collaborating midwife will fill out an online form designed to monitor the care offered. Said form will also be completed at the end of the work shift if the participant's care continues."
62599656|NCT05000203|ACTIVE_COMPARATOR|Routine intervention for fear of childbirth|"Usual care~Participants randomly assigned to the control group will be informed by telephone call of their inclusion in the first phase of the trial. The process under study will be explained in detail, resolving any doubts at that time.~Regular intranatal support~The participants in the control group will not be identified as pregnant women with fear of childbirth, and will receive the usual care in the obstetric-gynecological emergency area."
62599657|NCT03588078|EXPERIMENTAL|combination of APR246 and azacitidine|Following completion of the Dose Finding Phase, we will conduct a dose expansion, whereby patients will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing as in Phase 1b
62039361|NCT03074630|EXPERIMENTAL|Dapagliflozin 10mg and Rosuvastatin 10mg|Rosuvastatin 10mg once daily for 9 weeks, with 5 weeks of once daily Dapagliflozin 10mg added
62039362|NCT05958121|EXPERIMENTAL|Dose escalation/de-escalation (Phase Ia)|Dose-Finding of IMA402 (Phase Ia)
62432794|NCT01480271|EXPERIMENTAL|Part 1 Cohort 4 GSK2445053|200ng GSK2445053
62432795|NCT01480271|PLACEBO_COMPARATOR|Part 1 Cohort 4 Placebo|Placebo
62432796|NCT01480271|EXPERIMENTAL|Part 1 Cohort 5 GSK245053|400ng GSK2445053
62432797|NCT01480271|PLACEBO_COMPARATOR|Part 1 Cohort 5 Placebo|Placebo
62432798|NCT01480271|EXPERIMENTAL|Part 1 Cohort 6 GSK2445053|1000ng GSK2245053
62432799|NCT01480271|PLACEBO_COMPARATOR|Part 1 Cohort 6 Placebo|Placebo
62432800|NCT01480271|EXPERIMENTAL|Part 1 Cohort 7 GSK2445053|2000ng GSK2445053
62432801|NCT01480271|PLACEBO_COMPARATOR|Part 1 Cohort 7 Placebo|Placebo
62432802|NCT01480271|EXPERIMENTAL|Part 1 Cohort 8 GSK2445053|4000ng GSK2445053
62432803|NCT01480271|PLACEBO_COMPARATOR|Part 1 Cohort 8 Placebo|Placebo
62432804|NCT00340535||Individuals|Individuals recruited at U of Pittsburgh
62432805|NCT02306603||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Duodenal and Ampullary Lesions will be included in this cohort.
62432806|NCT03541213|OTHER|Control group|"Patients with no iron deficiency prior to inclusion and who did not receive intravenous iron prior to inclusion.~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
62432807|NCT03541213|OTHER|Iron deficiency group|"Patients with iron deficiency who did not receive intravenous iron prior to inclusion.~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
62039363|NCT05958121|EXPERIMENTAL|Dose extension (Phase Ib)|IMA402 monotherapy extension cohorts based on maximum tolerated dose (MTD) and/or recommended doses for extensions (RDEs) (Phase Ib)
62242467|NCT01330914||Gastric Bypass Surgery Patients|Obese men and women undergoing gastric bypass surgery
62432808|NCT03541213|OTHER|Iron treated group|"Patients with iron deficiency who received intravenous iron prior to inclusion (greater than or equal to 1 g ferric carboxymaltose).~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
62432809|NCT03899974|EXPERIMENTAL|70% amylose bread|Mixed meal with 80g of available carbohydrates coming mainly from high-amylose bread (made with 70% high-amylose flour)
62432810|NCT03899974|EXPERIMENTAL|85% amylose bread|Mixed meal with 80g of available carbohydrates coming mainly from high-amylose bread (made with 85% high-amylose flour)
62432811|NCT03899974|ACTIVE_COMPARATOR|Control bread|Mixed meal with 80g of available carbohydrates coming mainly from conventional bread
62432812|NCT03545737||Measurement|The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT.
62432813|NCT03545737||Formula|"The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube.~The depth of intubation = 0.1977\* height-4.2423"
62242468|NCT03218462|EXPERIMENTAL|Group 1|Sensory adapted dental environment (SADE) at first exam (visit 1)
62242469|NCT03218462|EXPERIMENTAL|Group 2|Sensory adapted dental environment (SADE) at recall exam (visit 2)
62242470|NCT02876835|EXPERIMENTAL|Daprodustat|Participants will receive oral daprodustat once daily.
62432814|NCT02450409|ACTIVE_COMPARATOR|gap technique (GT)|"The patients receive a total knee arthroplasty using the established gap technique (gold standard serving as control). The intervention is the implantation of a total knee arthroplasty with this specific technique.~Implantation of TKA using the gap technique is the intervention. Intervention is not a drug but a specific operative technique."
62242471|NCT02876835|ACTIVE_COMPARATOR|Darbepoetin alfa|Participants will be administered darbepoetin alfa subcutaneously (SC).
62432815|NCT02450409|EXPERIMENTAL|anatomical alignment (AA)|"The patients receive a total knee arthroplasty using the new anatomical alignment technique (experimental). The intervention is the implantation of a total knee arthroplasty with this specific technique.~Implantation of TKA using anatomical alignment Intervention is not a drug but a specific operative technique."
62432816|NCT04364542|EXPERIMENTAL|Suprascapular nerve block (SSNB)|Single shot using the blind block technique with 10 ml 0.75% ropivacaine and arthroscopic portals infiltration with 5 ml 0.75% diluted in 15 ml of distilled water.
62432817|NCT04364542|ACTIVE_COMPARATOR|Interscalene Nerve Block (ISB)|Single shot using US-guided interscalene brachial plexus block with 15 ml 0.5% ropivacaine and arthroscopic portals infiltration with 5 ml 0.75% diluted in 15 ml of distilled water.
62432818|NCT01477671||Study Group|Participants aged between 5 and 10 year-old on day of inclusion.
62432819|NCT01047904|EXPERIMENTAL|Iontophoresis-treated|Healthy volunteers will evaluate reliability and performance of Iontophoresis System in delivery of local anesthesia to the TM.
62432820|NCT02028702|ACTIVE_COMPARATOR|Red Clover extract|150 ml/d Red Clover extract
62432821|NCT02028702|PLACEBO_COMPARATOR|Placebo|150 ml/d sweetened and coloured water
62039364|NCT05958121|EXPERIMENTAL|Dose extension (Phase II)|Selected ISEC investigated on MTD/RDEs based on a manageable/favorable safety profile and initial signs of anti-tumor activity (Phase II)
62242472|NCT06211673||Patients and legal representatives|Minors and adults, without age limit, presenting with FOXP1 syndrome due to a genetic anomaly affecting the FOXP1 gene that has been identified, who have sought consultation at Necker-Enfants Malades Hospital, with at least one of the legal guardians or the legal representative being francophone.
62242473|NCT01127945|EXPERIMENTAL|atorvastatin 80mg|
62242474|NCT01127945|ACTIVE_COMPARATOR|conventional therapy (for heart failure)|
62242475|NCT02511678|EXPERIMENTAL|Cryoablation|All participants will have one cryoablation procedure on one painful metastatic lesion involving bone using a Galil Medical cryoablation system and needles within 14 days of screening. In the case of participants with multiple metastatic lesions involving bone, the most painful lesion is to be selected for cryoablation. If treatment could not be completed within 14 days of screening, the participant will be re-screened using the inclusion and exclusion criteria. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators.
62432822|NCT03386149|EXPERIMENTAL|Experimental Group|In the experimental group, 2.5g of Bosinji granule (Tsmura Co., Tokyo, Japan) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.
62432823|NCT03386149|ACTIVE_COMPARATOR|Control Group|In the control group, Loxonine tab. (loxoprofen 60mg, Dong Wha Pharm Co., Ltd, Seoul, Korea) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.
62242476|NCT01310803|EXPERIMENTAL|Maintenance therapy|Chemotherapeutic: EN3329-301 (VALSTAR)
62242477|NCT01310803|OTHER|No Maintenance (Standard of care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
62432824|NCT03256383||Adult|Patients aged 18+ years
62599658|NCT02998385|ACTIVE_COMPARATOR|Radiotherapy|"Arm A~Radiation therapy: 66 to 70 Gy in fractions of 2 Gy, 1 fraction/day, 5 fractions per week.~Radiation therapy will be conducted by conformational intensity modulation radiotherapy (IMRT) or protontherapy. Irradiation by 3D conformational radiotherapy can be discussed on a case by case with the Intergroup Coordinator GORTEC."
62599659|NCT02998385|EXPERIMENTAL|Radiotherapy + concomitant cisplatin|"Arm B Concomitant systemic treatment with cisplatin + radiotherapy~According to standard protocol of concomitant cisplatin 100 mg/m2 IV on day 1 - J22 - 43 (3 maximum cycles).~Radiation therapy: 66 to 70 Gy in fractions of 2 Gy, 1 fraction/day, 5 fractions per week.~Radiation therapy will be conducted by conformational intensity modulation radiotherapy (IMRT) or protontherapy. Irradiation by 3D conformational radiotherapy can be discussed on a case by case with the Intergroup Coordinator GORTEC"
62599660|NCT04451616||Group A - study group - patients with metabolic syndrome|"Patients with metabolic syndrome will be included.~Procedures:~1. blood sample collection~2. hair sample collection~3. urine sample collection~4. body composition analysis~5. questionnaires~6. blood pressure, pulse and blood oxygen saturation measurement"
62599661|NCT04451616||Group B - control group - patients without metabolic syndrome|"Patients without metabolic syndrome will be included.~1. blood sample collection~2. hair sample collection~3. urine sample collection~4. body composition analysis~5. questionnaires~6. blood pressure, pulse and blood oxygen saturation measurement"
62599662|NCT04898543|EXPERIMENTAL|Cohort 1: Subjects newly diagnosed no prior therapy or prior first line treatment|Cohort 1: Subjects with either newly diagnosed solid tumors who have not received prior therapy or subjects who have received prior first line treatment. Cohort 1 may subsequently enroll in cohort 2 part B if they have progressive disease after ≥ 2 prior therapies or if they have progressive disease within 12 months of receiving neoadjuvant or adjuvant chemotherapy and meet the inclusion criteria for cohort 2 part B.
62599663|NCT04898543|EXPERIMENTAL|Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors|Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors who have progressive disease after receiving ≥ 2 prior therapies or not a candidate for therapy of proven efficacy for their disease.
62599664|NCT02493010|EXPERIMENTAL|Intervention|Participants will undergo a 4-week intervention (once per week, 1 hour each session). Each intervention session consists of approximately 30 minutes of computerized cognitive behavioral therapy, and 30 minutes of Virtual Reality Exposure Therapy with our novel arousal-based biofeedback system. For Virtual Reality Exposure Therapy, the physiological variables of participants will be continuously monitored and presented to them as feedback. Participants will have to deliver speeches to videotaped audiences while striving to regulate their physiological arousal.
62039365|NCT04609891|EXPERIMENTAL|Avatrombopag Tablets Oral|When patient is diagnosed with thrombocytopenia induced by chemotherapy of malignant tumor, avatrombopag will be given to patients as a therapeutic plan.
62432825|NCT03256383||Children 7 - 17|Patients aged 7 - 17 years
62432826|NCT03256383||Children <7|Patients aged under 7 years
62432827|NCT05735782||Case-Control|Case group: Participants with persistent symptoms post-COVID-19 more than12 weeks after COVID-19 acute infection Control group: Participants without persistent symptoms after a COVID-19 acute infection.
62432828|NCT03839888|EXPERIMENTAL|0.125% atropine group|patients used the 0.125 % atropine eyedrop every night before sleep for 7 days
62432829|NCT05006183|EXPERIMENTAL|iFR-guided|One-stage, virtually planned, iFR-guided and optimized PCI.
62432830|NCT05006183|ACTIVE_COMPARATOR|Angiography-guided|Standard practice staged angiography-guided PCI
62432831|NCT04537819|EXPERIMENTAL|The main group|"1. soft diet; 2. Elimination of factors that irritate the mucous membrane of the pharynx (thermal, chemical); 4. Local NSAIDs - benzydamine hydrochloride. 5. Imupret oral drops in the age-related dosage of 6 times per day for 6 days with the subsequent transition to the regime of 15 drops / 3 times in a day according to the patient's condition.~6. Paracetamol as antipyretic, if necessary."
62818786|NCT06513858|ACTIVE_COMPARATOR|Drum Circle Control Group- Cohort 2|Control investigations will also be conducted to better understand the contribution communal drumming has on effects of anxiety and connectedness. All control investigations will take place in the same space and at the same frequency as the associated experimental arm but with no drumming. All participants will be asked to complete the same surveys and at the same frequency to those completed in the experimental arm.
62818787|NCT01343953|EXPERIMENTAL|Cord Blood Transplantation|
62818788|NCT04970134||Thyroid carcinoma|"Advanced and / or metastatic thyroid carcinoma with initial histological diagnosis date before January 1, 2021 of the types:~Differentiated thyroid carcinoma (DTC) refractory to radio-iodine, including papillary carcinomas, follicular carcinomas, poorly differentiated carcinomas of the thyroid and the different corresponding variants.~Medullary thyroid carcinoma (MTC)."
62039366|NCT06733090|EXPERIMENTAL|0.2% chlorhexidine glucanate solution|0.2% chlorhexidine glucanate solution
62039367|NCT06733090|EXPERIMENTAL|0.12% chlorhexidine glucanate solution|0.12% chlorhexidine glucanate solution
62039368|NCT03229954|EXPERIMENTAL|IV iron (Monofer) group|Iron isomaltoside(Monofer) will be injected intravenously and injection dose will be calculated using Ganzoni formula.
62432832|NCT04537819|OTHER|The comparison group|1. soft diet; 2. Elimination of factors that irritate the mucous membrane of the pharynx (thermal, chemical); 4. Local NSAIDs - benzydamine hydrochloride. 5. Paracetamol as antipyretic, if necessary.
62599665|NCT02493010|NO_INTERVENTION|Waitlist Control|Participants in Waitlist Control will receive no intervention in the first 4 weeks of the study. After the Intervention group has completed treatment, participants in the Waitlist Control will then undergo the same intervention as the Intervention group.
62818789|NCT01838395|EXPERIMENTAL|BL-8040 0.5mg/kg + Ara-C 1.5 or 3 g/m2/d per dose (based on age)|Arm 1: Participants will be dosed with SC injections of BL-8040 over two days followed by concurrent administration of 0.5 mg/kg BL-8040 with cytarabine (Ara-C) 1.5 or 3 g/m2/d per dose (based on age) during 5 days.
62039369|NCT03229954|ACTIVE_COMPARATOR|Oral iron group|Ferrous sulfate(Feroba-YOU) 160mg/day for 12 weeks will be taken per oral.
62242478|NCT05938855|OTHER|Standard of care plus additional questionaire|As part of this clinical investigation, the medical device under investigation is used in accordance with its usual use, and the patient's therapeutic procedure includes additional, non-invasive procedures. These additional procedures relate to the addition of an end-of-life visit and validated questionnaires assessing functional deficiencies and impact on daily life.
62242479|NCT02082041||Wounds on leg|
62242480|NCT00088907|ACTIVE_COMPARATOR|Arm I (docetaxel and placebo)|Patients receive docetaxel intravenously (IV) over 30-60 minutes on days 1, 8, and 15 and oral placebo once daily on days 1-28.
62599666|NCT06648902|EXPERIMENTAL|Arm A: First-line TKI therapy, Meldonium 500 mg|meldonium 500 mg orally daily for six weeks.
62818790|NCT01838395|EXPERIMENTAL|BL-8040 0.75mg/kg + Ara-C 1.5 or 3 g/m2/d (based on age)|Arm 2: Participants will be dosed with SC injections of BL-8040 over two days followed by concurrent administration of 0.75 mg/kg BL-8040 with cytarabine (Ara-C) 1.5 or 3 g/m2/d per dose (based on age) during 5 days.
62039370|NCT01039051|EXPERIMENTAL|Diet and Lifestyle counseling|increasing consumption of vegetables and fruits; maintaining energy balance through reducing excessive energy from meat, eggs and brown sugar and increasing energy expenditure from appropriate physical activity, such as doing maternal keep-fit exercises.
62818791|NCT01838395|EXPERIMENTAL|BL-8040 1.0mg/kg + Ara-C 1.5 or 3 g/m2/d (based on age)|Arm 3: Participants will be dosed with SC injections of BL-8040 over two days followed by concurrent administration of 1 mg/kg BL-8040 with cytarabine (Ara-C) 1.5 or 3 g/m2/d per dose (based on age) during 5 days.
62039371|NCT01845675|EXPERIMENTAL|temozolomide or dacarbazine-based chemotherapy, endostatin|Endostatin 15mg/d，IV infusion, d1-d14 Temozolomide 150-200mg/m2/d，p.o., d1-d7 or dacarbazine 250mg/m2/d, IV infusion, d1-5, 5-FU 500mg/m2/d, IV infusion d1-5 Repeat every 3 weeks.
62039372|NCT01579591|EXPERIMENTAL|VSL#3 PROBIOTIC PREPARATION|
62039373|NCT01579591|PLACEBO_COMPARATOR|Placebo|
62039374|NCT04879901|EXPERIMENTAL|Experimental group|Group measuring shoulder muscle activities by surface EMG with carrying backpacks forward
62039375|NCT05185531|EXPERIMENTAL|Neoadjuvant|PD-1(Tislelizumab) plus stereotactic body radiotherapy
62039376|NCT01257906|EXPERIMENTAL|CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL|Topical Gel Test Product
62039377|NCT01257906|ACTIVE_COMPARATOR|ZIANA®|Topical Gel Reference Product
62039378|NCT01257906|PLACEBO_COMPARATOR|Vehicle Control|Topical Gel Placebo
62039379|NCT06733571||patients undergoing elective intestinal anastomosis procedures|"The SMS Medical College Elective Intestinal Anastomosis Cohort is a prospective cohort study that includes patients undergoing elective intestinal anastomosis procedures at the Department of Surgery, SMS Medical College, Jaipur. This cohort consists of 86 patients who underwent various types of elective bowel reconnection surgeries, including jejuno-jejunal, ileo-ileal, ileo-colic, and colo-colic anastomoses, as well as stoma closures, between \[study period\]. The cohort includes both male and female patients aged 18 years and older who provided informed consent to participate.~The primary aim of this cohort study is to assess the incidence and risk factors of anastomotic leaks (AL)-a serious postoperative complication that can significantly impact patient outcomes. Detailed monitoring of preoperative conditions, surgical factors, and postoperative outcomes, the study aims to identify key risk factors associated with AL, including patient comorbidities"
62039380|NCT06733051|EXPERIMENTAL|Golidocitinib and Benmelstobart Combination|Patients will receive golidocitinib in combination with benmelstobart every 3 weeks for up to 24 months, until disease progression, unaccpetable toxicities or other reasons lead to discontinuation.
62039381|NCT03340519||Healthy Controls|Healthy Controls will undergo MR imaging to optimize MR techniques for bowel assessment and to acquire normative data
62432833|NCT00923195|EXPERIMENTAL|TBI 600cGy + PBL + HD IL-2+gp100:154-162|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population). One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14. Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).Radiation: 2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute.
62039382|NCT03340519||Newly Diagnosed Crohns Patients|MR imaging will be performed in newly diagnosed CD patients prior to initiation of infliximab therapy in order to obtain baseline measures in the setting of active intestinal inflammation
62039383|NCT02429882|EXPERIMENTAL|Brodalumab|
62599667|NCT06648902|EXPERIMENTAL|Arm B: Second-line TKI therapy, Meldonium 1,000 mg|meldonium 1,000 mg orally daily for six weeks.
62039384|NCT02429882|PLACEBO_COMPARATOR|Placebo|
62039385|NCT06109870|EXPERIMENTAL|PRECEDE-PROCEED|To identify predisposing, enabling, and reinforcing factors that could influence women's decision to participate in self-sample HPV testing and diagnostic follow-up.
62039386|NCT04876729|EXPERIMENTAL|Otago Exercise Program|An individualized Otago Exercise Program will be delivered by community health representatives (CHR) in participants homes. There will be 10 home visits over a 12 month period.
62818792|NCT01838395|EXPERIMENTAL|BL-8040 1.25mg/kg + Ara-C 1.5 or 3 g/m2/d (based on age)|Arm 4: Participants will be dosed with SC injections of BL-8040 over two days followed by concurrent administration of 1.25 mg/kg BL-8040 with cytarabine (Ara-C) 1.5 or 3 g/m2/d per dose (based on age) during 5 days.
62242481|NCT00088907|EXPERIMENTAL|Arm II (docetaxel and gefitinib)|"Patients receive docetaxel as in arm I and oral gefitinib once daily on days 1-28.~ZD1839 (Iressa, gefitinib) will be given at a dose of 250 mg (one tablet) orally each day starting on day 1 and continuing for days 1 to 28 of each cycle until progression.~In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression."
62242482|NCT04259294|EXPERIMENTAL|Telerehabilitation group via mobile apps|The experimental group will receive home-based treatment program through mobile apps
62432834|NCT00923195|EXPERIMENTAL|TBI 600cGy+PBL+HD IL-2+MART-1:26-35(27L)|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population). One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14. Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).Radiation: 2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute.
62242483|NCT04259294|ACTIVE_COMPARATOR|Control group via paper and pencil instructions|The control group will receive treatment via written home program sheets
62432835|NCT06529198|EXPERIMENTAL|treatment|Patient are undergoing neuromodulatioon
62432836|NCT00101205|EXPERIMENTAL|Arm I|Patients receive oxaliplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62242484|NCT06104644||Moderate-to-severe plaque psoriasis|
62242485|NCT06734663|PLACEBO_COMPARATOR|pterygium excision using sutured technique|This represents the main used technique in pterygium surgery that we will compare the less familiar sutureless technique to. pterygium is surgically removed and conjuctival graft is placed using sutures
62432837|NCT03689140|EXPERIMENTAL|App-only|The intervention will consist of participants will only use a smoking cessation app
62432838|NCT03689140|EXPERIMENTAL|Telemedicine counseling only|The intervention will consist of participants will only use telemedicine counseling
62432839|NCT03689140|EXPERIMENTAL|App + telemedicine counseling|The intervention will consist of participants will only use a smoking cessation app + telemedicine counseling
62432840|NCT03689140|NO_INTERVENTION|Usual Care|The participants will continue with usual care
62432841|NCT01634022|EXPERIMENTAL|Acupuncture|Adults with depression who are not currently taking an antidepressant medication.
62432842|NCT00595049|EXPERIMENTAL|bosentan|
62432843|NCT06221345|EXPERIMENTAL|HPG/HA group|Systane HYDRATION®
62432844|NCT06221345|ACTIVE_COMPARATOR|CMC/HA group|Optive Fusion®
62432845|NCT01824459|ACTIVE_COMPARATOR|S-1 + cisplatin(SP)|S-1：40\~60mg bid，d1\~14 q3W cisplatin：60mg/m2，iv drip ，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
62432846|NCT01824459|EXPERIMENTAL|S-1+Oxaliplatin（SOX）|S-1：40\~60mg bid，d1\~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
62432847|NCT03779594|EXPERIMENTAL|treatment group|patients who met the inclusion criteria will be allocated to the treatment group, and will receive acetazolamide from time of diagnosis until shunt surgery (2-6 weeks).
62432848|NCT02769000|EXPERIMENTAL|Subjects 1-30|15 subjects in each RT dose schedule 10 GY in 5 daily fractions 20 GY in 10 daily fractions
62432849|NCT01884870|OTHER|Surgical Treatment|Silent Ureteral Stone - Surgical Treatment
62432850|NCT04892966|EXPERIMENTAL|TXI (TXI group)|Arm undergoing normal colonoscopy with TXI light
62432851|NCT04892966|ACTIVE_COMPARATOR|WLI (White Light Imaging Group)|Arm undergoing normal colonoscopy with standard white light
62432852|NCT02577042|EXPERIMENTAL|Raltegravir + Atorvastatin|Switching the PI by raltegravir, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks
62432853|NCT02577042|ACTIVE_COMPARATOR|PI-based regimen + Atorvastatin|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.
62432854|NCT04601662|EXPERIMENTAL|Corticision|Patients in this group will be subjected to corticision to accelerate orthodontic movement
62432855|NCT04601662|ACTIVE_COMPARATOR|Traditional treatment|Patients in this group will undergo normal traditional treatment without any acceleration method.
62432856|NCT05480527|ACTIVE_COMPARATOR|Patients with bilateral neuropathic pain which treating active electrode|30 patients which treating with transcutaneous pulsed radiofrequency. All patients have diabetic polyneuropathy and confirmed with electroneuromyography.
62818793|NCT01838395|EXPERIMENTAL|BL-8040 1.5mg/kg + Ara-C 1.5 or 3 g/m2/d (based on age)|Arm 5: Participants will be dosed with SC injections of BL-8040 over two days followed by concurrent administration of 1.5 mg/kg BL-8040 with cytarabine (Ara-C) 1.5 or 3 g/m2/d per dose (based on age) during 5 days.
62818794|NCT01838395|EXPERIMENTAL|BL-8040 2mg/kg + Ara-C 1.5 or 3 g/m2/d (based on age)|Arm 6: Participants will be dosed with SC injections of BL-8040 over two days followed by concurrent administration of 2 mg/kg BL-8040 with cytarabine (Ara-C) 1.5 or 3 g/m2/d per dose (based on age) during 5 days.
62039387|NCT04876729|NO_INTERVENTION|Education|The control group will receive education on fall risk reduction. This will be delivered by the CHR with 6 home visits over 12 months
62242486|NCT06734663|ACTIVE_COMPARATOR|sutureless technique|this represents the experimented technique in which pterygium excision is done and the graft is placed sutureless.
62242487|NCT05344768|NO_INTERVENTION|control group|Patients in the control group will be asked to maintain their usual exercise and eating habits throughout the study. No intervention will be applied.
62242488|NCT05344768|EXPERIMENTAL|moderate continuous aerobic exercise training group|After the warm-up period (5 minutes), 35 minutes of continuous exercise training will be applied at 60% (moderate intensity) of the maximum oxygen consumption (VO2max) value obtained from cardiopulmonary exercise test with a bicycle ergometer. After the exercise training, the patients will be taken to a 5 minute cool-down period.
62242489|NCT05344768|EXPERIMENTAL|high-intensity interval training group|After the warm-up period (5 minutes), the patient will be asked to cycle for 1 minute at a workload of 90% (high intensity) of the VO2max obtained from cardiopulmonary exercise test with a bicycle ergometer, and the patient will be asked to cycle for 2 minutes at a workload of 25% of the VO2max value. This cycle will be repeated 10 times. The patient will then be placed in a 5 minute cool-down period.
62242490|NCT05344768|EXPERIMENTAL|resistance exercise training group|It will be planned as 3 sets of 10 repetitions resistance exercises with 50% of 1 maximum repetition. Exercises will be performed on chest press, pectoral, pulley, hip abductor and adductor, leg press, cable biceps curl, triceps push down, shoulder press, abdominal crunch machines. The program will be created with a rest period of 3 minutes between sets, 10 minutes of stretching before the exercise and 10 minutes of stretching and cooling exercises after the exercise.
62242491|NCT05344768|EXPERIMENTAL|combination of moderate continuous aerobic exercise training with resistance exercise training group|The combination of moderate continuous aerobic exercise training with resistance exercise training will be applied to the patients.
62242492|NCT05344768|EXPERIMENTAL|combination of high-intensity interval training with resistance exercise training|The combination of high-intensity interval training with resistance exercise training will be applied to the patients.
62242493|NCT06249945|EXPERIMENTAL|empagliflozin|Jardiance, 25 mg, QD, for 6 months
62242494|NCT06249945|PLACEBO_COMPARATOR|Placebo|QD, for 6 months
62242495|NCT01438021|EXPERIMENTAL|Treatment (intraventricular chemotherapy)|Patients receive intraventricular methotrexate continuously on days 1-14. Treatment continues in the absence of disease progression or unacceptable toxicity.
62242496|NCT01019980|EXPERIMENTAL|Diclofenac potassium|
62242497|NCT01019980|ACTIVE_COMPARATOR|Acetaminophen|
62242498|NCT03214133|EXPERIMENTAL|Epicatechin Dose Response|This arm will investigate varying doses of epicatechin on procollagen type I N-terminal propeptide (PINP) at varying doses CON, 1, 2, 3 mg/kg body mass.
62599668|NCT06648902|EXPERIMENTAL|Arm C: First-line IO-TKI therapy, Meldonium 1,000 mg|meldonium 1,000 mg orally daily for six weeks.
62039388|NCT05972551|EXPERIMENTAL|Romosozumab|Participants will receive romosozumab once a month (QM) for 12 months.
62242499|NCT03214133|PLACEBO_COMPARATOR|Epicatechin-rich cocoa on performance|Athletes will ingest the optimized dose of epicatechin-rich cocoa vs placebo alongside maximum power training to determine if this nutritional intervention results in a greater increase in RFD and performance than maximum power training alone.
62432857|NCT05480527|SHAM_COMPARATOR|Patients with bilateral neuropathic pain which applied sham electrode|Sham electrodes will be applied to 30 patients. All patients have diabetic polyneuropathy and confirmed with electroneuromyography.
62432858|NCT03958669||Sorafenib treated HCC patients|No intervention is performed. This is an observational study.
62599669|NCT05288894||Repaired Tetralogy of Fallot|A patient affected by Tetralogy of Fallot (right ventricle outflow obstruction, right ventricle hypertrophy, ventricular septal defect, aortic overriding of the ventricular defect) that already underwent cardiac surgery for the correction.
62242500|NCT04298463||COHORT A: dalbavancin|Patients hospitalized for at teast two days affected by ABSSSI and treated with dalbavancin.
62242501|NCT04298463||COHORT B: lipo and glyco-peptid drugs|Patients hospitalized for at teast two days affected by ABSSSI and treated with vancomycin, teicoplanin or daptomycin.
62432859|NCT01823484|EXPERIMENTAL|AN 69 ST hemofilter|Use AN 69 ST hemofilter during CRRT
62599670|NCT06060990|OTHER|Open-label single arm of patients with metastatic BTCs|"Systemic therapy:~Identification of trace elements as novel predictive and prognostic biomarkers for response to systemic therapy in metastatic BTCs"
62818795|NCT06705816||Study group|Patients with Rett Syndrome who are interested in Trofinetide treatment
62818796|NCT00782535|EXPERIMENTAL|Treatment A|Single therapeutic dose of CHF 4226 pMDI
62818797|NCT00782535|EXPERIMENTAL|Treatment B|Single therapeutic dose of CHF 4226 pMDI
62432860|NCT01823484|ACTIVE_COMPARATOR|AN 69 hemofilter|Use AN 69 hemofilter during CRRT
62818798|NCT00782535|EXPERIMENTAL|Treatment C|Single supratherapeutic dose of CHF 4226 pMDI
62818799|NCT00782535|EXPERIMENTAL|Treatment D|Single supratherapeutic dose of CHF 4226 pMDI
62818800|NCT00782535|PLACEBO_COMPARATOR|Treatment E|Single dose of placebo
62818801|NCT01869608|EXPERIMENTAL|postpartum screening|Oral glucose tolerance test 2 days post-partum
62818802|NCT05750251||Ptosis patient|Undergo conventional ptosis correction surgery, including levator muscle resection surgery and Müller's muscle-conjuctival resection surgery
62818803|NCT05750251||Eyelid retraction patient|Undergo conventional ptosis correction surgery, including full-thickness anterior blepharotomy surgery
62818804|NCT05734768||Preterm newborns and their parents|Thirty premature children born between 32 and 36+6 weeks of gestation, and their parents.
62818805|NCT05734768||term newborns and their parents|Thirty children, born at more than 37 weeks (≥37+0), and their parents
62242502|NCT06651632|EXPERIMENTAL|Aquablation Therapy|The Aquablation Therapy arm will receive Aquablation with either the AQUABEAM Robotic System or HYDROS Robotic System
62818806|NCT05476289||A|children who received partially hydrolyzed formula containing synbiotics in the first 17 weeks of life in the Dragon study.
62432861|NCT02580188|NO_INTERVENTION|Moderate block|Maintenance dose of 0.15-0.3 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
62818807|NCT05476289||B|children who received standard infant formula containing prebiotics in the first 17 weeks of life in the Dragon study.
62818808|NCT05476289||C|children who received full breastfeeding in the first 17 weeks of life in the Dragon study.
62818809|NCT04268641|EXPERIMENTAL|Use of positioning equipment order 1|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
62818810|NCT04268641|EXPERIMENTAL|Use of positioning equipment order 2|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
62599671|NCT05477485|OTHER|Usual Care|Usual Care participants will receive standard state-level care for missing ART prescription refill(s) for Virginia Medicaid enrollees with HIV.
62242503|NCT06651632|ACTIVE_COMPARATOR|Radical Prostatectomy|The radical prostatectomy arm will receive the standard of care radical prostatectomy procedure.
62599672|NCT05477485|EXPERIMENTAL|AIMS program - patient|Participants will receive patient-level support. Support will come from the participant's provider, pharmacy, managed-care organization or the community.
62599673|NCT03603470|OTHER|Patients with previous prothesis instability|
62599674|NCT03603470|OTHER|Patients without prothesis instability|
62599675|NCT00074997|EXPERIMENTAL|001|OZ1 Single intravenous infusion of 2-20 x 10 to the power of 7 OZ1 transduced autologous CD34+ cells per kilogram of body weight
62599676|NCT00074997|PLACEBO_COMPARATOR|002|Placebo Single intravenous infusion of placebo transduced autologous CD34+ cells per kilogram of body weight
62818811|NCT04268641|EXPERIMENTAL|Use of positioning equipment order 3|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
62818812|NCT04268641|EXPERIMENTAL|Use of positioning equipment order 4|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
62818813|NCT04268641|EXPERIMENTAL|Use of positioning equipment order 5|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
62818814|NCT04268641|EXPERIMENTAL|Use of positioning equipment order 6|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
62818815|NCT03824223|OTHER|new/old HCT component order|"new/old hypoxic challenge test (HCT) component order~Where the new test uses pulse oximetry and transcutaneous CO2 monitoring to guide use of ventilatory support and if necessary supplementary oxygen and the old test uses pulse oximetry to titrate supplementary oxygen."
62818816|NCT03824223|OTHER|old/new HCT component order|"old/new hypoxic challenge test (HCT) component order~Where the old test uses pulse oximetry to titrate supplementary oxygen and the new test uses pulse oximetry and transcutaneous CO2 monitoring to guide use of ventilatory support and if necessary supplementary oxygen."
62242504|NCT05390359|EXPERIMENTAL|High-intensity and short-duration|The technique consists of the percutaneous electrical stimulation of the tendon applying a galvanic current through a ultrasound-guided needle.
62599677|NCT04467242||COPD patients|COPD patients with severe emphysema and right heart dysfunction
62818817|NCT06444308|EXPERIMENTAL|Community Health Worker Care|Multimodal health systems intervention: hypertension management by trained CHWs equipped with a mobile clinical decision support (CDS) application and remote supervision and support by physicians. CHWs will meet with patients each month and, with the assistance of the CDS application, follow physician-approved and evidence-based protocols to initiate and titrate antihypertensives and medications to reduce cardiovascular risk; identify potential complications of hypertension or problems with medications; and provide lifestyle counseling. For patients with comorbid hypertension and diabetes, CHWs will also manage glycemic therapy and assess for diabetes complications with the assistance of the application.
62818818|NCT06444308|ACTIVE_COMPARATOR|Physician Care|
62818819|NCT01690143|EXPERIMENTAL|Carfilzomib + high dose melphalan|Single arm.
62818820|NCT03907852|EXPERIMENTAL|Lymphodepletion followed by gavo-cel|fludarabine 30 mg/m2/d on days -7 through -4 and cyclophosphamide 600 mg/m2/d on days -6 through -4 followed by gavo-cel
62818821|NCT03907852|EXPERIMENTAL|Lymphodepletion followed by gavo-cel plus nivolumab|fludarabine 30 mg/m2/d on days -7 through -4 and cyclophosphamide 600 mg/m2/d on days -6 through -4 followed by gavo-cel with nivolumab 360mg every 3 weeks starting on Day 21 post gavo-cel
62818822|NCT03907852|EXPERIMENTAL|Lymphodepletion followed by gavo-cel plus nivolumab and ipilimumab|fludarabine 30 mg/m2/d on days -7 through -4 and cyclophosphamide 600 mg/m2/d on days -6 through -4 followed by gavo-cel with nivolumab 360mg every 3 weeks starting on Day 21 post gavo-cel and ipilimumab 1mg/kg every 6 weeks starting on Day 42 post gavo-cel
62818823|NCT06701864|ACTIVE_COMPARATOR|Palpation|digital palpation used to identify the cricothyroid membrane
62818824|NCT06701864|EXPERIMENTAL|Ultrasound|"Ultrasonography (either String of pearls or TACA approach) used to identify the cricothyroid membrane"
62818825|NCT05355701|EXPERIMENTAL|Monotherapy dose escalation (Part 1)|Participants will receive PF-07799933
62818826|NCT05355701|EXPERIMENTAL|Combination dose escalation (Part 2)|Participants will receive PF-07799933 in combination with binimetinib or cetuximab
62242505|NCT05390359|EXPERIMENTAL|Low-intensity and long-duration|The technique consists of the percutaneous electrical stimulation of the tendon applying a galvanic current through a ultrasound-guided needle.
62242506|NCT05390359|EXPERIMENTAL|High-intensity, short-duration and 20 Hz|The technique consists of the percutaneous electrical stimulation of the tendon applying a alternating current through a ultrasound-guided needle.
62242507|NCT05390359|SHAM_COMPARATOR|Sham electrolysis|The technique consists of an introduction ultrasound-guided needle without electrical stimulation.
62242508|NCT06315842|EXPERIMENTAL|Levels of Diagnostic and Therapeutic Intervention tool|Medical doctors assigned to this group will incorporate a Levels of Diagnostic and Therapeutic Intervention tool into their clinical practice
62818827|NCT05355701|EXPERIMENTAL|Dose expansion (Part 3) - Tumor and mutation specific Cohort 1|Participants will receive PF-07799933
62818828|NCT05355701|EXPERIMENTAL|Dose expansion (Part 3) - Tumor and mutation specific Cohort 2|Participants will receive PF-07799933
62818829|NCT03511807|EXPERIMENTAL|Electrical/ Acoustic stimulation|
62818830|NCT05491616|EXPERIMENTAL|Nivolumab q4w|patients will receive Nivolumab at 480mg Q4W starting 10-14 weeks
62818831|NCT04750824||All afatinib patients|
62818832|NCT04750824||All non-afatinib (other systemic therapies)|
62818833|NCT06589284|OTHER|Silk 0-0 suture covered by chlorhexidine gluconate dressing|The provider will be asked to use standard straight suturing technique followed by a tegaderm dressing for securing the radial arterial catheter.
62818834|NCT06589284|OTHER|2-octyl cyanoacrylate covered by chlorhexidine gluconate dressing|The provider will be asked to use skin glue in a standardized fashion followed by a tegaderm dressing for securing the radial arterial catheter.
62818835|NCT06581016|EXPERIMENTAL|Single-use gastroscope|In the first period all gastroscopies in the operating theater will be performed with single-use gastroscopes.
62818836|NCT06581016|ACTIVE_COMPARATOR|Reusable gastroscope|In the second period all gastroscopies in the operation theater will be performed with reusable gastroscopes.
62818837|NCT06568159||MAD group|"* An oral and dental check-up will be carried out on the day of inclusion, and a sleep diary will be provided.~* Compliance will be assessed after 6 months' wear.~* As part of the research, specific questionnaires will be completed with the patient during a telephone interview after 6 months: assessment of compliance and quality of life."
62039389|NCT05972551|ACTIVE_COMPARATOR|Standard of Care Bisphosphonate|Participants will receive bisphosphonates per local standard of care treatment regimens, as determined by the investigator for 12 months.
62039390|NCT03722134|EXPERIMENTAL|MOCA|The refluxing GSV was treated with ClariVein catheter (endovenous mechanochemical ablation).
62242509|NCT06315842|ACTIVE_COMPARATOR|Usual clinical practice|Medical doctors assigned to this group will continue their clinical practice as usual
62242510|NCT00222053|NO_INTERVENTION|1|No specific intervention
62242511|NCT00222053|ACTIVE_COMPARATOR|2|Biphosphonates
62242512|NCT00222053|EXPERIMENTAL|3|Thalidomide
62242513|NCT01636414|ACTIVE_COMPARATOR|Hemovac drain|
62242514|NCT01636414|ACTIVE_COMPARATOR|Re-infusion drain|
62242515|NCT01636414|ACTIVE_COMPARATOR|Tranexamic drain|
62242516|NCT03476330|EXPERIMENTAL|Quercetin|All patients will be treated with oral quercetin.
62242517|NCT04989699|ACTIVE_COMPARATOR|OTX-TKI|
62242518|NCT04989699|ACTIVE_COMPARATOR|Aflibercept|
62599678|NCT02916394|EXPERIMENTAL|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+++|Patients in this group had IGF-1R overexpression tumors and did not receive any treatment before this study.
62818838|NCT06568159||CPAP group|"* An oral and dental check-up will be carried out on the day of inclusion.~* Compliance will be assessed after 6 months' wear.~* As part of the research, specific questionnaires will be completed with the patient during a telephone interview after 6 months: assessment of compliance and quality of life."
62818839|NCT06008860|OTHER|Primary Cohort - Azelastine|This is a double-blind clinical trial. All subjects will be sent an instructional video and be given written instructions which will educate them on how to use the drug or placebo nasal spray. Patients will follow the dosing instructions for Astepro® 0.15% nasal spray.
62818840|NCT06008860|PLACEBO_COMPARATOR|Primary Cohort - Placebo|This is a double-blind clinical trial. A Placebo will be provided by Bayer which features similar color and packaging. Both groups will also undergo recommendations for supportive care, which will be standardized. Any patients who develop severe disease will be given instructions for escalation of care.
62818841|NCT00892905||POC INR and APTT Hemochron|Adult patients undergoing elective on pump coronary artery bypass grafting surgery who have not received anticoagulants or clopidogrel within 5 days preoperatively.
62818842|NCT00848809||1|Slow-low efficiency daily dialysis group
62599679|NCT02916394|EXPERIMENTAL|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R++|Patients in this group had IGF-1R moderate expression tumors and did not receive any treatment before this study.
62818843|NCT00848809||2|Intermittent Hemodialysis group
62818844|NCT05188222|EXPERIMENTAL|Intervention Group|Patients in the intervention group will receive an oral preparation of 50 grams of Maltodextrin solution mixed in 400 millilitres (mL) of water twice the night before surgery and within 2-3 hours before surgery. The entire drink is meant to be consumed within 15 minutes.
62818845|NCT05188222|PLACEBO_COMPARATOR|Placebo Group|Patients in the intervention group will receive a placebo in 400 millilitres (mL) of water twice the night before surgery and within 2-3 hours before surgery. The entire drink is meant to be consumed within 15 minutes.
62818846|NCT05256901|EXPERIMENTAL|Sugammadex|The reversal agent, Sugammadex, will be administered at the start of closure.
62818847|NCT05256901|ACTIVE_COMPARATOR|Neostigmine/Glycopyrrolate|The reversal agent, Neostigmine, will be administered at the start of closure.
62599680|NCT02916394|EXPERIMENTAL|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+|Patients in this group had IGF-1R low expression tumors and did not receive any treatment before this study.
62599681|NCT02916394|EXPERIMENTAL|68Ga-NODAGA-ZIGF-1R:4：40：healthy volunteers|Patients in this group who are healthy volunteer.
62039391|NCT03722134|ACTIVE_COMPARATOR|EVLA|The refluxing GSV was treated with endovenous laser ablation.
62242519|NCT02024451|ACTIVE_COMPARATOR|Radial shock wave, Acupuncture|"Radial shock wave: 2 Hz with 2000 shock waves, and the energy level of 0.056mJ/mm2 in the trapezius muscle. It will be done once per week for 3 weeks.~Acupuncture: performed at Fenfchi (GB20) point over upper back. It will be performed once per week for 3 weeks ."
62599682|NCT04586218|ACTIVE_COMPARATOR|Manual control of vasopressor infusion|"Vasopressor will be manually titrated by intensive care unit nurses in charge of the patients to maintain mean arterial pressure \> 65 mmHg.~Fluid administration consists in optimization of stroke volume (assisted fluid management) during the postoperative period"
62242520|NCT02024451|NO_INTERVENTION|radial shock wave& no treatment|No treatment: patients recieved no intervention.
62242521|NCT03020238|PLACEBO_COMPARATOR|BiClamp group|BiClamp forcep (BiClamp® forcep, ERBE Elektromedizin, GmbH, Tuebingen, Germany) is used to dissect inferior hypogastric plexus
62242522|NCT03020238|ACTIVE_COMPARATOR|water jet group|water jet (ERBEJET®2, ERBE Elektromedizin, GmbH, Tuebingen, Germany) is used to dissect inferior hypogastric plexus
62242523|NCT04420650|ACTIVE_COMPARATOR|Anodal tDCS|Anodal tDCS of the hypothalamus-cognitive network
62599683|NCT04586218|EXPERIMENTAL|Computer guided vasopressor infusion|"Vasopressor will be titrated automatically by the closed-loop system to maintain mean arterial pressure \> 65 mmHg.~Fluid administration consists in optimization of stroke volume (assisted fluid management) during the postoperative period"
62818848|NCT01334021|EXPERIMENTAL|Diagnostic (biopsy, surgery, genetic testing)|Patients undergo biopsy or surgery to obtain tumor sample for genetic testing. Patients are then assigned to 4 treatment cohorts as determined by genetic test results.
62818849|NCT05804747||Edoxaban|Participants who were prescribed edoxaban within 8 weeks of study enrollment at the discretion of the physician and were prospectively followed to assess the efficacy and safety of prescribed edoxaban.
62818850|NCT01314196|ACTIVE_COMPARATOR|therapeutic exercises|therapeutic exercises for the shoulder and scapula stabilizers
62818851|NCT01314196|EXPERIMENTAL|progressive resistance training biceps|therapeutic exercises for the shoulder and scapula stabilizers and biceps resistance training.
62818852|NCT06599190|ACTIVE_COMPARATOR|Group (A) (Control group)|consists of 25 female athletes. They will receive nutritional instructions and pelvic floor muscle exercises three sessions/week for 3 months.
62818853|NCT06599190|EXPERIMENTAL|Group (B) (Study group)|consists of 25 female athletes. They will receive the same treatment for the control group and abdominal hypopressive exercises three sessions/week of 30 mins per week for 3 months.
62818854|NCT04697667|EXPERIMENTAL|Group I|Each subject in this group will receive a combined treatment protocol consisting of three PRP injections to knee joint and supervised exercise program.
62242524|NCT04420650|ACTIVE_COMPARATOR|Cathodal tDCS|Cathodal tDCS of the hypothalamus-cognitive network
62242525|NCT04420650|SHAM_COMPARATOR|Sham Stimulation|Double blind sham stimulation (ramp-up ramp-down stimulation will be applied in order to simulate the active condition without any further continuous administration of current)
62242526|NCT05302583|OTHER|SOC only then SOC plus Aromatherapy Inhaler|"1. Participant will receive standard of care pharmacological intervention (SOC) as needed throughout the day.~2. Participants will complete the Standard of Care Pharmacological Intervention Use Log.~3. At between 1300 and 1500 hours, study personnel will administer the NCCN Distress Thermometer and Problem List."
62242527|NCT05302583|OTHER|SOC and Aromatherapy Inhaler then SOC only|"1. Participant will use the aromatherapy inhaler as needed for up to two (2) hours in the morning and complete the Aromatherapy Inhaler Use Log.~2. At between 1300 and 1500 hours, study personnel will administer the NCCN Distress Thermometer and Problem List."
62818855|NCT04697667|ACTIVE_COMPARATOR|Group II|Each subject in this group will receive a treatment of supervised exercise program.
62818856|NCT04697667|ACTIVE_COMPARATOR|Group III|Each subject in this group will receive a treatment of three PRP injections to knee joint.
62242528|NCT02599454|EXPERIMENTAL|atezolizumab + SBRT|"DOSE ESCALATION PHASE: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Within 24-48 hours after receiving atezolizumab, patients also undergo 4-5 fractions of stereotactic body radiation therapy over days 1-5 of course 3.~EXPANSION PHASE: Patients receive atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Within 24-48 hours after receiving atezolizumab, patients also undergo 4-5 fractions of stereotactic body radiation therapy over days 1-5 of course 3."
62599684|NCT06649526||Group MC McGrath videolaryngoscope Group H Hugmed Videolaryngoscope|"All patients will receive intravenous premedication with midazolam 0.03 mg/kg approximately 30 minutes before induction of anaesthesia. Preoperatively, standard monitoring included a 3-lead electrocardiogram (ECG) with continuous ST-segment analysis and assessment of peripheral oxygen saturation (SpO2) and intermittent non-invasive blood pressure. Following preoxygenation with 100% oxygen for three minutes, general anaesthesia would be induced with propofol (3mg/kg) a few minutes after injection of fentanyl (2µg/kg). Neuromuscular paralysis will be induced with rocuronium (0.5 mg/kg) in all patients.In group MC, direct and indirect Modified Cormack Lehane score and POGO score will be evaluated with McGrath videolaryngoscope.~In Group H, direct and indirect Modified Cormack Lehane score and POGO score will be evaluated with Hugemed videolaryngoscope."
62599685|NCT03969303||NOTAL OCT v.2.5 and Commercial OCT on AMD Patients|OCT Images will be obtained in the central 10 degrees of the macula in AMD patients using the NOTAL OCT v.2.5 device and a Commercial device (Zeiss Cirrus/Heidelberg SPECTRALIS).
62818857|NCT05872737|EXPERIMENTAL|Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB)|A 12-week facilitator-guided Acceptance and Commitment Bibliotherapy, which includes general parenting advice and is delivered via a website
62039392|NCT03722134|ACTIVE_COMPARATOR|RFA|The refluxing GSV was treated with radiofrequency ablation.
62242529|NCT00609843|EXPERIMENTAL|1|
62242530|NCT04450654|EXPERIMENTAL|Gamunex-C IVIG|Gamunex-C IVIG dosed at 2g/kg will be given on week 0 and week 4.
62242531|NCT04450654|PLACEBO_COMPARATOR|Placebo|Albumin in a 1% solution at an equivalent volume to the corresponding Gamunex-C IVIG dose will be given at week 0 and week 4.
62242532|NCT01188473|EXPERIMENTAL|NPPV plus standard of care|NPPV initiated early and for a prolonged period of time in addition to standard of care in the management of children admitted to the hospital with status asthmaticus
62242533|NCT01188473|NO_INTERVENTION|Control: standard of care alone|standard of care in the management of children admitted to the hospital with status asthmaticus
62242534|NCT01557179|EXPERIMENTAL|Hyaluronic acid vaginal gel (Hyalofemme)|The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
62242535|NCT01557179|ACTIVE_COMPARATOR|Estriol cream (Ovestin)|The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
62242536|NCT04780932|PLACEBO_COMPARATOR|Control Arm|Oral Standard-of care riociguat from Day 1 to Week 42 (+/- 1 week). Posology 1mg tid - 2,5 mg tid. Oral Placebo 10 mg/day from Day 8 (+/- 3 days) to Week 42 (+/- 1 week). At week 16, subjects who are still symptomatic (WHO functional II to IV) and have PVR ≥ 240 dyn.sec.cm-5 will be offered additional treatment by BPA.
62599686|NCT04781829|NO_INTERVENTION|Control|Critically ill patients with pneumonia will be treated with an antibiotic strategy at the discretion of the treating clinician
62599687|NCT04781829|EXPERIMENTAL|Interventional|Critically ill patients with pneumonia will be treated with an antibiotic strategy based on results from the BioFire Pneumonia Panel
62599688|NCT05333939|EXPERIMENTAL|Moringa|4 g moringa leaf powder in green capsules divided into 4 capsules twice daily x 7 days
62599689|NCT05333939|PLACEBO_COMPARATOR|Control|comparable weight green capsules with cornstarch divided into 4 capsules twice daily x 7 days
62599690|NCT00403650|EXPERIMENTAL|1|
62818858|NCT05872737|PLACEBO_COMPARATOR|Control Group|Routine family support services and four video-conferencing sessions over the course of 12 weeks
62818859|NCT03288675|ACTIVE_COMPARATOR|Active aiTBS - active CCT+SSRI|Patients receive active aiTBS treatment in the first week, and starting from week 3 receive active CCT for a period of 4 weeks in combination with an antidepressant (SSRI)
62818860|NCT03288675|EXPERIMENTAL|Active aiTBS - sham CCT+SSRI|Patients receive active aiTBS treatment in the first week, and starting from week 3 receive a control training for a period of 4 weeks in combination with an antidepressant (SSRI)
62818861|NCT03288675|EXPERIMENTAL|Sham aiTBS - aiTBS - active CCT+SSRI|Patients receive sham aiTBS treatment in the first week, real aiTBS treatment in the third week, and starting from the fifth week receive CCT for a period of 4 weeks in combination with an antidepressant (SSRI)
62818862|NCT03288675|EXPERIMENTAL|Sham aiTBS - aiTBS - sham CCT+SSRI|Patients receive sham aiTBS treatment in the first week, real aiTBS treatment in the third week, and starting from the fifth week control training for a period of 4 weeks in combination with an antidepressant (SSRI)
62818863|NCT06704659|EXPERIMENTAL|Repeat breast conserving surgery and radiotherapy Arm|The patients in this arm undergo repeat breast conserving surgery and partial breast radiotherapy
62818864|NCT06704659|ACTIVE_COMPARATOR|Mastectomy Arm|The patients in this arm undergo mastectomy
62818865|NCT03851835|EXPERIMENTAL|Ondansetron Oral Solution|Ondansetron Oral Solution (4mg/5mL solution) - Dose = 0.15mg/kg. One dose every 8 hours (q8h). Six doses over 48 hours.
62039393|NCT06133387|EXPERIMENTAL|Arm 1|"* Subjects with benign final pathology and R0 resection is achieved; or,~* Subjects with benign (but not pre-cancerous) final pathology without R0 resection.~Subjects in Arm 1 will complete the study after Day 30."
62039394|NCT06133387|EXPERIMENTAL|Arm 2|"* Subjects with final pathology that is upstaged to cancer; or,~* Subjects with benign (and pre-cancerous) final pathology without R0 resection.~Subjects in Arm 2 will undergo 5-year follow-up to assess long-term oncological outcomes including local recurrence, disease-free survival and overall survival."
62039395|NCT01154920|EXPERIMENTAL|PCC Group + RT|Group A: Paclitaxel, Carboplatin and Cetuximab (PCC) Induction + Radiation (RT)
62039396|NCT01154920|EXPERIMENTAL|PCC Group + RT + Chemotherapy|Group A: Paclitaxel, Carboplatin and Cetuximab (PCC) Induction + Radiation (RT) + Chemotherapy
62039397|NCT01154920|EXPERIMENTAL|C-TPF Group + RT|Group B: Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) Induction + Radiation (RT)
62039398|NCT01154920|EXPERIMENTAL|C-TPF Group + RT + Chemotherapy|Group B: Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) Induction + Radiation (RT) + Chemotherapy
62039399|NCT06666491|EXPERIMENTAL|TQ/CQ|Participants in this group receive a single dose of TQ on Day 1 or Day 2 and a single dose of CQ daily, on Days 1 to 3.
62818866|NCT03851835|PLACEBO_COMPARATOR|Placebo Oral Solution|Compounded Placebo Oral Solution to match experimental arm
62818867|NCT05036096|EXPERIMENTAL|CBBCT Imaging Screening Patients|Patient undergo bilateral CBBCT imaging (or unilateral CBBCT imaging if the patient had mastectomy) within 4 weeks of screening mammography.
62242537|NCT04780932|EXPERIMENTAL|Experimental Arm|Oral Standard-of care riociguat from Day 1 to Week 42 (+/- 1 week). Posology 1mg tid - 2,5 mg tid. Oral Macitentan 10 mg/day from Day 8 (+/- 3 days) to Week 42 (+/- 1 week). At week 16, subjects who are still symptomatic (WHO functional II to IV) and have PVR ≥ 240 dyn.sec.cm-5 will be offered additional treatment by BPA.
62818868|NCT05036096|EXPERIMENTAL|CBBCT Imaging Diagnostic Patients|Patient undergo bilateral CBBCT imaging (or unilateral CBBCT imaging if the patient had mastectomy) within 4 weeks of diagnostic mammography.
62818869|NCT02558959|EXPERIMENTAL|Irinotecan and Capecitabine|irinotecan 180mg/m2 d1, capecitabine 1000mg/m2 bid d1-10, q2w
62818870|NCT02558959|ACTIVE_COMPARATOR|Irinotecan|irinotecan 180mg/m2 d1, q2w
62818871|NCT03839524|EXPERIMENTAL|TG4050 arm|Patients in this arm will receive injections of TG4050 Investigational Medicinal Product.
62818872|NCT02198014|EXPERIMENTAL|Manual Therapy group|We employed joint traction, passive muscle stretching and isometric exercises, active resisted and proprioception exercises. The treatment in this group consisted of two sessions per week for one hour each.
62818873|NCT02198014|EXPERIMENTAL|Educational gruop|"This group received educational sessions and home exercises. The exercises are aimed at improving quadriceps strength, flexibility, range of motion and knee proprioception.~Each educational session of 90 minute every two weeks, with exercises daily home"
62039400|NCT06666491|ACTIVE_COMPARATOR|PQ/CQ|Participants in this group receive a single dose of PQ daily from Day 1 or 2, up to Day 14 (or Day 15 if PQ started on Day 2) and a single dose of CQ daily, on Days 1 to 3.
62039401|NCT06010082|EXPERIMENTAL|STUDY GROUP|Intervention group Group one (study group, 40 pregnant women): received Music Therapy intervention.
62039402|NCT06010082|ACTIVE_COMPARATOR|Control group|Group two(the control group, 40 pregnant women):act as a control group/ waiting list
62242538|NCT02650414|EXPERIMENTAL|Pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia|
62432862|NCT02580188|EXPERIMENTAL|Deep block|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
62818874|NCT02198014|NO_INTERVENTION|Control group|The control group (group C) did not receive any treatment. The patients of this group were assessed by the same reviewers and under the same conditions as the subjects of the two intervention groups.
62818875|NCT05130008|EXPERIMENTAL|Intervention|Patients identified by the MGH readmission database and the EHR as eligible for the study will be enrolled. Participants will be paired with a community health worker and oriented to the digital platform ( mobile app, digital weight scale, digital blood pressure monitor, biosensor with armband). Participants will have access to the community health worker and the digital platform throughout the 30-day study interval.
62818876|NCT05130008|ACTIVE_COMPARATOR|Usual CHW Care|Patients identified by the MGH readmission database and the EHR as eligible for the study will be enrolled. Participants will be paired with a community health worker. Participants will have access to the community health worker throughout the 30-day study interval.
62818877|NCT06706193|ACTIVE_COMPARATOR|Control group|
62242539|NCT05999396|EXPERIMENTAL|Administration of CC-3, a bispecific CD276xCD3 antibody|"The DL in the accelerated titration phase is fixed in each patient and is applied once per week. The start dose for the first patient is 20µg. Dose increase in the next patient is determined by SRC, comprised of investigators and Sponsor, and can be up to 100% based on safety, PK and PD data. Accelerated titration is terminated and switched to a standard 3 + 3 design in case of any AE Grade ≥ 2 (except AEs unequivocally due to underlying disease or an extraneous cause), occurrence of DLT or decision of SRC based on PK, PD, and safety data.~In the dose expansion part, additional patients are treated to have 20 evaluabale patients at the MTD level defined in the dose escalation part."
62242540|NCT02877836|OTHER|Segmentary dystonia|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
62242541|NCT02877836|OTHER|Hemidystonia|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
62242542|NCT02877836|OTHER|Generalized dystonia|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
62242543|NCT02877836|OTHER|Healthy control subjects|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
62242544|NCT01177722|EXPERIMENTAL|Group 1: DTaP-IPV-Hep B-PRP-T (Lot A)|
62432863|NCT04287452|PLACEBO_COMPARATOR|Control|Emergency department patients enrolled in the control arm will receive usual care. Emergency department providers enrolled in the control arm will work their shift as usual.
62242545|NCT01177722|EXPERIMENTAL|Group 2: DTaP-IPV-Hep B-PRP-T (Lot B)|
62242546|NCT01177722|EXPERIMENTAL|Group 3: DTaP-IPV-Hep B-PRP-T (Lot C)|
62242547|NCT01177722|ACTIVE_COMPARATOR|Group 4: Active Control|
62242548|NCT05189769|EXPERIMENTAL|CP/No REACT|Traditional Coping Power for 7th graders, no school wide REACT training
62242549|NCT05189769|EXPERIMENTAL|CP/REACT|Traditional Coping Power for 7th graders and school wide REACT training
62242550|NCT05189769|EXPERIMENTAL|CP+/No REACT|New, adapted Coping Power for 7th graders intervention with no school wide REACT training
62242551|NCT05189769|EXPERIMENTAL|CP+/REACT|New, adapted Coping Power for 7th graders, school wide REACT training
62432864|NCT04287452|ACTIVE_COMPARATOR|Intervention|Emergency department patients and providers in the intervention arm will be exposed to and/or interact with a certified therapy dog and handler
62432865|NCT03739359|ACTIVE_COMPARATOR|Gas flow 50 L/min|In this group, nasal cannula gas flow will be set at 50 L/min.
62599691|NCT03231540|EXPERIMENTAL|intervention group|whey protein supplement enriched enteral nutrition, with protein intake of 1.5g/kg/day; in addition to standardized exercise training
62599692|NCT03231540|NO_INTERVENTION|control group|standard enteral nutrition, with protein intake of 1g/kg/day; in addition to standardized exercise training
62818878|NCT06706193|EXPERIMENTAL|Intervention group|
62242552|NCT04123990|EXPERIMENTAL|IBD|
62242553|NCT05915988|OTHER|open-label|UNEEG EpiSight solution
62242554|NCT00636688|EXPERIMENTAL|1|Behavioral (Lifestyle Counseling)
62242555|NCT00636688|ACTIVE_COMPARATOR|2|Control group
62432866|NCT03739359|EXPERIMENTAL|GF:IF=1|In this group, nasal cannula gas flow will be set at each individual patient's own inspiratory flow (GF:IF=1)
62432867|NCT03739359|EXPERIMENTAL|GF:IF=0.5|In this group, nasal cannula gas flow will be set at 50% of each individual patient's own inspiratory flow (GF:IF=0.5)
62432868|NCT05260151||Cross-sectional validation study|Each tracer's study will enroll 5 normal controls and 5 cases for each relevant disease, which means \[18F\]APN-1607 imaging with arterial line will be performed in 5 normal controls, 15 patients with Alzheimer's disease patients, progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD), and \[18F\] MNI-1126 imaging with Aline test will be performed in 5 normal controls, 15 patients with Alzheimer's disease, progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD); a total of 40 patients will be enrolled in this study group. Patients may choose to participate in the cross-sectional validation study for both tracers, or only for one of them.
62599693|NCT05817487|EXPERIMENTAL|HIIT group|
62818879|NCT06382168|EXPERIMENTAL|DFP-10917 + Venetoclax for 14 days|DFP-10917 4 mg/m\^2/day with venetoclax 400 mg once daily for 14 days
62818880|NCT06382168|EXPERIMENTAL|DFP-10917 + Venetoclax for 10 days|DFP-10917 4 mg/m\^2/day with venetoclax 400 mg once daily for 10 days
62242556|NCT03856658|EXPERIMENTAL|Floxuridine (FUDR) via HAI pump|Once enrolled, patients will undergo surgical placement of the HAI pump. This can be accomplished using minimally invasive or open techniques with an anticipated hospital stay of approximately 3-5 days. Prior to discharge from the hospital or at the first postoperative visit the pump is filled with FUDR according to the following equation: 0.12 mg/kg/d (using ideal body weight). This fill initiates day 1 of a 4-week cycle. The chemotherapy is infused by the pump continuously over 14 days. On day 15 (+/-4 days), the remaining chemotherapy is removed from the pump which is refilled with heparinized saline (30,000 units). This remains for an additional 2 weeks until the pump is refilled with FUDR at the start of the next cycle. Treatment is continued for a maximum of 6 cycles or as limited by toxicity. This regimen has been utilized with an acceptable safety profile in the setting of colorectal liver metastases.
62242557|NCT03382184|EXPERIMENTAL|Fraxel DUAL 1550 nm|The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth. 25 patients with alopecia will be part of this group.
62242558|NCT03382184|EXPERIMENTAL|Halo Hybrid Laser 1550 nm|The Halo laser will be used per protocol due to the dynamic thermal optimization technology for hair regrowth. 25 patients with alopecia will be part of this group.
62242559|NCT03331653|EXPERIMENTAL|Dry Needling and Ischemic Compression at the Trigger Point|Dry Needling and Ischemic Compression at the Trigger Point
62242560|NCT03331653|ACTIVE_COMPARATOR|Intervention at 1.5 cm from the Trigger Point|Dry Needling and Ischemic Compression at 1.5 centimeters from the Trigger Point
62039403|NCT01923259|EXPERIMENTAL|Donepezil Hydrochloride Tablets, 23 mg|Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd
62242561|NCT04536610|EXPERIMENTAL|Experimental group|Providing structured OP education in addition to the informative leaflet. (The leaflet contained the same information as the OP education program)
62242562|NCT04536610|ACTIVE_COMPARATOR|Control group|Giving only the informative leaflet. (The leaflet contained the same information as the OP education program)
62242563|NCT00902954|EXPERIMENTAL|A|anastrozole/letrozole 2-3 years switching to exemestane 3-2 years
62242564|NCT00902954|ACTIVE_COMPARATOR|B|anastrozole/letrozole 5 years
62242565|NCT01910116|PLACEBO_COMPARATOR|Placebo|Placebo 2 capsules, twice daily, for 12 weeks.
62242566|NCT01910116|ACTIVE_COMPARATOR|Shinbaro|Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
62242567|NCT00669487|EXPERIMENTAL|1. GPO-VIR S 1 pill orally every 12 hours|
62242568|NCT00669487|EXPERIMENTAL|2 GPO-VIR Z 1 pill orally every 12 hours|
62432869|NCT05260151||Longitudinal study|A total of 115 patients are planned to be enrolled in the study. Among them, AD group will enroll 10 cognitive normal controls, 15 prodromal Alzheimer's disease patients and 15 mild Alzheimer's disease patients. Non-AD group will enroll 15 patients with progressive supranuclear palsy (PSP) , 15 patients with frontotemporal dementia (FTD) carrying MAPT gene, 15 patients with FTD without MAPT gene (carrying other FTD related genes such as C9Orf, Progranulin, CHCHD10 or svPPA with TDP43 gene), 15 non-symptomatic carriers with MAPT mutation and 15 normal controls. Subjects who participated in cross-sectional validation study could also participate in this longitudinal study. Patients may also choose to participate only in the longitudinal study.
62599694|NCT05817487|EXPERIMENTAL|COP group|
62039404|NCT01923259|ACTIVE_COMPARATOR|Aricept|Aricept® 23 mg tablet of Eisai Inc
62039405|NCT06636877|EXPERIMENTAL|BR1019|
62242569|NCT00669487|EXPERIMENTAL|3 Truvada 1 pill oral q 24 hr and NVP 1 pill oral q 12 hr|
62242570|NCT01856465||Bariatric surgery of morbid obese|Morbid obese patient who undergo Bariatric surgery with NAFLD (NASH or SS) status
62242571|NCT06007742|EXPERIMENTAL|Intervention group: parent-administered pediatric tuina (n=20)|
62242572|NCT06007742|ACTIVE_COMPARATOR|Active control group: parent-child interactive exercise (n=20)|
62599695|NCT03369028||2d and 3D image|A 2D and 3D image of the participants' face will be taken. It will at least last 2-3 sec.
62039406|NCT06636877|ACTIVE_COMPARATOR|BR1019-2 + BR1019-3|
62039407|NCT01557231||No treatment|OA
62242573|NCT06007742|NO_INTERVENTION|Control group: usual care (n=20)|
62242574|NCT06227403|EXPERIMENTAL|Leadership, Engagement, and youth Activism Program with Mindfulness|The Leadership, Engagement, and youth Activism Program with Mindfulness intervention (LEAP-M) consists of 14 sessions focused on youth civic engagement, leadership, and mindfulness.
62242575|NCT06227403|ACTIVE_COMPARATOR|EnvisionIT|EnvisionIT is a college and career-readiness program designed for students in grades 6-12. The EnvisionIT program will be delivered over 14 sessions, and focus on skills and career/college readiness.
62242576|NCT01559194|ACTIVE_COMPARATOR|Low Fat Diet + Exercise|Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
62818881|NCT02437045|ACTIVE_COMPARATOR|Meropenem|Meropenem 1g every 8 hrs IV to day 4
62242577|NCT01559194|ACTIVE_COMPARATOR|Low Carbohydrate Diet + Exercise|Subjects were educated about a low carbohydrate diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
62242578|NCT00626210|EXPERIMENTAL|Modafinil|
62818882|NCT02437045|EXPERIMENTAL|Piperacillin-tazobactam combination product|Piperacillin tazobactam 4.5g every 6 hrs IV to day 4
62818883|NCT00717574|ACTIVE_COMPARATOR|Sevoflurane group|Sevoflurane based general anesthesia
62818884|NCT00717574|ACTIVE_COMPARATOR|Propofol group|Propofol based general anesthesia
62818885|NCT06597929|EXPERIMENTAL|Usual care plus the MV-ILPA and education program.|The experimental group will receive usual care plus the MV-ILPA and education program. First, a physiotherapist will conduct a face-to-face session with the patients detailing the health benefits of moderate to vigorous PA and the negative effects of not including it in their daily lives. Patients will receive a booklet with all the key information. Secondly, participants will take the MV-ILPA program.
62818886|NCT06597929|ACTIVE_COMPARATOR|Usual care|Usual care: appointments with the treating neurologist, medication, conventional physiotherapy (two/three times a week, including stretching, strength, and balance training), occupational therapy, and speech therapy if required.
62818887|NCT03556228|EXPERIMENTAL|VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)|
62818888|NCT04750317|EXPERIMENTAL|Patients with reduced oxygen saturation ≤93% treated with tofacitinib|Patients with oxygen saturation ≤93% on admission treated with tofacitinib and standard of care treatment
62818889|NCT04750317|NO_INTERVENTION|Patients with reduced oxygen saturation treated with SoC|Patients with oxygen saturation ≤93% on admission treated with standard of care only
62818890|NCT04750317|EXPERIMENTAL|Patients with preserved oxygen saturation >93% on admission treated with tofacitinib|Patients with oxygen saturation \>93% on admission treated with tofacitinib and standard of care
62242579|NCT04279847|EXPERIMENTAL|Part 1 : INCB057643 Monotherapy|INCB057643 dose escalation and dose expansion
62242580|NCT04279847|EXPERIMENTAL|Part 2 : INCB057643 Combination with Ruxolitinib|Combination arm in dose escalation and dose expansion
62818891|NCT04750317|NO_INTERVENTION|Patients with preserved oxygen saturation >93% on admission treated with SoC|Patients with oxygen saturation \>93% on admission treated with standard of care only
62818892|NCT06602154|ACTIVE_COMPARATOR|Control group ( light cure composite )|"Product: Denturum Light Cure Band Adhesive (Ortho Organizers). Composition: 4 mg composite adhesive paste and 6 ml Transbond primer. Storage: Stored at room temperature and protected from humidity.~Usage: Steps for light -cure composite bonding are:~1. Prepare teeth with oil-free pumice, and rinse thoroughly for 15 seconds with water.~2. Air dry tooth surface for 5 seconds until dry field is maintained and isolate with cotton rolls.~3. Etch enamel surface with 37% phosphoric acid for 15 seconds.~4. Rinse the etched surface for 20 seconds to remove the acid and precipitates that might have formed during the etching procedure.~5. Thoroughly dry etched surface with moisture free air. Tooth surface should appear frosty white, if not than reetch for 5 seconds.~6. Brush thin uniform amount of primer on every tooth surface.~7. Apply a small amount of adhesive paste onto bracket base and position the bracket on tooth surface.~8. After accurately placing bracket on tooth surfac"
62818893|NCT05973942|EXPERIMENTAL|Wingman-Connect|Wingman-Connect (Wyman et al., 2020) uses a network health theoretical framework to strengthen two suicide-protective functions of social networks: 1) Strengthening positive social bonds, and 2) Building healthy norms that incentivize adaptive coping. Training will be delivered in First Term Airmen classes among all Airmen arriving at base during the study period.
62818894|NCT05524025||Control Cohort: Adult Male Without HPV-positive throat cancer|Participants will receive 1x Salivary TTMV-HPV DNA Test. If test is negative there will not be follow up, if test is positive participants will have repeat Salivary TTMV-HPV DNA Test, a blood test and head and neck exam.
62599696|NCT06003907|ACTIVE_COMPARATOR|conventional physiotherapy|traditional and complementary medicine methods will not be used.
62818895|NCT05524025||Case Cohort: Any Adult With HPV-positive throat cancer|Participants will receive 1x Salivary and Blood TTMV-HPV DNA Test(s).
62039408|NCT03045666|EXPERIMENTAL|Intervention group|Patients stable on Macitentan therapy will exercise twice a week for 12 weeks, supervised by physiotherapists. The exercise program includes aerobic and strength exercises, at 2-3 minutes intervals.
62039409|NCT03045666|NO_INTERVENTION|Control Group|Patients stable on Macitentan therapy that will continue to receive it, without exercise.
62039410|NCT00097058||1|Continue current hormone therapy
62242581|NCT00147290|EXPERIMENTAL|BiV|ATP therapies are delivered in both the ventricles
62242582|NCT00147290|ACTIVE_COMPARATOR|RV|ATP delivered only in the right ventricle
62242583|NCT04309279|EXPERIMENTAL|Zentangle group|
62242584|NCT04309279|NO_INTERVENTION|Wait-list Control Group|
62242585|NCT03508167|EXPERIMENTAL|Thermal Band plus Dorilax®|
62242586|NCT03508167|OTHER|Thermal Band plus Placebo|
62242587|NCT06493682|EXPERIMENTAL|Experimental group|Motivational Interviews
62242588|NCT06493682|NO_INTERVENTION|Control group|Control
62242589|NCT00774865||Surgical|Patients who have previously undergone robotic bypass surgery
62242590|NCT00819260|EXPERIMENTAL|Harmonic Reduced Breast|harmonic scalpel used to reduce breast on that side
62242591|NCT00819260|ACTIVE_COMPARATOR|Electrocautery Reduced Breast|Electrocautery (current practice = control) used to reduce breast on that side
62242592|NCT05208164|EXPERIMENTAL|Mindfulness Meditation Classes|"8 mindfulness classes: Participants will engage in 8 two-hour mind and body practice classes over 8 weeks in-person or online (during the pandemic). You will receive compensation for your participation and a yoga mat. You will need to wear comfortable clothing. These sessions can be done sitting in chair, sitting on the floor, or standing.~Text messaging., in between classes you will receive text messages to encourage mind and body practices at home. Text messaging may appear as the following:~1.Do you have time to meditate right now? Yes or No. 2.Did you practice your mindfulness today? Yes or no. 3.Remember to wind down this evening and do not drink any caffeinated beverages 4 hours before bed."
62242593|NCT05208164|NO_INTERVENTION|Usual Care|
62242594|NCT06735508|EXPERIMENTAL|Arm A|Safe run-in phase and Dose Expansion phase
62599697|NCT06003907|EXPERIMENTAL|cupping therapy and graston|Complementary methods will be used alongside conventional physiotherapy.
62599698|NCT06648512||Newly diagnosed|Biobanked samples from AML patients taken at timepoint of initial diagnosis, before start of initial AML treatment.
62599699|NCT06648512||R/R AML (FLT3-mutated)|Biobanked samples from AML patients at relaps or refractory diagnosis (only if FLT3-mutated))
62242595|NCT00619190|EXPERIMENTAL|open aripipraprazole|Openly provided, flexibly dosed aripiprazole in doses from 1mg to 30mg
62242596|NCT00619190|NO_INTERVENTION|no medication control|group of children whose parents do not want them to take medications for autism over the year following enrollment in the trial.
62599700|NCT06028958|ACTIVE_COMPARATOR|Neck Isometrics Exercises|This group of participants will receive neck isometric exercises along with routine physical therapy and a hot pack. In this regimen, the patient is commanded to apply minimal resistance on the physiotherapist's hand in front, back, and lateral positions. This resistance is applied for 10 sec with a 15 sec hold with 10-15 repetitions. The protocol will be given to the participants for two weeks. Each session will be of 40 minutes.
62599701|NCT06028958|EXPERIMENTAL|Global Posture Re-Education|This group of participants will receive the Global Posture Re-Education technique with a hot pack. The protocol will be given to the participants for two weeks (1 session on an alternative day with the home plan). Each session will be of 40 minutes.
62599702|NCT04927377|EXPERIMENTAL|AI4DM Intervention Group|
62242597|NCT02513186|EXPERIMENTAL|Isatuximab|"VCDI cohort: Isatuximab (escalating dose) + bortezomib + cyclophosphamide + dexamethasone (VCDI): Induction phase will be 50 weeks (12 cycles). The duration of a cycle will be 42 days (6 weeks) for Cycle 1 (C1) and 28 days (4 weeks) for subsequent cycles. The duration of a cycle of the maintenance phase will be 28 days (4 weeks). After C12, isatuximab will be administered at its initial assigned dose and dexamethasone once every 28 days.~VRDI cohort parts A and B: Isatuximab + bortezomib + dexamethasone + lenalidomide (VRDI): Induction phase will be 24 weeks (4 cycles at 6 weeks/cycle). The duration of a cycle of the maintenance phase will be 28 days (4 weeks). Maintenance therapy may continue until disease progression, unacceptable AE or patient willingness to discontinue.~VRDI Part A: Enrollment to begin after the VCDI cohort is completed.~VRDI Part B: Enrollment to begin after the VRDI part A is completed."
62242598|NCT02869555||Patients with multiple myeloma diagnosis|
62242599|NCT05608577||Retrospective|Up to 1,750,000 patient admissions (up to 10 years of admissions) from one National Health Service Trust (Hospital group)
62242600|NCT05608577||Prospective Hospital Cohort|Up to 87, 500 will be screened by the digital platform to identify those who may have bled during the recruitment period, of which at least 40 will be approached for their consent to retain their blood samples (collected as part of routine care).
62242601|NCT00824824|EXPERIMENTAL|Brimonidine 0.2%-timolol 0.5% arm|Patients using timolol were switched to brimonidine tartrate / timolol maleate 0.2%/05% 1 get BID OU for six weeks.
62242602|NCT00824824|ACTIVE_COMPARATOR|Dorzolamide 2%-timolol 0.5% arm|Patients using timolol were switched ti dorzolamide hydrochloride / timolol 0.5% 2%/0.5% bid OU for six weeks
62242603|NCT04110964|EXPERIMENTAL|subjects treated with LGT|Subjects will be treated with a single IV dose of LGT (AAV-hTERT)
62242604|NCT01493258|NO_INTERVENTION|Control Group|The study participants randomized to the Group 2 will serve as a control. At the beginning of the study, they will receive a CERSG brochure printed from the AHRQ site. They will be asked to study it to the best of their ability throughout the day.
62242605|NCT01493258|EXPERIMENTAL|iCOPE Intervention group|iCOPE intervention group will receive a CERSG brochure via the iCOPE system.
62432870|NCT02938910||Healthy Volunteers|Healthy volunteers with normal blood pressure
62432871|NCT02938910||Primary Hyperaldosteronism|Subjects with hypertension and high levels of seric aldosterone.
62432872|NCT02938910||Secondary Hyperaldosteronism|Patient with Gitelman syndrome, with normal blood pressure and high level of aldosterone
62432873|NCT02938910||Essential Hypertension|Patient with hypertension without secondary cause of hypertension
62432874|NCT03054961||Epilepsy patients|Near-infrared spectroscopy for subjects with partial (focal) epilepsy seizures being studied in the EMU.
62242606|NCT01878643|PLACEBO_COMPARATOR|Drug: Placebo|normal saline 2 mL nebulized Q 8 hours placebo for gentamicin or vancomycin
62432875|NCT02355795|EXPERIMENTAL|low-fat diet|Participants will be provided low-fat diet for 6 months
62432876|NCT02355795|EXPERIMENTAL|moderate-fat diet|Participants will be provided moderate-fat diet for 6 months
62432877|NCT02355795|EXPERIMENTAL|high-fat diet|Participants will be provided high-fat diet for 6 months
62599703|NCT04927377|ACTIVE_COMPARATOR|Attention-control Group|
62432878|NCT06527300|EXPERIMENTAL|NHWD-870 HCl 1.5mg/2mg.|Take a fixed dose of NHWD-870 HCl tablets orally
62432879|NCT01706770|EXPERIMENTAL|enfilcon A|The test (experimental) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
62599704|NCT05824052|NO_INTERVENTION|Group 1|The synovial fluid taken from the patients and not treated in any way.
62599705|NCT05824052|ACTIVE_COMPARATOR|Group 2|The synovial fluid taken from the patients and injected 10 gamma ozone.
62599706|NCT05824052|ACTIVE_COMPARATOR|Group 3|The synovial fluid taken from the patients and injected 30 gamma ozone.
62039411|NCT00097058||2|Taper off hormone therapy
62242607|NCT01878643|EXPERIMENTAL|Drug: vancomycin or gentamicin|vancomycin 120 mg every 8 hours or gentamicin 80 mg every 8 hours
62242608|NCT06736015|EXPERIMENTAL|Myo-inositol and selenium supplementation|Supplement with Myo-Inositol 600 mg + Selenium 83 mcg once a day for 6 months
62242609|NCT06736015|NO_INTERVENTION|Control|No intervention
62432880|NCT01706770|ACTIVE_COMPARATOR|galyfilcon A|The control (active comparator) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
62432881|NCT04346290|NO_INTERVENTION|Control|Standard anesthesia care for kidney donor
62432882|NCT04346290|EXPERIMENTAL|Dexmedetomidine|Standard anesthesia care and perioperative infusion of dexmedetomidine for kidney donor
62432883|NCT01433952|PLACEBO_COMPARATOR|0 mg Thiamine|
62432884|NCT01433952|EXPERIMENTAL|100 mg Thiamine|
62432885|NCT01433952|EXPERIMENTAL|500 mg Thiamine|
62432886|NCT01433952|EXPERIMENTAL|1500 mg Thiamine|
62432887|NCT03670537||First trimester pregnant women|
62432888|NCT01613131|ACTIVE_COMPARATOR|Mirena + Estradiol Gel|Subjects will be assigned to use of Estradiol gel for use with Mirena.
62599707|NCT06620549||Patients after gastro-intestinal surgery|Postoperative patients after gastro-intestinal surgery (e.g. liver, pancreatic, colorectal or hyperthermic intraperitoneal chemotherapy (HIPEC) surgery)
62039412|NCT03321331|EXPERIMENTAL|Lark (JITAI)|"Participants in the intervention arm will use for 12 weeks the pro version of a mHealth app called Lark, developed by Lark Technologies Ltd. Lark is a coach app, which uses several variables to generate smart and empathic conversations. Variables include activity, sleep, meals, weight, and height data, weight goal set by the user/Lark coach, activity goal set by user/Lark coach, starchy food goal set by user/Lark coach. Lark uses all these variables to create a dynamic coaching system, constantly changing and adapting to the user in the moment and over time. For these features, Lark provides a just in time adaptive intervention (JITAI)."
62039413|NCT03321331|ACTIVE_COMPARATOR|MyFitnessPal (no JITAI)|"Participants in the control arm will be assigned to use MyFitnessPal. Similar to the intervention arm, they will be instructed to use the app for 12 weeks. MyFitnessPal does not include JITAI components, but allows users to keep track of their caloric intake and energy expenditure. MyFitnessPal has features that can be associated with effective behavior change techniques, including: self-monitoring of behavior and outcomes, goal setting and feedback (similar to Lark). In MyFitnessPal, social support is limited to comments and 'likes' from friends of its restricted user community, therefore tackling the techniques of social comparisons and social reward."
62242610|NCT02190669||exercise in individuals without diabetes|exercise in individuals without diabetes
62242611|NCT02190669||exercise in type 1 diabetes|exercise in type 1 diabetes
62242612|NCT02190669||exercise in type 2 diabetes|exercise in type 2 diabetes
62242613|NCT06693310|ACTIVE_COMPARATOR|Control group|continuation of current therapy
62242614|NCT06693310|ACTIVE_COMPARATOR|de-escalation group|de-escalation or discontinuation of therapy
62242615|NCT02037646|OTHER|Qualitative fecal immunochemical test|"Stool samples will be tested with the qualitative fecal immunochemical test (qFIT), and will be stratified for colonoscopy as follows:~\>200 ng/dL - colonoscopy with one month 100-200 ng/dL - colonoscopy as per waiting list \<100 ng/dL - no colonoscopy~Cost analysis, anxiety scores and patient satisfaction scores will be calculated for all patients."
62242616|NCT02037646|OTHER|Quantitative fecal immunochemical test|"Stool samples will be tested with the quantitative fecal immunochemical test (FIT), and will be scheduled for colonoscopy as follows:~Positive - colonoscopy as per waiting list Negative - no colonoscopy~Cost analysis, anxiety scores and patient satisfaction scores will be calculated for all patients."
62432889|NCT01613131|PLACEBO_COMPARATOR|Mirena + Placebo Gel|Subjects will be assigned to use of placebo gel for use with Mirena.
62242617|NCT03675776|EXPERIMENTAL|Rapastinel 450mg|Rapastinel (prefilled syringe, weekly intravenous IV administration).
62242618|NCT03675776|EXPERIMENTAL|Rapastinel 225mg|Rapastinel (prefilled syringe, weekly intravenous IV administration).
62599708|NCT02004821|EXPERIMENTAL|Renutryl® Booster|Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat).
62599709|NCT02262000|EXPERIMENTAL|A - 7.5 Gy x 10 daily fractions|Radiotherapy: 7.5 Gy x 10 daily fractions delivered with VMAT or regular IMRT at West Virginia University.
62599710|NCT02262000|EXPERIMENTAL|B - 12 Gy x 5 daily fractions|Radiotherapy: Optional schedule of 12 Gy x 5 daily fractions can may also be used ONLY in situations where dose constraints for organs at risk can be EASILY met while optimal PTV coverage is achieved
62039414|NCT00818116|EXPERIMENTAL|ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL)
62039415|NCT06490562|OTHER|PDCy group|Low dose Cy 30 mg/kg/d was administered on the 3rd and 4th day after gDLI to prevent GVHD
62039416|NCT06490562|OTHER|Non Cy group|Oral administration of low-dose CNI (CSA 25mg Q12H or FK506 0.25mg Q12H combined with azole fungal drugs) for 2 weeks to prevent GVHD at 0 days after gDLI
62039417|NCT01704170|EXPERIMENTAL|Renal Denervation Using Externally Focused Ultrasound Therapy|
62039418|NCT06445491|ACTIVE_COMPARATOR|control trial|Testing order: (1) forward step down test, (2) firefighter specific functional balance test \& y-balance test, (3) hip isokinetic strength \& knee isokinetic strength
62039419|NCT06445491|EXPERIMENTAL|sequenced trials|Participants will perform the following variations on testing order over 6 separate sessions: 1-2-3, 1-3-2, 2-1-3, 2-3-1, 3-1-2, and 3-2-1
62039420|NCT06488859|EXPERIMENTAL|Positive Affect Treatment|8 sessions of psychotherapy designed to augment reward anticipation, reward attainment, and reward learning.
62039421|NCT06488859|ACTIVE_COMPARATOR|Positive Affect Treatment and Negative Affect Treatment|8 sessions of psychotherapy. 3-5 sessions of psychotherapy designed to augment reward anticipation, reward attainment, and reward learning. Remaining sessions of psychotherapy designed to decrease threat avoidance, threat appraisal and arousal.
62039422|NCT00528775|EXPERIMENTAL|HPPH|Patients will receive 4 mg/m2 HPPH (given light exposure precautions) and approximately 2 days later be treated endoscopically with 150J/cm of 665 +-5nm light.
62039423|NCT01410773|EXPERIMENTAL|Intended Users of the System|Untrained subjects with diabetes (at least 70% of subjects will be insulin users) use an investigational blood glucose monitoring system (Ninja 2) to self-test capillary blood obtained from fingerstick and palm.
62039424|NCT05703100|ACTIVE_COMPARATOR|Control|Maximal test on a cycle ergometer
62039425|NCT05703100|EXPERIMENTAL|Hyperthermia|Maximal test on a cycle ergometer at 35º-38º C room temperature
62039426|NCT05703100|EXPERIMENTAL|Glycogen depletion|Maximal test on a cycle ergometer after a glycogen depletion protocol
62039427|NCT02308748|ACTIVE_COMPARATOR|Dofetilide|Dofetilide alone arm
62039428|NCT02308748|ACTIVE_COMPARATOR|Dofetilide + Mexiletine|Dofetilide combined with mexiletine
62039429|NCT02308748|ACTIVE_COMPARATOR|Dofetilide + Lidocaine|Dofetilide combined with lidocaine
62039430|NCT02308748|ACTIVE_COMPARATOR|Moxifloxacin + Diltiazem|Moxifloxacin with and without diltiazem.
62039431|NCT02308748|PLACEBO_COMPARATOR|Placebo|Placebo (#2 gelcap and intravenous saline)
62432890|NCT01357031|EXPERIMENTAL|Melatonin|Melatonin 3 mg at bedtime
62039432|NCT03860168|OTHER|PICU Up! pre- and post-implementation|Each unit will begin in the baseline, usual care phase and then be randomized to implement the PICU Up! program during a set time period, followed by the post-implementation phase.
62432891|NCT01357031|PLACEBO_COMPARATOR|Placebo|Placebo
62039433|NCT04429516|EXPERIMENTAL|Morphine Sulfate|
62039434|NCT04429516|PLACEBO_COMPARATOR|Placebo|
62039435|NCT00542802|EXPERIMENTAL|LEV|Levetiracetam
62039436|NCT00542802|ACTIVE_COMPARATOR|CAR|Carbamazepina
62039437|NCT06578962||Tested product RV3438G associated with gentle balancing shampoo|
62039438|NCT06578962||Tested product RV3438G associated with neutral shampoo|
62039439|NCT06578962||Control group|
62039440|NCT06625775|EXPERIMENTAL|Cohort 1a - Monotherapy Dose Escalation/Cohort Expansion|Participants enrolled in this cohort will receive BBO-10203 tablets orally (different dose levels will be evaluated) once daily (QD) as monotherapy. This cohort will enroll patients with advanced breast cancer, advanced colorectal cancer, and advanced lung cancer.
62039441|NCT06625775|EXPERIMENTAL|Cohort 1b - BBO-10203 Combination Dose Expansion|Participants enrolled in this cohort will receive BBO-10203 tablets orally QD in combination with trastuzumab IV (8mg/kg over 90 minutes on Cycle 1 Day 1, 6mg/kg over 30-90 minutes during subsequent cycles)/SC (600mg). This cohort will enroll patients with advanced breast cancer.
62039442|NCT06625775|EXPERIMENTAL|Combination Dose Escalation|Participants enrolled in this cohort will receive BBO-10203 tablets orally (different dose levels will be evaluated) QD in combination with trastuzumab IV (8mg/kg over 90 minutes on Cycle 1 Day 1, 6mg/kg over 30-90 minutes during subsequent cycles)/SC (600mg). This cohort will enroll patients with advanced breast cancer.
62039443|NCT03062969||Cleavage stage biopsy group|Patients undergoing a PGS cycle with single blastomere biopsy on day 3 and analysis using comparative genomic hybridation bacterial artificial chromosome (BAC) arrays (aCGH) If euploid blastocysts were available, patients underwent fresh blastocyst transfer on day 5.
62039444|NCT03062969||Trophectoderm biopsy group|Patients undergoing a PGS cycle with blastocyst biopsy on day 5-7 and analysis using comparative genomic hybridation bacterial artificial chromosome (BAC) arrays (aCGH). If euploid blastocysts were available, patients underwent frozen-thawed blastocyst transfer.
62039445|NCT01725828|EXPERIMENTAL|External Palpation group|External Palpation group will consist of 109 patients, who's CTM will be marked using traditional palpation technique of identifying the Cricothyroid membrane.
62432892|NCT01357031|ACTIVE_COMPARATOR|Amitriptyline|Amitriptyline 25 mg
62432893|NCT06013020|EXPERIMENTAL|Guided NOAC and DAPT|"The first month: rivaroxaban 2.5 mg twice daily (if CR≥24) plus standard DAPT (ticagrelor 90 mg twice daily or clopidogrel 75 mg daily plus aspirin 100 mg daily).~The following 11 months: lower-dose ticagrelor 60 mg twice daily (45 mg twice daily if \<50 kg, ≥75 yrs) or clopidogrel (75 mg daily) plus aspirin (100 mg daily)."
62242619|NCT03675776|PLACEBO_COMPARATOR|Placebo|Placebo (prefilled syringe, weekly IV administration).
62432894|NCT06013020|EXPERIMENTAL|Unguided DAPT|The first month: standard DAPT. The following 11 months: lower-dose ticagrelor or clopidogrel plus aspirin.
62599711|NCT06349512|EXPERIMENTAL|Triple Negative Breast Cancer|Patients with early-stage high-risk Triple Negative Breast Cancer
62818896|NCT04913610|EXPERIMENTAL|Part 1: ABBV-4083 400 mg + albendazole pbo for 7 days, then ABBV-4083 pbo for 7 days|Participants received ABBV-4083 400 mg administered orally as capsules plus placebo capsules for albendazole for 7 days followed by placebo capsules for ABBV-4083 for 7 days.
62818897|NCT04913610|EXPERIMENTAL|Part 1: ABBV-4083 400 mg + albendazole pbo for 7 days, then ABBV-4083 400 mg for 7 days|Participants received ABBV-4083 400 mg administered orally as capsules plus placebo capsules for albendazole for 7 days followed by ABBV-4083 400 mg administered orally as capsules for 7 days.
62599712|NCT01702675|EXPERIMENTAL|ACH15 - 50mg capsule|ACH15 50mg capsule by mouth single dose (Group 1)
62432895|NCT05612737|EXPERIMENTAL|"Sticky bone and tenting screw"|
62432896|NCT03405337||FVIII products (prospective)|"Qualitative patient/caregiver study:~Hemophilia A patients/caregivers (N=30) having initiated a FVIII products with improved half-life"
62432897|NCT03405337||Conventional FVIII replacement therapies|"Qualitative patient/caregiver study:~Hemophilia A patients/caregivers (N=30) receiving conventional FVIII replacement therapy for at least 6 months who are considering switching to a FVIII product with improved half-life within the next 1 year"
62599713|NCT01702675|EXPERIMENTAL|ACH15 - 250 mg capsule|ACH15 250mg capsule by mouth as single dose(Group 2)
62599714|NCT01702675|EXPERIMENTAL|ACH15 - 500mg capsule|ACH15 500mg capsule by mouth in a single dose(Group 3)
62599715|NCT01702675|EXPERIMENTAL|ACH15 - 1000 mg (two 500mg capsule)|ACH15 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)
62599716|NCT01702675|EXPERIMENTAL|ACH15 - 2000 mg (four 500 mg capsule)|ACH15 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)
62599717|NCT01702675|EXPERIMENTAL|ACH15 - 500 mg (twice a day for 7 days)|ACH15 500mg capsule by mouth twice a day for seven days (Group 6)
62599718|NCT01702675|PLACEBO_COMPARATOR|Placebo - 250 mg capsule|Placebo 250mg capsule by mouth single dose (Group 2)
62599719|NCT01702675|PLACEBO_COMPARATOR|Placebo - 500 mg capsule|Placebo 500mg capsule by mouth in a single dose(Group 3)
62818898|NCT04913610|EXPERIMENTAL|Part 1: ABBV-4083 400 mg + albendazole 400 mg for 7 days, then ABBV-4083 pbo for 7 days|Participants received ABBV-4083 400 mg administered orally as capsules plus albendazole 400 mg capsules for 7 days followed by placebo capsules for ABBV-4083 for 7 days.
62818899|NCT04913610|EXPERIMENTAL|Part 1: ABBV-4083/albendazole 400 mg 3 d; ABBV-4083 400 mg/albendazole pbo 4 d; ABBV-4083 pbo 7 d|Participants received ABBV-4083 400 mg administered orally as capsules plus albendazole 400 mg capsules for 3 days followed by ABBV-4083 400 mg and placebo capsules for albendazole for 4 days followed by placebo capsules for ABBV-4083 for 7 days.
62818900|NCT04913610|EXPERIMENTAL|Part 1: ABBV-4083 pbo + albendazole 400 mg for 7 days, then ABBV-4083 pbo for 7 days|Participants received placebo for ABBV-4083 administered orally as capsules plus albendazole 400 mg capsules for 7 days followed by placebo capsules for ABBV-4083 for 7 days.
62432898|NCT03405337||FVIII products (retrospective)|"Quantitative physician interview/ chart review study:~Hemophilia A patients (N=100) who have switched from conventional FVIII replacement therapy to FVIII products with improved half-life."
62432899|NCT05948293|EXPERIMENTAL|Intervention arm|In the intervention arm the first dose of FSH will be assigned by a machine learning model called IDoser.
62432900|NCT05948293|ACTIVE_COMPARATOR|Control arm|In the control arm the first dose of FSH will be determined by the clinician following standard practice.
62432901|NCT02108613|EXPERIMENTAL|Intervention|The intervention arm will receive sexual health counselling, exercise sessions, nutrition education, and will be assigned a peer support volunteer.
62432902|NCT02108613|NO_INTERVENTION|Control|The control group will receive sexual health counseling.
62432903|NCT02328261|EXPERIMENTAL|Icotinib|Icotinib (125 mg tablet) is orally administered three times daily
62432904|NCT01213355|EXPERIMENTAL|Placebo|placebo, plus scopolamine 0.5 mg
62432905|NCT01213355|EXPERIMENTAL|PF-05212377 5 mg, plus scopolamine 0.5 mg;|
62432906|NCT01213355|EXPERIMENTAL|PF-05212377 20 mg, plus scopolamine 0.5 mg;|
62599720|NCT01702675|PLACEBO_COMPARATOR|Placebo - 1000 mg (two 500mg capsule)|Placebo 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)
62432907|NCT01213355|EXPERIMENTAL|PF-05212377 60 mg, plus scopolamine 0.5 mg;|
62432908|NCT01213355|ACTIVE_COMPARATOR|donepezil 10 mg, plus scopolamine 0.5 mg.|
62599721|NCT01702675|PLACEBO_COMPARATOR|Placebo 2000 mg (four 500mg capsule)|Placebo 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)
62599722|NCT01702675|PLACEBO_COMPARATOR|Placebo - 500 mg (twice a day for 7 days)|Placebo 500mg capsule by mouth twice a day for seven days (Group 7)
62599723|NCT04346901|OTHER|Single Intervention|Before-and-After type of research
62599724|NCT00783315|ACTIVE_COMPARATOR|1|Self-Directed Weight Loss Program (Control Group)
62599725|NCT00783315|EXPERIMENTAL|2|Call-Center Directed (CCD) Weight Loss Program
62432909|NCT02741362|EXPERIMENTAL|ADSC arm|Single intravenous administration of Stromal Vacsular Fraction (SVF) cells soinating Adipose Derived Stem Cells (ADSC) 6 week baseline data prior to the injection of ADSC will be collected. 6 week, 3 months and 6 months follow up data will be compared against baseline.
62432910|NCT00933660|ACTIVE_COMPARATOR|Control-1|ERC-training by instructor
62039446|NCT01725828|EXPERIMENTAL|Ultrasound group|"Ultrasound group will consist of 114 patients, who's CTM will be marked using, ultrasonography to identify the CTM.~The Intervention by using the Ultrasound to determine the CTM."
62039447|NCT06724510|EXPERIMENTAL|ULTRAFOMER MPT|This arm receives the high-intensity focused ultrasound (HIFU) treatment, which is the primary intervention being evaluated for efficacy and safety in eyebrow lifting.
62242620|NCT01636791|ACTIVE_COMPARATOR|Cognitive Behavior Therapy|As the trial will include several different common mental disorders, the cognitive behavior therapy used in the study will be based on the protocols with best empirical support. Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
62242621|NCT01636791|EXPERIMENTAL|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
62818901|NCT05595486|NO_INTERVENTION|Usual Care|As a pragmatic trial, usual care will be defined by contemporary clinical standards. For maternal care, this includes a comprehensive medical visit between 4-12 weeks postpartum. This visit includes utilization of a validated screen for postpartum depression and, if that screen is positive, a clinical assessment and initiation of treatment (e.g. pharmacotherapy or referral for psychotherapy). In addition, this visit includes a discussion of contraception as well as supportive education on breastfeeding. For paternal care, clinical standards are gleaned from the AAP, ACOG, and USPSTF reports outlining mental health screening, reproductive health, and vaccine uptake. For infant care, standard pediatric care from the AAP and Bright Futures periodicity timeline and guidelines will be used. In addition, assignment in this arm will be given surveys at baseline, 1M, 2M, 4M, 6M, and 12M.
62242622|NCT01636791|EXPERIMENTAL|CBT and Return to work|Participants randomized to this arm will receive a combination of cognitive behavior therapy and the return to work treatment. This arm is included in the study as the clinically most relevant therapy, would the return to work treatment be effective in reducing sick leave, is a treatment were patients are provided support to return to work but also is clinically effective in reducing psychiatric symptoms.
62432911|NCT00933660|NO_INTERVENTION|Control-2|No intervention
62599726|NCT00783315|EXPERIMENTAL|3|In-Person Directed (IPD) Weight Loss Program
62599727|NCT03743103|EXPERIMENTAL|Brevibloc, 10 Mg/mL Intravenous Solution|10 mL/h every 5 minutes until reaching the pressure target
62818902|NCT05595486|EXPERIMENTAL|Baby2Home Intervention|Families randomized to the intervention arm will receive the B2H services. B2H is a novel digitized CC-based intervention delivered via a smartphone app available on iOS or Android phones, built by combining two successful programs: NICU2Home+ app and CC services. Using the UCD methodologies, AI-based communication within the app will include education for mothers and fathers on the standard of care regarding self-care and newborn care after hospital discharge as well as education, reminders and scheduling for recommended preventative healthcare services for themselves and their new infant.
62599728|NCT03743103|ACTIVE_COMPARATOR|Nitroprusside, Sodium|0.5 mcg / kg / min every 3 minutes until reaching the pressure target
62599729|NCT05961410|EXPERIMENTAL|Eltrombopag|ESHAP + Eltrombopag as peripheral blood stem cell mobilization
62599730|NCT04643418|EXPERIMENTAL|MPB-1734, single arm, dose escalation|intravenous, once per 3 weeks, starting at 10 mg/m˄2
62599731|NCT06620224|EXPERIMENTAL|Participant wear the Virtual Reality system|Establish a virtual reality acupuncture system, and introduce the technology acceptance model to systematically explore the effectiveness of acupuncture treatment and its related impact on the patient experience and doctor-patient interaction,
62039448|NCT06724510|NO_INTERVENTION|No Treatment|This arm does not receive any treatment, serving as a comparison group to evaluate the efficacy of the investigational device.
62039449|NCT06285877|ACTIVE_COMPARATOR|Control Group|Control Group (CG) which received their usual sessions of conventional therapy.
62039450|NCT06285877|EXPERIMENTAL|Experimental Group|Experimental Group (EG) which received therapy with Nintendo Switch plus their usual sessions of conventional therapy.
62432912|NCT00933660|EXPERIMENTAL|Experimental-1|Web-based training only
62432913|NCT00933660|EXPERIMENTAL|Experimental-2|Web-based training with a personal training manikin
62599732|NCT01726387|EXPERIMENTAL|Psychosocial Counseling|A Counseling Assistant offers a low-threshold intervention (self-management support, counseling, active guidance). This nurse practitioner collaborates extensively with the general practitioner, re-adjusting the intervention in order to meet the patient's needs.
62599733|NCT01726387|PLACEBO_COMPARATOR|Usual Care|Depending on the conditions, patients get usual care of their general practitioner.
62599734|NCT01668524|EXPERIMENTAL|Single Arm: ATS907|Single-cohort, dose-escalation
62599735|NCT01609634|ACTIVE_COMPARATOR|Key Group of interest|Subjects who started test product / control product 1 / control product 2 by 1-month of age
62242623|NCT06441890|OTHER|Single Treatment Arm|"One of the following Taxane options below per physician's choice~* Paclitaxel 80mg/m2 IV D1, 8, 15 Q21 days~* Nab-paclitaxel1 125mg/m2 IV D1, 8, 15 Q21 days~* Docetaxel1 75mg/m2 IV D1 Q-21 days~* Trastuzumab2 8mg/kg loading, then 6mg/kg IV/SQ D1 Q21 days~* Pertuzumab2 840 mg loading, then 420mg IV/SQ D1 Q21 days~* 1 may be substituted for paclitaxel for patients intolerant to paclitaxel or the steroid premed regimen, or at investigator discretion~* 2 Pertuzumab, trastuzumab, and hyaluronidase injection for subcutaneous use may be substituted with dose per package insert"
62818903|NCT02669953||AMD patients previously teated with Lucentis|"Adults ≥ 50 years; Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS; Willingness and ability to comply with regular visits; Signed informed consent form;~The patient can take his medicine in the prescribed manner. The prescribed drugs do not constitute an exclusion criteria."
62818904|NCT02669953||treatment naive AMD patients|Adults ≥ 50 years; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
62818905|NCT02669953||DME patients previously teated with Lucentis|Adults ≥ 50 years; Patients who have been treated with ranibizumab due to DME for up to one year; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
62242624|NCT00613054|EXPERIMENTAL|Zactima + Gleevec + Hydrea|
62242625|NCT00146757|EXPERIMENTAL|Aldurazyme (rhIDU) 100 U/kg ONLY every week|Patients received Aldurazyme (recombinant human alpha-L-iduronidase (rhIDU)) once per week at a dose of 100 Units/kg (approximately 0.58 mg/kg) for up to 52 weeks - labeled dose.
62242626|NCT00146757|EXPERIMENTAL|Aldurazyme (rhIDU) 100-200 U/kg every week|After receiving 100 Units/kg dose of Aldurazyme (rhIDU) for the first 25 weeks, patients enrolling after January 1, 2004 were eligible to receive an increased dose of 200 Units/kg from Week 26 onwards if the patient's urinary glycosaminoglycan (uGAG) levels were \>200µg/mg creatinine at Week 22.
62039451|NCT06102057|ACTIVE_COMPARATOR|Conventional Arm|standard FDG-PET-based radiotherapy with concurrent standard of care chemotherapy
62242627|NCT00979251|EXPERIMENTAL|ADS-8902|Amantadine and Ribavirin administered with Oseltamivir phosphate
62242628|NCT00979251|ACTIVE_COMPARATOR|Comparator|Oseltamivir Phosphate
62599736|NCT01609634|ACTIVE_COMPARATOR|Other-fed Group|Subjects who started test product / control product 1 / control product 2 and continued on breast-feeding
62599737|NCT01609634|ACTIVE_COMPARATOR|Breast Fed Reference Group|Subjects who are exclusively breast-fed up to 4 months of age and not started on test product / control product 1 / control product 2.
62818906|NCT02669953||treatment naive DME patients|Adults ≥ 50 years; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
62039452|NCT06102057|EXPERIMENTAL|Experimental Arm|FDG-PET-based small volume accelerated radiotherapy with concurrent standard of care chemotherapy
62599738|NCT06252051|EXPERIMENTAL|Trivalent Vaccine|
62599739|NCT04395781||Control cases|Children who suspected COVID-19 cases but tested negative for COVID-19
62818907|NCT06207188||Observational|Patients undergo ultrasound imaging on study.
62039453|NCT06654089|EXPERIMENTAL|Emergen-C Core Super Orange Powder (Test Product)|Participants will be instructed to take the study product as per label instructions. Participants will consume one sachet of Emergen-C Core Super Orange Powder stirred in 4-6 ounces of water, orally, once daily for up to 12 weeks.
62599740|NCT04395781||Confirmed cases|Children who tested positive for COVID-19
62818908|NCT06270147|EXPERIMENTAL|Early TAP block|Patients in this group will receive TAP blocks at the beginning of the procedure
62242629|NCT02294123|EXPERIMENTAL|Diabetes (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
62242630|NCT02294123|EXPERIMENTAL|Overweight (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
62242631|NCT02294123|EXPERIMENTAL|Healthy (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
62242632|NCT04689997|EXPERIMENTAL|computerized Substance Brief Intervention cSBI|Enhanced care PCPs will address the serious morbidity of teen substance use during routine check-up visits using cSBI and follow up care using a new Module of CHADIS that facilitates guideline-based care. The CHADIS c-SBI Module will include pre-visit screening tools and embedded education that cover substance use and strengths and goals. It will also include reminders to the patient about their goals and commitments for change and teleprompted interview hints for the PCP. These hints will be aimed at enhancing a patient focused discussion of individual strengths and barriers related to the teens' goals in a motivational interviewing style.
62242633|NCT04689997|NO_INTERVENTION|Standard care|Standard care PCPs will screen using a standard SU tool and carry out their usual health supervision visits without additional decision support.
62039454|NCT06654089|PLACEBO_COMPARATOR|Placebo (Reference Product)|Participants will be instructed to take the study product as per label instructions. Participants will consume one sachet of placebo stirred in 4-6 ounces of water, orally, once daily for up to 12 weeks.
62039455|NCT02821767||Participants|subjects with diagnosed or undiagnosed ocular conditions and/or their first-degree relatives
62242634|NCT04583891|EXPERIMENTAL|IntelliCare|IntelliCare is a self-guided, fully automated suite of apps designed for brief, frequent check-ins to promote skill acquisition. IntelliCare has been shown in both general deployment and human-supported trials to be efficacious in reducing symptoms of depression and anxiety.
62599741|NCT00773578||1|atopic asthmatic children exposed to environmental tobacco smoke
62599742|NCT00773578||2|atopic asthmatic children unexposed to environmental tobacco smoke
62599743|NCT05603195|EXPERIMENTAL|Cohort 1 Lowest IV Dose|Randomized 3:1
62599744|NCT05603195|EXPERIMENTAL|Cohort 2 Low IV Dose|Randomized 3:1
62599745|NCT05603195|EXPERIMENTAL|Cohort 3 Mid IV Dose|Randomized 3:1
62599746|NCT05603195|EXPERIMENTAL|Cohort 4 High IV Dose|Randomized 3:1
62818909|NCT06270147|ACTIVE_COMPARATOR|Late TAP block|Patients in this group will receive TAP blocks at the end of their procedure, which is the current standard practice.
62818910|NCT05237960|EXPERIMENTAL|Arm I (extended release metformin)|Patients receive extended release metformin hydrochloride PO QD for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients will also undergo biopsies and blood collections on study.
62818911|NCT05237960|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive a placebo PO QD for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients will also undergo biopsies and blood collections on study.
62242635|NCT04583891|ACTIVE_COMPARATOR|Patient Education|The patient education app will contain psychoeducational information about distress prevalence and distress management. It will serve as an active control condition to compare with the IntelliCare apps.
62599747|NCT05603195|EXPERIMENTAL|Cohort 5 Higher IV Dose|Randomized 3:1
62818912|NCT04771494|EXPERIMENTAL|Trained|Participants with at least 6 months of training with unstable devices
62818913|NCT04771494|EXPERIMENTAL|Untrained|Participants with no previous instability experience
62242636|NCT06552299|EXPERIMENTAL|Laypersons|Adult laypersons without cardiopulmonary resuscitation training within 2 years.
62242637|NCT06552299|ACTIVE_COMPARATOR|Health-Care Providers|Adult health-care providers (doctors, nurses and emergency medical technicians).
62242638|NCT01674712|EXPERIMENTAL|Fenofibrate/simvastatin 145/20 mg|
62242639|NCT01674712|ACTIVE_COMPARATOR|Simvastatin 20 mg|
62432914|NCT03151499|EXPERIMENTAL|BI 409306 (R), then BI 409306 after pretreatment with rifampicin (T)|"Subjects were administered during Period 1 on Day 1/Visit 2 a single dose of 50 milligrams (mg) of BI 409306 film-coated tablet orally with 240 millilitre (mL) of water (reference treatment, R).~On Days -7 to -1 /Visit 3 of Period 2 participants were administered rifampicin 600 mg Eremfat® film-coated tablet orally with 240 mL of water once per day during the evenings. Afterwards on Day 1/Visit 3, participants were administered a single dose of 50 mg BI 409306 orally approximately 14 hours after the last rifampicin dose (test treatment, T).~Due to the short half-life of BI 409306, trial period 2 directly followed trial period 1 without a wash-out period."
62432915|NCT02841540|EXPERIMENTAL|H3B-8800 (RVT-2001) Dose Escalation|H3B-8800 Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes/ Low Risk Myelodysplastic Syndromes/ Chronic Myelomonocytic Leukemia.
62432916|NCT02841540|EXPERIMENTAL|H3B-8800 (RVT-2001) MDS Expansion|Transfusion-dependent, lower-risk MDS subjects (very-low to intermediate risk categorization per IPSS-R) with missense mutations in SF3B1.
62432917|NCT02841540|EXPERIMENTAL|H3B-8800 (RVT-2001) Dose Optimization|Transfusion-dependent, lower-risk MDS subjects (very-low to intermediate risk categorization per IPSS-R) with missense mutations in SF3B1, and who have not been exposed to HMA's or lenalidomide in a prior line of therapy.
62432918|NCT02734615|EXPERIMENTAL|Arm A|Patients will get LSZ102 single agent during dose escalation.
62432919|NCT02734615|EXPERIMENTAL|Arm B|Patients will get LSZ102 in combination with LEE011 during dose escalation.
62432920|NCT02734615|EXPERIMENTAL|Arm C|Patients will get LSZ102 in combination with BYL719 during dose escalation.
62432921|NCT02734615|EXPERIMENTAL|Arm 1|Patients will get LSZ102 single agent during dose expansion
62432922|NCT02734615|EXPERIMENTAL|Arm 2|Patients will get LSZ102 + LEE011 (LEE011 intermittent regimen) during dose expansion
62432923|NCT02734615|EXPERIMENTAL|Arm 3|Patients will get LSZ102 + LEE011 (LEE011 continuous regimen) during dose expansion
62432924|NCT02734615|EXPERIMENTAL|Arm 4|Patient will get LSZ102 in combination with BYL719 during dose expansion
62432925|NCT05669196||standard thoracotomy group|Individuals who are between the ages of 18-75 and lung cancer patient, underwent lobectomy with standard thoracotomy
62432926|NCT05669196||muscle sparing thoracotomy group|Individuals who are between the ages of 18-75 and lung cancer patient, underwent lobectomy with muscle sparing thoracotomy
62242640|NCT01674712|ACTIVE_COMPARATOR|Fenofibrate 145 mg|
62242641|NCT01674712|EXPERIMENTAL|Fenofibrate/simvastatin 145/40 mg|
62432927|NCT05669196||VATS group|Individuals who are between the ages of 18-75 and lung cancer patient, underwent lobectomy with video-assisted thoracic surgery
62432928|NCT01511900|EXPERIMENTAL|Cohort 1: Dose level 1|Multiple dose orally: CAT-1004 Dose level 1 or placebo
62432929|NCT01511900|EXPERIMENTAL|Cohort 2: Dose level 2|Multiple dose orally: CAT-1004 Dose level 2 or placebo
62432930|NCT01511900|EXPERIMENTAL|Cohort 3: Dose level 3|Multiple dose orally: CAT-1004 Dose level 3 or placebo
62242642|NCT01674712|ACTIVE_COMPARATOR|Simvastatin 40 mg|
62432931|NCT01511900|EXPERIMENTAL|Cohort 4: Dose level 4|Multiple dose orally: CAT-1004 Dose level 4 or placebo
62432932|NCT01511900|EXPERIMENTAL|Cohort 5: Dose level TBD|Multiple dose orally: CAT-1004 Dose level TBD or placebo
62432933|NCT00839020|ACTIVE_COMPARATOR|1|Navigated total knee arthroplasty with a minimally invasive approach
62432934|NCT00839020|ACTIVE_COMPARATOR|2|Navigated total knee arthroplasty with a conventional approach
62432935|NCT04904432|OTHER|young ACS patients|
62432936|NCT05460026|ACTIVE_COMPARATOR|Group A|Routine physical therapy will be given to the participants of group A
62432937|NCT05460026|EXPERIMENTAL|Group B|Powerball exercises with routine physical therapy will be given to the participants of group B
62432938|NCT02778568|EXPERIMENTAL|Resistance Training|Patients performed resistance exercises
62432939|NCT02778568|ACTIVE_COMPARATOR|Control|Patients who performed flexibility exercise
62432940|NCT05388188||Sickle Cell Disease Vaso-Occlusive (SCD VOC) crisis|Adult patients with known sickle cell disease present in the ED with a SCD VOC and ED provider has ordered as part of the patient's standard of care, sublingual opioid called sufentanil \[Dsuvia\] (a strong pain medicine that dissolves under your tongue) for the patient.
62599748|NCT05603195|EXPERIMENTAL|Cohort 6 High SC Dose|Randomized 3:1
62599749|NCT05603195|EXPERIMENTAL|Cohort 7 Higher SC Dose|Randomized 3:1
62599750|NCT05603195|EXPERIMENTAL|Optional: Cohort 8 Highest IV or SC Dose|Randomized 3:1
62599751|NCT05603195|EXPERIMENTAL|Cohort 9 High SC Dose|Randomized 3:1
62599752|NCT05603195|EXPERIMENTAL|Optional: Cohort 10 Highest SC Dose|Randomized 3:1
62818914|NCT06027580||SPIO group|Standard Care Therapy option 1: parents may self-select this standard care combined option of therapy and use of SPIO® Core-MAX® Expedition thoracolumbosacral orthosis
62818915|NCT06027580||Control group|Standard Care Therapy option 2: parents may self-select this standard care option of therapy alone
62242643|NCT01762176|ACTIVE_COMPARATOR|Usual care group|Usual care
62818916|NCT05096195|EXPERIMENTAL|Intervention|60 mg of denosumab (Prolia) will be administered every 6 months over a 15 - month period. Monitoring of serum calcium and phosphate will occur and bloodwork will be drawn for 7 weeks following each denosumab injection. Correction of vitamin D deficiency (if required), the adjustment of calcium dialysate and the provision of intravenous (IV) or oral (po) calcitriol/calcidiol will be administered as needed following each denosumab injection as described in the Beside Protocol. Once the study monitoring period is over, serum calcium monitoring and management will occur as per routine care in the dialysis centre. All intervention activities will occur during regularly scheduled hemodyalisis sessions.
62242644|NCT01762176|ACTIVE_COMPARATOR|Intensive care group|Protocolized intensive treatment
62242645|NCT01793363|EXPERIMENTAL|tracheotomized patients|
62242646|NCT01230554|EXPERIMENTAL|Prism I|Bausch \& Lomb daily disposable cosmetic tint contact lens
62818917|NCT05096195|NO_INTERVENTION|Usual care|Usual care participants will continue to receive the typical standard of care in their dialysis unit which includes their routine dialysis monitoring and bloodwork. They will not receive denosumab, calcium and vitamin prophylaxis. There will be no extra monitoring or bloodwork.
62818918|NCT05006352|EXPERIMENTAL|DNL343 (High Dose)|
62818919|NCT05006352|EXPERIMENTAL|DNL343 (Low Dose)|
62818920|NCT05006352|PLACEBO_COMPARATOR|Placebo|
62818921|NCT04325789|NO_INTERVENTION|Group 1 Control|Group 1 will serve as the control and undergo routine rotator cuff repair with suture anchors without the nanofiber scaffold.
62818922|NCT04325789|ACTIVE_COMPARATOR|Group 2 Scaffold|Group 2 will undergo rotator cuff repair with suture anchors and incorporation of the nanofiber scaffold.
62242647|NCT04858906|ACTIVE_COMPARATOR|from neutral to sniffing position|The patients in this group will be assessed firstly in the neutral position then subsequently in the sniffing position.
62242648|NCT04858906|ACTIVE_COMPARATOR|from sniffing position to neutral position|The patients in this group will be assessed firstly in the sniffing position then subsequently in the neutral position.
62242649|NCT06495385||Study group|Full participation (medical + dietitian+ specialist nurse)
62242650|NCT06495385||Control 1|Partial participation (medical+ dietitian OR specialist nurse)
62818923|NCT04523714|ACTIVE_COMPARATOR|Online CBT-CP based program|Self-completed, online program in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills (no usual care services restricted)
62242651|NCT06495385||Control 2|No participation (medical visit only)
62242652|NCT06719544|EXPERIMENTAL|Lithium Carbonate|On Day 1 of Period 1, a single oral dose of lithium carbonate will be administered.
62242653|NCT06719544|EXPERIMENTAL|Enlicitide with Lithium Carbonate|On Day 1 of Period 2, a single oral dose of lithium carbonate will be coadministered with a single oral dose of enlicitide.
62242654|NCT04942028|EXPERIMENTAL|Internet-delivered exposure-based treatment|10 weeks of therapist-guided exposure-based treatment delivered via the Internet.
62242655|NCT04942028|ACTIVE_COMPARATOR|Internet-delivered standardized education and prolonged assessment|10 weeks of therapist-guided intervention based on prolonged assessment and routine care educational material delivered via the Internet.
62242656|NCT00642551|ACTIVE_COMPARATOR|MK-7|1 capsule per day existing of 180 µg menaquinone-7
62242657|NCT00642551|PLACEBO_COMPARATOR|Placebo|1 placebo capsule per day for three years
62242658|NCT05922020|ACTIVE_COMPARATOR|"Conservative O2"|During the first treatment session, which will last for 40 minutes, O2 supplementation will be titrated to an SpO2 between 90% and 94%.
62242659|NCT05922020|EXPERIMENTAL|"Liberal O2"|During the second treatment session, which will last for 40 minutes, O2 supplementation will be titrated to an SpO2 \> 96%.
62242660|NCT06634680||Group Child Preference|The children will prefer parents (mother or father) who will accompany them in the preoperative holding area and at induction.
62242661|NCT06634680||Group Both Parents|Both parents will accompany the child in the preoperative holding area and at induction.
62242662|NCT06629506|EXPERIMENTAL|Subjects with tunneling and/or undermining wounds|MicroMatrix Flex, MicroMatrix UBM Particulate, and Cytal Wound Matrix 2-Layer will be used to treat the wound.
62242663|NCT06717399|EXPERIMENTAL|Eight- session of mindfulness meditation|Each mindfulness meditation session will be 30 minutes long, consisting of a 5-minute introduction, 15 minutes of guided mindfulness meditation, and 10 minutes of educational discussion. Participants are required to complete two mindfulness meditation sessions per week. Participants must complete a minimum of 8 sessions over 4 to 5 weeks.
62242664|NCT03427125|EXPERIMENTAL|Tenapanor 10 mg, 20 mg, 30 mg BID|During the 26-week open label part, all enrolled subjects will receive 30 mg BID doses of tenapanor. Investigators may decrease or increase the dose in 10 mg increments to a minimum of 10 g BIDor a maximum of 30 mg BID
62242665|NCT03427125|PLACEBO_COMPARATOR|Placebo|Placebo
62432941|NCT05388188||Historical Sample|collection of retrospective data of SCD VOC patients.
62818924|NCT04523714|ACTIVE_COMPARATOR|Virtual coach-led CBT-CP based program|Live, coach-led program delivered by telephone or videoconference in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills (no usual care services restricted)
62818925|NCT04523714|NO_INTERVENTION|Usual Care plus information|Receipt of a bound copy of the 2020 edition of the American Chronic Pain Association Resource Guide to Chronic Pain Management and any pharmacologic and nonpharmacologic treatments available to them without restriction
62818926|NCT05236556|EXPERIMENTAL|Intervention|Receive best practice advisory (BPA)
62818927|NCT05236556|NO_INTERVENTION|Control|Does not receive best practice advisory (BPA)
62818928|NCT02615600|EXPERIMENTAL|lf-tRNS|Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): \<100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
62818929|NCT06702410|EXPERIMENTAL|the adapted mhGAP-IG|mhGAP-IG-based CMBDs mental health services (including screening, management and follow-up) delivered by trained kindergarten teachers
62818930|NCT03949569|EXPERIMENTAL|Arm 1|In this condition, children will interact with the therapy dog prior to the psychosocial stress task and with the stuffed toy dog prior to the prosocial behavior tests.
62818931|NCT03949569|EXPERIMENTAL|Arm 2|In this condition, children will interact with the stuffed toy prior to the psychosocial stress task collection and with the therapy dog prior to the prosocial behavior tests.
62818932|NCT03949569|EXPERIMENTAL|Arm 3|In this condition, children will watch a 5 minute puppy video prior to the psychosocial stress task collection and with the therapy dog prior to the prosocial behavior tests.
62242666|NCT03427125|ACTIVE_COMPARATOR|Sevelamer Carbonate|Subjects randomized into the active control group, for safety analysis, will receive sevelamer carbonate, open label, for the entire 52-week study period. Sevelamer carbonate will be dosed based on package insert instructions (standard of care)
62242667|NCT06198842|EXPERIMENTAL|intervention/treatment|Fludarabine 150mg/m2 (days -6, -5, -4, -3, -2) Treosulfan 21g/m2 (days -6, -5, -4) Thymoglobulin (Genzyme) 5mg/kg (days -5, -4) Rituximab 100mg/m2 (day -1) Cyclophosphamide 50mg/kg (days +3, +4)
62242668|NCT06589258|OTHER|breastfeeding mothers with CBD's consumption|Determination of delta 9-tetrahydrocannabinol (THC) and its metabolites , and of cannabidiol and its metabolites in blood and breast-milk by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Realization of THC/CBD ratio; qualitative research in mother's and breast-fed child's urine for the presence of cannabinoids (THC, CBD and its metabolites).
62242669|NCT01983397|EXPERIMENTAL|Resistance training|Resistance training
62242670|NCT01983397|EXPERIMENTAL|Multicomponent training|Multicomponent training
62432942|NCT01137409||Suspected or Diagnosed with Coronary artery disease|All patients with suspected or previously diagnosed coronary artery disease
62039456|NCT01886898|PLACEBO_COMPARATOR|Standard starter infant formula|starter infant formula from enrollment till 16 weeks of age
62242671|NCT01983397|NO_INTERVENTION|Control Group|The Control Group did not realize any intervention.
62242672|NCT00129623|EXPERIMENTAL|1|
62039457|NCT01886898|EXPERIMENTAL|starter infant formula with prebiotics|starter infant formula from enrollment till 16 weeks of age
62242673|NCT00129623|PLACEBO_COMPARATOR|2|
62242674|NCT03875287|EXPERIMENTAL|Decitabine and Cedazuridine|Treatment will be administered on an outpatient basis. Cycle length is 28 days. The dose of cedazuridine is fixed at 100mg and the dose and duration of decitabine will vary depending on when a patient enters the study.
62432943|NCT06039787|EXPERIMENTAL|moderate intensity continuous training|
62432944|NCT06039787|EXPERIMENTAL|High-intensity interval training|
62432945|NCT06039787|PLACEBO_COMPARATOR|Waiting condition|
62432946|NCT02087579|EXPERIMENTAL|Cohort A: Aripiprazole|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
62599753|NCT03398512|EXPERIMENTAL|Experimental|HIPEC with Raltitrexed at the time of fist surgery and twice repeat within one week after the surgery, following 3 cycles of 3-week Oxaliplatin/Capecitabine chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.
62818933|NCT06387264|EXPERIMENTAL|Medical Adhesive treatment group|
62818934|NCT06387264|ACTIVE_COMPARATOR|Endovenous Radiofrequency Ablation Catheter|
62818935|NCT05131165|NO_INTERVENTION|Control|This arm will receive care as usual, including the adherence support mechanisms that are part of usual care practices. At recruitment participant will be explained the importance of pill-taking. All participants (including in the control group) will receive a leaflet containing detailed information on how to establish healthy pill-taking routines. Finally, clinic staff will counsel participants on how to select an already regularly routine behavior that occurs at roughly the same time each day that forms the basis of their implementation plan.
62818936|NCT05131165|EXPERIMENTAL|Intervention group receiving messages (Messages Group)|"Participants will receive the same information as those in the Control Group, but in addition, receive the Daily Text Message Intervention."
62818937|NCT05131165|EXPERIMENTAL|Intervention group receiving messages and incentives (Incentives Group)|"Participants will receive the same information as the Control group. Additionally, they will receive the Daily Text Message Intervention and will be eligible for prize drawings."
62818938|NCT05107336|EXPERIMENTAL|Cohort 1: AZD2693|Japanese Participants will receive Dose A of AZD2693.
62818939|NCT05107336|EXPERIMENTAL|Cohort 2: AZD2693|Japanese Participants will receive Dose B of AZD2693.
62818940|NCT05107336|EXPERIMENTAL|Cohort 3: AZD2693|Japanese Participants will receive Dose C of AZD2693.
62818941|NCT05107336|EXPERIMENTAL|Cohort 4: AZD2693|Non-Asian Participants will receive Dose C of AZD2693
62818942|NCT05107336|PLACEBO_COMPARATOR|Placebo|Japanese and Non-Asian Participants will receive placebo matching Dose A, B, and C to AZD2693.
62818943|NCT01692561||normaL|Healthy subjects without symptoms of dysautonomia.
62818944|NCT01692561||Neurocardiogenic syncope|Fainting due to sudden drop in blood pressure.
62242675|NCT02616666|EXPERIMENTAL|Dapagliflozin 10 mg|Patients will be randomized to receive either dapagliflozin or SOC. As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs). Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
62432947|NCT02087579|EXPERIMENTAL|Cohort B: Olanzapine|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
62432948|NCT02087579|EXPERIMENTAL|Cohort C: Paliperidone|Administration of prolonged-release (extended-release) tablets or long-acting injectables (LAI) will continue at a participant's usual dose and dosing schedule.
62818945|NCT01692561||Orthostatic hypotension|Sudden decrease in blood pressure while standing.
62039458|NCT01886898|EXPERIMENTAL|starter infant formula with pro and prebiotics|starter infant formula from enrollment till 16 weeks of age
62432949|NCT02087579|EXPERIMENTAL|Cohort D: Quetiapine|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
62432950|NCT02087579|EXPERIMENTAL|Cohort E: Risperidone|Administration of oral formulation or LAI will continue at a participant's usual dose and dosing schedule.
62432951|NCT00367666|EXPERIMENTAL|Patients Diagnosed with Breast Cancer|
62432952|NCT03665571||Conventional Activation method|NK cell was incubated with either K562 cells
62432953|NCT03665571||Receptor specific activation method|NK cell was incubated with P815-ULBP1+CD48 cells that trigger NK cell synergy via NKG2D and 2B4
62432954|NCT03808220||post-surgical patients|post-surgical patients \> 18 years
62432955|NCT03808220||pediatric patients post-op day 1|pediatric patients \> 4 years on post-op day 1 (sub-project QUIPSI - PAIN OUTinfant)
62432956|NCT03627195|EXPERIMENTAL|DSP-1349M|Lurasidone injection suspension (30 mg, 75 mg, 150 mg, 300 mg, and 450 mg)
62432957|NCT03627195|PLACEBO_COMPARATOR|Placbo|placebo injection
62432958|NCT02768142|EXPERIMENTAL|Natural cesarean delivery|Placing the neonate on maternal chest immediately after the extraction from the uterus, and permitting breastfeeding during surgery.
62432959|NCT02768142|ACTIVE_COMPARATOR|Standard cesarean delivery|Presentation of the neonate to the mother during the operation.
62432960|NCT00686790|EXPERIMENTAL|PegIntron|All participants received PegIntron (Peginterferon alfa-2b) weekly based on their body weight.
62432961|NCT01583751|EXPERIMENTAL|control|excision and primer repair surgical technique will be perform
62432962|NCT02442882||Boxers|Individuals who participate in a boxing tournament will be tested on balance, neuropsychological, and visual functions before and after the tournament.
62432963|NCT04857216||Infraclavicular Group|Block Characteristics of Ultrasound Guided Infraclavicular Block with the Perfusion Index
62432964|NCT04857216||Costoclavicular Group|Block Characteristics of Ultrasound Guided costoclavicular Block with the Perfusion Index
62039459|NCT01886898|OTHER|breastfeeding group|exclusively breastfeeding during the first 16 weeks of age
62039460|NCT03158883|EXPERIMENTAL|Non-responders|"Patients who initially progress at first response assessment on a PD-1 inhibitor will be enrolled to the non-responder arm.~* Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 \[±2\] days).~* Stereotactic ablative radiotherapy (SAR): the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated."
62432965|NCT05309837|ACTIVE_COMPARATOR|Polydextrose (PDX)|Subject consumed a daily dose of 18g polydextrose enriched drink mixtures and biscuits (12 g from the drink mixtures and 6 g from the biscuits) providing 16.2 g dietary fibre/d.
62432966|NCT05309837|PLACEBO_COMPARATOR|Control (CON)|Subjects consumed placebo products, where maltodextrin replaced PDX and differed only in the amount of fibre per gram (1.7 g).
62432967|NCT03908983|EXPERIMENTAL|Implanted Patients|Implantation of Kalios Device
62432968|NCT02020733|OTHER|balloon catheter|
62432969|NCT02020733|OTHER|metal cannula|
62432970|NCT00720733|EXPERIMENTAL|1|Skills Building Group
62432971|NCT00720733|ACTIVE_COMPARATOR|2|Personal Interview Group
62432972|NCT02328547|EXPERIMENTAL|FMT capsules|Intervention: Fecal microbiota transplantation capsules containing extensively screened donor stool, prepared by OpenBiome, Medford, MA. 25 FMT capsules will be take on three consecutive days.
62818946|NCT01692561||Postural Orthostatic Tachycardic Syndrome|Increased heart rate when standing.
62818947|NCT06203054|EXPERIMENTAL|Penditure™ Left Atrial Appendage (LAA) Exclusion System|Penditure™ Left Atrial Appendage (LAA) Exclusion System
62242676|NCT02616666|ACTIVE_COMPARATOR|Standard of Care (SOC)|Patients will be randomized to receive either dapagliflozin or SOC. As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs). Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
62242677|NCT05207735|EXPERIMENTAL|GROUP 1|"Sintilizumab, 200 mg, intravenous infusion, a treatment cycle every 3 weeks, administration on the first day of each cycle, 6 cycles.~Capecitabine: 1250 mg/m2, orally, twice a day, 1-14 days, one treatment cycle every three weeks, 8 cycles."
62242678|NCT01765868|EXPERIMENTAL|Single Arm Oral and IV Betrixaban|
62242679|NCT02185209|EXPERIMENTAL|Placebo|Patients with periimplantitis undergoing surgical treatment with will receive placebo three times daily (TID)
62242680|NCT02185209|ACTIVE_COMPARATOR|amoxicillin + metronidazole|Patients with periimplantitis undergoing surgical treatment with amoxicillin (500 mg TID) + metronidazole (400 mg TID) for 7 days
62242681|NCT02185209|ACTIVE_COMPARATOR|phenoxymetylpencillin + metronidazol|Patients with periimplantitis undergoing surgical treatment with phenoxymetylpencillin, (800mg×2 TID) + metronidazol (400 mg TID) for 7 days
62242682|NCT02330510||Alzheimer's Disease|Individuals with early Alzheimer's Disease (AD) or amnestic or multi-domain Mild Cognitive Impairment who have extensive Periventricular White Matter Hyperintensities
62242683|NCT02330510||Transient Ischemic Attack/Mild Subcortical Stroke|Individuals who have had a mild subcortical stroke or a Transient Ischemic Attack (TIA) with extensive Periventricular White Matter Hyperintensities in the absence of cortical infarcts
62242684|NCT00517777|EXPERIMENTAL|1|continuous positive airway pressure ventilation + dietary and life style recommendations
62242685|NCT00517777|ACTIVE_COMPARATOR|2|dietary and life style recommendations
62242686|NCT01292798|EXPERIMENTAL|0.5mg and 2.0mgRanibizumab|Three consecutive intravitreal ranibizumab 0.5mg injections followed by three consecutive intravitreal ranibizumab 2.0mg injections if specific criteria is met.
62242687|NCT01428661|EXPERIMENTAL|tasimelteon|
62242688|NCT01428661|PLACEBO_COMPARATOR|placebo|
62432973|NCT02328547|PLACEBO_COMPARATOR|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug, prepared by OpenBiome, Medford, MA. 25 placebo capsules will be taken on three consecutive days.
62432974|NCT04310748|ACTIVE_COMPARATOR|Total Intravenous Anesthesia(TIVA)|Anesthesia is maintaining with TIVA (Group 1)
62242689|NCT04895072|ACTIVE_COMPARATOR|Standard group|standard injection rate will be applied
62242690|NCT04895072|ACTIVE_COMPARATOR|Long group|long injection rate will be applied
62242691|NCT02212873|NO_INTERVENTION|Control|Equal number of age-matched overweight and obese students will be selected from a control school. There will be no intervention, and students will participate in their usual health and physical education classes plus any other curriculum activities provided by the school.
62242692|NCT02212873|EXPERIMENTAL|MyBFF@school program|Students will participate in all 3 components of MyFF@school for a total of 32 weeks; 1-hour of SSG thrice weekly plus 30 to 45 minutes of either nutrition or psychology classes once a week. All students including those in the control arm will be assessed at baseline, week-16 and at end of the study. They will undergo anthropometric measurements, body fat assessment, clinical examination and fitness test by modified Harvard step-test.
62432975|NCT04310748|ACTIVE_COMPARATOR|Inhalation Anesthesia|Anesthesia is maintaining with inhalation anesthesia (Group 2)
62432976|NCT00984906|OTHER|Empty Easyhaler type A|
62432977|NCT00984906|OTHER|Empty Easyhaler type B|
62432978|NCT00984906|OTHER|Empty Turbohaler|
62242693|NCT03423823|EXPERIMENTAL|Study Drug Arm|Receiving 1.25mg of 0.05mL of Ziv-aflibercept intravitreal injection every month
62242694|NCT03423823|OTHER|Control Arm|Receiving bevacizumab, ranibizumab, or aflibercept intravitreal injection every 5 to 12 weeks (varied intervals based on individual need for treatment)
62242695|NCT01410435|EXPERIMENTAL|Treatment|
62242696|NCT06735313|OTHER|Periodontally healthy, systemically healthy individual|Before starting the treatment of the patients and after each planned treatment, routine periodontal status records (periodontal pocket depths of the teeth, attachment losses, mobility levels, furcation defect degrees, bleeding index on probing, gingival index, plaque index, amount of keratinized gingiva, gingival recession, body/mass index) are taken and archived. In addition, sociodemographic data and brushing habits of each patient participating in the study are recorded. Saliva samples will also be collected from the patients before the treatment.
62432979|NCT01700920|EXPERIMENTAL|Mesenchymal Stem Cell|"Cell suspension mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They employ a minimum dose of 0.5 x 106 MSC / kg and a maximum of 1, 0x106 CSM / kg of patient weight.~Pharmaceutical form: Suspension cell Route of administration: local implant intraosseous injection with trocar in the femoral head."
62432980|NCT05864352||High TiO2 Consumer|Participants with an estimated TiO2 stool content greater than the cohort median content, μg/mg dry stool.
62432981|NCT05864352||Low TiO2 Consumer|Participants with an estimated TiO2 stool content less than the cohort median content, μg/mg dry stool.
62432982|NCT04452500|EXPERIMENTAL|CORT108297|CORT108297- 180mg daily for 7 days
62432983|NCT04452500|PLACEBO_COMPARATOR|Placebo|Placebo- 180mg daily for 7 days
62432984|NCT00916422|EXPERIMENTAL|Depigoid Phleum pratense 1000DPP/Ml|Depigmented and Polymerized Allergen extract of Phleum Pratense.Subcutaneous Immunotherapy in an up-dosing cluster regimen for 4 weeks, followed by monthly injections for 2 years.
62432985|NCT00916422|PLACEBO_COMPARATOR|2|Placebo. Dosing regimen: An up-dosing cluster regimen for 4 weeks, followed by monthly injections for 2 years
62432986|NCT01270373|ACTIVE_COMPARATOR|FAC x 3 followed by Docetaxel x 3|
62432987|NCT01270373|EXPERIMENTAL|Docetaxel x 3 followed by FAC x 3|
62432988|NCT04225273|EXPERIMENTAL|Investigational Arm in pivotal study- 43USSA1705|Injection with Sculptra Aesthetic reconstituted with 8ml Sterile Water for Injection
62242697|NCT06735313|ACTIVE_COMPARATOR|periodontally healthy individuals with type 2 diabetes|Before starting the treatment of the patients and after each planned treatment, routine periodontal status records (periodontal pocket depths of the teeth, attachment losses, mobility levels, furcation defect degrees, bleeding index on probing, gingival index, plaque index, amount of keratinized gingiva, gingival recession, body/mass index) are taken and archived. In addition, sociodemographic data and brushing habits of each patient participating in the study are recorded. Saliva samples will also be collected from the patients before the treatment.
62242698|NCT06735313|ACTIVE_COMPARATOR|Systemically healthy individual with periodontitis|Before starting the treatment of the patients and after each planned treatment, routine periodontal status records (periodontal pocket depths of the teeth, attachment losses, mobility levels, furcation defect degrees, bleeding index on probing, gingival index, plaque index, amount of keratinized gingiva, gingival recession, body/mass index) are taken and archived. In addition, sociodemographic data and brushing habits of each patient participating in the study are recorded. Saliva samples will also be collected from the patients before the treatment.
62242699|NCT06735313|ACTIVE_COMPARATOR|Individual with periodontitis and type 2 diabetes|Before starting the treatment of the patients and after each planned treatment, routine periodontal status records (periodontal pocket depths of the teeth, attachment losses, mobility levels, furcation defect degrees, bleeding index on probing, gingival index, plaque index, amount of keratinized gingiva, gingival recession, body/mass index) are taken and archived. In addition, sociodemographic data and brushing habits of each patient participating in the study are recorded. Saliva samples will also be collected from the patients before the treatment.
62242700|NCT00425880||Pregnant Asthmatics|
62242701|NCT00425880||Pregnant Smokers|
62242702|NCT00425880||Healthy Pregnant Controls|
62599754|NCT06647745|EXPERIMENTAL|Study group|The participant will receive the investigational drugs THP-00101 (Dapagliflozin 10 mg), THP-00102 (Telmisartan 80 mg), and a placebo for THP-00103 once a day by per oral over 12 weeks
62242703|NCT03838354|EXPERIMENTAL|A|Chidamide 2.5 mg po tiw
62242704|NCT03838354|EXPERIMENTAL|B|Chidamide 5 mg po tiw
62242705|NCT01791023|EXPERIMENTAL|Physical exercise|Physical exercise
62242706|NCT06431009||Schizophrenia|Patients with a SSD (ICD-10: F20-29) aged ≥15 years.
62242707|NCT06431009||Ultra High Risk|Patients at UHR (ICD: 1\*.5) aged ≥15 years.
62242708|NCT06166979|ACTIVE_COMPARATOR|Study Group A: Probiotic Micrococcus luteus Q24 serum (high dose)|Group A: Probiotic Micrococcus luteus Q24 serum (dose: 1e8 colony forming units per application)
62242709|NCT06166979|ACTIVE_COMPARATOR|Study Group B: Probiotic Micrococcus luteus Q24 serum (low dose)|Group : Probiotic Micrococcus luteus Q24 serum (dose: 1e6 colony forming units per application)
62242710|NCT05682079||children with cerebral palsy|"After recording demographic data, Trunk control measurement scale (TCMS) to evaluate trunk control, Gorge motor function classification system (GMFCS) to measure gross motor functions, Pediatric Disability Assessment Inventory (PDI) to evaluate activities of daily living, balance 'Pediatric Berg Balance Scale' was used to evaluate functional capacities and '2-minute walking test' was used to evaluate functional capacities. In addition, respiratory muscle strength was evaluated with maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) measurements."
62242711|NCT05682079||typical kids|"After recording demographic data, Trunk control measurement scale (TCMS) to evaluate trunk control, Gorge motor function classification system (GMFCS) to measure gross motor functions, Pediatric Disability Assessment Inventory (PDI) to evaluate activities of daily living, balance 'Pediatric Berg Balance Scale' was used to evaluate functional capacities and '2-minute walking test' was used to evaluate functional capacities. In addition, respiratory muscle strength was evaluated with maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) measurements."
62242712|NCT05026710|EXPERIMENTAL|Silicone (Coloplast Imajin Hydro) ureteral stent|
62599755|NCT06647745|PLACEBO_COMPARATOR|Control group 1|The participant will receive the investigational drugs THP-00101 (Dapagliflozin 10 mg), Placebo of THP-00102, and Placebo of THP-00103 once a day by per oral over 12 weeks
62599756|NCT06647745|PLACEBO_COMPARATOR|Control group 2|The participant will receive the investigational drugs Placebo of THP-00101, THP-00102 (Telmisartan 80 mg), and Placebo of THP-00103 once a day by per oral over 12 weeks
62242713|NCT05026710|EXPERIMENTAL|Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer).|
62242714|NCT03462472|EXPERIMENTAL|15 minute lower leg heating|
62242715|NCT03462472|EXPERIMENTAL|45 minute lower leg heating|
62242716|NCT03462472|NO_INTERVENTION|Control|
62242717|NCT03462472|EXPERIMENTAL|15 minute lower leg TENS|
62242718|NCT03462472|EXPERIMENTAL|45 minute lower leg TENS|
62242719|NCT05497648|EXPERIMENTAL|Choose to Move|Individuals responsible for delivering Choose to Move and older adults enrolled in Choose to Move
62242720|NCT00526981|EXPERIMENTAL|Treatment|Prone position + all conventional treatment.
62599757|NCT06647745|OTHER|Exploratory group|The participant will receive the investigational drugs THP-00101 (Dapagliflozin 10 mg), Placebo of THP-00102, and THP-00103 (Telmisartan 40 mg) once a day by per oral over 12 weeks
62599758|NCT02076737|EXPERIMENTAL|VEO|
62242721|NCT00526981|NO_INTERVENTION|Control|Conventional treatment
62818948|NCT05684055|ACTIVE_COMPARATOR|Intervention villages|CC-VHWs do screen, diagnosis, first-line aHT treatment for eligible participants, treatment monitoring at community-level (ComBaCaL app guides them to provide first-line antihypertensive SPCs to eligible individuals and treatment monitoring/ support to all individuals with aHT). CC- VHW offers lifestyle counselling, lipid -lowering treatment to participants with high CVD risk and antiplatelet treatment to participants with history of stroke/ myocardial infarction. Trained, supervised, mentored by chronic care nurses (CC nurses) and guided by the ComBaCaL app they follow-up persons with aHT to monitor adherence, life-style changes, treatment response, side-effects. TwiC 1: individuals with uncomplicated aHT (baseline BP above treatment targets) TwiC 2: individuals with uncomplicated pharmacologically controlled aHT. In case of complicated disease or presence of clinical alarm signs/ symptoms, participants are referred to the closest health facility for further investigation.
62818949|NCT05684055|ACTIVE_COMPARATOR|Control villages|"Control villages will follow the standard of care in the ComBaCaL cohort study. CC-VHWs will also receive tablets with the ComBaCaL app installed. They are trained, supervised and equipped to screen and diagnose aHT with subsequent referral to facility-based follow-up and care. In control villages the ComBaCaL app supports clinical decision making and documentation for screening, diagnosis and referral, but not prescription/ provision of antihypertensive or lipid-lowering medication.~TwiC 1: enrols individuals with uncomplicated aHT with baseline BP values above treatment targets.~TwiC 2: enrols individuals with uncomplicated pharmacologically controlled aHT.~In case of complicated hypertension or presence of clinical alarm signs or symptoms, participants will be immediately referred to the closest health facility for further investigation."
62818950|NCT04672642|EXPERIMENTAL|SpyGlass DS after endoscopic treatment|
62818951|NCT06330623||Phase 1 Cohort|"These participants will be recruited from:~* Previous research studies~* COPD nursing ward~* Pulmonary rehabilitation"
62818952|NCT06330623||Phase 2 Cohort|These participants will be recruited from the pulmonary rehabilitation service.
62818953|NCT04641442|EXPERIMENTAL|MAS825|Experimental drug
62818954|NCT04641442|PLACEBO_COMPARATOR|Placebo|matching placebo
62818955|NCT04540185|EXPERIMENTAL|Standard dose bivalent oral polio vaccine|Biological: oral polio vaccine Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
62242722|NCT01515293|EXPERIMENTAL|Single Incision Laparoscopic Appendectomy|
62242723|NCT01515293|EXPERIMENTAL|Conventional appendectomy|Conventional appendectomy
62242724|NCT00984490|EXPERIMENTAL|Metformin|Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery
62242725|NCT04562194|OTHER|Intervention|NeVa Stent Retriever
62242726|NCT02796001|ACTIVE_COMPARATOR|RV16 infected volunteers re-challenged with RV16|volunteers re-challenged with RV16
62818956|NCT04540185|PLACEBO_COMPARATOR|Comparable Placebo- 0.10 mg/kg|Saline administered orally on a sugar lump
62818957|NCT04540185|EXPERIMENTAL|Standard dose of NA-831|Drug: neuroprotection NA-831 30 mg of NA-831in a capsule administered orally
62818958|NCT04540185|PLACEBO_COMPARATOR|Comparable Placebo- 30mg|30 mg of placebo in a capsule administered orally
62818959|NCT04540185|EXPERIMENTAL|Standard dose of bivalent OPV and NA-831|Biological: oral polio vaccine Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump Plus 30 mg of neuroprotection drug NA-831 in a capsule administered orally
62242727|NCT02796001|ACTIVE_COMPARATOR|RV infected volunteers re-challenged with RV39|volunteers re-challenged with RV39
62242728|NCT02796001|OTHER|RV infected not rechallenged|Volunteers who were infected with RV16 and eligible for re-challenge but who were not re-challenged due to voluntary withdrawal (3) or removal for exclusion criteria
62242729|NCT01387048|EXPERIMENTAL|Skinoren gel 15 %, topical|primary treatment 12 weeks with Skinoren gel®, followed by maintenance therapy with Skinoren gel® for another 24 weeks,
62242730|NCT01387048|ACTIVE_COMPARATOR|Differin Gel 0.1%|primary 12 weeks therapy with Differin gel®, followed by maintenance therapy with Differin gel® for another 24 weeks.
62242731|NCT01387048|EXPERIMENTAL|Skinoren|primary 12 weeks therapy with Skinoren gel®, followed by observation only for another 24 weeks,
62432989|NCT00476684|EXPERIMENTAL|radiofrequency neurotomy|Radiofrequency-neurotomy of the medial branch at 80 degr. C for 70 seconds, after diagnostic blocks
62818960|NCT04540185|PLACEBO_COMPARATOR|Comparable Placebo|Placebo of a vaccine administered orally on a sugar lump Plus 30 mg of a placebo in a capsule administered orally
62818961|NCT04785300|EXPERIMENTAL|Dasatinib plus Quercetin Treatment Goup|Subjects with MCI or Alzheimer's disease will take Dasatinib and Quercetin by mouth at the same times for 2 days out of every 15 days for 6 cycles lasting for a total of 77 days (12 concurrent doses of each agent).
62818962|NCT05393791|EXPERIMENTAL|Experimental group|In the experimental group, treatment will be paused if there is a \>50% decline in baseline PSA. AA/ENZ will be restarted if the PSA rises to the same level or higher than the pre-treatment PSA. AA/ENZ treatment will be paused again after the PSA declines \>50% from the baseline. This pause/restart cycle of adaptive therapy will be repeated presuming consent, tolerance and safety. Patients who do not have a \>50% decline of their baseline PSA level after restarting AA/ENZ remain on treatment until the criteria for treatment failure are met.
62818963|NCT05393791|ACTIVE_COMPARATOR|Control group|In the control group, patients will receive the standard continuous treatment with abiraterone or enzalutamide (AA/ENZ) until criteria for treatment failure are met.
62242732|NCT06735651|EXPERIMENTAL|Wild Blueberry|22 g of freeze-dried wild blueberry freeze-dried powder per day
62242733|NCT06735651|PLACEBO_COMPARATOR|Placebo|22 g of freeze-dried macronutrient-matched placebo powder per day
62242734|NCT00680563|EXPERIMENTAL|1|
62242735|NCT03533595|NO_INTERVENTION|Standard Suture|Standard suture for thoracolumbar fusion will be used per standard of care.
62818964|NCT06704399|ACTIVE_COMPARATOR|psycoeducation|Psychoeducation based on acceptance and commitment therapy will be applied to the experimental group of 25 people. Pre-test, post-test and follow-up test will be applied.
62818965|NCT06704399|ACTIVE_COMPARATOR|control|No intervention will be applied to the control group of 25 people. Pre-test, post-test and follow-up test will be applied.
62818966|NCT05131204|EXPERIMENTAL|Pozelimab and Cemdisiran|Randomized 1:1
62818967|NCT05131204|EXPERIMENTAL|Anti-C5 standard-of-care|Randomized 1:1
62432990|NCT00476684|SHAM_COMPARATOR|sham controls|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
62818968|NCT05889728|EXPERIMENTAL|68Ga Bombesin PET/CT (NeoB) imaging for staging breast cancer|All patients will undergo a single time point imaging at Day 0 with PET CT to be conducted 120 (+/- 30) minutes after intravenous administration with 68Ga NeoB (3.0MBq/kg or up to a maximum of 250 Mbq).
62818969|NCT02938130||Wellness Programs|Community Partners and Community LIFE programs
62242736|NCT03533595|ACTIVE_COMPARATOR|Stratafix Barbed Suture|Stratafix Barbed Suture for thoracolumbar fusion will be used.
62432991|NCT06188481|OTHER|Intervention group with WB-EMS Training|The Intervention group receives 1.5 times a week WB-EMS training, wears an activity tracker for 16 weeks and completes 6 sessions of an evidence-based lifestyle education program.
62432992|NCT06188481|OTHER|Control group with activity tracker and evidence-based lifestyle education program|The control group wears an activity tracker for 16 weeks and completes 6 sessions of an evidence-based lifestyle education program.
62432993|NCT06188481|OTHER|Control group with evidence-based lifestyle education program|The control group completes 6 sessions of an evidence-based lifestyle education program.
62432994|NCT05737888|EXPERIMENTAL|fMRI Neurofeedback|The participants receive visual feedback (displayed on a screen) related to BOLD activity from their auditory cortices, and they are asked to learn to down-regulate it.
62432995|NCT05737888|EXPERIMENTAL|EEG Neurofeedback|The participants receive visual feedback (displayed on a screen) related to the ratio of alpha to delta localized activity from their auditory cortices, and they are asked to learn to up-regulate it.
62818970|NCT01593826|ACTIVE_COMPARATOR|Charcoal and Symbicort Turbuhaler|
62818971|NCT01593826|ACTIVE_COMPARATOR|Symbicort Turbuhaler|
62818972|NCT01593826|EXPERIMENTAL|Charcoal and Budesonide/formoterol Easyhaler|
62818973|NCT01593826|EXPERIMENTAL|Budesonide/formoterol Easyhaler|
62818974|NCT06425380|EXPERIMENTAL|Resistant potato starch|This will be taken for four weeks by enrolled participants.
62818975|NCT04575155|EXPERIMENTAL|TEAM Strategy|Patients randomized to the TEAM intervention arm will receive at least one call from a Walgreens pharmacist to help them with their complex Rx regimens. Pharmacists will have read/write EHR access with established Epic security points. Through shared access to patients' medical records, pharmacists can perform comprehensive medication therapy management services, document and communicate patients' Rx challenges for review and action by primary care providers. After the pharmacist calls the patient for a Comprehensive Medication Review, they will add notes in their medication list for the prescriber, requesting the removal or discontinuation of prescribed drugs that patients report they are not taking and adding medications omitted from the provider's list. The pharmacist will provide notifications via secured Epic messaging direct to prescribers of any patient concerns.The prescriber will make changes to the patient's EHR and/or contact the patient as they see fit.
62818976|NCT04575155|NO_INTERVENTION|Enhanced Usual Care|Patients randomized to enhanced usual care will have the medical record available to a Walgreens pharmacist with 'read only' access. All patients at the five targeted health centers already have read-only access in place. This means the Walgreens pharmacist will have the capability to review a patient's record as necessary. The pharmacist may refer to the EHR as needed and in a reactive manner; such as if a patient were to request a medication requiring review for billing purposes (i.e. verify insurance, prior authorizations), or if a patient safety concern was raised (e.g. potential drug-drug or drug- disease interaction, therapeutic duplication, etc.). Similarly, read only EHR access means pharmacists must continue to use existing communication channels (e.g. phone, fax) to contact prescribers.
62818977|NCT05182372|EXPERIMENTAL|Enhanced dCBT-I|This group will complete d-CBTI and be assigned a coach that will help with completion of the treatment and will be available to call personally to discuss questions and issues.
62818978|NCT05182372|NO_INTERVENTION|Control dCBT-I|Participants in this group will complete dCBT-I individually without assistance from a healthcare provider
62818979|NCT04982250|EXPERIMENTAL|"Formal peer PrEP referral + HIVST delivery"|After a brief training, young female PrEP users will be encouraged to refer up to 4 peers to PrEP using strategies gained from the training, PrEP educational materials (i.e., brochures), HIVST kits (2 kits/peer = 8 kits total), and Kenya MOH-style referral cards.
62818980|NCT04982250|NO_INTERVENTION|"Informal peer PrEP referral"|Young female PrEP users will be encouraged to refer 4 peers to PrEP using informal word-of-mouth recruitment strategies and Kenya MOH-style referral cards.
62818981|NCT04364867|EXPERIMENTAL|Exparel|Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine
62818982|NCT04364867|ACTIVE_COMPARATOR|Pain pump|Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the Post Anesthesia Care Unit infusing at 4cc/hr. The patient will go home with that device until it runs out.
62818983|NCT06589492|NO_INTERVENTION|CT scan|Chest high-resolution CT scan will be performed for diagnosis of patients.
62242737|NCT02221232|EXPERIMENTAL|ZuraPrep Config 1|Isopropyl alcohol (IPA) 70% Standard scrub time.
62242738|NCT02221232|EXPERIMENTAL|ZuraPrep Config 2|Isopropyl alcohol (IPA) 70% Half scrub time.
62242739|NCT02221232|PLACEBO_COMPARATOR|ZuraPrep Vehicle|ZuraPrep without IPA
62242740|NCT02221232|ACTIVE_COMPARATOR|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
62432996|NCT05737888|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Group therapy is provided by trained clinicians for research participants. Participants are confronted with tinnitus-inducting situations and trained to use diverse cognitive and behavioral coping skills to reduce the subjective impact of tinnitus burden. Such coping skills include relaxation, distraction, and de-catastrophizing, among other strategies.
62432997|NCT00528879|PLACEBO_COMPARATOR|Placebo + Metformin|Participants received dapagliflozin-matching placebo once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
62432998|NCT00528879|EXPERIMENTAL|Dapagliflozin, 2.5 mg + Metformin|Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
62432999|NCT00528879|EXPERIMENTAL|Dapagliflozin, 5 mg + Metformin|Participants received dapagliflozin, 5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
62433000|NCT00528879|EXPERIMENTAL|Dapagliflozin, 10 mg + Metformin|Participants received dapagliflozin, 10 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
62818984|NCT06589492|NO_INTERVENTION|Age, gender|Age and gender information of patients will be obtained for comparison.
62818985|NCT06589492|EXPERIMENTAL|Measurement of MMP-9 and SIRT-1 levels in blood serum|It involves taking 5ml of blood from participants to measure mmp-9 and SIRT-1 levels in blood serum.
62818986|NCT06022861|EXPERIMENTAL|LY01015+ Fluorouracil + Cisplatin|
62818987|NCT06022861|ACTIVE_COMPARATOR|Opdivo® + Fluorouracil + Cisplatin|
62818988|NCT03624881|EXPERIMENTAL|VISITAG SURPOINT Module with EPU|Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
62818989|NCT05531643|EXPERIMENTAL|Active TENS|TENS delivered for 20 minutes to the forehead via the active Cefaly (R) device; at least 3 times per week in-home; for 6 months.
62818990|NCT05531643|SHAM_COMPARATOR|Sham TENS|Sham TENS delivered for 20 minutes to the forehead via the sham Cefaly (R) device; at least 3 times per week in-home; for 6 months.
62818991|NCT06586697|EXPERIMENTAL|Thoracic Radiotherapy|Thoracic Radiotherapy (45Gy /1.5Gy/bid/3w)
62818992|NCT06547684|ACTIVE_COMPARATOR|GROUP 1|1 session of fESWT
62242741|NCT01817855|EXPERIMENTAL|1|"Groups 1-4 multiple ascending doses of AZD7624 Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.~COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 patients will receive matching placebo."
62433001|NCT00168337|EXPERIMENTAL|Dexamethasone 700 μg|700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
62433002|NCT00168337|EXPERIMENTAL|Dexamethasone 350 μg|350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
62433003|NCT00168337|SHAM_COMPARATOR|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
62433004|NCT00482287|OTHER|1|Dose level 0.3 mg/kg with 6 active and 2 placebo
62818993|NCT06547684|EXPERIMENTAL|GROUP 2|3 sessions of fESWT (1 session per week for 3 consecutive weeks)
62818994|NCT04017052|OTHER|Booster vaccination|Intervention = one i. m. TBE booster vaccination (FSME-Immun) at visit 1.
62818995|NCT04240210|NO_INTERVENTION|To assess degree of adherence to ART in a real world seeting.|Part I of the study is a Cohort Survey of HIV+ outpatient clinic patients currently receiving ART to assess medication adherence and tolerability by determining a change in adherence and tolerability from baseline to 4 months, measured by standardized patient reported outcome and adherence surveys
62818996|NCT04240210|EXPERIMENTAL|Potential changes in ART adherence when switced to Symtuza.|Part 2 of the study is a prospective cohort analysis of change in adherence, tolerability and safety of subjects who reports poor adherence to ART due to intolerance/side effects from integrase inhibitor containing regimens when they are switched to DRV/COB/FTC/TAF and monitored for 4 months.
62818997|NCT06458855|EXPERIMENTAL|PRP-NR|Post radical prostatectomy nerve restoration procedure
62818998|NCT03600324|EXPERIMENTAL|Low Intensity/Low Frequency|Participants will be assigned T-REV with low intensity (30% of perceived effort) and low frequency (exercises performed 1x/day)
62818999|NCT03600324|EXPERIMENTAL|Low Intensity/ High Frequency|Participants will be assigned T-REV with low intensity (30% of perceived effort) and high frequency (exercises performed 2x/day)
62819000|NCT03600324|EXPERIMENTAL|High Intensity/Low Frequency|Participants will be assigned T-REV with high intensity (70% of perceived effort) and low frequency (exercises performed 1x/day)
62819001|NCT03600324|EXPERIMENTAL|High Intensity/High Frequency|Participants will be assigned T-REV with high intensity (70% of perceived effort) and high frequency (exercises performed 2x/day)
62242742|NCT01817855|PLACEBO_COMPARATOR|2|"Groups 1-4 multiple ascending doses of placebo Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.~COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 will receive matching placebo."
62433005|NCT00482287|OTHER|2|Dose level 0.6 mg/kg 6 patients active and 2 placebo
62433006|NCT00482287|OTHER|3|Dose level 1.2 mg/kg 6 active and 2 placebo
62433007|NCT00482287|OTHER|4|Dose level 2.4 mg/kg 6 active and 2 placebo
62433008|NCT02024698|ACTIVE_COMPARATOR|omafilcon A|Study participants are randomized to wear omafilcon A lenses.
62433009|NCT02024698|ACTIVE_COMPARATOR|etafilcon A|Study participants are randomized to wear etafilcon A lenses.
62433010|NCT00846196|EXPERIMENTAL|2|one commercial risedronate 35 mg DR tablet
62433011|NCT00846196|ACTIVE_COMPARATOR|1|one Phase III risedronate 35 mg DR tablet
62599759|NCT04235374|EXPERIMENTAL|FFC-AC-EIT|The stakeholder team will meet with the research nurse facilitator to review the details of the 12 month intervention and identify unit goals. The research nurse facilitator will then work with the identified champion for 10 hours weekly during months one and two and then for four hours weekly starting in month three for a total of 12 months to implement Steps 1 to 4 of FFC-AC-EIT \[(1) Environment and Policy Assessments; (2) Education; (3) Establishing Patient Goals; and (4) Mentoring and Motivating of Staff, Patients and Families\]. The stakeholder team will meet with the Research Nurse Facilitator monthly to review progress. In addition to monthly visits, weekly emails containing motivational Tidbits will be sent to all stakeholder team members within the cohort. The Tidbits include such things as updates about benefits of engaging patients with ADRD in physical activity while hospitalized.
62819002|NCT05228574|ACTIVE_COMPARATOR|High-salt group (group 1)|"All participants will be subjected to a low-salt diet (3.5 grams/day) for six weeks.~Group 1 will receive sodium chloride capsules (6 grams/day) for four weeks. In the last two weeks of the trial, all participants will be treated with amiloride tablets (20 mg daily) in open-label setting."
62819003|NCT05228574|PLACEBO_COMPARATOR|Low-salt group (group 2)|"All participants will be subjected to a low-salt diet (3.5 grams/day) for six weeks.~Group 2 will receive placebo capsules (6 grams/day) for four weeks. In the last two weeks of the trial, all participants will be treated with amiloride tablets (20 mg daily) in open-label setting."
62599760|NCT04235374|PLACEBO_COMPARATOR|Education Only|Education Only (EO) Control Intervention: Hospitals randomized to EO will be provided with an in-service for nursing staff on function focused care in patients with ADRD by an EO Research Nurse Facilitator using our developed PowerPoint presentations in 30-minute sessions as is currently done in usual practice.
62242743|NCT05593874||Diabetic foot ulcer with osteoarticular infections|Diabetic patients suffering from ulcer that led to an osteoarticular infection (e.g. chronic osteomyelitis, septic arthritis)
62599761|NCT05176548||Group 1|Patients in whom Cardiac Amyloidosis is confirmed
62599762|NCT05176548||Group 2|Patients in whom Cardiac Amyloidosis is ruled out
62819004|NCT06025916|ACTIVE_COMPARATOR|Tranexamic acid|Will receive 20ml of tranexamic acid 100mg/ml at a timepoint when the cervix is dilated 6 cn (for multipara) and 8 cm for primipara
62599763|NCT05700916|EXPERIMENTAL|MPL-rich dairy powder|Daily consumption of 50 g of dairy powder containing 6.5 g MPL for 8 weeks.
62819005|NCT06025916|PLACEBO_COMPARATOR|Placebo|Will receive 20ml of placebo solution, equivalent in appearance and taste to tranexamic acid solution but with no active ingredient, at a timepoint when the cervix is dilated 6 cn (for multipara) and 8 cm for primipara
62433012|NCT06392737|EXPERIMENTAL|MRI-AI-guided cTB (AI-cTB) group|The trained AI algorithms were embedded into proprietary structured reporting software. Before prostate biopsy, the MR images of patients in the AI-cTB group were uploaded to the AI software. The prostate gland and suspicious lesions were annotated and highlighted by AI software. The urologists who were blinded to the picture archiving and communication system (PACS) and MRI reports read the AI findings at their discretion and then conducted 3-5 core TB at each suspicious lesion, followed by 12 core SB. If there was no suspicious lesion detected by the AI, only SB would be performed.
62819006|NCT06109467|EXPERIMENTAL|Treatment with Neratinib with Trastuzumab, Pembrolizumb and mFOLFOX|All patients will be treated with combination of neratinib with trastuzumab, pembrolizumab and mFOLFOX. All patients will receive standard dose 5FU/oxaliplatin/trastuzumab every 2 weeks. Pembrolizumab 400 mg intravenously will be administered once every 6 weeks. Neratinib will be dosed 240 mg orally daily
62819007|NCT03573648|ACTIVE_COMPARATOR|Endocrine Therapy|Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET) in a 1:2 ratio. A 1:2 ratio means that twice as many participants will be assigned to the PET arm as compared to the ET arm. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
62599764|NCT05700916|PLACEBO_COMPARATOR|Control dairy powder|Daily consumption of 50 g of dairy powder containing \<0.1 g MPL for 8 weeks
62599765|NCT04442451|EXPERIMENTAL|Control Exercise|Low-load knee extension resistance training (20% of 1-RM) without blood flow restriction. A 10-cm wide inflatable cuff will be placed around the upper portion of the thigh but not inflated.
62242744|NCT01200108|EXPERIMENTAL|Budesonide high dose via AKITA (1mg/2ml)|
62242745|NCT01200108|EXPERIMENTAL|Budesonide low dose via AKITA (0.5mg/2ml)|
62242746|NCT01200108|ACTIVE_COMPARATOR|Budesonide high dose via conventional nebulizer (1mg/2ml)|
62242747|NCT01200108|NO_INTERVENTION|Placebo via AKITA|
62242748|NCT04031586||Children diagnosed with Solid Tumors|Children diagnosed with solid tumors in Managua, Nicaragua in Central America
62242749|NCT03201913|EXPERIMENTAL|Accelerated dose escalation study|"Dose escalation of TTC-352 administered as an oral capsule, twice a day for 28 days (one cycle).~Patients will receive sequential 28-day cycles of treatment until disease progression, unacceptable toxicity, patient refusal to continue treatment, any other reason to discontinue treatment (e.g., further participation is not in the patient's best interest) or study completion/termination."
62819008|NCT03573648|ACTIVE_COMPARATOR|Endocrine Therapy with Palbociclib|Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET) in a 1:2 ratio. A 1:2 ratio means that twice as many participants will be assigned to the PET arm as compared to the ET arm. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
62819009|NCT06425861|EXPERIMENTAL|THB335 single dose|Single dose of THB335 fasted
62819010|NCT06425861|EXPERIMENTAL|THB335 fasted and fed|Single dose of THB335 fasted and then fed
62433013|NCT06392737|EXPERIMENTAL|Routine cTB group|For patients in the cTB group, the MR images and reports were viewed by urologists preceding the biopsy. Then 3-5 core cTB were performed, followed by 12 core SB. In patients with negative MRI findings, only SB was performed. When urologists performed biopsies, ultrasound technicians and radiologists were present to provide necessary assistance.
62819011|NCT06425861|EXPERIMENTAL|THB335 multiple dose|14 days of multiple ascending doses of THB335
62819012|NCT06425861|PLACEBO_COMPARATOR|Single dose placebo|Single dose of placebo capsule, fasted
62819013|NCT06425861|PLACEBO_COMPARATOR|Fasted and fed placebo|Single dose of placebo capsule fasted and then fed
62819014|NCT06425861|PLACEBO_COMPARATOR|Multiple dose placebo|14 days of multiple doses of placebo capsule
62819015|NCT06433791|EXPERIMENTAL|Ascorbate Meglumine dose 1|"Patients receiving Stereotactic Radiosurgery (SRS) treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced Magnetic Resonance Imaging (MR) scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases. The first cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.16 g/min for 60 minutes.~Interventions:~Drug: Ascorbate-Meglumine"
62819016|NCT06433791|EXPERIMENTAL|Ascorbate Meglumine dose 2|"Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases.The second cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.31 g/min for 60 minutes.~Interventions:~Drug: Ascorbate-Meglumine"
62819017|NCT06433791|EXPERIMENTAL|Ascorbate Meglumine dose 3|"Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, includingpost-operative patients with 1-3 residual metastases. The third cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.63 g/min for 60 minutes.~Interventions:~Drug: Ascorbate-Meglumine"
62819018|NCT06433791|EXPERIMENTAL|Ascorbate Meglumine dose 4|"Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, includingpost-operative patients with 1-3 residual metastases. The fourth cohort of patients will receive ascorbate-meglumine at a dose administration rate of 1.25 g/min for 60 minutes.~Interventions:~Drug: Ascorbate-Meglumine"
62819019|NCT04701008||Patients with significative post-operative pain despite|Patients with significant pain despite receiving narcotics in PACU will receive a bolus dose of IV ketamine to assess its efficacy for pain score reduction. Bolus doses are given by 10mg IV increments, to reach approximate dose of 0,25mg/kg.
62819020|NCT05495815|ACTIVE_COMPARATOR|6 months of SAT|TJA DAIR, followed by 6 weeks of IV antibiotics then 6 months of oral suppressive antibiotic therapy
62819021|NCT05495815|ACTIVE_COMPARATOR|12 months of SAT|TJA DAIR, followed by 6 weeks of IV antibiotics then 12 months of oral suppressive antibiotic therapy
62819022|NCT05495815|ACTIVE_COMPARATOR|Indefinite SAT|TJA DAIR, followed by 6 weeks of IV antibiotics then indefinite oral suppressive antibiotic therapy
62819023|NCT05413291||family members|family members who are 2 years old or older of people with movement disorders
62819024|NCT05413291||patients|subjects with movement disorders who are 2 years old or older
62819025|NCT06706466||SIIR-Dec|Patients with an SIIR of ≥-0.3 after ICI treatment
62819026|NCT06706466||SIIR-non-Dec|Patients with an SIIR of \< -0.3 after ICI treatment
62819027|NCT06270784|ACTIVE_COMPARATOR|Traditional Extraction Group|
62819028|NCT06270784|EXPERIMENTAL|Orthodontic Extraction Group|
62819029|NCT04555486|EXPERIMENTAL|DCR-PHXC|Participants that are at least 12 years old will receive a single dose of 3 mg/kg DCR-PHXC (or nedosiran) via subcutaneous (SC) injection. Participants that are 6-11 years old will receive a single dose of 3.5 mg/kg DCR-PHXC (nedosiran) via SC injection.
62819030|NCT04555486|PLACEBO_COMPARATOR|Sterile Normal Saline (0.9% NaCl)|Participants will receive a single dose of Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo.
62819031|NCT03748823|EXPERIMENTAL|Ravulizumab SC Treatment Group|"In the Randomized Treatment Period, participants will receive an IV loading dose of ravulizumab on Day 1 followed by SC maintenance doses of ravulizumab administered via the ravulizumab OBDS on Day 15 and every week (qw) thereafter for a total of 10 weeks of study treatment.~In the Extension Period, ravulizumab SC will be administered via the ravulizumab OBDS from Day 71 qw through Day 1274."
62819032|NCT03748823|ACTIVE_COMPARATOR|Ravulizumab IV Treatment Group|"In the Randomized Treatment Period, participants will receive an IV loading dose of ravulizumab on Day 1 followed by IV maintenance doses of ravulizumab on Day 15.~In the Extension Period, ravulizumab SC will be administered via the ravulizumab OBDS from Day 71 qw through Day 1274."
62599766|NCT04442451|EXPERIMENTAL|Blood Flow Restriction Exercise|Low-load knee extension resistance training (20% of 1-RM) with blood flow restriction using a 10-cm wide inflatable cuff placed around the most proximal part of the exercising thigh. Blood flow will be restricted in the BFR leg at above the limb occlusion pressure of the and this will be determined prior to the exercise while the participant is seated in the knee extensor machine. The cuff pressure during the BFR protocol will be 10 mmHg above limb occlusion pressure.
62819033|NCT06647238|EXPERIMENTAL|Pharmacist Intervention|Pharmacist review of patient chart and follow up visits to prescribe appropriate therapy for hyperlipidemia.
62819034|NCT06647238|NO_INTERVENTION|Control|Chart review only
62819035|NCT04631042||impulsive compulsive|Individuals between 6 and 80 years of age with a wide range of impulsivity/compulsivity behaviors - ranging from normal to mildly/extremely impaired.
62819036|NCT05797233|EXPERIMENTAL|1/Conditioning chemotherapy plus CAR T-cells dose escalation|Escalating dose of anti-CD19 and anti-CD20 CAR T- cells/kg + conditioning chemotherapy
62819037|NCT05797233|EXPERIMENTAL|2/Conditioning chemotherapy plus CAR T-cells expansion phase|MTD dose or Optimal dose of Anti-CD19 and anti-CD20 CAR T- cells/kg + conditioning chemotherapy
62819038|NCT06705608||Adult patients with multiple sclerosis|Adult participants with Multiple Sclerosis (MS), identified through a validated case definition, were observed in this retrospective cohort study. This case definition requires an individual to have at least three health care encounters (any combination of inpatient encounters, outpatient encounter, or disease-modifying-therapy (DMT) dispensation) for MS in a 1-year window. In this study, administrative claims data of participants between 2003 to 2020 were evaluated. The lower bound of this time period was selected based on data availability for the main drugs of interest. MS patients who initiated treatment with fingolimod or the active comparator drugs were identified to compare the incidence of skin cancer.
62819039|NCT03443141|EXPERIMENTAL|Vitamin E dressing|Patients will receive a Vitamin E-containing dressing over the wound
62819040|NCT03443141|SHAM_COMPARATOR|Standard dressing|Patients will receive a standard dressing over the wound
62819041|NCT03651700|ACTIVE_COMPARATOR|Active TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz active TMS will be delivered to the inferior pars triangular. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
62819042|NCT03651700|SHAM_COMPARATOR|Sham TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz sham TMS will be delivered to the inferior pars triangular. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
62819043|NCT05282095||Women aged from 18-45 with histopathologically confirmed CIN2|In the enrollment, women whose cervical histopathological results have been diagnosed as cervical intraepithelial neoplasia (CIN2) for the last 3 months with abnormal results will be included in this study. All participants will be followed up four, at 3th month, 6th month, 9th month and 12th month.
62819044|NCT04421677|EXPERIMENTAL|Phenylbutyrate|Open-label phenylbutyrate
62819045|NCT06491186||Included patients|
62819046|NCT04188743|EXPERIMENTAL|Allogenic FMT|Participants in the allogenic FMT- group will receive FMT-treatment using healthy donor microbiota supplied by the Ghent Stool Bank. The donor stool (50g) is processed shortly after production and tested intensively. It's frozen at -80°C until administration via naso-duodenal/-jejunal tube (Cortrak).
62039461|NCT03158883|EXPERIMENTAL|Progressors|"Patients who initially present with PR, CR, or SD to a PD-1 inhibitor but subsequently progress will be enrolled to the progressor arm.~* Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 \[±2\] days).~* Stereotactic ablative radiotherapy (SAR): the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated."
62433014|NCT03957278|EXPERIMENTAL|DAISe System|The DAISe System consists of the DAISe thrombectomy device used in with the Q Aspiration Catheter.
62433015|NCT01860885||Patients requiring naloxone for respiratory depression|
62433016|NCT01312142||patients with difficult weaning|
62433017|NCT06322810|EXPERIMENTAL|Group E|Patients who receive erector spinae plane block(ESPB) before cardiac surgery
62819047|NCT04188743|PLACEBO_COMPARATOR|Autologous FMT|Participants in the autologous FMT- group will receive FMT-treatment using their own microbiota to account for effects due to the treatment itself. Their stool is processed as close to the treatment as feasible. It's processed and frozen at -80°C until administration via naso-duodenal/-jejunal tube (Cortrak).
62819048|NCT04188743|NO_INTERVENTION|No intervention|"Participants in the No intervention-group will not receive any treatment but will be monitored similarly as the Allogenic FMT and Autologous FMT groups."
62819049|NCT02961413||cohort 1|Compound glycyrrhizin tablets / injection
62819050|NCT02961413||cohort 2|Isoglycyrrhizinate magnesium injection / diammonium glycyrrhizinate enteric-coated capsules
62819051|NCT02961413||cohort 3|Bicyclol
62433018|NCT06322810|ACTIVE_COMPARATOR|Group P|Patients who receive Pecto-intercostal plane block(PIFB) before cardiac surgery
62433019|NCT04888260||Coronary Artery Disease Group|Patients who underwent angiography at the Department of Cardiology and newly diagnosed as coronary artery disease and who weren't on statin treatment were included in the patient group.
62433020|NCT04888260||Control Group|The control group consisted of healthy people with normal coronary arteries angiographically
62433021|NCT06460987||A group: FINE+RASI group;|Patients treated with RASI and finerenone
62433022|NCT06460987||B group: RASI group;|Patients treated with RASI only
62433023|NCT06460987||C group: immune suppressive + FINE + RASI;|Patients receiving immunosuppressive drugs and RASIs
62433024|NCT06460987||D group: immune suppressive + RASI;|Patients receiving immunosuppressants, RASI and finerenone
62433025|NCT04641572|NO_INTERVENTION|Supine position|group A ( control ) will follow the hospital routine positions either supine or lateral during labor
62433026|NCT04641572|EXPERIMENTAL|Upright position|Group B (intervention) will follow the Standing or walking, Squatting, Sitting, Hands /knees, and Kneeling, positions. Then the researcher will register the time ( minutes/hours) that will be taken and which will be more preferable by the participant.
62819052|NCT02961413||cohort 4|Silibinin capsules
62819053|NCT02961413||cohort 5|Ursodeoxycholic acid capsules
62819054|NCT02961413||cohort 6|N- acetylcysteine
62242750|NCT05737043|PLACEBO_COMPARATOR|myocardial performance and epicard thickness in case with polyhidramnios|we will do a fetal echo, and fetal screening with ultrasonography
62242751|NCT05737043|ACTIVE_COMPARATOR|pregnant women with polyhidramios|
62819055|NCT06705335||CONVERCAP patients|"The tumour sample (primary tumour or metastasis) will be taken either during a standard biopsy or during pancreatic or metastasis standard surgery.~Biopsy sampling of metastases is only authorised if the primary histological diagnosis of pancreatic adenocarcinoma has already been proven. If the patient has undergone a biopsy for diagnostic purposes, he/she cannot be included in the study.~The blood sample will be taken on the same day as the tumour sample."
62819056|NCT03302325||Stage IV solid tumors|adult patients with stage IV cancer that are starting a new line of treatment
62433027|NCT04698564|EXPERIMENTAL|Single-arm study in patients who are suspected or known to have prostate cancer|Perform metabolic magnetic resonance imaging on men suspected to have a prostate cancer to understand if metabolic MRI can be safely performed on this population
62433028|NCT01405105||Patients with Flares of IBD|Active flare of Crohn's or UC
62433029|NCT01405105||Control Group|Patients with quiescent Crohn's disease or UC
62433030|NCT01630265|ACTIVE_COMPARATOR|Written Discharge Instructions|Group of caregivers who read written discharge instructions that are the standard discharge instructions given in our pediatric ED
62433031|NCT01630265|EXPERIMENTAL|Video Discharge Instructions|Group of caregivers who watched the 3-minute video covering the information in the standard written discharge instructions
62242752|NCT02941133|EXPERIMENTAL|Neural Mobilization Group|Patients in this group will be treated with neural mobilization techniques.
62433032|NCT02995837||Obstructive Sleep Apnea Syndrome (OSAS)|"The study duration is estimated at 12-14 months approximately. However, this will depend on the timing of treatment as they will undergo testing pre- and post-OSAS treatment. Participation will entail a total of 8 visits including:~Pre-treatment - neurocognitive testing, and CBF during wakefulness testing duration is one full day. The CBF nighttime testing is one full night.~Post-treatment - Six to twelve weeks after clinically indicated surgical treatment, OSAS participants will have a repeat baseline polysomnogram (one full night) to assess for residual OSA. Six and twelve months after the surgical treatment, the sleep study with the nighttime CBF testing, as well as the daytime neurocognitive testing and CBF testing will be repeated to assess for changes."
62242753|NCT02941133|EXPERIMENTAL|Standard Care Group|Patients in this group will be treated with standard care (ultrasound, exercise, TENS, massage)
62242754|NCT03570333|EXPERIMENTAL|Progenitor Potential at Molar site|Harvested tissue from the back (molar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.
62433033|NCT02995837||Controls|The study will include 7 total visits for controls: a baseline sleep study to ensure normalcy, three full days of neurocognitive testing and CBF testing (baseline, 6 and 12 months), and three sleep studies with CBF testing (baseline, 6 and 12 months). A daytime visit and one night time visit may be scheduled during a 24-hour period if the participant and family wish so. Otherwise, they will be scheduled on separate days.
62242755|NCT03570333|EXPERIMENTAL|Progenitor Potential at Premolar site|Harvested tissue from the front (premolar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.
62242756|NCT02849158|EXPERIMENTAL|Biopsy|Patients will have new biopsy before starting RT-CT and samples will be taken on rectum surgery at the level of the tumor and away from the rectum.
62242757|NCT02653287|EXPERIMENTAL|Intervention|The experimental intervention is a unique combination of four individual counseling sessions based in motivational interviewing focusing on physical activity, dietary behavior and behavioral strategies. The individual sessions will provide a tailored personalized intervention including problem-solving and goal setting for increasing physical activity, and following a healthy diet. Healthy Lifestyle Coaches (RN or MPH) will be responsible for conducting the individual for a caseload of participants. There are no drugs involved in the intervention.
62433034|NCT01894113|ACTIVE_COMPARATOR|transbronchial forceps lung biopsy|transbronchial lung biopsy forceps
62433035|NCT01894113|ACTIVE_COMPARATOR|transbronchail cryo lung biopsy|transbronchial lungbiopsy with cryoprobe
62433036|NCT05692466||Active|Newly diagnosed cancer patients.
62433037|NCT05692466||Control|Historically diagnosed cancer patients.
62819057|NCT05048979|EXPERIMENTAL|Exercise|Prospective pre-post pilot study design. (N=54)
62819058|NCT05048979|NO_INTERVENTION|No exercise|Prospective cohort study design. (N=100)
62819059|NCT06518824|SHAM_COMPARATOR|Stimulation off|The deep brain stimulation device will be turned off.
62819060|NCT06518824|EXPERIMENTAL|Theta stimulation of associative STN region|The deep brain stimulation device will be set to a frequency of 6 Hz and will stimulate the associative STN region. If differential activation of the associative and sensorimotor STN networks is not feasible, ventral stimulation is employed.
62819061|NCT06518824|ACTIVE_COMPARATOR|Theta stimulation of STN sensorimotor region|The deep brain stimulation device will be set to a frequency of 6 Hz and will stimulate the sensorimotor region, acting as an anatomical control. If differential activation of the associative and sensorimotor STN networks is not feasible, dorsal stimulation is employed.
62242758|NCT02653287|ACTIVE_COMPARATOR|Control|The control group intervention will receive four individual phone calls checking in with participants regarding questions about the study or from the educational sessions focusing on SLE disease management, each lasting approximately 10-15 minutes.
62242759|NCT06683560|EXPERIMENTAL|infants born with complete unilateral cleft lip and palate|"photopolymer resin material graphy Tera Harz 85 will be used to print 3D printed aligners for nasoalveolar molding treatment"
62039462|NCT03199222|EXPERIMENTAL|Arm 1: Smart socket technology w/patient prompting|The prosthetic user WILL receive prompting by the smart socket technology regarding improper fit and suggestions for how to a restore a proper fit (i.e socks). Investigators will have access to the Smart Socket Technology database.
62242760|NCT01050907|EXPERIMENTAL|Miltefosine|2.5 mg/kg/day for 28 days
62819062|NCT06518824|ACTIVE_COMPARATOR|High frequency stimulation of associative STN region|The deep brain stimulation device will be set to a frequency of 135 Hz and will stimulate the associative STN region, acting as a frequency control. If differential activation of the associative and sensorimotor STN networks is not feasible, ventral VTA is employed.
62039463|NCT03199222|NO_INTERVENTION|Arm 2: Clinical protocol. No patient prompting|The prosthetic user WILL NOT receive prompting by the smart socket technology regarding improper fit and suggestions for how to a restore a proper fit (i.e socks). However, investigators will have access to the Smart Socket Technology database.
62242761|NCT01727583|ACTIVE_COMPARATOR|Lipid 1|Meal intake
62242762|NCT01727583|PLACEBO_COMPARATOR|Lipid-free|Maltodextrine + proteins
62819063|NCT06705634|EXPERIMENTAL|Experimental: Individuals with neck-shoulder pain|Individuals with neck-shoulder pain will receive dry needling to C5-C6 multifidus of the cervical spine.
62819064|NCT06704282|EXPERIMENTAL|Mindfulness Meditation Group|Participants in this arm will undergo a 15-minute VR-based mindfulness observational meditation session guided by a virtual coach. The intervention focuses on promoting mindfulness and reducing stress through structured guidance in a controlled virtual environment.
62819065|NCT06093282|EXPERIMENTAL|ARCH|4-month health outreach intervention to improve depressive symptoms, physical activity, and weight management
62242763|NCT01727583|ACTIVE_COMPARATOR|Lipid 2|Meal intake
62242764|NCT01727583|ACTIVE_COMPARATOR|Lipid 3|Meal intake
62242765|NCT01727583|ACTIVE_COMPARATOR|Lipid 4|meal intake
62242766|NCT06655610|EXPERIMENTAL|Active eTNS|
62242767|NCT06655610|SHAM_COMPARATOR|Sham eTNS|
62242768|NCT05493852||FARAPULSE Pulsed Field Ablation System|Patients diagnosed as paroxysmal atrial fibrillation with indication of ablation.
62819066|NCT06093282|ACTIVE_COMPARATOR|Traditional Health Outreach|4-month health outreach intervention focused on screening, referral to healthcare resources, and support
62819067|NCT06600620||Patients admitted or referred to Critical Care (NOTE-AF ICU)|
62819068|NCT06600620||Patients admitted to hospital with acute heart failure (NOTE-AF HF)|
62819069|NCT06600620||Patients admitted to Emergency Services with sepsis or infection (NOTE-AF Sepsis)|
62819070|NCT06600620||Patients post upper gastrointestinal surgery (NOTE-AF PULSE-GI)|
62039464|NCT01397838|EXPERIMENTAL|Pro-Bone|
62039465|NCT00299650|PLACEBO_COMPARATOR|A|
62039466|NCT00299650|ACTIVE_COMPARATOR|B|
62242769|NCT03430219||Subchondroplasty Procedure|The SCP Procedure targets and fills bone defects with AccuFill bone substitute material utilizing an arthroscopic / percutaneous approach
62242770|NCT03089554|EXPERIMENTAL|Therapeutic Intervention|Therapeutic Intervention
62242771|NCT02627222|ACTIVE_COMPARATOR|Treatment|Daily consumption of two cassava-based meals prepared with pro-vitamin A rich biofortified cassava
62242772|NCT02627222|PLACEBO_COMPARATOR|Control|Daily consumption of two cassava-based meals prepared with common white cassava
62433038|NCT00990626||1|Schizophrenic outpatients
62819071|NCT06600620||Patients post vascular interventions (NOTE-AF Vasc)|
62819072|NCT06600620||Patients with acute respiratory failure (NOTE-AF Resp)|
62819073|NCT06600620||Patients admitted after acute stroke (NOTE-AF stroke)|
62599767|NCT04599725||Pregnant people|
62819074|NCT03692208|EXPERIMENTAL|Intervention|Patients that are enrolled in the intervention arm will receive an email message via MyChart (University of Chicago patient portal) to complete an initial questionnaire. Completion of the questionnaire will be required prior to initiating risk factor tracking and opening the portal to requests for care management support. A study team member (diabetes nurse educator) will contact the patient, if requested via the survey, to initiate telephonic care management or links to additional support services. Upon completion the study, all patients will receive a post-survey via MyChart.
62433039|NCT03884933|EXPERIMENTAL|Mobile team community mental health services|
62819075|NCT03692208|ACTIVE_COMPARATOR|Delayed Intervention/Control|Patients enrolled in the delayed intervention arm will receive usual care for the first 6 months, and then will receive the survey and intervention as stated above.
62819076|NCT06442475|EXPERIMENTAL|Treatment (mosunetuzumab)|Patients receive mosunetuzumab IV over 2-4 hours on days 1, 8, 15 and 22. Patients also undergo blood sample collection and PET/CT on study. Patients may undergo CT and/or MRI as clinically indicated and may undergo collection of oral and/or rectal swabs on study.
62819077|NCT05200208|EXPERIMENTAL|Citicoline Supplement|Participants with AD will receive a dietary citicoline supplement
62433040|NCT03884933|NO_INTERVENTION|Current clinical services|
62433041|NCT03828656|EXPERIMENTAL|Open Label Treatment Arm|Open-label Intervention with the NightWare Therapeutic System every night.
62433042|NCT05815719|EXPERIMENTAL|Study group|Patients to carry out an experimental double ovarian stimulation and to receive 4 weekly injections of Corifollitropin alfa. Prospective group.
62433043|NCT05815719|ACTIVE_COMPARATOR|Control group|Patients to carry out a conventional double ovarian stimulation and to receive daily injections of gonadotropins. Retrospective group (data retrieved from strictly selected treatments carried out in our institution within the 24 months prior to the inclusion of the first patient in the study group and according to the standard guideline of the clinic).
62242773|NCT06735118|EXPERIMENTAL|neoadjuvant chemotherapy group|Cancer patients undergoing chemotherapy.
62242774|NCT06735118|NO_INTERVENTION|Non-neoadjuvant chemotherapy group|Cancer patients not undergoing chemotherapy.
62242775|NCT05990218|ACTIVE_COMPARATOR|control, experienced|Patients received colonoscopy with double insertion of right sided colon under white light by experienced endoscopist
62433044|NCT04477083|ACTIVE_COMPARATOR|inhalable hydroxychloroquine (HCQ).|supportive and symptomatic treatment and inhalable hydroxychloroquine (HCQ).
62433045|NCT04477083|PLACEBO_COMPARATOR|Placebo|supportive and symptomatic treatment
62433046|NCT04393155||COVID-19+|Hospitalized patients with acute respiratory failure (new oxygen requirement) due to COVID-19
62599768|NCT01300338|EXPERIMENTAL|Blood pressure with telemetry|Home blood pressure monitor with telemetry
62599769|NCT01300338|ACTIVE_COMPARATOR|Blood pressure without telemetry|Home blood pressure self monitor without telemetry.
62599770|NCT04087629|EXPERIMENTAL|CTCL group|Patients with CTCL being treated with mechlorethamine gel will receive StrataCTX® gel.
62599771|NCT04087629|EXPERIMENTAL|Skin Toxicity group|Patients with skin toxicity secondary to chemo/immunotherapy will receive StrataCTX® gel.
62599772|NCT02546791||Chronic myeloid leukemia patients treated with Dasatinib|patients with a diagnosis of chronic myeloid leukemia treated with Dasatinib for at least 45 days
62819078|NCT05200208|PLACEBO_COMPARATOR|Placebo|Participants with AD will receive a placebo supplement
62819079|NCT02402816|EXPERIMENTAL|MPP ON|Patients will be randomized to the MPP-ON Arm vs Standard ICD
62819080|NCT02402816|ACTIVE_COMPARATOR|Standard ICD|Patients will be randomized to the MPP-ON Arm vs Standard ICD
62819081|NCT05203614|OTHER|Household Contribution|Do something thoughtful or nice for your caregiver that would provide them with tangible support
62242776|NCT05990218|ACTIVE_COMPARATOR|control, beginner|Patients received colonoscopy with double insertion of right sided colon under white light by beginner endoscopist
62242777|NCT05990218|EXPERIMENTAL|AI, experience|Patients received colonoscopy with double insertion of right sided colon under AI by experienced endoscopist
62242778|NCT05990218|EXPERIMENTAL|AI, beginner|Patients received colonoscopy with double insertion of right sided colon under AI by beginner endoscopist
62242779|NCT04338152|EXPERIMENTAL|FFT-CHR|Family-Focused Therapy for Clinical High-Risk Individuals
62242780|NCT04338152|ACTIVE_COMPARATOR|Enhanced Care|Enhanced Care Psychoeducation for Clinical High-Risk Individuals
62242781|NCT03765775|EXPERIMENTAL|Anlotinib Hydrochloride+Sintilimab|Participants receive Sintilimab (IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle , Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD
62242782|NCT03265535||Healthy Volunteers|Subjects without history of coronary artery disease
62242783|NCT03265535||Subjects with coronary artery disease|Subjects with coronary artery disease and abnormal SPECT myocardial perfusion imaging within the last 12 months
62039467|NCT04514341||Federally Qualified Health Centers (FQHCs)|The cohort included four FQHCs, two of which were located in Illinois and two in Indiana.
62039468|NCT00003532|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62039469|NCT06219746|NO_INTERVENTION|Control arm|Subjects undergo bone scintigraphy and whole body CT
62039470|NCT06219746|EXPERIMENTAL|Experimental arm|Subjects undergo bone scintigraphy, whole body CT, 99mTc-MIP-1404 SPECT/CT, and 18F- PSMA-1007 PET/CT
62039471|NCT02975973|EXPERIMENTAL|2.5mA|Active stimulation group will receive 20 minutes of 2.5 mA transcranial direct current stimulation.
62039472|NCT02975973|EXPERIMENTAL|2.0mA|Active stimulation group will receive 20 minutes of 2.0 mA transcranial direct current stimulation.
62039473|NCT02975973|EXPERIMENTAL|1.5mA|Active stimulation group will receive 20 minutes of 1.5 mA transcranial direct current stimulation.
62242784|NCT03854396|ACTIVE_COMPARATOR|Intravaginal prasterone insert|Nightly intravaginal prasterone insert for 24 weeks
62599773|NCT04229602|EXPERIMENTAL|Venlafaxine Hydrochloride Sustained-Release Capsules|During the study session, healthy subjects will be administered a single dose of Hydrochloride Sustained-Release Capsules 75 mg under Fed conditions.
62599774|NCT04229602|ACTIVE_COMPARATOR|Active Comparator: EFEXOR® XR|During the study session, healthy subjects will be administered a single dose of EFEXOR® XR 75mg under Fed conditions.
62819082|NCT05203614|OTHER|Outside Contribution|Do something outside your home/household that contributes to the larger society
62039474|NCT02975973|SHAM_COMPARATOR|0mA|This will be an active sham involving transcranial direct current stimulation, though stimulation will be brief (15 msec) and have low current (0.11 mA) pulses every 550 ms.
62039475|NCT01088139|NO_INTERVENTION|Control|
62039476|NCT01088139|EXPERIMENTAL|Nutritional Supplementation|
62039477|NCT01814592|EXPERIMENTAL|coronally mucosal thickness flap|coronally mucosal thickness flap plus connective tissue graft for root coverage (subepithelial connective tissue graft)
62039478|NCT01814592|ACTIVE_COMPARATOR|coronally partial thickness flap|coronally partial thickness flap plus connective tissue for root coverage (subepithelial connective tissue graft)
62039479|NCT01395381|PLACEBO_COMPARATOR|Placebo|
62039480|NCT01395381|EXPERIMENTAL|Albendazole|
62039481|NCT02224768||HCP and Patient inclusion|"HCP inclusion - HCP Experience with treatment of patients with study compound who have been exposed to risk minimization tools~Patient inclusion - Patients treated with study compound as per label who have been exposed to the risk minimization materials"
62242785|NCT03854396|PLACEBO_COMPARATOR|Intravaginal placebo insert (Witepsol H-15)|Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks
62242786|NCT06704620|EXPERIMENTAL|Arm1|Tislelizumab intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d1 or Albumin paclitaxel intravenous infusion 260mg/m2 d1; Carboplatin intravenous infusion AUC5 d1 or Cisplatin intravenous infusion 75mg/m2 d1; Diphenhydramine intramuscular injection 20mg qd d0-2 Q3W
62242787|NCT06704620|ACTIVE_COMPARATOR|Arm2|Tislelizumab intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d1 or Albumin paclitaxel intravenous infusion 260mg/m2 d1; Carboplatin intravenous infusion AUC5 d1 or Cisplatin intravenous infusion 75mg/m2 d1; Q3W
62242788|NCT01012843|ACTIVE_COMPARATOR|Antibiotic|Patients who received antibiotic treatment after abscess drainage
62242789|NCT01012843|PLACEBO_COMPARATOR|Placebo|Patients who received placebo after abscess drainage
62242790|NCT05802992|EXPERIMENTAL|Experimental group|Patients will be treated with colchicine, lenalidomide and dexamethasone, every 28 days as a cycle.
62242791|NCT05802992|ACTIVE_COMPARATOR|Control group|Patients will receive lenalidomide and dexamethasone as background treatment, every 28 days as a cycle.
62039482|NCT03419481|EXPERIMENTAL|pembrolizumab|
62039483|NCT04084314|EXPERIMENTAL|Erenumab|Erenumab dose could be adjusted from 70 mg to 140 mg or vice versa at the discretion of the physician at any scheduled study visit.
62039484|NCT00335322|ACTIVE_COMPARATOR|1|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin efavirenz)
62039485|NCT00335322|ACTIVE_COMPARATOR|2|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)
62039486|NCT00335322|EXPERIMENTAL|3|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
62039487|NCT06373432|EXPERIMENTAL|Infrequent testing|Finger sticks every 4 hours in latent labor (less than 5cm cervical dilation) and every 2 hours in active labor (6cm and greater)
62039488|NCT06373432|PLACEBO_COMPARATOR|Frequent testing|Finger sticks every 2 hours in latent labor (less than 5cm cervical dilation) and every 1 hours in active labor (6cm and greater)
62039489|NCT05256589|EXPERIMENTAL|SARS_CoV_2 Antigen Rapid Test|"The same group of patients participate in two arms of the study:~One arm is for obtaining performance data of the Sona Saliva C-19 Rapid self test and the comparator arm is to obtain data from the primary care route using approved RT-PCR testing."
62039490|NCT03580733|PLACEBO_COMPARATOR|placebo|placebo
62039491|NCT03580733|EXPERIMENTAL|antifungal therapy|caspofungin
62819083|NCT05203614|OTHER|Control|Keep track of your daily activities
62599775|NCT06617728||Group 1: Regional Analgesia Cohort|Participants receiving regional analgesia for pain management.
62242792|NCT02676388|EXPERIMENTAL|Freeze-dried, Capsulized FMT|Patients included will receive bowel lavage and subsequent Freeze-dried, Capsulized FMT, and then will be followed up for 3 months.
62599776|NCT06617728||Group 2: Intravenous (IV) Analgesia Cohort|Participants receiving IV analgesia for pain management.
62599777|NCT06546631||Temozolamide treatment|Patients who are being started on Temozolamide treatment for high-grade glioma. Patients will provide blood, saliva and stool samples.
62599778|NCT06546631||Temozolamide toxicity|Patients who have developed dose-limiting haematological toxicity during treatment with TMZ for a high grade glioma. Patients will provide blood, saliva and stool samples
62599779|NCT06177769||Group I|Airway is secured with LMA classic
62599780|NCT06177769||Group II|Airway is secured with LMA proseal
62599781|NCT06177769||Group III|Airway is secured with I-gel
62599782|NCT04230512|EXPERIMENTAL|Locked|The prototype mechanical system is locked from compressing
62599783|NCT04230512|EXPERIMENTAL|Unlocked|The prototype mechanical system is free to compress normally
62039492|NCT06580678|EXPERIMENTAL|Group A|KH001
62039493|NCT06580678|PLACEBO_COMPARATOR|Group B|Water for Injection
62039494|NCT01659931|ACTIVE_COMPARATOR|Montelukast|10 mg Tablet
62039495|NCT01659931|ACTIVE_COMPARATOR|Singulair|10 mg Tablet
62039496|NCT01285583|OTHER|Olesoxime|All patients will receive the IMP as add-on to riluzole 50 mg bid orally, 50 mg morning and evening on an empty stomach ie at least 20 min before the meal.
62039497|NCT05554952|ACTIVE_COMPARATOR|Group 1|Indirect pulp capping with MTA
62242793|NCT02676388|EXPERIMENTAL|Fresh FMT|Patients included will receive bowel lavage and subsequent Fresh FMT, and then will be followed up for 3 months.
62242794|NCT04292028|EXPERIMENTAL|pilates group|The Pilates group participated in an 8-week clinical Pilates training program
62242795|NCT04292028|ACTIVE_COMPARATOR|Control group|Control group were given a home-based exercise program
62242796|NCT02322229|EXPERIMENTAL|Ocriplasmin|Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal (IVT) injection
62242797|NCT04997187|EXPERIMENTAL|Bacillus coagulans group|This group takes Bacillus coagulans for 12 weeks.
62599784|NCT06648018|ACTIVE_COMPARATOR|Nutritional information|Written information about food with high iron content.
62242798|NCT04997187|PLACEBO_COMPARATOR|Control group|This group takes placebo for 12 weeks.
62599785|NCT06648018|EXPERIMENTAL|100mg iron-succinate per day as a pill.|Participants get 56 pills of 100mg iron-succinate to take one/day for 8 weeks.
62599786|NCT06376136|EXPERIMENTAL|A/ Standard 3+3 2.1mg/kg of BAT8010|Drug: BAT8010, Dosage: 2.1mg/kg, Frequency: once every 3 weeks, Duration: 1year
62599787|NCT06376136|EXPERIMENTAL|B/ Standard 3+3 2.4mg/kg of BAT8010|Drug: BAT8010, Dosage: 2.4mg/kg, Frequency: once every 3 weeks, Duration: 1year
62599788|NCT06376136|EXPERIMENTAL|C/ Standard 3+3 2.7 mg/kg of BAT8010|Drug: BAT8010, Dosage: 2.7 mg/kg, Frequency: once every 3 weeks, Duration: 1year
62599789|NCT06376136|EXPERIMENTAL|Standard 3+3 15 mg/kg of BAT1006|Drug: BAT1006, Dosage: 15 mg/kg, Frequency: once every 3 weeks, Duration: 1year
62599790|NCT05994911|EXPERIMENTAL|Mindfulness Training adolescent|An 8-week interview will be conducted with the individuals in the experimental group in the research in which the mindfulness training psychiatric nursing approach is applied. The control group will continue their routine school life. Individuals in the experimental group will be trained as a group and initiatives will be implemented in line with the goals of the individuals and the objectives of the research.
62599791|NCT05994911|NO_INTERVENTION|Mindfulness|Individuals in the control group will continue their school life.
62599792|NCT05025358|EXPERIMENTAL|LP-118|"The classic 3+3 design at dose levels of 50mg, 100mg, 200mg, 300mg, 400mg and 500mg will be implemented in this study."
62599793|NCT01282164|EXPERIMENTAL|Study patients|patients with growth hormone deficiency or hypothalamic-pituitary disorders underwent fixed-dose glucagon stimulation test (GST), weight-based GST and insulin tolerance test (ITT).
62599794|NCT01282164|ACTIVE_COMPARATOR|Control|"The control group will consist of healthy volunteers matched to the study group for age, gender, Body mass index (BMI) and estrogen status. Note: Allegheny site is not enrolling in the control group.~Control subjects underwent fixed-dose glucagon stimulation test (GST), weight-based GST and insulin tolerance test (ITT)."
62599795|NCT03928548||Low Risk Malnutrition|Participants who are determined to be at low risk for malnutrition based on the Malnutrition Screening Tool (adults) or the STRONGkids (pediatrics).
62599796|NCT03928548||High Risk Malnutrition|Participants who are determined to be at high risk for malnutrition based on the Malnutrition Screening Tool (adults) or the STRONGkids (pediatrics).
62599797|NCT01766752|EXPERIMENTAL|GlucoTab System|Investigational system: GlucoTab system supports the glycaemic management of non-critically ill patients with type two diabetes at the general ward.
62599798|NCT01766752|NO_INTERVENTION|no intervention|standard care
62819084|NCT06254638|EXPERIMENTAL|Multicomponent school-based intervention|"The multicomponent intervention will be composed of:~Physically Active Learning: consists of incorporating physical activity (usually of moderate-vigorous intensity) into the educational content taught in non-physical education academic classes.~Active breaks: consists of short breaks during non-physical education academic classes that include moderate to vigorous intensity physical activity.~Active Recess: consists of promoting PA during school breaks. To this end, three strategies will be developed: i) modification of the environment; ii) loose equipment; iii) structured recess. The modification of the environment will consist of providing students with a greater number of spaces for them to be active during recess. Access to sports equipment consists of providing sports equipment to encourage PA practice during recess. Structured recess includes the organization of sports competitions and teacher-led activities."
62819085|NCT06254638|NO_INTERVENTION|Control Group|The control group will receive the usual academic classes without any methodological modification during the intervention period.
62819086|NCT05575830|EXPERIMENTAL|RZV or Shingrix®)|Recombinant Zoster Vaccine
62039498|NCT05554952|ACTIVE_COMPARATOR|Group 2|Pulpotomy with MTA
62242799|NCT00256334|EXPERIMENTAL|Resveratrol|GM-CSF administration to all subjects in addition to chemotherapy treatment.
62242800|NCT06426043|EXPERIMENTAL|Lusutrombopag|Administer lusutrombopag at 3mg/qd orally for 12 weeks (lusutrombopag starting dose is 3mg, once daily. After 2 weeks of continuous administration, the dose can be increased by 3mg every 2 weeks based on the platelet count and safety of the subject. The dose can be gradually increased to 9mg/d over a total of 12 weeks). The course should be at least 3 months. When the platelet increase is \<20×10\^9/L, the daily dose can be increased by 3mg up to a maximum of 9mg/day; when the platelet increase is ≥50×10\^9/L and ≤200×10\^9/L, the dose can be maintained; when the platelet count is ≥200×10\^9/L and ≤400×10\^9/L, the daily dose can be reduced by 3mg; when the platelet count is \>400×10\^9/L, the drug can be suspended and resumed when the platelet count decreases to \<200×10\^9/L, with the daily dose reduced by 3mg. In this case, if the lowest dose of 3mg/day is used, the drug can be suspended. Responders continue treatment until 6 months.
62242801|NCT01161901||blood sample|
62242802|NCT01883986|EXPERIMENTAL|Intervention|This is a 3 month nurse-led telephone based program integrating palliative care into usual oncologic care for patients diagnosed within 2 months of any type and stage of lung cancer.
62242803|NCT01883986|NO_INTERVENTION|Usual Care|Subjects randomized to usual care will receive medical oncology, radiation oncology, pulmonary, CT surgery as indicated by the type of cancer. At the completion of 3 months of usual care, subjects are invited to join the intervention arm.
62433047|NCT01940237|EXPERIMENTAL|Interpersonal Psychotherapy (IPT)|Interpersonal psychotherapy (IPT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) in several controlled trials. This study will test the efficacy of IPT in a group of prostate, colorectal, lung and pancreatic cancer patients with a diagnosis of major depressive disorder.
62433048|NCT00545181|EXPERIMENTAL|Metronidazole plus gel|Receive metronidazole plus vaginal gel
62819087|NCT04530981|EXPERIMENTAL|Repaglinide 0.5 mg + Ripretinib 150 mg QD|A single dose of repaglinide 0.5 mg (1 × 0.5-mg tablet) will be administered orally on Cycle 1 Day 1 and Cycle 1 Day 15. Ripretinib 150 mg QD (3 × 50-mg tablets) will be administered orally from Day 2 through Day 28 for Cycle 1 and will be administered continuously from Cycle 2 until disease progression as assessed by the Investigator, unacceptable toxicity, or withdrawal of consent.
62819088|NCT02753270|ACTIVE_COMPARATOR|Short catheter|Twenty-five patients will receive the sclerosant foam by a short catheter 18 G. They will be treated with 3% polidocanol foam prepared with a three-way tap and two plastic disposable syringes, according to Tessari's method.
62819089|NCT02753270|EXPERIMENTAL|Long catheter preceded by tumescence|Twenty-five patients will be receive foam sclerosant by an angiographic catheter 4 French. They will be treated with 3% polidocanol foam prepared with a three-way tap and two plastic disposable syringes, according to Tessari's method.
62433049|NCT00545181|ACTIVE_COMPARATOR|Control- metronidazole alone|Oral Metronidazole antibiotic therapy alone
62433050|NCT05379569|EXPERIMENTAL|conditioning regimen with Malilane,cyclophosphamide and fludarabine|Malilane 3.2mg/kg/d \*4d (-5,-4,-3,-2day) cyclophosphamide 25mg/kg/d\*4d (-9-8,-7,-6 day) fludarabine 30mg/m2/d\*4d (-9-8,-7,-6 day) Donor stem cells will be transfused at 0 days.
62819090|NCT06705270|ACTIVE_COMPARATOR|Response-focused education|Patient education that is focused on treatment response
62819091|NCT06705270|ACTIVE_COMPARATOR|Diagnosis-focused education|Patient education that is focused on the diagnosis of major depressive disorder
62819092|NCT03800381||Active TB only|Children with clinical diagnosis or acid-fast bacilli (AFB) smear positive TB disease
62819093|NCT03800381||Active TB with HIV Co-infection|Children with clinical diagnosis or AFB smear positive TB disease who test positive for HIV infection
62819094|NCT06503510|EXPERIMENTAL|Lebrikizumab|The initial doses will be subcutaneous Lebrikizumab 500 mg (two 250 mg injections) at both week 0 (baseline) and week 2, followed by 250 mg administered subcutaneously at week 4.
62039499|NCT01656551|ACTIVE_COMPARATOR|A: Gemcitabine|Single agent gemcitabine dose 1200 mg/m2 days 1 and 8, every 3 weeks
62039500|NCT01656551|EXPERIMENTAL|B: Gemcitabine + Cisplatin|Gemcitabine dose 1000 mg/m2 days 1 and 8, every 3 weeks
62242804|NCT00523120|ACTIVE_COMPARATOR|1|voltaren ophta
62242805|NCT00523120|ACTIVE_COMPARATOR|2|dexotic
62242806|NCT04411927||control group|this group included 25 typically developed children
62242807|NCT04411927||on-heamodialysis group|this group included children with CKD on-heamodialysis treatment
62039501|NCT01656551|ACTIVE_COMPARATOR|C: Pemetrexed|
62039502|NCT01656551|EXPERIMENTAL|D: Pemetrexed + Cisplatin|
62039503|NCT04732455|PLACEBO_COMPARATOR|Group Control (C)|20 adult breast cancer patients on Taxane chemo protocol will receive 200 ml normal saline over forty minutes pre each chemotherapy session until end of the cycle.
62599799|NCT01735968|EXPERIMENTAL|STI571 (imatinib mesylate) and BYL719|The study will comprise of 2 parts. A dose escalation and a dose expansion part. All patients in the dose escalation part will have a pharmacokinetic (PK) run-in period of 7 days receiving imatinib monotherapy. Patients will receive increasing doses of BYL719 (200, 300, 400 mg) in combination with 400mg imatinib daily until maximum tolerated dose (MTD) and rapid phase 2 dose (RP2D) is determined. Approximately 35 patients will enter the expansion phase.
62599800|NCT06051435|ACTIVE_COMPARATOR|Control group|They will receive hot packs and pelvic rocking exercises for one menstrual cycle.
62599801|NCT06051435|EXPERIMENTAL|Lumbar proprioception group|They will receive the same lumbar proprioception training plus hot packs and pelvic rocking exercises for one menstrual cycle.
62599802|NCT04699201|EXPERIMENTAL|Prosthesis|Firstly, a laparoscopic cholecystectomy is performed. After suturing the aponeurosis with a J needle and 0 Polydioxanone, a lightweight, large-pore mesh made of PVDF monofilament (polyvinylidene fluoride - DynaMesh-CICAT, FEC Textiltechnik, Germany) will be placed onlay, overlapping 2cm in all directions from the edge of the aponeurosis incision at the umbilical trocar site. The mesh will be fixed to the aponeurosis with cyanoacrylate glue (Glubran®, GEM, Viareggio, Italy).
62599803|NCT04699201|ACTIVE_COMPARATOR|Control|Firstly, a laparoscopic cholecystectomy is performed. Closure of the aponeurosis will be performed by standard procedure: under direct vision, suturing the aponeurosis with a J needle and 0 Polydioxanone, with a stitch interval of ≤ 5mm.
62599804|NCT06417177|EXPERIMENTAL|Hypoxia|Participants will be exposed to hypoxia (low oxygen air) using a mask.
62039504|NCT04732455|EXPERIMENTAL|Group lidocaine infusion (L)|20 adult breast cancer patients on Taxane chemo protocol will receive lidocaine i.v infusion (2 mg/kg) in 200ml saline over forty minutes with a maximum upper limit of 200 mg pre each chemotherapy session until end of the cycle. If any selected patient reported neuropathic pain (DN4 \> 4) during the course of chemotherapy lidocaine (2 mg/kg) re-infused after each session. If lidocaine side effects such as circumoral numbness, twitches, metal test, tachy or bradycardia recorded at any time, lidocaine infusion will be reduced to 1mg/kg, if side effects persist, the patients will be managed accordingly as well as lidocaine infusion will be stopped and patient will be excluded from the study.
62039505|NCT04732455|EXPERIMENTAL|Group duloxetine (D)|20 adult breast cancer patients on chemotherapy will take oral duloxetine tablet 30 mg once per day starting from the night pre chemotherapy session until the end of cycle. If any selected patient reported neuropathic pain (DN4 \> 4) during the course of chemotherapy the duloxetine dose will be adjusted to 60 mg daily till the end of the cycle. They also will receive 200 ml normal saline over forty minutes before each chemotherapy session until end of the cycle.
62599805|NCT06417177|EXPERIMENTAL|Cold pressor test|Participants will be exposed to the cold pressor test (ice water on the foot).
62599806|NCT06417177|EXPERIMENTAL|Hypercapnia|Participants will be exposed to hypercapnia (high carbon dioxide air) using a mask.
62599807|NCT02319967|NO_INTERVENTION|Enhanced usual care|Inhaler technique education and distribution of spacers to all participants.
62599808|NCT02319967|EXPERIMENTAL|ED-only|Inhaler technique education and distribution of spacers to all participants. Structured patient-centered ED discharge template (CAPE) to be completed by ED coordinator.
62599809|NCT02319967|EXPERIMENTAL|ED-plus-home|"Inhaler technique education and distribution of spacers to all participants. Structured patient-centered ED discharge template (CAPE) to be completed by ED coordinator.~Home visits by a community health worker (CHW)."
62599810|NCT00826592|EXPERIMENTAL|Video-based education arm|Subjects receiving the video-based educational material
62819095|NCT06548126|EXPERIMENTAL|Parenting Intervention|Participants will receive the PIMonline program and a list of Parenting resources.
62819096|NCT06548126|PLACEBO_COMPARATOR|Control|Participants will receive a list of Parenting resources. Once the study period ends, they will be given access to the PIMonline program.
62819097|NCT04386993|EXPERIMENTAL|IMRT|"-Five 5-Gy fractions of IMRT will be given to the pelvis with elective simultaneous boost to any suspicious lymph node or residual disease to 30 Gy.~-\*Brachytherapy boost (at the discretion of the PI) within 2 weeks of radiation therapy completion. Once or twice weekly for three weeks"
62819098|NCT02173769||Adults with COPD|
62819099|NCT06629168||"Study group Telemetrics"|Patients with diagnosed hydrocephalus undergoing surgery (VP shunt placement) in general anesthesia. During surgery telemetrical prechamber implantad.
62819100|NCT06629168||"Study group Normal"|Patients with diagnosed hydrocephalus undergoing surgery (VP shunt placement) in general anesthesia. During surgery telemetrical prechamber not implantad.
62819101|NCT04198870|OTHER|Control Arm|Mitral Valve Repair Surgery
62599811|NCT00826592|ACTIVE_COMPARATOR|Written education arm:|Subjects receiving the written educational material
62819102|NCT04198870|EXPERIMENTAL|Device Arm|MitraClip™ device implantation
62599812|NCT00791362|OTHER|improvement programme CVD|
62039506|NCT01972958|EXPERIMENTAL|comprehensive care|comprehensive assessment, physical activity training, community resources referral, health education, health promotion activity.
62819103|NCT03980509|EXPERIMENTAL|Curcumin|Curcumin will be given at 500mg by mouth twice a day, immediately after each meal. Curcumin will be given from the time surgical resection is scheduled until the night before surgical resection.
62819104|NCT03632239||Reverse Phenotyping Core|Individuals undergoing phenotyping by the Reverse Phenotyping Core (RPC)
62819105|NCT06593158|ACTIVE_COMPARATOR|HABIT-ILE at Camp with Caregivers|
62819106|NCT06593158|ACTIVE_COMPARATOR|HABIT-ILE at Home with Caregivers|
62819107|NCT03396809|EXPERIMENTAL|Punctal Plugs|This arm of the study receives punctal plug intervention.
62819108|NCT02081924|ACTIVE_COMPARATOR|Kisspeptin 0.1|Participants will receive kisspeptin hormone at a dose rate of 0.1nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
62819109|NCT02081924|PLACEBO_COMPARATOR|Saline|Participants will receive placebo (saline) via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
62599813|NCT00791362|OTHER|improvement programme other conditions|
62599814|NCT04055311|ACTIVE_COMPARATOR|Usual care enhanced|Bladder cancer patients \& caregivers receive standard instructions about post-op care from nursing staff plus the NCI published Facing forward cancer survivorship manual.
62433051|NCT05379569|ACTIVE_COMPARATOR|conditioning regimen with Malilane and cyclophosphamide|malilane 3.2mg/kg \*4d (-5,-4,-3,-2day) cyclophosphamide 50mg/kg/d\*2d (-2,-1day) Donor stem cells will be transfused at 0 days.
62599815|NCT04055311|EXPERIMENTAL|Intervention|Bladder cancer patients \& caregivers receive standard instructions about post-op care from nursing staff plus access to Internet based software program, specifically designed for this research study. Software program contains relevant bladder cancer care instructions through videos, text, and graphics.
62819110|NCT02081924|ACTIVE_COMPARATOR|Kisspeptin 0.3|Participants will receive kisspeptin hormone at a dose rate of 0.3nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
62819111|NCT02081924|ACTIVE_COMPARATOR|Kisspeptin 1.0|Participants will receive kisspeptin hormone at a dose rate of 1.0nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
62819112|NCT06599346|ACTIVE_COMPARATOR|Active Comparator: Standard Care for Mucositis|Participants in this arm will receive standard care for mucositis, which may include oral rinses, topical treatments, and supportive care. Standard care will be tailored based on the type and severity of the mucosal injury (oral, skin, or bladder).
62819113|NCT06599346|EXPERIMENTAL|Experimental: MSC Supernatant + Standard Care for Mucositis|"Participants in this arm will receive MSC supernatant in addition to standard care for mucositis. The MSC supernatant will be administered as follows:~15 mL for oral mucosal injuries (mouthwash) Topical application for skin mucosal injuries (based on body surface area) 50 mL for bladder injuries (bladder irrigation)"
62819114|NCT04410991|EXPERIMENTAL|SAR442168|Dose 1 of oral SAR442168 daily + placebo to match the teriflunomide tablet once daily
62599816|NCT00508287|EXPERIMENTAL|A|
62819115|NCT04410991|ACTIVE_COMPARATOR|Teriflunomide|Oral 14 mg oral teriflunomide + placebo to match the SAR442168 tablet once daily
62819116|NCT04506853|OTHER|Study Procedure|
62819117|NCT06100887|EXPERIMENTAL|Cohort 1|Drug: Sevasemten Drug: Placebo
62819118|NCT06100887|EXPERIMENTAL|Cohort 2|Drug: Sevasemten Drug: Placebo
62819119|NCT06100887|EXPERIMENTAL|Cohort 3|Drug: Sevasemten Drug: Placebo
62819120|NCT06560489|EXPERIMENTAL|Dose level(1.25mg)|This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
62819121|NCT06560489|EXPERIMENTAL|Dose level(2.5mg)|This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
62819122|NCT06560489|EXPERIMENTAL|Dose level(5mg)|This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
62242808|NCT04411927||non-dialysis group|this group included children with CKD who don't require dialysis
62599817|NCT00508287|ACTIVE_COMPARATOR|B|
62599818|NCT00508287|PLACEBO_COMPARATOR|C|
62819123|NCT06560489|EXPERIMENTAL|Dose level(10mg)|This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
62819124|NCT04191538|EXPERIMENTAL|Conditioning electrical stimulation|Patients will receive percutaneous electrical stimulation one week prior to carpal tunnel release. They will receive sham stimulation immediately after surgery to ensure blinding.
62819125|NCT04191538|ACTIVE_COMPARATOR|Postoperative electrical stimulation|Patients will receive electrical stimulation immediately following carpal tunnel release, per out previous studies. They will receive sham stimulation 1 week prior to surgery to ensure blinding.
62819126|NCT04191538|SHAM_COMPARATOR|No electrical stimulation|Patients will not receive electrical stimulation. They will receive electrical stimulation before and after surgery to ensure blinding.
62819127|NCT03901755||Prophylactic patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
62819128|NCT03901755||On demand patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for on-demand treatment
62819129|NCT06198933||Pulsed-field ablation group|Patient with atrial fibrillation will undergo catheter ablation using pulsed-field energy
62819130|NCT06705855||Adult cardiac surgery patients undergoing cardiopulmonary bypass surgery at risk for AKI|We will enroll a convenience sample of adult cardiac surgery patients undergoing procedures that require cardiopulmonary bypass (CPB) and who are at risk for AKI.
62819131|NCT04471714|EXPERIMENTAL|Control|Control participants will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other.
62819132|NCT04471714|EXPERIMENTAL|Spinal Cord Injury|Participants with a spinal cord injury will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other.
62599819|NCT02333721|EXPERIMENTAL|D2 Lymphadenectomy including No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
62433052|NCT01965535|EXPERIMENTAL|LDV/SOF|LDV/SOF FDC tablet plus placebo to match RBV for 24 weeks
62433053|NCT01965535|EXPERIMENTAL|LDV/SOF + RBV|Placebo to match SOF/LDV FDC plus placebo to match RBV for 12 weeks, followed by LDV/SOF FDC plus RBV for 12 weeks.
62599820|NCT02333721|ACTIVE_COMPARATOR|D2 lymphadenectomy excluding No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
62599821|NCT06618677|ACTIVE_COMPARATOR|LOW FODMAP-wash out- STANDARD FODMAPs|Arm starting with low fodmap diet
62599822|NCT06618677|ACTIVE_COMPARATOR|STANDARD FODMAPs-wash out-LOW FODMAP|Arm starting with standard fodmap diet
62039507|NCT01972958|NO_INTERVENTION|usual care|control group with usual care
62039508|NCT06645327||Group 1|(LVEF\>40%)
62039509|NCT06645327||Group 2|(LVEF\<40%),
62039510|NCT00879138|PLACEBO_COMPARATOR|Sugar pill|
62039511|NCT00879138|EXPERIMENTAL|VA106483 2 mg|
62039512|NCT00879138|EXPERIMENTAL|VA106483 4 mg|
62039513|NCT00879138|EXPERIMENTAL|VA106483 8 mg|
62039514|NCT03577717|EXPERIMENTAL|computerized cognitive training|"participants will be trained by the Cookies for the brainy day, including memory, attention, calculation, executive functions, and language training."
62039515|NCT03577717|ACTIVE_COMPARATOR|occupational therapy|participants will receive craft activities of occupational therapy, such as weaving, origami etc.
62039516|NCT01258608|EXPERIMENTAL|Sorafenib plus mapatumumab|Mapatumumab 30 milligrams (mg)/kilogram (kg) intravenously on Day 1 of each cycle (i.e. every 21 days) plus sorafenib 400 mg orally twice daily continuously in each cycle until radiologic disease progression or unacceptable toxicity
62039517|NCT01258608|PLACEBO_COMPARATOR|Sorafenib plus Placebo|Placebo intravenously on Day 1 of each cycle (i.e. every 21 days) plus sorafenib 400 mg orally twice daily continuously in each cycle until radiologic disease progression or unacceptable toxicity
62039518|NCT02535910|EXPERIMENTAL|breakfast rich in vitamin D3|subjects are asked to consume a breakfast with (20µg) vitamin D3 fortified milk and butter
62039519|NCT02535910|EXPERIMENTAL|breakfast rich in 25(OH) D3|subjects are asked to consume a breakfast with (20µg) 25(OH) D3 fortified milk and butter
62039520|NCT02535910|PLACEBO_COMPARATOR|Control|subjects are asked to consume a normal milk and butter (no vitamin D is added) in the breakfast
62039521|NCT06733311||Urine Proteomics Diagnostic Group|Participants in this group will undergo urine proteomic analysis before surgery to predict early-stage non-small cell lung cancer (NSCLC). The predictions include tumor histopathological subtypes, lymph node metastasis, and other pathological factors. The accuracy of the diagnostic model will be compared to pathological results after surgery. This group consists of approximately 240 participants, with an anticipated 10% loss accounted for.
62039522|NCT06733311||CT Diagnostic Group|Participants in this group will undergo standard preoperative chest CT imaging to predict early-stage non-small cell lung cancer (NSCLC). Predictions include tumor histopathological subtypes, lymph node metastasis, and other pathological factors. The accuracy of the imaging predictions will be compared to pathological results after surgery. This group also consists of approximately 240 participants, with an anticipated 10% loss accounted for.
62039523|NCT00965432|PLACEBO_COMPARATOR|Placebo|
62039524|NCT00965432|ACTIVE_COMPARATOR|STX107|
62039525|NCT05275192|EXPERIMENTAL|Videoscope-assisted periodontal regeneration minimally invasive surgery|Videoscope-assisted periodontal regeneration minimally invasive surgery - Test group
62039526|NCT05275192|ACTIVE_COMPARATOR|Periodontal regeneration minimally invasive surgery|Periodontal regeneration minimally invasive surgery - Control Group 1
62039527|NCT05275192|ACTIVE_COMPARATOR|Guided tissue regeneration surgery|Guided tissue regeneration - Control Group 2
62039528|NCT02067260|ACTIVE_COMPARATOR|X5 HairLaser|
62039529|NCT02067260|SHAM_COMPARATOR|X5 HairLaser Sham Device|
62039530|NCT03355326|EXPERIMENTAL|Glycerin Suppository Group|
62039531|NCT03355326|NO_INTERVENTION|Non-suppository Group|
62039532|NCT06576726||adolescents with tic disorder|
62242809|NCT04962789||with compaction|those whose endometrial thickness is calculated to decrease by the time of embryo transfer compared with the thickness at the day of ovulation trigger, analyzed according to the degree of compaction, i.e., 5%, 10%, 15%, or 20% decrease thickness
62242810|NCT04962789||without compaction|those who had an increase in their endometrial thickness or whose thickness decreased less than 5%
62433054|NCT02766387|EXPERIMENTAL|2 minutes walk test|fast walk test during 2 minutes in first and the 10 meters walk test, the 6 minutes walk test and the 2 kilometers walk test
62433055|NCT02766387|EXPERIMENTAL|6 minutes walk test|comfortable walk test during 6 minutes in first and the 10 meters walk test, the 2 minutes walk test and the 2 kilometers walk test
62433056|NCT03889457||Patients with venous thromboembolic disease|Patients with deep vein thrombosis, superficial or muscular vein thrombosis, pulmonary embolism, over 18 years of age.
62039533|NCT06576726||neurotypical adolescents (controls)|
62039534|NCT04398277|ACTIVE_COMPARATOR|Initial Low dose|Participants will receive only one daily positive emotion prompt in the first seven days of the toolkit use.
62039535|NCT04398277|ACTIVE_COMPARATOR|Initial high dose|Participants will receive two daily positive emotion prompts in the first seven days of use.
62039536|NCT02250612|EXPERIMENTAL|SYL040012 (bamosiran) 0.375% eye drops|1 drop in each eye once daily for 28 consecutive days
62039537|NCT02250612|EXPERIMENTAL|SYL040012 (bamosiran) 0.750% eye drops|1 drop in each eye once daily for 28 consecutive days
62039538|NCT02250612|EXPERIMENTAL|SYL040012 (bamosiran) 1.125% eye drops|1 drop in each eye once daily for 28 consecutive days
62039539|NCT02250612|EXPERIMENTAL|SYL040012 (bamosiran) 1.5% eye drops|1 drop in each eye once daily for 28 consecutive days
62039540|NCT02250612|ACTIVE_COMPARATOR|Timolol maleate 0.5% ophthalmic solution|1 drop in each eye twice daily for 28 consecutive days
62039541|NCT05560854|EXPERIMENTAL|Internet delivered prolonged exposure|Internet delivered prolonged exposure for ten weeks with therapist support.
62039542|NCT01838798||Study population|"See in inclusion/exclusion criteria.~Interventions: Baseline activities; Clinical interview with a psychologist; Telephone interview 2 months after ICU discharge; Clinical interview with a psychologist ."
62819133|NCT04917107|EXPERIMENTAL|Qigong First|Participants in this group will complete the 12-week Qigong intervention first and then the 12-week observation period.
62819134|NCT04917107|EXPERIMENTAL|Observation First|Participants in this group will complete the 12-week observation period first and then the 12-week Qigong intervention.
62819135|NCT06123325||Treatment group|Patients with unruptured intracranial aneurysms, opting for active intervention undergo microsurgical clipping or endovascular therapy to preemptively secure the aneurysm and prevent rupture.
62819136|NCT06123325||Observation group|Patients with unruptured intracranial aneurysms, opting for conservative management undergo regular monitoring with serial imaging to track aneurysm stability, deferring interventional treatment unless changes indicate an increased risk of rupture.
62819137|NCT05659030|EXPERIMENTAL|Experimental|It is planned to provide training on perinatal mental health to the experimental group in order to eliminate the lack of knowledge of women and to raise awareness. The pre-test will be applied during the pregnancy period before the training. These trainings, which will be held during pregnancy, consist of 3 modules. A training booklet in their preferred language (Turkish or Arabic) will be distributed to women at the end of each module. In addition, the effectiveness of the training will be evaluated at the end of each module and the knowledge deficiencies of women will be eliminated. The trainings will be carried out in the form of group training of 10-12 people, taking into account the physical conditions of the environment. A module training will be given every week and the training will be completed within three weeks. The effectiveness of the training will be evaluated in the postpartum period with the post-test.
62819138|NCT05659030|NO_INTERVENTION|Control|Routine clinical care will be given to women in the control group. The pre-test will be applied during the pregnancy period and the post-test will be applied in the postpartum period. At the end of the post-test, three module training booklets will be distributed to the women in their preferred language (Turkish or Arabic). In line with their needs, the information deficiencies they request will be corrected.
62433057|NCT00606671||1|lean control women without PCOS
62039543|NCT04432987|EXPERIMENTAL|Newly Diagnosed Patient Group (n=30)|"I. Dornase Alpha treated group (n=15)~ii. Control group (n=15)"
62433058|NCT00606671||2|lean women with PCOS
62433059|NCT00606671||3|Obese control women without PCOS
62039544|NCT04432987|EXPERIMENTAL|Patient Group Monitored by Mechanical Ventilation (n=30)|"I. Dornase Alpha treated group (n=15)~ii. Control group (n=15)"
62039545|NCT03105310|ACTIVE_COMPARATOR|Pegylated interferon|Pegylated interferon alfa alone 180 microgram subcutaneous weekly for 24 weeks
62039546|NCT03105310|EXPERIMENTAL|Pegylated interferon with ezetimibe|Pegylated interferon alfa 180 micro-gram subcutaneous weekly for 24 weeks and Ezetimibe 10 mg orally for 24 weeks
62433060|NCT00606671||4|Obese women with PCOS
62433061|NCT00606671||1xx - 04 LC|lean control women
62433062|NCT00606671||1xx-04 LP|lean women with PCOS
62433063|NCT00606671||1xx-04 OC|obese control women
62433064|NCT00606671||1xx-04 OP|obese women with PCOS
62433065|NCT02065791|EXPERIMENTAL|Canagliflozin 100 mg|Each participant will receive 100 mg of canagliflozin once daily
62433066|NCT02065791|PLACEBO_COMPARATOR|Placebo|Each participant will receive matching placebo once daily
62433067|NCT01693107||Operator Blinded to Contact Force|Physicians performing the ablation will be blinded to the contact force data
62433068|NCT01005264|ACTIVE_COMPARATOR|non-removable fiberglass|Softcast3M®, 3M Health Care, St. Paul, MN (USA) were used for construction of the pressure-relief apparatus
62433069|NCT01005264|ACTIVE_COMPARATOR|Stabil-D®|Composed of a specifically designed rigid, boat shaped, and fully rocker bottom sole
62433070|NCT04498156||CKD-Patients|Cohort consisting of adult patients with a known diagnosis of type 2 diabetes and evidence of chronic kidney disease (CKD)
62433071|NCT04498156||Physicians treating CKD|Cohort consisting of licensed general practitioners, endocrinologists and nephrologists who are currently treating patients with both chronic kidney disease (CKD) and type 2 diabetes
62433072|NCT02818478|OTHER|RA; at home first|Patients in this arm (10 patients with rheumatoid arthirtis, RA) will be randomised to initially fill in patient reported outcome measures from home via their own computer or tablet; subsequently these patients will fill in patient reported outcome measures at the outpatient clinic
62599823|NCT02228304|EXPERIMENTAL|NT-503-3 ECT implantation|
62599824|NCT02228304|ACTIVE_COMPARATOR|Eylea® injected intravitreally every 8 weeks|Eylea® injected intravitreally every 8 weeks
62819139|NCT03270436|EXPERIMENTAL|Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program|The Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program (WORD DPP) is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length. The first 8 modules are intended to be delivered weekly. The last 8 modules are intended to be delivered every other week. Participants in the WORD DPP will be encouraged to maintain a daily weight, nutrition, physical activity and prayer log.
62242811|NCT03203551|PLACEBO_COMPARATOR|C; Control; Saline solution|"Disinfection protocol:~* brushing the palate (3 times a day/ 2 minutes);~* brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~* immersing the total prostheses in Saline solution (once a day/ 20 minutes) before the last brushing of the day;~* the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~* the prostheses will be evidenced and photographed.~* the biofilm present on the inner surface of the prostheses will be collected;~* photographe of the participants' palate;~* collected the palate biofilm."
62242812|NCT03203551|EXPERIMENTAL|HS0.25%; 0.25% Sodium Hypochlorite|"Disinfection protocol:~* brushing the palate (3 times a day/ 2 minutes);~* brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~* immersing the total prostheses in 0.25% Sodium Hypochlorite (once a day/ 20 minutes) before the last brushing of the day;~* the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~* the prostheses will be evidenced and photographed.~* the biofilm present on the inner surface of the prostheses will be collected;~* photographe of the participants' palate;~* collected the palate biofilm."
62242813|NCT03203551|EXPERIMENTAL|RC10%; 10% Ricinus communis|"Disinfection protocol:~* brushing the palate (3 times a day/ 2 minutes);~* brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~* immersing the total prostheses in 10% Ricinus communis (once a day/ 20 minutes) before the last brushing of the day;~* the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~* the prostheses will be evidenced and photographed.~* the biofilm present on the inner surface of the prostheses will be collected;~* photographe of the participants' palate;~* collected the palate biofilm."
62242814|NCT03203551|EXPERIMENTAL|CT0.5%; 0.5% Chloramine T|"Disinfection protocol:~* brushing the palate (3 times a day/ 2 minutes);~* brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~* immersing the total prostheses in 0.5% Choramine T (once a day/ 20 minutes) before the last brushing of the day;~* the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~* the prostheses will be evidenced and photographed.~* the biofilm present on the inner surface of the prostheses will be collected;~* photographe of the participants' palate;~* collected the palate biofilm."
62819140|NCT03270436|EXPERIMENTAL|Partnership for Improving Lifestyle Intervention Diabetes Prevention Program|The Partnership for Improving Lifestyle Intervention Diabetes Prevention Program (PILI DPP) is a family and community based diabetes prevention curriculum that teaches participants to engage their social support (family and community) to have a healthy weight, eat healthy, and be physically active. The PILI DPP includes 14 modules that are intended to be delivered over a 24 week period and each module approximately 90 minutes in length. The first 4 modules are intended to be delivered weekly. The last 10 modules are intended to be delivered every other week. Participants will be encouraged to track their weight, physical activity, and their nutrition in a log on a daily basis.
62242815|NCT01215500|EXPERIMENTAL|Radiation therapy|
62242816|NCT02183636|EXPERIMENTAL|Treatment 1 (T1)|Linagliptin/pioglitazone, FDC formulation C5
62599825|NCT01063920|EXPERIMENTAL|LT-NS001|LT-NS001 1200 mg b.i.d. p.o. for 12 weeks
62599826|NCT01063920|ACTIVE_COMPARATOR|Naprosyn®|Naprosyn® 500 mg b.i.d for 12 weeks
62599827|NCT06618027|EXPERIMENTAL|Mindfulness-Based Intervention, BREATHE-T1D|Learning to BREATHE, an existing group-based mindfulness intervention, was adapted in a prior trial, using the input of teens with T1D, to utilize mindfulness as a strategy for supporting the management of T1D. The intervention is 7 sessions, one per week, 60-90 minutes each and teaches mindfulness strategies and promotes connection with other teens with T1D.
62599828|NCT06618027|PLACEBO_COMPARATOR|Diabetes Education and Support, HealthEd-T1D|HealthEd-T1D was designed using input of teens with T1D to be a 6 session, 60 minutes once per week program to promote knowledge and empowerment in diabetes management as well as to encourage connection with other teens with T1D.
62599829|NCT01046851|ACTIVE_COMPARATOR|Nopan|
62433073|NCT02818478|OTHER|RA; outpatient clinic first|Patients in this arm (10 patients with rheumatoid arthirtis, RA) will be randomised to initially fill in patient reported outcome measures at the outpatient clinic; subsequently these patients will fill in patient reported outcome measures from home via their own computer or tablet
62433074|NCT02818478|OTHER|AxSpa; at home first|Patients in this arm (10 patients with axial spondyloarthritis, AxSpa) will be randomised to initially fill in patient reported outcome measures from home via their own computer or tablet; subsequently these patients will fill in patient reported outcome measures at the outpatient clinic
62433075|NCT02818478|OTHER|AxSpa; outpatient clinic first|Patients in this arm (10 patients with axial spondyloarthritis, AxSpa) will be randomised to initially fill in patient reported outcome measures at the outpatient clinic; subsequently these patients will fill in patient reported outcome measures from home via their own computer or tablet
62599830|NCT01046851|PLACEBO_COMPARATOR|Placebo|
62599831|NCT06222060||Parents|Couples of parents of newborns
62599832|NCT06623565|EXPERIMENTAL|Intervention|Supramarginal resection using combination of ADC MRI and FET PET
62599833|NCT03867149|OTHER|patient with first thalamic infarct|Patient with first thalamic infarct, they will undergo detailed neuropsychological assessment of memory, language, executive functions and mood along detailed neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI.
62599834|NCT03867149|OTHER|healthy subject matched with control|Healthy subject matched with control, they will undergo detailed neuropsychological assessment of memory, language, executive functions and mood along detailed neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI.
62599835|NCT00900549|EXPERIMENTAL|CRT|
62599836|NCT00900549|SHAM_COMPARATOR|No CRT|
62599837|NCT06590402|EXPERIMENTAL|Anterior Cruciate Ligament (ACL) surgeries|Pediatric subjects who underwent a Anterior Cruciate Ligament (ACL) surgery and are randomized to receive either the adductor canal block (ACB) or the anterior femoral cutaneous nerve block (AFCNB).
62599838|NCT06590402|EXPERIMENTAL|Medial Patellofemoral Ligament (MPFL) surgeries|Pediatric subjects who underwent a Medial Patellofemoral Ligament (MPFL) surgery and are randomized to receive either the adductor canal block (ACB) or the anterior femoral cutaneous nerve block (AFCNB).
62039547|NCT02650648|EXPERIMENTAL|Humanized Anti-GD2 Antibody Hu3F8|This is a phase I study to assess the safety and feasibility of combining HLA-mismatched (KIR ligand incompatible) NK cells with hu3F8 in high-risk NB patients. Following chemotherapy, patients will be treated in sequential groups with a minimum of 3 patients/ dose of NK cells. Three dose levels of NK cells, starting at dose level 1, will be evaluated in this treatment protocol. The goal dose for each dose level is the high boundary (e.g. 9.9x10\^6/kg in level 1; 14.9x10\^6/kg in level 2, etc), but a range is provided to allow for cases where the goal dose cannot be achieved.
62242817|NCT02183636|EXPERIMENTAL|Treatment 2 (T2)|Linagliptin/pioglitazone, FDC formulation C8
62599839|NCT05367817|EXPERIMENTAL|Exercise therapy|The program consists of two parts. The first part of the program contains unloaded active ROM exercises for the wrist in flexion/extension, radial-/ulnardeviation and pronation/supination. The second part of the program consists of three neuromuscular exercises that focus on coordination, wrist stability and strength. The participants will perform the program twice a day for 12 weeks.
62599840|NCT05367817|ACTIVE_COMPARATOR|Training program|The training program for the control group will consist of ROM exercises only that will be also be performed twice a day for 12 weeks.
62599841|NCT06017089|EXPERIMENTAL|AI Advisor-driven at-home closed loop system initiation and parameter adaptation|In this single-arm intervention trial, all participants will use the study system (t:slim X2 with Control-IQ Technology and Dexcom Continuous Glucose Monitor) in closed-loop mode for 8 weeks at home with periodic parameter adjustment driven by an AI-based Advisor system.
62819141|NCT00948246||Easyband|Subjects who had the Easyband device implanted laparoscopically.
62819142|NCT05430854|EXPERIMENTAL|Daxdilimab|Daxdilimab injections over a total of 48 weeks.
62819143|NCT05330481||<70 kg body mass|Cyclists or triathletes with a body mass of less than 70 kg
62819144|NCT05330481||>70 kg body mass|Cyclists or triathletes with a body mass of less than 70 kg
62819145|NCT05491265|EXPERIMENTAL|Kangaroo mother care|To see the impact of intermittent kangaroo mother care on temperature ,oxygen saturation and heart rate.
62819146|NCT05491265|NO_INTERVENTION|standard of care|To observe temperature ,oxygen saturation and heart rate in preterm neonates not given kangaroo care
62819147|NCT04076696|EXPERIMENTAL|Scatter corrected s-DCT|The study scan, s-DCT and correction scan, will be performed within two weeks of the patient's clinical evaluations by chest CT and x-ray. The study scan may be done within 2 weeks prior or two weeks following standard of care imaging. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the standard of care (SOC) imaging and the s-DCT. All patients will have a breath held s-DCT scan in an anterior-posterior direction.
62819148|NCT03538197|OTHER|SUICID ATTEMPT YOUNG PEOPLE|Suicide Re Attempts in Young Adults after first suicide attempt : socio-demographic, clinical and biological correlates
62242818|NCT02183636|ACTIVE_COMPARATOR|Reference (R)|Linagliptin tablet and pioglitazone tablet (Actos®)
62433076|NCT00764998|ACTIVE_COMPARATOR|Fluviral|
62433077|NCT00764998|PLACEBO_COMPARATOR|placebo|
62599842|NCT05642260|NO_INTERVENTION|control group|"Patients in the control group will receive a conventional physiotherapy treatment (guided by the post-TKR protocol followed at Al-Razi Orthopedic Hospital). The treatment will be delivered by four allocated physiotherapists,The treatment will be delivered by four allocated physiotherapists, and will consist of:~1. Blood circulation exercise (i.e., ankle pumps)~2. Quadriceps isometric exercises (i.e., quad sets).~3. Knee ROM exercises (i.e., knee flexion and extension).~4. Lower limb strengthening exercises (e.g., straight leg raising, short/ long arch exercises)~5. Stretching exercises for the hamstring and calf muscles.~6. Gait training (with and without the assistive device).~7. Parallel bars exercises (e.g., standing hip abduction/adduction, knee flexion, squatting).~8. Ascending/descending stairs.~9. Home program."
62599843|NCT05642260|EXPERIMENTAL|intervention (treatment) group|"Patients in the experimental group will receive a comprehensive fall prevention program (described below) integrated into the conventional physiotherapy treatment. The fall prevention program will consist of:~1. Otago balance exercise for 12 weeks integrated with conventional physiotherapy treatment (described in the control group).~2. Individualized advice on assistive device usage based on the participant's Berg Balance Score (BBS) revised at the 3 data collection timepoints.~3. Environmental hazard checklist.~4. Advice on getting their eyes checked and the use of appropriate footwear to ensure the elimination of other risk factors.~5. Home program (consists of balance and strength training exercises).~The treatment will be delivered by four allocated physiotherapists. The physiotherapists will receive an introductory/training session on the fall prevention program prior to the commencement of the trial."
62599844|NCT04724902|EXPERIMENTAL|Compression Group|The volunteer must remain supine on a stretcher, with both legs extended and relaxed. The intervention will be performed with elastic bandages (Selecta® of 13cm x 160 cm, composed of 45% cotton, 20% elastodiene and 27% polyamide) involving the entire knee surface, positioned considering anatomical aspects: covering the femoral condyles and the anterior tibial tuberosity). The bandage will involve the knee from the distal to the proximal, respecting the blood flow of the venous return. The level of compression was defined according to recommendations in the literature on compression interventions in lymphedema and venous changes, and should be kept between 30 mmHg and 60 mmHg. Variations on stipulated values may be interfered according to the volunteer's self-report, which should indicate a level of moderate, comfortable and pain-free compression. The intervention will be carried out for 20 minutes, once a day, for 4 consecutive days.
62433078|NCT01843907|OTHER|Empowerment|Patients in the intervention group 1 receive a communication report which will also be sent to the physician and home care. In communication report includes the results and interpretation and explanation of the measurements in layman's terms. The report also includes relevant and targeted information on pain management, depression among the elderly, dementia and disability in old age and ways to maintain and improve functional capacity. Links and addresses of relevant, local organizations, and networks are also included. The information material is also included in the report sent to the General Practitioner (GP) and home care.
62819149|NCT06589466||Adults with diabetes having surgery in Alberta since November 2019|Adults with diabetes having surgery in Alberta since November 2019
62819150|NCT06705920|NO_INTERVENTION|control|patient who will undergo intraoral surgical procedures , will have his wound sutured without any addtives
62819151|NCT06705920|ACTIVE_COMPARATOR|test|patient who will undergo intraoral surgical procedures , will have his wound sutured with the addition of blue m gel twice daily
62819152|NCT06504628||low risk for fall subgroup|according to Manuel Montero-Odasso M, Nathalie van der Velde, Finbarr C Martin, Mirko Petrovic, Maw Pin Tan, Jesper Ryg, et al. World guidelines for falls prevention and management for older adults: a global initiative. Age and Ageing, Volume 51, Issue 9, September 2022
62819153|NCT06504628||intermediate risk for fall subgroup|according to Manuel Montero-Odasso M, Nathalie van der Velde, Finbarr C Martin, Mirko Petrovic, Maw Pin Tan, Jesper Ryg, et al. World guidelines for falls prevention and management for older adults: a global initiative. Age and Ageing, Volume 51, Issue 9, September 2022
62819154|NCT06504628||high risk for fall subgroup|"according to Manuel Montero-Odasso M, Nathalie van der Velde, Finbarr C Martin, Mirko Petrovic, Maw Pin Tan, Jesper Ryg, et al. World guidelines for falls prevention and management for older adults: a global initiative. Age and Ageing, Volume 51, Issue 9, September 2022.~Those patients will be contacted 3 mnths after inclusion for follow-up assessment"
62433079|NCT01843907|OTHER|Conversation with Nurse|"Patients in the intervention group 2 gets clarification and follow-up conversation with a nurse anchored in both medical department and municipalities. The nurse is blinded in relation to the patient's screening results. Problems identified in connection therewith are communicated to the GP and home care."
62433080|NCT01843907|NO_INTERVENTION|Controle Group|Patients in the control group are undergoing the same measurements and records at discharge, as the intervention group, but are otherwise receiving treatment and care as usual without further intervention.
62819155|NCT04571944|EXPERIMENTAL|Suvorexant|Participants will receive 15 mg of suvorexant orally once daily (QD) for 5 to 7 days.
62819156|NCT04571944|PLACEBO_COMPARATOR|Placebo|Participants will receive suvorexant-matching placebo orally QD for 5 to 7 days.
62819157|NCT00005942|EXPERIMENTAL|Treatment (liposomal danorubicin citrate, semaxanib)|Patients receive daunorubicin liposomal IV over 6 hours on days 1-3 and SU5416 IV twice a week for 2 months. The second course is administered for 1 month, then treatment continues every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
62819158|NCT03350529|EXPERIMENTAL|Localised PC prior to RP|MRI guided transurethral HIFU ablation is targeted to MRI visible, biopsy proven, index lesion(s) within prostate and if possible with 5mm angular extension (imaging based healthy tissue marginal) to both sides from the tumour boundary in transverse plane and 5 mm in coronal plane. The ablative effect is aimed to reach prostate capsule by heating the control boundary (3 mm from capsule) to temperature 57 °C. The focal approach is intended to be radical as for index lesion.
62433081|NCT02431403|EXPERIMENTAL|ESHAP-Imatinib 100mg|"Imatinib 100 mg combined with ESHAP~\* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
62433082|NCT02431403|EXPERIMENTAL|ESHAP-Imatinib 200mg|"Imatinib 200 mg combined with ESHAP~\* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
62039548|NCT06527638|EXPERIMENTAL|eHealth intervention for UI symptoms improvement|"Participants in the Experimental Group were integrated into an eHealth 8-week group intervention, based on the Health Action Process Approach (HAPA).~The eHealth (internet-based) cognitive-behavioural intervention developed to promote UI symptoms improvement consisted of: i) weekly group sessions (by Zoom platform), with a specific theme in each session, ii) weekly challenges, and iii) WhatsApp group interaction."
62242819|NCT04767737|EXPERIMENTAL|Topical lavender oil group|Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured, and then, 3 puffs (0.3 ml) of 100% lavender (Lavandula Angustifolia) essential oil to the topical lavender oil group were sprayed on the arms of the patients. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
62433083|NCT02431403|EXPERIMENTAL|ESHAP-Imatinib 400mg|"Imatinib 400 mg combined with ESHAP~\* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
62433084|NCT02431403|EXPERIMENTAL|ESHAP-Imatinib 300mg|"Imatinib 300 mg combined with ESHAP~\* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
62433085|NCT01638793|EXPERIMENTAL|Capnography|Capnographic respiration monitoring
62433086|NCT01638793|ACTIVE_COMPARATOR|Pulse-Oxymetry|pulse-oxymetric respiration monitoring
62433087|NCT02999373|EXPERIMENTAL|Autologous cord blood mononuclear cells|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 24 hours after birth ,dose is 50 million cells/kg
62433088|NCT02999373|NO_INTERVENTION|control|
62433089|NCT03788798|NO_INTERVENTION|Standard clinical pathway|A standard clinical pathway for TKA has been compulsively implemented for medical cost containment and quality assurance to meet with the Taiwan Diagnosis-Related Groups (TW-DRGs) payment system since 1997. The clinical pathway for TKA undertakes with preadmissions, anesthetic, surgery, and physiotherapy assessment. Medical, nursing, and physiotherapy assessment were put down for each postadmission day. The time from admission to surgery, the use of intravenous antibiotics injection and intravenous fluid were all assessed. Discharge criteria were active knee flexion to 90 degrees, having the ability to walk with aids and clean wound condition with any infection sign. The pathway was initially set for a 6-day postoperative length of stay.
62242820|NCT04767737|PLACEBO_COMPARATOR|Placebo group|Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured, and then, 3 puffs (0.3 ml) of topical distilled water to the placebo group were sprayed on the arms of the patients. No application was applied to the control group. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
62242821|NCT04767737|NO_INTERVENTION|Control groups|Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured.No application was applied to the control group. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
62242822|NCT04321980|EXPERIMENTAL|Cohort 1|Subjects in Cohort 1 will be administered 4 mg/kg OP-101 as a subcutaneous (SC) injection.
62242823|NCT04321980|EXPERIMENTAL|Cohort 2|Subjects in Cohort 2 will be administered 8 mg/kg OP-101 as a SC injection.
62242824|NCT02693769|EXPERIMENTAL|fluticasone/formoterol BAI|To compare the efficacy of fluticasone/formoterol BAI 125/5 μg (2 puffs b.i.d.)
62242825|NCT02693769|ACTIVE_COMPARATOR|Ultibro Breezhaler|Ultibro Breezhaler 85/43 µg (1 puff o.d.)
62433090|NCT03788798|EXPERIMENTAL|Patient Infotainment Terminal|Patients who have additional access to an integrated infotainment system and are cared by a standard clinical pathway. The patient infotainment system is a quasi-interactive computer program connected to a server that pushes messages and educational programs ordered from the caring physicians or on-demand by the patients. The server has parallel data exchange gateways to the Hospital Information System (HIS), Picture Archiving Communication System (PACS), and can record the patients' responses to surveys and questionnaires.
62433091|NCT03337737|PLACEBO_COMPARATOR|Placebo|Placebo will be composed of microcrystalline cellulose in a gel capsule
62819159|NCT03350529|EXPERIMENTAL|Symptomatic locally advanced PC|MRI guided transurethral HIFU ablation is targeted to main prostatic malignant tumour squeezing and/or invading the prostatic urethra and/or bladder neck. The approach is intended to be palliative.
62819160|NCT03350529|EXPERIMENTAL|Locally recurrent PC after EBRT|"MRI guided transurethral HIFU ablation is targeted to MRI visible, biopsy proven, local recurrent index lesion(s) within and/or surrounding prostate and if possible with 5 mm angular extension to either side from the tumour boundary in transverse plane and 5 mm in coronal plane. The approach is intended to be focal and salvage.~The whole-gland HIFU ablation approach will be considered in case of extensive organ confined recurrent prostate cancer (positive biopsies for malignancy from extensive/multiple area in prostate and/or extensive/multiple lesion(s) at baseline MRI) to cover whole prostate."
62242826|NCT00726934|ACTIVE_COMPARATOR|Neutropenic Diet|Participants will be instructed to follow a Neutropenic Diet. This group will receive the same information as the Food Safety Arm with some additional recommendations for avoiding high bacteria foods during length of time on study.
62242827|NCT00726934|ACTIVE_COMPARATOR|FDA Food Safety Guidelines|Participants will be instructed to follow the FDA Food Safety Guidelines
62039549|NCT06527638|ACTIVE_COMPARATOR|Control Group: Delivery of a Health Literacy single-leaflet|The control group received a health literacy single-leaflet, delivered through email.
62039550|NCT06733142|EXPERIMENTAL|Test Product|High protein commercially available spoonable yoghurt (1 serving = 45 g protein comprising 3 yoghurt pots totalling 480 g) (Danone Nutricia).
62242828|NCT00850850|ACTIVE_COMPARATOR|Physostigmine|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 mg of physostigmine.
62433092|NCT03337737|ACTIVE_COMPARATOR|Extreme Endurance|Dietary Supplement manufactured by LifeSpan International LLC
62242829|NCT00850850|PLACEBO_COMPARATOR|NaCl|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo).
62242830|NCT03211247|EXPERIMENTAL|Part A Viaskin Peanut 250 mcg|
62433093|NCT03746301||Treatment|Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions.
62819161|NCT03350529|EXPERIMENTAL|Symptomatic BPH|MRI guided transurethral HIFU ablation is targeted to adenomas of the prostate. The HIFU sector encompasses bilateral (anterolateral) transitional zones between bladder neck and verumontanum (colliculus seminalis).
62819162|NCT04504253|EXPERIMENTAL|Creatine monohydrate|"1. Week 1: Creatine monohydrate 5g PO QID~2. Week 2 up to Week 6: Creatine monohydrate 5g PO qday"
62819163|NCT04504253|PLACEBO_COMPARATOR|Placebo|"1. Week 1: Placebo 5g PO QID~2. Week 2 up to Week 6: Placebo 5g PO qday"
62242831|NCT03211247|EXPERIMENTAL|Part A Viaskin Peanut 100 mcg|
62242832|NCT03211247|PLACEBO_COMPARATOR|Part A Placebo|
62242833|NCT03211247|EXPERIMENTAL|Part B Viaskin Peanut 250 mcg|
62599845|NCT04724902|SHAM_COMPARATOR|Sham Group|For Sham application, the volunteer must remain supine on a stretcher, with both lower limbs extended and relaxed. Elastic bandages will be used (Selecta® of 13cm x 160 cm, composed of 45% cotton, 20% elastodiene and 27% polyamide) involving the entire knee surface, positioned considering anatomical aspects: covering the femoral condyles and the anterior tibial tuberosity) . The bandage will involve the knee from the distal (tibial tuberosity) to the proximal (femoral condyles), respecting the blood flow of the venous return. However, in this group, no compression force will be performed, maintaining the pressure at 00 mmHg according to a previous reliability study. The procedure will be carried out for 20 minutes, once a day, for 4 consecutive days.
62599846|NCT04724902|NO_INTERVENTION|Control Group|The Control group will be composed of individuals with knee osteoarthritis, who make up the study's waiting list and will carry out evaluations at the same time intervals as the other groups, but will not receive any type of intervention and will be instructed not to start another treatment during their participation.
62599847|NCT05142150||Patient|Patient satisfaction with end of life care. Questionnaire to be completed at baseline and every 8 week.
62819164|NCT04490174||Healthy participants|Healthy adults without a current active COVID-19 infection or current symptoms consistent with COVID-19 at the first clinic visit
62819165|NCT06051305|EXPERIMENTAL|Sensory Training|Daily protocol - gamified sensory training
62819166|NCT05552664|OTHER|Arm 1|Arm information details will not be provided at this time in order to preserve scientific integrity and will be updated once the study has resulted.
62039551|NCT06733142|ACTIVE_COMPARATOR|Micellar casein drink|Micellar casein drink (1 serving = 45 g protein/480 g).
62039552|NCT06733142|PLACEBO_COMPARATOR|Placebo|Flavoured water-based placebo jelly (1 serving = 0 g protein comprising 3 jelly pots totalling 480 g).
62242834|NCT03211247|PLACEBO_COMPARATOR|Part B Placebo|
62242835|NCT04980508|ACTIVE_COMPARATOR|Patients that had COVID-19 and were treated as outpatients|Patients underwent diagnostic evaluation including IIEF-5 form, penile color Doppler ultrasonography, corpus cavernosum electromyography, and fasting serum levels of testosterone, luteinizing hormone, follicle stimulating hormone, and prolactin measured in the morning (07-11 am). The relaxation degrees of cavernosal smooth muscles were calculated from the corpus cavernosum electromyography results.
62433094|NCT01405885|EXPERIMENTAL|Arm A - 0.9mg of INO-3605|
62433095|NCT01405885|EXPERIMENTAL|Arm B - 0.9mg of INO-3609|
62433096|NCT01405885|EXPERIMENTAL|Arm C- 0.9mg of INO-3401|
62433097|NCT01405885|EXPERIMENTAL|Arm D- 0.3mg of INO-3609|
62433098|NCT01405885|EXPERIMENTAL|Arm E - 0.45mg each INO-3605 , INO-3609|
62433099|NCT01405885|EXPERIMENTAL|Arm F - 0.3mg each of INO-3401,INO-3605,INO-3609|
62433100|NCT01405885|EXPERIMENTAL|Arm G - 0.9mg of INO-3609|
62433101|NCT01405885|EXPERIMENTAL|Arm H - 0.9mg of INO-3609|
62599848|NCT05142150||Carer|Carer satisfaction with care leading up to the time of death and the quality of the patient's death. Questionnaire to be completed at baseline and every 8 weeks,and 5-7 weeks after patient deceased.
62599849|NCT04939246|OTHER|Single-fraction SABR|Patients will receive SABR in a single-fraction regiment treatment with one single dose of radiation therapy per lesion. Patients may be treated for up to a total of ten lesions. Each lesion will be treated in one fraction.
62599850|NCT04326296|EXPERIMENTAL|Experimental Group|PD-L1 Monoclonal Antibody Combined With Lenalidomide
62819167|NCT05552664|OTHER|Arm 2|Arm information details will not be provided at this time in order to preserve scientific integrity and will be updated once the study has resulted.
62819168|NCT05552664|OTHER|Arm 3|Arm information details will not be provided at this time in order to preserve scientific integrity and will be updated once the study has resulted.
62819169|NCT05552664|OTHER|Arm 4|Arm information details will not be provided at this time in order to preserve scientific integrity and will be updated once the study has resulted.
62819170|NCT04211961|PLACEBO_COMPARATOR|Control|Participants randomised to the placebo group will receive one 15-minute IV infusion of Saline at 4 visits.
62242836|NCT04980508|ACTIVE_COMPARATOR|Patients who were hospitalized due to COVID-19|Patients underwent diagnostic evaluation including IIEF-5 form, penile color Doppler ultrasonography, corpus cavernosum electromyography, and fasting serum levels of testosterone, luteinizing hormone, follicle stimulating hormone, and prolactin measured in the morning (07-11 am). The relaxation degrees of cavernosal smooth muscles were calculated from the corpus cavernosum electromyography results.
62433102|NCT01405885|ACTIVE_COMPARATOR|Arm I - Seasonal influenza vaccine|
62433103|NCT01405885|EXPERIMENTAL|Arm J - 1.8mg of INO-3609|
62819171|NCT04211961|ACTIVE_COMPARATOR|Treatment|Participants randomised to the treatment group will receive one 15-minute IV infusion of Scopolamine at 4 visits.
62819172|NCT06705036||pituitary tumors in cavernous sinus group|The 20 pituitary tumor samples in this group were obtained from the cavernous sinus region removed during surgery and were paired with pituitary tumors in the intralellar region
62433104|NCT00612833|ACTIVE_COMPARATOR|cautery excision with fascial interposition|Contraception using cautery and excision with fascial interposition
62433105|NCT00612833|ACTIVE_COMPARATOR|B|Cautery and excision without fascial interposition
62433106|NCT00612833|ACTIVE_COMPARATOR|C|Ligation and excision with fascial interposition
62433107|NCT06039527||Young adults|N=50 of this group No intervention. Sampling at timepoint 0 and for 50% of the group another sample at 3 months If respiratory symptoms develop in the 3 months after timepoint 0, participants are invited to provide a NPS/OPS to identify causative agent, and if one is established, individuals are sampled 3 more times at months 1, 3 and 5 post symptom onset
62433108|NCT06039527||Vital elderly|N=60 of this group No intervention. Sampling at timepoint 0 and for 50% of the group another sample at 3 months If respiratory symptoms develop in the 3 months after timepoint 0, participants are invited to provide a NPS/OPS to identify causative agent, and if one is established, individuals are sampled 3 more times at months 1, 3 and 5 post symptom onset
62433109|NCT06039527||Frail elderly|N=60 of this group. Half with recurring respiratory infections, and half without No intervention. Sampling at timepoint 0 and for 50% of the group another sample at 3 months If respiratory symptoms develop in the 3 months after timepoint 0, participants are invited to provide a NPS/OPS to identify causative agent, and if one is established, individuals are sampled 3 more times at months 1, 3 and 5 post symptom onset
62819173|NCT06705036||pituitary tumors in sellar group|The 20 pituitary tumors in this group were obtained from intrasellar samples removed during surgery and were paired with pituitary tumors in the cavernous sinus region
62819174|NCT06052475|EXPERIMENTAL|Physiological Pacing (Conduction System Pacing or Biventricular Pacing)|The approach for physiological pacing will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
62819175|NCT06052475|ACTIVE_COMPARATOR|Right Ventricular Pacing|Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice)
62819176|NCT05974241|EXPERIMENTAL|Pharmacological treatment|During the first step, the subjects received pharmacological treatment of methylphenidate with flexible dosage for 4 weeks. Those subjects who had suboptimal response to methylphenidate entered the second step with aripiprazole. After 4 weeks of treatment, those had suboptimal response to aripiprazole entered the third step and received the treatment of combination of methylphenidate and aripiprazole for two weeks (3rd step).
62819177|NCT05690139||Obese patients|Obese patients received LSG surgery approval
62819178|NCT01456637|EXPERIMENTAL|CBT for insomnia with feedback|In this arm participants received internet based self-help CBT for insomnia with e-mail feedback form a therapist.
62819179|NCT01456637|EXPERIMENTAL|CBT for insomnia without feedback|In this arm participants receive internet based self-help CBT for insomnia without feedback from a therapist.
62819180|NCT03796650|EXPERIMENTAL|Fecal microbiota transplantation|Fecal microbiota from healthy, screened stool donors at the University Hospital of North Norway. Patients will receive one FMT enema immediately after enrolment.
62819181|NCT03796650|ACTIVE_COMPARATOR|Antibiotic treatment|Patients randomized to the control group will receive a ten-day course of oral vancomycin four times a day. This is according to international guidelines for primary C. difficile treatment.
62819182|NCT06581471|EXPERIMENTAL|Transcatheter Tricuspid Valve Replacement|Treatment with the TRiCares Topaz Tricuspid Transcatheter Valve Replacement System
62819183|NCT02595892|ACTIVE_COMPARATOR|Arm I (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.
62819184|NCT02595892|EXPERIMENTAL|Arm II (gemcitabine, ATR kinase inhibitor M6620)|Patients receive gemcitabine hydrochloride as in Arm I and ATR kinase inhibitor M6620 IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62433110|NCT05064488|EXPERIMENTAL|Part-1: Evobrutinib + Digoxin + Metformin + Rosuvastatin|
62433111|NCT05064488|EXPERIMENTAL|Part-2: Evobrutinib + Sumatriptan|
62433112|NCT01703338||Lumbar spinal surgery|The study included participants who were diagnosed by a neurological surgeon and received lumbar surgery according to relevant imaging findings
62433113|NCT01996176|EXPERIMENTAL|Intervention group|Intervention group
62433114|NCT01996176|PLACEBO_COMPARATOR|Intervention control|Control group
62433115|NCT04494178|EXPERIMENTAL|2.0g G-PUR® oral - Placebo|
62433116|NCT04494178|EXPERIMENTAL|Placebo - 2.0g G-PUR® oral|
62433117|NCT04396483|EXPERIMENTAL|"Tubal sterilization Pomeroy's method"|
62819185|NCT06692673|EXPERIMENTAL|Patients scheduled for Colonoscopy|Adult in-patients, 18 years of age and older, scheduled for an in-patient screening or diagnostic colonoscopy
62819186|NCT02702492|EXPERIMENTAL|Part A: KPT-9274 10mg|Participants received a 10 milligrams (mg) of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.
62819187|NCT02702492|EXPERIMENTAL|Part A: KPT-9274 20mg|Participants received a 20mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.
62819188|NCT02702492|EXPERIMENTAL|Part A: KPT-9274 30mg|Participants received a 30mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.
62819189|NCT02702492|EXPERIMENTAL|Part A: KPT-9274 40mg|Participants received a 40mg of oral tablets of KPT-9274 three times a week every other day during each 28 day cycle.
62819190|NCT02702492|EXPERIMENTAL|Part A: KPT-9274 40mg BIW|Participants received KPT-9274 40mg of oral tablet biweekly (BIW) during each 28-day cycle.
62819191|NCT02702492|EXPERIMENTAL|Part B: KPT-9274 30mg + Niacin 500mg|Participants received KPT-9274 30mg of oral tablet along with a starting dose of 500mg niacin extended release (ER) orally three times a week every other day during each 28-day cycle.
62819192|NCT02702492|EXPERIMENTAL|Part B: KPT-9274 40mg + Niacin 500mg|Participants received KPT-9274 40mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.
62819193|NCT02702492|EXPERIMENTAL|Part B: KPT-9274 60mg + Niacin 500mg|Participants received KPT-9274 60mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.
62819194|NCT02702492|EXPERIMENTAL|Part B: KPT-9274 80mg + Niacin 500mg|Participants received KPT-9274 80mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.
62819195|NCT02702492|EXPERIMENTAL|Part B: KPT-9274 100mg + Niacin 500mg|Participants received KPT-9274 100mg of oral tablet along with a starting dose of 500mg niacin ER orally three times a week every other day during each 28-day cycle.
62433118|NCT04396483|ACTIVE_COMPARATOR|Salpingectomy|
62433119|NCT04711122||Role of prophylactic antibiotics in childscore A|Role of prophylaxis against infections in progression of cirrhotic patients with childscore A
62433120|NCT03472833|EXPERIMENTAL|High-dose|"Intervention with high dose oral vitamin D3 supplementation.~1 drop equals 400 I.U. This group will get 180.000 I.U. on day 1, and then 4000 I.U. per day for 60 days."
62433121|NCT03472833|ACTIVE_COMPARATOR|Standard-dose|"Intervention with standard dose oral vitamin D3 supplementation.~1 drop equals 400 I.U. This group will get 800 I.U. per day for 60 days."
62433122|NCT00384358|EXPERIMENTAL|A|1.0 mg/mL rhBMP-2/CPM + surgical fixation
62433123|NCT00384358|EXPERIMENTAL|B|2.0 mg/mL rhBMP-2/CPM + surgical fixation
62433124|NCT00384358|OTHER|C|Control: Surgical fixation
62433125|NCT05334602|EXPERIMENTAL|study group|Dermal fat graft is added over the grafted bone in the alveolar cleft to protect the bone from resorption
62599851|NCT05195918|ACTIVE_COMPARATOR|EGCG 300 mg with Nintedanib|Patients enrolled in this group will be given oral capsule EGCG 300 mg daily with doctor provided Nintedanib for 12 weeks.
62599852|NCT05195918|ACTIVE_COMPARATOR|EGCG 300 mg with Pirfenidone|Patients enrolled in this group will be given oral capsule EGCG 300 mg daily with doctor provided Pirfenidone for 12 weeks.
62599853|NCT05195918|PLACEBO_COMPARATOR|Placebo for EGCG 300 mg|Patients enrolled in this group will be given oral capsule Placebo daily for 12 weeks with doctor provided Nintedanib or Pirfenidone. The number of placebo capsules will be equal to that of 300 mg EGCG.
62599854|NCT05195918|ACTIVE_COMPARATOR|EGCG 600 mg with Nintedanib|Patients enrolled in this group will be given oral capsule EGCG 600 mg daily with doctor provided Nintedanib for 12 weeks.
62599855|NCT05195918|ACTIVE_COMPARATOR|EGCG 600 mg with Pirfenidone|Patients enrolled in this group will be given oral capsule EGCG 300 mg daily with doctor provided Pirfenidone for 12 weeks.
62599856|NCT05195918|PLACEBO_COMPARATOR|Placebo for EGCG 600 mg|Patients enrolled in this group will be given oral capsule Placebo daily for 12 weeks with doctor provided Nintedanib or Pirfenidone. The number of placebo capsules will be equal to that of 600 mg EGCG.
62599857|NCT05431946||Palliative Care arm|"Intervention by Advance care planning (ACP) conversation:The goal is the identification, assessment, and treatment of physical, psychosocial, or spiritual symptoms and problems.~Advance care actions:These are the actions taken to fulfill the advance care plan and can include, but are not limited to:treatments: pharmacological, psychosocial (priest, psychologist, etc.) referrals: rehabilitation, specialized palliative care team, hospice, etc.~communication initiatives with relatives, primary care, public authorities"
62599858|NCT05431946||Non-participating arm|Will continue standard of care
62599859|NCT04186806|EXPERIMENTAL|3M Dry Mouth Moisturizing Spray|Dry mouth agent
62599860|NCT04186806|ACTIVE_COMPARATOR|Biotene Moisturizing Mouth Spray|Dry mouth agent
62599861|NCT02215863|ACTIVE_COMPARATOR|PCV13 and Fluad|437 concomitant Fluad-PCV13 recipients: one dose of each vaccine administered on Day 0
62819196|NCT02702492|EXPERIMENTAL|Part C: KPT-9274 20mg + Nivolumab 480mg|Participants received KPT-9274 20mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).
62433126|NCT05334602|NO_INTERVENTION|control group|Conventional procedure of alveolar cleft grafting
62433127|NCT02784860|ACTIVE_COMPARATOR|Lidocaine|Lidocaine. Administration of lidocaine is started with 1.5 mg/kg bolus injection followed by a continuous infusion of 4mg/kg/h.
62433128|NCT02784860|PLACEBO_COMPARATOR|Placebo|Placebo Administration of normal saline: same volume of saline as lidocaine.
62599862|NCT02215863|ACTIVE_COMPARATOR|Fluad alone|437 Fluad recipients: one vaccine injection administered on Day 0
62599863|NCT02215863|ACTIVE_COMPARATOR|PCV13 alone|437 PCV13 recipients: one vaccine injection administered on Day 0
62599864|NCT06564948|EXPERIMENTAL|Treatment as usual (TAU)|This arm will consist of 2160 eligible individuals identified to have had criminal legal involvement in Cambridge Health Alliance catchment area cities other than Cambridge (Everett, Somerville, Malden, Medford, Chelsea, Revere, Winthrop). Police departments in these Treatment as Usual cities have no programs that link police officers and clinicians to follow up on safety planning and services. These individuals will be identified as having police involvement between 2009 and 2019.
62599865|NCT06564948|EXPERIMENTAL|Family and Social Justice Section (FSJS)|Consists of 200 Cambridge Health Alliance Patients Ages 18-100 Individuals who have come into contact with the Cambridge Police Department (as identified in the Family and Social Justice Section data) between 2009 and 2019.
62599866|NCT06564948|EXPERIMENTAL|FSJS + Navigator|30 patients recruited during the study period in the Cambridge Health Alliance Emergency Department (ED) Ages 18-100 Individuals who are brought into the ED under police supervision (excluding individuals currently incarcerated) involuntarily brought to the ED for psychiatric evaluation because they are considered to be a risk to themselves or others (MA Law 123(12)); or the subject of a police call for service for a mental health issue who are willingly admitted to the ED
62599867|NCT05882838||Patients admitted to the physical medicine and rehabilitation outpatient clinic.|Patients admitted to the physical medicine and rehabilitation outpatient clinic and gave consent to participate.
62819197|NCT02702492|EXPERIMENTAL|Part C: KPT-9274 30mg + Nivolumab 480mg|Participants received KPT-9274 30mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).
62819198|NCT02702492|EXPERIMENTAL|Part C: KPT-9274 40mg + Nivolumab 480mg|Participants received KPT-9274 40mg of oral tablet three times a week every other day during each 28-day cycle along with 480mg of nivolumab intravenous infusion on Day 1 of each cycle (once every 4-week cycle).
62819199|NCT04603846|EXPERIMENTAL|Combined treatment group|All patients will receive 16 cycles of anti-PD-L1 antibody (5mg/kg, IV, every 3 weeks) , concurrently with 6 cycles of albumin-bound paclitaxel 260mg/m2 d1，q3w；
62819200|NCT02290392||1|African Americans age 30-55 years with severe controlled HTN or severe resistant HTN.
62433129|NCT00297479|EXPERIMENTAL|Mindfulness-Based Treatment Group (MBAT)|MBAT is 6 weeks of nicotine patch therapy; a Self-help guide; and In-person group therapy/counseling (8 sessions over 8 weeks) using a Mindfulness-Based Addiction Treatment for nicotine dependence.
62433130|NCT00297479|ACTIVE_COMPARATOR|Standard Care Group|Standard Care Group (ST) is 6 weeks of nicotine patch therapy, a Self-help guide and In-person group therapy/counseling (8 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
62433131|NCT00297479|ACTIVE_COMPARATOR|Usual Care Group|Usual Care (UC) is 6 weeks of nicotine patch therapy, a Self-help guide and In-person individual counseling (4 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
62433132|NCT04168762|EXPERIMENTAL|TUMS and Sham Group|During the subjects two visits they will receive a TUMS stimulation and a sham (placebo) stimulation at both visits.
62433133|NCT04168762|EXPERIMENTAL|TUMS or Sham Group|During the subjects first of two visits they will receive either a TUMS stimulation or a sham (placebo) stimulation and at the second visit they will receive the other.
62242837|NCT04980508|ACTIVE_COMPARATOR|Patients who did not have COVID-19|Patients underwent diagnostic evaluation including IIEF-5 form, penile color Doppler ultrasonography, corpus cavernosum electromyography, and fasting serum levels of testosterone, luteinizing hormone, follicle stimulating hormone, and prolactin measured in the morning (07-11 am). The relaxation degrees of cavernosal smooth muscles were calculated from the corpus cavernosum electromyography results.
62242838|NCT01180920||Periodontal disease|11 patients with periodontal disease, specifically generalized chronic or aggressive periodontitis will be selected. In general, the disease group will be comprised of subjects that need an open flap procedure.
62599868|NCT03958214|EXPERIMENTAL|Recipe 4 Success|For 12 weeks, home visitors will stop delivering the usual practice Early Head Start home visits and deliver the Recipe 4 Success curriculum instead. At the end of 12 weeks, home visitors will resume usual practice Early Head Start home visits.
62433134|NCT05522517|EXPERIMENTAL|Candin + Cosentyx|Participants will receive a single dose of candin injection intradermally on Day 6 along with a single dose of saline solution injection of 0.9 percent (%) sodium chloride (NaCl) and a single dose of Cosentyx injection subcutaneously on Day 1.
62039553|NCT03752684|EXPERIMENTAL|Low Oxalate Diet|"Subjects not colonized with Oxalobacter formigenes will be equilibrated to a low oxalate diet to determine baseline oxalate values in urine .~Subjects will be colonized with Oxalobacter formigenes (Intervention). Following colonization with Oxalobacter formigenes, urinary oxalate will be measured to determine the impact of colonization."
62433135|NCT05522517|NO_INTERVENTION|Candin Challenge|All participants will receive single dose of candin injection intradermally on Day 6 along with a single dose of saline solution injection of 0.9 percent (%) sodium chloride (NaCl) administered intradermally and no Cosentyx.
62433136|NCT01674842|EXPERIMENTAL|Cisplatin + Radiation Therapy|Cisplatin concurrently with radiation therapy
62433137|NCT01281579|EXPERIMENTAL|001|Canagliflozin 50 mg Tablets oral 50-mg once daily on Day 1 and on Days 4 through 9.
62599869|NCT03958214|ACTIVE_COMPARATOR|Usual practice Early Head Start|Home visitors will continue to deliver usual practice Early Head Start home visits that follow a standard curriculum and are tailored on an ongoing basis to meet individual family needs.
62599870|NCT06505915|EXPERIMENTAL|Group C|fasting protocol consuming carbohydrate drinks before elective caesarean delivery and sipping water until called to theatre
62039554|NCT03752684|EXPERIMENTAL|Moderately high oxalate/low calcium diet|"Subjects not colonized with Oxalobacter formigenes will be equilibrated to a moderately high oxalate/ low calcium oxalate diet to enhance dietary oxalate absorption.~Subjects will be colonized with Oxalobacter formigenes(Intervention). Following colonization with Oxalobacter formigenes, urinary oxalate will be measured to determine the impact of colonization."
62039555|NCT03752684|EXPERIMENTAL|Oxalobacter formigenes|Subjects will ingest a live preparation of O.formigenes
62039556|NCT05480475|EXPERIMENTAL|Study treatment (Period 1, 2, and 3)|Period 1: Treatment A1 - dabigatran etexilate; Treatment A2 - rosuvastatin Period 2: Treatment B - daridorexant Period 3: Treatment C1 - dabigatran etexilate and daridorexant; Treatment C2 - rosuvastatin and daridorexant
62039557|NCT04585932|ACTIVE_COMPARATOR|Group I (apalutamide, leuprolide, degarelix)|Patients receive apalutamide PO QD on days 1-28 and ADT consisting of leuprolide IM every 12 weeks or degarelix SC every 4 weeks. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
62242839|NCT01180920||Healthy periodontium|11 patients without periodontal disease will be selected. In general, the healthy group will be comprised of subjects that are requiring a gingivectomy or crown lengthening procedure.
62242840|NCT01629784|OTHER|CLE and sun counseling|
62242841|NCT00495404|OTHER|Arm 1|
62242842|NCT00495404|OTHER|Arm 2|
62433138|NCT01281579|EXPERIMENTAL|002|Canagliflozin 100 mg Tablets oral 100-mg once daily on Day 1 and on Days 4 through 9.
62433139|NCT01281579|EXPERIMENTAL|003|Canagliflozin 300 mg Tablets oral 300-mg once daily on Day 1 and on Days 4 through 9.
62433140|NCT02204683|OTHER|Aflibercept|Subjects who have had a vitrectomy previously
62433141|NCT02204683|OTHER|Aflibercept in Non-Vitrectomized eyes|Patients who have not had vitrectomy.
62433142|NCT01665859||Danish Ventral Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
62433143|NCT01017029|ACTIVE_COMPARATOR|Immediate introduction of everolimus|
62599871|NCT06505915|ACTIVE_COMPARATOR|Group S|fasting protocol NOT consuming carbohydrate drinks before elective caesarean delivery, but encouraged to sip water until called to theatre
62599872|NCT01275651||Ancillary-Correlative (AR activity in CRPC)|Previously collected bone marrow tissue and blood samples are analyzed for AR activity, AR splice variations, expression of androgen transport/synthesis/metabolism genes, AKR1C3 protein levels, and testosterone and dihydrotestosterone levels via RT-PCR, SNP microarrays, IHC, gene expression analysis, and mass spectrometry methods.
62599873|NCT00962975|EXPERIMENTAL|Single Arm|
62039558|NCT04585932|EXPERIMENTAL|Group II (apalutamide, leuprolide, degarelix, RT)|Patients receive apalutamide PO QD on days 1-28 and ADT consisting of leuprolide IM every 12 weeks or degarelix SC every 4 weeks. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo RT between cycles 4-7 in the absence of disease progression or unacceptable toxicity.
62819201|NCT05593380|EXPERIMENTAL|ICP monitoring|Intracranial pressure monitoring equipment enables continuous dynamic monitoring of changes in intracranial pressure values. This technology reflects sudden shifts in intracranial pressure resulting from hemorrhage and other cranial conditions, allowing for timely adjustments in the intensity of cerebral therapeutic interventions.
62819202|NCT05593380|OTHER|imaging-clinical examination (ICE)|According to routine head CT imaging examinations, dynamic observations of changes in the patient's condition should be conducted. This involves closely monitoring clinical consciousness, pupil response, limb activity, and other clinical manifestations. Adjustments to the intensity of cerebral intervention should be made based on the clinical reflections of these dynamic changes.
62039559|NCT06551974|EXPERIMENTAL|Guided self-help plus IPT|"The participants will have access to self-help materials (workbook and videoclips), forum groups (interactional materials), online interpersonal group sessions for 8 weeks. Participants will use self-help materials through a mobile app and online platform. Regarding anorexic symptoms and behaviours, the self-help material will focus on the topics of the New Maudsley model. Further modules will cover the ED overeating problems and the interpersonal difficulties related to EDs.~The weekly online forum group is focused on interactional material that will be delivered weekly through a synchronous 1-hour mobile chat with a peer mentor (a recovered influencer). Each session lasts 60 minutes and is themed following the structure of the video-clips materials.~Finally, 90-minute interpersonal group sessions will be led online by clinicians with an expertise in the treatment of eating disorders."
62039560|NCT06551974|ACTIVE_COMPARATOR|Treatment-as-usual|Treatment as usual will vary between centres and this will impact the effect size of the intervention (Ayling et al., 2015). We will therefore conduct structured interviews with clinicians at each study site to clarify the nature of treatment as usual at each centre. We will also use an adapted form of the Client Service Receipt Inventory (a well-established tool used in health economics) to track the amount of treatment received over the year (Beecham \& Knapp, 1992). The inventory will be administered at 8-week and 3-month, to measure patients' service usage.
62242843|NCT06734702|EXPERIMENTAL|Study group|Patients in this group will receive two cycles of neoadjuvant immuno-chemotherapy. After neoadjuvant therapy, they will undergo concurrent chemoradiotherapy, followed by consolidative immunotherapy for a maximum duration of 12 months.
62242844|NCT06734702|ACTIVE_COMPARATOR|Control group|Patients in this group will receive concurrent chemoradiotherapy followed by consolidative immunotherapy.
62242845|NCT03374995|EXPERIMENTAL|Group I (topical keratin)|Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks).
62242846|NCT03374995|ACTIVE_COMPARATOR|Group II (standard of care)|Patients receive standard of care as directed by radiation oncologist until the end of radiation therapy (approximately 3-6 weeks).
62242847|NCT05117255|EXPERIMENTAL|Experimental: Computer-delivered cognitive behavioral therapy hybrid for comorbidity|Four, approximately 60 minute each, computerized therapy sessions delivered on an interactive computerized platform. All participants are undergoing a standard 28 day residential alcohol treatment program.
62242848|NCT05117255|ACTIVE_COMPARATOR|Control: Progressive Muscle Relaxation Training (PMRT)|Four, one-hour computerized segments delivered on an interactive computerized platform teaching Progressive Muscle Relaxation Training (PMRT). All participants are undergoing a standard 28 day residential alcohol treatment program.
62819203|NCT05800210|EXPERIMENTAL|Allogeneic stem cell transplant with ⍺/β CD3+ T-cell and CD19+ B-cell depleted graft|
62819204|NCT05552846|EXPERIMENTAL|experimental group|chemo-immunotherapy followed by thoracic radiotherapy and PD-1/PD-L1 maintenance therapy
62819205|NCT05997225|EXPERIMENTAL|Enhanced Treatment|"Opt-out counseling enrollment. individually-tailored biofeedback linked to Chest CT and spirometry results.~Varenicline: Preloading regimen (prior to target quit date): 0.5 mg once a day for days 1-3, 0.5 mg twice a day for days 4-7, and 1 mg twice a day for days 8-28.~1 mg twice day for 12 weeks after target quit date."
62242849|NCT05117255|NO_INTERVENTION|Treatment as Usual (TAU)|Participants are undergoing a standard 28 day residential alcohol treatment program. No study intervention.
62242850|NCT01209871|EXPERIMENTAL|Treatment (vaccine therapy)|Patients receive autologous lymphoma immunoglobulin-derived scFV-chemokine DNA vaccine ID at 0, 4, and 8 weeks.
62242851|NCT06352411|EXPERIMENTAL|Group 1: Participants with normal renal function|
62819206|NCT05997225|ACTIVE_COMPARATOR|Standard Treatment|"Opt-in counseling enrollment. Standard tobacco cessation counseling.~Varenicline: Preloading regimen (prior to target quit date): 0.5 mg once a day for days 1-3, 0.5 mg twice a day for days 4-7, and 1 mg twice a day for days 8-28.~1 mg twice day for 12 weeks after target quit date."
62819207|NCT05702463|EXPERIMENTAL|EC ASA 162 mg once daily for 7 days|EC ASA 162 mg once daily for 7 days
62242852|NCT06352411|EXPERIMENTAL|Group 2: Participants with mild renal impairment|
62433144|NCT01017029|EXPERIMENTAL|Delayed introduction of everolimus|delayed introduction) + Cyclosporin + steroids
62433145|NCT04708405||Inflammatory bowel disease patients|Inflammatory bowel disease patients screened for Helicobacter Pylori Infection
62039561|NCT06551974|EXPERIMENTAL|Guided self-help|"The participants will have access to self-help materials (workbook and videoclips), and forum groups (interactional materials). Participants will use self-help materials through a mobile app and online platform. Regarding anorexic symptoms and behaviours, the self-help material will focus on the topics of the New Maudsley model. Further modules will cover the ED overeating problems and the interpersonal difficulties related to EDs.~The weekly online forum group is focused on interactional material that will be delivered weekly through a synchronous 1-hour mobile chat with a peer mentor (a recovered influencer). Each session lasts 60 minutes and is themed following the structure of the video-clips materials."
62039562|NCT06551974|NO_INTERVENTION|No treatment|The no-treatment control condition includes participants with sub-threshold eating symptoms who attend regular visits with their own primary care physician. In this context, it is important that participants, interested to take part to the study, offered number or contact of the own primary care physician in case of an illness worsening.
62242853|NCT06352411|EXPERIMENTAL|Group 3: Participants with moderate renal impairment|
62242854|NCT06352411|EXPERIMENTAL|Group 4: Participants with severe renal impairment|
62242855|NCT02577601|ACTIVE_COMPARATOR|UPA Only|During the first treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10). Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.
62242856|NCT02577601|NO_INTERVENTION|Washout Cycle|The month following this first treatment month (washout-cycle),there will be no study visits during this menstrual cycle but there will be contact with study staff (1 or 2 times) by telephone or email to discuss any health changes that are experiencing.
62819208|NCT05702463|EXPERIMENTAL|EC ASA 81 mg twice daily for 7 days|EC ASA 81 mg twice daily for 7 days
62819209|NCT05702463|EXPERIMENTAL|chewable ASA 40 mg twice daily for 7 days|chewable ASA 40 mg twice daily for 7 days
62242857|NCT02577601|ACTIVE_COMPARATOR|UPA + COC|During the second treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10) and then 2 days later start birth control pills. Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.
62242858|NCT06111482|EXPERIMENTAL|IPL only|Group A will be treated with an intense pulsed light (IPL) device only. They may also receive split treatments where one side of the face and/or body will be treated with the study device and the contralateral side will be treated with a similar IPL device that is cleared for use by the FDA.
62242859|NCT06111482|EXPERIMENTAL|RF Microneedling Only|Group B will be treated with a radiofrequency (RF) microneedling device only. They may also receive split treatments where one side of the face and/or body will be treated with the study device and the contralateral side will be treated with a similar RF microneedling device that is cleared for use by the FDA.
62242860|NCT06111482|EXPERIMENTAL|RF Only|Group C will be treated with an RF device only. They may also receive split treatments where one side of the face and/or body will be treated with the study device and the contralateral side will be treated with a similar RF device that is cleared for use by the FDA.
62242861|NCT06111482|EXPERIMENTAL|Combination|Group D will receive combination treatments and will be treated with 2 or more of the study devices.
62242862|NCT03951779|EXPERIMENTAL|Subjects with unexplained but suspected cardiac dyspnea|Subjects with unexplained but suspected cardiac dyspnea who are being scheduled for right heart catheterization will undergo an exercise cardiac magnetic resonance imaging (eCMR).
62242863|NCT05011682|EXPERIMENTAL|Joslin Diabetes Senter nutrition|all participants will first follow their own usual diet (2 weeks) and then the Joslin Diabetes Senter nutrition plan (2 weeks)
62242864|NCT04393025|OTHER|Intracranial Stenting|25 Patients presented with recurrent Ischemic CVS with Large ICSD received ICS
62242865|NCT04393025|ACTIVE_COMPARATOR|Aspirin+Clopidogrel|25 Patients presented with recurrent Ischemic CVS with Large ICSD received optimal medical treatment
62242866|NCT04390048|EXPERIMENTAL|Anodal tDCS and Balance Training (BT) Group|Participants will undergo 4 weeks of BT under anodal tDCS treatment.
62242867|NCT04390048|SHAM_COMPARATOR|Sham tDCS and BT Group|Participants will undergo 4 weeks of BT under sham tDCS.
62242868|NCT06735417|EXPERIMENTAL|Indashikirwa program|"The group will receive the Indashikirwa program, which includes:~1. Couple curriculum training for both husbands and wives. These sessions focus on promoting joint decision-making and transforming gender norm to promote healthier and more equitable relationships.~2. Establishment of safe spaces to foster community support and facilitate dialogue around gender-based issues."
62242869|NCT06735417|NO_INTERVENTION|Control group|This arm is the control group
62242870|NCT02177890|EXPERIMENTAL|Transcutaneous vagal nerve stimulation|Active vagal nerve stimulation to the left auricular branch of the vagus nerve
62242871|NCT02177890|PLACEBO_COMPARATOR|Sham vagal nerve stimulation|Placebo vagal nerve stimulation - stimulator attached to the ear but rotated 180 degrees so that it is not stimulating the vagus nerve.
62242872|NCT01846325|EXPERIMENTAL|DHA plus vitamin E|Cap DHA 460mg plus vitamin E 600mg per day
62242873|NCT01846325|ACTIVE_COMPARATOR|VitaminE plus placebo|vitamin E 600 mg plus placebo
62433146|NCT04826185|EXPERIMENTAL|IMB-1018972 200mg|
62433147|NCT04826185|PLACEBO_COMPARATOR|Placebo|
62819210|NCT05896163|EXPERIMENTAL|Phase 1b|Participants will be allocated to sequential dose levels of PF-07901801, administered in combination with fixed doses of glofitamab after a dose of obinutuzumab, to select two doses of PF-07901801 for further evaluation in Phase 2. Approximately 20 participants will be enrolled.
62819211|NCT05896163|EXPERIMENTAL|Phase 2|Participants will be randomized to 1 of 2 different dose levels of PF-07901801 which will be administered in combination with fixed doses of glofitamab after a dose of obinutuzumab. Approximately 50 participants will be enrolled (25 per dose).
62819212|NCT05896163|EXPERIMENTAL|PK Bridging Sub-Study|Participants will be allocated to 2 dose levels of PF-07901801 manufactured with process 3, administered in combination with fixed doses of glofitamab after a dose of obinutuzumab, to evaluate the pharmacokinetic of PF-07901801 using Process 3 material and determine a dose comparable to the recommended PF-07901801 dose for phase 3 determined in Phase 2. Approximately 20 participants will be enrolled.
62819213|NCT03925454||In-Centre Haemodiafiltration (ICHDF) Group|Participants undergoing ICHDF treatment will be recruited into this group, their treatment will follow the standard care pathway in this observational study.
62039563|NCT05381974|EXPERIMENTAL|Psilocybin|25mg of Psilocybin
62819214|NCT03925454||Home HaemoDialysis (HHD) Group|Participants undergoing HHD treatment will be recruited into this group, their treatment will follow the standard care pathway in this observational study.
62819215|NCT04418024|EXPERIMENTAL|AG10 800 mg|TTR stabilizer administered orally twice daily (BID)
62039564|NCT00931372|EXPERIMENTAL|Sequence 1: AVE0010/Placebo|"Period 1: lixisenatide 20 µg in 200 µL, one single dose~Period 2: placebo 200 µL, one single dose"
62039565|NCT00931372|EXPERIMENTAL|Sequence 2: Placebo/AVE0010|"Period 1: placebo 200 µL, one single dose~Period 2: lixisenatide 20 µg in 200 µL, one single dose"
62039566|NCT03818412|EXPERIMENTAL|Soft Tissue Sarcoma|"A sample of archival tumor tissue will be collected.~Blood samples (about 20-30 mL or 1-2 tablespoons each sample) will be taken:~* Prior to planned radiation treatment~* 2-4 weeks after cancer surgery~* Every 12 weeks after surgery for up to 2 years"
62039567|NCT02127424|EXPERIMENTAL|Combination of the nurse-driven HIV targeted screening and the|Nurses will offer screening to all patients at EDs, aged 18-64 years old, identified as high-risk by a self-administered questionnaire, not know to be HIV positive, accepting to participate by providing an informed consent and not being seen at ED for post-exposure prophylaxis or unstable medical illness. The questionnaire was previously tested in one ED. In case of reactive rapid test result, blood specimen will be collected for standard enzyme-linked immunosorbent assay and Western blot confirmation. A follow-up visit with an on-site infectious disease specialist will be arranged within the following 48 hours.
62039568|NCT02127424|ACTIVE_COMPARATOR|Current practice (no intervention)|Physician-directed HIV diagnostic testing
62039569|NCT04653766|EXPERIMENTAL|Ir-CPI - Dose 1|Participants received a single intravenous dose of 1.5 mg/kg of Ir-CPI during 6 hours
62039570|NCT04653766|EXPERIMENTAL|Ir-CPI - Dose 2|Participants received a single intravenous dose of 3.0 mg/kg of Ir-CPI during 6 hours
62819216|NCT04418024|PLACEBO_COMPARATOR|Placebo|Placebo administered orally twice daily (BID)
62819217|NCT06702072||Endobronchial valve treatment|Patients who are undergo a bronchoscopic treatment using endobronchial valves.
62819218|NCT02061787||cardiopulmonary exercise testing|patients diagnosed with pulmonary hypertension, including pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension, were evaluated by cardiopulmonary exercise testing before and after medical or balloon pulmonary angioplasty treatment
62819219|NCT04440033|EXPERIMENTAL|Parkinson's Disease group|Patients with stage 3 idiopathic Parkinson's Disease
62819220|NCT04440033|ACTIVE_COMPARATOR|Healthy control group|Age and sex-matched healthy adults
62819221|NCT06178796|ACTIVE_COMPARATOR|With graft|
62819222|NCT06178796|ACTIVE_COMPARATOR|Without graft|
62819223|NCT06178796|ACTIVE_COMPARATOR|Delayed healing site|
62819224|NCT03916133|OTHER|Intervention group|Included patients will undergo angiographic FDCT perfusion imaging.The study will be embedded in the standard procedure of pre-operative diagnostics and angiographic control after EC-IC bypass treatment of steno-occlusive disease and during pre-embolization mapping and embolization procedure. An informed consent will be acquired during consultations in the preparatory process of the different examinations and treatments
62039571|NCT04653766|EXPERIMENTAL|Ir-CPI - Dose 3|Participants received a single intravenous dose of 6.0 mg/kg of Ir-CPI during 6 hours
62039572|NCT04653766|EXPERIMENTAL|Ir-CPI - Dose 4|Participants received a single intravenous dose of 9.0 mg/kg of Ir-CPI during 6 hours
62039573|NCT04653766|PLACEBO_COMPARATOR|Placebo|Participants received a single intravenous dose of placebo during 6 hours
62039574|NCT02654808|ACTIVE_COMPARATOR|Standard trocar/ IAP 15 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the standard trocar insufflator at an intra-abdominal pressure (IAP) of 15 mmHg.
62039575|NCT02654808|ACTIVE_COMPARATOR|Standard trocar/ IAP 10 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the standard trocar insufflator at an intra-abdominal pressure (IAP) of 10 mmHg.
62039576|NCT02654808|ACTIVE_COMPARATOR|AirSeal trocar/ IAP 15 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the AirSeal trocar insufflator at an intra-abdominal pressure (IAP) of 15 mmHg.
62039577|NCT02654808|ACTIVE_COMPARATOR|AirSeal trocar/ IAP 10 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the AirSeal trocar insufflator at an intra-abdominal pressure (IAP) of 10 mmHg.
62039578|NCT02677116|EXPERIMENTAL|Olaratumab + Doxorubicin (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
62039579|NCT02677116|EXPERIMENTAL|Olaratumab + Vincristine + Irinotecan (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 15 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
62242874|NCT01846325|PLACEBO_COMPARATOR|placebo plus placebo|DHA shaped placebo plus vitamin E shaped placebo
62819225|NCT03889184|EXPERIMENTAL|rehabilitating meals-on-wheels service|the intervention group will for 8 weeks receive a rehabilitating meals-on-wheels service
62819226|NCT03889184|NO_INTERVENTION|Usual care|the control group will receive usual care
62819227|NCT03084146|EXPERIMENTAL|Psoriasis|Psoriasis patients will be placed on an individualized 12-week elimination diet
62819228|NCT03084146|NO_INTERVENTION|Healthy Control|Healthy Control patients will receive no intervention
62819229|NCT06277687|EXPERIMENTAL|perforator localization|Virtual Augmented Reality combined with Finder and Color Doppler Ultrasound were used to locate the perforating branch of the descending branch of the lateral circumflex femoral artery, and the position of the perforator was compared with real perforator respectively during the operation.
62819230|NCT06220214|EXPERIMENTAL|CEDM + CEDBT|Participants undergo CEDM + CEDBT imaging after every 4-6 cycles of neoadjuvant chemotherapy prior to surgery (imaging may occur up to 2 times)
62039580|NCT02677116|EXPERIMENTAL|Olaratumab + Ifosfamide (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
62039581|NCT02677116|EXPERIMENTAL|Olaratumab + Doxorubicin (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
62039582|NCT02677116|EXPERIMENTAL|Olaratumab + Vincristine + Irinotecan (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
62039583|NCT02677116|EXPERIMENTAL|Olaratumab + Ifosfamide (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
62039584|NCT02677116|EXPERIMENTAL|Olaratumab + Doxorubicin (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
62738572|NCT06147128||Experimental: PBP for Technical and Non-Technical emergency undocking skills|Participants in the PBP trained group will follow the exact same e-learning didactic course as the Traditional trained group but the PBP group will be required to pass a test of procedure knowledge on both TS and NTS before continuing to the robotic surgical training element. The trainees knowledge will be assessed in a formative and summative fashion. After the trainees initial assessment, procedure-specific and validated procedure metrics will be used to teach them the steps of the emergency undocking procedure, as well as the correct (and incorrect) way to perform it. The metrics will be used to give to the trainees performance feedback with specific advice on how they might improve their performance, in the regards of technical and non-technical skills.
62738573|NCT01019122||Dexa Scan|Eligible patients from 2003 study will receive a follow-up Dexa scan.
62738574|NCT05665335|EXPERIMENTAL|Renuvion APR System|Subjects treated with the Renuvion APR system in both breasts.
62738575|NCT01894048|EXPERIMENTAL|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
62738576|NCT06657820|EXPERIMENTAL|Desaturation|A central venous catheter will be placed in the right internal jugular vein and the catheter tip advanced retrograde to lie at the level of the jugular bulb. An arterial catheter will be placed in the forearm. A dedicated breathing circuit will be used to reduce the alveolar oxygen tension (PAO2) in stepwise fashion to produce a controlled oxygen desaturation sequence. The dedicated breathing circuit will be used to maintain the alveolar carbon dioxide tension (PACO2) at normocapnic value of 40 mmHg. At each step once steady state conditions are achieved, serial paired arterial and jugular bulb venous samples will be drawn. The blood gas samples will be analyzed by Radiometer ABL90 Flex CO-oximeter.
62738577|NCT06660485||Continuous CCTA Scanning Cohort|
62738578|NCT02303756|EXPERIMENTAL|Pillcam® COLON Capsule|Detection of neoplastic lesions in colon and rectum compared to colonoscopy
62738579|NCT01324050|EXPERIMENTAL|Internet-based Psychodynamic Therapy|
62738580|NCT01324050|ACTIVE_COMPARATOR|Internet-delivered therapist support|
62738581|NCT02088840||stem cell tranplant|All patients undergoing autologous or allogeneic stem cell tranplant for any underlying disease
62039585|NCT02677116|EXPERIMENTAL|Olaratumab + Vincristine + Irinotecan (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
62039586|NCT02677116|EXPERIMENTAL|Olaratumab + Ifosfamide (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
62039587|NCT02821273|EXPERIMENTAL|Modified INSURE|Modified INSURE is intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.
62242875|NCT01846325|ACTIVE_COMPARATOR|DHA plus placebo|460 mg DHA plus placebo
62242876|NCT01449877|ACTIVE_COMPARATOR|Trimethoprim-Sulfamethoxazole|1 tablet every other day, morning.
62039588|NCT02821273|ACTIVE_COMPARATOR|INSURE|INSURE technique meas surfactant administration through intubation-surfactant-extubation. And noninvasive ventilation is immediately used after surfactant.
62039589|NCT04326270|ACTIVE_COMPARATOR|nCPAP prongs|
62433148|NCT05154422||Normal body fat cohort|Determining the general amount of lipolysis, circulating insulin and growth hormone, and muscle quality of a group of recreational female endurance athletes with normal body fat determined by air displacement plethysmograph.
62433149|NCT05154422||Excess body fat cohort|Determining the general amount of lipolysis, circulating insulin and growth hormone, and muscle quality of a group of recreational female endurance athletes with excess body fat determined by air displacement plethysmograph.
62433150|NCT05784506|EXPERIMENTAL|Macronutrients loading test for healthy group|A total of 30 subjects with normal metabolic status underwent three successive food tolerance tests (glucose, protein and fat) at one-week intervals.
62433151|NCT05784506|EXPERIMENTAL|Mixed meal tolerance test (MMTT) for healthy group|A total of 40 subjects with normal weight and plasma glucose levels underwent MMTT.
62433152|NCT05784506|EXPERIMENTAL|Mixed meal tolerance test (MMTT) for overweight subjects with normal plasma glucose|A total of 40 overweight subjects without a history of diabetes underwent MMTT.
62433153|NCT05784506|EXPERIMENTAL|Mixed meal tolerance test (MMTT) for obese subjects with abnormal plasma glucose|A total of 40 obese subjects without a history of diabetes underwent MMTT.
62433154|NCT06208761|PLACEBO_COMPARATOR|Placebo capsule supplementation|Participants were randomized to receive an arm. In this arm, participants consumed placebo capsule for 2 capsules daily consisting of 1 capsule (500 mg) before breakfast and 1 capsule (500 mg) before dinner, 5 days/week - separated by a couple of days, for 8 weeks. Consumption was taken at participants' dwelling.
62433155|NCT06208761|EXPERIMENTAL|Triphala capsule supplementation|Participants were randomized to receive an arm. In this arm, participants consumed Triphala capsule for 2 capsules daily consisting of 1 capsule (500 mg) before breakfast and 1 capsule (500 mg) before dinner, 5 days/week - separated by a couple of days, for 8 weeks. Consumption was taken at participants' dwelling.
62433156|NCT06208761|EXPERIMENTAL|High-intensity interval training|Participants were randomized to receive an arm. In this arm, participants received leg cycling exercise program in the form of high-intensity interval training for 28 min/day, 3 days/week for 8 weeks. Exercise training was performed at Burapha University.
62433157|NCT06208761|EXPERIMENTAL|Triphala capsule supplementation and high-intensity interval training|Participants were randomized to receive an arm. In this arm, participants received both Triphala capsule and high-intensity interval training in the similar extent to the Triphala capsule supplementation and high-intensity interval training arms. Consumption was taken at participants' dwelling and exercise training was performed at Burapha University.
62433158|NCT06452823||Combined Thyroid Dysfunction|Atrial catheter radiofrequency ablation for atrial fibrillation combined with patients requiring prior thyroid hormone abnormalities
62433159|NCT06452823||Uncomplicated thyroid dysfunction|Atrial catheter radiofrequency ablation for atrial fibrillation in patients with uncomplicated need for prior thyroid hormone abnormalities
62433160|NCT02589769|EXPERIMENTAL|unsaturated fat|an intervention diet substituting unsaturated fats from oil and nuts for saturated fats from meat and dairy foods
62433161|NCT02589769|ACTIVE_COMPARATOR|saturated fat|a control diet with whole fat dairy and meat with saturated fats that are not fat reduced.
62039590|NCT04326270|ACTIVE_COMPARATOR|Infant cannula|
62242877|NCT01449877|PLACEBO_COMPARATOR|Starch tablet|1 starch tablet every other day, morning.
62242878|NCT00638560|EXPERIMENTAL|1|"Antioxidant treatment arm:~Vitamin E, 400 IU po, once daily Vitamin C, 1g po, twice daily"
62242879|NCT00638560|PLACEBO_COMPARATOR|2|Control
62242880|NCT04264429|EXPERIMENTAL|Infrapatellar strap|This group will perform the functional tests with the infrapatellar strap positioned on the painful knee.
62242881|NCT04264429|EXPERIMENTAL|Elastic Band|This group will perform the functional tests with the elastic band positioned on the painful knee.
62242882|NCT04264429|NO_INTERVENTION|Control|This group will perform the functional tests without elastic band or infrapatellar strap positioned on the painful knee.
62242883|NCT03085758|EXPERIMENTAL|Treatment Arm A|Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab (treatment arm A)
62242884|NCT03085758|EXPERIMENTAL|Treatment Arm B|Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab (treatment arm B)
62242885|NCT03085758|PLACEBO_COMPARATOR|Control group|Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab (control group)
62242886|NCT05111041|EXPERIMENTAL|#EnufSnuff.TXT- First Responder|Participants in this group will receive a mobile gradual smokeless tobacco reduction intervention
62242887|NCT05111041|ACTIVE_COMPARATOR|Enough Snuff Intervention|Participants in this group will receive tobacco cessation materials
62039591|NCT06653855|ACTIVE_COMPARATOR|Cupping group|This group (arm) will receive the dry static cupping intervention, along with the standard physical therapy treatment.
62039592|NCT06653855|SHAM_COMPARATOR|Placebo cupping group|This group (arm) will receive a placebo-form of cupping (low, and non-therapeutic pressure amount in the cups), along with the standard physical therapy treatment.
62039593|NCT05699733|EXPERIMENTAL|Mechanical traction force 30% of body weight|will receive continuous mechanical traction from semi flexed knee, for 30 minutes using 30% of the body weight as a traction force
62039594|NCT05699733|EXPERIMENTAL|Mechanical traction force 20% of body weight|will receive continuous mechanical traction from semi flexed knee, for 30 minutes using 20% of the body weight as a traction force
62039595|NCT05699733|EXPERIMENTAL|Mechanical traction force 10% of body weight|will receive continuous mechanical traction from semi flexed knee, for 30 minutes using 10 % of the body weight as a traction force
62039596|NCT02428114||5 days of filgrastim|Standard of care
62039597|NCT02428114||7 days of filgrastim|Standard of care
62039598|NCT02428114||10 days of filgrastim|Standard of care
62039599|NCT02141126|EXPERIMENTAL|Resistance training|Usual care and resistance exercises.
62039600|NCT02141126|OTHER|Usual care|Usual inpatient physiotherapy
62039601|NCT04070924|ACTIVE_COMPARATOR|Conventional post-operative bulky soft tissue dressing|"1. Intraoperative: MAC-Local Anesthesia; Local anesthetic mixture will be distributed in both the subcutaneous tissue and within the carpal canal~2. Postoperative: Non-opioid medications only; Conventional post-operative bulky soft tissue dressing (Xeroform, 4x4s, Webril, Ace Wrap; Worn until first postoperative visit)"
62039602|NCT04070924|EXPERIMENTAL|Bandaid post-operative dressing|"1. Intraoperative: MAC-Local Anesthesia; Local anesthetic mixture will be distributed in both the subcutaneous tissue and within the carpal canal~2. Postoperative: Non-opioid medications only; Bandaid over incision (Patient given an edema glove to wear starting post-operative day 1; Dressing change be changed post-operative day 2 and as needed after that)"
62039603|NCT00591890|EXPERIMENTAL|Single Arm|
62039604|NCT02434692|EXPERIMENTAL|Single-arm intervention ARGOS-IO system|The ARGOS-IO Pressure sensor will be additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery.
62039605|NCT01945606|EXPERIMENTAL|Placebo and BAY1067197|Patients will get both treatment 1 and 2
62242888|NCT02196623|EXPERIMENTAL|Hypoxic Exercise|Supervised, progressive aerobic exercise for 8 weeks under hypoxic conditions
62242889|NCT02196623|SHAM_COMPARATOR|Normoxic exercise|Supervised, progressive aerobic exercise for 8 weeks under normoxic conditions
62039606|NCT03190473|EXPERIMENTAL|Svelte|
62039607|NCT03190473|ACTIVE_COMPARATOR|Control|
62242890|NCT03690141|EXPERIMENTAL|tomivosertib (eFT508)|Tomivosertib (eFT508) is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics, Inc. as an anticancer therapy. Tomivosertib (eFT508) down regulates AR and acts by inhibiting mitogen-activated protein kinase-interacting serine/threonine kinase-1 (MNK1) and MNK2.
62242891|NCT04227951|SHAM_COMPARATOR|Drain|Participants enrolled in this arm have an abdominal drain positioned at the end of the operation (any type, inserted from right flank with the tip close to the esophago-jejunal or Gastro-jejunal anastomosis and the duodenal stump). Drain will stay in place until postoperative day (POD) 4th (drain output and quality will be registered). If normal drain debt and patient have no abdominal complications that need reoperation and/or percutaneous drain placement until POD 4, a methylene-blue test is be performed (200 ml water + 5 ml blue orally, check drain after 60 minutes: negative test if no blu was seen in the drain). If negative-blue test drain can be removed according to centre preference (no strict POD defined); if positive-blue test complication will be treated according to centre preference. Only in this arm drain related complications are registered. Need for reoperation and/or percutaneous drain placement (primary outcome) are registered.
62242892|NCT04227951|EXPERIMENTAL|No Drain|Participants enrolled in this arm do not have any abdominal drain placed at the end of the operation. Postoperative management (e.g. resume of oral intake, anastomosis integrity tests) is left to centre preference. Need for reoperation and/or percutaneous drain placement (primary outcome) are registered.
62242893|NCT04426955|EXPERIMENTAL|Arm A|Camrelizumb + Paclitaxel + Cisplatin + Radiotherapy.
62242894|NCT04426955|PLACEBO_COMPARATOR|Arm B|Placebo + Paclitaxel + Cisplatin + Radiotherapy.
62242895|NCT05981911||XIENCE Skypoint™ stent|Patients receiving Xience-Skypoint™ stents
62039608|NCT04171466|ACTIVE_COMPARATOR|Broad Spectrum Antibiotic Therapy + Microbial Consortia|
62039609|NCT04171466|PLACEBO_COMPARATOR|Broad Spectrum Antibiotic Therapy + Placebo|
62039610|NCT04171466|ACTIVE_COMPARATOR|No Antibiotic Therapy + Microbial Consortia|
62039611|NCT04171466|PLACEBO_COMPARATOR|No Antibiotic Therapy + Placebo|
62039612|NCT03404505|EXPERIMENTAL|Infant Achievements|Families randomized to the IA condition will receive 17 in-home sessions. These include a one-time start up session followed by twice-weekly visits in which they will be coached on how to implement the IA strategies. Families will receive a set of developmentally appropriate toys.
62039613|NCT03404505|EXPERIMENTAL|Caregiver Education|In this condition, parents will receive 17 sessions with a trained study team member focused on promoting child development and well-being. Sessions include a one-time start-up visit followed by one in-home visit and one phone contact per week. Families will receive a set of developmentally appropriate toys.
62039614|NCT06732193|ACTIVE_COMPARATOR|In-person respiratory physiotherapy|The patient must attend the respiratory physiotherapy sessions given by physiotherapists at the place and time established in each centre, before and after surgery.
62039615|NCT06732193|EXPERIMENTAL|Face-to-face respiratory physiotherapy plus use of the Fissios App|The same protocol will be followed as for the control group and, in addition, the steps for downloading the application and the start-up will be explained verbally and in writing. The researcher will encourage the patient to use the Fissios App©, read all the perioperative medical recommendations and perform the respiratory physiotherapy exercises freely without restrictions in terms of time, time of use or location.
62039616|NCT05911204||Mothers|One single group of mothers exposed to intense and sustained noises during pregnancy
62039617|NCT05245071|EXPERIMENTAL|Tusamitamab ravtansine|Tusamitamab ravtansine dose will be administered on Day 1 via IV infusion and repeated once every 2 weeks. The duration of 1 cycle will be 14 days (1 administration of tusamitamab ravtansine per cycle).
62039618|NCT06480773||HIV-associated Kaposi Sarcoma|Patients receive standard-of-care chemotherapy.
62039619|NCT04866017|EXPERIMENTAL|Ociperlimab + Tislelizumab + cCRT|Participants enrolled under PA1 recieved two cycles of ociperlimab combined with tislelizumab and cCRT, followed by ociperlimab combined with tislelizumab up to 1 year after the cCRT phase
62039620|NCT04866017|EXPERIMENTAL|Tislelizumab + cCRT|Participants enrolled under PA1 recieved two cycles of tislelizumab combined with cCRT, followed by tislelizumab up to 1 year after the cCRT phase
62039621|NCT04866017|EXPERIMENTAL|cCRT followed by Durvalumab|Participants enrolled under PA1 recieved two cycles of cCRT, followed by durvalumab to 1 year after the cCRT phase
62039622|NCT06732947||university students between age of 20 and 22|
62039623|NCT02275104||Ventricular arrhythmias|
62039624|NCT02275104||Persistent atrial fibrillation|
62433162|NCT05953285|EXPERIMENTAL|Restricted sleep on blood markers and subjective markers of homeostatic, and hedonic appetite|The proposed study will take the form of a within-subjects, randomized crossover experimental design. The data will be quantitative. The study will take place for total of approximately 5 weeks / 37 days (+ up to 6 weeks depending on their schedule: Minimum duration = 5 weeks (37 days), Maximum duration = Approximately 11 weeks (79 days).
62599874|NCT01612637|EXPERIMENTAL|Group 1|Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and they will perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
62599875|NCT01612637|ACTIVE_COMPARATOR|Group 2|Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
62039625|NCT03188848|EXPERIMENTAL|BPI-3016|Single-dose subcutaneous injection of BPI-3016 with escalating dose from 0.6 mg
62242896|NCT04994379|EXPERIMENTAL|1 mA tDCS|Participants receive the stimulation with an intensity of 1 mA.
62242897|NCT04994379|EXPERIMENTAL|1.5 mA tDCS|Participants receive the stimulation with an intensity of 1.5 mA.
62242898|NCT04994379|SHAM_COMPARATOR|Sham tDCS|Participants receive the sham stimulation (zero electric current after a short initial increase).
62242899|NCT01782118|EXPERIMENTAL|Lactobacillus GG|Lactobacillus GG given for six weeks two times per day.
62242900|NCT01782118|PLACEBO_COMPARATOR|Placebo|Placebo two times per day for six weeks
62433163|NCT05953285|EXPERIMENTAL|Restricted sleep on gastric emptying|The proposed study will take the form of a within-subjects, randomized crossover experimental design. The data will be quantitative. The study will take place for total of approximately 5 weeks / 37 days (+ up to 6 weeks depending on their schedule: Minimum duration = 5 weeks (37 days), Maximum duration = Approximately 11 weeks (79 days).
62039626|NCT03188848|PLACEBO_COMPARATOR|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
62433164|NCT02483481|OTHER|Shear Wave Ultrasound Elastography|
62433165|NCT05493033|EXPERIMENTAL|Intracorporeal anastomotic after LRC|
62433166|NCT05493033|ACTIVE_COMPARATOR|Extracorporeal anastomotic after LRC|
62039627|NCT04804553|EXPERIMENTAL|Apremilast|Participants will receive apremilast in the double-blind 16 week treatment phase. Then the participants will continue to receive apremilast in the active 36 weeks treatment phase.
62039628|NCT04804553|PLACEBO_COMPARATOR|Placebo to Apremilast|Participants will receive the matching placebo in the double-blind 16 week treatment phase. Then the participants will receive apremilast in the active 36 weeks treatment phase.
62039629|NCT00572741|EXPERIMENTAL|1|Nutritional supplementation
62039630|NCT00572741|PLACEBO_COMPARATOR|2|Placebo
62039631|NCT04699279|EXPERIMENTAL|Statin|
62039632|NCT04699279|NO_INTERVENTION|Blank|
62039633|NCT05293080|EXPERIMENTAL|Early rhythm control therapy|Patients with acute ischemic stroke and AF will receive either catheter ablation (mainly pulmonary vein isolation), or adequate antiarrhythmic drug therapy at an early time point. The initial therapy will be selected by the local investigator. In case of continuation or recurrence of AF, both modalities may be combined.
62039634|NCT05293080|ACTIVE_COMPARATOR|Usual care|Patients with acute ischemic stroke and AF will receive usual care following the current ESC guidelines for AF treatment.
62039635|NCT05108792||Patients deceased following a decision to limit or stop therapeutics|a
62242901|NCT06735339|EXPERIMENTAL|Clinic for multimorbidity|All participants will be assigned to the intervention but at different times according to the stepped wedge design. There are 6 clusters, to be assigned at different times.
62242902|NCT06504342|EXPERIMENTAL|Blue-blocking glasses and time-restricted eating|Participants will be wearing the experimental blue-blocking glasses and follow time-restricted eating from 6pm-8am.
62242903|NCT06504342|ACTIVE_COMPARATOR|Blue-blocking glasses and no time-restricted eating|Participants will only be wearing the experimental blue-blocking glasses from 6pm-8am.
62433167|NCT05519020||Ivacaftor/Tezacaftor/Elexacaftor eligible|People with cystic fibrosis who are eligible for and taking Ivacaftor/Tezacaftor/Elexacaftor
62433168|NCT05519020||Ivacaftor/Tezacaftor/Elexacaftor ineligible|People with cystic fibrosis who are not taking Ivacaftor/Tezacaftor/Elexacaftor for any reason
62819231|NCT04188912||Observational (sample collection, survey, imaging, spirometry)|Patients undergo collection of tears, saliva, buccal mucosa, and fecal samples before stem cell transplant, at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients also undergo collection of blood samples before stem cell transplant, at 1-2, 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients may undergo skin and mouth biopsy over 15-30 minutes before stem cell transplant, at 2-3 and 12 months after stem cell transplant, and at cGVHD onset. Patients undergo digital pictures of the eyes, mouth and skin, and optical coherence tomography before stem cell transplant, at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients without standard of care formal pulmonary function test undergo portable spirometry at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients also complete surveys and have their medical records reviewed.
62433169|NCT00512187|EXPERIMENTAL|first group|patients who adhered to a low-calorie diet associated to sub-optimal cyclosporine dose (2.5 mg/Kg/day)for 24 weeks
62433170|NCT05332626|EXPERIMENTAL|Probiotic group|The probiotic group will receive a supplement diet capsule consisting of Lactobacillus acidophilus UALa-01™ with a dose of 1x10\^9 CFU for 12 weeks
62433171|NCT05332626|PLACEBO_COMPARATOR|Placebo group|The placebo group will receive a capsule that consists of the excipient (maize starch and maltodextrins) for 12 weeks
62599876|NCT05012904|EXPERIMENTAL|Parent involvement Group|A parent was involved in the procedure. The parent held the children in their arms and holding the extremity from which the blood was drawn, holding the hands of children and communicating with their children in the child's room, and in this way the parent was involved in the procedure.
62819232|NCT04595773|EXPERIMENTAL|Aerobic Exercise Training and Education (AET+)|Participants will perform both exercise training and education for 10 weeks
62819233|NCT04595773|OTHER|Education only (CON)|Participants will perform only education for the first 10 weeks, then cross-over to perform exercise in the second 10 weeks
62819234|NCT05010707|ACTIVE_COMPARATOR|Transdermal estradiol plus spironolactone|"Starting dose will be 100 mcg/24hrs Plan to increase by 100 mcg/24hrs every month to a max dose of 400 mcg/24hrs Goal is to achieve a serum estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels~All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose."
62819235|NCT05010707|ACTIVE_COMPARATOR|Daily sublingual estradiol plus spironolactone|"Starting dose will be 2 mg daily Plan to increase every month by 2 mg daily Goal is to achieve serum estradiol level between 100-200 pg/mL mL and to suppress testosterone to cisgender female levels.~All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.~Spironolactone will be started at 50 mg daily and will increase to standard dose."
62242904|NCT06504342|ACTIVE_COMPARATOR|Lightly tinted glasses and time-restricted eating|Participants will be wearing the control lightly tinted glasses and follow time-restricted eating from 6pm-8am.
62433172|NCT00455533|EXPERIMENTAL|A|
62433173|NCT00455533|ACTIVE_COMPARATOR|B|
62433174|NCT01268800||AML induction|Adults AML patients who were referred for intensive induction therapy
62433175|NCT00360867|OTHER|1|Single Arm
62433176|NCT03615079|OTHER|Cognitive Behavioral Therapy (CBT) program|
62433177|NCT01881529||Limited Scleroderma|
62433178|NCT01881529||Diffuse Scleroderma|
62433179|NCT01047085|ACTIVE_COMPARATOR|Control group|Control group: Impedance pH measurements of healthy controls are performed to compare the results with the study group.
62433180|NCT01047085|EXPERIMENTAL|Study group|Study group: Pre-operative and post-operative impedance pH measurements are performed to patients in which elective cholecystectomy is planned.
62819236|NCT05010707|ACTIVE_COMPARATOR|Twice daily sublingual estradiol plus spironolactone|"Starting dose will be 1 mg twice daily Plan to increase every month by 2 mg daily divided BID Goal is to achieve serum estradiol level between 100-200 pg/mL mL and to suppress testosterone to cisgender female levels~All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.~Spironolactone will be started at 50 mg daily and will increase to standard dose."
62819237|NCT04496960|PLACEBO_COMPARATOR|Placebo group|Receiving placebo
62819238|NCT04496960|EXPERIMENTAL|Subjects with SS|Receiving tofacidinib
62819239|NCT05652010|EXPERIMENTAL|New coupling|The arm includes the new 2-piece coupling
62819240|NCT05652010|ACTIVE_COMPARATOR|Comparator device|The arm includes the existing 2-piece coupling
62599877|NCT05012904|NO_INTERVENTION|Control Group|Routine venipuncture procedure was applied to the control group. The parent was present in the child's room but did not participate in the procedure.
62599878|NCT01191775|EXPERIMENTAL|PNT2258|PNT2258 is composed of PNT100, a 24-mer oligonucleotide, the active drug substance encapsulated in a liposome.
62599879|NCT02615015||ST elevation myocardial infarction patient cohort|Patients who suffered from ST elevation myocardial infarction since 2006, referred to the General Hospital of Vienna and received primary percutaneous coronary intervention.
62599880|NCT02615015||Healthy proband cohort|Age matched healthy individuals who voluntarily participate in the study.
62599881|NCT00090987|EXPERIMENTAL|Imatinib mesylate|Imatinib mesylate (Gleevec) taken 400 mg orally once a day for up to 6 months
62433181|NCT03003533|EXPERIMENTAL|SPK-8011|All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8011.
62599882|NCT02161003|EXPERIMENTAL|Stem Cells Isolation|"Stem cell isolation technique and Stem Cells Injection Technique The method of isolation of MSC from bone marrow will be carried out using the Ficoll-Paque technique for the isolation of mononucleated cells followed by the separation of MSC by adherence to plastic. Finally, the cells will be resuspended and counted using a hemocytometer.~Mononucleated cells will be cultured and incubated at 37°C in an atmosphere of 95% relative humidity and 5% CO2."
62599883|NCT05189067|ACTIVE_COMPARATOR|paclitaxel + trastuzumab|"paclitaxel × 12, every week a cycle, trastuzumab × 4, every 3 weeks a cycle; followed by trastuzumab, every 3 weeks a cycle for 9 months.~Paclitaxel i.v. 80mg/m2, trastuzumab i.v. loading dose of 8 mg/kg, followed by 6mg/kg"
62599884|NCT05189067|EXPERIMENTAL|docetaxel + trastuzumab|"(docetaxel + trastuzumab) × 4, every 3 weeks a cycle; followed by trastuzumab, every 3 weeks a cycle for 9 months.~Docetaxel i.v. 100mg/m2, trastuzumab i.v. loading dose of 8 mg/kg, followed by 6mg/kg"
62599885|NCT05455359|EXPERIMENTAL|Arm 1|Patients will be undergo 1 week observation period followed by 4 weeks of prucalopride followed by 1 weeks of a wash out followed by 4 weeks of famotidine
62433182|NCT04896359|EXPERIMENTAL|Vitamin C|i.v. infusion of 12.5 g vitamin C 48 h before surgery, immediately before surgery, and 48 h after surgery
62433183|NCT04896359|PLACEBO_COMPARATOR|Control|i.v. infusion of placebo 48 h before surgery, immediately before surgery, and 48 h after surgery
62433184|NCT03610178|ACTIVE_COMPARATOR|very tight glycemic targets|
62433185|NCT03610178|ACTIVE_COMPARATOR|tight-moderate glycemic targets|
62433186|NCT03610178|NO_INTERVENTION|Control group|Only observation in women with normal glucose tolerance
62433187|NCT02340078|ACTIVE_COMPARATOR|HA IDF II|cross-linked HA filler
62433188|NCT02340078|EXPERIMENTAL|HA IDF II plus|cross-linked HA filler with lidocaine
62433189|NCT05322265||complicated patients|patients underwent to laparoscopic renal and adrenal surgery with intraoperative complications
62433190|NCT05322265||uncomplicated patients|patients underwent to laparoscopic renal and adrenal surgery with no complication during surgical procedure
62599886|NCT05455359|EXPERIMENTAL|Arm 2|Patients will be undergo 1 week observation period followed by 4 weeks of famotidine followed by 1 weeks of a wash out followed by 4 weeks of prucalopride
62599887|NCT04247464|NO_INTERVENTION|Standard diet|The participants will follow an standard diet during the chemotherapy treatment
62599888|NCT04247464|EXPERIMENTAL|Fasting|The participants will follow a short-term fasting period for 44-48 hours, starting 24 hours before chemotherapy treatment
62599889|NCT00534885|EXPERIMENTAL|1: Healive® Lot 1|
62819241|NCT05757843|EXPERIMENTAL|Consolidation to Durvalumab|All subjects will receive consolidation Durvalumab approximately every 4 weeks. The first mandatory ctDNA test will be done at screening for the bespoke ctDNA profiling. The next mandatory ctDNA test will be completed prior to the 5th cycle of consolidation Durvalumab. If it's negative and the subsequent test 4 weeks later prior to cycle 6 is negative, then Durvalumab will be stopped otherwise subject will continue consolidation durvalumab until 2 negative ctDNA analyses performed approximately 4 weeks apart or up to 1 year of consolidation per standard medical practice is complete.
62819242|NCT01787500|EXPERIMENTAL|Treatment (vemurafenib, cetuximab, irinotecan hydrochloride)|Patients receive vemurafenib PO BID on days 1-14, cetuximab IV over 90 minutes, and irinotecan hydrochloride IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62819243|NCT03928132|EXPERIMENTAL|CPD Workshop on Depression and Diabetes|Participants in this arm will take part in a clinical CPD activity on depression and diabetes. The activity will include considerations of sex and gender, e.g. the different risk factors and impacts of treatment among women and men.
62819244|NCT03928132|SHAM_COMPARATOR|CPD Workshop on Depression and Diabetes II|Participants in this arm will take part in a clinical CPD activity on depression and diabetes. The activity will exclude considerations of sex and gender, e.g. the different risk factors and impacts of treatment among women and men.
62819245|NCT05264779|NO_INTERVENTION|Usual Care (control)|Participants assigned to this group will proceed with usual medical care and treatment, consisting of counseling by the teams of obstetricians and/or neonatologists at the respective study sites.
62599890|NCT00534885|EXPERIMENTAL|2: Healive® Lot 2|
62599891|NCT00534885|EXPERIMENTAL|3: Healive® Lot 3|
62599892|NCT00534885|ACTIVE_COMPARATOR|4: control vaccine (Havrix)|
62599893|NCT01662921|ACTIVE_COMPARATOR|NPH and insulin lispro|Patients diagnosed with diabetes during pregnancy will be randomized to long acting insulin NPH and short acting insulin lispro in a basal bolus regimen to treat post prandial hyperglycemia using a dosing schedule of 50% NPH calculated by the patients weight and gestational age and 50% lispro pending their last three SMPG average.
62599894|NCT01662921|ACTIVE_COMPARATOR|NPH and insulin glulisine|Patients with a diagnosis of diabetes during pregnancy will be randomized to using long acting insulin NPH and short acting insulin glulisine as treatment for post prandial hyperglycemia with a 50% NPH dosing schedule based on the weight and gestational age and 50% glulisine schedule based on their last three SMBG result average.
62599895|NCT06648174|OTHER|Controlled group-Blood glucose meters (BGM) group|"The participants will receive structured questionnaires at 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, and 4-12 weeks postpartum, respectively.~Participants are required to use blood glucose meters (BGM) at 24-32 weeks of pregnancy and 33 weeks to before delivery. After 7-14 days of glucose monitoring at 24-32 weeks of pregnancy, glucose monitor reports will be given to the participants. After the 7-14 days of glucose monitoring at 33 weeks to before delivery , another glucose monitor reports will be given to the participants."
62599896|NCT06648174|EXPERIMENTAL|Experimental group1-Continuous glucose monitoring (CGM) group|"The participants will receive structured questionnaires at 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, and 4-12 weeks postpartum, respectively.~Participants will receive a set of continuous glucose monitor (CGM) respectively at 24-32 weeks of pregnancy (first set) and 33 weeks of pregnancy to before delivery (second set). After 7-14 days of glucose monitoring at 24-32 weeks of pregnancy, glucose monitor reports will be given to the participants. After the 7-14 days of glucose monitoring at 33 weeks to before delivery , another glucose monitor reports will be given to the participants."
62599897|NCT06648174|EXPERIMENTAL|Experimental group2-Continuous glucose monitoring (CGM) with nursing care group|"The participants will receive structured questionnaires at 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, and 4-12 weeks postpartum, respectively.~Participants will receive a set of continuous glucose monitor (CGM) respectively at 24-32 weeks of pregnancy (first set) and 33 weeks of pregnancy to before delivery (second set). After 7-14 days of glucose monitoring at 24-32 weeks of pregnancy, glucose monitor reports will be given to the participants. After the 7-14 days of glucose monitoring at 33 weeks to before delivery , another glucose monitor reports will be given to the participants.~Participants will receive nursing care for gestational diabetes at 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, and 4-12 weeks postpartum."
62599898|NCT05330273|EXPERIMENTAL|Period 1: KAF156 + LUM566 / Period 2: KAF156 + LUM566 + Efavirenz|"Participants enrolled will receive a single oral dose of ganaplacide and lumefantrine combination on Day 1 of Period 1.~In Period 2, participants will receive an oral dose of efavirenz q.d. in the evening on Days 1 through 24 and a single dose of ganaplacide and lumefantrine combination on the morning of Day 11."
62599899|NCT00176644|EXPERIMENTAL|Transdermal estradiol|
62599900|NCT03332420||Observational 1|Huaiqihuang Granule
62599901|NCT03332420||Observational 2|Standard treatment+Huaiqihuang Granule
62599902|NCT03332420||Observational 3|Standard treatment
62819246|NCT05264779|EXPERIMENTAL|Periviable GOALS DST Group|Participants randomized to the intervention will be presented with the Periviable GOALS DST and instructed to review the DST in its entirety. The participant will complete the education and values clarification components of the DST with the Recruitment RA present to confirm completion. Following completion of the GOALS DST, the Recruitment RA will repeat knowledge and decisional conflict instruments and assess acceptability.
62819247|NCT05296473|EXPERIMENTAL|ADHD Therapy|
62242905|NCT06253221|EXPERIMENTAL|Mavacamten|Participants assigned to this arm will receive mavacamten (1 mg to 15 mg) from day 1 to end of treatment at week 200.
62242906|NCT06253221|EXPERIMENTAL|Placebo|Participants assigned to this arm will receive mavacamten (1 mg to 15 mg) from week 28 to end of treatment at week 200.
62242907|NCT06735664|EXPERIMENTAL|Treatment (odronextamab, zanubrutinib)|Patients receive odronextamab IV over 4 hours on days 1, 2, 8, 9, 15 and 16 of cycle 1 and over 1-4 hours on days 1, 8 and 15 of cycles 2-4 and then on days 1 and 15 of remaining cycles. Patients with CR at cycle 9 may receive odronextamab on day 1 of remaining cycles. Starting with cycle 2, patients also receive zanubrutinib PO QD or BID of each cycle. Cycles repeat every 21 days for cycles 1-4 in the absence of disease progression or unacceptable toxicity then repeat every 28 days for up to cycle 12. After 12 cycles, patients may continue zanubrutinib at investigator's discretion. Patients also undergo ECHO or MUGA and optional bone marrow biopsy at screening and ultrasound guided biopsy of lymph node at screening and during days 2-12 of cycle 2. Additionally, patients undergo blood sample collection and PET, or CT throughout the study.
62242908|NCT00674193||Observational (pharmacological study)|Patients undergo blood and urine collection prior to, periodically during, and after treatment with dactinomycin and vincristine for pharmacokinetic, pharmacodynamic, and pharmacogenetic analysis. Samples are analyzed using a liquid chromatography-tandem mass spectrometry assay. Genomic DNA extracted from peripheral blood mononuclear cells is isolated and analyzed by polymerase chain reaction and genotyping assays for genetic variation in genes relevant to the pharmacology of dactinomycin and vincristine.
62242909|NCT06333288|OTHER|Treatment group|The intervention group will receive individual PST (60 min individual sessions for 6 weeks, in addition to engaging with APPLE Watch features including fitness tracking (such as regular walks), heart rate, and sleep management on a daily basis. Throughout the final 6 individual self-engaged sessions, participants will persist in engaging and utilizing APPLE Watch features, incorporating daily fitness tracking (such as regular walks), wellness applications, and sleep management and apply PST.
62819248|NCT05296473|ACTIVE_COMPARATOR|Control Therapy|
62242910|NCT06333288|OTHER|Control group|"Participants assigned to Education-only control will be asked to watch Quit Drinking Motivation, a 20-min video created by the MotivationHub. This video consists of a speech and conversation discussing the negative consequences resulting from their alcohol misuse and the importance of getting sober. The video will be followed by a 30-minute group discussion via zoom."
62242911|NCT03945006||Multiple Sclerosis Patients with Incontinence|Multiple Sclerosis with incontinence 24-58 years of age and being volunteered.
62242912|NCT03945006||Multiple Sclerosis Patients without incontinence|Multiple Sclerosis without incontinence 24-58 years of age and being volunteered.
62599903|NCT05581498|EXPERIMENTAL|GLAUCOMA|"we will recruit patients with a diagnosis of primary Glaucoma for the experimental group.~Exercise bikes and muscle-strength exercise belts will be used for exercise interventions."
62242913|NCT01357577|EXPERIMENTAL|Arm 1: TAU + CBT|The experimental group will receive treatment as usual (TAU) plus cognitive behavioral therapy (CBT).
62433191|NCT02330250|EXPERIMENTAL|Pharmaceutical Care|The patients will receive guidance from a pharmacist based on the Dader Method for Pharmaceutical Care, in addition to the medical care habitually delivered by the hospital.
62599904|NCT05581498|ACTIVE_COMPARATOR|CONTROL|"we will recruit normally sighted older adults for the control group.~Exercise bikes and muscle-strength exercise belts will be used for exercise interventions."
62819249|NCT04377971|EXPERIMENTAL|Ask-tell-ask method|Study team will provide participant education using the ask-tell-ask method. Participants will receive a post-operative instruction sheet containing detailed information regarding wound care for reference and will receive a phone call at 1 week to inquire about wound care adherence. Participants will come to clinic at 2 weeks to have wounds assessed in addition to answering surveys regarding wound care adherence and participant experience.
62599905|NCT03585153||T1D|Individuals with type 1 diabetes
62599906|NCT03585153||Control|Individuals without type 1 diabetes
62599907|NCT03585153||Aab+|Individuals without type 1 diabetes who possess 2+ type 1 diabetes-related autoantibodies
62599908|NCT03585153||MODY|Individuals with monogenic diabetes, or maturity-onset diabetes of the young (MODY)
62242914|NCT01357577|NO_INTERVENTION|Arm 2: TAU|"The no intervention group will receive treatment as usual (TAU)."
62433192|NCT02330250|SHAM_COMPARATOR|Control|The control group will receive the medical care habitually provided by the hospital, and the follow-up by a non-pharmacist professional.
62738582|NCT04929223|EXPERIMENTAL|Inavolisib + Cetuximab|"Participants will receive 9 milligrams (mg) of inavolisib by mouth once daily (QD) on Days 8-28 of Cycle 1, then QD on Days 1-28 from Cycle 2 onwards (1 cycle=28 days).~Participants will also receive cetuximab intravenous (IV) infusion 400 mg/m2 body surface area on Day 1 of Cycle 1. All subsequent weekly (QW) doses will be 250 mg/m2 each. This arm is active, and not recruiting participants."
62039636|NCT01930110|ACTIVE_COMPARATOR|Single-hormone closed-loop system|In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels
62242915|NCT03703245||Experimental Dentifrice|Participants were advised to brush their teeth twice daily with a full strip of experimental dentifrice containing 67% w/w sodium bicarbonate in 3 studies and additionally 62% w/w sodium bicarbonate in 3 studies covering the entire head of the toothbrush for 1 minute.
62738583|NCT04929223|EXPERIMENTAL|Inavolisib + Bevacizumab|Participants will receive 9 mg of inavolisib by mouth QD combined with bevacizumab 15 milligram/kilogram (mg/kg) IV once every three weeks (Q3W) on Day 1 of each cycle (1 cycle=21 days). This arm is active, and not recruiting participants.
62738584|NCT04929223|EXPERIMENTAL|Atezolizumab + Tiragolumab + Bevacizumab|Participants in this randomized cohort will receive 1200 mg of atezolizumab by IV infusion on Day 1 of each cycle, combined with tiragolumab at a dose of 600 mg IV infusion on Day 1 of each cycle and bevacizumab IV infusion at a dose of 15 mg/kg on Day 1 of each cycle. (Cycle length=21 days) This arm is active, and not recruiting participants.
62738585|NCT04929223|EXPERIMENTAL|Atezolizumab + Tiragolumab|Participants in this randomized cohort will receive 1200 mg of atezolizumab by IV infusion on Day 1 of each cycle combined with tiragolumab 600 mg IV infusion on Day 1 of each cycle. (Cycle length=21 days) This arm is active, and not recruiting participants.
62738586|NCT04929223|EXPERIMENTAL|Atezolizumab + SY-5609|Participants will receive 1680 mg of atezolizumab by IV infusion on Day 1 of each cycle Q4W in repeated 28-day cycles combined with SY-5609 at a dose of 3, 4, 5, 6, 7 or 10 mg by mouth for 7 days, followed by 7 days off. (Cycle length=28 days) This arm is closed.
62738587|NCT04929223|EXPERIMENTAL|Divarasib + Cetuximab + FOLFOX|Participants will receive cetuximab IV 500 mg/m2 body surface area on Days 1 and 15 and FOLFOX on Days 1 and 15 with divarasib PO QD on Days 1-28. (Cycle length=28 days) This arm is recruiting participants.
62738588|NCT04929223|EXPERIMENTAL|Divarasib + Cetuximab|Participants will receive cetuximab IV 500 mg/m2 body surface area on Days 1 and 15 with divarasib PO QD on Days 1-28. (Cycle length=28 days) This arm is active, and not recruiting participants.
62738589|NCT04929223|EXPERIMENTAL|Divarasib + Cetuximab + FOLFIRI|Participants will receive cetuximab IV 500 mg/m2 body surface area on Days 1 and 15 and FOLFIRI on Days 1 and 15 with divarasib PO QD on Days 1-28. (Cycle length=28 days) This arm is active, and not recruiting participants.
62738590|NCT04929223|EXPERIMENTAL|Divarasib + Bevacizumab + FOLFOX|Participants will receive Bevacizumab 5 mg/kg by IV infusion on Days 1 and 15 and FOLFOX on Days 1 and 15 with Divarasib PO QD on Days 1-28. (Cycle length=28 days) This arm is recruiting participants.
62738591|NCT04929223|EXPERIMENTAL|Divarasib + Bevacizumab + FOLFIRI|Participants will receive Bevacizumab 5 mg/kg by IV infusion on Days 1 and 15 and FOLFIRI on Days 1 and 15 with Divarasib PO QD on Days 1-28. (Cycle length=28 days) This arm is recruiting participants.
62738592|NCT02032758|EXPERIMENTAL|Golfers With Golfer's Cramp|Subjects in this arm will be tested with the Opal device, the Science and Motion PuttLab (SAM), and the Surface Electromyography (EMG) to collect movement parameters while putting before and after a single dose of 10 mg Propranolol.
62738593|NCT02032758|OTHER|Golf Pros|Subjects in this arm will be tested with the Opal device, the Science and Motion PuttLab (SAM), and the Surface Electromyography (EMG) to collect movement parameters while putting. The subjects in this arm will not receive any study drug.
62738594|NCT05657249|EXPERIMENTAL|US & MRI|All participants undergo biannual US (as a part of standard-of-care) and annual non-contrast focused MRI.
62819250|NCT04377971|ACTIVE_COMPARATOR|Standard of Care (SOC)|Participants will receive SOC education from the researcher. Participants will receive a post-operative instruction sheet containing detailed information regarding wound care for reference and will receive a phone call at 1 week to inquire about wound care adherence. Participants will come to clinic at 2 weeks to have wounds assessed in addition to answering surveys regarding wound care adherence and participant experience.
62242916|NCT03703245||Control Dentifrice|Participants were advised to brush their teeth with control dentifrice containing 0% w/w sodium bicarbonate covering the entire head of the toothbrush for 1 minute.
62242917|NCT02774902|EXPERIMENTAL|TAK-438 40 mg + Clarithromycin 500 mg|TAK-438 40 mg, tablets, orally once on Days 1 and 8 along with clarithromycin 500 mg, tablets, orally twice daily from Days 3 to 9.
62242918|NCT04093427|ACTIVE_COMPARATOR|softSTOPP active|
62242919|NCT04093427|NO_INTERVENTION|softSTOPP inactive|
62433193|NCT05798858|ACTIVE_COMPARATOR|Group A: NT+ NIPT|"Group A patients will undergo NT between 11+3 and 13+6 weeks. If the NT is \<3.5 mm, the patient will be offered to continue the screening with NIPT.~If NIPT comes back as positive result, the result will be confirmed by an invasive procedure (amniocentesis/villocentesis); if, on the other hand, the NIPT will give a negative result, the screening is concluded and the patient will not undergo further tests."
62242920|NCT00650065|EXPERIMENTAL|1|Cetirizine HCl Tablets 10 mg
62599909|NCT04888403|EXPERIMENTAL|Toripalimab combined with neoadjuvant radiotherapy and chemotherapy Single arm study|"Induction period:~Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 1 cycles.~Neoadjuvant radiotherapy after 2W: The radiotherapy dose is 41.4Gy, completed in 23 times, 5 times a week, using intensity-modulated radiotherapy (IMRT) or volume-modulated radiotherapy (VMAT); In the same period, albumin paclitaxel combined with nedaplatin chemotherapy: albumin paclitaxel 60mg/m2 + nedaplatin 25mg/m2, performed once a week, 5 times in total; Simultaneous immunotherapy: 240 mg of Toripalimab (PD-1 antibody), once every 3 weeks, 4 times in total; Received radical resection of esophageal cancer within 7 weeks after radiotherapy and chemotherapy."
62819251|NCT00581438||1|
62819252|NCT06477055|EXPERIMENTAL|Experimental group|All the patients were treated with osimertinib.
62242921|NCT00650065|ACTIVE_COMPARATOR|2|Zyrtec® Tablets 10 mg
62243235|NCT06388681|EXPERIMENTAL|Experimental|"Intervention Group Patients in the intervention group will be allowed to use a stress ball. The comfort level, vital signs and pain intensity of the patients in the intervention group will be evaluated with the Immolization comfort scale 2 hours before Sheath extraction. Pain intensity and vital signs will be evaluated 2 hours after sheath extraction, and comfort level, vital signs and pain intensity will be evaluated with Immolization comfort scale 4 hours after sheath extraction.~Stress Ball Use Practice for the Intervention Group The researchers will explain and demonstrate to the intervention group how to use the stress ball. Then, the patient will be asked to use the ball and it will be confirmed whether he/she uses it correctly. After angiography, it will be stated that the patients in the intervention group should count to 5 and squeeze it once for 10 minutes every hour and rotate with the right and left hand until they are mobilized."
62243236|NCT06388681|NO_INTERVENTION|Control Group|Control Group Patients in the control group will not undergo any intervention. Comfort level, vital signs and pain will be evaluated with Immolization comfort scale 2 hours before Sheath extraction. Pain and vital signs will be evaluated 2 hours after Sheath extraction and comfort level, vital signs and pain will be evaluated with Immolization comfort scale 4 hours after Sheath extraction.
62243237|NCT00517751|EXPERIMENTAL|X-STOP PEEK|In this arm, patients will undergo X-STOP PEEK surgery.
62433194|NCT05798858|ACTIVE_COMPARATOR|Group B|"Combined test + NIPT (n=200) The patients of group A will undergo NT between 11+3 and 13+6 weeks, according to the same protocol foreseen for Group A.~If the NT is \<3.5 mm, the patient will be offered continuation of the screening using the combined test.~In case of:~High risk (1:2-1:100), the patient will be offered an invasive procedure (amniocentesis/villocentesis) Intermediate risk (1:101-1:1000), the patient will be offered NIPT, according to the protocol already described for Group A. In the event of a positive result, the patient will undergo an invasive procedure (amniocentesis/villocentesis ); in the case of negative NIPT, the screening is concluded and the patient will not undergo further tests.~Low risk (\>1:1000), screening ends and the patient will not undergo further tests."
62433195|NCT04093726|EXPERIMENTAL|lollipop|
62433196|NCT04093726|NO_INTERVENTION|control|
62433197|NCT00875368|ACTIVE_COMPARATOR|Maraviroc|
62433198|NCT00875368|PLACEBO_COMPARATOR|Placebo|Placebo drug
62433199|NCT01298596|EXPERIMENTAL|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
62433200|NCT01298596|EXPERIMENTAL|Loop Electrosurgical Excision Procedure|Loop Electrosurgical Excision Procedure (LEEP) uses a low-voltage electrified wire loop to cut out diseased part of cervix
62433201|NCT03974984||"The Hvidovre population:"|We will include patients undergoing laparoscopic hemicolectomy for cancer scheduled for anesthesia with total intravenous anesthesia combined with epidural anesthesia and perioperative NSAID on Hvidovre Hospital.
62599910|NCT00978939|EXPERIMENTAL|Aggressive Drainage Arm|Patients will drain up to 1 liter of pleural fluid everyday
62599911|NCT00978939|ACTIVE_COMPARATOR|Standard Drainage Arm|Patients will drain up to 1 liter of pleural fluid every other day
62738595|NCT01334216|ACTIVE_COMPARATOR|CHICA Smoking Cessation Module|This arm had the CHICA smoking cessation module turned on
62738596|NCT01334216|PLACEBO_COMPARATOR|CHICA Placebo|This arm had CHICA without the smoking cessation module
62738597|NCT02580032||Child Treatment Naïve group (Group A)|Pre-pubertal boy or girl, ages of 9 to 13 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of equal or below 7.0 ng/ml.
62738598|NCT02580032||Child Maintenance group (Group B)|Pre-pubertal boy or girl, ages of 9 to 13 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of equal or below 10.0 ng/ml who have been taking prescription treatment for GHD for 6 months or more.
62738599|NCT02580032||Parent Treatment Naïve group (Group C)|Parents/guardians, who live with a pre-pubertal boy or girl, age 4 to 9 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of below or equal to 7.0 ng/ml.
62738600|NCT02580032||Parent Maintenance group (Group D)|Parents/guardians, who live with a pre-pubertal boy or girl, age 4 to 9 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of below or equal to 10.0 ng/ml who have been taking prescription treatment for GHD for 6 months or more.
62738601|NCT04873141||Case Group|All the patients suffering from severe covid pneumonia and laboratory parameter suggestive of cytokine release syndrome.
62738602|NCT04979793|ACTIVE_COMPARATOR|Placebo|Oral placebo, 3 grams milk powder sachet, taken once daily
62738603|NCT04979793|EXPERIMENTAL|Daily L-citrulline|L-citrulline, 3 grams L-citrulline sachet, taken once daily
62738604|NCT00815568|EXPERIMENTAL|Regimen|Conditioning regimen for AML with FLT3 mutation, AML/MDS unfavorable cytogenetic risk group, chemorefractory NHL or HD, or ALL/CML
62738605|NCT06657885|EXPERIMENTAL|single-arm|
62738606|NCT05092997|NO_INTERVENTION|Female SOC/Male SOC arm|Women will be provided the standard of care invitation letter for male partners for fast-track visit for HIV testing and laboratory HIV testing at enrollment and every 6 months until 6 months postpartum,
62738607|NCT05092997|ACTIVE_COMPARATOR|Female intervention/Male SOC arm|Women will be provided the standard of care invitation letter for male partners for fast-track visit for HIV testing and POC VL tests for women at enrollment, delivery, and 6 months post-partum;
62738608|NCT05092997|ACTIVE_COMPARATOR|Female SOC/Male intervention arm|Women will be provided an invitation letter for male partners for wellness visits and laboratory-based HIV VL testing for women at enrollment, delivery, and 6 months post-partum;
62738609|NCT05092997|ACTIVE_COMPARATOR|Female intervention/male intervention arm|Women will be provided an invitation letter for male partners invitation letter for male partners for wellness visits and POC viral load testing for women at enrollment, delivery, and 6 months post-partum.
62039637|NCT01930110|ACTIVE_COMPARATOR|Dual-hormone closed-loop system|In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels
62242922|NCT03739762|EXPERIMENTAL|i-STAND|i-STAND participants have a Baseline visit followed by the 1st Coaching visit. They receive wristbands that vibrate every 15 minutes to prompt a standing break, standing desks, workbook \& 10 phone-based coaching calls focused on sitting less/standing more. There is a 3 month measurement visit. Program ends at 6 months when they wear an activPAL \& have a measurement visit. Coach provides feedback on activPAL sitting time after all activPAL wears (Bsln, 3, 6 \& 12 month). They may opt to wear activPAL at 6 weeks \& get feedback. They are re-randomized at 6 months; half to be assigned to intervention boosters (5 more phone sessions/a 9-month optional activPAL) before the 12 month final activPAL \& final measurement visit. Those not randomized to boosters will have no contact until the 12 month visit. UPDATE: As of 3/31/2022, (final year 5), i-STAND ppts will no longer be re-randomized at 6 months. We will no longer follow to the 12-month timepoint \& will end all activities after 6-months.
62242923|NCT03739762|ACTIVE_COMPARATOR|Healthy Living control|In this arm, participants have a phone-based Baseline visit followed by the 1st phone-based Coaching visit. No prompting devices/desks are offered; coaching focuses on topics related to healthy living, but with no focus on sitting less/standing more. They have 10 phone calls with a health coach. Participants receive a workbook. All content is from KaiserPermanente WA and is available to all members. Participants select topics \& review them with their health coach. At 3 months, participants have a measurement visit. The program ends at 6 months where participants will wear an activPAL and have a measurement visit. After that, there is no contact with the study team until 12 months when they will again wear an activPAL \& have a final measurement visit. UPDATE: As of 3/31/2022, our final year (year 5) of the study, participants randomized to the control arm will no longer be followed to the 12-month timepoint and will end all activities after the 6-month timepoint.
62242924|NCT02073734|EXPERIMENTAL|Dexamethasone|Dexamethasone
62242925|NCT02073734|PLACEBO_COMPARATOR|Placebo|Sterile normal saline solution
62433202|NCT03974984||"The Zealand University Hospital population"|"The immunological and oxidative stress in relation to abdominal surgery (IMOX) study is ongoing at Zealand University Hospital, Roskilde. It is a prospective explorative study cohort that consists of 60 patients undergoing laparoscopic colorectal cancer surgery.~The population has been anesthetized according to the standard operating procedure with either total intravenous anesthesia with propofol and remifentanil or volatile anesthesia with sevoflurane combined with a fast acting opioid (remifentanil or sufentanil). Patients anaesthetized with other techniques including epidural or other regional blocks will be excluded from the analysis."
62433203|NCT00606879|EXPERIMENTAL|Single arm|
62819253|NCT06122688|NO_INTERVENTION|Care as usual|"All individuals within each site regardless of type of site or step period will begin with a control period of care as usual~Youth and parents within each site will have access to navigators who will share information about mental health and social services supports as well as referrals.~The duration of the control period (1, 2, or 3 years; collected via medical and/or other administrative records) will depend on the step period of the individual's site."
62039638|NCT03481049|EXPERIMENTAL|Usual CM|Participants will earn at least 3 prize draws each time they submit an alcohol negative urine samples during weeks 5-20, plus treatment as usual
62433204|NCT01410695|EXPERIMENTAL|masitinib 3 mg|masitinib 3 mg/kg/day, tablets, orally, twice a day
62433205|NCT01410695|EXPERIMENTAL|masitinib 6.0 mg|masitinib 6.0 mg/kg/day, tablets, orally, twice a day
62433206|NCT01410695|ACTIVE_COMPARATOR|methotrexate|methotrexate at the dose of 15 or 20 mg per week
62433207|NCT00904059|EXPERIMENTAL|Treatment Group A|
62433208|NCT00904059|EXPERIMENTAL|Treatment Group B|
62433209|NCT00904059|EXPERIMENTAL|Treatment Group C|Treatment Groups A and B are followed by Treatment Group C: A combination of BMS-650032 (200 mg) and BMS-790052 (30 mg)
62433210|NCT02437890|PLACEBO_COMPARATOR|Placebo|"Two s.c. injections with placebo every 2 weeks (q2w).~\*\*\*~Placebo was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to the placebo group received 2 s.c. injections q2w:~Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
62433211|NCT02437890|EXPERIMENTAL|ALX-0061 75 mg q4w|"ALX-0061 75 mg every 4 weeks (q4w).~\*\*\*~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 75 mg q4w received 2 s.c. injections q2w:~Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with ALX-0061 (0.5 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe B with placebo (0.5 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46."
62039639|NCT03481049|EXPERIMENTAL|High-Magnitude CM|Participants will earn twice as many prize draws than those in the Usual CM for alcohol abstinence during weeks 5-20, plus treatment as usual.
62039640|NCT03481049|EXPERIMENTAL|Shaping CM|Participants will earn prize draws for light drinking during weeks 5-8 instead of alcohol abstinence and will then earn prize draws for abstinence during weeks 9-20, plus treatment as usual.
62039641|NCT01588184|EXPERIMENTAL|Breast Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
62039642|NCT01588184|EXPERIMENTAL|Ovarian Cancer or Peritoneal Carcinoma|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
62039643|NCT01588184|EXPERIMENTAL|Renal Cell Carcinoma|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
62039644|NCT01588184|EXPERIMENTAL|Colorectal Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
62242926|NCT06134206|EXPERIMENTAL|Burr hole sonography|Patients within this arm (only arm of the study) undergo burr hole sonography
62242927|NCT00216203|EXPERIMENTAL|Investigational Treatment|Pemetrexed + cetuximab for patients with recurrent non-small cell lung cancer.
62242928|NCT04631926|OTHER|Hip Muscle Exercises|Hip Muscle Exercises
62242929|NCT05823701|EXPERIMENTAL|Chidamide, Azacitidine Combined With GM(CAGM) Regimen|R/R DLBCL patients were treated with 2 cycles of CAGM regimen including chidamide, azacitidine, obinutuzumab and liposomal mitoxantrone followed by imaging examination. Patients achieved CR/PR were exposed to ASCT/CAR-T therapy or additional 4 cycles of CAGM regimen in patients ineligible for ASCT/CAR-T therapy; whereas, patients with SD/PD were withdrawn from this study.
62039645|NCT01588184|EXPERIMENTAL|Non-Squamous, Non-Small Cell Lung Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
62242930|NCT05027763|NO_INTERVENTION|Control Arm|Standard care - patients will not receive specific dietary advice.
62242931|NCT05027763|EXPERIMENTAL|High Fiber/low fat|Patients will receive sample meals and education/support, will be asked to follow this diet for 10 days.
62242932|NCT05027763|EXPERIMENTAL|Fermented|Patients will receive sample meals and education/support, will be asked to follow this diet for 10 days.
62242933|NCT04254588||Phase I: Adult patients with abdominal pain|Adult patients with abdominal pain presenting to the MGH ED between February and March 2020.
62242934|NCT04254588||Phase II: Adult patients with abdominal pain|Adult patients with abdominal pain presenting to the MGH ED between July and December 2021.
62242935|NCT06467487|EXPERIMENTAL|Optimized Letter|Participants receive an 'optimized' letter.
62433212|NCT02437890|EXPERIMENTAL|ALX-0061 150 mg q4w|"ALX-0061 150 mg every 4 weeks (q4w).~\*\*\*~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 150 mg q4w received 2 s.c. injections q2w:~Syringe A with ALX-0061 (1 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe A with placebo (1 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46.~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
62433213|NCT02437890|EXPERIMENTAL|ALX-0061 150 mg q2w|"ALX-0061 150 mg every 2 weeks (q2w).~\*\*\*~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 150 mg q2w received 2 s.c. injections q2w:~Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
62433214|NCT02437890|EXPERIMENTAL|ALX-0061 225 mg q2w|"ALX-0061 225 mg every 2 weeks (q2w).~\*\*\*~Vobarilizumab (ALX-0061) was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 225 mg q2w received 2 s.c. injections q2w:~Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with ALX-0061 (0.5 mL) q2w starting at Day 1, up to and including Week 46."
62433215|NCT01561118|EXPERIMENTAL|Bicycle-Ergometer Training Group|"Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes, with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions).~In the second part of the study intervention will be prolonged for another 12 weeks."
62433216|NCT01561118|OTHER|Control|"No intervention during hemodialysis during the first 12 weeks of the study.~In the second part of the study a training program, according to that of the intervention group, will be performed with a performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes, with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions)."
62433217|NCT06110585|EXPERIMENTAL|Experimental: rTMS Treatment|20 sessions of TMS using the intermittent theta burst stimulation (iTBS) protocol
62433218|NCT06110585|SHAM_COMPARATOR|Sham Comparator: Sham Treatment|20 sham sessions using a placebo procedure with the TMS equipment.
62433219|NCT01823315|EXPERIMENTAL|Methotrexate Single-coure chemotherapy|Regimen: Methotrexate 0.4mg/(kg·d) intramuscularly (IM) on days 1-5. If 10-fold fall of hCG achieved 18 days after treatment completion, success of primary single-course chemotherapy was defined and further treatment was withheld; otherwise, failure was defined and the patient was referred to multi-course chemotherapy. During the period of observation for those with success, if the level of hCG became stationary for at least 3 weeks or rose again, the patient was also referred to multi-course chemotherapy. Additional consolidation chemotherapy with 1-3 courses was given for those who achieved CR by multi-course chemotherapy, but not by single-course regimen.
62738610|NCT01604525|SHAM_COMPARATOR|Control|Participants randomized to this group received access to an untailored general interest/lifestyle website.
62738611|NCT01604525|EXPERIMENTAL|Tailored Health and Lifestyle Web|Participants randomized to this arm received tailored web content about health and wellness, with weekly goal-setting and feedback.
62819254|NCT06122688|EXPERIMENTAL|Implementation|In this stepped wedge design, following a period of care as usual as a control, sites will then cross over to the experimental arm, during which, all youth and their caregivers at the enrolled site are encouraged to download and use the wellness app for the duration of the implementation period. Navigators promote and support use of the app.
62819255|NCT06091241|OTHER|Group 1: Erector Spinae Plane blocks|Erector Spinae Plane blocks
62819256|NCT06091241|OTHER|Group 2: Transversus Abdominis Plane blocks|Transversus Abdominis Plane blocks
62819257|NCT06589921|EXPERIMENTAL|Group T|take the tablet under fed condition ,1 tablet at a time, once a day.Test product (T): Pirfenidone Modified-Release Tablets Strength: 600 mg/tablet Batch No.: 08532 Content: 600 mg/tablet Valid to: January/2025 Storage Conditions: sealed at normal temperature (10-30°C) Manufacturer: Overseas Pharmaceuticals, Ltd.
62039646|NCT01588184|EXPERIMENTAL|Glioblastoma Multiforme|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
62039647|NCT06211205|EXPERIMENTAL|Customized nostril retainer combined with lip taping|
62039648|NCT06211205|ACTIVE_COMPARATOR|Lip taping|
62039649|NCT04592770|EXPERIMENTAL|The experimental intervention (walk):|In this group, the nature walk will take place in a conserved and by far the largest recreational area of Karachi city. The safari park covering an area of 148 acres (0.60 km2), It has a zoo, geared with woodland, mountain viewing, safari tracks, as well as two natural lakes. The experiment will take place in the afternoon on a 5 km marked area. The duration of the stretching exercise sessions will be of 10 minutes followed by 50 minutes' walk session five times per week (total 12 weeks). participants will be asked to walk at moderate pace.
62039650|NCT04592770|PLACEBO_COMPARATOR|The control intervention (sit & relax):|Subjects will undergo 12 weeks of nature therapy that includes exposure to natural landscapes. The duration of the sessions will be 60 minutes five times per week. The subjects will be asked to sit and relax in the evening, in the same recreational area which is used for the experimental group.
62039651|NCT06015204|ACTIVE_COMPARATOR|C5-C6 group|The C5-to-C6 nerve roots and supraclavicular nerves are blocked with 25 ml of 0.75% ropivacaine under ultrasound guidance.
62039652|NCT06015204|EXPERIMENTAL|C5-C8 group|The C5-to-C8 nerve roots and supraclavicular nerves are blocked with 25 ml of 0.75% ropivacaine under ultrasound guidance.
62242936|NCT06467487|EXPERIMENTAL|Optimized Message|Participants receive an 'optimized' message.
62242937|NCT06467487|EXPERIMENTAL|Optimized Letter + Optimized Message|Participants receive both a 'optimized' letter and a 'optimized' message.
62242938|NCT06467487|ACTIVE_COMPARATOR|Generic Letter|Participants receive a 'usual' letter.
62242939|NCT06467487|ACTIVE_COMPARATOR|Generic Message|Participants receive a 'usual' message.
62242940|NCT06467487|EXPERIMENTAL|Generic Letter + Generic Message|Participants receive both a 'usual' letter and a 'usual' message.
62819258|NCT06589921|ACTIVE_COMPARATOR|Group R|take the tablet under fed condition ,1 tablet at a time, three times a day.Reference product (R): Pirfenidone Tablets Strength: 200 mg/tablet Batch No.: 0239 Content: 200 mg/tablet Valid to: September 2026 Storage Conditions: sealed at room temperature Manufacturer: Shionogi \& Co., Ltd.
62819259|NCT05795049||IBS Patient|IBS patient with diarrhoea or alternating bowel habit
62819260|NCT05795049||Healthy subject|Participants without IBS
62242941|NCT04919525|EXPERIMENTAL|TrainPain Intervention|Daily TrainPain protocol - gamified sensory perceptual training
62242942|NCT02403622|EXPERIMENTAL|Intervention: Fecal Microbiota Preparation|"Open label single arm Dosage form: Screened human donor stool, sourced from human-derived microbes generated by healthy, screened donors.~Route of administration: either colonoscopic/sigmoidoscopic FMT or retention enema FMT Dosing Regimen: 250 mL x 1 dose. In the event of a clinical non-response, a repeat single 250 mL dose will occur from a different donor"
62242943|NCT04460014|EXPERIMENTAL|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
62242944|NCT04460014|PLACEBO_COMPARATOR|Attention placebo|Session 1: Digital activity for same amount of time (e.g. listening to podcast on own smartphone).
62819261|NCT01903356||Patients with T2DM|
62819262|NCT04090203|EXPERIMENTAL|Boiled Peanut Powder|Boiled Peanut Powder
62819263|NCT06472284|EXPERIMENTAL|Rocuronium infusion|Patients who are scheduled for elective, urgent or emergent surgery requiring the continuous infusion of the neuromuscular blocking agent, rocuronium.
62819264|NCT04907058|EXPERIMENTAL|Treatment with CO2|Patients were treated with an effective lowest concentration of CO2 delivered by the novel CO2 supply system.
62819265|NCT04533919||Basic science (dorsal root ganglia collection)|Patients' leftover dorsal root ganglia samples are collected during standard of care surgery.
62819266|NCT06147986|EXPERIMENTAL|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of diagnosis of ST-elevation Myocardial Infarction.
62819267|NCT06147986|OTHER|standard treatment|Standard-of-care for ST-elevation Myocardial Infarction
62819268|NCT04504734|ACTIVE_COMPARATOR|Bucillamine low dose|Bucillamine 100 mg 3 times a day (TID)
62819269|NCT04504734|ACTIVE_COMPARATOR|Bucillamine high dose|Bucillamine 200 mg 3 times a day (TID)
62819270|NCT04504734|PLACEBO_COMPARATOR|Placebo|Placebo, 3 times a day (TID)
62599912|NCT06311435|ACTIVE_COMPARATOR|Participants never infected by SARS-COV-2|Participants with no history of SARS-COV-2 infection. This is a control arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
62599913|NCT06311435|ACTIVE_COMPARATOR|Participants with SARS-COV-2 post-infection without long COVID|Participants with a history of SARS-COV-2 infection, but never developed long term sequalae. This is a control arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
62599914|NCT06311435|ACTIVE_COMPARATOR|Participants with long COVID and current/active respiratory symptoms|Participants with a history of SARS-COV-2 infection and developed long term sequalae associated with their respiratory system: continued shortness of breath, etc.. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
62819271|NCT06569368|EXPERIMENTAL|Standard of Care Neoadjuvant Therapy + Metronidazole|"Participants found to be eligible to take part in this study, will be randomly assigned (as in the flip of a coin) to receive standard therapy alone or standard therapy plus metronidazole.~Participants are assigned to the metronidazole group, will also take 1 tablet of metronidazole by mouth every 8 hours for 2 weeks."
62819272|NCT06569368|NO_INTERVENTION|Standard of Care Neoadjuvant Therapy|"Participants found to be eligible to take part in this study, will be randomly assigned (as in the flip of a coin) to receive standard therapy alone or standard therapy plus metronidazole.~Participants in both study groups will receive their standard of care treatment, as assigned by their treating doctor outside of the research study."
62819273|NCT06601283|EXPERIMENTAL|VC plus herbal medicine|nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
62819274|NCT06596863||Control group|Included 862 healthy subjects as control group
62819275|NCT06596863||DKD group|Included 912 patients with DN
62819276|NCT03381690||Epidural (ED) emergent C-sec|
62819277|NCT03381690||Non-ED emergent C-sec|
62242945|NCT04775251|EXPERIMENTAL|one group|The treatment program consisted of upward rotation exercises for 3 sessions/week, for 6 weeks.
62242946|NCT01536236|ACTIVE_COMPARATOR|Subthreshold programming|During one of the first 2 weeks of the trial the subject will be randomized to a subthreshold stimulation arm. They will be blinded and receiving therapy, but will it will be delivered at a level (subthreshold) that they will not feel the stimulation.
62242947|NCT01536236|PLACEBO_COMPARATOR|Placebo or Stimulation off arm|During one of the first two weeks of the study, the patient will be randomized to a no stimulation arm. They will be blinded and will not be receiving therapy.
62819278|NCT03381690||Non-ED elective C-sec|
62819279|NCT05547347||Observational (twinkle marker placement)|Patients undergo percutaneous ultrasound-guided breast clip placement with a conventional biopsy marker (if not already present) and a twinkling marker throughout the trial. Patients undergo a breast ultrasound during screening, on study, and as clinically indicated. Patient also undergoes a mammogram on study and as clinically indicated as well as a MRI as clinically indicated.
62819280|NCT04534075|EXPERIMENTAL|Additional dietary fiber through Psyllium husk|The participants are allocated to intake the fifteen capsules per day, for example, five capsules three times per day. Altogether the fifteen capsules contains 5.5 g dietary fiber in psyllium husk.
62819281|NCT04534075|PLACEBO_COMPARATOR|Placebo (no additional dietary fiber)|The participants are allocated to intake the fifteen capsules per day, for example, five capsules three times per day. The capsules contain placebo (maltodextrin) and have a similar look as in the experimental arm.
62819282|NCT05635461|ACTIVE_COMPARATOR|Suspension (fasted)|150 milligrams (mg) of CVN424 administered in a single dose of suspension formulation.
62819283|NCT05635461|ACTIVE_COMPARATOR|Tablet (fed)|150 milligrams (mg) tablet of CVN424 administered in a single dose after ingestion of a standardized high-fat, high-calorie meal according to FDA Guidance for Industry (Food-effect bioavailability and fed bioequivalence studies, Jun 2022).
62819284|NCT05635461|ACTIVE_COMPARATOR|Tablet (fasted)|150 milligrams (mg) tablet of CVN424 administered in a single dose.
62819285|NCT06520501|EXPERIMENTAL|Brisk Walking|Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.
62819286|NCT06520501|EXPERIMENTAL|Herbal Medicine Sambiloto|Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days.
62819287|NCT06520501|EXPERIMENTAL|Combination|"Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.~Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days."
62819288|NCT06520501|NO_INTERVENTION|Control Obese|Obese with no intervention
62819289|NCT06520501|NO_INTERVENTION|Control Normal|Normal with no intervention
62599915|NCT06311435|ACTIVE_COMPARATOR|Participants with long COVID and current/active neurological symptoms|Participants with a history of SARS-COV-2 infection and developed long term sequalae associated with their neurologic system: brain fog, confusion, etc.. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
62819290|NCT04337372|EXPERIMENTAL|Effects of shared book reading|There will be one arm since all participants will undergo the same intervention.
62819291|NCT06005467|EXPERIMENTAL|V shaped plate|its a new plate that have been used in fixation of fractures in various areas of the mandible,V shaped plate was used in the treatment of three angle fracture cases which provided the advantage of including both lines of osteosynthesis which are the superior border and the lateral surface of the external oblique ridge using one plate.
62039653|NCT04763902|EXPERIMENTAL|Time Restricted Eating (TRE) Schedule|For 8 weeks out of the 14-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calories-containing beverages within an 8 to 10-hour period that fits their schedule. The fasting period will ramp up during the first week (Days 1-3, 12-14 h per day, Days 4-6, 14-16 h per day, Days 7+, 16 h per day).
62819292|NCT06005467|ACTIVE_COMPARATOR|champy technique|champy technique is one of the standard methods that are used in fixation of mandibular angle fractures by applying a mini-plate in the superior border of the external oblique ridge.
62039654|NCT04763902|NO_INTERVENTION|Control Schedule|For 4 weeks out of the 14-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals, and a standardized breakfast and snacks menu. All meals and snacks will be culturally competent, and meal plans will be individualized to meet weight maintenance energy requirements.
62039655|NCT04439526||Participants with Facial Psoriasis|Participants with moderate facial psoriasis who are being treated with guselkumab in real world practice will be observed in this study.
62242948|NCT01536236|ACTIVE_COMPARATOR|Optimal stimulation programming|During the third week of the trial period, all subjects will receive optimal stimulation.
62242949|NCT06736301|EXPERIMENTAL|stent|a double pig-tail stent for cross fixation of a fully covered stent
62242950|NCT06065748|EXPERIMENTAL|Giredestrant + Investigator's Choice of CDK4/6i|Participants in the experimental arm will receive giredestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
62242951|NCT06065748|ACTIVE_COMPARATOR|Fulvestrant + Investigator's Choice of CDK4/6i|Participants in the control arm will receive fulvestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
62242952|NCT06734572|EXPERIMENTAL|dynamic PET scans|PET imaging will begin at 3 minutes, 15 minutes, 30min minutes, 60 minutes and 120 minutes after injection.
62242953|NCT01430351|EXPERIMENTAL|Arm 1 (temozolomide)|Patients receive temozolomide PO QD on days 1-5.
62242954|NCT01430351|EXPERIMENTAL|Arm 2 (temozolomide, memantine hydrochloride)|Patients receive temozolomide PO as in Arm 1 and memantine hydrochloride PO BID.
62242955|NCT01430351|EXPERIMENTAL|Arm 3 (temozolomide, mefloquine)|Patients receive temozolomide PO as in Arm 1 and 30 mg mefloquine PO QD on days 1-3 of week 1 and then days 2, 4, and 6 every other week.
62242956|NCT01430351|EXPERIMENTAL|Arm 4 (temozolomide, metformin hydrochloride)|Patients receive temozolomide PO as in Arm 1 and metformin hydrochloride PO BID.
62242957|NCT01430351|EXPERIMENTAL|Arm 5 (temozolomide, memantine hydrochloride, mefloquine)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, and mefloquine PO QD as in Arm 3.
62242958|NCT01430351|EXPERIMENTAL|Arm 6 (temozolomide, memantine hydrochloride, metformin)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, and metformin hydrochloride PO BID as in Arm 4.
62242959|NCT01430351|EXPERIMENTAL|Arm 7 (temozolomide, mefloquine, metformin hydrochloride)|Patients receive temozolomide PO as in Arm 1, mefloquine PO QD as in Arm 3, and metformin hydrochloride PO BID as in Arm 4.
62599916|NCT06311435|ACTIVE_COMPARATOR|Participants who have long COVID with current/active both respiratory and neurological symptoms|Participants with a history of SARS-COV-2 infection and developed long term sequalae associated with both their respiratory system and their neurologic system. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
62819293|NCT06600854|EXPERIMENTAL|BoneTape|
62819294|NCT06176118|EXPERIMENTAL|Unblinded Intervention|There is no control group in this study. Only intervention group due to phase of trial and study intentions.
62819295|NCT04991402||Pregnant women living with HIV initiating Dolutegravir (DTG) in pregnancy (iDTG)|Pregnant women living with HIV initiating DTG-based ART in pregnancy at the 1st visit
62039656|NCT04439526||Participants with Genital Psoriasis|Participants with moderate genital psoriasis who are being treated with guselkumab in real world practice will be observed in this study.
62039657|NCT03632382|OTHER|OSA diagnosis with 3D acquisition|OSA diagnosis with 3D acquisition
62242960|NCT01430351|EXPERIMENTAL|Arm 8 (TMZ, memantine hydrochloride, metformin, mefloquine)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, metformin hydrochloride PO BID as in Arm 4, and mefloquine PO QD as in Arm 3.
62242961|NCT05181722|ACTIVE_COMPARATOR|Intervention group|The study participants in this group will receive support from the patient navigator as part of this study.
62819296|NCT04991402||Pregnant women living with HIV already on DTG-based ART prior to pregnancy (cDTG)|Pregnant women living with HIV already on DTG-based ART prior to enrollment and continuing DTG use through pregnancy
62039658|NCT05856162|EXPERIMENTAL|Full Intervention|Participants randomized to this arm will receive the full ENRICH pilot which will consist of content on diet, physical activity, sleep, stress/mental health, and tobacco cessation. They will also receive usual home visiting services.
62242962|NCT05181722|NO_INTERVENTION|Usual care group|The study participants in this group will receive the usual care per the institutional protocol.
62242963|NCT05746481|EXPERIMENTAL|Single Treatment Arm|Tiragolumab in combination with atezolizumab, pemetrexed, and carboplatin.
62242964|NCT06318455|EXPERIMENTAL|breathing exercise group|breathing exercise group: make breathing exercise for 12 weeks
62242965|NCT06318455|NO_INTERVENTION|control group|control group: continue standart treartment
62819297|NCT04991402||HIV uninfected pregnant women|Pregnant women not living with HIV
62819298|NCT03541850|EXPERIMENTAL|Treatment (SBRT, ADT)|Patients undergo SBRT QOD for 14 days. Patients may also receive ADT comprised of a luteinizing hormone-releasing hormone agonist or a gonadotropin-releasing hormone antagonist, and an oral anti-androgen for 6 months at the discretion of the treating physician.
62819299|NCT06206447||Tunnel-cuffed Catheter Group|Hemodialysis patient with Tunnel-cuffed Catheter in right internal jugular vein
62599917|NCT06311435|ACTIVE_COMPARATOR|Participants who have other current/active long COVID symptoms|Participants with a history of SARS-COV-2 infection and developed long term sequalae not associated with respiratory or neurological conditions.
62599918|NCT06311435|ACTIVE_COMPARATOR|Participants with neurological symptoms prior to 1 November 2019 without SARS-COV-2 infection|Participants without a history of SARS-COV-2 infection and had neurological conditions prior to 1 November 2019.
62599919|NCT06311435|ACTIVE_COMPARATOR|Participants with respiratory symptoms before 1 November 2019 w/o SARS-COV-2 prior to 1 Nov 2019|Participants without a history of SARS-COV-2 infection and had respiratory conditions prior to 1 November 2019.
62599920|NCT06311435|ACTIVE_COMPARATOR|Participants with neurological symptoms prior to 1 November 2019 with SARS-COV-2 infection|Participants with a history of SARS-COV-2 infection and had neurological conditions prior to 1 November 2019.
62599921|NCT06311435|ACTIVE_COMPARATOR|Participants with respiratory symptoms prior to 1 November 2019 with SARS-COV-2 infection|Participants with respiratory symptoms prior to 1 November 2019 with SARS-COV-2 infection
62599922|NCT06311435|ACTIVE_COMPARATOR|Participants with resolved long COVID respiratory symptoms|Participants with a history of SARS-COV-2 infection and long term respiratory symptoms that have resolved
62242966|NCT03457350|EXPERIMENTAL|office hysteroscopy|Office hysteroscopy 30 degrees 2.6 mm telescope with an outer sheath of 3.2 mm (Storz Co., Tutlingen, Germany). Hysteroscopy is performed as usual by proper examination of the vagina and the ectocervix for any abnormality followed by introduction of the hysteroscope into the cervical canal. At this step, the hysteroscopist waits for a while until the distending fluid forms a micro-cavity. At this point, the telescope is advanced with necessary rotatory movements of the 30 degrees telescope guided by the vision of the dark spot which is the internal os. If it is reached, again waiting for some time to allow fluid distension of the internal os area.
62242967|NCT03457350|EXPERIMENTAL|blind cervical probing|Cervical probing is started with a 2 mm probe after grasping the cervix with a multi-tooth tenaculum put anteriorly or posteriorly according to prior transabdominal or transvaginal sonographic examination of the cervical canal. If the probe succeedes to bypass the internal os, a higher caliber probe is used. Thereafter, a uterine sound (4mm = 1.33 Fr) is introduced into the endometrial cavity. Lastly, gentle cervical dilatation up to Hegar's 8 is performed as usual with classic leaving each dilator for 30 seconds inside the internal os. If probes couldn't bypass the internal os, the procedure is considered failed. If the probe enters a cavity other than endometrial cavity, a false passage is considered.
62242968|NCT03292861|ACTIVE_COMPARATOR|Thymoglobulin®|"Thymoglobulin® (Genzyme) \[rabbit anti-thymocyte globulin (ATG)\] is a purified pasteurized, gamma immune globulin, obtained by immunization of rabbits with human thymocytes. This immunosuppressive product contains polyclonal cytotoxic antibodies directed against antigens expressed on human T-lymphocytes. Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 6 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4 hours.~In addition, there will be maintenance doses of mycophenolate mofetil, tacrolimus, sirolimus, and cumulative dose of corticosteroids at 12 months post-transplantation"
62242969|NCT03292861|NO_INTERVENTION|No induction therapy|Patients qualifying for the study will be randomized before the transplantation surgery in a 1:1 ratio to either Thymoglobulin® or no treatment.
62819300|NCT06206447||Non-ccuffed Catheter Group|Hemodialysis patient with Non-cuffed Catheter in right internal jugular vein
62242970|NCT04117009|EXPERIMENTAL|Remifentanil 2 ng/mL|Following baseline echocardiographic evaluation, Remifentanil (ultiva at a concentration of 20 micg/ml) infusion will be started at a rate to reach a target plasma level of 2 ng/mL. A target Controlled Infusion pump will be used to infuse the study drug. Once the target drug concentration is reached (which is expected to reach around 10-15 minutes), the final echocardiographic examination will be performed.
62242971|NCT04117009|EXPERIMENTAL|Baseline|Baseline transthoracic echocardiographic examination will be performed in the spontaneously breathing patients right before the surgical procedure and study drug infusion begins.
62599923|NCT06311435|ACTIVE_COMPARATOR|Participants with resolved long COVID neurological symptoms|Participants with a history of SARS-COV-2 infection and resolved long COVID neurological symptoms
62599924|NCT06311435|ACTIVE_COMPARATOR|Participants with resolved long COVID respiratory and neurological symptoms|Participants with history of SARS-COV-2 and resolved long COVID respiratory and neurological symptoms
62599925|NCT06311435|ACTIVE_COMPARATOR|Participants with other resolved long COVID symptoms|Participants with a history of SARS-COV-2 and other resolved long COVID symptoms
62599926|NCT03558152|EXPERIMENTAL|Arm 1a: UTTR1147A Dose Level 1 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 1 and Vedolizumab Placebo.~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
62599927|NCT03558152|EXPERIMENTAL|Arm 1b: UTTR1147A Dose Level 1 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 1 and Vedolizumab Placebo.~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
62599928|NCT03558152|EXPERIMENTAL|Arm 2a: UTTR1147A Dose Level 2 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 2 and Vedolizumab Placebo.~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
62599929|NCT03558152|EXPERIMENTAL|Arm 2b: UTTR1147A Dose Level 2 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 2 and Vedolizumab Placebo.~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
62599930|NCT03558152|EXPERIMENTAL|Arm 3a: UTTR1147A Dose Level 3 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 3 and Vedolizumab Placebo.~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
62599931|NCT03558152|EXPERIMENTAL|Arm 3b: UTTR1147A Dose Level 3 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 3 and Vedolizumab Placebo.~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
62819301|NCT03864783|EXPERIMENTAL|Curcumin (Meriva®)|Meriva® 500 mg tablet (contains 100 mg curcumin) Dosage: 2 tablets twice daily for 42 days (+/- 3 days)
62242972|NCT04783922||Benign Hematoma|Patients (having novel image markers or clinical features) suggestive of a benign hematoma relatively , that is having relatively good prognostic outcome and less likely to expand.
62242973|NCT04783922||Malignant Hematoma|Patients (having novel image markers or clinical features) suggestive of a malignant hematoma relatively, that is more likely to expand and have poor prognostic outcome.
62433220|NCT01823315|EXPERIMENTAL|Methotrexate+dactinomycin Single-dose chemotherapy|"Regimen: dactinomycin d 0.6mg/m2, IV, on day1, 2; methotrexate 100mg/m2, IV, on day1 (after Act-d); methotrexate 200mg/m2, IVgtt, on day1 (after methotrexate, 500ml NS, \>4h).~If 10-fold fall of hCG achieved 18 days after treatment completion, success of primary single-course chemotherapy was defined and further treatment was withheld; otherwise, failure was defined and the patient was referred to multi-course chemotherapy. During the period of observation for those with success, if the level of hCG became stationary for at least 3 weeks or rose again, the patient was also referred to multi-course chemotherapy. Additional consolidation chemotherapy with 1-3 courses was given for those who achieved CR by multi-course chemotherapy, but not by single-course regimen."
62433221|NCT01823315|ACTIVE_COMPARATOR|MTX multiple courses chemotherapy|"Regimen: methotrexate 0.4mg/(kg·d) intramuscularly (IM) on days 1-5, 2-week intervals. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive at least 1 additional consolidation treatment.~After treatment, all the patients were asked for contraception with condom or oral contraception. Regular hCG surveillance, once a month for 3 consecutive months and once every 3 months for 2 years, was performed. During follow-up period, pelvic ultrasound and pulmonary X ray or CT scan were conducted if needed."
62242974|NCT03269643|EXPERIMENTAL|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
62599932|NCT03558152|ACTIVE_COMPARATOR|Arm 4: Vedolizumab|Parts A and B: Vedolizumab and UTTR1147A Placebo.
62599933|NCT03558152|PLACEBO_COMPARATOR|Arm 5: Placebo|Parts A and B: UTTR1147A Placebo and Vedolizumab Placebo.
62599934|NCT01301781|EXPERIMENTAL|BLI801 laxative|BLI801 laxative - oral solution
62242975|NCT03269643|ACTIVE_COMPARATOR|Reference Group|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
62433222|NCT03953781||group 1|25 participants, were treated by valproate (VPA) as a monotherapy till became seizure free at the last 8-weeks before post treatment check-point, with ages ranged from 18-43 years
62433223|NCT03953781||group 2|25 participants were treated by levetiracetam (LEV) with the same regimens of valproate as a monotherapy, with ages ranged from 20-45 years.
62433224|NCT00240084|EXPERIMENTAL|Nesiritide infusion|Single arm study. 24-hour infusion of B-type Natriuretic Peptide at a dose of 0.01 mcg/kg/minute.
62433225|NCT05514028||Cyst Benign|100 patients
62433226|NCT05514028||Ovarian Cancer|120 patients
62433227|NCT05514028||Borderline Ovarian Cancer|30 patients
62599935|NCT01301781|PLACEBO_COMPARATOR|Placebo|BLI801 placebo - oral solution
62599936|NCT01248169||Hydralazine|This group will receive administration of the antihypertensive Hydralazine for the attempted control of their blood pressure and stabilization of their hemodynamic state.
62599937|NCT01248169||Labetalol|This group will receive administration of the antihypertensive Labetalol for the attempted control of their blood pressure and stabilization of their hemodynamic state.
62599938|NCT06492265|EXPERIMENTAL|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (between 4.5-6 hours after onset of symptoms) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
62599939|NCT06492265|PLACEBO_COMPARATOR|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (between 4.5-6 hours after onset of symptoms) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
62599940|NCT00784238|EXPERIMENTAL|Paliperidone|Paliperidone Extended-Release (ER) oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
62599941|NCT05320718|EXPERIMENTAL|erector spinae plane block|A needle is inserted until the tip contacted the T5 transverse process under ultrasound guidance. After confirming the needle tip position, 20 ml of 0.5% ropivacaine was injected in the plane between the erector spinae muscles and transverse process. A catheter is inserted through the needle and then connected to a Programmed Electronic Postoperative Analgesia Pump with a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery
62819302|NCT03864783|PLACEBO_COMPARATOR|Placebo|Placebo. Dosage: 2 tablets twice daily to mimic Meriva® tablets.
62819303|NCT05165667|EXPERIMENTAL|team meeting|the team meeting will help to measure the effectiveness of rehabilitation team meeting on disability among stroke patinets in Functional Independent Measure (FIM) score
62819304|NCT05165667|ACTIVE_COMPARATOR|patient|they will be the subject
62819305|NCT05099809||Hyperthermia|"Patients with locally advanced cancers reporting to Department of Radiotherapy at MGIMS who fulfil the eligibility criteria would be included in the study. Depending on the ongoing departmental protocols for various tumors the patients could be treated with either:~1. Radiotherapy and Hyperthermia~2. Concurrent chemoradiotherapy and hyperthermia~3. Neoadjuvant chemotherapy and hyperthermia followed by surgery and/or radiotherapy Hyperthermia would be delivered using a shortwave diathermy unit operating at 27.1 MHz.~Tumour response would be evaluated using RECIST criteria 1.1 while the acute and late morbidities would be scored as per CTCAE v5.0 guidelines. Outcome measures for each site would be undertaken and evaluated in terms of~1. Locoregional disease control~2. Disease free survival~3. Overall Survival~4. Acute morbidity~5. Late morbidity"
62242976|NCT01809535|EXPERIMENTAL|The Monthly EVL|Patients in the Monthly group were received EVL at 28-day treatment intervals.
62819306|NCT00759590||1|ALI/ARDS patients
62599958|NCT03020875|ACTIVE_COMPARATOR|PO Acetaminophen|"Preop:~Eligible patients will receive oral acetaminophen within 3 hours of OR start time.~Postop:~Eligible patients will be administered oral acetaminophen following 1 and 2 level LLIFs supplemented with instrumented posterior fusion to evaluate pain management outcomes. Dosing for the group will be the following:~• Oral Acetaminophen 1,000 mg every 6 hours for 48 hours postoperative. Medication will be given at least 6 hours following initial preoperative dose of oral acetaminophen.~Postop supplemental pain medications:~All patients will receive a standardized hydromorphone IV-PCA order set for 24 hours postoperatively. The use of tramadol and tapentadol will specifically be discouraged due to challenges in determining morphine-equivalent dosing with these specific agents. Similarly, acetaminophen containing combination products (e.g. oxycodone/acetaminophen or hydrocodone/acetaminophen) will not be allowed due to overlap with the primary study medications."
62599959|NCT03020875|ACTIVE_COMPARATOR|Intravenous Acetaminophen|"Preop:~Eligible patients will receive IV acetaminophen within 3 hours of OR start time.~Postop:~Eligible patients will be administered IV acetaminophen following 1 and 2 level LLIFs supplemented with instrumented posterior fusion to evaluate pain management outcomes. Dosing for the group will be the following:~• IV Acetaminophen 1,000 mg \[100 ml\] every 6 hours for 48 hours postoperative. Medication will be given at least 6 hours following initial preoperative dose of IV acetaminophen.~Postop supplemental pain medications:~All patients will receive a standardized hydromorphone IV-PCA order set for 24 hours postoperatively. The use of tramadol and tapentadol will specifically be discouraged due to challenges in determining morphine-equivalent dosing with these specific agents. Similarly, acetaminophen containing combination products (e.g. oxycodone/acetaminophen or hydrocodone/acetaminophen) will not be allowed due to overlap with the primary study medications."
62599960|NCT03653351|SHAM_COMPARATOR|Sham tDCS and MBSR|Includes a combination of 8 weeks of in-class group MBSR + sham tDCS and daily at home MBSR + sham tDCS.
62599961|NCT03653351|ACTIVE_COMPARATOR|Active tDCS and MBSR|Includes a combination of 8 weeks of in-class group MBSR + active tDCS and daily at home MBSR + active tDCS.
62599962|NCT04818385||Participants Receiving Risankizumab|Participants will receive risankizumab as prescribed by their physician.
62599963|NCT04818385||Participants Receiving All Other Biologics|Participants will receive all other biologics as prescribed by their physician.
62243469|NCT00403754|EXPERIMENTAL|Placebo-Ind 150 μg-Ind 300 μg-Ind 600 μg-Salmeterol|"In treatment period 1: patients received 2 placebo capsules; in treatment period 2: patients received 1 indacaterol (Ind) 150 μg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 indacaterol 300 μg capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
62599964|NCT04384861|EXPERIMENTAL|ACTIVE|The ACTIVE arm of the project received the Mayo Clinic SMART training (1 two-hour in-person workshop) and access to the Mayo Clinic's SMART eLearning Support study modules (4 x 45 minute modules in weeks 1-4; 20 x 10 minute modules weeks 5-24)
62599965|NCT04384861|NO_INTERVENTION|CONTROL|The CONTROL did not receive any interventions.
62599966|NCT01668966|EXPERIMENTAL|Tocilizumab|Participants will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenously (IV) every 4 weeks for up to 104 weeks.
62599967|NCT05028413|NO_INTERVENTION|Participants Blinded to BrAC reading (Control)|Participants randomized to this arm will consume three weight-based doses of alcohol with a target BAC of 0.10 and comple breathalyzer measurements every 20 minutes until a BAC of 0.03 is reached. They will complete a visual analog scale (the Self-Reported intoxication Survey) on their perceived fitness to drive and be blinded to their breath alcohol readings with the BACtrack Mobile Pro device.
62599968|NCT05028413|EXPERIMENTAL|Participants Aware of their BrAC reading|Participants randomized to this arm will consume three weight-based doses of alcohol with a target BAC of 0.10 and comple breathalyzer measurements every 20 minutes until a BAC of 0.03 is reached. They will be shown their breath alcohol readings with the BACtrack Mobile Pro device before completing a visual analog scale (the Self-Reported intoxication Survey) on their perceived fitness to drive.
62599969|NCT06620328|EXPERIMENTAL|Mechanical dilator|Dilation of the needle tract is initially performed with an ultra-tapered mechanical dilator (7Fr ES Dilator; Zeon Medical Co., Tokyo, Japan).
62599970|NCT06620328|ACTIVE_COMPARATOR|Electrocautery dilator|Dilation of the needle tract is initially performed with a diathermic sheath (6Fr Cyst-Gastro set; Endoflex, Voerde, Germany).
62599971|NCT05153148|PLACEBO_COMPARATOR|Placebo|Participants received placebo capsules, orally, QD for 12 weeks.
62599972|NCT05153148|EXPERIMENTAL|NDI-034858 Low Dose|Participants received NDI-034858 low dose, capsules, orally, QD for 12 weeks.
62599973|NCT05153148|EXPERIMENTAL|NDI-034858 Medium Dose|Participants received NDI-034858 medium dose, capsules, orally, QD for 12 weeks.
62599974|NCT05153148|EXPERIMENTAL|NDI-034858 High Dose|Participants received NDI-034858 high dose, capsules, orally, QD for 12 weeks.
62599975|NCT05342922|ACTIVE_COMPARATOR|Ultrasound group|Ultrasound assited technique will be used for spinal anesthesia performance.
62599976|NCT05342922|EXPERIMENTAL|Landmark group|Land-mark assisted technique will be used for spinal anesthesia performance.
62265877|NCT05482685||health literacy|The number of points scored by completing the scale
62819635|NCT04435288|ACTIVE_COMPARATOR|TNFi-induction group|"The patients in the TNFi-induction group will receive golimumab at a standard dose of 50 mg subcutaneously (SC) every 4 weeks (with matching methotrexate (MTX)-placebo). In case of potential intolerance or toxicity to MTX-placebo, the dose will be gradually tapered to a minimum of 7.5 mg per week. When there are no tolerability/toxicity issues, the weekly dose of MTX-placebo will be increased to 20 mg at week 4. At week 12, a Patient Acceptable Signs \& Symptoms Improvement ('PASSI') will be assessed by asking the question Taking into account both efficacy and side effects, did you experience over the past 12 weeks enough improvement in signs and symptoms of your' arthritis-enthesitis-dactylitis to consider continuation of the same treatment schedule for the next 12 weeks?. If yes, all study medication will be kept stable until week 24; if no, oral sulphasalazine at a dose of 2 g per day will be started (escape medication)."
62243470|NCT00403754|EXPERIMENTAL|Ind 150 μg-Ind 600 μg-Placebo-Ind 300 μg-Salmeterol|"In treatment period 1: patients received 1 indacaterol (Ind) 150 μg capsule + 1 placebo capsule; in treatment period 2: patients received 2 indacaterol 300 μg capsules; in treatment period 3: patients received 2 placebo capsules; and in treatment period 4: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
62265878|NCT05482685||self-perceived health|The number of points scored by completing the scale
62265879|NCT05482685||health-promoting behavior|The number of points scored by completing the scale
62265880|NCT04865328||OAB group|Group with diagnosed overactive bladder.
62433676|NCT02076191|EXPERIMENTAL|Myeloproliferative neoplasms|In phase I, increasing doses of ruxolitinib in combination with decitabine at a dose of 20 mg/m2 daily intravenously over 5 days. An initial dose of ruxolitinib of 10 mg orally twice daily is anticipated with planned, dose escalations of 15 mg orally twice daily, 25 mg orally twice daily and 50 mg orally twice daily. The dose can also be de-escalated to 5mg orally twice daily if dose limiting toxicities (DLTs) are observed at the initial 10mg dose. Patients will receive ruxolitinib as a single agent for the first 7 days followed by the administration of decitabine on day 8 for a total of 5 consecutive days. Patients will continue ruxolitinib at the assigned dose through the first cycle and may reduce the dose for specified toxicity beginning with the second cycle. Patients in Phase II will start at the recommended phase II dose (RPTD) of ruxolitinib in combination with decitabine at a dose of 20 mg/m2 daily intravenously over 5 days.
62599977|NCT00459706|EXPERIMENTAL|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
62599978|NCT00459706|EXPERIMENTAL|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
62599979|NCT01993498|OTHER|breast cancer treatment + blood sampling|Standard treatment of breast cancer with intervention : samples collection
62243471|NCT00403754|EXPERIMENTAL|Ind 300 μg-Placebo-Ind 600 μg-Ind 150 μg-Salmeterol|"In treatment period 1: patients received 1 indacaterol (Ind) 300 μg capsule + 1 placebo capsule; in treatment period 2: patients received 2 placebo capsules; in treatment period 3: patients received 2 indacaterol 300 μg capsules; and in treatment period 4: patients received 1 indacaterol 150 μg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation, device on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
62243472|NCT00403754|EXPERIMENTAL|Ind 600 μg-Ind 300 μg-Ind 150 μg-Placebo-Salmeterol|"In treatment period 1: patients received 2 indacaterol (Ind) 300 μg capsules; in treatment period 2: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 placebo capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
62599980|NCT03777813|EXPERIMENTAL|Arm A|"Concomitant administration of durvalumab (dose: 1500 mg):~Every 4 weeks during concurrent FOLFOX and after FOLFOX completion (total of 12 months of treatment)~Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of:~* 50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET)~* 45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node~FOLFOX 4 simplified protocol, 1 infusion every 2 weeks during 3 months starting with radiotherapy (+/- 1 day):~* IV oxaliplatin 85 mg/m² in 2 h on D1~* IV Leucovorin 200 mg/m² in 2 h on D1, followed by~* IV 5-FU 400 mg/m² in 10 minutes on D1 followed by~* IV continuous infusion 5-FU 2400 mg/m² in 46 h"
62433677|NCT04755218||Vaginal Misoprostol|"Patients will receive vaginal misoprostol 25 micrograms given every 3 hours for a maximum of 5 doses. Although labeled experimental for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States"
62433678|NCT04755218||Oral Misoprostol|Patients will receive standard oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses according to current labor induction protocol
62433679|NCT03385187|OTHER|NightOwl HSAT|Patient undergoes a NightOwl sleep apnea test whilst simultaneously undergoing a sleep study with a Type I sleep monitor (Lab-PSG) and optionally a Type IV sleep monitor.
62433680|NCT02662322|EXPERIMENTAL|HYPNOSIS|hypnotic communication, confusion procedure during peripheral intravenous catheterization
62433681|NCT02662322|ACTIVE_COMPARATOR|NOCEBO|negative connotation communication during peripheral intravenous catheterization
62433682|NCT02662322|PLACEBO_COMPARATOR|NEUTRAL|neutral connotation communication during peripheral intravenous catheterization
62433683|NCT04714099|EXPERIMENTAL|Topical CsA|Group A received topical CsA 0.05% for 3 months
62433684|NCT04714099|PLACEBO_COMPARATOR|Control|Placebo group
62433685|NCT02269215|EXPERIMENTAL|BIII 890 CL single rising dose|
62433686|NCT02269215|PLACEBO_COMPARATOR|Placebo|
62433687|NCT04109378|ACTIVE_COMPARATOR|Patients operated with conventional laparoscopic technique|Patients operated with conventional laparoscopic technique for colorectal DIE
62433688|NCT04109378|ACTIVE_COMPARATOR|Patients operated with NOSE laparoscopic technique|Patients operated with NOSE technique for colorectal DIE
62433689|NCT02931565|EXPERIMENTAL|IW-1701|Single 5-mg dose of IW-1701 administered orally
62433690|NCT02931565|PLACEBO_COMPARATOR|Placebo|Matching placebo administered orally
62433691|NCT03629847|EXPERIMENTAL|Everolimus & Radiolabeled Lu-177|Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
62433692|NCT06079086|ACTIVE_COMPARATOR|Group A - group with textured envelope|Group A - group with textured envelope
62433693|NCT06079086|ACTIVE_COMPARATOR|Group B - group with velvet/silicone foam envelope|Group B - group with velvet/silicone foam envelope
62433694|NCT02122211|EXPERIMENTAL|Betaine supplement|Will use powdered betaine (BetaPower, Dupont Nutrition) that is commercially available for food uses. This powder will be delivered as capsules containing 0.5 gram of powdered betaine which will be administered as eleven capsules twice per day (6 in the morning, 5 in the evening) for a daily total of 6 grams of betaine.
62433695|NCT05123027|EXPERIMENTAL|Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer|
62433696|NCT05123027|ACTIVE_COMPARATOR|Treatment As Usual Peer|
62039676|NCT03178149|EXPERIMENTAL|ASP7317 Dose Escalation/ Expansion (Group 1: Severe Vision Loss)|"Successive cohorts of participants (3 participants each) will be given escalating doses (cohort 1: low cells/dose; cohort 2: medium cells/dose; cohort 3: high cells/dose). Expansion cohorts (6 participants each) 3b will be opened after cohort 3 has been filled and 2b will be opened only if necessary. Dose levels for the expansion cohort will align with dose levels in escalation cohorts.~Sentinel dosing will be required for each dose level. After the first participant in Group 1 dose cohort is dosed and followed for 4 weeks, the Independent Data Monitoring Committee (IDMC) will review the 4 week safety data and recommend if the second and third participants in Group 1 dose cohort may be treated.~The IDMC recommendation to progress to the next dosing cohort will be based on 4 week follow-up safety review of the second and third participants in the preceding dose cohort. Participants will receive tacrolimus and other medicines to stop infection."
62243473|NCT06120166|EXPERIMENTAL|Administration of Metabolically Armed CD19 CAR-T cells|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. A dose of metabolically armed CD19 CAR-T cells will be infused on day 0.
62243474|NCT02659579|EXPERIMENTAL|The Reader Organisation's Shared Reading Programme|In the Reader Organisation's Shared Reading Programme, parents and children will attend The Reader Organisation's weekly shared reading programme for 8 weeks. The programme consists of two different modules. Parents will attend 'Magical Storytimes' with their children, in which a collection of shared book reading sessions are led by a project worker. Parents will also attend sessions on their own ('Stories for you and Yours') in which they will be informed how to choose books and read interactively with their child.
62819636|NCT04435288|ACTIVE_COMPARATOR|csDMARD-Step-up group|"The patients in the csDMARD-Step-up group will start with oral methotrexate (MTX) at a weekly dose of 15 mg for 4 weeks (with matching TNFi-placebo injections). In case of potential intolerance or toxicity to MTX , the dose will be gradually tapered to a minimum of 7.5 mg per week. When there are no tolerability/toxicity issues, the weekly dose of MTX will be increased to 20 mg at week 4. At week 12, a Patient Acceptable Signs \& Symptoms Improvement ('PASSI') will be assessed by asking the question Taking into account both efficacy and side effects, did you experience over the past 12 weeks enough improvement in signs and symptoms of your' arthritis-enthesitis-dactylitis to consider continuation of the same treatment schedule for the next 12 weeks?. If yes, all study medication will be kept stable until week 24; if no, oral sulphasalazine at a dose of 2 g per day will be started (escape medication)."
62819637|NCT06604260|EXPERIMENTAL|IBD patients|Ulcerative colitis and Crohn's disease patients
62819638|NCT06462625||Closing wedge|Patients undergoing closing wedge high tibial osteotomy in knee ostheoarthritis and lower limb malalignement
62819639|NCT06462625||Opening wedge|Patients undergoing opening wedge high tibial osteotomy in knee ostheoarthritis and lower limb malalignement
62819640|NCT03537963|OTHER|Pre-Intervention Qualitative Interviews|Hematopoietic cell transplant (HCT) survivors, caregivers and clinicians will participate in this part of the study. HCT survivor participants will be asked to nominate and provide contact information for the person who was their primary caregiver before, during, or after their HCT hospitalization. All participants will be asked to participate in either an in-person or telephone interview that will last approximately 1 hour. The interview will be digitally audio-recorded and will ask questions on the trajectory of sleep disturbance in HCT recipients and strategies to manage common barriers to quality sleep, as well as discuss the planned intervention for sleep disturbance in HCT survivors.
62819641|NCT03537963|EXPERIMENTAL|mHealth Stepped-care Intervention|For HCT survivors randomized to this group: Baseline survey, followed by mHealth Stepped-care intervention, post-intervention questionnaire and interview.
62819642|NCT03537963|ACTIVE_COMPARATOR|Educational Control Condition|For HCT survivors randomized to this group: Baseline survey, followed by Educational Control intervention, post-intervention questionnaire and interview.
62819643|NCT03537963|EXPERIMENTAL|mHealth Stepped-care Intervention + virtual reality relaxation|For HCT survivors randomized to this group: Baseline survey, followed by mHealth Stepped-care intervention + virtual reality relaxation component, post-intervention questionnaire and interview.
62243475|NCT02659579|ACTIVE_COMPARATOR|Shared Reading control|In the Shared Reading control parents and children will attend a weekly shared reading group at a library for 8 weeks where parents/children will read in a shared reading group which will be coordinated by a group facilitator.
62243476|NCT05216757|ACTIVE_COMPARATOR|Iguratimod group|subjects with Iguratimod
62243477|NCT05216757|PLACEBO_COMPARATOR|placebo group|subjects with placebo
62243478|NCT02792179|EXPERIMENTAL|[18F]RO6958948|Each participant will receive a single intravenous (IV) dose of \[18F\]RO6958948 and a single PET scan approximately 9-24 months after the baseline scan (in Study BP29409).
62819644|NCT06601673|EXPERIMENTAL|Intervention|Tablet-based bed-side cognitive training for 2h per day for the first five days after surgery (or until discharge from hospital, if earlier).
62819645|NCT06601673|SHAM_COMPARATOR|Audio book|Listening to an audio book for 2h per day for the first five days after surgery (or until discharge from hospital, if earlier).
62819646|NCT06601673|NO_INTERVENTION|Standard care|Standard care without any intervention.
62819647|NCT06529380|ACTIVE_COMPARATOR|Group 1 (DBS ON, then OFF)|"Group 1: DBS will be switched ON in Block 1 (three months) after the initial four-week post-operative period. The DBS device will then be turned OFF for two weeks (washout period). The device will remain OFF in Block 2 (three months)."
62243479|NCT00807963|EXPERIMENTAL|Stage 1: rHuPH20 plus ZA|Participants will receive one of several dose/concentrations of recombinant human hyaluronidase PH20 (rHuPH20) with zoledronic acid (ZA).
62819648|NCT06529380|PLACEBO_COMPARATOR|Group 2 (DBS OFF, then ON)|"Group 2: DBS will remain OFF in Block 1 (three months) after the initial four-week post-operative period. The device will remain off for two weeks thereafter (washout period). DBS will be switched ON in Block 2 (three months)."
62819649|NCT01648465|EXPERIMENTAL|Everolimus|
62819650|NCT04127604|EXPERIMENTAL|Integrated Treatment Adherence Program for Veterans (ITAP-VA)|A combination of in-person and phone sessions along with significant other involvement over 6 months post-hospitalization.
62599981|NCT03777813|ACTIVE_COMPARATOR|Arm B|"Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of:~* 50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET)~* 45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node~FOLFOX 4 simplified protocol, 1 infusion every 2 weeks during 3 months starting with radiotherapy (+/- 1 day):~* IV oxaliplatin 85 mg/m² in 2 h on D1~* IV Leucovorin 200 mg/m² in 2 h on D1, followed by~* IV 5-FU 400 mg/m² in 10 minutes on D1 followed by~* IV continuous infusion 5-FU 2400 mg/m² in 46 h"
62599982|NCT00732758|EXPERIMENTAL|Vitamin D3|Vitamin D3 1000 IU Tablet
62599983|NCT00732758|PLACEBO_COMPARATOR|Placebo|Placebo Tablet
62599984|NCT06622694|EXPERIMENTAL|RD13-02|"RD13-02 is a genetically engineered T cell product derived from healthy donors, designed to express a chimeric antigen receptor (CAR) targeting CD7 on its cell membrane. This modification enables the CAR T cells to specifically kill CD7-positive tumor cells. CD7 is expressed on the surface of both normal and malignant T cells. The extracellular domain of RD13-02 consists of a humanized single-chain antibody targeting CD7, while the co-stimulatory domain is derived from TNFRSF9 (CD137 or 4-1BB). The CAR is cloned into a clinical-grade retroviral vector and introduced into human T cells via retroviral transduction. To prevent fratricide, RD13-02 has had surface CD7 expression knocked out, and TCR knockout is implemented to prevent graft-versus-host disease (GvHD). HLA knockout and NK cell introduction further reduce the risk of rejection."
62599985|NCT05922319||Patients with cognitive impairment taking computerized cognitive training|The exposures and outcomes were measured repeatedly during the training process for each patient. The outcomes were compared to assess the effect of different exposures (computerized cognitive training with different doses). A mixed effects model was built to solve the random effects of patients.
62599986|NCT01585350|EXPERIMENTAL|Cohort 1|"Vaccines will be administered subcutaneously, intradermally or transdermally in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on days 1, 8, 15, 36, 57, and 78."
62599987|NCT01585350|EXPERIMENTAL|Cohort 2|"Vaccines will be administered subcutaneously, intradermally or transdermally in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on days 1, 8, 15, 36, 57, and 78."
62599988|NCT05662293||Patients with arrhythmia-induced cardiomyopathy (retrospective/prospective)|retrospective cohort and case-control study followed by a prospective observational cohort study.
62599989|NCT01995175|OTHER|Overall Group|Newborn subjects followed up for Lower Respiratory Tract Infections (LRTI) symptoms from birth until they are 2 years of age and for incidence of wheeze and asthma up to 6 years of age.
62599990|NCT03783234||Older Adult Patients|ED patients age of ≥ 75 who have nurse assessed Clinical Frailty Scale ≥ 4.
62599991|NCT02413242||ICU subjects, S. aureus+ at ICU admission|"Adult ICU patients, with a positive colonization status for S. aureus at ICU admission, who are mechanically ventilated within 24 hours of ICU admission and have an expected length of stay of 48h or more.~Colonization status will be measured at ICU admission using a nose swab and an ETA (or sputum/throat if unavailable). Positivity of either of the two qualifies the patient to be enrolled as a subject in this group."
62599992|NCT02413242||ICU subjects, S. aureus- at ICU admission|"Adult ICU patients, with a negative colonization status for S. aureus at ICU admission, who are mechanically ventilated within 24 hours of ICU admission and have an expected length of stay of 48h or more.~Colonization status will be measured at ICU admission using a nose swab and an ETA (or sputum/throat if unavailable). Negativity of both qualifies the patient to be enrolled as a subject in this group."
62599993|NCT02983435|EXPERIMENTAL|G1 - Thrust manipulation|G1 - Thrust manipulation is an osteopathic technique. The Group 1 (G1) will receive the Thrust technique applied at the level of dysfunction. Subject in lateral decubitus, with one lower limb extended and the other in flexion, to the level of the targeted vertebra; upper trunk rotated back until the same vertebra; at the end of the range of movement will be applied the high speed and low amplitude impulse (Thrust).
62599994|NCT02983435|ACTIVE_COMPARATOR|G2 - Muscle Energy|G2 - Muscle Energy is a manual therapy technique based in muscular contraction and stretching. The Group 2 (G2) will receive the Muscle Energy technique applied at the level of dysfunction. Subject in lateral decubitus, with the upper and lower trunk flexed until the target vertebra, and upper trunk rotated back to the level of the same vertebra; lumbar in lateral flexion (using the subject's feet) until the target vertebra. Following the command the subject will perform an isometric contraction of 3-5 seconds against the therapist's hand (pushing the hand towards the floor), repeated 3 times.
62599995|NCT01828333||Intravenous artesunate - new routine in DRC|"350 patients to be enrolled~A first study group with the currently used standard for treatment of severe malaria in the DRC, i.v. quinine, was enrolled from 21 October 2012 to 15 January 2013. This study was initially planned as limited scope implementation study with pure observational character (routine diagnosis and treatment, time and motion study, feasibility assessment and costing) and thus not registered. Due to additional publications on i.v. artesunate, non-routine testing for hemoglobin levels before and after treatment plus non-routine follow up was added: Registration of study at this point."
62599996|NCT00645281|EXPERIMENTAL|tolterodine ER group|
62819651|NCT04127604|ACTIVE_COMPARATOR|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced symptom monitoring and safety evaluation over 6 months post-hospitalization.
62819652|NCT06577181||Women undergoing preparation for Embryo transfer|Group who received intramuscular injection of HCG before embryo transfer
62819653|NCT06577181||Women undergoing preparation for Embryo transfer 1|Group who did not receive intramuscular injection of HCG before embryo transfer
62819654|NCT05231954|NO_INTERVENTION|Annual Well Visit or any other visit to Primary Care Doctor|Annual Well Visit or any other visit to Primary Care Doctor: This is the usual care arm. Electronic Health Record Data for patients from the clinics randomized to usual care will be collected for comparison with the other 2 arms. Patients from these primary care clinics must have had a visit to their doctor either as an annual well visit (AWV) or any other type of visit. These clinics will not have to do anything for the study but run their business as usual without altering anything.
62819655|NCT05231954|EXPERIMENTAL|Passive Digital Marker (PDM)|Passive Digital Marker (PDM): Electronic Health Record Data from those clinics randomized to PDM will be run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset.
62243480|NCT00807963|EXPERIMENTAL|Stage 2: ZA|Participants will receive a dose/concentration of ZA administered without rHuPH20.
62243481|NCT00807963|EXPERIMENTAL|Stage 3: rHuPH20 plus ZA|Participants will receive one of several dose/concentrations of rHuPH20 with ZA.
62243482|NCT00807963|EXPERIMENTAL|Stage 4: ZA|Participants will receive an intravenous (IV) dose of 5 milligrams (mg) ZA.
62243483|NCT00807963|EXPERIMENTAL|Stage 4: ZA with rHuPH20|Participants will receive a subcutaneous (SC) dose of ZA with rHuPH20.
62243484|NCT05397496|EXPERIMENTAL|PIT565 Group A (dose escalation part)|PIT565 in adult NHL patients for whom two or more lines of chemotherapy have failed and either having progressed (or relapsed) after autologous hematopoietic stem cell transplantation (HSCT), or being ineligible for or not consenting to the procedure
62243485|NCT05397496|EXPERIMENTAL|PIT565 Group B (dose escalation part)|PIT565 in adult R/R ALL patients
62243486|NCT05397496|EXPERIMENTAL|PIT565 Group A1 (dose expansion part)|PIT565 Recommended dose 1 (RD1) in adult R/R large B-cell lymphoma (LBCL) (DLBCL, double/triple hit High-grade B-cell lymphoma (HGBCL), Primary mediastinal large B-cell lymphoma (PMBCL), Follicular lymphoma grade 3B (FL3B)) patients
62243487|NCT05397496|EXPERIMENTAL|PIT565 Group A2 (dose expansion part)|PIT565 RD2 in adult R/R LBCL (DLBCL, double/triple hit HGBCL, PMBCL, FL3B) patients
62243488|NCT05397496|EXPERIMENTAL|PIT565 Group B1 (dose expansion part)|PIT565 in adult R/R ALL patients
62623370|NCT03845244|ACTIVE_COMPARATOR|FiO2 reduction first group|FiO2 reduction first -\> flow reduction -\> conventional oxygen therapy
62819656|NCT05231954|ACTIVE_COMPARATOR|Passive Digital Marker (PDM) + Quick Dementia Rating Scale (QDRS)|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
62819657|NCT06598995||Obstructive hypertrophic cardiomyopathy who underwent septal myectomy|All patients underwent angiography and without other coronary artery disease.
62819658|NCT04218240|EXPERIMENTAL|PGB/LFX;|0.54 mg lofexidine and 200 mg Pregabalin on days 1 -7 with taper for pregabalin and lofexidine starting on day 5
62819659|NCT04218240|ACTIVE_COMPARATOR|Lofexidine and PLACEBO|0.54 mg lofexidine and Placebo (PLB) on days 1-7 with taper for lofexidine starting on day 5
62819660|NCT06195748|EXPERIMENTAL|Group A (Kinesiotape Group)|The technique will follow manufacturer's guidelines, which is described in the Kinesio taping method. According to the manufacturer, the controllable variables in KT application included degree of pre-stretch applied to the tape (75-100%), the location and treatment goals. The subject will be asked to lie supine, with the ankle of the dominant side in neutral position. A Y shaped KT strip will be applied from the heel to lateral and medial femoral condyles. A I shaped KT strip will be applied from medial malleolus to lateral malleolus, passing under the heel. Another I shaped KT strip will be applied from slightly above the medial malleolus to slightly above the lateral malleolus, crossing on the instep at the malleoli level.
62819661|NCT06195748|PLACEBO_COMPARATOR|Group B (Placebo KT Group)|The same tape will be used for the interventional application. Two strips will be used, one from the heel to the proximal third of the leg, the other from the lateral malleolus to the medial malleolus crossing on the instep, both with 0 tension
62819662|NCT06595264||Vein of Galen malformation|All patients treated at Erasme hospital for a vein of Galen malformation.
62819663|NCT03745508|ACTIVE_COMPARATOR|Caffeinated Coffee (200 mg caffeine)|\~200 mg of caffeine from instant coffee
62819664|NCT03745508|ACTIVE_COMPARATOR|Caffeinated Coffee (400 mg caffeine)|\~400 mg of caffeine from instant coffee
62819665|NCT03745508|PLACEBO_COMPARATOR|Decaffeinated Coffee|Decaffeinated instant coffee
62819666|NCT03286036||Lung cancer patients|Patients with lung cancer who undergo surgical resection of the tumor
62819667|NCT03572517|ACTIVE_COMPARATOR|Subarachnoid block|"Subarachnoid block with hyperbaric bupivacaine 0,5% 3ml associate with morphine 50 mcg.~A general anesthetic with fentanyl 3 mcg / kg + propofol 2 mg / kg + rocuronium 0.6 mg / kg will be performed.~Anesthesia will be maintained with remifentanil (ng / ml) through Minto's pharmacokinetic model (BBraun infusion syringe - Perfusor® Space model) and desflurane (Fe%)."
62819668|NCT03572517|ACTIVE_COMPARATOR|Spinal morphine|"Spinal morphine with morphine 50 mcg. A general anesthetic with fentanyl 3 mcg / kg + propofol 2 mg / kg + rocuronium 0.6 mg / kg will be performed.~Anesthesia will be maintained with remifentanil (ng / ml) through Minto's pharmacokinetic model (BBraun infusion syringe - Perfusor® Space model) and desflurane (Fe%)."
62819669|NCT05643495|EXPERIMENTAL|Group A|Participants will receive VX-864 every 12 hours (q12h) for 48 weeks.
62819670|NCT05643495|EXPERIMENTAL|Group B|Participants will undergo a liver biopsy done before receiving VX-864 q12h for 48 weeks, and will undergo a second liver biopsy at either Week 24 or Week 48.
62819671|NCT06584552|EXPERIMENTAL|Lactobacillus Paracasei LPB27|"Formulation: Lactobacillus paracasei LPB27 (10 billion cfu/ serve) and Maltodextrin (up to 1g).~Dosage: 1mg daily for 12 weeks. Delivered orally through through breast milk, formula or solid food."
62243489|NCT00932685|ACTIVE_COMPARATOR|2. Video Game|
62243490|NCT00932685|ACTIVE_COMPARATOR|1. Midazolam 0.5mg/kg|
62243491|NCT02907710|EXPERIMENTAL|concurrent chemoradiotherapy + endostar|"Drug: Endostar~Endostar 7.5mg / m2,3 cycles of intravenous infusion for ten days, and 2 cycles of maintenance therapy after radiotherapy~Drug: DDP~DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles~Radiation: IMRT~IMRT:70-74Gy"
62243492|NCT02907710|ACTIVE_COMPARATOR|concurrent chemoradiotherapy|"Drug: DDP~DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles~Radiation: IMRT~IMRT:70-74Gy"
62243493|NCT01981239|EXPERIMENTAL|LPC analysis group|Voice sampling is executed before and immediately after drinking of 20ml N/S and linear voice analyses using LPC method are performed to calculate LPC index, residual variance, coefficiency mean, coeffiency variance, and coeffiency skewness.
62265881|NCT03332602|EXPERIMENTAL|free FeSO4|wheat bread fortified with free FeSO4
62819672|NCT06584552|PLACEBO_COMPARATOR|Maltodextrin|"Formulation: Maltodextrin 1g~Dosage: 1mg daily for 12 weeks. Delivered orally through through breast milk, formula or solid food."
62819673|NCT00860873|EXPERIMENTAL|Test 1|Oral Powder EMS
62819674|NCT00860873|EXPERIMENTAL|Test 2|Hard Capsules EMS
62819675|NCT00860873|ACTIVE_COMPARATOR|Comparator 1|Oral Powder Zodiac
62819676|NCT00860873|ACTIVE_COMPARATOR|Comparator 2|Hard capsules - Zodiac
62039677|NCT03178149|EXPERIMENTAL|ASP7317 Dose Escalation/ Expansion (Group 2: Moderate Vision Loss)|"Successive cohorts of participants (3 participants each) will be given escalating doses (cohort 4: low cells/dose; cohort 5: medium cells/dose; cohort 6: high cells/dose).~Expansion cohorts 5b and 6b (6 participants each) will be opened after cohorts 5 and 6 have been filled. Dose levels for the expansion cohorts will align with dose levels in escalation cohorts. Cohort 4 (low cells/dose) dosing may begin after the IDMC recommendation to begin dosing in Group 1 cohort 2 (medium cells/dose).~Cohort 5 (medium cells/dose) dosing may begin after IDMC review of the 4 week safety data of the first participant in Group 1 cohort 2 (medium cells/dose). Cohort 6 (high cells/dose) dosing may begin after IDMC review of 4 week safety data of the first participant in Group 1 cohort 3 (high cells/dose). Dosing in cohort 5 and 6 can only begin after the IDMC review and the completion of the preceding cohort. Participants will receive tacrolimus and other medicines to stop infection."
62039678|NCT06536127|EXPERIMENTAL|Arm 1|Blood samples
62039679|NCT06140199|ACTIVE_COMPARATOR|Pit-picking surgery|
62243494|NCT01981239|ACTIVE_COMPARATOR|spectral analysis group|Voice sampling is executed before and immediately after drinking of 20ml N/S and spectral voice analyses using Dr. Speech program are performed to calculate HNR (dB), RAP (%: Jitter), Mean and SD Fundamental Frequency (Hz: Fo), Shimmer (%) and SNR (dB).
62243495|NCT03953508|OTHER|Menthol|Participants who prefer smoking menthol cigarettes
62433697|NCT04741503|EXPERIMENTAL|Breast Cancer Screening Decision Support Tool|-After randomization, participants will complete pre-questionnaires, review the Breast Cancer Screening Decision support tool, and then complete the post-questionnaire.
62819677|NCT06305650|EXPERIMENTAL|Probiotic group|one bag/day BBr60, before meals
62819678|NCT06305650|PLACEBO_COMPARATOR|Placebo group|Maltodextrin, one bag/day, before meals
62819679|NCT03779256||Women with bowel endometriosis.|"Women with symptomatic bowel endometriosis scheduled for surgical treatment investigated with 2D transvaginal ultrasound before surgery at Hospital St John of God, Vienna, Austria; Oslo university hospital, Oslo, Norway and Nepean Hospital, Sydney, Australia.~The women recruited at Oslo university hospital, Norway will also have a magnetic resonance imaging (MRI) of the abdomen and pelvis before surger."
62433698|NCT04741503|ACTIVE_COMPARATOR|Standard Breast Cancer Screening Education|-After randomization, participants will complete pre-questionnaires, review the standard breast cancer screening education from the NCI, and then complete the post-questionnaire.
62433699|NCT04595227||Normal Subjects|Healthy eyes had intraocular pressure of less than 22 mmHg with no history of increased intraocular pressure and normal standard automated perimetry (SAP) results.
62433700|NCT04595227||Suspect Glaucoma|Eyes with suspect glaucoma were defined as those with suspicious neuroretinal rim thinning or retinal nerve fiber layer (RNFL) defects on masked stereophotographic assessment, without repeatable abnormal SAP results. Eyes with suspect glaucoma also included those with intraocular pressure (IOP) \> 21 mm Hg but with healthy-appearing optic discs and without repeatable abnormal SAP results
62623371|NCT03845244|ACTIVE_COMPARATOR|Simultaneous reduction group|Simultaneous (Flow and FiO2) reduction -\> conventional oxygen therapy
62819680|NCT06587711|EXPERIMENTAL|cheek acupuncture treatmnet|Patients in the experimental group are treated with cheek acupuncture.
62819681|NCT06587711|SHAM_COMPARATOR|sham acupuncture treatment|Patients in the control group are treated with sham acupuncture.
62819682|NCT05655741||Delphi Panel|Participants who meet the inclusion criteria ,who are willing to complete the 3 questionnaires within the study.
62819683|NCT05156281|EXPERIMENTAL|Remibrutinib - Core|Remibrutinib tablet and matching placebo of teriflunomide capsule
62819684|NCT05156281|ACTIVE_COMPARATOR|Teriflunomide - Core|Teriflunomide capsule and matching placebo remibrutinib tablet
62819685|NCT05156281|EXPERIMENTAL|Remibrutinib - Extension|Participants on remibrutinib in Core will continue on remibrutinib tablet
62819686|NCT05156281|EXPERIMENTAL|Remibrutinib - Extension (on teriflunomide in Core)|Participants on teriflunomide in Core will switch to remibrutinib tablet
62819687|NCT05014256|EXPERIMENTAL|STEPS Health System Surveillance and Outreach intervention|
62819688|NCT05014256|NO_INTERVENTION|Usual Kidney Care|
62819689|NCT06510660|EXPERIMENTAL|Adebrelimab+Sequential Concurrent Chemoradiotherapy|"Participants with CPS score ≥10 were enrolled.~Induction therapy: adebrelimab 1200mg iv d1 q3w x 2 cycles for 6 weeks.~Concurrent chemoradiotherapy: carboplatin AUC=2 / cisplatin 25mg/m2 d1 qw + paclitaxel 50mg/m2 / nab-paclitaxel 60mg/m2 d1 qw for a total of 5 weeks; radiotherapy:50Gy/25f, completed in 5 weeks."
62819690|NCT06510660|EXPERIMENTAL|Adebrelimab+Chemotherapy+Sequential Concurrent Chemoradiotherapy|"Participants with CPS score \<10 were enrolled.~Induction therapy: adebrelimab 1200mg iv d1 q3w + carboplatin AUC=6 / cisplatin 75mg/m2 d1 q3w + paclitaxel 175mg/m2 / nab-paclitaxel 260mg/m2 d1 q3w × 2 cycles for 6 weeks.~Concurrent chemoradiotherapy: carboplatin AUC=2 / cisplatin 25mg/m2 d1 qw + paclitaxel 50mg/m2 / nab-paclitaxel 60mg/m2 d1 qw for a total of 5 weeks; radiotherapy:50Gy/25f, completed in 5 weeks."
62039680|NCT06140199|EXPERIMENTAL|Pit-picking surgery with Sinus Laser assisted Closure|
62039681|NCT06733649|EXPERIMENTAL|Treatment education for perinatal women and the womens' community support|
62039682|NCT06734039|ACTIVE_COMPARATOR|Default Clinical Frequency Setting|The audio processor frequency setting will be programmed based on current frequency defaults in the clinical programming software
62039683|NCT06734039|ACTIVE_COMPARATOR|Default Anatomy-Based Fitting|The audio processor frequency setting will be programmed based on current anatomy-based fitting frequency defaults in the clinical programming software
62039684|NCT06734039|EXPERIMENTAL|Experimental Anatomy-Based Fitting 1|The audio processor frequency setting will be programmed using experimental settings for anatomy-based fitting using individual anatomical information obtained from analysis of post-operative imaging.
62243496|NCT03953508|OTHER|Non-menthol|Participants who prefer smoking non-menthol cigarettes
62623809|NCT04728698|EXPERIMENTAL|COVI-MSC|Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)
62623810|NCT04728698|PLACEBO_COMPARATOR|Placebo|Excipient
62819691|NCT02439723|EXPERIMENTAL|Regorafenib|All patients will be treated with 160 mg regorafenib taken orally once daily for the first 21 days of each 28-day cycle. Doses are to be taken immediately following a light breakfast. During the seven-day break period of cycle 1, patients will start pantoprazole 40 mg twice daily for 8 days
62599997|NCT04833725||COPD combined with OSA|All patients collect sleep monitoring information through wearable devices, together with demographic characteristics, pulmonary function tests, blood routines, biochemistry, electrocardiogram, chest radiograph, COPD assessment scale, modified British Medical Research Association dyspnea index, St. George's Quality of Life Questionnaire, Sleep Apnea Clinical Score, Berlin Questionnaire, Epworth Sleepiness Scale, Etc. This study estimates patient health status from the collected information, then diagnoses sleep apnea and calculates sleep apnea prevalence.
62599998|NCT03242174||Traditional Obstetrical Prenatal Care|Pregnant women receiving traditional obstetrical prenatal care and delivering in a hospital will be offered the Health Behavior questionnaire packet at third trimester prenatal appointment
62599999|NCT03242174||Prenatal Care from Midwife|Pregnant women receiving prenatal care from a midwife and delivering at the birth center will be offered the Health Behavior questionnaire packet at third trimester prenatal appointment
62600000|NCT02461524|OTHER|Abdominal Aortic Aneurysm Endovascular repair|Subjects who were appropriate candidates for endovascular repair of infrarenal abdominal aortic or aortoiliac aneurysms and who met the inclusion and exclusion criteria.
62039685|NCT06734039|EXPERIMENTAL|Experimental Anatomy-Based Fitting 2|The audio processor frequency setting will be programmed with experimental settings for anatomy-based fitting using individual anatomical information obtained from analysis of post-operative imaging.
62600001|NCT05297084||Aggressive periodontitis|25 young medically free patients with deep periodontal pockets \>5mm
62600002|NCT05297084||Periodontally healthy individuals|25 young medically free individuals with no periodontal inflammation signs
62600003|NCT00881439|PLACEBO_COMPARATOR|Placebo|
62600004|NCT00881439|ACTIVE_COMPARATOR|Aliskiren|
62600005|NCT06598384|EXPERIMENTAL|Venetoclax combined with Azacytidine|Patients were treated by venetoclax and azacytidine
62061584|NCT06618105|ACTIVE_COMPARATOR|E.Q. 90 mcg Base dose of R inhalation aerosol|One actuation (oral inhalation) each from the R inhalation aerosol and the placebo R inhalation aerosol and one actuation (oral inhalation) each from two different placebo T inhalation aerosols
62265882|NCT03332602|EXPERIMENTAL|free FeSO4 and empty microspheres|wheat bread fortified with free FeSO4, and empty microspheres
62433701|NCT04595227||Primary Open Angle Glaucoma, early stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -0.01dB≤MD≤-6.00dB)
62600006|NCT03136341|ACTIVE_COMPARATOR|Abobotulinum toxin A|
62265883|NCT03332602|EXPERIMENTAL|free FeSO4 with eudragit polymer|wheat bread fortified with free FeSO4, and eudragit polymer
62433702|NCT04595227||Primary Open Angle Glaucoma, moderate stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -6.01≤MD≤-12.00dB)
62433703|NCT04595227||Primary Open Angle Glaucoma, advanced stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -12.00≤MD≤-20.00dB)
62600007|NCT03136341|PLACEBO_COMPARATOR|Placebo|
62600008|NCT05454384||Forensic Medicine|The group of consultation records requested from the Department of Forensic Medicine
62600009|NCT05454384||Oncology|The group of consultation records requested from the Department of Oncology
62600010|NCT05454384||Neonatology|The group of consultation records requested from the Department of Neonatology
62600011|NCT05454384||Otorhinolaryngology|The group of consultation records requested from the Department of Otorhinolaryngology
62600012|NCT05454384||Neurology and Neurosurgery|The group of consultation records requested from the Department of Neurology and Neurosurgery
62600013|NCT05454384||Pediatrics|The group of consultation records requested from the Department of Pediatrics
62600014|NCT05454384||Emergency Medicine|The group of consultation records requested from the Department of Emergency Medicine
62265884|NCT03332602|EXPERIMENTAL|free FeSO4 with Hyaluronic Acid|wheat bread fortified with free FeSO4, and hyaluronic acid
62061585|NCT06618105|ACTIVE_COMPARATOR|E.Q. 180 mcg Base dose of R inhalation aerosol|One actuation (oral inhalation) each from two different R inhalation aerosols and one actuation (oral inhalation) each from two different placebo T inhalation aerosols
62265885|NCT03332602|EXPERIMENTAL|encapsulated FeSO4 3.2%|wheat bread fortified with encapsulated FeSO4 in a microsphere with 3.2% Fe loading
62265886|NCT03332602|EXPERIMENTAL|encapsulated FeSO4 20%|wheat bread fortified with encapsulated FeSO4 in a microsphere with 20% Fe loading
62265887|NCT03332602|EXPERIMENTAL|encapsulated FeSO4 3.2%, encap. Vitamin A|wheat bread fortified with encapsulated FeSO4 in a microsphere with 3.2% Fe loading, and encapsulated Vitamin A as microspheres
62265888|NCT03332602|EXPERIMENTAL|encapsulated FeSO4 3.2%, encap. Vitamin A, free folicacid|wheat bread fortified with encapsulated FeSO4 as microsphere with 3.2% Fe loading, encapsulated Vitamin A as microspheres and free folic acid
62265889|NCT03332602|EXPERIMENTAL|FeSO4 embedded in Hyaluronic Acid|wheat bread fortified with FeSO4 that is embedded in hyaluronic acid.
62265890|NCT03681119|EXPERIMENTAL|Advanced Demential Patients|
62265891|NCT03681119|EXPERIMENTAL|Hospice IDT Members|
62265892|NCT04292509|EXPERIMENTAL|SAP with predictive stop before low|Sensor-augmented pump therapy with the use of the predictive stop before low mode of action
62265893|NCT04292509|ACTIVE_COMPARATOR|SAP with stop on low|Sensor-augmented pump therapy with the use of the predictive stop on low mode of action
62265894|NCT05622526|EXPERIMENTAL|Group 1 or Experimental group|treatment with an initial dose of 24 oral capsules of MBK-01 and a maintenance dose of 12 oral capsules of MBK-01 every 3 months (4 maintenance doses).
62433704|NCT05909306|EXPERIMENTAL|Education Group|The education group was applied partograph education in addition to formal education by using the partograph e-learning tool that was developed.
62433705|NCT05909306|NO_INTERVENTION|Control Group|The control group continued their formal education.
62433706|NCT02346981|EXPERIMENTAL|Intervention gruop|The intervention group was submitted to a resistance training program that consisted of eight exercises performed in two sets of 10 to 15 repetitions, three times per week.
62433707|NCT02346981|NO_INTERVENTION|Control group|The control group performed a stretching training program for the major muscle groups, in sessions of 30 minutes, twice a week
62600015|NCT05454384||Other Departments|The group of consultation records requested from the Departments such as Plastic and Reconstructive Surgery, Cardiovascular Surgery, Internal Medicine, Ophthalmology, Urology, Gastroenterology, Palliative Care, Pulmonology, Sleep Medicine, and Infectious Diseases.
62600016|NCT01451944|EXPERIMENTAL|asthma education and case management|asthma education and case management
62600017|NCT03166540|EXPERIMENTAL|low consumers|1 cup of espresso coffee/day at 9.00 A.M. for 1 month
62600018|NCT03166540|EXPERIMENTAL|high consumers|3 cup of espresso coffee/day at 9.00 A.M. 12.00 P.M. and 3.00 P.M. for 1 month
62600019|NCT03166540|EXPERIMENTAL|medium consumers|1 cup of espresso coffee at 9.00 A.M. + cocoa-based products containing coffee at 12.00 P.M. and 3.00 P.M. for 1 month
62600020|NCT01644526|EXPERIMENTAL|Hemoaccess Valve System|Valve system for use with AV graft
62600021|NCT04691817|EXPERIMENTAL|Atezolizumab and Tocilizumab|Participants receive Atezolizumab 1200mg IV and Tocilizumab 6mg/kg IV (or Tocilizumab 4mg/kg IV) every 21 days
62600022|NCT03047720|OTHER|One: Study Phases (S1 and S2)|The therapeutic phase of this study for the participant in Arm One will be: 6 weeks of behavioral modifications plus the Lully device (S1), followed by 6 weeks of behavioral modifications only without the device (S2)
62600023|NCT03047720|OTHER|Two: Study Phases (S2 and S1)|The therapeutic phase of this study for the participant in Arm Two will be: 6 weeks of behavioral modifications only without the device (S2), followed by 6 weeks of behavioral modifications plus use of the Lully device(S1)
62600024|NCT00811824|ACTIVE_COMPARATOR|1|Immediate physical activity and dietary change intervention
62600025|NCT00811824|OTHER|2|Delayed physical activity and dietary change intervention
62600026|NCT06559384||German Dentists|Dentists who are working in dental offices in Germany
62600027|NCT06559384||German Oncologists|Oncologists who are working in private practice/clinics in Germany
62600028|NCT06559384||Patients with head-neck cancer|Patients with head and neck cancer or after therapy for head and neck tumors
62600029|NCT04458025|ACTIVE_COMPARATOR|Standard rehabilitation program|Standard postoperative 4 weeks immobilization rehabilitation program with a sling in adduction and internal rotation
62600030|NCT04458025|EXPERIMENTAL|Early rehabilitation program|Early rehabilitation program will start passive mobilization during second week after surgery, including controlled external rotation movements
62600031|NCT01381991|EXPERIMENTAL|i-scan-EGD|Examination of GE junction using conventional WL as well as i-scan mode
62600032|NCT03347734|EXPERIMENTAL|Eye Exercises Group (EEG)|For the individuals in the group of eye exercises (GEG), 10 repetitive eye exercises protocol was organized as a home program for 6 weeks, twice a day in the morning and evening each day of the week.
62819692|NCT05226442|EXPERIMENTAL|Argatroban|Continuous infusion of 0,3μg/kg/min to target an aPTT of 50-70sec and/or Hemoclot of 0,60 - 0,80 µg/mL
62819693|NCT05226442|ACTIVE_COMPARATOR|Unfractionated Heparin|Continuous infusion of Unfractionated Heparin to target an aPTT of 50-60 seconds and/or Anti-Xa level between 0.20 and 0.30 IU/ml and/or thrombin time \>20sec.
62819694|NCT03454763|EXPERIMENTAL|Arm A, Intensive|Arm A, Intensive every 5 weeks
62600033|NCT03347734|EXPERIMENTAL|Convergence Exercise Group (CEG)|For the individuals in the group of convergence exercise, 5 minutes convergence exercise protocol was organized as a home program for 6 weeks, twice a day in the morning and evening each day of the week.
62600034|NCT03347734|EXPERIMENTAL|Oculomotor Exercise Group (OMEG)|For the individuals in the group of oculomotor exercise, 10 repetitive, four different oculomotor exercise protocols with eye stabilization were organized as home programs for 6 weeks, twice a day in the morning and evening each day of the week.
62600035|NCT04631328|EXPERIMENTAL|Intervention|Growing Together program
62600036|NCT04631328|NO_INTERVENTION|Control|
62600037|NCT04605380||Novices|Junior doctors/interns
62600038|NCT04605380||Intermediates|Specialist trainees/Residents
62600039|NCT04605380||Experts|Consultants/Attendings
62600040|NCT02918903|EXPERIMENTAL|Minimal caries removal|the patients in this group will be treated by minimal caries removal technique, where only caries at lateral walls of cavity is removed, stainless steel crown preparation is performed and then stainless steel crown is placed as final restoration.
62600041|NCT02918903|ACTIVE_COMPARATOR|Complete caries removal|patients in this group will be treated by complete caries removal technique, where all caries will be removed, a base of resin modified glass ionomer is placed and then stainless steel crown is placed as final restoration.
62600042|NCT01203826|EXPERIMENTAL|asfotase alfa|asfotase alfa starting dose 3 mg/kg/week SC injection, increased to 6 mg/kg/week SC injection
62600043|NCT02089334|EXPERIMENTAL|RX-0201 plus everolimus (Stage 1 & 2)|RX-0201 and everolimus will be taken together as described in the Interventions description.
62600044|NCT05492487|EXPERIMENTAL|Mirena Arm|The patients in the Mirena arm will have a Mirena inserted at time of recruitment of the study. An endometrial biopsy will be performed to assess for disease progression, regression or persistence after 3 months. The endometrial biopsy will be performed via bedside endometrial sampling or hysteroscopic biopsy. As Mirena can be used for treatment of atypical hyperplasia as well as endometrial protection (decreases the risk of endometrial hyperplasia recurrence), the option of keeping or changing the Mirena during biopsy will be discussed with the patient.
62819695|NCT03454763|EXPERIMENTAL|Arm B, Non Intensive|Arm B, Non Intensive every 8-10 weeks
62819696|NCT06649045|EXPERIMENTAL|Orforglipron|"Participants will receive orforglipron orally.~Study 1 GZ01: Participants who are unable or unwilling to use PAP~Study 2 GZ02: Participants who plan to continue PAP therapy"
62433708|NCT01914315|EXPERIMENTAL|Cardiac Rehabilitation|Patients randomized to the multidisciplinary cardiac management program at the cardiac rehabilitation center will undergo evaluation by a trained rehabilitation physician and physiologist. The evaluation will include medical history, physical examination, vitals, review of post discharge graded exercise stress test and nursing staff consultation. Exercise prescription will be based on a pre-specified protocol in accordance with ESC position paper on cardiac rehabilitation of patients with heart failure.
62600045|NCT05492487|EXPERIMENTAL|Megace Arm|The patients in the megace arm will have be prescribed 3 months of oral megace at time of recruitment of the study. An endometrial biopsy will be performed to assess for disease progression, regression or persistence after 3 months. The endometrial biopsy will be performed via bedside endometrial sampling or hysteroscopic biopsy.
62600046|NCT06649461|EXPERIMENTAL|ozone injections|
62600047|NCT06649461|ACTIVE_COMPARATOR|splint|
62243497|NCT01843868|OTHER|R-CHOP and standard anti-emetics|"This is a single arm study.~All patients receive R-CHOP every 14 or 21 days for a minimum of 3 cycles. Standard anti-emetics will be used as follows:~* 5HT3 (5-Hydroxytryptamine 3) antagonists (ondansetron, granisetron or tropisetron) used as the local institutional standard of care will be permitted, although the preferential use of ondansetron or granisetron will be encouraged.~* Dexamethasone will not to be used as patients receive hydrocortisone and oral prednisolone in R-CHOP. In this study, the use of oral prednisolone on day 1 will be regarded as equivalent to dexamethasone. Prednisolone will be given PRIOR to the chemotherapy with the 5HT3 antagonist.~* Anti-emetics (metoclopramide, prochlorperazine and lorazepam) may be prescribed to be used 'as needed' for breakthrough emesis.~* Patients 'failing' the standard Chemotherapy Induced Nausea and Vomiting prophylactic regimen will be eligible to receive aprepitant (Days 1 to 3) for subsequent cycles."
62243498|NCT01764126|ACTIVE_COMPARATOR|Pneumococcal protein vaccine|Pneumococcal protein vaccine
62243499|NCT01764126|PLACEBO_COMPARATOR|Placebo|Placebo
62265895|NCT05622526|PLACEBO_COMPARATOR|Group 2 or Control group|treatment with an initial dose of 24 oral capsules of MBK-01 and a maintenance dose of 12 oral capsules of MBK-01 every 3 months for 12 months (4 maintenance doses)
62433709|NCT01914315|ACTIVE_COMPARATOR|Internal Medicine|Following discharge, patients will return to the internal medicine (IM) outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated.
62433710|NCT05910710||Subjects administered Neoadjuvant Pembrolizumab|Neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide add Pembrolizumab
62433711|NCT05910710||Subjects not administered Neoadjuvant Pembrolizumab|Neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide
62433712|NCT03543033|EXPERIMENTAL|Treatment|Patients will receive a corticosteroid epidural injection within 2 weeks of their scheduled lumbar surgery
62433713|NCT03543033|NO_INTERVENTION|Control|Patients will not receive a corticosteroid injection within 2 weeks of their scheduled lumbar surgery.
62433714|NCT03112993|EXPERIMENTAL|Sugammadex group|2 mg/kg of sugammadex, IV once at the end of the surgery. Dosing will be based on actual body weight not ideal body weight.
62433715|NCT03112993|ACTIVE_COMPARATOR|Neostigmine group|"50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.~Dosing will be based on actual body weight not ideal body weight."
62433716|NCT02012205|EXPERIMENTAL|wet cupping|patient will receive wet cupping
62433717|NCT02012205|NO_INTERVENTION|control|not cupping
62433718|NCT05436691|EXPERIMENTAL|Information and Coping with Anxiety Training Intervention|The intervention group received information and coping with anxiety training by an instructor.
62433719|NCT05436691|NO_INTERVENTION|Control|No intervention was applied to the control group.Data were collected from the control group simultaneously with the study group.
62433720|NCT04911920|OTHER|Patients with lateral epicondylitis|Patients with lateral epicondylitis who are treated with at least one ACP injection.
62433721|NCT05651620||Calorie Restriction (CR)|Individuals in the CR group were prescribed a 25% reduction from their baseline energy intake during the two-year CALERIE trial.
62433722|NCT05651620||Ad Libitum (AL)|Individuals in the AL group were asked to continue their usual dietary intake during the two-year CALERIE trial.
62433723|NCT00543790|EXPERIMENTAL|1|
62433724|NCT06214026|EXPERIMENTAL|Locked ankle articulation|The design is a randomized cross-over clinical trial following an A1-B1-B2-A2 design. In the locked condition, the 20 degree of frontal plane ankle motion is eliminated by a physical lock. The A conditions will be with the usual foot. The B conditions are randomized to the locked and unlocked investigational foot.
62600048|NCT03364764|EXPERIMENTAL|efficiency of sirolimus on PRCA|A prospective research of the sirolimus efficiency on refractory PRCA patients On refractory PRCA patients, sirolimus was tried. Dosage: 2mg QD for the first day, then 1 mg QD. Medication time should last at least 6 months.
62433725|NCT06214026|EXPERIMENTAL|Unlocked ankle articulation|The design is a randomized cross-over clinical trial following an A1-B1-B2-A2 design. In the unlocked condition, the 20 degree of frontal plane ankle motion is enabled. The A conditions will be with the usual foot. The B conditions are randomized to the locked and unlocked investigational foot.
62433726|NCT04452799|EXPERIMENTAL|expermintal|1000mg of (Hesperidin and Diosmin mixture) three times daily for 7 days 1000mg of (Hesperidin and Diosmin mixture) two times daily for 3 days
62600049|NCT01862939|EXPERIMENTAL|part 1 DS-7309 ascending dose|1, 2.5, 5, 10, 20 mg blinded DS-7309 powder in bottle.
62600050|NCT01862939|EXPERIMENTAL|part 2 DS-7309|1, 2.5, 5, and 15mg DS-7309 powder in bottle for oral solution.
62600051|NCT01862939|PLACEBO_COMPARATOR|part 2 placebo|placebo to match part 2 DS-7309
62265896|NCT00330902|ACTIVE_COMPARATOR|1|Sulfadoxine pyrimethamine plus three daily doses of artesunate
62433727|NCT04452799|ACTIVE_COMPARATOR|standard|standard care therapy in quarantine hospitals
62433728|NCT01015612|EXPERIMENTAL|Medtronic CoreValve® System Implantation|Patients with symptomatic severe aortic stenosis who have an elevated surgical risk
62433729|NCT05484271||Leaf-like and Cord-like type|Under arthroscopy, the anatomy of middle glenohumeral ligament was leaf-like or cord-like.
62433730|NCT05484271||Absent type|Under arthroscopy, the anatomy of middle glenohumeral ligament was absent.
62433731|NCT05484271||Burford complex type|Under arthroscopy, the anatomy of middle glenohumeral ligament manifested the burford complex.
62600052|NCT03665961||Central obesity|Cases with central obesity as defined by waist circumference cut-offs ≥ 90 cm in men and ≥ 80 cm in women for Asians
62600053|NCT03665961||No central obesity|Controls with no central obesity
62600054|NCT06618508|ACTIVE_COMPARATOR|Manual debridement|Manual debridement is a technique that has existed since 1952 and whose objective is to remove the irregular epithelium by scraping with an instrument, thus allowing the formation of a new superficial layer. Some surgeons use 20% ethanol which they apply to the cornea to debride it before using a blade or sponge to complete the procedure. In this technique, the basement membrane is preserved. This method is still used being simple and cost effective. Its effectiveness in the treatment of recurrent corneal erosions is demonstrated by a success rate estimated at 85%. Thus, it is one of the methods of treating epithelial basement membrane dystrophy. However, the recurrence rate associated with manual debridement is up to 24%, and the average duration before a first recurrence is estimated at 6 months. The formation of corneal opacities was recorded between 7 and 41 days following the intervention.
62600055|NCT06618508|EXPERIMENTAL|Phototherapeutic keratectomy|Over the past two decades, phototherapeutic keratectomy (PTK) has become an increasingly used approach for the treatment of several anterior corneal pathologies, including epithelial basement membrane dystrophy. This technique consists of directing a 193nm excimer laser towards the epithelial surface in order to break the molecular bonds between cells. PTK appears to be a more reliable, safe and precise alternative to manual debridement. Unlike manual debridement, PTK completely obliterates the basement membrane which would promote a reduction in the recurrence rate according to some experts. Thus, the success rate without recurrence has been estimated between 46 to 100% by certain studies and the associated complications are minimal.
62265897|NCT00330902|EXPERIMENTAL|2|Sulfadoxine pyrimethamine plus artesunate plus primaquine
62433732|NCT06351137|OTHER|IV first|Subjects in this group will be instructed to use intravenous administration in the first scenario and use intranasal administration in the second scenario.
62433733|NCT06351137|OTHER|IN first|Subjects in this group will be instructed to use intranasal administration in the first scenario and use intravenous administration in the second scenario.
62265898|NCT00250835|EXPERIMENTAL|Chemotherapy, Celecoxib, and Radiation|"Oxaliplatin weekly at 50 mg/m2 given intravenously over two hours for the duration of radiation.~Capecitabine: on the days of radiation at 850 mg/m2 orally twice a day \[1700 mg/m2/day\] (Monday through Friday during radiation therapy).~Celecoxib at 200 mg orally twice a day throughout the duration of radiation without a break."
62243500|NCT05037526|ACTIVE_COMPARATOR|Dexcom G System|The Dexcom G6 or current version intended use is for the management of diabetes. It is a small flexible device that records interstitial glucose levels every 5 min and is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. Interpretation of the Dexcom G6 or current version System results should be based on the glucose trends and several sequential readings over time. The system consists of a sensor, transmitter, receiver and mobile app.
62243501|NCT05037526|ACTIVE_COMPARATOR|Standard care of gestational diabetes with self monitoring blood glucose (SMBG)|SMBG (self-monitoring of blood glucose) is recommended for women with gestational diabetes that involves finger pricking up to six times daily.
62243502|NCT03878446|EXPERIMENTAL|Somapacitan 0.24 mg/kg/week|Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.
62243503|NCT03878446|EXPERIMENTAL|Somapacitan 0.20 mg/kg/week|Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.
62433734|NCT03996265|EXPERIMENTAL|Arm I (bupropion hydrochloride controlled-release)|Patients receive bupropion hydrochloride controlled-release PO QD for up to 13 weeks in the absence of disease progression or unacceptable toxicity.
62433735|NCT03996265|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD for up to 13 weeks in the absence of disease progression or unacceptable toxicity.
62433736|NCT04427696|ACTIVE_COMPARATOR|Aerobic walking|The participants in this arm were obligated to carry out one hour aerobic walking (goal setting walking) daily. The goal of aerobic walking: 1. at least 60 steps per minute; 2. continuously walking for 10 minutes.
62433737|NCT04427696|PLACEBO_COMPARATOR|No aerobic walking|The participants in this arm were requested to maintain sedentary life, without joining other physical exercise programmes.
62433738|NCT06356376||Healthy Participants|
62433739|NCT03208933|EXPERIMENTAL|Pirfenidone|Participants will be administered pirfenidone 2403 milligram per day (mg/d) orally for 26 weeks in participants with IPF.
62433740|NCT00095199|EXPERIMENTAL|Cetuximab & Pemetrexed|
62433741|NCT00095199|ACTIVE_COMPARATOR|Pemetrexed|
62433742|NCT00095199|EXPERIMENTAL|Cetuximab & Docetaxel|
62433743|NCT00095199|ACTIVE_COMPARATOR|Docetaxel|
62433744|NCT06526130||General anaesthesia|Intravenous or volatile general anesthesia was preformed with different type of airway management (endotracheal tube, laryngeal mask and bag mask ventilation)
62433745|NCT06526130||Neuraxial anaesthesia|Neuraxial anesthesia was administered using spinal or epidural injections of local anesthetic with or without opioid.
62433746|NCT02619071|EXPERIMENTAL|Refractory or relapsed acute myeloid leukemia|
62433747|NCT03273127|EXPERIMENTAL|Abediterol 5 μg|Out of 12 randomized patients, 9 will receive abediterol 5 μg as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive Abediterol 5.0 μg QD.
62433748|NCT03273127|PLACEBO_COMPARATOR|Placebo|Out of 12 randomized patients, 3 will receive placebo as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive placebo QD.
62433749|NCT03066440|PLACEBO_COMPARATOR|Normal Saline|Intervention: intravenous solutions containing only normal saline as the primary base during the entire treatment of diabetic ketoacidosis.
62433750|NCT03066440|EXPERIMENTAL|Lactated Ringers|Intervention: intravenous solutions containing only lactated ringers as the primary base during the entire treatment of diabetic ketoacidosis.
62433751|NCT05009628|EXPERIMENTAL|automated oxygenation with a sitting patient position in the ICU|
62433752|NCT05009628|NO_INTERVENTION|controlled oxygenation with a lying patient position in the ICU|
62433753|NCT05009628|EXPERIMENTAL|automated oxygenation with the patient lying down in the ICU|
62433754|NCT05009628|EXPERIMENTAL|control oxygenation with the patient in a sitting position in the ICU|
62433755|NCT05165511|EXPERIMENTAL|Executive Function-Enhanced Parent-Based Behavioral Treatment (PBT-EF)|PBT-EF will integrate executive function training with family-based behavioral treatment (FBT) for obesity, the gold-standard behavioral treatment for childhood obesity. PBT-EF will include self-monitoring, calorie reduction, and dietary and physical activity recommendations in addition to planning, organization, and problem-solving skills.
62433756|NCT05145296|OTHER|Patients with cPRA ≥99%|This is a non-randomized, single arm study, combination trial designed according to the Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. The study will enroll 12 patients with cPRA ≥99% on the deceased donor kidney transplant waiting list, who have not received a compatible donor offer for \>3 year. According to inclusion and exclusion criteria patients will be screened to participate in the trial.
62623372|NCT01183416|EXPERIMENTAL|3F8 monoclonal antibody and 13-cis-Retinoic Acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. The patients are post-transplant and in 1st complete/very good partial remission (CR/VGPR),89 with no evidence of NB by standard studies, but are at high risk for relapse.
62819697|NCT06649045|PLACEBO_COMPARATOR|Placebo|"Participants will receive placebo orally.~Study 1 GZ01: Participants who are unable or unwilling to use PAP~Study 2 GZ02: Participants who plan to continue PAP therapy"
62819698|NCT01235897|EXPERIMENTAL|Maximum tolerated dose|
62433757|NCT04116294|NO_INTERVENTION|Before|Standard of care for informatic prescription.
62433758|NCT04116294|ACTIVE_COMPARATOR|After|Computer-assisted prescription for radiological procedure
62433759|NCT02817854||Patients with acute diverticulitis|Patients admitted in emergency setting for acute diverticulitis
62433760|NCT00914797|ACTIVE_COMPARATOR|asthmatics|10 male asthmatic subjects
62433761|NCT00914797|ACTIVE_COMPARATOR|healthy|10 male healthy volunteers
62433762|NCT00914797|ACTIVE_COMPARATOR|elite athletes with asthma|10 elite athletes with asthma.
62623373|NCT05762640|EXPERIMENTAL|Ruxolitinib|
62623374|NCT03846544|NO_INTERVENTION|control group|
62623375|NCT03846544|EXPERIMENTAL|double pick up group|
62600056|NCT01373112|EXPERIMENTAL|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
62600057|NCT01373112|EXPERIMENTAL|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
62600058|NCT02817516|EXPERIMENTAL|Part 1: TAK-828 15 milligram (mg)|TAK-828 15 mg, solution (0.2 milligram per milliliter \[mg/mL\] or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
62039686|NCT06733181|EXPERIMENTAL|REMINDER intervention|The REMINDER intervention includes 20 face-to-face group sessions, each approximately 60 to 75 minutes, held twice a week over ten weeks. This program aims to optimize memory, attention, executive function, and emotional regulation while promoting lifestyle habits that protect the aging brain. The sessions include brain health education, cognitive exercises, compensatory memory strategies, training for managing personally relevant goals (with goal setting), and stress management techniques (compassion-based therapies, relaxation methods, and mindfulness). As for the structure of the sessions, each starts with a mindfulness exercise and concludes with a review of the homework assignments. Every session includes a psychoeducation component focused on a specific topic, a time for sharing and reflection, and a practical activity.
62243504|NCT03878446|EXPERIMENTAL|Somapacitan 0.16 mg/kg/week|Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.
62243505|NCT03878446|ACTIVE_COMPARATOR|Norditropin® 0.035 mg/kg/day|Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.
62600059|NCT02817516|EXPERIMENTAL|Part 1: TAK-828 45 mg|TAK-828 45 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
62600060|NCT02817516|EXPERIMENTAL|Part 1: TAK-828 75 mg|TAK-828 75 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
62600061|NCT02817516|EXPERIMENTAL|Part 1: TAK-828 100 mg|TAK-828 100 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
62600062|NCT02817516|EXPERIMENTAL|Part 2: TAK-828 45 mg|TAK-828 45 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy Japanese participants.
62600063|NCT02817516|EXPERIMENTAL|Part 2: TAK-828 100 mg|TAK-828 100 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy Japanese participants.
62600064|NCT02817516|PLACEBO_COMPARATOR|Part 1: Placebo|TAK-828 placebo-matching solution, orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
62243506|NCT03878446|ACTIVE_COMPARATOR|Norditropin® 0.067 mg/kg/day|Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.
62243507|NCT03793426||Fibryga|Fibryga (human plasma-derived fibrinogen concentrate)
62600065|NCT02817516|PLACEBO_COMPARATOR|Part 2: Placebo|TAK-828 placebo-matching solution, orally, twice daily on Days 1-14 in healthy Japanese participants.
62819699|NCT02700607|PLACEBO_COMPARATOR|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
62433763|NCT06049667|EXPERIMENTAL|NTQ2494|For each dose level, multiple doses of NTQ2494 tablets will be administered as 28-day treatment (per cycle).
62819700|NCT02700607|ACTIVE_COMPARATOR|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
62819701|NCT04999462|EXPERIMENTAL|Full-fat fermented dairy|1 serving per day of full-fat yogurt and full-fat fermented cheese
62819702|NCT04999462|ACTIVE_COMPARATOR|Low-fat fermented dairy|1 serving per day of low-fat yogurt and lower-fat fermented cheese (e.g., reduced-fat or low-fat fermented cheese).
62819703|NCT04999462|PLACEBO_COMPARATOR|Non-dairy, non-fermented foods|2 servings per day of nondairy, nonfermented foods with a macronutrient composition that is similar to that of the low-fat fermented dairy condition.
62243508|NCT01508546|EXPERIMENTAL|Arm 1: breast surgery with axillary lymphnodes removal|
62243509|NCT01508546|EXPERIMENTAL|Arm 2: breast surgery without axillary lymphnodes removal|
62265899|NCT04317495|EXPERIMENTAL|Computerized Cognitive Training (CCT)|The patients will receive CCT during their standard rTMS treatments (after having 5 days of treatment until the pre-taper treatment).
62265900|NCT06364111|EXPERIMENTAL|Trial group 1|Subjects in Trial Group 1 received polyethylene glycol combined with Vibrabot capsules for 2 weeks and then Vibrabot capsules for 4 weeks.
62433764|NCT01556178||Children without central nervous system tumors|Children without central nervous system tumors between the ages of 1 year and 21 years who are undergoing a neurosurgical procedure to address hydrocephalus
62433765|NCT05644912|EXPERIMENTAL|All subjects|Transanal irrigation (TAI) with new catheter
62433766|NCT02289924||Cohort 1|According to the recommendations of the Summary of Product Characteristics (SmPC) in Italy
62433767|NCT02436395|EXPERIMENTAL|Group A (povidone-iodine group)|"The surgical incision is washed by the mixed solution with 400ml 9% normal saline and 100ml 5% povidone-iodine solution.~We declare that we have no conflicts of interest."
62433768|NCT02436395|EXPERIMENTAL|Group B (normal saline group)|"The surgical incision is washed by the 500ml 0.9% normal saline.~We declare that we have no conflicts of interest."
62433769|NCT03578276|ACTIVE_COMPARATOR|LessDrops|Compounded eye drop containing Gatifloxacin (antibiotic), bromfenac (non-steroidal anti-inflammatory), and prednisolone acetate 1% used three times a day (TID) starting 1 day prior to surgery and continuing after surgery for 2 weeks then twice a day for a week and once a day for another week.
62433770|NCT03578276|ACTIVE_COMPARATOR|Standard of Care|"* Gatifloxacin 0.5%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.~* Bromfenac 0.07%: 1 drop QD starting 3 days before surgery, continue QD for 4 weeks after surgery and then discontinue.~* Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinue."
62433771|NCT03349918|EXPERIMENTAL|Mobile Health Monitoring|Participants will monitor their blood pressure using a wireless-enabled blood pressure cuff or mood using a mobile health application once per week at baseline. The investigators will monitor their medical records to determine if a medication change has occurred. After this, the investigators will increase the frequency of notifications to monitor the participant's specific health condition to once daily for 1 month. This monitoring will continue for a study duration of 6 months.
62433772|NCT03063489|EXPERIMENTAL|Loteprednol Etabonate Ophthalmic Gel|Formulated LE into a gel (loteprednol etabonate ophthalmic gel, \[Lotemax® gel\])
62433773|NCT00125931|EXPERIMENTAL|Pentazocine/Talwin|Talwin NX
62433774|NCT00515073|EXPERIMENTAL|Paclitaxel (Taxol) + Pelvic Radiation|"Paclitaxel (Taxol) 50 mg/m\^2 intravenous (IV) weekly over 1 hour for 5 weeks. Radiation therapy to the pelvis daily for 25 treatments.~Both radiation therapy and paclitaxel chemotherapy on Day 1 or 2, followed by radiation alone for four days, repeated every week for a total of 5 weeks, giving a total dose of 45 Gy with external beam radiation to pelvis and 5 courses of paclitaxel 50 mg/m\^2. Four-six weeks after pelvic radiation completed, 4 additional courses of paclitaxel 135 mg/m\^2 alone given every 21 days. Vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for additional 3 days. No chemotherapy given with vaginal apex boost."
62819704|NCT05672381||Lower leg Trauma|High-energy lower leg trauma at risk for Acute Compartment Syndrome
62819705|NCT05672381||Forearm Trauma|High-energy forearm trauma at risk for Acute Compartment Syndrome
62819706|NCT01146769|EXPERIMENTAL|Pelvic floor exercise|
62819707|NCT01146769|NO_INTERVENTION|Control|
62819708|NCT05017363|EXPERIMENTAL|Intervention Group (ENGAGE)|Therapists will consist of pairs within sites providing similar interventions to similar children so that treatment and child characteristics other than the goal-setting intervention will be similar within each site. Therapists will use principles-based goal-setting approaches and strategies in the goal-setting toolbox. It is anticipated that treatment block lengths will vary from 3-8 sessions over 2-8 weeks, representing typical clinical variation.
62819709|NCT05017363|NO_INTERVENTION|Usual Care Group (Control)|The control group will comprise usual care.
62039687|NCT06298916|EXPERIMENTAL|Experimental Part 1|"Six patients with metastatic sarcoma will receive 8 ± 1 millicurie (mCi) (\~50 μg mass dose) of 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent).~Six patients with metastatic sarcoma will receive 8 ± 1 millicurie (mCi) (\~90 μg mass dose) of 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent)."
62039688|NCT06298916|EXPERIMENTAL|Experimental Part 2|Part 2 will evaluate 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) correlation with FAP expression measured by IHC (SUVmax and SUVmean vs IHC score) in 20 evaluable patients with non-metastatic, operable, supposed FAP-expressing solid tumors (sarcomas, esophageal, gastric, pancreatic, colorectal) planned for surgery within 60 days (from study imaging).
62433775|NCT05938452|EXPERIMENTAL|Active|Active Comparator
62433776|NCT05938452|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62039689|NCT02696148|EXPERIMENTAL|Liraglutide|
62039690|NCT02696148|PLACEBO_COMPARATOR|Placebo|
62039691|NCT02265562|EXPERIMENTAL|Misoprostol|60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally
62039692|NCT02265562|PLACEBO_COMPARATOR|Placebo|60 minutes before the surgery 2 tablets of placebo tablets inserted rectally
62433777|NCT04384341|EXPERIMENTAL|Haemophilic patients|Blood sampling Bone Densitometry (BMD)
62433778|NCT04384341|OTHER|Healthy volunteers|Bone Densitometry (BMD)
62433779|NCT03968900|EXPERIMENTAL|Sleep Restriction|4 hours time in bed (1 am to 5 am)
62433780|NCT03968900|EXPERIMENTAL|Sleep Extension|10 hours time in bed (10 pm to 8 am)
62433781|NCT05415319|OTHER|Emotion regulation observation in middle childhood/pre-adolescence|All participants will engage in brief laboratory tasks that are designed to elicit a brief experience of emotion/uncertainty.
62433782|NCT03654911||aMCI subjects|EEG recording, ApoE testing
62433783|NCT04272177|EXPERIMENTAL|SDM group|Shared decision making using PDAs. PDAs is used as a tool explain the advantages and disadvantages of the traditional reversal drugs and sugammadex. And by following SDM principles, the patients are guided to consider their individual values and preferences and helped to make a choice that best meet their needs.
62433784|NCT04272177|NO_INTERVENTION|Control group|Current approach to explain details of anesthesia using a single introductory sheet made by the two hospitals or provided by the pharmaceutical companies is used.
62600066|NCT04159649|EXPERIMENTAL|letrozole, gonadotropins and fixed GnRH antagonist|letrozole (2.5 mg) will be given from the second day of the cycle and for 5 days, gonadotropins will be given from the third day of the cycle and GnRH antagonist will be added from the six day of the cycle for controlled ovarian stimulation in IVF (interventional group). Participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
62265901|NCT06364111|EXPERIMENTAL|Trial group 2|Subjects in Trial Group 2 received Vibrabot capsules for 12 consecutive weeks.
62265902|NCT06364111|EXPERIMENTAL|Control group|subjects in the control group received polyethylene glycol for 6 weeks.
62265903|NCT00718783||Retinoblastoma|
62265904|NCT02162524|NO_INTERVENTION|No Exercise Control|Healthy Living Group
62600067|NCT04159649|ACTIVE_COMPARATOR|gonadotropins and fixed GnRH antagonist (control group).|gonadotropins will be given from the third day of the cycle and GnRH antagonist will be added from the six day of the cycle for controlled ovarian stimulation in IVF(control group). Participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
62433785|NCT00436527|OTHER|1|
62433786|NCT03621085|EXPERIMENTAL|Ketamine|Subjects will receive up to 20 mg Ketamine Hydrochloride while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
62433787|NCT03621085|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
62433788|NCT01260428||healthy active subjects|with and without high altitude intolerance
62600068|NCT06302842|EXPERIMENTAL|Before and after treatment|"Nutraceutical (Bioritmon Immuno Defend), one oral preparation daily for 24 days.~Immunological parameters are investigated before and after the treatment."
62265905|NCT02162524|ACTIVE_COMPARATOR|Aerobic Exercise Group|Persons are aerobically exercising.
62265906|NCT00088374|EXPERIMENTAL|Von Hippel-Lindau (VHL) associated renal tumors|
62265907|NCT03456752|EXPERIMENTAL|Dexamethasone|Dexamethasone 8mg intravenously prior to anesthesia induction
62819710|NCT04621981|EXPERIMENTAL|Sodium Bicarbonate Ringer's Solution|Intravenous drip, 500\~1000ml per time. Infusion speed: 15ml/kg/h or according to guidelines or department routine.
62600069|NCT05435625|ACTIVE_COMPARATOR|FCO2|Fractional Carbon dioxide laser
62600070|NCT05435625|ACTIVE_COMPARATOR|FRF|Fractional Microneedling Radiofrequency
62600071|NCT03136458|EXPERIMENTAL|Real ischemic preconditioning|Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 50 mmHg above the systolic arterial pressure of the patient.
62600072|NCT03136458|ACTIVE_COMPARATOR|Dummy ischemic preconditioning|Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 10 mmHg above the diastolic arterial pressure of the patient.
62600073|NCT04342741|ACTIVE_COMPARATOR|Foley catheter inpatient|Participants had intracervical ripening with foley catheter after admission into the ward.
62600074|NCT04342741|ACTIVE_COMPARATOR|Foley catheter outpatient|Participants had intracervical ripening with foley catheter and allowed home.
62600075|NCT05427318|ACTIVE_COMPARATOR|PATH Active Intervention Arm|Participants assigned to this group will receive care as usual if they are assigned to this group. In addition, participants in this arm will receive HIV care support from a trained peer navigator and have access to a mHealth web application designed to support their health and HIV care.
62600076|NCT05427318|NO_INTERVENTION|Usual Care|Participants assigned to this group are in the control arm and will receive standard of care following the Ryan White model of care.
62600077|NCT05614778||Treatment group|Zoledronic Acid inj. 5mg/100mL
62600078|NCT06195631|EXPERIMENTAL|Standardized Checklist for Optimizing Procedural Ergonomics in Endoscopy (SCOPE- E) Bundle|Endoscopists in each unit that is randomized to the intervention will be asked to use an ergonomic check list to conduct a verbal time-out before commencing each colonoscopy procedure.
62600079|NCT06195631|NO_INTERVENTION|Standard of practice|Usual practice does not involve any of the core components of the SCOPE-E bundle. Endoscopy units in the control arm will not undergo any targeted intervention(s) to enhance ergonomic behaviors throughout the study period.
62600080|NCT06298695|EXPERIMENTAL|Individual Schema Therapy|A maximum of 40 sessions of individual schema therapy within one year
62600081|NCT06298695|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Treatment as usual in treatment-resistant anxiety disorders (psychological and/or psychiatric).
62600082|NCT04085224|ACTIVE_COMPARATOR|1|
62600083|NCT04085224|EXPERIMENTAL|2|
62600084|NCT04085224|EXPERIMENTAL|3|
62600085|NCT05072964|OTHER|FARAPULSE Pulsed Field Ablation System|Ablation using the FARAPULSE Pulsed Field Ablation System
62600086|NCT04780516||Participants Treated With Risankizumab|Participants will receive risankizumab (Skyrizi) as prescribed by the physician according to the local label.
62600087|NCT02987972|EXPERIMENTAL|V114 Lot 1|Infants will receive a 0.5 mL intramuscular injection of V114 Lot 1 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
62600088|NCT02987972|EXPERIMENTAL|V114 Lot 2|Infants will receive a 0.5 mL intramuscular injection of V114 Lot 2 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
62600089|NCT02987972|ACTIVE_COMPARATOR|Prevnar 13™|Infants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
62600090|NCT02706886|PLACEBO_COMPARATOR|Part A: SAD: Placebo|A single dose of matching placebo will be administered subcutaneously (SC).
62600091|NCT02706886|EXPERIMENTAL|Part A: SAD: Lumasiran 0.3 mg/kg|A single dose of 0.3 mg/kg lumasiran will be administered SC.
62600092|NCT02706886|EXPERIMENTAL|Part A: SAD: Lumasiran 1.0 mg/kg|A single dose of 1.0 mg/kg lumasiran will be administered SC.
62600093|NCT02706886|EXPERIMENTAL|Part A: SAD: Lumasiran 3.0 mg/kg|A single dose of 3.0 mg/kg lumasiran will be administered SC.
62600094|NCT02706886|EXPERIMENTAL|Part A: SAD: Lumasiran 6.0 mg/kg|A single dose of 6.0 mg/kg lumasiran will be administered SC.
62819711|NCT04621981|ACTIVE_COMPARATOR|Normal Saline|"Intravenous drip, 500\~1000ml per time. Dosage depends on age、weight and symptoms.~Infusion speed: According to the department process or clinician's decision."
62600095|NCT02706886|PLACEBO_COMPARATOR|Part B: MAD: Placebo|Participants with primary hyperoxaluria type 1 (PH1) will be treated with placebo matching one of the lumasiran dosages in the lumasiran arms (one placebo participant for each lumasiran arm). At Day 85 these placebo treated participants will cross over to their respective Part B lumasiran arms in the Part B: MAD Study Day 85-End of Study Period and will then be treated with lumasiran. The estimated total time on study was up to 546 days.
62600096|NCT02706886|EXPERIMENTAL|Part B: MAD: Lumasiran 1.0 mg/kg qM|Participants with PH1 will be treated with 1.0 mg/kg lumasiran SC once monthly (qM) on Days 1, 29 and 57. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
62600097|NCT02706886|EXPERIMENTAL|Part B: MAD: Lumasiran 3.0 mg/kg qM|Participants with PH1 will be treated with 3.0 mg/kg lumasiran SC qM on Days 1, 29 and 57. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
62600098|NCT02706886|EXPERIMENTAL|Part B: MAD: Lumasiran 3.0 mg/kg q3M|Participants with PH1 will be treated with 3.0 mg/kg lumasiran SC once every three months (q3M) on Days 1 and 85. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
62600099|NCT04612881||fitostimoline vaginal pessaries|
62600100|NCT01893580|EXPERIMENTAL|1. Experimental|Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery.
62600101|NCT01893580|EXPERIMENTAL|2. Experimental|Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery.
62600102|NCT01893580|EXPERIMENTAL|3. Experimental|Exercise in a team initiated two weeks after surgery.
62600103|NCT01893580|OTHER|4. Usual care|Exercise in a team initiated six weeks after surgery.
62819712|NCT00636025||Observational|
62819713|NCT05619575|EXPERIMENTAL|CP1170 sound processor|Take home use of CP1170 Sound processor for 2 weeks followed by in booth testing of the investigational device.
62819714|NCT05619575|ACTIVE_COMPARATOR|CP1150 sound processor|In booth testing of CP1150 sound processor.
62039693|NCT01329367|ACTIVE_COMPARATOR|Control group|"Control group: Subjects will receive Nutritional education together with weight management counselling for overweight and obesity.~-10 weekly personal interviews with a registered nutritionist for body weight control."
62039694|NCT01329367|EXPERIMENTAL|Protein group|"Protein group: Participants will receive Nutritional education and personalised structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of legumes and fish (protein rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
62819715|NCT02192580|ACTIVE_COMPARATOR|Omega-3|omega-3 (DHA+EPA) in divided 3 times/day in addition to standard regimens: Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
62265908|NCT03456752|PLACEBO_COMPARATOR|Control|Normal Saline 1.6ml intravenously prior to anesthesia induction
62265909|NCT03673774|EXPERIMENTAL|cardiac impedancemetry|"Monocentric cohort study, prospective, evaluating the variability of cardiac output measurement by resting and stress impedancemetry as a prognostic factor for PH. Patients are included via the competence center of the PHP of the Midi Pyrenees region. The cardiac output is measured by impedance measurement at rest and during the walking test. The NO / CO coupled transfer measurement is performed at rest. The physician performing the consultation will not know the results of the IPC and these results will not influence the subsequent management.~The patient will be followed for 18 months as part of the research."
62265910|NCT02443883|EXPERIMENTAL|Ramucirumab Regimen 1|Standard dose of 8 milligram per kilogram (mg/kg) ramucirumab given intravenously (IV) on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
62265911|NCT02443883|EXPERIMENTAL|Ramucirumab Regimen 2|Experimental dose of 12 mg/kg ramucirumab given IV on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
62265912|NCT02443883|EXPERIMENTAL|Ramucirumab Regimen 3|Experimental dose of 6 mg/kg ramucirumab given IV on day 1, 8, 15 and 22 of each cycle (28-day cycle) until discontinuation criteria are met.
62433789|NCT03392961|EXPERIMENTAL|IN-105 (Insulin Tregopil)|"Cohort1: Treatments A, B, and C: IN-105 administered at 30, 20 or 10 minutes before the ADA meal, respectively; Treatment D: Placebo administered at 20 minutes before the ADA meal.~Cohort 2: Treatments A, B, and C: IN-105 administered at 4, 5, and 6 hours after the previous ADA meal, respectively; Treatments D, E, and F: Placebo administered at 4, 5, and 6 hours after the previous ADA meal, respectively.~Cohort 3: For the first meal, IN-105 30 mg administered at the optimal pre meal time determined from Cohort 1 with ADA meal (Treatments A and D) or high fat meal (Treatments B and E) or high fiber meal (Treatments C or F)."
62433790|NCT03392961|PLACEBO_COMPARATOR|Placebo tablet|"Cohort1: Treatments A, B, and C: IN-105 administered at 30, 20 or 10 minutes before the ADA meal, respectively; Treatment D: Placebo administered at 20 minutes before the ADA meal.~Cohort 2: Treatments A, B, and C: IN-105 administered at 4, 5, and 6 hours after the previous ADA meal, respectively; Treatments D, E, and F: Placebo administered at 4, 5, and 6 hours after the previous ADA meal, respectively.~Cohort 3: For the first meal, IN-105 30 mg administered at the optimal pre meal time determined from Cohort 1 with ADA meal (Treatments A and D) or high fat meal (Treatments B and E) or high fiber meal (Treatments C or F)."
62433791|NCT02191579|ACTIVE_COMPARATOR|BOTOX®|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks for up to 3 treatments.
62819716|NCT02192580|NO_INTERVENTION|Control|control group received just standard regimens without omega-3
62265913|NCT02443883|EXPERIMENTAL|Ramucirumab Regimen 4|Experimental dose of 8 mg/kg ramucirumab given IV on day 1 and day 8 of each cycle (21-day cycle) until discontinuation criteria are met.
62265914|NCT00556452|EXPERIMENTAL|Clo/BU4|"Study will start at the 2nd dose level of three Clofarabine levels, in combination with Busulfan. The Clofarabine level that each subsequent patient is treated at is determined by a method using continual reassessment.~After pre-conditioning, subjects will receive a peripheral blood stem cell transplant."
62265915|NCT05940779|EXPERIMENTAL|Exercise group|
62265916|NCT05940779|NO_INTERVENTION|Control group|
62265917|NCT05217745|EXPERIMENTAL|Treatment|MLCT oil (provided through ready to eat meals and snacks)
62265918|NCT05217745|PLACEBO_COMPARATOR|Control|Corn oil (provided through ready to eat meals and snacks)
62265919|NCT05491356|EXPERIMENTAL|Intervention - tPA administered|This group will receive 2mL of intra-catheter tPA during twist drill craniostomy procedure
62265920|NCT05491356|PLACEBO_COMPARATOR|Placebo Control|This group will receive 2mL of intra-catheter saline solution during twist drill craniostomy procedure
62265921|NCT03473288|ACTIVE_COMPARATOR|Moderate Intensity Treadmill Exercise|Moderate intensity treadmill exercise three times per week for 10-12 weeks
62265922|NCT03473288|PLACEBO_COMPARATOR|Sedentary Controls|Serve as a sedentary (little exercise) control for 10-12 weeks
62265923|NCT01826253||Hypovolemia|Fluid expansion
62265924|NCT04715061|EXPERIMENTAL|Cancer patients with MRI|9 cancer patients will be recruited and received the 3 experimental conditions : first the rest condition (with MRI), then randomly MICE condition and HIIT condition (with MRI).
62819717|NCT01992796|EXPERIMENTAL|irbesartan|"Irbesartan (total dose of 75 mg) or placebo administered every 24 hrs for 15 days. Moreover, the sepsis management will follow standard international guidelines (Crit Care Med.2008 Jan;36(1):296-327. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock).~Duration of treatment: Irbesartan 75 mg daily for 15 days; only one cycle. Follow up will last 90 days both for treatment and control arm.~* Route of administration : oral by nasogastric tube.~* Medication permitted and not permitted during the trial:~all the therapeutic interventions for sepsis management as indicated by international guidelines are admitted. During the trial are not permitted: ACE inhibitors, ARBs different from Irbersartan, angiotensin I synthesis inhibitors"
62819718|NCT01992796|PLACEBO_COMPARATOR|Placebo|Packaging and labelling for blinding purposes: tablets of placebo looking like the study drug
62819719|NCT06253832|EXPERIMENTAL|conservative surgery|resective-constructive surgery: the excision of the placenta and its attachment site on the myometrium. Subsequently, uterine reconstruction is undertaken.
62433792|NCT02191579|ACTIVE_COMPARATOR|Topiramate|Topiramate starting at a daily oral dose of 25 mg/day titrated up to a maximum dose of 100 mg/day for 36 weeks. Participants who discontinue topiramate are eligible to receive treatment with BOTOX®.
62819720|NCT06253832|ACTIVE_COMPARATOR|hysterectomy 1|Standard hysterectomy is performed
62819721|NCT06253832|ACTIVE_COMPARATOR|hysterectomy 2|Standard hysterectomy is performed
62819722|NCT02315586||1|Participants will be enrolled at the NIH Clinical Center.
62819723|NCT02315586||2|IPF subjects will be recruited from the INOVA Fairfax Advanced Lung Disease Program
62819724|NCT05054309|ACTIVE_COMPARATOR|Probiotic|Bifidobacterium longum \[BL NCC3001\]
62819725|NCT05054309|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62819726|NCT00169182|EXPERIMENTAL|TPF|Docetaxel, Cisplatine, 5-FU
62819727|NCT00169182|ACTIVE_COMPARATOR|PF|Cisplatine, 5-FU
62819728|NCT05624606|EXPERIMENTAL|Group 1: Quadrivalent Influenza mRNA Vaccine MRT5410 low dose|participants will receive a single dose (low) of QIV mRNA vaccine
62819729|NCT05624606|EXPERIMENTAL|Group 2: Quadrivalent Influenza mRNA Vaccine MRT5410 medium dose|participants will receive a single dose (medium) of QIV mRNA vaccine
62819730|NCT05624606|EXPERIMENTAL|Group 3: Quadrivalent Influenza mRNA Vaccine MRT5410 high dose|participants will receive a single dose (high) of QIV mRNA vaccine
62819731|NCT05624606|ACTIVE_COMPARATOR|Group 4: RIV4|participants will receive a single dose of RIV4 vaccine
62819732|NCT05624606|ACTIVE_COMPARATOR|Group 5: QIV-SD|participants will receive a single dose of QIV-SD vaccine
62819733|NCT05624606|ACTIVE_COMPARATOR|Group 6: QIV-HD|participants will receive a single dose of QIV -HD vaccine
62433793|NCT02301962|EXPERIMENTAL|Panitumumab arm|Subjects will receive panitumumab 6 mg/kg intravenously as monotherapy every 14 days until disease progression, intolerability, withdrawal of consent, or death.
62433794|NCT01427803|EXPERIMENTAL|Arm 1|
62433795|NCT01824069|EXPERIMENTAL|Autologous mesenchymal stem cells|Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight in a dosis
62433796|NCT05571085|EXPERIMENTAL|Core Stability Exercises group|"Core stabilization exercises will be performed based on the program recommended by Jeffrey. Each session will take 40-50 minutes. The program consists of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period.~Children will be taught the abdominal cupping technique during the first two weeks of the exercises."
62433797|NCT05571085|OTHER|PNF Exercise Program|"PNF exercises will consist of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period, with each session lasting 40-50 minutes.~Individuals will be taught the abdominal cupping technique during the first two weeks of the program."
62433798|NCT05571085|NO_INTERVENTION|Control Group|No treatment program was applied. As a result of the study, an effective exercise program will be recommended to the participants.
62433799|NCT03675191|EXPERIMENTAL|orlistat|Orlistat 120Mg Cap (120mg, three times a day, within 1hour after meal) combined with phentermine pill (37.5mg, once a day, within 1hour after meal)
62433800|NCT03675191|PLACEBO_COMPARATOR|placebo|placebo (120mg, three times a day, within 1hour after meal) combined with phentermine pill (37.5mg, once a day, within 1hour after meal)
62433801|NCT05680207|ACTIVE_COMPARATOR|Intervention group|Type 2 Diabetes Mellitus patients who received a empowerment training program for 6 weeks, 2 hours a week
62433802|NCT05680207|NO_INTERVENTION|Control group|Type 2 Diabetes Mellitus patients who did not receive a empowerment training program
62433803|NCT05028686||Hospitalized heart failure cohort|Patients hospitalized with heart failure
62433804|NCT00780715|ACTIVE_COMPARATOR|Gliclazide MR|
62433805|NCT00780715|ACTIVE_COMPARATOR|Sitagliptin|
62433806|NCT00780715|ACTIVE_COMPARATOR|Pioglitazone|
62433807|NCT00780715|EXPERIMENTAL|Metformin|
62433808|NCT02891265|NO_INTERVENTION|Group A|Group A - smoking cessation with no assistance
62433809|NCT02891265|PLACEBO_COMPARATOR|Group B|Group B - smoking cessation with the addition of a smoking cessation patch
62433810|NCT01773174|EXPERIMENTAL|dabigatran etexilate|single dose treatment with dabigatran oral solution
62433811|NCT04668222|EXPERIMENTAL|Deficiency of Qi and Yang (QYang-group)|Participants will receive Yu-Ping-Feng and Xiang-Sha-Liu-Jun formula (Chinese Medicine Formula)
62433812|NCT04668222|PLACEBO_COMPARATOR|Placebo control of invigorating Qi and Yang (PQYang-group)|The placebo is made of 5% Yu-Ping-Feng and Xiang-Sha-Liu-Jun formula (Chinese Medicine Formula)
62433813|NCT04668222|EXPERIMENTAL|Deficiency of Qi and Yin (QYin-group)|Participants will receive Yu-Ping-Feng and Liu-Wei-Di-Huang formula (Chinese Medicine Formula)
62433814|NCT04668222|PLACEBO_COMPARATOR|Placebo control of invigorating Qi and Yin (PQYin-group)|The placebo is made of 5% Yu-Ping-Feng and Liu-Wei-Di-Huang formula (Chinese Medicine Formula)
62433815|NCT00948025|ACTIVE_COMPARATOR|Avance Nerve Graft|Commercially available Avance Nerve Graft for repair of nerve gap
62433816|NCT00948025|ACTIVE_COMPARATOR|Hollow Tube Conduit|Commercially available hollow tube conduit for repair of nerve gap.
62433817|NCT02477904|EXPERIMENTAL|ASD/KD|Children (2-21 years of age) diagnosed with autism spectrum disorder (ASD) will receive the ketogenic diet (KD) intervention.
62433818|NCT02477904|ACTIVE_COMPARATOR|ASD/non-KD|Children (2-21 years of age) diagnosed with autism spectrum disorder (ASD) will not receive the ketogenic diet (KD) intervention.
62433819|NCT02477904|ACTIVE_COMPARATOR|non-ASD/non-KD|Typically developing children (2-21 years of age) diagnosed as not having autism spectrum disorder (ASD) will not receive the ketogenic diet (KD) intervention.
62600104|NCT05995886|EXPERIMENTAL|Wiidookaage'win Facebook Group|The Wiidookaage'win Facebook Group is an online, asynchronous group intervention that will run for 3-months with approximately 30 days of content developed. It is private and hidden, meaning only those in the study will be able to see or find the group. It will be moderated by two women from the study team (one AIAN and one biracial). A back-up moderator will also have access to the group. Participants will be able to comment, react, view, and post in the intervention group, and are encouraged to interact with one another.
62433820|NCT01360632|EXPERIMENTAL|Phase B|"Drug: OPC-34712 + ADT~Drug: Placebo + ADT"
62433821|NCT01360632|PLACEBO_COMPARATOR|Phase A|Drug: Placebo + ADT
62433822|NCT04242966|ACTIVE_COMPARATOR|Usual Care|Patients will receive a usual protein/amino acid dose (≤1.2 g/kg/d)
62433823|NCT04242966|ACTIVE_COMPARATOR|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
62433824|NCT06092645|EXPERIMENTAL|surufatinib plus Cadonilimab|Surufatinib: 250mg , po,qd, d1-d21, every 3 weeks for a treatment cycle. Cardonilimab: 10mg/kg, iv, d1, every 3 weeks for a treatment cycle
62433825|NCT03678961||Group N|Neutral position
62433826|NCT03678961||Group E|External rotation of leg by 45 degrees
62433827|NCT03678961||Group EF45|External rotation of leg by 45 degrees, hip flexion by 45 degrees, and knee flexion by 45 degrees
62433828|NCT03678961||Group EF15|External rotation of leg by 45 degrees, hip flexion by 15 degrees, and knee flexion by 15 degrees
62433829|NCT01344395|EXPERIMENTAL|RK-group|
62433830|NCT01344395|ACTIVE_COMPARATOR|K-group|
62433831|NCT02565082|EXPERIMENTAL|Sickle cell disease|This arm will include an approximate number of 50 sickle cell disease patients, homozygous and heterozygous.
62433832|NCT02565082|OTHER|Control|This arm will include an approximate number of 30 healthy volunteers.
62433833|NCT05559216|OTHER|Basketball Players|
62600105|NCT05995886|NO_INTERVENTION|Online Resources Landing Page|The Online Resources Landing Page was developed by the study team using https://carrd.co. It includes links to local programs in family services, substance use recovery, legal advocacy, etc. which already exist and may help support their recovery.
62819734|NCT03008291||Heart Failure Group|Patients who have any QRS duration and left ventricular ejection fraction (LVEF) ≤ 50% will be enrolled in this arm. The primary care physician will have recommended either PM, CRT-D Implantation, CRT-P Implantation, HIBP or LBAP (including HIBP/LBAP for patients with HF, for patients who have failed CRT implant or patients who are CRT non-responders) . (This is Standard of Care for this patient population; the procedures will occur even if the patient does not participate in the study.)
62819735|NCT03008291||Atrioventricular Block/Bradycardia Group|Patients who have developed second or third degree atrioventricular block (AV block) or bradycardia will be enrolled in this arm. The primary care physician will have recommended dual chamber pacemaker implantation. (This is Standard of Care for this patient population; the procedures will occur even if the patient does not participate in the study.)
62061586|NCT06618105|EXPERIMENTAL|E.Q. 90 mcg Base dose of T inhalation aerosol|One actuation (oral inhalation) each from the T inhalation aerosol and the placebo T inhalation aerosol and One actuation (oral inhalation) each from two different placebo R inhalation aerosols
62433834|NCT03197961|EXPERIMENTAL|DMPA with tenofovir/emtricitabine PrEP|the drug combination of tenofovir disoproxil fumarate 300mg and emtricitabine 200mg which is known as Truvada® will be taken orally once daily for 14 days by all participants. Drug concentrations will be measured (blood sampling) and one dose of Depot medroxyprogesterone acetate (DMPA) 150mg will be administered to each participant as an intramuscular injection after the first course of tenofovir disoproxil fumarate/emtricitabine is completed. Then, a second round of the combination of tenofovir disoproxil fumarate 300mg and emtricitabine 200mg (Truvada®) will be taken orally once daily for 14 days by all participants.
62433835|NCT00947518|EXPERIMENTAL|Chlorhexidine skin cleansing|Wiping the skin (except the face) once immediately after birth using baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)
62433836|NCT00947518|PLACEBO_COMPARATOR|Saline skin cleansing|Wiping the skin (except the face) once immediately after birth using baby wipes containing normal saline
62433837|NCT00947518|NO_INTERVENTION|No skin cleansing|No skin application
62433838|NCT05463458|PLACEBO_COMPARATOR|control|included 51 patients who will receive Standard of nutrition Care (2.0 g/kg body weight/day(A I) Calories should be in range of 25-30 Kcal/kg body weight/day.
62433839|NCT05463458|EXPERIMENTAL|case|included 51 patients who will receive adjusted and calculated dose of omega-3 polyunsaturated fatty acids (PUFA) and anti-oxidants.
62433840|NCT01086215||Limb Ischemia|Patients presenting with limb ischemia for treatment
62433841|NCT01086215||Deep Vein Thrombosis|Patients presenting with deep vein thrombosis for treatment
62433842|NCT01086215||Hemodialysis Access|Patients presenting with thrombosed hemodialysis access for treatment
62433843|NCT01086215||Other Thrombotic Conditions|Patients presenting with a thrombotic condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment
62433844|NCT06545058||Study Cohort|All male children aged up to 16 years, who underwent a circumcision at UZ Brussel, between 1 January 2000 and 31 December 2021
62433845|NCT01234688|EXPERIMENTAL|Exercise training|Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
62600106|NCT06622460|EXPERIMENTAL|Healthy Hand Control Group (HHC Group)|The Healthy Hand Control Group (HHC Group) consists of participants without motor impairments, selected to establish baseline data for hand dexterity and grip strength using the Virtual Eggs Test (VET).
62600107|NCT00124202|PLACEBO_COMPARATOR|a fatty meal vs normal saline|Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
62600108|NCT05093426||Insomnia in Breast cancer cohort|A single cohort will be observed in Stage 1 to assess the prevalence of insomnia suffered by participants who suffer from breast cancer. A subset of participants will continue to Stage 2 to use a digital sleep diary app for an observational period of 3 weeks.
62600109|NCT03031574|ACTIVE_COMPARATOR|Food Effect|SUVN-D4010 tablets single dose
62600110|NCT03031574|ACTIVE_COMPARATOR|Gender Effect|SUVN-D4010 tablets single dose
62600111|NCT03031574|ACTIVE_COMPARATOR|Age Effect|SUVN-D4010 tablets single dose
62600112|NCT05818358|ACTIVE_COMPARATOR|Black Beans (cooked)|At one of the three visits, participants will consume a ¾ cup of cooked black beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink up to another 150 mL of water during the 2 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 3 visits have been completed.
62600113|NCT05818358|ACTIVE_COMPARATOR|Whole Wheat Grain (cooked)|At one of the three visits, participants will consume a ¾ cup of cooked whole wheat grain. Participants will be provided with 100 ml of water with the food, and will be allowed to drink up to another 150 mL of water during the 2 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 3 visits have been completed.
62623376|NCT01115387||ARM at risk individuals|"A group of 1,500 participants (from 49 to 65 years old) who have at least one parent with age related maculopathy.~These individuals with ARM-affected parents and relatives have a substantially higher risk (6-12 fold) of developing ARM than the general population. They will be followed prospectively with fundus photography every two years and questionnaires (distributed over six month intervals) to assess external risks for ARM development in order to investigate genotype-phenotype correlations of early onset clinical features of ARM."
62819736|NCT04747041|EXPERIMENTAL|Alternating each month for 1 year between Phytocyst herbal tea and Cyscontrol|Alternating each month (From Day1 to DAY15) for 1 year between Phytocyst herbal tea and Cyscontrol = Preventive Treatment In case of episode of cystitis : AROMAFEMINA, Capsules for the comfort of the urinary tract Oleocaps 2 : 2 capsules before meals, 3 times a day for 5 consecutive days.
62243510|NCT06736444|EXPERIMENTAL|BASICS + SLEEP|The BASICS + SLEEP intervention will integrate BASICS feedback and the Motivational Interviewing (MI) process described in the BASICS arm with Brief Behavioral Therapy for Insomnia (BBTI) content and materials. The BASICS + SLEEP intervention will be implemented in 2 sessions of 45-75 minutes and 2 telephone booster sessions. We will follow BBTI procedures, including provision of a physiological rationale for insomnia and the importance of behavioral strategies to regulate sleep; introduction of sleep hygiene; discussion of factors that can impede duration and quality of sleep; introduction of sleep restriction and stimulus control strategies and negotiation of an initial sleep restriction schedule; and follow-up evaluation of success and continued refinement to achieve sleep efficiency goals. Booster contacts serve as opportunities to adjust the sleep restriction schedule, problem-solve challenges, and further build motivation.
62433846|NCT01234688|NO_INTERVENTION|Control|Patients allocated to the control group remained in regular dialysis treatment during the same timeframe.
62433847|NCT04130945|ACTIVE_COMPARATOR|group 1|patients with erector spine plane block
62243511|NCT06736444|ACTIVE_COMPARATOR|BASICS|The BASICS condition will meet for 2 sessions of 45-75 minutes. Content depends on the degree to which participants discuss the feedback, have questions, and/or explore behavior change options. Therapists review feedback components with participants, eliciting personally relevant reasons to change as domains are explored. When the participant is ambivalent about change, therapists work with them to explore and resolve that ambivalence. The method is non-confrontational and utilizes exploration of personalized graphic feedback (i.e., frequency, quantity, and peak use alongside perceived and actual norms for alcohol/MJ use) to increase motivation for change by highlighting ways alcohol and/or marijuana use could be incongruent with goals or values. Beliefs, expectations, and motives for use are discussed as are strategies to minimize risks and consequences. Booster sessions address questions and problem-solve challenges that have arisen since the session.
62243512|NCT06736444|ACTIVE_COMPARATOR|SLEEP|The SLEEP intervention will be implemented in 2 sessions of 45-75 minutes and 2 telephone booster sessions. We will follow BBTI procedures, including provision of a physiological rationale for insomnia and the importance of behavioral strategies to regulate sleep; introduction of sleep hygiene; discussion of factors that can impede duration and quality of sleep; introduction of sleep restriction and stimulus control strategies and negotiation of an initial sleep restriction schedule; and follow-up evaluation of success and continued refinement to achieve sleep efficiency goals.
62265925|NCT04715061|EXPERIMENTAL|Cancer patients without MRI|9 cancer patients will be recruited and received the 3 experimental conditions : first the rest condition, then randomly MICE condition and HIIT condition, all without MRI.
62433848|NCT04130945|NO_INTERVENTION|group 2|patients without erector spine plane block
62433849|NCT00565370|EXPERIMENTAL|A|XP+sorafenib
62433850|NCT00565370|PLACEBO_COMPARATOR|B|XP
62433851|NCT03216200|EXPERIMENTAL|Experimental|5 Subjects with 20-75% Distal Subungual Onychomycosis (mild to moderate DSO) infection of their big toe (hallux) nail infected by the dermatophytes Trichophyton (T.) rubrum or T. mentagrophytes will be enrolled. All Subjects will receive three 45-minute plasma treatments performed over a week.
62061587|NCT02121678|EXPERIMENTAL|Run-in - Aerobic - Resistance|"* Week -12 to 0: Run-in period with no training~* Week 0 to 12: Aerobic training on ergometer bicycle~* Week 12 to 24: Resistance training with dumbbells"
62265926|NCT04715061|ACTIVE_COMPARATOR|Healthy patients|9 healthy patients will be recruited and received 2 experimental conditions : first the rest condition (with a MRI), then HIIT condition (with MRI).
62265927|NCT01982929|SHAM_COMPARATOR|Sham block & Oral Meds|Definition intervention. Sham procedure. Blocks mimicked the TAP blocks, but neither needle nor injectate was used. Patients had bilateral ultrasound scans over the lateral aspect of the abdomen. To mimic the injection of medicine, a blunt needleless syringe was firmly pressed on either side of the abdomen. An adhesive bandage was applied over the injection or sham injection sites.
62433852|NCT02115685|NO_INTERVENTION|One day testing|Aim 1 will be to measure bloodflow during exercise of the legs (below the injury). This aim will examine the control of bloodflow and muscle contractions and how it changes after spinal cord injury.
62433853|NCT02115685|EXPERIMENTAL|Effects of long term training|Aim 3 will then look at changes in bloodflow during exercise after training. Three different eight week exercise training programs will be tested including 1) treadmill training at high intensity as defined by 70-80% of HRR or 15-17 RPE 2) treadmill training at low intensity as defined by 30-40% of HRR or \<13 RPE
62600114|NCT05818358|PLACEBO_COMPARATOR|White Rice (cooked)|At one of the three visits, participants will consume a ¾ cup of cooked white rice. Participants will be provided with 100 ml of water with the food, and will be allowed to drink up to another 150 mL of water during the 2 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 3 visits have been completed.
62600115|NCT03584464|OTHER|Bifurcation Cohort|Subjects receiving stents 2.0 mm - 5.0 mm in diameter will be included in the Bifurcation Cohort.
62600116|NCT03144752||Cohort 1: Participants between 8 to 14 weeks gestation|Cohort 1 will include female participants who present for the first prenatal visit which takes place between Weeks 8 and 14 at maternity practices associated with University of North Carolina (UNC) Women's Care. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.
62600117|NCT03144752||Cohort 2: Participants between 15 to 36 weeks gestation|Cohort 2 will include female participants enrolled at various points in their pregnancy from Week 15 up through 36 weeks gestation. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.
62600118|NCT01544608||Subjects who are hospitalized due to acute psychotic episode.|All subjects who are hospitalized due to acute psychotic episode. The subjects should be managed according to normal clinical practice until discharge time.
62600119|NCT05976685|EXPERIMENTAL|LAAO and DOAC therapy|Left atrial appendage occlusion and therapy with direct oral anticoagulants
62600120|NCT05976685|OTHER|DOAC therapy only|Therapy with direct oral anticoagulants alone
62600121|NCT00897962||Metastatic Breast Cancer|Patients with metastatic breast cancer receiving treatment with chemotherapy, endocrine therapy or targeted therapy
62061588|NCT02121678|EXPERIMENTAL|Run-in - Resistance - Aerobic|"* Week -12 to 0: Run-in period with no training~* Week 0 to 12: Resistance training with dumbbells~* Week 12 to 24: Aerobic training on ergometer bicycle"
62433854|NCT00647166|EXPERIMENTAL|1|Drug: corticosteroid and azathioprine
62433855|NCT00647166|PLACEBO_COMPARATOR|2|Drug: corticosteroid and placebo
62433856|NCT02619331|EXPERIMENTAL|Atopic volunteers|Allergy tests will be performed in allergic patients with rhinoconjunctivitis and allergy test reading measured following two different methodologies. 1) test reading based on conventional wheal and flare measurement (wheal diameter in mm, CWFM), 2) test reading based on high speed laser doppler imaging (HS-LDI). Both type of tests reading will be compared.
62433857|NCT03553277|EXPERIMENTAL|Transfluthrin|transfluthrin
62433858|NCT03553277|PLACEBO_COMPARATOR|Placebo|inert ingredients
62433859|NCT05639673||NOPHO ALL2008|Children and adolescents treated according to the NOPHO ALL2008 protocol
62061589|NCT05089435|OTHER|14-day EZYPRO and 24-hr Holter|Patients wear simultaneously 14- day continuous ECG moniter (EZYPRO) and 24-hr Holter monitor.
62433860|NCT05639673||Australia|
62600122|NCT00897962||Non-cancer medical illness|Patients with non-cancer medical condition
62600123|NCT00897962||Healthy Controls|Healthy patients being seen for an annual exam
62819737|NCT05728463|EXPERIMENTAL|Single-incision laparoscopic cholecystectomy|SILC was defined as laparoscopic surgery done through a single trans-umbilical incision
62819738|NCT05728463|ACTIVE_COMPARATOR|Conventional laparoscopic cholecystectomy|CLC was defined as three or four port surgery carried out with either French or American position.
62819739|NCT06509659||Healthy controls|No lung disease or symptoms. Negative methacholine Challenge Test.
62433861|NCT05639673||Poland|
62433862|NCT05639673||Dutch Childhood Oncology Group|
62433863|NCT05639673||St. Jude|
62433864|NCT05570929||Kidney Donor|Defined as a human individual donating a kidney
62433865|NCT05570929||Kidney Recipient|Defined as a patient suffering from chronic kidney disease being the recipient of a kidney transplant
62433866|NCT04745780|EXPERIMENTAL|Study Arm|Treated with a formulation containing Myo-inositol (1950 mg), D-chiro-inositol (50 mg), Gymnema sylvestre (250 mg), Zinc (7,5 mg) and Alpha-lactalbumin (50 mg) - Two-times daily on an empty stomach, for 6 months.
62433867|NCT04745780|PLACEBO_COMPARATOR|Placebo Arm|Treated with Placebo - Two-times daily on an empty stomach, for 6 months.
62433868|NCT02751060||patients with coronary heart disease symptoms|
62600124|NCT01323413||stroke|acute ischemic stroke patients
62600125|NCT02973334|EXPERIMENTAL|Sugar|Effects of ingestion of sugar-sweetened beverages on acute stress response
62600126|NCT02973334|EXPERIMENTAL|Artificial sweetener|Effects of ingestion of artificially-sweetened beverages on acute stress response
62600127|NCT02973334|ACTIVE_COMPARATOR|Water|Effects of ingestion of water on acute stress response
62849076|NCT05067218|ACTIVE_COMPARATOR|buzzy device (intervention)|The wings of buzzy device will be kept frozen and once the child is ready, the frozen wing will be attached to the device and Buzzy will be placed extra-orally above the area/cheek where local anesthetic is to be delivered.
62600128|NCT05108142|EXPERIMENTAL|Control meal|Participants were asked to visit the lab and consume the control meal (hot, freshly cooked pasta)
62039695|NCT01329367|EXPERIMENTAL|Antioxidant group|"Antioxidant group: Participants will receive Nutritional education and personalized structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of fruits and vegetables (antioxidant rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
62243513|NCT06736444|OTHER|Attention Control|Attention Control (AC) participants complete all assessments (survey, daily, Fitbit, BAC) yoked to participants in the 3 active interventions, and attend the Zoom training to verify identity, orient to the Fitbit \& BAC monitoring, and provide rationale and instructions for daily diaries. To better control for time and attention, AC participants attend 4 weekly Zoom check-ins (\~20 minutes) in which clinically trained staff inquire about challenges encountered in monitoring, observations from monitoring, check in on mood/functioning, and provide referrals as needed. All conditions including AC receive community referrals to address substance uses, sleep, and mental health concerns. No participant is deprived of services; service use is tracked to assist with interpreting outcomes. AC participants will be offered BASICSSLEEP after completing 18-month follow-up.
62243514|NCT03152357||Patients implanted with a ConforMIS device|Previously underwent surgical implantation of a ConforMIS iUni, iDuo or iTotal knee replacement
62600129|NCT05108142|EXPERIMENTAL|Resistant starch meal|Participants were asked to visit the lab and consume the resistant starch meal (re-heated pasta)
62600130|NCT02222363|EXPERIMENTAL|VLX600|Dose of VLX600 in patients with refractory advanced solid tumors
62600131|NCT01328548||Nursing Home Elderly Cases|Non-ambulatory nursing home residents \>= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs (single nucleotide polymorphisms). A case will be considered failure to mount a high response.
62433869|NCT02856997|EXPERIMENTAL|Chidamide with ICE regimen|"Drugs:Chidamide and ICE regimen (ifosfamide, Mesna,Carboplatin and etoposide): Chidamide 20mg on d1,4,8,11;ifosfamide 1.2g/ m2，d1-4,ivg during 4 hours; Mesna 0.4g, 0,4,8 hours during Ifosfamide transfusion, ivg, d1-4; Carboplatin AUC=4, d2,ivg; etoposide 65mg/m 2, d1-4, ivg. 3 weeks as 1 course, for 6 courses.~if the effect is PR or better than PR, go to auto-stem cell transplantation, no further treatment with Chidamide is needed.~If the effect is PR or better than PR and no auto-stem cell transplantation available,Chidamide 20mg orally, twice every week, till the end of the trial."
62433870|NCT04843176|ACTIVE_COMPARATOR|Prototype AI algorithm|In-house prototype deep learning artificial intelligence algorithm
62433871|NCT04843176|PLACEBO_COMPARATOR|LI_RADS interpretation|LI-RADS criteria will be assessed independently by two specified abdominal radiologists with at least 10 years of experience in cross-sectional abdominal imaging
62433872|NCT01878656|ACTIVE_COMPARATOR|Sevoflurane|administration of sevoflurane with oxygen and nitrous oxide as same ratio of 3 L/min for maintenance of general anesthesia
62433873|NCT01878656|ACTIVE_COMPARATOR|Desflurane|administration of desflurane with oxygen and nitrous oxide as same ratio of 3 L/min for maintenance of general anesthesia
62433874|NCT06009900|ACTIVE_COMPARATOR|Non-steroidal drug (Celecoxib) group|Oral Celecoxib 200mg/time, twice a day, for three consecutive weeks.
62433875|NCT06009900|EXPERIMENTAL|Weak laser treatment group|Low intensity laser treatment: Both patients and doctors wear goggles during the irradiation process. Using 810nm (infrared)/658nm (red) dual wavelength output for direct skin contact point irradiation, the maximum output power is 100mW (red)/60mW (infrared). Select the treatment site based on the patient's anatomical positioning (muscle and tendon attachment points, nerve distribution aggregation points) and/or pain points, and perform spot laser irradiation. Low intensity laser treatment process: Treat once a day for 15 minutes each time, with 5 consecutive days of treatment and 2 days of rest per week. The patient received a total of 3 weeks (15 times) of low intensity laser treatment.
62433876|NCT03551366|NO_INTERVENTION|Control|Subjects in this group will continue with their usual PE curriculum for 15 weeks.
62600132|NCT01328548||Nursing Home Elderly Controls|Non-ambulatory nursing home residents \>= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs. A control will be a participant who mounted an adequate response as defined in primary outcomes.
62039696|NCT04322682|ACTIVE_COMPARATOR|Colchicine|Patients will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
62039697|NCT04322682|PLACEBO_COMPARATOR|Placebo|Patients will receive a placebo per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
62600133|NCT01328548||Community dwelling seniors|Community dwelling seniors ages 60-75 will be enrolled as a control group for the laboratory testing. They will be vaccinated and will provide pre- and post-vaccination blood. If nursing home residents do not show a response it is important to know that it is not a failure of the laboratory's measurement of immunogenicity.
62600134|NCT06621043|EXPERIMENTAL|Active NTI164 Arm|Participants in this arm receive Full-Spectrum Medicinal Cannabis Plant Extract containing 0.08% THC (NTI164), targeted at treating symptoms of Rett syndrome (RTT) in children and young people. The intervention starts with a daily initial dose of 5 mg/kg, which is increased gradually over a four-week up-titration phase to a maximum of 20 mg/kg per day, depending on individual tolerance. Participants then continue at their maximum tolerated dose for eight weeks during the treatment phase. The study concludes with a four-week down-titration phase, where the dosage is reduced by 5 mg/kg each week. The effectiveness of the treatment is monitored through specialized questionnaires and full blood examinations throughout the study duration.
62600135|NCT03238885||LARC-CRT|LARC patients who will receive neoadjuvant CRT before surgical resection.
62623377|NCT01115387||Partners/Spouses of ARM at risk individuals|"A group of 1,500 participants (from 49 to 65 years old) who are the spouses/partners of individuals with ARM affected parents.~We will invite the partners or spouses to participate in order to compare their risk of developing ARM with those individuals with an increased risk of ARM based on a positive family history."
62600136|NCT05070429|OTHER|Conventional hearing healthcare group|The conventional hearing healthcare group will have clinic-based visits every 6 months for the duration of the 2-year study. During Year 1, this group will receive clinic-based audiological rehabilitative service delivery and be able to use conventional options to address any unanticipated needs that arise, and then during Year 2, this group will also receive telehealth audiological rehabilitative service delivery and be able to utilize telehealth options, in addition to conventional options, to address any unanticipated needs that arise.
62819740|NCT06588556|EXPERIMENTAL|ICUconnect intervention|ICUconnect is essentially digital infrastructure for facilitating consistent person-centered communication. It is a web app platform that works on any digital device (smartphone, computer, tablet) and uses a series of automated and timed text messages and emails to direct family members and clinicians to perform timeline-driven tasks (e.g., surveys, content review, coaching features, family meetings) across the 7- to 10-day intervention period.
62039698|NCT06018480|EXPERIMENTAL|Creatine Monohydrate Supplementation|Participants will be provided with 20 grams of creatine monohydrate per day (100 grams total) in sealed and unopened packages (5 grams in each package). Participants will be asked to complete their supplementation protocol (20 grams/day) by mixing 5 grams of creatine monohydrate powder into water 4 times a day or 10 grams of creatine monohydrate powder into water twice a day. This supplementation will occur after a baseline visit in which participants consume a high-carb meal and have their vascular function studied before the meal and four hours post-prandial. Following the 5 days of supplementation participants will come back and consume a high-carb meal and have their vascular function studied before the meal and four hours post-prandial.
62600137|NCT05070429|OTHER|Telehealth hearing healthcare group|The telehealth hearing healthcare group will have clinic-based visits every 6 months for the duration of the 2-year study. This group will receive telehealth audiological rehabilitative service delivery and be able to utilize telehealth options, in addition to conventional options, to address any unanticipated needs that arise during both years of the study.
62061590|NCT04194372||Metabolic Patient|"Patients with a metabolic desease, defined as~1. Metabolic Syndrom~2. Diabetic~3. Obese"
62243515|NCT06735638|EXPERIMENTAL|Out of the Cage Minimally Invasive Esophagectomy (OTC MIE)|Consented patients will undergo minimally invasive esophagectomy (MIE) using the Out of the Cage (OTC) robotic approach. This approach follows the standard procedural steps typically used in minimally invasive esophagectomy (e.g., laparoscopy and robotic-assisted thoracic surgery), with the primary difference being the incisions. Instead of intercostal incisions, the thoracic component of the procedure will be performed using 1 to 4 subcostal ports, tailored to the patient's anatomy and the case requirements.
62243516|NCT03644654|ACTIVE_COMPARATOR|Standard care group|Fluid management will be done according standard care
62433877|NCT03551366|EXPERIMENTAL|Linear|Subjects in this group will receive a linear PE curriculum for 15 weeks. Linear Pedagogy is underpinned by neuro-computation approach to motor learning such as information processing theory and prescribes that an ideal movement pattern exists for each task and that the teacher's role is to help learners recreate that pattern. Furthermore, theorists have suggested that learning is a gradual, linear process. This linear pedagogy is supported by a teaching and learning approach that includes both prescriptive and repetitive actions, utilising technical demonstrations that provide learners with a 'visual template or criterion model' for the desired skill . As a consequence, a PE pedagogy has developed whereby the teacher's role is to make all the decisions, and the learner's role is to follow their instructions on cue - a teacher-led approach to PE.
62600138|NCT06389149|EXPERIMENTAL|Control: LEAP therapy, then no LEAP therapy|Participants will perform a bout of 2.5 hours of prolonged sitting with LEAP therapy. After a minimum period of 7 days, they will then perform a bout of 2.5 hours of prolonged sitting without LEAP therapy.
62600139|NCT06389149|EXPERIMENTAL|Control: No LEAP therapy, then LEAP therapy|Participants will perform a bout of 2.5 hours of prolonged sitting without LEAP therapy. After a minimum period of 7 days, they will then perform a bout of 2.5 hours of prolonged sitting with LEAP therapy.
62600140|NCT06389149|EXPERIMENTAL|PAD: LEAP therapy, then no LEAP therapy|Participants with peripheral artery disease will perform a bout of 2.5 hours of prolonged sitting with LEAP therapy. After a minimum period of 7 days, they will then perform a bout of 2.5 hours of prolonged sitting without LEAP therapy.
62600141|NCT06389149|EXPERIMENTAL|PAD: No LEAP therapy, then LEAP therapy|Participants with peripheral artery disease will perform a bout of 2.5 hours of prolonged sitting without LEAP therapy. After a minimum period of 7 days, they will then perform a bout of 2.5 hours of prolonged sitting with LEAP therapy.
62600142|NCT04712591||Acute Brain Injury Patients|Acute brain injury (ABI) patients will be recruited and studied using electroencephalogram (EEG) to monitor their brain response to auditory and visual stimuli.
62600143|NCT04712591||Healthy Volunteers|Healthy volunteers will serve as the control group and will undergo electroencephalogram (EEG) to monitor their brain response to auditory and visual stimuli.
62600144|NCT03615716|EXPERIMENTAL|Multi-level Violence Prevention Intervention - Boys|A study examining middle school boys who have a high potential of violence based on where they live. This arm will measure outcomes in the boys. as the result of the intervention, from the perspectives of the boys.
62061591|NCT03012061|PLACEBO_COMPARATOR|Placebo|Subjects will be administered placebo once daily via the ELLIPTA® dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks. ELLIPTA is a registered trademark of the GSK group of companies.
62243517|NCT03644654|EXPERIMENTAL|Noninvasive monitoring group|Fluid management will be provided using noninvasive hemodynamical monitor ClearSight (Edwards)
62243518|NCT06070194|EXPERIMENTAL|Time restricted eating (TRE)|Subjects randomized to this arm will be asked to follow an 8h eating duration/day for 4 weeks.
62243519|NCT06070194|NO_INTERVENTION|Habitual eating duration|Subjects randomized to this arm will be asked to continue habitual eating duration of \>14h/day for 4 weeks.
62243520|NCT03876314|EXPERIMENTAL|Physical Activity Condition (PAC)|Subjects will be asked to attend virtual exercise sessions 3 times a week for 1 year.
62600145|NCT03615716|EXPERIMENTAL|Multi-level Violence Prevention Intervention - Caregivers|In this study examining middle school boys who have a high potential of violence based on where they live, this arm will measure caregivers' perspectives of the boys ' outcomes. Caregivers will be surveyed pre-intervention and 4- and 6-month post intervention to explore the impact of the boys' intervention.
62600146|NCT01468753|EXPERIMENTAL|Vaginal Insemination|Women will perform vaginal insemination during the fertile period of the menstrual cycle with the collected semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
62600147|NCT06163040||Treated with Elotuzumab in combination with pomalidomide and dexamethasone|
62433878|NCT03551366|EXPERIMENTAL|Nonlinear|Subjects in this group will receive a nonlinear PE curriculum for 15 weeks. Nonlinear pedagogy is grounded in Ecological Dynamics theory. Ecological dynamics regards learners as complex adaptive systems which afford opportunities for action from their environment and generate movement solutions to satisfy the combination of personal, environmental and task constraints imposed upon them. According to nonlinear pedagogy, the teacher's role is to design learning experiences that create behavioural symmetry between learning and the performance environment. The teacher is a facilitator and manipulates constraints to channel the learner's physical development, while learners are left free to experiment and select the movement solutions that best answer their individual needs. This child-focused, less prescriptive approach may enhance a child's intrinsic motivation by offering freedom to choose, and an emphasis on exploration and problem solving.
62433879|NCT05699837|EXPERIMENTAL|hBET 1|Rhythmic stimulation (2 weeks) followed by non-rhythmic stimulation (2 weeks)
62433880|NCT05699837|EXPERIMENTAL|hBET 2|Non-rhythmic stimulation (2 weeks) followed by rhythmic stimulation (2 weeks)
62433881|NCT01526915|EXPERIMENTAL|Bone curettage + PRF|Bone curettage and PRF insertion
62433882|NCT01526915|OTHER|Bone curettage alone|Bone curettage without PRF insertion
62433883|NCT06078085|EXPERIMENTAL|Intervention|24 patients that receive a postoperative rehabilitation program to follow after they undergo surgery for abdominal rectus diastasis.
62433884|NCT06078085|NO_INTERVENTION|Control|24 patients that undergo surgery for abdominal rectus diastasis and can exercise freely after surgery.
62433885|NCT00409578|PLACEBO_COMPARATOR|Placebo|Placebo tablets and capsules
62433886|NCT00409578|EXPERIMENTAL|Aliskiren 300 mg|Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.
62433887|NCT00409578|EXPERIMENTAL|Valsartan 320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.
62433888|NCT00409578|EXPERIMENTAL|Aliskiren/valsartan 300/320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.
62600148|NCT06163040||Treated with Elotuzumab in combination with lenalidomide and dexamethasone|
62600149|NCT05906212|EXPERIMENTAL|Nonpenetrating deep sclerectomy&phacoemulsification&autotransplantation of anterior lens capsule|The intervention group will be undergoing non-penetrating deep sclerectomy and phacoemulsification with the use of an autotransplantation of the human anterior lens capsule as the spacer in the intrascleral lake.
62600150|NCT05906212|ACTIVE_COMPARATOR|Non-penetrating deep sclerectomy and phacoemulsification|The control group will be undergoing non-penetrating deep sclerectomy and phacoemulsification without any spacer.
62600151|NCT00805870|EXPERIMENTAL|Fish Oil|Lovaza, 3 grams/day for 65 days
62600152|NCT00805870|PLACEBO_COMPARATOR|Control|Wheat Germ Oil, 3 grams/day for 65 days
62600153|NCT05811052|EXPERIMENTAL|Suboccipital Release Group|
62600154|NCT05811052|SHAM_COMPARATOR|Control Group|
62600155|NCT00689624|EXPERIMENTAL|1|FOLFOXIRI+Erbitux
62600156|NCT03627377|NO_INTERVENTION|Control Phase|3-month initial control phase (no intervention, month 1-3)
62600157|NCT03627377|EXPERIMENTAL|Intervention Phase|6-month intervention phase - MIDAS Intervention Delivered. Followed by 6-month follow-up phase (no intervention, months 10-15).
62600158|NCT00801697|EXPERIMENTAL|1A|rAD5-naive participants will receive rAd35 intramuscularly at study entry and rAd5 intramuscularly at Month 6
62600159|NCT00801697|PLACEBO_COMPARATOR|1B|Participants will receive rAd35 placebo intramuscularly at study entry and rAd5 placebo intramuscularly at Month 6
62600160|NCT00801697|EXPERIMENTAL|2A|rAD5-naive participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd5 intramuscularly at Month 6
62600161|NCT00801697|PLACEBO_COMPARATOR|2B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd5 placebo intramuscularly at Month 6
62600162|NCT00801697|EXPERIMENTAL|3A|Participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd35 intramuscularly at Month 6
62600163|NCT00801697|PLACEBO_COMPARATOR|3B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd35 placebo intramuscularly at Month 6
62600164|NCT00801697|EXPERIMENTAL|4A|Participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd35 intramuscularly at Month 6
62039699|NCT06018480|PLACEBO_COMPARATOR|Placebo (Maltodextrin)|Participants will be provided with 20 grams of maltodextrin (placebo) per day (100 grams total) in sealed and unopened packages (5 grams in each package). Participants will be asked to complete their supplementation protocol (20 grams/day) by mixing 5 grams of maltodextrin (placebo) into water 4 times a day or 10 grams of maltodextrin (placebo) powder into water twice a day. This supplementation will occur after a baseline visit in which participants consume a high-carb meal and have their vascular function studied before the meal and four hours post-prandial. Following the 5 days of supplementation participants will come back and consume a high-carb meal and have their vascular function studied before the meal and four hours post-prandial.
62039700|NCT03335462|EXPERIMENTAL|Paravertebral injections|Lumbar paravertebral injections containing contrast will be performed. The needles are kept in their position and afterwards followed by CT scan.
62039701|NCT00827918|EXPERIMENTAL|MK-8998|MK-8998, 6 mg twice a day (BID) for Days 1 to 7, and 8 mg BID thereafter for a 4-week total treatment period
62039702|NCT00827918|ACTIVE_COMPARATOR|Olanzapine|Olanzapine, 5 mg BID for Day 1 to 7, and 15 mg (5 mg in the morning and 10 mg in the evening) thereafter for a 4-week total treatment period
62039703|NCT00827918|PLACEBO_COMPARATOR|Placebo|Placebo Comparator to MK-8998 or olanzapine
62039704|NCT06426537|ACTIVE_COMPARATOR|Colchicine Intervention in STEMI Patients Onset < 12 Hours Undergoing PCI|Patients receive colchicine according to protocol: Loading dose of 1 mg 1-2 hours before PCI, 0.5 mg colchicine 1 hour after loading, Maintenance dose of 1 x 0.5 mg colchicine for 1 month and OMT
62039705|NCT06426537|PLACEBO_COMPARATOR|Placebo in STEMI Patients Onset < 12 Hours Undergoing PCI|Patients receive placebo according to protocol: Placebo administration and OMT
62039706|NCT06426537|ACTIVE_COMPARATOR|Colchicine Intervention in STEMI Patients Onset < 12 Hours Not Undergoing Reperfusion|Patients receive colchicine according to protocol: Loading dose of 1 mg, 0.5 mg colchicine 1 hour after loading, Maintenance dose of 1 x 0.5 mg colchicine for 1 month and OMT
62039707|NCT06426537|PLACEBO_COMPARATOR|Placebo in STEMI Patients Onset < 12 Hours Not Undergoing Reperfusion|Patients receive placebo according to protocol: Placebo administration and OMT
62039708|NCT02634411|EXPERIMENTAL|8 days of effective antibiotic treatment|Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against PA of 8 days.
62039709|NCT02634411|SHAM_COMPARATOR|15 days of effective antibiotic treatment|Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against PA of 15 days.
62039710|NCT05706506|EXPERIMENTAL|5 milligrams (mg) Tirzepatide|Participants received 5 mg tirzepatide subcutaneously administered once weekly for 12 weeks.
62039711|NCT01913418|ACTIVE_COMPARATOR|Suan-Zao-Ren Tang|The SZRT formula used in this study is manufactured as a herbal extract powder from the good manufacturing procedures (GMP) of the certified company Kaiser Pharmaceutical Co., Ltd. (Taiwan). Granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
62039712|NCT01913418|PLACEBO_COMPARATOR|Suan-Zao-Ren Tang placebo|The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
62039713|NCT06423703|EXPERIMENTAL|Cebranopadol|once daily for 3 days
62039714|NCT06423703|ACTIVE_COMPARATOR|Oxycodone IR|four times per day for 3 days
62039715|NCT06423703|PLACEBO_COMPARATOR|Placebo|three times per day 3 days (with cebranopadol); four times per day for 3 days (placebo arm)
62039716|NCT00324870|EXPERIMENTAL|Arm I|"Phase I: Patients receive oral SAHA twice daily on days 1-14 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.~Phase II: Patients receive SAHA at the MTD determined in phase I and bevacizumab as in phase I."
62433889|NCT02037373||Octaplas™|Patients treated with Octaplas™ infusion solution for IV administration as prescribed by their treating physician.
62600165|NCT00801697|PLACEBO_COMPARATOR|4B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd35 placebo intramuscularly at Month 6
62600166|NCT03104400|EXPERIMENTAL|Upadacitinib 15 mg|"Period 1: Participants receive upadacitinib 15 mg orally once a day (QD) and matching placebo to adalimumab by subcutaneous injection every other week (EOW) for 56 weeks.~Period 2: Participants will continue to receive upadacitinib 15 mg once daily."
62039717|NCT06386588|EXPERIMENTAL|Schizophrenia|Adult outpatients with a diagnosis of schizophrenia.
62433890|NCT02037373||Plasma|Patients treated with regular plasma (e.g., fresh frozen plasma (FFP) and other FDA and American Association of Blood Banks (AABB) approved plasma products).
62433891|NCT02878278|EXPERIMENTAL|Chidamide BIW|Chidamide is given 30mg,5mg/pill,twice a week, for at least 6 weeks
62433892|NCT02878278|EXPERIMENTAL|Chidamide QD|Chidamide is given 10mg,5mg/pill, everyday,for at least 6 weeks.
62039718|NCT06386588|ACTIVE_COMPARATOR|Healthy Controls|Adult participants screened to exclude a personal history of mental illness, family history of schizophrenia spectrum disorder, and psychoactive medication use.
62039719|NCT05761860|ACTIVE_COMPARATOR|Oral oxycodone (5mg) + intranasal oxytocin (48 IU)|Combined effects of oxycodone and oxytocin.
62039720|NCT05761860|ACTIVE_COMPARATOR|Oral oxycodone (2.5mg) + intranasal oxytocin (48 IU)|Combined effects of oxycodone and oxytocin.
62039721|NCT05761860|ACTIVE_COMPARATOR|Oral placebo + intranasal oxytocin (48 IU)|Separate effects of oxytocin. As is standard methodology in abuse liability and pain assessments, a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo.
62600167|NCT03104400|EXPERIMENTAL|Upadacitinib 30 mg|"Period 1: Participants receive upadacitinib 30 mg orally once a day and matching placebo to adalimumab by subcutaneous injection every other week for 56 weeks.~Period 2: Participants will continue to receive upadacitinib 30 mg once daily."
62600168|NCT03104400|ACTIVE_COMPARATOR|Adalimumab|"Period 1: Participants receive adalimumab 40 mg by subcutaneous injection every other week and matching placebo to upadacitinib orally QD for 56 weeks.~Period 2: Participants continue to receive adalimumab 40 mg every other week."
62600169|NCT03104400|PLACEBO_COMPARATOR|Placebo / Upadacitinib 15 mg|"Period 1: Participants receive matching placebo to upadacitinib orally once a day for 24 weeks then upadacitinib 15 mg once daily for 32 weeks, and matching placebo to adalimumab by subcutaneous injection EOW for the entire 56 weeks.~Period 2: Participants will continue to receive upadacitinib 15 mg once daily."
62600170|NCT03104400|PLACEBO_COMPARATOR|Placebo / Upadacitinib 30 mg|"Period 1: Participants receive matching placebo to upadacitinib orally once a day for 24 weeks then upadacitinib 30 mg once daily for 32 weeks, and matching placebo to adalimumab by subcutaneous injection EOW for the entire 56 weeks.~Period 2: Participants will continue to receive upadacitinib 30 mg once daily."
62600171|NCT01443494|EXPERIMENTAL|NE group|Adjust NE dose to titrate MAP to usual level regardless of fluid responsiveness when after EGDT.
62600172|NCT00451295|PLACEBO_COMPARATOR|1|
62600173|NCT00451295|EXPERIMENTAL|2|
62600174|NCT01385488|EXPERIMENTAL|self-monitoring|participants will use bioelectrical impedance to self-monitor arm volume at home
62600175|NCT01385488|NO_INTERVENTION|completion of forms|participants will complete self-report forms
62600176|NCT01297127||Cohort|
62600177|NCT03702114||MMG group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
62600178|NCT03702114||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
62600179|NCT01048112|EXPERIMENTAL|Repeated dose group|Will receive one dose of Campylobacter jejuni strain CG8421 at day 0 and a second dose at approximately day 98.
62600180|NCT01048112|ACTIVE_COMPARATOR|Single dose group|Will receive one dose of Campylobacter jejuni strain CG8421
62600181|NCT04985175|EXPERIMENTAL|QPL group|receive 2-pages ESRD QPL leaflets, circle the questions they want to ask before consultation. encourage asking questions with doctor during consultation. receive the nurse-led coaching of shared decision-making (SDM)
62600182|NCT04985175|NO_INTERVENTION|Usual care group|without receiving provision of QPL encourage asking questions with doctor during consultation. receive the nurse-led coaching of shared decision-making (SDM)
62039722|NCT05761860|ACTIVE_COMPARATOR|Oral oxycodone (5mg) + intranasal placebo|Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments, a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo.
62039723|NCT05761860|ACTIVE_COMPARATOR|Oral oxycodone (2.5mg) + intranasal placebo|Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments, a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo.
62600183|NCT00621595|ACTIVE_COMPARATOR|1|Fasting
62600184|NCT02144207|ACTIVE_COMPARATOR|Glidescope: Unrestricted View|Unrestricted view of the larynx.
62600185|NCT02144207|ACTIVE_COMPARATOR|Glidescope: Restricted View|Restricted view of the larynx.
62600186|NCT05236972|EXPERIMENTAL|Sintilimab|Sintilimab 200mg iv drip Q3W for 8 courses
62600187|NCT05236972|EXPERIMENTAL|XELOX|Patients receive chemotherapy comprising oxaliplatin 130mg/m² ivdrip over 2 hours on day 1,capecitabine 2000 mg/m² on days 1-14, treatment repeats every 21 days for 4 or 8 courses
62600188|NCT05454046||Women|
62039724|NCT05761860|SHAM_COMPARATOR|Oral placebo + intranasal placebo|Serves as the control.
62039725|NCT05637840|EXPERIMENTAL|Sleep limited|Participants will be asked to limit their sleep
62039726|NCT05637840|EXPERIMENTAL|No sleep limitation|Participants will be asked to get their normal amount of sleep.
62039727|NCT03565887|EXPERIMENTAL|RVL-1201 ophthalmic solution 0.1%|RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
62039728|NCT03565887|PLACEBO_COMPARATOR|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
62600189|NCT05454046||Men|
62600190|NCT04142164|ACTIVE_COMPARATOR|MacInfo presentation|Patient will get access to an online version of the MacInfo presentation
62600191|NCT04142164|PLACEBO_COMPARATOR|Placebo presentation|Patient will get access to an online version of a placebo presentation
62600192|NCT06620315|ACTIVE_COMPARATOR|Hybrid (sand blasted acid etched implants)|
62600193|NCT06620315|ACTIVE_COMPARATOR|RBM|RBM implant
62600194|NCT00645125|ACTIVE_COMPARATOR|1|
62600195|NCT00645125|ACTIVE_COMPARATOR|2|
62600196|NCT01011166|EXPERIMENTAL|IDX184 50 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 50 mg or placebo once daily (QD) in combination with Peg-IFN/RBV on Days 14-28 and Peg-IFN/RBV on Days 14-28.
62600197|NCT01011166|EXPERIMENTAL|IDX184 100 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 50 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV alone on Days 14-28.
62039729|NCT03526822|EXPERIMENTAL|patients with newly diagnosed glioblastoma|
62039730|NCT00499031|EXPERIMENTAL|Treatment (cetuximab)|Patients receive cetuximab IV over 120 minutes on day 1.
62039731|NCT05646706|EXPERIMENTAL|Semaglutide 7.2 mg|Participants will receive once-weekly injection of semaglutide subcutaneously (s.c.) in 20 week dose escalation period with dose escalation (0.25 milligram \[mg\], 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks until week 72.
62039732|NCT05646706|EXPERIMENTAL|Semaglutide 2.4 mg|Participants will receive once-weekly s.c. injection of semaglutide in 20 week dose escalation period with dose escalation (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week until maintenance dose of 2.4 mg of semaglutide was reached. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 72.
62039733|NCT05646706|PLACEBO_COMPARATOR|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks.
62039734|NCT02118220|OTHER|Concussion Questionnaire|"The questionnaire is specifically designed to elicit occurrence and symptoms of a concussion. If the patient answers yes to question 2a, which asks At the time of the injury do you recall a blow to the head, neck, face or body that resulted in sustained symptoms of concussion (e.g., headache, dizziness, confusion, nausea, vomiting, etc.)?, the research team will administer the 22 item self-reporting symptom scale in the above mentioned SCAT3. The responses obtained from the questionnaire will be used to determine the incidence of symptomatic concussions, either known or unrecognized, in pediatric patients sustaining an orthopedic injury requiring surgical repair."
62039735|NCT04195308|EXPERIMENTAL|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
62039736|NCT04195308|SHAM_COMPARATOR|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation. Participants will have the option of open label TBS-DLPFC treatment following study completion.
62039737|NCT06233279|EXPERIMENTAL|Experimental Group|Charge-Balanced, Symmetric Nerve Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).
62039738|NCT06233279|SHAM_COMPARATOR|Control Group|Sham Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).
62819741|NCT06588556|OTHER|Usual care control|Control family participants will receive standard ICU care that includes the study team's suggestion to clinicians to conduct regular family meetings. While control participants will also report needs, all family meetings that occur, and other outcomes via texted or emailed links to surveys within the app platform, control group needs will not be visible to clinicians and ICUconnect content will not be visible to family members. However, basic study information and staff contacts will be available on a control group-specific website accessible via links sent by the platform at the time of each data collection.
62819742|NCT02928068|EXPERIMENTAL|Occupational Performance Coaching (OPC)|This group received approximately 12 sessions of the telehealth intervention. The intervention consisted of parent-therapist conversations via telehealth to increase child function and participation.
62819743|NCT06548776|EXPERIMENTAL|Healthy Volunteers|Participants will be recruited from DI volunteer pool to implement MRS spine on.
62819744|NCT06548776|EXPERIMENTAL|Patients|Participants will be recruited from DI volunteer pool to implement MRS spine on.
62819745|NCT06602557|EXPERIMENTAL|Amikacine nebulization associated with Standard of care|
62819746|NCT06602557|ACTIVE_COMPARATOR|Standard of care|
62039739|NCT05832138|EXPERIMENTAL|Intervention|"Usual care plus ONLOOP program materials:~1. Study invitation letter and invitation reminder 5 weeks later~2. For those who sign up: receipt of a personalized health toolkit and then a screening reminder 6 months later~3. Optional: Engagement of primary care provider through an introductory letter and then a reminder letter sent 6 months later"
62819747|NCT00467688|NO_INTERVENTION|A,1|Real time access to current measured glucose values; hyperglycemic or hypoglycemic alerts
62039740|NCT05832138|OTHER|Delayed Intervention|"Usual care plus delayed ONLOOP:~Survivors will receive usual care for 13 months after study invitation packages are mailed out to the intervention arm. At that point, survivors in this group will also receive the study invitation package."
62039741|NCT01970982|EXPERIMENTAL|Tobacco Heating System (THS 2.2)|Ad libitum use of THS 2.2 for 5 days in confinement
62039742|NCT01970982|SHAM_COMPARATOR|Smoking abstinence (SA)|Abstinence from smoking for 5 days in confinement
62039743|NCT01970982|ACTIVE_COMPARATOR|Conventional cigarette (CC)|Ad libitum use of Subject's own preferred brand of CC for 5 days in confinement
62039744|NCT01299168||Kidney Transplant Biopsies for Cause|The study population includes patients with a functioning kidney transplant undergoing a biopsy for clinical indications as standard of care to determine the cause of their graft dysfunction (deterioration in graft function, delayed graft function, proteinuria).
62819748|NCT00467688|NO_INTERVENTION|A,2|Retrospective analysis of glucose values
62819749|NCT02476617|EXPERIMENTAL|Ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV|Ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily \[QD\]) + dasabuvir (250 mg twice daily \[BID\]) + weight based Ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided BID)
62819750|NCT02318732|EXPERIMENTAL|Group 1|APPS intervention will be implemented in Group 1 communities prior to implementation in Group 2 communities.
62819751|NCT02318732|ACTIVE_COMPARATOR|Group 2|APPS intervention will be implemented in Group 2 communities following implementation in Group 1 communities.
62819752|NCT03774654|EXPERIMENTAL|CD19.CAR-aNKT cells (cohort A, non-ALL)|This cohort is for patients without refractory/relapsed B-cell NHL or leukemia (ALL). Three dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.
62819753|NCT03774654|EXPERIMENTAL|CD19.CAR-aNKT cells (cohort B, ALL).|This cohort is for patients with refractory/relapsed B-cell NHL or leukemia (ALL). Three dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.
62849077|NCT05067218|EXPERIMENTAL|Conventinal anasthesia ( control )|"* The site of injection will be dried then topical anesthetic gel of 20% benzocaine (Dharma Ophal-S) will be applied. The duration of application of gel will be 1 minute.~* Local anesthetic solution will be delivered using a standard aspirating syringe with 27-gauge, 21 mm short needles."
62849078|NCT04302909|ACTIVE_COMPARATOR|Active Comparator|fESWT
62849079|NCT04302909|SHAM_COMPARATOR|Sham Comparator|Sham fESWT
62039745|NCT01928368|ACTIVE_COMPARATOR|Experimental Arm|
62039746|NCT01928368|PLACEBO_COMPARATOR|Placebo Arm|
62039747|NCT05121519|EXPERIMENTAL|Avoid|Patients will undergo this intervention for up to 6 months, or whenever their AF returns, whichever comes first.
62039748|NCT05121519|EXPERIMENTAL|Consume|Patients will undergo this intervention for up to 6 months, or whenever their AF returns, whichever comes first.
62039749|NCT02429765|ACTIVE_COMPARATOR|ACL/FOR|The evening dose of twice-daily dual bronchodilator medication will consist of aclidinium/formoterol 400/12mcg . After 2-weeks of treatment with twice-daily aclidinium/formoterol 400/12mcg, subjects will be randomized to receive an evening dose consisting of active drug or placebo.
62039750|NCT02429765|PLACEBO_COMPARATOR|Placebo|The evening dose of twice-daily dual bronchodilator medication will consist of a placebo inhaler. After 2-weeks of treatment with twice-daily aclidinium/formoterol 400/12mcg, subjects will be randomized to receive an evening dose consisting of active drug or placebo.
62039751|NCT06732557|SHAM_COMPARATOR|Group A: Control group (Traditional treament)|patients will receive traditional treatment (isometric exercise for deep neck flexors plus sub occipital release).
62039752|NCT06732557|EXPERIMENTAL|Group B (muscle energy technique group)|Patients will receive muscle energy Technique for upper trapezius, elevator scapulae and sternocleidomastoid
62039753|NCT06732557|ACTIVE_COMPARATOR|Group C (Mulligan Mobilization Group)|Patients will receive Mulligan mobilization
62039754|NCT02099474|EXPERIMENTAL|Raltegravir|All women have been prescribed raltegravir before study participation.
62039755|NCT05615415||NP-PASC (neuropsychiatric post-acute sequelae of SARS-CoV-2)|Individuals with new onset a) cognitive and/or b) psychiatric symptoms following SARS-CoV-2 infection. Participants will undergo PET/MR scanning, during which a TSPO PET tracer and a Gadolinium-based MRI tracer will be administered intravenously and blood samples will be collected from an arterial line. In addition, blood samples will be taken at screening. Participants can elect to provide an optional cerebrospinal fluid (CSF) sample.
62039756|NCT05615415||CC (COVID Control)|Individuals with a history of SARS-CoV-2 infection who do not meet the criteria for any DSM-5 diagnosis and perform within normal limits on cognitive tests. Participants will undergo PET/MR scanning, during which a TSPO PET tracer and a Gadolinium-based MRI tracer will be administered intravenously and blood samples will be collected from an arterial line. In addition, blood samples will be taken at screening. Participants can elect to provide an optional cerebrospinal fluid (CSF) sample.
62039757|NCT05395091|EXPERIMENTAL|AVT03|AVT03 is the proposed biosimilar for Prolia.
62039758|NCT05395091|ACTIVE_COMPARATOR|Prolia|
62039759|NCT03339674|EXPERIMENTAL|Intervention|Psychoeducational Group Intervention on Alcohol Drinking Related to Stress: Psychological group intervention with 3 sessions of 60 min (Odenwald \& Semrau, 2012). Contains psychoeducation on alcohol drinking related to stress and PTSD.
62039760|NCT03339674|ACTIVE_COMPARATOR|Control|Cognitive Training: Psychological group intervention with 3 sessions of 60 min. The content is paper-and-pencil based cognitive training of memory and attention functions.
62433893|NCT03083132|ACTIVE_COMPARATOR|Early-start|24 weeks of modafinil 50 mg oral daily
62433894|NCT03083132|PLACEBO_COMPARATOR|Delayed-start|12 weeks of oral placebo followed by 12 weeks of modafinil 50 mg oral daily
62039761|NCT05758337|EXPERIMENTAL|A group with exposure of vibropneumostimulation|The first group is a group of subjects on whom, after implantation, a new technique was applied, including the effect of vibropneumostimulation on the pereimplant tissues.
62039762|NCT05758337|NO_INTERVENTION|A group of standart therapy|The second is a group of subjects whose rehabilitation was carried out by the well-known classical method.
62039763|NCT02018393||Prophylaxis group|Prophylaxis with FEIBA is defined in this study as the regular infusion of FEIBA for the prevention of bleeding at a dose of ≥50 UF/kg on at least three non-consecutive days a week. Patients must have been on this modality for at least 6 months prior to the study visit
62433895|NCT05890326|NO_INTERVENTION|Control group|No intervention was applied to fibromyalgia patients in this group. This was because it was a control group that would evaluate the effects on outcomes by comparing them with other intervention (behavioral) groups.
62039764|NCT02018393||On demand group|On-demand Treatment is defined as the administration of FEIBA only to control bleeding. Patients must have been on this modality for at least 6 months prior to the study visit.
62039765|NCT05196464|OTHER|VA primary care patients|VA primary care patients with psychological distress are being enrolled
62039766|NCT05331170|ACTIVE_COMPARATOR|Healthy|Subjects without asthma, COPD, rhinitis and with negative allergen test
62039767|NCT05331170|ACTIVE_COMPARATOR|Allergic Rhinitis|Subjects without asthma, COPD and with positive allergen test
62039768|NCT05331170|ACTIVE_COMPARATOR|Allergic Ashthma|Subjects with asthma and positive allergen test
62433896|NCT05890326|EXPERIMENTAL|Motor imagery-based exercise protocol (MIEP)|Motor imagery-based exercise protocol (MIEP) applied in this group.
62433897|NCT05890326|EXPERIMENTAL|Pain neuroscience education (PNE)|Pain neuroscience education (PNE) applied in this group.
62433898|NCT05890326|ACTIVE_COMPARATOR|Combination Group|Both Pain neuroscience education (PNE) and Motor imagery-based exercise protocol (MIEP) applied in this group.
62433899|NCT02729194|EXPERIMENTAL|Pazopanib|Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal) approximately, some sample meals are described in appendix 1) every day in 14 day cycles, with a starting dose of 400 mg and adjusted for the next cycle (dose level +1:600 mg; dose level +2: 800 mg; dose level -1: 200 mg) based on toxicity assessment during or at the end of each cycle.
62433900|NCT04273672||Parkinson's Disease|Subjects with Parkinson's Disease
62433901|NCT04273672||Control|Subjects without Parkinson's Disease
62039769|NCT05227001|EXPERIMENTAL|PF-07852352 Influenza saRNA, low dose|
62039770|NCT05227001|EXPERIMENTAL|PF-07852352 Influenza saRNA, mid dose|
62039771|NCT05227001|EXPERIMENTAL|PF-07852352 Influenza saRNA, high dose|
62039772|NCT05227001|EXPERIMENTAL|PF-07836391 Influenza saRNA, low dose|
62039773|NCT05227001|EXPERIMENTAL|PF-07836391 Influenza saRNA, mid dose|
62039774|NCT05227001|EXPERIMENTAL|PF-07836391 Influenza saRNA, high dose|
62600198|NCT01011166|EXPERIMENTAL|IDX184 100 mg BID + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 100 mg or placebo twice daily (BID) in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV alone on Days 14-28.
62600199|NCT01011166|EXPERIMENTAL|IDX184 150 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 150 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
62600200|NCT01011166|EXPERIMENTAL|IDX184 200 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 100 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
62600201|NCT01011166|EXPERIMENTAL|IDX184 200 mg BID + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 200 mg or placebo BID in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
62600202|NCT06011161|EXPERIMENTAL|Brief Relationship Checkup|Couples in the experimental condition will participate in three joint sessions of the Brief Relationship Checkup (BRC; Cordova 2014; Cigrang et al., 2016). This program has been tested in Air Force Primary Care but we do not know if veterans with mental health concerns will be able to attend it (feasibility), complete it safely (tolerability), and enjoy it (acceptability).
62600203|NCT04658524||Chonic kidney disease stages 3, 4 and 5|Patients with stage chronic kidney disease stages 3, 4 and 5. CKD stages were defined according to the Kidney Disease Improving Global Outcomes directives (KDIGO): a) stage 3A: eGFR 45 and 59 ml/min/1.73m2; b) stage 3B: eGFR between 30 and 44 ml/min/1.73m2; c) stage 4: eGFR between 15 and 29 ml/min/1.73 m2
62600204|NCT02317770|ACTIVE_COMPARATOR|Lidocaine Spray|20 puffs of 10% Lidocaine spray
62819754|NCT06246292|EXPERIMENTAL|landmark guided ESPB technique|The ESPB was performed using the landmarks described by Vadera et al. (5). Before initiating the block procedure, the spinous process of the T4 vertebra and a point situated 3 cm to its side are marked at the appropriate level. The needle was inserted perpendicularly to the skin and advanced in all planes until it contacts the vertebra's transverse process. The depth at which the thoracic vertebra's transverse process lies from the skin can vary, ranging from 2 to 4 cm, contingent upon the individual's physique. The needle tip was positioned between the erector spinae muscle and the transverse process. The volume of local anesthetics was injected in this plane.
62600205|NCT02317770|ACTIVE_COMPARATOR|Nebulized Lidocaine|2.5 mL of 10% Lidocaine
62600206|NCT02750475|EXPERIMENTAL|Arm 1|All subjects are patched.
62600207|NCT06142175||Relmacabtagene Autoleucel|Relmacabtagene Autoleucel administered as a single IV infusion at a target dose of 1 x 10\^8 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells on Day1.
62039775|NCT05227001|EXPERIMENTAL|PF-07836394 Influenza saRNA, low dose|
62039776|NCT05227001|EXPERIMENTAL|PF-07836394 Influenza saRNA, mid dose|
62600208|NCT02033070||Non-Dysplastic IM, LGD, HGD|
62600209|NCT06485349|EXPERIMENTAL|Experimental|Olive Leaf Extract (OLE) Nutricost ® 750mg 20% oleuropein with 250ml of water.
62600210|NCT06485349|PLACEBO_COMPARATOR|Placebo|100mg cellulose with 250ml of water.
62623811|NCT02711566|ACTIVE_COMPARATOR|Sensorimotor training|"Patients in this arm were assigned to the 'Physioassistant: Haptic training' intervention. The treatments were delivered through a planar robotic manipulandum, specifically designed for motor learning studies and robot-assisted rehabilitation.~All participating centers used the exact same apparatus and experimental set-up."
62819755|NCT06246292|ACTIVE_COMPARATOR|ultrasound-guided ESPB technique|The block was performed based on the original description by Forero et al. (2). A high-frequency linear transducer (MyLab 70 Xvision, Esaote SpA, Florence, Italy) was positioned in the parasagittal plane 2 cm lateral to the T4 vertebra. Once the transverse process and the overlying erector spinae muscle were visible on the ultrasound, the needle was introduced using the in-plane technique. The needle was inserted in the cranial-to-caudal direction until it reached the tip of the transverse process. Following a negative aspiration and a successful hydro dissection, the local anesthetic solution was injected beneath the erector spinae muscle's fascia.
62819756|NCT06590623|EXPERIMENTAL|exogenous ketone supplement|Participants will consume a ketone monoester supplement (KetoneAid KE4) at a dose of 0.75 g/kg of body weight.
62819757|NCT04445753|EXPERIMENTAL|Tai Chi program|Individuals in the intervention group will perform a 12-week Tai Chi exercise in company with a researcher.Following the warm-up movements (Qi-gong), the training protocol of the Tai Chi movements, which includes the 10-form Yang style, will continue for 12 weeks, with two sessions per week determined by the researchers.The first and second weeks of the exercise protocol will include introducing the Tai Chi philosophy and teaching 10 forms of Yang style to patients. For 12 weeks, individuals will practice 10 forms of Tai Chi exercises with a researcher in each session. Each session will be planned as one hour.
62039777|NCT05227001|EXPERIMENTAL|PF-07836394 Influenza saRNA, high dose|
62243521|NCT03876314|NO_INTERVENTION|Usual Care Control (UCC)|Participants in the usual care control will maintain their normal health practices for 1 year. Participants will receive a bi-weekly health newsletter and will be contacted bi-weekly to answer any questions and inquire about the participant's health. Participants self-reported physical activity will be assessed monthly. In this fashion, participants will be contacted by staff every week. Usual care control participants that complete all study related activities including pre-, mid-, and post-test will receive a short-term YMCA membership after post-test.
62243522|NCT03999658|EXPERIMENTAL|Extranodal NK/T-cell lymphoma (ENKTL)|Intravenous STI-3031 (anti-PD-L1 antibody)
62243523|NCT03999658|EXPERIMENTAL|Peripheral T-cell lymphomas (PTCL)|Intravenous STI-3031 (anti-PD-L1 antibody)
62819758|NCT04445753|OTHER|Control group|Individuals in the control group will be trained on heart failure. The only attempt to be made to the control group will be education.
62819759|NCT03415321|EXPERIMENTAL|Intervention group|Postpartum Mobile Support Application
62819760|NCT03415321|NO_INTERVENTION|Control Group|Routine care
62819761|NCT05015426|EXPERIMENTAL|Dose Level -1|"Dose Level -1 may be used as a de-escalation dose level due to Dose Limiting Toxicities (DLTs) from Dose Level 1~Participants will receive 1.0 x 106 cells/kg (0.75-1.25 x 106 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion"
62243524|NCT03999658|EXPERIMENTAL|Diffuse large B-cell lymphoma (DLBCL)|Intravenous STI-3031 (anti-PD-L1 antibody)
62243525|NCT03999658|EXPERIMENTAL|Biliary tract cancers (BTC)|Intravenous STI-3031 (anti-PD-L1 antibody)
62819762|NCT05015426|EXPERIMENTAL|Dose Level 1|Participants will receive 5.0 x 106 cells/kg (3.75-6.25 x 106 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion
62039778|NCT05227001|EXPERIMENTAL|PF-07836395 Influenza saRNA, low dose|
62039779|NCT05227001|EXPERIMENTAL|PF-07836395 Influenza saRNA, mid dose|
62039780|NCT05227001|EXPERIMENTAL|PF-07836395 Influenza saRNA, high dose|
62433902|NCT00299728|EXPERIMENTAL|Arm A; 100 μg NY-ESO-1 protein co-mixed with CpG 7909 and Montanide ISA-51 VG|100 μg NY-ESO-1 protein co-mixed with 2.5 mg CpG 7909 and 1.25 mL Montanide ISA-51 VG. The vaccine was administered subcutaneously every 3 weeks for a total of 4 doses (study weeks 1, 4, 7 and 10).
62433903|NCT00299728|EXPERIMENTAL|Arm B; 400 μg NY-ESO-1 protein co-mixed with CpG 7909 and Montanide ISA-51 VG|400 μg NY-ESO-1 protein co-mixed with 2.5 mg CpG 7909 and 1.25 mL Montanide ISA-51 VG. The vaccine was administered subcutaneously every 3 weeks for a total of 4 doses (study weeks 1, 4, 7 and 10).
62039781|NCT05227001|EXPERIMENTAL|PF-07836396 Influenza saRNA, low dose|
62039782|NCT05227001|EXPERIMENTAL|PF-07836396 Influenza saRNA, mid dose|
62039783|NCT05227001|EXPERIMENTAL|PF-07836396 Influenza saRNA, high dose|
62039784|NCT05227001|EXPERIMENTAL|PF-07867246 Influenza saRNA, mid dose|
62039785|NCT05227001|EXPERIMENTAL|PF-07867246 Influenza saRNA, low dose|
62039786|NCT05227001|EXPERIMENTAL|PF-07867246 Influenza saRNA, high dose|
62039787|NCT05227001|PLACEBO_COMPARATOR|Placebo|
62243526|NCT04971785|EXPERIMENTAL|SEMA + CILO/FIR FDC|Participants will receive semaglutide (SEMA) 0.24-2.4 mg once weekly (dose escalation every 4 weeks) and fixed-dose combination (FDC) of cilofexor and firsocostat (CILO/FIR 30 mg/20 mg) once daily for 72 weeks
62243527|NCT04971785|EXPERIMENTAL|SEMA + Placebo-To-Match (PTM) CILO/FIR|Participants will receive SEMA 0.24-2.4 mg once weekly (dose escalation every 4 weeks) and PTM CILO/FIR administered once daily for 72 weeks
62243528|NCT04971785|EXPERIMENTAL|PTM SEMA + CILO/FIR FDC|PTM Semaglutide once weekly and CILO/FIR 30 mg/20 mg FDC administered once daily for 72 weeks
62039788|NCT05227001|ACTIVE_COMPARATOR|Quadrivalent influenza vaccine (QIV)|
62243529|NCT04971785|PLACEBO_COMPARATOR|PTM SEMA + PTM CILO/FIR|PTM Semaglutide once weekly and PTM CILO/FIR once daily for 72 weeks
62433904|NCT02103647|ACTIVE_COMPARATOR|Immediate release capsule(lyrica capsule 150mg)|Immediate release capsule repeat treatment for 3days under fasted condition
62433905|NCT02103647|EXPERIMENTAL|sustained release tablet|sustained release tablet repeat treatment for 3days under fasted condition
62819763|NCT05015426|EXPERIMENTAL|Dose Level 2|Participants will receive 2.5 x 107 cells/kg (1.875-3.125 x 107 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion
62819764|NCT05015426|EXPERIMENTAL|Dose Level 3|Participants will receive 1.0 x 108 cells/kg (0.75-1.25 x 108 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion
62819765|NCT05015426|EXPERIMENTAL|Treatment at Maximum Tolerated Dose|Participants will receive Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells at the dose determined to be the Maximum Tolerated Dose, administered as a single infusion
62819766|NCT04448886|EXPERIMENTAL|Sacituzumab Govitecan + Pembrolizumab|"The research study procedures include: screening for eligibility, research blood collections, at least two research biopsies, paired research stool collections, and study treatment including evaluations and follow up visits. Each Cycle =21 Days~* Sacituzumab Govitecan (iv) fixed dose, administered twice per cycle~* Pembrolizumab (iv) fixed dose administered once per cycle"
62819767|NCT04448886|EXPERIMENTAL|Sacituzumab Govitecan|"The research study procedures include: screening for eligibility, research blood collections, at least two research biopsies, paired research stool collections, and study treatment including evaluations and follow up visits.~- Sacituzumab Govitecan (iv) fixed dose, administered twice per cycle"
62819768|NCT04448886|EXPERIMENTAL|Retreatment|Participants who have attained a confirmed complete response (CR) who have been treated for at least 24 weeks on protocol therapy and had at least three cycles (with pembrolizumab and sacituzumab govitecan (Arm A) or sacituzumab govitecan alone (Arm B)) beyond the date when the initial CR was declared may be eligible for additional sacituzumab govitecan and/or pembrolizumab therapy if they progress after stopping study treatment. This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the subject meets protocol-specified conditions.
62819769|NCT06604221|EXPERIMENTAL|Resistance Exercise Intervention Group|Resistance exercise intervention plan, developed through expert meetings and integrated review summaries, consists of 27 items including: participant preparation, team preparation, exercise prescription FITT-VP, process monitoring, discontinuation criteria, termination criteria, recovery methods, outcome measures, and special considerations.
62819770|NCT06604221|ACTIVE_COMPARATOR|control group|Routine care
62819771|NCT05578846|EXPERIMENTAL|Treatment sequence ABC|Participants will be administered Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions), Treatment B (single Dose A of ALXN2050 tablet under fasted conditions) and Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal) on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
62039789|NCT05227001|EXPERIMENTAL|PF-07871987 Influenza saRNA, low dose|
62039790|NCT05227001|EXPERIMENTAL|PF-07871987 Influenza saRNA, mid dose|
62243530|NCT04642599|EXPERIMENTAL|Chronic Cerebellar Stroke|Participants with a chronic cerebellar stroke
62433906|NCT02199652|PLACEBO_COMPARATOR|placebo|placebo pill
62819772|NCT05578846|EXPERIMENTAL|Treatment sequence ACB|Participants will be administered Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions), Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal) and Treatment B (single Dose A of ALXN2050 tablet under fasted conditions) on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
62819773|NCT05578846|EXPERIMENTAL|Treatment sequence BAC|Participants will be administered Treatment B (single Dose A of ALXN2050 tablet under fasted conditions), Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions) and Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal) and on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
62819774|NCT05578846|EXPERIMENTAL|Treatment sequence BCA|Participants will be administered Treatment B (single Dose A of ALXN2050 tablet under fasted conditions), Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal) and Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions) and on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
62849080|NCT03396952|EXPERIMENTAL|Treatment (pembrolizumab, ipilimumab, aspirin)|Patients receive pembrolizumab IV over 30 minutes on day 1, ipilimumab IV over 60 minutes on day 1 for courses 1-4, and aspirin PO BID (orally, twice a day) on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62039791|NCT05227001|EXPERIMENTAL|PF-07871987 Influenza saRNA, high dose|
62039792|NCT05227001|EXPERIMENTAL|PF-07914705 Influenza saRNA mid dose|
62039793|NCT05227001|EXPERIMENTAL|PF-07914705 Influenza saRNA, high dose|
62039794|NCT05227001|EXPERIMENTAL|PF-07915048 Influenza saRNA, high dose|
62039795|NCT01398150|PLACEBO_COMPARATOR|Sweetened Beverage|looks like and is given in the same way as the experimental treatment but contains no active ingredient
62039796|NCT01398150|EXPERIMENTAL|Cranberry Beverage|15 ounce bottle of cranberry beverage consumed daily for 70 days
62039797|NCT02145546|EXPERIMENTAL|Amiodarone|Patient will take Amiodarone orally
62039798|NCT02145546|EXPERIMENTAL|Sotalol|Patients will take sotalol orally
62039799|NCT02145546|EXPERIMENTAL|Propafenone|Patients will take propafenone orally
62243531|NCT04642599|ACTIVE_COMPARATOR|Healthy Individuals (Controls)|healthy participants
62243532|NCT06736431|EXPERIMENTAL|Text-based platform|Text-based resource referral platform with diabetes educational materials
62433907|NCT02199652|EXPERIMENTAL|prazosin|prazosin pill
62433908|NCT01718054|ACTIVE_COMPARATOR|vascular|In this intervention period children will receive a vascular ready-to-use supplementary food with added L-Arginine \& L-Citrulline plus daily chloroquine
62433909|NCT01718054|ACTIVE_COMPARATOR|regular|In this intervention period children will receive a regular ready-to-use supplementary food plus weekly dose of chloroquine
62600211|NCT04980651|ACTIVE_COMPARATOR|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
62243533|NCT01481623|OTHER|Gene identification and phenotyping|Identification of patients (probands), questionnaire and informed consent of patients and their families, biological sampling, DNA and RNA extraction, genetic study for gene identification, re-contact of family members and relatives (with consent) for metabolic study of mutation carriers, and complementary studies of homozygous patients in some cases
62243534|NCT05120856|EXPERIMENTAL|Active AAT-App|Participants will receive the active AAT-App.
62243535|NCT05120856|SHAM_COMPARATOR|Minimal AAT-App|Participants will receive the minimal version of AAT-App.
62039800|NCT02145546|NO_INTERVENTION|Control|Patients will take no antiarrhythmic drugs except β-blocker
62039801|NCT05358821|EXPERIMENTAL|SAGE-718|Participants will receive SAGE-718 1.2 mg softgel lipid capsule orally once daily in the morning for up to 28 days.
62039802|NCT05358821|PLACEBO_COMPARATOR|Placebo|Participants will receive SAGE-718-matching placebo capsule orally once daily in the morning for up to 28 days.
62243536|NCT05131581|NO_INTERVENTION|Group 1|Standard care for cervical screening test (CST) at the midwifery clinic (control group)
62243537|NCT05131581|EXPERIMENTAL|Group 2|Standard care for CST at the youth clinic (intervention group 1)
62243538|NCT05131581|EXPERIMENTAL|Group 3|Standard care for CST at the youth clinic with extra time allotted (intervention group 2)
62600212|NCT04980651|PLACEBO_COMPARATOR|Sham RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
62600213|NCT00793546|EXPERIMENTAL|1|combination of bosutinib and exemestane
62819775|NCT05578846|EXPERIMENTAL|Treatment sequence CAB|Participants will be administered Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal), Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions) and Treatment B (single Dose A of ALXN2050 tablet under fasted conditions) on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
62039803|NCT04262518|OTHER|Outcomes4Me App Users|This cohort will download and use the Outcomes4Me mobile app for breast cancer.
62039804|NCT03494387|EXPERIMENTAL|1|
62039805|NCT03494387|EXPERIMENTAL|2|
62039806|NCT04817449||Suspected Ovarian Cancer|Patients referred or self presenting to secondary care with signs or symptoms of ovarian cancer.
62039807|NCT06614127||Continuous glucose monitoring site: upper arm|Adult, non-cardiothoracic surgical patients with Dexcom G7® sensor placed in upper arm over the deltoid
62039808|NCT06614127||Continuous glucose monitoring site: anterior thigh|Adult, non-cardiothoracic surgical patients with Dexcom G7® sensor placed on the anterior aspect of the thigh
62243539|NCT05131581|EXPERIMENTAL|Group 4|Standard care for CST at the youth clinic with extra time allotted and the RLP-information (intervention group 3)
62243540|NCT04235023|OTHER|OSA patients|30 patients investigated for suspected OSA with an apnea hypopnea index ≥ 15 per hour
62243541|NCT04235023|OTHER|non OSA patients|30 patients investigated for suspected OSA with an apnea hypopnea index \< 15 per hour
62243542|NCT06579092|EXPERIMENTAL|Arm 1|Active IMP
62243543|NCT06579092|EXPERIMENTAL|Arm 2|Active IMP
62243544|NCT06579092|EXPERIMENTAL|Arm 3|Active IMP
62243545|NCT06579092|EXPERIMENTAL|Arm 4|Active IMP
62243546|NCT06579092|EXPERIMENTAL|Arm 5|Active IMP
62243547|NCT06579092|PLACEBO_COMPARATOR|Arm 6|Matching placebo for each of the 5 active arms
62243548|NCT06558227|EXPERIMENTAL|Group A|ZG005 10 mg/kg administered intravenously every 3 weeks (Q3w) + Bevacizumab (Avastin®) 15 mg/kg administered intravenously Q3w
62243549|NCT06558227|EXPERIMENTAL|Group B|ZG005 20 mg/kg administered intravenously Q3w + Bevacizumab (Avastin®) 15 mg/kg administered intravenously Q3w
62600214|NCT00793546|ACTIVE_COMPARATOR|2|exemestane
62600215|NCT01783600|OTHER|NanoCross .014 balloon catheter|NanoCross .014 balloon catheter
62600216|NCT05085106|EXPERIMENTAL|Test group|"Group Ⅰ, give the felbinac trometamol eye drops, 0.025%，1 drop，once. Group Ⅱ, give the felbinac trometamol eye drops, 0.05%，1 drop，once. Group Ⅲ, give the felbinac trometamol eye drops, 0.1%，1 drop，once. Group Ⅳ, give the felbinac trometamol eye drops, 0.2%，1 drop，once. Group Ⅴ, give the felbinac trometamol eye drops, 0.3%，1 drop，once. Multiple Group I, give the felbinac trometamol eye drops, 0.1%，1 drop per time，four times each day, for seven days totally.~Multiple Group II, give the felbinac trometamol eye drops, 0.2%，1 drop per time，four times each day, for seven days totally."
62600217|NCT05085106|PLACEBO_COMPARATOR|Placebo group|"Group Ⅰ, give the placebo eye drops, 0.0%，1 drop，once. Group Ⅱ, give the placebo eye drops, 0.0%，1 drop，once. Group Ⅲ, give the placebo eye drops, 0.0%，1 drop，once. Group Ⅳ, give the placebo eye drops, 0.0%，1 drop，once. Group Ⅴ, give the placebo eye drops, 0.0%，1 drop，once. Multiple Group I, give the placebo eye drops, 0.0%, 1 drop per time, four times each day, for seven days totally.~Multiple Group II, give the placebo eye drops, 0.0%, 1 drop per time, four times each day, for seven days totally."
62819776|NCT05578846|EXPERIMENTAL|Treatment sequence CBA|Participants will be administered Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal), Treatment B (single Dose A of ALXN2050 tablet under fasted conditions) and Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions) on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
62243550|NCT06558227|EXPERIMENTAL|Group C|Sintilimab 200 mg administered intravenously Q3w + Bevacizumab (达攸同®) 15 mg/kg administered intravenously Q3w
62243551|NCT05236114||Cohort 1|Cohort 1 will include patients with early-stage (Stages I-IIIB) who are candidates for treatment with curative intent, surgery with or without perioperative (neoadjuvant or adjuvant) therapy.
62243552|NCT05236114||Cohort 2|Cohort 2 will include patients with stage IV disease receiving first line immunotherapy (as monotherapy or in combination with chemotherapy).
62433910|NCT02893852|ACTIVE_COMPARATOR|standard CO-OP Approach|Task oriented and client-centred intervention with 12 sessions (10 interventional and 2 assessment sessions) with children and parents.
62433911|NCT02893852|EXPERIMENTAL|standard CO-OP Approach plus coaching parents|"Task oriented and client-centred intervention with 12 sessions (10 interventional and 2 assessment sessions) with children and parents with a boost of 4 group sessions of coaching for parents in groups."
62433912|NCT04264299|ACTIVE_COMPARATOR|T tube drainage|Closure of common bile duct after choledocholithotomy over T tube
62433913|NCT04264299|EXPERIMENTAL|Primary closure|Primary closure of the common bile duct after choledocholithotomy
62433914|NCT04264299|EXPERIMENTAL|Antegrade stenting|Closure of common bile duct over antegrade biliary plastic stent
62433915|NCT06527729|ACTIVE_COMPARATOR|Group 1|Topical 5% minoxidil gel was applied twice daily for a period of 8 weeks.
62433916|NCT06527729|EXPERIMENTAL|Group 2|Topical 1% sildenafil-loaded liposomes was applied twice daily for a period of 8 weeks.
62433917|NCT01880099|PLACEBO_COMPARATOR|placebo|Placebo (sugar Pill) will be given daily for 7 weeks.
62433918|NCT01880099|ACTIVE_COMPARATOR|galantamine 8mg|Galantamine extended release (8mg) will be given daily for 7 weeks.
62433919|NCT01880099|ACTIVE_COMPARATOR|Galantamine 16mg|Galantamine extended release (16mg) will be given daily for 5 weeks starting at week 3 after a two week titration with 8mg galantamine.
62433920|NCT00176683||All comers|capnography used for all consenting subjects
62433921|NCT04166669|EXPERIMENTAL|Cohort 1|Drugs: APX001, itraconazole
62433922|NCT04166669|EXPERIMENTAL|Cohort 2|Drugs: APX001, rifampin
62433923|NCT01313000||Autologous fat transfer|
62433924|NCT01473758|ACTIVE_COMPARATOR|Roflumilast|added on to standard therapy for acute COPD exacerbations
62819777|NCT05786625||Microwave ablation|Patients with a single or multiple soft tissue lung lesions that is medically inoperable or for which the patient has declined surgical resection.
62243553|NCT05905575|EXPERIMENTAL|Intervention|Patient-family member dyads in the family dyad intervention arm will receive 1) 10 sessions (8 weekly and 2 biweekly) over 12 weeks of family-dyad-focused, virtual group sessions on diabetes self-management and family support; 2) family dyad-focused support component in each group session; and 3) individual family feedback telephone sessions.
62433925|NCT01473758|PLACEBO_COMPARATOR|Placebo|added on to standard therapy for acute COPD exacerbations
62433926|NCT05339828||unroofing curettage|Surgery was performed with the patient lying in the prone position under local anesthesia. Next, a local anesthetic agent comprising a solution of lidocaine (20 mg/mL) and adrenaline (0.0125 mg/mL) was diluted with distilled water in a 1:2 ratio and applied. The tract was identified by passing small artery forceps along its length and was then opened by cutting directly down onto the forceps. The sinus and all its tracts were completely unroofed, and the base was curetted to remove all necrotic content, hair, and granulation tissue using a dry gauze. The fibrotic back wall was left as intact as possible to avoid delayed healing.
62433927|NCT02015923|EXPERIMENTAL|colonic resection|Arm A (experimental): surgery (complete tumoral resection; R0) followed by chemotherapy, regimen according to each center.
62433928|NCT02015923|ACTIVE_COMPARATOR|Chemotherapy|Arm B (control): chemotherapy alone, regimen according to each center
62433929|NCT02746458|NO_INTERVENTION|Standard of Care Physical Therapy|This group will receive the standard of care physical therapy program for 6 weeks.
62433930|NCT02746458|EXPERIMENTAL|Blood Flow Restriction Plus Standard of Care Physical Therapy|This group will receive the same standard of care physical therapy program for 6 weeks plus blood flow restriction.
62433931|NCT01840475||Botulinum toxin type A (BoNT-A) injection (Dysport®) Naïve|Subjects naïve to BoNT-A treatment.
62433932|NCT01840475||Botulinum toxin type A (BoNT-A) Pre-treated|"Subjects pre-treated with BoNT-A.~Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics \[SmPC\])."
62433933|NCT05296122|EXPERIMENTAL|Single arm|MR-Guided Laser Thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG ® Thermoguide Workstation.
62433934|NCT01386879|EXPERIMENTAL|TaperGuard Evac ETT|Trachea will be intubated with Mallinckrodt™TaperGuard™ Evac Endotracheal Tube with a suction port to facilitate removal of secretions from the region of the trachea below the vocal cords and above the inflated ETT cuff
62243554|NCT05905575|NO_INTERVENTION|Control|All control participants will receive usual care from their primary healthcare provider. A condensed family dyad diabetes intervention will be delivered to the control participants by the end of the study.
62243555|NCT05883540|EXPERIMENTAL|treatment arm|Subjects in the treatment arm will receive 100 μg LSD (first session) and 100 or 200 μg LSD (second session) per os.
62243556|NCT05883540|ACTIVE_COMPARATOR|control arm|Subjects in the control arm will receive 25 μg LSD (first session) and 25 μg LSD (second session) per os.
62243557|NCT05879913|EXPERIMENTAL|CCTA Group|
62243558|NCT05879913|NO_INTERVENTION|Usual Care Group|
62243559|NCT06735248|EXPERIMENTAL|mRNA-1195 Dose Level 1 (Low Dose)|Participants will receive 3 intramuscular (IM) injections at dose level 1 (low dose) on a 0-, 2-, and 6-month schedule.
62243560|NCT06735248|EXPERIMENTAL|mRNA-1195 Dose Level 2 (High Dose)|Participants will receive 3 IM injections at dose level 2 (high dose) on a 0-, 2-, and 6-month schedule.
62039809|NCT06388694|EXPERIMENTAL|Pharmacist Care|Pharmacists will provide ADHD medication refill orders in response to secure message requests by parents, under the authorization of appropriate physicians.
62039810|NCT06388694|ACTIVE_COMPARATOR|Primary Care Physician Care|Primary care pediatricians will provide ADHD medication refill orders in response to secure message requests by parents.
62243561|NCT06735248|PLACEBO_COMPARATOR|Placebo|Participants will receive 3 placebo IM injections on a 0-, 2-, and 6-month schedule.
62433935|NCT01386879|EXPERIMENTAL|Teleflex ISIS ETT|Trachea will be intubated with Teleflex ISIS HVT Cuffed Tracheal Tube with Subglottic Secretion suction port to facilitate removal of secretions from the region of the trachea below the vocal cords and above the inflated ETT cuff
62600218|NCT06184113|EXPERIMENTAL|Intervention Arm|Patients randomised to the intervention arm will receive an open-label dose adjusted apixaban twice a day. The treatment will be continued for three months. After the tree-month treatment period apixaban will be stopped and acetylsalicylic acid will be started.
62819778|NCT03512821|EXPERIMENTAL|Ursodiol 500mg tablets|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
62819779|NCT03512821|ACTIVE_COMPARATOR|Urso Forte 500mg tablets|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
62819780|NCT03909152|EXPERIMENTAL|PR+ Granulosa cell tumor (This Arm is CLOSED)|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days. This Arm is CLOSED.
62819781|NCT03909152|EXPERIMENTAL|PR+ Low grade serous ovarian cancer|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days
62819782|NCT03909152|EXPERIMENTAL|PR+ Endometrioid endometrial cancer|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days
62819783|NCT03909152|EXPERIMENTAL|PR+ Granulosa cell ovarian cancer|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart and anastrozole 1mg po QD in AM beginning Day 1 of Cycle 1. A Cycle is 28 days.
62433936|NCT01386879|ACTIVE_COMPARATOR|Standard ETT|Control group of patients will be intubated with a standard ETT without a suction port above the cuff (The Mallinckrodt Intermediate Hi-Lo Endotracheal Tube)
62039811|NCT05814913|EXPERIMENTAL|CaCBT for psychosis|CaCBT is a culturally adapted psychosocial intervention for people with early psychosis that comprises of 12 sessions. These sessions are conducted individually on a weekly basis and last 45-60 minutes
62039812|NCT05814913|EXPERIMENTAL|CulFI Intervention|CulFI is a culturally adapted psychosocial intervention delivered over 10 sessions of 40-60 minutes, weekly for the first 8 weeks and fortnightly for the remaining 4 weeks. Sessions are delivered to patients and their carers, though patient participation in sessions is not necessary.
62039813|NCT05814913|NO_INTERVENTION|Treatment as Usual (TAU)|TAU will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of TAU delivered to each participant over a period of 3 months.
62600219|NCT06184113|ACTIVE_COMPARATOR|Control Arm|Patients assigned to the control arm will receive an open-label low dose acetylsalicylic acid indefinitely.
62600220|NCT04658706|SHAM_COMPARATOR|Control|a physical activity prescription to be performed autonomously
62600221|NCT04658706|EXPERIMENTAL|Prehabilitation|They will receive a supervised exercise programat least 2 weeks before starting the conventional chemoradiotherapy treatment and concomitant
62819784|NCT06311838|EXPERIMENTAL|Motivational Interviewing/Community Reinforcement Approach + Services as Usual (MI/CRA + SAU)|"The current evidence base recommends integrating treatments targeting both Substance Use Disorder and psychiatric disorders, especially combining Motivational Interviewing with behavioral interventions such as CRA or Cognitive Behaviorial Therapy.~Enhancing intrinsic motivation for behavioral change is the central purpose of motivational interviewing (MI), a clinical method built on the insights and strategies described by Carl Rogers as client-centered therapy. MI is also directive, however, in selectively eliciting and reinforcing client change talk. Typically offered as a brief intervention of 1-2 sessions, MI has a strong record of efficacy in the treatment of alcohol and other drug use disorders, mental health and other problematic behaviors.~The Community Reinforcement Approach (CRA) offers an empirically-based multifaceted approach to substance abuse/mental health treatment that also addresses many of the clinical needs of multi-problem homeless individuals."
62819785|NCT06311838|EXPERIMENTAL|Strengths-Based Outreach and Advocacy + Services As Usual (SBOA +SAU)|"Some research suggests that engagement with an advocate is key to success when linking those experiencing homelessness to available services and supports in the community. The strengths model is based on the premise that the purpose of advocacy is to assist consumers in identifying, securing, and preserving the range of resources, both external and internal, needed to live in a normal, independent way in the community. Strengths-based interventions focus on enhancing well-being and happiness rather than attempting to correct deficits or pathology. The advocate takes responsibility for securing needed services for the youth and remains a support as they traverse the system of care. The focus of the first several weeks of advocacy is on obtaining identification and ensuring basic needs are met (food, safety, medical care, housing, etc.). As basic needs are addressed, youth and advocates focus on other high need areas including education, employment, mental health and substance use."
62061592|NCT03012061|EXPERIMENTAL|UMEC 62.5 mcg|Subjects will be administered UMEC 62.5 mcg once daily via the ELLIPTA dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks.
62061593|NCT03012061|EXPERIMENTAL|UMEC 31.25 mcg|Subjects will be administered UMEC 31.25 mcg once daily via the ELLIPTA dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks.
62600222|NCT04658706|EXPERIMENTAL|Rehabilitation|They will receive a supervised exercise programat 12 weeks after the first radiotherapy session, once standard treatment has finished
62061594|NCT03828396||High risk (positive)|Colorectal cancer and advanced adenoma
62061595|NCT03828396||Low risk (Negative)|Healthy people and other colorectal diseases
62061596|NCT06147518|ACTIVE_COMPARATOR|Metformin with Sitagliptin|Metformin: 1.5g/d CTPA,1g/d CTPB Sitagliptin: Assess HbA1c/HBSG at 8 weeks, increase sitagliptin to 100 mg if HbA1c\>7%
62600223|NCT03594019|PLACEBO_COMPARATOR|Control Group|Patients in the control group will follow the conventional treatment protocol combined with connective tissue graft. Briefly, hopeless tooth will be extracted atraumatically. Implant will be placed in the palatal side and grafting materials will be filled in the buccal gap. Then, connective tissue graft will be harvest from palatal and fixed between bucall mocosa and bucall bone. Healing abutment will placed and collegan sponge will be used to seal the wound. After 4 months, implant impression and crown delivery will be finished.
62600224|NCT03594019|EXPERIMENTAL|Test Group|Patients in the test group will receive conventional immediate implant placement combined with socket shield technique. Briefly, the hopeless teeth will be splited from mesial and distal, the buccal part will be preseved and the palatal part will extracted. Implant will be placed in the palatal side and grafting materials will be filled in the buccal gap. After 4 months, implant impression and crown delivery will be finished.
62600225|NCT01329926||Neural stem cells|
62600226|NCT06648460|OTHER|Effort-based decision-making|Participants perform a virtual-reality-based task in which they expend effort to receive virtual rewards.
62600227|NCT03375879|ACTIVE_COMPARATOR|Bandage contact lens|Placing a bandage contact lens in one eye.
62600228|NCT03375879|NO_INTERVENTION|Sham contact lens (immediate removal)|Sham contact lens will be placed on other eye, placing it and immediately removing it so patient does not know which eye will have a bandage contact lens.
62600229|NCT00721344|EXPERIMENTAL|1|
62600230|NCT00721344|EXPERIMENTAL|2|
62600231|NCT00721344|EXPERIMENTAL|3|
62600232|NCT00721344|EXPERIMENTAL|4|
62600233|NCT02474589|ACTIVE_COMPARATOR|Active|600 mg tecovirimat capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
62600234|NCT02474589|PLACEBO_COMPARATOR|Placebo|matching placebo capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
62600235|NCT01897662|EXPERIMENTAL|NUTRIOSE|Group of volunteers fed with NUTRIOSE
62600236|NCT01897662|ACTIVE_COMPARATOR|GLUCIDEX|Group of volunteers fed with GLUCIDEX
62600237|NCT02140528|EXPERIMENTAL|Mesenchymal stem cell receipients|Transplantation of allogenic adipose derived mesenchymal stem cells in patients with tibial fracture.
62600238|NCT02140528|PLACEBO_COMPARATOR|Placebo|Placebo injection in the site of fracture in patients with tibia fracture.
62600239|NCT03871738|EXPERIMENTAL|Proprioception training|The subjects included in the experimental group will carry out a protocol of proprioception exercises. Each session will last 25 minutes, taking place during 2 sessions a week, in a period of 4 weeks. All interventions will be made before the training session.
62819786|NCT06311838|EXPERIMENTAL|Motivational Interviewing/Community Reinforcement Approach (MI/CRA) + SBOA + SAU|This intervention combines all three interventional models: Motivational Interviewing/Community Reinforcement Approach along with Strengths-Based Outreach and Advocacy and the Services as Usual.
62819787|NCT06311838|ACTIVE_COMPARATOR|Services as Usual (SAU)|All youth will receive services as usual provided by the drop-in center.
62819788|NCT02157532|ACTIVE_COMPARATOR|Best standard treatment|intravenous r-tPA or any other medical management
62819789|NCT02157532|ACTIVE_COMPARATOR|Mechanical thrombectomy|Endovascular mechanical thrombectomy with stent-retrievers
62819790|NCT06513845|EXPERIMENTAL|Musicians group|Musicians will listen to segments (\~30 sec duration) of recordings taken from the music made during the previous drum circle and answer a survey asking how connected they felt while listening.Segments will be categorized as highly synchronized or not synchronized.
62600240|NCT03871738|NO_INTERVENTION|Control|The subjects included in the control group will not receive intervention and will continue to carry out their daily life in the same way as they have done up to now.
62600241|NCT00005711|NO_INTERVENTION|Usual care|Control group children received routine medical care by their primary care providers as well as study visits every 6 months. At each study visit, following assessment of technique for using peak flow and metered dose inhalers, errors were corrected and children/families were coached on correct technique.
62600242|NCT00005711|EXPERIMENTAL|Asthma self-management education|"Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish."
62600243|NCT06158659|EXPERIMENTAL|Feihe Investigational Formula|"Feihe Investigational Formula~1. With the highest lactoferrin content (more than blue)~2. Contains 2 kinds of HMOs~3. Double probiotic combination~4. Comprehensive nutrition: OPO, DHA\&ARA, CPP, nucleotide, choline, inositol, taurine, L-carnitine, GOS, lutein"
62600244|NCT06158659|ACTIVE_COMPARATOR|Control Formula|Control formula contains comparable macronutrients and micronutrients, but does not contain Lactoferrin fortified with HMO
62600245|NCT06158659|OTHER|Breastfeeding|breastmilk-feeding
62600246|NCT06183203|EXPERIMENTAL|Pulpotomy|Participants diagnosed with symptomatic irreversible pulpitis in vital primary molars will receive the pulpotomy treatment intervention.
62600247|NCT06183203|ACTIVE_COMPARATOR|Pulpectomy|Participants diagnosed with symptomatic irreversible pulpitis in vital primary molars will receive the pulpectomy treatment intervention.
62819791|NCT06513845|EXPERIMENTAL|Non-musicians group|Non-musicians will listen to segments (\~30 sec duration) of recordings taken from the music made during the previous drum circle and answer a survey asking how connected they felt while listening.Segments will be categorized as highly synchronized or not synchronized..
62819792|NCT04588545|EXPERIMENTAL|Radiation Therapy followed by 10 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 1 of 4 with 10 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
62061597|NCT06147518|EXPERIMENTAL|Metformin with Dapagliflozin|"Metformin: 1.5g/d CTPA,1g/d CTPB~Dapagliflozin: Assess HbA1c/HBSG at 8 weeks, increase dapagliflozin to 10 mg if HbA1c\>7%"
62061598|NCT06023602|EXPERIMENTAL|Generic cetrorelix acetate|
62061599|NCT06023602|ACTIVE_COMPARATOR|Reference cetrorelix acetate|
62433937|NCT06011473|EXPERIMENTAL|Experimental|Study subjects submitted to the General Surgery Clinic for colorectal surgery. On admission day, patients will have a CGM sensor placed on the outer part of the upper arm. Patients will undergo standard surgical procedures and perioperative care. Glycemia will be continuously monitored for 10 days. The CGM sensor will be taken off during visit in Outpatient Clinic.
62433938|NCT06110884|EXPERIMENTAL|Music therapy group|
62243562|NCT06736275|EXPERIMENTAL|group|"In this study, three dose levels are initially formulated, namely 2mg, 4mg, and 10mg of SXRN, adopting an accelerated titration followed by the traditional 3+3 design. The first day of infusion for each dose is referred to as C1D1, with the administration of QD for 5 consecutive days, followed by a 2-day break; Each treatment cycle will last 3 weeks (21 days), and the subsequent infusion regimen, including interval, frequency and dose, may be adjusted based on the initial safety and PK parameters."
62433939|NCT06110884|ACTIVE_COMPARATOR|Control group|
62243563|NCT06549530|EXPERIMENTAL|MVA-BN|Participants will receive 2 vaccinations at the standard dose of MVA-BN vaccine 4 weeks apart.
62243564|NCT05760846|EXPERIMENTAL|Bimanual Circuit version 1|Training on the REAplan® robot with a serious game based on proximal motor skill learning (bim-MSkL) with the bimanual version 1 of the Circuit task and training on the Dextrain Manipulandum with a serious game based on distal bim-MSkL
62243565|NCT05760846|EXPERIMENTAL|Bimanual Circuit version 2|Training on the REAplan® robot with a serious game based on motor skill learning (MSkL) with bimanual version 2 of the Circuit task and training on the Dextrain Manipulandum with a serious game based on distal bim-MSkL
62433940|NCT04021901||F21|balloon diameter F21
62061600|NCT02949401|NO_INTERVENTION|Standard of Care|"No research intervention to be administered.~Participants will have standard preparation for a procedure including discussion of the procedure with the provider the day before the procedure with all questions answered at that time."
62243566|NCT04666571|EXPERIMENTAL|Personalised (TOKA)|"During HTO surgery, the personalised plate will be inserted below the knee.~The investigational device and comparator are two types of metal plate used to fix the bone in place during a high tibial osteotomy (HTO)."
62243567|NCT04666571|ACTIVE_COMPARATOR|Standard (Tomofix or ActivMotion)|During HTO surgery, the standard plate will be inserted below the knee.
62243568|NCT06249386|EXPERIMENTAL|Behavioral Activation (BA)|Individual psychotherapy
62243569|NCT06249386|ACTIVE_COMPARATOR|Relapse Prevention (RP)|Individual psychotherapy
62433941|NCT04021901||F24|balloon diameter F24
62433942|NCT04023994|PLACEBO_COMPARATOR|Placebo|In Cohorts 1-5, there were ten participants in total who received placebo, two in each cohort.
62433943|NCT04023994|EXPERIMENTAL|RO7126209 (0.1 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (0.1 mg/kg).
62433944|NCT04023994|EXPERIMENTAL|RO7126209 (0.4 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (0.4 mg/kg).
62433945|NCT04023994|EXPERIMENTAL|RO7126209 (1.2 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (1.2 mg/kg).
62433946|NCT04023994|EXPERIMENTAL|RO7126209 (3.6 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (3.6 mg/kg).
62433947|NCT04023994|EXPERIMENTAL|RO7126209 (7.2 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (7.2 mg/kg).
62600248|NCT05497336|EXPERIMENTAL|IBI351+Cetuximab|IBI351 recommended dose+Cetuximab 500mg/m2 IV Q2W
62061601|NCT02949401|EXPERIMENTAL|Virtual Reality|The VR interactive module will consist of a 360° visit to the Hospital where patients encounter the various aspects of a procedure from the front door; through the pre-operative area where patients will receive an IV; to the catheterization lab and placement of the anesthesia mask; and back to the post anesthesia care unit. Patients will be accompanied by a child who acts as a guide to the experience. The guide will help explain what the patient is seeing and what to expect along the way. Health care professionals will be enmeshed within the scenarios and will also help with the explanations along the way. Patients will be prompted to enter the relaxation scenarios at different stressful times along the tour to practice relaxation and mindfulness techniques (i.e. before IV start, or upon entering catheterization laboratory). Relaxation scenarios will include a snow scene, tropical beach or other guided imagery scenes.
62061602|NCT01871558|ACTIVE_COMPARATOR|SU+metformin + Basal Insulin|Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG
62061603|NCT01871558|EXPERIMENTAL|Metformin/vildagliptin + Basal Insulin|Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG
62061604|NCT03496974|EXPERIMENTAL|Group A: 200 mg cohort|The dose of bermekimab for Group A is 200 mg (2ml of the 100 mg/ml formulation)
62061605|NCT03496974|EXPERIMENTAL|Group B: 400 mg cohort|The dose of bermekimab for Group B is 400 mg (2ml of the 200 mg/ml formulation) administered weekly by subcutaneous injection
62061606|NCT01799460||CR/CTR group|The complete remission group treated by the Comprehensive Treatment Regimen
62061607|NCT01799460||NR/CTR group|The non-remission group treated by the Comprehensive Treatment Regimen
62061608|NCT01799460||CR/IA group|The complete remission group treated by Immunosuppressive Agents
62061609|NCT01799460||NR/IA group|The non-remission group treated by Immunosuppressive Agents.
62061610|NCT05224635||subjects presenting to the emergency room|Chart review will include subjects presenting to the emergency room from the 1st of November 2021 through 1st of July 2024.
62061611|NCT00818363|EXPERIMENTAL|Group 1: SABER-Bupivacaine|5.0 mL SABER-Bupivacaine/Once
62061612|NCT00818363|PLACEBO_COMPARATOR|Group 2: SABER-Placebo|5.0 mL SABER-Placebo/Once
62243570|NCT06607172|ACTIVE_COMPARATOR|Group II: waterflosser + dilutable 0.075% CPC|Subjects assigned to this group will use a water flosser device and dilutable chemistry product (0.075% CPC) after dilution each time. Water flosser must be used for one minute. They must use this regimen treatment twice daily (in the morning and evening). No other oral hygiene will be allowed during the 21 days of follow-up.
62819793|NCT04588545|EXPERIMENTAL|Radiation Therapy followed by 20 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 2 of 4 with 20 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
62039814|NCT03474341||Resectable esophageal squamous cell- or adenocarcinoma|"Patients (\>18 years) with potentially resectable locally advanced squamous cell- or adenocarcinoma of the esophagus or gastroesophageal junction, receiving nCRT according to the CROSS regimen prior to surgery.~CROSS regimen: weekly carboplatin (doses titrated to achieve an area under the curve of 2 mg per milliliter per minute) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions, delivered 5 days per week on workdays with intensity modulated radiotherapy, including photon and proton therapy)"
62039815|NCT02554968||Study participants|Study participants will complete study related documents including a demographics questionnaire and the shoulder-related patient reported outcome measures.
62243571|NCT06607172|NO_INTERVENTION|Group III: negative control|Subjects assigned to this group will abstain for any oral hygiene during the 21 days of follow-up.
62243572|NCT06607172|EXPERIMENTAL|Group I: water flosser and water|Subjects assigned to this group will use a water flosser device and water each time. Water flosser must be used for one minute. They must use this regimen treatment twice daily (in the morning and evening). No other oral hygiene will be allowed during the 21 days of follow-up.
62039816|NCT02614716|EXPERIMENTAL|LY3090106|LY3090106 given subcutaneously (SC) in escalating dose cohorts once every 2 or 4 weeks for 16 weeks.
62039817|NCT02614716|PLACEBO_COMPARATOR|Placebo|Placebo given subcutaneously (SC) once every 2 or 4 weeks for 16 weeks.
62039818|NCT04867369|EXPERIMENTAL|Pecs II block|80 patients scheduled for open biceps tenodesis
62039819|NCT04867369|ACTIVE_COMPARATOR|Surgical infiltration|80 patients scheduled for open biceps tenodesis
62039820|NCT03321916|EXPERIMENTAL|Subthreshold Photothermal Therapy|
62039821|NCT03321916|SHAM_COMPARATOR|Sham|
62039822|NCT06411067|PLACEBO_COMPARATOR|Control|1ml 0.9% of saline once a month in addition to the standard of care practiced at NMCP.
62039823|NCT06411067|EXPERIMENTAL|Erenumab|140mg (1 ml) of Erenumab injected once a month in addition to the standard of care practiced at NMCP.
62243573|NCT06274723|EXPERIMENTAL|Source|Participants in source arm will receive e-cigarette education messages manipulated in one of two source types.
62600249|NCT05497336|EXPERIMENTAL|IBI351|IBI351 recommended dose
62819794|NCT04588545|EXPERIMENTAL|Radiation Therapy followed by 40 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 3 of 4 with 40 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
62600250|NCT00524004|EXPERIMENTAL|Anti-CsbD Bovine IgG|Anti CsbD Bovine Milk Immunoglobulin
62600251|NCT00524004|EXPERIMENTAL|Placebo|Lacto-free milk supplement
62600252|NCT00524004|EXPERIMENTAL|Anti-CS17 Bovin IgG|Anti-CS17 Bovin Milk Immunoglobulin
62600253|NCT06390774|EXPERIMENTAL|Part 1|Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation includes 6 levels, QW IV. Dose extension will be carried out at the selected level.
62600254|NCT06390774|EXPERIMENTAL|Part 2|Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation includes 6 levels, Q2W IV. Dose extension will be carried out at the selected level.
62600255|NCT06390774|EXPERIMENTAL|Part 3|Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation includes 6 levels, Q3W IV. Dose extension will be carried out at the selected level.
62600256|NCT06390774|EXPERIMENTAL|Part 4|Indication extension will be carried out at the selected level，including 3 dosage levels.
62819795|NCT04588545|EXPERIMENTAL|Radiation Therapy followed by 80 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 4 of 4 with 80 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
62819796|NCT00202280|PLACEBO_COMPARATOR|Placebo pill|Placebo pill daily for 3 months
62819797|NCT00202280|EXPERIMENTAL|5mg folic acid, 0.4mg B12, 50mg B6|5mg folic acid, 0.4mg B12, 50mg B6 in one pill, daily for 3 months
62243574|NCT06274723|EXPERIMENTAL|Sidedness|Participants in sidedness arm will receive e-cigarette education messages manipulated in one of two sidedness types.
62243575|NCT04567667|EXPERIMENTAL|Group 1|
62819798|NCT05139472|EXPERIMENTAL|Treatment Arm|This arm of the study will take 10 mg empagliflozin daily for 12 weeks
62819799|NCT04093297|ACTIVE_COMPARATOR|Group Ring|Patients in Group Ring will undergo tricuspid rigid ring annuloplasty
62819800|NCT04093297|ACTIVE_COMPARATOR|Group Band|Patients in Group Band will undergo flexible band annuloplasty
62819801|NCT04609943|EXPERIMENTAL|BAY1211163|Adult patients with moderate or severe Acute Respiratory Distress Syndrome (ARDS) diagnosis before study inclusion will receive BAY1211163.
62849081|NCT05767268||treated with Lokomat|Patients perform a rehabilitation treatment of 15 or 20 sessions with lokomat + 15 or 20 sessions of physiotherapy in 3 or 4 weeks as defined by the clinician. During two or three sessions they wear a wearable device Empatica E4 that measure their electrocardiographic (ECG) activity and electrodermal activity (EDA). They also have a baseline acquisition of these signals in their room at hospital.
62849082|NCT00886847|EXPERIMENTAL|EBUS FNA vs FNC|
62849083|NCT01106716|PLACEBO_COMPARATOR|A1: Placebo|Placebo
62243576|NCT04567667|EXPERIMENTAL|Group 2|
62600257|NCT04412837|EXPERIMENTAL|CBD Patch|Topical CBD patch to be worn for 24 hours and changed daily for the course of 4 weeks.
62600258|NCT04412837|PLACEBO_COMPARATOR|Control Patch|Control placebo patch to be worn for 24 hours and changed daily for the course of 4 weeks.
62600259|NCT01488669|EXPERIMENTAL|Robotic neck dissection|Robotic neck dissection was performed via modified face lift or retroauricular approach using the robotic arms, while conventional neck dissection was conducted after transverse skin incision from the mastoid tip to the midline.
62600260|NCT01488669|ACTIVE_COMPARATOR|Conventional neck dissection|Neck dissection is performed after an external transverse skin incision.
62600261|NCT05877417|NO_INTERVENTION|Control|"If you are in the control group, there will be no supplement or exercise procedures.~You will be asked to come in to the lab for 5 visits"
62243577|NCT05805709|EXPERIMENTAL|Multimodal Process of Care Intervention|A multimodal process-of-care intervention that includes 1) study physician oversight and follow up care recommendations at the time of hospital discharge; 2) involvement of a nurse navigator to provide kidney-disease related education, coordinate care, and assess symptoms; and 3) pharmacist-led medication reconciliation and review.
62433948|NCT06040957|EXPERIMENTAL|single intra-articular injection of BMAC|Patients randomized in this group will undergo single knee intra-articular injection of bone marrow aspirate concentrate (BMAC)
62243578|NCT05805709|ACTIVE_COMPARATOR|Usual Care|After receiving the same written information about kidney disease, nephrotoxins to be avoided and importance/need for follow up with a physician as individuals randomized to the multimodal intervention arm, participants randomized to the control arm will receive usual care as specified by their treating providers and will not be followed by nurse navigator, pharmacist, or the study team. The only subsequent study-related activities will be the follow-up study visits for ascertainment of endpoints with the research coordinator.
62600262|NCT05877417|EXPERIMENTAL|Creatine and Blood Flow Restriction Exercise|"* Of the other four groups, regardless of randomization, all 4 groups will be supplementing the same for the loading phase and throughout the study. Since this study is blinded, the research personnel will not know which supplement you are given and will therefore ensure everyone is following the same procedures.~* Loading here means to consume more than the daily amount of supplement. This visit will have participants consume 5g twice in one day and twice more at home. This is a normal practice and standard use of the supplement.~* If you are not in the control group, you will further be randomized into one of four possible supplementation groups. These groups will be double blinded and randomized into either placebo or creatine supplementation. Creatine monohydrate powder (Muscle Feast, Creapure®) will be used for the active supplement group. Dextrose powder (sugar) will be used for the placebo group.~* The supplement and placebo are flavorless and odorless powder."
62600263|NCT05877417|ACTIVE_COMPARATOR|Creatine and No-BFR with Training|"* Of the other four groups, regardless of randomization, all 4 groups will be supplementing the same for the loading phase and throughout the study. Since this study is blinded, the research personnel will not know which supplement you are given and will therefore ensure everyone is following the same procedures.~* Loading here means to consume more than the daily amount of supplement. This visit will have participants consume 5g twice in one day and twice more at home. This is a normal practice and standard use of the supplement.~* If you are not in the control group, you will further be randomized into one of four possible supplementation groups. These groups will be double blinded and randomized into either placebo or creatine supplementation. Creatine monohydrate powder (Muscle Feast, Creapure®) will be used for the active supplement group. Dextrose powder (sugar) will be used for the placebo group.~* The supplement and placebo are flavorless and odorless powder."
62600264|NCT05877417|PLACEBO_COMPARATOR|Placebo and Blood Flow Restriction Exercise|"* Of the other four groups, regardless of randomization, all 4 groups will be supplementing the same for the loading phase and throughout the study. Since this study is blinded, the research personnel will not know which supplement you are given and will therefore ensure everyone is following the same procedures.~* Loading here means to consume more than the daily amount of supplement. This visit will have participants consume 5g twice in one day and twice more at home. This is a normal practice and standard use of the supplement.~* If you are not in the control group, you will further be randomized into one of four possible supplementation groups. These groups will be double blinded and randomized into either placebo or creatine supplementation. Creatine monohydrate powder (Muscle Feast, Creapure®) will be used for the active supplement group. Dextrose powder (sugar) will be used for the placebo group.~* The supplement and placebo are flavorless and odorless powder."
62819802|NCT06597045||Immune checkpoint inhibitor monotherapy|"Patients who are given immune checkpoint inhibitor (ICI) monotherapy (decision on treatment is made by the clinical oncology team. Enrolment to this study had no influence or impact on choice of anti-cancer therapy.~Patients were allocated this group if they received at least one cycle of immune check point inhibitor. In the event that a patient is given ICI/VEGFI combination therapy but the VEGFi was stopped early (due to toxicity or lack of clinical effect, determined by the clinical team) and they had less than 50% exposure to VEGFi in the protocol window (24 weeks), the patient will be allocated to ICI monotherapy. Subsequent sensitivity analyses looking at any exposure to VEGFI vs those who had no exposure will be performed."
62849084|NCT01106716|EXPERIMENTAL|A2: KAI-1678|Experimental
62849085|NCT01106716|ACTIVE_COMPARATOR|A3: Lidocaine|Lidocaine
62849086|NCT01009619|EXPERIMENTAL|Azithromycin|250 mg daily for 5 days, followed by 250 mg three times a week (Mon.-Wed.-Fri.) until the end of study
62243579|NCT06562985|EXPERIMENTAL|Dose step 1 (Part A)|Participants will receive a single dose of BAY3018250 dose step 1 via infusion in part A.
62243580|NCT06562985|EXPERIMENTAL|Dose step 2 (Part A)|Participants will receive a single dose of BAY3018250 dose step 2 via infusion in part A.
62243581|NCT06562985|PLACEBO_COMPARATOR|Placebo (Part A)|Participants will receive a single dose of BAY3018250 matching placebo via infusion in part A.
62243582|NCT06562985|EXPERIMENTAL|Dose step 2 (Part B)|Participants will receive a single dose of BAY3018250 dose step 2 via injection in part B.
62243583|NCT06562985|PLACEBO_COMPARATOR|Placebo (Part B)|Participants will receive a single dose of BAY3018250 matching placebo via injection in part B.
62243584|NCT06064851|EXPERIMENTAL|Von Willebrand Disease (VWD) Patients|Participants with VWD Type 1 who are on hormone therapy. First Menstruation (baseline/no active tAN) followed by Second Menstruation (active tAN)
62243585|NCT06064851|EXPERIMENTAL|Heavy Menstrual Bleeding (HMB) Patients|Participants with no known cause of HMB who are not on hormonal therapy. First Menstruation (baseline/no active tAN) followed by Second Menstruation (active tAN)
62433949|NCT06040957|EXPERIMENTAL|single intra-articular injection of MM-AT|Patients randomized in this group will undergo single knee intra-articular injection of minimally manipulated adipose tissue (MM-AT)
62433950|NCT04271150|EXPERIMENTAL|Self-etch|Self-etch mode of the universal adhesive will be used
62849087|NCT01009619|PLACEBO_COMPARATOR|Placebo|PLacebo daily for 5 days, followed by placebo three times a week (Mon.-Wed.-Fri.) until end of study.
62433951|NCT04271150|ACTIVE_COMPARATOR|Total-etch|Total etch mode of the universal adhesive will be used
62433952|NCT03509051|EXPERIMENTAL|B vaccination|One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.
62600265|NCT05877417|SHAM_COMPARATOR|Placebo and No-BFR with Training|"* Of the other four groups, regardless of randomization, all 4 groups will be supplementing the same for the loading phase and throughout the study. Since this study is blinded, the research personnel will not know which supplement you are given and will therefore ensure everyone is following the same procedures.~* Loading here means to consume more than the daily amount of supplement. This visit will have participants consume 5g twice in one day and twice more at home. This is a normal practice and standard use of the supplement.~* If you are not in the control group, you will further be randomized into one of four possible supplementation groups. These groups will be double blinded and randomized into either placebo or creatine supplementation. Creatine monohydrate powder (Muscle Feast, Creapure®) will be used for the active supplement group. Dextrose powder (sugar) will be used for the placebo group.~* The supplement and placebo are flavorless and odorless powder."
62600266|NCT05451433|EXPERIMENTAL|Intervention Group|Get intervention drug Normagut capsule twice a day
62600267|NCT05451433|PLACEBO_COMPARATOR|Control Group|Get placebo capsule twice a day
62600268|NCT04299048|EXPERIMENTAL|PF-06946860|subcutaneous injection
62600269|NCT01506154|PLACEBO_COMPARATOR|Placebo|Therapy with placebo
62600270|NCT01506154|EXPERIMENTAL|MRX-7EAT|Therapy with experimental drug
62600271|NCT06181357|EXPERIMENTAL|two-stage ZEPHYR® valves|
62600272|NCT06181357|SHAM_COMPARATOR|one-stage ZEPHYR® valves|
62600273|NCT04172402|EXPERIMENTAL|NGS|"Eligible patients will receive Nivolumab 240mg on day 1, gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.~* BSA \< 1.25 m2: 80 mg/day~* 1.25 m2 ≤ BSA \< 1.5 m2: 100 mg/day~* BSA ≥ 1.5 m2: 120 mg/day The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study."
62600274|NCT05619718|EXPERIMENTAL|Treatment|Treatment group will receive Awareness, Courage, and Love Groups for loneliness.
62600275|NCT05619718|ACTIVE_COMPARATOR|Control|Control group will receive treatment as usual in the form of Mutual Help Meetings.
62600276|NCT01619644|EXPERIMENTAL|Sodium Valproate|Group of 40 patients receiving one year of sodium valproate
62600277|NCT01619644|PLACEBO_COMPARATOR|Placebo|Group of 20 patients receiving one year of placebo
62600278|NCT02083055|EXPERIMENTAL|dexmedetomidine|Intraoperative controlled hypotension by dexmedetomidine
62600279|NCT02083055|ACTIVE_COMPARATOR|nitroglycerin|Intraoperative controlled hypotension by nitroglycerin
62600280|NCT02975245||Men receiving chemotherapy|Semen collection and analysis
62600281|NCT04683939|EXPERIMENTAL|Part 1A - BNT141 monotherapy escalation|Administration once every three weeks (Q3W)
62600282|NCT04683939|EXPERIMENTAL|Part 1B - BNT141 in combination with nab-paclitaxel and gemcitabine|BNT141 was planned to be administered Q3W. Nab-paclitaxel and gemcitabine was planned to be administered on three days of each 28-day cycle.
62600283|NCT04683939|EXPERIMENTAL|Part 2 - predefined expansion cohorts|BNT141 in combination with nab-paclitaxel and gemcitabine
62600284|NCT01953835|EXPERIMENTAL|Cohort A|Cohort A is a single-sequence, open-label study in which each subject will receive Simvastatin 10 mg single dose oral tablet on Days 1 and 10, Rosuvastatin 10 mg single dose oral tablet on Days 3 and 12 and GSK2586184 standard formulation 400 mg twice daily oral tablet from Day 6 to Day 14 immediately after food. At Day 10 GSK2586184 and Simvastatin and at Day 12, GSK2586184 and Rosuvastatin will be co-administered.
62600285|NCT01953835|EXPERIMENTAL|Cohort B|Cohort B is a three-way crossover study in which each subject will receive a single dose of GSK2586184 standard formulation 400 mg oral tablet with food and two doses of a new formulation of GSK2586184 400 mg oral tablet, once with food and once in a fasted state, on Day 1, 4 and 7 according to their treatment sequence, with a 3-day wash out between doses.
62600286|NCT06624293||Subjects with heart failure|Targeting subjects in the acute care setting that present with suspicion of either new onset or worsening symptoms of heart failure
62600287|NCT05990192|OTHER|SBRT followed by Niraparib|"SBRT treatment will commence within 7 days post randomisation and will be administered as detailed in the SOPRANO Radiotherapy Planning and Delivery Guidelines document. Doses will vary between 3 fractions over 5 days to 8 fractions over 19 days depending on the location of the lesions being treated.~Niraparib treatment will start 4 weeks post completion of SBRT treatment and will continue daily until disease progression or other discontinuation criteria are met. Niraparib comes in oral tablet form and the starting dose will be 200mg per day (once a day) or 300mg per day (once a day) calculated by participant's weight and platelet count."
62600288|NCT05990192|OTHER|SBRT alone|SBRT treatment will commence within 7 days post randomisation and will be administered as detailed in the SOPRANO Radiotherapy Planning and Delivery Guidelines document. Doses will vary between 3 fractions over 5 days to 8 fractions over 19 days depending on the location of the lesions being treated.
62600289|NCT05203549||Gastric cancer patients|Patients with gastric cancer will undergo tumor biopsy before receiving neoadjuvant therapy, conversion therapy, or palliative therapy
62600290|NCT02863510|EXPERIMENTAL|Renal Denervation|Participation receiving renal sympathetic denervation
62600291|NCT05768750|EXPERIMENTAL|Control followed by intervention phase|"All participants will participate in 2 phases : control phase (12-week usual care) followed by an intervention phase (12-week home-based rehabilitation program).~The rehabilitation program consists of three domains of exercises divided by levels of difficulty: sitting balance (16 levels), standing balance (21 levels) and sit-to-stand transfer (12 levels), including 67 exercises. Each individualized home-based rehabilitation program will include 3 to 6 exercises, for a total duration of 15 to 20 minutes."
62600292|NCT01097421||Patient with parkinsons disease|
62039824|NCT03915782|EXPERIMENTAL|Remote Ischemic Conditioning (RIC) positive|Patients with remote ischemic conditioning
62600293|NCT03373058|EXPERIMENTAL|Experimental group|"1. Cytoreductive surgery~2. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Docetaxel 75 mg/m\^2 and cisplatin 75 mg/m\^2 intraperitoneally in succession~3. 6 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m\^2 IV\>3 hour(Docetaxel 75 mg/m\^2, if paclitaxel is not available.)+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks."
62849088|NCT04540016|OTHER|Arm Ⅰ|25 mg of 80 µCi \[14C\]HSK7653.
62849089|NCT03332849|EXPERIMENTAL|Cohort 1|T1DM: Multiple dose subcutaneous administration
62849090|NCT03332849|EXPERIMENTAL|Cohort 2|T1DM: Multiple dose subcutaneous administration
62849091|NCT03332849|EXPERIMENTAL|Cohort 3|T2DM: Multiple dose subcutaneous administration
62600294|NCT03373058|ACTIVE_COMPARATOR|Control group|"1. Cytoreductive surgery~2. 6 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m\^2 IV\>3 hour(Docetaxel 75 mg/m\^2, if paclitaxel is not available)+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks."
62819803|NCT06597045||VEGF inhibitor monotherapy|"Patients who are given VEGF inhibitor monotherapy (decision on treatment is made by the clinical oncology team. Enrolment to this study had no influence or impact on choice of anti-cancer therapy~Patients will be allocated this group if they are given VEGFi with no exposure to immunotherapy in the study period. If patients are enrolled in the study but stop VEGF inhibitor early they will still be included in this group, provided they do not receive immune checkpoint inhibitor. If during the study protocol window, the patient is exposed to other anti-cancer therapies (other than ICI), in addition to VEGF inhibitor, they will be remain in the VEGFI group."
62819804|NCT06597045||Immune checkpoint inhibitor / VEGF inhibitor combination therapy|"Patients who are given immune checkpoint inhibitor / VEGF inhibitor combination therapy (decision on treatment is made by the clinical oncology team. Enrolment to this study had no influence or impact on choice of anti-cancer therapy).~Patients were allocated this group if they received at least one cycle of immune check point inhibitor and VEGFI with more than 50% of the exposure in the study protocol window (24 weeks). Subsequent sensitivity analyses looking at any exposure to VEGFI vs those who had no exposure will be performed."
62243586|NCT06735755|EXPERIMENTAL|BEAM-301|BEAM-301 consists of adenine base editor messenger ribonucleic acid (mRNA) and single guide ribonucleic acid (gRNA) formulated in lipid nanoparticles (LNPs) for intravenous (IV) administration.
62819805|NCT03926208|ACTIVE_COMPARATOR|Control|Subjects in this group will receive the standard chlorhexadine prep of the foot (standard of care) prior to surgery, and a cotton swab will be collected from the hallux nail fold.
62819806|NCT03926208|EXPERIMENTAL|Soak and Scrub|In addition to the standard chlorhexadine prep of the foot prior to surgery, subjects in this group will also receive a betadine soak and scrub of the foot, and a cotton swab will be collected from the hallux nail fold.
62819807|NCT06408558|EXPERIMENTAL|Starting Hypobaric|Hypobaric to Ground level \& Ground level to Hypobaric
62433953|NCT06072690||Patients with treatment-naive moderate-to-severe COPD|Patients of any gender aged 40 years and older with newly diagnosed treatment-naive moderate-to-severe chronic obstructive pulmonary disease will have a comprehensive cardiovascular and respiratory examination as well as evaluation of quality of life before the treatment and after 12 weeks of treatment with dual bronchodilation.
62819808|NCT06408558|EXPERIMENTAL|Starting Ground level|Ground level to Hypobaric \& Hypobaric to Ground level
62243587|NCT04897009||Basic science (biospecimen collection)|Patients undergo blood sample collection at baseline (prior to first NAC treatment), after taxane and prior to first dose of A/C (for patients receiving a taxane), end of NAC, 1-4 weeks and 6 months post-surgery. Patients also undergo tissue collection at 1-4 weeks and 6 months post-surgery.
62243588|NCT03811639|ACTIVE_COMPARATOR|RF ablation|Patients treated with point-by-point radio-frequency ablation
62243589|NCT03811639|EXPERIMENTAL|Cryoballoon ablation|Patients treated with cryoballoon ablation
62433954|NCT04525157|EXPERIMENTAL|Afamelanotide and NB-UVB|Participants received Afamelanotide implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0).
62243590|NCT06447818||Airway groups|This group will consist of patients who will undergo airway surgery for obstructive sleep apnoea
62243591|NCT05440266|ACTIVE_COMPARATOR|First: half-sine wave stimulation; Second: rectangular shaped stimulation|"First appointment:~Intracutaneously applied electrical 25 ms half-sine wave stimulation with 2 Hz frequency.~Second appointment:~Intracutaneously applied electrical 500 µs rectangular shaped stimulation with 2 Hz frequency."
62433955|NCT04525157|PLACEBO_COMPARATOR|Placebo and NB-UVB|Participants received Placebo implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0).
62433956|NCT04525157|EXPERIMENTAL|Single-Arm, Open Label Group|"The study design was modified into a single-arm, open label study with only one treatment group receiving afamelanotide implants plus NB-UVB light.~Participants received Afamelanotide implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0)."
62433957|NCT04550715|EXPERIMENTAL|Brief intervention (BI) then Portal|The BI will be delivered at intake and the portal will occur for 4 weeks starting at intake.
62433958|NCT04550715|EXPERIMENTAL|Brief intervention (BI) then Enhanced Usual Care (EUC)|The BI will be delivered at intake and EUC will be added 4 weeks later.
62433959|NCT04550715|EXPERIMENTAL|Enhanced Usual Care (EUC) then Portal|EUC will be delivered at intake and the portal will occur for 4 weeks starting at intake.
62433960|NCT04550715|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC) then EUC|EUC will be delivered at intake and delivered again 4 weeks later.
62433961|NCT02731833|EXPERIMENTAL|Test dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute
62600295|NCT04481893|EXPERIMENTAL|using a virtual reality headset|
62600296|NCT05708677||Long-Term Extension|This study will follow one group of participants who were enrolled in a previous EB-101 study.
62600297|NCT02444364|EXPERIMENTAL|Sitagliptin|Subjects will receive 90 tablets of 100mg sitagliptin
62600298|NCT05124080|EXPERIMENTAL|Deucravacitinib 6 mg Daily|All participants will receive 6 mg of deucravacitinib daily.
62600299|NCT02046005|ACTIVE_COMPARATOR|General Rheumatoid Arthritis Education|Arm 1 participants will receive general information about RA.
62600300|NCT02046005|EXPERIMENTAL|PRE-RA|Arm 2 participants will receive personalized RA risk education by the PRE-RA risk tool.
62819809|NCT05878418|EXPERIMENTAL|Trunk Exercises, Pulmonary Rehabilitation and Pulmonary Care Program + Spinal Orthosis Group|Trunk Exercises, Pulmonary Rehabilitation and Pulmonary Care Program + Toracolumbosacral Spinal Orthosis
62819810|NCT05878418|ACTIVE_COMPARATOR|Trunk Exercises, Pulmonary Rehabilitation and Pulmonary Care Program Group|Trunk Exercises, Pulmonary Rehabilitation and Pulmonary Care Program
62600301|NCT02046005|EXPERIMENTAL|PRE-RA Plus|Arm 3 participants will receive personalized RA risk education by the PRE-RA risk tool and health educator.
62600302|NCT02312453|EXPERIMENTAL|Posterior approach|All patients were given a single shot ultrasound-guided posterior parasagittal in-plane approach infraclavicular brachial plexus block under aseptic technique. The blocks were performed using a 21G, 100 mm insulated short bevel needle (Stimuplex A, B Braun, Melsungen, Germany) without nerve stimulation. A 25-ml local anaesthetic admixture \[Lignocaine 2% (100mg) plus Ropivacaine 0.75% (150mg)\] was administered. We used an ultrasound machine (Sonosite M-Turbo; Sonosite®, Bothell, WA, USA) with HFL38x/ 13-6 MHz linear transducer probe.
62600303|NCT01446237|EXPERIMENTAL|Acne system - benzoyl peroxide 2.5%, Salicylic Acid 0.5%|open label - no comparator; only Acne system - benzoyl peroxide 2.5%, Salicylic Acid 0.5%
62243592|NCT05440266|ACTIVE_COMPARATOR|First: rectangular shaped stimulation; Second: half-sine wave stimulation|"First appointment:~Intracutaneously applied electrical 500 µs rectangular shaped stimulation with 2 Hz frequency.~Second appointment:~Intracutaneously applied electrical 25 ms half-sine wave stimulation with 2 Hz frequency."
62433962|NCT02731833|ACTIVE_COMPARATOR|Control dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip (1 inch) of toothpaste. Participants will then brush whole mouth thoroughly for at least 1 minute
62433963|NCT03250650|ACTIVE_COMPARATOR|Group 1: TTNS|Intervention for Group 1: transcutaneous tibial nerve electric stimulation (TTNS), using a Device Dualpex 961(Quark medical), with 2 silicone electrode in the tibial nerve path, being one on the lower border of the medial malleolus and another one, 10cm above. Once a week for 12 weeks. The parameters used on device were, 200 microseconds for pulse time and 10Hz for Frequency, during 30 minutes.
62433964|NCT03250650|EXPERIMENTAL|Group 2: ES + TTNS|Intervention for Group 2: transvaginal electric stimulation plus transcutaneous tibial nerve electric stimulation (ES + TTNS), using a Device Dualpex 961(Quark medical), with transvaginal electrode, located inside the vagina. Once a week for 12 weeks. The parameters used on device were 1milisecond for pulse time and 10Hz for Frequency, during 20 minutes. After transvaginal stimulation, the tibial stimulation will be applied like described on Group 1.
62243593|NCT01889056|EXPERIMENTAL|Erythropoietin (Epoetin beta)|Short infusion of 60.000 IU Epoetin beta in 0.9% sodium chloride solution (250 ml)
62433965|NCT02314273|EXPERIMENTAL|rhIL-11 group|patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80,000/mL
62433966|NCT02314273|NO_INTERVENTION|control group|control group
62433967|NCT03736395|ACTIVE_COMPARATOR|Control|Schools in this condition will be provided a four-day training about Schoolwide Positive Behavioral Interventions and Supports, and bi-yearly feedback about progress monitoring and action planning.
62433968|NCT03736395|EXPERIMENTAL|I-RIM Intervention|Schools in this condition will be provided the same basic training as the control condition, plus the elements of the Idaho Rural Implementation Model (I-RIM).
62819811|NCT04163562|EXPERIMENTAL|INP20 (Oral Immunotherapy)|
62819812|NCT04163562|PLACEBO_COMPARATOR|Placebo|
62819813|NCT05846789|ACTIVE_COMPARATOR|Black Monotherapy|
62039825|NCT03915782|SHAM_COMPARATOR|Control group|The control group will receive a sham procedure (same procedure than Remote Ischemic Conditioning (RIC) with brachial cuff inflation to 30 millimeters (mm) of mercury (Hg) during 40 minutes).
62243594|NCT01889056|PLACEBO_COMPARATOR|0.9% sodium chloride solution|Short infusion of 0.9% sodium chloride solution (250 ml)
62265928|NCT01982929|EXPERIMENTAL|TAP block & Oral Meds|Definition intervention. TAP block (Bupivacaine 0.25% with epinephrine 1:400,000 50 cc). TAP blocks were placed using ultrasound-guided identification of the transversus abdominis fascial plane, and in-plane needle guidance. Injection sites were near the Triangle of Petit, located at the lateral edge of the mid-abdomen, near the iliac crests. After negative aspiration for blood, the local anesthetic was injected in 5 cc aliquots. The total dosage injected never exceeded 0.25 mg/kg of 0.25% bupivacaine with epinephrine 1:400,000.
62433969|NCT00035165|EXPERIMENTAL|EPO906|
62433970|NCT06219382||Neurorehabilitation ecosystem (NEST)|Patients will use Nest apart from the regular neurorehabilitation treatment
62433971|NCT02896868|EXPERIMENTAL|LY3041658|LY3041658 administered intravenously (IV) once every two weeks over 6 weeks (four doses).
62433972|NCT02896868|PLACEBO_COMPARATOR|Placebo|Placebo administered IV once every two weeks over 6 weeks (four doses).
62433973|NCT01363609|EXPERIMENTAL|Liraglutide|12 week treatment with liraglutide in fixed dosage
62433974|NCT01363609|ACTIVE_COMPARATOR|Insulin glargine|12 week treatment, once daily, with insulin glargine. Dosage based on fasting blood glucose measurements
62039826|NCT04801550|ACTIVE_COMPARATOR|Millimeter wave emitter status 1|Somatosensory stimulus during Magnetoencephalography (MEG) records
62039827|NCT04801550|SHAM_COMPARATOR|Millimeter wave emitter status 2|Somatosensory stimulus during Magnetoencephalography (MEG) records
62039828|NCT00066248|EXPERIMENTAL|Subjects that respond to Periactin|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
62243595|NCT05686590|EXPERIMENTAL|Augmented Reality Enhanced Simulation (Treatment group)|Each simulation will have between two and five participants. After consent, demographic data will be collected. Then, a study RA will fit a Magic Leap One (ML1) headsets (Magic Leap Inc., Plantation, FL) to participants. Following a scripted briefing, the instructor will also orient the participants to the ML1 headset for those in that group. After orienting the participant to the use of the headsets, the instructor will remain in a room separate from the participants, who will conduct the scenario outside. This will enable assessment of the feasibility of providing simulation instruction remotely. Prior to starting the scenario, the simulation instructor will conduct an orientation to review the core tenets of effective communication skills during prehospital care.
62600304|NCT04169672|EXPERIMENTAL|Surufatinib & Toripalimab|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
62600305|NCT04169672|EXPERIMENTAL|Surufatinib|Surufatinib 300mg will be taken orally once daily continuously through a 21-day cycle of study treatment.
62600306|NCT04105946|ACTIVE_COMPARATOR|OFA Group|patients undergoing FESS under opiod free anesthesia
62243596|NCT00621894|EXPERIMENTAL|LGD4665|LGD-4665: Experimental Thrombopoietin mimetic
62243597|NCT00621894|PLACEBO_COMPARATOR|Placebo|Placebo
62243598|NCT06086886|EXPERIMENTAL|BMS-986454|
62243599|NCT06086886|PLACEBO_COMPARATOR|Placebo|
62243600|NCT05578495|OTHER|Chronic diseases|Cohort Study
62243601|NCT02112435|ACTIVE_COMPARATOR|Narval ORM ® or SomnoDent ®|Mandibular advancement splint (Narval ORM ® or SomnoDent ®)
62243602|NCT02112435|EXPERIMENTAL|Somnyx ®|Active mandibular advancement splint (Somnyx ®)
62243603|NCT05328583|EXPERIMENTAL|Treatment group A（Part A）|Drug1: HRS5685, dose 1; Drug2: Placebo
62243604|NCT05328583|EXPERIMENTAL|Treatment group B（Part A）|Drug1: HRS5685, dose 2; Drug2: Placebo
62243605|NCT05328583|EXPERIMENTAL|Treatment group C（Part A）|Drug1: HRS5685, dose 3; Drug2: Placebo
62039829|NCT00066248|EXPERIMENTAL|Non-responders to Periactin- Megace Arm|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
62039830|NCT04522076||COVID-19 with pneumonia|patients with positive COVID 19 by PCR and pneumonia by CT
62039831|NCT04522076||COVID-19 without pneumonia|patients with positive COVID 19 by PCR and absent of pneumonia by CT
62039832|NCT04522076||Patients with pneumonia and without COVID 19|patients with negative COVID 19 by PCR and with pneumonia by CT
62243606|NCT05328583|EXPERIMENTAL|Treatment group D（Part A）|Drug1: HRS5685, dose 4; Drug2: Placebo
62243607|NCT05328583|EXPERIMENTAL|Treatment group E（Part A）|Drug1: HRS5685, dose 5; Drug2: Placebo
62243608|NCT05328583|EXPERIMENTAL|Treatment group F（Part A）|Drug1: HRS5685, dose 6; Drug2: Placebo
62243609|NCT05328583|EXPERIMENTAL|Treatment group G（Part B）|Drug1: HRS5685, dose 3; Drug2: Placebo
62243610|NCT05328583|EXPERIMENTAL|Treatment group H（Part B）|Drug1: HRS5685, dose 4; Drug2: Placebo
62243611|NCT01710592|ACTIVE_COMPARATOR|Epirubicin, Oxaliplatin, Capecitabine|"* Epirubicin 50mg/m2 (day 1) bolus injection~* Oxaliplatin 130mg/m2 (day 1) in 250mls of 5% dextrose. i.v. over 2 hours~* Capecitabine 625mg/m2 (days 1-21) b.d. orally~* 8 x 3-weekly cycle"
62243612|NCT01710592|ACTIVE_COMPARATOR|Docetaxel, Oxaliplatin|"* Docetaxel 20mg/m2 (days 1, 8 \& 15)in 250mls of 5% dextrose. i.v. over 30mins (Dexamethasone 8mg i.v, Chlorpheniramine 10mg i.v,Ranitidine 50mg i.v. to be given 30 minutes prior to Docetaxel)~* Oxaliplatin 85mg/m2 (days 1 \& 15)in 250mls of 5% dextrose. i.v. over 2 hours~* 6 x 4-weekly cycle"
62243613|NCT06044922||Post-cardiac arrest patients|
62243614|NCT06611111|ACTIVE_COMPARATOR|Ceftriaxone|Participants will receive IV infusion of 2g Ceftriaxone, approximately every 5 days for 6 weeks for a total of 9 treatments.
62243615|NCT06611111|PLACEBO_COMPARATOR|Placebo|Participants will receive IV infusion of dextrose 5% in water, approximately every 5 days for 6 weeks for a total of 9 treatments
62243616|NCT06065735|EXPERIMENTAL|Paroxetine|
62600307|NCT04105946|ACTIVE_COMPARATOR|TIVA Group|patients undergoing FESS under total intravenous anesthesia
62600308|NCT01661933|EXPERIMENTAL|Necator americanus, gluten challenge|Single arm, vertical.
62039833|NCT04522076||Patients without pneumonia and COVID 19|Patients with suspected COVID-19 and/or pneumonia at the pre-hospital stage that were not confirmed in hospital
62039834|NCT06178991|EXPERIMENTAL|Cohort 1 Arm A: Influenza and COVID-19 Combination A and Placebo|Cohort 1 Arm A: Influenza and COVID-19 combination A vaccine and Placebo
62039835|NCT06178991|ACTIVE_COMPARATOR|Cohort 1 Arm B: COVID-19 vaccine and licensed influenza vaccine concomitant administration group|Cohort 1 Arm B: COVID-19 vaccine and licensed influenza vaccine concomitant administration group
62600309|NCT06649565||Breast cancer patients who achieved pathological complete response after neoadjuvant therapy|All enrolled breast cancer patients received normal neoadjuvant therapy and subsequent surgery without intervention in the diagnosis and treatment process. They were judged to have achieved pathological complete respone based on surgical pathology.
62819814|NCT05846789|EXPERIMENTAL|Black Combination treatment|
62819815|NCT05846789|ACTIVE_COMPARATOR|Non-Black Monotherapy|
62819816|NCT05846789|EXPERIMENTAL|Non-Black Combination treatment|
62433975|NCT01363609|OTHER|before start of treatment period|before start of the treatment period, one day with tests will be performed. During this test a GLP-1 receptor antagonist will be administered In the group with obesity and planned gastric bypass surgery, the GLP-1 receptor agonist will be administered during 1 test before and 1 test after the surgery
62819817|NCT06583135|EXPERIMENTAL|Intervention Group|The intervention group will be given face-to-face sleep hygiene training and and 4 online motivational interviewing will be held within 6 weeks.
62819818|NCT06583135|ACTIVE_COMPARATOR|Control Group|The control group will receive face-to-face sleep hygiene training, routine hemodialysis treatment, and nursing care in the hemodialysis unit.
62433976|NCT03700528|EXPERIMENTAL|Intervention|This is a single-cohort ACT based intervention.
62819819|NCT04788888|EXPERIMENTAL|Navitor Transcatheter Aortic Valve, FlexNav Delivery System|Navitor Transcatheter Aortic Valve System Navitor valves (23mm, 25mm, 27mm, 29mm, and 35mm Titan valve), FlexNav Delivery system (small and large) and and Navitor Loading System (small, large, and LG+)
62819820|NCT06594887|EXPERIMENTAL|SpaceOAR Vue|
62819821|NCT06594887|EXPERIMENTAL|BioProtect Balloon Implant System|
62819822|NCT02718898|EXPERIMENTAL|Ixekizumab|"Blinded Treatment Period: 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab every 2 weeks (Q2W) SC from week 2 to week 10. At week 12, 80 mg ixekizumab and placebo given SC.~Open Label Period: 80 mg ixekizumab given SC every 4 weeks (Q4W) with an option for Q2W dosing starting at week 24, week 28 or week 40."
62819823|NCT02718898|PLACEBO_COMPARATOR|Placebo|"Blinded Treatment Period: Placebo given SC at baseline followed by placebo given SC Q2W from week 2 to week 10. At week 12, 160 mg ixekizumab given SC.~Open Label Period: 80 mg ixekizumab given SC Q4W with an option for Q2W dosing starting at week 24, week 28 or week 40."
62819824|NCT06540053|EXPERIMENTAL|Study Group|Active Static Hamstring Stretching Participants will perform 10-minute active static hamstring exercises for 5 days a week over a period of 6 weeks.
62819825|NCT06540053|OTHER|Control Group|Participants will receive training on spinal protection principles within the office setting and will be sent short messages containing information on maintaining proper posture throughout the day on their phones for a period of 6 weeks.
62819826|NCT02706756|EXPERIMENTAL|Education, exercise and manual therapy|"One group will receive education and advice, manual therapy that is applied toward the impairments of the subject, a prescription of progressive rehabilitation exercises designed to strengthen weakened muscle groups and stretch joint movements that demonstrate range of motion limitations. Treatment is based on clinical presentation and identification of impairments by the treating clinician. Subjects will be seen twice weekly for 4 to 6 weeks, depending on the progression.~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
62243617|NCT04066049|ACTIVE_COMPARATOR|Treatment|Participants in the Treatment group will receive a hybrid therapist-implemented and caregiver-implemented intervention be compared to a BAU control group. Caregivers and children will be assessed at baseline, after the intervention, 6 months after intervention, and 12 months after intervention, and will receive a $50 gift card for participating in each assessment time point, $75 for completing all four assessments, and books and play/activity materials with target word lists in Spanish.
62243618|NCT04066049|NO_INTERVENTION|Control|Participants in the BAU group will be offered 10 caregiver support sessions after completing the 12-month follow-up. These home-based sessions will emphasize shared book reading, modeling vocabulary for school readiness in play and routines, and include general information for families about options for public school language related services. Each session will last about 30 minutes and be conducted by a trained staff member. Caregivers and children will be assessed at baseline, after the intervention, 6 months after intervention, and 12 months after intervention, and will receive a $50 gift card for participating in each assessment time point, $75 for completing all four assessments, and books and play/activity materials with target word lists in Spanish.
62243619|NCT06735794|ACTIVE_COMPARATOR|Compressed iTBS|After completing Visits 0-1 (Screening and Calibration), participants will undergo the iTBS-c condition in a randomized order during Visits 2 to 4. iTBS-c is the active comparator.
62849092|NCT03332849|EXPERIMENTAL|Cohort 4|T2DM: Multiple dose subcutaneous administration
62849093|NCT04927169|EXPERIMENTAL|CYT107|IM administration of CYT107 / Interleukin-7
62849094|NCT04927169|PLACEBO_COMPARATOR|PLACEBO|IM administration of Saline at the same volume
62039836|NCT06178991|EXPERIMENTAL|Cohort 2 Arm C:Influenza and COVID-19 Combination B and Placebo|Cohort 2 Arm C: Influenza and COVID-19 Combination B vaccine and Placebo
62039837|NCT06178991|ACTIVE_COMPARATOR|Cohort 2 Arm D: COVID-19 vaccine and licensed influenza vaccine concomitant administration group|Cohort 2 Arm D: COVID-19 vaccine and licensed influenza vaccine concomitant administration group
62243620|NCT06735794|EXPERIMENTAL|Spaced iTBS|After completing Visits 0-1 (Screening and Calibration), participants will undergo the iTBS-s condition in a randomized order during Visits 2 to 4. iTBS-s is the experimental study intervention.
62433977|NCT00410566|EXPERIMENTAL|1|
62039838|NCT06178991|EXPERIMENTAL|Cohort 3 Arm E:Influenza and COVID-19 Combination B|Cohort 3 Arm E:Influenza and COVID-19 Combination B
62433978|NCT00410566|EXPERIMENTAL|2|
62433979|NCT00410566|EXPERIMENTAL|3|
62433980|NCT00410566|EXPERIMENTAL|4|
62433981|NCT00410566|EXPERIMENTAL|5|
62433982|NCT05944549|EXPERIMENTAL|Enhanced Intervention group|
62433983|NCT05944549|ACTIVE_COMPARATOR|lifestyle-intervention group|
62433984|NCT05209061||Colo-rectal cancer patients|Patients receiving right colectomy or ileo-ceacal resection for colorectal cancer
62433985|NCT02708732||DLBCL Participants|A cohort of approximately 100 patients in first remission with DLBCL will complete questionnaires through a 15-minute postal or online survey.
62433986|NCT06540378||STP in RSE or SRSE|Patients received additional treatment of SE with STP
62433987|NCT01633749|EXPERIMENTAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
62039839|NCT06178991|ACTIVE_COMPARATOR|Cohort 3 Arm F: COVID-19 vaccine|Cohort 3 Arm F: COVID-19 vaccine
62039840|NCT06178991|ACTIVE_COMPARATOR|Cohort 3 Arm G: Licensed influenza vaccine|Cohort 3 Arm G: Licensed influenza vaccine
62243621|NCT06735794|SHAM_COMPARATOR|Sham iTBS|After completing Visits 0-1 (Screening and Calibration), participants will undergo the iTBS-sh condition in a randomized order during Visits 2 to 4. iTBS-sh is the sham comparator.
62243622|NCT06386640||Phase 3 participants|Phase 3 participants
62600310|NCT06649565||Breast cancer patients who did not achieve pathological complete response after neoadjuvant therapy|All enrolled breast cancer patients received normal neoadjuvant therapy and subsequent surgery without intervention in the diagnosis and treatment process. They were judged as not achieving pathological complete respone based on surgical pathology.
62243623|NCT06408649||TOTAL30 Sphere|Lehfilcon A spherical contact lenses worn in both eyes in a real-world setting
62600311|NCT01632904|EXPERIMENTAL|ruxolitinib and hydroxyurea (HU)-placebo|
62243624|NCT06408649||TOTAL30 for Astigmatism|Lehfilcon A toric contact lenses worn in both eyes in a real-world setting
62600312|NCT01632904|ACTIVE_COMPARATOR|HU and ruxolitinib-placebo|
62600313|NCT06406075|EXPERIMENTAL|Investigational arm|Induction of glycose dynamics and collection of transcutaneous spectral data and reference glucose values
62243625|NCT04458272|EXPERIMENTAL|DS-1001b|
62433988|NCT05841381|EXPERIMENTAL|arm 1|Pyrotinib Plus trastuzumab and paclitaxel
62243626|NCT06735092|ACTIVE_COMPARATOR|Exercise-Only Group (Control Group)|This is the control group, where the patients will only participate in an exercise program, without any additional support or devices like braces. This group helps assess the effectiveness of exercise alone compared to other interventions involving braces. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group.
62243627|NCT06735092|ACTIVE_COMPARATOR|Exercise + Forearm Counterforce Brace Group|This group will focus on a combined treatment approach, including exercise therapy alongside the use of a forearm counterforce brace. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group.
62433989|NCT05841381|ACTIVE_COMPARATOR|arm 2|trastuzumab and paclitaxel
62433990|NCT00689663|ACTIVE_COMPARATOR|1|Dissection staring at the triangle of calots. Dissection with electrocautery.
62243628|NCT06735092|ACTIVE_COMPARATOR|Exercise + Wrist Brace Group|This group will focus on a treatment combining exercise therapy with the use of a wrist brace. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group.
62243629|NCT06735404|EXPERIMENTAL|Hybrid care|
62433991|NCT00689663|ACTIVE_COMPARATOR|2|Dissection as fundus first with electrocautery.
62433992|NCT00689663|ACTIVE_COMPARATOR|3|Dissection as fundus first with ultrasonic dissection.
62243630|NCT02612740|EXPERIMENTAL|Test Group|The bone defect was filled with granules of deproteinized bovine bone (Bio-Oss, Geistlich Pharm, AG Wolhausen, Switzerland)
62243631|NCT02612740|NO_INTERVENTION|Control Group|No filling material was used in the bone healing
62433993|NCT03000868|EXPERIMENTAL|Cold EMR group|Patients who have small colorectal polyps (\<1cm) who receive endoscopic mucosal resection using snare without electrocautery.
62433994|NCT03000868|ACTIVE_COMPARATOR|Hot EMR group|Patients who have small colorectal polyps (\<1cm) who receive endoscopic mucosal resection using snare with the use of electrocautery.
62433995|NCT00124176|EXPERIMENTAL|1|Nebulized levalbuterol 10mg/hr given continuously
62433996|NCT00124176|ACTIVE_COMPARATOR|2|Racemic albuterol 20mg/hr given continuously
62849095|NCT03774719|EXPERIMENTAL|Hand-carried ultrasound arm|This is the only arm of the study. It will be comprised of 154 inpatients who had a renal ultrasound ordered or performed within the past 4 hours. The intervention will be performing hand-carried ultrasound to evaluate for presence and degree of hydronephrosis.
62849096|NCT01238484|ACTIVE_COMPARATOR|Control|Patients in the control group will be treated with the current standard of care including shoe modification and home stretching exercises.
62243632|NCT03858452|ACTIVE_COMPARATOR|Pelvic floor muscles training group|Pelvic floor muscles exercises twice a day for 30 min
62243633|NCT03858452|ACTIVE_COMPARATOR|Diaphragm muscles training group|Breathing exercises twice a day for 30 min
62243634|NCT03858452|ACTIVE_COMPARATOR|Abdominal muscles training group|Abdominal muscles exercises twice a day for 30 min
62243635|NCT04296097|EXPERIMENTAL|Deep Brain Stimulation (DBS) activated|Patients with severe permanent non-pulsatile tinnitus treated by Deep Brain Stimulation (DBS) in position ON
62433997|NCT04446832||Liver transplantation candidates|
62433998|NCT00235833|EXPERIMENTAL|Adalimumab 40 mg eow|
62433999|NCT01806883|EXPERIMENTAL|Rehabilitation using Nintendo-Wii|30 patients will receive rehabilitation using Nintendo-Wii.
62434000|NCT01806883|ACTIVE_COMPARATOR|Traditional physiotherapy|30 patients will receive traditional physiotherapy.
62434001|NCT02378506|EXPERIMENTAL|ETN 50mg QW|
62600314|NCT01746498|ACTIVE_COMPARATOR|Group 1|11 patients We Applied real anodal tDCS on the left dorsolateral prefrontal cortex (DLPFC)20 minutes every day for 10 consecutive days.
62600315|NCT01746498|ACTIVE_COMPARATOR|Group 2|11 patients we applied cathodal tDCS on left DLPFC for 20 minutes every day for 10 consecutive days.
62600316|NCT01746498|SHAM_COMPARATOR|Group 3|11 patients We applied sham stimulations(anodal tDCS) on the left DLPFC for few seconds the stop stimulations 2 mA every day for 10 days.
62600317|NCT04076423|EXPERIMENTAL|Experimental arm:|they will take 1 tablet (50 mg BIC + 200 mg FTC + 25 mg TAF), orally, once a day, from the moment of randomization.
62849097|NCT01238484|EXPERIMENTAL|Experimental|Patients assigned to the experimental group will receive the current standard of care as well as the Ankle Dorsiflexion Dynasplint.
62849098|NCT05203900|EXPERIMENTAL|Investigational formula|Infant formula with Human Milk Oligosaccharide
62849099|NCT05203900|PLACEBO_COMPARATOR|Control formula|Infant formula without Human Milk Oligosaccharide
62849100|NCT03323567|EXPERIMENTAL|MD Muscle Collagen group|Group with collagen intramuscular injections
62600318|NCT04076423|ACTIVE_COMPARATOR|Comparator arm|they will take 1 tablet of 50 mg of DTG orally, once a day + 1 tablet of 300 mg of 3TC orally, once a day, from the randomization moment.
62039841|NCT06178991|ACTIVE_COMPARATOR|Cohort 3 Arm H: Investigational influenza vaccine|Cohort 3 Arm H: Investigational influenza vaccine
62243636|NCT04296097|OTHER|Deep Brain Stimulation (DBS) non-activated|Patients with severe permanent non-pulsatile tinnitus treated by Deep Brain Stimulation (DBS) in position OFF
62039842|NCT06582745|EXPERIMENTAL|Prospective Treatment|Trametinib will be administered in 28-day cycles, given once daily or adjusted as per clinical judgment of the treating physician, with a maximum dosage of 2mg daily. Patients will be followed for 4 years after receiving treatment for two years. Patients may continue on the same treatment beyond two years if they and their treating physicians agree to do so in the best interest of the patient.
62243637|NCT06736184|EXPERIMENTAL|Potassium Variability and Myocardial Injury|
62243638|NCT06736184|NO_INTERVENTION|Control|
62819827|NCT02706756|ACTIVE_COMPARATOR|Education and exercise|"Group will receive a prescriptive intervention designed to strengthen the hip and surrounding regions as well as improve flexibility of the lower extremity. This group will not receive additional physiotherapy management but will be schedule bi-weekly to review the home exercises and to receive appropriate educational support.~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
62039843|NCT06582745|NO_INTERVENTION|Observation Only|Patients who have been receiving trametinib as a treatment for LCH since January 1, 2020 may be included in an observational chart review to track long-term follow-up.
62039844|NCT06307587|ACTIVE_COMPARATOR|DN group|
62039845|NCT06307587|NO_INTERVENTION|Control group|
62039846|NCT01605513|EXPERIMENTAL|recombinant interferon|PEG-IFN-SA 1.0μg/kg for 12 times, Peginterferon alfa-2a 180 μg for 12 times, PEG-IFN-SA 1.5 μg/kg for 12 times, PEG-IFN-SA 2 μg/kg for 12 times, PEG-IFN-SA 3 μg/kg for 12 times, PEG-IFN-SA 1.5μg/kg + ribavirin 0.45g/bid group for 12 times, Intergen 15μg/48hours for 7 times, ribavirin 0.45g/bid for 10 times
62039847|NCT06732622|EXPERIMENTAL|Laser acupuncture Group|
62039848|NCT06732622|SHAM_COMPARATOR|Sham laser acupuncture Group|
62039849|NCT06732622|OTHER|Control group|
62243639|NCT05419401|EXPERIMENTAL|Capivasertib|film-coated tablet, 200 mg
62243640|NCT05419401|EXPERIMENTAL|[14C]AZD5363 (Capivasertib)|Solution for Infusion 20 µg/mL (NMT 37.0 kBq/5 mL) and Oral Solution, 400 mg (NMT 4.8 MBq)
62434002|NCT01077115|EXPERIMENTAL|Laparoscopic cholecystectomy|
62434003|NCT01077115|ACTIVE_COMPARATOR|Open cholecystectomy|
62600319|NCT02971436|ACTIVE_COMPARATOR|FPH Device with SensAwake On + Pressure Support A|FPH Device with SensAwake On + Pressure Support A
62039850|NCT03889743|EXPERIMENTAL|Dexamethasone|
62600320|NCT02971436|ACTIVE_COMPARATOR|FPH Device with SensAwake Off + Pressure Support A|FPH Device with SensAwake Off + Pressure Support A
62849101|NCT03323567|EXPERIMENTAL|Lidocaine 2% group|Group with 2% Lidocaine intramuscular injections
62039851|NCT03889743|PLACEBO_COMPARATOR|controls|
62039852|NCT01171248||type 1 diabetes|
62600321|NCT02971436|ACTIVE_COMPARATOR|FPH Device with SensAwake On + Pressure Support B|FPH Device with SensAwake On + Pressure Support B
62039853|NCT01171248||non-diabetics|
62039854|NCT06315556||Premature infants diagnosed with ROP|Premature infants diagnosed with retinopathy of prematurity (ROP) and treated with aflibercept 0.4 mg using the Eylea 40 mg/mL prefilled syringe (PFS) in combination with the PICLEO paediatric dosing device (PDD) after marketing authorisation in UK and included in the National Neonatal Research Database (NNRD).
62039855|NCT03943030|EXPERIMENTAL|Pulmonary rehabilitation|The PR program will consist of supervised physical exercise sessions, which will be held 3 times a week for 8 weeks, and weekly educational sessions. Exercise sessions include aerobic exercise (30 min to 45 min) and lower limb and upper limb strength training, as well as warm-up and muscle stretching exercises after exercise. The exercise load will be individualized and determined from the patients' baseline tests, being increased progressively throughout the sessions. A baseline evaluation will be performed, which will be repeated after 9 weeks, including: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes usually used in the assistance to evaluate PR will also be measured.
62039856|NCT03943030|NO_INTERVENTION|Group control|The group will not receive pulmonary rehabilitation intervention. Patients will be guided and maintain their daily and routine lives normally during the evaluation process. However, a baseline evaluation will be performed, which will be repeated after 9 weeks: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes commonly used in the assistance to assess PR will also be measured.
62039857|NCT00353717|EXPERIMENTAL|1|
62039858|NCT05268679||Heart transplant recipients|Heart transplant recipients followed at Bichat Hospital and who were offered vaccination against SARS-CoV-2, regardless of whether they agreed to be vaccinated or not.
62243641|NCT06734182|EXPERIMENTAL|Intervention/Treatment|"Patients were treated with subcutaneous Envafolimab injections (300mg, d1, Q3W) combined with intravenous Disitamab Vedotin (2.5mg/kg, d1, Q3W) and carboplatin (AUC5, d1, Q3W)~Participants receive totally 4 cycles of Envafolimab combined with Disitamab Vedotin and carboplatin during perioperative period"
62243642|NCT01889238|EXPERIMENTAL|Enzalutamide|160 mg administered as four 40 mg soft gelatin capsules orally once daily
62243643|NCT05909059|EXPERIMENTAL|Moderate Renal Dysfunction|Moderate renal dysfunction will receive a 20% dose reduction of fludarabine and no dose reduction for cyclophosphamide.
62243644|NCT05909059|EXPERIMENTAL|Severe Renal Dysfunction|Several renal dysfunction will receive a 40% dose reduction of fludarabine and no dose reduction for cyclophosphamide.
62434004|NCT04976140|EXPERIMENTAL|Low dose group|The investigational product is intravenously administered according to the planned dose.
62434005|NCT04976140|EXPERIMENTAL|Intermediate dose group|The investigational product is intravenously administered according to the planned dose.
62434006|NCT04976140|EXPERIMENTAL|High dose group|The investigational product is intravenously administered according to the planned dose.
62434007|NCT05621200|ACTIVE_COMPARATOR|Transcranial direct current stimulation (tDCS)|Single session of anodal tDCS at 2 mA over the cerebellar hemispheres
62243645|NCT05909059|EXPERIMENTAL|Dialysis Participants|Participants on dialysis will receive a 50% dose reduction of fludarabine and a 25% dose reduction of cyclophosphamide.
62243646|NCT06734936|EXPERIMENTAL|experimental group|SGG applied group
62243647|NCT06734936|NO_INTERVENTION|control group|sgg unused group
62819828|NCT02706756|PLACEBO_COMPARATOR|Supervised neglect|"Group will receive supervised neglect. We will monitor this group for changes or emergent situations but no formal care will be provided.~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
62819829|NCT06700473|EXPERIMENTAL|Reiki|Before the intervention, when their cervical dilatation is 4-5 cm, EC-1, EC-2 and EC-3 will be applied to pregnant women in all groups. After the initial data collection, the researcher TC will apply reiki for approximately 15-20 minutes to pregnant women in the reiki group with cervical dilatation of 4-5 cm. Immediately after the first intervention, the second EC-2 and EC-3 measurements will be performed. The third EC-2 and EC-3 measurements will be performed when the cervical dilatation is 6-7 cm and then the fourth EC-2 and EC-3 measurements will be performed after 15 minutes of reiki application. The fifth EC-2 and EC-3 measurements will be performed when the cervical dilatation is 8-9 cm, followed by 15 minutes of reiki and the sixth EC-2 and EC-3 measurements. The final data will be collected one hour after delivery of the placenta with the seventh VAS measurement and EK-4. The EC-4 will also be re-evaluated by the researchers online at the sixth postpartum week.
62819830|NCT06700473|NO_INTERVENTION|Control|Pregnant women in the control group will receive routine midwifery care during labor. Both groups will not receive any non-pharmacologic intervention for pain management. All women will receive one-to-one support from midwives during labor.
62434008|NCT05621200|ACTIVE_COMPARATOR|Transcranial alternate current stimulation (tDCS)|Single session of gamma tACS (50 Hz) at 3 mA over the cerebellar hemispheres
62434009|NCT05621200|SHAM_COMPARATOR|Placebo stimulation (sham)|Single session of sham tDCS over the cerebellar hemispheres
62819831|NCT06599229||Patients with HCM initiated on cardiac myosin inhibitor therapy|Patients with HCM who are being initiated on cardiac myosin inhibitor therapy for clinically indicated reasons.
62849102|NCT03323567|PLACEBO_COMPARATOR|Saline|Group with 0,9% NaCl intramuscular injections
62243648|NCT06578117|EXPERIMENTAL|Visual Training in Cortically Blind cohort|
62243649|NCT06578117|EXPERIMENTAL|Visual Training in Control cohort|
62849103|NCT03272776||Protector Laryngeal Mask Airway|Patients undergoing anesthesia in which airway management includes a Protector Laryngeal Mask and fulfill the inclusion criteria of the study.
62849104|NCT04435717|EXPERIMENTAL|TCZ 8 mg / kg one dose|TCZ 8 mg / kg (with a maximum of 800 mg) in single dose + usual treatment
62849105|NCT04435717|EXPERIMENTAL|TCZ 8 mg / kg in two|TCZ 8 mg / kg in two doses at 0 and 12 hours (with a maximum of 800 mg per dose) + usual treatment
62849106|NCT04435717|NO_INTERVENTION|standard care treatment|Usual / standard care treatment
62849107|NCT02366884|EXPERIMENTAL|Anti-bacterial agents|Combination of two selected anti-bacterial agents with documented anti-cancer properties
62434010|NCT06267261|EXPERIMENTAL|Patients with face mask|Birch pollen allergen exposure in ALYATEC chamber with face mask
62849108|NCT02366884|EXPERIMENTAL|Anti-fungal agents|Combination of two selected anti-fungal agents with documented anti-cancer properties
62243650|NCT06155604|EXPERIMENTAL|Treatment group|standard maintenance therapy plus dapagliflozin 10 mg daily
62243651|NCT06155604|OTHER|Control group|standard maintenance therapy only
62243652|NCT05471908|EXPERIMENTAL|As-needed (PRN) post-hospitalization follow-up|At hospital discharge, participant receives a recommendation for PRN follow-up. Recommendation informs participant that scheduling a follow-up visit is not needed at discharge and suggests that participant follow symptoms after discharge to decide if a visit is ultimately needed or not.
62434011|NCT06267261|NO_INTERVENTION|Patients without face mask|Birch pollen allergen exposure in ALYATEC chamber without face mask
62434012|NCT00786110|EXPERIMENTAL|1 arm only|"One arm only with Sorafenib plus Paclitaxel Patients enrolled will undergo strict follow-up~Intervention: Sorafenib plus Paclitaxel"
62434013|NCT00219557|ACTIVE_COMPARATOR|Gemcitabine|
62434014|NCT00219557|EXPERIMENTAL|Axitinib [AG-013736] plus gemcitabine|
62434015|NCT03984136|EXPERIMENTAL|Intervention group|Men will be required to exchange the Center for Disease Control and Prevention certified online HIV results (COHIV) with friends conditionally.
62434016|NCT03984136|ACTIVE_COMPARATOR|Control group|Men will share the Center for Disease Control and Prevention certified online HIV results (COHIV) with friends freely without conditional exchange requirement.
62434017|NCT04964622|OTHER|nurofen|sodium ibuprofen 1 tablet (256) 30 minutes before treatment administered once (oral)
62600322|NCT02971436|ACTIVE_COMPARATOR|FPH Device with SensAwake Off + Pressure Support B|FPH Device with SensAwake Off + Pressure Support B
62600323|NCT02971436|ACTIVE_COMPARATOR|Competitor's PAP Released Device + Pressure Support A|Competitor's PAP Released Device + Pressure Support A
62849109|NCT02366884|EXPERIMENTAL|Anti-protozoal agents|Combination of two selected anti-protozoal agents with documented anti-cancer properties
62849110|NCT02366884|EXPERIMENTAL|Anti-bacterial + anti-fungal + anti-protozoal agents|Combination of six selected anti-bacterial agents, anti-fungal agents, and anti-protozoal agents with documented anti-cancer properties
62434018|NCT04964622|PLACEBO_COMPARATOR|placebo|starch tablet 30 minutes before treatment administered once (oral)
62849111|NCT01895621|EXPERIMENTAL|Lipoic|Median nerve decompression at the wrist, followed by Alpha lipoic acid post median nerve decompression: lipoic acid, 800 mg daily for 40 days from the day of the operation, tablets.
62039859|NCT02666950|EXPERIMENTAL|Arm B (cytarabine and WEE1 inhibitor AZD1775|Patients receive cytarabine and WEE1 inhibitor AZD1775 as in Arm A.
62243653|NCT05471908|ACTIVE_COMPARATOR|Automatic post-hospitalization follow-up|At hospital discharge, participant receives a recommendation for automatic follow-up. Recommendation instructs participant to schedule a follow-up visit and attend the visit even if symptoms get better.
62243654|NCT06735001|OTHER|Patients with FA|Patient with a documented Fibrillation Atrial within the last 18 months
62243655|NCT06735001|OTHER|Patients without FA|Patient without Fibrillation Atrial
62819832|NCT04231669|NO_INTERVENTION|Control: bolstered care|Female adolescents in the bolstered care will receive services/education as usual in their respective schools. The usual care will be bolstered by providing school notebooks and lunch in the control arm (bolstered care will also be provided to treatment arm). Primary school education is universal and free in Ghana. Yet notebooks and lunch are costly expenses for families that create a barrier to school attendance. Hence, these will be provided to participants in all study schools.
62819833|NCT04231669|EXPERIMENTAL|Anzansi Family Program|In addition to bolstered care, participants(adolescent girls and caregivers) in this arm will receive the ANZANSI that combines Family Economic Empowerment (EE) with Multiple Family Groups (MFG).
62434019|NCT04115176||smokers + periodontitis|Individuals clinically diagnosed with chronic periodontitis that smoke recruited for this group.
62434020|NCT04115176||nonsmoker + periodontitis|Individuals clinically diagnosed with chronic periodontitis that don't smoke recruited for this group.
62819834|NCT04139733||Prone group|"1. Prone position within 24 hours after VV-ECMO support.~2. Prone position for at least 16 hours per day for a minimum of 5 days."
62434021|NCT05895981|EXPERIMENTAL|Sacral nerve stimulation|
62434022|NCT01348542|ACTIVE_COMPARATOR|Trazodone|
62434023|NCT01348542|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|
62434024|NCT03782649|EXPERIMENTAL|RSP-08|All subjects undergo the same procedures. Subjects will be subjected to measurements on the IMD (Working Model 3.4NR), FreeStyle Libre, Dexcom, microdialysis, venous and capillary blood collection.
62434025|NCT05295602||Group|A CT scan of both legs will be made in patient scheduled for a primary knee arthroplasty. No other additional intervention will be made apart from those already routinely used for the operation.
62434026|NCT05496114|EXPERIMENTAL|Intervention group: with checklist|When starting the scenario, a checklist will be given to the emergency physician. The checklist outlines interventions to consider during management of a patient with tricyclic antidepressant poisoning. Each checklist will include indications, contra-indications and for medication, dose, route and rate of administration.
62434027|NCT05496114|NO_INTERVENTION|Control group: without checklist|Emergency physicians will be asked to perform the scenario as they would in their daily practice. They will be allowed to use their usual cognitive aids (eg, phone, internet) but not allowed to request help from others.
62819835|NCT04139733||Supine group|1. Supine group on ECMO.
62819836|NCT04412863|EXPERIMENTAL|Cohort 1d|VIR-2218 given by subcutaneous injection
62243656|NCT01994239|ACTIVE_COMPARATOR|Radiation|"Pelvic radiotherapy~* 46 Gy in 23 fractions of 2 Gy.~* prostate only-boost up to 66 Gy"
62243657|NCT01994239|EXPERIMENTAL|Radiation and Degarelix|"Radiotherapy:~* 46 Gy in 23 fractions of 2 Gy.~* prostate only-boost up to 66 Gy~Associated with hormonal therapy by degarelix:~* beginning in parallel to radiotherapy for 6 months~* First dose of 240 mg~* Maintenance dose of 80 mg"
62243658|NCT03057002||Cardiomyopathy|Patients with Cardiomyopathy will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.
62243659|NCT03057002||Control|Healthy control subjects will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.
62434028|NCT04816188|EXPERIMENTAL|Exercise and Activity Modification|
62434029|NCT04188223|EXPERIMENTAL|Recombinant Hepatitis B (Bio Farma) Vaccine|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg and purified and inactivated by several physicochemical steps such as ultracentrifugation, column chromatography and formaldehyde treatment.
62600324|NCT02971436|ACTIVE_COMPARATOR|Competitor's PAP Released Device + Pressure Support B|Competitor's PAP Released Device + Pressure Support B
62600325|NCT06307691|ACTIVE_COMPARATOR|Control: conventional drilling|Atraumatic extraction followed by osteotomy preparation. Osteotomy site will be prepared using conventional drills. Implant placement will follow.
62819837|NCT04412863|EXPERIMENTAL|Cohort 2d|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
62819838|NCT04412863|EXPERIMENTAL|Cohort 3d|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
62819839|NCT04412863|EXPERIMENTAL|Cohort 1e|VIR-2218 given by subcutaneous injection
62819840|NCT04412863|EXPERIMENTAL|Cohort 2e|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
62819841|NCT04412863|EXPERIMENTAL|Cohort 3e|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
62819842|NCT04412863|EXPERIMENTAL|Cohort 1f|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
62819843|NCT04412863|EXPERIMENTAL|Cohort 2f|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
62600326|NCT06307691|ACTIVE_COMPARATOR|Intervention: Osseodensification|Atraumatic extraction followed by osteotomy preparation. Osteotomy site will be prepared using Densah bur. Implant placement will follow.
62600327|NCT01729052|EXPERIMENTAL|Acupuncture and standard treatment|"Acupuncture at Neiguan (Pericardium-6) bilaterally with Seirin needles no 3 (0.20x15 mm) to a depth of approximately 7 mm will be performed on the children immediately after induction of anaesthesia and removed before they are fully awake.~Standard treatment: general anaesthesia"
62600328|NCT01729052|NO_INTERVENTION|Standard treatment|General anaesthesia
62039860|NCT02666950|EXPERIMENTAL|Arm C (WEE inhibitor AZD1775)|Patients receive WEE inhibitor AZD1775 PO daily on days 1-5, 8-12, 15-19, and 22-26.
62600329|NCT01566942|ACTIVE_COMPARATOR|FOLFOX|In this group, the patients will receive the adjuvant chemotherapy with mFOLFOX6.
62600330|NCT01566942|EXPERIMENTAL|FOLFIRI|in this arm, patients will receive adjuvant chemotherapy with FOLFIRI regimen for about 8 cycles
62600331|NCT00412217|EXPERIMENTAL|Erlotinib|Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive erlotinib tablets as 150 mg PO daily for 1 year until disease progression or intolerable toxicity.
62600332|NCT00412217|PLACEBO_COMPARATOR|Placebo|Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive placebo treatment for 1 year until disease progression or intolerable toxicity.
62600333|NCT06269263|EXPERIMENTAL|Home-based cardiac rehabilitation|Home-based cardiac rehabilitation
62600334|NCT02195310|EXPERIMENTAL|Prevena™ Incision Management System|Subjects will receive sternal wound treatment in the operating room using Prevena™ Incision Management System according to the intended use
62600335|NCT02195310|ACTIVE_COMPARATOR|Conventional sterile wound dressings|Subjects will receive standard conventional wound therapy (SCWT) placed in the operating room, defined as using conventional sterile wound dressings (gauze).
62600336|NCT02382835||Metal-on-Metal Hip Replacement|
62039861|NCT02846974||Calibration cohort|In this cohort, approximately 30 subjects will be put through a controlled desaturation study with controlled hypoxia until they arrive at approximately SpO2 = 70%. Measurements will be taken via arterial catheterization to resolve proper values to calibrate the device
62039862|NCT02846974||Validation cohort|In this cohort, approximately 250 patients will have a single pulse oximetry reading taken using the novel device and a gold standard device to ensure accurate validation.
62039863|NCT06732180|EXPERIMENTAL|single-arm. All participants receive the active molecule (once daily GT-02287 administration)|
62243660|NCT06259396|ACTIVE_COMPARATOR|The 8x5 Diet|The 8x5 Diet is a healthy dietary pattern administered virtually by a specialist dietitian
62243661|NCT06259396|NO_INTERVENTION|Control|Continuation of habitual diet, no dietary changes.
62434030|NCT04188223|ACTIVE_COMPARATOR|Control Product: Recombinant Hepatitis B (Bio Farma) Vaccine®|Registered Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg and purified and inactivated by several physicochemical steps such as ultracentrifugation, column chromatography and formaldehyde treatment.
62434031|NCT05050513||interventional group|kidney graft preserved with M101
62434032|NCT05050513||control group|kident graft preserved in standard condition (without M101)
62434033|NCT01040013|EXPERIMENTAL|Laparoscopy|Laparoscopic Left-Sided Colectomy
62434034|NCT01040013|ACTIVE_COMPARATOR|laparotomy|Laparotomic Left-Sided Colectomy
62243662|NCT06734910|NO_INTERVENTION|Control group|Standard antenatal care.
62434035|NCT05837559|ACTIVE_COMPARATOR|Traditional WHO Partograph for Uncomplicated Labour|With the Traditional WHO partograph, uterine contractions will be assessed every 30 minutes, fetal heart will be assessed every 30 minutes and maternal pulse 30 minutes, blood pressure is recorded every 4 hourly and temperature is recorded every 2 hourly. Urine output is recorded every time urine is passed. The woman is encouraged to pass urine every 2 hourly in labour and each specimen is tested for protein and ketones. Drugs, IV fluids, Drugs (Oxytocin) are recorded in the space provided.
62434036|NCT05837559|EXPERIMENTAL|Korle-Bu Modified WHO Partograph for Uncomplicated Labour|With the Korle-Bu modified partograph, uterine contractions will be assessed every hour (60 minutes), fetal heart will be assessed every 30 minutes and maternal pulse every hour. All other assessments remain as for the traditional partograph.
62600337|NCT02382835||Other Hip Replacement|Other types of hip replacement, such as metal-on-polyethylene or ceramic-on-ceramic
62600338|NCT00492596|EXPERIMENTAL|device|insertion of balloon system
62600339|NCT00492596|SHAM_COMPARATOR|sham|cystoscopy with sham system
62600340|NCT04656197||Patients with dry eye disease|
62600341|NCT04656197||Healthy controls|
62600342|NCT04873453|ACTIVE_COMPARATOR|Full-spectrum Cannabidiol|150mg/day of full-spectrum cannabidiol, containing less than 0.3%THC.
62600343|NCT04873453|EXPERIMENTAL|Broad-spectrum Cannabidiol|150mg/day of broad-spectrum cannabidiol, containing 0%THC.
62600344|NCT04873453|PLACEBO_COMPARATOR|Placebo|150mg/day of hemp-seed oil with no cannabinoids present.
62819844|NCT04412863|EXPERIMENTAL|Cohort 3f|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
62039864|NCT06733519|EXPERIMENTAL|Treatment|
62039865|NCT06733519|PLACEBO_COMPARATOR|Control|
62243663|NCT06734910|ACTIVE_COMPARATOR|HealthyPregnancy group|Digital care guide as supplement to standard antenatal care.
62243664|NCT04663308|EXPERIMENTAL|Part 1 Arm 1: Volixibat 20mg|Participants randomized to this arm will receive volixibat 20mg twice daily.
62243665|NCT04663308|EXPERIMENTAL|Part 1 Arm 2: Volixibat 80mg|Participants randomized to this arm will receive volixibat 80mg twice daily.
62243666|NCT04663308|PLACEBO_COMPARATOR|Part 1 Arm 3: Placebo|Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.
62819845|NCT05415761|ACTIVE_COMPARATOR|iCanQuit|iCanQuit is a modern, cognitive behavioral treatment which promotes cessation through greater acceptance of triggers for smoking and commitment to personal values. It is a smart phone-based acceptance and commitment therapy (ACT). For patients randomized to the iCanQuit arm (444 total), research staff will assist in downloading the app onto the patient's phone.
62600345|NCT06622512|ACTIVE_COMPARATOR|Control group|The three groups will receive RPWT with the device BTL-6000 Radial Shockwave Therapy (BTL Industries, Ltd.). Each patient, in supine position and knee flexion of 30 to 60 degrees, will receive 3 sessions of RPW, once per week, 2,000 impulses per session, 2.0 bar and frequency of 10Hz. The air pressure and frequency will be adjusted in response to discomfort. The control group will receive 1,000 pulses at the two most painful sites of the treated knee, in accordance with the technique employed in the majority of previous studies in this field.
62039866|NCT02970500|EXPERIMENTAL|Methylphenidate HCl 10Mg SR|Participants of the intervention group (n=20) will receive 1 capsule of Methylphenidate HCl 10 mg SR each morning during 14 days during phase 1 and 2 capsules of Methylphenidate HCl 10 mg SR each morning during 14 days during phase 2.
62039867|NCT02970500|PLACEBO_COMPARATOR|Placebo Group|Participants of the control group (n=20) will receive 1 capsule of placebo each morning during 14 days during phase 1 and 2 capsules of placebo each morning during 14 days during phase 2.
62039868|NCT04729114|EXPERIMENTAL|Phase 1a Dose Escalation: Group A|Participants with metastatic castration-sensitive prostate cancer (mCSPC), nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical relapse, or metastatic castration-resistant prostate cancer (mCRPC) will receive escalating doses of PRL-02 + prednisone.
62039869|NCT04729114|EXPERIMENTAL|Phase 1a Dose Escalation: Group B|Participants with mCSPC, nmCSPC with biochemical relapse, or mCRPC will receive escalating doses of PRL-02 + dexamethasone.
62039870|NCT04729114|EXPERIMENTAL|Phase 1a Dose Escalation: Group H|Participants with mCSPC or mCRPC will receive escalating doses of PRL-02 + dexamethasone + enzalutamide.
62039871|NCT04729114|EXPERIMENTAL|Phase 1b Dose Expansion: Group D|Participants with mCRPC with prior treatment with abiraterone acetate will receive escalating doses of PRL-02 + dexamethasone.
62434037|NCT04298125|EXPERIMENTAL|Exercise in Pregnancy in Community|The Expecting intervention at the ACNC includes three 30-45 minute, in-person exercise sessions per week. The sessions are gradually increased in length over the first weeks of participation, and are comprised of 15-30 minutes of moderate aerobic activity (recumbent bike, walking on a treadmill or on an elliptical machine) as well as 5-10 minutes of resistance training using hydraulic exercise equipment. The sessions conclude with stretching exercises. Throughout the session, a personal trainer assesses the rating of perceived exertion using the 6 to 20 point Borg scale of exhaustion.41 Between sessions, participants are asked to monitor their daily step count with a target of 10,000 steps per day using a pedometer provided to the participant. This number is reported to or downloaded by the personal trainer at each in-person session. These elements will be adapted to provide a similar exercise experience that is accessible to women in their local community.
62434038|NCT04298125|NO_INTERVENTION|Standard Care|Participants will receive guidance on exercise from their physician as usual.
62434039|NCT02391883||Clopidogrel|Patients in Clopidogrel or Dual Antiplatelet Therapy (Clopidogrel+Acetylsalicylic acid) at the time of admission AND who are operated \<24 hours after admission.
62434040|NCT02391883||Control|Patients NOT in anticoagulation treatment (Except acetylsalicylic acid) AND who are operated \<24 hours after admission.
62600346|NCT06622512|EXPERIMENTAL|Medial group|The three groups will receive RPWT with the device BTL-6000 Radial Shockwave Therapy (BTL Industries, Ltd.). Each patient, in supine position and knee flexion of 30 to 60 degrees, will receive 3 sessions of RPW, once per week, 2,000 impulses per session, 2.0 bar and frequency of 10Hz. The air pressure and frequency will be adjusted in response to discomfort. The medial group will receive 2,000 pulses at the medial interarticular line of the treated knee.
62600347|NCT06622512|EXPERIMENTAL|Medial and lateral group|The three groups will receive RPWT with the device BTL-6000 Radial Shockwave Therapy (BTL Industries, Ltd.). Each patient, in supine position and knee flexion of 30 to 60 degrees, will receive 3 sessions of RPW, once per week, 2,000 impulses per session, 2.0 bar and frequency of 10Hz. The air pressure and frequency will be adjusted in response to discomfort. The medial and lateral group will receive 1,000 pulses at the medial interarticular line and 1,000 pulses at the lateral interarticular line of the treated knee.
62600348|NCT05619536|EXPERIMENTAL|Cohort 1|9 subjects randomized in a 7:2 ratio to receive either 50 mg CD388 SQ injection or matching placebo injection
62243667|NCT04663308|EXPERIMENTAL|Part 2 Arm 1: Volixibat Selected Dose 20mg|Participants randomized to this arm will receive volixibat 20mg twice daily.
62243668|NCT04663308|PLACEBO_COMPARATOR|Part 2 Arm 2: Placebo|Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.
62600349|NCT05619536|EXPERIMENTAL|Cohort 2|9 subjects randomized in a 7:2 ratio to receive either 150 mg CD388 SQ injection or matching placebo injection
62819846|NCT05415761|ACTIVE_COMPARATOR|iCanQuit+Motiv8|Motiv8 is an internet-and smart phone-based contingency management (CM) intervention. Motiv8 verifies smoking status via a hand-held breath carbon monoxide (CO) monitor that is connected to a smart phone. For patients randomized to the iCanQuit+Motiv8 arm (444 total), research staff will assist in downloading the combined pp and connecting the iCO to the patient's phone. Smokers will also be asked to complete the first 4 iCanQuit modules, which contain exercises designed to prepare the users for their quit day. The end of the preparation phase will also mark each patient's quit date. During the intervention (7 weeks), participants will be considered abstinent from smoking if their breath CO sample is ≤ 5 ppm or if the CO value has decreased by 5% per hour from the last sample provided.
62819847|NCT05415761|ACTIVE_COMPARATOR|Florida quit line|The Florida quit line provides telephone counseling for smoking cessation. Patients randomized to the Florida quit line arm (444 total) will be enrolled after contact information is sent electronically.
62819848|NCT01345240|EXPERIMENTAL|RTS,S Regimen A Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
62849112|NCT01895621|PLACEBO_COMPARATOR|placebo|Median nerve decompression at the wrist, followed by placebo in the same form frequency and duration as alpha lipoic acid
62849113|NCT05680441||Healty group|The controls/Healthy group were the individuals with well-maintained oral hygiene without no periodontal disease history or symptoms with a probing pocket depth (PPD) of ≤3 mm and bleeding on probing (BOP) of (+) ≤10.
62243669|NCT04557085|PLACEBO_COMPARATOR|Placebo|Placebo
62243670|NCT04557085|EXPERIMENTAL|Cenobamate 100 mg/day|Cenobamate 100 mg/day
62243671|NCT04557085|EXPERIMENTAL|Cenobamate 200 mg/day|Cenobamate 200 mg/day
62243672|NCT04557085|EXPERIMENTAL|Cenobamate 400 mg/day|Cenobamate 400 mg/day
62243673|NCT03386513|EXPERIMENTAL|Escalation and Expansion|"Escalation: IMGN632 was administered by IV on 2 different schedules for participants with relapsed/refractory AML, ALL, or BPDCN.~Expansion: IMGN632 was administered by IV:~* Cohort 1: Relapsed or refractory BPDCN participants who have received 1-3 prior systemic therapies (incl. tagraxofusp-erzs and/or any other systemic therapy deemed appropriate for the treatment of BPDCN)~* Cohort 2: Relapsed AML~* Cohort 3: Relapsed or refractory ALL~* Cohort 4: Other relapsed or refractory hematologic malignancies~* Cohort 5: Relapsed or refractory AML at alternate dose or schedule~* Cohort 6: Pivotal cohort for frontline BPDCN participants who have not received prior systemic therapy and participants with frontline BPDCN who have prior or concomitant hematologic malignancy (PCHM) and have not received prior systemic therapy."
62600350|NCT05619536|EXPERIMENTAL|Cohort 3|9 subjects randomized in a 7:2 ratio to receive either 450 mg CD388 SQ injection or matching placebo injection
62849114|NCT05680441||Periodontitis stage 3 grade B|Stage III periodontitis patients had at least 4 interdental sites clinical attachment level (CAL)\> 5 mm due to periodontitis, radiographic bone loss reaching to the mid-third of the root or beyond, teeth loss less than 4 teeth due to periodontitis. These patients were graded according to the bone loss%/age index (Grade B, 0.25-1.00).
62243674|NCT06548750|EXPERIMENTAL|Intervention Group|Individuals with a diagnosis of pes planovalgus who underwent supervised exercise under the guidance of a physiotherapist for 8 weeks, 1 day a week.
62600351|NCT03445234|EXPERIMENTAL|Blueberry|Freeze-dried blueberry powder
62600352|NCT03445234|PLACEBO_COMPARATOR|Placebo|Placebo powder
62600353|NCT03445234|EXPERIMENTAL|Banana|Acute banana ingestion
62600354|NCT03445234|EXPERIMENTAL|No banana|No banana ingestion
62600355|NCT06439589|EXPERIMENTAL|HRS2398 given in combination with adebrelimab|
62600356|NCT03863457|EXPERIMENTAL|UPTAKE OF [18F]F-GLN BY PET/CT IN BREAST CANCER|Pilot data will be collected to evaluate image quality and collect preliminary information on the uptake of \[18F\]F-Gln in breast cancer. Uptake measures will be compared to tumor markers of glutamine metabolism, when tissue is available. The safety of \[18F\]F-Gln will also be evaluated in all subjects.
62819849|NCT01345240|EXPERIMENTAL|RTS,S Regimen A Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. In addition, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
62243675|NCT06548750|ACTIVE_COMPARATOR|Control Group|Individuals with a diagnosis of pes planovalgus who underwent supervised exercise under the guidance of a physiotherapist for 8 weeks, 1 day a week.
62600357|NCT03593421|EXPERIMENTAL|synthetic preImplantation factor 1 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
62039872|NCT04729114|EXPERIMENTAL|Phase 1b Dose Expansion: Group E|Participants with mCRPC with prior treatment with 1 of the following androgen receptor pathway inhibitor (ARPIs) (enzalutamide, apalutamide, and/or darolutamide) will receive escalating doses of PRL-02 + dexamethasone.
62434041|NCT06306027|EXPERIMENTAL|Experimental|When patients come to the polyclinic for a check-up 15 days after discharge, the web-designed training program site will be promoted. The patient who accepts the research will be given a user name and password specifically created by the researcher. The patient will be explained practically how to log in to the system at home via phone. Patients will be asked to watch educational videos on the website at least twice a week for one month. Then, pre-test data, Personal Information Form, Self-Efficacy Scale, Self-Care Power Scale and Quality of Life Scale data will be collected. Patients who receive training for a month will be asked to fill out the self-efficacy scale, self-care power scale and quality of life scale for post-test data via the mobile application at the end of the month.
62600358|NCT03593421|EXPERIMENTAL|synthetic preImplantation factor 2 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
62039873|NCT05981768|EXPERIMENTAL|Part 1: Cytisinicline 3 mg Once Daily (QD), Fasting|3 mg cytisinicline tablet administered in the morning, between 7:00 and 9:00 AM, in fasting conditions on Day 1 (Period 1) or Day 3 (Period 2). Participants will fast overnight for at least 10 hours before cytisinicline administration and will continue to fast for 4 hours after dosing.
62600359|NCT03593421|EXPERIMENTAL|synthetic preImplantation factor 3 mg/kg|Patients will be dosed SQ 14 doses
62600360|NCT03593421|EXPERIMENTAL|synthetic preImplantation factor 4 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
62600361|NCT03593421|EXPERIMENTAL|synthetic preImplantation factor 5 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
62243676|NCT02227225||Postoperative Delirium|
62243677|NCT05538897|EXPERIMENTAL|Phase Ib (megestrol acetate, ipatasertib)|Patients receive megestrol acetate PO QD on days 1-28 and ipatasertib PO QD on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI during screening, on study, and during follow-up. Patients also undergo collection of blood samples throughout the trial.
62243678|NCT05538897|ACTIVE_COMPARATOR|Phase II (megestrol acetate)|Arm I: Patients receive megestrol acetate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI during screening, on study, and during follow-up. Patients also undergo collection of blood samples throughout the trial.
62600362|NCT06620653|ACTIVE_COMPARATOR|Standard Care|"All patients with a recent admission for decompensated heart failure are seen in a first face-to-face appointment within two weeks of discharge as per current 2021 ESC Heart Failure Guidelines.~The standard care group will receive the usual nurse lead structured follow up and patients in the usual care will have a face-to-face appointment at week 6 and 12, and all the other contacts will be phone calls or face-to-face"
62623378|NCT01115387||ARM affected individuals and relatives.|"Individuals who have experienced vision loss from ARM and have at least one brother or sister who also has experienced vision loss from ARM can participate in the study. They also need to have at least one adult child (from 49 to 65 years old) who wishes to participate in this study.~We will allow for additional recruitment to compensate for additional family members (such as parents, aunts and uncles) who wish to participate as well as to address potential drop out and those who may be deemed ineligible based on review of their medical and/or eye records. As many as 4000 individuals in this group will be allowed to enroll."
62623379|NCT04638556||Normal|A healthy, disease-free population.
62061613|NCT06152068||Obesity|Subjects with obesity were assessed with body mass index or BMI (calculated with body weight in kg divided by body height square in m). The subjects were determined to be obese if BMI value z-score \> +2 SD of WHO child growth standard (assessed with WHO Anthroplus).
62243679|NCT05538897|EXPERIMENTAL|Phase II (megestrol acetate, ipatasertib)|Arm II: Patients receive megestrol acetate PO QD on days 1-28 and ipatasertib PO QD on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI during screening, on study, and during follow-up. Patients also undergo collection of blood samples throughout the trial.
62243680|NCT04911270|EXPERIMENTAL|Intervention Group- Computer Decision Support Tool|"Patients enrolled in the study will be started on IV vancomycin which will be dosed based on the LYV CDS tool, which will dose patients based on AUC24/MIC. Dosing will be adjusted based on vancomycin levels that will be drawn throughout the hospital stay.~All patients prospectively enrolled into this study will be in the intervention group. Results will be compared to the retrospectively matched historical controls."
62243681|NCT04911270|OTHER|Matched Historical Controls|Match historical controls are patients that were on IV vancomycin with dose adjustments based on vancomycin trough levels. Patients in this study arm will be retrospective patients that will be matched with the intervention group.
62243682|NCT05967351|EXPERIMENTAL|Delandistrogene Moxeparvovec|Participant received delandistrogene moxeparvovec in a previous clinical study.
62243683|NCT03039023|EXPERIMENTAL|Whole Hardboiled Eggs|Subjects will consume four (4) pre-cooked, pre-peeled whole hardboiled eggs per day for 28 days.
62243684|NCT03039023|EXPERIMENTAL|Choline Bitartrate Tablets|Subjects will consume two (2) 500mg choline bitartrate tablets per day for 28 days.
62243685|NCT03039023|EXPERIMENTAL|Hardboiled Eggs + Choline Bitartrate Tablets|Subjects will consume both four (4) whole, pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.
62243686|NCT03039023|EXPERIMENTAL|Egg Whites + Choline Bitartrate Tablets|Subjects will consume both the egg whites (no yolks) of four (4) pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.
62600363|NCT06620653|EXPERIMENTAL|Telemonitoring|"After the initial face-to-face appointment the telemonitoring group will have appointments at week 4 (phone call or videoconference), week 6 (videoconference), week 8 (phone call or videoconference) and week 12 (videoconference). In total, the patients will have 6 structured appointments.~Extra phone calls, videoconferences, and face-to-face visits will be made at any time, depending on the patient's needs, irrespective of the assigned group.~Patients assigned to the intervention group will receive a tablet (if the patients do not have a tablet, computer or smartphone), a weight scale and a blood pressure monitor. The patients will provide daily biometric data (weight, heart rate and blood pressure) and report symptoms through four questions to capture worsening symptoms of the cardiac condition.~The system will generate warning alarms (biometrics out of range or symptom reporting) and alerts (information related to the function of the household devices)."
62243687|NCT03039023|EXPERIMENTAL|Phosphatidylcholine Capsules|Subjects will consume six (6) 420 mg phosphatidylcholine capsules by mouth per day for 28 days.
62243688|NCT01350830|ACTIVE_COMPARATOR|pre-trasversalis mesh repair group|
62243689|NCT01350830|ACTIVE_COMPARATOR|trans-inguinal preperitoneal patch group|
62243690|NCT02243865|EXPERIMENTAL|Chordate S200 + control module (CT100), active|Chordate System S200 giving Kinetic Oscillation Stimulation Treatment for 15 minutes in each nostril
62243691|NCT02243865|PLACEBO_COMPARATOR|Chordate S200 + control module (CT100), placebo|Chordate System S200 giving Kinetic Oscillation Stimulation in placebo mode. Non-inflated and non-vibrating treatment
62243692|NCT06278207||Adult patients with CKD and T2D who initiate finerenone|The data sources used include a network of commercial electronic health records (EHRs) and national claims data in Japan and in the United States.
62243693|NCT06735352|NO_INTERVENTION|Control Group|No intervention was made to the elderly in this group.
62243694|NCT06735352|EXPERIMENTAL|virtual reality group|Evaluated the effect of using virtual reality in elderly people with mild cognitive impairment.
62243695|NCT02656420|PLACEBO_COMPARATOR|Placebos|Beverage (100 mL) containing pineapple juice, lime juice and water. Nightly for 10 days.
62039874|NCT05981768|EXPERIMENTAL|Part 1: Cytisinicline 3 mg QD, Fed|3 mg cytisinicline tablet administered in the morning, between 7:00 and 9:00 AM, in fed conditions on Day 1 (Period 1) or Day 3 (Period 2). After an overnight fasting of at least 10 hours, participants will consume a standard high-fat-high-calorie meal within 30 minutes. Cytisinicline will be administered with 240 mL of water within 5 minutes after completion of the meal.
62039875|NCT05981768|EXPERIMENTAL|Part 2: Cytisinicline 3 mg 3 Times Daily (TID)|3 mg cytisinicline tablet administered TID each day on Day 5 to 8 (Period 3) as follows: Dose 1 will be administered in the morning between 7:00 and 9:00 AM,; Dose 2 at 5 hours (±10 minutes) after Dose 1; Dose 3 at 5 hours (±10 minutes) after Dose 2. Cytisinicline will be administered on an empty stomach (cytisinicline given at least 2 hours before food or 1 hour after food).
62039876|NCT00398008|EXPERIMENTAL|1|DC-HIV plus buprenorphine maintenance.
62039877|NCT00398008|EXPERIMENTAL|2|DC-HIV plus naltrexone maintenance
62039878|NCT03734731|OTHER|Objective Nerve Conduction testing|Therapy of chronic pain and swelling with Monochromatic Infrared Photo Energy (MIRE) in combination with Transcutaneous Electrical Nerve Stimulation (TENS) and Cannabis or Opioids, to determine which treatment is deemed as the most successful, through objective nerve conduction testing with Neural Scan or AXON-II testing systems. Other types of therapies may be introduced during comparison reviews.
62039879|NCT06124040||Radio-chemotherapy|Cervical cancer patients undergoing radio-chemotherapy.
62039880|NCT06124040||Surgery|Cervical cancer patients undergoing surgery.
62039881|NCT06539429|EXPERIMENTAL|ANT-301|Vial containing allogenic adipose-derived mesenchymal stem cells and human fibrin hydrogel
62039882|NCT01198080|EXPERIMENTAL|femoral osteonecrosis patients|patientswith femoral head osteonecrosis
62039883|NCT04166357||Respiratory and autonomic complications of GBS|"Early detection of respiratory failure is among the main challenges raised by the management of GBS. Careful monitoring by an experienced team of nurses and physicians is crucial. The classic signs of respiratory failure occur late, and the early manifestations consist only of tachypnea, tachycardia, air hunger, broken sentences, and a need to pause between sentences; later, use of the accessory respiratory muscles, paradoxical breathing, and orthopnea indicate severe diaphragmatic weakness.~Autonomic dysfunction occurred in the affected patients, including cardiac arrhythmia, hypertension or hypotension, ileus, and urinary retention."
62039884|NCT05973110|EXPERIMENTAL|Cognitive Remediation|
62039885|NCT05973110|ACTIVE_COMPARATOR|Active Control|
62039886|NCT02897713|EXPERIMENTAL|intensive EN|Intensive enteral nutrition is to performed until discharge with max during of 7 days
62039887|NCT02897713|ACTIVE_COMPARATOR|routine EN|Routine enteral nutrition is to performed until discharge with max during of 7 days
62039888|NCT03085485|ACTIVE_COMPARATOR|Ivacaftor|Ivacaftor, 150 mg PO every 12 hrs for 84 days
62039889|NCT03085485|PLACEBO_COMPARATOR|Placebo|matching placebo
62039890|NCT03579498||Patient group|Patients who have suffered a cardiac arrest at Uppsala University Hospital or who were admitted to this hospital after the event.
62039891|NCT03579498||Control group|The control group will, as far as it is possible, match the patient group regarding mean age, age distribution, sex and educational attainments.
62243696|NCT02656420|EXPERIMENTAL|High Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (600 micromole) and sulforaphane-rich (40 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
62243697|NCT02656420|EXPERIMENTAL|Medium Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (300 micromole) and sulforaphane-rich (20 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
62434042|NCT06306027|NO_INTERVENTION|Control Group|When patients come to the outpatient clinic for a check-up 15 days after discharge, they will be asked to fill out the Personal Information Form, Self-Efficacy Scale, Self-Care Ability Scale, and Quality of Life Scale by face-to-face information collection method.Patients will receive routine treatment, care and checks in line with the institutional policy. A web designed training program will not be implemented. One month after the pre-test data is collected, patients will be called and asked to fill out the self-efficacy scale, self-care ability scale and quality of life scale when they come to the outpatient clinic.
62434043|NCT01993420|EXPERIMENTAL|DRM02|DRM02 Topical Gel, 0.25%
62434044|NCT01993420|PLACEBO_COMPARATOR|Vehicle|DRM02 Topical Gel, Vehicle
62600364|NCT03467763|ACTIVE_COMPARATOR|Metformin Hydrochloride Extended Release|Patients will be assigned to take their baseline medication regimen plus 2 weeks of 250 mg per day of metformin extended release, followed by 500 mg metformin XR, 750 mg, and 1,000 mg metformin XR with each treatment period separated by a 2-week course of placebo.
62039892|NCT04669171|EXPERIMENTAL|Cohort 1|Safety Lead-In, Dose-Finding, Cohort, with a 3-by-3 design of EO2463 for 6 weeks followed by addition of lenalidomide week 7 and rituximab week 19 (depending on response). Four to 18 evaluable (previously treated) patients with Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) will be Included based on safety findings
62039893|NCT04669171|EXPERIMENTAL|Cohort 2|15 Previously untreated patients with FL Or MZL. Evaluation of EO2463 monotherapy at the established dose in Cohort 1
62039894|NCT04669171|EXPERIMENTAL|Cohort 3|15 Previously untreated patients with FL or MZL. Evaluation of EO2463 at the established dose in cohort 1 as monotherapy for 6 weeks and in combination with rituximab from week 7
62039895|NCT04669171|EXPERIMENTAL|Cohort 4|15 Previously treated patients with FL Or MZL. Evaluation of EO2463 at the established dose in Cohort 1 in combination with lenalidomide and with addition of rituximab from week 19 onwards (depending on response)
62039896|NCT06158698|EXPERIMENTAL|Colchicine|Patients treated with colchicine 0.5-1 mg (1 mg if tolerated) for 6 months.
62039897|NCT06158698|PLACEBO_COMPARATOR|Placebo|Patients treated with placebo tablets.
62039898|NCT03712644|NO_INTERVENTION|Conservative|Patients will receive primarily optimal medical therapy alone and followed, according to protocol. Any further cardiologic investigation will be performed only in case of clinical suspicion of myocardial ischemia related symptoms.
62243698|NCT02656420|EXPERIMENTAL|Low Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (120 micromole) and sulforaphane-rich (8 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
62434045|NCT06481826||treatment group|Glofitamab
62623380|NCT04638556||T2DM|T2DM group was simple type 2 diabetes mellitus.
62243699|NCT04261569|EXPERIMENTAL|Illuminated arm|patients with intraventricular near-infrared light illumination
62434046|NCT02609737|EXPERIMENTAL|68Ga-DOTA-JR11 and 177Lu-DOTA-JR11|Pts get a PET/CT study with approx.150-200 MBq of 68Ga-DOTA-JR11. Lesions with focal radiotracer uptake not explained by physiologic sstr2 expression will be interpreted as metastatic disease. If 68Ga-DOTA-JR11 uptake by metastases with a diameter of more than 2 cm is less than the physiologic radiotracer uptake by the liver, no further imaging \& therapy will be performed as part of the study, as it is unlikely that pts with this low radiotracer uptake will benefit from PRRT (2). All other pts will undergo a dosimetric study with 1850 MBq (less than 100 μg peptide) of 177Lu-DOTA-JR11. Results of the dosimetry study, will determine the balance of activity of 177Lu-DOTA-JR11 that can be administered without exceeding the radiation dose limits. This activity will be split into 2 equal amounts to be delivered in 2 cycles, approximately 3 months apart. After each therapy cycle, pts will be followed clinically for 3 months.
62434047|NCT04313283|EXPERIMENTAL|Parents Taking Action|A peer-led intervention, Parents Taking Action is the psychoeducational and child behavior management intervention led by trained Parent Leaders for 12 weeks.
62434048|NCT04692220||Patients with an Adverse Drug Events or Drug-Related Problems|Patients with an Adverse Drug Events or Drug-Related Problems
62434049|NCT04692220||Patients without an Adverse Drug Events or Drug-Related Problems|Patients without an Adverse Drug Events or Drug-Related Problems
62819850|NCT01345240|EXPERIMENTAL|RTS,S Regimen A Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
62819851|NCT01345240|EXPERIMENTAL|RTS,S Regimen B Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
62819852|NCT01345240|EXPERIMENTAL|RTS,S Regimen B Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
62061614|NCT06152068||non-obesity|Subjects non-obesity were assessed with body mass index or BMI (calculated with body weight in kg divided by body height square in m). The subjects were determined to be non-obesity if BMI value z-score \< +2 SD of WHO child growth standard (assessed with WHO Anthroplus).
62061615|NCT01845974|EXPERIMENTAL|Low Flow Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
62243700|NCT04261569|NO_INTERVENTION|control arm|patients without any medical device
62434050|NCT00879515||1|Males and females with fragile X syndrome, ages 5 to 25 years old
62243701|NCT00354081|ACTIVE_COMPARATOR|1|folic acid (0.8 mg) plus vitamin B12 (0.4 mg) and vitamin B6 (40 mg)
62434051|NCT00879515||2|Males and females with the FMR1 premutation, ages 5 to 25 year old
62434052|NCT00879515||3|Males and females with Down syndrome, ages 5 to 25 years old
62434053|NCT00879515||4|Males and females with normal development, ages 5 to 25 years old
62434054|NCT05373433|EXPERIMENTAL|Experimental group|SSD8432 750mg and Ritonavir 100mg
62434055|NCT05373433|PLACEBO_COMPARATOR|Control group|SSD8432 placebo and Ritonavir placebo
62434056|NCT05792410|EXPERIMENTAL|SHR-A1811 combined with Dalpiciclib Isethionate Tablets|
62434057|NCT05792410|EXPERIMENTAL|SHR-A1811 combined with Fulvestrant|
62434058|NCT05792410|EXPERIMENTAL|SHR-A1811 combined with Bevacizumab injection|
62434059|NCT05853510||Unilateral developmental dysplasia of the hip|Diagnosed with developmental dysplasia of the hip and treated with a hip abduction brace in one hip.
62819853|NCT01345240|EXPERIMENTAL|RTS,S Regimen B Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
62039899|NCT03712644|EXPERIMENTAL|Invasive|"In the Invasive group in addition to optimal medical therapy elective coronary angiography will be performed. Coronary catheterization is preferably scheduled within a maximum of 14 days after peripheral revascularization~All lesions of 50-90% diameter stenosis in a major coronary artery will be evaluated by fractional flow reserve (FFR) and intervened by percutaneous coronary intervention (PCI) if FFR≤0.80 or left for medical therapy if FFR\>0.80. All lesions of ≥90% diameter stenosis in a major coronary artery will be intervened. This includes also efforts to recanalize chronic total occlusions (CTO) of large supplied viable myocardial territory.~For complex cases revascularization by coronary artery bypass surgery might be considered, however PCI is preferred whenever possible."
62039900|NCT01494831|EXPERIMENTAL|TF-CBT|
62039901|NCT01494831|NO_INTERVENTION|Waiting List control|
62039902|NCT01834131|NO_INTERVENTION|Usual Care|Clinics assigned to usual care will not receive any of the intervention components. Physicians in these clinics will continue to treat patients using their usual methods. Participants from these clinics will not receive community health worker visits or the mobile health intervention
62039903|NCT01834131|EXPERIMENTAL|Comprehensive Intervention|"1. Physicians will receive training in the use of treatment algorithms based on hypertension guidelines.~2. Community health workers (CHW) will be trained in facilitating behavioral change through BP monitoring, medication management, and lifestyle modifications. CHW will serve as a source of education, motivation, and social support, and as facilitators of healthcare utilization for participants. CHW will conduct home visits, schedule appointments with primary care physicians, deliver antihypertensive medications to patients' homes, and provide tailored counseling to address barriers to behavior change.~3. Individualized text messages to promote lifestyle changes and reminders to reinforce medication adherence will be sent to participants weekly."
62600365|NCT03467763|PLACEBO_COMPARATOR|Placebo|Patients will be assigned to take their baseline medication regimen plus 2 weeks of 250 mg per day of placebo, followed by 500 mg placebo, 750 mg, and 1,000 mg placebo with each treatment period separated by a 2-week course of metformin XR in the same increments of dosage.
62600366|NCT06350695|PLACEBO_COMPARATOR|low grade compression stocking arm|Patients will be assigned to receive 2 pairs of low grade compression stockings (10-15 mmHg), that they will be wearing at least 8 hours a day 5 days a week.
62600367|NCT06350695|EXPERIMENTAL|high grade compression stocking arm|Patients will be assigned to receive 2 pairs of high grade compression stockings (20-30 mmHg), that they will be wearing at least 8 hours a day 5 days a week.
62039904|NCT06145763|EXPERIMENTAL|Arm I (iCanQuit app)|Participants use the iCanQuit app, which includes setting up a personalized quit plan, participating in eight levels of the content, receiving on-demand help in coping with smoking urges, and tracking their daily smoking behaviors for at least 45 days on study.
62243702|NCT00354081|ACTIVE_COMPARATOR|2|folic acid (0.8 mg) plus vitamin B12 (0.4 mg)
62243703|NCT00354081|ACTIVE_COMPARATOR|3|vitamin B6 (40 mg)
62243704|NCT00354081|PLACEBO_COMPARATOR|4|placebo
62243705|NCT06735807|EXPERIMENTAL|Generated AI (Emohaa)|
62243706|NCT06735807|ACTIVE_COMPARATOR|Group ACT|
62243707|NCT06735807|SHAM_COMPARATOR|Waitlist Group (WLG)|
62243708|NCT06402838|EXPERIMENTAL|RO7269162|Participants will receive daily doses of RO7269162 for up to 72 weeks.
62243709|NCT06402838|PLACEBO_COMPARATOR|Placebo|Participants will receive daily doses of placebo for up to 72 weeks.
62600368|NCT04751773|NO_INTERVENTION|Standard care alone (CON)|"Participants allocated to CON receive the standard patient care program, as provided by Rigshospitalet, Copenhagen, Denmark.~Participants allocated to CON are allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise training program."
62600369|NCT04751773|EXPERIMENTAL|Postoperative exercise training and standard care (EX)|"Participants allocated to EX receive the standard patient care program, as provided by Rigshospitalet, Copenhagen, Denmark, and postoperative exercise training.~The postoperative exercise training program consists of 8 weeks of supervised and home-based exercise 5 times/week. The intensity and duration are progressively increased during the postoperative period"
62600370|NCT05366985|EXPERIMENTAL|Socket shield with guided root sectioning|Tooth extraction and immediate implant placement using the socket shield technique with computer guided sectioning of the root.
62600371|NCT03837964|EXPERIMENTAL|Treatment T|Fed
62600372|NCT03837964|EXPERIMENTAL|Treatment R|Fasted
62243710|NCT01324206||Healthy Volunteers|Healthy Volunteers, 18 or older years
62243711|NCT01034540|EXPERIMENTAL|POM3|POM3 for the first six weeks of treatment. Placebo for the second six weeks of treatment
62243712|NCT01034540|PLACEBO_COMPARATOR|Placebo|Placebo for the first six weeks of treatment. POM3 for the second six weeks of treatment
62434060|NCT05853510||Bilateral developmental dysplasia of the hip|Diagnosed with developmental dysplasia of the hip and treated with a hip abduction brace in two hips.
62434061|NCT05585619||Chronic pain patients|New chronic pain consults seen by a trainee and attending pain physician
62434062|NCT05271201|EXPERIMENTAL|mild intensity group|Received mild intensity treadmill training according to Martti Karvonen's formula.
62434063|NCT05271201|EXPERIMENTAL|moderate intensity group|Received moderate intensity treadmill training according to Martti Karvonen's formula.
62039905|NCT06145763|ACTIVE_COMPARATOR|Arm II (NCI QuitGuide app)|Participants use the NCI QuitGuide app for at least 45 days on study.
62039906|NCT04731779|PLACEBO_COMPARATOR|Placebo|Participants will ingest 3ml of non-CBD containing MCT (medium-chain triglycerides) oil.
62039907|NCT04731779|EXPERIMENTAL|25 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 25 mg of CBD.
62039908|NCT04731779|EXPERIMENTAL|50 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 50 mg of CBD.
62039909|NCT04731779|EXPERIMENTAL|200 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 200 mg of CBD.
62039910|NCT06179524|EXPERIMENTAL|CAR-T-19 cells|CAR-T-19 cells injection: 1.5 x10\^6 cells/kg（range 0.5-1.5×10\^6 cells/kg）
62039911|NCT04421781||Salvage HIFU for local recurrence after prostatectomy and EBRT|Between July 2005 and November 2018, at Edouard Herriot Hospital (Lyon, France), 22 consecutive patients were treated with S-HIFU for a local recurrence after RP and salvage or adjuvant EBRT. The oncological outcomes (treatment failure-free survival, progression-free survival), the adverse events and urinary incontinence were retrospectively reviewed.
62039912|NCT06386315|EXPERIMENTAL|ARM 1 (reduced dose ISRT)|Patients undergo reduced dose ISRT once daily (excluding weekends) over 3 treatment fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.
62243713|NCT03050996||robotic radical prostatectomy patients|Patient scheduled to undergo robotic assisted radical prostatectomy
62243714|NCT06736392|ACTIVE_COMPARATOR|group C|(Group-C (control) (n=30); will have PENG block using 20ml of isobaric bupivacaine 0.25%
62243715|NCT06736392|ACTIVE_COMPARATOR|group D|Group-D (n=30); will have PENG block with 1.5μg/kg dexmedetomidine as an adjuvant to 20ml of isobaric bupivacaine 0.25%
62243716|NCT06506565|EXPERIMENTAL|Ketamine|Ketamine infusion (0.3 mg/kg/hr) to begin 1 hour before wound care, continuing through and for 1 hour following wound care.
62243717|NCT06506565|PLACEBO_COMPARATOR|Placebo|0.9% saline to begin 1 hour before wound care, continuing through and for 1 hour following wound care.
62243718|NCT04711798||Patients receiving cardiac surgery|Patients receiving cardiac surgery will be included. All patients received a passive leg raising maneuver (PLR) for preload status evaluation using the PICCO system, a lung recruitment maneuver (LRM) and an echographic evaluation of the right cardiac function.
62243719|NCT02275585||Cirrhosis|Patients with cirrhosis will be followed looking about the event of portal vein thrombosis
62600373|NCT02170090|EXPERIMENTAL|Gemcitabine plus Cisplatin|"Chemotherapy will be administered on days 1 and 8 every 3 weeks, Cisplatin (25 mg per square meter of body-surface area) and Gemcitabine (1000 mg per square meter) for 24 weeks (8 cycles)~and Observation"
62039913|NCT06386315|ACTIVE_COMPARATOR|ARM 2 (SOC ISRT)|Patients undergo standard of care (SOC) radiation therapy once daily (excluding weekends) over 12 treatment fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.
62039914|NCT01986465|EXPERIMENTAL|Depomedrol|The trial pharmacist prepares a series of similar vials containing either 4 mg of Depomedrol or Normal Saline and coded them either 1, 2, 3 or 4, the group assignments are not decoded until the end of the trial when the final analysis is due to take place. Patients take their envelopes to the trial pharmacist who give them a coded vial which they take to the orthopaedic surgeon who make the injection. After the injection the trial clerk take the patients to a technician who give patients in groups 1 and 3 long arm splints.
62039915|NCT01986465|PLACEBO_COMPARATOR|Placebo|The trial pharmacist prepares a series of similar vials containing either 4 mg of Depomedrol or Normal Saline and coded them either 1, 2, 3 or 4, the group assignments are not decoded until the end of the trial when the final analysis is due to take place. Patients take their envelopes to the trial pharmacist who give them a coded vial which they take to the orthopaedic surgeon who make the injection. After the injection the trial clerk take the patients to a technician who give patients in groups 1 and 3 long arm splints.
62039916|NCT01429532||Group I|1.8-mm-incision-size phacoemulsification system
62039917|NCT01429532||Group II|2.2-mm-incision-size phacoemulsification system
62039918|NCT01429532||Group III|3.0-mm-incision-size phacoemulsification system
62039919|NCT05574660|EXPERIMENTAL|High-Fat/High-Sugar (HF/HS) Diet|Participants randomized to consume an HF/HS yoghurt (40.8 % kcal from fat, 45.6 % kcal from carbohydrates, 13 % kcal from protein of 79.5 total kcal) two times a day for eight weeks in addition to their normal diet.
62243720|NCT04139265||Hospitalized patients aged 65 and over|- Patients aged 65 and over hospitalized in the department of Internal Medicine and Geriatry
62243721|NCT06710067||Disease Cohort|
62434064|NCT02360657|EXPERIMENTAL|JNJ-54861911, 10 mg|JNJ-54861911, 10 milligram (mg) (2\*5 mg tablet) orally once daily for 4 weeks.
62434065|NCT02360657|EXPERIMENTAL|JNJ-54861911, 50 mg|JNJ-54861911, 50 mg (2\*25 mg tablet) orally once daily for 4 weeks.
62434066|NCT02360657|PLACEBO_COMPARATOR|Placebo|Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
62600374|NCT02170090|ACTIVE_COMPARATOR|Capecitabine|"Capecitabine will be administered from day 1 to 14 every 3 weeks (1250 mg per square meter of body-surface area, twice daily) for 24 weeks (8 cycles)~and Observation"
62600375|NCT02634034|EXPERIMENTAL|NK-104-CR (8mg), Pitavastatin IR (4mg), Pitavastatin IR (8mg)|
62600376|NCT02634034|EXPERIMENTAL|Pitavastatin IR (4mg), Pitavastatin IR (8mg), NK-104-CR (8mg)|
62243722|NCT06549556|PLACEBO_COMPARATOR|Group 1 (Healthy Control)|24 Patients receiving Placebo Capsule per oral once daily for 60 days.
62243723|NCT06549556|ACTIVE_COMPARATOR|Group 2 (Healthy control)|26 Patients receiving Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA), one capsule per oral once daily for 60 days.
62243724|NCT06549556|PLACEBO_COMPARATOR|Group 3 (Diabetes Type 2)|23 Patients receiving Placebo Capsule per oral once daily for 60 days.
62243725|NCT06549556|ACTIVE_COMPARATOR|Group 4 (Diabetes Type 2)|27 Patients Receiving Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA), one capsule per oral once daily for 60 days.
62243726|NCT05851274|EXPERIMENTAL|Transradial access|In this group, the transradial access (TRA) was used, which was to puncture the radial artery and insert a radial sheath to establish a surgical pathway for embolization of the aneurysm.
62243727|NCT05851274|ACTIVE_COMPARATOR|Transfemoral access|In this group, transfemoral access (TFA) was used to embolize the aneurysms, which was to puncture the femoral artery and insert the femoral sheath to establish a surgical pathway for embolizing the aneurysm.
62243728|NCT04813926||Patients diagnosed with PAH|
62243729|NCT02064634||Shinbaro (only)|
62243730|NCT02064634||Celecoxib (only)|
62243731|NCT02064634||Shinbaro + NSAIDs|
62600377|NCT02634034|EXPERIMENTAL|Pitavastatin IR (8mg), NK-104-CR (8mg), Pitavastatin IR (4mg)|
62600378|NCT05977075|EXPERIMENTAL|"ApisMela/Unstuck Group"|Six children belonging to the experimental group. ApisMela training teaches to focus on the purpose of the task, check that you understand it, and make explicit the procedures to be implemented. Being a crossover clinical trial, the group ending with the ApisMela protocol continues with the Ustuck protocol.
62600379|NCT05977075|EXPERIMENTAL|"Unstuck/ApisMela Group"|Six children belonging to the experimental group. Unstuck protocol teaches people to be more flexible, skillful in planning and goal-oriented. Being a crossover clinical trial, the group ending with the Unstuck protocol continues with the ApisMela protocol.
62600380|NCT03959826|ACTIVE_COMPARATOR|Job activity contracting|Standard services plus job activity contracting
62600381|NCT03959826|EXPERIMENTAL|Reinforcement for completing activities|Standard services plus job activity contracting plus reinforcement for completing job-related activities
62600382|NCT03613558|EXPERIMENTAL|Dexmedetomidine Sedation|This group will receive 1mcg/kg bolus of dexmedetomidine over 15 minutes after intubation followed by an infusion of dexmedetomidine at 0.5mcg/kg/hr until approximately 30 minutes before the end of surgery.
62600383|NCT03613558|PLACEBO_COMPARATOR|Placebo|This group will receive a colorless, odorless liquid (i.e. normal saline) in order to resemble Dexmedetomidine.
62600384|NCT03616067|EXPERIMENTAL|Botox® injection arm|Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars).
62600385|NCT03616067|ACTIVE_COMPARATOR|Scopoderm® patches arm|Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear
62243732|NCT02064634||Shinbaro + Celecoxib|
62243733|NCT05341648|EXPERIMENTAL|Experimental Group|Aerobic Training for 3 days/week with 40-70% Intensity for 6 Weeks
62243734|NCT05341648|PLACEBO_COMPARATOR|Control group|Home plan: Positioning, Breathing Exercises, Muscle Relaxation, and Flexibility exercises for 6 weeks
62039920|NCT05574660|EXPERIMENTAL|Low-Fat/Low-Sugar (LF/LS) Diet|Participants randomized to consume an LF/LS yoghurt (17.1 % kcal from fat, 29.1 % kcal from carbohydrates, 51.9 % kcal from protein of 78 total kcal) two times a day for eight weeks in addition to their normal diet.
62039921|NCT02610348|EXPERIMENTAL|Group A|Toddlers vaccinated with Hexaxim®/Hexyon®/Hexacima® in study A3L12
62039922|NCT02610348|EXPERIMENTAL|Group B|Toddlers vaccinated with Infanrix hexa® in study A3L12
62039923|NCT00796302|EXPERIMENTAL|1|Children will receive active methylphenidate HCl and active risperidone. Parents will receive parent management training.
62039924|NCT00796302|ACTIVE_COMPARATOR|2|Children will receive methylphenidate HCl and placebo instead of the active risperidone. Parents will receive parent management training.
62039925|NCT01335204|EXPERIMENTAL|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle. Bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
62243735|NCT06174987|EXPERIMENTAL|T-DXd|"Participants who choose to continue treatment with T-DXd may be enrolled. Participants who were on the comparator arm in the parent study will be provided the option to access the drug through standard of care (SoC) or other available options.~Participants will remain on their current dosage regimen of T-DXd as the last dose administered in the parent study, unless they experience an AE that requires dose reduction at the EOT of the parent study, in which case the starting dose in this study will be the next lower dose-level."
62434067|NCT02170129|ACTIVE_COMPARATOR|100% AAB|Surgical procedures were performed according to a lateral approach technique at the edentulous region distal to the position of the first premolar. A mucoperiosteal buccal flap was elevated, exposing the lateral bony wall of the sinus antrum. A round diamond bur, 2 mm in diameter, was used to outline the demarcation of the lateral window, which was removed, thus completely exposing the underlying Schneiderian membrane. The membrane was separated from the housing bone, and a tension-free reflection exposing the sinus walls was achieved by gently pushing it away using a large flat curette (Kramer-Nevins, Hu-Friedy, Chicago, IL). The established voids were then filled with 100% AAB (Bio-Oss) followed by sealing the open lateral window by the placement of a collagen membrane (Bio Gide) and primary soft tissue closure using Vicryl 4.0 sutures (Vicryl, Ethicon J\&J International, Sint-Stevens-Woluwe, Belgium).
62849115|NCT05680441||Periodontitis stage 3 grade C|Stage III periodontitis patients had at least 4 interdental sites clinical attachment level (CAL)\> 5 mm due to periodontitis, radiographic bone loss reaching to the mid-third of the root or beyond, teeth loss less than 4 teeth due to periodontitis.Since the bone loss (%)/age values were \>1.0, all periodontitis patients were considered grade C.
62039926|NCT03728829||Trastuzumab+TP neoadjuvant chemotherapy|100 cases of patients with stage II-III HER2+ breast cancer will be assigned participants to neoadjuvant treatment regimen, including Trastuzumab combined with Docetaxel and Carboplatin. 5-10 ml peripheral blood will be collected from each patient and formalin fixed paraffin embedded (FFPE) blocks/sections or fresh tumor tissues/biopsies will be obtained from the hospitals before and after neoadjuvant therapy. The genomic characteristics between patients achieved pCR and non-pCR will be analyzed. The clinically actionable mutations for future therapy instructions will be identified.
62039927|NCT01988779|ACTIVE_COMPARATOR|oral placebo with nebulized intranasal levofloxacin|Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days
62039928|NCT01988779|ACTIVE_COMPARATOR|oral antibiotics with nebulized intranasal placebo|Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.
62819854|NCT01345240|EXPERIMENTAL|RTS,S Regimen C Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
62819855|NCT01345240|EXPERIMENTAL|RTS,S Regimen C Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
62849116|NCT05680441||Gingivitis|Only generalized gingivitis patients were included in this study. Individuals presenting with a BOP≥30% and PPD≤3 mm without radiographic bone loss and attachment loss were considered to have gingivitis.
62849117|NCT05179200|EXPERIMENTAL|"Group 1: Frequent plasma donors"|Donors will donate 650 ml plasma (excluding anticoagulant) by plasmapheresis three times every 2 weeks for 16 weeks.
62849118|NCT05179200|ACTIVE_COMPARATOR|"Group 2: Regular plasma donors"|Donors will donate 650 ml plasma (excluding anticoagulant) by plasmapheresis once every 14 days for 16 weeks.
62849119|NCT05179200|PLACEBO_COMPARATOR|"Group 3: Regular whole blood donors"|Donors will donate 450 ml (405-495 ml) whole blood every 3 months for 16 weeks.
62849120|NCT00461071|ACTIVE_COMPARATOR|Internet-based self-help|Internet-based self-help behavioural
62849121|NCT00461071|ACTIVE_COMPARATOR|Bibliotherapy|bibliotherapy
62039929|NCT06723912|NO_INTERVENTION|Control Group|No program will be applied to the control group. Routine treatment and care in the hospital will continue. At the end of the study, a Handbook for Adherence to Hemodialysis Treatment will be given.
62039930|NCT06723912|EXPERIMENTAL|Intervention Group|Program based on the Health Action Process Approach will be implemented. Hemodialysis Treatment Compliance Handbook will be given.
62039931|NCT05092191|EXPERIMENTAL|CBD alone|"* Dosage form : Softgel~* Dosage \& frequency : 40 mg /day of CBD up to 200 mg in two doses a day~* Duration : 4 weeks of treatment followed by 12 additional weeks of follow up."
62039932|NCT05092191|EXPERIMENTAL|THC alone|"* Dosage form : Softgel~* Dosage \& frequency : 4 mg /day of THC up to 20 mg in two doses a day~* Duration : 4 weeks of treatment followed by 12 additional weeks of follow up."
62819856|NCT01345240|EXPERIMENTAL|RTS,S Regimen C Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
62039933|NCT05092191|EXPERIMENTAL|THC and CBD combined|"* Dosage form : Softgel~* Dosage \& frequency : 40 mg /day of CBD up to 200 mg and 4 mg /day of THC up to 20 mg in two doses a day~* Duration : 4 weeks of treatment followed by 12 additional weeks of follow up."
62039934|NCT05092191|PLACEBO_COMPARATOR|Placebo|"* Dosage form : Softgel~* Dosage \& frequency : caps of placebo twice a day~* Duration : 4 weeks of treatment followed by 12 additional weeks of follow up."
62039935|NCT02061202|EXPERIMENTAL|Mometasone Furoate|1 puff daily (220mcg) for 16 weeks
62039936|NCT02061202|PLACEBO_COMPARATOR|Placebo|1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo).
62243736|NCT03579082|EXPERIMENTAL|Arm A|"R±DHAP + decitabine:~decitabine:10mg/d,ivgtt,d(-5)-(-1);R±DHAP:rituximab,375mg/m2,d0,ivgtt;cytarabine,2g/m2,q12h,d2,ivgtt;cisplatin,100mg/m2,used for 3 days,ivgtt;dexamethasone,40mg,d1-4,ivgtt/po.21 days for one cycle."
62243737|NCT03579082|NO_INTERVENTION|Arm B|R±DHAP:rituximab,375mg/m2,d0,ivgtt;cytarabine,2g/m2,q12h,d2,ivgtt;cisplatin,100mg/m2,used for 3 days,ivgtt;dexamethasone,40mg,d1-4,ivgtt/po.21 days for one cycle.
62600386|NCT04367493|EXPERIMENTAL|1. Group 55% cocoa intervention|55% cocoa intervention
62243738|NCT04979052|ACTIVE_COMPARATOR|Interferon-Gamma|Recombinant Interferon-Gamma 1b combined with standard therapy
62243739|NCT04979052|NO_INTERVENTION|Standard of care|Standard of care antifungal therapy according tot ESCMID/EFISG (Europe) or ISDA (US) guidelines.
62600387|NCT04367493|EXPERIMENTAL|2. Group White Chocolate|White chocolate
62600388|NCT04367493|NO_INTERVENTION|3. Control Group|Control Group
62819857|NCT01345240|ACTIVE_COMPARATOR|Engerix B Regimen A Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the Engerix-B Vaccination Regimen A. This regimen included 3 doses of Engerix B™ co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™ at Weeks 0, 4 and 8, and 2 doses of Rotarix™, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. Engerix B™ was administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
62039937|NCT05750953|EXPERIMENTAL|eHealth@H-2-H|"The intervention group will participate in a 42-day nurse-assisted intervention eHealth@ Hospital-2-Home. The intervention includes monitoring of vital signs, self-reports of symptoms, health and well-being, access to information about illness and health resources , and communication between the patients and a hospital-based Nurse Navigator."
62039938|NCT05750953|NO_INTERVENTION|Care as usual|The control group will receive care as usual
62039939|NCT06647836||untreated sq-NSCLC patients|Patients diagnosed with sq-NSCLC for the first time
62039940|NCT06647836||sq-NSCLC patients treated with immunotherapy for -2-3 cycles|sq-NSCLC patients treated with immunotherapy combined with or without chemotherapy as first-line treatment for 2-3 cycles.
62039941|NCT06647836||sq-NSCLC patients receiving immunotherapy with poor efficacy|sq-NSCLC patients treated with immunotherapy combined with or without chemotherapy as first-line treatment and experience disease progression within six months.
62243740|NCT04692454|EXPERIMENTAL|the scalp and ear acupuncture|CHIAN HUEI ACUPUNCTURE NEEDLE
62243741|NCT03628937|EXPERIMENTAL|Intervention group|"Interventions: Decaffeinated green tea polyphenol capsule (400 mg, EGCG accounted for 50%) will be given to participants in intervention group, and they need take it once a day after breakfast for 12 weeks.~Decaffeinated green tea polyphenol: 400mg/capsule, 1 capsule/d, qd, 12 weeks"
62819858|NCT01345240|ACTIVE_COMPARATOR|Engerix B Regimen B Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the Engerix-B Vaccination Regimen B. This regimen included 3 doses of Engerix B™ co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™ vaccine, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. Engerix B™ was administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
62819859|NCT05724134|ACTIVE_COMPARATOR|Maintenance hyperinsulinemia (MH) protocol|The basal insulin infusion rate (IIR) necessary to maintain participants' mean basal fasting plasma glucose (mbFPG) will be determined during the basal titration period. Then, during the intervention period, the IIR will remain at 100% of basal for the full duration (225 min). The IIR and resulting insulin levels are expected to be relatively high (cf. hyperinsulinemia) because of underlying insulin resistance.
62819860|NCT05724134|EXPERIMENTAL|Reduction toward euinsulinemia (RE) protocol|The basal insulin infusion rate (IIR) necessary to maintain participants' mean basal fasting plasma glucose (mbFPG) will be determined during the basal titration period. Then, during the intervention period, the basal IIR will be reduced by up to 50%. Thus, the basal hyperinsulinemia expected due to underlying insulin resistance will be reduced toward euinsulinemia.
62819861|NCT06459674|EXPERIMENTAL|Inspiratory Muscle Training (IMT) group|The test protocol requires participants to inhale maximally (maximum inspiratory pressure, MIP) against 2mm diameter leak and sustain inhalation (sustained maximal inspiratory pressure, SMIP) until task failure. Participants will complete 3 SMIP maneuvers with each training session and use the best of the three for that day's training template (corresponding to about 80% SMIP for the IMT group) via the PrO2Fit software. Participants must match or exceed the SMIP template with each increasing level of the work-rest ratio. Work at each level consists of 6 breaths, 36 breaths total. If six breaths are completed, the next level starts. Rest intervals will progressively shorten as training continues from 40-seconds to 5-seconds. The session will be terminated if participants are unable to match at least 90% of the training template for two consecutive breaths or have completed all 36 breaths. Training will be done 4 times a week, and over 8-weeks.
62819862|NCT06459674|SHAM_COMPARATOR|Sham Inspiratory Muscle Training (Sham-IMT) group|Similar to the IMT group protocol, participants will be required to complete 3 SMIP maneuvers with each training session. Participants will use the best of the three for that day's training template (corresponding to about 30% SMIP for the Sham-IMT group) via the PrO2Fit software. Participants must match or exceed the SMIP template with each increasing level of the work-rest ratio. Work at each level consists of 6 breaths, 36 breaths total. If six breaths are completed, the next level starts. Rest intervals will progressively shorten as training continues from 40-seconds to 30-, 20-, 15-, 10-, and 5-seconds. The training session will be terminated if participants are unable to match at least 90% of the training template for two consecutive breaths or have completed all 36 breaths. Training will be done 4 times a week, and over 8-weeks.
62819863|NCT06706128|ACTIVE_COMPARATOR|Group (A)|Consisted of twelve Preterm neonates
62819864|NCT06706128|ACTIVE_COMPARATOR|Group (B)|Consisted of twelve Preterm neonates
62039942|NCT06647836||sq-NSCLC patients receiving immunotherapy with good efficacy|sq-NSCLC patients treated with immunotherapy combined with or without chemotherapy as first-line treatment and having progression-free survival longer than six months.
62039943|NCT04321239|EXPERIMENTAL|Intervention group|Participants will engage in a 7-week positive psychology-based chronic pain self-management program.
62039944|NCT04321239|NO_INTERVENTION|Usual care control group|After completing the follow-up telephone survey, individuals in the control condition will be given access to the online program, a wearable physical activity tracker to use and keep, and will be invited to attend a one-time 2.5-hour in-person or telephone workshop that summarizes intervention content and that will be led jointly by study staff and a community health worker.
62039945|NCT00740948|EXPERIMENTAL|1|Rituximab
62039946|NCT00740948|PLACEBO_COMPARATOR|2|Placebo
62039947|NCT03001284||Multiple sclerosis patients|patients with confirmed multiple sclerosis, diagnosed according to the revised McDonald's criteria
62243742|NCT03628937|PLACEBO_COMPARATOR|Control group|The placebo control group will be given placebo capsules, and participants need take it once a day after breakfast for 12 weeks.
62039948|NCT03001284||Control subjects|control subjects, matched for age, gender, and presence of cardiovascular risk factors
62039949|NCT01727739|ACTIVE_COMPARATOR|PLLA bioscrew|poly-L-lactic acid bioscrew
62039950|NCT01727739|ACTIVE_COMPARATOR|PLLA+TCP bioscrew|poly-l-lactic acid with beta tricalcium phosphate bioscrew
62039951|NCT03352791|ACTIVE_COMPARATOR|DSM-H Hospice Edition|training, assigning of champions to serve as mentors and performance improvement leads, and workflow changes including caregiver education pamphlets, interdisciplinary care plans, treatment algorithms, and assessment instruments.
62243743|NCT05296798|OTHER|Induction Therapy: Phesgo plus Taxane-Based Chemotherapy|
62243744|NCT05296798|ACTIVE_COMPARATOR|Arm A, Maintenance Therapy: Phesgo|
62039952|NCT03352791|ACTIVE_COMPARATOR|Control Arm|Usual Care
62039953|NCT05016505|EXPERIMENTAL|Compliance through reduction (relocation and reduction of personal smoking) and cessation|Smokers will be referred by the survey team to peer educators from a community-based organization trained to provide peer to peer health education including tobacco cessation support. The peer educator will coordinate smoking cessation support, including serving as a liaison between participant and research team, providing information regarding the smoke-free policy and opportunities for relocation, and connecting participant to access to tobacco replacement therapy and/or physician support if deemed appropriate.
62600389|NCT03694444|ACTIVE_COMPARATOR|AMY-101 treatment|Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. In the AMY-101 treatment arm after clinical assessments and sample collection at baseline, test treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.
62600390|NCT03694444|PLACEBO_COMPARATOR|Placebo|Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. In the placebo arm, after clinical assessments and sample collection at baseline, placebo treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.
62600391|NCT05801510|EXPERIMENTAL|Treatment|The treatment group will receive seven sessions of CMT over a 14 week period.
62819865|NCT05958082|EXPERIMENTAL|Educational intervention|Patients will be asked questions about genetic testing for prostate cancer before and after an educational intervention.
62819866|NCT05189275|EXPERIMENTAL|Cannabidiol 40 mg (CBD40)|Subjects consume beverages with 40mg of CBD.
62061616|NCT01845974|ACTIVE_COMPARATOR|High Flow Catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
62061617|NCT03873220||Monitoring scratch in children|Sensor technology and digital measures will be used to evaluate scratch and sleep in children with atopic dermatitis who will wear watch-like wrist actigraphy devices, sleep monitor, polysomnography, and videography.
62243745|NCT05296798|EXPERIMENTAL|Arm B, Maintenance Therapy: Giredestrant plus Phesgo|
62243746|NCT03255057|EXPERIMENTAL|Hemolung plus SOC IMV|Low-flow ECCO2R with the Hemolung Respiratory Assist System as an alternative or adjunct to standard-of-care (SOC) invasive mechanical ventilation (IMV)
62243747|NCT03255057|ACTIVE_COMPARATOR|SOC IMV|Standard-of-care (SOC) invasive mechanical ventilation (IMV) alone
62600392|NCT00574210|EXPERIMENTAL|1|Bilastine oral 20 mg once per day (1 x 20 mg bilastine tablet plus 1 placebo tablet)
62600393|NCT00574210|EXPERIMENTAL|2|Bilastine oral 20 mg twice per day (2 x 20 mg bilastine tablets)
62600394|NCT00574210|EXPERIMENTAL|3|Bilastine oral 10 mg once per day (1 x 10 mg bilastine tablet plus 1 placebo tablet)
62600395|NCT00574210|EXPERIMENTAL|4|Bilastine oral 10 mg twice per day (2 x 10 mg bilastine tablets)
62600396|NCT00574210|PLACEBO_COMPARATOR|5|Placebo oral twice per day (2 placebo tablets)
62600397|NCT02375880|EXPERIMENTAL|150 mg DKN-01 Part A|Patients will receive 150 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
62600398|NCT02375880|EXPERIMENTAL|300 mg DKN-01 Part A|Patients will receive 300 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
62600399|NCT02375880|EXPERIMENTAL|MTD mg DKN-01 Part B|Patients are treated at the maximum tolerated dose (MTD) of DKN-01 (or highest dose tested in Part A if the MTD is not defined) followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
62600400|NCT04558606|EXPERIMENTAL|Sonic toothbrush|"* All patients receive full periodontal charting, a session of professional oral hygiene and OHI (oral hygiene instruction).~* Each patient is instructed by the hygienist in the correct use of the sonic toothbrush"
62819867|NCT05189275|EXPERIMENTAL|Cannabidiol 20 mg (CBD20)|Subjects consume beverages with 20mg of CBD.
62819868|NCT05189275|EXPERIMENTAL|Cannabidiol 0 mg (CBD0)|Subjects consume beverages with 0mg of CBD.
62243748|NCT01286454|EXPERIMENTAL|A|4 mg fesoterodine IR beads in capsule under fasting condition
62243749|NCT01286454|EXPERIMENTAL|B|4 mg fesoterodine 10% coated ER beads in capsule under fasting condition
62243750|NCT01286454|EXPERIMENTAL|C|4 mg fesoterodine 15% coated ER beads in capsule under fasting condition.
62243751|NCT01286454|EXPERIMENTAL|D|4 mg fesoterodine 20% coated ER beads in capsule under fasting condition.
62243752|NCT01286454|EXPERIMENTAL|E|4 mg fesoterodine ER tablets under fasting condition.
62243753|NCT01286454|EXPERIMENTAL|F|4 mg fesoterodine TBD % coated ER beads in capsule under fed condition.
62819869|NCT05189275|PLACEBO_COMPARATOR|Placebo Beverage (PLAC)|Subjects consume calorie matched beverages with 0 CBD.
62243754|NCT04304820|EXPERIMENTAL|SAA|Subjects with SAA treated with early initiation of oral treatment
62243755|NCT05323084|EXPERIMENTAL|Dietary supplement|Green tea extract 5 grams, Chicory extract 1gram and collagen peptides 5 grams in 60ml with sugar, erythritol and 2% potassium sorbate and 1% flavor
62243756|NCT05323084|PLACEBO_COMPARATOR|Placebo|60ml of water, sugar, erythritol, 2% potassium sorbate, and 1% flavor
62600401|NCT04558606|ACTIVE_COMPARATOR|Manual toothbrush|"* All patients receive full periodontal charting, a session of professional oral hygiene and OHI (oral hygiene instruction).~* Each patient is instructed by the hygienist in the correct use of the manual toothbrush"
62600402|NCT04253405|ACTIVE_COMPARATOR|High Flow Nasal Cannula (HFNC)|The HFNC (Airvo2 Fisher \& Paykel, Auckland, New Zealand) consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers flow up to 60 L/ min.
62243757|NCT05146284|EXPERIMENTAL|PXL770 500 mg QD|
62243758|NCT05146284|EXPERIMENTAL|PXL770 250 mg BID|
62243759|NCT05591274|EXPERIMENTAL|Interactive VR|Patients will be wearing a virtual reality headset preloaded with an interactive VR scenario.
62243760|NCT05591274|EXPERIMENTAL|Static VR|Patients will be wearing a virtual reality headset preloaded with a static, non-interactive VR scenario.
62243761|NCT05591274|NO_INTERVENTION|Control|Patients will not be wearing any virtual reality headset.
62243762|NCT06135727|OTHER|Pathology (glaucoma) arm|
62243763|NCT06135727|OTHER|Normal arm|
62243764|NCT06070649|ACTIVE_COMPARATOR|Group 1|Bolus of 0.3mg/kg/min DMT (5min) + Normal Saline infusion (60 min)
62243765|NCT06070649|ACTIVE_COMPARATOR|Group 2|Bolus of 0.2 mg/kg/min DMT (5 min) + 0.01mg/kg/min infusion (60 min)
62434068|NCT02170129|ACTIVE_COMPARATOR|50% AAB plus 50% autologous bone|Surgical procedures were performed according to a lateral approach technique at the edentulous region distal to the position of the first premolar. A mucoperiosteal buccal flap was elevated, exposing the lateral bony wall of the sinus antrum. A round diamond bur, 2 mm in diameter, was used to outline the demarcation of the lateral window, which was removed, thus completely exposing the underlying Schneiderian membrane. The membrane was separated from the housing bone, and a tension-free reflection exposing the sinus walls was achieved by gently pushing it away using a large flat curette (Kramer-Nevins, Hu-Friedy, Chicago, IL). The established voids were then filled with 50% AAB (Bio-Oss) plus 50% autologous bone harvested locally with a bone scraper followed by sealing the open lateral window by the placement of a collagen membrane (Bio Gide) and primary soft tissue closure using Vicryl 4.0 sutures (Vicryl, Ethicon J\&J International, Sint-Stevens-Woluwe, Belgium).
62600403|NCT04253405|ACTIVE_COMPARATOR|Non-invasive positive pressure ventilation (NIPPV)|NIPPV will be performed using the devices available on centers. Both a dedicated NIPPV device or an invasive mechanical ventilator with NIPPV mode are accepted. The interface should be an oronasal or full face mask.
62819870|NCT03598036|EXPERIMENTAL|Voclosporin|"Cohort 1:~Maximum dose of 3 capsules (7.9mg) BID~Cohort 2~Dosing to be decided based on the safety from the first 5 or 6 subjects in Cohort 1."
62243766|NCT06070649|PLACEBO_COMPARATOR|Group 3|Bolus of 25 mg Diphenhydramine (5 min) + Normal Saline infusion (60 min)
62434069|NCT03640000|EXPERIMENTAL|Determination of impedance signals|This single arm study is designed to measure impedance signals from implanted leads in different positions in the heart. Signals obtained at different pre specified position are compared to each other to determine the robustness of the acquired measurements.
62600404|NCT01296061||Failed Kidney Transplant|Adults ≥ 18 years, initiating chronic dialysis
62600405|NCT00640653|EXPERIMENTAL|Abstinence-only|Participants will receive the abstinence-only HIV/STD risk-reduction intervention.
62243767|NCT02754882|ACTIVE_COMPARATOR|Bevacizumab (Avastin)|Avastin® + Carboplatin/Paclitaxel
62819871|NCT05789537|EXPERIMENTAL|SerpinPC|Participants will receive SerpinPC 1.2 milligrams/kilogram (mg/kg) subcutaneous (SC) injection every 2 weeks (Q2W) for 48 weeks after a prospective observation of 12 weeks for all participants, either in a prior non-interventional study (AP-0105\[NCT05605678\]) or as part of the ongoing study observational period.
62849122|NCT05032469|EXPERIMENTAL|Refloxology Intervention|The first foot reflexology was applied to the intervention group for 30 min (20 min on the right foot, 10 min on the left foot) on the first postoperative day (24 h after the surgery). On the second postoperative day, 30 min of foot reflexology was applied to the patients who decided to chest tube removal (CTR). After the foot reflexology applied by the researcher, CTR was performed by the doctor within 10 min. Immediately after CTR, the patient's pain and anxiety level during CTR was measured. At the 15th minute after CTR, the pain and anxiety level of the patients was measured, their satisfaction with the reflexology application was measured. Then, the patients were asked to describe the pain and feelings and thoughts during CTR, 1 hr after CTR, pain level was measured, and they were asked to express their feelings and thoughts about the reflexology application.
62243768|NCT02754882|EXPERIMENTAL|SB8 (A proposed bevacizumab biosimilar)|SB8 + Carboplatin/Paclitaxel
62243769|NCT06548828|ACTIVE_COMPARATOR|Control (Group 1)|Participants in this arm will continue their usual consumption of NNS throughout pregnancy and lactation without any intervention. They will not receive any specific NNS-restriction intervention.
62243770|NCT06548828|ACTIVE_COMPARATOR|NNS Restriction in Lactation (Group 2)|Participants in this arm will maintain their usual NNS consumption during pregnancy but will receive an intervention to restrict NNS intake during lactation.
62243771|NCT06548828|ACTIVE_COMPARATOR|NNS Restriction in Pregnancy and Lactation (Group 3)|Participants in this arm will receive an intervention to restrict NNS intake both during pregnancy and lactation.
62434070|NCT03586830|EXPERIMENTAL|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 12-week treatment phase.
62434071|NCT03586830|EXPERIMENTAL|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly for 12-week treatment phase.
62434072|NCT03586830|EXPERIMENTAL|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly for 12-week treatment phase.
62434073|NCT03586830|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 12-week treatment phase.
62434074|NCT00931567|ACTIVE_COMPARATOR|Vaselitulle|after surgery, the loss of substance is treated using vaseline dressing
62434075|NCT00931567|EXPERIMENTAL|Autologous platelets gel|after surgery, the loss of substance is treated with Autologous platelets gel
62434076|NCT01712230|PLACEBO_COMPARATOR|Placebo|Monthly placebo injections for 6 months
62600406|NCT00640653|EXPERIMENTAL|Safer-sex only|Participants will receive the safer-sex-only HIV/STD risk-reduction intervention.
62600407|NCT00640653|EXPERIMENTAL|Comprehensive-long|Participants will receive the 12-h long comprehensive HIV/STD risk-reduction intervention.
62600408|NCT00640653|EXPERIMENTAL|Comprehensive-short|Participants will receive the 8-h short comprehensive HIV/STD risk-reduction intervention.
62819872|NCT04935606|EXPERIMENTAL|Usual Care|Usual Care participants will receive their standard medical care as usual (no provider advice or telephone coaching sessions) and all screening and study assessments. To reduce biases, Usual Care arm patients will be given a cancer screening booklet and will be shown a cancer screening Video Doctor. They will also receive 2 re-contact telephone sessions at weeks 2 and 6 corresponding to the timing of the coaching sessions for the QUIT and QUIT-Mobile arms. All participants will also receive re-contact calls monthly from 7-weeks to 12-months. The re-contact calls (5 min) provide attention control for the Usual Care arm, motivate continued trial participation by reminding them of the next research assessment, but do not provide an active intervention. At study end, the Usual Care arm will receive the QUIT video doctor and drug use reduction booklet brochure materials including overdose prevention materials and a list of clinic/community resources to help them reduce substance use.
62819873|NCT04935606|EXPERIMENTAL|QUIT|The QUIT brief intervention protocol will consist of 5 steps corresponding to the 5A's approach for assisting behavior change in the clinic setting (Ask, Advise, Assess, Assist, and Arrange) that will focus on patients' HSD (highest scoring drug on the baseline ASSIST) use in the past 30 days.
62819874|NCT04935606|EXPERIMENTAL|QUIT-Mobile|"QUIT-Mobile will include a mobile platform with self-monitoring surveys and feedback message and robust data transfer protocols across three mobile technology platforms to meet diverse patient's preferences and needs regardless of literacy and phone type: a mobile-optimized web-app (using any smart phone's web-browser, not native apps), SMS (text-messaging), and IVR (automated voice calls for low literacy patients). Data collected during this study on patient platform preferences and exploratory analyses on intervention efficacy across platform types will inform the development of future effectiveness trials that can evaluate effectiveness of different mobile platforms."
62819875|NCT06196008|EXPERIMENTAL|Arm I (Telephone-based coaching session)|Patients attend telephone-based coaching sessions over 20-50 minutes once 7-14 days before standard of care surgery, and then at days 7, 14, 21, and 51 post-discharge, for a total of 5 sessions. Patients also receive a personalized physical activity program and set fitness goals. FCGs also receive coaching and serve as a walking buddy for their patient. Patients and FCGs also wear an activity monitor throughout the trial.
62819876|NCT06196008|ACTIVE_COMPARATOR|Arm II (Written education)|Patients receive written educational materials on physical activity and cancer survivorship. Patients and FCGs also wear an activity monitor throughout the trial.
62819877|NCT06406855|EXPERIMENTAL|Brain-Computer Interface (BCI)-Transcutaneous Spinal Cord Stimulation (TSCS)|Subjects will participate in the therapy for up to 6 months
62819878|NCT02025543||Patient Group|Subjects with known or suspected iron overload will undergo serum ferritin measurement and an MRI scan.
62819879|NCT02025543||Control Group|Subjects with no known history of iron overload or liver disease will undergo an MRI scan.
62243772|NCT06089239|ACTIVE_COMPARATOR|High Intensity Coaching|"In Quarter 1, high intensity initiation coaching will consist of a four-hour orientation session that will include:~* comprehensive information on behavior and organizational change theory,~* suggested approaches, and~* in-depth training on behavioral and organization-focused change techniques to stimulate implementation efforts.~Commencing in Quarter 2, high intensity sustainability coaching will consist of:~* weekly virtual follow up sessions for the first month, followed by private monthly coaching follow up sessions via a virtual format.~* Access to additional monthly web-based, synchronous office hours for group discussion on progress and customized troubleshooting to assist in navigating barriers.~* Sites will also have access to on call assistance with coaches to assist with navigating challenges in real time."
62819880|NCT06285396|NO_INTERVENTION|Control|The myometrial samples are bathed in physiological salt solution (PSS) only.
62819881|NCT06285396|ACTIVE_COMPARATOR|Ephedrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine.
62243773|NCT06089239|SHAM_COMPARATOR|Low Intensity Coaching|"In Quarter 1, low intensity initiation coaching will be conducted. It will consist of:~* initial two-hour orientation session with introductory content on behavior change and organizational change theory and techniques,~* an overview of implementation phases, and~* selection of tailored de-implementation strategies for that site based on readiness for change, focus group data and local resources.~Implementation coaches will provide the Fuld Toolkit for the site with suggestions for assigning strategies, local leaders, and development of timelines for de-implementation.~Coaches will instruct site Team Leaders to establish the primary mechanism for sharing baseline and trended data in real time."
62819882|NCT06285396|ACTIVE_COMPARATOR|Phenylephrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine.
62243774|NCT06679803|EXPERIMENTAL|PA-ChatS Intervention|Participants will receive 6, 20-30 minute intervention sessions delivered over the telephone by an occupational therapist over 6 weeks (1 session/week). They will also complete self-monitoring of step counts using a Fitbit Inspire.
62434077|NCT01712230|ACTIVE_COMPARATOR|GnRH agonist|Monthly GnRH agonist injections for 6 months
62434078|NCT01712230|ACTIVE_COMPARATOR|GnRH agonist + exercise|Monthly GnRH agonist injections for 6 months plus supervised cardiovascular exercise intervention
62434079|NCT01222871|EXPERIMENTAL|Triamcinolone|Triamcinolone soaked nasopore dressing
62434080|NCT01222871|PLACEBO_COMPARATOR|Control Group|Saline soaked sponge
62434081|NCT04411719||EEG and Microexpression Analysis|Participants will be acutely unresponsive ICU patients. They will undergo non-invasive observational procedures, including EEG monitoring during exposure to emotional auditory stimuli, and concurrent video recording for microexpression analysis. Patient outcomes will be assessed at three, six, and twelve-month intervals post-initial observation.
62819883|NCT06285396|ACTIVE_COMPARATOR|Norepinephrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine.
62434082|NCT00179452|EXPERIMENTAL|Intervention|Subjects invited to participate in yoga practice.
62039954|NCT05016505|EXPERIMENTAL|Compliance through resident endorsement|Buildings assigned will be targeted for a series of 2 in-residence programs that involve community forums and the creative arts to garner resident endorsements of smoke-free living environments. Premised on resident engagement, this arm seeks to impact social and physical dimensions of the residential environment to achieve compliance. The sessions will: 1) inform residents of risks associated with smoking and secondhand smoke; 2) identify reasons to have a smoke-free home, 3) ask residents to sign a pledge on paper and/or virtually; 4) display smoke-free signage on doors and/or social media pages with an original hashtag (#Smokefree\[building address\]); and 5) refer residents to the Smoke-free NYCHA website for information on the policy and existing cessation resources.
62039955|NCT05016505|EXPERIMENTAL|Compliance through reduction/cessation plus resident endorsement (combined)|The combined intervention will be carried out in the buildings assigned to this RCT arm, which will provide in-residence programs based on the resident endorsement treatment and the smoking relocation/cessation treatment. Both will occur simultaneously with one geared toward all building residents (resident endorsement) and the other targeting smokers (smoking relocation/cessation) with the goal of reducing both personal smoking and secondhand smoke exposure.
62819884|NCT06285396|ACTIVE_COMPARATOR|Control + oxytocin|The myometrial samples are bathed in physiological salt solution (PSS) and oxytocin.
62819885|NCT06285396|ACTIVE_COMPARATOR|Ephedrine + oxytocin|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine and oxytocin..
62039956|NCT05016505|NO_INTERVENTION|Standard NYCHA approach (control)|Buildings and study participants assigned to this arm will be recruited and followed over a 12-month period to assess outcomes. No additional programs or services will be delivered to the buildings or residents assigned to this arm beyond standard programs that NYCHA may provide to support the smoke-free mandate. Field staff will document any policy-related signage, activities or information to which these participants are exposed.
62039957|NCT01550458|EXPERIMENTAL|Mibefradil|
62039958|NCT01550458|PLACEBO_COMPARATOR|Placebo|
62039959|NCT05653219|EXPERIMENTAL|Treatment arm 1|Participants will receive eltrombopag and ianalumab lower dose
62039960|NCT05653219|EXPERIMENTAL|Treatment arm 2|Participants will receive eltrombopag and ianalumab higher dose
62039961|NCT05653219|PLACEBO_COMPARATOR|Treatment arm 3|Participants will receive eltrombopag and placebo
62039962|NCT04975516|EXPERIMENTAL|Group I (SBRT, chemotherapy)|Patients undergo SBRT QD or every other day for 5 fractions, and receive chemotherapy per standard of care.
62039963|NCT04975516|ACTIVE_COMPARATOR|Group II (chemotherapy)|Patients receive chemotherapy per standard of care.
62039964|NCT06733779||Eastern region Western region|Located in eastern region of China
62600409|NCT00640653|ACTIVE_COMPARATOR|Health-promotion control|Participants will receive the health promotion control intervention.
62819886|NCT06285396|ACTIVE_COMPARATOR|Phenylephrine + oxytocin|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine and oxytocin..
62819887|NCT06285396|ACTIVE_COMPARATOR|Norepinephrine + oxytocin|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine and oxytocin..
62039965|NCT06733779||Centrel region|Located in the central region of China
62039966|NCT06733779||Western region|Located in western region of China
62039967|NCT04004611|EXPERIMENTAL|Open Label (OL) Induction Period: 5 milligram per kilogram (mg/kg) Miri intravenous (IV)|Participants (≤40 kg weight) received 5 mg/kg mirikizumab given as an IV infusion every 4 weeks (Q4W) on weeks 0, 4, 8 for 12 weeks.
62243775|NCT02076217||unprotected intercourse 6-14 days prior to contraception|Women who initiate highly effective reversible contraception within 6-14 days of unprotected intercourse.
62600410|NCT05331768|EXPERIMENTAL|24-h group|The 24-h group received intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) as an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 24 hours.
62819888|NCT05592665|OTHER|Patient Perspective|Study participants will complete several questionnaires/assessments related to adverse events and quality of life.
62849123|NCT05032469|NO_INTERVENTION|Standart Care|Participants in the control group will receive standart postoperative care.
62849124|NCT00992589|EXPERIMENTAL|Rabeprazole sodium 5 mg|
62039968|NCT04004611|EXPERIMENTAL|Open Label Induction Period: 10 mg/kg Miri IV|Participants (≤40 kg weight) received 10 mg/kg mirikizumab given as an IV infusion Q4W on weeks 0, 4, 8 for 12 weeks.
62039969|NCT04004611|EXPERIMENTAL|Open Label Induction Period: 300 mg Miri IV|Participants (\>40 kg weight) received 300 mg mirikizumab given as an IV infusion Q4W on weeks 0, 4, 8 for 12 weeks.
62039970|NCT04004611|EXPERIMENTAL|Open Label Maintenance Period: 50 mg Miri subcutaneous (SC)|Participants (≤20 kg weight) who were responders to mirikizumab at week 12 in induction received 50 mg subcutaneously (SC) Q4W from week 12 through week 48 or until loss of response was confirmed.
62039971|NCT04004611|EXPERIMENTAL|Open Label Maintenance Period: 100 mg Miri SC|Participants (\>20 to ≤40 kg weight) who were responders to mirikizumab at week 12 in induction received 100 mg SC Q4W from week 12 through week 48 or until loss of response was confirmed.
62039972|NCT04004611|EXPERIMENTAL|Open Label Maintenance Period: 200 mg Miri SC|Participants (\>40 kg weight) who were responders to mirikizumab at week 12 in induction received 200 mg SC Q4W from week 12 through week 48 or until loss of response was confirmed.
62039973|NCT04004611|EXPERIMENTAL|Open Label Maintenance Period: Non-Responders: 10 mg/kg Miri IV/ 50 mg Miri SC|Participants (≤40 kg) who were non responders to miri at Week 12 in induction received 10 mg SC Q4W for 12 weeks or discontinued after repeat induction, and then received 50 mg miri (≤20 kg weight) SC Q4W through week 48 or until loss of response was confirmed.
62039974|NCT04004611|EXPERIMENTAL|Open Label Maintenance Period: Non-Responders: 10 mg/kg Miri IV/100 mg Miri SC|Participants (≤40 kg) who were non responders to miri at week 12 in induction received 10 mg SC Q4W for 12 weeks or discontinued after repeat induction, and then received 100 mg miri (\>20 to ≤40 kg weight) SC Q4W through week 48 or until loss of response was confirmed.
62849125|NCT00992589|EXPERIMENTAL|Rabeprazole sodium 10 mg|
62849126|NCT00992589|PLACEBO_COMPARATOR|Placebo|
62849127|NCT03515317|EXPERIMENTAL|LoRETA Z-score NF group|BrainMaster Discovery 24E (BrainMaster Technologies, Inc.) combined with Neuroguide software (Applied Neuroscience, Inc.) to conduct both LoRETA Z-score NF. A total treatment dosage of 600 minutes is needed.
62600411|NCT05331768|ACTIVE_COMPARATOR|72-h group|The 72-h group received the standard treatment with administration of intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) with an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 72 hours. Terlipressin was administered blinded after endoscopic treatment and infused as a 5 ml bolus in a pre-prepared syringe
62039975|NCT04004611|EXPERIMENTAL|Open Label Maintenance Period: Non-Responders: 300 mg Miri IV /200 mg Miri SC|Participants (\>40 kg) who were non responders to miri at week 12 in induction received 300 mg SC Q4W for 12 weeks or discontinued after repeat induction, then received 200 mg miri SC Q4W through week 48 or until loss of response was confirmed.
62039976|NCT06099626||A:autoimmune hepatitis|
62039977|NCT06099626||B:autoimmune hepatitis/primary biliary cirrhosis|
62039978|NCT06099626||C:/primary biliary cirrhosis|
62039979|NCT06099626||D:Subjects tested positive for COVID-19 antigen or COVID-19 nucleic acid|
62039980|NCT06099626||E|Subjects who have no previous history of COVID-19 infection and have been vaccinated against COVID-19.
62039981|NCT05156658|ACTIVE_COMPARATOR|Group A: With HIV receiving Monthly CARLA: ENG subcutaneous implant|Participants with HIV-1 receiving monthly cabotegravir-long acting and rilpivirine-long acting (CARLA) (not provided by the study) will receive ENG implant immediately after enrollment.
62039982|NCT05156658|ACTIVE_COMPARATOR|Group B: Without HIV: ENG subcutaneous implant|Participants without HIV-1 will receive ENG implant immediately after enrollment.
62039983|NCT06008717|EXPERIMENTAL|active subthalamic nucleus deep brain stimulation plus optimal drug therapy|active subthalamic nucleus deep brain stimulation; plus optimal drug therapy
62039984|NCT06008717|ACTIVE_COMPARATOR|inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy|inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy
62039985|NCT00977353|EXPERIMENTAL|sarcosine|sarcosine
62039986|NCT00977353|ACTIVE_COMPARATOR|citalopram|citalopram
62039987|NCT02660632|PLACEBO_COMPARATOR|Thoracic epidural analgesia (TEA)|Patients who will be subjected for midline laparotomy, will receive epidural analgesia through an inserted thoracic epidural catheter before induction of general anesthesia
62039988|NCT02660632|ACTIVE_COMPARATOR|Rectus sheath catheter block|After insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected on each side, then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
62039989|NCT00403416|ACTIVE_COMPARATOR|Mycophenolic Acid / tacrolimus|
62039990|NCT00403416|EXPERIMENTAL|AEB071 / tacrolimus arm 1|
62039991|NCT00403416|EXPERIMENTAL|AEB071 / tacrolimus arm 2|
62039992|NCT01421563|ACTIVE_COMPARATOR|Anplag|
62434083|NCT02361190|PLACEBO_COMPARATOR|Placebo nasal spray|Subjects will inhale approximately 40ml aqueous solution via intranasal route
62434084|NCT02361190|EXPERIMENTAL|Testosterone nasal spray|Subjects will inhale approximately 40ml aqueous, testosterone-containing solution via intranasal route
62849128|NCT03515317|EXPERIMENTAL|theta/beta NF group|BrainMaster Discovery 24E (BrainMaster Technologies, Inc.) combined with Neuroguide software (Applied Neuroscience, Inc.) to conduct both theta/beta NF. A total treatment dosage of 600 minutes is needed.
62039993|NCT01421563|EXPERIMENTAL|DP-R202|
62039994|NCT06722248|EXPERIMENTAL|Intervention group with HFS baby|"For intervention group, the high fidelity simulation session will be arranged earlier.~."
62039995|NCT06722248|OTHER|Control group with conventional|For control group, they will undergo convention training. An identical simulation session will be provided for the control group after completion of the study
62039996|NCT02242864||Patients with hypertension and diabetes mellitus|
62039997|NCT05536362|EXPERIMENTAL|TCI propofol mixed with clonidine and ketamine|Patient group,in which they got intravenous anaesthesia with TCI propofol mixed with clonidine and ketamine
62039998|NCT05536362|EXPERIMENTAL|TCI propofol mixed with a placebo|Control group,in which they received intravenous anaesthesia with TCI propofol mixed with a placebo (NaCl 0.9%)
62039999|NCT02460718|NO_INTERVENTION|control group|Participants received 1-hour group diabetes education class covering diabetes basics, healthy eating, stress reduction, physical activity, social support, and how to get the most out of their doctors visit. Participants also received a diabetes report card showing their Hba1c, blood pressure, ldl cholesterol, and body weight.
62040000|NCT02460718|EXPERIMENTAL|Encourage study|"Participants in the intervention arm were paired with a peer coach, interacting by telephone weekly for the first 8 weeks and then monthly for a total of 10 months.~Participants also received 1-hour group diabetes education class covering diabetes basics, healthy eating, stress reduction, physical activity, social support, and how to get the most out of their doctors visit. Participants also received a diabetes report card showing their Hba1c, blood pressure, ldl cholesterol, and body weight."
62040001|NCT00195910|ACTIVE_COMPARATOR|Morphine|"single dose of intravenous (IV) morphine, 0.1 mg/kg~intervention: 0.1 mg/kg IV morphine"
62040002|NCT00195910|EXPERIMENTAL|Hydromorphone|"single dose of intravenous (IV) hydromorphone, 0.015 mg/kg~intervention: 0.015 mg/kg IV hydromorphone"
62040003|NCT03552874||Patient Group|Children whose ages between 5-10 years with Duchenne Muscular Dystrophy.
62434085|NCT01691365|ACTIVE_COMPARATOR|vitamins pills|"antioxidant and B vitamins vitamins vitamin~--------------------------------------------------------------------------------"
62040004|NCT03552874||Healthy Group|Healthy peers
62040005|NCT03871595|EXPERIMENTAL|BI 894416 30 mg fed (T)|3 tablets with 10 milligram (mg) of BI 894416 (total: 30 mg) were administered as one single oral dose with 240 milliliter (mL) of water after a high-fat, high-calorie meal (fed conditions) as test treatment (T).
62434086|NCT01691365|PLACEBO_COMPARATOR|pills|MICROCRYSTALLINE CELLULOSE
62434087|NCT01110499|EXPERIMENTAL|Part 1, AGN-210961 Formulation 1|AGN-210961 Formulation 1 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
62434088|NCT01110499|EXPERIMENTAL|Part 1, AGN-210961 Formulation 2|AGN-210961 Formulation 2 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
62434089|NCT01110499|EXPERIMENTAL|Part 1, AGN-210961 Formulation 3|AGN-210961 Formulation 3 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
62040006|NCT03871595|EXPERIMENTAL|BI 894416 30 mg fast (R)|3 tablets with 10 milligram (mg) of BI 894416 (total: 30 mg) were administered as one single oral dose with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (fasted conditions) as reference treatment (R).
62819889|NCT06592677|EXPERIMENTAL|Condensed internet-delivered prolonged exposure (CIPE) + Treatment-as-usual (TAU)|Participants in this condition will receive Treatment-as-usual (TAU) the first four weeks post trauma, and after Condensed internet-delivered prolonged exposure (CIPE). Participants will receive CIPE between 4 and 10 weeks after trauma. In CIPE, participants are encouraged to have daily contact with their therapist through a secured email system within the platform. Therapists are also available for phone sessions. Total therapist contact for each participant is generally less than 60 minutes during the whole program. Participants are expected to work on intervention tasks for six hours each week and to complete the intervention in three weeks. The intervention is delivered by psychosocial crisis teams' staff in 14 municipalities in the central-eastern part of Norway. Content, frequency, and quantity of the CIPE+TAU-condition will be measured.
62819890|NCT06592677|ACTIVE_COMPARATOR|Treatment-as-usual (TAU) only|Participants in this arm will receive Treatment-as-usual (TAU) throughout the trial. The TAU-condition is delivered by the same 14 municipality psychosocial crisis teams as the Condensed internet-delivered prolonged exposure (CIPE) +TAU arm. The crisis teams follow a national guideline (The Norwegian Directorate of Health, 2016), recommending proactive contact with victims, screening for psychosocial difficulties, and offering interventions to individuals with significant levels of trauma-related problems. Most municipalities organize interdisciplinary crisis services consisting of physicians, police, priests, nurses, and psychologists who receive referrals from emergency services after a traumatic event. There is currently considerable heterogeneity in the frequenzy and quantity of intervention across municipalities.
62819891|NCT00829426|EXPERIMENTAL|Alprazolam|Alprazolam 3mg ER Tablet (test) dosed in first period followed by Xanax XR® 3 mg Tablet (reference) dosed in second period
62819892|NCT00829426|ACTIVE_COMPARATOR|Xanax XR®|Xanax XR® 3 mg Tablet (reference) dosed in first period followed by Alprazolam 3 mg ER Tablet (test) dosed in second period
62819893|NCT03016728|EXPERIMENTAL|Physical Activity|Participants in the experimental arm (i.e., physical activity) will be asked to complete the 12-week home-based physical activity program and to complete all study assessments.
62819894|NCT03016728|NO_INTERVENTION|Wait-List Control|Participants in the no intervention arm (i.e., wait-list control) will be asked to maintain their usual lifestyle activities and to complete all study assessments. Participants in this arm will be provided with the 12-week home-based physical activity program in the exact same way as participants in the experimental arm (i.e., physical activity) at the end of the study.
62819895|NCT04732845|EXPERIMENTAL|Group A - NHL/CLL|"Upon enrollment, peripheral blood mononuclear cells will be collected, and T-cell selection and manufacture of CAR-T cells will be done.~Participants will receive 60 mg/Kg/IV Cyclophosphamide on day -6 and 25 mg/m\^2 Fludarabine from day -5 to day -3.~Participants with CD19+ lymphomas and chronic lymphocytic leukemia will be enrolled on this arm sequentially in a 3 + 3 design starting with infusion of CAR-T cells at dose level 1 (DL1) on day 0.~The maximum tolerated dose (MTD) will be determined and then 6 additional participants will be enrolled at the MTD."
62819896|NCT04732845|EXPERIMENTAL|Group B - ALL|"Upon enrollment, peripheral blood mononuclear cells will be collected, and T-cell selection and manufacture of CAR-T cells will be done.~Participants will receive 60 mg/Kg/IV Cyclophosphamide on day -6 and 25 mg/m\^2 Fludarabine from day -5 to day -3.~Participants with Acute Lymphoblastic Leukemia (and lymphoblastic lymphoma as a solid tumor equivalent) will be enrolled on this arm sequentially in a 3 + 3 design starting with infusion of CAR-T cells at DL1 on day 0 and 7.~The maximum tolerated dose (MTD) will be determined and then 6 additional participants will be enrolled at the MTD."
62819897|NCT04628039||COVID Positive|Veterans aged 18 years or older who have a positive SARS-CoV-2 diagnosis (confirmed or presumptive) or who have been discharged home within 2 weeks to 1 year of diagnosis
62040007|NCT03896646|EXPERIMENTAL|Treatment (personalized radioembolization, SPECT/CT HIDA)|Patients undergo yttrium-90 microsphere radioembolization with yttrium Y 90 glass microspheres using personalized dose measurements. Patients also undergo SPECT/CT HIDA scan before radioembolization and 2-4 months after radioembolization.
62040008|NCT02952352|EXPERIMENTAL|Diabetes Intervention|Diabetes Prevention Program
62040009|NCT02952352|OTHER|Delayed Intervention|Diabetes Prevention Program
62040010|NCT01659190|EXPERIMENTAL|Oiled-limestone liniment|the removal of the collecting bag is made with the Oiled-limestone liniment.
62819898|NCT04628039||COVID Negative and Lower Respiratory Tract Infection (LRTI)|Veterans aged 18 years or older with a negative SARS-CoV-2 test (PCR and/or antigen test) and diagnosis of LRTI after discharge home or after diagnosis if not hospitalized
62040011|NCT01659190|NO_INTERVENTION|without Oiled-limestone liniment|the removal of the collecting bag is made without any special precautions
62040012|NCT03505112|EXPERIMENTAL|Goal-directed therapy group|The patients in goal-directed therapy (GDT) group will be managed according to the goal-directed therapy protocol during the surgery.
62040013|NCT03505112|NO_INTERVENTION|Control group|The patients in control group will be managed according to standard perioperative care.
62243776|NCT06116136|EXPERIMENTAL|S095029 and pembrolizumab|Participants diagnosed with gastric cancer (GC) or gastroesophageal junction cancer (GEJ), not previously treated with checkpoint inhibitors (CPIs) may first be enrolled into a Phase 1b safety lead-in part which will be used to identify the recommended Phase 2 dose (RP2D) of S095029 in combination with pembrolizumab. During the Phase 2 part, participants will receive the recommended Phase 2 dose (RP2D) of S095029, along with pembrolizumab.
62040014|NCT04820855|EXPERIMENTAL|Treatment|This is an individual treatment program devised by a pelvic floor physical therapist including a daily yoga series and mindfulness via a Smartphone app.
62040015|NCT04820855|ACTIVE_COMPARATOR|Control|These are participants undergoing regular treatment for interstitial cystitis with their providers
62040016|NCT06454552||irritant medications group|Patients who used midline catheter to infuse irritant medications.
62040017|NCT06454552||nonirritant medications group|Patients who used midline catheter to infuse nonirritant medications.
62040018|NCT01012830|EXPERIMENTAL|Huperzine A|200 micrograms (mcg) of HuperzineA taken twice daily.
62040019|NCT06732596|EXPERIMENTAL|Group 1- ECA and technical support|Participants randomized into this arm will be engaged in ECA use and technical support only
62819899|NCT05627830|EXPERIMENTAL|Ultrasound Guided Prolotherapy forTreatment of Internal Derangement of TMJD.|"Injection procedure in TMJ Space guided by ultrasound probe the injection materials will be composition of ( !0% Dextrose ) + (Saline ) + (2% Lidocaine, plain anesthesia ).~The intervention procedure will done after TMJ MRI assessment for patients who have anterior disc displacement with reduction (DDWR)"
62819900|NCT05627830|ACTIVE_COMPARATOR|Non-Guided Ultrasound ( Blind) Prolotherapy for Treatment of Internal Derangement of TMJD.|"Injection procedure in TMJ Space by anatomical land mark (blindly), and we also call it ( conventional prolotherapy ) the injection materials will be composition of ( !0% Dextrose ) + (Saline ) + (2% Lidocaine, plain anesthesia ).~The intervention procedure will done after TMJ MRI assessment for patients who have anterior disc displacement with reduction (DDWR)"
62819901|NCT06706011|EXPERIMENTAL|Intervention|Virtuel Patient
62819902|NCT06706011|NO_INTERVENTION|Control|No Virtuel Patient
62819903|NCT06472141|ACTIVE_COMPARATOR|Control group|The control group will receive a standard treatment (education + home exercises) program.
62819904|NCT06472141|EXPERIMENTAL|Stabilization group|The stabilization group will receive cervical stabilization exercises in addition to standard treatment.
62040020|NCT06732596|EXPERIMENTAL|Group 2- ECA, technical support, and additional ECA messages|Participants randomized into this arm will be engaged in ECA use and additional ECA messages reminding the use of the ECA app on behalf of OBAT clinical staff
62040021|NCT06732596|EXPERIMENTAL|Group 3- ECA, technical support, additional ECA messages, and incentives|Participants randomized into this arm will be engaged in ECA use and additional ECA messages reminding the use of the ECA app on behalf of OBAT clinical staff with added incentives
62243777|NCT06723418||Pediatric patients with Inflammatory Bowel Disease (Crohns disease & ulcerative colitis)|
62819905|NCT06536413|EXPERIMENTAL|All-Trans Retinoic Acid (ATRA), Carfilzomib, and Dexamethasone|"Carfilzomib will be given at Cycle 1 (20 mg/m2 on Days 1, 70 mg/m2 on Days 8 and 15) and Cycles 2 - onward (70 mg/m2 on Days 1, 8, and 15) as a 30-minute intravenous (IV) infusion to evaluate tolerability to treatment.~Dexamethasone will be given \[20 mg, PO/IV\] on the days of carfilzomib treatment.~ATRA will be given for 3 weeks (21 days) out of every 4 weeks (28 days) up to a maximum of 24 weeks (6 cycles). Only for Cycle 1, patients will start oral ATRA 25 mg/m2 7 days prior to Cycle 1 Day 1 through Cycle 1 Day 21 for a total of 28 days of dosing.~To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options."
62819906|NCT04224870||Surgical Incision|A single cohort study, of 12 participants with a scheduled surgical procedure, of at least 4 hours, for up to six (6) timed tissue sampling at surgical incision. No investigational therapy is planned.
62819907|NCT02339974|EXPERIMENTAL|Severe Tricuspid Regurgitation|This is a non-blinded (open label), non-randomized safety and feasibility study of the heterotopic implantation of the Edwards Sapien 3 valve.
62040022|NCT06732596|NO_INTERVENTION|Treatment as usual group|Participants randomized into this arm will receive treatment as usual
62040023|NCT02526732|EXPERIMENTAL|individual training program|Patients will be offered an individual training program. Physical performance and surrogate parameters of liver inflammation will assessed in physical examinations before and after the training phase.
62040024|NCT06308510||Gastric cancer patients|Operable patients who will undergo DLS for GC. Patients will be identified from the MDT (multidisciplinary tumor board).
62040025|NCT06308510||non-cancer controls|Patients who will undergo a planned laparoscopy for bariatric or gallbladder disease
62434090|NCT01110499|EXPERIMENTAL|Part 1, AGN-210961 Formulation 4|AGN-210961 Formulation 4 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
62819908|NCT03583099|ACTIVE_COMPARATOR|COPD Education|Practice clinicians will receive basic COPD education only.
62040026|NCT04735549|EXPERIMENTAL|Laser Treatment|"Laser treatment of the vagina, vulva, and paraurethral region with a Magic Max laser (Magic Gyno). In total, three procedures will be performed with an interval of 4-6 weeks.~During the procedure, the following sequence of actions will be performed: 1st Stage - vaginal processing with a conical mirror handpiece, 2nd Stage - vaginal processing with a corner mirror handpiece, 3d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece."
62040027|NCT04735549|ACTIVE_COMPARATOR|Topical hormone|Local hormone therapy with estriol. The course of treatment will be of 2 weeks of daily use, and then a maintenance therapy for 12 months to prevent symptoms.
62243778|NCT03654014|EXPERIMENTAL|SofPulse active|SofPulse active group. Patients who will be treated with the SofPulse activated on their heads for up to seven days in intensive care or as long as they are in the unit The PEMF device is kept on throughout and provides a 15 min pulsed treatment every hour.
62243779|NCT03654014|PLACEBO_COMPARATOR|SofPulse inactive|SofPulse inactive. The SofPulse will be placed on the patient's head but not activated for as long as they are in intensive care.
62243780|NCT03654014|SHAM_COMPARATOR|Normal pressure hydrocephalus|CSF and serum samples from 15 normal pressure hydrocephalus patients will be used to compare CSF and serum biomarker levels in the 30 TBI patients.
62819909|NCT03583099|EXPERIMENTAL|CAPTURE + COPD Education|Practice clinicians will receive basic COPD education, and patient-level CAPTURE information with CAPTURE interpretation education. As the second aim address the optimal format for delivering practice CAPTURE education this will be incorporated at the sites randomized to this arm.
62819910|NCT06705777|OTHER|Aesculus hippocastanum, Polygonum acre, Smilax Pepyracea, and Rutin|Self-paired study
62243781|NCT05614661|EXPERIMENTAL|Mom Power|Mom Power is an evidence-based 13-session psychosocial mother-child group intervention that improves sensitive caregiving, parental stress, and depression
62434091|NCT01110499|EXPERIMENTAL|Part 1, AGN-210961 Formulation 5|AGN-210961 Formulation 5 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
62819911|NCT06578364|EXPERIMENTAL|Educational Program about Preconception Care|
62819912|NCT06384495|EXPERIMENTAL|Real anodal tDCS group (REAL-A)|Participants randomized to REAL-A
62819913|NCT06384495|EXPERIMENTAL|Real cathodal tDCS group (REAL-C)|Participants randomized to REAL-C
62819914|NCT06384495|SHAM_COMPARATOR|Sham group (SHAM)|Participants randomized to SHAM group
62819915|NCT06473389|ACTIVE_COMPARATOR|Pulse Radiofrequency Ablation|Pulse RF application will be applied to the suprascapular nerve once under US guidance with a TOP-TLG10 STP generator at a maximum temperature of 42 degrees, 2 Hz, 20 ms and 45 V for 2 minutes.
62819916|NCT06473389|ACTIVE_COMPARATOR|Suprascapular Nerve Block Injection|Suprascapular block will be performed once with a mixture consisting of 5 ml (1 ml betamethasone, 2% lidocaine 2 ml, 0.9% saline 2 ml).
62819917|NCT06473389|ACTIVE_COMPARATOR|Intra-articular Steroid İnjection|Intra-articular steroid will be performed once with a mixture consisting of 5 ml (2 ml lidocaine 2 ml, 0.9% saline 2 ml and 1 ml betamethasone 5 mg).
62819918|NCT05177393||Participants with Esophageal Cancer|Participants with esophageal cancer will be administered questionnaires, and medical charts will be accessed to collect study related data.
62819919|NCT05710718|EXPERIMENTAL|PureWick™ System|The PureWick™ System includes the PureWick™ Female External Catheter and the PureWick™ Urine Collection System. The PureWick™ Female External Catheter (PureWick™ FEC) is marketed in both the United States and Europe. In the U.S. PureWick™ FEC is a Class I, 510(k) exempt device. In Europe, the PureWick™ FEC is a Class I, Conformitè Europëenne (CE) marked, non-sterile device.
62819920|NCT05710718|ACTIVE_COMPARATOR|Hollister® Female Urinary Pouch External Collection Device|The urinary collection pouch with a skin barrier is suitable for non-ambulatory females with urinary incontinence.
62819921|NCT06572683|EXPERIMENTAL|Experimental RF|"All participants will then undergo six 3000-pulse rTMS treatment sessions: two at RFMAX (or rTMSRF-MAX), two at RFMIN (or rTMSRF-MIN), and two at 10 Hz in random order."
62819922|NCT00496522|OTHER|Proton Beam Therapy|Proton Beam Therapy - A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
62819923|NCT04843566|ACTIVE_COMPARATOR|Transrectal|Patients will receive a transrectal MRI-guided prostate biopsy.
62819924|NCT04843566|ACTIVE_COMPARATOR|Transperineal|Patients will receive a transperineal MRI-guided prostate biopsy.
62819925|NCT06595225|EXPERIMENTAL|Nutrition Education Sessions Group|this group received nutrition education sessions each month for a period of 6 months. Where they were followed up once a week via Whatsapp, reminded of the previous session's message and had their questions answered.
62819926|NCT06595225|NO_INTERVENTION|Control group|this group did not receive the intervention that the experimental group received
62819927|NCT06301490|NO_INTERVENTION|control group|18 participants will have strengthening exercises, rang of motion exercises and ice application for 10 mins
62819928|NCT06301490|EXPERIMENTAL|experimental group|18 participants will have strengthening exercises, rang of motion exercises and ice application for 10 mins, with adding Myofascial Release
62819929|NCT05371886|OTHER|Dose-effect relationship of morphine +/- midazolam administration|
62819930|NCT05567458|EXPERIMENTAL|Luspatercept|
62819931|NCT05567458|PLACEBO_COMPARATOR|Placebo|
62819932|NCT01419236|EXPERIMENTAL|Testosterone Solution 2% 60 milligrams (mg)|Testosterone Solution 2% 60 mg applied topically once daily with possible 1-time titration to 30 milligrams per day (mg/day) or 90 mg/day for 16 weeks
62819933|NCT01419236|PLACEBO_COMPARATOR|Placebo|Placebo solution applied topically once daily for 16 weeks
62243782|NCT05614661|SHAM_COMPARATOR|Control|Controls participants for the intervention receive 10 weekly mailings, with content relevant for the postpartum period (i.e., information on baby sleep, developmental milestones, box breathing and other self-care/coping strategies, fun games to play with a baby, and community resources, and general parenting); plus 10 brief check-in phone calls verifying that material was received, and additional longer phone calls to assess any imminent family needs and provide resources as needed/requested.
62243783|NCT06528964||Patients with neurodegenerative disease|Patients diagnosed with either Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism or amyotrophic lateral sclerosis.
62243784|NCT06528964||Patients with normal pressure hydrocephalus|Patients diagnosed with normal pressure hydrocephalus, because of their clinical presentation (acute or subacute gait abnormalities, memory loss or personality changes and urinary incontinence) with radiological confirmation of ventriculomegaly and normal cerebrospinal fluid opening pressure.
62243785|NCT06528964||Healthy control subjects|Person, men or women, above 45 years old, that don't have history of family or personal neurodegenerative disease.
62243786|NCT05630768|EXPERIMENTAL|Actonel®|Risedronate Sodium 35mg
62434092|NCT01110499|EXPERIMENTAL|Part 1, AGN-210961 Formulation 6|AGN-210961 Formulation 6 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
62434093|NCT01110499|EXPERIMENTAL|Part 2, AGN-210961 Formulation 7|AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
62600412|NCT05970770|EXPERIMENTAL|Hypotension Prediction Index|Patients will be monitored with Hypotension Prediction Index which will guide vasopressor therapy with boluses of norepinephrine
62600413|NCT05970770|ACTIVE_COMPARATOR|Non Invasive Blood Pressure|Spinal-induced hypotension will be prevented by continuous preventive norepinephrine infusion and blood pressure will be monitored by non invasive arm cuff every minute
62600414|NCT06192992|SHAM_COMPARATOR|Sham|Blood flow without heating
62600415|NCT06192992|EXPERIMENTAL|Two feet|Blood flow during heating of two feet
62600416|NCT05222022|EXPERIMENTAL|Design validation of mechanism of action of an eye movement measurement device|Participants have retinal images captured with the Retitrack device to measure eye movements. The eye movement measurements are intended to validate the mechanism of action of the device.
62600417|NCT00355706|ACTIVE_COMPARATOR|Group I - without Steroids|Thoracic Facet Joint Nerve Blocks with Local Anesthetic(0.25% Bupivacaine)
62600418|NCT00355706|ACTIVE_COMPARATOR|Group II - with steroid|Thoracic Facet Joint Nerve Blocks with Local Anesthetic (0.25% Bupivacaine) and Sterioids(0.15 mg of non-particulate betamethasone)
62600419|NCT02008747|ACTIVE_COMPARATOR|Magnesium sulphate|"The patients in this group underwent general anaesthesia with total intravenous anesthesia containing Remifentanyl (0,3 mg/kg ideal body weight/h), Propofol (4 mg/kg ideal body weight/h) and Atracurium.~They also received 40mg/kg ideal body weight magnesium sulphate by bolus injection before the operation started, followed by a continuous application of 10mg/kg ideal body weight/hour for 24 hours."
62434094|NCT01110499|ACTIVE_COMPARATOR|Part 2, bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% in both eyes once daily for 4 weeks.
62434095|NCT00557973|EXPERIMENTAL|XP19986 SR1 10 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 10 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
62434096|NCT00557973|EXPERIMENTAL|XP19986 SR1 20 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 20 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
62600420|NCT02008747|NO_INTERVENTION|No treatment|The patients in this group underwent general anaesthesia with total intravenous anesthesia containing Remifentanyl (0,3 mg/kg ideal body weight/h), Propofol (4 mg/kg ideal body weight/h) and Atracurium. They received no additional medication.
62600421|NCT05692531|EXPERIMENTAL|A Story Within A Story|This is a single event that will be evaluated using quasi-experimental design methods.
62243787|NCT06179160|EXPERIMENTAL|Part 1a: Dose Escalation monotherapy|INCB161734 at the protocol-defined dose strength based on cohort assignment.
62243788|NCT06179160|EXPERIMENTAL|Part 1b: Dose Expansion monotherapy|INCB161734 at the protocol-defined dose strength based on cohort assignment.
62243789|NCT06179160|EXPERIMENTAL|Part 1c: Pharmacodynamic cohort|INCB161734 at the protocol-defined dose strength based on cohort assignment.
62600422|NCT03644836|EXPERIMENTAL|Retraining with respiratory effort+ amino acids|
62600423|NCT03644836|PLACEBO_COMPARATOR|Retraining with respiratory effort+ placebo|
62600424|NCT05686161|EXPERIMENTAL|A single 25 μg dose mRNA vaccine SW-BIC-213|Intervention Name :COVID-19 mRNA vaccine Type :Investigational Vaccine Dose :Formulation mRNA Unit Dose Strength(s) :0.5ml; Dosage Level(s) :0.25ml; Route of Administration: injection Intramuscular
62600425|NCT05686161|ACTIVE_COMPARATOR|A third dose of COVID-19 Inactivated vaccine|Intervention Name: COVID-19 Inactivated Vaccine Type : Control Vaccine Dose :Inactive Unit Dose Strength(s) : 0.5ml; Route of Administration: injection Intramuscular
62600426|NCT05686161|ACTIVE_COMPARATOR|A single 30μg dose mRNA vaccine Pfizer(BNT162b2)|Type :mRNA COVID -19 vaccine - Pfizer(BNT162b2) Dose :Formulation mRNA Unit Dose Strength(s) :30ug; Dosage Level(s) :0.3ml; Route of Administration: injection Intramuscular
62600427|NCT00878969|ACTIVE_COMPARATOR|Valsartan|80 mg of valsartan (ARB) taken orally on a daily basis for 1 week followed by 160 mg of valsartan taken orally on a daily basis for 18 months
62600428|NCT00878969|ACTIVE_COMPARATOR|Ramipril|2.5 mg of ramipril (ACE inhibitor) taken orally on a daily basis for 1 week followed by 5 mg of ramipril taken orally on a daily basis for 18 months
62600429|NCT00878969|PLACEBO_COMPARATOR|Placebo|matching placebo taken orally on a daily basis for 1 week followed by matching placebo taken orally on a daily basis for 18 months
62040028|NCT04735549|EXPERIMENTAL|Laser Treatment + Topical hormone|"Laser treatment of the vagina, vulva, and paraurethral region with a Magic Max laser (Magic Gyno). In total, three procedures will be performed with an interval of 4-6 weeks. During the procedure, the following sequence of actions will be performed: 1st Stage - vaginal processing with a conical mirror handpiece, 2nd Stage - vaginal processing with a corner mirror handpiece, 3d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece.~At the same time local hormone therapy with estriol. The course of treatment will be of 2 weeks of daily use, and then a maintenance therapy for 12 months to prevent symptoms."
62040029|NCT00694603|EXPERIMENTAL|Cetuximab|400mg/m2 IV x 1 and then 250mg/m2 IV weekly
62040030|NCT01475968|ACTIVE_COMPARATOR|Ultrafine Air Pollution Particulate Matter|\<2.5 microns concentrated from outside ambient air
62040031|NCT01475968|SHAM_COMPARATOR|Filtered Air|Filtered Air
62040032|NCT05618574|ACTIVE_COMPARATOR|Beet-It nitrate beverage|Participant will receive 140 ml per day of Beet-It nitrate beverage for for 14 days. All participants will be encouraged to undergo physical therapy 2-3 times per week based on tolerance for activity and recovery needed after each session. Physical therapy will be standardized to include strength, balance, inspiratory muscle training, and aerobic training.
62040033|NCT05618574|PLACEBO_COMPARATOR|Nitrate-depleted placebo.|Participants will receive 210 ml of nitrate-depleted placebo for 14 days. All participants will be encouraged to undergo physical therapy 2-3 times per week based on tolerance for activity and recovery needed after each session. Physical therapy will be standardized to include strength, balance, inspiratory muscle training, and aerobic training.
62040034|NCT03801785|EXPERIMENTAL|Children induced to suck pacifiers.|Children will suck a pacifier of identical shape and type and will be allowed other NNS habits.
62040035|NCT03801785|NO_INTERVENTION|Children induced to stop sucking.|Children will be induced by DDSs to stop sucking and their parents will be advised how to stop their children's NNS habits.
62040036|NCT01702727|EXPERIMENTAL|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
62819934|NCT01544205|EXPERIMENTAL|Emotion network up-regulation|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
62819935|NCT01544205|ACTIVE_COMPARATOR|Place processing network up-regulation|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to place and house pictures (as identified during a functional localiser scan).
62040037|NCT01702727|ACTIVE_COMPARATOR|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
62040038|NCT01702727|EXPERIMENTAL|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
62040039|NCT06304831|EXPERIMENTAL|Intervention|The intervention group will receive biweekly updates about quality ratings of recently visited health care providers for children by everyone enrolled in the study.
62040040|NCT06304831|NO_INTERVENTION|Control|The control group will not receive any information about health care providers for children.
62040041|NCT06727513|ACTIVE_COMPARATOR|Control|A single-operator technique for GlideScope intubation.
62040042|NCT06727513|EXPERIMENTAL|Experimental|A double-operator technique for GlideScope intubation
62040043|NCT04435366|EXPERIMENTAL|Avacincaptad Pegol|Participants received avacincaptad pegol (ACP) 2 milligram (mg)/eye via intravitreal (IVT) injections monthly through Month 11 (Year 1). At month 12, participants were re-randomized to receive ACP 2 mg/eye via IVT injections monthly from month12 through month 23 (Year 2).
62040044|NCT04435366|SHAM_COMPARATOR|Sham|Participants received sham injections; through Month 11 (Year 1). At month 12, participants continued to receive monthly sham administration from month 12 through month 23 (Year 2).
62600430|NCT05269888||Study group - Ocrelizumab|30 patients with multiple sclerosis on Ocrelizumab (standard of care)
62243790|NCT06179160|EXPERIMENTAL|Part 2a: Dose Escalation combination|INCB161734 in combination at the protocol-defined dose strength based on cohort assignment.
62243791|NCT06179160|EXPERIMENTAL|Part 2b: Dose Expansion combination|INCB161734 in combination at the protocol-defined dose strength based on cohort assignment.
62600431|NCT05269888||Study group - Natalizumab|30 patients with multiple sclerosis on Natalizumab (standard of care)
62600432|NCT05269888||Study group - Alemtuzumab|30 patients with multiple sclerosis on Alemtuzumab (standard of care)
62600433|NCT05269888||Study group - Tecfidera|30 patients with multiple sclerosis on Tecfidera (standard of care)
62600434|NCT05269888||Study group - Fingolimod|30 patients with multiple sclerosis on Fingolimod (standard of care)
62600435|NCT05269888||Study group - Interferon|30 patients with multiple sclerosis on Interferon (standard of care)
62600436|NCT05269888||Study group - off DMT|30 patients with multiple sclerosis off disease modification treatment (DMT) (standard of care)
62819936|NCT02452736|EXPERIMENTAL|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|This is a Single arm, Non-randomized Study. All patients meet the eligibility criteria and sign the informed consent form will participate in this study.
62819937|NCT05453526||Race - American Indian or Alaska Native|Being identified as American Indian or Alaska Native
62819938|NCT05453526||Race - Asian|Being identified as Asian
62819939|NCT05453526||Race - Black or African-American|Being identified as Black or African-American
62819940|NCT05453526||Race - Native Hawaiian or Other Pacific Islander|Being identified as Native Hawaiian or Other Pacific Islander
62819941|NCT05453526||Race - White|Being identified as White
62243792|NCT06179160|EXPERIMENTAL|Part 1d: Food-Effect|Evaluate food effect on drug exposure as defined in the protocol.
62434097|NCT00557973|EXPERIMENTAL|XP19986 SR1 30 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 30 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
62819942|NCT05453526||Ethnicity - Spanish/Hispanic/Latino|Being identified as Spanish/Hispanic/Latino
62434098|NCT06344702||The CPAP treatment group|CPAP standardized treatment+standard obstetric care
62819943|NCT05291260|EXPERIMENTAL|Cast immobilization|Cast immobilization to immobilize the thumb for 4 weeks. After 2 weeks the thumb will be re-examined to determine if surgery is required. It is expected that at re-evaluation at 2 weeks after starting the cast treatment about 1 in 10 patients will still need surgery.
62243793|NCT02136745|EXPERIMENTAL|Relaxation Response Mind-Body Intervention|The Relaxation Response Mind-Body Intervention (RR-MBI) involved a 9-week group program conducted by a nurse practitioner or psychologist skilled in MBI, which included a GI-specific session conducted by a physician. The groups met once weekly for 1.5 hours. The program was multidimensional and included daily elicitation of the RR using a variety of methods (including breath focus, single-pointed focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills, health enhancing behaviors, and the promotion of optimism and acceptance. Throughout the course of treatment, participants were asked to elicit the RR at home each day for 15-20 minutes.
62243794|NCT05118724|EXPERIMENTAL|Atezolizumab 840mg|Atezolizumab 840mg i.v. (q2w) for a total of 12 cycles (24 doses)
62434099|NCT06344702||OSAS control group|standard obstetric care
62819944|NCT05291260|ACTIVE_COMPARATOR|Surgery|The intervention is compared to surgery, which is standard treatment for complete ulnar collateral ligament ruptures.
62819945|NCT06614881|PLACEBO_COMPARATOR|Control Group|
62819946|NCT06614881|ACTIVE_COMPARATOR|Group D-1|
62819947|NCT06614881|ACTIVE_COMPARATOR|Group D-2|
62819948|NCT06614881|ACTIVE_COMPARATOR|Group D-3|
62819949|NCT06264843||Patency of lower extremity vein bypass grafts|Primary patency of lower extremity vein bypass grafts at one year
62849129|NCT03515317|NO_INTERVENTION|control group|The control group involves no NF training. The control group will be designed to parallel the cognitive tasks to control for practice effects due to repeated testing (pre- and post- assessments) and the time effect on cognitive function recovery (spontaneous recovery of cognition).
62040045|NCT04435366|EXPERIMENTAL|Avacincaptad pegol and Sham|Participants who received ACP 2mg monthly through Month 11 (Year 1) were re-randomized at month 12, to receive ACP 2 mg/eye via IVT injections every other month at months 13, 15, 17, 19, 21, and 23 and sham injections at months 12, 14, 16,18, 20, and 22.
62600437|NCT05269888||Control group|30 healthy volunteers
62243795|NCT05112926|EXPERIMENTAL|Embosphere Microspheres group|Participants in this group who are receiving standard of care (SOC) embolization surgery for the treatment of moderate to severe knee osteoarthritis will receive the Embospheres Microspheres during scheduled SOC surgery.
62600438|NCT03085992|EXPERIMENTAL|Single Arm|INDUCTION TREATMENT WITH FOLFOXIRI PLUS BEVACIZUMAB FOLLOWED BY PREOPERATIVE CHEMORADIOTHERAPY PLUS BEVACIZUMAB
62819950|NCT05891704|EXPERIMENTAL|Intervention group|The Intervention Group (IG) will receive 12-16 meetings of the standard conventional hand-therapy program according to OT intervention protocols used for clients with HI. The IG will receive one hour of 2-3 sessions a week according to patient needs and convenience. In each treatment session, the participant will receive 30 minutes of preparatory activities and therapeutic exercise, 15 min of Occupation-Based Activities, and 15 min for the culturally adjusted intervention that will be based on Focused Acceptance and Commitment Therapy (FACT) with major emphasis on values. In IG Arabic cultural values will be considered in the entire therapy process, the participant will have a companion in the therapy session. The participants in IG will be provided with a home-therapy protocol, and will complete a home program that will be based on enhancement of work values. Checklist diary will be provided to participants
62819951|NCT05891704|ACTIVE_COMPARATOR|Control group|The Control Group (CG) will follow the identical therapy protocol as the IG which will last for 45 minutes, with no culturally relevant interventions. In addition, each participant in the CG group will receive 15 minutes of free conversation with narrative feedback regarding the therapy, the challenges and opportunities in his daily life. Home-therapy protocol that will be based on conventional intervention will be provided.
62243796|NCT06736288|ACTIVE_COMPARATOR|BUCCALIN® gastro-resistant tablets|mixture of Streptococcus pneumoniae I, II, III, Streptococcus agalactiae, Staphylococcus aureus, Haemophilus influenzae
62243797|NCT06736288|PLACEBO_COMPARATOR|Placebo|gastro-resistant tablets containing only excipients
62243798|NCT05696626|EXPERIMENTAL|Treatment|Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.
62243799|NCT05696626|ACTIVE_COMPARATOR|Reference Therapy|Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.
62243800|NCT06579989|EXPERIMENTAL|Cough|Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have neurogenic cough for which superior laryngeal nerve block is recommended will undergo this procedure under ultrasound guidance. Patients without neurogenic cough will also be recruited for ultrasound assessment to establish landmarks and normal variation.
62243801|NCT06579989|EXPERIMENTAL|Vocal Cord Atrophy|Adult patients with vocal fold atrophy, paresis, or paralysis diagnosed at the Sean Parker Institute for the Voice who are planned to undergo injection laryngoplasty will be invited to take part in the study.
62243802|NCT06579989|EXPERIMENTAL|Vocal Cord Paresis|Adult patients with vocal fold atrophy, paresis, or paralysis diagnosed at the Sean Parker Institute for the Voice who are planned to undergo injection laryngoplasty will be invited to take part in the study.
62600439|NCT05550987|EXPERIMENTAL|Vibramoov Device|Rehabilitation program with the use of mechanical vibration using the Vibramoov device and conventional physiotherapy
62600440|NCT05550987|EXPERIMENTAL|Ekso GT exoskeleton Device|Rehabilitation program with gait training using the Ekso GT exoskeleton and conventional physiotherapy
62849130|NCT02238067||Chronic Renal Anemia Participants|Participants with CKD who are not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, will be interviewed by physician who will complete the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
62600441|NCT05550987|EXPERIMENTAL|RoboGait Device|Rehabilitation program with the use of gait training with the use of a RoboGait stationary robot and conventional physiotherapy.
62600442|NCT05550987|EXPERIMENTAL|ZEBRIS Device|Rehabilitation program with the use of gait training with the use of the ZEBRIS treadmill and conventional physiotherapy
62243803|NCT06579989|EXPERIMENTAL|Vocal Cord Paralysis|Adult patients with vocal fold atrophy, paresis, or paralysis diagnosed at the Sean Parker Institute for the Voice who are planned to undergo injection laryngoplasty will be invited to take part in the study.
62434100|NCT06344702||Non OSAS group|standard obstetric care
62434101|NCT02726217|EXPERIMENTAL|CareSmarts Intervention|Participants in the program receive text messages about diabetes self-care
62434102|NCT02726217|ACTIVE_COMPARATOR|Control|Standard of Care reminders and assessments for individuals with Diabetes
62434103|NCT02784717||Rivaroxaban (Xarelto, BAY 59-7939)|Female and male patients, who are at least 18 years of age with a diagnosis of non-valvular atrial fibrillation will be enrolled after the decision for a pharmacologic prophylaxis with rivaroxaban to prevent stroke or non-CNS systemic embolism has been made.
62434104|NCT02604069|EXPERIMENTAL|Continuous Glucose Monitor|Application of CGM for 6 days following free flap reconstruction in conjunction with clinical monitoring
62600443|NCT05550987|EXPERIMENTAL|PABLO Device|Rehabilitation program with the use of upper limb function training with the use of the PABLO device and conventional physiotherapy
62600444|NCT05550987|EXPERIMENTAL|Control Group|Rehabilitation program with conventional physiotherapy
62600445|NCT00177307|EXPERIMENTAL|Oxaliplatin, Capecitabine, and Bevacizumab|
62600446|NCT05725265|EXPERIMENTAL|Large-area low-level laser therapy|Large-area low-level laser therapy(Venusure) was administered at proximal forearm, upper arm and axillary region of affected side. The wavelength was 980±15nm, average dose was 10-40nm/cm2 and maximal output was 1000mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks.
62600447|NCT05725265|PLACEBO_COMPARATOR|Conventional low-level laser therapy|Conventional low-level laser therapy was administrated on antecubital fossa and the axilla of affected side. The wavelength was 808nm and maximal output was 60 mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks.
62819952|NCT01864018|EXPERIMENTAL|Treatment (ixazomib citrate, cyclophosphamide, dexamethasone)|"INDUCTION THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15 and cyclophosphamide PO and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62243804|NCT06579989|EXPERIMENTAL|Dysphagia|Adult patients referred to the Sean Parker Institute for the Voice for swallowing assessment will undergo standard medical history including collection of age, gender, occupation, characteristics of swallowing complaints, and prior evaluation and treatments. Adult patients without swallowing complaints will also be recruited to define normal anatomy and variation.
62040046|NCT06241248||Ocean Test|The OCEAN Dx tests for the diagnosis of sepsis will be performed on 9 milliliters of blood collected at the patient's bedside.The sample will be collected at the same time as the blood cultures are taken. The blood tubes will then be transported to OCEAN Dx laboratories.
62040047|NCT03756428|EXPERIMENTAL|Deep dry needling in tibialis posterior|Deep dry needling will be applied in the tibialis posterior myofascial trigger point
62040048|NCT03756428|PLACEBO_COMPARATOR|Sham technique in tibialis posterior|Placebo tibialis dry needling
62040049|NCT05203926|EXPERIMENTAL|Crohn's disease (CD) subjects|These subjects will then undergo T1 and STIR sequence MRI of SI joints (pelvis MRI) as well as SIJ plain X-ray for assessment of radiographic sacroiliitis.
62243805|NCT06579989|EXPERIMENTAL|Dysphonia|Adult patients referred to the Sean Parker Institute for the Voice for voice assessment will undergo standard medical history including collection of age, gender, occupation, characteristics of voice complaints, and prior evaluation and treatments. Additionally, patients diagnosed with muscle tension dysphonia will be evaluated by ultrasound for the presence, size, and function of their suprahyoid musculature.
62243806|NCT02761486|ACTIVE_COMPARATOR|Aspirin|The subjects will receive 325 mg of aspirin once a day for 6 weeks followed by a 6-week washout.
62243807|NCT02761486|PLACEBO_COMPARATOR|Placebo|The subjects will receive placebo once a day for 6 weeks followed by a 6-week washout.
62819953|NCT04038359|EXPERIMENTAL|Duvelisib, Continuous and Intermittent Dosing|Duvelisib 25 milligrams (mg) twice daily (BID) continuously for 10 weeks, followed by 25 mg BID dosed 2 weeks off and 2 weeks on for each subsequent 4-week cycle.
62243808|NCT06734715||Conservative oxygenation|Patients that have previously received treatment in paediatric intensive care with conservative oxygenation
62819954|NCT04038359|EXPERIMENTAL|Duvelisib, Intermittent Dosing|Duvelisib 25 mg BID dosed 2 weeks on and 2 weeks off.
62243809|NCT06734715||Liberal oxygenation|Patients that have previously received treatment in paediatric intensive care with liberal oxygenation
62243810|NCT01668719|ACTIVE_COMPARATOR|Arm I (bortezomib, lenalidomide, dexamethasone)|"INDUCTION: Patients receive bortezomib SC or IV on days 1, 4, 8, and 11; lenalidomide PO QD on days 1-14; and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity (patients who received a course of chemotherapy prior to registration will begin protocol treatment with course 2 and receive a total of 7 courses of protocol therapy).~MAINTENANCE: Patients receive bortezomib SC or IV on days 1, 8, and 15; lenalidomide PO QD on days 1-21; and dexamethasone PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62600448|NCT04662788|EXPERIMENTAL|Administration of NK cells/Combined Monoclonal Antibodies|
62600449|NCT02650947|EXPERIMENTAL|Sucralose|Subjects in this group ate capsule filled with sucralose 200 mg for 4 weeks (week 1-4) and measured oral glucose tolerance test (OGTT), acute insulin response (AIR), and gut microbe examination at week 4.
62600450|NCT02650947|PLACEBO_COMPARATOR|Placebo|Subjects ate empty capsule (placebo) for 4 weeks (week 1-4) and measured OGTT, AIR, and gut microbe examination at week 4.
62600451|NCT03202537|EXPERIMENTAL|dexlansoprazole|dexlansoprazole 90mg per day (60mg am, 30mg pm dosing) for 4 weeks
62600452|NCT05716906|EXPERIMENTAL|Melatonin|5mg melatonin gummy 30 min before bedtime for 2 consecutive nights
62600453|NCT02684409|EXPERIMENTAL|PROT-CL-NP101-015.01|
62040050|NCT04050683|EXPERIMENTAL|Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Right Atrial Pressure (RAP) ≥ 15mmHg or change in RAP ≥ 10 mmHg or Peak Systolic Right Ventricular (PSRV) Pressure ≥ 46 mmHg
62040051|NCT04050683|ACTIVE_COMPARATOR|Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Normal hemodynamic parameters
62040052|NCT06733506|EXPERIMENTAL|Chlorhexidine Swabs|Participants randomized to the experimental condition received a 2-week supply of chlorhexidine gluconate pre-saturated, single-use swabs that they were instructed to use for cleaning their skin prior to injecting for the next 2 weeks.
62040053|NCT06733506|ACTIVE_COMPARATOR|Usual Care|Participants randomized to a usual care condition received a 2-week supply of isopropyl alcohol swabs that that they were instructed to use for the next 2 weeks to clean their skin prior to injecting.
62040054|NCT06291428||Raman spectroscopy|Patients with acute lymphoblastic leukemia, in assessment for measure residual disease.
62040055|NCT06291428||flow citometry|Patients with acute lymphoblastic leukemia, in assessment for measure residual disease.
62040056|NCT06583031|EXPERIMENTAL|Group 1 RSV/hMPV dose A1|Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule.
62040057|NCT06583031|EXPERIMENTAL|Group 2 RSV/hMPV dose A2|Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule.
62040058|NCT06583031|EXPERIMENTAL|Group 3 RSV/hMPV dose A3|Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule.
62040059|NCT06583031|EXPERIMENTAL|Group 4 RSV/hMPV dose B1|Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule.
62040060|NCT06583031|EXPERIMENTAL|Group 5 RSV/hMPV dose B2|Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule.
62040061|NCT06583031|EXPERIMENTAL|Group 6 RSV/hMPV dose B3|Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule.
62040062|NCT06583031|EXPERIMENTAL|Group 7 RSV/hMPV dose C1|Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule.
62040063|NCT06583031|EXPERIMENTAL|Group 8 RSV/hMPV dose C2|Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule.
62040064|NCT06583031|EXPERIMENTAL|Group 9 RSV/hMPV dose C3|Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule.
62040065|NCT06583031|EXPERIMENTAL|Group 10 RSV/hMPV dose 1|Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule.
62040066|NCT06583031|EXPERIMENTAL|Group 11 RSV/hMPV dose 2|Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule.
62849131|NCT01649089|EXPERIMENTAL|Treatment (cone biopsy/lymphadenectomy or hysterectomy)|Patients undergo cone biopsy and pelvic lymphadenectomy or simple hysterectomy and pelvic lymphadenectomy.
62849132|NCT04377347||Confirmed spontaneous subarachnoid haemorrhage|"Patients, minimum 18 years of age, identified with the diagnosis in the Danish National Patient Register. The diagnosis is verified by medical record review.~All patients were initially admitted to a hospital in the Capital Region of Denmark.~In a national labour marked register and the civil registration register the patients are then followed for four years."
62849133|NCT01966718|EXPERIMENTAL|Repository corticotropin injection|Repository corticotropin injection, 80 United States Pharmacopeia (USP) Units per mL, dosed as 1 mL (80 Units) subcutaneous injection every 72 hours for 12 weeks
62040067|NCT06583031|EXPERIMENTAL|Group 12 RSV/hMPV dose 3|Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule.
62040068|NCT06583031|EXPERIMENTAL|Group 13 Monovalent RSV Vaccine|Participants will receive a single IM injection on day 1 of a Monovalent (MV) RSV vaccine according to their randomization schedule.
62040069|NCT02415101|ACTIVE_COMPARATOR|Resective surgery after 4-6 weeks|Resective surgery 4-6 weeks after completed chemoradiotherapy (CRT)
62040070|NCT02415101|ACTIVE_COMPARATOR|Resective surgery after 10-12 weeks|Resective surgery 10-12 weeks after completed chemoradiotherapy (CRT)
62243811|NCT01668719|EXPERIMENTAL|Arm II (bortezomib, lenalidomide, dexamethasone, elotuzumab)|"INDUCTION: Patients receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Patients also receive elotuzumab IV on days 1, 8, and 15 of courses 1 and 2 and on days 1 and 11 of courses 3-8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Patients also receive elotuzumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62243812|NCT04457466||Healthy musicians|Men and women aged 18-60, who must be enrolled in a music conservatory performance program or be professionally active, and must speak and understand English.
62040071|NCT05008146|EXPERIMENTAL|PET|\[C-11\]NOP-1A
62040072|NCT03144713|EXPERIMENTAL|Terlipressin|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
62243813|NCT04457466||Healthy non-musicians|Men and women aged 18-60, must speak and understand English and not have any kind of musical training.
62243814|NCT04457466||Musicians with chronic pain|Men and women aged 18-60 with chronic and idiopathic musculoskeletal upper limb and/or neck pain lasting more than 6 months. They must be enrolled in a music conservatory performance program or be professionally active and must speak and understand English.
62243815|NCT04457466||Non-musicians with chronic pain|Men and women aged 18-60 with chronic and idiopathic musculoskeletal upper limb and/or neck pain lasting more than 6 months. They must not have any kind of musical training and must speak and understand English.
62600454|NCT04058106||A patient who need the spine surgery|A patient who go the propofol based total intravenous anesthesia due to intraoperative neuromonitorung for spine surgery
62600455|NCT01575275|EXPERIMENTAL|Diagnostic (aminolevulinic acid)|Patients receive aminolevulinic acid PO 2-4 hours before surgery.
62819955|NCT06510153|EXPERIMENTAL|Environmental Music Therapy|Environmental Music Therapy (EMT) is a music therapy technique that uses live music to modulate the potentially stressful effects of the environment towards an atmosphere that provides a sense of comfort and security. The instruments used will be an acoustic guitar (Yamaha C-40), an ocean drum (a drum with a double skin on which small metal balls roll imitating the sound of the waves) and a Samafon (an instrument consisting of aluminum tubes of different sizes that are struck with a soft mallet producing long-lasting single or combined tones). The music will consist of improvised music at a slow to moderate tempo, using free-flowing melodies, and simple chord progressions, focusing on creating moments of tension and resolution. The music therapist will also use his/her voice, but without any lyrics or words. After approximately 20 minutes, the music therapist will gradually decrease the volume until the music stops.
62819956|NCT06510153|EXPERIMENTAL|Pre-recorded music|The protocol for pre-recorded music is the same as for EMT, but instead of using live improvised music, a recording will be used that will consist of the same musical features and musical instruments as the live music. The recording will be made by the same music therapists who will perform the EMT intervention.
62819957|NCT06510153|PLACEBO_COMPARATOR|Standard care only|The control group will receive standard care in the emergency room waiting room as provided by each hospital, but without being exposed to EMT or pre-recorded music.
62819958|NCT05278260|PLACEBO_COMPARATOR|Control|
62819959|NCT05278260|EXPERIMENTAL|Active|
62819960|NCT02250326|EXPERIMENTAL|Combination arm: nab-paclitaxel and CC-486|Subjects in the combination arm will receive nab-paclitaxel 100 mg\^/m2 intravenous (IV) infusion over 30 minutes on Days 8 and 15 and CC-486 200 mg orally daily (QD) on Days 1 to14 of each 21-day treatment cycle
62819961|NCT02250326|EXPERIMENTAL|Monotherapy arm: nab-paclitaxel IV infusion|Subjects in the monotherapy arm will receive nab-Paclitaxel 100 mg/m\^2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day treatment cycle
62819962|NCT02250326|EXPERIMENTAL|Nab-paclitaxel and Durvalumab combination|subjects in the nab-Paclitaxel/durvalumab combination arm will receive nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and durvalumab 1125 mg IV infusion over approximately 1 hour on Day 15 of each 21-day treatment cycle
62819963|NCT06706050|EXPERIMENTAL|Arm 1: LP-51|test substance was applied on participants
62819964|NCT06706050|PLACEBO_COMPARATOR|Arm 2: Placebo|cream without active substance (M23004-03) was applied on the participants
62819965|NCT05236816|EXPERIMENTAL|Healthy|Subjects were evaluated before and after a fatiguing exercise of hip abductor muscles that consisted to repeat hip abduction with rate and range of motion until a target decrease of force is attempt
62819966|NCT06388226|EXPERIMENTAL|Heat therapy|Patients will be provided with water-circulating trousers, a water heater, and a water tank coupled to a water pump. The heater will be adjusted to warm up the water to 42ºC. Participants will be asked to apply the therapy daily for 90 min while in the supine position.
62819967|NCT06388226|SHAM_COMPARATOR|Sham control|Patients will be provided with water-circulating trousers, a water heater, and a water tank coupled to a water pump. The heater will be adjusted to warm up the water to 33ºC. Participants will be asked to apply the therapy daily for 90 min while seated or in the supine position.
62819968|NCT06016387|EXPERIMENTAL|Tucatinib, Transtuzumab, Capecitabine|Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+ Metastatic Breast Cancer and Leptomeningeal Disease.
62819969|NCT01657383||Hepatopancreaticobiliary (HPB) Surgery Patients|Patients undergoing surgical HPB procedures
62243816|NCT02575040|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation only
62243817|NCT01927185|ACTIVE_COMPARATOR|Long Axis strategy|The central venous catheterization will be performed by the long axis approach
62243818|NCT01927185|ACTIVE_COMPARATOR|Short Axis Strategy|The central venous catheterization will be performed by the short axis approach
62819970|NCT06033222|EXPERIMENTAL|750 mg castor oil treatment group|Subjects will take ricinoleic acid daily on an empty stomach in the morning 30 minutes before breakfast for a total of 4 days
62819971|NCT06033222|EXPERIMENTAL|1500 mg castor oil treatment group|Subjects will take ricinoleic acid daily on an empty stomach in the morning 30 minutes before breakfast for a total of 4 days
62040073|NCT03144713|ACTIVE_COMPARATOR|Midodrine|Midodrine 7.5 mg thrice daily for 3 days.
62243819|NCT00757003|EXPERIMENTAL|Treatment Arm - Placement of TAG device|A TAG device will be used to repair the pathology in the thoracic aorta
62243820|NCT05758714||Hartford Commuters|
62243821|NCT06120283|EXPERIMENTAL|Dose Escalation|Phase 1a: Sequential cohorts of increasing dose levels of BGB-43395 will be evaluated as monotherapy and in combination with either fulvestrant or letrozole to assess for safety and tolerability.
62243822|NCT06120283|EXPERIMENTAL|Dose Expansion|Phase 1b: The recommended dose for expansion (RFDE) for BGB-43395 (in combination with fulvestrant or letrozole) from Phase 1a will be evaluated in HR+ breast cancer and selected tumor-specific cohorts.
62243823|NCT06538038||Group 1|Osimertinib
62243824|NCT06538038||Group 2|Osimertinib + Chemotherapy
62600456|NCT05574803|EXPERIMENTAL|Active tDCS|The experimental group will receive 20 minutes of anodal HD-tDCS for five sessions, combined with 20 minutes of behavioural therapy.
62040074|NCT03144713|ACTIVE_COMPARATOR|Standard Medical Therapy|Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
62040075|NCT03657277|OTHER|Micropatch Application|This is the only study arm, which all participants complete. Five sites each on each the upper arm, forearm, and abdomen will be identified. Baseline measurements of trans-epidermal water loss, electrical resistance, hydration, and skin color will be made. Micropatches will be applied at three sites (at each body location). This only occurs on the first study day. Trans-epidermal water loss and electrical resistance are re-measured immediately after micropatch application. The sites will be covered with a small patch secured with medical tape. One site at each location will just be covered with a patch. The last site will not have micropatch application or patches. Electrical resistance will be re-measured at all sites for 3 days. Measurements from the 4th and 5th sites allow each subject to serve as their own control in data analysis.
62040076|NCT03176836|EXPERIMENTAL|MRI Imaging|"Participants will be imaged with the standard MRI technique (STIR-MRI) and also new MRI techniques called diffusion weighted or DW MRI and Positron Emission Tomography (PET)-MRI. PET-MRI will be indicated if the results from the routine MRI and DW MRI are contradictory or if laboratory results do not correspond to the standard MRI and DW MRI results."
62040077|NCT05321498|EXPERIMENTAL|1.0 mg/kg XPro1595|1.0 mg/kg XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
62040078|NCT05321498|PLACEBO_COMPARATOR|1.0 mg/kg Placebo|1.0 mg/kg of Placebo will be administered via subcutaneous injection once a week for 12 weeks.
62040079|NCT01499004|EXPERIMENTAL|Treatment A|tofacitinib (CP-690,550) modified-release formulation A-Fed
62040080|NCT01499004|EXPERIMENTAL|Treatment B|tofacitinib (CP-690,550) modified-release formulation B1-Fed
62040081|NCT01499004|EXPERIMENTAL|Treatment C|tofacitinib (CP-690,550) modified-release formulation A-Fasted
62434105|NCT00229450|EXPERIMENTAL|Treatment|0.625 mg/day of conjugated estrogen
62040082|NCT01499004|EXPERIMENTAL|Treatment D|tofacitinib (CP-690,550) modified-release formulation B1-Fasted
62040083|NCT01499004|EXPERIMENTAL|Treatment E|tofacitinib (CP-690,550) modified-release formulation B2-Fasted
62040084|NCT01499004|EXPERIMENTAL|Treatment F|tofacitinib (CP-690,550) immediate-release formulation-Fasted
62040085|NCT04197713|EXPERIMENTAL|Treatment (olaparib, adavosertib)|Patients receive olaparib PO BID on days 1-5 and 15-19 of each cycle and adavosertib PO QD on days 8-12 and 22-26 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62040086|NCT06580639||Healthy Individuals|Patients with a negative IGRA (Quantiferon) who are apparently healthy.
62040087|NCT06580639||Close contacts to patients with active TB|Close contacts to patients with active, smear positive pulmonary TB.
62040088|NCT06580639||Patients with (latent) tuberculosis infection|Patients without active TB who have a positive IGRA (Quantiferon Plus) result.
62040089|NCT06580639||Patients with active TB|Culture or PCR-verified active TB who are initiated on treatment.
62040090|NCT05830162|PLACEBO_COMPARATOR|Placebo|"The Pharmacy of the main capital region provides the bioclavid (amoxicillin with Clavulanic acid) and placebo tablets for this study. They are responsible for the randomization and packing of the tablets. The randomization will be in randomly variating block sizes.~Women in the placebo arm will get 3 calcium tablets to take within the fist 24 hours of the delivery. The first tablet must be administrated within 6 hours of the delivery."
62243825|NCT06368167|EXPERIMENTAL|SHR2554|
62243826|NCT05716087|EXPERIMENTAL|Rocbrutinib|Subjects who have previously received BTK inhibitors treatment failed or relapsed after remission or intolerated
62243827|NCT05864001|EXPERIMENTAL|Intervention|Immediate access to the digital coaching intervention
62243828|NCT05864001|NO_INTERVENTION|Control|Delayed access to the digital coaching intervention, six months
62434106|NCT00229450|PLACEBO_COMPARATOR|Placebo|Daily placebo for conjugated estrogen
62434107|NCT04356573|PLACEBO_COMPARATOR|Gold Kiwifruit First, then Green Hayward Kiwifruit|Subjects first ate 2 gold kiwifruit with midday meal for 2 weeks before crossing over to the green Hayward kiwifruit intervention
62434108|NCT04356573|ACTIVE_COMPARATOR|Green Hayward Kiwifruit first, then Gold Kiwifruit|Subjects first ate 2 green Hayward kiwifruit with midday meal for 2 weeks before crossing over to the gold kiwifruit intervention
62819972|NCT06033222|EXPERIMENTAL|3000 mg castor oil treatment group|Subjects will take ricinoleic acid daily on an empty stomach in the morning 30 minutes before breakfast for a total of 4 days
62600457|NCT05574803|SHAM_COMPARATOR|Sham tDCS|The control group will only receive one minute of anodal HD-tDCS stimulation which aims to create a similar sensation on the scalp as those in the experimental group, with 20 minutes of behavioural therapy.
62600458|NCT02863081||Healthcare providers|All healthcare providers working in the participating LTACH will be asked to complete 2 surveys and invited to participate in focus group meetings
62600459|NCT02863081||Patients|81 LTACH patients will be enrolled over the course of a 9 month period. Each patient and their LAR will be interviewed at the time of LTACH admission to garner information about their pre hospitalization physical, functional, and cognitive health status. Each day enrolled patients will undergo daily symptom assessments and medical record reviews. At the time of LTACH discharge all enrolled patients will be interviewed again to garner information about their discharge physical, functional, and cognitive health status.
62040091|NCT05830162|EXPERIMENTAL|Antibiotics (bioclavid)|"The Pharmacy of the main capital region provides the bioclavid (amoxicillin with Clavulanic acid) and placebo tablets for this study. They are responsible for the randomization and packing of the tablets. The randomization will be in randomly varying block sizes.~Women in the antibiotic arm will get 3 tablets bioclavid (amoxicillin and Clavulanic acid) to take within the fist 24 hours of the delivery. The first tablet must be administrated within 6 hours of the delivery."
62819973|NCT06033222|PLACEBO_COMPARATOR|Placebo group|Subjects will take placebo daily on an empty stomach in the morning 30 minutes before breakfast for a total of 4 days
62040092|NCT03781752|EXPERIMENTAL|Methylphenidate|Youth with ADHD
62819974|NCT04863729|EXPERIMENTAL|Intervention|The program consists of 11 weekly sessions conducted with girls ages 10-14 and their female caregivers. 5 of the 11 sessions will be taught to groups of 9-13 girls and their female caregivers, and 6 of the sessions will be taught to individual girl/female caregiver dyads. The choice to use a mix of group- and individual sessions is based on findings from the formative phase indicating certain topics should be taught in groups (e.g. Navajo history and reproductive health 101), and certain topics be taught in individual dyads (e.g. family values and the clan system).
62040093|NCT06732297|EXPERIMENTAL|Immediate Treatment Group|Participants in the immediate treatment group will undergo the intervention after baseline assessment and randomization. The intervention consists of 1.5-hour art-therapy sessions which happen every week for 10 weeks. The topics of intervention sessions include building rapport, emotional expression \& regulation, self-care, communication \& collaboration, and reflection \& community.
62040094|NCT06732297|OTHER|Waitlist Control Group|Participants in the waitlist control group will undergo the intervention after participants in the immediate treatment group complete the intervention. Participants in the two group undergo the same intervention.
62040095|NCT01515410|EXPERIMENTAL|DM-1992|DM-1992, a gastric-retentive extended-release tablet containing 72.5mg carbidopa (CD) and 230mg levodopa (LD)
62040096|NCT01515410|ACTIVE_COMPARATOR|Sinemet IR|An Immediate-release (IR) tablet containing 25mg carbidopa (CD) and 100mg levodopa (LD)
62040097|NCT04348305|EXPERIMENTAL|Hydrocortisone|"Continuous intravenous infusion of hydrocortisone 200 mg over 24 hours (total 104 ml). The trial intervention will be given in addition to standard care.~If continuous intravenous infusion is not possible, we will allow the use of bolus injection of the trial medication (50 mg (10 ml) every 6 hours)."
62040098|NCT04348305|PLACEBO_COMPARATOR|Isotonic Saline|"Continuous intravenous infusion of matching isotonic saline (0.9%) placebo at a dose volume of 104 ml over 24 hours in addition to standard care (no corticosteroid treatment).~If continuous intravenous infusion is not possible, we will allow the use of bolus injection of matching saline placebo (10 ml every 6 hours)."
62040099|NCT02934490|EXPERIMENTAL|Treatment group|
62040100|NCT05663424|EXPERIMENTAL|immediate rehabilitation group|rTMS plus immediate rehabilitation programs
62434109|NCT00478361|EXPERIMENTAL|Gemcitabine, Paclitaxel and Doxorubicin|Paclitaxel 135 mg/m\^2 intravenous (IV) over 1 hour; Gemcitabine 900 mg/m\^2 IV over 90 min; Doxorubicin 40 mg/m\^2 IV over 20 min; treatment may repeat every 2 weeks for up to nine courses. Injection of Pegfilgrastim on day 1.
62434110|NCT04978285||Postoperative anemia|All patients enrolled in the RELIEF trial in which a postoperative Day 1-3 hemoglobin concentration was measured. Anaemia will be defined according to the World Health Organisation definition (males Hb \<130 g/L, and female Hb \<120 g/L).
62600460|NCT04761081||South Asians who are lean|"The south Asian group who are lean will be of south Asian ethnicity and a waist circumference \<90cm.~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.~Metabolic markers will be analysed and presented in a participant characteristics table."
62623812|NCT02711566|EXPERIMENTAL|Haptic training|Patients in this arm were assigned to the 'Physioassistant: Sensorimotor training' intervention. The treatments were delivered through a planar robotic manipulandum, specifically designed for motor learning studies and robot-assisted rehabilitation. All participating centers used the exact same apparatus and experimental set-up.
62623813|NCT00497055|EXPERIMENTAL|Aripiprazole|Aripiprazole 5mg daily for week one. Aripiprazole 10mg daily for week two. Aripiprazole 20mg daily for weeks three through twelve.
62819975|NCT04863729|NO_INTERVENTION|Control|Girls and their female caregivers randomized to the control group will receive 4 retention incentives that are mailed to them monthly. These incentives will each be \<$10 per dyad, examples include: water bottles, lanyards, pencil cases and tote bags. The control condition was selected by community members and allows for minimal contamination and/or overlap between the AB curriculum and control group
62040101|NCT05663424|EXPERIMENTAL|delayed rehabilitation group|rTMS plus delayed rehabilitation programs
62040102|NCT05663424|SHAM_COMPARATOR|sham rTMS group|sham rTMS + rehabilitation programs
62040103|NCT02990533|PLACEBO_COMPARATOR|Placebo|Placebo Supplement Placebo Injection
62040104|NCT02990533|EXPERIMENTAL|Testosterone|Placebo Supplement Testosterone Injection
62040105|NCT02990533|EXPERIMENTAL|Protein Supplement|Protein Supplement Placebo Injection
62040106|NCT02990533|EXPERIMENTAL|Protein Supplement + Testosterone|Protein Supplement Testosterone Injection
62040107|NCT06354634|EXPERIMENTAL|All participants|Each participant will receive a BioFLX crown and a stainless steel crown.
62040108|NCT00798720|EXPERIMENTAL|Vorinostat + Bortezomib|Vorinostat 400 mg + Bortezomib 1.3 mg/m2
62040109|NCT05215587|NO_INTERVENTION|Medical Therapy|Patients will be treated with standard medical therapy, i.e., antihypertensives, pulse-rate regulators, and pain medication.
62040110|NCT05215587|ACTIVE_COMPARATOR|Stent Therapy|Patients will be treated with both standard medical therapy, in addition to placement of a thoracic endovascular aortic repair stent graft.
62623814|NCT00497055|PLACEBO_COMPARATOR|Placebo|Placebo (for Aripiprazole) 5mg daily for week one. Placebo (for Aripiprazole) 10mg daily for week two. Placebo (for Aripiprazole) 20mg daily for weeks three through twelve.
62040111|NCT03609112||Patients treated for a brain tumor|As part of their usual follow-up, these patients have neuropsychological evaluations following their treatment. A complete neuropsychological evaluation will therefore be performed as part of their usual follow-up during the inclusion period of this study and only the data from this evaluation will be taken into account for the statistical analysis of this study.
62040112|NCT03609112||Patients treated for a non-cerebral tumor|A single neuropsychological assessment will be proposed to these patients after the end of treatment and during the inclusion period of this study. This evaluation will be carried out during a visit to Gustave Roussy as part of their usual follow-up. If on the occasion of this evaluation, cognitive disorders or psychological disorders were highlighted, a neuropsychological and / or psychological follow-up would be proposed.
62040113|NCT03609112||Patients who received Methotrexate|"Methotrexate is used in the treatment of certain brain tumors as in that of non-cerebral tumors. Some of these patients, particularly those who have had neurological complications with methotrexate, will already have longitudinal neuropsychological follow-up as part of their usual follow-up. For these patients, only one complete neuropsychological assessment will be performed during the inclusion period and will be considered for statistical analysis.~For patients in the course of treatment with methotrexate, during the period of inclusion of this study, a longitudinal follow-up will be carried out with neuropsychological evaluations close and successive at the time of their coming to Gustave Roussy within the usual framework of their care."
62040114|NCT06733246|EXPERIMENTAL|Ceretrieve treatment arm - patient will be treated with the Ceretrieve device - aspiration approach|This is the only study arm. All patients found to be eligible will be treated with the Ceretrieve device.
62040115|NCT04064489|NO_INTERVENTION|neutral|No specific instructions for prescribing prophylaxis or not
62040116|NCT04064489|ACTIVE_COMPARATOR|TRIPscore|calculation of the TRIPcast score and prescription of prophylactic or not according to the result (score \> or = 7 : treatment (low molecular weight heparin or fondaparinux); score \< 7 : no treatment)
62040117|NCT00951041|EXPERIMENTAL|GSK2340272A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine. The first vaccine dose was administered intramuscularly in the deltoid region of the non-dominant arm at Day 0, and the second vaccine dose was administered intramuscularly in the deltoid region of the dominant arm at Day 21.
62040118|NCT00951041|EXPERIMENTAL|GSK2340269A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine. The first vaccine dose was administered intramuscularly in the deltoid region of the non-dominant arm at Day 0, and the second vaccine dose was administered intramuscularly in the deltoid region of the dominant arm at Day 21.
62434111|NCT04978285||No postoperative anemia|All patients enrolled in the RELIEF trial in which a postoperative Day 1-3 hemoglobin concentration was measured. No anaemia will be defined according to the World Health Organisation definition (males Hb ≥130 g/L, and females Hb ≥120 g/L).
62434112|NCT02598193|EXPERIMENTAL|Pirfenidone+Nintedanib|Participants with IPF will receive pirfenidone at 1602-2403 milligrams per day (mg/day) dose and nintedanib at the 200-300 mg/day dose up to 24 weeks.
62819976|NCT03891706|EXPERIMENTAL|TCR-T cell infusion|Patient will exposed to Individualized Tumor-t Cell Receptor (TCR) -Mediated T Cells therapy
62819977|NCT06219694|EXPERIMENTAL|laser acupuncture|CM patients with unsatisfactory pharmacological effects receive laser acupuncture for 8 sessions that spanned 4 weeks. Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
62819978|NCT06219694|SHAM_COMPARATOR|Sham treatment|CM patients with unsatisfactory pharmacological effects receive sham treatment for 8 sessions that spanned 4 weeks. Sham treatment had no laser output.
62819979|NCT02546609|EXPERIMENTAL|Leu Met Sil 0.5mg|Leu-Met-Sil 0.5: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
62819980|NCT02546609|EXPERIMENTAL|Leu Met Sil 1.0mg|Leu-Met-Sil 1.0: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
62819981|NCT02546609|PLACEBO_COMPARATOR|Placebo|Placebo: 3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
62819982|NCT06068309|EXPERIMENTAL|CareAide Interventional Group|Participants allocated to the Interventional group (IG) uses the CareAide® app on their smartphones in addition to prescribed usual therapeutic care.
62819983|NCT06068309|NO_INTERVENTION|Control Group|Participants allocated to the Control group (CG) receives prescibed usual therapeutic care
62819984|NCT04638907||Observational study group|Consenting adult male patients undergoing elective robot-assisted prostatectomy. No further selection or randomisation. Enrollment as availability for the study.
62849134|NCT04099264|EXPERIMENTAL|Intervention group: Personalized music|This arm will receive an intervention which will be personalized music. It will be provided by Music Care application (https://www.music-care.com/fr).
62243829|NCT02296450||Quality of Life (QoL) Assessment|Patients involved in this study will have a wide range of dermatologic conditions for which they will be assessed and managed by the treating physician. An appropriate QoL instrument will be administered at the initial visit, and if applicable, at subsequent follow-up visit(s). Treatment of the dermatologic condition will be at physician's discretion based on the patient's presenting symptoms and is not an intervention itself within this study.
62040119|NCT01001052|EXPERIMENTAL|Colcrys™ - young subjects (18-30 yrs)|One single dose of Colcrys™ 0.6mg taken by mouth on day 1
62040120|NCT01001052|EXPERIMENTAL|Colcrys™ - elderly subjects (≥60 yrs)|One single dose of Colcrys™ 0.6mg taken by mouth on day 1
62040121|NCT04080804|EXPERIMENTAL|Nivolumab + Relatlimab|Nivolumab 480mg IV + Relatlimab 480mg IV D1 - optional Nivolumab 480 mg IV + Relatlimab 480mg IV D28 (D28 at clinician discretion i.e. surgery postponed)
62040122|NCT04080804|EXPERIMENTAL|Nivolumab + Ipilimumab|Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg D1 then Nivolumab 3 mg /kg D14 and then optional Nivolumab 3 mg/kg D28 (D28 at clinician discretion i.e., surgery postponed)
62040123|NCT04762368|ACTIVE_COMPARATOR|Active + Training|Participants in this arm will be exposed to active stimulation for the first 25 minutes of a roughly hour - long perceptual training procedure in which participants must verbally read sentences presented at various speeds and sizes.
62040124|NCT04762368|SHAM_COMPARATOR|Sham + Training|Participants in this arm will be exposed to sham stimulation for the first 25 minutes of a roughly hour - long perceptual training procedure in which participants must verbally read sentences presented at various speeds and sizes.
62040125|NCT03141060|EXPERIMENTAL|Arm 1: Delamanid|Participants will receive delamanid (DLM) twice daily for 24 weeks. Participants will also receive non-study prescribed OBR for MDR-TB.
62623815|NCT05447156|OTHER|Aim 2: Tailored App (pilot run of Aim 3)|All participants will use the tailored QuitGuide app, a smoking cessation app, downloaded to their personal phone.
62819985|NCT04718415|EXPERIMENTAL|sintilimab + carboplatin + nab-paclitaxel|"Treatment with sintilimab, nab-paclitaxel and carboplatin for up to 2 - 4 cycles:~Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
62623816|NCT05447156|EXPERIMENTAL|Aim 3:Tailored App|Randomized subset of participants will use the tailored QuitGuide app, a smoking cessation app, downloaded to their personal phone.
62819986|NCT05642676|EXPERIMENTAL|Interventions clinics to be remodeled|
62819987|NCT06458283|EXPERIMENTAL|Experimental Group|Investigation of the effectiveness of scenario-based standardized patient simulation training and breastfeeding management of midwifery students
62040126|NCT03902054|EXPERIMENTAL|Experimental Group - High dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of high dosage investigational sIPV
62040127|NCT03902054|EXPERIMENTAL|Experimental Group - Medium dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of medium dosage investigational sIPV
62040128|NCT03902054|EXPERIMENTAL|Experimental Group - Low dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of low dosage investigational sIPV
62040129|NCT03902054|ACTIVE_COMPARATOR|Control Group -commercialized sIPV|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized sIPV
62040130|NCT03902054|ACTIVE_COMPARATOR|Control Group -commercialized IPV|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized IPV
62040131|NCT01087892|ACTIVE_COMPARATOR|Dietary supplement Probiotic drink|"Double blind~Probiotic containing the live strain 100g/day orally, twice daily for the duration of the course of antibiotics plus seven days"
62243830|NCT03518554|EXPERIMENTAL|JAB-3068 (SHP2 inhibitor)|Daily oral administration of JAB-3068
62434113|NCT03175783|EXPERIMENTAL|Treatment Group|Treatment group will receive intervention by putting on Fitbit Zip activity tracker with automatic step counts feedback throughout the study.
62434114|NCT03175783|SHAM_COMPARATOR|Control Group|Control group will be put on intervention with same Fitbit Zip activity tracker but without automatic feedback for same duration of intervention.
62819988|NCT06458283|EXPERIMENTAL|Control Group|Standard training of midwifery students with low fidelty breast model
62819989|NCT01264341|EXPERIMENTAL|Bevacizumab combined with temsirolimus|Bevacizumab 10mg/kg intravenous every 2 weeks Temsirolimus 25mg intravenous once weekly
62819990|NCT00079417|EXPERIMENTAL|Treatment (chemotherapy, surgery)|Patients receive chemoreduction comprising carboplatin IV over 60 minutes followed by vincristine IV over 1-2 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the first course of chemoreduction, patients undergo standardized local ophthalmic therapy comprising local laser therapy, cryotherapy, and/or radioactive plaque comprising iodine I 125 or ruthenium Ru 106.
62819991|NCT05507723|EXPERIMENTAL|Treat-to-target|All participants will have the GoutSMART application installed on their phones, and be offered a management plan including the use of flare prophylaxis and maximum advised dose of allopurinol based on renal function. All Participants in the treat-to-target group will be provided with a BeneCheck hand-held device and taught to perform urate finger prick self-testing. Participants will be prompted to submit urate readings by the GoutSMART app and if urate levels remain above target their allopurinol will be increased incrementally up to the pre-specified maximum dose of allopurinol.
62819992|NCT05507723|ACTIVE_COMPARATOR|Usual care|All participants will have the GoutSMART application installed on their phones, and be offered a management plan including the use of flare prophylaxis and maximum advised dose of allopurinol based on renal function to achieve urate target. Participants in the usual care arm of the study will have their treatment reviewed and escalated by their GPs in line with usual practice.
62040132|NCT01087892|PLACEBO_COMPARATOR|Dietary supplement probiotic placebo drink|"Double blind~'placebo' is actually a control product~Placebo drink contains no strain 100gs orally, twice daily for the duration of the course of antibiotics plus seven days"
62040133|NCT05808101||With Neuro-QoL Depression scale T-score > 55|"1. Collection of demographic and clinical data (age, gender, BMI, ethnicity, age of onset, number of relapses).~2. Administration of the Neuro-QoL depression scale~3. Neurological exam to evaluate disability and calculate the EDSS score (ranging from 0 to 10)~4. Neurological cognitive and functional assessments: a 9-hole Peg Test and 25-ft Timed Walk from the Multiple Sclerosis Functional Composite (MSFC); the Symbol Digit Modality Test (SDMT)~5. Administration of the Fatigue Severity Scale (FSS)~6. Collection of a 4-days food diary to evaluate diet composition of enrolled pwMS~7. Administration of the Stanford 7-day Physical Activity Recall Scale (PAR)~8. Evaluation of sleep quality by administration of the Neuro-QoL sleep disturbance scale~9. Collection of a stool sample for gut microbiome and metabolome analyses~10. Collection of a saliva sample for microbiome and metabolome analyses"
62040134|NCT05808101||With Neuro-QoL Depression scale T-score < 55|"1. Collection of demographic and clinical data (age, gender, BMI, ethnicity, age of onset, number of relapses).~2. Administration of the Neuro-QoL depression scale~3. Neurological exam to evaluate disability and calculate the EDSS score (ranging from 0 to 10)~4. Neurological cognitive and functional assessments: a 9-hole Peg Test and 25-ft Timed Walk from the Multiple Sclerosis Functional Composite (MSFC); the Symbol Digit Modality Test (SDMT)~5. Administration of the Fatigue Severity Scale (FSS)~6. Collection of a 4-days food diary to evaluate diet composition of enrolled pwMS~7. Administration of the Stanford 7-day Physical Activity Recall Scale (PAR)~8. Evaluation of sleep quality by administration of the Neuro-QoL sleep disturbance scale~9. Collection of a stool sample for gut microbiome and metabolome analyses~10. Collection of a saliva sample for microbiome and metabolome analyses"
62040135|NCT01506193|ACTIVE_COMPARATOR|Group A|Subjects in this arm will receive MMRV vaccine at Visit 1 (Day 0) and MenC vaccine at Visit 2 (Days 35-49).
62819993|NCT05650749|EXPERIMENTAL|Dose Escalation Arm|The dose escalation arm will determine the maximum tolerated dose of GPC2 CAR T cells using a standard 3+3 trial design.
62819994|NCT05650749|EXPERIMENTAL|Dose Expansion Arm|If at least one dose from the dose expansion arm is determined to be safe, additional patients will be enrolled to the dose expansion arm to preliminarily evaluate the rate of response to GPC2 CAR T cells and further characterize the safety profile of GPC2 CAR T cells.
62040136|NCT01506193|EXPERIMENTAL|Group B|Subjects will receive MMRV vaccine and MenC vaccine at Visit 1 (Day 0).
62243831|NCT06272435|EXPERIMENTAL|Water, Multiplier, Sugar with Amino Acids, and Sugar Free|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62819995|NCT04181359|EXPERIMENTAL|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
62819996|NCT04181359|PLACEBO_COMPARATOR|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
62243832|NCT06272435|EXPERIMENTAL|Water, Multiplier, Sugar Free, and Sugar with Amino Acids|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62819997|NCT05478265||Axial Spine only, Age 65+|
62040137|NCT01506193|ACTIVE_COMPARATOR|Group C|Subjects will receive Men C vaccine at Visit 1 (Day 0) and MMRV vaccine at Visit 2 (Day 35-49).
62819998|NCT05478265||Axial Spine only, Age 18-64|
62819999|NCT05478265||Peripheral Joint only, Age 65+|
62243833|NCT06272435|EXPERIMENTAL|Water, Sugar with Amino Acids, Multiplier, and Sugar Free|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62243834|NCT06272435|EXPERIMENTAL|Water, Sugar with Amino Acids, Sugar Free, and Multiplier|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62243835|NCT06272435|EXPERIMENTAL|Water, Sugar Free, Multiplier, and Sugar with Amino Acids|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62243836|NCT06272435|EXPERIMENTAL|Water, Sugar Free, Sugar with Amino Acids, and Multiplier|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62243837|NCT06272435|EXPERIMENTAL|Multiplier, Water, Sugar with Amino Acids, and Sugar Free|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62243838|NCT06272435|EXPERIMENTAL|Multiplier, Water, Sugar Free, and Sugar with Amino Acids|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62243839|NCT06272435|EXPERIMENTAL|Multiplier, Sugar with Amino Acids, Water, and Sugar Free|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62243840|NCT06272435|EXPERIMENTAL|Multiplier, Sugar with Amino Acids, Sugar Free, and Water|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62243841|NCT06272435|EXPERIMENTAL|Multiplier, Sugar Free, Water, and Sugar with Amino Acids|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62243842|NCT06272435|EXPERIMENTAL|Multiplier, Sugar Free, Sugar with Amino Acids, and Water|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62434115|NCT02685761|NO_INTERVENTION|Low Transverse|Patients in this arm will undergo their cesarean section using the standard low transverse skin incision location
62434116|NCT02685761|EXPERIMENTAL|Midline Vertical|Patients in this arm will undergo their cesarean section using a midline vertical skin incision
62434117|NCT02685761|EXPERIMENTAL|High Transverse|Patients in this arm will undergo their cesarean section using a high transverse skin incision, above the pannus
62040138|NCT05800535||JUMP Cohort|This study concerns adults with cancer treated with chemotherapy, radiotherapy, hormonal therapy or immunotherapy, in remission or cured. Patients took part in the dedicated post-cancer assessment day.
62040139|NCT02823951||Rebif - 1 year MRI cohort|Treatment naive patients starting with Rebif, 1 year follow-up available, MRI scan available at baseline and at 12 months
62434118|NCT03229993|EXPERIMENTAL|OCT guided PCI|
62434119|NCT03229993|EXPERIMENTAL|OCT guided medicine|
62434120|NCT03229993|NO_INTERVENTION|SPECT guided PCI|
62434121|NCT03229993|NO_INTERVENTION|SPECT guided medicine|
62434122|NCT02457728|EXPERIMENTAL|Inguinal herniation|In patients with bilateral herniations it should be explored if one glue device (LiquiBandFix8) for mesh fixation and closure of peritoneum is sufficient.
62434123|NCT04793503|ACTIVE_COMPARATOR|conventional complete denture|the patients receive conventional complete denture constructed from heat cure acrylic resin
62434124|NCT04793503|ACTIVE_COMPARATOR|CADCAM 3D printed denture|the patients receiveCADCAM 3D printed denture constructed by using printing machine
62623817|NCT05447156|PLACEBO_COMPARATOR|Aim 3: Standard App|Randomized subset of participants will use the standard QuitGuide app, a smoking cessation app available to the public, downloaded to their personal phone.
62623818|NCT03130270|EXPERIMENTAL|Apatinib group|Apatinib mesylate tablet：the starting dose was 500 mg, orally, qd; tolerance assessment for a cycle, patients with poorly tolerance were treated with low dose (500 mg, qd), and patients with well tolerance were treated with high dose (750 mg, qd).
62820000|NCT05478265||Peripheral Joint only, Age 18-64|
62820001|NCT05478265||Axial + Peripheral Joint, Age 65+|
62820002|NCT05478265||Axial + Peripheral Joint, Age 18-64|
62434125|NCT04793503|ACTIVE_COMPARATOR|CAD/CAM milled denture|the patients receiveCADCAM 3D printed denture constructed by using milling machine
62820003|NCT01561014|EXPERIMENTAL|Treatment (chemotherapy, enzyme inhibitor therapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy QD, 5 days a week and receive fluorouracil IV continuously and erlotinib hydrochloride PO QD on days 1-38. Patients also receive oxaliplatin IV over 2 hours on days 1, 15, and 29.~SURGERY: Within 4-8 weeks after completion of chemoradiotherapy, patients with potentially resectable disease (i.e., complete response, partial response, or stable disease) undergo surgery to remove the tumor.~CONSOLIDATION CHEMOTHERAPY: Within 2-4 weeks after surgery, patients with tumors that demonstrate positive immunohistochemistry for EGFR and/or cyclin D1 (in the pretreatment biopsy or in the residual tumor in the esophagectomy specimen) receive consolidation chemotherapy comprising erlotinib hydrochloride PO QD for 12 weeks."
62040140|NCT02823951||Rebif - 1 year clinical cohort|Treatment naive patients starting with Rebif, 1 year follow-up available, MRI scan available at baseline
62434126|NCT05952427||Infertile women|Any patient consulting for the first time at the Grenoble University Hospital in a context of infertility, between 18 and 43 years old
62434127|NCT05952427||Non-infertile women|Any patient consulting her gynecologist in town for a reason other than infertility, and having no known infertility, between 18 and 43 years old
62434128|NCT00693784|EXPERIMENTAL|Biostat® Disc Augmentation System|Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
62434129|NCT00971204|EXPERIMENTAL|Treatment with HeartLight System|Treatment of paroxysmal atrial fibrillation (PAF) with HeartLight System
62434130|NCT02799316|OTHER|rheumatic disease with HBs-ag positive|• HBV core antibodies testing. • Real time PCR testing.
62820004|NCT06705543|ACTIVE_COMPARATOR|Congenital Heart Defects population|
62820005|NCT06705543|PLACEBO_COMPARATOR|control population|
62434131|NCT00139386|ACTIVE_COMPARATOR|Candesratan|
62820006|NCT05568225|EXPERIMENTAL|Etavopivat 400 mg QD daily|Non-transfusion dependent (NTD), Low transfusion burden (LTB) , and High transfusion burden (HTB) patients
62820007|NCT05735327||Brigatinib|Participants receiving Brigatinib as part of their first-line treatment in scope of their routine clinical practice within the frames of National Drug Program (NDP) will be observed at baseline, and every 3 months (± 1 month) at routine follow-up for up to 33 months.
62820008|NCT05388877|EXPERIMENTAL|Treatment (E6201, dabrafenib)|Patients receive MEK-1/MEKK-1 inhibitor E6201 IV over 2 hours on days 1, 4, 8, 11, 15, and 18, and dabrafenib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62820009|NCT03612817|ACTIVE_COMPARATOR|Tafluprost/timolol with PM dosing|Therapy with Tafluprost/timolol fixed combination drops dosed PM (20:00)
62434132|NCT00139386|NO_INTERVENTION|Non-candesartan|
62040141|NCT02823951||Rebif - early discontinuation cohort - tolerability|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to tolerability
62040142|NCT02823951||Rebif - early discontinuation cohort - adverse events|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to adverse events
62040143|NCT02823951||Rebif - early discontinuation cohort - disease activity|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to disease activity
62040144|NCT02823951||Tecfidera - 1 year MRI cohort|Treatment naive patients starting with Tecfidera, 1 year follow-up available, MRI scan available at baseline and at 12 months
62040145|NCT02823951||Tecfidera - 1 year clinical cohort|Treatment naive patients starting with Tecfidera, 1 year follow-up available, MRI scan available at baseline
62040146|NCT02823951||Tecfidera - early discontinuation cohort - tolerability|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to tolerability
62040147|NCT02823951||Tecfidera - early discontinuation cohort - adverse events|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to adverse events
62040148|NCT02823951||Tecfidera - early discontinuation cohort - disease activity|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to disease activity
62243843|NCT06272435|EXPERIMENTAL|Sugar with Amino Acids, Water, Multiplier, and Sugar Free|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62243844|NCT06272435|EXPERIMENTAL|Sugar with Amino Acids, Water, Sugar Free, and Multiplier|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62820010|NCT03612817|ACTIVE_COMPARATOR|Tafluprost/timolol with AM dosing|Therapy with Tafluprost/timolol fixed combination drops dosed AM (08:00)
62820011|NCT06706687|OTHER|Frontotemporal Dementia, Behavioral Variant (bvFTD)|
62820012|NCT06706687|OTHER|Bipolar Disorder (BD)|
62820013|NCT06706687|OTHER|Healthy controls (HC)|
62820014|NCT05139680||Patients with mixed phenotype ATTRv-CM|Hereditary ATTR-CM patients presenting with mixed phenotype
62820015|NCT06589544|EXPERIMENTAL|Virtual Reality-based Cognitive Remediation (VR-COG)|"Virtual Reality-based Cognitive Remediation (VR-COG) + Treatment as usual (TAU)~The VSail 3D experimental protocol includes scenarios (virtual environments) dedicated to the sport of sailing. It is based on the software CEREBRUM-VELA (Idego-Promind, srl, Rome, Italy).~Frequency: 24 sessions, 2 times a week, for 12 consecutive weeks. The duration of each session is 50 minutes."
62820016|NCT06589544|EXPERIMENTAL|Repetitive transcranial magnetic stimulation (rTMS)|"Repetitive transcranial magnetic stimulation (rTMS) + Treatment as usual (TAU)~rTMS group will receive active rTMS using the MagVenture MagPro X100 System (MagVenture A/S, Denmark) equipped with a MagVenture Cool-B65 A/P double-faced coil and a neuronavigation system (Localite GmbH, Sankt Augustin, Germany).~Frequency: 24 sessions, 2 times a week, for 12 consecutive weeks. The duration of each session is 60 minutes."
62820017|NCT06589544|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|"Treatment as Usual (TAU)~The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https://www.aiom.it), includes an initial psychiatric visit and eventual pharmacological therapy with psychiatric follow-up plus psychological counseling.~Frequency: 12 weeks. Each counseling session lasts 45-50 minutes, and will be conducted on a monthly basis."
62820018|NCT05368038||Newborn infants born at a ScreenPlus pilot hospital|Parents who give permission will have their infant's sample screened for the ScreenPlus panel. Infants who screen positive after multi-tiered testing will be referred to a ScreenPlus doctor for confirmatory testing and care coordination.
62820019|NCT05268809|EXPERIMENTAL|Ketogenic Diet|The ketogenic diet is a normo-caloric diet composed of high-fat (70%), low-carbohydrate (10%), and adequate protein (20%) that induces fasting-like effects and the production of ketone bodies. Metabolic Meals will be delivered to KETO subjects' homes via courier, consisting of 3 meals a day plus snacks, targeting 70% fat, 20% protein, 10% carbohydrates.
62820020|NCT05268809|NO_INTERVENTION|Diet as usual|The Diet As Usual (DAU) participants will be asked to maintain their current dietary habits and will be discouraged from starting new diets during the 4-week study.
62820021|NCT04963920|EXPERIMENTAL|SoC+CytoSorb treatment|patients allocated to this group, will receive CytoSorb therapy in addition to the standard of care therapy according to applicable guidelines
62040149|NCT06733467|EXPERIMENTAL|Manipulations of Visual Working Memory (Expt 2.3)|Participants will be shown a colorful moving dot stimulus at a random location in the periphery while maintaining fixation. After a 12 sec delay period where nothing is presented on the screen, they will be shown a new dot array at the dot array location and they will have to adjust either the color/motion of the array to match what was shown at the beginning of the trial (or do nothing if it is the remember nothing condition).
62040150|NCT02703922|OTHER|GCA suspicion|A first screening is performed using color Doppler ultrasound. In case of negative results, patients undergo TAB.
62243845|NCT06272435|EXPERIMENTAL|Sugar with Amino Acids, Multiplier, Water, and Sugar Free|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62243846|NCT06272435|EXPERIMENTAL|Sugar with Amino Acids, Multiplier, Sugar Free, and Water|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62243847|NCT06272435|EXPERIMENTAL|Sugar with Amino Acids, Sugar Free, Water, and Multiplier|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62623819|NCT05886907|OTHER|LID223188, then Ultra MFT|Lehfilcon A multifocal toric contact lenses worn first, with samfilcon A multifocal toric contact lenses worn second. Each product will be worn bilaterally (in both eyes) during waking hours for approximately 2 days. CLEAR CARE will be used for daily contact lens cleaning and disinfection.
62820022|NCT04963920|NO_INTERVENTION|Standard of Care (SoC)|patients allocated to this group will receive only standard of care therapy according to applicable guidelines
62820023|NCT06235515|EXPERIMENTAL|group I|conventional treatment As conventional treatment, patients will receive 20 minutes of hotpack and 20 minutes of TENS, 5 sessions a week for a total of 15 sessions for 3 weeks. Additionally, patients will be given cervical isometric exercises as a home exercise program.
62820024|NCT06235515|EXPERIMENTAL|group II|"conventional treatment and virtual reality As conventional treatment, patients will receive 20 minutes of hotpack and 20 minutes of TENS, 5 sessions a week for a total of 15 sessions for 3 weeks. Additionally, patients will be given cervical isometric exercises as a home exercise program.~In addition to conventional treatment, virtual reality treatment will allow patients to play games in which they can perform neck movements in all directions for 30 minutes a day, 5 sessions a week for 3 weeks.."
62040151|NCT02306070|EXPERIMENTAL|Metformin + lifestyle modification|Metformin + lifestyle modification pre, during and post HCV antiviral therapy
62040152|NCT02306070|PLACEBO_COMPARATOR|No Metformin + Lifestyle modification|No metformin + lifestyle modification pre, during and post HCV antiviral therapy.
62040153|NCT00006213|EXPERIMENTAL|Treatment (BMS-214662)|Patients receive BMS-214662 IV over 1 hour weekly for 4 weeks. Treatment continues every 4 weeks for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression.
62040154|NCT05061238|OTHER|Vibrating Device|you will be asked to walk up and down a hallway 5 times with the vibrating device strapped to different parts of your leg.
62040155|NCT04492254|EXPERIMENTAL|Enoxaparin|(40 mg o/d if \< 100 kg, 40 mg b/d if ≥ 100 kg)
62040156|NCT04492254|NO_INTERVENTION|Current standard of care (no enoxaparin)|Standard of care
62040157|NCT00440531|ACTIVE_COMPARATOR|1|RECOMBIVAX HB™
62040158|NCT00440531|EXPERIMENTAL|2|Modified Process Hepatitis B Vaccine
62040159|NCT00440531|ACTIVE_COMPARATOR|3|ENGERIX-B™
62040160|NCT00514735|EXPERIMENTAL|1|Ablation Management
62040161|NCT00514735|ACTIVE_COMPARATOR|2|Medical Management
62040162|NCT05356260|ACTIVE_COMPARATOR|Care as usual|CAU will be that typically provided by GPs. Also patients will be informed about a page on thuisarts.nl regarding male LUTS. The pragmatic trial design means that care can vary depending on the preferences of patients and GPs in this group.
62243848|NCT06272435|EXPERIMENTAL|Sugar with Amino Acids, Sugar Free, Multiplier, and Water|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62434133|NCT04336267|EXPERIMENTAL|Transcranial direct current stimulation (tDCS) group|7-day detoxification protocol + 5 consecutive days of anodal tDCS treatment over the primary motor cortex.
62434134|NCT04336267|SHAM_COMPARATOR|Sham group|7-day detoxification protocol + 5 consecutive days of sham treatment over the primary motor cortex.
62434135|NCT01866683|EXPERIMENTAL|Group 1|1 month respiratory training
62434136|NCT01866683|EXPERIMENTAL|Group 2|1 month waiting period
62434137|NCT05934279|EXPERIMENTAL|Resistance Training|Training aimed at improving balance and strengthening muscle strength (RT) will be held twice a week, 45 min per session for 8 weeks
62434138|NCT05934279|NO_INTERVENTION|Control Group|Group without training program
62434139|NCT03180983|OTHER|INTERVENTIONAL GROUP|The intervention group will receive a blended-learning intervention.
62434140|NCT03180983|NO_INTERVENTION|CONTROL GROUP|No intervention
62820025|NCT04582903||Biological Relative|Biological relative of a participant being studied under this protocol. Relatives may be biological mother, father, siblings, children, grandparents, aunts, uncles, or first cousins
62434141|NCT03401645|EXPERIMENTAL|Treatment (Alarm Active)|"Participants will be wearing the wrist device with an alarm timer that sends out signals every 5 minutes. The alarm is a buzzing noise and a vibration. Participants must turn off the alarm then perform a series of visuomotor tasks. This will be done for one hour, twice a day for two weeks.~Intervention: Device - Wrist Alarm; Behavioral - Home-based Arm and Hand Exercise"
62600461|NCT04761081||South Asians with central obesity|"The south Asian group with central obesity will be of south Asian ethnicity and a waist circumference of 90cm or greater.~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.~Metabolic markers will be analysed and presented in a participant characteristics table."
62820026|NCT04582903||Confirmed or Suspected SARS-CoV-2 infection|Patient with a known or suspected diagnosis of SARS-CoV-2 infection (past or current), typically but not always supported by a positive PCR test for viral RNA
62040163|NCT05356260|EXPERIMENTAL|Online self-management intervention|"Participants in the intervention group will be given access to an online self-management program that will be personalized. This program was developed based on the results of a literature search, the opinions of expert Dutch GPs and urologists, and a pilot study in secondary care, with further preliminary testing in primary care. The program consists of nine components: information, pelvic floor exercises, bladder training, sitting voiding position, urethral milking, fluid management, caffeine avoidance, alcohol avoidance, and physical activity increase. Information is presented as text with supportive figures, plus audio (a read aloud function for all text) and video fragments to facilitate engagement by men with low literacy levels."
62820027|NCT04582903||Exposed but Uninfected|Individual who has remained uninfected with negative SARS-CoV-2 serologies despite heavy or extensive COVID-19 exposure in the workplace or home environment
62820028|NCT03101917|EXPERIMENTAL|Visual assessment of electrode insertion|This arm will include the first 6 participants. In this group, a cut will be made near the eardrum and it will be lifted up so the surgeon can see the electrode as it goes into the cochlea.
62040164|NCT03644186|ACTIVE_COMPARATOR|Paclitaxel plus trastuzumab and pertuzumab|Receiving paclitaxel 80mg/m2 i.v. on day 1, 8, 15 every 28 days for 4 cycles, trastuzumab 600mg s.c. every 3 weeks for a total of 5 doses and pertuzumab 840 mg i.v. loading dose followed by 420 mg i.v. every 3 weeks for a total of 5 doses.
62434142|NCT03401645|SHAM_COMPARATOR|Control (Sham Control)|"Participants will perform the same tasks as the Alarm/Treatment group, but without the alarm timer. This is a series of visuomotor tasks for one hour, twice per day for two weeks.~Intervention: Behavioral - Home-based Arm and Hand Exercise"
62434143|NCT01967888|EXPERIMENTAL|Reparixin|Solution for intravenous (IV) infusion with active compound
62820029|NCT03101917|EXPERIMENTAL|Camera assessment of electrode insertion|This arm will include the next 6 participants. In this group, a tube with a camera will be inserted past the ear drum, by making a small hole in the ear drum, to see the electrode as it goes into the cochlea.
62434144|NCT01967888|PLACEBO_COMPARATOR|Placebo|Physiologic solution
62434145|NCT00876733||HIV treatment|
62434146|NCT00802750|EXPERIMENTAL|A|
62434147|NCT00802750|EXPERIMENTAL|B|
62434148|NCT04339088||HIFU|Patients that have undergone high focused ultrasound treatment for varicose veins
62434149|NCT05664750|EXPERIMENTAL|TNM002|If randomized to TNM002, participant will receive a single IM gluteal injection of TNM002
62434150|NCT05664750|ACTIVE_COMPARATOR|Human tetanus immunoglobulin (HTIG)|If randomized to HTIG, participant will receive a single IM gluteal injection of HTIG
62434151|NCT00038129|EXPERIMENTAL|1|Participants will receive reaming of the intramedullary canal prior to insertion of an intramedullary nail.
62434152|NCT00038129|EXPERIMENTAL|2|Participants will receive insertion of an intramedullary nail without prior reaming of the intramedullary canal.
62820030|NCT06493760|EXPERIMENTAL|SSGJ-707(dose 1)+ XELOX|
62820031|NCT06493760|EXPERIMENTAL|SSGJ-707(dose 1)+ mFOLFOX6|
62820032|NCT06493760|EXPERIMENTAL|SSGJ-707(dose 2)+ XELOX|
62820033|NCT06493760|EXPERIMENTAL|SSGJ-707(dose 2)+ mFOLFOX6|
62820034|NCT06493760|EXPERIMENTAL|SSGJ-707+XELOX/mFOLFOX6|
62820035|NCT06493760|ACTIVE_COMPARATOR|Bevacizumab+XELOX/mFOLFOX6|
62243849|NCT06272435|EXPERIMENTAL|Sugar Free, Water, Multiplier, and Sugar with Amino Acids|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62820036|NCT06493760|EXPERIMENTAL|SSGJ-707 monotherapy|
62820037|NCT04873037|ACTIVE_COMPARATOR|Emsella Chair Active Treatment|Active subjects will be asked to sit on the center of the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will be decreased slightly and stay unchanged for the reminder of the treatment. The treatment threshold should be increased with every treatment until the subject reaches 100%.
62243850|NCT06272435|EXPERIMENTAL|Sugar Free, Water, Sugar with Amino Acids, and Multiplier|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62243851|NCT06272435|EXPERIMENTAL|Sugar Free, Multiplier, Water, and Sugar with Amino Acids|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62243852|NCT06272435|EXPERIMENTAL|Sugar Free, Multiplier, Sugar with Amino Acids, and Water|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62820038|NCT04873037|PLACEBO_COMPARATOR|Emsella Chair Sham Treatment|Sham treatment subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level (less than 10% power).
62243853|NCT06272435|EXPERIMENTAL|Sugar Free, Sugar with Amino Acids, Water, and Multiplier|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62243854|NCT06272435|EXPERIMENTAL|Sugar Free, Sugar with Amino Acids, Multiplier, and Water|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
62243855|NCT04175639|EXPERIMENTAL|Mobile Health Pain Coping Skills Training (mPCST)|Mobile Health Pain Coping Skills Training (mPCST) protocol for breast cancer survivors with persistent pain that will produce significant improvements in pain, pain disability, fatigue, physical disability, and adherence to post-treatment lifestyle recommendations that are impacted by pain (i.e., daily activity, self-monitoring of symptoms).
62243856|NCT04175639|NO_INTERVENTION|mHealth-Education (mHealth-Ed)|mHealth-Education (mHealth- Ed): Participating in mHealth will involve four 50-minute individual intervention sessions conducted over the course of 8 weeks with tele-video-conferencing at patient's community-based clinic with a nurse about cancer care.
62243857|NCT06088199|EXPERIMENTAL|Apremilast|Apremilast will be dosed by participant's body weight and administered twice daily (BID) in the form of oral tablets, approximately 12 hours apart, without restriction of food or drink.
62243858|NCT04661501|ACTIVE_COMPARATOR|AlloDerm group|Device for immediate implant based breast reconstruction.
62243859|NCT04661501|ACTIVE_COMPARATOR|AlloMax group|Device for immediate implant based breast reconstruction.
62243860|NCT04661501|ACTIVE_COMPARATOR|DermACELL group|Device for immediate implant based breast reconstruction.
62243861|NCT04661501|ACTIVE_COMPARATOR|Flex HD group|Device for immediate implant based breast reconstruction.
62820039|NCT06341166||Prospective Cohort|Prospectively enrolled patients will undergo a complete assessment, as clinically indicated, including clinical evaluation, TTE, rest ECG, 24h ECG-monitoring, and CMR. CMR will be performed no more than 6 months apart from other examinations (TTE, rest ECG, 24h ECG-monitoring).
62623820|NCT05886907|OTHER|Ultra MFT, then LID223188|Samfilcon A multifocal toric contact lenses worn first, with lehfilcon A multifocal toric contact lenses worn second. Each product will be worn bilaterally (in both eyes) during waking hours for approximately 2 days. CLEAR CARE will be used for daily contact lens cleaning and disinfection.
62040165|NCT03644186|EXPERIMENTAL|Palbociclib plus letrozole plus trastuzumab and pertuzumab|Receiving palbociclib 125 mg/day orally for 21 days followed by 7 day's rest, for four 28 day cycles, letrozole 2.5 mg/day orally for 16 weeks and trastuzumab 600 mg s.c. every 3 weeks for a total of 5 doses and pertuzumab 840 mg i.v. loading dose followed by 420 mg i.v. every 3 weeks for 5 doses.
62623821|NCT01121263||Angiogram Review Group|All consecutive and consenting patients undergoing diagnostic cardiac catheterization in a 3 month period
62820040|NCT06341166||Retrospective Cohort|Patients will be enrolled retrospectively, in case they have already performed all examinations between 2016 and 2023
62820041|NCT06594731|EXPERIMENTAL|Low back pain patients|Low back pain subjects performing hip belt squat training twice per week for 6 weeks.
62820042|NCT06594731|ACTIVE_COMPARATOR|Healthy individuals|Healthy individuals performing hip belt squat training twice per week for 6 weeks.
62820043|NCT04477759|EXPERIMENTAL|50 Gray (Gy) Radiation Therapy|50 Gy of ionizing radiation therapy will be administered in 15 fractions.
62040166|NCT06283472|EXPERIMENTAL|High-Intensity|Participants will receive high-intensity episodic future-thinking cue images, and high-intensity episodic recent-thinking cue images during an MRI decision-making task.
62040167|NCT06283472|ACTIVE_COMPARATOR|Low-Intensity (Control)|Participants will receive low-intensity episodic future-thinking cue images, and low-intensity episodic recent-thinking cue images during an MRI decision-making task.
62040168|NCT04886024||women with endometriosis|It consists of women between the ages of 18-45 who have been diagnosed with endometriosis by surgery or ultrasonography.
62434153|NCT01401478||Stage 5 Chronic Kidney Disease|Planned for Zemplar administration due to secondary hyperparathyroidism
62434154|NCT02464878|OTHER|Main study treatment|
62820044|NCT04477759|EXPERIMENTAL|55 Gray (Gy) Radiation Therapy|55 Gy of ionizing radiation therapy will be administered in 15 fractions.
62820045|NCT04477759|EXPERIMENTAL|60 Gray (Gy) Radiation Therapy|60 Gy of ionizing radiation therapy will be administered in 15 fractions.
62040169|NCT04886024||control|It consists of healthy women between the ages of 18-45
62040170|NCT02243605|EXPERIMENTAL|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62040171|NCT01140217|EXPERIMENTAL|Active treatment|Norethindrone Acetate Transdermal Delivery System
62040172|NCT06296550|EXPERIMENTAL|CGM Group|Participants will be provided continuous glucose monitors (Dexcom G7) to monitor blood glucose for the entire duration of this study (i.e., one new device every 10 days for a total of 18 devices to last up to 6 months).
62040173|NCT06296550|OTHER|Usual Care Blood Glucose Monitoring Group|Participants will use standard blood glucose monitoring devices that are covered by health insurance.
62040174|NCT06734000||Individuals with spinal cord injury|Collection of blood, urine and feces during the 5 years after the lesion.
62040175|NCT04504487|EXPERIMENTAL|Early drain removal - POD3|Drain removal on POD3 if drain bilirubin is less than 3mg/dl and serous in nature.
62040176|NCT04504487|PLACEBO_COMPARATOR|Routine Drain Removal|Drain removed routinely when the output is less than 100ml and serous in nature
62040177|NCT02598492||Imputation of SF to PF|Patients required invasive mechanical ventilation within 6 hours after intubation
62434155|NCT03057288|EXPERIMENTAL|fiducial markers placement|Prospective study with one arm evaluating the feasibility of fiducial markers placement under echoendoscopic guidance, for patients with esophageal or rectal cancer
62434156|NCT05238506|EXPERIMENTAL|Lidocaine|1% lidocaine intravenous bolus of 0.15 ml/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 0.15 ml/kg/h intraoperatively will be administered. The infusion will be discontinued before the patients' transfer to the postanesthesia care unit.
62434157|NCT05238506|PLACEBO_COMPARATOR|Control|0.9% NaCl intravenous bolus of 0.15 ml/kg over 5 min before induction of anesthesia followed by 0.9% NaCl infusion at 0.15 ml/kg/h intraoperatively will be administered. The infusion will be discontinued before the patients' transfer to the postanesthesia care unit.
62434158|NCT03703739|ACTIVE_COMPARATOR|Reference meal 1|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulfate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
62040178|NCT06113848|ACTIVE_COMPARATOR|Intra-Arterial TNK and Albumin|
62040179|NCT06113848|ACTIVE_COMPARATOR|Intra-Arterial TNK|
62040180|NCT06113848|ACTIVE_COMPARATOR|Intra-Arterial Albumin|
62040181|NCT06113848|SHAM_COMPARATOR|sham|
62040182|NCT06367166|EXPERIMENTAL|А- Varicose vein patients with Conservative treatment with a venoactive drug|"20 patients with varicose veins who will be treated conservatively - receive the drug Venarus® (diosmin in combination with hesperidin) at a dosage of 1000 mg once daily for 6 months along with elastic compression"
62600462|NCT04761081||White Europeans who are lean|"The white European group who are lean will be of white European ethnicity and a waist circumference \<94cm.~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.~Metabolic markers will be analysed and presented in a participant characteristics table."
62600463|NCT04761081||White Europeans with central obesity|"The white European group with central obesity will be of white European ethnicity and a waist circumference of 94cm or greater.~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.~Metabolic markers will be analysed and presented in a participant characteristics table."
62600464|NCT02618694|EXPERIMENTAL|Group 1|patient had posterior retroperitoneoscopic adrenalectomy
62600465|NCT02618694|ACTIVE_COMPARATOR|Group 2|patient had Transperitoneal laparoscopic adrenalectomy
62040183|NCT06367166|EXPERIMENTAL|B- Varicose veins patients without invasive treatment or a venoactive drug|20 patients with varicose veins C2s-C3s who are not prescribed conservative therapy with a venoactive drug and will not undergo invasive treatment; the patients will receive elastic compression
62040184|NCT06367166|EXPERIMENTAL|C- Varicose veins patients who will undergo EVLA and conservative treatment with a venoactive drug|20 patients with varicose veins who will undergo invasive treatment (endovenous laser ablation with miniphlebectomy), followed by Venarus at a dosage of 1000 mg once daily for 6 months; the patients will also receive elastic compression
62040185|NCT06367166|EXPERIMENTAL|D- Varicose veins patients who will undergo EVLA|20 patients with varicose veins patients who will undergo invasive treatment (EVLK with miniphlebectomy), after which no venoactive drugs will be prescribed; the patients will also receive elastic compression
62040186|NCT06367166|EXPERIMENTAL|E-healthy volunteers|20 healthy volunteers without clinical and ultrasound signs of varicose veins receiving no treatment
62040187|NCT06205342|EXPERIMENTAL|Experimental Cohort|MSC
62040188|NCT06205342|PLACEBO_COMPARATOR|Validation Cohort|Placebo
62243862|NCT00162890||Patient with degenerative cervical disease|
62243863|NCT02296151|PLACEBO_COMPARATOR|Group A|Four iliotibial band stretches; to be completed 3 days per week.
62243864|NCT02296151|ACTIVE_COMPARATOR|Group B|Four conventional hip exercises (Hip abductor, gluteus medius strengthening); to be completed 3 days per week.
62600466|NCT04055376|EXPERIMENTAL|Daily exposure to active stimulation|Subjects in this arm will receive daily exposure to active stimulation
62820046|NCT05075265||Methadone Group|adult patients undergoing cardiac surgery with extracorporeal circulation
62820047|NCT05380427|EXPERIMENTAL|Single Dose 1|0.0025%(0.025 mg/mL)
62820048|NCT05380427|EXPERIMENTAL|Single Dose 2|0.005%（于0.05 mg/mL）
62820049|NCT05380427|EXPERIMENTAL|Single Dose 3|0.01%（0.1 mg/mL）
62820050|NCT05380427|EXPERIMENTAL|Single Dose 4|0.02%（0.2 mg/mL）
62820051|NCT05380427|EXPERIMENTAL|Multiple Dose 1|0.05%（0.05 mg/mL）
62820052|NCT05380427|EXPERIMENTAL|Multiple Dose 2|0.01%（0.01 mg/mL）
62820053|NCT05380427|EXPERIMENTAL|Multiple Dose 3|0.02%（0.02 mg/mL）
62820054|NCT05380427|PLACEBO_COMPARATOR|Placebo|Liniment containing anhydrous ethanol, propylene glycol and polyethylene glycol 400
62820055|NCT04636814|EXPERIMENTAL|CHF6001 1600µg|
62600467|NCT04055376|SHAM_COMPARATOR|Daily exposure to control stimulation|Subjects in this arm will receive daily exposure to control stimulation
62820056|NCT04636814|EXPERIMENTAL|CHF6001 3200µg|
62820057|NCT04636814|PLACEBO_COMPARATOR|Placebo|
62820058|NCT04636814|ACTIVE_COMPARATOR|Roflumilast|
62820059|NCT06527066|PLACEBO_COMPARATOR|Placebo Group (G1)|The Placebo Group (G1) will be composed of those whose intervention will only be with the carrier base, the All.me Beauty® Gel Sérum Biocompatível, which constitutes a way of diluting the EO and does not interfere with its action and therapeutic process, acting as a placebo.
62820060|NCT06527066|EXPERIMENTAL|Intervention Group (G2)|In the Intervention Group (G2) there will be participants who will receive intervention with geranium EO (Pelargonium graveolens), diluted in All.me Beauty® Gel Sérum Biocompatível, respecting a concentration of 1%, determined based on a work where tolerability was shown in the application of this 1% EO, on oral mucosa, for the treatment of denture stomatitis; For the present study, the sensitivities of the facial skin and smell were taken into account.
62820061|NCT04077801||Study group (group A)|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure Postpartum pain Intervention 'Visual analogue scale'"
62849135|NCT04099264|ACTIVE_COMPARATOR|Control: Audio Books|Control will consist of audio books.
62040189|NCT02444065|EXPERIMENTAL|Cognitive Behavior Therapy (CBT)|In this arm, participants receive the Cognitive behavior therapy (CBT) intervention as an augmentative treatment to standard day hospital treatment as usual.
62040190|NCT02444065|ACTIVE_COMPARATOR|Motivational Interviewing (MI)|In this arm, participants receive the Motivational Interviewing intervention as an augmentative treatment to standard day hospital treatment as usual.
62243865|NCT02296151|EXPERIMENTAL|Group C|Four conventional hip exercises progressed during the 8-weeks, totalling 16 exercises over the 8-week period (Hip abductor, gluteus medius strengthening). Exercises to be completed 3 days per week.
62243866|NCT06716333|EXPERIMENTAL|Intensive Training Group|
62243867|NCT03801902|EXPERIMENTAL|Arm I (CLOSED) (Durvalumab and ACRT)|Starting 2 weeks prior to radiation therapy, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 4 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ACRT 1 fraction per day, 5 days per week for 15 fractions. Patients also undergo brain MRI or CT scan during screening and as clinically indicated, chest CT scans on study and during follow up, and collection of blood samples during screening and on study.
62434159|NCT03703739|ACTIVE_COMPARATOR|Reference 2|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulfate was added Prior to give to participants. Rice meal consumed with bean sauce.
62434160|NCT03703739|EXPERIMENTAL|Test meal A|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice cofortified with zinc oxide and ethylenediaminetetraacetic acid (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
62600468|NCT03200847|EXPERIMENTAL|Pembrolizumab with All-Trans Retinoic Acid|Patients will receive pembrolizumab infusions every three weeks. Patients will also receive 3 days of all-trans retinoic acid treatment surrounding each of the first 4 infusions of pembrolizumab, beginning one day prior to the infusion (a total of 12 days of all-trans retinoic acid).
62600469|NCT05213793||ischemic stroke|The cohort includes patients with acute stroke who underwent CTP, multi-delay ASL, DWI, CTA or TOF-MRA scanning.All patients will be examined within 24 hours of onset. CBF, CBV, MTT and Tmax cerebral blood flow parameter images of CTP will be obtained. CBF, CBV and ATT cerebral blood flow parameter images in multi-delay ASL will be obtained by the quantitative evaluation system. The volume of reversible ischemic tissue will be calculate according to CTP and multi-delay ASL respectively.
62040191|NCT01991626|OTHER|LNS|Maize meal mixed with Lipid Nutrient Supplement (LNS) containing micronutrient powder
62040192|NCT01991626|OTHER|FePP-Emulsion mixed|Fat emulsion mixed to the meal containing FePP
62040193|NCT01991626|OTHER|FeSO4-Mixed|meals containing FeSO4 mixed with a fat emulsion
62040194|NCT01991626|OTHER|FePP-Emulsion before|Fat emulsion taken before a meal containing FePP
62040195|NCT01991626|OTHER|FeSO4- Emulsion before|Fat emulsion taken before a maize meal containing FeSO4
62600470|NCT02409381|EXPERIMENTAL|Motore|Curcuma longa complexed with phosphatidylcholine - 250 mg (Motore®), two (02) capsules orally every twelve (12) hours
62600471|NCT02409381|ACTIVE_COMPARATOR|Alivium|Ibuprofen 600 mg (Alivium®), one (01) coated tablet orally, every six (06) hours.
62820062|NCT04077801||Control group (group B):|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure Postpartum pain Intervention 'Visual analogue scale'"
62820063|NCT03735875|EXPERIMENTAL|Phase I: Treatment (venetoclax, quizartinib)|Dose finding: Patients receive quizartinib PO QD on days 1-28 and venetoclax PO QD beginning on day 8 of cycle 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment beyond 24 cycles at the discretion of the treating physician.
62820064|NCT03735875|EXPERIMENTAL|Phase II: Treatment (venetoclax, quizartinib)|"Patients will be treated at the established dose from the phase I portion of the study.~Patients receive quizartinib PO QD on days 1-28 and venetoclax PO QD beginning on day 8 of cycle 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment beyond 24 cycles at the discretion of the treating physician."
62820065|NCT05241873|EXPERIMENTAL|Phase I - Part 1A Dose Escalation|BLU-451 monotherapy with dose escalation in participants with metastatic cancer with EGFR Ex20ins or other selected EGFR mutations that have progressed after prior systemic therapies.
62820066|NCT05241873|EXPERIMENTAL|Phase I - Part 1B Dose Escalation (US only)|BLU-451 with dose escalation in combination with carboplatin and pemetrexed in participants with metastatic NSCLC with common EGFR mutations. This arm will enroll participants only in the United States.
62820067|NCT05241873|EXPERIMENTAL|Phase I - Part 2 BLU-451 Monotherapy Enrichment|BLU-451 enrichment at select doses.
62820068|NCT05241873|EXPERIMENTAL|Phase II - Cohort 2A|EGFR Ex20ins participants who have previously received platinum-based chemotherapy and either amivantamab or mobocertinib will receive BLU-451.
62820069|NCT05241873|EXPERIMENTAL|Phase II - Cohort 2B|EGFR Ex20ins participants who have previously received platinum-based chemotherapy but have not received a prior EGFR Ex20ins-targeted agent will receive BLU-451.
62040196|NCT01991626|OTHER|LNS-Phytase|Maize meal mixed with LNS containing micronutrient powder and phytase
62434161|NCT03703739|EXPERIMENTAL|Test meal B|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate and ethylenediaminetetraacetic acid (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
62600472|NCT01730651|EXPERIMENTAL|Tomotherapy|"1. Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)~2. Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)"
62600473|NCT03935542||MPI arm|For the MPI arm, patients with severe jailed diagonal branch disease with available MPI in 3 months were selected from the Seoul National University Hospital Cardiac Catheterization and MPI database.
62600474|NCT03935542||CCTA arm|For the CCTA arm, patients from a previous multicenter prospective CCTA registry were retrospectively reviewed for a post-hoc analysis.
62600475|NCT03051698|EXPERIMENTAL|C1-inhibitor|One gift of intravenous administration of C1-inhibitor (Cinryze, 100U/kg) during one hour
62040197|NCT01991626|OTHER|phytase|Maize meal containing micronutrient powder and phytase
62040198|NCT01991626|OTHER|MNP-control|maize meal containing micronutrient powder (MNP)
62040199|NCT01991626|OTHER|FePP control|Maize meal containing FePP
62040200|NCT01991626|OTHER|FeSO4 control|Maize meal containing FeSO4
62040201|NCT05684796|ACTIVE_COMPARATOR|Anticoagulation (AC)|Subjects will have their pulmonary embolism treated with anticoagulants alone. There will be no procedure for this group.
62040202|NCT05684796|ACTIVE_COMPARATOR|Indigo|Subjects will have their pulmonary embolism treated with anticoagulants and mechanical aspiration thrombectomy with the Indigo® Aspiration System.
62040203|NCT04737460|EXPERIMENTAL|AAV9/CLN7|"AAV9/CLN7 is an intrathecally administered AAV9-based gene therapy vector that expresses the fully functional form of MFSD8 under the control of a synthetic promoter. AAV9/CLN7 is designed to achieve stable, potentially life-long expression of MFSD8 in non-dividing cells.~The first participant will receive a low dose of 5X1014 vg, subsequent participants will receive a higher dose of 1x1015 vg of the AAV9/CLN7 agent."
62434162|NCT03703739|EXPERIMENTAL|Test meal C|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate, citric acid and trisodium citrate (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
62434163|NCT03703739|EXPERIMENTAL|Test meal D|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfafe and sodium pyrophosphate (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
62600476|NCT03051698|PLACEBO_COMPARATOR|Saline|One gift of intravenous administration of 0.9% NaCl during one hour.
62600477|NCT03051698|EXPERIMENTAL|Antibiotics|broad spectrum antibiotics (vancomycin, ciprofloxacin, metronidazole) for 7 days (washout 36 hours before study day).
62600478|NCT06619288||HIV early presenters (TDF+3TC+EFV)|100 HIV-infected early presenters diagnosed between Jan 2020 and Jun 2023.
62600479|NCT06619288||HIV late presenters (TDF+3TC+EFV)|100 HIV-infected late presenters diagnosed between Jan 2020 and Jun 2023.
62600480|NCT06619288||HIV early presenters(DTG/3TC)|100 HIV-infected early presenters diagnosed between Jan 2020 and Jun 2023.
62600481|NCT06619288||HIV late presenters (DTG/3TC)|100 HIV-infected late presenters diagnosed between Jan 2020 and Jun 2023.
62600482|NCT06619288||HIV early presenters (B/F/TAF)|115 HIV-infected early presenters diagnosed between Jul 2024 and Jun 2025.
62820070|NCT05241873|EXPERIMENTAL|Phase II - Cohort 2C|EGFR Ex20ins participants with at least one measurable lesion in brain per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 who have previously received platinum-based chemotherapy will receive BLU-451. Previous treatment with EGFR Ex20Ins-targeted therapies is allowed but not required.
62820071|NCT05241873|EXPERIMENTAL|Phase II - Cohort 2D|Participants with EGFR Ex20ins who have previously received platinum-based chemotherapy and both amivantamab AND mobocertinib, OR received any investigational Ex20Ins targeted agent(s) will receive BLU-451. Participants with Ex20ins or atypical mutations enrolled in other cohorts and who have other oncogenic drivers by central testing at baseline will be moved to this arm.
62820072|NCT05241873|EXPERIMENTAL|Phase II - Cohort 2E|Participants with EGFR Ex20ins who have not received prior systemic therapy in metastatic setting will receive BLU-451.
62820073|NCT05241873|EXPERIMENTAL|Phase II - Cohort 2F|Participants with EGFR atypical mutations (e.g., G719X, L861Q) who have previously received at least one EGFR tyrosine kinase inhibitor (TKI) will receive BLU-451. Participants with with other atypical EGFR mutations, such as S768I, may be enrolled if approved by Sponsor Medical Monitor.
62820074|NCT05241873|EXPERIMENTAL|Phase II - Cohort 2G|Participants with EGFR atypical mutations (e.g., G719X, L861Q) who have not received prior systemic therapy in metastatic setting will receive BLU-451. Participants with with other atypical EGFR mutations, such as S768I, may be enrolled if approved by Sponsor Medical Monitor.
62820075|NCT06599333||Patients|Patients coming to community pharmacies and taking at least the same medication for 6 months
62820076|NCT06050265|EXPERIMENTAL|Intervention arm - CGM|Participants randomized to intervention arm will be given standard of care nutrition and exercise counseling to optimize weight, nutrition and glycemic status AND will be asked to wear a DEXCOM CGM for 90 days.
62820077|NCT06050265|NO_INTERVENTION|Control arm|Participants randomized to control arm will ONLY be given standard of care nutrition and exercise counseling to optimize weight, nutrition and glycemic status.
62820078|NCT05665738|EXPERIMENTAL|HDR brachytherapy|Participants will receive the same radiotherapy technique, methods, and delivery will as standard of care 3 hours apart instead of receiving the radiotherapy on separate days.
62820079|NCT04125836|EXPERIMENTAL|CAM2029 (octreotide subcutaneous depot)|CAM2029 (octreotide subcutaneous depot) 20mg/1.0 mL for 20 mg dose, subcutaneous injection once monthly, 12 months treatment with an option of extension. If down-titration is required, 10mg/0.5 mL for 10 mg dose is available.
62820080|NCT06258369|OTHER|Patients with primary coxarthrosis (any stage).|
62820081|NCT06258369|EXPERIMENTAL|Patients with primary coxarthrosis (any stage) and operated with Total Hip prosthesis (THP).|
62820082|NCT06258369|EXPERIMENTAL|Patients with primary coxarthrosis (any stage) and operated with RTH (Hip resurfacing).|
62820083|NCT06704490||Cesarean section surgery|Observational research
62434164|NCT03703739|EXPERIMENTAL|Test meal E|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate, citric acid and trisodium citrate (mixing ratio 100:1), Rice meal consumed with bean Sauce.
62600483|NCT06619288||HIV late presenters (B/F/TAF)|115 HIV-infected late presenters diagnosed between Jul 2024 and Jun 2025.
62820084|NCT05849454|EXPERIMENTAL|Messy Memories Intervention|All participants enrolled in the study will be assigned to the experimental arm and participate in the Messy Memories intervention.
62820085|NCT06366217|EXPERIMENTAL|MydCombi|Patients will be dilated using MydCombi drug: (tropicamide 1% and phenylephrine HCl 2.5%) ophthalmic spray in one eye for a few seconds once
62820086|NCT06366217|NO_INTERVENTION|Standard of Care|Participants will receive the standard of care dilation: tropicamide 1% and phenylephrine 2.5%
62434165|NCT01783769|NO_INTERVENTION|Normal O.R. Traffic|"This Normal O.R. Traffic protocol follows the national standards of care."
62434166|NCT01783769|ACTIVE_COMPARATOR|"Low O.R. Traffic"|"This protocol will restrict personnel movement thru the operating room to a bare minimum of personnel traffic."
62820087|NCT00562224|EXPERIMENTAL|Arm 1|All study subjects will receive PCI-24781 (study drug).
62820088|NCT06596551|EXPERIMENTAL|Pre-Post ARCH Intervention|Participants will receive the ARCH intervention, a 4-weekly, 6-hour, strength-based dyadic programme that integrates psychoeducation, psychosocial support, and self-compassion practices to encourage and inspire families recovering from a first-time stroke. Specific intervention components include family education, facilitated dyadic communication and mindful self-compassion practices. Weekly therapeutic objectives build upon each other to provide affected families with the necessary means to process the trauma of experiencing a stroke and learning to live amidst multiple post-stroke losses.
62820089|NCT04564898|EXPERIMENTAL|trifluridine/tipiracil plus capecitabine and bevacizumab|
62820090|NCT01514799|ACTIVE_COMPARATOR|standard length bp limb, long alimentary limb|our normal way of doing a gastric bypass 60 cm BP limb
62820091|NCT01514799|EXPERIMENTAL|Long BP limb|200 cm BP limb
62820092|NCT06590922|EXPERIMENTAL|Using a new oropharyngeal airway set|Prior to induction of anesthesia and until the end of the gastroenteroscopy, oxygen was continuously supplied through a catheter partially attached to the endoscopic bite.
62820093|NCT06590922|ACTIVE_COMPARATOR|The conventional endoscopic bite group|Oxygen was administered continuously through a common nasal catheter until the end of the gastroenteroscopy prior to induction of anesthesia
62820094|NCT06587152|EXPERIMENTAL|Robot-assisted surgery|Robot-assisted thoraco-laparoscopic esophagectomy
62434167|NCT06381726|ACTIVE_COMPARATOR|Spontaneous motor reorganization: observation|Only neurological and neuropsychological assessment as per normal clinical routine and conventional and advanced functional, resting-state MRI acquisitions
62820095|NCT06592547|ACTIVE_COMPARATOR|Metoprolol group|The group that received intravenous metoprolol
62820096|NCT06592547|PLACEBO_COMPARATOR|Control group|The group that received standard care
62434168|NCT06381726|EXPERIMENTAL|Enhanced motor reorganization: upfront Motor Rehabilitation|Patients submitted to motor rehabilitation program aimed at learning unimanual and bimanual coordinated sequences, along with personalized exercise according to tumor location (frontal vs parietal). For 6 months each patient will perform the motor training program in outpatient training session, checked by a physiotherapist for corrected execution at home 3 times/week, and is assessed for the correct training execution and progresses in training sessions each month, by physical therapists at the Rehabilitation Unit and on a weekly schedule by on-line distant monitoring (telemedicine).
62820097|NCT04232566||Weight loss surgery|Gastric bypass surgery will be followed by weight loss as standard of care. Liver fibrosis by elastography will be determined before surgery.
62434169|NCT06381726|EXPERIMENTAL|Enhanced motor reorganization: upfront Chemotherapy|Temozolomide-based regimen of 6 months duration is applied. Treatment will be discontinued in case of toxicity (G2-G4).
62820098|NCT06292169|EXPERIMENTAL|RSA with pectoralis minor release|
62820099|NCT06292169|ACTIVE_COMPARATOR|RSA without pectoralis minor release|
62820100|NCT06487988|ACTIVE_COMPARATOR|The direct conventional laryngoscopy group|The direct conventional laryngoscopy group will be performed with N3 (for females) or N4 (for males) Macintosh laryngoscope blade.
62820101|NCT06487988|EXPERIMENTAL|The fiberoptic guided intubation group|The fiberoptic guided intubation will be performed.
62820102|NCT04993651|EXPERIMENTAL|Continuous Positive Airway Pressure|Those randomized to CPAP will be fitted with CPAP face mask or nasal device by the respiratory therapist and permitted to trial the machine to ensure proper use and fit. CPAP settings: CPAP AUTO 5-20 cm H20 will be utilized. The CPAP device will then be removed. The subject will then be placed in the supine position with a standard roll placed under the right maternal hip. Those randomized to CPAP will have the device applied and machine turned on. For those randomized to routine airway management, nasal cannula with oxygen 2L/min will be applied and this will be titrated to achieve a maternal SpO2 \> 95%. End tidal CO2 monitors will be applied to both patient groups.
62820103|NCT04993651|NO_INTERVENTION|Nasal Cannula|For those randomized to routine airway management, nasal cannula with oxygen 2L/min will be applied and this will be titrated to achieve a maternal SpO2 \> 95%. End tidal CO2 monitors will be applied to both patient groups.
62820104|NCT06333314|EXPERIMENTAL|Dostarlimab|Patient will receive dostarlimab intravenously 500 mg every 3 weeks for 4 cycles followed by 1000 mg every 6 weeks for all cycles thereafter until disease progression, unacceptable toxicity, death, investigator's decision, patient's decision or for a maximum of 24 months.
62820105|NCT06333314|ACTIVE_COMPARATOR|Standard of care|Patients will receive the standard of care chemotherapy
62820106|NCT06593483|NO_INTERVENTION|Assessment Only|
62820107|NCT06593483|ACTIVE_COMPARATOR|Motivational Interview Only|
62820108|NCT06593483|EXPERIMENTAL|Motivational Interview Plus Video|
62820109|NCT03879512|EXPERIMENTAL|Active vaccination arm|All patients receive depletion of regulatory T cells, reoperation, followed by a personalized cancer vaccine and double checkpoint blockade.
62820110|NCT06587438|EXPERIMENTAL|Real-time Continuous glucose monitor|In the first two weeks of every four-week period, rt-CGM is used to monitor blood glucose levels, while in the latter two weeks, SBMG is employed for usual care
62820111|NCT06587438|ACTIVE_COMPARATOR|Self-monitoring of blood glucose|Using SMBG for usual care only.
62820112|NCT05520203||Patient - cohort 1|Patients (and their parents) recruited before introduction of the NP
62820113|NCT05520203||Patient - cohort 2|Patients (and their parents) recruited after introduction of the NP
62820114|NCT05520203||Healthcare providers|Healthcare providers involved in the process of development, implementation and evaluation as well as all healthcare providers who come into close contact with the Nurse Practitioner
62820115|NCT06594718||Endoscopic treatment with (Z-POEM)|Patients undergoing a peroral endoscopic myotomy using a tunneling method to access the target zone.
62820116|NCT06594718||Endoscopic treatment using a non-tunnelization technique|Patients undergoing a peroral endoscopic myotomy using a no-tunneling method (Diverticuloscope, Knife Septotomy, and Clutch Cutter) to access the target zone.
62820117|NCT04008368|OTHER|1|patients with HLA-matched sibling donors
62820118|NCT04008368|OTHER|2|patients with haploidentical donors
62820119|NCT05518500|EXPERIMENTAL|Healthy Older Adults|Will receive FDA-approved influenza vaccine (Fluzone HD Year 1, FLUAD Year 2, Flublok Quadrivalent Year 3)
62820120|NCT03955198|EXPERIMENTAL|Patients with NSCLC metachronous oligometastatic disease|
62820121|NCT00688116|EXPERIMENTAL|ganetespib|
62820122|NCT04494841|EXPERIMENTAL|DuoTherm VibraCool Back Device|Patients will be offered a pain relief belt device incorporating multiple speeds of vibration and optional heat, cold, and pressure delivered through a sculpted metal plate. They will be able to choose from 8 patterns of vibration with the multiple motors (50, 100, 200Hz), and hot or cold, and will wear the device for 20 minutes.
62820123|NCT06590753|ACTIVE_COMPARATOR|conventional|One will be placed using the conventional drill method site preparation technique on one side of the mandible
62820124|NCT06590753|EXPERIMENTAL|osseodensification|One will be placed using osseodensification (no cutting) implant site preparation technique on the other side.
62820125|NCT05146388|NO_INTERVENTION|Pre-Implementation - Usual Care|In pre-implementation phase, patient e-Rxs will be generated by the EHR in the usual fashion.
62820126|NCT05146388|EXPERIMENTAL|Post-Implementation - EHR-Based Approach|
62820127|NCT06247813|EXPERIMENTAL|Nerve Health|
62040204|NCT06732895|EXPERIMENTAL|Navepegritide|Once weekly double-blinded treatment with SC injection of 100 µg/kg of navepegritide for 52 weeks
62040205|NCT06732895|PLACEBO_COMPARATOR|Placebo for Navepegritide|Once weekly double-blinded treatment with SC injection of 100 µg/kg of placebo for navepegritide for 52 weeks
62623822|NCT01121263||Therapeutic Intervention Group|"* Cohort 2 Therapeutic Intervention Group - HCR Patients (including those from the angiogram review group) who undergo Hybrid coronary revascularization (HCR) with minimally invasive LIMA-LAD CABG, OR~* Cohort 2 Therapeutic Intervention Group - PCI Patients (including those from the angiogram review group) who meet the proposed anatomic and clinical eligibility criteria and undergo multivessel Percutaneous Coronary Intervention with Drug Eluting Stents"
62820128|NCT06247813|EXPERIMENTAL|Oxidative Stress|
62040206|NCT02373800||The study population|"The study population is composed of pregnant women with a medical indication for the induction of pre-term (37-42 weeks of gestation) labor and who are consulting in the participating center.~Intervention: Cervical ultrasound with elastography"
62040207|NCT04710810|EXPERIMENTAL|Experimental|Patients receive group and rhesus compatible UCB cells through intravenous bolus injections (4 injections at 2-week intervals) after pre-medication with Clemastine (0.025 mg/kg body weight, intravenously). One dose is 250±10 x 10⁶ viable cells per sample.
62040208|NCT04710810|NO_INTERVENTION|Control|Patients receives standard therapy (applied behavioral analysis, speech therapy).
62040209|NCT00952367||Per-protocol population|In all, 3641 participants were enrolled; however, 38 were excluded because of violation of inclusion/exclusion criteria and 3 participants were excluded for unavailability of nasopharyngeal swab sample. The record presents demographic and result data for 3600 participants in the per-protocol population. These participants completed collection of the nasopharyngeal swab sample, the Epidemiology questionnaire, and 24 hours safety observation.
62040210|NCT03983512|EXPERIMENTAL|PULSTA TPV|PULSTA Transcatheter Pulmonary Valve (TPV) System
62820129|NCT06247813|EXPERIMENTAL|Inflammation|
62820130|NCT05976087|EXPERIMENTAL|Experimental group|
62820131|NCT04340895|EXPERIMENTAL|Intervention arm|"Treatment optimization (escalation/de-escalation) performed by the investigator based on participant self-monitoring of FC values and/or clinical symptoms (patient-reported outcome-2 \[PRO-2\] scoring).~The FC Test and/or PRO-2 scoring will be done by the participant at home every month during active disease, every 3 months in remission, or when a participant feels the need/presents clinical symptoms."
62820132|NCT04340895|ACTIVE_COMPARATOR|Reference arm|"Treatment optimization (escalation/de-escalation) performed by the investigator based on clinical symptoms (PRO-2 scoring) only.~The PRO-2 scoring will be assessed during clinic visits every 3-months during active disease, every 6 months during remission, or when a participant feels the need; as per recommended standard practice."
62820133|NCT04659044|EXPERIMENTAL|Treatment (rituximab, polatuzumab vedotin, venetoclax)|"INDUCTION: Patients receive rituximab IV on day 1 of cycle 1 and rituximab and hyaluronidase human SC over 5 minutes on day 1 of cycles 2-6. Patients also receive polatuzumab vedotin IV over 30-90 minutes on day 1 and venetoclax PO daily on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive venetoclax PO daily on days 1-21 and rituximab and hyaluronidase human SC over 5 minutes every 60 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
62820134|NCT02444338|ACTIVE_COMPARATOR|Control Group|optimal standard of care therapy
62820135|NCT02444338|EXPERIMENTAL|Device Group|MitraClip device plus optimal standard of care therapy
62820136|NCT05865990|EXPERIMENTAL|Patritumab deruxtecan (HER3-DXd)|"HER3-DXd will be dosed at 5.6 mg/kg body weight as an intravenous (IV) infusion administered on day 1 (D1) of each 21-day cycle for patients from all cohorts until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.~* Cohort 1: MBC with untreated or progressing BM after local treatment.~* Cohort 2: aNSCLC with untreated or progressing BM after local treatment.~* Cohort 3: advanced solid tumor with treatment-naive LMD or LMD progressing after radiotherapy."
62820137|NCT06222099|ACTIVE_COMPARATOR|Standard Care (Control)|Device installed at home, capturing data without sending health alerts or measurement data to RPMC.
62820138|NCT06222099|EXPERIMENTAL|Direct-to-patient health alerts|Device provides direct health alerts to patients/family, but does not transmit measurement data to RPMC.
62820139|NCT06222099|EXPERIMENTAL|RPMC Care Only|Device transmits measurement data to RPMC without direct patient alerts.
62820140|NCT06222099|EXPERIMENTAL|RPMC + Direct-to-Patient Health Alerts|Device sends measurement data to RPMC and provides direct alerts to patients/family.
62820141|NCT06409806|EXPERIMENTAL|Intervention arm|
62820142|NCT05255679|EXPERIMENTAL|Early FES|Receives standard care plus FES cycling in Phase 1 (starting 14 to 21 days after injury and for 3 months) and Phase 2 (from month 3 to month 6 after enrollment).
62820143|NCT05255679|EXPERIMENTAL|Delayed FES|Receives standard care only in Phase 1 (considered Control group in Phase 1), and standard care plus FES cycling in Phase 2 (from month 3 to month 6 after enrollment).
62820144|NCT05255679|NO_INTERVENTION|Control|Receives standard care only
62820145|NCT05188443||COVID-19|Patients tested for COVID-19 with current or previous (last 3 years) radiological imaging
62040211|NCT02319811||Cryopreserved meniscus transplant|Intervention: Lateral or medial cryopreserved meniscus transplant implanted into appropriately indicated patients.
62040212|NCT02496624|OTHER|Lung cancer|
62600484|NCT05336292|ACTIVE_COMPARATOR|Meaningful life intervention|We will work with psychological skills, meaningful life model, mindfulness skills ,personal values, the Wellbeing Model (Ryff, 1989) . The strengths of character (Park et al., 2004) and sources meaningful life. We will identify ways to use strengths and enhance meaningful life and develop an action plan to improve strengths. ). To identify the Meaning at the work. Link our strengths and values to our goals and purposes. Apply the SMART Method to achieve meaningful goals. Visualizing Our Best Future Self (Burton \& King, 2004).
62600485|NCT05336292|ACTIVE_COMPARATOR|Meaningful life and emotional regulation|Program Based on meaningful life and Emotional Regulation (MLI+ER) Session 1 Emotional regulation as a path towards the meaningful life Mindfulness training (emotional mindfulness) Generate knowledge of emotions and their functioning Session 2 Emotional Psychoeducation Emotional care To Know the well-being model Carol Ryff and Vital Sense To Understand the process of emotional regulation Session 3 Strengths and Personal Values Cultivate introspection and self-knowledge (Mindfulness, Carlson, 2013; Klussman, 2020) To Know the strengths of character (Park et al., 2004) and sources of vital meaning Identify ways to use strengths and enhance the sense of life Making Core Values Real (My 80th Birthday Speech; Harris, 2009) Note: Sessions 4, 5 and 6 are the same as the intervention based on meaningful life
62040213|NCT03230708|EXPERIMENTAL|Erythrocytes derived MPs containing MTX|Suspension of erythrocytes derived MPs containing MTX, qd×6, 6 units MPs a time , Two courses.
62040214|NCT03230708|ACTIVE_COMPARATOR|convention drugs|Chemotherapeutic drugs, biologicals or traditional Chinese medicine.Dosage form, dosage, frequency and duration according to respective medicine instructions.
62600486|NCT05336292|ACTIVE_COMPARATOR|Control group|The waiting list will be the control group. Participants will not be part of the program. They will participate in a day of positive psychology
62820146|NCT05590377|EXPERIMENTAL|Phase 1 Dose Escalation|Modakafusp alfa 60 to 240 mg, infusion, intravenously, once every 4 weeks (Q4W) with daratumumab 1800 mg, subcutaneously (SC), once weekly (QW) in Cycles 1 and 2, twice weekly (Q2W) in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression.
62820147|NCT05590377|EXPERIMENTAL|Phase 2a Dose Finding: Modakafusp Alfa (DL1) + Daratumumab|Modakafusp alfa at dose level 1 (DL1) \[selected from Phase 1 Dose Escalation\] with daratumumab SC 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression.
62820148|NCT05590377|EXPERIMENTAL|Phase 2a Dose Finding: Modakafusp Alfa (DL2) + Daratumumab|Modakafusp alfa at dose level 2 (DL2) \[selected from Phase 1 Dose Escalation\] with daratumumab SC 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression.
62040215|NCT04828954|ACTIVE_COMPARATOR|2 weeks of immobilization|Subjects randomized to this arm will be rigidly immobilized in a plaster postoperative thumb spica splint for 2 weeks following their thumb CMC arthroplasty
62820149|NCT05100121|EXPERIMENTAL|Intervention|The intervention consists of standard care and an app for routine symptom reporting, weekly the first month and thereafter as mutually agreed, at minimum once a month in one year, with instant self-managment advice in combination with supportive care with a study-specific nurse. At health dialogues with the nurse, the patient-reported assessments in the app will be used to discuss the individual's current situation and to plan eventual additional actions needed. The intervention will last for 6 months.
62820150|NCT05100121|NO_INTERVENTION|Control|The participants in the control group will only receive standard care. Usually after ended curative treatment the follow-up is a blood sample (PSA) every three or six months the first year, this can be handled either by a nurse or a physician in secondary care. Most hospitals also have one physical meeting with a physician three months after ended treatment (Regional Cancer Centers, 2020). All patients are allocated a contact nurse with a telephone number to contact when needed.
62040216|NCT04828954|ACTIVE_COMPARATOR|6 weeks of immobilization|Subjects randomized to this arm will be rigidly immobilized in a plaster postoperative thumb spica splint, transitioned to cast, for a total of 6 weeks following their thumb CMC arthroplasty
62820151|NCT05621070|EXPERIMENTAL|JS002 150mg Q2W|JS002 150mg Q2W SC for 52 weeks
62820152|NCT05621070|PLACEBO_COMPARATOR|JS002 450mg Q4W|JS002 450mg Q4W SC for 52 weeks
62820153|NCT05621070|PLACEBO_COMPARATOR|Placebo Q2W|Placebo Q2W SC for 12 weeks, then switch to JS002 150mg Q2W SC for 40 weeks
62820154|NCT05621070|PLACEBO_COMPARATOR|Placebo Q4W|Placebo Q4W SC for 12 weeks, then switch to JS002 450mg Q4W SC for 40 weeks
62820155|NCT03300128|EXPERIMENTAL|Incredible Years - ASD|The intervention, The Incredible Years Parent Program for Autism Spectrum and Language Delays (IY-ASD; more information is here: http://www.incredibleyears.com/programs/parent/autism-spectrum-language-delays/) is a 14-week course that meets for 2 hours every week. Ideally, an IY-ASD group will be composed of approximately 10 parents and other primary caregivers of children who have autism.
62820156|NCT03300128|ACTIVE_COMPARATOR|Circle of Parents|"Circle of Parents, the comparison condition, is an open parent support group led by a parent leader. (For more information, see http://circleofparents.org/). Participants are encouraged to share resources and other support both during groups, and between meetings."
62820157|NCT04327700|EXPERIMENTAL|Regorafenib and TheraBionic|"TheraBionic is a device that consists of battery-driven radiofrequency electromagnetic field generator. The metal mouth spoon antenna is placed on the anterior part of the tongue during treatment.~Regorafenib is a 40 mg tablet administered orally."
62820158|NCT00242931|EXPERIMENTAL|Fludarabine, TBI, Cyclosporine, MMF|"Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0 For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop~For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181."
62820159|NCT05238675|EXPERIMENTAL|BI 1291583: Low dose group|
62040217|NCT06062680|EXPERIMENTAL|Treatment group A|Take Herombopag Olamine Tablets 7.5mg 4h after high-fat meal in the first cycle, and take Herombopag Olamine Tablets 7.5mg on an empty stomach in the second cycle. In the third cycle, take Herombopag Olamine Tablets 7.5mg 30min after a standard meal;
62040218|NCT06062680|EXPERIMENTAL|Treatment group B|Take Herombopag Olamine Tablets 7.5mg on an empty stomach in the first cycle, and take Herombopag Olamine Tablets 7.5mg 30min after a standard meal in the second cycle. In the third cycle, Herombopag Olamine Tablets 7.5mg were taken 4h after a high-fat meal
62040219|NCT06062680|EXPERIMENTAL|Treatment group C|Take Herombopag Olamine Tablets 7.5mg 30min after standard meal in the first cycle, and take Herombopag Olamine Tablets 7.5mg 4h after high-fat meal in the second cycle. In the third cycle, Herombopag Olamine Tablets 7.5mg were taken on an empty stomach
62040220|NCT01353352|OTHER|Cervical spine injury|We enrolled consecutive alert adults who were in stable condition and who presented with potential cervical spine injury after acute blunt trauma, including patients with posterior neck pain and those presenting by ambulance with immobilization of the cervical spine.
62040221|NCT06732024|EXPERIMENTAL|group A|Vaccum Assisted Closure of Wound
62040222|NCT06732024|EXPERIMENTAL|group B|primary closure Closure of Wound
62600487|NCT05615870|ACTIVE_COMPARATOR|Intervention Group (Active Filter)|"The intervention group will use two Winix 5500-2 HEPA filtration units (Appendix A) (https://winixamerica.com/product/5500-2/). One will be placed in the child's sleep space and one will be placed in another common room with both units running continuously on the high (i.e., level 3 / second from highest) setting. Each unit is 8.2 x 15.0 x 23.6 inches, and verified for a 360 sq. foot room. If a home is too small to accommodate 2 Winix units (for example, a single room residence'), one Winix unit may be used for the study. Additional features beyond HEPA and carbon filter, include plasmawave technology to reduce volatile organic compounds and odors. The plasmawave feature will be turned off to avoid ozone production."
62600488|NCT05615870|SHAM_COMPARATOR|Control Group (No Filter)|The control group will use identical-appearing Winix 5500-2 units and identical setup procedures as described above, but with no HEPA or carbon filters.
62600489|NCT04002999|ACTIVE_COMPARATOR|Ceramic braces, directly placed|Patients in this group will be treated with directly-bonded traditional tooth-colored ceramic brackets
62600490|NCT04002999|EXPERIMENTAL|Ceramic braces, indirectly placed|Patients will be treated with the same brackets from treatment group 1 but using the indirect bonding technique
62600491|NCT04002999|EXPERIMENTAL|3D printed customized ceramic braces|Patients will be treated using indirectly bonded 3D-printed ceramic (tooth-closed) brackets
62600492|NCT06042361|OTHER|Intervention|All participants will receive the intervention of the Smokefree Implementation Framework and Toolkit
62600493|NCT02119221|EXPERIMENTAL|[14C]Copanlisib|
62040223|NCT05620875||Group with DO2i <280 ml/min/m2 during cardiopulmonary bypass|
62040224|NCT05620875||Group with DO2i >280 ml/min/m2 during cardiopulmonary bypass|
62040225|NCT03206203|EXPERIMENTAL|Arm 1 (atezolizumab, carboplatin)|Patients receive atezolizumab IV over 30-60 minutes and carboplatin IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62040226|NCT03206203|EXPERIMENTAL|Arm 2 (atezolizumab, carboplatin)|Patients receive carboplatin as in Arm 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may cross-over to Arm 1 upon disease progression.
62040227|NCT05195931||Preload and Afterload|10 participants with heart failure who are supported by LVADs will undergo hemodynamic monitoring and observation while undergoing changes in preload (head-up tilt and saline infusion), and afterload (nitroprusside and phenylephrine infusion).
62040228|NCT05195931||Contractility|10 participants with heart failure who are supported by LVADs will undergo hemodynamic monitoring and observation while undergoing changes in contractility with adjustments in heart rate (by adjusting pacemaker), dobutamine infusion, and during exercise.
62040229|NCT06733974|NO_INTERVENTION|Usual care|
62040230|NCT06733974|EXPERIMENTAL|Multi-faceted Intervention|
62040231|NCT02270333|ACTIVE_COMPARATOR|Treatment group|Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device .
62040232|NCT02270333|SHAM_COMPARATOR|Control group|Sham: Control group received sham inspiratory muscle training using POWERbreathe Classic threshold loading device .
62040233|NCT04518787||Control|Healthy child
62040234|NCT04518787||Experimental|Patients with language disorder
62040235|NCT03154216|EXPERIMENTAL|Exercise only|90 minutes of exercise
62600494|NCT05721248|NO_INTERVENTION|Cohort 1: Observational Continue Anti-HER2 Therapy|"Participants will have scans 30 days prior to starting study then undergo clinical follow-up 4-6 weeks after study initiation, at 12 weeks, and every 12 weeks thereafter. Visits will include interval history, physical exam, concomitant medications and blood draw for tumor marker assessment and research blood.~Participants will undergo restaging scans every 12 weeks (+/- 2 weeks)."
62623823|NCT02739659|EXPERIMENTAL|carbon-ion radiotherapy|Five dose levels \[59.2 GyE(Gray equivalent)/16Fx, 60.8 GyE/16Fx, 62.4 GyE/16Fx, 64.0 GyE/16Fx and 65.6 GyE/16Fx\] are planned within the Phase I part. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 65.6 GyE/16Fx are safely delivered, the recommended dose (or 65.6 GyE/16Fx) will be the prescribed dose in the Phase II part of the study.
62820160|NCT05238675|EXPERIMENTAL|BI 1291583: Medium dose group|
62820161|NCT05238675|EXPERIMENTAL|BI 1291583: High dose group|
62820162|NCT05238675|PLACEBO_COMPARATOR|Placebo|
62820163|NCT04676529|EXPERIMENTAL|PXS-5505, Dose Level 1, Escalation Phase (Cohort A)|Patients will receive PXS-5505 dose level 1, twice daily for a period of 4 weeks.
62820164|NCT04676529|EXPERIMENTAL|PXS-5505, Dose Level 2, Escalation Phase (Cohort B)|Patients will receive PXS-5505 dose level 2, twice daily for a period of 4 weeks.
62820165|NCT04676529|EXPERIMENTAL|PXS-5505, Dose Level 3, Escalation Phase (Cohort C)|Patients will receive PXS-5505 dose level 3, twice daily for a period of 4 weeks.
62820166|NCT04676529|EXPERIMENTAL|PXS-5505, Expansion Phase|All patients will receive PXS-5505 at the selected twice daily dose for a period of 24 weeks, or until progressive disease, unacceptable toxicity, dose-limiting toxicity or withdrawal of consent.
62040236|NCT03154216|EXPERIMENTAL|Exercise and high glycemic index drink|90 minutes of exercise followed by consumption of high-glycemic index Gatorade drink matched for calories expended during the exercise
62040237|NCT03154216|EXPERIMENTAL|Exercise and low glycemic index drink|90 minutes of exercise followed by consumption of low-glycemic index milk drink matched for calories expended during the exercise
62040238|NCT03154216|NO_INTERVENTION|No exercise and no beverage|No exercise and no beverage
62040239|NCT02961465||Sacral Neuromodulation (SNM)|
62040240|NCT05251051|ACTIVE_COMPARATOR|Intervention Group|"At NICU discharge, infants will be referred to Illinois Early Intervention. A coordinator (the navigator) will assist families in engaging with Early Intervention and completing all enrollment requirements.~At NICU discharge, infants will be provided with standard home pediatric therapy services weekly for up to 14 weeks. These will be initiated within 2 weeks of discharge."
62040241|NCT05251051|OTHER|Control Group|At NICU discharge, infants will be referred to Illinois Early Intervention. A coordinator (the navigator) will assist families in engaging with Early Intervention and completing all enrollment requirements. If transitional services were recommended by the NICU providers, the navigator will help families identify these services and obtain the necessary referrals.
62040242|NCT06372470||Study Arm|Single cohort
62600495|NCT05721248|EXPERIMENTAL|Cohort 2: - Stop Anti-HER2 Therapy|"Participants will have scans 30 days prior to starting study. Week 1 participants will stop anti-HER2 therapy then undergo clinical follow-up every 4-6 weeks, at 12 weeks, and every 12 weeks thereafter. Visits will include interval history, physical exam, concomitant medications and blood draw for tumor marker assessment and research blood.~Participants will undergo restaging scans every 12 weeks (+/- 2 weeks). Participants remaining progression-free after one year off treatment, may continue off anti-HER2 therapy indefinitely, with imaging surveillance suggested to be every 3-6 months at the discretion of the treating oncologist and will be followed up to 10 years Participants with disease progression after stopping anti-HER2 therapy, treatment is at discretion of the treating physician but resuming the pre-study regimen is strongly encouraged."
62820167|NCT04676529|EXPERIMENTAL|PXS-5505, Add-on Phase|Patients already receiving a stable dose of ruxolitinib for at least 12 weeks, will receive PXS-5505 (the dose used in the cohort expansion phase) on top of their ruxolitinib dose for up to 52 weeks or until progressive disease, unacceptable toxicity, dose-limiting toxicity, or withdrawal of consent.
62820168|NCT06594315||Cohort 1: Healthy Controls|Twenty healthy controls for will have 2H-glucose metabolism in measured for development of robust strategy in optimizing acquisition parameters.
62820169|NCT06594315||Cohort 2: Glioma participants (Single Time point)|Thirty participants with glioma who may or may not have received prior treatment for testing the optimized imaging protocol developed in Cohort 1.
62820170|NCT06594315||Cohort 3: Glioma participants (Multiple Time points)|Thirty participants who will receive non-investigational treatment for glioma enrolled to test the evaluation for treatment induced metabolic changes at baseline and post- non-investigational treatment.
62040243|NCT00772226|ACTIVE_COMPARATOR|music|
62600496|NCT06376422|EXPERIMENTAL|Spongioflex®|As for any surgical procedure, the patient receives an antibiotic shot non-interventional medicinal product (NIMP) just before surgery. The patient will be arthroscopically treated via the arthroscopic portal with implantation of a demineralized bone block (IMP: Spongioflex ®, appropriate size (DIZG gGmbH, Berlin, Germany)) as a partial meniscus substitute. The block will be adapted to the defect size and secured with 2-4 inside-out sutures (Etibond 0, Ethicon, Somerville, NJ). No dosing, the IMP has no systemic effect. The surgery (Intervention) will last between 60-90 minutes. The hospital stay is between 2-3 days after surgery. Follow-up visits: at the end of the hospital stay, after 6 weeks, after 6, 12 and 24 months and after 5 years for the operated group.
62820171|NCT01855529|EXPERIMENTAL|Ropivacaine arm|Ropivacaïne 2 mg/ml 10ml/h
62820172|NCT01855529|PLACEBO_COMPARATOR|NaCl arm|NaCl 0,9% 250ml 10 ml/h
62820173|NCT06654011|EXPERIMENTAL|Study group|IN10018 is administered orally at a dose of 100 mg once daily; cadonilimab is given at a dose of 10 mg/kg via intravenous infusion on Day 1 of each cycle, every 3 weeks; and nab-paclitaxel is administered at a dose of 260 mg/m² via intravenous infusion on Day 1 of each cycle, also every 3 weeks. Patients will undergo a maximum of 6 cycles of this combination chemotherapy. Following this regimen, maintenance therapy will consist of a combination of cadonilimab and IN10018.
62820174|NCT00541372|EXPERIMENTAL|1|Needle 5 mm
62820175|NCT00541372|ACTIVE_COMPARATOR|2|Needle length 8 mm
62040244|NCT00772226|PLACEBO_COMPARATOR|Pillow without music|
62040245|NCT03974620|EXPERIMENTAL|Individual Placement and Support (IPS)|IPS is a vocational support program to facilitate return to employment in individuals with severe and enduring mental illnesses.
62040246|NCT03974620|EXPERIMENTAL|Cognitive Remediation Therapy (CRT)|CRT will be delivered twice weekly individual computerised CRT with therapist input. This therapy will be delivered by a CRT trained assistant psychologist.
62040247|NCT03974620|EXPERIMENTAL|IPS and CRT|A combination of IPS and CRT will be provided to participants in this arm.
62040248|NCT03974620|NO_INTERVENTION|Treatment as usual|Continued input as normal with treating psychiatrist.
62040249|NCT03671005|EXPERIMENTAL|Mindfulness-based group therapy (MBGT)|The mindfulness-based group therapy (MBGT) involves a four-week manual with three group therapy sessions per week in addition to TAU. The therapy represents the first German group-based mindfulness manual for psychosis. One sixty-minute session was held by a certified psychotherapist who is experienced in mindfulness-based therapy. A trained co-therapist implements two 30-minute sessions. On a weekly basis, a new theme is discussed in the three sessions to ensure the internalization of different mindfulness concepts. Namely, the topics Mindfulness of the Breath (1), Mindfulness of the Senses in the Context of Nature (2), Mindfulness of Detachment (3), and Mindfulness in the Context of Bodily Awareness (4) are addressed during the group-sessions.
62243868|NCT03801902|EXPERIMENTAL|Arm II (CLOSED) (Durvalumab and standard RT)|Starting 2 weeks prior to radiation therapy, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 4 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo conventionally fractionated radiation therapy 1 fraction per day, 5 days per week for 30 fractions. Patients also undergo brain MRI or CT scan during screening and as clinically indicated, chest CT scans on study and during follow up, and collection of blood samples during screening and on study.
62820176|NCT05057637||Complete cohort|In all patients included in the study subsequent optical coherence tomography (OCT) measurements will be performed pre and post stent placement.
62600497|NCT06376422|OTHER|non-operated|no surgical treatment, no antibiotic shot, no visit at the end of the hospital stay, and no visit after 6 weeks. Follow-up visits after 6, 12 and 24 months and after 5 years.
62434170|NCT06381726|EXPERIMENTAL|Enhanced motor reorganization: upfront Chemotherapy + Motor Rehabilitation|"Temozolomide-based regimen of 6 months duration is applied. Treatment will be discontinued in case of toxicity (G2-G4).~Patients will also be submitted to motor rehabilitation program aimed at learning unimanual and bimanual coordinated sequences, along with personalized exercise according to tumor location (frontal vs parietal). For 6 months each patient will perform the motor training program in outpatient training session, checked by a physiotherapist for corrected execution at home 3 times/week, and is assessed for the correct training execution and progresses in training sessions each month, by physical therapists at the Rehabilitation Unit and on a weekly schedule by on-line distant monitoring (telemedicine)."
62434171|NCT03317145|ACTIVE_COMPARATOR|Arm A (NMES followed by IPC)|Arm A (NMES followed by IPC). Following baseline blood flow measurements using ultrasound, the neuromuscular electrostimulation (NMES) device will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The NMES device will be removed. After a 30 minute rest period, the intermittent pneumatic compression (IPC) device will be fitted, activated for 10 minutes and then blood flow measurements repeated.
62600498|NCT01841450|EXPERIMENTAL|iStent|Implantation of one iStent in conjunction with cataract surgery
62600499|NCT01841450|ACTIVE_COMPARATOR|Cataract surgery|Cataract surgery alone
62600500|NCT00655733|EXPERIMENTAL|HMPL-004|Subjects who fulfilled all entry criteria and randomized HMPL-004 arm will receive HMPL-004 400 mg 3 times daily 3 times daily for 56 days (8 weeks) with a 28-day (4-week) follow-up.
62600501|NCT00655733|PLACEBO_COMPARATOR|Placebo|Subjects who fulfilled all entry criteria and randomized Placebo arm will receive matching placebo 400 mg 3 times daily 3 times daily for 56 days (8 weeks) with a 28-day (4-week) follow-up.
62820177|NCT05520034|EXPERIMENTAL|Intervention group|The participants provided health education regarding understanding stroke and the risk factors, lifestyle changes related to modifiable factors, (self)-monitoring of daily blood pressure (BP), and compliance with medication and hospital/clinic visits. At 6 and 12 months RA nurses collected data and samples for lab tests from the patient's house if the patient cannot come to NINSH for any reason. We provided all the patients with lab test costs and transportation fees if they visited any healthcare center for any lab test related to our study.
62820178|NCT05520034|NO_INTERVENTION|Control Group|The participants received a one-time telephone call from research nurses every month to keep in contact (telephone calls did not include health education). At 6 and 12 months RA nurses collected data and samples for lab tests from the patient's house if the patient cannot come to NINSH for any reason. We provided all the patients with lab test costs and transportation fees if they visited any healthcare center for any lab test related to our study.
62434172|NCT03317145|ACTIVE_COMPARATOR|Arm B (IPC followed by NMES)|Arm B (IPC followed by NMES). Following baseline blood flow measurements using ultrasound, the intermittent pneumatic compression device (IPC) will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The IPC device will be removed. After a 30 minute rest period, the neuromuscular electrostimulation (NMES) device will then be fitted, activated for 10 minutes and then blood flow measurements repeated
62434173|NCT01286337|EXPERIMENTAL|vessel sealing|axilla dissection using this device
62434174|NCT01286337|ACTIVE_COMPARATOR|control|standard surgical technique
62434175|NCT06276179|EXPERIMENTAL|Oxycodone (study group)|Patient will receive a bolus dose of 0.15 mg/kg plus 20 ml bupivacaine 0.25% followed by an infusion 0.03 mg/kg/h oxycodone plus 0.1 mL/Kg/h bupivacaine 0.125%.
62434176|NCT06276179|ACTIVE_COMPARATOR|Bupivacaine (control group)|Patient will receive a bolus 20 ml bupivacaine 0.25% followed by an infusion 0.1 mL/Kg/h bupivacaine 0.125%.
62434177|NCT01434706|OTHER|Nucleic Acid Amplification Testing|Nucleic Acid Amplification Testing
62820179|NCT06086795|ACTIVE_COMPARATOR|Egg whites|3 large egg equivalent of liquid egg whites per day for 4 weeks
62600502|NCT03431662|EXPERIMENTAL|Ellipse IM HTO Nail|In this arm, the subjects varus malalignment is corrected with Ellipse Intramedullary High Tibial Osteotomy Intramedullary Nail, which is a CE device. The device achieves the correction via progressive distraction osteogenesis.
62820180|NCT06086795|EXPERIMENTAL|Egg yolks|3 large egg equivalent of liquid egg yolks per day for 4 weeks
62820181|NCT06086795|EXPERIMENTAL|Whole eggs|3 large whole eggs per day for 4 weeks
62820182|NCT04534244|NO_INTERVENTION|Control group|Treatment of the tributary veins by phlebectomy
62820183|NCT04534244|EXPERIMENTAL|Experimental group|Endovenous steam treatment of the tributary veins
62040250|NCT03671005|ACTIVE_COMPARATOR|treatment as usual (TAU)|Treatment as usual (TAU) at the ward consists of a variety of daily activity groups the patients can choose from. Every patient at the ward receives a daily schedule depending on individual needs for therapy. The therapies offered at the ward include occupational therapy, physiotherapy, psychoeducative groups, and concentration practice of two levels, all not related to mindfulness interventions. In addition to the group activities at the ward, every patient receives individual psychotherapy sessions at least once a week, held by a certified psychiatrist or psychologist. Psychopharmacological treatment is provided by the physicians, and social workers are available in order to support patients in managing their everyday lives after the stationary treatment. Weekly group meetings at the ward, together with the treating physicians, psychotherapists, social workers and the respective patient, foster the exchange success and possible improvements of the treatment.
62040251|NCT01724138|EXPERIMENTAL|Deferasirox|The study will provide PK, safety, tolerability and efficacy data collected during 48 weeks of treatment with deferasirox in Chinese pediatric patients with transfusion dependent -thalassemia major, aged 2 to \<6 years at enrollment. The target patient pool consists of 20 patients with evidence of iron overload measured by serum ferritin level at the start of study. Patients will start their deferasirox treatment with a dose of 20 mg/kg/day. Serum ferritin will be monitored every month and the dose of deferasirox will be adjusted if necessary every 3 months based on the trends in serum ferritin. Other possible dose adjustments will be based on the patient's safety assessments.
62434178|NCT03671265|EXPERIMENTAL|SHR-1210 + Chemotherapy + Radiotherapy|"Radiotherapy(IMRT or VMAT): 95%PTV 54Gy/30 fraction,95%PTV 60Gy/30 fraction ,5 fractions per week, for 6 weeks. Radiation begun the day on which first dose of SHR-1210.~SHR-1210 (200mg fixed dose every 2 weeks, one cycle is four weeks, total 8 cycles ) will be administered as an intravenous infusion over 30 minutes.~Chemotherapy: Docetaxel 25mg/m2/w, intravenous infusion on days 1, 8, 15, 22, total 4 cycles; Cisplatin 25mg/m2/w, intravenous infusion on days 1, 8, 15, 22;, total 4 cycles.~Apatinib: 250mg/d，PO Qd(4 weeks after Radiotherapy, until the end of 8th ycle )"
62434179|NCT01179282|PLACEBO_COMPARATOR|PLACEBO|PLACEBO NASAL SPRAY
62600503|NCT03431662|ACTIVE_COMPARATOR|TomoFix|In this arm, the subjects varus malalignment is corrected with Synthes TomoFix system, which is a CE device. The device achieves the correction via fixating an accute intraoperative correction of the varus malalignment.
62600504|NCT02253771|EXPERIMENTAL|shockwave therapy|shockwave therapy
62600505|NCT02253771|PLACEBO_COMPARATOR|Placebo treatment|sham shockwave therapy by an identically looking device without any function
62820184|NCT03373240|EXPERIMENTAL|TAU plus Cognitive Remediation Program|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on learning and decision making.
62820185|NCT03373240|PLACEBO_COMPARATOR|TAU plus Control Tasks|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.
62434180|NCT01179282|ACTIVE_COMPARATOR|DUST MITE ALLERGEN|Subjects will use dust mite Dermatophagoides pteronyssinus (Dp) extract or placebo nasal spray at home for 2 weeks, with a 1 month washout period followed by 2 weeks of the other nasal spray.
62600506|NCT05512806|EXPERIMENTAL|Treatment A|Participants will receive Dose A orally as a film-coated tablet.
62820186|NCT02085460|PLACEBO_COMPARATOR|Placebo|6 times daily
62820187|NCT02085460|EXPERIMENTAL|2% Rebamipide liquid|6 times daily
62040252|NCT06211569||Patients|Women of childbearing age, consulting for elective fertility preservation
62040253|NCT03073148|EXPERIMENTAL|Tangible Boost|Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.
62040254|NCT03073148|PLACEBO_COMPARATOR|Control|"Participants will treat their lenses with a placebo Tangible Boost kit containing saline after 30 days and again after 60 days."
62040255|NCT02381886|EXPERIMENTAL|IDH305|
62040256|NCT06584136||Oura ring|All participants will be assigned to a single group receiving a smart ring paired with their phone monitoring sleep and daily activity.
62820188|NCT02085460|EXPERIMENTAL|4% Rebamipide liquid|6 times daily
62600507|NCT05512806|EXPERIMENTAL|Treatment B|Participants will receive Dose A orally as a film-coated tablet.
62600508|NCT05512806|EXPERIMENTAL|Treatment C|Participants will receive Dose B orally as a film-coated tablet.
62600509|NCT05512806|EXPERIMENTAL|Treatment D|Participants will receive Dose B orally as an oral solution.
62040257|NCT01851148|SHAM_COMPARATOR|sham therapy|subtracting serial sevel (McPartland 2003)
62040258|NCT01851148|OTHER|usual care|triptans treatment only
62040259|NCT01851148|EXPERIMENTAL|OMT|8 sessions of osteopathic manipulative treatment
62600510|NCT05512806|EXPERIMENTAL|Treatment E|Participants will receive Dose C orally as a film-coated tablet.
62600511|NCT05512806|EXPERIMENTAL|Treatment F|Participants will receive Dose C orally as a film-coated tablet.
62040260|NCT04602728|EXPERIMENTAL|Back2Life Program|Youth with chronic SCD pain and their parents or caregivers receiving an adaptive cognitive behavioral treatment program for pain coping skills.
62040261|NCT05465161|EXPERIMENTAL|StingMark Fiducial Marker|Device insertion will occur with the designated needles and through the appropriate organ-specific route and imaging guidance. Multiple STING-MARK fiducials will be inserted. Plain film x-rays in 3 planes of the organs with the marker inserted will be taken and recorded.
62040262|NCT04354467||Neonates exposed to Nephrotoxic Medications|Neonates exposed to Nephrotoxic Medications as defined by the NINJA inclusion criteria
62040263|NCT03018405|EXPERIMENTAL|Hematological tumors|The dose escalation arm for hematological tumors will use a 3 +3 design to determine the maximum tolerated dose. Two additional cohorts will be added in this dose escalation arm with the aim to provide a more intense treatment during the induction treatment (cycle 1 of injection). Cohort 10-11 (only in AML/MDS) will evaluate a tighter schedule of NKR-2 injections at 1x109 or potentially 3x109 NKR-2 per injection with the three first injections within the induction cycle (cycle 1) separated by a 1-week interval followed two weeks later by a second cycle (cycle 2) with a 2-weeks interval between each three NKR 2 injections.
62040264|NCT03018405|EXPERIMENTAL|Solid Tumors|The dose escalation arm for solid tumors will use a 3 +3 design to determine the maximum tolerated dose. Two additional cohorts will be added in this dose escalation arm with the aim to provide a more intense treatment during the induction treatment (cycle 1 of injection). Cohort cohort 8-9 ( only in CRC) will evaluate a tighter schedule of NKR-2 injections at 1x109 or potentially 3x109 NKR-2 per injection with the three first injections within the induction cycle (cycle 1) separated by a 1-week interval followed two weeks later by a second cycle (cycle 2) with a 2-weeks interval between each three NKR 2 injections.
62040265|NCT04929769|EXPERIMENTAL|1|the group of LRH
62040266|NCT04929769|ACTIVE_COMPARATOR|2|the group of ARH
62434181|NCT02530632|ACTIVE_COMPARATOR|Sevoflurane anesthesia|Anesthesia maintained with inhalational sevoflurane
62434182|NCT02530632|EXPERIMENTAL|Propofol anesthesia|Anesthesia maintained with intravenous propofol continuous infusion
62434183|NCT05037682|OTHER|Primary Care Practices|Dissemination and Implementation Research
62434184|NCT03163095|ACTIVE_COMPARATOR|Open Abdomen Management with ANPPT dressing|The abdominal fascia will not be closed, but a temporally abdomenal closure (TAC) dressing (such as AbThera dressing) will be placed to protect the viscera with active Negative Pressure Peritoneal drain. Formal abdominal closure or dressing change at 24-72 hours from placement should be performed.
62434185|NCT03163095|SHAM_COMPARATOR|Closed Abdomen Management|Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain). Any decision to perform a re-laparotomy will be at the discretion of the treating surgical team.
62434186|NCT04257240||study group|patients subjected to major hepatectomy with vascular control of blood inflow and outflow of the whole liver
62040267|NCT04364373|ACTIVE_COMPARATOR|D2 lymph node dissection|"For tumours in splenic flexure and proximal and mid part of descending colon lymph nodes 232 and 231 will be removed.~For tumours in distal part of descending colon and proximal sigmoid lymph nodes 231, 232 and partially 241, 242 (considering variation of the feeding artery) will be removed.~For tumours in the mid part of sigmoid colon lymph nodes 241, 242 will be removed.~For tumours in the rectosigmoid junction 251, 252 groups of the lymph node will be removed."
62600512|NCT06137287|EXPERIMENTAL|Group 1|In Period 1, participant will receive 6 injections of BOTOX VISTA Dose A on Day 1. In Period 2, participants who meet the retreatment criteria will receive 6 injections of BOTOX VISTA Dose A on either Day 180, 210, 240, or 270.
62040268|NCT04364373|EXPERIMENTAL|D3 lymph node dissection|"For tumours in splenic flexure and proximal and mid part of descending colon lymph nodes 232, 231 and 253 will be removed.~For tumours in distal part of descending colon and proximal sigmoid lymph nodes 231, 232 and 253 and partially 241, 242 (considering variation of the feeding artery) will be removed.~For tumours in the mid part of sigmoid colon lymph nodes 241, 242 and 253 will be removed.~For tumours in the rectosigmoid junction 251, 252 and 253 groups of the lymph node will be removed."
62600513|NCT06137287|EXPERIMENTAL|Group 2|In Period 1, participant will receive 6 injections of BOTOX VISTA Dose B on Day 1. In Period 2, participants who meet the retreatment criteria will receive 6 injections of BOTOX VISTA Dose B on either Day 180, 210, 240, or 270.
62040269|NCT02680873|OTHER|SASI bypass|sleeve gastrectomy done and gastro-ileum anastomosis 2.5 meter from the ileocecal valve . the anastomosis is less than 3cmm in diameter . the concept to push undigested food early to the ileum to stimulate intestinal hormones secretion to control diabetes .
62434187|NCT04257240||control group|patients subjected to major hepatectomy by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor
62243869|NCT03801902|EXPERIMENTAL|Arm III (durvalumab, monalizumab, standard RT)|Starting 2 weeks prior to radiation therapy, patients receive durvalumab IV over 60 minutes and monalizumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 4 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo conventionally fractionated radiation therapy 1 fraction per day, 5 days per week for 30 fractions. Patients also undergo brain MRI or CT scan during screening and as clinically indicated, chest CT scans on study and during follow up, and collection of blood samples during screening and on study.
62243870|NCT03801902|EXPERIMENTAL|Arm IV (durvalumab, oleclumab, standard RT)|Starting 2 weeks prior to radiation therapy, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Patients also receive oleclumab IV over 60 minutes on days 1 and 15 of cycles 1-2, then on day 1 of cycles thereafter. Treatment repeats every 4 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo conventionally fractionated radiation therapy 1 fraction per day, 5 days per week for 30 fractions. Patients also undergo brain MRI or CT scan during screening and as clinically indicated, chest CT scans on study and during follow up, and collection of blood samples during screening and on study.
62243871|NCT01839162|EXPERIMENTAL|Pelvic drape|Pelvic shield drape over the patient
62243872|NCT01839162|EXPERIMENTAL|Arm drape|Right radial arm drape over the patient
62040270|NCT05474274||Post-Surgery data collection system|Subjects undergoing standard of care low-risk plastic surgery be provided with wearable sensors to take home and start recording heart rate, body temperature and body movements
62243873|NCT01839162|EXPERIMENTAL|Pelvic and arm drape|Pelvic and arm drpaes placed over the patient
62243874|NCT01839162|SHAM_COMPARATOR|No drapes|Standard radioprotection devices
62243875|NCT06734832|EXPERIMENTAL|trial group|Bivalent enterovirus inactivated vaccine (Vero cell)
62243876|NCT06734832|ACTIVE_COMPARATOR|control group|Enterovirus Type 71 Vaccine (Vero Cell), Inactivated
62243877|NCT01224704|EXPERIMENTAL|Lean: hypertonic first|Lean: Hypertonic solution at day 6 and water deprivation at day 10
62243878|NCT01224704|EXPERIMENTAL|Lean: water deprivation first|Lean: Water deprivation at day 6 and hypertonic solution at day 10
62243879|NCT01224704|EXPERIMENTAL|Obese: hypertonic first|Obese: Hypertonic solution at day 6 and water deprivation at day 10
62243880|NCT01224704|EXPERIMENTAL|Obese: water deprivation first|Obese: Water deprivation at day 6 and hypertonic solution at day 10
62243881|NCT05359991|ACTIVE_COMPARATOR|Healthy Controls|"Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in healthy controls. Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur:~* The child will be in a fasted state.~* An IV will be placed into the child's arm.~* Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise."
62434188|NCT04703725|EXPERIMENTAL|Experimental Group|Infertile women recruited to the experimental group by randomization will be given a counseling program including psychosocial care in addition to routine (drug explanation during the treatment, preparation before the egg pick up and embryo transfer and post operative care). IVF treatment
62434189|NCT04703725|NO_INTERVENTION|Control Group|Routine (drug explanation during the treatment, preparation before the egg pick up and embryo transfer and post operative care) IVF treatment will be applied to infertile women who are randomized to the control group.
62040271|NCT04049175|EXPERIMENTAL|Treatment A|Administration of CHF 6532 Dose #1
62600514|NCT06137287|EXPERIMENTAL|Group 3|In Period 1, participant will receive 6 injections of BOTOX VISTA placebo on Day 1. In Period 2, participants who meet the retreatment criteria will receive 6 injections of BOTOX VISTA Dose A on either Day 180, 210, 240, or 270.
62820189|NCT05776940|ACTIVE_COMPARATOR|Probiotic group|Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy combined with Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules( 250mg/time, bid,up to 3 months).
62600515|NCT06137287|EXPERIMENTAL|Group 4|In Period 1, participant will receive 6 injections of BOTOX VISTA placebo on Day 1. In Period 2, participants who meet the retreatment criteria will receive 6 injections of BOTOX VISTA Dose B on either Day 180, 210, 240, or 270.
62040272|NCT04049175|EXPERIMENTAL|Treatment B|Administration of CHF 6532 Dose #2
62040273|NCT04049175|EXPERIMENTAL|Treatment C|Administration of CHF 6532 Dose #3
62040274|NCT04049175|PLACEBO_COMPARATOR|Treatment D|Administration of CHF 6532 Placebo
62040275|NCT06733857|EXPERIMENTAL|Plant-based|Participants were to consume a high protein plant-based diet while completing a 10-week exercise program consisting of 5 exercise sessions per week.
62600516|NCT05724459|EXPERIMENTAL|Peer Education Group|Training on stem cell transplantation for a total of 12 hours, two days a week for three weeks, two lesson hours a day (60 min. + 60 min.)
62040276|NCT06733857|ACTIVE_COMPARATOR|Omnivorous|Participants were to consume a high protein omnivorous diet while completing a 10-week exercise program consisting of 5 exercise sessions per week.
62040277|NCT06720259|EXPERIMENTAL|Oxantel Single Dose|Treatment with oxantel pamoate (20 mg/kg), orally administered on day 0
62040278|NCT06720259|EXPERIMENTAL|Oxantel Multiple Dose|Treatment with oxantel pamoate (20 mg/kg), orally administered on each of day 0, 1 and 2
62040279|NCT06720259|ACTIVE_COMPARATOR|Mebendazole Single Dose|Mebendazole (500mg), orally administered on day 0
62040280|NCT03583255|EXPERIMENTAL|Arm I (dexamethasone, exercise)|Patients receive dexamethasone PO BID for 7 days. Patients also complete resistance training and moderate intensity walking at home for minimum 5 days per week over 4 weeks.
62040281|NCT03583255|ACTIVE_COMPARATOR|Arm II (placebo, exercise)|Patients receive placebo PO BID for 7 days. Patients also complete resistance training and moderate intensity walking as in Arm I.
62040282|NCT02069782|EXPERIMENTAL|Home visiting|Home visiting programs in the United States grew from three major approaches that first became prominent in the 1960s: visits by public health nurses to promote infant and child health in disadvantaged families, Head Start home visiting to promote school readiness in hard-to-reach families, and home-based family support to promote positive parenting and prevent child abuse in high-risk families. All of these approaches sought to foster early childhood health and development by intervening in the home to support and improve socialization, health, and education practices.Today, home visiting is seen as a particularly important strategy for high-risk families who may be difficult to engage in other services.
62040283|NCT05392062|OTHER|Respiratory insufficiency|Subject with respiratory insufficiency
62040284|NCT01175850|EXPERIMENTAL|Drug-Coated Balloon (DCB)|IN.PACT Admiral: Balloon Angioplasty
62040285|NCT01175850|ACTIVE_COMPARATOR|Standard PTA|Standard Percutaneous Transluminal Angioplasty (PTA) Balloon: Balloon Angioplasty
62040286|NCT06732648|EXPERIMENTAL|Treatment group A: HRS8179 injection|
62820190|NCT05776940|ACTIVE_COMPARATOR|Control group|Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy without any probiotics.
62040287|NCT06732648|EXPERIMENTAL|Treatment group B: HRS8179 injection|
62040288|NCT06732648|PLACEBO_COMPARATOR|Treatment group C: HRS8179 blank preparation.|
62243882|NCT05359991|EXPERIMENTAL|Children With Documented History of SARS CoV-2 Infection|"Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in children with a documented history of SARS CoV-2 Infection. Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur:~* The child will be in a fasted state.~* An IV will be placed into the child's arm.~* Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise."
62600517|NCT05724459|NO_INTERVENTION|Control Group|
62820191|NCT02420717|EXPERIMENTAL|Cohort A (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62040289|NCT05394246|EXPERIMENTAL|FluoAB intraoperative fluorescence imaging|The patients will receive an injection of FluoAB. Surgery will be performed with guidance by FluoAB fluorescence imaging.
62040290|NCT02669784|ACTIVE_COMPARATOR|Low Dose Contrast (40mL)|CTA of the chest: 40 mL of intravenous contrast at a rate of 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. The Low Dose scan will then be compared to the standard of care high dose scan of the same area taken at a previous date.
62040291|NCT02669784|ACTIVE_COMPARATOR|Low Dose Contrast (50mL)|CTA of the abdomen OR or CTA of the chest and abdomen or CTA of the abdomen and pelvis or CTA of the chest, abdomen and pelvis: 50 mL of intravenous contrast at a rate 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. The Low Dose scan will then be compared to the standard of care high dose scan of the same area taken at a previous date.
62040292|NCT03533712|EXPERIMENTAL|Fortified BEP supplement|Intervention: Dietary Supplement: Fortified balanced energy-protein (BEP) supplement + iron and folic acid supplement.
62243883|NCT05359991|EXPERIMENTAL|Children With Sickle Cell Disease (SCD)|"Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in children with Children With Sickle Cell Disease (SCD). Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur:~* The child will be in a fasted state.~* An IV will be placed into the child's arm.~* Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise."
62040293|NCT03533712|ACTIVE_COMPARATOR|Fe and folic acid|Dietary Supplement: Fe and folic acid supplement.
62040294|NCT04088552|EXPERIMENTAL|ActuaYa Arm|Participants will receive educational sessions, facilitated discussions and an exercise program.
62040295|NCT05095610||Adult Type 1 Diabetes|"All adult patients with type 1 diabetes previously followed in the DIACAM study (see bellow reference).~Sastre J, Pinés PJ, Moreno J, Aguirre M, Blanco B, Calderón D, Herranz S, Roa C, Lopez J; Grupo de estudio DIACAM 1. Metabolic control and treatment patterns in patients with type 1 diabetes in Castilla-La Mancha: the DIAbetes tipo 1 in Castilla La Mancha study. Endocrinol Nutr. 2012 Nov;59(9):539-46. doi: 10.1016/j.endonu.2012.07.003."
62040296|NCT05722002|OTHER|NSAID regimen|Surgical teams will elect for one of the medications within the treatment arm to which the patient is randomized.
62040297|NCT05722002|OTHER|Opioid regimen|
62040298|NCT06431503|EXPERIMENTAL|Tok-Sen massage|Tok-Sen massage uses a mallet to hit a wooden wedge to produce impact and sound.
62040299|NCT06431503|ACTIVE_COMPARATOR|Pressure massage|Pressure massage uses the wooden wedge to press.
62040300|NCT04711889|EXPERIMENTAL|Ulinastatin|Ulinastatin 10 0000 Units is taken intravenously three times a day.
62040301|NCT04711889|SHAM_COMPARATOR|Blank control|Blank control.
62040302|NCT06722183|EXPERIMENTAL|Futibatinib plus tislelizumab plus mFOLFOX|Futibatinib 20 mg orally, once daily, continuously, plus tislelizumab (i.v., 200 mg) on day 1 and day 22 at each 6-week cycle and mFOLFOX (SOC chemotherapy)
62040303|NCT06441968|EXPERIMENTAL|Cohort 1|Healthy adults between 18 - 64 years who have received a primary series and at least one booster with an authorized or licensed mRNA SARS-CoV-2 parenteral vaccine will receive 1 x 10\^4 PFU of MPV/S-2P administered intranasally (approximately 0.5 mL per nostril) using VaxINator (Teleflex) for 1 year. N=20
62040304|NCT06441968|EXPERIMENTAL|Cohort 2|Healthy adults between 18 - 64 years who have received a primary series and at least one booster with an authorized or licensed mRNA SARS-CoV-2 parenteral vaccine will receive 1 x 10\^5 PFU of MPV/S-2P administered intranasally (approximately 0.5 mL per nostril) using VaxINator (Teleflex) for 1 year. N=20
62040305|NCT06441968|EXPERIMENTAL|Cohort 3|Healthy adults between 18 - 64 years who have received a primary series and at least one booster with an authorized or licensed mRNA SARS-CoV-2 parenteral vaccine will receive 1 x 10\^6 PFU of MPV/S-2P administered intranasally (approximately 0.5 mL per nostril) using VaxINator (Teleflex) for 1 year. N=20
62040306|NCT04702568|EXPERIMENTAL|Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group|This group included participants who, prior to enrolling in their previous BCX9930 study, were either naïve to eculizumab or ravulizumab treatment, or naive to treatment with any complement inhibitor therapy (or had received no treatment in the prior 12 months), and with anemia due to ongoing intravascular hemolysis.
62040307|NCT04702568|EXPERIMENTAL|C5 INH Inadequate Response Group|This group included participants who, prior to enrolling in their previous BCX9930 study, were receiving stable treatment with eculizumab or ravulizumab and had an inadequate response to that therapy (ie, residual anemia and/or ongoing need for transfusion). Depending on the prior study, participants may have continued the C5 inhibitor, with BCX9930 provided as an add-on therapy.
62434190|NCT00665197|ACTIVE_COMPARATOR|Protracted Course Radiotherapy|"High Dose Rate brachytherapy 8.0 Gy x 2~External beam radiotherapy 30 Gy in 10 fractions of 3.0 Gy"
62623824|NCT00293800|EXPERIMENTAL|Travoprost/Timolol|One drop Travoprost 0.004%/Timolol 0.5% in the study eye(s) each morning at 8 a.m. and one drop Timolol vehicle in the study eye(s) each evening at 8 p.m. for 3 months
62040308|NCT01320007|EXPERIMENTAL|Group 1: Optivol Group|
62040309|NCT01320007|ACTIVE_COMPARATOR|Group 2: Optivol alarm muted|
62040310|NCT06733805|EXPERIMENTAL|Group 1 - Early Portrait + Letter|This group received the prescribing portrait and therapeutics letter on January 15, 2024. The materials were uploaded to the Portrait Online interface on this date, and recipients were sent an email notifying them of the new material available.
62040311|NCT06733805|EXPERIMENTAL|Group 2 - Delayed Control|This group received the prescribing portrait and therapeutics letter on October 15, 2024 (9 months after Group 1 received the materials). The materials were uploaded to the Portrait Online interface on this date, and recipients were sent an email notifying them of the new material available.
62820192|NCT02420717|EXPERIMENTAL|Cohort B (dasatinib)|Patients receive dasatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62040312|NCT00773968|EXPERIMENTAL|Methoxy Polyethylene Glycol-Epoetin Beta|Participants will receive methoxy polyethylene glycol-epoetin beta once monthly by subcutaneous (SC) injection for 28 weeks.
62040313|NCT04212091|EXPERIMENTAL|Part A (Group 1): PGT121.414.LS (3 mg/kg)|Participants will receive 3 mg/kg of PGT121.414.LS by intravenous (IV) infusion at Month 0.
62434191|NCT00665197|EXPERIMENTAL|Short Course Radiotherapy|"High Dose Rate brachytherapy 8.0 Gy x 2~External beam radiotherapy 20 Gy in 5 fractions of 4.0 Gy"
62040314|NCT04212091|EXPERIMENTAL|Part A (Group 2): PGT121.414.LS (10 mg/kg)|Participants will receive 10 mg/kg of PGT121.414.LS by IV infusion at Month 0.
62040315|NCT04212091|EXPERIMENTAL|Part A (Group 3): PGT121.414.LS (30 mg/kg)|Participants will receive 30 mg/kg of PGT121.414.LS by IV infusion at Month 0.
62040316|NCT04212091|EXPERIMENTAL|Part A (Group 4): PGT121.414.LS (5 mg/kg)|Participants will receive 5 mg/kg of PGT121.414.LS by subcutaneous (SC) infusion at Month 0.
62040317|NCT04212091|EXPERIMENTAL|Part B (Group 5): PGT121.414.LS + VRC07-523LS (20 mg/kg)|Participants will receive 20 mg/kg of PGT121.414.LS and 20 mg/kg of VRC07-523LS by IV infusion sequentially in this order at Months 0, 4, and 8.
62040318|NCT04212091|EXPERIMENTAL|Part B (Group 6): PGT121.414.LS + VRC07-523LS (5 mg/kg)|Participants will receive 5 mg/kg of PGT121.414.LS and 5 mg/kg of VRC07-523LS by SC infusion sequentially in this order at Months 0, 4, and 8.
62040319|NCT05884346|OTHER|Heart Failure Preserved Ejection Fraction with coronary disease|
62040320|NCT05884346|OTHER|Heart Failure Preserved Ejection Fraction without coronary disease|
62040321|NCT01112579|EXPERIMENTAL|Treatment|
62040322|NCT01112579|OTHER|Control|
62040323|NCT06722976|EXPERIMENTAL|face-to-face|"The program is organized into three phases: (1) Initial assessment; (2) Multicomponent training sessions; (3) Final assessment.~1. The initial assessment will consist of physical fitness tests (lasting around 1 hour) and Neuropsychological Assessment tests (lasting around 1.5 hours).~2. The multicomponent training sessions will last 3 months, twice a week, 50 minutes each session, held in person at the institution.~3. The final assessment will be the same as the initial assessment (physical fitness tests (about 1 hour) and Neuropsychological Assessment tests (about 1.5 hours)."
62040324|NCT06722976|EXPERIMENTAL|Synchronous distance (video call)|"The program is organized into three phases: (1) Initial assessment; (2) Multicomponent training sessions; (3) Final assessment.~1. The initial assessment will consist of physical fitness tests (lasting around 1 hour) and Neuropsychological Assessment tests (lasting around 1.5 hours).~2. The multicomponent training sessions will last 3 months, twice a week, 50 minutes each, carried out by video call.~3. The final assessment will be the same as the initial assessment (physical fitness tests (about 1 hour) and Neuropsychological Assessment tests (about 1.5 hours)."
62040325|NCT06722976|NO_INTERVENTION|Control group|"In the control group, the participants take part in the training sessions, and the program is organized into two phases: (1) Initial assessment; (2) Final assessment.~1. The initial assessment will consist of physical fitness tests (lasting around 1 hour) and Neuropsychological Assessment tests (lasting around 1.5 hours).~2. The final assessment will be the same as the initial assessment (physical fitness tests (duration approx. 1h) and Neuropsychological Assessment tests (duration approx. 1.5h).~After completing the assessment, participants will be given the opportunity to do the exercise sessions."
62040326|NCT06253494|EXPERIMENTAL|Arm 1|AdHER2DC vaccine + pembrolizumab + de-escalating doses of lenvatinib
62434192|NCT05244824||Rheumatoid Arthritis|To translate the EDAQ, which determines the difficulties experienced by individuals with rheumatoid arthritis in daily life, into Turkish.
62820193|NCT02420717|EXPERIMENTAL|Phase 1|Patients Receive ruxolitinib Phosphate PO BID. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62820194|NCT04351711||Patients SARS-CoV-2 with respiratory failure|Patients in intensive care
62820195|NCT04351711||Patients SARS-CoV-2 without respiratory failure|Patients hospitalized in normal hospital wards
62820196|NCT04351711||HEALTHY VOLUNTEERS|HEALTHY VOLUNTEERS
62820197|NCT04351711||NON-COVID-19 PATIENTS|Patient hospitalized at the CHU of Nîmes for an infection by a virus other than SARS-CoV-2
62820198|NCT04351711||PAUCISYMPTOMATIC SARS-COV-2+ PATIENTS|Patient positive for SARS-CoV-2 by RT-PCR at the CHU of Nîmes and presenting at most moderate clinical signs without respiratory insufficiency (O2 saturation greater than or equal to 96%) during the confinement period
62820199|NCT04351711||convalescent patients|Additional 1-year follow-up visit
62040327|NCT06253494|EXPERIMENTAL|Arm 2|AdHER2DC vaccine + N-803 + pembrolizumab + RP2D of lenvatinib
62040328|NCT03064568|EXPERIMENTAL|Misoprostol 100Mcg Tab|Patients will receive misoprostol 400mcg per rectum 30 minutes preoperatively.
62040329|NCT03064568|PLACEBO_COMPARATOR|Placebo|Patients will receive identical inert tablets per rectum 30 minutes preoperatively.
62040330|NCT01832948|EXPERIMENTAL|Treatment|Endostar d1-d7 15mg/d Oxaliplatin 85 mg/m2 d6 Folinic acid 400 mg/m2 d6 5-FU 400 mg/m2 d6, and then 5-FU 2,400 mg/m2 INTRAVENOUS over 46 h
62040331|NCT06202287||stroke patient|The specified tests will be administered to 50 patients who have experienced strokes and meet the criteria.
62434193|NCT05926882|EXPERIMENTAL|Apremilast tablet|Patients will be given Oral Apremilast 30 mg twice daily after 05 days initial titration dose. The effect of treatment will be evaluated using photographs of the patients before and after the study and clinical evaluation of patients.
62820200|NCT05410743|EXPERIMENTAL|177Lu-LNC1010 1|The patients were intravenously injected with single dose 2.22GBq (60 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
62820201|NCT05410743|EXPERIMENTAL|177Lu-LNC1010 2|The patients were intravenously injected with single dose 3.33GBq (90 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
62820202|NCT05410743|EXPERIMENTAL|177Lu-LNC1010 3|The patients were intravenously injected with single dose 4.99 GBq (135mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
62040332|NCT04957537|OTHER|6 weeks phase A|"According to SCED methodology design :~Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 6 weeks (i.e. 18 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week."
62040333|NCT04957537|OTHER|8 weeks phase A|"According to SCED methodology design :~Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 8 weeks (i.e. 24 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week."
62040334|NCT06470165|EXPERIMENTAL|DLS patients undergoing correction surgery in reference to our novel criteria|Correcting deformity according to the priority-matching correction technique.
62040335|NCT06470165|OTHER|DLS patients undergoing correction surgery in reference to Obeid classification|Correcting deformity according to the standard proposed by Obeid and colleagues.
62243884|NCT05359991|EXPERIMENTAL|Children With Cystic Fibrosis (CF)|"Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in children with Children With Cystic Fibrosis (CF). Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur:~* The child will be in a fasted state.~* An IV will be placed into the child's arm.~* Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise."
62243885|NCT05739942|EXPERIMENTAL|[177Lu]Lu-NeoB in Combination with Radiotherapy (RT) and Temozolomide (TMZ)|In newly diagnosed glioblastoma
62243886|NCT05739942|EXPERIMENTAL|[177Lu]Lu-NeoB as Single Agent|In recurrent glioblastoma
62243887|NCT06191484|EXPERIMENTAL|WELL Behavioral Probe|Digital monitoring of sleep, meals, and social activity, for 3 months.
62243888|NCT04640961|EXPERIMENTAL|Cingal|Single injection of Cingal into the shoulder joint of subjects diagnosed with osteoarthritis of the shoulder.
62243889|NCT06734559|ACTIVE_COMPARATOR|ultrasound group|Apical periodontitis' is a general term used to describe the periapical inflammatory process that occurs in response to the presence of micro-organisms and other irritants within the root canal system of a tooth. The length and mass of the masseter muscle will be measured on the first and 28th day of root canal treatment in patients with acute apical periodontitis..
62243890|NCT06734559|SHAM_COMPARATOR|sham group|Masseter muscle length and weight will be measured on the first and 28th day.
62434194|NCT02092233||Blinded, Prospective Arm|The diagnostic accuracy for lesions from individuals suspected of having a herpes infection will be evaluated in prospectively collected, left-over de-identified, clinical specimens accrued between pre-defined dates.
62243891|NCT04134559|EXPERIMENTAL|Pembrolizumab|Pembrolizumab will be administered every 3 weeks at a dose of 2mg/kg/dose (max: 200mg) with 21 consecutive days defined as a treatment cycle.
62243892|NCT03272763|EXPERIMENTAL|F&P Toffee mask|Participants will be placed on this arm for a total of 14 ± 5 days from Visit two. Participants will be using the trial full-face mask during this treatment arm.
62243893|NCT02877212|EXPERIMENTAL|Study subjects|Steroid refractory ITP patients will be given Eltrombopag to investigate the association of treatment outcome with Fc Receptor polymorphism and THPO expression in responders and non responders following comparison correlation with ITP patients treated with standard IST as control group
62243894|NCT05843123|ACTIVE_COMPARATOR|Pressure control (PC)|In PC physicians set the inspiratory pressure and time, the respiratory rate and the PEEP while the ventilator measures tidal volume and the actual respiratory rate
62434195|NCT02092233||Blinded, Pre-selected Arm|For specimen types that are less common, banked, pre-selected, positive clinical specimens will be tested.
62434196|NCT02351973|ACTIVE_COMPARATOR|Hydrochlorthiazide|Hydrochlorothiazide (HCTZ) ATC class: C03AA03 Form: Tablet Dose range: Phase 1: 25mg (2 x 12.5mg tablet) Phase 2: 50mg (4 x 12.5mg tablet) Maximum allowed dose: 50mg Administration: oral
62434197|NCT02351973|ACTIVE_COMPARATOR|Amiloride|Amiloride ATC class: C03DB01 Form: Tablet Dose range: Phase 1: 10mg (2 x 5mg tablet) Phase 2: 20mg (4 x 5mg tablet) Maximum allowed dose: 20mg Administration: oral
62040336|NCT06064396|EXPERIMENTAL|Gong's Mobilization with Stecco Fascial Therapy|Participants in this group will receive Gong's Mobilization with Stecco Fascial Therapy
62040337|NCT06064396|ACTIVE_COMPARATOR|Gong's Mobilization|Participants in this group will receive Gong's Mobilization
62040338|NCT05845320||Obese|BMI\>30
62040339|NCT05845320||Non-obesse|BMI\<25
62040340|NCT03925077|ACTIVE_COMPARATOR|Movement to Music (M2M)|All M2M sessions are delivered using videos uploaded to a secure study website (the SCIPE website). Participants in M2M will have access to the website and attend three 60-minute M2M sessions per week for a total of 8 weeks. Each session provides rhythmic-based exercises that are choreographed to music to target range of motion, muscular strength, cardiorespiratory fitness, and balance. In addition, participants in M2M will receive and read weekly educational articles on health and fitness through the SCIPE website.
62040341|NCT03925077|ACTIVE_COMPARATOR|Standardised Exercise Training (SET)|All M2M sessions are delivered using videos uploaded to the SCIPE website. Participants in SET will have access to the website and attend three 60-minute SET sessions per week for a total of 8 weeks. Each session provides traditional exercises that target range of motion, muscular strength, cardiorespiratory fitness, and balance. In addition, participants in M2M will receive and read weekly educational articles on health and fitness through the SCIPE website.
62434198|NCT02351973|ACTIVE_COMPARATOR|Hydrochlorthiazide and Amiloride|Hydrochlorothiazide (HCTZ) + Amiloride Form: Tablets (separate tablet of each drug) Dose range: Phase 1: HCTZ 12.5mg (1 tablet) + Amiloride 5mg (1 tablet) Phase 2: HCTZ 25mg (2 x 12.5mg tablet) + Amiloride 10mg (2 x 5mg tablet) Maximum allowed dose: HCTZ 25mg/ Amiloride 10mg Administration: oral
62434199|NCT01963819|NO_INTERVENTION|Control|Standard treatment
62434200|NCT01963819|EXPERIMENTAL|Intervention|Endometrial biopsy before standard treatment
62040342|NCT03925077|NO_INTERVENTION|Attention Control (AC)|Participants in AC will not have access to any exercise videos. They will have access to the weekly educational articles on health and fitness, same as the ones received by the M2M and SET groups, through the SCIPE website.
62040343|NCT05229068|EXPERIMENTAL|Prior_RSV MAT Group|Maternal participants who received a single 120 µg dose of RSV MAT vaccine at Day 1 in RSV MAT-004 (NCT04126213), RSV MAT-009 (NCT04605159) or RSV MAT-012 (NCT04980391) parent studies, will receive a single dose of RSV MAT vaccine at Day 1 in the current study and are followed-up until the study end (Day 181 post-delivery).
62243895|NCT05843123|ACTIVE_COMPARATOR|Pressure regulated volume control (PRVC)|In PRVC physicians set a target tidal volume and the respiratory rate. An algorithm delivers pressure using a decelerating flow pattern to reach the target tidal volume based on the lung compliance measured during previous breaths.
62243896|NCT04534933|EXPERIMENTAL|FCV|Artificial ventilation will be performed with individualized flow-controlled ventilation (Evone, Ventinova Medical B.V., Eindhoven, the Netherlands) during thoracic surgery. Individualization will be established by compliance guided end-expiratory and peak pressure setting during two lung ventilation as well as one lung ventilation, flow setting will be adjusted to secure normocapnia during two lung ventilation and the targeted paCO2 during one lung ventilation is 40-60 mmHg, provided that pH \>7.2. The I:E ratio will be set to 1:1. The FiO2 will be set to achieve normoxia during two lung ventilation, increased to 100% before lung isolation and after 15 minutes of one-lung ventilation again decreased to secure normoxia or mild hyperoxia (target paO2 of 75-120 mmHg). No recruitment maneuver will be performed for re-inflation of the separated lung and after regain of spontaneous breathing tracheal extubation performed in the operating room.
62434201|NCT01562470|EXPERIMENTAL|herbal-based cellulite cream|Trial subjects will apply the treatment cream to one thigh and placebo to the other thigh, by random allocation.
62434202|NCT05995145|EXPERIMENTAL|Experimental group|The hamstring stretching exercises program will be conducted five times a week, 20 min per session, for 8 weeks. The exercises will be supervised by an experienced physiotherapist with five years of clinical experience. The intervention will be divided into two parts. The first part will include exercises with a massage foam roller. The second part will include exercises of active hamstring flexibility exercises with hip flexion mobilization and the development of the habit of correct hip flexion technique, protecting the lower spine.
62600518|NCT01741792|EXPERIMENTAL|Blinatumomab|By study design, two dose regimens were assessed in this study. In Stage 1, Cohort 1, participants received blinatumomab in a dose-escalating manner: 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during cycle 1. In Cohort 2, the next participants enrolled and received a constant dose of 112 µg/day blinatumomab. The dosing regimen with the more favorable benefit-risk profile was then selected for Stage 2, Cohort 3.
62600519|NCT00723190|EXPERIMENTAL|Arm A|CLONICEL (Clonidine HCl sustained release)
62820203|NCT05410743|EXPERIMENTAL|177Lu-LNC1010 4|Patients received a single, fixed dose of 177Lu-LNC1010 via intravenous injection, utilizing the well-tolerated and safe dose identified in Phase 1. They also underwent 68Ga-DOTA-TATE PET/CT scans both before and after the treatment to monitor their response.
62820204|NCT03457493|EXPERIMENTAL|Baseline Cohort Healthy Controls, DPA-714-PET/MRI|n-105
62820205|NCT03457493|EXPERIMENTAL|Baseline Cohort Early Parkinson's Disease, DPA-714-PET/MRI|n-100
62040344|NCT05229068|EXPERIMENTAL|Prior_Placebo Group|Maternal participants who received a single dose of placebo at Day 1 in RSV MAT-004 (NCT04126213), RSV MAT-009 (NCT04605159) or RSV MAT-012 (NCT04980391) parent studies or who did not participate in the parent studies and did not receive any RSV vaccine in the past\*, will receive a single dose of RSV MAT vaccine at Day 1 in the current study and are followed-up until the study end (Day 181 post-delivery). \*The unvaccinated participants are enrolled if the study cannot enroll sufficient numbers of the maternal participants who received placebo in the parent studies.
62040345|NCT02633826||kidney transplant recipients|kidney transplant recipients of an allograft from a living donor, no intervention
62040346|NCT06720662|ACTIVE_COMPARATOR|IPE Supplementation Group|Dietary Supplement: Icosapent Ethy capsules
62820206|NCT03457493|EXPERIMENTAL|UDALL 5-year Follow-up Cohort|n-67 from baseline early Parkinson's disease cohort
62820207|NCT03457493|EXPERIMENTAL|Metabolite Analysis Cohort|n-5 from baseline early Parkinson's disease cohort
62820208|NCT02346123||Single group|Group which contains all the patients of the study.
62040347|NCT06720662|PLACEBO_COMPARATOR|Placebo Group|Dietary Supplement: Corn oil Control
62820209|NCT03555422|EXPERIMENTAL|Selinexor|Participants will receive fixed dose of selinexor 80 mg (or 60 mg for participants with a body mass index \[BMI\] less than \[\<\] 20 kilogram per meter square \[kg/m\^2\]) oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.
62820210|NCT03555422|PLACEBO_COMPARATOR|Matching placebo for selinexor|Participants will receive matching placebo for selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.
62040348|NCT06221189|EXPERIMENTAL|ACT-CSP|Three sessions of acceptance and commitment therapy.
62040349|NCT06221189|NO_INTERVENTION|Usual Care|Usual treatment provided at the participating site.
62040350|NCT06723301|EXPERIMENTAL|Chatbot group|Use a specialized Chatbot designed to provide real-time guidance and support for ASD-related parenting challenges
62040351|NCT01696201|NO_INTERVENTION|Control group|Sedentary pregnant women
62040352|NCT01696201|EXPERIMENTAL|Exercise group|Exercise program
62040353|NCT06443268||Patients with ischemic / hemorrhagic stroke, transient ischemic attack, intracerebral hemorrhage|Patients with ischemic / hemorrhagic stroke, transient ischemic attack, intracerebral hemorrhage
62820211|NCT06590805|EXPERIMENTAL|Electroacupoint combined with postnatal care|Electroacupoint stimulation using the Electroacupoint device and postnatal care diet in form of balanced diet and drinking sufficient clean water and routine postnatal care.
62040354|NCT06443268||Caregivers of patients described above|Caregivers of patients with ischemic / hemorrhagic stroke, transient ischemic attack, intracerebral hemorrhage
62820212|NCT06590805|ACTIVE_COMPARATOR|postnatal care only|Postnatal care diet in form of balanced diet and drinking sufficient clean water and routine postnatal care.
62820213|NCT00129402|EXPERIMENTAL|Pooled subjects who received ezetimibe with simvastatin|Pooled subjects who received ezetimibe 10 mg plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg
62820214|NCT00129402|ACTIVE_COMPARATOR|Pooled subjects who received simvastatin monotherapy|Pooled subjects who received ezetimibe matching placebo plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg
62820215|NCT04156373|EXPERIMENTAL|Fuerte|This group will receive the Fuerte prevention program over the span of six to eight weeks.
62820216|NCT04156373|NO_INTERVENTION|Delayed waitlist control|This group will be the delayed waitlist control group. They will not receive the Fuerte prevention program until the following semester.
62434203|NCT05995145|NO_INTERVENTION|Control group|Participants assigned to the control group will receive an self-care recommendations book.
62820217|NCT03456128|EXPERIMENTAL|Intervention|The experimental group will receive CAPABLE services. These include ≤10 sessions: ≤ 6 with an Occupational Therapist (OT) and ≤ 4 sessions with a Registered Nurse (RN) and up to ≤ $1,500 of home safety and home modifications from a licensed handyman who is guided by the OT. The OT and RN sessions will target participants' self-identified functional goals (e.g., getting safely into the tub, getting upstairs to sleep in own bed).
62820218|NCT03456128|NO_INTERVENTION|Usual Care|Participants in the usual care group will not receive visit from study clinicians and will continue to receive their usual VNSNY CHOICE benefits and healthcare.
62434204|NCT01724398|EXPERIMENTAL|Conventional treatment|Participants will receive conventional treatment and then be followed until the week 48 study visit.
62820219|NCT06704256||Patients Undergoing Non-Oncologic and Neck surgery|Non-oncologic patients presenting for head and neck surgery with available neck CT scans.
62040355|NCT06443268||Patients WITHOUT ischemic / hemorrhagic stroke, transient ischemic attack, intracerebral hemorrhage|Patients WITHOUT ischemic / hemorrhagic stroke, transient ischemic attack, intracerebral hemorrhage or with an event \> 3 years ago AND no disability
62434205|NCT01724398|EXPERIMENTAL|Conventional plus UC-MSC treatment|Participants will receive conventional treatment plus a dose of UC-MSC and then be followed until the week 48 study visit.
62434206|NCT01724398|EXPERIMENTAL|Conventional plus PE treatment|Participants will receive conventional treatment plus plasma exchange and then be followed until the week 48 study visit.
62820220|NCT01149096|ACTIVE_COMPARATOR|Arm I (conventional bone marrow harvest)|Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
62040356|NCT06443268||Caregivers of patients above|may include close relatives
62040357|NCT05661734|EXPERIMENTAL|VX-548|Participants will receive VX-548 every 12 hours (q12h) up to 14 days.
62040358|NCT04981678|OTHER|Buprenorphine Dose Reduction|Patients instructed to reduce buprenorphine to 8mg prior to surgery
62040359|NCT04981678|OTHER|Buprenorphine Full Dose Continuation|Patients instructed to continue taking the full prescribed dose of buprenorphine.
62040360|NCT04733040|EXPERIMENTAL|MOR202 5 Doses|5 doses administered on Day 1, 8, 15, 29, and 57
62040361|NCT04733040|EXPERIMENTAL|MOR202 2 Doses|2 doses administered on Day 1 and 15
62820221|NCT01149096|EXPERIMENTAL|Arm II (filgrastim, bone marrow harvest)|Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
62820222|NCT06567145|EXPERIMENTAL|Narrative Enhancement and Cognitive Therapy (NECT)|Patients assigned to the experimental gropu will receive the Narrative Enhancement and Cognitive Therapy (NECT), a structured psychological intervention aimed at reducing self-stigma in individuals with severe mental illness. It was developed in early 2000s in the USA by Philip Yanos, David Roe and Paul Lysaker. Patients in the experimental group will also receive routine treatment typically provided within their usual care settings.
62040362|NCT01413568|EXPERIMENTAL|Donor (Phase I and Phase II)|"On Day 1 (and possibly Day 2) POL6326 IV Infusion with increasing dose levels in Phase I or with random dose assignment (from the 2 selected from Phase I) in phase II~Leukapheresis collection on Day 1 (and possibly Day 2)"
62040363|NCT01413568|EXPERIMENTAL|Recipient|Day 0 - PBSC transplant with stem cells mobilized with IV POL6326
62600520|NCT03861312|EXPERIMENTAL|Neck Laterality|It was done with 20 images of necks and 4 seconds for each image in the Vanilla program of the tablet application.
62820223|NCT06567145|NO_INTERVENTION|Control group|Patients in the control group will continue to receive the routine treatment typically provided within their usual care settings, which usually includes pharmacological treatment + outpatient visits (for monitoring pharmacological treatment and symptom management) + (if needed) other psychosocial treatments (e.g., individual or group therapy, family psychoeducation, cognitive rehabilitation, job placements/supported employment).
62600521|NCT03861312|EXPERIMENTAL|Foot Laterality|It was done with 20 images of feet and 4 seconds for each image in the Vanilla program of the tablet application.
62820224|NCT06039579|EXPERIMENTAL|Part 1a - Participants Receiving VH4004280 Dose 1|
62820225|NCT06039579|EXPERIMENTAL|Part 1a - Participants Receiving VH4004280 Dose 2|
62820226|NCT06039579|PLACEBO_COMPARATOR|Part 1a - Participants Receiving VH4004280 Matching Placebo|
62820227|NCT06039579|EXPERIMENTAL|Part 1b - Participants Receiving VH4011499 Dose 1|
62820228|NCT06039579|EXPERIMENTAL|Part 1b - Participants Receiving VH4011499 Dose 2|
62820229|NCT06039579|PLACEBO_COMPARATOR|Part 1b - Participants Receiving VH4011499 Matching Placebo|
62820230|NCT06039579|EXPERIMENTAL|Part 2a - Participants Receiving VH4004280 Dose 3|
62820231|NCT06039579|PLACEBO_COMPARATOR|Part 2a - Participants Receiving VH4004280 Matching Placebo|
62820232|NCT06039579|EXPERIMENTAL|Part 2b - Participants Receiving VH4011499 Dose 3|
62820233|NCT06039579|PLACEBO_COMPARATOR|Part 2b - Participants Receiving VH4011499 Matching Placebo|
62820234|NCT02173080||Polycystic liver disease patients|will receive PLD-Q, EORTC QLQ-30 symptoms subscale, EQ5D-VAS score and SF36
62820235|NCT02173080||ADPKD group without PLD|will receive PLD-Q
62820236|NCT02173080||Healthy controls|receive PLD-Q
62820237|NCT02173080||PLD patient focus group|to discuss and improve PLD-Q
62820238|NCT02173080||PLD clinical expert focus group|to discuss and improve PLD-Q
62820239|NCT05031520||Intervention group|Participants will be identified by review of the cardiac catheterization laboratory schedule each day by the principal investigator, a co-investigator, or a research coordinator. Participants with no obstructive CAD and completed microvascular testing will undergo a research CCTA.
62820240|NCT06336005|EXPERIMENTAL|NNC6022-0001|Participants will be randomised to NNC6022-0001.
62820241|NCT06336005|PLACEBO_COMPARATOR|Placebo (NNC6022-0001)|Participants will be randomised to placebo.
62820242|NCT05502562||Participants with type 2 diabetes|Adult participants with type 2 diabetes and naive to injectable glucose-lowering treatment.
62820243|NCT02300792|ACTIVE_COMPARATOR|honey|Each patient in the honey group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
62820244|NCT02300792|PLACEBO_COMPARATOR|molasses|Each patient in the molasses (placebo) group (group 1) took molasses in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
62820245|NCT06704165|EXPERIMENTAL|Evaluate the possible apical root resorption by double slot bracket withwire in high level slot.|Control group : patients will receive a conventional therapy with Double slot bracket with the wire in high level for the treatment of anterior deep bite .
62820246|NCT06704165|EXPERIMENTAL|Evaluate the possible apical root resorption by double slot bracket with wire in low level slot.|investigational group will receives the new treatment therapy by using Double slot bracket with the wire in low level for the treatment of anterior deep bite .
62820247|NCT05813574||COVID-19 survivors|COVID-19 survivors: patients (≥18 years old) who were tested positive for SARS-CoV-2 infection as confirmed by polymerase-chain-reaction (PCR) testing and were subsequently hospitalised, were followed after discharge from hospitals in Enschede (MST), Hengelo or Almelo (ZGT).
62820248|NCT00810823||1:Gastric bypass/diabetes|Patients undergoing gastric bypass surgery, and who are diagnosed with type 2 diabetes.
62040364|NCT04376138|EXPERIMENTAL|Motor Imagery|A Brain-Computer Interaction (BCI) based intervention while receiving conventional therapy. Use of motor imagery training, allied with brain-computer interaction, as a solution to promote motor and cognitive gains in stroke survivors.
62040365|NCT04376138|ACTIVE_COMPARATOR|Conventional Therapy|Extra Occupational Therapy sessions while receiving conventional therapy. Use of conventional therapy techniques and tools for motor rehabilitation, following the original therapeutic intervention plan of the participants.
62040366|NCT04728529|EXPERIMENTAL|USSM protocol|patient in the intervention group receive fluid resuscitation and inotropic-vasoactive agent, if needed, in accordance to USSM protocol of fluid resuscitation.
62623825|NCT00293800|ACTIVE_COMPARATOR|Xalatan + Timolol 0.5%|One drop Timolol 0.5% in the study eye(s) each morning at 8 a.m. and one drop Xalatan in the study eye(s) each evening at 8 p.m. for 3 months
62040367|NCT04728529|EXPERIMENTAL|ACCM protocol|patient in the control group receive fluid resuscitation and inotropic-vasoactive agent, if needed, in accordance to ACCM protocol of fluid resuscitation.
62243897|NCT04534933|ACTIVE_COMPARATOR|PCV|Artificial ventilation will be performed with pressure-controlled ventilation (Primus, Dräger, Lübeck, Germany) during thoracic surgery. Peak pressure will be set to achieve a tidal volume of 6-8 ml/kg predicted body weight (PBW) at a compliance titrated positive end-expiratory pressure during two lung ventilation and the tidal volume will be reduced to 4-6 ml/kg PBW during one lung ventilation. Respiratory rate will be set to maintain normocapnia during two lung ventilation and a targeted paCO2 level during one lung ventilation of 40-60 mmHg, provided that pH \> 7.2. The I:E ratio will be set to 1:1.5 except extension of expiration is necessary in order to avoid air trapping. The FiO2 will be set to achieve normoxia during two lung ventilation, increased to 100% before lung isolation until 15 minutes of one lung ventilation and decreased thereafter to achieve a targeted paO2 level of 75-120 mmHg. For re-inflation a manual recruitment maneuver will be performed under surgical guidance.
62243898|NCT05342181|EXPERIMENTAL|Static exercises|static exercises i.e traditional exercises along with base line treatment of TENS and hot pack
62243899|NCT05342181|EXPERIMENTAL|Dynamic exercises|dynamic (Swiss ball) exercises along with base line treatment of TENS and hot pack
62600522|NCT01820507|EXPERIMENTAL|High Flow Conditioned Oxygen Therapy|Intervention: The Optiflow(R) device supplies oxygen in controlled concentrations and at high flow (from 10 to 70 liters/min) through special nasal cannulae. The device also humidifies the gases mixtures up to 100% relative humidity.
62820249|NCT00810823||2:Gastric bypass/not Diabetic|Patients undergoing gastric bypass surgery, not diagnosed with diabetes.
62243900|NCT02251925|EXPERIMENTAL|Natural cycle|In natural cycle without hCG, daily monitoring of urinary LH is started from day eight of the cycle and frozen-thawed embryo transfer is planned 3-5 days after detection of LH surge, observing mature follicles in ultrasound and endometrial thickness over 7mm for cleavage embryos.
62243901|NCT02251925|EXPERIMENTAL|Natural cycle + hCG for ovulation induction|In natural cycle with hCG, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000IU hCG is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage.
62434207|NCT01724398|EXPERIMENTAL|Conventional plus UC-MSC and PE therapy|Participants will receive conventional treatment plus umbilical cord mesenchymal stem cells transplantation combined with plasma exchange. Participants will then be followed until the week 48 study visit.
62434208|NCT03457025|ACTIVE_COMPARATOR|Standard of Care Therapy|Reference Therapy
62434209|NCT03457025|EXPERIMENTAL|Standard of Care + HOTB|Reference therapy in addition to Hyperbaric Oxygen Therapy
62820250|NCT06594380|EXPERIMENTAL|Using a new oropharyngeal airway set|In the new oropharyngeal airway group (experimental group), oxygen was continuously supplied through a catheter partially attached to the endoscopic bite before induction of anesthesia until the end of gastroenteroscopy
62820251|NCT06594380|ACTIVE_COMPARATOR|The conventional endoscopic bite group was used|In the conventional endoscopic bite group (control group), oxygen was continuously supplied through a conventional nasal catheter before induction of anesthesia and until the end of gastroenteroscopy
62820252|NCT04964362||Individuals with Spinal Cord Injury|Individuals with recent spinal cord injuries, both veterans and civilians, will be followed for 1 year for inquiry into injustice appraisals.
62820253|NCT02832258||Children with urinary tract infection due to E-ESBL|In this prospective observational study between March 2013 and March 2017, children (0 to 18 years) with E-ESBL UTI (febrile UTI or cystitis) were enrolled in 24 pediatric departments in France. Clinical and biological characteristics, risk factors of infection of E-ESBL, first and second lines of antibiotic therapies were analyzed. We used the Kaplan-Meier method to estimate the time to apyrexia and length of hospital stay, and Log-rank test to assess equality of survivor functions. We also analyzed the resistance patterns and molecular characterization of ESBL types in the isolates.
62820254|NCT06424236|EXPERIMENTAL|Gantenerumab Open Label Extension|Gantenerumab: Subcutaneously every 4 weeks, at escalating doses
62820255|NCT06099184|EXPERIMENTAL|EYP-1901 1343 µg|EYP-1901 1343 µg, single dose
62820256|NCT06099184|EXPERIMENTAL|EYP-1901 2686 µg|EYP-1901 2686 µg, single dose
62820257|NCT06099184|ACTIVE_COMPARATOR|Aflibercept|Aflibercept 2 mg/0.05mL solution, single dose
62040368|NCT01361503||Autism Spectrum Disorder (ASD)|
62434210|NCT02390219|EXPERIMENTAL|Lumacaftor/Ivacaftor combination|Lumacaftor 400 milligram (mg) and ivacaftor 250 mg combination tablet orally twice daily for 24 weeks.
62434211|NCT03648333|EXPERIMENTAL|Lodivixx tab. 5/160mg|S-amlodipine nicotinate (5mg as S-amlodipine), valsartan 160mg
62434212|NCT03648333|ACTIVE_COMPARATOR|Exforge tab. 10/160mg|amlodipine besylate (10mg as amlodipine), valsartan 160mg
62434213|NCT02012179|EXPERIMENTAL|Low sodium diet|Low sodium diet (65 mmol or 1500 mg/day)
62434214|NCT02012179|NO_INTERVENTION|Usual Care|General advice to limit dietary sodium as it is provided during routine clinic practice
62434215|NCT05354531|EXPERIMENTAL|INFIX group|Those group of cases will be managed by INFIX for their pelvic ring disruption
62434216|NCT03306602|EXPERIMENTAL|Bulk Fill Composite|In the experimental cavity, Filtek Bulk Fill Posterior Restorative (3M ESPE) will be placed in 5 mm increments, eliminating the need for additional layers or multiple steps.
62600523|NCT01820507|ACTIVE_COMPARATOR|Standard Oxygen Therapy|The standard way of oxygen supply after extubation is either by nasal cannulae at flow between 1 and 5 liters/min or by mask with controlled oxygen concentration from 24% to 50%.
62040369|NCT01361503||Controls|
62243902|NCT02251925|EXPERIMENTAL|Hormonally controlled cycle with GnRH-a|In this group , injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.
62820258|NCT04335253|EXPERIMENTAL|Multiple Ascending Dose|Dose escalation according to cohort allocation
62820259|NCT06280924|ACTIVE_COMPARATOR|Standard Care|Participants in this group will receive exercise counseling as per standard care for 10-weeks. This will include: (1) counseling on remaining active during chemotherapy; (2) handouts on the benefits of exercise during chemotherapy, exercise behavior change strategies, and how to exercise safely. Participants will be encouraged to remain as physical active as possible. As per American College of Sports Medicine 2019 guidelines, participants will be advised to take part in moderate intensity exercise for a total of 90 minutes per week.
62820260|NCT06280924|EXPERIMENTAL|Supported Exercise Group|Participants assigned to the exercise group will take part in a 10-week exercise program delivered in-person and through the HEAL-ME app. The program comprises (1) a minimum of one supervised session (in-person or virtual through a Zoom platform embedded in HEAL-ME), (2) a minimum of one independent exercise workout within the HEAL-ME app, and (3) exercise specific education content as per standard care.
62820261|NCT06184529|EXPERIMENTAL|Virtual Reality Group|Participants in this group will receive the virtual reality simulation for up to 6 weeks.
62820262|NCT05068752|EXPERIMENTAL|Vemurafenib in Combination with Sorafenib|
62820263|NCT00965354||Influenza diagnosis|Patients admitted to hospital with a suspected or confirmed influenza diagnosis on admission
62820264|NCT03204188|EXPERIMENTAL|Ibrutinib, Fludarabine, and Pembrolizumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Ibrutinib, Fludarabine, and Pembrolizumab combination therapy will be administered in participants with High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Ibrutinib will be administered daily by mouth starting cycle -3 at 420 mg until end study or disease progression or intolerable side effects occur. Fludarabine will be administered intravenously only on cycle -2 at 25mg/m\^2 x5 days. Pembrolizumab will be administered intravenously every 3 weeks at 200 mg starting from cycle 1 through cycle 17 or 1 year of immunotherapy phase.
62820265|NCT06357247|EXPERIMENTAL|Feasibility Arm|Wearing a stochastic resonance device at home in chronic stroke patients (six months or more post stroke).
62820266|NCT06345313|ACTIVE_COMPARATOR|Day Group|Participants who underwent inguinal herniography operation between 08.00-12.00
62040370|NCT04269499|OTHER|Study patients|All patients receive holmium radioembolization as per usual
62040371|NCT05680272|EXPERIMENTAL|extrimental group|The experimental group will be given training on empathetic communication and the positive birth perception awareness scale will be applied to the experimental group.
62243903|NCT02251925|EXPERIMENTAL|Hormonally controlled cycle without GnRH-a|In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
62040372|NCT05680272|NO_INTERVENTION|control group|No intervention will be made in the control group.
62040373|NCT05318287|EXPERIMENTAL|PeriGrief|A brief four-module intervention delivered via computer or mobile device. Modules utilize mindfulness and cognitive behavioral therapy strategies to reduce distress following perinatal loss.
62040374|NCT03136445|EXPERIMENTAL|Intervention Arm|Tranexamic acid (TXA). Dose schedule TXA 1g every eight hours IV or 1.5g every eight hours PO.
62040375|NCT03136445|PLACEBO_COMPARATOR|Control Arm|Placebo (saline) if administration is IV. Placebo tablet matched for appearance to TXA if oral.
62040376|NCT04556578|EXPERIMENTAL|High-flow ECCO2R|Extracorporeal support using high flow circulation
62040377|NCT01358695|PLACEBO_COMPARATOR|Placebo Comparator|
62040378|NCT01358695|EXPERIMENTAL|Dose 1|Dose 1
62040379|NCT01358695|EXPERIMENTAL|Dose 2|Dose 2
62040380|NCT01358695|EXPERIMENTAL|Dose 3|Dose 3
62040381|NCT01358695|EXPERIMENTAL|Dose 4|Dose 4
62623826|NCT00282685|EXPERIMENTAL|Intra-arterial stemcell therapy|Patients were treated with intra-arterial stemcells delivered via catheter examination
62820267|NCT06345313|ACTIVE_COMPARATOR|Night Group|Participants who underwent inguinal herniography operation between 18.00-22.00
62820268|NCT00619034|EXPERIMENTAL|latanoprost|Medical intervention cross-over
62820269|NCT00619034|ACTIVE_COMPARATOR|diclofenac|medical intervention
62820270|NCT00619034|EXPERIMENTAL|dorzolamide|dorzolamide eyedrops twice daily in one week
62820271|NCT03868423|EXPERIMENTAL|Treatment (brigatinib)|Patients receive brigatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62820272|NCT05088876|ACTIVE_COMPARATOR|Paracetamol|
62820273|NCT05088876|PLACEBO_COMPARATOR|Placebo|
62820274|NCT06521749|ACTIVE_COMPARATOR|the Bougie group (group A)|Endotracheal intubation will be attempted using the video laryngoscope and the USB device will be used as a bougie.
62820275|NCT06521749|ACTIVE_COMPARATOR|the stylet group ( B group)|Endotracheal intubation will be attempted using the video laryngoscope and using the USB device as a stylet.
62820276|NCT06521749|NO_INTERVENTION|the control group (C group)|Intubation of the trachea with an endotracheal tube will be attempted by using only the video laryngoscopy.
62820277|NCT02968134|OTHER|Posaconazole|The study will enrol eight patients with presumed or confirmed systemic fungal infections, who are admitted to ICU
62820278|NCT06594965|EXPERIMENTAL|HS-20106 Cohort 1|Part A: Non-transfusion dependent population
62820279|NCT06594965|EXPERIMENTAL|HS-20106 Cohort 2|Part A: Transfusion-Dependent Population（low-transfusion burden (LTB) and high-transfusion burden (HTB)）
62820280|NCT01282034|ACTIVE_COMPARATOR|Marrow stimulation|
62820281|NCT01282034|EXPERIMENTAL|Medical device: MaioRegen|
62820282|NCT03587506||Patients: group|Group I (n=10) included patients who did not develop any major or minor seizure during the follow-up period and their follow up EEG was free of any epileptiform discharge
62820283|NCT03587506||Patients: group II|Group II (n=11) included patients who developed only minor seizures and their follow up EEG showed epileptiform discharge
62820284|NCT03587506||Patients: group III|Group III (n=9) were patients who developed one or more major seizures during the follow-up period whatever their EEG findings.
62820285|NCT03587506||Controls|healthy volunteers (n=30) who were not related to the patients and had no family history of epilepsy.
62820286|NCT06600022|EXPERIMENTAL|Arms|SCTB41 of different doses,IV,every 3 weeks
62820287|NCT03541083|EXPERIMENTAL|Blinatumomab|After a 5-day steroid prephase patients will receive two weeks continuous infusion of blinatumomab. Then the first remission-induction course will be given after one week interruption. Subsequent therapy with 4 cycles of chemotherapy and two 4-week courses of blinatumomab will follow, and subsequently depending on risk group, eligibility and a suitable donor either allogeneic stem cell transplantation or 2 year maintenance treatment.
62820288|NCT03729453||Intraoperative Pancreatoscopy|All subjects will undergo the intraoperative pancreatoscopy with SpyGlass procedure.
62820289|NCT04084158|EXPERIMENTAL|Toripalimab+chemoradiation|"Induction immunotherapy: Toripalimab injection (JS001) 3mg/kg IV q 14 days x 2 cycles.~Concurrent Chemoradiotherapy: Starting within 4 weeks after the first cycle induction immunotherapy. carboplatin AUC = 2 + albumin-bound paclitaxel 60 mg/m2 or paclitaxel liposome 45 mg/m2 or paclitaxel 45 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 50.4 Gy given in 1.8 Gy fractions daily x 28 fractions.~Progression of disease (PD): The progress of the disease will be assessed within 4 weeks after concurrent chemoradiotherapy. Patients without disease progression continue to receive consolidation and adjuvant therapy.~Consolidation chemotherapy: carboplatin AUC = 6 + albumin-bound paclitaxel 260 mg/m2 or paclitaxel liposome 135 mg/m2 or paclitaxel 135 mg/m2 IV q 21 days x 6 cycles.~Adjuvant immunotherapy:Toripalimab injection (JS001) 3mg/kg IV q 14 days up to 1 year."
62820290|NCT04084158|ACTIVE_COMPARATOR|chemoradiation|"Concurrent Chemoradiotherapy: carboplatin AUC = 2 + albumin-bound paclitaxel 60 mg/m2 or Liposome paclitaxel 45 mg/m2 or paclitaxel 45 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 50.4 Gy given in 1.8 Gy fractions daily x 28 fractions.~Progression of disease (PD): The progress of the disease will be assessed within 4 weeks after concurrent chemoradiotherapy. Patients without disease progression continue to receive consolidation therapy.~Consolidation chemotherapy: carboplatin AUC = 6 + albumin-bound paclitaxel 260 mg/m2 or paclitaxel liposome 135 mg/m2 or paclitaxel 135 mg/m2 IV q 21 days x 6 cycles."
62820291|NCT04408989|EXPERIMENTAL|MB02-SP (Bevacizumab Biosimilar)|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
62820292|NCT04408989|EXPERIMENTAL|MB02-DM (Bevacizumab Biosimilar)|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
62820293|NCT04408989|ACTIVE_COMPARATOR|US licenced Avastin®|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
62820294|NCT03178214|EXPERIMENTAL|Infacort - Yoghurt|One single 5mg dose of Infacort will be sprinkled onto 5mL of yoghurt and swallowed within three minutes. This will be taken with 240mL of water.
62040382|NCT01358695|EXPERIMENTAL|Dose 5|Dose 5
62040383|NCT04907708|NO_INTERVENTION|Normal healthy controls|females in second trimester with normal glucose levels
62040384|NCT04907708|NO_INTERVENTION|Diet controlled|females in second trimester with blood sugar levels below 129mg/dl
62040385|NCT04907708|EXPERIMENTAL|Metformin|females in second trimester with blood sugar levels above 130mg/dl treated with Metformin
62040386|NCT04907708|EXPERIMENTAL|Insulin|females in second trimester with blood sugar levels above 130mg/dl being treated with Insulin
62820295|NCT03178214|EXPERIMENTAL|Infacort - Soft Food|One single 5mg dose of Infacort will be sprinkled onto 5mL of soft food (such as applesauce) and swallowed within three minutes. This will be taken with 240mL of water.
62820296|NCT03178214|ACTIVE_COMPARATOR|Infacort - Dry Granules|One single 5mg dose of Infacort will be administered as dry granules to the back of the tongue and swallowed. This will be taken with 240mL of water.
62820297|NCT05177965||Shift workers|Measurements repeated during a series of day shifts and during a series of night shifts
62820298|NCT02784080||HLA-alloantibodies exposure|Preformed, persistent, and de novo HLA-alloantibody exposure in the whole cohort.
62820299|NCT05699408|EXPERIMENTAL|INS068 injection|
62820300|NCT05699408|ACTIVE_COMPARATOR|Insulin Glargine|
62040387|NCT04891419|EXPERIMENTAL|JUVÉDERM® VOLUMA® with Lidocaine|Participants will be treated with JUVÉDERM® VOLUMA® with Lidocaine injectable gel in temple. Participants are eligible for touch up treatment
62040388|NCT04891419|NO_INTERVENTION|Control- No treatment|No treatment is administered. Optional treatment at month 6.
62040389|NCT01937052||Breast cancer patients|All patients planned to initiate hormonal therapy with either Tamoxifen, Raloxifene (Evista®), Anastrozole (Arimidex®), Letrozole (Femara®) or Exemestane (Aromasin®) are eligible to participate in sample collection and data for patient-reported outcomes/questionnaires.
62040390|NCT06722170|EXPERIMENTAL|Dose escalation - Low dose group|
62040391|NCT06722170|EXPERIMENTAL|Dose escalation - Medium dose group|
62040392|NCT06722170|EXPERIMENTAL|Dose escalation - High dose group|
62040393|NCT06597487|ACTIVE_COMPARATOR|Root Canal Treatment|The patients allocated to this arm will receive conventional root canal treatment. They will be followed up for 1, 3 and 6 months to assess clinical and radiographic success.
62040394|NCT06597487|EXPERIMENTAL|Full Pulpotomy|The patients allocated to this arm will receive full pulpotomy. They will be followed up for 1, 3 and 6 months to assess clinical and radiographic success.
62040395|NCT06542536|EXPERIMENTAL|Monlunabant dose 1|Dose 1 of monlunabant treatment
62040396|NCT06542536|EXPERIMENTAL|Monlunabant dose 2|Dose 2 of monlunabant treatment
62040397|NCT06542536|EXPERIMENTAL|Monlunabant dose 3|Dose 3 of the monlunabant treatment
62040398|NCT06542536|PLACEBO_COMPARATOR|Placebo (monlunabant)|Placebo treatment
62040399|NCT00695643|EXPERIMENTAL|A|
62040400|NCT00695643|PLACEBO_COMPARATOR|B|
62434217|NCT03306602|ACTIVE_COMPARATOR|Layered Composite|The control restoration will be filled with Filtek Z350 XT (3M ESPE) using the 2 mm incremental layering technique.
62820301|NCT06592469||Fresh cases|Outcome of URS in fresh stone ureter
62040401|NCT02855931|EXPERIMENTAL|Middle turbinate resection|Resection of one middle turbinate
62040402|NCT02855931|NO_INTERVENTION|Middle turbinate preservation|Preservation of one middle turbinate
62040403|NCT01689064|ACTIVE_COMPARATOR|Posterior Septectomy|Patient will be randomized to a study arm. The patient will be blinded to the approach. The surgeon will have performed at least 10 procedures previous for each approach. The surgeon will maintain the following surgical practives: preservation of both middle turbinates, preservation of one superior turbinate (to minimize olfactory injury), elevation of a nasoseptal flap, the use of a combination of gelform, surgicel and nasapore dissolvable spacer placed within the surgical defect. These practices are all standard of care. Patient will start Neilmed high volume low pressure saline irrigation three times daily starting on post operative day five. Patients will receive prophylactic antibiotics for fourteen days post operatively.
62040404|NCT01689064|EXPERIMENTAL|Stamm Approach|Patient will be randomized a study arm. The patient will be blinded to the approach. The surgeon will have performed at least 10 procedures previous for each approach. The surgeon will maintain the following surgical practives: preservation of both middle turbinates, preservation of one superior turbinate (to minimize olfactory injury), elevation of a nasoseptal flap, the use of a combination of gelform, surgicel and nasapore dissolvable spacer placed within the surgical defect. These practices are all standard of care. Patient will start Neilmed high volume low pressure saline irrigation three times daily starting on post operative day five. Patients will receive prophylactic antibiotics for fourteen days post operatively.
62040405|NCT04715568|EXPERIMENTAL|Placebo then Losartan|Placebo tablets will be administered for the first 4 weeks followed by a washout period of 2 weeks. After the washout period has been completed, losartan tablets will be administered for the next 4 weeks.
62040406|NCT04715568|EXPERIMENTAL|Losartan then Placebo|Losartan tablets will be administered for the first 4 weeks followed by a washout period of 2 weeks. After the washout period has been completed, placebo tablets will be administered for the next 4 weeks.
62243904|NCT01365585||Sildenafil ≥20mg three times daily|Subjects receiving sildenafil ≥20mg three times daily for the treatment of PAH
62040407|NCT04861987|EXPERIMENTAL|PCS6422 + Capecitabine|Fixed dose of PCS6422 combined with various doses of Capecitabine administered in 14 day cycles
62040408|NCT05506787|EXPERIMENTAL|Esketamine Group|The patients in S-ketamine group received 0.25 mg/kg intravenous S-ketamine (Jiangsu Hengrui Pharmaceutical Co., Ltd., Jiangsu, China) drip under general anesthesia induction, followed by continuous infusion of S-ketamine with 0.12 mg/kg/h for more than 30 minutes through target-controlled infusion. Drug A: S-ketamine, diluted to 1mg/ml with normal saline, total 50ml).
62040409|NCT05506787|PLACEBO_COMPARATOR|Placebo Group|Patients in Placebo group received intravenous infusion of 0.9% saline during anesthesia induction and were maintained through the infusion pump of drug B (50 ml 0.9% saline) for more than 30 minutes.
62040410|NCT05082038|OTHER|Group IF|Two Tapered IF implants will be installed in one side of the mandible
62243905|NCT03225131||0|participants without AMD meaning no large drusen (= 125 microns) or advanced AMD in either eye
62243906|NCT03225131||1|participants with large drusen (= 125 microns) in the study eye and no large drusen or advanced AMD (choroidal neovascularization (CNV) or geographic atrophy (GA)) in the fellow eye
62243907|NCT03225131||2|participants with bilateral large drusen (= 125 microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes
62243908|NCT03225131||3|participants with large drusen (= 125 microns) in the study eye and advanced AMD (CNV or GA) in the fellow eye
62243909|NCT03225131||4|participants with findings of reticular pseudodrusen (RPD) in the study eye, without advanced AMD in the study eye, and any level of AMD in the fellow eye
62243910|NCT06003192|OTHER|Universal Opt-out HIV Screening|The intervention is offering universal opt-out HIV screening to all adolescents 15 to 21 years of age that are seeking care in the emergency department.
62243911|NCT04174755|EXPERIMENTAL|Semaglutide 0.25/0.5/1 mg plus standard of care|
62243912|NCT04174755|OTHER|Standard of care alone|
62243913|NCT01965639|EXPERIMENTAL|High Risk group|Extension of Care
62820302|NCT06592469||Recurrent cases|Outcome of URS in recurrent cases of stone ureter post ESWL ,URS , open surgery
62243914|NCT04975256|EXPERIMENTAL|Dose escalation|Dose escalation of MRTX849 and BI 1701963 to determine maximum tolerated dose in combination
62243915|NCT04975256|EXPERIMENTAL|Dose expansion|Expansion cohorts in NSCLC and CRC patients to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with BI 1701963
62243916|NCT05697731||obese|Vidiac score Mallampati score upper lip bite test Thyromental distance Mandible ramus length Mouth opening distance
62434218|NCT01864720|ACTIVE_COMPARATOR|Professionally Administered CBT-I (Standard Care)|Patients (n = 59) assigned to this group will receive 6 weekly sessions of cognitive-behavioral therapy for insomnia (CBT-I) of approximately 50 minutes, offered individually by a licensed psychologist with significant experience (at least 2 years) in the administration of CBT-I with cancer patients.
62434219|NCT01864720|EXPERIMENTAL|Stepped Care CBT-I|Patients having an ISI score \> 7 but \< 15 (n = 65), will all receive first a web-based CBT-I for six weeks. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). Patients with an ISI score \> 14 (n = 53) will receive six weekly sessions of CBT-I administered individually by a professional.
62434220|NCT02094937|EXPERIMENTAL|Arm 1 FF/VI 100/25 mcg|Subjects will receive Fluticasone Furoate/Vilanterol 100/25 mcg once-daily via a dry powder inhaler for 8 weeks in the open-label treatment period.
62434221|NCT02094937|EXPERIMENTAL|Arm 2 FF 100 mcg|Subjects will receive Fluticasone Propionate matching placebo twice-daily (morning and evening) and Fluticasone Furoate 100 mcg once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
62434222|NCT02094937|EXPERIMENTAL|Arm 3 FP 250 mcg|Subjects will receive Fluticasone Propionate 250 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
62623827|NCT05772611||Antibody characterized|Patients with well-characterized antibody (HU, YO, RI, CASPR2, NMDAr, GAD, ...)
62820303|NCT05975255|EXPERIMENTAL|Study group|Remimazolam administration and evaluation of sedative effect
62040411|NCT05082038|OTHER|Group CF|Two Tapered IF implants will be installed in the other side of the mandible
62243917|NCT05697731||non-obese|Vidiac score Mallampati score upper lip bite test Thyromental distance Mandible ramus length Mouth opening distance
62243918|NCT04307381|EXPERIMENTAL|Donidalorsen|Participants will be administered donidalorsen SC for up to 53 weeks. Participants will also be administered donidalorsen in the extended treatment period for an additional 156 weeks, up to week 209.
62243919|NCT05675579|EXPERIMENTAL|Sacituzumab Govitecan and Pembrolizumab|"Participants will receive drug on Days 1 and 8 of Cycles 1-4, Participants will receive sacituzumab govitecan by vein.~Participants will receive drug on Days 1, 8, and 15 of each cycle, Participants will receive pembrolizumab by vein."
62243920|NCT04752293||Hypertension Cohort|Participants with newly diagnosed primary hypertension
62243921|NCT04752293||Control Cohort|Healthy participants with normal blood pressure
62434223|NCT02094937|EXPERIMENTAL|Arm 4 FP 100 mcg|Subjects will receive Fluticasone Propionate 100 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
62434224|NCT05692752||Test Group|"The study group included 10 patients,~1. men and women~2. between age of 35-60 year~3. chest pain lasting for at least 30 minutes,~4. electrocardiogram (ECG) finding that display ST-segment elevation (STEMI)"
62623828|NCT05772611||Atypical|Patients with atypical antibody
62623829|NCT05772611||Without antibody|Patients without antibody
62820304|NCT06601530|EXPERIMENTAL|Transversus Thoracic Muscle Plane Block Group|Transversus thoracic muscle plane block is a single-shot nerve block technique that provides analgesia for the anterior chest wall
62820305|NCT06601530|ACTIVE_COMPARATOR|Control Group|
62820306|NCT04717635|EXPERIMENTAL|Canakinumab|All participants receive canakinumab (ACZ885) as open-label study medication. Participants are administered canakinumab 4 mg/kg every 4 weeks. The maximal total single dose of canakinumab allowed is 300 mg.
62040412|NCT02626780|EXPERIMENTAL|SVF Injection|Liposuction of a small amount of adipose tissue will be taken from each subject. Stromal Vascular Fraction (SVF) will be disassociated within the GID SVF-2 from the autologous adipose tissue to be injected into a small (approximately 2x2cm) area of the scalp in men or women with androgenic alopecia.
62040413|NCT06733948|EXPERIMENTAL|Arm 1|Radiotherapy with dental stent +/- Concurrent systemic therapy
62820307|NCT03715556|ACTIVE_COMPARATOR|Amiodarone|Amiodarone (5 mg / kg EV in 30 minutes) will be the drug of choice in the Restricted group blinded to the principal investigator. If there is no reversal / control and there is no adverse event, a further dose of the same previously administered medicinal product will be performed within 30 minutes, amiodarone 3 mg / kg. After the second dose, continuous infusion of amiodarone at a dose of 900 mg in 24 hours will be initiated. Administration of the drug will be blinded within the first hour to the principal investigator.
62600524|NCT06073275|EXPERIMENTAL|Beetroot juice intake|Beetroot juice was administered 3 h before the start of the rowing ergometer test since the peak of nitrite in the blood occurs 2-3 h after nitrate ingestion. Beetroot juice was provided in a 140 mL maroon plastic bottle with no label. Participants were provided with a randomized bottle containing 140 mL (\~12.8 mmol, \~808 mg of nitrate) of BRJ Beet-It-Pro Elite Shot concentrate (Beet IT; James White Drinks Ltd., Ipswich, UK).
62600525|NCT06073275|PLACEBO_COMPARATOR|Placebo intake|Placebo was administered 3 h before the start of the rowing ergometer test. Placebo was provided in a 140 mL maroon plastic bottle with no label. Participants were provided with a randomized bottle containing 140 mL. The placebo drink was made by dissolving in 1 liter of water 2g of powdered SUPER BEETROOT (\~ 0.01 mmol, 0.620 mg of nitrate, diet, food, Poland), 100% natural beetroot juice and organic label, and adding lemon juice to imitate the flavor and texture of the beetroot juice drink
62820308|NCT03715556|PLACEBO_COMPARATOR|No intervention|The Liberal group will receive only 0.9% physiological solution, also blinded to the principal investigator.
62820309|NCT06177483|ACTIVE_COMPARATOR|95% curcumin extract powder|1,265 mg of 95% curcumin extract (minimum 1,200 mg of curcuminoids) in three #0 vegetarian capsules as a single oral dose
62820310|NCT06177483|EXPERIMENTAL|curQ+ curcumin formulation|2,860 mg of curQ+® containing a total of 400 mg of curcuminoids in six #0 vegetarian capsules as a single oral dose
62820311|NCT01066013|EXPERIMENTAL|Prospective Antimicrobial de-escalation arm|Antimicrobial de escalation team will assess therapy and make recommendations to (a) change to antibiotic(s) with narrow spectrum,(b) stop antibiotics, (c) order new cultures/investigations or (d) consult with specialists or ID service for full evaluation (if patient's condition is worsening).
62820312|NCT01066013|NO_INTERVENTION|Restrospective control arm|The control subjects will be drawn from historic data of patients on the same medical unit(s) and will be matched based on age, antibiotics, sex, and infectious diseases diagnosis.
62820313|NCT06467825|NO_INTERVENTION|Control|
62820314|NCT06467825|EXPERIMENTAL|Hypovolemic|Furosemide and potassium supplement.
62820315|NCT06467825|EXPERIMENTAL|Hypovolemic plus garment|Furosemide and potassium supplement plus OIG.
62820316|NCT05077215|EXPERIMENTAL|Arm 1: EG-007+ Len+Pem Regimen|
62820317|NCT05077215|ACTIVE_COMPARATOR|Arm 2: Len+Pem Regimen|
62820318|NCT06476132|EXPERIMENTAL|Belumosudil plus maintenance IS|Eligible lung transplant recipients who experience a qualifying biopsy 90 to 410 days posttransplant will be randomized into the study. 200 mg of Belumosudil (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS will be administered daily for one year from randomization.
62040414|NCT06733948|OTHER|Control|Radiotherapy with no dental stent +/- Concurrent systemic therapy
62600526|NCT05487378|OTHER|1st PKU GOLIKE 2nd AA protein substitute|7 days with usual protein substitute and PKU GOLIKE as their last dose of protein substitute for the day (at least one sachet with15g PE) in an amount equivalent to their usual protein substitute PE followed by a 2-week washout period on their usual protein substitute, and then 7 days with AA protein substitute for all daily doses.
62820319|NCT06476132|PLACEBO_COMPARATOR|Placebo + maintenance IS|Eligible lung transplant recipients who experience a qualifying biopsy 90 to 410 days posttransplant will be randomized into the study. Placebo plus maintenance immunosuppression (IS) will be administered for one year
62820320|NCT06704737|EXPERIMENTAL|AR training group|Dichoptic augmented reality training with dual-pathway (parvocellular pathway and magnocellular pathway) and interocular push-pull paradigms developed based on neural deficits in adults with unilateral amblyopia.
62040415|NCT01394965|NO_INTERVENTION|ECG Mapping|
62040416|NCT05682053|OTHER|patients with medullary sponge kidney|Patients with medullary sponge kidney attending medical consultation
62040417|NCT05682053|OTHER|Patients with glomerular filtration rate > 60 mL/min/1.73m2 without kidney stone|Patients with glomerular filtration rate \> 60 mL/min/1.73m2 without kidney stone attending a renal exploration.
62243922|NCT05186025||Adults|adult patients aged ≥ 18 with rhinitis, conjunctivitis and/or mild to moderate bronchial asthma, caused by an IgE-mediated allergy to grass/rye or tree pollen; who are treated with MATA grass or MATA trees as part of their routine medical care
62820321|NCT06704737|ACTIVE_COMPARATOR|Patching group|Conventional patching therapy.
62820322|NCT05996575||MCI Patients|Adult participants who are seeking neurological assessments for Mild Cognitive Impairment (MCI) at a participating clinic/study site.
62040418|NCT05645328|EXPERIMENTAL|Intervention Hospital Administrators, Providers, and Data Monitoring Staff|"This is a health-system-level intervention, designed as two-arm intervention trial, where four participating hospitals will be offered support in the areas of training and education, cancer data collection and reporting, quality improvement and clinical peer-to-peer support.~Hospitals that are eligible for the intervention had to be located in an Iowa county classified as non-metropolitan according to rural urban continuum codes (RUCC) 4 through 9 and diagnose or treat at least 100 cancer patients each year. We selected 4 of the 9 rural hospitals meeting this criteria to administer the intervention."
62040419|NCT05645328|NO_INTERVENTION|Control arm|Hospitals that are eligible for the intervention had to be located in an Iowa county classified as non-metropolitan according to rural urban continuum codes (RUCC) 4 through 9 and diagnose or treat at least 100 cancer patients each year. The remaining 5 hospitals meeting this criteria that were not selected for the intervention will serve as controls.
62040420|NCT04235036|EXPERIMENTAL|Rituximab + Ibrutinib|Eligible patients will be those with a first episode of symptomatic cGVHD, requiring systemic immunosuppression for control of symptoms. Following study entry, patients will be started on rituximab plus ibrutinib.
62040421|NCT06401356|EXPERIMENTAL|Pelabresib|"This is a multicenter, open-label extension study for patients previously enrolled in studies with pelabresib. The study does not define separate treatment arms. The study provides continued pelabresib treatment for patients who previously received pelabresib in a parent study.~Patients previously enrolled in studies with pelabresib who discontinued treatment with placebo or pelabresib may be enrolled in this extension study for the purpose of survival follow-up."
62040422|NCT05420103||Pre-ASAP|Conventional Stroke Rehabilitation Program
62600527|NCT05487378|OTHER|1st AA protein substitute 2nd PKU GOLIKE|7 days with AA protein substitute for all daily doses followed by a 2-week washout period on their usual protein substitute, and then 7 days with usual protein substitute and PKU GOLIKE as their last dose of protein substitute for the day (at least one sachet with15g PE) in an amount equivalent to their usual protein substitute PE
62600528|NCT03195023|ACTIVE_COMPARATOR|RAS Blockers|Patients in this arm will receive Lisinopril 20mg/day
62820323|NCT05996575||Healthy Controls|Healthy participants without a prior MCI or memory impairment diagnosis.
62820324|NCT03293615|EXPERIMENTAL|Dermatomyositis (DM)|Patients with dermatomyositis according to ENMC criteria
62820325|NCT03293615|ACTIVE_COMPARATOR|Non-dermatomyositis inflammatory myopathies|Patients with other inflammatory myopathy than dermatomyositis according to ENMC criteria
62820326|NCT03293615|NO_INTERVENTION|No myopathy|Patients without myopathy on muscle biopsy
62243923|NCT05186025||Children|children aged from \>5 to 17 years with rhinitis, conjunctivitis and/or mild to moderate bronchial asthma, caused by an IgE-mediated allergy to grass/rye or tree pollen; who are treated with MATA grass or MATA trees as part of their routine medical care
62243924|NCT06260956|ACTIVE_COMPARATOR|Arm 1 Consumption|Subjects must consume peanuts and peanut products and egg and egg products.
62820327|NCT03361137|EXPERIMENTAL|PwHA With Inhibitors, Emicizumab: Surgery Not Performed Cohort|This cohort included participants with Hemophilia A (PwHA) with inhibitors that were enrolled but did not have surgery. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
62820328|NCT03361137|EXPERIMENTAL|PwHA With Inhibitors, Emicizumab: CVAD Removal Cohort|This cohort included participants with Hemophilia A (PwHA) with inhibitors that were enrolled and had surgery for central venous access device (CVAD) removal. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
62820329|NCT03361137|EXPERIMENTAL|PwHA With Inhibitors, Emicizumab: Simple Dental Extraction Cohort|This cohort included participants with Hemophilia A (PwHA) with inhibitors that were enrolled and had surgery for simple dental extraction. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
62820330|NCT03361137|EXPERIMENTAL|PwHA Without Inhibitors, Emicizumab: CVAD Removal Cohort|This cohort included participants with Hemophilia A (PwHA) without inhibitors that were enrolled and had surgery for central venous access device (CVAD) removal. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
62820331|NCT03361137|EXPERIMENTAL|PwHA Without Inhibitors, Emicizumab: Simple Dental Extraction Cohort|This cohort included participants with Hemophilia A (PwHA) without inhibitors that were enrolled and had surgery for simple dental extraction. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
62243925|NCT06260956|ACTIVE_COMPARATOR|Arm 2 Avoidance|Subjects must avoid eating peanuts and peanut products and egg and egg products.
62243926|NCT02721823|EXPERIMENTAL|lifestyle-modification|Once a week for 10 weeks with a circumference of 60 hours with mindfulness-based stress reduction and further process of the Mind / body medicine.
62243927|NCT02721823|ACTIVE_COMPARATOR|control group|A unique education unit within the scope of 3 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training.
62243928|NCT03718663||Knee OA patients (part 1)|Painful knee OA patients signed up for standardized exercise therapy
62243929|NCT03718663||Healthy subjects (part 2)|Healthy subjects (age 18-28) signed up military service in Defence Command Denmark
62434225|NCT05692752||Control Group|"The study group included 10 patients,~1. men and women~2. between age of 35-60 year~3. having no complaint of health issue,"
62600529|NCT03195023|ACTIVE_COMPARATOR|Non RAS Blockers|Patients in this arm will receive Amlodipine 10mg/day or Lercanidipine 20mg/day +/- diuretics
62243930|NCT04000035|EXPERIMENTAL|Health in work|The interdisciplinary Health in work intervention consists of three information sessions over the course of one year, with work place processes in between. In the meetings, structured health information about musculoskeletal- and mental disorders is given and put in the context of working and the specific workplace. It is an integrated intervention where information is given together by both healthcare- and NAV-personnel.
62243931|NCT04000035|ACTIVE_COMPARATOR|Regular work place measures|Regular work place measures offered by NAV workplace service. Those are interventions given by NAV personnel without healthcare involvement and can be varying.
62243932|NCT04795843|EXPERIMENTAL|Exercise and patient education|6-months
62243933|NCT04795843|ACTIVE_COMPARATOR|Usual Care|6-months
62243934|NCT06179511|EXPERIMENTAL|Module 1: Dose Escalation|Ascending dose level cohorts of AZD9829 in AML and MDS participants.
62243935|NCT06179511|EXPERIMENTAL|Module 1: Dose Optimization|Characterizing the safety, tolerability, PK/PD, and preliminary antitumor activity of AZD9829 in CD123+ R/R AML participants, based on the data collected during dose escalation, dose optimization and backfill.
62243936|NCT00733694|OTHER|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
62243937|NCT05014295|NO_INTERVENTION|Control Group|Survey questions at baseline and at one week. The control group will have had one week to reflect on the questions, and investigators anticipate some influence of this on responses.
62243938|NCT05014295|ACTIVE_COMPARATOR|Intervention Group|The intervention group will be prompted about accessing their medical records from the major local health systems online, with links to directions provided by each hospital system. They will then be asked to fill out the same questionnaire.
62243939|NCT06734520|EXPERIMENTAL|Severe β -thalassemia|Children with β-thalassemia major received super transplantation, and chimerism tests were performed at 3 months, 6 months, 9 months, and 1 year after transplantation to evaluate the safety and effectiveness.
62820332|NCT03389477|EXPERIMENTAL|Cohort 1: 1: palbociclib, 2: Cisplatin & IMRT, 3: palbociclib|"* Step 1: Neoadjuvant palbociclib monotherapy (125 mg/day, Days 1-21 of a 28-day cycle for two cycles)~* Step 2: Cisplatin 100 mg/m\^2 given on Days 1 and 22 with accelerated IMRT 70 Gy to be administered over 6 weeks~* Step 3: Adjuvant palbociclib 125 mg/day, days 1-21 of each 28-day cycle for six cycles. Adjuvant palbociclib will begin 16 to 22 weeks following completion of cisplatin \& IMRT"
62820333|NCT03389477|EXPERIMENTAL|Cohort 2: 1: palbociclib, 2: Cetuximab & IMRT, 3: palbociclib|"* Step 1: Neoadjuvant palbociclib monotherapy (125 mg/day, Days 1-21 of a 28-day cycle for two cycles)~* Step 2: Cetuximab given one week before RT and then weekly with accelerated IMRT 70 Gy to be administered over 6 weeks~* Step 3: Adjuvant palbociclib 125 mg/day, days 1-21 of each 28-day cycle for six cycles. Adjuvant palbociclib will begin 16 to 22 weeks following completion of cetuximab \& IMRT"
62243940|NCT04412538|EXPERIMENTAL|Low dosage vaccine on a 0- and 28-day schedule|Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
62243941|NCT04412538|EXPERIMENTAL|Low dosage vaccine on a 0- and 14-day schedule|Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
62243942|NCT04412538|EXPERIMENTAL|Medium dosage vaccine on a 0- and 28-day schedule|Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
62243943|NCT04412538|EXPERIMENTAL|Medium dosage vaccine on a 0- and 14-day schedule|Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
62243944|NCT04412538|EXPERIMENTAL|High dosage vaccine on a 0- and 28-day schedule|Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
62243945|NCT04412538|EXPERIMENTAL|High dosage vaccine on a 0- and 14-day schedule|Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
62243946|NCT04412538|PLACEBO_COMPARATOR|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0, 28
62243947|NCT04412538|PLACEBO_COMPARATOR|Placebo on a 0- and 14-day schedule|Two doses of placebo at the vaccination schedule of day 0, 14
62243948|NCT04164199|EXPERIMENTAL|A - Tislelizumab Monotherapy|
62600530|NCT06461065|EXPERIMENTAL|AIDS group|patients with T1DM with automatized insulin delivery systems (AIDS)
62600531|NCT06461065|OTHER|TS group|standard treatment: patients with T1DM treated with insulin pump + blood glucose sensors
62243949|NCT04164199|EXPERIMENTAL|B - Pamiparib Monotherapy|
62243950|NCT04164199|EXPERIMENTAL|C - Sitravatinib Monotherapy|
62243951|NCT04164199|EXPERIMENTAL|D - BGB-15025 Monotherapy|
62243952|NCT04164199|EXPERIMENTAL|E - Zanidatamab Monotherapy|
62243953|NCT04164199|EXPERIMENTAL|F - Pamiparib and Temozolomide Combination Therapy|
62243954|NCT04164199|EXPERIMENTAL|G - Tislelizumab and Pamiparib Combination Therapy|
62243955|NCT04164199|EXPERIMENTAL|H - Tislelizumab and Sitravatinib Combination Therapy|
62600532|NCT06461065|OTHER|Control group|age-matched control subjects without T1DM
62820334|NCT03268317||Patients with chronic hepatitis C treated by DAAs|All subjects will be given the same treatment regimen which includes Sofosbuvir 400 mg orally/24 hours (pre-breakfast) and Daclatasvir 60 mg orally/24 hours after lunch with or without ribavirin for a total period of 12 weeks.
62040423|NCT05420103||Post-ASAP|Standardized functional assessment, standardized intensive early ambulation with modern technologies such as Knee-Ankle-Foot Orthoses and Robotic-Assisted Gait Training. In order to monitor the progress of each patient proactively, Stroke Registry and Reference Modified Rivermead Mobility Index (MRMI) Gain were developed. Stroke Registry was a longitudinal stroke rehabilitation database to monitor patients' functional outcomes and therapists' intervention compliance so as to pave the way for future clinical big data movement to bridge the gap between evidence-practice and clinical practice. Reference MRMI Gain was a clinical prediction model apply business intelligence concept to support goal-orientated approach of physiotherapists in stroke rehabilitation. Stroke treatment library, a standardized exercise prescription in video format was also developed to facilitate standardized prescription of interventions to patients with different level of ability.
62040424|NCT03621605|EXPERIMENTAL|VIB9600|"Single dose of VIB9600 administered by IV infusion or SC injection.~Multiple dose VIB9600 administered by IV infusion every 2 weeks for 4 weeks."
62040425|NCT03621605|PLACEBO_COMPARATOR|Placebo|Placebo comparator administered by slow IV infusion or SC injection.
62040426|NCT06733545||PB-011|Patients starting chemotherapy treatment are given (double blinded) moisturizing cream PB-011 to use once a day in hands. If sensory discomfort appears in hands or feet, the dosage could be increased up to twice a day in hands and feet.
62243956|NCT04164199|EXPERIMENTAL|I - Tislelizumab and Ociperlimab Combination Therapy|
62623830|NCT00543673|EXPERIMENTAL|Milk based formula A|Experimental milk based infant formula
62623831|NCT00543673|ACTIVE_COMPARATOR|Standard formula|standard milk based infant formula
62820335|NCT01901159|EXPERIMENTAL|RO4995819 capsule|
62820336|NCT01901159|EXPERIMENTAL|RO4995819 tablet|
62820337|NCT04292275|EXPERIMENTAL|Digital Health Tools + Standard of Care|
62820338|NCT04292275|OTHER|Standard of Care|
62820339|NCT02429323|ACTIVE_COMPARATOR|sevoflurane concentration 8%|sevoflurane concentration 8% from the start
62820340|NCT02429323|ACTIVE_COMPARATOR|incremental sevoflurane (1-8%)|incremental increase of the concentration each few breaths from 1% to 8%
62820341|NCT04487366|ACTIVE_COMPARATOR|Double Operator Ultrasound-Guided Regional Anesthesia|resident control block needle and ultrasound probe and asistant operator inject the solution. resident reach the target area created in the phantom model using a block needle with ultrasound guidance
62820342|NCT04487366|ACTIVE_COMPARATOR|Jedi Grip|resident control block needle, ultrasound probe and syringe independently with jedi grip; reach the target area created in the phantom model using a block needle with ultrasound guidance; inject and aspirate the solution.
62820343|NCT04487366|ACTIVE_COMPARATOR|On-lock grip|resident control block needle, ultrasound probe and syringe independently with on-lock grip; reach the target area created in the phantom model using a block needle with ultrasound guidance; inject the solution.
62820344|NCT04487366|ACTIVE_COMPARATOR|Bedforth alternative grip|resident control block needle, ultrasound probe and syringe independently with bedforth's alternative grip; reach the target area created in the phantom model using a block needle with ultrasound guidance; inject the solution.
62820345|NCT06212947||Children with Hypochondroplasia|Children with Hypochondroplasia
62820346|NCT04944277|NO_INTERVENTION|Without ThoughtFullChat Application|Participants will not use the app during the 3 months
62820347|NCT04944277|EXPERIMENTAL|With ThoughtFullChat Application|Participants will be using the app during the 3 months
62820348|NCT06432153||participant|The only group of participant. Participants are outpatient clinical patients diagnosed with cardiovascular disease.
62820349|NCT06179303|EXPERIMENTAL|Treatment (FFNP-PET/CT, estradiol, abemaciclib, ET)|Patients receive FFNP IV and undergo PET/CT imaging at baseline. Patients then receive estradiol orally Q8H over a 24-hour period, followed again by FFNP IV and PET/CT imaging. Patients then receive abemaciclib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive ET of the treating physician choice. Patients also receive FDG IV and undergo PET/CT imaging at baseline, with additional diagnostic imaging for tumor assessment every 3 cycles, and undergo blood sample collection throughout the study.
62820350|NCT05313984||Patients planned for the 2-staged tined-lead procedure.|"Patients with the following indications:~* Overactive bladder without urgency urinary incontinence.~* Overactive bladder with urgency urinary incontinence.~* Non-obstructive urinary retention.~* Dysfunctional voiding or Fowler Syndrome.~* Fecal incontinence."
62820351|NCT05579782|EXPERIMENTAL|NIRAF Detection Technology (+)|Parathyroid gland identification will be performed with PTeye using NIRAF detection technology as an adjunctive tool in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND).
62820352|NCT05579782|NO_INTERVENTION|NIRAF Detection Technology (-)|Parathyroid gland identification will be performed by the surgeon using only visual identification and without using PTeye - NIRAF detection technology in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND).
62820353|NCT05865028|EXPERIMENTAL|APG-157 Therapy|Participants will receive APG-157 for up to 12 weeks.
62820354|NCT05119647|EXPERIMENTAL|Aspiration thrombectomy|Since this is a single-arm objective performance criteria trial, patients with acute stoke caused by artery occlusion shall not be divided into two groups.
62820355|NCT06356337|ACTIVE_COMPARATOR|Light Googles then Orange Glasses|Participants use blue light goggles then cross over to orange glasses.
62820356|NCT06356337|ACTIVE_COMPARATOR|Orange Glasses then Light Googles|Participants use orange glasses then cross over to blue light goggles.
62820357|NCT05514977|ACTIVE_COMPARATOR|L group|Patients are given 20 ml of 2 % lidocaine for ESPB
62820358|NCT05514977|ACTIVE_COMPARATOR|H group|Patients are given 40 ml of 1 % lidocaine for ESPB
62820359|NCT02741128|EXPERIMENTAL|CYD Dengue vaccine group|Subjects will receive 3 doses of CYD dengue vaccine at 0, 6, and 12 months
62820360|NCT02741128|PLACEBO_COMPARATOR|Placebo vaccine group|Subjects will receive 3 doses of placebo (NaCl, 0.9%) vaccine at 0, 6, and 12 months
62820361|NCT06067516||Group CRT-R|If the CRT measured at T1 decreased equal to or more than 25% compared to the CRT measured at T0
62820362|NCT06067516||Group CRT-NR|If the CRT measured at T1 decreased by less than 25% compared to the CRT measured at T0
62434226|NCT05257603|EXPERIMENTAL|Revictimization Prevention for College Women (RPCW)|Active intervention that includes information to reduce hazardous drinking and increase sexual assault risk perception.
62820363|NCT01506596|EXPERIMENTAL|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
62820364|NCT06599216|EXPERIMENTAL|Treatment Group|
62434227|NCT05257603|ACTIVE_COMPARATOR|Health Education Control (HEC)|Time and attention control.
62434228|NCT02971514|EXPERIMENTAL|Floss-Brush group|The participants flossed first followed by brushing
62434229|NCT02971514|ACTIVE_COMPARATOR|Brush-Floss group|They used dental floss after brushing
62434230|NCT02998333|ACTIVE_COMPARATOR|Open surgical ankle stabilization|These patients will receive open surgical stabilization of the ankle joint after failed conservative treatment with complaints for at least 6 months.
62434231|NCT02998333|ACTIVE_COMPARATOR|Arthroscopic surgical ankle stabilization|These patients will receive arthroscopic surgical stabilization of the ankle joint after failed conservative treatment with complaints for at least 6 months.
62434232|NCT05385029||Thyroid functions in neonates born to COVID 19 positive mothers|thyroid hormone or antithyroid drugs
62434233|NCT05385029||Neonates born to mothers without COVID 19 infection|Thyroid drugs if indicated
62434234|NCT05187403|EXPERIMENTAL|Laquinimod - Single Ascending Doses|One single dose of laquinimod eye-drops. There are up to four planned dose levels.
62820365|NCT05221931|ACTIVE_COMPARATOR|DES group|"Patients will be randomized to either the DCB group or the DES group with 1:1 ratio during the index procedure after diagnostic angiography.~In DES group, latest second-generation DES will be used (Ultimaster Tansei) during the index procedure"
62820366|NCT05221931|EXPERIMENTAL|DCB group|"Patients will be randomized to either the DCB group or the DES group with 1:1 ratio during the index procedure after diagnostic angiography.~In DCB group, Agent (Boston Scientific, USA), Prevail (Medtronic, USA), or SeQuent Please, SeQuent Please NEO (B-Braun, Germany) will be used during the index procedure."
62040427|NCT06733545||PB-012|Patients undergoing chemotherapy treatment are given (double blinded) moisturizing cream PB-012 to use once a day in hands. If sensory discomfort appears in hands or feet, the dosage could be increased up to twice a day in hands and feet.
62040428|NCT03331198|EXPERIMENTAL|Phase 1 JCAR017 monotherapy|Subjects will be assigned to receive JCAR017 (lisocabtagene maraleucel)
62040429|NCT03331198|EXPERIMENTAL|Phase 1 JCAR017 + ibrutinib|Subjects receiving ibrutinib at baseline will be assigned to receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm + ibrutinib
62434235|NCT05187403|PLACEBO_COMPARATOR|Placebo - Single Ascending Doses|One single dose of placebo eye-drops.
62434236|NCT05187403|EXPERIMENTAL|Laquinimod - Multiple Ascending Doses|Eye-drops administered once daily for 14-21 days. There are up to two planned dose levels. The first dose level will be defined in the SAD-part of the study.
62434237|NCT05187403|PLACEBO_COMPARATOR|Placebo - Multiple Ascending Doses|Eye-drops administered once daily for 14-21 days.
62434238|NCT05164848|EXPERIMENTAL|Cohort A|"JMT101 combined with two dose levels of afatinib will be tested according to the 3 + 3 dose-escalation design. The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days)."
62434239|NCT05164848|EXPERIMENTAL|Dose Expansion Cohort|Once the safe and effective dose has been determined, an expansion cohort will be recruited to further evaluate the efficacy and safety of the selected dose.
62434240|NCT02831348||Uncontrolled asthma|Indicated by an asthma control test (ACT) score of \<20 and asthma symptoms of cough, wheeze, or chest tightness for more than 2 days in the prior 2 weeks, OR current asthma exacerbation indicated by the prescription of a short course (3-5 days) of systemic corticosteroids by treating provider at the time of visit.
62434241|NCT02831348||Controlled asthma|Indicated by an ACT score of \>19, or spirometry results within 10% of year's best value (based on FEV1).
62434242|NCT02831348||Pneumonia|Indicated by an admission diagnosis of pneumonia with chest X-ray consistent with the diagnosis, based on attending radiologist's interpretation.
62434243|NCT02831348||Controlled allergic rhinitis|Indicated by a rhinitis control assessment test (RCAT) score of \>= 21.
62623832|NCT00543673|OTHER|Reference|Human milk
62623833|NCT00543673|EXPERIMENTAL|Milk based formula C|Experimental milk based infant formula
62820367|NCT04126161|ACTIVE_COMPARATOR|CT|Patients have standard of care CT prior to primary hip replacement
62820368|NCT04126161|EXPERIMENTAL|Ultrasound|Patients have ultrasound scans together with standard of care CT prior to primary hip replacement
62820369|NCT04339764|EXPERIMENTAL|Participants receiving intervention|Participants receiving intervention
62820370|NCT02278510|EXPERIMENTAL|Direct infusion of topotecan|The experimental Cleveland Multiport Catheter will be used to inject a chemotherapy, topotecan, and a contrast agent, gadolinium DTPA, into the high grade brain tumors of study participants
62820371|NCT06211179|EXPERIMENTAL|Sequence ABC|
62040430|NCT03331198|EXPERIMENTAL|Phase 2 JCAR017 monotherapy|Subjects will receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm
62040431|NCT03331198|EXPERIMENTAL|Phase 1 JCAR017 + venetoclax|Subjects will receive venetoclax as bridging anticancer therapy until lymphodepletion chemotherapy/ JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm. After JCAR017 infusion subjects will receive venetoclax until Day 90.
62040432|NCT03331198|EXPERIMENTAL|Phase 2 JCAR017 Double-Exposed Monotherapy Expansion (DEME)|Subjects will receive JCAR017 monotherapy
62040433|NCT05828979|EXPERIMENTAL|UroMems artificial urinary sphincter|Female adults (18+) with urinary incontinence with reduced outlet resistance due to intrinsic sphincter deficiency.
62040434|NCT05304169|EXPERIMENTAL|Leuprorelin Acetate (Eligard® 45 mg)|Patients received two subcutaneous injections of Eligard® 45 mg (leuprorelin acetate), with the first injection given at baseline (Visit 1) and the second after 168 ± 3 days at Visit 4.
62040435|NCT05277571|EXPERIMENTAL|UCB1381 dosing regime 1 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
62040436|NCT05277571|EXPERIMENTAL|UCB1381 dosing regime 2 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
62820372|NCT06211179|EXPERIMENTAL|Sequence BCA|
62820373|NCT06211179|EXPERIMENTAL|Sequence CAB|
62040437|NCT05277571|EXPERIMENTAL|UCB1381 dosing regime 3 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
62040438|NCT05277571|EXPERIMENTAL|UCB1381 dosing regime 4 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
62040439|NCT05277571|EXPERIMENTAL|UCB1381 dosing regime 5 in Part A|Participants will be randomized to receive a single dose UCB1381 subcutaneously (sc).
62434244|NCT02831348||Uncontrolled allergic rhinitis|Indicated by an RCAT score of \<21.
62434245|NCT02831348||Cystic fibrosis (exacerbated)|Indicated by treating physician's assessment of cystic fibrosis respiratory exacerbation within 24 hours of initial antibiotic therapy.
62820374|NCT03939143|EXPERIMENTAL|Test drug, Reference drug group|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fasting study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
62820375|NCT03939143|ACTIVE_COMPARATOR|Reference drug,Test drug group|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fasting study is 14 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar."
62040440|NCT05277571|EXPERIMENTAL|UCB1381 dosing regime 6 in Part A|Participants will be randomized to receive a single dose UCB1381 subcutaneously (sc).
62040441|NCT05277571|EXPERIMENTAL|UCB1381 dosing regime 7 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
62040442|NCT05277571|EXPERIMENTAL|UCB1381 dosing regime 8 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
62040443|NCT05277571|EXPERIMENTAL|UCB1381 dosing regime 9 in Part B|Participants will be randomized to receive repeated doses UCB1381 intravenously (iv).
62040444|NCT05277571|PLACEBO_COMPARATOR|Placebo iv Arm Part A|Participants will be randomized to receive a single dose of placebo iv to maintain the blinding.
62040445|NCT05277571|PLACEBO_COMPARATOR|Placebo sc Arm Part A|Participants will be randomized to receive a single dose of placebo sc to maintain the blinding.
62040446|NCT05277571|PLACEBO_COMPARATOR|Placebo iv Arm Part B|Participants will be randomized to receive repeated doses of placebo iv to maintain the blinding.
62623834|NCT01784926|OTHER|IOL repositioning|Operation method: Intraocular lens repositioning by scleral suturing
62623835|NCT01784926|OTHER|IOL exchange|Operation method: Intraocular lens exchange with retropupillary iris-claw lens
62820376|NCT02908061|ACTIVE_COMPARATOR|Surgery (Usual approach group)|standard surgery
62820377|NCT02908061|EXPERIMENTAL|Surgery + Mesh Placement|prophylactic mesh at the time of standard surgery
62849136|NCT03645434|EXPERIMENTAL|Treatment sequence A|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 2: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 3: Matching placebo of AZD8871 and Anoro® Ellipta®"
62040447|NCT06731881|ACTIVE_COMPARATOR|Photodisinfection|The photodisinfection product consists of a CE-marked light source (SW4000), a disposable single-use nasal light diffuser, and a single-use photosensitiser applicator that can be used in hospital settings.
62040448|NCT06731881|ACTIVE_COMPARATOR|Control|The control group will have nares swabbed with 'photosensitizer formulation' (0.01% methylene blue with 0.25% chlorhexidine solution) prior to surgery.
62243957|NCT04164199|EXPERIMENTAL|J - Tislelizumab and BAT1706 Combination Therapy, or BAT1706 Monotherapy|
62040449|NCT04594031|EXPERIMENTAL|ECT-001-CB|"* An Umbilical Cord Blood for transplant will undergo CD34+ selection and expansion. The CD34- fraction is infused on Day +1 post-transplant.~* Patients will receive standard supportive care and GVHD prophylaxis"
62040450|NCT01177904|ACTIVE_COMPARATOR|Progesterone 5 Weeks|The study group stop receiving P4 on the day of their first US at 5 weeks pregnancy
62434246|NCT02831348||Cystic fibrosis (stable)|Indicated by diagnosis of cystic fibrosis with baseline symptoms and with spirometry results (based on FEV1) within 5% of year's best value.
62600533|NCT01756781|EXPERIMENTAL|Sequence 1|Subjects randomized to Sequence 1 will receive Treatment A followed by Treatment B. Treatment A is a single 2 mg oral dose of midazolam alone. Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991 and a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
62040451|NCT01177904|OTHER|Control Group : P4 8 weeks|Progesterone will be given until 8 weeks of pregnancy
62040452|NCT06722846||Randomized Case Vignette Study|"If participants agree to take part in this study, participants will complete about 16 questionnaires that will have questions about participants quality of life, anxiety, health, and case scenarios that are not real or based on your actual health situation. It should take a bit more than an hour to complete all the questionnaires. If participants find that any of these questions are difficult to read, understand, or otherwise complete; or if they cause distress, participants may ask the study team for clarification, skip the question, or even stop the study at any time.~Additionally, information will be collected from participants medical record about participants health and treatment, as well as participants demographic information (age, race, sex, and so on). Investigators may also ask participants for additional demographic information not found in your medical record."
62040453|NCT05110742|EXPERIMENTAL|Phase 1 Dose Level|"CAR.5/IL15-transduced CB-NK cells Dose level 1, 1e7 cryopreserved cells flat dose Dose level 2, 1e8 cryopreserved cells flat dose Dose level 3, 1e9 cryopreserved cells flat dose Dose level 4, 1e10 cryopreserved cells flat dose~All patients will receive Lymphodepleting Chemotherapy of Cyclophosphamide and Fludarabine."
62040454|NCT05110742|EXPERIMENTAL|Phase 2 Dose Level|"Patients will be randomized between the 2 optimal doses of CAR.5/IL15-transduced CB-NK cells determined by Phase 1.~All patients will receive Lymphodepleting Chemotherapy of Cyclophosphamide and Fludarabine."
62243958|NCT04164199|EXPERIMENTAL|K - Tislelizumab and Fruquintinib Combination Therapy|
62243959|NCT04164199|EXPERIMENTAL|L - Tislelizumab and BGB-A445 Combination Therapy|
62243960|NCT04164199|EXPERIMENTAL|M - Tislelizumab and Surzebiclimab Combination Therapy|
62243961|NCT04164199|EXPERIMENTAL|N - Tislelizumab and BGB-15025 Combination Therapy|
62434247|NCT02831348||Control|Indicated by a negative history of any of the conditions characterizing the other groups.
62434248|NCT05881265|EXPERIMENTAL|Chi-Ven treatment|Patients receive chidamide and venetoclax treatment
62434249|NCT00211783||Autism|
62434250|NCT00211783||Control|
62600534|NCT01756781|EXPERIMENTAL|Sequence 2|Subjects randomized to Sequence 2 will receive Treatment B followed by Treatment A with a washout of no less than 14 days in between.Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991 and a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose. There will be a minimum washout of 14 days prior to beginning Treatment A. Treatment A is a single 2 mg oral dose of midazolam alone.
62243962|NCT04164199|EXPERIMENTAL|O - Tislelizumab and Lenvatinib Combination Therapy|
62434251|NCT06141382|EXPERIMENTAL|English Language-Sensory based narrative intervention|This experimental group participants will receive sensory based intervention in English language.
62600535|NCT02585271|OTHER|Transanal decompression tube|Patients undergo placement of the transanal decompression tube as a bridge to surgery
62600536|NCT02585271|OTHER|Stent|Patients undergo placement of the stent as a bridge to surgery
62600537|NCT00079586|ACTIVE_COMPARATOR|Heparin|unfractionated heparin will be administered as per institutional practice
62600538|NCT00079586|EXPERIMENTAL|Angiomax|1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
62600539|NCT03128320|EXPERIMENTAL|BAY1193397/Placebo (sequence A-B-C)|Subjects with type II diabetes who follow treatment sequence A-B-C. Single oral dose of a placebo tablet in the first intervention period (Treatment A); followed by single oral dose of 1 mg BAY1193397 (Treatment B); then single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the third intervention period (Treatment C). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
62623836|NCT01466075|EXPERIMENTAL|Intended Users of the Monitoring System|Untrained subjects with diabetes use the Apollo Evolution Investigational BG Monitoring System.
62243963|NCT04164199|EXPERIMENTAL|P - Tislelizumab and Zanidatamab Combination Therapy|
62243964|NCT04164199|EXPERIMENTAL|Q - Tislelizumab and LBL-007 Combination Therapy|
62243965|NCT04164199|EXPERIMENTAL|R - Tislelizumab and Surzebiclimab and LBL-007 Combination Therapy|
62243966|NCT02193360|EXPERIMENTAL|Single arm Dose Escalation|
62243967|NCT02249624||Survivors of TTTS|Infants who have survived TTTS to hospital discharge, have an MRI at term, and return for nursery follow-up clinic.
62243968|NCT04663737|EXPERIMENTAL|Group A|Group A will receive the best supportive care and/or recommended standard of care (at this point no standard of care drugs are recommended by CDC for patients with moderate COVID-19) in combination with the study drug Silmitasertib
62040455|NCT04499092|ACTIVE_COMPARATOR|Personalized neuropsychological treatment (CORE-ABI)|Each patient will receive greater stimulation of the most deficient cognitive function(s), while at the same time being trained on all the other functions.
62040456|NCT04499092|EXPERIMENTAL|Sequential neuropsychological treatment (SET-ABI)|Each patient will receive a fixed-dose stimulation of each cognitive function following a sequential order.
62040457|NCT06665386||Control Group|Patients will receive best medical management (BMM) plus EVT according to the clinical guidelines.
62040458|NCT06665386||IA-SCI group|Patients will receive BMM and EVT combined with selective intra-arterial cold saline infusion.
62040459|NCT06733077|EXPERIMENTAL|Feasibility of using the MachineMD and gaitQ devices|To complete gaitQ and MachineMD digital feasibility assessment and intervention service development
62040460|NCT06733428||Normal|Subjects with healthy cornea
62040461|NCT06733428||Cornea|Subjects with abnormal cornea
62040462|NCT06733428||Glaucoma|Subjects with glaucoma
62040463|NCT06506435|ACTIVE_COMPARATOR|Informational Video|Participants in this group will watch a two-dimensional (2D) informational video that explains the radiation treatment process. Total participation is up to 8 weeks.
62434252|NCT06141382|ACTIVE_COMPARATOR|English Language-Narrative intervention|This Control group participants will receive narrative intervention in English language.
62040464|NCT06506435|EXPERIMENTAL|Virtual Reality: 1st Person Perspective|Participants in this group will have a virtual reality experience presented from a first-person perspective. Participants will wear a Meta Quest Pro virtual reality headset, immersing themselves in a scenario that replicates the radiation treatment process. Total participation is up to 8 weeks.
62040465|NCT06506435|EXPERIMENTAL|Virtual Reality: 3rd Person Perspective|Participants in this group will wear a Meta Quest Pro virtual reality headset and use virtual reality to observe the radiation treatment scenario from a standing position within the room, enabling them to witness both the CT scan and radiation machine from an external viewpoint. Total participation is up to 8 weeks.
62040466|NCT06621238|EXPERIMENTAL|Vsisual Analog scale (VAS)|It will be used to measure pain in the intervention and control groups during the postpartum period.
62040467|NCT06621238|EXPERIMENTAL|State anxiety scale|It will be used to evaluate the mother's current anxiety status in the postpartum period.
62434253|NCT06141382|EXPERIMENTAL|Urdu Language-Sensory based narrative intervention|This experimental group participants will receive sensory based narrative intervention in Urdu language.
62040468|NCT06621238|EXPERIMENTAL|Breastfeedıng Success|It will be used to evaluate the breastfeeding success of mothers in the experimental and control groups in the postpartum period.
62040469|NCT00449176|EXPERIMENTAL|001|tapentadol (CG5503) ER 50 100 150 200 250 mg twice daily for 15 weeks
62040470|NCT00449176|ACTIVE_COMPARATOR|002|oxycodone CR 10 20 30 40 50 mg twice daily for 15 weeks
62040471|NCT00449176|PLACEBO_COMPARATOR|003|placebo matching placebo twice daily for 15 weeks
62040472|NCT02352038|EXPERIMENTAL|LLLT group|LLLT group: orthodontic treatment and low-level laser therapy
62040473|NCT02352038|PLACEBO_COMPARATOR|control group|Control group: orthodontic treatment and no laser treatment.
62040474|NCT06663722|EXPERIMENTAL|Axatilimab in combination with ECP Group|"Participants in this group will receive Axatilimab in combination with extracorporeal photopheresis (ECP) therapy for up to seven (7) four-week cycles.~Total participation duration is about 15 months."
62040475|NCT06731946||Surpass Evolve Flow Diverter|
62040476|NCT02612311|EXPERIMENTAL|Arm A: Ublituximab + Umbralisib|Participants received ublituximab, 150 milligrams (mg), intravenously (IV), on Day 1, 750 mg on Day 2, followed by 900 mg on Days 8 and 15 of Cycle 1 (cycle length=28 days), Day 1 of Cycles 2-6, and once every 3 cycles thereafter, along with umbralisib, 800 mg, orally, once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 87 months.
62040477|NCT02612311|ACTIVE_COMPARATOR|Arm B: Obinutuzumab + Chlorambucil|Participants received Obinutuzumab 100 mg, IV on Day 1, 900 mg on Day 2, followed by 1000 mg on Days 8 and 15 of cycle 1 (cycle length = 28 days), Day 1 of Cycle 2-6 along with Chlorambucil 0.5 milligram per kilogram (mg/kg) tablet orally on Days 1 and 15 once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 87 months.
62040478|NCT02612311|EXPERIMENTAL|Arm C: Ublituximab|Participants received ublituximab, 150 mg, IV, on Day 1, 750 mg on Day 2, followed by 900 mg on Days 8 and 15 of Cycle 1 (cycle length=28 days), Day 1 of Cycles 2-6, and once every 3 cycles thereafter, until disease progression, lack of tolerability, or until the treatment is commercially available or up to 87 months.
62040479|NCT02612311|EXPERIMENTAL|Arm D: Umbralisib|Participants received umbralisib, 800 mg tablets, orally, once daily during each cycle (cycle length= 28 days) until removal from study or up to 87 months.
62040480|NCT05911503|EXPERIMENTAL|2% Ganciclovir Eye Drops therapy Group|Administration method and dosage adjustment: 2% ganciclovir eye drops, 10 times/day for two weeks, 8 times/day for two weeks, 6 times/day for two weeks, 4 times/day for more than 6 weeks
62040481|NCT04369560|EXPERIMENTAL|Magnetic Resonance Imaging|Prior to planned surgical resection, subjects will undergo a single Magnetic Resonance Imaging study: a single breath-hold pre-contrast image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumoxytol (5 mM) and a second, single breath hold post-contrast image.
62040482|NCT06333587||image-guided thermal ablation|image-guided thermal ablation in patients with diagnosis of micropapillary thyroid carcinoma
62040483|NCT03204253|EXPERIMENTAL|rFSH + r-LH in combination|treatment group
62040484|NCT03204253|ACTIVE_COMPARATOR|rFSH alone|control group
62040485|NCT03155997|EXPERIMENTAL|150 mg Abemaciclib + Endocrine Therapy|Participants received Abemaciclib orally at 150 milligrams (mg) twice daily with at least 6 hours between doses for up to 2 years or until evidence of disease recurrence or other discontinuation criteria were met, whichever occurs first. Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
62040486|NCT03155997|OTHER|Endocrine Therapy|Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
62040487|NCT03581981|EXPERIMENTAL|Prolonged Exposure for Primary Care (PE-PC)|Brief version of PE provided in 30 minute sessions in PC
62040488|NCT03581981|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Veterans assigned to Primary Care (PC) Mental Health Integration (PCMHI)- Treatment as Usual (TAU) will receive standard PCMHI care for PTSD in PC that does not include any PTSD-specific therapy in PCMHI but may include referral for specialty care (including specialty Mental Health (MH)), medication management or general supportive contact while awaiting referral. All PTSD care received during the study will be collected and monitored as TAU.
62040489|NCT02285439|EXPERIMENTAL|Phase 1|Patients with non-hematologic malignancies that are recurrent, progressive, or refractory after standard up-front therapy receiving MEK162 will define the MTD, DLT, and toxicity profile.
62040490|NCT02285439|EXPERIMENTAL|Phase 2|Children with recurrent tumors signaling through the Ras/Raf pathway will be treated in 3 strata to define the activity of MEK162. S1: Children with LGG characterized by a BRAF truncated fusion (KIAA1549 and similar translocations). S2: Children with NF1 and LGG. S 3: Children with tumors involving the Ras/Raf pathway not included in strata 1 or 2.
62243969|NCT04663737|ACTIVE_COMPARATOR|Group B|Group B (control) that will receive the same care as the Group A but without Silmitasertib
62243970|NCT06678945|ACTIVE_COMPARATOR|Bar-Clip attachment|on the 2nd stage, implants will be loaded with bar-clip attachments to support overdenture
62623837|NCT05114564|EXPERIMENTAL|Lens A, Then Lens B|Participants will wear Lens A for one month and then cross over to wear Lens B for one month.
62434254|NCT06141382|ACTIVE_COMPARATOR|Urdu Language-Narrative intervention|This control group participants will receive narrative intervention in Urdu language.
62820378|NCT05942586|ACTIVE_COMPARATOR|Probiotic Arm|30 Participants in this arm will undergo a two-week run-in period consuming placebo sachet (maltodextrin) for the first week and then increasing the dosage in the second week. Following the run-in period, Participants will receive an eight-week intervention consisting of daily consumption of placebo sachets and probiotic capsule containing L. reuteri PB-W1™.
62820379|NCT05942586|ACTIVE_COMPARATOR|Prebiotic Arm|30 Participants in this arm will undergo a two-week run-in period consuming prebiotic sachets (Prebiotic Blend) for the first week and then increasing the dosage in the second week. During the eight-week intervention, Participants will consume prebiotic sachets three times daily and placebo capsule.
62820380|NCT05942586|EXPERIMENTAL|Synbiotic Arm|30 Participants in this arm will undergo a two-week run-in period consuming prebiotic sachets (Prebiotic Blend) for the first week and then increasing the dosage in the second week. Following the run-in period, Participants will receive an eight-week intervention consisting of daily consumption of prebiotic sachets, probiotic capsule containing L. reuteri PB-W1™.
62820381|NCT05942586|PLACEBO_COMPARATOR|Placebo Arm|30 Participants in this arm will undergo a two-week run-in period consuming placebo sachet (maltodextrin) for the first week and then increasing the dosage in the second week. During the eight-week intervention, Participants will consume placebo sachets three times daily and placebo capsule.
62820382|NCT06420882|EXPERIMENTAL|The rehabilitation group.|rehabilitation group.
62434255|NCT06141382|EXPERIMENTAL|Bilingual-Sensory based narrative intervention|This experimental group participants will receive sensory based narrative intervention in both English and Urdu language.
62434256|NCT06141382|ACTIVE_COMPARATOR|Bilingual-Narrative intervention|This control group participants will receive narrative intervention in both English and Urdu language.
62820383|NCT06420882|ACTIVE_COMPARATOR|The home exercise group|The home exercise group
62040491|NCT02285439|EXPERIMENTAL|Target Validation|Patients eligible for phase 2 (any stratum) for whom tumor biopsy or resection is clinically indicated may be enrolled on the target validation arm. Patients will receive MEK162 for 7 to 21 days prior to their surgery. Tumor sample will be analyzed for drug concentration and target inhibition.
62434257|NCT05826249|EXPERIMENTAL|SIM0417/Ritonavir|Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
62434258|NCT05175495||Normal young|Aged less than 45 years old,no underlying heart disease
62434259|NCT05175495||Young people diagnosed with coronary heart disease|Aged less than 45 years old,Diagnosed coronary heart disease;Confirmed by coronary angiography;Diagnosed myocardial infarction;Typical symptom of ischemic chest pain with positive stress test;
62434260|NCT05175495||Coronary heart disease|Older than 65 years, diagnosed with coronary heart disease
62623838|NCT05114564|EXPERIMENTAL|Lens B, Then Lens A|Participants will wear Lens B for one month and then cross over to wear Lens A for one month.
62820384|NCT01251965|EXPERIMENTAL|Ruxolitinib 50 mg BID|Phase I - Starting dose of Ruxolitinib 50 mg by mouth twice a day for 28 day cycle.
62820385|NCT01251965|EXPERIMENTAL|Ruxolitinib 100 mg BID|Phase I dose of Ruxolitinib 100 mg by mouth twice a day for 28 day cycle.
62820386|NCT01251965|EXPERIMENTAL|Ruxolitinib 200 mg BID|Phase I dose of Ruxolitinib 200 mg by mouth twice a day for 28 day cycle.
62040492|NCT06682234|EXPERIMENTAL|Obeldesivir (ODV)|Participants will receive ODV for 10 days
62243971|NCT06678945|EXPERIMENTAL|Bar- OT Equator attachment|on the 2nd stage, implants will be loaded with Bar- OT Equator attachments to support overdenture
62243972|NCT06540547|EXPERIMENTAL|MomMA Intervention|
62243973|NCT05976581|EXPERIMENTAL|Electronic alert plus structured communication of test results|An electronic health record alert will guide diagnostic testing for pneumonia. For patients with low or moderate probability of bacterial pneumonia, test results will be communicated to the primary team with guidance to consider discontinuing or de-escalating antibiotics.
62820387|NCT00148278|EXPERIMENTAL|1|norepinephrine plus dobutamine
62820388|NCT00148278|ACTIVE_COMPARATOR|2|epinephrine
62820389|NCT06345079|ACTIVE_COMPARATOR|Continue SSA|Patients randomised to continue SSA will receive a SSA injection ≥28 days prior to the first PRRT cycle, during PRRT cycle, and every 4 weeks after completion of PRRT.
62820390|NCT06345079|EXPERIMENTAL|Cease SSA|Patients randomised to cease SSA will receive SSA injection ≥28 days prior to their first cycle of PRRT. Patients will not receive any further long acting SSA injections after this time.
62820391|NCT06222853|EXPERIMENTAL|CAR-T treatment group|This trial was designed as an open, single-arm, multicenter, dose-increasing trial. three dose groups (0.3×10\^5/kg, 1×10\^5/kg, 3×105/kg) are set up, starting from the low dose group to explore the safe and effective dose.
62040493|NCT06508281|EXPERIMENTAL|experimental group|After the anatomy course topic is explained in class, students will answer the theoretical questions about the subjects and the pre-test online via a Google Forms survey. Anatomy model videos prepared by the researchers for the experimental group students will be uploaded to Google Drive and sent via link. Students will be asked to log in from their computer or mobile phone and watch anatomy model videos whenever and wherever they want. Students in the experimental group will answer the final test after studying for a week and watching videos on Facial Muscles, Neck Anatomy and Muscles (Anterior Side Region Muscles and Triangles), Forearm Anterior Region Muscles, Forearm Posterior Region Muscles and Hand Muscles.
62040494|NCT06508281|NO_INTERVENTION|control group|"No application will be made to the control group and their training will continue only with the traditional method. Control group students will fill out the theoretical questions test again on the topics Facial Muscles, Neck Anatomy and Muscles (Anterior Side Region Muscles and Triangles), Forearm Anterior Region Muscles, Forearm Posterior Region Muscles and Hand Muscles"
62040495|NCT04205838|EXPERIMENTAL|Prevention (anakinra, CAR T-cell therapy)|Patients receive standard lymphodepleting therapy including fludarabine and cyclophosphamide on days -5 to -3, then receive axicabtagene ciloleucel CAR T-cell infusion. Patients with clinical evidence of ICANS of any grade, or CRS \>= grade 3 receive anakinra SC every 6-12 hours for 12-36 doses over 9 days in the absence of unacceptable toxicity.
62040496|NCT02351804|EXPERIMENTAL|Ropivacaine + dexamethasone|20 ml ropivacaine 0.5% + 0.5 ml dexamethasone 4 mg7ml
62040497|NCT02351804|PLACEBO_COMPARATOR|Ropivacaine + placebo|20 ml ropivacaine 0.5% + 0.5 ml isotonic saline ad
62040498|NCT06733402|EXPERIMENTAL|Trifarotene Cream 0.005%|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
62040499|NCT06733402|ACTIVE_COMPARATOR|AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
62040500|NCT06733402|ACTIVE_COMPARATOR|AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
62040501|NCT06733402|PLACEBO_COMPARATOR|Placebo Control|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
62040502|NCT06229860||Adult patients with CML in chronic phase (CML-CP)|
62040503|NCT00313820|ACTIVE_COMPARATOR|Pregabalin|The change from in pain scores from baseline to endpoint among stroke subjects receiving pregabalin will be compared to change in pain scores from baseline to endpoint among stroke subjects receiving matched placebo.
62040504|NCT00313820|PLACEBO_COMPARATOR|Placebo|The change in pain scores from baseline to endpoint will be compared among the two treatment groups- ie subjects receiving 12 weeks of pregabalin treatment vs subjects receiving 12 weeks of placebo treatment.
62040505|NCT02807558|EXPERIMENTAL|R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy|Participants with R/R non-APL AML or R/R HR-MDS will receive tamibarotene at 6 mg/m\^2/day in 2 divided doses on Days 1-28 of a 28-day cycle.
62434261|NCT03295539|OTHER|Acute or Chronic clot|If chronic clot, no intervention given via Indigo
62434262|NCT03786510|ACTIVE_COMPARATOR|Active control|The control group received Community Center for Dementia's usual care of regular health check-up.
62820392|NCT03299556||WHT|The WHT group includes only patients newly enrolled in the Geisinger MPP program who consent to participate in the study. WHT subjects will be recruited over 1 year, with 1 year of follow-up.
62820393|NCT03299556||Historic Control|Patients who were enrolled in the MPP in the preceding year. These patients received the MPP educational program but received no WHT as part of their treatment.
62820394|NCT03299556||Concurrent Control|Patients being treated for chronic pain in the Geisinger Medical Pain Management (MPM) program over the same time period as the WHT group. These subjects do not receive the MPP educational program nor use WHT as part of their treatment
62820395|NCT00575185|ACTIVE_COMPARATOR|Valomaciclovir|Valomaciclovir 2 grams orally twice daily for 21 days
62820396|NCT00575185|PLACEBO_COMPARATOR|placebo|placebo 2 tablets twice daily for 21 days
62820397|NCT00683527|EXPERIMENTAL|1|Starting oral iron at day 14 of life (Early Iron group)
62820398|NCT00683527|NO_INTERVENTION|2|No iron supplementation till 60 days of life (Control group)
62820399|NCT01440959|EXPERIMENTAL|TKI258|
62820400|NCT06706284|EXPERIMENTAL|SCI and T2DM Treatment Group|Participants with spinal cord injury (SCI) and type 2 diabetes (T2DM) will be assigned to semaglutide weekly for 24 weeks. Semaglutide administration: once-weekly self-administration of SGT, titrated to a dose of 2 mg/week as per FDA approved guidelines. All subjects will be instructed how to inject and titrate up the dose.
62820401|NCT06706284|PLACEBO_COMPARATOR|SCI and T2DM Placebo Group|Participants with spinal cord injury (SCI) and type 2 diabetes (T2DM) will be assigned to the placebo group and inject normal saline weekly for 24 weeks. All subjects in the placebo group will be instructed how to inject and titrate up the dose to mimic the semaglutide administration to a maximum dose of 2 mg in 12 weeks and then continue for remainder of study.
62820402|NCT05375461|EXPERIMENTAL|TQB3616 capsules plus fulvestrant|"The dose of TQB3616 capsules is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.~Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days."
62820403|NCT05375461|PLACEBO_COMPARATOR|TQB3616-matching placebo plus fulvestrant|"The dose of placebo is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.~Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days."
62820404|NCT06494020|EXPERIMENTAL|Task Practice with stimulation|Participants in this group will receive combined Transcutaneous cervical spinal cord stimulation with task practice for up to 4 months.
62820405|NCT06512584|EXPERIMENTAL|PJ009|subcutaneous injections, 0.05 mg/kg once daily
62820406|NCT06512584|PLACEBO_COMPARATOR|PJ009 Placebo|subcutaneous injections, once daily
62820407|NCT04381832|EXPERIMENTAL|Stage 1 and 2: Etrumadenant + zimberelimab + enzalutamide|Participants will receive oral etrumadenant in combination with intravenous (IV) zimberelimab and standard oral enzalutamide
62820408|NCT04381832|ACTIVE_COMPARATOR|Stage 2: enzalutamide|Participants will receive standard oral enzalutamide
62600540|NCT03128320|EXPERIMENTAL|BAY1193397/Placebo (sequence B-C-A)|Subjects with type II diabetes who follow treatment sequence B-C-A. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the second intervention period (Treatment C), then single oral dose of a placebo tablet under fasted conditions in the third intervention period (Treatment A). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
62820409|NCT04381832|EXPERIMENTAL|Stage 1 and 2: Etrumadenant + zimberelimab + docetaxel|Participants will receive oral etrumadenant in combination with IV zimberelimab and standard IV docetaxel
62434263|NCT03786510|EXPERIMENTAL|Intensive + Maintenance program|The INT+MNT group participated in a 4-week intensive program followed by a 20-week maintenance program
62434264|NCT03786510|EXPERIMENTAL|Intensive program only|The INT only group participated in a 4-week intensive program
62820410|NCT04381832|ACTIVE_COMPARATOR|Stage 2: docetaxel|Participants will receive standard dose of IV docetaxel
62820411|NCT04381832|EXPERIMENTAL|Stage 1 and 2: Etrumadenant + zimberelimab|Oral etrumadenant in combination IV zimberelimab
62040506|NCT02807558|EXPERIMENTAL|Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy|Newly diagnosed, treatment-naive participants with non-APL AML who were unlikely to tolerate standard intensive chemotherapy will receive tamibarotene at 6 mg/m\^2/day in 2 divided doses on Days 1-28 of a 28-day cycle.
62434265|NCT04303052|ACTIVE_COMPARATOR|over-the-wire technique with 145 cm guidewire|Catheter tip placement using Seldinger over-the-wire technique with 145 cm guidewire
62820412|NCT04381832|EXPERIMENTAL|Stage 2: Etrumadenant + zimberelimab + quemliclustat|Participants will receive oral etrumadenant in combination with IV zimberelimab and IV quemliclustat
62820413|NCT04381832|EXPERIMENTAL|Stage 2: Etrumadenant + quemliclustat|Participants will receive oral etrumadenant in combination with IV quemliclustat
62820414|NCT04381832|EXPERIMENTAL|Stage 1: Etrumadenant + zimberelimab PK Sub-Study|Participants will receive oral etrumadenant in combination with IV zimberelimab
62820415|NCT04381832|EXPERIMENTAL|Stage 1 and 2: Etrumadenant + SG|Participants will receive oral etrumadenant in combination with IV SG.
62434266|NCT04303052|ACTIVE_COMPARATOR|modified technique with 70 cm guidewire|Catheter tip placement using Seldinger modified technique with 70 cm guidewire
62434267|NCT00936884|EXPERIMENTAL|Methylnaltrexone double-blind|Methylnaltrexone once every other day.
62434268|NCT00936884|PLACEBO_COMPARATOR|Placebo|Placebo once every other day.
62434269|NCT00936884|OTHER|Methylnaltrexone open-label|Subjects who completed the double-blind period had the option to receive methylnaltrexone once every other day during a 12-week, open-label extension period.
62434270|NCT05827900|EXPERIMENTAL|Intervention|Metacognitive Group Training
62434271|NCT05827900|NO_INTERVENTION|Treatment as usual|Treatment as usual
62434272|NCT00856778|OTHER|Virtue® Male Sling|Subjects implanted with Virtue® Male Sling
62434273|NCT01326702|EXPERIMENTAL|Treatment (veliparib, bendamustine hydrochloride, rituximab)|"Patients receive veliparib PO BID on days 1-7 and bendamustine hydrochloride IV over 30-60 minutes on days 1-2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Once the maximum-tolerated dose is determined, a cohort of patients receives veliparib and bendamustine hydrochloride as above and rituximab IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
62623839|NCT04812314|EXPERIMENTAL|Exercise|"This exercise prescription represents a common or conventional form of physical activity (e.g., moderate/brisk walking). If assigned to this group, participants will perform 45 minutes of moderate intensity continuous steady-state exercise at 70% maximal heart rate (HRmax) to expend 250 calories 4 days per week."
62820416|NCT04381832|EXPERIMENTAL|Stage 1 and 2: Etrumadenant + Zimberelimab + SG|Participants will receive oral etrumadenant in combination with IV zimberelimab and SG.
62820417|NCT05794321|EXPERIMENTAL|IV TXA Group|Patients in the experimental group will receive a loading dose of IV tranexamic acid (TXA) at a concentration of 1g/10ml over a period of 10 minutes, administered immediately following anesthesia induction. Postoperative care will be standard and based on established UCSF guidelines.
62040507|NCT02807558|EXPERIMENTAL|Newly Diagnosed Non-APL AML: Tamibarotene and Azacitidine|Newly diagnosed, treatment-naive participants with non-APL AML who are unlikely to tolerate standard intensive chemotherapy will receive tamibarotene at 6 mg/m\^2/day in 2 divided doses on Days 8-28 of a 28-day cycle, and azacitidine at 75 mg/m\^2 once daily on Days 1-7 of a 28-day cycle.
62434274|NCT02092961|EXPERIMENTAL|Dosing Group A|Oral treatment and subcutaneous injection.
62434275|NCT02092961|ACTIVE_COMPARATOR|Dosing Group D|Oral treatment and subcutaneous injection.
62434276|NCT02092961|PLACEBO_COMPARATOR|Dosing Group E|Placebo bid for 6 weeks followed by switch to 100 mg fostamatinib bid for 24 weeks, plus placebo subcutaneous injection every 2 weeks.
62434277|NCT00922792|EXPERIMENTAL|A|
62434278|NCT00922792|EXPERIMENTAL|B|
62434279|NCT01447329|EXPERIMENTAL|Standard treatment plus ear acupuncture|Standard treatment plus ear acupuncture
62434280|NCT01447329|PLACEBO_COMPARATOR|standard|placebo
62434281|NCT00773526|EXPERIMENTAL|1|
62434282|NCT01252238|PLACEBO_COMPARATOR|Valsartan and Aliskiren|Valsartan 150 mg and Aliskiren (150 mg followed by force titration to 300 mg)
62434283|NCT01252238|EXPERIMENTAL|Aliskiren|
62434284|NCT01252238|PLACEBO_COMPARATOR|Placebo Group|Only taking Amlodipine
62434285|NCT01361607|EXPERIMENTAL|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligram \[mg\]/milliliter \[mL\]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
62434286|NCT01361607|PLACEBO_COMPARATOR|Placebo (GA-0034)|Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorings.
62434287|NCT02305368||Oncogramme|Taking a fragment of colon tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
62820418|NCT05794321|NO_INTERVENTION|Control Group|Patients in the control group will not receive any IV TXA intraoperatively and will undergo a traditional gender affirming mastectomy following the established standard of care.
62040508|NCT02807558|EXPERIMENTAL|LR-MDS: Tamibarotene Monotherapy|Participants with transfusion-dependent LR-MDS without the del 5q abnormality who are refractory to erythropoietin (EPO) treatment or unlikely to respond to EPO treatment will receive tamibarotene at 6 mg/m\^2/day in 2 divided doses on Days 1-28 of a 28-day cycle.
62040509|NCT02807558|EXPERIMENTAL|R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab|Participants with R/R non-APL AML or R/R HR-MDS will receive tamibarotene at 6 mg/m\^2/day in 2 divided doses during a 7-day lead-in and on Days 1-28 of a 28-day cycle. Participants will also receive daratumumab at 16 mg/kg starting on Cycle 1 Day 1 once weekly for 8 weeks, followed by dosing every 2 weeks for 16 weeks, followed by dosing every 4 weeks.
62040510|NCT02807558|EXPERIMENTAL|R/R non-APL AML: Tamibarotene and Azacitidine|Participants with R/R non-APL AML will receive tamibarotene at 6 mg/m\^2/day in 2 divided doses on Days 8-28 of a 28-day cycle, and azacitidine at 75 mg/m\^2 once daily on Days 1-7 of a 28-day cycle.
62434288|NCT03501342|EXPERIMENTAL|Virtual reality group|In virtual reality group, 30 minutes of Pilates training, 10 minutes of rest and then 20 minutes of virtual reality will be applied.
62820419|NCT05321134|EXPERIMENTAL|Single Port Robotic Surgery Arm|Study subjects will undergo the colorectal surgical procedure (determined based on routine standard clinical care) using the Intuitive Da Vinci Single Port SP system
62820420|NCT06592365|ACTIVE_COMPARATOR|GTE (Green tea extract)|three tablets once daily
62820421|NCT06592365|PLACEBO_COMPARATOR|Placebo|three tablets once daily
62820422|NCT05743868|EXPERIMENTAL|IR participants with standardized dinner|"Participants with global IR and tissue-specific IR. Participants with global IR (in both skeletal muscle and adipose tissue) and tissue-specific IR (in adipose tissue). Glucose tolerance, skeletal muscle/whole-body insulin sensitivity and adipose tissue insulin sensitivity will be evaluated prior to intervention.~Contribution of DNL to hepatic VLDL will be measured using a deuterated water drink, to be ingested prior to the standardized dinner. Blood will be drawn the following morning for the measurement of deuterium incorporation into triglycerides. Plasma deuterium will be allowed to wash out over several weeks, and the 2nd deuterated water study will be performed."
62820423|NCT05743868|EXPERIMENTAL|IR participants with standardized dinner and premeal exercise|"Participants with global IR and tissue-specific IR. Participants with global IR (in both skeletal muscle and adipose tissue) and tissue-specific IR (in adipose tissue). Glucose tolerance, skeletal muscle/whole-body insulin sensitivity and adipose tissue insulin sensitivity will be evaluated prior to intervention.~DNL will be assessed in all participants after a single day with short bouts of premeal exercise with a standardized dinner.~Contribution of DNL to hepatic VLDL will be measured using a deuterated water drink, to be ingested prior to the standardized dinner. Blood will be drawn the following morning for the measurement of deuterium incorporation into triglycerides. Plasma deuterium will be allowed to wash out over several weeks, and the 2nd deuterated water study will be performed."
62820424|NCT03905707|EXPERIMENTAL|Glepaglutide SC injections twice weekly|"Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection twice weekly.~In this long term safety study, there is no placebo arm."
62820425|NCT03905707|EXPERIMENTAL|Glepaglutide SC injections once weekly and placebo once weekly|"Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection once weekly and placebo once weekly.~In this long term safety study, there is no placebo arm."
62820426|NCT04005378|OTHER|CSC Step-down intervention|Web-based telemedicine and a smartphone app, to decrease disengagement likelihood
62434289|NCT03501342|ACTIVE_COMPARATOR|Dynamic Balance Training|"In the Dynamic Balance Training group, 20 minutes of dynamic balance exercises will be applied after Pilates training."
62820427|NCT04005378|OTHER|Usual Care|Usual care provided by CSC center
62434290|NCT03501342|NO_INTERVENTION|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
62434291|NCT06525441|EXPERIMENTAL|Plant-based diet|Participants assigned to the plant-based diet group will be provided three meals daily for 3 weeks. Of the energy of each meal, 60% is from carbohydrates, 15% from plant protein, and 25% from fat. The main dietary sources of plant protein will be soybeans, flat beans, nuts, grains, and algae.
62623840|NCT04812314|EXPERIMENTAL|No exercise|Subjects assigned to this group are to remain sedentary (no planned physical exercise) throughout the duration of the study.
62820428|NCT02352025|EXPERIMENTAL|S-equol|After having a core needle biopsy of the breast confirming triple negative breast cancer, eligible women enrolled on the study will be treated with S-equol at a dose of 50 mg PO twice daily for 14 days.
62820429|NCT02524327|EXPERIMENTAL|Toolbox: Automated group|"Toolbox: Automated administration of intravenous anesthetic (propofol 1%) and analgesic (remifentanil, Ultiva(r)) guided by the Bispectral index through a controller with a previously described algorithm.~Objective of depth anesthesia: 40-60"
62040511|NCT04359472|OTHER|Treatment Arm|Collection and reapplication of amniotic fluid.
62040512|NCT06482359|ACTIVE_COMPARATOR|Lot 1 (Group 1)|CIC vaccine will be administered as a single 0.5 mL IM injection in the deltoid on Day 0
62040513|NCT06482359|ACTIVE_COMPARATOR|Lot 2 (Group 2)|CIC vaccine will be administered as a single 0.5 mL IM injection in the deltoid on Day 0
62040514|NCT06482359|ACTIVE_COMPARATOR|Lot 3 (Group 3)|CIC vaccine will be administered as a single 0.5 mL IM injection in the deltoid on Day 0
62600541|NCT03128320|EXPERIMENTAL|BAY1193397/Placebo (sequence B-A-C)|Subjects with type II diabetes who follow treatment sequence B-A-C. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of a placebo tablet in the second intervention period (Treatment A), then 5 mg BAY1193397 IR tablet under fasted conditions in the third intervention period (Treatment C). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
62820430|NCT02524327|ACTIVE_COMPARATOR|Manual group|"Manual administration of intravenous anesthetic (propofol 1%) and analgesic (remifentanil, Ultiva(r)) guided by the Bispectral index as usually performed in the operative theater.~Objective of depth anesthesia: 40-60"
62820431|NCT05990296|NO_INTERVENTION|Control|Clinicians in this arm will not receive CDS or focused education and will experience usual care.
62820432|NCT05990296|EXPERIMENTAL|Multiprong CDS with GDMT order set|Clinicians and patients with HFrEF in this arm will receive electronic notification of GDMT care gaps encouraging treatment options. The CDS will inform, encourage, and facilitate prescribing of GDMT via a focused order set.
62040515|NCT06482359|ACTIVE_COMPARATOR|Fluzone HD|Fluzone HD trivalent will be administered as a suspension 1M Injection at 0.5mL on Day 0
62434292|NCT06525441|ACTIVE_COMPARATOR|Animal-based diet|Participants assigned to the animal-based diet group will be provided three meals daily for 3 weeks. Of the energy of each meal, 60% is from carbohydrates, 15% from animal protein, and 25% from fat. The main dietary sources of animal protein will be chicken, beef, pork, fish, eggs, and dairy products.
62600542|NCT01759316|ACTIVE_COMPARATOR|heliox|Heliox is use in this group
62600543|NCT01759316|PLACEBO_COMPARATOR|Placebo|Oxygen is used in this group
62820433|NCT05990296|EXPERIMENTAL|Multiprong CDS with referral to pharmacist co-management|Clinicians and patients with HFrEF in this arm will receive electronic notification of GDMT care gaps encouraging treatment options. The clinician-facing BPA will include an option to refer patients to embedded pharmacist co-management. Pharmacists are expected to meet with patients and optimize GDMT through a collaborative practice agreement with clinicians.
62820434|NCT05990296|EXPERIMENTAL|Focused education|Clinicians in this arm will receive focused education and no CDS.
62820435|NCT05990296|EXPERIMENTAL|Multiprong CDS with GDMT order set + focused education|Clinicians in this arm will receive focused education in addition to clinician BPA heads-up and BPA with GDMT order set for their eligible patients with HFrEF.
62820436|NCT05990296|EXPERIMENTAL|Multiprong CDS with referral to pharmacist co-management + focused education|Clinicians in this arm will receive focused education along with clinicians/patient CDS. The clinician-facing BPA will include an option to refer patients to embedded pharmacist co-management. Pharmacists are expected to meet with patients and optimize GDMT through a collaborative practice agreement with clinicians.
62820437|NCT03192267||No treatment|No treatment
62820438|NCT04244253|EXPERIMENTAL|OPC-64005 20 mg|
62820439|NCT04244253|EXPERIMENTAL|OPC-64005 10 mg|
62820440|NCT04244253|PLACEBO_COMPARATOR|Placebo|
62820441|NCT03904394|PLACEBO_COMPARATOR|Placebo Mouthwash|
62820442|NCT03904394|ACTIVE_COMPARATOR|Antibacterial Mouthwash|
62820443|NCT06491446|ACTIVE_COMPARATOR|Experimental: Cohort 1|Participants in this arm will receive either ABI 2280 (Dose 1) or matching placebo
62820444|NCT06491446|ACTIVE_COMPARATOR|Experimental: Cohort 2|Participants in this arm will receive either ABI 2280 (Dose 2) or matching placebo
62820445|NCT06491446|ACTIVE_COMPARATOR|Experimental: Cohort 3|Participants in this arm will receive either ABI 2280 (Dose 3) or matching placebo
62820446|NCT06491446|ACTIVE_COMPARATOR|Experimental: Cohort 4|Participants in this arm will receive either ABI 2280 (Dose 4) or matching placebo
62820447|NCT06491446|ACTIVE_COMPARATOR|Experimental: Cohort 5|Participants in this arm will receive either ABI 2280 (Dose 5) or matching placebo
62820448|NCT06491446|ACTIVE_COMPARATOR|Experimental: Cohort 6|Participants in this arm will receive either ABI 2280 (Dose 6) or matching placebo
62820449|NCT06491446|ACTIVE_COMPARATOR|Experimental: Cohort 7|Participants in this arm will receive either ABI 2280 (Dose 7) or matching placebo
62820450|NCT06491446|ACTIVE_COMPARATOR|Experimental: Cohort 8|Participants in this arm will receive either ABI 2280 (Dose 8) or matching placebo
62820451|NCT06491446|ACTIVE_COMPARATOR|Experimental: Cohort 9|Participants in this arm will receive either ABI 2280 (Dose 9) or matching placebo
62820452|NCT06491446|ACTIVE_COMPARATOR|Experimental: Cohort 10|Participants in this arm will receive either ABI 2280 (Dose 10) or matching placebo
62820453|NCT06491446|ACTIVE_COMPARATOR|Experimental: Cohort 11|Participants in this arm will receive either ABI 2280 (Dose 11) or matching placebo
62820454|NCT05567198||Group 1|SLE patients receiving CYC alone
62820455|NCT05567198||Group 2|SLE patients receiving both CYC and leuprolide acetate (GnRH-a)
62820456|NCT05567198||Group 3|Control subjects, Age-matched female SLE patients without a history of reproductive disorders
62820457|NCT01480154|EXPERIMENTAL|Treatment (Akt inhibitor MK2206, hydroxychloroquine)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15. Beginning on cycle 2, patients also receive hydroxychloroquine PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62820458|NCT04942574|EXPERIMENTAL|First experimental visit : Total Sleep Deprivation|The participants enrolled in this arm will have a total sleep deprivation on their first experimental visit and a normal sleep on their second experimental visit.
62820459|NCT04942574|EXPERIMENTAL|First experimental visit : Normal Sleep|The participants enrolled in this arm will have a normal on their first experimental visit and a total sleep deprivation sleep on their second experimental visit.
62820460|NCT00599872|ACTIVE_COMPARATOR|Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract administered via the sublingual oral route (27.6 to 77.3 Amb a 1 Units)
62820461|NCT00599872|PLACEBO_COMPARATOR|Placebo|Standardized Ragweed Allergenic Extract Placebo via the sublingual oral route
62820462|NCT04514887|EXPERIMENTAL|Mild Hyperventilation|In this study arm, patients were mildly hyperventilated intraoperatively so their end-tidal CO2 levels are brought down to 30-32 mmHg.
62820463|NCT04514887|NO_INTERVENTION|Control|In this study arm patients' ventilation is managed according to guidelines with end-tidal CO2 levels kept in the normal range of 35-40 mm Hg
62820464|NCT06565429|EXPERIMENTAL|5-Step Method Intervention Group|Receives the 5-Step Method intervention self-help handbook and emails every two weeks to encourage continued use
62040516|NCT06717295||Cancer Patients (Phase 1)|This arm will include 3,500 individuals with confirmed diagnoses of common cancers such as Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, and Pancreatic Cancer.
62434293|NCT01325532|EXPERIMENTAL|Active CES|"Active CES: The FW-100 Cranial Stimulator headset was placed on the scalp over the two dorsolateral prefrontal cortex areas. The power knob was turned to maximum setting. The waveform contains a 15000Hz square wave carrier from 0-4 mAmp. The first 15Hz modulating signal provides 50msec of on and 16.7msec of off time (total 66.7msec, 50% duty cycle). A second 500Hz modulating signal changes the on time series of 15000Hz pulses (750 pulses/50msec) into 25 smaller bursts of 15 pulses of the 15000Hz carrier signal, for 375 pulses in 50msec. The consecutive positive burst and off time is followed by an opposite negative burst and off time, balancing the current component to zero. Output voltage ranges from 0-40V, positive and negative. CES automatically shut off after 20 mins."
62434294|NCT01325532|SHAM_COMPARATOR|Sham CES|Shame CES: The sham devices were modified to not deliver current to the headset. The current from the active device departs from the posts at the top of the device into the headsets, creating a loop when the headset is worn by the subject with the wet electrode sponges. This loop is eliminated in the sham devices by wrapping wire around the posts, thus containing the loop within the device, with no electricity leaving the headsets. This approach allows the loop to be maintained, and therefore all of the device's green and yellow amperage lights still light up, protecting the blind.
62434295|NCT05775458||Adult neurosurgical patients|Adult neurosurgical patients with a brain lesion suspected for GBM, candidate to gross total tumor resection (GTR), followed by radiotherapy and chemotherapy (concomitant and adjuvant).
62434296|NCT03210259|EXPERIMENTAL|BI 695501|
62820465|NCT06565429|NO_INTERVENTION|Control Group|Standard of care.
62040517|NCT06717295||Healthy Individuals|This arm will consist of 1,500 age- and sex-matched cancer-free individuals serving as controls.
62040518|NCT06717295||Cancer Patients Undergoing Treatment|This cohort will include 1,000 patients diagnosed with Hepatocellular Carcinoma (HCC) or Non-Small Cell Lung Cancer (NSCLC) across stages I to IV who are about to commence standard cancer therapy.
62040519|NCT01750073|EXPERIMENTAL|Treatment (chemotherapy, surgery, post-operative therapy)|See Detailed Description
62820466|NCT04872413|EXPERIMENTAL|Screening (biospecimen collection)|Patients undergo blood, saliva or tissue sample collection for mRNA analysis and drug efficacy testing. Patients assigned treatment per the results are followed every 1 cycle of therapy for 1 year, every 2 months for 1 year, every 4 months for 1 year then every 6 months thereafter.
62820467|NCT03128866|EXPERIMENTAL|Arm I (tranexamic acid)|Patients receive tranexamic acid IV over 15 minutes 30 minutes prior to surgery and continuously during hemipelvectomy procedure in the absence of disease progression or unacceptable toxicity.
62820468|NCT03128866|EXPERIMENTAL|Arm II (no tranexamic acid)|Patients undergo standard of care hemipelvectomy in the absence of disease progression or unacceptable toxicity.
62820469|NCT06271291||Observational|Participants undergo blood sample collection, complete questionnaires, have their medical records reviewed and undergo pancreatic cyst fluid collection during standard of care endoscopic ultrasounds fine needle aspiration.
62820470|NCT06363461|EXPERIMENTAL|TDM-180935 topical ointment 1.0%|Daily dose of 1.0% of TDM-180935 topical ointment
62820471|NCT06363461|EXPERIMENTAL|TDM-180935 topical ointment 2.0%|Daily dose of 2.0% of TDM-180935 topical ointment
62820472|NCT06363461|PLACEBO_COMPARATOR|TDM-180935 topical vehicle ointment 1|Daily dose of placebo color matched to TDM-180935 topical ointment 1.0%
62820473|NCT06363461|PLACEBO_COMPARATOR|TDM-180935 topical vehicle ointment 2|Daily dose of placebo color matched to TDM-180935 topical ointment 2.0%
62820474|NCT00375999|EXPERIMENTAL|docetaxel and epirubicin|salvage docetaxel and epirubicin
62820475|NCT04456023|EXPERIMENTAL|Tisagenlecleucel|All patients eligible for treatment with tisagenlecleucel will receive a single dose of tisagenlecleucel.
62040520|NCT00743366|EXPERIMENTAL|Quetiapine (200mg/day), Marijuana (6.2%, 0.0%)|"Quetiapine (200mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (200 mg) were administered 2 times per day ((1100 and 2300 hours).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
62820476|NCT03043014|EXPERIMENTAL|Mifépristone group|
62820477|NCT03043014|ACTIVE_COMPARATOR|misoprostol group|
62820478|NCT04239911|ACTIVE_COMPARATOR|Enhanced usual care|Home health aides in the enhanced usual care arm will receive a virtual heart failure training course.
62820479|NCT04239911|EXPERIMENTAL|Intervention arm|Home health aides in the intervention arm will receive a virtual heart failure training course and a communication-based messaging app.
62820480|NCT06066788|OTHER|Feasibility Arm|A 10 sessions over 5 week virtual interaction between an occupational therapist and a person who is post-stroke, engage in meta-cognitive coaching to develop strategies to overcome barriers to daily living experienced in early stages of stroke. Outcomes anticipated are related to the American Heart Association's Healthy 8.
62820481|NCT06587529|EXPERIMENTAL|Treatment|READY to Stand© curriculum
62820482|NCT06587529|NO_INTERVENTION|Control|control
62820483|NCT06268808|OTHER|Intervention|FreeStyle Libre 2 Flash Glucose Monitoring System
62040521|NCT00743366|PLACEBO_COMPARATOR|Placebo, Marijuana (6.2%, 0.0%)|Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.
62820484|NCT03975010|EXPERIMENTAL|BUP TDS 20 mg for 3 days|Subjects will be randomized into the arms, use BUP TDS 20 mg for 3 days.
62040522|NCT02503748|EXPERIMENTAL|Intervention|Online Tutorial
62040523|NCT06733883|EXPERIMENTAL|Music therapy|All participants get 10 sessions of music therapy, each lasting for 45 to 60 minutes.
62040524|NCT05830955|EXPERIMENTAL|Lullaby Group|The preterm newborns who are going to listen a live lullaby from their mothers' voice will be the first group (Lullaby group).
62820485|NCT03975010|EXPERIMENTAL|BUP TDS 40 mg for 3 days|Subjects will be randomized into the arms, use BUP TDS 40 mg for 3 days.
62820486|NCT03975010|EXPERIMENTAL|BUP TDS 40 mg for 4 day|Subjects will be randomized into the arms, use BUP TDS 40 mg for 4 days.
62820487|NCT04771156|EXPERIMENTAL|Experimental group (Ketorolac)|
62820488|NCT04771156|PLACEBO_COMPARATOR|Control Group|
62820489|NCT05315102|EXPERIMENTAL|Experimental group|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
62820490|NCT05315102|SHAM_COMPARATOR|Control group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor.No spinal adjustment will be performed during any control intervention.
62820491|NCT05156047|ACTIVE_COMPARATOR|Double-blind pitolisant|Double-blind pitolisant administered once daily in the morning upon wakening for 4 weeks during the Double-Blind Randomized Withdrawal Phase
62040525|NCT05830955|EXPERIMENTAL|Breast milk Group|The preterms in the second group (Breast milk group) are going to smell their mothers' breast milk.
62040526|NCT05830955|OTHER|Control Group|The preterms in the third group (Control group) are going to recieve rutin nursing care interventions.
62243974|NCT05976581|ACTIVE_COMPARATOR|Electronic alert without structured communication of test results|An electronic health record alert will guide diagnostic testing for pneumonia. The primary care team will access and interpret test results and decide upon composition and duration of antimicrobial without external guidance.
62600544|NCT00731757|EXPERIMENTAL|1|Patients being treated with Humira.
62820492|NCT05156047|PLACEBO_COMPARATOR|Double-blind placebo|Matching placebo administered once daily in the morning upon wakening for 4 weeks during the Double-Blind Randomized Withdrawal Phase
62820493|NCT05156047|EXPERIMENTAL|Open-label pitolisant|Open-label pitolisant administered once daily in the morning upon wakening for 8 weeks during the Open-Label Phase
62820494|NCT03088696|ACTIVE_COMPARATOR|stimulation of the acupuncture point|"a acupuncture needle and bandage will be applied at pericardium channel 6, point Neiguan"
62040527|NCT06359665|EXPERIMENTAL|Oral curcumin|Oral curcumin 500 mg capsules taken twice each day for 4 weeks.
62243975|NCT05583201|EXPERIMENTAL|KD-496 cell infusion|Each subject will receive KD-496 cell infusion
62243976|NCT00518414|ACTIVE_COMPARATOR|Marketed infant formula with DHA and ARA|Marketed milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA)
62600545|NCT03203759|ACTIVE_COMPARATOR|Inpatient hospitalization|Control / usual care arm. Patients are admitted per usual to an inpatient service. Patients' medical records will be closely monitored. Patients will wear a vital sign and activity monitor whose data is used only retrospectively. On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
62040528|NCT06359665|PLACEBO_COMPARATOR|Placebo|Oral placebo capsules taken twice each day for 4 weeks.
62040529|NCT03101748|EXPERIMENTAL|Group A (Cohort 1 Phase Ib)|Patients receive neratinib PO QD on days 1-21, paclitaxel IV over 1-3 hours on days 1, 8, and 15, pertuzumab IV over 1 hour on day 1, and trastuzumab IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without progression or excessive toxicity with metastatic disease may receive up to 4 additional courses and with locally advanced disease may receive up to 2 additional courses.
62040530|NCT03101748|EXPERIMENTAL|Group B (Cohort 1 Phase II)|Patients receive neratinib, paclitaxel, pertuzumab, and trastuzumab as in Group A. Patients then receive doxorubicin IV and cyclophosphamide IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
62243977|NCT00518414|EXPERIMENTAL|Milk-based infant formula with DHA and ARA|Experimental milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA)
62243978|NCT00518414|EXPERIMENTAL|Milk-based formula with DHA, ARA, prebiotics|Experimental milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA) and prebiotic blend
62243979|NCT04065776|EXPERIMENTAL|Hippocampal-avoidance proton therapy|Hippocampal-avoidance proton therapy
62243980|NCT00954291||Granisetron|14 mg Granisetron
62820495|NCT03088696|PLACEBO_COMPARATOR|no stimulation of the acupuncture point|"only a bandage will be applied at pericardium channel 6, point Neiguan"
62820496|NCT06587802|EXPERIMENTAL|Experimental group|SBRT radiotherapy (radiotherapy dose: 40Gy, 5 times, 8Gy each time, number of metastatic radiotherapy: ≤5).At the end of radiotherapy, 240mg of triplizumab was administered intravenously every cycle (21 days)
62820497|NCT02288286|EXPERIMENTAL|2.5IU/ml in humans aged 10-20 years old|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 10-20 years old on days 0,3,7,14,28
62820498|NCT02288286|EXPERIMENTAL|2.5IU/ml in humans aged 21-50|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 21-50 years old on days 0,3,7,14,28
62820499|NCT02288286|EXPERIMENTAL|2.5IU/ml in humans aged 51-60|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 51-60 years old on days 0,3,7,14,28
62040531|NCT03101748|EXPERIMENTAL|Group C (Cohort 2)|Patients receive neratinib PO QD on days 1-21, paclitaxel IV over 1-3 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery/ Patients then receive doxorubicin and cyclophosphamide as in Group B. Patients then undergo standard of care surgery.
62040532|NCT02767258|ACTIVE_COMPARATOR|Sham Comparator: Eye drop|Eye drop LACRIBELL® - two drops each eye, two times a day, after eye cleansing.
62040533|NCT02767258|EXPERIMENTAL|VIDISIC® GEL|Ocular gel VIDISIC® GEL applied two times a day at the lower palpebra from medium line to the lateral border.
62434297|NCT03210259|ACTIVE_COMPARATOR|Humira®|
62820500|NCT02288286|PLACEBO_COMPARATOR|2.5IU/ml in humans(from 10-20 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 10-20 years old on days 0,3,7,14,28
62820501|NCT02288286|PLACEBO_COMPARATOR|2.5IU/ml in humans(from 21-50 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 21-50 years old on days 0,3,7,14,28
62820502|NCT02288286|PLACEBO_COMPARATOR|2.5IU/ml in humans(from 51-60 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 51-60 years old on days 0,3,7,14,28
62434298|NCT00770315|EXPERIMENTAL|SCH 39641 1.5 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
62820503|NCT02453737|OTHER|Catheter-based brachytherapy APBI|7 Gy x 3 fractions
62820504|NCT02453737|OTHER|3D-CRT APBI|7.3 Gy x 3 fractions
62820505|NCT02453737|OTHER|Proton APBI|7.3 Gy x 3 fractions
62820506|NCT03641417|EXPERIMENTAL|GLWL-01|Oral administration of GLWL-01 300mg BD for 10 days
62820507|NCT03641417|PLACEBO_COMPARATOR|Placebo|Identical oral capsules with no active ingredient, administered BD for 10 days
62820508|NCT06191458|EXPERIMENTAL|Primaquine|Twelve healthy postpartum women who are breast feeding healthy neonates 48 hours - 5 days old will receive primaquine 0.5 mg/kg once daily for 14 days.
62820509|NCT00829569|EXPERIMENTAL|Intralipid with/without Omegaven|Lipid infusion with/without marine n-3 fatty acids
62820510|NCT06598046|EXPERIMENTAL|One arm involving utidelone and capecitabine|Combination use of utidelone and capecitabine Utidelone 30 mg/m2 d1-5(single-day dose allowed ± 10% fluctuation) , once every three weeks; capecitabine: 1000 mg/m2, twice daily, orally after meal (one in the morning and one in the evening, with an interval of about 12 hours, equivalent to a daily dose of 2000 mg/m2) ; The drug was administered consecutively on days 1-14, with a 21-day cycle.
62820511|NCT04956120|EXPERIMENTAL|Citrate Dialysate then Standard Dialysate|Participants receiving hemodialysis using a citrate acid concentrate dialysate for the first year of the study, then receiving hemodialysis using a non-citrate acid concentrate dialysate (standard dialysate) for the second year of the study.
62820512|NCT04956120|ACTIVE_COMPARATOR|Standard Dialysate|Participants receiving hemodialysis using a non-citrate acid concentrate dialysate for the first year of the study, then receiving hemodialysis using a citrate acid concentrate dialysate for the second year of the study.
62820513|NCT02516280|EXPERIMENTAL|Hyperbaric gaseous cryotherapy group|Conventional rehabilitation with Cryoton ™ hyperbaric cryotherapy
62820514|NCT02516280|ACTIVE_COMPARATOR|Control ice bag group|Conventional rehabilitation with ice bag cryotherapy. Application of a bag of crushed ice directly on the anterior aspect of the knee.
62820515|NCT05357625|EXPERIMENTAL|Treatment group|Clients in the treatment group received the usual floating support service as described for the control group together with feedback. The support workers received feedback from the clients through the ORS and SRS scales of the feedback tool (Bargmann and Robinson 2011). The support worker evaluated the progress of the outcome for the client and the alliance between the support worker and the client from session to session.
62820516|NCT05357625|NO_INTERVENTION|Control group|Clients in the control group received the usual floating support service without Feedback. Therefore, there was no systematic feedback between clients and support workers in the control group. The service was provided in the clients' homes, and there was no fixed limit of sessions for the support. The support covered any problem, including setting up tenancies, working with clients around practical things, so they could live independently, making sure that clients received all relevant benefits and helping clients with access to physical and mental health services. Some support workers saw their clients on a weekly basis, but there was a large variation in the frequency of meetings. Furthermore, the duration of the support service varied, from a few weeks to several years.
62820517|NCT00746681|EXPERIMENTAL|A|Tolterodine SR 2 mg once daily combined with pregabalin 75 mg twice daily
62820518|NCT00746681|ACTIVE_COMPARATOR|B|Tolterodine SR 4 mg once daily
62820519|NCT00746681|PLACEBO_COMPARATOR|C|Placebo
62820520|NCT00746681|EXPERIMENTAL|D|Tolterodine SR 4 mg once daily combined with pregabalin 150 mg twice daily
62820521|NCT00746681|EXPERIMENTAL|E|Pregabalin 150 mg twice daily
62820522|NCT06579300|EXPERIMENTAL|Part 1: Group 1 ABBV-1088 Dose A|Participants will receive ABBV-1088 dose A for 7 days
62820523|NCT06579300|EXPERIMENTAL|Part 1: Group 1 Placebo|Participants will receive placebo for 7 days
62820524|NCT06579300|EXPERIMENTAL|Part 1: Group 2 ABBV-1088 Dose B|Participants will receive ABBV-1088 dose B for 21 days
62820525|NCT06579300|EXPERIMENTAL|Part 1: Group 2 Placebo|Participants will receive placebo for 21 days
62820526|NCT06579300|EXPERIMENTAL|Part 1: Group 3 ABBV-1088 Dose C|Participants will receive ABBV-1088 dose C for 7 days
62820527|NCT06579300|EXPERIMENTAL|Part 1: Group 3 Placebo|Participants will receive placebo for 7 days
62820528|NCT06579300|EXPERIMENTAL|Part 1: Group 4 ABBV-1088 Dose D|Participants will receive ABBV-1088 dose D for 21 days
62820529|NCT06579300|EXPERIMENTAL|Part 1: Group 4 Placebo|Participants will receive placebo for 21 days
62820530|NCT06579300|EXPERIMENTAL|Part 1: Group 5 ABBV-1088 Dose D|Participants older than 60 years of age will receive ABBV-1088 dose D for 21 days
62040534|NCT05620823|EXPERIMENTAL|Povorcitinib Dose A|Participants will receive Povorcitinib Dose A for 54 weeks.
62040535|NCT05620823|EXPERIMENTAL|Povorcitinib Dose B|Participants will receive Povorcitinib Dose B for 54 weeks.
62040536|NCT05620823|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo for 12 weeks, followed by Povorcitinib (Dose A or Dose B) for 42 weeks.
62623841|NCT03865719|OTHER|Healthy Habits for Life Intervention|Participants will receive the Healthy Habits for Life Intervention
62623842|NCT01238341||Pancreatobiliary disease|Patients who have altered gastric anatomy who need an ERCP with an overtube for evaluation of pancreatobiliary disease.
62243981|NCT05044819|EXPERIMENTAL|Cannabidiol|Cannabidiol solution 100 milligrams per milliliter (mg/mL) will be administered orally at a dose level of 5 mg/kg/day for 1 week, then increase to 10 mg/kg/day by the participant or their caregiver twice each day (morning and evening).
62820531|NCT06579300|EXPERIMENTAL|Part 1: Group 5 Placebo|Participants older than 60 years of age will receive placebo for 21 days
62820532|NCT06579300|EXPERIMENTAL|Part 2: Period 1 ABBV-1088 Dose A|Participants will receive ABBV-1088 Dose A on day 1
62820533|NCT06579300|EXPERIMENTAL|Part 2: Period 2 ABBV-1088 Dose A with ITZ|Participants will receive ABBV-1088 dose A on day 4 with itraconazole (ITZ) for 10 days
62820534|NCT06579300|EXPERIMENTAL|Part 3: Group 1 ABBV-1088 Han Chinese Participants|Han Chinese participants will receive ABBV-1088 dose E on day 1
62820535|NCT06579300|EXPERIMENTAL|Part 3: Group 2 ABBV-1088 Japanese Participants|Japanese participants will receive ABBV-1088 dose E on day 1
62820536|NCT05271578|EXPERIMENTAL|Smokers|Conventional tobacco cigarette smokers
62820537|NCT05271578|EXPERIMENTAL|Vapers|Electronic cigarette vapers
62820538|NCT02179697|ACTIVE_COMPARATOR|Surgery + Bracing vs. Bracing Alone|"Randomize between 2 treatments:~Treatment 1: Surgery + Bracing Treatment 2: Bracing alone"
62820539|NCT02179697|OTHER|Patient's choice|Patient will decide which group is best for him/her. The patient will be followed at the same points as Group 1.
62820540|NCT06419270||Patients|Patients with post-surgical hypoparathyroidism
62820541|NCT06419270||Controls|Gender and age matched controls from the general population
62820542|NCT05163158|EXPERIMENTAL|Central BP target|Participants randomized to central BP target will be treated with anti-hypertensive agents to achieve a clinic central SBP \< 130 mmHg.
62820543|NCT05163158|ACTIVE_COMPARATOR|Brachial BP target (standard of care)|Participants randomized to a brachial BP target will be treated with anti-hypertensive drugs to achieve a clinic brachial SBP \<130 mmHg.
62820544|NCT05810740|EXPERIMENTAL|Binimetinib 15 mg then Binimetinib 45 mg|Participants first received a single dose of 3 tablets of Binimetinib 15 mg orally in fasted conditions in the morning on day 1 of a 5-day period. After a washout period of 7 days, they then received a single dose of 1 tablet of Binimetinib 45 mg orally in fasted conditions in the morning for five days on day 1 of a second 5-day period.
62820545|NCT05810740|EXPERIMENTAL|Binimetinib 45 mg then Binimetinib 15 mg|Participants first received a single dose of 1 tablet of Binimetinib 45 mg orally in fasted conditions in the morning on day 1 of a 5-day period. After a washout period of 7 days, they then received a single dose of 3 tablets of Binimetinib 15 mg orally in fasted conditions in the morning for five days on day 1 of a second 5-day period.
62820546|NCT06423885|EXPERIMENTAL|Study treatment|Participants received BL-M07D1+PD-1 monoclonal antibody and BL-M07D1+PD-1 monoclonal antibody+ capecitabine in the first cycle (3 weeks). Participants who had a clinical benefit could receive additional cycles of additional treatment. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
62820547|NCT03850379|EXPERIMENTAL|Levo|Levofloxacin 500 mg once daily
62243982|NCT06735326|EXPERIMENTAL|Fluzoparib monotherapy|Fluzoparib capsules with a treatment cycle of 28 days, for a total of 2 cycles.
62820548|NCT03850379|ACTIVE_COMPARATOR|Cipro|Ciprofloxacin 500 mg BID
62820549|NCT04338321|EXPERIMENTAL|Esketamine Arm|Participants will receive treatment with esketamine nasal spray (28 milligram \[mg\] \[initial dose for elderly participants 65 to 74 years of age and adults of Japanese ancestry; may be used throughout the study in these populations; may be uptitrated in 28 mg increments\], 56 mg \[initial dose for adult participants aged 18 to 64 years and may be used for all age groups throughout the study\], or 84 mg \[maximum dose esketamine nasal spray may be uptitrated to\]) twice-weekly with a flexible dose regimen from Day 1 until Week 4, once weekly from Week 5 to Week 8 and once-weekly or once every 2 weeks from Week 9 to Week 32 in combination with continuing serotonin-norepinephrine reuptake inhibitor/selective serotonin reuptake inhibitor (SSRI/SNRI).
62820550|NCT04338321|ACTIVE_COMPARATOR|Comparator Arm|Participants will continue to take their current SSRI/SNRI augmented with quetiapine extended release (XR) as per the Summary of Product Characteristics (SmPC) (or local equivalent, if applicable). In adult participants aged 18 to 64 years, the initial dose is 50 mg/day on Days 1-2, 150 mg/day on Days 3-4 \[lowest effective dose\]; a further dose increase to 300 mg/day on Day 5 and onward will be based on individual participant evaluation. In elderly participants aged 65 to 74 years, the initial dose is 50 mg/day on Days 1-3, 100 mg/day on Days 4-7, and 150 mg/day on Day 8; a further dose increase to 300 mg/day will be based on individual participant evaluation no earlier than Day 22.
62820551|NCT05953389|EXPERIMENTAL|Pitolisant|One tablet of pitolisant 5 mg, two tablets of pitolisant 5 mg, one tablet of pitolisant 20 mg or two tablets of pitolisant 20 mg per day for 12 weeks.
62820552|NCT05953389|PLACEBO_COMPARATOR|Placebo|One or two tablets of matching placebo per day for 12 weeks.
62243983|NCT06735326|EXPERIMENTAL|Fluzoparib in combination with Bevacizumab|Fluzoparib capsules with a treatment cycle of 28 days, for a total of 2 cycles; in combination with Bevacizumab injection (7.5mg/kg, intravenous infusion, administered once every three weeks), for a total of 2 doses.
62243984|NCT06735326|ACTIVE_COMPARATOR|Paclitaxel plus Carboplatin|Paclitaxel injection plus Carboplatin injection, administered once every three weeks for a total of 3 doses. If there is an allergy to Paclitaxel, it is recommended to replace it with Docetaxel or Liposomal Doxorubicin.
62434299|NCT00770315|EXPERIMENTAL|SCH 39641 6 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
62820553|NCT02262806|OTHER|Leptin therapy|leptin administered via SC injections BID
62820554|NCT05289310|EXPERIMENTAL|Normobaric hypoxia (NH)|8 weeks of overnight exposure (8 hrs/night) to NH conditions (\~15% oxygen; achieved with nitrogen dilution, equivalent to \~8500 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
62820555|NCT05289310|SHAM_COMPARATOR|Normobaric normoxia (NN)|8 weeks of overnight exposure (8 hrs/night) to NN conditions (\~21% oxygen; sea level) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
62623843|NCT03302507|EXPERIMENTAL|BESS, biportal endoscopic spine surgery|Biportal endoscopic decompression surgery for lumbar spinal stenosis
62040537|NCT06733324|EXPERIMENTAL|Participants will receive SCERTS intervention|Participants in the experimental group will receive the SCERTS (Social Communication, Emotional Regulation, and Transactional Support) intervention program. This is an evidence-based, individualized program designed to improve social communication, emotional regulation, and adaptive behaviors in children with Autism Spectrum Disorder (ASD) aged 3-6 years. The intervention will be delivered over 8 weeks, with weekly structured sessions involving parents and educators to ensure skill generalization across home and school settings. The program includes strategies to enhance joint attention, emotion sharing, symbolic play, and the use of non-verbal cues. Parents will be actively engaged to facilitate ongoing support and reinforcement in real-life environments.
62040538|NCT06733324|ACTIVE_COMPARATOR|Control Group|Participants in the treatment-as-usual (TAU) group will receive the standard care typically available for children with Autism Spectrum Disorder (ASD) in the community. This may include therapies such as speech-language therapy, occupational therapy, and applied behavior analysis, depending on the availability of services and individual needs. These interventions focus on addressing core ASD symptoms like communication deficits, behavioral challenges, and sensory integration difficulties. The TAU group will not receive any components of the SCERTS intervention during the study period. This group will serve as an active comparator to evaluate the relative effectiveness of the SCERTS program in improving social communication, emotional regulation, and adaptive behaviors. After the study concludes, participants in the TAU group will have the opportunity to receive the SCERTS intervention to ensure equitable access to the experimental treatment.
62820556|NCT02152891|EXPERIMENTAL|CHAP-EMS/CP@clinic Program Intervention|12 month implementation of the intervention
62820557|NCT02152891|NO_INTERVENTION|Control|Will complete a survey at baseline and at 1 year, no program or intervention provided
62434300|NCT00770315|EXPERIMENTAL|SCH 39641 12 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
62434301|NCT00770315|PLACEBO_COMPARATOR|Placebo|Participants receive matching placebo rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
62434302|NCT04846218|ACTIVE_COMPARATOR|Group 1|They will receive a single dose of 0.2 mg triptorelin (Decapeptyl® Ipsen Pharmaceutical Company, France) and follow up with daily 125 IU HCG injections
62434303|NCT04846218|ACTIVE_COMPARATOR|Group 2|They will receive a single dose of HCG 10000 IU was given followed by progesterone supplementation with 100mg IM (Prontogest®).
62434304|NCT03938298|EXPERIMENTAL|Intervention group|
62623844|NCT03302507|ACTIVE_COMPARATOR|ULBD, unilateral laminotomy bilateral decompression|Minimally invasive ULBD for lumbar spinal stenosis
62820558|NCT05215431|EXPERIMENTAL|systemic sclerosis group|Patients with established diagnoses of systemic sclerosis and periodontitis
62623845|NCT00038870|EXPERIMENTAL|Dendritic Cell Activated Lymphocytes|
62820559|NCT05215431|EXPERIMENTAL|periodontitis group|Systemically healthy periodontitis patients
62820560|NCT04436991||Amoxicillin-clavulanate|Administration of amoxicillin-clavulanate as standard care therapy (4x or 6x 1g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
62820561|NCT04436991||Piperacillin-tazobactam|Administration of piperacillin-tazobactam as standard care therapy (4x 4g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
62820562|NCT04436991||Temocillin|Administration of temocillin as standard care therapy (2x or 3x 2g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
62820563|NCT05005182|EXPERIMENTAL|Cohort A (luspatercept)|Patients receive luspatercept SC on day 1. Cycles repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow biopsy and aspirate at baseline and on study.
62040539|NCT00765674|EXPERIMENTAL|Aliskiren / amlodipine|Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
62040540|NCT00765674|EXPERIMENTAL|Aliskiren / hydrochlorothiazide|Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
62040541|NCT00765674|EXPERIMENTAL|Amlodipine / hydrochlorothiazide|Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
62040542|NCT00765674|EXPERIMENTAL|Aliskiren / amlodipine / hydrochlorothiazide|Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
62040543|NCT04593433|EXPERIMENTAL|Intervention|Group with the virtual museum guided tours
62040544|NCT05708612|EXPERIMENTAL|Implantation of SimplyFI|Long-term non-active implant
62040545|NCT06733766||ultrasound-guided thermal ablation|ultrasound-guided thermal ablation
62040546|NCT04473885|EXPERIMENTAL|Perturbation-based balance training group|Participants in the experimental group will receive the balance training under perturbation on Balance SystemTM SD, including limits of stability training, maze control training, random control training. The intervention is 40 min/session, 3 sessions/week for 6 weeks.
62040547|NCT04473885|NO_INTERVENTION|Control group|Participants in the control group will remain their regular activity without additional training.
62040548|NCT06397768|EXPERIMENTAL|Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months)|Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 6 months. Vaccines administered at age 6 months: RSVt Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered non-concomitantly at 7 months of age
62040549|NCT06397768|EXPERIMENTAL|Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months)|Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 7 months. Vaccines administered at age 6 months: Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered concomitantly at 6 months of age
62243985|NCT03482778||AYA Patients - AIM1A|Qualitative data collection will occur through one-on-one semi-structured interviews with AYA patients (n=36). AYA patients are eligible if they: (1) are 15 to 39 years of age, (2) were diagnosed with cancer at 15 to 39 years of age; (3) are able to read and understand English; (4) have a new cancer diagnosis and are receiving curative treatment OR are currently 0 to 5 years post-treatment. AYA patients will be excluded if they: (1) were diagnosed with basal cell skin cancer; (2) experienced a cancer recurrence; (3) are currently receiving palliative or hospice care; (4) had an infertility diagnosis prior to their cancer diagnosis, or (5) report a significant psychiatric history.
62243986|NCT03482778||AYA Providers - AIM1A|Qualitative data collection will occur through one-on-one semi-structured interviews with AYA providers (n=36). Providers will be health professionals who provide supportive care for AYAs to help address financial, body image, and fertility/future parenthood concerns or needs. Psychosocial providers (e.g., social workers, patient navigators, psychologists) will all be eligible to participate. We will also include reproductive endocrinologists, nurse practitioners, and other medical professionals who have expertise in the appropriate area of health-related quality of life (HRQOL). Additional inclusion criteria will be: (1) provision of care to AYAs; (2) ≥2 years practicing; (3) English-speaking.
62243987|NCT03482778||Content Experts - AIM1A|Qualitative data collection will occur through one-on-one semi-structured interviews with content experts (n=36). Content experts are a purposive sample of scientists and clinicians who have recognized expertise in each of the three domains of interest to this project - financial burden, body image, and fertility/future parenthood.
62040550|NCT06397768|EXPERIMENTAL|Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months)|Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 12 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered non-concomitantly at 13 months of age
62243988|NCT03482778||AYA Patients - AIM1B|Five forms have been created for AYA patients (n=25). Each form consists of 25 to 30 items. Forms for AYA patients include an even number of items from the body image, financial burden, and fertility domains counterbalanced in order of administration to reduce the potential for order effects. Participants will also complete a sociodemographic form and, to evaluate literacy and reading grade equivalent, an interviewer-administered Wide Range Achievement Test (WRAT-5) will also be completed. Only the Word Reading portion of the WRAT-5 will be administered to the participants. Cognitive interviews will be conducted over 2 rounds with half the sample comprising each round. Items substantially revised from Round 1 will be re-evaluated in Round 2.
62434305|NCT03938298|ACTIVE_COMPARATOR|Control group|
62434306|NCT04316598|EXPERIMENTAL|Cannabis (B)|"Subjects will be admitted in the center to receive 4 doses of inhaled cannabis in 3 days.~Vital signs, blood test and electroencephalogram (Starlab® helmet) will be performed before and after every cannabis administration. Cannabis subjective effects will be assessed and a psychiatric research interview will also be performed at different times after administration."
62820564|NCT05005182|EXPERIMENTAL|Cohort A (luspatercept, hydroxyurea)|Patients receive luspatercept SC on day 1 and hydroxyurea PO on days 1-21. Cycles repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow biopsy and aspirate at baseline and on study.
62820565|NCT02732275|EXPERIMENTAL|Dose Escalation - DS-3201b|Dose escalation is to identify the recommended phase 2 dose of DS-3201b guided by the modified continuous reassessment method using a Bayesian logistic regression model following escalation.
62820566|NCT02732275|EXPERIMENTAL|Dose Expansion - DS-3201b|Part 2 is a dose expansion to examine the safety and efficacy of DS-3201b.
62820567|NCT05454033|EXPERIMENTAL|JUVÉDERM® VOLITE™|Participants in the treatment group will receive a single dose at the study initiation. Participants are eligible for touch up treatment.
62820568|NCT05454033|OTHER|Control - No Treatment|Participants in the control group will receive no treatment. At Month 2, these participants will have the option to receive the treatment.
62820569|NCT01708408||community|
62820570|NCT01452906|EXPERIMENTAL|PA21 and Omeprazole with food|
62820571|NCT01452906|EXPERIMENTAL|No PA21; Omeprazole with food|
62820572|NCT01452906|EXPERIMENTAL|PA21 with food, Omeprazole 2 hrs later|
62040551|NCT06397768|EXPERIMENTAL|Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months)|Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 13 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered concomitantly at 12 months of age
62434307|NCT04316598|PLACEBO_COMPARATOR|Cannabis placebo (B)|"Subjects will be admitted in the center to receive 4 doses of an inhaled treatment based on placebo-THC in 3 days.~Vital signs, blood test and electroencephalogram (Starlab® helmet) will be performed before and after every administration. Cannabis subjective effects will be assessed and a psychiatric research interview will also be performed at different times after administration."
62434308|NCT03406130|ACTIVE_COMPARATOR|Insignia orthodontic treatment|
62820573|NCT04930367|ACTIVE_COMPARATOR|Enhanced Standard of Care|To be implemented at all 12 clinic sites, includes a set of interventions aimed at optimizing the national standard of care (billboards/posters and radio shows, healthcare worker training, one-stop adolescent and youth friendly services, information/motivation walls, pill containers and tools to be used by clinic staff during clinical visits)
62820574|NCT04930367|EXPERIMENTAL|CombinADO Strategy|"To be implemented at 6 randomly selected clinic sites, includes all interventions in the Enhanced Standard of Care arm plus five additional intervention components, including 1) Mental health screening and linkage to adolescent-focused mental health support, 2) peer navigation support, 3) an informational video, 4) peer support groups for AYAHIV and 5) support groups for caregivers of AYAHIV"
62040552|NCT02385305|OTHER|Pressure support ventilation|Usual anesthesia management
62040553|NCT01982357||premature infant|Laser Speckle Imaging and Diffuse Optical Spectroscopy
62040554|NCT05352802|EXPERIMENTAL|Prehabilitation group|The prehabilitation group received multimodal prehabilitation combined with ERAS before the gastrectomy.
62040555|NCT05352802|ACTIVE_COMPARATOR|ERAS group|The ERAS group patients were treated according to the ERAS pathway.
62820575|NCT01375140|EXPERIMENTAL|Ruxolitinib + Lenalidomide|Ruxolitinib 15 mg orally twice daily continuously + Lenalidomide orally 5 mg/day on days 1-21, followed by 7 days of no therapy (28-day cycle). Prednisone will be added for patients who have not responded after 3 cycles of therapy. Prednisone 30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued.
62243989|NCT03482778||AYA Caregivers - AIM1B|Two forms for AYA caregivers (n=10). Each form consists of 25 to 30 items. Forms for AYA caregivers only include items from the financial burden domain. Participants will also complete a sociodemographic form and, to evaluate literacy and reading grade equivalent, an interviewer-administered Wide Range Achievement Test (WRAT-5) will also be completed. Only the Word Reading portion of the WRAT-5 will be administered to the participants. Cognitive interviews will be conducted over 2 rounds with half the sample comprising each round. Items substantially revised from Round 1 will be re-evaluated in Round 2.
62243990|NCT05122897|EXPERIMENTAL|Pagalinor®2 (PA) test arm|All patients will wear both the test and control ring material for a within-subject comparison. Ideally, biofilm sampling can be performed in a split mouth design (randomly allocated materials within subjects) with one patient having two implants for placing the test and the control material at the same time. In addition, patients providing one implant, will receive test and control push-on rings in a randomly assigned order, so that both materials are assessed in a consecutive manner.
62243991|NCT05122897|ACTIVE_COMPARATOR|Titanium-6Aluminum- 7Niobium alloy (TAN) control arm|All patients will wear both the test and control ring material for a within-subject comparison. Ideally, biofilm sampling can be performed in a split mouth design (randomly allocated materials within subjects) with one patient having two implants for placing the test and the control material at the same time. In addition, patients providing one implant, will receive test and control push-on rings in a randomly assigned order, so that both materials are assessed in a consecutive manner.
62434309|NCT03406130|EXPERIMENTAL|Piezocision-assisted Insignia orthodontic treatment|
62434310|NCT05450666|EXPERIMENTAL|YOUNG GROUP|The same exercise program will be applied to both groups. Participants will be included in the exercise program for eight weeks. Athletes between the ages of 18 and 30 will be included in this group.
62623846|NCT06283433|ACTIVE_COMPARATOR|Control Group (venipuncture)|Conventional blood sampling via venipuncture method by a skilled drawing facility
62820576|NCT02574624|EXPERIMENTAL|Intraocular Assistance|Intraocular assistance in patients undergoing standard of care vitreous surgeries
62820577|NCT04415944|EXPERIMENTAL|Second Look Laparoscopy and HIPEC with Carboplatin|Laparoscopic assessment of disease status of the peritoneal cavity with lysis of adhesions as necessary noting either no gross residual disease or minimal residual disease prior to or after resection. This is performed prior to establishment of a peritoneal perfusion circuit and hyperthermic intraperitoneal chemotherapy.
62820578|NCT04776083|EXPERIMENTAL|radiotherapy arm|after first line systemic therapy, patients will receive radiotherapy to the primary lesion, hypo-fractionated regimen 45gy will be given over 15 fractions
62820579|NCT04776083|ACTIVE_COMPARATOR|no intervention arm|after first line systemic therapy, patients will be kept under follow up
62820580|NCT06537726||No invasive fungal disease|Patients, that retrospectively do not have evidence of IFI
62820581|NCT06537726||Possible invasive fungal disease|Patients, that retrospectively have a possible IFI (according to EORTC guidelines). There is suspicion of IFI by clinical or radiological features, but no microbiological evidence of IFI.
62040556|NCT06005766|EXPERIMENTAL|Intervention group|Patients with a psychosis spectrum disorder participating in the group-based metacognitive skills training and receiving treatment as usual
62040557|NCT06005766|ACTIVE_COMPARATOR|Patient controls|Patients with a psychosis spectrum disorder receiving standard long-term care in the hospital
62040558|NCT06005766|NO_INTERVENTION|Non-patient controls|Control group consisting of test subjects without a diagnosis of psychosis spectrum disorder
62040559|NCT04790240|ACTIVE_COMPARATOR|Inflammation (I)|"1. Upper respiratory inflammation.~2. Fever.~3. Lower respiration inflammation."
62040560|NCT04790240|ACTIVE_COMPARATOR|Inflammation (II)|Cough, chest pain
62040561|NCT04790240|ACTIVE_COMPARATOR|Inflammation (III)|"1. Metabolites~2. Clots"
62040562|NCT00765388|EXPERIMENTAL|SenSura Uro|The test product is a CE-marked non-sterile one-piece urostomy multi-chamber bag with the SenSura adhesive.
62040563|NCT00765388|ACTIVE_COMPARATOR|hollister Uro|The comparator product is CE-marked and non-sterile and produced for urostomy operated. It is a flat one-piece urostomy product, Hollister Moderma Flex Urostomy beige, Cut-to-Fit Bag, flat adhesive
62040564|NCT05925127|EXPERIMENTAL|Group-A Monovalent NVX-CoV2373 (5 μg)|The Monovalent NVX-CoV2601 of 5 μg of antigen with 50 μg of Matrix-M adjuvant
62040565|NCT05925127|EXPERIMENTAL|Group-B Monovalent NVX-CoV2601 (5 μg)|Monovalent NVX-CoV2601 (5 μg of antigen with 50 μg of Matrix-M adjuvant)
62040566|NCT05925127|EXPERIMENTAL|Group-C Monovalent NVX-CoV2601 (5 μg)|Monovalent NVX-CoV2601 (5 μg of antigen with 75 μg of Matrix-M adjuvant)
62040567|NCT05925127|EXPERIMENTAL|Group-D Monovalent NVX-CoV2601 (35 μg)|Monovalent NVX-CoV2373 (35 μg of antigen with 50 μg of Matrix-M adjuvant)
62040568|NCT05925127|EXPERIMENTAL|Group-E Monovalent NVX-CoV2601(35)|Monovalent NVX-CoV2601 (35 μg of each antigen with a 75 μg of Matrix-M adjuvant)
62040569|NCT05925127|EXPERIMENTAL|Group-F Monovalent NVX-CoV2601 (50 μg)|Monovalent NVX-CoV2601 (50 μg of each antigen with a 100 μg of Matrix-M adjuvant)
62040570|NCT05925127|EXPERIMENTAL|Group-G Bivalent XBB.1.5|Bivalent XBB.1.5 Omicron subvariant/prototype COVID-19 licensed mRNA vaccine
62040571|NCT06132880|EXPERIMENTAL|Intervention group|Intravenous injections of urinary kallidinogenase (0.15 peptide nucleic acids (PNA) in 0.9% NaCl) intravenous drip quaquedie (QD) for 10 days.
62040572|NCT06132880|OTHER|Control group|Conventional therapy of acute ischemic stroke after based on Chinese guidelines.
62820582|NCT06537726||Probable invasive fungal disease|Patients, that retrospectively have a probable IFI (according to EORTC guidelines). There is suspicion of IFI by clinical or radiological features, and indirect microbiological evidence of IFI.
62820583|NCT06537726||Proven invasive fungal disease|Patients, that retrospectively have a proven IFI (according to EORTC guidelines). There is histological (angioinvasive growth of a fungus) or definitive microbiological evidence of IFI, e.g. evidence of a fungus from a sterile tissue.
62820584|NCT05487612|ACTIVE_COMPARATOR|Minimal Invasive Extracorporeal Circulation (MiECC)|Patients undergoing coronary artery bypass grafting (CABG), aortic valve replacement (AVR), or combined procedure (AVR+CABG) with Minimal Invasive Extracorporeal Circulation (MiECC).
62820585|NCT05487612|ACTIVE_COMPARATOR|Conventional Cardiopulmonary Bypass (cCPB)|Patients undergoing coronary artery bypass grafting (CABG), aortic valve replacement (AVR), or combined procedure (AVR+CABG) with conventional cardiopulmonary bypass (cCPB)
62820586|NCT04515771|EXPERIMENTAL|Active PARTNER-MH|Participants in this arm received the intervention immediately after study enrollment. They continued to receive usual mental health services in addition to intervention.
62820587|NCT04515771|OTHER|Waitlist Control|The waitlist control arm participants received usual mental health services. They were offered to receive the intervention after the 6-month wait period.
62820588|NCT05748275||Argos, Then IOLMaster 700|Biometry measurements first with the Argos device followed by the IOLMaster 700 device.
62820589|NCT05748275||IOLMaster 700, Then Argos|Biometry measurements first with the IOLMaster 700 device followed by the Argos device.
62820590|NCT04092504|NO_INTERVENTION|Control group|Standard care at the unit
62820591|NCT04092504|EXPERIMENTAL|Gero-Erat|New care pathway that is built on the concept of ERAS and CGA
62820592|NCT02916212|EXPERIMENTAL|Experimental|Hospital units where alarms have been optimized
62820593|NCT02916212|NO_INTERVENTION|Control|Hospital units where alarms remain unchanged
62040573|NCT04406493|EXPERIMENTAL|COVID 19 patients|"COVID 19 patients are admitted to the Infectious Diseases Unit, will undergo examination using a lung impedance device. The first value that has been measured will be set as BASAL.~During the hospitalization each patient will undergo this examination twice a day until discharged.~Changes in impedance values during admission will be evaluated as POSITIVE AND NEGATIVE PREDICTIVE values for clinical deterioration and improvement of COVID 19 patients and as a factor which predicts mechanical ventilation The time between lung impedance started to decrease (expression of the lung fluids accumulation) and the need for mechanical ventilation will be measured."
62600546|NCT03203759|EXPERIMENTAL|Home hospitalization|Intervention arm. Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
62600547|NCT01609309|EXPERIMENTAL|Laparoscopic gastrectomy|Laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
62040574|NCT06582706|EXPERIMENTAL|Extended -Release Niacin|500 mg daily
62040575|NCT06582706|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose tablets
62040576|NCT03728673|EXPERIMENTAL|Escitalopram|This is an open-label study. Escitalopram will be administered to all participants as 10 mg capsules to be taken by mouth daily for 90 days.
62040577|NCT06710834|ACTIVE_COMPARATOR|Hemodiafiltration alone|
62040578|NCT06710834|EXPERIMENTAL|Hemodiafiltration plus hemoadsorption|
62040579|NCT03746366|EXPERIMENTAL|Alcohol use disorders|\[C-11\]Pittsburgh Compound B (PiB) PET scan
62820594|NCT06592482|EXPERIMENTAL|Group 1: AZD0780|Participants with severe renal impairment (eGFR \< 30 mL/min), not on dialysis.
62820595|NCT06592482|EXPERIMENTAL|Group 2: AZD0780|Participants with ESRD (eGFR \< 15 mL/min) on a stable intermittent HD schedule for at least 3 months prior to planned dosing.
62820596|NCT06592482|EXPERIMENTAL|Group 3: AZD0780|Participants with normal renal function demographically matched by sex, age, and body mass index (BMI) to the impaired participants (eGFR of ≥ 90 mL/min)
62820597|NCT06592482|EXPERIMENTAL|Group 4 (optional): AZD0780|Participants with moderate renal impairment (eGFR ≥ 30 to \< 60 mL/min).
62820598|NCT05266222||People with respiratory infection|Persons with suspected or documented respiratory infection
62820599|NCT05924633|EXPERIMENTAL|Intervention group|The intervention group will receive a supplement to take daily for 4 weeks. The supplement contains a combination of a protein hydrolysate and beta-glucan (Wellmune®).
62040580|NCT03746366|EXPERIMENTAL|Healthy controls|\[C-11\]Pittsburgh Compound B (PiB) PET scan
62600548|NCT01609309|ACTIVE_COMPARATOR|Open gastrectomy|Open distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
62820600|NCT05924633|PLACEBO_COMPARATOR|Control group|The control group will consume a placebo supplement containing maltodextrin daily for 4 weeks.
62820601|NCT05176314|EXPERIMENTAL|Rosuvastatin + Pirtobrutinib|"Participants received study intervention through oral administration as follows:~* Day 1: 20 milligram (mg) rosuvastatin alone~* Day 6: 20 mg rosuvastatin co-administered with 200 mg pirtobrutinib~* Days 7 to 12: Once daily (QD) doses of 200 mg pirtobrutinib alone~* Day 13: 20 mg rosuvastatin co-administered with 200 mg pirtobrutinib~* Days 14 to 17: QD doses of 200 mg pirtobrutinib alone."
62820602|NCT04421950|ACTIVE_COMPARATOR|Wild Blueberry Supplement|30 grams of wild blueberry powder per day in foods items provided to them
62820603|NCT04421950|PLACEBO_COMPARATOR|Placebo supplement|Food items will be provided to them without the wild blueberry power.
62820604|NCT06096519|PLACEBO_COMPARATOR|Information only control|The attention matched control arm will include information based text messages about general health and sexual health topics such as human immunodeficiency virus (HIV), sexually transmitted infections (STIs), relationships, and biomedical methods of HIV prevention (e.g., Pre-exposure prophylaxis (PrEP), Post-exposure prophylaxis (PEP)). No motivational or behavioral skill based text messages aimed at increasing HIV testing or reducing HIV risk behavior will be included. All participants will receive 8-10 messages/day for 6 weeks, with a 1 week booster. Participants in the control arm will have modified access to the interactive features such as quizzes, badges, an external chatbot feature, a website with sexual health resources and a group chat feature (a group of 3-5 total participants with whom participants can discuss program content).
62040581|NCT06733688|EXPERIMENTAL|Tedizolid Phosphate Oral Formulation 1 (Reference)|Participants receive tedizolid phosphate formulation 1 orally.
62040582|NCT06733688|EXPERIMENTAL|Tedizolid Phosphate Oral Formulation 2 (Test)|Participants receive tedizolid phosphate formulation 2 orally.
62434311|NCT05450666|EXPERIMENTAL|ADULT GROUP|The same exercise program will be applied to both groups. Participants will be included in the exercise program for eight weeks. Athletes between the ages of 30 and 60 will be included in this group.
62040583|NCT06479070|OTHER|Interventional arm|12 blood samples will be taken from patients suffering from non-metastatic stage III and IV SCC-UADT (oral cavity, larynx, oropharynx, hypopharynx, maxillary sinus), naïve to any treatment
62040584|NCT01417572|EXPERIMENTAL|lidocaine|
62040585|NCT03783182|ACTIVE_COMPARATOR|Betapred|16 'Betamethason Sodium Phosphate' tablets dissolved in one ml of water as part of the premedications given to the patient 30 min before the surgery
62434312|NCT05569733||VSS|Patients with visual snow syndrome
62820605|NCT06096519|EXPERIMENTAL|Information, motivation, behavioral skills treatment arm|The active treatment arm consists of text messages with information, motivation, and behavioral skill based text messages aimed at increasing HIV testing, our primary outcome. Secondary outcomes include STI testing, PrEP uptake, condomless sex, and discussions with providers about PrEP/HIV care. Hypothesized mediators of HIV testing include testing/prevention information, motivation, and behavioral skills. All participants will receive 8-10 messages/day for 6 weeks, with a 1 week booster session following the intervention. In the active treatment arm, participants will have full access to interactive features such as quizzes, badges, an external chatbot feature, a website with sexual health resources, and a group chat feature (a group of 3-5 total participants with whom participants can discuss program content) to promote engagement and enhance learning and skills acquisition.
62820606|NCT03025971|OTHER|Single arm observational study|Intervention: J-Valve Transcatheter Aortic valve replacement. Prospective, multi-center, single arm observational study. Subjects will include patients with severe aortic valve stenosis and/or severe aortic regurgitation who require replacement of their native aortic valve.
62040586|NCT03783182|PLACEBO_COMPARATOR|Placebo|One ml of 10% glucose solution as part of the premedications given to the patient 30 min before the surgery
62040587|NCT00575575|EXPERIMENTAL|A,2|
62040588|NCT04224077|EXPERIMENTAL|Intervention|Healthy volunteers
62040589|NCT05038267||Femous patients|Adults undergoing general anesthesia for an elective cardiac surgery requiring cardiopulmonary bypass
62040590|NCT05258110|EXPERIMENTAL|Reference (R): midazolam alone|First treatment period
62040591|NCT05258110|EXPERIMENTAL|Test (T): midazolam + BI 425809|Second treatment period
62434313|NCT05569733||controls|healthy, screened age-matched controls
62040592|NCT03163758|EXPERIMENTAL|rTMS treatment group|The rTMS treatment group received a 10-day real repetitive transcranial magnetic stimulation (rTMS) treatment beginning within 1 week after stroke onset.
62040593|NCT03163758|SHAM_COMPARATOR|sham group|The sham group received a 10-day sham repetitive transcranial magnetic stimulation (rTMS) treatment beginning within 1 week after stroke onset.
62040594|NCT06300229|ACTIVE_COMPARATOR|Denosumab|Subcutaneous injection with 60 mg Denosumab once
62040595|NCT06300229|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection with NaCl once
62040596|NCT03154008|EXPERIMENTAL|Active Treatment|Group cognitive behavioral therapy (CBT) for 8 weeks.
62040597|NCT06088290|EXPERIMENTAL|Phase IIb (& Phase III if selected), Doxorubicin (dose A) + Lurbinectedin (dose B)|Participants will receive doxorubicin and lurbinectedin intravenously every three weeks (q3wk) on day 1 of each treatment cycle (treatment cycle = three weeks).
62040598|NCT06088290|EXPERIMENTAL|Phase IIb (& Phase III if selected), Doxorubicin (dose C) + Lurbinectedin (dose D)|Participants will receive doxorubicin intravenously q3wk on day 1 of each treatment cycle (treatment cycle = three weeks).
62040599|NCT06088290|ACTIVE_COMPARATOR|Phase IIb & Phase III, Doxorubicin|Participants will receive doxorubicin intravenously q3wk on day 1 of each treatment cycle (treatment cycle = three weeks).
62434314|NCT01805310|OTHER|Bowel Preparation|Women randomized to the bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one. They will also be placed on a clear liquid diet on preoperative day number one.
62820607|NCT06002919|ACTIVE_COMPARATOR|MindWalk Intervention|12 week intervention: 1) a mindful walking training followed by 2) a prescribed mindful walking regimen, 3) self-reporting of adherence to regimen by the participants using activity logbooks and use of a user-friendly PA tracker (Fitbit) for daily step count, and 4) personalized text messages with reminders and motivational messages for participants to do the mindful walking as prescribed including a weekly check-in call or text message for accountability.
62040600|NCT05530174|EXPERIMENTAL|Treatment A, Single-dose practice|"One preoperative single dose of either Dicloxacillin/Cloxacillin 2g OR Cefuroxime 1.5g administered intravenously prior to surgical incision.~As the study is a non-inferiority trial, we have chosen the Experimental design category."
62040601|NCT05530174|ACTIVE_COMPARATOR|Treatment B, Multiple-dose practice|One preoperative dose of either Dicloxacillin/Cloxacillin 2g OR Cefuroxime 1.5g administered intravenously prior to surgical incision followed by 3 postoperative doses of Dicloxacillin/Cloxacillin 1g x 3 OR Cefuroxime 750mg x 3 within 24 hours after the preoperative dose.
62040602|NCT01873924||Batten disease|Individuals with any form of Batten disease (Neuronal Ceroid Lipofuscinosis)
62243992|NCT06731777|SHAM_COMPARATOR|Vehicle Group|Toothbrushing with dental gel and local application of the PHTALOX® oral gel vehicle
62243993|NCT06731777|ACTIVE_COMPARATOR|Chlorhexidine Group|Toothbrushing with dental gel and local application of 0.12% chlorhexidine oral gel.
62243994|NCT06731777|EXPERIMENTAL|PHTALOX® Group|Toothbrushing with dental gel and local application of 1% PHTALOX® oral gel
62243995|NCT06678438|EXPERIMENTAL|Intervention group|Ultrasound-guided brachial plexus nerve block. A total of 30 ml of lidocaine (10 mg/ml) with adrenaline (5 ug/ml) will be administered in multiple injections.
62243996|NCT06678438|ACTIVE_COMPARATOR|Control group|Haematoma block with local anaesthetics i.e. lidocaine with adrenaline
62243997|NCT06538311|EXPERIMENTAL|AD, aMCI, lvPPA patients, and preclinical AD|All participants will receive the same study interventions in a within-subject crossover design.
62243998|NCT01109329|EXPERIMENTAL|HMPV challenge virus|Participants will receive the HMPV challenge virus.
62040603|NCT02530489|EXPERIMENTAL|Treatment (atezolizumab, nab-paclitaxel)|"NEOADJUVANT: Patients receive atezolizumab IV over 60 minutes on day 1 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo definitive breast surgery within 6 weeks of the completion of treatment.~ADJUVANT: Within 4 weeks after surgery, patients receive atezolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity."
62600549|NCT04385290|EXPERIMENTAL|MODULE trial: dose escalation|Phase I (Trial part MODULE): The treatment plan combines increasing doses levels of midostaurin (25/50 mg BID) and gemtuzumab ozogamicin (3 mg/m\^2 i.v. max 4.5 mg on day(s) 1, (4, 7)) with 7+3 standard chemotherapy scheme using cytarabine (200 mg/m\^2 cont. inf. i.v. on days 1 to 7) and daunorubicin (60 mg/m\^2 i.v. on days 1 to 3).
62434315|NCT01805310|OTHER|No bowel preparation|Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
62434316|NCT00230633||Patients with HHT|People with molecularly confirmed HHT. No intervention, blood sample only
62849137|NCT03645434|EXPERIMENTAL|Treatment sequence B|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follows:~Treatment period 1: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 2: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 3: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg."
62040604|NCT06571266|EXPERIMENTAL|Risankizumab Formulation 1|Participants will receive a single dose of Risankizumab formulation 1 on day 1.
62040605|NCT06571266|EXPERIMENTAL|Risankizumab Formulation 2|Participants will receive a single dose of Risankizumab formulation 2 on day 1.
62040606|NCT06571266|EXPERIMENTAL|Risankizumab Formulation 3|Participants will receive a single dose of Risankizumab formulation 3 on day 1.
62040607|NCT05592275|EXPERIMENTAL|LY3540378 Dose 1|Participants will receive LY3540378 subcutaneously (SC).
62040608|NCT05592275|EXPERIMENTAL|LY3540378 Dose 2|Participants will receive LY3540378 SC.
62040609|NCT05592275|EXPERIMENTAL|LY3540378 Dose 3|Participants will receive LY3540378 SC.
62040610|NCT05592275|PLACEBO_COMPARATOR|Placebo|Participants will be given placebo SC.
62040611|NCT05351801|ACTIVE_COMPARATOR|THC (Syndros)|Target dose of 10mg per day.
62040612|NCT05351801|ACTIVE_COMPARATOR|CBD (Epidolex)|Target dose of 800 mg per day.
62040613|NCT05351801|ACTIVE_COMPARATOR|THC + CBD (Nabiximols)|Target dose of 10.8 mg / 10 mg per day.
62040614|NCT05351801|PLACEBO_COMPARATOR|Placebo|Identical in appearance to the three active comparators.
62040615|NCT05670899|EXPERIMENTAL|CAD PEEK frame-work|Construction of PEEK framework will be done conventionally by lost wax technique using a vacuum press device. The wax pattern will be invested in a mold using special investment. Then it will be heated and melted to produce a mold into which PEEK will be vacuum pressed. The framework will be fitted on the master cast
62040616|NCT05670899|ACTIVE_COMPARATOR|CAD metallic frame-work|A metallic framework will be obtained using the conventional lost wax technique and casting. After de-investing, finishing and polishing, the framework will be fitted on the master cast. Intraoral try in of the framework will be done followed by bite registration record. The next step will be teeth setting and try in. Heat cured acrylic resin denture base will be processed, finished and polished conventionally. The finished removable partial denture will then be checked intraorally for any needed modifications and finally delivered.
62040617|NCT06723717|EXPERIMENTAL|Dornase alfa|Daily infusion of dornase alfa at a dose of 125 microg/kg as an IV bolus until day 14 after SAH, on top of usual care
62040618|NCT06723717|NO_INTERVENTION|Usual care|Usual care
62040619|NCT06732804|EXPERIMENTAL|AVT80|Single subcutaneous administration of AVT80
62040620|NCT06732804|ACTIVE_COMPARATOR|Geographical region 1 Entyvio|Single subcutaneous administration of Geographical region 1 Entyvio
62040621|NCT06732804|ACTIVE_COMPARATOR|Geographical region 2 Entyvio|Single subcutaneous administration of Geographical region 2 Entyvio
62040622|NCT05756387||COPD patients with Chronic Respiratory Failure|
62434317|NCT00230633||Controls|People without HHT No intervention, blood sample only
62434318|NCT06147219|ACTIVE_COMPARATOR|primary dynamization interlocking intramedullary tibial nail|
62434319|NCT06147219|ACTIVE_COMPARATOR|standard interlocking intramedullary tibial nail|
62040623|NCT05275257|EXPERIMENTAL|Uricap group|the new incontinence device
62040624|NCT05275257|NO_INTERVENTION|Control group|the usual incontinence care
62040625|NCT05514353|EXPERIMENTAL|PBI-100 Topical Cream|"SAD: 4 cohorts of subjects are planned to receive a single dose of PBI-100 topical cream in one of three dosage strengths, administered once or twice daily~MAD: 3 cohorts of subjects are planned to receive one of three dosage strengths of PBI-100 administered once or twice daily for periods of 14 consecutive days"
62434320|NCT01203319|EXPERIMENTAL|60mcg/1.0ml recombinant hepatitis B vaccine|600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 60mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
62040626|NCT05514353|PLACEBO_COMPARATOR|Vehicle|
62040627|NCT06205667|EXPERIMENTAL|Computer Guided Arthrocentesis|a study group injected intra-articularly through TMJ using a computer-guided template.
62040628|NCT06205667|ACTIVE_COMPARATOR|Conventional Arthrocentesis|a control group which injected intra-articular through TMJ using conventional method based on anatomical landmark determination
62040629|NCT05011760|EXPERIMENTAL|PET|\[C-11\]NPA PET Scan
62434321|NCT01203319|EXPERIMENTAL|30mcg/1.0ml recombinant hepatitis B vaccine|600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
62600550|NCT04385290|EXPERIMENTAL|MAGNOLIA-trial: conventional chemotherapy+GO and midostaurin|Phase II (Trial part MAGNOLIA): midostaurin (recommended phase II dose, RP2D) is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m\^2 cont. inf. i.v. and daunorubicin 60 mg/m\^2 i.v.) plus GO (recommended phase II dose, RP2D) in CBF AML
62623847|NCT06283433|EXPERIMENTAL|Intervention Group (DBS)|Blood sampling via dried blood spotting (DBS) method at patient's home
62623848|NCT04979533|EXPERIMENTAL|Oxygen Insufflation|Oxygen insufflation via oxygen tubing at 15 L/min
62040630|NCT05534009||Heath care workers (HCW)|Adult (\>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status. For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA
62040631|NCT03859635|ACTIVE_COMPARATOR|Ultrasound guided Liposomal Bupivacaine Erector Spinae Block|All the erector spinae plane blocks will be placed preoperatively using Liposomal Buvicaine. All procedures will be placed under the supervision of the attending anesthesiologist on the acute pain service or the attending anesthesiologist in the operating room.
62600551|NCT04385290|ACTIVE_COMPARATOR|MAGNOLIA-trial: conventional chemotherapy+GO|Phase II (Trial part MAGNOLIA): treatment standard of CBF AML (7+3 standard chemotherapy scheme using cytarabine 200 mg/m\^2 cont. inf. i.v. and daunorubicin 60 mg/m\^2 i.v. plus GO (3 mg/m\^2 i.v. max 4.5 mg) on days 1, 4, 7). No additional Midostaurin is given.
62243999|NCT04600479|EXPERIMENTAL|prevalence and follow-up of HCV positive patients|"1. Cross-sectional assessment of prevalence : evaluation of the prevalence of HCV, HBV and HIV viral infections~2. Cohort follow-up of HCV positive patients : evaluation of care pathway and barriers to care for hepatitis C"
62244000|NCT06671730|EXPERIMENTAL|8-Week Telehealth-delivered Occupational Therapy Program|The telehealth-based OT program will be grounded in SDT. The program will be designed to help BC survivors transition from recovery after surgery to achieving levels of aerobic PA and MSE that are recommended according to each participants' specific treatment course and desired outcomes. Participants will engage in eight once-weekly OT sessions with a licensed occupational therapist via Zoom-lasting for up to about an hour. Each session will teach psychoeducational and skill-building techniques that support decreasing functional limitations associated with BC and BC treatment as well as improving behavioral skill sets necessary for maintenance of aerobic PA and MSE. Participants will receive study-provided exercise equipment and a fitness tracker (Fitbit Charge 6) for use engaging in greater amounts of aerobic PA and MSE (keeping these materials post-study).
62244001|NCT03228667|OTHER|Cohort 1|"Patients with any of the cancers listed below who have progressed on or after single-agent checkpoint inhibitor therapy after experiencing an initial complete response (CR) or partial response (PR) while taking a checkpoint inhibitor.~1a - Non-small cell lung cancer~1b - Small cell lung cancer~1c - Urothelial carcinoma~1d - Head and neck squamous cell carcinoma~1e - Merkel cell carcinoma~1f - Melanoma~1g - Renal cell carcinoma~1h - Gastric cancer~1i - Cervical cancer~1j - Hepatocellular carcinoma~1k - Microsatellite instability-high or mismatch repair deficient solid tumor cancer or colorectal cancer"
62244002|NCT03228667|OTHER|Cohort 2|Patients with NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%) and who relapsed on a PD-1 checkpoint inhibitor after experiencing an initial CR or PR when they received checkpoint inhibitor as a single-agent for first-line treatment.
62244003|NCT03228667|OTHER|Cohort 3|Patients with NSCLC who had an initial CR or PR but subsequently relapsed on maintenance PD-1 checkpoint inhibitor therapy when they initially received checkpoint inhibitor therapy in combination with chemotherapy as first-line treatment.
62244004|NCT03228667|EXPERIMENTAL|Cohort 4|Patients who are currently receiving PD-1/PD-L1 checkpoint inhibitor therapy and have disease progression after experiencing stable disease (SD) for at least 6 months during their previous treatment with PD-1/PD-L1 checkpoint inhibitor therapy.
62244005|NCT03228667|EXPERIMENTAL|Cohort 5|Patients that have experienced disease progression by Investigator-assessment per irRECIST while receiving treatment in Cohorts 1-4.
62434322|NCT01203319|PLACEBO_COMPARATOR|10mcg/1.0ml recombinant hepatitis B vaccine|300 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
62434323|NCT02125578|EXPERIMENTAL|BIIB017 (PEGylated Interferon Beta-1a)|Varying doses (63 mcg up to 188 mcg) of BIIB017 will be administered SC every other week for a total of 6 weeks.
62600552|NCT04385290|EXPERIMENTAL|MAGMA-trial: conventional chemotherapy+midostaurin and GO|Phase II (Trial part MAGMA): GO (recommended phase II dose, RP2D) is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m\^2 cont. inf. i.v. and daunorubicin 60 mg/m\^2 i.v.) plus Midostaurin (recommended phase II dose, RP2D) in FLT3 mutated AML
62600553|NCT04385290|ACTIVE_COMPARATOR|MAGMA-trial: conventional chemotherapy+midostaurin|Phase II Trial (MAGMA): treatment standard of FLT3 mutated AML (7+3 standard chemotherapy scheme using cytarabine 200 mg/m\^2 cont. inf. i.v. and daunorubicin 60 mg/m\^2 i.v plus midostaurin). No additional GO is given.
62820608|NCT06002919|NO_INTERVENTION|Control group|The participants in the control group will be provided with psychoeducation materials on benefits of walking without any components of mindfulness. The control group will receive neutral text messages with identical frequency and amount of messages that do not include motivational content or reminders related to mindful walking. At the end of study, the control group will also be given access to the recorded virtual mindful walking training (this includes the 30 minutes introductory training and the weekly 10-minute mindfulness topics/modules).
62434324|NCT02125578|EXPERIMENTAL|BIIB017 (PEGylated Interferon Beta-1a) and Placebo|Varying doses (63 mcg up to 188 mcg) of BIIB017 will be administered SC every 4 weeks for a total of 6 weeks. To ensure blinding, each subject will receive placebo every other week.
62434325|NCT02125578|PLACEBO_COMPARATOR|Placebo|Placebo dose will be administered SC every other week for a total of 6 weeks.
62040632|NCT03859635|ACTIVE_COMPARATOR|Ultrasound guided Standard Bupivacaine Erector Spinae Block|All the erector spinae plane blocks will be placed preoperatively using Liposomal Buvicaine. All procedures will be placed under the supervision of the attending anesthesiologist on the acute pain service or the attending anesthesiologist in the operating room.
62434326|NCT00782236|ACTIVE_COMPARATOR|Straumann BoneCeramic|In the test group, the subjects will receive the Bone Graft Material Straumann BoneCeramic in combination with a collagen membrane for preservation of the alveolar ridge after tooth extraction.
62623849|NCT01488747|EXPERIMENTAL|Coromega Omega-3 Squeeze|5.03 g
62623850|NCT01488747|EXPERIMENTAL|Coromega Nectar|12.22 g
62040633|NCT03859635|ACTIVE_COMPARATOR|Surgeon Infiltration|At the end of the surgery, the surgeon will infiltrate liposomal bupivacaine under thoracoscopic guidance along the intercostal nerves from T4-T8.
62040634|NCT04446858||With TIPS|Prospective cohort that received TIPS
62040635|NCT04446858||Without TIPS|Prospective cohort that did not receive TIPS
62040636|NCT06647550|EXPERIMENTAL|HD-6277 100mg tab|Oral tablet
62040637|NCT06647550|EXPERIMENTAL|HD-6277 50mg tab|Oral tablet
62434327|NCT00782236|ACTIVE_COMPARATOR|Freeze Dried Allograft Bone|In the control group, the subjects will receive Bone Graft Material Freeze Dried Allograft Bone in combination with a collagen membrane for preservation of the alveolar ridge after tooth extraction.
62434328|NCT00874900|EXPERIMENTAL|Game|
62434329|NCT00874900|EXPERIMENTAL|Game + Activation|
62434330|NCT00874900|NO_INTERVENTION|Booklet|
62600554|NCT02083185|EXPERIMENTAL|Relugolix 80 mg|Relugolix 320 mg (loading dose), tablets, orally, on Day 1 followed by relugolix 80 mg, tablets, orally, once daily for 48 weeks plus an optional 48 week extension at the investigator's discretion.
62600555|NCT02083185|EXPERIMENTAL|Relugolix 120 mg|Relugolix 320 mg (loading dose), tablets, orally, on Day 1 followed by relugolix 120 mg, tablets, orally, once daily for 48 weeks plus an optional 48 week extension at the investigator's discretion.
62040638|NCT06647550|EXPERIMENTAL|HD-6277 25mg tab|Oral tablet
62040639|NCT06647550|PLACEBO_COMPARATOR|Placebo|Oral tablet
62244006|NCT03228667|EXPERIMENTAL|Cohort 6|Patients who have progressed after an initial response (CR or PR) to a PD-1/PD-L1 checkpoint inhibitor but now exhibit acquired resistance. They have received exactly one line of anti-PD-1 or anti-PD-L1 therapy (either pembrolizumab or nivolumab) for advanced NSCLC (Stage IV or recurrent).
62244007|NCT04104321|EXPERIMENTAL|Aramchol free acid|Aramchol 300 mg oral tablet
62434331|NCT00874900|EXPERIMENTAL|Booklet + Activation|
62434332|NCT01710852|EXPERIMENTAL|Group A|ISIS CRP Rx followed by Placebo
62434333|NCT01710852|EXPERIMENTAL|Group B|Placebo followed by ISIS CRP Rx
62600556|NCT02083185|ACTIVE_COMPARATOR|Leuprorelin 22.5 mg|Leuprorelin 22.5 mg, subcutaneous, injection on Day 1 and every 12 Weeks for up to 4 injections (48 weeks).
62600557|NCT00307632|EXPERIMENTAL|Norelgestromine (NLGM)/Ethinyl Estradiol (EE)|
62040640|NCT02170740|EXPERIMENTAL|BIBR 1048 MS|
62040641|NCT02170740|EXPERIMENTAL|BIBR 1048 MS + Pantoprazole|
62040642|NCT06733558||Participants undergoing ECT|Participants undergoing ECT for depressive episode
62040643|NCT04450264|OTHER|Breast Cancer Education Program|
62244008|NCT04104321|PLACEBO_COMPARATOR|Placebo|Placebo matching oral tablet
62244009|NCT05443594|EXPERIMENTAL|Pulsed Field Ablation (Phase 1)|PHASE 1 only
62244010|NCT05443594|EXPERIMENTAL|Pulsed Field Ablation (Phase 2)|PHASE 2 only
62040644|NCT03372200|EXPERIMENTAL|FYU-981|
62040645|NCT03372200|ACTIVE_COMPARATOR|Febuxostat|
62040646|NCT03464968|EXPERIMENTAL|mFOLFOX|D1 oxaliplatin 100mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr 5FU 2400mg/m2 over 46hr Every 2 weeks
62040647|NCT03464968|EXPERIMENTAL|mFOLFIRI|D1 Irinotecan 150mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr 5FU 2400mg/m2 over 46hr Every 2 weeks
62040648|NCT01310387|EXPERIMENTAL|active pain management|active pain management (APM) by specialized nurses for cancer pain
62040649|NCT04098939||Participants|Participants undergoing ultrasound and fluoroscopy assessment of diaphragm excursion.
62040650|NCT02425839|EXPERIMENTAL|Experimental group|"* ultrasound exam by Supersonic Shear Imaging® technique~* EMG examination by electromyograph Keypoint system."
62244011|NCT01207596|ACTIVE_COMPARATOR|Hydromorphone|
62244012|NCT00504153|EXPERIMENTAL|Treatment (tyrosine Kinase Inhibitor)|Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62244013|NCT02719431|OTHER|Warfarin/Warfarin + K-877|
62244014|NCT01025492|ACTIVE_COMPARATOR|Trilipix|Trilipix (fenofibric acid) 135 mg tablet orally, once daily for 12 weeks
62244015|NCT01025492|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet orally, once daily for 12 weeks
62244016|NCT02374398|ACTIVE_COMPARATOR|Tranexamic Acid|TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes
62244017|NCT02374398|ACTIVE_COMPARATOR|Aquamantys System|The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts
62244018|NCT02374398|ACTIVE_COMPARATOR|TXA plus Aquamantys|"TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.~The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts."
62244019|NCT02374398|PLACEBO_COMPARATOR|Control|Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes
62244020|NCT00668031|EXPERIMENTAL|Arm 1|
62244021|NCT00668031|PLACEBO_COMPARATOR|Arm 2|
62244022|NCT05939440|EXPERIMENTAL|Proactive Cost of Care (P-COC) intervention|"One time session with trained educator to review:~1. Cost Information Flyer: Anticipated out of pocket costs flyer by cancer type and stage~2. Cost Tracking workbook: Out-of-pocket cost tracker Participants also review a Insurance, Employment, and Financial Assistance flyer Participants will be reminded to track their costs once a month through an automated text message or e-mail based on patient preference.~Participants also receive an existing patient pamphlet Patient and Family Guide"
62244023|NCT05939440|ACTIVE_COMPARATOR|Usual Care|"Participants receive an existing patient pamphlet Patient and Family Guide"
62244024|NCT06162494|EXPERIMENTAL|Recombinant Zoster Vaccine Administration and Testing|all participants will receive 2 doses of recombinant zoster vaccine (Shingrix)
62244025|NCT02651051|SHAM_COMPARATOR|High Fat Breakfast Meal|High fat breakfast meal served without addition of whey protein isolate
62244026|NCT02651051|EXPERIMENTAL|High Fat Breakfast Meal + Whey Protein|High fat breakfast meal served with addition of whey protein isolate
62244027|NCT06704594|NO_INTERVENTION|Control|"Participants delegated to the control arm will be individuals without premenstrual symptoms in the luteal phase of the menstrual cycle. Participants will be asked to track mood across one menstrual cycle, answer self-report surveys, and complete four blood draws."
62040651|NCT06626412|EXPERIMENTAL|Premanifest HD|At baseline and 2-year follow-up
62040652|NCT06626412|ACTIVE_COMPARATOR|Healthy controls|At baseline and 2-year follow-up
62434334|NCT02856867|ACTIVE_COMPARATOR|mFOLFOX6 + Nintedanib|"Patients will receive nintedanib in combination with mFOLFOX6 (5-Fluorouracil 400 mg/m2 bolus on day 1, 5-Fluorouracil 2400 mg/m2 continuous infusion over 46 hours starting on day 1, Leucovorin 400 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1) via IV infusions every 2 weeks (14 days).~Dose modification of nintedanib and mFOLFOX6 is allowed. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression."
62820609|NCT04851691|EXPERIMENTAL|EHR CDS tool|"Patients with an encounter in which the physician attempts to place an order for a new antipsychotic prescription. Physician has been assigned to the EHR CDS tool.~Multi-pronged electronic health record (EHR) clinical decision support (CDS) tool intervention to reduce physician prescriptions of new antipsychotic medications among older adults with ADRD"
62820610|NCT04851691|EXPERIMENTAL|Control|"Patients with an encounter in which the physician attempts to place an order for a new antipsychotic prescription. Physician has been assigned to the control.~Physicians will not receive intervention and perform duties as usual."
62040653|NCT00328510|EXPERIMENTAL|GTC Frame|Participant undergoes SRT using a GTC frame to immobilize the participant's heading during radiation therapy
62820611|NCT05960097|EXPERIMENTAL|Part A, Group A: CV0701 High dose|Participants receive high dose of CV0701.
62820612|NCT05960097|EXPERIMENTAL|Part A, Group B: CV0701 Medium dose|Participants receive medium dose of CV0701.
62820613|NCT05960097|EXPERIMENTAL|Part A, Group C: CV0701 Low dose|Participants receive low dose of CV0701.
62820614|NCT05960097|EXPERIMENTAL|Part A, Group D: CV0601 High dose|Participants receive high dose of CV0601.
62820615|NCT05960097|ACTIVE_COMPARATOR|Part A, Group E: Control vaccine|Participants receive control vaccine.
62040654|NCT00328510|EXPERIMENTAL|BrainLab thermoplastic mask|Participant undergoes SRT using the BrainLab thermoplastic mask to immobilize the participant's head during radiation therapy
62040655|NCT06429254|EXPERIMENTAL|Emotional Freedom Techniques group|"First, the Personal Information Form, Visual Analogue Scale, and Quality of Life Scale will be administered as pre-tests to the EFT group. A high score obtained from the quality of life scale indicates a high quality of life.~After the pre-tests, the first EFT session will be conducted. A second EFT session will take place 30 days later, followed by post-tests. During this period, affirmations will be provided as needed based on individual difficulties, perspectives, support systems, past traumas, and emotional blockages experienced by the woman. Each session is planned to last approximately 45 minutes to 1 hour.~Procedure: Administering pre-tests followed by the first EFT session. Procedure: After 30 days, conducting post-tests followed by the second EFT session.~Procedure: After another 30 days, only post-tests will be conducted."
62244028|NCT06704594|ACTIVE_COMPARATOR|PMDD with sertraline|"Participants delegated to the PMDD with sertraline arm will be individuals with severe premenstrual symptoms in the luteal phase of the menstrual cycle (to qualify for Premenstrual Symptoms Screening Tool (PSST) and Endicott scoring diagnosis of Premenstrual Dysphoric Disorder). Participants will be asked to track mood across two menstrual cycles, answer self-report surveys, and complete eight blood draws (four in each menstrual cycle). In the second cycle, participants in this arm will take a daily pill of 50 mg of sertraline from the confirmed day of positive ovulation until menses onset (end of menstrual cycle 2)."
62434335|NCT02856867|PLACEBO_COMPARATOR|mFOLFOX6 + Placebo|"Patients will receive placebo in combination with mFOLFOX6 (5-Fluorouracil 400 mg/m2 bolus on day 1, 5-Fluorouracil 2400 mg/m2 continuous infusion over 46 hours starting on day 1, Leucovorin 400 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1) via IV infusions every 2 weeks (14 days).~Dose modification of placebo and mFOLFOX6 is allowed. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression."
62434336|NCT00872391|EXPERIMENTAL|Hypofractionated LINAC radiotherapy|
62434337|NCT02588131|EXPERIMENTAL|tremelimumab plus MEDI4736|Tremelimumab in combination with MEDI4736
62434338|NCT04242186|EXPERIMENTAL|Nursing home residents and staff|Nursing home residents at high risk for injurious falls, as well as nursing home staff at participating facilities
62820616|NCT05960097|EXPERIMENTAL|Part B, Condition 1: Baseline-control|Participants receive one dose of CV0801.
62820617|NCT05960097|EXPERIMENTAL|Part B, Condition 2: Intermediate storage|Participants receive one dose of CV0801.
62820618|NCT05960097|EXPERIMENTAL|Part B, Condition 3: Maximum storage conditions|Participants receive one dose of CV0801.
62820619|NCT03525379|EXPERIMENTAL|Resveratrol|1) Resveratrol- (Transmax) trans- resveratrol (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules. One capsule will be taken orally 2 times per day (BID) for 8 weeks.
62820620|NCT03525379|PLACEBO_COMPARATOR|Placebo|2) Placebo- 500mg (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules. One capsule will be taken orally 2 times per day (BID) for 8 weeks.
62820621|NCT01527149|EXPERIMENTAL|Treatment (monoclonal antibody and combination chemotherapy)|"COURSES 1, 3, and 5 (O-HyperCVAD): Patients receive ofatumumab IV on day 1, cyclophosphamide IV over 2 hours every 12 hours for 6 doses on days 3-5, doxorubicin hydrochloride IV continuously over 72 hours on days 6-8, vincristine sulfate IV on days 6 and 13, and dexamethasone IV or PO on days 3-6 and 13-16.~COURSES 2, 4, and 6 (O-HD-MA): Patients receive ofatumumab IV on day 1, methotrexate IV continuously over 24 hours on day 3, and cytarabine IV over 2 hours every 12 hours on days 4-5.~All courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Eligible patients then undergo standard HDC-ASCT."
62820622|NCT06601452|EXPERIMENTAL|Chinese medicine treatment group（PCOS）|Beginning on day 5 of the menstrual cycle, the treatment group was treated with a combination of Zi Yin and Yang Formula sequential treatment based on the control group, and Zi Yin and Yang Formula sequential treatment (Tuning Zhou Zi Yin Granules + Tuning Zhou and Yang Granules) was used in the 3 menstrual cycles prior to the IVF advancement week. Starting on the 5th day of the menstrual cycle, take the Tuning Zhou Zi Yin Granules (in-hospital preparation) orally. 2 packets each time, 3 times a day, 14 days of treatment; regulating Zhou Zhi Yin Granules (hospital preparation development), oral. Take 2 sachets each time, 3 times a day for 14 days.
62600558|NCT02236806|EXPERIMENTAL|Arm 1|bisoprolol plus ramipril
62600559|NCT02236806|ACTIVE_COMPARATOR|Arm 2|Bisoprolol plus placebo
62600560|NCT02236806|ACTIVE_COMPARATOR|Arm 3|Ramipril plus placebo
62600561|NCT02236806|PLACEBO_COMPARATOR|Arm 4|Placebo
62600562|NCT04848792|EXPERIMENTAL|SFN supplement|The oral sulforaphane supplement is a myrosinase-active whole broccoli sprout material (EnduraCell Bioactive, Cell-Logic, Queensland, AU) containing 14 mg SFN per capsule. Three capsules will be consumed 90 min prior to the start of the acute exercise trial. The dose of 3 capsules is equivalent to approximately 220 µmol of SFN, which is comparable to that of other studies using broccoli sprout extracts and the recommended single dose.
62600563|NCT04848792|PLACEBO_COMPARATOR|Placebo|Placebo capsules provided by Cell-Logic.
62600564|NCT03641534||Sepsis|
62600565|NCT03641534||Severe malaria|
62600566|NCT03641534||Uncomplicated malaria|
62040656|NCT06429254|NO_INTERVENTION|Control group|"After obtaining consent from the women included in the group, pre-tests will be conducted followed by breathing exercises. A program will be tailored according to the suitability of the women. Once an appropriate environment is provided for meeting with the women, information about the study will be provided. Pain coping methods will be explained, and breathing exercises will be taught. The exercises will commence when the woman feels ready. The breathing exercises typically last around 15-20 minutes.~With a plan for a total of 8 breathing exercises to be conducted over four weeks, consisting of 2 sessions per week, they will be scheduled to coincide with the EFT group, with sessions held every 5 days."
62040657|NCT00778765|EXPERIMENTAL|1|400 mg Gabapentin Capsules of Ranbaxy
62040658|NCT00778765|ACTIVE_COMPARATOR|2|Neurontin® 400 mg Gabapentin Capsules
62040659|NCT04603352|EXPERIMENTAL|Intervention group: Hip Helpers home program|Participants in the intervention group will be given a custom pair of Hip Helpers® to use at home. Parents will begin the Hip Helpers® home program upon study entry and stop the program once the child is able to pull to stand independently. The Hip Helpers® home program protocol, which consists of using the orthotic garment twice daily for 30 minutes each time, will be given to the parents and supervised by the physical therapist. The Hip Helpers® should be donned when the child is actively playing, and not used sleep or when child is inactive.
62040660|NCT04603352|NO_INTERVENTION|Control group: No additional home program|Participants assigned to the control group will continue with their usual care.
62040661|NCT03747341|EXPERIMENTAL|Part A (Healthy Participants): Placebo-Buprenorphine Low|"Three treatment periods consisting of 3 days each of investigational treatment~* 1=placebo + fentanyl,~* 2=low dose buprenorphine + fentanyl,~* 3 (optional)=low dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
62040662|NCT03747341|EXPERIMENTAL|Part A (Healthy Participants): Placebo-Buprenorphine High|"Three treatment periods consisting of 3 days each of investigational treatment~* 1=placebo + fentanyl,~* 2=high dose buprenorphine + fentanyl,~* 3 (optional)=high dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
62040663|NCT03747341|EXPERIMENTAL|Part A (Healthy Participants): Buprenorphine Low-Placebo|"Three treatment periods consisting of 3 days each of investigational treatment~* 1=low dose buprenorphine + fentanyl,~* 2=placebo + fentanyl,~* 3 (optional)=low dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
62244029|NCT06704594|PLACEBO_COMPARATOR|PMDD with placebo|"Participants delegated to the PMDD with placebo arm will be individuals with severe premenstrual symptoms in the luteal phase of the menstrual cycle (to qualify for PSST and Endicott scoring diagnosis of Premenstrual Dysphoric Disorder). Participants will be asked to track mood across two menstrual cycles, answer self-report surveys, and complete eight blood draws (four in each menstrual cycle). In the second cycle, participants in this arm will take a daily placebo pill from the confirmed day of positive ovulation until menses onset (end of menstrual cycle 2)."
62600567|NCT06406634|EXPERIMENTAL|Experimental: Cadonilimab +Lenvatinib+Hepatic Arterial Infusion Chemotherapy (HAIC)|HAIC(FOLFOX)+Cadonilimab (AK104) (10 mg/kg, Q3W, iv) + Lenvatinib (8 mg (if patient body weight was \<60 kg) or 12 mg (if patient body weight was ≥60 kg) )
62600568|NCT05443438|NO_INTERVENTION|3D-3D|All items presented in 3D form
62600569|NCT05443438|EXPERIMENTAL|3D-2D|Initial items in 3D, generalization in 2D
62600570|NCT05443438|EXPERIMENTAL|2D-3D|Initial items in 2D, generalization in 3D
62600571|NCT05443438|EXPERIMENTAL|2D-2D|Initial items in 2D, generalization in 2D
62600572|NCT02133794|EXPERIMENTAL|Tomosynthesis|
62600573|NCT06622265||Cohort 1|Subjects whose ECG is interpreted as normal sinus rhythm during the screening assessment
62600574|NCT06622265||Cohort 2|Subjects whose ECG is interpreted as atrial fibrillation during the screening assessment
62600575|NCT06017817|EXPERIMENTAL|Non-surgical treatment, Study group (NST-1)|Lumoral Treatment; Standard, non-surgical anti-infective treatment by scaling and root planing (SRP); and Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use.
62600576|NCT06017817|ACTIVE_COMPARATOR|Non-surgical treatment, Control group (NST-2)|Standard, non-surgical anti-infective treatment by scaling and root planing (SRP); and Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use.
62600577|NCT06017817|EXPERIMENTAL|Surgical treatment, Study group (ST-1)|Lumoral Treatment; Surgical anti-infective peri-implantitis treatment; and Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use.
62600578|NCT06017817|ACTIVE_COMPARATOR|Surgical treatment, Control group (ST-2)|Surgical anti-infective peri-implantitis treatment; and Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use.
62600579|NCT00774527|NO_INTERVENTION|ArmI(CyATG)|•Conditioning therapy will start on day -5 in patients who are randomized to receive Cy+ATG. Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter
62600580|NCT05668143|EXPERIMENTAL|Experimental group|During the surgery, patients will be shown nature and landscape images with virtual reality glasses.
62600581|NCT05668143|NO_INTERVENTION|Control group|The control group will receive standard procedure without any intervention.
62600582|NCT02426749|ACTIVE_COMPARATOR|Active Coil|Participants of this arm will receive active rTMS intervention (treatment).
62600583|NCT02426749|SHAM_COMPARATOR|Sham|Participants of this arm will receive sham rTMS intervention (treatment).
62040664|NCT03747341|EXPERIMENTAL|Part A (Healthy Participants): Buprenorphine High-Placebo|"Three treatment periods consisting of 3 days each of investigational treatment~* 1=high dose buprenorphine + fentanyl,~* 2=placebo + fentanyl,~* 3 (optional)=high dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
62040665|NCT03747341|EXPERIMENTAL|Part B (Opioid-Tolerant): Placebo-Buprenorphine Low|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.~Two treatment periods:~* 1=placebo (Day 1),~* 2=low dose buprenorphine + fentanyl (Day 3)~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
62600584|NCT01335880|ACTIVE_COMPARATOR|Promotion I|Three month time horizon
62600585|NCT01335880|EXPERIMENTAL|Promotion II|One week time horizon
62244030|NCT01423383||Random Populations|The aim of this study is to determine the prevalence and incidence of keloid in large populations.
62244031|NCT02473042|EXPERIMENTAL|Electrical Stimulation + Standard of Care Antiemetics|"Participants receive light electrical stimulation to the wrist area during surgery. Participants also receive standard of care drugs to reduce post-operative nausea and vomiting (PONV).~Questionnaire completed about participant's pre-treatment expectations and their nausea about 15 minutes after they wake up after surgery, then every 30 minutes until they leave the clinic."
62600586|NCT06042049|EXPERIMENTAL|MEDI8897|Anti-RSV monoclonal antibody
62820623|NCT06601452|EXPERIMENTAL|Chinese medicine treatment group（DOR）|Beginning on day 5 of the menstrual cycle, the treatment group was treated with a combination of Zi Yin and Yang Formula sequential treatment based on the control group, and Zi Yin and Yang Formula sequential treatment (Tuning Zhou Zi Yin Granules + Tuning Zhou and Yang Granules) was used in the 3 menstrual cycles prior to the IVF advancement week. Starting on the 5th day of the menstrual cycle, take the Tuning Zhou Zi Yin Granules (in-hospital preparation) orally. 2 packets each time, 3 times a day, 14 days of treatment; regulating Zhou Zhi Yin Granules (hospital preparation development), oral. Take 2 sachets each time, 3 times a day for 14 days.
62244032|NCT02473042|ACTIVE_COMPARATOR|Standard of Care Antiemetics|"Participants receive standard of care drugs to reduce post-operative nausea and vomiting (PONV).~Questionnaire completed about participant's pre-treatment expectations and their nausea about 15 minutes after they wake up after surgery, then every 30 minutes until they leave the clinic."
62244033|NCT04379336|EXPERIMENTAL|Bacille Calmette-Guérin (BCG)|Participants will receive an intradermal injection of 0.1ml of the suspended BCG vaccine which accounts for 0.075mg of attenuated Mycobacterium bovis. BCG-Vaccin SSI \[Statens Serum Institut\], Danish strain 1331.
62244034|NCT04379336|PLACEBO_COMPARATOR|Placebo|The placebo used for this study is 0.9% Sodium Chloride (NaCl). Participants that are randomized to the control arm will receive a placebo injection of 0.1ml 0.9% NaCl, which is the same volume and has the same colour as the suspended BCG vaccine.
62244035|NCT06734208|EXPERIMENTAL|Cohort 1|Participants will receive a single oral dose of Divarasib on Day 1.
62244036|NCT06734208|EXPERIMENTAL|Cohort 2|Participants will receive a single oral dose of Divarasib on Day 1.
62600587|NCT05447767|ACTIVE_COMPARATOR|intra-articular injection of BMAC|intra-articular injection of BMAC
62600588|NCT05447767|ACTIVE_COMPARATOR|intra-osseous and intra-articular injection of BMAC|intra-osseous and intra-articular injection of BMAC
62600589|NCT05447767|ACTIVE_COMPARATOR|intra-articular injection of at- SVF|intra-articular injection of at- SVF
62600590|NCT05447767|ACTIVE_COMPARATOR|intraosseous and intra-articular injection of at-SVF|intraosseous and intra-articular injection of at-SVF
62600591|NCT03279796|EXPERIMENTAL|Autologous adipose-derived MSCs|The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 \^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
62244037|NCT06734208|EXPERIMENTAL|Cohort 3|Participants will receive a single oral dose of Divarasib on Day 1.
62244038|NCT06734208|EXPERIMENTAL|Cohort 4|Participants will receive a single oral dose of Divarasib on Day 1.
62244039|NCT06655493||ASCVD with CKD|Study participants diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD) with Chronic Kidney Disease (CKD)
62244040|NCT06655493||HFpEF or HFmrEF|Study participants diagnosed with Heart Failure (HF) with preserved ejection fraction (HFpEF) or HF with mildly reduced ejection fraction (HFmrEF)
62244041|NCT04109950|EXPERIMENTAL|SEP-363856|SEP-363856 25mg, 50mg, 75mg, 100mg flexibly dosed once daily
62600592|NCT03279796|ACTIVE_COMPARATOR|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
62600593|NCT04909749|EXPERIMENTAL|PGx-guided antidepressant therapy|These individuals will be prescribed medication guided by the Oneome RightMed Test.
62600594|NCT04909749|NO_INTERVENTION|Treat as usual based on Clinical Physician Recommendation|These individuals will receiving medication as usual based on the clinics internal guidelines and physician recommendations.
62600595|NCT06394856|ACTIVE_COMPARATOR|knotless group|rotator cuff repair with a modified knotless anchors
62820624|NCT04825574|EXPERIMENTAL|Patients with GIST previously enrolled in avapritinib clinical trials|
62820625|NCT03632135|ACTIVE_COMPARATOR|Physician Choice treatment|"Participants will be treated with control chemotherapy treatment (standard-of-care chemotherapy chosen by the Physician from the provided list).~Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~* Carboplatin;~* Irinotecan;~* Etoposide;~* BCNU;~* CCNU;~* Temozolomide;~* Procarbazine;~* Vincristine;~* Imatinib;~* Procarbazine, CCNU, Vincristine;~* Carboplatin, Irinotecan;~* Carboplatin, Etoposide;~* Temozolomide, Etoposide;~* Temozolomide, Imatinib. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
62040666|NCT03747341|EXPERIMENTAL|Part B (Opioid-Tolerant): Placebo-Buprenorphine Mid|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.~Two treatment periods:~* 1=placebo (Day 1),~* 2=mid dose buprenorphine + fentanyl (Day 3)~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
62244042|NCT02042430|EXPERIMENTAL|Treatment (IDO1 inhibitor INCB024360)|Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-14 and undergo surgery on day 15. Treatment continues in the absence of disease progression or unacceptable toxicity. In circumstances where there are medical or administrative reasons for delaying surgery, treatment with IDO1 inhibitor INCB024360 may continue for up to 3 weeks.
62244043|NCT06734845||Total Knee Arthroplasty|Patients undergoing first total knee replacement
62244044|NCT06734845||Total Hip Arthroplasty|Patients undergoing first total hip replacement
62244045|NCT04375228|EXPERIMENTAL|Rituximab|Patients with histologically confirmed advanced (metastatic or unresectable) solid tumors that have documented irAEs will receive Rituximab.
62244046|NCT04375228|EXPERIMENTAL|Tocilizumab|Patients with histologically confirmed advanced (metastatic or unresectable) solid tumors that have documented irAEs will receive Tocilizumab.
62244047|NCT06736106|EXPERIMENTAL|Patients|patients with degenerative pathology of the thoraco-lumbar-sacral spine
62244048|NCT06506461|EXPERIMENTAL|Autologous, genetically modified CD34+ HSPCs Treatment|All eligible participants receive intervention as described in the Detailed Description with the following: plerixafor, busulfan, and autologous, gene-modified CD34+ cells
62244049|NCT06734013|EXPERIMENTAL|Patients with post-OLT rejection|The patient will be enrolled in a single visit, as per standard of care, clinical and general data will be collected and the biopsy will be performed
62244050|NCT06283719|EXPERIMENTAL|Dose Escalation|A total of six dose escalations were preset: 0.1 mg, 0.3 mg, 1 mg, 3 mg, 10 mg, and 30 mg.
62244051|NCT06283719|EXPERIMENTAL|Dose Expansion|Participants will receive the RP2D identified in Dose exploration of the study.
62244052|NCT04784767|EXPERIMENTAL|1A: 25 µg of SpFN + ALFQ on Days 1, 29 and 181.|Up to 20 participants will receive 25 µg of SpFN_1B-06-PL vaccine with 0.5 mL ALFQ adjuvant in a total 1.0 mL injection volume.
62244053|NCT04784767|PLACEBO_COMPARATOR|1B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1, 29 and 181.|4 participants will receive 1.0mL of normal saline as Placebo on Study Days 1, 29, and 181.
62244054|NCT04784767|EXPERIMENTAL|2A: 50 µg of SpFN + ALFQ on Days 1, 29, and 181.|Up to 20 participants will receive 3 intramuscular injections of: 50 ug of SpFN_1B-06-PL with 0.5 mL ALFQ adjuvant.
62434339|NCT04340700|EXPERIMENTAL|THC|A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each.
62623851|NCT01488747|EXPERIMENTAL|Barleans Swirl|17.45 g
62244055|NCT04784767|PLACEBO_COMPARATOR|2B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1, 29, and 181.|4 participants will receive 1.0mL of normal saline as Placebo on Study Days 1, 29, and 181.
62600596|NCT06394856|ACTIVE_COMPARATOR|knot-tying group|rotator cuff repair with classic knot-tying double-row suture bridge technique by classic anchors
62600597|NCT01325116|ACTIVE_COMPARATOR|Control|Usual post-STEMI care
62600598|NCT01325116|EXPERIMENTAL|Intervention|Recurrent, personalized, educational reminders sent via post on behalf of the interventional cardiologist to the patient and their family physician urging long-term adherence to secondary prevention medications post-STEMI. A copy of the letter will be provided to the patient to take to their pharmacist.
62600599|NCT00312065|EXPERIMENTAL|Patient|Once stabilized, a trimmed reflective shield to cover only the probe itself will be placed over the thermistor probe. Changes in measured skin temperature and warmer power output will be recorded non-invasively, as well as the time taken to reestablish baseline status. A full-sized reflective shield will then be placed over the thermistor probe and the same observations recorded, then repeated 15 minutes later. At the time of a subsequent routine change in thermistor position, the same procedure will be followed, but omitting the intermediate step of using the smaller trimmed shield. Continuous core temperatures will be monitored via a short rectal probe during the study periods.
62820626|NCT03632135|EXPERIMENTAL|ChemoID-guided treatment|"Participants will be treated with ChemoID-guided standard-of-care chemotherapy drugs from the provided list.~ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:~* Carboplatin;~* Irinotecan;~* Etoposide;~* BCNU;~* CCNU;~* Temozolomide;~* Procarbazine;~* Vincristine;~* Imatinib;~* Procarbazine, CCNU, Vincristine;~* Carboplatin, Irinotecan;~* Carboplatin, Etoposide;~* Temozolomide, Etoposide;~* Temozolomide, Imatinib.~The treating physician will receive the ChemoID assay results from the ChemoID lab."
62040667|NCT03747341|EXPERIMENTAL|Part B (Opioid-Tolerant): Placebo-Buprenorphine High|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.~Two treatment periods:~* 1=placebo (Day 1),~* 2=high dose buprenorphine + fentanyl (Day 3)~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
62040668|NCT03930342|EXPERIMENTAL|Native CHOICES Intervention|Native-CHOICES will comprise usual care plus 2 MI sessions delivered over 4 weeks; a contraception counseling session at a local clinic; and 3 months of electronic messaging to boost the effects of MI and counseling by increasing perceptions of social connection and social support for behavior change. Contraception counseling will be completed within 2 weeks after the second MI session, so the maximum duration of MI and counseling for each participant will be 6 weeks. Electronic messaging will include positive motivational content consistent with alcohol and contraception use goals set in the MI sessions.
62040669|NCT03930342|NO_INTERVENTION|Wait-list Control Group|The control condition will comprise usual care for the 6-month study period, with a wait-list design that offers women the Native- CHOICES program after they have completed the 6-month data collection.
62040670|NCT06716034|EXPERIMENTAL|Personalized Nutrition Plan and Support|This group will receive the nutrition intervention
62244056|NCT04784767|EXPERIMENTAL|3A: 50 µg of SpFN + ALFQ on Days 1 and 181.|Up to 20 participants will receive 2 intramuscular injections of: 50 ug of SpFN_1B-06-PL with 0.5 mL ALFQ adjuvant.
62244057|NCT04784767|PLACEBO_COMPARATOR|3B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1 and 181.|4 participants will receive 1.0mL of normal saline as Placebo on Study Days 1 and 181.
62244058|NCT05255120|EXPERIMENTAL|Intensified preoperative information|The patient participating in the intervention group is evaluated preoperatively based on an algorithm. This information is designed according to a checklist which includes how the procedure is performed, rules of conduct in connection with and after the procedure and what the patient can expect after surgery.
62244059|NCT05255120|NO_INTERVENTION|Control group|The patient who participates in the control group receives information about participation in the study as a control, ie without information about the intervention. The patient will then be planned for the procedure according to current, local routines.
62600600|NCT04754620|NO_INTERVENTION|Standard face to face visit|This group will receive a traditional outpatient visit
62600601|NCT04754620|EXPERIMENTAL|Online visit|This group will receive a smartphone-based real-time video conference visit
62600602|NCT01513811|ACTIVE_COMPARATOR|group PEG|This group is set as a control group and received 2 packets of Polyethylene glycol electrolyte solutions on the morning of the examination day as us we usually done.
62600603|NCT01513811|ACTIVE_COMPARATOR|group PEG+Itp|Patients in group were assigned to itopride half hour before administration of lavage solution in the morning of examination day.
62600604|NCT01513811|ACTIVE_COMPARATOR|group PEG+4Itp|Patients in this group received itopride three times 24 hours before the examination day and another time 30 min before administration of lavage solution.
62623852|NCT01488747|ACTIVE_COMPARATOR|Nordic Omega-3 Softgel|4 softgels
62820627|NCT05907174|NO_INTERVENTION|Enhanced Treatment as Usual (Healthcare Workers)|Monitoring of treatment as usual (i.e., routine interactions between healthcare workers and patients). Treatment as usual will be enhanced by providing healthcare workers with a substance use psychoeducation and screening training.
62040671|NCT06716034|NO_INTERVENTION|Control|This group will receive information about Canada's food guide, a recommended healthy diet.
62244060|NCT05275881|EXPERIMENTAL|Virtual Reality headset Group|30 patients will be included in the virtual reality arm
62434340|NCT04340700|PLACEBO_COMPARATOR|Placebo|Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
62600605|NCT03812562|EXPERIMENTAL|Treatment (yttrium Y 90 glass microspheres, nivolumab)|Patients receive standard of care yttrium Y 90 glass microspheres IV. Within 1-2 weeks of completing of yttrium-90 treatment, patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. If imaging shows adequate FLR and at least stable disease, patients will undergo resection within 2 weeks after the last dose of nivolumab. Patients who do not complete resection due to feasibility and have progressed or have evidence of high-risk explant may continue to receive nivolumab IV every 2 weeks for up to 1 year.
62600606|NCT03763461|EXPERIMENTAL|HFNC|HFNC will be started at flow of 40 L/min and FiO2 of 40%.
62820628|NCT05907174|EXPERIMENTAL|Siyakhana - P (Healthcare Workers)|Providers working with PRC. Siyakhana - P healthcare workers will also receive a substance use psychoeducation and screening training, and a workshop for healthcare workers to get to know the PRC and learn more about the PRC role.
62820629|NCT05907174|NO_INTERVENTION|Enhanced Treatment as Usual (Patients)|Monitoring of treatment as usual (i.e., routine interactions between healthcare workers and patients). Treatment as usual will be enhanced by providing healthcare workers with a substance use psychoeducation and screening training.
62820630|NCT05907174|EXPERIMENTAL|Siyakhana - P (Patients)|Patients seen by the team of health care workers with an integrated PRC. Patients will have the opportunity to meet with the PRC for about 3-months after their baseline assessment. Siyakhana - P healthcare workers will also receive a substance use psychoeducation and screening training, and a workshop for healthcare workers to get to know the PRC and learn more about the PRC role.
62820631|NCT05025020|EXPERIMENTAL|Standard consultation with interactive 3D visualization|Participants in this group will use the interactive 3D tool in addition to receiving the standard surgical consultation before their breast reconstruction procedure.
62820632|NCT05025020|ACTIVE_COMPARATOR|Standard consultation|Participants in this group will receive a standard surgical consultation before their breast reconstruction procedure.
62040672|NCT02721082|EXPERIMENTAL|Opt Out|"Participants in this arm will be first enrolled to receive cessation treatment and will only not receive it by opting out. Participant will receive a Opt Out treatment program. Participants will receive counseling and nicotine replacement therapy."
62244061|NCT05275881|ACTIVE_COMPARATOR|Control group with usual practices|30 patients will be included the usual practices
62040673|NCT02721082|ACTIVE_COMPARATOR|Opt In|"Traditional approach to tobacco treatment program. Participants must first indicate they are ready to quit smoking by opting in to receive Opt In treatment program."
62040674|NCT01695564||WATCHMAN|Patients that had the WATCHMAN device implanted
62244062|NCT00960908||Resolute|Prospective recruitment of Resolute arm will start in March 2009
62244063|NCT00960908||Endeavor|The retrospective recruiting period of Endeavor arm comprises a fixed 2-year time between January 2006 and December 2008. The patients, who were treated with Endeavor in that period, will be enrolled if they agree to participate in this study.
62434341|NCT00971672||Toddlers from Jewish origin|Toddlers from Jewish origin aged 18 to 36 months
62434342|NCT00971672||Toddlers from non Jewish origin|Toddlers aged 18 to 36 months belonging to non Jewish (Arab) population
62434343|NCT06325982|EXPERIMENTAL|Triethanolamine cream group|Triethanolamine cream retention enema was given once every night before going to bed during radiotherapy until the end of radiotherapy. Triethanolamine cream retention enema was given once before going to bed the day after radiotherapy for 3 months
62434344|NCT01888328|EXPERIMENTAL|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
62040675|NCT01695564||LARIAT LAA Device|patients that had LARIAT LAA device implanted
62040676|NCT04214704|EXPERIMENTAL|Genteel arm|In the Genteel arm, the subjects exclusively use the Genteel device for the first 12 weeks, and then switch to the conventional method of SMBG for an additional 12 weeks. This arm will use Butterfly Touch Lancets (BTL) throughout the study.
62434345|NCT01888328|ACTIVE_COMPARATOR|ACCUTANE|ACCUTANE 40 mg of Roche Laboratories Inc
62600607|NCT03763461|OTHER|Oxygen Mask|Standard non-humidified oxygen therapy via an oxygen mask at 6 l/min will be performed.
62820633|NCT06551610|NO_INTERVENTION|Standard of Care|
62820634|NCT06551610|ACTIVE_COMPARATOR|Triage tool|
62849138|NCT03645434|EXPERIMENTAL|Treatment sequence C|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follows:~Treatment period 1: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 2: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 3: Matching placebo of AZD8871 and Anoro® Ellipta®"
62040677|NCT04214704|ACTIVE_COMPARATOR|Conventional arm|In the Conventional arm, the subjects use the conventional method of SMBG for the first 12 weeks and then switch to the Genteel device for an additional 12 weeks. This arm will use the lancet and lancing device which they were using prior to randomization to the study.
62040678|NCT06579807|EXPERIMENTAL|Exercise training|The multimodal supervised exercise program will include aerobic, resistance, and flexibility exercises during 12 weeks, performed in 3 weekly sessions lasting 60 minutes each.
62820635|NCT05507541|EXPERIMENTAL|Arm A (pembrolizumab, TTI-621) -- CLOSED TO ACCRUAL 8/16/2024|Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle and TTI-621 IV over 60-120 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT scans or CT scans of the chest, abdomen, and pelvis prior to cycle 3 and every 4 cycles thereafter. If no disease progression after cycle 12, patients then receive pembrolizumab IV over 30 minutes on day 1 of each cycle and TTI-621 IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT and/or CT and blood sample collection throughout the study. Patients may undergo biopsy on study.
62820636|NCT05507541|EXPERIMENTAL|Arm B (pembrolizumab, TTI-622)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle and TTI-622 IV over 60-90 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT scans or CT scans of the chest, abdomen, and pelvis prior to cycle 3 and every 4 cycles thereafter. If no disease progression after cycle 12, patients then receive pembrolizumab IV over 30 minutes on days 1 of each cycle and TTI-622 IV over 60-90 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.
62820637|NCT05335330||First trimester pregnant women (first pregnancy)|Pregnant women who are in their first pregnancy and in their first trimester will be evaluated.
62820638|NCT05335330||Second trimester pregnant women (first pregnancy)|Pregnant women who are in their first pregnancy and in their second trimester will be evaluated.
62820639|NCT05335330||Third trimester pregnant women (first pregnancy)|Pregnant women who are in their first pregnancy and in their third trimester will be evaluated.
62820640|NCT04613362|EXPERIMENTAL|TENACITY Telehealth Cognitive Behavioral Therapy for Migraine|Six sessions of standardized Cognitive Behavioral Therapy for patients with diagnosed chronic migraine headaches will be delivered by a clinical health psychologist via telehealth platform. All patients have access to a set of standardized educational, headache self-management materials.
62820641|NCT04613362|ACTIVE_COMPARATOR|Behavioral Usual Care|Behavioral usual care may include outpatient clinic-based health psychology in the VA or Community Care, or mindfulness sessions with LCSW. Behavioral usual care will be delivered by clinicians for patients with diagnosed chronic migraine.
62040679|NCT06579807|NO_INTERVENTION|Control healthy|A reference group composed of healthy individuals without intervention will be included.
62820642|NCT05990179|EXPERIMENTAL|Enrolled in the study|All newborns enrolled in the study will be evaluated.
62820643|NCT04747964|EXPERIMENTAL|A single lowest dose of treatment group|
62820644|NCT04747964|EXPERIMENTAL|A single low dose of treatment group|
62820645|NCT04747964|EXPERIMENTAL|A single low-intermediate dose of treatment group|
62820646|NCT04747964|EXPERIMENTAL|A single intermediate dose of treatment group|
62820647|NCT04747964|EXPERIMENTAL|A single high dose of treatment group|
62820648|NCT04747964|EXPERIMENTAL|A single highest dose of treatment group|
62820649|NCT06599112|ACTIVE_COMPARATOR|Conventional drilling for implant placement|Implant placement in this group will be by conventional drilling according to the manufacturer's instructions (consequent drills according to the kit provided)
62820650|NCT06599112|EXPERIMENTAL|Implant placement using Densah Burs|Densah Burs provided by Versah will be used as the Osseodensification drilling technique for implant placement in this group. (consequent drilling according to the kit provided)
62820651|NCT06599112|EXPERIMENTAL|Implant placement using Osteotomes|Osteotomes with different serial diameters will be used following the pilot drill to expand and condense the osteotomy site as a technique for implant placement.
62820652|NCT06335849|EXPERIMENTAL|Treatment 1 (LYB004 25µg)|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
62820653|NCT06335849|EXPERIMENTAL|Treatment 2 (LYB004 50µg)|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
62040680|NCT03346226|EXPERIMENTAL|Dexmedetomidine Hydrochloride|Dex Group: 0.5 μg/kg of Dex is given 10 minutes before operation through injection pump during 15 minutes. After the operation starts, the initial pumping ratio of Dex is 0.5ug/kg/h and adjusted under BIS surveillance to keep BIS between 70-80 until 30 minutes before the end of surgery. Meanwhile, OAA/S grade is evaluated every 15 minutes to maintain OAA/S at grade 4. If discrepancy occurs, OAA/S prevails.
62434346|NCT01340950|ACTIVE_COMPARATOR|Better-Penetrating ART|zidovudine 300 mg orally every 12 hours lamivudine 300 mg orally daily nevirapine 200 mg orally every 12 hours
62434347|NCT01340950|ACTIVE_COMPARATOR|Worse-Penetrating ART|tenofovir disoproxil fumarate 300 mg orally daily lamivudine 150 mg orally every 12 hours efavirenz 600 mg orally daily
62434348|NCT05959369|EXPERIMENTAL|elite kickboxer|athletes who have completed the age of 18 professionally, participating in fighting competitions and actively training
62434349|NCT03779516|ACTIVE_COMPARATOR|Group C|In Control Group, 4 mL of saline solution was administered using a face mask and a compressed gas-powered jet nebulizer for 15 min
62434350|NCT03779516|ACTIVE_COMPARATOR|Group L|In Lidocaine Group 4 mL of 4% lidocaine was administered using a face mask and a compressed gas-powered jet nebulizer for 15 min
62434351|NCT00071409|PLACEBO_COMPARATOR|placebo|1.5 mL SC injection
62434352|NCT00071409|EXPERIMENTAL|300 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
62820654|NCT06335849|ACTIVE_COMPARATOR|Treatment 3 (SHINGRIX)|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
62820655|NCT01849263|EXPERIMENTAL|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease at the end of course 2 may continue on therapy until the end of course 5 at the discretion of the treating physician.
62820656|NCT05781542|EXPERIMENTAL|Group 1|a total of approximately 9 participants will receive 3 administrations of sD-NP-GT8 DNA at a dose of 0.4 mg, coformulated with IL-12 DNA at a dose of 0.1 mg at days 1, 29, and 85. Study products will be administered intradermally via EP of the skin on each upper arm
62820657|NCT05781542|EXPERIMENTAL|Group 2|a total of approximately 18 participants will receive 3 administrations of sD-NP-GT8 DNA at a dose of 1.6 mg, coformulated with IL-12 DNA at a dose of 0.4 mg at days 1, 29, and 85. Study products will be administered intradermally via EP of the skin on each upper arm
62040681|NCT03346226|ACTIVE_COMPARATOR|Propofol|Prop Group: Propofol is given with an initial ratio of 2-10mg/kg/h, when the operation starts. Under BIS surveillance, dripping rate is adjusted to keep BIS between 70-80 until 5 minutes before the end of surgery. Meanwhile, OAA/S grade is evaluated every 15 minutes to maintain OAA/S at grade 4. If discrepancy occurs, OAA/S prevails.
62040682|NCT04496180|EXPERIMENTAL|PREVENA (CiPNT)|"Target population is every patient undergoing a laparotomic procedure and responding to inclusion criteria marked in paragraph 3.8 (see forward) A member of the medical surgery team should apply all parts just after the surgical procedure.~A medical member (nurse specialist in wound care) of the surgical team removes the dressing. All other manipulations of the therapy unit, the connector and the cartridge can be carried out by any nurse practitioner in hospital or extra hospital environment but must warn the investigators.~The aspiration will be stopped 24 hours before and the dressing is removed by a nurse at home or in the hospital.~The specialized nurse who will take a photo and assess the condition of the wound in the treatment room.~One of the investigators, non-operators, who will also assess the condition of the wound by photo."
62040683|NCT04496180|ACTIVE_COMPARATOR|Simple dressing|Simple dressing; standard, waterproof dressing applied to wound
62040684|NCT00668122|EXPERIMENTAL|Arm 1|
62040685|NCT00668122|EXPERIMENTAL|Arm 2|
62820658|NCT05781542|EXPERIMENTAL|Group 3|a total of approximately 18 participants will receive 3 administrations of sD-NP-GT8 DNA at a dose of 1.6 mg, coformulated with IL-12 DNA at a dose of 0.4 mg at days 1, 29, and 85. These doses will be administered intradermally via EP of the skin on each upper arm. All participants in Group 3 will also receive 2 administrations of Trimer 4571 at a dose of 100 mcg adjuvanted with 5 mcg of 3M-052-AF + 500 mcg Alum via IM injections into the deltoid muscle at days 85 and 169
62820659|NCT06060899|ACTIVE_COMPARATOR|Standard pneumoperitoneum pressure|Laparoscopic liver resection performed in standard (14mmHg) pneumoperitoneum pressure
62820660|NCT06060899|EXPERIMENTAL|Low pneumoperitoneum pressure|Laparoscopic liver resection performed in low (10mmHg) pneumoperitoneum pressure
62820661|NCT04991649|EXPERIMENTAL|ACT Group|One two-weekly 2-hour of positive parenting program plus a four-weekly 2-hour group ACT program and routine pediatric asthma out-patient services, including medical follow-up, asthma education by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare by psychiatrist/medical social worker for parental training in ADHD care.
62820662|NCT04991649|OTHER|Treatment-as-usual (TAU) Group|Routine pediatric asthma out-patient services, including medical follow-up, asthma education by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare by psychiatrist/medical social worker for parental training in ADHD care.
62820663|NCT04907370|EXPERIMENTAL|Toripalimab Combined with Induction Chemotherapy Followed by Radiotherapy Alone|All participants will receive induction chemotherapy (IC; every 3 weeks × 3 cycles; gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1) followed by intensity-modulated radiotherapy (IMRT; 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day) alone. PD-1 blockade toripalimab (240 mg per cycle) will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone. The first and last 3 cycles of toripalimab are administrated concurrently with IC and IMRT, respectively. After 3 weeks of the completion of IMRT, adjuvant toripalimab (240 mg per cycle) will begin every 3 weeks for 11 cycles.
62820664|NCT04907370|ACTIVE_COMPARATOR|Toripalimab Combined with Induction Chemotherapy Followed by Concurrent Chemoradiotherapy|All participants will receive induction chemotherapy (IC; every 3 weeks × 3 cycles of gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1) followed by concurrent chemoradiotherapy (CCRT; every 3 weeks × 2 cycles of cisplatin + IMRT 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day). PD-1 blockade toripalimab (240 mg per cycle) will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of CCRT, involving the whole-course of IC + CCRT. The first and last 3 cycles of toripalimab are administrated concurrently with IC and CCRT, respectively. After 3 weeks of the completion of CCRT, adjuvant toripalimab (240 mg per cycle) will begin every 3 weeks for 11 cycles.
62820665|NCT04935658|EXPERIMENTAL|Virtual Reality Group|in this group, patients will use virtual reality during the oocyte retrieval plus the standard anesthesic procedure (local anesthesia)
62820666|NCT04935658|SHAM_COMPARATOR|Standard Group|in this group, patients will receive the standard anesthesic procedure during the oocyte retrieval wich is local anesthesia
62820667|NCT02135250|EXPERIMENTAL|placebo|the placebo is not drug
62820668|NCT02135250|EXPERIMENTAL|Xinkeshu tablet|4 Xinkeshu tablets are given three times per day
62820669|NCT06703320||Healthy subjects|Healthy subjects without history of stroke or cognitive impairment.
62820670|NCT06703320||PSCI|Healthy subjects without history of stroke or cognitive impairment.
62820671|NCT06703320||NPSCI|Stroke patients without post-stroke cognitive impairment.
62849139|NCT03645434|EXPERIMENTAL|Treatment sequence D|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 2: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 3: AZD8871 600 µg and Anoro® Ellipta® matching placebo."
62820672|NCT06367764|ACTIVE_COMPARATOR|Cognitive Processing Therapy|Cognitive Processing Therapy is a \~12 session trauma-focused therapy that teaches cognitive restructuring skills to help clients change beliefs and process emotions related to a specific traumatic event, which can be generalized to other traumatic experiences as well as everyday stressors. After initial psychoeducation and practice with cognitive restructuring skills, patients use skills to identify and challenge maladaptive beliefs about the traumatic event itself as well as those related to five themes thought to be affected by trauma-safety, trust, power, control, esteem, and intimacy.
62820673|NCT06367764|ACTIVE_COMPARATOR|STAIR Narrative Therapy|STAIR Narrative Therapy is a \~16-session multicomponent therapy that includes a coping skills component (10 sessions) focused on increasing skills in emotion regulation and interpersonal relationships to address day-to-day life stressors and improve functioning, and a trauma-focused component (6 sessions) which reviews a patient-selected series of traumatic experiences in which the meaning of the events is re-appraised particularly regarding sense of self and relationship to others.
62820674|NCT06412159|OTHER|selective laser melting removable partial denture frameworks fabricated by conventional technique|selective laser melting removable partial denture frameworks fabricated by conventional technique
62820675|NCT06412159|OTHER|selective laser melting framework was fabricated using completely digital workflow|selective laser melting framework was fabricated using completely digital workflow
62820676|NCT01742143||Phase I: Refinement|10 Black, Hispanic, and/or low-SES patients with TNBC (5 Spanish-speaking), will be recruited from MSK
62820677|NCT01742143||Phase II, Arm 1: Usual and Customary Care (U&C)|Participants in this group will receive the same referrals on social and economic resources as ICCAN group.
62820678|NCT01742143||Phase II, Arm 2: ICCAN-IO|Arm 2 will consist of everything in Arm 1
62820679|NCT04458051|EXPERIMENTAL|SAR442168|Dose 1 of oral SAR442168 once daily
62040686|NCT05154279|ACTIVE_COMPARATOR|intramyometrial Terlipressin|intramyometrial injection of Terlipressin in women undergoing laparoscopic myomectomy procedure
62040687|NCT05154279|ACTIVE_COMPARATOR|intramyometrial carbitocin|intramyometrial injection of Carbetocin in women undergoing laparoscopic myomectomy procedure
62040688|NCT05154279|PLACEBO_COMPARATOR|intramyometrial saline|intramyometrial injection of saline in women undergoing laparoscopic myomectomy procedure
62820680|NCT04458051|PLACEBO_COMPARATOR|Placebo|Placebo to match the SAR442168 once daily
62820681|NCT02020265|EXPERIMENTAL|NF group|This group will train modulation of the amygdala EEG fingerprint by EEG neurofeedback.
62820682|NCT02020265|SHAM_COMPARATOR|Sham NF|This group preform the same procedure as the NF group only reviving sham feedback
62820683|NCT02020265|ACTIVE_COMPARATOR|A\T NF|This group will train modulation of A\\T ratio by EEG neurofeedback
62820684|NCT05404828||OSAS|All adult patients consulting the pneumology department for possible OSAS with \>1x/night nocturia
62820685|NCT05404828||Insomnia|All adult patients consulting the center for integrative medicine for insomnia with \>1x/night nocturia
62820686|NCT05404828||Urological|All adult patients consulting the urology department with \>1x/night nocturia
62820687|NCT01782027|EXPERIMENTAL|3H-cholesterol|
62040689|NCT02070055||No treatment|No treatment
62820688|NCT02893397|EXPERIMENTAL|Group I (supervised exercise)|Patients wear a fitbit and undergo supervised physical therapy exercise sessions over 40 minutes 3-5 times a week for at least 4 weeks.
62820689|NCT02893397|EXPERIMENTAL|Group II (fitbit)|Patients wear a fitbit.
62820690|NCT05728411|EXPERIMENTAL|Remote temperature monitoring + enhanced usual care|Enrollment in remote foot temperature monitoring in addition to enhanced usual care (described below)
62820691|NCT05728411|OTHER|Enhanced usual care|"Usual care is based on the VA's amputation prevention program (PAVE - Preventing Amputation in Veterans Everywhere - VHA Directive 1410), which provides a model of care for patients at risk for amputation as well as patients who have already undergone an amputation.~Usual care will be enhanced by providing resources (e.g., information through written newsletters) relevant to a population of Veterans with diabetes, including information on nutrition and cooking, physical activities, and Whole Health opportunities"
62820692|NCT06597175|EXPERIMENTAL|Device: ORIGO|
62820693|NCT02711891|EXPERIMENTAL|5% Loperamide gel|Participants received 5% loperamide gel (0.2gm equivalent to 10 mg) applied following a single surgilance to the 5th digit. The loperamide gel was applied 10 minutes following the first lance, rubbed in for one minute within an 8 mm mold surrounding the lance site. The mold was removed and the gel was covered with a transparent occlusive dressing and left in place for 30 minutes. The forearm was also swabbed with the loperamide gel which was left in place for 30 minutes. The placebo gel contained the same ingredients without the loperamide. The loperamide gel formulation includes: Loperamide 5%, Propylene Glycol; Ethanol (190 proof USP); Ethyl acetate; and Klucel HF 1%.
62820694|NCT02711891|PLACEBO_COMPARATOR|Placebo gel|Participants received placebo gel (0.2gm) applied following a single surgilance to the 5th digit. The placebo gel was applied 10 minutes following the first lance, rubbed in for one minute within an 8 mm mold surrounding the lance site. The mold was removed and the gel was covered with a transparent occlusive dressing and left in place for 30 minutes. The forearm was also swabbed with the placebo gel which was left in place for 30 minutes. .The placebo gel contained the same ingredients without the loperamide. The placebo gel formulation includes: Propylene Glycol; Ethanol (190 proof USP); Ethyl acetate; and Klucel HF 1%.
62820695|NCT06366711|EXPERIMENTAL|Home antenatal CTG monitoring|Participants will be asked to use the remote monitoring devices twice a week, on mutually agreed days for a minimum of 30 minutes each time. Ideally participants will use the home CTG monitor for at least a four-week period or until delivery.
62820696|NCT06366711|EXPERIMENTAL|Home antenatal ultrasound monitoring|Participants will be asked to use the remote monitoring devices once a fortnight, on mutually agreed days for the duration by which the scan has been completed. Ideally participants will use the home ultrasound monitor for at least a 8-week period or until delivery.
62820697|NCT06366711|EXPERIMENTAL|Usage of both home antenatal ultrasound and CTG monitoring devices|Follow both device plans above.
62820698|NCT05690308|EXPERIMENTAL|Experimental visual perturbation treadmill training|Participants assigned to the experimental intervention will receive 6 weeks, 2x per week of visual perturbation treadmill training using the GRAIL system. This will consist of maximum 30 minutes of walking on the treadmill while translations and rotations of the projected environment are applied.
62820699|NCT05690308|SHAM_COMPARATOR|Control treadmill training|Participants assigned to the control intervention will receive 6 weeks, 2x per week of treadmill only training. This will consist of maximum 30 minutes of walking on the treadmill without any visual perturbations.
62820700|NCT06194448|EXPERIMENTAL|Open-Label Osimertinib Induction Treatment|Patients will receive open-label osimertinib induction treatment for 8 weeks (± 1 week window to account for patient variability and CRT scheduling), followed by CRT treatment for 6 weeks (± 1 week) and then osimertinib maintenance treatment until RECIST 1.1-defined radiological progression by investigator unless there is evidence of unacceptable toxicity or if the patient requests to stop the study treatment.
62820701|NCT01730599||PD patients|PD patients carriers of the G2019S mutation in the LRRK2 gene
62820702|NCT04733326|EXPERIMENTAL|Cryothrapy|5 ml Saline at low temperature (2.5°C) will be used as intra-canal irrigantion during single visit endodontics treatment, to study the effect on reduction of post-operative pain and expression of IL-8.
62040690|NCT05962788|EXPERIMENTAL|Open Label|All subjects will receive open label voclosporin initially at the same number of capsules as assigned at Week 24 (End of Study Visit) in AUR-VCS-2020-03 (VOCAL ; NCT05288855). At the Investigator's discretion and after consultation with the Medical Monitor, dose titration up or down in the study will be permitted up to the maximum dose that was studied in AUR-VCS-2020-03.
62040691|NCT05624125|ACTIVE_COMPARATOR|Beetroot juice|The beetroot juice intervention comes in a single 70 ml drink and is manufactured by James White Drinks. Each drink contains beetroot juice and 2% lemon juice, made from concentrates. Each serving of 70 mL of beetroot juice contains 400 mgs (6.45 millimoles) of nitrate and will be taken twice daily for a total daily dose of 800 mgs (12.90 millimoles) of nitrate.
62434353|NCT00071409|EXPERIMENTAL|600 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
62040692|NCT05624125|PLACEBO_COMPARATOR|Placebo|The placebo comes in a single 70 ml drink and is manufactured by James White Drinks. The placebo contains beetroot juice and 2% lemon juice, made from concentrates, and is filtered to remove nitrate.
62040693|NCT04958109|EXPERIMENTAL|Kisspeptin|• Intravenous administration of kisspeptin 112-121 x 16 hours
62040694|NCT04958109|PLACEBO_COMPARATOR|Placebo|• Intravenous administration of placebo x 16 hours
62040695|NCT02194270|EXPERIMENTAL|Ambroxol hydrochloride - soft pastille|
62040696|NCT02194270|ACTIVE_COMPARATOR|Ambroxol hydrochloride - syrup - low dose|
62040697|NCT02194270|ACTIVE_COMPARATOR|Ambroxol hydrochloride - syrup - high dose|
62434354|NCT06321237|ACTIVE_COMPARATOR|The true-true stimulus group|During the 8-week intervention, the patient used the ear nail stimulator to give true stimulation, that is, the vagus nerve stimulation with a pulse width of 200μs and a frequency of 30Hz
62600608|NCT03412188|EXPERIMENTAL|group 1 Eltrombopag arm|"Group 1 (eltrombopag arm n=20 patients): Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy. patients will receive a total daily dose of eltrombopag of (25-50mg/d). Dose adjustments may be made based on platelets count with an increment of 25mg once per day at 2 weeks intervals (Maximum dose: 75 mg orally once a day).~Patients, who responded poorly to eltrombopag in 6 months or developed adverse effects, were asked to discontinue the medication. Those who responded were followed for further 6 month period."
62244064|NCT06653426|EXPERIMENTAL|Sodium butyrate (NaBu)|Participants in the study will be administered Sodium Butyrate (NaBu) in tablet form. Each participant will take a dosage of 2.4 grams, which equates to two tablets, once daily. This regimen will be maintained for a duration of 12 weeks. The supplement is self-administered, and participants are required to record their daily symptom severity in an electronic diary (eDiary) throughout the study period. This intervention aims to assess the effectiveness of NaBu in reducing menstrual symptoms by comparing the average symptom scores during the 12-week treatment period to the baseline scores recorded before starting the supplement.
62244065|NCT05204329|ACTIVE_COMPARATOR|Low dose of allogenic MSC drops|Escalating doses of allogenic MSC eye drops will be assigned at the lowest dose level.
62434355|NCT06321237|EXPERIMENTAL|The true-false stimulus group|During the 8-week intervention, the first 4 weeks of the auricular stimulator used by the patient were given true stimulation, that is, vagus nerve stimulation with a pulse width of 200μs and a frequency of 30Hz; The next 4 weeks were given as false stimuli
62434356|NCT06321237|EXPERIMENTAL|The false-true stimulus group|During the 8-week intervention, the first 4 weeks of the patient's ear nail stimulator gave false stimulation; The stimulation given in the last 4 weeks is true stimulation, that is, vagus nerve stimulation with pulse width of 200μs and frequency of 30Hz
62434357|NCT06321237|PLACEBO_COMPARATOR|The false-false stimulus group|Over the course of the 8-week intervention, the patient used an ear nail stimulator that gave false stimulation
62434358|NCT06447454||GC (gemcitabine + cisplatin) + radiotherapy + slulimumab Group|First-line treatment for patients with intrahepatic bile duct carcinoma involves the administration of GC (gemcitabine plus cisplatin) along with radiotherapy and sintilimab.
62434359|NCT02611999|NO_INTERVENTION|Control|Physicians in this Arm received only a paper memo with a list of common imaging tests and procedures.
62434360|NCT02611999|EXPERIMENTAL|Single Price|Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
62434361|NCT02611999|EXPERIMENTAL|Paired Inside/Outside Prices|Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
62434362|NCT06238492|EXPERIMENTAL|Experimental|pre-specified computer tasks using an Internet-based cognitive training portal, to be completed 3x per week for 60 minutes each session for 12 weeks total
62244066|NCT05204329|ACTIVE_COMPARATOR|Medium dose of allogenic MSC drops|Escalating doses of allogenic MSC eye drops will be assigned at the medium dose level.
62434363|NCT06238492|PLACEBO_COMPARATOR|Placebo Control|pre-specified computer tasks using an Internet-based cognitive training portal, to be completed 3x per week for 60 minutes each session for 12 weeks total
62434364|NCT05997485||Participants receiving Paxlovid Treatment|Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.
62434365|NCT01297192|OTHER|Treatment Arm 1|The effect of mirabegron on the pharmacokinetics of solifenacin
62434366|NCT01297192|OTHER|Treatment Arm 2|The effect of solifenacin on the pharmacokinetics of mirabegron
62434367|NCT00826631|ACTIVE_COMPARATOR|1|Fast food intake, doubling of caloric intake, in combination with sedentary behavior (no exercise)
62434368|NCT00826631|NO_INTERVENTION|2|Control group, parallel
62434369|NCT00253097|NO_INTERVENTION|Control|Patients in the control group had the usual care provided at the stroke unit, that is counselling on avoiding risky health behavior, compliance with preventive medication, measurement of blood pressure and a 3 months' visit in the outpatient clinic
62434370|NCT00253097|EXPERIMENTAL|Intervention|Patienta allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
62600609|NCT03412188|ACTIVE_COMPARATOR|group 2 conventional Treatment|"Group 2 (n=20 patients) Patients who are currently receiving other lines of treatment (steroids, IVIG, azathioprine, and rituximab).~patients will continue on the conventional line of treatment"
62600610|NCT06619418|EXPERIMENTAL|device group|
62244067|NCT05204329|ACTIVE_COMPARATOR|High dose of allogenic MSC drops|Escalating doses of allogenic MSC eye drops will be assigned at the high dose level.
62244068|NCT04910568|EXPERIMENTAL|Single-Agent Cevostamab (Arm A)|"Cohort A1S is a safety run-in arm evaluating cevostamab administered in 28-day cycles on a modified weekly schedule.~Cohort A1E, an expansion cohort, has been opened and finished enrolling participants. Participants will be treated with single-agent cevostamab administered in 28-day cycles on a modified weekly schedule."
62244069|NCT04910568|EXPERIMENTAL|Cevostamab plus Pomalidomide and Dexamethasone (Pd) (Arm B)|"Participants will be treated with cevostamab monotherapy during a 14-day period prior to the start of pomalidomide treatment (cevostamab pre-phase).~Cohort B1S is a safety run-in arm evaluating cevostamab and Pd administered in 28-day cycles every 2 weeks (Q2W) followed by every 4 weeks (Q4W) schedule. Additional safety run-in cohort(s) with lower target dose levels of cevostamab may be opened prior to opening the expansion cohorts.~Two target dose levels of target dose level 1 (DL1) and lower dose level -1 (DL-1) of cevostamab will be selected for randomization in expansion cohorts. Expansion cohorts will follow the same Q2W/Q4W dosing schedule as Cohort B1S."
62820703|NCT04733326|EXPERIMENTAL|Ketroloc tromethamine|2ml 30 mg Ketroloc tromethamine will be used as intra-canal irrigantion during single visit endodontics treatment, to study the effect on reduction of post-operative pain and expression of IL-8.
62820704|NCT04733326|PLACEBO_COMPARATOR|Saline at room temperature|30 ml Saline at room temperature will be used as intra-canal irrigantion during single visit endodontics treatment, to study the effect on reduction of post-operative pain and expression of IL-8.
62244070|NCT04910568|EXPERIMENTAL|Cevostamab plus Daratumumab and Dexamethasone (Dd) (Arm C)|"Cohort C1S is a safety run-in arm evaluating cevostamab and Dd administered in 21 day cycles from Cycle(C)1 - C8 every 3 weeks (Q3W) and 28-day cycles from C9 onwards Q4W. Additional safety run-in cohort(s) with lower target dose levels of cevostamab may be opened prior to opening the expansion cohorts.~Two target dose levels of DL1 and DL-1 of cevostamab will be selected for randomization in expansion cohorts. Expansion cohorts will follow the same Q3W/Q4W dosing schedule as Cohort C1S."
62244071|NCT06063317|EXPERIMENTAL|CF33-CD19 IT Administration Monotherapy|
62244072|NCT06063317|EXPERIMENTAL|CF33-CD19 IV Administration Monotherapy|
62244073|NCT06063317|EXPERIMENTAL|CF33-CD19 IT Administration in Combination with Blinatumomab|
62600611|NCT06619418|ACTIVE_COMPARATOR|Integrative health modality group|
62600612|NCT06619119|EXPERIMENTAL|Escape room simulation group|Intervention Group: In addition to the traditional training method within the scope of emergency nursing training, an escape room application was applied to this group after 14 weeks of emergency nursing training.
62600613|NCT06619119|NO_INTERVENTION|Control group|Control Group: No intervention other than the traditional education method was applied to this group within the scope of the 14-week emergency nursing education. In the traditional education, narration, question and answer, and discussion techniques were used with a powerpoint presentation containing visuals and text in the classroom environment.
62820705|NCT06508333|ACTIVE_COMPARATOR|Alarm therapy|These patients will receive alarm therapy for 8 weeks
62820706|NCT06508333|EXPERIMENTAL|Alarm therapy combined with short-term high dose exogenous vitamin D supplementation|These patients will receive high-dose vitamin D supplementation (more than 2000IU daily) and alarm therapy for 8 weeks
62820707|NCT04192565|EXPERIMENTAL|Robotic Transanal Endoluminal Resection|Robotic Transanal Endoluminal Resection of Colorectal Lesions
62820708|NCT03401801|ACTIVE_COMPARATOR|4 ml of 1% lidocaine|Procedure: 4 ml of 1% lidocaine is injected for stellate ganglion block using the Ultrasound(US)-guided lateral approach at the sixth cervical vertebral level.
62820709|NCT03401801|ACTIVE_COMPARATOR|6 ml of 1% lidocaine|Procedure: 6 ml of 1% lidocaine is injected for stellate ganglion block using the US-guided lateral approach at the sixth cervical vertebral level.
62820710|NCT03401801|ACTIVE_COMPARATOR|8 ml of 1% lidocaine|Procedure: 8 ml of 1% lidocaine is injected for stellate ganglion block using the US-guided lateral approach at the sixth cervical vertebral level.
62820711|NCT03771716|EXPERIMENTAL|African Dance|This is the experimental group. Dance classes will be held 3 times per week for 1 hour. Participants will learn traditional Africana dance moves and sequences.
62820712|NCT03771716|ACTIVE_COMPARATOR|African Cultural Immersion|This is the active control group. Participants will participate in a variety of educational activities related to African Culture, including traditional cooking, lectures, crafts, music and films. They will meet 3 times per week for the same duration as the Dance group. However, they will not participate in aerobic activity during the classes, and most activities will be conducted in a seated position.
62820713|NCT04940299|EXPERIMENTAL|Cohort 1 (ipilimumab, nivolumab, tocilizumab)|"Patients with melanoma will receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment with ipilimumab and nivolumab repeats every 3 weeks for 4 doses, then treatment with nivolumab repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.~Cohort 1 will be divided into 2 sub-groups: sub-group 1 of 25 patients, and subgroup 2 of 10 patients that will consist of varying Tocilizumab administration doses. For sub-group 1, Tocilizumab 162mg will be administered subcutaneously every 2 weeks starting week 0, up to 12 weeks for a total of 6 doses. For sub-group 2 , Tocilizumab 162mg will be administered subcutaneously once every week starting at week 0 up to week 6 followed by Tocilizumab administered subcutaneously every 2 weeks starting at week 6 up to 12 weeks for a total of 9 doses."
62820714|NCT04940299|EXPERIMENTAL|Cohort 2 (ipilimumab, nivolumab, tocilizumab)|Patients with urothelial cancer will receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment with ipilimumab and nivolumab repeats every 3 weeks for 4 doses, then treatment with nivolumab repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Starting on week 1, patients also receive tocilizumab SC every 2 weeks for up to 12 weeks (6 doses) in the absence of disease progression or unacceptable toxicity.
62820715|NCT04940299|EXPERIMENTAL|Cohort 3 (ipilimumab,, nivolumab, tocilizumab)|Patients with NSCLC receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 2 weeks for up to 2 years. Patients also receive tocilizumab SC every 2 weeks for up to 12 weeks (6 doses). Treatment continues in the absence of disease progression or unacceptable toxicity.
62820716|NCT05287113|EXPERIMENTAL|Treatment Group 1: Retifanlimab Monotherapy|Retifanlimab will be administered intravenously every 4 weeks. Placebos for INCAGN02385 and INCAGN02390 will be administered intravenously every 2 weeks.
62820717|NCT05287113|EXPERIMENTAL|Treatment Group 2: Retifanlimab + INCAGN02385|Retifanlimab will be administered intravenously every 4 weeks. INCAGN02385 and Placebo for INCAGN02390 will be administered intravenously every 2 weeks.
61458603|NCT05861024||Ileocystoplasty|Urinary Calculi After Ileocystoplasty in Children
61458604|NCT05861024||Sigmoidocystoplasty|Urinary Calculi After Sigmoidocystoplasty in Children
62244074|NCT06063317|EXPERIMENTAL|CF33-CD19 IV Administration in Combination with Blinatumomab|
62244075|NCT03599895|EXPERIMENTAL|3D printing group|the radical gastrectomy for gastric cancer of Davinci robotic surgery with the assistance of 3D printing model
62244076|NCT03599895|EXPERIMENTAL|non 3D printing group|the radical gastrectomy for gastric cancer of Davinci robotic surgery without the assistance of 3D printing model
62244077|NCT06397716|EXPERIMENTAL|Genotype Revealed|Subjects with ALDH2 mutation will be notified of positive genotype results after testing completed.
62600614|NCT01696149|EXPERIMENTAL|electrical nerve stimulation|All subjects participated, randomly, in a 4 Hz transcutaneous electrical nerve stimulation session, a 110 Hz transcutaneous electrical nerve stimulation session, and a control (off-transcutaneous electrical nerve stimulation) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period
62600615|NCT02619396|ACTIVE_COMPARATOR|"Group 20 W / LSI 4"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
62600616|NCT02619396|ACTIVE_COMPARATOR|"Group 40 W / LSI 4"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
62820718|NCT05287113|EXPERIMENTAL|Treatment Group 3: Retifanlimab + INCAGN02385 + INCAGN02390|Retifanlimab plus INCAGN02385 and INCAGN02390 will be administered intravenously. Retifanlimab will be administered intravenously every 4 weeks. INCAGN02385 and INCAGN02390 will be administered every 2 weeks.
62244078|NCT06397716|PLACEBO_COMPARATOR|Gentoype Not-Revealed|Subjects with ALDH2 mutation will not be notified of positive genotype results until after study completed.
62600617|NCT02619396|ACTIVE_COMPARATOR|"Group 20 W / LSI 5"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
62600618|NCT02619396|ACTIVE_COMPARATOR|"Group 40 W / LSI 5"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
62600619|NCT06619106||Patients|Population with chronic liver disease or the presence of portal-systemic shunts, attending the BLIPS day hospital
62820719|NCT02205736|OTHER|Living Room Visit participants|Latino women who received breast health education while attending a Living Room Visit.
62820720|NCT04709068||COVID19+|
62820721|NCT06705400|EXPERIMENTAL|Intervention|"The Bloom Intervention adds to standard municipal care (5-6 home visits) with a prenatal visit, visits at 18 and 30 months, up to eight phone consultations, parent groups, and a video library.~Home visits: Three extra visits include one in pregnancy week 22-24 to build trust and assess needs using a dialogue tool focused on social and demographic factors. Visits at 18 and 30 months support sustained progress and address new challenges.~Phone consultations: Up to eight calls support breastfeeding, bottle-feeding, and complementary feeding. Phone consultations at 12 and 24 months aid in maintaining healthy habits during key transitions, like starting daycare.~Parent groups: Encourage shared experiences among parents, with policies promoting father participation.~Video library: Includes 62 videos on nutrition, motor skills, sleep, etc., with 48 available in multiple languages for wider access."
62244079|NCT06096610|EXPERIMENTAL|Resistance exercise training|Participants undergo 24 sessions of resistance exercise training over about 8 weeks.
62244080|NCT06096610|NO_INTERVENTION|Control|Participants do not perform resistance exercise training.
62244081|NCT06718452|PLACEBO_COMPARATOR|Placebo|Patients in this group will be treated using placebo
62244082|NCT06718452|EXPERIMENTAL|Ultramicronized PEALUT Single dose|umPEALUT 1 sachet/day every day for 60 days
62244083|NCT06718452|EXPERIMENTAL|Ultramicronized PEALUT Double dose|umPEALUT 2 sachet/day every day for 60 days
62600620|NCT05657600||Video-based yoga group|The pranayama (respiration), asana (poses), yoga exercises and meditation were given to by means of video at home for 6 weeks (2days/week) as 12 sessions, and 60 min.
62600621|NCT05657600||Face-to-face yoga group|The pranayama (respiration), asana (poses), yoga exercises and meditation were given to face to face at Volunteer Training and Consultation Centre for 6 weeks (2days/week) as 12 sessions, and 60 min.
62600622|NCT05657600||physical exercise|The exercises for respiration, muscle strengthening, stabilization, and flexibility were given face-to-face at Volunteer Training and Consultation Centre for 6 weeks (2days/week) as 12 sessions, and 60 min.
62600623|NCT01533636||Healthy Control|This group will be comprised of healthy individuals without evidence of lung disease.
62600624|NCT01533636||Cystic Fibrosis|This group will be comprised of individuals who have been diagnosed with cystic fibrosis.
62244084|NCT06500676|EXPERIMENTAL|GFH375|
62244085|NCT04416061||Subjects underwent COVID-19 test|Subjects who underwent COVID-19 test in HKSH during the study period
62244086|NCT05577078||TEER|Patients with tricuspid valve regurgitation eligible for transcatheter edge-to-edge repair (TEER)
62244087|NCT01748942|EXPERIMENTAL|Arm I (treatment)|Patients receive dexamethasone IV at the time of surgery and PO every 8 hours for up to 4 days following surgery.
62244088|NCT01748942|ACTIVE_COMPARATOR|Arm II (control)|Patients receive dexamethasone IV at the time of surgery and placebo PO every 8 hours for up to 4 days following surgery.
62244089|NCT05838196|NO_INTERVENTION|Control|Participant will follow standard of care
62600625|NCT03976167|ACTIVE_COMPARATOR|Common nasal cannula|Oxygen administration up to 4 liters according defined protocol
62600626|NCT03976167|EXPERIMENTAL|High flow nasal cannula|Oxygen administered with high flow nasal cannula according child weight and protocol designed for this study
62600627|NCT01500408|OTHER|Commercial INFB followed by Investigational INFB|Process A (currently-approved manufacturing process involving FBS) first, then Process B (new serum-free manufacturing process, without FBS)
62820722|NCT06705400|NO_INTERVENTION|Control|The families in the control municipalities will receive standard deliveries from the community health nurses
62820723|NCT02587676||denture liners|Evatouch Super (EVA; Neo Dental Chemical products, Washington, USA), GC RELINE (GCR; GC Dental Products Corp, Tokyo, Japan), Mucopren soft (MCP; Kettenbach GmbH \& Co KG, California, USA) Soften (SFT; KAMEMIZU CHEM, Osaka, Japan), FD Soft (FDS; KAMEMIZU CHEM, Osaka, Japan), and Bio Liner (BIO; Nissin Dental Products, Kyoto, Japan).
62820724|NCT02898181|EXPERIMENTAL|Tragus Stimulation|In this group patients will receive neuromodulation for 2 hours daily
62244090|NCT05838196|EXPERIMENTAL|Point-of-care Ultrasound|Participant will receive point-of-care ultrasound at time of clinic appointment and clinician will use result to inform treatment decision
62600628|NCT01500408|OTHER|Investigational INFB followed by Commercial INFB|Process B (new serum-free manufacturing process, without FBS) first, then Process A (currently-approved manufacturing process involving FBS)
62600629|NCT02634268|ACTIVE_COMPARATOR|Lifestyle intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
62600630|NCT02634268|NO_INTERVENTION|Usual Care|Participants continue with usual diet and exercise activities as they desire
62600631|NCT05426213|OTHER|Robot-assisted Bronchoscopy|Participants with 8-50 millimeters (mm) diameter size lung lesions identified on computed tomography (CT) scan will be enrolled for robotic assisted bronchoscopy (Monarch Platform) biopsy procedure.
62600632|NCT05760742|PLACEBO_COMPARATOR|Placebo group|2 capsules of Maltodextrin per day
62600633|NCT05760742|EXPERIMENTAL|MicAlgae100|2 capsules per day containing 100mg of microalgae based ingredient
62600634|NCT05760742|EXPERIMENTAL|MicAlgae250|2 capsules per day containing 250mg of microalgae based ingredient
62600635|NCT05760742|EXPERIMENTAL|MicAlgae500|2 capsules per day containing 500mg of microalgae based ingredient
62600636|NCT06318052|EXPERIMENTAL|CO2 laser treatment|The FemTouch delivery system is used in conjunction with the AcuPulse CO2 laser system and the AcuScan120 microscanner to provide fractional treatments in gynecology. The system enables the delivery of laser energy along the vaginal walls. Through the use of the scanner, this laser energy is delivered in a fractional manner, selectively treating less than 100% of the tissue surface. This allows the tissue to heal much faster than when treating non-fractionally (100% of the surface) because much of the tissue is left unharmed, while the efficacy of the treatment remains significant.
62600637|NCT06318052|ACTIVE_COMPARATOR|Gynomunal gel treatment|Gynomunal is a hormone/free, vaginal moisturizing gel for women with vaginal dryness. Gynomunal has been clinically proven in treating vaginal dryness, and its symptoms, including itching, burning, and pain (as well as discomfort during sex). Gynomunal is a liposomal formulation containing natural hop extract, Vitamin E and hyaluronic acid.
62600638|NCT01152359|EXPERIMENTAL|Arm 1|Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.
62623853|NCT01372540|EXPERIMENTAL|Treatment (filanesib and carfilzomib)|Patients receive filanesib IV over 1 hour on days 1, 2, 15, and 16 and carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 8 courses of therapy, patients may continue with dosing of carfilzomib on days 1, 2, 15, and 16 and filanesib as tolerated. If patient progresses on carfilzomib maintenance with administration on days 1, 2, 15, and 16 they may increase the intensity and add in days 8 and 9 dosing.
62820725|NCT02898181|NO_INTERVENTION|Control group|Sham neuromodulation will be done
62820726|NCT04414111||Kidney transplant recipient|Kidney transplant recipient
62820727|NCT06226649|EXPERIMENTAL|Digital Dyadic Empowerment|The intervention group (Digital Dyadic Empowerment) will utilize LINE, a prominent instant messaging App in Taiwan, to assist in lifestyle modification, along with support from the significant other.
62820728|NCT06226649|NO_INTERVENTION|Control group|The control group receives routine education and care.
62820729|NCT04071990|ACTIVE_COMPARATOR|Family-based cognitive behavioral group therapy (FB-CBGT)|One family member of each patient will be involved during all 12 CBGT sessions. The CBGT program that will be employed in the present study is a protocoled therapy consisting of psychoeducation, ERP techniques, cognitive tools to change dysfunctional thoughts and beliefs, strategies to prevent relapses, discussion on the family involvement (e.g. FA, burden, ...) and homework exercises after each session.
62820730|NCT04071990|PLACEBO_COMPARATOR|Cognitive-behavioral group therapy (CBGT) without family|Each patient will be involved during all 12 CBGT sessions. The CBGT program that will be employed in the present study is a protocoled therapy consisting of psychoeducation, ERP techniques, cognitive tools to change dysfunctional thoughts and beliefs, strategies to prevent relapses, discussion on the family involvement (e.g. FA, burden, ...) and homework exercises after each session., without the involvement of family members.
62244091|NCT06735820|EXPERIMENTAL|APG-115 and Selumetinib|There is only one arm. It is combination therapy of APG-115 and Selumetinib.
62434371|NCT05093283|EXPERIMENTAL|Workgroup|The probes will be fixed by giving the left lateral position for NST to the pregnant women in the intervention group by the researcher. After providing internet connection with a smart phone for the image, by clicking on youtube.com link, Relaxation (https://www.youtube.com/watch?v=H1iboKia3AQ) nature video watching virtual reality glasses will be provided. The name and surname of the pregnant woman will be written on the NST trace and the trace will be photographed. After the NST process is completed, the NST traces will be evaluated by the researchers.
62820731|NCT04558060|EXPERIMENTAL|Virtual Standardized Patient|Training for 45 minutes at each training time point with a computer program that presented a virtual human patient and two simulated patient encounters. The virtual standardized patient involves a branching story line. Participants select 1 of 3 computer-generated response options at each conversational pause: 1) a response that is consistent with the principles and skills of MI, 2) an MI inconsistent response, or 3) a response that is mixed - partly consistent and partly inconsistent with MI.
62434372|NCT05093283|NO_INTERVENTION|Control|Unlike the study group, only video monitoring will not be applied to the pregnant women included in the control group. Other applications will be done in the same way.
62600639|NCT01152359|ACTIVE_COMPARATOR|Arm 2|Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
62244092|NCT05500001|EXPERIMENTAL|Family Psychoeducation Intervention Arm|These participants will receive the psychoeducation intervention and outcome measures will be taken from them and their young adult service user. The intervention includes psychoeducation on stages of a family's journey, the biopsychosocial basis of psychosis, and skills for coping (Acceptance and Commitment Therapy for Caregivers) and communicating (LEAP).
62600640|NCT02101372|ACTIVE_COMPARATOR|treatment as usual|
62244093|NCT04559828|ACTIVE_COMPARATOR|Pomace olive oil|50 g of pomace olive oil will be administered in a single dose together with a breakfast composed of 3 slices of whole-grain bread, 5 g of tomato pureé and 200 ml of milk.
62600641|NCT02101372|EXPERIMENTAL|Psychoeducation Group|
62434373|NCT04080882|ACTIVE_COMPARATOR|AbobotulinumtoxinA dose 1|AbobotulinumtoxinA dose 1 injected into platysma bands
62434374|NCT04080882|PLACEBO_COMPARATOR|placebo|placebo injected into platysma bands
62600642|NCT00327743|EXPERIMENTAL|larotaxel + Capecitabine|
62600643|NCT04913727|EXPERIMENTAL|Treatment Arm|Patients undergoing transcatheter mitral edge-to-edge repair in this single-arm study.
62600644|NCT06215469|EXPERIMENTAL|Portable Scalp Cooling System (PSCS)|Participants will participate in training in AMMA use and will be asked to bring the device for use during each non-investigational, chemotherapy treatment visit. The device will be used for 30 minutes prior to the start of chemotherapy, during chemotherapy, and for at least 2.5 hours after chemotherapy. Scalp photos will be obtained at baseline and 3 weeks after the last chemotherapy treatment. Questionnaires will be given throughout the study and 3 weeks after the last after the last chemotherapy treatment.
62600645|NCT04826887||Solep Arm|Use of SOLTIVE Thulium Laser for HoLEP (Holmium Laser Enucleation of the Prostate) procedure
62600646|NCT04826887||Control Arm|Use of Holmium Laser for HoLEP (Holmium Laser Enucleation of the Prostate) procedure
62600647|NCT03566875|EXPERIMENTAL|Total knee arthroplasty with the Stryker's MAKO™ system|The total knee arthroplasty is performed with Stryker's MAKO™ robotic system. It allows to place precisely the prosthetic implants.
62600648|NCT03566875|ACTIVE_COMPARATOR|Total knee arthroplasty with mechanical ancillary|The total knee arthroplasty is performed using a mechanical ancillary. It's the conventional method.
62244094|NCT04559828|ACTIVE_COMPARATOR|High-oleic sunflower oil|50 g of high-sunflower oil will be administered in a single dose together with a breakfast composed of 3 slices of whole-grain bread, 5 g of tomato pureé and 200 ml of milk.
62244095|NCT02824731|ACTIVE_COMPARATOR|supratentorial, grade III/IV, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.
62244096|NCT02824731|EXPERIMENTAL|supratentorial, grade III/IV, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.
62434375|NCT04080882|ACTIVE_COMPARATOR|AbobotulinumtoxinA dose 2|AbobotulinumtoxinA dose 2 injected into platysma bands
62434376|NCT04080882|ACTIVE_COMPARATOR|AbobotulinumtoxinA dose 3|AbobotulinumtoxinA dose 3 injected into platysma bands
62434377|NCT03198988|EXPERIMENTAL|General|One arm study: smART Feeding Tube System.
62434378|NCT05705440|OTHER|RSVPreF3 Group|Participants received the RSVPreF3 vaccine during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-011, RSV MAT-010, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study.
62434379|NCT05705440|OTHER|Control Group|Participants received any control (placebo, Tdap or influenza vaccine) during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-011, RSV MAT-010, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study.
62600649|NCT06304805|EXPERIMENTAL|Group A|cycle 1: treatment drug + fasted cycle 2: reference drug + fasted cycle 3: treatment drug + food
62600650|NCT06304805|EXPERIMENTAL|Group B|cycle 1: reference drug + fasted cycle 2: treatment drug + food cycle 3: treatment drug + fasted
62600651|NCT06304805|EXPERIMENTAL|Group C|cycle 1: treatment drug + food cycle 2: treatment drug + fasted cycle 3: reference drug + fasted
62600652|NCT06304805|EXPERIMENTAL|Group D|cycle 1: treatment drug + food cycle 2: reference drug + fasted cycle 3: treatment drug + fasted
62600653|NCT06304805|EXPERIMENTAL|Group E|cycle 1: reference drug + fasted cycle 2: treatment drug + fasted cycle 3: treatment drug + food
62600654|NCT06304805|EXPERIMENTAL|Group F|cycle 1: treatment drug + fasted cycle 2: treatment drug + food cycle 3: reference drug + fasted
62820732|NCT04558060|ACTIVE_COMPARATOR|Academic Study|Study of a summary handout of motivational interviewing concepts and techniques for 45-minutes.
62820733|NCT01441999|ACTIVE_COMPARATOR|Less rigid rods|Titanium rods that have a soft, plastic end
62244097|NCT02824731|ACTIVE_COMPARATOR|supratentorial, grade I/II, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients, bening tumors.
62434380|NCT05835206|EXPERIMENTAL|microbiome therapeutic|The study intervention is manufactured from a healthy screened donor as an investigational product (IP) and delivered via swallowed capsule after room reset of the patient's hospital room.
62434381|NCT05835206|PLACEBO_COMPARATOR|Placebo|The control arm will remain in routine contact precautions per standard of care, take placebo capsules, and have a room reset.
62434382|NCT04535583||EMA plus passive sensing|Participants will be responding to up to 3 ecological momentary assessments per day plus carrying a smartphone and wearing a smartwatch. Both the smartphone and smartwatch will passively collect sensor data continuously.
62600655|NCT02393924||Participants With HER2-Positive Breast Cancer|Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.
62600656|NCT04973059|ACTIVE_COMPARATOR|Summer Conditions with SmartDrive|This arm is with the participant using the SmartDrive during a week in the summer. The SmartDrive is a manual wheelchair accessory that provide power assistance to reduce the necessary level of propulsion force. The goal is to increase participation by reducing propulsion effort.
62434383|NCT01405170|EXPERIMENTAL|methylprednisolone suspension|
62434384|NCT01405170|ACTIVE_COMPARATOR|methylprednisolone tablets|
62434385|NCT01792856|EXPERIMENTAL|intervention group|Subjects are scheduled to receive a 6-month group-based recovery-oriented coaching program. This is a structured, manualised treatment program based on life coaching principles with cognitive-behavioural and solution-focused elements incorporated. It guides subjects to undergo an active, yet stepwise change process by stimulating motivation, setting achievable goals, generation of action plans via collaborative exploration, fostering self-regulatory capacity, and provision of autonomy-supportive treatment environment and peer support. Subjects' perceived competence, sense of control, self-management skills and hence functioning will be improved via successful experiences and positive feelings generated after attainment of self-initiated goals. Cognitive-behavioural techniques such as self-monitoring, activity scheduling and behavioural modification will be employed.
62820734|NCT01441999|ACTIVE_COMPARATOR|Rigid Rods|Titanium rods
62820735|NCT04984616|EXPERIMENTAL|ATORVASTATIN 40|40 mg Atorvastatin/day for 120 days P.O.
62820736|NCT04984616|EXPERIMENTAL|ATORVASTATIN 80|80 mg Atorvastatin/day for 120 days P.O.
62820737|NCT04984616|PLACEBO_COMPARATOR|Placebo|Placebo/day for 120 days P.O.
62244098|NCT02824731|EXPERIMENTAL|supratentorial, grade I/II, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients, bening tumors.
62244099|NCT02824731|ACTIVE_COMPARATOR|infratentorial, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.
62040698|NCT03806270||Midazolam|"Demizolam, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with cherry juice of maximum 5 ml. in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication and doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
62040699|NCT03806270||Midazolam&Hydroxyzine dihydrochloride1/2|"Midazolam and Hydroxyzine dihydrochloride, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with hydroxyzine dihydrochloride (dose of 0.5 mg/kg) in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
62244100|NCT02824731|EXPERIMENTAL|infratentorial, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.
62244101|NCT02824731|ACTIVE_COMPARATOR|pre-radiation, photon|\> 40Gy in the region of recurrence. Radiation with photons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)/fraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).
62244102|NCT02824731|EXPERIMENTAL|pre-radiation, proton|\> 40Gy in the region of recurrence. Radiation with protons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)/fraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).
62244103|NCT04981821|EXPERIMENTAL|GO-EXCAP|GO-EXCAP Mobile App involves the use of a mobile app delivery platform to deliver an exercise program \[Exercise for Cancer Patients (EXCAP©®)\]. EXCAP©®) is a progressive walking and resistance exercise program
62600657|NCT04973059|NO_INTERVENTION|Summer Conditions activity measurement only|This arm is with the participant using their wheelchair during a week in the summer no power assist.
62600658|NCT04973059|NO_INTERVENTION|Winter Conditions activity measurement only|This arm is with the participant using their wheelchair during a week in the winter no power assist
62244104|NCT04981821|ACTIVE_COMPARATOR|Behavioral Placebo Control|Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
62244105|NCT02094833|EXPERIMENTAL|Group A|Participants will receive 3 injections of the study vaccine (DTaP-IPV-Hep B-PRP\~T combined vaccine) at 2, 4, and 6 months of age
62244106|NCT02094833|ACTIVE_COMPARATOR|Group B|Participants will receive 2 injections of monovalent Hep B vaccine (Euvax B®) at age 1 and 6 months and 3 injections of DTaP IPV//PRP\~T vaccine (Pentaxim™) at age 2, 4, and 6 months
62244107|NCT05614973|ACTIVE_COMPARATOR|Conventional|Percutaneous liver biopsy is carried out through multiple punctures of liver capsule.
62244108|NCT05614973|EXPERIMENTAL|Coaxial/plugging|Percutaneous liver biopsy is carried out through single puncture of liver capsule using coaxial needle and subsequent needle tract plugging.
62244109|NCT06314776|ACTIVE_COMPARATOR|Pre-Usual physiotherapy|Pre-intervention (GMFM, Test 10M, Test Time Up and Go)
62244110|NCT06314776|ACTIVE_COMPARATOR|Usual physiotherapy without Whole-Body Vibration|Two days a week of physical therapy (mobilizations, manual therapy, stretching, respiratory techniques)
62244111|NCT06314776|ACTIVE_COMPARATOR|Post-Usual physiotherapy|Post-intervention (GMFM, Test 10M, Test Time Up and Go)
62600659|NCT04973059|ACTIVE_COMPARATOR|Winter Conditions with SmartDrive|This arm is with the participant using the SmartDrive during a week in the winter. The SmartDrive is a manual wheelchair accessory that provide power assistance to reduce the necessary level of propulsion force. The goal is to increase participation by reducing propulsion effort.
62600660|NCT00131365|EXPERIMENTAL|ExAblate MRgFUS|Treatment with the ExAblate 2000 system Version 4.1
62820738|NCT06583668|EXPERIMENTAL|Experimental: Therapeutic Story group|I. Assessment:Before the burn dressing II. Assessment: During burn dressing II. Assessment: After burn dressing
62434386|NCT01792856|EXPERIMENTAL|control group|Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
62434387|NCT02118753|NO_INTERVENTION|ischemic preconditioning|"After baseline recordings of contractile function, the investigators will assign 2 trabeculae of each patient to either a stimulus for (1) ischemic preconditioning (IP) or (2) no IP. Subsequently, the trabeculae will be exposed to 90 min of ischemia, followed by 120 minutes of recovery. The investigators will measure the recovery of contractile function in both trabeculae.~This experiment serves as a positive control, to ensure that our model is still working properly."
62244112|NCT03203421|ACTIVE_COMPARATOR|Low Dose (Group 1)|One low dose of ChAdOx1 LS2 (5 x 10\^9 vp) on day 0.
62434388|NCT02118753|EXPERIMENTAL|eplerenone|In the next patients, a similar ischemia-reperfusion experiment will be performed, but now the 2 trabeculae will be randomized to pretreatment with eplerenone or DMSO. The percentage recovery (compared to baseline) of contractile force of the trabeculae at the end of reperfusion will serve as the primary endpoint.
62434389|NCT05970601|EXPERIMENTAL|high salt group|Intake of 9 g sodium chloride
62434390|NCT05970601|ACTIVE_COMPARATOR|low salt group|Intake of 6 g sodium chloride
62244113|NCT03203421|ACTIVE_COMPARATOR|Prime-Boost (Group 2)|One high dose of ChAdOx1 LS2 (2.5 x 10\^10 vp) on day 0 and one dose of MVA LS2 (2 x 10\^8 pfu) on day 56.
62244114|NCT03203421|NO_INTERVENTION|Control Group A|No vaccinations will be administered.
62244115|NCT03203421|NO_INTERVENTION|Control Group B|No vaccinations will be administered.
62244116|NCT06736223|EXPERIMENTAL|Mild HI|Patients with mild HI (Child-Pugh class A)
62244117|NCT06736223|EXPERIMENTAL|Moderate HI|Patients with moderate HI (Child-Pugh class B)
62820739|NCT06583668|NO_INTERVENTION|Standard care|I. Assessment:Before the burn dressing II. Assessment: During burn dressing II. Assessment: After burn dressing
62820740|NCT04205448|EXPERIMENTAL|Exercize group|10 weeks of physical exercise. Testing of strength and balance.
62820741|NCT04205448|NO_INTERVENTION|Control group|Testing of strength and balance.
62820742|NCT03333343|EXPERIMENTAL|Arm 1|EGF816+ trametinib in escalation phase
62820743|NCT03333343|EXPERIMENTAL|Arm 2|EGF816 + ribociclib in escalation phase
62820744|NCT03333343|EXPERIMENTAL|Arm 3|EGF816 + LXH254 in escalation phase
62820745|NCT03333343|EXPERIMENTAL|Arm A|EGF816 + INC280 in expansion phase (patients with no known resistance mechanism)
62820746|NCT03333343|EXPERIMENTAL|Arm B|EGF816 + trametinib in expansion phase
62820747|NCT03333343|EXPERIMENTAL|Arm C|EGF816 + ribociclib in expansion phase
62820748|NCT03333343|EXPERIMENTAL|Arm D|EGF816 + LXH254 in expansion phase (patients with no known resistance mechanism)
62820749|NCT03333343|EXPERIMENTAL|Arm E|EGF816 + LXH254 in expansion phase (patients with known resistance mechanism)
62820750|NCT03333343|EXPERIMENTAL|Arm F|EGF816 + gefitinib in expansion phase
62820751|NCT03333343|EXPERIMENTAL|Arm G|EGF816 + INC280 in expansion phase (patients with known resistance mechanism)
62820752|NCT00879736|ACTIVE_COMPARATOR|THT PACE eLearning module|The PACE (prepare, ask, check, express) training methodology will be available to patients before their 2nd doctor visit
62820753|NCT00879736|ACTIVE_COMPARATOR|THT PACE eLearning module & nurse-led workshop training|THT PACE eLearning and then nurse-led workshop for training on PACE methodology
62820754|NCT00879736|PLACEBO_COMPARATOR|Usual care|Patients just go to their doctor as they normally would but get some disease specific information in the form of brochures as do intervention arms
62820755|NCT06602895|ACTIVE_COMPARATOR|Male group|The male group received intensive short-term functional strength training and balance training consecutively for one hour each, six days a week for two weeks.
62820756|NCT06602895|ACTIVE_COMPARATOR|Female group|The female group received balance training and intensive short-term functional strength training consecutively for one hour each, six days a week for two weeks.
62820757|NCT03818854|EXPERIMENTAL|Human Mesenchymal Stromal Cells|A single dose of 10 million cells/kg predicted body weight (PBW) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells will administered intravenously over approximately 60-80 minutes.
62820758|NCT03818854|EXPERIMENTAL|Cell Reconstitution Media|A single dose of cell reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40) will administered intravenously over approximately 60-80 minutes.
62820759|NCT05884554|EXPERIMENTAL|Cohort 1|No hepatic impairment
62820760|NCT05884554|EXPERIMENTAL|Cohort 2|Mild hepatic impairment
62820761|NCT05884554|EXPERIMENTAL|Cohort 3|Moderate hepatic impairment
62434391|NCT05970601|ACTIVE_COMPARATOR|substitution group|Intake of 6 g sodium chloride plus 3 g potassium chloride
62434392|NCT03370484|PLACEBO_COMPARATOR|Control|Water with artificial sweetener
62434393|NCT03370484|EXPERIMENTAL|Milk mineral supplement|Milk Minerals containing 1000 mg calcium with artificial sweetener and water
62244118|NCT06736223|EXPERIMENTAL|Healthy Volunteers|Participants with normal hepatic function (control group)
62434394|NCT04160949||Patients|Patients who have been diagnosed with Fatty Liver.
62434395|NCT06382779||allograft prosthetic composite|patients treated with resection and reconstruction with reverse prostheses included in cryopreserved allografts
62434396|NCT06382779||cement sleeve|patients treated with resection and reconstruction with suspended prostheses with proximal metaphyseal reconstruction using a cement sleeve
62434397|NCT06000189||Participants who received phototherapy for various dermatological indications|A case-control study will be conducted participants who received narrow-band ultraviolet B (NBUVB) or ultraviolet A-1 (UVA-1) therapy for various dermatological indications. Standardized skin surface biopsies (SSSB) were performed before and after phototherapy to assess Demodex density. Demographic data, medical information, and the presence of demodex-related skin conditions were recorded using a standardized form. Statistical analysis will be performed to compare the demodex densities and prevalence of demodicosis between baseline and 20th session of phototherapy.
62600661|NCT01618851|EXPERIMENTAL|IMRT with SBRT Boost|Patients with clinically localized prostate cancer will be treated with three radiosurgical treatments (6.5 Gy per fraction to PTV) followed by IMRT (45 Gy in 25 fractions) over 6-7 weeks.
62244119|NCT00165256|EXPERIMENTAL|Observation (omission of RT)|Wide excision of DCIS; no radiotherapy (RT).
62244120|NCT06077812|ACTIVE_COMPARATOR|In-Person Migraine Self-Management|
62244121|NCT06077812|ACTIVE_COMPARATOR|Remote Migraine Self-Management|
62820762|NCT05884554|EXPERIMENTAL|Cohort 4|Severe hepatic impairment
62820763|NCT06026033||Patients scheduled for general anesthesia|Patients scheduled for elective general anesthesia will be included, if accepts and signs the informed consent. The inhalational anesthetic should be desflurane. No other inhalational agent should be used during the induction of anesthesia. The inspiratory and expiratory concentration of any inhalational agent should be zero before the induction of anesthesia.
62820764|NCT06610682|EXPERIMENTAL|Recurrent BRAF-V600E mutant gliomas previously received BRAFi* +/- MEKi** ,|"\*BRAFi (v-raf murine sarcoma viral oncogene homolog B1 inhibitor)~\*\*MEKi (Methyl ethyl ketone inhibitor)"
62820765|NCT05914623|ACTIVE_COMPARATOR|rTMS|Patients are treated with repetitive transcranial magnetic stimulation (rTMS).
62820766|NCT05914623|PLACEBO_COMPARATOR|sham-rTMS|Patients are treated with sham repetitive transcranial magnetic stimulation (sham-rTMS).
62820767|NCT00534612|EXPERIMENTAL|1|fine needle aspiration biopsy of the parotid gland mass
62820768|NCT06378229|EXPERIMENTAL|Open label: full dose Psilocybin|2 doses of 25mg Psilocybin, 3 weeks apart (week 3 and week 6), accompanied by 7,5 hours of preparation sessions and 9 hours of integration sessions.
62820769|NCT05522660|EXPERIMENTAL|standard systemic treatment with stereotactic radiosurgery (SRS)|Arm A
62820770|NCT05522660|ACTIVE_COMPARATOR|standard systemic treatment without stereotactic radiosurgery|Arm B
62820771|NCT03536572|ACTIVE_COMPARATOR|Sleep Apnea Self-Management Program|Protocol-based sleep apnea and CPAP education and support
62820772|NCT03536572|EXPERIMENTAL|Individualized Pressure Adjustment|Additional education and support that will allow them to adjust their PAP pressures
62040700|NCT03806270||Midazolam&Hydroxyzine dihydrochloride|"Midazolam and Hydroxyzine dihydrochloride, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with the maximum dose of 1mg/kg hydroxyzine dihydrochloride in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
62040701|NCT05137132|ACTIVE_COMPARATOR|Best Standard of Care + CARDIO®|6 gram/day ( 1000 mg per capsule) of unrefined salmon oil, duration of 20 weeks. CARDIO® capsule contains 1000 mg of full spectrum of omega fatty acids, including 21 different fatty acids, with a minimum of 270 mg polyunsaturated fatty acids (PUFA) and10 mg lipopeptides
62600662|NCT03843424|ACTIVE_COMPARATOR|Enhanced Standard of Care (eSOC)|This group will receive the eSOC program. A minimum of 6 visits to the primary care provider (PCP) and includes assessment of weight status, patient/family motivation and readiness to change, promotion of healthy eating and activity habits, and use of health behavior change strategies.
62820773|NCT06602323|OTHER|TMLI/Flu/Mel conditioning regimen (Single-arm)|"Single-arm.~TMLI:~Dose level 1: 1200 cGy = 150 cGy x 8 doses (liver, brain, and hepatic portal limited to 720 cGy) Dose level -1: 1100 cGy = 137.5 cGy x 8 doses (liver, brain, and hepatic portal limited to 720 cGy) Dose level -2: 1000 cGy = 125 cGy x 8 doses (liver, brain, and hepatic portal limited to 720 cGy) Dose levels above 1,200 cGy will not be considered in this protocol, as the dose to off-target avoidance organs would exceed the recommended levels in reduced-intensity transplants.~TMLI will be administered by helical tomotherapy for 4 consecutive days (day -7 to day -4), delivering 2 fractions per day (a total of 8 doses) with a minimum of 6 hours between fractions.~FLURADABINE:~Dose: 25 mg/m2 Route of administration: intravenous. Treatment duration: for 4 consecutive days (day -7 to day -4 pre-transplant).~MELPHALAN:~Dose: 140 mg/m2 Route of administration: intravenous Treatment duration: for 1 day (day -2 pre-transplant)."
62820774|NCT05703945|EXPERIMENTAL|Training group|Participants benefit from an 8-week training program of muscle strengthening
62820775|NCT05703945|SHAM_COMPARATOR|Control group|Participants in the control group will be asked to maintain their habits and lifestyle (without training program) for the duration of the study.
62820776|NCT06472518|EXPERIMENTAL|pharmaco mechanical thrombolysis|thrombolysis intervention combined with anticoagulant treatment with direct oral anticoagulants
62600663|NCT03843424|ACTIVE_COMPARATOR|Family-Based Behavioral Treatment (FBT + eSOC)|This group will receive eSOC plus the FBT program. Family-based behavioral treatment (FBT), an effective treatment that targets both child and parents meeting regularly with a health coach for healthy eating, activity, positive parenting strategies, and managing environmental cues.
62600664|NCT05272696|EXPERIMENTAL|Experimental|"All enrolled patients will receive two cycles of chemotherapy consisting of nab-paclitaxel (260 mg/m² on days 1), cisplatin (75 mg/m² on days 1), and Pembrolizumab (200 mg on days 1). Each cycle is repeated every 21 days.~After induction therapy, patients with PR but the maximum diameter of tumor \> 3cm or SD or PD can receive surgery directly. After surgery, adjuvant CRT will be given for patients with high-risk factors.~After induction therapy, patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive CRT. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment."
62600665|NCT02440542||Postoperative Popliteal nerve block|All patients in the cohort are receiving a postoperative popliteal nerve block as part of their surgical plan. Outcomes including length of stay, Visual Analog Scale Scores, narcotic intake, and patient satisfaction will be collected as the intervention.
62600666|NCT05491525|EXPERIMENTAL|Cohort 1: Vibegron Adolescents (12 to < 18 years)|"Part A: Participants aged 12 to \< 18 years will receive vibegron based on their weight, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times.~Part B: Participants will receive a Data and Safety Monitoring Board (DSMB)-selected vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A."
62600667|NCT05491525|EXPERIMENTAL|Cohort 2: Vibegron Children (2 to < 12 years)|"Part A: Participants aged 2 to \< 12 years will receive vibegron based on their weight, after DSMB review of Cohort 1, Part A data, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times.~Part B: Participants will receive a DSMB-selected vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A."
62600668|NCT04933916|EXPERIMENTAL|EMB-001 Active|720 mg metyrapone/24 mg oxazepam mg BID, for a total daily dose of 1440 mg metyrapone and 48 mg oxazepam
62600669|NCT05119868|EXPERIMENTAL|Group 1|Group 1 will receive standard obstetrical and gynecological follow-up and nutritional intervention based on Mediterranean Diet provided by certified dietitians
62600670|NCT05119868|NO_INTERVENTION|Group 2|Group 2 will receive standard obstetrical and gynecological follow-up alone
62600671|NCT04395092|EXPERIMENTAL|K-NK002|
62600672|NCT00347919|EXPERIMENTAL|monotherapy arm|1500 mg (6 x 250 mg tablets) oral lapatinib once daily
62600673|NCT00347919|EXPERIMENTAL|Cohort 1 combination arm|1000 mg (4 x 250 mg tablets) of oral lapatinib and 400 mg (4 x 100 mg tablets) of oral pazopanib taken together once daily
62820777|NCT06472518|ACTIVE_COMPARATOR|oral anticoagulant alone|a reference treatment arm for patients receiving direct oral anticoagulant alone and stenting angioplasty in case of venous claudication or moderate post-thrombotic syndrome six months after the initial thrombosis.
62040702|NCT05137132|PLACEBO_COMPARATOR|Best Standard of Care + Placebo|6 gram/day (1000 mg per capsule) of natural oil, duration of 20 weeks. The placebo is a medium-chain triglyceride (MCT), with triglyceride from natural fatty acid, mainly caprylic- and capric acid.
62600674|NCT00347919|EXPERIMENTAL|Cohort 2 combination arm|1500 mg (6 x 250 mg tablets) of oral lapatinib and 800 mg (1 x 500 mg tablets plus 3 x 100 mg tablets) of oral pazopanib taken together once daily
62600675|NCT05822362|ACTIVE_COMPARATOR|Full Spectrum Cannabidiol|200mg/day of full-spectrum cannabidiol, containing less than 0.3% THC.
62600676|NCT05822362|ACTIVE_COMPARATOR|Broad Spectrum Cannabidiol|200mg/day of broad-spectrum cannabidiol, containing 0.0% THC.
62244122|NCT04454437|EXPERIMENTAL|Sacituzumab Govitecan-hziy|Participants will receive sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
62820778|NCT00687596|EXPERIMENTAL|TAC-101|Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 milligram per day (mg/day) of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion.
62820779|NCT00687596|PLACEBO_COMPARATOR|Placebo|Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion.
62820780|NCT05943639|EXPERIMENTAL|Experimental group|The Cultural Marginality Theory-Based Education program will be held in a face-to-face classroom environment for the students in the experimental group. This training program has been developed based on the concepts of Cultural Marginality Theory. The content and topics of the sessions in the program are arranged according to the conceptual structure and flow of the theory. The training program was created in a certain flow, based on the concepts of recognizing intercultural conflict (2 sessions), marginal living (2 sessions) and alleviating cultural tension (2 sessions). There are 6 sessions in the program and the frequency of sessions is 2 times a week, and each session lasts approximately 45 minutes. The training program will be applied to 33 foreign nursing students in the experimental group.
62600677|NCT05822362|PLACEBO_COMPARATOR|Hemp Seed Oil|200mg/day of hemp seed oil with no cannabinoids present.
62820781|NCT05943639|NO_INTERVENTION|Control group|There will be no training or intervention.
62820782|NCT04725773||PD DBS|Patients with Parkinson's disease and deep brain stimulation
62820783|NCT03400735|EXPERIMENTAL|Cefdinir/clavulanic acide 300/125 mg Film Coated Tablets|
62820784|NCT03400735|ACTIVE_COMPARATOR|Cefdinir 300 mg Capsules|
62820785|NCT06351124|NO_INTERVENTION|standard of care therapy (control)|Arm does not receive the BHB supplement
62820786|NCT06351124|ACTIVE_COMPARATOR|Standard of care therapy plus BHB supplementation (intervention).|Arm does receives the BHB supplement
62820787|NCT04315948|EXPERIMENTAL|Remdesivir|"Remdesivir will be administered as a 200 mg intravenous loading dose on Day 1, followed by a 100 mg once-daily intravenous maintenance dose for the duration of the hospitalization up to a 10 days total course.~n=475"
62820788|NCT04315948|EXPERIMENTAL|Lopinavir/ritonavir (stopped on June 29, 2020)|"Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube.~n=620"
62820789|NCT04315948|EXPERIMENTAL|Lopinavir/ritonavir plus Interferon ß-1a (stopped on June 29)|"Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube.~Interferon ß1a will be administered subcutaneously at the dose of 44 µg for a total of 3 doses in 6 days (day 1, day 3, day 6).~n=620"
62820790|NCT04315948|EXPERIMENTAL|Hydroxychloroquine (stopped on May 24, 2020)|Hydroxychloroquine will be administered orally as a loading dose of 400 mg twice daily for one day followed by 400 mg once daily for 9 days. The loading dose of hydroxychloroquine through a nasogastric tube will be increased to 600 mg twice a day for one day, followed by a maintenance dose of 400 mg once a day for 9 days n=620
62820791|NCT04315948|ACTIVE_COMPARATOR|Standard of care alone|Standard of care alone before March, 2021.
62820792|NCT04315948|EXPERIMENTAL|AZD7442|"Participants randomized to the AZD7442 group will receive a total dose of 600 mg AZD7442 via a co-administered (300 mg AZD8895 and 300 mg AZD1061) single IV infusion on Day 1.~n=620"
62820793|NCT04315948|ACTIVE_COMPARATOR|Standard of care with placebo|Standard of care with placebo since April, 2021 n=620
62820794|NCT05877521|PLACEBO_COMPARATOR|Wait List Control (WLC) Usual Care Procedure|Participants in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers.
62820795|NCT05877521|EXPERIMENTAL|16-hour MORE treatments|Patients in the 16-hour MORE format will receive one 2hrs treatment a week for 8 consecutive weeks (as per study schema: from week 1 to week 8).
62820796|NCT05877521|EXPERIMENTAL|8-hour MORE treatments|Patients in the 8-hour MORE format will receive one 2hrs treatment a week for 4 consecutive weeks (as per study schema: from week 1 to week 4).
62820797|NCT05877521|EXPERIMENTAL|2-hour MORE treatments|Patients in the 2-hour MORE format will receive one 2hrs treatment (as per study schema: in week 1).
62820798|NCT06579261|EXPERIMENTAL|Fibromyalgia participants - Shamanic Intervention|
62820799|NCT02242773|EXPERIMENTAL|Active Surveillance|Participants in this group will receive a Multi-Parametric Magnetic Resonance Imaging (MP-MRI) of the prostate/pelvis and MRI-guided prostate biopsy at baseline (0-3 months from enrollment) and at the 12th, 24th and 36th month follow up.
62820800|NCT04606134|EXPERIMENTAL|Experimental|
62820801|NCT04606134|PLACEBO_COMPARATOR|Control|
62820802|NCT03505762|EXPERIMENTAL|Arm I (tailored prednisone dose)|Participants receive rituximab IV, vincristine sulfate IV, doxorubicin hydrochloride IV, and cyclophosphamide IV on day 1. Participants also receive tailored prednisone dose PO QD on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62244123|NCT06480513|EXPERIMENTAL|yoga group|following live yoga classes twice a week and using yoga video's at home once a week
62600678|NCT01877356|EXPERIMENTAL|bilateral spinal anesthesia|bilateral spinal anesthesia prilocaine plain 20% 50 mg ambulatory surgery
62244124|NCT06480513|OTHER|control group|Waiting list control group. The control group will be offered live remote yoga classes after the intervention period
62244125|NCT06726174|EXPERIMENTAL|Cell|
62600679|NCT01877356|EXPERIMENTAL|unilateral spinal anesthesia|unilateral spinal anesthesia prilocaine hyperbaar 2% 30 mg ambulatory surgery
62820803|NCT03505762|ACTIVE_COMPARATOR|Arm II (usual care prednisone dose)|Participants receive rituximab, vincristine sulfate doxorubicin hydrochloride, and cyclophosphamide as in Arm I. Participants also receive usual care prednisone dose PO QD on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62820804|NCT04985617|EXPERIMENTAL|Warmed Fluids|When patients recovered from the effect of anesthesia, awakened and were able to switch to normal spontaneous breathing, they were taken from the sober unit to the service or intensive care unit, and subsequent follow-ups were carried out by the researcher in these units. The IV fluid given to the patients in the intervention group was heated to 36ºC using the medical heating device.
62820805|NCT04985617|NO_INTERVENTION|Room Temperature Fluids|When patients recovered from the effect of anesthesia, awakened and were able to switch to normal spontaneous breathing, they were taken from the sober unit to the service or intensive care unit, and subsequent follow-ups were carried out by the researcher in these units. The IV fluid given to the patients in the control group was given at room temperature without heating and without intervention
62820806|NCT05866952||Post-Acute Sequelae of SARS-CoV-2 (PASC) Group|Subjects with PASC with a documented history of COVID-19 and persistent symptoms of fatigue, dyspnea, and/or exercise intolerance
62820807|NCT05866952||Control: Fully recovered COVID-19|Subjects with a history of COVID-19 who have fully recovered from COVID-19 with no post-acute sequelae of SARS-Cov-2
62820808|NCT05866952||Control: No history of COVID-19|Healthy subjects without a documented history of COVID-19, no current symptoms, and a normal baseline High resolution CT of the chest
62820809|NCT01231906|EXPERIMENTAL|Arm A (combination chemotherapy)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 5, 6, 9, and 10; doxorubicin hydrochloride IV over 1-15 minutes (or as per institutional policies up to 60-minutes) on days 1 and 2 and cyclophosphamide IV over 30-60 minutes on day 1 in weeks 1, 5, and 9; and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 in weeks 3, 7, and 11.~CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 7, 8, 9, 10, 13, 14, 17, 18, 21, and 22; doxorubicin hydrochloride IV on days 1 and 2 in weeks 1 and 9; cyclophosphamide IV over 30-60 minutes on day 1 in weeks 1, 7, 9, 13, 17, and 21; and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 in weeks 3, 5, 11, 15, and 19. Patients received Dexrazoxane with doxorubicin hydrochloride in weeks 1 and 9."
62820810|NCT01231906|EXPERIMENTAL|Arm B (combination chemotherapy, topotecan hydrochloride)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 5, 6, 9, 10, 11 and 12; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 9; cyclophosphamide IV over 15-30 minutes on days 1-5 in weeks 1 and 9, and over 30-60 minutes on day 1 of weeks 5 and 11; ifosfamide and etoposide as in arm A; and doxorubicin hydrochloride IV on days 1 and 2 in weeks 5 and 11.~CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 7-10, 13-16, 19, and 20; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1, 7, and 15; cyclophosphamide IV over 15-60 minutes on days 1-5 in weeks 1, 7, and 15, and over 30-60 minutes on day 1 in weeks 9, 13, and 19; ifosfamide IV over 1 hour and etoposide IV over 1- 2 hours on days 1-5 in weeks 3, 5, 11, 17, and 21; and doxorubicin hydrochloride IV on days 1 and 2 in weeks 9,13, and 19. Patients received Dexrazoxane with doxorubicin hydrochloride in weeks 13 and 19."
62820811|NCT04088890|EXPERIMENTAL|R/R ALL|"Relapsed/refractory ALL~Lymphodepletion prior to CD22 CAR T cell infusion (Day 0) will occur as follows:~* Fludarabine 30 mg/m2 per day IV for days 5, 4, 3~* Cyclophosphamide 500 mg/m2 per day IV for days 5, 4, 3~Autologous CD22 CAR T cells will be administered intravenously at Dose1: 3 x 10\^5cells/kg (± 20%) 10"
62820812|NCT04088890|EXPERIMENTAL|R/R aggressive B-cell NHL|"Relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.~Lymphodepletion prior to CD22 CAR T cell infusion (Day 0) will occur as follows:~* Fludarabine 30 mg/m2 per day IV for days 5, 4, 3~* Cyclophosphamide 500 mg/m2 per day IV for days 5, 4, 3~Autologous CD22-CAR T cells will be administered in 3 escalating doses (Dose Level 1, 2, and 3) to determine MTD/RP2D.~Dose1: 1 x 10\^6 cells/kg (± 20%) Dose2: 3 x 10\^6 cells/kg (± 20%) Dose3: 1 x 10\^7 cells/kg (± 20%)"
62820813|NCT06595277||Cardiac surgery with NMBA|All patients undergoing cardiac surgery at Hôpital Érasme between October 1, 2024 and May 31, 2025 who receive any neuromuscular blocking agent.
62820814|NCT05235009||Sub-Study 1|"Adults \>= 18 years old with cancer or imminent cancer diagnosis (cases) versus cancer-free and no imminent cancer diagnosis (controls).~Sub-Study 1 is intended for the development of 3 free GAGome MCED tests."
62820815|NCT05235009||Sub-Study 2|"Adults between 35 - 80 years old asymptomatic for cancer and with no recent history of cancer (\> 5 years since curative-intent treatment for cancer).~Sub-Study 2 is intended for the validation of the combined free GAGome MCED test (primary endpoint) and the plasma and urine free GAGome MCED tests (secondary endpoints)."
62820816|NCT06705829||Hepatocellular insufficiency with coagulopathy|Patients with an hepatocellular insufficiency generally associated with coagulopathy (with an intensity proportional to the degree of hepatic impairment).
62820817|NCT06112093|ACTIVE_COMPARATOR|Repetitive transcranial magnetic stimulation (rTMS)|12 sessions (3 sessions/week) of active rTMS at the left motor cortex to upregulate brain excitability and reduce headaches and post-concussion symptoms.
62434398|NCT02371967||No Gorlin Syndrome Participants With No Prior HPI Exposure|BCC participants with advanced disease and no Gorlin syndrome, and who have not been exposed previously to an Hedgehog Pathway Inhibitor (HPI) (e.g., Vismodegib, LDE225) prior to diagnosis of advanced disease; will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
62434399|NCT02371967||No Gorlin Syndrome Participants With Prior HPI Exposure|BCC participants with advanced disease and no Gorlin syndrome, and who have been exposed previously to an HPI (e.g., during clinical studies with vismodegib \[SHH4476g {NCT00833417}, MO25616 {NCT01367665}\] or LDE225); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
62040703|NCT03327987||31-90 days|Patient 31-90 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
62040704|NCT03327987||91-180 days|91-180 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
62040705|NCT03327987||181-365 days|181-365 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
62040706|NCT02800850|EXPERIMENTAL|Bright Light Group|Bright Light Exposure
62820818|NCT06112093|SHAM_COMPARATOR|Sham rTMS|12 sessions (3 sessions/week) of sham rTMS will be administered at the same location and duration as the active rTMS but will not modulate brain function. After the study is completed, participants will be offered an opportunity to receive active rTMS.
62820819|NCT06335329|ACTIVE_COMPARATOR|standard vaping cessation counseling (SOC) + ultrasound (US)|Participants will receive SOC via a publicly available infographic from the Food and Drug Administration). They will also be provided with a discussion of lung US findings
62820820|NCT06335329|NO_INTERVENTION|Standard vaping cessation counseling (SOC) alone|Participants will receive a SOC alone. They will be kept blinded to their lung point-of-care ultrasound findings and will not be able to visualize the images as the ultrasound is performed.
62820821|NCT03279081|PLACEBO_COMPARATOR|Placebo|Placebo (saline) 24 milliliters (mL) was administered once by local injection.
62820822|NCT03279081|EXPERIMENTAL|Cx601|Cx601 expanded adipose-derived stem cells (eASCs) 120 million cells (5 million cells per mL) was administered once by local injection.
62820823|NCT05183828|EXPERIMENTAL|Treatment (letrozole)|Patients receive letrozole PO QD for 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of saliva samples. If tumor resection occurs before or after day 22, letrozole administration must occur for a minimum of 14 days and a maximum of 70 days of total treatment.
62820824|NCT03590028|EXPERIMENTAL|Early Nephrology Consult (ENC)|The ENC will be a structured consultative note that will provide detailed recommendations around issues such as Differential Diagnosis, Drug Dosing and Volume Status. The research ENC will have a daily follow-up with documented recommendations.
62040707|NCT02800850|PLACEBO_COMPARATOR|Control Group|Placebo Light Exposure
62040708|NCT02045394||Patients presenting with haemoptysis|
62040709|NCT06732661|NO_INTERVENTION|Preserve pre-cardial fat pad|For this group, a sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 10 mm lateral to the esophagus is respected without dissection of pre-cardial fat pad.
62040710|NCT06732661|EXPERIMENTAL|Dissect pre-cardial fat pad|For this group, a sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. Dissect the pre-cardial fat pad, and a security distance of 10 mm lateral to the esophagus is respected.
62434400|NCT02371967||Gorlin Syndrome Participants With/Without Prior HPI Exposure|BCC participants with advanced disease and Gorlin syndrome, and who have or have not been previously exposed to an HPI (e.g., during clinical studies); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
62434401|NCT05045794|EXPERIMENTAL|Hypothermic oxygenated perfusion (HOPE)|Ex-vivo donor liver preservation using static cold storage followed by HOPE using the VitaSmart Liver Machine
62434402|NCT05045794|OTHER|Static cold storage|Ex-vivo donor liver preservation using static cold storage only
62434403|NCT03229031|EXPERIMENTAL|ES135|
62434404|NCT03229031|PLACEBO_COMPARATOR|Placebo|
62434405|NCT04719897|EXPERIMENTAL|FIRST: Repairing Thoughts|
62434406|NCT05064865|EXPERIMENTAL|Freeze-dried table grape powder|The intervention group will consume 46 g/day of a freeze-dried table grape powder.
62434407|NCT05064865|PLACEBO_COMPARATOR|Placebo grape powder|The control group will consume the same amount of a placebo with a similar taste to the table grape powder.
62820825|NCT03590028|ACTIVE_COMPARATOR|Standard of Care (SOC)|Subjects will receive nephrology consultation at the typical timepoint after symptoms of AKI appear.
62820826|NCT06071234|EXPERIMENTAL|3D-reconstruction group|The participant's breast blood supply was assessed preoperatively using 3D reconstruction technology, and the flap was separated intraoperatively using a combination of cold knife and electrosurgical knife.
62820827|NCT06071234|ACTIVE_COMPARATOR|Normal group|Participants are not evaluated preoperatively using 3D reconstruction technology and flap separation is performed using electrosurgical knife intraoperatively.
62820828|NCT06070454|EXPERIMENTAL|Positive Perioperative Vaginitis|Participants who test positive for BV, candida, and/or trichomonas on perioperative vaginitis swab.
62820829|NCT00576706|EXPERIMENTAL|1|
62820830|NCT00576706|ACTIVE_COMPARATOR|2|
62820831|NCT04588922|EXPERIMENTAL|Group 1. Dose escalation in patients with r/r AML|In the dose escalation part, the dose levels will be escalated following the Bayesian optimal interval (BOIN) design. China study sites only. (Completed).
62820832|NCT04588922|EXPERIMENTAL|Group 2. Dose escalation in patients with r/r CLL/SLL or lymphoma|In the dose escalation part, the dose levels will be escalated following the Bayesian optimal interval (BOIN) design. China and US study sites. (Completed).
62820833|NCT04588922|EXPERIMENTAL|Group 3 Cohort 1. 45 mg QW in patients with r/r AML|SLS009 (45 mg QW) in combination with venetoclax and azacitidine in patients with r/r AML who have relapsed on or are refractory to venetoclax-based regimens. US study sites only. (Cohort completed)
62820834|NCT04588922|EXPERIMENTAL|Group 3 Cohort 2. 60 mg QW in patients with r/r AML.|SLS009 (60 mg QW) in combination with venetoclax and azacitidine in patients with r/r AML who have relapsed on or are refractory to venetoclax-based regimens. US study sites only. (Cohort completed).
62820835|NCT04588922|EXPERIMENTAL|Group 3 Cohort 3. 30 mg BIW in patients with r/r AML.|SLS009 (30 mg BIW) in combination with venetoclax and azacitidine in patients with r/r AML who have relapsed on or are refractory to venetoclax-based regimens. US study sites only. (Cohort completed).
62820836|NCT04588922|EXPERIMENTAL|Group 3 Cohort 4. 30 mg BIW in patients with r/r AML with ASXL1 mutation.|SLS009 (30 mg BIW) in combination with venetoclax and azacitidine in patients with r/r AML who have relapsed or are refractory to venetoclax-based regimens and with documented ASXL1 mutation.
62820837|NCT04588922|EXPERIMENTAL|Group 3 Cohort 5. 30 mg BIW in pts with r/rAML with other than ASXL1 mutations|SLS009 (30 mg BIW) in combination with venetoclax and azacitidine in patients with r/r AML who have relapsed or are refractory to venetoclax-based regimens and with documented Defining somatic mutations, Cytogenetic abnormalities defining acute myeloid leukemia, myelodysplasia related, other than ASXL1 mutation per WHO 5th Edition classification.
62040711|NCT05335317|EXPERIMENTAL|Laser Treatment|"Laser treatment of the vagina, vulva, and paraurethral region with a Magic Max laser (Magic Gyno). In total, three procedures will be performed with an interval of 4-6 weeks.~During the procedure, the following sequence of actions will be performed: 1st Stage - vaginal processing with a conical mirror handpiece, 2nd Stage - vaginal processing with a corner mirror handpiece, 3d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece."
62040712|NCT05335317|ACTIVE_COMPARATOR|Topical hormone|Local hormone therapy with estriol. The course of treatment will be of 2 weeks of daily use, and then a maintenance therapy, when the suppository will be used of 2 times a week for 1.5-2 months to prevent symptoms.
62244126|NCT06736210|EXPERIMENTAL|Health Control Group|The healthy control group consisted of 10 participants with no history of foot or ankle injuries or systemic diseases, ensuring a baseline for comparison. Assessments included isokinetic testing for plantar flexor (PF) and dorsiflexor (DF) muscle strength and endurance at angular velocities of 30°/s and 120°/s, respectively. Additionally, functional evaluations such as the physical performance (heel-rise) test and patient-reported outcome measures (AOFAS and FAOS scores) were conducted. These evaluations provided a comprehensive understanding of muscle performance and functional status in healthy individuals, serving as a reference point for interpreting deviations observed in the Lisfranc injury group.
62600680|NCT02560324|EXPERIMENTAL|Ramelteon|"The study will be performed using 8mg of ramelteon, which is currently marketed for the treatment of sleep problems. The proposed study follows the typical dosing regimen for ramelteon (8mg once a day) for 5 days during each quit assessment period.~Ramelteon will be purchased and packaged into blister packs by the Investigational Drug Service (IDS) at the University of Pennsylvania. In accordance with FDA recommendations, subjects will be instructed to take study medication within 30 min prior to going to bed and avoid taking study medication with or immediately after a high fat meal."
62600681|NCT02560324|PLACEBO_COMPARATOR|Placebo|"5-day placebo-controlled medication period.~Placebo ingredients will be purchased, encapsulated, and packaged into blister packs by the IDS at UPenn. Both active medication and placebo will look identical.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take ramelteon during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by ramelteon during the second medication period."
62820838|NCT05920590|EXPERIMENTAL|PNF Group|Participants allocated to this group will receive 18 sessions of therapeutic exercise program based on the PNF concept (Bello et al. 2011).
62244127|NCT06736210|EXPERIMENTAL|IWDGF-0|The IWGDF 0 group included 10 patients classified as having no immediate risk for diabetic foot ulcers. Assessments focused on evaluating the biomechanical and functional parameters of extrinsic foot muscles. Muscle elasticity and dynamic stiffness were measured using the MyotonPro device, while muscle oxygenation levels (SmO2) were recorded pre- and post-exercise using the MOXY device. Plantar pressure analysis was performed under both static and dynamic conditions to identify subtle variations in pressure distribution and foot biomechanics. These evaluations aimed to detect early indicators of potential foot complications, even in patients without apparent risk, providing critical data for preventive strategies.
62820839|NCT05920590|EXPERIMENTAL|PNF and Tendon Vibration Group|Participants allocated to this group will receive the same PNF protocol with Group 1 in combination with the application of tendon vibration.
62820840|NCT05920590|ACTIVE_COMPARATOR|Control|Participants allocated to this group will be given an exercise leaflet for home-based exercises
62820841|NCT06103591|EXPERIMENTAL|EmStop Embolic Protection System|Transcatheter aortic valve replacement (TAVR) procedures with the EmStop Embolic Protection System (EmStop System).
62820842|NCT06545929|EXPERIMENTAL|Sunobinop|
62434408|NCT02457624||Experienced endoscopists|All the experienced endoscopists will receive education and feedback on the diagnosis for premalignant lesion of chronic atrophic gastritis and intestinal metaplasia
62600682|NCT05520970|EXPERIMENTAL|2 doses of AdCLD-CoV19-1|Group 1 will receive 2 doses of AdCLD-CoV19-1
62600683|NCT05520970|EXPERIMENTAL|1 dose of AdCLD-CoV19-1|Group 2 will receive 1 doses of AdCLD-CoV19-1 followed by 1 dose of placebo
62820843|NCT06545929|PLACEBO_COMPARATOR|Placebo to match sunobinop|
62820844|NCT05106959|EXPERIMENTAL|Pilot Training|In this arm participants will complete a variety of baseline assessments then participate in 15-20 minute conversation based on motivational interviewing principles in which they are trained in shame resilience. Follow-ups will be conducted a month later. Assessments will be repeated and then participants will engage in a qualitative interview regarding the training.
62820845|NCT03117010||Hemophagocytosis|"Subjects should fulfill the following criteria~1. Subjects should have at least one of the following problems~   1. Presence of hemophagocytosis in tissue or bone marrow~  2. Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria~2. Age \> 18 years~3. Written informed consents~Subjects receive steroids and etoposide"
62040713|NCT05335317|OTHER|No treatment|Participants without vaginal atrophy (no complaints of vaginal health and a vaginal health index greater than 20) and not receiving any treatment.
62849140|NCT03645434|EXPERIMENTAL|Treatment sequence E|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 2: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 3: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg."
62040714|NCT06343610|ACTIVE_COMPARATOR|Test group|
62040715|NCT06343610|PLACEBO_COMPARATOR|Placebo group|
62040716|NCT02392013|EXPERIMENTAL|Home Modification Group|A tailored home-modification (home-hazard removal) intervention delivered in the home by occupational therapists over three visits and with a booster session at six months.
62040717|NCT02392013|NO_INTERVENTION|Usual Care Group|Usual care by an Area Agency on Aging
62040718|NCT01911039|EXPERIMENTAL|Regulatory T Cells|Cohort 1 at 1x105 Treg cells/kg, Cohort 2 at 5x105 Treg cells/kg and Cohort 3 at 1.5x106 Treg cells/kg with an extension phase at the MTD (or maximum administered dose if the MTD is not reached).
62040719|NCT01184287|EXPERIMENTAL|ranpirnase|All patients who do not progress after two cycles of pemetrexed-carboplatin will receive the study drug, ranpirnase
62434409|NCT00581659||Lens A, Lens B|The first independent variable is the contact lens. Each subject will wear both PureVision (TM0 aspheric contact lenses and conventional spherical contact lenses on separate visits. The second independent variable is visibility condition. Subjects will complete the study drive both in clear nighttime conditions and at night under glare conditions. In both cases, the driver will experience oncoming traffic; however, in the glare condition, the simulator will be equipped with a point light source sufficient to provide glare similar to that provided by oncoming traffic in the real world.
62434410|NCT03017599|EXPERIMENTAL|Intervention group|EUS-FNB using 20-gauge procore needle
62434411|NCT01596816|EXPERIMENTAL|Boost by CyberKnife|
62600684|NCT05520970|PLACEBO_COMPARATOR|Placebo|Group 2 will receive 1 doses of placebo followed by 1 dose of AdCLD-CoV19-1 after an interim analysis
62040720|NCT04859504|ACTIVE_COMPARATOR|Active tACS|Active tACS will be applied twice daily for 5 days. In each session, dual-channel high-density theta(7Hz) tACS stimulations will be delivered over the right DLPFC (one anodal electrode at F4, between -1.2mA and 1.2 mA; two cathodal electrodes at AF4 and FC6, between -0.6mA and 0.6mA) and cerebellum (one anodal electrode at Oz, between -1 mA and 1mA; two cathodal electrodes at PO3 and PO4, between -0.5mA and 0.5mA) lasting 20 minutes.
62040721|NCT04859504|SHAM_COMPARATOR|Sham tACS|Sham tACS will be also applied twice daily for 5 days.The parameters of tACS electrodes numbers, locations, and current duration are all the same with active tACS. But sham tACS begin with a fade in over 3s to the peak, followed immediately by no current stimulation for 20 minutes and a fade out of 3s.
62434412|NCT01596816|EXPERIMENTAL|Boost by linear accelerator|
62434413|NCT01270841|PLACEBO_COMPARATOR|Placebo|Placebo
62434414|NCT01270841|ACTIVE_COMPARATOR|Testim (topical testosterone)|Testim (topical testosterone)
62434415|NCT01270841|EXPERIMENTAL|Androxal 12.5 mg|Androxal 12.5 mg/day
62434416|NCT01270841|EXPERIMENTAL|Androxal 25 mg|Androxal 25 mg/day
62434417|NCT00480220|EXPERIMENTAL|1|Specific Intervention as Global care and support program
62434418|NCT00480220|NO_INTERVENTION|2|'No specific intervention'
62600685|NCT00920127|PLACEBO_COMPARATOR|Placebo|
62600686|NCT00920127|ACTIVE_COMPARATOR|AKL1|
62040722|NCT06430983||Training Set for Recurrent Liver Cancer Patient|The training set for recurrent liver cancer patients is a subset of data collected from individuals who have been diagnosed with liver cancer that has returned after a period of remission or initial treatment. This data set is used to train machine learning models or other statistical methods to identify patterns or biomarkers that are indicative of cancer recurrence. The training set typically includes information such as patient demographics, medical history, previous treatments, and biological data, such as genetic mutations, protein levels, or imaging results. The goal is to use this data to develop a model that can accurately predict the recurrence of liver cancer in other patients, which can then be validated and tested using a separate data set, known as the validation set.
62040723|NCT06430983||Validation Set for Recurrent Liver Cancer Patient|The validation set for recurrent liver cancer patients is a distinct subset of data that is used to assess the performance and generalizability of a model or hypothesis developed from a training set. This set includes data from patients with recurrent liver cancer who were not part of the original training set. The purpose of the validation set is to test the model's ability to accurately predict or classify cases of recurrent liver cancer in a population that it has not been exposed to during its training phase.
62040724|NCT03058588||Analysis with molecular biology|"Any patient with acute leukemia or other myeloid malignancy AND~1. a first- or second-degree relative with acute leukemia or other myeloid malignancies~2. a first- or second-degree relative with lymphoproliferative neoplasms~3. or with clinical features that resemble one of the familial myeloid malignancies predisposition syndromes"
62434419|NCT03560622|ACTIVE_COMPARATOR|ET cohort|Ten adults with refractory ET (ET cohort) will undergo multi-modality neuroimaging (structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI)). In addition the ET cohort will also undergo imaging with the identical protocol immediately after and 24 hours after FUS-T.
62820846|NCT06180343|EXPERIMENTAL|Mandala coloring group|"Participants will be asked to choose the pages they want from the 12 colored felt-tip pen paint sets and mandala coloring book given to each participant by the researcher, and color them in the colors they want, for 6 weeks, once a week, at any time of the day and for an average of 20-30 minutes each time.~Participants will be asked to send a message before they start painting the mandala, and after the process, they will be asked to take a picture of the mandala they have painted and send it to the researcher. If the participants forget to color the mandala, a reminder message will be sent by the researcher twice a week."
62820847|NCT06180343|NO_INTERVENTION|Control group|Participants in this group will consist of people who do not routinely do any practice on their own to reduce anxiety symptoms. Participants will be asked by telephone by the researcher twice a week for 6 weeks whether they have taken any action to reduce their anxiety symptoms. Participants who use any of the pharmacological or non-pharmacological practices to reduce anxiety symptoms will be excluded from the study.
62820848|NCT05957835|EXPERIMENTAL|BR-HIGH|Participants will ingest an elevated dose of nitrate 2.5 hours prior to exercise.
62434420|NCT03560622|EXPERIMENTAL|control cohort|Twenty adult healthy controls (control cohort) will undergo multi-modality neuroimaging (structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI)).
62434421|NCT04158479||Pulmonary Support|ECMO support for acute respiratory failure, ARDS
62434422|NCT04158479||Cardiac Support|ECMO support for heart failure, cardiogenic shock
62434423|NCT04158479||Extracorporeal Cardiopulmonary Resuscitation|ECMO support for cardia arrest
62434424|NCT02226692||nonspecific chronic low back pain|Physical examination and follow-up assessment by questionnaires at 2, 4, 6, and 12 months
62434425|NCT02939638|ACTIVE_COMPARATOR|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
62820849|NCT05957835|EXPERIMENTAL|BR-MOD|Participants will ingest a moderate dose of nitrate 2.5 hours prior to exercise.
62434426|NCT02939638|ACTIVE_COMPARATOR|Control diet|Half of the participants will be asked to continue their usual diets for the 16-week study period.
62820850|NCT05957835|EXPERIMENTAL|BR-LOW|Participants will ingest a low dose of nitrate 2.5 hours prior to exercise.
62040725|NCT06580964|EXPERIMENTAL|Local Heat Therapy|"Phase 1: Heat pads will be applied to both legs and set to a pre-determined, optimized temperature to raise the intramuscular temperature to \~40°C. Each heating session will last for 90 min/d, 7d/wk (6 at-home and 1 in-lab) for 12 wks.~Phase 2: High-intensity interval training will be performed 3 d/wk for 12 wks. Each exercise session will consist of 4 cycling exercise intervals at 90-95% HRpeak for 4 min with 3 min active rest."
62040726|NCT06580964|SHAM_COMPARATOR|Thermoneutral Therapy|"Phase 1: Heat pads will be applied to both legs and set to a pre-determined temperature to keep the intramuscular temperature in a thermoneutral state (\~35-37°C). Each heating session will last for 90 min, 7d/wk (6 at-home and 1 in-lab) for 12 weeks.~Phase 2: High-intensity interval training will be performed 3 d/wk for 12 wks. Each exercise session will consist of 4 cycling exercise intervals at 90-95% HRpeak for 4 min with 3 min active rest."
62040727|NCT06580964|ACTIVE_COMPARATOR|High-Intensity Interval Training|"Phase 1: High-intensity interval training will be performed 3 d/wk for 12 wks. Each exercise session will consist of 4 cycling exercise intervals at 90-95% HRpeak for 4 min with 3 min active rest.~Phase 2: N/A"
62434427|NCT01888471|OTHER|Cases Group|"Cases Group will be defined as:~Maternal subjects identified with invasive GBS disease from the enrolled maternal-newborn dyad Study cohort: Cases will be classified as follows:~* EOD (Early onset disease): isolation of GBS from the blood or cerebrospinal fluid (CSF) within 0-6 days of birth.~* LOD (Late onset disease): isolation of GBS from the blood or cerebrospinal fluid (CSF) within 7-90 days of birth."
62434428|NCT01888471|OTHER|Controls Group|Controls will be defined as newborns to mothers, enrolled into the study and identified as colonized by a serotype which is homologous to that of cases, but who do not develop invasive GBS disease.
62434429|NCT00124449|ACTIVE_COMPARATOR|1|
62434430|NCT00124449|PLACEBO_COMPARATOR|2|
62434431|NCT03568500|EXPERIMENTAL|Aripiprazole|Participants received 1 oral tablet of CoEncapsulated (CoE) aripiprazole, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
62434432|NCT03568500|EXPERIMENTAL|Olanzapine|Participants received 1 oral tablet of CoE olanzapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
62434433|NCT03568500|EXPERIMENTAL|Quetiapine|Participants received 1 oral tablet of CoE quetiapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
62434434|NCT03568500|EXPERIMENTAL|Risperidone|Participants were to receive 1 oral tablet of CoE risperidone, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. No participant took risperidone in this trial.
62434435|NCT05977751|EXPERIMENTAL|FemBloc|Investigational device and procedure
62434436|NCT05693181|EXPERIMENTAL|Cell Therapy|Patients having acute severe contusion spinal cord injury (cervical, thoracic or upper-lumbar) and ASIA A/B neurological deficit, within 7 days post-SCI, after primary decompressive and stabilizing surgery. All participants meet inclusion and exclusion criteria. All participants obtain 4 infusions of allogenic non-related group- and rhesus-compatible mononuclear cord blood cells samples (500 +/- 50 x 10\*6 cells each) with a 1-week interval. All participants are followed up for 12 months post-SCI.
62623854|NCT02784288|EXPERIMENTAL|Neck Dissection|Patients undergo up-front neck dissection of the cervical lymph nodes to determine stratification into one of three standard-of-care treatment groups: transoral surgery of the primary site, radiation or chemoradiation.
62623855|NCT02683239|EXPERIMENTAL|Fasinumab dosing regimen 1|
62820851|NCT05957835|PLACEBO_COMPARATOR|PL|Participants will ingest a negligible amount of nitrate 2.5 hours prior to exercise.
62820852|NCT06058533|NO_INTERVENTION|Control Group|No intervention will be given to this group. Each treatment visit will move forward as routine.
62820853|NCT06058533|EXPERIMENTAL|Previsit Imagery Group|This group will be given previsit imagery (picture book) before treatment visit.
62820854|NCT06269120||Patients with type 2 diabetes|Participants with Type 2 Diabetes (T2D) will initiate oral semaglutide at the discretion of the treating physician, based on approved oral semaglutide label in Hungary and independent from the decision to include the patient in the study.
62820855|NCT04906668|ACTIVE_COMPARATOR|Cryoballoon pulmonary-vein isolation|
62820856|NCT04906668|ACTIVE_COMPARATOR|Ablation of atrioventricular-node and pacemaker implantation|
62820857|NCT05734027|EXPERIMENTAL|Sectional matrix band|precontoured sectional matrix band
62820858|NCT05734027|ACTIVE_COMPARATOR|Circumferential matrix band|Circumferential matrix band applied by tofflemire retainer
62820859|NCT06705452|EXPERIMENTAL|Patients with unruptured and untreated aneurysms|Patients in radiology for the first diagnostic evaluation or the follow-up of unruptured and untreated aneurysms.
62820860|NCT02506543|EXPERIMENTAL|COMPASS intervention|Subjects in this group will be pre-tested at the same time with the subjects in the Wait-list control group. Subjects in this group will receive the intervention immediately after the initial pre-test/baseline assessment, which includes life skills education, access to mentors in safe spaces, and a structured parenting intervention for girls' caregivers. Then, the subjects in this group have completed the intervention (at 12-months post-intervention initiation), the subjects in this group will take the post-test at the same time with the subjects in the Wait-list control group.
62820861|NCT02506543|ACTIVE_COMPARATOR|Wait-list control|No intervention
62820862|NCT06444659|EXPERIMENTAL|Adaptive physical activities|"1. Intervention time: 6 months~2. Exercise frequency: 3 times/week~3. Exercise type: aerobic exercise~4. Exercise intensity: 40-80% HRmax~5. Collaborating with families to create a parent-supported exercise environment"
62040728|NCT03833999|EXPERIMENTAL|Ondansetron and lactulose|Ondansetron 8mg three times daily for 48 hours lactulose 20ml twice daily for 48 hours Serial abdominal MRI imaging
62244128|NCT06736210|EXPERIMENTAL|IWDGF-1|The IWGDF 1 group comprised 10 patients identified as having low risk for diabetic foot ulcers. Comprehensive assessments were conducted to evaluate the biomechanical and functional properties of their extrinsic foot muscles. Elasticity and dynamic stiffness of the tibialis anterior, gastrocnemius medialis, gastrocnemius lateralis, and peroneus longus muscles were measured using the MyotonPro device. Muscle oxygenation levels (SmO2) were monitored pre- and post-exercise using the MOXY device to determine oxygen utilization and recovery capacity. Additionally, plantar pressure was analyzed under static and dynamic conditions to assess changes in pressure distribution and foot biomechanics. These detailed evaluations highlighted early biomechanical and functional changes, emphasizing the importance of targeted interventions in this low-risk group to prevent progression to higher risk categories.
62244129|NCT05548452|EXPERIMENTAL|Intestinal Microbiota Transplant capsules|Capsules will be provided twice during the trial
62434437|NCT05693181|PLACEBO_COMPARATOR|Vehicle|Patients having acute severe contusion spinal cord injury (cervical, thoracic or upper-lumbar) and ASIA A/B neurological deficit, within 7 days post-SCI, after primary decompressive and stabilizing surgery. All participants meet inclusion and exclusion criteria. All participants obtain 4 infusions of vehicle (sterile saline) with a 1-week interval. All participants are followed up for 12 months post-SCI.
62820863|NCT06444659|NO_INTERVENTION|Traditional physical education|Continue to carry out the original regular physical education activities during the same period of time, and maintain the original daily habits.
62820864|NCT00886379|ACTIVE_COMPARATOR|1|Mongolian milk without D
62434438|NCT02460874|EXPERIMENTAL|Pilot Portion|"Step 1: Patients with brain metastases requiring SRS and not taking corticosteroids 5 days prior to SRS. Treatment planning MRI may be done within 21 days prior to SRS treatment.~Step 2: Take Glyburide 1.25mg (twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education- begin glucose monitoring (4 times a day).~Step 3: 1 week after SRS, return to clinic to review glucose logs- continue glyburide and blood glucose monitoring.~Step 4: 1 month after SRS, discontinue both glyburide and blood glucose monitoring, undergo MRI.~Step 5: 3 months after SRS, undergo MRI."
62600687|NCT02951845|EXPERIMENTAL|Part 1: Treatment Sequence A1B1C1|Participants in Part 1 will only receive single dose of Treatment A1 oral Suspension (25 milligram \[mg\], Fasted) then Treatment B1 (Direct Compression Tablets, 5\*5 mg Tablets, Fasted) followed by Treatment C1 (Direct Compression Tablets (5\*5 mg Tablets, Fed) on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
62244130|NCT05548452|PLACEBO_COMPARATOR|Placebo capsules|Capsules will be provided twice during the trial
62600688|NCT02951845|EXPERIMENTAL|Part 1: Treatment Sequence B1C1A1|Participants in Part 1 will only receive single dose of Treatment B1 then Treatment C1 followed by Treatment A1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
62244131|NCT06014242|EXPERIMENTAL|Peripheral vascular flow reserve measurement|Post-procedure peripheral vascular flow reserve by thermodilution will be measured by the pressure wire.
62244132|NCT02495350||Initially didn't want an epidural and didn't receive one.|
62820865|NCT00886379|EXPERIMENTAL|2|Mongolian milk with vitamin D
62820866|NCT00886379|EXPERIMENTAL|3|Ultra High Temperature (UHT) milk
62600689|NCT02951845|EXPERIMENTAL|Part 1: Treatment Sequence C1A1B1|Participants in Part 1 will only receive single dose of Treatment C1 then Treatment A1 followed by Treatment B1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
62600690|NCT02951845|EXPERIMENTAL|Part 1: Treatment Sequence A1C1B1|Participants in Part 1 will only receive single dose of Treatment A1 then Treatment C1 followed by Treatment B1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
62820867|NCT00886379|EXPERIMENTAL|4|Milk Substitute
62623856|NCT02683239|EXPERIMENTAL|Fasinumab dosing regimen 2|
62820868|NCT00886379|EXPERIMENTAL|5|Seasonal D
62623857|NCT02683239|EXPERIMENTAL|Placebo|
62820869|NCT00886379|EXPERIMENTAL|6|Daily D
62820870|NCT06542302||Idiopathic neck pain group|Pain was unilateral or bilateral between the superior nuchal line and 1st thoracic vertebra; Neck pain persisting for 3 months and above; Average pain intensity of last pain episode was between 2 and 8 based on the numerical rating scale (NRS).
62820871|NCT06542302||Asymptomatic adult group|Do not have any complaints of current pain and impairments of neuromusculoskeletal systems within the last 6 months.
62820872|NCT06066697|EXPERIMENTAL|SOVA Peer Ambassador Program|"Participants will be given login information for a website sova.pitt.edu. They will be given weekly emails notifications about new posts. The participant will be onboarded as a blogging peer ambassador. The participant will be expected to contribute content to the website at least once a month by~1. writing a blog article~2. sending information (de-identified photo or video or music) to post~   • If they choose this option they will be encouraged to submit their own photo, video, or music to the website or they will be encouraged to write a response to a photo, video, or music piece.~3. being interviewed by the RA and then the RA ghostwriting an article about the interview which they pre-approve prior to it being posted."
62849141|NCT03645434|EXPERIMENTAL|Treatment sequence F|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 2: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 3: AZD8871 600 µg and Anoro® Ellipta® matching placebo."
62244133|NCT02495350||Initially didn't want an epidural and did receive one.|
62244134|NCT02495350||Initially wanted an epidural and didn't received one|
62244135|NCT02495350||Initially wanted an epidural and did receive one.|
62244136|NCT06660264|OTHER|Immediate Return of Pharmacogenomic Results|Participants will be randomized to immediate versus delayed return of pharmacogenomic results obtained from testing conducted by an independent biobanking study (Pitt+Me Discovery). Participants in the immediate group will receive a pharmacist Personalized Medication Review with PGx results.
62244137|NCT06660264|OTHER|Delayed Return of Pharmacogenomic Results|Participants will be randomized to immediate versus delayed return of pharmacogenomic results obtained from testing conducted by an independent biobanking study. Participants in the delayed group with receive a pharmacist Personalized Medication Review without PGx results. The delayed group will receive results from the independent biobanking study (Pitt+Me Discovery) at 12 months after the Personalized Medication Review.
62244138|NCT06593249||TBE in Infectious Diseases Department|patients with TBE referred to ID
62244139|NCT06593249||TBE in Neurology Department|Patients with TBE in Neurology Department
62244140|NCT06735677|EXPERIMENTAL|Education|These sessions covered reproductive health, sexual activity during pregnancy and the postpartum period, personal and sexual hygiene, domestic violence during pregnancy, and misconceptions about pregnancy.
62820873|NCT06066697|ACTIVE_COMPARATOR|attention control: brief psychoeducational independent assignments|Participants will be sent a REDCap form where they will receive a link to a SOVA article to read and a question for them to answer about what they read that will be accessible only to the study team. They will be asked to do this a couple times a month and will be reminded about their participation.
62820874|NCT05753046|EXPERIMENTAL|Early TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the initiation of the procedure (immediately following placement of the robotic / laparoscopic camera port).
62244141|NCT05096351||Patients with venous allograft|
62244142|NCT04836936|PLACEBO_COMPARATOR|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy will be performed in the pre-operative setting by PI or trained designee using an empty cryopuncture device without nitrogen gas. The patient will otherwise receive standard of care treatment for surgery and post-operative pain management.
62244143|NCT04836936|ACTIVE_COMPARATOR|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy will be performed in the pre-operative setting by PI or trained designee using a cryopuncture device with nitrogen gas. The patient will otherwise receive standard of care treatment for surgery and post-operative pain management.
62244144|NCT05615844|EXPERIMENTAL|Antibiotic Cement Bead Pouch|"The antibiotic cement bead pouch involves placing temporary non-absorbable antibiotic-laden cement beads into the open fracture wound and sealing the wound with a large occlusive dressing for prophylaxis against bacteria.~The antibiotic beads used will be prepared intraoperatively by the surgical team. The bead recipe will be comprised of a ratio of 2 grams of vancomycin, 2.4 grams of tobramycin, and 40g (one bag) of PMMA cement. The beads will be handmade and approximately 10-mm in diameter. The number of beads placed in the wound will be at the discretion of the treating surgeon based on recipient wound size. As commonly practiced, the antibiotic beads may be exchanged for new beads at each subsequent irrigation and debridement surgery. The number of beads, the number of replaced beads, and the removal of the antibiotic beads will be recorded."
62434439|NCT02460874|PLACEBO_COMPARATOR|Randomized Portion|"Step 1: Patients with brain metastases requiring SRS and not taking corticosteroids 5 days prior to SRS.Treatment planning MRI may be done within 21 days prior to SRS treatment.~Step 2: Randomization (1:1)~* Group 1: take Glyburide (1.25mg, twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education. Begin glucose monitoring (once a day) {This portion will be double blinded}.~* Group 2: Take Placebo (1 pill, twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education. Begin glucose monitoring (once a day) {This portion will be double blinded}.~Step 3: 1 week after SRS, return to clinic to review glucose logs, continue investigation medication, but discontinue glucose monitoring.~Step 4: 1 month after SRS, discontinue investigation medication, undergo MRI.~Step 5: 3 months after SRS, undergo MRI."
62434440|NCT05351385||Covid +|Patients SARS-CoV-2 positive.
62434441|NCT05351385||Control|Patients with Pneumonia non-SARS-CoV-2 related
62434442|NCT03479385|EXPERIMENTAL|Integrative Medicine Intervention|Study participants randomized to the Integrative Medicine intervention will attend 14 sessions with an Integrative Medicine clinician over the course of 6 months potentially followed by a 6 month maintenance phase. The treatment modalities employed in the study will include nutrition and lifestyle recommendations.
62434443|NCT03479385|EXPERIMENTAL|Health Education Intervention|Study participants randomized to the Health Education intervention will attend 14 sessions with a Health Educator over the course of 6 months. The emphasis in the sessions will be to provide engaging educational information on common survivorship issues.
62434444|NCT00840359|EXPERIMENTAL|1 PDT|Leishmania lesion
62820875|NCT05753046|EXPERIMENTAL|Late TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone either at the conclusion of the procedure (immediately preceding removal of the robotic / laparoscopic camera port).
62434445|NCT00840359|ACTIVE_COMPARATOR|Cryo|Leishmania lesion
62849142|NCT03665025|EXPERIMENTAL|immediate implant placement with xenograft|Immediate implant placement with the use of xenograft as grafting material
62434446|NCT02943681|EXPERIMENTAL|Measles vaccine|Measles vaccine, 1 dose of 0.5 ml
62434447|NCT02943681|NO_INTERVENTION|Control|Nothing
62434448|NCT04261296|EXPERIMENTAL|Dry needling|Arm 1: Dry needling group. Dry needling will be done with painful trigger point and it will be waited for about 20 minutes. This treatment will be repeated once a week for 3 weeks.No medication is used in this treatment.
62600691|NCT02951845|EXPERIMENTAL|Part 1: Treatment Sequence B1A1C1|Participants in Part 1 will only receive single dose of Treatment B1 then Treatment A1 followed by Treatment C1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
62600692|NCT02951845|EXPERIMENTAL|Part 1: Treatment Sequence C1B1A1|Participants in Part 1 will only receive single dose of Treatment C1 then Treatment B1 followed by Treatment A1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
62849143|NCT03665025|EXPERIMENTAL|immediate implant using mixed allograft and xenograft|Immediate implant placement with using mixture of allograft and xenograft material
62849144|NCT02231099|EXPERIMENTAL|prolift + m|surgery with mesh (prolift+M)
62434449|NCT04261296|EXPERIMENTAL|balneotherapy|Arm 2: Balneotherapy A total of 15 sessions, 20 minutes a day, 5 days a week for 3 weeks, will be held in the spa, which operates within the body of Kırşehir Ahi Evran University Physical Therapy and Rehabilitation Center.
62434450|NCT04261296|EXPERIMENTAL|Dry needling + balneotherapy|Arm3: dry needling + balneotherapy Both of these methods will be applied to patients in the third group.
62040729|NCT03833999|PLACEBO_COMPARATOR|Placebo and lactulose|placebo oral capsule, one three times daily for 48 hours lactulose 20ml twice daily for 48 hours Serial abdominal MRI imaging
62040730|NCT05280301|EXPERIMENTAL|Sous vide device|The intervention will be the use of a sous vide device to heat the water bath to 38 degrees celsius, rather than the traditional methods of manual water exchanges or placing the frostbitten tissue under running water.
62040731|NCT05385120|EXPERIMENTAL|Group A-Shunt group|Patients who undergo temporary porto caval shunt (TPCS) during recipient hepatectomy in adult elective live donor liver transplantation
62040732|NCT05385120|NO_INTERVENTION|Group B-No Shunt group|Patients who donot undergo temporary porto caval shunt (TPCS) during recipient hepatectomy in adult elective live donor liver transplantation
62040733|NCT06635486|EXPERIMENTAL|Intervention arm|Participants randomized to this arm will receive the CBT adapted intervention.
62040734|NCT06635486|NO_INTERVENTION|Wait list control arm|Participants randomized to this arm will be placed on a wait list for the CBT adapted intervention.
62244145|NCT05615844|ACTIVE_COMPARATOR|Negative Pressure Wound Therapy (NPWT)|"The NPWT system is a sealed dressing placed over the open fracture wound that includes an occlusive plastic wound dressing connected to a vacuum pump, tubing, and a canister to collect fluid. The pump creates a vacuum seal and exerts negative pressure on the wound to remove fluid and maintain a sealed environment. NPWT promotes wound healing through four primary mechanisms: 1) wound shrinkage or macrodeformation; 2) microdeformation at the foam-wound surface interface; 3) fluid removal; and 4) stabilization of the wound environment.~125 mmHg continuous negative pressure is the recommended NPWT device setting; however, the treating surgeon will be allowed to adjust these settings as clinically necessary.~The frequency and timing of NPWT changes will also be at the surgeon's discretion but is expected to primarily coincide with the timing of repeat debridement, typically every 24-72 hours until definitive management has occurred."
62244146|NCT01294150|ACTIVE_COMPARATOR|UroLift System|The treatment group subjects underwent the UroLift system procedure. The subject was blinded to his randomization into control or treatment group. Unblinding will occurred at 3 months post procedure after the assessments were completed. Between 3 and 12 month follow-up assessments, a subject was allowed to retreat with the UroLift system if he met the retreatment inclusion and exclusion criteria. Subjects that went on to UL retreatment within the first 12 months started their follow-up schedule over and were considered treatment failures. All UL subjects will be followed a minimum of 5 years.
62600693|NCT02951845|EXPERIMENTAL|Part 2: Treatment Sequence A2B2C2|Participants in Part 2 will only receive single dose of Treatment A2 oral Suspension (25 mg, Fasted) then Treatment B2 (Fluid Bed Granulation Tablets (5\*5 mg Tablets, Fasted) followed by Treatment C2 (Fluid Bed Granulation Tablets, 5\*5 mg Tablets, Fed) on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
62600694|NCT02951845|EXPERIMENTAL|Part 2: Treatment Sequence B2C2A2|Participants in Part 2 will only receive single dose of Treatment B2 then Treatment C2 followed by Treatment A2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
62600695|NCT02951845|EXPERIMENTAL|Part 2: Treatment Sequence C2A2B2|Participants in Part 2 will only receive single dose of Treatment C2 then Treatment A2 followed by Treatment B2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
62600696|NCT02951845|EXPERIMENTAL|Part 2: Treatment Sequence A2C2B2|Participants in Part 2 will only receive single dose of Treatment A2 then Treatment C2 followed by Treatment B2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
62600697|NCT02951845|EXPERIMENTAL|Part 2: Treatment Sequence B2A2C2|Participants in Part 2 will only receive single dose of Treatment B2 then Treatment A2 followed by Treatment C2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
62600698|NCT02951845|EXPERIMENTAL|Part 2: Treatment Sequence C2B2A2|Participants in Part 2 will only receive single dose of Treatment C2 then Treatment B2 followed by Treatment A2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
62600699|NCT06494332|EXPERIMENTAL|Experimental|3 weekly sessions (12 sessions in total) of approximately 35 minutes each of exercise and stretching.
62600700|NCT06494332|NO_INTERVENTION|Control|No intervention.
62600701|NCT03573219|EXPERIMENTAL|Healthy participant|Healthy volunteers that fulfill the inclusion criteria. Intervention: Short-wave diathermy (Radiation)
62600702|NCT02846038||Patient|Patients at St. Jude Children's Research Hospital who meet the eligibility criteria and consent to participate.
62040735|NCT03680755|EXPERIMENTAL|Tr1 group|Participants assigned to Tr1 will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
62040736|NCT03680755|EXPERIMENTAL|Tr2 group|Participants assigned to Tr2 will complete the experimental dental anxiety management program, which will be facilitated by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
62820876|NCT05464667|EXPERIMENTAL|Radiation Therapy (RT)|"Preoperative Dose-escalated RT (5 Cohorts):~The first 3 patients to consent to the study will be registered to Cohort 1; the second 3 patients to consent will be registered to Cohort 2; the next 3 patients to consent will be registered to Cohort 3. The remaining patients will be assigned 2 patients to each Cohort, starting with Cohort 4. From that point on, a statistical analysis will be done to calculate the dose for the next Cohort (5)."
62820877|NCT04948645|ACTIVE_COMPARATOR|Fosigotifator Low Dose|
62244147|NCT01294150|SHAM_COMPARATOR|Cystoscopy|The control group subjects underwent a cystoscopy procedure. The subject was blinded to his randomization into the control or treatment group. Unblinding will occurred at 3 months post procedure, after follow-up assessments were completed. Between 3 and 12 month follow-up assessments, a subject was allowed to crossover and undergo a UL procedure if he met crossover inclusion and exclusion criteria. Subjects crossing over will then be followed for 5 years post-treatment. The subject can also be treated by other approved therapies, or receive no treatment at all, which would require participation through 12 months.
62434451|NCT03635684|EXPERIMENTAL|SC Acetaminophen|Palliative Care or Geriatric Patients who receive subcutaneous Acetaminophen for pain or fever relief
62600703|NCT02846038||Primary oncologist|Primary pediatric oncologists who meet the eligibility criteria and consent to participate.
62600704|NCT02846038||Parents of patient|Parents of the enrolled patient who meet eligibility criteria and consent to participate.
62600705|NCT01621451|ACTIVE_COMPARATOR|immediate|Patients who receive pantoprazole plus aspirin and/or clopidogrel within 3\~4 days after EMR/ESD
62820878|NCT04948645|ACTIVE_COMPARATOR|Fosigotifator Medium Dose|
62040737|NCT03680755|NO_INTERVENTION|Active control|Participants assigned to the control group, will not complete the experimental dental anxiety management program at this time. They will complete study paperwork and watch a non-dental video for 45 minutes before their scheduled dental appointment. Immediately after the dental appointment, they will complete a brief interview with the research staff person.
62040738|NCT06669624|EXPERIMENTAL|ABC Program - no wait|Participants immediately receive the home-based ABC, which targets parenting sensitivity and nurturance.
62040739|NCT06669624|OTHER|Waitlist-Control (ABC after delay)|Participants will be placed on a four-month waitlist and then receive ABC in the same manner as the Experimental Group
62244148|NCT01294150|ACTIVE_COMPARATOR|Crossover|Between 3 and 12 month follow-up assessments, a subject was allowed to crossover and undergo a UL procedure if he met crossover inclusion and exclusion criteria. Subjects crossing over will then be followed for 5 years post-treatment. The subject can also be treated by other approved therapies, or receive no treatment at all, which would require participation through 12 months.
62244149|NCT06700356|EXPERIMENTAL|Thalamus seizure detection with a DBS system|Thalamus seizure detection by a DBS system, validated with concurrent in-hospital gold standard video EEG monitoring.
62244150|NCT05309668|EXPERIMENTAL|Selumetinib single arm|This study consists of a screening period (up to 28 days), a treatment period (25 cycles) and a long term safety follow-up for participants until they are 5 years old or commence an alternative systemic NF1-PN treatment, whichever is the earlier. Participants may continue treatment with selumetinib throughout the long term safety follow-up as long as they are considered to be receiving clinical benefit in the opinion of their Investigator. A safety follow up assessment will be performed 30 days after the last dose of study intervention for all study participants.
62434452|NCT04894994|EXPERIMENTAL|FLX475 and ipilimumab combination therapy|Participants received FLX475 tablets orally and ipilimumab by IV infusions
62600706|NCT01621451|ACTIVE_COMPARATOR|2 weeks|Patients who receive pantoprazole plus aspirin and/or clopidogrel at 2 weeks after EMR/ESD
62600707|NCT00819780|EXPERIMENTAL|Panitumumab Plus mFOLFOX6|Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and modified FOLFOX6 (mFOLFOX6) chemotherapy regimen consisting of oxaliplatin (85 mg/m\^2), leucovorin (400 mg/m\^2) and 5-fluorouracil (5-FU) (2400 mg/m\^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
62820879|NCT04948645|ACTIVE_COMPARATOR|Fosigotifator High Dose|
62820880|NCT04948645|PLACEBO_COMPARATOR|Placebo|
62820881|NCT01283841|EXPERIMENTAL|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets of Dr. Reddy's Laboratories Limited
62820882|NCT01283841|ACTIVE_COMPARATOR|Cellcept|Cellcept 500 mg tablets of Roche Laboratories Inc.
62434453|NCT00694499||Observation|Patients with blunt liver injury
62600708|NCT00819780|ACTIVE_COMPARATOR|Bevacizumab Plus mFOLFOX6|Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 regimen consisting of oxaliplatin (85 mg/m\^2), leucovorin (400 mg/m\^2), followed by 5-FU (2400 mg/m\^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
62820883|NCT03261271|EXPERIMENTAL|Weight Loss and Weight Maintenance|Participants will take part in a weight loss program for at least 4 weeks (and up to 16 weeks) before their prostatectomy, and a weight maintenance program for 6 months after their surgery.
62820884|NCT03261271|ACTIVE_COMPARATOR|Control|Participants will receive a standardized educational flyer about a healthy diet and exercise.
62434454|NCT04388033|EXPERIMENTAL|Safety Evaluation Group|"Basic treatment phase:~The patients have surgery followed by concomitant radiation (2 Gy/day x 30 days) and TMZ-chemotherapy (75 mg/m2/ day x 42 days).~Immunotherapy phase:~Maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle. Fusion cells will be suspended in 0.5 mL normal saline and then injected intradermally close to a cervical lymph node. IL-12 will be injected subcutaneously at the same side at dose of 6ug twice for interval of one hour."
62820885|NCT01630148|ACTIVE_COMPARATOR|Bemiparin|group one will be women who are risky for venous thromboembolic diseases after benign gynaecological surgeries, each will receive Bemiparin
62040740|NCT06700343|EXPERIMENTAL|ABP 692|Participants affected by relapsing-remitting multiple sclerosis (RRMS) will receive an initial dose of 300 mg ABP 692 intravenous (IV) infusion on Day 1, followed by a second dose of 300 mg ABP 692 IV infusion on Day 15. A subsequent dose of 600 mg ABP 692 IV infusion will be administered 24 weeks after the initial dose.
62434455|NCT01950754|OTHER|depressive patients|
62820886|NCT01630148|NO_INTERVENTION|control group|women will undergo benign gynaecological surgeries and are risky for venous thrombosis, they will not receive any intervention. The patients will be followed up to 30 days after surgery.
62244151|NCT05317247||Discovery Cohort|An anticipated number of 473 participants will be recruited in Cape Town, South Africa. Data (cough audio) will be collected and used to train a machine learning algorithm. The cough audio signal specific for TB will be refined. During the discovery phase, the ground truth obtained through biological testing of sputum specimens will be used to inform the machine learning.
62434456|NCT01950754|OTHER|nondepressed controls|
62600709|NCT01835275|EXPERIMENTAL|Music conditioning|Subjects are tested with music, sound, and silence, after conditioning to enhance music induced analgesia
62600710|NCT01835275|ACTIVE_COMPARATOR|Sound|Subjects are tested with music, sound, and silence, after conditioning to enhance sound induced analgesia
62820887|NCT04031105|EXPERIMENTAL|Condition 1|Priming sham TBS, followed by iTBS after an inter-stimulation-interval (ISI) of 0 minutes
62820888|NCT04031105|EXPERIMENTAL|Condition 2|Priming cTBS, followed by iTBS after an ISI of 0 minutes
62820889|NCT04031105|EXPERIMENTAL|Condition 3|Priming cTBS, followed by iTBS after an ISI of 10 minutes
62820890|NCT04031105|EXPERIMENTAL|Condition 4|Priming cTBS, followed by iTBS after an ISI of 20 minutes
62820891|NCT04434482|EXPERIMENTAL|IMP4297(senaparib) and temozolomide|IMP4297 and temozolomide
62820892|NCT00904943|EXPERIMENTAL|Test First|Topiramate Capsules, 25 mg
62820893|NCT00904943|ACTIVE_COMPARATOR|Reference First|Topamax® Capsules, 25 mg
62820894|NCT04208919|EXPERIMENTAL|DCreg Prior to Weaning|Regulatory dendritic cells that were derived from the recipient's liver donor will be infused into the recipient one week prior to the initiation of immunosuppression weaning.
62820895|NCT03216772|EXPERIMENTAL|Olympus PK Morcellator in PneumoLiner|Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using the Olympus PK Morcellator in PneumoLiner containment device
62820896|NCT04714892||Healthy control|BMI of 18.5-29.9 kg/m2
62820897|NCT04714892||Obese|BMI of 30-39.9 kg/m2
62820898|NCT04500912|ACTIVE_COMPARATOR|Supraflex Cruz stent|Randomization to Supraflex Cruz stent
62820899|NCT04500912|ACTIVE_COMPARATOR|Ultimaster Tansei stent|Randomization to Ultimaster Tansei stent
62820900|NCT05111210||Gp 1: 10 patients with cutaneous psoriasis|Visits for research are done as part of the care, no visits are added. There is only 1 visit for patients of this group, they will be sampled once with 51 mL of blood before initiation of a biotherapy and some data will be collected
62820901|NCT05111210||Gp 2: 80 patients with a medical decision to treat cutaneous psoriasis with an anti-IL-23 biologic|Visits for research are done as part of the care, no visits are added. Two visits are planned for this group of patients : before and after initiation of therapy. These patients will be sampled twice with 51 mL of blood. Skin biopsies will be obtained from a subset of 30 patients to analyse the skin transcriptome, before and after treatment with anti-IL-23 biologics Data will be collected at the two timepoints.
62820902|NCT05791643|EXPERIMENTAL|Real-time intervention for promoting safety plan and coping strategy use|"Momentary surveys in which elevated (non-zero but \< 8 out of 10) levels of suicidal intent or high (\>= 8 out of 10) suicidal urges are reported will be randomized either to receive a real-time intervention that consists of automated, interactive reminders with suggested strategies for coping with suicidal thoughts or no intervention.~If randomized to receive an intervention, the intervention type will also be randomized (at equal probabilities) to suggest either coping strategies from the participant's personalized safety plan or general common coping strategies."
62820903|NCT01578447|OTHER|Depo-SubQ Provera 104 in Uniject|
62820904|NCT01578447|OTHER|Intramuscular DMPA|
62820905|NCT06543745|EXPERIMENTAL|All subjects|All subjects will participate in the low-resistance training
62820906|NCT03745495||Group 1|300 To determine the effect of HIVST on PrEP uptake among older adolescent MSM and TGW
62820907|NCT03745495||Group 2|300 To determine the effect of HIVST on retention of older adolescent MSM and TGW in HIV service
62820908|NCT01372709||Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Adult male and female patients will be consecutively screened for the study. Eligible patients must meet all of the inclusion criteria and none of the exclusion criteria.
62820909|NCT06308718||Patients enrolled in the FBX-101-LTFU study|The participants will be followed for 36 months after they have concluded their participation in the interventional trial. They will complete 5 scheduled visits with assessments as specified in the schedule of assessments, to collect data for safety and additional signs of efficacy for FBX-101. Those patients enrolled from any other early terminated trial, will first complete pending evaluations from that trial.
62820910|NCT06603415|OTHER|PATTERN OF HASHIMOTO'S THYROIDITIS IN UPPER EGYPT|the pathological pattern, characteristics, treatment, complications and prognosis of Hashimoto's thyroiditis in upper egypt .
62849145|NCT02231099|ACTIVE_COMPARATOR|conventional vaginal prolapse surgery|conventional vaginal prolapse surgery; anterior colporrhaphy or posterior colporrhaphy or spinal ligament fixation
62849146|NCT05401578|ACTIVE_COMPARATOR|Study Intervention: Canakinumab|"Standard dose of canakinumab (Ilaris®; Novartis Switzerland), i. e. 150 mg subcutaneously.~Canakinumab (Ilaris®, Novartis) is a recombinant, human monoclonal IgG1/kappa antibody inhibiting IL-1β by neutralizing its biological activity through binding to the IL-1 receptor."
62820911|NCT06046924|EXPERIMENTAL|Fruits and vegetables (F+V)|51 participants with hypertension, normal estimated glomerular filtration rate (eGFR) (\>90 ml/min/m2) and macroalbuminuria (albumin \[mg\] to creatinine \[g\] ratio \> 200 mg/g) will receive a prescribed amount of base-producing fruits and vegetables (F+V) designed to reduce their dietary acid intake by half. Depending on the particular foods used, this amounts to 2-4 cups daily of fruits and vegetables given in weekly allotments. They will otherwise receive standard care for their medical concerns including angiotensin converting enzyme inhibitor therapy for albuminuria and followed annually for 5 years.
62820912|NCT06046924|EXPERIMENTAL|NaHCO3 (HCO3)|51 participants with hypertension, normal estimated glomerular filtration rate (eGFR) (\>90 ml/min/m2) and macroalbuminuria (albumin \[mg\] to creatinine \[g\] ratio \> 200 mg/g) will receive 0.4 mEq/kg/bw oral tablet dose of sodium bicarbonate (NaHCO3) designed to match the alkali intake of F+V. They will otherwise receive standard care for their medical concerns including angiotensin converting enzyme inhibitor therapy for albuminuria and followed annually for 5 years.
62820913|NCT06046924|ACTIVE_COMPARATOR|Usual Care (UC)|51 participants with hypertension, normal estimated glomerular filtration rate (eGFR) (\>90 ml/min/m2) and macroalbuminuria (albumin \[mg\] to creatinine \[g\] ratio \> 200 mg/g) will receive no additional alkali (neither F+V or NaHCO3) and will receive standard care for their medical concerns, including angiotensin converting enzyme inhibitor therapy for albuminuria and followed annually for 5 years.
62820914|NCT06704685|EXPERIMENTAL|Butylphthalide group|The Butylphthalide group received 100ml of butylphthalide injection twice a day for 7±2 days, followed by butylphthalide soft capsules (2 capsules, three times a day) from the day of discharge to day 30±2.
62820915|NCT06704685|PLACEBO_COMPARATOR|Placebo group|The placebo group received 100ml of butylphthalide placebo injection twice a day for 7±2 days, followed by butylphthalide placebo soft capsules (2 capsules, three times a day) from the day of discharge to day 30±2.
62820916|NCT04936945|ACTIVE_COMPARATOR|arthroscopy plus platelet rich plasma.|Group A: will be treated with operative arthroscopy plus intra-articular injection of platelet rich plasma
62820917|NCT04936945|ACTIVE_COMPARATOR|arthroscopy plus hyaluronic acid.|Group B: will be treated with operative arthroscopy plus intra-articular injection of hyaluronic acid
62820918|NCT05975840|ACTIVE_COMPARATOR|FLU Q-PAN H5N8 Formulation 1_B Group|Medically stable participants receive two doses of FLU Q-PAN H5N8 Formulation 1 vaccine and AS03B adjuvant. Participants receive the first dose at Day 1 and the second dose at Day 22.
62820919|NCT05975840|ACTIVE_COMPARATOR|FLU Q-PAN H5N8 Formulation 1_A Group|Medically stable participants receive two doses of FLU Q-PAN H5N8 Formulation 1 vaccine and AS03A adjuvant. Participants receive the first dose at Day 1 and the second dose at Day 22.
62820920|NCT05975840|ACTIVE_COMPARATOR|FLU Q-PAN H5N8 Formulation 2_B Group|Medically stable participants receive two doses of FLU Q-PAN H5N8 Formulation 2 vaccine and AS03B adjuvant. Participants receive the first dose at Day 1 and the second dose at Day 22.
62820921|NCT05975840|ACTIVE_COMPARATOR|FLU Q-PAN H5N8 Formulation 2_A Group|Medically stable participants receive two doses of FLU Q-PAN H5N8 Formulation 2 vaccine and AS03A adjuvant. Participants receive the first dose at Day 1 and the second dose at Day 22.
62820922|NCT06597825|EXPERIMENTAL|İrrigation protocols (Group I)|Group I: the root canal was irrigated with 1 ml of 17% EDTA (Microvem, Istanbul, Turkey), and the solution was kept in the canal for 1 minute. The canal was subsequently irrigated with 2 ml of distilled water and 3 ml of 2.5% NaOCl for 1 minute.
62820923|NCT06597825|EXPERIMENTAL|İrrigation protocols (Group II)|Group II: HEDP (DualRinse HEDP, Medcem, Vienna, Austria), containing 0.9 mg of etidronic acid per capsule, was added to 10 ml of 2.5% NaOCl in a sterile container according to the manufacturer's instructions. The solution, which was prepared just before use in the canal, was mixed for 1 min to ensure that the powder was fully dissolved. The canal was then irrigated with 4 ml of the 2.5% NaOCl - 9% HEDP combined solution for 2 minutes.
62820924|NCT06597825|EXPERIMENTAL|İrrigation protocols (Group III)|Group III: A similar irrigation protocol to that of Group I was followed, with an additional 1-minute sonic activation using the EA device on 3 ml of 2.5% NaOCl. The tip of the EA was placed 2 mm away from the WL and the irrigant was activated with 10,000 cycles per minute with a tip size 0.04/35.
62820925|NCT06597825|EXPERIMENTAL|İrrigation protocols (Group IV)|Group IV: Similar to Group II, the canal was filled with 4 ml of the 2.5% NaOCl - 9% HEDP combined solution for 1 minute. The tip of the EA was placed 2 mm away from the WL, followed by 1 minute of sonic activation with the EA device (10,000 cycles per minute with a tip size 0.04/35).
62434457|NCT01140269|NO_INTERVENTION|No PCR testing|Control patients will not have PCR testing. This group will have routine testing and treatment as defined by the standard of care.
62820926|NCT02677493|EXPERIMENTAL|IL-YANG Quadrivalent Influenza Vaccine|The QIV is included both B strain (Yamagata, Victoria).
62820927|NCT02677493|ACTIVE_COMPARATOR|IL-YANG Flu Vaccine Prefilled Syringe|This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.
62820928|NCT02677493|ACTIVE_COMPARATOR|IL-YANG Trivalent Influenza Vaccine|This TIV is included the B/Victoria strain.
62820929|NCT05464680|EXPERIMENTAL|Patients positive to SARS-CoV 2|Patients admitted to the ICU and placed on VM following SARS-CoV-2 pneumonia
62820930|NCT05464680|SHAM_COMPARATOR|Patients negative to SARS-CoV 2|Patients admitted to the ICU and placed on VM outside of SARS-CoV-2 pneumonia
62820931|NCT05740137|NO_INTERVENTION|Control|Conventional colonoscopy, without AI-assistance.
62820932|NCT05740137|ACTIVE_COMPARATOR|AI-assisted colonoscopy|AI-assisted colonoscopy (AIC) using a computer-aided polyp detection and characterization (CADe and CADx) system.
62040741|NCT06700343|EXPERIMENTAL|Ocrelizumab (US)/ABP 692|Participants affected by RRMS will receive an initial dose of 300 mg Ocrelizumab (US) IV infusion on Day 1, followed by a second dose of 300 mg Ocrelizumab (US) IV infusion on Day 15. At Week 24, the treatment will switch to a 600 mg Ocrelizumab (US) IV infusion of ABP 692.
62040742|NCT06700343|EXPERIMENTAL|Ocrelizumab (EU)|Participants affected by RRMS will receive an initial dose of 300 mg Ocrelizumab (EU) IV infusion on Day 1, followed by a 300 mg Ocrelizumab (EU) IV infusion on Day 15. At Week 24, participants will receive a dose of 600 mg Ocrelizumab (EU) IV infusion.
62040743|NCT04763200|EXPERIMENTAL|Impella Arm|Impella CP® or Impella 2.5 placement prior to high-risk PCI
62600711|NCT01835275|NO_INTERVENTION|Calibration|Subjects are tested with music, sound, and silence, with no enhanced audio received
62820933|NCT05243823||Danish cohort|Danish cohort starts on 1 January 2000 and ends on 31 December 2019. It consists of new users of low dose vaginal estrogens (LDVE) (split into Vagifem® and other LDVE products) in the study period, and a comparator group consisting of women using no hormone replacement therapy.
62040744|NCT04763200|ACTIVE_COMPARATOR|Control Arm|Subjects randomized to the Control group will be treated per standard of care PCI with or without an intra-aortic balloon pump (IABP).
62820934|NCT05243823||US cohort|US cohort starts on 1 January 2007 and ends on 31 December 2019. It consists of new users of low dose vaginal estrogens (LDVE) (split into Vagifem® and other LDVE products) in the study period, and a comparator group consisting of women using no hormone replacement therapy.
62820935|NCT03297450|ACTIVE_COMPARATOR|Aphasia therapy and tDCS|
62820936|NCT03297450|SHAM_COMPARATOR|Aphasia therapy and sham-tDCS|
62820937|NCT03297450|SHAM_COMPARATOR|Standard of care and sham-tDCS|
62040745|NCT06162767|ACTIVE_COMPARATOR|Ivor-Lewis Procedure|Arm A: Esophagectomy was conducted through right side thoracotomy plus midline laparotomy approach: Ivor-Lewis Procedure.
62040746|NCT06162767|ACTIVE_COMPARATOR|Optimized Sweet Procedure|Arm B: Esophagectomy was conducted by single-incision thoracoscope combined with laparoscopy with the patient in a right oblique side position at 45 degrees: Optimized Sweet Procedure.
62040747|NCT04490486|EXPERIMENTAL|Group 1: (UCMSCs)|Participants in this group will receive the 2 intravenous (IV) UCMSCs intervention on day 0 and day 3.
62040748|NCT04490486|PLACEBO_COMPARATOR|Group 2: (Placebo)|Participants in this group will receive the placebo, a solution of 1% human serum albumin in Plasmalyte A, on day 0 and day 3.
62040749|NCT02568930||Heart Transplantation (HT)|The cohort includes advanced heart failure patients (60-80 years of age) listed for HT and their caregivers.
62040750|NCT02568930||Mechanical Circulatory Support (MCS)|The cohort includes advanced heart failure patients (60-80 years of age) scheduled for DT MCS and their caregivers.
62040751|NCT04250129||SLNB (-)&level 1-3 RT|SLNB (-)\&level 1-3 RT
62244152|NCT05317247||Validation Cohort|In the validation phase, the cough audio signature will have its sensitivity and specificity measured in new patients in Cape Town, South Africa (n=511) and Kampala, Uganda (n=767). The data will be used to evaluate the performance of the algorithm.
62820938|NCT05853497|NO_INTERVENTION|Standard Care Control|Standard care
62820939|NCT05853497|EXPERIMENTAL|Intervention|Multi-component weight loss intervention
62820940|NCT03486912|EXPERIMENTAL|BMS-986036 Dose Level 1|
62820941|NCT03486912|EXPERIMENTAL|BMS-986036 Dose Level 2|
62820942|NCT03486912|EXPERIMENTAL|BMS-986036 Dose Level 3|
62040752|NCT04250129||SLNB (+)&level 1-3 RT|SLNB (+)\&level 1-3 RT
62040753|NCT04250129||SLNB(+)&ALND&level 3 RT (+/-level 1-2)|SLNB(+)\&ALND\&level 3 RT (+/-level 1-2)
62820943|NCT03486912|PLACEBO_COMPARATOR|Placebo|
62820944|NCT04174417|ACTIVE_COMPARATOR|systolic blood pressure (SBP)|Systolic blood pressure (SBP) for group 1 patients 80-90 mmHg
62820945|NCT04174417|ACTIVE_COMPARATOR|mean blood pressure (MBP)|Mean blood pressure (MBP) for group 2 patients 50-65 mmHg
62820946|NCT06221995||Ulcerative Colitis patients undergoing proctocolectomy|Measurement of resting energy expenditure among patients with Ulcerative Colitis about to undergo proctocolectomy with ileoanal j-pouch anastomosis
62820947|NCT05908487|OTHER|Clinician Trainees- Cluster 1|Within each participating institution, clinician clusters are randomized to 1 of 4 start date training times for the African American Communities Speak (AACS) Education Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
62820948|NCT05908487|OTHER|Clinician Trainees- Cluster 2|Within each participating institution, clinician clusters are randomized to 1 of 4 start date training times for the African American Communities Speak (AACS) Education Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period
62820949|NCT05908487|OTHER|Clinician Trainees- Cluster 3|Within each participating institution, clinician clusters are randomized to 1 of 4 start date training times for the African American Communities Speak (AACS) Education Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period
62600712|NCT04574492||Participants receiving Upadacitinib|Participants receiving Upadacitinib for moderate to severe rheumatoid arthritis (RA).
62820950|NCT05908487|OTHER|Clinician Trainees- Cluster 4|Within each participating institution, clinician clusters are randomized to 1 of 4 start date training times for the African American Communities Speak (AACS) Education Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period
62820951|NCT04324827|EXPERIMENTAL|Graston Technique® Group|The application was applied by a GT® certified therapist with 12 years of experience in orthopedic rehabilitation and soft tissue treatments. Hamstring, gastrosoleus and plantar fascia were scanned with GT® instruments and the treated soft tissue was treated. The instruments used differ according to the application protocol and regions are determined with reference to the GT® manual. The treatment lasted 8 minutes for each leg and was applied to both legs equally and by the same person for a total of 16 minutes.
62820952|NCT04324827|EXPERIMENTAL|Foam Roller Group|FR was applied to gastrosoleus and hamstring muscle groups and plantar fascia. TriggerPoint Grid X Foam Roller and Nano Foot X Roller were used in the application. Hamstring, gastrosoleus and plantar fascia for 3 minutes were performed for a single leg. The treatment lasted 8 minutes on one leg and was applied equally to both legs for a total of 16 minutes. Before the application, the participants were informed with verbal and visual warnings about how to do the applications. During the application, the participant was instructed about the time with a stopwatch. The patient himself regulated the pressure applied to the FR; however, the participant was instructed to apply FR as much body weight as possible. The frequency of application was about 0.5 Hz (ie, each rolling cycle lasted for about 2 seconds).
62820953|NCT04324827|EXPERIMENTAL|Dynamic Stretch|DS protocol was prepared with reference to the work of Faigenbaum et al 2005. The protocol consists of 10 dynamic exercises of 10 minutes of medium and high intensity. Each dynamic stretching exercise was performed at a distance of 13 meters. The participants were given a 10-second rest period between each exercise. The participants were given verbal feedback about their postures during the exercises and the video of the exercises was shown to the participant.
62820954|NCT06706245|ACTIVE_COMPARATOR|Low-immersion (mobile device)|
62820955|NCT06706245|EXPERIMENTAL|High-immersion (head-mounted display)|
62820956|NCT06595160||Observational|Patients complete a dietary survey and undergo fecal sample collection on study.
62820957|NCT01364636||Acute Heart Failure|Patients admitted to emergency room in Acute Heart Failure at Hospital PróCardíaco and Hospital Universitario Antonio Pedro
62820958|NCT04935034|EXPERIMENTAL|Vitamin D enriched mixed micelles dairy drink|20ug vitamin D in pre-formed mixed micelle dairy drink
62820959|NCT04935034|ACTIVE_COMPARATOR|Vitamin D enriched olive oil dairy drink|20ug vitamin D in olive oil dairy drink
62820960|NCT04935034|ACTIVE_COMPARATOR|Vitamin D enriched fish oil dairy drink|20ug vitamin D in fish oil dairy drink
62820961|NCT04935034|ACTIVE_COMPARATOR|Vitamin D enriched fat-free dairy drink|20ug vitamin D in fat-free dairy drink
62820962|NCT06051201|EXPERIMENTAL|Shared-Decision-Making group|
62600713|NCT05785013|EXPERIMENTAL|Interventional|25 children diagnosed with Hirschsprung disease and planned for elective surgery will be supplemented with Zinc 7 days before the operation . Outcomes will be evaluated thorugh measuring the hospital length stay. Other parameters including inflammatory markers as CRP , CRP /albumin ratio and development of postoperative complications will be assesed and compared between cases and controls
62820963|NCT06051201|EXPERIMENTAL|Physician decision group|
62820964|NCT06603506||tumour and blood collection|tumour and blood collection for realization ex vivo organoid models
62820965|NCT06179199|EXPERIMENTAL|Active tDCS stimulation|
62244153|NCT05829707|ACTIVE_COMPARATOR|Diclofenac|All patients underwent quadrantectomy or mastectomy with axillary lymph node dissection. They received diclofenac 2 x 75 mg intravenously on the first day after surgery. During the 3 subsequent days, from day 2 to day 4 postoperatively patients were given 3 x 50 mg diclofenac tablets orally. The medicine was delivered by the nurse, and the patients drank tablets in front of her.
62040754|NCT06350032|EXPERIMENTAL|preservative-free parenteral treprostinil|Patients will be treated with either SC or IV preservative-free treprostinil formulation. Dosing is not stipulated by the study protocol and will be done according to investigators discretion based on patient needs.
62040755|NCT03575325|EXPERIMENTAL|CPX-351 Treatment|"Participants will receive induction with CPX-351 at a dose of 100 u/m\^2 administered intravenously over 90 minutes on days 1, 3 and 5 of a 28 day cycle.~This may be followed by consolidation with CPX-351 at a dose of 65 u/m\^2 administered intravenously over 90 minutes on days 1 and 3 of a 28 day cycle (up to 3 cycles)."
62040756|NCT06720948||Cervical|Previously implanted bilaterally intra-facet with the SurGenTec ION 3D Facet Screw System at one or two contiguous levels of the cervical spine (C2-C7)
62040757|NCT06720948||Lumbar|Previously implanted bilaterally intra-facet with the SurGenTec ION 3D Facet Screw System at one or two contiguous levels of the lumbar spine (L1-S1)
62040758|NCT04659655|OTHER|surgical aortic valve replacement|n=20 patients with aortic valve pathology and indication for surgical aortic valve replacement
62040759|NCT04659655|OTHER|surgical mitral valve replacement|n=10 patients with mitral valve pathology and indication for surgical mitral valve replacement
62040760|NCT04994834|EXPERIMENTAL|Intervention|Probiotics
62040761|NCT05402657|EXPERIMENTAL|Frontoparietal ECT Group|Participants will receive ultrabrief right unilateral ECT with a frontoparietal placement of ECT electrodes.
62040762|NCT05402657|ACTIVE_COMPARATOR|Temporoparietal ECT Group|Participants will receive ultrabrief right unilateral ECT with the conventional temporoparietal placement of ECT electrodes.
62244154|NCT05829707|EXPERIMENTAL|Levobupivacaine bolus analgesia|Group Levobupivacaine Bolus received 0.5 mg/kg 0.5% Levobupivacaine HCl every 8 h via wound catheter. The dose of levobupivacaine was prescribed by the doctor and the drug was delivered by the nurse.
62820966|NCT06179199|PLACEBO_COMPARATOR|Placebo tDCS stimulation|
62820967|NCT02601612|EXPERIMENTAL|Group 1: D46cpΔM2-2 Vaccine|RSV-seropositive children will receive a single dose of 10\^6 PFU D46cpΔM2-2 vaccine at study entry (day 0).
62040763|NCT02624362|EXPERIMENTAL|Odor+ Positive belief|Participants receive 15 minute odor presentation (Phenylethyl Alcohol odor) accompanied by the suggestion that this odor improves asthma symptoms (therapeutic suggestion)
62600714|NCT05785013|NO_INTERVENTION|Control|25 children diagnosed with Hirschsprung disease and planned for elective surgery will recieve the standard care provided for the cases and will not be supplemented with Zinc . Outcomes will be evaluated thorugh measuring the hospital length. Other parameters including inflammatory markers as CRP , CRP /albumin ratio and development of postoperative complications will be assesed and compared between cases and controls
62820968|NCT02601612|PLACEBO_COMPARATOR|Group 1: Placebo|RSV-seropositive children will receive a single dose of placebo at study entry (day 0).
62820969|NCT02601612|EXPERIMENTAL|Group 2: D46cpΔM2-2 Vaccine|RSV-seronegative infants and children will receive a single dose of 10\^5 PFU D46cpΔM2-2 vaccine at study entry (day 0).
62820970|NCT02601612|PLACEBO_COMPARATOR|Group 2: Placebo|RSV-seronegative infants and children will receive a single dose of placebo at study entry (day 0).
62040764|NCT02624362|EXPERIMENTAL|Odor + Negative belief|Participants receive 15 minute odor presentation (Phenylethyl Alcohol odor) accompanied by the suggestion that this odor worsens asthma symptoms (asthmogenic suggestion)
62040765|NCT06636981|EXPERIMENTAL|cohort1: All trans retinoic acid+Toripalimab+Chemotherapy|
62040766|NCT06636981|EXPERIMENTAL|cohort2: ATRA+Toripalimab+TPC|
62040767|NCT06731998|ACTIVE_COMPARATOR|Laparoscopic Transversus Abdominis Plane Block with Local Anesthetic|Patient would be receiving Laparoscopic Transversus Abdominis Plane block in addition to Local Anesthetic per standard of care.
62040768|NCT06731998|ACTIVE_COMPARATOR|Laparoscopic Transversus Abdominis Plane block only|Patient would be receiving Laparoscopic Transversus Abdominis Plane block without Local Anesthetic per standard of care.
62244155|NCT05829707|EXPERIMENTAL|Levobupivacaine PCA group|Group Levobupivacaine patient-controlled analgesia (PCA) received 0.05 mg/kg 0.5% Levobupivacaine HCl continuously via wound catheter delivered by CADD - Legacy® PCA Pump. These patients were allowed to add a dose of 7.5 mg 0.5% levobupivacaine in case of pain by pressing the patient's button on the PCA pump, with a lock-out period of 4 hours.
62244156|NCT06736119|EXPERIMENTAL|Task-oriented intervention|task-oriented intervention for individual of developmental coordination disorder
62244157|NCT02868970|OTHER|Community (2 in NB, 2 from NS)|There are four communities involved in the study, two in New Brunswick and two in Nova Scotia. All pharmacies in each community will be allocated to one intervention. Interventions include: High-Dose TIV, Meningococcal B Vaccine, Meningococcal ACWY vaccine, Tdap, Herpes Zoster vaccine and Travel Health vaccines (Hepatitis A, Hepatitis B, Typhoid Fever).
62244158|NCT05552326|EXPERIMENTAL|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
62244159|NCT05552326|PLACEBO_COMPARATOR|Placebo|Olezarsen-matching placebo will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
62244160|NCT02885194|OTHER|Patients who underwent Deep Brain Stimulation (DBS)|Patients who underwent Subthalamic Nucleus (STN)-DBS at Lyon
62244161|NCT02823626||Intervention|Spironolactone and patiromer
62244162|NCT01633866||Advances in Radio Frequency for MRI|advances in radio frequency (RF) coil magnetic resonance imaging (MRI)
62244163|NCT05472961|EXPERIMENTAL|Within Subjects Experimental Design|All participants are tested in all conditions.
62244164|NCT02294435|EXPERIMENTAL|Primary Study Arm|The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcation and the Visceral Manifold and the Unitary Manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
62244165|NCT02294435|EXPERIMENTAL|Expanded Selection Arm|The expanded selection arm is for subjects not eligible for open repair or other endovascular options due to comorbidities or anatomical limitations and do not meet inclusion in the primary study arm. The Thoracic Bifurcation and the Visceral Manifold as well as the Unitary Manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
62244166|NCT06734949||UNIMORE - University of Modena and Reggio Emilia|"Adults patients suffering HNDMs~Blood samples, skin/biopsy sample, MRI data collection from adults to classify patient with HNMD through an AI system"
62244167|NCT06734949||FSM - FONDAZIONE STELLA MARIS|"Adults and kids patients suffering HNDMs~Blood samples, skin/biopsy sample, MRI data collection from minors to classify patient with HNMD through an AI system"
62244168|NCT06734949||LMUM - LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN|"Adults patients suffering HNDMs~Blood samples, skin/biopsy sample, MRI data collection from adults to classify patient with HNMD through an AI system"
62244169|NCT05724121||Cohort A|includes all patients prior to starting therapy with a BTKi
62244170|NCT05724121||Cohort B|includes all patients already on therapy with a BTKi
62244171|NCT05724121||Cohort C|includes all patients prior to starting therapy with venetoclax
62244172|NCT05024630|EXPERIMENTAL|RDN+PVI group|The experimental group received renal artery cryoablation and pulmonary vein cryoablation. Pulmonary vein cryoablation was first followed by renal artery cryoablation.
62244173|NCT05024630|SHAM_COMPARATOR|PVI only group|The control group received pulmonary vein cryoablation alone. To ensure single blindness, the control group received femoral artery puncture and renal arteriography after cryoablation.
62244174|NCT04694508|EXPERIMENTAL|Group A|Headphones (Disok, Alicante, España)
62244175|NCT04694508|NO_INTERVENTION|Group B|Without music therapy
62244176|NCT06237218|EXPERIMENTAL|COTID program|"The intervention takes place entirely in the homes of elderly people with neurocognitive disorders.~It takes an average of 10 hours of intervention per treatment, spread over 5 to 10 weeks.~The COTID program is divided into several phases:~* Phase A: Problem definition and analysis~* Phase B: Formulation of objectives and treatment plan~* Phase C: Implementation of the treatment plan."
62434458|NCT01140269|EXPERIMENTAL|PCR testing|PCR will be used in parallel with routine laboratory tests such as culture. Treatment for PCR results will be based on the standard of care. Treatment of the patient will be dependent on the physician's clinical judgment based on existing clinical information including PCR, microbiology, patient physical presentation, and other laboratory results.
62040769|NCT06731998|ACTIVE_COMPARATOR|Local Anesthetic only|Patient would be receiving Local Anesthetic per standard of care.
62244177|NCT06237218|NO_INTERVENTION|Routine care|Patient's needs without a COTID program.
62244178|NCT04722341|EXPERIMENTAL|Time-Restricted Eating (TRE)|8-hour daily eating period, starting 1-3 hours after waking up
62244179|NCT04722341|ACTIVE_COMPARATOR|Control|More than equal to a 12-hour daily eating period
62244180|NCT04091386||Hemophilia A patients|Patients with hemophilia A who are being treated with Damoctocog alfa pegol (Jivi, BAY94-9027) in routine medical practice and are enrolled in Bayer-sponsored study NCT03932201
62040770|NCT02122133||PC 400|Patients treated with the PC 400 according to the IFU
62244181|NCT06736080|EXPERIMENTAL|MUNC|
62244182|NCT01096212|EXPERIMENTAL|generic sevoflurane|
62244183|NCT01096212|ACTIVE_COMPARATOR|origianl sevoflurane|
62244184|NCT01141088|EXPERIMENTAL|Bilateral stent-in-stent insertion|The passage of the bilateral metal stent across the stricture, stent-in-stent method.
62244185|NCT01141088|ACTIVE_COMPARATOR|Bilateral side-by-side insertion|The passage of the bilateral metal stent across the stricture, side-by-side method.
62244186|NCT06734130|EXPERIMENTAL|Adaptive Androgen Deprivation and Docetaxel Treatment|This study will consist of various visits: a screening visit, 1-3 visits during the screening standard of care treatment period and visits every 4 weeks during the adaptive therapy period.
62040771|NCT02122133||Conventional Embolic Coils|These are any approved embolic coils on the market used as part of the standard of care for treating intracranial aneurysms.
62820971|NCT05983211|EXPERIMENTAL|Accelerated cTBS Neuromodulation|"Stage 2 \[CURRENTLY ENROLLING\]:~ALS patients receiving an accelerated schedule of continuous theta burst rTMS bilaterally at multiple M1 regions at a regimen of 40 seconds, 1 minute 20 seconds, 2 minutes, or 4 minutes per treatment for up to 8 treatment sessions per day, delivered one per hour, over 5 days. Additional single-day maintenance treatments will follow these 5 days at a frequency of every 2 weeks for 12 weeks, then every 4 weeks for 12 weeks."
62820972|NCT04781478|ACTIVE_COMPARATOR|Biorepair Gel (Q1-Q3) and Chlorhexidine 1% gel (Q2-Q4)|The patients receive Biorepair Gel application in quadrants Q1 and Q3, whereas they receive chlorhexidine 1% gel in quadrants Q2 and Q4.
62040772|NCT02635269|EXPERIMENTAL|Sugar|The subjects exercise on the cycle-ergometer until exhaustion or for a maximum of 1 hour at an intensity that corresponds to 60-65% of VO2max.
62600715|NCT03441607|ACTIVE_COMPARATOR|Drug|Intervention: 40 mg of micronized human amnion chorion membrane biologic (mHACMb); administered 1(x) on second visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
62623858|NCT04854070|EXPERIMENTAL|IVUS-guided PCI|Method is already used in standard care, but in this trial compared to another method also already used in standard care
62820973|NCT04781478|ACTIVE_COMPARATOR|Chlorhexidine 1% gel (Q1-Q3) and Biorepair Gel (Q2-Q4)|The patients receive chlorhexidine 1% gel in quadrants Q1 and Q3, whereas they receive Biorepair Gel application in quadrants Q2 and Q4.
62820974|NCT04797611|OTHER|Investigational Treatment 1|Investigational treatment mode (stimulation pattern) 1
62434459|NCT03168685|EXPERIMENTAL|Experimental|"Multiple device intervention~1. SureSource Engage mobile application~2. ActiGraph Link~3. weight scale"
62244187|NCT05992623|ACTIVE_COMPARATOR|Output synchronized to 200J using Zoll Rectilinear Biphasic Waveform (RBW) defibrillator|Participants receiving Direct Current Cardioversion (DCCV) using full output Rectilinear Biphasic Waveform (RBW) shocks from a Zoll defibrillator (200 Joules) up to 2 shocks.
62244188|NCT05992623|ACTIVE_COMPARATOR|Output synchronized to 360J Lifepak Biphasic Truncated Exponential Waveform (BTE) defibrillator|Participants receiving Direct Current Cardioversion (DCCV) using full output Biphasic Truncated Exponential Waveform (BTE) shocks from a Physiocontrol/Medtronic Lifepak defibrillator (360 Joules) up to 2 shocks.
62820975|NCT04797611|OTHER|Investigational Treatment 2|Investigational treatment mode (stimulation pattern) 2
62040773|NCT05668962|EXPERIMENTAL|SELPERCATINIB + I-131 NaI|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~* Participants will be treated with Selpercatinib for 4 weeks.~* In the fourth week of treatment, participants will receive a therapeutic dose of I-131 NaI.~  * Those participants in whom radioiodine uptake has been restored may be offered a second 4-week course of selpercatinib plus I-131 NaI treatment"
62600716|NCT03441607|PLACEBO_COMPARATOR|Placebo|Intervention: 1cc of saline will be administered as a one time injection on visit 2, administered 1(x) on first visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
62623859|NCT04854070|ACTIVE_COMPARATOR|Angio-guided PCI|Method is standard care
62244189|NCT05992623|ACTIVE_COMPARATOR|Zoll defibrillator waveform used after unsuccessful second full output shock.|Participants who received first shock via Zoll that do not have success after a second full output shock will be crossed over to the Lifepak defibrillator waveform and receive up to 2 full output shocks with a minimum of 1 minute between each shock to ascertain the outcome of the immediately prior shock.
62244190|NCT05992623|ACTIVE_COMPARATOR|Lifepak defibrillator waveform used after unsuccessful second full output shock.|Participants who received first shock via Lifepak that do not have success after a second full output shock will be crossed over to the Zoll defibrillator waveform and receive up to 2 full output shocks with a minimum of 1 minute between each shock to ascertain the outcome of the immediately prior shock.
62820976|NCT06182137|EXPERIMENTAL|rTMS and CBT|During 5 weeks of therapy, the subjects will undergo 12 CBT sessions combined with 15 rTMS procedures lasting about 30-60 minutes.
62820977|NCT06182137|SHAM_COMPARATOR|Sham and CBT|During 5 weeks of therapy, the subjects will undergo 12 CBT sessions combined with 15 rTMS procedures (coil replaced with sham) lasting about 30-60 minutes.
62820978|NCT05032040|EXPERIMENTAL|vudalimab|
62820979|NCT02753283|EXPERIMENTAL|Women Denosumab|Semi-annual dose for women: denosumab 60 mg semi-annual injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements).
62820980|NCT02753283|PLACEBO_COMPARATOR|Women Placebo Group|Semi-annual for women: placebo saline injection; Vitamin D 800-1000 IU/daily and Calcium approximately1200 mg/daily (dietary + supplements).
62820981|NCT02753283|EXPERIMENTAL|Men Denosumab|Semi-annual dose for men: denosumab 60 mg semi-annual injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements).
62820982|NCT02753283|PLACEBO_COMPARATOR|Men Placebo Group|Semi-annual for men: placebo saline injection; Vitamin D 800-1000 IU/daily and Calcium approximately1200 mg/daily (dietary + supplements)
62040774|NCT06135337|EXPERIMENTAL|Group THIODERM ELATE|Subjects who will receive THIODERM ELATE into upper and lower lip (66.7% of enrolled subjects)
62244191|NCT04277637|EXPERIMENTAL|BGB-11417 Monotherapy Dose Finding: Part 1|Participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) or transformed NHL, mantle cell lymphoma (MCL); Waldenströms macroglobulinemia (WM); and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) will receive oral BGB-11417 until the maximum tolerated dose (MTD) (or maximum ascending dose (MAD)) and recommended phase 2 dose can be determined
62244192|NCT04277637|EXPERIMENTAL|BGB-11417 Monotherapy Expansion Cohorts: Part 2|Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 at the RP2D dose to further define the safety profile
62434460|NCT00923494|ACTIVE_COMPARATOR|Group R20|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
62434461|NCT00923494|ACTIVE_COMPARATOR|Group R30|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
62434462|NCT00923494|ACTIVE_COMPARATOR|Group R40|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
62434463|NCT04204486|EXPERIMENTAL|Face to face exercise intervention|Participants will participate in face to face exercise programme delivered by a strength and conditioning coach. Sessions will last 1 hour, 3 times a week, and will be offered at the work place. The coach will register attendance in order to monitor compliance.
62434464|NCT04204486|ACTIVE_COMPARATOR|Online exercise intervention|"Participants will be given the same training programme as the face to face group, but via an online app. Sessions should last 1 hour and should be completed 3 times a week. Participants will be asked to post a work-out picture on the social platform of the app as proof that they completed their session."
62434465|NCT04204486|NO_INTERVENTION|Control|This group will undergo all pre and post tests, but will not receive an intervention.
62434466|NCT05717829|EXPERIMENTAL|modified hip capsular incision|make re -suturing of the capsule easier with multiple stitches.
62434467|NCT01403454|NO_INTERVENTION|usual care|
62434468|NCT01403454|ACTIVE_COMPARATOR|Health Communication Application|
62434469|NCT04295460|EXPERIMENTAL|Dual Therapy|Dolutegravir plus lamivudine
62434470|NCT04295460|ACTIVE_COMPARATOR|Triple Therapy|Dolutegravir plus TAF/FTC
62434471|NCT01448031|EXPERIMENTAL|1|Capsule ASA 81mg/esomeprazole 20mg
62434472|NCT01448031|ACTIVE_COMPARATOR|2|ASA (Acetylsalicylzuur Apotex cardio 80 mg) Tablet 80 mg
62434473|NCT06526715|EXPERIMENTAL|Morton.s extension treatment|Appliation of Morton´s extension treatment simulation
62434474|NCT03786913||children with muscle disease|fifty children diagnosed to have inflammatory myositis or Duchenne muscular dystrophy in whom Quantitative muscle ultrasound measurements will be performed .The captured images will be analyzed for echo intensity by means of computer-assisted grayscale histogram analysis at baseline and after 24 months.
62040775|NCT06135337|ACTIVE_COMPARATOR|Group JUVÉDERM ULTRA 3|Subjects who will receive JUVÉDERM ULTRA 3 into upper and lower lip (33.3% of enrolled subjects)
62434475|NCT03786913||control group|20 healthy children matching age and sex as control group in whom Quantitative muscle ultrasound measurement will be performed at baseline
62820983|NCT02616640|EXPERIMENTAL|Durvalumab monotherapy|Intravenous (IV) durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle
62820984|NCT02616640|EXPERIMENTAL|Durvalumab + pomalidomide (POM)|IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle and Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle
62820985|NCT02616640|EXPERIMENTAL|Durvalumab + pomalidomide (POM) + dexamethasone (dex)|IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle with Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle and Oral dex 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle
62820986|NCT06211088|ACTIVE_COMPARATOR|famotidine plus10ml normal saline|Group A:(n. 25) will receive a 5 mg of famotidine that will be diluted to 10ml normal saline in 2 minutes preinduction.
62820987|NCT06211088|PLACEBO_COMPARATOR|10ml normal saline|Group B: Controlled group (n. 25) will receive a10ml normal saline preinduction.
62820988|NCT03095495|EXPERIMENTAL|Early use of HHHFNC|Heated Humidified High Flow Nasal Cannula
62820989|NCT03095495|ACTIVE_COMPARATOR|Standard Therapy and Rescue HHHFNC|Low Flow Nasal Cannula only if the patient needs oxygenation and Rescue HHHFNC if the patient needs PICU
62820990|NCT06290115||Case group: NSSI patient group|"1. Patients who meet the diagnostic criteria in DSM-5 and are clinically diagnosed as NSSI;~2. Age range: 15-25 years old;~3. Clear consciousness, normal speech function, able to communicate in Chinese and reading chinese;"
62040776|NCT06723808||University staff in the Autonomous Community of Madrid|This cohort consists of university staff from the University of Alcalá, including both men and women, with varying occupational physical activity (OPA) levels.
62434476|NCT04443283||LTBI Group|IGRA(+)
62820991|NCT06290115||Control group 1: non-NSSI patients|"1. psychiatric outpatients or inpatients can read and understand the contents of the questionnaire;~2. Patients who do not meet the diagnostic criteria in DSM-5 and are clinically diagnosed as NSSI.~3. Age range: 15-25 years old;~4. Clear consciousness, normal speech function, able to communicate in Chinese and reading chinese;"
62820992|NCT06290115||Control group 2: healthy group|"1. No mental illness;~2. Age range: 15-25 years old;~3. Clear consciousness, normal speech function, able to communicate in Chinese and reading chinese;"
62820993|NCT05550779|EXPERIMENTAL|Mental Exercise A|Participants follow instructions on a 10-minute audio clip
62820994|NCT05550779|ACTIVE_COMPARATOR|Mental Exercise B|Participants follow instructions on a 10-minute audio clip
62040777|NCT01375348|ACTIVE_COMPARATOR|Remifentanil|"Investigate the effect of remifentanil on cognitive function in healthy volunteers by use of experimental pain models:~* tonic muscle pain induced by the tourniquet pain model~* cognitive tests~* recording of brain activity by use of 64 channel cap"
62434477|NCT04443283||No LTBI Group|IGRA(+)
62820995|NCT06604676|ACTIVE_COMPARATOR|guided soft tissue grafting technique|aguide was fabricated for harvesting the graft and patient and operater centered outcomes is recorded
62820996|NCT06604676|ACTIVE_COMPARATOR|non-guided soft tissue grafting technique|the graft was taken with the scalpel without guide
62040778|NCT01375348|PLACEBO_COMPARATOR|Placebo infusion|"To blind the study and use as comparator in the investigation of the effect of remifentanil on cognitive function in healthy volunteers by use of experimental pain models:~* tonic muscle induced pain by the tourniquet pain model~* cognitive tests~* brain activity by use of a 64 channel cap"
62040779|NCT04802538|EXPERIMENTAL|Study Group|All patients will begin the study by using their normal ostomy pouching equipment for 28 days. This will be followed by a transition to using the OstoRing® for 28-47 days.
62040780|NCT06323928|PLACEBO_COMPARATOR|Group A: Placebo|Participants will receive 2 injections of placebo.
62040781|NCT06323928|EXPERIMENTAL|Group B: Lu AG09222|Participants will receive 1 injection of placebo and 1 injection containing Lu AG09222.
62040782|NCT06323928|EXPERIMENTAL|Group C: Lu AG09222|Participants will receive 1 injection of placebo and 1 injection containing Lu AG09222.
62040783|NCT06323928|EXPERIMENTAL|Group D: Lu AG09222|Participants will receive 1 injection of placebo and 1 injection containing Lu AG09222.
62040784|NCT06323928|EXPERIMENTAL|Group E: Lu AG09222|Participants will receive 2 injections, each containing Lu AG09222.
62040785|NCT06732778|EXPERIMENTAL|Pain neuroscience education group (PNE)|The cases in this group will be given online PNE training one week before menstruation.
62040786|NCT06732778|OTHER|Control Group (CG)|No training or application will be given to the control group
62040787|NCT05949723|EXPERIMENTAL|Golf simulator device training|
62040788|NCT04603534|EXPERIMENTAL|Intervention group|
62040789|NCT06135103|EXPERIMENTAL|talfirastide (TXA127)|TXA127 will be given daily for 12 weeks at a dose of 0.5.mg/kg via SC injection.
62040790|NCT06135103|PLACEBO_COMPARATOR|placebo|Placebo will be given daily for 12 weeks via SC injection.
62040791|NCT05183971||(1) Degenerative Cervical Myelopathy|Chinese subjects aged 50 or above who have radiological evidence of Degenerative Cervical Myelopathy, symptomatic with Nurick Grade less than 3 will be included.
62040792|NCT05183971||(2) Healthy Controls|Chinese healthy controls aged 50 or above who have no myelopathic signs of Degenerative Cervical Myelopathy with Nurick Grade less than 3 will be included.
62040793|NCT04407390|PLACEBO_COMPARATOR|Control|Patients receiving placebo.
62040794|NCT04407390|EXPERIMENTAL|NR|Patients receiving nicotinamide riboside (NR-E)
62040795|NCT06580665|EXPERIMENTAL|Cryoablation alone (CA group)|Patients undergo cryoablation alone.
62040796|NCT06580665|EXPERIMENTAL|Cryoablation combined with immunotherapy (I-CA group)|Patients undergo cryoablation. If there are no significant postoperative complications, Serplulimab should be administered immediately. Cycles with Serplulimab repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
62040797|NCT04062357|ACTIVE_COMPARATOR|lidocaine 5% spray|Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system).
62040798|NCT04062357|PLACEBO_COMPARATOR|Placebo|Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks (One to two applications (1-2 ml) of alcohol 70% sprays).
62040799|NCT06438588|EXPERIMENTAL|Supportive Care (FMD)|Patients receive nutrition counseling with a nutritionist over 60 minutes, receive FMD over 4 days for 3 cycles of immunotherapy and educational guidelines for day 5 to transition to a regular diet. Patients undergo blood sample collection throughout the study.
62040800|NCT05884840|EXPERIMENTAL|Intervention group PAD screening program|Patients aged 50-74 years free of any symptomatic or history of CVD and a Framingham-REGICOR risk ≥7%, will be candidates for PAD screening program using REASON's function predicative capacity
62040801|NCT05884840|NO_INTERVENTION|Control group PAD screening program|Patients aged 50-74 years free of any symptomatic or history of CVD will be candidates as a comparison group to calculate the cost-utility and reduction of CVD risk and events.
62040802|NCT05054608||COVID-19 ICU cohort|All patients, 18 to 63 years old, admitted to a Swedish ICU with COVID-19 with at least one year of follow up. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish intensive care registry.
62040803|NCT05054608||COVID-19 hospital admission control cohort|Four random control patients per ICU patient matched on age legal gender and region. Controls selected from all patients admitted to a Swedish hospital with COVID-19 with at least one year of follow up. Not including patients in the COVID-19 ICU cohort. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish national patient registry.
62040804|NCT05054608||General population control cohort|Four general population controls per ICU patient, matched on age, legal gender and region drawn from the total population register of Sweden. Not including ICU and hospital admitted COVID-19 patients.
62623860|NCT00368459|EXPERIMENTAL|raloxifene|oral raloxifene 120 mg once daily
62623861|NCT00368459|PLACEBO_COMPARATOR|placebo|identical appearing oral placebo
62040805|NCT06732570|ACTIVE_COMPARATOR|group A: manual therapy and exercise|will receive the therapeutic exercises (rotator cuff strengthening, cools ex's, serratus punch ex, pectoralis minor flexibility and posterior capsule modified sleeper stretching ex's) and manual therapy (mulligan abduction, deep transverse friction technique on the supraspinatus muscle, scapular mobilization, caudal and posterior humeral mobilization), they will receive 15 consecutive sessions (three session weekly over 5 weeks).
62244193|NCT04277637|EXPERIMENTAL|BGB-11417 + Zanubrutinib Combination Therapy Dose Finding: Part 3|Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; R/R MCL; R/R or treatment-naïve (TN) CLL/SLL will receive oral BGB-11417 until RP2D can be determined in combination with zanubrutinib
62244194|NCT04277637|EXPERIMENTAL|BGB-11417 + Zanubrutinib Combination Therapy Dose Expansion: Part 4|Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; R/R MCL; R/R or treatment-naïve (TN) CLL/SLL will receive oral BGB-11417 at an RP2D dose to further define the safety profile in combination with zanubrutinib
62244195|NCT04277637|EXPERIMENTAL|: BGB-11417 + Zanubrutinib Combination Therapy Dose Escalation: Part 5|Participants with treatment naïve CLL/SLL will receive oral BGB-11417 until RP2D can be determined in combination with obinutuzumab without and with zanubrutinib.
62244196|NCT04277637|EXPERIMENTAL|BGB-11417 + Zanubrutinib Combination Therapy Dose Expansion: Part 6|Participants with treatment naïve CLL/SLL will receive oral BGB-11417 at an RP2D dose to further define the safety profile in combination with obinutuzumab without and with zanubrutinib
62244197|NCT05085665|EXPERIMENTAL|Ivermectin|All eligible participants received a single dose (150 ug/kg) ivermectin by mouth
62600717|NCT05999422||Patients with primary immunodeficiency|"Maximal exercise capacity measured with Cardiopulmonary exercise testing, functional exercise capacity with six minute walk test, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, muscle oxygenation using Moxy monitor, respiratory muscle endurance using incremental threshold loading test, life quality using Pediatric Quality of Life Inventory™ 4.0 (PedsQL™ 4.0) (Turkish version)."
62040806|NCT06732570|EXPERIMENTAL|group (B): high intensity laser, manual therapy, exercise therapy|"will receive high intensity laser therapy (PAGANI scanner 16 j/cm2, high power laser BI-POWER SN/ 477 made in Italy will be used)three sessions weekly over 5 weeks. the patient will be in supine position with shoulder uncovered from clothes and wearing laser protective eye glass, the dose will be selected from device pathologies list programs number thirty-four with 30% power, frequency continuous, density 16 j/cm2, time automatically adjusted by the device according to the width of scanning area ( superiorly from the acromioclavicular joint down to end of biceps tendon and medially from the coracoid process to the middle fiber of deltoid laterally) and the infrared will be ON.~therapeutic exercises (rotator cuff strengthening, cools ex's, serratus punch ex, pectoralis minor flexibility and posterior capsule modified sleeper stretching ex's) and manual therapy (mulligan abduction, deep transverse friction on supraspinatus, scapular mobilization, caudal and posterior humerla glide)"
62820997|NCT02177123|EXPERIMENTAL|InnFocus MicroShunt Surgery|InnFocus MicroShunt implantation in the anterior chamber of the eye on patients with primary open angle glaucoma after am antiproliferative treatment of mitomycin C (MMC)
62040807|NCT03785561||Exposed (intervention) group|Patients diagnosed with a musculoskeletal disorder, who are currently participating in a health research study at the outpatient osteoarthritis clinic at Frederiksberg Hospital.
62040808|NCT03785561||Unexposed (comparator) group|The unexposed group is defined as patients, diagnosed with a musculoskeletal disorder receiving standard clinical care at the outpatient osteoarthritis clinic at Bispebjerg and Frederiksberg Hospital. They are not currently enrolled in a health research study concerning their musculoskeletal disorder at Bispebjerg and Frederiksberg Hospital
62040809|NCT04332042|EXPERIMENTAL|tofacitinib|Tofacitinib cp 5mg: 2pills twice a day for 14 days
62820998|NCT05131945|EXPERIMENTAL|Group 1: Standard Suction Thoracentesis|treatment techniques suction is a standard of care and used for draining fluid around the lung.
62820999|NCT05131945|EXPERIMENTAL|Group 2: Gravity Thoracentesis.|treatment techniques (gravity ) is a standard of care and used for draining fluid around the lung.
62040810|NCT02942108|ACTIVE_COMPARATOR|healthy, conventional surgery|Surgical bone removal by conventional rotary burs in healthy patients during third molar surgery
62040811|NCT02942108|EXPERIMENTAL|healthy, piezo surgery|Surgical bone removal by piezoelectric vibrations in healthy patients during third molar surgery
62040812|NCT05129319|ACTIVE_COMPARATOR|OLD (4 U per 0.1 mL)|The total Jeuveau dose will be 20U divided into 5 injections. Each subject will receive a total of 0.5 mL of Jeuveau during the treatment.
62040813|NCT05129319|ACTIVE_COMPARATOR|COLD (4 U per 0.02 mL group)|The total Jeuveau dose will be 20U divided into 5 injections. Each injection will receive a total of 0.1 mL of Jeuveau during the treatment.
62040814|NCT00528138||1|Simple appendicitis
62040815|NCT00528138||2|Perforated appendicitis
62040816|NCT01292928|EXPERIMENTAL|Stent|Stent implantation into SFA/PPA
62040817|NCT03576157|EXPERIMENTAL|Kilkari|Pregnant and postpartum women randomized to the Kilkari arm will receive health information messages over their mobile phone during pregnancy and up to 1 year postpartum.
62040818|NCT03576157|NO_INTERVENTION|Comparison|Existing standard of care; no new health messages
62040819|NCT06107426||Cohort A: ABBV-951|Participants naïve to ABBV-951 will receive ABBV-951 as prescribed by their physician according to the local label.
62040820|NCT06107426||Cohort B: ABBV-951|Participants transitioning from the Open-Label Extension studies M15-737 and M20-098 will continue to receive ABBV-951.
62040821|NCT06107426||Country Specific Sub-Study|Participants located in the United States, Germany and Spain, that participated in Cohort A, will participate in a single initial interview and those who continue on the treatment after 6 months will participate in a follow-up interview to explore the longitudinal impact of the treatment. Those participants who discontinue prior to the 6 months time point will engage in a discontinuation interview to understand reasons for their discontinuation of treatment.
62821000|NCT02046967|ACTIVE_COMPARATOR|Endovenous laser ablation|Endovenous laser ablation with 940 nm bare fiber.
62821001|NCT02046967|ACTIVE_COMPARATOR|Endovenous steam ablation|Endovenous steam ablation with steam vein sclerosis system.
62821002|NCT06582446|EXPERIMENTAL|Single experimental arm|"RT prostate (HDR brachytherapy): 15 Gy (D90) in 1 fraction HDR RT prostate~EBRT elective pelvis (Ultra-hypofractionated RT - UHF): 25 Gy in 5 Gy per fraction~Technique: IMRT/IGRT/HDR brachytherapy~Duration: 6 fractions, 3 weeks~Androgen deprivation therapy (ADT) - Goserelin: all patients receive ADT; luteinising-hormone-releasing hormone agonists or antagonists for 24 months~Follow-up (FU) per patient: minimum FU time is 5 years (60 months), the study ends when the last enrolled patients reaches 60 months of FU time~Further FU: by the end of this clinical trial it will be decided whether further FU is necessary, amendment to this clinical trial protocol will be done in appropriate time"
62821003|NCT06623240|EXPERIMENTAL|Cohort 2: Group AB|Cohort 2 - Group AB will receive allogeneic HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) at study weeks 0, 4, and 8. Then, Group AB will receive placebo (Sterile Saline Solution 0.9%) at weeks 20, 24, and 28 after a washout period of 12 weeks between active treatment and placebo.
62040822|NCT04768400|EXPERIMENTAL|rocuronium|Neuromuscular blockade will be performed using rocuronium.
62040823|NCT04987879|EXPERIMENTAL|Exercise Arm 1|Aerobic exercise will be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking and dynamic exercises. A 5-min walking cool down will end the session. The training dose for this arm is 750 MET-min/wk for 3-5 days per week, 22-45 minutes per session at a moderate to vigorous intensity. The exercise can be completed in person or virtually.
62040824|NCT04987879|EXPERIMENTAL|Exercise Arm 2|Aerobic exercise will be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking and dynamic exercises. A 5-min walking cool down will end the session. The training dose for this arm is 1,000 MET-min/wk for 3-5 days per week, 30-60 minutes per session at a moderate to vigorous intensity. The exercise can be completed in person or virtually.
62040825|NCT04987879|NO_INTERVENTION|Standard of Care|This group will receive best NASH clinical practices counseling at baseline and end-of-trial in accordance with NAFLD clinical practice guidelines and be reinforced by handouts from the American Liver Foundation.
62040826|NCT03404570|EXPERIMENTAL|High Dose (4 mg)|Oral tablet containing 2 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
62040827|NCT03404570|EXPERIMENTAL|Low Dose (2 mg)|Oral tablet containing 1 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
62040828|NCT03404570|PLACEBO_COMPARATOR|Placebo|Oral tablet containing no active drug. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
62040829|NCT03424005|ACTIVE_COMPARATOR|Atezolizumab + Nab-Paclitaxel|"1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab + nab-paclitaxel until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Enrollment is closed."
62040830|NCT03424005|EXPERIMENTAL|Atezolizumab + Nab-Paclitaxel + Tocilizumab|"1L PD-L1-positive participants will receive combination treatment with atezolizumab plus nab-paclitaxel and tocilizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Enrollment is closed."
62040831|NCT03424005|EXPERIMENTAL|Atezolizumab + Sacituzumab Govitecan|"1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab plus sacituzumab govitecan until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Enrollment is closed."
62040832|NCT03424005|ACTIVE_COMPARATOR|Capecitabine|"2L CIT-naive participants will receive capecitabine until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1).~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.~Enrollment is closed."
62040833|NCT03424005|EXPERIMENTAL|Atezolizumab + Ipatasertib|"2L CIT-naive participants will receive doublet combination treatment with atezolizumab + ipatasertib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.~Enrollment is closed."
62040834|NCT03424005|EXPERIMENTAL|Atezolizumab + SGN-LIV1A|"2L CIT-naive participants will receive doublet combination treatment with atezolizumab plus SGNLIV1A until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.~Enrollment is closed."
62244198|NCT03760341|ACTIVE_COMPARATOR|cold adenoidectomy group|this group of patient will undergo adenoidectomy by the cold method intervention: adenoidectomy - cold method
62821004|NCT06623240|EXPERIMENTAL|Cohort 2: Group BA|Cohort 2 - Group BA will receive placebo (Sterile Saline Solution 0.9%) at study weeks 0, 4, and 8. Then, Group BA will receive allogeneic HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) at weeks 20, 24, and 28 after a washout period of 12 weeks between placebo and active treatment.
62244199|NCT03760341|ACTIVE_COMPARATOR|hot method adenoidectomy|this group of patient will undergo adenoidectomy by the cold method intervention: adenoidectomy - hot method
62244200|NCT00450216|EXPERIMENTAL|1|HZT-501: Ibuprofen 800mg/famotidine 26.6mg
62244201|NCT00450216|ACTIVE_COMPARATOR|2|Ibuprofen 800mg
62821005|NCT06623240|EXPERIMENTAL|Cohort 1: Group A|Cohort 1 - Group A will receive allogeneic HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) at study weeks 0, 4, and 8.
62821006|NCT05120830|EXPERIMENTAL|Phase 1 Study Arm|Participants assigned to 1 of 3 dose-escalation cohorts will receive a single dose of NTLA-2002 on Day 1 and will then be followed for 104 weeks. Primary observation period is 16 weeks.
62821007|NCT05120830|EXPERIMENTAL|Phase 2 Experimental Study Arm|Participants randomized to NTLA-2002 (2 dose levels), will receive a single dose of NTLA-2002 on Day 1 and will then be followed for 104 weeks. Primary observation period is 16 weeks.
62821008|NCT05120830|PLACEBO_COMPARATOR|Phase 2 Placebo Comparator Study Arm|Participants randomized to placebo will receive IV normal saline on Day 1 and will then be followed for up to 104 weeks. Primary observation period is 16 weeks.
62821009|NCT05120830|EXPERIMENTAL|Placebo Crossover and Follow-On Dosing Substudy Arm|Participants assigned to this Substudy Arm (participants who previously received either 25mg or placebo only) will have the opportunity to receive a single dose of NTLA-2002 (50mg) and will then be followed for 52 weeks.
62849147|NCT05401578|PLACEBO_COMPARATOR|Control Intervention: Placebo (0.9% NaCl)|Placebo: 1 ml of 0.9 % NaCl
62244202|NCT05546554|EXPERIMENTAL|Suvorexant, then Placebo|"Participants will first receive Suvorexant for a 4-week period. A starting dose will be 5 mg at bedtime and can be increased by 5 mg only if needed and if well tolerated on a weekly basis until the maximum dose of 20 mg/day is reached. Participants will be maintained on the lowest effective dose.~Participants will then receive Placebo (fake tablet) for a 4-week period. A starting dose will be 5 mg at bedtime and can be increased by 5 mg only if needed and if well tolerated on a weekly basis until the maximum dose of 20 mg/day is reached. Participants will be maintained on the lowest effective dose."
62821010|NCT06596902|EXPERIMENTAL|Intervention Program|The 12-month intervention will progressively increase in intensity \& complexity to teach parents/children more complex sports skills \& behavioral techniques, \& to prepare them to become future team leaders for nutrition education and sports sessions. In addition, the family Olympics events will take place after every 3-month to reinforce progression, social support, \& progressive improvements: Phase 1: Beginner (months 0-3) will focus on introductory concepts \& basic sports skills \& will focus on establishing consistent behavioral patterns \& social support. Phase 2: Intermediate (months 4-6) will begin to introduce slightly more complex nutrition \& behavioral concepts, increase difficulty of sport skills, \& reinforce behavioral patterns from phase 1. Phase 4: Advanced (months 10-12) will teach parents \& children advanced sports skills \& nutrition knowledge so that they may become team leaders to help implement future activity sessions and nutrition education sessions.
62244203|NCT05546554|EXPERIMENTAL|Placebo, then Suvorexant|"Participants will first receive Placebo (fake tablet) for a 4-week period. A starting dose will be 5 mg at bedtime and can be increased by 5 mg only if needed and if well tolerated on a weekly basis until the maximum dose of 20 mg/day is reached. Participants will be maintained on the lowest effective dose.~Participants will then receive Suvorexant for a 4-week period. A starting dose will be 5 mg at bedtime and can be increased by 5 mg only if needed and if well tolerated on a weekly basis until the maximum dose of 20 mg/day is reached. Participants will be maintained on the lowest effective dose."
62244204|NCT05211401|EXPERIMENTAL|Active arm 200 mg|Active arm 200 mg: 1 bag containing 200 mg of rituximab (MabThera® or biosimilar ) in 100ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
62434478|NCT05499494|EXPERIMENTAL|injectable composite|The material will be applied according to manufacturer instructions. BEAUTIFIL Flow Plus X will be applied directly into the cavity and create the shape desired in layers not exceeding 2 mm, and light cured for 20 seconds.
62434479|NCT05499494|ACTIVE_COMPARATOR|Nanohybrid resin composite|The nanohybrid resin composite will be applied to the the cavity using the conventional incremental technique according to manufacturer instructions.
62434480|NCT01944189|EXPERIMENTAL|Food Supplement|"Population PK Study will enroll 70 children receiving standard AL dose at 0, 8, 24, 36, 48, 60 hour with recommended milk or maize porridge plus oil. Both foods contain sufficient fat therefore will contribute to pool evaluations as a single cohort.~A subset, 48 children will have participated in nested comparative bio-availability study as follows Standard arm children receiving single dose with milk (12) Standard arm children receiving double dose with milk (12) Experimental arm children receiving single dose with maize porridge plus oil (12) Experimental arm children receiving double dose with maize porridge plus oil (12) The rest, 22 children will have participated exclusively in PPK, receiving appropriate single or double dose with milk similar to those in standard arm"
62434481|NCT01944189|EXPERIMENTAL|Food Supplement Arm|"Population PK Study will enroll 70 children receiving standard AL dose at 0, 8, 24, 36, 48, 60 hour with recommended milk or maize porridge plus oil. Both foods contain sufficient fat therefore will contribute to pool evaluations as a single cohort.~A subset, 48 children will have participated in nested comparative bio-availability study as follows Standard arm children receiving single dose with milk (12) Standard arm children receiving double dose with milk (12) Experimental arm children receiving single dose with maize porridge plus oil (12) Experimental arm children receiving double dose with maize porridge plus oil (12) The rest, 22 children will have participated exclusively in PPK, receiving appropriate single or double dose with milk similar to those in standard arm"
62434482|NCT00353938|EXPERIMENTAL|Full Dose MDMA-assisted therapy (125 mg)|Three 8-hour sessions of MDMA-assisted therapy with 125 mg of MDMA, followed by a supplemental dose of 62.5 mg MDMA
62434483|NCT00353938|ACTIVE_COMPARATOR|Active Placebo MDMA-assisted therapy (25 mg)|Three 8-hour sessions of MDMA-assisted therapy with 25 mg of MDMA, followed by a supplemental dose of 12.5 mg MDMA
62244205|NCT05211401|EXPERIMENTAL|Active arm 1000 mg|Active arm 1000 mg: 1 bag containing 200 mg of rituximab (MabThera® or biosimilar ) in 100ml of NaCl 0.9%; 1 bag containing 800 mg rituximab (MabThera® or biosimilar ) in 400 ml of NaCl 0.9%.
62434484|NCT05775809||Patients with major depressive disorder|We collect data of patients with major depressive disorder at different point (baseline, 2nd weekend±7days, 6th weekend±14days, 8th weekend±14days, 12th weekend±14days, Week 14-104 Every 4 weekends ± 14 days).
62434485|NCT04942041||local thrombectomy|Large vessel occlusion stroke patients that received thrombectomy at the local center
62434486|NCT04942041||distant thrombectomy|Large vessel occlusion stroke patients that received thrombectomy at the distant center
62244206|NCT05211401|PLACEBO_COMPARATOR|Placebo arm|1 bag of 100 ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
62244207|NCT03471936|OTHER|Acquisition of pressure-volume loops|
62434487|NCT06477315||post surgery patients|
62434488|NCT02544061|EXPERIMENTAL|NM-IL-12 plus Standard of Care (SOC)|"Single 12 µg unit subcutaneous dose of NM-IL-12 plus SOC.~Standard wound management: wet to dry dressing care and perioperative antimicrobial therapy"
62434489|NCT02544061|PLACEBO_COMPARATOR|Placebo plus SOC|"Single subcutaneous dose of placebo plus SOC~Standard wound management: wet to dry dressing care and perioperative antimicrobial therapy"
62434490|NCT00625001||1|Women with Turner syndrome
62434491|NCT00625001||2|Healthy control women
62434492|NCT06282588|EXPERIMENTAL|Phase 2 Open Label|Darolutamide for up to 96 weeks (24 months) and primary SOC RT
62244208|NCT06689618|EXPERIMENTAL|Healthy Adults|"All participants will receive the WB-EMS Exercise intervention 2 times per week for 4 weeks. Participants will only perform leveled exercise programs in the Strength Training Mode. These programs are 20-minute videos led by exercise professionals. They are full-body workouts with no one muscle group receiving more attention than another. They consist of 10-12 exercises performed for 14 repetitions. Each repetition takes 4 seconds to complete (the time that the stimulation is on) and is followed by a 4 second rest (the time that the stimulation is off). All exercises occur in a double-limb stance position. Most exercises occur with feet in wide base of support, hips width or more apart. All exercises are modifiable by the healthcare professional administering and monitoring the intervention based on participant's safe and available range of motion (i.e. arm movements, torso positions, extent of knee bend)."
62244209|NCT01938131|PLACEBO_COMPARATOR|placebo|Patients in this group will be subjected to a treatment with muscle released in which the probe of CroSystem instrument will be approached to the quadriceps, without making contact. The instrument in these conditions emits a buzz but not provokes muscle vibration
62244210|NCT01938131|EXPERIMENTAL|repeated Muscle Vibration|The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
62244211|NCT06210009|EXPERIMENTAL|DASH-Style Diet|For seven days, participants will consume a diet characterized by higher intake of fruits, vegetables, and low-fat dairy, in addition to whole grains, poultry, fish, and nuts, but smaller amounts of red meat, sweets, and sugar-containing beverages.
62244212|NCT06210009|OTHER|Western-Style Diet|For seven days, participants will consume a diet characterized by characterized by higher intake of red meat, sweets, and items containing added sugar, processed starches, and seed oils, in addition to lower intake of fruits, vegetables, and low-fat dairy.
62244213|NCT05791383|EXPERIMENTAL|transcutaneous auricular neurostimulation (low dose)|All taVNS procedures will be conducted using the Spark Biomedical device. Electrodes will be placed on the left auricle and we will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes. The low dose taVNS group will receive up to 3 treatments per day over the course of 3 days (for a total of up to 9 treatments).
62244214|NCT05791383|EXPERIMENTAL|transcutaneous auricular neurostimulation (high dose)|All taVNS procedures will be conducted using the Spark Biomedical device. Electrodes will be placed on the left auricle and we will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes. The high dose taVNS group will receive up to 9 treatments in a single day.
62244215|NCT05683171|EXPERIMENTAL|Phase 1 Dose Escalation|The dose escalation phase will assess the safety/tolerability of escalating doses of valemetostat and lenalidomide when combined with rituximab
62244216|NCT06518681|EXPERIMENTAL|PoliaValve (Aortic)|Patients receiving the PoliaValve (Aortic) from HearrHill Medical
62244217|NCT06138639|EXPERIMENTAL|Cohort 1: SGT-003|All participants will receive a single IV infusion of SGT-003 on Day 1.
62244218|NCT06138639|EXPERIMENTAL|Cohort 2: SGT-003|All participants will receive a single IV infusion of SGT-003 on Day 1.
62244219|NCT06095505|EXPERIMENTAL|Alisertib|50 mg of alisertib PO BID on days 1-7 of each 21-day cycle
62244220|NCT04521361|EXPERIMENTAL|Patients with Low extent of disease|Adult men with bone mCRPC having \< 6 bone metastases
62244221|NCT04521361|EXPERIMENTAL|Patients with High extent of disease|Adult men with bone mCRPC having ≥ 6 bone metastases
62244222|NCT05410353|EXPERIMENTAL|Active Intervention Group|Look AHEAD Intervention program adapted for delivery via Health IT modified for cultural and social norms applicable to under-served population groups
62244223|NCT05410353|ACTIVE_COMPARATOR|Comparison Group|Look AHEAD DSE (Diabetes Support and Education) Comparison Group intervention adapted to be delivered via the EHR patient portal with telephonic support
62244224|NCT06631430|EXPERIMENTAL|Part A: BI 3810477 formulation A dose group 1|single dose group 1
62600718|NCT05999422||Healthy control|"Maximal exercise capacity measured with Cardiopulmonary exercise testing, functional exercise capacity with six minute walk test, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, muscle oxygenation using Moxy monitor, respiratory muscle endurance using incremental threshold loading test, life quality using Pediatric Quality of Life Inventory™ 4.0 (PedsQL™ 4.0) (Turkish version)."
62244225|NCT06631430|EXPERIMENTAL|Part A: BI 3810477 formulation A dose group 2|single dose group 2
62244226|NCT06631430|EXPERIMENTAL|Part A: BI 3810477 formulation A dose group 3|single dose group 3
62244227|NCT06631430|EXPERIMENTAL|Part A: BI 3810477 formulation A dose group 4|single dose group 4
62244228|NCT06631430|EXPERIMENTAL|Part A: BI 3810477 formulation A dose group 5|single dose group 5
62244229|NCT06631430|EXPERIMENTAL|Part A: BI 3810477 formulation A dose group 6|single dose group 6
62600719|NCT06620367|ACTIVE_COMPARATOR|conventional guided bone regeneration|a medium horizontal ridge defect will receive bone graft and covered with membrane
62600720|NCT06620367|ACTIVE_COMPARATOR|digital guided bone regeneration|digital designed guide will be used in a medium horizontal ridge defect to place bone graft and covered with membrane
62244230|NCT06631430|EXPERIMENTAL|Part A: BI 3810477 formulation A dose group 7|single dose group 7
62849148|NCT04813367||Twisted fallopian tubes cohort|Description of girls who went through surgery for twisted fallopian tubes
62040835|NCT03424005|EXPERIMENTAL|Atezolizumab + Selicrelumab + Bevacizumab|"2L-CIT-naive participants will receive doublet combination treatment with atezolizumab plus selicrelumab and bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.~Enrollment is closed."
62600721|NCT01447927|EXPERIMENTAL|Arm I|Patients receive extended-release metformin hydrochloride PO QD on week 1, and BID on weeks 2-12 (QAM QPM on week 3) in the absence of unacceptable toxicity or disease progression.
62849149|NCT00160667|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets administered twice a day.
62040836|NCT03424005|EXPERIMENTAL|Atezolizumab + Chemo (Gemcitabine + Carboplatin or Eribulin)|"2L CIT-naive participants enrolled in the active comparator arm who experience disease progression per RECIST v1.1 and 2L CIT-naive participants enrolled in an experimental arm who experience loss of clinical benefit as determined by the investigator may receive doublet combination treatment with atezolizumab plus chemotherapy (gemcitabine + carboplatin or eribulin) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Enrollment is closed."
62600722|NCT01447927|PLACEBO_COMPARATOR|Arm II|Patients receive extended-release placebo PO QD on week 1and BID on weeks 2-12 (QAM and QPM on week 3) in the absence of unacceptable toxicity or disease progression.
62600723|NCT01459718|EXPERIMENTAL|Deferasirox / Deferasirox + Deferoxamine (DFO)|During Phase A, the induction treatment at entry, participants received Deferasirox -DFO combination. During Phase B, when participants transitioned to less intensive chelation therapy, participants received Deferasirox monotherapy.
62600724|NCT02066818|ACTIVE_COMPARATOR|Lidocaine Injection|Incision and drainage performed after patient received placebo patch with injection of 1% lidocaine into the site of the abscess.
62600725|NCT02066818|EXPERIMENTAL|Lidocaine/tetracaine patch|Incision and drainage performed after patient received active lidocaine/tetracaine patch and injection of 10cc of saline into site of abscess
62040837|NCT03424005|EXPERIMENTAL|Inavolisib + Abemaciclib + Fulvestrant|Hormone receptor-positive (HR+) participants will receive treatment with inavolisib plus abemaciclib plus fulvestrant until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
62600726|NCT04246138|ACTIVE_COMPARATOR|kinematically alignment|
62600727|NCT04246138|ACTIVE_COMPARATOR|mechanical alignment|
62600728|NCT04206176|EXPERIMENTAL|Single group crossover|The patients who are on a maintenance dose of clopidogrel 75mg once daily will be transitioned to ticagrelor 45mg twice daily after which they will be tested.
62600729|NCT05108415||Cohort A|"Blood specimen collection.~Study samples must be collected prior to any treatment."
62600730|NCT05108415||Cohort B|"Blood specimen collection.~Samples must be collected prior to perform the ultrasonography."
62600731|NCT05108415||Cohort C|"Blood specimen collection.~Study samples must be collected prior to any treatment."
62600732|NCT00093847|EXPERIMENTAL|1 Oral SAMe Tosylate|Participants receiving the oral SAMe tosylate
62600733|NCT00093847|PLACEBO_COMPARATOR|2 Oral Placebo Pill Twice Daily|Participants receiving placebo
62600734|NCT02718183|EXPERIMENTAL|PH|Hydrogen peroxide 35% to intracoronal bleaching in discoloration teeth eith endodontic treatment
62040838|NCT03424005|EXPERIMENTAL|Inavolisib + Ribociclib (dose #2) + Fulvestrant|Hormone receptor-positive (HR+) participants will receive treatment with inavolisib plus ribociclib plus fulvestrant until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
62434493|NCT06282588|EXPERIMENTAL|Phase 3 Blinded Experimental|Darolutamide + LHRHA for up to 96 weeks (24 months) and primary SOC RT
62600735|NCT02718183|EXPERIMENTAL|PC|Carbamide peroxide 37% to intracoronal bleaching in discoloration teeth eith endodontic treatment
62600736|NCT00971035|EXPERIMENTAL|A|
62600737|NCT00971035|EXPERIMENTAL|B|
62849150|NCT00160667|EXPERIMENTAL|Brivaracetam 200 mg/day|Brivaracetam 200 mg/day (100 mg administered twice a day).
62600738|NCT00971035|EXPERIMENTAL|C|
62600739|NCT00971035|PLACEBO_COMPARATOR|D|
62600740|NCT01004224|EXPERIMENTAL|BGJ398|
62600741|NCT02775877|EXPERIMENTAL|letrozole and clomiphene|Letrozole 5 mg tablet orally from 3-7 day of once a day menstrual cycle and clomiphene100 mg tablet orally once a day from 11-15 day of menstrual cycle.
62600742|NCT02775877|ACTIVE_COMPARATOR|Letrozole and human menopausal gonadotropin (HMG)|Letrozole 5 mg tablet orally from 3-7 day of once a day menstrual cycle and HMG 75u once a day by intramuscular injection from 11-15day of menstrual cycle
62600743|NCT05190822||Students|
62600744|NCT02252900|EXPERIMENTAL|cerebral MRI during follow-up of IE|All patients will undergo the diagnostic test specific to the study (Magnetic resonance imaging)
62600745|NCT04496505|SHAM_COMPARATOR|Control Arm|Participants will use a sham device twice per day for 16 minutes per day for 8 weeks. They will be assessed for symptoms of depression at baseline, along with symptoms every two weeks thereafter until the 8 week mark. Participants will also be assessed for anxiety, irritability, future orientation, quality of life, and rumination.
62600746|NCT04496505|EXPERIMENTAL|Treatment Arm|Participants will use a device twice per day for 16 minutes per day for 8 weeks. They will be assessed for symptoms of depression at baseline, along with symptoms every two weeks thereafter until the 8 week mark. Participants will also be assessed for anxiety, irritability, future orientation, quality of life, and rumination.
62849151|NCT00160667|EXPERIMENTAL|Brivaracetam 400 mg/day|Brivaracetam 400 mg/day (200 mg administered twice a day).
62849152|NCT02141737|PLACEBO_COMPARATOR|Group C|Induction protocol: patients will be given 2 ml normal saline solution, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
62040839|NCT03424005|EXPERIMENTAL|Inavolisib (dose #1) + Trastuzumab Deruxtecan|HER2+/HER2-low participants will receive inavolisib + trastuzumab deruxtecan until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
62040840|NCT03424005|EXPERIMENTAL|Inavolisib + Ribociclib (dose #1) + Letrozole|Hormone receptor-positive (HR+) participants will receive treatment with inavolisib plus ribociclib plus letrozole until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
62600747|NCT03211923||Nemaline myopathy type 6 (NEM6)|Patients diagnosed with nemaline myopathy type 6 (mutation in KBTBD13 gene). The aim is to measure five male and five female patients.
62821011|NCT06596902|NO_INTERVENTION|Control Group|Centers that are randomly assigned to the control group will continue with regularly schedule programing and activities. Families recruited from control centers will be allowed to take part in all the programs offered at the recreation centers, with exception to the AFL program since it will not be offered at those centers. Control group families will also receive publicly available information regarding the benefits of PA and strategies to become physically active (e.g., CDC PA guidelines websites \& handbook). 12-month sustainability phase will involve assessments at the organizational and individual levels. At the organizational level, we will examine the number of AFL sessions held at each recreation center and document the number of phone consultations, length of calls, and barriers addressed. At the individual level, we will examine the number of minutes of adult and child habitual PA.
62821012|NCT06521476|EXPERIMENTAL|Acetazolamide|All participants in this group will receive one acetazolamide 250 mg pill in the evening for 7 days.
62821013|NCT06521476|PLACEBO_COMPARATOR|Placebo|All participants in this group will receive one matching placebo pill in the evening for 7 days.
62040841|NCT03424005|EXPERIMENTAL|Inavolisib + Ribociclib (dose #1) + Fulvestrant|Hormone receptor-positive (HR+) participants will receive treatment with inavolisib plus ribociclib plus fulvestrant until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
62821014|NCT05636748||Ischaemic Stroke|
62821015|NCT06592729|EXPERIMENTAL|conflict and problem solving scenario training (Experimental groups)|The experimental group will be taken to scenario-based simulation. The simulation application will be taken to the case suitable for the conflict resolution skills and problem solving skills of the final year students. Before the simulation, students will be informed about the scenario (prebriefing) and expectations will be shared. This stage will take approximately 10 minutes. The student will be given time to solve the conflict for 15 minutes. At the end of the scenario, the student will be taken to the debriefing session.
62821016|NCT06592729|NO_INTERVENTION|conflict and problem solving curriculum training (Control groups9|Control group students will take 8 hours of theoretical courses on Conflict Resolution (4 hours) and Problem Solving (4 hours).
62821017|NCT05670093|EXPERIMENTAL|Neural Pressure Support|Patients will be ventilated in Pressure Support and Neural Pressure Support at 3 different levels of support in randomized order
62821018|NCT04227899|EXPERIMENTAL|Esprit BTK|Participants who receives Esprit BTK device will be included in this arm
62821019|NCT04227899|ACTIVE_COMPARATOR|Percutaneous Transluminal Angioplasty (PTA)|Participants who receives PTA treatment will be included in this arm
62821020|NCT03980769|EXPERIMENTAL|Treatment (chemotherapy, transplant)|Patients receive thiotepa IV BID over 2 hours on day -7, treosulfan IV over 120 minutes on days -6 to -4, fludarabine phosphate IV over 60 minutes on days -6 to -2, and rabbit anti-thymocyte globulin IV over 4-6 hours on days -4 to -2. Patients then undergo allogeneic hematopoietic cell transplant via infusion on day 0. Patients may also undergo bone marrow biopsy and aspiration and MRI as clinically indicated and blood sample collection on study.
62821021|NCT06297083|EXPERIMENTAL|High-dose peanut OIT combined with probiotic (HD PPOIT)|High-dose rapid escalation peanut OIT combined with probiotic (HD PPOIT) taken daily for 18 months.
62821022|NCT06297083|EXPERIMENTAL|High-dose peanut OIT combined with probiotic placebo (HD OIT)|High-dose rapid escalation peanut OIT combined with probiotic placebo (HD OIT) taken daily for 18 months
62821023|NCT06297083|ACTIVE_COMPARATOR|Low-dose peanut OIT combined with probiotic placebo (LD OIT)|Low-dose slow escalation peanut OIT combined with probiotic placebo (LD OIT) taken daily for 18 months.
62244231|NCT06631430|EXPERIMENTAL|Part B: BI 3810477 formulation B dose group 1|single dose group 1
62244232|NCT06631430|EXPERIMENTAL|Part B: BI 3810477 formulation B dose group 2|single dose group 2
62244233|NCT06631430|EXPERIMENTAL|Part B: BI 3810477 formulation B dose group 3|single dose group 3
62244234|NCT06631430|PLACEBO_COMPARATOR|Part A and Part B_Placebo|single dose of placebo
62244235|NCT02509897|ACTIVE_COMPARATOR|Hypoxic training|Endurance training
62244236|NCT02509897|PLACEBO_COMPARATOR|Normoxic training|Endurance training
62244237|NCT05462795||Indeterminate pulmonary nodule study cohort|Patients undergoing a biopsy of an indeterminate lung nodule by surgical excision, bronchoscopic biopsy or Interventional Radiology directed biopsy
62434494|NCT06282588|PLACEBO_COMPARATOR|Phase 3 Blinded Comparator|Darolutamide matched placebo + LHRHA for up to 96 weeks (24 months) and primary SOC RT
62434495|NCT05316103|EXPERIMENTAL|Endoscopic biopsy and probe-based confocal laser endomicroscopy biopsy|In this study , endoscopic biopsy and pCLE-targeted optical biopsy will be successively performed for local rectal scars in rectal cancer patients after neoadjuvant chemoradiotherapy.
62434496|NCT04139551||1XXX Denono PD|Newly diagnosed unmedicated PD patients
62434497|NCT04139551||2XXX Mild /Moderate PD|Early to moderate stage PD patients well controlled on medication(typically fewer than 8 years since diagnosis)
62434498|NCT04139551||3XXX Advanced PD|Advanced PD patients (typically greater than 8 years duration)
62821024|NCT05722873|EXPERIMENTAL|Fasting|Subjects will fast one-day per week for 12 weeks
62821025|NCT05722873|EXPERIMENTAL|Fasting with weight maintenance|Subjects will fast one-day per week for 12 weeks and maintain body weight
62821026|NCT05722873|PLACEBO_COMPARATOR|Counseling|Subjects will be counseled on optimal diet and activity recommendations to maintain/achieve a normal BMI (standard of care)
62821027|NCT04049604||1|Women with prenatal testing results that suggest an incidental detection of maternal neoplasia
62821028|NCT01761916|EXPERIMENTAL|CLONIDINE|Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
62821029|NCT01761916|ACTIVE_COMPARATOR|CAPTOPRIL|Postpartum patients with very high blood pressure will be treated with oral CAPTOPRIL (25mg)
62040842|NCT03424005|EXPERIMENTAL|Inavolisib + Ribociclib (dose #2) + Letrozole|Hormone receptor-positive (HR+) participants will receive treatment with inavolisib plus ribociclib plus letrozole until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
62040843|NCT03424005|EXPERIMENTAL|Inavolisib + Abemaciclib + Letrozole|Hormone receptor-positive (HR+) participants will receive treatment with inavolisib plus abemaciclib plus letrozole until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
62040844|NCT03424005|EXPERIMENTAL|Inavolisib (dose #2) + Trastuzumab Deruxtecan|HER2+/HER2-low participants will receive inavolisib + trastuzumab deruxtecan until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
62040845|NCT05600920|EXPERIMENTAL|Single Cohort|Patients with ICL who are enrolled in 09-I-0102.
62821030|NCT02363920|PLACEBO_COMPARATOR|spontaneous breathing trial|the patients will be asked to breathe spontaneously using their acutal low oxygen flow
62821031|NCT02363920|ACTIVE_COMPARATOR|HOF20|the patients will be asked to breathe with HOF of 20 L/min
62821032|NCT02363920|ACTIVE_COMPARATOR|HOF30|the patients will be asked to breathe with HOF of 30 L/min
62821033|NCT02363920|ACTIVE_COMPARATOR|noninvasive mechanical ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
62821034|NCT05735743|NO_INTERVENTION|Standard of Care|Standard of Care
62821035|NCT05735743|EXPERIMENTAL|Participants receiving intervention|Motivational interviewing intervention
62821036|NCT05684835||Vagus nerve tumor group|patients with neck peripheral nerve sheath tumors originating from the vagus nerve
62821037|NCT05684835||Sympathetic nerve tumor group|patients with neck peripheral nerve sheath tumors originating from the sympathetic nerve
62821038|NCT05684835||Cervical spinal nerve tumor group|patients with neck peripheral nerve sheath tumors originating from the cervical spinal nerve
62821039|NCT04243564|ACTIVE_COMPARATOR|PLMA|The PLMA, a second generation gastric access SGD, is used as temporary ventilatory device before tracheal intubation. Performance is evaluated.
62821040|NCT04243564|ACTIVE_COMPARATOR|I-gel|The I-gel, a second generation gastric access SGD, is used as temporary ventilatory device before tracheal intubation. Performance is evaluated.
62040846|NCT00419263|EXPERIMENTAL|Peramivir 150 mg|
62040847|NCT00419263|EXPERIMENTAL|Peramivir 300 mg|
62040848|NCT00419263|PLACEBO_COMPARATOR|Placebo|
62040849|NCT02068807|ACTIVE_COMPARATOR|Lutein drops|oral administration of 0.28 mg of lutein in two doses: within 6 hours (hrs) after birth and at 36 hrs of life
62040850|NCT02068807|PLACEBO_COMPARATOR|Glucose drops|oral administration of 0.28 mg of vehicle (0.5 mL of 5% glucose solution) in two doses: within 6 hours (hrs) after birth and at 36 hrs of life
62244238|NCT05462795||Known lung cancer for surgical resection study cohort|Patients with known non-small cell lung cancer who will have surgical resection for treatment
62244239|NCT05462795||Healthy volunteer cohort|Healthy volunteers with a) no current diagnosis of cancer; b) no history of cancer over the last 5 years; and c) no existing known benign lung disease that is currently requiring treatment with medication.
62821041|NCT06706102|EXPERIMENTAL|CAR T cell treatment|Major patients for whom CAR-T treatment is indicated.
62821042|NCT06598813||Children with haeadche|Children reporting headache for at least 3 month
62821043|NCT04699864|EXPERIMENTAL|Diabetic Retinopathy (DR)|Screening of DR with artificial intelligence (NeoRetina algorithm) and diagnostic evaluation with a standard of care ophthalmological examination.
62821044|NCT02374450||Active surveillance 6-12 weeks|Children were identified at the first administration of Diphtheria-tetanus-whole- cell pertussis-hepatitis B- Haemophilus influenza type b pentavalent (DTP/HepB/Hib) vaccine (usually given at 6weeks of age) and home visits were conducted according to DTP/HepB/Hib vaccine schedule.
62821045|NCT02374450||Active surveillance 5-17 months|Children who were either identified at the first administration of the DTP/HepB/Hib vaccine (usually given at 6 weeks of age), with home visits scheduled from 5 months of age onwards or identified at first encounter with the study staff, with home visits started within one week of the first encounter with study staff.
62821046|NCT02374450||Enhanced hospitalization surveillance|All children under the age of 5 years within the study areas, who were not already enrolled in active surveillance were eligible for enrolment in enhanced hospitalization surveillance during any hospitalizations throughout the entire study period.
62040851|NCT05571280|EXPERIMENTAL|Standard Intervention|"The Standard package includes a series of actions carried out by the Community and Health Development Agents (ADECOS), who improves access to primary health care practices and promotes well-being behaviors at community levels. ADECOS has the potential to facilitate improvements in the health state and quality of life in rural communities. Activities performed by ADECOS can be grouped into two blocks:~* Health awareness-raising, and promotion activities at the community level (against malnutrition and promoting adequate nutrition).~* Preventive community activities involving the promotion of treatment against malnutrition at the community level and direct referral to local health facilities when necessary."
62040852|NCT05571280|ACTIVE_COMPARATOR|Standard Intervention plus nutritional supplementation (Standard+NUT Arm)|"In addition to the services performed by the ADECOS, it is included a supply of complementary food rations (individual + family) at the relative level, being:~* One individual portion composed by nutritional lipid supplements in small quantities (SQ-LNS)~* One complementary family portion composed by local foods."
62821047|NCT06376253|EXPERIMENTAL|Arm1|Patients will receive \[68Ga\]Ga-EVS459 and, if eligible, \[177Lu\]Lu-EVS459
62821048|NCT06706453||Medical staff|Anyone who works in medicine with any on call commitment (student, intern, fellow, resident, consultant)
62821049|NCT05444465|EXPERIMENTAL|Isolated Bioinductive Repair|Surgical treatment of partial-thickness rotator cuff tears with the REGENETEN Bioinductive Implant system.
62821050|NCT05444465|ACTIVE_COMPARATOR|Completion and Repair|Surgical treatment of partial-thickness rotator cuff tears using the standard surgical technique 'Completion and Repair'.
62821051|NCT06303869|EXPERIMENTAL|Deep Brain Stimulation of the Motor Thalamus|Individuals who have speech and motor deficits due to a stroke.
62821052|NCT05731583||Recovering COVID|Subjects with hospitalization due to a confirmed diagnosis of Sars-CoV-2 infection, that were considered eligible for home monitoring.
62821053|NCT05731583||Ongoing COVID|Subjects with confirmed new diagnosis of Sars-CoV-2 infection, not requiring immediate hospitalization.
62821054|NCT05708703||Study cohort|Individuals receiving treatment for metastatic breast cancer or advanced stage ovarian cancer, will complete a baseline survey, install a mobile app on their smartphone to track daily activities, short daily surveys, and a study end survey
62434499|NCT04139551||4XXX DBS patients|PD patients with deep brain stimulation systems
62434500|NCT04139551||5XXX PSP patients|PSP patients
62821055|NCT04425967|ACTIVE_COMPARATOR|25x2Gy|the conventional schedule of 25 x 2 Gy, once daily fractionation in a five-week OTT
62821056|NCT04425967|EXPERIMENTAL|14x3Gy|the study schedule of 14 x 3 Gy, once daily fractionation in a three-week overall treatment time
62821057|NCT06592651|EXPERIMENTAL|Parental Reflective Functioning intervention Group|participants will attend four psycho-educational workshop sessions, where they will learn strategies for emotion regulation and mentalization to enhance open and secure communication within the family, strengthen the parent-child bond, and reinforce feelings of safety and stability.
62434501|NCT04139551||6XXX Healthy Controls|Age-frequency matched healthy controls
62434502|NCT04579497|EXPERIMENTAL|38° C footbath|Footbath with warm water at a constant temperature of 38° C
62434503|NCT04579497|EXPERIMENTAL|40° C footbath|Footbath with warm water at a constant temperature of 40° C
62434504|NCT04579497|EXPERIMENTAL|42° C footbath|Footbath with warm water at a constant temperature of 42° C
62434505|NCT04579497|EXPERIMENTAL|Rising temperature footbath|Footbath with warm water rising from 38° C to 42° C
62821058|NCT03361800|EXPERIMENTAL|Entinostat|Nine days prior to their scheduled surgery, entinostat 5mg PO given once weekly on day 1 and day 8
62600748|NCT03211923||Myotonic dystrophy type 2 (DM2)|Patients diagnosed with myotonic dystrophy type 2 (pathological repeat expansion in CNBP gene). The aim is to measure five male and five female patients.
62821059|NCT02689440|EXPERIMENTAL|Treatment (dasatinib, venetoclax)|Patients receive dasatinib PO QD for 15 years in the absence of disease progression or unacceptable toxicity. After 3 months of dasatinib treatment, patients also receive venetoclax PO QD on days 1-14 of each month for 3 years in the absence of disease progression or unacceptable toxicity (patients enrolled prior to 4/1/2018 receive only dasatinib).
62821060|NCT06600880|EXPERIMENTAL|Focused ultrasound treatment|Neuronavigation-guided focused ultrasound treatment in Alzheimer's disease patients using a single-element transducer in conjunction with microbubbles.
62040853|NCT05571280|EXPERIMENTAL|Standard Intervention plus money transfers (Standard+TM Arm)|In addition to the services performed by the ADECOS, it will be delivered a total of 14,000.00 Kz per month and per relative with 4 or more people living in the same household by the end of the study. It will be delivered a total of 11,000.00 Kz per month and per relative with 3 or fewer people living in the same household by the end of the study. The monetary value will be delivered in cash with unconditional format, and it will not be determined by the investigator team the use and the destination of said amount and nothing will be requested in return.
62040854|NCT06533943|EXPERIMENTAL|Experimental group|Participants in the experimental group (EG) undergo the exercise program designed for the purpose of the study. The outdoor sessions will be carried out in groups (2 sessions per week, lasting 1 hour each one) and administered by trainers with a master's degree in Science and Technique of Preventive and Adapted Physical Activity (kinesiologists).
62040855|NCT06533943|NO_INTERVENTION|Control Group|The control group (CG) will be asked to abstain from structured exercise or training, limiting their physical effort to activities needed for daily life.
62600749|NCT03211923||McArdle disease (McA)|Patients diagnosed with McArdle disease (mutation in PYGM gene). The aim is to measure five male and five female patients.
62434506|NCT04962126|EXPERIMENTAL|Treatment naive advanced follicular lymphoma|All consenting participants will be receive an intravenous infusion of Obinutuzumab (1000mg) + Atezolizumab (1200mg) q3/52 x 6 cycles (plus 1000mg Obinutuzumab on day 8 and 15 of cycle 1). Responding participants (PR or SD) who do not achieve a CR at the end of cycle 2 will receive involved site radiotherapy (4Gy, 2 fractions) between cycle 3 and 4. At the end of cycle 6 and completion of the induction phase, responding participants (CR/PR/SD) will receive maintenance phase Obinutuzumab (1000mg IV) q8/52 for up to 12 cycles.
62434507|NCT02050490||Before group, no diary|
62434508|NCT02050490||After group, with symptom diary|
62434509|NCT02311426||Norway|"500 consecutive patients with stroke from the stroke units at the University Hospital of North Norway located in the cities Narvik, Harstad and Tromsø.~At baseline 155 patients with first ever stroke were registered. At 3 and 12 months follow-up 135-155 patients were enrolled."
62434510|NCT02311426||Denmark|500 consecutive patients from the stroke unit at Århus Hospital in Denmark. At baseline 402 patients with first ever stroke were included. At 3 and 12 months follow-up 318/ 170 patients were enrolled.
62600750|NCT03211923||Healthy controls|14 male and 10 female healthy subjects were measured in a previous study
62600751|NCT03211923||Controls with positive muscle phenomena|9 male and 8 female subjects with positive muscle phenomena but no myopathy, ruled out by normal muscle biopsy, CK level, and genetic testing. These subjects were measured in a previous study.
62600752|NCT03211923||Brody disease|4 male patients diagnosed with Brody disease (ATP2A1 mutation). All Dutch patients suffering from Brody disease (n=4) were measured in a previous study
62600753|NCT04007107|EXPERIMENTAL|DV3396 followed by PDS290|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
62040856|NCT06592664|EXPERIMENTAL|SoC chemotherapy plus LSTA1 IV push and LSTA1 infusion|
62040857|NCT06592664|EXPERIMENTAL|SoC chemotherapy plus LSTA1 IV push and placebo infusion|
62040858|NCT06592664|ACTIVE_COMPARATOR|SoC chemotherapy plus Placebo IV push and placebo infusion|
62040859|NCT04908735|EXPERIMENTAL|Ruxolitinib Treatment|
62040860|NCT06216054|EXPERIMENTAL|LPM3770164|LPM3770164 sustained-release tablets will be administrated with multiple doses from 5mg to 30mg on day 1\~10
62040861|NCT06216054|PLACEBO_COMPARATOR|Placebo|LPM3770164 sustained release tablet simulant will be administrated on day 1\~10
62040862|NCT06733935|EXPERIMENTAL|NKX019 - CAR NK cell therapy|Phase 1: NKX019 plus cyclophosphamide
62434511|NCT00446264|EXPERIMENTAL|islet transplantation|Each participant received up to three sequential fresh islet infusions within three months.
62600754|NCT04007107|EXPERIMENTAL|PDS290 followed by DV3396|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
62040863|NCT05908786|EXPERIMENTAL|Atezo + Bev|Participants in the atezolizumab plus bevacizumab (Atezo + Bev) arm will receive up to three cycles of treatment until surgery or unacceptable toxicity, whichever occurs first.
62040864|NCT05908786|EXPERIMENTAL|Atezo + Bev +Tira|Participants in the atezolizumab plus bevacizumab plus tiragolumab (Atezo + Bev +Tira) arm will receive up to three cycles of treatment until surgery or unacceptable toxicity, whichever occurs first.
62040865|NCT05908786|EXPERIMENTAL|Tobe + Bev|Participants in the Tobemstomig + Bev arm will receive up to three cycles of treatment until surgery or unacceptable toxicity, whichever occurs first.
62040866|NCT03091374|EXPERIMENTAL|Growth Hormone|
62040867|NCT03298009|PLACEBO_COMPARATOR|Treatment 1|placebo oral capsule will be administered once daily, for 2 weeks
62040868|NCT03298009|EXPERIMENTAL|Treatment 2|Canagliflozine 100mg once daily, for 2 weeks
62040869|NCT00965224|EXPERIMENTAL|standard therapy + vaccination|
62040870|NCT05242991|ACTIVE_COMPARATOR|Intraoral photobiomodulation protocol|Patients will receive the PBMT from the first day of RT, 5 times a week (Monday to Friday), for 6 to 7 weeks, or until there are no more mucositis lesions, just before the RT session. Intraoral protocol will utilize a low-level laser device (MMOptics Ltda, Sao Carlos, Sao Paulo, Brazil) with wavelength 660nm, power 100 mW, spot 0.03 cm², dose 10 J/cm², and time 3 seconds. The irradiations will be punctual and in a contact form, with 1 cm between the points, perpendicular to the oral mucosa, avoiding the tumor site and will be performed: 6 points on the labial mucosa (3 in the upper and 3 in the lower), 2 points on the labial commissure (1 on the right and 1 on the left), 8 points on the jugal mucosa (4 on the right and 4 on the left), 8 points on the lateral border of the tongue (4 on the right and 4 on the left), 5 points on the ventral tongue (2 on the right, 2 on the left side and 1 point on the apex), 4 points on the oral floor (2 on the right and 2 on the left side).
62040871|NCT05242991|ACTIVE_COMPARATOR|Extraoral photobiomodulation protocol|"Patients will receive the PBMT from the first day of RT, 5 times a week (Monday to Friday), for 6 to 7 weeks, or until there are no more mucositis lesions, just before the RT session.~Extraoral protocol will utilize a defocused high-level laser device (Gemini® Diode Laser - UltraDent) with wavelength 810 + 980 nm, power 1 W, spot 4.91 cm², dose 6.11 J/cm², and time 30 seconds.~The irradiations will be punctual and in a contact form, perpendicular to the skin, avoiding the tumor site and will be performed:~* 5 points on the face (2 on both right and left cheeks, 2 points on both right and left parotid gland region and 1 on the lip);~* 5 points on the neck area (1 point on the sublingual gland region, 2 points on the right and left submandibular spaces and 2 points on the neck nearby lymphatic chain)."
62040872|NCT01219348|EXPERIMENTAL|Indeolamine 2,3 deoxygenase|To inhibit immune suppression and tolerance, by blocking the IDO enzyme with vaccination against IDO.
62040873|NCT04250454|NO_INTERVENTION|Control|Elsass Standard Care
62244240|NCT05462795||Benign lung disease cohort|"Patients with the following categories of benign lung disease:~* COPD/emphysema~* Granulomatous infection~* Interstitial lung disease including pulmonary fibrosis and interstitial lung disease."
62244241|NCT06149156|EXPERIMENTAL|Healthy Minds Program (HMP) intervention|Participants will receive access to the 4-week HMP Foundations module. The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). The full HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose. At post-treatment, participants will be given access to additional HMP content to support their continued practice.
62600755|NCT05176626|EXPERIMENTAL|Phentermine|Participants randomized to active treatment in LEAP will be provided with phentermine hydrochloride 8 mg scored tablets. This formulation of the drug is commercially available and marketed as Lomaira TM.
62040874|NCT04250454|ACTIVE_COMPARATOR|Intervention|Enriched eviroment, Feed back training, Electrical stimulation, nutrition
62040875|NCT06471530|EXPERIMENTAL|Part A SAD Cohort 1|Each participant will receive TE-8105 administered by subcutaneous injection.
62040876|NCT06471530|EXPERIMENTAL|Part A SAD Cohort 2|Each participant will receive TE-8105 administered by subcutaneous injection.
62040877|NCT06471530|EXPERIMENTAL|Part A SAD Cohort 3|Each participant will receive TE-8105 administered by subcutaneous injection.
62040878|NCT06471530|EXPERIMENTAL|Part A SAD Cohort 4|Each participant will receive TE-8105 administered by subcutaneous injection.
62040879|NCT06471530|EXPERIMENTAL|Part A SAD Cohort 5 (Adaptive Cohort)|Each participant will receive TE-8105 administered by subcuteneous injection.
62040880|NCT06471530|EXPERIMENTAL|Part B MAD Cohort 1|Each participant will receive TE-8105 administered by subcutaneous injection.
62040881|NCT06471530|EXPERIMENTAL|Part B MAD Cohort 2|Each participant will receive TE-8105 administered by subcutaneous injection.
62040882|NCT05356910|EXPERIMENTAL|OPPEN Intervention|OPPEN consists of three small-group and two one-on-one sessions to train YMSM of color engaged in HIV or PrEP care to be peer PrEP educators within their social networks.
62244242|NCT06149156|ACTIVE_COMPARATOR|Waitlist Control|Participants will receive a list of well-being resources. They will be given access to HMP at the end of the study.
62244243|NCT05228730|ACTIVE_COMPARATOR|Standard Pfizer-BioNTech booster group|Received two doses of AstraZeneca or Pfizer-BioNTech as primary COVID-19 vaccine
62244244|NCT05228730|EXPERIMENTAL|Fractional Pfizer-BioNTech booster group|Received two doses of AstraZeneca or Pfizer-BioNTech as primary COVID-19 vaccine
62244245|NCT05228730|ACTIVE_COMPARATOR|Standard Elasomeran booster group|Received two doses of AstraZeneca or Pfizer-BioNTech as primary COVID-19 vaccine
62600756|NCT05176626|PLACEBO_COMPARATOR|Placebo|Participants randomized to the control arm of LEAP will be provided with placebo tablets consisting of cellulose and corn starch and manufactured to have the same characteristics of the active drug, including size, shape, weight, and sensory perceptions.
62600757|NCT04306159|SHAM_COMPARATOR|General anesthesia|Basal blood pressure and heart rate were recorded after midazolam administration of 0.02 mg/kg. Anesthesia was induced with sufentanil 0.4 μg/kg and propofol 2-2.5 mg/kg, IV route. An IV bolus of cisatracurium 0.1 mg/kg IV was given to facilitate tracheal intubation. Anesthesia was maintained with propofol 4-6 mg/kg/h combined dexmedetomidine 0.2 μg/kg/h(after 0.2 μg/kg/h loading dose within 15min)by bispectral index (BIS) 40-60 and additional bolus doses of remifentanil 0.2-0.5 μg/kg/min to keep arterial pressure values around 20% below baseline values. Sufentanil 0.1-0.2 μg/kg and flurbiprofen 100mg was administrated once the abdomen was closed, then a patient controlled analgesia pump was used. No RSB was performed.
62244246|NCT05228730|EXPERIMENTAL|Fractional Elasomeran booster group|Received two doses of AstraZeneca or Pfizer-BioNTech as primary COVID-19 vaccine
62434512|NCT04684784|EXPERIMENTAL|Deep Dry Needling|Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle
62821061|NCT05397145|ACTIVE_COMPARATOR|Group IPB = Iliopsoas plane block|While the patient is in the supine position, the probe will be placed in the transversal plane distal to the anterior superior iliac spine. Then, the probe will be rotated approximately 30° counterclockwise and slid along the inguinal ligament until the femoral head enters the edge of the acetabulum. The block needle will be passed through the sartorius and iliopsoas muscles and the iliopsoas plane between the iliopsoas muscle and the iliofemoral ligament will be reached. After the block site is confirmed with 5 ml of saline, 10 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
62821062|NCT05397145|ACTIVE_COMPARATOR|Group PENG = PENG block|The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process, and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block site is confirmed with 5 ml of saline, 20 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
62821063|NCT01703910|ACTIVE_COMPARATOR|Arm A|Control treatment and will be treated with any of the schemes used in the study according to the discretion of the physician.
62821064|NCT01703910|EXPERIMENTAL|Arm B|Treatment guided by the gene expression profiles obtained from the CTC
62821065|NCT06594211|EXPERIMENTAL|ACT-001 CAR-NK cell|
62821066|NCT06502483|EXPERIMENTAL|PRISM Program|"Participants will be enrolled and will complete study procedures as follows:~* Baseline visit with questionnaires.~* 6 weekly or bi-weekly remote or in-clinic, psychotherapy sessions with psychologist.~* Final questionnaires and post-study exit interview"
62849153|NCT02141737|EXPERIMENTAL|Group L1|Induction protocol: patients will be given 2 ml diluted lidocaine injection in which 20 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
62434513|NCT04684784|PLACEBO_COMPARATOR|Sham Dry Needling|Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle
62434514|NCT03922659|PLACEBO_COMPARATOR|Regular treatment (symptomatic treatment) with blank TMS|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation
62434515|NCT03922659|ACTIVE_COMPARATOR|Regular treatment (RT) with blank TMS and CBT|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation and cognitive behavioral therapy
62434516|NCT03922659|ACTIVE_COMPARATOR|RT with right DLPFC hf-rTMS|Regular treatment with right dorsolateral prefrontal cortex (DLPFC) high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
62434517|NCT03922659|ACTIVE_COMPARATOR|RT with right DLPFC hf-rTMS and CBT|Regular treatment with right DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
62434518|NCT03922659|ACTIVE_COMPARATOR|RT with left DLPFC hf-rTMS|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
62434519|NCT03922659|ACTIVE_COMPARATOR|RT with left DLPFC hf-rTMS and CBT|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
62600758|NCT04306159|EXPERIMENTAL|Subcostal TAP combined with General anesthesia|After induction, TAP was performed. The transversus abdominis plane is imaged with the ultrasound probe obliquely on the upper abdominal wall, along the subcostal margin near the midline.The needle tip was advanced to the desired position where 20 mL 0.375%ropivacaine(Dexamethasone 5mg was added)were injected.The technique is repeated on the opposite side. Anesthesia method and management was same as general anesthesia group.
62244247|NCT04616248|EXPERIMENTAL|Cohort A (immunomodulators, radiation therapy)|Patients receive recombinant Flt3 ligand IT on days 1-5 and undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody CDX-1140 IT and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
62244248|NCT04616248|EXPERIMENTAL|Cohort B (immunomodulators, radiation therapy)|Patients receive recombinant Flt3 ligand IT on days 1-5 and also receive pembrolizumab (IV), tocilizumab (SC) as well as undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody IT and IV over 90 minutes and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
62244249|NCT06506604|EXPERIMENTAL|Participants with low back pain. Multiple Base Line Single Case Design - 7 days wait|Positive body image-based intervention. Main Components: Psychoeducation, Body Awareness, Acceptance, Functionality Appreciation and Gratitude toward the body.
62244250|NCT06506604|EXPERIMENTAL|Participants with low back pain. Multiple Base Line Single Case Design - 10 days wait|Positive body image-based intervention. Main Components: Psychoeducation, Body Awareness, Acceptance, Functionality Appreciation and Gratitude toward the body.
62244251|NCT06506604|EXPERIMENTAL|Participants with low back pain. Multiple Base Line Single Case Design - 14 days wait|Positive body image-based intervention. Main Components: Psychoeducation, Body Awareness, Acceptance, Functionality Appreciation and Gratitude toward the body.
62244252|NCT06506604|EXPERIMENTAL|Participants with low back pain. Multiple Base Line Single Case Design - 11 days wait|Positive body image-based intervention. Main Components: Psychoeducation, Body Awareness, Acceptance, Functionality Appreciation and Gratitude toward the body.
62244253|NCT04154332||Healthy Controls|
62244254|NCT04154332||Preeclampsia Group|
62821067|NCT04137952|EXPERIMENTAL|deterministic visual error gain|"Day1(Pretest):~1. stabilometer stance, 3 times/1 min~2. air pillow stance, 3 time/30 sec~3. poture-supraposture dual task, 3 times/1 min~Day2 to Day5:~1. Exp.group:27 times of posture tracking with high visual error gain.~2. Control group:27 times of posture training with normal visual error gain.~Day6 (Posttest):~1. stabilometer stance, 3 times/1 min~2. air pillow stance, 3 time/30 sec~3. poture-supraposture dual task, 3 times/1 min"
62244255|NCT06420661|EXPERIMENTAL|SPACE Intervention|The intervention consists of four monthly virtual visits between the school nurse, diabetes care and education specialist (DCES), parent, and any other school-related supports identified by the parent (e.g., coaches, counselors, social workers). At the first visit, the parent and child, school nurse, and DCES will discuss and determine a shared treatment plan. This will include a diabetes medical management plan and shared treatment goals for the child. At each virtual visit, the DCES and school nurse will co-lead the group through review of the shared treatment plan, a review of glucose records and insulin dosing for diabetes management, provide counseling/education, and identify any needed internal (academic) or external (health-related) supports or referrals. Families will be encouraged to set new treatment goals if any milestones are met.
62244256|NCT06420661|ACTIVE_COMPARATOR|Control|In addition to usual care (clinical and in school), parents of children enrolled in the control group will receive four monthly phone calls from the DCES to review diabetes management, mirroring the timing of the virtual visits of the intervention group. This study will employ a wait list control.
62244257|NCT05103228|EXPERIMENTAL|Lower gonadotropin dose stimulation|"Low-dose group:~* 150 IU follitropin alpha + 75 IU highly purified human menopausal gonadotropin (hpHMG)~* 10 mcg follitropin delta + 75 IU hpHMG"
62244258|NCT05103228|EXPERIMENTAL|Higher gonadotropin dose stimulation|"High-dose group:~* 225 IU follitropin alpha + 150 IU highly purified human menopausal gonadotropin (hpHMG)~* 15 mcg follitropin delta + 150 IU hpHMG"
62244259|NCT02905422|NO_INTERVENTION|Waitlist Control Group|Six month delayed access to the H.E.A.L.T.H. II Intervention - Intensive intervention (wait-list control)
62244260|NCT02905422|ACTIVE_COMPARATOR|Active Intervention Group|Immediate access to the H.E.A.L.T.H. II Intervention - Intensive intervention
62244261|NCT00328744|EXPERIMENTAL|1|Behavioral: Behavioral weight loss (Standard)
62244262|NCT00328744|EXPERIMENTAL|2|Behavioral: Behavioral weight loss (Limited Variety)
62244263|NCT06613100|EXPERIMENTAL|Xaluritamig|Xaluritamig will be administered prior to radical prostatectomy.
62434520|NCT04162392|EXPERIMENTAL|Experimental group|
62244264|NCT04605445|EXPERIMENTAL|1 visit endodontics|Root canal treatment is performed in one visit.
62244265|NCT04605445|ACTIVE_COMPARATOR|2 visits endodontics|Root canal treatment is performed in two visits.
62244266|NCT05715723||The control group|Standard therapy
62244267|NCT05715723||The test group|Standard therapy + Reamberin
62434521|NCT04162392|ACTIVE_COMPARATOR|Control group|
62821068|NCT04137952|EXPERIMENTAL|stochastic visual noise|"Day1(Pretest):~1. stabilometer stance, 3 times/1 min~2. air pillow stance, 3 time/30 sec~3. poture-supraposture dual task, 3 times/1 min~Day2 to Day5:~1. Exp.group A:27 times of posture training with posture tracking signal-to-noise ratio=2:1.~2. Exp.group B:27 times of posture training with posture tracking signal-to-noise ratio=4:1.~3. Control group:27 times of posture training with normal visual error gain.~Day6(Posttest):~1. stabilometer stance, 3 times/1 min~2. air pillow stance, 3 time/30 sec~3. poture-supraposture dual task, 3 times/1 min"
62434522|NCT02009956|OTHER|DESyne Novolimus Eluting CSS|Enrollment of up to 50 patients with up to two de novo native coronary artery lesions measuring between 2.5 and 4.0 mm in diameter and \</= 34 mm in length receiving the DESyne Novolimus Eluting CSS.
62434523|NCT01669044||dexmedetomidine,hemodynamics,injection|Group 1:when the patient can be roused after major abdominal surgery ，we will inject dexmedetomidine at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h for 6 to 24hours.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
62040883|NCT05356910|OTHER|Control Condition|The time- and attention-matched control condition consists of three small-group and two one-on-one sessions to support diet and nutrition behavior change.
62821069|NCT04137952|EXPERIMENTAL|intermittent visual gain|"Day1 (Pretest):~1. stabilometer stance with wearing flash glasses (low frequency with opaque ratio 50%), 4 times/45 sec~2. stabilometer stance with wearing flash glasses (high frequency with opaque ratio 50%), 4 times/45 sec.~3. stabilometer stance with wearing flash glasses (clear), 4 times/45 sec~4. air pillow stance, 8 times/1 min~Day2 (training section):~1. Exp. group:Posture tracking with wearing flash glasses (low frequency with opaque ratio 50%), 12 times/45 sec.~2. Control group:Posture tracking with wearing flash glasses (clear), 12 times/45 sec.~Day3 (Posttest):~1. stabilometer stance with wearing flash glasses (low frequency with opaque ratio 50%), 4 times/45 sec~2. stabilometer stance with wearing flash glasses (high frequency with opaque ratio 50%), 4 times/45 sec~3. stabilometer stance with wearing flash glasses (clear), 4 times/45 sec~4. air pillow stance, 8 times/1 min"
62040884|NCT05965687|EXPERIMENTAL|NBO group|Normobaric Hyperoxia combined with intravenous thrombolysis
62040885|NCT05965687|PLACEBO_COMPARATOR|Control group|Nasal oxygen combined with intravenous thrombolysis
62244268|NCT05323591||Filgotinib|Participants will receive treatment for moderate to severe active RA with at least one dose of filgotinib in accordance with the product label.
62821070|NCT05495789|EXPERIMENTAL|Virtual Reality Group|In addition to the routine procedure, virtual reality glasses will be applied to the high-risk pregnant in the virtual reality group of the research. Virtual reality glasses is a device that works on compatible smart mobile phones. After the NST device is connected and, the high-risk pregnant included in the experimental group will be made to watch a video lasting an average of 40 minutes with virtual reality glasses until the procedure is completed.
62821071|NCT05495789|EXPERIMENTAL|Music Group|In addition to the routine procedure, the high-risk pregnant women in the music group of the research will listen to the relaxing music used in the virtual reality application with headphones.
62821072|NCT05495789|NO_INTERVENTION|Control Group|The high-risk pregnants in the control group of the study will not be subjected to any treatment other than the routine procedure.
62040886|NCT02675387|ACTIVE_COMPARATOR|Traditional Group|Children will be administered buccal infiltration anesthesia using a 21mm needle and 1.8ml of 2%Lidocaine
62040887|NCT02675387|EXPERIMENTAL|Buzzy|Children will be administered buccal infiltration anesthesia using a 21mm needle and 1.8ml of 2%Lidocaine after sensitizing the area with a vibrating device
62040888|NCT04980118|PLACEBO_COMPARATOR|Control group|Individual nutritional intervention.
62040889|NCT04980118|EXPERIMENTAL|Experimental group|Individual nutritional intervention with two groupal sessions and physical activity.
62040890|NCT06023329|EXPERIMENTAL|Group1|
62040891|NCT06023329|PLACEBO_COMPARATOR|Group 2|
62821073|NCT05538325||Group A|40 females who experienced cesarean birth
62244269|NCT05551767|EXPERIMENTAL|Experimental arm|3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\\m2, 5-FU 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg) followed by (chemo)radiation. Effect of induction therapy will be assesed by PET/CT and by endoscopic evaluation with biopsy of suspected residual tumor. Managemant of any residual tumor will be performed according with local rules and standards.
62821074|NCT05538325||Group B|15 females who experienced vaginal birth
62040892|NCT06732141|EXPERIMENTAL|Personalized telephone-based psychological support|Participants in this group will receive weekly, personalized 30-minute telephone sessions for 8 weeks, including medication education, lung rehabilitation guidance, motivational interviewing (MI), and progressive muscle relaxation (PMR).
62040893|NCT06732141|PLACEBO_COMPARATOR|Standard Care with Weekly Follow-Up Calls|Participants in this group will receive weekly standard care calls for 8 weeks, focusing on health status, asthma symptoms, and medication use, without psychological or educational interventions.
62244270|NCT06263023||Hard-to-Place (HTP) Donor Kidneys|The study will be open to all eligible HTP kidneys from male and female donors at all participating Organ Procurement Organization (OPO) study sites. Consent for both organ donation for transplant and medical research will be obtained from the legally authorized party (LAP) by the OPO Coordinator using industry standard consent procedures and documents.
62244271|NCT06734871|EXPERIMENTAL|CAR-T cells（ chimeric antigen receptor T cells）|CT1190B cells infusion
62244272|NCT05874713|EXPERIMENTAL|Arm A|Eligible subjects who have been randomized to receive aH5N8c on Day 1, Day 22 and Day 202
62821075|NCT05538325||Group C|40 females who were the controls, did not experience any pregnancy
62040894|NCT06724965|EXPERIMENTAL|PrEP Well + Trans STAIR|Participants assigned to this condition will be enrolled in 3 sessions of PrEP Well + 8 sessions of Trans STAIR over 90 days. PrEP Well is a multi-level implementation strategy for providing PrEP in TGD-serving contexts by integrating peer-led PrEP navigation with programming that addresses other social and structural needs of the TGD community (e.g., housing, legal, employment, gender-affirmation, primary care). Trans STAIR (Experimental Treatment) Skills Training in Affect and Interpersonal Regulation (STAIR) adapted for TGD is 8-session, group delivery of transdiagnostic evidenced-based treatment for individuals who have experienced multiple traumas. STAIR is based in cognitive-behavioral principles and delivered in a flexible manner, with demonstrated efficacy for the treatment of PTSD, depression and other mental health symptoms known to be associated with poor medication adherence.
62244273|NCT05874713|EXPERIMENTAL|Arm B|Eligible subjects who have been randomized to receive aH5N8c on Day 1, aH5N6c on Day 22, and aH5N8c on Day 202
62821076|NCT02852655|EXPERIMENTAL|Pre-surgery MK-3475|"-After a screening phase of 14 days, eligible subjects will be randomized into two groups.~* Pembrolizumab (MK3475) pre-surgery at pre-determine dosage followed by Pembrolizumab at pre-determine dosage every 3 weeks post surgery.~* MK-3475 will be administered intravenously"
62821077|NCT02852655|ACTIVE_COMPARATOR|No MK-3475 at Pre-Surgery|"-After a screening phase of 14 days, eligible subjects will be randomized into two groups.~* Pembrolizumab (MK-3475) at pre-determine dosage every 3 weeks post surgery.~* MK-3475 will be administered intravenously"
62821078|NCT01325077|EXPERIMENTAL|Conventional model, Study model|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
62821079|NCT04126798||Healthy adults|Standardization and collecting normative age-related data for cognitive and motor single tasks, as well as cognitive-motor dual-tasks
62821080|NCT04126798||Bilateral vestibulopathy|Validation of cognitive and motor single tasks, as well as cognitive-motor dual-tasks
62821081|NCT04126798||Unilateral vestibular impairment|Cross-sectional study on cognitive and motor single tasks, as well as cognitive-motor dual-tasks, in persons with unilateral vestibular impairment
62244274|NCT05874713|EXPERIMENTAL|Arm C|Eligible subjects who have been randomized to receive aH5N6c on Day 1 and aH5N8c on Day 22 and Day 202
62600759|NCT04306159|EXPERIMENTAL|Modified RSB combined with General anesthesia|After induction, Modified RSB was performed based on midline incision-guided. The rectus muscle is imaged with the ultrasound probe in a transverse orientation below the xiphisternum and above the umbilicus.The needle tip was advanced to the two desired position where 10 mL ropivacaine 0.375% were injected causing hydrodissection of the rectus muscle away from the posterior rectus sheath.The technique is repeated on the opposite side.Anesthesia method and management was same as general anesthesia group.
62600760|NCT00102141|EXPERIMENTAL|Arm 1|
62821082|NCT06704360|EXPERIMENTAL|VR group (virtual reality cognitive training group)|Immersive VR cognitive training with suitable training intensity.
62821083|NCT06704360|ACTIVE_COMPARATOR|OT group (occupational therapy group)|Conventional cognitive training (occupational therapy) with suitable training intensity.
62821084|NCT06593626|EXPERIMENTAL|[18F]Florbetazine, 10mCi|Evaluate the safety and pharmacokinetics of \[18F\]Florbetazine injection in healthy subjects.
62821085|NCT06593626|EXPERIMENTAL|[18F]Florbetazine, 10mCi, 8mCi, 5mCi|AD and MCI
62821086|NCT06177132|EXPERIMENTAL|VIS-REHAB Protocol|The VIS-REHAB protocol entails 30-minute sessions conducted twice a week over a span of 9 weeks. These sessions are structured with 20 minutes dedicated to enhancing postural stability and 10 minutes focused on improving gaze stability. In greater detail, a minimum of 5 minutes time is reserved for counselling and providing background information on the exercises, focused on the vestibular issue. Apart from the counselling part, each session consist of 3 different exercise categories ((static postural stability, dynamic postural stability, general gross motor training (focus on PS), oculomotor function, gaze stability, or general gross motor training (focus on GS)), each carried out for 5 to 10 minutes.
62600761|NCT00102141|EXPERIMENTAL|Arm 3|
62600762|NCT00102141|EXPERIMENTAL|Arm 4|
62600763|NCT00102141|PLACEBO_COMPARATOR|Arm 5|
62600764|NCT00102141|EXPERIMENTAL|Arm 2|
62600765|NCT06297993||Adult patients with a confirmed diagnosis of large duct PSC.|"1. Adult patients between 18 and 75 years of age (inclusive) who can comprehend instructions, follow the study procedures and are willing to sign an Informed Consent Form (ICF).~2. Confirmed clinical diagnosis of large duct PSC based on current AASLD Guidelines."
62821087|NCT06177132|NO_INTERVENTION|CTRL Protocol|In the control (CTRL) protocol, all forms of physical therapy in the context of motor development are ceased. Occupational therapy, speech-language therapy and physical therapy for other purposes are not covered by this commitment. Additionally, the child and parents are asked to not do any home exercises on their own. However, sports activities and other recreational hobbies will not be asked to be temporary halted, since they will be continued in the active rehabilitation programme as well.
62821088|NCT05883501|EXPERIMENTAL|Group I|"Pregnant women will be given love cards containing positive affirmations that will be trained outside the classroom by asking the mother to practice alone once a day between waking up, before bed, or when relaxing.~The suggestions will be implanted using simple language, easy to understand, in detail, and straightforward. For example, From now, I know how to take care of myself in pregnancy and trust in my ability to birth my baby.~Love cards will be developed through literature studies and expert tests containing positive affirmations for pregnancy and childbirth."
62821089|NCT05883501|EXPERIMENTAL|Group 2|"The researcher will be used the heel of the hands, moving along the spine; using the palms moving hands with rocking movements from the top of the shoulder blade to the backbone; pressing fingertips, along both sides of the spine from the neck to the backbone and then stroking upward from the hip to the neck; stroking the shoulder muscles(trapezius); inching up the back, using fingertips placed on sides of spine, starting from the hipbone to the neck and then reversing the direction downward using fingertips in a raking fashion; massaging the lower back from the backbone across the waistline using the heel of the palm to make large circles; long gliding strokes from the hip up and over the shoulder (Nair ,. 2020 ; El-Hosary et al,. 2019).~Back massage will be done in four sessions each session takes 10 minutes and will be performed every week."
62821090|NCT03818256|EXPERIMENTAL|Miricorilant 600 mg|Patients who meet the entry criteria will be randomized to receive 600 mg miricorilant for 12 weeks.
62821091|NCT03818256|PLACEBO_COMPARATOR|Placebo|Patients who meet the entry criteria will be randomized to receive placebo for 12 weeks.
62244275|NCT06137833|EXPERIMENTAL|APPORTAL®|APPORTAL® sachet, 1 sachet per day dissolved in a glass of water. To be consumed in the morning, about 10 minutes after breakfast. Dosage form: powder Route: Oral Treatment duration: 8 weeks
62821092|NCT06513871|EXPERIMENTAL|Component 2d. Social Perception Tasks|Participants will take part in social perception tasks in speed-dating like interactions with individuals in which they are not allowed to verbally communicate. After silently interacting with each partner, subjects will be prompted to answer survey questions about their perceptions of their partner and their interaction. This task will take place in a variety of settings.
62821093|NCT06586749|NO_INTERVENTION|Control group: Group A|No education and implementation of teleinterventions, whereas implementation of standard care based on the existing protocol of the Clinical Department is going to be applied
62821094|NCT06586749|EXPERIMENTAL|Group B: nurse-led education|The participants in Group B will be guided and trained by the principal investigator based on a specially designed educational booklet. Group B will also receive teleinterventions.
62821095|NCT06586749|EXPERIMENTAL|Group C: nurse-led education and implementation of teleinterventions|The participants in Group C will be guided and trained by the principal investigator based on a specially designed educational booklet. Group C will also receive teleinterventions and a guidance video will be presented to them
62244276|NCT06137833|PLACEBO_COMPARATOR|PLACEBO|PLACEBO sachet, 1 sachet per day dissolved in a glass of water To be consumed in the morning, about 10 minutes after breakfast. Dosage form: powder Route: Oral Treatment duration: 8 weeks
62244277|NCT05580744|ACTIVE_COMPARATOR|Traditional occupational therapy|Traditional occupational therapy delivered skill training related to daily living tasks.
62600766|NCT01518231|EXPERIMENTAL|cell transplantation|The study group will not only be implanted with autologous hematopoietic stem cells, but also receive drug therapy.
62600767|NCT01518231|NO_INTERVENTION|Convention therapy|The control group just receive drug therapy.
62244278|NCT05580744|ACTIVE_COMPARATOR|Mirror therapy using a mirror box|Exercise of mirror therapy included movements of forearm, wrist, fingers and thumb, as well as a tendon gliding exercise using a mirror box .
62244279|NCT05580744|EXPERIMENTAL|Augmented reality-based mirror therapy|"Exercise of augmented reality-based mirror therapy included movements of forearm, wrist, fingers and thumb, as well as a tendon gliding exercise using an augmented reality mirror therapy system~."
62434524|NCT01669044||propofol,hemodynamics,injection|Group 2 :when the patient can be roused after major abdominal surgery ，we will inject propofol at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg.h for 6 to 24hours.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores
62434525|NCT01132287|EXPERIMENTAL|1 FID 112903|FID 112903
62244280|NCT06734481|PLACEBO_COMPARATOR|Saline group|Participants will receive a daily intrapleural injection of 200 mL of saline in 7 days besides standard antibiotic therapy.
62244281|NCT06734481|EXPERIMENTAL|Sodium bicarbonate group|Participants will receive a daily intrapleural injection of 200 mL of 2.5% sodium bicarbonate in 7 days besides standard antibiotic therapy.
62434526|NCT01132287|NO_INTERVENTION|No Intervention|
62434527|NCT00606268|EXPERIMENTAL|1|1.0 mg/kg
62434528|NCT00606268|EXPERIMENTAL|2|1.5 mg/kg
62434529|NCT04987177|EXPERIMENTAL|Workload conditions to be tested|The intervention is the external workload a participant propels against. Participants will propel against N=20 different external workloads.External workload will be controlled by the wheelchair ergometer.
62040895|NCT06724965|ACTIVE_COMPARATOR|PrEP Well|Participants assigned to this condition will be enrolled in 3 sessions of PrEP Well over 90 days, PrEP Well is a multi-level implementation strategy for providing PrEP in TGD-serving contexts by integrating peer-led PrEP navigation with programming that addresses other social and structural needs of the TGD community (e.g., housing, legal, employment, gender-affirmation, primary care).
62040896|NCT06733103|EXPERIMENTAL|sCST Intervention Group|There is only one arm of this intervention, it involves stroke survivors attending a cognitive stimulation group designed for post-stroke frailty. This involves strategies and psychoeducation and take-home sheets for stroke survivors and their carers. After the group is finished, stroke survivors will attend interviews and the findings of these interviews will be analysed through the theoretical framework of accepatability. The same will be the case for carers.
62040897|NCT05400330|EXPERIMENTAL|Previously administered LX1001|"This is a long-term follow-up study to evaluate the safety following LX1001, a gene therapy, for participants who are APOE4 homozygotes with clinical diagnoses varying from MCI or dementia due to AD who have previously received LX1001. Study LX1001-01 was designed to assess the safety of LX1001 at 3 ascending doses (1.4 × 1010, 4.4 × 1010, 1.4 × 1011 gene copy \[gc\]/mL CSF) as per droplet digital polymerase chain reaction methodology, with each group consisting of approximately n=5 individuals for a total of approximately 15 participants for the entire study.~In this study, participants who have received LX1001 in the parent protocol (LX1001-01) will be followed for up to 260 weeks post gene therapy administration"
62040898|NCT06681909||Food Insecure Students|Undergraduate students who reported high to moderate food insecurity, are at least 18 years of age, speak English, and plan to return to the University at Buffalo campus in Spring 2025 will receive weekly fruit and vegetable incentives encouraging them to shop at the UB Veggie Van (intervention). They will complete incentivized data collection after 13 weeks of the intervention (incentives/access to UB Veggie Van).
62040899|NCT01901068||MonoMax|Elective primary laparotomy
62040900|NCT06722482|EXPERIMENTAL|FDBA arm|
62040901|NCT06722482|ACTIVE_COMPARATOR|CEBX arm|
62040902|NCT01716429|ACTIVE_COMPARATOR|Low Calorie|Participants in this arm will be instructed on how to reduce their caloric intake and follow a low calorie diet
62040903|NCT01716429|EXPERIMENTAL|Vegan diet|Participants in this arm will follow a very low fat diet (\~10% kcals from fat) and also a diet that has a low glycemic index and is free of animal products (vegan)
62040904|NCT06526299|EXPERIMENTAL|Treatment (177Lu-PSMA-617)|Patients receive 177Lu-PSMA-617 IV over 30 minutes on days 1, 8, 50, 57, 99 and 141. Treatment repeats every 7 days for cycles 1 and 3 and every 6 weeks for cycle 2 and subsequent cycles for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PSMA-PET/CT during screening and SPECT/CT on study. Patients also undergo CT or MRI, bone scan, as well as blood sample collection throughout the study.
62040905|NCT06356220|EXPERIMENTAL|GFFG|Our Canadian collaborators have created Gluten Free-Food Guide (GFFG), a validated nutritional educational intervention, which targets increasing consumption of natural gluten free foods and limiting UPFs. However, this intervention has not yet been applied to a pediatric cohort in the United States. Preliminary data demonstrate enrollment feasibility and generalizability of the intervention. The GFFG arm will have increased focus on plant proteins, minimally processed food intake and fruit/vegetable intake with emphasis on naturally gluten-free foods. The GFFG class will highlight that not all gluten-free foods have the same nutritional and health benefits.
62040906|NCT06356220|ACTIVE_COMPARATOR|Conventional GFD Nutrition Education|Diet counselling in both the conventional GFD nutrition education and the GFFG intervention arm will include concepts related to nutrition literacy (food label reading, gluten identification, nutritional adequacy). The control group will be provided with the GFFG at the end of the study.
62244282|NCT06358326|EXPERIMENTAL|Treatment Group|In addition to the exercise given to the control group, the treatment group will receive dry needling in the carpal tunnel area, 2 days a week for 3 weeks, for a total of 5 sessions.
62244283|NCT06358326|ACTIVE_COMPARATOR|Control Group|The control group will be taught and asked to perform stretching, nerve mobilization and tendon-shifting exercises for 3 weeks.
62434530|NCT00804349|NO_INTERVENTION|Control|Patients will receive standard medical therapy for heart failure only and will not receive Autotitrating Positive Airway Pressure therapy.
62434531|NCT00804349|ACTIVE_COMPARATOR|Autotitrating Positive Airway Pressure|Patients will receive Autotitrating Positive Airway Pressure therapy in addition to standard medical care for heart failure.
62434532|NCT01484990|EXPERIMENTAL|1|
62821096|NCT05317728|EXPERIMENTAL|BAL-FAIOL|BAL-FAIOL IOL implanted in both eyes during cataract surgery (bilateral implantation)
62821097|NCT05317728|ACTIVE_COMPARATOR|Monofocal|Monofocal IOL implanted in both eyes during cataract surgery (bilateral implantation)
62821098|NCT03247647|EXPERIMENTAL|Enhanced Intervention|Participants assigned to this arm will complete a personal values task before reviewing their personalized feedback (eCheckUpToGo).
62821099|NCT03247647|PLACEBO_COMPARATOR|Standard Intervention|Participants assigned to this arm will complete a writing task about the food they have eaten in the past 48 hours immediately before reviewing their personalized feedback (eCheckUpToGo).
62821100|NCT06270888|EXPERIMENTAL|Group 1 - Dose Schedule 1|"In this study, there will be 4 different radiation schedules, ranging from 1-10 daily treatments. Participants will be assigned to one of the dose schedules and they will know this ahead of time. The study doctor will tell each participant which study group and dose schedule they been assigned.~For most participants, the actual time on the radiation treatment machine will be in the range of 30 to 60 minutes. The mold will be removed after the treatment. The number of treatments to each tumor will depend on which treatment group the participant is enrolled on: The longest possible treatment group would be 10 treatments in duration of about 2 weeks of treatment and the shortest possible treatment group would be 1 treatment."
62849154|NCT02141737|EXPERIMENTAL|Group L2|Induction protocol: patients will be given 2 ml diluted lidocaine injection in which 30 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
62434533|NCT05081752|NO_INTERVENTION|No fixation|
62434534|NCT05081752|ACTIVE_COMPARATOR|Stent Suturing|
62821101|NCT06270888|EXPERIMENTAL|Group 2 - Dose Schedule 2|"In this study, there will be 4 different radiation schedules, ranging from 1-10 daily treatments. Participants will be assigned to one of the dose schedules and they will know this ahead of time. The study doctor will tell each participant which study group and dose schedule they been assigned.~For most participants, the actual time on the radiation treatment machine will be in the range of 30 to 60 minutes. The mold will be removed after the treatment. The number of treatments to each tumor will depend on which treatment group the participant is enrolled on: The longest possible treatment group would be 10 treatments in duration of about 2 weeks of treatment and the shortest possible treatment group would be 1 treatment."
62040907|NCT06722261|EXPERIMENTAL|Single Case Research Design: Phase 1|A randomized selection method will be employed to select deaf children to participate in single case research. Two children will be selected from each age group between 5 and 10, making a total of eight students. Their language skills will be closely monitored and evaluated over the course of the year. Following the noncurrent multiple baseline design, in succession across 8 child participants in 4 classes, 2 Phase 1 participants in a class will begin receiving SISI while other children remain in the baseline for 3 to 9 weeks.
62434535|NCT05081752|EXPERIMENTAL|OTSC Stentfix|
62821102|NCT06270888|EXPERIMENTAL|Group 3 - Dose Schedule 3|"In this study, there will be 4 different radiation schedules, ranging from 1-10 daily treatments. Participants will be assigned to one of the dose schedules and they will know this ahead of time. The study doctor will tell each participant which study group and dose schedule they been assigned.~For most participants, the actual time on the radiation treatment machine will be in the range of 30 to 60 minutes. The mold will be removed after the treatment. The number of treatments to each tumor will depend on which treatment group the participant is enrolled on: The longest possible treatment group would be 10 treatments in duration of about 2 weeks of treatment and the shortest possible treatment group would be 1 treatment."
62821103|NCT06270888|EXPERIMENTAL|Group 4 - Dose Schedule 4|"In this study, there will be 4 different radiation schedules, ranging from 1-10 daily treatments. Participants will be assigned to one of the dose schedules and they will know this ahead of time. The study doctor will tell each participant which study group and dose schedule they been assigned.~For most participants, the actual time on the radiation treatment machine will be in the range of 30 to 60 minutes. The mold will be removed after the treatment. The number of treatments to each tumor will depend on which treatment group the participant is enrolled on: The longest possible treatment group would be 10 treatments in duration of about 2 weeks of treatment and the shortest possible treatment group would be 1 treatment."
62821104|NCT06281587||Group 1 - low-risk (LR) keratoplasty|if the patient was diagnosed with keratoconus and there were no concomitant complicating diagnoses (n = 42)
62434536|NCT06429761|EXPERIMENTAL|Single Arm|Trastuzumab deruxtecan
62040908|NCT06722261|EXPERIMENTAL|Single Case Research Design: Phase 2|A randomized selection method will be employed to select deaf children to participate in single case research. Two children will be selected from each age group between 5 and 10, making a total of eight students. Their language skills will be closely monitored and evaluated over the course of the year. Following the noncurrent multiple baseline design, in succession across 8 child participants in 4 classes, three weeks after Phase 1 participants have begun SISI, Phase 2 participants in a class will begin receiving SISI while other children remain in the baseline.
62434537|NCT05610605|NO_INTERVENTION|Control Group|Participants who do not receive attention from the Fragsalud program. The control group follows the usual care and preventive measures in Primary Care, according to different protocols implemented and the criteria of nurses and family doctors responsible for their care.
62434538|NCT05610605|EXPERIMENTAL|Intervention Group|The FRAGSALUD Programme is a multidomain intervention programme, which covers the prevention and treatment of frailty from different aspects, fundamentally from a physical and cognitive aspect and to maintain social integration, although other modifiable factors that are related to the presence of fragility such as hearing impairment, visual deficit or depression.
62434539|NCT01557491|ACTIVE_COMPARATOR|Straight Incision|incision made perpendicular to scalp surface
62434540|NCT01557491|ACTIVE_COMPARATOR|Bevelled Incision|Incision made at 45 degrees to scalp surface
62434541|NCT02270983|EXPERIMENTAL|Linaclotide 145 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
62434542|NCT02270983|EXPERIMENTAL|Linaclotide 290 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
62040909|NCT06722261|EXPERIMENTAL|Single Case Research Design: Phase 3|A randomized selection method will be employed to select deaf children to participate in single case research. Two children will be selected from each age group between 5 and 10, making a total of eight students. Their language skills will be closely monitored and evaluated over the course of the year. Following the noncurrent multiple baseline design, in succession across 8 child participants in 4 classes, 2 SCRD participants in a class will begin receiving SISI while other children remain in the baseline for 3 weeks.
62040910|NCT06722261|EXPERIMENTAL|Single Case Research Design: Phase 4|A randomized selection method will be employed to select deaf children to participate in single case research. Two children will be selected from each age group between 5 and 10, making a total of eight students. Their language skills will be closely monitored and evaluated over the course of the year. Following the noncurrent multiple baseline design, in succession across 8 child participants in 4 classes, 2 SCRD participants in a class will begin receiving SISI while other children remain in the baseline for 3 weeks.
62040911|NCT02618967|EXPERIMENTAL|AMG 570 - 7 mg|Participants will receive a single dose 7 mg dose of AMG 570 administered subcutaneously.
62040912|NCT02618967|EXPERIMENTAL|AMG 570 - 21 mg|Participants will receive a single 21 mg dose of AMG 570 administered subcutaneously.
62040913|NCT02618967|EXPERIMENTAL|AMG 570 - 70 mg|Participants will receive a single 70 mg dose of AMG 570 administered subcutaneously.
62040914|NCT02618967|EXPERIMENTAL|AMG 570 - 140 mg|Participants will receive a single 140 mg dose of AMG 570 administered subcutaneously.
62040915|NCT02618967|EXPERIMENTAL|AMG 570 - 210 mg|Participants will receive a single 210 mg dose of AMG 570 administered subcutaneously.
62040916|NCT02618967|EXPERIMENTAL|AMG 570 - 420 mg|Participants will receive a single 420 mg dose of AMG 570 administered subcutaneously.
62040917|NCT02618967|EXPERIMENTAL|AMG 570 - 700 mg|Participants will receive a single 700 mg dose of AMG 570 administered subcutaneously.
62040918|NCT02618967|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of the matching AMG 570 placebo administered subcutaneously.
62040919|NCT00536133|EXPERIMENTAL|Zinc group|children with recurrent acute lower respiratory infections receiving zinc supplementation
62040920|NCT00536133|PLACEBO_COMPARATOR|Placebo group|children with recurrent acute lower respiratory infections receiving placebo syrup
62040921|NCT06580223|ACTIVE_COMPARATOR|Aspirin|Aspirin,100mg qd, for six months
62434543|NCT02270983|EXPERIMENTAL|Placebo|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
62040922|NCT06580223|EXPERIMENTAL|Rivaroxaban|Rivaroxaban, 10mg qd, for six months
62040923|NCT03805724||Periodontally healthy subjects|They will be selected from healthy subjects who attend the restorative dental clinic and has clinically healthy gingiva with zero plaque index, gingival index and clinical attachment level \& probing depth ≤ 3 mm. Plaque samples will be collected.
62040924|NCT03805724||Chronic Periodontitis|Chronic periodontitis patients having probing depth of ≥3 mm and clinical attachment level ≥ 1 mm. Plaque samples will be collected.
62040925|NCT03805724||Chronic Gingivitis|Gingivitis patients having signs of clinical inflammation with no clinical attachment loss. Plaque samples will be collected
62040926|NCT06336330||HFpEF|Adult patients with preserved ejection fraction (HFpEF; EF≥50%) who receive treatment with dapagliflozin in accordance with the local dapagliflozin product label for symptomatic chronic heart failure.
62434544|NCT06530563|EXPERIMENTAL|Oliceridine|In the experimental group, the acute pain after surgery will be treated with Oliceridine fumarate injection via patient controlled analgesia for 48 hours. Oliceridine 0.4mg/kg will be supplied to 100ml analgesia pump, loading dose for 1-2ml, background infusion dose for 2ml/h, bolus for 2ml/ time, locked for 15min, maximum dose for 12ml/h.
62040927|NCT06336330||HFmrEF|Adult patients with mildly reduced ejection fraction (HFmrEF; EF 41-49%) who receive treatment with dapagliflozin in accordance with the local dapagliflozin product label for symptomatic chronic heart failure.
62040928|NCT06336330||HFrEF|Adult patients with reduced ejection fraction (HFrEF; EF ≤40%) who receive treatment with dapagliflozin in accordance with the local dapagliflozin product label for symptomatic chronic heart failure.
62040929|NCT06502366|ACTIVE_COMPARATOR|BDA MDI HFO|160/180 µg Budesonide/albuterol pressurized inhalation suspension, HFO
62040930|NCT06502366|ACTIVE_COMPARATOR|BDA MDI HFA|160/180 µg Budesonide/albuterol pressurized inhalation suspension, HFA
62040931|NCT06502366|PLACEBO_COMPARATOR|Placebo MDI HFA|Placebo pressurized inhalation suspension, HFA
62434545|NCT06530563|ACTIVE_COMPARATOR|Sufentanil|In the control group, the acute pain after surgery will be treated with Sufentanil citrate via patient controlled analgesia for 48 hours. Sufentanil 2ug/kg will be supplied to 100ml analgesia pump, loading dose for 1-2ml, background infusion dose for 2ml/h, bolus for 2ml/ time, locked for 15min, maximum dose for 12ml/h.
62821105|NCT06281587||Group 2 - high-risk (HR) keratoplasty|in the presence of corneal dystrophy (pseudophakic bullous keratopathy, primary dystrophy), corneal inflammatory pathology (erosions, corneal ulcers, corneal fistulas,leucoma), complicated keratoconus, CGR or rekeratoplasty (n = 51)
62821106|NCT06093477|PLACEBO_COMPARATOR|3mg fast-dissolve pill|Participants will take a placebo of 3mg fast-dissolve pill (without melatonin), complete surveys, and wear an actigraphy device during the specified study period.
62821107|NCT06093477|EXPERIMENTAL|3mg fast-dissolve pill (containing melatonin)|Participants will take 3mg in fast-dissolve pill form containing the active ingredient melatonin, complete surveys, and wear an actigraphy device during the specified study period.
62434546|NCT01033864|EXPERIMENTAL|MMF, Prednisone|Participants received mycophenolate mofetil (MMF) orally (PO) at a dose of 1 gram per day (g/day) twice daily (BID), and prednisone, PO, up to 5 milligrams per day (mg/day) for at least 1 month.
62434547|NCT01033864|ACTIVE_COMPARATOR|EC-MPS|Participants received mycophenolate sodium (EC-MPS), PO, at a dose of 720 mg/day BID, and prednisone PO up to 5 mg/day for at least 1 month.
62434548|NCT04905719||Patients with dyspnea|Patients who visit a general practitioner for dyspnea will undergo a Point-of-Care ultrasound examination of the lungs to identify the presence or the absence of A-profile, B-profile and pleural effusion.
62434549|NCT04905719||Patients with abdominal pain|Patients who visit a general practitioner for abdominal pain in the right upper quadrant will undergo abdominal Point-of-Care ultrasound examination to identify cholecystolithiasis.
62434550|NCT04905719||Patients with suspected deep vein thrombosis|Patients who visit a general practitioner for pain and / or swelling of the lower extremity will undergo compression ultrasound testing to identify proximal deep vein thrombosis.
62434551|NCT04848350|PLACEBO_COMPARATOR|placebo group|Only a saline solution was applied to the placebo group
62434552|NCT04848350|ACTIVE_COMPARATOR|lavender group|The lavender essential oil was added to the nebulizer and operated on in the SWL room before the procedure,
62434553|NCT04848350|ACTIVE_COMPARATOR|frankincense group|The frankincense essential oil was added to the nebulizer and operated on in the SWL room before the procedure,
62434554|NCT01902134|EXPERIMENTAL|DKP/TRAM followed by DKP/TRAM|Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
62821108|NCT05196269|EXPERIMENTAL|Artificial Intelligence and Digital Health Arm|Using an Artificial Intelligence approach integrated in a cloud-based healthcare platform CANKADO to give the patient complete information about the proposed type of locoregional treatment and access to photographs and data of patients with similar characteristics previously treated with the same technique. All interaction will be through the CANKADO Platform.
62821109|NCT05196269|OTHER|Control Comparator|The standard approach of proposing patients for locoregional treatment with or without printed or digital materials and hypothetic visualization of results.
62434555|NCT01902134|ACTIVE_COMPARATOR|DKP followed by DKP|Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
62434556|NCT01902134|ACTIVE_COMPARATOR|TRAM followed by TRAM|Tramadol-single dose followed by Tramadol-multiple doses
62434557|NCT01902134|OTHER|Placebo followed by DKP/TRAM|Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
62434558|NCT01902134|OTHER|Placebo followed by DKP|Placebo single dose followed by Dexketoprofen-multiple doses
62434559|NCT01902134|OTHER|Placebo followed by TRAM|Placebo single dose followed by Tramadol-multiple doses
62434560|NCT02314520|ACTIVE_COMPARATOR|PICC|Patients randomly assigned to receive a peripherally inserted central catheter and they will be monitored for either having a complication or no complication.
62821110|NCT05136976|PLACEBO_COMPARATOR|Placebo|"Patient with anti-MAG neuropathy will be included. They will randomized in placebo or Rituximab group.~They will have the same premedications prior to rituximab or placebo infusions:~* IV Dexchlorpheniramine Maleate IV: 10 mg~* IV Methylprednisolone: 40 mg~* PO Paracetamol : 1 gram"
62821111|NCT05136976|ACTIVE_COMPARATOR|Rituximab|"Patient with anti-MAG neuropathy will be included. They will randomized in placebo or Rituximab group.~They will have the same premedications prior to rituximab or placebo infusions:~* IV Dexchlorpheniramine Maleate IV: 10 mg~* IV Methylprednisolone: 40 mg~* PO Paracetamol : 1 gram"
62040932|NCT06504615||Cohort 1|Participants with a diagnosis of gastric adenocarcinoma, gastro-esophageal junction adenocarcinoma or esophageal adenocarcinoma
62040933|NCT06504615||Cohort 2|Participants with a diagnosis of untreated, unresectable, advanced, recurrent, or metastatic esophageal squamous cell carcinoma
62040934|NCT05000957|EXPERIMENTAL|"Magic Max (Magic Gyno) Laser Treatment + Colporrhaphy"|"Laser treatment of the vagina, vulva, and paraurethral region with a Magic Max (Magic Gyno) laser. In total, three procedures will be performed with an interval of 4 weeks.~During the procedure, the following sequence of actions will be performed:~1. st Stage - vaginal processing with a conical mirror handpiece,~2. nd Stage - vaginal processing with a corner mirror handpiece,~3. d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece.~A/R colporrhaphy will be performed 1 month after last laser treatment."
62040935|NCT05000957|ACTIVE_COMPARATOR|Colporrhaphy (control group 1)|A/R colporrhaphy only will be performed.
62040936|NCT05000957|OTHER|No Treatment (control group 2)|Any surgery which do not affect condition of vagina, vulva and paraurethral region will be performed.
62040937|NCT05230173|OTHER|Switching Targeted Immunomodulators Treatment|"Participants randomized to a strategy of switching TIM will be switched to one of the preferred agents recommended by clinical guidelines and covered by the participants' insurance formulary as part of routine care, and at the discretion of the site investigator and treating provider. No study-related medications will be provided.~For participants randomized to switch to an alternative TIM, selection of alternative agent will be determined at the discretion of the local site physician in accordance with clinical guidelines on the management of moderate to severe ulcerative colitis, and management of moderate to severe CD from the AGA and ACG.9, 34, 35 These guidelines include recommendations on positioning of TIMs for first line use (TIM-naïve patients) and second-line use (in patients with prior exposure to TIMs)."
62244284|NCT06616272|ACTIVE_COMPARATOR|Early cervical spine focused treatment and standard concussion care|The cervical spine focused treatment will start concurrently with the standard care once the participant is randomized to this group. The participants will receive early cervical spine focused treatment 2x/week for 4 weeks. In addition to the cervical spine focused treatment, this group will also receive standard concussion care interventions individualized to the participant's needs 1x/week concurrently during the same 4-week period of time. After 4 weeks, the participant will discontinue the cervical spine focused treatment but may continue with standard concussion care for an additional 4 weeks (maximum total treatment duration is 8 weeks).
62244285|NCT06616272|ACTIVE_COMPARATOR|Standard concussion care alone followed by delayed cervical spine focused treatment|Participants randomized to the delayed cervical spine focused treatment group will only receive the standard concussion care (individualized to their needs) 1x/week for the initial 4 weeks. At the 4-week timepoint, the cervical spine focused treatment will be added to the standard concussion care at a frequency of twice a week for 4 weeks. Should a participant be cleared for return to activity prior to the end of the 4-week period, cervical spine focused treatment will be suspended. The maximum total treatment duration is 8 weeks; 1x/week for weeks 1-8 for the standard concussion care and 2x/week for weeks 4-8 for the cervical spine focused treatment.
62244286|NCT06575738|NO_INTERVENTION|Observational|Participants complete a set of standardized measures before bariatric surgery, 3 months postoperatively, and 12 months postoperatively.
62244287|NCT06575738|EXPERIMENTAL|Active Medication + Usual Postoperative Care|Participants can be enrolled between 1 and 2 years postoperatively and will receive usual interdisciplinary postoperative care plus weekly subcutaneous injectable semaglutide for 26 weeks. Initial dose is 0.25mg and is escalated every 4 weeks as tolerated (0.5mg, 1.0mg, 1.7mg, 2.4mg) for a total exposure of 26 weeks.
62244288|NCT06575738|ACTIVE_COMPARATOR|Usual Postoperative Care|Participants can be enrolled between 1 and 2 years postoperatively and will receive usual interdisciplinary postoperative care.
62623381|NCT04638556||DPN|The screening criteria for T2DM patients with DPN are as follows: 1. Clear history of type 2 diabetes mellitus. 2. Neuropathy at or after the diagnosis of diabetes. 3. The clinical symptoms and signs were consistent with those of DPN. Clinical symptoms include: numbness or sensation; tingling or tingling; pain; abnormal sensitivity or tenderness after touching. 4. Examination: A. abnormal temperature sense; B. 10 g nylon thread examination, foot sensation decreased or disappeared; C. abnormal vibration sense; D. ankle reflex disappeared; e. two or more items of nerve conduction velocity were slowed down (electromyography or sensory threshold measurement). 5. Nerve injury caused by other diseases or drugs was excluded. Two of the above five items were abnormal, or clinical symptoms + 1 item were abnormal.
62040938|NCT05230173|OTHER|Continuing Index Targeted Immunomodulators Treatment|Participants randomized to a strategy of continuing TIM will continue on their concomitant therapy.
62040939|NCT06429176|ACTIVE_COMPARATOR|SPL84|
62040940|NCT06429176|PLACEBO_COMPARATOR|Placebo|
62244289|NCT06735976|OTHER|PAVM Embolization|This study consists of one group. All participants will undergo PAVM embolization with a LOBO™ device.
62244290|NCT04121403|ACTIVE_COMPARATOR|Rituximab|Biosimilar rituximab concentrate for solution for infusion
62244291|NCT04121403|ACTIVE_COMPARATOR|Cladribine|Mavenclad oral cladribine tablets
62434561|NCT02314520|ACTIVE_COMPARATOR|CVC|Patients randomly assigned to receive a centrally inserted central catheter and they will be monitored for either having a complication or no complication.
62434562|NCT01543815|EXPERIMENTAL|WBT-WEB|Well-Being Therapy based on Web Mobile technology
62600768|NCT02260869|ACTIVE_COMPARATOR|Cooled radiofrequency ablation|Patient is placed in supine position on a fluoroscopic table with a pillow under the popliteal fossa. An anterio-posterior fluoroscopic view of the tibio-femoral joint is obtained. Skin and subcutaneous tissues are anesthetized and a 17 g introducer needle is advanced percutaneously towards the junction of shaft with epicondyle until bone contact is made. The needle is then laterally displaced away from the bone. This process is performed at the superior medial and superior lateral aspects of the femur, and the inferior medial aspect of the tibia. The fluoroscope is placed in lateral view to guide the needle depth to be at the medial third of the femur or tibia. A cooled radiofrequency probe from a Pain Management Radiofrequency kit is advanced through the introducer. Following sensory and motor stimulation, cooled genicular nerve radiofrequency ablation is carried out at 60 Celsius for 150 seconds.
62623382|NCT01184612|ACTIVE_COMPARATOR|(BSF) MI sessions|5 semi-structured manualised MI sessions was conducted by existing prison staff having undergone 3 days of Motivational Interviewing workshop training and 2 days of training with the BSF manual.
62821112|NCT03609645|ACTIVE_COMPARATOR|Fascia iliaca block (FIB)|Group will receive Fascia iliaca block (FIB) with local anesthetic and femoral articular branch block (FAB) with normal saline (Placebo).
62821113|NCT03609645|EXPERIMENTAL|Femoral articular branches block(FAB)|Group will receive Fascia iliaca block (FIB) with normal saline (Placebo) and Femoral AON articular branch block (FAB) with local anesthetic.
62821114|NCT00581308|EXPERIMENTAL|GORE® HELEX® Septal Occluder|Subjects who received a GORE® HELEX® Septal Occluder
62821115|NCT04629508|EXPERIMENTAL|Part 1 : Dose Escalation of itacitinib|Participants will be dosed at different dose levels with a maximum of up to 9 participants per dose level.
62821116|NCT04629508|EXPERIMENTAL|Part 2 : Dose Expansion of itacitinib|Participants will be dosed at the recommended Phase 2 dose (RP2D) identified in Part 1.
62821117|NCT04819451|EXPERIMENTAL|MACSF group|In the experimental group, patients with intracerebral hemorrhage ruptured into the ventricle and patients with subarachnoid hemorrhage were included in the stratified random method. Use Magnesium-Rich Artificial Cerebrospinal Fluid(MACSF) in the CSF replacement, and the remaining treatments should strictly follow the guidelines as same as the control group. The total amount of replacement was generally 30ml, and the replacement was performed once every 3 days. When the RBC count in CSF is less than 100×10\^6/L, the CSF is considered to be cleared. Cerebrospinal fluid replacement is performed up to four times.
62821118|NCT04819451|NO_INTERVENTION|NS group|In the control group, patients with intracerebral hemorrhage ruptured into the ventricle and patients with subarachnoid hemorrhage were included according to the stratified random method. Use the normal saline (0.9% Sodium Chloride Injection) in the CSF replacement, and the remaining treatments should strictly follow the guidelines. The total amount of replacement was generally 30ml, and the replacement was performed once every 3 days. When the RBC count in CSF is less than 100×10\^6/L, the CSF is considered to be cleared. Cerebrospinal fluid replacement is performed up to four times.
62821119|NCT05330897|EXPERIMENTAL|Treatment arm|Implantation of an eCLIPs™ device
62821120|NCT05018624|EXPERIMENTAL|Intervention group|Alcohol brief intervention, leaflets, regular personalized messages on ABI through IM Apps, real-time chat-based support through IM Apps
62821121|NCT05018624|ACTIVE_COMPARATOR|control group|Alcohol brief intervention, leaflets, regular messages on general health through IM Apps
62821122|NCT06062433|EXPERIMENTAL|Pediatric Asthma Intervention Group|Along with clinical standard of care for asthma, subjects will have Asthma-Guidance and Prediction System (A-GPS) with AsthmaTuner (AT) integrated into care.
62821123|NCT06062433|NO_INTERVENTION|Pediatric Asthma Control Group|Subjects will receive clinical standard of care for asthma.
62821124|NCT06062433|NO_INTERVENTION|Clinician Control Group|Clinicians will provide clinical standard of care for pediatric asthma patients.
62821125|NCT06062433|EXPERIMENTAL|Clinician Intervention Group|Clinicians will integrate Asthma-Guidance and Prediction System (A-GPS) with AsthmaTuner (AT) into clinical standard of care for asthma.
62821126|NCT06062433|NO_INTERVENTION|Asthma Care Coordinator Control Group|Asthma Care Coordinators will provide clinical standard of care for pediatric asthma patients.
62821127|NCT06062433|EXPERIMENTAL|Asthma Care Coordinator Intervention Group|Asthma Care Coordinators will integrate Asthma-Guidance and Prediction System (A-GPS) with AsthmaTuner (AT) into clinical standard of care for asthma.
62434563|NCT01543815|ACTIVE_COMPARATOR|CBT|Cognitive Behavior Therapy
62434564|NCT01543815|NO_INTERVENTION|CM|Standardized Care Management
62244292|NCT06534437|EXPERIMENTAL|MEN1703 + glofitamab|"• Participants who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) will be given MEN1703 orally at a dose of 150 mg daily for 7 days or 125 mg daily for 14 days, in 21-day cycles for a maximum of 12 cycles, in combination with glofitamab administered as an IV infusion in a step-up dosing schedule starting with 2.5 mg on day 8 of cycle 1, and10 mg on day 15 of cycle 1, and 30 mg on day 1 from cycle 2 onward until disease progression or withdrawal, for a maximum of 12 cycles (parts 1, 2, 3)).~All participants will be administered 1,000 mg of obinutuzumab as an IV infusion on cycle 1 day 1.~• Participants who have exhausted all standard treatment options (group 2) will receive MEN1703 as a single-agent, at a dose of 125 mg orally every-day for 14 consecutive days in consecutive 21-day treatment cycles, until progressive disease (parts 1 and 2)."
62600769|NCT02260869|ACTIVE_COMPARATOR|Monopolar radiofrequency ablation|Patient is placed in supine position on a fluoroscopic table with a pillow under the popliteal fossa. An anterio-posterior fluoroscopic view of the tibio-femoral joint is obtained. Skin and subcutaneous tissues are anesthetized and a 16 g introducer needle is advanced percutaneously towards the junction of shaft with epicondyle until bone contact is made. The needle is then laterally displaced away from the bone. This process is performed at the superior medial and superior lateral aspects of the femur, and the inferior medial aspect of the tibia. The fluoroscope is placed in lateral view to guide the needle depth to be at the medial third of the femur or tibia. A conventional radiofrequency probe from a Pain Management Radiofrequency kit is advanced through the introducer. Following sensory and motor stimulation, genicular nerve radiofrequency ablation will be carried out at 80 Celsius for 90 seconds.
62821128|NCT02426398||People with Alzheimer's disease|People with Alzheimer's disease
62821129|NCT02426398||Healthy volunteers|Healthy volunteers
62821130|NCT02362815|ACTIVE_COMPARATOR|Apple juice|Patient are allowed to drink up to 400 ml of apple juice
62821131|NCT02362815|NO_INTERVENTION|Control|Patient are not allowed to drink
62821132|NCT05417438|EXPERIMENTAL|Wearable device deployment|Participants will be enrolled in the experimental trial to receive Fitbits and a smartphone app.
62600770|NCT00769067|ACTIVE_COMPARATOR|A|
62821133|NCT03582475|EXPERIMENTAL|Treatment (pembrolizumab, platinum-based chemotherapy)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising either etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1 (Cohort 1), or etoposide IV on days 1-3, carboplatin IV on day 1, and docetaxel IV on day 1 (Cohort 2). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62821134|NCT04431479||Observational (questionnaire, biospecimen, chart review)|Patients complete questionnaires over 10 minutes about physical symptoms, activity level, and emotional well-being and have their medical records reviewed at baseline, 1, 3, and 6 months after starting index treatment, and at start of a new systemic treatment. Patients also undergo collection of blood samples over 1-2 minutes at baseline and at 1 month after starting index treatment, or at a treatment change visit if new therapy has not started.
62821135|NCT05653492|ACTIVE_COMPARATOR|Group 1|30-50 lbs; 1 tablet (30mg/d) 50-70 lbs; 2 tablets (60mg/d) 70-90 lbs; 3 tablets (90mg/d) \>90 lbs; 4 tablets (120 mg/d)
62821136|NCT05653492|ACTIVE_COMPARATOR|Group 2|30-50 lbs; 1 tablet (30mg/d) 50-70 lbs; 1 tablet (30mg/d) 70-90 lbs; 2 tablets (60mg/d) \>90 lbs; 2 tablets (60 mg/d)
62821137|NCT05653492|ACTIVE_COMPARATOR|Group 3|30-50 lbs; 1 tablet (30mg/d) 50-70 lbs; 1 tablet (30mg/d) 70-90 lbs; 1 tablet (30mg/d) \>90 lbs; 1 tablet (30 mg/d)
62821138|NCT06590571|EXPERIMENTAL|TRAcelet™ compression group|the group using TRAcelet™ received 2 hours and 15 minutes of compression from the device with 13 cc of air being blown in, followed by 3 stepwise releases every 15 minutes through counterclockwise rotation of the dial without extracting air using a syringe. This achieved the same 3 hours of compression. The dial started at the triangle position and was set to nine, six, and three at every stepwise decompression. After three hours, the device was released.
62821139|NCT06590571|OTHER|Conventional compression group|Patients who were assigned to the conventional group received radial artery compression by a gauze pad folded into a cuboid shape, fastened with 3M™ Durapore™ surgical tape. The gauze pad was not impregnated with prothrombotic material. Compression was released at 3 hours to check for complications. An additional one hour of compression was applied when incomplete hemostasis or hematoma was identified.
62821140|NCT04451525||Cohort I|Cohort I will focus on data collection on the SOFIA® Flow Plus 6F Aspiration Catheter used with the direct aspiration as first line treatment technique with the intent to evaluate per prespecified endpoints.
62821141|NCT04451525||Cohort II|Cohort II will focus on data collection on MicroVention devices used for acute ischemic stroke treatment with the intent to evaluate standard outcomes while also generating additional research questions for analysis based on data collected.
62821142|NCT00979940|NO_INTERVENTION|No atorvastatin|Patients do not receive Atorvastatin prior to PCI in cath lab
62821143|NCT00979940|EXPERIMENTAL|atorvastatin|Atorvastatin 80mg po given prior to PCI in cath lab
62821144|NCT05556473|EXPERIMENTAL|[18F]FETrp PET radiotracer|All participants will receive the tracer to evaluate the uptake of \[18F\]FETrp PET/CT on intra- and extracranial cancers.
62821145|NCT05070923|EXPERIMENTAL|HealthyLifetime Group|"HL is an 8-week, personalized health coaching program that includes a comprehensive assessment made through a survey and a virtual' home visit (via video), a goal-directed strengthening action plan developed by the participant with the guidance of the nurse, a tailored daily planning guide to enhance action steps and goal attainment, and six weekly 30 minute nurse coaching sessions with participants the Healthie application technology via their personal home computer, Tablet or Smartphone device. If a participant does not use a personal device or the device cannot support the Healthie platform, the HL program will provide a Tablet to them for their use during the program. All video sessions ( ie, home visit, strengthening plan, and weekly coaching sessions will use a two-way video but only the audio portions of the sessions will be recorded. The HL program, tailored to each participant's need for strong and resilient function, encompasses the following key elements:"
62600771|NCT00769067|EXPERIMENTAL|B|
62600772|NCT04868851|ACTIVE_COMPARATOR|Here for Health only|Patients will complete the Here for Health Healthy Lifestyle intervention designed by the Paediatric Diabetes Dietitians at Oxford University Hospitals NHS Foundation Trust.
62244293|NCT06534437|ACTIVE_COMPARATOR|Gofitamab|Participants who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) will receive glofitamab as a single-agent administered as an IV infusion in a step-up dosing schedule starting with 2.5 mg on day 8 of cycle 1, and10 mg on day 15 of cycle 1, and 30 mg on day 1 from cycle 2 onward until disease progression or withdrawal, for a maximum of 12 cycles (part 3).
62600773|NCT04868851|EXPERIMENTAL|mHealth technology assisted exercise counselling (mHealth)|Patients will complete the Here for Health Healthy Lifestyle intervention before completing a 12 week mHealth technology assisted exercise counselling intervention. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 5 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
62821146|NCT05070923|NO_INTERVENTION|Usual Care Group|Participants randomized to the usual care group will be given information about when to expect reminders on the Healthie platform to complete future surveys at the end of week 8, and after three months that will be available on the Healthie Platform for them to fill out and save on the platform. They will also be reminded how to contact the study coordinator if they should have questions. Participants in this group will have the view to other functions on the platform turned off. They will only be able to view documents as the reminders appear for them to complete.
62821147|NCT06584695|EXPERIMENTAL|Transversus abdominis plane group|patients will receive unilateral ultrasound-guided oblique subcostal transversus abdominis plane block block
62821148|NCT06584695|EXPERIMENTAL|External oblique intercostal group|Patients will receive unilateral ultrasound-guided external oblique intercostal block
62821149|NCT06584695|ACTIVE_COMPARATOR|Control group|Patients will receive IV morphine 0.1mg/kg after induction of general anesthesia.
62821150|NCT04250857||Suspected Sudden Cardiac Arrest|All subject with suspected of a circulatory arrest for any cause.
62821151|NCT04216524|EXPERIMENTAL|Treatment (SL-401, venetoclax, chemotherapy)|See detailed description.
62821152|NCT04440475|EXPERIMENTAL|Tap Block|"TAP block at the end of the surgery, in addition to conventional postoperative oral medication as needed~postoperative conventional oral medication as needed: Acetaminophen 650 mg Q 6 hours Ibuprofen 600 mg Q 6 hours Tramadol 50 mg Q 6 hours"
62821153|NCT04440475|NO_INTERVENTION|Conventional postoperative oral medication|postoperative conventional oral medication as needed: Acetaminophen 650 mg Q 6 hours Ibuprofen 600 mg Q 6 hours Tramadol 50 mg Q 6 hours
62244294|NCT05017753|ACTIVE_COMPARATOR|Control group|Standard-of-care medical treatment.
62244295|NCT05017753|EXPERIMENTAL|Intervention group|Thoracentesis in addition to standard-of-care medical treatment.
62821154|NCT05632653|EXPERIMENTAL|CTO-PCI|
62821155|NCT05632653|NO_INTERVENTION|non-CTO-PCI|
62821156|NCT06603116|EXPERIMENTAL|Bioactive Giomer restoration.|material applied according to manufacturer instructions. BEAUTIFIL II LS applied directly into the cavity and create the shape desired in layers not exceeding 2 mm and light cured for 20 seconds
62821157|NCT06603116|ACTIVE_COMPARATOR|Nano-hybrid Composite restoration.|applied to the cavity use the conventional incremental technique according to manufacturer instruction
62821158|NCT02226393|EXPERIMENTAL|Prolonged exposure|See intervention description
62821159|NCT02226393|ACTIVE_COMPARATOR|Child-parent Play Therapy|see intervention description
62821160|NCT06596850|EXPERIMENTAL|Wheelchair Skills Training Program (WSTP)|Standardized wheelchair skills training program.
62434565|NCT04852991|ACTIVE_COMPARATOR|Modified Purandare cervicopexy|Apical prolapse will be corrected by Modified Purandare cervicopexy
62821161|NCT06596850|NO_INTERVENTION|Control|Wait-list control group where participants will receive usual care from their clinician.
62821162|NCT06595316|EXPERIMENTAL|Exercise intervention group|For this group (N=15) the intervention will consist of two supervised sessions per week, which include aerobic and resistance exercise, carried out as previuosly described.
62244296|NCT03769766|ACTIVE_COMPARATOR|Curcumin|"* Other names for the supplement: BCM-95 CG (Biocurcumax),Tumeric~* Manufacture- DolCas Biotech, LLC.~* Classification - type of agent: Supplement~* Protocol dose: 500 mg twice"
62434566|NCT04852991|ACTIVE_COMPARATOR|Abdominal sacrohysterpexy|Apical prolapse will be corrected by Abdominal sacrohysterpexy
62434567|NCT04602390|EXPERIMENTAL|ANK-700 SAD Cohort 1, Dose A|All enrolled patients will receive one dose of ANK-700 Dose A
62434568|NCT04602390|EXPERIMENTAL|ANK-700 SAD Cohort 2, Dose B|All enrolled patients will receive one dose of ANK-700 Dose B
62434569|NCT04602390|EXPERIMENTAL|ANK-700 SAD Cohort 3 Dose C|All enrolled patients will receive one dose of ANK-700 Dose C
62434570|NCT04602390|EXPERIMENTAL|MAD Cohort 4 ANK-700 Dose A or Placebo|All enrolled patients will receive three doses of ANK-700 Dose A or placebo
62600774|NCT02048917|EXPERIMENTAL|High Intensity Counseling + Long Acting NRT + PRN NRT|High Intensity Counseling + Long Acting NRT + PRN NRT
62600775|NCT02048917|EXPERIMENTAL|High Intensity Counseling + bupropion + PRN NRT|High Intensity Counseling + bupropion + PRN NRT
62600776|NCT02048917|EXPERIMENTAL|High Intensity Counseling + varenicline + PRN NRT|High Intensity Counseling + varenicline + PRN NRT
62600777|NCT02048917|EXPERIMENTAL|High Intensity Counseling + Long Acting NRT|High Intensity Counseling + Long Acting NRT
62600778|NCT02048917|EXPERIMENTAL|High Intensity Counseling + bupropion|High Intensity Counseling + bupropion
62600779|NCT02048917|EXPERIMENTAL|High Intensity Counseling + varenicline|High Intensity Counseling + varenicline
62600780|NCT02048917|EXPERIMENTAL|Low Intensity Counseling + Long Acting NRT + PRN NRT|Low Intensity Counseling + Long Acting NRT + PRN NRT
62600781|NCT02048917|EXPERIMENTAL|Low Intensity Counseling + bupropion + PRN NRT|Low Intensity Counseling + bupropion + PRN NRT
62600782|NCT02048917|EXPERIMENTAL|Low Intensity Counseling + varenicline + PRN NRT|Low Intensity Counseling + varenicline + PRN NRT
62434571|NCT04602390|EXPERIMENTAL|MAD Cohort 5 ANK-700 Dose B or placebo|All enrolled patients will receive three doses of ANK-700 Dose B or placebo
62600783|NCT02048917|EXPERIMENTAL|Low Intensity Counseling + Long Acting NRT|Low Intensity Counseling + Long Acting NRT
62600784|NCT02048917|EXPERIMENTAL|Low Intensity Counseling + bupropion|Low Intensity Counseling + bupropion
62600785|NCT02048917|EXPERIMENTAL|Low Intensity Counseling + varenicline|Low Intensity Counseling + varenicline
62244297|NCT03769766|PLACEBO_COMPARATOR|Placebo|"Drug: placebo~placebo orally twice a day Other Names: •sugar pill"
62244298|NCT06735170|EXPERIMENTAL|biologic tuberoplasty group|massive irreparable rotator cuff tear involving the supraspinatus and infraspinatus, no involvement of the subscapularis, centered humeral head on X-Ray examination, and a primary complaint of pain, randomized to biologic tuberoplasty surgery.
62244299|NCT06735170|EXPERIMENTAL|subacromial balloon spacer group|massive irreparable rotator cuff tear involving the supraspinatus and infraspinatus, no involvement of the subscapularis, centered humeral head on X-Ray examination, and a primary complaint of pain, randomized to subacromial balloon spacer.
62600786|NCT00960349|OTHER|Treatment A|Cediranib 20mg + Cisplatin + S-1
62600787|NCT00960349|OTHER|Treatment B|Cediranib 20mg + Cisplatin + Capecitabine
62600788|NCT03090724|EXPERIMENTAL|BIA 5-453 (Young)|"Each subject participated in the study for approximately 7 weeks. Participation included the screening evaluations within 28 days before the first administration, phase A (single dose, a 2-day inpatient period followed by 4 ambulatory visits), phase B (multiple-dose during 7 days, 6 ambulatory visits, followed by a 2-day inpatient period and by 5 ambulatory visits) and a follow-up visit 7 to 10 days after the last administration.~Phase A: single-dose on Day 1, followed by a wash out period Phase B: repeated dose from Day 6 to Day 12 (7 days, steady-state)"
62623383|NCT01184612|ACTIVE_COMPARATOR|(BSF+) MI sessions with supervision|5 semi-structured manualised MI sessions was conducted by ordinary prison staff having undergone 3 days of Motivational Interviewing workshop training and 2 days of training with the BSF manual, followed by ongoing Motivational Interviewing training with feedback based on audio taped sessions in peer supervision groups.
62821163|NCT06595316|NO_INTERVENTION|Control group (usual care)|For the Control group or usual care (N=15), there will be no exercise sessions. Although, the same assessments as the intervention group will be carried out, at the same time-points.
62821164|NCT05537909|EXPERIMENTAL|Patients|adult patients with aseptic abscess syndrome
62821165|NCT05537909|EXPERIMENTAL|control|control An adult person living in the same environment as the case.
62244300|NCT06476314|EXPERIMENTAL|Virtual Reality Glasses Group|Apart from the routine clinic procedure, VR video scenes (contain nature views) will be watched for 5-10 minutes during the procedure.
62244301|NCT06476314|EXPERIMENTAL|Stress Ball Group|Apart from the routine clinic procedure, it will be asked squeezing the stress ball for about 5-10 minutes (squeezing it once every time he counts to five)during the procedure.
62244302|NCT06476314|NO_INTERVENTION|Control Group|Only dressing will be changed just as routine clinic procedure without any intervention
62244303|NCT06736561||Cohort 1|Data on the efficacy and safety of patients who had previously used enshatinib in the neoadjuvant phase were retrospectively collected
62244304|NCT06736561||Cohort 2|Akl-positive patients received enshatinib monotherapy neoadjuvant therapy for 6-12 weeks
62244305|NCT06736561||Cohort 3|Alk-positive patients received neoadjuvant therapy that included enshatinib and did not meet cohort 2 inclusion criteria
62600789|NCT03090724|EXPERIMENTAL|BIA 5-453 (Elderly)|"Each subject participated in the study for approximately 7 weeks. Participation included the screening evaluations within 28 days before the first administration, phase A (single dose, a 2-day inpatient period followed by 4 ambulatory visits), phase B (multiple-dose during 7 days, 6 ambulatory visits, followed by a 2-day inpatient period and by 5 ambulatory visits) and a follow-up visit 7 to 10 days after the last administration.~Phase A: single-dose on Day 1, followed by a wash out period Phase B: repeated dose from Day 6 to Day 12 (7 days, steady-state)"
62600790|NCT03156179||Girls with type 1 diabetes|
62600791|NCT03276468|EXPERIMENTAL|Experimental|Combination of venetoclax, atezolizumab and obinutuzumab
62600792|NCT02758444|ACTIVE_COMPARATOR|Micronutrient Powder (MNP) + 15 mg Zn|1 sachet of Micronutrient Powder (MNP) + 15 mg Zn will be added to a single meal on study day 8
62600793|NCT02758444|ACTIVE_COMPARATOR|MNP + 10 mg Zn|1 sachet of MNP + 10 mg Zn will be added to a single meal on study day 8
62600794|NCT02758444|ACTIVE_COMPARATOR|MNP + 5 mg Zn|1 sachet of MNP + 5 mg Zn will be added to a single meal on study day 8
62600795|NCT02758444|PLACEBO_COMPARATOR|MNP without Zn|1 sachet of MNP without Zn will be added to a single meal on study day 8
62600796|NCT04125784||Lipid-profile|The cohort includes male and female patients diagnosed and confirmed HIV diagnosis who receive HIV related treatment in an extramural setting. All patients are adults (older than 18 years old) and have participated in the original study in 2014.
62600797|NCT05754580|EXPERIMENTAL|High Dose Rate (HDR) Brachytherapy and Stereoscopic Body Radiation (SBRT) treatment|High dose rate Brachytherapy in combination with stereoscopic body radiation therapy.
62600798|NCT06648746||Endoscopic ampullectomy|Consecutive adult patients submitted to endoscopic resection of an ampullary adenoma in each of the participating center for which endoscopic ampullectomy was performed from 1st January 2019 to 31th December will be included. Clinical and demographic data related to the patient, and data pertaining to the ampullary lesion and the endoscopic ampullectomy procedure will be obtained by reviewing the medical records of each participating center.
62600799|NCT04908215|EXPERIMENTAL|INM-755 (cannabinol) cream|Cannabinol cream, topically applied daily in thin layer on non-wound index areas and every 1, 2 or 3 days in thick layer on dressings for index wounds for a 28-day period.
62600800|NCT04908215|PLACEBO_COMPARATOR|Vehicle cream|Vehicle cream, topically applied daily in thin layer on non-wound index areas and every 1, 2 or 3 days in thick layer on dressings for index wounds for a 28-day period.
62600801|NCT06162845|EXPERIMENTAL|Experimental arm recieving free smartohone-based pelvic floor muscle exercise application|Smartphone-based home exercise program for performing pelvic floor muscle exercises
62244306|NCT05424757||Children who are taking PEG 3350|"* Children less than 17 years old who have taken PEG 3350 daily for at least 30 days.~* Dose of PEG 3350 greater than or equal to 0.4 grams/kg/day.~* Preference will be given to children taking at least 17 grams/day.~Notes:~Only children who are already taking PEG 3350 as part of their current medical regimen will be included. Changes to medical therapy are not recommended as part of this study.~Children in three subgroups will be enrolled:~1. Children with no known bowel or nervous system disease or neuropsychiatric symptoms.~2. Children with bowel problems that might increase intestinal permeability.~3. Children with neurologic disease or with neuropsychiatric disorders or symptoms."
62600802|NCT06162845|ACTIVE_COMPARATOR|Control arm recieving paper-based home exercise program|Paper-based home exercise program for performing pelvic floor muscle exercises.
62600803|NCT00279617|ACTIVE_COMPARATOR|Levetricetam|open label treatment
62600804|NCT06624189||Intervention: Auto-pended bot liver ultrasound order|Participants in the intervention group will receive an auto-pended bot liver ultrasound order that will prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening.
62600805|NCT06624189||Control: Usual Care|Participants in the control group will not receive the auto-pended bot liver ultrasound order.
62600806|NCT05561946||Hospitalized Infants|Hospitalized infants that are planned/scheduled to remain in-house for at least 2 days will wear the sock for a minimum of 48 hours and a maximum of 14 days.
62600807|NCT05561946||Healthy Infants|Healthy infants, accompanied by their parent or legal guardian, that are able to stay at a clinical site for 2 days to complete a minimum of 48 hours of monitoring.
62600808|NCT05278338|EXPERIMENTAL|Group a|JMT103 45 mg
62600809|NCT05278338|EXPERIMENTAL|Group b|JMT103 60 mg
62821166|NCT01450020|EXPERIMENTAL|Arm I (PN and ACS material)|Participants receive 4 PN sessions tailored to their needs followed by a 6 month booster session and ACS materials.
62244307|NCT05424757||Children who are not taking PEG 3350|"* Children less than 17 years old who have NOT taken PEG 3350 for at least 30 days.~Children in three subgroups will be included:~1. Children with no known bowel or nervous system disease or neuropsychiatric symptoms.~2. Children with bowel problems that might increase intestinal permeability.~3. Children with neurologic disease or with neuropsychiatric disorders or symptoms."
62821167|NCT01450020|ACTIVE_COMPARATOR|Arm II (ACS material)|Participants receive ACS materials only.
62821168|NCT01063049|ACTIVE_COMPARATOR|Nulytely|Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
62821169|NCT01063049|EXPERIMENTAL|Gatorade/Miralax + Placebo|Gatorade 64 oz (1/2 gallon), Miralax 306 g and a placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy as follows: Miralax 51 g and placebo at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
62821170|NCT01063049|EXPERIMENTAL|Gatorade/Miralax + Bisacodyl|Gatorade 64 oz (1/2 gallon), Miralax 306 g and Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy as follows: Miralax 51 g and Bisacodyl 10 mg at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
62244308|NCT04486157|EXPERIMENTAL|IN-A012|Intravenous administration of IN-A012
62244309|NCT04486157|ACTIVE_COMPARATOR|Akynzeo capsules|Single oral administration of Akynzeo capsules
62244310|NCT05121662||Individuals with Multiple Sclerosis (MS)|Individuals with MS on B-cell depleting therapy, non-cell depleting therapy, or no therapy.
62244311|NCT04961996|EXPERIMENTAL|Arm A: Giredestrant|
62244312|NCT04961996|ACTIVE_COMPARATOR|Arm B: Endocrine Therapy of Physician's Choice|
62244313|NCT04961996|EXPERIMENTAL|Substudy: Giredestrant + Abemaciclib, Then Giredestrant|In this substudy, participants will receive giredestrant in combination with abemaciclib for up to 2 years. Participants will continue with giredestrant monotherapy for an additional 3 years in order to complete a total of 5 years on study treatment.
62244314|NCT06735053|EXPERIMENTAL|Virtual Reality group|The intervention group will carry out a physiotherapy program using virtual reality and conventional treatment for 10 weeks. They will receive 2 weekly treatment sessions of 60 minutes distributed in 45 minutes of physiotherapy using the virtual reality based device (Dynamics VR) following a therapeutic protocol where patients will have exercise sessions based on the theory of motor learning with upper limb and trunk work including fine motor and gross motor exercises, trunk control and postural control exercises, increasing the level of demand or difficulty of the exercises as the weeks go by. Additionally, they will receive a complement of 15 minutes of treatment with conventional physiotherapy directed to the specific needs of each patient.
62244315|NCT06735053|PLACEBO_COMPARATOR|Placebo Virtual reality group|The control group will carry out a conventional physiotherapy program for 10 weeks in which they will receive 2 weekly treatment sessions of 60 minutes distributed in 45 minutes of physiotherapy and 15 minutes of treatment with online virtual reality placebo.
62434572|NCT05842577|EXPERIMENTAL|Telerehabilitation Group (TG)|The TG consisted of 30 sessions lasting approximately 45 minutes (3-5/week for 6-10 weeks) of motor, and cognitive rehabilitation exercises in non-immersive VR-based TR modality using the VRRS Tablet system (Khymeia Srl, Noventa Padovana, Italy).
62434573|NCT05842577|ACTIVE_COMPARATOR|Control Group (CG)|The CG carried consisted of 30 sessions lasting approximately 45 minutes (3-5 days/week for, 6-10 weeks) of at-home conventional rehabilitation via structured self-administered exercises without the use of any technological devices.
62821171|NCT03160638|EXPERIMENTAL|Azithromycin arm|Patients in this arm will be treated with azithromycin 250 mg once daily on top of standard HRZE treatment.
62821172|NCT03160638|NO_INTERVENTION|Standard of care arm|Patients in this arm will receive no additional treatment on top of standard HRZE treatment
62821173|NCT05773937|EXPERIMENTAL|9MW2821|
62821174|NCT02449122|EXPERIMENTAL|Nano drug|Lung cancer patients received nano drug interventional therapy using digital subtraction angiography（DSA）. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
62821175|NCT02449122|ACTIVE_COMPARATOR|Drug MicroSpheres|Lung cancer patients received drug microspheres (HepaSphere Microspheres) interventional therapy using digital subtraction angiography（DSA）.
62821176|NCT02449122|NO_INTERVENTION|Control|Liver cancer patients never received any interventional therapy.
62821177|NCT04854174|EXPERIMENTAL|Healthy Volunteer|Healthy Volunteer
62821178|NCT00960622|EXPERIMENTAL|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
62821179|NCT00960622|ACTIVE_COMPARATOR|Combivir or Trizivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months or Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
62821180|NCT04506437|EXPERIMENTAL|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
62821181|NCT04506437|ACTIVE_COMPARATOR|Standard of care, then family-based mental health navigation|During wait-list period receive standard of care engagement practices and services-as-usual, and after the wait-list period the participants receive the family-based navigator intervention combined with mHealth practices
62821182|NCT06584006|EXPERIMENTAL|Combination Therapy Group|Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections
62244316|NCT06548360|EXPERIMENTAL|Ruxolitinib 1.5 % Cream|Participants received ruxolitinib 1.5% cream, applied topically to the affected area as defined in the protocol.
62600810|NCT05278338|EXPERIMENTAL|Group c|JMT103 90 mg
62600811|NCT05278338|ACTIVE_COMPARATOR|Group d|Denosumab 60 mg
62821183|NCT06584006|EXPERIMENTAL|Monotherapy Group|Recombinant Human Interleukin-2 Injections as a monotherapy
62821184|NCT06584006|NO_INTERVENTION|Control Group|non-intervention
62821185|NCT06582524|EXPERIMENTAL|Weekly subcutaneous (SC) administration of pegzilarginase|All subjects will receive a once weekly (QW) SC dose of pegzilarginase for 12 weeks
62434574|NCT06524778|EXPERIMENTAL|brachytherapy|Patients with locally unresectable giant osteosarcoma masses who meet the criteria are enrolled in the experimental group, and all patients receive a single dose of 10Gy of implantable brachytherapy. Record treatment-related acute events during and after treatment. Follow up on survival and local control after treatment ends, marking the end of the trial treatment.
62434575|NCT02117479|EXPERIMENTAL|Ruxolitinib plus capecitabine|
62600812|NCT05278338|PLACEBO_COMPARATOR|Group e|Placebo
62600813|NCT04355429|EXPERIMENTAL|CAPTOPROL|Inhalation administration by nebulization
62600814|NCT04355429|NO_INTERVENTION|STANDARS CARE|According to surviving covid-Campaign guidelines
62821186|NCT04526613||'healthy' LTBI+ controls who are negative for all of the conditions|'healthy' LTBI+ controls who are negative for all of the listed conditions
62821187|NCT04526613||healthy LTBI negative controls with none of the above conditio|healthy LTBI negative controls with none of the above conditions
62821188|NCT04526613||LTBI+ and helminth infection (positive stool qPCR and/or serol|LTBI+ and helminth infection (positive stool qPCR and/or serology)
62821189|NCT04526613||LTBI+ and severe to moderate malnutrition (BMI <17 kg/m2)|LTBI+ and severe to moderate malnutrition (BMI \<17 kg/m2)
62821190|NCT04526613||LTBI+ and uncontrolled DM (HbA1c >8%)|LTBI+ and uncontrolled DM (HbA1c \>8%)
62040941|NCT04286139|EXPERIMENTAL|SHAPE Intervention|This group will receive the online group based self-management course develop self-management skills in areas including decision making, symptom management and social interaction and to provide information on the disease process and the development of healthy behaviours in a supportive learning environment to prevent problems that are common in the later stages of the disease. Key themes of the intervention will include positive actions to improve and maintain health, how to talk about the impact of the disease on the life of the person with dementia, fear of losing independence and how to tackle and solve other sensitive issues. Running in parallel there will be an e-learning resource available to the carers which covers the similar material covered in the group sessions for the person with dementia, as well as some additional resources and signposting to help them in their role supporting the person with dementia.
62244317|NCT06548360|PLACEBO_COMPARATOR|Vehicle Cream|Participants received vehicle cream, applied topically to the affected area as defined by the protocol.
62244318|NCT04047797|EXPERIMENTAL|Treatment (ixazomib, rituximab)|Patients receive ixazomib by mouth on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of cycle 1. Beginning in cycle 3, patients receive rituximab Intravenous over 4-8 hours on day 1. Treatment repeats every 28 days up to cycle 12 in the absence of disease progression or unacceptable toxicity. Patients benefiting from treatment may continue to receive ixazomib indefinitely in the absence of disease progression or unacceptable toxicity.
62244319|NCT04192435|ACTIVE_COMPARATOR|Tranexamic acid|At induction of anesthesia and prior to surgical incision a bolus of 0.15 ml/kg ( up to a maximum of 15 ml) , and then commence an infusion of 0.05 ml/kg/h until the end of surgery. The total maximal administered study drug volume will be 30 ml.
62434576|NCT02117479|ACTIVE_COMPARATOR|Placebo plus capecitabine|
62600815|NCT02673801||Patient referred to orthopedic clinic|Orthopedic assessment in the outpatient clinic as well as a new algorithm (using patient-reported symptoms and radiographic evaluation) will be applied
62821191|NCT04526613||LTBI+ with more than one of the conditions defined in groups 1|LTBI+ with more than one of the conditions defined in groups 1-3
62821192|NCT04569240|OTHER|Dexcom G6 continuous glucose monitor|All patients will have a Dexcom G6 continuous glucose monitor placed pre-operatively. The glucose readings will be collected for 10 days or upon discharge from the ICU and data will be compared with arterial blood glucose readings or venous Accu-Check Inform II glucose readings
62600816|NCT00801281|ACTIVE_COMPARATOR|R-CVP|Standard arm 1. R-CVP - Rituximab, Cyclophosphamide, Vincristine, Prednisone 2
62600817|NCT00801281|EXPERIMENTAL|R-CHOP|Study arm 2. R-CHOP - Rituximab, Cyclophosphamide, Hydroxyldaunorubicine (doxorubicin), Oncovin (vincristine), Prednisone 1
62600818|NCT00108485|ACTIVE_COMPARATOR|Extended release niacin|Extended release niacin 1500-2000 mg daily versus placebo comparator
62600819|NCT00108485|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62600820|NCT05685862||Group 1|All patients eligible to participate in this study.
62600821|NCT02879994|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62600822|NCT05759429|ACTIVE_COMPARATOR|Integrated multidisciplinary body weight reduction program (BWRP)|
62821193|NCT05525416|EXPERIMENTAL|Low Altitude|Participants will be assessed at an altitude of \<1050m.
62821194|NCT05525416|EXPERIMENTAL|High Altitude|Participants will be assessed on a high-altitude expedition at an elevation of 3,800m.
62821195|NCT03675126|EXPERIMENTAL|SRP-5051|Participants will receive SRP-5051 via intravenous (IV) infusion. Dosage and frequency will be determined from the safety profile of other ongoing SRP-5051 studies.
62600823|NCT05759429|ACTIVE_COMPARATOR|Integrated multidisciplinary body weight reduction program (BWRP) + melatonin|
62244320|NCT04192435|PLACEBO_COMPARATOR|Placebo|At induction of anesthesia and prior to surgical incision a bolus of 0.15 ml/kg ( up to a maximum of 15 ml) , and then commence an infusion of 0.05 ml/kg/h until the end of surgery. The total maximal administered study drug volume will be 30 ml.
62600824|NCT04417972|EXPERIMENTAL|SHR7280 dose 1|oral administration for 21days,Phase I
62600825|NCT04417972|EXPERIMENTAL|SHR7280 dose 2|oral administration for 21days,Phase I
62600826|NCT04417972|EXPERIMENTAL|SHR7280 dose 3|oral administration for 21days,Phase I
62821196|NCT06586905|EXPERIMENTAL|Multiplo Complete Syphilis (TP/nTP) Antibody Test|Participants are tested with investigational devices and conventional syphilis serology tests
62821197|NCT04817670|EXPERIMENTAL|Cohort 1|Participants receive VIT-2763 60 mg, twice a day during 8 weeks.
62821198|NCT04817670|EXPERIMENTAL|Cohort 2|Participants receive VIT-2763 120 mg, twice a day during 8 weeks.
62821199|NCT04817670|EXPERIMENTAL|Cohort 3|Participants receive VIT-2763 120 mg, three times a day during 8 weeks.
62821200|NCT04817670|PLACEBO_COMPARATOR|Cohort 4a|Participants receive a placebo, twice a day during 8 weeks.
62040942|NCT04286139|NO_INTERVENTION|Treatment as usual|Participants in the TAU arm will receive normal services such as clinical reviews, psychiatric appointments and other services when needed. With TAU as the comparator condition ensures that participants receive any needed services and enable comparison between current best practice and the new intervention of SHAPE
62040943|NCT06634030|PLACEBO_COMPARATOR|Saline matrix|Participants receive wound matrix saturated with normal saline.
62040944|NCT06634030|EXPERIMENTAL|rhPDGF-BB matrix|Participants receive wound matrix saturated with rhPDGF-BB.
62040945|NCT06442956|EXPERIMENTAL|Rapid Heat Stress|Participants in the rapid heat stress arm will perform an exercise protocol on a treadmill in a hot, humid environment while wearing firefighter protective gear. This results in an uncompensable heat environment with a rapid increase in core temperature.
62600827|NCT04417972|EXPERIMENTAL|SHR7280 dose 4|oral administration for 21days,Phase I
62600828|NCT04417972|ACTIVE_COMPARATOR|SHR7280 low dose|oral administration for 84days,Phase II
62600829|NCT04417972|ACTIVE_COMPARATOR|SHR7280 high dose|oral administration for 84days, Phase II
62600830|NCT04417972|PLACEBO_COMPARATOR|Placebo|oral administration for 84days, Phase II
62600831|NCT04792671||Perinatal group|females who are pregnancy
62600832|NCT04792671||postpartum group|female who get delivery(from day 1 up to 1 year)
62821201|NCT04817670|PLACEBO_COMPARATOR|Cohort 4b|Participants receive a placebo, three times a day during 8 weeks.
62821202|NCT06586060|EXPERIMENTAL|LUS group|"lung ultrasound guided fluid management guided by B-line score (BLS). In patients with no or mild extravascular lung water (EVLW) increase (BLS = 0-14), a zero fluid balance (FB) will be targeted if no signs of shock are present. In patients with a moderate or severe increase in EVLW (BLS ≥ 15), a daily negative FB of -250 to -1000 mL will be targeted until BLS drops under 15.~To reach daily targeted FB, furosemide-induced diuresis and RRT will be used. Furosemide will be administrated in a stepwise manner considering the previous furosemide dose and the FB achieved. If the targeted FB is achieved from the first day of diuretic administration, the furosemide dose will be maintained. If FB is outside the targeted range, the furosemide dose will be progressively reduced or increased until the goal is achieved. RRT will be used in patients with moderate and severe EVLW increase (BLS ≥ 15) if the targeted FB cannot be reached despite using the maximum furosemide dose of 800 mg/day."
62244321|NCT03715088|EXPERIMENTAL|Older Adults (BMI ≥30 kg/m2)|Individuals aged 65-75 living with obesity will perform the Resistance Training Intervention.
62244322|NCT03715088|EXPERIMENTAL|Younger Adults (BMI ≥30 kg/m2)|Individuals aged 18-30 living with obesity will perform Resistance Training Intervention.
62600833|NCT01837225||Control|Patients in the control arm will not receive the fluorescent contrast agent (5-ALA); however, intraoperative fluorescence imaging will still be performed. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
62600834|NCT01837225||Low Dose Contrast Agent|Patients in the low dose arm will receive 15 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
62244323|NCT06736132|ACTIVE_COMPARATOR|High-flow nasal oxygen, flow rate 45 l/min|Preoxygenation using high-flow nasal oxygen with a flow rate of 45 l/min
62244324|NCT06736132|EXPERIMENTAL|High-flow nasal oxygen, flow rate 70 l/min|Preoxygenation using high-flow nasal oxygen with a flow rate of 70 l/min
62244325|NCT06736132|EXPERIMENTAL|High-flow nasal oxygen, flow rate 95 l/min|Preoxygenation using high-flow nasal oxygen with a flow rate of 95 l/min
62244326|NCT05314764|EXPERIMENTAL|Cefiderocol|Participants will receive intravenous cefiderocol at a dosing regimen consistent with the current prescribing information and according estimated renal function. Each dose will be infused over 3 hours.
62244327|NCT06679413|EXPERIMENTAL|Treatment Arm|Study participants will receive a single dose of the cocktail of probe drugs at pre-specified timepoints followed by a wash out period. The same study participants will then receive repeated oral doses of fenfluramine HCl (ZX008) and a single dose of the cocktail of probe drugs at pre-specified time points during this Treatment Period.
62600835|NCT01837225||High Dose Contrast Agent|Patients in the high dose arm will receive 30 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
62600836|NCT01837225||Intermediate Dose Contrast Agent|Patients in the intermediate dose arm will receive 20 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
62600837|NCT02603068|EXPERIMENTAL|Individual Maximum Tolerated Dose (iMTD)|Subjects are allowed to titrate oral treprostinil up to a maximum dose of 12 mg TID.
62600838|NCT02603068|EXPERIMENTAL|Fixed Dose (FD)|Subjects are allowed to titrate oral treprostinil up to a maximum dose of 1 mg TID.
62821203|NCT06586060|ACTIVE_COMPARATOR|control group|fluid management will be guided to maintain an adequate intravascular volume while minimising weight gain.fluid and diuretics administration will be given according to the clinical judgement of the treating ICU physician. Various parameters will be used to attain this goal based on case-by-case clinical judgment: lung sounds, heart rate, blood pressure, temperature, urine output, FB, lactate, haemoglobin, haematocrit, serum urea, creatinine, sodium, potassium, chloride, and bicarbonate values
62821204|NCT06360380|EXPERIMENTAL|AquaPass|An AquaPass treatment session (up to 5-Hrs.) will be administered in the outpatient settings or at home and supervised by a certified study staff
62821205|NCT06360380|NO_INTERVENTION|Control|An observation visit, during which data will be collected on fluid intake, fluid output, congestion score, body weight, and quality of life. These data will serve as a control for the efficacy primary endpoint comparison.
62821206|NCT06439017||Cases with functional movement disorders|The cases will complete the Mind Excessively Wandering Scale (MEWS) and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), a 36-item self-administered questionnaire. The individual responses will remain anonymous.
62821207|NCT06439017||Healthy controls|The controls will complete the Mind Excessively Wandering Scale (MEWS). The individual responses will remain anonymous.
62434577|NCT01773278|EXPERIMENTAL|antioxidant effects on retinal function|Patients with SLOS will be treated with both cholesterol supplementation and antioxidants. Retinal function will be followed by serial electroretinogram (ERG) testing and pigmentary retinopathy will be followed by Serial Ophthalmologic exams under anesthesia
62600839|NCT02042300||IRIS-Xpedition/Alpine/Sierra Cohort|XIENCE Xpedition/Alpine/Sierra
62821208|NCT06601881|EXPERIMENTAL|Experimental Group- Group I|individuals will do thoracic mobilization exercises and Diaphragmatic Breathing Training
62821209|NCT06601881|ACTIVE_COMPARATOR|Control group- Group II|Control Group will do plasebo Diaphragmatic Breathing Training and plaseboThoracic mobilization exercises
62244328|NCT05393713|EXPERIMENTAL|Treatment (STI-3031)|Patients receive STI-3031 intra-lymphatically via the DoseConnect device over 1-8 hours QW on days 1, 8, 15, 22, 29, and 36 of cycle 1, and Q2W on days 1, 15, and 29 of cycle 2. Treatment repeats every 42 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR at the end of cycle 2 receive 1-2 additional cycles in the absence of disease progression or unacceptable toxicity. Patients with PR or SD at the end of cycle 2 continue treatment for a total of 9 cycles in the absence of disease progression or unacceptable toxicity.
62244329|NCT06046586|EXPERIMENTAL|Internet-delivered psychological treatment, arm #1|Support and information + Behavioral activation
62244330|NCT06046586|EXPERIMENTAL|Internet-delivered psychological treatment, arm #2|Support and information + Systematic exposure with mindfulness training
62244331|NCT06046586|EXPERIMENTAL|Internet-delivered psychological treatment, arm #3|Support and information + Promotion of health behaviors
62040946|NCT06442956|ACTIVE_COMPARATOR|Gradual Heat Stress|Participants in the rapid heat stress arm will perform an exercise protocol on a treadmill in a hot, humid environment while wearing light exercise clothing. This results in an uncompensable heat environment but with a gradual increase in core temperature.
62623384|NCT01184612|ACTIVE_COMPARATOR|(UPI) Usual Planning Interview|5 sessions was conducted by prison staff according to usual working practices, with the exception that content was structured into 5 sessions and audio recorded. The provision of a government decree served as a basis for the intervention, covering planning of prison activities and post release arrangements including strategies for drug use cessation.
62244332|NCT06046586|EXPERIMENTAL|Internet-delivered psychological treatment, arm #4|Support and information + Behavioral activation + Systematic exposure with mindfulness training
62040947|NCT01521676|EXPERIMENTAL|breast cancer|blood and tumor sample
62040948|NCT03458572|EXPERIMENTAL|Intervention|1.5mm Seirin Pyonex needle at LI11 point
62040949|NCT03458572|SHAM_COMPARATOR|Control|0.3mm Seirin Pyonex needle at TB10 point
62040950|NCT04086628||Asthmatic children vaccinated|
62040951|NCT04086628||Asthmatic children unvaccinated|
62244333|NCT06046586|EXPERIMENTAL|Internet-delivered psychological treatment, arm #5|Support and information + Behavioral activation + Promotion of health behaviors
62244334|NCT06046586|EXPERIMENTAL|Internet-delivered psychological treatment, arm #6|Support and information + Systematic exposure with mindfulness training + Promotion of health behaviors
62623385|NCT02112019|EXPERIMENTAL|Sialoendoscopy with saline|By performing a sialoendoscopy, the ducts of the salivary glands are rinsed with saline and possible strictures are dilated
62821210|NCT06561295|NO_INTERVENTION|Early morning timing of spontaneous breathing trial|Early Morning Group: Patients in this group will undergo their SBTs between 4:00 AM and 5:00 AM, following the traditional early morning schedule used in some ICUs.
62821211|NCT06561295|EXPERIMENTAL|Later morning timing of spontaneous breathing trial|Later Morning Group: Patients in this group will have their SBTs scheduled between 8:00 AM and 9:00 AM, closer to the time of day shift rounds.
62821212|NCT03199976|EXPERIMENTAL|Tiotropium Bromide & Salbutamol|Inhaled Tiotropium Bromide 5 µg once a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
62040952|NCT06048822|EXPERIMENTAL|Cancer Survivors|Participation will last approximately 4-6 months. Participants will be encouraged to attend Pickleball sessions at the YMCA at least twice a week. Each session will last 2 hours, and participants will be encouraged to attend at least one hour. Participants will receive a Fitbit to wear continuously 24/7 over 4-6 months to track steps and activity intensity. Participants will also be asked to wear an electronic device (accelerometer) over their right hip during specific time points throughout the study to better understand how pickleball participation contributes to physical activity levels.
62040953|NCT06048822|EXPERIMENTAL|Family or Friend of Cancer Survivors|Participation will last approximately 4-6 months. Participants will be encouraged to attend Pickleball sessions at the YMCA at least twice a week. Each session will last 2 hours, and participants will be encouraged to attend at least one hour. Participants will receive a Fitbit to wear continuously 24/7 over 4-6 months to track steps and activity intensity. Participants will also be asked to wear an electronic device (accelerometer) over their right hip during specific time points throughout the study to better understand how pickleball participation contributes to physical activity levels.
62821213|NCT03199976|ACTIVE_COMPARATOR|Fluticasone Propionate & Salbutamol|Inhaled Fluticasone Propionate 125 µg twice a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
62040954|NCT00679471||Pre-Term|Infants born pre-term with birthweight less than 1KG
62040955|NCT00679471||Full-Term Infants|Well infants who are born full-term
62040956|NCT05750290|EXPERIMENTAL|CKD-702 in combination with irinotecan|
62040957|NCT06170541|EXPERIMENTAL|UHR-CT (Ultra-High-Resolution Computed Tomography-Aquilion Precision)|Participants in this arm undergo CT scans using the Ultra-High-Resolution CT imaging modality.
62040958|NCT06170541|ACTIVE_COMPARATOR|CR-CT (Conventional Resolution Computed Tomography)|Participants in this arm receive CT scans using the Conventional Resolution CT imaging modality.
62040959|NCT06475612||Trauma Patients|The study cohort included 46,808 trauma patients from the Trauma Registry System, covering the period from 2009 to 2021. Of these, 40,068 were adult patients aged 20 years and older.
62040960|NCT06545097|EXPERIMENTAL|Treatment A|Cebranopadol 400/400 ug (once daily)
62821214|NCT03199976|ACTIVE_COMPARATOR|Salbutamol|Inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
62040961|NCT06545097|EXPERIMENTAL|Treatment B|Cebranopadol 200 ug (once daily)
62040962|NCT06545097|PLACEBO_COMPARATOR|Treatment C|Placebo
62040963|NCT05501054|EXPERIMENTAL|Ipilimumab, Nivolumab, and Ciforadenant|To help control advanced renal cell carcinoma.
62040964|NCT04859608|EXPERIMENTAL|Therapeutic drug monitoring|Tailored dosing schedule for eculizumab based on therapeutic drug monitoring
62244335|NCT06046586|EXPERIMENTAL|Internet-delivered psychological treatment, arm #7|Support and information + Behavioral activation + Systematic exposure with mindfulness training + Promotion of health behaviors
62040965|NCT04859608|NO_INTERVENTION|Control|Initial eculizumab schedule is continued (real-life arm). No eculizumab dosages are performed in this arm.
62040966|NCT06720051|EXPERIMENTAL|Group A will undergo intraosseous dexamethasone injection after 3rd molar surgery|In Group A, patients will receive 4 mg dexamethasone intraosseous injection into the bone distal to the socket of impacted third molar immediately after extraction of the third molar and before suturing
62040967|NCT06720051|ACTIVE_COMPARATOR|Group B will undergo submucosal dexamethasone injection after 3rd molar surgery|In Group B, patients will receive 4 mg dexamethasone submucosal injection into the buccal vestibule opposite to the surgical site of impacted third molar immediately after surgery.
62040968|NCT06733714|EXPERIMENTAL|tACS+DCT|5 daily sessions of 30 minutes of DCT using the BrainHQ platform while simultaneously receiving theta tACS (6Hz, 1.6mA) targeting the Left Dorsolateral Prefrontal Cortex.
62244336|NCT06046586|EXPERIMENTAL|Internet-delivered psychological treatment, arm #8|Support and information
62244337|NCT06735066||Transplantation group|adult patients who underwent kidney transplantation
62821215|NCT06420947|EXPERIMENTAL|Group A|Participants in the A group received 2% lidocaine by A model atomizer.
62821216|NCT06420947|EXPERIMENTAL|Group B|Participants in the B group received 2% lidocaine by B model atomizer.
62821217|NCT06420947|EXPERIMENTAL|Group C|Participants in the C group received 2% lidocaine by C model atomizer.
62244338|NCT06226285|EXPERIMENTAL|Informal caregivers|Informal caregivers will participate in a participatory process of development, testing and validation of a technological platform aimed at improving their quality of life, impact of care, occupational balance, self-management of health and empowerment.
62821218|NCT06420947|EXPERIMENTAL|Group D|Participants in the D group received 2% lidocaine by D model atomizer.
62821219|NCT04664517|ACTIVE_COMPARATOR|FIN (Flexible intramedullary nail)|Fracture reduction and fixation using flexible intramedullary nails. Nails size is 0.4 times the smallest diameter of the medullary canal of radius or ulna measured in radiographs.
62821220|NCT04664517|ACTIVE_COMPARATOR|Long arm cast|Fractures are reduced under general anesthesia within 3 days from injury and a synthetic circular above elbow cast in neutral pro-supination is applied for six weeks.
62821221|NCT04664517|OTHER|Patient Choice FIN|Fracture reduction and fixation using flexible intramedullary nails. Nails size is 0.4 times the smallest diameter of the medullary canal of radius or ulna measured in radiographs.
62040969|NCT06733714|SHAM_COMPARATOR|SHAM+DCT|5 daily sessions of 30 minutes of DCT using the BrainHQ platform while simultaneously receiving stimulation with the device in SHAM mode (with Ramp Up, no current during the session period and Ramp down) targeting the Left Dorsolateral Prefrontal Cortex.
62244339|NCT00450658|EXPERIMENTAL|1|HZT-501: Ibuprofen 800mg/Famotidine 26.6mg
62244340|NCT00450658|ACTIVE_COMPARATOR|2|Ibuprofen 800mg
62600840|NCT03170466|EXPERIMENTAL|Primary Palliative Care|The intervention will be delivered through four primary mechanisms. First, an existing HF nurse will deliver the intervention to patients during regularly scheduled visits. Second, telephone calls will reinforce topics. Third, patients will regularly report symptoms through the MyUPMC patient portal. Fourth, the nurse will act as a liaison to communicate concerns to the patient's cardiologist and primary care physician, as well as facilitating other resources (e.g., home health). In addition, follow-up assessments will be completed via phone or email at least 2 weeks post-intervention delivery. Caregivers will complete surveys during the first in-person visit and then during the follow-up assessments.
62600841|NCT03170466|NO_INTERVENTION|Usual Care|Patients randomized to the control arm of this study will continue to receive the standard of high-quality HF care provided to all patients. Control patients may still receive palliative care outside of the study.
62600842|NCT03337581|SHAM_COMPARATOR|group 1.1|Normal saline group
62821222|NCT04664517|OTHER|Patient Choice cast|Fractures are reduced under general anesthesia within 3 days from injury and a synthetic circular above elbow cast in neutral pro-supination is applied for six weeks.
62821223|NCT04665401|ACTIVE_COMPARATOR|Standard MERIT|24 sessions of Metacognition Reflection and Insight Therapy
62040970|NCT06720545|NO_INTERVENTION|Therapeutic HGNS (HGNS-on)|Prior to enrollment in this study, participants will have been implanted with and stabilized on HGNS therapy. As part of clinical care, a therapeutic voltage setting will have been confirmed via overnight sleep study. This arm of the study maintains the participants on the HGNS therapy at the a therapeutic voltage they have been using. This is a representation of the patient's baseline status.
62244341|NCT05285683|ACTIVE_COMPARATOR|Methylphenidate|0.5mg/kg
62244342|NCT05285683|ACTIVE_COMPARATOR|Carbidopa/levodopa,|25mg/100mg
62244343|NCT05285683|PLACEBO_COMPARATOR|Placebo|Oral Pill
62244344|NCT05794906|EXPERIMENTAL|Darolutamide+ADT|Participants will receive darolutamide plus ADT twice daily with food for a pre-specified duration of 24 months.
62244345|NCT05794906|PLACEBO_COMPARATOR|Placebo+ADT|Participants will receive Placebo plus ADT twice daily with food for a pre-specified duration of 24 months.
62244346|NCT06375733|EXPERIMENTAL|Phase 1b:GFH009 & Zanubrutinib|
62600843|NCT03337581|EXPERIMENTAL|group 1.2|0.25μg/kg dexmedetomidine group
62600844|NCT03337581|EXPERIMENTAL|group 1.3|0.5μg/kg dexmedetomidine group
62600845|NCT03337581|EXPERIMENTAL|group 1.4|0.75μg/kg dexmedetomidine group
62600846|NCT03337581|EXPERIMENTAL|group 1.5|1.0μg/kg dexmedetomidine group
62600847|NCT01283334|EXPERIMENTAL|A|Treatment arm with carboplatin, cetuximab and RAD001
62600848|NCT04428242||Group 1|Subjects with normal macular thickness in one or both eyes.
62600849|NCT04428242||Group 2|Subjects with center-involving macular edema due to w/AMD in one or both eyes.
62821224|NCT04665401|EXPERIMENTAL|Tailored MERIT|24 sessions of personalized Metacognition Reflection and Insight Therapy (sessions personalized using real-world interactions)
62821225|NCT06603142|EXPERIMENTAL|AR882 50MG|Titrated from 12.5 mg to 25 mg (2 weeks each), then 50 mg for 4 weeks, with matching Febuxostat placebo.
62821226|NCT06603142|ACTIVE_COMPARATOR|Febuxostat 40MG|Titrated from 20 mg (4 weeks) to 40 mg (4 weeks) Febuxostat, with matching AR882 placebo.
62821227|NCT06603142|EXPERIMENTAL|AR882 75MG|Titrated from 25 mg to 50 mg (2 weeks each), then 75 mg for 4 weeks, with matching Febuxostat placebo.
62821228|NCT05418179|PLACEBO_COMPARATOR|Placebo|Maltodextrin (1 capsule/day)
62821229|NCT05418179|ACTIVE_COMPARATOR|Probiotic|Probiotic (Bifidobacterium animalis subsp. Lactis, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus rhamnosus) - 1 capsule/day
62821230|NCT04214535|EXPERIMENTAL|Tritanium C Anterior Cervical Cage|50 subjects undergoing anterior cervical discectomy and fusion surgery using the Tritanium C Cervical Cage at one or two-levels
62821231|NCT03282656|EXPERIMENTAL|Treatment arm|open-label, non-randomized, single center, pilot and feasibility, single arm cohort study of a single infusion of autologous bone marrow derived CD34+ HSC cells transduced with lentiviral vector containing a short-hairpin RNA targeting BC11A.
62244347|NCT06375733|EXPERIMENTAL|Phase 2: GFH009 & Zanubrutinib|
62244348|NCT03914742|EXPERIMENTAL|Phase 1: Dose Finding|"Recurrent IDH1/2-mutant grade II-III glioma: BGB290: Days 1-28, 60 mg PO BID TMZ: Days 1-28, 20 QD starting dose~TMZ de-escalated treatment schedule if necessary (days 1-21; days 1-14; days 1-7) BGG held constant at 60mg PO BID"
62244349|NCT03914742|EXPERIMENTAL|Phase 2: Arm A Alkylator-resistant|"Grade II-III: Recurrent IDH1/2-mutant glioma (WHO grades II/III) who have failed TMZ AND another alkylator~BGB290 + TMZ at dose combination established in Phase 1"
62244350|NCT03914742|EXPERIMENTAL|Phase 2: Arm B NOT Alkylator-resistant|"Grade II-III:Recurrent IDH1/2-mutant glioma (WHO grades II/III) Failed TMZ OR another alkylator;~\>/=12 months since last treatment~BGB290 + TMZ at dose combination established in Phase 1"
62244351|NCT03914742|EXPERIMENTAL|GBM Arm|Exploratory grade IV patients only BGB290 at Ph II dose for 7 days pre-surgery Progressed following RT + Chemo
62244352|NCT03914742|EXPERIMENTAL|Surgical Arm|Recurrent IDH1/2-mutant glioma (WHO grade II-IV) eligible for re-resection BGB-290: 60mg PO BID for 6 days AND day once day of surgery (day 7)
62244353|NCT00298168|EXPERIMENTAL|1|
62244354|NCT00298168|EXPERIMENTAL|2|
62821232|NCT06602115||Hematoma Expansion Group|Hematoma Expansion Group
62821233|NCT06602115||No Hematoma Expansion Group|Patients without hematoma expansion as defined in the study
62821234|NCT06446453|NO_INTERVENTION|Control|The control group will receive surfactant therapy based on our unit's current surfactant guidelines, including but not limited to a FiO2 requirement ≥ 0.3 on non-invasive positive pressure ventilation.
62821235|NCT06446453|EXPERIMENTAL|Treatment|The treatment group will receive surfactant therapy if the initial LUS at 1-2 hours of life is \> 9 or if they meet our unit's current surfactant therapy guidelines (irrespective of the LUS).
62821236|NCT01412697|EXPERIMENTAL|Fruit and Vegetable Intake Behavioral Intervention|measure fruit and vegetable intake in rural youth based on specific behavioral intervention.
62821237|NCT01412697|NO_INTERVENTION|Control Group|control group received the standard health information
62821238|NCT06599476|EXPERIMENTAL|BioProtect Balloon Implant System|The Bio Protect Balloon Implant System (BioProtectLtd.,TzurYigal,Israel) is an Food and Drug Administration approved rectal spacer that consists of a solid biodegradable balloon-shaped material composed of poly L-Lactide-co-caprolactone
62821239|NCT06507943|EXPERIMENTAL|Promotora|Two Hispanic Federation Promotoras (community health workers) will provide culturally competent, bilingual home visits for asthma-related education and evaluation and support for health-harming legal needs (e.g., mold, rodents), including an initial visit and a follow-up visit 6-8 weeks later.
62821240|NCT06594328|EXPERIMENTAL|mHealth|participants of intervention group will receive text message reminder once a week on their mobile phones to brush and floss properly for the study duration
62821241|NCT06594328|NO_INTERVENTION|Non mHealth|Participants of non-intervention group will not receive text message reminder once a week on their mobile phones to brush and floss properly for the study duration
62821242|NCT01508689|OTHER|Receive cereal bars first|This group will receive Kellogg's Nutri-Grain® cereal bars during the second three weeks of the study.
62821243|NCT01508689|OTHER|Receive cereal bars second|This group will receive Kellogg's Nutri-Grain® cereal bars during the last three weeks of the study.
62821244|NCT03439306||healthy adult volunteer|"Subject is 18 to 50 years of age.~Subject is a non-smoker or who has not smoked within 2 days prior to the study."
62821245|NCT05869708|EXPERIMENTAL|Active Arm|Subjects randomized into the Active arm will receive RS-EFP-NF Prism training as an adjunct to standard of care.
62244355|NCT00298168|PLACEBO_COMPARATOR|3|
62600850|NCT04428242||Group 3|Subjects with center-involving macular edema due to DR or RVO in one or both eyes.
62821246|NCT05869708|SHAM_COMPARATOR|Control Arm|Subjects randomized into the Control arm will receive a Sham-EFP-NF training with the same schedule as the active arm, adjunct to standard of care.
62244356|NCT06736249|EXPERIMENTAL|Sarcopenic group|This group will undergo a DXA total body to confirm sarcopenia
62244357|NCT06736249|OTHER|Control|This group is a control group of young active patients to compare with the sarcopenic group
62244358|NCT03704350|ACTIVE_COMPARATOR|20-24.9 BMI|Participants with a BMI that falls between 20 and 24.9 who will receive the controlled diet
62244359|NCT03704350|ACTIVE_COMPARATOR|25-29.9 BMI|Participants with a BMI that falls between 25 and 29.9 who will receive the controlled diet
62244360|NCT03704350|ACTIVE_COMPARATOR|30-34.9 BMI|Participants with a BMI that falls between 30 and 34.9 who will receive the controlled diet
62244361|NCT03704350|ACTIVE_COMPARATOR|35-39.9 BMI|Participants with a BMI that falls between 35 and 39.9 who will receive the controlled diet
62600851|NCT06648330||Gynaecological cancer surgeries with paraaortic retroperitoneal lymph node dissection|Paraaortic retroperitoneal lymph node dissection was performed in 75 patients with gynaecological cancer surgery
62821247|NCT06604728||Patients affected by IBD in therapy with biological therapies|cohort of patients affected by IBD in therapy with biological drugs, already subjected (retrospective cohort) or who will undergo (prospective cohort) for reasons of clinical practice to switch from the intravenous indication to the corresponding subcutaneous prescription (in particular, from vedolizumab or intravenous infliximab intravenously and to vedolizumab or subcutaneous infliximab).
62821248|NCT05222529|EXPERIMENTAL|Glycopyrronium 25μg|Glycopyrronium 25μg for two weeks
62821249|NCT05222529|EXPERIMENTAL|Glycopyrronium 12.5μg|Glycopyrronium 12.5μg for two weeks
62821250|NCT05222529|PLACEBO_COMPARATOR|Placebo|Placebo for two weeks
62821251|NCT06603909|EXPERIMENTAL|group 1: Use AI to assist nutrition management|"The first step: Preliminary clinical nutrition screening and evaluation. Information of patients' age, stage of nasopharyngeal cancer, treatment stage (radiotherapy, chemotherapy stage) and other information were collected, and the management plan was determined.~The second step: AI-assisted HEN management mode. Regular nutritional monitoring and follow-up of patients were conducted by means of intelligent computer, intelligent App body fat device and mobile communication network collection, and basic signs, nutritional status, nutritional risks and implementation of support programs of patients were managed. Nutritional analysis model and index model are used to start the intelligent daily monitoring management and acute attack early warning mechanism.~The third step: Monitor and alert. The AI system popularized the basic knowledge of nutrition to patients through the App platform."
62821252|NCT06603909|EXPERIMENTAL|group 2: Contact the nutritionist team of the hospital for nutrition management|Contact the nutritionist team of the hospital for nutrition management according to patients' own situation
62244362|NCT03704350|ACTIVE_COMPARATOR|40-44.9 BMI|Participants with a BMI that falls between 40 and 44.9 who will receive the controlled diet
62244363|NCT03704350|ACTIVE_COMPARATOR|45-50 BMI|Participants with a BMI that falls between 45 and 50 who will receive the controlled diet.
62600852|NCT02407054|EXPERIMENTAL|Part A: 200 mg LY3023414 BID + 160 mg of Enzalutamide QD|Participants received 200 milligrams (mg) LY3023414 orally twice daily (BID) during the initial week to assess pharmacokinetics (PK). Thereafter, participants received 200 mg of LY3023414 BID in combination with 160 mg of enzalutamide QD beginning Cycle 1 Day 1. A treatment cycle was defined as 28 days.
62600853|NCT02407054|EXPERIMENTAL|Part B: 200 mg LY3023414 BID + 160 mg Enzalutamide QD|Participants received 200 mg LY3023414 orally BID in combination with 160 mg enzalutamide orally once daily (QD).
62821253|NCT06603909|NO_INTERVENTION|group 3: Do not adopt the two management methods.|blank control group
62849155|NCT02141737|EXPERIMENTAL|group L3|Induction protocol: patients will be given 2 ml lidocaine injection in which 40 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
62849156|NCT03264053|EXPERIMENTAL|SOCKET SHIELD TECHNIQUE|Socket shield is the surgical removal of the frontal aspect of the badly broken root and retaining the lingual aspect so as to prevent crestal bone loss with insertion of the dental implant behind it
62040971|NCT06720545|OTHER|No HGNS therapy (HGNS-off)|HGNS therapy will be turned off by the participant for this arm of the study. This arm will mimic the participant's untreated OSA statement before they had HGNS therapy activated.
62040972|NCT04251819|PLACEBO_COMPARATOR|Placebo|Participants randomized to this arm will receive Placebo.
62040973|NCT04251819|EXPERIMENTAL|Baclofen 5mg|Participants randomized to this arm will receive 5 mg of Baclofen.
62040974|NCT04251819|EXPERIMENTAL|Baclofen 10mg|Participants randomized to this arm will receive 10 mg of Baclofen.
62244364|NCT04408014||HC-USP|Home contacts of health professionals diagnosed with COVID-19 at the Hospital of Clínic of Medicine School of the University of São Paulo
62244365|NCT04408014||CORAS|Refugees living in the city of São Paulo
62244366|NCT04408014||Hemocenter|Blood Donors of the Pró-Sangue Hemocenter Foundation of São Paulo
62244367|NCT04408014||CPP - Butantan Penitentiary Progression Center|Participants of the CPP - Butantan Penitentiary Progression Center
62244368|NCT04408014||CHSP - Penitentiary System Hospital Center|Participants of the CHSP - Penitentiary System Hospital Center
62600854|NCT02407054|ACTIVE_COMPARATOR|Part B: Placebo + 160 mg Enzalutamide QD|Participants received placebo in combination with 160 mg enzalutamide QD.
62821254|NCT06588127|EXPERIMENTAL|Nudge Group|The research formed an intervention team comprising 1 project leader, 2 project members, 1 community general practitioner, and 3 community nurses. The project leader oversees the project's progress and quality, while the project members implement specific intervention measures. The community general practitioner addresses the health issues faced by patients in their daily lives, and the nurses communicate with both patients and project team members. The intervention is executed on-site and online, with online efforts primarily utilizing WeChat, a widely used social tool in China. The research will span 6 months, with data collection occurring at baseline, 3, and 6 months.
62821255|NCT06588127|NO_INTERVENTION|Control Group|According to the Basic Public Health Service Specification of China and the Prevention and Control Management Guidelines for Hypertension and Diabetes in Primary Health care, routine community care for HP and T2DM patients should be conducted, including monitoring blood pressure and blood sugar, follow-up on the health status of patients, and distribution of community health promotion materials.
62821256|NCT03628768||Healthy / Non fallers|Older cognitively healthy individuals Non fallers
62821257|NCT03628768||Healthy / Fallers without injuries|Older cognitively healthy individuals Fallers without injuries
62821258|NCT03628768||Healthy / Fallers with injuries|Older cognitively healthy individuals Fallers with injuries
62821259|NCT03628768||MCI / Non fallers|Older individuals with MCI and mild dementia Non fallers
62821260|NCT03628768||MCI / Fallers without injury|Older individuals with MCI and mild dementia Fallers without injuries
62821261|NCT03628768||MCI / Fallers with injury|Older individuals with MCI and mild dementia Fallers with injuries
62821262|NCT05206708|ACTIVE_COMPARATOR|Standard care group|Standard psychodynamic therapy
62821263|NCT05206708|EXPERIMENTAL|Personalized care|Psychodynamic therapy or interactive guidance therapy
62244369|NCT04408014||SABE (Health, Wellness and Aging)|Participants of the SABE Project (Health, Wellness and Aging)
62244370|NCT04408014||ILPI - Long-Term Care Institution for the Elderly|Residents of the Long-Term Care Institution for the Elderly of Botucatu
62244371|NCT04408014||ICR-USP - Children's Institute of HCFMUSP|Home contacts of children and adolescents diagnosed with COVID-19, attended at the Children's Institute of HCFMUSP
62244372|NCT05315947|EXPERIMENTAL|Treatment A-B|Study participants randomized to this arm will receive a single dose of brivaracetam tablet (Treatment A) as reference and single dose of brivaracetam dry syrup (Treatment B) as test in the treatment sequence A-B at pre-specified timepoints.
62244373|NCT05315947|EXPERIMENTAL|Treatment B-A|Study participants randomized to this arm will receive a single dose of brivaracetam tablet (Treatment A) as reference and single dose of brivaracetam dry syrup (Treatment B) as test in the treatment sequence B-A at pre-specified timepoints.
62821264|NCT05160181||Yogatherapy|Retrospective study on medical file of patients seen in consultation for chronic pain with prescription of Yogatherapy
62821265|NCT03044509||TB exposure|
62821266|NCT03044509||TB infection (latent TB)|
62821267|NCT03044509||TB disease (active TB)|
62821268|NCT05632159|PLACEBO_COMPARATOR|conventional anaesthesia group|Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation.
62821269|NCT05632159|ACTIVE_COMPARATOR|Mg sulphate group|Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation. With extra administration of intraoperative Magnesium sulphate 30 mg /kg as loading dose over 10 min then 10 mg /kg/ has maintenance dose
62821270|NCT06598982||patients with systemic sclerosis|
62244374|NCT06734260|ACTIVE_COMPARATOR|H-KA-dual-14|"14 days(Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 1000mg/ time, 3 times/day, oral)"
62244375|NCT06734260|EXPERIMENTAL|L-KA-dual-14|"14 days(Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 1000mg/ time, 2 times/day, oral)"
62821271|NCT04073875||Bioprosthetic aortic valve|Single 18F-GP1 PET-CT
62821272|NCT04073875||Bioprosthetic aortic valve thrombus - repeat imaging|18F-GP1 PET-CT at baseline and 3 months
62849157|NCT03264053|ACTIVE_COMPARATOR|Conventional immediate implantation|Conventional immediate implantation is the surgical removal of the entire badly broken root
62849158|NCT04334083|EXPERIMENTAL|Emergency physicians|actors during the work
62849159|NCT04334083|EXPERIMENTAL|medical externship student|spectator during the emergency physician work
62849160|NCT04645719|PLACEBO_COMPARATOR|Lactate ringer group|Patients will receive only general anesthesia
62040975|NCT06639061|ACTIVE_COMPARATOR|Trauma memory reactivation + targeted hippocampal TMS|Brain stimulation using repetitive transcranial magnetic stimulation (rTMS) will be given after a deliberate memory re-activation, using repetitive pulses at 1Hz frequency for 15 minutes, once a week over 5 weeks. The scalp stimulation area will be determined based on a resting state fMRI scan identifying a cortical area that is most strongly functionally connected to the left hippocampal target of each patient.
62040976|NCT06639061|SHAM_COMPARATOR|Trauma memory reactivation + targeted sham TMS|Brain stimulation using repetitive transcranial magnetic stimulation (rTMS) will be given after a deliberate memory re-activation, using repetitive pulses at 1Hz frequency for 15 minutes, once a week over 5 weeks. The scalp stimulation area will be determined based on a resting state fMRI scan identifying a cortical area that has near zero functional connectivity with the left hippocampal target of each patient.
62040977|NCT06265350|ACTIVE_COMPARATOR|Bevacizumab+Cadonilimab group|Patients accepted Bevacizumab (7.5mg/kg，Q3W， IV) plus Cadonilimab (375mg，Q3W， IV)
62040978|NCT06265350|EXPERIMENTAL|Cryoablation+Bevacizumab+Cadonilimab|Patients accepted Cryoablation of pulmanary metastases combined with Bevacizumab (7.5mg/kg，Q3W， IV) and Cadonilimab (375mg，Q3W， IV)
62040979|NCT02808624|EXPERIMENTAL|Treatment group|this arm will receive L-CARNOSINE PO (each patient will receive 1 tablet daily and each tablet contains 500 mg thus a total of 500 mg per day) together with their chemotherapy wich is oxaliplatin.
62040980|NCT02808624|NO_INTERVENTION|Control group|This arm wont receive L-CARNOSINE, they will receive their chemotherapy (oxaliplatin) only.
62040981|NCT06479161|ACTIVE_COMPARATOR|TXA|- 1.95 grams oral TXA (tranexamic acid) (3- 650 mg tablets) administered postop day one, postop day two and postop day three. Compounded by registered pharmacist and labeled with subject name and instructions for use.
62244376|NCT06734260|EXPERIMENTAL|H-KA-dual-10|"10 days(Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 1000mg/ time, 3 times/day, oral)"
62040982|NCT06479161|PLACEBO_COMPARATOR|Placebo|- 3 tablets administered postop day one, postop day two and postop day three. Compounded by registered pharmacist and labeled with subject name and instructions for use.
62040983|NCT02635854|EXPERIMENTAL|Test group|The test group (Septic choc group) includes 15 patients suffering from septic shock in intensive care unit.
62040984|NCT02635854|OTHER|Control group|The control group (Orthopedic surgery group) includes 15 patients recruited from the orthopedic surgical anesthesia consultation programmed for a prosthetic hip or knee pose.
62040985|NCT03849274|EXPERIMENTAL|Smart Scar Care Pad+Pressure Garment|For experiment group, subject will be intervened by SSCP plus PG
62040986|NCT03849274|ACTIVE_COMPARATOR|Pressure Garment|For control group, subject will be intervened by conventional PG only
62434578|NCT01773278|EXPERIMENTAL|antioxidant effects on hearing|Patients with SLOS will be treated with cholesterol and antioxidant medication and their hearing will be followed by serial brainstem audiometry (ABR)
62849161|NCT04645719|ACTIVE_COMPARATOR|Real weight group|Patients who will receive general anesthesia and magnesium sulfate infused at a dose of 15 mg.kg-1.h-1 based on the actual body weight
62849162|NCT04645719|ACTIVE_COMPARATOR|Corrected ideal weight group|Patients who will receive general anesthesia and magnesium sulfate infused at a dose of 15 mg.kg-1.h-1 based on the corrected ideal weight
62849163|NCT04013061||Standard consultation|
62849164|NCT04013061||Pharmacist-anesthesiologist consultation|
62849165|NCT04660097|OTHER|Outcome of Durvalumab-Etoposide-platinum in untreated ES-SCLC(CASPIAN trial)|The outcome of CASPIAN
62849166|NCT01461109|EXPERIMENTAL|Assess [18F] CFPyPB and PET imaging|To assess \[18F\]CFPyPB and PET imaging
62821273|NCT02674035|ACTIVE_COMPARATOR|Device: 2-0 monofilament nylon suture|Plication of the anterior rectus sheath (correction of diastasis of the rectus abdominis muscles) was performed in two layers with Device 2-0 monofilament nylon suture (control group). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
62040987|NCT03849274|NO_INTERVENTION|Non-eligible patients (with VSS less than 4)|Non-eligible subjects with VSS less than 4 will be followed up for 6 months and assessment results will be recorded.
62821274|NCT02674035|ACTIVE_COMPARATOR|Device: Single layer 2-0 monofilament|Single layer with a Device 2-0 monofilament nylon suture (correction of diastasis of the rectus abdominis muscles) (group I). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
62821275|NCT02674035|ACTIVE_COMPARATOR|Device: Barbed suture Quill Nylon 1|Using a continuous Device Barbed suture Quill Nylon 1 (correction of diastasis of the rectus abdominis muscles) (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
62821276|NCT04370301|EXPERIMENTAL|Cohort I (JAK inhibitor, conditioning, GVHD prophylaxis)|"JAK INHIBITOR THERAPY: Patients receive a JAK inhibitor at least 8 weeks prior to the start of HCT conditioning through day -4 before transplantation.~CONDITIONING: Patients receive melphalan IV over 1 hour on day -5, fludarabine IV over 30-60 minutes on days -5 to -2, and undergo TBI on day -1 or day -1 and day 0.~TRANSPLANT: Patients receive peripheral blood stem cell infusion on day 0.~GVHD PROPHYLAXIS: Patients then receive cyclophosphamide IV over 3 hours on days 3-4, tacrolimus IV beginning day 5 then PO for about 6 months, mycophenolate mofetil PO BID or TID beginning day 5 for 6 weeks, and G-CSF SC beginning day 7 until neutrophil recovery is \> 1,500/mm\^3.~All patients undergo MRI, CT, bone marrow biopsy and aspiration and blood sample collection throughout the trial. Patients also undergo ECHO or MUGA on the trial."
62849167|NCT02223702|ACTIVE_COMPARATOR|amoxicillin+metronidazole|amoxicillin+metronidazole group received a combination of 500 mg of amoxicillin and 500 mg metronidazole three times per day for 7 days.
62040988|NCT06229145|EXPERIMENTAL|Pegloticase + Methotrexate Q4W|16 mg pegloticase will be administered intravenously every 4 weeks for 24 weeks during double blind treatment and 24 weeks during open label.
62040989|NCT06229145|EXPERIMENTAL|Pegloticase + Methotrexate Q2W|8 mg pegloticase will be administered intravenously every 2 weeks for 24 weeks during double blind treatment and 16 mg pegloticase every 4 weeks for 24 weeks during open label.
62849168|NCT02223702|EXPERIMENTAL|moxifloxacin|The moxifloxacin group received 400 mg moxifloxacin, once in a day for 7 days.
62040990|NCT02807896||pancreatic cancer|pancreatic cancer 88
62040991|NCT02807896||bile duct cancer|bile duct cancer 101
62040992|NCT02807896||stomach cancer|stomach cancer 9
62040993|NCT02807896||colon cancer|colon cancer 5
62040994|NCT02807896||normal group|normal group 29
62040995|NCT01191164|EXPERIMENTAL|Study Arm|
62040996|NCT05652270|ACTIVE_COMPARATOR|Goal Attainment Intervention|
62040997|NCT05652270|ACTIVE_COMPARATOR|Goal Development Intervention|
62040998|NCT05652270|ACTIVE_COMPARATOR|Goal Development and Tracking Intervention|
62040999|NCT06724900|EXPERIMENTAL|KB304|
62849169|NCT05553301|EXPERIMENTAL|Group 1: Quadrivalent Influenza mRNA Vaccine MRT5407 dose level 1|participants will receive a single dose of QIV mRNA vaccine (dose level 1)
62849170|NCT05553301|EXPERIMENTAL|Group 2: Quadrivalent Influenza mRNA Vaccine MRT5407 dose level 2|participants will receive a single dose of QIV mRNA vaccine (dose level 2)
62849171|NCT05553301|ACTIVE_COMPARATOR|Group 3: RIV4|participants will receive a single dose of RIV4 vaccine
62041000|NCT06724900|PLACEBO_COMPARATOR|Placebo|
62041001|NCT05051761|EXPERIMENTAL|Jaktinib 50mg BID|Participants received Jaktinib 50mg tablets, orally, twice daily (BID) for up to 24 weeks.
62041002|NCT05051761|EXPERIMENTAL|Jaktinib 75mg BID|Participants received Jaktinib 75mg tablets, orally, twice daily (BID) for up to 24 weeks.
62041003|NCT05051761|PLACEBO_COMPARATOR|placebo|Participants received Jaktinib matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.
62041004|NCT06495294|EXPERIMENTAL|Whole Blood (WB)|"The use of Whole Blood (WB), leukocytes reduced is indicated for treatment of patients with clinically significant bleeding and have low anti-A and anti-B titres.~Patients will be administered up to 2 units of whole blood administered via either intravenous (IV) or intraosseous (IO) route, according to standard practice at Ornge AAS."
62041005|NCT06495294|ACTIVE_COMPARATOR|Red Blood Cells and Plasma|"The control arm will consist of 2 units of RBC and 2 units of plasma (dependent on the standard practice of the Ornge AAS).~RBC and plasma may be administered via either the intravenous (IV) or intraosseous (IO) route, according to standard clinical practice at Ornge AAS."
62041006|NCT01292239|EXPERIMENTAL|TMC435 100 mg 12 Wks + PR 24/48|Participants received TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment was stopped at Week 24 for participants who achieved HCV RNA \< 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable HCV RNA at Week 12. All other participants continued PR until Week 48.
62041007|NCT01292239|EXPERIMENTAL|PBO 12 Wks + PR 48|Participants received placebo (PBO) once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.
62041008|NCT00361374|EXPERIMENTAL|EPA|Eicosapentaenoic acid (EPA) Omega-3, 1g/day
62041009|NCT00361374|EXPERIMENTAL|DHA|Docosahexaenoic acid (DHA) Omega-3, 1g/day
62041010|NCT00361374|PLACEBO_COMPARATOR|Placebo|Placebo capsule (980mg soybean oil)
62041011|NCT02846623|EXPERIMENTAL|Cohort I (obinutuzumab, atezolizumab, venetoclax)|Patients receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-9 and atezolizumab IV over 30-60 minutes on days 3-4 of cycle 1 and on days 1-2 of cycles 2-9. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 3, patients also receive venetoclax PO on days 1-28. Treatment repeats every 28 days for 14 cycles in the absence of disease progression or unacceptable toxicity.
62821277|NCT04370301|EXPERIMENTAL|Cohort II (JAK inhibitor, conditioning, GVHD prophylaxis)|"JAK INHIBITOR THERAPY: Patients receive a JAK inhibitor at least 8 weeks prior to the start of HCT conditioning through day -4 before transplantation. Additionally, patients receive a JAK inhibitor following transplantation beginning day 5 through 9-12 months after transplant.~CONDITIONING: Patients receive melphalan IV over 1 hour on day -5, fludarabine IV over 30-60 minutes on days -5 to -2, and undergo TBI on day -1 or day -1 and day 0.~TRANSPLANT: Patients receive peripheral blood stem cell infusion on day 0.~GVHD PROPHYLAXIS: Patients then receive cyclophosphamide IV over 3 hours on days 3-4, tacrolimus IV beginning day 5 then PO for about 6 months, mycophenolate mofetil PO BID or TID beginning day 5 for 6 weeks, and G-CSF SC beginning day 7 until neutrophil recovery is \> 1,500/mm\^3.~All patients undergo MRI, CT, bone marrow biopsy and aspiration and blood sample collection throughout the trial. Patients also undergo ECHO or MUGA on the trial."
62821278|NCT06318468|EXPERIMENTAL|Humanoid diagrams training program|The experimental group will receive the nursing health assessment teaching for 50 minutes and discussion using humanoid diagrams for 40 minutes to learn comprehensive nursing assessment.
62821279|NCT06318468|ACTIVE_COMPARATOR|comparison group|The comparison group will receive health assessment teaching for 50 minutes and discussion using case discussion for 40 minutes to learn comprehensive nursing assessment.
62821280|NCT04310462|EXPERIMENTAL|New eRX Interface|Providers assigned to the intervention arm will be presented with a new eRX interface upon writing new prescriptions for hydroxychloroquine in the EHR.
62821281|NCT04310462|NO_INTERVENTION|Standard Interface|Providers assigned to the no intervention arm will be presented with the usual ordering interface when prescribing new prescriptions for hydroxychloroquine in the EHR.
62821282|NCT05175547|ACTIVE_COMPARATOR|Intensive blood pressure management group|Target blood pressure of 90-120mmHg (Intensive BP management group)
62821283|NCT05175547|ACTIVE_COMPARATOR|Standard blood pressure management group|Target blood pressure of 90-160mmHg (Standard BP management group)
62821284|NCT04760613|ACTIVE_COMPARATOR|Cannabidiol (CBD)|
62821285|NCT04760613|PLACEBO_COMPARATOR|Placebo (PCB)|
62821286|NCT06600217||Healthy subjects|
62821287|NCT05830812||adenocarcinoma in situ|Adenocarcinoma in situ is defined as a small (≤3 cm) localized nodule with lepidic growth, mostly non-mucinous.
62821288|NCT05830812||minimally invasive adenocarcinoma|Minimally invasive adenocarcinoma defined as a small (≤3 cm) solitary adenocarcinoma with a predominantly lepidic pattern and ≤5 mm invasion in greatest dimension.
62821289|NCT05830812||invasive adenocarcinoma|Invasive adenocarcinoma is a malignant epithelial tumor with glandular differentiation, mucin production, or pneumocyte marker expression. The tumors show an acinar, papillary, micropapillary, lepidic, or solid growth pattern, with either mucin or pneumocyte marker expression. The invasive ademocarcinoma component should be present in at least one focus measuring \>5mm in greatest dimension.
62821290|NCT05542420||Real world adult population with type 2 diabetes mellitus (T2DM)|
62821291|NCT05292664|EXPERIMENTAL|Cohort A|"For Part 1, participants will receive:~* Patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). It is expected that up to 18 people will participate in Part 1 (Dose Determination) and an additional 14-20 people will participate in Part 2 (Dose Expansion) of this cohort Treatment cycle is approximately 28 days for up to 4 cycles~  * Venetoclax-once daily on predetermined days per protocol~* Azacitidine-once daily on predetermined days per protocol~  * Cytarabine, Methotrexate, Hydrocortisone and Leucovorin will be given only if MDS/leukemia cells are detected in spinal fluid per determination of treating physician"
62821292|NCT05292664|EXPERIMENTAL|Cohort B|"Patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) with an underlying genetic condition that increases their risk for developing treatment-related toxicities. It is expected that up to 18 people will participate in Part 1 (Dose Determination) and an additional 6 people will participate in Part 2 (Dose Expansion) of this cohort.~* Venetoclax-once daily on predetermined days per protocol~* Azacitidine-once daily on predetermined days per protocol~* Cytarabine, Methotrexate, Hydrocortisone and Leucovorin will be given only if MDS/leukemia cells are detected in spinal fluid per determination of treating physician"
62821293|NCT05292664|EXPERIMENTAL|Cohort C|"Patients with relapsed/refractory acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LBL) or acute leuekmai of ambiguous lineage. It is expected that up to 18 people will participate in Part 1 (Dose Determination) and an additional 12 people will participate in Part 2 (Dose Expansion) of this cohort.~Cohort C: Treatment cycle is approximately 32 days for one cycle and will be a single treatment cycle:~Dosage, duration and timings as outlined in protocol.~* Venetoclax~* Dexamethasone~* Vincristine~* Doxorubicin~* Dexrazoxane~* Calaspargase pegol~  ---Short acting Erwinia preparations (recombinant or native Erwinia asparaginase) may be used for participants with known pegaspargase or calaspargase pegol allergy~* Cytarabine~* Methotrexate~* Hydrocortisone~* Leucovorin- \*Cytarabine, Methotrexate, Hydrocortisone and Leucovorin may be given more frequently if leukemia/lymphoma cells are detected in spinal fluid),"
62821294|NCT05642741||Hypoparathyroidism after total thyroidectomy|Adult patients definitive post-thyroidectomy HoPT defined by a parathyroid hormone (PTH) concentration ≤ 25 pg/mL more than 6 months after the operation and who require treatment with vitamin D and/or calcium supplementation. Each patient will complete a questionnaire twice (3 weeks apart +/- 7 days). The questionnaire, which evaluates the severity of clinical symptoms related to HoPT and their impact on quality of life, is adapted to this pathology.
62821295|NCT04927442||Covid-19 patients|Patients, male or female, 18 to 65 years old, who tested positive for COVID-19 (PCR or rapid test) =5 days before enrollment.
62821296|NCT03571438|EXPERIMENTAL|CK2(CX4945) and ATM(Ku 60019)|Treatment of cell culture with a combination of CK2 and ATM inhibitors serine/ threonin Kinase combination
62041012|NCT02846623|EXPERIMENTAL|Cohort II (obinutuzumab, atezolizumab, venetoclax)|Patients receive obinutuzumab intravenously IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-9 and atezolizumab IV over 30-60 minutes on days 3-4 of cycle 1 and on days 1-2 of cycles 2-9. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 2, patients receive venetoclax PO on days 1-28. Treatment repeats every 28 days for 25 cycles in the absence of disease progression or unacceptable toxicity.
62821297|NCT03571438|ACTIVE_COMPARATOR|Sunitinib|Treatment of cell culture with Sunitinib
62041013|NCT04508699|EXPERIMENTAL|Developmental language disorder|Children with language impairment but in the absence of cognitive deficits
62041014|NCT04508699|ACTIVE_COMPARATOR|Typical language|Children with typical language development and typical cognitive development
62041015|NCT04666610|EXPERIMENTAL|Brivaracetam 200 mg|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to brivaracetam (BRV) 200mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period."
62041016|NCT04666610|EXPERIMENTAL|Placebo to 200 mg brivaracetam|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to 'placebo to BRV 200mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 200mg/day (or equivalent dose) during the AT period."
62041017|NCT04666610|EXPERIMENTAL|Brivaracetam 100 mg|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to BRV 100mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period."
62041018|NCT04666610|EXPERIMENTAL|Placebo to 100 mg brivaracetam|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to 'placebo to BRV 100mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 100mg/day (or equivalent dose) during the AT period."
62041019|NCT04666610|EXPERIMENTAL|Optimal dose of BRV (defined following Stage 1)|"Placebo-Controlled (PC) and Active Treatment Period (AT):~Stage 2: Study participants will be randomized in Stage 2 to receive a fixed dose of the optimal dose of brivaracetam (defined following Stage 1). Study participants randomized to the BRV optimal dose will receive this dose during the 2-week PC period and subsequent 11-week AT period."
62041020|NCT04666610|EXPERIMENTAL|Placebo to BRV optimal dose (defined following Stage 1)|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 2: Study participants will be randomized in Stage 2 of the study to 'placebo to BRV optimal dose'. Study participants randomized to placebo to brivaracetam (BRV) optimal dose will receive placebo during the PC period followed by BRV optimal dose during the AT period."
62041021|NCT04666610|EXPERIMENTAL|Brivaracetam received during RDW|"Randomized Withdrawal (RDW) Period:~Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Participants who are randomized to this arm will continue on the Brivaracetam dose they were receiving in the AT period."
62041022|NCT04666610|EXPERIMENTAL|Placebo received during RDW|"Randomized Withdrawal (RDW) Period:~Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Study participants who are randomized to the placebo arm in the RDW Period will be tapered down to 0 mg and receive 0 mg for 2 weeks."
62041023|NCT01106833|ACTIVE_COMPARATOR|calcineurin inhibitor|Sirolimus + calcineurin inhibitor + prednisone
62041024|NCT01106833|EXPERIMENTAL|Sirolimus and prednisone|Sirolimus + prednisone
62041025|NCT06643117|EXPERIMENTAL|FYB206|
62041026|NCT06643117|ACTIVE_COMPARATOR|Keytruda|
62821298|NCT03571438|ACTIVE_COMPARATOR|Pazopanib|Treatment of cell culture with Pazopanib
62821299|NCT03571438|ACTIVE_COMPARATOR|Temsirolimus|Treatment of cell culture with Temsirolimus
62041027|NCT01394393|EXPERIMENTAL|ECT|Experiential-Cognitive Therapy for Obesity
62244377|NCT06686394|EXPERIMENTAL|Patritumab deruxtecan plus trastuzumab|Participants receive patritumab deruxtecan intravenous (IV) infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.
62244378|NCT06686394|EXPERIMENTAL|Patritumab deruxtecan plus pertuzumab and trastuzumab|Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.
62244379|NCT06686394|EXPERIMENTAL|Patritumab deruxtecan plus trastuzumab and tucatinib|Participants receive patritumab deruxtecan IV infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks), and tucatinib is administered orally twice daily for each 21-day cycle, until disease progression, intolerable toxicity, or investigator decision.
62244380|NCT05908344|EXPERIMENTAL|Activated Sleep Pad controller|Treatment dosing is under participant control, by physical proximity/orientation to the Sleep Pad pad portion of the Sleep Pad system, and by a manually operated power button on an activated bedside controller portion of the Sleep Pad system. Dosing is pre-set at a stable level across all participants. Dosing occurs throughout a participant's typical nocturnal sleep period, nightly, unless manually paused by the participant.
62041028|NCT01394393|ACTIVE_COMPARATOR|BCT|Cognitive behavioral treatment program
62041029|NCT01394393|SHAM_COMPARATOR|NT|Nutritional groups In this condition (NT) the participants enter only 5 weekly nutritional groups held by dietitians.
62244381|NCT05908344|SHAM_COMPARATOR|Deactivated Sleep Pad controller|Use of the Sleep Pad system is consistent with the Experimental arm, excepting that a deactivated bedside controller portion of the Sleep Pad system is used.
62821300|NCT06494267|EXPERIMENTAL|Experimental|Students will be videotaped while performing a nasogastric tube placement and will be asked to make a self-assessment.
62821301|NCT06494267|NO_INTERVENTION|Control|No application will be made.
62849172|NCT05553301|ACTIVE_COMPARATOR|Group 4: QIV-SD|participants will receive a single dose of QIV-SD vaccine
62244382|NCT06138782|EXPERIMENTAL|TMS (Aim 2)|Our protocol consists of five treatments of inhibitory continuous TBS (cTBS) to the R OFC lasting three minutes delivered every hour over the course of 10 days (2 weeks) for a total of 50 treatments.
62244383|NCT06736158|EXPERIMENTAL|Early Genomic Testing Diagnostic Pathway|Participants will receive early genomic testing in addition to standard diagnostic testing.
62244384|NCT06736158|NO_INTERVENTION|Standard Diagnostic Pathway|Participants will receive standard diagnostic testing with the option of receiving genomic testing after 12 months.
62244385|NCT03691935|EXPERIMENTAL|Ropivicaine|Erector Spinae Block of 20ml 0.5% ropivicaine bolus, connected to a pump containing 0.2% ropivicaine receiving 15ml every 3 hrs.
62244386|NCT03691935|SHAM_COMPARATOR|Normal Saline|Erector Spinae Block of 20ml normal saline placebo bolus, then connected to pump of normal saline receiving 15ml every 3 hrs.
62244387|NCT04640298|EXPERIMENTAL|Cingal|Single injection of Cingal into the hip joint of subjects diagnosed with osteoarthritis of the hip.
62244388|NCT00041054|EXPERIMENTAL|carboplatin + etoposide + exisulind|"Patients receive carboplatin IV over 30 minutes on day 1 and etoposide IV over 30-60 minutes on days 1-3. Patients also receive oral exisulind twice daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year and then every 4 months for 2 years."
62434579|NCT01773278|EXPERIMENTAL|Antioxidant effect on Oxysterols|Patients with SLOS will be treated with antioxidants and cholesterol. Blood oxysterol levels will be measured. Future focus will be on being able to use oxysterol levels to regulate antioxidant doses, and to determine which particular antioxidants might have the most benefit in lowering oxysterols
62600855|NCT04678427|EXPERIMENTAL|Supportive Care (TEAM Me)|Patients complete a 6-minute walk test and a timed get up and go test on the day of hospital admission, on days 0 (day of stem cell transplant) and 21, the day of discharge, and day 100. Patients also complete surveys over 10 minutes about quality of life and fatigue levels on the day of hospital admission, on days 0 (day of stem cell transplant) and 21, the day of discharge, and day 100. Patients who are able and allowed to, may also walk and participate in other intense physical activities to earn stickers. Patients who are unable to walk have tailored goals created by a physical/occupational therapist to earn stickers and participate in physical activity as prescribed by their therapist.
62600856|NCT05795920|EXPERIMENTAL|Patients with advanced pancreatic cancer that is inoperable and not suitable for local treatment|Patients with advanced pancreatic cancer that is inoperable and not suitable for local treatment
62821302|NCT05730023|EXPERIMENTAL|Active tDCS plus individualized language training|The group will receive five consecutive days a week for two weeks of 25 minutes sessions of Active tDCS combined with an individualized language training
62600857|NCT04958148|EXPERIMENTAL|High sodium|Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with pills containing salt to achieve an intake of 4,300 mg/d sodium for 4 weeks.
62821303|NCT05730023|ACTIVE_COMPARATOR|Placebo tDCS plus individualized language training|The group will receive five consecutive days a week for two weeks of 25 minutes sessions of Placebo tDCS combined with an individualized language training
62821304|NCT06122831|EXPERIMENTAL|TQ05105 Tablets + TQB3617 Capsules|"TQ05105 Tablets combined with TQB3617 Capsules, orally administered. 21 days as a treatment cycle.~TQB3617 Capsules, orally administered, 21 days as a treatment cycle."
62821305|NCT04753190|PLACEBO_COMPARATOR|Dim Room Light Control|Participants in the dim room light control group will not receive any bright light exposure.
62434580|NCT00665522||001|fentanyl iontophoretic transdermal system (40mcg) No Placebo 40 mcg per dose maximum of 6 doses/hourtotal maximum 80 doses/24 hours
62600858|NCT04958148|PLACEBO_COMPARATOR|Placebo|Subjects will be counseled to consume a diet with 2,300 mg/d sodium and will supplement with taking placebo pills for 4 weeks.
62600859|NCT02971475|EXPERIMENTAL|ESWL alone|Patients in this group would be treated with extracorporeal shock wave lithotripsy only. Otherwise, extra endoscopic procedures will be carried out in case of continuous and aggravated pain. Analgesics will be administrated as needed and recorded.
62623386|NCT02112019|ACTIVE_COMPARATOR|Sialoendoscopy: saline and hydrocortisone|By performing a sialoendoscopy, the ducts of the salivary glands are rinsed with saline and hydrocortisone and possible strictures are dilated
62434581|NCT00665522||002|IV PCA with standard of care opioid analgesia per 24 hour period
62849173|NCT05553301|ACTIVE_COMPARATOR|Group 5: QIV-HD|participants will receive a single dose of QIV -HD vaccine (for elderly only)
62434582|NCT04229797|ACTIVE_COMPARATOR|Comparator|Extraction of the unerupted third molars before distalization of mandibular first molar using Mandibular buccal shelf mini-screws.
62434583|NCT04229797|EXPERIMENTAL|Intervention|Leaving the unerupted third molars and distalizing using Mandibular buccal shelf mini-screws.
62041030|NCT06732700|EXPERIMENTAL|Experimental Group: 1|"INIT+ Posture Corrective Exercises INIT consists of Ischemic Compression, Strain-Counter Strain and Muscle Energy Technique. INIT will be performed on Upper Trapezius, Levator Scapulae and Sternocleidomastoid. The patient will be lying supine; First We will identify the TrPs in the muscle. After that the patient will be placed in comfortable position, first technique applied will be Ischemic Compression. The technique will be applied for 90 secs. After this SCS will be applied, moderate digital pressure will maintained over the active TrP as the position of ease will be identified, it will be held for 20-30 s and repeated for three to five repetitions. Lastly, the subjects will receive MET directed towards the involved muscle. Each isometric contraction will be held for 7-10 sec and stretch will be held for 30 seconds and will be repeated three to five times per treatment session.~Posture corrective exercises given to control group will also be performed"
62041031|NCT06732700|ACTIVE_COMPARATOR|Control Group: 2|"Posture corrective exercise Strengthening exercises: a) chin tuck in supine lying with the head in contact with the floor, (1 sets, 10 reps) b) Y-to-I exercise in a prone position (1 sets, 10 reps) c) Prone horizontal abduction with external rotation (1 sets, 10 reps).~Stretching Exercises:~d) one-sided unilateral self-stretch of pectoralis minor in standing position (stretch 30 sec, 5 reps) e) static sternocleidomastoid stretch (stretch 30 sec, 5 reps) f) static levator scapulae stretch (stretch 30 sec, 5 reps)."
62041032|NCT06089577|EXPERIMENTAL|Cangrelor|In the Experimental group, before performing PCI, all patients will be treated with Cangrelor (Kangrexal) with an i.v. loading bolus (30mg/Kg) followed by i.v. infusion (4mg/Kg/min) for 2 hours. At the end of the infusion, as per current clinical practice, a loading dose of Clopidogrel (600mg) will be administered. A manteinance daily dose of 75mg will be associated with oral ASA (100mg).
62041033|NCT06089577|NO_INTERVENTION|Control|In the Control group, either before or after PCI a loading dose of Clopidogrel will be administered and a manteinance daily dose of 75mg will be associated with oral ASA (100mg). PCI procedure will be performed as per current cinical practice, according clinical guidelines and at operator discretion.
62041034|NCT00944502|EXPERIMENTAL|Dexamethasone and complex vitamins|"Group A: Vitatonus dexa injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group B: Vitatonus DEXA tablet:~1 tablet orally every 8 hours for 10 days."
62041035|NCT00944502|ACTIVE_COMPARATOR|Dexamethasone|"Group C: Dexamethasone Injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group D: Dexamethasone tablet:~1 tablet orally every 8 hours for 10 days."
62041036|NCT03390439|ACTIVE_COMPARATOR|Nd-Yap 1340nm laser|The randomly assigned segment of the abdomen will receive 5 sessions with monthly intervals of Nd-yap 1340nm laser.
62041037|NCT03390439|EXPERIMENTAL|Microneedling|The randomly assigned segment of the abdomen will receive 5 sessions with monthly intervals of dermaroller 2,5mm.
62041038|NCT04766684|EXPERIMENTAL|J-Tip with 0.25mL of 1% Xylocaine MPF with placebo cream|
62041039|NCT04766684|ACTIVE_COMPARATOR|L.M.X.4 cream with J-Tip saline injection|
62041040|NCT02411565|ACTIVE_COMPARATOR|Fermented Wheat Germ Extract (FWGE)|FWGE administration 2 - 4 weeks prior to planned surgery, + Quality of Life (QoL) Surveys: FACT-O.
62041041|NCT02411565|PLACEBO_COMPARATOR|Placebo Administration|Placebo administration 2 - 4 weeks prior to planned surgery, + Quality of Life (QoL) Surveys: FACT-O.
62041042|NCT06487195|EXPERIMENTAL|Peer-facilitated, Recovery-based Self-illness-management programme (Peer-RESIM)|The Peer-RESIM consists of 10 1.5-hour sessions (7-12 day intervals; 4 months), based on the modified CORE program manual and psychoeducation programs developed by the research team. The printed/online program is based on a self-care, personal plan for recovery workbook with 4 key components: personal recovery goals, plans to re-establish community functioning and support networks following a crisis, identifying early warning signs and creating a relapse prevention plan, and strategies and coping resources for problem-solving and maintaining wellbeing. After completing the recovery plan, participants will be empowered and supported by a peer-support worker and group members during scheduled sharing sessions.
62434584|NCT03294278|ACTIVE_COMPARATOR|Ablation plus ICD|Epicardial ablation by radio-frequency
62434585|NCT03294278|ACTIVE_COMPARATOR|ICD alone|Implantation of ICD
62434586|NCT04057755|EXPERIMENTAL|Botulinum toxin A vs placebo|50 Allergan units (diluted in 0,5 ml sterile NaCl) or 0,5 ml of sterile NaCl will be injected in the bulbocavernosus muscle just inside the hymenal ring. The injection with the same substance, dose and volume will be repeated after 3 months.
62821306|NCT04753190|EXPERIMENTAL|Morning Bright Light Only (MBL)|"Participants in the morning bright light (MBL) group will receive a 3-h bright light exposure from 2 light boxes on 3 consecutive mornings in the laboratory. Bright light will be timed for each individual based on their baseline sleep schedule to shift the circadian timing system earlier (phase advance)."
62434587|NCT04057755|ACTIVE_COMPARATOR|Botulinum toxin A|50 Allergan units (diluted in 0,5 ml sterile NaCl) will be injected in the bulbocavernosus muscle just inside the hymenal ring. The injection with the same substance, dose and volume will be repeated after 3 months.
62821307|NCT04753190|EXPERIMENTAL|Afternoon Light Only (ABL)|"Participants in the afternoon bright light (ABL) group will receive a 3-h bright light exposure from 2 light boxes on 3 consecutive afternoons in the laboratory. Bright light will be timed for each individual based on their baseline sleep schedule to shift the circadian timing system earlier (phase advance)."
62821308|NCT04753190|EXPERIMENTAL|Morning + Afternoon Light (MBL+ ABL)|"Participants in the morning bright light + afternoon bright light (MBL+ ABL) group will receive bright light from 2 light boxes on 3 consecutive days in the laboratory. The morning exposure will be 1.5 h and the afternoon exposure will be 1.5 h. Bright light exposures will be timed for each individual based on their baseline sleep schedule to shift the circadian timing system earlier (phase advance)."
62821309|NCT05204719|EXPERIMENTAL|Prophylactic Delivery Room Continuous Positive Airway Pressure|If the infant is spontaneously breathing and allocated to the experimental arm, s/he will receive 20 min of 5 cm H2O of prophylactic continuous airway pressure using either a face mask or the appropriate size of nasal prong.
62821310|NCT05204719|NO_INTERVENTION|No Prophylactic Delivery Room Continuous Positive Airway Pressure|"Alternatively, spontaneously breathing infants assigned to control group will receive the standard of care with no prophylactic delivery room continuous positive airway pressure (CPAP).~In both groups, CPAP can be used to help babies with persistent labored breathing or cyanosis after the initial steps as per the participating institution's neonatal resuscitation protocol. At any time, if the patient does not present spontaneous breathing, an escalation on the resuscitation measures will be performed and the study intervention will be terminated."
62821311|NCT02649582|EXPERIMENTAL|Single Arm|Dendritic cell vaccine plus temozolomide chemotherapy
62821312|NCT03160261|EXPERIMENTAL|Exenatide|Single injection of 10 μg Exenatide subcutaneously.
62821313|NCT03008278|EXPERIMENTAL|Treatment (olaparib, ramucirumab)|Patients receive olaparib PO BID on days 1-14 of each cycle and ramucirumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62821314|NCT02257138|EXPERIMENTAL|Treatment (ruxolitinib phosphate, decitabine) Ph1|Patients receive ruxolitinib phosphate PO BID on days 1-28 and decitabine IV on days 1-5. Treatment repeats every 4-6 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62434588|NCT04057755|PLACEBO_COMPARATOR|NaCl|0,5 ml of sterile NaCl will be injected in the bulbocavernosus muscle just inside the hymenal ring. The injection with the same substance and volume will be repeated after 3 months.
62821315|NCT02257138|EXPERIMENTAL|Treatment (ruxolitinib phosphate, decitabine) Ph2|Patients receive 50mg ruxolitinib phosphate PO BID on days 1-28 and decitabine IV on days 1-5. Treatment repeats every 4-6 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62821316|NCT06601582|EXPERIMENTAL|Intervention|Device: Use of a operative blood salvage system The surgical team will use a operative blood salvage system
62821317|NCT06601582|NO_INTERVENTION|No intervention|
62821318|NCT06565962|EXPERIMENTAL|Education group|The participants randomly assigned to the groups will first be administered data collection forms as a pre-test. Then, the experimental group will be made to watch the training videos prepared by AFAD on disaster preparedness, disaster moment and post-disaster by using virtual reality goggles. Then, data collection for the post-test will be carried out from both groups. After a 3-month follow-up period, follow-up test questionnaires will be collected from both groups.
62821319|NCT06565962|NO_INTERVENTION|Control group|No intervention will be made to the control group. Personal information form, disaster literacy scale, disaster preparedness scale and disaster resistance scale will be used to collect the research data.
62821320|NCT06212856|EXPERIMENTAL|Group-A (Plyometric training)|
62821321|NCT06212856|OTHER|Group-B (Conventional)|
62821322|NCT05620628|EXPERIMENTAL|Savoritinib and Durvalumab|A fixed dose of 1500 mg Q4W durvalumab (equivalent to 20 mg/kg Q4W) is used in the present study for patients \>30 kg (dosing by bodyweight only required for patients ≤30 kg).And Savolitinib will be administered orally 600mg once a day for 28 days as one cycle.
62821323|NCT06210646|ACTIVE_COMPARATOR|citicoline 2000 mg arm|The citicoline arm consists of 400 patients who received 2000 mg citicoline once daily for 12 months and an open-label double antiplatelet in the form of 75 mg aspirin and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
62821324|NCT06210646|ACTIVE_COMPARATOR|citicoline 1000 mg arm|The placebo arm consists of 400 patients who received citicoline 1000mg daily for 12 months and an open-label double antiplatelet in the form of 75 mg aspirin and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
62821325|NCT06591429||Participants|Adults with MS taking part in this study.
62821326|NCT04631510|EXPERIMENTAL|Critically ill patients|Administer gabapentin 300 mg PO at 8 PM for sleep
62623387|NCT02112019|NO_INTERVENTION|Control: no treatment|
62821327|NCT05809908|ACTIVE_COMPARATOR|Tricaprilin|Tricaprilin formulation twice daily for 26 weeks, liquid for oral administration
62821328|NCT05809908|PLACEBO_COMPARATOR|Placebo|Placebo formulation, twice daily for 26 weeks, liquid for oral administration
62600860|NCT02971475|ACTIVE_COMPARATOR|ESWL combined with ERCP|People in this group would be treated with ESWL followed be endoscopic drainage of the main pancreatic duct in 48 hours. Analgesics will be administrated as needed and recorded.
62244389|NCT05873569|EXPERIMENTAL|Mothers and Babies Virtual Group Intervention|Women randomized to the Mothers and Babies Virtual Group (MBVG) arm will receive the 10 session MBVG intervention. Sessions are delivered weekly or bi-weekly via Zoom, making 20 weeks the longest possible MB-VG cohort. Sessions were designed to last 60 minutes, with an additional 15 minutes for sessions including a Resource Advocate or pediatrician. Prior to the first session, a member of the research team will test Zoom connections with each participant. All MB-VG groups will be delivered in Spanish by a trained MB-VG facilitator, with a study team member available to provide tech support as needed. MB-VG sessions will be delivered in chronological order.
62244390|NCT05873569|NO_INTERVENTION|Usual Family Support Services|Women randomized to the usual family support services arm will receive family support services from the early childhood center in which they are enrolled but no MB-VG intervention.
62244391|NCT02338011|EXPERIMENTAL|Gefitinib alone|Patients harboring an EGFR mutation with multiple BM from NSCLC will receive Gefitinib 250mg per day until progression of disease.
62600861|NCT02909829|EXPERIMENTAL|Closed Loop Delivery|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm. Participants will eat breakfast and bolus, then eat lunch and not bolus.
62600862|NCT02909829|EXPERIMENTAL|Closed Loop Delivery with Meal Detection Module|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm with an overlying meal detection module which detects missed meals and will increase insulin infusion rates based on a predictive meal detection algorithm. Participants will eat breakfast and bolus, then eat lunch and not bolus.
62600863|NCT02909829|ACTIVE_COMPARATOR|Conventional Pump Therapy|Insulin will be delivered by subcutaneous insulin infusion pump with participants usual infusion rate. Participants will eat breakfast and bolus as per usual, then eat lunch and not bolus.
62821329|NCT06274060|NO_INTERVENTION|Standard of care|"The TB HIV Care programme standard of care includes full-time peer educators employed by the programme to engage women, layered PrEP promotion across prevention programmes, and refer a friend strategies, information, education and communication (IEC) materials, service user testimonials, risk reduction posters to better align young women's perception of risk, working after hours/weekends to reach young women, working with school governing bodies, and door-to-door outreach."
62244392|NCT02338011|EXPERIMENTAL|Gefitinib concurrent WBRT|Patients harboring an EGFR mutation with multiple BM from NSCLC will receive Gefitinib concurrent WBRT until progression of disease.Gefitinib was given 250mg per day. WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
62244393|NCT06145724|NO_INTERVENTION|Hospital Stakeholders|Hospital stakeholders at the partnering hospitals who participate in 90 min focus group discussion about maternal sepsis bundle implementation.
62821330|NCT06274060|EXPERIMENTAL|Case management|Participants will receive case management layered on existing standard of care.
62041043|NCT06487195|ACTIVE_COMPARATOR|Psycho-education group|The psychoeducation group (6 subgroups; 10-12 participants per group) will be led by one experienced psychiatric nurse trained in psychiatric rehabilitation and psychoeducation group programs. The program will be guided by a validated treatment protocol based on psychoeducation programs for psychotic disorders developed by the research team and McFarlane et al. The psychoeducation program consists of ten 2-hour sessions held weekly/biweekly (similar to the Peer-RESIM, completed within 4 months), with 4 key components, including introduction and goal setting; an education workshop on psychosis, treatments, and community services; group exercises and rehearsals and discussions on illness management, coping and self-care; and a summary, evaluation and future plan.
62041044|NCT06487195|OTHER|Treatment-as-usual only (TAU)|Participants in the usual care only group (and the two intervention groups) will receive routine community mental healthcare services.
62041045|NCT04960111|EXPERIMENTAL|knee arthroplasty with radiostereometry tecnique|patient underwent total knee arthroplasty with insertion of microsphere in tantallium for radiostereometry tecnique.
62041046|NCT05773573|EXPERIMENTAL|Experimental group|Hyrax-type rapid maxillary expander anchored on the 2nd deciduous molars (V)
62041047|NCT05773573|ACTIVE_COMPARATOR|Control group|Hyrax-type rapid maxillary expander anchored on the 1st permanent molars (6)
62821331|NCT06274060|EXPERIMENTAL|Food vouchers|Participants will receive food vouchers layered on existing standard of care.
62041048|NCT03728972|EXPERIMENTAL|Early-Stage NK/T-cell Lymphoma/ENKTL (Stage I/II)|
62041049|NCT03728972|EXPERIMENTAL|Early-Stage NK/T-cell Lymphoma/ENKTL (Stage III/IV)|
62041050|NCT02920827|EXPERIMENTAL|Dapivirine Vaginal Ring|Vaginal ring containing 25 mg dapivirine
62041051|NCT02920827|PLACEBO_COMPARATOR|Placebo Vaginal Ring|Placebo vaginal ring
62821332|NCT06274060|EXPERIMENTAL|PrEP support buddy|Participants will receive the PrEP support buddy intervention layered on existing standard of care.
62244394|NCT06145724|NO_INTERVENTION|Patients Admitted for Delivery (Pre-implementation)|Patients admitted for delivery at one of the partnering hospitals. EHR records from Columbia, Lincoln, Harlem, and Allen hospitals will be reviewed to evaluate process and outcome measures pre-maternal sepsis bundle implementation. EHR data will be used from delivery hospitalizations from 2021-2022.
62244395|NCT06145724|EXPERIMENTAL|Patients Admitted for Delivery (Post-Implementation)|Patients admitted for delivery at one of the partnering hospitals. EHR records from Columbia, Lincoln, Harlem, and Allen hospitals will be reviewed to evaluate process and outcome measures post-maternal sepsis bundle implementation. EHR data will be used from delivery hospitalizations.
62821333|NCT06274060|EXPERIMENTAL|Community-based PrEP pickup points|Participants will receive the community-based PrEP pickup point intervention layered on existing standard of care.
62821334|NCT06274060|EXPERIMENTAL|PrEP support buddy + Community-based PrEP pickup points|Participants in this arm will receive both the PrEP support buddy and community-based PrEP pickup point interventions in combination.
62041052|NCT06732323|EXPERIMENTAL|ESG401 for injection|IV infusion on day 1, 8 and15 of each 28 day cycle
62041053|NCT06732323|ACTIVE_COMPARATOR|Investigator's Choice Chemotherapy|If no prior taxane, or prior taxane in the (neo)adjuvant setting and disease-free interval (DFI) \>12 months: paclitaxel or nab-paclitaxel. Note: If subjects are intolerant or contraindicated to receive paclitaxel or albumin-paclitaxel, the investigator may choose other chemotherapy options listed in the study protocol) If prior taxane and DFI ≤ 12 months: capecitabine, eribulin. If known BRCA1/2 mutation: carboplatin
62041054|NCT01749982|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62041055|NCT01749982|EXPERIMENTAL|Choline bitartrate|Choline bitartrate 700 mg by mouth daily
62041056|NCT01749982|EXPERIMENTAL|Betaine|Betaine 1000 mg by mouth daily
62041057|NCT01749982|EXPERIMENTAL|Choline bitartrate + Betaine|Choline bitartrate 700 mg + Betaine 1000 mg daily
62244396|NCT05553366|EXPERIMENTAL|VX-548|Participants will be randomized to receive VX-548.
62244397|NCT05553366|ACTIVE_COMPARATOR|Hydrocodone bitartrate/acetaminophen (HB/APAP)|Participants will be randomized to receive HB/APAP.
62244398|NCT05553366|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive placebo matched to VX-548 and HB/APAP.
62244399|NCT05728502||vericiguat arm|Chinese adult patients with Heart Failure with Reduced Ejection Fraction (HFrEF) who are prescribed vericiguat under routine treatment conditions. Data will be prospectively collected.
62821335|NCT06274060|EXPERIMENTAL|Food vouchers + Community-based PrEP pickup points|Participants in this arm will receive both the food voucher and community-based PrEP pickup point interventions in combination.
62821336|NCT06274060|EXPERIMENTAL|Food vouchers + PrEP support buddy|Participants in this arm will receive both the food voucher and PrEP support buddy interventions in combination.
62821337|NCT06274060|EXPERIMENTAL|Case management + Community-based PrEP pickup points|Participants in this arm will receive both the case management and community-based PrEP pickup point interventions in combination.
62041058|NCT02679261|EXPERIMENTAL|Atorvastatin|Oral administration Atorvastatin 20 mg per day
62821338|NCT06274060|EXPERIMENTAL|Case management + PrEP support buddy|Participants in this arm will receive both the case management and PrEP support buddy interventions in combination.
62041059|NCT02679261|PLACEBO_COMPARATOR|Control|Oral administration of Placebo
62041060|NCT04404712|EXPERIMENTAL|[11C]MK-3168 PET Scan|
62041061|NCT00515502|ACTIVE_COMPARATOR|Seq 1: UMEC 250 µg, UMEC 500 µg, Tiotropium 18 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: umeclidinium bromide (UMEC) 250 micrograms (µg), UMEC 500 µg, Tiotropium 18 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
62041062|NCT00515502|ACTIVE_COMPARATOR|Seq 2: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
62041063|NCT00515502|ACTIVE_COMPARATOR|Seq 3: UMEC 250 µg, placebo, UMEC 500 µg, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, UMEC 500 µg and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
62434589|NCT05015881|ACTIVE_COMPARATOR|Ketone ester + echocardiogram + PET FDG scanning visit.|"Subjects will drink single dose of ketone ester 1.9 kcal/kg + echocardiogram + PET scanning visit. Dietary Supplement: Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (R)-3-hydroxybutyrate (commercially available as DeltaG, (TdeltaS, Orlando, FL). 2-Deoxy-2-\[18F\] fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) scan."
62434590|NCT05015881|OTHER|Echocardiogram + PET FDG scanning visit.|Subjects will complete a echocardiogram + PET scanning visit. 2-Deoxy-2-\[18F\] fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) scan.
62434591|NCT05182398||Multiple sclerosis patient|First day, first evaluator will perform all tests, and second day, second evaluator will perform Modified Four Square Step Test.
62434592|NCT01268449|ACTIVE_COMPARATOR|Laser group|
62821339|NCT06274060|EXPERIMENTAL|Case management + Food vouchers|Participants in this arm will receive both the case management and food voucher interventions in combination.
62434593|NCT01268449|PLACEBO_COMPARATOR|Placebo group|Randomly,half of the patients receive placebo.
62434594|NCT02032290|ACTIVE_COMPARATOR|ticagrelor|ticagrelor: loading dose of 180 mg and maintaining dose of 90 mg twice daily in NSTEMI and STEMI (Class I B) patients;
62434595|NCT02032290|ACTIVE_COMPARATOR|clopidogrel|clopidogrel: loading dose of 600 mg and maintaining dose of 75 mg daily in NSTEMI (Class I B) and STEMI (Class I C) patients.
62434596|NCT00538187|EXPERIMENTAL|Treatment (obatoclax mesylate, bortezomib)|Patients will receive a 3-hour infusion of obatoclax and an infusion of bortezomib once a week for 4 weeks
62434597|NCT01484171|ACTIVE_COMPARATOR|idarubicin|The patients will receive induction chemotherapy containing standard dose of idarubicin in combination with cytarabine.
62434598|NCT01484171|EXPERIMENTAL|microtransplantation|The patients will receive induction chemotherapy containing high dose of idarubicin in combination with cytarabine and follow by infusioning granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells
62600864|NCT05428202|EXPERIMENTAL|GN 037 cream|"Healthy volunteers will receive GN037 cream in 2 to 1 ration~Application will be done twice daily, to selected area of body on the fore arm:~Increasing dosages of dosages: Low dose to a 5 cm2 skin area, Medium dose to15 cm2 skin area, High dose to 30 cm2 skin area~Psoriatic patients will receive GN037 cream Aplication twice daily, to a selected body target lesion High dose 30 cm2"
62600865|NCT05428202|PLACEBO_COMPARATOR|Placebo Cream|"Placebo cream will be applied in 2 to 1 ratio twice daily, to selected area of fore arm.~Low dose to 5 cm2 skin area, Medium dose 15 cm2 skin area, High dose 30 cm2 skin area"
62600866|NCT03205735||normal DPD result group|patients group with a normal DPD result
62600867|NCT03205735||elevated DPD result group|patients group with an elevated DPD result
62821340|NCT06274060|EXPERIMENTAL|Food voucher + PrEP support buddy + Community-based PrEP pickup points|Participants in this arm will receive the food voucher, PrEP support buddy, and community-based PrEP pickup point interventions in combination.
62821341|NCT06274060|EXPERIMENTAL|Case management + PrEP support buddy + Community-based PrEP pickup points|Participants in this arm will receive the case management, PrEP support buddy, and community-based PrEP pickup point interventions in combination.
62623388|NCT04470479|EXPERIMENTAL|Pilocarpine Hydrochloride|Patients with Sjögren's syndrome were allocated to receive oral pilocarpine 20mg per day, (5mg every 6 hours, for ten weeks.
62821342|NCT06274060|EXPERIMENTAL|Case management + Food vouchers + Community-based PrEP pickup points|Participants in this arm will receive the case management, food vouchers, and community-based PrEP pickup point interventions in combination.
62821343|NCT06274060|EXPERIMENTAL|Case management + Food vouchers + PrEP support buddy|Participants in this arm will receive the case management, food vouchers, and PrEP support buddy interventions in combination.
62041064|NCT00515502|ACTIVE_COMPARATOR|Seq 4: UMEC 250 µg, UMEC 500 µg, placebo, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, UMEC 500 µg, placebo and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
62244400|NCT05728502||external control arm|Chinese adult HFrEF patients who received SoC treatment will be collected from China Heart Failure Center registry database. This control arm will be retrospectively collected from the patients in the database in the same period, from FPFV to LPFV of the vericiguat arm, and matched by propensity score based on baseline characteristics.
62821344|NCT06274060|EXPERIMENTAL|Case management + Food vouchers + PrEP support buddy + Community-based PrEP pickup points|Participants in this arm will receive the case management, food vouchers, PrEP support buddy, and community-based PrEP pickup point interventions in combination.
62821345|NCT06704815||Viacoram® plus educational program|naïve treatment hypertensive patients who will be initiated to Viacoram® plus an educational program
62821346|NCT06704815||other antihypertensive drugs (except Viacoram®)|naïve treatment hypertensive patients who will be initiated to any antihypertensive drug (except single pill combination)
62821347|NCT03814811||Bone metastasis(+) with low cOC|Patients who have bone metastasis with low number of circulating osteocalcin-positive (cOC) cells
62244401|NCT06718907|EXPERIMENTAL|Stress Exposure and Management|All pregnant participants will be exposed to a 50 second-mild stressful stimulus and a 50 second- relaxant to record physiological responses. The participants will then independently practice easy stress management techniques at home, such as breathing and listening to music. They will do so for one week after the initial data collection.
62821348|NCT03814811||Bone metastasis(+) with high cOC|Patients who have bone metastasis with high number of circulating osteocalcin-positive (cOC) cells
62821349|NCT03814811||Bone metastasis(-) with low cOC|Patients who have metastasis only in extraskeletal sites with low number of circulating osteocalcin-positive (cOC) cells
62821350|NCT03814811||Bone metastasis(-) with high cOC|Patients who have metastasis only in extraskeletal sites with high number of circulating osteocalcin-positive (cOC) cells
62244402|NCT06675565|EXPERIMENTAL|ALN-AGT01 RVR|Participants will be administered a single dose of ALN-AGT01 RVR.
62434599|NCT02984683|EXPERIMENTAL|SAR566658 90 mg/m^2|Participants received SAR566658 90 milligram per square meter (mg/m\^2) as intravenous infusion on Day 1 and Day 8 of each 21-day treatment cycle (maximum number of cycles received was 3).
62623389|NCT04470479|PLACEBO_COMPARATOR|placebo|Patients with Sjögren's syndrome were allocated to receive placebo administered in the same way (1 tablet every 6 hours), for ten weeks
62821351|NCT01607957|EXPERIMENTAL|TAS-102|
62821352|NCT01607957|PLACEBO_COMPARATOR|Placebo|
62821353|NCT01212835|SHAM_COMPARATOR|no ring|Patients at this group will have RING REMOVED AT THE END OF SURGERY.
62041065|NCT00515502|ACTIVE_COMPARATOR|Seq 5: Placebo, UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, UMEC 250 µg, UMEC 500 µg and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
62821354|NCT01212835|ACTIVE_COMPARATOR|RYGBP-Ring|Open Roux-en-Y gastric bypass with a silastic ring which is performed with linear cut stapler 100 mm and a biliopancreatic limb of 60 cm long and a alimentary limb of 100 cm long. All patients will have a 6.5 cm silastic ring located at the middle of the pouch above of the gastroenteroanastomosis.
62244403|NCT06675565|PLACEBO_COMPARATOR|Placebo|Participants will be administered a single dose of placebo.
62244404|NCT06735261|NO_INTERVENTION|Control group|Pain management according to the protocol in force in the neurosurgical intensive care unit (analgesics: Paracetamol, Nefopam and morphine PCA).
62244405|NCT06735261|EXPERIMENTAL|Sphenopalatine Ganglion Block using 2% lidocaine|Addition of (BGSP) Sphenopalatine ganglion block with Lidocaine 2% Injectable Solution (2mg/ml) 1.5ml \* 3 consecutive times maximum if EN \>3/10, to be repeated every 12h for 7 days if necessary. BGSP performed by the department's Ides after training by the anesthetists.
62434600|NCT02984683|EXPERIMENTAL|SAR566658 120 mg/m^2|Participants received SAR566658 120 mg/m\^2 as intravenous infusion on Day 1 and Day 8 of each 21-day treatment cycle (maximum number of cycles received was 3).
62434601|NCT03727464|EXPERIMENTAL|Propofol Abstract Priming|Patients undergoing propofol general anesthesia and stimulation with a list of abstract words
62434602|NCT03727464|EXPERIMENTAL|Propofol Concrete Priming|Patients undergoing propofol general anesthesia and stimulation with a list of concrete words
62041066|NCT00515502|ACTIVE_COMPARATOR|Seq 6: UMEC 250 µg, placebo, Tiotropium 18 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, Tiotropium 18 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
62041067|NCT00515502|ACTIVE_COMPARATOR|Seq 7: Placebo, Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, Tiotropium 18 µg, UMEC 250 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
62041068|NCT00515502|ACTIVE_COMPARATOR|Seq 8: Tiotropium 18 µg, placebo, UMEC 250 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, placebo, UMEC 250 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
62600868|NCT02564445|EXPERIMENTAL|Control|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.~They will be given information on the federal and CDC guidelines for physical activity and will also be told that they should strive to achieve 10,000 steps per day to help promote weight loss."
62600869|NCT02564445|EXPERIMENTAL|Gamification|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.~All participants play a game with their teammate that includes points, levels and the opportunity to win a trophy, plaque or medal. They will advance or not advance based on their progress with weight loss and physical activity through 24 weeks. During the 12-week follow-up they'll be asked to maintain or make progress toward their weight loss goal."
62821355|NCT06453746|ACTIVE_COMPARATOR|Home-based cognitive training exercises|"The cognitive training exercises program includes a total of 19 exercises and activities. The 19 exercises are divided into 8 groups: (1) warm up and cool down (relaxation exercise), (2) episodic memory, (3) digit span and calculation, (4) language, (5) Linking Letters \& Numbers, (6) Imagery, (7) Visuoconstructional skills, (8) linking ADL/IADL tasks.~Subjects are provided with 19 exercises and instructed to perform them at home. Home-based exercises will be assessed weekly. Subjects are provided with a logbook to track their progress with the home exercises and were given the opportunity to provide feedback, ask questions, and receive support for any difficulties encountered during the process.~All cognitive training exercises are based on the Technical Procedure Instructions issued by the Vietnamese Ministry of Health."
62041069|NCT00515502|ACTIVE_COMPARATOR|Seq 9: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
62244406|NCT05001880|EXPERIMENTAL|Arm I (carboplatin, pemetrexed, bevacizumab, atezolizumab)|Patients receive atezolizumab IV over 60 minutes, bevacizumab IV over 30-90 minutes, carboplatin IV over 30 minutes, and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery may receive atezolizumab and bevacizumab in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and PET scan on study. Patients also undergo blood and tissue sample collection on study.
62434603|NCT03727464|ACTIVE_COMPARATOR|Propofol Controls|Patients undergoing propofol anesthesia without any intraoperative priming
62434604|NCT03727464|EXPERIMENTAL|Sevoflurane Abstract Priming|Patients undergoing sevoflurane general anesthesia and stimulation with a list of abstract words
62434605|NCT03727464|EXPERIMENTAL|Sevoflurane Concrete Priming|Patients undergoing sevoflurane general anesthesia and stimulation with a list of concrete words
62849174|NCT04351789|EXPERIMENTAL|Intervention Group|Patients randomized to the intervention group will receive a minimal psychoeducational intervention just prior to discharge from the hospital. The goal of the intervention is that patients will be prepared and learn to interpret and react to physical and psychological symptoms that are related to recovering from a COVID-19 infection. The intervention is based on psychoeducational theory and consists of both written and verbal information. A manual describing the content and procedures of the intervention will be developed to ensure that the intervention is both replicable and transparent. The intervention has a planned duration of 30 minutes and will be conducted by a designated study affiliated researcher, who has a background in healthcare (i.e. nurse or medical doctor).
62434606|NCT03727464|ACTIVE_COMPARATOR|Sevoflurane Controls|Patients undergoing sevoflurane general anesthesia without any intraoperative priming
62434607|NCT02614937|EXPERIMENTAL|Squalamine and ranibizumab to Week 10|"All eyes received an initial 10 week mandatory loading period of topical Squalamine Lactate Ophthalmic Solution, 0.2% therapy.~All eyes received mandatory intravitreal injections of ranibizumab 0.5mg at the conclusions of weeks 2 and 6.~Randomize at Week 10 to 2 different groups - Squalamine and No Squalamine, continue PRN ranibizumab in both groups"
62434608|NCT02614937|EXPERIMENTAL|Continue Squalamine, ranibizumab PRN|Continue use of Squalamine Lactate Ophthalmic Solution, 0.2% after Week 10; continue ranibizumab 0.5 mg IVT PRN
62434609|NCT02614937|EXPERIMENTAL|Stop Squalamine, ranibizumab PRN|Discontinue use of Squalamine Lactate Ophthalmic Solution, 0.2% after Week 10; continue ranibizumab 0.5 mg IVT PRN
62623390|NCT03737799||Group 1 Age 18-50 at diagnosis|Diagnosed with diabetes within the previous 1 year. Aged between 18 and 50 years at the time of diabetes diagnosis
62434610|NCT00058617|EXPERIMENTAL|Injection of EBV Specific CTLs|Subjects will receive autologous EBV Specific CTLs. Patients that agree will recieve CTLs that have been marked with the neomycin resistance gene.
62434611|NCT01287780|ACTIVE_COMPARATOR|Collagen-gentamicin sponges|Two sponges of collagen-gentamicin will be inserted into the hip immediately before closure of the wound. Each sponge (10 by 10 cm) contains 280 mg of collagen and 130 mg of gentamicin.
62434612|NCT01287780|NO_INTERVENTION|No intervention|
62434613|NCT01063725|EXPERIMENTAL|Femarelle|Women will receive Femarelle twice daily for 12 weeks
62434614|NCT01063725|PLACEBO_COMPARATOR|Placebo|Women will take placebo capsules twice daily for 12 weeks
62434615|NCT00303316|EXPERIMENTAL|DTacP IPV HepB PRP-T Combined Vaccine Group|Participant will receive a booster dose of PENTAXIM™ having received DTacP-IPV-HepB-PRP-T (primary series) in Study A3L02.
62244407|NCT05001880|ACTIVE_COMPARATOR|Arm II (carboplatin, pemetrexed, bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes, carboplatin IV over 30 minutes, and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery may receive bevacizumab with or without atezolizumab at the discretion of the investigator in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and PET scan on study. Patients also undergo blood and tissue sample collection on study.
62244408|NCT01924221||CRT|Patients with implanted cardiac resynchronization therapy defibrillator
62600870|NCT02564445|EXPERIMENTAL|Gamification + Share Data with PCP|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.~Participants will be asked to allow the study team to share their weight and step data with their primary care physician (PCP).~All participants play a game with their teammate that includes points, levels and the opportunity to win a trophy, plaque or medal. They will advance or not advance based on their progress with weight loss and physical activity through 24 weeks. During the 12-week follow-up they'll be asked to maintain or make progress toward their weight loss goal."
62821356|NCT06453746|EXPERIMENTAL|Supervised cognitive training exercises|"The cognitive training exercises program includes a total of 19 exercises and activities. The 19 exercises are divided into 8 groups: (1) warm up and cool down (relaxation exercise), (2) episodic memory, (3) digit span and calculation, (4) language, (5) Linking Letters \& Numbers, (6) Imagery, (7) Visuoconstructional skills, (8) linking ADL/IADL tasks.~The subjects are given exercises at the hospital under the supervision of physiotherpist/ physiatrist, and are also instructed to do the exercises at home.~Home-based exercises will be assessed weekly. Subjects are provided with a logbook to track their progress with the home exercises and were given the opportunity to provide feedback, ask questions, and receive support for any difficulties encountered during the process.~All cognitive training exercises are based on the Technical Procedure Instructions issued by the Vietnamese Ministry of Health."
62821357|NCT05784844|ACTIVE_COMPARATOR|Meropenem Arm|Patients who meet inclusion criteria may be randomized to meropenem (routine standard of care) dose according to local dosing guidelines to include the use of extended-infusions and adjustments to account for renal function. Duration will be managed by the primary team.
62244409|NCT06578156|EXPERIMENTAL|Nasal High Flow Cannula|Nasal High Flow cannula at 70 liters per minute for 30 minutes. Given that this is a cross-over study, participants on this arm will be then crossed over to Nasal Low Flow Cannula at less than or equal to 4 liters per minute with supplemental oxygen for 30 minutes
62244410|NCT06578156|ACTIVE_COMPARATOR|Nasal Low Flow Cannula|Low Flow Nasal Cannula at less than or equal to 4 liters per minute with supplemental oxygen at patient's baseline for 30 minutes. Given that this is a cross-over study, participants on this arm will be then crossed over to High Flow Cannula at 70 liters per minute for 30 minutes
62244411|NCT05621616|EXPERIMENTAL|mirabegron|Participants will receive mirabegron prolonged-release microgranula-based oral suspension.
62244412|NCT06487858|EXPERIMENTAL|Phase 1a: Part A: Dose Escalation Monotherapy|Sequential cohorts of increasing dose levels of BGB R046 will be evaluated as monotherapy.
62244413|NCT06487858|EXPERIMENTAL|Phase 1a: Part B: Dose Escalation Combination Therapy|Sequential cohorts of increasing dose levels of BGB R046 will be evaluated in combination with tislelizumab.
62244414|NCT06487858|EXPERIMENTAL|Phase 1b: Dose Expansion|The recommended dose for expansion (RDFE) for BGB-R046 in combination with tislelizumab from Phase 1a will be evaluated in selected indications.
62041070|NCT00515502|ACTIVE_COMPARATOR|Seq 10: Tiotropium 18 µg, UMEC 250 µg, placebo, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, UMEC 250 µg, placebo and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
62244415|NCT03399409|EXPERIMENTAL|Motivational Interviewing|
62244416|NCT03399409|ACTIVE_COMPARATOR|Anti-inflammatory information program|
62434616|NCT00303316|ACTIVE_COMPARATOR|PENTAXIM™ and ENGERIX B® Vaccine Group|Participant will receive a booster dose of PENTAXIM™ having received ENGERIX B® and PEDIATRICO in Study A3L02 (Primary series)
62434617|NCT04128449|EXPERIMENTAL|docosahexaenoic acid|1,66 grams/24 hours (5 dragees)
62434618|NCT04128449|PLACEBO_COMPARATOR|Placebo|sunflower oil (5 dragees)
62434619|NCT00591422|EXPERIMENTAL|Single Arm|
62821358|NCT05784844|ACTIVE_COMPARATOR|Micafungin Arm|Patients who meet inclusion criteria may be randomized to micafungin dosed as 150mg intravenously every 24 hours according to local dosing guidelines. Duration will be managed by the primary team.
62244417|NCT05702021|EXPERIMENTAL|Science of Service Laboratory implementation strategy|The Science of Service Laboratory implementation strategy consists of: didactic training (contingency management workshops; monthly contingency management coaching calls), performance feedback (practice sessions and electronic medical record feedback); and facilitation (monthly facilitation calls).
62244418|NCT05702021|NO_INTERVENTION|Stepped wedge comparator|Our hybrid trial uses a unidirectional crossover stepped wedge design. All sites cross over in the same direction from usual care to intervention. All sites therefore act as their own comparison prior to the sequential roll-out of the implementation strategy.
62244419|NCT05267587|EXPERIMENTAL|Hypofractionated Stereotactic Radiosurgery prior to resection|Participants will be given hypofractionated stereotactic radiosurgery (fSRS) in 9 Gray Units (Gy) per fraction x 3 consecutive daily fractions (27 Gy total) to the index metastasis that will be resected on Days 1-3 (3 consecutive days). If there are additional non index brain metastasis, they will be treated with standard stereotactic radiosurgery at the time of fSRS. Participants will then undergo stereotactic craniotomy for surgical resection of the index metastasis within 5 days following completion of fSRS.
62041071|NCT00515502|ACTIVE_COMPARATOR|Seq 11: Placebo, UMEC 250 µg, Tiotropium 18 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, UMEC 250 µg, Tiotropium 18 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
62821359|NCT00941746|EXPERIMENTAL|Lowest dose of PG110|single, slow intravenous infusion
62821360|NCT00941746|EXPERIMENTAL|Second dose of PG110|single, slow intravenous infusion
62041072|NCT00515502|ACTIVE_COMPARATOR|Seq 12: UMEC 250 µg, placebo, UMEC 500 µg, Tiotropium 18 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, UMEC 500 µg and Tiotropium 18 µg. Treatment periods were seperated by a washout period of at least 14 days.
62041073|NCT05717634||TAM|Patients with previous breast cancer with hormonal receptor expression that are treated with tamoxifen.
62041074|NCT05717634||Ais|Patients with previous breast cancer with hormonal receptor expression that are treated with Ais.
62041075|NCT05717634||No Therapy|Patients with previous breast cancer that are not treated with none hormonal therapies.
62041076|NCT02869087|EXPERIMENTAL|Single Group|Single Arm study, study subjects are assigned to treatment with the Akesys Prava Scaffold
62244420|NCT05563948|EXPERIMENTAL|High THC : High CBD|Cannabis that is high in THC and high in CBD will be administered.
62434620|NCT06362876|EXPERIMENTAL|Breastfeeding Counseling Based on Motivational Interviewing|Breastfeeding Counseling Based on Motivational Interviewing: An announcement was made on social media. Women who were willing to participate in the research and met the inclusion criteria were informed about the research and an appointment was made with them and they were scheduled to log in. All sessions were held with women individually and through online platforms. Motivational Interview-Based Breastfeeding Training Hypnobreastfeeding training program consists of 6 sessions and 4 parts. A total of 6 sessions were held with each woman, 3 implementation and 3 follow-ups.
62434621|NCT06362876|EXPERIMENTAL|Standard Breastfeeding Consultancy|Standard Breastfeeding Consultancy: The standard breastfeeding counseling program was prepared by the researchers with reference to the Breastfeeding Counseling Handbook published by the Ministry of Health of the Republic of Turkey in 2015. Training program consists of 6 sessions and 4 parts. A total of 6 sessions were held with each woman, 3 implementation and 3 follow-ups.
62600871|NCT01004406|EXPERIMENTAL|intensive LDL-lowering therapy (ILLT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to LDL-apheresis and an oral daily dose of 40-80mg of Atorvastatin or equivalent
62821361|NCT00941746|EXPERIMENTAL|Third dose of PG110|single, slow intravenous infusion
62821362|NCT00941746|EXPERIMENTAL|Fourth dose of PG110|single, slow intravenous infusion
62821363|NCT00941746|EXPERIMENTAL|Fifth dose of PG110|single, slow intravenous infusion
62821364|NCT00941746|EXPERIMENTAL|Top dose of PG110|single, slow intravenous infusion
62821365|NCT00941746|EXPERIMENTAL|Placebo|single, slow intravenous infusion that matches PG110 in appearance
62821366|NCT00941746|EXPERIMENTAL|Seventh Dose of PG110|single, slow intravenous infusion
62821367|NCT00941746|EXPERIMENTAL|Eight Dose of PG110|single, slow intravenous infusion
62821368|NCT02099864|EXPERIMENTAL|Treatment (Enzalutamide)|Patients receive enzalutamide PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo a tumor biopsy of a metastatic site at study entry (prior to initiation of enzalutamide) and after the time of progression. Per the investigator, patients may continue treatment beyond progression.
62821369|NCT04199351|EXPERIMENTAL|Part A|AMG 171 or placebo, 2 SAD cohorts
62821370|NCT04199351|EXPERIMENTAL|Part B|AMG 171 or placebo, 1 MAD cohort
62821371|NCT04199351|EXPERIMENTAL|Part C|AMG 171 or placebo, 3 titration cohorts
62821372|NCT06041763|EXPERIMENTAL|BEAR Implant|Adult patients with meniscus injury indicated for isolated meniscus repair. In the experimental group, the BEAR Implant will be utilized in the repair procedure.
62821373|NCT06041763|ACTIVE_COMPARATOR|Standard Repair|adult patients with meniscus injury indicated for isolated meniscus repair. In the standard repair group, participants will undergo an isolated meniscus repair without the implant.
62821374|NCT03985839||MICRORAPTOR™ REGENESORB™ Suture Anchor|MICRORAPTOR™ REGENESORB™ Suture Anchor
62821375|NCT03985839||MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor|MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
62821376|NCT03985839||MICRORAPTOR™ Knotless PEEK Suture Anchor|MICRORAPTOR™ Knotless PEEK Suture Anchor
62821377|NCT03496844|NO_INTERVENTION|Routine F-18 fluciclovine-PET/CT scan|This arm will consist of prostate cancer patients who have had an F-18 fluciclovine-PET/CT scan for routine standard of care for biochemical recurrence. These patients would be asked to participate in the study only if there is a need for a standard of care bone biopsy.
62821378|NCT03496844|ACTIVE_COMPARATOR|Research F-18 fluciclovine-PET/CT scan|This arm will consist of prostate cancer patients who would not ordinarily obtain an Axumin-PET scan for routine standard of care but have a need for bone biopsy. This will include patients with metastatic castrate resistant prostate cancer. For example, a patient with known lymph node recurrence of prostate cancer and suspicious finding on a bone scan would be asked to participate in the study and get a F-18 fluciclovine-PET/CT scan prior to the standard of care bone biopsy.
62821379|NCT00445081|ACTIVE_COMPARATOR|1|
62041077|NCT03647306|ACTIVE_COMPARATOR|Extended Overnight Fast|The extended overnight fast group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session. Subjects will consume approximately 33% of their daily calories at breakfast, lunch and dinner, respectively. This is a model for fasting dietary chronotype.
62041078|NCT03647306|EXPERIMENTAL|Early Total Caloric Intake|The Early Total Caloric Intake study group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session and will consume 60% of their daily calories during breakfast. The remaining 40% of daily calories will be consumed during lunch and dinner. This is a model for early dietary chronotype.
62041079|NCT03647306|EXPERIMENTAL|Late Total Caloric Intake|The Late Total Caloric Intake study group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session and will consume 40% of daily calories during breakfast and lunch. The remaining 60% of daily calories will be consumed during dinner. This is a model for late dietary chronotype.
62821380|NCT00445081|ACTIVE_COMPARATOR|2|
62041080|NCT01814969|EXPERIMENTAL|Hyperfractionated Radiochemotherapy|"radiotherapy in rectal tumor area due to the placing of pelvic nodal groups to a total dose of 42 Gy, 1.5 Gy d fx 2 times a day; (gap between the factions min. 6-8h) - duration of treatment 2.5 weeks with simultaneous two cycles of chemotherapy according to the scheme: 5FU-325mg/m2 (bolus) on 1-3 and 16-18 (last 3 days of radiotherapy).~Surgical resection has to be done within 14 days or 5-6 weeks after the completion of hyperfractionated radiochemotherapy (HRTCT)."
62041081|NCT01814969|ACTIVE_COMPARATOR|Hyperfractionated Radiotherapy|"radiotherapy in rectal tumor area due to the placing of pelvic nodal groups to a total dose of 42 Gy, 1.5 Gy d fx 2 times a day; (gap between the factions min. 6-8h) - duration of treatment 2.5 weeks.~Surgical resection has to be done within 14 days or 5-6 weeks after the completion of hyperfractionated radiotherapy (HRT)."
62041082|NCT01746693|EXPERIMENTAL|amblyopia ex anisometropia|20 male and female volunteers with amblyopia ex anisometropia
62041083|NCT01746693|EXPERIMENTAL|amblyopia ex strabismus|20 male and female volunteers with amblyopia ex strabismus
62041084|NCT01746693|EXPERIMENTAL|control subjects|20 healthy male and female control subjects
62821381|NCT01856270|EXPERIMENTAL|Amitriptyline Immediate|The Amitriptyline Immediate group will begin study drug immediately after enrollment. Immediate Drug participants will be started on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
62821382|NCT01856270|EXPERIMENTAL|Amitriptyline Delayed|The Amitriptyline Delayed group will start the study drug at the Day 30 visit on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
62041085|NCT05763628|EXPERIMENTAL|Control Lens, then Test Lens|Participants wore Control Lens for 2 weeks, then crossed over to Test Lens for 2 weeks.
62041086|NCT05763628|EXPERIMENTAL|Test Lens, then Control Lens|Participants wore Test Lens for 2 weeks, then crossed over to Control Lens for 2 weeks.
62041087|NCT03512652|OTHER|Patello|
62041088|NCT04524871|ACTIVE_COMPARATOR|Stage 1: Atezolizumab + Bevacizumab|Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
62041089|NCT04524871|EXPERIMENTAL|Stage 1: Atezolizumab + Bevacizumab + Tiragolumab|Participants will receive atezolizumab plus bevacizumab plus tiragolumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
62041090|NCT04524871|EXPERIMENTAL|Stage 1: Atezolizumab + Bevacizumab + Tocilizumab|Participants will receive atezolizumab plus bevacizumab plus tocilizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
62244421|NCT05563948|EXPERIMENTAL|High THC : Low CBD|Cannabis that is high in THC and low in CBD will be administered.
62434622|NCT06036654|EXPERIMENTAL|Local Hyperthermia for the Treatment of Onychomycosis|(1) In months 0-2, local hyperthermia treatment was given once a week for 20 minutes each time, for a total of 9 times; (2) In months 2-4, at the same target lesion, once every 2 weeks, for a total of 4 times; (3) In months 4-6, once every 4 weeks, for a total of 2 times. The frequency of this course of treatment was 15 times lasting for 6 months, and follow-up ended 12 months from the first treatment.
62434623|NCT02175407|EXPERIMENTAL|ASP1707 alone|
62434624|NCT02175407|EXPERIMENTAL|ASP1707 + itraconazole|
62434625|NCT05017376||group A|small optical zone
62434626|NCT05017376||group B|large optical zone
62434627|NCT01488019|EXPERIMENTAL|Perforomist, nebulization, COPD|Active
62434628|NCT01488019|PLACEBO_COMPARATOR|Perforomist-Placebo|Placebo
62821383|NCT04771455|EXPERIMENTAL|Condition 1|Behavioral weight loss intervention
62821384|NCT04771455|EXPERIMENTAL|Condition 2|Behavioral weight loss intervention and decrease negative affect
62821385|NCT04771455|EXPERIMENTAL|Condition 3|Behavioral weight loss intervention and decrease unhealthy weight control practices
62821386|NCT04771455|EXPERIMENTAL|Condition 4|Behavioral weight loss intervention, decrease unhealthy weight control practices, and decrease negative affect
62821387|NCT04771455|EXPERIMENTAL|Condition 5|Behavioral weight loss intervention and decrease overvaluation of weight and shape
62821388|NCT04771455|EXPERIMENTAL|Condition 6|Behavioral weight loss intervention, decrease overvaluation of weight and shape, and decrease negative affect
62821389|NCT04771455|EXPERIMENTAL|Condition 7|Behavioral weight loss intervention, decrease overvaluation of weight and shape, and decrease unhealthy weight control practices
62821390|NCT04771455|EXPERIMENTAL|Condition 8|Behavioral weight loss intervention, decrease overvaluation of weight and shape, decrease unhealthy weight control practices, and decrease negative affect
62821391|NCT01500733|EXPERIMENTAL|Elderly greater than 65|
62821392|NCT01500733|EXPERIMENTAL|17p Deletioin|
62821393|NCT05974722|OTHER|Mesh-based crural reinforcement|Patient will receive Ovitex mesh to reinforce the crural repair
62821394|NCT05974722|OTHER|Pledgeted suture-based crural reinforcement|Patient will receive pledgeted sutures to reinforce the crural repair
62821395|NCT05884307|EXPERIMENTAL|Trans and Nonbinary Adults|
62041091|NCT04524871|EXPERIMENTAL|Stage 1: Atezolizumab + Bevacizumab + TPST-1120|Participants will receive atezolizumab plus bevacizumab plus TPST-1120 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
62041092|NCT04524871|EXPERIMENTAL|Stage 1: Tobemstomig 2100 mg Q2W + Bevacizumab|Participants will receive Tobemstomig plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
62041093|NCT04524871|EXPERIMENTAL|Stage 1: Tobemstomig 600 mg Q3W + Bevacizumab|Participants will receive Tobemstomig plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
62821396|NCT05313295|EXPERIMENTAL|Home-based Physiotherapy|Two days a week of physical therapy (mobilizations, manual therapy, stretching, respiratory techniques) + 3 hours extra of home-based physiotherapy (stretching, active mobilizations)
62821397|NCT05313295|ACTIVE_COMPARATOR|Usual physiotherapy|Two days a week of physical therapy (mobilizations, manual therapy, stretching, respiratory techniques)
62821398|NCT06218316|EXPERIMENTAL|Botox for spasticity|Botox for spasticity in lower limbs in cerebral palsy children
62821399|NCT06218316|EXPERIMENTAL|transcranial magnetic stimulation for spasticity|transcranial magnetic stimulation for spasticity in cerebral palsy children
62821400|NCT06218316|EXPERIMENTAL|Botox combined with transcranial magnetic stimulation for spasticity|Botox combined with transcranial magnetic stimulation for spasticity in cerebral palsy children
62821401|NCT06591507|EXPERIMENTAL|Preoperative and Postoperative BCAA Nutritional Intervention|
62821402|NCT06591507|EXPERIMENTAL|Preoperative and Postoperative BCAA Nutritional Intervention + Postoperative Muscle Rehabilitation|
62041094|NCT04524871|EXPERIMENTAL|Stage 1: Tobemstomig 1200 mg Q3W + Bevacizumab|Participants will receive Tobemstomig plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
62821403|NCT06591507|EXPERIMENTAL|Postoperative BCAA Nutritional Intervention|
62821404|NCT06591507|EXPERIMENTAL|Postoperative Muscle Rehabilitation|
62821405|NCT06591507|PLACEBO_COMPARATOR|Standard Nutritional Therapy|
62821406|NCT05719103|ACTIVE_COMPARATOR|HFNC SP|HFNC flow at 60 L/min or maximum tolerable flow at supine position
62821407|NCT05719103|ACTIVE_COMPARATOR|HFNC PP|HFNC flow at 60 L/min or maximum tolerable flow at prone position
62821408|NCT05719103|ACTIVE_COMPARATOR|NIV SP|CPAP with full face mask at 10 cmH2O at supine position
62821409|NCT05719103|ACTIVE_COMPARATOR|NIV PP|CPAP with full face mask at 10 cmH2O at prone position
62041095|NCT04524871|EXPERIMENTAL|Stage 1: Atezolizumab + Bevacizumab + ADG126|Participants will receive atezolizumab plus bevacizumab plus ADG126 until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
62041096|NCT04524871|EXPERIMENTAL|Stage 1: Atezolizumab + Bevacizumab + IO-108 1200 mg Q3W|Participants will receive atezolizumab plus bevacizumab plus IO-108 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
62821410|NCT05719103|PLACEBO_COMPARATOR|MC SP|Mask oxygen at supine position
62821411|NCT05719103|PLACEBO_COMPARATOR|MC PP|Mask oxygen at prone position
62821412|NCT06586567||Group 1 (SLE group):|50 patients fulfilling the1997 revised American Collage of Rheumatology classification criteria for SLE according to (Hochberg, 1997)., and h_pylori positive
62821413|NCT06586567||Group 2 (RA group):|50 RA patients diagnosed according to the American college of rheumatology (ACR)-EULAR RA classification criteria 2010. And H_pylori positive
62244422|NCT05563948|EXPERIMENTAL|Low THC : High CBD|Cannabis that is low in THC and high in CBD will be administered.
62434629|NCT02544100||Database Entry / Biospecimen Collection|Systematic Medical information of infants born with severe encephalopathy entered into database. In addition, Blood, urine, CFS samples will be collected.
62434630|NCT04180189|ACTIVE_COMPARATOR|Weighted fiber blanket|Using a weighted blanket
62434631|NCT04180189|PLACEBO_COMPARATOR|Regular fiber blanket|Using a specially designed fiber blanket without extra weight.
62434632|NCT06531265|EXPERIMENTAL|study group|Endobronchial cryobiopsy and cryotherapy using flexible bronchoscopy
62600872|NCT01004406|ACTIVE_COMPARATOR|standard statin monotherapy (SMT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to an oral daily dose of 40-80mg of Atorvastatin or equivalent without LDL-apheresis
62600873|NCT02004899|ACTIVE_COMPARATOR|F20|Patients randomized to this arm of the study receive 20 mcg fentanyl and 8 mg bupivacaine as their epidural loading dose
62600874|NCT02004899|EXPERIMENTAL|F50|Patients randomized to this arm of the study receive 50 mcg fentanyl with 8 mg bupivacaine as their epidural loading dose
62600875|NCT02004899|EXPERIMENTAL|F100|Patients randomized to this arm of the study receive 100 mcg fentanyl and 8 mg bupivacaine as their epidural loading dose
62600876|NCT05002517|EXPERIMENTAL|Tociliziumab group|Patients assigned to this arm will receive an intravenous dose of tocilizumab. Patients weighing 75 kg or more will receive 600 mg. Those weighing less than 75 kg will receive 400 mg.
62600877|NCT05002517|ACTIVE_COMPARATOR|Metilprednisolone group|Patients in this arm will receive a daily intravenous dose of 250 mg methylprednisolone for 3 days.
62600878|NCT01883947|EXPERIMENTAL|Touch massage|Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
62600879|NCT01883947|SHAM_COMPARATOR|non-TENS|The sham treatment will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
62600880|NCT01439022|EXPERIMENTAL|Exercise Programme|6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist.
62600881|NCT01439022|ACTIVE_COMPARATOR|Hand writing programme|6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
62600882|NCT00215527|EXPERIMENTAL|intrathecal laronidase|laronidase dose 1.74 mg, route intrathecal, frequency every 30 days, duration three months
62600883|NCT06638385|EXPERIMENTAL|DCE + SPACE SHIELD|Patients in the experimental group receive a DCE with implantation of a space-expanding shield.
62600884|NCT06638385|ACTIVE_COMPARATOR|DCE + CP|Patients in the control group receive a DCE similar to the intervention group, but without implantation of a space-expanding shield. Cranioplasty (CP) is performed after \~ 90 days in the customary manner.
62244423|NCT05563948|PLACEBO_COMPARATOR|Low THC : Low CBD|Cannabis that is low in THC and low in CBD will be administered.
62244424|NCT06360796|EXPERIMENTAL|ADC189|45 mg (about 100 μCi) \[(14)C\]ADC189
62244425|NCT05756153|EXPERIMENTAL|GFH925+Cetuximab|
62244426|NCT05495971|EXPERIMENTAL|Presbyopia|Subject's baseline vision will be compared with vision wearing treatment product
62434633|NCT01208402|ACTIVE_COMPARATOR|oral long acting beta blocker|oral administration of long acting beta blocker as standard of care on the day of surgery
62434634|NCT01208402|EXPERIMENTAL|Esmolol infusion|given 30 minutes prior to induction up to 12 hours post-op
62434635|NCT02678897|NO_INTERVENTION|Pain management in early pregnancy MTOP|Patients in early pregnancy (pregnancy weeks \<9weeks) undergoing medical termination of pregnancy gets Ibuprofen (tbl 600mg 3 times a day) and Paracetamol (tbl 1000mg 3 times a day).
62434636|NCT02678897|EXPERIMENTAL|Patient controlled analgesia (PCA)|"Pregnancy weeks 9-20. All patients get baselineanalgesics: Ibuprofein 600mg and Paracetamol 1000mg both x3 a day.~Patients get pain medication (Oxynorm) via PCA"
62434637|NCT02678897|ACTIVE_COMPARATOR|Oxynorm on-demand|"Pregnancy weeks 9-20. All patients get baselineanalgesics: Ibuprofein 600mg and Paracetamol 1000mg both x3 a day.~Patients get extra pain medication (Oxynorm) on-demad from the nurse."
62434638|NCT04302428||Pediatric CF Patients|Pediatric patients ages 3 months to 3 years with CF identified via newborn screening.
62600885|NCT03338543|EXPERIMENTAL|percutaneous stimulation|PENS in 2/100 hertz (HZ), 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
62600886|NCT03338543|EXPERIMENTAL|transcutaneous stimulation|TENS in 2/100 HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
62600887|NCT03338543|NO_INTERVENTION|Control|Conventional analgesic medication is offered.
62600888|NCT05970016|EXPERIMENTAL|5mg treatment group|Administered orally once a day (QD)
62600889|NCT05970016|EXPERIMENTAL|10mg treatment group|Administered orally once a day (QD)
62600890|NCT05970016|EXPERIMENTAL|20mg treatment group|Administered orally once a day (QD)
62600891|NCT05970016|EXPERIMENTAL|40mg treatment group|Administered orally once a day (QD)
62600892|NCT05970016|EXPERIMENTAL|60mg treatment group|Administered orally once a day (QD)
62600893|NCT05970016|EXPERIMENTAL|80mg treatment group|Administered orally once a day (QD)
62600894|NCT05970016|EXPERIMENTAL|100mg treatment group|Administered orally once a day (QD)
62821414|NCT06586567||Group 3|50 heqlthy age and sex matched adults were selected as control group
62821415|NCT03995368|EXPERIMENTAL|People with Schizophrenia|People who have been diagnosed with schizophrenia and meet the investigators' research criteria for symptoms indicative of schizophrenia within their lifetime.
62821416|NCT03995368|EXPERIMENTAL|People with TBI|People who have been diagnosed with a mild or moderate traumatic brain injury (TBI) and meet research criteria indicative of TBI within their lifetime.
62041097|NCT04524871|EXPERIMENTAL|Stage 1: Atezolizumab + Bevacizumab + NKT2152|Participants will receive atezolizumab plus bevacizumab plus NKT2152 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
62041098|NCT04524871|EXPERIMENTAL|Stage 1: Atezolizumab + Bevacizumab+ IO-108 1800 mg Q3W|Participants will receive atezolizumab plus bevacizumab plus IO-108 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic andbiochemical data, local biopsy results (if available), and clinical status
62041099|NCT05809596|OTHER|Device Group|WATCHMAN FLX Pro LAAC Device Implantation
62041100|NCT01492075|ACTIVE_COMPARATOR|Continuous infusion|Continuous infusion of LA intraabdominally
62041101|NCT01492075|EXPERIMENTAL|PCRA (Intermittent injection)|Patient controlled LA intraabdominally
62041102|NCT06353321||Single group non blinded|Single Center Study, pilot/feasibility, private for profit observational study
62041103|NCT06733896|EXPERIMENTAL|study group|
62600895|NCT01954134||thyroid cancer, healty|Thyroid cancer group: patients with differentiated or dedifferentiated thyroid cancer Healty: control group
62821417|NCT03995368|EXPERIMENTAL|Healthy Controls|People without a history of psychiatric illness or TBI and who do not meet research criteria for a psychiatric illness or TBI.
62821418|NCT04879030|ACTIVE_COMPARATOR|beta-lactam monotherapy|only beta-lactam antibiotics
62041104|NCT06733896|ACTIVE_COMPARATOR|control group|
62041105|NCT01245712|EXPERIMENTAL|Treatment (APBI)|Within 10 weeks of last breast cancer surgery, patients undergo APBI delivered with proton radiation BID for 5 days.
62041106|NCT06126783|EXPERIMENTAL|IBI311|The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W
62041107|NCT06732531|EXPERIMENTAL|BH011|BH011 is administered intravesically through a urinary catheter and is retained in the bladder for 1 hour.
62041108|NCT03457753|EXPERIMENTAL|Subjects with ALS|Riluzole Oral Soluble Film (ROSF) 50 mg will be administered in subjects with ALS twice daily. It is intended that at least five (5) of the twenty-five (25) subjects enrolled will be subjects scoring greater than 20 on the Eating Assessment Tool (EAT-10) (representative of ALS patients reporting moderate swallowing impairments in a patient report validated scale).
62041109|NCT02251990|EXPERIMENTAL|Immediate Treatment Group (ITG): Grazoprevir/Elbasvir|Participants receive a grazoprevir/elbasvir FDC tablet once daily (q.d.) by mouth during a 12-week Active Treatment period (Week 1 to Week 12) and are followed-up for 24 weeks to Week 36.
62041110|NCT02251990|PLACEBO_COMPARATOR|Deferred Treatment Group (DTG): Placebo > Grazoprevir/Elbasvir|Participants receive a placebo tablet q.d. by mouth for 12 weeks (placebo treatment period). After a 4-week Follow-Up period, participants receive open-label grazoprevir/elbasvir FDC during a 12-week Active Treatment period (Week 16 to Week 28). Participants are then followed-up for 24 weeks to Week 52.
62041111|NCT02792166|ACTIVE_COMPARATOR|BPD-DS|BPD-DS involves creating a sleeve gastrectomy and creation of a Roux-en-Y bypass involving a Roux limb (150cm) which is anastomosed to the transected first-stage of the duodenum and a short common channel (100cm).
62041112|NCT02792166|EXPERIMENTAL|SADI-S|SADI-S involves creating a sleeve gastrectomy but simplifies the bypass part of the BPD-DS by a single anastomosis of a loop of jejunum at 250cm from the ileocecal valve (longer common channel) to the transected first-stage of the duodenum instead of the Roux-en-Y construct.
62041113|NCT04072159|EXPERIMENTAL|Pharmacist-Administered HPV Vaccine Series Completion group|For the Pharmacist-Administered HPV Vaccine Series Completion group (intervention group), primary care providers will refer patients who have received the initial HPV vaccine to receive the additional doses at patients' community retail pharmacies. Patients between ages 9-14 will need to receive one additional HPV vaccine dose with their community pharmacist 6-12 months after receiving Dose 1. Patients aged 15 and older will need to receive the 2nd dose 1-2 months after receiving the first HPV vaccine dose and the 3rd dose 6-months after receiving the initial dose.
62600896|NCT05644431||Gastric and gastroesophageal junctional adenocarcinomas|Patient under standard chemotherapy in localized and resectable gastric and gastroesophageal junctional adenocarcinomas
62821419|NCT04879030|EXPERIMENTAL|beta-lactam and fluoroquinolone combination therapy|one beta-lactam antibiotic and one fluoroquinolone
62041114|NCT04072159|NO_INTERVENTION|Primary Care Provider HPV Vaccine Series Completion|Participant in the Primary Care Provider HPV Vaccine Series Completion (control group) will receive standard care and will be scheduled to return to the clinic for the remaining HPV vaccine doses.
62041115|NCT06698887||Participants receiving idecabtagene vicleucel|
62041116|NCT05356806||One|Patients with treated periodontitis who have had dental implants placed at the Periodontics Specialist Clinic of the UCM School of Dentistry, and are going to be rehabilitated.
62821420|NCT05682508|EXPERIMENTAL|Education group|The training planned four step. In the first interview, a pre-test will be applied by the researcher. The patient will then be trained and given a training booklet. The second interview will take place 30 days after the end of the first training. The topics will be summarised and the benefits of adherence to diet and fluid control will be emphasised. The third interview will be held 30 days after the second interview. In this interview, the patient's questions will be answered and the necessary training sections will be explained again for patient. The issues that prevent the patient from complying with fluid and diet control will be discussed with the patient and positive developments in the patient prognosis will be reinforced. The last interview will be held 30 days after the third interview. In all interviews, data will be collected with data collection tools and clinical parameters of the patient will be recorded.
62244427|NCT05152927|EXPERIMENTAL|Parathyroid Eye (PTeye)|For patients assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
62244428|NCT05152927|NO_INTERVENTION|Usual Standard of Care|The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
62244429|NCT03001128||Cohort A: ART initiated during chronic infection|Cohort A will include 36 participants who initiated ART during chronic infection.
62244430|NCT03001128||Cohort B: ART initiated during acute or early infection|Cohort B will include 30 participants who initiated ART during acute/early HIV infection.
62244431|NCT04274764|EXPERIMENTAL|Personalized eHealth Education & Motivational Interviewing|Personalized eHealth Glaucoma Education \& Motivational Interviewing
62244432|NCT04274764|NO_INTERVENTION|Standard Education|Participant will receive standard glaucoma education.
62244433|NCT04109365|EXPERIMENTAL|Electrical Epidural Stimulation Test (EST)|Laboring women are given EST test initially before local anesthetic is administered and 1 hour post-anesthetic in order to measure sensory and motor responses.
62821421|NCT05682508|NO_INTERVENTION|Control grup|No training will be given to the control group. In the first interview will be applied data collection tools and will be recorded clinical parameters. Last interview with control group will be held 90 days after first interview. Data collection tools will be applied and clinical parameters will be recorded in last interview. The training booklet will be given also to patients in control group at the end of the research.
62821422|NCT06450067||Diagnosed relapsed or refractory B-cell acute lymphoblastic leukemia|Diagnosed relapsed or refractory B-cell acute lymphoblastic leukemia
62434639|NCT06217133|NO_INTERVENTION|control group|The analysis of heart rate variability will be carried out in theIn the control group (NT), data collection will be carried out in the Rooming Room in a single reference collection lasting 20 minutes, and analyzed in 4 5-minute intervals. Newborns will be full term and will be in the supine position, lying in the common crib and resting. All collections for this group will be carried out in the afternoon on a day to be agreed with the mother or responsible companion.
62821423|NCT05202119|ACTIVE_COMPARATOR|Active stimulation|Active stimulation at 2mA
62041117|NCT05494853||HCC|HCC positive
62434640|NCT06217133|ACTIVE_COMPARATOR|CPAP Group|The analysis of heart rate variability will be carried out in the in the CPAP group, conventional and in the bubble CPAP.
62244434|NCT05753345|EXPERIMENTAL|Intervention: aquatic occupational therapy (AquOTic-NM)|aquatic occupational therapy 30 minutes, self care training 15 minutes
62244435|NCT05540574|EXPERIMENTAL|Zolpidem, then Placebo|"Participants will first receive Zolpidem for a 4-week period. A 5 mg dose of Zolpidem will be given at bedtime for one week and then will increase to 10 mg if needed and if well tolerated.~Participants will then receive Placebo (fake tablet) for a 4-week period. A 5 mg dose of matching Placebo will be given at bedtime for one week and then will increase to 10 mg if needed and if well tolerated."
62821424|NCT05202119|SHAM_COMPARATOR|Sham stimulation|
62821425|NCT05358236|OTHER|training + written and illustrated training brochure|"Postpartum first day was given wound care and genital hygiene training (one hour).~At the end of the training, the mothers were given a written and illustrated training brochure."
62821426|NCT05358236|NO_INTERVENTION|Standard of care (Control group)|Standard of care (Control group) Left to the usual care of the hospital
62041118|NCT05494853||Non HCC|HCC negative
62244436|NCT05540574|EXPERIMENTAL|Placebo, then Zolpidem|"Participants will first receive Placebo (fake tablet) for a 4-week period. A 5 mg dose of matching Placebo will be given at bedtime for one week and then will increase to 10 mg if needed and if well tolerated.~Participants will then receive Zolpidem for a 4-week period. A 5 mg dose of Zolpidem will be given at bedtime for one week and then will increase to 10 mg if needed and if well tolerated."
62434641|NCT03010085|ACTIVE_COMPARATOR|A (Open left-sided hepatectomy)|Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
62434642|NCT03010085|EXPERIMENTAL|B (Laparoscopic left-sided hepatectomy)|Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
62041119|NCT04754607|ACTIVE_COMPARATOR|Low Level Laser Therapy Group|"Low Level Laser Therapy (LLLT): Low-level laser therapy will be applied to the cases in addition to LT4 hormone replacement therapy.~LLLT group will be treated using a continuous wave GaAIAs type diode laser (Intelect® Mobile Laser, Model No: 2779, Production Year: 2016; Chattanooga Group) device in the treatment area of 0.07 cm2. Continuous mode at 850 nm wavelength, 100 mW output power,1.43 W/cm2 power density and 28.57 J / cm2 energy density will be used."
62041120|NCT04754607|SHAM_COMPARATOR|Sham Group|Probes were placed in the sham laser group in a similar way as in the treatment group.
62041121|NCT05072873|EXPERIMENTAL|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
62041122|NCT05072873|PLACEBO_COMPARATOR|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
62041123|NCT06733220||STR-CONG|Patients with congenital strabismus will undergo a comprehensive eye and orthoptic examination and balance test before strabismus surgery at 30 days after surgery, at 90 days after surgery, and at 180 days after surgery.
62041124|NCT06733220||STR-ACQ|Patients with acquired strabismus will undergo a comprehensive eye and orthoptic examination and balance test before strabismus surgery, at 30 days after surgery, at 90 days after surgery, and at 180 days after surgery.
62041125|NCT01953848|EXPERIMENTAL|1: Low dose EC905|
62041126|NCT01953848|EXPERIMENTAL|2: High dose EC905|
62041127|NCT01059565|EXPERIMENTAL|AZLI|Participants were randomized to receive AZLI for up to 24 weeks and may have continued to receive AZLI during the open-label phase for up to an additional 24 weeks.
62041128|NCT01059565|PLACEBO_COMPARATOR|Placebo|Participants were randomized to receive placebo to match AZLI for up to 24 weeks and may have switched to AZLI during the open-label phase for up to 24 weeks.
62041129|NCT05081713|OTHER|Phase 1|Observational evaluations for 6 months followed by 3-4 months of high-intensity training (HIT)
62041130|NCT05081713|OTHER|Phase 2|Observational evaluations for 1 month followed by 3-4 months of high-intensity training (HIT)
62041131|NCT04155866||Healthy participants|Measurement of lower-limb muscle activation from healthy participants.
62041132|NCT04155866||Chronic Stroke Survivors|Measurement of lower-limb muscle activation from chronic stroke survivors
62041133|NCT00476372||Parkinson's disease|Pt with parkinsons disease
62041134|NCT01744652|EXPERIMENTAL|Arm A - Crizotinib + Dasatinib|"Arm A: Patients receive dose of crizotinib plus an increasing dose of dasatinib. All participants take dasatinib by mouth 1 time each day. Patients take this drug alone on Day 1 of Cycle 1, before the first day they receive the study drug combination. Final dose level in both arms (dose level number 5) is identical. In the case that both arms define dose level 5 as the MTD, then the expansion cohort for safety will include 10 patients with that dose. If two different MTDs on both arms defined, then both MTDs cohorts expanded with 10 patients and 20 patients included on the safety expansion analysis.~Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle.~Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle. Dasatinib Expansion Dose: MTD from dose escalation group."
62041135|NCT01744652|EXPERIMENTAL|Arm B - Dasatinib + Crizotinib|"Arm B: Patients receive dasatinib plus an increasing dose of crizotinib. All participants take dasatinib by mouth 1 time each day. Patients take this drug alone on Day 1 of Cycle 1, before the first day they receive the study drug combination. Final dose level in both arms (dose level number 5) is identical. In the case that both arms define dose level 5 as the MTD, then the expansion cohort for safety will include 10 patients with that dose. If two different MTDs on both arms defined, then both MTDs cohorts expanded with 10 patients and 20 patients included on the safety expansion analysis.~Dasatinib 140 mg by mouth daily in a 28 day cycle. Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle.~Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group."
62041136|NCT05773768|EXPERIMENTAL|New care program|The health care provider will use the EHRA-PATHS' newly developed care pathways to assess whether there is an indication for presence of risk factors and comorbidities. If this is the case, the care pathways will show possible next steps for confirming the presence of these risk factors and comorbidities. If confirmed, treatment according to the current guidelines should be initiated. Since this leads to an individualized management plan, procedures can differ between patients and will also depend on local processes.
62041137|NCT05773768|NO_INTERVENTION|Routine clinical care|The health care provider follows current clinical practice with regards to history taking, physical examination etc.
62041138|NCT06733207||Patients in Intensive Care|"This prospective diagnostic study involves a single cohort of patients undergoing pupil assessment. Within this cohort, the evaluations will be performed by three distinct sub-cohorts of healthcare providers:~* Senior physicians : Experienced anesthesiologists or critical care specialists with extensive training in pupil evaluation and neurological assessment.~* Anesthesiology Residents: Trainees responsible for assessing the pupils of the patients, focusing on their developing assessment skills.~* Nurses: Registered nurses involved in the assessment of patients' pupils as part of their routine care."
62041139|NCT00934284||Injection only|Participants receive a therapeutic selective nerve root block and advice to return to normal activity as tolerated.
62041140|NCT00934284||Injection plus physical therapy|Participants are referred to physical therapy within one week of receiving a therapeutic selective nerve root block. Physical therapy consists of end-range movements in a directional preference and/or mechanical traction to reduce radicular symptoms.
62041141|NCT05320731|ACTIVE_COMPARATOR|Nebulization with lidocaine|A face mask nebulizer with oxygen flow rate of 8 L/min will be used to deliver 10 mL of 2% lidocaine. Patients will be encouraged to inhale deeply to facilitate entrainment of nebulized LA into their airway. Adequate topical anesthesia will be confirmed by heaviness or numbness of the tongue.
62244437|NCT05978284|EXPERIMENTAL|Part 1: Dose Escalation|"During the dose-escalation, an accelerated titration design (ATD) will be utilized for the first two dose groups (0.03mg and 0.1 mg), and the conventional 3+3 dose escalation method will be used for the subsequent dose groups. The entire duration of 28 days after the first dose of ZG006 is defined as the dose-limiting toxicity (DLT)."
62244438|NCT05978284|EXPERIMENTAL|Part 2: Dose Expansion|Participants will receive the RP2D/MTD identified in Part 1 (dose exploration) of the study.
62623391|NCT03737799||Group 2 Late Onset (insulin)|Diagnosed with diabetes within the previous 1 year. Aged \>50 at the time of diabetes diagnosis and treated with insulin therapy
62244439|NCT05090995|ACTIVE_COMPARATOR|Self-Monitoring and Feedback|The intervention consists of subjects wearing a PPG device for 6 weeks. Subjects will monitor their own health and report their sleep behaviors daily during this time. On weeks two, four, and six subjects will receive personalized health feedback based on the PPG device data and sleep diaries.
62244440|NCT05090995|PLACEBO_COMPARATOR|Self-Monitoring|The intervention consists of subjects wearing a PPG device for 6 weeks. Subjects will monitor their own health and report their sleep behaviors daily during this time.
62600897|NCT00072436|EXPERIMENTAL|Treatment|"Some patients receive an initial dose of alvocidib IV over 1-7 hours on day 1 (course 0). Beginning 1 week later and for all subsequent courses, all patients receive gemcitabine hydrochloride IV over 60-150 minutes on days 1 and 15 and alvocidib IV over 1-7 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of gemcitabine hydrochloride and alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment at that dose."
62244441|NCT06734780||Adult patients (age ≥18) diagnosed with CD|Patients who underwent intestinal resections due to Crohn's disease or its complications
62434643|NCT03474705|EXPERIMENTAL|Eccentric Training Group|Eccentric training of the upper trapezius muscles. The intervention will consist of ten sessions of 25-30 minutes (twice a week over 5 consecutive weeks) of eccentric exercises of the shoulder muscles, as neural activation increases after 4 weeks of eccentric training. The total duration of the intervention will be 2 hours and a half.
62434644|NCT04887545||Thoracentesis|Patients who need removal of excess pleural effusion and assessed for the possibility of lung cancer.
62600898|NCT05839106|EXPERIMENTAL|PM1032 monotherapy|PM1032 0.3mg/kg-12mg/kg
62600899|NCT06618833|EXPERIMENTAL|Patient admitted for first atrial fibrillation ablation|
62600900|NCT03576534|NO_INTERVENTION|Control|Standard of care
62244442|NCT02909985|EXPERIMENTAL|Visual response to IR in healthy eyes|"15 healthy participants will describe IR light passing through narrow bandpass filters over a broad-spectrum light source.~As intensity increases from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broadband Tungsten halogen light with narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see."
62244443|NCT02909985|EXPERIMENTAL|Visual response to IR in colorblind eyes|"6 colorblind participants will describe IR light passing through narrow bandpass filters over a broad-spectrum light source.~As intensity increases from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broadband Tungsten halogen light with narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see."
62434645|NCT05213507|EXPERIMENTAL|Inhaled Amikacin plus Conventional Therapy|"0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 7-10 days per month, for 3 months.~In order to observe and cope with adverse events timely, subjects will be admitted to the ward during the course of medication.~Subjects will take conventional therapy at the same time."
62244444|NCT06735560|EXPERIMENTAL|89Zr-TLX250|Patients will be injected with a single dose of 89Zr-TLX250.
62244445|NCT04711668|EXPERIMENTAL|Group Ketamin|0.5 mg / kg i.v. ketamine bolus at induction and 0.25 mg / kg / hr i.v. ketamine infusion intraoperatively
62244446|NCT04711668|EXPERIMENTAL|Group Lidokain|1.5 mg / kg i.v. lidocaine bolus at induction and 1.5 mg / kg / hr i.v. lidocaine infusion intraoperatively
62434646|NCT05213507|OTHER|Conventional Therapy|According to the subjects' personal characteristics and guidance of The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2021, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled glucocorticoids and long-term oxygen therapy.
62434647|NCT02157233|EXPERIMENTAL|Hot environment|Subjects will perform the intervention in a hot environment (33°C)
62434648|NCT02157233|SHAM_COMPARATOR|Neutral environment|Subjects will perform the intervention in a neutral environment (22°C)
62434649|NCT01155063||Main Group|Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer Who Are Disease-Free After 2-3 Years Of Initial Adjuvant Tamoxifen Therapy
62244447|NCT04711668|PLACEBO_COMPARATOR|Group Placebo|i.v. saline (in the same volume and duration like group ketamine/lidokain)
62434650|NCT02323659|ACTIVE_COMPARATOR|Methotrexate arm|Patients assigned to receive methotrexate
62434651|NCT02323659|ACTIVE_COMPARATOR|Interferon Alfa-2b|Patients assigned to receive Interferon alfa 2b
62434652|NCT06366672|EXPERIMENTAL|MVA-BN vaccinated|MVA-BN vaccine administered: day 0 and day 28 Phlebotomy: within 30 days prior to first vaccine dose, day 0, day 14, day 28, day 35, day 42, day 56, day 90, day 110, day 150, day 210, day 395 Research bronchoscopy: within 30 days prior to first vaccine dose, day 42, day 210, day 395 Skin punch biopsy: within 30 days prior to first vaccine dose, day 42, day 210, day 395 Bone marrow aspiration: within 30 days prior to first vaccine dose, day 56, day 110, day 210, day 395
62244448|NCT00659893|EXPERIMENTAL|1|Cohort 1 One 25 cm2 treatment area; on one arm
62244449|NCT00659893|EXPERIMENTAL|2|Cohort 2 One 50cm2 contiguous treatment area; on one arm
62244450|NCT00659893|EXPERIMENTAL|3|Cohort 3 Two 25cm2 treatment areas; one on each arm
62821427|NCT06511258|EXPERIMENTAL|Prehabilitation|The intervention consists of exercise, nutritional support and breathing techniques. The exercise component consists of 1) strength training; 2) cardio and 3) stretching. Participants will be encouraged to complete self-directed and/or group sessions \>= 3 times per week. Each intervention participant will be provided a unique login to the virtual prehabilitation platform, which is the STRIVE Trial website. The nutrition component includes: 1) protein supplementation; 2) nutrition advice to support healthy eating. For the breathing component, participants will be encouraged to watch the video on Inspiratory Muscle Training (IMT) which involves diaphragmatic breathing and coughing/huffing. They will also be provided with an instruction booklet to take to hospital with them to support postoperative conduct of IMT during early recovery.
62821428|NCT06511258|NO_INTERVENTION|Control|To support blinding, improve enrollment and reflect usual care, widely available physical activity (World Health Organization Recommendations for Physical Activity for ages 18-64 and \>65) and healthy eating recommendations (Canada's Food Guide Snapshot) documents will be provided to control participants (without active or online support).
62821429|NCT05638256|EXPERIMENTAL|68Ga-NY104|
62821430|NCT01752426|EXPERIMENTAL|Heavy Water + PCI-32765|Subjects given 50ml 70% 2H2O (Heavy Water) 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks (labeling phase). Subjects given first dose in clinic. Subjects then given individual doses of 2H2O to consume at home; after the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765. PCI-32765 administered with 8 ounces (\~240mL) of water at a dose of 420 mg (3 x 140mg capsules) orally once daily and continued daily. Treatment duration is 12 cycles, with each cycle consisting of 28 days.
62821431|NCT06496620|EXPERIMENTAL|Biological: Solrikitug High Dose|Solrikitug
62821432|NCT06496620|OTHER|Placebo|Placebo
62821433|NCT06496620|EXPERIMENTAL|Biological: Solrikitug Low Dose|Solrikitug
62821434|NCT05611151|EXPERIMENTAL|CADe Colonoscopy|CADe Colonoscopy: Patient undergoes WISE VISION® Endoscopy CADe colonoscopy
62821435|NCT05611151|ACTIVE_COMPARATOR|HDWL Colonoscopy|HDWL Colonoscopy: Patient undergoes HDWL colonoscopy without CADe
62821436|NCT05917626|EXPERIMENTAL|Digital SPA|A psychological intervention for chronic pain in adolescents administered using an app co-created with patients.
62821437|NCT05917626|NO_INTERVENTION|Usual Care|Participants assigned to this arm will receive usual care from their hospital.
62821438|NCT06079697|EXPERIMENTAL|Arm I (prehabilitation)|Patients wear a Fitbit or a personal wearable device beginning on day 1 and receive the prehabilitation exercise intervention consisting of 2000-4000 steps per day, sit-to-stand training 3 days per week, and standing therapeutic exercises 3 days per week beginning on day 2 for up to 2-5 weeks prior to surgery. Patients continue wearing the Fitbit or personal wearable device from post-operative day 1 until hospital discharge or until 14 days post-surgery.
62821439|NCT06079697|ACTIVE_COMPARATOR|Arm II (usual care)|Patients wear a Fitbit or personal wearable device beginning on day 1 up until day of surgery and then from post-operative day 1 until hospital discharge or until 14 days post-surgery.
62821440|NCT02864394|EXPERIMENTAL|Pembrolizumab|Participants with NSCLC receive pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes every 3 weeks (Q3W) for up to 35 doses (approximately 24 months).
62244451|NCT00659893|EXPERIMENTAL|4|Cohort 4 One 25cm2 treatment area; and one 50cm2 contiguous treatment area; one on each arm
62434653|NCT03279484|EXPERIMENTAL|NAVIGO 4LV implant|All patients will be attempted to implant or implanted with NAVIGO 4LV lead
62434654|NCT01814137|EXPERIMENTAL|IDegAsp BID + IAsp OD|
62434655|NCT01814137|EXPERIMENTAL|IDeg OD + IAsp TID|
62600901|NCT03576534|ACTIVE_COMPARATOR|Study|PBUF used prior to Cardiopulmonary bypass
62600902|NCT02455609|ACTIVE_COMPARATOR|dexmedetomidine (I)|intrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine in 1 ml volume.
62821441|NCT02864394|EXPERIMENTAL|Docetaxel|Participants with NSCLC receive Docetaxel 75 mg/m\^2 IV over 1 hour Q3W until disease progression, toxicity, investigator's decision to discontinue, or consent withdrawal.
62821442|NCT03799107||Retrospective|Children born with assistance
62821443|NCT03799107||Prospective|People who have sought evaluation/treatment for infertility
62821444|NCT01280903|EXPERIMENTAL|STAR Intervention|Staying Active with Arthritis Intervention
62821445|NCT01280903|PLACEBO_COMPARATOR|Attention-Control|Senior Health Information Intervention
62244452|NCT00659893|EXPERIMENTAL|5|Cohort 5 One 75cm2 contiguous treatment area; on one arm
62244453|NCT00659893|EXPERIMENTAL|6|Cohort 6 Two 50cm2 contiguous treatment area; one on each arm
62244454|NCT00659893|EXPERIMENTAL|7|Cohort 7 One 25cm2 treatment area; and one 75cm2 contiguous treatment area; one on each arm
62244455|NCT00659893|EXPERIMENTAL|8|Cohort 8 One 100cm2 contiguous treatment area; on one arm
62244456|NCT06734494||Airseal group (A)|Patients who underwent a laparoscopic appendectomy using Airseal
62244457|NCT06734494||Standard group (S)|Patients who underwent a laparoscopic appendectomy using standard insufflation
62600903|NCT02455609|ACTIVE_COMPARATOR|ketamine (II)|intrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume.
62623392|NCT03737799||Group 3 Late Onset (no insulin)|Diagnosed with diabetes within the previous 1 year. Aged \>50 at the time of diabetes diagnosis and treated without insulin
62821446|NCT05164289||Control group|Patients in the control group will have simple consultations on D15, D30, D45, D60 and D75
62821447|NCT05164289||EMDR group|Patients in the EMDR group will have EMDR session on D15, D30, D45, D60 and D75
62244458|NCT05933863||immunotherapy cohort|Extensive stage SCLC patients receiving first-line chemotherapy plus PD-(L)1 antibody treatment will be enrolled in this cohort. Baseline tumor tissue samples and peripheral blood samples will be collected for transcriptome and immunohistochemistry analysis etc.
62821448|NCT04503070||Baseball Batters|Participants must be healthy volunteers who accept all provisions of the study and agree to complete the program in its entirety. Participants should have their own bat and relative experience of at least 2 years of hitting a baseball. Ages accepted will be 16-40.
62244459|NCT05933863||chemotherapy cohort|Extensive stage SCLC patients receiving only first-line etoposide plus platinum chemotherapy will be enrolled in this cohort. Baseline tumor tissue samples and peripheral blood samples will be collected for transcriptome and immunohistochemistry analysis etc.
62244460|NCT03652259|EXPERIMENTAL|Cohort 1: SRP-9003|Participants will receive a single intravenous (IV) infusion of SRP-9003 at a prespecified dose.
62244461|NCT03652259|EXPERIMENTAL|Cohort 2: SRP-9003|Participants will receive a single IV infusion of SRP-9003. Dose will be determined based on the findings from Cohort 1.
62244462|NCT03226704||1|Patients \>/=3 - \</=65 years of age, at least 15 kg, with relapsed/refractory cancer that has recurred after or not responded to at least one standard regimen
62244463|NCT05978180|EXPERIMENTAL|Medical Device : HO-1|"Single injection Hyaluronic acid associated with tranexamic acid 4.8 ml will be injected in one time Intra-articular single injection~* Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~* The injection will be performed at Day 1."
62244464|NCT05978180|EXPERIMENTAL|Medical Device : HS-3|"Three injections Hyaluronic acid associated with tranexamic acid 2.2 ml will be injected in three times (one injection per week) Intra-articular single injection~* Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~* The injections will be performed at Days 1, 8 and 15."
62244465|NCT05978180|ACTIVE_COMPARATOR|Medical Device : SINOVIAL® ONE|"Hyaluronic acid 2.5 ml will be injected in one time Intra-articular single injection~* Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~* The injection will be performed at Day 1."
62244466|NCT04202250|ACTIVE_COMPARATOR|CEMP (closed-ended multiport catheter) group|closed-ended multiport femoral nerve catheter will be included in the patients undergoing total knee arthroplasty surgery for postoperative analgesia
62244467|NCT04202250|ACTIVE_COMPARATOR|OESP (open-ended single port catheter) group|open-ended single port femoral nerve catheter will be included in the patients undergoing total knee arthroplasty surgery for postoperative analgesia
62244468|NCT03878472|EXPERIMENTAL|Neoadjuvant immunotherapy with PD-1|
62244469|NCT03878472|EXPERIMENTAL|Neoadjuvant immunotherapy with PD-1+apatinib|
62244470|NCT03878472|EXPERIMENTAL|Neoadjuvant immunotherapy with PD-1+apatinib+S1|
62434656|NCT06019130|EXPERIMENTAL|Patients < 26 years with non-metastatic disease with CR or PR after induction therapy|"Participants receive Nivolumab (4.5 mg/kg BW (max. 360 mg) every three weeks) during induction chemotherapy for a total of 3 doses, starting on day 1 of cycle 1 of induction standard chemotherapy with cisplatin 100 mg/m2 on day 1, plus 5-fluorouracil 1,000 mg/m2/d from day 1-5.~After induction therapy patients will undergo standard radiochemotherapy. Primary PTV1 including elective irradiated LN-levels, will be 45Gy, with a boost ad 59.4Gy in patients with PR or a reduced boost at 54Gy in patients with CR. Cisplatin will be administered at 3x20mg/m2 in the first and last week of radiotherapy, each.~Radiochemotherapy is followed by maintenance therapy with recombinant interferon-ß1a at 3x6Mio IU/week s.c. for 6 months."
62449142|NCT03181438|SHAM_COMPARATOR|Saline Group|"The block will be performed under general anesthesia, according to the technique described below:~* The patient will be placed supine with the abdomen exposed between the iliac crest and the costal margin~* After skin antisepsis, a high-frequency ultrasound transducer will be placed transversely across the anterior axillary line above the iliac crest~* In this region, the abdominal musculature (external oblique, internal oblique and transverse abdomen) is identified, and the transverse abdominal plane of the abdomen~* The needle (BD-A-50mm) will be inserted in the technique in plane to the region of the transverse plane of the abdomen, where the solution will be administered.~* In this group, will be administered 20 mL of Saline"
62449143|NCT00919581||Healthy controls|
62821449|NCT06297525|EXPERIMENTAL|Phase 1a (Part 1, Dose Escalation)|Up to 5 dose levels with STP938 administered as oral monotherapy
62821450|NCT06297525|EXPERIMENTAL|Phase 1b (Part 2, Safety Expansion)|Further evaluation of STP938 administered as oral monotherapy at the RP2D
62244471|NCT03878472|EXPERIMENTAL|Neoadjuvant immunotherapy with PD-1+apatinib+S1+Oxaliplatin|
62821451|NCT05649969|EXPERIMENTAL|STRONG Program|the STRONG program includes consultations with a Moffitt dietician, logging intake of food daily into a food diary with a Fitbit smartphone app, and completing questionnaires.
62244472|NCT05046171|EXPERIMENTAL|Arm 1: Pharmacist-led deprescribing intervention|Pharmacists will complete a comprehensive medication assessment with the participant via telemedicine and discuss tailored recommendations for discontinuations of potentially inappropriate medications. The pharmacist will document the evaluation and recommendations and communicate to the participant and care team members. The pharmacist will telephone each participant at least one time after the initial intervention to assess adherence to instructions and recommendations, and to assess any symptoms potentially related to medication discontinuation.
62244473|NCT05046171|ACTIVE_COMPARATOR|Arm 2: Patient education brochure|Participants will receive a brochure discussing medication appropriateness and deprescribing in general terms
62244474|NCT05406752|EXPERIMENTAL|paracetamol Uniflash (125 mg/ 1.25 mL)|1 sachet of paracetamol Uniflash 125mg / 1.25 mL
62244475|NCT05431361|EXPERIMENTAL|Prehabilitation|PREHAB participants will receive a multimodal intervention comprising of exercise, nutrition, and psycho/behavioural/educational support provided by an interprofessional prehab team comprising kinesiologists, dietitians, psychologists, and a previous LLD study partner. To facilitate overall compliance and appropriate adaptation to the home-based intervention components, participants will receive printed material, and a study coordinator will communicate weekly with patients to provide encouragement, monitor adherence, and clarify any questions or concerns.
62449144|NCT00919581||Subjects with spinal cord injury|
62821452|NCT04774289||1|Participants with NF1 seen at the NIH from 1/1/1998 to 1/1/2020
62041142|NCT05320731|ACTIVE_COMPARATOR|Atomization with lidocaine|Our simple atomization device, a modification of the McKenzie technique, will be used. One end of oxygen bubble tubing will be cut to fit into the barrel of 1 mL syringe and attached to one connector of a 3-way tap. A 10-mL syringe filled with 2% lidocaine will be attached to the other connector of the 3-way tap. A 6 Fr suction catheter, with its colored end cut and its distal blind end cut open, will be attached to oxygen bubble tubing via the male Luer connector of the 3-way tap. The other end of bubble tubing will be then attached to an oxygen source turned on to deliver a flow of 6 L/min. As LA is slowly atomized as a jet-like spray, the catheter will be directed towards the soft palate and posterior pharynx in a controlled fashion during patients' inspiration to topicalize the airway. Patients will be asked to take full vital capacity breaths of atomized LA contained oxygen. Adequate topical anesthesia will be confirmed by tongue heaviness or numbness
62041143|NCT03853109|EXPERIMENTAL|Cohort 1|Cohort 1
62041144|NCT03853109|EXPERIMENTAL|Cohort 2|Cohort 2
62041145|NCT03853109|EXPERIMENTAL|Cohort 3|Cohort 3
62041146|NCT03853109|EXPERIMENTAL|Cohort 4|Cohort 4
62041147|NCT03853109|EXPERIMENTAL|Cohort 6|Cohort 6
62041148|NCT03853109|EXPERIMENTAL|Cohort 7|Cohort 7
62041149|NCT03853109|EXPERIMENTAL|Cohort 8|Cohort 8
62041150|NCT03853109|EXPERIMENTAL|Cohort 9|Cohort 9
62041151|NCT06711510|OTHER|Standardized protocol for all participants|"Nine evaluations (every 3 months) over a 2-year follow-up, with the same standardized protocol for all participants, including:~* At the inclusion visit (M0), after 12 months (M12) and after 24 months (M24):~  * clinical (neurological) evaluation~ * behavioral examination~ * cognitive testing~ * blood sampling (determination of carrier / non-carrier status by means of GRN testing will be done at M0 visit; results will remain strictly confidential and not disclosed to study participants and investigators)~ * brain MRI~ * olfactory swab sampling with nasal brush~ * skin punch biopsy (optional)~ * lumbar puncture for CSF sampling (optional)~* For the remaining visits (M3, M6, M9, M15, M18, M21):~  * clinical evaluation~ * blood sampling"
62041152|NCT06340620|ACTIVE_COMPARATOR|Standard echoendoscope|Standard echoendoscope will be used and EUS examination will be performed per standard of care.
62041153|NCT06340620|ACTIVE_COMPARATOR|EndoSound Vision System|EndoSound Vision System will be used and EUS examination will be performed per standard of care.
62041154|NCT06732427|EXPERIMENTAL|Fospropofol Disodium|Painless gastrointestinal endoscopy in group L was mainly performed using fospropofol Disodium for injection
62041155|NCT06732427|ACTIVE_COMPARATOR|propofol|Painless gastrointestinal endoscopy in group B was mainly performed using propofol
62041156|NCT04378348|EXPERIMENTAL|Motivational Interview|
62041157|NCT04378348|EXPERIMENTAL|Participatory Group Activity|
62041158|NCT04378348|PLACEBO_COMPARATOR|Control Condition|
62041159|NCT05460325|EXPERIMENTAL|Lanadelumab 300 mg|Participants received lanadelumab 300 milligrams (mg), subcutaneously (SC), once every 2 weeks (Q2W) from Day 0 to Day 182 (26 weeks).
62449145|NCT03767777|EXPERIMENTAL|Intervention arm|Participants will be treated with Artery Stent Graft System Intervention: Device: Artery Stent Graft System
62449146|NCT04959695|EXPERIMENTAL|Prolonged exposure with PE Coach|The mobile application will be incorporated into each PE psychotherapy session and used to support homework between sessions.
62449147|NCT04959695|ACTIVE_COMPARATOR|Prolonged exposure without PE Coach|Standard PE treatment protocol without PE Coach
62600904|NCT02455609|ACTIVE_COMPARATOR|Dexmedetomidine + Ketamine group (III)|intrathecal drug administartion of patients in this arm received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine plus 0.1 mg/kg of Ketamine in 1 ml volume.
62041160|NCT04632927|EXPERIMENTAL|Secukinumab|AIN457
62041161|NCT04632927|EXPERIMENTAL|Ustekinumab|
62041162|NCT02739282|ACTIVE_COMPARATOR|Systematic therapeutic drug monitoring|"Systematic therapeutic drug monitoring performed at each clinic consultation and automatically transmitted to the clinician will be compared with clinically required therapeutic drug monitoring (rescue therapeutic drug monitoring, transmitted only in case of predefined inefficacy or tolerance problems, as defined in the combine endpoint below), to assess if systematic therapeutic drug monitoring can prevent a proportion of treatment failure or adverse events."
62041163|NCT02739282|NO_INTERVENTION|"Rescue therapeutic drug monitoring"|"In the rescue therapeutic drug monitoring arm, communication of levels results will only be provided if a study endpoint (treatment failure or side effect as discussed below) is reached."
62041164|NCT04731688|EXPERIMENTAL|Weight Maintenance Group|Individuals in this group will receive all aspects of the Provider Directed Group plus a comprehensive behavioral fat mass loss intervention with food provision. Individuals in this group will be provided foods to eat to support weight maintenance and loss of body fat throughout pregnancy. They will be asked to attend two behavioral counseling sessions at the beginning of the study to help learn the program and set goals. They will return for brief visits with a lifestyle counselor every two weeks until 20 weeks gestation and at least once a month until delivery. Individuals will be provided a scale to help keep track of weight during pregnancy.
62041165|NCT04731688|NO_INTERVENTION|Provider Directed Group|Individuals in this group will receive what is standard practice by their prenatal care providers during pregnancy. In addition, individuals in this group will be asked to attend a brief session at the time of randomization to familiarize with the study and what is expected. They will also be provided with materials describing healthy behaviors in pregnancy.
62041166|NCT06418373|ACTIVE_COMPARATOR|Conventional intervention group|Based on the current congenital heart disease care standards at Fudan University Children's Hospital, health education and medical management for adolescent CHD
62821453|NCT02946580|EXPERIMENTAL|MOVANTIK™ (naloxegol)|Subjects in the treatment group will be administered MOVANTIK™ (naloxegol) 25 mg tablet or placebo once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing). Subjects with renal impairments (creatine clearance rate of less than 60 mL/min) will receive a 12.5 mg dose tablet of naloxegol in place of the 25 mg dose as advised by FDA guidelines. For patients who are unable to swallow the tablet whole, the tablet can be crushed and given orally or administered via nasogastric tube.
62041167|NCT06418373|EXPERIMENTAL|Intervention group|"Patients and their caregivers implement the Get Ready with My Heart Program"
62041168|NCT06568237|EXPERIMENTAL|TEV-56286|Orally administered capsules once daily
62244476|NCT05431361|NO_INTERVENTION|Usual Care|Usual care participants will be instructed to resume typical lifestyle behaviours until the date of the surgery. To standardize exposure to publicly available resources, usual care participants will receive the 24-Hour Movement Guidelines for Adults,33 Canada's Food Guide,27 a list of stress management resources (website, apps, free reading material), and reference to the Smoker's Helpline.
62244477|NCT04447768|EXPERIMENTAL|Venetoclax and Obinutuzumab|All patients will receive a minimum of 9 cycles (cycle = 28 days) of therapy with venetoclax and obinutuzumab during the treatment period. For patients who remain MRD positive at Cycle 9 of therapy, an additional 12 cycles of venetoclax monotherapy will be given.
62244478|NCT01182766|EXPERIMENTAL|topiramate|topiramate with brief behavioral enhancement therapy
62434657|NCT06019130|EXPERIMENTAL|Patients < 26 y with no metastases and SD or PD after induction therapy or patients with metastases|"Participants receive Nivolumab (4.5 mg/kg BW (max. 360 mg) every three weeks) during induction chemotherapy for a total of 3 doses, starting on day 1 of cycle 1 of induction standard chemotherapy with cisplatin 100 mg/m2 on day 1, plus 5-fluorouracil 1,000 mg/m2/d from day 1-5. Patients with metastases responding to induction therapy may have a fourth cycle of induction therapy, including a fourth dose of Nivolumab.~After induction therapy patients will undergo standard radiochemotherapy. Primary PTV1 including elective irradiated LN-levels, will be 45Gy, with a boost ad 59.4Gy. Cisplatin will be administered at 3x20mg/m2 in the first and last week of radiotherapy, each. Nivolumab (4.5 mg/kg BW (max. 360 mg) every three weeks) will be continued during radiochemotherapy, adding a total of 3 further doses of Nivolumab.~Radiochemotherapy is followed by maintenance therapy with recombinant interferon-ß1a at 3x6Mio IU/week s.c. for 6 months."
62434658|NCT06019130|EXPERIMENTAL|Patients >25 years with non-metastatic disease with CR or PR after induction therapy|"Participants receive Nivolumab (4.5 mg/kg BW (max. 360 mg) every three weeks) during induction chemotherapy for a total of 3 doses, starting on day 1 of cycle 1 of induction standard chemotherapy with cisplatin 100 mg/m2 on day 1, plus 5-fluorouracil 1,000 mg/m2/d from day 1-5.~After induction therapy patients will undergo standard radiochemotherapy as outlined in current international guidelines (e.g. NCCN, ESMO)."
62434659|NCT06019130|EXPERIMENTAL|Patients > 25 years with non-metastatic disease with SD or PD after induction therapy|"Participants receive Nivolumab (4.5 mg/kg BW (max. 360 mg) every three weeks) during induction chemotherapy for a total of 3 doses, starting on day 1 of cycle 1 of induction standard chemotherapy with cisplatin 100 mg/m2 on day 1, plus 5-fluorouracil 1,000 mg/m2/d from day 1-5.~After induction therapy patients will undergo standard radiochemotherapy as outlined in current international guidelines (e.g. NCCN, ESMO). Nivolumab (4.5 mg/kg BW (max. 360 mg) every three weeks) will be continued during radiochemotherapy, adding a total of 3 further doses of Nivolumab."
62434660|NCT06019130|EXPERIMENTAL|Patients > 25 years with metastatic disease at diagnosis|"Participants receive Nivolumab (4.5 mg/kg BW (max. 360 mg) every three weeks) during induction chemotherapy for a total of 3 doses, starting on day 1 of cycle 1 of induction standard chemotherapy with cisplatin 80 mg/m2 on day 1, plus gemcitabine 1,000 mg/m2/d on day 1 and day 8, respectively. Patients responding to induction therapy may have a fourth cycle of induction therapy, including a fourth dose of Nivolumab.~After induction therapy patients will undergo standard radiochemotherapy as outlined in current international guidelines (e.g. NCCN, ESMO). Nivolumab (4.5 mg/kg BW (max. 360 mg) every three weeks) will be continued during radiochemotherapy, adding a total of 3 further doses of Nivolumab."
62434661|NCT03700710|ACTIVE_COMPARATOR|Self-Guided Approach|"In the self-guided arm, participants will receive access to web-based tools to help achieve healthy lifestyle changes to lower their blood pressure.~The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to an evidence-based program (Evolve, formerly BMIQ), which includes program materials for weight loss and leading a healthy lifestyle as well as the ability for capturing dietary data entry."
62449148|NCT01333241|EXPERIMENTAL|Lifestyle behavior intervention group|The 6-month lifestyle behavior intervention includes group education and individual teaching and coaching.
62449149|NCT01333241|SHAM_COMPARATOR|Control group|Disaster Preparedness/Home Safety group education and teaching
62600905|NCT06623110|EXPERIMENTAL|RP2 Injection|"Enrolled participants will complete the following:~* A 3 subject safety run-in will be conducted with participants enrollment staggered. If \> 1 subject experiences a grade 4-5 adverse event (AE), study enrollment will pause for review by PI and study sponsor. If there are 0 grade 4-5 AEs, enrollment will proceed.~* Baseline in-clinic visit with assessments, oral mucosal punch biopsy, and RP2 injection (week 1).~* In-clinic visits on weeks 3, 5, 7, 8, 9, 11, 13, 15, and 16.~* RP2 injections on weeks 1, 3, 5, 7, 9, 11, 13, and 15.~* Repeat oral mucosal punch biopsy at week 8.~* Follow up: every 3 months for up to 2 years."
62600906|NCT00688233|EXPERIMENTAL|F-seifi|
62600907|NCT02381938|EXPERIMENTAL|Intervention|6-month intervention to increase physical activity and improve other health related behaviors
62600908|NCT02381938|OTHER|Control|6-month intervention to educate and improve financial health
62600909|NCT01942317|EXPERIMENTAL|Balneotherapy|16 balneotherapy treatments, each of 45 minutes, twice a week, for 8 consecutive weeks
62600910|NCT01942317|NO_INTERVENTION|Physiotherapy|16 physiotherapy treatments (no balneotherapy), each of 45 minutes, twice a week, for 8 consecutive weeks
62600911|NCT01563367|ACTIVE_COMPARATOR|Iron isomaltoside 1000 (Monofer®)|Iron isomaltoside 1000 (Monofer®) - Intravenous Infusion
62600912|NCT01563367|PLACEBO_COMPARATOR|0,9% sodium saline|Placebo (0.9% sodium saline) - Intravenous infusion
62600913|NCT02794701||people with silicosis|
62821454|NCT02946580|PLACEBO_COMPARATOR|Sugar pill|Matching placebo consists of an inert mixture supplied by AstraZeneca in identical-appearing tablets. Subjects in the placebo group will be administered a placebo tablet once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing).
62041169|NCT06568237|PLACEBO_COMPARATOR|Placebo|Orally administered capsules once daily
62041170|NCT05630547|EXPERIMENTAL|SAR443820|Oral SAR443820
62244479|NCT01182766|PLACEBO_COMPARATOR|Placebo|Placebo with brief behavioral enhancement therapy
62244480|NCT04650724|EXPERIMENTAL|T cell infusion agent targeting BCMA chimeric antigen receptor|
62244481|NCT05076175|EXPERIMENTAL|Ozanimod High Dose|
62244482|NCT05076175|EXPERIMENTAL|Ozanimod Low Dose|
62041171|NCT05630547|PLACEBO_COMPARATOR|Placebo|Oral placebo
62244483|NCT06222697||Post-marketing surveillance cohort|Participants follow their usual medical visits with data collection occurs continuously in a 36-week observational period.
62244484|NCT06734676|EXPERIMENTAL|SCAN|14-day iTBS on personalized SCAN localized by precision functional mapping
62434662|NCT03700710|EXPERIMENTAL|Dietitian-led Approach|"In the dietitian-led arm, dietitian will use motivational interviewing in 15-30 minute telephone calls with participants.~The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to an evidence-based program (Evolve, formerly BMIQ), which includes program materials for weight loss and leading a healthy lifestyle as well as the ability for capturing dietary data entry.~The web platform will be used to share participant dietary and weight data with dietitians."
62434663|NCT00748813|OTHER|1|
62434664|NCT00851266|EXPERIMENTAL|1|V512
62434665|NCT00851266|PLACEBO_COMPARATOR|2|Placebo to V512
62821455|NCT00005975|ACTIVE_COMPARATOR|Megestrol Acetate/Placebo 20 mg/day|Double blinded Megestrol Acetate 20 mg/day or Megestrol Acetate Placebo 20 mg/day taken for 3 months
62821456|NCT00005975|ACTIVE_COMPARATOR|Megestrol Acetate/Placebo 40 mg/day|Double blinded Megestrol Acetate 40 mg/day or Megestrol Acetate Placebo 40 mg/day taken for 3 months
62041172|NCT05031013||Dialysis patients|Dialysis patients
62041173|NCT04945317|OTHER|ROSE clot arm|Presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist. Sample prepared as tissue clot.
62041174|NCT04945317|OTHER|NO-ROSE clot arm|Absence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist. Sample prepared as tissue clot.
62041175|NCT04945317|OTHER|ROSE liquid arm|Presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist. Sample prepared as liquid.
62041176|NCT04945317|OTHER|NO-ROSE liquid arm|Absence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist. Sample prepared as
62244485|NCT06734676|ACTIVE_COMPARATOR|Effector|14-day iTBS on personalized effector-specific network localized by precision functional mapping
62244486|NCT04624880||Participants with HIP previously measured|This cohort of patients will have their genetics analyzed and compared to their HIP scores.
62434666|NCT04315012|EXPERIMENTAL|Receiving mobile app-based education|to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
62434667|NCT04315012|NO_INTERVENTION|Standart|not to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
62434668|NCT00828490||Pediatric Asthmatics|Medicaid beneficiaries ≤21 years of age who meet the HEDIS criteria for persistent asthma
62041177|NCT06721000||PCEA group|Epidural catheter is inserted and patient is given a remote to control the amount of drug given through patient control epidural pump.
62041178|NCT06721000||Non-PCEA group|Epidural catheter is inserted and the amount of drug set will be delivered via infusion pump.
62041179|NCT06733792|EXPERIMENTAL|App-assisted CBT-based intervention|Participants have access to a 4-week digitalized CBT-based intervention. Participants will have access to seven weekly modules. Modules include cannabis-related psychoeducation (i.e., benefits concerning cannabis use reduction/quitting, short- and long-term consequences, myths), training in emotional regulation strategies, stimulus control (i.e., alternatives to cannabis use), behavioral activation strategies and relapse prevention (i.e., training in assertiveness skills and problem-solving abilities).
62041180|NCT06733792|ACTIVE_COMPARATOR|App-assisted self-help guide|Participants receive a self-help guide based on psychoeducation on cannabis use and its physical/mental health effects.
62041181|NCT05222282|EXPERIMENTAL|Intervention|"Intervention with~1. nurseled sexual consultations with screening questionnaire prior to consultation~2. genital examintaion with doctor"
62041182|NCT05222282|OTHER|Kontrol|Usual care
62041183|NCT06383585|EXPERIMENTAL|oZTEo MRI pulse sequence|All patients will have the FDA approved MRI pulse sequence, oZTEo, added to their already ordered standard of care MRI examination.
62041184|NCT04106726|EXPERIMENTAL|Test: Ivermectin cream 1%|Manufactured by Zydus Worldwide DMCC; Apply cream to the affected areas of the face once daily for 12 weeks.
62041185|NCT04106726|ACTIVE_COMPARATOR|Reference: Soolantra® cream, 1%|Manufactured by Galderma Laboratories, L.P.; Apply cream to the affected areas of the face once daily for 12 weeks.
62041186|NCT04106726|PLACEBO_COMPARATOR|Placebo: Placebo for Ivermectin cream 1%|Manufactured by Zydus Worldwide DMCC; Apply to the affected areas of the face once daily for 12 weeks.
62041187|NCT03094260|EXPERIMENTAL|High intensity light therapy|Treatment with light therapy in high intensity (10,000 lux)
62041188|NCT03094260|PLACEBO_COMPARATOR|Low intensity light therapy|Treatment with light therapy in low intensity (\<500 lux)
62041189|NCT00360438|EXPERIMENTAL|Rasburicase|
62041190|NCT06453265|EXPERIMENTAL|Dose Selection- 600ug (Part A)|Cebranopadol 600 ug single dose
62041191|NCT06453265|EXPERIMENTAL|Dose Selection - 800 ug (Part A)|Cebraopadol 800 ug single dose
62434669|NCT00828490||Antipsychotic Therapy|Medicaid beneficiaries ≥18 years of age and enrolled ≥6 months of the past 12 months with enrollment in at least one of the past 3 months and ≥3 antipsychotic Rx within past 12 months
62434670|NCT00828490||Bipolar Therapy|Medicaid beneficiaries ≥18 years of age and enrolled ≥6 months of the past 12 months with enrollment in at least one of the past 3 months and a diagnosis of Bipolar in past 3 years, and ≥ 1 antidepressant Rx in past 6 months, and no mood stabilizer in past 6 months.
62434671|NCT00828490||Opioid Therapy|"Medicaid beneficiaries ≥18 years and enrolled ≥6 of prior 12 months with enrollment in ≥1 of prior 3 months and ≥1 opioid fill in prior 3 months and none of the following in prior 12 months:~Hospice CPT code or Primary diagnosis of cancer or Oncology CPT code"
62434672|NCT00828490||Fraud and Abuse|Medicaid beneficiaries who filled at least 3 opioid Rx in the last 12 months
62434673|NCT00828490||Pediatric Antipsychtotic Therapy|Medicaid beneficiaries \<18 years of age with at least 3 antipsychotic Rx's in the past year.
62434674|NCT05589935|PLACEBO_COMPARATOR|Control 1|Relief Product Form 1 - control
62434675|NCT05589935|EXPERIMENTAL|Active Product 1.1|Relief Product Form 1 - active product 1
62434676|NCT01423565|EXPERIMENTAL|Deep Brain Stimulation|
62821457|NCT04746391|EXPERIMENTAL|Solacea_60min|"* blood sampling from dialyzer inlet and outlet line at 60min, just before dialysis termination~* microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
62041192|NCT06453265|EXPERIMENTAL|Dose Selection- 1000 ug (Part A)|Cebranopadol 1000 ug single dose
62821458|NCT04746391|EXPERIMENTAL|Solacea_120min|"* blood sampling from dialyzer inlet and outlet line at 120min, just before dialysis termination~* microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
62821459|NCT04746391|EXPERIMENTAL|Solacea_240min|"* blood sampling from dialyzer inlet and outlet line at 240min, just before dialysis termination~* microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
62821460|NCT04746391|EXPERIMENTAL|FX800_60min|"* blood sampling from dialyzer inlet and outlet line at 60min, just before dialysis termination~* microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
62821461|NCT04746391|EXPERIMENTAL|FX800_120min|"* blood sampling from dialyzer inlet and outlet line at 120min, just before dialysis termination~* microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
62821462|NCT04746391|EXPERIMENTAL|FX800_240min|"* blood sampling from dialyzer inlet and outlet line at 240min, just before dialysis termination~* microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
62821463|NCT03723655|EXPERIMENTAL|Group 1|Active Treatment for participants with base target trough concentration
62821464|NCT03723655|EXPERIMENTAL|Group 2|Active Treatment for participants with higher target trough concentration
62041193|NCT06453265|ACTIVE_COMPARATOR|Qualification Phase - Oxycodone (Part B)|Oxycodone 40mg
62041194|NCT06453265|PLACEBO_COMPARATOR|Qualification Phase - Placebo (Part B)|Matching Placebo
62041195|NCT06453265|EXPERIMENTAL|Treatment Phase A- (Part B)|-Treatment A: Cebranopadol
62041196|NCT06453265|ACTIVE_COMPARATOR|Treatment Phase B- (Part B)|- Treatment B: Oxycodone HCl IR 40 mg
62041197|NCT06453265|PLACEBO_COMPARATOR|Treatment Phase C (Part B)|- Treatment C: Placebo
62041198|NCT04866550||Connected tablet|Patients aged over 60, living at home, with heart failure and / or chronic obstructive pulmonary disease, potentially requiring care cross-border (France and Belgium).
62041199|NCT04401514|EXPERIMENTAL|Experiemntal intervention|The experimental intervention is a 20 min. long rocking chair with music therapy.
62041200|NCT04401514|ACTIVE_COMPARATOR|Control intervention|Control intervention is also transferred to the rocking chair, but the therapy program will not be turned on.
62244487|NCT04624880||Participants without HIP measured|This cohort of patients from the control group of the knee replacement trial (who did not have their HIP measured) will have their genetics, pain, and opioid use analyzed, and compared to the genetics, pain, and opioid use of the hypnosis group from that trial.
62821465|NCT03723655|EXPERIMENTAL|Group 3|Active Treatment for participants dose titrated to clinical response
62821466|NCT06588140|ACTIVE_COMPARATOR|conventional heat-cured duplication technique.|Duplication of refitted complete removable dentures by conventional heat-cured technique from heat-cured polymethyl methacrylate resin.
62041201|NCT06733636|EXPERIMENTAL|Olfactory Training|Participants will receive the ScentCare olfactory training device, which includes eight encapsulated scents: Eucalyptus, Cinnamon, Lemon, Coffee, Campfire, Cherry, Vanilla, and Lavender. To guide the participant in using the device, participants will have access to either a web-based application or a booklet, depending on the participant's preference. These resources will provide instructions on how to perform the smell training effectively. The training will be conducted twice daily over a period of three months.
62041202|NCT06733636|OTHER|Control Arm (Sudoku Puzzles)|Participants will be asked to complete sudoku puzzles twice daily over a period of three months.
62041203|NCT04674124|EXPERIMENTAL|Online Mindfulness Course|Participants will be enrolled on a 9 week online mindfulness course.
62041204|NCT04674124|NO_INTERVENTION|Delayed course materials|Participants will have access to the course materials at the closure of their involvement in the study.
62244488|NCT06519773|SHAM_COMPARATOR|Collagen sponge group :|"ten sites will be treated by MPI technique+ cortical lamina membrane and collagen sponge.~The jumping gap between implant and buccal plate of bone will be filled with collagen sponge."
62434677|NCT01055444|EXPERIMENTAL|Heated lidocaine/tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
62600914|NCT06382441|EXPERIMENTAL|Tele-excercise|In Group A (intervention), the 12 participants will form 2 groups (6 participants per group) according to their individual exercise intensity levels determined prior to the intervention for each participant. Each group will receive online coach-supervised training sessions 3 times per week for 4 weeks (a total of 12 sessions), which will be delivered by a certified coach and an assistant (a student helper, major in sports and health). Each session will consist of warm-up, aerobic exercise, resistance exercise, stretching and cool-down, with exercise period progressively increasing from 30 minutes to 50 minutes and exercise intensity progressively increasing from low to moderate levels (Table 1). Lighter intensity may be adopted when there is a need (e.g., for those with severe conditions). Target heart rate during exercise will be monitored by a pulse oximeter. Cameras will be requested to be turned on all the time.
62821467|NCT06588140|EXPERIMENTAL|3d Printed CAD/CAM duplication technique from Pink polymethyl methacrylate base resin|Duplication of a refitted complete removable denture will be produced using a 3D-printed CAD/CAM technique where the denture base will be printed separately using pink base polymethyl methacrylate resin, and the teeth will be printed as one unit using tooth-colored resin, followed by assembling the two components.
62821468|NCT06588140|EXPERIMENTAL|3d Printed CAD/CAM duplication technique from white polymethyl methacrylate base resin|Duplication of a refitted complete removable denture will be produced using a 3D-printed CAD/CAM technique where the denture will be printed as a single unit using tooth-colored resin, and the denture flange will be veneered with pink resin.
62821469|NCT02977663|OTHER|Magnetic Resonance Imaging (MRI)|Thoracic Magnetic Resonance Imaging (MRI)
62821470|NCT06599450|ACTIVE_COMPARATOR|One median implant|One median implant to retain mandibular complete overdenture
62821471|NCT06599450|ACTIVE_COMPARATOR|One parasymphyseal implant|One parasymphyseal implant to retain mandibular complete overdenture
62244489|NCT06519773|ACTIVE_COMPARATOR|Bone graft group:|"ten sites will be treated by MPI technique +cortical lamina membrane and xenograft collagen.~The jumping gap between implant and buccal plate of bone will be filled with xenograft collagen."
62434678|NCT03568825|EXPERIMENTAL|Number of Osteopatic Manual Therapy|Intervention: OMT. Osteopatic Manual treatment consisting of Thoracic spine, Diaphragm mobilisation, Traction of the cardia and posture correction.
62434679|NCT03568825|EXPERIMENTAL|Interval in days between each OMT|Intervention: OMT. The time between each OMT's is calculated by the study design. Each OMT intervantion consists of Thoracic spine and Diaphragm mobilisation, Traction of the cardia and Posture correction.
62434680|NCT03311009|EXPERIMENTAL|GLPG1972|
62434681|NCT03311009|PLACEBO_COMPARATOR|Placebo|
62434682|NCT02879747|ACTIVE_COMPARATOR|Interventional|Unchanged dose Genotropin
62434683|NCT02879747|ACTIVE_COMPARATOR|Interventional 2|reduced dose 50% Genotropin
62434684|NCT03354156||High-LDL|patients with LDL cholesterol levels of \>4.9 mmo/l, who have not been treated with statins in the past years, and who have an indication for treatment with statins.
62434685|NCT03354156||Control|control subjects with an LDL cholesterol level of \<3.5 mmol/l
62041205|NCT04875481||ASD group|450 ASD from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007.
62244490|NCT05078619|EXPERIMENTAL|TAVI without routine PCI|Patients who are randomized to the experimental or index group undergo TAVI without routine PCI
62244491|NCT05078619|NO_INTERVENTION|TAVI with routine PCI|Patients who are randomized to the control or reference group undergo TAVI with routine PCI
62244492|NCT03412045|EXPERIMENTAL|treatment|this preliminary study will be a convenience sample of patients admitted to hospital for vaso-occlusive sickle cell crisis to be treated with hyperbaric oxygen in an effort to ameliorate pain and shorten the length of stay. In this sense, hyperbaric oxygen will be used as a treatment drug. Results will be compared with historical controls
62434686|NCT00212771|EXPERIMENTAL|Arm 1|
62434687|NCT00212771|ACTIVE_COMPARATOR|Arm 2|
62244493|NCT02612051|EXPERIMENTAL|Part A, Cohort 1: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram \[mcg\]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
62600915|NCT06382441|NO_INTERVENTION|Control|Participants in Group B (active control) will receive an essay on exercise and health every week for four weeks (a total of 4 essays). Proposed topics include: 1) beneficial effects of exercise and recommended exercise for breast cancer survivors; 2) WHO's recommendations for physical activity; 3) exercise intensity; 4) principles of exercise.
62600916|NCT02021136|EXPERIMENTAL|Rebel reliever|Rebel Reliever(R) knee brace + usual antalgic treatment + physical exercises recommendations.
62821472|NCT06599450|ACTIVE_COMPARATOR|Two implants|Two implants in the intraforaminal distance to retain mandibular complete overdenture
62041206|NCT04875481||TD group|100 healthy typical developing control (TDC) from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007.
62041207|NCT06017024|EXPERIMENTAL|Current microprocessor-controlled knee (MPK) then New MPK|Start using current MPK for 4 weeks before fitting new MPK and use it for 4 weeks
62041208|NCT06017024|EXPERIMENTAL|New MPK then Current MPK|Start using new MPK for 4 weeks before fitting back current MPK and use it for 4 weeks
62041209|NCT04412044|EXPERIMENTAL|Asthmatics|Patients receive anti-IL5 treatment as part of their prescribed routine. Immunological and clinical parameters will be evaluated at the start of the treatment and after 6 months of treatment
62041210|NCT06579599|NO_INTERVENTION|Routine operating room nursing|Routine nursing interventions were put into practice in the operating room for the control group.
62041211|NCT06579599|EXPERIMENTAL|an integrated working group nursing|Received intervention through the establishment of an integrated working group comprising medical staff in the operating room.
62041212|NCT05952180|EXPERIMENTAL|Virtual reality and Cycloergometer|The session performed uses a standard cycloergometer, with the participant pedaling in a seated position with the lower limbs. A 43 inches TV screen is placed in front of the cycloergometer where the participant will watch a video of a walk through a natural environment on. The speed of the walk is linked to the pedaling speed so that the faster the participant pedals, the faster the video goes too. The session last 30 minutes in the participant's room.
62041213|NCT05952180|ACTIVE_COMPARATOR|Standard cycloergometer|"For the standard cycloergometer intervention, the session uses usual cycloergometer with the participant pedaling in a seated position with the lower limbs. No virtual reality is used. The session last 30 minutes in the participant's room"
62041214|NCT04776980|EXPERIMENTAL|Ferumoxytol Infused MRI|Ferumoxytol is an iron replacement product that is FDA approved to treat iron deficiency anemia in patients with chronic kidney disease (CKD). In this study, ferumoxytol is used to quantify tumor-associated macrophages. The infused dose would be 5mg/kg.
62041215|NCT03178617|ACTIVE_COMPARATOR|Arm I (standard of care LIP)|Parents or caregivers attend standard of care LIP consisting of a meeting to review results of a neurocognitive evaluation and to discuss recommendations for optimal learning and school performance for 1 session.
62244494|NCT02612051|EXPERIMENTAL|Part A, Cohort 2: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram \[mcg\]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
62434688|NCT02611206|EXPERIMENTAL|Period 1: 80% of MT|All participants who qualify will undergo 6 weeks of open-label rTMS with a stimulation intensity of 80% of MT
62821473|NCT04227808|EXPERIMENTAL|Lenvatinib Arm|Experimental: Participants will be given lenvatinib (12 mg/d for body weight≥60kg, 8 mg/d for body weight \< 60kg) for 12 months until disease recurrence or intolerance AEs or death.
62821474|NCT04304768|EXPERIMENTAL|HIV positive opioid users|Participants will continue their standard of care antiretroviral therapy (ART) and receive flu vaccination as part of the study
62041216|NCT03178617|EXPERIMENTAL|Arm II (HIP)|Parents or caregivers attend HIP consisting of individual parental skill training sessions with a bilingual therapist over 60-90 minutes every 2 weeks for a total of 8 sessions.
62041217|NCT04871789||Patients with severe COVID-19 pneumonia|
62041218|NCT04871789||Patients who had an asymptomatic COVID-19 3 months ago|
62041219|NCT04871789||People who had close contact with patients with confirmed COVID-19 3 months ago but did not get sick|
62041220|NCT02883738|EXPERIMENTAL|upper limb tremor|
62434689|NCT02611206|EXPERIMENTAL|Period 2: 100% of MT|All participants who qualify will undergo 6 weeks of open-label rTMS with a stimulation intensity of 100% of MT
62600917|NCT02021136|ACTIVE_COMPARATOR|Control|usual antalgic treatment + physical exercises recommendations.
62821475|NCT04304768|EXPERIMENTAL|HIV positive non-opioid users|Participants will continue their standard of care antiretroviral therapy (ART) and receive flu vaccination as part of the study
62821476|NCT04304768|EXPERIMENTAL|HIV negative opioid users|Participants will receive flu vaccination as part of the study
62821477|NCT04304768|EXPERIMENTAL|HIV negative non-opioid users|Participants will receive flu vaccination as part of the study
62041221|NCT00701038|EXPERIMENTAL|Device|Provided with an auto adjusting bi-level positive airway pressure device
62041222|NCT00701038|NO_INTERVENTION|Control|No device
62041223|NCT05323318||Neuropsychological Sequelae|Post-COVID-19 symptomatic patients with neuropsychological sequelae
62041224|NCT05323318||Without Neuropsychological Sequelae|Post-COVID-19 symptomatic patients Without neuropsychological sequelae
62041225|NCT06732401|ACTIVE_COMPARATOR|Arm A (Durvalumab)|Starting 4-12 weeks after surgery, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and blood sample collection throughout the study and may undergo echocardiography as clinically indicated.
62041226|NCT06732401|EXPERIMENTAL|Arm B (Durvalumab and AZD6738)|Starting 4-12 weeks after surgery, patients receive AZD6738 PO BID on days 1-7 and durvalumab IV over 60 minutes on day 8 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and blood sample collection throughout the study and may undergo echocardiography as clinically indicated.
62041227|NCT01918995|EXPERIMENTAL|Regadenoson low dose|Administered over approximately 10 seconds followed by 2 repeat low doses at 10 minute intervals
62041228|NCT01918995|EXPERIMENTAL|Regadenoson medium dose|Administered over approximately 10 seconds followed by 2 repeat medium doses at 10 minute intervals
62041229|NCT01918995|EXPERIMENTAL|Regadenoson high dose|Administered over approximately 10 seconds followed by 1 repeat high dose at 10 minute intervals
62041230|NCT01918995|PLACEBO_COMPARATOR|Placebo|Administered over approximately 10 seconds followed by 1 or 2 repeat doses at 10 minute intervals
62041231|NCT03083899|EXPERIMENTAL|Diatast|Free patient-initiated use of out-patient services
62041232|NCT03083899|PLACEBO_COMPARATOR|Control|Scheduled diabetes control
62244495|NCT02612051|EXPERIMENTAL|Part A, Cohort 3: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram \[mcg\]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
62244496|NCT02612051|EXPERIMENTAL|Part B, Cohort 4: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of \[18F\]-FBA-A20FMDV2 for the PET scanning in period 2.
62244497|NCT02612051|EXPERIMENTAL|Part B, Cohort 5: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of \[18F\]-FBA-A20FMDV2 for the PET scanning in period 2.
62434690|NCT02611206|EXPERIMENTAL|Period 3: 120% of MT|All participants who qualify will undergo 6 weeks of open-label rTMS with a stimulation intensity of 120% of MT
62434691|NCT03382210||ERP group|A prospective series of patients (N=100) undergoing elective colorectal resection and completing a standardized enhanced recovery protocol in 2013-2015 (ERP group) at the S. Anna University Hospital in Ferrara (Italy).
62821478|NCT00072462|ACTIVE_COMPARATOR|Anastrozole|
62821479|NCT00072462|ACTIVE_COMPARATOR|Tamoxifen|
62821480|NCT06423326|EXPERIMENTAL|Treatment (nab-paclitaxel, cisplatin, gemcitabine)|Patients receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 15 of each cycle. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease, partial or complete response undergo surgical resection per standard of care. Additionally, patients undergo biopsy on study and undergo blood sample collection and CT or MRI at pre-study and on study.
62821481|NCT03804840|PLACEBO_COMPARATOR|Placebo|
62821482|NCT03804840|ACTIVE_COMPARATOR|7.5 mg THC|
62821483|NCT03804840|ACTIVE_COMPARATOR|15 mg THC|
62821484|NCT01803009|EXPERIMENTAL|One arm|View CRC RAT and view presentation regarding risk of advanced adenoma
62849175|NCT04351789|NO_INTERVENTION|Control Group|Standard of Care at discharge of patients with COVID-19 from hospital is to inform the patients whom to contact in case of worsening of the physical condition, such as increasing e.g. shortness of breath, and of precautions regarding further isolation to avoid infection of household and other contacts, if relevant. Information regarding the patient´s psychological condition is not part of a standard conversation at discharge.
62041233|NCT03258580|EXPERIMENTAL|Substudy 1: All participants|Measuring facial response to painful stimulation.
62041234|NCT03258580|NO_INTERVENTION|Substudy 2: Healthy volunteers|Measuring pain assessment accuracy
62041235|NCT03258580|NO_INTERVENTION|Substudy 3: Control|Subjects will judge stimuli with the same instructions as Sub-Study 2 (which provides a test of replication).
62041236|NCT03258580|EXPERIMENTAL|Substudy 3: Feedback Group|Participants in substudy 3's Feedback Group will be informed about their performance after every trial when making judgments about other people's pain.
62041237|NCT05731128|EXPERIMENTAL|Dupilumab|Initial loading dose followed by regular administration for the duration of the treatment period.
62041238|NCT05731128|PLACEBO_COMPARATOR|Placebo|Initial loading dose followed by regular administration for the duration of the treatment period.
62041239|NCT05731128|OTHER|Open-label arm (optional)|Regular administration of open label dupilumab
62041240|NCT04538742|EXPERIMENTAL|Module 1- T-DXd and Durvalumab|T-DXd and Durvalumab
62041241|NCT04538742|EXPERIMENTAL|Module 2- T-DXd and Pertuzumab|T-DXd and Pertuzumab
62041242|NCT04538742|EXPERIMENTAL|Module 3- T-DXd and Paclitaxel|T-DXd and Paclitaxel (Arm not initiated in Part 2)
62041243|NCT04538742|EXPERIMENTAL|Module 4- T-DXd and Durvalumab and Paclitaxel|T-DXd and Durvalumab and Paclitaxel (Arm not initiated in Part 1 and Part 2)
62821485|NCT05713630|ACTIVE_COMPARATOR|Standard care + TXA|Patients will be given a single oral or IV loading dose of TXA within three hours of being randomized or whenever possible prior to surgery. Patients who are able to swallow will be given an oral loading dose of 1g TXA. Patients who are unable to swallow will be given an IV loading dose of 1g TXA which will be added to a 100mL infusion bag of NaCl 0.9% and infused by slow intravenous injection over 20 minutes as per the recommended rate of administration in the Product Monograph for Sandoz-Tranexamic Acid Injection BP. After 12 hours of the loading dose, patients will be given 500mg TXA by mouth (or 500mg TXA in NaCl 0.9% 100mL by IV for those unable to swallow) three times daily, totalling 1500mg/day, for 45 days.
62821486|NCT05713630|PLACEBO_COMPARATOR|Standard care + placebo|Patients will be given a single oral or IV loading dose of placebo within three hours of being randomized or whenever possible prior to surgery. Patients who are able to swallow will be given an oral loading dose of 1g placebo (gelatin capsule composed of microcrystalline cellulose 105 powder NF). Patients who are unable to swallow will be given an IV loading dose of 1g placebo (sodium chloride also known as NaCl 0.9%) which will be added to a 100mL infusion bag of NaCl 0.9% and infused by slow intravenous injection over 20 minutes. After 12 hours of the loading dose, patients will be given 500mg placebo by mouth (or IV for those unable to swallow) three times a day, totalling 1500mg/day, for 45 days.
62821487|NCT04905134|ACTIVE_COMPARATOR|Patients evaluated using flexible nasopharyngoscope prototype device|
62041244|NCT04538742|EXPERIMENTAL|Module 0- T-DXd|T-DXd
62041245|NCT04538742|EXPERIMENTAL|Module 5 - T-DXd and Tucatanib|T-DXd and tucatinib (Arm not initiated in Part 2)
62041246|NCT04538742|EXPERIMENTAL|Module 6 - T-DXd and Tucatinib|T-DXd and tucatinib in patients with active brain metastases (Part 2 Only) (Arm not initiated)
62041247|NCT04538742|EXPERIMENTAL|Module 7 - T-DXd|T-DXd monotherapy in patients with active brain metastases (Part 2 Only)
62041248|NCT00907829|ACTIVE_COMPARATOR|Arm 1|persons with severe hand impairment following hemiparetic stroke
62041249|NCT00907829|ACTIVE_COMPARATOR|Arm 2|persons with severe hand impairment following hemiparetic stroke
62041250|NCT00713648|EXPERIMENTAL|rFXIII|
62041251|NCT06523673|EXPERIMENTAL|SBRT arm|SBRT is administered to the site of progression. During SBRT treatment, maintenance therapy was with ICI or bevacizumab or combined single-agent chemotherapy. After the occurrence of progression that is no longer suitable for SBRT treatment, switch to second-line systemic therapy (same as SOC).
62041252|NCT06523673|ACTIVE_COMPARATOR|SOC arm|Second-line systemic therapy is based on docetaxel or albumin-paclitaxel. The combination of immunotherapy or anti-vascular drugs is evaluated by the study physician. The specific drug regimen is determined in conjunction with the patient's wishes. Palliative radiotherapy is acceptable.
62041253|NCT06096493||Patients with cancer rectum underwent curative surgery|Patients with cancer rectum underwent curative surgery
62600918|NCT03161145||Unresectable or metastatic renal cell carcinoma (mRCC)|Medical records will be reviewed for treatment patterns and outcomes
62041254|NCT06615921||Participants With CMV Infection Refractory|Participants who had a CMV infection/disease that is refractory to treatment (with or without resistance). Data will be retrospectively collected from date of solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT) up to the start date of chart abstraction, death or loss to follow-up, whichever comes first. Participants will be considered as refractory if they show no change or increased viremia after at least 2 weeks of appropriately dosed antiviral therapy.
62041255|NCT06615921||Participants With CMV Infection Intolerant|Participants with CMV infection intolerant to anti-CMV treatment. Data will be retrospectively collected from date of SOT/HSCT up to the start date of chart abstraction, death or loss to follow-up, whichever comes first. Intolerant participants identified based on physician judgment.
62041256|NCT00970138|EXPERIMENTAL|A 850|apatinib 850 mg qd, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62041257|NCT00970138|EXPERIMENTAL|B 425|apatinib 425 mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62041258|NCT00970138|PLACEBO_COMPARATOR|C pla|placebo bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62244498|NCT02612051|EXPERIMENTAL|Part B, Cohort 6: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of \[18F\]-FBA-A20FMDV2 for the PET scanning in period 2.
62434692|NCT03382210||Pre-ERP group|A retrospective series of patients (N=100) operated on at the the S. Anna University Hospital in Ferrara (Italy) in 2009-2011 (Pre-ERP group), before the introduction of ERP methodology.
62434693|NCT01217203|EXPERIMENTAL|IPH2101 and lenalinomide|
62600919|NCT05410041|EXPERIMENTAL|CAR-NK-CD19 Cells|After preconditioning with chemotherapy, CAR-NK-CD19 Cells will be evaluated.
62821488|NCT04905134|NO_INTERVENTION|Patients evaluated using standard of care nasopharyngoscope|
62821489|NCT04905134|ACTIVE_COMPARATOR|Providers using flexible nasopharyngoscope prototype device|
62821490|NCT06596928|EXPERIMENTAL|Test Supplement Group|Participants in this group will receive the test supplement (Essential Elements T-Hero Platinum). The supplement contains ingredients aimed at supporting testosterone levels, including Shoden® Ashwagandha Root and Leaf Extract.
62821491|NCT06596928|PLACEBO_COMPARATOR|Placebo Group|Participants in this group will receive a placebo containing rice flour in a vegetable cellulose capsule.
62041259|NCT06723262|OTHER|ABF arm|At 6 month post-activation: tonotopic fitting FS4T the participant wears FS4T during 6 weeks.
62041260|NCT01761097|ACTIVE_COMPARATOR|Endocuff assisted colonoscopy|Endocuff attachment
62041261|NCT01761097|PLACEBO_COMPARATOR|Control standard colonoscopy|Standard colonoscopy
62041262|NCT04598724||Bladder Cancer Patient Participants|Participants will be scheduled for one-on-one interviews that will occur over Zoom or telephone.
62041263|NCT04598724||Care Givers for Bladder Cancer Patient Participants|Participants will be scheduled for one-on-one interviews that will occur over Zoom or telephone.
62821492|NCT04441905|EXPERIMENTAL|Cohort 1|0.3 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
62244499|NCT02612051|EXPERIMENTAL|Part B, Cohort 7: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of \[18F\]-FBA-A20FMDV2 for the PET scanning in period 2.
62244500|NCT02612051|EXPERIMENTAL|Part C, Cohort 8: GSK3008348, IPF, PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per Part B) in two treatment periods. There will be washout period of 6 to 14 days between the doses. Subjects will receive up to three microdose administrations of \[18F\]-FBA-A20FMDV2 for the PET scanning in both periods.
62244501|NCT05200104|EXPERIMENTAL|PXL065|PXL065 22.5 mg QD
62244502|NCT06736197|EXPERIMENTAL|Group TVB|Group TVB patients who could not reach 90% ETO2 at the end of the 3rd minute were continued with tidal volume breathing.
62244503|NCT06736197|EXPERIMENTAL|Group PSV|Group PSV received 6 cm H2O positive pressure ventilation.
62244504|NCT06736197|EXPERIMENTAL|Group PSV+PEEP|In addition to 6 cmH2O pressure support, 4 cmH2O end-expiratory positive pressure support was added to the patients included in Group PEEP.
62821493|NCT04441905|EXPERIMENTAL|Cohort 2|1 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
62244505|NCT06618859|EXPERIMENTAL|Time-restricted eating|
62244506|NCT06618859|ACTIVE_COMPARATOR|Active control|
62244507|NCT06736509|EXPERIMENTAL|Open-Label|Experimental: AXS-05 (dextromethorphan-bupropion) up to 25 weeks
62244508|NCT06318897|EXPERIMENTAL|Pathologic Complete Response|If a participant's tissue shows a pathological complete response to treatment, participants will receive up to 13 cycles of pembrolizumab alone. Pathological complete response means that the study team cannot find any evidence of cancer in the breast or lymph node tissue sample that was removed during the participants surgery, after the participant completes the 4 cycles of carboplatin, pembrolizumab and paclitaxel.
62244509|NCT06318897|EXPERIMENTAL|Non-Pathologic Complete Response|If a participant's tissue does not show a pathological complete response, the participant will receive 4 cycles of pembrolizumab plus 2 other drugs (doxorubicin and cyclophosphamide), followed by 9 cycles of pembrolizumab alone.
62244510|NCT02954939|ACTIVE_COMPARATOR|MMF-MMF|Class III/IV+V LN patients who receive prednisolone (PRED) (0.8mg/kg/d) plus mycophenolate mofetil (MMF) (1g bd) as induction-maintenance therapy
62600920|NCT01588457|ACTIVE_COMPARATOR|Lithium|This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, lithium \[Li\] at baseline. Lithium is one of these two mood stabilizers. The person may or may not stay solely on lithium throughout the study.
62434694|NCT03105115|ACTIVE_COMPARATOR|intrathecal fentanyl|heavy bupivacaine 14mg and fentanyl 20mcg will be injected intrathecally during spinal anesthesia
62821494|NCT04441905|EXPERIMENTAL|Cohort 3|3 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
62821495|NCT04441905|EXPERIMENTAL|Cohort 4|10 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
62821496|NCT04441905|EXPERIMENTAL|Cohort 5|20 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
62821497|NCT05745909|ACTIVE_COMPARATOR|Loop transverse colostomy|Laparoscopic or open low-anterior resection of the rectum with total mesorectal excision and created loop transverse colostomy
62821498|NCT05745909|EXPERIMENTAL|Loop ileostomy|Laparoscopic or open low-anterior resection of the rectum with total mesorectal excision and created loop ileostomy
62821499|NCT06593145|EXPERIMENTAL|FCTX-CL19-1 (Tarcidomgen Kimleucel)|FCTX-CL19-1 (Tarcidomgen Kimleucel) - active IMP - consists of autologous T-cells with chimeric antigen receptor (CAR), Advanced Therapy Medicinal Product, ATMP, Gene Therapy Medicinal Product, GTMP
62821500|NCT03558711|EXPERIMENTAL|study group|
62821501|NCT05777187|EXPERIMENTAL|Clinical Decision Support|Clinical decision support alerts in the electronic health record directed towards anesthesiologists caring for patients with preexisting cognitive impairment.
62821502|NCT05777187|NO_INTERVENTION|Standard of Care|No clinical decision support will appear, and standard of care procedures will take place.
62434695|NCT03105115|EXPERIMENTAL|bupivacaine only|heavy bupivacaine 14mg will be injected intrathecally during spinal anesthesia
62600921|NCT01588457|ACTIVE_COMPARATOR|Divalproex|This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, divalproex (DV)at baseline. Divalproex is one of these two mood stabilizers. The person may or may not stay solely on divalproex throughout the study.
62600922|NCT01588457|ACTIVE_COMPARATOR|Lithium plus Quetiapine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + quetiapine \[QT\].
62600923|NCT01588457|ACTIVE_COMPARATOR|Lithium plus Lamotrigine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + lamotrigine (LM).
62821503|NCT06330805|EXPERIMENTAL|Arm 1 (leuprolide)|Patients receive definitive therapy for prostate cancer with ADT (leuprolide via injection once every 3 months, for a total of 6 months) in the absence of disease progression or unacceptable toxicity and definitive radiotherapy within 90 days of starting ADT. Patients receive gadolinium-based contrast intravenously (IV) and undergo exercise-stress cardiac MRI perfusion and comprehensive exercise physiology testing before starting ADT and at 6 months after starting ADT. Patients also undergo blood and urine sample collection throughout the study, as well as completion of quality-of-life questionnaires.
62244511|NCT02954939|PLACEBO_COMPARATOR|CTX-AZA|Class III/IV+V LN patients who receive prednisolone (PRED) (0.8mg/kg/d) plus Cyclophosphamide (CTX) (1.5-2mg/kg/d) followed by Azathioprine (AZA) (1-1.5mg/kg/d) as induction-maintenance therapy
62244512|NCT03531788|EXPERIMENTAL|Armon Ayura (Kinova)|Participants will trial the Armon Ayura dynamic arm support.
62600924|NCT01588457|ACTIVE_COMPARATOR|Divalproex plus Quetiapine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + quetiapine \[QT\].
62600925|NCT01588457|ACTIVE_COMPARATOR|Divalproex plus Lamotrigine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + lamotrigine (LM).
62041264|NCT06075108|OTHER|P-KIDs CARE|The P-KIDs CARE intervention will include two components: 1) the World Health Organization (WHO) Basic Emergency Care Course for training on patient assessment and stabilization, and 2) a decision support tool which integrates adaptation of two evidence-based tools: a) the Pediatric Resuscitation and Trauma Outcome model for mortality risk assessment, and 3) the Field Triage Decision Scheme to assist with timely referral decisions. WHO Basic Emergency Care Course includes modules delivered via PowerPoint with hands-on training components. The decision support tool will be online with checkboxes that healthcare providers can cross as they fill it out in real time. The team will adapt the tool for use in Northern Tanzania, with particular attention to local contextual and cultural factors.
62041265|NCT02816151|EXPERIMENTAL|Group 1|
62600926|NCT03289598|EXPERIMENTAL|Interventionsgroup|
62600927|NCT03289598|NO_INTERVENTION|Controlgroup|
62041266|NCT02816151|EXPERIMENTAL|Group 2|
62041267|NCT06121063|ACTIVE_COMPARATOR|CCT-102 Regimen|CCT-102 A/B regimen
62041268|NCT06121063|NO_INTERVENTION|Expectant management|Non-treatment, 'waitful watching'
62041269|NCT05279170|EXPERIMENTAL|children|"Compression of adjacent vessels (jugular vein and carotid artery), near the left paratracheal area. The risk of compression of the vessels will be assessed before performing the maneuver.~At the screening time before the intervention, we will perfom an ultrasonography measurement while we applied the maneuver in order to eliminate a risk of compression of the vessels, defined as a reduction in diameter of 50%."
62041270|NCT01328080|EXPERIMENTAL|Targeted UV-B (Left)|Targeted UV-B on left side of the scalp.
62041271|NCT01328080|EXPERIMENTAL|Targeted UV-B (Right)|Targeted UV-B on right side of the scalp.
62244513|NCT03531788|EXPERIMENTAL|JAECO WREX|Participants will trial the JAECO Wilmington Robotic EXoskeleton (WREX) dynamic arm support.
62244514|NCT06735482|EXPERIMENTAL|Group A Experimental|"Therapeutic Play Activities program for children with mild intellectual disability.~a program of therapeutic play activities aimed at improving the adaptive motor skills of children with intellectual disabilities. The program consists of 24 sessions of play-based activities that will be applied in 2 months on a day-by-day basis. Therapeutic Play programs include activities that address core strength, bilateral coordination, motor skills, visual skills, body awareness, outdoor sensory activities, vestibular, and balance skills. Activities will be simulated for the child by the therapist to ensure the child understands them."
62600928|NCT05168878|NO_INTERVENTION|Patient > 9 yo, no video|Caregivers of patients greater than or equal to 10 years old will not be shown a video in the PED.
62600929|NCT05168878|ACTIVE_COMPARATOR|Patient > 9 yo, 3 minute video|Caregivers of patients greater than or equal to 10 years old will be shown a 3-minute BeSMART video in the PED.
62600930|NCT05168878|EXPERIMENTAL|Any age, 30-second video|Caregivers of patients of any age will be shown a 30 second BeSMART video in the PED.
62600931|NCT05168878|EXPERIMENTAL|Any age, 3 minute video|Caregivers of patients of any age will be shown a 3-minute BeSMART video in the PED.
62600932|NCT02594189|OTHER|1|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
62600933|NCT06157112||Norwegian University students|Norwegian fulltime University students
62600934|NCT05849922|EXPERIMENTAL|SAR442970|Participants will receive SAR442970 once every two weeks (Q2W) in Period A (Day 1 to Week 16). Participants will receive SAR442970 Q2W in Period B (Up to Week 28).
62041272|NCT06596642||Adults participants diagnosed with β-thalassemia major|
62041273|NCT00775710|ACTIVE_COMPARATOR|1|Non-invasive ventilation is maintained during three nights after recovery of an episode of hypercapnic respiratory failure.
62041274|NCT00775710|NO_INTERVENTION|2|Discontinuation of NIV after the recovery of hypercapnic respiratory failure, without prolong it during night.
62041275|NCT04973605|EXPERIMENTAL|Part 1 Dose Escalation|Dose-escalation and de-escalation to determine maximum tolerated dose (MTD)
62041276|NCT04973605|EXPERIMENTAL|Part 2 Cohort Expansion|There will be 5 expansion cohorts to further evaluate the safety and efficacy of BGB-11417
62041277|NCT04889430|EXPERIMENTAL|Iptacopan 200 mg b.i.d|Single arm open-label with 50 adult patients receiving 200mg oral twice daily doses of iptacopan
62041278|NCT03979573|OTHER|Intervention Arm|"* PSA testing~* Multiparametric MRI (mp-MRI)~* Radiomics~* MR-guided biopsy (MR-guided and systematic US-guided)~* Molecular Markers (Histological analysis of biopsy cores)"
62041279|NCT05109091|EXPERIMENTAL|ATH434 Arm 1|
62041280|NCT05109091|EXPERIMENTAL|ATH434 Arm 2|
62244515|NCT06735482|NO_INTERVENTION|Group B control|Children will not receive any intervention
62600935|NCT05849922|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo Q2W in Period A (Day 1 to Week 16). Participants will receive SAR442970 Q2W in Period B (Up to Week 28).
62600936|NCT04291105|EXPERIMENTAL|Melanoma intratumoral|Melanoma, IT VV1 + IV cemiplimab Patients will receive both treatments on Day 1 and every 3 weeks thereafter until lack of clinical benefit or limiting toxicity. VV1 or cemiplimab can continue after the first dose in combination or as a single agent treatment in subsequent doses.
62821504|NCT06330805|EXPERIMENTAL|Arm 2 (relugolix)|Patients receive definitive therapy for prostate cancer with ADT (relugolix orally once daily for a total of 6 months) in the absence of disease progression or unacceptable toxicity and definitive radiotherapy within 90 days of starting ADT. Patients receive gadolinium-based contrast intravenously (IV) and undergo exercise-stress cardiac MRI perfusion and comprehensive exercise physiology testing before starting ADT and at 6 months after starting ADT. Patients also undergo blood and urine sample collection throughout the study, as well as completion of quality-of-life questionnaires.
62821505|NCT06234228|EXPERIMENTAL|BHD synced with mobile game|At the beginning of the vascular access procedure, the BHD will be applied 5 cm above the needle insertion site and maintained in place throughout the procedure. It delivers a constant low-frequency vibration as well as tactile feedback from the game (GF).
62821506|NCT06234228|OTHER|BHD only|The patient will wear the BHD 5 cm above the needle insertion site for the duration of the procedure. The BHD will deliver constant low-frequency vibration (CF).
62821507|NCT06401486|ACTIVE_COMPARATOR|Videolaryngoscope group|For patients assigned to the videolaryngoscope Group, the operator will use a videolaryngoscope on the first laryngoscopy attempt.
62821508|NCT06401486|ACTIVE_COMPARATOR|Macintosh laryngoscope Group|For patients assigned to the laryngoscope Group, the operator will use a Macintosh laryngoscope on the first laryngoscopy attempt.
62821509|NCT03910634|EXPERIMENTAL|IMRT combined with carboplatin|Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
62821510|NCT03910634|PLACEBO_COMPARATOR|IMRT combined with carboplatin and fluorouracil|Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip; Fluorouracil 1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks
62821511|NCT04125589|EXPERIMENTAL|Speaking Activity and Talking Activity|Participants will engage in a speaking activity first and a talking activity second.
62821512|NCT04125589|EXPERIMENTAL|Talking Activity and Speaking Activity|Participants will engage in a talking activity first and a speaking activity second.
62821513|NCT04895644|EXPERIMENTAL|No Hard Collar|Patient randomised to not wearing a Hard Collar for 12 weeks
62821514|NCT04895644|NO_INTERVENTION|Standard Care Arm - Hard Collar|Patient randomised to wearing a Hard Collar for 12 weeks - standard care
62821515|NCT04895033|EXPERIMENTAL|Responsibility vs No Responsibility|Within-subjects experimental manipulation of responsibility vs. no-responsibility condition
62821516|NCT04782713|OTHER|PCP Evaluation of Smart PSA Screening Guidelines|Completing surveys at baseline, 3, 6, 9 and 12 months
62821517|NCT04308122|ACTIVE_COMPARATOR|Cervical Orthosis (CO)|Cervical orthosis will be worn at all times for 6 weeks according the standard of care after posterior cervical fusion
62821518|NCT04308122|EXPERIMENTAL|No Orthosis (NO)|No cervical orthosis will be worn after posterior cervical fusion
62821519|NCT03774732|EXPERIMENTAL|Pembrolizumab+ Chemotherapy + Radiotherapy|"In the experimental arm, patients will receive the same treatment as the control arm (chemotherapy plus pembrolizumab) in addition with conformal 3D radiotherapy (3D-CRT) or stereotactic ablative radiotherapy (SABR) that will be delivered at C2D1, 21 days after the beginning of pembrolizumab using photons/electrons with standard field encompassing tumour.~Irradiation technique (3D-CRT or SABR) will be at physician discretion. Ideally, oligometastatic patient (defined by the presence of less than 6 metastases) should be treated with SABR and those with non-oligometastatic disease should be treated with 3D-CRT.~Radiotherapy will be delivered a dose of at least 18 Gy in 3 X 6 Gy for 3D-CRT (cf. protocol for possible schemes and volumes restriction).~Irradiated tumor size will be ≤5 cm (GTV \<65 mL sphere); partial tumor irradiation should be delivered if larger tumor size while respecting dose constraints."
62244516|NCT01134835|EXPERIMENTAL|IMP Pioglitazone|Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
62821520|NCT03774732|ACTIVE_COMPARATOR|Pembrolizumab+ Chemotherapy|"Squamous-cell lung carcinoma:~Pembrolizumab every 3 weeks and carboplatin + paclitaxel or nab paclitaxel every 3 weeks for 4 cycles then pembrolizumab every 3 or 6 weeks (according to the current version of the SmPC )~Non squamous-cell lung carcinoma:~Pembrolizumab every 3 weeks and carboplatin or cisplatin + pemetrexed every 3 weeks for 4 cycles, and then pemetrexed plus pembrolizumab every 3 weeks (according to the current version of the SmPC)~Pembrolizumab treatment may be continued as long as patient is experiencing clinical benefit, as assessed by an investigator, in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression after an integrated assessment of radiographic data, biopsy results (if available) and clinical status."
62821521|NCT03882021|OTHER|Mapping protocol with Advisor™ HD Grid Mapping Catheter, Sensor Enabled™ (GRID) catheter|All patient will undergo a protocol required mapping protocol using the GRID catheter.
62041281|NCT05109091|PLACEBO_COMPARATOR|Placebo|
62041282|NCT03509116||Patient group 1|Observations only
62041283|NCT03509116||Patient group 2|Qualitative interview, key stakeholders, documentary analysis
62041284|NCT05968651|EXPERIMENTAL|Clinical|This group consists of individuals with at least moderate symptoms of social anxiety disorder. This group will receive either an oxytocin or placebo administration (blind randomization).
62434696|NCT06059742|EXPERIMENTAL|Action Observation Therapy with Acoustic Stimulation|The patients in the action observation therapy with acoustic stimulation group will be required to observe the lower limb movements or functional actions with sound of beats in video clips. (i.e., the observation phase) and to execute what they had observed to the best of their ability with sound of beats given through headphones (i.e., the execution phase). Three common categories of movements will be elected in the protocol for each week based on the related literature
62244517|NCT01134835|PLACEBO_COMPARATOR|Placebo|Placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
62244518|NCT03666000|EXPERIMENTAL|Dose Level 1|"Azer-cel 3 x 10\^5 CAR T cells per kilogram (kg) body weight.~Route of Administration: Intravenous infusion."
62244519|NCT03666000|EXPERIMENTAL|Dose Level 2|Azer-cel, 1 x 10\^6 CAR T cells per kg body weight
62244520|NCT03666000|EXPERIMENTAL|Dose Level 3a|Azer-cel, 3 x 10\^6 CAR T cells per kg body weight.
62821522|NCT06603701|OTHER|Impedance measurement for acute stroke patient|Acute stroke patients will benefit from impedance measurement and dynamometry to determine the evolution of sarcopenia rates.
62821523|NCT05758168|NO_INTERVENTION|Layered Closure|A cutaneous layer of sutures will be placed on one side of wound, as is standard of care.
62821524|NCT05758168|EXPERIMENTAL|Layered Closure with Tie-Over Bolster Dressing|The other side of wound will have a cutaneous layer of sutures with the addition of a bolster dressing.
62821525|NCT06435351|EXPERIMENTAL|Dendritic Cell (DC) Vaccine|"The tumor specimen collected from the primary tumor will undergo whole exome sequencing (WES). The WES data will be analyzed to select up to 20 neoantigens. From this screen up to 10 peptides will be selected to be synthesized for testing and use on the DC pheresis product that will be collected.~The ready vaccine product will be cryopreserved and then thawed once the patient is ready to under the vaccination sequence."
62821526|NCT02137746|EXPERIMENTAL|DCVAC/PCa Arm|Dendritic Cells DCVAC/PCa Experimental therapy
62821527|NCT04156087|EXPERIMENTAL|MIMIPAC|Intervention: MIS-MWA plus immunotherapy using the combination of durvalumab with tremelimumab
62041285|NCT05968651|PLACEBO_COMPARATOR|Controls|This group consists of a healthy sample of individuals (no lifetime diagnoses of mania or psychotic disorders). This group will receive either an oxytocin or placebo administration (blind randomization).
62041286|NCT01027936||Normal Healthy Volunteers|
62244521|NCT03666000|EXPERIMENTAL|Dose Level 4|Azer-cel, 6 x 10\^6 CAR T cells per kg body weight as 2 administrations of 3 x 10\^6 CAR T cells per kg body weight administered after a single lymphodepletion.
62600937|NCT04291105|EXPERIMENTAL|Head and Neck SCC intratumoral|HNSCC, IT VV1 + IV cemiplimab, Patients will receive both treatments on Day 1 and every 3 weeks thereafter until lack of clinical benefit or limiting toxicity. VV1 or cemiplimab can continue after the first dose in combination or as a single agent treatment in subsequent doses.
62821528|NCT00641433|EXPERIMENTAL|experimental|Subjects will daily dress their nail bed with oxidized regenerated cellulose collagen-silver, until healing occurs.
62821529|NCT00641433|ACTIVE_COMPARATOR|Control|Topical silver sulfadiazine cream will be applied daily to the wound bed until healing has occured.
62041287|NCT05615649|EXPERIMENTAL|Study procedure|This single-arm, repeated-measures study includes study visits at baseline, surgery, device activation, and at 1, 3, 6, and 12 months post-activation.
62041288|NCT06340906|EXPERIMENTAL|Treatment Arm|Each participant will attend a total of 8 treatment visits (one visit per week), over the course of 8 weeks. Each EA session will be approximately 1 hour. Participants in the treatment arm will receive EA at 10 standardized acu-points that were chosen for their therapeutic effects.
62041289|NCT06326905|EXPERIMENTAL|Open Label Pilot|The Open Label Pilot will include testing the CAPABLE Transplant intervention with 3 individuals on the waitlist.
62244522|NCT03666000|EXPERIMENTAL|Dose Level 4b|Azer-cel, 500 x 10\^6 CAR T cells (flat dose)
62244523|NCT03666000|EXPERIMENTAL|Dose level 4c|Azer-cel, 1000 x 10\^6 CAR T cells (flat dose) given as 2 administrations of 500 × 106 cells/per dose on Day 0 and Day 5.
62244524|NCT04849741|EXPERIMENTAL|zilganersen|Zilganersen will be administered by intrathecal bolus (ITB) injection once every 12 weeks through Week 49. The 60-week double-blind treatment period will be followed by the open-label and long-term extension periods, where participants will receive zilganersen by ITB injection from Week 61 to Week 229.
62821530|NCT05537103||1|15-17 year olds from US general population
62821531|NCT06591533|EXPERIMENTAL|Music therapy + standard care|
62041290|NCT06326905|EXPERIMENTAL|Randomized Control Pilot- Intervention Arm|After the open label pilot, 15 participants will be randomized to the CAPABLE Transplant intervention. They will be assessed at baseline, after the 4 month intervention, and after the waitlist control arm.
62821532|NCT06591533|OTHER|Standard care|
62821533|NCT04036682|EXPERIMENTAL|Phase 1 Dose Escalation (Accelerated Titration)|CLN-081 BID in single patient dose escalation cohorts enrolling NSCLC patients with EGFR exon 20 insertion mutations that either have received or never received prior EGFR TKIs.
62821534|NCT04036682|EXPERIMENTAL|Phase 1 Dose Escalation (Rolling Six)|CLN-081 BID in Rolling Six dose escalation cohorts enrolling NSCLC patients with EGFR exon 20 insertion mutations.
62821535|NCT04036682|EXPERIMENTAL|Phase 2a Dose Expansion(s)|CLN-081 BID in expansion cohorts that may be opened at doses that meet pre-specified efficacy and safety criteria.
62821536|NCT04036682|EXPERIMENTAL|Module A Food Affect|Single-dose CLN-081 150 mg with and without high fat food intake.
62821537|NCT04036682|EXPERIMENTAL|Module B|CLN-081 BID in NSCLC patients with EGFR exon 20 insertion mutations that have received prior systemic therapy for locally advanced or metastatic disease.
62821538|NCT04036682|EXPERIMENTAL|Module C|CLN-081 BID to patients with EGFR exon 20 insertion mutant NSCLC after prior therapy with an agent approved for the treatment of ex20ins mutant NSCLC.
62821539|NCT03755934|PLACEBO_COMPARATOR|Placebo|Participants received 6 doses of intravenous (IV) placebo infusion matched to MEDl7352 during 12-week treatment period.
62821540|NCT03755934|EXPERIMENTAL|MEDl7352 Low Dose|Participants received 6 doses of IV MEDl7352 low dose during 12-week treatment period.
62821541|NCT03755934|EXPERIMENTAL|MEDl7352 Medium Dose|Participants received 6 doses of IV MEDl7352 medium dose during 12-week treatment period.
62821542|NCT03755934|EXPERIMENTAL|MEDI7352 High Dose|Participants received 6 doses of IV MEDl7352 high dose during 12-week treatment period.
62821543|NCT05226624|EXPERIMENTAL|Rooming-in care|Rooming-in care
62821544|NCT05226624|ACTIVE_COMPARATOR|Base line|Base line prior to implementation
62821545|NCT05799287|EXPERIMENTAL|Telitacicept|Subjects will be given Telitacicept 240 mg SC once a week in phase A for a total of 39 doses and once every 2 weeks in phase B for a total of 32 doses.
62821546|NCT05799287|PLACEBO_COMPARATOR|Placebo|Subjects will be given placebo SC once a week in phase A for a total of 39 doses and once every 2 weeks in phase B for a total of 32 doses.
62821547|NCT01652235|EXPERIMENTAL|Endovascular|Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft
62821548|NCT04699591|OTHER|Overall Study|Receive domperidone 4 times a day, weight-dependent dose
62821549|NCT06008730|EXPERIMENTAL|Treatment (proton beam radiation therapy)|Patients undergo radiation treatment planning and then undergo proton beam radiation therapy on study. Patients also undergo collection of blood samples.
62821550|NCT06054126||T2DM with good CCC|T2DM was diagnosed according to the criteria of the American Diabetes Association. The diagnosis of CTO was made if at least one lesion was angiographic 100% occlusion. Coronary collateral circulation development was graded according to the Cohen-Rentrop method, grade 2 (partial filling of the epicardial segment by collateral vessels); grade 3 (complete filling of the epicardial artery by collateral vessels) were defined as good coronary collateral circulation.
62821551|NCT06054126||T2DM with poor CCC|T2DM was diagnosed according to the criteria of the American Diabetes Association. The diagnosis of CTO was made if at least one lesion was angiographic 100% occlusion. Coronary collateral circulation development was graded according to the Cohen-Rentrop method, grade 0 (no filling of any collateral vessels) and grade 1 (filling of side branches of the artery to be perfused by collateral vessels without visualization of the epicardial segment) were defined as poor coronary collateral circulation.
62821552|NCT06602440|OTHER|3cm group|When performing Dural Puncture Epidural technique with Programmed Intermittent Epidural Bolus（PIEB） mode for labor analgesia, the indwelling depth of the epidural catheter is 3 centimeters.
62821553|NCT06602440|OTHER|5cm group|When performing Dural Puncture Epidural technique with Programmed Intermittent Epidural Bolus（PIEB） mode for labor analgesia, the indwelling depth of the epidural catheter is 5 centimeters.
62821554|NCT06602440|OTHER|7cm group|When performing Dural Puncture Epidural technique with Programmed Intermittent Epidural Bolus（PIEB） mode for labor analgesia, the indwelling depth of the epidural catheter is 7 centimeters.
62821555|NCT06586424||MACE group|Patient with STEMI who suffered major adverse cardiovascular events (MACE) after underwent primary percutaneous coronary intervention (PPCI)
62821556|NCT00563056|EXPERIMENTAL|Flutiform|2 puffs 50/5 or 125/5 mcg
62821557|NCT00563056|ACTIVE_COMPARATOR|Flixotide plus Foradil|Flixotide 2 puffs 50 or 125 mcg; Foradil 1 puff 12 mcg
62821558|NCT02484391|EXPERIMENTAL|Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)|See Detailed Description
62821559|NCT00823316|EXPERIMENTAL|1|at a dose of 1x1,000,000 hMSC/kg
62821560|NCT00823316|EXPERIMENTAL|2|at a dose of 5x1,000,000 hMSC/kg
62821561|NCT06587737|EXPERIMENTAL|colchicine 0.5mg OD|
62821562|NCT06587737|PLACEBO_COMPARATOR|placebo|
62821563|NCT05062785|EXPERIMENTAL|Intranasal insulin|A total of 11 possible doses will be tested, ranging from 0 to 1000 U insulin.
62821564|NCT05916183|EXPERIMENTAL|Dehydration and Rehydration Arm|Participants will complete exercise until 5% body mass loss, followed by ad libitum rehydration throughout 2 hours of recovery.
62821565|NCT06587581|ACTIVE_COMPARATOR|T2DM Medical Nutrition Therapy|Participants from control groups will receive the usual care, which will be a three-monthly nutrition consultation by a visiting dietitian
62041291|NCT06326905|ACTIVE_COMPARATOR|Randomized Control Pilot- Waitlist Control Arm|The waitlist control group, 15 participants, will receive the intervention after they have served as controls to the immediate treatment group, ensuring all participants have access to the intervention.
62041292|NCT01417299|ACTIVE_COMPARATOR|RPh201 group|Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
62041293|NCT01417299|PLACEBO_COMPARATOR|placebo group|Patients will receive 400 microliter s.c., of saline twice a week for 3 months
62041294|NCT04610671|EXPERIMENTAL|Participants Receiving CG0070 & Nivolumab|Both CG0070 (x 6 instillations) and nivolumab (x 2 doses) will be administered at their single-agent dose and schedule.
62041295|NCT06491511||ICU patients|ICU patient with mechanical ventilator
62041296|NCT02101229|NO_INTERVENTION|unsual treatment|The patient will have his usual treatment in this arm
62041297|NCT02101229|EXPERIMENTAL|The Diabeloop algorithm|In this arm, the insulin Asp(B28) dose is calculated by the algorithm based on the usual treatment of the patient, the ratio I / C, the intensity of physical activity and blood glucose sensor.
62041298|NCT00745745|ACTIVE_COMPARATOR|1|Apical ICD lead placement
62041299|NCT00745745|EXPERIMENTAL|2|Mid-Septal ICD lead placement
62041300|NCT01092338|ACTIVE_COMPARATOR|4000IU|Subjects in this arm take a daily dose of 4000IU of Vitamin D3
62041301|NCT01092338|ACTIVE_COMPARATOR|7000IU|Subjects in this arm of the study take a daily dose of 7000IU of Vitamin D3
62041302|NCT04063189|EXPERIMENTAL|First Relapsed Multiple Myeloma|
62041303|NCT06733233|EXPERIMENTAL|T-DXd combined with immune checkpoint inhibitor|
62041304|NCT04310592|EXPERIMENTAL|Dose escalation/MTD or MPD determination in MRD positive AML patients|Cyclophosphamide + Fludarabine prior to CYNK-001 on Days 0, 7, and 14; CYNK-001 at 3 varying dose levels.
62041305|NCT04310592|EXPERIMENTAL|Dose escalation/MTD or MPD determination in Relapsed/Refractory AML patients|Cyclophosphamide + Fludarabine prior to CYNK-001 on Days 0, 7, and 14; CYNK-001 at 3 varying dose levels.
62041306|NCT05979909|EXPERIMENTAL|Intravesical mitomycin C (MMC)|
62041307|NCT05979909|NO_INTERVENTION|No intervention|
62041308|NCT05536349|EXPERIMENTAL|Pirtobrutinib plus Venetoclax plus Obinutuzumab (combination)|Participants will receive the study drugs in cycles. Each cycle is 28 days.
62821566|NCT06587581|EXPERIMENTAL|T2DM Medical Nutrition Therapy and Text Messages|Participants from the intervention group will receive the usual care and an additional three text messages per week via WhatsApp over the 6-month intervention period
62821567|NCT00817297|OTHER|V60 Mask, Then Conventional Mask|Experimental V60 Mask Ventilator for treating adult patients with COPD, then Comparator Conventional Mask Ventilator for treating adult patients with COPD
62821568|NCT00817297|OTHER|Conventional Mask, Then V60 Mask|Comparator Conventional Mask noninvasive Ventilator for treating adult patients with COPD, then Experimental V60 Mask noninvasive Ventilator for treating adult patients with COPD.
62821569|NCT05552287|EXPERIMENTAL|Intensified induction scheme with Infliximab|Intensified induction scheme with Infliximab. IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks.
62041309|NCT03543930||Major open vascular surgery|Surgical procedures on the abdominal aorta requiring median abdominal incision
62041310|NCT03543930||Endovascular aortic repair|Abdominal aortic repair with endovascular approach
62041311|NCT06723678|EXPERIMENTAL|Two distally inclined 45-degree angle posterior implants.|During the surgery, two axially placed anterior implants and two distally inclined 45-degree angle posterior implants.
62041312|NCT06723678|ACTIVE_COMPARATOR|Two distally inclined 30-degree angle posterior implants.|During the surgery, two axially placed anterior implants and two distally inclined 30-degree angle posterior implants.
62041313|NCT03663231|EXPERIMENTAL|Biotene|People who present with dry mouth and will receive a single dose of Biotene.
62041314|NCT03663231|PLACEBO_COMPARATOR|Placebo|People who present with dry mouth and will receive a single dose of an alternative agent.
62041315|NCT06031272|EXPERIMENTAL|Arm A: 30 mg/kg 3BNC117-LS-J + 10 mg/kg 10-1074-LS-J|Participants will receive 30 mg/kg 3BNC117-LS-J and 10 mg/kg 10-1074-LS-J, administered as two intravenous (IV) infusions at Step 1 entry (Day 0). Participants will discontinue ART on Day 2.
62041316|NCT06031272|PLACEBO_COMPARATOR|Arm B: Placebo|Participants will receive dose-volume equivalent placebo IV infusions for both 3BNC117-LS-J and 10-1074-LS-J at Step 1 entry (Day 0). Participants will discontinue ART on Day 2.
62041317|NCT00614666|EXPERIMENTAL|A|nikkomycin Z 50 mg BID versus placebo BID x 14 days
62041318|NCT00614666|EXPERIMENTAL|B|nikkomycin Z 250 mg BID versus placebo BID x 14 days
62041319|NCT00614666|EXPERIMENTAL|C|nikkomycin Z 500 mg BID versus placebo BID x 14 days
62041320|NCT00614666|EXPERIMENTAL|D|nikkomycin Z 750 mg TID versus placebo TID x 14 days
62041321|NCT05105594|ACTIVE_COMPARATOR|Study Group|People who have lymphedema
62041322|NCT05105594|ACTIVE_COMPARATOR|control group|healty people
62041323|NCT00785655|EXPERIMENTAL|1|Dermacyd PH_DETINLYN (Lactic Acid)
62849176|NCT04832269||MP exposed group|children and adolescents (aged 8 to 18 years) of mothers with prenatal exposition to MP in the context of an MS relapse therapy
62244525|NCT04849741|PLACEBO_COMPARATOR|Placebo|Matching placebo will be administered by ITB injection once every 12 weeks through Week 49. It will be followed by the open-label and long-term extension periods, where participants will receive zilganersen by ITB injection from Week 61 to Week 229.
62244526|NCT05770375|EXPERIMENTAL|MDMA|Each subject will receive 3 doses of MDMA in ascending order: 40mg, 80mg, 120mg.
62434697|NCT06059742|ACTIVE_COMPARATOR|Action Observation Therapy Without Acoustic Stimulation|The patients in the action observation therapy without acoustic stimulation group will be required to observe the lower limb movements or functional actions without sound of beats in video clips. (i.e., the observation phase) and to execute what they had observed to the best of their ability without sound of beats (i.e., the execution phase). Three common categories of movements will be elected in the protocol for each week based on the related literature
62821570|NCT06269133||Study Patients|Patients who have received cemiplimab in combination with platinum-doublet chemotherapy for the 1L treatment of aNSCLC in the US with no documented EGFR, ALK and ROS1 variants as described in the protocol.
62600938|NCT04291105|EXPERIMENTAL|Colo-rectal Carcinoma intratumoral (Arm closed)|(CLOSED) IT VV1 + IV cemiplimab, Patients will receive both treatments on Day 1 and every 3 weeks thereafter until lack of clinical benefit or limiting toxicity. VV1 or cemiplimab can continue after the first dose in combination or as a single agent treatment in subsequent doses.
62821571|NCT04328714|EXPERIMENTAL|Adult Population|Study participants aged 18 or older who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs).
62821572|NCT04328714|EXPERIMENTAL|Pediatric Population|Study participants under 18 years of age who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs).
62821573|NCT05804591|PLACEBO_COMPARATOR|Multimodal analgesia group|Patients receiving placebo per os 1 hour preoperatively and anesthesia with standard, multimodal analgesia afterwards.
62821574|NCT05804591|EXPERIMENTAL|Multimodal analgesia with preemptive pregabalin group|Patients receiving pregabalin 150mg per os 1 hour preoperatively and anesthesia with standard, multimodal analgesia afterwards.
62821575|NCT06587698|OTHER|Sitagliptin|"100mg/day Sitagliptin by oral for 3 months~detail：1 piece(100mg) at morning"
62821576|NCT06587698|OTHER|BeiDouGen|"120mg/day BeiDouGen capsule by oral for 3 months~detail：2 piece(30mg) at morning and night"
62244527|NCT03446391||Kinematic alignment with GMK Sphere®|Patients enrolled prospectively with surgeries planned to get kinematic alignment
62600939|NCT02012465|EXPERIMENTAL|Insulin protocol|"For diabetic patients, as part of the initial chemotherapy orders on admission, the following will be calculated by the primary oncologist to determine the amount of neutral protamine Hagedorn (NPH) insulin needed to cover steroid use in prednisone equivalents (all insulin in this study is to be administered subcutaneously):~* Use 0.1 (mg of prednisone equivalent - 20)/20 x weight (kg) to estimate total insulin in 24 hours (Total daily dose (TDD))~* Total daily NPH dose will be divided equally based on the frequency of steroid administration, and given with each steroid dose.~For nondiabetic participants with hyperglycemia recruited during admission, the inpatient oncology team will consult the endocrine team within 24 hours of eligibility for NPH dosing as above."
62600940|NCT06466876|EXPERIMENTAL|Word Learning|Each autistic child will be taught novel words in a behavioral task.
62600941|NCT02620241|OTHER|sitting position|infants are in a sitting position for 20 minutes
62600942|NCT04799548|EXPERIMENTAL|neoadjuvant TACE plus Tislelizumab|
62600943|NCT03506568|NO_INTERVENTION|Control - no reminder|For Group 1, there will be no changes to their instructions or smart phone, which is the most common clinical situation.
62600944|NCT03506568|EXPERIMENTAL|Integrated daily reminder using the D3 app|For Group 2, they will have their D3 app turned on to deliver both a push notification reminder to their smart phone and audio and visual reminders to their D3 device.
62821577|NCT06587698|OTHER|Sitagliptin+BeiDouGen|"100mg/day Sitagliptin+120mg/day BeiDouGen capsule by oral for 3 months~detail：1 piece(100mg) Sitagliptin and 2 piece(30mg) BeiDouGen capsule at morning 2 piece(30mg) BeiDouGen capsule at night"
62821578|NCT03939624||Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Patients who received a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
62041324|NCT03452007|EXPERIMENTAL|Bladder Mapping and Training|Individuals already implanted or newly implanted with a spinal cord epidural stimulator will receive epidural stimulation targeted at enhancing both the storage and voiding phase of micturition cycle.
62244528|NCT03446391||Mechanical alignment with GMK Sphere®|Historical group who had mechanical alignment, match-paired with the prospective group
62244529|NCT05661578|EXPERIMENTAL|Tiragolumab and Atezolizumab IV FDC|Participants will receive tiragolumab and atezolizumab as an intravenous fixed dose combination (IV FDC) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
62244530|NCT02321826|EXPERIMENTAL|Music|Listening to music for 45 minutes at bedtime
62244531|NCT02321826|ACTIVE_COMPARATOR|Audiobook|Listening to audiobook for 45 minutes at bedtime
62244532|NCT02321826|NO_INTERVENTION|Control|No intervention control group
62434698|NCT06090747|ACTIVE_COMPARATOR|Evaluate the effect of hybrid educational intervention in Lifestyle behavior.|Group 1: hybrid educational intervention
62600945|NCT06188702|EXPERIMENTAL|Dose Escalation|
62600946|NCT03257878||Systemic sclerosis (SSc)|validated Korean version of the SF36 and EQ-5D
62600947|NCT03257878||Rheumatoid arthritis (RA)|validated Korean version of the SF36 and EQ-5D
62600948|NCT03257878||Systemic lupus erythematosus (SLE)|validated Korean version of the SF36 and EQ-5D
62600949|NCT03257878||Sjogren's syndrome|validated Korean version of the SF36 and EQ-5D
62821579|NCT03939624||Dipeptidyl peptidase-4 (DPP-4) inhibitors|Patients who received a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
62821580|NCT05498610|EXPERIMENTAL|1.7 mg NNC0408-0389 plus 0.5 mg semaglutide|Participants will receive a single subcutanous dose of 1.7 mg of NNC0408-0389 in combination with a fixed dose of 0.5 mg semaglutide administered as separate injections
62821581|NCT05498610|EXPERIMENTAL|8.6 mg NNC0480-0389 plus 0.5 mg semaglutide|Participants will receive a single subcutanous dose of 8.6 mg of NNC0408-0389 in combination with a fixed dose of 0.5 mg semaglutide administered as separate injections
62600950|NCT03257878||Control|validated Korean version of the SF36 and EQ-5D
62600951|NCT06118814|EXPERIMENTAL|Body Awareness Therapy Group|In addition to the home program, basic body awareness exercises will be applied.
62244533|NCT03909815|EXPERIMENTAL|Intervention|Insertion of dual mobility cup
62600952|NCT06118814|EXPERIMENTAL|Virtual Reality Exercise Group|In addition to the home program, virtual reality-supported core stabilization exercises will be applied.
62821582|NCT05498610|EXPERIMENTAL|30 mg NNC0480 0389 plus 0.5 mg semaglutide|Participants will receive a single subcutanous dose of 30 mg of NNC0408-0389 in combination with a fixed dose of 0.5 mg semaglutide administered as separate injections
62821583|NCT06604273|EXPERIMENTAL|Group 2|This group undergoes FAPi-PET CT imaging
62821584|NCT06604273|NO_INTERVENTION|Group 1|Does not undergo a FAPi scan
62821585|NCT02439853|EXPERIMENTAL|Check-In group|Subjects in the Check-In group will undergo three check-in sessions with the speech therapist. These sessions will happen remotely, via video-chat, and will last less than an hour. They will occur at 3-, 4-, and 5-months from the subject's enrollment date.
62821586|NCT02439853|NO_INTERVENTION|Control Arm|Subjects in the Control arm will not undergo three check-in sessions with the speech therapist.
62821587|NCT05458908|EXPERIMENTAL|Cranial non-contrast syngo DynaCT Sine Spin scan|There is only one arm as all patients undergo the same intervention. Subjects with clinical features/symptoms of a stroke (hemorrhagic and non-hemorrhagic stroke patients) will be enrolled. All patients will undergo first a non-contrast MDCT scan and then a non-contrast syngo DynaCT Sine Spin head scan within a maximum timespan of 4 hours between both scans. Only patients in which no invasive procedure in between is planned can be enrolled.
62821588|NCT05195398|EXPERIMENTAL|A-tDCS|Participants randomized to tDCS will undergo 15- 30 minute sessions over 5 weeks of A-tDCS to the ipsilesional frontoparietal cortex while participating in computerized cognitive therapy (CCT).
62821589|NCT05195398|ACTIVE_COMPARATOR|Sham Intervention|Participants randomized to sham will undergo 15- 30 minute sessions over 5 weeks of a sham-intervention, also applied to the ipsilesional frontoparietal cortex, while participating in computerized cognitive therapy (CCT).
62821590|NCT06588010|EXPERIMENTAL|Patients in the experimental arm|
62821591|NCT06588010|ACTIVE_COMPARATOR|Patients in the control arm|
62821592|NCT06587048|EXPERIMENTAL|Piezo group|The bone window osteotomy will be created with a piezoelectric device during endodontic microsurgery
62600953|NCT06118814|EXPERIMENTAL|Core Stability Exercise Group|In addition to the home program, core stabilization exercises will be performed.
62600954|NCT06118814|ACTIVE_COMPARATOR|Home Exercise Group|A home program will be implemented.
62600955|NCT04982068|EXPERIMENTAL|Adult Group 1a|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low adjuvant dose at Day 0 and Day 28
62244534|NCT03909815|ACTIVE_COMPARATOR|Control|Insertion of standard cup
62244535|NCT02595931|EXPERIMENTAL|Treatment (irinotecan, M6620)|Patients receive irinotecan hydrochloride IV over 90 minutes and M6620 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy and collection of blood samples throughout the study and undergo CT at screening, throughout the study, and during follow up.
62600956|NCT04982068|EXPERIMENTAL|Adult Group 1b|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low antigen dose at Day 0 and Day 28
62600957|NCT04982068|EXPERIMENTAL|Adult Group 1c|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV standard dose at Day 0 and Day 28
62821593|NCT06587048|ACTIVE_COMPARATOR|conventional bur group|The bone window osteotomy will be created with a conventional rotary burs in slow-speed handpiece during endodontic microsurgery
62821594|NCT05118022|EXPERIMENTAL|Intervention|Patients randomized to intervention will be cared by physicians under AI-ECG support.
62821595|NCT05118022|NO_INTERVENTION|Control|Patients randomized to control will be cared by routine practice.
62041325|NCT03213652|EXPERIMENTAL|Treatment (ensartinib)|Patients receive ensartinib PO QD on days 1-28. Cycles repeat every 28 days for 2 years (up to 26 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, PET scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.
62041326|NCT06732921|EXPERIMENTAL|Recovery Control Tower (RCT)|Clinicians in the RCT will remotely work with PACU clinicians to care for patients assigned to one of the two study bays. A version of AlertWatch® (AlertWatch, Ann Arbor, Michigan) decision-support software, customized for the PACU environment, will assist clinicians in the RCT to perform core PACU-related functions remotely. Caregility's iObserver, from the Caregility Cloud™ Virtual Care Platform, will be used for two-way video communication When feasible, RCT clinicians will join handoff activities from the OR to the PACU and discuss pertinent intraoperative events with clinical teams on the ground. RCT clinicians will document patient specific recovery tasks within AlertWatch to assist in tracking patient recovery progresses. RCT clinicians will be the initial point of contact for ongoing recovery care, such as order placements. The attending anesthesiologist in the RCT will assess patients' discharge readiness throughout their PACU stay.
62041327|NCT06724601||Preterm infants < 37 weeks gestation at birth or birthweight <2.5 kg (within 48 hours of discharge)|Preterm infants with gestational age up to 36 6/7 weeks at birth and/or birthweight \< 2.5 kg will be included. They must fulfill all criteria for discharge from the Neonatal Intensive Care Unit and be discharged home within 48 hours at the time of measurement.
62821596|NCT01404741|ACTIVE_COMPARATOR|5-azacytidine treatment until progress|5-azacytidine until progress
62821597|NCT01404741|EXPERIMENTAL|allogeneic stem cell transplantation|after 4 cycles 5-azacytidine and if donor available: allogeneic stem cell transplantation after reduced intensity conditioning
62041328|NCT06733493|EXPERIMENTAL|IPS-Intervention Group|Implementation of a trained ward psychologist for 12 months, supporting patients, relatives and staff according to the IPS-intervention manual
62041329|NCT06733493|NO_INTERVENTION|Control Group: Standard Care|No intervention will be admitted. ICU wards receive the usual care, e.g. consiliary psychological service, optional consultation for staff
62244536|NCT04509960|NO_INTERVENTION|proseal laryngeal mask insertion|no intervention
62600958|NCT04982068|PLACEBO_COMPARATOR|Adult Placebo|Adult healthy subjects (18 to 59 years of age, inclusive) receive 2 doses of placebo (saline) at Day 0 and Day 28
62821598|NCT06603441||Samsung Galaxy Watch technology|All participants screened will utilize the Samsung Galaxy Watch technology to monitor sleep patterns, oxygen saturation, PPG, and heart rate variability amongst other physiologic parameters. All data will be collected over the course of two intervention nights in the sleep lab and at home for three nights
62821599|NCT05225038|ACTIVE_COMPARATOR|Control Arm (Standard of Care)|Participants will receive the current standard preoperative education and counseling. Participants will receive information regarding exercise and nutrition from a member of the surgical team. Participants will meet with a behavioral medicine specialist for additional education regarding factors affecting postoperative stress and relaxation techniques. Participants who are actively smoking will be counseled regarding smoking cessation and offered a referral to smoking cessation resources.
62821600|NCT05225038|EXPERIMENTAL|Intervention Arm (Prehabilitation)|"Participants in the intervention arm will receive all of the standard of care, as listed above, as well as individualized exercise and nutritional prehabilitation regimens.~During the data analysis, participants will be subdivided into treatment groups, upfront surgical resection versus neoadjuvant chemotherapy, in order to determine whether length of prehabilitation affected outcomes and distinguish any possible effect of chemotherapy toxicity."
62821601|NCT06281730|EXPERIMENTAL|Karl Storz fetoscopes|Participants will receive In utero surgery using the new generation Karl Storz fetoscopes (11508AAK and 11506AAK) for fetal conditions amenable to treatment with fetoscopy.
62821602|NCT06480747|EXPERIMENTAL|Resistance exercise training|
62821603|NCT06480747|NO_INTERVENTION|Control|
62821604|NCT05048459|ACTIVE_COMPARATOR|Standard surveillance|This surveillance approach involves the participant coming to the clinic for in-person follow-up visits and having routine endoscopy and cancer imaging procedures as needed
62821605|NCT05048459|EXPERIMENTAL|Telemedicine surveillance (tele-surveillance)|Tele-surveillance involves the participant staying at home while their healthcare providers follow their condition and give them the care they need. They can communicate with their healthcare team through face-to-face video conferencing on their desktop computer, laptop, smart phone, or tablet. They can also communicate with their healthcare team by phone.
62821606|NCT04097470|ACTIVE_COMPARATOR|Arm A: Decitabine|"Cycles 1-3: Decitabine 10-day; depending on day +28 bone marrow (BM) blasts after the previous cycle, next cycle consists of either 5-day (BM blasts \< 5%) or 10-day (BM blasts ≥5%) decitabine. Cycles 4 and beyond: 5-day decitabine (in cycles of 4-8 weeks); continuation of these cycles until progression.~Dosage for Decitabine 20 mg/m2 i.v."
62849177|NCT04832269||MP non-exposed group/control group|children and adolescents of mothers suffering from MS aged 8 to 18 years
62244537|NCT04509960|EXPERIMENTAL|proseal laryngeal mask insertion with laryngoscope|with the help of direct laryngoscopy
62041330|NCT01563536|EXPERIMENTAL|ABT-267 1.5 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV|ABT-267 (1.5 mg once daily) as monotherapy for 2 days, then ABT-267 (1.5 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks
62041331|NCT01563536|EXPERIMENTAL|ABT-267 25 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV|ABT-267 (25 mg once daily) as monotherapy for 2 days, then ABT-267 (25 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks
62041332|NCT06399614||Intervention Group|Participants who attend an emergency department or injury unit with access to occupational therapy will be referred to an occupational therapy-led hand therapy clinic. Assessment and intervention for their hand injury will be provided by the occupational therapist, based on existing hand therapy protocols and guidelines. The consultant in charge and the occupational therapist will make clinical judgements with regard suitability for occupational therapy clinics for conservative management of their condition based on patient need at point of triage. Types of interventions provided by the occupational therapist will include customised splinting, targeted exercises and activities, swelling reduction, scar management, desensitisation, education on type of injury, and occupation based intervention. All interventions provided are within occupational therapists' scope of practice and are evidence based.
62041333|NCT06399614||Care as Usual Group|Participants attending an emergency department of injury unit, do not have access to occupational therapy services and will undergo 'care as usual' in line with the services' protocols and procedures. Care as usual involves standard nursing and medical care and may include: wound care, use of 'off the shelf' orthosis, education, and onward referral to other healthcare professionals.
62041334|NCT05047120|EXPERIMENTAL|Hypnosis Enhanced Cognitive Therapy|This arm will receive 4 sessions of hypnosis enhanced cognitive therapy for pain. Subjects will receive recordings of sessions for practice between therapist sessions.
62041335|NCT05047120|ACTIVE_COMPARATOR|Pain Education|This arm will receive 4 sessions of spinal cord injury pain education. Subjects will receive pain education materials for review between therapist sessions.
62041336|NCT02176551|EXPERIMENTAL|Product 0405|Topical active investigational Product 0405
62041337|NCT02176551|PLACEBO_COMPARATOR|Placebo for Product 0405|Topical Placebo for Product 0405
62041338|NCT06579703|EXPERIMENTAL|Reduced dose Ketorolac Arm A|a reduced dose of Ketorolac, 15 mg/mL
62041339|NCT06579703|ACTIVE_COMPARATOR|Standard of care dose Ketorolac Arm B|standard of care dose of Ketorolac, 30mg/mL
62600959|NCT04982068|EXPERIMENTAL|Elderly Group 1d|Adult healthy subjects (60 years of age and above) receive 202-CoV low adjuvant dose at Day 0 and Day 28
62849178|NCT05816499|EXPERIMENTAL|Arm A (cadonilimab，anlotinib，docetaxel )|Patients receive anlotinib 6mg/8mg/10mg qd 2W/3W and cadonilimab IV over 90 minutes on day 1. Patients also receive docetaxel 60-75 mg/m2 IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62849179|NCT00221468|EXPERIMENTAL|Quetiapine|Patients will begin 100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
62041340|NCT06481592|EXPERIMENTAL|Patients with Endometrial Cancer|
62041341|NCT05807074|EXPERIMENTAL|TXA, Saline|Each participant will have one breast exposed to TXA in the breast pocket and the other to saline only prior to closure. During surgery and prior to wound closure, the wound surface will be moistened on one side with 20 cc of dilute TXA 25mg/ml solution, and the contralateral with 20cc of saline.
62041342|NCT06723834|EXPERIMENTAL|PTSD Service Dog + Prolonged Exposure Therapy|Participants will receive 12 weeks of Prolonged Exposure once per week with the addition of a service dog
62041343|NCT06723834|ACTIVE_COMPARATOR|Prolonged Exposure Therapy Alone|Participants will receive 12 weeks of Prolonged Exposure once per week
62041344|NCT03319940|EXPERIMENTAL|Part A|Tarlatamab monotherapy
62041345|NCT03319940|EXPERIMENTAL|Part C|Tarlatamab with Pembrolizumab
62041346|NCT03319940|EXPERIMENTAL|Part D|Tarlatamab with additional CRS mitigation strategies
62041347|NCT03319940|EXPERIMENTAL|Part E|Tarlatamab administration with 24-hour monitoring
62041348|NCT03319940|EXPERIMENTAL|Part F|"Tarlatamab administered in outpatient infusion centers with 8-hour monitoring~Optional wearable digital device substudy (US sites only)"
62041349|NCT03319940|EXPERIMENTAL|Part G|"Tarlatamab additional dosing schedule~Optional wearable digital device substudy (US sites only)"
62041350|NCT05746845||Healthy individuals|"Group 1: Healthy individuals, so-called control donors whose blood samples will be collected from the EFS (French Blood Establishment)"
62041351|NCT05746845||Stable MS patients treated with high efficacy treatment|Group 2: Stable MS patients without inflammatory activity of the disease treated with high efficacy treatment (Natalizumab or Ocrelizumab)
62041352|NCT05746845||Stable MS patients treated with moderately effective treatment|Group 3: Stable MS patients without inflammatory disease activity treated with moderately effective treatment (Teriflunomide or Fumarate)
62041353|NCT06191627|ACTIVE_COMPARATOR|Patch testing on the legs|Patches to be applied on the legs
62041354|NCT06191627|ACTIVE_COMPARATOR|Patch testing on the back|Patches to be applied on the back
62041355|NCT04050865|EXPERIMENTAL|OTX-DP|
62041356|NCT04050865|PLACEBO_COMPARATOR|Placebo|
62041357|NCT06043739|ACTIVE_COMPARATOR|Treatment A:|filgotinib administered under fasting conditions
62041358|NCT06043739|EXPERIMENTAL|Treatment B:|filgotinib administered under fasting conditions
62041359|NCT06043739|EXPERIMENTAL|Treatment C:|filgotinib administered under high-fat fed conditions
62041360|NCT06732882|EXPERIMENTAL|AZD4604 dose A via Genuair|Participants will receive dose A of AZD4604 via Genuair device twice daily
62041361|NCT06732882|EXPERIMENTAL|AZD4604 dose A via Turbuhaler|Participants will receive dose A of AZD4604 via Turbuhaler device twice daily
62434699|NCT06090747|EXPERIMENTAL|Evaluate the effect of hybrid personalized intervention in Lifestyle behavior|Group 2: hybrid personalized lifestyle intervention delivered by a multidisciplinary team of specialists in oncology, nutrition, psychology, rehabilitation and mindfulness.
62434700|NCT01559974|ACTIVE_COMPARATOR|Vitamin D|
62434701|NCT01559974|PLACEBO_COMPARATOR|Placebo|
62434702|NCT04917900|EXPERIMENTAL|Pyrotinib combined with albumin-bound paclitaxel and trastuzumab|Pyrotinib: 400mg, po,qd,with warm water within 30 minutes after breakfast, q3weeks, 6 cycles in total. Albumin-bound paclitaxel: 260mg/m2, iv, Day1, q3weeks, 6 cycles in total. Trastuzumab: The first cycle dose is 8mg/kg, and each subsequent cycle is 6mg/kg, iv, Day 1, q3weeks, a total of 6 cycles.
62434703|NCT03183271|EXPERIMENTAL|Experimental: External beam radiotherapy|A total of 20 patients will be irradiated with protons after photon IMRT
62434704|NCT04797156|EXPERIMENTAL|High Dose Intravenous TXA (hTXA group)|Patients assigned to hTXA group will receive 50mg/kg IV TXA loading dose with a 5mg/kg/hr maintenance dose, and normal saline poured over 5 minutes at the wound prior to closure.
62041362|NCT06732882|EXPERIMENTAL|AZD4604 dose B via Turbuhaler|Participants will receive dose B of AZD4604 via Turbuhaler device twice daily
62041363|NCT06732882|PLACEBO_COMPARATOR|Placebo via Genuair|Participants will receive placebo via Genuair device twice daily
62041364|NCT06732882|PLACEBO_COMPARATOR|Placebo via Turbuhaler|Participants will receive placebo via Turbuhaler device twice daily
62041365|NCT01753687|OTHER|50 patients with dry eye syndrome|
62041366|NCT06733961||Patient group|It consists of patients diagnosed with Pulmonary Thromboembolism who meet the inclusion and exclusion criteria.
62041367|NCT06733961||Control group|It was composed of healthy volunteers of similar age and gender who did not have any acute complaints.
62041368|NCT02472964|ACTIVE_COMPARATOR|Herceptin© + Taxane|"Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.~Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject withdrawal ."
62041369|NCT02472964|EXPERIMENTAL|MYL- 1401O + Taxane|"Part 1:MYL-1401O Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.~Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to MYL-1401O alone once every 3 weeks until DP or subject withdrawal."
62041370|NCT06078904|ACTIVE_COMPARATOR|Colchicine 0.5 MG|Colchicine 0.5 MG, one pill a day, oral intake
62041371|NCT06078904|ACTIVE_COMPARATOR|Colchicine 0.375 MG|Colchicine 0.375 MG, one pill a day, oral intake
62041372|NCT06078904|ACTIVE_COMPARATOR|Colchicine 0.25 MG|Colchicine 0.25 MG, one pill a day, oral intake
62041373|NCT06078904|PLACEBO_COMPARATOR|Placebo|Placebo, one pill a day, oral intake
62041374|NCT03814733|EXPERIMENTAL|Rapastinel High Dose|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
62041375|NCT03814733|EXPERIMENTAL|Rapastinel Low Dose|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
62041376|NCT03814733|ACTIVE_COMPARATOR|Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
62244538|NCT01563185|EXPERIMENTAL|DUEXIS|800 mg ibuprofen/26.6 mg famotidine
62434705|NCT04797156|EXPERIMENTAL|Low Dose Intravenous TXA (lTXA group)|Patients assigned to lTXA group will receive 20mg/kg IV TXA loading dose with a 5mg/kg/hr maintenance dose, and normal saline poured over 5 minutes at the wound prior to closure.
62434706|NCT04797156|PLACEBO_COMPARATOR|Combined Intravenous and Topical TXA group (cTXA group)|Patients assigned to cTXA group will received 20mg/kg V TXA loading dose with a 5mg/kg/hr maintenance dose, and 2g topical TXA poured over 5 minutes at the would prior to closure
62434707|NCT02360397|EXPERIMENTAL|Ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
62434708|NCT01505595|EXPERIMENTAL|Proprioceptive training|
62041377|NCT03814733|ACTIVE_COMPARATOR|Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
62041378|NCT03814733|PLACEBO_COMPARATOR|Placebo for Rapastinel|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
62041379|NCT03814733|PLACEBO_COMPARATOR|Placebo for Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
62041380|NCT03814733|PLACEBO_COMPARATOR|Placebo for Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
62041381|NCT06476197|EXPERIMENTAL|SAT-003|
62041382|NCT06721026|EXPERIMENTAL|Continuous amino acid infusion|Tracer infusions combined with infusion of a mixture of amino acids
62041383|NCT06297486|EXPERIMENTAL|Cohort A (Primary Cohort)|Participants with severe or moderately severe hemophilia A without FVIII inhibitors using routine FVIII prophylaxis
62041384|NCT06297486|EXPERIMENTAL|Cohort B|Participants with severe or moderately severe hemophilia A without FVIII inhibitors using on-demand FVIII replacement therapy
62041385|NCT06297486|EXPERIMENTAL|Cohort C|Participants with severe or moderately severe hemophilia A without FVIII inhibitors using emicizumab prophylaxis
62041386|NCT06723327||Patients with 2 sterile urine cultures|Before retrograde intrarenal surgery, patients with sterile urine culture 2 weeks before the surgery and morning urine culture
62041387|NCT06723327||Patients with only one sterile urine culture|Before retrograde intrarenal surgery, patients having sterile urine culture 2 weeks before the surgery and positive morning urine culture
62041388|NCT06723873|EXPERIMENTAL|Kinesiology Taping Group|Each taping method was carefully designed to address the unique muscle imbalances and functional deficits commonly seen in stroke patients.
62041389|NCT06723873|SHAM_COMPARATOR|Placebo-Controlled Sham Group|Utilizing three 'I'-shaped strips placed superficially on the skin to ensure no therapeutic effects were achieved.
62041390|NCT05770479|EXPERIMENTAL|ME-CCT Booster Training|3-4 Sessions of ME-CCT Booster Training
62041391|NCT05770479|OTHER|Treatment as Usual|Treatment as Usual
62041392|NCT01580072|NO_INTERVENTION|Control group|Participants in the control group receive usual care.
62041393|NCT01580072|EXPERIMENTAL|Self monitoring for patients with COPD|
62041394|NCT01580072|EXPERIMENTAL|Nurse monitoring for patients with COPD|
62041395|NCT05509296|EXPERIMENTAL|SINOMED CBC|Cutting balloon catheter (Sino Medical Sciences Technology Inc.)
62041396|NCT05509296|ACTIVE_COMPARATOR|NSE Coronary Dilatation Catheter|NSE Coronary Dilatation Catheter (Goodman Co.,Ltd)
62041397|NCT06085430|EXPERIMENTAL|Right eyes: Treatment|
62041398|NCT06085430|NO_INTERVENTION|Left eyes: Control|
62041399|NCT04739813|EXPERIMENTAL|Arm 1: Dose Escalation|Venetoclax (PO) 800mg at escalating doses (2 dose levels) on days 2-14, ibrutinib (PO) 560mg on days 1-14, prednisone (PO) 100mg on days 1-7, obinutuzumab 1000mg (IV) on days 1 and 2, lenalidomide (PO) 15mg on days 1-14, and polatuzumab (IV) at escalating doses (2 dose levels) on day 2 of each 21-day cycle (maximum 6 cycles) to determine MTD of polatuzumab and venetoclax
62041400|NCT04739813|EXPERIMENTAL|Arm 2: Dose Expansion|Venetoclax (PO) at the MTD days 2-14, ibrutinib (PO) 560mg on days 1-14, prednisone (PO) 100mg on days 1-7, obinutuzumab 1000mg (IV) on days 1 and 2, lenalidomide (PO) 15mg on days 1-14, and polatuzumab (IV) at the MTD of each 21-day cycle (maximum 6 cycles)
62041401|NCT02948569|EXPERIMENTAL|3-V Bioscience-2640|Subjects will take a singly daily dose of 3-V Bioscience-2640 before bedtime or 22:30, whichever comes first, for 10 days.
62434709|NCT01505595|SHAM_COMPARATOR|Sham proprioceptive training|
62434710|NCT02041585||Elder discharge cohort|There will be no intervention in this observational survey research.
62600960|NCT04982068|EXPERIMENTAL|Elderly Group 1e|Adult healthy subjects (60 years of age and above) receive 202-CoV low antigen dose at Day 0 and Day 28
62041402|NCT01446081|EXPERIMENTAL|Exercise|Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP).
62041403|NCT01446081|NO_INTERVENTION|Control|Participants assigned to this arm will receive usual care.
62041404|NCT05694741|EXPERIMENTAL|Cohort 1 (healthy volunteers)|The planned number of cohorts is up to 6 cohorts; additional cohorts may be included if it is considered necessary to repeat a dose level or if additional dose steps are required for safety purposes. Six subjects will receive AZD0186, and two subjects will receive placebo.
62041405|NCT05694741|EXPERIMENTAL|Cohort 2 (healthy Japanese volunteers)|The planned number of Japanese cohorts is 1, but more than 1 cohort may be included if the SRC considers it necessary to repeat a dose level or if additional dose steps are required. No sentinel dosing will be performed for the Japanese cohort.
62041406|NCT05694741|EXPERIMENTAL|Cohort 3 (healthy Chinese volunteers)|The planned number of Chinese cohorts is 1, but more than 1 cohort may be included if it is considered necessary to repeat a dose level or if additional dose steps are required. No sentinel dosing will be performed for the Chinese cohort.
62041407|NCT05694741|EXPERIMENTAL|Cohort 4 (healthy volunteers - food effect)|One of the Part 1 cohorts (planned for Cohort 6, can be updated pending emerging data) will continue into the food-effect part after a washout period. This part will be initiated after SRC review of all available data from preceding cohorts in this study.
62041408|NCT05566600|EXPERIMENTAL|Dose level 1|100 million iPSC-CMs administration
62041409|NCT05566600|EXPERIMENTAL|Dose level 2|200 million iPSC-CMs administration
62041410|NCT05566600|EXPERIMENTAL|Dose level 3|400 million iPSC-CMs administration
62041411|NCT05566600|NO_INTERVENTION|Control|Participants will received CABG surgery only
62041412|NCT06695195|EXPERIMENTAL|Oral CBD|Oral CBD 25 mg capsules taken twice each day for 4 weeks.
62821607|NCT04097470|EXPERIMENTAL|Arm B: Decitabine and Midostaurin|"Cycle 1:Decitabine; 10-day schedule (start day +1) + midostaurin (start day +11). Midostaurin is given until 2 days before start next cycle of decitabine. Cycles 2-3: Decitabine 5 or 10-day schedule; depending on day +28 bone marrow blasts of the previous cycle, next cycle consist of either 5-day (BM blasts \< 5%) or 10-day (BM blasts ≥5%) decitabine + midostaurin (daily, starting the day after the last dose of decitabine (i.e. day +6 or +11). Midostaurin is given until 2 days before start next cycle. Cycles 4 and beyond: 5-day decitabine (in cycles of 4-8 weeks) followed by midostaurin starting at day +6 until two days before start of next cycle of decitabine; continuation of these cycles until progression. Midostaurin is given until 2 days before start next cycle of decitabine.~Dosage for Decitabine 20 mg/m2 i.v.~Dosage for Midostaurin 50 mg b.i.d."
62041413|NCT06695195|PLACEBO_COMPARATOR|Placebo|Oral placebo capsules taken twice each day for 4 weeks
62041414|NCT06618547|EXPERIMENTAL|TENEO 317 Model 2 excimer laser|
62600961|NCT04982068|EXPERIMENTAL|Elderly Group 1f|Adult healthy subjects (60 years of age and above) receive 202-CoV standard dose at Day 0 and Day 28
62600962|NCT04982068|PLACEBO_COMPARATOR|Elderly Placebo|Adult healthy subjects (60 years of age and above) receive 2 doses of placebo (saline) at Day 0 and Day 28
62600963|NCT00643461||Adhesive A|
62821608|NCT06599177|EXPERIMENTAL|Intervention group|These participants will receive the informational leaflet
62821609|NCT06599177|NO_INTERVENTION|Control group|These participants will not receive the informational leaflet
62821610|NCT01870206|EXPERIMENTAL|Trivalent OPV Birmex|Newborns receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine. A second dose four weeks after the first application.
62821611|NCT01870206|ACTIVE_COMPARATOR|Trivalent OPV Sanofi Pasteur|Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine. A second dose four weeks after the first application.
62821612|NCT02800668||DJBL implant-group|"T2DM Patients implanted with a DJBL (Duodenal jejunal Bypass liner, EndoBarrier, GI Dynamics) due to medical reasons.~The subjects were regular in-patients of the Diabetes Center at the Heart and Diabetes Center NRW, Germany and gave informed consent for related procedures and data handling. The subjects had BMI ≥35 kg/m2, T2DM, and a history of frustrated weight loss attempts. Exclusion criteria: history of gastric surgery, gastric or duodenal ulcers, thyroid disorders, gastrointestinal disorders with intestinal resorption dysfunction, therapy with oral anticoagulants, use of acetyl salicylic acid or non-steroidal anti-inflammatory drugs, drug abuse (incl. alcohol), symptomatic cardiovascular disease, renal insufficiency (GFR \<50 ml/min), pregnancy or breast feeding."
62821613|NCT04252911||Anaesthetised patients|50 patients undergoing robotic surgeries under general anesthesia
62821614|NCT06590935||Acute pancreatitis|Patients with a complete diagnosis of MSAP and SAP
62821615|NCT00412984|ACTIVE_COMPARATOR|1|
62821616|NCT00412984|EXPERIMENTAL|2|
62821617|NCT06313736|EXPERIMENTAL|15-minute single-session depression intervention|This is the adult version of the Action Brings Change (ABC) Project.
62821618|NCT06313736|EXPERIMENTAL|10-minute single-session depression intervention|This includes a shortened version of the ABC Project.
62821619|NCT06313736|EXPERIMENTAL|6-minute single-session depression intervention|This includes a shortened version of the ABC Project.
62821620|NCT06313736|EXPERIMENTAL|2-minute single-session depression intervention|This includes a shortened version of the ABC Project.
62821621|NCT05856734||University students living at home|Group of university students
62821622|NCT05856734||University students living in private accommodation|Group of university students
62821623|NCT05856734||University students living in the halls of residence|Group of university students
62821624|NCT05856734||Non-university participants living in Aberdeen|Group of age-matched volunteers living in the same city
62821625|NCT06405932|EXPERIMENTAL|Mental Fitness Training Camp|The self-help mental fitness training camp, comprising 21 learning modules structured around animated thinking videos, audio, text, and moving images, lasts 21 days. Each learning module is automatically pushed to the intervention group on a daily basis, with an estimated completion time of 30-50 minutes.
62821626|NCT06405932|NO_INTERVENTION|health education|The control group received routine-care
62821627|NCT01861314|EXPERIMENTAL|Treatment (bortezomib, sorafenib tosylate, decitabine)|"STEP A: Patients receive bortezomib SC on days 1 and 4, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 5-14.~STEP B: Patients receive bortezomib SC on days 1, 4, and 8 or 1, 4, 8 and 11, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 9-18 or 12-21.~STEP C: Patients receive bortezomib SC on days 1, 4, and 8 or 1, 4, 8 and 11, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 5-14.~Treatment repeats every 28 days for up to 4 courses in the absence of unacceptable toxicity. Patients achieving CR or CRi receive maintenance therapy comprising decitabine IV on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62821628|NCT05170126||Ozanimod-exposed|Pregnant women with a diagnosis of Multiple sclerosis (MS) who are exposed to ozanimod at any time during pregnancy
62821629|NCT05170126||Unexposed comparator cohort with MS|Pregnant women with a diagnosis of MS who are not exposed to ozanimod at any time during pregnancy
62821630|NCT05170126||Unexposed comparator cohort without MS|Pregnant women without a diagnosis of MS who are not exposed to ozanimod at any time during pregnancy
62821631|NCT06184061|NO_INTERVENTION|Control Group|Placebo will be given to this group (100ml, contain same carbohydrate amount as herbal supplement)
62821632|NCT06184061|ACTIVE_COMPARATOR|Interventional Group|Herbal Supplement will be given to this group (100ml, Herbal Supplement)
62821633|NCT06593964|EXPERIMENTAL|TACE with Thermosensitive Nanogel Embolic Agent|"Equipment:~Thermosensitive Nanogel Embolic Agent"
62041415|NCT05974449|EXPERIMENTAL|C1, C2 dosing group|C1 and C2 dosing groups: The drug is administered on the day of the C1 and C2 chemotherapy cycles for 10 days, washing the vulva and placing the drug deep into the vagina, once a night, 1 capsules each time.
62041416|NCT05974449|EXPERIMENTAL|C3, C4 dosing group|C3 and C4 dosing groups: The drug is given on the day of the C3 and C4 chemotherapy cycles and is administered for 10 days. The drug is placed deep into the vagina after washing the vulva, once a night, 1 capsules each time.
62041417|NCT06348199|EXPERIMENTAL|SB27|SB27 will be administered followed by Pemetrexed and Carboplatin (Carboplatin will be administered for the first 4 cycles).
62041418|NCT06348199|ACTIVE_COMPARATOR|Keytruda|Keytruda will be administered followed by Pemetrexed and Carboplatin (Carboplatin will be administered for the first 4 cycles).
62041419|NCT06467331|EXPERIMENTAL|The group in which hippotherapy activity will be applied|In the implementation of the experimental group, hippotherapy implementation consisting of a total of 5 stations created by the researchers, lasting 30 minutes individually, will be applied to the individuals in the intervention group for 8 weeks, with the participation of the riding coaches. Research data will be collected by the researchers before the implementation (0th), in the 4th and 8th weeks.
62041420|NCT06467331|NO_INTERVENTION|The group in which hippotherapy activity will not be applied|In the control group, no interventions will be administered to the participants; data collection will occur solely at the outset (week 0) and at the research period's conclusion (week 8). After completing the main research activities, participants in the control group will be invited to an activity involving horses.
62041421|NCT01889433|EXPERIMENTAL|Algeron|Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight \<65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight \> 105 kg).
62041422|NCT01889433|ACTIVE_COMPARATOR|Pegasys|Pegasys in a dose of 180 µg subcutaneously, once a week, in combination with Rebetol, orally, at a daily dose of 800 mg for patients with genotype 2 or 3, and for genotypes 1 or 4 at a daily dose of 1000 mg (for body weight \<75 kg) or 1200 mg (for body weight ≥75 kg)
62041423|NCT06658431|EXPERIMENTAL|Experimental group|90 minutes music group therapy
62041424|NCT06658431|NO_INTERVENTION|control group|Without any intervention
62041425|NCT06731985||Women operated with shorter incontinence tapes|Women operated at AHUS between 2009 and 2020 for stress urinary incontinence with shorter incontinence tapes.
62244539|NCT02826447||Patients|500 patients who are going to be hospitalized for at least 24 hours at Ain Shams University Teaching Hospital in the following departments: surgery, internal medicine, gynecology/obstetrics and toxicology.
62434711|NCT01690520|ACTIVE_COMPARATOR|Arm I (standard of care)|"CONDITIONING REGIMEN: One of two possible conditioning regimens is chosen by the attending physician: Patients receive fludarabine phosphate IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6., and undergo high dose TBI BID on days -4 to -1 OR Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo middle intensity TBI QD on days -2 to -1.~TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclosporine IV over 1 hour BID (adults) or TID (children) or PO on days -3 to 100 with taper beginning on day 101. Patients also receive MMF IV TID a day on days 0-7 then may receive MMF PO TID. Patients remain on MMF TID for a minimum of 30 days, and then may begin a taper if there is no evidence of GVHD and are well-engrafted from one donor unit."
62821634|NCT06593964|ACTIVE_COMPARATOR|TACE with Embosphere Microspheres|"Equipment:~Embosphere Microspheres"
62600964|NCT00643461||Adhesive B|
62821635|NCT03223766||Participants|Participants will be those enrolled to receive proton therapy on other protocols at SJCRH on or after November 18, 2015.
62821636|NCT01460212|EXPERIMENTAL|Cognitive-Behavior Therapy group|treatment with Cognitive-Behavior Therapy
62041426|NCT02506842|EXPERIMENTAL|nab-paclitaxel + gemcitabine (AG)|nab-paclitaxel at 100 mg/m\^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m\^2 on days 1, 8, and 15
62041427|NCT02506842|EXPERIMENTAL|oxaliplatin + folinic acid + fluorouracil (OFF)|oxaliplatin at 85mg/m\^2 on days 8 and 22, folinic acid at 200mg/m\^2 on days 1,8,15 and 22, fluorouracil at 2000mg/m\^2 on days 1,8,15 and 22.
62041428|NCT05286827|EXPERIMENTAL|Arm 1|Olaparib, taken orally, twice daily
62041429|NCT06416800|EXPERIMENTAL|Cohort 1: Dose|Digoxin and povorcitinib will be administered at protocol defined doses.
62041430|NCT06416800|EXPERIMENTAL|Cohort 2: Dose|Rosuvastatin and povorcitinib will be administered at protocol defined doses.
62041431|NCT06416800|EXPERIMENTAL|Cohort 3: Dose|Metformin and povorcitinib will be administered at protocol defined doses.
62600965|NCT00643461||Adhesive C|
62821637|NCT01460212|ACTIVE_COMPARATOR|SSRI antidepressants|treatment by SSRI antidepressant
62041432|NCT06416800|EXPERIMENTAL|Cohort 4: Dose|Probenecid and povorcitinib will be administered at protocol defined doses.
62041433|NCT00100685|EXPERIMENTAL|Arm 1|Volociximab administered intravenously at a dose of 10 mg/kg qowk
62041434|NCT00100685|EXPERIMENTAL|Arm 2|Volociximab administered intravenously at a dose of 15 mg/kg qwk
62041435|NCT04380402|EXPERIMENTAL|Treatment|40 mg
62041436|NCT04380402|NO_INTERVENTION|Control|Standard care
62041437|NCT01791725|EXPERIMENTAL|ELND005 BID|ELND005 250 mg BID
62041438|NCT01791725|EXPERIMENTAL|ELND005 QD|ELND005 250 mg QD
62041439|NCT01791725|PLACEBO_COMPARATOR|Placebo|Placebo BID
62244540|NCT02826447||Healthcare workers|50 healthcare workers working at Ain Shams University Teaching Hospital in the following departments: surgery, internal medicine, gynecology/obstetrics and toxicology.
62244541|NCT05828082|EXPERIMENTAL|Treatment (tuvusertib)|Patients receive tuvusertib PO QD on days 1-14 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy, MRI, CT, PET/MRI, PET/CT or U/S and collection of blood samples throughout the trial.
62600966|NCT03707119||S4BE|"The intervention consisted of the use of Student 4 Best Evidence blog to teach EBP competence. The section S4BE about has been used to teach the EBP principles and their key steps and the section S4BE topics has been used to teach critical thinking and the clinical practice in rehabilitation for a total of 24 training hours."
62434712|NCT01690520|EXPERIMENTAL|Arm II (experimental)|"CONDITIONING REGIMEN: Patients receive the conditioning regimen chosen by the attending physician as in Standard of Care Arm.~TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day 0. Patients also undergo infusion of ex vivo-expanded cord blood progenitor cell infusion at least 4 hours after completion of UCB transplant.~GVHD PROPHYLAXIS: Patients receive cyclosporine IV or PO and mycophenolate mofetil IV or PO as in Standard of Care Arm."
62600967|NCT00212472|ACTIVE_COMPARATOR|1|Low-dose treatment (50 FVIII u/kg three times a week).
62600968|NCT00212472|ACTIVE_COMPARATOR|2|High-dose treatment (200 FVIII u/kg per day).
62821638|NCT02486718|EXPERIMENTAL|Atezolizumab|Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed \[non-squamous cell NSCLC only\]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: Participants will receive atezolizumab 1200 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles and will undergo periodic chest X-ray and CT scan.
62821639|NCT02486718|ACTIVE_COMPARATOR|Best Supportive Care|Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed \[non-squamous cell NSCLC only\]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: After enrollment phase participants will receive only the best supportive care and will undergo periodic chest X-ray and CT scan.
62821640|NCT03844347|EXPERIMENTAL|C-Bien|
62821641|NCT03844347|NO_INTERVENTION|Control|
62821642|NCT05760365|ACTIVE_COMPARATOR|Slide-based presention group|Received a regular learning
62821643|NCT05760365|EXPERIMENTAL|3D-printed presention group|Received a regular learning plus 3D printing model
62821644|NCT00580619|EXPERIMENTAL|1 (markers of sympathetic activity)|To evaluate if the various indices of sympathetic activity (Autonomic Function Testing) differ between patients with chronic fatigue syndrome and postural tachycardia syndrome (CFS-P), and CFS without POTS.
62821645|NCT00580619|EXPERIMENTAL|2 (saline)|To test the null hypothesis that there is no difference between two saline therapies (pulse saline vs. sham saline) in improving both the fatigue score and postural tachycardia syndrome.Saline infusions
62821646|NCT00580619|EXPERIMENTAL|3 (NO inhibition/ autonomic blockade)|Response to nitric oxide inhibition in the presence and absence of an intact autonomic nervous system will be evaluated. L-NMMA trimethaphan will be used for NO inhibition and autonomic blockade, respectively.
62821647|NCT00580619|ACTIVE_COMPARATOR|4 (methyldopa)|The effects of chronic autonomic withdrawal on improving symptoms of chronic fatigue and postural tachycardia syndrome will be evaluated
62821648|NCT05449418|ACTIVE_COMPARATOR|Enhanced Usual Care|Distribution of COVID-19 vaccine promotion materials from the Centers for Disease Control and Prevention \[CDC\] or other national organization with limited distribution support at long-term care centers.
62434713|NCT00395200|EXPERIMENTAL|MSC Treatment|
62600969|NCT03435224|EXPERIMENTAL|INVSENSOR00012|All subjects consented are enrolled into the test group and will receive the INVSENSOR00012.
62600970|NCT03203928|EXPERIMENTAL|Occupational Therapy for Women with ADHD|7-week tailored intervention for women with ADHD who have difficulty carrying out student, worker, spousal, and parenting roles due to poor time management, organization of their physical environments, management of internal and external stressors, and regulation of internal and external stimulation. Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments.
62434714|NCT06223022|EXPERIMENTAL|Intervention|Receiving regular telephone nurse-led support
62434715|NCT06223022|NO_INTERVENTION|Control|Receiving care as usual
62600971|NCT03203928|NO_INTERVENTION|Control|No treatment provided.
62600972|NCT06107946|OTHER|symptom assessment|Patients will have assessed symptom burden using the Dutch validated ESAS (called USD), build in the MuSt-PC tool. Thereafter, they will record symptom burden in a diary during 2 weeks.
62600973|NCT05107791|EXPERIMENTAL|Stulln Eyedrops|Augentropfen Stulln Mono Eye Drops (Stulln eyedrops) will be provided to participants in individual single-use vials. Participants will apply the drops to the two eyes 3 times a day, six days a week before sustained eye use (except Sunday).
62600974|NCT05107791|SHAM_COMPARATOR|Theta Tears|Thera Tears (Sodium Carboxymethylcellulose 0.25%) will be provided to participants in individual single-use vials. Participants will apply the drops to the two eyes 3 times a day, six days a week before sustained eye use (except Sunday).
62600975|NCT02945397|ACTIVE_COMPARATOR|Individual activity|The individual activity consists of a 3 month membership card at a given gym. This is in addition to regular follow-up from welfare authorities.
62821649|NCT05449418|EXPERIMENTAL|Full Intervention|Development of materials co-designed with and tailored to language/cultural affinity groups and distributed with assistance from co-design participants who will serve as peer advocates.
62821650|NCT03842358|EXPERIMENTAL|Phase I - Training Set|"* 20 patients will be recruited to undergo US-DOT and CEM to allow for training study readers in assessing US-DOT data, intra-observer variability and to assess inter-observer variability in the assessment of US-DOT data~* A hand-held hybrid probe will be used for the scans"
62434716|NCT02921347|EXPERIMENTAL|Intervention group|Patients in this group are received ventilator weaning by switching between invasive and noninvasive ventilation
62434717|NCT02921347|NO_INTERVENTION|Control group|Patients in this group are weaned from ventilator as conventional methods.
62244542|NCT04269005|NO_INTERVENTION|Treatment as usual|"phase 0: Treatment as usual in combination with baseline and follow-up Survey but without any screening procedures (facilitating the study as a run-in phase to establish study procedures).~phase 1: randomized and main control condition with TAU + collection of information on psychosocial distress in the baseline~Intervention effects will be estimated, using the distressed focus sample, contrasting Phase 2 vs. Phase 1.~We intend to conduct additional statistical analyses to compare data from phases 2 and 1 vs. phase 0 to estimate potential effects of introducing parts of the screening 1 without consequences."
62244543|NCT04269005|EXPERIMENTAL|Intervention condition|"phase 2: implementation of the SCCM~The intervention (SSCM) will be implemented step-wise in predefined sections at all three sites using a stepped-wedge cluster randomized trial design. Clusters will be randomized to different sequences that dictate the timing at which each cluster will switch from the control to the intervention condition."
62244544|NCT02649153|EXPERIMENTAL|smoked plum|Patients will receive smoked plum (3 piece each time, three times per day) starting in the first day after resection until flatus.
62821651|NCT03842358|EXPERIMENTAL|Phase 2: Prospective Trial|"* US-DOT (US/NIR) Imaging Exam~* Breast biopsy or FNA performed (standard of care)~* A hand-held hybrid probe will be used for the scans"
62821652|NCT04019379|EXPERIMENTAL|Sequence A|High Phos crossover to Low Phos
62244545|NCT02649153|ACTIVE_COMPARATOR|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
62244546|NCT02649153|NO_INTERVENTION|empty control|This group patients will not receive gum chewing or smoked plum.
62821653|NCT04019379|EXPERIMENTAL|Sequence B|Low Phos crossover to High Phos
62821654|NCT06600061|EXPERIMENTAL|Erector Spinae Plane Block group|Patients will receive erector spinae plane block after induction of anesthesia.
62821655|NCT06600061|NO_INTERVENTION|Control group|Patients will not receive erector spinae plane block.
62244547|NCT03387475|EXPERIMENTAL|Deferasirox|efficacy of 3.5mg/kg/day
62244548|NCT06734637|EXPERIMENTAL|Peginterferon α-2b|
62244549|NCT05393401|EXPERIMENTAL|VOP1k|Medical Device
62244550|NCT02632760|ACTIVE_COMPARATOR|ferric carboxymaltose|ferric carboxymaltose 1000 mg or Iron isomaltoside 1000 mg given Intravenously
62244551|NCT02632760|PLACEBO_COMPARATOR|Placebo|Placebo intravenous infusion
62244552|NCT05539833|EXPERIMENTAL|TCR-T cells|
62600976|NCT02945397|ACTIVE_COMPARATOR|Group-based activity|The group-based activity consists of a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services. This is in addition to regular follow-up from welfare authorities.
62244553|NCT05964998|EXPERIMENTAL|Active stimulation|
62600977|NCT02920541|EXPERIMENTAL|S 055746|
62600978|NCT06648941|OTHER|Supraspinatus muscle release|supraspinatus muscle release in retracted rotator cuff tear
62821656|NCT06056596|EXPERIMENTAL|Lamivudine|Lamivudine 300mg PO once daily for three days
62244554|NCT05964998|SHAM_COMPARATOR|Sham stimulation|
62244555|NCT06601842|EXPERIMENTAL|ICP monitoring|ICP monitoring
62244556|NCT06181461|EXPERIMENTAL|Gong's Mobilization|Group A received Gong's mobilization with routine physical therapy included a 30-45 min session with 15-min TENS. Patients followed daily care instructions, using the affected shoulder in daily activities, and performed pendulum and active shoulder exercises twice a day.
62434718|NCT02235961|EXPERIMENTAL|Part 1|
62434719|NCT02235961|EXPERIMENTAL|Part 2|
62600979|NCT02824016|ACTIVE_COMPARATOR|with supraclavicular irradiation|Patients received supraclavicular irradiation according to local policies. Biological samples were obtained in order to evaluate hypothyroidism during the follow-up period
62821657|NCT06056596|PLACEBO_COMPARATOR|Placebo|Placebo once daily for three days
62821658|NCT05889104|EXPERIMENTAL|The Progressive Loading Group (PLG)|using Progressive Loading protocol.
62821659|NCT05889104|OTHER|TheControl Group (CG)|using a randomization program
62821660|NCT02275702|PLACEBO_COMPARATOR|Group 1|saline solution IV, bolus
62821661|NCT02275702|ACTIVE_COMPARATOR|Group 2|0,1mg/kg systemic dose of dexamethasone, bolus
62821662|NCT03365414|OTHER|Phase I|Placebo ( Normal Saline 0.9% Infusion Solution Bag) or active comparator (Albumin (Human) 5%, USP)
62821663|NCT03365414|OTHER|Phase II|Placebo ( Normal Saline 0.9% Infusion Solution Bag) or active comparator (Albumin (Human) 5%, USP), whichever was not not administered in Phase I
62821664|NCT06070779|EXPERIMENTAL|neuro linguistic programming group for primiparous|"NLP application to the experimental group will be done by the researcher Ayşegül Kılıçlı. The application session will 20 minutes. The application will be started in the active phase of labour when the cervical opening is 4 cm.~In the neuro linguistic programming (NLP); The system of representation of women in practice will be determined first. Then, with the anchoring technique, negative feelings and thoughts about labour will be tried to be erased from the mind or their severity will be reduced. Then, positive feelings and thoughts will be created instead of the mother's negative feelings and thoughts with belief change strategies. Then, with the swish technique, the mother's positive feelings and thoughts about labour will be made aware of and reinforced."
62821665|NCT06070779|NO_INTERVENTION|control group for primiparous|The control group will not receive only the neuro-linguistic programming, but all other assessments will be parallel to the experimental group (neuro linguistic programming group for primiparous).
62821666|NCT06070779|EXPERIMENTAL|neuro linguistic programmig group for multiparous|"NLP application to the experimental group will be done by the researcher Ayşegül Kılıçlı. The application session will 20 minutes. The application will be started in the active phase of labour when the cervical opening is 4 cm.~In the neuro linguistic programming (NLP); The system of representation of women in practice will be determined first. Then, with the anchoring technique, negative feelings and thoughts about labour will be tried to be erased from the mind or their severity will be reduced. Then, positive feelings and thoughts will be created instead of the mother's negative feelings and thoughts with belief change strategies. Then, with the swish technique, the mother's positive feelings and thoughts about labour will be made aware of and reinforced."
62821667|NCT06070779|NO_INTERVENTION|control group for multiparous|The control group will not receive only the neuro-linguistic programming, but all other assessments will be parallel to the experimental group (neuro linguistic programming group for muliparous).
62821668|NCT05857995|EXPERIMENTAL|Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program (KLCLCSC)|The Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program (KLCLCSC) is a targeted and tailored lung cancer survivorship care intervention built on principles of patient-centered care, shared decision making, and motivational interviewing to build survivor engagement and improve lung cancer outcomes.
62821669|NCT05857995|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|The enhanced usual care condition involves usual care plus bibliotherapy and assessment.
62821670|NCT06600958||patients with knee osteoarthritis|
62821671|NCT06600958||patients with knee arthritis related to chronic inflammatory rheumatism|
62821672|NCT04557410|EXPERIMENTAL|Receiving Supplement|Participants receive supplement PolyMVA. Dose is 2 teaspoons twice a day.
62821673|NCT03548532|ACTIVE_COMPARATOR|36.6°C|Embryos of these patients will be cultured at 36.6°C from day 0 after ICSI, untill day 6.
62821674|NCT03548532|EXPERIMENTAL|37.1°C|Embryos of these patients will be cultured at 37.1°C from day 0 after ICSI, untill day 6.
62821675|NCT01968746||ED patients with suspected infection|
62821676|NCT05535257|EXPERIMENTAL|Sequential Compression Device (SCD) on upper extremity|Subjects post stroke with upper extremity weakness have the SCD sleeve placed on the arm for up to 4 hours for one day only
62244557|NCT06181461|EXPERIMENTAL|Kaltenborn Mobilization|Group B will receive Kaltenborn mobilization (Grade III posterior translation) with routine therapy. Posterior translation is applied in 30-sec sets, repeated 15 times over 10 mins, with 10-sec rests. Routine physical therapy includes 30-45 min sessions with 15-min TENS. Patients follow daily care instructions, use the affected shoulder in daily activities, and perform pendulum and active shoulder exercises twice a day.
62600980|NCT02824016|ACTIVE_COMPARATOR|without supraclavicular irradiation|Patients did not receive supraclavicular irradiation according to local policies. Biological samples were obtained in order to evaluate hypothyroidism during the follow-up period
62600981|NCT06250907|EXPERIMENTAL|Dynamic navigation|
62600982|NCT06250907|ACTIVE_COMPARATOR|Static template|
62600983|NCT02607852|OTHER|Arm A|Patients between the ages of 5-18 years. They will complete the 5-18 version of the BOQ on iPads or through the HTTPS Tonic link.
62600984|NCT02607852|OTHER|Arm B|Patients between the ages of 0-4 years. They will complete the 0-4 version of the BOQ and appropriate Pediatric Symptom Checklists (i.e. baby or preschool) on iPads or through the HTTPS Tonic link.
62600985|NCT06158815|NO_INTERVENTION|control group|Participants in the control group will be placed on a waiting list without any intervention during the 6-week study period.
62600986|NCT06158815|EXPERIMENTAL|exercise group|Participants in the exercise group will have face-to-face Proprioceptive Neuromuscular Facilitation Exercises during the 6-week study period.
62600987|NCT04990349|EXPERIMENTAL|Extracorporeal normoxemia|"* After randomization, extracorporeal normoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 60%.~* The objective is to maintain oxygen partial pressure measured on the arterial cannula (PO2 postoxygenator) between 100 and 150 mmHg.~* PO2 postoxygenator is monitored at least twice a day by the nurse.~* If PO2 postoxygenator is less than 100 mmHg or more than 150 mmHg, FmO2 is modified by 10% and PO2 postoxygenator is monitored 10 minutes after.~* Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg.~* Intervention will be applied for 7 days after randomization."
62821677|NCT06599528|EXPERIMENTAL|T-R Group (Test-Reference drug)|SJ04 is injected first and Ovidrel® is injected after 2-week period
62821678|NCT06599528|EXPERIMENTAL|R-T Group(Reference-Test drug)|Ovidrel® is injected first and SJ04 is injected after 2-week period
62821679|NCT06247124|OTHER|HPV vaccination|Multi-channel campaign to promote HPV vaccination
62821680|NCT04246788|EXPERIMENTAL|Cohort 1 : experimental group|5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
62821681|NCT04246788|ACTIVE_COMPARATOR|Cohort 2 : controle group|3 sessions per week of 30 minutes of classical physiotherapy during two weeks
62821682|NCT03809728|OTHER|IBD patients|All patients with an established Crohn's disease or ulcerative colitis
62821683|NCT01210313||Physical exercise|No treatment, only physical examinations accompanying physical exercise
62821684|NCT01729780|SHAM_COMPARATOR|Sham EEG-NF|Subjects who will undergo sham EEG-NF.
62821685|NCT01729780|ACTIVE_COMPARATOR|True EEG-NF|Subjects who will undergo true EEG-NF training in order to lessen their anxiety symptoms.
62821686|NCT03735537|ACTIVE_COMPARATOR|Teriparatide and zoledronic acid|Teriparatide (TPTD) 20mcg daily using Teriparatide Pen Injector, given subcutaneously using a self-administered injection device for two years (24 months) followed by a single intravenous 5mg infusion of zoledronic acid.
62821687|NCT03735537|NO_INTERVENTION|Standard Care|Continuation of existing bone modifying treatment (i.e. bisphosphonate treatment) or no active bone modifying treatment according to the clinical judgement of the local investigator.
62600988|NCT04990349|ACTIVE_COMPARATOR|Extracorporeal hyperoxemia|"* After randomization, extracorporeal hyperoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 100%.~* The objective is to maintain PO2 postoxygenator higher than 300 mmHg.~* PO2 postoxygenator is monitored at least twice a day by the nurse.~* If PO2 postoxygenator is less than 300 mmHg, membrane change should be discussed.~* Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg.~* Intervention will be applied for 7 days after randomization."
62244558|NCT06069206|ACTIVE_COMPARATOR|Usual Care|Patients will receive blood cultures and will not receive direct-from-blood testing.
62600989|NCT00082017|EXPERIMENTAL|UCN-01 for T-cell lymphomas - Cohort 1 - Every 28 days|"Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2~Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 28 days."
62600990|NCT00082017|EXPERIMENTAL|UCN-01 for T-cell lymphomas - Cohort 2 -Every 21 days|"Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2~Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 21 days."
62244559|NCT06069206|ACTIVE_COMPARATOR|Direct-from-blood testing|In addition to usual care, patients will receive direct-from-blood testing using the T2Bacteria® Panel.
62244560|NCT01287364|EXPERIMENTAL|ciclesonide HFA followed by mometasone|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily in first intervention period, followed by a 7-14 day washout period, after which the second intervention of mometasone nasal inhalation 200 μg once daily will be administered.
62600991|NCT05400733|OTHER|Healthy male older adults|Healthy male older adults
62600992|NCT05400733|OTHER|Healthy female older adults|Healthy female older adults
62821688|NCT06508385|ACTIVE_COMPARATOR|Control Group|NLP-supported patient education will be given and breath therapy will be applied to the Control Group
62821689|NCT06508385|EXPERIMENTAL|Virtual Reality Group-1|NLP-supported patient education will be given. Visual feedback and metaphor-assisted breathing therapy over the three most painful points in the McGill-Melzack Pain Scale (real painful points) were given to this group in virtual reality environment.
62821690|NCT06508385|EXPERIMENTAL|Virtual Reality Group-2|NLP-supported patient education will be given. Visual feedback and metaphor-assisted breathing therapy over the contralateral of the points reported as the three most painful points in the McGill-Melzack Pain Scale (virtual painful points) to this group in a virtual reality environment
62821691|NCT06250205|EXPERIMENTAL|Treatment B+C: Obicetrapib + Drospirenone/Ethinyl Estradiol (COC)|Obicetrapib 10 mg tablets and Drospirenone (3mg)/Ethinyl Estradiol (0.02mg) tablet
62821692|NCT06250205|EXPERIMENTAL|Treatment B: Obicetrapib|Obicetrapib 10 mg tablets (daily)
62821693|NCT06250205|EXPERIMENTAL|Treatment C: Drospirenone/Ethinyl Estradiol tablets (COC)|Drospirenone (3mg)/Ethinyl Estradiol tablets (0.02mg) tablet
62821694|NCT04759274|EXPERIMENTAL|Diuretic Tuner users|The Diuretic Tuner is a mobile device application that integrates a patient's estimated dry weight and starting diuretic dose (both defined by a healthcare provider) with daily weights and blood pressures to provide individualized guidance to the patient in day-to-day adjustments to his or her diuretic regimen. In addition, the application generates a diary of daily weights, blood pressures, fluid intake, and medication compliance.
62821695|NCT04921241||SARS-CoV-2 Exposed Dyads|Mothers who had SARS-CoV-2 during pregnancy and their offspring
62821696|NCT04921241||SARS-CoV-2 Unexposed Dyads|Mothers who were not known to have SARS-CoV-2 during pregnancy and their offspring
62821697|NCT06485479|EXPERIMENTAL|Ads about response efficacy for quitting smoking|Participants will view ads designed to increase response efficacy for quitting cigarettes.
62821698|NCT06485479|EXPERIMENTAL|Ads about self-efficacy for quitting smoking|Participants will view ads designed to increase self-efficacy to quit smoking.
62600993|NCT02611505|EXPERIMENTAL|Cohort 1|Participants with moderate hepatic impairment will receive esketamine solution (containing 14 milligram \[mg\] of esketamine base per 100 microliter \[mcl\]) by intranasal route into each nostril using nasal spray pump at 0 hour (h) on Day 1.
62600994|NCT02611505|EXPERIMENTAL|Cohort 2|Participants with mild hepatic impairment will receive esketamine solution (containing 14 mg of esketamine base per 100 mcl) by intranasal route into each nostril using nasal spray pump at 0h on Day 1.
62434720|NCT04410341|PLACEBO_COMPARATOR|Placebo group|Escitalopram 20 mg tablet once daily for 12 week plus placebo tablet once daily for 12 weeks
62821699|NCT06485479|EXPERIMENTAL|Ads about motivation to quit smoking|Participants will view ads designed to increase motivation to quit smoking.
62821700|NCT06485479|OTHER|Ads about reading|Participants will view non-smoking related ads on the benefits of reading.
62434721|NCT04410341|EXPERIMENTAL|Vildagliptin group|Escitalopram 20 mg tablet once daily for 12 week plus Vildagliptin 50mg tablet once daily for 12 weeks
62434722|NCT00618397|EXPERIMENTAL|Arm 1|Ketamine will be administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to in PICU patients that meet eligibility criteria.
62600995|NCT02611505|EXPERIMENTAL|Cohort 3|Participants with normal hepatic function and no evidence of liver damage will receive esketamine solution (containing 14 mg of esketamine base per 100 mcl) by intranasal route into each nostril using nasal spray pump at 0h on Day 1.
62821701|NCT06485479|OTHER|Ads about passwords|Participants will view non-smoking related ads on passwords.
62821702|NCT06527560|ACTIVE_COMPARATOR|Intravenous cefuroxime|Intravenous cefuroxime 750 mg every 8 hours + oral placebo every 12 hours
62821703|NCT06527560|EXPERIMENTAL|Oral axetil cefuroxime|Oral axetil cefuroxime 500 mg every 12 hours + intravenous saline solution every 8 hours
62821704|NCT00270985|ACTIVE_COMPARATOR|nut free diet|ADA recommended diabetes diet without any nuts
62821705|NCT00270985|EXPERIMENTAL|almond group|calorie controlled diet with prescribed daily amount of almonds
62821706|NCT00001711||Healthy Volunteers and Patients|Healthy volunteers and patients age 18 and older.
62821707|NCT03020303|PLACEBO_COMPARATOR|Placebo Oral Tablet|A tablet with no active medication that will be an exact match of the active spironolactone in taste and appearance
62821708|NCT03020303|ACTIVE_COMPARATOR|Spironolactone 25 MG Tablet|25 mg of active spironolactone in tablet form
62821709|NCT05407389|EXPERIMENTAL|KT-301 (formerly US-APR2020)|
62600996|NCT00771251|EXPERIMENTAL|CNTO 148 50 mg|
62600997|NCT00771251|EXPERIMENTAL|CNTO 148 100 mg|
62600998|NCT00771251|EXPERIMENTAL|Placebo|
62821710|NCT02338674|EXPERIMENTAL|COM|COM group receives combination therapy of tenofovir and telbivudine (TDF and LdT) for at least 48 weeks
62821711|NCT02338674|ACTIVE_COMPARATOR|TDF|TDF group receives single therapy of tenofovir (TDF) for at least 48 weeks
62821712|NCT05720143|EXPERIMENTAL|Osseodensification group:|Ridge splitting by piezosurgery and osseodensification bur
62821713|NCT05720143|EXPERIMENTAL|Magnetic mallet group:|Ridge splitting by piezosurgery and chisels by magnetic mallet
62821714|NCT05720143|EXPERIMENTAL|Piezo-surgery group|Ridge splitting by inserts of piezosurgery and bone expander
62821715|NCT03173560|EXPERIMENTAL|Lenvatinib 14 mg plus everolimus 5 mg|Participants will receive oral lenvatinib 14 mg once daily (QD) plus oral everolimus 5 mg QD as the starting dose for Cycle 1. If there are no intolerable Grade 2 or any \>= Grade 3 treatment-emergent adverse events (TEAEs) that require dose reduction in the first 28-day cycle (that is, the first 4 weeks of treatment), the lenvatinib dose will be escalated to 18 mg QD (plus everolimus 5 mg) beginning in Cycle 2 or later (cycle length equal to \[=\] 28 days) during randomization phase. After the data cutoff for the primary analysis, participants will receive study treatment as continuous 56-day cycles.
62434723|NCT00654043|EXPERIMENTAL|A|Subjects received Par formulated products under fed conditions
62434724|NCT00654043|ACTIVE_COMPARATOR|B|Subjects received Roche formulated products
62434725|NCT02309203|EXPERIMENTAL|Flow Re-Direction Endoluminal Device|Flow Re-Direction Endoluminal Device (FRED Device)
62600999|NCT01279070|EXPERIMENTAL|REPYFLEC cognitive remediation training|REPYFLEC cognitive remediation as a Problem solving and Cognitive flexibility group training.
62244561|NCT01287364|ACTIVE_COMPARATOR|mometasone followed by ciclesonide HFA|mometasone nasal inhalation 200 μg once daily in first intervention period followed by a 7-14 day washout period after which the second intervention of ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily will be administered
62244562|NCT06294769|EXPERIMENTAL|Group 1: 2% lavender essential oil.|Group will receive application of aromatherapy with 2% lavender essential oil dermal and inhalation via by a nurse, associated with usual care, in the immediate postoperative period.
62434726|NCT03827785|EXPERIMENTAL|rTMS treatment group|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 30 days.
62434727|NCT03827785|SHAM_COMPARATOR|sham rTMS treatment group|Stimulate the dorsal lateral prefrontal cortex with the sham iTBS pattern and coil. The therapy will be conductedfor 30 days.
62434728|NCT01684722|ACTIVE_COMPARATOR|Vitamin D + fish oil|Vitamin D and omega-3 fatty acids (fish oil)
62821716|NCT03173560|EXPERIMENTAL|Lenvatinib 18 mg plus everolimus 5 mg|Participants will receive oral lenvatinib 18 mg QD plus oral everolimus 5 mg QD as the starting dose in Cycle 1 or later (cycle length =28 days) during randomization phase. After the data cutoff for the primary analysis, participants will receive study treatment as continuous 56-day cycles.
62821717|NCT04615949|EXPERIMENTAL|Cannabidiol, pharmaceutically produced with < 5 ppm THC|CardiolRx
62821718|NCT04615949|PLACEBO_COMPARATOR|Placebo|Placebo
62821719|NCT06474676|EXPERIMENTAL|Part A,|Participants enrolled in Part A, the dose of attIL2-TIL cell therapy a participant receive will depend on when the participant joins this study. The first group of participants will receive the lowest dose level of attIL2-TIL cell therapy. Each new group will receive a higher dose of attIL2-TIL cell therapy than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of attIL2-TIL cell therapy is found.
62821720|NCT06474676|EXPERIMENTAL|Part B|Participants enrolled in Part B, will receive attIL2-TIL cell therapy at the recommended dose that was found in Part A.
62821721|NCT03593525|EXPERIMENTAL|SPARK Intervention|"Participants will complete symptom screening using SPARK once daily on a study-supplied iPad. For inpatients, daily reminders to complete SSPedi will appear on the iPad. Reports will be available to the child at any time. For outpatients, clinical research associates will provide the iPad in person daily and reports may be viewed at those encounters. The intervention is daily symptom screening with provision of reports to the healthcare team. Severe symptoms will result in email alerts. More specifically, SSPedi reports will be printed daily and provided in the patient chart. On days 1 and 3, an alert will be emailed to the physician providing direct medical care if any symptom is a lot or extremely bothersome (score 3 or 4 on 0-4 scale). Reports and alerts will have links to SPARK-housed CPGs."
62821722|NCT03593525|NO_INTERVENTION|Standard of Care Arm|Participants randomized to the control arm will not complete daily symptom screening. They will complete SSPedi on days 1 and 5 to obtain the primary outcome. Health care providers will not be notified of their SSPedi scores and no symptom reports or symptom alerts will be generated.
62821723|NCT06159790|EXPERIMENTAL|GME751 + pemetrexed + carboplatin or cisplatin|Participants will receive GME751 + pemetrexed + carboplatin or cisplatin via intravenous (IV) infusion.
62821724|NCT06159790|ACTIVE_COMPARATOR|Keytruda-EU + pemetrexed + carboplatin or cisplatin|Participants will receive Keytruda-EU + pemetrexed + carboplatin or cisplatin via intravenous (IV) infusion.
62821725|NCT06118866|PLACEBO_COMPARATOR|placebo-Q2W|placebo, 0mg/vials
62821726|NCT06118866|ACTIVE_COMPARATOR|HMI-115-120mg-Q4W|HMI-115, 60mg/vials
62821727|NCT06118866|ACTIVE_COMPARATOR|HMI-115-240mg-Q4W|HMI-115, 60mg/vials
62821728|NCT06118866|ACTIVE_COMPARATOR|HMI-115-240mg-Q2W|HMI-115, 60mg/vials
62821729|NCT02548546|ACTIVE_COMPARATOR|Surveillance|No Surgery with ECHO and ECG-gated MRA imaging.
62821730|NCT02548546|ACTIVE_COMPARATOR|Surgery-Open|Open Surgery with ECHO and ECG-gated MRA imaging.
62821731|NCT02548546|ACTIVE_COMPARATOR|Surgery-EVAR|EVAR with ECHO and ECG-gated MRA imaging.
62821732|NCT06590844|EXPERIMENTAL|experimental group|On the first day, we will treat patients with Tybo Sulsintilimab ® 200mg IV and Dalutin ® Bevacizumab 15mg/kg IV every 21 days. The first to third days were treated with injectable coenzyme I, 100mg/day IV, every 21 days as a cycle.
62821733|NCT05338528|EXPERIMENTAL|BE-FIT|The quasi-experimental unblinded interrupted time-series (ITS) design will be conducted in three phases: pre-intervention/ (10 weeks); during intervention (16 weeks); post-intervention (20 weeks). A cohort of patients on selected wards will receive the BE-FIT program intervention.
62821734|NCT05338528|NO_INTERVENTION|Usual care|We will adopt a before-and-after analysis methodology for complications, functional performance, and patient satisfaction. A control cohort of patients on the same ward will be compared to who received usual care prior to the intervention; this may include physiotherapy consultations ordered at the discretion of the surgical team or any other independent activity initiated by the patient (e.g., walking).
62821735|NCT01700413|EXPERIMENTAL|Idarubicin|Cohort 1: Idarubicin 14 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day Cohort 2: Idarubicin 16 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day Cohort 3: Idarubicin 18 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day
62821736|NCT04576156|EXPERIMENTAL|Imetelstat|Participants will receive imetelstat sodium at 9.4 mg/kg intravenous (IV) every 21 days (±3 days), until disease progression or unacceptable toxicity, treatment discontinuation or study end.
62821737|NCT04576156|ACTIVE_COMPARATOR|Best Available Therapy (BAT)|"Participants will receive BAT (investigator-selected non-JAK-inhibitor treatment), until disease progression or unacceptable toxicity, treatment discontinuation or study end.~Participants on BAT who meet protocol-defined criteria for progressive disease may crossover to receive imetelstat treatment after sponsor's approval."
62244563|NCT06294769|PLACEBO_COMPARATOR|Group 2: grape seed vegetable oil.|Placebo group will only receive the application of grape seed vegetable oil associated with usual care in the post anesthetic recovery room.
62244564|NCT04858854|ACTIVE_COMPARATOR|BSE group (Broccoli sprout group)|The BSE Group will receive 50 µmmol/day of sulforaphane administered by BSE (Lantmännen®) from week 0 to week 4. If no side-effects are reported, the sulforaphane dose will increase to 100 µmmol/day from week 5 to week 8 and in the absence of side-effects, the dose will increase to 150 µmmol/day from week 9 to week 12.
62244565|NCT04858854|PLACEBO_COMPARATOR|Control group|The Control Group will receive a placebo (maltodextrin sprayed with copper-chlorophyllin) for 12 weeks.
62601000|NCT01279070|ACTIVE_COMPARATOR|Leisure group|"Leisure group is a stimulating activity focused on socialization through group dynamics, board games, coffee and talk."
62244566|NCT04160052|EXPERIMENTAL|Treatment (venetoclax, azacitidine)|Patients receive venetoclax orally PO QD on days 1-7 or 1-14 and azacitidine SC or IV over 15 minutes on days 1-5. Cycles repeat every 4-8 weeks in the absence of disease progression or unacceptable toxicity.
62434729|NCT01684722|ACTIVE_COMPARATOR|Vitamin D + fish oil placebo|Vitamin D and fish oil placebo
62434730|NCT01684722|ACTIVE_COMPARATOR|Vitamin D placebo + fish oil|Vitamin D placebo and omega-3 fatty acids (fish oil)
62601001|NCT01470781|EXPERIMENTAL|Cognitive Remediation|This arm will receive computer-based cognitive remediation treatment 3 times per week for 24 weeks, for a total of 70 hours of treatment
62244567|NCT05339087|EXPERIMENTAL|Riociguat|patients will undergo a titration phase starting with 1mg riociguat oral tablets tid (three times daily) up to a maximum dosage of 2.5mg tid that will be continued for the remainder of the study.
62434731|NCT01684722|PLACEBO_COMPARATOR|Vitamin D placebo + fish oil placebo|Vitamin D placebo and fish oil placebo
62821738|NCT06592235||Individuals with chronic obstructive lung disease|Individuals with chronic obstructive lung disease
62821739|NCT06592235||Individuals with asthma|Individuals with asthma
62821740|NCT06592235||Individuals with bronchiectasis|Individuals with bronchiectasis
62821741|NCT06592235||Individuals with interstitial lung disease|Individuals with interstitial lung disease
62244568|NCT05339087|PLACEBO_COMPARATOR|Placebo|Placebo tablets with the same treatment regimen (tid) as the verum therapy will be provided. Patients will undergo a sham titration phase with sham doses individually adjusted as in the experimental arm
62434732|NCT05548218|NO_INTERVENTION|New diagnosis of diabetes control group|
62434733|NCT05548218|EXPERIMENTAL|New diagnosis of diabetes intervention group|
62434734|NCT05548218|NO_INTERVENTION|Uncontrolled diabetes control group|
62244569|NCT02199600|OTHER|GMK Sphere Knee Replacement|Patients who comply with the protocol and received GMK Sphere component.
62244570|NCT06734546|EXPERIMENTAL|High intensity exercise training group|This arm will receive 6 months of exercise training at high intensity (105% VT2)
62601002|NCT01470781|PLACEBO_COMPARATOR|Computer Control|Group will receive 70 hours of computer time playing pre-selected computer games administered in a similar format as the Cognitive Remediation condition
62601003|NCT04250350|EXPERIMENTAL|Lebrikizumab 250 mg|Participants received two subcutaneous (SC) injections of 250 milligram(mg) Lebrikizumab at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 up to (but not including) Week 52.
62601004|NCT01241877|EXPERIMENTAL|astaxanthin|
62601005|NCT01241877|PLACEBO_COMPARATOR|placebo|
62601006|NCT01122407|EXPERIMENTAL|trimethaphan|Trimethaphan infusion doses of 4 mg/min
62244571|NCT06734546|EXPERIMENTAL|Moderate intensity exercise training group|This arm will receive 6 months of exercise training at moderate intensity (60% VT2)
62434735|NCT05548218|EXPERIMENTAL|Uncontrolled diabetes intervention group|
62434736|NCT04929171||Patients with myofascial pain having centralized pain features|Adult patients with myofascial pain having centralized pain features who will be undergoing physical therapy
62601007|NCT01122407|EXPERIMENTAL|Trimethaphan plus L-NMMA|Trimethaphan infusion 4 mg/min L-NMMA (L-NG-monomethyl Arginine citrate) infusion 250 mpg/kg/min A small group of arm 1 will receive both drugs.
62821742|NCT03076697||Diabetic Eye Disease|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing diabetic retinopathy along with the stage of diabetic retinopathy. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of diabetic retinopathy diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
62041440|NCT06698250|EXPERIMENTAL|Safety Lead-in - Zanzalintinib (XL-092) + Tremelimumab (IV) + Durvalumab (IV)|Safety Lead-in: XL-092: Dose escalation or de-escalation - Level 1 = 100 mg; Level 0 = 60 mg; Level -1 = 40 mg. The ﬁrst dose level (dose level 0) will follow the rolling 6 design. Starting with cycle 1 then cycle 3 and subsequent cycles, participants will receive XL-092 60 mg orally (PO) once daily on days 1 through 28 of every 28-day cycle. Durvalumab: Flat dose of 1500 mg intravenously (IV) Infusion on day 1 of every 28-day cycle. Dosing will start with cycle 2; Tremelimumab (IV): One priming dose of 300 mg IV infusion. The dose will be given with cycle 2 day 1
62041441|NCT06698250|ACTIVE_COMPARATOR|Zanzalintinib (XL-092) + Tremelimumab (IV) + Durvalumab (IV) (First Cyle Zanzalintinib)|"Phase 2: XL092 dose as determined by results of safety lead-in phase orally (PO). Once daily on days 1 - 28 of every 28-day cycle. Dosing will start with cycle 1 then cycle 3 and subsequent cycles.~Durvalumab: Flat dose of 1500 mg intravenously (IV) Infusion on day 1 of every 28-day cycle. Dosing will start with cycle 2; Tremelimumab (IV): One priming dose of 300 mg IV infusion. The dose will be given with cycle 2 day 1"
62041442|NCT06698250|ACTIVE_COMPARATOR|Zanzalintinib (XL-092) + Durvalumab (IV) + Tremelimumab (IV) (First Cyle Durvalumab + Tremelimumab)|"Phase 2: XL092 dose as determined by results of safety lead-in phase orally (PO). Once daily on days 1 - 28 of every 28-day cycle. Dosing will start with cycle 2.~Durvalumab: Flat dose of 1500 mg intravenously (IV) Infusion on day 1 of every 28-day cycle. Dosing will start with cycle 1.~Tremelimumab (IV): One priming dose of 300 mg IV infusion. The dose will be given with cycle 1 day 1"
62041443|NCT03663868|EXPERIMENTAL|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo)
62041444|NCT03663868|NO_INTERVENTION|Day 3 transfer control group|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 3 of embryo growth (cleavage stage embryo)
62821743|NCT03076697||Glaucoma|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing glaucoma. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional optic disc photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of glaucoma. We will also assess the sensitivity and specificity of glaucoma diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
62041445|NCT03663868|NO_INTERVENTION|Day 5 transfer control group|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 5 of embryo growth (blastocyst stage embryo)
62041446|NCT04041362|ACTIVE_COMPARATOR|Arm1 (Standard ART)|Standard ART
62041447|NCT04041362|EXPERIMENTAL|Arm 2 (ART plus UB-421)|ART plus weekly UB-421 IV infusion at 5 mg/kg dose level for 16 weeks
62041448|NCT06733376|OTHER|Initial Course of Cognitive Processing Therapy|All participants will start in Arm 1 where they receive 10-sessions of Cognitive Processing Therapy.
62041449|NCT06733376|ACTIVE_COMPARATOR|Subsequent Treatment|At one-week follow up after initial Cognitive Processing Therapy, participants whose scores are 28 or above on the PTSD Checklist for DSM-5 will be offered a subsequent course of treatment.
62821744|NCT03076697||Age related macular degeneration (AMD)|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing age-related macular degeneration along with the stage. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of age-related macular degeneration diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
62821745|NCT03076697||Retinopathy of Prematurity (ROP)|Photographs will be taken with our smartphone-based camera along with the standard of care, including Retcam photography or traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing ROP. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of ROP diagnosis with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
62244572|NCT06734546|NO_INTERVENTION|Control group|This arm won't receive exercise training
62821746|NCT03016533|EXPERIMENTAL|Dolutegravir (Tivicay)|All participants will receive dolutegravir film-coated tablets or film-coated dispersible tablets at appropriate doses selected as per their age and weight bands. For those participants who were previously receiving dolutegravir in study P1093 (parent study), dolutegravir will be supplied as film-coated tablets containing 50 mg; and 5 mg film-coated dispersible tablets of dolutegravir. Participants will receive dolutegravir until age-appropriate formulations are available to them from some other source, or until participant is no longer deriving benefit from treatment, or participant is discontinued, or until development of dolutegravir is terminated.
62434737|NCT03230032|EXPERIMENTAL|Intervention Group|Sessions will use a pacifier-activated device (PAL) system. The device sensor attaches to a routinely-used pacifier and measures timing and pressure of the sucks. If the infant reaches the preset suck pressure, he receives 10 seconds of mother's voice. The receiver/speaker box controls the volume to \< 65dB on scale C. PAM will be set to the lowest settings for the first session. Using sensor measurements, the therapist will increase the threshold for number of sucks and strength once the infant produces three consecutive sucks above current level and continue per protocol.
62244573|NCT06735430|EXPERIMENTAL|Ciprofol|Ciprofol for anesthesia induction (0.5mg / kg) and anesthesia maintenance (1-2.5mg/ (kg·h))
62244574|NCT06735430|OTHER|Propofol|Propofol for anesthesia induction (2mg / kg) and maintenance of anesthesia (4-10 mg / (kg·h))
62244575|NCT05264974|EXPERIMENTAL|mRNA-nanoparticle (mRNA-NP) vaccine|
62244576|NCT05484882||GENEFORECAST|African American men and women residing in the Washington DC area
62434738|NCT03230032|NO_INTERVENTION|Control Group|Infants will receive 2 daily 15-min listening sessions of mother's voice recording, contiguous but not simultaneous with PAM NNS sessions without suck-contingent reinforcement (no voice).
62821747|NCT03016533|EXPERIMENTAL|ABC/DTG/3TC|All participants will receive ABC/DTG/3TC immediate release tablets or film-coated dispersible tablets at appropriate doses selected as per their weight bands. For those participants who were previously receiving ABC/DTG/3TC in study P2019 (parent study), ABC/DTG/3TC will be supplied as immediate release tablets containing 600 mg, 50 mg and 300 mg of ABC, DTG, and 3TC respectively and film-coated dispersible tablets containing 60 mg, 5 mg and 30 mg of ABC, DTG, and 3TC respectively. Participants will receive ABC/DTG/3TC until age-appropriate formulations are available to them from some other source, until participant is no longer deriving benefit from treatment, or until participant is discontinued, or until development of ABC/DTG/3TC is terminated.
62821748|NCT06562205|EXPERIMENTAL|PAP System A (with Amalfi) then PAP System B (with CLA11)|Participants will be asked to take home the investigational PAP system (Amalfi) to use at night while they sleep in place of their own PAP system. The participant's therapy and comfort settings will not be altered. Participants will be randomized as to the order they will trial PAP System A and PAP System B. This arm will first use the Amalfi for 7 days and then use the CLA 11 for 7 days.
62821749|NCT06562205|ACTIVE_COMPARATOR|PAP System B (with CLA11) then PAP System A (with Amalfi)|Participants will be asked to take home the comparator PAP system B (CLA 11) to use at night while they sleep in place of their own PAP system. The participant's therapy and comfort settings will not be altered. Participants will be randomized as to the order they will trial PAP System B and PAP System A. This arm will first use the CLA 11 for 7 days and then use the Amalfi for 7 days.
62821750|NCT01417533||GNE|Patients with a diagnosis of GNE myopathy
62821751|NCT01417533||GNE-Related Diseases|Patient with a GNE related disease
62821752|NCT01417533||non-GNE|Subjects that are a carrier family member or a caregiver of a patient on the study are eligibleto participate.
62821753|NCT05512897|NO_INTERVENTION|standard care|standard analgesic treatment
62821754|NCT05512897|EXPERIMENTAL|standard care + ESP block|intraoperativeESP block + standard analgesic treatment
62821755|NCT05514548|EXPERIMENTAL|INV 202 10 mg|INV-202 10 mg Arm
62821756|NCT05514548|EXPERIMENTAL|INV-202 25 mg|INV-202 25 mg Arm
62821757|NCT05514548|PLACEBO_COMPARATOR|Placebo|Placebo Arm
62821758|NCT05379803|EXPERIMENTAL|Furmonertinib|furmonertinib 160 mg orally QD
62821759|NCT05543265|NO_INTERVENTION|Control|Routine postpartum care
62821760|NCT05543265|EXPERIMENTAL|Facilitated Transition|Behavioral science informed interventions to assist in the transition from postpartum to primary care providers
62821761|NCT04515615|EXPERIMENTAL|Camrelizumab and chemotherapy|Participants receive camrelizumab 200 mg intravenously (IV) on the first day (q3w), then oxaliplatin 130 mg/m\^2, IV on the first day (q3w), and tegafur gimeracil oteracil potassium capsule 80 mg/m\^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Three weeks as a course of treatment, a total of 8 courses.
62244577|NCT06704932|EXPERIMENTAL|SAR446959|Participants will receive a single intra-articular dose of SAR446959 on Day 1
62434739|NCT06173895|EXPERIMENTAL|LY3454738 (Test Formulation)|
62434740|NCT06173895|EXPERIMENTAL|LY3454738 (Reference Formulation)|
62434741|NCT00853931|EXPERIMENTAL|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 \[i.e. Cycles 1, 2, 3, etc.\]) until disease progression or intolerance panitumumab as determined by the investigator.
62434742|NCT01625845|EXPERIMENTAL|Pentoxifylline + Standard Treatment|"Pentoxifylline: Pentoxifylline is phosphodiesterase inhibitor that interferes with proinflammatory cytokine signaling and synthesis. Participants will be instructed to take pentoxifylline 400 mg p.o. t.i.d. for 12 weeks.~Standard Treatment: Beating the Blues (BtB) is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions."
62821762|NCT05079334|OTHER|High Risk / MeTree|High risk for hereditary cancer and completes the MeTree questionnaire
62821763|NCT05322343||Prospective cohort|The general population from the age of 55.
62821764|NCT05882591|EXPERIMENTAL|Main arm of the study|Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).
62821765|NCT04786743|EXPERIMENTAL|non-urgent endoscopy group|undergo endoscopy between 6 and 24 hours after gastroenterological consultation
62821766|NCT04786743|OTHER|urgent endoscopy group|undergo endoscopy within 6 hours after gastroenterological consultation
62821767|NCT04074044|EXPERIMENTAL|BHmApp users|Participants using BHmApp tor bladder education and training
62821768|NCT05058365|EXPERIMENTAL|Intervention group|
62821769|NCT05058365|NO_INTERVENTION|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after their counterparts in experimental group completed the intervention.
62244578|NCT06704932|PLACEBO_COMPARATOR|Placebo|Participants will receive a single intra-articular dose of placebo on Day 1. The injection volume of the placebo will be the same as the injection volume for SAR446959 in the corresponding dose level cohort.
62244579|NCT04115826|PLACEBO_COMPARATOR|Extracorporeal Shock-Wave Lithotripsy|Stone localization will first be performed by obtaining high-quality plain films of the pancreatic area in left and right oblique positions using a two-dimensional radiologic targeting system.Depending on the stone localization, ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.
62244580|NCT04115826|ACTIVE_COMPARATOR|Per-oral Pancreatoscopy-guided Lithotripsy|Standard ERP will be performed to cannulate the PD, perform pancreatic sphincterotomy, and stricture dilation as necessary. A pancreatoscope (Spyglass Digital System, Boston Scientific, Marlborough, MA) will then be inserted through the duodenoscope into the PD. For PPL, electrical pulses will be delivered through an aqueous medium by EHL or LL with the probe tip in contact with or 1-2mm away from the stone. Settings for EHL (1.9F fiber; Autolith, Northgate Technologies, Elgin, IL) are 10-20 pulses/second with a power of 50-100; and for LL (200, 272, or 365 micrometer fiber, Versa Pulse Power Suite 20-W Holmium laser, New Star, Roseville, CA) ranging from 0.8 - 2.5 Joules with a frequency of 8-15Hz and power of 9-30 W. A maximum of 1 hour of intraductal lithotripsy will be allowed to reduce performance bias.
62821770|NCT04640545|EXPERIMENTAL|LBL-007+Toripalimab+Axitinib Tablets|"Study Part A： LBL-007 Dose A/Dose B/Dose C/Dose D Q2W iv+Toripalimab 3mg/kg Q2W iv；~Study Part B： LBL-007 Dose A/Dose B/Dose C/Dose D Q2W iv+Toripalimab 3mg/kg Q2W iv+Axitinib Tablets 5mg + Axitinib Tablets 1mg"
62244581|NCT03633708|EXPERIMENTAL|Etelcalcetide|Randomized in a 3:1 ratio to receive etelcalcetide in addition to standard of care
62434743|NCT01625845|PLACEBO_COMPARATOR|Placebo + Standard Treatment|"Placebos: Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.~Standard Treatment: Beating the Blues (BtB) is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions."
62434744|NCT00562692|EXPERIMENTAL|A|Nesiritide
62434745|NCT00562692|PLACEBO_COMPARATOR|B|Placebo
62821771|NCT06594484||General Anesthesia Group|The need for ES was recorded in patients undergoing cardiovascular surgery.
62821772|NCT05759728|EXPERIMENTAL|CNA3103 Monotherapy|Single intravenous dose of CNA3103 at Day 0
62821773|NCT06508580|EXPERIMENTAL|Component 1: Calorie Goal Attainment|Participants will be randomized to either receive or not receive feedback based on calorie goal attainment.
62821774|NCT06508580|EXPERIMENTAL|Component 2: Diet Quality|Participants will be randomized to either receive or not receive feedback based on diet quality.
62821775|NCT06508580|EXPERIMENTAL|Component 3: Physical Activity Goal Attainment|Participants will be randomized to either receive or not receive feedback based on physical activity goal attainment.
62821776|NCT06508580|EXPERIMENTAL|Component 4: Goal Setting|Participants will be randomized to either receive or not receive feedback based on weekly goal setting.
62244582|NCT03633708|ACTIVE_COMPARATOR|Control|Randomized in a 3:1 ratio to receive etelcalcetide in addition standard of care alone (control arm)
62244583|NCT01974388|ACTIVE_COMPARATOR|LSG started 2 cm from the pylorus|laparoscopic sleeve gastrectomy starting 2 cm from the pylorus
62041450|NCT05480150|EXPERIMENTAL|bipolar disorder|Patients with BD depressive episode received standard treatment with quetiapine fumarate tablets, starting from 50mg/ night, titrated to a therapeutic dose of 300-400mg/ night within 10 days, and maintained treatment for 4 weeks. According to the patient's condition, patients with BD depressive episode could receive another standard treatment with lurasidone, starting from 20mg/ night, titrated to a therapeutic dose of 40mg/ night within 6 days, and maintained treatment for 4 weeks. Adverse reactions and changes in condition of all patients were recorded
62041451|NCT05480150|EXPERIMENTAL|major depressive disorder|MDD depressive episode patients received standard treatment with escitalopram oxalate tablets, starting from 5mg/ day once, titrated to a therapeutic dose of 10-20mg/ day within 1 week, and maintained treatment for 4 weeks
62041452|NCT05480150|NO_INTERVENTION|healthy control|no interventions
62041453|NCT06247319||Participants Treated with Risankizumab|Participants with a recent diagnosis of moderate plaque PsO (defined as ≤24 months since the first diagnosis of moderate PsO), and naïve to advanced treatments (biologics, apremilast, and deucravacitinib) will receive risankizumab as prescribed by their physician according to local label.
62821777|NCT05519241|EXPERIMENTAL|Phase I dose-escalation and expansion cohort|There are three doses at the dose escalation stage: Dose level I: paclitaxel (PTX) 25 mg or 0.5 mg/ml; Dose Level II: PTX 50 mg or 1.0 mg/ml; Dose Level III: PTX 75 mg or 1.5 mg/ml. At the expansion cohort, up to 12 patients will be recruited and treated with PPM at the PTX dose of 50 mg or 1.0 mg/ml to determine the efficacy.
62041454|NCT01458197|EXPERIMENTAL|Tarafenacin 0.2 mg|Group 1
62041455|NCT01458197|EXPERIMENTAL|Tarafenacin 0.4 mg|Group 2
62244584|NCT01974388|ACTIVE_COMPARATOR|LSG started 6 cm from pylorus|LSG started 6 cm from pylorus
62244585|NCT04130503|EXPERIMENTAL|PAP treatment- Acute|"Acute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support.~All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur."
62434746|NCT06326268|OTHER|Photobiomodulation|• Patients: In induction of acute myeloblastic leukemia OR Allografts in first remission with myeloablative conditioning OR Autografts in the context of aggressive lymphoma;
62601008|NCT06619301|ACTIVE_COMPARATOR|Insulin Glargine|Insulin Glargine dosed 1-2 times daily throughout pregnancy for management of diabetes mellitus.
62601009|NCT06619301|ACTIVE_COMPARATOR|Insulin NPH|Insulin NPH dosed 1-2 times daily throughout pregnancy for management of diabetes mellitus.
62821778|NCT06588335|EXPERIMENTAL|S004+ Toripalimb+Chemotherapy (paclitaxel + cisplatin)|Neoadjuvant therapy stage: JS004+ triplizumab + chemotherapy (paclitaxel + cisplatin), 2 cycles; Operation stage: Surgery 3-8 weeks after the last neoadjuvant; Postoperative maintenance treatment stage: Maintenance therapy was started at 4 weeks ±7 days after surgery. Postoperative maintenance therapy should be initiated no later than 10 weeks after surgery.
62041456|NCT01458197|PLACEBO_COMPARATOR|Placebo|Group 3
62041457|NCT03328299|ACTIVE_COMPARATOR|Dexmedetomidine group|patients were given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine + dexmedetomidine 1 μg•kg-1 diluted in 20 ml saline
62244586|NCT04130503|ACTIVE_COMPARATOR|Usual Care (HLE)|All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur.
62601010|NCT02273271|EXPERIMENTAL|Imaging arm|18F-FLT-PET/CT and DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 4 cycles of chemotherapy
62601011|NCT06258928||patients with a distal radius fracture|Functional examination included evaluating range of motion (ROM), grip strength, and isokinetic evaluation of force moments (Biodex) for wrist flexion, extension, forearm pronation, and forearm supination. Michigan's questionnaire and the Disability of the Arm, Shoulder, and Hand (DASH) questionnaire were used to subjectively evaluate the effects of therapy.
62041458|NCT03328299|PLACEBO_COMPARATOR|bupivacaine group|patients will given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine
62041459|NCT02698124||Decitabine|"Decitabine 20mg/m2 will be given IV daily on Days 1-5 in 28-day cycles. Treatment should be given for at least 4 cycles in the absence of unacceptable toxicity or disease progression requiring alternative therapy.~Beyond 4 cycles, treatment should continue as long as the subject continues to benefit based on investigator's judgment of no definitive progression."
62041460|NCT03318523|PLACEBO_COMPARATOR|Placebo|"Year 1: Participants will receive matching placebo to BIIB054 on Day 1 and then every 4 weeks.~Year 2: Participants who received placebo in year 1 will be randomized into one of the active treatment arms in year 2 and will receive BIIB054 intravenous (IV) infusion on Week 52 and then every 4 weeks."
62601012|NCT05481528|EXPERIMENTAL|Part 1 - Dose group 1|Single oral dose of elinzanetant or placebo.
62041461|NCT03318523|EXPERIMENTAL|BIIB054 250 mg|Participants will receive BIIB054 250 milligrams (mg) intravenous (IV) infusion on Day 1 and then every 4 weeks.
62601013|NCT05481528|EXPERIMENTAL|Part 1 - Dose group 2|Single oral dose of elinzanetant or placebo
62041462|NCT03318523|EXPERIMENTAL|BIIB054 1250 mg|Participants will receive BIIB054 1250 mg IV infusion on Day 1 and then every 4 weeks.
62041463|NCT03318523|EXPERIMENTAL|BIIB054 3500 mg|Participants will receive BIIB054 3500 mg IV infusion on Day 1 and then every 4 weeks.
62041464|NCT03321396|EXPERIMENTAL|Endoscopic submucosal dissection|All participants in the study received Endoscopic submucosal dissection with Sodium Alginate mixed with Calcium Lactate prior to endoscopic resection.
62041465|NCT05496374|PLACEBO_COMPARATOR|Double Blind: Placebo|Participants will receive matching placebo 4 capsules, orally once daily (QD) for 56 days.
62041466|NCT05496374|EXPERIMENTAL|Double Blind: SPR720 500 mg|Participants will receive SPR720 500 milligrams (mg) \[250 mg × 2 capsules and 2 matching placebo capsules, orally QD for 56 days.
62041467|NCT05496374|EXPERIMENTAL|Double Blind: SPR720 1000 mg|Participants will receive SPR720 1000 mg \[250 mg × 4 capsules\], orally QD for 56 days.
62601014|NCT05481528|EXPERIMENTAL|Part 1 - Dose group 3|Single oral dose of elinzanetant or placebo
62821779|NCT05300503|NO_INTERVENTION|Control|Participants will be asked to continue their usual day to day activities and take their current medications as directed. They will be sent a link by email or through MyChart to the standard video \& education session on managing hypertension. They will watch the video at home on their own time. Participants will use a home blood pressure monitor to track their blood pressure (those without a blood pressure cuff will be provided one) for the 3-month intervention period. Patients will be provided instructions of when they should seek medical attention (clinical symptoms or SBP \<100 or SBP \>160). They will be encouraged to track their blood pressure daily and any symptoms they may be feeling.
62821780|NCT05300503|EXPERIMENTAL|Intervention|Participants will be asked to continue their usual day to day activities and take their current medications as directed. They will be sent a link by email or through MyChart to the educational session described above in the control group section. They will receive an Aetonix aTouchAway platform monitor, which is a disease specific home monitoring device to take home for 3 month intervention period. The device will prompt the participant to check their blood pressure on a daily basis and will send all readings to the UOHI Telehome monitoring program. The telehome monitoring nursing team will monitor the readings for each participant. For hypertensive patients who are not at target with their BP, the telehome monitoring nurse will titrate medications based on an advanced medical directive every 2 weeks. Patients will be provided instructions of when they should seek medical attention (clinical symptoms or SBP \<100 or SBP \>160).
62041468|NCT05496374|EXPERIMENTAL|Open-label: SPR720 1000 mg|Participants will receive SPR720 1000 mg \[250 mg × 4 capsules\], orally QD for 56 days.
62821781|NCT03043794|EXPERIMENTAL|SBRT to the breast then surgery|Stereotactic Body Radiation Therapy (SBRT) of 21Gy followed by standard of care surgery
62041469|NCT05496374|EXPERIMENTAL|Open Label: SPR720 500 mg|Participants will receive SPR720 500 mg \[250 mg × 2 capsules\], orally twice daily (BID) for 56 days.
62244587|NCT04130503|EXPERIMENTAL|PAP treatment- Subacute|"Acute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support.~All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur."
62601015|NCT05481528|EXPERIMENTAL|Part 1 - Dose group 4|Single oral dose of elinzanetant or placebo
62601016|NCT05481528|EXPERIMENTAL|Part 2: Moxifloxacin - Placebo|Participants of Dose Groups 1 and 4 will receive a single dose of moxifloxacin in Period 1 and a single dose of placebo in Period 2.
62821782|NCT05194969|ACTIVE_COMPARATOR|Wet-to-dry Dressings|Participants in this arm will receive standard of care wet-to-dry dressings.
62821783|NCT05194969|EXPERIMENTAL|Petrolatum with Non-Stick Gauze|Participants in this arm will receive petrolatum with non-stick gauze.
62041470|NCT06141148||group A,|group A ( Pulmonary Tuberculosis).
62601017|NCT05481528|EXPERIMENTAL|Part 2: Placebo - Moxifloxacin|Participants of Dose Groups 1 and 4 will receive a single dose of placebo in Period 1 and a single dose of moxifloxacin in Period 2.
62244588|NCT04130503|OTHER|Exploratory arm|Non-randomized comparison/exploratory group of subjects with ischemic stroke and Apnea-Hypopnea Index (AHI) \<15 (approximately 120 participants) and approximately 60 subjects with ICH (who do not need legally authorized representative for consent - most likely mild form of ICH) and any level of AHI.
62601018|NCT01609166|EXPERIMENTAL|Allopurinol 3% cream|Allopurinol 3% cream in one side of the body
62601019|NCT01609166|PLACEBO_COMPARATOR|Placebo cream|Placebo cream in the other side of the body
62623393|NCT05233215|EXPERIMENTAL|GROW Support Program|"Patient participants will fill out questionnaires about emotional and physical health with responses used to develop an individualized survivorship plan conducted through 1x monthly virtual or in-clinic check-ins as well as GROW support meetings as needed for 6 months.~Caregiver participants will fill out questionnaires used to develop patient individualized survivorship plan and participate in 1x monthly check-in meetings with patients or separately for 6 months."
62041471|NCT06141148||group B|group B ( Extra pulmnary Tuberculosis).
62041472|NCT03345498||ETV 0.5 mg|Group of study participants who were started on 0.5 mg/day of entecavir
62041473|NCT03345498||ETV 1.0 mg|Group of study participants who were started on 1.0 mg/day of entecavir
62041474|NCT05945875|EXPERIMENTAL|Diagnostic (panitumumab-IRDye800, 111In-panitumumab, SPECT/CT)|Patients receive panitumumab-IRDye800 IV over 15 minutes followed by 111In-panitumumab IV on day 0. Patients then undergo SPECT/CT between days 1 and 5, prior to standard of care surgical resection with fluorescence imaging.
62821784|NCT03891134|EXPERIMENTAL|enriched Branched Chain Amino Acid intervention|enriched Branched Chain Amino Acid nutrition supplement 3.6 g twice a day for 5 weeks then withdrawal nutrition supplement for 12 weeks
62041475|NCT06435286|EXPERIMENTAL|Artificial Intelligence Mobile High Resolution Microendoscope (AI-mHRME) imaging|All subjects will receive White Light Imaging (WLI) and Lugol's Chromoendoscopy (LCE), the current standard of care (SOC) procedure. Following LCE, all subjects will receive the artificial intelligence (AI) mobile high-resolution microendoscopy (mHRME) imaging with Proflavine Hemisulfate of any LCE abnormal and LCE normal areas (4:1 ratio). For both WLI and LCE, we will record the subjective clinician read (neoplastic, non-neoplastic), the confidence level in their diagnoses (high, low), and the action plan (biopsy vs. no biopsy vs. treat). With the AI-mHRME, we will image the same LCE abnormal and normal areas and record the software read, the clinician confidence level, and action plan. Finally, the imaged LCE abnormal areas will be biopsied or resected, and evaluated by a pathologist.
62041476|NCT00999258|ACTIVE_COMPARATOR|sirolimus|the subjects will undergo conversion from tacrolimus to sirolimus OR they will continue to receive tacrolimus.
62821785|NCT04150614|ACTIVE_COMPARATOR|Arm 1|ARM 1 -transdermal granisetron plus intravenous dexamethasone
62821786|NCT04150614|ACTIVE_COMPARATOR|ARM 2|ARM 2 -intravenous ondansetron plus intravenous dexamethasone
62041477|NCT00999258|NO_INTERVENTION|tacrolimus|
62041478|NCT04113122|EXPERIMENTAL|Cross-sectional study:|Testicular cancer survivors who were treated between 2000 and 2005 or between 2006 and 2012 with cisplatin-combination chemotherapy and who were extensively phenotypically mapped within two longitudinal trials (15,16) will be invited to participate in a single cross-sectional follow-up study visit 5-20 years after chemotherapy.
62041479|NCT04113122|EXPERIMENTAL|Longitudinal study - chemotherapy group|"Patients with metastasized testicular cancer who are about to start with cisplatin-combination chemotherapy will be invited in the longitudinal part of this study. Study participation involves four study visits:~Visit 1: before start of chemotherapy Visit 2:before third cycle of chemotherapy Visit 3: one month after completion of chemotherapy Visit 4: one year after start of chemotherapy"
62623394|NCT01831271|OTHER|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
62821787|NCT06088823||No paresthesia|Patients that had no registration of post-operative paresthesia in hand or lower arm after cardiac surgery
62821788|NCT06088823||Paresthesia|Patients that had one o more registrations of post-operative paresthesia in hand or lower arm after cardiac surgery
62821789|NCT06598358||Children aged 3-12 with ASD diagnosis and their parent/guardian/legal representative|
62821790|NCT06339099|EXPERIMENTAL|control arm|The control group (n=26) received a conventional physical therapy program.
62821791|NCT06339099|ACTIVE_COMPARATOR|Intervention arm|The intervention group (n=26) received conventional physical therapy program and loaded gait training.
62821792|NCT04673643|EXPERIMENTAL|taVNS group|"taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution.~Drug: Hyaluronic acid eye drops Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day."
62041480|NCT04113122|OTHER|Longitudinal study - stage I control group|"Patients with stage I testicular cancer will serve as control group with three study visits:~Visit 1: at time of orchidectomy Visit 2: one month Visit 3: one year after orchidectomy"
62041481|NCT01994954|NO_INTERVENTION|Arm A:Standard therapy|Infants' oxygen will be increased, decreased, or maintained based on brief structured assessments during monthly clinic visits. Polysomnograms will be utilized prior to final discontinuation of oxygen. RHO will only be utilized on the night prior to and during the polysomnogram to compare these two modalities.
62041482|NCT01994954|EXPERIMENTAL|Arm B:RHO|"Infants will have the same monthly clinic assessments as in Arm A, but also will utilize RHO to potentially increase, decrease or maintain oxygen between monthly visits.~Parents will transmit a minimum of 4 days of stored RHO data (min 8 hrs per day) every 4-7 days. Changes in oxygen needs will be made based on standardized objective criteria. To determine discontinuation of oxygen, RHO will be utilized instead of polysomnography."
62041483|NCT06560931||Retrospective cohort|This study consists of a programme of work that is centred around a UK-based, multi-centre cohort study of women who are pregnant or have recently been pregnant. The study will use retrospective data from three representative collaborator NHS hospitals (who will form part of the retrospective cohort).
62601020|NCT06620835|EXPERIMENTAL|Clinical Trial population|"All advanced non-small cell lung cancer (NSCLC) patients with ALK rearrangements treated with brigatinib in first line of non-curable setting will be screened.~If the disease assessment done between 3 to 9 months after initiation of brigatinib shows:~* a tumor response or stabilization (according to RECIST 1.1)~* a disease which meets the definition of an oligometastatic disease (five metastatic lesions or less and a maximum of two lesions per organ)~* all tumor targets are accessible to a local ablative therapy (confirmed by an expert panel of clinicians before inclusion): surgery, stereotactic radiosurgery (SRS), For liver, adrenal, or other metastases, percutaneous thermal ablation will be accepted.~Eligible patients will benefit from local ablative therapy with continuation of brigatinib."
62041484|NCT06560931||Prospective cohort|This study consists of a programme of work that is centred around a UK-based, multi-centre cohort study of women who are pregnant or have recently been pregnant.
62821793|NCT04673643|PLACEBO_COMPARATOR|Control Group|taVNS device were applied using the same stimulator, stimulation parameters and same sessions. However, the electrodes were placed on the antihelix around the affected ear, which is the region of few vagus nerve branch distribution. Drug: Hyaluronic acid eye drops Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
62821794|NCT05922137|PLACEBO_COMPARATOR|Usual Diet advice|Usual diet advice + standard medical treatment
62821795|NCT05922137|ACTIVE_COMPARATOR|ORIENT diet intervention|6 month intervention of ORIENT diet + standard medical treatment
62041485|NCT06560931||MBRRACE-UK cohort|The study will use data from MBRRACE-UK, reviewing deaths, near-miss and pre-near-miss cases to estimate identification performance using the new definitions.
62821796|NCT04522765||Health|Healthy individuals with no known medical condition and taking no regular medication
62434747|NCT04601064|EXPERIMENTAL|Collaborate Care (CC) Model|For patients randomized to the CC arm, in addition to the provider being alerted to the positive Mental Health and Substance Use Disorder screener, the patient will also be assigned to a peer case manager (P-CM). The P-CM will provide longitudinal care for the patient as part of their care management case load. The collaborative care support team will include the P-CM, a consultant addiction psychiatrist and the patient's HIV provider who will implement a stepped care program consisting of: 1) an initial assessment, determination of and implementation of an individualized care plan to provide; 2) psychosocial and medication adherence support; 3) evidence-based brief intervention incorporating motivational interviewing informed strategies; 4) measurement-based care for Mental Health and Substance Use Disorder provided directly by the HIV primary care provider or in collaboration with specialty Mental Health and Substance Use Disorder services.
62601021|NCT05320107|EXPERIMENTAL|Ketamine first, then placebo|0.5mg/kg bodyweight (or 0.25mg/kg bodyweight) ketamine, will be determined in pilot study, then placebo
62601022|NCT05320107|EXPERIMENTAL|Placebo frist, then ketamine|0.9% NaCl, then ketamine
62601023|NCT00902343|EXPERIMENTAL|1|nomogram-based selection for acute normovolemic hemodilution
62601024|NCT00902343|ACTIVE_COMPARATOR|2|standard selection for ANH based on a planned resection of 3 or more segments.
62821797|NCT04522765||Acute kidney injury|Individuals with acute kidney injury as defined by KDIGO criteria
62821798|NCT04522765||Chronic kidney disease|Individuals with chronic kidney disease as defined by KDIGO criteria
62601025|NCT03147131|ACTIVE_COMPARATOR|Fitmore short stem|"Intervention: Total hip arthroplasty with an uncemented femoral short stem, the Fitmore short stem (Zimmer, Warsaw, USA). Furthermore, an uncemented cup (Allofit, Zimmer, Warzaw, USA).~Device: Fitmore Short Stem"
62821799|NCT04522765||Small vessel vasculitis|Individuals with active small vessel vasculitis an diagnosed by a specialist physician
62821800|NCT04522765||Kidney transplant recipient|Individuals who have received a kidney transplant
62821801|NCT04522765||Kidney donor|Individuals who have donated a kidney for transplantation
62821802|NCT06595979||Intracranial Administration Group|Participants in this group will receive polymyxin B administered directly into the brain (intracranial administration) without intravenous (IV) infusion.
62821803|NCT06595979||Intracranial Administration with IV Infusion Group|Participants in this group will receive polymyxin B both intracranially and via intravenous infusion.
62821804|NCT06600438|EXPERIMENTAL|100% exercise increase|Participants motivated towards a 100% increase in physical activity level over 3 years, using the Slow-SPEED app
62821805|NCT06600438|ACTIVE_COMPARATOR|10% exercise increase|Participants motivated towards a 10% increase in physical activity level over 3 years, using the Slow-SPEED app
62821806|NCT03848325|EXPERIMENTAL|Sleep deprivation|All subjects will be provided an 8 hour opportunity for sleep (Night 1) followed by outcome assessment the next morning (Day 1). They will then be kept awake the subsequent 24 hours including Night 2, followed by outcome assessment the following morning (Day 2).
62821807|NCT05750264|ACTIVE_COMPARATOR|ibuprofen group|intravenous ibuprofen 800mg in 200 ml normal saline+IV paracetamol 1000mg+Transversus abdominis plane block
62821808|NCT05750264|NO_INTERVENTION|Control group|200 ml normal saline+IV paracetamol1000mg+Transversus abdominis plane block
62821809|NCT06599866||Multiple Sclerosis Group|Individuals between the ages of 18-65 who have been diagnosed with multiple sclerosis by a specialist physician.
62041486|NCT06560931||Patient interviews (escalation pathway)|This study consists of a programme of work that is centred around a UK-based, multi-centre cohort study of women who are pregnant or have recently been pregnant. All women in the cohort are likely to have had one of the near-miss or pre-near-miss events (as defined in WS1) or death.
62041487|NCT06560931||Staff interviews/focus groups (escalation pathway)|"Staff members will be involved in focus groups, interviews and testing the eMOEWS user interface.~Inclusion criteria~* Staff members aged 16 or over in a partner hospital.~* Involved in the care, management and escalation of hospitalised women who deteriorate in maternity services."
62244589|NCT05754073|EXPERIMENTAL|1. Intranasal Oxytocin|Intranasal oxytocin spray (30 IU twice daily) for 12 months in the double-blinded phase followed by intranasal oxytocin spray (30 IU twice daily) for 6-months in the open-label phase
62601026|NCT03147131|ACTIVE_COMPARATOR|CLS straight stem|"Intervention: Total hip arthroplasty with an uncemented femoral straight stem, the CLS short stem (Zimmer, Warsaw, USA).Furthermore, an uncemented cup (Allofit, Zimmer, Warzaw, USA).~Device: CLS Straight Stem"
62821810|NCT00734149|EXPERIMENTAL|Bortezomib+Melphalan+Prednisone|Bortezomib 1.3 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 4, 8, and 11 of a 28 day cycle. Six cycles are planned. On days when both melphalan and bortezomib are given, melphalan is given at least one hour prior to bortezomib. Melphalan 6 mg/m2 is administered orally on an empty stomach daily on days 1-7 of each cycle. Prednisone 60 mg/m2 is administered orally daily on days 1-7 of each cycle.
62244590|NCT05754073|PLACEBO_COMPARATOR|2. Placebo|Intranasal placebo spray (30 IU twice daily (total 60 IU per day) for 12 months followed by intranasal oxytocin spray (30 IU twice daily) for 6-months in the open-label phase
62244591|NCT03769064|EXPERIMENTAL|Qualification Phase (Part A)|Placebo/Methylphenidate (60 mg) on days 1 and 3
62244592|NCT03769064|EXPERIMENTAL|Qualification Phase (Part B)|Methylphenidate (60 mg)/Placebo on days 1 and 3
62244593|NCT03769064|EXPERIMENTAL|Treatment Phase Sequence 4213|Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg
62601027|NCT00493233|EXPERIMENTAL|1|
62821811|NCT04179175|ACTIVE_COMPARATOR|secukinumab 1 HiSCR Responder|HiSCR responder at Week 52 in core trial, secukinumab 300mg every 2 weeks
62821812|NCT04179175|ACTIVE_COMPARATOR|secukinumab 2 HiSCR Responder|HiSCR responder at Week 52 in core trial, secukinumab 300mg every 4 weeks
62821813|NCT04179175|PLACEBO_COMPARATOR|placebo 1 HiSCR Responder|HiSCR responder at Week 52 in core trial, placebo to secukinumab 300mg every 2 weeks
62821814|NCT04179175|PLACEBO_COMPARATOR|placebo 2 HiSCR Responder|HiSCR responder at Week 52 in core trial, placebo to secukinumab 300 mg every 4 weeks
62821815|NCT04179175|OTHER|HiSCR non-responders|non-responder at Week 52 in core trial treatment; secukinumab 300mg every 2 weeks
62821816|NCT06007872|EXPERIMENTAL|Intervention|Intracardiac Echocardiography (ICE)
62244594|NCT03769064|EXPERIMENTAL|Treatment Phase Sequence 2134|Methylphenidate 60 mg/Placebo Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg
62601028|NCT00493233|PLACEBO_COMPARATOR|2|
62601029|NCT06255379|EXPERIMENTAL|Fuquinitinib +Tegafur Gimeracil Oteracil|
62601030|NCT00373958|EXPERIMENTAL|13vPnC vaccine|
62601031|NCT00373958|ACTIVE_COMPARATOR|7vPnC vaccine|
62601032|NCT01650545|EXPERIMENTAL|Liposomal Aerosol Cyclosporine|Arm 1) Aerosol liposomal cyclosporine Open label randomized trial using experimental inhalational therapy with liposomal aerosol cyclosporine in addition to standard immune suppression (tacrolimus , mycophenolate mofetil and prednisone) for 6 month duration at inhalational doses (5mg and 10 mg bid), to be defined by transplant type respectively (single, double lung transplant )
62821817|NCT04742491|EXPERIMENTAL|Immediate Intervention Arm Descovy in the US|PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) one tablet daily in the US
62821818|NCT04742491|EXPERIMENTAL|Deferred Intervention Arm Descovy in the US|0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) one tablet daily in the US
62821819|NCT04742491|EXPERIMENTAL|Immediate Intervention Arm Truvada in Brazil|PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in Brazil
62821820|NCT04742491|EXPERIMENTAL|Deferred Intervention Arm Truvada in Brazil|0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in Brazil
62601033|NCT01650545|ACTIVE_COMPARATOR|Conventional oral immune suppression|"Arm 2) Standard immune suppression consisting of typical oral immune suppression for lung transplant recipients typically tacrolimus, mycophenolate mofetil and prednisone.~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone rapamycin described in the subsequent section as well."
62601034|NCT06622473|EXPERIMENTAL|Stroke group|each participant will perform the VET, NHPT, Abilhand-ULA, and Motricity Index with their most affected hand, followed by the VET and NHPT with the less affected hand.
62601035|NCT01984489|PLACEBO_COMPARATOR|Placebo/Metformin|patients are administered oral tablets of placebo once daily and 500mg TID for 4 weeks at the run-in period. After randomized ,patients administer the drugs too.
62601036|NCT01984489|EXPERIMENTAL|SHR117887 (50mg q.d)/Metformin|patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 50mg QD and metformin 500mg TID for 12 weeks.
62601037|NCT01984489|EXPERIMENTAL|SHR117887 (100mg q.d)/Metformin|patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 100mg QD and metformin 500mg TID for 12 weeks.
62601038|NCT02481271|NO_INTERVENTION|Usual care|Does not receive a specific study intervention
62821821|NCT04742491|EXPERIMENTAL|Immediate Intervention Arm Truvada in the US|PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in the US
62821822|NCT04742491|EXPERIMENTAL|Deferred Intervention Arm Truvada in the US|0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in the US
62821823|NCT06598579|EXPERIMENTAL|MBCT-VN|
62821824|NCT06598579|PLACEBO_COMPARATOR|Buddhist Meditation - Treatment-as-Usual|
62821825|NCT05919875|EXPERIMENTAL|Unguided iMBCT intervention|
62601039|NCT02481271|EXPERIMENTAL|preoperative relaxation program|preoperative relaxation program
62601040|NCT02481271|EXPERIMENTAL|preoperative surgery education|single education unit to understand the complete surgical procedures
62601041|NCT02481271|EXPERIMENTAL|preoperative relaxation program+preoperative surgery education|preoperative relaxation program AND single education unit
62601042|NCT01871402|EXPERIMENTAL|Active Arm|Topical lotion, applied twice daily
62041488|NCT06560931||Staff interviews/focus groups (eMOEWS interface development)|"Staff members will be involved in focus groups, interviews and testing the eMOEWS user interface.~Inclusion criteria~* Staff members aged 16 or over in a partner hospital.~* Involved in the care, management and escalation of hospitalised women who deteriorate in maternity services."
62041489|NCT06560931||Staff training (simulation scenarios)|"Staff will also take part in scenario simulations (MOET). Inclusion criteria~* Staff members aged 16 or over in a partner hospital.~* Involved in the care, management and escalation of hospitalised women who deteriorate in maternity services."
62601043|NCT01871402|PLACEBO_COMPARATOR|Vehicle Arm|Topical lotion, applied twice daily
62601044|NCT06622681||Participant of the study|Adolescents at 13- 15 years of age, currently studying in MOE-registered secondary school in Singapore and part of the DREAMS cohort.
62601045|NCT01482962|EXPERIMENTAL|Alisertib|Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).
62821826|NCT05919875|EXPERIMENTAL|Guided iMBCT intervention|
62821827|NCT05919875|NO_INTERVENTION|Waiting list group|
62821828|NCT06598163|EXPERIMENTAL|Five Lives MED|"Participants will use the Five Lives MED app, where they will be offered \~30 min daily sessions including a healthy-habit-forming component and cognitive training.~They will be able to complete maximum one session per day and will be advised to complete a minimum of 3 sessions per week. The participants can complete more sessions if they wish.~After each session they have ad-libitum access to the cognitive-training games and educational articles."
62821829|NCT06598163|NO_INTERVENTION|Control|Participants in the control group will receive an informational leaflet with up-to-date standard advice on sleep hygiene, diet, and physical exercise, with an explanation on how these relate to brain health.
62821830|NCT02194387|EXPERIMENTAL|Supportive care (energy balance interventions)|"TELEPHONE COACHING VS EMAIL COACHING: Participants receive telephone coaching once per week for 16 weeks or 1 email per week for 16 weeks (with follow-up responses if the participant responds) from a coach trained in motivational interviewing.~TEXT MESSAGES: Participants receive daily text messages promoting adherence to diet and exercise recommendations daily 1-3 times per day or no text messages.~SOCIAL NETWORKING: Participants are invited to an online forum for study participants available for 16 weeks or do not receive an invitation for social networking.~SELF-MONITORING: Participants are asked to record their dietary intake 4-7 days per week or 1 day per week on a website or smartphone app."
62244595|NCT03769064|EXPERIMENTAL|Treatment Phase Sequence 1342|Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo
62601046|NCT01482962|ACTIVE_COMPARATOR|Pralatrexate, or Romidepsin, or Gemcitabine|Pralatrexate 30 mg/m\^2, intravenous (IV) push over 3 to 5 minutes, once weekly, for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles were repeated every 7-weeks provided the participant continued to benefit from and tolerate the therapy (Up to 115 Weeks), or Gemcitabine 1,000 mg/m\^2 over 30 minutes, intravenously, on Days 1, 8, and 15 of a 28-day cycle until the absence of disease progression or unacceptable toxicity (Up to 32 Weeks), or Romidepsin 14 mg/m\^2, intravenously over a 4-hour period, on Days 1, 8, and 15 of a 28-cycle. Cycles were repeated every 28 days provided the patient continued to benefit from and tolerate the therapy (Up to 30 Weeks).
62601047|NCT01221714||Active/Placebo|ACTIVE VITAMIN; PLACEBO OMEGA MAX
62601048|NCT01221714||Active/Active|ACTIVE VITAMIN; ACTIVE OMEGA MAX
62601049|NCT01221714||Placebo/Active|PLACEBO VITAMIN; ACTIVE OMEGA MAX
62601050|NCT01221714||Placebo/Placebo|PLACEBO VITAMIN; PLACEBO OMEGA MAX
62601051|NCT01789580|NO_INTERVENTION|Control group|The participants play on their preferred online gambling site (experimental gambling session) without gambling moderator.
62601052|NCT01789580|EXPERIMENTAL|Bonus group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : bonus (with different modalities of the moderator).
62601053|NCT01789580|EXPERIMENTAL|Auto-exclusion group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : auto-exclusion.
62601054|NCT01789580|EXPERIMENTAL|Auto- limitation group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : auto- limitation(with different modalities of the moderator).
62601055|NCT01789580|EXPERIMENTAL|Information group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : information (with different modalities of the moderator).
62601056|NCT04827966|ACTIVE_COMPARATOR|Fluoride Varnish|Clinpro® is 5% sodium fluoride varnish and is indicated to be used for hypersensitive as well as for demineralized teeth. It flows smoothly on moist teeth and binds firmly to their surfaces. 1ml of Clinpro® contain 50 mg of sodium fluoride. 0.2-0.5ml of the varnish is applied onto the tooth surface after through cleaning. One coats of the varnish will be applied and patient will be instructed not to rinse with water or eat for 30 minutes. This is based on the manufacturer's instructions.
62821831|NCT06600464||Group 1|Patients with various stages of 1st carpometacarpal (CMC) joint osteoarthritis (OA) were assessed using standard radiographs based on the Modified Eaton Litter classification
62244596|NCT03769064|EXPERIMENTAL|Treatment Phase Sequence 3421|Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo Placebo/Placebo
62244597|NCT04782388|EXPERIMENTAL|Staccato alprazolam|Study participants will receive Single dose of Staccato alprazolam on Day 1 of the Treatment Period.
62244598|NCT04782388|PLACEBO_COMPARATOR|Staccato placebo|Study participants will receive placebo on Day 1 of the Treatment Period.
62244599|NCT05100706|EXPERIMENTAL|Continuous adductor canal block (CACB)|Will receive an infusion of 0.2% ropivacaine 5mL/h through adductor canal catheter.
62244600|NCT05100706|PLACEBO_COMPARATOR|Sham continuous adductor canal block (ShACB).|Will receive an infusion of NaCl 0.9% 5mL/h through adductor canal catheter.
62244601|NCT05622812|EXPERIMENTAL|Treatment group|Initial Restylane Lyft Lidocaine injection and one optional touch-up treatment at 1 month after treatment
62601057|NCT04827966|ACTIVE_COMPARATOR|Tooth Mousse|Tooth Mousse® contains Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP) is product from the milk casein. This delivers the necessary Calcium and Phosphate ions to the tooth, which will reduce the risk of caries and white spot by enhancing tooth remineralization. One tube of the Tooth Mousse will be prescribed to the patient. Patient will be instructed to apply the product using finger every night after brushing and flossing. This is continued till the prescribed product is finished. This is approximately calculated to be about 8 to 12 weeks.Patient is instructed to leave the paste for about 3 minutes and then rinse. This is based on the manufacturer's instructions.
62821832|NCT06600464||Group 2|In the healthy control group, subjects were matched based on age and hand dominance
62821833|NCT04094285|EXPERIMENTAL|1|
62821834|NCT04094285|EXPERIMENTAL|2|
62821835|NCT06279351|EXPERIMENTAL|Test group|Thalidomide+cetuximab+FOLFOX/FOLFIRI
62244602|NCT05622812|NO_INTERVENTION|No-treatment control group|Optional treatment will be administered at 12 months
62821836|NCT06279351|NO_INTERVENTION|control group|cetuximab+FOLFOX/FOLFIRI
62821837|NCT06698653|EXPERIMENTAL|Phase A : Experimental|Phase A corresponds to the experimental phase where the patient will use the experimental device during 7 days.
62821838|NCT06698653|ACTIVE_COMPARATOR|Phase B : Control|Phase B corresponds to the control phase where the patient will use the control device during 7 days.
62821839|NCT06477536|EXPERIMENTAL|HB0034|single-arm and all the patients would receive HB0034 300mg i.v. every other four weeks
62821840|NCT05583552|EXPERIMENTAL|Single-arm imetelstat|
62601058|NCT04827966|ACTIVE_COMPARATOR|MI Paste|MI Paste® which is Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF) additional contains fluoride in addition to CPP-ACP. The level of fluoride is 900ppm which approximates that in adult strength toothpastes. Recent studies have investigated the remineralization potential of CPP-ACP combined with fluoride and have found a synergistic effect when these are administered together, which is the composition in MI paste. One tube of the MI Paste will be prescribed to the patient. Patient will be instructed to apply the product using finger every night after brushing and flossing. This is continued till the prescribed product is finished. This is approximately calculated to be about 8 to 12 weeks.Patient is instructed to leave the paste for about 3 minutes and then rinse. This is based on the manufacturer's instructions.
62821841|NCT03270982||Comprehensive SRS Replacement|Comprehensive SRS Device
62821842|NCT02388308||Patient volunteers|Patients who have received radiotherapy for prostate cancer which included a planning CT scan, or who are currently receiving radiotherapy including a CT scan.
62821843|NCT02388308||Gold fiducial marker group|Patients receiving radiotherapy for prostate cancer as part of a clinical trial or standard care which includes gold FM or EM insertion, or patients who have previously received RT for prostate cancer which included EM insertion.
62821844|NCT02388308||Electromagnetic marker group|Patients receiving radiotherapy for prostate cancer as part of a clinical trial or standard care which includes gold FM or EM insertion, or patients who have previously received RT for prostate cancer which included EM insertion.
62821845|NCT02388308||General patients|Patients who are receiving radiotherapy for prostate cancer and who are not receiving FMs. Attempts will be made to match Group 4 patients BMI and time receiving hormone therapy to patients in group 2 and 3 (see below, section 6.1 recruitment.
62821846|NCT02798666|EXPERIMENTAL|High intensity exercise training|The participants exercised for 40 minutes, twice a week, under supervision of two physiotherapists for in total 10 weeks. Each training session included a warming up, a sprint interval block \[10 minutes\], continuous aerobic exercise \[10 minutes\], another sprint interval block \[10 minutes\] and cooling down. For the first 5 weeks, each sprint interval block consisted of 10 sprint bouts \[\>100 r/min\] of 15 seconds at a cycling resistance matching with the ventilatory threshold \[VTR\], alternated with 45 seconds relative rest \[50 r/min at VTR\]. Starting from week 6 until week 10, the intensity of sprinting and relative rest was increased up to 110% of VTR.
62601059|NCT04827966|ACTIVE_COMPARATOR|Acidulated phosphate fluoride gel|A stable thixotropic gel providing 1.23% fluoride ion. This is only for professional use and applied by the dentist. The teeth is cleaned and polished and the gel is applied onto a tray. It is filled upto one third of the tray according to manufacturer's instructions. The tray is then inserted into the mouth and the patient is asked to gently bite down lightly for 1 to 4 minutes.The tray is then removed and patient is asked to expectorate any material in the mouth. The patient is instructed not to eat, rinse or drink for 30 minutes.
62601060|NCT04827966|ACTIVE_COMPARATOR|Fluoride Mouthrinse|Listerine® Sodium fluoride (0.2%) mouth rinses are effective in reducing caries and inhibit carbohydrate utilization of oral microorganisms by blocking enzymes involved in the bacterial glycolytic pathway studies have shown sodium fluoride mouth rinse to be effective in reducing S. mutans counts.
62821847|NCT02798666|ACTIVE_COMPARATOR|Continuous exercise training|The comparative group performed a continuous aerobic training \[CAT\] for 10 weeks, twice a week and 40 minutes per session \[volume and frequency is equal to HIIT\]. The protocol of the CAT group consisted of warming up \[stretching of the large muscle groups and cardiovascular exercises at 30% of peak cycling power output for five minutes\], continuous aerobic exercise training \[3 times 10 minutes\] and cooling down \[stretching of the large muscle groups and cardiovascular exercises at 30% of peak cycling power output for five minutes\]. During the continuous aerobic protocol \[cycling or stepping\] participants exercised for 10 minutes at a HR similar to the HR at VT \[60 r/min\], which was increased to 110% of VT from week 6 onwards.
62821848|NCT01263769|EXPERIMENTAL|Axitinib|Axitinib Starting dose: 5 mg by mouth twice each day for 12 weeks.
62821849|NCT06463795|EXPERIMENTAL|tDCS Group|"Electrode placement: Anodal electrode placed over primary motor cortex area (M1) while the cathode placed over contralateral orbit.~Duration of 20 minutes with intensity of 2mA, ramping up and down at 8 seconds. the density of 0.07 C/cm2 for 3 days/week for 8 weeks"
62821850|NCT06463795|SHAM_COMPARATOR|Sham Group|"Electrode placement: Anodal electrode placed over primary motor cortex area (M1) while the cathode placed over contralateral orbit.~Duration of 20 minutes with intensity of 0.5mA, ramping up and down at 150 and 30 seconds respectively. There will be brief stimulation period of 3-5% active session duration the density of 0.07 C/cm2 for 3 days/week for 8 weeks"
62849180|NCT05155891|EXPERIMENTAL|Embosphere Microspheres group|Participants in this group who are undergoing standard of care (SOC) prostate artery embolization (PAE) for treatment of their symptomatic benign prostatic hyperplasia (BPH) will receive Embosphere Microspheres during scheduled SOC PAE surgery.
62601061|NCT05742893|EXPERIMENTAL|diagnostic|all patients have the study test
62601062|NCT00003910|EXPERIMENTAL|Methotrexate (Cy if no response to MTX)|MTX given orally at 10 mg/m2 in divided doses once weekly. Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days. Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule.
62041490|NCT03646799|EXPERIMENTAL|Group 1|Period 1: 1 tablet of reference drug(D484) Period 2: 1 tablet of test drug(CKD-387)
62041491|NCT03646799|EXPERIMENTAL|Group 2|Period 1: 1 tablet of test drug(CKD-387) Period 2: 1 tablet of reference drug(D484)
62601063|NCT04028973|EXPERIMENTAL|Evaluation of fatigue level in BPCO patients (condition 1)|
62601064|NCT04028973|EXPERIMENTAL|Evaluation of fatigue level in BPCO patients (condition 2)|
62821851|NCT06403514|EXPERIMENTAL|Trial|Psychological Skills Training (PST). The PST will include elements, both generalized and idiosyncratic, for each participant and is considered an adapted model of stress inoculation skills training protocol. The specifics will include each participant's unique optimal and poor ranges of performance (i.e., IZOFs), which will be calculated utilizing HRV, BPM, EMG, respiration and subjective affect. The participants will be introduced to their IZOFs and then taught general and specific approaches to self-regulation using elements of a mindfulness protocol for BFB in a clinical environment. A dual-monitor setup for the BFB application will be employed.
62821852|NCT06261021|EXPERIMENTAL|ruxolitinib 1.5% cream (Sequence 1)|ruxolitinib 1.5% cream without occlusion for Area 1 and ruxolitinib 1.5% cream under occlusion at night for Area 2
62821853|NCT06261021|EXPERIMENTAL|ruxolitinib 1.5% cream ( Sequence 2)|ruxolitinib 1.5% cream under occlusion at night for Area 1 and ruxolitinib 1.5% cream without occlusion for Area 2
62821854|NCT06593340|EXPERIMENTAL|Real-Time Exposure Data|Participants in this arm will get their data reported-back in real-time. There will be a total of 4 different strategies tested based on a combination of two (2) messengers and two (2) formats tested.
62041492|NCT06723587|EXPERIMENTAL|Instep weights|Instep weight use
62601065|NCT04028973|ACTIVE_COMPARATOR|Evaluation of fatigue in control patients (condition 1)|
62601066|NCT04028973|ACTIVE_COMPARATOR|Evaluation of fatigue in control patients (condition 2)|
62041493|NCT06723587|NO_INTERVENTION|No instep weights|No instep weight.
62601067|NCT05286359|EXPERIMENTAL|NxTekTM Malaria Plus Rapid Diagnostic Test (RDT) Devices|
62601068|NCT05556850|EXPERIMENTAL|Rehabilitation using STABL platform|Patients undergoing minor knee procedures (defined as meniscectomy and synovectomy) will be randomized to virtual rehabilitation using the STABL platform
62601069|NCT05556850|NO_INTERVENTION|Rehabilitation using standard physical therapy|Patients undergoing minor knee procedures (defined as meniscectomy and synovectomy) will be randomized to standard physical therapy.
62601070|NCT04579445||TAVI patients|Consecutive, severe aortic stenosis patients undergoing transcatheter aortic valve implantation (TAVI) (there will be a retrospective part: documentation of 30 patients who underwent transfemoral TAVI; and a prospective part enrolling 50 patients undergoing transfemoral TAVI)
62601071|NCT05490602||Running subcutaneous sutures technique|Abdominoplasty patients will be recruited. 50 patients will undergo the running subcutaneous sutures technique closures.
62601072|NCT05490602||Classical closures|Abdominoplasty patients will be recruited. 50 patients will undergo classical closures.
62821855|NCT06593340|EXPERIMENTAL|Delayed Exposure Data|Participants in this arm will get their data reported-back only after all exposure data are collected (i.e., delayed approximately 2 months). There will be a total of 4 different strategies tested based on a combination of two (2) messengers and two (2) formats tested.
62821856|NCT06592716|OTHER|Identify recurrence|The aim is to identify recurrence through longitudial analyses of cell-free HPV-DNA from blood samples.
62601073|NCT03796442|EXPERIMENTAL|AVALUS group|patients who will undergo aortic valve replacement with Avalus bioprosthesis
62821857|NCT04196777|EXPERIMENTAL|Intervention|We will randomly select 3 intervention sites from the top quartile of all VHA sites, as ranked by the frequency of excessive post-procedural antimicrobial use after the 3 urologic procedures of interest. We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be shared at baseline with the intervention sites. Updated data will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail. These data will include an anonymous comparison to all other VHA hospitals.
62821858|NCT05225090|OTHER|Smartphone App Intervention|Cancer patients taking at least one oral anti-cancer drug or oral medication to manage a chronic condition in conjunction with any cancer treatment will receive messages through the Medisafe App.
62821859|NCT05743400|EXPERIMENTAL|Experimental treatment arm|Children over two years and adults undergoing a first hematopoietic stem cell transplantation will receiveThymoglobulin® as part of the conditioning.
62821860|NCT04375150||Patients with advanced renal cell carcinoma (RCC)|
62821861|NCT00671294|EXPERIMENTAL|Ramelteon and Placebo QD (9 possible combinations total)|
62821862|NCT06478550||Patient Support Solution (PSS) app with connectivity to Mallya|Participants will be treated with commercially available semaglutide subcutaneously (s.c.) according to routine clinical practice and local label at the discretion of the Health Care Providers (HCP) and receive PSS app with connectivity to Mallya device.
62821863|NCT06478550||PSS app without connectivity to Mallya|Participants will be treated with commercially available semaglutide s.c. according to routine clinical practice and local label at the discretion of the HCP and receive PSS app without connectivity to Mallya device.
62821864|NCT06478550||Mallya|Participants will be treated with commercially available semaglutide s.c. according to routine clinical practice and local label at the discretion of the HCP and use only Mallya device without PSS app.
62821865|NCT06478550||No intervention (Control arm)|Participants will be treated with commercially available semaglutide s.c. according to routine clinical practice and local label at the discretion of the HCP and will not receive PSS app or Mallya device.
62821866|NCT04513951|EXPERIMENTAL|mFOLFOXIRI + Cetuximab + Avelumab|"* Avelumab, 800 mg intravenous \[IV\] dose over 60 minutes, day 1, followed by~* Cetuximab, 500 mg/m2 IV dose over 2 hours at cycle 1 (if well tolerated, it is administered over 90 minutes at cycle 2 and over 60 minutes by cycle 3), day 1, followed by~* Irinotecan 150 mg/ m2 IV dose over 60 minutes day 1, followed by~* Oxaliplatin 85 mg/m2 IV dose over 2 hours, day 1 in two-way with~* L-Leucovorin 200 mg/ m2 IV dose over 2 hours, day 1 followed by~* 5-fluoruracil 2400 mg/m2 IV dose 48 h-continuous infusion, starting on day 1; to be repeated every 14 days for a maximum of 12 cycles. If no progression occurs during the induction treatment, patients will receive maintenance with 5-FU/LV plus cetuximab and avelumab at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus cetuximab and avelumab will be repeated biweekly until disease progression, unacceptable toxicity, patient's refusal or consent withdrawal."
62821867|NCT01504815|ACTIVE_COMPARATOR|Cisplatinum + conventional RT|Cisplatinum 100mg/m2 on days 1, 22 and 43, with conventional RT 70 Gy in 7 weeks
62041494|NCT05978921|EXPERIMENTAL|Intervention group|"An additional strength training programme will be carried out for 12 weeks with 2 sessions per week. The sessions will last approximately 50 minutes and will be divided into 3 distinct parts: The first part will consist of a warm-up with a part of aerobic exercise that will last approximately 15 minutes. This will be followed by the main part of strength training with a circuit of 6 exercises (3 series x 12 repetitions) which will last approximately 25 minutes.~Finally, there will be a cool down phase with breathing exercises to allow people to recover."
62601074|NCT03796442|ACTIVE_COMPARATOR|CEPME group|patients who will undergo aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis
62821868|NCT01504815|EXPERIMENTAL|Cisplatinum + adaptive high dose RT|Cisplatinum, 100 mg/m2 on days 1, 22 and 43 with adaptive high dose RT to 84 Gy max on 50% uptake GTV in 7 weeks
62849181|NCT05155891|ACTIVE_COMPARATOR|HoLEP Group|Participants in this group who are undergoing SOC PAE for treatment of their symptomatic benign prostatic hyperplasia (BPH) will receive SOC Holmium laser enucleation of prostate (HoLEP).
62601075|NCT03419598||All study participants|All virtual participants who received a virtual opening wedge high tibial osteotomy. The baseline information was the individual CT-based geometry of tibia.
62601076|NCT01573767|ACTIVE_COMPARATOR|Arm 1|Vilanterol 25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
62601077|NCT01573767|ACTIVE_COMPARATOR|Arm 2|Vilanterol 12.5mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
62601078|NCT01573767|ACTIVE_COMPARATOR|Arm 3|Vilanterol 6.25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
62244603|NCT06725225|PLACEBO_COMPARATOR|The group with milder symptoms and better quality of life|the group uses unsupervised machine learning to identify patients with severe symptoms and poor functionality who are receiving immunotherapy for non-small cell lung cancer, and implements a symptom cluster care intervention.
62244604|NCT06725225|ACTIVE_COMPARATOR|The group with more severe symptoms and poorer quality of life|
62601079|NCT01573767|PLACEBO_COMPARATOR|Arm 4|Placebo inhalation powder inhaled once daily in the PM via the new powder inhaler
62601080|NCT03794661|EXPERIMENTAL|Single Arm|Clinician programmer electrode screening mode tool
62601081|NCT02142361|ACTIVE_COMPARATOR|Omafilcon A/Enfilcon A|Subject's habitual hydrogel toric lenses Omafilcon A will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
62821869|NCT05628363|EXPERIMENTAL|Adaptive stereotactic body radiotherapy (SBRT)|"* Treatment consists of adaptive dose-escalated stereotactic body radiotherapy (SBRT) to the pelvic nodes to 25 Gy in 5 once or twice weekly fractions with simultaneous integrated boosts (SIB) to the prostate and proximal seminal vesicles to 36.25 Gy in 5 fractions (full seminal vesicles if involved), to the prostate to 40 Gy in 5 fractions, and to the involved MR-detected nodule(s) to up to 50 Gy in 5 fractions.~* Androgen deprivation therapy (ADT) will be administered to study patients according to institutional standard. Unfavorable Intermediate-risk Disease: Patients should receive a minimum of 4 months of ADT. Patients can receive longer duration of ADT at the discretion of the treating physician. High-risk disease: Patients should receive a minimum of 1 year of ADT. Patients can receive up to 2 years of ADT at the discretion of the treating physician."
62821870|NCT04837443|EXPERIMENTAL|Synchronous working group|
62821871|NCT04837443|SHAM_COMPARATOR|Asynchronous working group|
62821872|NCT06006299|EXPERIMENTAL|taVNS|Participants will use the transauricular Vagus Nerve Stimulator provided to them by the lab for 14 days, 15 minutes prior to sleeping. Data will be collected via surveys, interviews, and Fitbit wear over the course of 2 months. A sleep diary will be kept to record sleep quality.
62821873|NCT02678182|NO_INTERVENTION|A1: Surveillance|Patients in this Arm will follow current UK standard of care for this setting and will be reviewed every 4 weeks
62041495|NCT05978921|SHAM_COMPARATOR|Control group|Subjects in the control group will continue with their normal life and carry out all the activities they have been doing previously.
62244605|NCT06735144|EXPERIMENTAL|Queue A|
62821874|NCT02678182|EXPERIMENTAL|Arm A2: Capecitabine Maintenance|1250 mg/M2/DAY on days 1-21
62821875|NCT02678182|EXPERIMENTAL|Arm A3: MEDI4736 (Durvalumab)|IV treatment on day 1 +15, on a 28 day cycle.
62821876|NCT02678182|ACTIVE_COMPARATOR|Arm B1: Trastuzumab Maintenance|6mg/kg on day 1 every 21 days
62821877|NCT02678182|EXPERIMENTAL|Arm A4: Rucaparib|600mg PO twice daily
62821878|NCT02678182|EXPERIMENTAL|Arm A5: Capecitabine and Ramucirumab|capecitabine 1250 mg/m2/day PO in two divided doses continuously from days 1-21 of each 21 day cycle (see section 12) and ramucirumab 8mg/kg IV day 1 and day 8
62821879|NCT03793244||Experimental: TARGET protocol EN 1.5 kcal/mL|Enteral (EN) feed 1.5 kcal/mL. Indirect calorimetry and/or VCO2 measurements will be taken periodically while in the TARGET main study
62821880|NCT03793244||Active Comparator: TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL Indirect calorimetry and/or VCO2 measurements will be taken periodically while in the TARGET main study
62821881|NCT03153592|ACTIVE_COMPARATOR|conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure \<28 cmH2O.
62821882|NCT03153592|EXPERIMENTAL|transpulmonary pressure strategy|13 patients will undergo volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, and with a inspiratory transpulmonary pressure less than 20 cmH2O and an expiratory transpulmonary pressure and inspired oxygen set accordingly to predefined criteria.
62041496|NCT06724068||Diabetes|
62041497|NCT06724068||Insulin resistance|
62041498|NCT06724068||Control|
62041499|NCT06379919|ACTIVE_COMPARATOR|Normal Saline Irrigation Arm (Group 1)|After deep dissection, and prior to implantation of components, 100 cc of normal saline will be irrigated into the deep wound and progress outward through more superficial planes to the skin. Cultures will then be taken at multiple wound depths and time points.
62244606|NCT06735144|EXPERIMENTAL|Queue B|
62244607|NCT05927922|EXPERIMENTAL|Premedication with 600 mg of Oral Ibuprofen|Premedication with 600 mg of Oral Ibuprofen (Abbott, Egypt) will be given 1 hour before IANB.
62244608|NCT05927922|PLACEBO_COMPARATOR|Placebo will be given 1 hour before inferior alveolar nerve block|
62601082|NCT02142361|ACTIVE_COMPARATOR|Ocufilcon D/Enfilcon A|Subject's habitual hydrogel toric lenses Ocufilcon D will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
62601083|NCT02142361|ACTIVE_COMPARATOR|Methafilcon B/ Enfilcon A|Subject's habitual hydrogel toric lenses Methafilcon B will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
62601084|NCT05387681|EXPERIMENTAL|Envafolimab, Endostatin and SOX regimen|Preoperative short course radiotherapy with Envafolimab, Endostatin and SOX regimen
62821883|NCT04979546|EXPERIMENTAL|Intensive PROMs Intervention Arm|The intervention group will be asked to complete PROM questionnaires at baseline, 6 months, and 12 months via an online web-based delivery system. The treating neurologist will be prompted to view the text response to the 3-item prompt in addition to the PROM questionnaire scores for participants in the interventional group. Treating neurologist will also be alerted if participates reach certain critical threshold scores or decrement on their PROM questionnaires. Participants randomized to the intervention group will be asked to complete CSQ and CollaboRATE questionnaires at baseline and at 12 months.
62821884|NCT04979546|ACTIVE_COMPARATOR|Control Arm|The control group will be asked to complete PROM questionnaires at baseline and 12 months via an online web-based delivery system. The treating neurologist will only be prompted to view the text response to the 3-item prompt, and will not be able to access the PROM questionnaire scores for participants in the control group (unless critical values are reached on questionnaires - see below). Treating neurologist will also be alerted if participates reach certain critical threshold scores or decrement on their PROM questionnaires. Participants randomized to the intervention group will be asked to complete CSQ and CollaboRATE questionnaires at baseline and at 12 months.
62821885|NCT05662462|ACTIVE_COMPARATOR|ACHIEVE Intervention|The intervention includes a multi-component, including a mobile health (mHealth) application (app), provider dashboard, DEXCOM continuous glucose monitoring (CGM), and care team coaching for medical and social needs. The intervention group will also receive standard of care as described below.
62821886|NCT05662462|NO_INTERVENTION|Standard of care|Standard of care includes prenatal visits, self-monitored blood glucose, and certified diabetes care and education specialist support.
62821887|NCT06594120||3-week work-specific rehabilitation|This group is referred to the work-specific rehabilitation programme immediately upon arrival at the rehabilitation centre.
62821888|NCT06594120||4-week work-specific rehabilitation|This group first underwent a three-week medical-focused rehabilitation programme prior to commencing the work-specific rehabilitation programme.
62821889|NCT04151212|EXPERIMENTAL|BAT5906 injection|Single dose escalation starting from 0.3mg. Route of administration: intravitreal injection.
62821890|NCT05901298|EXPERIMENTAL|Mobile Application|"My Breastfeeding Guide mobile nursing application, which was developed based on Dennis' Breastfeeding Self-Efficacy Theory and Pender's Health Promotion Model."
62821891|NCT05901298|NO_INTERVENTION|Standart Care|Standard antenatal and postnatal care from health care providers.
62821892|NCT06603467|ACTIVE_COMPARATOR|group 1|gingival recession will be covered with de-epithelialized free gingival graft harvested without guide
62821893|NCT06603467|ACTIVE_COMPARATOR|group 2|gingival recession will be covered with de-epithelialized free gingival graft harvested with guide
62821894|NCT06585800||1.Undergoing surgery|For participants undergoing surgery, research tissue specimens will be sampled from resected tissue - no additional solid tissue research samples will be removed from patients undergoing surgery. Samples taken from surgery will be either from the margins of the resected specimen, or the specimen itself. However this will be done only with agreement with the clinical team and the histopathologist to ensure that clinical pathology is not affected.
62821895|NCT06585800||2.1. Undergoing Invasive Procedures (Endoscopy)|Endoscopy (oesophagogastroduodenoscopy, small bowel enteroscopy, colonoscopy, sigmoidoscopy, proctoscopy) for suspected gastrointestinal disease e.g. coeliac disease or for surveillance of known conditions/ diseases. For participants undergoing endoscopy as part of their routine clinical care, additional tissue biopsies will be taken for the purpose of this study only in cases where it is safe to do so.
62821896|NCT06585800||2.2. Undergoing Invasive Procedures (Biopsy)|Tissue Biopsies of solid organs. For participants undergoing tissue biopsy as part of their routine clinical care, additional tissue biopsies will be taken for the purpose of this study only in cases where it is safe to do so. For those undergoing high risk biopsies, e.g. liver biopsies, samples for research will only be taken from clinical specimens, i.e. no additional specimens will be taken solely for the purpose of research.
62821897|NCT03733626|ACTIVE_COMPARATOR|ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle Screw System|20 subjects undergoing one or two-level instrumented posterolateral lumbar fusion surgery using ViviGen Cellular Bone Matrix mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system
62821898|NCT03733626|PLACEBO_COMPARATOR|Local Bone Autograft with DePuy Synthes Spinal Pedicle Screw System|20 subjects undergoing open, one or two-level posterolateral lumbar fusion surgery using local autograft mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system.
62041500|NCT06379919|ACTIVE_COMPARATOR|Irrisept irrigation Arm (Group 2)|After deep dissection, and prior to implantation of components, 100 cc of Irrisept solution will be irrigated into the deep wound and progress outward through more superficial planes to the skin. Cultures will then be taken at multiple wound depths and time points.
62041501|NCT05847933|EXPERIMENTAL|cTBS 50 Hz experiment|Active brain stimulation on the temporo-occipital cortex using the cTBS 50 Hz protocol.
62244609|NCT05777720|NO_INTERVENTION|Control|No intervention will be administered in this arm. Investigators will give families a CO2 monitor to measure average CO2 levels in the home. Investigators will provide a link to the basic CDC isolation guidelines which would be part of standard of care. Investigators will test family members at day 0-1 for baseline testing; and again on day 7 for assessing secondary transmission among susceptible contacts.
62244610|NCT05777720|EXPERIMENTAL|Intervention|Families are provided with one filtration fan unit per room in their home (and one for the index case; if the family lives in a studio, they would receive 2 units). Investigators will advise families on ventilation improvements in their home. Investigators will provide an instructional pamphlet that describes how the fans work and the importance of ventilation. Investigators will follow-up on day 3-4 to check in and run through a checklist to ensure the fans are working and ventilation improvements are being attempted. Investigators will give families a CO2 monitor to measure average CO2 levels in the home. Investigators will test family members at day 0-1 for baseline testing; and again on day 7 for assessing secondary transmission among susceptible contacts.
62601085|NCT01829178|PLACEBO_COMPARATOR|Control arm|Placebo 420 mg daily in three divided doses for 65 days as control along with \[cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2\]
62821899|NCT06036745|EXPERIMENTAL|Pembrolizumab + SOX|
62601086|NCT01829178|ACTIVE_COMPARATOR|Exprimental: Silymarin and chemotherapy|silymarin 420 mg daily in three divided doses for 65 days along with standard chemotherapy \[cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2 control
62821900|NCT01999608||Vitamin D deficient patients|Serum 25-OH Vitamin D levels \<20ng/L
62821901|NCT01999608||Vitamin D sufficient patients|Serum 25-OH Vitamin D levels ≥20ng/L
62821902|NCT05734391||inpatients|Individuals in inpatient wards
62821903|NCT04526730|EXPERIMENTAL|Neoadjuvant Treatment|"Neoadjuvant Phase: (3 x 4-week cycles, total 12 weeks): At every cycle, intratumoral tavo-EP will be administered (on Days 1 and 8) concurrently with 480 mg nivolumab IV infusion on Day 8 of each cycle (tavo-EP will be administered prior to nivolumab infusion).~Definitive Surgery Phase: Surgery may be scheduled about 2-4 weeks after the last dose of nivolumab following radiologic and clinical assessment at that point. Pathologic response will be determined by institutional pathologist.~Adjuvant Phase: Adjuvant therapy with nivolumab monotherapy will begin approximately 2-4 weeks following definitive surgery; recovery from surgery is required (Day 1 of Cycle 4 will be determined by the treating investigator once the subject is cleared to initiate systemic therapy). Nivolumab (480 mg IV infusion on Day 1 of each 4-week cycle) will be administered for up to 9 cycles during the Adjuvant phase."
62821904|NCT06590012|EXPERIMENTAL|Tertinat|
62821905|NCT06590012|PLACEBO_COMPARATOR|Placebo|
62821906|NCT03649880|EXPERIMENTAL|Diagnostic (FMISO, PET/MRI or PET/CT)|Participants receive FMISO intravenously (IV). Participants also undergo dynamic PET/computed tomography (CT) or PET/MRI over 120 minutes beginning 1 minute prior to FMISO injection, and static PET/CT or PET/MRI over 20-40 minutes approximately 90 minutes after FMISO injection. Participants then undergo a retest examination within 7 days. Participants may undergo 2 more PET/MRI or PET/CT scans no sooner than every 4 weeks. Supplemental oxygen may be administered to effect MRI signal.
62041502|NCT05847933|SHAM_COMPARATOR|cTBS sham|Sham brain stimulation on the temporo-occipital cortex using the cTBS 50Hz protocol pattern
62601087|NCT01903785|EXPERIMENTAL|Salbutamol|400ug of salbutamol (one single inhalation) will be inhaled 60min prior to the begin of a time trial. Mean power output during the following 10km time trial will be described to 1600ug salbutamol and placebo.
62601088|NCT01903785|PLACEBO_COMPARATOR|Placebo|400ug of placebo (one single inhalation) will be inhaled 60min prior to the begin of a time trial. Mean power output during the following 10km time trial will be described to 400ug and 1600ug salbutamol.
62821907|NCT05468099|EXPERIMENTAL|Orthodontic debonding|
62041503|NCT05847933|ACTIVE_COMPARATOR|cTBS 50Hz active control|Active brain stimulation on the right superior frontal cortex using the cTBS 50 Hz protocol
62041504|NCT05847933|EXPERIMENTAL|High frequency|Active brain stimulation on the temporo-occipital cortex using the 20Hz protocol
62041505|NCT05847933|EXPERIMENTAL|Low frequency|Active brain stimulation on the temporo-occipital cortex using the 1Hz protocol
62041506|NCT05847933|EXPERIMENTAL|cTBS 30Hz|Active brain stimulation on the temporo-occipital cortex using the cTBS 30 Hz protocol.
62601089|NCT00801437||Xalacom treatment|patients with primary glaucoma
62601090|NCT00565916|EXPERIMENTAL|estrogen plus progesterone|Hormone replacement therapy (HRT): estrogen plus progesterone
62041507|NCT05847933|ACTIVE_COMPARATOR|cTBS 30 Hz Active control|Active brain stimulation on the right superior frontal cortex using the cTBS 30 Hz protocol
62041508|NCT05847933|ACTIVE_COMPARATOR|High frequency Active control|Active brain stimulation on the right superior frontal cortex using the 20 Hz online protocol
62041509|NCT05847933|ACTIVE_COMPARATOR|Low frequency Active control|Active brain stimulation on the right superior frontal cortex using the 1 Hz offline protocol
62041510|NCT05847933|SHAM_COMPARATOR|High frequency sham|Brain stimulation on the dominant temporo-occipital cortex using 10% maximum system output (MSO) and 20 Hz online protocol.
62821908|NCT04251715|EXPERIMENTAL|mFOLFIRINOX, Floxuridine-DEX, mFOLFIRI|"Treatment Period 1 - mFOLFIRINOX for 4 cycles (cycle = 14 days) Cycle 1~* Oxaliplatin 85 mg/m2 intravenously (iv) over 2 hours~* Folinic acid 400 mg/m2 iv over 2 hours~* Irinotecan 165 mg/m2 iv over 90 minutes~* Fluorouracil 400 mg/m2 iv bolus after folinic acid~* Fluorouracil 2,400 mg/m2 continuous infusion over 46 hours~Dosages on Cycle 2, 3, and 4 will be reduced by 25% Treatment Period 2 - HAI delivery of floxuridine + mFOLFIRI for 2 cycles (cycle = 28 days)~* Floxuridine-DEX (with heparin and saline) - 0.12 mg/kg/day; via HAI pump, adjusted for weight and flow rate~mFOLFIRI on Day 15~* Irinotecan 180 mg/m2 iv over 30 minutes to 1 hour~* Folinic acid 400mg/m2 iv over 30 minutes to 1 hour~* 5-FU 1000 mg/m2 continuous infusion over 46 hours"
62041511|NCT04278287|EXPERIMENTAL|Albumin-Bound Paclitaxel and Cisplatin based chemoradiotherapy|Chemoradiotherapy arm receives intensity-modulated radiation therapy, volume modulated arc therapy or tomotherapy concurrently with albumin-bound paclitaxel and cisplatin (weekly intravenous infusion in 5-6 weeks).
62041512|NCT03042065|EXPERIMENTAL|vibrating Mesh nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer
62041513|NCT03042065|ACTIVE_COMPARATOR|jet nebulizer|Receive, in the same aerosol solution, 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using a jet nebulizer
62041514|NCT02071173|EXPERIMENTAL|Enrolled Patients|Subjects undergo an implant procedure to receive at least one investigational lead -- ACUITY X4 left ventricular (LV) CRT lead, RELIANCE 4-FRONT right ventricular (RV) ICD lead
62041515|NCT03854071|OTHER|Group 1|Heart failure patients with preserved ejection fraction
62041516|NCT03854071|OTHER|Group 2|Heart failure patients with reserved ejection fraction
62041517|NCT03854071|OTHER|Group 3|Patients with pulmonary hypertension
62041518|NCT03854071|OTHER|Group 4|Patients with acute myocardial infarction
62041519|NCT03854071|OTHER|Group 5|Patients with suspected but not treated coronary artery disease
62244611|NCT00376181|EXPERIMENTAL|Pioglitazone 45 mg/Azilsartan 20 mg QD|
62821909|NCT04057144|EXPERIMENTAL|ACT with mindfulness|4-hour weekly session of acceptance and commitment therapy (ACT) with mindfulness exercises during 8 weeks in groups of 8
62821910|NCT04057144|EXPERIMENTAL|ACT without mindfulness|4-hour weekly acceptance and commitment therapy (ACT) without mindfulness exercises during 8 weeks in groups of 8
62601091|NCT00565916|ACTIVE_COMPARATOR|estrogen plus placebo|Hormone replacement therapy (HRT): estrogen plus placebo
62601092|NCT02522013|EXPERIMENTAL|Aminophylline group|IV injection of aminophylline
62601093|NCT02522013|PLACEBO_COMPARATOR|isotonic saline group|IV injection of isotonic saline group
62041520|NCT03854071|OTHER|Group 6|Healthy Volunteers
62821911|NCT04057144|ACTIVE_COMPARATOR|Education program|Self-management education program during 8 weeks in groups of 8.
62821912|NCT04434768|EXPERIMENTAL|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of stroke.
62041521|NCT04881201|OTHER|Patients Charcot-Marie-Tooth|
62041522|NCT04881201|OTHER|Control subjects|
62041523|NCT02301702|EXPERIMENTAL|Tdap Vaccine|Combination Tetnus Toxoid, Reduced Diptheria Toxoid and Acellular Pertusis (Tdap)
62041524|NCT02301702|ACTIVE_COMPARATOR|Td Vaccine|Tetanus toxoid and reduced diphtheria toxoid vaccine (Td)
62244612|NCT00376181|EXPERIMENTAL|Pioglitazone 45 mg/Azilsartan 40 mg QD|
62244613|NCT00376181|ACTIVE_COMPARATOR|Pioglitazone 45 mg QD|
62244614|NCT05012982|EXPERIMENTAL|AirBand followed by uninflated AirBand|The order of study days will be randomized. participants will wear an uninflated AirBand as the control intervention during the session in which BFR is not performed,
62244615|NCT05012982|EXPERIMENTAL|Uninflated Airbnd followed by AirBand|The order of study days will be randomized. participants will wear an uninflated AirBand as the control intervention during the session in which BFR is not performed,
62244616|NCT05477953||Pregnant women exposed to nifurtimox|The study will examine the effects of nifurtimox on fetuses, neonates and infants through 12 months of age who were exposed to nifurtimox in utero and maternal complications of pregnancy in women who were exposed to at least one dose of nifurtimox during pregnancy.
62821913|NCT04910048|ACTIVE_COMPARATOR|Standard of Care|The first arm consists of UAMS standard of care (SOC), including providing a brochure with information (contact information, brief educational information) for the patient to consult with a nutritionist to help with self-directed weight loss.
62601094|NCT05648175|EXPERIMENTAL|Artificial Intelligence Allocation|"Allocation of treatment intensity by the proposed AI algorithm will be based on the machine learning and natural language processing (NLP) of textual data provided by participants and their PHQ-9 score collected through a pre-treatment screening module called the Triage Module. This module, developed by the research team, (1) provides psychoeducation on the effects of psychotherapy, (2) collects PHQ-9 scores, and (3) asks participants six open-ended questions regarding their mental health history, their experiences with mental health disorders, and what mental health difficulties they are currently facing. Based on the participant's answers to the open-ended questions, a variable called Symptomatic Score will be calculated using the NLP algorithm."
62601095|NCT05648175|ACTIVE_COMPARATOR|Healthcare Team Allocation|"Allocation of treatment intensity by the multi-professional healthcare team will be based on the following criteria:~1. The severity of MDD symptoms (using DSM-5 criteria).~2. Mental health factors (prior treatments and responses, current and past psychotic/manic episodes, current and past suicidal/homicidal ideation/attempts, family mental health history, past psychiatric history, and hospital admissions).~3. Medical factors (current medical conditions and medications, personal and family medical history).~4. Social factors (support system and living situation, and occupational, social, and personal functional impairment)."
62041525|NCT04538326|OTHER|Single|Participants exercised in two counter balanced blocks: repeated (standard of care and self-paced repeated custom game) and random (Kinect game and game-paced random custom game). Exercise bouts were for 8.5 minutes with ten minutes of rest in between so they could return to physiological baseline. Data were collected in a single session lasting two hours.
62041526|NCT06351358|EXPERIMENTAL|Sculptra and Restylane Treatment Group|Subjects in the treatment group will receive the intervention with Sculptra and Restylane Lyft or Restylane Contour.
62041527|NCT06637371|EXPERIMENTAL|Part A: Single Ascending Dose (SAD)|Healthy participants will be randomized in a 3:1 ratio to receive either AMG 691 or placebo.
62041528|NCT06637371|EXPERIMENTAL|Part B: Multiple Ascending Dose (MAD)|Healthy participants will be randomized in a 3:1 ratio to receive either AMG 691 or placebo.
62041529|NCT06637371|EXPERIMENTAL|Part C: Multiple Dose|Participants with mild-to-moderate asthma will be randomized in a 2:1 ratio to receive either AMG 691 or placebo.
62601096|NCT06272045|EXPERIMENTAL|ENRICHed home visiting|Home Visiting with the addition of cardiovascular health promotion content
62601097|NCT06272045|ACTIVE_COMPARATOR|Usual Home Visiting|Usual home visiting without cardiovascular health promotion content
62601098|NCT05454540|ACTIVE_COMPARATOR|TRANSCRANIAL MAGNETIC STIMULATION|repetitive TRANSCRANIAL MAGNETIC STIMULATION (rTMS) will be applied over the precuneus. The rTMS treatment will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day at 20 Hz for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 50 weeks (80.000 pulses)
62601099|NCT05454540|SHAM_COMPARATOR|SHAM TRANSCRANIAL MAGNETIC STIMULATION|SHAM TMS will be applied over the precuneus. The sham rTMS treatment will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day at 20 Hz for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 50 weeks (80.000 pulses)
62601100|NCT04516382|EXPERIMENTAL|Intravenous|PTG-300 Intravenous
62821914|NCT04910048|EXPERIMENTAL|Intervention (POPOP)|The second arm is a specified 2-month POPOP focused on weight loss administered by the external partner, 20Lighter. The program includes customized meal plans; vitamin, mineral and nutritional supplementation; and daily engagement via a smartphone app with a 20Lighter health care provider. Video conferencing appointments will occur approximately every 3 weeks. The program does not require any exercise or physical engagement but does necessitate that patients have a smartphone or tablet with Bluetooth capability, cell signal or WIFI connection. During the first 40 days the customized meal plans are adhered to, then from days 41-60 patients will transition back to a normal dietary lifestyle via a customized plan based on considerations including, food preferences, physical engagement and height. Patients who achieve a BMI below 40.0 before the end of the 60 day program may be seen sooner than 90d for follow-up appointment in the UAMS clinic.
62821915|NCT06498583|EXPERIMENTAL|E group|
62821916|NCT06498583|EXPERIMENTAL|P group|
62821917|NCT06602700|EXPERIMENTAL|HIIT intervention|
62041530|NCT03954782|EXPERIMENTAL|Nintedanib|Oral treatment of Nintedanib 150 mg soft capsule
62821918|NCT06602700|EXPERIMENTAL|MICT intervention|
62821919|NCT06602700|NO_INTERVENTION|Rest control|
62821920|NCT03679923|EXPERIMENTAL|NEM® brand eggshell membrane|NEM, 500 mg, #0 capsule, once daily orally for 2 weeks
62821921|NCT03679923|PLACEBO_COMPARATOR|Placebo|Placebo, 500 mg, #0 capsule, once daily orally for 2 weeks
62821922|NCT04892823||Supportive care (EAR, questionnaires, biospecimen collection)|Participants will complete comprehensive assessments of social processes at 100 days and 1 year after HCT that combine reports of social support, strain, and isolation with a naturalistic observation tool, the Electronically Activated Recorder (EAR), which captures ambient sound bites to assess social interactions in survivors' daily lives. At each time point, participants will also provide reports of symptoms to characterize phenotypic aging, including cognitive, physical, and functional complaints, and blood samples to assess biological aging, including cellular senescence, DNA damage, SASP, and cellular stress using genome wide RNA sequencing. Relevant clinical information that could influence biological aging will also be collected from patients' medical records to consider as covariates.
62821923|NCT00520949|EXPERIMENTAL|Quadruple Therapy|
62821924|NCT06598345|EXPERIMENTAL|Pet Fish with Integrated Diabetes Care + Collaborative Communication|Participants will receive specific instructions for coupling daily and weekly fish care and diabetes care throughout the 12-week intervention and how to conduct weekly collaborative communication meetings.
62821925|NCT06598345|ACTIVE_COMPARATOR|Pet Fish with Integrated Diabetes Care Only|Participants in the Pet Fish with Integrated Diabetes Care Only Group will be provided specific instructions for coupling the fish care and diabetes care throughout the 12-week intervention.
62821926|NCT06598345|NO_INTERVENTION|Control|Participants in the Control Group will be told to monitor BG (blood glucose) four times daily, review BG readings with their parent weekly and document on their device's software.
62821927|NCT06598098|EXPERIMENTAL|Aerobic Exercise (AE)|All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data. The AE group will exercise on aerobic machines (i.e. treadmill, elliptical, bicycle) for all of their sessions.
62821928|NCT06598098|EXPERIMENTAL|Resistance Exercise (RE)|All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data. The RE group will perform 12-15 repetitions of 10-12 resistance exercises in a circuit, for 3 sets with rest period of 30-60 seconds between sets as needed.\[100\] Seated isokinetic exercise using Cybex machines will target all major muscle groups. Light dumbbells and resistance bands will be used if the participant is unable to lift the minimal load on Cybex machines. Core exercises will be performed at the end of the session (i.e. seated side bends).
62821929|NCT06598098|EXPERIMENTAL|Combination Exercise (AERE)|All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data. The AERE group will switch between AE exercise and RE; for this group, RE exercises will consist of 1 set of 12-15 repetitions of 4 resistance exercises, then 5 minutes of AE, then repeated repeat with different exercises.\[106-108\] The investigators will also calculate the metabolic minutes per week (METmin/wk) of all participants in order to account for potential differences in energy expenditure based on activity, though the dose of 150 min/wk at moderate intensity is held constant between exercise groups.
62821930|NCT06598098|NO_INTERVENTION|Control (no exercise)|The Control group will participate in weekly sessions that focus on stretching, breathing, and healthy lifestyle.
62821931|NCT06598956|ACTIVE_COMPARATOR|Mild Renal Impairment(GFR:60~89 mL/min)|15 mg orally , single dose
62821932|NCT06598956|ACTIVE_COMPARATOR|Moderate Renal Impairment(GFR:30~59 mL/min)|10 mg orally , single dose
62821933|NCT06598956|ACTIVE_COMPARATOR|Severe Renal Impairment(GFR:15~29 mL/min)|5 mg orally , single dose
62821934|NCT06598956|ACTIVE_COMPARATOR|Normal(GFR≥90mL/min)|15 mg orally , single dose
62821935|NCT00626106|ACTIVE_COMPARATOR|Arm A: AMG 479 12 mg/kg IV Q2W + Endocrine Therapy|
62041531|NCT03954782|PLACEBO_COMPARATOR|Placebo|Oral treatment of placebo soft capsule
62041532|NCT05215340|EXPERIMENTAL|Pembrolizumab + Datopotamab Deruxtecan (Dato-DXd)|Participants will be randomized to receive 200 mg pembrolizumab followed by 6.0mg/kg Dato-DXd.
62041533|NCT05215340|ACTIVE_COMPARATOR|Pembrolizumb|Participants will be randomized to receive 200 mg pembrolizumab.
62244617|NCT03745924||Patients with haemophilia B|Patients with haemophilia B without current inhibitors
62821936|NCT00626106|PLACEBO_COMPARATOR|Arm B: placebo IV Q2W + Endocrine Therapy|
62434748|NCT04601064|NO_INTERVENTION|Usual Care (UC)|For patients randomized to the UC referral arm, the patient's HIV provider will receive an electronic alert of the patient's positive screen for a Mental Health and Substance Use Disorder. The patient will not be contacted by the P-CM. The provider, at their discretion, will initiate referral to the psychiatry service available onsite. For patients with Substance Use Disorder, providers refer to the in-clinic Substance Use Disorder treatment program that is managed by a nurse practitioner with Substance Use Disorder care experience. Once referred, the patient is seen by the nurse practitioner (separate from the HIV provider) who manages prescription of and assessment of adherence to buprenorphine, including monitoring of urine toxicology results with support from an addiction counselor. The Bartlett Clinic runs 2 substance use groups weekly and has processes for referral to a higher level of Substance Use Disorder care at offsite Substance Use Disorder treatment programs.
62821937|NCT04586530|EXPERIMENTAL|Memory and Attention Adaptation Training (MAAT)|"A videoconference-delivered cognitive-behavioral therapy (CBT) for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors consisting of 8 weekly 45-minute visits with a survivor workbook, that targets: 1) enhancement of survivor self-awareness of at risk situations where memory failures occur; 2) emotion regulation through modification of survivor causal attributions and negative cognitive appraisals of memory failures; and 3) training in compensatory strategies to improve performance on daily tasks for which memory."
62244618|NCT03148678|EXPERIMENTAL|Mindfulness first; Contingent RT-fMRI-NF|"Participants start with the mindfulness intervention followed by the mind wandering intervention. The arm type experimental refers to contingent RT-fMRI-NF, during which participants are provided with contingent RT-fMRI-NF of their own brain activity."
62244619|NCT03148678|SHAM_COMPARATOR|Mindfulness first; Non-Contingent Neurofeedback|"Participants start with the mindfulness intervention followed by the mind wandering intervention. The arm type sham comparator refers to non-contingent RT-fMRI-NF, during which participants are provided with sham RT-fMRI-NF of brain activity of previously recorded subject."
62244620|NCT03148678|EXPERIMENTAL|Mind wandering first; Contingent Neurofeedback|"Participants start with the mind wandering intervention followed by the mindfulness intervention. The arm type experimental refers to contingent RT-fMRI-NF, during which participants are provided with contingent RT-fMRI-NF of their own brain activity."
62244621|NCT03148678|SHAM_COMPARATOR|Mind wandering first; Non-Contingent Neurofeedback|"Participants start with the mind wandering intervention followed by the mindfulness intervention. The arm type sham comparator refers to non-contingent RT-fMRI-NF, during which participants are provided with sham RT-fMRI-NF of brain activity of previously recorded subject."
62434749|NCT01933828|ACTIVE_COMPARATOR|OPEN lobectomy|Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
62434750|NCT01933828|ACTIVE_COMPARATOR|VATS lobectomy|Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
62434751|NCT01933828|OTHER|ROBOT-assisted lobectomy|Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
62434752|NCT01663714|EXPERIMENTAL|open-label, single arm|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. CVP will be repeated every 21 days for a total of six cycles. tositumomab and iodine I 131 tositumomab will begin within 56 days following the first day of the sixth cycle of CVP. Patient will undergo two dosing phase for the tositumomab and iodine I 131 tositumomab therapy.
62434753|NCT05547893|NO_INTERVENTION|control group|workshop discussing the clinical ethical case scenario
62434754|NCT05547893|EXPERIMENTAL|Intervention group|a simulated clinical ethical situation with simulation patients
62434755|NCT05178589|NO_INTERVENTION|Control|During the control condition cycle (no TENS), participants will refrain from using or taking other analgesics, besides ibuprofen.
62434756|NCT05178589|EXPERIMENTAL|One Unit TENS|Participants will use one-unit TENS set-up where the TENS unit has 2 channels.
62434757|NCT05178589|EXPERIMENTAL|Two Unit TENS|Participants will use a two-unit TENS set-up where the TENS unit has 4 channels.
62434758|NCT00789178||patients with fibromyalgia|
62434759|NCT00789178||patients with active RA|
62244622|NCT03695315||OSA with hypoxia|People with obstructive sleep apnea and hypoxia before and after treatment with continuous positive airway pressure
62434760|NCT03330028|EXPERIMENTAL|Hyperthermic Intraperitoneal Chemoperfusion (HIPEC)|Participants receive heated Mitomycin, Cisplatin, and Paclitaxel as a liquid that is injected through 3 to 4 small incisions into the abdomen over about 1 hour.
62434761|NCT02713503||Healthy Drivers|Driving Observation and VisionCoach
62601101|NCT04516382|EXPERIMENTAL|Subcutaneous Low Concentration|PTG-300 Subcutaneous Low Concentration
62601102|NCT04516382|EXPERIMENTAL|Subcutaneous High Concentration|PTG-300 Subcutaneous High Concentration
62601103|NCT04516382|EXPERIMENTAL|Intramuscular|PTG-300 Intramuscular
62244623|NCT03695315||OSA without hypoxia|People with obstructive sleep apnea and without hypoxia before and after treatment with continuous positive airway pressure
62821938|NCT04586530|ACTIVE_COMPARATOR|Supportive Therapy (ST)|"Standard attention control condition therapy for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors consisting of 8, 45-minutes visits. ST, emphasizes non-specific psychotherapeutic factors of clinician-participant alliance: empathy, support and warmth. ST will be directed at concerns with cancer survivorship and CRCD. Clinicians will set expectations with ST participants that they will be provided validation of experience, support, and encouragement of building their own coping resources if asked directly about what to do about cognitive problems. ST emphasizes reflective listening to help deepen knowledge of the emotional experience of the participant."
62041534|NCT05891002||Biopsy Patient|Patient with a confirmed intracranial neoplasm scheduled for a biopsy with Cirq® Robotic Alignment Module Cranial and registration via Auto-Registration Software Universal Automatic Image Registration Cranial and Loop-X® Mobile Imaging Robot.
62041535|NCT05594979|EXPERIMENTAL|TOTUM-070|Experimental active diet supplement TOTUM-070 taken 2 times per day
62601104|NCT01595958|EXPERIMENTAL|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
62434762|NCT01265966||Moderate Sedation|Children undergoing moderate sedation for procedures.
62821939|NCT06527469||PhysZou emPOWER|Strength, power, and gait-based intervention for kids with cerebral palsy is embedded within a curricular pro-bono student physical therapy clinic. The group will meet for 2 hours, 2 times per week for 15 weeks.
62821940|NCT06091163|EXPERIMENTAL|Ketogenic Diet (KD)|Participants allocated to this condition will receive 6-weeks of home-delivered pre-prepared ketogenic diet (KD) meals (3 meals/day, snacks) from a vetted ketogenic diet food supplier. The 6-week intervention includes a weekly 30-minute dietary counselling call with a registered dietitian to support following a ketogenic diet. Participants receive educational materials with information about foods that are compatible with the diet, common symptoms and how to manage them, and strategies to help maintain the diet during and after the 6-week intervention period.
62821941|NCT06091163|PLACEBO_COMPARATOR|Phytonutrient Diet (PD)|Participants in the control group will receive weekly 30-minute dietary counselling with a registered dietitian and be asked to increase vegetable consumption and reduce saturated fat intake as part of a phytonutrient diet (PD). Participants will receive food vouchers every 2-weeks to help purchase food items or replacements that support high vegetable, low saturated fat intake. This aims to be a plausible placebo dietary treatment for depression. There is no clear evidence that these manipulations will change depression severity. The dietitian will provide materials to explain the diet and suggest foods by colour with supporting recipe suggestions.
62821942|NCT03792633|EXPERIMENTAL|Newly Diagnosed VHR B-ALL or High-Risk Relapse of B|
62821943|NCT03792633|EXPERIMENTAL|Poor Response to Prior B Cell Directed Engineered cell therapy|
62821944|NCT04347798||Inflammatory arthritis patients on biologic + anti-malarial|Patients in northern Alberta receiving hydroxychloroquine or chloroquine +/- other disease modifying anti-rheumatic drug + biologic (anti-TNF inhibitor or anti-IL-6 blocker or B-cell depletor or JAK kinase inhibitor or T-cell c-stimulation inhibitor or IL-17 blocker)
62821945|NCT04347798||Inflammatory arthritis patients on biologic + NO anti-malarial|Patients in northern Alberta receiving a biologic (anti-TNF inhibitor or anti-IL-6 blocker or B-cell depletor or JAK kinase inhibitor or T-cell c-stimulation inhibitor or IL-17 blocker) +/- any disease modifying anti-rheumatic drug except for anti-malarials (hydroxychloroquine or chloroquine)
62821946|NCT03025282|EXPERIMENTAL|CD10367 3% Solution - Non-desquamated zone|
62821947|NCT03025282|EXPERIMENTAL|CD10367 1% Solution - Non-desquamated zone|
62821948|NCT03025282|PLACEBO_COMPARATOR|CD10367 solution placebo - Non-desquamated zone|CD10367 solution placebo serves as negative control.
62041536|NCT00318357||CRT in CARE-HF|"In the CARE-HF study patients treated with standard medical treatment plus CRT were compared to patients treated with standard medical treatment. In the CARE-HF Long Term Follow-up part, all patients received CRT therapy on top of Optimal Medical Treatment. The CARE-HF LTFU study aims to further investigate mortality.~CARE-HF LTFU study continued ot follow up the original CARE-HF CRT group patients."
62041537|NCT00318357||Control in CARE-HF|"In the CARE-HF study patients treated with standard medical treatment. In the CARE-HF Long Term Follow-up part, almost all patients received CRT therapy on top of Optimal Medical Treatment. The CARE-HF LTFU study aims to further investigate mortality.~CARE-HF LTFU study continued to follow up the original CARE-HF control group patients."
62434763|NCT01265966||Deep Sedation|Children undergoing deep sedation for procedures.
62434764|NCT01052805||harvest nerve|harvest nerve from cadaveric donor and patients receiving nerve graft operation
62434765|NCT06526845|EXPERIMENTAL|Telerehabilitation Group|All exercises in the brochure will be performed by patients via telerehabilitation.It will be applied twice a week for 6 weeks.
62601105|NCT01595958|ACTIVE_COMPARATOR|Control|usual care of cardiac arrest
62601106|NCT03035435||study group|fast-track rehabilitation
62601107|NCT03035435||control group|standard care rehabilitation
62821949|NCT03025282|ACTIVE_COMPARATOR|Betneval ointment - Non-desquamated zone|This comparator containing Betamethasone valerate 0.1% serves as positive control.
62821950|NCT03025282|EXPERIMENTAL|CD10367 3% Solution - Desquamated zone|
62821951|NCT03025282|PLACEBO_COMPARATOR|CD10367 solution placebo - Desquamated zone|
62821952|NCT06594549||Staff|NUS Staff
62821953|NCT03657628|EXPERIMENTAL|Physical activity|"* The exercise intervention will consist of a supervised, moderate-intensity aerobic exercise program.~* Will receive social/behavioral support~* Will receive research staff contact time to encourage them to increase their physical activity level~* The participants will be given the option of a third supervised session each week"
62821954|NCT02740946|EXPERIMENTAL|Exercise therapy|Exercise therapy 5 months
62041538|NCT01297959|EXPERIMENTAL|E-101 Solution 300 GU/mL|Participants will receive E-101 Solution at porcine myeloperoxidase (pMPO) concentration of 300 guaiacol units per milliliter (GU/mL) applied topically twice to surgical wound site. The first topical application will occur just after incision to the level of the rectus fascia or linea alba without penetration through the peritoneum and the second topical application will occur just after closure of the rectus fascia or linea alba but prior to closure of the incisional wound.
62041539|NCT01297959|PLACEBO_COMPARATOR|Placebo (Saline solution)|Participants will receive placebo (saline solution) matched to E-101 Solution applied topically twice to surgical wound site. The first topical application will occur just after incision to the level of the rectus fascia or linea alba without penetration through the peritoneum and the second topical application will occur just after closure of the rectus fascia or linea alba but prior to closure of the incisional wound.
62041540|NCT02200731|EXPERIMENTAL|FAMOS: psychosocial family intervention|The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience.
62041541|NCT02200731|NO_INTERVENTION|Control|In Denmark, standard care after treatment does not include systematic psychosocial support. Families are able to seek support on their own or contact a support group offered by the Danish Cancer Society. However support specializing the families with childhood cancer survivors and their siblings after ending medial treatment is limited.
62041542|NCT06732375|EXPERIMENTAL|Interventional arm|Study participation will involve attending 8 weekly, one hour, live online group sessions and completing daily 5 minute activities such as guided imageries and CBT (cognitive behavioral therapy) check-in within the app.
62041543|NCT02968784|EXPERIMENTAL|ExAblate MRgFUS|"Up to 50% of the prostate gland will be treated. Treatment will include the Index lesion which is visible on MRI + tumor free margins of 3-mm; tumor free margins will not extend beyond the posterior aspect of the prostate capsule.~Urethral and bilateral neurovascular bundle preservation will be preferred whenever clinically justified.~Additional foci in the same hemisphere that are confirmed by biopsy and are \< Gleason Score 7 (up to 3+4 or 4+3) or suspected to be positive for malignancy based on multi parametric-MRI) will also be included in the treated volume, providing total treatment volume does not exceed 50% of the gland."
62041544|NCT05415813|ACTIVE_COMPARATOR|Ischemic Compression|Ischemic Compression will be applied to the upper trapezius trigger points in patients recruited in group 1.
62041545|NCT05415813|EXPERIMENTAL|Ischemic compression and Muscle Energy Technique|ischemic compression along with muscle energy technique will be applied to the upper trapezius trigger points in patients allocated to group 2.
62434766|NCT06526845|ACTIVE_COMPARATOR|Home-Based Exercise Group|Patient education will be provided by showing all the exercises in practice. Then, brochures will be given to the patients so that they can practice them at home.It will be applied twice a week for 6 weeks.
62601108|NCT03912818|EXPERIMENTAL|Cohort II (durvalumab, cis-gem)|Durvalumab (MEDI4736), at 1500 mg fixed dose, administered intravenously (IV) over 60 minutes. Standard chemotherapy will be administered as an IV infusion during each of the 4 cycles. Cisplatin 70 mg/m2 on Cycle Day 2, and gemcitabine 1,000 mg/m2 on Cycle Day 1 and Day 8 in 21 day cycles (3 weeks). Patients undergo cystectomy within 6 weeks.
62601109|NCT03912818|EXPERIMENTAL|Cohort III (Durvalumab, carbo-gem)|Durvalumab (MEDI4736), at 1500 mg fixed dose, administered intravenously (IV) over 60 minutes. Standard chemotherapy will be administered as an IV infusion during each of the 4 cycles. Carboplatin: AUC 5 on Cycle Day 1 and gemcitabine 1,000 mg/m2 on Cycle Day 1 and Day 8 in 21 day cycles (3 weeks). Patients undergo cystectomy within 6 weeks.
62041546|NCT01055821|ACTIVE_COMPARATOR|Arm A|Standard of care (SOC)
62041547|NCT01055821|EXPERIMENTAL|Arm B|Vaccine and Standard of care
62041548|NCT01055821|EXPERIMENTAL|Arm C|vaccine and standard of care
62041549|NCT04914611||HBsAg Positive|Patients with chronic hepatitis B infection as defined by HBV surface antigen positive
62041550|NCT05901545|EXPERIMENTAL|Diagnostic (panitumumab, 111In-panitumumab, SPECT/CT, surgery)|Patients receive loading dose of panitumumab IV over 15 minutes followed by 111In-panitumumab IV bolus on day 0. Patients then undergo SPECT/CT scan between day 1 and day of standard of care surgery (up to day 5). During standard of care surgery, patients receive local injection of optical dye per surgeon's preference and undergo intraoperative and NIR imaging. Patients additionally undergo blood sample collection during screening and ECG during screening, on day 0, and on day 15 if indicated.
62434767|NCT05509322|EXPERIMENTAL|Invitation to fertility consult with subsidy|This group will be invited to purchase a fertility consult, and will be offered a subsidy if they choose to purchase the consult.
62434768|NCT05509322|ACTIVE_COMPARATOR|Invitation to fertility consult without subsidy|This group will be invited to purchase a fertility consult at full price.
62434769|NCT05509322|NO_INTERVENTION|Control (no invitation)|This group will not receive invitations to purchase a fertility consult.
62041551|NCT00912548|EXPERIMENTAL|TAM+OFS(E) group|"Patients should be premenopausal women ,prior to the start of chemotherapy, less than or equal to 45 years of age with oestrogen receptor positive ± progesterone receptor positive who have undergone a primary mass excision, received an neo-/adjuvant chemotherapy ± radiotherapy for their stage I, II or III breast cancer. This arm is ovarian suppression group which have a various starting time of ovarian function suppression after neo-/adjuvant chemotherapy.~Ovarian function suppression will be done by administration of LHRH agonist (ZOLADEXTM) for 2 years. After that, the patients will complete taking tamoxifen 20mg/day for 5 years."
62601110|NCT03912818|EXPERIMENTAL|Cohort I (durvalumab, DD MVAC)|Durvalumab (MEDI4736), at1500 mg fixed dose, administered intravenously (IV) over 60 minutes. Standard chemotherapy will be administered as an IV infusion during each of the 4 cycles. Dose Dense Methotrexate, Vinblastine, Doxorubicin, Cisplatin (DD MVAC), in 14 day cycles (2 weeks), Methotrexate 30 mg/m2 on Cycle Day 1, Vinblastine 3 mg/m2 on Cycle Day 2, Doxorubicin 30 mg/m2 on Cycle Day 2 and Cisplatin 70 mg/m2 on Cycle Day 2. Patients undergo cystectomy within 6 weeks.
62821955|NCT03502928|ACTIVE_COMPARATOR|Conventional Treatment|Motor Control + Manual Therapy
62821956|NCT03502928|EXPERIMENTAL|Experimental Treatment|Motor Control + Manual Therapy + Dry Needling
62041552|NCT00912548|ACTIVE_COMPARATOR|TAM(D) group|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 0, 6, 12, 18 and 24 months since the baseline asTsessment(0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized into the additional ovarian function suppression group or tamoxifen only group. The latter will complete taking tamoxifen 20mg/day for 5 years.
62041553|NCT00912548|NO_INTERVENTION|Permanent postmenopausal(A) group|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. Eligible patients except for premenopausal status at the baseline will be followed up until 2 years after the baseline assessment for evaluating the menopausal status. This group still remains to postmenopausal status and will taking tamoxifen 20mg/day for 5 years if they remain in the study.
62041554|NCT00912548|ACTIVE_COMPARATOR|TAM(B)|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 6, 12, 18 and 24 months since the baseline assessment (0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized into the additional ovarian function suppression group or tamoxifen only group. This group, patients are premenopausal women, they will be randomized into tamoxifen only group, complete taking tamoxifen 20mg/day for 5 years.
62244624|NCT02803853|EXPERIMENTAL|Intervention|The intervention is a multi-level, multi-component intervention designed to increase access to and consumption of healthier foods in Native American Communities. Intervention components will occur at the policy level; food retail outlet level; neighborhood level- schools and worksites, and household level.
62434770|NCT04102228|EXPERIMENTAL|Multi-modality aphasia therapy plus 1Hz rTMS|Participants receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of 1Hz rTMS delivered at 100% of resting motor threshold over the right pars triangularis.
62434771|NCT04102228|SHAM_COMPARATOR|Multi-modality aphasia therapy plus sham rTMS|Participants receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of sham rTMS is achieved using a sham TMS coil which attenuates the magnetic output of the stimulator by 80%.
62601111|NCT00560287|ACTIVE_COMPARATOR|1|Volume assist non-invasive ventilation
62601112|NCT00560287|ACTIVE_COMPARATOR|2|Pressure Assist mode
62601113|NCT06648421||Healthy individuals aged 18 to 80 years old|Healthy individuals aged 18 to 80 years old
62821957|NCT06220643|ACTIVE_COMPARATOR|Echoguide steroid injection without exercise (only education)|received 40mg triamcinolone acetonide 1cc plus 2cc lidocaine (1%) injected into the inflamed subacromial bursa with ultrasound guidance
62821958|NCT06220643|EXPERIMENTAL|Echoguide steroid injection with exercise|experimental group received 40mg triamcinolone acetonide 1cc plus 2cc lidocaine (1%) injected into the inflamed subacromial bursa with ultrasound guidance, and a 12-week elastic band progressive resistance exercise
62821959|NCT04758351||Cases - Patients with chronic cough|Patients referred to secondary care clinic for investigation and treatment for explained chronic cough, refractory chronic cough, and unexplained chronic.
62821960|NCT06503263|EXPERIMENTAL|Maintenance Therapy|Patients were treated by Zanubrutinib plus Lenalidomide as Maintenance Therapy
62821961|NCT06503263|NO_INTERVENTION|No maintenance Therapy|Patients received no maintenance Therapy
62821962|NCT06595576|EXPERIMENTAL|Placebo Cannabis Edibles (0 mg THC)|Participants consume a placebo dose of cannabis edibles (0 mg THC).
62821963|NCT06595576|EXPERIMENTAL|Low Dose Cannabis Edibles (2 mg THC)|Participants consume a low dose of cannabis edibles (2 mg THC).
62601114|NCT02044874|EXPERIMENTAL|APD356 10 mg b.i.d.|APD356 - lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks
62601115|NCT02044874|EXPERIMENTAL|APD356 10 mg q.d.|APD356 - lorcaserin hydrochloride 10 mg tablet administered once daily and one matching placebo tablet administered once daily for 12 weeks
62821964|NCT06595576|EXPERIMENTAL|Medium Dose Cannabis Edibles (10 mg)|Participants consume a medium dose of cannabis edibles (10 mg THC).
62821965|NCT06595576|EXPERIMENTAL|High Dose Cannabis Edibles (20 mg)|Participants consume a high dose of cannabis edibles (20 mg THC).
62821966|NCT04139330|EXPERIMENTAL|NPC-06 (high dose)|Infuse diluted NPC-06 18mg/kg solution with 3 to 4 times volume of saline. Administarate NPC-06 gradually (slowly) over 18 minutes.
62821967|NCT04139330|EXPERIMENTAL|NPC-06 (low dose)|Infuse diluted NPC-06 12mg/kg solution with 3 to 4 times volume of saline. Administarate NPC-06 gradually (slowly) over 12 minutes
62821968|NCT04139330|PLACEBO_COMPARATOR|NPC-06 (placebo)|Infuse NPC-06 (placebo) over 12 minutes or 18 minutes
62821969|NCT05998018|EXPERIMENTAL|pdSTIM System Therapy|
62821970|NCT05998018|NO_INTERVENTION|Standard of Care|
62821971|NCT05562791|EXPERIMENTAL|Patients with metastatic urothelial carcinoma lesions|Patients will initially undergo a standard of care FDG PET with diagnostic CT scan followed by an investigational 68Ga PSMA PET/CT scan.
62821972|NCT05562791|EXPERIMENTAL|Patients with melanoma lesions|Patients with melanoma who have 1 or more radiographically assessable metastatic lesions on standard of care imaging will undergo a 68Gallium PSMA-PET/CT and standard of care imaging (either FDG PET or CT scan).
62821973|NCT06474767|EXPERIMENTAL|Pediatric Collaborative Goal Setting Participant|Participants will receive pediatric collaborative goal setting (P-CGS) intervention one to three days prior to the child's identified well visit and will be asked to complete it before or at the time of the visit. Participants will identify 1 goal for the child's health and the parent's own health, covering both medical and social domains. Participants will then be prompted to share the content with the child's provider when asked about the parent's priorities during the child's visit. One week and two months after the child's well visit where pediatric collaborative goal setting was used, participants will complete follow up surveys.
62821974|NCT05123001|EXPERIMENTAL|Device physiological monitoring|Patients will receive wearable sensor devices (Biostrap arm band)
62821975|NCT05123001|NO_INTERVENTION|Microsampling|Blood microsamples will be collected at start of conditioning chemotherapy, daily while in the hospital, and after leaving the hospital and outpatient appointments.
62821976|NCT05123001|NO_INTERVENTION|Biostrap mobile App|Data collection from wearable sensor.
62821977|NCT02764385|OTHER|AAC only|This is a system-based intervention that involves changes in the EHR regarding documenting tobacco assessment and the capability to order an eReferral to the Quitline. This system-based intervention also changes the role of the medical technical assistant.
62821978|NCT02764385|OTHER|AAC + TMCP|The Teachable Moment Communication Process is a clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
62821979|NCT03736863|EXPERIMENTAL|CohortA：Apatinib+SHR-1210（Camrelizumab）|Apatinib+SHR-1210（Camrelizumab）for ESCC who progressed or were intolerant to first-line systemic chemotherapy
62821980|NCT03736863|EXPERIMENTAL|CohortB：Apatinib+SHR-1210（Camrelizumab）|Apatinib+SHR-1210（Camrelizumab）for ESCC who have failed prior immune checkpoint inhibitor therapies
62821981|NCT03736863|EXPERIMENTAL|CohortC：Apatinib+SHR-1316（Adebrelimab）|Apatinib+SHR-1316（Adebrelimab）for ESCC who have failed prior immune checkpoint inhibitor therapies
62821982|NCT03736863|EXPERIMENTAL|CohortD：SHR-1316（Adebrelimab）+SHR-A2009|SHR-1316 was administered intravenously, 1200mg, Q3W; SHR-A2009 8mg/kg, iv, Q3W, for ESCC who have failed prior immune checkpoint inhibitor therapies.
62821983|NCT06262412|EXPERIMENTAL|Internet-delivered cognitive-behaviour therapy (ICBT)|"A therapist-guided, Internet-delivered cognitive-behaviour therapy (ICBT) programme for children and adolescents with BDD.~Cognitive-behaviour therapy, Exposure and response prevention (ERP)"
62821984|NCT06262412|ACTIVE_COMPARATOR|Internet-delivered relaxation treatment (IRT)|"A therapist-guided, Internet-delivered relaxation treatment (IRT) programme for children and adolescents with BDD.~Relaxation training (deep breathing, progressive muscle relaxation, imagery)"
62821985|NCT05737069|EXPERIMENTAL|Ibuprofen arginine granules 400 mg|Participants will be randomly assigned as per cross-over design to receive one sachet of Ibuprofen arginine granules 400 mg (test product) on day 1 of period 1 and will receive one sachet of Ibuprofen arginine granules 400 mg (Spedifen) (reference product) on day 1 of period 2 with at least 2 days washout period. Participants will be instructed to consume the product orally by dissolving it in 240 mL of warm water.
62821986|NCT05737069|ACTIVE_COMPARATOR|Ibuprofen arginine granules 400 mg (Spedifen)|Participants will be randomly assigned as per cross-over design to receive one sachet of Ibuprofen arginine granules 400 mg (Spedifen) (reference product) on day 1 of period 1 and will receive one sachet of Ibuprofen arginine granules 400 mg (test product) on day 1 of period 2 with at least 2 days washout period. Participants will be instructed to consume the product orally by dissolving it in 240 mL of warm water.
62821987|NCT05941702|EXPERIMENTAL|Intervention|Full session plan of the 8 sessions is uploaded to documents. This arm will consist of weekly 1 hour 1:1 sessions with Trainee Clinical Psychologist doing exercises aimed at improving interoception. Exercises will include tuning into the body under different circumstances e.g., while having a drink, looking at pictures to induce a positive mood state.
62821988|NCT03594513|ACTIVE_COMPARATOR|MCAF+PR+CTG|The partial restoration of the NCCL will be performed prior the surgeries and will be carried out with composite resin.The surgical procedure for root coverage will be carried out by means modified coronally advanced flap and will be performed by starting with oblique incisions in the interdental areas, which continued with the intrasulcular incision at the recession defects.Each surgical papilla will be dissected in a split-thickness and the envelope flap will be raised with a split-full-split thickness in the coronal-apical direction. Additionally, this group will receive the connective tissue graft harvested from the palate on the recessed area before the sutures.Then, the flap will be coronally positioned and sutured to completely cover the graft.
62821989|NCT03594513|EXPERIMENTAL|MCAF+PR+XMD(Mucoderm®)|The partial restoration of the NCCL will be performed prior the surgeries and will be carried out with composite resin.The surgical procedure for root coverage will be carried out by means modified coronally advanced flap and will be performed by starting with oblique incisions in the interdental areas, which continued with the intrasulcular incision at the recession defects.Each surgical papilla will be dissected in a split-thickness and the envelope flap will be raised with a split-full-split thickness in the coronal-apical direction. Additionally, this group will receive a porcine acellular dermal matrix on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
62821990|NCT06016803|EXPERIMENTAL|Subjects having undergone a Cryotherapy for benign cutaneous lesions, warts, or hyperpigmentation|Group applying the tested medical device
62821991|NCT06016803|EXPERIMENTAL|Subjects having undergone a Laser or IPL procedure for dermatological or aesthetical indications|Group applying the tested medical device
62821992|NCT06016803|EXPERIMENTAL|Subjects having undergone a skin lesion excision for which stitches were removed|Group applying the tested medical device
62821993|NCT04369729||Post-Traumatic Headache|Individuals who have post-traumatic headache attributed to mild traumatic brain injury according to ICHD-3 diagnostic criteria
62434772|NCT03295058|EXPERIMENTAL|Non ATG regimen|the first 50% of patients will receive Fludarabine + cyclophosphamide prior to hematopoietic cell transplantation. GVHD Prophylaxis: Cyclosporine A All the patient will do allogenic stem cell transplantation from peripheral blood
62244625|NCT02803853|NO_INTERVENTION|Control|Similar to many community- based public health research programs, the control arm will not receive any intervention components during the initial intervention period. However, after all assessments are completed they will receive a 'delayed intervention' protocol, where the community receives the intervention elements as described in the intervention arm after assessment measures have been completed.
62434773|NCT03295058|EXPERIMENTAL|ATG regimen|the other 50% will receive Cyclophosphamide + ATG prior to hematopoietic cell transplantation. GVHD Prophylaxis: Cyclosporine A All the patient will do allogenic stem cell transplantation from peripheral blood
62601116|NCT02044874|PLACEBO_COMPARATOR|Placebo 10 mg b.i.d|Placebo tablet matching the APD356-lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks
62601117|NCT00638742|EXPERIMENTAL|1|
62244626|NCT00331123|PLACEBO_COMPARATOR|Placebo|Placebo patch
62244627|NCT00331123|EXPERIMENTAL|Testosterone Patch|
62244628|NCT01701674|EXPERIMENTAL|Combination Therapy|The combination of ipilimumab followed by lymphodepletion with chemotherapy, TIL infusion, and high dose IL-2.
62434774|NCT00651547|EXPERIMENTAL|1|
62434775|NCT00651547|ACTIVE_COMPARATOR|2|
62601118|NCT02267135|EXPERIMENTAL|Secukinumab|Eligible patients will receive secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 20 inclusive
62821994|NCT04369729||Healthy Control|Healthy controls will have no history of traumatic brain injury and no history of migraine or other headaches
62821995|NCT02254863|EXPERIMENTAL|Intrathecal administration of DUOC-01|Administration of DUOC-01, given intrathecally, between day 26 and 28 post unrelated cord blood transplant
62434776|NCT00651547|ACTIVE_COMPARATOR|3|
62434777|NCT04133519|ACTIVE_COMPARATOR|Arm 1|Arm 1 is an active behavioral treatment for IBS (Regulora; Gut-Directed Hypnotherapy Software as a Medical Device - SaMD).
62434778|NCT04133519|ACTIVE_COMPARATOR|Arm 2|Arm 2 is a behavioral treatment (MR-1; Muscle Relaxation, Software as a Medical Device - SaMD)
62041555|NCT00912548|EXPERIMENTAL|TAM+OFS (C)|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 6, 12, 18 and 24 months since the baseline assessment (0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized. This group, patients are premenopausal women, they will be randomized into the additional ovarian function suppression group. Ovarian function suppression will be done by administration of LHRH agonist (ZOLADEXTM) for 2 years. Then, Patients will complete taking tamoxifen 20mg/day for 5 years.
62041556|NCT05292625|EXPERIMENTAL|UC-MSC infusion via intravenous route|1.5 x 10\^6 umbilical Cord Mesenchymal Stem Cells per body kg will be infusion via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication
62041557|NCT05292625|EXPERIMENTAL|UC-MSC infusion via intrathecal route|1.5 x 10\^6 umbilical Cord Mesenchymal Stem Cells per body kg will be infusion via the intrathecal at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication
62041558|NCT05292625|OTHER|control arm|standard stroke treatment and rehabilitation therapy
62041559|NCT04526366||The study population|All (full scientific) study designs and publication types written in English and reporting Bland-Altman test results (or other tests suggesting the presence of the required data) between simultaneous, paired, polysomnography (PSG)-derived AND Continuous Positive Airway Pressure (CPAP)-derived data describing sleep disordered breathing.
62434779|NCT04878874|NO_INTERVENTION|No Intervention:hip flexion|hip flexion pre measurement with extension knee will be performed
62821996|NCT05632042|EXPERIMENTAL|lifestyle-modification group|erectile dysfunction (ED) psoriatic men with metabolic syndrome (group = 30 patients) will receive lifestyle changes (12 weeks of low calorie diet and moderate-intensity walking on treadmill, the walking duration will be 40 minutes, the walking will be three times per week)
62821997|NCT05632042|NO_INTERVENTION|control group|erectile dysfunction (ED) psoriatic men with metabolic syndrome (number of the patients will be 30) that will receive no lifestyle changes/modifications.
62821998|NCT06224205|NO_INTERVENTION|Annual Well Visit or any other visit to Primary Care Doctor|Annual Well Visit or any other visit to Primary Care Doctor: This is the usual care arm. Electronic Health Record Data for patients from the clinics randomized to usual care will be collected for comparison with the other 2 arms. Patients from these primary care clinics must have had a visit to their doctor either as an annual well visit (AWV) or any other type of visit. These clinics will not have to do anything for the study but run their business as usual without altering anything.
62821999|NCT06224205|EXPERIMENTAL|Passive Digital Marker (PDM)|Passive Digital Marker (PDM): Electronic Health Record Data from those clinics randomized to PDM will be run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset.
62822000|NCT06224205|ACTIVE_COMPARATOR|Passive Digital Marker (PDM) + Quick Dementia Rating Scale (QDRS)|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
62822001|NCT05035537|EXPERIMENTAL|Group 1 (PGDT)|Group 1(PGDT, intervention group) where minimally invasive continuous CI monitor (Edwards ClearSight) was used to guide a goal directed fluid administration protocol
62822002|NCT05035537|NO_INTERVENTION|Group 2 (control)|Group 2 (control) managed according to local and international best practice guidelines using standard hemodynamic monitoring
62822003|NCT03112681|EXPERIMENTAL|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet Once daily for 16 weeks
62822004|NCT03112681|EXPERIMENTAL|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet Once daily for 16 weeks
62822005|NCT03112681|PLACEBO_COMPARATOR|Placebo|Placebo tablet Once daily for 16 weeks
62822006|NCT05038475||Mild group|"As per the WHO guidelines, the patients were divided into two groups based on disease severity: Mild and Moderately severe.~This was based on the self-reported symptoms experienced by the patients during the infection period (March 2020).~Intervention:~COVID-19 Antibody testing at different time points"
62822007|NCT05038475||Moderately-severe group|"As per the WHO guidelines, the patients were divided into two groups based on disease severity: Mild and Moderately severe.~This was based on the self-reported symptoms experienced by the patients during the infection period (March 2020).~Intervention:~COVID-19 Antibody testing at different time points"
62822008|NCT00834977|EXPERIMENTAL|Amlodipine Benazepril|Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period
62822009|NCT00834977|ACTIVE_COMPARATOR|Lotrel®|Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsules (test) dosed in second period
62041560|NCT06733389||peripheral waveform collection group|"1. Peripheral Venous Pressure Variation~2. Pulse Pressure Variation~3. Pleth Variability Index"
62041561|NCT02899780|EXPERIMENTAL|Ultraviolet arm|This arm will have their dialysis catheters treated with an ultraviolet light emitting optical fiber.
62041562|NCT02934620|EXPERIMENTAL|CSD500 Condom|Receive CSD500 condoms with condom counseling to use them for sexual pleasure.
62434780|NCT04878874|EXPERIMENTAL|Experimental: hip flexion|hip flexion post experimental application measurement with Magnetic tape Application with extension knee will be performed
62434781|NCT04878874|PLACEBO_COMPARATOR|Placebo Comparator: hip flexion|hip flexion post placebo application measurement with kinesiology tape Application with extension knee will be performed
62822010|NCT00400179|ACTIVE_COMPARATOR|A|In Arm A, S-1 25 mg/m² was administered orally BID from Day 1 through Day 21 followed by a recovery period from Days 22 through Day 28. On Day 1, the morning dose of S-1 was administered before cisplatin 75 mg/m2 administration as a 1- to 3-hour IV infusion. This regimen was repeated every 4 weeks. S-1 was administered one hour before or one hour after a meal with a glass of water (approximately 100 mL).
62822011|NCT00400179|ACTIVE_COMPARATOR|B|In Arm B, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion (CIV) over 120 hours (on Days 1 through 5). This regimen was repeated every 4 weeks. 5-FU CIV followed cisplatin infusion on Day 1. All 5-FU used in this study was commercially available product.
62041563|NCT02934620|ACTIVE_COMPARATOR|Standard Condom|Receive the standard condom with condom counseling to use them for pregnancy and disease prevention.
62041564|NCT03721939|EXPERIMENTAL|FLEX Scoring Catheter plus DEB|The target lesion is prepared by the FLEX Scoring Catheter® with a 30° rotation between each passage. Angioplasty is performed during 3 minutes with paclitaxel-coated balloon(s) (PCB), all along the target lesion.
62822012|NCT05700669|EXPERIMENTAL|Dose Escalation|Three dose levels of AsiDNA delivered intravenously weekly in combination with Olaparib
62822013|NCT05700669|EXPERIMENTAL|Dose Expansion: Recurrent Epithelial Ovarian Cancer Cohort|Recommended Phase 2 dose of AsiDNA delivered intravenously weekly in combination with Olaparib
62822014|NCT05700669|EXPERIMENTAL|Dose Expansion: Metastatic Castration-resistant Prostate Cancer Cohort|Recommended Phase 2 dose of AsiDNA delivered intravenously weekly in combination with Olaparib
62822015|NCT05700669|EXPERIMENTAL|Dose Expansion: Recurrent Breast Cancer Cohort|Recommended Phase 2 dose of AsiDNA delivered intravenously weekly in combination with Olaparib
62822016|NCT04576988|EXPERIMENTAL|Sotatercept plus background PAH therapy|Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy
62822017|NCT04576988|PLACEBO_COMPARATOR|Placebo plus background PAH therapy|Placebo administered (SC) every 21 days plus background PAH therapy
62822018|NCT05841186|OTHER|24h group|Pegfilgrastim is administrated 24 hours after completing the chemotherapy in the 24-hour group.
62822019|NCT05841186|OTHER|48h group|Pegfilgrastim is administrated 48hours after completing the chemotherapy in the 48-hour group.
62822020|NCT05841186|OTHER|72h group|Pegfilgrastim is administrated 72 hours after completing the chemotherapy in the 72-hour group.
62822021|NCT05612854|ACTIVE_COMPARATOR|catheter directed therapy group in intermediate risk pulmonary embolism patients|"in this arm, intermediated risk pulmonary embolism patients is treated by intervention in the form of:~* A. Mechanical embolectomy: by hydromechanical defragmentation by pigta~* B. Suction embolectomy: using The Penumbra Indigo aspiration system~* C. Catheter directed thrombolysis:"
62041565|NCT02763800|EXPERIMENTAL|Group 1: BIA 3-202 50 mg/placebo|"Group 1: BIA 3-202 50 mg/placebo on Day 1; BIA 3-202 50 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 50 mg/placebo on Day 9.~50 mg BIA 3-202: 5 x 10 mg BIA 3-202 tablets"
62822022|NCT05612854|ACTIVE_COMPARATOR|medical therapy group in intermediate risk pulmonary embolism patients|in this arm, intermediated risk pulmonary embolism patients is treated by routine anticoagulation only.
62822023|NCT04590885|OTHER|Couple Communication and Support|CCST includes components to assist couples in communicating effectively, decreasing avoidance of important cancer-related issues, and providing each other with support. It includes training in skills for sharing one's thoughts and feelings and listening to one's partner and responding in a supportive manner, and joint problem solving. Participants will be asked to participate inactivities at home between sessions to strengthen skills acquisition.
62822024|NCT04590885|OTHER|Healthy Lifestyle Informaion|Healthy Lifestyle Information provides couples with health information relevant to cancer in a supportive environment. Sessions focus on the following topics: fatigue, sleep disturbance, nutrition, physical activity, survivorship care plans, and palliative care. Patients and partners are invited to discuss their experiences around the session topics with the therapist and ask questions about the information presented.
62822025|NCT03614182|EXPERIMENTAL|physical training concurrent with cognitive training|The physical training concurrent with cognitive training group (the P+C group) will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
62822026|NCT03614182|ACTIVE_COMPARATOR|physical training followed by cognitive training|The physical training followed by cognitive training will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
62041566|NCT02763800|EXPERIMENTAL|Group 2: BIA 3-202 100 mg/placebo|"Group 2: BIA 3-202 100 mg/placebo on Day 1; BIA 3-202 100 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 100 mg/placebo on Day 9.~100 mg BIA 3-202: 1 x 100 mg BIA 3-202 tablet"
62041567|NCT02763800|EXPERIMENTAL|Group 3: BIA 3-202 200 mg/placebo|"Group 3: BIA 3-202 200 mg/placebo on Day 1; BIA 3-202 200 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 200 mg/placebo on Day 9.~200 mg BIA 3-202: 2 x 100 mg BIA 3-202 tablets"
62244629|NCT04565041|EXPERIMENTAL|Social Support|
62822027|NCT03614182|ACTIVE_COMPARATOR|physical training without cognitive training|The physical training without cognitive training group will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
62822028|NCT05569759|EXPERIMENTAL|zetomipzomib + standard-of-care (glucocorticoids)|Initial 30 mg dose of zetomipzomib, followed by weekly 60 mg doses of zetomipzomib, for the remaining 23 weeks of the treatment period.
62822029|NCT05569759|PLACEBO_COMPARATOR|placebo + standard-of-care (glucocorticoids)|Initial 30 mg dose of placebo (sterile water for injection), followed by weekly 60 mg doses of placebo, for the remaining 23 weeks of the treatment period.
62822030|NCT05569759|EXPERIMENTAL|zetomipzomib + standard-of care (glucocorticoids) open-label extension period|Initial 30 mg dose of zetomipzomib at the open-label extension (OLE) Week 1 visit, followed by weekly doses of 60 mg of zetomipzomib, for a total of 24 additional weeks of treatment.
62822031|NCT06570577|ACTIVE_COMPARATOR|Routine Pain Management|Routine Pain Management will include standard of care pharmacological management, by using patient-controlled opioid analgesia, oral acetaminophen, intravenous Ketorolac (Toradol), and Gabapentin. As needed (PRN), Intravenous hydromorphone will be given for breakthrough pain.
62822032|NCT06570577|EXPERIMENTAL|Routine Pain Management plus an Inter-semispinalis Plane Block|"Routine Pain Management, as described above, plus and ISP Block. After general anesthesia has begun, in the operating room, and the patient is moved to the prone position, before surgery start, those patients who are randomized to the block group, will receive a bilateral ISP nerve block in the back of the neck under ultrasound guidance, by a qualified, experienced Anesthesiologist.~Under complete aseptic technique using an ultrasound guidance, 20 ml of Bupivacaine 0.25 % with 2 mg of Dexamethasone will be injected between two muscles in the back of the neck, bilaterally, to block the nerves that run in this plane.~Once the block is completed, the surgical procedure will proceed as usual."
62822033|NCT04323956|EXPERIMENTAL|Arm I (parsaclisib, R-CHOP)|Patients receive parsaclisib PO QD on days 1-10 or 1-14, rituximab IV or biosimilar substitute, cyclophosphamide IV over 30 minutes, doxorubicin hydrochloride IV, and vincristine sulfate IV over 15 minutes on day 1. Patients also receive prednisone PO on days 1-5 and pegfilgrastim SC or biosimilar substitute on day 2. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62601119|NCT02267135|PLACEBO_COMPARATOR|Placebo|Eligible patients will receive placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8. Prior to taking the Week 12 dose, the patient will be assessed for response to treatment using the Psoriasis Scalp Severity Index (PSSI). If the subject is a responder, the subject will continue on placebo dosing weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20. Subjects who are not responders will be switched to treatment with secukinumab 300 mg and will dose once weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20.
62601120|NCT04709419|EXPERIMENTAL|Celliant Sock|"Celliant® Diabetic Medical Socks (Celliant Socks) are intended to provide infrared radiation (IR) to increase tissue oxygen thereby increasing blood flow and circulation in the affected area leading to an effect on wound closure outcomes and possible pain reduction. Celliant® fibers are comprised of a proprietary blend of infrared (IR) emitting ceramic materials mixed with polyethylene terephthalate (PET). The proprietary blend consists of the following components: alumina oxide; silicon dioxide; and titanium dioxide. The Celliant fibers are woven or knitted into yarn and used to manufacture the Celliant Sock. The Celliant Sock content will be 82% Celliant polyester, 13% Nylon and 5% Spandex. Celliant fibers absorb energy (heat) generated by the wearer's body by radiation, convection and conduction, and also from the environment, and re emit the energy as infrared radiation back into the wearer's body."
62601121|NCT04709419|SHAM_COMPARATOR|Control Sock|The Control Sock will be visually identical to the Active Celliant® Sock. The sock will be made of identical materials without the Celliant® components. The Control sock will be 82% standard polyester, 13% Nylon, and 5% Spandex.
62822034|NCT04323956|ACTIVE_COMPARATOR|Arm II (parsaclisib, R-CHOP, polatuzumab vedotin)|Patients receive parsaclisib PO once daily QD on days 1-10 or 1-14, polatuzumab vedotin IV over 90 minutes, rituximab IV or biosimilar substitute, cyclophosphamide IV over 30 minutes, doxorubicin hydrochloride IV, and vincristine sulfate IV over 15 minutes on day 1. Patients also receive prednisone PO on days 1-5 and pegfilgrastim SC or biosimilar substitute on day 2. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62822035|NCT03448926||DCIS|Patients must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast without evidence of invasive cancer (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable)
62822036|NCT03387670|ACTIVE_COMPARATOR|Simvastatin|
62822037|NCT03387670|PLACEBO_COMPARATOR|Placebo|
62244630|NCT06736457|EXPERIMENTAL|Long-bone injuries|Group formed by subjects with long-bone injuries treated using AdvanCore blocks, wedges, or granules.
62822038|NCT06596967|SHAM_COMPARATOR|SHAM|In the sham group, water at 33ºC will be circulated through the leg sleeves.
62434782|NCT05521490|OTHER|Usual Care Control|Children allocated to the control group will continue with their usual curriculum, which includes the stipulated 30 minutes of daily physical activity.
62434783|NCT05521490|EXPERIMENTAL|Physical Activity Enhanced Curriculum|Children allocated to the intervention group will receive enhanced physical fitness and healthy lifestyle education and a physical activity enhanced curriculum during their school year.
62434784|NCT04650607||PHA SA CO|patients having a severe infection treated by injection of phages, with or without surgery
62601122|NCT05912231|EXPERIMENTAL|Accelerated Proton Beam Radiation Therapy (PBT) Group|"Participants will be randomized 1:1 to XRT group and stratified by receipt of chemotherapy and cardiac risk factors and will complete:~* Cardiac MRI and blood tests within 1 month prior to start of radiation therapy.~* Radiation therapy 1x daily for 5 days over 1 week.~* End of radiation therapy visit with blood tests.~* 6 month follow up visit with cardiac MRI, blood tests, questionnaires, and photographic imaging.~* 12 month follow up visit with questionnaires and photographic imaging."
62601123|NCT05912231|EXPERIMENTAL|Accelerated Photon Radiation Therapy (XRT) Group|"Participants will be randomized 1:1 to XRT group and stratified by receipt of chemotherapy and cardiac risk factors and will complete:~* Cardiac MRI and blood tests within 1 month prior to start of radiation therapy.~* Radiation therapy 1x daily for 5 days over 1 week.~* End of radiation therapy visit with blood tests.~* 6 month follow up visit with cardiac MRI, blood tests, questionnaires, and photographic imaging.~* 12 month follow up visit with questionnaires and photographic imaging."
62601124|NCT03114501|EXPERIMENTAL|Yoga Program Group|"Participants take part in the partner-based yoga program.~Questionnaire completed during each week of radiation therapy about participant's feelings about the yoga sessions.~Questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later)."
62822039|NCT06596967|EXPERIMENTAL|HEAT THERAPY|In the leg heat therapy group, water at 42ºC will be circulated through the leg sleeves.
62822040|NCT06589362|ACTIVE_COMPARATOR|Transcutaneous auricular vagus nerve stimulation|Active vagus nerve stimulation.
62434785|NCT04650607||PhageRESPONSE|ancillary study : Establish a biobanking of serums, plasmas and PBMC (Peripheral Blood Mononuclear Cells) of patients who have been treated with phage therapy for a bacterial infection.
62434786|NCT02156349|OTHER|Control Group|Patients treated by usual customary medical practice (Usual Care) in the out-patient facility i.e. Diabetes specialized medical practice, Medical Care Center or hospital outpatient clinic.
62434787|NCT02156349|OTHER|Intervention group|"Patients are treated according to the concept Integrated personalized diabetes management."
62434788|NCT06356870|EXPERIMENTAL|Allograft mixed with BMAC|Allograft mixed with BMAC used for alveolar cleft grafting
62434789|NCT06356870|ACTIVE_COMPARATOR|Anterior iliac crest cancellous bone only|Anterior iliac crest cancellous bone only used for alveolar cleft grafting
62434790|NCT06120881|EXPERIMENTAL|Experimental|1350mg metformin twice per day
62601125|NCT03114501|EXPERIMENTAL|Waitlist Control Group (WLC)|"Participants receive standard of care.~Questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later).~After the study has been completed, participant and caregiver/alternative caregiver offered the opportunity to take part in the partner-based yoga program."
62434791|NCT06120881|ACTIVE_COMPARATOR|Active Comparator|1000mg metformin twice per day
62601126|NCT04875988|ACTIVE_COMPARATOR|POCUS-assisted IV placement|using ultrasound to help with placement
62822041|NCT06589362|SHAM_COMPARATOR|Sham Transcutaneous auricular vagus nerve stimulation|Sham vagus nerve stimulation.
62822042|NCT06437769|EXPERIMENTAL|Reiki|. Reiki therapy will be applied to the participants for 30 minutes while they lie down with their eyes closed. A total of 4 sessions of Reiki application will be applied to the intervention group at the 4th hour, 8th hour, 24th hour and 28th hour after the cesarean section. Reiki application will be applied at the 4th hour after the cesarean section. Comfort, anxiety, depression and breastfeeding symptoms after the 4th session will be recorded.
62822043|NCT06437769|NO_INTERVENTION|control group|will provided with standard midwifery care.
62822044|NCT05374785|EXPERIMENTAL|CPL409116 60mg|60 mg BID of CPL409116
62822045|NCT05374785|EXPERIMENTAL|CPL409116 120mg|120 mg BID of CPL409116
62822046|NCT05374785|EXPERIMENTAL|CPL409116 240mg|240 mg BID of CPL409116
62822047|NCT05374785|PLACEBO_COMPARATOR|Placebo|Placebo
62244631|NCT06736457|EXPERIMENTAL|Spine injuries|Group formed by subjects with spine injuries treated using AdvanCore granules.
62434792|NCT01764854|EXPERIMENTAL|AZD1722- in patient|Tenapanor administered in a clinical pharmacology unit
62434793|NCT01764854|PLACEBO_COMPARATOR|Placebo- in patient|Placebo (size and color matched to experimental drug) administered in a clinical pharmacology unit
62434794|NCT01764854|EXPERIMENTAL|AZD1722 out-patient|Tenapanor
62434795|NCT01764854|EXPERIMENTAL|Placebo out-patient|Placebo
62434796|NCT00630682|ACTIVE_COMPARATOR|Dextroamphetamine|Active drug
62434797|NCT00630682|PLACEBO_COMPARATOR|Placebo|Placebo of drug
62434798|NCT05056337|EXPERIMENTAL|Treatment group|Patients with potentially resectable HCC who meet the study inclusion criteria will be treated with lenvatinib(8mg/d for BW\<60kg and 12mg for BW≥60kg) in combination with toripalimab(240mg iv Q3W) and TACE (on demand). Tumor response will be regularly evaluated, data will be collected, and complete surgical resection will be evaluated by an independent review committee, the conversion resection rate will be calculated, and patient survival will be assessed.
62434799|NCT05056337|ACTIVE_COMPARATOR|Control group|Patients with potentially resectable HCC who meet the study inclusion criteria will be treated with TACE alone. Tumor response will be regularly evaluated, data will be collected, and complete surgical resection will be evaluated by an independent review committee, the translational resection rate will be calculated, and patient survival will be assessed.
62601127|NCT04875988|ACTIVE_COMPARATOR|Traditional IV placement|Standard of care
62601128|NCT06315153||symptomatic group|An ischemic stroke was defined as occurring if the patient developed clinical symptoms related to neurological deficits and/or new infarcted lesions were detected on magnetic resonance imaging, and patients who developed ischemic strokes were classified in the symptomatic group.
62601129|NCT06315153||asymptomatic group|Patients without an ischemic stroke were classified in the asymptomatic group.
62601130|NCT01596153|PLACEBO_COMPARATOR|Placebo|BID
62822048|NCT03012399|EXPERIMENTAL|Group I (hypnosedation)|Patients undergo hypnosedation performed by a mind-body specialist before surgery begins and continuing until after surgery is complete.
62822049|NCT03012399|ACTIVE_COMPARATOR|Group II (verbal support)|Patients speak to a mind-body specialist before surgery and prior to receiving general anesthesia.
62822050|NCT05443295|EXPERIMENTAL|Intervention Group|The intervention group will carry out the MoveUS Program.
62822051|NCT05443295|ACTIVE_COMPARATOR|Control Group|The control group will be subjected to the conventional guidelines in the approach to shoulder instability.
62822052|NCT05018000|ACTIVE_COMPARATOR|Arm 1: Enhanced usual care|Participants in this arm will receive their usual care plus a Financial Resource Sheet. The financial resource sheet lists and describes existing organization and community resources available to KP members.
62822053|NCT05018000|EXPERIMENTAL|Arm 2: Brief financial navigation intervention|Participants in this arm will receive their usual care, and the Financial Resource Sheet described in Arm 1, plus one (1) cycle of financial navigation (total cycles: 1; total length: 6 months). In each intervention cycle participants will get at least one (1) phone call with a CAFÉ Financial Navigator, the navigator will talk with participants to identify financial questions or concerns. The navigator will create a personalized plan for each participant. Participants can request extra support from the navigator for up to 6 months.
62822054|NCT05018000|EXPERIMENTAL|Arm 3: Extended financial navigation intervention|Participants in this arm will receive their usual care, a Financial Resource Sheet and the brief intervention described in Arm 2 (i.e., one (1) cycle of financial navigation). Plus, they will receive two (2) additional cycles of financial navigation (total cycles: 3; total length: 6 months).
62822055|NCT06602661|ACTIVE_COMPARATOR|Fissureless Lobectomy with Non-Reinforced Staple Lines Using ECHELON™ 3000|Arm Description: Participants in the control arm will undergo fissureless lobectomy using the ECHELON™ 3000 stapler without any reinforcement. This intervention involves: Thorough patient assessment and confirmation of eligibility criteria. Informed consent process emphasizing the use of non-reinforced staplers. Standard general anesthesia with double lumen endotracheal tube and patient positioning for lobectomy. Utilization of video-assisted thoracoscopic surgery (VATS). Division of pulmonary artery branches, veins, and bronchus with non-reinforced stapler. Division of lung parenchyma using the ECHELON™ 3000 stapler without reinforcement. Placement of chest tube size 28 Fr for all patients. Standard postoperative monitoring in the recovery room and monitored bed afterward. Implementation of standardized pain management protocols. Regular assessment for air leaks and drainage amount using a digital drainage system (Thopaz). Performing daily chest X-rays (CXR) until tube removal.
62849182|NCT03805659|EXPERIMENTAL|HD-tDCS, then Sham|Subjects receive High Dose transcranial Direct Current Stimulation (HD-tDCS) lasting 20 minutes at an electric current intensity of up to 2mA in the left posterior temporo-parietal cortex (TPC). Stimulation sessions are delivered once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday). After a washout period of 16 weeks, subjects receive Sham sessions (no electric current) once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday).
62041568|NCT02763800|EXPERIMENTAL|Group 4: BIA 3-202 200 mg/placebo|"Group 4: BIA 3-202 200 mg/placebo on Day 1; BIA 3-202 200 mg/placebo t.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 200 mg/placebo on Day 9.~200 mg BIA 3-202: 2 x 100 mg BIA 3-202 tablets"
62434800|NCT05565183|EXPERIMENTAL|Patients with diagnosed Atrial fibrillation and an indication of catheter ablation|
62601131|NCT01596153|ACTIVE_COMPARATOR|Go Live Rx Probiotic|BID
62601132|NCT06623500||Excessive iodine group|Residents with thyroid cancer who have lived in high iodine areas for a long time (5 years or more). According to the report of Shandong Institute of Endemic Disease Prevention and Control, three sub centers were selected in Excessive iodine group (Jining/Liaocheng/Heze).
62601133|NCT06623500||Suitable iodine group|Residents with thyroid cancer who have lived in suitable iodine areas for a long time (5 years or more). According to the report of Shandong Institute of Endemic Disease Prevention and Control, three sub centers were selected in suitable iodine (Jinan/Shenyang/Haerbin) areas.
62601134|NCT06621485||Training cohort|The training cohort was comprised of patients from 9 participating hospitals (First Hospital of Jilin University, Mengchao Hepatobiliary Hospital, the Fourth Hospital of Harbin, Pu'er People's Hospital, Liuyang People's Hospital, Ziyang First People's Hospital, First Affiliated Hospital of Shandong First Medical University \& Shandong Provincial Qianfoshan Hospital, First Affiliated Hospital of Harbin Medical University, and Fuyang People's Hospital).
62822056|NCT06602661|EXPERIMENTAL|Fissureless Lobectomy with Reinforced Staple Lines Using ECHELON™ 3000 and ENDOPATH™ Reinforcement|Participants in the experimental arm will undergo fissureless lobectomy using the ECHELON™ 3000 stapler equipped with the ENDOPATH™ stapler line reinforcement. This intervention involves:Thorough patient assessment and confirmation of eligibility criteria. Informed consent process emphasizing the use of reinforced staplers. Standard general anesthesia with double lumen endotracheal tube and patient positioning for lobectomy. Utilization of video-assisted thoracoscopic surgery (VATS). Division of pulmonary artery branches, veins, and bronchus with non-reinforced stapler. Division of lung parenchyma using the ECHELON™ 3000 stapler with ENDOPATH™ reinforcement. Placement of chest tube size 28 Fr for all patients. Standard postoperative monitoring in the recovery room and monitored bed afterward. Implementation of standardized pain management protocols. Assessment for air leaks and drainage amount using a digital drainage system (Thopaz). Performing daily chest X-rays (CXR) until removal.
62822057|NCT06369142|EXPERIMENTAL|Lesion preparation using coronary intravascular lithotripsy|
62822058|NCT06369142|ACTIVE_COMPARATOR|Lesion preparation using other methods than intravascular lithotripsy|e.g. cutting or super high pressure balloons and/or ablative procedures
62822059|NCT00742612|ACTIVE_COMPARATOR|1|ARC1779 Injection
62822060|NCT00742612|PLACEBO_COMPARATOR|2|Placebo (normal saline)
62434801|NCT03049956|EXPERIMENTAL|Patients with clinical suspicion of ocular myasthenia gravis|
62822061|NCT06590662|EXPERIMENTAL|Solriamfetol|Solriamfetol will be taken once a day upon awakening during 7-weeks
62822062|NCT06590662|PLACEBO_COMPARATOR|Placebo|Placebo will be taken once a day upon awakening during 7-weeks
62822063|NCT04052334|EXPERIMENTAL|Infusion of Tumor-infiltrating lymphocyte|"Participants will undergo tumor resection from which the tumor infiltrating lymphocyte (TIL) product will be generated. All participants will receive nonmyeloablative lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T-cell persistence and effectiveness in vivo. Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS). Fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB). All participants will receive not less than 10\^9, and up to 1x10\^12 T cells in ≥250 mL NS as an inpatient by intravenously (IV).~Eight (8) to sixteen (16) hours after completing the T cell infusion, all participants will receive high-dose interleukin-2 (IL-2) on an inpatient basis at the standard dose of 600 000 IU/kg as an intravenous bolus over an approximate 15-minute period every 8 to 16 hours for up to 15 doses on days 1 to 5, as tolerated."
62822064|NCT02380573|EXPERIMENTAL|Healthy Aging MB|Methylene Blue (USP grade, 282mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
62822065|NCT02380573|PLACEBO_COMPARATOR|Healthy Aging Placebo|Drug: FD\&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
62822066|NCT02380573|EXPERIMENTAL|Mild Cognitive Impairment (MCI) MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
62822067|NCT02380573|PLACEBO_COMPARATOR|Mild Cognitive Impairment (MCI) Placebo|Drug: FD\&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
62822068|NCT02380573|EXPERIMENTAL|Mild Alzheimer's Disease (AD) MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
62822069|NCT02380573|PLACEBO_COMPARATOR|Mild Alzheimer's Disease (AD) Placebo|Drug: FD\&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
62822070|NCT02380573|EXPERIMENTAL|Healthy Middle Age MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
62822071|NCT02380573|PLACEBO_COMPARATOR|Healthy Middle Age Placebo|Drug: FD\&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
62822072|NCT02800538|EXPERIMENTAL|Lauric acid|the nutrient that can be widely found in daily food.
62822073|NCT02800538|EXPERIMENTAL|Palmitic acid|the nutrient that can be widely found in daily food.
62822074|NCT02800538|EXPERIMENTAL|Capric acid|the nutrient that can be widely found in daily food.
62244632|NCT06736457|EXPERIMENTAL|Maxillofacial injuries|Group formed by subjects with maxillofacial injuries treated using AdvanCore granules.
62434802|NCT05214157|EXPERIMENTAL|group A|interventional group, final two operative steps applied
62434803|NCT05214157|NO_INTERVENTION|group B|control group
62822075|NCT02800538|PLACEBO_COMPARATOR|Saline|physiological salt water
62822076|NCT06595082|ACTIVE_COMPARATOR|30 grams Lupin|30 grams per week of lupins in brine
62041569|NCT06701435||1 Degree Cold Compression Group|Cold compression application was performed using Game Ready for 15 minutes. The target temperature was manually set to 1°C and the pressure was set to high compression (75 mm Hg). Since it is known that the applied pressure increases the effect of cold application and oxygenation in the tissue increases as the compression intensity increases (108), it was applied in the high option. Duration was preferred because the optimal range for the duration of cold applications is given as 11-15 minutes in the literature (120). Pneumatic intermittent compression with a standard ∼3-minute cycle was applied to both lower legs using a thigh wrap. The application was performed with the athletes in the supine semi-recumbent position.
62601135|NCT06621485||Validation cohort|The validation cohort consisted of patients from the remaining two hospitals (Beijing Tsinghua Changgung Hospital and Eastern Hepatobiliary Surgery Hospital of Shanghai)
62822077|NCT06595082|EXPERIMENTAL|600 grams Lupin and dietary suggestion|600 grams per week of lupins in brine and dietary suggestion of lowering of two servings per week among meat, processed meat and/or cheese.
62041570|NCT06701435||10 Degree Cold Compression Group|Cold compression application was performed using Game Ready for 15 minutes. The target temperature was manually set to 10°C and the pressure to high compression (75 mm Hg). Pneumatic intermittent compression in a standard ∼3 min cycle was applied to both lower legs using a thigh wrap. The application was performed with the athletes in the supine semi-recumbent position.
62041571|NCT06701435||Passive Rest Control Group|The athletes rested passively in the supine semi-recumbent position for 15 minutes after the training.
62601136|NCT00228319|ACTIVE_COMPARATOR|Standard of Care Group|carboplatin and paclitaxel chemotherapy
62822078|NCT06166654|ACTIVE_COMPARATOR|Acetazolamide|1. 500 mg IV bolus of acetazolamide at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- Metolazone tablet together with each acetazolamide-injection.
62822079|NCT06166654|ACTIVE_COMPARATOR|Metolazone|2.5 mg oral Metolazone at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- acetazolamide injection together with each metolazone-tablet.
62822080|NCT06166654|PLACEBO_COMPARATOR|Placebo|Usual care with loop-diuretics as the sole diuretic (SGLT2-inhibitors allowed) including guideline-recommended increase in loop-diuretic dose and fluid and salt-restriction. This arm will also receive both a placebo-acetazolamide injection together with a placebo-metolazone-tablet at randomization and repeated the next 3 mornings (day 1, day 2 and day 3).
62822081|NCT06593821|EXPERIMENTAL|Control (C)|The control group received only preventive recommendations
62822082|NCT06593821|EXPERIMENTAL|Occlusal splint (O)|Occlusal splint applied to the upper jaw
62822083|NCT06593821|EXPERIMENTAL|Botulinum toxin (B)|Botulinum toxin injection applied
62822084|NCT06593821|EXPERIMENTAL|Occlusal splint and Botulinum toxin (OB)|Both occlusal splint and botulinum toxin were applied
62822085|NCT03096808|EXPERIMENTAL|Adaptive Radiotherapy|Eligible patients will receive IMRT of 60-70Gy in 30-35 once-daily fractions with or without concurrent chemotherapy according to the current standard of care.
62822086|NCT06052761|EXPERIMENTAL|Making Toys from Medical Materials|"The purpose of the study will be explained to the children and their parents before the procedure, and verbal and written consent will be obtained from the parents who agree to participate in the study. Children's anxiety will be evaluated using the Children's State Anxiety Scale (CSA) before and after the procedure (half an hour after the first measurement), based on the statements of both the mother and the child."
62822087|NCT06052761|NO_INTERVENTION|Control group|"The purpose of the study will be explained to the children and their parents before the procedure, and verbal and written consent will be obtained from the parents who agree to participate in the study. No procedures will be performed other than routine procedures performed in the hospital. Children's anxiety will be evaluated based on the statements of both the mother and the child, using the Children's State Anxiety Scale (CSA) after obtaining consent from the parents and half an hour after the first measurement."
62822088|NCT06590207|EXPERIMENTAL|200ml of neutralizing plasma|The plasma of the convalescents: produced in the blood bank of Sheba Medical Center, from the blood of Sheba workers who participated in the SPRI study (Helsinki 0196-23) and whose blood was found to have neutralizing antibodies to WNV (above 1:524). The blood units from the volunteers who will donate will meet all the requirements of a normal blood donation and will only include men or women who were not pregnant, and the units will pass all the tests accepted at the blood bank before donation.
62822089|NCT06590207|PLACEBO_COMPARATOR|Saline|200 ml Saline
62822090|NCT04966013|ACTIVE_COMPARATOR|RD-X19 Device, Dose A|RD-X19. Investigational device that delivers 24 J/cm2 of electromagnetic energy to the oropharynx.
62822091|NCT04966013|ACTIVE_COMPARATOR|RD-X19 Device, Dose B|RD-X19. Investigational device that delivers 32 J/cm2 of electromagnetic energy to the oropharynx.
62822092|NCT04966013|SHAM_COMPARATOR|Sham Device|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro.
62822093|NCT05159830|EXPERIMENTAL|Cannabidiol (CBD)|CBD Group from 20mg x 2/day up to 600mg/day
62434804|NCT03618082|ACTIVE_COMPARATOR|usual practice|control group (usual practice): patients receiving a general anesthesia with propofol, ketamine and remifentanil with or without curare for the induction, and desflurane and remifentanil (with or without curare) for the maintenance. The dosage of the anesthetic agent, as well as the prophylactic administration of morphine at the end of the intervention, will be decided by the anesthesiologist.
62822094|NCT05159830|PLACEBO_COMPARATOR|PLACEBO (PCB)|PCB Group from 20mg x 2/day up to 600mg/day
62822095|NCT06589622|EXPERIMENTAL|ART|Atraumatic restorative technique
62822096|NCT06589622|EXPERIMENTAL|Hall technique|Stainless steel crown placement without tooth preparation
62822097|NCT04017546|EXPERIMENTAL|CYC065 and venetoclax|CYC065 will be administered intravenously via 4-hour infusion on Day 1 and Day 15. Venetoclax will be taken daily on Day 1 through Day 15. One cycle will be 28 days or 4 weeks.
62822098|NCT01658371||efavirenz|HIV patients on efavirenz
62822099|NCT04500587|EXPERIMENTAL|ZN-d5 Single Agent Dose Escalation - NHL|Non-Hodgkin Lymphoma
62822100|NCT04500587|EXPERIMENTAL|ZN-d5 Single Agent Dose Escalation - AML|Acute Myeloid Leukemia
62822101|NCT06600386|ACTIVE_COMPARATOR|C-PEEP|PEEP is standard (5cmH2O)
62822102|NCT06600386|ACTIVE_COMPARATOR|I-PEEP|PEEP is individualized following standard recruitment maneuvres
62822103|NCT01048918||No Treatment|
62822104|NCT03376880||Obese Boys|Obese boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI \> 95th percentile, which will be expressed as a percentage above the 95th percentile \< 150% of the 95th percentile.
62822105|NCT03376880||Obese Girls|Obese girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI \> 95th percentile, which will be expressed as a percentage above the 95th percentile \< 150% of the 95th percentile.
62822106|NCT03376880||Normal Weight Boys|Normal weight boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI between 16th and 84th percentile.
62822107|NCT03376880||Normal Weight Girls|Normal weight girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI between 16th and 84th percentile.
62822108|NCT03376880||Obese Boys Misdiagnosed with Asthma|Obese boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI \> 95th percentile, which will be expressed as a percentage above the 95th percentile \< 150% of the 95th percentile.This group will have a prior diagnosis of asthma without confirmation by lung function testing.The absence of asthma will be confirmed by a negative response (\<10% increase in FEV1) to spirometry before and after bronchodilator (and on visit 2 by a negative bronchial challenge test \[\<10% decrease in FEV1\]; i.e., EVH).
62822109|NCT03376880||Obese Girls Misdiagnosed with Asthma|Obese girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI \> 95th percentile, which will be expressed as a percentage above the 95th percentile \< 150% of the 95th percentile.This group will have a prior diagnosis of asthma without confirmation by lung function testing.The absence of asthma will be confirmed by a negative response (\<10% increase in FEV1) to spirometry before and after bronchodilator (and on visit 2 by a negative bronchial challenge test \[\<10% decrease in FEV1\]; i.e., EVH).
62822110|NCT06594809|PLACEBO_COMPARATOR|Group one|Neck-focused training consisted of a) cervical stretching, b) craniocervical flexion, and c) cervical retraction exercises d) Manual therapy, for three sessions per week for four weeks (Yildiz et al., 2018).
62822111|NCT06594809|ACTIVE_COMPARATOR|Group two|The patients will receive Traditional treatment of neck pain and Scapular stabilization exercises (Blackburn exercises).
62822112|NCT06594809|EXPERIMENTAL|Group three|Patients will receive combination of traditional treatment of neck pain, SS (Blackburn exercises) and upper extremity PNF patterns.
62822113|NCT03056794||PDC Deficiency|Pyruvate Dehydrogenase Complex Deficiency Disease
62822114|NCT05924243|EXPERIMENTAL|RO7486967 Arm|Participants will receive RO07486967 for approximately 28 days with 14 days of follow up after the last dose.
62601137|NCT00228319|EXPERIMENTAL|Standar of Care + Ascorbic Acid Group|carboplatin and paclitaxel chemotherapy, plus intravenous sodium ascorbate. In addition, participants will take a mix of vitamins including oral ascorbic acid, oral mixed natural carotenoids with vitamin A and oral vitamin E.
62822115|NCT05924243|PLACEBO_COMPARATOR|Placebo|Matching placebo
62822116|NCT01876836|EXPERIMENTAL|i-gel|i-gel placed after induction
62822117|NCT01876836|ACTIVE_COMPARATOR|C-LMA|C-LMA placed after induction
62822118|NCT00434317|EXPERIMENTAL|ZOL446|
62601138|NCT00553397||Live Lung Donors|Participants had a living donor lobectomy at one of the two participating study centers, the University of Southern California and the Washington University Medical Center between 1993 and 2006.
62822119|NCT06594172|EXPERIMENTAL|MPR|combined Memantine and Pioglitazone with radiation therapy
62822120|NCT05446649|EXPERIMENTAL|dry needling|the patient will receive dry needling and conventional therapy three times per week for four weeks
62822121|NCT05446649|EXPERIMENTAL|instrumented assisted soft tissue mobilization|the patient will receive instrumented assisted soft tissue mobilization and conventional therapy three times per week for four weeks
62822122|NCT05446649|ACTIVE_COMPARATOR|conventional therapy|the patient will receive conventional therapy three times per week for four weeks
62601139|NCT06621056||asthma with frequent exacerbations|asthma with frequent exacerbations
62601140|NCT06621056||asthma without frequent exacerbations|asthma without frequent exacerbations
62601141|NCT02743390|ACTIVE_COMPARATOR|TNF-alpha inhibitor drug|Infliximab infusion (TNF-α inhibitor, 3 mg/kg, 250mL)
62601142|NCT02743390|PLACEBO_COMPARATOR|Placebo drug|Saline infusion (250mL)
62601143|NCT00146653||Xa|An additional 20 patients will be enrolled to address the validation of heparin concentrations calculated by the Hepcon machine with laboratory-measured heparin concentrations. These patients will not be randomized and therefore will not receive an intervention. .
62601144|NCT05663944|PLACEBO_COMPARATOR|Placebo|15 participants will receive a non-identical placebo tablet. They will be asked to take the placebo daily, exactly as instructed for the intervention arm, be subject to monitoring and random titration to mirror the study drug
62601145|NCT05663944|EXPERIMENTAL|Sirolimus|30 participants will be randomised to the study drug.
62601146|NCT01765777|NO_INTERVENTION|Control Group|Subjects in this arm continue with standard medical care
62601147|NCT01765777|EXPERIMENTAL|Osteopathic Manipulative Medicine Group|Subjects in this arm will receive an OMM intervention.
62601148|NCT01765777|EXPERIMENTAL|Phototherapy Group|Subjects in this arm will receive a phototherapy intervention.
62601149|NCT01765777|EXPERIMENTAL|OMM and Phototherapy Group|Subjects in this arm will receive both the OMM and phototherapy interventions.
62822123|NCT05636917||radiculopathy|Patients with suspected radiculopathy who are prescribed the nerve conduction test at the Lozano-Blesa University Hospital and who have undergone or are awaiting an MRI scan.
62822124|NCT04086927|NO_INTERVENTION|Control Group|Patients will not receive compression dressing
62822125|NCT04086927|EXPERIMENTAL|Experimental Group|Patients will receive compression dressing
62822126|NCT06589739|EXPERIMENTAL|virtual reality headset|Patients in this arm will have a reality helmet placed during chest drain insertion
62822127|NCT06589739|NO_INTERVENTION|control group|
62822128|NCT02052778|EXPERIMENTAL|Phase 1: Dose Escalation: QOD Dosing: 8 mg|Participants with or without fibroblast growth factor \[FGF\]/fibroblast growth factor receptor \[FGFR\] gene abnormalities received orally TAS-120 8 milligrams (mg) orally every other day (QOD; Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822129|NCT02052778|EXPERIMENTAL|Phase 1: Dose Escalation: QOD Dosing: 16 mg|Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 16 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822130|NCT02052778|EXPERIMENTAL|Phase 1: Dose Escalation: QOD Dosing: 24 mg|Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 24 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62601150|NCT01432561|EXPERIMENTAL|Cysteamine bitartrate|Cysteamine bitartrate, 500mg once a day, three days.
62601151|NCT00828724|EXPERIMENTAL|Lorcaserin 10mg|
62601152|NCT04145375|EXPERIMENTAL|Experimental: ZEN003694 in Combination with Enzalutamide|Patients who have completed participation in their original ZEN003694-002 protocol and have clinical benefit as determined by the investigator may continue to receive treatment with ZEN003694 in combination with enzalutamide
62601153|NCT02641886|EXPERIMENTAL|Jian Pi Yi Shen Hua Tan Granules group|Treat with the prescription of Jianpi Yishen Huatan Granules and conventional treatment of ischemic stroke.
62601154|NCT02641886|PLACEBO_COMPARATOR|the Placebo Group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin and conventional treatment of ischemic stroke.
62601155|NCT05593536|EXPERIMENTAL|Group 1 (biological nurturing)|In biological feeding, the mother takes a semi-sitting position and the baby lies face down on the mother's breast and belly, with every part of her body in contact with the mother.
62601156|NCT05593536|EXPERIMENTAL|Group 2 (classic breastfeeding)|In classical breastfeeding, the mother holds her baby in her arms and breastfeeds while she is in a sitting position.
62601157|NCT05593536|NO_INTERVENTION|Group 3 (control)|The mother will breastfeed her baby as she wishes.
62822131|NCT02052778|EXPERIMENTAL|Phase 1: Dose Escalation: QOD Dosing: 36 mg|Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 36 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822132|NCT02052778|EXPERIMENTAL|Phase 1: Dose Escalation: QOD Dosing: 56 mg|Participants with FGF/FGFR gene abnormalities received orally TAS-120 56 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822133|NCT02052778|EXPERIMENTAL|Phase 1: Dose Escalation: QOD Dosing: 80 mg|Participants with FGF/FGFR gene abnormalities received orally TAS-120 80 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822134|NCT02052778|EXPERIMENTAL|Phase 1: Dose Escalation: QOD Dosing: 120 mg|Participants with FGF/FGFR gene abnormalities received orally TAS-120 120 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822135|NCT02052778|EXPERIMENTAL|Phase 1: Dose Escalation: QOD Dosing: 160 mg|Participants with FGF/FGFR gene abnormalities received orally TAS-120 160 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822136|NCT02052778|EXPERIMENTAL|Phase 1: Dose Escalation: QOD Dosing: 200 mg|Participants with FGF/FGFR gene abnormalities received orally TAS-120 200 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62041572|NCT06731907|ACTIVE_COMPARATOR|Pembrolizumab and Chemotherapy|Pembrolizumab will be administered as a 200mg IV infusion on Day 1 of every three weeks (Q3W) for up to 35 cycles (\~ 2 years). The doublet platinum-based chemotherapy treatments used in this substudy are standard-of care regimens for squamous (paclitaxel/Nab-paclitaxel and carboplatin) and nonsquamous (pemetrexed and carboplatin) NSCLC. Pemetrexed is administered as a 500mg/m\^2 IV infusion Q3W until discontinuation criterion is met. Nab-paclitaxel will be administered as a 100mg/m\^2 IV infusion on Days 1, 8, and 15 Q3W for 4 cycles. Paclitaxel will be administered as a 200 mg/m\^2 IV infusion on Day 1 Q3W for up to 4 cycles. Carboplatin will be administered as an IV infusion area under the time x concentration curve (AUC) for 4 cycles as per local practice and labels. The dose will be AUC5 or 6 mg/mL•min Q3W and will not exceed 900mg.
62822137|NCT02052778|EXPERIMENTAL|Phase 1: Dose Escalation: QD Dosing: 4 mg|Participants with or without FGF/FGFR gene abnormalities received a dose between 4 mg orally once daily (QD) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62041573|NCT06731907|EXPERIMENTAL|Pembrolizumab and HER3-DXd|Pembrolizumab will be administered as a 200mg IV infusion on Day 1 Q3W for up to 35 cycles (\~ 2 years). HER3-Dxd will be administered as 5.6mg/kg IV infusion on Day 1 Q3W until discontinuation criteria is met.
62244633|NCT06291285|EXPERIMENTAL|Formulation A followed by Formulation B|Participants will receive a single oral dose of decitabine and tetrahydrouridine (THU) immediate release tablets (Formulation A) on Day 1 of treatment period 1 followed by a single oral dose of decitabine and THU delayed release capsules (Formulation B) on Day 1 of treatment period 2. A washout period of 7- 21 days will be maintained between the two treatment periods.
62244634|NCT06291285|EXPERIMENTAL|Formulation B followed by Formulation A|Participants will receive a single oral dose of decitabine and THU delayed release capsules (Formulation B) on Day 1 of treatment period 1 followed by a single oral dose of decitabine and THU immediate release tablets (Formulation A) on Day 1 of treatment period 2. A washout period of 7- 21 days will be maintained between the two treatment periods.
62244635|NCT05758545|ACTIVE_COMPARATOR|COMS One device|"The COMS One device is the housing unit for the user controls, displays and functions including embedded software, lithium-ion battery, optical (LEDs) and a magnetic stimulation coil. The COMS One device is reusable (the component can be used on multiple subjects and is cleaned between uses).~The COMStouch is a sterile single-use component. The COMStouch provides a base and sterile barrier for the COMS One device.~The COMSfix component is a self-adhesive single-use strap used to hold the COMS One device and COMStouch components in place during treatment."
62244636|NCT05758545|SHAM_COMPARATOR|Sham device|"The sham device is the housing unit for the user controls, displays and functions including embedded software, lithium-ion battery, optical (LEDs) and a magnetic stimulation coil. The sham device is reusable (the component can be used on multiple subjects and is cleaned between uses).~The COMStouch is a sterile single-use component. The COMStouch provides a base and sterile barrier for the sham device.~The COMSfix component is a self-adhesive single-use strap used to hold the sham device and COMStouch components in place during treatment."
62434805|NCT03618082|EXPERIMENTAL|targeted analgesia to ANI|"experimental group: patients receiving a general anesthesia with propofol, ketamine and remifentanil with or without curare for the induction, and desflurane and remifentanil (with or without curare) for the maintenance, as well as the prophylactic administration of morphine at the end of the intervention, will be administered according to the ANI.~- In addition, desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC)."
62434806|NCT06385977||case group|participates diagnosed with Chronic prostatitis/chronic pelvic pain syndrome
62822138|NCT02052778|EXPERIMENTAL|Phase 1: Dose Escalation: QD Dosing: 8 mg|Participants with or without FGF/FGFR gene abnormalities received a dose between 8 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822139|NCT02052778|EXPERIMENTAL|Phase 1: Dose Escalation: QD Dosing: 16 mg|Participants with or without FGF/FGFR gene abnormalities received a dose between 16 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822140|NCT02052778|EXPERIMENTAL|Phase 1: Dose Escalation: QD Dosing: 20 mg|Participants with or without FGF/FGFR gene abnormalities received a dose between 20 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822141|NCT02052778|EXPERIMENTAL|Phase 1: Dose Escalation: QD Dosing: 24 mg|Participants with or without FGF/FGFR gene abnormalities received a dose between 24 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822142|NCT02052778|EXPERIMENTAL|Phase 1: Dose Expansion Cohort 1|Participants with intra-hepatic or extrahepatic cholangiocarcinoma (iCCA or eCCA) harboring FGFR2 gene fusions or rearrangements and who were treated or not treated with prior FGFR inhibitors received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62041574|NCT06733831||Married Women of reproductive age (MWRA, ages 15-49)|Mainly the data will be collected from randomly selected Married Women of reproductive age (MWRA, ages 15-49). To enrich the data for an in-depth understanding of multiple dynamics of the use of modern contraceptive methods, there will be some qualitative in-depth interviews collected with select participants.
62041575|NCT04331704|EXPERIMENTAL|Personalized Information|Participants randomized to this condition will complete a web-based questionnaire and then receive personalized information regarding their alcohol use and sexual health behavior. They will complete daily, phone-based IVR monitoring for assessment purposes and receive further personalized information based on their responses.
62601158|NCT03438461|EXPERIMENTAL|Part 1|In Part 1, all participants will receive a single oral dose of seltorexant (40 milligram \[mg\]) in all the 6 treatments as Treatment A (Formulation 1 in fasted state), B (Formulation 1 in semi-fasted state), C (Formulation 2 in fasted state), D (Formulation 2 in semi-fasted state), E (Formulation 3 in fasted state) and F (Formulation 3 in semi-fasted state) and the participants will be assigned to one of the 8 sequences (that is, ADBCEF, ADBCFE, BACDEF, BACDFE, CBDAEF, CBDAFE, DCABEF, DCABFE). A washout period of at least 7 days between subsequent study drug administrations on Day 1 of each treatment period will be maintained.
62601159|NCT03438461|EXPERIMENTAL|Part 2 (Optional)|Optional Part 2 will only be performed if considered to be warranted by the sponsor based on the preliminary pharmacokinetic (PK) analysis of the results from Part 1. Participants will receive a single oral dose of seltorexant (20 mg) as 3 different formulations assigned to one of the either 6 or 4 treatment sequences under fasted or semi-fasted conditions. The treatment will be assigned in 1 of the 6 or 4 assigned sequences per treatment period that is either Period 1 to 6 or Period 1 to 4).
62601160|NCT00762008||Heart Failure|
62041576|NCT04331704|ACTIVE_COMPARATOR|Educational Information|Participants randomized to this condition will complete a web-based questionnaire and then receive educational material regarding their alcohol use and sexual health behavior. They will complete daily phone-based IVR monitoring for assessment purposes.
62041577|NCT04039399|EXPERIMENTAL|Ischemic Conditioning|Study participants will receive one session of ischemic conditioning on their affected leg with cuff inflation to 225 mmHg.
62434807|NCT06385977||control group|participates without Chronic prostatitis/chronic pelvic pain syndrome
62434808|NCT04959110|EXPERIMENTAL|Acute Liver Failure|Acute liver failure critically ill patients receiving CRRT
62601161|NCT06618885|EXPERIMENTAL|Children (18 months - 5 years)|Children (18 months - 5 years) will not be randomised. The first 3 participants will be enrolled as sentinel participants prior to the 6 follower participants. The nine participants of Group 1 will receive three administrations of the SUM-101 vaccine (25µg MSP1 + 5µg GLA-SE) in an open-label design.
62244637|NCT06730438|EXPERIMENTAL|Transcranial pulse stimulation|Patients belonging to this group will receive real transcranial pulse stimulation over a 4-weeks period, once a day for five days a week.
62601162|NCT06618885|EXPERIMENTAL|Infants (5-17 months)|"For safety reasons, vaccination of infants will be staggered based on the dosage of MSP1 and the GLA-SE adjuvant used. The following dosages will be evaluated:~* Group 2: 10µg MSP1 + 2.5µg GLA-SE~* Group 3: 10µg MSP1 + 5µg GLA-SE~* Group 4: 25µg MSP1 + 2.5µg GLA-SE~* Group 5: 25µg MSP1 + 5µg GLA-SE Enrollment and vaccination of infants will start with Groups 2 and 3, and only proceed to Groups 4 and 5 if there are no safety concerns. The first infants enrolled into each group will be sentinels (4 per group). The At least tThree out four sentinels will receive the SUM-101 vaccine dose assigned to their respective groups. The participants enrolled into Groups 2-5 (both sentinels and followers) will be randomised at a ratio of 4:1 into vaccine and control arms. In total, 12 participants per group will receive the SUM-101 vaccine (either 25µg or 10µg of MSP1 and either 5µg or 2.5µg of GLA-SE) and 3 participants will receive the control vaccine (rabies vaccine, Verorab®)."
62434809|NCT04959110|EXPERIMENTAL|Acute on top Chronic Liver Failure|Acute on top chronic liver failure critically ill patients receiving CRRT
62434810|NCT02884661||Hospitalization in Cardiology department|Patients cared by the Cardiology department
62822143|NCT02052778|EXPERIMENTAL|Phase 1: Dose Expansion: Cohort 2|Participants with primary central nervous system (CNS) tumors harboring FGFR gene fusions or FGFR1 activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822144|NCT02052778|EXPERIMENTAL|Phase 1: Dose Expansion: Cohort 3|Participants with advanced urothelial carcinoma harboring FGFR3 gene fusions or FGFR3 activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822145|NCT02052778|EXPERIMENTAL|Phase 1: Dose Expansion: Cohort 4|Participants with breast or gastric cancer with harboring FGFR2 amplification received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822146|NCT02052778|EXPERIMENTAL|Phase 1:Dose Expansion: Cohort 5|Participants with tumor types harboring FGFR gene fusions or activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822147|NCT02052778|EXPERIMENTAL|Phase 1: Dose Expansion: Cohort 6|Participants who were not included in Cohorts 1 to 5 received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62434811|NCT02884661||Hospitalization in Geriatric unit|Patients cared by the Geriatric unit
62434812|NCT02707432|EXPERIMENTAL|Time 1 (T1) Intervention Group|"This group will be the first to receive the adapted intervention, Heart Matters (adapted from the PREMIER intervention). The intervention will be 12 months long."
62434813|NCT02707432|EXPERIMENTAL|Time 2 (T2) Intervention Group|"This delayed intervention group will receive the adapted intervention, Heart Matters, six months after the T1 Intervention group. The intervention will be 12 months long."
62434814|NCT06092606|PLACEBO_COMPARATOR|Control group:DH001 placebo|"Medication: Once per day on an empty stomach in the morning. Treatment cycle: 3 days before the first administration of doxorubicin to the entire treatment cycle of doxorubicin.~Dosage: DH001 placebo (8 tablets)"
62434815|NCT06092606|EXPERIMENTAL|Trial group: DH001 low-dose group|"Medication: once per day on an empty stomach in the morning. Treatment cycle: 3 days before the first administration of doxorubicin to the entire treatment cycle of doxorubicin.~Dosage: DH001 200mg (4 tablets) + DH001 placebo (4 tablets)"
62434816|NCT06092606|EXPERIMENTAL|Trial group: DH001 high-dose group|"Medication: Once per day on an empty stomach in the morning. Treatment cycle: 3 days before the first administration of doxorubicin to the entire treatment cycle of doxorubicin.~Dosage: DH001 400mg (8 tablets)."
62434817|NCT01710826|EXPERIMENTAL|Genz-682452|This study will include three cohorts for doses of Genz-682452: Dose 1, Dose 2, Dose 3. Each cohort will include 12 participants, 9 of whom will be administered Genz-682452 and 3 will be administered placebo.
62434818|NCT01710826|PLACEBO_COMPARATOR|Placebo|Placebo comparator taken by participants randomized to the placebo arm in each of the three cohorts. Each cohort will include 12 participants, 9 of whom will be administered Genz-682452 and 3 will be administered placebo.
62434819|NCT01456702|NO_INTERVENTION|control arm|volume therapy via standard operating procedure
62434820|NCT01456702|EXPERIMENTAL|intervention arm|goal-directed volume therapy due to svv in dependence of preoperative risk stratefication
62434821|NCT05476679|EXPERIMENTAL|RZL-012 50mg/ml|
62434822|NCT05463783|EXPERIMENTAL|Biktarvy|15 subjects will get Biktarvy (single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide) once daily.
62434823|NCT05463783|EXPERIMENTAL|Symtuza|15 subjects will get Symtuza (single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide) once daily.
62434824|NCT04277819||Patients with cystic fibrosis related liver disease|Patients with cystic fibrosis, who meet the criteria for diagnosis of liver disease according to the European Cystic Fibrosis Society best practice guidelines
62434825|NCT04277819||Patients without cystic fibrosis related liver disease|
62244638|NCT06730438|SHAM_COMPARATOR|Sham stimulation Group|Patients belonging to this group will receive sham transcranial pulse stimualtion over a 4-weeks period, once a day for five days a week.
62434826|NCT01720940|EXPERIMENTAL|continuous vancomycin infusion|
62822148|NCT02052778|EXPERIMENTAL|Phase 1: Dose Expansion: Sub-cohort 1|Participants with iCCA who were enrolled prior to the confirmation of the recommended Phase 2 dose (RP2D) received TAS-120 16 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822149|NCT02052778|EXPERIMENTAL|Phase 1: Dose Expansion: Sub-cohort 2|Participants with other tumor types who were enrolled prior to the confirmation of the RP2D received TAS-120 16 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62041578|NCT04039399|SHAM_COMPARATOR|Sham Ischemic Conditioning|Study participants will receive one session of sham ischemic conditioning on their affected leg with cuff inflation to 10 mmHg.
62434827|NCT01720940|ACTIVE_COMPARATOR|intermittent vancomycin infusion|vancomycin in this arm will be administered as intermittent infusion
62434828|NCT01248312||morbidly obese|BMI \>45
62822150|NCT02052778|EXPERIMENTAL|Phase 2|Participants with iCCA with tumors harboring FGFR2 gene rearrangements received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
62822151|NCT06029322|ACTIVE_COMPARATOR|Collagen membrane|BioGide Compressed® 13x25 mm, Geistlich Pharma AG, Wolhusen, Switzerland
62822152|NCT06029322|EXPERIMENTAL|collagen matrix|Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland
62041579|NCT02593994||Onyx Drug Eluting Stent|
62041580|NCT04884334||VAC-Stent® treatment|spontaneous, iatrogenic or postoperative leakage of the oesophagus or colon
62434829|NCT01248312||thin patients|BMI \<45
62434830|NCT01051622|EXPERIMENTAL|PBMC Trafficking|In part B, Patients undergo a blood draw (up to150 mL) and the PBMC's are separated and selected or 99mTc-HMPAO labeling. The purified and labelled cells will be re-introduced into the patient by intravenous infusion and one SPECT scan and up to 8 serial planar scintigraphy scans will initially be conducted over up to 6 hours within 1 scan session. All suitable patients showing evidence of cellular uptake in the ileo-caecal region and/or small bowel at Visit 1 will be progressed to an identical second cell labeling and scanning session at Visit 2 (48 hours later). Subjects showing no evidence of cellular uptake in the ileo-caecal region or small bowel at Visit 1 (negative scan) will be withdrawn from the study and proceed to the follow-up.
62601163|NCT00084318|EXPERIMENTAL|RT + cisplatin + cetuximab|Loading dose of cetuximab followed by radiation therapy with weekly cisplatin and cetuximab.
62601164|NCT00084318|EXPERIMENTAL|RT + docetaxel + cetuximab|Loading dose of cetuximab followed by radiation therapy (RT) with weekly docetaxel and cetuximab.
62822153|NCT02575586|EXPERIMENTAL|Dry Needling into MTrPs.|Intervention-Dry Needling: Deep Dry Needing into the medial Myofascial Trigger Point of the soleus muscle.
62601165|NCT00497770||Caucasian|Caucasian patients receiving Alimta for 2nd line NSCLC
62822154|NCT02575586|ACTIVE_COMPARATOR|Dry Needling out of MTrPs.|Control-Dry Needling: Deep Dry Needling distal to Myofascial Trigger Point of the soleus muscle (in the same taut band).
62041581|NCT04914286|EXPERIMENTAL|GFH018+Toripalimab|Patient will be dosed in GFH018 in combination with Toripalimab. In the PhaseIb part, the dose levels will be escalated following the Bayesian optimal interval (BOIN) design. In the Phase II part, patients will be assigned based on tumor type(s).
62041582|NCT06177158|ACTIVE_COMPARATOR|cigarette smoker with gingivitis.|oral hygiene instructions
62601166|NCT00497770||African American|African American patients receiving Alimta for 2nd line NSCLC
62601167|NCT00497770||Asian American|Asian American patients receiving Alimta for 2nd line NSCLC
62244639|NCT06691165|EXPERIMENTAL|Room air control; lot oxygen therapy; recovery/washout|"Participants with chronic cervical spinal cord injury will undergo a 4-day low oxygen therapy intervention.~Measurements will first be taken at least three days before the beginning of the intervention to establish baseline characteristics, immediately before and after the first day of the intervention to assess the acute response to the intervention, and on the first and fourth days after the end of the intervention to assess persistent effects and washout."
62244640|NCT05476068||Epidemic area (Nanchang, Nanchang university)|
62434831|NCT01051622|EXPERIMENTAL|T Lymphocyte Trafficking|"In part B, Patients undergo a blood draw (up to150 mL) and the T lymphocyte cells are separated and selected or 99mTc-HMPAO labeling. The purified and labelled cells will be re-introduced into the patient by intravenous infusion and one SPECT scan and up to 8 serial planar scintigraphy scans will initially be conducted over up to 6 hours within 1 scan session. All suitable patients showing evidence of cellular uptake in the ileo-caecal region and/or small bowel at Visit 1 will be progressed to an identical second cell labeling and scanning session at Visit 2 (48 hours later). Subjects showing no evidence of cellular uptake in the ileo-caecal region or small bowel at Visit 1 (negative scan) will be withdrawn from the study and proceed to the follow-up.~visit."
62601168|NCT00497770||Hispanic|Hispanic patients receiving Alimta for 2nd line NSCLC
62434832|NCT04536233|PLACEBO_COMPARATOR|control group|
62434833|NCT04536233|EXPERIMENTAL|experimental group|
62601169|NCT04416737|EXPERIMENTAL|Upper Peritoneal, then Lower Peritoneal, then Subcutaneous|Ultra-fast acting insulin will be injected into the upper peritoneum then lower peritoneum then subcutaneous space.
62601170|NCT04416737|EXPERIMENTAL|Lower Peritoneal, then Upper Peritoneal, then Subcutaneous|Ultra-fast acting insulin will be injected into the lower peritoneum then upper peritoneum then subcutaneous space.
62601171|NCT05930834|EXPERIMENTAL|Exercise|All subjects will undergo exercise training for 4 wks. 45-60 min of exercise, 4 sessions/wk supervised, 1 session unsupervised. intensity 60% of VO2 max
62041583|NCT06177158|ACTIVE_COMPARATOR|electronic cigarette smoker with gingivitis.|oral hygiene instructions
62601172|NCT02200237|PLACEBO_COMPARATOR|Placebo|Phosphate Buffer Saline with adjuvant aluminium phosphate
62041584|NCT06177158|ACTIVE_COMPARATOR|non-smoker with gingivitis.|oral hygiene instructions
62041585|NCT06550986|EXPERIMENTAL|Experimental: Intervention|Device: False Lumen Embolization System Device: IMPEDE-FX RapidFill
62041586|NCT04766944||Critically ill trauma patients of 50 years old and above|Patients of 50 years old and above admitted to the Montreal General Hospital intensive care unit for trauma
62244641|NCT05476068||Non-epidemic area (Kaifeng, Henan university)|
62434834|NCT03900611|EXPERIMENTAL|Active stimulation|
62434835|NCT03900611|SHAM_COMPARATOR|Sham stimulation|
62434836|NCT03900611|NO_INTERVENTION|healthy control|
62244642|NCT06734767|OTHER|Mindfulness Based Stress Reduction course faculty participants|Faculty physicians who have chosen to take the free 8-week course are offered the opportunity to anonymously enroll in the study.
62434837|NCT04351191|ACTIVE_COMPARATOR|HCQ Regular dose|Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care
62601173|NCT02200237|EXPERIMENTAL|EV71 with adjuvant aluminium phosphate|Inactive whole monovalent EV71 virion vaccine formulated with phosphate-buffered saline based adjuvanted aluminium phosphate 150 μg/0.5ml
62601174|NCT02944500|EXPERIMENTAL|Liraglutide followed by placebo|Participants will receive liraglutide with dose titration over 5 weeks (0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, and 3.0mg for 1 week) followed by a minimum of 3 weeks wash-out and then return for the same dose of placebo for the same amount of time.
62822155|NCT04245111||Open Fracture Cohort|Patients 18 years of age or older. Open extremity fracture. Planned definitive fracture management with external fixation, internal fixation, or joint fusion. Open fracture wound management that includes formal surgical debridement within 72 hours of their injury. Will have all planned fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent.
62822156|NCT04245111||Complication Cohort|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
62822157|NCT04245111||Closed Fracture Cohort|"Patients 18 years of age or older Closed extremity fracture Planned definitive fracture management with external fixation, internal fixation, or joint fusion.~Provision of informed consent"
62822158|NCT04488666|EXPERIMENTAL|npSIMS|Group will receive the Aatru Medical npSIMS device
62822159|NCT03264404|EXPERIMENTAL|Pembrolizumab|Patients with advanced pancreatic cancer will receive pembrolizumab with the hypomethylating agent azacitidine.
62244643|NCT06734767|OTHER|Mindfulness Based Stress Reduction course trainee participants|Trainee physicians who have chosen to take the free 8-week course are offered the opportunity to anonymously enroll in the study.
62601175|NCT02944500|EXPERIMENTAL|Placebo followed by liraglutide|Participants will receive placebo with dose titration (0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, and 3.0mg for 1 week) followed by a minimum of 3 weeks wash-out and then return for the same dose of liraglutide for the same amount of time.
62601176|NCT03600012|EXPERIMENTAL|intervention group|"intervention group: Cycling Functional Electrical Stimulation \& Physiotherapy~Children in intervention group were taken in a therapy program withRT 300 SLSA FES system for cycling functional electrical stimulation training additionly to physiotherapy program including weight shifting, knee and hip strenging and gait training for 8 weeks, 3 sessions in a week and 45 min per session."
62601177|NCT03600012|ACTIVE_COMPARATOR|control group|"control group: Physiotherapy~Children with cp in control group were taken physiotherapy program including weight shifting, knee and hip strenging and gait training for 8 weeks, 3 times in a week, 45 min per session."
62601178|NCT06621433|EXPERIMENTAL|Coronally advanced flap (CAF) in conjunction with titanium prepared PRF|
62601179|NCT06621433|ACTIVE_COMPARATOR|CAF in conjunction with subepithelial connective tissue graft (SECTG)|
62822160|NCT01502293|EXPERIMENTAL|Main Study: tavo-EP|Patients received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 3-month intervals until disease progression or unacceptable toxicity for up to 5 cycles.
62822161|NCT01502293|EXPERIMENTAL|Addendum: Regimen A tavo-EP|Patients received one cycle (3 daily treatments on Days 1, 8, and 15) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 6-week intervals until disease progression or unacceptable toxicity for up to 9 cycles.
62822162|NCT01502293|EXPERIMENTAL|Addendum: Regimen B tavo EP|Patients received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 6-week intervals until disease progression or unacceptable toxicity for up to 2 cycles.
62822163|NCT03991221|OTHER|Dental exam by orthodontic non-specialists|Detection of the presence of at least one malocclusion by orthodontic non-specialists with the graphic chart
62822164|NCT03991221|OTHER|Dental exam by orthodontic experts|Detection of the presence of at least one malocclusion by orthodontic experts
62244644|NCT06734065|NO_INTERVENTION|Usual care group|Patients in the usual care group will receive usual care.
62244645|NCT06734065|EXPERIMENTAL|ReDS-guided heart failure management group|
62244646|NCT02673606|EXPERIMENTAL|Estradiol 2mg Dose|2mg dose of estradiol (oral administration)
62434838|NCT04351191|EXPERIMENTAL|HCQ Loading dose|Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care
62244647|NCT02673606|EXPERIMENTAL|Estradiol 4mg Dose|4mg dose of estradiol (oral administration)
62244648|NCT02673606|PLACEBO_COMPARATOR|Placebo|placebo (oral administration)
62434839|NCT04351191|ACTIVE_COMPARATOR|CQ regular dose|Cholorquine 500 mg BID for 5 days plus standard of care
62434840|NCT04351191|PLACEBO_COMPARATOR|Placebo|Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)
62434841|NCT00096382|OTHER|TBI 200cGy + TIL +HD IL-2, prior IL-2|"Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.~Lymphocytes that that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient."
62434842|NCT00096382|OTHER|TBI 200cGy + TIL +HD IL-2, No prior IL-2|"Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.~Lymphocytes that that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient."
62601180|NCT05740176|EXPERIMENTAL|Synergy Disc|The Synergy Disc is a cervical disc prosthesis that can be inserted between C3-C7 in skeletally mature patients after anterior discectomy to provide restoration of motion to the functional spinal unit. The Synergy Disc is designed to restore kinematics to the cervical spine. The Synergy Disc is intended for use in the cervical spine for reconstruction of the disc following a two level discectomy for intractable radiculopathy and/or myelopathy.
62601181|NCT06207240|EXPERIMENTAL|FES Therapy|Intention-driven assistive functional electrical stimulation provided during approximately 1 hour of task-oriented therapy. Sessions will be scheduled 3 days per week for 8 weeks.
62601182|NCT06623331||Group A|Colonoscopies performed by endoscopists trained in AI-ehnanced environment. In the trial the quality indicators are measured after completing training, without AI enhancement.
62434843|NCT04304326|EXPERIMENTAL|Intervational|"FT: Functional training with elastic band Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group.~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension."
62244649|NCT06664879|EXPERIMENTAL|Treatment with MBG453 + Azacitidine|Participants will be randomized to arm
62244650|NCT04539366|EXPERIMENTAL|Treatment (GD2 CAR T)|"LYMPHODEPLETION CHEMOTHERAPY: Patients receive fludarabine phosphate IV daily on days -5 to -2 and cyclophosphamide IV daily on days -4 to -2.~GD2CART: Patients receive GD2CART cells IV on day 0.~Patients also undergo ECHO, MUGA or cardiac MRI scan during screening, blood sample collection throughout the trial, and tumor biopsies and bone marrow aspiration and biopsy as clinically indicated. In addition, patients undergo standard imaging scans throughout the trial."
62822165|NCT06052319||Participants with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) or Both|Participants with CAD or PAD or both will be directed to download the Care4Today® (C4T) Connect CAD-PAD mobile application on iPhone or Android device to assess engagement and usefulness of C4T in disease management for 3 months. No study drug and other treatment(s) will be provided as a part of this study. All aspects of treatment and clinical management of participants will continue to be in accordance with local clinical practice and applicable local regulations, and at the discretion of the participating physician.
62822166|NCT06600035||Group I - Diabetic|Diabetic patients
62822167|NCT06600035||Group II - Non-diabetic|Non-diabetic patients
62822168|NCT06593613|EXPERIMENTAL|RUBI-A|Recently redesigned version of the RUBI program for autistic adults and their caregivers
62822169|NCT06593613|ACTIVE_COMPARATOR|R-ISLEA|Psychoeducation control condition
62822170|NCT05911984|EXPERIMENTAL|9MW3811 Injection|
62822171|NCT05101902||Overall Study|Participants will undergo antibody and genetic screen, initial pre-screening, eligibility monitoring and eligibility confirmation for potential transition to the treatment trial center once a treatment assignment in the study CAH-301 becomes available. Participation in Study CAH-300 is permitted to continue until treatment assignment is available in the treatment trial or unless, during eligibility monitoring or eligibility
62822172|NCT05696054||SBP group|Patients diagnosed as spontaneous bacterial peritonitis based on ascitic fluid study.
62822173|NCT05696054||non-SBP group|Patients without spontaneous bacterial peritonitis based on ascitic fluid study
62822174|NCT03389828||1|The study population will consist of approximately 340 focus groups participants.
62822175|NCT06587867|OTHER|efgartigimod|active treatment with efgartigimod.
62822176|NCT05344950||AURA|In addition to usual care, participants assigned to this arm will have access to our Audio + Radio (AURA) system.
62822177|NCT03940352|EXPERIMENTAL|treatment arm1: HDM201+MBG453|Phase Ib (escalation)
62822178|NCT03940352|EXPERIMENTAL|treatment arm2: HDM201+venetoclax|Phase Ib (escalation)
62822179|NCT06599827|EXPERIMENTAL|Experimental group|This study examines combined radiotherapy, chemotherapy, and immunotherapy for high-risk locally advanced rectal cancer. After a week post-radiotherapy, patients start CapeOx chemotherapy with anti-PD-1 mAb. Surgery follows after 3 cycles of this regimen.
62244651|NCT04144907|EXPERIMENTAL|Phenylalanine intake|
62244652|NCT06735183||Observation Group|"To investigate patients' understanding of the content of the anesthesia visit after listening to the visit. A questionnaire was used to collect data.~The questionnaire included the contents of the visit that the patients could recall, their understanding of the physician's explanation, their concerns, and their suggestions for improving the preoperative visit."
62244653|NCT06072482|EXPERIMENTAL|Group A: Avacopan + Standard of Care (SoC)|Avacopan 30 mg twice daily for 5 years + SoC background immunosuppressive therapy.
62244654|NCT06072482|EXPERIMENTAL|Group B: Avacopan/Placebo + SoC|Avacopan 30 mg twice daily for 1 year, followed by placebo twice daily for 4 years + SoC background immunosuppressive therapy.
62244655|NCT06072482|PLACEBO_COMPARATOR|Group C: Placebo + SoC|Placebo twice daily for 5 years + SoC background immunosuppressive therapy.
62244656|NCT04662619|EXPERIMENTAL|B. infantis|A once-daily feeding of activated B. infantis EVC001 (8.0 \*10\^9 colony forming units \[CFU\]) will be provided to infants for 12 weeks.
62244657|NCT04662619|PLACEBO_COMPARATOR|Placebo|A once-daily oral feeding of lactose placebo will be provided to infants for 12 weeks.
62822180|NCT06062563|EXPERIMENTAL|Anlotinib+ penpulimab|Anlotinib：12 mg once daily for 2 weeks, followed by a rest of 1 week (21-day cycle)； Penpulimab：200mg Q3 W
62822181|NCT06225128||Patients with AML|
62822182|NCT03269422|EXPERIMENTAL|MR Image Guided, Intensity-Modulated Radiotherapy|Patients enrolled in this study will undergo MR-based, image-guided, intensity-modulated radiotherapy using similar equipment, techniques, and treatment-planning procedures as currently practiced at MSKCC.
62822183|NCT05820581|EXPERIMENTAL|Mentalisation|4 mentalisation groups will be defined: hypomentalisation, hypermentalisation, mentalisation correct and lack of mentalisation
62822184|NCT03733717|EXPERIMENTAL|Isatuximab|Administered intravenously every week in Cycle 1 (4 weeks) followed by every 2 weeks (Q2W) in subsequent cycles.
62822185|NCT05325736||sleeve gastrectomy surgery|participants undergoing sleeve gastrectomy surgery for weight reduction
62244658|NCT05533775|EXPERIMENTAL|Arm A|Participants will receive glofitamab + R-ICE chemoimmunotherapy for up to 3 cycles (cycle length = 21 days).
62244659|NCT05533775|EXPERIMENTAL|Arm B|Participants will receive glofitamab monotherapy for up to 12 cycles (cycle length = 21 days).
62244660|NCT04354090|EXPERIMENTAL|Cohort 0.3-mg|Eligible subjects received 0.3 mg placebo or JY09 on day 1 in this cohort
62244661|NCT04354090|EXPERIMENTAL|Cohort 0.7-mg|Eligible subjects received 0.3 mg placebo or JY09 on days 1, and 0.7 mg placebo or JY09 on days 22
62244662|NCT04354090|EXPERIMENTAL|Cohort 1.5-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 1.5 mg placebo or JY09 on days 22
62822186|NCT05325736||gastric bypass surgery|participants undergoing gastric bypass surgery for weight reduction
62244663|NCT04354090|EXPERIMENTAL|Cohort 3.0-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 3.0 mg placebo or JY09 on days 22
62822187|NCT05325736||cholecystectomy|participants undergoing cholecystectomy
62822188|NCT06485843|EXPERIMENTAL|OA-SYS|Treatment with OA-SYS
62822189|NCT06000540|EXPERIMENTAL|Hypercapnia Group A|Healthy subjects without a history of coronary artery disease will undergo computer-controlled gas challenges.
62822190|NCT06000540|EXPERIMENTAL|Hypercapnia Group B|Healthy subjects without a history of coronary artery disease will undergo computer-controlled gas challenges.
62822191|NCT06000540|EXPERIMENTAL|Hypercapnia Group C|Healthy subjects without a history of coronary artery disease will undergo computer-controlled gas challenges.
62822192|NCT06000540|EXPERIMENTAL|Hypoxia Group|Healthy subjects without a history of coronary artery disease will undergo computer-controlled gas challenges.
62822193|NCT01666249|EXPERIMENTAL|Immunoglobulin Anti-RhD|Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).
62822194|NCT04102423||CCUS|All participants meeting the criteria for CCUS
62041587|NCT02515279||Participants With Hepatitis C|All participants were treated with Peginterferon alfa-2a+Ribavirin (Pegasys/Copegus) according to the summary of product characteristics and to the investigator's discretion. The daily recommended dose for Pegasys, for the treatment of chronic Hepatitis C, was 180 micrograms once weekly by subcutaneous administration. Copegus was administered orally in doses according to the physician's decision (depending on the participant's weight and genotype). All participants were observed for 12 months.
62041588|NCT00609427|EXPERIMENTAL|EA|Training in external memory aids
62244664|NCT04354090|EXPERIMENTAL|Cohort 6.0-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 1.0 mg placebo or JY09 on days 15, and 6.0 mg placebo or JY09 on days 30
62244665|NCT05433168|EXPERIMENTAL|SHIATSU GROUP|The patients will benefit from shiatsu treatments by a professional according to the shiatsu protocol developed by the Syndicate's evaluation commission Shiatsu Professionals (SPS).
62822195|NCT04102423||CHIP|Subjects will be split into five cohorts depending on specific mutations
62822196|NCT03792659||Neurological Outpatients|Participants in this group will be recruited from the outpatient clinical population at the Yale University Department of Neurology. Treating physicians will make the initial determination of patients' potential eligibility to participate in the study.
62822197|NCT06587984|NO_INTERVENTION|Cohort 1a|Patients within Cohort 1 have an upcoming well child visit between September-December 2024. Patients within Cohort 1a are those randomized to CONTROL and will not receive a text message reminder about getting their flu shot at their upcoming visit.
62822198|NCT06587984|EXPERIMENTAL|Cohort 1b|Patients within Cohort 1 have an upcoming well child visit between September-December 2024. Patients within Cohort 1b are those randomized to INTERVENTION MESSAGE #1 and will receive text message reminder (variation #1) about getting their flu shot at their upcoming visit.
62041589|NCT00609427|EXPERIMENTAL|MT|Mnemonic training intervention
62041590|NCT00609427|NO_INTERVENTION|WL|Wait-list control
62244666|NCT05433168|EXPERIMENTAL|DUMMY SHIATSU GROUP|Exercising a fake shiatsu is a real problem as opinions differ. The consensus of the different schools and styles of the technique is that shiatsu pressure is weight transfer. We are therefore going to remove this aspect from the SFASPA shiatsu protocol. The professional will run the same sequence of points, without any weight transfer, being only in contact with the receiver.
62244667|NCT01842386|EXPERIMENTAL|Rituximab|Adults (=18 years of age) with anticytokine autoantibodyassociated diseases who are refractory to conventional treatment and who test negative for the human immunodeficiency virus (HIV)
62434844|NCT04304326|EXPERIMENTAL|Arms and Interventions|"Resistance exercise with weight training machines. Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises was 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension."
62244668|NCT05932342|EXPERIMENTAL|Integrated program of cognitive remediation, physical exercise and socially- stimulating activity|"Cognitive Remediation (CR) is a well-established intervention that aims to improve neurocognitive abilities (such as memory performance, executive functioning, processing speed, and attention) using four techniques: didactic teaching, computerized drills, in-class strategic monitoring and discussions of the generalization of cognitive skills to daily life.~The physical exercise component consists of physical activities designed for the geriatric population that aim to reduce sedentary behaviors while increasing social engagement.~The socially stimulating activity aim to decrease social isolation, improve well-being, community connection and rapport.~The integrated, 12-week, group-based program consists of CR 1h/day, 2 days/week, 30min of physical exercises 1day/week and 1h of socially stimulating activities 1day/week"
62244669|NCT05479890|NO_INTERVENTION|Treatment as Usual (TAU)|TAU will receive no training during the intervention period.
62434845|NCT04614974|EXPERIMENTAL|Speech Language Therapy Alone|Patients in this group will receive a routine swallowing evaluation by a speech language pathologist. Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.
62434846|NCT04614974|ACTIVE_COMPARATOR|Speech Language Therapy and Acid Suppression Therapy|Patients in this group will receive a routine swallowing evaluation by a speech language pathologist and famotidine (acid suppression therapy). Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.
62434847|NCT05163379||INTENSIVE CARE PATIENTS|EARLY MOBILIZATION OF INTUBE PATIENTS
62822199|NCT06587984|EXPERIMENTAL|Cohort 1c|Patients within Cohort 1 have an upcoming well child visit between September-December 2024. Patients within Cohort 1c are those randomized to INTERVENTION MESSAGE #2 and will receive text message reminder (variation #2) about getting their flu shot at their upcoming visit.
62822200|NCT06587984|NO_INTERVENTION|Cohort 2a|Patients within Cohort 2 do not have an upcoming well visit between September-December 2024, but completed their well visit between January 2023 through August 2024. Patients within Cohort 2a are those randomized to CONTROL and will not receive a text message reminder about getting their flu shot.
62822201|NCT06587984|EXPERIMENTAL|Cohort 2b|Patients within Cohort 2 do not have an upcoming well visit between September-December 2024, but completed their well visit between January 2023 through August 2024. Patients within Cohort 2b are those randomized to INTERVENTION MESSAGE #1 and will receive text message reminder (variation #3) about getting their flu shot this upcoming flu season.
62244670|NCT05479890|EXPERIMENTAL|ClientBot (CB)|CB trainees will engage in 5 weekly practice sessions with ClientBot
62822202|NCT06587984|EXPERIMENTAL|Cohort 2c|Patients within Cohort 2 do not have an upcoming well visit between September-December 2024, but completed their well visit between January 2023 through August 2024. Patients within Cohort 2b are those randomized to INTERVENTION MESSAGE #2 and will receive text message reminder (variation #4) about getting their flu shot this upcoming flu season.
62822203|NCT06535880|EXPERIMENTAL|Electric Stimulation|Electric stimulation with a Digitimer DS7AH HV Current Stimulator delivered with 4 shielded electrodes mounted on the participants head and arm.
62822204|NCT05494788|EXPERIMENTAL|CardiolRx|pharmaceutically produced Cannabidiol
62434848|NCT05723627|EXPERIMENTAL|Remimazolam|Patient group who receives remimazolam for sedation during endoscopy
62822205|NCT03353688|ACTIVE_COMPARATOR|Directional DBS guided by behavior|Directional stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by behavioral assessments during device activation.
62822206|NCT03353688|PLACEBO_COMPARATOR|Omnidirectional DBS guided by behavior|"Omnidirectional (ring mode) stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by behavioral assessments during device activation."
62822207|NCT03353688|ACTIVE_COMPARATOR|Directional DBS guided by biomarkers|Directional unilateral subthalamic stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by electrophysiology biomarkers measured during surgery (nested exploratory treatment arm).
62822208|NCT05096403|ACTIVE_COMPARATOR|Pegcetacoplan|1080 mg, subcutaneus injection, twice weekly
62822209|NCT05096403|PLACEBO_COMPARATOR|Placebo|Sodium acetate, subcutaneus injection, twice weekly
62822210|NCT05420935|OTHER|IgG group|Patient in the IgG group will benefit from a blood sampling of 5 ml (for realization of a basophil activation test) and a blood sampling of 250 ml
62822211|NCT05420935|OTHER|IgE group|Patient in the IgE will benefit from a blood sampling of 5 ml (for realization of a basophil activation test) and a bone marrow sampling (approx 2 ml)
62822212|NCT05420935|OTHER|IgG group + IgE group|Patient in the IgG + IgE will benefit from a blood sampling of 5 ml (for realization of a basophil activation test), a blood sampling of 250 ml and a bone marrow sampling (approx 2 ml)
62822213|NCT05635656|EXPERIMENTAL|Digital symptom mapping and biofeedback treatment|
62822214|NCT02435212|ACTIVE_COMPARATOR|DFX DT|Participants will be administered deferasirox dispersible tablets orally once daily based on body weight for 48 weeks.
62822215|NCT02435212|EXPERIMENTAL|DFX Granule|Participants will be administered deferasirox granules orally once daily in the form of stick packs based on body weight for 48 weeks.
62822216|NCT06371768|ACTIVE_COMPARATOR|Education Control|The education control condition will match AYA STEPS in delivery format \[videoconferencing, web-based platform, frequency (biweekly sessions)\], and session number (six) and length.
62822217|NCT06371768|EXPERIMENTAL|AYA STEPS|Participants will receive the AYA STEPS digital health intervention, which includes six sessions delivered remotely (i.e., videoconferencing) by a clinical psychologist with intervention content accessed using a web-based platform.
62822218|NCT06384222|EXPERIMENTAL|Treatment (Abiraterone/Prednisone, Hyperpolarized (HP) 13C Pyruvate)|Neoadjuvant abiraterone (1000mg) will be administered for three 28-day cycles, in conjunction with 5mg of prednisone. Participants will undergo a paired multi-parametric/hyperpolarized MRI of the prostate at screening, cycle 2 day 1, and after completion of neoadjuvant therapy. With each scan, a hyperpolarized 13C-pyruvate injection will be administered. A planned, non-investigational RP will be completed within 7-56 days after last dose/discontinuation of neoadjuvant study drug. Participants will be followed up until death, withdrawal of consent, or end of study, whichever occurs first.
62822219|NCT06595784||COPD patients with cardiovascular comorbidities|
62822220|NCT06655376|EXPERIMENTAL|Warfarin without Aspirin|Participants will only take Warfarin.
62434849|NCT05723627|ACTIVE_COMPARATOR|Propofol|Patient group who receives propofol for sedation during endoscopy
62244671|NCT06002750||Dermatomyositis patients|
62244672|NCT06002750||The control group was comprised of age- and gender-matched healthy volunteers|
62244673|NCT05215132|OTHER|Patient w/ Contrast|Patients will add 15 minutes to their SOC MRI for research purposes
62434850|NCT00628394|OTHER|Atomox/CR|Patients are given the drug Atomoxetine and Cognitive Remediation training.
62434851|NCT00628394|OTHER|Atomox/Control|Patients are given the drug Atomoxetine and Remediation Control training.
62434852|NCT00628394|OTHER|Placebo/CR|Patients are given a Placebo and Cognitive Remediation training.
62434853|NCT00628394|OTHER|Placebo/Control|Patients are given Placebo and Remediation Control training.
62434854|NCT02277873||No Treatment|Defined population (pregnant women) compared on a environmental moon luminosity influence
62434855|NCT02961452||Peanut allergic children|
62822221|NCT06655376|ACTIVE_COMPARATOR|Warfarin and Aspirin|This is the control arm. Participants will take Warfarin and aspirin, which is the standard of care.
62822222|NCT05943834||Patients with a minor or major neurocognitive disorder|"Every patient will receive one semi-automated phone call, during the call a series of cognitive tasks will be performed.~Each task will be recorded in a secondary audio stream which records the participant responses to allow for deep speech analysis of performance on these tasks"
62822223|NCT01373021|PLACEBO_COMPARATOR|F|Fentanyl+Normal saline
62822224|NCT01373021|EXPERIMENTAL|D|Fentanyl+Dexmedetomidine
62822225|NCT02209714|EXPERIMENTAL|BIIF 1149 BS|
62822226|NCT02209714|PLACEBO_COMPARATOR|Placebo|
62601183|NCT06623331||Group B|Colonoscopies performed by endoscopists trained conventionally. In the trial the quality indicators are measured after completing training, without AI enhancement.
62601184|NCT05632315|EXPERIMENTAL|ESCRE/CRE BL-BLI|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: Beta Lactamase Inhibitors (BL-BLI)
62822227|NCT04683042|ACTIVE_COMPARATOR|TENS with PT|TENS with PT group: The TENS with PT group will receive usual PT care and following enrollment, during the second PT visit, participants will receive TENS units and instruction on use of the TENS units. TENS will be applied to the upper and lower back with butterfly electrodes using the following parameters: mixed frequency (2-125Hz), strong but comfortable intensity, variable pulse duration from 100-250 microseconds. TENS to be applied when the patient is active and doing exercises at home and during PT sessions for 30 minutes at least 2 hours per day. The TENS with PT group will complete TENS use to the end of the study at 6 months.
62822228|NCT04683042|OTHER|No TENS with PT|The No TENS group will receive usual PT care until the primary endpoint timeframe of 60 days. After completion of the research homework at 60 days, TENS units will be mailed to the participants and a study team member will complete virtual TENS instruction. The no TENS group will complete TENS to the end of the study at 6 months.
62822229|NCT04957485|ACTIVE_COMPARATOR|JYNNEOS + TPOXX|An oral dose of 600 mg (3 × 200 mg capsules) TPOXX BID (every 12 hours \[±30 minutes\]) for 28 days and a single AM SC dose of 0.5 mL JYNNEOS on Day 1 and Day 29. JYNNEOS will be administered with TPOXX concomitantly on Day 1
62244674|NCT05215132|OTHER|Patient no contrast|Patients will add 15 minutes to their SOC MRI for research purposes
62822230|NCT04957485|PLACEBO_COMPARATOR|JYNNEOS + matching TPOXX placebo|An oral dose of placebo (3 capsules identical to TPOXX) BID (every 12 hours \[±30 minutes\]) for 28 days and a single AM SC dose of 0.5 mL JYNNEOS on Day 1 and Day 29. JYNNEOS will be administered with TPOXX placebo concomitantly on Day 1.
62244675|NCT05215132|OTHER|Volunteer w/ contrast|Volunteers undergo 1 research MRI for research purposes
62244676|NCT05215132|OTHER|Volunteer no contrast|Volunteers undergo 1 research MRI for research purposes
62244677|NCT06467617|EXPERIMENTAL|Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab|Participants will receive Adebrelimab 1200mg IV on Day 1 of a 21-Day cycle plus albumin-bound paclitaxel 260 mg/m2, IV, divided by D1,8 of a 21-Day cycle plus Carboplatin AUC 5mg/mL/min, IV, and recaticimab 150 mg, SC on the Day 1 of a 21-Day cycle
62601185|NCT05632315|NO_INTERVENTION|ESCRE/CRE BL-BLI standard of care (SOC)|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: Beta Lactamase Inhibitors (BL-BLI) standard of care (SOC)
62601186|NCT05632315|EXPERIMENTAL|ESCRE/CRE carbapenem +/- BLI|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: carbapenem +/- BLI
62601187|NCT05632315|NO_INTERVENTION|ESCRE/CRE carbapenem +/- BLI standard of care (SOC)|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: carbapenem +/- BLI standard of care (SOC)
62601188|NCT05632315|EXPERIMENTAL|ESCRE/CRE Fluoroquinolone|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: Fluoroquinolone
62822231|NCT04969939|EXPERIMENTAL|Semaglutide 2.4 mg and NNC0165-1875 2.0 mg|Participants will receive two doses of NNC0165-1875 as an add on to semaglutide s.c. 2.4 mg
62244678|NCT04142177|ACTIVE_COMPARATOR|Internet-based pain self-management program|Internet-based treatment (Step 1 Treatment)
62822232|NCT04969939|PLACEBO_COMPARATOR|Semaglutide 2.4 mg and placebo 2.0 mg(NNC0165-1875 2.0 mg)|Participants will receive placebo as an add on to semaglutide 2.4 mg.
62822233|NCT04969939|EXPERIMENTAL|Semaglutide 2.4 mg and NNC0165-1875 1.0 mg|Participants will receive two doses of NNC0165-1875 as an add on to semaglutide s.c. 2.4 mg
62244679|NCT04142177|ACTIVE_COMPARATOR|Enhanced Physical Therapy|Intervention that combines the internet-based pain self-management program with tailored exercise and physical activity guided by a physical therapist (Step 1 treatment)
62434856|NCT05358873|EXPERIMENTAL|Human IgG1 anti-SARS-CoV-2 antibody cocktail|Subjects will receive the Hypromellose-based nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail (i.e., applied into both nostrils by spraying two times per nostril) 3 times a day from Day 1 to Day 7. Each day the study products will be self-administered at 8 am, 2 pm, and 8 pm.
62822234|NCT04969939|PLACEBO_COMPARATOR|Semaglutide 2.4 mg and placebo 1.0 mg(NNC0165-1875 1.0 mg)|Participants will receive placebo as an add on to semaglutide 2.4 mg.
62822235|NCT03240601|SHAM_COMPARATOR|Subthreshold|Individuals will undergo their standard physical therapist directed locomotor training while receiving transcutaneous spinal cord stimulation. The stimulation intensity will briefly ramp up to the lowest intensity that is first detected by the participant and then ramped down to a level no longer detected by the participant. Participants will continue their locomotor training.
62822236|NCT03240601|EXPERIMENTAL|Active|Individuals will undergo their standard physical therapist directed locomotor training while receiving transcutaneous spinal cord stimulation. The stimulation intensity will ramp up slowly to a level that produces parasthesia (tingling) throughout the lower extremity. This intensity will be applied for 30 minutes while participants continue their locomotor training.
62822237|NCT02582528|EXPERIMENTAL|cognitive remediation treatment and MI|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS) and motivational interviewing, a client-centered, directive method for enhancing intrinsic motivation to change.
62822238|NCT02582528|ACTIVE_COMPARATOR|cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
62822239|NCT05418816|EXPERIMENTAL|SelfWrap-treated|Treated with SelfWrap Bioabsorbable Perivascular Wrap during AVF creation surgery
62849183|NCT03805659|EXPERIMENTAL|Sham, then HD-tDCS|Subjects receive Sham sessions (no electric current) once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday). After a washout period of 16 weeks, subjects receive High Dose transcranial Direct Current Stimulation (HD-tDCS) lasting 20 minutes at an electric current intensity of up to 2mA in the left posterior temporo-parietal cortex (TPC). Stimulation sessions are delivered once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday).
62849184|NCT04316091|EXPERIMENTAL|Experimental group|neoadjuvant chemotherapy+SPIONs/SMF
62434857|NCT05358873|PLACEBO_COMPARATOR|Placebo|Subjects will receive the Normal saline solution (0.9% NaCl) nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail (i.e., applied into both nostrils by spraying two times per nostril) 3 times a day from Day 1 to Day 7. Each day the study products will be self-administered at 8 am, 2 pm, and 8 pm.
62434858|NCT05423691|EXPERIMENTAL|Arm 1|CK0804 will be administered intravenously (IV) 100 million Treg Cells every 28 days up to 6 infusions.
62434859|NCT05636033||Alcohol use disorder patients|
62434860|NCT05636033||Healthy controls|
62601189|NCT05632315|NO_INTERVENTION|ESCRE/CRE Fluoroquinolone standard of care (SOC)|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: Fluoroquinolone standard of care (SOC)
62601190|NCT05632315|EXPERIMENTAL|MRSA lipo/glycopeptide|MRDO: methicillin-resistant S. aureus (MRSA) Antibiotic Class: lipo/glycopeptide
62601191|NCT05632315|NO_INTERVENTION|MRSA lipo/glycopeptide standard of care (SOC)|MRDO: methicillin-resistant S. aureus (MRSA) Antibiotic Class: lipo/glycopeptide standard of care (SOC)
62822240|NCT05586581|EXPERIMENTAL|People living with treated suppressed HIV infection (PLWH)|"40 PLWH participants will be scanned using anatomical magnetic resonance imaging (MRI) and undergo two SV2A (11C-UCB-J) PET scans with arterial sampling and full radio metabolite analysis to obtain measures of synaptic density at baseline and 24 months (2 years). For each SV2A PET, up to 20 millicurie (mCi) of \[11C\], UCB-J will be administered by an intravenous line (IV) with a scan duration of up to 120 minutes.~A subset of PLWH (n=20) will participate in TSPO (11C-PBR28) PET scans on the same day as the baseline SV2A PET scan. For a TSPO PET, up to 20 mCi of \[11C\], PBR28 will be administered by an intravenous line (IV) with a scan duration of up to 120 minutes."
62434861|NCT01914822|EXPERIMENTAL|methylphenidate hydrochloride|The study will include two sessions which will be conducted at the same time of the day, one week apart from each other. Each session will last approximately 6 hours. In each session subjects will be exposed to baseline experimental pain models and auditory tests. Then they will receive either one MP SR 20 mg tablet or an identical looking placebo.
62822241|NCT05586581|EXPERIMENTAL|HIV-Negative Control (HIV-)|30 HIV-Negative Control (HIV-) participants will be scanned using anatomical magnetic resonance imaging (MRI) and undergo two SV2A (11C-UCB-J) PET scans with arterial sampling and full radio metabolite analysis to obtain measures of synaptic density at baseline and 24 months (2 years). For each SV2A PET, up to 20 mCi of \[11C\], UCB-J will be administered by an intravenous line (IV) with a scan duration of up to 120 minutes.
62849185|NCT04316091|SHAM_COMPARATOR|Control group|neoadjuvant chemotherapy
62849186|NCT05361447|EXPERIMENTAL|GAD65 Associated Epilepsy|Subjects diagnosed with GAD65 associated epilepsy, serum high-titer GAD65 positivity, trialed and failed at least 2 anti-seizure medications, at least 4 seizures per month will be started on diazepam.
62041591|NCT04439292|EXPERIMENTAL|Treatment (dabrafenib, trametinib)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62434862|NCT01914822|PLACEBO_COMPARATOR|Sugar pill|The study will include two sessions which will be conducted at the same time of the day, one week apart from each other. Each session will last approximately 6 hours. In each session subjects will be exposed to baseline experimental pain models and auditory tests. Then they will receive either one MP SR 20 mg tablet or an identical looking placebo.
62434863|NCT05992545|EXPERIMENTAL|Mobile application 'DangDang Care' under usual care|The intervention group receives 'DangDang Care' alongside usual diabetes care.
62434864|NCT05992545|NO_INTERVENTION|Usual care|The control group receives only usual diabetes care.
62434865|NCT01489878||β-lactams|amoxicillin-clavulanate or penicillins M
62434866|NCT01489878||macrolides|
62434867|NCT01489878||fluoroquinolones|
62434868|NCT01489878||synergistins|
62434869|NCT02963298|ACTIVE_COMPARATOR|CRRT after cardiac arrest|Continuous renal replacement therapy (CRRT) after cardiac arrest for 72 hours for elimination of Glutamate. Repetitive testing of blood Glutamate levels.
62434870|NCT02963298|NO_INTERVENTION|control|Repetitive testing of blood Glutamate levels without CRRT
62434871|NCT06242730||People living with HIV participating in the Swiss HIV Cohort Study on doxycycline STI PEP|The target population for this study are MSM or TGW at high risk for a bacterial STI (≥1 occasional partners within the preceding 6 months) taking teh doxycycline STI PEP
62434872|NCT04270526|ACTIVE_COMPARATOR|Active treatment|50 mL 1% lidocaine + 45ml of 0.9% normal saline + 5 mL 8.4% sodium bicarbonate
62434873|NCT04270526|PLACEBO_COMPARATOR|Placebo treatment|50 mL 1% lidocaine + 50ml of 0.9% normal saline
62434874|NCT04505514|EXPERIMENTAL|Intravenous Iron Group|
62434875|NCT04505514|ACTIVE_COMPARATOR|Oral Iron Group|
62434876|NCT01876199|EXPERIMENTAL|Intense follow up|2-week follow up appointment with addition of a reminder mobile phone call or short text message (SMS) if possible, plus a home visit by a community counselor if the participant fails to present on the appointed date.
62434877|NCT01876199|NO_INTERVENTION|standard follow-up|2-week follow-up appointment with no reminders
62434878|NCT00995332|EXPERIMENTAL|ATRA+valproc acid+low-dose cytarabine|
62434879|NCT03016078|OTHER|Mepilex Border Post-Op Ag Dressing|A soft silicone foam dressing that absorbs wound exudate maintains a moist wound healing environment and has antimicrobial properties
62601192|NCT05632315|EXPERIMENTAL|MRSA oxazolidinone|MRDO: methicillin-resistant S. aureus (MRSA) Antibiotic Class: oxazolidinone
62601193|NCT05632315|NO_INTERVENTION|MRSA oxazolidinone standard of care (SOC)|MRDO: methicillin-resistant S. aureus (MRSA) Antibiotic Class: oxazolidinone standard of care (SOC)
62601194|NCT05632315|EXPERIMENTAL|MDR-PA BL-BLI|MDRO: two-class non-susceptible Pseudomonas aeruginosa (MDR-PA) Antibiotic Class: Beta Lactamase Inhibitors (BL-BLI)
62244680|NCT04142177|PLACEBO_COMPARATOR|Continued Care and Active Monitoring (CCAM)|CCAM will not be standardized keeping in line with the pragmatic nature of this trial. CCAM may be variable across sites and for individual participants reflecting de facto clinical practice for cLBP. Clinical practice may involve pharmacological and non-pharmacological treatments for cLBP. Current analgesics (including opioids, acetaminophen, NSAIDs, topical analgesics (capsaicin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, skeletal muscle relaxants, and alpha-2-delta ligands (gabapentin-like drugs)) and non-pharmacological treatments may be continued by participants. CCAM participants will be encouraged to discuss pain problems with their treating physician, but not begin new treatments if possible. Patients will specifically be discouraged from starting CBT, chiropractic, or yoga. Other than this, there will be no attempt by study personnel to influence pain management (Step 1 Treatment)
62244681|NCT04142177|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT)|Participants randomized to CBT in Step 2 will receive treatment with a trained therapist using the VA's CBT-chronic pain (CBT-CP) protocol involving one planning session and 9 treatment sessions (10 total) over 3 months (Step 2 Treatment).
62244682|NCT04142177|ACTIVE_COMPARATOR|Spinal Manipulation Therapy (SMT)|After examination by a qualified Doctor of Chiropractic (DC), a SMT intervention consisting of up to 10 sessions over 3 months will be designed focusing on spinal manipulation and/or mobilization of the lower thoracic, lumbar and/or sacroiliac joints. Adjunctive use of myofascial and/or stretching techniques are allowed as they are commonly used along with SMT, and can be considered a standard accompaniment to SMT (Step 2 Treatment).
62601195|NCT05632315|NO_INTERVENTION|MDR-PA BL-BLI standard of care (SOC)|MDRO: two-class non-susceptible Pseudomonas aeruginosa (MDR-PA) Antibiotic Class: Beta Lactamase Inhibitors (BL-BLI) standard of care (SOC)
62601196|NCT05632315|EXPERIMENTAL|MDR-PA carbapenem +/- BLI|MDRO: two-class non-susceptible Pseudomonas aeruginosa (MDR-PA) Antibiotic Class: carbapenem +/- BLI
62601197|NCT05632315|NO_INTERVENTION|MDR-PA carbapenem +/- BLI standard of care (SOC)|MDRO: two-class non-susceptible Pseudomonas aeruginosa (MDR-PA) Antibiotic Class: carbapenem +/- BLI standard of care (SOC)
62601198|NCT05632315|EXPERIMENTAL|MDR-PA Fluoroquinolone|MDRO: two-class non-susceptible Pseudomonas aeruginosa (MDR-PA) Antibiotic Class: Fluoroquinolone
62601199|NCT05632315|NO_INTERVENTION|MDR-PA Fluoroquinolone standard of care (SOC)|MDRO: two-class non-susceptible Pseudomonas aeruginosa (MDR-PA) Antibiotic Class: Fluoroquinolone standard of care (SOC)
62601200|NCT05632315|EXPERIMENTAL|VRE lipopeptide|MDRO: vancomycin resistant Enterococcus (VRE) Antibiotic Class: lipopeptide
62601201|NCT05632315|NO_INTERVENTION|VRE lipopeptide standard of care (SOC)|MDRO: vancomycin resistant Enterococcus (VRE) Antibiotic Class: lipopeptide standard of care (SOC)
62601202|NCT05632315|EXPERIMENTAL|VRE oxazolidinone|MDRO: vancomycin resistant Enterococcus (VRE) Antibiotic Class: oxazolidinone
62601203|NCT05632315|NO_INTERVENTION|VRE oxazolidinone standard of care (SOC)|MDRO: vancomycin resistant Enterococcus (VRE) Antibiotic Class: oxazolidinone standard of care (SOC)
62601204|NCT05632315|EXPERIMENTAL|ESCRE/CRE cefepime/cefidericol|MDRO: ESCRE/CRE Antibiotic Class: cefepime/cefidericol
62601205|NCT05632315|NO_INTERVENTION|ESCRE/CRE cefepime/cefidericol standard of care (SOC)|MDRO: ESCRE/CRE Antibiotic Class: cefepime/cefidericol standard of care (SOC)
62601206|NCT05632315|EXPERIMENTAL|MDR-PA cefepime/cefidericol|MDRO: two-class non-susceptible Pseudomonas aeruginosa (MDR-PA) Antibiotic Class: cefepime/cefidericol
62822242|NCT04040569|EXPERIMENTAL|Single-fraction stereotactic partial breast radiotherapy|The primary objective is to escalate the dose of 1 fraction stereotactic partial breast radiotherapy utilizing the MR Linac,Gammapod or Cyberknife system to an ablative dose in the pre-operative setting to the primary tumor without exceeding the maximum tolerated dose in patients with early stage breast cancer.
62822243|NCT04570371|EXPERIMENTAL|Intervention|Per a stepped-wedge cluster randomized pragmatic clinical trial design, all patients within whole surgical practices will be randomized to implementation tranches in which the intervention will be implemented per the study schedule.
62244683|NCT04142177|ACTIVE_COMPARATOR|Yoga|The Yoga for Veterans with cLBP program consists of up to 10 weekly, 60-minute instructor-led sessions along with 15-20 minutes of yoga practiced at home each non-session day. The initial session is 75 minutes (15 minutes longer than the other sessions). The yoga program can be considered classical hatha yoga with influences from Iyengar and Viniyoga yoga. These styles emphasize modifications and adaptations including the use of props such as straps and blocks to minimize the risk of injury and make the poses accessible to people with health problems and limitations (Iyengar, 1979). The instructor leads participants through a series of 23 yoga poses (32 total variations) at a slow-moderate pace (Step 2 Treatment).
62822244|NCT04570371|NO_INTERVENTION|Control Arm|Per a stepped-wedge cluster randomized pragmatic clinical trial design, all patients within whole surgical practices will be randomized to implementation tranches. The control arm consists of all patients receiving surgery in implementation tranches in which the intervention has not been implemented yet (per the study schedule).
62822245|NCT04104256|EXPERIMENTAL|Alert 1|Patients with a pre-op encounter in which the physician attempts to place an order for a pre-op test. Physician has been assigned to the Nudge #1 group.
62822246|NCT04104256|EXPERIMENTAL|Alert 2|Patients with a pre-op encounter in which the physician attempts to place an order for a pre-op test. Physician has been assigned to the Nudge #2 group.
62822247|NCT04104256|EXPERIMENTAL|Alert 3|Patients with a pre-op encounter in which the physician attempts to place an order for a pre-op test. Physician has been assigned to the Nudge #3 group.
62601207|NCT05632315|NO_INTERVENTION|MDR-PA cefepime/cefidericol standard of care (SOC)|MDRO: two-class non-susceptible Pseudomonas aeruginosa (MDR-PA) Antibiotic Class: cefepime/cefidericol standard of care (SOC)
62601208|NCT06554990|OTHER|control|physical therapy excersises
62822248|NCT04104256|EXPERIMENTAL|Control|Patients with a pre-op encounter in which the physician attempts to place an order for a pre-op test. Physician has been assigned to the Control group. Encounter continues as usual.
62822249|NCT06589752||Treat|TRF-budesonide enteric-coated capsule（TARPEYO）
62601209|NCT06554990|EXPERIMENTAL|intervention|sensory perceptual training
62601210|NCT06160284|EXPERIMENTAL|Current OUD diagnosis + psilocybin|All participants will receive a \[11C\]-UCB-J PET scan and fMRI with in 1-2 weeks pre and post treatment with one dose of Psilocybin. Intravenous lines will be used for phlebotomy and administration of the \[11C\]-UCB-J radiotracer. On the PET scanning day, a radial arterial catheter may be inserted.
62601211|NCT05654428|EXPERIMENTAL|Experimental Group|"55 patients~Standard treatment:~TENS (4-pole) + Hot pack for 15 minutes Standard treatment:~TENS (4-pole) + Hot pack for 15 minutes~New Intervention:~Mckenzie Extension~* Prone press-ups~* Head life in prone~* Prone on elbow~* Prone on hands~* Prone on pillow"
62601212|NCT05654428|ACTIVE_COMPARATOR|Control Group|"55 patients~Standard treatment:~TENS (4-pole) + Hot pack for 15 minutes Standard treatment:~TENS (4-pole) + Hot pack for 15 minutes~New Intervention:~William Flexion~* Single knee to chest~* Double knee to chest~* Straight Leg Raise~* Bridging~* Pelvic tilt"
62601213|NCT04181437|EXPERIMENTAL|NVP-1203-R1|"Drug: NVP-1203-R1~1 tablet, oral dosing"
62601214|NCT04181437|EXPERIMENTAL|NVP-1203-R2|"Drug: NVP-1203-R2~1 tablet, oral dosing"
62822250|NCT06589752||Control|RAS blocker
62041592|NCT04217681|EXPERIMENTAL|Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
62434880|NCT03960918|NO_INTERVENTION|usual neuro-rehab training|stroke patient under usual neuro-rehab training
62601215|NCT04181437|EXPERIMENTAL|NVP-1203-R1 and NVP-1203-R2|Drug: NVP-1203-R1 1 tablet and NVP-1203-R2 1 tablet co-administration(oral dosing)
62601216|NCT06575660|EXPERIMENTAL|Patients with IBD who self-report mild to moderate levels of anxiety or depression|
62601217|NCT02395237|EXPERIMENTAL|Amaryl® M IR 2/1000 (manufactured in India)|Investigational products :Reference formulation Trade Name: Amaryl® M IR 2/1000 (manufactured in India) Dosage Form: Film coated tablet 1x1 Active Substance: Glimepiride/metformine HCl 2 mg/1000 mg Manufacturer: Goa, India
62601218|NCT02395237|EXPERIMENTAL|Amaryl® M IR 2/1000 (manufactured in Turkey)|Dosage form: Film coated tablet 1x1 Active substance : Glimepiride/metformine HCl 2 mg/1000 mg Manufacturer: Zentiva TR, Lüleburgaz
62822251|NCT04856358|EXPERIMENTAL|GLPG3121 SAD|Single doses of GLPG3121 at up to 3 dose levels in ascending order
62822252|NCT04856358|PLACEBO_COMPARATOR|Placebo SAD|Single doses of placebo
62822253|NCT04856358|EXPERIMENTAL|GLPG3121 MAD|Multiple doses of GLPG3121 at up to 3 dose levels in ascending order
62822254|NCT04856358|PLACEBO_COMPARATOR|Placebo MAD|Multiple doses of placebo
62822255|NCT04856358|EXPERIMENTAL|GLPG3121 FE fed|Single dose of GLPG3121 in fed state
62822256|NCT04856358|EXPERIMENTAL|GLPG3121 FE fasted|Single dose of GLPG3121 in fasted state
62822257|NCT06588114|EXPERIMENTAL|experimental group (skin cooler device)|Hemodialysis patients in this group will be provided with skin temperature reduction by the researcher with a skin cooling device for 10 minutes before the arteriovenous fistula attempt is made.
62041593|NCT04217681|EXPERIMENTAL|Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
62041594|NCT04217681|EXPERIMENTAL|Self-hypnosis/self-care motivation|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
62041595|NCT04217681|EXPERIMENTAL|Self-hypnosis/self-care malignant pain|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
62041596|NCT05584410|EXPERIMENTAL|App-based model of care|"The app-based model of care includes at least one physical visit at the clinic. The majority of the treatment is provided by the app, containing five different sections:~1) My information: specific information regarding osteoarthritis and generic lifestyle advice. 2 \& 3) My exercise \& My plan: individualized exercises where instructions are given through real-time video or pictures and written descriptions. The patient has access to a calendar and an overview of scheduled rehabilitation/exercises and care meetings. 4) My progress: weekly assessment of pain + every six-month with valid patient reported outcome measures and test of function. 5) My messages (asynchronous chat with the responsible physiotherapist). The app sends automatic and daily reminders and / or motivational notifications."
62244684|NCT06588504|EXPERIMENTAL|Adult Cohort: Dasiglucagon then Glucagon|Participants will receive a single subcutaneous (s.c.) injection of dasiglucagon in first dosing visit then a single intra-mascular (i.m.) injection of glucagon in next dosing visit.
62244685|NCT06588504|EXPERIMENTAL|Adult Cohort: Glucagon then Dasiglucagon|Participants will receive a single i.m. injection of glucagon in first dosing visit then a single s.c. injection of dasiglucagon in next dosing visit.
62822258|NCT06588114|EXPERIMENTAL|experimental group (Antistress Ball Group)|Hemodialysis patients in this group will be asked to look away by giving an antistress ball to the non-arteriovenous fistula hand and squeezing and then loosening the ball during the arteriovenous fistula intervention.
62822259|NCT06588114|EXPERIMENTAL|experimental group (Valsalva Maneuver Group)|The Valsalva maneuver is a breathing method that can slow down a heart with a very fast pulse rate. In this maneuver, the individual breathes strongly through his mouth while his nose is tightly closed, and while holding his breath, a strong tension occurs. This maneuver allows the heart to react and return to a normal rhythm. Hemodialysis patients in this group will perform the valsalva maneuver taught to them by the researcher during arteriovenous intervention.
62822260|NCT06588114|NO_INTERVENTION|control group|Hemodialysis patients aged 18 years and older who have arteriovenous fistula and have been on hemodialysis for more than three months will be included in the control group. No intervention will be made to the control group. Patients in this group will receive routine check-ups and hemodialysis treatments.
62822261|NCT06354647|EXPERIMENTAL|Zirconia-based primary anterior crowns with retention grooves|Participants will receive zirconia-based primary anterior crowns with retention grooves
62822262|NCT06354647|EXPERIMENTAL|Zirconia-based primary anterior crowns without retention grooves|Participants will receive zirconia-based primary anterior crowns without retention grooves
62822263|NCT05270057|EXPERIMENTAL|Loncastuximab Tesirine Dose Escalation 0.075 mg/kg by IV.|The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD.
62822264|NCT05270057|EXPERIMENTAL|Loncastuximab Tesirine Dose Escalation 0.12 mg/kg by IV.|The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD.
62822265|NCT05270057|EXPERIMENTAL|Loncastuximab Tesirine Dose Escalation 0.15 mg/kg by IV.|The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD.
62849187|NCT03081936|ACTIVE_COMPARATOR|A1 formula|Oral consumption of Nutricia Aptamil Stage 1 formula (traditional cow milk)
62244686|NCT06588504|EXPERIMENTAL|Adolescent Cohort: Dasiglucagon|Participants will receive a single s.c. injection of dasiglucagon.
62601219|NCT00707902|ACTIVE_COMPARATOR|2|"Drug: Echinacea/sage~patients received additionally a placebo-spray for the synthetical comparator (chlorhexidine/lidocaine) as the study was double dummy blinded.~Patients had to apply spray every 2 hours with two puffs to the pharyngeal area up to a maximum of 10 times daily. Treatment duration was until illness was resolved or for a maximum of 5 consecutive days.~Arms: 1"
62601220|NCT00707902|ACTIVE_COMPARATOR|1|"Drug: Chlorhexidine/lidocaine~patients received additionally a placebo-spray for the synthetical comparator (echinacea/sage) as the study was double dummy blinded.~Patients had to apply spray every 2 hours with two puffs to the pharyngeal area up to a maximum of 10 times daily. Treatment duration was until illness was resolved or for a maximum of 5 consecutive days."
62601221|NCT06647680|EXPERIMENTAL|Patients with rectal cancer receiving neoadjuvant chemotherapy and PD-1 inhibitor|Experimental: Combination of drugs prior to surgery Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles prior to surgery and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years. The time in the study will take approximately four - six hours during pre-study, study and end of study visits.
62041597|NCT05584410|ACTIVE_COMPARATOR|Web-based model of care|The patient will get access to information about osteoarthritis and generic osteoarthritis exercises program from a web-based platform Individualization of the training can be done by the responsible physiotherapist informing about changes in the training via the message function and / or during physical follow-up visits. An individualized rehabilitation program can be given to the patient, via the platform or at a physical visit at the clinic, in form of a document with pictures and descriptive information. As long as the patient is under treatment (approximately three months), he/she can contact their responsible physiotherapist by sending a message from the platform.
62041598|NCT05584410|ACTIVE_COMPARATOR|Standard care|Patients who are randomized to standard care receive osteoarthritis specific information at three different group meetings (physical or digital) led by a physiotherapist, an occupational therapist and / or dietitian (each rehab clinic makes its own arrangement). After the theory sessions, the patient is booked for another physical visit to the responsible physiotherapist where an individual training program is tested. The patient is then offered to regularly exercise at the clinic, individually or in a group under supervision from a physiotherapist.
62822266|NCT05270057|EXPERIMENTAL|Loncastuximab Tesirine Dose Escalation Maximum Tolerated Dose|The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD. This dose will be added to this record when it is determined.
62822267|NCT05270057|EXPERIMENTAL|Dose Expansion Phase|Subjects will receive the recommended phase 2 dose (RP2D) identified from dose-escalation phase. This dose will be added to this record when it is determined.
62434881|NCT03960918|EXPERIMENTAL|Novel exercise training|stroke patient under aerobic exercise training
62601222|NCT05152654|NO_INTERVENTION|Fixation|Total extra peritoneal repair will be performed in this arm for the patients due to unilateral inguinal hernia. The 15x12 cm mesh will be marked with titanium clips from its 4 corners and placed in the hernia area. The mesh will be fixed to the hernia area by the non-absorbable tacker.This method is the method used routinely in the treatment of laparoscopic hernia today.
62601223|NCT05152654|EXPERIMENTAL|Non-Fixation|Total extra peritoneal repair will be performed in this arm for the patients due to unilateral inguinal hernia. The 15x12 cm mesh will be marked with titanium clips from its 4 corners and placed in the hernia area. The mesh will not be detected in any way.
62601224|NCT02573831|PLACEBO_COMPARATOR|Placebo|The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if needed
62601225|NCT02573831|EXPERIMENTAL|Oxycodone|The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
62601226|NCT06623552||Control Group|the population without cervical pain or with a cut off value of less than 15 for neck pain and disability score(NPDS) were selected as the control group
62601227|NCT06623552||Study Group|the population without cervical pain or with a cut off value of more than 15 for neck pain and disability score(NPDS) were selected as the study group
62601228|NCT06622551|EXPERIMENTAL|Overweight/obese arm|In this arm, those who are overweight and obese will be assigned. Each participant will be given 90 days of IFA supplement.
62601229|NCT06622551|ACTIVE_COMPARATOR|Normal-weight arm|In this arm, those with normal-weight will be assigned. Each participant will be given 90 days of IFA supplement.
62822268|NCT06498349|OTHER|DBS-group|"Within indication and clinical routine:~bilateral high frequency deep brain stimulation of the subthalamic nucleus combined with best medical treatment"
62434882|NCT03120702|EXPERIMENTAL|Neonatal Test Subjects|All test subjects in this group are neonatal patients who will receive a investigational Rainbow SpHb sensor.
62434883|NCT05105139||A1: Allantoin / Coal Tar / Clioquinol (Sebryl®)|Pharmaceutical Form: Shampoo Dosage: 0.2 g/ 5.0 g/ 3.0 g Administration way: For scalp use
62601230|NCT01892709|EXPERIMENTAL|Hydromorphone|"All eligible patients will receive 1 mg IV hydromorphone. Thereafter, they will be repeatedly asked the question, Do you want more pain medicine? This question will be asked 30 minutes after they answered no or 30 minutes after the completion of the next dose of 1 mg IV hydromorphone, which occurs when the patients answers yes. Patients will receive a maximum of 4 mg IV hydromorphone over a 4 hour period."
62601231|NCT03191864|EXPERIMENTAL|APT-1011 1.5 mg HS|Placebo after breakfast, APT-1011 1.5 mg HS
62601232|NCT03191864|EXPERIMENTAL|APT-1011 1.5 mg BID|APT-1011 1.5 mg after breakfast, APT-1011 1.5 mg HS
62601233|NCT03191864|EXPERIMENTAL|APT-1011 3 mg HS|Placebo after breakfast, APT-1011 3 mg HS
62601234|NCT03191864|EXPERIMENTAL|APT-1011 3 mg BID|APT-1011 3 mg after breakfast, APT-1011 3 mg HS
62601235|NCT03191864|PLACEBO_COMPARATOR|Placebo BID|Placebo 30 minutes after breakfast and HS
62822269|NCT06498349|OTHER|BMT-group|"Within indication and clinical routine:~best medical treatment"
62822270|NCT06590324|EXPERIMENTAL|apabetalone|apabetalone selectively binds to the second bromodomain \[BD2\] of bromodomain extra terminal (BET) proteins, curbing the transcription of multiple disease associated genes that promote vascular inflammation, complement, acute phase response (APR), fibrosis, dyslipidemia, and vascular calcification.
62822271|NCT01076478|PLACEBO_COMPARATOR|Arm 1|2 tablets BID
62822272|NCT01076478|EXPERIMENTAL|Arm 2|100 mg Cilostazol (2 tablets BID)
62822273|NCT01076478|EXPERIMENTAL|Arm 3|200 mg Cilostazol (2 Tablets BID)
62822274|NCT01705119|EXPERIMENTAL|Mechanically Ventilated|
62822275|NCT04897711|EXPERIMENTAL|Perceptual training with a speaker with dysarthria - Amyotrophic Lateral Sclerosis (ALS)|To examine the effect of perceptual training with different speakers with dysarthria, we use a standard three-phase perceptual training protocol involving pretest, training, and posttest phases. Speech samples from a single speaker with dysarthria are utilized for all three phases. In this arm, listener participants were assigned to Speaker 1 (mixed flaccid-spastic dysarthria due to amyotrophic lateral sclerosis)
62041599|NCT04672941||COPD patients|"COPD patients switching from Tiotropium monotherapy to dual therapy with Tiotropium bromide plus Olodaterol.~All eligible Chronic Obstructive Pulmonary Disease (COPD) patients who had recently switched (within one week) from tiotropium monotherapy (Spiriva® Handihaler®) to dual therapy with tiotropium bromide plus olodaterol (Spiolto® Respimat®), in the Greek private and public sector pulmonary offices and clinics. The follow-up period was 3 months. Participants were visited at baseline (Visit 1) and at 3 months after baseline visit (Visit 2)."
62041600|NCT03683069|EXPERIMENTAL|Epleronone Arm|
62244687|NCT06735391|EXPERIMENTAL|JMT101|JMT101 6mg/kg,intravenous drip,once every two weeks (Q2W), and osimertinib 80mg,orally,once daily(QD),with every 4weeks as a treatment cycle
62601236|NCT06619678|EXPERIMENTAL|Islatravir+MK-8507|Period 1: Participants receive single dose of Islatravir on Day 1. Period 2: Participants receive single dose of MK-8507 on Days 1 and Days 8. Period 3: Participants receive single dose of Islatravir and single dose of MK-8507 on Day 1, 7 days after the Day 8 dose of MK-8507, during Period 2. Participants will receive additional MK-8507 single doses on Days 8, 15, 22, and 29.
62601237|NCT06628778|EXPERIMENTAL|Dalteparin Thromboprophylaxis|This arm will receive the study intervention, dalteparin thromboprophylaxis during pediatric intensive care unit hospitalization
62601238|NCT06628778|NO_INTERVENTION|Standard-of-Care Arm|This arm will receive standard of care (i.e., no pharmacological thromboprophylaxis)
62601239|NCT06234696|EXPERIMENTAL|experimental group|"The group consists of 30 people and this group will be given psychoeducation for 4 weeks.~Training will be provided 2 days a week (monday and friday)."
62822276|NCT04897711|EXPERIMENTAL|Perceptual training with a speaker with dysarthria - Ataxic 1|To examine the effect of perceptual training with different speakers with dysarthria, we use a standard three-phase perceptual training protocol involving pretest, training, and posttest phases. Speech samples from a single speaker with dysarthria are utilized for all three phases. In this arm, listener participants were assigned to Speaker 2 (Ataxic dysarthria due to cerebellar degeneration)
62822277|NCT04897711|EXPERIMENTAL|Perceptual training with a speaker with dysarthria - Parkinson's disease (PD) 1|To examine the effect of perceptual training with different speakers with dysarthria, we use a standard three-phase perceptual training protocol involving pretest, training, and posttest phases. Speech samples from a single speaker with dysarthria are utilized for all three phases. In this arm, listener participants were assigned to Speaker 3 (hypokinetic dysarthria due to Parkinson's disease)
62822278|NCT04897711|EXPERIMENTAL|Perceptual training with a speaker with dysarthria - Ataxic 2|To examine the effect of perceptual training with different speakers with dysarthria, we use a standard three-phase perceptual training protocol involving pretest, training, and posttest phases. Speech samples from a single speaker with dysarthria are utilized for all three phases. In this arm, listener participants were assigned to Speaker 4 (Ataxic dysarthria due to cerebellar degeneration)
62822279|NCT04897711|EXPERIMENTAL|Perceptual training with a speaker with dysarthria - Parkinson's disease (PD) 2|To examine the effect of perceptual training with different speakers with dysarthria, we use a standard three-phase perceptual training protocol involving pretest, training, and posttest phases. Speech samples from a single speaker with dysarthria are utilized for all three phases. In this arm, listener participants were assigned to Speaker 5 (hypokinetic dysarthria due to Parkinson's disease)
62822280|NCT04865627||independent walking with walking aid|the participant is able to walk with a walking aid and does not need further assistance.
62822281|NCT04865627||dependent walking with walking aid|the participant is able to walk with assistance and a walking aid
62822282|NCT03896438|EXPERIMENTAL|right active-tDCS|2-3 times/week for 12 weeks: ramp-up for 30 seconds, 2mA right (AF4 anode - AF3 cathode) for 20 min, and then ramp-down for 30 seconds.
62822283|NCT03896438|EXPERIMENTAL|left active-tDCS|2-3 times/week for 12 weeks: ramp-up for 30 seconds, 2mA left (AF3 anode - AF4 cathode) for 20 min, and then ramp-down for 30 seconds.
62822284|NCT03896438|SHAM_COMPARATOR|sham tDCS|Current will be turned off immediately after the initial 30-second ramp-up period.
62849188|NCT03081936|EXPERIMENTAL|A2 formula|Oral consumption of a2® Platinum Stage 1 formula (containing 100% A2® beta -casein)
62041601|NCT03683069|EXPERIMENTAL|Amlodipine Arm|
62244688|NCT06735391|EXPERIMENTAL|Osimertinib|Osimertinib 80 mg, orally, QD, with every 4 weeks as a treatment cycle.
62601240|NCT06234696|NO_INTERVENTION|control group|The group consists of 30 people and this group will not be trained.
62601241|NCT04285515|EXPERIMENTAL|Lumateperone 42mg|Lumateperone 42mg administered once daily in the evening
62244689|NCT01187849|ACTIVE_COMPARATOR|Metformin|
62601242|NCT04285515|PLACEBO_COMPARATOR|Placebo|Matching placebo administered once daily in the evening
62601243|NCT04324736||Patients with diabetes|
62601244|NCT04324736||Patients without diabetes|
62244690|NCT01187849|PLACEBO_COMPARATOR|Placebo|
62244691|NCT04523350|EXPERIMENTAL|Instylla HES|
62244692|NCT04523350|ACTIVE_COMPARATOR|Control|TAE or cTACE
62244693|NCT03608267|EXPERIMENTAL|Intervention|
62244694|NCT05993559|EXPERIMENTAL|No PMRT|No radiation therapy after neoadjuvant chemotherapy and surgery.
62434884|NCT05105139||A2: Allantoin/ Coal Tar/ Clioquinol/ Triclosan (Sebryl Plus®)|Pharmaceutical Form: Shampoo Dosage: 0.2 g/ 3.0 g/ 3.0 g/ 0.3 g Administration way: For scalp use
62041602|NCT05982457|EXPERIMENTAL|virtual reality group|After the introduction and information is given, the lens and pupil distances of the virtual reality glasses will be adjusted according to each student and the students will be provided to wear them. The application will be made one-on-one with each student. The application will be carried out sitting in the laboratory. While the students are inside the application, the interface will be introduced through the images projected to the computer simultaneously. Cervical dilatation and effacement application will be watched using virtual glasses. Then, the students will be asked to use their hands to touch the perineum of the woman and make the image transparent, and it will be ensured that they watch the cervix structures again. Each student will use the virtual glasses for an average of 20-25 minutes.
62041603|NCT05982457|NO_INTERVENTION|Model group|After the introduction and briefing, the students will be provided to perform cervical dilatation and effacement application on the model in accordance with the Cervical Dilatation and Effacement Learning Guide with each student in the laboratory environment.
62434885|NCT04347590|EXPERIMENTAL|Unblinded CGM|"CGM data will be unblinded, with Hypo/hyperglycemia alarms on. Data will be recorded from CGM every three hours and intervention to adequate glucose intake will be performed to keep glycemia in normal range (72-144mg/dl) if necessary."
62601245|NCT05328596|EXPERIMENTAL|CBT treatment|The CBT-treatment arm includes a review of the patient´s social conditions and overall health. It also includes manual based Cognitive Behavioural Treatment (CBT) in 10 individual sessions.
62041604|NCT06117280|EXPERIMENTAL|Intervention (Dose One)|In this crossover trial, all participants will test both active comparators and the placebo comparator.
62041605|NCT06117280|EXPERIMENTAL|Intervention (Dose Two)|In this crossover trial, all participants will test both active comparators and the placebo comparator.
62041606|NCT06117280|PLACEBO_COMPARATOR|Placebo|In this crossover trial, all participants will test both active comparators and the placebo comparator.
62041607|NCT05112965|EXPERIMENTAL|Atezolizumab Monotherapy|Participants will continue to receive atezolizumab monotherapy as per parent protocol, until disease progression or beyond if the participant continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; participant non-compliance; or study termination by the Sponsor, whichever occurs first.
62041608|NCT05112965|EXPERIMENTAL|Combined Agents with Atezolizumab|Participants will continue to receive atezolizumab with other agent(s) as per parent protocol, until disease progression or beyond if the participant continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; participant non-compliance; or study termination by the Sponsor, whichever occurs first.
62822285|NCT04638231|ACTIVE_COMPARATOR|Text Message Group|This group will receive daily supportive messages through Short Messaging Service (SMS) on their mobile phones in addition to standard care
62822286|NCT04638231|EXPERIMENTAL|Email Message Group|This group will receive same supportive message as the Text Message group but through their email addresses, in addition to receiving standard care
62822287|NCT05322954|EXPERIMENTAL|Oral Psilocybin|Psilocybin with psychological support: Psilocybin will be administered in the form of capsules, taken orally with water. Each participant will receive 2 doses, approximately 4 weeks apart.
62822288|NCT01893307|EXPERIMENTAL|Arm I (IMRT)|Patients undergo IMRT QD five days a week for approximately 6.5 weeks.
62822289|NCT01893307|EXPERIMENTAL|Arm II (IMPT)|Patients undergo IMPT QD five days a week for approximately 6.5 weeks.
62822290|NCT06299475|EXPERIMENTAL|Online counseling and invitation|Participants receive structured online contraceptive counseling and an online invitation to a clinic for contraceptive provision
62822291|NCT06299475|NO_INTERVENTION|Control|Participants receive standard praxis i.e. no contraceptive counseling or online invitation
62822292|NCT06294626||Examination of neuromotor development of cases diagnosed with scaphocephaly|21 cases with scaphocephaly were included. Neuromotor development was evaluated with the Denver-II Developmental Screening Test and Alberta Infant Motor Scale.
62434886|NCT04347590|OTHER|Blinded CGM|Hypo/hyper alarms are off. CGM data will be blinded. Glucose intake will be adequate according to at least 2 capillary glycemic tests per day.
62434887|NCT00446654|EXPERIMENTAL|CGC-11047 once every 2 weeks|16.5 mg CGC-11047 as a subconjunctival injection once every two weeks.
62822293|NCT05178810|EXPERIMENTAL|FAB122|
62822294|NCT05178810|PLACEBO_COMPARATOR|Placebo|
62822295|NCT03453164|EXPERIMENTAL|Radiotherapy + Nivolumab|Localized short-term radiotherapy (22.5 Gy/5 fractions/5 days, Day 1-5) + nivolumab (starting on Day 15-22, a dose of 3 mg/kg (body weight) or 240 mg/body, every 2 weeks to a total of 6 courses)
62822296|NCT06588569|EXPERIMENTAL|Multi-mode Ablation|This arm includes patients with primary liver cancer or colorectal cancer liver metastasis (five cases each, totaling ten cases) who will receive multi-mode ablation, a novel ablation therapy that combines cryoablation and radiofrequency ablation.
62822297|NCT06588569|ACTIVE_COMPARATOR|Conventional Radiofrequency Ablation|This arm includes patients with primary liver cancer or colorectal cancer liver metastasis (five cases each, totaling ten cases) who will receive conventional radiofrequency ablation treatment.
62822298|NCT06032871|EXPERIMENTAL|Chest physiotherapy|Patients receive airway clearance by chest physiotherapy for 30 minutes twice a day.
62434888|NCT00446654|EXPERIMENTAL|CGC-11047 once every four weeks|16.5 mg CGC-11047 as a subconjunctival injection once every four weeks.
62434889|NCT05341557|EXPERIMENTAL|Dose Escalation|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with BPI-371153 administered, once daily (QD).
62434890|NCT05341557|EXPERIMENTAL|Dose Expansion|"Oral capsules administered at recommended doses. Each treatment cycle will be 21 days in duration with BPI-371153 administered, once daily (QD).~Cohort 1: Advanced NSCLC Cohort 2: Relapsed/refractory lymphoma Cohort 3: Advanced HCC Cohort 4: Other Advanced Solid Tumors"
62244695|NCT05993559|PLACEBO_COMPARATOR|PMRT|"Arm Description: Proceed with postoperative radiotherapy, following the guidelines of the respective institution, but advising patients to apply the following points whenever possible.~* If radiation therapy is administered, include the chest wall and regional LNs.~* If PMRT field to regional LN, include Axillary LN level III, level IV, Internal mammary LN (1-3rd ICS)."
62434891|NCT02112812|EXPERIMENTAL|Eradication therapy|The patients who were positive for H.pylori infection are entered into an eradication therapy protocol which includes oral esomeprazole 40mg daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
62434892|NCT06521034|EXPERIMENTAL|Treatment Group (arm A, Dose Escalation Study)|"In Phase I, patients with NSCLC harboring the EGFRT790M mutation and prior failure with EGFR-TKIs were enrolled. Using a 3+3 design, dose escalation and expansion studies were conducted to evaluate the safety and pharmacokinetics of FHND-9041 at doses of 40, 80, 120, and 180 mg/day, with 3 to 9 patients per group. Phase II utilized the RP2D of 80 mg QD, determined from Phase I, to assess the efficacy and safety of FHND-9041 in patients with locally advanced or metastatic NSCLC. The primary endpoint was Objective Response Rate (ORR), with Progression-Free Survival (PFS) as a secondary endpoint. Tumor response and disease progression were evaluated according to RECIST 1.1 criteria, and safety was assessed per CTCAE-5.0 standards."
62434893|NCT06521034|EXPERIMENTAL|Treatment Group (arm B, Dose Expansion Study)|In Phase Ⅱ, after comprehensive analysis and consultation, at least 30 patients were enrolled according to the inclusion and exclusion criteria. 37 patients with locally advanced or metastatic EGFR-mutated NSCLC receiving first-line treatment were enrolled. Tumor response and disease progression were evaluated according to RECIST 1.1 criteria, and safety was assessed per CTCAE-5.0 standards.
62434894|NCT05880563|EXPERIMENTAL|ALS patients|ALS patients will get two imaging sessions with \[18F\]RoSMA-18-d6 PET/CT and MRI-scans one year apart
62822299|NCT06032871|EXPERIMENTAL|High frequency chest wall oscillation|Participants received high frequency chest wall oscillation therapy twice a dy
62822300|NCT06588088|PLACEBO_COMPARATOR|Early eaters|The diet of these healthy volunteers was such that no calories were consumed after 19.30 in the evening in the first week of the study.
62822301|NCT06588088|ACTIVE_COMPARATOR|Night time Eaters|The diet of the same healthy volunteers was 25% of the daily calorie need calculated according to the Harris - Benedict formula was taken, taking into account the night time eating syndrome (NES) criteria, after 20.30 in the evening.
62822302|NCT02939807|EXPERIMENTAL|advanced HCC, tumor progression with sorafenib|Patients with advanced HCC who have experienced tumor progression with sorafenib will receive ABC294640.
62434895|NCT05880563|EXPERIMENTAL|Healthy volunteers|Healthy volunteers will get only one pair of \[18F\]RoSMA-18-d6 PET/CT and MRI scans
62822303|NCT05932862|EXPERIMENTAL|Dose Escalation Single Agent Evaluation|Patients will receive XL309 once daily in sequential cohorts of increasing doses.
62822304|NCT05932862|EXPERIMENTAL|Dose Escalation Combination Therapy|Patients will receive XL309 once daily in sequential cohorts of increasing dose in combination with olaparib.
62601246|NCT05328596|ACTIVE_COMPARATOR|Wait list control|The control treatment includes a review of the patient´s social conditions, overall health and psychoeducation.
62601247|NCT01647919|EXPERIMENTAL|cogniVida™ 100 mg/day|
62601248|NCT01647919|PLACEBO_COMPARATOR|Placebo|
62041609|NCT05112965|ACTIVE_COMPARATOR|Comparator Treatment|Participants will continue to receive comparator agent(s) as per parent protocol, until disease progression or beyond if the participant continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; participant non-compliance; or study termination by the Sponsor, whichever occurs first.
62434896|NCT03875391|EXPERIMENTAL|Oxytocin and trauma film paradigm|Intervention: Drug: Oxytocin nasal spray
62601249|NCT06493656|EXPERIMENTAL|Isolated corticosteroid injection|Ultrasound-guided posterior approach of glenohumeral space injection for adhesive capsulitis of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine.
62601250|NCT06493656|ACTIVE_COMPARATOR|Concomitant hydrodilatation with corticosteroid injection|Ultrasound-guided posterior approach of glenohumeral space hydrodilatation for adhesive capsulitis of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, and 15 mL normal saline
62822305|NCT05932862|EXPERIMENTAL|Cohort Expansion Stage Single Agent Evaluation|The recommended dose as determined in the Escalation Stage will be further studied in advanced solid tumor-specific cohorts.
62849189|NCT03081936|ACTIVE_COMPARATOR|Breast feeding|Oral consumption of breast milk
62244696|NCT05965440|OTHER|impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients|"* Addition of 3 blood tubes of 5mL during the collection for the treatment~* Collection of fresh urine (7 mL)~* Collection of stools by the participant at his home~* Collection of fresh stools for patients participating in the ancillary study~* Constitution of a biocollection (blood, urine and stool)~* Food collection for 3 days with no impact on patient follow-up~* Stool appearance sheet to be completed by the patient at each collection"
62041610|NCT05934370|OTHER|Study Participants|Participants will receive an intervention kit that will include two at-home visits and the following products: child bedroom HEPA-air purifier, HEPA upright vacuum, hypoallergenic dust-mite cover for child's mattress and pillow covers; Non-toxic household cleaning products and non-toxic pest/rodent traps.
62244697|NCT01580033|EXPERIMENTAL|A+C+hib Conjugate Vaccine|600 infants aged 3-5 months, will be vaccinated on day0, 28, 56
62822306|NCT05932862|EXPERIMENTAL|Cohort Expansion Stage Combination Therapy Evaluation|The recommended dose as determined in the Escalation Stage will be further studied in combination with olaparib in advanced solid tumor-specific cohorts.
62822307|NCT01775501|EXPERIMENTAL|Experimental Treatment Arm|FOLFOX (Leucovorin, Fluorouracil and Oxaliplatin) + Sorafenib Sorafenib: orally, twice daily FOLFOX: injected via portacath once every two weeks
62041611|NCT01460550|EXPERIMENTAL|gastrointestinal reconstruction|
62041612|NCT06732973|EXPERIMENTAL|Experimental：JS005 AI|The drug was administered by a single subcutaneous injection via AI
62041613|NCT06732973|ACTIVE_COMPARATOR|Experimental：JS005 PFS|The drug was administered by a single subcutaneous injection via PFS
62434897|NCT03875391|PLACEBO_COMPARATOR|Placebo and trauma film paradigm|Intervention: Drug: Placebos
62601251|NCT01671072|EXPERIMENTAL|TissueGene-C|Single intra-articular injection to the damaged knee joint a dose of 1.8 x 10\^7 cells
62601252|NCT01671072|PLACEBO_COMPARATOR|Normal Saline|Single intra-articular injection to the damaged knee joint at the same volume
62822308|NCT02689427|EXPERIMENTAL|Treatment (enzalutamide, paclitaxel)|"Patients receive enzalutamide PO daily on days 1-7 and paclitaxel IV over 2 hours on day 1. Treatments repeat every 7 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: After 12 cycles of therapy, patients undergo surgical resection of primary tumor with or without lymph node biopsy or complete axillary dissection."
62849190|NCT00732719|PLACEBO_COMPARATOR|Profile A|Device worn; no pressure given (placebo)
62041614|NCT03927950|EXPERIMENTAL|Escitalopram bupropion open-label|No comparator
62244698|NCT01580033|ACTIVE_COMPARATOR|Walvax AC vaccine, Pasteur Hib vaccine|300 infants aged 3-5 months, will be vaccinated on day0, 28, 56
62601253|NCT02742454|ACTIVE_COMPARATOR|Standard 30-60 Seconds Cord Clamping|Standard treatment for extremely preterm infants which is delayed cord clamping 30-60 seconds after birth, and assisted ventilation after cord clamping.
62822309|NCT05615922|EXPERIMENTAL|Remotely Supervised tDCS and Word-Naming Practice|At each session, the tDCS device will deliver 2.0 mA electric current for 30 minutes over the left frontotemporal lobe with focus on the inferior frontal gyrus (IFG). Participants will receive 20 intervention sessions over the course of the interventional period (4 weeks) on weekdays (Monday-Friday). During the stimulation period, participants will engage in a picture-naming exercise as guided by the study tDCS clinicians.
62041615|NCT06682520|EXPERIMENTAL|Postpartum NEST-Rural Program Group|"Postpartum women randomized to this group will receive the usual postpartum care from an Obstetrics provider and the following NEST-Rural Program:~* Information about services and resources available in your community~* A blood pressure monitor.~* Access to the Babyscripts smartphone app.~* A nurse visit(s) at home or via telehealth.~* A visit(s) from a Family Outreach Specialist, if needed.~* A follow-up phone call from a Coordinator in about 6 weeks"
62822310|NCT06139276|EXPERIMENTAL|Small Needle-Knife|The small needle-knife (SNF) group undergoes rehabilitation treatment, with additional small needle-knife treatment once a week after acupuncture needle insertion at the Tiaokou (ST38) and Chengshan (BL57) acupoints. This treatment regimen will span over a duration of 3 weeks.
62244699|NCT06305780|EXPERIMENTAL|IVIG|In the IVIG study, randomization will be implemented with 1:1:1:1 allocation among the combination of IVIG/placebo and coordinated/ usual non-pharmacologic care. All participants will receive IVIG or placebo for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months). See NCT06305793 for additional details.
62244700|NCT06305780|EXPERIMENTAL|Ivabradine|In the ivabradine study, randomization will be implemented with 1:1:1:1 allocation among the combinations of ivabradine/placebo and coordinated/usual care. All participants receive either ivabradine or placebo for 3 months (12 weeks) with a follow-up period for an additional 3 months (total study duration of 6 months). See NCT06305806 for additional details.
62244701|NCT06074198|EXPERIMENTAL|Physical Therapy Exercise|There will be no control group and only one intervention delivered
62041616|NCT06682520|NO_INTERVENTION|Postpartum Usual Care Group|"Postpartum women randomized to this group will receive the usual postpartum care from an Obstetrics provider and the following:~* Information about services and resources available in your community~* A follow-up phone call from a Coordinator in about 6 weeks"
62041617|NCT03673306||Pregnant cohort|Women with one or more pregnancies any time after breast cancer diagnosis
62244702|NCT01205438|EXPERIMENTAL|LY2127399 every 2 weeks|
62244703|NCT01205438|EXPERIMENTAL|LY2127399 every 4 weeks|During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
62244704|NCT01205438|PLACEBO_COMPARATOR|Placebo|
62244705|NCT03078595||von Willebrand disease type 2 and 3|Examinations (haematologically and periodontally) of von Willebrand disease patients with type 2 and 3 and healthy controls to evaluate whether type 2 and 3 VWD determines an increased susceptibility to gingival bleeding in response to the oral biofilm
62434898|NCT00448682|EXPERIMENTAL|FUdR + Leucovorin + Oxaliplatin + Docetaxel (Taxotere)|"Treatment will be administered on an outpatient basis. Chemotherapy will be administered weekly, 3 out of 4 weeks, on days 1, 8 and 15:~Day 1 and Day 15 Chemotherapy Administration: Patients will be administered oxaliplatin (85 mg/m2) and docetaxel (25 mg/m2) followed by FUdR/Leucovorin (110 mg/kg//500 mg/m2) on Day 1 and Day 15 of each cycle.~Day 8 Chemotherapy Administration On Day 8, treatment will consist of docetaxel (25 mg/m2) followed by FUdR/Leucovorin (110mg/kg//500mg/m2).~There will be no treatment delivered week 4 (Day 22). For the purpose of this study, one cycle equals four weeks. There will be a maximum of 6 cycles."
62244706|NCT03078595||controls|For each case (VWD) a respective haematologically healthy control is recruited from the gingivitis and periodontitis patients of the Department of Periodontology, Centre for Dentistry and Oral Medicine (Carolinum), Johann Wolfgang Goethe-University Frankfurt/Main. Each control is matched to one of the respective cases for sex, age (±5 years), self-reported smoking status (current smoker/non-smoker), number of remaining teeth (±2 teeth), and periodontal diagnosis (gingivitis, chronic or aggressive periodontitis).
62244707|NCT02049034|PLACEBO_COMPARATOR|Placebo|Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
62434899|NCT01489956|EXPERIMENTAL|Immucothel alone (Part A)|100 µg Immucothel subcutaneously (SQ) on Day 0 and Day 9.
62434900|NCT01489956|EXPERIMENTAL|Immucothel+Montanide (Part A)|If an immune response was not observed in at least nine out of the first 10 participants after receiving Immucothel alone, 10 additional healthy subjects would be recruited and immunized with Immucothel (SQ) plus Montanide (SQ) on Day 0 and Day 9.
62601254|NCT02742454|EXPERIMENTAL|VentFirst 120 Seconds Cord Clamping|Assisted ventilation (face mask continuous positive airway pressure, CPAP, or positive pressure ventilation, PPV) is provided prior to cord clamping at 120 seconds.
62822311|NCT06139276|ACTIVE_COMPARATOR|Standard treatment|Rehabilitation treatment (based on the physician's assessment of the patient's clinical condition, using methods such as heat therapy, electrotherapy, manual therapy, or joint injections) at least once a week. This treatment regimen will span over a duration of 3 weeks.
62601255|NCT03664830|EXPERIMENTAL|Plerixafor|Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
62601256|NCT06592755||the Subclavian Approach group|The patients chose to undergo total thyroidectomy and central compartment neck dissection via the single-incision subclavian approach.
62601257|NCT06592755||the conventional open surgery group|The patients chose to undergo total thyroidectomy and central compartment neck dissection via the conventional open surgery approach.
62601258|NCT06443801|NO_INTERVENTION|THE GROUP THAT WILL NOT TAKE WEB-BASED BREASTFEEDING EDUCATION IN PREGNANCY|This group will not take web-based education.
62601259|NCT06443801|EXPERIMENTAL|THE GROUP THAT WİLL TAKE WEB-BASED BREASTFEEDİNG EDUCATION İN PREGNANT|this group will take web-based education.
62601260|NCT03518970|EXPERIMENTAL|Nursing intervention|The experimental group will receive the Nursing intervention to reduce uncertainty in illness and increase quality of life in family caregivers of patients with cancer in palliative care
62601261|NCT03518970|NO_INTERVENTION|Conventional care|The control group will receive the nursing care conventionally given in the health care institution
62601262|NCT00483106|ACTIVE_COMPARATOR|Ritalin|
62601263|NCT00483106|PLACEBO_COMPARATOR|Placebo|
62601264|NCT06483243|EXPERIMENTAL|Group A|"* Phase 1: CKD-501 1 tablet, D745 1 tablet, D150 2 tablets(Reference)~* Phase 2: CKD-383 2 tablets(Test)"
62601265|NCT06483243|EXPERIMENTAL|Group B|"* Phase 1: CKD-383 2 tablets(Test)~* Phase 2: CKD-501 1 tablet, D745 1 tablet, D150 2 tablets(Reference)"
62601266|NCT06517901|ACTIVE_COMPARATOR|Software fusion biopsy|Software fusion biopsy: Biopsy of the MRI-detected lesion using an image fusion platform such as UroNav or similar.
62601267|NCT06517901|EXPERIMENTAL|Cognitive fusion biopy|Cognitive fusion biopsy: Biopsy of the MRI-detected lesion using visual estimation and/or measurements to identify landmarks and lesions.
62601268|NCT04110561|OTHER|Spinal Cord Injury patients with motor complete paralysis|
62601269|NCT05985473|OTHER|Professionally active adults with a moderate hearing loss|
62601270|NCT02180997|EXPERIMENTAL|Tamsulosin 1|Volunteers will be taken Tamsulosin and solifenacin
62601271|NCT02180997|EXPERIMENTAL|Solifenacin 1|Volunteers will be taken Tamsulosin and solifenacin
62822312|NCT05014971|EXPERIMENTAL|Tele-neurohub|This group will receive the tele-neurohub intervention which includes telemedicine appointments with the neurologist, speech therapist, social worker, and nutritionist at baseline, 3 months and 6 months, and PT and OT every 2 weeks for maintenance neuro-rehabilitation.
62601272|NCT02180997|EXPERIMENTAL|Co-administration 1|Volunteers will be taken Tamsulosin and solifenacin
62601273|NCT02180997|EXPERIMENTAL|Tamsulosin 2|Volunteers will be taken Tamsulosin and solifenacin
62041618|NCT03673306||Non-pregnant cohort|Women with no subsequent pregnancies after breast cancer diagnosis
62601274|NCT02180997|EXPERIMENTAL|Solifenacin 2|Volunteers will be taken Tamsulosin and solifenacin
62601275|NCT02180997|EXPERIMENTAL|Co-administration 2|Volunteers will be taken Tamsulosin and solifenacin
62601276|NCT05097547|EXPERIMENTAL|Contingency management|This arm will include data from participants who received CM
62601277|NCT06204406||Patients with non-metastatic upper tract urothelial carcinoma receiving kidney-sparing therapy|The enrolled patients were patients with limited-stage or locally advanced UTUC, who were classified into the following four categories according to the 2022 EAU guidelines as low-risk and high-risk: 1) low-risk patients who were willing to undergo kidney-sparing surgery directly; 2) High-risk patients, with solitary kidney, functional single kidney, bilateral tumors, and absolute kidney-sparing indications; 3) High-risk patients with renal insufficiency, or diseases that lead to renal insufficiency, have relative indications for kidney protection; 4) High-risk patients with good renal function, but a particularly strong willingness to preserve the kidney, willing to accept clinical studies and participate in kidney preservation.
62601278|NCT04481035|EXPERIMENTAL|N-Acetylcysteine|Participants will be dosed with 70 mg/kg/dose (max dose 900 mg) three times per day of N-Acetylcysteine (NAC) for eight (8) weeks. This is a double-blind study, neither study participant nor study team members will know whether the participant is given study drug or placebo until after all data is collected.
62601279|NCT04481035|PLACEBO_COMPARATOR|Placebo|Participants will be dosed three times per day with a placebo for eight (8) weeks. This is a double-blind study, neither study participant nor study team members will know whether the participant is given study drug or placebo until after all data is collected.
62601280|NCT04409535||Rural Living Community Member|Adult residents of a New Mexico rural county (as federally designated)
62601281|NCT04409535||Urban/Suburban Living Community Member|Comparison group: adult resident of a New Mexico urban/suburban city or town (as federally designated)
62601282|NCT01067625|EXPERIMENTAL|TOGA subjects|
62601283|NCT02079142|EXPERIMENTAL|High Intensity Strategy: Train-the-trainer|One therapist from each counseling center randomized to this arm will be selected to become the trainer and will be trained to train their colleagues.
62601284|NCT02079142|ACTIVE_COMPARATOR|Low Intensity Strategy: Expert Consultation|The IPT expert from Washington University will travel to all counseling centers randomized to this condition and train all participating therapists on site and be available for monthly phone consultation for up to one year following training on site.
62601285|NCT02387528|EXPERIMENTAL|1- Mindfulness Intervention|"Mindfulness-Based Intervention: The intervention model tested was Breathworks for Stress.The mindfulness intervention used in the study had a total of eight encounters, lasting 120 minutes, that took place once a week. In order to accommodate employees' schedule. There was a recommendation of daily practice lasting an average of 15 minutes, as well as the suggestion to use the tools in everyday life.~In each session a theme was presented, with distinct practices and well-defined objectives"
62601286|NCT02387528|PLACEBO_COMPARATOR|2- Relaxation Intervention|Relaxation-Based Intervention was composed of four meetings, of two hours duration, held every two weeks. The activities involved mutual help conversations about work situations, psychoeducation on stress and various techniques of stress inoculation, such as: diaphragmatic breathing, progressive muscle relaxation, relaxing visualization and stretching. Each session had its own objective to promote the relaxation response effect.
62601287|NCT02387528|OTHER|3- Wait List Control Group|The wait list passive control group did not receive any intervention while the study was been enrolling.
62601288|NCT06356974|EXPERIMENTAL|Treatment of seropositives|"* acoziborole three 320-mg tablets (960 mg dose), administered by the oral route to adolescent and adults ≥15 years as single dosing regimen on Day 1 of the study in fed or fasting state~* acoziborole two 320-mg tablets (640 mg dose), administered by the oral route to children 11-14 years (and ≥30kg) as single dosing regimen on Day 1 of the study in fed or fasting state No active comparative treatment will be used in this study~Doses and treatment regimens~* Adolescent and adults ≥15 years: 960 mg (3x320mg) oral unique dose in fed or fasting state~* Children 11-14 years (and ≥30kg): 640 mg (2x320mg) oral unique dose in fed or fasting state"
62601289|NCT05716854|ACTIVE_COMPARATOR|Part 1: Clarithromycin Administration Only|Subjects in this arm will be administered Clarithromycin only over 3 days of dosing.
62244708|NCT02049034|EXPERIMENTAL|Lixisenatide|"Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days."
62601290|NCT05716854|ACTIVE_COMPARATOR|Part 1: Pimozide Administration Only|Subjects in this arm will be administered Pimozide only over 3 days of dosing.
62601291|NCT05716854|PLACEBO_COMPARATOR|Part 1: Placebo|Subjects in this arm will not be administered any drug. Will serve as placebo comparator arm.
62601292|NCT05716854|ACTIVE_COMPARATOR|Part 2: Moxifloxacin Administration Only|Subjects in this arm will be administered Moxifloxacin only for 1 day of dosing.
62822313|NCT05014971|ACTIVE_COMPARATOR|Usual care group|Receive usual care but will have study visit assessments at baseline and 6 months.
62822314|NCT05071287|PLACEBO_COMPARATOR|Control Group (mHealth+low-fat diet group)|The low-fat group will be asked to restrict total calorie and total fat consumption according to the Look AHEAD intervention and MyPlate guidelines, with 26-44% carbs, 10-30% protein, and less than 30% fat.
62601293|NCT05716854|ACTIVE_COMPARATOR|Part 2: Cobicistat Administration Only|Subjects in this arm will be administered Cobicistat only for 1 day of dosing.
62601294|NCT05716854|ACTIVE_COMPARATOR|Part 2: Moxifloxacin and Cobicistat Administration|Subjects in this arm will be administered both Cobicistat and Moxifloxacin for 1 day of dosing.
62822315|NCT05071287|EXPERIMENTAL|Intervention Group (mHealth + low-carbohydrate/ketogenic diet group)|Total calories will be set according to Look AHEAD intervention, and carbohydrate consumption restriction will be set based on recommendations from American Diabetic Association, National Kidney Foundation, and other evidence-based resources. Participants in this group will be asked to consume a low-carb/ketogenic diet. Specially, participants will receive a carbohydrate, protein, and fat intake goal based on 1.5 : 1 ratio (1.5 grams of fat to 1 gram of carbohydrate and protein combined). Daily macronutrient and calorie consumption will be individualized for each participant using ideal body weight as inferred from wrist circumference and activity level. Carbohydrate consumption will be less than 10% (20\~50 g), protein 10-20% (1.0\~1.2g/kg ideal body weight), and fat 70-80% of total daily energy, respectively. Nutritional ketosis will be reached by consuming such diet (0.5 mmol/L).
62244709|NCT04323839||Pregnant Women|Women who are currently pregnant and are suspected or diagnosed COVID-19 positive.
62601295|NCT05716854|PLACEBO_COMPARATOR|Part 2: Placebo|Subjects in this arm will not be administered any drug. Will serve as placebo comparator arm.
62601296|NCT04128722|EXPERIMENTAL|Sirolimus 1mg/mL|Application of 1 mg/mL sirolimus solution, 0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation, the experimental intervention versus usual care (no treatment), the control condition.
62601297|NCT04128722|NO_INTERVENTION|Control condition|Usual care, i.e. no intervention
62822316|NCT03668873|EXPERIMENTAL|Sleep Parent Training|The five SPT sessions (each 60-90 minutes in duration) are individually delivered over 10-week virtually (HIPAA compliant video-chat). After Session A, session order may be adjusted to address child-specific problems. One-on-one delivery of SPT permits flexibility for child-specific problems within the program.
62041619|NCT02769286|EXPERIMENTAL|Osimertinib in cohort 1|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA
62244710|NCT04323839||Post-partum women|Women who have been pregnant in the past 6 weeks and are suspected or diagnosed COVID-19 positive.
62601298|NCT05866367|EXPERIMENTAL|Low dose Intranasal Insulin|One dose of 40 international units of regular insulin administered intranasally using the SipNose SP1N1C1 device.
62601299|NCT05866367|EXPERIMENTAL|High dose Intranasal Insulin|One dose of 80 international units of regular insulin administered intranasally using the SipNose SP1N1C1 device.
62601300|NCT05296902||SILKAM®|SILKAM® is a non-absorbable sterile suture material made from braided silk fibrils. It is available either undyed (white) or dyed black with hematein and is coated with refined paraffin wax or beeswax.
62244711|NCT06734312|EXPERIMENTAL|Gastric Fundal Mucosal Ablation (GFMA) following discontinuation of GLP-1 therapy|Subjects will undergo endoscopic Gastric Fundal Mucosal Ablation (GFMA) following following discontinuation of GLP-1 therapy. This will be performed by an experienced endoscopist specialized in bariatric endoscopy in a single endoscopic session.
62244712|NCT06564844|EXPERIMENTAL|Dato-DXd + rilvegostomig|Participants in the Dato-DXd in combination with rilvegostomig group will receive Dato-DXd and rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W).
62244713|NCT06564844|EXPERIMENTAL|Rilvegostomig|Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W).
62434901|NCT01489956|EXPERIMENTAL|Immucothel alone or Immucothel+Montanide (Part B)|"Dependent on the results for Part A.~Briefly: Ten new, healthy participants were to be fed 50 mg of native keyhole limpet hemocyanin (KLH), a protein extracted from a mollusk (a sea animal), on Days 0 through 4 and Days 10 through 14, for a total dose of 500 mg. The participants were then immunized using the strategy that produced an immune response in at least nine out of 10 participants in Part A (Immucothel alone or Immucothel plus Montanide) on Days 26 and 35."
62601301|NCT00526019||Complete remission of their asthma|Subjects in complete remission of their asthma Subjects in complete remission of their asthma: absence of respiratory symptoms, no rescue asthma medication need and an optimal pulmonary function and normal PC20 methacholine (\>16 mg/ml) for more than two years (with no current treatment).
62601302|NCT00526019||Symptomatic remission ofasthma|Subjects in symptomatic remission of their asthma (No asthma symptoms in the last 2 years, no asthma medication, PC20 methacholine \<16 mg/ml)
62601303|NCT00526019||Current asthma (mild asthma)|Subjects with current asthma (Mild asthma)
62601304|NCT00526019||Healthy controls|Healthy controls
62601305|NCT05735314|EXPERIMENTAL|Step 1 (3 clinics) - 6 months control followed by 24 months of intervention|
62041620|NCT02769286|EXPERIMENTAL|Osimertinib in cohort 2|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring T790M which were detected from circulating tumor DNA
62041621|NCT06732466|EXPERIMENTAL|0.3% chlorhexidine toothpaste|Test group assigned to use a 0.3% chlorhexidine + 3% AmCl toothpaste and brushing with a commercially available adult soft bristle toothbrush
62434902|NCT03372369|ACTIVE_COMPARATOR|CDC Poster|After collecting baseline contraceptive knowledge, method preference, if participant were to switch methods during the next year, and current perceived pregnancy risk, participants will view CDC poster for contraceptive effectiveness.
62434903|NCT03372369|EXPERIMENTAL|Patient-Centered Poster|After collecting baseline contraceptive knowledge, method preference, if participant were to switch methods during the next year, and current perceived pregnancy risk, participants will view Patient-Centered poster for contraceptive effectiveness.
62434904|NCT01960933|ACTIVE_COMPARATOR|Culprit lesion revascularization|Only the culprit lesion is treated whereas other study lesions are left un-treated.
62434905|NCT01960933|ACTIVE_COMPARATOR|Full revascularization|Culprit lesion is treated initially and all other lesions with diameter stenosis angiographically \>50% and FFR \<0.80 are treated in a separate procedure within the index hospitalization. Stenoses \> 90% are treated without prior FFR.
62434906|NCT04726917||Patients with COPD|Patients qualified for 3-week in-hospital pulmonary rehabilitation
62601306|NCT05735314|EXPERIMENTAL|Step 2 (3 clinics) - 12 months control followed by 18 months of intervention|
62601307|NCT05735314|EXPERIMENTAL|Step 3 (3 clinics) - 18 months control followed by 12 months of intervention|
62601308|NCT05735314|EXPERIMENTAL|Step 4 (4 clinics) - 24 months control followed by 6 months of intervention|
62434907|NCT01551550|EXPERIMENTAL|GDD & Amniotic Membrane Graft|After GDD implantation, amniotic membrane graft (AmnioGuard™, Bio-Tissue inc, Miami, FL) is used to cover the GDD tube.
62434908|NCT01551550|ACTIVE_COMPARATOR|GDD & Pericardial Graft|After GDD implantation, a pericardial graft (Tutoplast®, IOP Inc, Costa Mesa, CA) is used to cover the GDD tube.
62601309|NCT04181515|PLACEBO_COMPARATOR|placebo stressor, sham rTMS|placebo stressor (lactose), sham rTMS (inactive coil)
62601310|NCT04181515|ACTIVE_COMPARATOR|placebo stressor, active rTMS|placebo stressor (lactose), active rTMS (10 Hz dlPFC in group 1; 1 Hz mPFC in group 2)
62601311|NCT04181515|ACTIVE_COMPARATOR|stressor, sham rTMS|stressor (yohimbine 54mg + hydrocortisone 20mg), sham rTMS (inactive coil)
62601312|NCT04181515|ACTIVE_COMPARATOR|stressor, active rTMS|stressor (yohimbine 54mg + hydrocortisone 20mg), active rTMS (10 Hz dlPFC in group 1; 1 Hz mPFC in group 2)
62601313|NCT03873415|EXPERIMENTAL|Formulation A|Dosage formulation and area of release varies between arms
62601314|NCT03873415|EXPERIMENTAL|Formulation B|Dosage formulation and area of release varies between arms
62601315|NCT03873415|EXPERIMENTAL|Formulation C|Dosage formulation and area of release varies between arms
62244714|NCT06564844|ACTIVE_COMPARATOR|Standard of Care (SoC)|Patients in SoC group will undergo observation or will receive Investigator's Choice of Chemotherapy (ICC).
62244715|NCT00164619|EXPERIMENTAL|1|Standard STD clinic services and the VOICES/VOCES intervention
62601316|NCT03873415|EXPERIMENTAL|Formulation D|Dosage formulation and area of release varies between arms
62601317|NCT03873415|EXPERIMENTAL|Formulation E|Dosage formulation and area of release varies between arms
62244716|NCT00164619|ACTIVE_COMPARATOR|2|Standard STD clinic services
62601318|NCT03873415|EXPERIMENTAL|Formulation F|Dosage formulation and area of release varies between arms
62244717|NCT01910909|EXPERIMENTAL|Stereotactic body radiotherapy|Stereotactic body radiotherapy 60 Gy/3 fraction standard dose The highest allowable dose with maintain normal tissue constraints
62244718|NCT04671667|ACTIVE_COMPARATOR|Arm B (cisplatin, carboplatin, IMRT, PBRT)|Patients receive cisplatin or carboplatin IV on day 1. Treatment repeats every 7 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo IMRT or PBRT QD for a total of 30 fractions in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout the trial.
62244719|NCT04671667|EXPERIMENTAL|Arm C (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 6 weeks for 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout the trial.
62244720|NCT06726616||Adult Cohort; n=100 (50 Hispanic American adults and 50 non-Hispanic American adults)|The participants in this PASOS pilot will include 50 self-identified HA individuals and 50 self-identified non-HA individuals between the ages of 55-85 years, with no psychometric evidence of neuropsychological decline. We plan to enroll an equal number of women and men. Race and ethnicity in this study will be determined via self-report or self-identification by participants.
62244721|NCT03118037||Sonata|Women who undergo transcervical radiofrequency(RF) ablation with the Sonata System for treatment of their fibroids
62244722|NCT03519867|EXPERIMENTAL|1) Zemuron® 0.6 mg/kg + MK-8616 0.5 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced neuromuscular blockade (NMB) reaches 1 to 2 PTCs.
62244723|NCT03519867|EXPERIMENTAL|2) Zemuron® 1.2 mg/kg + MK-8616 0.5 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
62244724|NCT03519867|EXPERIMENTAL|3) Zemuron® 0.6 mg/kg + MK-8616 1.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
62244725|NCT03519867|EXPERIMENTAL|4) Zemuron® 1.2 mg/kg + MK-8616 1.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
62244726|NCT03519867|EXPERIMENTAL|5) Zemuron® 0.6 mg/kg + MK-8616 2.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
62244727|NCT03519867|EXPERIMENTAL|6) Zemuron® 1.2 mg/kg + MK-8616 2.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
62244728|NCT03519867|EXPERIMENTAL|7) Zemuron® 0.6 mg/kg + MK-8616 4.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
62244729|NCT03519867|EXPERIMENTAL|8) Zemuron® 1.2 mg/kg + MK-8616 4.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
62244730|NCT03519867|EXPERIMENTAL|9) Zemuron® 0.6 mg/kg + MK-8616 8.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
62601319|NCT03873415|EXPERIMENTAL|Formulation G|Dosage formulation and area of release varies between arms
62601320|NCT03873415|EXPERIMENTAL|Formulation H|Dosage formulation and area of release varies between arms
62601321|NCT06457360|EXPERIMENTAL|group 1 sterile gauze with chitosan|Chitosan-based dressing gauze after extraction in patients with end stage liver disease
62041622|NCT06732466|PLACEBO_COMPARATOR|Negative Control|Negative Control group assigned to use a placebo toothpaste without chlorhexidine and AmCl and brushing with a commercially available adult soft bristle toothbrush
62041623|NCT00024479||suspected or confirmed rheumatic disease|autoimmune, autoinflammatory, or degenerative conditions
62041624|NCT01292954|ACTIVE_COMPARATOR|Low dose blueberry|
62434909|NCT00654303|EXPERIMENTAL|1|Rosuvastatin
62601322|NCT06457360|EXPERIMENTAL|group 2 sterile gauze with ankaferd blood stopper|ankaferd blood stopper dressing gauze after extraction in patients with end stage liver disease
62601323|NCT06457360|ACTIVE_COMPARATOR|group 3 sterile gauze with tranexamic acid|tranexamic acid dressing gauze after extraction in patients with end stage liver disease
62849191|NCT00732719|ACTIVE_COMPARATOR|Profile B|Foot at 30mm Hg, Gaiter at 40 mm Hg, mid-calf at 30 mm Hg and upper cuff at 20mm Hg
62822317|NCT03668873|ACTIVE_COMPARATOR|Sleep Parent Education|SPE consists of five 60-90 minute sessions, delivered individually over 10 weeks. SPE provides useful information to families of young children with ASD and sleep problems. Session A is designed to develop rapport. The sleep hygiene session (Session B) has been modeled from the RUBI manual. The other sessions include a systematic presentation on several relevant topics. An example of a SPE session is provided in the Intervention section. This condition is intended to parallel what would be offered in typical care, but by telehealth, where a parent might be educated about ASD as well as attend an outpatient appointment at a sleep clinic.
62822318|NCT02265458|EXPERIMENTAL|Musical intervention and sensory isolation|30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
62822319|NCT02265458|ACTIVE_COMPARATOR|Sensory isolation|Sensory isolation
62822320|NCT02265458|NO_INTERVENTION|Standard of care|Standard of care
62822321|NCT06586268||Patients scheduled for elective surgery with a diagnosis of obstructive sleep apnea (OSA)|"* Patients scheduled for elective surgery at the operating theatres of the AUMC with a diagnosis of OSA with or without treatment~* Patients with continuous positive airway pressure (CPAP) or mandibular advancement device (MAD) are considered patients with treatment for OSA~* Patients ≥ 18 years~* Dutch or English speaking~* Willing and able to sign consent for re-use of care data"
62822322|NCT04060303|ACTIVE_COMPARATOR|ENRICH-US Implementation- early|"Baseline, pre-intervention data will be collected. This phase consists primarily of individual-level patient (ages 10-18 years undergoing elective GI surgery) data collection. This phase involves abstraction of existing electronic health records data by the Site Coordinator about current, standard perioperative care received by patients. Patients and parents will complete web-based HRQoL assessments preoperatively, and 5 days and 4-6 weeks post-operatively. Site-specific barriers and facilitators to implementation will be assessed by semi-structured, telephone interviews, conducted by each Site's PI and Coordinator.~Intervention phase will span 12 months with an implementation curriculum. Sites will be randomized to this implementation phase based on stepped-wedge cluster assignment. A sustainability phase will collect post intervention data."
62041625|NCT01292954|ACTIVE_COMPARATOR|medium dose blueberry|
62041626|NCT01292954|ACTIVE_COMPARATOR|high dose blueberry|
62434910|NCT04898023|EXPERIMENTAL|zinc-green tea extract-ascorbic acid|Randomized patients will take three (3) capsules taken orally two (2) hours following a meal twice daily x5 days and be blinded to study assignment.
62434911|NCT04898023|PLACEBO_COMPARATOR|Placebo|Randomized patients will take three (3) capsules taken orally two (2) hours following a meal twice daily x5 days and be blinded to study assignment.
62601324|NCT02613429|ACTIVE_COMPARATOR|Cranial horizontal|identification of the airway by from the cranial end. Marking of the airway, including the cricothyroid membrane, on the skin, by starting the examination from the cranial end at the level of the thyroid catilage , horizontally and thereafter moving caudally
62849192|NCT00732719|ACTIVE_COMPARATOR|Profile C|Foot at 20mm Hg, Gaiter at 30 mm Hg, mid-calf at 20 mm Hg and upper cuff at 10mm Hg
62849193|NCT00732719|ACTIVE_COMPARATOR|Profile D|Foot at 10mm Hg, Gaiter at 20 mm Hg, mid-calf at 10 mm Hg and upper cuff at 0mm Hg
62849194|NCT00732719|ACTIVE_COMPARATOR|Profile E|Foot at 30mm Hg, Gaiter at 40 mm Hg, mid-calf at 40 mm Hg and upper cuff at 40mm Hg
62849195|NCT00732719|ACTIVE_COMPARATOR|Profile F|Foot at 20mm Hg, Gaiter at 30 mm Hg, mid-calf at 30 mm Hg and upper cuff at 30mm Hg
62849196|NCT00732719|ACTIVE_COMPARATOR|Profile G|Foot at 10mm Hg, Gaiter at 20 mm Hg, mid-calf at 20 mm Hg and upper cuff at 20mm Hg
62041627|NCT01292954|PLACEBO_COMPARATOR|control|
62041628|NCT02878473|EXPERIMENTAL|Liver transplantation|The intervention will consist of liver transplantation
62041629|NCT05376891||Advanced Non-small Cell Lung Cancer with METex14 skipping alterations|Participants diagnosed with advanced NSCLC and who receive available therapies in routine clinical practice setting will be part of this registry. Data will be collected routinely from the point of enrollment of a participants into the registry until death, loss to follow-up (drop-out), subsequent enrollment into a clinical trial, or end of data collection period for the registry.
62041630|NCT00587327|EXPERIMENTAL|Barusiban|
62041631|NCT00587327|EXPERIMENTAL|Atosiban|
62822323|NCT04060303|ACTIVE_COMPARATOR|ENRICH-US Implementation- mid|"Baseline, pre-intervention data will be collected. This phase consists primarily of individual-level patient (ages 10-18 years undergoing elective GI surgery) data collection. This phase involves abstraction of existing electronic health records data by the Site Coordinator about current, standard perioperative care received by patients. Patients and parents will complete web-based HRQoL assessments preoperatively, and 5 days and 4-6 weeks post-operatively. Site-specific barriers and facilitators to implementation will be assessed by semi-structured, telephone interviews, conducted by each Site's PI and Coordinator.~Intervention phase will span 12 months with an implementation curriculum. Sites will be randomized to this implementation phase based on stepped-wedge cluster assignment. A sustainability phase will collect post intervention data."
62822324|NCT04060303|ACTIVE_COMPARATOR|ENRICH-US Implementation- late|"Baseline, pre-intervention data will be collected. This phase consists primarily of individual-level patient (ages 10-18 years undergoing elective GI surgery) data collection. This phase involves abstraction of existing electronic health records data by the Site Coordinator about current, standard perioperative care received by patients. Patients and parents will complete web-based HRQoL assessments preoperatively, and 5 days and 4-6 weeks post-operatively. Site-specific barriers and facilitators to implementation will be assessed by semi-structured, telephone interviews, conducted by each Site's PI and Coordinator.~Intervention phase will span 12 months with an implementation curriculum. Sites will be randomized to this implementation phase based on stepped-wedge cluster assignment. A sustainability phase will collect post intervention data."
62822325|NCT06604338||RPL group|The RPL group will include women with a history of at least two spontaneous pregnancy losses, regardless of whether they have living children, and whose etiology for the pregnancy losses was not determined by the care team's protocols.
62822326|NCT06604338||Control group|Women with at least two full-term pregnancies and no history of difficulty getting pregnant, pregnancy loss or other infertility factors will be enrolled in the control group.
62822327|NCT04768738|EXPERIMENTAL|Above Threshold Group|In the above threshold group, biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The current intensity was kept constant where the participant felt the current comfortably and applied for 5 minutes.
62244731|NCT03519867|EXPERIMENTAL|10) Zemuron® 1.2 mg/kg + MK-8616 8.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
62434912|NCT06407895|EXPERIMENTAL|Lower Limb Fitness Program|Group A will receive Range of motion for 5 minutes involving movements that stretch and strengthen the muscles and improve the stability. Proprioceptive training for 5 minutes which involve Single-leg balance Start with 20-30 seconds per leg and gradually increase to 1 minute 2-3 sets per leg. Weight bearing exercises on an uneven surface (such as Bosu ball or stability disc) and jumping rope 5-10 minutes/session. All proprioceptive training done firstly with eyes open and then with close eyes. Squat-to-stand training proprioceptive training lower extremity.
62849197|NCT05856695|EXPERIMENTAL|Carboplatin + Paclitaxel + Durvalumab|Carboplatin AUC 6, day 1 of three-week cycle for four cycles Paclitaxel 200 mg/m² day 1 of a three-week cycle for four cycles Durvalumab 1500 mg every 3 weeks for 4 cycles followed by 1500 mg maintenance every 4 weeks until progression, unacceptable toxicity, or consent withdrawal
62849198|NCT01159431|EXPERIMENTAL|Active|
62041632|NCT00587327|PLACEBO_COMPARATOR|Placebo|
62041633|NCT04293146|ACTIVE_COMPARATOR|pre-pectoral IBBR|
62041634|NCT04293146|ACTIVE_COMPARATOR|sub-pectoral IBBR|
62434913|NCT06407895|ACTIVE_COMPARATOR|Routine Therapy|In control group routine therapy will be given 3 times a week for 6 weeks with session conducting 45 minutes per sessions which involve standing balance exercises, sitting from chair to stand, heal to toe stand will be performed.
62849199|NCT01159431|OTHER|Control|
62244732|NCT00177138|ACTIVE_COMPARATOR|Group 2|Tacrolimus/MMF/TMG
62434914|NCT01347398|EXPERIMENTAL|MicroMESAM|Sleep study made by MicroMESAM system
62041635|NCT06733844|EXPERIMENTAL|Intervention pilot districts|Consisted of 4 districts from four provinces of Pakistan
62244733|NCT00177138|EXPERIMENTAL|Group 1|Campath/MMF/TMG
62822328|NCT04768738|EXPERIMENTAL|Subthreshold Group|In the subthreshold group, biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The parameters were the same with Above Threshold Group but the current was reduced to where the participant did not feel the current after the threshold value was reached and again applied for 5 minutes.
62822329|NCT04768738|SHAM_COMPARATOR|Control Group|In the control group, bicycle exercise was performed under the same load with the current-free headset produced for sham applications for 5 minutes. Participants were shown that the device was working, but no current was given.
62822330|NCT01082861|EXPERIMENTAL|HPV&HBV vaccin|HPV\&HBV vaccin
62041636|NCT06733844|NO_INTERVENTION|Control districts|For each intervention district within every province, a corresponding control district was selected. The control districts were identified and selected based on being the closest match to the intervention district in terms of prevalence of anemia and nutritional status (BMI) among adolescent girls as reported in the National Nutritional Survey 2018. The rate of anemia and iron folic acid intake in last pregnancy (an indicator of nutrition services being accessed) between the intervention and control districts was also comparable for the women of reproductive age (15-49 years). Comparison districts were selected for not having an ongoing WIFAS or adolescent nutrition program for adolescents.
62244734|NCT00955851||Pneumonia patients|The study group will consist of individuals diagnosed with pneumonia and admitted to the Medicine ward under the Pneumonia Core Measure Protocol.
62434915|NCT01347398|ACTIVE_COMPARATOR|PSG|Sleep study made by PSG (polysomnography)
62434916|NCT05750225||690AD IOL|50 eyes /patients implanted with 690AD IOL
62434917|NCT05750225||690ADY IOL|50 eyes /patients implanted with 690ADY IOL
62434918|NCT04942379|EXPERIMENTAL|Asthma Link|Site providers will be trained to efficiently discuss school-supervised medication administration with families and school nurses. Providers identify children with poorly controlled asthma and poor medication adherence and offer enrollment in Asthma Link to provide school-supervised asthma therapy. Ongoing communication occurs between the pediatric practice, school nurse and families through electronic medical record messaging and phone communication. Data will be collected at baseline (study entry) and at 3-, 6-and 12-month follow-up.
62434919|NCT04942379|ACTIVE_COMPARATOR|Enhanced Usual Care|Sites will receive pediatric pulmonologist-delivered training and a workbook for pediatric practices to provide to patients on behavioral strategies to help promote asthma medication adherence. Providers identify children with poorly controlled asthma and poor medication adherence and offer enrollment to this Enhanced Usual Care condition of study (receipt of workbook). Data will also be collected at baseline (study entry) and at 3-, 6-and 12-month follow-up.
62434920|NCT00879970|ACTIVE_COMPARATOR|pioglitazone|PIO tablet was administered in the dose of 30 milligrams (mg) OD initially and could be titrated to a maximum dose of 45 mg at or after the 6-month visit. After 1 year of treatment, the dose of PIO was increased to 45 mg OD for the duration of 5.5 years.
62434921|NCT00879970|ACTIVE_COMPARATOR|rosiglitazone|RSG tablet was administered in the dose of 4 mg OD initially and could be titrated to a maximum dose of 8 mg at or after the 6-month visit. After 1 year of treatment, the dose of RSG was increased to 8 mg OD for the duration of 5.5 years.
62434922|NCT00879970|PLACEBO_COMPARATOR|TZD placebo|Matching placebo tablet was administered once a day (OD) for the duration of 5.5 years
62434923|NCT00879970|ACTIVE_COMPARATOR|Vitamin D|Active comparator
62434924|NCT00879970|PLACEBO_COMPARATOR|Vitamin D placebo|Placebo Comparator
62434925|NCT01537575|PLACEBO_COMPARATOR|saline solution|
62822331|NCT01082861|EXPERIMENTAL|HPV vaccination|HPV vaccination
62822332|NCT01082861|EXPERIMENTAL|HBV vaccination|HBV vaccination
62822333|NCT06585657|EXPERIMENTAL|brain visual perception training group|Conduct brain visual perception training through a visual training system to improve binocular visual balance. Train 2 projects per day, each lasting 10 minutes.
62822334|NCT06585657|NO_INTERVENTION|control group|no intervention
62822335|NCT05101096|EXPERIMENTAL|Sacituzumab Govitecan-hziy 6 mg, Advanced Solid Tumors|(Phase 1 Cohort A: dose escalation) Japanese participants with advanced solid tumors will receive sacituzumab govitecan-hziy (SG) 6 mg/kg by intravenous (IV) injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
62822336|NCT05101096|EXPERIMENTAL|Sacituzumab Govitecan-hziy 8 mg, Advanced Solid Tumors|(Phase 1 Cohort A: dose escalation) Japanese participants with advanced solid tumors will receive SG 8 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
62041637|NCT06258109||Women with pregnancy after index CeAD|Women who became pregnant at least once after first index CeAD
62041638|NCT06258109||Women without pregnancy after index CeAD|Women who did not became pregnant after first index CeAD
62244735|NCT00694850|EXPERIMENTAL|Arm 1|
62244736|NCT04697810|EXPERIMENTAL|Namodenoson|Namodenoson capsules orally 25 mg every 12 hours for 36 weeks
62244737|NCT04697810|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules orally 25 mg every 12 hours for 36 weeks
62244738|NCT01028222|EXPERIMENTAL|Nilotinib|400 mg twice daily
62244739|NCT01028222|ACTIVE_COMPARATOR|DTIC|850 mg/m2 IV every 3 weeks
62434926|NCT01537575|EXPERIMENTAL|intravenous immunoglobulins|
62434927|NCT03757585|EXPERIMENTAL|Omega-3 Fatty Acids + Inositol|Subjects will be treated with 1020mg QAM + 1020mg QPM of omega-3 fatty acids and inositol based on weight (subjects under 25kg: 1000mg QD; Subjects weighing 25kg or more: 2000mg QD).
62434928|NCT03757585|EXPERIMENTAL|N-acetylcysteine|Subjects will be treated with N-acetylcysteine capsules (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2400 mg QD) or effervescent tablets (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2700 mg QD) based on age.
62434929|NCT01188954|ACTIVE_COMPARATOR|Doxycycline|Doxycyline, family of tetracycline antibiotics, used to scleroses the lymphatic vessels that may have transected during dissection.
62434930|NCT01188954|PLACEBO_COMPARATOR|Normal Saline/Water|The standard care is wetting and suctioning fluids followed with suturing of the groin.
62434931|NCT00778271|EXPERIMENTAL|1|Gabapentin 400mg capsules
62434932|NCT00778271|ACTIVE_COMPARATOR|2|Neurontin® 400 mg capsules
62041639|NCT06002165|PLACEBO_COMPARATOR|Usual Care Arm|The Usual Care Arm is comprised of the clinics that are not yet receiving the intervention. All clinics participating in the study are in the Usual Care Arm until they begin the Active Implementation phase.
62041640|NCT06002165|ACTIVE_COMPARATOR|Active Implementation Arm|The Active Implementation Arm is comprised of the clinics that have started to receive the intervention, which is the ACHIEVE multi-component implementation strategy delivered by the Nurse Coordinators. All clinics (divided into 3 Cohorts) move from the Usual Care Arm into the Active Implementation Arm in sequential order (six months apart).
62041641|NCT04330638|PLACEBO_COMPARATOR|Usual Care|
62822337|NCT05101096|EXPERIMENTAL|Sacituzumab Govitecan-hziy 10 mg, Advanced Solid Tumors|(Phase 1 Cohort A: dose escalation) Japanese participants with advanced solid tumors will receive SG 10 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
62041642|NCT04330638|ACTIVE_COMPARATOR|Anakinra|
62822338|NCT05101096|EXPERIMENTAL|Sacituzumab Govitecan-hziy 6 mg, UGT1A1 Polymorphism|(Phase 1 Cohort B: dose escalation) Japanese participants with UGT1A1 polymorphism will receive SG 6 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
62822339|NCT05101096|EXPERIMENTAL|Sacituzumab Govitecan-hziy 10 mg, UGT1A1 Polymorphism|(Phase 1 Cohort B: dose escalation) Japanese participants with UGT1A1 polymorphism will receive SG 10 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
62822340|NCT05101096|EXPERIMENTAL|Sacituzumab Govitecan-hziy, Metastatic Triple-negative Breast Cancer (mTNBC)|(Phase 2: dose expansion) Japanese participants with mTNBC will receive SG at the recommended Phase 2 dose (RP2D) on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
62041643|NCT04330638|ACTIVE_COMPARATOR|Siltuximab|
62041644|NCT04330638|ACTIVE_COMPARATOR|Anakinra + Siltuximab|
62041645|NCT04330638|ACTIVE_COMPARATOR|Tocilizumab|
62041646|NCT04330638|ACTIVE_COMPARATOR|Anakinra + Tocilizumab|
62041647|NCT06574009|EXPERIMENTAL|Multimodal pain care 9 months|Findings from the comprehensive pain assessment will be used to inform an individualized, multimodal plan crafted by the team physician with the subject's collaboration
62041648|NCT06574009|EXPERIMENTAL|Medication optimization|Findings from the comprehensive pain assessment will be used to inform a medication-focused pain plan.
62041649|NCT06574009|EXPERIMENTAL|Multimodal pain care 6 months / Opioid tapering 3 months|Findings from the comprehensive pain assessment will be used to inform an individualized, multimodal plan crafted by the team physician with the subject's collaboration. After 6 mo, subjects will attempt to taper opioids
62041650|NCT06574009|EXPERIMENTAL|Medication optimization 9 months|Findings from the comprehensive pain assessment will be used to inform a medication-focused pain plan. Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain.
62041651|NCT06574009|EXPERIMENTAL|Medication optimization 6 months/ Buprenorphine rotation 3 months|Findings from the comprehensive pain assessment will be used to inform a medication-focused pain plan. Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain. After 6mo, subjects will receive buprenorphine and attempt to taper opioids for following 3 mo.
62041652|NCT06574009|EXPERIMENTAL|Medication optimization 6 months/ Opioid tapering 3 months|Findings from the comprehensive pain assessment will be used to inform a medication-focused pain plan. Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain. After 6mo, subjects will attempt to taper opioids for following 3 mo.
62041653|NCT01536132|ACTIVE_COMPARATOR|Levosimendan|levosimendan at a dose of 0.2 micrograms/kg/min for 6 hours intravenous infusion
62041654|NCT01536132|PLACEBO_COMPARATOR|Placebo|placebo (same appereance than levosimendan in colour) at a dose of 0.2 micrograms/kg/min for 6 hours intravenous infusion
62041655|NCT01643590|PLACEBO_COMPARATOR|Placebo|
62041656|NCT01643590|EXPERIMENTAL|15 mg dose of JVS-100|15 mg dose of JVS-100
62041657|NCT01643590|EXPERIMENTAL|30 mg dose of JVS-100|30 mg dose of JVS-100
62041658|NCT04436068|EXPERIMENTAL|Outpatients with known or suspected hydrocephalus|
62434933|NCT01557270|EXPERIMENTAL|ropivacaine + dexmedetomidine|This group represents the standard of care drug (ropivacaine) plus the new additive to be studied (dexmedetomidine)
62434934|NCT01557270|ACTIVE_COMPARATOR|ropivacaine + saline|This group represents the current standard of care in peripheral nerve blockade
62434935|NCT04447833|EXPERIMENTAL|Mesenchymal Stromal Stem Cell Treatment|Infusion of allogeneic bone marrow derived mesenchymal stromal stem cells (MSC). First three patients receive a singe dose of 1x10\^6 MSC/kg dose, next six patients receive a single dose of 2x10\^6 MSC/kg.
62601325|NCT02613429|ACTIVE_COMPARATOR|caudal longitudinal|identification of the airway from the distal end. Marking of the airway, including the cricothyroid membrane, on the skin, by starting the examination caudally, and then moving cranially
62041659|NCT04436068|EXPERIMENTAL|Outpatients with other known or suspected neurological condition|
62041660|NCT03716908||P51S+ group|"Group 1 affected subjects (P51S+) Family member P51S mutation carrier~interventions/ Questionnaire (DHI, OS, EQ-D5-5L, ABC) Pure Tone audiometry VNG vHIT c- and o-VEMP"
62041661|NCT03716908||P51S- group (healthy control)|"Group 2: healthy control Family member P51S non-carrier~interventions: Questionnaire (DHI, OS, EQ-D5-5L, ABC) Pure Tone audiometry VNG vHIT c- and o-VEMP"
62041662|NCT05169515|EXPERIMENTAL|Arm 1|Participants will receive subcutaneous (SC) mosunetuzumab + CC-220 (dose escalation only) or SC mosunetuzumab + CC-99282.
62041663|NCT05169515|EXPERIMENTAL|Arm 2|Participants will receive intravenous (IV) glofitamab + CC-99282.
62041664|NCT03535337|ACTIVE_COMPARATOR|CPS-Rsp-T|After 3 months of intervention, this group of CPS Rsp will receive 3 months of CPS-T intervention followed by SC.
62041665|NCT03535337|ACTIVE_COMPARATOR|CPS-Rsp-SC|After 3 months of intervention, this group of CPS Rsp's intervention will discontinue and they'll receive SC only
62601326|NCT06649084|EXPERIMENTAL|Multicomponent Lexical Retrieval Training (Multi-LRT)|
62434936|NCT02525029|EXPERIMENTAL|Arm 1: Phase 1 Dose Level -2: 125 USP hCG/875 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62822341|NCT05101096|EXPERIMENTAL|Sacituzumab Govitecan-hziy, HR+/HER2- Metastatic Breast Cancer (HR+/HER2- mBC)|(Phase 2) Japanese participants with HR+/HER2- mBC will receive SG at the recommended Phase 2 dose (RP2D) on Day 1 and Day 8 of a 21 day cycle until disease progression or unacceptable toxicity.
62434937|NCT02525029|EXPERIMENTAL|Arm 1: Phase I Dose Level -1: 250 USP hCG/1,750 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62822342|NCT05101096|EXPERIMENTAL|Sacituzumab Govitecan-hziy, Metastatic Urothelial Carcinoma (mUC)|(Phase 2) Japanese participants with mUC will receive SG at the recommended Phase 2 dose (RP2D) on Day 1 and Day 8 of a 21 day cycle until disease progression or unacceptable toxicity.
62601327|NCT06649084|EXPERIMENTAL|Multicomponent Video Implemented Script Training in Aphasia (Multi-VISTA)|
62822343|NCT05762757|EXPERIMENTAL|Colposcopy educational material|Participants will complete a 9-question quiz that will assess knowledge of colposcopy. They will then view the colposcopy educational material and answer the same 9-question quiz to assess their knowledge of colposcopy. Participants will complete the Acceptability Intervention Measure, the Intervention Appropriateness Measure, and the Feasibility of Intervention Measure. Participants will also be asked whether the educational material influences their intention to adhere to colposcopy.
62822344|NCT04896060||Ecological Momentary Assessment (EMA) volunteers|Volunteers with access to mobile device with Wi-Fi and data recruited for an additional 1-week daily assessment study utilizing EMA to examine COVID-19 related stress and eating behavior in real-time
62822345|NCT04896060||General global population volunteers|Newly recruited volunteers 18 and above from the general global population that agree to participate in the COVID study
62822346|NCT04896060||NIDDK-Phoenix study volunteers|Previous research participants, who signed consents that allow data sharing that agree to participate in the COVID study
62822347|NCT06414798|EXPERIMENTAL|Group 1- ABBV-1088 Dose A|Participants will receive single dose of ABBV-1088 dose A on day 1
62822348|NCT06414798|EXPERIMENTAL|Group 1- Placebo|Participants will receive single dose of placebo day 1
62822349|NCT06414798|EXPERIMENTAL|Group 2- ABBV-1088 Dose B|Participants will receive single dose of ABBV-1088 dose B on day 1
62822350|NCT06414798|EXPERIMENTAL|Group 2- Placebo|Participants will receive single dose of placebo day 1
62822351|NCT06414798|EXPERIMENTAL|Group 3- ABBV-1088 Dose C|Participants will receive single dose of ABBV-1088 dose C on day 1
62822352|NCT06414798|EXPERIMENTAL|Group 3- Placebo|Participants will receive single dose of placebo day 1
62822353|NCT06414798|EXPERIMENTAL|Group 4- ABBV-1088 Dose D|Participants will receive single dose of ABBV-1088 dose D on day 1
62822354|NCT06414798|EXPERIMENTAL|Group 4- Placebo|Participants will receive single dose of placebo day 1
62822355|NCT06414798|EXPERIMENTAL|Group 5- ABBV-1088 Dose E|Participants will receive single dose of ABBV-1088 dose E on day 1
62822356|NCT06414798|EXPERIMENTAL|Group 5- Placebo|Participants will receive single dose of placebo day 1
62822357|NCT06414798|EXPERIMENTAL|Group 6- ABBV-1088 Dose F|Participants will receive single dose of ABBV-1088 dose F on day 1
62822358|NCT06414798|EXPERIMENTAL|Group 6- Placebo|Participants will receive single dose of placebo day 1
62822359|NCT05315414|EXPERIMENTAL|Single tooth restorations|A single, open-label group with patients in need of single tooth restorations will receive PrimeTaper EV implant system with diameters 3.6, 4.2, 4.8, 5.4 mm, and lengths 6.5, 8, 9, 11, 13, 15 and 17 mm.
62822360|NCT06601426|OTHER|NBI-NearFocus|Narrow Band Imaging-NearFocus
62041666|NCT03535337|ACTIVE_COMPARATOR|CPS-NRsp-I|After 3 months of intervention, this group of CPS NRsp will receive 3 months of CPS-I followed by 3 months of CPS-T and 3 months of SC.
62041667|NCT03535337|ACTIVE_COMPARATOR|CPS-NRsp-SMS-I|After 3 months of intervention, this group of CPS NRsp will receive 3 months of SMS-I followed by 3 months of SMS-T and 3 months of SC
62041668|NCT03535337|ACTIVE_COMPARATOR|SMS-Rsp-T|After 3 months of intervention, this group of SMS Rsp will receive 3 months of SMS tapered (SMS-T) intervention followed by SC.
62041669|NCT03535337|ACTIVE_COMPARATOR|SMS-Rsp-SC|After 3 months of intervention, this group of SMS Rsp, intervention will discontinue and they'll receive SC only
62601328|NCT06649084|EXPERIMENTAL|Multicomponent Communicaiton Partner Training (Multi-CPT)|
62601329|NCT03310658|EXPERIMENTAL|Single Study Site: UANL|As the only study arm, 10 enrolled subjects received vaginal cuff closure with the Zip-Stitch Soft Tissue Closure System as part of Total Laparoscopic Hysterectomy.
62601330|NCT03772977|EXPERIMENTAL|Brain Health Champion (BHC)|"A health coach intervention with weekly phone calls"
62822361|NCT06151288|EXPERIMENTAL|Group 1|Participants will receive a single low dose of VAX-31 administered as an intramuscular injection at Day 1.
62822362|NCT06151288|EXPERIMENTAL|Group 2|Participants will receive a single mid dose of VAX-31 administered as an intramuscular injection at Day 1.
62822363|NCT06151288|EXPERIMENTAL|Group 3|Participants will receive a single high dose of VAX-31 administered as an intramuscular injection at Day 1.
62822364|NCT06151288|ACTIVE_COMPARATOR|Group 4|Participants will receive a single intramuscular injection of the standard dose of PCV20 at Day 1.
62822365|NCT02006472|EXPERIMENTAL|Pridopidine 45 mg|Twice daily
62822366|NCT02006472|EXPERIMENTAL|Pridopidine 67.5 mg|Twice daily
62822367|NCT02006472|EXPERIMENTAL|Pridopidine 90 mg|Twice daily
62822368|NCT02006472|EXPERIMENTAL|Pridopidine 112.5 mg|Twice daily
62822369|NCT02006472|PLACEBO_COMPARATOR|Placebo|Twice daily
62822370|NCT06291441||Women's single sample|"INSTRUMENTS:~* UI Survey: A survey, written in Italian by the authors, will collect women's socio-demographic, economic and clinical characteristics~* Italian version of International Consultation of Incontinence Modular Questionnaire Urinary Incontinence Short Form (ICIQ UI-SF)~* Italian version of Incontinence Impact Questionnaire-7 (IIQ-7)"
62822371|NCT06589375|ACTIVE_COMPARATOR|Normosmic|"Participants in this group have normal olfactory function, as determined by the Sniffin' Sticks test. They will undergo EEG analysis while being exposed to various olfactory stimuli to establish baseline brain wave patterns for normal olfactory responses.~(n=550)"
62822372|NCT06589375|ACTIVE_COMPARATOR|Hyposmic|Participants in this group have impaired olfactory function (hyposmia), confirmed through the Sniffin' Sticks test. They will undergo EEG analysis during olfactory stimulation to identify differences in brain wave patterns compared to normosmic individuals. (n=150)
62601331|NCT03772977|NO_INTERVENTION|Standard of Care (SOC)|The current physician/provider counseling on brain health to reduce cognitive decline or incidence of cognitive impairment that occurs, per providers' own practice
62041670|NCT03535337|ACTIVE_COMPARATOR|SMS-NRsp-CPS-I|After 3 months of intervention, this group of SMS NRsp will receive 3 months of CPS-I followed by 3 months CPS-T and 3 months SC
62601332|NCT05328375|EXPERIMENTAL|Telehealth-enhanced Hybrid CR|Participants will receive a hybrid version of cardiac rehabilitation.
62041671|NCT03535337|ACTIVE_COMPARATOR|SMS-NRsp-I|After 3 months of intervention, this group of SMS NRsp will receive 3 months of SMS-I followed by 3 months of SMS-T and 3 months of SC
62601333|NCT05328375|ACTIVE_COMPARATOR|Traditional CR|Participants will receive a standard of care version of cardiac rehabilitation.
62601334|NCT05913635|EXPERIMENTAL|No-breakfast|One-day meal plan with no breakfast. The dietary plan has been developed according to the Dietary Guidelines for Chinese Residents (2022), and the energy distribution of the two meals (lunch and dinner) is 1:1, with the energy percentage of carbohydrates, proteins, and fats being 55%, 15%, and 30%, respectively. The total daily calorie intake has been calculated based on the gender difference of the participants. Since the recommended daily calorie intake for males is 2000 kcal while for females it is 1600 kcal, each meal for males is designed to provide 667 kcal calories, comprising 92g carbohydrates, 22g fat, and 25g protein; each meal for females is designed to provide 533 kcal calories, comprising 73g carbohydrates, 18g fat, and 20g protein. The carbohydrates are sourced from buckwheat flour and mixed grain rice, which create similar glycemic indexes for each meal. Additionally, the one-day meal for both males and females includes 450g of vegetables and 320g of fruits.
62822373|NCT06589375|ACTIVE_COMPARATOR|Tinnitus Patients with Hyposmia|This group includes participants who have both tinnitus and hyposmia. They will be subjected to EEG analysis during olfactory testing to investigate the interaction between olfactory and auditory disorders and how these conditions may influence brain wave responses. (n=150)
62822374|NCT06589375|ACTIVE_COMPARATOR|Tinnitus Patients without Hyposmia|Participants in this group have tinnitus but normal olfactory function. They will undergo the same EEG and olfactory tests to explore the impact of tinnitus on brain wave patterns in the absence of olfactory disorders and to compare their responses with those of other groups. (n=150)
62822375|NCT02818907|OTHER|Additional biological samples|"Additional blood samples will be realized specifically to the study at baseline, after neoadjuvant chemotherapy (if applicable) and before surgery, 1 month after surgery and 1 month after the last adjuvant chemotherapy cycle.~Peripheral blood mononuclear cell (PBMC), plasma and circulating tumor DNA and RNA will be collected.~Tumor tissue will be collected during surgery."
62822376|NCT04346745|EXPERIMENTAL|Treatment group|The treatment group will receive intervention of a peer mentoring program plus usual services they could receive from community agencies.
62822377|NCT04346745|NO_INTERVENTION|Control group|The control group received a package of educational materials on knowledge of dementia, caregiving skills.
62822378|NCT06273774|EXPERIMENTAL|Panel A: MK-8189 Dosing Regimen 1|Participants will receive MK-8189 once daily (QD) at dosing regimen 1 for up to 14 days.
62822379|NCT06273774|EXPERIMENTAL|Panel B: MK-8189 Dosing Regimen 2|Participants will receive MK-8189 QD at dosing regimen 2 for up to 14 days.
62822380|NCT06273774|EXPERIMENTAL|Panel C: MK-8189 Dosing Regimen 3|Participants will receive MK-8189 QD at dosing regimen 3 for up to 14 days.
62822381|NCT06273774|PLACEBO_COMPARATOR|Placebo|Participants will receive MK-8189-matching placebo QD for up to 14 days.
62822382|NCT02586181|PLACEBO_COMPARATOR|Vitamin D and Calcium|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate"
62822383|NCT02586181|EXPERIMENTAL|Vitamin D, Calcium, Vitamins B9, B6, B12|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
62041672|NCT06579742|EXPERIMENTAL|Live Conscious Beyond Collagen Supplement|Participants in this arm will receive the Live Conscious Beyond Collagen supplement. The supplement contains Vitamin C (90 mg), Biotin (2500 mcg), and a Proprietary Collagen Blend (10.1 g) including Types I \& III Bovine Collagen, Type II Marine Collagen, Type II Chicken Sternum Collagen, and Types I, V \& X Eggshell Membrane Collagen.
62244740|NCT03167203|EXPERIMENTAL|hESC-RPE cells|Participants previously enrolled into an Astellas Institute for Regenerative Medicine (AIRM) sponsored clinical trial and treated with Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial (hESC-RPE) cells
62822384|NCT00498875||Questionnaire + Depression Intervention|
62041673|NCT06579742|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive a placebo product. The placebo contains Maltodextrin.
62822385|NCT05708755|EXPERIMENTAL|Lung Transplant Recipients|Lung transplant recipients with pre-transplant serological immunity to CMV. CMV-TCIP will be measured every 3 months post-transplant with antiviral prophylaxis discontinued when threshold is exceeded.
62822386|NCT05467007|EXPERIMENTAL|BioFire® Respiratory Panel 2.1-EZ|EXP group will receive the BioFire RP2.1-EZ panel, designed to test for a variety of bacterial and/or viral causes for illness
62822387|NCT05467007|NO_INTERVENTION|Standard of Care|Standard care procedures are essentially yes/no to patient having SARS-COV-2, the SC group will receive the standard nasal swab used in the IPCs.
62601335|NCT05913635|EXPERIMENTAL|No-dinner|One-day meal plan with no dinner. The dietary plan has been developed according to the Dietary Guidelines for Chinese Residents (2022), and the energy distribution of the two meals (breakfast and lunch) is 1:1, with the energy percentage of carbohydrates, proteins, and fats being 55%, 15%, and 30%, respectively. The total daily calorie intake has been calculated based on the gender difference of the participants. Since the recommended daily calorie intake for males is 2000 kcal while for females it is 1600 kcal, each meal for males is designed to provide 667 kcal calories, comprising 92g carbohydrates, 22g fat, and 25g protein; each meal for females is designed to provide 533 kcal calories, comprising 73g carbohydrates, 18g fat, and 20g protein. The carbohydrates are sourced from buckwheat flour and mixed grain rice, which create similar glycemic indexes for each meal. Additionally, the one-day meal for both males and females includes 450g of vegetables and 320g of fruits.
62601336|NCT00894790|EXPERIMENTAL|1|
62822388|NCT04777851|EXPERIMENTAL|Regorafenib + Pembrolizumab|Investigational arm: regorafenib at a dose of 90 mg orally once per day (on days 1 to 21 of a 28-day cycle), in combination with pembrolizumab 400 mg using a 30-minute intravenous infusion, on day 1 of a 6-week cycle.
62601337|NCT00894790|ACTIVE_COMPARATOR|2|
62822389|NCT04777851|ACTIVE_COMPARATOR|Loco-regional therapy|"Control arm: Patients will be treated with TACE or TARE on-demand according to site's standard of practice."
62822390|NCT04584255|EXPERIMENTAL|Arm A Triple Negative Breast Cancer (TNBC)|"Participants will be randomized 1:1 to treatment with the combination (Arm A)~* Niraparib-Daily beginning with week 1, day 1~* Dostarlimab-Once every three weeks beginning with week 1, day 1"
62822391|NCT04584255|EXPERIMENTAL|Arm B TNBC|"Participants will be randomized 1:1 to treatment with the combination (Arm B)~* 3-week lead-in of niraparib monotherapy followed by treatment with the combination~* Niraparib Daily beginning with week 1, day 1~* Dostarlimab Once every three weeks beginning with week 4, day 1"
62041674|NCT06721091|EXPERIMENTAL|Part 1 (SAD): Active|Single oral dose of VNA-318
62041675|NCT06721091|PLACEBO_COMPARATOR|Part 1 (SAD): Placebo|Single oral dose of Matching Placebo
62601338|NCT01793688||Sulbactam Sodium/Ampicillin Sodium|Patients with the following disease who received high doses of UNASYN (exceeding 6 g per day) by intravenous injection or intravenous drip infusion from the first dosing date or the second dosing date: Pneumonia, Lung Abscess, Peritonitis.
62601339|NCT06244498||TXA|Tranexamic acid was administered to the participants at a dose of 1.0 g during the induction of anaesthesia and immediately after the operation.
62601340|NCT06244498||Non-TXA|Tranexamic acid were not administred to the participants .
62601341|NCT05292417|EXPERIMENTAL|Experimental Group|hypofractionation radiotherapy combined with sintilimab,GM-CSF and Fruquintinib in the third-line or above treatment of MSS Metastatic Colorectal Carcinoma(mCRC)
62041676|NCT06721091|EXPERIMENTAL|Part 2 (MAD): Active|Multiple oral doses of VNA-318
62601342|NCT06559189|EXPERIMENTAL|Lymphodepleting chemotherapy with CD19x22 CAR T cohort|"A single participant will receive each dose and will be evaluated for at least the DLT period of 28 days post-infusion before the next participant receives a dose.~CD19x22 CAR T will be dosed based on recipient body weight.~Phase I Dose Level (DL) CD19x22 CAR T dose~-1 1 x 10(to the 5th) Viable CD3+ CAR+ cells/kg of cell dosing weight~1. (starting dose) 3 x 10(to the 5th) Viable CD3+ CAR+ cells/kg of cell dosing weight~2. 1 x 10(to the 6th) Viable CD3+ CAR+ cells/kg of cell dosing weight~3. 3 x 10(to the 6th) Viable CD3+ CAR+ cells/kg of cell dosing weight"
62601343|NCT01306045|ACTIVE_COMPARATOR|A/ Erlotinib|Arm A - Erlotinib 150 mg by mouth (PO) every morning (QAM)
62041677|NCT06721091|PLACEBO_COMPARATOR|Part 2 (MAD): Placebo|Multiple oral doses of Matching Placebo
62601344|NCT01306045|ACTIVE_COMPARATOR|B/ AZD6244|AZD6244 Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours
62601345|NCT01306045|ACTIVE_COMPARATOR|C/ MK-2206|MK-2206 200 mg by mouth (PO) every (Q) Week
62601346|NCT01306045|ACTIVE_COMPARATOR|D/ Lapatinib|Lapatinib 1500 mg by mouth (PO) every day (QD)
62601347|NCT01306045|ACTIVE_COMPARATOR|E/Sunitinib|Sunitinib 50 mg by mouth (PO) on days 1-28
62601348|NCT01306045|OTHER|F/ Not Otherwise Specified (NOS)|Participants who do not meet the eligibility criteria for enrollment
62601349|NCT01615211|NO_INTERVENTION|Standard treatment|patients will receive standard treatment with 200mg Mifepristone and after 36-48 hours 800 mcg of misoprostol vaginally
62601350|NCT01615211|ACTIVE_COMPARATOR|trilostane|patients will receive Day 1: Mifepristone 200 mg and Trilostane 120mg 1 tablet twice and Day 2 Trilostane 240mg twice. On Day 3 800 mcg misoprostol will be given vaginally.
62041678|NCT05755308|EXPERIMENTAL|Faecal microbiota transplantation|
62041679|NCT05755308|PLACEBO_COMPARATOR|Placebo arm|
62041680|NCT01860703|EXPERIMENTAL|Arm A - Maximum Therapeutic Dose|Single dose of 33 mg/kg rounded to the nearest 250 mg of deferiprone tablets
62041681|NCT01860703|EXPERIMENTAL|Treatment Arm B - Supratherapeutic Dose|Single dose of 50 mg/kg rounded to the nearest 250 mg of deferiprone tablets
62041682|NCT01860703|EXPERIMENTAL|Arm C - Placebo Control|Single dose of matching deferiprone and moxifloxacin placebo tablets.
62041683|NCT01860703|EXPERIMENTAL|Arm D - Positive Control|Single dose of one 400 mg moxifloxacin tablet.
62601351|NCT01615211|ACTIVE_COMPARATOR|Letrozole|Patients will receive on Day 1 Mifepristone 200mg and Letrozole 2,5mg 3 tablets and on Day 2 Letrozole 2,5mg 3 tablets. On day 3 800mcg of misoprostol will be given vaginally
62822392|NCT04584255|EXPERIMENTAL|Arm C ER+/HER2-|"exploratory cohort of estrogen receptor (ER) positive HER2-negative participants will be enrolled to Arm C.~* Niraparib Daily beginning with week 1, day 1~* Dostarlimab Once every three weeks beginning with week 1, day 1"
62822393|NCT03932344||SJIA patients on Kineret treatment|SJIA patients on Kineret treatment enrolled in the Pharmachild JIA registry
62822394|NCT05535387|EXPERIMENTAL|FamilyNet smart speaker/mobile application|In a 4- to 6-week period, families will use a prototype of the FamilyNet integrated and coordinated smart speaker/mobile application designed to provide families with in-situ experiential support for building positive behavior plans.
62041684|NCT06087341|EXPERIMENTAL|NKG2D-CAR memory T cells infusion|If the primary tumor and/or metastases are not accessible, the patient will be included in Arm A.This group will receive an intravenous infusion of NKG2D-CAR memory T cells.
62041685|NCT06087341|EXPERIMENTAL|Systemic and locally transduced NKG2D-CAR memory T cells infusion|If the primary tumor and/or metastases are accessible, the patient will be included in Arm B. This group will receive an intravenous infusion of NKG2D-CAR memory T cells and an intratumoral dose of NKG2D-CAR memory T cells.
62041686|NCT02567084|OTHER|"CERAMENT™ |BONE VOID FILLER"|"Intraoperativ application of medical device: CERAMENT™ \|BONE VOID FILLER 5cc/10cc/18cc"
62041687|NCT04733287|EXPERIMENTAL|Effect of High Intensity Interval Training|"Young and older subjects will participate in single-leg, high-intensity interval training of the right knee extensors (4 intervals of 4 minutes at 80% of max aerobic power with 4 minute rest intervals between, 3x per week for 6 weeks).~Muscle function and knee extensor critical power will be measured before and after the 6 weeks of treatment."
62041688|NCT04733287|EXPERIMENTAL|Effect of Muscle Heat Therapy|"Young and older subjects will participate in single-leg,heat therapy training of a single leg ( quadriceps femoris, 120 minutes of shortwave diathermy to raise the muscle temperature to \~39C) 3 times a week for 6 weeks.~Muscle function and knee extensor critical power will be measured before and after the 6 weeks of treatment."
62041689|NCT04733287|SHAM_COMPARATOR|Effect of Sham Muscle Heat Therapy|"Young and older subjects will participate in a sham treatment of single-leg,heat therapy training of the right knee extensors (120 minutes with shortwave diathermy unit positioned on leg, but not turned on) 3 times a week for 6 weeks.~Muscle function and knee extensor critical power will be measured before and after the 6 weeks of treatment."
62041690|NCT04733287|SHAM_COMPARATOR|Effect of Immobilization with Daily Sham Heat Therapy|"Young subjects (18-35 years) will undergo 2 weeks of leg immobilization while receiving 2 hours of a sham heat therapy treatment each day. For the sham treatment, the heating device will be applied to the limb, but, unbeknownst to the participant, it will not be turned on.~Muscle function and knee extensor critical power will be measured before and after the 2 weeks of leg immobilization."
62601352|NCT01570634|EXPERIMENTAL|Open Label CASAD|Treatment with CASAD for 14 days
62601353|NCT00094536|EXPERIMENTAL|Extended Treatment Regimen|Extended treatment regimens using the Her Option Endometrial Cryotherapy System to more effectively ablate the endometrial lining, reducing menstrual levels to normal or less.
62601354|NCT05878821|EXPERIMENTAL|Postural correction exercise|"All women in both groups (A\&B) will receive postural correction exercises which includes:~A.mckenzie exercises:~The exercise routine consists of seven types of movements,at static maximum strength, with 15_20 repetitions, holding each repetition for seven seconds.the subjects complete one 20-minutes set per day,three times a week for four weeks B.strengthening exercise targeted the periscapular muscles (Y to W,l to W), scapular retraction.strengthening exercises will be progressively performed for 3sets, with 10 to15 repetitions C.pectoralis flexibility on a foam roller.Hold for 5seconds and repeated 10 time s"
62601355|NCT05878821|EXPERIMENTAL|Shockwave therapy|"All women in group (B) will receive shockwave therapy once a week for the duration of the trial (4 weeks)~The dosage used will be as the following:~Energy flux Density (EFD)=0,25 ml/mm2 Number of shocks=1000 shocks(kamel et al.,2020). Time:2-5minutes per session."
62601356|NCT04264117|ACTIVE_COMPARATOR|FlexAbility (Mesh-like irrigated tip catheter) group|
62601357|NCT04264117|EXPERIMENTAL|TactiCath (Contract force monitoring catheter) group|
62601358|NCT02763397|EXPERIMENTAL|NBM-DBS on|DBS is programmed to stimulate the NbM
62822395|NCT05109325|NO_INTERVENTION|Enhanced usual care + assessment|Daily assessments (without delivery of intervention components) will be conducted with EUC participants and they will receive a brochure with violence, substance use, and mental health resources.
62822396|NCT05109325|EXPERIMENTAL|IntERact|Participants will receive three remotely delivered behavioral therapy sessions (combining motivational interviewing, cognitive behavioral skills training, and care management), with an smartphone APP supporting the therapy and delivering therapeutic content in-between therapy sessions.
62822397|NCT06431048|EXPERIMENTAL|Patients receiving PEG nutrition, scheduled for tracheostomy placement.|
62822398|NCT06431048|EXPERIMENTAL|Patients receiving naso-enteral feeding, scheduled for PEG placement.|
62601359|NCT02763397|PLACEBO_COMPARATOR|DBS off|DBS is turned off, no stimulation will be exerted
62601360|NCT03370575|EXPERIMENTAL|ethiodized poppyseed oil|
62601361|NCT03370575|ACTIVE_COMPARATOR|the second-generation non-ionic monomer contrast|
62244741|NCT06736067|EXPERIMENTAL|Moderate-intensity aerobic exercise|Thirty minutes of exercise on a treadmill, including a 5-minute warm-up followed by increments in speed until reaching optimal moderate to high intensity (60-80% of age-predicted maximal heart rate), which will be maintained for 20 min, followed by a 5-minute cool-down. Age-predicted maximal HR will be defined as 220 beats-per-minute (BPM) minus age in years.
62601362|NCT06572423|EXPERIMENTAL|Treatment (PULSAR and HyperArc)|Patients undergo standard of care CT simulation for radiation treatment planning using HyperArc software. 1 week later, patients undergo PULSAR fraction therapy once daily on days 0, 14, 28, 42, and 56. Patients may also undergo Positron Emission Tomography (PET) scan and MRI during follow-up.
62601363|NCT01471717|EXPERIMENTAL|C 1:INX-08189 50 mg qd X 5 days|Cohort 1: Subjects will begin administration of INX-08189 50 mg every day (QD) on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
62041691|NCT04733287|EXPERIMENTAL|Effect of Immobilization with Daily Heat Therapy|"Young subjects (18-35 years) will undergo 2 weeks of leg immobilization while receiving 2 hours of heat therapy treatment each day. Heat therapy will consist of 120 minutes of shortwave diathermy to raise the quadriceps femoris muscle temperature to \~39C.~Muscle function and knee extensor critical power will be measured before and after the 2 weeks of leg immobilization."
62041692|NCT02478411|EXPERIMENTAL|Cycle ergometer physiotherapy|15 minutes of cycle ergometer physiotherapy plus 15 minutes of conventional physiotherapy, once daily, five days a week, as long as patients remain in the intensive care unit
62601364|NCT01471717|ACTIVE_COMPARATOR|C1: INX-08189 / Victrelis 800 mg TID X 3 days|Cohort 1:INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg three times a day (TID) for 3 additional days
62822399|NCT02947685|EXPERIMENTAL|Arm A|Palbociclib 125 mg daily + AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt) until confirmed disease progression
62041693|NCT02478411|ACTIVE_COMPARATOR|Conventional physiotherapy|30 minutes of conventional physiotherapy, once daily, five days a week, as long as patients remain in the intensive care unit
62041694|NCT06732128|EXPERIMENTAL|Treatment Group|Participants will receive nature-based applications available on the Oculus platform, as well as nature-based 360 videos with the same content as the control group however in a 360 format.
62041695|NCT06732128|ACTIVE_COMPARATOR|Control Group|Participants will receive YouTube links to watch nature-based videos on a device (e.g., a tablet).
62244742|NCT05975801|ACTIVE_COMPARATOR|Dry Cupping Therapy Group|In addition to the conventional treatment, moving cup application was applied for 10 minutes twice a week. During the treatment, the patients were placed in a side-lying position with the affected side on top. Liquid petroleum jelly was applied on the skin and negative pressure was created with a manual pump, allowing the cup to be slid on the skin. Care was taken to ensure that the negative pressure would not cause increased pain and would allow the cup to slide. Deltoid, Trapeze, Supraspinatus, Infraspinatus, Pectoral muscles were applied in the origo insertion direction for a total of 10 minutes.
62601365|NCT01471717|ACTIVE_COMPARATOR|C2: Victrelis 800 mg TID x 3 days|Cohort 2: Subjects will begin administration of Victrelis 800 mg three times a day (TID) on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days
62601366|NCT01471717|ACTIVE_COMPARATOR|C 2:Victrelis 800 mg TID with INX-08189 50 mg QD|Cohort 2: Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days
62601367|NCT01471717|PLACEBO_COMPARATOR|C1: Placebo with Victrelis 800 mg|Cohort 1: Placebo QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days
62601368|NCT01471717|PLACEBO_COMPARATOR|C 2: Victrelis 800 mg with Placebo|Cohort 2: Victrelis 800 mg TID will be administered concurrently with Placebo QD for 5 additional days
62601369|NCT00985517|EXPERIMENTAL|Phase 1: Cohort 1|CERE-120 9.4 x 10\^11 vg, injected by a neurosurgeon directly in the substantia nigra and in the putamen
62601370|NCT00985517|EXPERIMENTAL|Phase 1: Cohort 2|CERE-120 2.4 x 10\^12 vg, injected by a neurosurgeon directly in the substantia nigra and in the putamen
62601371|NCT00985517|EXPERIMENTAL|Phase 2: CERE-120|CERE-120 2.4 x 10\^12 vg, injected by a neurosurgeon directly in the substantia nigra and in the putamen
62601372|NCT00985517|SHAM_COMPARATOR|Phase 2: Sham Surgery|Neurosurgical procedure that mimics the procedure for CERE-120 delivery. No injections were administered during sham surgery.
62601373|NCT01286168|EXPERIMENTAL|Antisepsis Side|A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days. The drainage bulb will be irrigated with 10ml of 0.125% sodium hypochlorite (Dakin's solution) twice a day.
62822400|NCT02947685|ACTIVE_COMPARATOR|Arm B|AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant) until confirmed disease progression
62822401|NCT04452721||Retrospective cohort|340 to 400 patients
62822402|NCT04452721||Validation cohort|120 patients
62041696|NCT05737082|EXPERIMENTAL|Sequence 1|"* Period 1, Period 3: RLD2205 + RLD2206~* Period 2, Period 4: HCP2201"
62822403|NCT03221556|ACTIVE_COMPARATOR|Engagement-Focused Care Coordination (EFCC)|The brief intervention in Engagement-Focused Care Coordination is the Engagement Interview. In this model, providers meet one to two times with mothers who screen positive for depression, and use techniques of shared decision-making to help mothers process the results of the screen; explore treatment options; and connect with formal mental health services. Engagement-Focused Care Coordination emphasizes referral to formal mental health services.
62601374|NCT01286168|OTHER|Control Side|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
62822404|NCT03221556|ACTIVE_COMPARATOR|Problem Solving Education (PSE)|The brief Problem Solving Education (PSE) is a six-session cognitive-behavioral program. PSE offers immediate intervention in the PCMH, followed by referral to further treatment if symptoms persist.
62822405|NCT06061094|ACTIVE_COMPARATOR|A: Imatinib + low dose chemotherapy|Imatinib 600mg QD + low dose chemotherapy induction and consolidation I (Standard Arm of Randomization I)
62822406|NCT06061094|EXPERIMENTAL|B: Ponatinib + low dose chemotherapy|Ponatinib 45mg QD (reduction to 30mg QD after Induction) + low dose chemotherapy induction and consolidation I (Experimental Arm of Randomization I)
62822407|NCT06061094|ACTIVE_COMPARATOR|C: Molecular CR: End of therapy with indication for SCT|Molecular CR: End of therapy with indication for SCT (Standard Arm of Randomization II)
62822408|NCT06061094|EXPERIMENTAL|D: Molecular CR: continuation with Imatinib/Ponatinib (per Rando I), chemotherapy and Blinatumomab|Molecular CR: No end of therapy with indication for SCT but and continuation with Imatinib/Ponatinib (per Randomization I), chemotherapy and Blinatumomab (Experimental Arm of Randomization II)
62822409|NCT06061094|EXPERIMENTAL|E: Mol Fail / Mol NE: Continuation with Imatinib/Ponatinib (per Rando I) and addition of Blina|Molecular Failure / Molecular Not Evaluable: Continuation with Imatinib/Ponatinib (per Randomization I) and addition of Blinatumomab (Experimental Arm)
62822410|NCT06590779|EXPERIMENTAL|Finasteride 1 mg & Aminexil® active+ lotion|Administration of Finasteride 1 mg + Aminexil® active+ lotion
62822411|NCT06590779|ACTIVE_COMPARATOR|Finasteride 1 mg|Administration of Finasteride 1 mg
62822412|NCT03026062|EXPERIMENTAL|Arm I (sequential tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Upon progression, patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 cycles in the absence of disease progression or unacceptable toxicity. This arm is closed to enrollment.
62822413|NCT03026062|EXPERIMENTAL|Arm II (combination tremelimumab, durvalumab)|Patients receive tremelimumab IV and durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 cycles in the absence of disease progression or unacceptable toxicity.
62822414|NCT06419465|EXPERIMENTAL|Peer-Led Health Protection and Promotion Training Program|
62822415|NCT06419465|EXPERIMENTAL|Health Protection and Promotion Training Program under the Leadership of a Public Health Nurse|
62822416|NCT02656381||Anterior Uveitis|Participants with AU at entry
62822417|NCT02656381||Intermediate Uveitis|Participants with IU at entry
62822418|NCT02656381||Other|Participants not fitting above criteria
62822419|NCT02656381||Posterior/Pan Uveitis|Participants with non-infectious posterior or pan-uveitis
62822420|NCT05220618|EXPERIMENTAL|PESCAR Training Group|This group will receive an online two-week intervention to train the specificity and savoring of autobiographical memories. During the two-week intervention and the following two weeks, participants will complete continuous assessments (i.e. once a day) rate the their mood (positive and negative affect) as well as the level of positivity, specificity and savoring of positive memories recalled during practice session. For this study, we included continuous assessments to monitor essential project variables throughout the intervention (2 weeks; from Day 0 to Day 15) and then as a follow-up (2 weeks after; from Day 16 to Day 30).
62822421|NCT05220618|NO_INTERVENTION|Control Group|This group will receive no intervention to train the specificity of autobiographical memories. During two weeks (from Day 0 to Day 15), participants will complete continuous assessments (i.e. once a day) to monitor their positive and negative affect.
62849200|NCT02711228|EXPERIMENTAL|Subcutaneous Immune Globulin (Human) (Hizentra)|Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.
62849201|NCT00943072|EXPERIMENTAL|VEGF Trap-Eye|Monthly IVT injection of VEGF Trap-Eye 2.0 mg until Week 24 Primary Endpoint
62849202|NCT00943072|SHAM_COMPARATOR|Sham|Monthly Sham IVT injection until Week 24 Primary Endpoint
62849203|NCT00795587|ACTIVE_COMPARATOR|mannitol high dose|mannitol 20% 0,8 g/ kg on minutes
62041697|NCT05737082|EXPERIMENTAL|Sequence 2|"* Period 1, Period 3: HCP2201~* Period 2, Period 4: RLD2205 + RLD2206"
62601375|NCT06621524||Device: EucaLimus coronary stent system|The EucaLimus coronary stent system is a drug-coated coronary stent system, indicated for use in patients with symptomatic ischaemic coronary heart disease due to de novo lesions or restenosed lesions of the coronary arteries.
62601376|NCT00880581|EXPERIMENTAL|PF-3512676|Patients will be treated with 18 mg PF-3512676 by intratumoral injection on day 2 following local radiotherapy, then weekly for a total of 10 injections over 10 weeks.
62849204|NCT00795587|ACTIVE_COMPARATOR|mannitol low dose|mannitol 20% 0,4 g/ kg on minutes
62434938|NCT02525029|EXPERIMENTAL|Arm 1: Phase 1 Dose Level 1 500 USP hCG/3,500 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort have reached day 21 in order to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62041698|NCT00626028|EXPERIMENTAL|Nitric Oxide First, Oxygen Last|10 minute dose of Nitric Oxide (NO) at 80 ppm, then 10 minute dose of NO plus Oxygen, then 10 minute washout, then 10 minute dose of 100% Oxygen on Day 1.
62041699|NCT00626028|EXPERIMENTAL|Oxygen First, Nitric Oxide Last|10 minute dose of 100% Oxygen, then 10 minute dose of NO plus Oxygen, then 10 minute washout, then 10 minute dose of NO at 80 ppm on Day 1.
62601377|NCT06312111|EXPERIMENTAL|A physically inactive subgroup|Patients who walked \<5,000 steps per day during the first two weeks
62041700|NCT06648915||Patients with mild to moderate AVS|Patients with measurements of Lp(a) and mild to moderate AVS
62041701|NCT03598270|PLACEBO_COMPARATOR|Arm A (Control Arm)|"Placebo of atezolizumab in combination with one of the platinum based regimens below (investigator's choice) followed by maintenance niraparib with placebo:~* Carboplatin (AUC = 5, d1) plus paclitaxel and placebo every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks~* Carboplatin (AUC = 4, d1) plus gemcitabine and placebo every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks.~* Carboplatin (AUC = 5, d1) plus pegylated liposomal doxorubicin (PLD) and placebo every 4 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks."
62434939|NCT02525029|EXPERIMENTAL|Arm 1: Phase 1 Dose Level 2 1,000 USP hCG/7,000 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort have reached day 21 in order to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62601378|NCT06312111|ACTIVE_COMPARATOR|A physically active subgroup|Patients who walked \>5,000 steps per day during the first two weeks
62041702|NCT03598270|EXPERIMENTAL|Arm B (experimental arm)|"Atezolizumab in combination with one of the platinum based regimens below (investigator's choice) followed by maintenance niraparib with atezolizumab:~* Carboplatin (AUC = 5, d1) plus paclitaxel and atezolizumab every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks.~* Carboplatin (AUC = 4, d1) plus gemcitabine and atezolizumab every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks.~* Carboplatin (AUC = 5, d1) plus pegylated liposomal doxorubicin (PLD) and atezolizumab every 4 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks."
62041703|NCT01938612|EXPERIMENTAL|MEDI4736 Q2W|Evaluate MEDI4736 given every 2 weeks
62041704|NCT01938612|EXPERIMENTAL|MEDI4736 Q3W|Evaluate MEDI4736 given every 3 weeks
62041705|NCT01938612|EXPERIMENTAL|MEDI4736 Dose Expansion|evaluate MEDI4736 given every 2 weeks
62041706|NCT01938612|EXPERIMENTAL|MEDI4736 Q4W|Evaluate MEDI4736 given every 4 weeks
62601379|NCT00739505|EXPERIMENTAL|Cohort 1|3 HPP patients are to be enrolled in Cohort 1 and receive a single IV dose and three weekly SC doses of Asfotase Alfa . End of Study for patients in Cohort 1 is at 8 weeks.
62601380|NCT00739505|EXPERIMENTAL|Cohort 2|Cohort 2 will begin when the safety and PK data for Cohort 1 weeks 1-4 has been reviewed by the DSMB. Cohort 2 will enroll 3 HPP patients and will receive a higher dose level than Cohort 1. Cohort 2 patients will have a single IV dose and three weekly SC doses of Asfotase Alfa . End of Study for patients in Cohort 2 is at 8 weeks.
62601381|NCT05039567|EXPERIMENTAL|optimal heart team group|Heart teams in this group will be established according to the optimal heart team protocol. Each team consists of two interventional cardiologists and two cardiac surgeons. Team members will be trained systematically before the heart team meeting.
62601382|NCT05039567|NO_INTERVENTION|conventional heart team group|Heart teams in this group will be established according to the basic elements recommended by guidelines. Each team consists of an interventional cardiologist, a cardiac surgeon, and a non-interventional cardiologist. No team training will be held before the heart team meeting.
62434940|NCT02525029|EXPERIMENTAL|Arm 1: Phase 1 Dose Level 3 2,000 USP hCG/14,000 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort have reached day 21 in order to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62601383|NCT06051474|EXPERIMENTAL|Caregivers of hospitalized children|
62601384|NCT02289846|PLACEBO_COMPARATOR|Placebo BID|Placebo once in the morning and once in the evening.
62601385|NCT02289846|EXPERIMENTAL|IW-9179 QD AM + Placebo QD PM|IW-9179 once in the morning and placebo once in the evening.
62601386|NCT02289846|EXPERIMENTAL|Placebo QD AM + IW-9179 QD PM|Placebo once in the morning and IW-9179 once in the evening.
62601387|NCT02289846|EXPERIMENTAL|IW-9179 BID|IW-9179 once in the morning and once in the evening
62601388|NCT03295552|EXPERIMENTAL|DC|DNA demethylating agent decitabine plus carboplatin
62601389|NCT06336837||No arm used.|
62601390|NCT01685957|ACTIVE_COMPARATOR|Standard dietary treatment (STD)|Dietary treatment - 6 individual sessions with a registered dietitian
62601391|NCT01685957|EXPERIMENTAL|"Ned i vaegt (NIV)"|Dietary treatment - 3 individual sessions and 3 group sessions. All sessions with a registered dietitian.
62601392|NCT01685957|EXPERIMENTAL|"Verdens bedste kur (VBK)"|Dietary treatment - 3 individual sessions and 3 group sessions. All sessions with a registered dietitian.
62041707|NCT01938612|EXPERIMENTAL|MEDI4736 combined with another drug|evaluate MEDI4736 in combination with another drug given every 4 weeks
62601393|NCT03911986|OTHER|Immediate External Loop Recorder|Participants randomized to the Immediate External Loop Recorder group will be monitored for the duration of the first week of the study using the Novacor R-Test 4.
62601394|NCT03911986|OTHER|Delayed External Loop Recorder|Participants randomized to the Delayed External Loop Recorder group will be monitored for the duration of the second week of the study using the Novacor R-Test 4.
62822422|NCT06600737||Disease Control (IMID and no CV disease)|"Control subjects will be asked to consent to a limited routine clinical, laboratory and imaging assessment and separate consent will be sought for imaging and biological sample collection. Consent for genetic (DNA) sample collection will be sought separately also.~Where indicated, two groups of disease control patients will be recruited: (i) patients with an IMID and no CV disease and (ii) patients with CVD and no IMID diagnosis.~The following assessments will be conducted (if indicated as part of a participants standard care):~Clinician Questionnaires~Clinical/medical, health and social care and social determinants~Routine laboratory assessments~Routine cardiovascular imaging and electrophysiology assessments~Investigations to evaluate for cardiac conduction abnormalities and arrythmia may also be performed as part of routine care~Routine peripheral vascular imaging assessment~Patient reported outcome measures (PROMs) Questionnaires"
62822423|NCT06600737||Disease Control (CV disease and no IMID)|"Control subjects will be asked to consent to a limited routine clinical, laboratory and imaging assessment and separate consent will be sought for imaging and biological sample collection. Consent for genetic (DNA) sample collection will be sought separately also.~Where indicated, two groups of disease control patients will be recruited: (i) patients with an IMID and no CV disease and (ii) patients with CVD and no IMID diagnosis.~The following assessments will be conducted (if indicated as part of a participants standard care):~Clinician Questionnaires~Clinical/medical, health and social care and social determinants~Routine laboratory assessments~Routine cardiovascular imaging and electrophysiology assessments~Investigations to evaluate for cardiac conduction abnormalities and arrythmia may also be performed as part of routine care~Routine peripheral vascular imaging assessment~Patient reported outcome measures (PROMs) Questionnaires"
62822424|NCT06600737||Healthy Control (no IMID history or CV disease)|"Control subjects will be asked to consent to a limited routine clinical, laboratory and imaging assessment and separate consent will be sought for imaging and biological sample collection. Consent for genetic (DNA) sample collection will be sought separately also.~Healthy Control participants will have a limited number of assessments performed which may include:~* Demographics, employment~* Medical history, diagnoses, co-morbidities, symptoms, signs, lifestyle (smoking status (pack years) and alcohol intake (units/week), CVD risk scores~* Detailed family history of autoimmune, vascular and rheumatic disease~* Medications, vaccinations~* Physical status (e.g. height and weight, blood pressure), IMID disease activity assessment as indicated~* Data on hospital attendances and admissions, MACE, death registry information."
62822425|NCT06600737||Main Study (IMID 'at risk' CVD)|"Individuals who have a risk of developing CVD (based on traditional risk factors and/or IMID-specific factors) but no history of major adverse cardiovascular events (MACE).~The main study represents standard clinical care and includes the routine clinical, laboratory and imaging assessments. Patients may be recruited at any point along their CVD continuum (eg when considered at risk, at time of or after a diagnosis of a CVD).~The following assessments will be conducted (if indicated as part of a participants standard care):~Clinician Questionnaires~Clinical/medical, health and social care and social determinants~Routine laboratory assessments~Routine cardiovascular imaging and electrophysiology assessments~Investigations to evaluate for cardiac conduction abnormalities and arrythmia may also be performed as part of routine care~Routine peripheral vascular imaging assessment~Patient reported outcome measures (PROMs) Questionnaires"
62849205|NCT05800301|ACTIVE_COMPARATOR|Only WJ-MSCs|Consisted of 34 eyes of 32 RP patients treated with only WJ-MSCs, and it was applied only once following necessary preparations. After the inoculation of stem cells, the patients were followed up regularly on the 10th day, 3rd month, and every 6 months after that until 36 th months. For ethical reasons, the worse eye was selected to inject the stem cells instead of both eyes.
62041708|NCT05047250|EXPERIMENTAL|Atezolizumab|Participants will receive IV infusion of atezolizumab on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.
62822426|NCT06600737||Main Study (Incident (new) IMID-CVD)|"Patients with IMID that present with a MACE.~The main study represents standard clinical care and includes the routine clinical, laboratory and imaging assessments. Patients may be recruited at any point along their CVD continuum (eg when considered at risk, at time of or after a diagnosis of a CVD).~The following assessments will be conducted (if indicated as part of a participants standard care):~Clinician Questionnaires~Clinical/medical, health and social care and social determinants~Routine laboratory assessments~Routine cardiovascular imaging and electrophysiology assessments~Investigations to evaluate for cardiac conduction abnormalities and arrythmia may also be performed as part of routine care~Routine peripheral vascular imaging assessment~Patient reported outcome measures (PROMs) Questionnaires"
62822427|NCT06600737||Main Study (Established IMID-CVD)|"Patients with IMID and a history of previous MACE.~The main study represents standard clinical care and includes the routine clinical, laboratory and imaging assessments. Patients may be recruited at any point along their CVD continuum (eg when considered at risk, at time of or after a diagnosis of a CVD).~The following assessments will be conducted (if indicated as part of a participants standard care):~Clinician Questionnaires~Clinical/medical, health and social care and social determinants~Routine laboratory assessments~Routine cardiovascular imaging and electrophysiology assessments~Investigations to evaluate for cardiac conduction abnormalities and arrythmia may also be performed as part of routine care~Routine peripheral vascular imaging assessment~Patient reported outcome measures (PROMs) Questionnaires"
62822428|NCT06600737||Imaging Sub-Study|"In addition to the main study, patients will be offered the opportunity to consent to participate in the imaging Sub-Study.~Patients consenting to the Imaging Sub-Study must also have consented to participate in the Main Study. Assessments conducted as part of the Main Study are outlined in the relevant 'Main Study' Group/Cohort descriptions.~Individuals participating in the Imaging Sub-Study may be asked to undergo additional imaging tests above standard of care (undertaken separately to the main study assessments/visits) using dedicated research protocols.~The following assessments may be conducted:~Echocardiography~Cardiovascular Magnetic Resonance Imaging (CMR)~Peripheral vascular imaging techniques:~Laser Doppler Imaging (LDI) and laser speckle contrast imaging (LSCI)~Nailfold capillaroscopy~Multispectral imaging~Non-vascular skin imaging techniques:~High frequency ultrasound"
62601395|NCT04964297|OTHER|Cohort 1: Predetermined points measurement|"Cohort 1: Predetermined points measurement: 10 subjects with measurement of bowel gas at 8 predetermined time points during right laparoscopic colectomy as follow:~1. Initiation of surgery/laparoscopy start Insufflation~2. Abdominal exploration~3. Completion of colon mobilization~4. Colon transection~5. At Colotomy~6. At Enterotomy~7. Anastomosis completion~8. End of surgery- after re-insufflation before closure"
62601396|NCT04964297|OTHER|Cohort 2: Continuous monitoring|Cohort 2: Continuous monitoring: 10 subjects with continuous monitoring of bowel gases through the surgery. The level of H2 and CH4 gases will be noted at the 8 predetermined time points during the continuous monitoring as well.
62822429|NCT06600737||Biological Sub-Study|"In addition to the Main Study, patients will be offered the opportunity to consent to participate in the Biological Sub-Study.~Patients consenting to the Biological Sub-Study must also have consented to participate in the Main Study. Assessments conducted as part of the Main Study are outlined in the relevant 'Main Study' Group/Cohort descriptions.~Biological samples as part of the Sub-Study are in addition to standard of care blood samples.~A maximum of 75mls of blood may be taken to enable the range of experimental studies. The samples may be taken at initial time of recruitment (baseline) and/or may be repeated at certain time points depending on the diagnosis and if a change in the clinical status (excluding genotyping).~The blood may be drawn into a combination of EDTA, lithium heparin, red clotted, citrate and PAXGENE/TEMPUS tubes, according to planned experiments at each time point."
62822430|NCT03975491|EXPERIMENTAL|Aerobic Exercise|Moderate-intensity aerobic exercise
62822431|NCT03975491|SHAM_COMPARATOR|Control|Wait-list control
62041709|NCT05188469|EXPERIMENTAL|EG-COVID-003|"Subjects will receive one single IM vaccination, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~Component Description (per dose):~EG-COVID-003 0.5mL (mRNA 100μg)~Route of administration: Intramuscular injection"
62244743|NCT05975801|OTHER|Conservative Treatment Group|The patients in the control group received a conservative treatment program including hotpack (20 min), transcutaneous electrical nerve stimulation(TENS) (COMPEX Rehab 400 - 20 min), ultrasound (Chattanooga Ultrasound - 1 megahertz, 1.5 W/cm², 5 min) for 4 weeks, 5 days a week, and wand, Codman, stretching and strengthening exercises were applied.Stretching exercises were added to the treatment for the shoulder girdle and scapular region muscles, while strengthening exercises were added to the treatment by increasing the resistance at the pain limit. In addition, the home exercise program was taught to be 10 repetitions 2 times a day.
62244744|NCT06729918|EXPERIMENTAL|virtual reality group|Thoracic lung physical examination will be studied using a virtual reality-based thoracic and lung physical examination learning tool.
62244745|NCT06729918|EXPERIMENTAL|simulated patient group|Thoracic lung physical examination will be studied using a simulated patient.
62244746|NCT06729918|NO_INTERVENTION|control (traditional education) group|No applicationwas madeto the control group. He/she will practice the thoracic lung physical examination on a classmate who is not in the sample group.
62822432|NCT04663763|EXPERIMENTAL|Neoadjuvant short-course radiotherapy+immunotherapy+chemotherapy|"A total of 40 patients receive 5\*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TME surgery and another 4 cycles of CAPOX chemotherapy.~Interventions:~Shor-course radiotherapy: 25Gy/5Fx;~Induction immunotherapy: Sintilimab 200mg ivgtt d1 q3w x 4 cycles;~Concurrent Chemotherapy: Oxaliplatin: 130mg/m2 d1 q3w + Capecitabine: 1000mg/m2 d1-14 q3w x 4 cycles;"
62822433|NCT04836429|EXPERIMENTAL|Treatment (porfimer sodium, photodynamic therapy)|Patients receive porfimer sodium IV over 3-5 minutes 24-48 hours prior to standard of care VATS, followed by photodynamic therapy
62822434|NCT04142203||23 h surgery|Adult patients who were treated in 23 h surgical unit
62041710|NCT05188469|EXPERIMENTAL|EG-COVID-001|"Subjects will receive one single IM vaccination, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~Component Description (per dose):~EG-COVID-001 0.5mL (mRNA 200μg)~Route of administration: Intramuscular injection"
62041711|NCT05188469|EXPERIMENTAL|A: EG-COVID|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 0.5mL (mRNA 400μg)~Route of administration: Intramuscular injection"
62822435|NCT00248625|ACTIVE_COMPARATOR|N-acetylcysteine (NAC)|Eligible children were adaptively allocated by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) infused over 24 hours for up to 7 consecutive days
62822436|NCT00248625|PLACEBO_COMPARATOR|placebo|Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive 5% dextrose (D5W) infused over 24 hours for up to 7 consecutive
62849206|NCT05800301|ACTIVE_COMPARATOR|Only rEMS|Consisted of 32 eyes of 16 RP patients treated with only rEMS. rEMS was applied with a custom-designed helmet once a week for 30 min for 36 months. Both eyes are stimulated at the same time with the specially designed system for ophthalmologic use (MagnoVisionTM).
62041712|NCT05188469|EXPERIMENTAL|B: EG-COVID|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 1mL (mRNA 800μg)~Route of administration: Intramuscular injection"
62244747|NCT06540768|ACTIVE_COMPARATOR|Therapeutic Normothermia Group|Participants randomized to this group will be placed under a targeted temperature model aiming for normothermia for 72 hours. Temperature and interventions will be monitored every 4 hours for the entirety of the 24 hours. Participants will be followed post-discharge and will undergo cognitive assessments at 3 and 6 months.
62244748|NCT06540768|NO_INTERVENTION|Control Group|Participants randomized to this group will undergo usual care in the Critical Care Trauma Centre. Temperature will be monitored as per standard of care. Participants will be followed post-discharge and will undergo cognitive assessments at 3 and 6 months.
62601397|NCT03186534|EXPERIMENTAL|2GETHER|2GETHER is an HIV prevention and relationship education program designed for young male couples. 2GETHER consists of 4 sessions (2 group sessions, 2 individualized couple session) administered over the course of 1 month (1 session per week). Group sessions focus on developing skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
62601398|NCT03186534|ACTIVE_COMPARATOR|Positive Affect Enhancement|The control condition is a positive affect enhancement program for couples. This is an active and attention-matched control condition. Group sessions focus on developing various coping skills that aim to enhance positive emotions in couples, and individualized couple sessions focus on skills implementation.
62601399|NCT02813005|EXPERIMENTAL|Jet ventilation/ group A|Frequency : 120-200/min Pressure : 1-2 bars Inspiratory fraction of oxygen : 100% and 50% if Expiratory pressure : 5 -10 cmH2O
62041713|NCT05188469|EXPERIMENTAL|C: EG-COVARo|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVARo 0.5mL (mRNA 800μg)~Route of administration: Intramuscular injection"
62041714|NCT00254202|EXPERIMENTAL|Iloperidone|Oral iloperidone
62041715|NCT00254202|ACTIVE_COMPARATOR|Ziprasidone|Oral ziprasidone
62041716|NCT00254202|PLACEBO_COMPARATOR|Placebo|Oral placebo
62041717|NCT02184793|OTHER|EMD (Inclinomax) then usual care|"EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on for 24h.~Usual care : recording the head of bed inclination degree with masked digital display and alarm off for 24h."
62041718|NCT02184793|OTHER|usual care then EMD (Inclinomax)|"Usual care : recording the head of bed inclination degree with masked digital display and alarm off for 24h.~EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on for 24h."
62601400|NCT02813005|SHAM_COMPARATOR|Standard ventilation/ group B|Apnea made by the anesthesiologist to the request of the radiologist.
62601401|NCT00570349|EXPERIMENTAL|Low Dose Cohort|Subjects in the low dose cohort receive 20 part per million (ppm) of nitric oxide via nasal cannula over a 44 hour period.
62244749|NCT05309551|EXPERIMENTAL|Inspiratory Muscle training- Intervention group|Along with standard post-transplant physical therapy, the intervention group will begin daily respiratory exercise training utilizing the IMT trainer device (POWERbreathe Medic Plus®) with weekly incremental increases in respiratory load. Patients will be asked to use the IMT device twice per day, 7 days per week, for 8 weeks.
62601402|NCT00570349|EXPERIMENTAL|High-Dose Cohort|Subjects in the high dose cohort receive 40 ppm of nitric oxide via nasal cannula over a 44 hour period.
62244750|NCT05309551|SHAM_COMPARATOR|Inspiratory Muscle training - Placebo group|Along with standard post-transplant physical therapy, the placebo group will begin daily respiratory exercise training utilizing the IMT trainer device (POWERbreathe Medic Plus®) with no increase of respiratory load. Patients will be asked to use the IMT device twice per day, 7 days per week, for 8 weeks.
62601403|NCT00570349|PLACEBO_COMPARATOR|Nitrogen|100% Nitrogen (placebo) will be administer at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
62601404|NCT05928559||Young Male Basketball Players|Male athletes between the ages of 10-24 who are involved in a local basketball academy and have been involved in basketball for more than a year
62601405|NCT06559852|EXPERIMENTAL|Yoga Intervention|
62601406|NCT02210286|EXPERIMENTAL|Magtein|All participants will orally take a total of 1800 mg/day for 60 days. Oral administration includes two pills 2 hours before bed time and one pill in the morning, each pill containing 600 mg of MgT-1219.
62601407|NCT00735137|NO_INTERVENTION|A|Expectant management in twin pregnancy
62601408|NCT00735137|EXPERIMENTAL|B|Vaginal pessary treatment in twin pregnancy
62601409|NCT00735137|NO_INTERVENTION|C|Expectant management in singleton pregnancy with short cervix; Women with cervix \<15 mm will be commenced on vaginal progesterone
62601410|NCT00735137|EXPERIMENTAL|D|Vaginal pessary treatment in singleton pregnancy with short cervix; Women with cervix \<15 mm will be commenced on vaginal progesterone
62601411|NCT05102825||Respiratory Disease|Any physician-diagnosed lung disease
62822437|NCT05171816|EXPERIMENTAL|olaparib plus abiraterone|"Olaparib is available as a film-coated tablet containing 100 milligrams (mg) or 150 milligrams (mg) of olaparib. Subjects will be administered olaparib orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
62041719|NCT00713440|EXPERIMENTAL|1|10 healthy Caucasian subjects without family history of diabetes
62041720|NCT05438927|EXPERIMENTAL|Nutritional Support|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth and remote monitoring through a smart phone app and wearable sensor to allow participants to log food intake while sharing data with a dietician
62041721|NCT06723275||Subset 1|Decompensated cirrhosis as primary diagnosis, irrespective of liver disease etiology
62244751|NCT05309551|NO_INTERVENTION|Usual care group|Patients will only participate in standard post-transplant physical therapy.
62601412|NCT05102825||Healthy|Healthy control with no physician-diagnosed lung disease
62601413|NCT05237284|EXPERIMENTAL|SAR443820|twice daily (BID) oral SAR443820
62601414|NCT05237284|PLACEBO_COMPARATOR|Placebo|twice daily (BID) oral placebo
62601415|NCT00232596|PLACEBO_COMPARATOR|Placebo|
62601416|NCT00232596|EXPERIMENTAL|Retigabine|
62601417|NCT06631482|EXPERIMENTAL|HPI Group|Use the hypotension predictive index (HPI)-guided protocol to prevent intraoperative hypotension, initiating treatmentusing the fluid administration or intravenous norepinephrine infusion to keep intraoperative HPI below 85.
62601418|NCT06631482|ACTIVE_COMPARATOR|73mmHg MAP Alarm Group|Intraoperative maintenance of the mean arterial pressure (MAP) at 73 mmHg or higher by using the fluid administration or intravenous norepinephrine infusion.
62041722|NCT06723275||Subset 2|Other chronic end-stage liver diseases requiring LT, listed under MELD offering schemes, including notably but not exclusively cholestatic diseases, primary biliary cholangitis, primary sclerosing cholangitis
62041723|NCT06723275||Subset 3|Hepato-cellular carcinoma as primary diagnosis, whatever the etiology of the underlying liver disease with or without underlying cirrhosis
62822438|NCT05171816|PLACEBO_COMPARATOR|placebo plus abiraterone|"Placebo to match olaparib is available as a film-coated tablet in 100 milligrams (mg) or 150 milligrams (mg). Subjects will be administered placebo orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
62041724|NCT06733298|EXPERIMENTAL|Arm 1|Participants will receive one oral dose of \[14C\]-labeled RO7269162 on Day 1.
62041725|NCT03640208|EXPERIMENTAL|Complete colorectal screening|11 step process divided into three phases: 1. Community Outreach Event; 2. Data Collection; 3. Navigation and Program Monitoring
62601419|NCT03156907|EXPERIMENTAL|Chronic pain patients|The primary objective of this study is to assess the success rate at 6 months of opioid temporary rotation by High Dosage Buprenorphine (HDB) taper dose in chronic non cancer pain patients (CNCP) with physical withdrawal symptoms making opioid withdrawal impossible.
62601420|NCT02957058|ACTIVE_COMPARATOR|SERT 0, SCAR (low risk)|Patients with Sydney EMR Recurrence Tool (SERT scoring) score 0. These patients will be invited to return for follow up at 18 months and will have thermal ablation (SCAR technique) of the endoscopic resection defect margin.
62601421|NCT02957058|ACTIVE_COMPARATOR|SERT 1-4, SCAR (high risk)|Patients with Sydney EMR Recurrence Tool score 1-4 (SERT scoring). These patients will be invited to return for follow up at 4-6 months and will have thermal ablation (SCAR technique) of the endoscopic resection defect margin.
62041726|NCT06577714|ACTIVE_COMPARATOR|3D EWI|Electromechanical Wave Imaging (EWI) is an ultrasound-based technique that takes 10-15 minute to non-invasively image arrhythmias by visualizing the electromechanical wave corresponding to electromechanical coupling. A full 3D EWI noninvasive ultrasound technique which can construct an entire 4 chamber cardiac activation map using a single heartbeat of arrhythmia acquired in one apical transthoracic echocardiographic image.
62244752|NCT06736483|EXPERIMENTAL|Dexmedetomidine|Intravenous administration of 1 µg /kg of dexmedetomidine in 10 ml of 0.9% sodium chloride at the time of incision.
62244753|NCT06736483|PLACEBO_COMPARATOR|Placebo|Intravenous administration of 10 ml sodium chloride 0.9% at the time of incision
62822439|NCT06576505||Sarcoidosis patients|This study only consists of one arm. The investigators follow patients prospectively and observe clinical parameters including disease course (resolving, non-resolving, which organs are involved, inflammatory markers, chest X-ray etc) and effect of treatment. In this respect the study is observational. However, the patients undergo repeated peripheral blood samples and some also undergo sampling from upper airways, faeces and a bronchoscopy and hence, the study falls in the interventional category
62822440|NCT04042441||Ryzodeg® as per local practice|Real-world population of patients with Diabetes Mellitus, Type 2 (T2DM), who have been initiated or switched to Ryzodeg® from previous antihyperglycaemic treatment according to local clinical practice.
62822441|NCT06540742||Observation group|In this study, preoperative image data of patients with hepatic hydatid were taken as the research object
62822442|NCT06540742||Control group|Hepatic cyst, hepatic abscess and normal liver were the control group
62822443|NCT04091620|EXPERIMENTAL|Transanal Total Mesorectal Excision|For transanal total mesorectal excision, a two team approach will be adopted. One surgical team will be performing the abdominal phase dissection using standard laparoscopic approach, while the other will be simultaneously performing the transanal dissection and total mesorectal excision in a 'down-to-up' fashion using laparoscopic instruments.
62822444|NCT04091620|ACTIVE_COMPARATOR|Robotic Total Mesorectal Excision|For robotic total mesorectal excision, a fully robotic approach will be adopted. Left-sided colonic mobilization, division of lymphovascular pedicle, and 'top-to-down' total mesorectal excision will be performed using the robotic platform.
62822445|NCT04329247|EXPERIMENTAL|Median nerve neural mobilization|Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 6 weeks.
62822446|NCT04329247|NO_INTERVENTION|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 6 weeks. After this period of time, participants will begin the best treatment available.
62822447|NCT06600997|EXPERIMENTAL|Intervention group|Flow diversion for endovascular treatment of intracranial aneurysms
62822448|NCT06600997|ACTIVE_COMPARATOR|Control group|Conventional endovascular therapy (stent-assisted coiling, balloon-assisted coiling, or coiling) for endovascular treatment of intracranial aneurysms
62822449|NCT00896402|ACTIVE_COMPARATOR|Chlorhexidine|skin antisepsis with chlorhexidine
62822450|NCT00896402|ACTIVE_COMPARATOR|Povidone-iodine|skin antisepsis with povidone-iodine
62822451|NCT02582021||Women|Women undergoing clinically-ordered coronary angiography for signs and symptoms of ischemia who have no obstructive coronary artery disease (CAD)
62822452|NCT02582021||Women or men|Women and men hospitalized for signs and symptoms of ischemia and evidence of Heart Failure with preserved ejection fraction (HFpEF) who have not undergone a clinically-ordered coronary angiography
62822453|NCT06588712||Patients with liver cirrhosis|Patients with liver cirrhosis are included in the cohort
62822454|NCT04154072|ACTIVE_COMPARATOR|NLY01 (2.5 mg)|NLY01 2.5 mg injection
62822455|NCT04154072|ACTIVE_COMPARATOR|NLY01 (5.0 mg)|NLY01 5.0 mg injection
62822456|NCT04154072|PLACEBO_COMPARATOR|Vehicle|inactive drug, injection
62041727|NCT06577714|NO_INTERVENTION|Standard of Care|Ablation without image guided ablation
62244754|NCT05855941||Cervix cancer|Newly diagnosed cervix cancer.
62244755|NCT05855941||Endometrial cancer|Newly diagnosed endometrial cancer.
62822457|NCT04833361||Mothers|Mothers of children with coloboma.
62822458|NCT05442554|EXPERIMENTAL|Brentuximab Vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg, IV on Day 1 of each 21-day cycle for up to a total of 16 cycles.
62822459|NCT04081493|EXPERIMENTAL|Group 1 (BFRE)|Low-load blood flow restricted exercise 3/weekly for 8 weeks before TKR 10-min warm-up followed by unilateral leg press and unilateral knee extension
62822460|NCT04081493|NO_INTERVENTION|Group 2 (CON)|No training before TKR
62822461|NCT06147037|EXPERIMENTAL|Dose Exploration and Dose Escalation|"The study conducted in two parts: Part A Dose Exploration and Part B Dose Escalation~FPI-2053 dose exploration to determine the optimal pre-dose administration of FPI-2053 with a fixed dose of \[225Ac\]-FPI-2068.~\[225Ac\]-FPI-2068 dose escalation with the optimal dose of FPI-2053 as determined in Part A."
62244756|NCT05855941||Ovarian cancer|Strong suspicion of newly diagnosed epithelial ovarian cancer; histopathological confirmation required within 6 months after inclusion.
62434941|NCT02525029|EXPERIMENTAL|Arm 2A: Phase 1 Dose Level -2: 125 USP hCG/875 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62601422|NCT04420585|EXPERIMENTAL|Treatment Group|Desmopressin 0.2mg tablets, dose titrated to effect
62601423|NCT03835598||Patients with cardiac biological prosthesis|
62244757|NCT03549000|EXPERIMENTAL|NZV930 Monotherapy|Single Agent NZV930
62601424|NCT06618846||bariatric patients|Patients who were qualified for bariatric or metabolic surgery
62601425|NCT04875390|OTHER|group E|Intraoperative Erector spina plane block ( 0.3 ml/kg bupivacaine 0.25% at thoracic level 7 and 0.3 ml/kg bupivacaine 0.25% bupivacaine at thoracic level 11, totaling 0.6 ml/kg of 0.25% bupivacaine) will be performed after the surgery is completed.
62601426|NCT04875390|OTHER|group L|Intraoperative local infiltration (0.6 ml/kg of 0.25% bupivacaine will be given to the wound lips at the end of the surgery.
62601427|NCT05528913|EXPERIMENTAL|Benralizumab|Fasenra 60mg s.c. administration
62601428|NCT05528913|PLACEBO_COMPARATOR|Placebo|Placebo s.c. administration
62601429|NCT04242446|EXPERIMENTAL|Bimekizumab dosing regimen 1|Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.
62601430|NCT04242446|EXPERIMENTAL|Bimekizumab dosing regimen 2|Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.
62601431|NCT04242446|EXPERIMENTAL|Bimekizumab dosing regimen 3|Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.
62601432|NCT04242446|PLACEBO_COMPARATOR|Placebo Group|Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.
62601433|NCT06582407||Ambulatory Patients|Patient undergoing anesthesia in an ambulatory setting.
62601434|NCT06582407||Hospitalised Patients|Patient undergoing anesthesia in a hospitalisation setting.
62601435|NCT03366324|EXPERIMENTAL|Combination of CAR-T therapy and HSCT|After patients achieve MRD- remissions through Second generation CAR-T cells, they will subsequently receive hematological stem cell transplantations within 30 days.
62601436|NCT04531618|EXPERIMENTAL|Emotional Exchange (EE)|Receives a facilitated emotional exchange session over Zoom in the Well Baby Nursery and up to 7 subsequent Zoom sessions over the next 4 months.
62601437|NCT04531618|ACTIVE_COMPARATOR|Newborn Care (NC)|Receives didactic newborn parenting education delivering developmentally appropriate content over zoom at the same time points as the emotional exchange group.
62601438|NCT02847923|EXPERIMENTAL|Group Experimental|All the volunteers will use the software and then answer the questionnaire. They will be familiar with the software interface, performs an initial test to learn how to use the software, run a test script and answer the questionnaire.
62601439|NCT04593095|EXPERIMENTAL|Experimental|Each SSC session will last 2-hr during the day including a 15-min of auditory stimulation with maternal voice and controlled levels of NICU light and noise. The 2-hr SSC will be followed by a 1-hr quiet period where infants will rest in their incubator/crib with a pad immersed with their mother breast milk for olfactory stimulation and where the control of light and noise levels will be continued. The NeuroN-QI will be done 4 times/wk for each dyad.
62601440|NCT04593095|NO_INTERVENTION|Control|Mothers-infant dyads will do 4 SSC/wk. During these sessions, no attempt will be made by the RA to control the light and noise levels nor to encourage auditory stimulation. The SSC periods will not be followed by a quiet period nor olfactory stimulation.
62822462|NCT03690193|EXPERIMENTAL|Ketogenic Diet Arm|All participants will be assigned to the 3-month ketogenic diet intervention. Study partners will be instructed to assist participants in adherence to a 1:1 ketogenic diet (approximately 70% fat, \<10% carbohydrate, and 20% protein). Participants will be provided medium chain triglyceride oil with a target intake of 1-2 tablespoons per day and micronutrient supplements consisting of multivitamin, vitamin D, calcium, and phosphorus. After the 3-month ketogenic diet, participants will complete a 1-month washout period in which they halt adherence to the ketogenic diet and resume their normal diet.
62822463|NCT02535481|EXPERIMENTAL|Epidermal Graft|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts as per existing normal clinical practice.
62822464|NCT02535481|EXPERIMENTAL|Split Thickness Skin Graft|Split thickness skin graft will be harvested using air dermatome as per normal clinical practise.
62041728|NCT06695897||Dupilumab arm|Patients who receive dupilumab for eosinophilic esophagitis (EoE) treatment in a real-world setting in Germany
62244758|NCT03549000|EXPERIMENTAL|NZV930 with PDR001 Doublet Therapy|Combination of NZV930 with PDR001
62244759|NCT03549000|EXPERIMENTAL|NZV930 with NIR178 Doublet Therapy|Combination of NZV930 with NIR178
62244760|NCT03549000|EXPERIMENTAL|NZV930 with NIR178 & PDR001 Triplet Therapy|Combination of NZV930 with NIR178 and PDR001
62244761|NCT06626425|EXPERIMENTAL|Healthy Minds Program (HMP) App|The HMP is a smartphone meditation-based well-being training.
62244762|NCT06626425|ACTIVE_COMPARATOR|Hydro Coach active control group (HC)|The water tracking app is a publicly available, user-designed hydration app that prompts users to enter in daily liquid consumption and provides optimized hydration recommendations based on user input.
62041729|NCT04919213||Individuals with Intellectual Disabilities|Individuals will be invited to take part in an online survey (paper version will also be available). The participants will be recruited through advertisements on relevant platforms (e.g., Facebook, Twitter) and through relevant social care organisations. The study hopes to recruit 100 individuals from all over England (UK). A subgroup will be asked if they would like to take part in a one-to-one open-ended interview (n=20) and/or in direct observations (n=30).
62244763|NCT03903874|EXPERIMENTAL|DIAL intervention|Deep south Interactive voice response system Active Lifestyle (DIAL) intervention. Participants will receive 12 months of automated physical activity phone counseling. Participants will report their physical activity to the IVR system each day for 3 months, twice/week in months 3-6, and once/week in months 6-12 and receive progress feedback via IVR system, along with community health worker support.
62244764|NCT03903874|NO_INTERVENTION|Wait List Control|The wait list control participants will be instructed to maintain their normal routine until completion of the 6-month assessments and then receive the same 12-month DIAL intervention. To maintain engagement, these participants will be involved in monthly lunch and learns, focus groups, etc on cancer topics other than PA (e.g., screening) during the wait period.
62244765|NCT05917041|EXPERIMENTAL|SAT-001|
62244766|NCT05917041|NO_INTERVENTION|Control Group|Wearing glasses or not
62244767|NCT06607263|EXPERIMENTAL|CPC + Zn mouthwash + Brushing|A regimen composing a CPC + Zn mouthwash + Brushing with a fluoride toothpaste and a commercially available toothbrush
62244768|NCT06607263|ACTIVE_COMPARATOR|Essential oils mouthwash + Brushing|A regimen composing a essential oils mouthwash + Brushing with a fluoride toothpaste and a commercially available toothbrush
62822465|NCT05928936|EXPERIMENTAL|Exercise Training plus Sodium Bicarbonate|Participants with CKD will undergo exercise training for 20-45 minutes, 3 times per week, for 12 weeks. Additionally, participants take 650-1300 mg of sodium bicarbonate twice daily.
62822466|NCT05928936|ACTIVE_COMPARATOR|Exercise Training plus Placebo|Participants with CKD will undergo exercise training for 20-45 minutes, 3 times per week, for 12 weeks. Additionally, participants take placebo tablets to match 650-1300 mg of sodium bicarbonate twice daily.
62822467|NCT05928936|NO_INTERVENTION|Healthy control|Baseline measurements in healthy participants without CKD will be measured and compared to participants with CKD. Healthy controls will not receive any interventions.
62822468|NCT05355532||"CMVO+ (patients has presented CMVO in PCI)"|Patients with 1 type MI that has presented CMVO in emergency PCI.
62601441|NCT04887636||Normal women group|I. Women of childbearing age who are physically and mentally healthy, have regular menstruation and are between 20-45 years old; II. Women who are evaluated as normal by vaginal microbiome morphological characterization; III. Women who agree to participate in this study and have signed an informed consent form; IV. Those who have full capacity for civil and legal conduct; V. The quality of vaginal samples meets the evaluation requirements of this program.
62822469|NCT05355532||"CMVO- (patients hasn't presented CMVO in PCI)"|Patients with 1 type MI that hasn't presented CMVO in emergency PCI.
62822470|NCT01953640||Ancillary-correlative (gene expression with CYP-17 inhibition)|Laboratory Biomarker Analysis: Tissue, blood, and urine samples are collected at baseline and after 12-14 weeks of treatment and assessed for circulating tumor cells, genome-wide SNP, and exome sequencing. Subjects will also receive a Quality-of-Life Assessment.
62822471|NCT06589557|OTHER|Experimental: VR Therapy and Standard Rehabilitation|Standard Rehabilitation supplemented with VR Therapy
62822472|NCT06589557|OTHER|Control: Standard Rehabilitation|Control group - Standard Rehabilitation, without VR Therapy
62822473|NCT06190158||type 2 diabetes at risk for chronic kidney disease|type 2 diabetes at risk for chronic kidney disease
62822474|NCT04696692|OTHER|Patient with histologically confirmed diffuse large B-cell lymphoma|
62822475|NCT05804838|EXPERIMENTAL|Mindfulness Group|"Research inclusion criteria~* Being between 20-35 years old~* Being her first pregnancy~* Being between 13 and 24 weeks of gestation~* Having applied to the pregnant outpatient clinic where the research will be conducted.~* Not having a hearing-visual impairment~* Ability to read and write Turkish~* Volunteering to participate in the research~* Not having a diagnosis that would constitute an obstacle to physical activity~* Agreeing to participate in the 8-week MBSR training~* Being able to use ZOOM Cloud Meetings program"
62601442|NCT00566956|EXPERIMENTAL|1|For those assigned to Group 1, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
62822476|NCT01285557|EXPERIMENTAL|S-1+Cisplatin|Participants received S-1 25 milligrams per meter square (mg/m\^2) orally twice daily (BID) every 12 hours from Day 1 through Day 21, 1 hour before or after meal with a glass of water; followed by a 7-day rest period from Day 22 to Day 28 in a 28-day cycle. Participants received a single dose of cisplatin 75 mg/m\^2 as a 1- to 3-hour intravenous (IV) infusion on Day 1 following the morning dose of S-1 for a maximum of 8 cycles (each cycle of 28 days). Participants received study medication until progression of disease (PD), adverse event (AE), withdrawal of consent, or other reason for discontinuation, whichever happened earlier.
62822477|NCT01285557|ACTIVE_COMPARATOR|5FU+Cisplatin|Participants received 5-Fluorouracil (5-FU) 800 mg/m\^2 per 24 hours as continuous IV infusion over 120 hours from Day 1 through Day 5 followed by a 16-day rest period on Days 6 through 21 in a 21-day cycle. Participants received a single dose of cisplatin 80 mg/m\^2 as a 1- to 3-hour IV infusion on Day 1 prior to the start of the 5-FU infusion on Day 1 for a maximum of 8 cycles (each cycle of 21 days). Participants received study medication until PD, AE, withdrawal of consent, or other reason for discontinuation, whichever happened earlier.
62822478|NCT03294707|EXPERIMENTAL|AG10 single oral dose|AG10 oral tablet, administered by mouth, once
62244769|NCT06607263|ACTIVE_COMPARATOR|Flossing + Brushing|A regimen composing flossing + Brushing with a fluoride toothpaste and a commercially available toothbrush
62601443|NCT00566956|NO_INTERVENTION|2|Patients assigned to group 2 will not have the hydrosalpinx aspirated
62601444|NCT06359314|EXPERIMENTAL|Intervention|Participants will go through a 5-week online self-guided positive emotion skills course.
62601445|NCT05265091|EXPERIMENTAL|KL590586|Multiple doses of KL590586 capsule
62601446|NCT06647927||BrS Affected|The Study population will be composed by patients affected by the Brugada Syndrome, including both the ones already under teatment and subjects with new diagnosis.
62601447|NCT02779335|OTHER|Enteral formula tube feeding|Enteral fed children, ages 1-13, with establish enteral feeding access
62601448|NCT03714646|PLACEBO_COMPARATOR|Placebo|
62601449|NCT03714646|ACTIVE_COMPARATOR|beta glucan|
62822479|NCT03294707|PLACEBO_COMPARATOR|Placebo single oral dose|Placebo Oral Tablet, administered by mouth, once
62822480|NCT06590077|ACTIVE_COMPARATOR|Test blend of five essential oils in a carrier oil - rollerball|The test product contains a blend of 5 essential oils (orange, lavender, frankincense, vetiver, and neroli), diluted in apricot kernel oil. It was formulated by a clinical aromatherapist (Fiona Hedigan) to promote wellbeing and aid relaxation. To date there have been no reports of adverse events. Permission has been given to supply this formula for the research study. The rollerball product ('REST') is available commercially under the FLORA \& FIONA brand.
62822481|NCT06590077|PLACEBO_COMPARATOR|Control oil - rollerball|Juniper essential oil in apricot kernel oil - presentation as a rollerball. The control oil has a mild aroma and is at low concentration.
62822482|NCT05425979|ACTIVE_COMPARATOR|Mepivacaine group|Subjects will receive an ultrasound-guided peripheral nerve block at the ankle with mepivacaine prior to undergoing foot surgery
62822483|NCT05425979|ACTIVE_COMPARATOR|Bupivacaine group|Subjects will receive an ultrasound-guided peripheral nerve block at the ankle with bupivacaine prior to undergoing foot surgery
62822484|NCT04044950|EXPERIMENTAL|Arm 1|Approximately 3x10\^8 E7 TCR T cells (based on the number of disease sites the patient has) will be injected on day 0.
62822485|NCT01874002||Combo stent|Consecutive patients in whom a treatment with a Combo stent in the setting of routine clinical care is attempted are entered into the registry.
62822486|NCT06601491|EXPERIMENTAL|Intervention|
62822487|NCT06601491|NO_INTERVENTION|Control|
62822488|NCT05701423||Natalizumab (NTZ)|Participants who receive NTZ intravenously (IV) or subcutaneously (SC) as standard interval dosing (SID), or as SC extended interval dosing (EID) will be followed prospectively for up to 30 weeks.
62601450|NCT03714646|EXPERIMENTAL|beta glucan and Resistant Starch|
62822489|NCT03532451|EXPERIMENTAL|Cohort 1: Nivolumab|Nivolumab 480 mg IV on week 0 and week 4
62244770|NCT05254496|EXPERIMENTAL|US Healthy Diet|Participants in this group will be assigned to follow the Healthy US dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern is based on the types and amounts of foods Americans typically consume. The main types of food in this eating pattern include a variety of vegetables; fruits; whole grains; fat-free or low-fat dairy; seafood, poultry, meat, and eggs; and nuts, seeds, and soy products.
62822490|NCT03532451|EXPERIMENTAL|Cohort 2: Nivolumab/Lirilumab|Nivolumab 480 mg IV and Lirilumab 240 mg on week 0 and week 4
62601451|NCT03048123|EXPERIMENTAL|Hepatic arterial infusion chemotherapy|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: Folfox Protocol. Hepatic intraarterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
62601452|NCT03048123|ACTIVE_COMPARATOR|Transarterial chemoembolization|Procedure/Surgery: Transarterial chemoembolization Drug: TACE Drug Protocol. Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA)
62601453|NCT05212220|EXPERIMENTAL|Intervention|The intervention group will first receive 5 times EMA per day for one week. The EMA will document participants smoking behaviors, smoking cues, smoking cravings, etc. The intervention group will receive 15-30 minutes of a nurse-led phone call, and 10-week instant messaging after completing the one-week EMA documentation.
62822491|NCT04247139|EXPERIMENTAL|Commercial Kefir|Commercially produced kefir
62822492|NCT04247139|EXPERIMENTAL|Traditional Kefir|Traditionally grown kefir
62822493|NCT06595654|OTHER|Method 1|One stimulation session per day for 20 working days, so 4 weeks (frequency of 10 Hz, 80% 100% of motor threshold). Each session lasts 20 min. The duration of the train is 4 s, an inter-train of 56s.
62822494|NCT06595654|OTHER|Method 2|Two stimulations sessions per day, with 1 hour apart, for 20 working days, so 4 weeks (frequency of 20 Hz, 100% of motor threshold).Each session lasts 28 min. The duration of the train of 10 s, an inter-train of 80s The total number of pulses is 40000 in 20 trains or 2000 per day.
62822495|NCT06595654|OTHER|Method 3|Two stimulations session per day for 10 working days, so 2 weeks. The protocol is delivered in bursts containing 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., 5 Hz). Stimulation intensity is set at 80% of the idle motor threshold intensity
62434942|NCT02525029|EXPERIMENTAL|Arm 2A: Phase I Dose Level -1: 250 USP hCG/1,750 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62434943|NCT02525029|EXPERIMENTAL|Arm 2A: Phase 1 Dose Level 1 500 USP hCG/3,500 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62434944|NCT02525029|EXPERIMENTAL|Arm 2A: Phase 1 Dose Level 2 1,000 USP hCG/7,000 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62434945|NCT02525029|EXPERIMENTAL|Arm 2A: Phase 1 Dose Level 3 2,000 USP hCG/14,000 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62434946|NCT02525029|EXPERIMENTAL|Arm 2B: Phase 1 Dose Level -2: 125 USP hCG/875 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62434947|NCT02525029|EXPERIMENTAL|Arm 2B: Phase I Dose Level -1: 250 USP hCG/1,750 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62434948|NCT02525029|EXPERIMENTAL|Arm 2B: Phase 1 Dose Level 1 500 USP hCG/3,500 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62434949|NCT02525029|EXPERIMENTAL|Arm 2B: Phase 1 Dose Level 2 1,000 USP hCG/7,000 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62434950|NCT02525029|EXPERIMENTAL|Arm 2B: Phase 1 Dose Level 3 2,000 USP hCG/14,000 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62601454|NCT05212220|NO_INTERVENTION|Control|The control group will first receive 5 times EMA per day for one week. The EMA will document participants smoking behaviors, smoking cues, smoking cravings, etc. No intervention will be provided to the control group after completing the one-week EMA documentation.
62601455|NCT02925715|EXPERIMENTAL|supraclavicular|ultrasound guided central venous cannulation done by supraclavicular approach
62822496|NCT06595654|OTHER|Method 4|Five to ten sessions per day, 50 minutes apart, with 90% SM for 10 working days, so 2 weeks. 1 of stimuli every 20 ms (50Hz) repeated 3 times, this train itself repeated every 200 ms (5 Hz) or 60 cycles of 10 blocks of 3 stimuli. The duration of the train is 2 seconds with an inter-train of 8 seconds. So there are 1800 stimuli per session
62822497|NCT06586619|EXPERIMENTAL|Tai chi/qigong group|This is a behavioral intervention that consist of tai chi/qigong group classes via Zoom twice a week for 12 weeks.
62822498|NCT06586619|ACTIVE_COMPARATOR|Health education group|This is a general health education control group class that will also be delivered via Zoom and will be twice a week for 12 weeks.
62244771|NCT05254496|EXPERIMENTAL|Mediterranean diet|Participants in this group will be assigned to follow the Mediterranean dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains more fruits and seafood and less dairy than the Healthy U.S.-Style Eating Pattern.
62244772|NCT05254496|EXPERIMENTAL|Vegetarian diet|Participants in this group will be assigned to follow the Vegetarian dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains no meat, poultry, or seafood. Compared with the Healthy U.S.-Style Eating Pattern, it contains more soy products, eggs, beans and peas, nuts and seeds, and whole grains.
62244773|NCT05100862|EXPERIMENTAL|Follicular Lymphoma Arm A: Zanubrutinib plus Obinutuzumab|Participants will receive zanubrutinib and Obinutuzumab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.
62601456|NCT02925715|EXPERIMENTAL|infraclavicular|ultrasound guided central venous cannulation done by infraclavicular approach
62601457|NCT00005072|EXPERIMENTAL|Leuvectin|Leuvectin
62601458|NCT02174913|ACTIVE_COMPARATOR|bispectral index/TCI propofol/fentanyl|Bispectral index guides the target controlled infusion of propofol by keeping BIS 40-60 throughout operation. Fentanyl is used for analgesia and atracurium is used for tracheal intubation.
62601459|NCT02174913|PLACEBO_COMPARATOR|clinical signs/TCI propofol/fentanyl|Clinical signs (heart rate, blood pressure and movement) guide target controlled infusion(TCI) of propofol. Fentanyl is used for analgesia and atracurium is used for tracheal intubation.
62601460|NCT01342250|EXPERIMENTAL|Conventional plus hUC-MSCs treatment (low dose)|
62601461|NCT01342250|EXPERIMENTAL|conventional therapy plus hUC-MSCs treatment （medium dose）|
62601462|NCT01342250|EXPERIMENTAL|conventional therapy plus hUC-MSCs treatment （high dose）|
62601463|NCT02035748|EXPERIMENTAL|Ocriplasmin|Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal injection
62601464|NCT03240523|EXPERIMENTAL|Group A1: Vilaprisan (3/1 regimen)|Orally, 2 mg, once daily, 3 months treatment followed by 1 menstrual bleeding episode
62601465|NCT03240523|EXPERIMENTAL|Group A2: Vilaprisan (6/2 regimen)|Orally, 2 mg, once daily, 6 months treatment followed by 2 menstrual bleeding episodes
62601466|NCT03240523|EXPERIMENTAL|Group A3/B (3/2 regimen)|"Orally, 2 mg, once daily, 3 months treatment followed by 2 menstrual bleeding episodes~With protocol version 5.0 the blinded study arms A3 and B were converted to one open-label study arm called A3/B."
62822499|NCT02663492|EXPERIMENTAL|TEAS group|Patients with transcutaneous electrical acupoint stimulation (TEAS) group receive electrical stimulation of acupoints including Dazhui (DU14), Geshu (BL17), Zusanli (ST36), Sanyinjiao (SP6), and Hegu (LI4).
62822500|NCT02663492|ACTIVE_COMPARATOR|Medication group|On the basis of routine nursing care, patients need to take Sanguisorba officinalis L., named Diyu Shengbai Pian (a Traditional Chinese Medicine) 3 times per day.
62822501|NCT02663492|NO_INTERVENTION|Control group|The patients of control group receive routine nursing care, including (1) to be observed the changes in patient condition, (2) to eat high-calories, high-protein, high-vitamin, easy-to-digest foods during chemotherapy, (3) to be treated by psychological care, (4) to be prevented against the occurrence of phlebiti, and (5) to use Ondansetron and Omeprazole as direction.
62822502|NCT05618613|EXPERIMENTAL|Elacestrant / Onapristone|Elacestrant and Onapristone combination
62822503|NCT05363020|EXPERIMENTAL|S-Adenosyl-L-Methionine (SAMe)|Participants receive S-Adenosyl-L-Methionine (SAMe) 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period.
62244774|NCT05100862|ACTIVE_COMPARATOR|Follicular Lymphoma Arm B: Lenalidomide plus Rituximab|Participants will receive lenalidomide and rituximab.
62434951|NCT02525029|EXPERIMENTAL|Arm 2B: Phase 1 Dose Level 4 3,500 USP hCG/24,500 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62822504|NCT05363020|PLACEBO_COMPARATOR|Placebo|Participants receive identically appearing 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period.
62822505|NCT06599931|ACTIVE_COMPARATOR|tACS session 50 Hz|"Three single sessions of tACS, each lasting 20 minutes, will be conducted 7-15 days apart, with a different frequency (50 or 70 Hz, corresponding to gamma oscillations) or a placebo frequency known as sham."
62434952|NCT02525029|EXPERIMENTAL|Arm 2B: Phase 1 Dose Level 5 5,000 USP hCG/35,000 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
62601467|NCT01189734|PLACEBO_COMPARATOR|laparoscopic common bile duct exploration|
62601468|NCT01189734|ACTIVE_COMPARATOR|laparoscopic cholecystectomy with intraoperative ES|
62822506|NCT06599931|ACTIVE_COMPARATOR|tACS session 70 Hz|"Three single sessions of tACS, each lasting 20 minutes, will be conducted 7-15 days apart, with a different frequency (50 or 70 Hz, corresponding to gamma oscillations) or a placebo frequency known as sham."
62244775|NCT05100862|EXPERIMENTAL|Marginal Zone Lymphoma Arm C: Zanubrutinib plus Rituximab|Participants will receive zanubrutinib and rituximab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.
62244776|NCT05100862|ACTIVE_COMPARATOR|Marginal Zone Lymphoma Arm D: Lenalidomide plus Rituximab|Participants will receive lenalidomide and rituximab.
62244777|NCT06734507||A Group|Group of patient who underwent laparoscopic cholecystectomy using Airseal
62601469|NCT05519137|ACTIVE_COMPARATOR|Active lighting intervention then Control lighting condition|Each lighting condition will be 8 weeks in length. After a 4 week washout, each participant will crossover to the opposite condition.
62822507|NCT06599931|SHAM_COMPARATOR|tACS Sham session|"Three single sessions of tACS, each lasting 20 minutes, will be conducted 7-15 days apart, with a different frequency (50 or 70 Hz, corresponding to gamma oscillations) or a placebo frequency known as sham."
62822508|NCT05708196|NO_INTERVENTION|control group|ten extraction sockets left for normal healing (blood clot).
62822509|NCT05708196|EXPERIMENTAL|group 2|ten extraction sockets filled with Alloplast bone grafting material (EthOss, Ethoss Regeneration Ltd, Silsden, UK).
62822510|NCT05708196|EXPERIMENTAL|group 3|ten extraction sockets filled with Allograft bone grafting material.
62822511|NCT06305364|EXPERIMENTAL|Gixam followed by standard of care colonoscopy|This is a single-arm study. All participants will undergo the Gixam test following a standard of care colonoscopy
62822512|NCT02012439|ACTIVE_COMPARATOR|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
62822513|NCT02012439|ACTIVE_COMPARATOR|Cognitive therapy|Cognitive Therapy
62244778|NCT06734507||S Group|Group of patient who underwent laparoscopic cholecystectomy using a standard insufflator
62244779|NCT03546335|EXPERIMENTAL|1 mCi injection of 89Zr-DFO-CZP|The first 2 patients will receive 1 mCi of 89Zr-DFO-CZP.
62244780|NCT03546335|EXPERIMENTAL|0.5 mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
62822514|NCT02541097|ACTIVE_COMPARATOR|Language therapy-Individual treatment|Participants will receive intervention for naming impairment based on either phonological or semantic cues.
62822515|NCT02541097|ACTIVE_COMPARATOR|Language therapy-Group treatment|Following the individual therapy, participants will be randomly assigned to either verbal or non-verbal group
62822516|NCT04531176|EXPERIMENTAL|Obesity-centric approach + AOM|Participants will receive Cleveland Clinic's Integrated Medical WMP with medication for chronic weight management (Rx) for approximately two years. After discussing with the study doctor, participants will receive one of the following listed 4 drugs approved by the Food and Drug Administration (FDA) for long-term weight loss: 1) orlistat, 2) phentermine/topiramate extended-release, 3) naltrexone/bupropion extended-release and 4) liraglutide 3.0 mg
62244781|NCT03546335|EXPERIMENTAL|1.5 mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
62244782|NCT03546335|EXPERIMENTAL|2 mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
62244783|NCT06244641|EXPERIMENTAL|Intervention|
62822517|NCT04531176|EXPERIMENTAL|Obesity-centric approach without AOM|Participants will receive Cleveland Clinic's Integrated Medical WMP alone for approximately two years.
62244784|NCT05977946|EXPERIMENTAL|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|
62244785|NCT05977946|EXPERIMENTAL|Transcutaneous Auricular Neurostimulation (tAN)|
62434953|NCT02525029|EXPERIMENTAL|Arm 1: Phase 2 MTD|After completion of the dose finding trial for each arm, the final doses will be carried forward into a two-stage phase II extension trial to confirm safety and make a preliminary determination of the activity level for Arm 1 and Arm 2. If the phase I trial enrolls fewer than 13 patients at the MTD, we will employ Simon's Minmax two-stage design with the possibility to discontinue after the 1st stage if the response rate is low
62601470|NCT05519137|ACTIVE_COMPARATOR|Control lighting condition then Active light intervention|Each lighting condition will be 8 weeks in length. After a 4 week washout, each participant will crossover to the opposite condition.
62244786|NCT06279871|EXPERIMENTAL|Group 1a (ARCT-2303/Influenza vaccine)|Participants will receive one 0.5-mL IM (intramuscular) dose of ARCT-2303 and one 0.5-mL IM dose of influenza vaccine on Day 1 followed by a 0.5-mL IM dose of placebo on Day 29.
62601471|NCT03043157|OTHER|Dose-finding group|The first patient will receive rocuronium 0,6mg/kg. After that, every patient's dose will depend on the outcome of the previous patient. It will go up 0,1mg/kg if the laparoscopic conditions were not excellent or go down 0,1mg/kg otherwise.
62244787|NCT06279871|EXPERIMENTAL|Group 2a (ARCT-2303)|Participants will receive one 0.5-mL IM dose of ARCT-2303 and one 0.5-mL IM dose of placebo on Day 1 followed by a 0.5-mL IM dose of influenza vaccine on Day 29.
62822518|NCT04531176|ACTIVE_COMPARATOR|Usual care approach (Comorbidity-centric approach)|Participants will receive the traditional usual care/standard of care approach to T2D, hypertension, hypercholesterolemia management for approximately two years.
62244788|NCT06279871|ACTIVE_COMPARATOR|Group 3a (Influenza vaccine)|Participants will receive one 0.5-mL IM dose of influenza vaccine and one 0.5-mL IM dose of placebo on Day 1 followed by a 0.5-mL IM dose of ARCT-2303 on Day 29.
62601472|NCT04695951|EXPERIMENTAL|Renalof|A total of 120 patients treated with the study product Renalof® at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
62601473|NCT04695951|PLACEBO_COMPARATOR|Control|A total of 35 patients treated with the study product Placebo at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
62822519|NCT05362656|EXPERIMENTAL|Atrial mapping and dispersion auto-tagging with VX1+|
62822520|NCT06596590|EXPERIMENTAL|Modified Water Vapor Thermal Therapy|The Rezum System is designed to treat patients with urinary symptoms associated with large volume BPH.
62822521|NCT03747549|EXPERIMENTAL|Acupuncture and Home Exercise|Acupuncture and home exercise.
62822522|NCT03747549|ACTIVE_COMPARATOR|Home Exercise Alone|The prescribed home exercise program alone.
62822523|NCT06595017|PLACEBO_COMPARATOR|Saline arm|After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger points at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of saline
62822524|NCT06595017|ACTIVE_COMPARATOR|Lidocaine arm|After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger points at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of lidocaine
62822525|NCT06595017|ACTIVE_COMPARATOR|Magnesium Sulphate arm|
62822526|NCT06604000|ACTIVE_COMPARATOR|GMT Usual (+ GMT No Boost)|"Participants will receive Goal Management Training in groups of 4-6 patients, as implemented in a rehabilitation hospital setting (St. Olavs Hospital, Trondheim University Hospital). The standard treatment (GMT Usual) consists of 10 sessions, delivered as 2 sessions a day, one day per week, over 5 weeks."
62822527|NCT06604000|EXPERIMENTAL|GMT Usual + GMT Boost|"Participants will receive Goal Management Training in groups of 4-6 patients, as implemented in a rehabilitation hospital setting (St. Olavs Hospital, Trondheim University Hospital). The standard treatment (GMT Usual) consists of 10 sessions, delivered as 2 sessions a day, one day per week, over 5 weeks. After completion of the 10 GMT sessions and the first post-treatment assessment immediately after the main treatment period, the participants will receive an additional booster module (GMT Boost) 3 months after the last ordinary GMT module - intended to facilitate a prolonged treatment response."
62822528|NCT06604000|EXPERIMENTAL|GMT Usual + GMT Cuing (+ GMT No Boost)|"Participants will receive Goal Management Training in groups of 4-6 patients, as implemented in a rehabilitation hospital setting (St. Olavs Hospital, Trondheim University Hospital). The standard treatment (GMT Usual) consists of 10 sessions, delivered as 2 sessions a day, one day per week, over 5 weeks. In this arm participants will also receive extended cuing through a smartphone application (GMT Cuing) - intended to facilitate the effect of between-session tasks (homework) completed by the participants. These participants will, in addition to the standard treatment (as in GMT Usual), on a daily basis receive a message that says STOP as a reminder to do their home assignments. An sms with the the text STOP as a reminder everyday from the third session until the fifth session. The message is pseudorandomly sent on different timepoints ranging from 11am to 8pm, including in weekends."
62822529|NCT06604000|EXPERIMENTAL|GMT Usual + GMT Cuing + GMT Boost|"Participants will receive GMT Usual + GMT Cuing (see description above). In this arm, after completion of the 10 GMT sessions and the first post-treatment assessment immediately after the main treatment period, the participants will also receive an additional booster module (GMT Boost) 3 months after the last ordinary GMT module - intended to facilitate a prolonged treatment response."
62244789|NCT06279871|EXPERIMENTAL|Group 1b (ARCT-2303/ Influenza vaccine)|Participants will receive one 0.5-mL IM dose of ARCT-2303 and one 0.5-mL IM dose of influenza vaccine on Day 1 followed by a 0.5-mL IM dose of placebo on Day 29.
62244790|NCT06279871|EXPERIMENTAL|Group 2b (ARCT-2303)|Participants will receive one 0.5-mL IM dose of ARCT-2303 and one 0.5-mL IM dose of placebo on Day 1 followed by a 0.5-mL IM dose of influenza vaccine on Day 29.
62244791|NCT06279871|ACTIVE_COMPARATOR|Group 3b (Influenza vaccine)|Participants will receive one 0.5-mL IM dose of influenza vaccine and one 0.5-mL IM dose of placebo on Day 1 followed by a 0.5-mL IM dose of ARCT-2303 on Day 29.
62601474|NCT06649474|OTHER|comparate the Serum HMGB1 concentrations between patients with grade <2 SOS and those with grade 2,3|
62822530|NCT06285825|EXPERIMENTAL|Emapalumab|"If you are found to be eligible to take part in this research study, you will be assigned to 1 of 2 dose levels of emapalumab, based on when you enroll on the study. Up to 16 participants will receive each dose level of the study drug.~* The first group of 5 participants will be enrolled at the lower dose level.~* Depending on the safety data seen in this first group, the next 11 participants will be enrolled at the lower dose.~* After reviewing the early safety data from that first group of 16 participants, the study team will enroll the next 5 participants at the higher dose level and be checked for serious side effects.~* Depending on the safety information from the first 5 participants in the higher dose level group, the other 11 will then be enrolled."
62822531|NCT03392480||Adult non-haptoglobin 2-2 group|Patients are 45 to 65 years old.
62822532|NCT03392480||Adult haptoglobin 2-2 group|Patients are 45 to 65 years old.
62244792|NCT03877107|OTHER|single cohort|Participants presenting at least 2/3 of symptom triad : gait disturbance, urinary symptoms and cognitive disturbance Ventricular enlargement non explained by cortical atrophy Cognitive capacity to understand the study and give informed consent (mini mental state \> 13), speaking and reading french.
62244793|NCT05043090|EXPERIMENTAL|Arm A|savolitinib 600mg plus durvalumab 1500mg
62244794|NCT05043090|ACTIVE_COMPARATOR|Arm B|sunitinib 50mg
62244795|NCT05043090|EXPERIMENTAL|Arm C|durvalumab 1500mg
62244796|NCT04680351|EXPERIMENTAL|phrenic stimulation|
62244797|NCT06292650|EXPERIMENTAL|group 1|IVT administration of a single low dose ZM-02 injection
62244798|NCT06292650|EXPERIMENTAL|group 2|IVT administration of a single high dose ZM-02 injection
62244799|NCT06292650|SHAM_COMPARATOR|group 3|Sham IVT injection
62244800|NCT00786812|OTHER|CAMN107A2109 Extension Patients|
62244801|NCT00786812|OTHER|AMN107 Naive|
62601475|NCT05908331|EXPERIMENTAL|MagicTouch Sirolimus-Coated Balloon|Magic TouchTM is a Sirolimus Coated Balloon catheter intended to be used in coronary applications, treats the atherosclerosis of the coronary arteries by eluting the immunosuppressant agent Sirolimus without leaving behind a metallic scaffold.
62601476|NCT05908331|ACTIVE_COMPARATOR|POBA|plain old balloon angioplasty
62822533|NCT03392480||Elder non-haptoglobin 2-2 group|Patients are elder than 65 years.
62822534|NCT03392480||Elder haptoglobin 2-2 group|Patients are elder than 65 years.
62244802|NCT06735586|EXPERIMENTAL|Neuromuscular control exercises plus taping|İnvestigators will apply the Mulligan knee taping technique to the participants in the randomized exercise and taping group, in addition to the hip focused and quadriceps strengthening exercises, 3 times a week for a total of 6 weeks.
62244803|NCT06735586|ACTIVE_COMPARATOR|Neuromuscular control exercises|All of the 17 participants participating in the study will be included in the 6-week exercise program investigators created after the initial evaluations. Exercises will be done 3 times a week, 10 sets of each exercise. And the participants will be given a rest period of 3 minutes between each set.
62244804|NCT00607880|ACTIVE_COMPARATOR|Standard Port|Patients undergo insertion of the conventional vascular access port (C. R. Bard, Inc., Murray Hill, NJ). Patients then receive standard chemotherapy.
62244805|NCT00607880|EXPERIMENTAL|Vortex Implantable Access Port|Patients undergo insertion of the Vortex® implantable vascular access port (Horizon Medical Products, Manchester, GA). Patients then receive standard chemotherapy.
62244806|NCT05054257|EXPERIMENTAL|Autologous CAR19 T lymphocytes|Human Autologous T Lymphocytes Expressing the Chimeric Antigen Receptor Specific to CD19
62244807|NCT05590689|EXPERIMENTAL|Radiodynamic therapy (RDT)|All patients will be treated with RDT. Patients are devided into cohorts which differs in the total amount and frequence of RDT.
62244808|NCT05304065|ACTIVE_COMPARATOR|SAFETY-Acute within Usual ED Care|The SAFETY-Acute (A) approach to safety planning and stabilization will be integrated within usual ED Care. SAFETY-A was formerly called the Family Intervention for Suicide Prevention, FISP.
62601477|NCT06645912|EXPERIMENTAL|ONS and standard nutrition support|Patients receiving high protein containing oral nutritional supplement with standart nutritional support
62601478|NCT06645912|NO_INTERVENTION|standart nutrition support|Patients receiving only standart nutritional support
62041730|NCT04919213||Family carers|Family carers (n=50) of people with intellectual disabilities in England, who use the internet, will be invited to take part in an online survey. A subgroup of family carers (n=7) will be asked if they would like to take part in a focus group.
62822535|NCT03459079|ACTIVE_COMPARATOR|lanifibranor arm|Two arm, randomized (1:1), double-blind, placebo-controlled, 24-week treatment study receiving lanifibranor 800 mg/day.
62822536|NCT03459079|PLACEBO_COMPARATOR|Placebo|Two arm, randomized (1:1), double-blind, placebo-controlled, 24-week treatment study receiving placebo.
62041731|NCT04919213||Paid carers|Paid carers (n=50) of people with intellectual disabilities in England, who use the internet, will be invited to take part in an online survey. A subgroup of paid carers (n=7) will be asked if they would like to take part in a focus group.
62041732|NCT04919213||Professionals with safeguarding responsibilities|Professionals with safeguarding duties (e.g., social workers, learning disability nurses, police and safeguarding adults board members) supporting people with ID in England who use the internet will also be invited to take part in an online survey (n=50). A subgroup (n=7) from London and Kent (England, UK) will be asked if they would like to take part in a focus group.
62244809|NCT05304065|ACTIVE_COMPARATOR|Combined|The combined treatment arm includes both 1) SAFETY-A integrated within usual ED Care, and 2) therapeutic follow-up contacts using the Coping Long Term with Active Suicidality Program (CLASP) model.
62822537|NCT05902117|EXPERIMENTAL|Troponin and Copeptin assay|Collection of an additional blood tube for copeptin determination during blood collection for troponin testing as part of care.
62434954|NCT02525029|EXPERIMENTAL|Arm 2A: MTD|After completion of the dose finding trial for each arm, the final doses will be carried forward into a two-stage phase II extension trial to confirm safety and make a preliminary determination of the activity level for Arm 1 and Arm 2. If the phase I trial enrolls fewer than 13 patients at the MTD, we will employ Simon's Minmax two-stage design with the possibility to discontinue after the 1st stage if the response rate is low
62601479|NCT05336942||MCI-HI group|Mild cognitive impairment and hearing impairment group
62041733|NCT04185805|EXPERIMENTAL|Sequence 1 (Tablet B - Tablet A)|Period 1 : DWP14012 tablet B Period 2: DWP14012 tablet A
62041734|NCT04185805|EXPERIMENTAL|Sequence 2 (Tablet A - Tablet B)|Period 1 : DWP14012 tablet A Period 2: DWP14012 tablet B
62244810|NCT04582370|EXPERIMENTAL|Theater program|"The design of the 10-week theater program is based on the principles of acting as written and practiced by Constantin Stanislavski in his revolutionary text on acting: An Actor Prepares \[Stanislavsky C, 1989\]. The exercises target concentration, voice, physical skills, emotion memory, observation, and dramatic analysis and include 3 components: 1. Preparation for the Actor (which involves relaxation , collaboration, movement, posture, and vocality; 2. Learning the Components of the Repeatable Acting Process (which involves physicality, attention, and concentration); and 3. Synthesizing Components into Characterization (which involves creativity and emotional expression).~Each of these components will be addressed during each of 20 sessions through the use of group warm ups, group ensemble exercises, and group recitations. Participants will perform physical, mental, and emotional exercises similar to those given to beginning acting students in traditional theater schools."
62601480|NCT05336942||MCI-nHI group|Mild cognitive impairment and no hearing impairment group
62601481|NCT05336942||Control group|Control group
62601482|NCT04808232|EXPERIMENTAL|health education and progressive muscle relaxation exercise|Health education and progressive muscle relaxation exercise training was given to women in this group.
62601483|NCT04808232|EXPERIMENTAL|progressive muscle relaxation exercise|Progressive muscle relaxation exercise training was given to women in this group.
62601484|NCT04808232|NO_INTERVENTION|Control group|women in this group were not intervened.
62041735|NCT06280196|EXPERIMENTAL|BAT3306|25 mg/mL concentrate for solution for infusion.200 mg on Day 1 of each 21-day cycle
62601485|NCT05470010|EXPERIMENTAL|Immediate Mindfulness|A 4 week smartphone app-based mindfulness intervention program with in-app activities for 20-30 minutes everyday, with a minimum of 4 days of activity in a week.
62601486|NCT05470010|OTHER|Control Mindfulness|No intervention and usual care for 4 weeks, after which there will be assessments immediately post-waiting and at 3 months post-baseline. After this, participants will get the same 4 week smartphone app-based mindfulness intervention program.
62822538|NCT06292286|EXPERIMENTAL|Chemotherapy and surgery arm|Patients receive platinum-based chemotherapy with or without bevacizumab, and then undergo cytoreductive operation, for the first recurrence of EOC.
62822539|NCT06406751|EXPERIMENTAL|MI Paste Application for 7 days|Subjects will apply 1 cubic centimeter of MI Paste for 7 days.
62822540|NCT02039115|EXPERIMENTAL|prednisone|Daily oral prednisone is taken for 6 weeks, at a dose of 40mg/day in week 1, 30mg/day in week 2, 20mg/day week 3 and 4, 10mg/day in week 5, and 5mg/day in week 6. Prednisone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage complete Barretts excision.
62041736|NCT06280196|ACTIVE_COMPARATOR|EU-Keytruda® arm|25 mg/mL concentrate for solution for infusion.200 mg on Day 1 of each 21-day cycle
62041737|NCT06280196|ACTIVE_COMPARATOR|US-Keytruda® arm|25 mg/mL concentrate for solution for infusion. 200 mg on Day 1 of each 21-day cycle
62041738|NCT03752216|EXPERIMENTAL|NIRAPARIB|Oral Niraparib Daily
62041739|NCT05985538|EXPERIMENTAL|Vaping prevention text messages|Participants will receive text messages (2 daily, on average) about the harms of e-cigarette use and vaping for 28 days, with introductory messages sent on day 1 and concluding messages sent on day 28.
62041740|NCT05985538|ACTIVE_COMPARATOR|Wellness behavior text messages|Participants will receive text messages (2 daily, on average) about general wellness topics, with introductory messages sent on day 1 and concluding messages sent on day 28.
62041741|NCT03691116|EXPERIMENTAL|Digital Health Profile|A digital health check-up, with questions, brief feedback and information about alcohol, tobacco, diet and exercise, as a complement to treatment as usual. (Psychological assessment and treatment)
62041742|NCT03691116|ACTIVE_COMPARATOR|Treatment as usual|Psychological assessment and treatment as usual.
62041743|NCT05750459|EXPERIMENTAL|Arm 1|Participants will receive the standard of care with IV artesunate for treatment of severe malaria. Each 60-mg vial of artesunic acid will be dissolved in 1 mL of 5% sodium bicarbonate to form sodium artesunate and then mixed with 5 mL of 5% dextrose. This will be injected as a bolus into an indwelling IV cannula. Children weighing \<20 kg will receive IV artesunate at a dose of 3.0 mg/kg/dose compared to older children weighing \>/= 20kg who will receive 2.4 mg/kg/dose, at times 0, 12, 24. If unable to take oral medication, IV artesunate will continue at 48 and 72 hours. Children who recover and are able to transition to oral antimalarial therapy after a minimum of 24 hours, will initiate a 3-day course of oral artemisinin-combination therapy per national guidelines. N = 100
62041744|NCT04867837|EXPERIMENTAL|Octaplex Low-dose|Participants to receive 1 Octaplex infusion intravenously
62041745|NCT04867837|EXPERIMENTAL|Octaplex High-dose|Participants to receive 1 Octaplex infusion intravenously
62041746|NCT05274074|NO_INTERVENTION|Aim 1|
62244811|NCT04582370|NO_INTERVENTION|Wait-list control|During the study period, the control group will not receive any type of intervention. However, they will be offered the same theater program experience after the primary data collection period ends.
62601487|NCT06612437|ACTIVE_COMPARATOR|Priming iTBS with 3-Minute Interval|short interval(3min) between cTBS and iTBS
62822541|NCT02039115|PLACEBO_COMPARATOR|placebo|Placebo tablets will be taken in the same manner as the prednisone arm.
62244812|NCT06734754|EXPERIMENTAL|Experimental Group|fetal heart sound listening
62244813|NCT06734754|NO_INTERVENTION|Control Group|fetal heart sound was not played
62822542|NCT06604247|EXPERIMENTAL|4-session|Participants randomized to this condition received 4 weekly CBT-I sessions.
62822543|NCT06604247|EXPERIMENTAL|8-session|Participants randomized to this condition received 8 weekly CBT-I sessions.
62244814|NCT03410017||Normally-hearing|Children with normal hearing
62244815|NCT06313073|EXPERIMENTAL|Neoadjuvant radiotherapy|The patient received synchronous radiotherapy and chemotherapy before surgery. CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.
62244816|NCT06313073|ACTIVE_COMPARATOR|Adjuvant radiotherapy|The patient underwent postoperative adjuvant radiotherapy. CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.
62434955|NCT02525029|EXPERIMENTAL|Arm 2B: MTD|After completion of the dose finding trial for each arm, the final doses will be carried forward into a two-stage phase II extension trial to confirm safety and make a preliminary determination of the activity level for Arm 1 and Arm 2. If the phase I trial enrolls fewer than 13 patients at the MTD, we will employ Simon's Minmax two-stage design with the possibility to discontinue after the 1st stage if the response rate is low
62601488|NCT06612437|EXPERIMENTAL|Priming iTBS with 10-Minute Interval|experimental interval(10min) between cTBS and iTBS
62601489|NCT06612437|SHAM_COMPARATOR|Priming iTBS with 20-Minute Interval|long interval(20min) between cTBS and iTBS
62601490|NCT02982616|EXPERIMENTAL|positive emotion and fatty acid|positive emotion induction combine with 2.g Dodecanoic acid intragastric infusion
62601491|NCT02982616|EXPERIMENTAL|neutral emotion and fatty acid|neutral emotion induction combine with 2.g Dodecanoic acid intragastric infusion
62601492|NCT02982616|EXPERIMENTAL|positive emotion and saline|positive emotion induction combine with saline intragastric infusion
62601493|NCT02982616|PLACEBO_COMPARATOR|neutral emotion and saline|neutral emotion induction combine with saline intragastric infusion
62822544|NCT06604247|EXPERIMENTAL|10-session|Participants randomized to this condition received 10 weekly CBT-I sessions.
62601494|NCT04546516||HYAcorp Lips|HYAcorp Lips is indicated for the restoration of volume and contour of the lips.
62601495|NCT04546516||HYAcorp Face|HYAcorp Face is indicated for volume replacement (filling of folds), medium to deep folds, nasolabial folds, cheek area, glabella. It is not intended for injection to the periorbital region (eyelid, crow's feet, circles under the eyes).
62601496|NCT06293040|PLACEBO_COMPARATOR|Placebo cannabis + placebo alcohol|Participants administer vaporized cannabis containing 0mg THC in combination with a placebo alcohol drink.
62601497|NCT06293040|EXPERIMENTAL|Low dose cannabis with placebo alcohol|Participants administer vaporized cannabis containing 5mg THC in combination with a placebo alcohol drink.
62822545|NCT06604247|EXPERIMENTAL|12-session|Participants randomized to this condition received 12 weekly CBT-I sessions.
62822546|NCT01962350|EXPERIMENTAL|Active H1-Coil deep brain rTMS|"Deep Brain Transcranial Magnetic Stimulation~18Hz Active H1-Coil deep brain rTMS for 4-weeks over the cortex prefrontal. n=25"
62822547|NCT01962350|EXPERIMENTAL|Sham H1-Coil deep brain rTMS|"Deep Brain Transcranial Magnetic Stimulation~Sham H1-Coil deep brain rTMS for 4-weeks over the cortex prefrontal. n=25"
62041747|NCT05274074|EXPERIMENTAL|Aim 2|We will be utilizing the Life Enhancing Activities or Caregivers (LEAF) intervention to display that social networks' can be used as a means of reinforcing the positive life skills of the intervention; and that these same skills will enhance social networks, increase mutual satisfaction in social interactions, and boost motivation to reach out to others, thus combatting social isolation.
62041748|NCT03624465|EXPERIMENTAL|Levita Magnetic Surgical System|Levita Magnetic Surgical System use of surgical tool
62041749|NCT04526795|EXPERIMENTAL|Treatment (pegcrisantaspase, fludarabine, cytarabine)|"INDUCTION: Patients receive pegcrisantaspase IV over 60 minutes on days 1 and 15, and fludarabine IV over 15-30 minutes and cytarabine IV over 2 hours on days 8-11 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive pegcrisantaspase IV over 60 minutes on days 1 and 15, and fludarabine IV over 15-30 minutes and cytarabine IV over 2 hours on days 8-10. Treatment repeats every 5 weeks for up 3 cycles in the absence of disease progression or unacceptable toxicity."
62041750|NCT06575140|EXPERIMENTAL|Group A|Treatment
62041751|NCT06575140|ACTIVE_COMPARATOR|Group B|Control
62041752|NCT03248102|EXPERIMENTAL|Patients with suspected appendicitis|Patients with suspected appendicitis Aged 5 and up to their 16th birthday on arrival to A\&E
62041753|NCT03048851|EXPERIMENTAL|Low dosage SES group|Low dosage SES group received the low dosage SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
62041754|NCT03048851|EXPERIMENTAL|High dosage SES group|High dosage SES group received the high dosage SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
62434956|NCT04808245|EXPERIMENTAL|Standard patient cohort|"All fifteen patients will receive in total 11 doses of H3K27M peptide vaccine starting with standard radiotherapy (RT) and 14 doses of the human anti-PD-L1 antibody Atezolizumab/ Tecentriq® (every three weeks, q3w) starting four weeks after completion of RT. The first 3 vaccines will be given bi-weekly (q2w) in combination with RT. One dose of vaccination will be given at the beginning of recovery (RE) period following RT. Vaccines 5-11 (q6w) will be initiated with Atezolizumab after completion of RE. The H3K27M peptide vaccine is administered in combination with topical Imiquimod that serves as an adjuvant.~For safety reasons, the first three patients will be enrolled sequentially: Each patient will receive the first vaccination at the earliest 28 days after the previous patient has received the first vaccination."
62822548|NCT06222554|EXPERIMENTAL|Patients Hospitalized following Kidney or Liver Transplant|Patients in the study will be introduced to the exercise software program and provided with a demonstration. Measurements will be taken at baseline (post-operation) and at the final study visit. Participants will remain in the study until the end of their hospital stay, typically no longer than 6 months post-operation.
62822549|NCT04939610|EXPERIMENTAL|Phase 1: Dose Escalation|Up to 30 patients with solid tumors.
62822550|NCT04939610|EXPERIMENTAL|Phase 2: Specific Solid Tumors|Up to 192 participants treated with \[177Lu\]Lu-FAP-2286 in tumor-specific participant groups in monotherapy and in combination with chemotherapy.
62822551|NCT03635892|EXPERIMENTAL|Cohort 1: Unclassified, papillary, and HL RCC|Cohort 1 is designed as a single stage study with a total sample size of 20. This design discriminates between ORR rates of 10 and 35%.
62822552|NCT03635892|EXPERIMENTAL|Cohort 2: Chromophobe RCC|Cohort 2 is designed as a Simon's optimal two-stage design with a total possible sample size of 17. This design discriminates between ORR rates of 5 and 25%.
62822553|NCT03635892|EXPERIMENTAL|Cohort 3: Unclassified, papillary, and HL RCC|Cohort 3 is designed as an expansion cohort of Cohort 1 with 20 additional patients to obtain a more precise estimate of the ORR and clinical outcomes
62822554|NCT03635892|EXPERIMENTAL|Cohort 4: Unclassified, papillary, and HL RCC|Cohort 4 is an expansion of Cohorts 1+3, which will accure an additional 40 patients
62822555|NCT04389775|EXPERIMENTAL|Cohort A|Subcutaneously administer a single dose of XW003, ranging from 0.03mg to 1.0mg, every cohort by the body weight.
62041755|NCT03048851|EXPERIMENTAL|VRCIT group|VRCIT group received the VRCIT training in addition to traditional rehabilitation.Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 1.5 hours per day.
62041756|NCT03048851|EXPERIMENTAL|VRCIT+SES group|VRCIT+SES group received the VRCIT and SES training in addition to traditional rehabilitation.
62822556|NCT04389775|PLACEBO_COMPARATOR|Placebo A|Subcutaneously administer a single dose of volume-matching placebo, ranging from 0.03mg to 1.0mg, every cohort by the body weight.
62041757|NCT03048851|ACTIVE_COMPARATOR|traditional rehabilitation group|Shame control group received the shame SES and traditional rehabilitation programs.
62822557|NCT04389775|EXPERIMENTAL|Cohort B|Subcutaneously administer multiple SC doses of XW003, ranging from 0.2mg to 0.6mg, once weekly for 6 weeks.
62041758|NCT06496490|EXPERIMENTAL|TQB2102 for injection|Intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle.
62041759|NCT06496490|EXPERIMENTAL|TQB2102 for injection+Benmelstobart injection|TQB2102 for injection, intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle; Benmelstobart injection, intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle.
62244817|NCT06062264|ACTIVE_COMPARATOR|Portal-Based PCP Video Reminder Message|Participants in their arm will receive up to 3 portal-based messages with a video recorded message from their own primary care physician encouraging them to receive the influenza vaccine.
62244818|NCT06062264|ACTIVE_COMPARATOR|Portal-Based PCP Infographic Reminder Message|Participants in their arm will receive up to 3 portal-based messages with an infographic message with an image of their own primary care physician encouraging them to receive the influenza vaccine.
62244819|NCT06062264|NO_INTERVENTION|Standard Health System Portal Messages|Participants in this arm will only receive standard-of-care health system portal messages, and will not receive study-based messages.
62244820|NCT05736159||3 years old age group|Children from 2 years 10 months 16 days to 3 years 2 months 29 days
62244821|NCT05736159||3.6 years old age group|Children from 3 years 3 months to 3 years 8 months 29 days
62244822|NCT05736159||4 years old age group|Children from 3 years 9 months to 4 years 2 months 29 days
62601498|NCT06293040|EXPERIMENTAL|High dose cannabis with placebo alcohol|Participants administer vaporized cannabis containing 25mg THC in combination with a placebo alcohol drink.
62601499|NCT06293040|EXPERIMENTAL|Low dose cannabis with low dose alcohol|Participants administer vaporized cannabis containing 5mg THC in combination with an alcohol drink (0.05 percent BAC).
62822558|NCT04389775|PLACEBO_COMPARATOR|Placebo B|Subcutaneously administer multiple SC doses of volume-matching placebo, ranging from 0.2mg to 0.6mg, once weekly for 6 weeks.
62244823|NCT05736159||4.6 years old age group|Children from 4 years 3 months to 4 years 8 months 29 days
62244824|NCT05736159||5 years old age group|Children from 4 years 9 months to 5 years 2 months 29 days
62244825|NCT05736159||5.6 years old age group|Children from 5 years 3 months to 5 years 8 months 29 days
62244826|NCT05736159||6 years old age group|Children from 5 years 9 months to 6 years 2 months 29 days
62244827|NCT05736159||6.6 years old age group|Children from 6 years 3 months to 6 years 8 months 29 days
62244828|NCT05736159||7 years old age group|Children from 6 years 9 months to 7 years 5 months 29 days
62822559|NCT06598644|OTHER|Cervical SNAGS (C3-C7) + Conventional PT|
62822560|NCT06598644|ACTIVE_COMPARATOR|IASTM (ergon) + Conventional PT|
62822561|NCT06604494|EXPERIMENTAL|Early group|For an IL 10 level on postoperative day 2 below 72 pg/mL (group said to be at low risk of developing a fistula defined from the DEFILAC pilot study), resumption of food on the 3rd or 4th postoperative day with a mixed diet.
62822562|NCT06604494|PLACEBO_COMPARATOR|late group|For an IL 10 level on postoperative day 2 below 72 pg/mL (group said to be at low risk of developing a fistula defined from the DEFILAC pilot study), resumption of food on the 3rd or 4th postoperative day with a mixed diet.
62822563|NCT06604494|NO_INTERVENTION|No intervention|For an IL 10 level on postoperative day 2 greater than 72 pg/mL (group at high risk of postoperative fistula), these patients will constitute a third, exploratory group, whose management will be left to the investigator's discretion.
62822564|NCT05772390|EXPERIMENTAL|Partial breast re-irradiation|partial breast re-irradiation in patients with local recurrence of breast cancer, previously treated with breast conservative surgery and whole breast radiotherapy. A total dose of 35 Gy in 10 daily fractions, 5 fractions per week, will be prescribed.
62822565|NCT05506384|EXPERIMENTAL|Relaps prevention treatment|The treatment will be administered in an individual format and consist of seven to nine sessions of 45 minutes over a period of seven to nine weeks. The number of sessions can vary to be able to accommodate the fact that participants may have different levels of motivation for changing their primary problem behavior, which is why some participants may require one or two extra sessions at the start of the treatment. The treatment will be offered to participants both in person and via video link to facilitate participation for children and adolescents living further away from the participating clinics.
62822566|NCT05506384|OTHER|Treatment as usual|The patients in this arm will get treatment as usual at their Child and Adolescent psychiatry clinic.
62822567|NCT03160118|OTHER|Seasonal,quadrivalent,influenza vaccine|1 vaccine will be administered to all participants, namely Alfa-Rix Tetra 2016-2017
62822568|NCT05536336|EXPERIMENTAL|Okamoto Lubricated Synthetic Polyurethane Male Condom|The test device name is Okamoto 001 Lubricated Polyurethane Male Condom. The condom is made in Japan and conforms to ASTM D6324-11 (2017) Standard Test Methods for Male Condoms Made from Polyurethane.
62822569|NCT05536336|ACTIVE_COMPARATOR|Latex condom|Commercially available latex lubricated condom.
62244829|NCT05736159||8 years old age group|Children from 7 years 6 months to 8 years 5 months 29 days
62244830|NCT06164301|EXPERIMENTAL|Elemental Amino group|Elemental Amino group ; post-operative within the first 3 hours the patient will receive 250 ml of elemental protein( 250 ml Peptamen = 6 scoops (55g) + 210ml water ) repeated at ( 6, 8 , 10 , 12 hours postoperative ) in order to reach total protein in order to reach total protein 50 mg in the first 12 hour post-operative, Second day ordinary food will be introduced supplemented by half the dose of the first day from elemental protein (250 ml / 6 hours ) or to the dose to achieve the daily protein adequacy 1.3 mg/kg/day.
62244831|NCT06164301|ACTIVE_COMPARATOR|standard|Standard group; The patients in this group will receive the standard protocol in which they will be made NPO till the return of bowel functions. Thereafter, water and clear fluids will be given followed by soft food and, eventually a regular diet.
62244832|NCT06585488|EXPERIMENTAL|Phase 1a: Part A (Monotherapy Dose Escalation)|Sequential cohorts will be evaluated to determine the Recommended Dose for Expansion (RDFE) of BGB-53038 as a monotherapy.
62244833|NCT06585488|EXPERIMENTAL|Phase 1a: Part B (Monotherapy Safety Expansion)|Participants will be enrolled at dose levels determined in Part A with the Safety Monitoring Committee to confirm the final RDFE(s) for BGB-53038 monotherapy.
62244834|NCT06585488|EXPERIMENTAL|Phase 1a: Part C (Combination Therapy Dose Escalation)|Sequential cohorts with increasing doses will be evaluated to determine the RDFE(s) for BGB-53038 in combination with tislelizumab or cetuximab.
62244835|NCT06585488|EXPERIMENTAL|Phase 1b: Part D (Monotherapy Dose Expansion)|Participants will be enrolled to receive the RDFE(s) of BGB-53038 monotherapy
62434957|NCT05683314||Acetabular_Pelvic_Sacral fracture with open reduction and internal fixation|
62434958|NCT05683314||Acetabular_Pelvic_Sacral fracture with minimally invasive internal fixation|
62434959|NCT00003533|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62822570|NCT04162288|EXPERIMENTAL|Online training on SDM in prenatal screening|
62822571|NCT04162288|PLACEBO_COMPARATOR|Online training on prenatal screening|
62822572|NCT06088992|EXPERIMENTAL|HG004|
62822573|NCT06000228|EXPERIMENTAL|Shallow vestibule|Miller class III/ RT2 labial gingival recession associated with vestibular depth less than 6mm
62822574|NCT06000228|ACTIVE_COMPARATOR|Deep vestibule|Miller class III/ RT2 labial gingival recession associated with vestibular depth more than 6mm
62822575|NCT03074136|EXPERIMENTAL|Photodinamic therapy|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that, HELBO treatment (Helbo Photodynamic System, Bredent, Senden, Germany) will be applied.
62822576|NCT03074136|EXPERIMENTAL|Diode laser|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that high power diode laser therapy will be applied by using Epic diode laser (Biolase® Technology, Inc., San Clemente, CA, USA).
62041760|NCT06308380|ACTIVE_COMPARATOR|Rehabilitation only|All patients who do not wish to undergo mini- invasive surgery to lengthen the calf muscles are part of the control group. They will be subjected to a specific protocol of rehabilitation exercise 3times a week for 12 weeks.
62041761|NCT06308380|EXPERIMENTAL|Surgery|All patients who wish to undergo mini invasive surgery to lengthen the calf muscles are part of the experimental group. they will be subjected to a specific protocol of rehabilitation exercise exercise 3times a day every day for 4weeks.
62041762|NCT04611503|EXPERIMENTAL|Subretinal injection of rAAV.hPDE6A|Single subretinal injection of rAAV.hPDE6A
62041763|NCT06732869|EXPERIMENTAL|Experimental Group - Pulmonary rehabilitation + eHealth physical activity coaching intervention|Patients will attend a PR program for 10 weeks and receive an eHealth PA coaching intervention (smartband connected to a mobile application) in the week 5 of PR until months after end of PR.
62041764|NCT06732869|OTHER|Control group - pulmonary rehabilitation|Patients will attend pulmonary rehabilitation program for 10 weeks.
62041765|NCT00336674|ACTIVE_COMPARATOR|DV001|Recombinant human intranasal insulin formulation in a buffered solution of benzalkonium chloride and glycerol presented in multi-dose nasal spray devices with actuators (Pfeiffer) designed to deliver 100ul spray doses to nasal mucosa. The product is formulated at a dose strength of 1100 IU / mL (40mg/mL) manufacturing formulation. The product will be self administered by eligible participants as two 100 microlitre spray doses per nostril. Treatment will be administered daily for 7 consecutive days then on one day each week for 12 months. Participants will be followed until they develop diabetes or until 5 years after the last participant has been randomised (maximum period of follow up is expected to be 10 years.
62041766|NCT00336674|PLACEBO_COMPARATOR|Placebo|Placebo insulin carrier solution of benzalkonium chloride and glycerol presented in multi-dose nasal spray devices with actuators (Pfeiffer) designed to deliver 100ul spray doses to nasal mucosa. The product will be self administered by participants as two 100 microlitre spray doses per nostril. Treatment will be administered daily for 7 consecutive days then on one day each week for 12 months. Participants will be followed until they develop diabetes or until 5 years after the last participant has been randomised (maximum period of follow up is expected to be 10 years.
62041767|NCT00717860|EXPERIMENTAL|Caspofungin|caspofungin acetate (MK0991)
62601500|NCT06293040|EXPERIMENTAL|High dose cannabis with low dose alcohol|Participants administer vaporized cannabis containing 25mg THC in combination with an alcohol drink (0.05 percent BAC).
62041768|NCT00717860|ACTIVE_COMPARATOR|Micafungin|Micafungin sodium
62041769|NCT05491148||medical workers|medical workers of the resuscitation and intensive care unit of newborns
62601501|NCT06293040|EXPERIMENTAL|Placebo cannabis + low dose alcohol|Participants administer vaporized cannabis containing 0mg THC in combination with an alcohol drink (0.05 percent BAC).
62601502|NCT06293040|EXPERIMENTAL|Placebo cannabis + high dose alcohol|Participants administer vaporized cannabis containing 0mg THC in combination with an alcohol drink (0.08 percent BAC).
62041770|NCT01568671|EXPERIMENTAL|Healthy older lean white men|White men aged 55-75 years with BMI between 18.5 and 25.0 kg/m2
62041771|NCT01568671|EXPERIMENTAL|Healthy young lean black men|Black men aged 18-35 years with BMI between 18.5 and 25.0 kg/m2
62041772|NCT01568671|EXPERIMENTAL|Healthy young lean white men|White men aged 18-35 years with BMI between 18.5 and 25.0 kg/m2
62041773|NCT01568671|EXPERIMENTAL|Healthy young lean white women|White women aged 18-35 years with BMI between 18.5 and 25.0 kg/m2
62041774|NCT01568671|EXPERIMENTAL|Healthy young white men with obesity|White men aged 18-35 years with BMI between 30.0 and 40.0 kg/m2
62041775|NCT03605095|ACTIVE_COMPARATOR|8 mg/ml nitroglycerin|Higher concentration of NO donor (Nitromint) vs dilution
62041776|NCT03605095|ACTIVE_COMPARATOR|1 mg/ml nitroglycerin|Lower concentration of NO donor (Nitropohl) vs physiological saline
62041777|NCT01505023|ACTIVE_COMPARATOR|Partial meal replacement|
62041778|NCT01505023|EXPERIMENTAL|Partial meal replacement with inulin|
62041779|NCT01505023|ACTIVE_COMPARATOR|Inulin|
62041780|NCT01505023|NO_INTERVENTION|No intervention|
62041781|NCT02578238||Participants With Pediatric CD|Participants with pediatric CD who have been prescribed Humira® (adalimumab) by the treating physician.
62041782|NCT03260166|EXPERIMENTAL|nicotinamide|Patients will receive 10 nicotinamide tablets orally twice daily (nicotinamide 500 mg, p.o., Bid) for a period of 3 months. Each tablet contains 50 mg of nicotinamide.
62601503|NCT04086589||Young|Observational study without intervention
62601504|NCT04086589||Elderly|Observational study without intervention
62822577|NCT03074136|EXPERIMENTAL|0.5% Sodium hypochlorite|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius).
62822578|NCT05713656||Physiotherapy and bikefit|Physiotherapy care including a bike fit, education and exercises provided by a physiotherapist with a BikePT bronze to gold certification.
62822579|NCT00791635||Observational (questionnaires)|"RETROSPECTIVE PORTION: Patients who have undergone pelvic exenteration complete one set of QOL questionnaires.~PROSPECTIVE PORTION: Patients undergoing pelvic exenteration complete questionnaires over 20-40 minutes within 2 weeks before surgery, and at 4-12 weeks, 6 months, and 1, 2, 3, 4, 5, and 10 years after surgery regarding feelings, abilities, depression, coping, social support, sexual function and body image. Patients with cervical cancer may complete 1 additional questionnaire during each of these visits."
62434960|NCT03723590|EXPERIMENTAL|Esterified hyaluronic acid matrix|
62822580|NCT03897777|EXPERIMENTAL|Hypertension (Exercise Intervention)|Participants with hypertension will submit blood and fecal samples for comparison to control participants with normal blood pressure. Control group will only donate fecal and blood samples and will not participate in the exercise intervention. Participants with hypertension will also perform 3 months of supervised aerobic exercise (5 days/week) and submit blood and fecal samples every 4 weeks until the completion of the study.
62822581|NCT04305834|EXPERIMENTAL|Treatment (abemaciclib)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62822582|NCT04570930|EXPERIMENTAL|Just-in-time adaptive intervention (JITAI)|Participants will wear the Fitbit®, provide daily reports of Health- Related Quality of Life (HRQOL) and receive personalized pushes over a six-month (180 day) period.
62434961|NCT00677924|EXPERIMENTAL|Zalutumumab 8 mg/kg|Zalutumumab in combination with Irinotecan
62822583|NCT04570930|ACTIVE_COMPARATOR|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a six-month (180 day) period (without the personalized feedback).
62822584|NCT06597643|ACTIVE_COMPARATOR|Control Group|Twenty-one patients will be assigned to group A, who will receive eccentric exercise program in addition to sham massage in the form of skin rubbing for patient blinding. for a total of 12 treatment sessions (3 sessions per week) for 4 weeks 3 sets of 15 repetitions, it takes 5 seconds to complete each repetition and between each set there is 30 seconds of rest
62041783|NCT05008666|EXPERIMENTAL|L-DEP, Sintinimab+Chidamide, Sintinimab+Azacitidine|"【L-DEP】~L-asparaginase: 2000U/m2 d5, im~Doxorubicin liposome: 25mg/m2 d1, ivd~Etoposide: 100mg/m2 d1, d8, d15, ivd~Methylprednisolone: 15mg/kg/day d1-3, 0.75mg/kg/day, d4-7, 0.25mg/kg/day, d8-14, ivd~【Sintinimab+Chidamide】~Sintinimab: 200mg，d1,ivd,q21d Chidamide：30mg biw, continued oral~【Sintinimab+Azacitidine】~Sintinimab:200mg，d1, ivd, q21d Azacitidine:75mg/m2, d1-d7, ih, q28d"
62041784|NCT01869010||HIV Tenofovir|
62041785|NCT01869010||HIV No tenofovir|
62041786|NCT01869010||Seronegative controls|
62434962|NCT00677924|EXPERIMENTAL|Zalutumumab 16 mg/kg|Zalutumumab in combination with Irinotecan
62434963|NCT05207319|EXPERIMENTAL|the MRDI group (Moral Reasoning Development Intervention)|The MRDI is comprised of 4 components that are run concurrently: moral reasoning, strategies of anger management and problem-solving and social skills.
62601505|NCT04612777|EXPERIMENTAL|Opening Doors to Recovery|Participants will receive services from the team of three ODR navigators: one professional social worker, one navigator who is a family member of someone with SMI, and one peer navigator with lived experience.
62601506|NCT04612777|ACTIVE_COMPARATOR|Intensive Case Management or Case Management|Participants randomized to the control group will either receive standard services of Intensive Case Management or Case Management, depending on the services that are available in their county.
62822585|NCT06597643|EXPERIMENTAL|Experimental Group|Twenty-one patients will be assigned to group B who will receive the same exercises as in control group (eccentric training exercises) in addition to deep friction massage (DFM) for a total of 12 treatment sessions (3 sessions per week) for 4 weeks. Before starting the exercises DFM will be performed. The patient will sit on a chair while holding a pillow. DFM will be performed in perpendicular direction to the Extensor carpi radialis brevis tendon the site of the application will be on the upper attachment of the common extensor origin (palpated one cm distal to the lateral epicondyle of the humerus) for 5 minutes. Using the thumb, Firm pressure will be applied to compress the extensor tendons, their origins, and the musculotendinous junctions between the underlying bone and the fingertips. This pressure will be maintained while the therapist applies DFM in the direction of their fingers,
62822586|NCT04266067|ACTIVE_COMPARATOR|PNF exercise|In the PNF exercise group; exercises were performed in company with a physiotherapist 5 days a week (30 minutes ) for 4 weeks. Five specific techniques were applied to the patients: dynamic stabilization, rhythmic stabilization, combined isotonic contractions, and hold-relax active motion
62041787|NCT02524392|EXPERIMENTAL|Independent medical evaluation|Independent medical evaluation (IME) of another doctor than the treating general practitioner.
62041788|NCT02524392|NO_INTERVENTION|Treatment as usual|Treatment as usual by the treating general practitioner. There will be one randomized control group in one county. Sick-listed in other counties serve as an extra control group.
62041789|NCT03115983|EXPERIMENTAL|LimiFlex|Posterior dynamic stabilization with the LimiFlex Paraspinous Tension Band
62041790|NCT03115983|ACTIVE_COMPARATOR|Fusion|Transforaminal lumbar interbody fusion with concomitant posterolateral fusion with pedicle screw instrumentation
62434964|NCT05207319|NO_INTERVENTION|the control group|The control group is the Treatment as Usual (TAU).
62434965|NCT02557594|EXPERIMENTAL|Viread → DA-2802|"* Viread 300mg(Tenofovir disoproxil fumarate)~* DA-2802 319mg(Tenofovir disoproxil orotate)"
62041791|NCT06732388|EXPERIMENTAL|Arm I (itraconazole)|Patients receive itraconazole PO BID on days 1-42 of each cycle. Cycles repeat every 6 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo standard of care endoscopy and radiofrequency ablation on study. Patients also undergo blood sample collection throughout the study as well as tissue biopsy on study.
62041792|NCT06732388|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID on days 1-42 of each cycle. Cycles repeat every 6 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo standard of care endoscopy and radiofrequency ablation on study. Patients also undergo blood sample collection throughout the study as well as tissue biopsy on study.
62041793|NCT05747196|EXPERIMENTAL|Open Label Treatment Arm|Hospitalized patients with acute decompensated heart failure that meet eligibility criteria will have an eLym System temporarily placed via left internal jugular access. The eLym System will be in place for up to 72 hours.
62041794|NCT04014920|ACTIVE_COMPARATOR|Oxygen Group|Patient will receive standard oxygenotherapy
62041795|NCT04014920|EXPERIMENTAL|NIV Group|Patient will receive non invasive ventilation
62041796|NCT06226246|EXPERIMENTAL|HEROS VR|Trainee trained by HEROS VR CPR training program
62041797|NCT06226246|ACTIVE_COMPARATOR|Conventional HEROS|Trainee trained by conventional HEROS CPR training program
62041798|NCT01421576|ACTIVE_COMPARATOR|High fat meal|
62041799|NCT01421576|EXPERIMENTAL|DP-R202|under fed condition
62041800|NCT00142493|EXPERIMENTAL|1|
62041801|NCT00142493|EXPERIMENTAL|2|
62041802|NCT00142493|EXPERIMENTAL|3|
62041803|NCT00142493|EXPERIMENTAL|4|
62041804|NCT00142493|PLACEBO_COMPARATOR|5|
62041805|NCT01311674|ACTIVE_COMPARATOR|Schedule 1- Standard dose primary vaccination series|Schedule 1 subjects received 20 µg/1.0 mL of Engerix-B® on Day 0, Day 30, Day 180 with booster of 20 µg/1.0 mL of Engerix-B® every 120 days (4 months) (after Day 180 vaccination)
62041806|NCT01311674|EXPERIMENTAL|Schedule 2 - High dose primary vaccination series|Schedule 1 subjects received 40 µg/1.0 mL of Engerix-B® on Day 0, Day 30, Day 60, Day 180 with booster of 20 µg/1.0 mL of Engerix-B® every 120 days (4 months) (after Day 180 vaccination)
62244836|NCT06585488|EXPERIMENTAL|Phase 1b: Part E (Combination Therapy Dose Expansion)|Participants will be enrolled to receive BGB-53038 at the RDFE(s) as determined in Part C of Phase 1a in combination with tislelizumab and in combination with cetuximab, respectively.
62822587|NCT04266067|ACTIVE_COMPARATOR|Frenkel exercise|In the Frenkel exercise group, Frenkel coordination exercises were given in home exercise program 5 days a week for 4 weeks.The physiotherapist demonstrated Frenkel exercises to them once.
62822588|NCT06604377||Shanghai East Hospital, Tongji University School of Medicine|Patients diagnosed with prostate cancer undergoing PSMA PET/MR examination prior to surgery.
62822589|NCT06600841|EXPERIMENTAL|Immunotherapy group|Drug: Adebrelimab, Non-platinum chemotherapy（Doxorubicin liposome/Paclitaxel-albumin/ or Gemcitabine）, fluzoparib Intervention：Adebrelimab plus Non-platinum chemotherapy（Doxorubicin liposome/Paclitaxel-albumin/ or Gemcitabine） induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib.
62041807|NCT05003349|EXPERIMENTAL|Experimental group|Occlusal Splint (OS) + Pain Neuroscience Education (PNE) + Motor Imagery (MI) + Action Observation (AO) + Jaw and Neck Exercises (JNE) All participants in this arm will receive OS (they must use every night during the study) and will receive physiotherapy treatment including PNE, MI, AO and JNE, in 2 sessions per week, each lasting 60 minutes, during 5 weeks. For PNE a power-point presentation with metaphors, images and videos will be employed. For the MI, the participants will be asked to judge the laterality of different cervical images presented on the screen of a cell phone. The laterality task will be executed using an application called Recognize Neck, developed by the NOI group. The AO will be carried out using videos of mandibular and cervical exercises. The JNE program will be performed 3 sets of 10 repetitions. The exercises will be executed with a total time per session of 20 minutes, initially at the clinic and later at home.
62041808|NCT05003349|ACTIVE_COMPARATOR|Active comparator|"Occlusal Splint (OS) + Counselling + Jaw and Neck Exercises (JNE). All participants in this arm will receive OS and will receive physiotherapy treatment including Counselling and JNE, in 2 sessions per week, each lasting 40 minutes, during 5 weeks. The JNE will be administered in the same way as in the other arm of the study.~Counselling include education about the anatomical, biomechanical and psychosocial factors relationed with temporomandibular disorders, guidance regarding the parafunction jaw activities for eg will be taught the resting postural position of the mandible (teeth apart, lips slightly touching and tongue not pushing against the teeth)."
62041809|NCT02125201|EXPERIMENTAL|intranasal fentanyl|Intranasal Fentanyl 1.5-2 mcg/kg
62041810|NCT02125201|ACTIVE_COMPARATOR|intravenous fentanyl|Intravenous Fentanyl 1-1.5 mcg/kg
62244837|NCT06147076|NO_INTERVENTION|Usual Pre-Transplant Counseling Intervention|Participants in control arm will undergo usual pre-transplant counseling as per the standard of care.
62434966|NCT02557594|EXPERIMENTAL|DA-2802 → Viread|"* Viread 300mg(Tenofovir disoproxil fumarate)~* DA-2802 319mg(Tenofovir disoproxil orotate)"
62434967|NCT00772252||1|patient with hepatic failure undergoing liver support treatment in surgical intensive care unit
62822590|NCT05354596|EXPERIMENTAL|STRICT LUNG|Central Tumors in the Lung The tumor is considered central when the tumor is located within 0.5 -2.5 cm in all directions of the PBT or the esophagus. The PBT includes trachea, main bronchi and intermediate bronchus and 5 lobar bronchi. In addition, the tumor is also considered central, if it is located \<0.5 cm from the spinal cord, heart and aorta.
62822591|NCT05354596|EXPERIMENTAL|STAR LUNG|Ultra-Centrally Tumors in the Lung Ultra-centrally located tumors are tumors located within the 0.0 to 0.5 cm zone of trachea, main bronchi or intermediate bronchus. The patient will be excluded if the tumor invades the trachea, bronchi, esophagus, or pericardium/heart (radiological or by bronchoscopy assessment).
62244838|NCT06147076|EXPERIMENTAL|Social Support Network Counseling Intervention|Participants in the intervention arm will undergo an additional pretransplant counseling session along with members of their social support networks after their initial transplant evaluation and counseling.
62434968|NCT05681377|EXPERIMENTAL|Flumazenil group|After discontinuation of remimazolam administration, flumazenil is administered to help the patient recover consciousness.
62601507|NCT04000698|EXPERIMENTAL|intervention/treatment|"Preparative chemotherapy before allogeneic HSCT~* Fludarabin~* Cytarabine~* Venetoclax~* Daratumomab~* Vecanoid~* treosulfan~* fludarabine~* thiophosphomide~* Venetoclax~* Plerixafor~* abatacept~* tocilizumab~* rituximab~* HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes"
62601508|NCT05622045||Story-LCSS|
62822592|NCT01522222|NO_INTERVENTION|Control|half of the study subjects will receive standard of care during their open heart surgery.
62822593|NCT01522222|EXPERIMENTAL|Treatment|half of the study subjects will receive the prescribed ventilatory support during open heart surgery.
62822594|NCT06597604|EXPERIMENTAL|Experimental Group|Thoracic Surgeons will apply the experimental device TenaTac® after major lung resection
62822595|NCT06597604|ACTIVE_COMPARATOR|Control Group|Thoracic Surgeons will apply other (usual) sealing device after major lung resection
62822596|NCT02941263||Affected Participants|Participants with unilateral or bilateral GA associated with atrophic AMD.
62822597|NCT06601127|EXPERIMENTAL|Tiprogrel Dose 1|Loading dose of Tiprogrel followed by daily maintenance dose until day 90.
62822598|NCT06601127|EXPERIMENTAL|Tiprogrel Dose 2|Loading dose of Tiprogrel followed by daily maintenance dose until day 90.
62822599|NCT06601127|ACTIVE_COMPARATOR|Clopidogrel|Loading dose of Clopidogrel followed by daily maintenance dose until day 90.
62822600|NCT05617755|EXPERIMENTAL|AB-1015|Patients receive fludarabine and cyclophosphamide intravenously on days -5 to -3. Patients receive a single dose of AB-1015 intravenously on day 0.
62822601|NCT01292486|EXPERIMENTAL|Patients with multiple myeloma|Multiple myeloma patients who receive autologous stem-cell transplants, collected using the Spectra Optia Apheresis System, following myeloablative therapy. The study is limited to subjects who are expected demonstrate normal neutrophil recovery.
62822602|NCT06470971|EXPERIMENTAL|Treatment (PD1 antibody, PD-L1 antibody, Siltuximab)|Patients receive anti-PD1 or anti-PD-L1 monoclonal antibody therapy either every 3 or 6 weeks, or every 2 or 4 weeks per physicians choice. Patients also receive siltuximab IV over 1 hour on day 1 of each cycle prior to the administration of anti-PD1 or anti-PD-L1 therapy. Treatment repeats either every 3 weeks for up to 8 doses or every 4 weeks for up to 6 doses in the absence of disease progression or unacceptable toxicity. Patients may undergo biopsy and bone scan on study, as well as blood sample collection and CT or MRI throughout the study.
62822603|NCT02367898|EXPERIMENTAL|Cognitive Training|Lumosity cognitive training program.
62822604|NCT02367898|ACTIVE_COMPARATOR|Crossword Puzzles|Timed online crossword puzzles
62822605|NCT06035068||Combined ICG dye and blue tracer dye|This study is being done to see if a different way of finding and removing lymph nodes during surgery, using a special camera and a dye called Indocyanine Green (ICG), works as well as the usual method with blue dye plus a radioactive tracer called radiocolloid. By comparing the two ways directly, we hope to make it simpler for people with vulvar cancer to get their lymph nodes checked during surgery.
62244839|NCT03132532|EXPERIMENTAL|Arm A (platinum doublet chemotherapy, lower dose PBT)|Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo lower dose proton beam radiation therapy daily for a total of 60 Gy for up to 30 weekdays in the absence of disease progression or unacceptable toxicity.
62822606|NCT05854966|EXPERIMENTAL|Treatment - CPI-613 with Metformin|"Induction therapy with CPI-613 and Metformin (ideally 2 hours prior to start of CPI-613 infusions on days 1-5) for two cycles of treatment.~Maintenance therapy with CPI-613 and Metformin (ideally 2 hours prior to start of CPI-613 infusions on days 1-5) until progression, intolerable toxicity of withdrawal of consent."
62244840|NCT03132532|EXPERIMENTAL|Arm C (platinum doublet chemotherapy, higher dose PBT)|Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo higher dose proton beam radiation therapy daily for a total of 72 Gy for up to 36 weekdays in the absence of disease progression or unacceptable toxicity.
62244841|NCT05011058|EXPERIMENTAL|Nanatinostat with Valganciclovir|"Patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week with valganciclovir 900 mg orally once daily.~Up to 10 PTCL patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week."
62244842|NCT03222531|EXPERIMENTAL|HCV seropositive non-viremic (HCV Ab+/NAT-) donor|"HCV seropositive non-viremic (HCV Ab+/NAT-) donor hearts to HCV seronegative recipients.~Heart recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.~Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).~Intervention: Drug: sofosbuvir/velpatasvir"
62244843|NCT03222531|EXPERIMENTAL|HCV seropositive viremic (HCV Ab+/NAT+) donor|"HCV seropositive viremic (HCV Ab+/NAT+) donor hearts to HCV seronegative recipients.~Starting post-operative day 1, heart recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).~Intervention: Drug: sofosbuvir/velpatasvir"
62244844|NCT01879787|EXPERIMENTAL|physiotherapy + anodal tDCS + mCIMT|Before a anodal tDCS with duration of 13 minutes and intensity of 1mA applied at the injured motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
62244845|NCT01879787|EXPERIMENTAL|Physiotherapy + cathodal tDCS + mCIMT|Before a cathodal tDCS with duration of 9 minutes and intensity of 1mA applied at the healthy motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
62244846|NCT01879787|EXPERIMENTAL|Physiotherapy+bi-hemispheric tDCS+mCIMT|Before a bi-hemispheric tDCS with duration of 13 minutes and intensity of 1mA applied at the healthy (cathode) and injured (anode) motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
62244847|NCT01879787|SHAM_COMPARATOR|Physiotherapy+sham tDCS+mCIMT|Before a sham tDCS with duration of 30 seconds and intensity of 1mA applied at the injured motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
62244848|NCT01879787|EXPERIMENTAL|Physiotherapy+tDCS+mental practice|Before a tDCS protocol applied during de mental practice training , the patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
62244849|NCT01879787|SHAM_COMPARATOR|Physiotherapy+sham tDCS+mental practice|Before a sham tDCS protocol applied during the mental practice training, the patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
62244850|NCT01879787|NO_INTERVENTION|Physiotherapy|The patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
62822607|NCT01375829|EXPERIMENTAL|Treatment (ixabepilone, temsirolimus)|Patients receive ixabepilone IV over 3 hours on day 1 and temsirolimus IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62822608|NCT05884645||Patients undergoing endotracheal intubation|Patients across all ages undergoing endotracheal intubation.
62244851|NCT03444727|EXPERIMENTAL|Ice Pre-treatment|Participants will hold an exam glove filled with ice to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
62601509|NCT05538767|EXPERIMENTAL|Emodepside 30 mg|
62601510|NCT05538767|ACTIVE_COMPARATOR|Albendazole 400 mg|
62601511|NCT02829827|EXPERIMENTAL|Radiprodil|Each subject will enter an individualized dose titration schedule.
62822609|NCT00900653|EXPERIMENTAL|Gynoflor|
62822610|NCT00900653|NO_INTERVENTION|Control|
62601512|NCT01768975|EXPERIMENTAL|OLT1177 Gel|4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
62244852|NCT03444727|PLACEBO_COMPARATOR|Room Temperature Water Pre-Treatment|Participants will hold an exam glove filled with room temperature water to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
62822611|NCT06600828||The Internal Medicine Unit arm|It includes all patients hospitalized in the Internal Medicine Unit. Patients may have been previously hospitalized in the emergency department or in another department such as intensive care.
62822612|NCT06600828||The hepato-gastro-enterology Unit arm|It includes all patients hospitalized in the Gastroenterology unit. Patients may have been previously hospitalized in the emergency department or in another department such as intensive care.
62822613|NCT06067802|EXPERIMENTAL|Triheptanoin|Open label study
62822614|NCT06599814|ACTIVE_COMPARATOR|RetroMTA Conventional group|After controlling the bleeding, RetroMTA is mixed with the supplied liquid at a W/P ratio of 3 drops per 0.3 g. After 150 seconds, selective etching, application of adhesive material and application of resin composite restorations will occur according to the manufacturer's instructions.
62822615|NCT06599814|ACTIVE_COMPARATOR|TheraCal Conventional group|Subsequent to controlling the bleeding, using a needle-tip syringe, gently apply TheraCal LC resin-modified calcium silicate (Bisco Inc., Schamburg, IL, USA) light-hardening paste to the exposed portion of the pulp in accordance with the manufacturer's recommendations for thickness (1 mm) and curing time (20 Seconds).
62822616|NCT06599814|ACTIVE_COMPARATOR|RetroMTA laser group|Consequent to controlling the bleeding, Diode laser is focused to the exposure sites before the placement of pulp capping materials. The hemostasis is obtained by the diode 808-nm, laser-assisted procedure (Picasso-AMD, USA) using 1.5 W, continuous wave, fiber diameter of 400 μm, non-initiated and in contact mode, Decontamination of the cavity is performed by 1 W, continuous wave, fiber diameter of 400 μm, non-initiated and in contact mode, tip angle set at 90°, an area with 2-mm diameter per second, power density 31.83 W/cm2, energy density 31.83 J/cm2 per second (28), and circular movement (23). The use of diode laser will be used for 1 to 3 Application of RetroMTA are occurred as RetroMTA Conventional group.
62822617|NCT06599814|ACTIVE_COMPARATOR|TheraCal laser group|Consequent to controlling the bleeding, Diode laser is focused to the exposure sites before the placement of pulp capping materials. The hemostasis is obtained by the diode 808-nm, laser-assisted procedure (Picasso-AMD, USA) using 1.5 W, continuous wave, fiber diameter of 400 μm, non-initiated and in contact mode, Decontamination of the cavity is performed by 1 W, continuous wave, fiber diameter of 400 μm, non-initiated and in contact mode, tip angle set at 90°, an area with 2-mm diameter per second, power density 31.83 W/cm2, energy density 31.83 J/cm2 per second (28), and circular movement (23). The use of diode laser will be used for 1 to 3 Application of TheraCal are occurred as TheraCal Conventional group.
62822618|NCT00632229|EXPERIMENTAL|Paliperidone|Recieves study medication called paliperidone
62822619|NCT00632229|PLACEBO_COMPARATOR|Pill placebo|Placebo comparator
62822620|NCT05777486|EXPERIMENTAL|TikTok Influencer Ads with Food|Participants randomized to view TikTok influencers' posts with food will view 4 ads associated with their condition and 2 filler ads, all of which are presented in counterbalanced order. They will report their reaction to the ads using the icons available on the TikTok platform (i.e. like, comment, or share). After viewing all of the TikTok ads, youth participants will complete the virtual snack selection task where they will see a virtual vending machine. All items will cost $2. Participants will be asked to select one snack and one beverage from the vending machine. After the snack selection task, participants will review the TikTok ads again and complete survey questions.
62822621|NCT05777486|EXPERIMENTAL|TikTok Influencer Ads without Food|Participants randomized to view TikTok influencers' posts without food will view 4 ads associated with their condition and 2 filler ads, all of which are presented in counterbalanced order. They will report their reaction to the ads using the icons available on the TikTok platform (i.e. like, comment, or share). After viewing all of the TikTok ads, youth participants will complete the virtual snack selection task where they will see a virtual vending machine. All items will cost $2. Participants will be asked to select one snack and one beverage from the vending machine. After the snack selection task, participants will review the TikTok ads again and complete survey questions.
62244853|NCT05589064|EXPERIMENTAL|Dietary intervention and nutritional supplements (group A)|Patients in group A will receive four consultations with a dietitian over eight weeks, in addition to conventional physiotherapy treatments. These patients will receive nutritional counselling and omega-3 (2500mg/day), vitamin D (2000 IU/day) and creatine monohydrate (10mg/day) supplements prescribed by their doctor.
62244854|NCT05589064|ACTIVE_COMPARATOR|Nutritional supplements (group B)|Patients in group B will be prescribed omega-3 (2500mg/day), vitamin D (2000 IU/day) and creatine monohydrate (10mg/day) supplements and receive physiotherapy treatments over eight weeks.
62244855|NCT05589064|OTHER|Physiotherapy treatment (control group)|Patients in the control group will receive physiotherapy treatments over eight weeks.
62244856|NCT03410836|EXPERIMENTAL|intravenous lidocaine (IVL)|Will receive during the colorectal surgery under General Anesthesia intravenous lidocaine bolus 1.5mg/kg at the beginning of anesthesia (induction) and 1.5mg/kg/h until the end of anesthesia.
62601513|NCT01768975|PLACEBO_COMPARATOR|Placebo gel|Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
62822622|NCT06589193|EXPERIMENTAL|HOCl|
62822623|NCT06589193|ACTIVE_COMPARATOR|CHX|
62822624|NCT06585098|EXPERIMENTAL|intervention group|The intervention group experienced game-based virtual reality application in addition to standard training and hybrid simulation.
62244857|NCT03410836|PLACEBO_COMPARATOR|Placebo|Will receive the same volume of normal saline for the entire duration of anesthesia.
62434969|NCT05681377|NO_INTERVENTION|Control group|After discontinuation of remimazolam administration, wait until the patient's consciousness is restored naturally without flumazenil administration.
62434970|NCT06528223|EXPERIMENTAL|PDAC|According to the PANDA output results, those with the highest probability of PDAC among nonPDAC, PDAC, and normal categories are categorized into the PDAC group.
62601514|NCT02079636|EXPERIMENTAL|Abemaciclib + Pemetrexed|150 milligram (mg) or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 500 milligrams/square meter (mg/m\^2) pemetrexed given intravenously (IV) over approximately 10 minutes on Day 1 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62822625|NCT06585098|NO_INTERVENTION|control group|The control group experienced standard training and hybrid simulation
62822626|NCT06279000|EXPERIMENTAL|Colchicine|The first dose of the IMP is administered in the evening prior to the surgical procedure. Administrations of the study drug follow a 1-0-1 schedule (colchicine 0.5 mg per intake). The last study drug is administered in the evening of the third postoperative day.
62822627|NCT06279000|PLACEBO_COMPARATOR|Control (Placebo)|"Patients in the control group will receive the same perioperative anaesthetic, surgical and medical treatment as patients in the experimental group, the sole difference being that patients will be given a placebo instead of the IMP colchicine.~The first dose of the placebo is administered in the evening prior to the surgical procedure. Administrations of the placebo follow a 1-0-1 schedule. The last placebo is administered in the evening of the third postoperative day."
62822628|NCT03038061|EXPERIMENTAL|Experimental group|Patients undergoing Laparoscopic Surgery
62041811|NCT06732934|EXPERIMENTAL|Basic Body Awareness Therapy Group|Participants will engage in 12 weeks of Basic Body Awareness Therapy (BBAT) three times a week. The exercises will include body scanning, stretching, strength accumulation, sound resonance, and midline orientation, supervised by an experienced physiotherapist. Each session lasts 40 minutes, with 5 minutes of meditation and a group feedback session after every exercise. The group will consist of a maximum of 10 participants.
62041812|NCT06732934|EXPERIMENTAL|Aerobic Exercise Group|Participants will undergo aerobic exercise on a treadmill, following ACSM guidelines. Exercise duration will start at 30 minutes in the first week and gradually increase to 45 minutes by the 12th week. The exercise intensity will be monitored using the target heart rate method (64-77% HRmax) and will be supervised by a physician. Heart rate monitoring will be done during the exercises, and participants will be asked to maintain their usual diet.
62822629|NCT05962541|EXPERIMENTAL|PPD-TURBT (no Re-TURBT)|Primary PDD-TURBT, not followed by Re-TURBT
62822630|NCT05962541|NO_INTERVENTION|WL TURBT plus Re-TURBT (Standard of Care)|Standard of care consisting in primary WL TURBT followed by WL Re-TURBT within 2 - 6 weeks from initial WL TURBT
62822631|NCT06030648|EXPERIMENTAL|IV-MSC for cALD (Early Disease/Bridge Therapy)|Patients with active, cerebral adrenoleukodystrophy (cALD) as a bridge to hematopoietic stem cell transplant or gene therapy.
62822632|NCT06030648|EXPERIMENTAL|IV-MSC for cALD (Advanced Disease)|Patients with active, cerebral adrenoleukodystrophy (cALD) who are too advanced for gene therapy or HSCT.
62822633|NCT05826314|EXPERIMENTAL|Experimental group 1 (adapted boxing)|Experimental boxing - The general structure of adapted boxing will include a 10-minute warm-up consisting of walking at a slow, self-selected speed, and at the same time joint rotation exercises; followed by 25-30 minutes of adapted boxing (consisting of non-contact activities, distributed in coordination and balance/footwork, shadow boxing-choreography (sequence of arm and leg movements that simulate an imaginary fight and punching bag), to end the session there will be a content fixation exercise, relaxation with gentle movements and breathing for 5 -10 minutes.
62822634|NCT05826314|ACTIVE_COMPARATOR|Experimental group 2 (multi-component training)|Sessions will be divided in 10 minutes warm-up (including slow walk, postural and mobility exercises for general activation, and stretching exercises), specific training (25-30 minutes, including balance/coordination training, strength, and aerobic exercises) and cool down 5 - 10 minutes (breathing and stretching exercises for the main worked joints and muscles) following the main guidelines recommended by the American College of Sports Medicine (4) and the WHO (3).
62822635|NCT05826314|NO_INTERVENTION|Control group|Participants from the control group will participate in all assessments moments, and will be asked to maintain their usual activities. At the end of the intervention period, the control group will be invited to participate in a physical activity program that takes place at the University.
62041813|NCT06732934|NO_INTERVENTION|Control Group|No intervention or recommendations will be provided to the control group.
62822636|NCT06592105||EVAR patient|
62041814|NCT03826160||Tesamorelin|Individuals who plan to initiate tesamorelin clinically
62041815|NCT03826160||No Treatment|Individuals who decline to initiate tesamorelin despite a clinical indication
62041816|NCT00850473|EXPERIMENTAL|Positron Emitting Image|Patient will have a PET/CT imaging study to determine cardiac stenosis, F-18 FDG and heparin/intralipid infusion and Contrast Dye.will be administered.
62041817|NCT05441163|EXPERIMENTAL|APA and nutrition program|
62041818|NCT05441163|NO_INTERVENTION|control group|
62244858|NCT00239226|EXPERIMENTAL|1. IAS pacing - study group|"Patients were first submitted to electrophysiological study to assess Delta CTos \> or \< 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (1) includes patients with Delta CTos \>50 ms and randomized IAS pacing.~IAS Pacing -Study Group: Patients with Delta CTos \>50 ms (study group) at the electrophysiologic study and randomized Interatrial Septum Pacing"
62434971|NCT06528223|NO_INTERVENTION|nonPDAC|According to the PANDA output results, those with the highest probability of nonPDAC among nonPDAC, PDAC, and normal categories are categorized into the nonPDAC group.
62822637|NCT05733832|NO_INTERVENTION|Control group|Patients in the usual care arm will receive standard follow-up care from their usual providers based on recommendations made by inpatient providers at the time of discharge from the hospital.
62822638|NCT05733832|ACTIVE_COMPARATOR|Transitional Liver Clinic (TLC)|Enrolled patients discharged during the experimental TLC intervention implementation period will receive a phone call from TLC staff within 2 business days of discharge followed by an in-person or video telehealth clinic visit with a hepatology APP within 14 days of discharge. TLC staff will provide additional care based on individual patient needs during the 30-day transitional period.
62822639|NCT06603662|ACTIVE_COMPARATOR|Intervention A - Prednisone|Subjects assigned to the Intervention A group will receive prednisone 50 mg once a day for 5 days, plus ibuprofen 600 mg every 8 hours for 5 days.
62822640|NCT06603662|ACTIVE_COMPARATOR|Intervention B - Dexamethasone|Subjects assigned to the Intervention B group will receive a single dose of dexamethasone 10 mg, plus ibuprofen 600 mg every 8 hours for 5 days.
62822641|NCT06603662|PLACEBO_COMPARATOR|Control - Placebo|Subjects assigned to the Control group will receive placebo once a day for 5 days, plus ibuprofen 600 mg every 8 hours for 5 days.
62822642|NCT01485029|EXPERIMENTAL|NP children|Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
62822643|NCT00441909|EXPERIMENTAL|1A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 8 hours
62822644|NCT00441909|PLACEBO_COMPARATOR|1B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 8 hours
62822645|NCT00441909|EXPERIMENTAL|2A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 4 hours
62822646|NCT00441909|PLACEBO_COMPARATOR|2B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 4 hours
62822647|NCT00441909|EXPERIMENTAL|3A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 2 hours
62822648|NCT00441909|PLACEBO_COMPARATOR|3B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 2 hours
62822649|NCT00441909|EXPERIMENTAL|4A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 0 hours
62822650|NCT00441909|PLACEBO_COMPARATOR|4B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 0 hours
62822651|NCT05223920|EXPERIMENTAL|Bomedemstat|Participants will receive bomedemstat daily for 169 days with additional treatment continuing in participants deriving clinical benefit.
62822652|NCT01394016|EXPERIMENTAL|Abemaciclib|"Participants received oral Abemaciclib administered on Days 1 through 28 of a 28-day cycle except in Cycle 1, where the study drug was administered as appropriate on Day -3 and then on Days 1 to 27. The treatment was continued until a discontinuation criterion was met or under Sponsor's discretion.~Participants belonging to different Parts received the study drug as specified below:~Part A: 50 mg/100 mg/150 mg/225 mg every 24 hours (Q24H) or 75mg/100 mg/150 mg/200 mg/275 mg every 12 hours (Q12H).~Parts B, C, D, and E: 150 mg/200 mg Q12H. Part F: 150 mg Q12H. Part G: 200 mg Q12H along with 500 mg Fulvestrant administered intramuscularly."
62822653|NCT05306899|ACTIVE_COMPARATOR|Ketamine infusion|Intravenous Ketamine
62822654|NCT05306899|PLACEBO_COMPARATOR|Placebo infusion|
62822655|NCT06591377|ACTIVE_COMPARATOR|Ticagrelor and aspirin arm|The ticagrelor arm will receive (a 180 mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90 mg twice daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
62822656|NCT06591377|ACTIVE_COMPARATOR|cilostazol and aspirin|The cilostazol arm will receive (a 200 mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
62041819|NCT05691478|ACTIVE_COMPARATOR|Efficacy Phase Arm A (MAP)|"Standard risk patients receive methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day induction cycles, followed by appropriate local control. Patients then receive consolidation with methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day cycles and methotrexate IV and doxorubicin IV for two additional 35-day cycles. Patients also undergo X-ray, CT, MRI, and PET or bone scintigraphy at diagnosis and additonal time points throughout the trial. All patients also undergo collection of blood samples during screening and on study."
62041820|NCT05691478|EXPERIMENTAL|Efficacy Phase Arm B (cabozantinib, MAP)|"Standard risk patients receive cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day induction cycles, followed by appropriate local control. Patients then receive consolidation with cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day consolidation cycles, and cabozantinib PO, methotrexate IV, and doxorubicin IV for two additional 35-day cycles. Patients then receive cabozantinib PO for six 28-day maintenance cycles. Patients also undergo X-ray, CT, MRI, and PET or bone scintigraphy at diagnosis and additonal time points throughout the trial. All patients also undergo collection of blood samples during screening and on study."
62434972|NCT06528223|NO_INTERVENTION|Normal|According to the PANDA output results, those with the highest probability of Normal among nonPDAC, PDAC, and normal categories are categorized into the Normal group.
62434973|NCT03994588|ACTIVE_COMPARATOR|study arm|In this arm a light weight, wide pore, soft polypropylene mesh will be used for intraperitoneal hernia repair
62822657|NCT05823363|EXPERIMENTAL|Exparel and Bupivacaine Group|The participants in this group will receive 10 ml of xxparel and 10 ml of bupivacaine in the vaginal cuff
62822658|NCT05823363|ACTIVE_COMPARATOR|Bupivacaine Only Group|This group will receive 20ml of bupivicaine in the vaginal cuff
62822659|NCT06587607|EXPERIMENTAL|VA CALM|This group will receive the VA CALM mindfulness programming.
62822660|NCT05294978||Patients|-Availability of macular optical coherence tomography (OCT)
62822661|NCT05294978||Controls|-Availability of macular optical coherence tomography (OCT)
62822662|NCT02867436|EXPERIMENTAL|Gluten-free diet|Gluten-free diet
62244859|NCT00239226|EXPERIMENTAL|2. IAS pacing-control group|"(Delta CTos\<50ms)~Patients were first submitted to electrophysiological study to assess Delta CTos \> or \< 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (2) includes patients with Delta CTos \<50 ms and randomized IAS pacing.~IAS Pacing -Control Group: Patients with Delta CTos \<50 ms (control group) at the electrophysiologic study and randomized Interatrial Septum Pacing"
62244860|NCT00239226|ACTIVE_COMPARATOR|3. RAA Pacing - study group|"Patients were first submitted to electrophysiological study to assess Delta CTos \> or \< 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (3) includes patients with Delta CTos \>50 ms and randomized Right Atrial Appendage pacing.~RAA Pacing -Study Group: Patients with Delta CTos \>50 ms (study group) at the electrophysiologic study and randomized Right Atrial Appendage pacing"
62822663|NCT02867436|NO_INTERVENTION|Conventional diet|Conventional diet
62822664|NCT06103500|EXPERIMENTAL|Clinical Decision Support Algorithm for Empiric Antibiotics in Sepsis|The planned intervention consists of a pharmacist-facilitated clinical decision support intervention, where pharmacists provide options and recommendations on empiric sepsis antibiotic selection to hospital providers.
62822665|NCT06103500|NO_INTERVENTION|Standard of Care|Non-intervention group. No decision support is provided. Patient care is routine.
62244861|NCT00239226|ACTIVE_COMPARATOR|4. RAA Pacing - control group|"Patients were first submitted to electrophysiological study to assess Delta CTos \> or \< 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (4) includes patients with Delta CTos \<50 ms and randomized Right Atrial Appendage pacing.~RAA Pacing -Control Group: Patients with Delta CTos \<50 ms (control group) at the electrophysiologic study and randomized Right Atrial Appendage pacing"
62822666|NCT01869907|PLACEBO_COMPARATOR|Placebo|Placebo, once daily
62822667|NCT01869907|ACTIVE_COMPARATOR|Amitriptyline|Amitriptyline 25mg, once daily
62822668|NCT01869907|ACTIVE_COMPARATOR|Minocycline|Minocycline 100mg, once daily
62822669|NCT02480972|OTHER|Magnetic resonance imaging|multiparametric MRI including perfusion, diffusion, MR fat quantification and MR elastography
62822670|NCT06171009|ACTIVE_COMPARATOR|Pain Coping Information|
62244862|NCT05966662|EXPERIMENTAL|Single-Arm|Subjects with de novo, calcified coronary artery lesions presenting with stable, unstable, or silent ischemia that are suitable for percutaneous coronary intervention (PCI).
62244863|NCT02887027|EXPERIMENTAL|Exercise Group 1|Participants assigned to this group will complete a baseline period of 8 days and an Exercise4Mood Intervention period of 21 days.
62244864|NCT02887027|EXPERIMENTAL|Exercise Group 2|Participants assigned to this group will complete a baseline period of 11 days and an Exercise4Mood Intervention period of 18 days.
62244865|NCT02887027|EXPERIMENTAL|Exercise Group 3|Participants assigned to this group will complete a baseline period of 15 days and an Exercise4Mood Intervention period of 14 days.
62434974|NCT03994588|ACTIVE_COMPARATOR|control|in this arm a double mesh (vicryl + polypropylene mesh) will be used for intraperitoneal hernia repair.
62822671|NCT06171009|EXPERIMENTAL|Mindful Pain Management|
62822672|NCT06590909|ACTIVE_COMPARATOR|A prospective comparative split face study|
62822673|NCT04340505||Active uveitis patients.|Any patient with a diagnosis of uveitis, who is deemed active or recently active (6 months) by a uveitis specialist and requires an injectable fluocinolone acetonide implant to treat their inflammation.
62822674|NCT05433662||Veterans|Veterans will be ages 65 and older, cognitively intact, and experiencing pandemic-related stress.
62822675|NCT04124848||Somali Descent|Study participants who are of Somali origin.
62822676|NCT04124848||Non-Somali Descent|Study participants who are not of Somali origin.
62822677|NCT05148156|EXPERIMENTAL|Urolift|This is a single-arm study involving 1 year of follow-up. Study intervention involves a one-time administration of Urolift prior to SBRT for prostate cancer treatment.
62434975|NCT03845478|ACTIVE_COMPARATOR|Control Group (CG)|Education, modifying diet and physical activity
62041821|NCT05691478|ACTIVE_COMPARATOR|Efficacy Phase Arm C (MAP)|"High risk patients receive methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day induction cycles, followed by appropriate local control. Patients then receive consolidation with methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day cycles and methotrexate IV and doxorubicin IV for two additional 35-day cycles. Patients also undergo X-ray, CT, MRI, and PET or bone scintigraphy at diagnosis and additonal time points throughout the trial. All patients also undergo collection of blood samples during screening and on study."
62244866|NCT06734273|EXPERIMENTAL|SG-T: sleeve gastrectomy with tirzepatide|In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months after surgery they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery.
62244867|NCT06734273|ACTIVE_COMPARATOR|SG-A: sleeve gastrectomy alone|In this study the control group (n=21) are patients who will undergo sleeve gastrectomy alone.
62822678|NCT06559267|ACTIVE_COMPARATOR|Remaking Recess|Remaking Recess is a school-based social engagement intervention designed to enhance elementary school contextual factors to better support peer engagement during recess. Remaking Recess is delivered to educators through direct training and in vivo coaching by a certified Remaking Recess Coach.
62822679|NCT06559267|EXPERIMENTAL|TEAM|Schools that are randomized to the TEAM condition will receive an additional implementation support intervention. TEAM will leverage existing human resources in the school to specifically focus on developing an implementation blueprint to foster a supportive implementation context for paraeducators to use Remaking Recess.
62822680|NCT06587126||Children with Cystic Fibrosis|Childrens ages 1-18 with a diagnosis of CF based on 2 known cystic fibrosis transmembrane conductance regulator (CFTR) mutations and/or sweat chloride \>60 mmol/L, thought to be clinically stable at the time of study consent.
62822681|NCT06587126||Healthy Controls|Children ages 1-18 with no underlying respiratory of cardiac conditions including chronic cough, CF, asthma, obstructive sleep apnea, or congenital heart disease thought to cause chronic nighttime symptoms.
62822682|NCT06056297|EXPERIMENTAL|Mavorixafor|Participants will receive mavorixafor orally once daily starting from Day 1 through Week 52.
62822683|NCT06056297|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo to match mavorixafor orally once daily starting from Day 1 through Week 52.
62822684|NCT01650532|EXPERIMENTAL|Yoga Condition|Participants will be instructed to learn yoga postures as well as yoga based breathing and meditative practices by certified yoga instructors. Primary Hatha yoga postures will be performed using props like yoga mats, blocks, belts and blankets. Classes will be held 3 times a week for 8 weeks.
62822685|NCT01650532|ACTIVE_COMPARATOR|Stretching Condition|Exercises focusing on stretching and strengthening for all muscle groups will be performed at one-hour long sessions held 3 times a week for 8 weeks. Classes are led by trained exercise specialists.
62822686|NCT06382727|EXPERIMENTAL|Intervention group: Continuation of enteral nutrition (EN) prior to extubation|Maintenance of EN at the same hourly rate until the point of extubation. Maximal suction of the EN tube prior to extubation will take place.
62822687|NCT06382727|NO_INTERVENTION|Control group: Cessation of EN prior to extubation|Cessation of EN at least 4-6 hours prior to the point of extubation. Maximal suction of the EN tube prior to extubation will take place.
62822688|NCT04370691||JETi™ Hydrodynamic Thrombectomy System|Subjects who were treated with JETi™ Hydrodynamic Thrombectomy System will be included.
62601515|NCT02079636|EXPERIMENTAL|Abemaciclib + Gemcitabine|150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 1250 milligram/square meter (mg/m\^2) gemcitabine given intravenously over approximately 30 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62822689|NCT02731469|EXPERIMENTAL|BCD-131, 0.05 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.05 mcg/kg subcutaneously
62822690|NCT02731469|EXPERIMENTAL|BCD-131, 0.15 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.15 mcg/kg subcutaneously
62822691|NCT02731469|EXPERIMENTAL|BCD-131, 0.40 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.40 mcg/kg subcutaneously
62822692|NCT02731469|EXPERIMENTAL|BCD-131, 1.05 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 1.05 mcg/kg subcutaneously
62822693|NCT02731469|EXPERIMENTAL|BCD-131, 1.70 mcg/kg SC|Healthy volunteers will receive BCD-131 in a dose 1.70 mcg/kg subcutaneously
62822694|NCT02731469|EXPERIMENTAL|BCD-131, 2.25 mcg/kg SC|Healthy volunteers will receive BCD-131 in a dose 2.25 mcg/kg subcutaneously
62822695|NCT02731469|EXPERIMENTAL|BCD-131, 4.45 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 4.45 mcg/kg subcutaneously
62822696|NCT02731469|ACTIVE_COMPARATOR|Mircera®, 1.20 mcg/kg subcutaneously|Healthy volunteers will receive Mircera in a dose 1.20 mcg/kg subcutaneously
62822697|NCT02731469|ACTIVE_COMPARATOR|Aranesp®, 0.45 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.45 mcg/kg subcutaneously
62822698|NCT02731469|EXPERIMENTAL|BCD-131, optimal dose, intravenously|Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial intravenously
62822699|NCT02731469|EXPERIMENTAL|BCD-131, optimal dose, subcutaneously|Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial subcutaneously
62822700|NCT04476862||Cerliponase alfa patients|Patients who are currently on or plan to start taking cerliponase alfa within 60 days of signing the study informed consent form.
62822701|NCT04521413|EXPERIMENTAL|A1: Monotherapy Escalation|Dose escalation arm with CFI-402411. CFI-402411 is administered orally once daily.
62822702|NCT04521413|EXPERIMENTAL|A2: Monotherapy Biomarker|Dose escalation biomarker arm with CFI-402411. CFI-402411 is administered orally once daily.
62601516|NCT02079636|EXPERIMENTAL|Abemaciclib + Ramucirumab|150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Day 1 or 8 to 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62244868|NCT06044493|EXPERIMENTAL|Myreptic-N Tablet|Mycophenolate sodium
62601517|NCT02079636|EXPERIMENTAL|Abemaciclib + LY3023414|100 mg or 150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 100, 150, or 200 mg LY3023414 given orally every 12 hours on Days 1 through 21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62244869|NCT06044493|ACTIVE_COMPARATOR|Myrept Tablet/Capsule|Mycophenolate mofetil
62244870|NCT02817230||Patients|Patients referred to the out-patient clinic with LDL levels \>4.9 mmol/l
62244871|NCT02817230||Controls|Matched normocholesterolemic control subjects
62244872|NCT04987489|EXPERIMENTAL|Etavopivat 400 mg daily - SCD with transfusions|Patients with sickle cell disease on chronic red blood cell transfusions
62434976|NCT03845478|EXPERIMENTAL|Intervention Group (IG)|Education and modifying diet and physical activity with prescription and goal setting
62601518|NCT02079636|EXPERIMENTAL|Abemaciclib + Pembrolizumab|100 mg or 150 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 200 mg pembrolizumab given intravenously over approximately 30 minutes on day 1 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62601519|NCT04505384|EXPERIMENTAL|Left bundle branch pacing|Left bundle branch pacing
62601520|NCT04505384|ACTIVE_COMPARATOR|Biventricular pacing|Biventricular pacing
62244873|NCT04987489|EXPERIMENTAL|Etavopivat 400 mg daily - Thalassemia with transfusions|Patients with thalassemia on chronic red blood cell transfusions
62244874|NCT04987489|EXPERIMENTAL|Etavopivat 400 mg daily - Thalassemia|Patients with thalassemia not on chronic red blood cell transfusions
62244875|NCT06561386|EXPERIMENTAL|Arm A|
62244876|NCT06561386|ACTIVE_COMPARATOR|Arm B|
62244877|NCT02550522|EXPERIMENTAL|BCI|Brain-computer interface (BCI) platform including two implanted remotely powered ElectroCorticoGraph (ECoG) recording devices and an exoskeleton
62244878|NCT05458024|ACTIVE_COMPARATOR|Ergocalciferol (Vitamin D2)|300,000 international units (IUs) of Ergocalciferol in 6 50,000 IU capsules. These will be given in a single dose prior to discharge from the Emergency Department.
62244879|NCT05458024|PLACEBO_COMPARATOR|Ergocalciferol placebo|Inert substance will be administered in 6 capsules indistinguishable from the 50,000 IU Ergocalciferol capsules administered in the active treatment arm.
62244880|NCT06053749||Pregnancies exposed to IFNB only|With dispensed IFNB, no other MS disease modifying drugs (MSDMDs) during the pre-pregnancy period or during pregnancy
62244881|NCT06053749||Pregnancies unexposed to IFNB nor other MSDMDs|No dispensed IFNB nor any other MSDMDs during the pre-pregnancy period nor any time during pregnancy
62244882|NCT06053749||Pregnancies exposed to IFNB (regardless of other MSDMDs)|With dispensed IFNB, regardless of other MS disease modifying drugs (MSDMDs) during the pre-pregnancy period or during pregnancy
62434977|NCT04376489|EXPERIMENTAL|Brief cognitive/behavioral strategies|
62434978|NCT04376489|EXPERIMENTAL|Effortful self-regulatory activities|
62434979|NCT04376489|NO_INTERVENTION|No activities|
62822703|NCT04521413|EXPERIMENTAL|A3: Monotherapy Expansion|Dose expansion arm with CFI-402411 at its recommended phase 2 dose.
62822704|NCT04521413|EXPERIMENTAL|B1: Combination Escalation|Dose escalation arm with CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).
62244883|NCT06053749||Pregnancies unexposed to IFNB (regardless of other MSDMDs)|"No dispensed IFNB during the pre-pregnancy period nor any time during pregnancy, regardless of other MSDMDs~Outcomes:"
62244884|NCT01984944|OTHER|Autistic Patient|"* 50 adults~* 25 childs"
62244885|NCT01984944|OTHER|Controls|"* 50 adults~* 25 childs"
62244886|NCT06708520|EXPERIMENTAL|Renal impairement mild|
62244887|NCT06708520|EXPERIMENTAL|Renal impairement moderate|
62244888|NCT06708520|EXPERIMENTAL|Renal impairement severe|
62244889|NCT06708520|EXPERIMENTAL|Renal normal functions|
62244890|NCT06735157|SHAM_COMPARATOR|Sham rTMS|
62244891|NCT06735157|ACTIVE_COMPARATOR|Real rTMS|
62244892|NCT01107340|OTHER|AMIStem Hip System|Patients who comply with the protocol and received an AMIStem femoral component.
62244893|NCT04936243|EXPERIMENTAL|FOLLOW UP VISIT-TELEMEDICINE|After initial in-person routine followup care, participants will be randomly assigned to receive telemedicine care delivery for their subsequent follow up appointment. Participants will complete a survey after each visit.
62244894|NCT04936243|EXPERIMENTAL|FOLLOW UP VISIT-FACE TO FACE|After initial in-person routine followup care, participants will be randomly assigned to receive face-to-face care delivery for their subsequent follow up appointment. Participants will complete a survey after each visit.
62244895|NCT05790850|NO_INTERVENTION|Control|Usual preoperative care prior to radical cystectomy
62244896|NCT05790850|EXPERIMENTAL|Intervention|Preoperative pre-habilitation
62244897|NCT05900050|EXPERIMENTAL|VS-01 on top of SOC (Active Treatment Group)|Patients randomized to Active Treatment group will receive VS-01 on top of SOC
62244898|NCT05900050|OTHER|SOC (Control Group)|Patients randomized to Control group will receive SOC defined as the standard medical management of patients with decompensated cirrhosis and ACLF
62434980|NCT01280864||Interstitial Cystitis Alone|
62434981|NCT01280864||Irritable Bowel Syndrome Alone|
62434982|NCT01280864||Healthy Controls|
62434983|NCT01122472|EXPERIMENTAL|Lenalidomide|Lenalidomide daily for 3 weeks every 4 weeks for 24 months
62434984|NCT01122472|PLACEBO_COMPARATOR|Placebo|Placebo daily for 3 weeks every 4 weeks for 24 months
62434985|NCT02057510||Patients receiving head and neck RT|No intervention
62601521|NCT03228316|EXPERIMENTAL|the study group one|20 patients with superior hypogastric plexus block
62601522|NCT03228316|EXPERIMENTAL|the study group two|20 patients with superior hypogastric plexus block combined to pulsed radiofrequency on sacral nerve roots 2,3 and 4
62601523|NCT01115556|EXPERIMENTAL|Lucentis 2.0 mg|Lucentis 2.0 mg
62244899|NCT04090853|OTHER|Patient Treatment Group|Up to three Diode and Radio Frequency treatments and up to three additional radio frequency treatments will be performed per patient at the discretion of the principal investigator. Diode treatments will be spaced six weeks apart while the radio frequency treatments will be spaced between 2-3 weeks apart.
62244900|NCT06616298|EXPERIMENTAL|Older patients with advanced cancer|Older adults with advanced cancer from the University of Colorado Hospital being discharged to skilled nursing facilities (SNF).
62244901|NCT06616298|EXPERIMENTAL|Caregivers of older patients with advanced cancer|Caregivers of older adults with advanced cancer from the University of Colorado Hospital being discharged to skilled nursing facilities.
62244902|NCT06616298|NO_INTERVENTION|Control Arm|Control arm participants will receive usual care. Patients will interact with SNF staff and involved providers who may refer them to palliative care or hospice like previous rigorous palliative care trials.
62244903|NCT02253368|ACTIVE_COMPARATOR|Sleep Arm 1|Sleep Arm 1
62244904|NCT02253368|ACTIVE_COMPARATOR|Sleep Arm 2|Sleep Arm 2
62244905|NCT06007898|EXPERIMENTAL|Parent self-help psychological resource|A self-help psychological resource will be provided for parents to use with their CYP in the home.
62244906|NCT06007898|NO_INTERVENTION|Wait list control|Parents randomised to the control arm will be put on the waiting list (wait-list controls) to receive the group intervention after they have completed their final follow-up at 2 months.
62244907|NCT03435016|OTHER|Diagnosis|
62244908|NCT03525535||Pulmonary embolism|data from routine care will be collected for patient eligible and willing to participate
62244909|NCT05667285||BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System|Subject implanted with BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System in stent implantation operation.
62822705|NCT04521413|EXPERIMENTAL|B2: Combination Expansion|Dose expansion arm with the recommended phase 2 dose of CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).
62244910|NCT06444217|EXPERIMENTAL|Huntington's patient|skin biopsy
62244911|NCT05928286||The test group|Standard therapy + Remaxol
62244912|NCT05928286||The control group|Standard therapy
62244913|NCT03220477|EXPERIMENTAL|pembrolizumab plus guadecitabine and mocetinostat|Pembrolizumab given IV; guadecitabine given SQ, mocetinostat given PO.
62244914|NCT05206695|EXPERIMENTAL|Multi-condition Pathway Intervention|The multi-condition pathway intervention consists of pathways clinicians select from to guide the care of children with asthma, pneumonia, or bronchiolitis. Key implementation strategies include audit and feedback, plan-do-study-act cycles, and electronic order sets.
62434986|NCT03503656||CompuFlo|All the consecutive patients undergoing to an epidural catheter placement in Gynecological and Obstetric setting
62822706|NCT04236817|EXPERIMENTAL|Pre-packed blisters for distribution of medications|Patients in the intervention group received prescriptions pre-packaged in individual packets that were delivered by the pharmacy.
62244915|NCT05206695|NO_INTERVENTION|Standard of Care|Hospitals randomized to the control arm will not receive the multi-condition pathway intervention or any external supports for implementation. They will continue to provide current standards of care.
62244916|NCT04723147|EXPERIMENTAL|Carbidopa Levodopa followed by Placebo|Participants will receive first Carbidopa Levodopa at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA with a starting dose of 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day; and then placebo.
62244917|NCT04723147|EXPERIMENTAL|Placebo followed by Carbidopa Levodopa|Participants will receive first placebo, and then Carbidopa Levodopa (L-DOPA) at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA with a starting dose of 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day.
62244918|NCT05751434|EXPERIMENTAL|Participants Assigned to Exercise Therapy|Participants with histologically confirmed localized prostate cancer undergoing active surveillance
62244919|NCT05751434|NO_INTERVENTION|Participants Assigned to Usual Care|Participants with histologically confirmed localized prostate cancer undergoing active surveillance
62244920|NCT05901246|EXPERIMENTAL|PS-containing dietary supplement|Sachet containing a powdered ingredient source of microencapsulated free plant sterols (2,25 g ingredient/day)
62244921|NCT05901246|PLACEBO_COMPARATOR|Placebo|Sachet containing the excipients of the ingredient (2,25 g placebo/day)
62244922|NCT05440409||1|Retrospective chart review of children and adults with cancer enrolled on immunotherapy treatment protocols
62244923|NCT06734429||Urinary Artificial Sphincter (UAS) in Children|Patients aged under 18 years old with UAS
62434987|NCT01127191||Military|
62601524|NCT01115556|ACTIVE_COMPARATOR|LUCENTIS 0.5 mg|
62601525|NCT01576276|EXPERIMENTAL|Morphine condition|
62244924|NCT04977869|ACTIVE_COMPARATOR|RIC+Standard medical treatment|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days after endovascular thrombectomy. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2018.
62822707|NCT04236817|PLACEBO_COMPARATOR|Routine distribution of medications|Patients in the control group continued to receive medications from pharmacies as they did prior to enrollment.
62822708|NCT06602999|EXPERIMENTAL|Supportive Care (Instacart voucher, nutrition navigation)|Participation receive a booklet on nutrition and physical activity for cancer survivors and 1 Instacart grocery delivery voucher to use over 4 weeks on study. Participation also receive nutrition navigation phone calls for assistance with following nutrition guidelines and ordering groceries on Instacart every week for 4 weeks.
62822709|NCT05922878|EXPERIMENTAL|ALTO-300|Participants will receive ALTO-300 capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open-label (OL) treatment period will receive ALTO-300 capsule once daily in the evening from OL baseline until the end of OL period/early termination visit (Up to 8 weeks).
62822710|NCT05922878|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period.
62244925|NCT04977869|PLACEBO_COMPARATOR|Sham RIC+Standard medical treatment|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days after endovascular thrombectomy. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2018.
62244926|NCT06736171|EXPERIMENTAL|Stroke RE|Participants in the stroke RE group will participate 3-4 weeks, 2-3 times a week for a total of 9 robotic exoskeleton gait training sessions provided by a trained, licensed physical therapist.
62244927|NCT06736171|ACTIVE_COMPARATOR|Stroke SOC|Participants in the stroke SOC group will participate 3-4 weeks, 2-3 times a week for a total of 9 standard of care gait training sessions provided by a trained, licensed physical therapist.
62244928|NCT04408820||Roxadustat|Participants will receive oral dose of roxadustat.
62822711|NCT06526676|EXPERIMENTAL|Subjects with short neck infrarenal, juxtarenal, suprarenal and extent IV TAA|Subjects will have their aortic aneurysms repaired using an investigational physician-modified graft
62244929|NCT06601660|EXPERIMENTAL|Control|Women who will be assessed in the morning period from 7 am to 10 am and in the evening from 6 pm to 9 pm, who will not receive intervention with combined physical training.
62244930|NCT06601660|EXPERIMENTAL|Morning Physical Training|Women who will perform the combined physical training at morning from 7 am to 10 am.
62244931|NCT06601660|EXPERIMENTAL|Night Physical Training|Women who will perform the combined physical training at night from 6 pm to 9 pm.
62244932|NCT06735612||Patients during the RSV season|
62244933|NCT06735612||Patients outside the RSV season|
62244934|NCT02978534||Quetiapine|Patients taking quetiapine during pregnancy are eligible to participate in the study. Their dose and plasma concentration levels of quetiapine will be monitored throughout pregnancy and up to three months postpartum.
62244935|NCT05129241||Cohort 1|Patients for whom the treating physician has decided to initiate lipid-lowering treatment with the PRALUENT® 2 ml SYDNEY auto-injector, irrespective of participation in the study
62244936|NCT04276922|EXPERIMENTAL|Visual Arts Group|Visual Arts group - sketch journals
62244937|NCT04276922|EXPERIMENTAL|Music Group|Music group involves music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making.
62244938|NCT04276922|EXPERIMENTAL|Dance/Movement Group|Dance/Movement group - movement check-in, gentle physical warm-up, and then either a structured or improvisational movement process.
62244939|NCT04276922|EXPERIMENTAL|Writing/Poetry Group|Writing/Poetry group uses writing workshops using integral elements of good writing.
62244940|NCT04276922|EXPERIMENTAL|Control Group|Surveys at baseline and 12 weeks later.
62244941|NCT06736340|EXPERIMENTAL|Hepatic imparement mild|
62434988|NCT04104711|EXPERIMENTAL|Home visits+Health education group|"Home visits were paid 3 times at 3-month intervals. After the home visits started, reminder messages supporting the home visit process were sent at two-week intervals.~Nursing interventions were applied in accordance with the subscales of the Health Belief Model by taking into account the individual differences of the participants and were performed within the scope of the basic dimensions of diabetes management such as nutrition, exercise, medication management, oral care and foot care. In addition, the importance of annual monitoring of HBA1c, blood lipid, albumin/ creatinine levels, fundus examination, blood pressure monitoring, sleep hygiene, avoidance of smoking and alcohol was also explained."
62434989|NCT04104711|NO_INTERVENTION|No nursing intervention group|"The participants in the control group who have standart care by other health services were contacted 3 times at 3-month intervals through telephone calls, and were applied the data collection tools only. They have no nursing intervention by the researcher.~At the end of the study, for ethical statement the participants in the control group were given health training and the training booklet was distributed to them."
62434990|NCT02958878|EXPERIMENTAL|A|Tamsulosin 0.4mg given the night before surgery and another dose the day of surgery in the morning.
62434991|NCT02958878|PLACEBO_COMPARATOR|B|Placebo medication given the night before surgery and another dose the day of surgery in the morning
62601526|NCT01576276|EXPERIMENTAL|Ketorolac condition|
62601527|NCT04742660|PLACEBO_COMPARATOR|group R|Participants are administered a dose of 0.3mg of ramosetron (conventional antiemetics) intravenously followed by continuous infusion of 120mL normal saline at a rate of 10mL/min.
62601528|NCT04742660|ACTIVE_COMPARATOR|group G|participants are administered a dose of 0.3mg of ramosetron followed by continuous infusion of mixture of 20mL glycyrrhizin and 100mL normal saline (total 120mL) at a rate of 10mL/min.
62601529|NCT06197503|EXPERIMENTAL|Conduction system pacing|"Lead placed in the His-Purkinje system (His or left bundle branch) in order to achieve QRS shortening and physiologic pacing.~Crossover from physiological pacing to right ventricular pacing will be allowed in case of failed His bundle pacing or left bundle branch pacing."
62601530|NCT06197503|ACTIVE_COMPARATOR|Right ventricular pacing|Lead placed in the right ventricle (conventional pacing).
62434992|NCT01565382|EXPERIMENTAL|Independent, blinded reader trainees|Seven practicing nuclear medicine physicians with no prior training in reading scans from florbetapir-PET, or other amyloid imaging agents.
62041822|NCT05691478|EXPERIMENTAL|Efficacy Phase Arm D (cabozantinib, MAP)|"High risk patients receive cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day induction cycles, followed by appropriate local control. Patients then receive consolidation with methotrexate IV, doxorubicin IV, and cisplatin IV for one 35-day cycle, followed by cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV for one 35-day cycle and cabozantinib PO, methotrexate IV, and doxorubicin IV for two additional 35-day cycles. Patients then receive cabozantinib PO for six 28-day maintenance cycles. Patients also undergo X-ray, CT, MRI, and PET or bone scintigraphy at diagnosis and additonal time points throughout the trial. All patients also undergo collection of blood samples during screening and on study."
62041823|NCT05691478|EXPERIMENTAL|Feasibility phase (cabozantinib, MAP)|"Patients receive cabozantinib orally (PO), methotrexate intravenously (IV), doxorubicin IV, and cisplatin IV for two 35-day induction cycles. Patients are then considered for appropriate local control. Then they receive consolidation with methotrexate IV, doxorubicin IV, and cisplatin IV for one 35-day cycle, followed by cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV for one 35-day cycle, and cabozantinib PO, methotrexate IV, and doxorubicin IV for two 35-day cycles. Patients then receive cabozantinib PO for six 28-day maintenance cycles."
62041824|NCT06235801|EXPERIMENTAL|Dose Escalation Phase 1/Phase 2|Participants who are enrolled in Part 1, the dose of momelotinib you receive will depend on when you join this study. Participants you are enrolled in Part 2, you will receive momelotinib at the recommended dose that was found in Part 1. All participants will receive the same dose level of gilteritinib. Cycle 1 will be 35 days in length. Momelotinib will be administered once daily by mouth on days 1-35. Gilteritinib will be administered once daily by mouth on days 8-35. Cycles 2 and beyond will be 28 days in length. Momelotinib and gilteritinib will be administered once daily by mouth on days 1-28.
62041825|NCT06310291|PLACEBO_COMPARATOR|Matched Placebo (SAD)|2 placebo comparators; 1 for each part of the study
62041826|NCT06310291|EXPERIMENTAL|VTP-1000 Dose 1 (SAD)|3 dose levels in SAD and MAD parts of trial
62041827|NCT06310291|EXPERIMENTAL|VTP-1000 Dose 2 (SAD)|3 dose levels in SAD and MAD parts of trial
62041828|NCT06310291|EXPERIMENTAL|VTP-1000 Dose 3 (SAD)|3 dose levels in SAD and MAD parts of trial
62041829|NCT06310291|PLACEBO_COMPARATOR|Matched Placebo (MAD)|2 placebo comparators; 1 for each part of the study
62041830|NCT06310291|EXPERIMENTAL|VTP-1000 Dose 1 (MAD)|3 dose levels in SAD and MAD parts of trial
62244942|NCT06736340|EXPERIMENTAL|Hepatic imparement moderate|
62244943|NCT06736340|EXPERIMENTAL|Hepatic imparement severe|
62244944|NCT06736340|EXPERIMENTAL|Hepatic normal functions|
62434993|NCT06267547|EXPERIMENTAL|HAIL Online Platform + Fit and Strong! Program|Participants (N=60) will be recruited from two racially diverse churches or senior centers (30 participants per church/center) to examine the efficacy of the HAIL Online platform + F\&S! program for older adults in black communities. Participants will complete the 8-week F\&S! exercise program (with access to the adjunct HAIL online platform), which will be delivered in-person as well as remote, and then continue to use the HAIL online platform during the 3-mo follow-up.
62434994|NCT06267547|ACTIVE_COMPARATOR|Fit and Strong! Program|Participants (N=60) will be recruited from two racially diverse churches or senior centers (30 participants per church/center) to examine the feasibility and acceptability of the HAIL Online platform. Participants will complete the 8-week F\&S! exercise program (without access to the adjunct HAIL online platform), which will be delivered in-person as well as remote, and then complete the 3-mo follow-up.
62434995|NCT05456828|EXPERIMENTAL|ASKG712|Single or multiple ascending dose of ASKG712 by intravitreal injection
62434996|NCT00879554|EXPERIMENTAL|1|
62434997|NCT02749682||constipation & hernia group|The effect of constipation on study group whether there is a correlation between subgroups of operated patients on the view of direct and indirect hernias(Nyhuss classification).
62601531|NCT02494375|EXPERIMENTAL|Sleep and glucose assessement.|
62601532|NCT02873572|EXPERIMENTAL|online poker gamblers|Recruitment by forums of online poker gamblers: an explanation of the research is sent with the dedicated link of the research.
62601533|NCT02873572|EXPERIMENTAL|casino gamblers|Recruitment to the casino gates: an explanation of the research is sent with the dedicated e-link of the research and they could answer directly to the questionnaire (1st step) on sites.
62601534|NCT02873572|EXPERIMENTAL|MMORPG gamers|Recruitment by forums of MMORPG (as guilds): an explanation of the research is sent with the dedicated link of the research.
62601535|NCT02873572|EXPERIMENTAL|no gamer subjects|Recruitment by poster.
62601536|NCT03129282|NO_INTERVENTION|Control|"Participants allocated to the control group will receive treatment as usual for cardiac rehabilitation"
62601537|NCT03129282|ACTIVE_COMPARATOR|Intervention|"Participants allocated to the intervention group will receive treatment as usual for cardiac rehabilitation plus the home-based metacognitive therapy (Home-MCT)"
62601538|NCT02719938|EXPERIMENTAL|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
62822712|NCT06526676|EXPERIMENTAL|Subjects with thoracoabdominal aortic aneurysms|Subjects will have their aortic aneurysms repaired using an investigational physician-modified graft
62041831|NCT06310291|EXPERIMENTAL|VTP-1000 Dose 2 (MAD)|3 dose levels in SAD and MAD parts of trial
62041832|NCT06310291|EXPERIMENTAL|VTP-1000 Dose 3 (MAD)|3 dose levels in SAD and MAD parts of trial
62041833|NCT06346899||Group L: Lanadelumab|Participants with HAE who have used only lanadelumab during the study-level retrospective observation period will be observed retrospectively from the start date of the participant-level overall baseline period until the end of participant-level retrospective observation period.
62601539|NCT02719938|NO_INTERVENTION|Control|Usual care.
62601540|NCT04940611||Participants With CPF-CD|Participants diagnosed with CPF-CD will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.
62601541|NCT04940611||Participants With CD-RVF|Participants diagnosed with CD-RVF will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.
62601542|NCT04940611||Participants With CCF|Participants diagnosed with CCF will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.
62601543|NCT04935840|EXPERIMENTAL|FertyBiotic Pregnancy|Participants received FertyBiotic Pregnancy one capsule a day
62822713|NCT06526676|EXPERIMENTAL|Subjects with urgent or emergent aneurysms|Subjects will have their aortic aneurysms repaired using an investigational physician-modified graft
62601544|NCT04935840|PLACEBO_COMPARATOR|Control|Participants received 400 mcg of folic acid once a day
62601545|NCT03962231|ACTIVE_COMPARATOR|Rotator Cuff Unloading Exercise Program|Patients in this group will perform semi-closed kinetic chain elevation exercises, deltoid re-education exercises, assisted arm elevation and scapula control exercises.
62601546|NCT03962231|ACTIVE_COMPARATOR|Rotator Cuff Loading Exercise Program|Patients in this group will perform conventional exercises with focus on lateral rotation, medial rotation and arm elevation.
62041834|NCT06346899||Group I: Icatibant|Participants with HAE who have used only icatibant during the study-level retrospective observation period will be observed retrospectively from the start date of the participant-level overall baseline period until the end of participant-level retrospective observation period.
62041835|NCT06346899||Group B: Lanadelumab + Icatibant|Participants with HAE who have used both lanadelumab and icatibant during the study-level retrospective observation period will be observed retrospectively from the start date of the participant-level overall baseline period until the end of participant-level retrospective observation period.
62041836|NCT03901235|EXPERIMENTAL|Mesenchymal Stromal Cells|
62434998|NCT02749682||constipation & normal population|The level of constipation on normal population using constipation severity scale.
62601547|NCT03711149|EXPERIMENTAL|Intervention Arm|Intervention: Activity monitor feedback loop: (1) Subjects will receive activity monitor with feedback on daily step count from the in-room TV screen, and (2) access to the Art Tour application
62601548|NCT03711149|NO_INTERVENTION|Standard-of-care Arm|"Subjects in the control arm will receive a blinded activity monitor post-op (without feedback on step count) and the usual standard of care. Nurses and doctors will not monitor ambulation with the activity monitor, they will use standard methods of observation."
62822714|NCT01474317|EXPERIMENTAL|Intended Users of the Monitoring System|Untrained subjects with diabetes use the G3 investigational blood glucose monitoring system.
62822715|NCT01831024|EXPERIMENTAL|Treatment Group|Dignicap System
62822716|NCT01831024|NO_INTERVENTION|Control Group|Concurrent age and chemotherapy matched control
62822717|NCT01910285|EXPERIMENTAL|Remifentanyl- sufentanil placebo|3 mg/kg of propofol combined with 3 µg/kg of remifentanil
62822718|NCT01910285|ACTIVE_COMPARATOR|Sufentanil - remifentanyl placebo|3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil
62822719|NCT03197298||Clopidogrel Period|ACS patients treated by PCI with newer-generation DES before the guideline suggested change in primary DAPT-regimen
62244945|NCT06086301|EXPERIMENTAL|PICTURE-THIS services|This group receives a Run-In Phase followed by outpatient transitional care management (up to 8 visits over 3 months), activity-based rehabilitation (up to 10 visits over 3 months), and social support for patients and families (ongoing screening and referral). They will also undergo outcome assessments at discharge, 3 and 6 months.
62434999|NCT01714505|EXPERIMENTAL|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in Control to Range (CTR) or in Safety Only mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct for hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
62822720|NCT03197298||Ticagrelor Period|ACS patients treated by PCI with newer-generation DES after the guideline suggested change in primary DAPT-regimen
62822721|NCT05446129|EXPERIMENTAL|Cohort A: Ezabenlimab + BI 765063|
62435000|NCT01714505|NO_INTERVENTION|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. The subject will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
62601549|NCT01383473||Leukemia Patients|6-12 year old pediatric oncology patients' perceptions of their school experiences pre and post cancer diagnosis will be done through interviews and drawings.
62601550|NCT01383473||Solid Tumor Patients|6-12 year old pediatric oncology patients' perceptions of their school experiences pre and post cancer diagnosis will be done through interviews and drawings.
62601551|NCT05959408|EXPERIMENTAL|men who have sex with men|
62601552|NCT03480698||Cerebrolysin and standard stroke care|
62822722|NCT05446129|EXPERIMENTAL|Cohort B: Pembrolizumab + BI 765063|
62822723|NCT06596252|EXPERIMENTAL|Arm A|Budesonide 2 mg orodispersible tablet once daily
62822724|NCT06596252|ACTIVE_COMPARATOR|Arm B|Budesonide 1 mg orodispersible tablet twice daily
62244946|NCT06086301|ACTIVE_COMPARATOR|Enhanced Usual Care|Enhanced Usual Care (EUC) control group will rececive a Run-in Phase followed by an informational brochure with regular assessments on the same schedule as the PICTURE-THIS group (i.e., discharge, 3 and 6 months)
62435001|NCT03877874||Asthmatic children|"* Aironyl syrup(Terbutaline sulfate ................. 1.5mg) 0.075-0.29 mg/ kg body weight 3 times daily~* Apidone syrup(Dexamethone) (0.02 to 0.3 mg per kilogram (kg) of body weight per day, divided and taken 3 or 4 times a day)."
62435002|NCT03877874||Non-Asthmatic children|no intervention
62601553|NCT03480698||Standard stroke care|
62601554|NCT00771355||1|Subjects with vitiligo.
62601555|NCT00771355||2|Subjects with melasma.
62601556|NCT00771355||3|Subjects with post-inflammatory hyper-pigmentation.
62601557|NCT00771355||4|Subjects with post-inflammatory hypo-pigmentation.
62601558|NCT05048212|EXPERIMENTAL|Nivolumab|by vein every 3 weeks for 4 doses
62601559|NCT05048212|EXPERIMENTAL|Ipilimumab|by vein over 30 minutes every 3 weeks for 4 doses
62601560|NCT05048212|EXPERIMENTAL|Cabozantinib|tablets by mouth 1 time every day.
62601561|NCT02351193||Group I|poor responder females with age less than 35
62822725|NCT06582160|EXPERIMENTAL|Patient-centered Pre-conception Screening|"A short form, 2 question screening form which asks patients which preconception health topics they would like to discuss with their doctor today. Includes an option for None of these. I would not like to discuss how my health can affect fertility and any future pregnancies"
62822726|NCT06582160|ACTIVE_COMPARATOR|Risk-based Pre-conception Screening|A long form questionnaire screening for a range of preconception health risk factors including: age, weight, exercise, diet, nutrition, health conditions, risky behaviors, immunization status, prescription medications, birth control use
62822727|NCT06582160|NO_INTERVENTION|Control|"Patient is asked a single question: Your health today can make a difference for the pregnancy you experience tomorrow. Do you agree with the statement above?"
62822728|NCT06593470|ACTIVE_COMPARATOR|Sport: Prevention Plus Wellness (PPW)|Sport: Prevention Plus Wellness (PPW) is a brief, evidence-based substance use prevention program for youth. PPW consists of a single remote-delivered 45-minute session by a research assistant (RA) trained in PPW that is interactive and intended for use by youth in the home setting. It involves screening youth to increase awareness of their current health behaviors; motivational enhancement for change; and establishing a behavior goal plan.
62822729|NCT06593470|EXPERIMENTAL|MINDS-UP with MRI + PPW|MINDS-UP consists of 4 x 60-minute sessions, once weekly over 4 weeks. MINDS-UP will be delivered to participants remotely, in a 1:1 setting, taught by the meditation teachers that will be hired and trained by Dr. Saunders. Additionally, participants will be provided audio files of 5-10-minute guided meditation practices, led by Dr. Saunders, as homework. Half of those randomized to receive MINDS-UP + PPW (n=10) will receive functional and structural MRI before and after MINDS-UP to evaluate feasibility and acceptability of our MRI procedures and study design. Participants randomized to MINDS-UP with MRI arm will also complete PPW.
62601562|NCT02351193||Group II|poor responder females with age more than 35
62601563|NCT04329091|EXPERIMENTAL|Dexmedetomidine Arm|Dexmedetomidine: Administration of a 0.5 mcg/kg bolus followed by an infusion of 0.5-0.7 mcg/kg/hr, titrated up by 0.1 mcg every 1 minute until the subject spontaneously closes his or her eyes. When the subject spontaneously closes his or her eyes the infusion continues for 90 minutes from that point.
62601564|NCT05678244|ACTIVE_COMPARATOR|Comparator|"Standard of care + IV acetaminophen:~Baseline fentanyl infusion, with dosage escalations, deescalations, and additional boluses and analgesics (excluding oral or rectal acetaminophen) determined by the patient's physician (this represents standard of care at this institution) with the addition of IV acetaminophen every 4 or 6 hours at weight-appropriate doses based on the patient's gestational age."
62822730|NCT06593470|EXPERIMENTAL|MINDS-UP without MRI + PPW|MINDS-UP consists of 4 x 60-minute sessions, once weekly over 4 weeks. MINDS-UP will be delivered to participants remotely, in a 1:1 setting, taught by the meditation teachers that will be hired and trained by Dr. Saunders. Additionally, participants will be provided audio files of 5-10-minute guided meditation practices, led by Dr. Saunders, as homework. Participants randomized to MINDS-UP without MRI arm will also complete PPW.
62041837|NCT04879550||thrombotic event developing / not|Group I: Patients with no bleeding/thrombosis complications Group II: Patients with Thrombotic and/or thromboembolic complications Group III: Patients with bleeding complications
62244947|NCT04786951|EXPERIMENTAL|Cognitive-behavioral therapy plus VR-based body exposure and Attentional Bias Modification Training.|In this group, five sessions of VRE will be added to the usual CBT, as in the other experimental group, but, in addition, at the beginning of each of the exposure sessions, the training aimed at reducing the attentional bias will be carried out. The training will be developed through the visual selection of geometric figures that fit approximately with specific parts of the body. Each of these figures can have different colors. Specifically, the patient must detect and identify the figures that will appear in different parts of the avatar's body. In half of the trials, the shape of the figure must be discriminated and in the remaining 50%, the discrimination will be based on color. Throughout the training, the geometric figures will appear on weight-related body parts in 45% of the trials, and in another 45% of the trials, it will appear on non-weight-related body parts. In the remaining trials (10%), the test will appear on one of three neutral stimuli located next to the avatar.
62244948|NCT04786951|EXPERIMENTAL|Cognitive-behavioral therapy for anorexia and VR-based body exposure:|Patients assigned to this group will receive the usual CBT from the clinical unit or the hospital where they are, and additionally, five sessions of VR-based body exposure intervention. In these weekly sessions patients will go through a body exposure intervention in which they will own a virtual avatar with their real measurements, that will progressively increase its BMI values throughout the following exposure sessions until a healthy BMI value is reached.
62244949|NCT04786951|ACTIVE_COMPARATOR|Cognitive behavioral therapy|Patients assigned to this group will receive the usual treatment from the center in which they are recruited for the study (CBT), and will have to complete the evaluations following the same schedule as the experimental group.
62244950|NCT03566433|ACTIVE_COMPARATOR|Endoscopic TEP surgery|Routine total extraperitoneal technique surgery for inguinal hernia
62244951|NCT03566433|ACTIVE_COMPARATOR|Open Lichtenstein hernioplasty|Routine lichtenstein surgery for inguinal hernia
62244952|NCT05987449|EXPERIMENTAL|NXT007 Dose Escalation|
62244953|NCT04649268|ACTIVE_COMPARATOR|Optokinetic stimulation treatment with visual motion DVDs|Customised vestibular rehabilitation programme which includes optokinetic stimulation treatment with visual motion DVDs
62435003|NCT02262949|EXPERIMENTAL|LifeStent Vascular Stent|This is a single arm study and all subjects receive PTA and implantation of one Life Stent Vascular Stent.
62435004|NCT01710306|NO_INTERVENTION|Outreach|To evaluate and test differences in VA mental health care engagement for those who screen positive for PTSD by randomly assigned route: existing OEF/OIF/OND outreach. VA mental health care engagement is defined as participation in any of the following: PTSD psychotherapy, cognitive processing therapy, or prolonged exposure therapy.
62435005|NCT01710306|EXPERIMENTAL|Nurse Care Manager (NCM)|To evaluate and test differences in VA mental health care engagement for those who screen positive for PTSD by randomly assigned route: Study concierge nurse case manager (NCM). VA mental health care engagement is defined as participation in any of the following: PTSD psychotherapy, cognitive processing therapy, or prolonged exposure therapy.
62435006|NCT01387971||ocular surface disorders|various ocular surface disorders
62435007|NCT01984281|EXPERIMENTAL|Pedometer-based prescription|After baseline assessments, the control group will receive a educational session, regarding important aspects of asthma (symptoms, treatment, exacerbations, triggers, etc) plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes) and a pedometer-based physical activity prescription, consisting of targets to be achieved (in terms of steps per day).
62435008|NCT01984281|NO_INTERVENTION|Control|After baseline assessments, the control group will receive a educational session, regarding important aspects of asthma (symptoms, treatment, exacerbations, triggers, etc) plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes).
62601565|NCT05678244|PLACEBO_COMPARATOR|Placebo|"Standard of care + placebo:~Baseline fentanyl infusion, with dosage escalations, deescalations, and additional boluses and analgesics (excluding oral or rectal acetaminophen) determined by the patient's physician (this represents standard of care at this institution) with the addition of an IV saline placebo every 4 or 6 hours at a rate which would mimic their dose of acetaminophen."
62822731|NCT06597552|ACTIVE_COMPARATOR|Control Group|
62822732|NCT06597552|EXPERIMENTAL|Training Group|
62435009|NCT01181661|EXPERIMENTAL|Full Group Contingency|This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
62822733|NCT05097079|EXPERIMENTAL|MYOBLOC Low Dose|MYOBLOC Low Dose will be administered as a single treatment via intraglandular injection (60 Units/kg)
62822734|NCT05097079|EXPERIMENTAL|MYOBLOC High Dose|MYOBLOC High Dose will be administered as a single treatment via intraglandular injection (100 units/kg)
62822735|NCT05097079|PLACEBO_COMPARATOR|Placebo|Volume-matched placebo will be administered as a single treatment via intraglandular injection
62041838|NCT06050850||Aim 1a: Adapting the NOURISH-ALL Intervention for Families of Youth with ALL (Year 1)|The purpose of Aim 1a is to adapt the NOURISH-T intervention to meet the specific needs of families during the early phases of ALL treatment. To achieve this goal, the study will initiate a three-step intervention adaptation process that includes (1) initial integration of cognitive behavioral therapy (CBT) and family systems frameworks, (2) formative assessment with families of youth with ALL, and (3) formative assessment with multidisciplinary experts.
62435010|NCT01181661|EXPERIMENTAL|Mixed Group Contingency|This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
62435011|NCT03559764|EXPERIMENTAL|Anti-BCMA CAR T cells|Total dose of 0.5-6 millions /kg cells will be administered at day -2, day -1 and day 0 by split dose (30%, 30% and 40% respectively).
62435012|NCT05745064|ACTIVE_COMPARATOR|TL-925 Arm|TL-925 will be administered OU BID
62435013|NCT05745064|PLACEBO_COMPARATOR|Placebo Arm|Placebo will be administered OU BID
62435014|NCT04929197|EXPERIMENTAL|Wear Personalized breast holder system (PERSBRA) to receiving radiotherapy|Wear PERSBRA to the end of radiotherapy.
62435015|NCT05380830|NO_INTERVENTION|Control|The group will be only submitted to evaluations (body composition, hematological, lipid and cytokines profile, food intake, and maximal effort under treadmill and deep-water running) at the beginning and the end of the study.
62435016|NCT05380830|EXPERIMENTAL|Group Hypoxia|During the intervention of 8 weeks the participants will have the deep-water running training under normoxia, but during the rest they will be under hypoxia (FiO2=13%).
62822736|NCT02231086|ACTIVE_COMPARATOR|Standard adjuvant systemic chemotherapy|Standard adjuvant systemic chemotherapy according to the Dutch colon cancer guideline, using a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) schedule. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
62041839|NCT06050850||Aim 1b: Iteratively Refining the NOURISH-ALL Intervention (Year 2)|"The purpose of Aim 1b is to adaptively refine NOURISH-ALL through sequential testing with individual families during the early phases of ALL treatment, with the goal of optimizing feasibility and acceptability from the family perspective. In line with the ORBIT model, the study will utilize an adaptive approach, similar to the commonly known PDSA cycle, to maximize responsivity to individual patient/family feedback. Participants will receive NOURISH-ALL and provide feedback throughout the intervention (i.e., after each session and upon intervention completion), which will be iteratively analyzed and incorporated to improve intervention delivery for the next family"
62041840|NCT06050850||Aim 2: Pilot Single-Arm Trial of NOURISH-ALL Focused on Participant Engagement (Years 3-5)|Pilot testing key components of engagement is critical to optimizing design and methodology of fully powered efficacy trials. The purpose of Aim 2 is to pilot a single-arm trial of the finalized NOURISH-ALL intervention in a sample of families of youth in the early phases of ALL treatment to assess recruitment, retention, and dose received. Results will directly inform the design of the fully powered randomized control trial to test intervention efficacy (R01 application to be submitted in Year 4).
62041841|NCT03278262||>= 70 letters|Baseline VA \>= 70 letters
62041842|NCT03278262||36-69 letters|Baseline VA 36-69 letters
62041843|NCT03278262||<=35 letters|Baseline VA \<=35 letters
62041844|NCT05864781|NO_INTERVENTION|Control group|With the students in the control group, a standard individual article review will be conducted under the supervision of the instructor.
62041845|NCT05864781|EXPERIMENTAL|Experimental group|The students in the experimental group will be divided into 8 main groups of 7 students according to their academic grade point average. In these groups, each member will be responsible for one of the 7 sections of the article. Those who take the same section in the groups will unite to form expert groups and specialize by working on this section. Students will then return to their main groups and analyze an experimental article. From the groups presenting their reviews, a winner will be selected and a prize will be awarded.
62041846|NCT06733012|EXPERIMENTAL|Splanchnic nerve ablation|Catheter based ablation on the right greater splanchnic nerve
62041847|NCT06733012|SHAM_COMPARATOR|Sham control|Sham-control procedure
62041848|NCT03687749||Women with breast cancer-related lymphedema|Individuals with upper limb lymphedema developed after breast cancer treatment
62041849|NCT03687749||Healthy control subjects|Healthy individuals without breast cancer-related lymphoedema.
62041850|NCT06459297||Upadacitinib|Participants will receive upadacitinib as prescribed by their physician according to local label.
62041851|NCT03740282|EXPERIMENTAL|Lapiplasty|All study participants receiving Lapiplasty procedure
62435017|NCT05380830|PLACEBO_COMPARATOR|Group Normoxia|During the intervention of 8 weeks the participants will have the deep-water running training under normoxia, and during the rest they will keep under normoxia (FiO2=20%).
62435018|NCT05206136||Neck Pain Group|Patients with neck pain
62435019|NCT05206136||Low Back Pain Group|Patients with low back pain
62435020|NCT05206136||Healthy Individuals|Patients with no pain in neck or low back region
62435021|NCT05687656|EXPERIMENTAL|InnovaMatrix AC porcine placental ECM therapy|Eligible subjects will be treated with a weekly application of sterilized, porcine placental ECM followed by standard of care wound therapy and offloading
62435022|NCT00636428|ACTIVE_COMPARATOR|1|Oral midazolam
62435023|NCT00636428|ACTIVE_COMPARATOR|2|IV Midazolam
62435024|NCT00644371|EXPERIMENTAL|1|
62435025|NCT05824299|ACTIVE_COMPARATOR|General Anesthesia|Patients in this group will receive general anesthesia during TURBT.
62435026|NCT05824299|EXPERIMENTAL|Spinal Anesthesia|Patients in this group will receive spinal anesthesia during TURBT.
62601566|NCT04282291||SIPB (block)|patients who underwent a modified BRILMA (intercostal rami block, middle axilary line) ultrasound-guided block with portable device with lineal probe and needle 80 mm. With the patient lying supine, the probe was placed in the sagittal plane of the middle axillary line to identify the aim thoracic structures. Under aseptic conditions, the needle was inserted in plane, caudo-craneal, to reach the fascial plane between the serratus anterior muscle and the external intercostal muscle at the eighth rib. A bolus dose of levobupivacaine 0.25% was administered, 3 ml of local anesthetic for each segment we want to block
62601567|NCT04282291||control (morphine)|PCA (patient controlled analgesia) morphine was initiated immediately postoperatively using CADD Smith Medical pumps. All patients received PCA-morphine with the initial dose being 0.5-1 mg. The bolus dose was 0.01mg/kg mg morphine, with lockout time interval of 15 - 30 min, limiting of 8mg/hour, as the default program. The continuous (basal) dose was increased after 12-24 hours if using frequent demand doses or if pain not controlled and decreasing if no bolus was taken.
62601568|NCT06100692||vit D and zinc group|will receive combination of oral vit D and zinc 30 patients
62601569|NCT06100692||placebo group|receive Placebo or no treatment 30 patients
62601570|NCT03720145|EXPERIMENTAL|Treatment Group|lifestyle medicine group
62822737|NCT02231086|EXPERIMENTAL|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC will be performed simultaneously with primary tumor resection, or as a staged procedure (\<10 days or 5-8 weeks postoperatively). The chemotherapy during oxaliplatin-HIPEC consists of an intravenous phase with leucovorin 20 mg/m2 (maximum 40 mg) and 5-fluorouracil 400 mg/m2 (maximum 800 mg) and an intraperitoneal phase with oxaliplatin 460 mg/m2 (maximal 920 mg). Standard adjuvant systemic chemotherapy according to the national guideline will be given within 3 weeks from HIPEC. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
62822738|NCT05847517|ACTIVE_COMPARATOR|Metoprolol|Participants will be administered IV Metoprolol tartrate 15 mg (3 ampoules of 5 ml) diluted in 100 ml of saline.
62601571|NCT03720145|NO_INTERVENTION|CAU group|Care-As-Usual group
62244954|NCT04649268|EXPERIMENTAL|Optokinetic stimulation treatment with Virtual Reality|Customised vestibular rehabilitation programme which includes optokinetic stimulation treatment with Virtual Reality environments delivered with headset (e.g. Oculus Quest headset)
62601572|NCT00437827|ACTIVE_COMPARATOR|1|Each subject in this arm will receive depression therapy similar to that used by the Star\*D study - a major depression study conducted in the United States (Sequenced Treatment Alternatives to Relieve Depression (STAR\*D) trial. Am J Psychiatry 2006; 163:1905-1917)
62601573|NCT00437827|EXPERIMENTAL|2|Each subject in this arm will receive therapy based upon an individualized rEEG report which provides one or more treatment options with the highest probability of success.
62244955|NCT03579849|EXPERIMENTAL|Perfusion SPECT|"Included patients with a diagnosis of acute PE on CTPA and who had a subtraction iodine mapping CT will undergo a SPECT/CT within 24 hours.~Each lung subtraction iodine mapping CT will be interpreted blindly by 3 radiologists. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused.~Each perfusion SPECT will be interpreted blindly by 3 nuclear medicine physicians. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused."
62244956|NCT06456658|ACTIVE_COMPARATOR|Interruptive Reminder Group|Providers will receive education via a pop-up alert at the time that the chart is opened for eligible patient visits assigned to the interruptive reminder group.
62435027|NCT00525031|EXPERIMENTAL|Temozolomide (TMZ)|Temozolomide = TMZ - 150 mg/m\^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.
62822739|NCT05847517|PLACEBO_COMPARATOR|Saline|Participants will be administered IV saline (0.9% sodium chloride) (3 ampoules of 5 ml) diluted in 100 ml of saline.
62435028|NCT00525031|EXPERIMENTAL|Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI)|"Temozolomide = TMZ and PGI = Pegylated Interferon-alpha 2b~Temozolomide 150 mg/m\^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks. Pegylated Interferon-alpha 2b 0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks."
62822740|NCT03002870|OTHER|Endometriosis|Patients whom pathology results post surgery document endometriosis
62822741|NCT06426342|EXPERIMENTAL|Mindguide_employee|
62822742|NCT05207774|EXPERIMENTAL|oxytocin|8 U/oxytocin three-times daily, 30 min before breakfast, lunch and dinner, using a nasal atomizer for 8 weeks
62822743|NCT05207774|PLACEBO_COMPARATOR|placebo|intranasal spray containing placebo three-times daily, 30 min before breakfast, lunch and dinner, using a nasal atomizer for 8 weeks
62822744|NCT04583618|EXPERIMENTAL|SP0202-IIb|One dose at Day 1
62435029|NCT03157063||Inactive, normal weight|Less than 30 minutes per day of moderate to vigorous physical activity (MVPA), and body mass index percentile (BMI%) between 5th to 75th percentile.
62435030|NCT03157063||Inactive, overweight/obese|Less than 30 minutes per day MVPA, BMI% between 85th and 99th.
62435031|NCT03157063||Active, normal weight|More than 60 minutes per day MVPA, BMI% between 5th and 75th.
62435032|NCT03157063||Active, overweight/obese|More than 60 minutes per day MVPA, BMI% between 85th and 99th.
62435033|NCT00689403|EXPERIMENTAL|Part A: 2x2 crossover|4 different AZD1305 ER formulations
62435034|NCT00689403|EXPERIMENTAL|Part B: 3x3 crossover|2 different AZD1305 ER formulations and a reference formulation
62435035|NCT04221581||Patients receiving FHK ASYMETRIQUE prosthesis|
62435036|NCT01975090|EXPERIMENTAL|SENTRY IVC Filter|The SENTRY IVC Bioconvertible Filter
62435037|NCT02700802|EXPERIMENTAL|Feed1st: Face-to-face provider delivered referral|In this arm of the study, caregivers will receive usual care and a brief face-to-face referral to the Feed1st program delivered by the provider.
62435038|NCT02700802|EXPERIMENTAL|Feed1st: Text message delivered referral|In this arm of the study, caregivers will receive usual care and an automated brief text message referral to the Feed1st program from the health care provider. The text message referral will align as closely as possible with the face-to-face referral.
62435039|NCT02700802|NO_INTERVENTION|Standard of Care|Usual care includes passive delivery of information from nursing staff about all available food options in the hospital including the self-serve food pantries in the standard Caregiver FYI Admissions Packet.
62822745|NCT04583618|EXPERIMENTAL|SP0202-VI|One dose at Day 1
62041852|NCT05938270|OTHER|Saruparib (AZD5305) only|Participant will receive Saruparib (AZD5305) once daily for 21 days (+ up to 7 days) unless unacceptable toxicity or withdrawal of consent. Following the 21 days of study treatment, participants should undergo radical prostatectomy on Day 22 (+ up to 7 days)
62041853|NCT05938270|OTHER|Saruparib (AZD5305) + Darolutamide|Participant will receive Saruparib (AZD5305) once daily + darolutamide twice daily for 21 days (+ up to 7 days) unless unacceptable toxicity or withdrawal of consent. Following the 21 days of study treatment, participants should undergo radical prostatectomy on Day 22 (+ up to 7 days).
62041854|NCT05938270|OTHER|No Treatment|No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice
62435040|NCT01508156|EXPERIMENTAL|Group A: Healthy Participants|Healthy participants take IDX719 (5 mg - 100 mg) or matching placebo by mouth as either 1 single dose or as 7 daily doses.
62601574|NCT04250233||Standard neuraxial opioids|Standard neuraxial anesthesia for cesarean delivery (heavy bupivacaine 10 mg; fentanyl 10-25 mic; and low dose intrathecal morphine
62822746|NCT04583618|EXPERIMENTAL|SP0202-VII|One dose at Day 1
62601575|NCT04250233||Non standard neuraxial opioids|"Non standard low-dose morphine group (with heavy bupivacaine 10 mg; fentanyl 10-25 mic)~Women are offered - if they prefer not to receive low dose morphine, the option of either ultra-low dose morphine or no morphine - instead they can receive postoperative bilateral quadratus lumborum block (QLB), TAP or erector spinus block."
62601576|NCT05274542|EXPERIMENTAL|high intensity with blood flow restriction group|
62822747|NCT04583618|ACTIVE_COMPARATOR|Prevnar 13|One dose at Day 1
62822748|NCT04583618|ACTIVE_COMPARATOR|Pneumovax 23|One dose at Day 1
62822749|NCT04272242|EXPERIMENTAL|Arm 1: DTG + INH + RPT|"Participants received 50 mg of DTG orally twice daily (\~12 hours apart). Participants received 300 mg of INH and 600 mg of RPT orally each morning for 4 weeks.~Participants also received 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH.~Participants remained on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. Participants took non-study supply of DTG for morning doses, and study-supplied DTG for evening doses."
62822750|NCT04272242|EXPERIMENTAL|Arm 2: DTG + INH + RPT|"Participants were to receive 50 mg of DTG orally each morning and 300 mg of INH and 600 mg of RPT orally each morning for 4 weeks.~Participants were also to have received 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH.~Participants were to remain on once-daily DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study with DTG supplied from non-study ARV supply.~It was decided to not move forward with Arm 2 of the study based on the Arm 1 PK assessment and no participants were enrolled in Arm 2."
62041855|NCT05938270|OTHER|Darolutamide Only|Participant will receive darolutamide twice daily for 21 days (+ up to 7 days) unless unacceptable toxicity or withdrawal of consent. Following the 21 days of study treatment, participants should undergo radical prostatectomy on Day 22 (+ up to 7 days).
62041856|NCT06676319|EXPERIMENTAL|Lunsekimig|Participants will receive lunsekimig (SC injection) every 4 weeks
62041857|NCT06676319|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo (SC injection) every 4 weeks
62041858|NCT02982005|EXPERIMENTAL|KHK4827|KHK4827 administered SC
62041859|NCT02982005|PLACEBO_COMPARATOR|Placebo|Placebo administered SC
62041860|NCT03998787||Patients with Parkinson's disease|Patients with Parkinson's disease
62041861|NCT03998787||Healthy Subjects|Healthy subjects
62041862|NCT03407599|EXPERIMENTAL|Faster aspart followed by insulin aspart (NovoRapid®)|Participants will receive single dose of fast-acting insulin aspart followed by single dose of NovoRapid® on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days.
62041863|NCT03407599|EXPERIMENTAL|Insulin aspart (NovoRapid®) followed by faster aspart|Participants will receive single dose of NovoRapid® followed by single dose of fast-acting insulin aspart on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days.
62601577|NCT05274542|ACTIVE_COMPARATOR|high intensity without blood flow restriction group|
62601578|NCT06623045|EXPERIMENTAL|PFM strength|This group carries out a 12-week training intervention based on Kegel exercises to improve strength and muscle activation
62822751|NCT06603194|ACTIVE_COMPARATOR|Bovine Collagen|10g powder format taken daily for duration of the study.
62822752|NCT06603194|ACTIVE_COMPARATOR|Marine Collagen|10g powder format taken daily for duration of the study.
62822753|NCT06603194|PLACEBO_COMPARATOR|Placebo|
62822754|NCT03811821|ACTIVE_COMPARATOR|Biofeedback (BIO)|Participants will receive biofeedback intervention during five (5) required weekly 1-hour sessions. A 6th treatment session will be made available for participants if it is shown through anorectal manometry that they are having trouble understanding directions given during the first five sessions.
62822755|NCT03811821|ACTIVE_COMPARATOR|Injection (INJ)|Bulking agent injected into rectal wall to narrow opening. Two visits each lasting 45 minutes at weeks 0 and 6 respectively.
62822756|NCT06493864|EXPERIMENTAL|BL-B16D1|Participants receive BL-B16D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62822757|NCT06589700|ACTIVE_COMPARATOR|Known Paroxysmal AF|Paroxysmal AF known before stroke onset (KAF).
62822758|NCT06589700|ACTIVE_COMPARATOR|ECG-AFDAS|Paroxysmal AF found on an admission or Emergency Department ECG (ECG-AFDAS)
62822759|NCT06589700|ACTIVE_COMPARATOR|PCM-AFDAS|Paroxysmal AF found on 14-day Holter monitoring (PCM-AFDAS)
62822760|NCT05782283|NO_INTERVENTION|Usual Care Group|Primary care providers will treat subject per standard of care
62601579|NCT06623045|NO_INTERVENTION|Control Group|This group is used as a control group. They keep training their sports discipline but don't join the 12-week PFM training protocol.
62601580|NCT05832918|EXPERIMENTAL|core stability exercises with cognitive tasks group|"This research will use core stability exercises to strengthen local muscles (transversus abdominis and multifidus) based on the training program provided by Shamsi et al., which is modified from the exercise program of Koumantakis et al.. Participants will be treated for six weeks, three sessions a week, and 16 sessions.~We will also combine stabilization exercises with cognitive tasks."
62601581|NCT05832918|ACTIVE_COMPARATOR|general exercises with cognitive tasks group|"This research will use general exercises to strengthen global muscles (abdominal flexor muscles and back extensor muscles) based on the training program provided by Shamsi et al.(110), which is modified by Koumantakis et al.. Participants will be treated for six weeks, three sessions a week, and 16 sessions.~We will also combine general exercises with cognitive tasks."
62601582|NCT04080674||Parkinson's disease|30 participants
62601583|NCT04080674||Essential Tremor|10 participants
62601584|NCT04080674||Dystonia|20 participants
62601585|NCT05631106|ACTIVE_COMPARATOR|Stretching, Balance, Range of Motion|Participants will engage stretching, balance, and range of motion exercises 2 days per week for 12-weeks.
62601586|NCT05631106|EXPERIMENTAL|High Intensity Interval Resistance Training|Participants will perform resistance training exercises at high intensity intervals 2 days per week for 12-weeks.
62601587|NCT03118141|ACTIVE_COMPARATOR|PGS group|Subjects in the PGS group will have blastocyst biopsy and sequencing done with 3 good-quality embryos on Day 5. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by blastocyst morphologic score. The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
62822761|NCT05782283|EXPERIMENTAL|Electrocardiogram AI Group|The ACE (AI-Cirrhosis-ECG) 2.0 will be used to alert primary care providers to the likelihood of advanced liver disease with a recommendation for laboratory tests.
62041864|NCT06732492|EXPERIMENTAL|RD13-02 cell infusion|RD13-02 cells targeting CD7 were injected intravenously
62244957|NCT06456658|ACTIVE_COMPARATOR|Non-Interruptive Reminder Group|Providers will be able to seek out education at their own initiative via an on-demand reminder within a section of the chart for eligible patient visits assigned to the non-interruptive reminder group.
62822762|NCT00566774|EXPERIMENTAL|1|
62822763|NCT00566774|ACTIVE_COMPARATOR|2|
62041865|NCT01029054|EXPERIMENTAL|carfilzomib, lenalidomide w/dexamethasone|"Phase I: carfilzomib will be taken with a combination of lenalidomide plus dexamethasone in a series of escalating dosages to determine the maximum tolerated dose level~Phase II: carfilzomib will be given at the MTD established in the Phase I portion of the study"
62244958|NCT06456658|ACTIVE_COMPARATOR|No Reminder Group|"No alert recommending a statin will be displayed/available to the provider. The system will record eligibility through triggering a silent reminder, which is not displayed to the clinician and exists solely for data collection purposes."
62244959|NCT05484050|OTHER|VEGF in iris tissue in primary congenital glaucoma|Estimation of VEGF grade in iris tissue in primary congenital glaucoma through Immunohistochemistry
62822764|NCT06384469||Patients undergoing open rhinoplasty approach|Patients undergoing open rhinoplasty approach, of which most of will be augmented by using autologous cartilage grafts.
62822765|NCT06384469||Patients undergoing closed approach rhinoplasty.|Patients undergoing closed approach rhinoplasty of which only few will be augmented by using autologous cartilage grafts.
62041866|NCT06431802|ACTIVE_COMPARATOR|Conventional intervention group|On-site course training in pain assessment
62601588|NCT03118141|ACTIVE_COMPARATOR|IVF group|Subjects in the IVF group will also comply with the principle of freeze-all and single thawed blastocyst transfer. The order of transfer will be determined by blastocyst morphologic score. The outcome of up to 3 transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
62822766|NCT06450418||Carers/Realtives/ Healthy - No Diagnosis of a Neurodegenerative Disorder|
62822767|NCT06450418||Motor Neuron Disease|
62822768|NCT06450418||Multiple Sclerosis|
62041867|NCT06431802|EXPERIMENTAL|Platform intervention group|Pain assessment training using the visualization training platform based on a multimodal standardized dataset for pain assessment in critically ill children
62041868|NCT04943874|OTHER|Technology Based Intervention 1 (Phase 1)|
62244960|NCT05484050|OTHER|VEGF in iris tissue from ocular trauma or congenital cataract|Estimation of VEGF grade in iris tissue from ocular trauma or congenital cataract through Immunohistochemistry
62244961|NCT06734091|EXPERIMENTAL|Donors undergoing intraoperative examination|Donors undergoing intraoperative extemporaneous examination to define the oncological risk of donation during the study period
62244962|NCT06245356|OTHER|Colorectal adenocarcinoma|"Trifluridine/tipiracil in association with oxaliplatin with or without:~* Panitumumab in RAS wild type tumors~* Bevacizumab in RAS wild type of right colon or RAS mutated tumors"
62244963|NCT06245356|OTHER|Gastroesophageal adenocarcinoma|"Trifluridine/tipiracil in association with oxaliplatin with or without:~* Trastuzumab in HER2-positive tumors (3+ IHC or 2+/FISH+)~* Nivolumab if CPS≥5 and HER2-negative tumors"
62244964|NCT05776225||Experimental study arm|All enrolled patients in this single arm study will receive a RHC.
62601589|NCT06648616|EXPERIMENTAL|Elastic Band Group|Athletes that have participated in a bi-weekly elastic band resistance training program.
62601590|NCT03667872|EXPERIMENTAL|Device|MRI compatible and LFP recordable implantable stimulator
62601591|NCT02170467|EXPERIMENTAL|Control|Assessment of intestinal permeability in small intestine (Lactulose/ Mannitol ratio) in controls and camparison with pateints with anorexia nervosa.
62822769|NCT06450418||Dementia|
62822770|NCT06450418||Parkinson's Disease|
62822771|NCT05665634|EXPERIMENTAL|All participants|
62822772|NCT06462937|EXPERIMENTAL|Exercise with personal supervision 0-3 months|Exercise
62822773|NCT06462937|NO_INTERVENTION|Control 0-3 months|Usual care
62822774|NCT06462937|EXPERIMENTAL|Exercise with personal supervision 3-6 months|Exercise
62822775|NCT06462937|ACTIVE_COMPARATOR|Exercise without personal supervision 3-6 months|Exercise
62041869|NCT04943874|OTHER|Technology Based Intervention 1 (Phase 2)|
62041870|NCT04943874|OTHER|Technology Based Intervention 2 (Phase 2)|
62041871|NCT03362333|EXPERIMENTAL|pain neuroscience education and exercise|This group received pain neuroscience education and exercise once a week over 4 weeks
62041872|NCT03362333|ACTIVE_COMPARATOR|Exercise|This group received exercise directed at the neck and shoulder regions once a week over 4 weeks
62041873|NCT04341701|OTHER|COPD|COPD according to GOLD 2019 but unrestricted to any level of bronchial reversibility established by the pulmonologist
62601592|NCT02170467|EXPERIMENTAL|patients with anorexia nervosa|Assessment of intestinal permeability in small intestine (Lactulose/ Mannitol ratio) in patients with anorexia nervosa before and after re-feeding.
62601593|NCT04574934|EXPERIMENTAL|the study group|study group received the traditional physical therapy program plus aquatic therapy
62822776|NCT02862678|EXPERIMENTAL|Patients with head and neck squamous cell carcinoma|
62822777|NCT04715191|EXPERIMENTAL|CARE T cells + Fludarabine and Cytoxan|GPC3-CAR and the IL15 plus IL21 (CARE T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with GPC3-positive solid tumors.
62822778|NCT06204705||Veterans with Bipolar Disorders|Veterans with a diagnosis of a bipolar disorder.
62041874|NCT04341701|OTHER|Asthma|asthma according to GINA 2019 but without any smoking restriction
62041875|NCT05953337|EXPERIMENTAL|EYE90 Microspheres Treatment|Radioembolization with Eye90 Microspheres
62041876|NCT06513351|NO_INTERVENTION|Standard Care - Comparator Arm A|Standard Care, which includes a category-based risk assessment tool as part of nursing admission workflow. The prophylactic interventions in the intervention are recommended by the tool but not specifically tied to provider-facing clinical decision support.
62041877|NCT06513351|ACTIVE_COMPARATOR|Novel PPH Risk Prediction Model - Comparator Arm B|Standard Care with addition of a recently developed, novel PPH risk prediction model.
62041878|NCT06144840|EXPERIMENTAL|MT-7117|
62041879|NCT06144840|PLACEBO_COMPARATOR|Placebo|
62041880|NCT06732206|EXPERIMENTAL|Experimental Group|"The short solution-oriented program intervention group will be applied for 6 weeks, a total of 7 lesson hours."
62041881|NCT06732206|NO_INTERVENTION|Control Group|
62435041|NCT01508156|EXPERIMENTAL|Group B: HCV Participants|Treatment-naive participants infected with HCV genotype (GT) 1, GT2, or GT3 take IDX719 (1 mg - 100 mg) or matching placebo as either 1 single dose or as 7 daily doses.
62041882|NCT05807451||Monoplanar Osteotomy group|High Tibial Osteotomy using single plane osteotomy
62041883|NCT05807451||Biplanar Osteotomy group|High Tibial Osteotomy using two plane osteotomy
62041884|NCT01487811|EXPERIMENTAL|Formulation 1|
62041885|NCT01487811|ACTIVE_COMPARATOR|Formulation 2|
62041886|NCT04856722|EXPERIMENTAL|mini-PNL group|In which PCNL will be performed using miniature nephroscope
62041887|NCT04856722|EXPERIMENTAL|RIRS group|In which RIRS will be performed using a flexible ureteroscope
62041888|NCT04856722|EXPERIMENTAL|SWL group|In which extracorporeal shock wave lithotripsy will be performed using Dornier lithotripter SII
62041889|NCT06678178|PLACEBO_COMPARATOR|Control (QR) Labels|"A black label featuring a QR code and white text that reads SCAN HERE will be placed beneath all main menu items. Explanatory text describing the label's meaning will be displayed at the top of the menu."
62041890|NCT06678178|EXPERIMENTAL|Warning High Climate Impact Labels|"A red icon-plus-text label that reads WARNING: HIGH CLIMATE IMPACT in white text will be placed beneath main menu items with a high climate impact using a predetermined threshold of estimated greenhouse gas emissions set at \>=9.2 kgCO2e. Labels will include a white globe icon directly preceding the label text. Explanatory text describing the label's meaning will be displayed at the top of the menu."
62601594|NCT04574934|NO_INTERVENTION|the control group|control group received traditional physical therapy program only.
62601595|NCT01949441|EXPERIMENTAL|ToleroMune HDM|
62601596|NCT01949441|PLACEBO_COMPARATOR|Placebo|
62601597|NCT04791540||Patients with trachestomy|Patients, attending a respiratory rehabilitation program, who underwent tracheostomy decannulation
62601598|NCT00821223|ACTIVE_COMPARATOR|manual small incision cataract surgery|surgical intervention by small incision cataract surgery
62041891|NCT06678178|EXPERIMENTAL|Traffic Light Labels|"Traffic Light labels will be placed beneath all main menu items. Using predetermined estimated greenhouse gas emission thresholds, each item will be assigned one of three icon-plus-text labels within this scheme: low-, medium-, or high-impact label, set in kgCO2e at \<2.6, \>=2.6 \& \<9.2, and \>=9.2, respectively. Each will read, HIGH CLIMATE IMPACT within a red label, MED. CLIMATE IMPACT in a yellow label, and LOW CLIMATE IMPACT in a green label. Text for all labels written in white, and a white globe icon will precede the text. Explanatory text describing the meaning of the labels will be displayed at the top of the menu."
62435042|NCT04199780|EXPERIMENTAL|Group 1- real tDCS and real CBI|4 active treatments of tDCS and active cognitive behavioral intervention (CBI)
62601599|NCT00821223|OTHER|phacoemulsification|surgical intervention by phacoemulsification
62601600|NCT06361303||SNOO users|Caregivers who use the SNOO Bassinet with their infant and who meet eligibility criteria
62822779|NCT06204705||VA clinicians and administrators|VA clinicians and administrators who provide or oversee clinical care of Veterans with bipolar disorders
62822780|NCT04446416|EXPERIMENTAL|Bevacizumab plus NaviFUS System|"Device: NaviFUS System BBB Disruption by FUS in recurrent GBM Microbubbles (MB) (SonoVue®) 0.1 mL/kg and optimal ultrasound exposure doses (based on the acoustic emission feedback FUS power control algorithm) generated from the NaviFUS System every 2 weeks to transiently open the BBB.~Drug: Bevacizumab 10 mg/kg every 2 weeks for up to 36 weeks or until evidence of progressive disease, unacceptable toxicity, non-compliance with study follow-up, or withdrawal of consent."
62822781|NCT06593184|EXPERIMENTAL|Active trans-spinal magnetic stimulation|
62822782|NCT06593184|SHAM_COMPARATOR|Sham trans-spinal magnetic stimulation|
62822783|NCT06592170|EXPERIMENTAL|Experimental group|"Safe import period: Linperlisib: 80 mg, oral (pre - and post meal), QD; obinutuzumab: 1000 mg, intravenous infusion, administered on the first day (1st cycle on days 1, 8, and 15); Every 28 days, there is one cycle in total.~Extended treatment period: Combination induction: Linperlisib: RP2D, oral (pre - and post meal), QD; obinutuzumab: 1000 mg/time, intravenous infusion, administered on the first day (1st cycle on days 1, 8, and 15); Every 28 days, there are 2 cycles in total. Afterwards, single drug maintenance: Linperlisib: RP2D, oral (before and after meals), QD; every 28 days per cycle."
62041892|NCT06678178|EXPERIMENTAL|Climate Grade Labels|"Climate Grade labels will be placed beneath all main menu items, using predetermined estimated greenhouse gas emission thresholds to assign one of five icon-plus-text labels which indicate a specific climate impact grade (A, B, C, D, and F). Thresholds are set in kgCO2e as follows: \[A\] \<1.7, \[B\] \>=1.7 \& \<2.6, \[C\] \>=2.6 \& \<9.2, \[D\] \>=9.2 \& \<28, \[F\] \>=28. All labels are solid black with a white globe icon followed by white text which reads CLIMATE GRADE. On the left side of each label, a grade is displayed, capitalized and in a white font within a solid-colored box. The color of the box corresponds with each letter grade: A = dark green, B = light green, C = yellow, D = orange, F = red. Beneath the letter grade, a gradient of all possible grades is displayed horizontally in smaller font, each grade atop a small solid box in the respective grade color. Explanatory text describing the meaning of the labels will be displayed at the top of the menu."
62244965|NCT04886154|EXPERIMENTAL|ABCWY low dose Group|Participants receive MenABCWY-2Gen low dose vaccine and are followed up until Day 211 in study Phase I.
62041893|NCT06678178|EXPERIMENTAL|Numeric Carbon Footprint Labels|"Numeric Carbon Footprint labels will be placed beneath all main menu items and display the estimated greenhouse gas emissions in kilograms of carbon dioxide equivalents (kgCO2e) for each item. All labels have a solid black background and an icon-plus-text design. A white globe icon is followed by text stating the value of the items estimated emissions and the unit kgCO2e. Explanatory text describing the meaning of the labels will be displayed at the top of the menu."
62041894|NCT02732938|EXPERIMENTAL|PF-04136309 + Nab-p + Gem|"PF-04136309 oral dosing~Nab-paclitaxel IV dosing Gemcitabine IV dosing"
62041895|NCT00454948|EXPERIMENTAL|Home based Nutrition and Physical Activity|Home-based nutrition sessions and park play activity sessions
62041896|NCT00454948|ACTIVE_COMPARATOR|Group Nutrtion|Group based nutrition classes and activity booklets
62244966|NCT04886154|PLACEBO_COMPARATOR|Placebo low dose Group|Participants receive NaCl as a control for ABCWY low dose group and are followed up until Day 211 in study Phase I.
62244967|NCT04886154|EXPERIMENTAL|ABCWY high dose Group|Participants receive MenABCWY-2Gen high dose vaccine and are followed up until Day 211 in study Phase I.
62435043|NCT04199780|EXPERIMENTAL|Group 2- real tDCS and sham CBI|4 active treatments of tDCS and education-only-control cognitive intervention
62435044|NCT04199780|EXPERIMENTAL|Group 3- sham tDCS and real CBI|4 sham treatments of tDCS and active cognitive behavioral intervention (CBI)
62435045|NCT04199780|SHAM_COMPARATOR|Group 4- sham tDCS and sham CBI|4 sham treatments of tDCS and education-only-control cognitive intervention
62435046|NCT03520621||High Prevalence Population|Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is \>2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo
62435047|NCT03520621||Low Prevalence Population|Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is \<2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo
62822784|NCT03136887||JOURNEY II XR TKA|This is a single arm study, all subjects will receive JOURNEY II XR TKA
62822785|NCT01048593|EXPERIMENTAL|Dose 1|114ug
62435048|NCT02101320|NO_INTERVENTION|Group 1|Patients with a resection of the lesions according to the procedure SNOLL without the use of TReCam.
62435049|NCT02101320|EXPERIMENTAL|Group 2|Patients with a resection of the lesions according to the procedure SNOLL with the use of TReCam.
62435050|NCT00436878|EXPERIMENTAL|Portion Size|Each experiment manipulated food portion size of beverages, entrees, and side dishes
62822786|NCT01048593|EXPERIMENTAL|Dose 2|513ug
62822787|NCT01048593|EXPERIMENTAL|Dose 3|684ug
62822788|NCT03063528|EXPERIMENTAL|Healthy Eating/Physical Activity (HEPA)|"The goals of the HEPA condition are to encourage healthy eating and physical activity behaviors for gaining a healthy amount of weight during pregnancy and to provide motivation and social support to help overcome challenges to eating healthier and becoming more physically active while pregnant.~* 12 weeks of group-based health behavior (nutrition/PA focused) challenges and weight tracking; podcasts (10); weekly pregnancy tips~* website and mobile app"
62822789|NCT03063528|EXPERIMENTAL|Stress Reduction/Management (SRAM)|"The goals of the SRAM condition are to encourage stress reduction and management techniques as well as to provide motivation and social support to reduce stress levels during pregnancy.~* 12 weeks of group-based health behavior (stress reduction/management) challenges and weight tracking; podcasts (10); weekly pregnancy tips~* website and mobile app"
62822790|NCT06347705|EXPERIMENTAL|Cohort A|Men presenting with clinically localized intermediate-risk disease for whom surgery can be safely delayed for neoadjuvant treatment.
62822791|NCT06347705|EXPERIMENTAL|Cohort B|Men presenting with clinically localized or locoregional high-risk disease.
62244968|NCT04886154|PLACEBO_COMPARATOR|Placebo high dose Group|Participants receive NaCl as a control for ABCWY high dose group and are followed up until Day 211 in study Phase I.
62244969|NCT04886154|EXPERIMENTAL|ABCWY low dose_06 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0, 6 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
62244970|NCT04886154|EXPERIMENTAL|ABCWY low dose_02 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0, 2 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
62244971|NCT04886154|EXPERIMENTAL|ABCWY high dose_06 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0, 6 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
62244972|NCT04886154|EXPERIMENTAL|ABCWY high dose_02 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0,2 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
62822792|NCT06347705|EXPERIMENTAL|Cohort C|Men presenting with low-volume metastatic disease for whom a multimodality therapeutic approach including removal of the primary has the potential to eliminate all disease.
62822793|NCT06498206|EXPERIMENTAL|AR training group|Dichoptic augmented reality training with dual-pathway (parvocellular pathway and magnocellular pathway) and interocular push-pull paradigms developed based on neural deficits in unilateral amblyopia.
62822794|NCT06498206|ACTIVE_COMPARATOR|Patching group|Conventional patching therapy.
62822795|NCT06072794|EXPERIMENTAL|Treatment Arm|
62822796|NCT06522256|OTHER|High-resolution anoscopy|
62822797|NCT02905461|EXPERIMENTAL|Intervention|Contraceptive text messages
62822798|NCT02905461|PLACEBO_COMPARATOR|Control|Text messages not about contraception
62822799|NCT02208310|ACTIVE_COMPARATOR|Low Dose Vitamin D|Patients will be given 400 IU cholecalciferol once daily for 30 days. \<-THIS IS THE Active Comparator Intervention. To maintain the blind, a random few will be given another round at the 30 day mark. For patients who enroll in the summer, a random few will again receive 400 IU cholecalciferol in March.
62822800|NCT02208310|EXPERIMENTAL|High Dose Vitamin D|Patients will be given cholecalciferol 10,000 IU daily for 30 days. \<-THIS IS THE INTERVENTION. At that point, if their vitamin D levels remain below 50 ng/ml, the 30 day course will be repeated. For patients who enroll in the summer, levels will be rechecked in March and if \<50 ng/ml, a 30 day course will be administered.
62822801|NCT06601985||J-pouch anastomosis group|Patient with ultra-low rectal cancer undergoing Sphincter- preserving surgery with one-stage anastomosis using a colon J-pouch.
62822802|NCT06601985||direct anastomosis group|Patient with ultra-low rectal cancer undergoing Sphincter- preserving surgery with one-stage direct anastomosis.
62822803|NCT05416203|EXPERIMENTAL|BEAST Condition|A one-session intervention that can be delivered effectively by a clinician via telehealth and supplemented with a mobile app to provide opportunities to practice the skills learned in the face-to-face session.
62822804|NCT04146597|EXPERIMENTAL|Neural mobilization|The intervention is always performed after Jiu Jitsu practice and at the training site itself. Neural mobilization consisted of the execution of a sciatic nerve sliding technique in three sets of one minute for each lower limb with an interval of one minute between sets, twice a week, for five consecutive weeks, totaling 10 interventions (Garber et al., 2011). The order of the first lower limb to be submitted to the intervention is not standardized, being at the discretion of the subjects.
62822805|NCT06598735|EXPERIMENTAL|Treatment group: HRS-4508|
62822806|NCT02678949|EXPERIMENTAL|Inhaled Fluticasone 50 mcg/twice day|Group 2; Inhaled fluticasone. 50 mcg/twice day for a period of 4 weeks.
62822807|NCT02678949|EXPERIMENTAL|Inhaled Fluticasone 100 mcg/twice day|Group 3;Inhaled fluticasone. 100 mcg/twice day for a period of 4 weeks
62822808|NCT02678949|EXPERIMENTAL|Inhaled Albuterol|Group 2 and group 3, inhaled albuterol one dose of 400 mcg.
62041897|NCT02434380|ACTIVE_COMPARATOR|Low dose vitamin D|Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.
62244973|NCT04886154|ACTIVE_COMPARATOR|Control Group|Participants randomized to Control Group receive 2 doses of Bexsero (MenB) vaccine and 1 dose of Menveo (MenACWY), 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
62244974|NCT04886154|EXPERIMENTAL|ABCWY low dose_01 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0,1 month schedule and are followed up until Day 211 in study Phase II (Sourcing).
62244975|NCT04886154|EXPERIMENTAL|ABCWY high dose_01 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0,1 month schedule and are followed up until Day 211 in study Phase II (Sourcing).
62244976|NCT04886154|EXPERIMENTAL|ABCWY low doseS_02 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0, 2 month schedule and are followed up until Day 241 in study Phase II (Sourcing).
62435051|NCT01294878|EXPERIMENTAL|treatment with omalizumab|Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used
62435052|NCT00864487|EXPERIMENTAL|1|Neratinib alone
62435053|NCT00864487|EXPERIMENTAL|2|Neratinib plus rifampin
62435054|NCT03659968|EXPERIMENTAL|EXPERIMENTAL GROUP|patients in advanced phase of pediatric cancer Physical activity training will be performed in drug development
62822809|NCT06595186|EXPERIMENTAL|Dose Escalation Cohort|"Participants will receive JK-1201I as an intravenous (IV) infusion at each 14-day cycle (Q2W) until a treatment discontinuation criterion is met as specified in the protocol. Escalating doses of JK-1201I will be evaluated by the traditional 3+3 design.~Temozolomide will be administered per drug label."
62822810|NCT06595186|EXPERIMENTAL|Dose Expansion Cohort|"Participants will receive JK-1201I as an intravenous (IV) infusion as the recommended Phase 2 dose at each 14-day cycle (Q2W) until a treatment discontinuation criterion is met as specified in the protocol.~Temozolomide will be administered per drug label."
62822811|NCT06305182|EXPERIMENTAL|Metreleptin-assisted therapy|"25 patients will receive a daily subcutaneous injection of metreleptin for 14 days.~The dose starts with 0.4 ml daily, and gradually increases until 1.8 ml; until 1.2 ml in male patients daily."
62822812|NCT06305182|PLACEBO_COMPARATOR|Placebo-therapy|25 patients will receive a daily subcutaneous injection of inactive substance (placebo) for 14 days. To ensure blinding, the dosing scheme of placebo will have the identical volume to the dosing scheme of metreleptin (verum).
62822813|NCT03913936|EXPERIMENTAL|NEWLY DIAGNOSED|"Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.~The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
62822814|NCT03913936|EXPERIMENTAL|SURVIVOR|"* Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.~* The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
62822815|NCT03913936|EXPERIMENTAL|LIVING WITH ADVANCED DISEASE|"* Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.~* The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
62822816|NCT05587764||Standard of Care|Standard of Care for emergency care
62822817|NCT04163341|EXPERIMENTAL|Common Elements Treatment Approach (CETA) protocol|Adapted Common Elements Treatment Approach (CETA): The intervention is a transdiagnostic cognitive behavioral therapy approach to treating any combination of depression, anxiety, post-traumatic stress, or substance use disorder that has been adapted the needs of adults with HIV and to additionally address HIV care engagement.
62822818|NCT04163341|NO_INTERVENTION|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC): Usual care at the 1917 Clinic for patients with mental health concerns includes referral to a clinic social worker or counselor or to an external mental health clinic as needed. Usual care was enhanced by providing the participant's medical provider with information about the participant's elevated mental health symptoms at enrollment and recommendations for treatment.
62822819|NCT06452784||All study participants|Alle study participants will receive standard of care. For this study participants will complete two short questionnaires (the STOPBANG and ESS) and will undergo three home sleep apnea tests with the WatchPat one. These will be performed during the night seven days prior to surgery and during night one and three after surgery.
62822820|NCT05589662||Hemophilia group|Patients with hemophilia, older than 18 years, with a diagnosis of hemophilic arthropathy of the knee and ankle. The different study variables will be evaluated following the indicated protocol.
62822821|NCT05589662||Healthy peers.group|Healthy subjects, older than 18 years, without joint damage at the time of the study, and physically active. The different study variables will be evaluated following the indicated protocol.
62822822|NCT06603974|EXPERIMENTAL|Benmelstobart combined with antiangiogenic drugs and neoadjuvant chemotherapy|"Benmelstobart: 1200mg, diluted to 250ml with normal saline, infusion time 60 ± 10mins. The first day of each cycle, 3 weeks (21 days) as a treatment cycle; antiangiogenic drugs are decided by the investigator according to the actual situation; tegafur: it needs to be administered according to the patient's body surface area\< 40mg / time at 1.25m2; \> 50mg/ time for 1.25m2 and \<1.5m2; \> 60mg/ time at 1.5m2; Oral, twice a day, after morning and evening meals, for 14 consecutive days, rest for 7 days, as a treatment cycle; Repeat every 3 weeks; oxaliplatin: 130mg/m2, administered on the first day of each cycle, repeated every 3 weeks; Chemotherapy drugs can also be selected by the investigator.~albumin paclitaxel: 260mg/m2, intravenous infusion, 30 minutes per infusion, once every 3 weeks, administered on the first and eighth days of each cycle"
62822823|NCT04011176|PLACEBO_COMPARATOR|Standard treatment + placebo|Placing the microcurrent pads on the patient but not turning on the microcurrent box for 30 minutes once a week for 6 weeks
62435055|NCT03806322|EXPERIMENTAL|Cold-pack Group|One group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and cold packs
62435056|NCT03806322|EXPERIMENTAL|Intermittent Pneumatic Compression|The second group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and intermittent pneumatic compression
62822824|NCT04011176|EXPERIMENTAL|Standard treatment + Microcurrent Therapy|100-300µA microcurrent delivered for 20-300 minutes, once a week for 6 weeks
62822825|NCT06122194|EXPERIMENTAL|Period 1 formulation 1 PF-07817883|Single oral dose of PF-07817883 tablet under fasted condition
62822826|NCT06122194|EXPERIMENTAL|Period 2 formulation 2 PF-07817883|Single oral dose of PF-07817883 tablet under fasted condition
62435057|NCT01503359|EXPERIMENTAL|Dietary Supplement: Sarcosine|Sarcosine Group
62822827|NCT06122194|EXPERIMENTAL|Period 3 formulation 3 PF-07817883|Single oral dose of PF-07817883 tablet under fasted condition
62435058|NCT01503359|PLACEBO_COMPARATOR|Placebo|Control Group
62435059|NCT05700357|ACTIVE_COMPARATOR|Thoracic Paravertebral Block 20 ml|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 20 ml of 0.25% bupivacaine will be injected into this area.
62822828|NCT06122194|EXPERIMENTAL|Period 4 formulation 4 PF-07817883|Single oral dose of PF-07817883 tablet under fasted condition
62822829|NCT06595368|NO_INTERVENTION|Control Group|Consisted of 30 newborns who will receive conventional hospital care with no additional interventions.
62822830|NCT06595368|EXPERIMENTAL|Study group I (Vimala group)|Consisted of 30 neonates who will receive Vimala massage.
62822831|NCT06595368|ACTIVE_COMPARATOR|Study group II (Hydrotherapy)|Consisted of 30 neonates who will receive hydrotherapy.
62822832|NCT06210711|PLACEBO_COMPARATOR|Treatment as Usual|Participants in the Treatment as Usual group (TAU) will not receive the Brief PE therapy, but the standard clinical treatment received by all patients admitted to BUMC, BSWMC Temple or FH/MCW trauma centers. Treatment as usual participants will have follow-up assessments at 1, 3, and 6 months from Baseline.
62041898|NCT02434380|ACTIVE_COMPARATOR|High dose vitamin D|Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
62041899|NCT06714955|EXPERIMENTAL|Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.|Drug: BGM0504 Administered SC
62041900|NCT06714955|EXPERIMENTAL|Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.|Drug: BGM0504 Administered SC
62041901|NCT06714955|PLACEBO_COMPARATOR|Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.|Drug: Placebo Administered SC
62244977|NCT04886154|EXPERIMENTAL|ABCWY high doseS_02 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0, 2 month schedule and are followed up until Day 241 in study Phase II (Sourcing).
62435060|NCT05700357|ACTIVE_COMPARATOR|Thoracic Paravertebral Block 25 ml|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 25 ml of 0.25% bupivacaine will be injected into this area.
62822833|NCT06210711|EXPERIMENTAL|Brief Prolonged Exposure|Participants in the experimental group will receive Brief Prolonged Exposure Therapy. In addition to the standard clinical treatment received by all patients at BUMC, BSWMC Temple and FH/MCW (treatment as usual), participants randomized to the intervention condition will also receive three 60-minute sessions of Brief PE. Participants in the BPE group will complete a screener and then questionnaires/interviews at 1, 2, and 6 months from Baseline.
62822834|NCT01729741|NO_INTERVENTION|No drain|No drain was inserted after Thyroid surgery
62822835|NCT01729741|EXPERIMENTAL|Drain|A drain was inserted after thyroid surgery
62822836|NCT03646877|EXPERIMENTAL|Ozone (O3)|The O3 level during the exposures will be 200 ppb, which has previously been used in human exposure studies without short or long term, untoward side effects (and comparable to peak levels attained during the summer in the Raleigh-Durham area of North Carolina) (REF - Bromberg review).
62822837|NCT03646877|PLACEBO_COMPARATOR|Filtered Air (FA)|Control will be treadmill walk with filtered room air in chamber.
62822838|NCT05583422|EXPERIMENTAL|Cases|This arm will be compiled of prospectively recruited cases for confirmatory testing based on their suspected genotype per Michigan Genomics Initiative and patients who have been retrospectively identified as any patient who had clinical genotype testing and had a variant that was their clinician used to guide the chemotherapy treatment. Prospective patients will undergo confirmatory genetic testing by a CLIA lab and those results will be provided to the patients clinical team at that time.
62822839|NCT05583422|NO_INTERVENTION|Controls|This arm will be compiled of all retrospective patients where genetic information was not known prior to receiving treatment.
62822840|NCT06537700||Group1 (>=10years) and Group1 (<10years)|Patients will be divided into 2 groups according to their CM history (duration): A) those from 1 to 9 years and B) those with 10 or more years of CM history.
62822841|NCT01056822|ACTIVE_COMPARATOR|1|Mycophenolate mofetil
62822842|NCT01056822|EXPERIMENTAL|2|Miycophenolate sodium
62822843|NCT03783143||Clinical Cohort|This study population will consist of patient volunteers that visit one of our clinical sites with an undiagnosed febrile illness.
62822844|NCT03783143||Cross-sectional Cohort|This study population will consist of patient volunteers that visit one of our clinical sites with an undiagnosed febrile illness.
62822845|NCT05591092||Observational (I-123, planar imaging, SPECT/CT scan)|Patients receive iodine-123 PO and then undergo planar imaging and a SPECT/CT scan on study.
62822846|NCT03354949||Positioning hemiplegic.|"Positioning all hemiplegic by stroke requiring a single wheelchair even at the exit of the SSR and hemiplegic patient with sequelae.~Measurement of sitting postural control of the adult (MCPAA). Assessment of wheelchair pain in the spine and ischia by a self-evaluation scale (EVA).~Propulsion speed of a wheelchair."
62822847|NCT04261244|EXPERIMENTAL|Experimental Arm|preoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
62822848|NCT04261244|ACTIVE_COMPARATOR|Standard treatment|standard treatment (postoperative radiotherapy) in breast cancer after neoadjuvant chemotherapy
62822849|NCT05935735|EXPERIMENTAL|BBTI Group|Participants will receive 4 in-person sessions of Brief Behavioral Therapy for insomnia as part of their intensive outpatient treatment of substance use recovery
62822850|NCT05935735|NO_INTERVENTION|SOC Group|Participants will receive their usual substance abuse treatment as part of their intensive outpatient treatment of substance use recovery
62822851|NCT01312857|EXPERIMENTAL|Randomization to panitumumab|Patients whose liver metastases have been completely resected will be randomized Arm A will receive Panitumumab in addition to HAI FUDR/Dexamethasone plus systemic CPT-11/5FU/LV
62822852|NCT01312857|EXPERIMENTAL|Randomization to No Panitumumab|Patients whose liver metastases have been completely resected will be randomized and patients randomized to Arm B will receive HAI FUDR/Dex plus systemic CPT-11/5FU/LV alone.
62822853|NCT05082857|ACTIVE_COMPARATOR|"traditional Parents as Teachers (PAT)"|A twice-a-month home visits from trained family educators. Home visits will continue for the remainder of the study period as will the other components of the Parents as Teachers model: regular Group Connections for peer interactions and support, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to community agencies that include the Child Development Services Agency (which provides screening for Individuals with Disabilities in Education Act (IDEA) Part C services), family services, intensive mental health services, among others. The study team will collect baseline data during the first home visit and complete monthly questionnaires during each month the mother is enrolled. An outcome assessment and participation in a focus group will be administered the last month of the study.
62822854|NCT05082857|EXPERIMENTAL|"hybrid PAT model"|A six-week virtual evidence-based parenting class entitled What You Do Matters, which will be delivered in partnership with the Pediatric Advocacy Program at WFBMC which combines short parent-educator discussions followed by interactive activities and peer to peer networking. Young moms will participate in Group Connections for peer interactions and support. After completing the six-week course, teens will begin receiving once a month home visits, ongoing Group Connections, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to other community agencies and resources, as listed above. The study team will collect baseline data prior to the beginning of the virtual What You Do Matters program and will complete monthly questionnaires during each month the mother is enrolled. An outcome assessment and participation in a focus group will be administered the last month of the study.
62041902|NCT06717685|EXPERIMENTAL|Group A: Conventional Valsalva|Performance of forced expiration in the standard manometer tubing to generate a pressure of 40 mmHg for 15 seconds while lying on back or sitting position.
62244978|NCT04886154|EXPERIMENTAL|ABCWY low doseS_06 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0, 6 month schedule and are followed up until Day 361 in study Phase II (Sourcing).
62822855|NCT03613532|EXPERIMENTAL|Venetoclax|"This study has three periods: 1) Screening 2) Treatment with venetoclax + FluBu2 chemotherapy and transplantation and 3) Post-Transplant follow up.~Dose escalations begin in level I with dose cohorts and rules for escalation/de-escalation.~Part 1 dose escalation will occur using a 3+3 approach. Post-transplant period includes routine follow-up.~* Venetoclax: 6-7 total doses based on level assigned~* Busulfan: given 2x daily for 4 days~* Fludarabine: given 1x daily for 4 days~Part 2 post-transplant period includes therapy with azacitidine and venetoclax. Dose escalation will occur using a 10+10 approach.~* Venetoclax: 14 doses for 8-12 cycles based on level assigned~* Azacitidine: 5 doses for 8-12 cycles based on level assigned~Part 3 post-transplant period includes therapy with oral decitabine/cedazuridine and venetoclax. Dose escalation will occur using a 10+10 approach.~* Venetoclax: 14 doses for 8 cycles~* Decitabine/cedazuridine: 3 doses for 8 cycles"
62822856|NCT03874338||Colchicine|
62822857|NCT03874338||Placebo|
62822858|NCT03716180|EXPERIMENTAL|Paclitaxel+Trastuzumab+Pertuzumab|Paclitaxel is administered intravenously on days 1, 8, and 15 of each 21-day cycle Trastuzumab is administered intravenously on day 1 of each 21-day cycle Pertuzumab is administered intravenously on Day 1 of each 21-day cycle
62822859|NCT06150638|EXPERIMENTAL|Biofeedback|
62822860|NCT06150638|PLACEBO_COMPARATOR|Placebo|
62822861|NCT04825678|EXPERIMENTAL|Erenumab|
62822862|NCT06592690|ACTIVE_COMPARATOR|VDD|A pacing mode which allows sensing of intrinsic sinus rhythm as much as possible to avoid unnecessary atrial pacing is the preferred programming in patients with CRT without atrial pacing indication. VDD pacing mode met these criteria.
62822863|NCT06592690|EXPERIMENTAL|DDDR|DDDR pacing mode added atrial support to these using an accelerometer-based rate-responsive sensor which should be able to increase heart rate when needed.
62435061|NCT05700357|ACTIVE_COMPARATOR|Thoracic Paravertebral Block 30 ml|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.
62822864|NCT04909450|EXPERIMENTAL|CSB-001 Investigational Treatment Arm|One drop CSB-001 four times daily for 8 weeks in the study eye
62244979|NCT04886154|EXPERIMENTAL|ABCWY high doseS_06 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0, 6 month schedule and are followed up until Day 361 in study Phase II (Sourcing).
62244980|NCT05009160||Patients with Multiple Sclerosis (PwMS)|PwMS will download the Healios+Me platform App which contains the dreaMS App and will follow the study schedule.
62244981|NCT05009160||Healthy Control Persons (HC)|HC will download the Healios+Me platform App which contains the dreaMS App and will follow the same study schedule as PwMS.
62244982|NCT05775562|OTHER|Diving arm|The standard arm involves all participants in the study. Subjects will perform pre-dive and post-dive examinations to characterize the respiratory impact of deep water diving
62244983|NCT05789797||The control group|Ademethionine, lyophilisate for solution for intravenous and intramuscular injection, by intravenous drop infusion in the dose of 800 mg/day, on everyday basis for 14 days
62244984|NCT05789797||The test group|Remaxol®, solution for infusions, by intravenous drop infusion in the dose of 400 ml/day, on everyday basis for 12 days
62435062|NCT03826485|EXPERIMENTAL|A group|Period 1: PRIC Period 2: Pranlukast hydrate
62435063|NCT03826485|EXPERIMENTAL|B group|Period 1: Pranlukast hydrate Period 2: PRIC
62435064|NCT02429401|EXPERIMENTAL|Culturally adapted brief intervention|
62601601|NCT00876226|EXPERIMENTAL|Pharmacokinetics of Citalopram in Patients With Short Bowel Syndrome|"Citalopram pharmacokinetics will be studies in subjects with short bowel syndrome.~Citalopram 20mg orally will be given to the subjects and on the seventh day blood will be drawn at hours 0,1,2,3,4,6,8,12,16 and 24 hours post-dose."
62435065|NCT02429401|ACTIVE_COMPARATOR|Non-adapted brief intervention|
62435066|NCT03469271|OTHER|Training and Placebo|Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo for eight weeks
62435067|NCT03469271|OTHER|Sham Training and Vitamin D3 Metabolite|Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25 (OH)2 D3 orally for eight weeks
62435068|NCT03469271|OTHER|Training and Vitamin D3 Metabolite|Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25(OH)2 D3 orally for eight weeks
62435069|NCT03469271|OTHER|Sham Training and Placebo|Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo orally for eight weeks
62435070|NCT05744661|EXPERIMENTAL|Group A (Mechanical Method)|In Group A, Calcium Hydroxide Intracanal Medicament will be removed by using Mechanical Method in which Rotary Master Apical File will be used .
62435071|NCT05744661|EXPERIMENTAL|Group B ( Chemomechanical Method)|In Group B, Calcium Hydroxide Intracanal Medicament will be removed by using Chemomechanical Method which involves Sonic Agitation of Endodontic irrigants.
62435072|NCT01792284|EXPERIMENTAL|LY2605541 Fixed Time Dosing|"Participant-specific dose of LY2605541 administered subcutaneously (SQ) at approximately the same time every evening for 12 weeks in the Lead-in Period and in Randomization Period 1 or Randomization Period 2.~Participant-specific dose of insulin lispro SQ when \>20% of calories were consumed (pre-meal).~Insulin dose and adjustments to insulin dose were determined by insulin algorithms based on self-monitored blood glucose (SMBG). Target glucose values were as follows:~Preprandial and bedtime BG between 71 and 130 milligrams/deciliter (mg/dL) Insulin adjustment and glucose correction between 71 and 100 mg/dL."
62435073|NCT01792284|EXPERIMENTAL|LY2605541 Variable Time Dosing|"Participant-specific dose of LY2605541 administered SQ on a variable time schedule (8- and 40-hour dosing intervals) for 12 weeks in Randomization Period 1 or Randomization Period 2. Dosing schedules were to remain approximately the same throughout the 12 weeks.~Participant-specific dose of insulin lispro SQ when \>20% of calories were consumed (pre-meal).~Insulin dose and adjustments to insulin dose were determined by insulin algorithms based on SMBG. Target glucose values were as follows:~Preprandial and bedtime BG between 71 and 130 mg/dL Insulin adjustment and glucose correction between 71 and 100 mg/dL."
62435074|NCT03119064|EXPERIMENTAL|Dose 1|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 1 50mg/m2 IV every 2 weeks"
62435075|NCT03119064|EXPERIMENTAL|Dose 2|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 2 70 mg/m2 IV every 2 weeks"
62435076|NCT03119064|EXPERIMENTAL|Dose 3|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 3 80mg/m2 IV every 2 weeks"
62435077|NCT03269175|OTHER|Experimental arm 15 years ago|This long term study does not imply current study medication. It looks at the status 15 years after the clinicial trial (BENEFIT)
62601602|NCT01721915|EXPERIMENTAL|Vitamin D supplementation|The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)
62041903|NCT06717685|EXPERIMENTAL|Group B: Modified Valsalva Maneuver|Patient will be placed in semi-recumbent position and instructed to exhale forcefully in manometer to generate pressure of 40 mmHg for 15 seconds, immediately followed by supine repositioning of the bed, and simultaneous passive leg raising to 45 degree with the help of one assistant standing on the foot side, for 15 seconds.
62244985|NCT06584071|EXPERIMENTAL|Cohort 1- combination treatment|Combination regimen：PM8002 combined with PM1009. The drugs are administered on the first day every 3 weeks (Q3W), until disease progression or intolerable toxicity or patient withdrawal or study discontinuation(Whichever occurs first).
62435078|NCT03269175|OTHER|Placebo arm, offered treatment at MS diagnosis or at Month 24|This long term study does not imply current study medication. It looks at the status 15 years after the clinicial trial (BENEFIT)
62435079|NCT06206733|EXPERIMENTAL|Group A|Treatment with intravenous infusion of ASKB589 on day 1 of each cycle. The infusion duration should be at least 3 hours, and can be shortened or extended in subsequent cycles as appropriate according to the patient's tolerability. Interruption or slow down of intravenous infusion is allowed to manage toxicity. Dosing is continued every cycle until participants meet the criteria of treatment discontinuation.
62435080|NCT06206733|PLACEBO_COMPARATOR|Group B|Treatment with intravenous infusion of placebo on day 1 of each cycle. The infusion duration should be at least 3 hours, and can be shortened or extended in subsequent cycles as appropriate according to the patient's tolerability. Interruption or slow down of intravenous infusion is allowed to manage toxicity. Dosing is continued every cycle until participants meet the criteria for treatment discontinuation.
62041904|NCT06717685|ACTIVE_COMPARATOR|Group C: Modified Valsalva Maneuver|Patient will be placed in semi-recumbent position and instructed to exhale forcefully in manometer to generate pressure of 40 mmHg for 15 seconds, immediately followed by supine repositioning of the bed, and simultaneous passive leg raising to 45 degree with the help of one assistant standing on the foot side, for 15 seconds.
62601603|NCT01721915|PLACEBO_COMPARATOR|Placebo|the placebo group will receive oily drops without vitD
62601604|NCT03613883|EXPERIMENTAL|Primary Study Arm|The intervention is done to those patients that are managed by endovascular stent that is inserted in the parent artery to induce slowness in the blood flow thus initiate thrombosis in the aneurysmal sac.
62601605|NCT03613883|EXPERIMENTAL|Expanded Selection Arm|The intervention is done to the expanded selection arm and is managed by embolic materials (coils / glue) that occlude the aneurysm by proximal occlusion, proximal and distal occlusion or sac packing
62601606|NCT01947426|EXPERIMENTAL|DHA supplementation|mother consuming 400 mg/day of DHA and tehir neonates
62601607|NCT01947426|PLACEBO_COMPARATOR|Control (milk without DHA)|Mothers comsuming placebo and their neonates
62601608|NCT05621005|EXPERIMENTAL|treatment group or Rifaximin group|they received Rifaximin 550 milligram every 12 hour
62435081|NCT01164735||Correlative studies|Archived tumor tissue samples are analyzed for topoisomerase 2-alpha gene alteration and expression and chromosome 17 polysomy by FISH and IHC. Clinical information associated with each endometrial carcinoma sample (e.g., age, race/ethnicity, cell type, histologic grade, disease stage, and regimen type) is also collected.
62435082|NCT06319391||donor/acceptor expression group|
62822865|NCT04909450|PLACEBO_COMPARATOR|Vehicle Control Arm|One drop matching vehicle four times daily for 8 weeks in the study eye
62601609|NCT05621005|ACTIVE_COMPARATOR|control group or Norfloxacin group|they received Norfloxacin 400 milligram per day
62601610|NCT06648291|EXPERIMENTAL|Telehealth|Through remote monitoring of various physiological data uploaded by the patient, immediate contact will be made when abnormal values are detected to provide individualized health education. This approach encourages the maintenance of a healthy lifestyle and facilitates early problem detection to prevent the worsening of symptoms.
62601611|NCT06648291|PLACEBO_COMPARATOR|Usual care|Provide post-operative education on the day of discharge and follow up with a phone call one week after discharge to check on the patient.
62601612|NCT02062710|EXPERIMENTAL|A, B, then C|"Subjects received the following: Period 1: single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg, in naturally-flavored cocoa syrup (treatment A). Period 2: dextromethorphan syrup 30 mg (treatment B); Period 3: placebo liquid, dextrose in water, 20 mL (treatment C).~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.Each dosing period separated by 1-2 day washout period."
62601613|NCT02062710|EXPERIMENTAL|A, C, then B|"Subjects received the following: Period 1: single oral doce of diphenhydramine 25 mg and phenylephrine 10 mg, in naturally-flavored cocoa syrup (treatment A); Period 2: placebo liquid, dextrose in watwer, 20 mL (treatment C); Period 3: dextromethorphan syrup 30 mg (treatment B).~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.Each dosing period separated by 1-2 day washout period."
62601614|NCT02062710|EXPERIMENTAL|B, A, then C|Subjects received the following: Period 1: dextromethorphan syrup 30 mg (treatment B); Period 2: single dose of oral diphenhydramine 25 mg and phenylephrine 10 mg, in a naturally-flavored cocoa syrup (treatment A); Period 3: placebo liquid, dextrose in water, 20 mL (treatment C). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
62601615|NCT02062710|EXPERIMENTAL|B, C, then A|"Subjects received the following: Period 1: dextromethorphan 30 mg syrup (treatment B); Period 2: placebo liquid, dextrose in water, 20 mL (treatment C); Period 3: single dose of oral diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A).~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period."
62601616|NCT02062710|EXPERIMENTAL|C, A, then B|Subjects received the following: Period 1: placebo liquid, dextrose in water, 20 mL (treatment C); Period 2: a single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A); Period 3: dextromethorphan 30 mg syrup (treatment B). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
62822866|NCT04914364||Patients who have tested positive for COVID-19|"Patients who are designated as COVID recovered in the electronic medical record and who fit the inclusion criteria."
62041905|NCT03931148|EXPERIMENTAL|Intervention|"After first consultation for diagnosis of neurodegenerative disorder :~* Geriatric Assessment with specific neuropsychologic tests of decision making~* fRMI~* EEG High Resolution~* Qualitative interview"
62041906|NCT03360942|EXPERIMENTAL|DBS Long Term Follow Up|5 participants who were in a prior study to receive DBS are enrolled to have their progress and DBS devices monitored for a period of 12 years.
62435083|NCT06319391||donor expression/acceptor non-expression|
62822867|NCT06220435|EXPERIMENTAL|HYPO-RT-PC boost|Ultra-hypofractionated seven-fraction radiotherapy regimen including focal boost and lymph node irradiation.
62041907|NCT02264678|EXPERIMENTAL|Module 2 Part A1|Module 2 Part A1: ascending doses of ceralasertib will be administered alone to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD) to take into Module 2 Part A2.
62435084|NCT06319391||donor non-expression/acceptor expression|
62435085|NCT06319391||donor/acceptor non-expression group|
62435086|NCT00707174|ACTIVE_COMPARATOR|1|"Topical imiquimod group:~treat the LM site two centimeters beyond the perimeter margin with topical imiquimod 5% cream Monday thru Friday of each week for a total of twelve weeks. After three months of topical treatment, a one-month wash out period will be observed to allow for resolution of inflammation that can obscure the pathologist's ability to evaluate the excised tumor/treatment site."
62435087|NCT00707174|EXPERIMENTAL|2|"Topical imiquimod and topical tazarotene 0.1% cream group:~Patients randomized to this group will undergo an identical treatment protocol as the topical imiquimod group with the addition of topical tazarotene 0.1% cream on Saturday and Sunday of each week."
62435088|NCT03221946|ACTIVE_COMPARATOR|Diclofenac sodium oral|Group A which included 30 patients of either gender. Dosage drug: Diclofenac sodium Dosage form: Oral medication Frequency: twice daily Dose: 50mg Duration: 2 days
62435089|NCT03221946|EXPERIMENTAL|diclofenac sodium patch|Group B which included 30 patients who were prescribed Drug: Diclofenac sodium Dose: 100mg Drug form: transdermal patch to equate the oral dosage of 50mg Duration: for 2 days Frequency: Once daily
62822868|NCT05358665||Group 1|There are individuals who use masks for less than 4 hours daily.
62822869|NCT05358665||Group 2|There are individuals who use masks for 4-8 hours daily.
62822870|NCT05358665||Group 3|There are individuals who use masks for more than 8 hours daily.
62822871|NCT05520255|EXPERIMENTAL|18F-PSMA-1007|18F-PSMA-1007, 4 MBq/kg (max 400 MBq; +/- 15%), intravenous, single dose
62822872|NCT03911505|EXPERIMENTAL|Cipaglucosidase Alfa (ATB200)/Miglustat(AT2221)|Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat (AT2221) capsule
62822873|NCT05630924|EXPERIMENTAL|SI! Program-NYC Children|Receives 4 month health promotion educational intervention.
62822874|NCT05630924|NO_INTERVENTION|NYC Elementary School Children|The control group will be participating school children not enrolled in the program
62822875|NCT00399308|ACTIVE_COMPARATOR|Control|Multi-layer compression bandaging (Profore)
62601617|NCT02062710|EXPERIMENTAL|C, B, then A|Subjects received the following: Period 1: placebo liquid, dextrose in water, 20 mL (treatment C); Period 2: dextromethorphan 30 mg syrup (treatment B); Period 3: a single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
62601618|NCT01605032|EXPERIMENTAL|Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)|"CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.~TRANSPLANT: Patients undergo autologous PBSCT on day 0."
62601619|NCT02222597||positive infrascanner finding|
62601620|NCT03633149|EXPERIMENTAL|Computer tablet-delivered C4H|Two session CHOICES4Health intervention delivered by a computer tablet to address no use or ineffective use of contraception, and risky alcohol use, or cigarette smoking, or marijuana use.
62244986|NCT06584071|EXPERIMENTAL|Cohort 2- combination treatment|Combination regimen：PM8002 combined with PM1009(low dose). The drugs are administered on the first day every 3 weeks (Q3W), until disease progression or intolerable toxicity or patient withdrawal or study discontinuation(Whichever occurs first).
62601621|NCT03633149|EXPERIMENTAL|Person-delivered C4H|Two session CHOICES4Health intervention delivered by a counselor to address no use or ineffective use of contraception, and risky alcohol use, or cigarette smoking, or marijuana use.
62601622|NCT03633149|ACTIVE_COMPARATOR|Brief Advice|Women will receive advice and educational material from a research assistant about risk drinking, smoking, marijuana, and contraception, depending on their specific risk behaviors, as well as information about women's health. In addition, the women will receive referrals to the Harris Health System's SBIRT clinic if needed.
62601623|NCT04965441||Computer-assisted surgery (CAS) group|
62601624|NCT04965441||Non-CAS group|
62601625|NCT00083941|EXPERIMENTAL|TroVax and IL-2|TroVax: Intramuscular into the deltoid muscle of the upper arm, 10x dose (6.83 x 108 pfu/ml). IL 2: High dose IL 2, 600,000 IU/kg intravenously every 8 hours up to a maximum of 15 injections.
62601626|NCT05501327|EXPERIMENTAL|Cohort A|"Injection of SLI-F06 on Treatment Day 0, immediately after wound closure:~* Formulation buffer (control)~* 3.75 mg SLI-F06 total dose per wound (1X)~* 7.5 mg SLI-F06 total dose per wound (2X)~* 15 mg SLI-F06 total dose per wound (4X)"
62601627|NCT05501327|EXPERIMENTAL|Cohort B|"Injection of SLI-F06 on Treatment Day 0, immediately after wound closure and on Days 1, 2, 3, 4:~* Formulation buffer (control)~* 3.75 mg SLI-F06 total dose per wound (1X)~* 7.5 mg SLI-F06 total dose per wound (2X)~* 15 mg SLI-F06 total dose per wound (4X)"
62244987|NCT06584071|EXPERIMENTAL|Cohort 3- monotherapy|PM8002 administered on the first day every 3 weeks (Q3W), until disease progression or intolerable toxicity or patient withdrawal or study discontinuation(Whichever occurs first).
62601628|NCT05501327|EXPERIMENTAL|Cohort C|"Injection of SLI-F06 on Treatment Day 0, immediately after wound closure and then 3 hours after for wounds dosed twice:~* Formulation buffer (control) once~* 7.5 mg SLI-F06 total dose per wound (2X) once~* 3.75 mg SLI-F06 dose per wound (1X) twice, total dose 7.5 mg~* 7.5 mg SLI-F06 total dose per wound (2X), total dose 15 mg"
62601629|NCT02222675|EXPERIMENTAL|Sonographically assisted breast surgery|Sonographically assisted breast surgery
62601630|NCT02222675|ACTIVE_COMPARATOR|Conventional breast surgery|Conventional breast surgery
62601631|NCT01837173||Extracapsular LNI|Patients with positive lymph nodes that show extracapsular lymph node involvement
62601632|NCT01837173||Intracapsular LNI|Patients with positive lymph nodes that show NO extracapsular lymph node involvement
62601633|NCT05295979|EXPERIMENTAL|Inflammatory skin disease formula (ISDF)|Subjects will receive ISDF granules (10.85g twice daily) for 12 weeks.
62601634|NCT05295979|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo granules (10.85g twice daily) for 12 weeks.
62601635|NCT03147859|EXPERIMENTAL|Group A-150mg dose of vedolizumab per infusion followed by ATI - Low Dose|\* Please note that the previous low dose arm was 75mg of vedolizumab per infusion, but no participant was ever given this dose. The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 150 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 doses as tolerated. ATI will begin between weeks 6 and 7, and infusions continued at weeks 8, 12, 16 and 20.
62822876|NCT00399308|EXPERIMENTAL|Celaderm, Bi-Weekly|Celaderm, bi-weekly applications, up to a maximum of four applications
62822877|NCT00399308|EXPERIMENTAL|Celaderm, Weekly|Celaderm, applied weekly, up to a maximum of four applications
62041908|NCT02264678|EXPERIMENTAL|Module 2 Part A2|Module 2 Part A2: ascending doses of ceralasertib will be administered in combination with olaparib to patients to define the dose, frequency and schedule of ceralasertib and olaparib to take into Module 2 Part B.
62244988|NCT06584071|ACTIVE_COMPARATOR|Cohort 4|Combination regimen：atezolizumab combined with bevacizumab. The drugs are administered on the first day every 3 weeks (Q3W), until disease progression or intolerable toxicity or patient withdrawal or study discontinuation(Whichever occurs first).
62244989|NCT04091022|ACTIVE_COMPARATOR|Diclofenac + DFMO|Participants in this arm will apply topical diclofenac to bilateral forearms once per day and topical DFMO to bilateral forearms once per day.
62244990|NCT04091022|PLACEBO_COMPARATOR|Placebo + Placebo|Participants in this arm will apply placebo for topical diclofenac to bilateral forearms once per day and placebo for topical DFMO to bilateral forearms once per day.
62041909|NCT02264678|EXPERIMENTAL|Module 2 Part B1|Module 2 Part B1: Patients with second line 'ATM deficient' gastric adenocarcinoma including GEJ adenocarcinoma will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
62435090|NCT03221946|OTHER|Diclofenac sodium injection|Group C which included 30 patients of either gender Drug: diclofenac sodium intra muscular injections Dose: 75mg which was the nearest available dosage to 100 mg availability in India Frequency: once daily Duration: for 2 days
62822878|NCT01043068|EXPERIMENTAL|Pain control|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
62822879|NCT03123692|EXPERIMENTAL|Treatment|14 days treatment with NBMI 300 mg/day
62435091|NCT01890187||Advanced dry AMD with geographic atrophy|Patients diagnosed with advanced dry AMD with geographic atrophy
62822880|NCT03123692|PLACEBO_COMPARATOR|Placebo|14 days treatment with Placebo
62822881|NCT03059849|ACTIVE_COMPARATOR|Temporary increase in adalimumab|
62822882|NCT03059849|NO_INTERVENTION|Continued monitoring as per standard of care|
62822883|NCT01074970|ACTIVE_COMPARATOR|Arm A: Cisplatin Monotherapy|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
62822884|NCT01074970|ACTIVE_COMPARATOR|Arm B: Combination Therapy|"Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles~Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles"
62822885|NCT05684237|OTHER|HiSMILE treatment option|HiSMILE treatment option
62041910|NCT02264678|EXPERIMENTAL|Module 2 Part B2|Module 2 part B2: Patients with second line 'ATM proficient' gastric adenocarcinoma including GEJ adenocarcinoma will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
62435092|NCT00323674|ACTIVE_COMPARATOR|Light Weight Mesh|
62435093|NCT00323674|ACTIVE_COMPARATOR|Polysoft Mesh|
62435094|NCT06186167||High-Risk Cardiac Device Recipients|Participants in this cohort are individuals undergoing clinically indicated cardiac device implantation, such as pacemakers, ICDs, ILRs, or CRT-D/Ps. During the standard implantation procedure, chest wall fat tissue typically excised to create space for the device is collected for histopathological analysis to identify amyloid deposits. This study involves no additional intervention beyond the routine clinical care received by the patients.
62435095|NCT02602340|EXPERIMENTAL|Behavioral Activation therapy|Participants will complete 10, 90-minute sessions of Behavioral Activation therapy, conducted using a group format. Each group will include 8-12 participants. Behavioral Activation therapy seeks to target behaviors that might maintain or worsen the depression.
62435096|NCT01716754|EXPERIMENTAL|QGE031 240 mg every 2 weeks (q2w)|Participants received QGE031 240 mg subcutaneously (s.c.) q2w for 16 weeks.
62435097|NCT01716754|EXPERIMENTAL|QGE031 240 mg q4w|Participants received QGE031 240 mg s.c. q4w for 16 weeks.
62435098|NCT01716754|EXPERIMENTAL|QGE031 180 mg q2w|Participants received QGE031 180 mg s.c. q2w for 16 weeks.
62435099|NCT01716754|EXPERIMENTAL|QGE031 120 mg q2w|Participants received QGE031 120 mg s.c. q2w for 16 weeks.
62822886|NCT05817890|EXPERIMENTAL|Up to 8 subjects will be enrolled and studied as a single group|The purpose of this study is to determine the absorption, metabolism, and excretion (AME) of \[14C\]CYC065 and to characterize and determine, where possible, the metabolites present in plasma, urine, and feces in healthy male subjects following a single oral administration.
62435100|NCT01716754|EXPERIMENTAL|QGE031 36 mg q2w|Participants received QGE031 36 mg s.c. q2w for 16 weeks.
62435101|NCT01716754|EXPERIMENTAL|QGE031 12 mg q2w|Participants received QGE031 12 mg s.c. q2w for 16 weeks.
62822887|NCT04986865|EXPERIMENTAL|Single experimental arm for ATG-101|Subjects with advanced or metastatic solid tumors and mature B-NHLs will be enrolled.
62822888|NCT04186429||traumatic brain injury|Children with traumatic brain injury
62822889|NCT04186429||orthopedic injury|Children with orthopedic injury
62822890|NCT03241732|ACTIVE_COMPARATOR|Dietary (AID) Cohort|Anti-inflammatory Diet: This arm will focus on adjusting dietary practices to eat foods that have lower amounts of inflammatory foods that might help reduce overall inflammation in the brain and body. This arm will introduce patients to an integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.
62822891|NCT03241732|ACTIVE_COMPARATOR|Intravenous/Oral NAC Cohort|N-acetyl Cysteine: This arm provide patients with a natural supplement, n-acetyl cysteine (NAC) which is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine, that supports antioxidants to reduce oxidative damage in the body. NAC is a common over-the-counter supplement.Laboratory studies have suggested that NAC might have a beneficial effect in neurodegenerative disorders such as TBI. Patients in this arm will receive IV NAC once a week plus oral NAC supplement 500 mg twice per day for approximately 3 months until the follow up evaluation.
62822892|NCT03241732|NO_INTERVENTION|Control Cohort|Control Group: Standard of Care Treatment for at least 3 months. After the first 3 month, participants in this arm may crossover to the NAC study arm.
62244991|NCT01789099|EXPERIMENTAL|UV1 synthetic peptide vaccine and GM-CSF|GM-CSF (Leukine) followed by UV1 peptide vaccine with escalating concentrations (100, 300 and 700 microgram) will be injected intradermally in the lower abdomen.
62601636|NCT03147859|EXPERIMENTAL|Group B-300mg dose of vedolizumab per infusion followed by ATI - Mid Dose|The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 300 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 (and up to 12) doses as tolerated. ATI will begin between week 10, and infusions continued at weeks 12, 16 and 20. Infusions may also be given at weeks 24, 28, 32, 36 and 40 depending on tolerance and pVL response.
62822893|NCT03241732|ACTIVE_COMPARATOR|Neuro Emotive Technique (NET)|Eligible participants would be evaluated (or re-evaluated) receive neurocognitive tests, and receive baseline PET-MRI and follow up MRI imaging; pre-screening measures distress by the Subjective Units of Distress interview, biofeedback measures of heart rate variability (HRV) and galvanic skin resistance (GSR) and Baseline and post NET blood plasma and serum analysis to measure inflammation and immune function. Participants from the initial study will be re-consented if enrolled in the Neuro Emotive Technique Substudy. SUDS, biofeedback and surveys, MRI imaging and blood draws will be completed again after the 5 NET sessions are complete.
62244992|NCT03732651|EXPERIMENTAL|non-pulsatile blood flow|
62822894|NCT01852877||Jail: HIV testing, corrections case mgt|For all jail detainees regardless of HIV status, we observed the uptake of opt-out and opt-in HIV testing. For HIV-positive jail detainees leaving jail, we observed 1) health outcomes for corrections case management versus other than corrections case management, 2) the impact of an incentive to visit an HIV service organization after release from jail
62822895|NCT01852877||Prison: telemed, corrections case mgt|We compared outcomes for for HIV-positive prisoners before and after the implementation of telemedicine to deliver HIV medical care. For HIV-positive prisoners released from prison and returning to Chicago, we observed health outcomes for those enrolled in corrections case management those not enrolled in corrections case management.
62822896|NCT06603363|EXPERIMENTAL|Intensified Statin Arm|Participants will receive one capsule (40 mg of rosuvastatin), taken once daily for 3 months, orally with or without food. After the 3-month visit, the dose will be reduced to a dose per standard of care.
62822897|NCT06603363|PLACEBO_COMPARATOR|Placebo Arm|Participants will receive one capsule (a placebo for rosuvastatin), taken once daily for 3 months, orally with or without food. After the 3-month visit standard rosuvastatin therapy will be initiated.
62822898|NCT03458676|EXPERIMENTAL|Advanced MR Imaging (AMRI) Scan|"AMRI scan performed within 2 weeks before standard of care brain surgery.~During the surgery, neurosurgeon(s) use the information collected from the AMRI to decide what area of the brain tumor will be biopsied."
62822899|NCT03079921|ACTIVE_COMPARATOR|Group 1-Propranolol Intra-hepatic islet|The dose of propranolol will be 0.48 μg/kilogram•minute, which will provide a total dose of 0.10 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
62822900|NCT03079921|ACTIVE_COMPARATOR|Group 1-Phentolamine Intra-hepatic islet|The dose of phentolamine will be 0.95 μg/kg•min, which will provide a total dose of 0.20 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
62822901|NCT03079921|PLACEBO_COMPARATOR|Group 1- Placebo Intra-hepatic islet|Placebo in 100mL NSS. Infuse Intravenously at 0.0095 ML/KG/MIN. 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
62822902|NCT03079921|NO_INTERVENTION|Group 2 - Extra-hepatic islet|Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.
62822903|NCT03079921|NO_INTERVENTION|Group 3 - Intra-hepatic auto islet|Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.
62244993|NCT03732651|EXPERIMENTAL|pulsatile blood flow|
62244994|NCT04692818|EXPERIMENTAL|Clinically indicated breast tumor biopsy|Subjects with breast lesion and are scheduled for clinically-indicated biopsy will have 3D Multimodal Ultrasound Imaging performed
62244995|NCT04246086|EXPERIMENTAL|Intravenous (IV) Mosunetuzumab + Lenalidomide (Non-randomized)|Participants will receive treatment with IV mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
62822904|NCT06589817|EXPERIMENTAL|Hydrochloride Carliprazine capsules + Aripiprazole tablet placebo|
62822905|NCT06589817|ACTIVE_COMPARATOR|Aripiprazole tablets + Hydrochloride Carliprazine capsules placebo|
62041911|NCT02264678|EXPERIMENTAL|Module 2 Part B3|Module 2 Part B3: Patient with second or third line breast cancer with BRCA mutations (somatic or germline), excluding HER2 positive breast cancer will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
62244996|NCT04246086|EXPERIMENTAL|Subcutaneous (SC) Mosunetuzumab + Lenalidomide (Non-randomized)|Participants will receive treatment with SC mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward). Participants that have received complete metabolic response (CMR) or partial metabolic response (PMR) after 12 cycles of induction therapy with mosunetuzumab + lenalidomide will receive maintenance therapy with SC mosunetuzumab every 8 weeks (Q8W) for an additional 9 cycles.
62244997|NCT04246086|EXPERIMENTAL|Arm A: IV Mosunetuzumab + Len (Randomized)|Participants will receive treatment with IV mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
62244998|NCT04246086|EXPERIMENTAL|Arm B: SC Mosunetuzumab + Len (Randomized)|Participants will receive treatment with SC mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
62244999|NCT04280276|ACTIVE_COMPARATOR|Group 1 - Patients with high IPV (designated as ≥ 30%).|Patients with high IPV (designated as ≥ 30%).
62245000|NCT04280276|ACTIVE_COMPARATOR|Group 2 - patients with normal IPV (< 30%).|Patients with normal IPV (\< 30%). Will assess risk of subclinical acute rejection in patients with high IPV compared to normal IPV. All tacrolimus 12 h trough levels in patients with stable allograft function at least 3 months post-transplant.
62601637|NCT03147859|EXPERIMENTAL|Group C-600mg dose of vedolizumab per infusion followed by ATI - High Dose|The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 600 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 (and up to 12) doses as tolerated. ATI will begin between week 10, and infusions continued at weeks 12, 16 and 20. Infusions may also be given at weeks 24, 28, 32, 36 and 40 depending on tolerance and pVL response.
62601638|NCT02850016|EXPERIMENTAL|Group A|Two treatment cycles each consisting of 3BNC117 infusions (30mg/kg) + three romidepsin infusions (5mg/m2). 3BNC117 will be administered on Days 0 and 56. Romidepsin will be administered on days 2, 9, 16, 58, 65, and 72 .
62601639|NCT02850016|EXPERIMENTAL|Group B|Two treatment cycles each consisting of three romidepsin infusions (5mg/m2). Romidepsin will be administered on days 0, 7, 14, 56, 63, and 70 .
62601640|NCT04455698|EXPERIMENTAL|Remote Telegenetics: TELEPHONE (ARM A)|"Remote Phone Telegenetics:~Participants with complete pre-test and disclosure counseling with a Genetic Counselor using remote services - TELEPHONE."
62601641|NCT04455698|EXPERIMENTAL|Remote Telegenetics: VIDEOCONFERENCING (ARM B)|"Remote Videoconferencing Telegenetics:~Participants with complete pre-test and disclosure counseling with a Genetic Counselor using remote services - VIDEOCONFERENCING."
62601642|NCT04455698|EXPERIMENTAL|USUAL CARE (ARM C)|"Usual Care:~Participants will receive referrals to genetic counseling providers, initiating services on their own. At 6 months, if participants have not sought and received genetic counseling services, they will be offered randomization to ARM A/ARM B."
62601643|NCT06463483|EXPERIMENTAL|Automated insulin delivery using Medtronic 780G System|
62601644|NCT06463483|OTHER|Usual care plus continuous glucose monitoring|
62601645|NCT03679338|OTHER|Ablation Therapy With Bipolar Radio Frequency|
62435102|NCT01716754|ACTIVE_COMPARATOR|Omalizumab (as per locally approved dosing table)|Participants received omalizumab as per locally approved dosing table s.c. q2w or q4w for 16 weeks.
62435103|NCT01716754|PLACEBO_COMPARATOR|Placebo to QGE031 240 mg q2w|Participants received matching placebo to QGE031 240 mg s.c. q2w for 16 weeks.
62601646|NCT03168737|EXPERIMENTAL|Group A (18F-fluoroazomycin arabinoside, PET-CT scans)|Patients receive 18F-fluoroazomycin arabinoside IV and after 60 minutes undergo 5 PET-CT scans at 60, 90, 120, 150, and 180 minutes on days 1 and 2.
62601647|NCT03168737|EXPERIMENTAL|Group B (18F-fluoroazomycin arabinoside, PET-CT scans)|Patients receive 18F-fluoroazomycin arabinoside IV and after 60 minutes undergo 5 or less PET-CT scans on day 1 and 5 or less PET-CT scans \>= 24 hours later up to 10 days.
62601648|NCT04727034|ACTIVE_COMPARATOR|Control group|Propofol（1.5mg/kg）
62601649|NCT04727034|EXPERIMENTAL|Test group 1（Remimazolam tosylate 0.15mg/kg）|Remimazolam tosylate 0.15mg/kg
62041912|NCT02264678|EXPERIMENTAL|Module 2 Part B4|Module Part B4: Patients with second or third line triple negative breast cancer with no known BRCA mutations. This expansion will be enriched for patients with disease harbouring a HRR-related gene mutation (HRRm) will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
62435104|NCT01716754|PLACEBO_COMPARATOR|Placebo to QGE031 240 mg q4w|Participants received placebo to QGE031 240 mg s.c. q2w for 16 weeks.
62435105|NCT01716754|PLACEBO_COMPARATOR|Placebo to QGE031 180 mg q2w|Participants received QGE031 180 mg s.c. q2w for 16 weeks.
62435106|NCT01716754|PLACEBO_COMPARATOR|Placebo to QGE031 120 mg q2w|Participants received QGE031 120 mg s.c. q2w for 16 weeks.
62435107|NCT01716754|PLACEBO_COMPARATOR|Placebo to QGE031 36 mg q2w|Participants received QGE031 36 mg s.c. q2w for 16 weeks.
62435108|NCT01716754|PLACEBO_COMPARATOR|Placebo to QGE031 12 mg q2w|Participants received QGE031 12 mg s.c. q2w for 16 weeks.
62822906|NCT01727284|EXPERIMENTAL|MR-guided cryoablation (freezing of tissue and/or tumors)|Patients undergo cryoablation using the Galil MR-compatible cryoablation system and MRI while on study.
62822907|NCT04956796||Group A|At the beginning of Phase 1, participants from Group A will be exposed to the video airway library in addition to the conventional airway training. At the beginning of Phase 2, participants will continue with conventional airway training only. Each phase will last for 1 month.
62822908|NCT04956796||Group B|At the beginning of Phase 1, participants from Group B will be exposed to the conventional airway training only. At the beginning of Phase 2, the participants in Group B will be exposed to the video airway library. Each phase will last for 1 month.
62822909|NCT06543940|EXPERIMENTAL|Vancomycin|administration with vancomycin 7.5 to 10 mg/kg IV q 12 hours in patient received CRRT with oXiris membrane
62822910|NCT02027155|ACTIVE_COMPARATOR|AR09 solution|AR09, Randomized, Double-blind, Placebo-controlled, Rising-dose Study to Assess the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single IV Doses of AR09 in Healthy Subjects
62822911|NCT02027155|PLACEBO_COMPARATOR|Placebo (for AR09 solution)|Placebo; normal saline
62435109|NCT01716754|PLACEBO_COMPARATOR|Placebo to omalizumab|Participants received placebo to omalizumab s.c. q2w or q4w for 16 weeks.
62435110|NCT06527053|EXPERIMENTAL|digital obturator|new approach to create device
62435111|NCT06527053|EXPERIMENTAL|conventional obturator|old approach to create device
62435112|NCT03145610|PLACEBO_COMPARATOR|Placebo toothpaste|Fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.
62435113|NCT03145610|EXPERIMENTAL|triclosan/copolymer/fluoride toothpaste|triclosan/copolymer/fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.
62435114|NCT01811797|EXPERIMENTAL|Low Intensity Shockwave treatment|4 weekly sessions of Low Intensity Shockwave treatment.
62435115|NCT01811797|SHAM_COMPARATOR|Control group|
62435116|NCT06360731|EXPERIMENTAL|Experimental Group|Experimental group who consists of subjective tinnitus patients will receive 1 hour of informative session on tinnitus and also perform 4-7-8 breathing exercises for 6 weeks
62435117|NCT06360731|ACTIVE_COMPARATOR|Control Group|Control group who consists of subjective tinnitus patients will receive 1 hour of informative session on tinnitus only
62601650|NCT04727034|EXPERIMENTAL|Test group 2（Remimazolam tosylate 0.2mg/kg）|Remimazolam tosylate 0.2mg/kg
62822912|NCT04033926|OTHER|Arm A|"* Treatment Period 1: KZR-616 30 mg SC weekly for 2 weeks, then 45 mg SC weekly for 14 weeks~* Treatment Period 2: Placebo SC weekly for 16 weeks"
62822913|NCT04033926|OTHER|Arm B|"* Treatment Period 1: Placebo SC weekly for 16 weeks~* Treatment Period 2: KZR-616 30 mg SC weekly for 2 weeks, then 45 mg SC weekly for 14 weeks"
62822914|NCT01796145|EXPERIMENTAL|TACE|
62601651|NCT04024267|EXPERIMENTAL|Eurythmy therapy (ERYT)|"Eurythmy therapy (ERYT) is a standardized movement therapy and for each medical condition standardized ERYT exercise (series) exist. In such, in the present study, the cancer series O-E-M-L-I-B-D that is specific and standardized for breast cancer patients will be applied. Patients can perform and maintain the postures without stress and tension. Patients are instructed by ERYT therapists in sessions with 1 to 4 patients."
62601652|NCT04024267|ACTIVE_COMPARATOR|CoordiFit|The CoordiFit program consists of standardized exercises that address physical coordination, stability, balance and dexterity. These exercises serve as a control intervention and are non-specific with respect of cancer-related fatigue and breast cancer. They mimic those of ERYT but have no mindfulness features. Patients are instructed by physical therapists in session with 1 to 4 patients.
62601653|NCT00467961|EXPERIMENTAL|Miltenyi system transplant recipients|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach. Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. Determine appropriate level of post transplant immunosuppression
62245001|NCT06252519|EXPERIMENTAL|NAC, then neuro-NAC, then Neuro-NAC XS|Participants receive single dose of NAC while on controlled diet. One week later, participants receive 1 dose Neuro-NAC while on controlled diet. One week later, participants receive 1 dose Neuro-NAC XS while on controlled diet.
62435118|NCT01637025|EXPERIMENTAL|Traumastem - oxidized cellulose strip|
62435119|NCT01637025|ACTIVE_COMPARATOR|Surgicel® Original - oxidized regenerated cellulose strip|
62435120|NCT06462001|ACTIVE_COMPARATOR|Arm A: Standard Intravesical BCG|Standard intravesical BCG therapy given as per usual standard of care
62435121|NCT06462001|EXPERIMENTAL|Arm B: Experimental BCG + MM|Combination therapy with BCG and MM, given on specific protocol sessions
62435122|NCT01072019|ACTIVE_COMPARATOR|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
62601654|NCT04869319||MyChart message|MyChart message subjects with high A1C blood tests to help manage their diabetes and prevent some of the complications caused by high sugars. The message recommends that they schedule a visit with their doctor who can recheck the blood test and help get their diabetes under control.
62822915|NCT01796145|EXPERIMENTAL|Systemic Therapy|
62435123|NCT01072019|ACTIVE_COMPARATOR|MRI generated patient specific custom cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
62435124|NCT05059782|ACTIVE_COMPARATOR|Group A (drug treatment group)|Group A (drug treatment group) : Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.
62601655|NCT04869319||No MyChart message|No message
62822916|NCT01796145|EXPERIMENTAL|Surgery|
62822917|NCT02802306|EXPERIMENTAL|Tack Implant|Implantation of a Tack implant using the Intact Vascular Tack Endovascular System for the repair of post DCB-angioplasty dissections.
62822918|NCT03063892|PLACEBO_COMPARATOR|Control Arm|Will receive intravenous Saline solution placebo bolus dose in the Emergency Center over 10 minutes. The subject will also receive intravenous Saline solution over 8 hours prior to surgery. Another dose will be administered at the time of incision and the final dose three hours later.
62601656|NCT04690725|EXPERIMENTAL|TQB3525 arm|3+3 design for phase I for RP2D (Recommended Phase 2 Dose) for adolescents (12-17 years old) (15mg QD or 20mg QD); phase II for efficacy exploration for another 17 patients using RP2D QD
62041913|NCT02264678|EXPERIMENTAL|Module 3 Part A|Module 3 Part A: cohort escalation of ceralasertib in combination with durvalumab in HNSCC or NSCLC patients to define the dose, frequency and schedule of ceralasertib and durvalumab to take into Module 3 Part B. Additionally, Module 3 Part A will include a serial tumour biopsy cohort to evaluate the Proof of Mechanism of ceralasertib in HNSCC and NSCLC patients.
62601657|NCT06620445|EXPERIMENTAL|Interventional Group|The Intervention or CBT group included 40 children aged 8-16 years with malignancies recieving chemotherapy. They will recieve weekly five sessions of CBT (30-35 minutes per session)
62601658|NCT06620445|NO_INTERVENTION|Control or Usual Care Group|The Control or No Intervention Group also known as Comparision Group or Usual Group will recieve the standard care or usual care for their condition. It will serve as a baseline for the CBT or Intervention Group.
62601659|NCT02285543|EXPERIMENTAL|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed with surgery and radiotherapy/chemoradiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
62601660|NCT02285543|OTHER|Control group|The patients in the control group received the radical surgery and radiotherapy/chemoradiotherapy.
62601661|NCT02378415|PLACEBO_COMPARATOR|Normal Saline Infusion|A single IV bolus dose of normal saline solution.
62435125|NCT05059782|EXPERIMENTAL|Group B (radiotherapy group)|IFRT, IMRT or SBRT is applied. Irradiation techniques and doses can be selected based on the previous experience of each center, but all patients enrolled within the center need to be consistent.
62822919|NCT03063892|EXPERIMENTAL|Experimental Arm|Will receive intravenous Tranexamic Acid (TXA) 15mg/kg (maximum 1 gram) bolus dose over 10 minutes in the Emergency Center. The subject will also receive an intravenous dose of Tranexamic Acid (TXA) 15mg/kg over 8 hours prior to surgery. Another 15mg/kg dose of Tranexamic Acid (TXA) will be administered over 10 minutes at the time of incision and the final dose (15mg/kg) of Tranexamic Acid (TXA) intravenously over 10 minutes three hours later.
62601662|NCT02378415|EXPERIMENTAL|Subanesthetic IV Bolus Ketamine|a single sub-anesthetic rapid IV bolus dose of ketamine administered to acutely depressed patients with or without suicidality
62041914|NCT02264678|EXPERIMENTAL|Module 3 Part B|Module 3 Part B: cohort expansions of ceralasertib in combination with durvalumab in HNSCC or NSCLC patients at dose, frequency and schedule from Module 3 Part A.
62435126|NCT05059782|EXPERIMENTAL|Group C (radiotherapy + drug group)|Drug therapy is the same as group A; IFRT is the same as group B.
62601663|NCT01633008|EXPERIMENTAL|1|Attend three 2-hour sessions held over two consecutive days
62601664|NCT01971333||Liver transplantation|"Compare intraoperative change of dynamic parameters after fluid loading:~1. pulse pressure variation~2. stroke volume variation~3. plethysmographic variation index"
62601665|NCT01896947||MRI and MRA group|All patients will receive 3T MRI and MR arthrogram
62601666|NCT00955968|EXPERIMENTAL|Continue HAART|Continue receiving HAART within 0-42 days after delivery or other pregnancy outcome.
62601667|NCT00955968|ACTIVE_COMPARATOR|Stop HAART|Stop receiving HAART within 0-42 days after delivery or other pregnancy outcome and resume HAART when protocol specified criteria were met.
62601668|NCT03508752|EXPERIMENTAL|Radiation|Stereotactic Radiosurgery
62601669|NCT00919997||Specimen collection|Single group study. Blood, saliva, anal cytology, and penile cytology samples, and questionnaire responses will be collected from participants at a single study visit.
62601670|NCT00900757|EXPERIMENTAL|Palonosetron|Single Arm trial of Palonosetron for the prevention of RINV in primary malignant glioma patients receiving radiation therapy (RT) and concomitant temozolomide (TMZ)
62601671|NCT02284568|PLACEBO_COMPARATOR|Placebo|once daily oral dose
62822920|NCT04794855||preganant women|observation from 6-8 weeks.
62041915|NCT02264678|EXPERIMENTAL|Module 2 Part B5|Patients with BRCA mutant or RAD51C/D mutant (either germline or somatic) or HRD-positive status epithelial ovarian, fallopian tube, or primary peritoneal cancer according to local testing. Patients must be platinum sensitive and previously progressed on a licensed PARPi. The cohort will be split into 2 groups: Cohort 1 - without intervening chemotherapy following progression on a PARPi, Cohort 2 - with intervening chemotherapy following progression on a PARPi. Patients will receive ceralasertib and olaparib, at the RP2D dose, frequency and schedule established from Module 2 Part A2.
62245002|NCT06252519|EXPERIMENTAL|NAC, Neuro-NAC XS, then Neuro-NAC|"Participants receive single dose of NAC while on controlled diet. One week later, participants receive 1 dose Neuro-NAC XS while on controlled diet.~One week later, participants receive 1 dose Neuro-NAC while on controlled diet."
62435127|NCT04304950|EXPERIMENTAL|Morning|Participants with Ulcerative Colitis or Crohn's Disease taking 6-Mercatopurine or Azathioprine orally once a day in the evening were assigned to the morning group. Instead of taking their medication at their usual PM time, they were instructed to take their medications in the morning for the duration of the study-10 weeks. The dosage amount is per clinical care and not defined by the study protocol.
62601672|NCT02284568|EXPERIMENTAL|Laquinimod 0.6 mg|1 capsule containing 0.6 mg laquinimod and 2 capsules containing placebo were administered orally once daily for at least 48 weeks.
62822921|NCT05879185|EXPERIMENTAL|XmAb23104 in People With Sarcoma|Patients will receive the recommended phase II dose of XmAb23104 monotherapy on day 1 and 15 of each 28-day cycle. Patients will continue XmAb23104 (day 1 \& 15, q 28 days) for up to 24 months depending on their response and tolerability to treatment. Treatment will be continued until progressive disease (PD) or toxicity or a total of 24 months of study therapy has been completed.
62041916|NCT02264678|EXPERIMENTAL|Module 4 (FE/QT)|Ceralasertib monotherapy will be administered on a number of days during Cycle 0 to assess the effect of food on ceralasertib absorption and effect of ceralasertib on ECG parameters under various conditions (fasted, fed, steady state). From C1 onwards, patients who participated in C0 will be allocated to either ceralasertib in combination with olaparib or durvalumab, or ceralasertib monotherapy and assessed for safety.
62041917|NCT02264678|EXPERIMENTAL|Module 5 Part A|"Module 5 Part A: ascending doses of ceralasertib will be administered in combination with AZD5305 to patients to define the MTD, RP2D.~In case this first dose level is not tolerated, alternative schedules will be evaluated."
62041918|NCT02264678|EXPERIMENTAL|Module 5 Part B|Module 5 Part B: cohort expansions of ceralasertib in combination with AZD5305 in ovarian patients at dose, frequency and schedule from Module 5 Part A.
62041919|NCT02264678|EXPERIMENTAL|Module 1 Part A|Module 1 Part A: ascending doses of ceralasertib in combination with carboplatin AUC5 will be administered to patients to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD).
62822922|NCT04080635|EXPERIMENTAL|Standard of care - brodalumab|Patients will continue to receive brodalumab according to standard care dosing regimen, i.e. loading dose first (210mg), once a week for 2 weeks (210mg), then a regular dose regimen (210mg) every 2 weeks.
62822923|NCT02658526||control|children without anesthesia / surgery
62822924|NCT02658526||anesthesia|children with anesthesia for diagnostic reason
62435128|NCT04304950|EXPERIMENTAL|Evening|Participants with Ulcerative Colitis or Crohn's Disease taking 6-Mercatopurine or Azathioprine orally once a day in the morning were assigned to the evening group. Instead of taking their medication at their usual AM time, they were instructed to take their medications in the evening for the duration of the study-10 weeks. The dosage amount is per clinical care and not defined by the study protocol.
62435129|NCT04918615|EXPERIMENTAL|Sirolimus coated balloon catheter|Manufacturer: Shanghai MicroPort Medical Group Co, Ltd.
62822925|NCT02658526||surgery|children with anesthesia / surgery
62041920|NCT02264678|EXPERIMENTAL|Module 1 Part B|Module 1 Part B: patients with advanced lung adenocarcinoma with low expression of ATM will receive ceralasertib and carboplatin, at the dose, frequency and schedule recommended from Module 1 Part A.
62041921|NCT04830475|EXPERIMENTAL|NIV Group|In poostoperative period, patients allocated in NIV Group fulfilled a 120-minute cycle of PSV + PEEP with full-face mask. Ventilation was performed with a Draeger Ventilator with the following basic settings: DeltaPInsp 10 mmHg + PEEP 5 mmHg + Fio2 60%.
62041922|NCT04830475|ACTIVE_COMPARATOR|Control Group|In the postoperative period, patients were offered VenturiMask with Fio2 60% at 15 l / m.
62041923|NCT04452149|PLACEBO_COMPARATOR|Observation Arm|Subjects will receive a Reveal LINQ™ Insertable Cardiac Monitor with an investigational ALLEVIATE-HF RAMware download, and will be managed per standard of care for heart failure management without visibility to the heart failure sensor data. Subjects will transition to the intervention arm after 13 months.
62041924|NCT04452149|EXPERIMENTAL|Intervention Arm|Subjects will receive a Reveal LINQ™ Insertable Cardiac Monitor with an investigational ALLEVIATE-HF RAMware download, and will be managed using an integrated device diagnostic-based risk stratification algorithm combined with a clinical medication plan.
62041925|NCT06732154|EXPERIMENTAL|HRS-5632|
62041926|NCT06732154|PLACEBO_COMPARATOR|Placebo|
62041927|NCT05400434|EXPERIMENTAL|Randomized Standard-PCIT group|Participants enrolled in the randomized portion of the study and randomized to receive only Standard PCIT for a maximum of 18 weeks.
62041928|NCT05400434|EXPERIMENTAL|Randomized PCIT plus Natural Helper group|Participants enrolled in the randomized portion of the study and randomized to receive PCIT plus Natural Helper for a maximum of 18 weeks.
62041929|NCT05400434|EXPERIMENTAL|Opt-out Only Standard PCIT group|Participants enrolled in the non-randomized portion of the study and opted in to receive only Standard PCIT for a maximum of 18 weeks.
62435130|NCT04918615|ACTIVE_COMPARATOR|Paclitaxel coated balloon catheter|Manufacturer: Liaoning Yinyi Biotechnology Co., Ltd
62435131|NCT05278585||RAP TAVI group|All patients in sinus rhythm with TAVI
62435132|NCT00164203|EXPERIMENTAL|Cognitive Behavioral Therapy|School-based, 12-session protocol, weekly
62435133|NCT00164203|ACTIVE_COMPARATOR|activity control condition|Structured games and activities, weekly for 12 weeks
62435134|NCT05293587|EXPERIMENTAL|Physical Activity|Physical activity sessions at public parks led by a Serenity Behavioral Health Certified Peer Specialist
62822926|NCT06478420|EXPERIMENTAL|Group 1A: Low dose challenge|Intranasal viral challenge with 1x10\^5 TCID50 in healthy volunteers (n=5-7).
62822927|NCT06478420|EXPERIMENTAL|Group 1B: Medium dose #1 challenge|Intranasal viral challenge with 1x10\^6 TCID50 in healthy volunteers (n=5-7).
62822928|NCT06478420|EXPERIMENTAL|Group 1C: Medium dose #2 challenge|Intranasal viral challenge with 1x10\^7 TCID50 in healthy volunteers (n=5-7).
62822929|NCT06478420|EXPERIMENTAL|Group 1D: High dose challenge|Intranasal viral challenge with 1x10\^8 TCID50 in healthy volunteers (n=5-7).
62435135|NCT05293587|NO_INTERVENTION|Waitlist|Participants will continue their usual care in the PEERS program. They will be offered the intervention after they have completed posttest measures.
62601673|NCT02284568|EXPERIMENTAL|Laquinimod 1.5 mg|3 capsules containing 0.5 mg laquinimod were administered orally once daily for at least 48 weeks. However this arm was discontinued as of 01 January 2016 and no participants reached the 48 week timeframe.
62601674|NCT01647984|PLACEBO_COMPARATOR|Placebo|Inert Placebo - Vitamin B complex + diet
62601675|NCT01647984|ACTIVE_COMPARATOR|Ritmonutra|Omega-3 polyunsaturated fatty acids, Hawthorn, Astaxanthin, Vitamin E, Vitamin B complex + diet
62601676|NCT03721042|EXPERIMENTAL|exhaled air|exhaled air analysis of patients
62601677|NCT06002139|EXPERIMENTAL|Immersive Virtual Reality Therapy|Conventional orthopedic rehabilitation supplemented by VR therapy
62601678|NCT06002139|ACTIVE_COMPARATOR|Conventional rehabilitation|Conventional orthopedic rehabilitation
62601679|NCT06590025|EXPERIMENTAL|INtegral Cognitive REMediation program (INCREM)|The functional remediation (FR) program of INCREM intervention consists of 12 sessions (1s/wk) in a group format, which is devoted to improve the daily functioning of patients and therefore, is based on very ecological tasks where compensation techniques are used. An computerized cognitive training will follow the INCREM arm in individual sessions. 12 individually tailored modules of 20 minutes will be created with a licensed software (NeuronUp).
62601680|NCT06590025|ACTIVE_COMPARATOR|PSYCHOEDUCATION|The psychoeducation program for Major Depression was also developed in the context of the previous project (PI17/00056). It consists of 12 sessions (1s/wk) in a group format and includes all aspects related to MDD (Raventós, González \& Portella. Protocolo de Psicoeducación para depresión. Ed Permanyer: Barcelona. 2020). To ensure the similarity between the two intervention arms, in the comparator arm, participants will play a previously selected mental skill game on a digital device for 20 minutes.
62601681|NCT05222152|EXPERIMENTAL|Chronocort|Chronocort (hydrocortisone modified-release hard capsule) supplied as 5 mg and 10 mg strengths will be administered orally. Chronocort 10 mg will be taken on waking (typically between 06:00 and 08:00 hours) and Chronocort 15 mg will be taken just prior to going to bed (typically between 22:00 hours and midnight).
62601682|NCT05222152|ACTIVE_COMPARATOR|Plenadren|Plenadren (hydrocortisone modified-release tablet) supplied as 5 mg and 20 mg strengths and administered orally. Plenadren 25 mg will be taken on waking (typically between 06:00 and 08:00 hours).
62601683|NCT04253782|EXPERIMENTAL|Team Intervention Arm|Recovery coaches and trained health educators will team together and meet with participants (remotely/electronically and/or by phone or in person, when appropriate) at least twice and for a maximum of 7 times. This includes access to mediation, trained mental healthcare providers, and educational resources.
62601684|NCT04512599|EXPERIMENTAL|Single Arm|Open-label consumption of prebiotic bar(s); 1 bar for 3 days; followed by 2 bars for 7 days
62435136|NCT03453502|NO_INTERVENTION|Before-intervention phase|All the very low birth weight (VLBW) and extremely low birth weight (ELBW) infants who were admitted from January 2017 to December 2017 to the NICUs of different hospitals.
62601685|NCT00197002|ACTIVE_COMPARATOR|Havrix Group|Healthy male or female subjects, 15 months of age, who received Havrix® vaccine administered intramuscularly in the right anterolateral thigh, at Day 0 and at Month 6-9.
62601686|NCT00197002|EXPERIMENTAL|Havrix+Prevnar Group|Healthy male or female subjects, 15 months of age, who received Havrix® and Prevnar™ vaccines co-administered intramuscularly in the right and left anterolateral thighs, respectively, at Day 0 and Havrix® vaccine administered intramuscularly in the right anterolateral thigh, at Month 6-9.
62601687|NCT00197002|ACTIVE_COMPARATOR|Prevnar Havrix Group|Healthy male or female subjects, 15 months of age, who received Prevnar™ vaccine administered intramuscularly in the left anterolateral thigh, at Day 0 and Havrix® vaccine, administered intramuscularly in the right anterolateral thigh, at Day 30 and at Month 7-10.
62822930|NCT06478420|EXPERIMENTAL|Group 2: Dose confirmation group|Intranasal viral challenge with the dose identified from group 1A-D (n=up to 24)
62822931|NCT03152760||Abstinent Group (AB)|Current AUD diagnosis, currently abstaining from alcohol
62601688|NCT06079307|NO_INTERVENTION|Control|Won't receive an oxygenated mouthwash nor oxygenated mouth foam yet will be provided a fluoridated toothpaste and a toothbrush (20 participants)
62601689|NCT06079307|EXPERIMENTAL|Oxygenated mouthwash Group|Provided with oxygenated mouthwash bottle 2 per individual for 3 months (40 bottles in total). -20 participants -
62435137|NCT03453502|EXPERIMENTAL|Intervention phase|All the VLBW and ELBW infants who were admitted from January 2018 to December 2018 to the NICUs.During this phase,multiple intervention bundles of quality improvement will be implemented.
62601690|NCT06079307|EXPERIMENTAL|Oxygenated mouth foam Group|Provided with oxygenated mouth foam/ day- 20 participants- 2 oxygenated mouth foam bottle per individual for 3 months (40 bottles in total).
62601691|NCT03160222|OTHER|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
62822932|NCT03152760||Current Drinking Group (CD)|Current AUD diagnosis, not seeking AUD treatment
62822933|NCT03152760||Healthy Control Group (HC)|NO current or past AUD diagnosis
62822934|NCT03198650|EXPERIMENTAL|Part 1 / Part 2|Acalabrutinib
62822935|NCT03198650|EXPERIMENTAL|Part 3|Acalabrutinib in combination with Obinutuzumab
62822936|NCT05546827|EXPERIMENTAL|Surgical resection|Patients will have surgical resection after receiving neodjuvant combination immunotherapy followed by radiation therapy.
62822937|NCT04421820|EXPERIMENTAL|Part B - Dose Expansion - 1L Gastric Cancer (ARM I)|Arm closed to enrollment.
62822938|NCT04421820|EXPERIMENTAL|Part B - Dose Expansion - 2L Gastric Cancer (ARM II)|Arm closed to enrollment.
62822939|NCT04421820|EXPERIMENTAL|Part B - Dose Expansion - 2L Pancreatic Cancer (ARM III)|Arm closed to enrollment.
62822940|NCT04421820|EXPERIMENTAL|Part B - Dose Expansion - 2L Colorectal Cancer (ARM IV)|Arm closed to enrollment.
62822941|NCT04421820|EXPERIMENTAL|Part B - Dose Expansion - 3L Colorectal Cancer (ARM VI)|Arm closed to enrollment.
62822942|NCT04421820|EXPERIMENTAL|Part B - Dose Expansion - 2L Cholangiocarcinoma (ARM V)|Arm closed to enrollment.
62601692|NCT05487885|EXPERIMENTAL|TMS and PAT|All open label with no randomization to placebo
62601693|NCT05487885|EXPERIMENTAL|TMS and PAT, then Ketamine|All open label with no randomization to placebo
62601694|NCT03714334|EXPERIMENTAL|DNX-2440 injection|all the patients included will be treated with the experimental agent
62601695|NCT05073029|ACTIVE_COMPARATOR|standard care group|3-month course of individually selected nutrition program developed by a gastroenterologist-nutritionist and modification of physical activity (8000-10000 steps daily)
62601696|NCT05073029|EXPERIMENTAL|intervention group|additionally to previous group recieved treatment with synbiotic (Fructooligosaccharides+Lactobacillus rhamnosus GG ATCC 53103) and vitamin D3 - 2000 IU. The students were instructed to take vitamin D3 and synbiotic sachets twice a day for 3 months.
62601697|NCT04645602|EXPERIMENTAL|Lenvatinib + Pembrolizumab|"Participants will take:~Lenvatinib - At a pre-determined dose, 1x daily during each 3 week study cycle up to 35 cycles/2 years~Pembrolizumab - At a pre-determined dose, 1x on Day 1 of each 3 week study cycle up to 35 cycles/2 years~Participants will be given a drug diary and asked to document information in the drug diary about the study treatment.~Participants will be asked to check their blood pressure 3x every week and document in a supplied diary.~Participants will be followed up to one (1) year after study treatment."
62601698|NCT06258551||Intensive Care Unit|Patients admitted to an intensive care unit (No interventions administered)
62601699|NCT06258551||Bone Marrow Transplant Unit|Patients admitted to a cancer treatment center for allogeneic stem cell transplantation (No interventions administered)
62601700|NCT03940274|EXPERIMENTAL|Intervention|Participants will undergo a walking program using a treadmill, a body-weight support system, and an assistive device.
62601701|NCT02651805|EXPERIMENTAL|Mechanical Insufflation-Exsufflation Group|Patients will receive usual care except suctioning or cough augmentation techniques+Mechanical Insufflation-Exsufflation
62601702|NCT02651805|ACTIVE_COMPARATOR|Usual Care Group|Patients will receive the usual care provided by the hospital, all interventions to control respiratory secretion will be verified in patient chart
62601703|NCT04647656|ACTIVE_COMPARATOR|HBOT treatment group|40 daily hyperbaric oxygen treatment sessions will be administered 5 days per week
62601704|NCT04647656|SHAM_COMPARATOR|HBOT sham group|40 daily Sham non-hyperbaric oxygen treatment will be administered 5 days per week
62601705|NCT05080283|EXPERIMENTAL|CP1110 Sound Processor System with ForwardFocus On (SCAN)|
62601706|NCT05080283|EXPERIMENTAL|CP1110 Sound Processor System with ForwardFocus Off (SCAN)|
62601707|NCT05080283|ACTIVE_COMPARATOR|Nucleus 7 Sound Processor (model: CP1000) system|
62601708|NCT05129293|EXPERIMENTAL|Prospective Memory Intervention|Participants randomized to the PM intervention (active group) will meet with an interventionist twice a week for four weeks. The first four sessions will focus on visual imagery, while the last four sessions will focus on implementation intentions. Participants will be led through a manualized treatment.
62601709|NCT05129293|ACTIVE_COMPARATOR|Educational|The control group (Education) will meet with a research assistant for the same frequency of sessions and will receive psychoeducation on MS and cognitive functioning. The interventionists will be following a manual and accompanying PowerPoint slides.
62601710|NCT02231281|EXPERIMENTAL|cART(TDF/AZT+3TC+LPV/r)|cART(TDF/AZT+3TC+LPV/r)
62601711|NCT02231281|EXPERIMENTAL|CTL infusion|cART plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion
62601712|NCT01658592|EXPERIMENTAL|NAC-VC Deep Brain Stimulation|The contractors located in NAc and VC are ON at the same time
62601713|NCT01658592|SHAM_COMPARATOR|Placebo A|Stimulator setting is OFF
62601714|NCT01658592|EXPERIMENTAL|Placebo B|The contractor located in NAc is on
62601715|NCT01658592|EXPERIMENTAL|Placebo C|The contactor located in VC is on
62601716|NCT02054910|EXPERIMENTAL|Celiac Plexus Block|Celiac Plexus Block will be administered following EUS
62601717|NCT02054910|SHAM_COMPARATOR|Sham|A celiac plexus block will not be administered for pain management
62601718|NCT03359798|EXPERIMENTAL|Narcotic counseling script|Study participants will be read a script regarding post-cesarean section narcotic use.
62601719|NCT03359798|SHAM_COMPARATOR|Post-partum depression counseling script|Study participants will be read a script of the same length, and much of the same wording as the experimental script. However, this script's content is focused on post-partum depression.
62822943|NCT04421820|EXPERIMENTAL|Part A - Dose Escalation - Gastric Cancer|Arm closed to enrollment.
62601720|NCT00932698|EXPERIMENTAL|Dose Escalation Cohort 1: Ixazomib 0.24 mg/m^2|Ixazomib 0.24 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 220 days).
62601721|NCT00932698|EXPERIMENTAL|Dose Escalation Cohort 2: Ixazomib 0.48 mg/m^2|Ixazomib 0.48 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 270 days).
62601722|NCT00932698|EXPERIMENTAL|Dose Escalation Cohort 3: Ixazomib 0.8 mg/m^2|Ixazomib 0.8 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 137 days).
62601723|NCT00932698|EXPERIMENTAL|Dose Escalation Cohort 4: Ixazomib 1.2 mg/m^2|Ixazomib 1.2 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1436 days).
62822944|NCT04421820|EXPERIMENTAL|Part A - Dose Escalation - Pancreatic Cancer|Arm closed to enrollment.
62822945|NCT04421820|EXPERIMENTAL|Part A - Dose Escalation - Colorectal Cancer|Arm closed to enrollment.
62822946|NCT04421820|EXPERIMENTAL|Part A - Dose Escalation - Cholangiocarcinoma|Arm closed to enrollment.
62822947|NCT04421820|ACTIVE_COMPARATOR|Part B - Dose Expansion - 2L Colorectal Cancer (ARM VII) - Randomized|Arm open to enrollment.
62822948|NCT00904969|EXPERIMENTAL|AMS Transobturator Male Sling System|
62822949|NCT05935670|EXPERIMENTAL|Ischemic Conditioning - High|During each testing session, the investigators will be measuring how one treatment of ischemic conditioning effects leg blood flow and muscle function. One day participants will receive a high cuff inflation pressure on the leg, called ischemic conditioning - high (225 mmHg).
62822950|NCT05935670|EXPERIMENTAL|Ischemic Conditioning - Low|During each testing session, the investigators will be measuring how one treatment of ischemic conditioning effects leg blood flow and muscle function. One day participants will receive a low cuff inflation pressure on the leg, called ischemic conditioning - low (25 mmHg).
62822951|NCT05991414|EXPERIMENTAL|Pharmacist care in conjunction with home blood pressure monitoring|Patients will have BP assessed at baseline in the pharmacy by the pharmacist, and they will receive a home blood pressure monitor in addition to education and counselling provided by the pharmacist. Patients will measure their BP at home for seven days every four weeks and input their results into a data management system called REDCap that is accessible by the pharmacist. The pharmacist will follow up with the patient every 4 weeks to review their readings and at 24-weeks the patient will come into the pharmacy for a final follow-up and BP readings. The pharmacist will fax BP readings as well as suggestions for therapy modification to the patient's prescribing clinician. Patients will then have their care returned to their prescribing clinician with no pharmacist specific interventions outside of usual pharmacy care activities and have a single follow-up at month-12 with the pharmacist reviewing home BP monitor use and reporting of data to prescribing clinician.
62849207|NCT05800301|ACTIVE_COMPARATOR|WJ-MSCs and rEMS combination|Consisted of 32 eyes of 16 RP patients treated with the WJ-MSCs and rEMS combination. WJ-MSCs were applied first into the deep subtenon space of both eyes after necessary preparations. rEMS application was started 10 days after the WJ-MSC application with a custom-designed helmet for 30 min. WJ-MSCs were inoculated only once, and rEMS was applied regularly once a week for 30 min for 36 months. Both eyes are stimulated at the same time with the specially designed system for ophthalmologic use (MagnoVisionTM).
62435138|NCT03453502|EXPERIMENTAL|Sustainability intervention phase|All the VLBW and ELBW infants who were admitted from January 2019 to December 2019to the NICUs.In the Sustainability intervention phase,multiple intervention bundles of quality improvement will be continuous implemented.
62435139|NCT03093545|OTHER|Normal BMI or underweight (< 24 Kg/m2)|
62435140|NCT03093545|EXPERIMENTAL|Obese (BMI > 30 Kg/m2)|
62435141|NCT03473834|EXPERIMENTAL|Modified exercise programme|Modified exercise program is the intervention for the exercise group that they will be received this programm over 1 month.
62435142|NCT03473834|ACTIVE_COMPARATOR|Parkinson's disease Medication|Medication is the standard treatment for individuals with Parkinson's disease. Therefore, the control group will be received the medication only.
62435143|NCT04090684|EXPERIMENTAL|Fixed dose Ciprofloxacin and Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day
62435144|NCT05443555|ACTIVE_COMPARATOR|Intervention: Gabapentin|Participants randomized to the intervention group will receive active gabapentin for 3 months and brief (5-minute) evidence-based counseling for alcohol use.
62435145|NCT05443555|PLACEBO_COMPARATOR|Control: Placebo|Participants randomized to the control group will receive placebo capsules, identical in appearance to gabapentin, and the same brief (5-minute) one-time evidence-based counseling for alcohol use as the intervention group.
62435146|NCT05516212|ACTIVE_COMPARATOR|CAFMONO supplementation|The experimental procedure for each participant assume random blind acute ingestion of CAFMONO in individual dose providing 3mg/kg BM of CAF at one of the study visits, which will be separated from other study visits with 7-days wash-out. The preparation will be provided in the form of powder and the individual doses of CAFMONO will be dissolved in 200 mL of water. The test preparation will be ingested within up to 5 minutes. The ingestion will take place 60 minutes before the test exercise.
62435147|NCT05516212|ACTIVE_COMPARATOR|CAFMIPS_1 supplementation|The experimental procedure for each participant assume random blind acute ingestion of CAFMIPS_1 in individual dose providing 3mg/kg BM of CAF at one of the study visits, which will be separated from other study visits with 7-days wash-out. The preparation will be provided in the form of powder and the individual doses of CAFMIPS_1 will be dissolved in 200 mL of water. The test preparation will be ingested within up to 5 minutes. The ingestion will take place 60 minutes before the test exercise.
62435148|NCT05516212|ACTIVE_COMPARATOR|CAFMIPS_2 supplementation|The experimental procedure for each participant assume random blind acute ingestion of CAFMIPS_2 in individual dose providing 3mg/kg BM of CAF at one of the study visits, which will be separated from other study visits with 7-days wash-out. The preparation will be provided in the form of powder and the individual doses of CAFMIPS_2 will be dissolved in 200 mL of water. The test preparation will be ingested within up to 5 minutes. The ingestion will take place 60 minutes before the test exercise.
62601724|NCT00932698|EXPERIMENTAL|Dose Escalation Cohort 5: Ixazomib 1.68 mg/m^2|Ixazomib 1.68 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 456 days).
62601725|NCT00932698|EXPERIMENTAL|Dose Escalation Cohort 6: Ixazomib 2.0 mg/m^2|Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1621 days).
62601726|NCT00932698|EXPERIMENTAL|Dose Escalation Cohort 7: Ixazomib 2.23 mg/m^2|Ixazomib 2.23 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 2434 days).
62849208|NCT05800301|NO_INTERVENTION|The natural course|The natural course (control) group consisted of 32 eyes of 16 RP patients who received no treatment and were regularly followed until the 36th month. This group comprised patients who did not accept any treatment and/or were in good condition at baseline.
62041930|NCT05400434|EXPERIMENTAL|Opt-in PCIT plus Natural Helper group|Participants enrolled in the non-randomized portion of the study and opted in to receive PCIT plus Natural Helper for a maximum of 18 weeks.
62435149|NCT05516212|PLACEBO_COMPARATOR|Placebo treatment|The experimental procedure for each participant assume random blind acute ingestion of placebo (PLA) at one of the study visits, which will be separated from other study visits with 7-days wash-out. The PLA preparation will be provided in the form of powder and dissolved in 200 mL of water. PLA will be ingested within up to 5 minutes. The ingestion will take place 60 minutes before the test exercise.
62435150|NCT06531291|EXPERIMENTAL|Surufatinib + serplulimab + standard chemotherapy|
62435151|NCT00703378|EXPERIMENTAL|Group 1|Group 1: normal liver function
62435152|NCT00703378|EXPERIMENTAL|Group 2|Group 2: AST and/or ALT up to 1-5 x upper limit of normal; SAP 1- 5x upper limit of normal, total bilirubin within normal limits
62435153|NCT00703378|EXPERIMENTAL|Group 3|Group 3: Any SAP and AST/ALT \>5-10 x upper limit of normal and/or total bilirubin 1-1.5 x upper limit of normal
62435154|NCT01724476|ACTIVE_COMPARATOR|folate with B12|Subjects randomized to the folate with B12 group will take 1 capsule of 400mcg per day of folate with B12.
62435155|NCT01724476|PLACEBO_COMPARATOR|placebo|Subjects randomized to the placebo group will take 1 capsule of placebo per day.
62435156|NCT04993781|EXPERIMENTAL|eSTEPS Clinical Decision Support|Use of clinical decision support to assist in exercise-related fall prevention care planning will be compared to usual care.
62435157|NCT04993781|NO_INTERVENTION|Usual Care|Usual primary care practices regarding exercise-related fall prevention planning
62435158|NCT04191512||Upper airway stimulation|
62435159|NCT04191512||Continuous positive airway pressure|
62435160|NCT02758093|EXPERIMENTAL|Speed of Processing Training (10 hours)|Participants randomized to this arm will receive 10 hours of speed of processing training; this training is designed to improve the speed/accuracy in which they identify and locate visual information using five games/exercises from the POSIT Science Speed of Processing Training. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
62435161|NCT02758093|EXPERIMENTAL|Speed of Processing Training (20 hours)|Participants randomized to this arm will receive 20 hours of speed of processing training; this training is designed to improve the speed/accuracy in which they identify and locate visual information using five games/exercises from the POSIT Science Speed of Processing Training. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
62435162|NCT02758093|SHAM_COMPARATOR|Internet Navigational (10 hours)|In this group, participants will receive 10 hours of Internet Navigation Training. Specifically, participants will be given instructional materials and exercises on how to navigate the Internet. For more computer savvy participants, they will be directed to the Thinks.com website. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
62435163|NCT04157270||Patients with acute ischemic stroke|Patients with acute ischemic stroke secondary to intracranial large vessel occlusion (LVO)
62435164|NCT04275219|EXPERIMENTAL|Tong-Fu-Xing-Shen herbal formula|Tong-Fu-Xing-Shen herbal formula prescription (0.4g\*36 capsules/bottle，1-4 capsules each time, three times a day.) for 10-12days.
62435165|NCT04275219|PLACEBO_COMPARATOR|The Placebo of Tong-Fu-Xing-Shen herbal formula|The Placebo of Tong-Fu-Xing-Shen herbal formula prescription (0.4g\*36 capsules/bottle，1-4 capsules each time, three times a day.) for 10-12 days.
62435166|NCT05603078|EXPERIMENTAL|preoperative tumor-bed boost|The participants receive preoperative tumor-bed boost, oncoplastic surgery and adjuvant WBRT±RNI.
62435167|NCT02763735||Pulmonary Arterial Hypertension|Patients diagnosed with idiopathic or heritable pulmonary arterial hypertension according to consensus guidelines. RV oxidative metabolism and glycolysis will be measured using PET 11C acetate and \[18F\]fluoro-deoxy-Dglucose (FDG) imaging and measure myocardial lipid accumulation using MRS imaging.
62435168|NCT02763735||Subjects without cardiopulmonary disease|Subjects without known cardiopulmonary disease. RV oxidative metabolism and glycolysis will be measured using PET 11C acetate and \[18F\]fluoro-deoxy-Dglucose (FDG) imaging and measure myocardial lipid accumulation using MRS imaging
62435169|NCT06545734|ACTIVE_COMPARATOR|Endovascular therapy|
62435170|NCT06545734|EXPERIMENTAL|Endovascular therapy plus direct ischemic post-conditioning|
62435171|NCT01301131|EXPERIMENTAL|Probiotic|80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily
62849209|NCT05344404|EXPERIMENTAL|Nicotinamide Riboside|Nicotinamide riboside 3000mg daily for the duration of the trial (4 weeks). Administered in tablet form in doses of 1500mg twice daily.
62849210|NCT05344404|PLACEBO_COMPARATOR|Placebo|Placebo, no active ingredients. Administered in tablet form twice daily for the duration of the trial (4 weeks).
62849211|NCT01481194|EXPERIMENTAL|ACVDL|ACVDL is a combination of doxorubicin, cyclophosphamide, bortezomib, dexamethasone, and lenalidomide
62041931|NCT01263808|EXPERIMENTAL|Indacaterol 150 µg|Indacaterol 150 µg
62041932|NCT01263808|EXPERIMENTAL|Indacaterol 300 µg|Indacaterol 300 µg
62245003|NCT06252519|EXPERIMENTAL|Neuro-NAC, then NAC, then Neuro-NAC XS|Participants receive single dose of Neuro-NAC while on controlled diet. One week later, participants receive 1 dose NAC while on controlled diet. One week later, participants receive 1 dose Neuro-NAC XS while on controlled diet.
62245004|NCT06252519|EXPERIMENTAL|Neuro-NAC, then Neuro-NAC XS, then NAC|"Participants receive single dose of Neuro-NAC while on controlled diet. One week later, participants receive 1 dose Neuro-NAC XS while on controlled diet.~One week later, participants receive 1 dose NAC while on controlled diet."
62245005|NCT06252519|EXPERIMENTAL|Neuro-NAC XS, then NAC, then Neuro-NAC|Participants receive single dose of Neuro-NAC XS while on controlled diet. One week later, participants receive 1 dose NAC while on controlled diet. One week later, participants receive 1 dose Neuro-NAC while on controlled diet.
62822952|NCT05991414|ACTIVE_COMPARATOR|Usual pharmacist care|Patients will have BP assessed at baseline, 12-, and 24-weeks in the pharmacy by the pharmacist. Patients will not receive a home blood pressure monitor. Pharmacist will provide them usual care, education and counselling on BP management. Pharmacists will fax BP readings to the patient's prescribing clinician but will not provide any suggestions for therapy modification. After 24-weeks patients will be offered a home blood pressure monitor with education on its use. They will then be offered to crossover to the intervention group for the next 6-months or have their care returned to their prescribing clinician with no pharmacist specific interventions outside of usual pharmacy care activities and have a single follow-up at month-12 with the pharmacist reviewing home BP monitor use and reporting of data to prescribing clinician.
62822953|NCT00685230|EXPERIMENTAL|1|Alacramyn and midazolam as needed
62822954|NCT00685230|PLACEBO_COMPARATOR|2|placebo and midazolam as needed
62822955|NCT04006405||Cohort 1|140 patients with a minimum follow-up of 12 months
62822956|NCT04006405||Cohort 2|up to 140 patients with a minimum follow-up of 12 months
62822957|NCT03913455|OTHER|Guadecitabine and Carboplatin|Each cycle = 28 days; Subjects receive 4 cycles
62822958|NCT05525897|EXPERIMENTAL|Life skills course|Participants will take part in the psychoeducational course
62822959|NCT05525897|NO_INTERVENTION|Waitlist|
62822960|NCT06371612|ACTIVE_COMPARATOR|Standard Care|First, the physical comfort of the children will be ensured in the invasive procedure room. In standard care practice, the parental presence is supported during all invasive procedures performed on children. Two minutes before the removal of the peripheral intravenous cannula, cotton balls soaked in antiseptic solution and squeezed will be gently applied to the fixation area.
62822961|NCT06371612|ACTIVE_COMPARATOR|Adhesive Remover Spray|First, the physical comfort of the children will be ensured in the invasive procedure room. Two minutes prior to the removal of the peripheral intravenous cannula, an alcohol-free silicone-based aresol spray for medical use will be gently applied to the fixation site. The children will be supported by their parents.
62822962|NCT06371612|EXPERIMENTAL|Ball Squeezing + Adhesive Remover Spray|: First, the physical comfort of the children will be ensured in the invasive procedure room. Two minutes prior to the removal of the peripheral intravenous cannula, an alcohol-free silicone-based aresol spray for medical use will be gently applied to the fixation site. At the same time, children will start squeezing the stress ball. The ball squeezing intervention will be terminated when the removal of the peripheral intravenous cannula is completed. The children will be supported by their parents.
62822963|NCT06602648||CAYA Melanoma patients|Patients under 30 years of age at the moment of melanoma diagnosis. The patients have been divided in Children (1-14 yrs), Adolescents (15-18 yrs) and Young Adults (18-30 yrs) based on the age of diagnosis.
62245006|NCT06252519|EXPERIMENTAL|Neuro-NAC XS, then Neuro-NAC, then NAC|Participants receive single dose of Neuro-NAC XS while on controlled diet. One week later, participants receive 1 dose Neuro-NAC while on controlled diet. One week later, participants receive 1 dose NAC while on controlled diet.
62245007|NCT03875209|EXPERIMENTAL|Arm 1: 10E8.4/iMab IV or SC HIV-|Arm 1; Groups A-C; 3 dosing groups: HIV-uninfected individuals
62245008|NCT03875209|EXPERIMENTAL|Arm 2: 10E8.4/iMab IV HIV-|Arm 2; Groups D-F; 3 dosing groups: HIV-uninfected individuals
62245009|NCT03875209|EXPERIMENTAL|Arm 3 and 3a: 10E8.4/iMab IV HIV+|Arm 3; Group H; 1 dosing group: HIV-infected individuals with HIV-1 RNA levels between 1,000 and 100,000 copies/mL and cluster of differentiation 4 (CD4)\>350 cells/mm3; Arm 3a; Group I; 1 dosing group: HIV-infected and suppressed individuals
62435172|NCT01301131|NO_INTERVENTION|control|
62822964|NCT06020014|EXPERIMENTAL|Arm 1|AZD4604
62822965|NCT06020014|PLACEBO_COMPARATOR|Arm 2|Placebo
62822966|NCT05561920||Adult laryngectomised patients|Patients who have undergone total laryngectomy and completed minimal their 6-month period without disease after surgery and post-operative treatments such as radiotherapy or chemotherapy
62822967|NCT05611931|EXPERIMENTAL|Selinexor|Participants will receive a fixed dose of selinexor 60 milligrams (mg) oral tablets once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle.
62822968|NCT05611931|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo for selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.
62041933|NCT01263808|EXPERIMENTAL|Indacaterol 600 µg|Indacaterol 600 µg
62041934|NCT01263808|PLACEBO_COMPARATOR|Placebo|Placebo
62041935|NCT01263808|ACTIVE_COMPARATOR|Placebo/moxifloxacin|Placebo/moxifloxacin
62041936|NCT06533449|EXPERIMENTAL|Couplet Care Bassinet|125 mother-infant pairs will be assigned the Couplet Care bassinet. This bassinet has adjustability features to allow for bassinet positioning over the mother to enable access to the baby, secures the tub in the frame, and has a wall with access points.
62041937|NCT06533449|ACTIVE_COMPARATOR|Standard Bassinet|125 mother-infant pairs will be assigned the current hospital bassinet offered at the research site. The current bassinet is an unanchored acrylic tub with high walls on a wheeled cart with some storage.
62601727|NCT00932698|EXPERIMENTAL|Relapsed and Refractory Expansion Cohort: Ixazomib 2 mg/m^2|Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months, Participants must also be refractory to their most recent therapy as evidenced by PD while on therapy or within 60 days after their last dose of therapy (Up to 1621 days).
62601728|NCT00932698|EXPERIMENTAL|Velcade-Relapsed (VR) Expansion Cohort: Ixazomib 2.0 mg/m^2|Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after \>=1 prior therapy but have relapsed after previous Velcade exposure and were not treated with any other proteasome inhibitors (Up to 1573 days).
62822969|NCT05995210|EXPERIMENTAL|Kinesio taping group|In addition to the standard exercise program, kinesio taping was applied to the knee for 6 weeks.
62822970|NCT05995210|EXPERIMENTAL|Orthosis group|In addition to the standard exercise program, they were asked to use a knee orthosis for 6 weeks.
62822971|NCT05995210|ACTIVE_COMPARATOR|Control group|A standard exercise program was applied for 6 weeks.
62822972|NCT02657798||Depressed patients taking sertraline|Patients with depression who have been randomised to the sertraline arm in the PANDA trial
62822973|NCT02657798||Depressed patients taking placebo|Patients with depression who have been randomised to the placebo arm in the PANDA trial
62822974|NCT02657798||Healthy controls|Healthy participants with no history of depression
62822975|NCT05549960|OTHER|pancreatic lesions|Individuals with a histological diagnosis of locally advanced or metastatic (stage III or IV) pancreatic adenocarcinoma, functioning or non-functioning neuroendocrine tumor, pancreatic metastasis from inoperable renal cell carcinoma, or in affected patients not prone to treatment.
62822976|NCT05475015||Training cohort|Training cohort was set to develop the novel non-invasive model for virtual HVPG
62822977|NCT05475015||Validation cohort|Validation cohort was set to validate the novel non-invasive model for virtual HVPG in different people in same environments
62822978|NCT06327945|EXPERIMENTAL|Lung uDCD Protocol|
62822979|NCT03558659|EXPERIMENTAL|Positional Therapy Belt|Use of positional therapy belt (SlumberBUMP) during sleep.
62822980|NCT03558659|NO_INTERVENTION|Standard Care|No positional therapy belt provided for use during sleep.
62822981|NCT04984551|EXPERIMENTAL|Arm I: ECHO Participants (ECHO clinics, workshop, education)|Participants participate in online ECHO clinics over 1 hour twice monthly for 12 months and in-country workshops twice per year. Participants also receive 5 core lectures through an internet-based professional education curriculum.
62822982|NCT04984551|EXPERIMENTAL|Arm II: Patients (questionnaire, medical chart review)|Patients complete 3 in-person or phone questionnaires over a total of 20 minutes every 3 months for 2 years about their symptoms, emotional and physical well-being, and their experience and satisfaction with outpatient oncology care. Patients' medical charts are reviewed for data collection. Patients complete a 15 minute interview in person or phone about the care they received by their physician at baseline, end of month 4 and month 12.
62822983|NCT04984551|EXPERIMENTAL|Arm III: Caregivers (questionnaire)|Caregivers complete an in-person or phone questionnaire over 5 minutes up to 8 times about their experience and satisfaction with the cancer care their family member has received. Caregivers complete a 15-minute interview in person or by phone their family member received by their physician.
62822984|NCT05363527|EXPERIMENTAL|Endotoxin|Endotoxin 0.8 ng/kg body weight
62822985|NCT05363527|PLACEBO_COMPARATOR|Placebo|same volume of 0.9% saline
62822986|NCT03659396|EXPERIMENTAL|individualized Tai Chi|patient received individualized Tai Chi program training.
62822987|NCT03659396|ACTIVE_COMPARATOR|Entire Tai Chi|patient received Entire Tai Chi program training.
62041938|NCT03607929|EXPERIMENTAL|optimal and hydration|Physiological Saline Solution 300 ml/h AND drink freely mineral water during labor
62041939|NCT03607929|ACTIVE_COMPARATOR|variability and hydration|Other Solutions \>o \< 300 ml/h AND uncontrolled drink during labor
62041940|NCT05712356|EXPERIMENTAL|LSTA1 arm for Untreated Cholangiocarcinoma|
62041941|NCT05712356|EXPERIMENTAL|LSTA1 arm for Second-Line Cholangiocarcinoma|
62041942|NCT05712356|PLACEBO_COMPARATOR|Placebo arm for Untreated Cholangiocarcinoma|
62041943|NCT05712356|PLACEBO_COMPARATOR|Placebo arm for Second-Line Cholangiocarcinoma|
62041944|NCT04881006|EXPERIMENTAL|Test Product|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Drug: Dapagliflozin 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
62245010|NCT03875209|EXPERIMENTAL|Arm 4: 10E8.4/iMab SC HIV-|Arm 4; Groups J and K: HIV-uninfected individuals
62822988|NCT03659396|PLACEBO_COMPARATOR|home-based program|patient received home-based program training.
62822989|NCT06010654|EXPERIMENTAL|Experimental Group|The general treatment of the standard treatment method and the test device that provides self-talk training based on acceptance and commitment therapy (ACT) are used concurrently for 10 weeks.
62041945|NCT04881006|ACTIVE_COMPARATOR|Reference Product|Manufactured by AstraZeneca Pharmaceuticals LP Drug: Farxiga® 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
62041946|NCT04937153|EXPERIMENTAL|acasunlimab monotherapy|
62601729|NCT00932698|EXPERIMENTAL|Proteasome Inhibitor-Naive Expansion Cohort: Ixazomib 2 mg/m^2|Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after \>=1 prior therapy which must include thalidomide (or lenalidomide) and corticosteroid, but who never received a proteasome inhibitor (Up to 550 days).
62601730|NCT00932698|EXPERIMENTAL|Carfilzomib Expansion Cohort: Ixazomib 2.0 mg/m^2|Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants who previously received carfilzomib and had relapsed or refractory disease (Up to 123 days).
62601731|NCT00318851|EXPERIMENTAL|Carotid Artery Stenting|
62601732|NCT01930344|ACTIVE_COMPARATOR|3D laparoscopic visual system|Laparoscopic cholecystectomy to be performed with 3D laparoscopic imaging system
62041947|NCT04937153|EXPERIMENTAL|acasunlimab + pembrolizumab combination therapy|
62041948|NCT04536272|ACTIVE_COMPARATOR|Target of 2-2.5 times baseline aPTT (usual care, about 60-75)|Administration of heparin during ECLS with an aPTT target of 2-2.5 times baseline.
62601733|NCT01930344|PLACEBO_COMPARATOR|2D Laparoscopic Visual System|Laparoscopic cholecystectomy to be performed using normal, 2D, laparoscopic visual system
62601734|NCT01819103||Acute myocardial infarction|Drug Adherence
62601735|NCT01096589|EXPERIMENTAL|Arm 1 - 3M Coban 2|3M Coban 2 - 2 apps/wk
62601736|NCT01096589|EXPERIMENTAL|Arm 2 - 3M Coban 2|3M Coban 2 - 3 apps/wk
62601737|NCT01096589|EXPERIMENTAL|Arm 3 - 3M Coban 2|Arm 3 - 3M Coban 2 - 5 apps/wk
62601738|NCT01096589|ACTIVE_COMPARATOR|Arm 4 - Comprilan|Comprilan short-stretch bandage 5 apps/wk
62435173|NCT04190238|EXPERIMENTAL|Spasticity after stroke 1|Physical therapy with super inductive system on the agonist and antagonist muscles
62601739|NCT04000737|EXPERIMENTAL|Sorafenib + YIV-906|Patients in the study arm will be treated orally for 28-day courses with YIV-906 + sorafenib
62601740|NCT04000737|ACTIVE_COMPARATOR|Sorafenib + Placebo|Patients in the placebo arm will be given sorafenib with placebo
62822990|NCT06010654|NO_INTERVENTION|Control Group|Treatment as usual (TAU) is a standard treatment for 10 weeks, which is the clinical trial period.
62822991|NCT03134196|PLACEBO_COMPARATOR|Placebo|Encapsulated masked placebo
62822992|NCT03134196|ACTIVE_COMPARATOR|Masked Oral Valacyclovir 1000 mg daily|Valacyclovir, 500 mg, oral pill, two 500mg pills daily
62822993|NCT00801957|EXPERIMENTAL|1|tacrolimus ointment 0.03%
62822994|NCT00801957|ACTIVE_COMPARATOR|2|hydrocortisone acetate 1% and butyrate 0.1%
62041949|NCT04536272|ACTIVE_COMPARATOR|Target of 1.5-2.0 times baseline aPTT (45-60 sec.)|Administration of heparin during ECLS with an aPTT target of 1.5-2.0 times baseline.
62435174|NCT04190238|ACTIVE_COMPARATOR|Spasticity after stroke 2|Physical therapy with super inductive system on the antagonist muscles
62435175|NCT02196506|EXPERIMENTAL|Brexpiprazole + ADT|Brexpiprazole + ADT
62435176|NCT02196506|PLACEBO_COMPARATOR|Placebo + ADT|Placebo + ADT
62435177|NCT01974570|EXPERIMENTAL|Marealis refined peptide concentrate|Participants are provided in double blinded fashion to Marealis refined peptide concentrate
62435178|NCT01974570|PLACEBO_COMPARATOR|Placebo|Participants are provided in double blinded fashion to Placebo
62435179|NCT05842083|ACTIVE_COMPARATOR|Intervention|Each oncologist will have a total of three intervention days with a psychologist sitting in and observing the doctor-patient consultations and subsequently providing feedback.
62822995|NCT00801957|OTHER|3|Control group vaccination and challenge dose only
62822996|NCT02681523|EXPERIMENTAL|Single arm study|3 x 3 weekly cycles at the recommended dose of eribulin as the ready to use solution, 1.23 mg/m2, administered intravenously over 2-5 minutes on days 1 and 8 of every 21 day cycle. This will then be followed by 9 weeks of AI treatment, to be followed again by 3 x 3 weekly cycles of eribulin and 9 weeks AI treatment. Patients will remain on treatment for up to 9 months, or until disease progression or unacceptable toxicities, whichever is sooner.
62435180|NCT05842083|NO_INTERVENTION|Control|Oncologists in the control group will conduct consultations as usual.
62435181|NCT04670822|EXPERIMENTAL|Breastfeeding intervention group|A multicomponent behavioral intervention to promote breastfeeding
62435182|NCT04670822|PLACEBO_COMPARATOR|Attention placebo control group|General infant care counseling and support
62435183|NCT02587156|EXPERIMENTAL|Meal serving at high dietary protein|Test the handling of meal-served protein when habituated to high dietary protein at an amount above 1.5 g protein/kg/day
62435184|NCT02587156|ACTIVE_COMPARATOR|Meal serving at low dietary protein|Test the handling of meal-served protein when habituated to high dietary protein at an amount below 0.8 g protein/kg/day
62435185|NCT02569840|OTHER|Amino Acid Feed|An amino acid based multi-nutrient powdered feed
62435186|NCT05399719||Tumor tissue from BMT recipients|tumor tissue sections from patients received allogeneic bone marrow transplantation before
62435187|NCT05399719||Peripheral blood from healthy volunteer|peripheral blood from peripheral blood stem cell donors or healthy control
62435188|NCT03935659|ACTIVE_COMPARATOR|Standard gauze therapy|The control group will receive a standard sterile gauge dressing over the groin incision. The dressing will be removed on post-operative day #2 and the wound will be inspected for any complications, followed by daily dressing changes and wound inspections until discharge.
62822997|NCT04230304|EXPERIMENTAL|Treatment (daratumumab, ibrutinib)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, on days 1 and 15 of cycles 3-6, and then on day 1 of subsequent cycles. Beginning in cycle 2, patients also receive ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62822998|NCT02422745|ACTIVE_COMPARATOR|Cocoa extract + multivitamin|
62601741|NCT00460265|ACTIVE_COMPARATOR|ARM 2|Arm 2 consists of Cisplatin and 5-FU
62601742|NCT00460265|EXPERIMENTAL|ARM 1|ARM 1 Consists of Panitumumab plus Cisplatin and 5-FU
62601743|NCT00535847|EXPERIMENTAL|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 24 weeks.
62601744|NCT00535847|EXPERIMENTAL|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 48 weeks.
62601745|NCT00535847|EXPERIMENTAL|Other|"Subjects received telaprevir 750 mg tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, discontinued treatment before Week 12 in this study (VX06-950-107 \[NCT00535847\]) and had a partial response, viral breakthrough, or relapse in the parent study (VX05-950-104 \[NCT00336479\], VX05-950-104EU \[NCT00372385\] or VX06-950-106 \[NCT00420784\]) were included in Other reporting group."
62601746|NCT06619665|EXPERIMENTAL|MK-6552-Placebo-Modafinil|Participants were treated in period 1 with MK-6552; in period 2 with placebos to Modafinil and MK-6552; and in period 3 with Modafinil; with a 7-day washout between each period.
62601747|NCT06619665|EXPERIMENTAL|MK-6552-Modafinil-Placebo|Participants were treated in period 1 with MK-6552; in period 2 with Modafinil; and in period 3 with placebos to Modafinil and MK-6552; with a 7-day washout between each period.
62601748|NCT06619665|EXPERIMENTAL|Placebo-Modafinil-MK-6552|Participants were treated in period 1 with placebos to Modafinil and MK-6552; in period 2 with Modafinil; and in period 3 with MK-6552; with a 7-day washout between each period.
62601749|NCT06619665|EXPERIMENTAL|Placebo-MK-6552-Modafinil|Participants were treated in period 1 with placebos to Modafinil and MK-6552; in period 2 with MK-6552; and in period 3 with Modafinil; with a 7-day washout between each period.
62601750|NCT06619665|EXPERIMENTAL|Modafinil-MK-6552-Plaebo|Participants were treated in period 1 with Modafinil; in period 2 withMK-6552; and in period 3 with placebos to Modafinil and MK-6552; with a 7-day washout between each period.
62822999|NCT02422745|ACTIVE_COMPARATOR|Cocoa extract + multivitamin placebo|
62823000|NCT02422745|ACTIVE_COMPARATOR|Cocoa extract placebo + multivitamin|
62823001|NCT02422745|PLACEBO_COMPARATOR|Cocoa extract placebo + multivitamin placebo|
62823002|NCT03589716|OTHER|Participants with Vital Signs Within Normal Range|All participants will be asked to have an arm and finger measurement conducted and undergo vital sign measurements using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiration rate, blood oxygen saturation, and temperature. Participants with vital signs within the normal physiological range will also be asked to perform an optional exercise testing and/or undergo arterial blood gas measurement.
62823003|NCT03589716|OTHER|Participants with Vital Signs Outside of Normal Range|All participants will be asked to have an arm and finger measurement conducted and undergo vital sign measurements using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiration rate, blood oxygen saturation, and temperature. Participants with vital signs outside of the normal physiological range would be documented.
62823004|NCT06586866|EXPERIMENTAL|JK-1201I|Participants will receive JK-1201I as an intravenous (IV) infusion at dose of 125mg/m2 on Day 1 of each 14-day cycle until a treatment discontinuation criterion is met as specified in the protocol.
62849212|NCT00854113|EXPERIMENTAL|EGT0001474|Ascending doses of EGT0001474
62601751|NCT06619665|EXPERIMENTAL|Modafinil-Plaebo-MK-6552|Participants were treated in period 1 with Modafinil; in period 2 with placebos to Modafinil and MK-6552; and in period 3 with MK-6552; with a 7-day washout between each period.
62601752|NCT00108342|ACTIVE_COMPARATOR|Nicotine Replacement Treatment (NRT) Sampling|"Sampling = 3 minute testing of each of 6 NRTs (3 forms x 2 dosages)~2 mg and 4 mg nicotine gum; 2 mg and 4 mg nicotine lozenges; frequent and infrequent puffing on a nicotine inhaler (can yield 4 mg from 10 mg device)."
62601753|NCT00108342|SHAM_COMPARATOR|NRT Computer Learning|Computer learning: learning about 6 NRTs (3 forms x 2 dosages) by computer only
62601754|NCT05909813|EXPERIMENTAL|Individualized Piano Instruction (IPI)|Participants will receive six weeks of individualized piano instruction and two weeks follow-up for a total of eight weeks.
62041950|NCT04536272|ACTIVE_COMPARATOR|LMWH guided by weight and renal function.|Administration of LMWH guided by weight and renal function during ECLS.
62601755|NCT00358956|EXPERIMENTAL|1|
62601756|NCT02638675|EXPERIMENTAL|Wellness program, accelerometer, incentives|During the intervention period (weeks 1 to 12), intervention participants will be eligible to earn daily reward points contingent on step count goal achievement. Intervention participants will earn 100 reward points (i.e. $1) for each day that specific step count goals are reached. During weeks 13 to 24, participants will no longer receive daily reward points for completing specific step count goals.
62601757|NCT02638675|ACTIVE_COMPARATOR|Wellness program and accelerometer|During the 24 week trial, control participants will receive no additional incentives when step count goals are reached.
62601758|NCT04008706|EXPERIMENTAL|Acalabrutinib|Participants will be enrolled into 3 cohorts. In the treatment-naive cohort, a minimum of 300 participants with treatment-naïve chronic lymphocytic leukemia will be enrolled. In the relapsed/refractory cohort, approximately 200 participants with relapsed/refractory chronic lymphocytic leukemia will be enrolled. In the prior ibrutinib cohort, approximately 40 participants with Prior ibrutinib therapy will be enrolled.
62601759|NCT06618781|ACTIVE_COMPARATOR|group sedation|Preoperatively, 2 mg intravenous midazolam was administered to the patients. Intravenous 0.5 mg/kg propofol and 0.5 mcg/kg fentanyl were used for induction. Intravenous 0.5-1 mg/kg propofol was administered to provide an intraoperative bispectral index of 40-60, and when the Vizel analog score was \>4, intravenous 0.1-1 mcg/kg remifentanil was administered. Postoperatively, 1 g paracetamol was routinely administered. When the Vizel analog score was \>4, 50 mg dexketoprofen was administered as a rescue analgesic. Postoperative 2nd, 6th, 12th and 24th hour visual analog scores of the patients were recorded.
62601760|NCT06618781|ACTIVE_COMPARATOR|Group sedation+ Quadratus Lumborum Block|Before the procedure, the patient was placed in the left lateral position and a Quadratus Lumborum Block was applied at the thoracic 8-10 level. A total of 20 cc blocking fluid consisting of 14 cc of 0.5% bupivacaine and 6 cc of 2% lidocaine was used for the block. A minimum of 30 minutes was waited after the block. 2 mg of intravenous midazolam was administered before being taken to the operating room. Intravenous 0.5 mg/kg propofol and 0.5 mcg/kg fentanyl were used for induction. Intravenous 0.5-1 mg/kg propofol was administered to provide an intraoperative bispectral index of 40-60, and intravenous 0.1-1 mcg/kg remifentanil was administered when the Vizel analog score was \> 4. Postoperatively, 1 g of paracetamol was routinely administered. When the Vizel analog score was \> 4, 50 mg of dexketoprofen was administered as a rescue analgesic. Postoperative 2nd, 6th, 12th and 24th hour visual analog scores of the patients were recorded.
62601761|NCT06619431||Focus Group|The group consisted of three subgroups of Spanish-speakers: women, men, and caretakers.
62601762|NCT00668187||Gangliosidosis Diseases Study Population|This study observes one cohort: 42 infantile or juvenile Tay-Sachs disease, Sandhoff disease, or GM1 gangliosidosis affected subjects; and 10 late-onset gangliosidosis disease affected subjects.
62601763|NCT06642311|ACTIVE_COMPARATOR|Empty bladder group|"Patients in the empty bladder group will be instructed to empty the bladder immediately before the procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is empty.~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures"
62849213|NCT00854113|PLACEBO_COMPARATOR|Placebo|Placebo
62849214|NCT05650918|EXPERIMENTAL|MesoPher and mitazalimab combination therapy|"MesoPher. 25 million lysate loaded DCs administered in the form of 3 biweekly and 2 additional vaccinations (3 and 6 months after the third vaccination). 1/3 intradermal injection in the forearm and 2/3 via the intravenous route.~mitazalimab, 75µg/kg-150µg/kg-300µg/kg-600µg/kg or 1200µg/kg via intravenous route in the form of 3 biweekly and 2 additional infusions (3 and 6 months after the third vaccination)."
62041951|NCT06732167|EXPERIMENTAL|Lyoplant®|
62041952|NCT06732167|ACTIVE_COMPARATOR|Bio-Gide®|
62245011|NCT04038840|EXPERIMENTAL|Healthy Control (HC) Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the \[11C\]UCB-J radiotracer
62849215|NCT00932061|ACTIVE_COMPARATOR|Traditional Acupuncture|Acupuncture sites will be used for active intervention.
62849216|NCT00932061|SHAM_COMPARATOR|Sham Treatment|Sham acupuncture is used.
62849217|NCT01063413||Coleman Afterschool Program|Children enrolled in a community center-based after-school program.
62849218|NCT01063413||YMCA Fun Company|Children enrolled in a school-based after-school program.
62849219|NCT05056584|EXPERIMENTAL|Healthy control subjects|Healthy control subjects, matched for age, sex and BMI
62849220|NCT05056584|EXPERIMENTAL|Patients with End-stage Renal Disease|Patients with hemodialysis-treated ESRD.
62849221|NCT05056584|EXPERIMENTAL|Patients with liver cirrhosis|Patients with Child-Pugh A or B Cirrhosis
62245012|NCT04038840|EXPERIMENTAL|Schizophrenia (SZ) Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the \[11C\]UCB-J radiotracer
62245013|NCT06352827|OTHER|Observational Cohort|This cohort will complete a baseline survey.
62245014|NCT06225986|EXPERIMENTAL|LMH-4-DCP Intervention|
62601764|NCT06642311|ACTIVE_COMPARATOR|Bladder distension group|"Patients in the bladder distension group will be instructed to drink one liter of water and to avoid urination during a period of 2 h before the scheduled procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is distended .~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures."
62601765|NCT04437875|EXPERIMENTAL|Component 1|rAd26 Component, 1 vaccination Component 1 consists of a recombinant adenovirus vector based on the human adenovirus type 26, containing the SARS-CoV-2 S protein gene.
62601766|NCT04437875|EXPERIMENTAL|Component 2|rAd5 Component, 1 vaccination Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene.
62601767|NCT04437875|EXPERIMENTAL|Prime-Boost Immunization|Day 1 rAd26 Component Day 21 rAd5 Component
62601768|NCT02523235|ACTIVE_COMPARATOR|proximal catheter insertion|"Adductor canal catheters: Inserted as described by Jæger et al., 2013: ...we performed an ultrasound survey at the medial part of the thigh, halfway between the superior anterior iliac spine and the \[superior border of the\] patella. In a short axis view, we identified the femoral artery underneath the sartorius muscle, with the vein just inferior and the saphenous nerve just lateral to the artery.~Popliteal catheters: Using an ultrasound, the bifurcation of the sciatic nerve will be identified in short axis and marked at a point immediately distal at which point the two main branches of the sciatic nerve are separate and a hypoechoic area can be viewed between the two. This level will be marked on the skin. The needle will be inserted to intersect the sciatic nerve 6-7 cm proximal to the mark on the skin (therefore, proximal to the sciatic bifurcation) and injection with saline used to ensure subepimyseal spread."
62601769|NCT02523235|EXPERIMENTAL|distal catheter insertion|"Adductor canal catheters: Inserted as described by Manickam et al. 2009~Popliteal catheters: Using an ultrasound, the bifurcation of the sciatic nerve will be identified in short axis and marked at a point immediately distal at which point the two main branches of the sciatic nerve are separate and a hypoechoic area can be viewed between the two. This level will be marked on the skin. The needle tip will be inserted into the hypoechoic area between the two branches of the sciatic nerve immediately distal to the sciatic nerve bifurcation between the paraneurium and epineurium (the subparaneural space/compartment). As described by Tran et al, An adequate position was defined as the presence of circular expansion of the paraneural sheath... Once circular expansion was obtained, we injected."
62601770|NCT05577910|EXPERIMENTAL|Group A|One session VTP at month 0.
62601771|NCT05577910|EXPERIMENTAL|Group B|Four sessions IPL+MGX at month 0,1,2,3.
62601772|NCT05577910|ACTIVE_COMPARATOR|Group C|Twice daily EW for 15 months.
62601773|NCT05366309|ACTIVE_COMPARATOR|Standard Care (Control) Group|Participants randomised to this group will receive usual care in terms of their education.
62601774|NCT05366309|EXPERIMENTAL|Tailored Education Group|Participants randomised to this group will receive tailored education, which is additional to standard care.
62245015|NCT06225986|ACTIVE_COMPARATOR|Attention Control Arm|
62245016|NCT05512247|EXPERIMENTAL|Meal Delivery|Behavioral intervention program designed to improve diet quality and promote healthy weight gain in women with overweight/obesity through meal delivery and behavioral strategies during pregnancy.
62601775|NCT03181503|PLACEBO_COMPARATOR|Placebo|Participants received 3 subcutaneous injections of placebo (matched to nemolizumab) every 4 weeks (Q4W) up to Week 8.
62601776|NCT03181503|EXPERIMENTAL|Nemolizumab 0.5 mg/kg|Participants received 3 subcutaneous injections of nemolizumab 0.5 milligram per kilogram (mg/kg) Q4W up to Week 8.
62601777|NCT04257162|OTHER|Experimental Arm|Patients treated with Trastuzumab Deruxtecan (T-DXd; DS-8201a)
62601778|NCT05262712|EXPERIMENTAL|Stimulation|During motor training participants in the stimulation arm receive vitro-tactile feedback applied to the feet when touching an object as measured by force-sensing resistors mounted to the sole of the feet.
62601779|NCT05262712|PLACEBO_COMPARATOR|Control|The control group receives the same motor training with the same derives (force-sensing resistors, vibro-tactile stimulators) mounted to the feet but receives no stimulation.
62601780|NCT05984264|EXPERIMENTAL|Pridocaine cream|Pridocaine cream (lidocaine 2.5% and prilocaine 2.5%) will be applied at least 30 min before the pleurocentesis on the skin overlying the chosen aspiration site using ultrasound under occlusive dressing over a 5 × 5 cm area.
62601781|NCT05984264|ACTIVE_COMPARATOR|Standardized local lidocaine infiltration|Anesthetize the skin over the insertion site with 1% lidocaine using the 5 ml syringe with a 25 or 27-gauge needle. Next, anesthetize the superior surface of the rib and the pleura. The needle is inserted over the top of the rib (superior margin) to avoid the intercostal nerves and blood vessels that run on the underside of the rib (the intercostal nerve and the blood supply are located near the inferior margin). As the needle is inserted, aspirate back on the syringe to check for pleural fluid. Once fluid returns, note the depth of the needle and mark it with a hemostat. This gives an approximate depth for the insertion of the thoracentesis needle. Remove the anesthetizing needle.
62601782|NCT04836364||Pediatric Cohort|Parents of children ages 2 to 15 years old will provide data using the APICHS.
62601783|NCT06098703|EXPERIMENTAL|CARD (multi-faceted intervention)|CARD will be integrated in the pharmacy vaccination process. This includes education, environment (e.g., clinic spaces), engagement (interactions), and evaluation (surveys/feedback).
62601784|NCT06098703|NO_INTERVENTION|Control (standard care)|There are no specific procedures being undertaken to plan or execute vaccine clinics. Usual practices will be instituted by participating pharmacies.
62601785|NCT04182568|EXPERIMENTAL|nab-paclitaxel|
62601786|NCT04182568|ACTIVE_COMPARATOR|Docetaxel|
62601787|NCT02847143|EXPERIMENTAL|secure|healthy adult male with secure attachement
62601788|NCT02847143|EXPERIMENTAL|avoidant|healthy adult male with avoidant attachement
62601789|NCT02847143|EXPERIMENTAL|enmeshed/fearfull|healthy adult male with enmeshed/fearfull attachement
62245017|NCT04179448|EXPERIMENTAL|Side Access Mucosal Releasing Incision (SAMRI)|SAMRI incision to allow for coronally advanced flap and placement of acellular dermal matrix (ADM) graft
62601790|NCT02847143|EXPERIMENTAL|dual style|healthy adult male with dual attachement style
62245018|NCT04179448|ACTIVE_COMPARATOR|Sulcular Tunnell access|Sulcular tunnel access incision to allow for coronally advanced flap and placement of acellular dermal matrix (ADM) graft
62041953|NCT06388499|EXPERIMENTAL|TECC intervention group|The intervention will comprise of a 6-week disease-agnostic exercise-based telerehabilitation programme for people with chronic health conditions delivered by a chartered physiotherapist. The intervention will consist of weekly synchronous exercise sessions and guided social component, and synchronous educational webinars to promote self-management of health and well-being. The intervention will be delivered remotely via telehealth. The intervention will include two exercise level groups (one seated class group conducting exercises in sitting, the other standing class conducting exercises in a range of standing/dynamic/functional positions). Allocation to the appropriate exercise level will be based on participants' baseline functional mobility level which will be assessed using the Activities-specific Balance Confidence (ABC) Scale.
62435189|NCT03935659|EXPERIMENTAL|Negative Pressure wound therapy|The intervention group will receive a negative pressure dressing which will be applied in the operating room under sterile conditions. The brand of negative pressure dressing will be based on surgeon preference or center availability. The NPWT dressing will be removed on day 5 postoperatively or at discharge, whichever occurs first, and the groin wound inspected for any evidence of infection or dehiscence, and daily thereafter until discharge.
62601791|NCT05288608||Simple palliation|Treatment of patients who are referred for palliative radiotherapy to uncomplicated metastases.
62601792|NCT05288608||Complex palliation|Treatment of patients who require treatment to a site of previous radiation, patients undergoing concurrent systemic therapy, and those requiring a radiation dose exceeding 8 Gy.
62823005|NCT00907426|EXPERIMENTAL|Bimatoprost 0.03% Followed by Bimatoprost 0.03%|Treatment period one (0-6 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin.
62823006|NCT00907426|OTHER|Bimatoprost 0.03% Followed by Vehicle|Treatment period one (0-6 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin.
62823007|NCT00907426|OTHER|Vehicle Followed by Bimatoprost 0.03%|Treatment period one (0-6 months), once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin.
62041954|NCT05667051||Controlled type 2 diabetes mellitus|
62041955|NCT05667051||Diabetes mellitus free patients|
62041956|NCT06325969||Women with PCOS|Women aged 18 to 45 who meet the 2003 Rotterdam criteria for PCOS.
62041957|NCT06325969||Women without PCOS|Non-PCOS women aged 18 to 45.
62435190|NCT02880215|EXPERIMENTAL|Attention Bias Modification|Behavioral intervention designed to improved negative attention bias.
62435191|NCT02880215|EXPERIMENTAL|Cognitive Control Training|Behavioral intervention designed to improve sustained attention.
62435192|NCT02880215|NO_INTERVENTION|Assessment Only|Assessment only with no active intervention.
62435193|NCT01708876|ACTIVE_COMPARATOR|Artesunate-mefloquine|3 doses artesunate-mefloquine - daily over 3 days (dosage according to bodyweight - 4mg/kg and 8.3mg/kg respectively).
62601793|NCT04106089|EXPERIMENTAL|Observation-Intervention-Observation|5 days of observation, 5 days of extended vitals check, 5 days returning to regular vitals checks
62435194|NCT01708876|ACTIVE_COMPARATOR|Chloroquine|4 doses chloroquine over 3 days - total dose 25mg/kg. 10mg/kg at 0 hours, 5mg/kg at 6-8, 24, 48 hours.
62435195|NCT03476915||screened infants|Asymptomatic infants under age of 6 months, presenting to the pediatric orthopaedic outpatient clinic at Assiut university hospital for other problems will be subjected to ultrasound examination of the hip joint.
62435196|NCT05024071|EXPERIMENTAL|Swiss Ball|Swiss ball practice can create an unstable environment, promote the recovery of muscle function and develop joint stability. It can train the muscle groups in chest, abdomen, back, buttocks and legs, which play an important role in maintaining body balance and improving athletes' body.
62435197|NCT05024071|EXPERIMENTAL|Balance Plate|The balance board can exercise athletes' waist explosive force and body balance ability in an unstable state.
62601794|NCT04106089|EXPERIMENTAL|Observation-Observation-Intervention|5 days of observation, 5 more days of observation, 5 days of extended vitals check
62601795|NCT01264666|EXPERIMENTAL|Chinese tea flavor liquor|
62601796|NCT01264666|PLACEBO_COMPARATOR|Water|Water combined with meal as control.
62601797|NCT01264666|PLACEBO_COMPARATOR|Chinese Meijiao Liquor|
62823008|NCT06601088|NO_INTERVENTION|Control group with standard lower-limb immobilization|The control group will be treated according to the standard regimen with a lower limb immobilization in a stable orthosis during eight weeks.
62823009|NCT06601088|EXPERIMENTAL|Intervention group with additional Neuromuscular Electrical Stimulation'|The intervention group will during the eight weeks lower limb immobilization receive an additional intervention with calf Neuromuscular Electrical Stimulation (C-NMES) underneath the orthosis.
62823010|NCT02129543||Arm A: Treatment for Malignancy/Failure Group|Participants in this group will be those who are undergoing treatment for hematologic malignancy or bone marrow failure state.
62823011|NCT02129543||Arm B: Standard-of-Care SCT Group|Participants in this group will be cancer participants being treated with standard of care stem cell therapy
62823012|NCT02129543||Arm C: Adoptive T Cell Therapy Group|Participants in this group will be participants being treated with adoptive T cell therapy.
62823013|NCT02129543||Arm D: Control Group|Participants without cancer for studies of immunophenotype and immunologic function.
62823014|NCT06591013|EXPERIMENTAL|the Bai nationality-UC|Ulcerative colitis subjects will be treated with bacterial solution from the Bai nationality by colonoscope
62823015|NCT06591013|EXPERIMENTAL|the Han nationality-UC|Ulcerative colitis subjects will be treated with bacterial solution from the Han nationality by colonoscope
62823016|NCT06243458|EXPERIMENTAL|Single-arm RVU120|
62823017|NCT06310187|EXPERIMENTAL|High Oxidant Unflavored Little Cigar - Group A|
62245019|NCT05619744|EXPERIMENTAL|Part 1: RO7616789 QW: Dose Escalation|Participants will receive a fixed dose of RO7616789 intravenously once weekly (QW) per dose level on Day 1, 8, and 15 of each 21-day cycle. In case of toxicity, step-up (single or double) dosing may be explored.
62435198|NCT04634721|ACTIVE_COMPARATOR|Laparoscopic TAP block|Laparoscopic assisted TAP block will be done by surgeon intra-operatively
62435199|NCT04634721|ACTIVE_COMPARATOR|Ultrasaund TAP block|injecting bupivacaine in transversus abdominis plane to block the somatic nerves
62435200|NCT04634721|NO_INTERVENTION|no TAP block|no TAP block would be done
62435201|NCT03995303|ACTIVE_COMPARATOR|NCP and home-delivered meals|Preventing malnutrition with NCP by a registered dietician and home-delivered meals
62435202|NCT03995303|NO_INTERVENTION|Current practice|Current practice after discharge from the University Hospital of Iceland.
62435203|NCT04697355|EXPERIMENTAL|Naringenin + Beta carotene|Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day
62435204|NCT02768740|ACTIVE_COMPARATOR|200 mg group|Patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days.
62435205|NCT02768740|EXPERIMENTAL|300 mg group|Patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
62435206|NCT06530082|EXPERIMENTAL|CircFam53B-219aa DC vaccine|Subjects enrolled in the dose-escalation phase will receive CircFam53B-219aa DC vaccine once every 3 weeks according to the study protocol. Evaluations will be conducted every 6 weeks. If the investigator deems that the subject is deriving clinical benefit and with the subject's consent, additional vaccinations may be administered until unacceptable toxicity occurs, consent is withdrawn, or disease progression is observed.
62435207|NCT06530082|EXPERIMENTAL|CircFam53B-219aa DC vaccine+camrelizumab|Subjects enrolled in the sample size expansion phase will receive CircFam53B-219aa DC vaccine combined with camrelizumab once every 3 weeks. Evaluations will be conducted every 6 weeks. If the investigator deems that the subject is deriving clinical benefit and with the subject's consent, additional vaccinations may be administered until unacceptable toxicity occurs, consent is withdrawn, or disease progression is observed.
62435208|NCT00592020|ACTIVE_COMPARATOR|1|Short Transverse Incision
62435209|NCT00592020|ACTIVE_COMPARATOR|2|Hockey Stick Incision
62435210|NCT04749186|ACTIVE_COMPARATOR|Structured Didactic Model Group|A standardized video lessons (anatomy and technique), construction of a 3D epidural plastic module, practical training by using an epidural simulator with the CompuFlo Trainer instrument, and practical training with the eye-tracking assisted technique.
62435211|NCT04749186|NO_INTERVENTION|Standard Training Model|The standard local institutional teaching program
62435212|NCT01965652|EXPERIMENTAL|Naldemedine|Participants received 0.2 mg naldemedine tablets orally once daily for 52 weeks.
62823018|NCT06310187|EXPERIMENTAL|Low Oxidant Unflavored Little Cigar - Group B|
62823019|NCT06310187|EXPERIMENTAL|High Oxidant Flavored Little Cigar - Group C|
62245020|NCT05619744|EXPERIMENTAL|Part 2: RO7616789 Q3W: Dose Escalation|Participants will receive a fixed dose of RO7616789, at a dose determined in Part 1, intravenously once every 3 weeks (Q3W) on Day 1 of each 21-day cycle. In case of toxicity, step-up (single or double) dosing may be explored.
62435213|NCT01965652|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo tablets orally once daily for 52 weeks.
62823020|NCT06310187|EXPERIMENTAL|Low Oxidant Flavored Little Cigar - Group D|
62823021|NCT06310187|OTHER|Usual Cigarette - Group E|Control Condition - this is the subject's normal cigarette/cigar
62823022|NCT06310187|SHAM_COMPARATOR|Unlit Little Cigar - Group F|
62823023|NCT05377996|EXPERIMENTAL|XMT-1660|Single arm XMT-1660 alone (monotherapy)
62849222|NCT05637528||MagTrace patients|Patients who underwent sentinel lymph node biopsy with MagTrace one year ago.
62849223|NCT03051867||Third-trimester pregnant women|Women differing in their reproductive state (pregnant versus nonpregnant) will consume equivalent dietary intakes of vitamin D and related nutrients as part of a feeding study.
62601798|NCT06649188|EXPERIMENTAL|Group A: Magnesium Sulphate Iontophoresis|
62245021|NCT05619744|EXPERIMENTAL|Part 3: Dose Expansion|Based on emerging data from Part 1 and 2, one or more dosing regimens will be further investigated in Part 3.
62435214|NCT04314427||Gastric by-pass|Roux-en-Y gastric bypass (RYGB); the stomach is divided with staplers to create a small gastric pouch, while the jejunum is divided 30 to 50 cm distal to the ligament of Treitz. The distal limb is then anastomosed to the small gastric pouch and a jejunojejunostomy is performed 50 to 150 cm distal from the gastrojejunostomy.
62435215|NCT04314427||Sleeve gastrectomy|Sleeve gastrectomy reduces the stomach size by vertical stapling
62435216|NCT01042496|ACTIVE_COMPARATOR|Bipolar Group|Subjects underwent proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC) before and after treatment with Lamotrigine.
62435217|NCT01042496|ACTIVE_COMPARATOR|Control Group|Subjects underwent proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).
62435218|NCT02102490|EXPERIMENTAL|Abemaciclib|200 milligrams (mg) abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.
62435219|NCT06469346|EXPERIMENTAL|Eccentric Exercise Group (EEG)|These participants will be subjected to 6 weeks of Nordic hamstring eccentric exercise (3 times per week)
62041958|NCT06616831|EXPERIMENTAL|Remote Transcutaneous Auricular Vagal Nerve Stimulation Paired with Task Specific Training|Task-specific training (TST) paired with EMG activated Transcutaneous Auricular Vagal Nerve Stimulation (taVNS) three times a week for two weeks in an At-Home setting.
62435220|NCT06469346|EXPERIMENTAL|Static Stretching Group (SSG)|These participants will be subjected to 6 weeks of passive static stretching on hamstring muscle (3 times per week)
62435221|NCT06469346|OTHER|Control Group|These participants will not be under any type of treatment during the intervention protocol
62435222|NCT02476552|EXPERIMENTAL|Niraparib Oral and IV|Single Oral dose of Niraparib capsules (unlabeled active pharmaceutical ingredient) orally and a 15-minute IV infusion of Niraparib (labeled active pharmaceutical ingredient)
62435223|NCT02476552|EXPERIMENTAL|Niraparib Oral|Single Oral dose of Niraparib capsules (labeled active pharmaceutical ingredient)
62435224|NCT01730859|EXPERIMENTAL|Balance exrercise and ankle taping|"Balance Exercises:Balance exercises for 6 weeks, 3 sessions per week and each session was 40 minutes for training group.~Ankle taping: Ankle joint taping was performed for 6 weeks and was renewed three times a week."
62435225|NCT05704218|OTHER|domestic HP|"All the patients will be in the same arm until obtention of the final diagnosis.~The final diagnosis will be used to compare data of serology to determine thresholds"
62435226|NCT06090578|EXPERIMENTAL|TabCAT-Brain Health Assessment Clinical Pathway|Primary care providers concerned that their patients are exhibiting signs of cognitive decline based on patient, informant (family), or provider concerns will refer them for a TabCAT-BHA assessment and follow-up care.
62435227|NCT06090578|NO_INTERVENTION|Usual Care Clinical Pathway|Patients in the control practices will continue with usual care workflows.
62435228|NCT04499456|ACTIVE_COMPARATOR|Control|Waiting list control receiving the PNF after the last assessment
62435229|NCT04499456|EXPERIMENTAL|Single PNF|Receives PNF after the first assessment only
62435230|NCT04499456|EXPERIMENTAL|Boosted PNF|Receives PNF after every assessment
62435231|NCT02132741||Treated hypertension|Patients on treatment for hypertension
62435232|NCT02132741||CKD-ESRD|Pre- \& post haemodialysis
62435233|NCT02132741||Healthy individuals|Healthy volunteers
62435234|NCT02132741||Chronic kidney disease|Pre-dialysis CKD \& those with a functional renal transplant
62245022|NCT00458341|EXPERIMENTAL|Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg|During Cycle 1, participants will receive ataluren at 4 mg/kg in the morning, 4 mg/kg at midday, and 8 mg/kg in the evening for 14 days, followed by a 14-day follow-up period without treatment. Then, the participants will crossover to the other ataluren dose regimen (ataluren 10, 10, and 20 mg/kg) for Cycle 2.
62245023|NCT00458341|EXPERIMENTAL|Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg|During Cycle 1, participants will receive ataluren at 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 14 days, followed by a 14-day follow-up period without treatment. Then, the participants will crossover to the other ataluren dose regimen (ataluren 4, 4, and 8 mg/kg) for Cycle 2.
62435235|NCT02132741||Hypertension|Untreated
62435236|NCT02903576|ACTIVE_COMPARATOR|injection of hESC-RPE in suspension|6 patients will receive cell suspension injections on the sub retinal space prior to the surgeries, to access safety
62435237|NCT02903576|ACTIVE_COMPARATOR|injection hESC-RPE seeded in a substrate|15 patients will receive a sub-retinal implantation of a polymeric scaffold seeded hesc- RPE in monolayer
62435238|NCT02033876|EXPERIMENTAL|Ursodiol|Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
62435239|NCT02033876|PLACEBO_COMPARATOR|Placebo|matching placebo capsules to be taken twice daily
62435240|NCT00160030|EXPERIMENTAL|1|
62435241|NCT00160030|ACTIVE_COMPARATOR|2|
62435242|NCT01872689|PLACEBO_COMPARATOR|Monotherapy (Cohort A): Placebo|Participants will receive monotherapy with placebo matched to lebrikizumab administered via subcutaneous (SC) injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
62601799|NCT06649188|SHAM_COMPARATOR|Group B: Control|
62601800|NCT00526903|EXPERIMENTAL|Fiber|Fiber added to diet for a total of 6 weeks.
62601801|NCT00526903|PLACEBO_COMPARATOR|Placebo|Placebo powder taken for a total of 6 weeks.
62849224|NCT03051867||Nonpregnant control women|Women differing in their reproductive state (pregnant versus nonpregnant) will consume equivalent dietary intakes of vitamin D and related nutrients as part of a feeding study.
62823024|NCT06434116|EXPERIMENTAL|Immersive virtual reality in patient with VAS dyspnea ≥ 3|"Once included in the study, the patient will undergo a 15-minute session of mechanical ventilation followed by a 15-minute weaning trial without intervention (control period).~A respiratory discomfort VAS is performed following the spontaneous breathing trial. If the VAS is ≥ 3 cm, the patient is randomised between the intervention group (immersive virtual reality) and the control group (standard care).~The spontaneous breathing trial will be continued for a further 15 minutes in accordance with usual management, with one of the two interventions according to randomisation."
62823025|NCT06434116|EXPERIMENTAL|Control in patient with VAS dyspnea ≥ 3|"Once included in the study, the patient will undergo a 15-minute session of mechanical ventilation followed by a 15-minute weaning trial without intervention (control period).~A respiratory discomfort VAS is performed following the spontaneous breathing trial. If the VAS is ≥ 3 cm, the patient is randomised between the intervention group (immersive virtual reality) and the control group (standard care).~The spontaneous breathing trial will be continued for a further 15 minutes in accordance with usual management, with one of the two interventions according to randomisation."
62823026|NCT03560037|NO_INTERVENTION|Standard Colonoscopy|Patients randomly assigned to this group will receive standard colonoscopy without the use of a distal attachment.
62823027|NCT03560037|EXPERIMENTAL|Endocuff Vision Assisted Colonoscopy|Patients randomly assigned to this group will receive colonoscopy with the use of the Endocuff Vision distal attachment.
62823028|NCT06328686|EXPERIMENTAL|Arm A (IV L-arginine, WBRT)|Patients receive L-arginine IV over 10-20 minutes followed by WBRT approximately 1 hour later for up to 10 days of treatment over 2 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo CT at screening, undergo collection of blood samples and spectroscopy on study, and undergo MRI at screening and follow up.
62823029|NCT06328686|EXPERIMENTAL|Arm B (oral L-arginine, WBRT)|Patients receive L-arginine PO followed by WBRT approximately 1 hour later for up to 10 days of treatment over 2 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo CT at screening, undergo collection of blood samples and spectroscopy on study, and undergo MRI at screening and follow up.
62823030|NCT06183762||ICIs|Patients receiving in first-line immunotherapy with or without anti-angiogenic or chemotherapy
62823031|NCT06183762||Savolitinib|Patients receiving in first-line savolitinib treatment
62823032|NCT06183762||Glumetinib|Patients receiving in first-line glumetinib treatment
62823033|NCT06183762||Bozitinib|Patients receiving in first-line bozitinib treatment
62435243|NCT01872689|EXPERIMENTAL|Monotherapy (Cohort A): Lebrikizumab|Participants will receive monotherapy with lebrikizumab at a dose of 250 milligrams (mg) administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
62601802|NCT02691429|ACTIVE_COMPARATOR|acai dye (Euterpe oleracea) 10%|"Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).~Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in"
62823034|NCT02717234|ACTIVE_COMPARATOR|Impact Advanced Recovery|Oral nutrition supplement intended for consumption at 3 servings per day
62823035|NCT02717234|EXPERIMENTAL|Impact Advanced Recovery-R|Oral nutrition supplement intended for consumption at 3 servings per day
62823036|NCT06597682|EXPERIMENTAL|Experimental Group 1|Cardiovascular Symptoms-Experimental Group: Oral prednisone tablet treatment, taking 40mg (8 tablets) daily, with a reduction of 1 tablet (5mg) per week for the first 2 weeks, followed by a reduction of 0.5 tablets (2.5mg) per week from the 3rd week onwards, for a total duration of 3 months.
62245024|NCT06734195|EXPERIMENTAL|Group A (propofol group)|30 patients will receive propofol 1mg/kg before the start of skin closure, administered over 10 minutes and caudal block using 1 ml/kg of bupivacaine 0. 25 % plus 2 ml normal saline.
62823037|NCT06597682|PLACEBO_COMPARATOR|Control Group 1|Cardiovascular Symptoms-Control Group: Oral placebo (cornstarch tablets), taking 8 tablets daily, with a reduction of 1 tablet (5mg) per week for the first 2 weeks, followed by a reduction of 0.5 tablets (2.5mg) per week from the 3rd week onwards, for a total duration of 3 months.
62823038|NCT06597682|EXPERIMENTAL|Experimental Group 2|Respiratory Symptoms-Experimental Group: Inhalation treatment with budesonide/formoterol powder inhaler (160µg; 4.5µg), inhaled twice daily, for a total duration of 2 weeks.
62823039|NCT06597682|PLACEBO_COMPARATOR|Control Group 2|Respiratory Symptoms-Control Group: Inhalation of placebo (saline solution), inhaled twice daily, for a total duration of 2 weeks.
62245025|NCT06734195|EXPERIMENTAL|Group B (caudal dexmedetomidine group)|30 patients will receive caudal dexmedetomidine block using 1 ml/kg of bupivacaine 0. 25 % mixed with dexmedetomidie 1mic/kg diluted in 2 ml normal saline.
62245026|NCT06734195|EXPERIMENTAL|Group C (propofol with caudal dexmedetomidine group)|30 patients will receive both propofol .5 mg/kg before the start of skin closure, administered over 10 minutes and caudal dexmedetomidine block using 1 ml/kg of bupivacaine 0. 25 % mixed with dexmedetomidie 1mic/kg diluted in 2 ml normal saline.
62823040|NCT06597682|EXPERIMENTAL|Experimental Group 3|Neurological Symptoms-Experimental Group: Combination therapy with cognitive enhancer drugs and oral prednisone, starting dose of prednisone is 1mg per kilogram of body weight, with a reduction of 1 tablet (5mg) every 2 weeks, for a total duration of 6 months.
62823041|NCT06597682|PLACEBO_COMPARATOR|Control Group 3|Neurological Symptoms-Control Group: Combination therapy with cognitive enhancer drugs and oral placebo (cornstarch tablets), starting dose of cornstarch tablets is 1mg per kilogram of body weight, with a reduction of 1 tablet (5mg) every 2 weeks, for a total duration of 6 months.
62823042|NCT06597682|EXPERIMENTAL|Experimental Group 4|Fatigue Group-Experimental Group: Oral prednisone tablet treatment, taking 40mg (8 tablets) daily, with a reduction of 1 tablet (5mg) per week for the first 2 weeks, followed by a reduction of 0.5 tablets (2.5mg) per week from the 3rd week onwards, for a total duration of 3 months.
62041959|NCT03079154|EXPERIMENTAL|Teacher-led MBCT course|Eight-session mindfulness-based cognitive therapy course, including an initial orientation session, led by a qualified mindfulness teacher working with the Sussex Mindfulness Centre, a part of the NHS Sussex Partnership Mental Health Trust.
62041960|NCT03079154|ACTIVE_COMPARATOR|Self-guided MBCT course|Mindfulness-based cognitive therapy course, after an initial information session, which is self-guided using the audiobook Mindfulness: A practical guide to finding peace in a frantic world by Mark Williams and Danny Penman (2011). It consists of eight substantive chapters that map on to the eight-session MBCT course taught by teachers to groups of students. Students will be asked to work through one chapter a week, thus matching the pace of the teacher-led intervention.
62041961|NCT03079154|NO_INTERVENTION|Wait list control|Students in the wait list (control) arm do not receive any intervention for the same length of time as the experimental and active comparator arms of the intervention are taking place. Students are invited to complete the self-guided MBCT course after the end of the research project.
62041962|NCT04150003|EXPERIMENTAL|Pulmonary Rehabilitation program|10-weeks structured exercise-based intervention protocol on the restoration of lung blood flow after an acute PE
62041963|NCT04150003|ACTIVE_COMPARATOR|Usual care|Protocolized usual care for patient suffering PE
62041964|NCT00610116|OTHER|LV lead electronically repositioning|Single arm study
62245027|NCT04155268|EXPERIMENTAL|Floatation-REST|Participants will float in a shallow pool of water with about 1000 pounds of epsom salt, in a light and sound attenuated device, for up to 60 minutes. Following the session, participants' ratings of the experience will be measured.
62823043|NCT06597682|PLACEBO_COMPARATOR|Control Group 4|Fatigue Group-Control Group: Oral placebo (cornstarch tablets), taking 8 tablets daily, with a reduction of 1 tablet (5mg) per week for the first 2 weeks, followed by a reduction of 0.5 tablets (2.5mg)
62245028|NCT04155268|ACTIVE_COMPARATOR|Dark Room|Participants will lay on an air mattress in a dark and quiet room, with reduced environmental stimulation, for up to 60 minutes. Following the session, participants' ratings of the experience will be measured.
62245029|NCT04683731|ACTIVE_COMPARATOR|Group 1|Patients view decision aid without personalized message and whose providers do not receive the personalized message.
62245030|NCT04683731|EXPERIMENTAL|Group 2|Patients view decision aid with personalized message and whose providers do not receive the personalized message.
62245031|NCT04683731|EXPERIMENTAL|Group 3|Patient view decision aid without the personalized message and whose providers receive the personalized message.
62601803|NCT02691429|ACTIVE_COMPARATOR|acai dye (Euterpe oleracea) 25%|"Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).~Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in"
62601804|NCT05475587||Prediabetes cases|
62601805|NCT05475587||Healthy controls|
62823044|NCT05228470|EXPERIMENTAL|Elranatamab|BCMA-CD3 bispecific antibody
62823045|NCT05304039||Asthma exacerbation|Patients with an asthma exacerbation who are diagnosed with mild to severe asthma according to the GINA guidelines
62823046|NCT05197426|EXPERIMENTAL|Oral Azacitidine|
62041965|NCT05205330|EXPERIMENTAL|30 mg (Dose Level 1)|14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 30 mg twice a day for 14 days
62601806|NCT01886586|ACTIVE_COMPARATOR|Problem Solving Therapy|8-12 sessions of Problem Solving Therapy (both members of dyad)
62601807|NCT01886586|ACTIVE_COMPARATOR|Problem Solving Therapy + Exercise|6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
62601808|NCT01886586|ACTIVE_COMPARATOR|Enhanced Usual Care|Staff will will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
62601809|NCT01179737|EXPERIMENTAL|Nilotinib|Participants in cohort 1 were assigned to receive nilotinib 50 mg during 14 days, followed by 150 mg during 14 days, followed by 300 mg during 140 days. Participants in cohort 2 were assigned to receive nilotinib 300 mg during 168 days
62601810|NCT01179737|PLACEBO_COMPARATOR|Placebo|Participants were assigned to receive placebo to nilotinib to match 50 mg and 150 mg capsules during 168 days.
62823047|NCT05197426|PLACEBO_COMPARATOR|Placebo|
62823048|NCT06008951|EXPERIMENTAL|Self-chosen music|The self-chosen music playlist will be assembled by the participant in advance.
62041966|NCT05205330|EXPERIMENTAL|90 mg (Dose Level 2)|14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 90 mg twice a day for 14 days
62041967|NCT05205330|EXPERIMENTAL|180 mg (Dose Level 3)|14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 180 mg twice a day for 14 days
62601811|NCT01794793|EXPERIMENTAL|Pasireotide subcutaneous|0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines. Cabergoline may be combined in this arm for Cushing's Disease and Acromegaly patients.
62601812|NCT01794793|EXPERIMENTAL|Pasireotide Long Acting Release (LAR)|10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
62601813|NCT04108221|EXPERIMENTAL|Arm A : c-TAP Block performed by surgeon|c-TAP Block Block performed by surgeon
62601814|NCT04108221|ACTIVE_COMPARATOR|Arm B : us-TAP Block performed by anesthetist|us-TAP Block by anesthetist
62823049|NCT06008951|EXPERIMENTAL|Researcher-chosen music|The researcher-chosen music playlists will primarily be composed by the Music as Medicine research group from Erasmus Medical Center, based on current expert opinion. The playlist will be created with the goal to help while experiencing pain based on previous literature.
62823050|NCT06008951|ACTIVE_COMPARATOR|Podcast (control)|The choice of podcast will be based on expert opinion of the sociology department of the Erasmus University Rotterdam.
62823051|NCT01195766|EXPERIMENTAL|Ofatumumab|Ofatumumab in addition to ESHAP therapy
62823052|NCT05003505||Women with cervical cytology (TCT) abnormalities|In the enrollment, women who have undergone cervical cytology (TCT) examination for the last 3 months with abnormal results will be included in this study. All participants will be followed up three times, at 6 months, 12 months and 24 months.
62245032|NCT04683731|EXPERIMENTAL|Group 4|Patients view decision aid with the personalized message and whose providers receive the personalized message.
62823053|NCT04080661|EXPERIMENTAL|Standard of care - secukinumab|Patients will continue to receive secukinumab according to the standard dosing schedule: subcutaneous injections once a week for 5 weeks, then every 4 weeks (300 mg).
62823054|NCT01967849||Obese/overweight chldren/adolescents|Obese or overweight children and adolescents between ages 7-21 that are at risk for developing type 2 diabetes will undergo an Oral Glucose Tolerance test (OGTT) to asses glucose status.
62823055|NCT01967849||Lean children/adolescents|Lean children/adolescents between the ages of 7-21. This cohort should have family members that have type 2 diabetes or was the result of a gestational diabetes pregnancy. They will undergo an Oral Glucose Tolerance Test to assess glucose status.
62041968|NCT05205330|EXPERIMENTAL|other mGI cancers|14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 90 mg twice a day for 14 days
62245033|NCT06289673|EXPERIMENTAL|Newly diagnosed ALL, LLy, and MPAL patients|"All eligible patients receive the following intervention:~Dexamethasone, Vincristine, Daunorubicin, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)"
62601815|NCT06459570|EXPERIMENTAL|Virtual reality based exercises|
62601816|NCT06459570|OTHER|standard physical therapy|
62601817|NCT01917344|OTHER|Adults with PKU|MRI, EEG, neuropsychological testing, neurological examination, blood draw, diet diary, physical examination. These activities were performed for the study, but no drug or other interventions took place.
62823056|NCT06593743|EXPERIMENTAL|Perianal NRL001 Gel 3 strengths|A single peri-anal application of NRL001 0.3%, 1%, 3% gel in stepwise dose ascending fashion.
62823057|NCT06593743|EXPERIMENTAL|Intraanal NRL001 Gel 2 strengths|A single intra-anal application of 3% or 1% NRL001 gel.
62823058|NCT06593743|EXPERIMENTAL|Intrarectal NRL001 Gel|A single intra-rectal application of 1% NRL001 gel.
62823059|NCT06593743|EXPERIMENTAL|NRL001: 10mg suppository|One 10mg NRL001 suppository applied to rectum.
62823060|NCT06331559|EXPERIMENTAL|SIM0501 mono dose escalation|
62823061|NCT06331559|EXPERIMENTAL|SIM0501 mono dose optimization|
62823062|NCT06331559|EXPERIMENTAL|SIM0501 combination dose escalation|
62823063|NCT06331559|EXPERIMENTAL|SIM0501 combination dose optimization|
62823064|NCT05261646|EXPERIMENTAL|Hetrombopag|
62823065|NCT05261646|PLACEBO_COMPARATOR|Matching placebo|
62823066|NCT05546879|EXPERIMENTAL|Experimental|NP137+Atezolizumab-Bevacizumab
62823067|NCT04774393|EXPERIMENTAL|Arm A (decitabine/cedazuridine, venetoclax, ivosidenib)|Patients receive decitabine/cedazuridine PO daily on days 1-5, venetoclax PO daily on days 1-14, and ivosidenib PO daily on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
62823068|NCT04774393|EXPERIMENTAL|Arm B (decitabine/cedazuridine, venetoclax, enasidenib)|Patients receive decitabine/cedazuridine PO daily on days 1-5, venetoclax PO daily on days 1-14, and enasidenib PO daily on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
62823069|NCT06594601||lung recruitment potential assessed by 3D EIT in ARDS|Diagnosis of ARDS was based on the Berlin definition, who have receivied mechanical ventilation. The enrolled patients received a lung recruitment potential assessment by 3D EIT( as the follwoing mentioned )
62823070|NCT06594601||PEEP titration by 3D EIT for ARDS|Diagnosis of ARDS was based on the Berlin definition, who have receivied mechanical ventilation. The enrolled patients received a lung PEEP tirtation by 3D EIT( as the follwoing mentioned )
62823071|NCT06281756|PLACEBO_COMPARATOR|Subjects treated with Cognitive Behavior Treatment for Insomnia (CBT-I) with placebo|Subjects with insomnia treated with Cognitive Behavior Treatment for Insomnia (CBT-I) for 8 weeks, then non-remitting subjects received placebo for 8 weeks.
62823072|NCT06281756|ACTIVE_COMPARATOR|Subjects treated with Cognitive Behavior Treatment for Insomnia (CBT-I) with Trazodone|Subjects with insomnia treated with Cognitive Behavior Treatment for Insomnia (CBT-I) for 8 weeks, then non-remitting subjects received trazodone for 8 weeks.
62823073|NCT05929274|EXPERIMENTAL|Active Comparator - real tDCS|real tDCS: anodal transcranial direct current stimulation were delivered over the left DLPF cortex in patients
62245034|NCT03715023|EXPERIMENTAL|Active + SoC|Daily doses of PC786 for 3 days + SoC
62245035|NCT03715023|PLACEBO_COMPARATOR|Placebo + SoC|Daily doses of Placebo for 3 days + SoC
62245036|NCT06735365||Oxiris|The group which we used oxiris filter for CRRT.
62245037|NCT06735365||Non-Oxiris|The group which we used other filters like M150 for CRRT.
62245038|NCT05505045|EXPERIMENTAL|Treatment Group: Cognitive Orientation to daily Occupational Performance (CO-OP)|Each CO-OP session will last 60 minutes and subjects will complete one session per week over the course of 10 weeks. All sessions will be delivered remotely via the Zoom platform.
62601818|NCT02954653|EXPERIMENTAL|Dose Escalation|Single agent PF-06747143 dose escalation
62601819|NCT02954653|ACTIVE_COMPARATOR|Cohort 1|PF-06747143 with standard dose cytarabine and daunorubicin.
62823074|NCT05929274|SHAM_COMPARATOR|Sham Comparator - sham tDCS|sham transcranial direct current stimulation were delivered over the left DLPF cortex in patients.
62823075|NCT06229444|EXPERIMENTAL|Proactive ILI content & Predictions|Participants will receive predictive alerts, reactive content after reporting symptoms or receiving an asymptomatic prediction, and ILI-related health educational content
62823076|NCT06229444|EXPERIMENTAL|No Proactive ILI content & Predictions|Participants will receive predictive alerts and reactive content after reporting symptoms or receiving an asymptomatic prediction, but will not receive proactive ILI content
62823077|NCT06229444|EXPERIMENTAL|Proactive ILI content & No Predictions|Participants will not receive predictive alerts or reactive content after reporting symptoms but will receive proactive ILI content
62823078|NCT06229444|EXPERIMENTAL|No Proactive ILI content & No Predictions|Participants will not receive predictive alerts or reactive content after reporting symptoms or proactive ILI content
62823079|NCT02814006|EXPERIMENTAL|every other day|participants will visualize educational video with timed intercourse as recommended by NICE and ASRM
62823080|NCT02814006|EXPERIMENTAL|fertile window|participants will visualize educational video with timed intercourse as recommended by well-know evidence of better conception rates when using this strategy
62823081|NCT02814006|NO_INTERVENTION|CG|participants will respond to questionnaire with no knowledge of intervention
62601820|NCT02954653|ACTIVE_COMPARATOR|Cohort 2|PF-06747143 in combination with Azacitidine or Decitabine.
62041969|NCT06732245|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Placebo Comparator: Placebo to oral NA-931 120 mg daily + no Tirzepatide Participants will receive oral placebo at baseline and at Weeks 4, 12, and 24, 36, and 48 during the core treatment period and will switch during the extension period to receive NA-931 60 mg daily at Weeks 60 and 72.
62041970|NCT06732245|PLACEBO_COMPARATOR|Placebo + Tirzepatide 5 mg|Other: Placebo + Tirzepatide 5 mg Participants will receive oral placebo at baseline and at Weeks 4, 12, and 24, 36, and 48, and s.c. Tirzepatide 5 mg weekly per the dose escalation schedule.
62041971|NCT06732245|PLACEBO_COMPARATOR|Placebo + Tirzepatide 10 mg|Placebo + Tirzepatide 10 mg Participants will receive oral placebo at baseline and at Weeks 4, 12, and 24, 36, and 48 and s.c. Tirzepatide 10 mg weekly per the dose escalation schedule.
62245039|NCT05505045|ACTIVE_COMPARATOR|Attention Control Group|Each session will last 60 minutes and subjects will complete one session per week over the course of 10 weeks. All sessions will be delivered remotely via the Zoom platform.
62245040|NCT03898492|OTHER|Intervention|The participants in this group participated in exercise two times/week for 8 weeks
62245041|NCT03898492|NO_INTERVENTION|Control|The participants in the control group were instructed to maintain their daily routines.
62601821|NCT02954653|EXPERIMENTAL|Cohort 3|PF-06747143 dose expansion as a single agent.
62823082|NCT06593379|EXPERIMENTAL|Safety planning, treatment as usual, and MIST|Participants will get a safety plan, treatment as usual, and the MIST intervention.
62823083|NCT06593379|ACTIVE_COMPARATOR|Safety planning and treatment as usual|Participants will get a safety plan and treatment as usual.
62245042|NCT06212999|EXPERIMENTAL|Cohort A|Povorcitinib at the protocol-defined dose strength based on cohort assignment.
62823084|NCT06588920||Parkinson disease|People with Parkinson disease
62823085|NCT06588920||Healthy older adults|Healthy older adults
62823086|NCT03558737|ACTIVE_COMPARATOR|Nasal high-frequency jet ventilation (nHFJV)|
62041972|NCT06732245|EXPERIMENTAL|NA-931 60mg to NA-931 150 mg + no Tirzepatide|Experimental: NA-931 60mg to NA-931 150 mg + no Tirzepatide Participants will receive oral NA-931 60 mg at baseline and at Weeks 4, 12, and 24, 36, and 48 during the core treatment period and will switch during the extension period to receive NA-931 60 mg at Weeks 60 and 72.
62041973|NCT06732245|ACTIVE_COMPARATOR|NA-931 60 mg + Tirzepatide 5 mg|NA-931 60 mg + Tirzepatide 5 mg Participants will receive oral NA-931 60 mg at baseline and at Weeks 4, 12, and 24, 36, and 48 and s.c. Tirzepatide 5 mg weekly per the dose escalation schedule.
62245043|NCT06212999|EXPERIMENTAL|Cohort B|Povorcitinib at the protocol-defined dose strength based on cohort assignment.
62245044|NCT06212999|EXPERIMENTAL|Cohort C|Povorcitinib at the protocol-defined dose strength based on cohort assignment.
62245045|NCT05666518||vericiguat arm|Japanese patients with a diagnosis of chronic heart failure who received standard treatment and will start vericiguat therapy for chronic heart failure.
62823087|NCT03558737|ACTIVE_COMPARATOR|Nasal intermittent positive pressure ventilation (NIPPV)|
62823088|NCT05297409||Hyperkalemia patient with Chronic kidney disease|
62245046|NCT05666518||control arm|Japanese patients a diagnosis of chronic heart failure who received standard treatment and will continue standard of care treatment for chronic heart failure.
62245047|NCT04972929|EXPERIMENTAL|Spinal Manipulation|The spinal manipulation (SM) group will receive manually delivered SM limited to the thoracic spine.
62245048|NCT04972929|SHAM_COMPARATOR|Sham Spinal Manipulation|Sham-spinal manipulation will be delivered by setting the expansion control knob on an Activator II (Activator Methods®) device to the zero position (off; no thrust) and placed onto the dorsal thumb surface of the clinician. At a setting of zero, no excursion of the Activator II stylus occurs, despite the device delivering an audible clicking sound, with no biomechanical force being imparted.
62435244|NCT01872689|PLACEBO_COMPARATOR|Combination Therapy (Cohort B): Placebo + Pirfenidone|Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day \[9 capsules daily\] for a total of 2403 mg/day) or at maximum tolerated dose (MTD) administered orally along with placebo matched to lebrikizumab administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
62823089|NCT05297409||hyperkalemia patient with heart failure|
62823090|NCT06135805|EXPERIMENTAL|Active Comparator: Fluocinonide 0,,05% oral gel|Patients were treated with a topical gel of Fluocinonide 0.05%, applied to oral lesions twice daily for 1 month.
62823091|NCT06135805|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Patients were treated with a topical gel of placebo, applied to oral lesions twice daily for 1 month.
62823092|NCT02783690|NO_INTERVENTION|Conventional Fractionation|50.0 Gy (RBE) in 25 daily fractions
62823093|NCT02783690|EXPERIMENTAL|Hypofractionation|40 Gy (RBE) in 15 daily fractions
62823094|NCT03105713|EXPERIMENTAL|Patient Safety Checklist Intervention|The intervention to be administered is a patient safety checklist (two parts) for patients to be performed on paper or electronically: a) before admission to hospital, and b) under hospital stay (discharge)
62823095|NCT03105713|NO_INTERVENTION|Controls|Patients do not receive the safety checklist intervention. Care as usual.
62601822|NCT03250481|ACTIVE_COMPARATOR|'Sedation guidance with RASS-group|Sedation is guided with RASS. Targeted sedation level is RASS -3 - 0. Propofol: an initial rate of 2.4 mg/kg/h for one hour. Thereafter, the infusion rate of propofol is 0.8-4 mg/kg/h to reach or maintain the target RASS score. Propofol bolus of 20-40 mg is allowed. Oxycodone as 3-6 mg boluses for pain management. Other opiates are not allowed. Midazolam may given if the maximum dose of propofol is reached and pain management by oxycodone restricted achievement of the target sedation level. Midazolam will supply intravenously in boluses of 1-2 mg (based on the weight of the patient), starting at 3 boluses/h for the first hour. Dexmedetomidine and other sedatives are not allowed.
62601823|NCT03250481|EXPERIMENTAL|'Sedation guidance with RI|Sedation is guided with RI. Targeted sedation level is RI 40-80. Propofol: an initial rate of 2.4 mg/kg/h for one hour. Thereafter, the infusion rate of propofol is 0.8-4 mg/kg/h to reach or maintain the target RI score. Propofol bolus of 20-40 mg is allowed. Oxycodone as 3-6 mg boluses for pain management. Other opiates are not allowed. Midazolam may given if the maximum dose of propofol is reached and pain management by oxycodone restricted achievement of the target sedation level. Midazolam will supply intravenously in boluses of 1-2 mg (based on the weight of the patient), starting at 3 boluses/h for the first hour. Dexmedetomidine and other sedatives are not allowed.
62601824|NCT05169112|NO_INTERVENTION|Standard of Care|Standard of Care
62601825|NCT05169112|EXPERIMENTAL|Standard of Care plus Androgen Deprivation Therapy (Lupron Depot)|22.5 mg intra-muscular injection of Lupron Depot every 3 months for 12 months (4 injections total)
62601826|NCT03274557|ACTIVE_COMPARATOR|Radiofrequency microtenotomy|Treatment of Achilles tendinose with radio-frequency microtenotomy
62601827|NCT03274557|ACTIVE_COMPARATOR|Phusical therapy|Supervised eccentric training
62601828|NCT02681757|ACTIVE_COMPARATOR|Control- triple antibiotic ointment|triple antibiotic ointment (TAO) impregnated Adaptic gauze, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
62601829|NCT02681757|EXPERIMENTAL|Variable- mepitel Ag|mepitel Ag, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
62601830|NCT01843114|OTHER|Patients with Type I Diabetes|24 patients with type I diabetes with no or mild non-proliferative retinopathy
62041974|NCT06732245|ACTIVE_COMPARATOR|NA-931 120 mg + Tirzepatide 5 mg|NA-931 120 mg + Tirzepatide 5 mg Participants will receive oral NA-931 60 mg at baseline and at Weeks 4, 12, and 24, 36, and 48 and s.c. Tirzepatide 5 mg weekly per the dose escalation schedule.
62245049|NCT05593055|ACTIVE_COMPARATOR|Eplerenone|Participants be placed on enalapril 10 mg and weaned off their other anti-hypertensives prior to the Pre-Treatment Assessment. Amlodipine (5 to 10 mg) will be added if needed to control blood pressure. After the Pre-Treatment Assessment, participants randomized to this arm will receive 50 mg eplerenone . At 2 weeks, eplerenone will be increased to 100 mg. Amlodipine (5 to 10 mg) will be added at 6 weeks or later if needed to achieve the BP target of \<135/85 mmHg.
62245050|NCT05593055|ACTIVE_COMPARATOR|Chlorthalidone + potassium|Participants be placed on enalapril 10 mg and weaned off their other anti-hypertensives prior to the Pre-Treatment Assessment. Amlodipine (5 to 10 mg) will be added if needed to control blood pressure. After the Pre-Treatment Assessment, participants randomized to this arm will receive 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium. Amlodipine (5 to 10 mg) will be added at 6 weeks or later if needed to achieve the BP target of \<135/85 mmHg.
62601831|NCT01843114|OTHER|Healthy subjects|24 healthy age-and sex- matched control subjects
62245051|NCT05862818|EXPERIMENTAL|Day shift protocol with diet A|Day shift protocol with diet A condition. Since this is a single-blind study, the details of the meal conditions cannot be released during the recruitment stage but will be made public once enrollment closes.
62245052|NCT05862818|EXPERIMENTAL|Day shift protocol with diet B|Day shift protocol with diet B condition. Since this is a single-blind study, the details of the meal conditions cannot be released during the recruitment stage but will be made public once enrollment closes.
62245053|NCT05862818|EXPERIMENTAL|Night shift protocol with diet A|Night shift protocol with diet A condition. Since this is a single-blind study, the details of the meal conditions cannot be released during the recruitment stage but will be made public once enrollment closes.
62435245|NCT01872689|EXPERIMENTAL|Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone|Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day \[9 capsules daily\] for a total of 2403 mg/day) or at MTD administered orally along with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
62435246|NCT01478633|EXPERIMENTAL|Galantamine|
62435247|NCT03582371|EXPERIMENTAL|Aqua SUP|Patients in the Aqua SUP group will benefit from a 1 hour Aqua SUP session, twice a week, for 8 weeks in a therapeutic pool.
62435248|NCT03582371|ACTIVE_COMPARATOR|Physiotherapy|Patients in the control group will receive a conventional physiotherapy session of 1 hour, twice a week, for 8 weeks.
62601832|NCT05972291|EXPERIMENTAL|Oral Glutamine|You will be asked to consume 5 grams of glutamine three times a day for 12 weeks. At week four, you will be asked to return to the CRC to be assessed, and then to return every four weeks until week 12, which will be the conclusion of the study.
62601833|NCT05972291|PLACEBO_COMPARATOR|Whey Protein Powder|You will be asked to consume 5 grams of whey protein powder three times a day for 12 weeks. At week four, you will be asked to return to the CRC to be assessed, and then to return every four weeks until week 12, which will be the conclusion of the study.
62849225|NCT01127828|ACTIVE_COMPARATOR|Probiotic yoghurt (Cultura)|Cultura yoghurt containing: L bulgaricus, S thermophilus
62435249|NCT02088528|ACTIVE_COMPARATOR|Aurolab glaucoma drainage device|
62041975|NCT06732245|EXPERIMENTAL|NA-931 150 mg + no Tirzepatide|Experimental: NA-931 150 mg + no Tirzepatide Participants will receive oral NA-931 150 mg at baseline and at Weeks 4, 12, 24, 36 and 48
62245054|NCT05862818|EXPERIMENTAL|Night shift protocol with diet B|Night shift protocol with diet B condition. Since this is a single-blind study, the details of the meal conditions cannot be released during the recruitment stage but will be made public once enrollment closes.
62245055|NCT00501826|EXPERIMENTAL|Treatment (nelarabine and combination chemotherapy)|See Detailed Description
62435250|NCT02088528|ACTIVE_COMPARATOR|Trabeculectomy with mitomycin-c|
62849226|NCT01127828|PLACEBO_COMPARATOR|Yoghurt with no probiotic|
62823096|NCT06397456|EXPERIMENTAL|Intensive Intervention (iPREP RRT)|"The intervention is administered by a patient educator (PE), a culturally concordant health educator. S/he will review the CKD and RRT education materials on a tablet device with the participant, answer any questions they have, and using motivational interviewing techniques get a commitment for future action. The participant and the patient educator will work together to decide on potential CKD self-management and RRT options and/or next steps. The PE will teach the participant how to use the home blood pressure monitor and will leave it with the participant.~The patient educator will check in with the participant through text messages and follow-up phone calls."
62041976|NCT06732245|ACTIVE_COMPARATOR|NA-931 150 mg + Tirzepatide 2.5 mg|NA-931 150 mg + Tirzepatide 2.5 mg Participants will receive oral NA-931 150 mg at baseline, and at Weeks 4, 12, and 24, 36, and 48 and s.c. Tirzepatide 2.5 mg weekly per the dose escalation schedule.
62041977|NCT06732245|ACTIVE_COMPARATOR|NA-931 150 mg + Tirzepatide 5 mg|NA-931 150 mg + Tirzepatide 5 mg Participants will receive oral NA-931 150mg at baseline and at Weeks 4, 12, and 24, 36, and 48 and s.c. Tirzepatide 5 mg per the dose escalation schedule.
62041978|NCT06732089||rTMS|Participants in this group are enrolled to recieve rTMS treatment as part of their clinical care in the Interventional Psychiatry Program.
62245056|NCT06735781||Neoadjuvant nivolumab plus chemotherapy treatment|
62823097|NCT06397456|PLACEBO_COMPARATOR|Enhanced Usual Care|"The enhanced usual care is administered by a patient educator (PE), a culturally concordant health educator. The PE will drop off written general health education materials.~The patient educator will check in with the participant through text messages."
62245057|NCT03226418|EXPERIMENTAL|Group I|"INTENSIVE INDUCTION THERAPY: Patients receive cytarabine intravenously (IV) on days 1-7 and idarubicin over 10-15 minutes on days 1-3 (7+3), or liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3 and 5. Gemtuzumab or midostaurin are added to 7+3 as per the standard of care. Treatment continues for 1 course in the absence of unacceptable toxicity.~INTENSIVE CONSOLIDATION THERAPY: Patients who go into remission, receive cytarabine IV over 1-3 hours twice daily (BID) on days 1, 3, and 5. Treatment repeats every 4 weeks for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients treated with liposome-encapsulated daunorubicin-cytarabine receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 5-8 weeks for 2 courses in the absence of disease progression, unacceptable toxicity."
62435251|NCT05723822|EXPERIMENTAL|Walkasins and PhySens-IMM System--Single Arm|Participants who meet the eligibility criteria will don a pair of Walkasins and the PhySens-IMM System. They will perform some brief balance exercises (i.e., sensory integration exercises) and then complete the outcome assessments with their Walkasins turned off and without the use of an assistive device. After a rest period of about five minutes, they will repeat the outcome assessments with their Walkasins turned on.
62435252|NCT05349331|EXPERIMENTAL|Resection group|Surgical resection group: The patients underwent liver cancer resection and were followed up regularly after surgery.
62435253|NCT05349331|NO_INTERVENTION|Non-surgical resection group|Stop hepatic artery interventional therapy (chemoembolization/infusion chemotherapy), continue the original targeted and immunotherapy for no more than 1 year
62823098|NCT03280719|ACTIVE_COMPARATOR|Supine Hypofractionated Radiotherapy|"Supine Radiotherapy and Hypofractionation:~Whole breast + regional nodal irradiation in supine position with a median dose of 15 x 2.67 Gy prescribed to the whole breast and nodal regions. Median dose of the simultaneously integrated boost is 3.12 Gy per fraction."
62041979|NCT06732089||IVK|Participants in this group are enrolled to receive intravenous ketamine (IVK) treatment as part of their clinical care in the Interventional Psychiatry Program.
62041980|NCT06732089||ECT|Participants in this group are enrolled to receive electroconvulsive therapy (ECT) as part of their clinical care in the Interventional Psychiatry Program.
62601834|NCT05565001|ACTIVE_COMPARATOR|Levcromakalim|Intravenous infusion of 1 mg levcromakalim followed by intravenous sumatriptan infusion.
62041981|NCT04554914|EXPERIMENTAL|EBV+ PID LPD|Participants with R/R or newly diagnosed EBV+ PID LPD for whom standard first-line therapy is inappropriate, will receive IV tabelecleucel.
62041982|NCT04554914|EXPERIMENTAL|EBV+ AID LPD|Participants with R/R or newly diagnosed EBV+ AID LPD for whom standard first-line therapy is inappropriate, will receive IV tabelecleucel.
62041983|NCT04554914|EXPERIMENTAL|EBV+ CNS PTLD|Participants with R/R or newly diagnosed EBV+ CNS PTLD for whom standard first-line therapy is inappropriate, will receive IV tabelecleucel.
62041984|NCT04554914|EXPERIMENTAL|EBV+ PTLD (inappropriate for first-line therapy or CD20-negative)|Participants with EBV+ PTLD for whom standard first-line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, will receive IV tabelecleucel.
62245058|NCT03226418|EXPERIMENTAL|Group II|"LOW-INTENSITY: Patients receive venetoclax in combination with azacitidine or decitabine or other standard of care low-intensity therapy such as azacitidine or decitabine alone or in combination with FLT3 inhibitor such as midostaurin, low-dose cytarabine in combination with glasdegib.~Venetoclax dose varies depending on drug interaction with antifungal agents. Given daily continuous for \>= 3 months orally. Glasdegib dose is 100 mg oral daily.~Decitabine IV over 1-3 hours daily for 5-10 days. Treatment repeats every 4-5 weeks for \>= 3 courses in the absence of disease progression, unacceptable toxicity or receipt of allogeneic stem cell transplant. Azacitidine IV infusion over 10 to 40 minutes days 1 -7. Treatment repeats every 4-5 weeks for \>= 3 courses in the absence of disease progression, unacceptable toxicity or receipt of allogeneic stem cell transplant."
62245059|NCT06735729||surgeons involved in stoma|All the surgeons were coming from either general surgery, gastrointestinal surgery, surgical oncology, emergency, and other departments involved stoma creation. their concepts and attitudes regarding to enterostomy management were investigated by a electronic questionnaire which comprised of five parts: personnel qualification and training, attitude toward stoma-related complications, preoperative siting, process of acquiring ostomy-related surgical skills, and awareness and adoption of relevant techniques (37 items in total).
62245060|NCT03382145||postmenopausal bleeding women|Retrospective review on outcome of One stop Postmenopausal bleeding clinic in New Territorial Eastern Cluster, Hong Kong. Single group study, no intervention.
62245061|NCT01553877|ACTIVE_COMPARATOR|Pushti Packet|
62245062|NCT01553877|EXPERIMENTAL|Rice based Ready to Use Complementary Food Supplements|
62435254|NCT03101423|ACTIVE_COMPARATOR|interleukin-2|interleukin-2 treatment per month
62435255|NCT03101423|ACTIVE_COMPARATOR|DLI|donor lymphocyte infusion (DLI) treatment per month
62435256|NCT00618423|PLACEBO_COMPARATOR|Physiologic saline|
62435257|NCT00618423|ACTIVE_COMPARATOR|Ketamine|
62601835|NCT05565001|PLACEBO_COMPARATOR|placebo (isotonic saline)|Intravenous infusion of placebo (isotonic saline) followed by intravenous sumatriptan infusion.
62041985|NCT04554914|EXPERIMENTAL|EBV+ sarcoma, including LMS, or smooth muscle tumors|Participants with newly diagnosed EBV+ sarcoma for whom the standard first-line therapy is inappropriate, including LMS or smooth muscle tumor, will receive IV tabelecleucel.
62041986|NCT06097728|EXPERIMENTAL|Volrustomig + Carboplatin + pemetrexed|Volrustomig in combination with carboplatin plus pemetrexed
62041987|NCT06097728|ACTIVE_COMPARATOR|Investigator's choice of standard care|The investigator's choice of nivolumab plus ipilimumab or platinum plus pemetrexed chemotherapy for participants with epithelioid histology, and nivolumab plus ipilumab for participants with non-epithelioid histology.
62041988|NCT02676375|OTHER|Standard Monotherapy|Treatment as usual starting with one smoking cessation medication plus group therapy.
62041989|NCT02676375|EXPERIMENTAL|Combination Extended Treatment|Extended treatment with multiple standard medications plus group therapy.
62041990|NCT02676375|EXPERIMENTAL|Combination Extended Treatment + Home Visits/Calls|Extended treatment with multiple standard medications plus group therapy plus home visits.
62245063|NCT01553877|ACTIVE_COMPARATOR|Chick-pea based Ready to Use Complementary Food Supplements|
62245064|NCT00002860|OTHER|surgery|
62245065|NCT03508258||Participants with NVAF starting Apixaban|
62245066|NCT03508258||Participants with NVAF starting Warfarin|
62245067|NCT01357421|EXPERIMENTAL|TT301|Investigational drug TT301
62245068|NCT01357421|PLACEBO_COMPARATOR|Placebo|Normal saline
62245069|NCT04744571|EXPERIMENTAL|DCB group|Patients treated with Drug-Coated Balloon Angioplasty after revascularization of Chronic Total Occlusions
62245070|NCT04744571|ACTIVE_COMPARATOR|DES group|Patients treated with Drug eluting stents Angioplasty after revascularization of Chronic Total Occlusions
62435258|NCT03695133|EXPERIMENTAL|intervention group|"1. Group-based interventions Group-based interventions include physical activity, sightseeing, picnics, theater, cinema, group educations.~2. Individual interventions Individual interventions include interventions in the Omaha System Nursing Interventions Scheme that is specific to health problems of elderly women."
62435259|NCT03695133|NO_INTERVENTION|control group|The control group will not take any intervention, the post-tests will be collected at the end of 12 weeks.
62601836|NCT01537627|ACTIVE_COMPARATOR|Low-intensity training (LT)|
62601837|NCT01537627|ACTIVE_COMPARATOR|High-intensity training (HT)|
62601838|NCT00854334||1.|Children with both obesity and obstructive sleep apnea
62601839|NCT00854334||2|Children without the presence of both obesity and obstructive sleep apnea
62601840|NCT05814042|EXPERIMENTAL|Nutrient based intervention|Nutrition supplement used to stop diarrhea
62601841|NCT05814042|ACTIVE_COMPARATOR|Standard of Care oral rehydration solution|Standard of care nutrition supplement used to stop diarrhea.
62601842|NCT03499405|EXPERIMENTAL|Intervention group|Intervention group will receive a family navigator intervention from a culturally matched family navigator.
62601843|NCT03499405|NO_INTERVENTION|Control group|Control group will not receive a family navigator intervention from a culturally matched family navigator.
62849227|NCT02753439|EXPERIMENTAL|3rd molar|Drug: Geistlich Bio Oss
62041991|NCT04219540|EXPERIMENTAL|extended-release buprenorphine (XR-B)|Subjects who agree to XR-B treatment will receive an XR-B injection to the abdomen. The injection is a liquid medication in the amount of either 100 or 300 mg buprenorphine in 1.5 cc volume and will last in the body for about 30 days. The medication is stored in a small nodule under the skin of the belly where it was injected. The buprenorphine is gradually released into the body over time for a 30-day period.
62823099|NCT03280719|EXPERIMENTAL|Prone Hypofractionated Radiotherapy|"Prone Radiotherapy and Hypofractionation:~Whole breast + regional nodal irradiation in prone position with a 15 x 2.67 Gy dose prescription to the whole breast and nodal regions. Median dose of the simultaneously integrated boost is 3.12 Gy per fraction."
62823100|NCT03280719|EXPERIMENTAL|Supine Accelerated Radiotherapy|"Supine Radiotherapy and Acceleration:~Whole breast + regional nodal irradiation in supine position with a median dose of 5 x 5.7 Gy to the whole breast. Lymph node regions receive a median dose of 5 x 5.4 Gy. Median dose of the simultaneously integrated boost is 6.2 Gy per fraction."
62823101|NCT03280719|EXPERIMENTAL|Prone Accelerated Radiotherapy|"Prone Radiotherapy and Acceleration:~Whole breast + regional nodal irradiation in prone position with a median dose of 5 x 5.7 Gy to the whole breast. Lymph node regions receive a median dose of 5 x 5.4 Gy. Median dose of the simultaneously integrated boost is 6.2 Gy per fraction."
62823102|NCT04876521|EXPERIMENTAL|Amisulpride Group|The patients will receive low dose Amisulpride at 100-300 mg/day.
62041992|NCT04219540|EXPERIMENTAL|extended release naltrexone XR-NTX|Subjects who agree to XR-NTX treatment will receive an injection of XR-NTX to the outer upper part of your buttock. The injection is a liquid medication in the amount of 380 mg naltrexone in 4 cc volume (about 1 teaspoon) and will last in your body for about 30 days. Following release, visits with study physicians at Bellevue Hospital will offer further counseling or medication treatment referrals, the option to receive additional XR-NTX injections once a month following the first injection and continued encouragement to avoid relapses and stay on treatment.
62041993|NCT04219540|NO_INTERVENTION|Treatment as Usual (TAU)|In this group you will not receive any study medication. You will be able to receive any treatments available to individuals in the jail or prison who are not in the study. Trained study staff at the first two visits will provide counseling focusing on relapse and overdose prevention, treatment engagement, and navigating re-entry challenges.
62041994|NCT01428076|EXPERIMENTAL|High Dose Polidocanol Endovenous Microfoam|
62041995|NCT01428076|EXPERIMENTAL|Medium Dose Polidocanol Endovenous Microfoam|
62041996|NCT02036489|EXPERIMENTAL|Induction and consolidation treatment|
62041997|NCT06191198|EXPERIMENTAL|Communication Bridge™|Participants receive Communication Bridge™, a multi-component, participation-focused, dyadic intervention in which both the person with PPA and their co-enrolled communication partner are intervention recipients. Communication Bridge™ is modelled on the Living with Aphasia: Framework for Outcome Measurement (A-FROM) and the Care Pathway Model that was developed for persons living with primary progressive aphasia. Consistent with participation-focused intervention models personally salient training stimuli are incorporated into all therapy activities in the Experimental arm.
62041998|NCT06191198|ACTIVE_COMPARATOR|Evidence-Based Impairment Focused|The Control arm includes a non-dyadic intervention in which the person with PPA is the active intervention recipient and their communication partner is in a supporting role. In the Control arm, participants receive a speech-language intervention designed to address impairment and functional limitations, comprised of activities that address word retrieval and 'automatic' speech production using fixed, non-personalized, stimuli across participants.
62041999|NCT02559336|NO_INTERVENTION|Control|Usual care: Oncology team refers patients to palliative care team if deemed appropriate
62042000|NCT02559336|EXPERIMENTAL|Intervention|Integrated oncology care and palliative care
62042001|NCT02753790|EXPERIMENTAL|Intensity Modulated Radiotherapy (IMRT)|Radiation therapy to a dose of 60 Gray (Gy)/45 Gy to gross disease and 30 Gy to subclinical sites, delivered over 15 fractions
62601844|NCT03740321|EXPERIMENTAL|Embospheres 500-700 microns|Intervention.Embolization with 500-700 micron particles will be performed with 1 ml vials. Embolization procedure will be continued with vials until the stasis in SRAE will be achieved. Procedure will be performed only one time.
62823103|NCT04876521|ACTIVE_COMPARATOR|Olanzapine-Fluoxetine Group|the patients will receive Olanzapine-Fluoxetine Combinations at 5/10 + 20 mg/day.
62823104|NCT00181168|EXPERIMENTAL|Euthyroid Group|Euthyroid Group: Subjects received rhTSH to prepare for radioiodine therapy.
62823105|NCT00181168|NO_INTERVENTION|Hypothyroid Group|Hypothyroid Group: Thyroid hormone treatment was withheld before radioiodine therapy.
62823106|NCT05165134|EXPERIMENTAL|Experimental kinesiotape group A|Kinesiotape group
62823107|NCT05165134|PLACEBO_COMPARATOR|Placebo kinesiotape group B|Control group
62042002|NCT06732479|NO_INTERVENTION|Control group: Treatment as usual (TAU)|"These included general safety tips, and the detailed instructions taught to children by teachers in special school during academic programme. As part of the curriculum, teachers taught children about safe touch and unsafe touch and instructed children to say No to unsafe touches. Teachers mainly focused on inappropriate touches and the main mode of instruction was lecturing."
62435260|NCT01735591|EXPERIMENTAL|Probiotic|Capsules with 3x10\^9 colony forming units (Lactococcus lactis PB 411 - 50%; Lactobacillus casei PB 121 - 25%; Lactobacillus acidophilus PB 111 - 12,5%; Bifidobacterium bifidum PB 211 - 12,5%). 1 capsule a day from inclusion until liver transplantation
62435261|NCT01735591|PLACEBO_COMPARATOR|Placebo|Placebo, 1 capsule a day from inclusion until the date of liver transplantation
62042003|NCT06732479|EXPERIMENTAL|Behavioral skill Training (BST)|The Behavioural Skill Training (BST) was developed by modifying the Body Safety Training programme developed by Dr.Sandy.K.Wurtele.The Module was organized under 10 lessons. Each lesson was taught through stories, and each story had a picture that goes along with it. Children were taught first about the general safety (poison safety, fire safety, pedestrian safety, and vehicle safety) as a way of establishing rapport, and then moved to body safety rules (stranger safety, concept of private parts, appropriate and inappropriate touches, self-protection skills). Appropriate and inappropriate situations were presented using video and training was given to children on how to respond appropriately to each situation using role play. The Module was delivered over a period of one month, three sessions per week.
62042004|NCT05297812||Moderate to Advanced Emphysema|Patients with moderate or advanced Emphysema as measured by baseline inspiratory PERC-15 below the study median
62042005|NCT05297812||Minimal Emphysema|Patients with minimal emphysema as measured by baseline inspiratory PERC-15 above the study median
62042006|NCT05776173|EXPERIMENTAL|BD211 Single-Dose group|Route of Administrate: infusion intravenously. Dosage form: injection solution. Dose: 5×10\^6 cells /kg \~ 10×10\^6 cells /kg. Frequency of administration: One dosing intravenously. Intervention: Single dose of BD211
62042007|NCT05130970|EXPERIMENTAL|Garadacimab|Administered IV and SC
62042008|NCT05130970|PLACEBO_COMPARATOR|Placebo|Administered IV and SC
62435262|NCT00769899|EXPERIMENTAL|1|
62435263|NCT00769899|PLACEBO_COMPARATOR|2|
62435264|NCT03974581||Pharmacoinvasive strategy|Patients whom received pharmacoinvasive strategy (fibrinolysis and subsequently PCI) as reperfusion treatment.
62435265|NCT03974581||Primary PCI|Patients whom primary PCI as reperfusion treatment.
62435266|NCT02151461|EXPERIMENTAL|Low Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
62435267|NCT02151461|EXPERIMENTAL|Mid Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
62435268|NCT02151461|EXPERIMENTAL|High Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
62435269|NCT02151461|EXPERIMENTAL|Metformin Monotherapy|3 Capsules BID each containing 166.7 mg of metformin with dose escalation to 283.3 mg capsules BID (1,700 mg/Day) at Day 14.
62435270|NCT02273206|ACTIVE_COMPARATOR|Prevention Care Management for Cancer Screening|The Care Manager will focus on cancer screening, providing education, patient navigation, and motivational support to overcome screening barriers and form favorable attitudes towards screening.
62042009|NCT04496219|EXPERIMENTAL|Arm I (acupuncture, BCG)|Patients undergo acupuncture therapy and receive BCG via intravesical injection on days 1, 8, 15, 22, 29, and 36 in the absence of unacceptable toxicity. Patients also receive standard of care symptom management.
62042010|NCT04496219|ACTIVE_COMPARATOR|Arm II (BCG, standard of care)|Patients receive BCG via intravesical injection on days 1, 8, 15, 22, 29, and 36 in the absence of unacceptable toxicity. Patients also receive standard of care symptom management. Patients may undergo acupuncture therapy after completion of intravesical BCG therapy.
62042011|NCT06724276|EXPERIMENTAL|combined treatment|Combined treatment (balloon angioplasty or stenting + fibroblast transplantation).
62042012|NCT06724276|ACTIVE_COMPARATOR|Endovascular treatment|Endovascular interventions + traditional debridement.
62601845|NCT03740321|EXPERIMENTAL|Embospheres 700-900 microns|Intervention.Embolization with 700-900 micron particles will be performed with 1 ml vials. Embolization procedure will be continued with vials until the stasis in SRAE will be achieved. Procedure will be performed only one time.
62042013|NCT06644287||Diagnosis of advanced soft tissue sarcomas|Patients diagnosis of advanced soft tissue sarcomas require immunotherapy or combination immunotherapy after evaluation
62042014|NCT06733610|EXPERIMENTAL|UCAR T-cell group|Universal allogeneic anti-CD19/BCMA CAR T-cells.
62042015|NCT06229002|EXPERIMENTAL|Active tACS stimulation|Transcranial alternative current stimulation (tACS) at alpha frequency Single session of tACS : 30 minutes, 2mA, frequency = 10Hz, both electrodes located on the dorsolateral prefrontal cortex (left and right)
62042016|NCT06229002|PLACEBO_COMPARATOR|Sham stimulation|Single session of tACS sham stimulation : both electrodes located on the dorsolateral prefrontal cortex (left and right) ; real current delivered for the first and last 30s of the total stimulation time (ramp-in and ramp-out)
62042017|NCT06368765|EXPERIMENTAL|Oral Rehydration Solution|Oral rehydration solution with carbohydrate
62042018|NCT06368765|EXPERIMENTAL|Water|Water with flavor
62042019|NCT06568562|EXPERIMENTAL|Treatment: All Patients|XL092 is an oral tablet that will be taken once per day on a 28 day cycle. Participants will take a 100mg dose. Dose reductions to 60mg or 40mg may apply for in cases of dose interruption due to treatment-related toxicity.
62042020|NCT05905926|EXPERIMENTAL|Tenapanor|Eligible patients from the parent study will continue tenapanor at the same dose assigned in the parent study which can be titrated to either 50 mg BID or 25 mg BID per Investigator guidance after a patient's first week on the assigned dose.
62042021|NCT04253522|EXPERIMENTAL|Arm 1 (early phase B)|3 phases of cognitive training: Phase A1: rehabilitation program in standard ergotherapy during 3 weeks Phase B: cognitive training using Covirtua software and Transcranial random noise stimulation during 4 weeks Phase A2: return to the standard rehabilitation program in standard ergotherapy during 5 weeks
62042022|NCT04253522|EXPERIMENTAL|Arm 2 (mid phase B)|3 phases of cognitive training: Phase A1: rehabilitation program in standard ergotherapy during 4 weeks Phase B: cognitive training using Covirtua software and Transcranial random noise stimulation during 4 weeks Phase A2: return to the standard rehabilitation program in standard ergotherapy during 4 weeks
62042023|NCT04253522|EXPERIMENTAL|Arm 3 (late phase B)|3 phases of cognitive training: Phase A1: rehabilitation program in standard ergotherapy during 5 weeks Phase B: cognitive training using Covirtua software and Transcranial random noise stimulation during 4 weeks Phase A2: return to the standard rehabilitation program in standard ergotherapy during 3 weeks
62042024|NCT03842995|PLACEBO_COMPARATOR|Genetic Counselor|Standard of Care. Parents/caregivers of neonates enrolled in SouthSeq will receive counseling on their child's Whole Genome Sequencing (WGS) results from Genetic Counselors
62601846|NCT02788370|SHAM_COMPARATOR|Sham-PEP breathing|Patients will perform a constant work load cycling test with sham-positive expiratory pressure breathing util symptom limit.
62601847|NCT02788370|EXPERIMENTAL|Conical-PEP breathing|Patients will perform a constant work load cycling test with positive expiratory pressure breathing using a conical positive expiratory pressure device until symptom limit.
62601848|NCT04765995|EXPERIMENTAL|HZBio1 0.96mg/kg|Participants will receive intramuscularly 0.96 milligram per kilogram (mg/kg) of HZBio1.
62042025|NCT03842995|EXPERIMENTAL|Trained Healthcare Provider|Healthcare providers (e.g., neonatologists and neonatology nurse practitioners) will receive training to competently deliver Whole Genome Sequencing results to parents/caregivers of neonates enrolled in SouthSeq
62042026|NCT05140928|ACTIVE_COMPARATOR|Dadiah Pudding|The mother received 1 cup or 100 g dadiah pudding containing 75-gram dadiah which provide ±260 kcal energy, 6.12g protein, 23.31g fat, 6.49g carbohydrate, and 6.1x 109 CFU/ml lactic acid bacteria.
62245071|NCT05185986|EXPERIMENTAL|Home based Pilates exercises|This group will perform two weekly sessions of Pilates for eight weeks, completed with at least 48-hours between sessions, in their own home, supported by a DVD developed and previously implemented and evaluated by the lead researcher in a feasibility trial among people with Multiple Sclerosis. Each Pilates session will last approximately one hour and is comprised of seven Pilates warm-up exercises and fourteen mat-based beginner's level exercise. Four repetitions of each Pilates movement will be performed during sessions in the first two weeks, with intensity being self-regulated by the participant based on level of physical condition. Repetitions will gradually progress at biweekly intervals, resulting in ten repetitions being performed for the final two weeks of the trial (Weeks 7 and 8). Six post-training stretches will be maintained for a minimum of thirty seconds.
62435271|NCT02273206|EXPERIMENTAL|Prevention Care Management for Depression and Cancer Screening|"The Care Manager will provide depression care management and motivational support (supportive counseling) and act as a critical link between primary care, mental health care provider, and the patients, helping to develop and implement a treatment plan.~In addition, the Care Manager will work with participants on cancer screening, providing education, patient navigation, and motivational support to overcome screening barriers and form favorable attitudes towards screening."
62435272|NCT00796159||Olmesartan medoxomil + HCTZ|
62435273|NCT01938300|EXPERIMENTAL|Magnesium|"Magnesium sulfate infusion during a operation period.~Infusion regimen:~1. Bolus 50 mg/kg of magnesium sulfate in 100 ml normal saline over 15 minutes~2. Infusion 15 mg/kg/h of magnesium sulfate throughout the operation"
62435274|NCT01938300|PLACEBO_COMPARATOR|Control|administration of normal saline as a same volume of magnesium sulphate as a same method.
62435275|NCT01491659|ACTIVE_COMPARATOR|Amoxicillin/clavulanate/Idoform Plus|
62435276|NCT01491659|PLACEBO_COMPARATOR|Amoxicillin/clavulanate/Placebo|
62601849|NCT04765995|EXPERIMENTAL|HZBio1 3mg/kg|Participants will receive intramuscularly 3 milligram per kilogram (mg/kg) of HZBio1.
62849228|NCT04734899|ACTIVE_COMPARATOR|Control grup|"All individuals participating in the study will be taught the exercises given to strengthen weakened muscles, stretch shortened structures and increase proprioception by the physiotherapist and will be asked to do these exercises at least twice a day for 8 weeks.~The home program will be followed by the exercise daily form."
62042027|NCT05140928|PLACEBO_COMPARATOR|Pudding without dadiah|The mother received 1 cup or 100 g pudding without dadiah containing ±75 kcal energy, 0.3g protein, 0.45 g fat, and 16.2g carbohydrate.
62435277|NCT02693678|EXPERIMENTAL|Massage|10 min massage therapy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
62435278|NCT02693678|EXPERIMENTAL|Diathermy|10 min diathermy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
62042028|NCT06732336|EXPERIMENTAL|89Zr-trastuzumab PET/CT imaging of HER2-low patients|Following their inform consent, HER2-low breast cancer patients will be invited to come to our research center twice. The first time patients will receive an intravenous dose of 10-50mg trastuzumab, followed by a 0.5 MBq/kg (max 60 MBq) dose of 89Zr-trastuzumab. Patients will come back for a second visit 3-6 days later to get their PET/CT imaging examination. Images will be evaluated by two PET-trained physicians, and analysed by an imaging scientist.
62042029|NCT05612880||Non-intervention controls|Men with advanced prostate cancer initiating androgen receptor signaling inhibitor treatment.
62042030|NCT06025474|EXPERIMENTAL|Vortioxetine+Pregabalin|VO group(20mg)+ PGB (75mg) N= 136 Vortioxetine 20 mg, encapsulated tablets, orally, once daily, then pregabalin 75 mg, encapsulated tablets, orally, once daily. Pregabalin (75mg/day) was added, with a potential dosage increase to 150mg/day for inadequate responders after 12 weeks
62435279|NCT02693678|SHAM_COMPARATOR|Sham diathermy|10 min sham diathermy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
62435280|NCT00767689|EXPERIMENTAL|vitamin B6|patient receiving xeloda and vitamin B6
62435281|NCT00767689|PLACEBO_COMPARATOR|2 placebo|patient receiving xeloda and placebo
62435282|NCT03526107|ACTIVE_COMPARATOR|CF Control|CF Control: 587 mg of cocoa flavanols (101 mg epicatechin), \<1 mg caffeine and \<1 mg theobromine
62435283|NCT03526107|EXPERIMENTAL|CF-Theobromine|CF-Theobromine: 575 mg of cocoa flavanols (102 mg epicatechin), 11 mg caffeine and 93 mg theobromine
62435284|NCT03526107|EXPERIMENTAL|CF-Caffeine|CF-Caffeine: 587 mg of cocoa flavanols (101 mg epicatechin), 112 mg caffeine and \<1 mg theobromine(Experimental)
62435285|NCT04214951||Recombinant human thrombopoietin (rh-TPO) group|Patients who fail previous steroids and eltrombopag and then switch to Rh-TPO will be enrolled. The reason for switch will be recorded. Patients will be given rh-TPO 300 U/kg once daily for 21 days. Rh-TPO will be terminated any time the platelet counts increased above 100 × 10\^9/L. The efficacy, safety, and patient/physician preference will be assessed.
62601850|NCT04765995|EXPERIMENTAL|HZBio1 6mg/kg|Participants will receive intramuscularly 6 milligram per kilogram (mg/kg) of HZBio1.
62601851|NCT04765995|EXPERIMENTAL|HZBio1 9mg/kg|Participants will receive intramuscularly 9milligram per kilogram (mg/kg) of HZBio1.
62601852|NCT04765995|EXPERIMENTAL|HZBio1 12mg/kg|Participants will receive intramuscularly 12 milligram per kilogram (mg/kg) of HZBio1.
62245072|NCT05185986|EXPERIMENTAL|Combination of Home-based Pilates exercises and Home-based Cognitive Rehabilitation exercises|In addition to performing home-based Pilates exercises described in arm 1, this group will also perform home-based cognitive rehabilitation exercises for 8 weeks and 3 sessions per week. The interval between each session is at least 48 hours and each session will take between 30 to 45 minutes. Cognitive rehabilitation exercises are in pen and paper and each session includes two exercises in the areas of planning, cognitive organization, cognitive flexibility and working memory. All exercises will be explained to the subjects by a cognitive rehabilitation specialist, and in addition, explanations of all the exercises in each session will be available for participants in the separate voices. During the intervention period, in addition to the Pilates specialist, the cognitive rehabilitation specialist contacts the group 2 participants on a weekly basis and monitors their rehabilitation exercises.
62245073|NCT05185986|OTHER|Waiting list group|This group is the waiting list group and acts as a control group and will be instructed to maintain their preintervention physical and cognitive activity levels during the intervention. After 8 weeks of intervention, Pilates exercises and cognitive rehabilitation exercises will be provided to the participants of this group for their own use.
62042031|NCT06025474|ACTIVE_COMPARATOR|Paroxetine+Pregabalin|P group (20mg) + PGB (75mg); N= 10 Paroxetine 20 mg, encapsulated tablets, orally, once daily, then pregabalin 75 mg, encapsulated tablets, orally, once daily. Pregabalin (75mg/day) was added, with a potential dosage increase to 150mg/day for inadequate responders after 12 weeks
62042032|NCT06025474|ACTIVE_COMPARATOR|Sertraline+Pregabalin|S group (50mg) + PGB (75mg); N= 8 Sertraline 50 mg, encapsulated tablets, orally, once daily, then pregabalin 75 mg, encapsulated tablets, orally, once daily. Pregabalin (75mg/day) was added, with a potential dosage increase to 150mg/day for inadequate responders after 12 weeks
62245074|NCT06418204||Observational|Participants complete surveys and have their medical records reviewed on study.
62245075|NCT06709196|EXPERIMENTAL|Targeted antimicrobial prophylaxis|The participants in this arm will receive a single-day orally administered targeted antimicrobial prophylaxis on the day of ureteral stent removal based on the microbiological analysis of a postoperative urine culture.
62245076|NCT06709196|ACTIVE_COMPARATOR|Empiric antimicrobial prophylaxis|The participants in this arm will receive three doses of orally administered pivmecillinam 400mg morning, noon, and evening on the day of ureteral stent removal.
62435286|NCT04214951||Eltrombopag group|Patients who fail previous steroids and rh-TPO and then switch to eltrombopag will be enrolled. The reason for switch will be recorded. Patients will be given eltrombopag 50mg once daily for 6 weeks. Eltrombopag will be terminated any time the platelet counts increased above 300× 10\^9/L.The efficacy, safety, and patient/physician preference will be assessed.
62042033|NCT06025474|ACTIVE_COMPARATOR|Citalopram+Pregabalin|C group (20mg)+ PGB (75mg) N= 8 Citalopram 20 mg, encapsulated tablets, orally, once daily, then pregabalin 75 mg, encapsulated tablets, orally, once daily. Pregabalin (75mg/day) was added, with a potential dosage increase to 150mg/day for inadequate responders after 12 weeks
62435287|NCT02427906||TIPS group|patients who have transjugular intrahepatic portosystemic shunt
62042034|NCT06025474|ACTIVE_COMPARATOR|Escitalopram+Pregabalin|E group (10mg) + PGB (75mg); N= 8 Escitalopram 10 mg, encapsulated tablets, orally, once daily, then pregabalin 75 mg, encapsulated tablets, orally, once daily. Pregabalin (75mg/day) was added, with a potential dosage increase to 150mg/day for inadequate responders after 12 weeks
62435288|NCT02427906||Non-TIPS group|patients who have endoscopic variceal ligation
62042035|NCT06025474|ACTIVE_COMPARATOR|Duloxetine+Pregabalin|D group (60mg)+ PGB (75mg) N= 33 Duloxetine 60 mg, encapsulated tablets, orally, once daily, then pregabalin 75 mg, encapsulated tablets, orally, once daily. Pregabalin (75mg/day) was added, with a potential dosage increase to 150mg/day for inadequate responders after 12 weeks
62042036|NCT06406309|EXPERIMENTAL|Settle down to sleep|All participants will engage in a 1 week home-based baseline measurement, 1 lab visit for training and measurement, and 2 week intervention trial.
62042037|NCT01176162||"Group < 28"|• Gestational Age \< 28 weeks
62042038|NCT01176162||"Group 28 - < 33"|• Gestational Age : 28 - \< 33 weeks
62042039|NCT01176162||"Group 33- < 37"|Gestational Age : 33- \< 37 weeks
62042040|NCT01176162||"Group > 37"|Gestational Age \> 37 weeks
62042041|NCT02159742||Cohort 1|
62042042|NCT04859764|EXPERIMENTAL|Reparel Sleeve Group|Reparel sleeve and corticosteroid injection
62042043|NCT04859764|PLACEBO_COMPARATOR|Placebo Sleeve Group|Placebo sleeve and corticosteroid injection
62042044|NCT06684119|EXPERIMENTAL|Electrical Impedance Tomography positive end-expiratory pressure|Patients will be monitored using Electrical Impedance Tomography and the positive end-expiratory pressure titration tool as their positive end-expiratory pressure is adjusted according to a step wise positive end-expiratory pressure titration protocol.
62042045|NCT05451251|EXPERIMENTAL|Deep brain stimulation|Implantation of deep brain stimulation lead within the pontine lesion
62245077|NCT06252233|EXPERIMENTAL|Patient- and physician-centered QoL monitoring|Quality of life (QoL) of patients is assessed with an electronic patient- and physician-centered QoL monitoring system using the questionnaires EORTC QLQ-C30 and QLQ-LC29 at study entry and at 1, 2, 3, 4, 5, and 6 months during follow-up care. Results of QoL monitoring are automatically transferred to a QoL profile. Patients and their treating physicians receive the results of their QoL monitoring in real-time. In order to be able to treat QoL deficits a multiprofessional network of therapists is established (e.g. pain therapy, psychotherapy, social support, nutrition counselling, physiotherapy, fitness, respiratory therapy). Intervention group physicians and patients receive complete lists of QoL healthcare professionals of this network practicing in their region. To provide continuous medical education, quality circles for therapy options have been founded.
62245078|NCT06252233|PLACEBO_COMPARATOR|Routine care|QoL of patients is also assessed with the same QoL monitoring system used in the intervention group at study entry and at 1, 2, 3, 4, 5, and 6 months but neither patients nor treating physicians have access to the QoL profiles. The therapist network is also available for control arm.
62245079|NCT05900388||Pediatric patients with VTE|Pediatric patients under two years who initiate an anticoagulation therapy with rivaroxaban oral suspension or Standard of care (SOC) following a VTE diagnosis.
62245080|NCT05856123|NO_INTERVENTION|Standard of Care Transfer|After cardiac catheterization lab or electrophysiology lab procedure, the subject will be moved from one bed to another using the current standard of practice lateral patient transfer methods by nursing staff.
62435289|NCT03378349|EXPERIMENTAL|Internet-delivered CBT over 10 weeks|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that aim to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
62435290|NCT03378349|PLACEBO_COMPARATOR|Treatment as usual wait list|Patients randomized to the treatment as usual wait list arm will receive standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health. Thus, the treatment as usual arm will control for the provision of basic patient information, but without the guidance of a psychologist or any CBT interventions.
62435291|NCT02432261|EXPERIMENTAL|Group 1|5.0 mL of the 1.62% Nestorone® /testosterone gel (containing 8.3 mg NES + 62.5 mg T) applied each day on the arms and shoulders
62435292|NCT02432261|EXPERIMENTAL|Group 2|4.4 mL of the 1.62% Testosterone only gel (AndrogelTM) (containing 62.7 mg T) applied each day to the arms and shoulders
62435293|NCT01735045|EXPERIMENTAL|Test Group myopia control|Subjects wearing contact lenses made of LSH (mangofilcon A) Soft (hydrophilic) Contact Lens for myopia control
62435294|NCT01735045|ACTIVE_COMPARATOR|Myopia Control|Subjects wearing Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens for myopia control
62435295|NCT01484665|EXPERIMENTAL|Participants (Males, age 50-75 yrs)|Eligible men will be identified from the administrative database and electronic medical record at the University of Minnesota (EMR) at least 24 hours prior to the clinic visit. They will be asked to complete the PROCASE Decision-Aid.
62435296|NCT02722824|PLACEBO_COMPARATOR|Placebo|Wearable stimulators will be placed on the patients and controls without stimulation for 20 minutes
62435297|NCT02722824|EXPERIMENTAL|Active Stimulation|Instrinsic auricular muscles will be stimulated for 20 minutes
62435298|NCT02722824|SHAM_COMPARATOR|Sham|An area out of the instrinsic auricular muscles region will be stimulated with the same parameters of the active group for 20 minutes
62435299|NCT02722824|NO_INTERVENTION|Passive Control|Only the electrodes of the wearable stimulators will be inserted but there will not be electrostimulation for 20 minutes
62435300|NCT04809428||vNOTES Salpingectomy|Elective bilateral salpingectomy by vaginal Natural Orifice Transluminal Endoscopic Surgery approach
62435301|NCT04809428||LS Salpingectomy|Elective bilateral salpingectomy by conventional laparoscopy
62435302|NCT05686278||Hip hemiarthroplasty with BiPolar i and cemented stems (Meije or Oceane+)|Subjects clinically suitable for a hip hemiarthroplasty surgery with Corin hip devices
62435303|NCT03189264|ACTIVE_COMPARATOR|Percutaneous nephrolithotomy with Coaxial Dilatation|Percutaneous nephrolithotomy with Coaxial Dilatation for treatment of kidney stones greater than 2 cm.
62435304|NCT03189264|PLACEBO_COMPARATOR|Percutaneous nephrolithotomy with Pneumatic Balloon|Percutaneous nephrolithotomy with Pneumatic Balloon for treatment of kidney stones greater than 2 cm.
62435305|NCT02415361|NO_INTERVENTION|Arm A|"Standard care consists of:~* a phone call from a CLP-nurse after the referral from the local birth hospital has been received~* telephone service at parents request and at the staffs availability~* invitation to a one-day-information course before surgery"
62435306|NCT02415361|ACTIVE_COMPARATOR|Arm B|"Systematic follow up by a special trained nurse consists of:~* telephone contact with the parents shortly after birth~* visit at the maternity ward within 36 hours after the referral has been received~* telephone follow ups at specific times and at parents request~* guidance and support in feeding and treatment~* written information~* cooperation with the staff at the maternity unit and the health centre~* follow up in accordance with a check-list and log~* invitation to a one-day-information course before surgery"
62435307|NCT02356081|EXPERIMENTAL|ASyMS intervention Group|Patients in the intervention group will be instructed to use the ASyMS intervention once daily (and whenever they feel unwell) for up to 6 cycles of chemotherapy treatment.
62435308|NCT02356081|NO_INTERVENTION|Control Group|Patients in the control group will receive standard care as is currently available at their clinical site.
62849229|NCT04734899|EXPERIMENTAL|Foot core grup|In addition to the exercise program given to the control group, foot core training will be added and taught by the physiotherapist and they will be asked to do these exercises at least twice a day for 8 weeks.
62042046|NCT06395272|EXPERIMENTAL|EXPERIMENTAL|The first phase of the intervention (device-on rest phases) will consist of the activation of the device on the muscle motor points of the medial belly of the gastrocnemius, soleus and peroneus muscles.The second phase (OFF activity-device phase) consists of carrying out the therapy as the patient had been doing normally in the Neurorehabilitation department at the center at a rate of 3 sessions per week on an outpatient basis according to their individualized needs.
62245081|NCT05856123|EXPERIMENTAL|SimPull Device Transfer|After cardiac catheterization lab or electrophysiology lab procedure, the subject will be moved from one bed to another using the SimPull device.
62245082|NCT06734988||Mechanically ventilated adult ARDS patients|Adult mechanically ventilated patients (≥ 16 years old) with esophageal pressure monitoring, expected to receive invasive mechanical ventilator for more than 48 hours
62245083|NCT04433806|EXPERIMENTAL|Intervention|25 subjects, all referred to community based program for weight loss at ExercisAbilities
62245084|NCT00570817|OTHER|1|"The child will receive prehydration at the methotrexate infusions in the following order:~At the 1st methotrexate infusion the child will receive 4 hours prehydration. At the 2nd methotrexate infusion the child will receive 12 hours prehydration. At the 3rd methotrexate infusion the child will receive 4 hours prehydration. At the 4th methotrexate infusion the child will receive 12 hours prehydration. At the 5th methotrexate infusion the child will receive 4 hours prehydration. At the 6th methotrexate infusion the child will receive 12 hours prehydration. At the 7th methotrexate infusion the child will receive 4 hours prehydration. At the 8th methotrexate infusion the child will receive 12 hours prehydration."
62245085|NCT00570817|OTHER|2|"The child will receive prehydration at the methotrexate infusions in the following order:~At the 1st methotrexate infusion the child will receive 12 hours prehydration. At the 2nd methotrexate infusion the child will receive 4 hours prehydration. At the 3rd methotrexate infusion the child will receive 12 hours prehydration. At the 4th methotrexate infusion the child will receive 4 hours prehydration. At the 5th methotrexate infusion the child will receive 12 hours prehydration. At the 6th methotrexate infusion the child will receive 4 hours prehydration. At the 7th methotrexate infusion the child will receive 12 hours prehydration. At the 8th methotrexate infusion the child will receive 4 hours prehydration."
62245086|NCT03952338|EXPERIMENTAL|Nutrition Coupons|Participants in the FMNCP group will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets. To ensure participants receive all 16 coupon sheets, community partners will provide two coupon sheets per household during the first 1-6 weeks of the intervention. Participants in the FMNCP group will also be invited to participate in nutrition skill-building activities (e.g., cooking classes) offered by community partners throughout the intervention period, however participation is not required (this is consistent with the existing FMNCP).
62245087|NCT03952338|NO_INTERVENTION|Control|No intervention provided. Participants will be eligible to participate in the BC Farmers' Market Nutrition Coupon Program during the next farmers' market season (i.e. one year following the current intervention).
62245088|NCT01930149|EXPERIMENTAL|Mailed patient outreach intervention|Participants randomized to this arm will receive mailed letter from health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
62245089|NCT01930149|NO_INTERVENTION|Usual Care Control Group|Participants randomized to this arm will receive usual care.
62245090|NCT02061605|EXPERIMENTAL|Laser Tissue Welding Device|"The laser tissue welding device is intended for use in patients requiring laparoscopic surgery requiring hemostasis and sealing of the resected kidney after partial nephrectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure.~The device's intended use is to seal the kidney surface using a laser to weld human albumin based biomaterials after surgical removal of kidney tumors during a laparoscopic partial nephrectomy."
62435309|NCT02189395|EXPERIMENTAL|NPH and regular insuline group|For the group receiving NPH and regular 2/3 and 1/3 formula will be followed. If Nil per os (NPO), patient will receive NPH twice daily but AM dose will equal to PM dose. Regular insulin given along with NPH will be held while patient is NPO. A correctional dose of regular insulin will be given for any blood glucose \>180 mg/dL. If subjects were not eating, they could also receive correctional doses of regular insulin. Correctional insulin could be given four times daily with meals or at bedtime.
62435310|NCT02189395|ACTIVE_COMPARATOR|glargine and humalog group|Half of the total insulin dose will be given as glargine once daily, either in the AM or in the PM, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as humalog; doses were divided equally between breakfast, lunch, and dinner. An additional correctional dose of humalog will be given for any blood glucose \>180 mg/dL. If subjects were not eating, they received glargine once daily and could also receive correctional doses of humalog. Correctional humalog could be given four times daily with meals or at bedtime.
62435311|NCT03792971|EXPERIMENTAL|Fixed Sequence|
62435312|NCT05940883|EXPERIMENTAL|Y-2 sublingual tablet dose group 1|
62435313|NCT05940883|EXPERIMENTAL|Y-2 sublingual tablet dose Group 2|
62435314|NCT05940883|EXPERIMENTAL|Y-2 sublingual tablet dose Group 3|
62435315|NCT05940883|EXPERIMENTAL|Y-2 sublingual tablet dose Group 4|
62435316|NCT05940883|EXPERIMENTAL|Y-2 sublingual tablet dose Group 5|
62435317|NCT05940883|PLACEBO_COMPARATOR|Placebo|Certain subjects in group 1 and group 2 will receive placebo.
62042047|NCT06395272|SHAM_COMPARATOR|COMPARATOR|The first phase of the intervention (device-on rest phases) will consist of the activation of the device on the muscle motor points of the medial belly of the gastrocnemius, soleus and peroneus muscles.The second phase (OFF activity-device phase) consists of carrying out the therapy as the patient had been doing normally in the Neurorehabilitation department at the center at a rate of 3 sessions per week on an outpatient basis according to their individualized needs.The control group will perform the same activity, but without the device activated during the device-on rest phases and adapted to the needs of each participant in their usual sessions without a standardized protocol.
62042048|NCT05240716|EXPERIMENTAL|FES program|
62042049|NCT03952858|EXPERIMENTAL|Telerehabilitation Group|Physiotherapist-supervised Telerehabilitation as home exercise in Groups. Participants in the intervention group receive supervised Telerehabilitation by an experienced physiotherapist two days a week during four weeks. A computer and a camera will be installed where the exercise should take place. It will make it possible for the physiotherapist to see how the participants follow the exercise program and for the participants to follow the physiotherapist instructions on the screen. The participants will be instructed in the use of computer and receive a written guide. After four weeks the participants will on their own continue the Otago exercise Program for another 4 weeks by video sessions and still together in their already established groups. Otago Exercise Program consist of a walking plan, balance exercises, and a set of leg muscle strengthening exercises all progressing in degree of difficulty.
62245091|NCT03763240|ACTIVE_COMPARATOR|BSE|Sulforaphane-containing broccoli sprout extract (BSE). The study product is BSE with standardized amounts of sulforaphane. BSE contains a mixture of maltodextrin as a bulking agent and copper chlorophyllin (E 141) as a food additive. BSE is a dried powder of an aqueous extract of broccoli sprouts that provides a consistent and stable source of sulforaphane.
62245092|NCT03763240|PLACEBO_COMPARATOR|Placebo|A mixture of maltodextrin and copper chlorophyllin will be used as placebo. The active compound and the placebo are the same except BSE. The placebo will look similar to the BSE-containing mixture.
62245093|NCT06402357|EXPERIMENTAL|High Intensity Focused Ultrasound|
62245094|NCT05047263|EXPERIMENTAL|Finerenone (BAY94-8862)|Participants will receive finerenone.
62245095|NCT05047263|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62245096|NCT06735196|OTHER|Healthy volunteers|After standard gastrointestinal preparation, healthy volunteers swallowed SCEs to collect intestinal fluids in different intestinal areas.
62435318|NCT03706677|ACTIVE_COMPARATOR|CRYO group|"Within the CRYO arm the ablation will be performed using the Arctic Front Advance Cardiac CryoAblation Catheter, including next generation systems as applicable and approved by Medtronic for the trial.~Intervention performed: Cryoballoon ablation; Cryoballoon (Arctic Front Advance Cryoballoon)"
62435319|NCT03706677|ACTIVE_COMPARATOR|RF group|"Within the RF arm the ablation will be performed using a catheter out of the ThermoCool Smarttouch catheter family, including next generation contact force systems as applicable.~Intervention performed: Radiofrequency ablation; Radiofrequency Catheter (ThermoCool Smarttouch)"
62435320|NCT01398592|EXPERIMENTAL|Vildagliptin|Experimental
62245097|NCT04622046|EXPERIMENTAL|ALXN2060|Participants will receive ALXN2060.
62245098|NCT03519464|OTHER|ICL and Healthy Volunteers|Biological/Vaccine
62245099|NCT03631745|EXPERIMENTAL|NAMI Mental Health 101 and NAMI FaithNet|Mental Health 101 and FaithNet
62245100|NCT03631745|NO_INTERVENTION|Wait-list Control|After the 12-month follow-up, wait-list control churches will be provided with the opportunity to receive Mental Health 101 and NAMI FaithNet interventions.
62245101|NCT05681572|EXPERIMENTAL|Premedication Group (Midazolam)|Midazolam (0,5 mg/kg; max 10 mg), oral administration, 45 minutes prior entering in the operating room
62245102|NCT05681572|EXPERIMENTAL|Premedication Group (Dexmedetomidine)|Dexmedetomidine (2 µg/kg), oral administration, 45 minutes prior entering in the operating room
62245103|NCT05681572|PLACEBO_COMPARATOR|Placebo Group|grenadine syrup (3 mL), oral administration, 45 minutes prior entering in the operating room
62245104|NCT06525675||Fulvestrant plus palbociclib (interventional arm)|Postmenopausal women and premenopausal women receiving Luteinizing Hormone-Releasing Hormone (LHRH) analogues, aged ≥ 18 years with ER positive and HER2 negative locally advanced or metastatic breast cancer that had not received any therapy for the metastatic disease. Patients are not eligible if they are candidates for a local treatment with a radical intention. Subjects must have histologic confirmation of the estrogen and/or progesterone-positive and HER2 negative receptors breast cancer. Evidence of measurable or evaluable metastatic disease is required.
62245105|NCT06525675||Letrozole plus palbociclib (control arm)|Postmenopausal women and premenopausal women receiving Luteinizing Hormone-Releasing Hormone (LHRH) analogues, aged ≥ 18 years with ER positive and HER2 negative locally advanced or metastatic breast cancer that had not received any therapy for the metastatic disease. Patients are not eligible if they are candidates for a local treatment with a radical intention. Subjects must have histologic confirmation of the estrogen and/or progesterone-positive and HER2 negative receptors breast cancer. Evidence of measurable or evaluable metastatic disease is required.
62245106|NCT00408330|ACTIVE_COMPARATOR|1|azelaic acid 15%
62245107|NCT00408330|PLACEBO_COMPARATOR|2|Inactive 15% gel base
62245108|NCT02811549|EXPERIMENTAL|HiResolution Bionic Cochlear Implant|HiRes 90K™ Advantage implant with HiFocus™ 1J electrode, HiRes 90K™ Advantage implant with the HiFocus Helix™ electrode, HiRes 90K™ Advantage implant with the HiFocus™ Mid-Scala electrode or the HiRes™ Ultra Implant with the HiFocus™ Mid-Scala electrode will be implanted in adults who have severe to profound sensorineural hearing loss in one ear, and up to moderate sensorineural hearing loss in the other ear (asymmetric hearing loss).
62245109|NCT06143839||Acute Myeloid Leukemia (AML)|Participants with newly diagnosed AML-MRC (Acute myeloid leukemia with myelodysplasia-related changes) or t-related AML (Therapy related Acute myeloid leukemia) receiving Vyxeos liposomal as part of their standard of care treatment.
62435321|NCT01398592|ACTIVE_COMPARATOR|Sitagliptin|Active comparator (drug)
62435322|NCT03500965|EXPERIMENTAL|Text-only PWL, absol risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
62435323|NCT03500965|EXPERIMENTAL|text-only PWL, relative risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
62435324|NCT03500965|EXPERIMENTAL|graphic PWL, absol risk|Exposure to FDA-mandated warning labels, paired with a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
62435325|NCT03500965|EXPERIMENTAL|graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
62435326|NCT04684810||Treatment Group|Participants seeking treatment completed longitudinal data
62435327|NCT01004666||Women with equivocal findings on Mammography, US and/or MRI|Women with equivocal findings on Mammography, US and/or MRI
62435328|NCT01004666||Discrepancy between clinical examination and imaging|Women with discrepancy between clinical examination and breast imaging
62435329|NCT01004666||Women with dense breast|Women with dense breast
62245110|NCT06734806||Endocrown|
62245111|NCT06734806||Overlay|
62245112|NCT01558583|OTHER|Rating and Ranking Group|A group of individuals from the United States and Australia who complete a rating and ranking task.
62245113|NCT01558583|OTHER|Discrete Choice Group|A group of individuals from the United States and Australia who complete a discrete choice experiment task.
62245114|NCT01558583|OTHER|Balance Sheet Group|Individuals from the United States and Australia who will complete an implicit values clarification task
62435330|NCT01004666||Women in high risk for Breast Cancer|Women in high risk for Breast Cancer. Including patients with genetic high risk and/or strong family history.
62435331|NCT03111888|EXPERIMENTAL|Patient-Specific Tracheobronchial Stent|Observe and document the ability of a patient-specific tracheobronchial stent to improve a patient's quality of life and symptoms associated with airway stenosis.
62435332|NCT02685956||Vela Sentosa SA HSV1/2 PCR Test|Male and female subjects of any age with sample collected from a lesion and submitted to a clinical laboratory for the purpose of testing for the presence of HSV1 or HSV2 and diagnosing HSV infection.
62435333|NCT03121781|ACTIVE_COMPARATOR|CPAP with binasal prongs|Edi will be recorded while the infant is on nasal CPAP with the binasal prongs, with a PEEP of 5-8 cm H2O, for 2 hours. Then, the infant will be switched the interface to the RAM cannula, with a PEEP 2 cmH2O higher, during 2 hours.
62435334|NCT03121781|ACTIVE_COMPARATOR|CPAP with RAM cannula|Edi will be recorded while the infant is on nasal CPAP with the RAM cannula with a PEEP 2 cmH20 higher than the levels the infant was receiving before starting the study protocol, for 2 hours. Then, the infant will be switched the interface to the binasal prongs with a PEEP between 5-8 cmH2O, during 2 hours.
62435335|NCT04605523||Patients with Ataxia Telangiectasia|
62435336|NCT04605523||Healthy controls|
62601853|NCT01967641|EXPERIMENTAL|buprenorphine/naloxone combination|Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be followed at the Substance Use Research Center (SURC) and maintained on 16/4 mg Bup/Nx.
62601854|NCT01889121||Methadone maintenance program|Mothers on methadone treatment at time of delivery who delivered at Good Samaritan Hospital but were not enrolled in psychosocial intervention offered through the HOPE (Helping Opiate-addicted Pregnant women Evolve) program.
62601855|NCT01889121||Psychosocial intervention|Pregnant women who were in methadone maintenance program PLUS structured psychosocial intervention at the time of delivery (HOPE Program).
62823108|NCT03988400|EXPERIMENTAL|Sensory augmentation|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.
62823109|NCT03988400|ACTIVE_COMPARATOR|Random vibration|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration applied to the hip abductors will vary randomly (following a normal distribution) on a step-by-step basis.
62601856|NCT00477997|PLACEBO_COMPARATOR|1|Saline bolus + OGTT
62601857|NCT00477997|OTHER|2|GH-bolus and OGTT
62823110|NCT00880516||control|Adults with normal sinuses
62823111|NCT00880516||case|Adults with chronic sinusitis and positive findings on imaging.
62823112|NCT06289101|EXPERIMENTAL|text4FATHER|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of baby's age.
62823113|NCT06289101|NO_INTERVENTION|Usual care|Usual care that is consistent with typical maternity care in involving fathers-to-be.
62823114|NCT01535339||Phase I - Normative|Athletes who does not participate in contact sport with no recent concussion
62823115|NCT01535339||Phase IIa - Concussed|Athletes with recent concussion
62823116|NCT01535339||Phase IIa - Control|Athletes with no recent concussion
62823117|NCT01535339||Phase IIb - Athletes|Athletes with no recent concussion
62245115|NCT06179498|EXPERIMENTAL|Intervention|"In addition to standard HCV results disclosure for the comparator arm, intervention participants will have two counseling sessions:~Session 1: Immediately after HCV results disclosure, a staff-facilitated session with the index to (1) Establish HCV Treatment Goals, fostering commitment, and (2) Engage the Injecting Partner, identifying ways to support treatment initiation.~Session 2: One week later, involving both the index and injecting partner, to (1) Enhance Partner Support with specific strategies for HCV treatment initiation and (2) Collaborative Navigation Mapping, using a navigation map tool. By Session 2's end, both will have a completed navigation map, a visual guide for the HCV treatment journey.~Both sessions stress communication and dyadic coordination. The navigation map tool ensures a personalized plan for the index's treatment initiation and the partner's supportive navigator role."
62601858|NCT00477997|OTHER|3|GH-bolus
62623395|NCT01831271|OTHER|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
62623396|NCT03793959|EXPERIMENTAL|Synbiotic Supplement|Daily synbiotic supplement (5g prebiotic fiber + 8 billion CFU probiotic B. lactis, identical to Placebo-- white powder), along with a daily Fe supplement (140 mg FeSO4/d) for 8 weeks.
62823118|NCT06584630||endometrial cancer patients that underwent molecular classification|
62823119|NCT02151864|EXPERIMENTAL|LDE225|LDE225 200mg-800mg oral daily
62823120|NCT05406232||Observational (RT, biopsy)|Patients undergo RT on day 1. Patients also undergo tumor punch biopsies and blood sample collection prior to the first fraction and on days 1, 3, and 7.
62823121|NCT06524297|EXPERIMENTAL|Metaverse system|Residents use the Metaverse system before surgery to simulate wound closure locations on digital twin organs of the patient.
62823122|NCT06524297|NO_INTERVENTION|Crontrol group|The control group do not use the Metaverse system.
62849230|NCT03011021|EXPERIMENTAL|UCB-Treg plus Liraglutide|Subjects will receive a single infusion of ex vivo expanded umbilical cord blood derived Treg product (2 x 10\^6). Dose escalation of liraglutide up to 1.2 mg will be started 3 days after Treg infusion only if no severe side effects showed. Subjects continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as a routine therapy.
62823123|NCT02043457||Lifestyle intervention|Opt-in intervention to include the following procedures, called 'phenotyping' performed at baseline, after 10-15% weight loss from baseline weight or 6 months (whichever comes first) and at end of 2 years while in weight maintenance: oral glucose tolerance test, mixed meal tolerance test, with fasting leptin, biased and unbiased metabolomic profiling, DNA, RNA, muscle and adipose tissue biopsies: measurement of resting energy expenditure by indirect calorimetry; oxidative capacity (V02 peak/max); body composition by Dual Energy X-ray Absorptiometry (DEXA) or air displacement plethysmograph (Bod Pod); inventories of depression and health related quality of life instruments, measures of impulsivity, measures of hunger and appetite, work performance (including presenteeism and absenteeism) and pain survey.
62435337|NCT02100566|EXPERIMENTAL|Behavioral Counseling|Provide an advance directive document to patients along with counseling that either focuses on care giver burden or on patient autonomy.
62601859|NCT00979524|EXPERIMENTAL|Comprehensive Mental Health Services|Intervention group participants will receive an array of mental health education and services based on their level of need. Study participants will fall into low, moderate, or elevated risk based on results of baseline screening. Services will be provided to each group as specified below. Low risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) education activities to promote knowledge and change attitudes around mental health; Moderate risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) Short-term mental health services delivered by the LCSW-C, (c) Depression prevention intervention, (d) Education activities to promote knowledge and change attitudes around mental health; High risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) Mental health treatment services, (c) Education activities to promote knowledge and change attitudes around mental health.
62435338|NCT02100566|NO_INTERVENTION|Standard AD|The topic of advance directives (AD) is introduced but patient receives an AD document only upon request.
62623397|NCT03793959|PLACEBO_COMPARATOR|Placebo Supplement|Daily placebo supplement (5g maltodextrin, identical to Experimental -- white powder), along with a daily Fe supplement (140 mg FeSO4/d) for 8 weeks.
62823124|NCT01617824|EXPERIMENTAL|Linagliptin|Linagliptin 5 mg tablets daily for 4 days
62823125|NCT01617824|PLACEBO_COMPARATOR|Placebo|Placebo tablets 1 daily for 4 days
62823126|NCT06184633|ACTIVE_COMPARATOR|Intervention|Semaglutide injections + combined lifestyle intervention
62823127|NCT06184633|PLACEBO_COMPARATOR|Placebo|Placebo Semaglutide injections + combined lifestyle intervention
62823128|NCT03982121|EXPERIMENTAL|A|FOLFOX IV + NIVOLUMAB IV
62823129|NCT03982121|EXPERIMENTAL|B|FOLFOX IV + GLA IT
62823130|NCT03982121|EXPERIMENTAL|C|FOLFOX IV + IPILIMUMAB IT
62823131|NCT03982121|EXPERIMENTAL|D|FOLFOX IV + NIVOLUMAB IV + GLA IT
62823132|NCT03982121|EXPERIMENTAL|E|FOLFOX IV + NIVOLUMAB IV + IPILIMUMAB IT
62823133|NCT03982121|EXPERIMENTAL|F|LFOX IV + NIVOLUMAB IV + GLA IT + IPILIMUMAB IT
62435339|NCT06529991|EXPERIMENTAL|Self-Myofascial Release Treatment|
62435340|NCT03855319|EXPERIMENTAL|SMR neurofeedback training to MCI|"A sensorimotor/theta neurofeedback training consisted of 20 individuals sessions, twice a week during 11 weeks maximum. For each subject, NF was planned and conducted by a neuropsychologist experienced in neurophysiology an neurofeedback. Each session lasted 1h10 minutes and was conducted as follows:~* Preparation and installation of the electrodes, verification of the impedance, adjustement of the calibration.~* NF training (tasks and video described below)(45minutes)~* Feedback and debriefing about the session (15 minutes)"
62435341|NCT00251628|ACTIVE_COMPARATOR|Group A|
62435342|NCT00251628|ACTIVE_COMPARATOR|Group B|
62435343|NCT00251628|EXPERIMENTAL|Group C|
62435344|NCT01555281|EXPERIMENTAL|Nelfinavir and Lenalidomide/Dexamethasone|"Phase I: Cycles 1-4 (1 cycle = 28 days) Lenalidomide: 25 mg per day p.o., day 1 to 21 Dexamethasone: 40/20 mg per day p.o., days 1, 8, 15, 22 Nelfinavir: Dose escalation in cohorts of 3 patients~Phase II: Cycles 1-4 (1 cycle = 28 days) Lenalidomide: 25 mg per day p.o., day 1 to 21 Dexamethasone: 40/20 mg per day p.o., days 1, 8, 15, 22 Nelfinavir: Dose established in phase I twice daily p.o., day 1 to 21"
62435345|NCT01170260|ACTIVE_COMPARATOR|Info-only sexual risk reduction|Corresponding intervention gives information only on STDs/HIV
62435346|NCT01170260|EXPERIMENTAL|Sex plus alcohol risk reduction|Corresponding intervention gives info focusing on sex and alcohol risk reduction only
62435347|NCT01170260|EXPERIMENTAL|Sex + alcohol + marijuana risk reduction|Corresponding intervention gives info on sex, alcohol, and marijuana risk reduction
62435348|NCT05329428|EXPERIMENTAL|Vitamin D Supplementation 20 µg/day|Dietary supplements containing 20 µg of vitamin D per day will be provided to study subjects.
62823134|NCT06398652|EXPERIMENTAL|Experimental Arm|CMAB015
62823135|NCT06398652|ACTIVE_COMPARATOR|Active Comparator Arm|Secukinumab
62823136|NCT06226129|EXPERIMENTAL|Gadopiclenol|Gadopiclenol in dose, route of administration, and indication that is FDA-approved.
62823137|NCT04809987|EXPERIMENTAL|Virtual Gait and Physical Exercise|
62823138|NCT04809987|SHAM_COMPARATOR|Documental projection and Physical Exercise|
62823139|NCT04809987|EXPERIMENTAL|Virtual Gait|
62823140|NCT04809987|SHAM_COMPARATOR|Documental Projection|
62823141|NCT04777799|EXPERIMENTAL|URGOnight|Use of the URGOnight neurofeedback training headband and its associated application
62823142|NCT05186233|ACTIVE_COMPARATOR|Non-personalized light condition|Participants will receive light exposure recommendations from the SHIFT mobile application based on their habitual sleep schedule. Participants will follow these recommendations over the course of two weeks.
62823143|NCT05186233|EXPERIMENTAL|Personalized light condition|Participants will receive light exposure recommendations from the SHIFT mobile application based on their activity levels. Participants will follow these recommendations over the course of two weeks.
62245116|NCT06179498|NO_INTERVENTION|Control|Standard of care HCV disclosure. This staff-facilitated session follows the California HIV/HCV test counselor certification protocol with the Index alone.
62245117|NCT05861739|EXPERIMENTAL|Intervention group|Endometriosis Self Care Support Program (Endometriosis Training and Motivational Interview) will be applied to the women in the intervention group.
62245118|NCT05861739|NO_INTERVENTION|Control group|Women in the control group will receive standard treatment. Training and motivational interviewing will not be applied.
62435349|NCT05329428|EXPERIMENTAL|Vitamin D Supplementation 40 µg/day|Dietary supplements containing 40 µg of vitamin D per day will be provided to study subjects.
62435350|NCT05329428|ACTIVE_COMPARATOR|Usual Antenatal Care|Women randomized to usual antenatal care will receive advise about vitamin D supplementation according to usual antenatal care routines.
62435351|NCT01433900|ACTIVE_COMPARATOR|Tafluprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
62435352|NCT01433900|ACTIVE_COMPARATOR|Latanoprost|1 drop of latanoprost to eligible eye(s) once daily (at 9 pm)
62435353|NCT03214458|OTHER|Nasal high flow with oxygen|During HFNC-oxygen, oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep Arterial oxygen saturation (SaO2) \> 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience.
62245119|NCT05168124|ACTIVE_COMPARATOR|Acceptance Commitment Therapy for chronic fatigue|ACT for chronic fatigue involves psychoeducation on the clinical picture of CFS/ME and teaching coping strategies for dealing with symptoms, most notably fatigue, postexertional malaise, unrestful sleep, cognitive decline, and orthostatic dysregulation. For this purpose, the therapy manual designed for generalized anxiety disorders is adapted to the needs of patients with CFS, i.e., the exercises and worksheets that teach the acceptance- and mindfulness-based techniques are adapted to the symptoms (fatigue, powerlessness, unrestful sleep, among others). In addition, value goals and scopes of action are defined, in which the individual stress limits of each participant are identified and taken into account. In addition, it is recommended that the participants move within their respective energy limits under the regular evaluation of activity and rest phases using a diary, as well as regularly apply study-specific interventions between the appointments of group therapy.
62435354|NCT02629133|EXPERIMENTAL|SHE Program|"Participants received a 50 minute intervention on the computer immediately after their baseline assessment and a 15 minute booster session on the computer within 2 weeks after the intervention. There was also a 3 and 6 month follow-up after completion of the SHE program."
62435355|NCT02629133|NO_INTERVENTION|Control Condition|Control condition consisted of a series of questions regarding television show preferences and viewing a brief series of videos of popular entertainers/shows, with subsequent requests for rating of subjective preference. Participants in this condition completed a baseline assessment as well as a television show booster and a follow-up assessment 3 and 6 months later.
62435356|NCT06460428|EXPERIMENTAL|Active Comparator: 1. group|Couples in the pre-wedding period will receive information about fertility awareness with the developed interactive video
62435357|NCT06460428|NO_INTERVENTION|No Intervention: 2. Group|Control Group (non- education): No intervention will be made
62435358|NCT04229316|EXPERIMENTAL|zLock Facet Locking Implant System|
62435359|NCT03299530||patients with corneal astigmatism|Patients who had received phacoemulsification surgery with or without implantation of toric IOL are with a certain amount of corneal astigmatism.
62435360|NCT05500495||prolonged mechanical ventilation group|patients had 96 hours or more (PMV group).
62435361|NCT05500495||control group|patients had less than 96 hours of mechanical ventilation (control group)
62435362|NCT04539002|EXPERIMENTAL|MS: Cycle|Twenty-two participants in the clinical trial arm will be randomized to MS:Cycle: an aerobic exercise intervention on a stationary ergometer. Participants will exercise thrice weekly for 30 minutes with graded supervision for 24 weeks.
62435363|NCT04539002|ACTIVE_COMPARATOR|MS: Take Control|Twenty-two participants in the clinical trial arm will be randomized to MS: Take Control (MSTC): a monthly, hour-long MS education control group led by a trained facilitator.
62435364|NCT03056326|EXPERIMENTAL|CHF6333 Active|
62435365|NCT03056326|PLACEBO_COMPARATOR|Placebo|
62435366|NCT02106169|EXPERIMENTAL|Therapeutic education group|"At first, all patients will be invited to participate in a study of troop having for objective to estimate their quality of life. Then, the doctors offer patients randomized to therapeutic education to have a therapeutic education before the 4th month.~The sessions will be led by a multidisciplinary equip. Each child and his family will have a therapeutic session (2 times 2 hours)."
62435367|NCT02106169|NO_INTERVENTION|Control group|At first, all patients will be invited to participate in a study of troop having for objective to estimate their quality of life. Then, the patients randomized in this group will have the habitual medical care.
62435368|NCT03413527|EXPERIMENTAL|rTMS Treatment|
62435369|NCT05771831|EXPERIMENTAL|Thrombosomes®|Thrombosomes® (TBX®) up to 3 doses
62435370|NCT05771831|ACTIVE_COMPARATOR|Standard platelet concentrate|Standard platelet concentrate up to 3 doses
62435371|NCT04948307|OTHER|SL BUP/NAL SOC background therapy|standard of care. Subjects in both groups will receive the assigned treatment for 24 weeks. Subjects in both groups may also be encouraged to participate in behavioral health therapies in accordance with the Investigator's standard of practice.
62601860|NCT00979524|ACTIVE_COMPARATOR|Usual Care (Employment Training Services)|"Newly enrolling Westside YO members will receive usual care services, which constitute a moderate level of mental health services and supports. The usual care services related to mental health at the Westside will include (1) the ACASI screen for all newly enrolling Westside YO members, (2) the initial visit with a LCSW-C, and (3) mental health training for Westside Case Advocates. More extensive mental health educational activities and services (e.g., additional sessions with LCSW-C, SOS Club) provided to the intervention group will not be available at the Westside YO Center during the initial study period. Also, Eastside Case Advocates will receive more extensive and ongoing mental health training."
62601861|NCT03229148|ACTIVE_COMPARATOR|General anaesthesia|In the general anesthesia group, rapid sequence induction is used. Conduction of general anesthesia and drugs used are left to the expertise of each investigating center. Systolic blood pressure has to be maintained between 140 and 180 mmHg with an intravenous norepinephrine infusion if necessary, tele-expiratory carbon dioxyde concentration (EtCO2) has to be maintained between 30 and 35 mmHg and SpO2 has to be maintained between 94 and 98 %.
62823144|NCT02273934|EXPERIMENTAL|Reablement|Reablement is an intensive, multidisciplinary, client-centered, home-based type of rehabilitation, where ordinary activities of daily living are used for rehabilitative purposes. It is a rehabilitation alternative that may be offered to adults, and there is no lower age limit. An occupational therapist and physical therapist, or nurse, constitutes the key personal, while home helpers, assistants and others with lower education, are the ones who work rehabilitative with the person on a daily basis focusing on self-help.
62042050|NCT03952858|ACTIVE_COMPARATOR|Community Center group|"The Community Center Group will receive the traditional exercise programs offered in a Community Center for older people. The exercise program can vary dependent on the offer in the individual community center. Often the training consists of exercises carried out in a range of different training equipments such as exercise bikes, steppers, rowing machines etc. often supervised by a physiotherapist. At some community centers the training will be performed in groups on appointed times. Some citizens are offered one or two times instruction and hereafter they have to train on their own. Some times the citizens are offered few times of training in their own home and hereafter follow the offer at the community center for older people. Before discharge, at the hospital, their plan for rehabilitation will be completed.~Participants in the Community Center Group will be tested by the same instruments at baseline and after 4 and 8 weeks and at 6 months of follow-up."
62042051|NCT03548740||Group A|
62042052|NCT03548740||Group B|
62823145|NCT02273934|ACTIVE_COMPARATOR|Standard treatment|This arm consists of the standard treatment home-dwelling elderly persons receive when applying for home-based help. Some elderly may receive home-based nursing or home help services assisting them in daily activities, while others may receive occupational therapy or physical therapy measures for rehabilitative purposes.
62823146|NCT06350643|EXPERIMENTAL|Black Health Block Culturally Tailored training alone|Providers in this arm will only complete the Black Health Block Culturally Tailored training. This online course will be developed for healthcare providers and will fill gaps in knowledge and attitudes toward lung cancer screening and smoking not covered by Health Disparities and Lung Cancer Screening (HDLCS) training.
62823147|NCT06350643|EXPERIMENTAL|Black Health Block Culturally Tailored training + Health Disparities and Lung Cancer Screening|In this arm, providers will complete the Health Disparities and Lung Cancer Screening training and the Black Health Block Culturally Tailored training. The Black Health Block Culturally Tailored training is an online course being developed to fill gaps in knowledge and attitudes toward lung cancer screening and smoking not covered by Health Disparities and Lung Cancer Screening.
62823148|NCT04965025|EXPERIMENTAL|Multi-stage urethroplasty with graft inlay in first stage|
62823149|NCT04965025|ACTIVE_COMPARATOR|Multi-stage urethroplasty with graft inlay in second stage|
62823150|NCT03200249|EXPERIMENTAL|Treatment|"1. - Treatment : concomitant preoperative radio-chemotherapy (during 5 weeks)~   Chimiotherapy: Capecitabine 1600 mg/m2/j ; 5/7 days during the 5 weeks of radiotherapy~   Radiotherapy RT + SIB-IMRT (5 weeks ; 5 sessions/week ; 25 sessions): Pelvic prophylactic dose of 45 Gy (1,8 Gy/session); boost with a dose of 60 Gy on the tumor PTV (2,4 Gy/session) - Total dose: 60 Gy in 25 sessions during 5 weeks.~2. - TME surgery (8 weeks after the end of treatment)"
62435372|NCT04948307|EXPERIMENTAL|SL BUP/NAL + OXD01|standard of care + OXD01 (digital therapy). Subjects in both groups will receive the assigned treatment for 24 weeks. Subjects in both groups may also be encouraged to participate in behavioral health therapies in accordance with the Investigator's standard of practice.
62435373|NCT02218359|EXPERIMENTAL|Amikacin Fosfomycin Inhalation Solution|300 mg of amikacin and 120 mg of fosfomycin to be administered by aerosol via the AFIS Inline System.
62435374|NCT02218359|PLACEBO_COMPARATOR|Aerosolized Placebo|Aerosolized placebo to be administered by aerosol using the AFIS Inline System.
62823151|NCT06586762||Daily-Use Prosthesis (DUP)|Participants are going video recorded in the sagittal plane, to convert knee flexion motion into angles for the amputated and intact knee and to make measurements using the software's virtual goniometer. The recording will be taken during walking at self-selected walking speed with DUP.
62823152|NCT06586762||Running-Specific Prosthesis (RSP)|Participants are going video recorded in the sagittal plane, to convert knee flexion motion into angles for the amputated and intact knee and to make measurements using the software's virtual goniometer. The recording will be taken during slow-running (heel-strike jogging) with RSP.
62823153|NCT03288532|NO_INTERVENTION|Arm A (active monitoring)|Participants randomised to Arm A will be allocated to active monitoring for 1 year, in line with current standard-of-care in resected primary RCC at high or intermediate risk of relapse
62435375|NCT03179475|OTHER|Oxycodone Naloxone Combination|Open-Label
62042053|NCT05111561|EXPERIMENTAL|Treatment (ZEN-3694, binimetinib)|Patients receive ZEN-3694 PO QD and binimetinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. During the dose expansion phase, patients will have two mandatory biopsies - one before beginning the study and the second at day 15 of cycle 1. The study biopsy takes small pieces of cancer tissue from patient's body to look for markers (substances made by, on, or in tumor cells) related to how the study treatment works. Patients also undergo collection of blood samples at screening and on study and undergo CT or MRI throughout the trial.
62042054|NCT06171542|EXPERIMENTAL|CTM Shoulder Injection|
62042055|NCT04073238|NO_INTERVENTION|Single vision spectacle lens|Single vision lens with power for correcting distance refraction.
62042056|NCT04073238|EXPERIMENTAL|Repeated low-level red-light therapy|Single vision lens \& repeated low-level red-light therapy
62042057|NCT05714514||Imlifidase administered in the ConfIdeS study|
62245120|NCT05168124|ACTIVE_COMPARATOR|Micro breaks in everyday life for chronic fatigue|Micro breaks in everyday life (MBEL) includes restructuring the patients' daily routine in terms of how they organize their breaks. A therapy manual is developed for this purpose, which is divided into three phases. In the first phase, patients learn to allow or integrate regular MB of one to five minutes in their daily routine. Appropriate examples are used to show when and where MB can be incorporated and this is practiced at home over the first few weeks until a routine has been established. Patients are encouraged to keep a break diary. In the second phase, the MBs are filled in with content. MB can be designed differently, e.g., with physical activity of moderate or high intensity, with short breathing or relaxation exercises, with nutrition or even with doing nothing. In the third phase, an individual optimization of the design of breaks in everyday life follows and an expansion towards meaningful mental time-out, a combination of relaxation break and mental activation.
62245121|NCT05168124|NO_INTERVENTION|Waiting Group|
62245122|NCT06130501|EXPERIMENTAL|Active tAN|Participants receive active tAN with the Sparrow Ascent device from Spark Biomedical (Dallas, TX).
62245123|NCT06130501|SHAM_COMPARATOR|Active Sham|Participants receive the active sham version of the Sparrow Ascent device that limits stimulation to trigeminal innervation only and at a charge that is approximately 1000x lower than the active tAN condition.
62435376|NCT03563027|NO_INTERVENTION|Control|This arm serves as control and uses a wearable device to track daily step counts
62435377|NCT03563027|EXPERIMENTAL|Social Incentive Gamification|This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, and selects a support sponsor
62435378|NCT03563027|EXPERIMENTAL|Social Incentive Gamification and Financial Incentive|This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, selects a support sponsor, and receives a financial incentive
62042058|NCT05714514||Best available treatment administered in the ConfIdeS study|
62042059|NCT04665635|ACTIVE_COMPARATOR|Rectosigmoid resection|
62042060|NCT04665635|ACTIVE_COMPARATOR|Rectosigmoid seromuscular tumor shaving|
62042061|NCT06723366|EXPERIMENTAL|ANP group|
62042062|NCT06723366|OTHER|Control|standard treatment
62823154|NCT03288532|EXPERIMENTAL|Arm B (durvalumab monotherapy)|Participants randomised to Arm B will receive durvalumab (1500mg) 4 weekly for 1 year (13 cycles maximum)
62823155|NCT03288532|EXPERIMENTAL|Arm C (durvalumab + tremelimumab)|Participants randomised to Arm C will receive durvalumab (administered as per arm B, i.e. 13 cycles maximum) and tremelimumab (75mg) on day 1 and week 4 visits (i.e. 2 cycles)
62601862|NCT03229148|ACTIVE_COMPARATOR|Conscious Sedation|In the conscious sedation group, drugs choice as well as pharmacological modulation will be left to the expertise of each investigating center. A sedation level between 0 and -3 with spontaneous breathing will be targeted, using the Richmond Agitation Sedation Scale (RASS) score validated in French. The lightest sedation level will be targeted, i.e. minimal to moderate sedation according to the US recommendations for sedation / analgesia. Systolic blood pressure will be maintained between 140 and 180 mmHg with an intravenous norepinephrine infusion if necessary and SpO2 will be maintained between 94 and 98%.
62601863|NCT04606823|OTHER|Single-arm|In this single-arm study the patients will be undergoing a minimally invasive surgery after which they will re-visit the clinic at five occasions for follow-up visits (1-3 extra compared to routine clinical practice at the hospitals) and complete a quality of life-questinnaire three months after surgery.
62245124|NCT04995419|EXPERIMENTAL|Enfortumab Vedotin 1.25 mg/kg|Participants received 1.25 milligrams per kilogram (mg/kg) of body weight enfortumab vedotin by intravenous (IV) infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first. Participants who had intense PK Sampling were enrolled in PK Cohort.
62245125|NCT05444335|OTHER|Intervention arm|Women older than 70 who would wear the Zio patch for 2 weeks
62245126|NCT01297764|EXPERIMENTAL|carfilzomib for MML|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone - This study will be conducted as an open-label Phase I/II, single-center study in which subjects will receive carfilzomib, lenalidomide, vorinostat and dexamethasone, for relapsed and/or refractory multiple myeloma. Study treatment will be administered in sequential cohorts, with 3-6 subjects in each cohort. Treatment will be administered in 28-day cycles, with the fourth week as a rest week, for 12 cycles or until disease progression or unacceptable toxicity develops.
62042063|NCT03965897|ACTIVE_COMPARATOR|Attention Control (AC)|The primary purpose of this workshop is to provide attention and education to participants. Topics of discussion will include: a) the pathophysiology of postoperative pain and how it differs from preoperative pain, b) the role of contextual factors (e.g., depressive or anxiety symptoms, expectation) on the experience of pain, d) the role of inflammation in pain and healing, e) types of pain medications and other pain relief strategies provided following surgery, and f) goals of pain medications. Additionally, deep (diaphragmatic) breathing strategies will be taught and a progressive muscle relaxation exercise will be performed in the workshop at strategic times to maintain Veteran engagement.
62823156|NCT03913533|ACTIVE_COMPARATOR|Control group|Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate by listening to the heart beat for 6-sec and then compute the heart rate of the newborn infant.
62042064|NCT03965897|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT)|"The ACT intervention will include: 1) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from, unhelpful thoughts such as I can't take this pain anymore or This is unfair) and learning how to willingly face experiences that cannot be changed; and 2) Behavioral Change Training involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise. The workshop will also include information on pain and pain control post-TKA."
62042065|NCT05368779|EXPERIMENTAL|Internet-based Psychosocial Intervention Group|The internet-based psychosocial intervention, which was based on Social Learning Theory and Cognitive Behavioral Therapy techniques, was delivered individually and electronically to the participants in the experimental group in eight sessions, each lasting up to 120 minutes, using videoconferencing.
62042066|NCT05368779|NO_INTERVENTION|Control Group|No intervention was applied to the participants in the control group.
62245127|NCT06736314|EXPERIMENTAL|a removable titanium clip|
62245128|NCT06518603|EXPERIMENTAL|Oral Caffeine Citrate 20mg/kg/day|Caffeine Citrate 20 mg/kg/day given orally once a day for 28 days. (2mg/ml)
62245129|NCT06518603|PLACEBO_COMPARATOR|Placebo|Sterile water 1ml/kg/day given orally once a day for 28 days.
62245130|NCT03798678|EXPERIMENTAL|Treatment (CB-839 HCI, dexamethasone, carfilzomib)|Patients receive glutaminase inhibitor CB-839 Patients receive glutaminase inhibitor CB-839 hydrochloride PO every 12 hours on days 1-28, dexamethasone PO on days 1, 2, 8, 9, 15, 16, and 23, and carfilzomib IV over 10 minutes on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
62823157|NCT03913533|EXPERIMENTAL|Intervention group|Heart rate assessment using Tap-based smartphone application At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate using a Tap-based smartphone application by tapping the screen for 3 beats at that time a heart rate will be displayed.
62823158|NCT04179500|EXPERIMENTAL|Study Participants|Participants will receive bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg once daily (BPaMZ) for 26 weeks.
62042067|NCT05807139|EXPERIMENTAL|Placebo 1st visit|stage 1: Placebostage 2: 2x50 mg/day spironolactonestage 3: 2x100 mg/day spironolactonestage4: 2x200 mg/day spironolactone
62042068|NCT05807139|EXPERIMENTAL|Placebo 2nd visit|stage 1: 2x50 mg/day spironolactonestage 2: Placebostage3: 2x100 mg/day spironolactonestage 4: 2x200 mg/day spironolactone
62849231|NCT03011021|ACTIVE_COMPARATOR|UCB-Treg|Subjects will receive a single infusion of ex vivo expanded Treg product (2 x 10\^6). Insulin will be continued as a routine therapy.
62042069|NCT05807139|EXPERIMENTAL|Placebo 3rd visit|stage1: 2x50 mg/day spironolactonestage 2: 2x100 mg/day spironolactonestage 3: Placebostage4: 2x200 mg/day spironolactone
62823159|NCT04403204||Established SSI Fracture Cohort|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
62823160|NCT04403204||Established SSI Fracture Cohort Subset (DCE-MRI)|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
62849232|NCT03011021|ACTIVE_COMPARATOR|Liraglutide|Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.
62849233|NCT03011021|ACTIVE_COMPARATOR|Insulin|Patients will receive insulin injection as a routine therapy.
62245131|NCT04782011|EXPERIMENTAL|ATC/DDD arm|The intervention is the introduction of the ATC/DDD including the training of healthcare workers on its importance and usage in monitoring antibiotic use. The unit of intervention will be a health facility. Antibiotic prescriptions and antibiotic utilization records for adult patients (in-patients and ambulatory) from the selected facilities will be enrolled in the study.
62245132|NCT04782011|NO_INTERVENTION|Control arm|The health care workers will continue with standard practice. However, the research team will collect data on antibiotic prescriptions and antibiotic utilization for adult patients (in-patients and ambulatory) from the selected facilities. The data will be compared with that of the intervention arm.
62245133|NCT06460233||Patients with class III obesity (BMI ≥ 40) or class II obesity (BMI 35-40) with comorbidities|Consecutive patients with class III obesity (BMI ≥ 40kg/m2) or class II obesity (BMI 35-40kg/m2) with comorbidities admitted for bariatric surgery (sleeve gastrectomy)
62435379|NCT03932084|EXPERIMENTAL|Control group|"During hospitalization:~1. Monitor subjects' blood glucose;~2. One-on-one education: Education includes skills related to diabetes self-management, basic knowledge of diabetes, diet, exercise, medication, blood glucose monitoring, risks of glucose fluctuations;~3. Teaching patients and their families to use blood glucose meters and correctly record results. The diabetes specialist nurses demonstrate correct methods for self-monitoring blood glucose.~During discharge: Patients were given standard hospital discharge instructions and were asked to monitor their blood glucose 5 times daily after discharge.~Follow-up: If a patient FPG was less than 7 mmol/L, 2hPG was less than 10 mmol/L, or A1c was less than 7%, no intervention would be implemented. If one of these items was above the numbers, a referral would be made to an endocrinologist for medication adjustment. Participants received telephone follow-up one week after discharge, thereafter, follow-up were conducted once a month."
62849234|NCT00826462|EXPERIMENTAL|1|"Corticosteroid injection in combination with physical therapy~Injection with triamcinolone 10 mg and 10 mg of lidocaine at start and at 3 weeks in combination with physiotherapy for 6 weeks (12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises) Naprosyn Entero 500 mg bid for 14 days"
62042070|NCT05807139|EXPERIMENTAL|Placebo 4th visit|Stage1: 2x50 mg/day spironolactoneStage 2: 2x100 mg/day spironolactonestage 3: 2x200 mg/day spironolactonestage 4: Placebo
62245134|NCT02908425|OTHER|Healthy taking statin|healthy subjects currently taking cholesterol lowering statin
62245135|NCT06734286|EXPERIMENTAL|Intervention Group|The Intervention Group (N = 5) Participants will be instructed to do CogMed intervention (computerized working memory activity carried out for 25 minutes daily for 5 days per week for a total of 10 weeks).
62435380|NCT03932084|EXPERIMENTAL|Glucose fluctuation targeted intervention|We set achieving goals for this intervention group (both A1c\<7% and LAGE\<80mg/dl). Participants received the same usual care as the control group; though additional attention was paid to glucose fluctuation on the basis of glucose control. Even the patient's FPG, 2hPG, and A1c were all well controlled, If his or her LAGE≥80mg/dl, we would carefully assess the patient's diet and exercise and daily activities first. If it was caused by lifestyle or events, the researchers worked with patients to find a self-care behavioral solution for the glucose fluctuation, and set behavioral goals, otherwise, the researchers would refer the patient to an endocrinologist for medication adjustment. During next follow-up, we evaluated the glucose fluctuation and target completion.
62435381|NCT00637442|EXPERIMENTAL|CASL-MRI|Drug monitoring with CASL-MRI for new diagnosed patients with mild to moderate Alzheimer's Disease treated with Reminyl
62601864|NCT04300452|ACTIVE_COMPARATOR|Carbetocin group|In the carbetocin group will be administered 100 mcg of carbetocin diluted in 100 cc of N/S 0.9% in a continuous rapid-flow intravenous infusion.
62601865|NCT04300452|ACTIVE_COMPARATOR|Ergometrin group|In the ergometrine maleate group will be administered intravenously 0.2 mg of the substance slowly in a bolus administration.
62042071|NCT03795298|EXPERIMENTAL|WATCHMAN FLX|WATCHMAN FLX implant including modified post-implant drug regimen.
62245136|NCT06734286|NO_INTERVENTION|Control Group|The Control group(N = 5) follow there Treatment as usual(TAU). For ethical reasons, at the end of trial, the control group will also be offered the CogMed intervention.
62245137|NCT05890222|EXPERIMENTAL|Community Model|In addition to the facility model, village clusters in this arm will receive community intervention strategies delivered by community volunteers.
62245138|NCT05890222|ACTIVE_COMPARATOR|Facility Model|The HAP, a manualized and evidence-based psychological treatment based on behavioural activation, will be delivered by existing healthcare workers (called counsellors from here onwards) within the health centres who will be trained to deliver the HAP.
62245139|NCT06145516|EXPERIMENTAL|Cognitive behavioral therapy for insomnia (CBT-I)|The CBT-I treatment will be administered in self-guided digital format over 4 weeks with addition of telehealth video-consultations with a psychologist one time per week. The CBT-I will focus on sleep restriction therapy and stimulus control, which have shown the highest efficacy for sleep improvement among components typically incorporated. A booster session will be provided 1-2 weeks postoperative.
62245140|NCT06145516|ACTIVE_COMPARATOR|Sleep education therapy (SET)|The sleep education therapy will be administered in self-guided digital format over 4 weeks with addition of telehealth video-consultations with a research nurse one time per week. The SET will focus on sleep physiology, different sleep disturbances and sleep hygiene measures. A booster session will be provided 1-2 weeks postoperative.
62435382|NCT03557710|EXPERIMENTAL|Behavioral Response Training|In Arm 1 of Devaluing energy-dense foods for cancer-control, participants will complete computer delivered versions of the stop-signal, go/no-go, and dot-probe training tasks in 8 30-min biweekly visits to the lab, with breaks between training blocks in which participants sit with their eyes closed to allow consolidation of learning. Participants will also complete a weekly 15-min training task online from home. Total training time = 345 min. Training will involve 100 images of cancer risk foods that participants regularly eat, including red and processed meats; high-sugar foods; heavily salted, smoked, and pickled foods; fries, chips, and snacks with trans-fats, and 100 images of healthy foods that participants rate as palatable, including vegetables, fruits, nuts, and whole grains.
62435383|NCT03557710|EXPERIMENTAL|Cognitive Reappraisal Training|Arm 2 of the Devaluing energy-dense foods for cancer-control intervention will be delivered via computer-assisted in-person training. Between baseline and endpoint sessions, participants will practice reappraisal on a computer, under close supervision of a facilitator, in 8 30-min twice-weekly individual sessions. During sessions, participants will practice cognitive reappraisal to reduce the value of cancer risk foods. Participants will also practice reappraisal of cancer risk foods on a computer at home, twice weekly for 15 minutes, for a total intervention time of contact of 345 minutes. The facilitator will review homework completed by participants and offer corrective feedback. The home practice is intended to promote generalization of use of this skill in the natural environment.
62435384|NCT03557710|ACTIVE_COMPARATOR|Generic Response Training|In Arm 3 (active control) of the Devaluing energy-dense foods for cancer-control intervention will be identical in duration and contact time to the behavioral response training described above (345 min total), but will involve nonfood images (birds and flowers), as described in the pilot trial. Participants will be informed that this intervention is designed to improve response inhibition, which should lead to eating change and weight loss given that impulsivity increases the risk for overeating, ensuring the credibility of the control arm.
62435385|NCT04132739|NO_INTERVENTION|Control|
62435386|NCT04132739|EXPERIMENTAL|Exercise only|
62435387|NCT04132739|EXPERIMENTAL|Diet only|
62435388|NCT04132739|EXPERIMENTAL|Diet + Exercise|
62435389|NCT00583869|PLACEBO_COMPARATOR|1|Patient to receive placebo beginning on the day of surgery until discharge.
62435390|NCT00583869|EXPERIMENTAL|2|Patient to receive 75mg PO BID pregabalin beginning on the day of surgery until discharge.
62435391|NCT00583869|EXPERIMENTAL|3|Patient to receive 150mg PO BID pregabalin beginning on the day of surgery until discharge.
62435392|NCT01862328|EXPERIMENTAL|MLN4924 and Docetaxel (Arm 1)|
62435393|NCT01862328|EXPERIMENTAL|MLN4924 + Paclitaxel + Carboplatin (Arm 2)|
62435394|NCT01862328|EXPERIMENTAL|MLN4924 + Gemcitabine (Arm 3)|
62435395|NCT00366379|EXPERIMENTAL|1|
62435396|NCT00366379|EXPERIMENTAL|2|
62435397|NCT00366379|EXPERIMENTAL|3|
62435398|NCT00366379|EXPERIMENTAL|4|
62435399|NCT00366379|EXPERIMENTAL|5|
62435400|NCT03250910|EXPERIMENTAL|HIV/HCV compensated liver disease|Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) received a generic version of Sofosbuvir and Velpatasvir fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
62435401|NCT03250910|EXPERIMENTAL|HIV/HCV decompensated liver disease|Patients with decompensated cirrhosis (Child-Pugh B or C) received Sofosvel® 1 tablet per day in combination with weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight \< 75 mg) for 12 weeks.
62435402|NCT03250910|ACTIVE_COMPARATOR|HCV compensated liver disease|Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) received a generic version of Sofosbuvir and Velpatasvir fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
62849235|NCT00826462|PLACEBO_COMPARATOR|2|"Placebo injection in combination with physical therapy~Injection with sodium chloride and 10 mg of lidocaine at start and at 3 weeks in combination with physiotherapy for 6 weeks (12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises) Naprosyn entero 500 mg bid for 14 days"
62042072|NCT03795298|ACTIVE_COMPARATOR|Market-approved OAC|Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
62823161|NCT06578468|NO_INTERVENTION|Control period|The control period includes a period whereby clinicians will not have access to ETO2 monitoring and routine RSI practices will be documented including all study variables. At all institutions, RSI is performed in a similar manner, utilising an airway checklist. There is no 'standard operating procedure' for RSI in any of the EDs and methods, therefore, vary depending on clinician preference and the condition of the patient, however, each site is a tertiary-level, university teaching hospital and therefore clinical practice is up to date and evidence-based. Standard preoxygenation methods in the Emergency department often consist of a bag-valve mask, with or without a PEEP valve, set at 15L/min, or the use of non-invasive ventilation or a non-rebreather mask, with or without a nasal cannula, set at 15 L/min or flush rate oxygen (\>40 L/min). US sites have access to high-flow (\>30L/min) oxygen. This is the only difference in the preoxygenation method.
62601866|NCT04216446|EXPERIMENTAL|Mobile Health Coaching Program during pregnancy|Eligible pregnant women would be randomized to intervention or the non-intervention arm after consenting to participate. Participants in the intervention arm will receive free subscription of m-Health program for six months of coaching. The program will provide individualized coaching on diet, supplement use and physical activity. Participants would undergo dietary screening at five points i.e. at baseline and at 6, 12, 18 and 24 weeks follow-up to monitor the improvement (if any) in diet, supplement use and physical activity. Women will receive advice in the form of recommendations after completing the questionnaire. Also, push messages containing tips and recommendations for diet, supplement use and physical activity would be delivered a maximum of three times a week. Furthermore, a subset of participants would undergo objective dietary assessment through biochemical testing of serum folate, serum ferritin, and serum calcium and serum vitamin D at baseline and at end line.
62601867|NCT04216446|NO_INTERVENTION|Standard Counseling|"For the non-intervention arm, dietary counseling will be provided face to face by the trained research assistant at the baseline and scheduled follow-ups using the AKUH educational leaflet Diet during Pregnancy and American College of obstetricians and gynaecologists guidelines for physical activity. Alike intervention group, the non-intervention group will complete an interviewer based paperless screening questionnaire at five points i.e. at baseline and at 6, 12, 18 and 24 weeks follow up. Furthermore, a subset of participants would undergo objective dietary assessment through biochemical testing of serum folate, serum ferritin, and serum calcium and serum vitamin D at baseline and at end line."
62601868|NCT04316442|EXPERIMENTAL|STI-6129 infusion|Intravenous infusion to be given with prophylaxis for infusion reactions if necessary.
62042073|NCT04447170||Laparoscopic repair|Patients undergoing laparoscopic treatment
62601869|NCT02678585|ACTIVE_COMPARATOR|Nalbuphine|53 patients received intravenous regional lidocaine plus Nalbuphine
62042074|NCT04447170||Open repair|Patients undergoing open treatment
62042075|NCT00109291|PLACEBO_COMPARATOR|Placebo|Single injection of placebo administered intravenously
62042076|NCT00109291|EXPERIMENTAL|Peginesatide 0.025 mg/kg|Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.
62042077|NCT00109291|EXPERIMENTAL|Peginesatide 0.05 mg/kg|Single peginesatide dose of 0.05 mg/kg administered intravenously.
62435403|NCT03250910|ACTIVE_COMPARATOR|HCV decompensated liver disease|Patients with decompensated cirrhosis (Child-Pugh B or C) received Sofosvel® 1 tablet per day in combination with weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight \< 75 mg) for 12 weeks.
62435404|NCT06373406|EXPERIMENTAL|MHB036C|MHB036C IV every 3 weeks
62435405|NCT04261478|ACTIVE_COMPARATOR|Acute Stenting|All patients in this arm will receive standard of care with regards to intracranial thrombectomy and use of intravenous thrombolysis. In this arm, the cervical carotid artery stenosis will be revascularized with a stent during the acute thrombectomy procedure.
62601870|NCT02678585|OTHER|Control group|53 patients received intravenous regional lidocaine
62849236|NCT00826462|ACTIVE_COMPARATOR|3|Control group: wait-and-see treatment Naprosyn entero 500 mg bid for 14 days
62849237|NCT06135298|ACTIVE_COMPARATOR|OSTEOSYNTHESIS + SYSTEMIC ZOLEDRONIC ACID|After osteosynthesis, systemic Zoledronic acid 5mg will be given intravenously at day 5 after surgery, during hospitalization.
62042078|NCT00109291|EXPERIMENTAL|Peginesatide 0.10 mg/kg|Single peginesatide dose of 0.10 mg/kg administered intravenously.
62042079|NCT06723015|NO_INTERVENTION|Control Group|Untreated historical controls enrolled in Mayo Clinic Study of Aging (IRB 14-004401), Mayo Alzheimer's Disease Research Center (IRB 712-98), and Brain Amyloid Imaging with Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia (IRB 08-005553).
62042080|NCT06723015|EXPERIMENTAL|Treatment Group|Subjects with a diagnosis of mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease and amyloid positive, who are starting anti-amyloid immunotherapy.
62042081|NCT06732063|OTHER|Separate length determination method|
62042082|NCT06732063|OTHER|Simultaneous length determination method|
62042083|NCT01105611|EXPERIMENTAL|Raltegravir|Raltegravir in combination with Tenofovir/Emtricitabine
62435406|NCT04261478|NO_INTERVENTION|No Acute Stenting|All patients in this arm will receive standard of care with regards to intracranial thrombectomy and use of intravenous thrombolysis. In this arm, the cervical carotid artery stenosis will be not revascularized with a stent during the acute thrombectomy procedure.
62435407|NCT05256732|EXPERIMENTAL|AT-527|
62435408|NCT05256732|PLACEBO_COMPARATOR|Placebo|
62435409|NCT05256732|EXPERIMENTAL|AT-527 BID|
62435410|NCT05256732|EXPERIMENTAL|AT-527 single dose fasted/fed|
62435411|NCT05357794|EXPERIMENTAL|Brentuximab vedotin|Participant will receive radiation therapy to the entire skin surface over the course of 2 days. Each dose will take about 60 to 90 minutes and will vary from one patient to another
62435412|NCT04696562|EXPERIMENTAL|Intervention group|The intervention group is the group in which the investigors applied deep breathing exercises with triflo.
62435413|NCT04696562|NO_INTERVENTION|Control group|The control group is the group that receives standard clinical care.
62435414|NCT01212783|ACTIVE_COMPARATOR|Present-Centered Therapy|Mothers will receive 15 weekly sessions of PCT plus two monthly booster sessions following the 15th session.
62435415|NCT01212783|EXPERIMENTAL|In-Home Cognitive Behavioral Therapy|Mothers will receive 15 weekly sessions of IH-CBT plus two booster sessions scheduled monthly following the 15th session.
62435416|NCT00040859|EXPERIMENTAL|oxaliplatin + capecitabine|"Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response (CR) receive 2 additional courses after CR.~Quality of life is assessed at baseline and then every 3 weeks (prior to each course of chemotherapy).~Patients are followed every 3 months for 1 year and then every 6 months for 2 years."
62435417|NCT04363736|ACTIVE_COMPARATOR|TCZ 8 mg/kg|Participants will receive intravenous (IV) tocilizumab (TCZ) at a dose of 8 mg/kg in addition to standard-of-care treatment.
62435418|NCT04363736|EXPERIMENTAL|TCZ 4 mg/kg|Participants will receive IV tocilizumab (TCZ) at a dose of 4 mg/kg in addition to standard-of-care treatment.
62435419|NCT01581983|EXPERIMENTAL|Internet Mindfulness Meditation|
62435420|NCT01581983|EXPERIMENTAL|Individual Mindfulness Meditation|
62435421|NCT02348970|EXPERIMENTAL|mandibular advancement devices ONIRIS®|The patients will use the mandibular advancement devices ONIRIS®
62435422|NCT02348970|ACTIVE_COMPARATOR|laboratory devices TALI|The patients will use the laboratory devices TALI
62435423|NCT00560547|EXPERIMENTAL|1|
62435424|NCT04926896|EXPERIMENTAL|Minimally invasive bone harvesting surgery|"1. .Applying routine approach in iliac crest bone harvesting surgery, make a 4cm long incision before or after the iliac crest, slice skin and subcutaneous tissue by layer., exposing the iliac crest ridge, outer plate and part of the iliac crest bone.~2. Use the cortical bone opening device to open two bone holes with a diameter of 7.5 mm side by side in the iliac bone cortex ,place disposable battery-powered bone harvesting device for iliac crest bone harvesting operations.~3. The direction of the tool bit should be parallel to the outer iliac plate, to avoid penetration of inner iliac layer, and avoid the injury to iliac blood vessels, nerves or internal organs.~4. .Scrap and collect the cancellous bone by tool bit during operation.~5. . After collecting sufficient amount of cancellous bone, turn off the power, screw out the cabin, and pour out the cancellous bone.~6. . Suturing the iliac crest periosteum and deep fascia, closing the incision layer by layer, no drainage."
62435425|NCT04926896|PLACEBO_COMPARATOR|Traditional iliac crest bone harvesting surgery|"1. .Applying routine approach in iliac crest bone harvesting surgery, make a 4cm long incision before or after the iliac crest, slice skin and subcutaneous tissue by layer., exposing the iliac crest ridge, outer plate and part of the iliac crest bone.~2. Use a bone chisel to open a lid on the iliac crest ridge cortex ,open the cover length at 3cm.~3. Lift the iliac crest ridge cortex plate cover, use bone knife and scraper to harvest bone in the iliac bone marrow cavity.~4. Avoid violence when using bone knives and scrapers, to avoid penetration of inner iliac layer, and avoid the injury to iliac blood vessels, nerves or internal organs.~5. After collecting sufficient amount of cancellous bone, suturing the iliac crest periosteum and deep fascia, closing the incision layer by layer, no drainage"
62435426|NCT02050464||Healthy controls|Healthy controls
62435427|NCT02050464||Alzheimer's disease|Patients with mild Alzheimer's disease
62435428|NCT02050464||Vascular dementia|Patients with vascular dementia
62435429|NCT02050464||Fronto-temporal dementia|Patients with fronto-temporal dementia
62435430|NCT02050464||Mild cognitive impairment|Patients with mild cognitive impairment
62435431|NCT04576793|EXPERIMENTAL|Cognitive impairment|"* Mild Cognitive Impairment~* Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties~* Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties~* Amnestic Alzheimer's disease - a typical version of Alzheimer's disease with memory difficulties"
62435432|NCT04576793|ACTIVE_COMPARATOR|No cognitive impairment|Healthy controls
62435433|NCT04267796|EXPERIMENTAL|Group I (lifestyle intervention)|Participants complete lifestyle intervention consisting of 1-3 sets of high-resistance circuit training sessions per week, up to 150 minutes of aerobic training per week, and diet recommendations from a health coach or registered dietitian twice per week for 16 weeks.
62435434|NCT04267796|ACTIVE_COMPARATOR|Group II (wait-list, lifestyle intervention)|Participants are placed on a wait-list and then complete lifestyle intervention after 4 months.
62435435|NCT01082445|EXPERIMENTAL|N-acetylcysteine|50 patients that receive 600 mg of acetylcysteine for 3 times a day.
62435436|NCT01082445|PLACEBO_COMPARATOR|Placebo|50 subjects taking placebo pills 3 times a day
62435437|NCT02235428|EXPERIMENTAL|Ipratropium bromide|
62435438|NCT02235428|ACTIVE_COMPARATOR|Salbutamol|
62601871|NCT00787098|NO_INTERVENTION|1|RA begins data collection with chart review for demographic and explanatory variables, collects data for baseline muscle strength. During standard care period, PM will obtain information about the plan for activity for enrolled patients (turning, complete or partial weight-bearing i.e., reverse Trendelenberg positioning, ROM, sitting and walking) through discussion with the direct providers. RA will interview one provider about factors which influence the decision to implement activity or provide bedrest, including the presence of orders for bedrest or physical therapy. If activity is planned, the PM will observe and record the type and duration of activity, drawing serum biomarkers 20 minutes before and 20 minutes after the activity. If no activity is planned or activity duration is less than 10 minutes, serum for only baseline inflammatory biomarkers will be drawn. The RA will collect outcomes data within 24 hours of discharge from the ICU.
62601872|NCT00787098|EXPERIMENTAL|2|Identical procedures for date recruitment, consent and data collection will occur. In this phase, the Project Manager will promote the use of the ETM protocol through coaching (e.g., reminding staff of benefits of mobility, identification of available resources, or suggesting cessation of bedrest orders) and by participating in planning at least one 20-minute activity.
62601873|NCT03722940|ACTIVE_COMPARATOR|Magnesium sulphate|Group M
62601874|NCT03722940|PLACEBO_COMPARATOR|Na CL 0.9%|group C
62601875|NCT06344533|EXPERIMENTAL|JMKX003142 Injection|Single and multiple doses of JMKX003142 Injection administered intravenously.
62601876|NCT06344533|PLACEBO_COMPARATOR|Placebo|Placebo administered intravenously.
62601877|NCT00984061|EXPERIMENTAL|colchicine alone|colchicine baseline pharmacokinetics
62042084|NCT01105611|ACTIVE_COMPARATOR|Atazanavir/Ritonavir|Atazanavir 300mg orally once daily with Ritonavir 100mg orally once daily; together with combination of Tenofovir/Emtricitabine
62042085|NCT06733194||Group I|Patients who underwent an ileocystoplasty
62601878|NCT00984061|EXPERIMENTAL|colchicine with clarithromycin|colchicine pharmacokinetics in presence of clarithromycin
62601879|NCT04855617||Patients Receiving Multiple Sclerosis care|Patients currently receiving ocrelizumab or initiating ocrelizumab per their MS treating physician.
62601880|NCT06371729|EXPERIMENTAL|group 1|Substrate-based DEEP Mapping
62601881|NCT06371729|EXPERIMENTAL|group 2|VT Activation Mapping
62601882|NCT06245447||CASPR2- Patients|
62601883|NCT06245447||Patients affected by autoimmune encephalitis with antibodies against CASPR2|
62601884|NCT06056804|EXPERIMENTAL|cCRT+tislelizumab+thymalfasin|A total of 20 pMMR/MSS locally advanced middle and low rectal cancer patients will receive long-course concurrent chemoradiotherapy combined with 3 cycles of tislelizumab and 11 weeks of thymalfasin therapy.
62601885|NCT02395263|EXPERIMENTAL|Yuxintine 200mg per day|Yuxintine 200mg oral, once a day, 6 weeks
62823162|NCT06578468|EXPERIMENTAL|Study period|"For all patients involved in the study, the only intervention will be the use of ETO2 to guide preoxygenation. All aspects of RSI will be at the discretion of the treating clinician including sedative/paralytic medications, positioning of the patient, preoxygenation method, intubation techniques and post-intubation sedation.~Clinicians will be encouraged to aim for the highest ETO2 result possible with a goal of \>85%. Clinicians will be able to view the ETO2 values and can decide on any changes to the preoxygenation techniques if deemed necessary. These techniques may include improved patient positioning, improved face mask seal, increased oxygen flow, length of preoxygenation time, or altering the preoxygenation device."
62823163|NCT06517446|EXPERIMENTAL|Control Group|A conventional rehabilitation program based on structured Cawthorne Cooksey exercises will be applied for 45 minutes with the support of a physiotherapist, once a week for 8 weeks. Exercises will be done twice a day, 10 repetitions. A home exercise program will be created for patients and they will be asked to do 10 repetitions every day, twice a day. The exercise program will be developed individually, progressively, under the guidance of a vestibular therapist.
62042086|NCT06733194||Group S|Patients who underwent a sigmoidocystoplasty
62042087|NCT02644187|OTHER|Left side first -Aktilite CL128|Randomized left side first with application of 5-aminolevulinic acid under occlusion during 3h. After that Aktilite CL128.
62042088|NCT02644187|OTHER|Right side first -Aktilite CL128|Randomized right side first with application of 5-aminolevulinic acid under occlusion during 3h. After that Aktilite CL128.
62601886|NCT02395263|EXPERIMENTAL|Yuxintine 300mg per day|Yuxintine 300mg oral, once a day, 6 weeks
62601887|NCT02395263|EXPERIMENTAL|Yuxintine 400mg per day|Yuxintine 400mg oral, once a day, 6 weeks
62601888|NCT02395263|PLACEBO_COMPARATOR|Placebo|Placebo oral, once a day, 6 weeks
62601889|NCT03889470|ACTIVE_COMPARATOR|200 microgram NTG|200 microgram NTG through the radial sheath
62601890|NCT03889470|PLACEBO_COMPARATOR|Saline|Saline infusion through the radial sheath
62042089|NCT02644187|OTHER|Left side first -BF-RhodoLED|Randomized left side first with application of 5-aminolevulinic acid under occlusion during 3h. After that BF-RhodoLED.
62042090|NCT02644187|OTHER|Right side first -BF-RhodoLED|Randomized right side first with application of 5-aminolevulinic acid under occlusion during 3h. After that BF-RhodoLED.
62601891|NCT06400706|EXPERIMENTAL|EEG Group|EEG guided general anesthesia: General anesthesia is guided by SedLine (EEG-guided care). The goal of EEG-guided care is to maintain spectral edge frequency (SEF) between 10 and 15 and patient state index (PSI) between 25 and 50.
62601892|NCT06400706|NO_INTERVENTION|Control|Standard general anesthesia: Anesthesia management is performed to keep the minimal alveolar concentration (MAC) value at 0.9 and intraoperative drug use is adjusted according to the experience of the anesthesiologist.
62601893|NCT02550600|EXPERIMENTAL|Intervention group|Intervention: iLA activve treatment. iLA activve treatment also requires anticoagulation with un-fractionized heparin and pre-defined PTT-goals (45s-60s depending on blood flow).
62601894|NCT02550600|ACTIVE_COMPARATOR|Control group|"Controls: standard care according to good clinical practice and recent guidelines; no extracorporeal lung assist.~For ethical reasons patients of the control group can be treated with iLA activve after fulfilling the primary endpoint criterium of an increase in SOFA ≥3 points. These cross-over patients will be analyzed as controls (intention to treat)."
62601895|NCT04185935||Ancillary-correlative (biospecimen collection)|Participants may provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue.
62601896|NCT01623973|EXPERIMENTAL|With restraint|The group with restraint underwent specific training of paretic upper limb and use of restraint.
62042091|NCT00493922|ACTIVE_COMPARATOR|2|Microscopy for diagnosis of malaria
62042092|NCT00493922|ACTIVE_COMPARATOR|3|Clinical diagnosis for malaria
62601897|NCT01623973|ACTIVE_COMPARATOR|no restraint|"The group control without restraint submitted only to the specific training of paretic upper limb"
62601898|NCT03410732|EXPERIMENTAL|Radical surgery plus activated DCs|In 21 days after a radical surgery, activated DCs are iv infused
62601899|NCT03410732|ACTIVE_COMPARATOR|Radical surgery only|Radical surgery only group as a control group
62042093|NCT00493922|EXPERIMENTAL|1|Rapid Diagnostic Test for Malaria
62042094|NCT01106768||test cohort|Evaluation of oral health needs of children with attention deficit disorder with or without hyperactivity
62042095|NCT01106768||not disorder cohort|children without attention deficit disorder
62042096|NCT00059358|EXPERIMENTAL|1|Participants will begin receive either Rebetron or PEG-Intron plus ribavirin therapy from Weeks 2 through 48
62042097|NCT04244032|EXPERIMENTAL|Working Memory Training (WM)|Participants complete training in a working memory task designed to utilize individually-adapted difficulty levels.
62042098|NCT04244032|EXPERIMENTAL|Inhibitory Control Training (IC)|Participants complete training in an inhibitory control task designed to utilize individually-adapted difficulty levels.
62042099|NCT04244032|ACTIVE_COMPARATOR|Bias Modification Training (BM)|Participants complete training in an active comparator task designed to weaken approach responses to alcohol-associated cues.
62042100|NCT04244032|NO_INTERVENTION|Non-Trained control (NTC)|No active intervention is delivered beyond typical care.
62601900|NCT04587349|ACTIVE_COMPARATOR|Exercise+FU 2/week|Post stroke group that received 2 years of intensive therapy. (2/week)
62601901|NCT04587349|ACTIVE_COMPARATOR|Exercise+FU 3/week|Post stroke group that received 2 years of intensive therapy. (3/week)
62823164|NCT06517446|EXPERIMENTAL|Working group|In addition to the program of the participants in the vestibular exercise group, optokinetic stimulation will be given through oculus glasses. Application will be made 1 day a week for 8 weeks.
62823165|NCT05467527|EXPERIMENTAL|PACT Group|A combination of 6 online modules and 4 group-based video conferencing sessions of Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice via a mobile app across 12 weeks
62042101|NCT01239030|ACTIVE_COMPARATOR|10 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 10 mg
62823166|NCT05467527|PLACEBO_COMPARATOR|Control Group|A combination of 6 online modules and 4 group-based video conferencing sessions of daily parenting challenges in caring for a child with SHCN plus positive parenting advice via a mobile app across 12 weeks
62823167|NCT04650815||0.5 - 5 Years|Infants and Children up to age 5 years in the Sabou Health District
62042102|NCT01239030|ACTIVE_COMPARATOR|15 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 15 mg
62042103|NCT01239030|ACTIVE_COMPARATOR|20 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 20 mg
62042104|NCT01239030|ACTIVE_COMPARATOR|40 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 40 mg
62042105|NCT01239030|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62042106|NCT01239030|EXPERIMENTAL|Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg)|Biphentin Methylphenidate Hydrochloride Extended Release Capsules (10, 15, 20, 40, 50 or 60 mg) - Open Label Phase
62042107|NCT05732909|EXPERIMENTAL|First Ketone, then placebo|Ingestion of ketone monoester D-β-hydroxybutyrate / D 1,3 butanediol monoester on first experimental day and ingestion of a fat placebo drink on the second experimental day.
62601902|NCT04587349|ACTIVE_COMPARATOR|physiotherapy|Post stroke group that received 2 years of traditional physiotherapy. (3/week)
62601903|NCT04587349|NO_INTERVENTION|Exercise+FU - controll|He did not receive treatment after 4 weeks of intensive care. it functions only as a control group.
62601904|NCT01647191|EXPERIMENTAL|intervention group|The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
62823168|NCT04650815||10 - 18 Years|Children ranging in age 10 to 18 years in the Sabou Health District
62823169|NCT04650815||19 + Years|Adults ranging in ages 19 years to 65 years in the Sabou Health District
62042108|NCT05732909|EXPERIMENTAL|First placebo, then ketone|Ingestion of a fat placebo drink on the first experimental day followed by ingestion of ketone monoester D-β-hydroxybutyrate / D 1,3 butanediol monoester on the second experimental day.
62042109|NCT05936567|EXPERIMENTAL|Povorcitinib Dose A|Participants will receive dose A of povorcitinib for a 12 week period, followed by dose A for an additional 24 week period.
62042110|NCT05936567|EXPERIMENTAL|Povorcitinib Dose B|Participants will receive dose B of povorcitinib for a 12 week period, followed by dose B for an additional 24 week period.
62042111|NCT05936567|EXPERIMENTAL|Povorcitinib Dose C|Participants will receive dose C of povorcitinib for a 12 week period, followed by dose C for an additional 24 week period.
62042112|NCT05936567|EXPERIMENTAL|Placebo followed by Povorcitinib Dose A, B, or C|Participants will receive placebo for a 12 week period, followed by randomization to either Dose A, Dose B, or Dose C for an additional 24 week period.
62601905|NCT01647191|ACTIVE_COMPARATOR|control group|The investigators will adopt previous treatment in the clinics to intervent the patients without any type of target intervention for this group.
62601906|NCT06387706|EXPERIMENTAL|GAP group|Participants will be invited in the process of developing the GAP, the pain education materials, exercise videos, gameing elements and activities. Each stages of development of the GAP will be jointly monitored by the research team and the participants, feedback and comments will be constantly seek via biweekly meeting.
62601907|NCT04620590|EXPERIMENTAL|Treatment Arm|Patients will receive dapagliflozin 10 mg tablets once daily for 14±1 days.
62601908|NCT01729520|EXPERIMENTAL|Knee extension strength training|
62601909|NCT01433068|EXPERIMENTAL|NBTXR3|
62601910|NCT01038596||osteoarthritic donors|pelvic compartment advanced-stage (Kellgren and Lawrence grade 3 or 4) osteoarthritic donors
62601911|NCT01038596||healthy donors|age-matched healthy donors
62435439|NCT05528926|OTHER|Non-Violent Resistance (NVR) program|The Non-Violent Resistance (NVR) parent group-format program has been designed to develop a positive form of authority based on parental presence, a parental support network, strategies of nonviolent responses which avoid escalation and reconciliation gestures.
62823170|NCT04650815||5 - 10 Years|Children ranging in age 5 years through 10 years in the Sabou Health District
62042113|NCT05530551|EXPERIMENTAL|Treatment A, Single-dose practice|"One preoperative single dose of either Dicloxacillin/Cloxacillin 2g OR Cefuroxime 1.5g administered intravenously prior to surgical incision.~As the study is a non-inferiority trial, we have chosen the Experimental design category."
62042114|NCT05530551|ACTIVE_COMPARATOR|Treatment B, Multiple-dose practice|One preoperative dose of either Dicloxacillin/Cloxacillin 2g OR Cefuroxime 1.5g administered intravenously prior to surgical incision followed by 3 postoperative doses of Dicloxacillin/Cloxacillin 1g x 3 OR Cefuroxime 750mg x 3 within 24 hours after the preoperative dose.
62042115|NCT02048332|EXPERIMENTAL|Viral Specific VST Infusion|Viral reactivation or infection. VST Reinfusion required.
62042116|NCT03464812|OTHER|DSMES Group|Patients with type 2 diabetes will undergo a diabetes education program (DSMES) and evaluated for outcomes before and after completing the program.
62042117|NCT04895722|ACTIVE_COMPARATOR|Pembrolizumab|Participants receive pembrolizumab 400 mg intravenously (IV) every 6 weeks (Q6W) for up to approximately 2 years.
62042118|NCT04895722|EXPERIMENTAL|Pembrolizumab/Quavonlimab|Participants receive co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) Q6W for up to approximately 2 years.
62042119|NCT04895722|EXPERIMENTAL|Pembrolizumab/Favezelimab|Participants receive co-formulated pembrolizumab/favezelimab (200 mg/800 mg) every 3 weeks (Q3W) for up to approximately 2 years.
62042120|NCT04895722|EXPERIMENTAL|Pembrolizumab/Vibostolimab|Participants receive co-formulated pembrolizumab/vibostolimab (200 mg/200 mg) Q3W for up to approximately 2 years.
62042121|NCT04895722|EXPERIMENTAL|Pembrolizumab Plus MK-4830|Participants receive pembrolizumab 200 mg plus MK-4830 800 mg Q3W for up to approximately 2 years.
62042122|NCT04401267|EXPERIMENTAL|Intensive Antihypertensive Therapy|Patients will begin Intensive antihypertensive therapy to achieve the targeted blood pressure (targeted to the 50-75th percentile for age, sex, and height) on day 4 of Remission Induction on TOT17 and continue during steroid containing phases until the completion of reinduction II.
62042123|NCT04401267|ACTIVE_COMPARATOR|Conventional Antihypertensive Therapy|Patients will begin Conventional antihypertensive therapy to achieve the targeted blood pressure (targeted to the 90-95th percentile for age, sex, and height) on day 4 of Remission Induction on TOT17 and continue during steroid containing phases until the completion of reinduction II.
62435440|NCT05528926|OTHER|Parent Management Training (PMT) program based on Barkley's program for defiant children|The Parent Management Treatment (PMT) program is an evidence-based treatment for disruptive behaviour disorder in which the child's social environment is modified according to principles of operant conditioning and contingency management. The parental response to the child's behaviour increases or decreases the likelihood of targeted behaviour.
62435441|NCT05528926|OTHER|Treatment as usual (TAU)|The TAU group receives non-pharmacological and pharmacological therapies as usually provided in the participating centres but without having had a structured parent program.
62435442|NCT00635388|SHAM_COMPARATOR|1|
62435443|NCT00635388|EXPERIMENTAL|2|
62435444|NCT00635388|EXPERIMENTAL|3|
62435445|NCT02974374|EXPERIMENTAL|PF-06835919|
62435446|NCT02974374|PLACEBO_COMPARATOR|Placebo|
62823171|NCT03729115|OTHER|Screening Arm|Enrolled patients will undergo Magnetic Resonance Imaging (MRI) every 6 months (2x/year) in addition to an annual screening mammogram.
62823172|NCT04649229|EXPERIMENTAL|placebo, aprepitant, placebo, aprepitant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and aprepitant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and aprepitant, respectively.
62042124|NCT03939377|EXPERIMENTAL|Osteopathy|Management will be centered on the skull, the sacrum, the cranio-sacral axis, the entire visceral abdominal and thoracic system.
62042125|NCT03939377|PLACEBO_COMPARATOR|Simulate|The simulated treatment will be characterized by placing the practitioner's hands on the patient in the areas tested without any intention of treatment.
62042126|NCT04130516|OTHER|Active|Phase 1/2 open-label
62042127|NCT02063828|EXPERIMENTAL|Group A|Group A - Device Guided Breathing Low Dose
62042128|NCT02063828|EXPERIMENTAL|Group B|Group B - Device guided breathing high dose
62435447|NCT04860635|EXPERIMENTAL|F14 (sustained release celecoxib)|Intra-articular F14 administration immediately following TKR surgery, and concurrent with multimodal standard of care analgesia
62435448|NCT01677559|EXPERIMENTAL|Dose Level 0|"MLN8237 20 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
62435449|NCT01677559|EXPERIMENTAL|Dose Level 1|"MLN8237 30 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
62435450|NCT01677559|EXPERIMENTAL|Dose Level 2|"MLN8237 40 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
62435451|NCT01677559|EXPERIMENTAL|Dose Level 3|"MLN8237 50 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
62435452|NCT01677559|EXPERIMENTAL|MTD Expansion Phase|"MLN8237 as determined during the dose escalation phase on Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
62435453|NCT04366388||Frail hospitalized old adults|Over than 65-years of age Admitted into Acute Unit Nonambulatory
62823173|NCT04649229|EXPERIMENTAL|placebo, aprepitant, aprepitant, placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and aprepitant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive aprepitant and placebo, respectively.
62042129|NCT02063828|SHAM_COMPARATOR|Group C|Group C - Usual Breathing Control Group
62042130|NCT05596448|ACTIVE_COMPARATOR|Cocygeal nerve radiofrequency ablation group|During the procedure, after imaging the sacral and coccygeal corns with ultrasonography, a radiofrequency ablation needle is inserted at the level of the coccygeal horn and radiofrequency ablation is applied at 90 degrees for 60 seconds.
62042131|NCT05596448|NO_INTERVENTION|Conservative treatment group|This group includes patients receiving conservative treatment such as nonsteroidal anti-inflammatory group drugs, physical therapy, and exercise for coccygeal pain.
62042132|NCT05554354|EXPERIMENTAL|Cohort I (Arm I) (fulvestrant, binimetinib)|Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles and binimetinib PO BID on days 15 to 28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT, MRI, or bone scan, ECHO or MUGA, and tumor biopsy, as well as possible blood sample collection during screening and on study.
62042133|NCT05554354|ACTIVE_COMPARATOR|Cohort I (Arm II)|Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who progress on fulvestrant alone may migrate to cohort II if they meet the migration eligibility criteria. Patients not willing to migrate to cohort II will have further therapy at the investigator's discretion. Patients undergo a CT, MRI, or bone scan and tumor biopsy, as well as ECHO or MUGA and possible blood sample collection during screening and on study.
62042134|NCT05554354|EXPERIMENTAL|Cohort II (fulvestrant, binimetinib)|Patients receive fulvestrant IM on day 1 of each cycle and binimetinib PO BID on days 15-28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT, MRI, or bone scan, ECHO or MUGA and tumor biopsy, as well as possible blood sample collection during screening and on study.
62042135|NCT01421433|ACTIVE_COMPARATOR|Tandrilax|Reference product Intervention: Drug: Tandrilax (caffeine+carisoprodol+sodium diclofenac+paracetamol)
62042136|NCT01421433|EXPERIMENTAL|Dolamin Flex|Test product Intervention: Drug: Dolamin Flex (Lysine clonixinate and cyclobenzaprine)
62042137|NCT04466748|EXPERIMENTAL|Anaprazole Sodium enteric-coated tablet|"Multiple ascendinng dose, anaprazole 20mg QD(20mg QD group), 40mg QD(40mg QD group), 20mg Bid(20mg Bid group) , 6 days, fasting oral administration."
62042138|NCT04466748|PLACEBO_COMPARATOR|Placebo|Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.
62601912|NCT04890977|EXPERIMENTAL|Talking Story|Talking Story is a modular behavioral intervention intended to increase mental health treatment-seeking among Pacific Islanders through the use of narrative films and other culturally syntonic approaches.
62601913|NCT04890977|PLACEBO_COMPARATOR|Wait-list control|The wait-list control will be administered as a control arm to the active Talking Story arm.
62823174|NCT04649229|EXPERIMENTAL|aprepitant, placebo, placebo, aprepitant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and aprepitant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and aprepitant, respectively.
62042139|NCT02668081|EXPERIMENTAL|Endoscopic papillary balloon dilation|For EPBD group, after selective cannulation of the common bile duct by the catheter, cholangiography will be performed to confirm the diagnosis of bile duct pathology. A 0.025-0.035-inch guidewire will then be inserted into the bile duct through the catheter. A dilating balloon (The controlled radial expansion (CRE) balloon dilation catheter, CRE balloon 5.5 cm (centimeter) in length, 1-1.2 cm/1.2-1.5 cm/1.5-2.0 cm in diameter) will be passed via the pre-positioned guidewire into the bile duct. Using fluoroscopic and endoscopic guidance, the balloon will be inflated with contrast medium up to the optimal size and duration (normally 5min (minutes)) after the waist on the balloon disappeared according to the patients' condition and tolerance.
62042140|NCT02668081|ACTIVE_COMPARATOR|Endoscopic sphincterotomy|"For EST group,endoscopic sphincterotomy(EST) will be done as large as possible with a pull type sphincterotome (The TRUEtome, Biliary sphincterotomy sphincterotome, Single-use sphincterotome CleverCut2V)~Other interventions: surgical intervention, endoscopic stenting, percutaneous transhepatic cholangiogram with balloon dilation"
62042141|NCT05390970|EXPERIMENTAL|Platelet-rich Plasma|These subjects will have the active PRP injected into their anterior vaginal wall.
62042142|NCT05390970|PLACEBO_COMPARATOR|Placebo (saline)|These subjects will have a saline placebo injected into the anterior vaginal wall.
62435454|NCT02947061|EXPERIMENTAL|test group|S1 plus Docetaxel ：S-1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
62435455|NCT02947061|ACTIVE_COMPARATOR|control group|Capecitabine plus Docetaxel ：Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
62435456|NCT06371547|EXPERIMENTAL|Sustained stretching of the gastrocnemius muscle with a towel|The participant will place a towel under the plantar surface of the foot and, using both hands, pull the towel towards themselves until they feel a stretch in the calf muscle. Subsequently, they will be asked to maintain this position for 3 minutes. The stretching exercise will be performed in 3 sets per day.
62435457|NCT06371547|EXPERIMENTAL|Intermittent stretching of the gastrocnemius muscle with a towel|In intermittent stretching with a towel, the individual will place a towel under the plantar surface of the foot and, using both hands, pull the towel towards themselves until they feel a stretch in the calf muscle. Subsequently, they will be instructed to maintain this position for 20 seconds. The stretching exercise will be performed in 2 sets per day, with 5 repetitions in each set.
62601914|NCT00713661|EXPERIMENTAL|TachoSil®|
62601915|NCT02994758|OTHER|Personalised medicine arm|"This is a prospective n-of-1 type of trial where every patient is his/her own control. This is a study further developing the translational use of an existing framework and infrastructure for systematic sample collection an analytics previously established in the HUB project incorporating NGS and DSRT into clinical care."
62042143|NCT06733116||Group of experts in the field of isokinetic testing|A panel of experts in isokinetic testing, including physicians, physiotherapists, kinesiologists and exercise physiologists with significant expertise and recognition, will participate in a Delphi process to establish a consensus on standardizing data reporting.
62042144|NCT05060016|EXPERIMENTAL|Part 1: Tarlatamab Low Dose|Participants will receive the low dose of Tarlatamab.
62042145|NCT05060016|EXPERIMENTAL|Part 1: Tarlatamab High Dose|Participants will receive the high dose of Tarlatamab.
62042146|NCT05060016|EXPERIMENTAL|Part 2: Dose Expansion|Participants will receive the selected target dose of Tarlatamab based on findings in Part 1.
62042147|NCT05060016|EXPERIMENTAL|Part 3: Modified Monitoring Substudy|Participants will receive the selected target dose of Tarlatamab based on findings in Part 1 with reduced Cycle 1 monitoring requirements.
62042148|NCT05471960|OTHER|iRBD Group: Progression over time|Each subject be assessed at baseline and approximately 2 years later. At each time point, each participant will attend eight testing sessions (MRI scanning, two TMS-motor test visits, two TMS-prefrontal test visits, motor assessments, neuropsychological testing, and overnight sleep testing (polysomnography - PSG).
62042149|NCT05471960|OTHER|Control Group: Progression over time|Each subject be assessed at baseline and approximately 2 years later. At each time point, each participant will attend eight testing sessions (MRI scanning, two TMS-motor test visits, two TMS-prefrontal test visits, motor assessments, neuropsychological testing, and overnight sleep testing (polysomnography - PSG).
62042150|NCT05934513|EXPERIMENTAL|GFH009|all patients will be administrated with GFH009
62042151|NCT05697848|EXPERIMENTAL|Pain Education group|The patients of the experimental group will undergo pain education in addition to individual physiotherapy ( manual therapy and active exercises ).
62042152|NCT05697848|ACTIVE_COMPARATOR|Control group|The patients of the control group will undergo individual physiotherapy ( manual therapy and active exercises ).
62042153|NCT04967417|EXPERIMENTAL|Non-squamous cell carcinoma|"* 4 cycles of pemetrexed 500mg/m2 + carboplatin AUC 5.0 + pembrolizumab 200mg every 3 weeks~* Followed by pemetrexed 500mg/m2 + pembrolizumab 200mg every 3 weeks up to 35 cycles"
62042154|NCT04967417|EXPERIMENTAL|Squamous cell carcinoma|"* 4 cycles of paclitaxel 200mg/m2 + carboplatin AUC 6.0 + pembrolizumab 200mg every 3 weeks~* Followed by pembrolizumab 200mg every 3 weeks up to 35 cycles"
62435458|NCT06371547|EXPERIMENTAL|Sustained stretching against the wall|In sustained stretching against the wall, individuals will be asked to place their hands on the wall at shoulder width apart. One leg will be positioned behind the other. Then, the front knee will be bent while keeping the back knee in extension and the heel in contact with the ground. Individuals will be instructed to bend their knees until they feel a stretch in the calf muscle. Subsequently, they will be asked to maintain this position for 3 minutes. The stretching exercise will be performed in 3 sets per day.
62435459|NCT06371547|EXPERIMENTAL|Intermittent stretching against the wall|During intermittent stretching against the wall, individuals will be instructed to place their hands on the wall at shoulder width apart. One leg will be positioned behind the other. Then, the knee of the front leg will be bent while the knee of the back leg continues to stay in extension, and the heel remains in contact with the ground. Individuals will be asked to bend their knee until they feel a stretch in the calf muscle. Subsequently, they will be instructed to maintain this position for 20 seconds. The stretching exercise will be performed in 2 sets per day, with 5 repetitions in each set.
62435460|NCT03998085|EXPERIMENTAL|anlotinib|
62435461|NCT05682794||taTME|patients who underwent transanal total mesorectal excision
62435462|NCT05682794||laTME|patients who underwent laparoscopic total mesorectal excision
62435463|NCT04804332|EXPERIMENTAL|EXPECTANT MANAGEMENT|No treatment will be offered.
62042155|NCT03351972|ACTIVE_COMPARATOR|Bowel Prep routine|Participants randomised to this arm will receive their bowel prep (Klean Prep) with the routine guidance of taking the contents the day before their capsule endoscopy
62042156|NCT03351972|ACTIVE_COMPARATOR|Bowel Prep Split|Participants randomised to this arm will receive their bowel prep (Klean Prep) with the guidance stating to take the first dose the day before the capsule endoscopy and the second dose the morning of the capsule endoscopy
62435464|NCT04804332|EXPERIMENTAL|OPERATIVE HYSTEROSCOPY|Operative hysteroscopy using hysteroscopic morcellation (TruClearTM Hysteroscopic Tissue Removal System (Medtronic, Minneapolis, MN, USA)) is performed.
62435465|NCT02418910||bipolar outpatients|Patients with Bipolar Disorder in any clinical state
62435466|NCT04433845|EXPERIMENTAL|Psilocybin|25mg of Psilocybin
62435467|NCT02917954|NO_INTERVENTION|ePRO Control (3 or 6 months)|Control participants will complete surveys at baseline, 3 months, and/or 6 months. Surveys will capture patient demographics, their assessment of quality-of-life, chronic disease management, and primary care experience. A part from completing these surveys, no change to routine care will be seen.
62601916|NCT02308813|EXPERIMENTAL|Braking and functionality with hip osteoarthritis|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with hip osteoarthritis
62601917|NCT02308813|EXPERIMENTAL|Braking and functionality with hip arthroplasty|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with total hip arthroplasty
62042157|NCT03351972|EXPERIMENTAL|No bowel prep|Participants randomised to this arm will be advised to drink clear liquids only ahead of their capsule endoscopy procedure
62042158|NCT00201084|ACTIVE_COMPARATOR|1|Uncertainty reduction tools, at physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
62042159|NCT00201084|NO_INTERVENTION|2|Usual primary care
62042160|NCT03528070|EXPERIMENTAL|Tranilast|
62042161|NCT04283448|EXPERIMENTAL|Lentil|0.66 cups lentils
62042162|NCT04283448|SHAM_COMPARATOR|Control|0.0 cups lentils
62042163|NCT01229540|NO_INTERVENTION|Lifestyle counseling|
62042164|NCT00643916|EXPERIMENTAL|Vaccinated at Age 9 and 12 Months|Participants received Menactra® vaccine at 9 and 12 Months of age
62042165|NCT00643916|EXPERIMENTAL|Vaccinated at Age 9 and 15 Months|Participants received Menactra® vaccine at 9 and 15 Months of age
62245141|NCT05778578|NO_INTERVENTION|Control|All participants will receive the following: 1) a ClinCard and instructions for completing a weekly financial journal to record participants' spending patterns and social needs during the first 6 months of the study; 2) materials about financial literacy and community-based resources that provide support to low-income individuals; 3) description and instructions for follow-up assessments and check-ins; 4) a copy of signed medical release, consent, and HIPAA forms; 5) respondent-driven sampling referral cards; 6) 3 study referral cards, and 7) information about voter registration services provided through the Pulaski County Circuit and County Clerk's Office (https://www.pulaskiclerk.com/voter-registration/). Participants will be provided information about the importance of voting, restoration of voting rights, and the process of voting and sealing records.
62823175|NCT04649229|EXPERIMENTAL|aprepitant, placebo, aprepitant, placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and aprepitant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive aprepitant and placebo, respectively.
62042166|NCT00643916|EXPERIMENTAL|Vaccinated at Age 12 and 15 Months|Participants received Menactra® vaccine at Age 12 and 12 Months of age
62042167|NCT00643916|EXPERIMENTAL|Vaccinated at Age 15 Months|Participants received Menactra® vaccine at 15 Months of age
62042168|NCT00643916|EXPERIMENTAL|Vaccinated at Age 18 Months|Participants received Menactra® vaccine at 18 Months of age
62601918|NCT00387010|EXPERIMENTAL|fentanyl buccal tablets|Successful dose strength for each participant was determined during a titration period of no more than 10 days. Participants used the successful dose of 100, 200, 400, 600, or 800 mcg during the four week open-label treatment period.
62601919|NCT02529904|EXPERIMENTAL|MF59 - ATIV|"All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.~Adult participants will receive one dose of MF59-ATIV."
62601920|NCT04221620|EXPERIMENTAL|EEG neurofeedback|All participants will receive 20 sessions of traditional occupational therapy services while receiving EEG neurofeedback.
62601921|NCT00877955|ACTIVE_COMPARATOR|alprazolam sublingual tablet reference|
62601922|NCT00877955|EXPERIMENTAL|alprazolam sublingual tablet test|
62601923|NCT00380666|OTHER|PET/CT defined target|Target defined by use of fluoro-deoxy-glucose (FDG)-PET/CT scan for planning af stereotactic radiotherapy.
62042169|NCT00643916|ACTIVE_COMPARATOR|Vaccinated at Age 3 Years to <6 Years|Participants received Menomune® vaccine at Age 3 years to \<6 years of age
62823176|NCT04334824||Hydrochlorothiazide|Patients who received a new prescription for hydrochlorothiazide (alone or in combination with non-ACE inhibitor antihypertensive drugs) at cohort entry, and did not have a previous prescription for any antihypertensive drug any time before cohort entry.
62823177|NCT04334824||Angiotensin-converting enzyme (ACE) inhibitors|Patients who received a new prescription for an ACE inhibitor (alone or in combination with non-hydrochlorothiazide antihypertensive drugs) at cohort entry, and did not have a previous prescription for any antihypertensive drug any time before cohort entry.
62042170|NCT06733532|EXPERIMENTAL|Propel, Essentia, Smart|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will consume the assigned treatment (one treatment per visit in order state in arm title) and additional experimental measurements will be collected.
62042171|NCT06733532|EXPERIMENTAL|Propel, Smart, Essentia|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will consume the assigned treatment (one treatment per visit in order state in arm title) and additional experimental measurements will be collected.
62042172|NCT06733532|EXPERIMENTAL|Essentia, Smart, Propel|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will consume the assigned treatment (one treatment per visit in order state in arm title) and additional experimental measurements will be collected.
62823178|NCT03933007|OTHER|Pharmacokinetic study|all participants will undergo pharmacokinetic study and take colchicine (1.5 mg over 1 hour), midazolam (1 mg) and fexofenadine (120 mg)
62823179|NCT04109547|EXPERIMENTAL|Oral semaglutide 3mg|Subjects will remain on 3 mg for the entire treatment period (26 weeks)
62245142|NCT05778578|EXPERIMENTAL|Intervention|Participants in Arm 2 will receive a monthly UBI stipend of $500 for 6 months. Study staff will explain that UBI payments will continue for 6 months and that the UBI payments will be suspended if an individual is reincarcerated (e.g. the participant will not receive UBI payments to their ClinCard during months of incarceration and will not receive additional months post-release from incarceration). Participants will receive their monthly UBI payment, along with all study-related compensation for completing baseline and follow-up assessments, through a ClinCard, which is a loadable debit card with an ID number unique to the participant. The UBI will be loaded to the participant's ClinCard on the first day of each month.
62042173|NCT06733532|ACTIVE_COMPARATOR|Essentia, Propel, Smart|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will consume the assigned treatment (one treatment per visit in order state in arm title) and additional experimental measurements will be collected.
62042174|NCT06733532|EXPERIMENTAL|Smart, Essentia, Propel|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will consume the assigned treatment (one treatment per visit in order state in arm title) and additional experimental measurements will be collected.
62042175|NCT06733532|EXPERIMENTAL|Smart, Propel, Essentia|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will consume the assigned treatment (one treatment per visit in order state in arm title) and additional experimental measurements will be collected.
62042176|NCT02395042|PLACEBO_COMPARATOR|LiRIS Placebo, LiRIS Placebo (Tx 1)/LiRIS® (Tx 2)|Treatment 1 Period (Tx 1): Matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 10 and then removed and a second matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 14 and removed on Day 28. Treatment 2 Period (Tx 2): optional LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 and removed on Day 14.
62042177|NCT02395042|EXPERIMENTAL|LiRIS®, LiRIS® (Tx 1)/LiRIS® (Tx 2)|Treatment 1 Period: LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 then removed and a second LiRIS® 400 mg inserted into the bladder on Day 14 and removed on Day 28. Treatment 2 Period: optional LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 and then removed on Day 14.
62042178|NCT02395042|EXPERIMENTAL|LiRIS Placebo, LiRIS® (Tx 1)/ LiRIS® (Tx 2)|Treatment 1 Period: Matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 0 and then removed and LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 14 then removed on Day 28. Treatment 2 Period: optional LiRIS® 400 mg inserted into the bladder by cystoscopy on Day 0 then removed on Day 14.
62042179|NCT04428879|EXPERIMENTAL|Phase I single arm trial|
62042180|NCT04528069|EXPERIMENTAL|PanOptix Toric Trifocal IOL|PanOptix Toric Trifocal IOL implanted in the capsular bag in the posterior chamber following cataract surgery and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
62042181|NCT03034642|EXPERIMENTAL|Healthy Participants|"Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages.~Drugs: No test substances, only moderate conscious sedation using standard medications.~Devices: No test devices."
62042182|NCT03034642|EXPERIMENTAL|COPD participants|"Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages.~Drugs: No test substances, only moderate conscious sedation using standard medications.~Devices: No test devices."
62042183|NCT02799966|OTHER|Early Treatment Group|Initiate treatment with MyndMove device on or after 10 days to 6 months (182 days) post spinal cord injury
62042184|NCT02799966|OTHER|Late Treatment Group|Initiate treatment with MyndMove device on or after 6 months plus one day (183 days+) post spinal cord injury
62245143|NCT06736093|ACTIVE_COMPARATOR|Vitamin D Supplementation Arm|
62042185|NCT01025440|ACTIVE_COMPARATOR|CPAP|"Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA.~Dose: The CPAP pressure will be set to the individual subject's therapeutic pressure -as determined by PSG on Night 2.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)"
62435468|NCT02917954|EXPERIMENTAL|ePRO intervention (12 or 9 months)|"During the ePRO Tool intervention participants will complete surveys at every 3 months intervals starting month at 4 or month 7, for study duration. Surveys capture patient demographics, assessment of quality-of-life, chronic disease management, primary care experience, and Electronic Patient Reported Outcome (ePRO) Mobile Application tool usability.~Participants will also meet with their provider to setup and monitor a health goal to track during the study via the ePRO application. During the study, participants will meet with their primary care providers 4-5 times to discuss their health goal monitoring. Post-study participants will discuss their experience using the ePRO app in an interview or focus group setting."
62042186|NCT01025440|ACTIVE_COMPARATOR|HFCPAP|"Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA.~Dose: During HF CPAP 35 L/min wil be administered.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)"
62042187|NCT00160680|EXPERIMENTAL|Continuous Treatment|5 mg of Levocetirizine (LCTZ) was taken orally once a day.
62042188|NCT00160680|EXPERIMENTAL|On Demand Treatment|5 mg of Levocetirizine (LCTZ) was taken whenever needed.
62245144|NCT06736093|PLACEBO_COMPARATOR|Placebo Arm|
62245145|NCT06593769|OTHER|Randomization sequence 1|Whey-protein microgel (day 2 -5); placebo (water) (day 9 to day 12) Crossover design - all participants will undergo the same experimental conditions
62435469|NCT02889328|EXPERIMENTAL|regorafenib|regorafenib 100 mg po od daily, every 4 weeks (28 day)
62823180|NCT04109547|EXPERIMENTAL|Oral semaglutide 7mg|Subjects will receive 3 mg for for the first 4 weeks, 7 mg for the remainder of the treatment period
62823181|NCT04109547|EXPERIMENTAL|Oral semaglutide 14mg|Subjects will receive 3 mg for the first 4 weeks, 7 mg for the next 4 weeks and 14 mg for the remainder of the treatment period
62823182|NCT04109547|PLACEBO_COMPARATOR|Placebo (oral semaglutide)|Subjects will receive placebo tablets for the entire treatment period
62823183|NCT06596746||Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders|
62823184|NCT06596746||Patients affected by cognitive impairment (CI) and dementia|
62042189|NCT04701684|EXPERIMENTAL|Direct tot Angiography Suite (DTAS) triage workflow|
62823185|NCT06588699|EXPERIMENTAL|Digoxin (titration-based)|Digoxin (titration-based) taken orally once daily. In this arm, the intervention will be administered dosed by weight and renal function using a well-studied digoxin nomogram.
62042190|NCT04701684|ACTIVE_COMPARATOR|Conventional CT/MR triage workflow|
62042191|NCT03280121|EXPERIMENTAL|TIF using EsophyX ZR transoral device|Transoral incisionless fundoplication which is a minimally invasive treatment for gastroesophageal reflux disease (GERD) using EsophyX ZR transoral device
62042192|NCT00526643|EXPERIMENTAL|Arm B|combination chemotherapy
62042193|NCT00526643|ACTIVE_COMPARATOR|Arm A|monochemotherapy
62042194|NCT04009369|NO_INTERVENTION|Emergency Physician Group|Usual care by the EP without the intervention of the ED PT.
62042195|NCT04009369|EXPERIMENTAL|Physical Therapist Group|Direct access to a PT in the ED immediately after triage and prior to physician assessment.
62042196|NCT01958632||N|nerve suture
62042197|NCT01958632||NT|nerve transplantation
62042198|NCT01958632||VM|vein-in-muscle conduit
62042199|NCT06481865||Early weight-bearing of patients operated on for a pelvic ring fracture|Clinical outcomes and complications will be compared between the two groups
62042200|NCT06481865||Delayed weight -bearing of patients operated on for a pelvic ring fracture|Clinical outcomes and complications will be compared between the two groups
62042201|NCT05636527||NEXUS Aortic Arch Stent Graft System|
62042202|NCT05636527||Custom-made NEXUS DUO™ Aortic Arch Stent Graft System|
62042203|NCT05591027|EXPERIMENTAL|Centella asiatica water extract product (CAP) 4g|A sachet of containing 4g dried hot water extract (CAW) of Centella asiatica combined with inactive ingredients (excipients) will be dissolved in water and orally consumed daily as a drink for six weeks. Assessments will be collected at baseline and after six weeks of daily intervention.
62042204|NCT05591027|PLACEBO_COMPARATOR|Placebo|A sachet of inactive ingredients (excipients) identical in composition to those found in the active arm will be be dissolved in water and orally consumed daily for six weeks. Assessments will be collected at baseline and after six weeks of daily intervention.
62042205|NCT04393974||Cancer patients with COVID-19|All cancer patients can be recruited onto this research following a positive test for Sars-Cov2. The research will follow what treatments they are given for the infection, but also look at their past medical history including prior and any current anti-cancer therapy.
62245146|NCT06593769|OTHER|Randomization sequence 2|Placebo (water) (day 2 -5); whey-protein microgel (day 9 to day 12) Crossover design - all participants will undergo the same experimental conditions
62042206|NCT04208841|NO_INTERVENTION|Control - Patient|Participants who receive maternal health services at a facility not participating in the Quality Improvement Intervention or implementing the change package
62042207|NCT04208841|EXPERIMENTAL|Sustaining - Patients|Participants who received maternal health services at a facility where a quality improvement collaborative had been implemented
62823186|NCT06588699|EXPERIMENTAL|Digoxin (weight-based)|Digoxin (weight-based) taken orally once daily. In the weight-based digoxin arm, the intervention will be oral digoxin 0.15mcg/kg/day.
62042208|NCT04208841|EXPERIMENTAL|Spread - Patients|Participants who received maternal health services at a facility that was provided a change package of ideas developed during the quality improvement collaborative (in phase 1) and used to make improvements on person-centered care
62601924|NCT02737228|EXPERIMENTAL|CG200745 PPA|CG200745 PPA plus Gemcitabine and Erlotinib
62245147|NCT04618133|EXPERIMENTAL|Early time-restricted eating|Duration: 12 weeks
62823187|NCT06588699|PLACEBO_COMPARATOR|Placebo|Placebo, taken orally once daily
62823188|NCT06581211|EXPERIMENTAL|Group I (LOA)|Patients inhale LOA for 20 minutes prior to SOC BMAB and throughout the procedure.
62823189|NCT06581211|EXPERIMENTAL|Group II (LA)|GROUP II: Patients inhale LA for 20 minutes prior to SOC BMAB and throughout the procedure.
62823190|NCT06581211|PLACEBO_COMPARATOR|Group III (jojoba)|Patients inhale jojoba oil for 20 minutes prior to SOC BMAB.
62042209|NCT04208841|NO_INTERVENTION|Control - Providers|Providers who work at a facility not participating in the Quality Improvement Intervention or implementing the change package
62245148|NCT04618133|EXPERIMENTAL|Late time-restricted eating|Duration: 12 weeks
62245149|NCT04618133|ACTIVE_COMPARATOR|Active control|Duration: 12 weeks
62245150|NCT04568759|ACTIVE_COMPARATOR|Standard care group|Observation or brace plus conventional physiotherapy exercises on video
62042210|NCT04208841|EXPERIMENTAL|Sustaining - Providers|Providers who work at a facility where a quality improvement collaborative had been implemented
62042211|NCT04208841|EXPERIMENTAL|Spread - Providers|Participants who work at a facility that was provided a change package of ideas developed during the quality improvement collaborative (in phase 1) and used to make improvements on person-centered care
62245151|NCT04568759|EXPERIMENTAL|GPR group|GPR interventions added to standard care (observation or brace)
62245152|NCT05151848|EXPERIMENTAL|Adalimumab group|Adalimumab 40mg injected subcutaneously every 2 weeks for 78 weeks.
62245153|NCT05151848|ACTIVE_COMPARATOR|Tofacitinib 5MG group|Tofacitinib 5mg BID taken orally for 78 weeks.
62245154|NCT06557148||Biopsy-proven ER+ Metastatic Invasive Lobular Carcinoma/ILC|Participants will have biopsy-proven metastatic ILC, confirmed ER+ breast cancer
62245155|NCT05029414|EXPERIMENTAL|Intervention group: EVT + BMT|Patients randomized to the EVT arm will undergo endovascular therapy (EVT) in addition to best medical treatment (BMT). All decisions regarding EVT device and EVT technique will be made by the treating physician.
62601925|NCT05637970|ACTIVE_COMPARATOR|Perclose Only|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
62601926|NCT05637970|EXPERIMENTAL|Perclose with Statseal Device|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manual pressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
62601927|NCT02286648|EXPERIMENTAL|Mineral Trioxide Aggregate|pulpotomy with MTA
62601928|NCT02286648|ACTIVE_COMPARATOR|Formocresol|pulpotomy with FC
62042212|NCT05253248|EXPERIMENTAL|Healthy adults|"We are planning to supplement healthy adult volunteers, once a day, with a standard over-the-counter multivitamin supplement for a period of 30 consecutive days. Supplementation will provide the daily dietary recommendations of micronutrients, as these are established by the Department of Health, on top of the participant's free diet. Supplementation aims to correct any subclinical deficiencies the participants might have particularly those which are common in the general community. In the UK, a typical example is Vitamin D, due to lack of sunshine and selenium (a geochemical) whose content in the UK soil is depleted and therefore intake is often below the recommendations.~Fasted blood and urine samples will be collected before, and again two-to-three days, post-supplementation."
62042213|NCT03765866|NO_INTERVENTION|Massive Transfusion Protocol Guided|Clinicians will only transfuse patients according to standard massive transfusion protocol (MTP)
62042214|NCT03765866|EXPERIMENTAL|Thromboelastometry guided transfusion|Clinicians will transfuse patients according to ROTEM results.
62245156|NCT05029414|NO_INTERVENTION|Control group: BMT|Patients randomized to the control arm will NOT undergo EVT but will get best medical treatment (BMT) including intravenous thrombolysis (IVT) or antiplatelet therapy if indicated under current international guidelines and according to routine clinical practice.
62245157|NCT06540391|EXPERIMENTAL|MB097 and pembrolizumab|MB097 PO (2 capsules once a day) for 6 months Pembrolizumab IV 200mg Q3W for 6 months
62245158|NCT06540391|EXPERIMENTAL|MB097 and pembrolizumab with vancomycin preconditioning|Vancomycin 125mg QID for 5 days plus 2 day wash-out prior to receiving MB097 PO (2 capsules once a day) for 6 months Pembrolizumab IV 200mg Q3W for 6 months
62245159|NCT06540391|EXPERIMENTAL|Extended treatment|Patients experiencing clinical benefit may continue to receive study intervention (pembrolizumab only IV 200mg Q3W) until such time as a criterion for discontinuation is met or 35 doses of pembrolizumab have been administered.
62601929|NCT05519488|EXPERIMENTAL|Intervention group|Patients who have scheduled appointments for cancer restaging. Participants will listen to music using Rubato Life app at least 45 minutes per day, for a period of 2 weeks coming up to their scheduled restaging appointment (or at least 12 total hours of listening), and for one hour immediately after the appointment. Patients in the Intervention group will wear smartwatches to monitor heart rate variability throughout the study
62601930|NCT05519488|ACTIVE_COMPARATOR|Control group|Patients who have scheduled appointments for cancer restaging. Participants will listen to music of their own choice that they believe to be stress reducing
62601931|NCT00616980|ACTIVE_COMPARATOR|Low Dose|
62601932|NCT00616980|ACTIVE_COMPARATOR|High Dose|
62601933|NCT00616980|PLACEBO_COMPARATOR|Saline|
62601934|NCT02400567|ACTIVE_COMPARATOR|Chemotherapy|3 cycles of FEC 100 followed by 3 cycles of Docetaxel Drugs: Fluorouracile, Epirubicine, Cyclophosphamide, Docetaxel
62042215|NCT04199949|NO_INTERVENTION|Control|5 consecutive days of normal daily levels of physical activity and matched food intake
62042216|NCT04199949|EXPERIMENTAL|Inactivity|5 consecutive days of reduced step count by 80% compared to the Control trial, whilst placing the non-dominant arm in a sling, and reduced food intake (\~ 20%) to match the reduction in energy expenditure induced by inactivity
62042217|NCT02355002|EXPERIMENTAL|Active Transcranial Magnetic Stimulation (TMS) treatment|In this arm subjects will receive real, active TMS with a standard, water-cooled, figure-8 shaped TMS coil.
62042218|NCT02355002|SHAM_COMPARATOR|Sham-TMS treatment|This arm serves as the sham/placebo control. In TMS a sham coil is used to create a sensory experience which is similar to active TMS, but in which the magnetic field is blocked by a metal shield built into the coil.
62245160|NCT06654947|EXPERIMENTAL|Experimental: Experimental|
62245161|NCT04352296|EXPERIMENTAL|Experimental group|Individualized BP management during mechanical thrombectomy with the administration of diluted norepinephrine (5-10 µg/ml) or nicardipine (1 mg/ml) or urpidil (5 mg/ml) to maintain the MAP within 10% of the first MAP measured in the angiography suit.
62245162|NCT04352296|ACTIVE_COMPARATOR|Control group|Standard BP management based on international guidelines: Treatment of hypotension defined by a systolic blood pressure \<140 mm Hg, and treatment of hypertension defined by a systolic blood pressure \> 180 mm Hg or diastolic blood pressure \>105 mm Hg) with usual treatments (norepinephrine, ephedrine or phenylephrine for hypotension; intravenous nicardipine or uradipil for hypertension).
62435470|NCT00680576|ACTIVE_COMPARATOR|1|Eight weeks of individual CBT for adolescents who have completed six weeks of group therapy and continue to use drugs.
62435471|NCT00680576|ACTIVE_COMPARATOR|2|Eight weeks of FFT for adolescents who have received six weeks of group therapy and continue to use drugs.
62601935|NCT02400567|EXPERIMENTAL|Letrozole Palbociclib|Drugs: letrozole + palbociclib combination
62601936|NCT03863704|SHAM_COMPARATOR|nerve stimulation ear then leg|Subjects in this arm will be randomized to receive nerve stimulation with TENS of the ear followed by leg stimulation
62042219|NCT03602170|EXPERIMENTAL|High-Intensity Interval Training|8 weeks of high-intensity interval training. Three sessions per week will be performed (24 total sessions).
62042220|NCT03602170|ACTIVE_COMPARATOR|Moderate-Intensity Continuous Training|8 weeks of moderate-intensity continuous training. Three sessions per week will be performed (24 total sessions).
62042221|NCT01543061|ACTIVE_COMPARATOR|New study eye drop|One month of contact lens wear with use of the Test study eye drops
62601937|NCT03863704|SHAM_COMPARATOR|nerve stimulation leg then ear|Subjects in this arm will be randomized to receive leg nerve stimulation with TENS followed by ear nerve stimulation
62601938|NCT03863704|OTHER|Subjects receiving Infliximab|Subjects on Infliximab as part of their clinical care will not be randomized as the study treatment for these subjects will be the same. The sham arm is not included for patients on infliximab.
62601939|NCT02928770|EXPERIMENTAL|Nastent|A baseline sleep study is obtained from the subject, without wearing the device. The individual wears the device at home for at least 7 nights, and then returns to the sleep lab for an in-laboratory sleep study while wearing the device.
62601940|NCT05818241||Cast|Patients that are conservatively treated (in a cast, either without or with reduction)
62601941|NCT05818241||Surgery|Patients that undergo surgical treatment (regardless of method)
62601942|NCT04053985|EXPERIMENTAL|TAI+lenvatinib group|TAI combine lenvatinib
62245163|NCT06734299|EXPERIMENTAL|Sunscreen A|"At each visit, each enrolled subject will be randomly assigned 1 of the 3 Sunscreens to apply to both lower legs (between the knee and ankle) and then her full face. The subject will cleanse her hands with soap and water between the lower legs and face Sunscreen applications.~After lower legs and facial Sunscreen applications are completed, a trained designee will delineate six 4 cm x 4 cm test sites on the subject's volar forearms (3 test sites per volar forearm). Then a trained designee will apply the assigned Sunscreen to the designated test sites in a consistent manner at a randomly assigned dose density of 0.25, 0.50, 0.75, 1.00, 1.50, and 2.00 mg/cm2 (± 10%) per the randomization schedule using a 1cc tuberculin syringe (without a needle) or pipette and a clean finger cot for approximately 20 to 50 seconds."
62601943|NCT04053985|ACTIVE_COMPARATOR|lenvatinib group|lenvatinib only
62601944|NCT06305312|ACTIVE_COMPARATOR|Usual Care|
62601945|NCT06305312|EXPERIMENTAL|Intervention|
62601946|NCT00509379|EXPERIMENTAL|1|All patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
62601947|NCT04801472|OTHER|Patients with oral cavity or oropharyngeal squamous cell carcinoma|
62601948|NCT05288296|EXPERIMENTAL|Athletes in Taiwan|"In the first year, we would recruit senior high school soccer athletes (n=30) to observe the difference with/without dynamic taping on landing error scoring system under fatigue status. (2x2 cross-over study)~In the second year, we would recruit junior/senior high school and college athlete (n=900) to establish a native model of single-leg and double-leg LESS, then in advanced, confirm the ability to predict ACL injuries.~In the third year, we will focus on high-risk subjects evaluated by LESS and athlete with ACL reconstruction (n=60) to observe the supportive effect of dynamic taping. (2x2 cross-over study)"
62042222|NCT01543061|PLACEBO_COMPARATOR|No Eyedrop|One month of contact lens wear with no eye drop use
62601949|NCT02122770|EXPERIMENTAL|MLN4924 + Fluconazole|"Part A: MLN4924, 8 milligram per square meter (mg/m\^2), intravenously, once on Days 1 and 8; and fluconazole, 400 milligram (mg), tablets, orally, once on Day 4, and 200 mg, once daily on Days 5-10.~Part B: MLN4924, at a dose previously deemed tolerable, given on Days 1, 3, and 5 of each 21-day Cycle (Study C15010, Clinicaltrials.gov Identifier # NCT01862328) in combination with docetaxel or carboplatin + paclitaxel at standard dose regimen on Day 1 of each 21-day Cycle."
62601950|NCT02122770|EXPERIMENTAL|MLN4924 + Itraconazole|"Part A: MLN4924, 8-mg/m\^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part A (safety lead-in step): MLN4924, 15mg/m\^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part A: MLN4924, 20mg/m\^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part B: MLN4924, at a dose previously deemed tolerable given, on Days 1, 3, and 5 of each 21-day Cycle (Study C15010, ClinicalTrails.gov Identifier # NCT01862328) in combination with docetaxel or carboplatin + paclitaxel at standard dose regimen on Day 1 of each 21-day Cycle."
62601951|NCT01382225|EXPERIMENTAL|Sodium Hyaluronate|Sodium Hyaluronate Ophthalmic Solution, 0.18%, 1-2 drops instilled in each eye 3-6 times a day for 14 days
62601952|NCT01382225|PLACEBO_COMPARATOR|Vehicle|Inactive ingredients, 1-2 drops instilled in each eye 3-6 times a day for 14 days
62601953|NCT06608186|EXPERIMENTAL|Drospirenone|25 cases will receive drospirenone in the form of 1 tablet / d from day 5 of stimulation till hCG trigger day
62601954|NCT06608186|ACTIVE_COMPARATOR|cetrorelix|25 cases will receive cetrorelix from day 5 of stimualtion till hCG trigger day
62601955|NCT03750747|EXPERIMENTAL|Intervention (Pulse Oximeter)|The intervention facilities will provide IMCI services with PO in addition to following existing IMCI guidelines. The IMCI service providers will classify and treat children presenting with cough and difficult breathing based on history and clinical signs. In addition, they will use PO to measure the SpO2 status of the sick children. Children clinically classified as 'Pneumonia' but having SpO2\<90% will be referred to higher-level facilities for in-patient management. Only the children clinically classified 'Pneumonia' and having SpO2\>90% will be treated through home-based management with oral antibiotics (amoxicillin, twice daily for five day).
62042223|NCT01543061|ACTIVE_COMPARATOR|BLINK Contacts Lubricating eye drop|One month of contact lens wear with use of the Control study eye drops
62042224|NCT06089356|ACTIVE_COMPARATOR|zolmitriptane|zolmitriptane tablet daily
62042225|NCT06089356|ACTIVE_COMPARATOR|topiramate|topiramate tablet daily
62042226|NCT06089356|ACTIVE_COMPARATOR|valproate|valproate once daily
62042227|NCT01214876||Children 1-5 years old|
62042228|NCT01214876||Children 6-10 years old|
62042229|NCT01214876||Adults 25 years and above|
62042230|NCT03871179|OTHER|ASD Diagnostic Device|"The ASD Diagnostic Device is a machine learning algorithm-based software as a medical device that is incorporated into a parent/caregiver-facing mobile application, the Cognoa App, used outside of a clinical setting"
62042231|NCT01847703|EXPERIMENTAL|Robotic surgery|Experimental method, to be compared with standard care
62042232|NCT01847703|ACTIVE_COMPARATOR|Abdominal surgery|Conventional open surgery (laparotomy)
62823191|NCT04335669|ACTIVE_COMPARATOR|Arm A (Platinum-based dose dense EC):|ddEC x 4 + pembrolizumab→ PK x 4 + pembrolizumab, Two-weekly epirubicin/cyclophosphamide (EC) x 4 (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2), followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2). Pembrolizumab is given as a 400 mg iv dosis every 6 weeks for the duration of preoperative chemotherapy.\*
62823192|NCT04335669|EXPERIMENTAL|Arm B (Platinum-based with capecitabine):|"CEX x 4→ PK x 4, Three-weekly cyclophosphamide/epirubicin/capecitabine (CEX) (epirubicin 75 mg/m2, cyclophosphamide 600 mg/m2 and capecitabine 900 mg/m2) x 4, followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2).Pembrolizumab is given as a 400 mg iv dosis every 6 weeks for the duration of preoperative chemotherapy.\*~\*The addition of pembrolizumab is strongly recommended to all participating patients. However, patients with a documented contraindication, or unwilling to receive immunotherapy may be included in the study without the administration of pembrolizumab."
62823193|NCT05083923|EXPERIMENTAL|Diroximel Fumarate (DRF)|Japanese and Chinese participants will initiate treatment with DRF 231 milligrams (mg), oral capsule, twice daily on Day 1 through Day 7, followed by DRF 462 mg, oral capsules, twice daily from Day 8 up to Week 48.
62601956|NCT03750747|NO_INTERVENTION|Comparison|The comparison facilities will continue providing routine IMCI services as per the existing guidelines. In routine IMCI services, IMCI service providers classify and treat children presenting with cough and difficult breathing based on history and clinical signs only. In routine IMCI services in Bangladesh, PO has not been introduced. Therefore, in the comparison facilities all children clinically classified as 'Pneumonia' will be treated through home-based management with oral antibiotics (amoxicillin, twice daily for five day)
62823194|NCT05533385|EXPERIMENTAL|Extract J. oxycedrus + extract C. arizonica + positive control + negative control|"There is only one treatment arm. In each subject, one drop of each of the 3 concentrations of each allergenic extract (2 extracts) will be applied in addition to the positive control (histamine 10 mg/mL) and the negative control, with prick test.~Juniperus oxycedrus: 300, 60 and 12 µg/mL Cupressus arizonica: 100, 20 and 4 µg/mL"
62823195|NCT05823571|EXPERIMENTAL|Itacitinib|Itacitinib will be given at 200 mg orally daily from day -3 to day 90. Itacitinib will be given in conjunction with one of four different regimens for immunosuppression. These 4 regimens are listed in Table 2, Section 5.2 of the protocol. Itacitinib may continue beyond day +90 if there is GVHD. NOTE: If patient develops GVHD requiring treatment after all immune suppression, including itacitinib, is stopped on day +90, the itacitinib will not be restarted and the patient will be treated per standard of care.
62435472|NCT06204172|EXPERIMENTAL|Experimental group|patients will receive Neurowave multisensory stimulation with concurrent event-related potential acquisition. This intensive training spans five days a week over four weeks, with each session lasting 45 minutes, summing up to 20 sessions. During each session, participants will encounter personalized visual and auditory stimuli. Neurowave treatment comprises an intensive intervention, presenting emotionally significant audio-visual content linked to the patient's life history. Within Neurowave use, visual stimuli will be complemented by primary auditory stimulation, involving exposure to emotionally charged everyday sounds.
62823196|NCT05272007||Acute cholecystitis|
62823197|NCT02825693|ACTIVE_COMPARATOR|Femtosecond laser cataract surgery|Cataract surgery with femtosecond laser treatment for corneal incisions, astigmatic keratotomies, capsulotomy and nuclear fragmentation
62449150|NCT00658320|EXPERIMENTAL|Everolimus + Reduced dose of cyclosporine|An initial everolimus dose of 0.75 mg orally twice daily (1.5 mg/day) was administered 24-36 hours from reperfusion after transplantation and dose adjustments based on everolimus trough level (target trough level 3-8 ng/mL). Reduced dose of cyclosporine was initiated either pre-transplantation or within 24 hours after transplantation following the local regimen. Patients were treated with antibody induction therapy using 20 mg basiliximab two hours prior to transplant and 20 mg basiliximab 4 days post transplant or according to local practice. Corticosteroids were administered according to local practice. Patients were treated for 12 months in the core study and 12 months in the extension study. Everolimus was available after 24 months for compassionate use.
62601957|NCT06451328|EXPERIMENTAL|TM02®|Two capsules of TM02®, once daily after meals (breakfast or dinner), totaling 600 mg TM02® daily for 30 days. Subsequently, two capsules of 300 mg TM02®, twice a day after breakfast and dinner daily, totaling 1200 mg TM02® daily for an additional 60 days.
62042233|NCT02002026|ACTIVE_COMPARATOR|Ligation group|Uterine artery ligation will be done for patients in this group
62042234|NCT02002026|PLACEBO_COMPARATOR|Control group|Conventional CS
62042235|NCT00917579|OTHER|Reference|10 mg atorvastatin
62042236|NCT00917579|EXPERIMENTAL|Test|New 10 mg atorvastatin tablet
62435473|NCT06204172|ACTIVE_COMPARATOR|Control group|Participants will receive primary auditory stimulation featuring familiar and emotionally evocative everyday sounds. This involves exposure to audio tapes and sounds related to their daily life, including voices of family and friends, snippets of favorite songs, and sounds associated with past work or leisure activities. The control group will undergo a program called Intensive Sensorial Emotional Stimulation (ISES), matching the frequency, intensity, and session duration of the experimental group but without Neurowave system utilization. Distinctively, the control group will not utilize Neurowave technology. Instead, they will follow a traditional rehabilitation approach incorporating paper materials, live photos, face-to-face interaction with the therapist, and the conventional listening of music tapes. This method aims to replicate an emotionally engaging environment, serving as a comparative reference to the experimental group's Neurowave-assisted experience.
62601958|NCT06027034|EXPERIMENTAL|Online program for psoriasis (GAIA-PSO-01) + TAU|Participants allocated to the intervention group will receive access to an online program for psoriasis (GAIA-PSO-01) in addition to treatment as usual (TAU).
62823198|NCT02825693|ACTIVE_COMPARATOR|Conventional phacoemulsification surgery|Conventional phacoemulsification surgery
62823199|NCT04142606||Control Group (Group 1)|Having prenatal ultrasound screening without detected abnormality
62823200|NCT04142606||Non Optimal Ultrasound Scan Group (Group 2)|Having an ultrasound examination without abnormality detected but in whom ultrasound examination is not optimal (poor technical conditions, multiple pregnancies, obese patients)
62823201|NCT04142606||Malformation Group (Group 3)|Standardized prenatal screening with ultrasound examination finding an isolated anomaly that does not currently constitute a commonly accepted indication of fetal MRI
62823202|NCT04142606||TOP Group (Group 4)|A medical termination of pregnancy, (TOP), in addition to a fetopathological examination (virtopsy)
62823203|NCT04818671|EXPERIMENTAL|efgartigimod PH20 SC|Patients receiving efgartigimod PH20 subcutaneous (SC) treatment
62823204|NCT02415608|EXPERIMENTAL|Ibrutinib 420 mg/day|Participants receive ibrutinib daily on days 1 to 28, at 420 mg/day in 28-day cycles
62823205|NCT02415608|EXPERIMENTAL|Ibrutinib 560 mg/day|Participants receive ibrutinib daily on days 1 to 28, at 560 mg/day in 28-day cycles
62042237|NCT02215122|EXPERIMENTAL|MGR001|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via CRC749 inhaler.
62042238|NCT02215122|EXPERIMENTAL|Advair® Diskus®|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via Diskus® inhaler.
62435474|NCT05521750||Age|Patient age
62435475|NCT05521750||Gender|Patient's gender
62435476|NCT05521750||Surgical Time|Duration of surgery, begin from incision until skin closure
62823206|NCT04561206|EXPERIMENTAL|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
62823207|NCT00417326|PLACEBO_COMPARATOR|P|
62042239|NCT02215122|EXPERIMENTAL|Seretide™ Accuhaler™|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via Accuhaler™ inhaler.
62042240|NCT04909242|EXPERIMENTAL|single oral dose of DZD9008|single dose of DZD9008 (50 mg, 100 mg, 200 mg, 300 mg and 400 mg, tablet)
62042241|NCT04909242|PLACEBO_COMPARATOR|single oral dose of placebo|single dose of placebo (matching placebo, 50 mg, 100 mg, 200 mg, 300 mg and 400 mg, tablet)
62042242|NCT04909242|EXPERIMENTAL|single oral dose of DZD9008 (300 mg, tablet)|
62042243|NCT04909242|EXPERIMENTAL|single oral dose of DZD9008 (100 mg, tablet or suspension)|
62042244|NCT03575273|EXPERIMENTAL|Opioid dependence receiving methadone|Patients with a history of opioid dependence receiving methadone maintenance therapy will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
62042245|NCT03575273|EXPERIMENTAL|Opioid dependence not on methadone|Patients with a history of opioid dependence not current receiving methadone maintenance therapy will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
62435477|NCT05521750||Intraoperative Blood loss|Total blood loss during operation
62435478|NCT05521750||Length of Stay|Duration of hospitalization
62435479|NCT05521750||VAS Pre-op|Pain scale measured with visual analog scale (VAS) prior to the operation
62435480|NCT05521750||1 Month VAS|Pain scale measured with visual analog scale (VAS) 1 month after the operation
62435481|NCT05521750||3 Month VAS|Pain scale measured with visual analog scale (VAS) 3 month after the operation
62601959|NCT06027034|NO_INTERVENTION|TAU|Participants allocated to the control group will receive access to treatment as usual (TAU).
62601960|NCT02402634||Mechanical ventilatory lung care|liver transplantation recipients under mechanical ventilatory lung care
62823208|NCT00417326|EXPERIMENTAL|E|
62823209|NCT03104868|NO_INTERVENTION|Usual Care|Patients in this group will receive the usual standard of care.
62823210|NCT03104868|EXPERIMENTAL|Intervention|Patients in this group will receive the TAKE IT strategy components.
62823211|NCT05523089|PLACEBO_COMPARATOR|Placebo (Arm 1)|In Cohort 1, up to 30 participants will be randomized to receive a single dose of placebo, administered by subcutaneous (SQ) injection, prior to being inoculated with the influenza challenge virus. Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, additional participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in an extension of this Arm 1, to receive a single dose of placebo by SQ injection prior to viral challenge.
62823212|NCT05523089|EXPERIMENTAL|CD388 High Dose (Arm 2)|In Cohort 1, up to 30 participants will be randomized to receive a single dose of 150 milligrams (mg) CD388, administered by SQ injection, prior to being inoculated with the influenza challenge virus. Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, additional participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in an extension of this Arm 2, to receive a single dose of 150 mg CD388 by SQ injection prior to viral challenge.
62435482|NCT05521750||Decrease VAS 1 month|Difference of VAS score within 1 month of evaluation
62823213|NCT05523089|EXPERIMENTAL|CD388 Low Dose 1 (Arm 3)|In Cohort 1, up to 30 participants will be randomized to receive a single dose of 50 mg CD388, administered by SQ injection, prior to being inoculated with the influenza challenge virus. Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, additional participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in an extension of this Arm 3, to receive a single dose of 50mg CD388 by SQ injection prior to viral challenge.
62823214|NCT05523089|EXPERIMENTAL|CD388 Low Dose 2 (Optional Arm 4)|Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in this Optional Arm 4, to receive a single dose of CD388 lower than 150 mg (TBD based on PK results obtained in the first-in-human study CD388.IM.SQ.1.01, as well as the interim analysis), administered by SQ injection, prior to being inoculated with the influenza challenge virus.
62435483|NCT05521750||Decrease VAS 3 month|Difference of VAS score within 3 month of evaluation
62435484|NCT05521750||Disc weight|Estimation of total disc weight
62435485|NCT05521750||Removed disc weight|weight of removed disc measured after operation
62435486|NCT05521750||Percentage of Removed Disc|Percentage of removed disc as seen on the axial MRI
62435487|NCT00794326|EXPERIMENTAL|PDsol 12|Treatment with a peritoneal dialysis solution containing a low concentration of sodium.
62435488|NCT00794326|ACTIVE_COMPARATOR|Gambrosol trio 40|Treatment with the peritoneal dialysis solution Gambrosol trio 40 isotonic bag (1.5%)
62435489|NCT04905654|ACTIVE_COMPARATOR|Levcromakalim|
62435490|NCT04905654|PLACEBO_COMPARATOR|Saline|
62435491|NCT03676959|EXPERIMENTAL|ZKAB001 5mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
62435492|NCT03676959|EXPERIMENTAL|ZKAB001 10 mg/kg|Three or six patients will be treated with the dose of 10 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
62435493|NCT03676959|EXPERIMENTAL|ZKAB001 15 mg/kg|Three or six patients will be treated with the dose of 15 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
62435494|NCT01218620|EXPERIMENTAL|Regimen I (Arm I)|"Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral ketoconazole once daily on days 1-10 for course 2 only."
62435495|NCT01218620|EXPERIMENTAL|Regimen I (Arm II)|"Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral rifampin once daily on days 1-10 for course 2 only."
62435496|NCT01218620|EXPERIMENTAL|Regimen II (Arm I)|"Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral ketoconazole once daily on days 1-10 for course 2 only."
62435497|NCT01218620|EXPERIMENTAL|Regimen II (Arm II)|"Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral rifampin once daily on days 1-10 for course 2 only."
62435498|NCT04956406|EXPERIMENTAL|MIAKTR|MIAKTR is an acronym that defines Motivational Interviewing for Adult Kidney Transplant Recipients
62435499|NCT04956406|ACTIVE_COMPARATOR|Control Group|routine care
62435500|NCT05701267||MDD|Major depressive disorder patients (unipolar)
62435501|NCT05701267||CON|(Control) non-depressed
62435502|NCT02867020|ACTIVE_COMPARATOR|Abiraterone acetate + Prednisone + ADT (Goserelin)|"* Abiraterone administered at a single 1000 mg daily oral dose (4 x 250-mg tablets)~* Prednisone administered at a 5 mg twice daily oral dose~* Goserelin administered as subcutaneous injections of 10.8mg every 3 months"
62823215|NCT05523089|EXPERIMENTAL|CD388 Low Dose 3 (Optional Arm 5)|Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in this Optional Arm 5, to receive a single dose of CD388 lower than 150 mg (TBD based on PK results obtained in the first-in-human study CD388.IM.SQ.1.01, as well as the interim analysis), administered by SQ injection, prior to being inoculated with the influenza challenge virus.
62823216|NCT05523089|EXPERIMENTAL|CD388 Low Dose 4 (Optional Arm 6)|Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in this Optional Arm 6, to receive a single dose of CD388 lower than 150 mg (TBD based on PK results obtained in the first-in-human study CD388.IM.SQ.1.01, as well as the interim analysis), administered by SQ injection, prior to being inoculated with the influenza challenge virus.
62823217|NCT03587844|EXPERIMENTAL|not been previously treated with brentuximab vedotin.|Patients with MF/SS who have not been previously treated with brentuximab vedotin. For MF patients: Treatment delays lasting longer than 8 weeks for toxicity will result in removal from study. As of October 2020, the Simon two stage design for Cohort 1 has restarted at the 1.2 mg/kg dose.
62823218|NCT03587844|EXPERIMENTAL|treated with reduced dose brentuximab vedotin|Patients with MF/SS who were previously treated with brentuximab vedotin. Up to 10 patients will be enrolled onto this cohort. Following identification of a promising dose after the completion of the full Cohort 1 Simon two stage design, enrollment will initiate onto cohort 2 at the dose found to be promising in cohort 1. For MF patients: Treatment delays lasting longer than 8 weeks for toxicity will result in removal from study. The 0.9mg/kg dose did not meet the primary endpoint for response, therefore 1.2 mg/kg has been chosen as the dose for Cohort 2. As of October 2020, enrollment on our exploratory Cohort 2 has opened at the 1.2 mg/kg dose.
62823219|NCT03587844|EXPERIMENTAL|Patients with LyP|Patients with LyP patients with lymphomatoid papulosis will receive brentuximab vedotin 0.9 mg/kg as an intravenous infusion over 30 minutes every three weeks. Cohort 3 will enroll patients concurrently with Cohort 1. Treatment may be held if felt to be in patient's best interest (for example: for toxicity or no active disease). Treatment can be reinitiated after discussion with MSK PI as long as the study is still open and patient has not received alternate systemic therapy.
62823220|NCT04524637||Traumatic brain injury|Patients who are delivered within 24 hours after head trauma and sustain isolated traumatic brain injury are included in this study.
62823221|NCT02230410|EXPERIMENTAL|focal cryo ablation|Subjects with residual barrett's esophagus (less than 3 cm) post ablation will under go one CryoBalloon Focal Ablation treatment
62823222|NCT05923125|EXPERIMENTAL|Healthy Adults|Participants engage in a maximal exercise test. Before and after this test, blood samples are collected. At a separate, optional control visit, blood samples are collected as during the exercise visit, but participants do not participate in an exercise protocol.
62823223|NCT04762290|ACTIVE_COMPARATOR|Active Group|This group will receive the intervention in the first 10 weeks of the study. The intervention is a dance intervention that consists of a series of expressive movements.
62823224|NCT04762290|OTHER|Waitlist Control|This group will receive the intervention in the second 10 weeks of the study (after the active group and after pre-post assessments in the first 10 weeks during the time of no intervention).
62823225|NCT02514135||Elevated Intra-abdominal Pressure|Patients with intra-abdominal pressure \> 12 mmHg at any time throughout admission
62823226|NCT02514135||Normal Intra-abdominal Pressure|Patients with intra-abdominal pressure \< 12 mmHg throughout admission
62823227|NCT06569901|EXPERIMENTAL|Cluster A|Cluster A will participate in the Hope Intervention shortly after randomization. Prior the intervention the participants will serve as controls.
62435503|NCT02867020|EXPERIMENTAL|APALUTAMIDE monotherapy|o APALUTAMIDE administered at a single 240 mg daily oral dose (4 x 60 mg tablets)
62435504|NCT02867020|EXPERIMENTAL|Abiraterone acetate + Prednisone + APALUTAMIDE|"* Abiraterone administered at a single 1000 mg daily oral dose (4 x 250 mg tablets)~* Prednisone administered at a 5 mg twice daily oral dose~* APALUTAMIDE administered at a single 240 mg daily oral dose (4 x 60 mg tablets)"
62435505|NCT00580983|EXPERIMENTAL|Chemo-IMRT|"Chemotherapy:~Chemotherapy will consist of Paclitaxel 30mg/m² IV over 1 hour, followed by Carboplatin (AUC 1) IV over 30 minutes, or Carboplatin 100mg/m² per IV over 30 minutes or Cisplatin 100mg/m² per IV over 1 hour, or Cisplatin (80mg/m²) or Carboplatin (AUC 5) IV on day 1 and 5-Fluorouracil (1000mg/m²) as a 24-hour continuous infusion, daily x 4 days.~Intensity-modulated Radiation Therapy (IMRT):~Primary RT: 70 Gy to gross disease and 56-63 Gy to subclinical disease in 35 fractions.~Post-operative RT: 64 Gy to high-risk targets (postoperative tumor bed, first-echelon nodes) and 57.6 Gy to low-risk targets, in 32 fractions."
62601961|NCT05766345|EXPERIMENTAL|BCG vaccine|BCG-Vaccine SSI \[Statens Serum Institut\]) Danish strain 1331 0.1ml (=0.0075mg) One-time vaccination intradermally
62823228|NCT06569901|EXPERIMENTAL|Cluster B|Cluster B will participate in the Hope Intervention when Cluster A ends, approximately four weeks after randomization. Prior the intervention the participants will serve as controls.
62823229|NCT06569901|EXPERIMENTAL|Cluster C|Cluster C will participate in the Hope Intervention when Cluster B ends, approximately eight weeks after randomization. Prior the intervention the participants will serve as controls.
62823230|NCT06569901|EXPERIMENTAL|Cluster D|Cluster D will participate in the Hope Intervention when Cluster C ends, approximately 12 weeks after randomization. Prior the intervention the participants will serve as controls.
62245164|NCT06734299|EXPERIMENTAL|Sunscreen B|"At each visit, each enrolled subject will be randomly assigned 1 of the 3 Sunscreens to apply to both lower legs (between the knee and ankle) and then her full face. The subject will cleanse her hands with soap and water between the lower legs and face Sunscreen applications.~After lower legs and facial Sunscreen applications are completed, a trained designee will delineate six 4 cm x 4 cm test sites on the subject's volar forearms (3 test sites per volar forearm). Then a trained designee will apply the assigned Sunscreen to the designated test sites in a consistent manner at a randomly assigned dose density of 0.25, 0.50, 0.75, 1.00, 1.50, and 2.00 mg/cm2 (± 10%) per the randomization schedule using a 1cc tuberculin syringe (without a needle) or pipette and a clean finger cot for approximately 20 to 50 seconds."
62435506|NCT06278402|EXPERIMENTAL|Tofacitinib|tofacitinib 5mg twice daily for 6 months
62435507|NCT02791659|ACTIVE_COMPARATOR|Left lateral decubitus|In this group, the position will be assigned to Left lateral decubitus during ERCP. The radiation from fluoroscopy will be adjusted by automatic beam adjustment function to obtain the image quality.
62435508|NCT02791659|EXPERIMENTAL|Prone|In this group, the position will be assigned to Prone during ERCP. The radiation from fluoroscopy will be adjusted by automatic beam adjustment function to obtain the image quality.
62435509|NCT00660790||Patients with Type 2 Diabetes|diabetic subjects, above targets
62435510|NCT05817526|ACTIVE_COMPARATOR|BMAC/ collagen|Bone marrow aspirate concentrate loaded on collagen utilization for filling peri-implant gap around immediate dental implants in the Maxillary esthetic zone
62435511|NCT05817526|ACTIVE_COMPARATOR|Autograft|Autograft harvested from chin utilization for filling peri-implant gap around immediate dental implants in the Maxillary esthetic zone
62435512|NCT03658278|EXPERIMENTAL|Nutritional supplement group|Subjects in this group will be asked to consume the nutritional supplement on a daily basis, in addition to standard nutrition. Subjects will have pain medication and postoperative therapies per standard of care.
62435513|NCT03658278|NO_INTERVENTION|Standard nutrition group|Subjects in this group will have standard nutrition provided per dietitian recommendation. Subjects will have pain medication and postoperative therapies per standard of care.
62435514|NCT05619042||Presence / absence of CAC|Participants with or without a level/extension of CAC
62435515|NCT02945280|EXPERIMENTAL|patients with acute UEDVT|Patients will receive 10 mg PO apixaban for 7 days and then 5 mg PO for 11 weeks, for a total of 12 weeks of treatment.
62601962|NCT05766345|PLACEBO_COMPARATOR|Placebo vaccine|0.9% NaCl placebo 0.1ml One-time vaccination intradermally
62601963|NCT00633776|EXPERIMENTAL|1|Formoterol fumarate 20 mcg (Perforomist) nebulized via Pari C nebulizer at Test Visit 1; Formoterol 12 mcg (Foradil) via aerosolizer dry powder inhaler at Test Visit 2
62823231|NCT06569901|EXPERIMENTAL|Cluster E|Cluster E will participate in the Hope Intervention when Cluster D ends, approximately 16 weeks after randomization. Prior the intervention the participants will serve as controls.
62823232|NCT05522153|EXPERIMENTAL|Arista group|this group of randomized patients will receive 5 grams of arista hemostatic powder intra-operatively in their wound in addition to 1 gram of IV transexemic acid prior to incision
62823233|NCT05522153|NO_INTERVENTION|control group|this group of randomized patients will receive just the 1 gram of IV transexemic acid prior to incision
62823234|NCT06358612|EXPERIMENTAL|Stress Balls|Patients given a stress ball in each hand.
62435516|NCT00300092|NO_INTERVENTION|No antibioitcs|Group 1 received no antibiotics
62435517|NCT00300092|ACTIVE_COMPARATOR|Cephalexin|Group 2 received cephalexin at 50 mg/kg divided 3 times daily for 7 days
62435518|NCT02048397|OTHER|Pulmonary Rehabilitation (PRP)|Pulmonary Rehabilitation (PRP)
62435519|NCT02048397|OTHER|Pulmonary Rehabilitation plus oral nutritional supplement|Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB)
62435520|NCT04203706|EXPERIMENTAL|Normal-weight subjects|
62435521|NCT00830063|EXPERIMENTAL|1|
62435522|NCT00830063|EXPERIMENTAL|2|
62435523|NCT00830063|ACTIVE_COMPARATOR|3|
62435524|NCT00830063|PLACEBO_COMPARATOR|4|
62435525|NCT01676584|PLACEBO_COMPARATOR|Placebo|
62435526|NCT01676584|EXPERIMENTAL|RO6811135|
62435527|NCT03365921|EXPERIMENTAL|Hepatitis E vaccine lot 1|
62435528|NCT03365921|EXPERIMENTAL|Hepatitis E vaccine lot 2|
62435529|NCT03365921|EXPERIMENTAL|Hepatitis E vaccine lot 3|
62601964|NCT00633776|ACTIVE_COMPARATOR|2|Formoterol fumarate 12 mcg (Foradil) via aerosolizer dry powder inhaler at Test Visit 1; Formoterol fumarate 20 mcg (Perforomist) nebulized via Pari C nebulizer at Test Visit 2
62823235|NCT06358612|NO_INTERVENTION|No Stress Balls|Patients NOT given a stress ball in each hand.
62823236|NCT00262340|EXPERIMENTAL|1|This arm will have treatment changed based on measures of inflammation
62823237|NCT00262340|ACTIVE_COMPARATOR|2|Treatment will be changed on the basis of reported asthma symptoms
62435530|NCT06537492|EXPERIMENTAL|REBOA|In this quasi-experimental pilot study, a Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) will be introduced by a specifically dedicated team with physicians trained in this practice. In order to allow a chance for return of spontaneous circulation (ROSC) with standard care, REBOA will be placed after 10 minutes of conventional CPR. Conventional CPR will be performed using innovative devices to enhance circulation and cerebral perfusion pressure during CPR, including progressive elevation of the head and thorax, an active chest compression device, and an impedance threshold valve.
62435531|NCT02177097||40 patients (uTHA)|Patients undergoing primary uncemented total hip arthroplasty surgery.
62042246|NCT03575273|ACTIVE_COMPARATOR|Healthy controls|Healthy controls without history of opioid use will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
62042247|NCT05125770||new crown vaccination|Collect all the couples who gave birth in Ditan Hospital or one of the mothers and newborns who were injected with the new crown vaccine during the peri-pregnancy period as the observation group
62042248|NCT05125770||non new crown vaccination|Collect the pregnant women and newborns who were not vaccinated with the new crown vaccine during the peri-pregnancy of the couples who gave birth in our hospital during the same period as the control group
62435532|NCT02177097||40 patients (hTHA)|40 patients undergoing primary hybrid total hip replacement surgery.
62435533|NCT02177097||40 patients (TKA)|40 patients undergoing total knee replacement surgery.
62435534|NCT05947552||Chronic kidney disease Patients|Chronic kidney Disease Patients stage 3 to stage 5
62435535|NCT06048328|EXPERIMENTAL|Intervention|peer-led, multi-session advocacy training group intervention
62823238|NCT06306105|PLACEBO_COMPARATOR|placebo drink|
62823239|NCT06306105|EXPERIMENTAL|Marine Collagen Peptides drinks|
62042249|NCT02696421||Non diabetic, non obese|
62042250|NCT02696421||Non diabetic obese|
62435536|NCT06048328|NO_INTERVENTION|Wait-list control|Usual care/no intervention
62435537|NCT00586300|ACTIVE_COMPARATOR|1|Physical training program
62435538|NCT00586300|ACTIVE_COMPARATOR|2|Self-management training program
62435539|NCT00586300|ACTIVE_COMPARATOR|3|Physical and self-management training programs
62435540|NCT04854694|EXPERIMENTAL|All Subjects|"All participants will be fit tested for the masks to ensure that the appropriate size is used. Some participants will wear the FaceView Mask™ (first) for 5 minutes before wearing the conventional surgical N95 respirator for 5 minutes. Others will wear the conventional surgical N95 respirator (first) for 5 minutes before wearing the FaceView Mask™ for 5 minutes.~All subjects will complete the study survey after exposure to the interventions."
62435541|NCT02971605|EXPERIMENTAL|Psilocybin|Participants will be administered a 25 mg/70 kg dose of psilocybin
62435542|NCT00111189|EXPERIMENTAL|001|Paliperidone Palmitate 25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
62435543|NCT00111189|PLACEBO_COMPARATOR|002|Placebo Placebo every 4 wk up to 24 mo
62435544|NCT05478811|ACTIVE_COMPARATOR|Er,Cr:YSSG laser|NaOCl, Er,Cr:YSSG will be activated by laser during the final irrigation
62435545|NCT05478811|ACTIVE_COMPARATOR|Control|Routine final irrigation procedure will be done, NaOCl will not be activated by any method.
62435546|NCT03843437|EXPERIMENTAL|Tencel Therapeutic Garments|Children in this group will wear Tencel Therapeutic Garments
62435547|NCT03843437|PLACEBO_COMPARATOR|Cotton Therapeutic Garments|Children in this group will wear Cotton Therapeutic Garments
62823240|NCT06586476|NO_INTERVENTION|Control|Standard of care, which includes in-clinic urotherapy at evaluation and 30-minutes psychotherapy sessions (every 3 weeks).
62823241|NCT06586476|EXPERIMENTAL|Nightly Timed Awakening|Control-arm therapy plus a nightly timed-awakening intervention.
62823242|NCT05562466|EXPERIMENTAL|QMF149|QMF149 75/40μg
62823243|NCT05562466|ACTIVE_COMPARATOR|Budesonide|Budesonide 200μg o.d
62823244|NCT04430452|EXPERIMENTAL|Arm I (hypofractionated RT, durvalumab)|Patients undergo standard of care hypofractionated RT over 5 fractions QD for 5 days in the absence of disease progression or unacceptable toxicity. Within 3-10 days after completion of RT, patients receive durvalumab IV over 1 hour on day 1. Treatment repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62849238|NCT06135298|EXPERIMENTAL|OSTEOSYNTHESIS + LOCAL CERAMENT BONE VOID FILLER (BVF) + SYSTEMIC ZOLEDRONIC ACID|During osteosynthesis, cerament BVF will be used for the augmentation of the helical blade. Then, systemic Zoledronic acid 5mg will be given intravenously at day 5 after surgery, during hospitalization.
62849239|NCT02120040|OTHER|Hemangioblastoma (HB) of the Central nervous system (CNS)|
62849240|NCT04708977|ACTIVE_COMPARATOR|Group 1: Indirect Decompression|Lateral lumbar interbody fusion (LLIF), with indirect decompression
62849241|NCT04708977|ACTIVE_COMPARATOR|Group 2: Direct Decompression|Lateral lumbar interbody fusion (LLIF), with direct decompression
62849242|NCT01741740||retrospective surgical patients|consecutive elective umbilical hernia repair patients during two years from two hospitals,- retrospective id with prospective follow up
62849243|NCT04502173||Training|Study participants trained on how to use the Ellavi intra-uterine balloon tamponade via virtual webinar training. Feedback on training course elements will be obtained for future improvements prior to scaling.
62849244|NCT04502173||Managing PPH|Study participants who provided refractory PPH care using an Ellavi UBT device will give feedback on the barriers and facilitators to use of the newly registered, low-cost medical device.
62849245|NCT03613142|EXPERIMENTAL|Double tract anatomosis|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.
62823245|NCT04430452|EXPERIMENTAL|Arm II (hypofractionated RT, durvalumab, tremelimumab)|Patients undergo standard of care hypofractionated RT over 5 fractions QD for 5 days in the absence of disease progression or unacceptable toxicity. Within 3-10 days after completion of RT, patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment with durvalumab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who complete the first dose of tremelimumab and demonstrate clinical benefit based upon radiographic tumor regression and/or other clinical response without progression for at least 6 cycles or 6 months on treatment, whichever is shorter, and subsequently have evidence of progressive disease during the durvalumab monotherapy portion may receive a repeat dose of tremelimumab at the next scheduled cycle of treatment with durvalumab per physician discretion.
62823246|NCT05052125|ACTIVE_COMPARATOR|High oxygen saturation|Peripheral oxygen saturation level \>94% Intervention: Drug: Oxygen gas
62245165|NCT06734299|EXPERIMENTAL|Sunscreen C|"At each visit, each enrolled subject will be randomly assigned 1 of the 3 Sunscreens to apply to both lower legs (between the knee and ankle) and then her full face. The subject will cleanse her hands with soap and water between the lower legs and face Sunscreen applications.~After lower legs and facial Sunscreen applications are completed, a trained designee will delineate six 4 cm x 4 cm test sites on the subject's volar forearms (3 test sites per volar forearm). Then a trained designee will apply the assigned Sunscreen to the designated test sites in a consistent manner at a randomly assigned dose density of 0.25, 0.50, 0.75, 1.00, 1.50, and 2.00 mg/cm2 (± 10%) per the randomization schedule using a 1cc tuberculin syringe (without a needle) or pipette and a clean finger cot for approximately 20 to 50 seconds."
62245166|NCT06107933||City Mother-Infant Pairs|Mother-infant pairs living in a Baltimore City, Maryland zip code exposed to micro and nano plastics.
62245167|NCT06107933||County Mother-Infant Pairs|Mother-infant pairs living in a Baltimore County, Maryland zip code exposed to micro and nano plastics.
62245168|NCT02901925|EXPERIMENTAL|ABY-029 1X dose group|ABY-029 will be administered at the 1X dose level prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.
62823247|NCT05052125|ACTIVE_COMPARATOR|Low oxygen saturation|Peripheral oxygen saturation level 88-92% Intervention: Drug: Oxygen gas
62823248|NCT03090360|PLACEBO_COMPARATOR|Placebo comparator (Control)|Starter infant formula with a probiotic and without a prebiotic. Volumes of feed depend on age, weight and appetite.
62823249|NCT03090360|EXPERIMENTAL|Experimental Formula (Test)|Starter infant formula with a probiotic and prebiotic. Volumes of feed depend on age, weight and appetite.
62245169|NCT02901925|EXPERIMENTAL|ABY-029 3X dose group|ABY-029 will be administered at the 3X dose level prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.
62435548|NCT05326087|ACTIVE_COMPARATOR|Antagonist group|Women will receive antagonist (Cetrotide 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
62823250|NCT03090360|NO_INTERVENTION|Breastfed reference group|Breastfed reference group
62823251|NCT06602375|EXPERIMENTAL|Standard care plus physical therapy|Participants randomized to this group will receive standard care from their treating dental provider. In addition, they will receive routine physical therapy interventions over a 6-week (+/- 2 week) period. Study participants will receive treatments based on their clinical examination. Subjects will attend up to 12 sessions over 6-weeks (+/- 2 weeks). The initial physical therapy visit will be 60-minutes long with all subsequent appointments being 30-minutes, to include any booster sessions. The interventions will be pragmatic in nature, with provided treatment being specific to the subject's specific complaints, goals, and examination identified impairments.
62245170|NCT02901925|EXPERIMENTAL|ABY-029 6X dose group|ABY-029 will be administered at the 6X dose level prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.
62435549|NCT05326087|EXPERIMENTAL|PPOS group|Women will receive oral MPA 10mg qd from Day 3 till the day of ovulation trigger.
62042251|NCT02696421||Diabetic|
62042252|NCT01519531|EXPERIMENTAL|VIA-3196|
62245171|NCT03509636|EXPERIMENTAL|Treatment|Fluzoparib capsule
62245172|NCT06387394|EXPERIMENTAL|Double-Blind Period: BOTOX|Participants will receive BOTOX injections across both the right and left masseter muscle on Day 1.
62245173|NCT06387394|PLACEBO_COMPARATOR|Double-Blind Period: Placebo|Participants will receive placebo injections across both the right and left masseter muscle on Day 1.
62245174|NCT06387394|EXPERIMENTAL|Open-Label Period: BOTOX|Participants who are eligible for re-treatment will receive BOTOX injections on either the Day 180, 210, 240, or 270 visit and will be followed for up to 6 months.
62435550|NCT04409002|EXPERIMENTAL|Niraparib+Dostarlimab + Radiation|"Each study treatment cycle lasts 21 days~* Niraparib oral, once a day, predetermined dose.Dosing will commence on cycle 1 day 1 and will continue until the participant is taken off treatment~* Dostarlimab by intravenous infusion once every cycle for as long as they remain on the study~* Radiation therapy on every other week day of cycle 2 only. Radiation will begin on Cycle 2 Day 1"
62435551|NCT03113058|EXPERIMENTAL|study group|
62435552|NCT05452538||cancer surgery|all adult patients operated at the Léon Bérard Centre for cancer surgery (excluding endoscopy, interventional radiology, brachytherapy, vascular access)
62042253|NCT01519531|PLACEBO_COMPARATOR|Placebo|Multiple, ascending dosing groups (cohorts) will be evaluated.
62823252|NCT06602375|ACTIVE_COMPARATOR|Standard Care|Those randomized to the standard care (control) group will follow the plan of care determined by their treating dental provider. This group will receive standard (routine) care from the dental provider for the treatment of TMD. These decisions will be based on the clinical judgment of the dental provider, as is customary with routine care for TMD.
62823253|NCT06600503|EXPERIMENTAL|application inttervention group|The experimental group will receive standard postoperative care, including chest rehabilitation, a mobile application for remote self-training every day after surgery, and an interactive healthcare web platform for health education.
62823254|NCT06600503|ACTIVE_COMPARATOR|Usual care group|The usual care group will receive standard postoperative care, including chest rehabilitation and an interactive healthcare web platform for health education
62823255|NCT06559696|EXPERIMENTAL|internal mammary nodal irradiation|chest wall/whole breast and supraclavicular+-axillary nodal plus internal mammary nodal irradiation
62042254|NCT04133155||nab-P + GEM|Nab-paclitaxel plus gemcitabine
62245175|NCT05937347|EXPERIMENTAL|TAU + UP4H|UP4H is a face-to-face and virtual non-pharmacological program based on Mindfulness Training and Cognitive Training.
62245176|NCT05937347|ACTIVE_COMPARATOR|TAU + M4H|M4H is a face-to-face non-pharmacological program based on Mindfulness Training.
62435553|NCT03465228|EXPERIMENTAL|Training group|This group will do the Deep Water Running, with intervals and continuous training twice a week, and before each session, will be applied the LED equipment. The training will be thirty minutes and will be controlled by heart rate, 70% to 80% maximum heart rate in continuous training, and maximum heart rate in intervals training.
62435554|NCT03465228|EXPERIMENTAL|Training and LED group|This group will receive the photobiomodulation treatment and the same training model of training group.
62435555|NCT03465228|EXPERIMENTAL|LED group|This group will receive only the photobiomodulation treatment with 30 seconds of light emitting in four points of lumbar region.
62435556|NCT02958540|EXPERIMENTAL|SynGEM low dose|Group 1: 18 subjects receiving SynGEM low dose
62601965|NCT05141643|EXPERIMENTAL|Participants with pancreatic ductal adenocarcinoma (PDAC)|Participants will have histologically-confirmed pancreatic ductal adenocarcinoma (PDAC). The experimental design of this study is to perform a single \[18F\]-FAC PET scan prior to the administration of chemotherapy with an optional second \[18F\]-FAC PET scan procedure during SOC treatment to observe changes in tumor uptake and biodistribution. Patients will be offered a second \[18F\]-FAC PET scan procedure during their SOC treatment. This second scan will be optional.
62601966|NCT05451537||Sepsis associated encephalopathy group|Patients were diagnosed with sepsis related encephalopathy
62601967|NCT05451537||None sepsis associated encephalopathy group|Patients were not diagnosed with sepsis related encephalopathy
62823256|NCT06559696|ACTIVE_COMPARATOR|No internal mammary node irradiation|chest wall/whole breast and supraclavicular+-axillary nodal irradiation
62823257|NCT06601790|EXPERIMENTAL|intervention group|The Smart Homespital system can be applied for the first 3 months (12 weeks), and then the primary and secondary variables will be evaluated at 3, 6, 9months.
62042255|NCT05977231||Bladder training (BT)|Data obtained before and after the training.
62042256|NCT05977231||biofeedback-assisted pelvic floor muscle training (bPFMT)|Data obtained before and after the training.
62601968|NCT03053648|EXPERIMENTAL|Self-acupressure Group|Subjects in this group will attend two weekly 120-minute self-acupressure training sessions in a classroom at the School of Nursing, the Hong Kong Polytechnic University. The subjects will be instructed on how to perform the self-acupressure treatment by a trained instructor. To enhance interaction and ensure the quality of teaching, each course will be conducted in a small group of 6 participants. Subjects will perform self-acupressure daily for 4 consecutive weeks.
62823258|NCT06601790|EXPERIMENTAL|attention-waitlist control group|The waiting list-control group will receive general medical services for the first 3 months and will receive the Smart Homespital system for 3-6 months. Primary and secondary variables will be evaluated between 3, 6, and 9 months.
62042257|NCT05977231||intra-vaginal electric stimulation (iVES)|Data obtained before and after the training.
62042258|NCT05977231||BT+bPFMT|Data obtained before and after the training.
62245177|NCT05937347|ACTIVE_COMPARATOR|TAU + CT|CT is a virtual non-pharmacological program based on Cognitive Training.
62435557|NCT02958540|EXPERIMENTAL|SynGEM high dose|Group 2: 18 subjects receiving SynGEM high dose
62435558|NCT02958540|PLACEBO_COMPARATOR|placebo|12 subjects receiving placebo
62435559|NCT04088578|EXPERIMENTAL|Vagus nerve stimulation (VNS)|Stroke and control subjects will undergo 3 testing sessions and 8 training sessions in these experiments. Subjects will hold a force transducer between the index finger and thumb to control the path of an object through targets displayed on a computer monitor. VNS will be delivered when a minimum level of accuracy has been achieved.
62823259|NCT01772472|ACTIVE_COMPARATOR|Trastuzumab|
62823260|NCT01772472|EXPERIMENTAL|Trastuzumab emtansine|
62823261|NCT04897997||non smokers|never having smoked patients
62823262|NCT04897997||smokers|actively smoking patients
62042259|NCT05977231||BT+iVES|Data obtained before and after the training.
62042260|NCT05977231||bPFMT+iVES|Data obtained before and after the training.
62042261|NCT01790269||fingolimod treated patients|Indication for on-label treatment with fingolimod (Gilenya®) according to the current approval
62042262|NCT05616962|OTHER|Vasculera|Vasculera 630 milligrams, two times per day
62245178|NCT05937347|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Treatment as Usual (TAU) consisted of the prescribed drugs adapted to the ADHD symptomatic profile of each child.
62245179|NCT02634203|EXPERIMENTAL|Balloon Pulmonary Angioplasty (BPA)|Non-operable patients with CTEPH allocated to BPA arm
62601969|NCT03053648|ACTIVE_COMPARATOR|Sleep Hygiene Education Group|To control the contact time with professional person in the treatment group, participants in this group will receive two sessions of 120-minute sleep hygiene training session. The participants will be asked to follow the health hygiene instructions daily for 4 consecutive weeks.
62245180|NCT02634203|ACTIVE_COMPARATOR|Riociguat|Non-operable patients with CTEPH allocated to Riociguat arm
62245181|NCT05714956|EXPERIMENTAL|Intervention|eMB consists of 8 sessions that correspond with key cognitive-behavioral therapy (CBT) elements: pleasant activities, thoughts, and social support/contact with others. Integrated throughout eMB are activities and skills based on attachment theory that emphasize how each CBT module relates to promoting a strong, nurturing connection between parent and child. eMB includes informational pages, short audio/video clips, images of infants and pregnant women, and worksheets for participants to enter personalized information in response to the lesson content. eMB is individually guided without facilitation, b) clients control the pace by which they review online content, c) and clients can review online content as many times as they like. Participants who receive eMB will also complete assessments at baseline, 1 week post-intervention, and 3 months post-intervention.
62245182|NCT05714956|NO_INTERVENTION|Home Visiting Usual Care|Core content of home visiting program services typically address: (a) preparation for childbirth and having a young child in the home, (b) provision of emotional and tangible \[e.g., diapers, formula\] support, (c) discussion of infant and young child development, (d) linkages to prenatal and pediatric care, and (e) referrals to community resources for social and health services. Those receiving usual care home visiting will not receive any eMB or MB course content. Once study participation is completed, the home visitor may introduce eMB to the participant if they are interested. Participants in the control group will also complete assessments at baseline, 1 week post-intervention (i.e., following 8 weeks of usual home visiting services), and 3 months post-intervention (i.e.g, following 8 weeks of usual home visiting services).
62245183|NCT06736574|EXPERIMENTAL|Omecamtiv Mecarbil|Participants randomized to omecamtiv mecarbil will be dosed based on their omecamtiv mecarbil plasma concentration at 25, 37.5 or 50 mg twice daily until at least 850 primary composite endpoint events have occurred.
62601970|NCT06622967|EXPERIMENTAL|CadAI-B intervention group|Participants in this arm will receive the CadAI-B system for the detection of lesions. The AI-based tool will assist healthcare professionals in identifying lesions through enhanced image analysis.
62601971|NCT04473820|ACTIVE_COMPARATOR|Vapocoolant spray|Patients in this arm will receive vapocoolant spray before IV cannulation.
62601972|NCT04473820|ACTIVE_COMPARATOR|Lidocaine-Prilocaine cream|Patients in this arm will receive Lidocaine-Prilocaine cream before IV cannulation.
62601973|NCT00951834|EXPERIMENTAL|Epigallocatechin-Gallate|"* Months 1-3: 200 mg EGCG/die (200-0-0 mg)~* Months 4-6: 400 mg EGCG/die (200-0-200 mg)~* Months 7-9: 600 mg EGCG/die (400-0-200 mg)~* Months 10-18: 800 mg EGCG/die (400-0-400 mg)~add-on to Donepezil."
62601974|NCT00951834|PLACEBO_COMPARATOR|Placebo|add-on to Donepezil.
62245184|NCT06736574|PLACEBO_COMPARATOR|Placebo|Participants randomized to placebo will receive placebo twice daily until at least 850 primary composite endpoint events have occurred.
62245185|NCT04679753|ACTIVE_COMPARATOR|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)
62245186|NCT04679753|ACTIVE_COMPARATOR|Brainsway DTMS with High Frequency Stimulation (HF)|Brainsway DTMS with High Frequency Stimulation (HF)
62245187|NCT06113471|EXPERIMENTAL|Experimental: Povorcitinib Dose A|Participants will receive Povorcitinib Dose A for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.
62245188|NCT06113471|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.
62245189|NCT04275297|EXPERIMENTAL|Psychosocial Treatment|The psychosocial self-management intervention consists of 8 weekly 50-minute individual visits with an assigned trained therapist. Sessions follow a structured protocol that has been developed with the patient population. Treatment modules are individualized and include topics such as pain coping strategies, relaxation training, education on IC/BPS, and communication strategies.
62245190|NCT04275297|PLACEBO_COMPARATOR|Attention Control|The attention control condition consists of 8 weekly telephone calls with a study interventionist. Sessions will occur via scheduled telephone calls and follow a structured procedure. Telephone calls are designed to monitor symptoms and overall wellness. Each week, participants will be asked about current symptoms, flare patterns, and physical and emotional wellbeing.
62245191|NCT05655091|ACTIVE_COMPARATOR|intervention group|Subjects randomized into the intervention group will receive FLU or CZO respectively as continuous infusion as soon as targeted S. aureus treatment is initiated (+24h). The choice of antibiotic is determined by the treating physician in accordance to the recommendations of the infectious diseases (ID) specialists. The loading dose and dose adjustments of FLU and CZO will be determined by the use of a pharmacokinetic modelling application. The maximum daily dose will not exceed the daily licensed dose according to the Summary of Product Characteristics (SmPC).
62435560|NCT04088578|SHAM_COMPARATOR|Sham stimulation|Stroke and control subjects will undergo 3 testing sessions and 8 training sessions in these experiments. Subjects will hold a force transducer between the index finger and thumb to control the path of an object through targets displayed on a computer monitor. Sham stimulation will be delivered when a minimum level of accuracy has been achieved.
62435561|NCT04878978|ACTIVE_COMPARATOR|Routine care|Women who present with PPROM or threatened PTL and have routine care
62601975|NCT01616849|EXPERIMENTAL|PF+ Nimotuzumab|Patients treated with cisplatin and 5-Fu combined with nimotuzumab
62601976|NCT03848806|EXPERIMENTAL|HAT1 topical|HAT1 topical cream will come in a blinded bottle. Patients, investigators, and the trial sponsor will be unaware of the trial group assignments. Packaging and labeling of the test and comparator products will be identical to maintain the blind.
62601977|NCT03848806|ACTIVE_COMPARATOR|Calcipotriol|Calcipotriol topical cream will come in a blinded bottle. Patients, investigators, and the trial sponsor will be unaware of the trial group assignments. Packaging and labeling of the test and comparator products will be identical to maintain the blind.
62601978|NCT00386425|EXPERIMENTAL|Standard therapy|24 microgram/kilogram/hour (mcg/kg/hr) for 24 hours, followed by 24 mcg/kg/hr for an additional 72 hours
62601979|NCT00386425|EXPERIMENTAL|Alternative therapy:moderate protein C deficiency|24 mcg/kg/hr for 24 hours, followed by 24 mcg/kg/hr for an additional 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)
62823263|NCT04897997||acute coronary syndrome|patients with the coronary indication of ACS
62823264|NCT04897997||stable|patients with the coronary indication of stable or silent ischemia
62823265|NCT05773664|EXPERIMENTAL|Arm I (azeliragon, dexamethasone)|Patients receive azeliragon PO and dexamethasone PO or IV throughout the study. Patients also undergo collection of cavity fluid and blood samples, CT scan, and brain MRI with or without contrast throughout the study.
62823266|NCT05773664|ACTIVE_COMPARATOR|Arm II (dexamethasone)|Patients receive dexamethasone PO or IV throughout the study. Patients also undergo collection of cavity fluid and blood samples, CT scan, and brain MRI with or without contrast throughout the study.
62823267|NCT04786119|EXPERIMENTAL|CORI Robotics|Subjects having robotic assisted knee arthroplasty as decided by their doctor and treated with CORI Robotics.
62823268|NCT06587477||Male childhood and adolescent cancer survivors|Male childhood and adolescent cancer survivors
62823269|NCT06587477||Controls|Aged-matched controls from men attending the Family Planning Association for premarital check-up
62823270|NCT03255603|EXPERIMENTAL|Modified potato starch|Modified potato starch is a resistant starch type IV and will be used as an experimental arm.
62823271|NCT03255603|EXPERIMENTAL|Modified corn starch|Modified corn starch is a resistant starch type IV and will be used as an experimental arm.
62823272|NCT03255603|EXPERIMENTAL|Modified tapioca starch|Modified tapioca starch is a resistant starch type IV and will be used as an experimental arm.
62823273|NCT03255603|PLACEBO_COMPARATOR|Corn starch|Corn starch is digestible and will therefore will be used as a placebo control for the study.
62823274|NCT05307575||Post-COVID syndrome (PCS) Severe COVID-19|Severe COVID-19 with PCS with cognitive complains
62823275|NCT05307575||Post-COVID syndrome (PCS) Mild COVID-19|Mild COVID-19 with PCS with cognitive complains
62042263|NCT06576362|EXPERIMENTAL|Echoguided transuterine vaginal biopsy|Echoguided transuterine vaginal biopsy on women presenting to hospital with a surgical indication for myomectomy or hysterectomy
62042264|NCT06733727|ACTIVE_COMPARATOR|Letrozole|Letrozole 10mg per day from day 1-3 orally, placebo mifepristone Sublingual misoprostol 800 microgram on day 3
62245192|NCT05655091|ACTIVE_COMPARATOR|control group|Subjects randomized to the control group will receive standard of care intermittent bolus infusion FLU or CZO dosed according to the recommendations of the ID specialist and treating physician. Drug concentration will be analysed directly, but the results will not be communicated to the study team or a physician involved in the treatment of the patient. No TDM-guided dose adjustment will be performed in the control group.
62245193|NCT06734611|EXPERIMENTAL|FISFA arm|Dietary Supplement: fortified iodized salt with folic acid (FISFA)
62601980|NCT00386425|EXPERIMENTAL|Alternative therapy:severe protein C deficiency|24 mcg/kg/hr for 24 hours, followed by 30 or 36 mcg/kg/hr for 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)
62601981|NCT04864158|EXPERIMENTAL|RSA-group|Surgery
62823276|NCT05307575||Controls|Healthy adult controls
62823277|NCT06593717|EXPERIMENTAL|Entire Study Population|The entire study population will undergo serial hemodynamic assessments throughout the course of ECMO therapy. Hemodynamic variables are obtained using transthoracic echocardiography, uncalibrated pulse contour analysis, and optionally - depending on device availability - transpulmonary thermodilution, bioreactance and esophageal doppler. Maneuvers for assessing volume responsiveness include passive leg raising (PLR), respiratory pulse pressure variation (PPV), stroke volume variation (SVV), inferior vena cava ultrasound (IVC), and end-inspiratory or end-expiratory occlusion tests.
62042265|NCT06733727|ACTIVE_COMPARATOR|Mifepristone|Mifepristone 200mg orally on day 1, placebo letrozole on day 1-3 Sublingual misoprostol 800 microgram on day 3
62042266|NCT00483184|PLACEBO_COMPARATOR|1|(placebo)0 IU IFNa
62042267|NCT00483184|EXPERIMENTAL|2|(Veldona)500 IU IFNα bid
62245194|NCT05084833|EXPERIMENTAL|Group1: Control (C)|Electronic educational materials (C).
62245195|NCT05084833|EXPERIMENTAL|Group 2: Patient Activation (PA)|C + patient activation (PA) consisting of interactive tailored text messages with links to videos and resources
62245196|NCT05084833|EXPERIMENTAL|Group 3: Patient Activation and PCP Activation (PA + PCP)|C + PA + PCP activation (PA+PCP) with physician materials about colorectal cancer risk in this population
62245197|NCT06094504|EXPERIMENTAL|Lighting cycling (Spectral vs Conventional)|The study protocol will commence the Monday after study subject enrollment, if medically feasible, and will consist of four weeks of alternating periods of 3 days of daytime conventional (CON) hospital lighting followed by 4 days of daytime full spectrum lighting (FS) including violet and blue light wavelengths.
62823278|NCT02698215|EXPERIMENTAL|Varenicline plus Naltrexone|VAR (1 mg twice daily) + NTX (50 mg once daily)
62823279|NCT02698215|PLACEBO_COMPARATOR|Varenicline|VAR (1 mg twice daily)
62823280|NCT03548285|EXPERIMENTAL|patient with low risk|"Low-risk is defined by:~* Planning target volume (PTV) less than 10 cc, AND~* No reported smoking within 1 month from registration~Radiation Therapy will be delivered twice per week for 5 fractions (total 42.5 Gy)"
62823281|NCT03548285|EXPERIMENTAL|patient with moderate risk|"Moderate-risk is defined by:~* Planning target volume (PTV) greater than or equal to 10 cc, OR~* Smoking within 1 month from registration (no more than 1 pack per day)~Radiation Therapy will be delivered daily for 16 fraction (total 58.08 Gy)"
62823282|NCT06698289||Sarcopenia|"Patients who meet the diagnostic criteria for sarcopenia will be included in this group. The diagnosis of sarcopenia will be made using the criteria defined by the European Working Group on Sarcopenia in Older People (EWGSOP). This requires the presence of both low muscle strength (e.g. low handgrip strength) and low muscle quantity/quality (e.g. low skeletal muscle index on CT scan). Patients will further classified into stages of probable sarcopenia, sarcopenia, and severe sarcopenia based on the severity."
62042268|NCT00483184|EXPERIMENTAL|3|(Veldona)1000 IU IFNα bid
62435562|NCT04878978|EXPERIMENTAL|Amniocentesis and biofire directed antibiotic use|Women who present with PPROM or threatened PTL and randomised to amniocentesis and biofire directed antibiotic treatment
62601982|NCT04864158|EXPERIMENTAL|Exercise-group|Exercise
62601983|NCT02978391|EXPERIMENTAL|UI-EWD Hemostatic system|Patients with upper gastrointestinal bleeding treated with UI-EWD
62042269|NCT01532128|EXPERIMENTAL|Group 1|Period 1: rasagiline 1 mg Period 2: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg Period 3: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg
62042270|NCT01532128|EXPERIMENTAL|Group 2|Period 1: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg Period 2: rasagiline 1 mg Period 3: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg
62042271|NCT01532128|EXPERIMENTAL|Group 3|Period 1: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg Period 2: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg Period 3: rasagiline 1 mg
62042272|NCT02801994|EXPERIMENTAL|Ventilator settings, PAV|"A first 30-minutes recording in PSV will be performed. Dyspnea-VAS, IC-RDOS will be measured at the beginning and at the end of this period. EMG and EEG will be recorded continuously. Patients will be subsequently switched to PAV.~The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min."
62435563|NCT01614613|EXPERIMENTAL|Intended BGM Users|Subjects were assigned to subgroups according to their initial glucose levels. SUBGROUP 1 goal: safely decrease subject glucose levels during the visit. SUBGROUP 2 goal: safely raise subject glucose levels. Also, blood samples were modified to obtain glucose concentrations across the needed glucose ranges while maintaining subject safety. Staff tested the blood samples using the 6 Blood Glucose Monitoring Systems. Bayer G3/Tatsu System;Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips; Freestyle Lite® Meter and Test Strips with ZipwikTM tabs;OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips;One Touch® VerioTM Pro/One Touch® VerioTM Test Strips;Truetrack® Meter/Truetrack® Test Strips
62435564|NCT02370784|ACTIVE_COMPARATOR|Active Drug|atorvastatin 40 mg once daily for sixteen weeks
62435565|NCT02370784|PLACEBO_COMPARATOR|Placebo control|receive a placebo of similar appearance once daily for sixteen weeks
62435566|NCT01916564|ACTIVE_COMPARATOR|Same-morning whole-dose|2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy
62435567|NCT01916564|ACTIVE_COMPARATOR|Split-dose|1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy
62435568|NCT02005640||MSCT-based prothesis sizing|
62435569|NCT02005640||Echocardiographic-based prothesis sizing|
62435570|NCT01569503|EXPERIMENTAL|VSN|VNS therapy
62435571|NCT01698320|PLACEBO_COMPARATOR|Placebo MDPI-Albuterol MDPI|"During the 12-week double-blind period, participants take 2 inhalations of placebo MDPI (multi-dose dry powder inhaler), four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.~The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise."
62601984|NCT02978391|ACTIVE_COMPARATOR|epinephrine|Patients with upper gastrointestinal bleeding treated with submucosal epinephrine injection
62042273|NCT02305927|EXPERIMENTAL|Vitamin D3 (cholecalciferol)|
62042274|NCT02305927|PLACEBO_COMPARATOR|Placebo|
62042275|NCT03963674|EXPERIMENTAL|Diacutaneous fibrolysis|
62042276|NCT03963674|NO_INTERVENTION|Control|
62042277|NCT05668533|ACTIVE_COMPARATOR|1. Interscalene group|Patients received ipsilateral ultrasound-guided interscalene nerve after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg).
62042278|NCT05668533|ACTIVE_COMPARATOR|2. PENG Block|Patients received ultrasound-guided PENG block after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg).
62042279|NCT01059175|EXPERIMENTAL|CRT With Dual Site LV Pacing|Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
62042280|NCT01059175|ACTIVE_COMPARATOR|Standard CRT|Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
62042281|NCT05964478|EXPERIMENTAL|Intervention arm of schools in Nigeria and Palestine|The participating schools in this arm will receive the multi-component hand hygiene intervention package for a duration of one year
62042282|NCT05964478|NO_INTERVENTION|Control arm of schools in Nigeria and Palestine|The participating schools in this arm will not receive the multi-component hand hygiene intervention package until the conclusion of the study, which occurs one year after the completion of data collection at the endline assessment
62823283|NCT06698289||Non-sarcopenia|Patients who do not meet the diagnostic criteria for sarcopenia will be included in this group. They will have normal or above-normal muscle strength and muscle quantity/quality measurements. This group will serve as the comparison cohort to evaluate the impact of sarcopenia on surgical outcomes.
62823284|NCT06192654|EXPERIMENTAL|Small intestinal submucosa (SIS) graft urethroplasty|this group will use a small intestinal submucosa graft in urethroplasty.
62823285|NCT06192654|ACTIVE_COMPARATOR|Autologous oral bucal mucosa graft urethroplasty|this group will use an autologous oral bucal mucosa graft in urethroplasty.
62042283|NCT01338025|ACTIVE_COMPARATOR|Arm A, non-suppressive HAART regimen|"In Step 1, subjects were randomized to continue their non-suppressive HAART regimen.~In Step 2, subjects either began a new HAART regimen, continued randomized treatment, or discontinued therapy while remaining on follow-up, as decided by their provider."
62042284|NCT01338025|ACTIVE_COMPARATOR|Arm B, 3TC or FTC monotherapy|"In step 1, subjects were randomized to receive 3TC or FTC (the choice of 3TC or FTC was left to the provider).~In Step 2, subjects either began a new HAART regimen, continued randomized treatment, or discontinued therapy while remaining on follow-up, as decided by their provider."
62042285|NCT03549650|EXPERIMENTAL|Pentosan Polysulfate Na 100Mg Cap|Drug intervention of Pentosan Polysulfate Na 100Mg Cap (ELMIRON) thrice daily PO for 6 weeks, after meeting the eligibility criteria during the the two-week Screening period.
62042286|NCT03549650|PLACEBO_COMPARATOR|Placebo oral capsule|Participants will receive Placebo oral capsule, similar to (ELMIRON 100mg) thrice daily PO for 6 weeks, , after meeting the eligibility criteria during the the two-week Screening period.
62042287|NCT04760093|OTHER|Low-to-High group|As this is a crossover study, each participant will be assigned to each treatment intervention. Participants (randomly) assigned to Arm 1 will first receive low polyphenol concentration EVOO for consumption, followed by high polyphenol concentration EVOO for consumption following a 14- day washout phase.
62601985|NCT04254107|EXPERIMENTAL|SEA-TGT Monotherapy (Parts A and B)|SEA-TGT
62823286|NCT04780061|EXPERIMENTAL|Treatment|"Specific Product: Vitamin D3 50,000 IU~Formulation: Capsule. Each capsule will contain 500 mg (50,000 units) cholecalciferol (vitamin D3) Dose: One capsule on day 1 of the intervention period~Specific Product: Vitamin K2/D~Formulation: Liquid. Each 0.0285 mL drop contains 30 mcg menaquinone-7 (MK-7, vitamin K2) and 3.125 mcg (125 units) cholecalciferol (vitamin D3).~Dose: 0.114 mL (four drops) twice daily for 21 days totalling 240mcg MK-7 and 1,000 units cholecalciferol per day.~Specific Product: Vitamin C/Zinc~Formulation: Capsule. Each capsule will contain 666 mg ascorbic acid (vitamin C) and 8.3 mg of zinc acetate Dose: Three capsules three times daily for 21 days totalling 6 g ascorbic acid and 75 mg zinc acetate per day."
62823287|NCT04780061|PLACEBO_COMPARATOR|Control|"Specific Product: Vitamin D3 50,000 IU~Placebo Equivalent: microcrystalline cellulose capsule, 350 mg~Specific Product: Vitamin K2/D~Placebo Equivalent: Medium chain triglyceride oil~Specific Product: Vitamin C/Zinc~Placebo Equivalent: microcrystalline cellulose capsule, 350 mg"
62245198|NCT01005745|EXPERIMENTAL|TIL With High Dose IL-2|"Day -7 and -6: Cyclophosphamide 60 mg/kg/day I.V. in 250 ml NS over approximately 2 hours. Mesna 20 mg/kg with D5W or NS at 125 ml/hour infused intravenously over 24 hours.~Day -5 to Day -1: Fludarabine 25 mg/m\^2 intravenous piggyback (IVPB0 daily over approximately 30 minutes for 5 days.~Day 0: T cell infusion in 250-1000 ml NS over approximately 15-60 minutes depending on volume to be infused.~Days 1-5: High dose IL-2, 720,000 IU/kg IV bolus (about 15 minutes) every 8-16 hours for up to 15 doses, beginning approximately 12-16 hours after T cell infusion."
62245199|NCT03219320|PLACEBO_COMPARATOR|Placebo Oral Capsule|Up to 300 subjects: Placebo
62042288|NCT04760093|OTHER|High-to-Low group|As this is a crossover study, each participant will be assigned to each treatment intervention. Participants (randomly) assigned to Arm 2 will first receive high polyphenol concentration EVOO for consumption, followed by low polyphenol concentration EVOO for consumption following a 14- day washout phase.
62245200|NCT03219320|EXPERIMENTAL|NYX-2925|Up to 300 subjects: Multiple dose levels of NYX-2925 daily for 28 days
62042289|NCT05741216|EXPERIMENTAL|OTF Test 1|One application of ocular lubricant to each eye at night for 5 consecutive nights
62245201|NCT05944016|EXPERIMENTAL|Dapagliflozin|Dapagliflozin (standard dose 10 mg p.o. once daily).
62245202|NCT05944016|PLACEBO_COMPARATOR|Placebo|Placebo therapy.
62245203|NCT03617003|EXPERIMENTAL|phototherapy with WST11|Patients with urothelial cancer that includes involvement of the upper urinary tract and have failed prior endoscopic treatment, refuse standard treatment, or are ineligible for curative surgical resection of the kidney or ureter will be offered WST11 VTP treatment to be provided at the time of scheduled endoscopic procedure. At the time of endoscopy, patients will be treated with VTP therapy applied to the site of the tumor.
62245204|NCT03781323|EXPERIMENTAL|mFOLFOX (5-Fluorouracil Leucovorin Oxaliplatin)|"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."
62823288|NCT06705296|EXPERIMENTAL|Open label|1) Open label phase (from surgery until postoperative week 24)
62823289|NCT06705296|PLACEBO_COMPARATOR|"Double-blinded on/off phase"|"Double-blinded on/off phase (from postoperative week 25 to 33)"
62245205|NCT00813319|EXPERIMENTAL|1 - Girls OnGuard/HPV awareness|Adolescents will watch a short (10 min), interactive DVD designed to promote HPV awareness and initial GARDASIL vaccination and receive a keepsake to help them remember to return to the clinic for their second and third vaccine doses.
62245206|NCT00813319|NO_INTERVENTION|2 - General health promotion|Adolescents will watch an equally short (10 min) DVD on healthy lifestyles and behaviors. HPV awareness and vaccination will not be addressed.
62823290|NCT06705296|EXPERIMENTAL|Prolonged exposure therapy|Prolonged exposure therapy (from postoperative week 34to 44)
62823291|NCT06705296|EXPERIMENTAL|Closed-loop DBS|Closed-loop DBS (from postoperative week 45 to 60).
62823292|NCT04058717|EXPERIMENTAL|NNC cigarettes + High Nicotine Containing E-cigarette|Participants are provided with normal nicotine content (NNC) cigarettes (11.6 mg nicotine/cigarette) plus e-cigarette with high nicotine e-liquid.
62823293|NCT04058717|EXPERIMENTAL|NNC cigarettes + Zero Nicotine Containing E-cigarette|Participants are provided with normal nicotine content (NNC) cigarettes (11.6 mg nicotine/cigarette) plus e-cigarette with zero nicotine e-liquid.
62823294|NCT04058717|EXPERIMENTAL|VLNC cigarettes + High Nicotine Containing E-cigarette|Participants are provided with very low nicotine content (VLNC) cigarettes (0.2 mg nicotine/cigarette) plus e-cigarette with high nicotine e-liquid.
62245207|NCT05817942||Arm A: Filgotinib|Participants diagnosed with moderately or severely active UC taking filgotinib according to local treatment guidelines or routine clinical practice and product information.
62245208|NCT05159154||Septic Shock Patients|Patients admitted with diagnosis of septic shock
62245209|NCT06178341|EXPERIMENTAL|Intervention|"Kata Inhalations-App with the following functions:~1. Inhalation reminder~2. Inhalation trainer~3. Health parameter documentation~4. Diary~5. Audio and video recording of user's inhalation maneuvers~6. Provision of study-specific questionnaires~7. Reminder to fill out study-specific questionnaires"
62601986|NCT04254107|EXPERIMENTAL|SEA-TGT + sasanlimab Combination Therapy (Part C)|SEA-TGT + sasanlimab
62601987|NCT04254107|EXPERIMENTAL|SEA-TGT + brentuximab vedotin Combination Therapy (Part D)|SEA-TGT + brentuximab vedotin
62823295|NCT04058717|EXPERIMENTAL|VLNC cigarettes + Zero Nicotine Containing E-cigarette|Participants are provided with very low nicotine content (VLNC) cigarettes (0.2 mg nicotine/cigarette) plus e-cigarette with zero nicotine e-liquid
62823296|NCT03317405|EXPERIMENTAL|Cohort I (endoxifen hydrochloride)|Participants apply endoxifen hydrochloride gel to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
62601988|NCT06646510|ACTIVE_COMPARATOR|control group|traditional treatment of hand tremors
62601989|NCT06646510|EXPERIMENTAL|study group|traditional treatment in addition to sensory electrical stimulation
62042290|NCT05741216|EXPERIMENTAL|OTF Test 2|One application of ocular lubricant to each eye at night for 5 consecutive nights
62042291|NCT05741216|EXPERIMENTAL|OTF Test 3|One application of ocular lubricant to each eye at night for 5 consecutive nights
62601990|NCT05015621|ACTIVE_COMPARATOR|study group|all subjects will receive study treatment in 21-day cycle, Surufatinib 250mg, QD and Toripalimab, 240mg, IV drip, Q3W, D1, the treatment will continue until one of the following conditions occurs: progression of disease, death, intolerable toxicity, or the end of study treatment (as other criteria specified in the protocol are met), whichever occurs first
62601991|NCT05015621|OTHER|control group|FOLFIRI group subjects will receive study treatment in 14- day cycle, Irinotecan: 180 mg/m\^2, iv drip over 30～90 minutes, on Day 1; Calcium folinate: 400 mg/m\^2, iv drip for about 2 hours, given upon completion of infusion of Irinotecan on Day 1; 5-FU: 400 mg/m\^2, iv bolus, given upon completion of infusion of Calcium folinate on Day 1, followed by 2400 mg/m\^2 continuously iv drip for 46～48 hours.
62601992|NCT04430231||Wait list time 0-2 weeks|Wait list time 0-2 weeks
62601993|NCT04430231||Wait list time 2-4 weeks|Wait list time 2-4 weeks
62601994|NCT04430231||Wait list time 4-6 weeks|Wait list time 4-6 weeks
62601995|NCT04430231||Wait list time > 6 weeks|Wait list time \> 6 weeks
62601996|NCT02521779|EXPERIMENTAL|Test Meal Saturated Fat|Saturated-fat Treatment Meal
62601997|NCT02521779|EXPERIMENTAL|Test Meal N-6 Fat|N-6 fat Treatment Meal.
62042292|NCT05741216|ACTIVE_COMPARATOR|Ocular lubricant|One drop of ocular lubricant applied to each eye at night for 5 consecutive nights
62042293|NCT05697094|EXPERIMENTAL|Meditation to Remove Stress and Create A Proper System in Mind|The study intervention will be administered to participants randomized to the intervention arm. The meditation intervention will be delivered virtually via the hospital-approved Microsoft Teams platform. Participants will be taught an evidence-based meditation technique which includes two online sessions (60 minutes/day) with a trained, experienced, and certified teacher of Prasanna Wellness, a non-profit service organization. Participants will learn how to respond to experiences that arise in meditation, will discuss what enhances or detracts from effective meditation, and review methods for meditating at home. The participants in the intervention arm will complete 60-minute follow-up sessions with the Prasanna Wellness staff which will include 33 minutes of guided meditation practice, and then a discussion of participants' experiences with meditation during the week, additional observations, and a review of relevant knowledge to support their home practice.
62042294|NCT05697094|NO_INTERVENTION|Usual Care|Participants will continue with their usual care.
62042295|NCT06648772|EXPERIMENTAL|Roflumilast Cream 0.3%|For topical use, Q.D.
62042296|NCT06648772|PLACEBO_COMPARATOR|Vehicle cream|For topical use, Q.D.
62042297|NCT02795273|EXPERIMENTAL|Grass-SPIRE|Eight intradermal injections of Grass-SPIRE
62042298|NCT02795273|PLACEBO_COMPARATOR|Placebo|Eight intradermal injections of Placebo
62601998|NCT02521779|EXPERIMENTAL|Test Meal N-3 Fat|N-3 fat Treatment Meal.
62601999|NCT02521779|EXPERIMENTAL|Test Meal Low-fat|Low-fat Treatment Meal.
62823297|NCT03317405|PLACEBO_COMPARATOR|Cohort II (placebo)|Participants apply placebo to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
62823298|NCT01473134|EXPERIMENTAL|Oxford Cementless Partial Knee|Oxford Partial Knee implanted without bone cement.
62602000|NCT02873637|EXPERIMENTAL|under sartorial catheter|catheter under sartorial
62602001|NCT02873637|OTHER|femoral catheter|femoral catheter
62823299|NCT01473134|ACTIVE_COMPARATOR|Oxford Cemented Partial Knee|Oxford Partial Knee applied with bone cement.
62602002|NCT03931317|OTHER|Latanoprostene bunod 0.024% QD|4 weeks of Latanoprostene bunod 0.024% QD, then a 2 Week washout, followed by 4 weeks of Timolol maleate 0.5% BID
62602003|NCT03931317|OTHER|Timolol maleate 0.5% BID|4 weeks of Timolol maleate 0.5% BID, then a 2 Week washout, followed by 4 weeks of Latanoprostene bunod 0.024% QD
62602004|NCT05976308|EXPERIMENTAL|Therapy group|
62602005|NCT05976308|PLACEBO_COMPARATOR|Control group|
62823300|NCT04291781|EXPERIMENTAL|RC18 160mg|RC18 160mg subcutaneous injection (S.C.) once weekly ,and a total of 24 doses
62602006|NCT06264752|EXPERIMENTAL|Protocolized stage-based intervention|The intervention uses an automated alerting system to identify patients: 1) receiving a high-risk drug or drug combination associated with AKI and at low-risk for progression to either stage 2 AKI or stage 3 AKI (Level A) and 2) patients without AKI or stage 1 AKI receiving a high-risk drug or drug combination associated with AKI and at high risk for progression to either stage 2 AKI or stage 3 AKI, and patients with AKI stage 2 or stage 3 receiving a high-risk drug or drug combination associated with AKI or a medication that requires renal dose adjustment (Level B). This patient specific risk-profile will be coupled with recommendations for medication management and delivered to the physician by a pharmacist for consideration and approval.
62602007|NCT06264752|ACTIVE_COMPARATOR|Usual Care|A Cerner EMR-based AKI passive alert which is standard of care at UPMC.
62602008|NCT03817957|EXPERIMENTAL|Polyglucoferron|once intravenously, dosing according to Hb-levels and body weight, 500 - 2000 mg
62602009|NCT03817957|ACTIVE_COMPARATOR|Ferric Carboxymaltose|Once intravenously (a second administration is allowed), dosing according to Hb-levels and body weight (500 - 2000 mg, max. single dose of 1000 mg)
62602010|NCT03817957|ACTIVE_COMPARATOR|Ferrous sulfate|capsules, orally, dosing 50 mg - 200 mg (50 mg: 1 capsule in total, 200 mg: 4 capsules in total, taken as 2 capsules twice daily), duration of treatment 28 days
62823301|NCT04291781|EXPERIMENTAL|RC18 240mg|RC18 240mg S.C. once weekly ,and a total of 24 doses
62823302|NCT04291781|PLACEBO_COMPARATOR|Placebo|Placebo S.C. once weekly ,and a total of 24 doses
62823303|NCT04442022|EXPERIMENTAL|Phase 2: Selinexor 40 mg + R-GDP|Patients with RR DLBCL will receive combination therapy of selinexor 40 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally once weekly (QW) for each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
62042299|NCT06164470|OTHER|Support Group|Non-randomized pre-post trial, in which each participant will serve as their own control. Participants will be recruited from a bronchiectasis specialty clinic.
62042300|NCT01469533|EXPERIMENTAL|experimental group|The experimental group receives the real spinal mechanical manipulation.
62042301|NCT01469533|SHAM_COMPARATOR|control group|The control group receives the sham-manipulation procedure.
62042302|NCT03059108|EXPERIMENTAL|Early Loading|Implant early loading: prosthesis delivery 4 weeks after implant placement
62042303|NCT03059108|ACTIVE_COMPARATOR|Conventional Loading|Implant conventional loading: prosthesis delivery 8 weeks after implant placement
62042304|NCT06579508|NO_INTERVENTION|Control|No intervention, only the evaluations will be done.
62042305|NCT06579508|PLACEBO_COMPARATOR|Normoxia - Placebo|High-intensity interval cycle ergometer train, with inter effort normoxia (FiO2 = 21%).
62042306|NCT06579508|PLACEBO_COMPARATOR|Normoxia - Taurina|High-intensity interval cycle ergometer train, with inter effort normoxia (FiO2 = 21%).
62602011|NCT00900731|EXPERIMENTAL|Indacaterol 150 µg|Participants received indacaterol 150 μg delivered via a single-dose dry-powder inhaler (SDDPI) plus placebo to tiotropium delivered via the manufacturer's proprietary inhalation device (HandiHaler®) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.
62042307|NCT06579508|PLACEBO_COMPARATOR|Hypoxia - Placebo|High-intensity interval cycle ergometer train, with inter effort hypoxia (FiO2 = 12%).
62042308|NCT06579508|EXPERIMENTAL|Hypoxia - Taurina|High-intensity interval cycle ergometer train, with inter effort hypoxia (FiO2 = 12%).
62042309|NCT02425982||Conservative treatment|Patients who will opt conservative treatment or patients treated conservatively by surgeon decision.
62042310|NCT02425982||Operative treatment|Patients who opt for surgery when offered.
62042311|NCT02672787|ACTIVE_COMPARATOR|ED usual care plus education|ED usual care plus education
62042312|NCT02672787|EXPERIMENTAL|Intervention|Subjects will receive the ED-based behavioral intervention
62823304|NCT04442022|EXPERIMENTAL|Phase 2: Selinexor 60 mg + R-GDP|Patients with RR DLBCL will receive combination therapy of selinexor 60 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
62823305|NCT04442022|ACTIVE_COMPARATOR|Phase 2: R-GDP|Patients with RR DLBCL will receive R-GDP on specified days (Days 1, 2, 3, 4, and 8) for each 21-day cycle for up to 6 cycles.
62823306|NCT04442022|EXPERIMENTAL|Phase 3: Selinexor (Selected Dose) + R-GDP followed by Selinexor 60 mg|Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
62042313|NCT01634542||Cohort|
62042314|NCT02021838||California|Lethality Assessment Program
62042315|NCT02021838||North Carolina|Lethality Assessment Program
62042316|NCT02021838||Ohio|Domestic Violence High Risk Team
62042317|NCT02021838||Illinois|Lethality Assessment Program
62042318|NCT02021838||Michigan|Lethality Assessment Program
62042319|NCT02021838||Tennessee|Lethality Assessment Program
62602012|NCT00900731|ACTIVE_COMPARATOR|Tiotropium 18 µg|Participants received tiotropium 18 μg delivered via the manufacturer's proprietary inhalation device (HandiHaler®) plus placebo to indacaterol delivered via a single-dose dry-powder inhaler (SDDPI) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.
62042320|NCT01274195|EXPERIMENTAL|Busulfan|
62042321|NCT01355393|EXPERIMENTAL|Stage I, Arm 1 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 1: HER2 peptide vaccine + 4 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
62042322|NCT01355393|ACTIVE_COMPARATOR|Stage II, Arm I (HER-2/neu peptide vaccine and sargramostim)|Patients receive synthetic HER-2/neu peptide vaccine admixed with GM-CSF ID.
62042323|NCT01355393|EXPERIMENTAL|Stage II, Arm II (HER-2 vaccine, sargramostim, rintatolimod)|Patients receive synthetic HER-2/neu peptide vaccine admixed with GM-CSF and rintatolimod ID
62042324|NCT01355393|EXPERIMENTAL|Stage I, Arm 2 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 2: HER2 peptide vaccine + 20 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
62042325|NCT01355393|EXPERIMENTAL|Stage I, Arm 3 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 3: HER2 peptide vaccine + 79 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
62042326|NCT01355393|EXPERIMENTAL|Stage I, Arm 4 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 4: HER2 peptide vaccine + 495 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
62042327|NCT01355393|EXPERIMENTAL|Stage I; Arm 5 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 5: HER2 peptide vaccine + 2000 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
62042328|NCT04732806|NO_INTERVENTION|Treatment as usual|
62042329|NCT04732806|EXPERIMENTAL|Intervention|Six months of ad lib Mightier play in home
62435572|NCT01698320|EXPERIMENTAL|Albuterol MDPI-Albuterol MDPI|"During the 12-week double-blind period, participants take 2 inhalations of albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation, four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total daily dose of 720 micrograms per day.~The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise."
62042330|NCT04557072||The selective alpha-blockade group|Patients treated with selective alpha-blockade before pheochromocytoma surgery
62042331|NCT04557072||The non-selective alpha-blockade group|Patients treated with non-selective alpha-blockade before pheochromocytoma surgery
62042332|NCT06217367|EXPERIMENTAL|50 mg Diphenhydramine|
62602013|NCT02895724|EXPERIMENTAL|HBOT receivers|Participants in a post breast cancer surgery randomized controlled trial detected with lymphedema 1 year postoperatively are invited to 40 consequtive treatments of hyperbaric oxygen therapy to reduce lymphedema. The experimental drug is 100% medical oxygen given in a pressure chamber of 2,4 bar,every treatment lasting approximately 100 minutes.
62602014|NCT02895724|NO_INTERVENTION|blodsample comparison|Matched Lymphedema free participants from LYCA Exercise recruited to donate blood samples for comparison on important blod biomarkers and collagen levels.
62602015|NCT04624776|ACTIVE_COMPARATOR|Methylprednisolone|A five minutes bolus infusion of 250 mg (4 mL) methylprednisolone to inhibit inflammatory and neurological damage following resuscitated out-of-hospital cardiac arrest. The infusion of methylprednisolone will be given following five minutes of sustainable ROSC in the prehospital setting.
62823307|NCT04442022|EXPERIMENTAL|Phase 3: Selinexor (Selected Dose) + R-GDP followed by Placebo|Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
62823308|NCT04442022|PLACEBO_COMPARATOR|Phase 3: Placebo + R-GDP followed by Placebo|Patients with RR DLBCL will receive combination therapy of placebo matching for selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
62042333|NCT06217367|EXPERIMENTAL|10 mg Loratadine|
62823309|NCT04644952||Observational (medical record review)|Patients' medical records are reviewed retrospectively.
62823310|NCT06206031|EXPERIMENTAL|"Intraosseous ultrasonography"|All subjects of each sub-protocol receive identical intervention (single group assignment for each of 2 sub-protocols).
62823311|NCT06591494|ACTIVE_COMPARATOR|Classic quadruple therapy|Esomeprazole 20 mg BID Bismuth pectin 200 mg BID Amoxicillin 1 g BID Clarithromycin 500 mg BID for 14 days
62823312|NCT06591494|EXPERIMENTAL|Quadruple therapy with sodium bicarbonate instead of bismuth|Esomeprazole 20 mg BID Sodium bicarbonate 500 mg TID Amoxicillin 1 g BID Clarithromycin 500 mg BID for 14 days
62823313|NCT06591494|EXPERIMENTAL|Quadruple therapy with sodium bicarbonate instead of clarithromycin|Esomeprazole 20 mg BID Bismuth pectin 200 mg BID Amoxicillin 1 g BID Sodium bicarbonate 500 mg TID for 14 days
62823314|NCT06580704|EXPERIMENTAL|Lumbosacral Erector Spinae Plane Block|Patients will receive ultrasound-guided lumbosacral erector spinae plane block.
62823315|NCT06580704|EXPERIMENTAL|Psoas Muscle Compartment With Sciatic Nerve Block|Patients will receive ultrasound-guided psoas muscle compartment with sciatic nerve block.
62823316|NCT05136586|EXPERIMENTAL|Biofeedback|Relaxing breathing exercise coupled with biofeedback before the circuit, no intervention after
62823317|NCT05136586|EXPERIMENTAL|Meditation|Meditative stimulation audio tape before the circuit, no intervention after
62823318|NCT05136586|EXPERIMENTAL|Control and biofeedback post OSCE|Standardised video before the circuit, Relaxing breathing exercise coupled with biofeedback after the OSCE
62823319|NCT05136586|SHAM_COMPARATOR|Control and control post OSCE|Standardised video before the circuit, no intervention after
62823320|NCT06145737|OTHER|MS Participant with Cognitive Dysfunction|"Participants will receive the HOBSCOTCH-MS intervention consisting of 1:1 sessions delivered once per week including:~* 1 pre-HOBSCOTCH Session (on webcam or by phone)~* 1 educational session (on webcam)~* 6 HOBSCOTCH intervention sessions (webcam or phone)~* 1 wrap-up session (webcam or phone)"
62823321|NCT04921670||Group A-Standard monitoring group (Reactive drug monitoring)|Participants assigned to this group will be managed the same as normally done per routine care, which involves adjusting their infliximab dose and/or dosing interval based on Inflammatory Bowel Disease (IBD) symptoms and routine care laboratory test results. The primary gastroenterologist will not be given the results of the infliximab and infliximab antibody level results of participants in this group unless their routine laboratory test results or IBD symptoms suggest their IBD may be worsening.
62849246|NCT03613142|ACTIVE_COMPARATOR|Esophagogastrostomy|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. Next, end-to-end or side to end esophagogastrostomy is performed with a circular stapler.
62042334|NCT06217367|EXPERIMENTAL|5 mg Desloratadine|
62042335|NCT06217367|PLACEBO_COMPARATOR|Placebo (Sugar pill)|
62042336|NCT01918735|EXPERIMENTAL|Group/dose level 1a|25 mg GWP42006 oral solution. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
62042337|NCT01918735|PLACEBO_COMPARATOR|Group/dose level 1b|Matching placebo for Group/dose level 1a. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
62823322|NCT04921670||• Group B- Infliximab level and infliximab antibody monitoring group (Proactive drug monitoring)|Participants assigned to the infliximab level and infliximab antibody level monitoring group will be managed based on the infliximab level and infliximab antibody level results as well as their IBD symptoms and the results of routine care laboratory tests. The goal is to keep infliximab levels in the optimal range with little to no antibodies. The primary gastroenterologist will remain blinded to the results of the infliximab level/infliximab antibody level test results and the participants' dose will be adjusted by one of the other study doctors who is not blinded to the results.
62042338|NCT01918735|EXPERIMENTAL|Group/dose level 2a|75 mg GWP42006 oral solution. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
62245210|NCT06178341|NO_INTERVENTION|Control|"Messinstrument (Measurement)-App. Smartphone application with the following functions:~1. Audio and video recording of user's inhalation maneuvers~2. Provision of study-specific questionnaires~3. Reminder to fill out study-specific questionnaires~Note: the Messinstrument-App does not provide any inhalation training, inhalation reminders, or feedback."
62245211|NCT04560660|EXPERIMENTAL|Ketamine and prolonged exposure (PE)|Single IV ketamine 0.5 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
62245212|NCT04560660|PLACEBO_COMPARATOR|Midazolam and prolonged exposure (PE)|Single IV midazolam 0.045 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
62245213|NCT05050942|EXPERIMENTAL|CAM2029|
62245214|NCT05050942|ACTIVE_COMPARATOR|Octreotide LAR or lanreotide ATG|
62435573|NCT02888132|EXPERIMENTAL|Hypertrophic Obstructive Cardiomyopathy|
62435574|NCT01261520|OTHER|Culturally-tailored video|The culturally-tailored video was designed to focus on Chinese women's cultural health beliefs and align with Chinese customs, norms, and values, which includes two segments: 1) a soap-opera and 2) recommendation from a Chinese female physician.
62435575|NCT06307808||Kidney transplant recipients, tacrolimus treated|Prevalent kidney transplant recipients, receiving tacrolimus as main immunosuppresant
62435576|NCT06307808||Liver transplant recipients, tacrolimus treated|Prevalent liver transplant recipients, receiving tacrolimus as main immunosuppressant
62435577|NCT06307808||Kidney transplant recipients, belatacept treated|Prevalent kidney transplant recipients, receiving belatacept as main immunosuppressant
62435578|NCT05470790||athletes with anterior cruciate ligament injuries|
62435579|NCT05470790||control|
62602016|NCT04624776|PLACEBO_COMPARATOR|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
62602017|NCT03254212|EXPERIMENTAL|Oxygen therapy|Fixed nightime oxygen therapy throughout the protocol duration
62602018|NCT03303443||Younger|20-40 years old patients
62602019|NCT03303443||Elderly|over 60 years old patients
62602020|NCT04195555|EXPERIMENTAL|Treatment (ivosidenib)|Patients receive ivosidenib PO QD. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62602021|NCT03379844|EXPERIMENTAL|Holmium-166 radioembolization|
62823323|NCT05794620||Children with Autism|A child with a diagnosis of Autism
62823324|NCT05794620||Neurotypical siblings|A full sibling of the child with Autism
62849247|NCT04655651||Frailty|patients with a FRAIL Scale of 3 to 5
62849248|NCT04655651||Non-frailty|patients with a FRAIL Scale of 0 to 2
62602022|NCT02063178|EXPERIMENTAL|Counselor-Initiated|Participants will receive 28 telephone sessions over a 12 month period by interventionists trained in behavior change skills and motivational interviewing techniques. Participants will be asked to monitor food intake and physical activity using the LoseIt website/app and weight daily using a Body Trace e-scale. Participants will receive feedback on self-monitoring through e-mail. Dietary goals will be based on weight and participants' weight-loss progress. Participants will be encouraged to replace 2 meals and a snack with meal replacements (provided). Participants will be asked to gradually increase their moderate to vigorous exercise to 225-250 minutes per week. The Toolbox includes additional treatment options (e.g., food scales, exercise videos, cookbooks) for those who wish to take advantage of them. There will be several challenges that will provide a specific goal (e.g. increase self-monitoring), with a small award for completion.
62823325|NCT03119259|ACTIVE_COMPARATOR|ABC Clinical Program Only and Usual Care|Patients and informal caregivers randomized to the comparison group will receive care provided by the ABC Clinical Program and IUHP. The ABC Clinical Program is the standard of ADRD care at Eskenazi Health and Primary Care Visits at Indiana University Health is the usual care.
62823326|NCT03119259|EXPERIMENTAL|BCN Mobile App Plus ABC and BCN Mobile app only|Patients and caregivers randomized to the intervention group will continue to receive care in ABC clinical program and IUHP, and have the BCN software installed on either the caregiver's personal mobile device (assuming it meets minimal technical requirements) or a device provided by the study, per participant preference. A research assistant will orient participants to the device, provide training on the BCN software, and troubleshoot technical issues. Participants will receive daytime technical support by phone, electronic support request through a separate app, or printed and in-app help manuals. Hardware, software, and connectivity check-ups will be provided by study research personnel.
62849249|NCT02081326|EXPERIMENTAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
62435580|NCT04405206||Group A:Clinical complete response (cCR)|Group A:Clinical complete response (cCR) Patients who achieve cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Nonoperative Management(NOM).
62435581|NCT04405206||Group B:Near-cCR|Patients who achieve near-cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Local Excision(LE) or Nonoperative Management(NOM).
62435582|NCT04405206||Group C:Residual tumor|Patients with residual tumor when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation
62435583|NCT06391905|OTHER|Late standard first-line treatment regimen group|Fluorouracil and platinum were used as the basic chemotherapy regimens, with or without targeted therapy, and no additional injection of PCSK9 inhibitors
62435584|NCT06391905|EXPERIMENTAL|PCSK9 inhibitor in combination with standard advanced first-line regimen group|Fluorouracil and platinum as the base chemotherapy regimen, with or without targeted therapy, was administered subcutaneously at a fixed dose of 150 mg of PCSK9 inhibitor every two weeks starting on day 1 of patient enrollment
62435585|NCT00686374|EXPERIMENTAL|Any adalimumab|Adalimumab was administered via subcutaneous injection. Dosage was based on body weight and clinical status, and ranged from 10, 20, or 40 mg every other week to 20 or 40 mg every week.
62435586|NCT06529835|ACTIVE_COMPARATOR|NeuroGen Nerve Guide|The control arm will comprise of subjects requiring injury repair of 0.5-1.0cm. These subjects will receive the NeuraGen Nerve Guide.
62435587|NCT06529835|ACTIVE_COMPARATOR|Nerve Autograft|The control arm will comprise of subjects requiring injury repair of 1.1-3.0cm. These subjects will receive the Nerve Autograft.
62435588|NCT06536712|EXPERIMENTAL|Mesenchymal Stem Cells Derived Exosomes|10 patients in this arm will receive Mesenchymal Stem Cells Derived Exosomes at the end of their low anterior resection surgery
62849250|NCT02081326|PLACEBO_COMPARATOR|Saline injection|2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
62435589|NCT06536712|PLACEBO_COMPARATOR|Placebo|10 patients in this arm will receive placebo at the end of their low anterior resection surgery
62435590|NCT02367079|ACTIVE_COMPARATOR|Switched on diathermy|Switched on diathermy was used on DOMS compared to sham diathermy
62435591|NCT02367079|SHAM_COMPARATOR|Switched OFF diathermy|Switched OFF diathermy was used on DOMS compared to REAL diathermy
62435592|NCT00648856|EXPERIMENTAL|1|Sertraline Hydrochloride Tablets 100 mg
62435593|NCT00648856|ACTIVE_COMPARATOR|2|Zoloft® Tablets 100 mg
62435594|NCT05658614|ACTIVE_COMPARATOR|Arm 1 (Group Vacc3)|Volunteers will receive three (3) intramuscular injections into the deltoid muscle of 0.5mL of of the Sm14+ GLA-SE vaccine on D0, W4 and W8. (D = Day; W = Week). (Vaccination schedule used in previous phases).
62435595|NCT05658614|EXPERIMENTAL|Arm 2 (Group Vacc2+1)|Volunteers will receive three (3) intramuscular injections of the Sm14+ GLA-SE vaccine into the deltoid muscle of 0.5mL of vaccine on D0, W4 and W20 (new vaccination schedule).
62602023|NCT02063178|ACTIVE_COMPARATOR|Self-Paced|The Self-paced group uses a less intense approach, where the participants can receive the same telephone counseling sessions as the counselor-initiated group, only if they call the counselor. Participants will be asked to monitor food intake and physical activity using the LoseIt website/app and weight daily using a Body Trace e-scale. Participants will receive feedback on self-monitoring through e-mail only upon request. Dietary goals will be based on weight and participants' weight-loss progress. Participants will be asked to gradually increase their moderate to vigorous exercise to 225-250 minutes per week.
62602024|NCT03559868|ACTIVE_COMPARATOR|Digoxin 3 mcg/Kg/day|Patients receiving oral digoxin 3 mcg/Kg/day
62245215|NCT02834416|EXPERIMENTAL|Group-Supervised|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
62435596|NCT05366556|EXPERIMENTAL|Experimental group|Patients in the experimental group will be informed about the using virtual reality glasses during the taking blood. During this process, their anxiety and pain will be assesed. Patients in the study group will be evaluated 2 times, before the intervention and after the intervention, through data collection tools.
62602025|NCT03559868|ACTIVE_COMPARATOR|Digoxin 0.15 mcg|Patients receiving oral digoxin 0.15 mcg/Kg/day
62602026|NCT03559868|PLACEBO_COMPARATOR|Placebo|oral placebo
62823327|NCT05130580|EXPERIMENTAL|Arm I (educational materials, enhanced consult, decision aid)|Patients receive newly-developed educational materials about breast reconstruction and attend an enhanced consultation visit with their plastic surgeon to discuss options for breast reconstruction surgery, during which a decision aid application containing a customized presentation of possible breast reconstruction outcomes is presented. At the end of the consultation visit, patients complete questionnaires about decision-making and psychological well-being. Within 4-6 weeks and 3-6 months after beginning the reconstruction process, patients also complete questionnaires about satisfaction with their breasts, body image, and psychological well-being, and undergo two-dimensional (2D) and 3D imaging of the torso.
62245216|NCT02834416|EXPERIMENTAL|Home-Based|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as the supervised group). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
62245217|NCT00108069|EXPERIMENTAL|GBM (Glioblastoma multiforme)|
62245218|NCT00108069|EXPERIMENTAL|AG (Anaplastic glioma)|
62435597|NCT05366556|NO_INTERVENTION|Control group|The control group will receive standard procedure without any intervention
62435598|NCT06025175|EXPERIMENTAL|Lazer group|30 patients will receive low level lazer therapy 3 times per week for 12 weeks.
62823328|NCT05130580|ACTIVE_COMPARATOR|Arm II (educational materials, standard of care consultation)|Patients receive newly-developed educational materials about breast reconstruction and attend a standard of care consultation visit with their plastic surgeon to discuss options for breast reconstruction surgery. At the end of the consultation visit, patients complete questionnaires about decision-making and psychological well-being. Within 4-6 weeks and 3-6 months after beginning the reconstruction process, patients also complete questionnaires about satisfaction with their breasts, body image, and psychological well-being, and undergo 2D and 3D imaging of the torso.
62823329|NCT03175679|EXPERIMENTAL|iNKT cell loading dose:3x10^7/m2|"Autologous in vitro expanded iNKT cells in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with advanced HCC.~iNKT Cell Loading Dose：3x10\^7/m2.~IL-2: IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.~Tegafur: Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks."
62849251|NCT06429553|EXPERIMENTAL|Hematoma puncture group|Minimally invasive hematoma aspiration drainage combined with urokinase injection
62849252|NCT06429553|SHAM_COMPARATOR|Drug conserved group|Drug conserved group
62042339|NCT01918735|PLACEBO_COMPARATOR|Group/dose level 2b|Matching placebo for Group/dose level 2a. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
62042340|NCT01918735|EXPERIMENTAL|Group/dose level 3a|200 mg GWP42006 oral solution (single dose) followed by an intravenous administration of 5 mg GWP42006 after the oral dose
62042341|NCT01918735|PLACEBO_COMPARATOR|Group/dose level 3b|Matching placebo for Group/dose level 3a
62042342|NCT01918735|EXPERIMENTAL|Group/dose level 4a|400 mg GWP42006 oral solution
62042343|NCT01918735|PLACEBO_COMPARATOR|Group/dose level 4b|Matching placebo for Group/dose level 4a
62042344|NCT01918735|EXPERIMENTAL|GWP42006 1, 2, or 3 times daily|Subjects will receive the selected dose of GWP42006 once, twice or three times daily (the number of daily doses and actual dose will be decided upon based on results from Part 1 of the study) for a total of 5 days, with the final dose given on the morning of Day 5.
62042345|NCT01918735|PLACEBO_COMPARATOR|Placebo 1, 2, or 3 times daily|Subjects will receive placebo once, twice or three times daily (the number of daily doses and actual dose will be decided upon based on results from Part 1 of the study) for a total of 5 days, with the final dose given on the morning of Day 5.
62042346|NCT05630183|EXPERIMENTAL|Part 1: Combination (Safety Lead-in Phase)|Participants will receive botensilimab in combination with standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).
62042347|NCT05630183|EXPERIMENTAL|Part 2: Combination|Participants will receive botensilimab in combination standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).
62042348|NCT05630183|ACTIVE_COMPARATOR|Part 2: Standard of Care|Participants will receive standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).
62042349|NCT00790010|EXPERIMENTAL|Bevacizumab Plus Ipilimumab Cohort 1|5 subjects for this cohort
62042350|NCT00790010|EXPERIMENTAL|Bevacizumab Plus Ipilimumab Cohort 2|17 subects for this cohort
62042351|NCT00790010|EXPERIMENTAL|Bevacizumab Plus Ipilimumab Cohort 3|12 subjects
62042352|NCT00790010|EXPERIMENTAL|Bevacizumab Plus Ipilimumab Cohort 4|12 subjects
62042353|NCT00520780|EXPERIMENTAL|1|
62042354|NCT00520780|PLACEBO_COMPARATOR|2|
62042355|NCT03195192|OTHER|Single arm|This is a biomarker study analyzing tissue for baseline biomarkers and collecting tissue at progression for further analysis of biomarkers changes after treatment with CDK 4/6 inhibitors and endocrine therapy
62042356|NCT02744144||Non-infection|Patients without clinical infection or positive wound culture
62042357|NCT02744144||Infection|Patients with clinical infection and positive wound culture
62823330|NCT03175679|EXPERIMENTAL|iNKT cell loading dose:6x10^7/m2|"Autologous in vitro expanded iNKT cells in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with advanced HCC.~iNKT Cell Loading Dose：6x10\^7/m2.~IL-2: IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.~Tegafur: Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks."
62042358|NCT04319211||People who isolate at home with the danger of coronavirus|Demographic data of the individuals participating in the study will be recorded. International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. Parameters such as housework, home care and family care, rest, sports and leisure physical activities, sitting time will be evaluated. Short Form 12 (Short Form12- SF12) quality of life scale will be used to evaluate health-related quality of life. Beck Depression Scale will be applied to investigate the stress levels of the individuals participating in our study.
62435599|NCT06025175|OTHER|Control group|30 patients will receive only exercises.
62042359|NCT04840810|ACTIVE_COMPARATOR|Out of plane/ short axis central venous cannulation|"In a short-axis view, the image plane is perpendicular to the course of the vessel and to the needle (needle is out of plane). The vessel appears as an anechoic circle on the screen of ultrasound with the needle visualized as a hyperechoic point in cross-section. The central venous cannulation was done in out of plane axis."
62042360|NCT04840810|ACTIVE_COMPARATOR|In-plane/long axis central venous cannulation|"In a long-axis view, the image plane is parallel to the course of the vessel (needle is in-plane). The image shows the course of the vessel across the screen and the shaft and point of the needle as it is advanced. The central venous cannulation was done in in-plane axis."
62042361|NCT06382012|EXPERIMENTAL|Investigational Intervention|Fosaprepitant 150mg IV administered over 15 minutes
62042362|NCT06382012|ACTIVE_COMPARATOR|Standard-of-Care Intervention|Ondansetron 4mg IV administered over 15 minutes
62042363|NCT05072080|EXPERIMENTAL|Group 1|Group 1 - PXVX0317 lot A (Lot 104)
62435600|NCT05213078|EXPERIMENTAL|Supportive Care (teaching intervention, questionnaire)|Participants attend 2 teaching sessions with a research nurse. Participants also complete questionnaires at baseline, 3, and 7 weeks.
62042364|NCT05072080|EXPERIMENTAL|Group 2|Group 2 - PXVX0317 lot B (Lot 105)
62042365|NCT05072080|EXPERIMENTAL|Group 3|Group 3 - PXVX0317 lot C (Lot 106)
62042366|NCT05072080|PLACEBO_COMPARATOR|Group 4|Group 4 - Placebo
62042367|NCT04279223|ACTIVE_COMPARATOR|5 mm trocar group|A study with 107 patients was planned to compare the development of trocar site hernia.
62042368|NCT04279223|SHAM_COMPARATOR|10 mm trocar group|A study with 107 patients was planned to compare the development of trocar site hernia.
62042369|NCT01698684|PLACEBO_COMPARATOR|Placebo|
62042370|NCT01698684|EXPERIMENTAL|Avanafil 100 mg|
62042371|NCT01698684|EXPERIMENTAL|Avanafil 200 mg|
62042372|NCT00675389|EXPERIMENTAL|A|Peer Health Workers Intervention
62245219|NCT05119621|EXPERIMENTAL|TENS application|TENS application will be applied to the experimental group before mobilization after abdominal surgery. TENS will be applied for an average of 40 minutes.
62602027|NCT05845450|EXPERIMENTAL|Cohort 1: HER2 positive|"Patients selected for the presence of pMMR/MSS status and HER2 overexpression/amplification defined as HER2 IHC 3+ or IHC 2+/ISH+ will receive the HER2 directed ADC trastuzumab deruxtecan 5.4 mg/kg IV on day 1.~After receiving the short-course preoperative treatment, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant chemotherapy as per national and international guidelines and according to the suggestion of a central multidisciplinary team. Then, standard follow up will be started as per local guidelines."
62602028|NCT05845450|EXPERIMENTAL|Cohort 2: POLE/D1 mutated with ultra-mutated status (>100 Mut/Megabase)|"Patients selected for the presence of a proof-read domain pathogenic mutation of POLE/D1 associated with ultra-mutated status will receive a short-course preoperative immunotherapy treatment with the anti-PDL-1 monoclonal antibody durvalumab 1500 mg IV on day 1.~After receiving the short-course preoperative treatment, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant chemotherapy as per national and international guidelines and according to the suggestion of a central multidisciplinary team. Then, standard follow up will be started as per local guidelines."
62602029|NCT05845450|EXPERIMENTAL|Cohort 3: EGFR-dependent|"Patients selected for the presence of pMMR/MSS status, RAS and BRAF wild type status, PRESSING negative status and left-sided primary cancer will receive treatment with the anti-EGFR agent panitumumab 6 mg/kg IV on days 1 and 15.~After receiving the short-course preoperative treatment, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant chemotherapy as per national and international guidelines and according to the suggestion of a central multidisciplinary team. Then, standard follow up will be started as per local guidelines."
62602030|NCT05845450|EXPERIMENTAL|Cohort 4: pMMR/MSS status|"Patients selected for the presence of pMMR/MSS status and absence of HER2 overexpression/amplification, absence of POLE/D1 proof-read domain pathogenic mutation associated with ultra-mutated status will receive a short-course preoperative treatment with the anti-CTLA4 antibody botensilimab 1 mg/kg on day 1.~After receiving the short-course preoperative treatment, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant chemotherapy as per national and international guidelines and according to the suggestion of a central multidisciplinary team. Then, standard follow up will be started as per local guidelines."
62602031|NCT05845450|EXPERIMENTAL|Cohort 5: pMMR/MSS status|"Patients selected for the presence of pMMR/MSS status and absence of HER2 overexpression/amplification, absence of POLE/D1 proof-read domain pathogenic mutation associated with ultra-mutated status will receive a short-course preoperative treatment with the anti-CTLA4 antibody botensilimab 1 mg/kg on day 1 plus the anti-PD-1 balstilimab 3 mg/kg on days 1 and 15~After receiving the short-course preoperative treatment, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant chemotherapy as per national and international guidelines and according to the suggestion of a central multidisciplinary team. Then, standard follow up will be started as per local guidelines."
62823331|NCT03175679|EXPERIMENTAL|iNKT cell loading dose:9x10^7/m2|"Autologous in vitro expanded iNKT cells in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with advanced HCC.~iNKT Cell Loading Dose：9x10\^7/m2.~IL-2: IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.~Tegafur: Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks."
62823332|NCT03175679|EXPERIMENTAL|iNKT cell loading dose:1x10^10/m2|"Autologous in vitro expanded iNKT cells in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with advanced HCC.~iNKT Cell Loading Dose：1x10\^10/m2.~IL-2: IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.~Tegafur: Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks."
62823333|NCT06599957||Bone and soft tissue sarcomas|Patients affected by sarcoma and undergoing surgical removal of the tumor or performing a biopsy will be enrolled. Only patients whose resection will provide sufficient tumor tissue that exceed what is necessary for pathological diagnosis characterization and banking will be enrolled.
62823334|NCT06585826||Syrian female|
62823335|NCT06585826||Turkish female|
62823336|NCT06407921|EXPERIMENTAL|Whole Body Vibration Therapy|This group will receive Whole Body Vibration Therapy
62823337|NCT06407921|EXPERIMENTAL|BOSU ball therapy|This group will receive BOSU ball therapy
62823338|NCT04066283||Older transgender women|This cohort will consist of transgender women aged 50-75 years old who have taken estradiol and spironolactone for at least one year.
62823339|NCT04066283||Younger transgender women|This cohort will consist of transgender women aged 18-40 years old who have taken estradiol and spironolactone for at least one year.
62823340|NCT06594055|ACTIVE_COMPARATOR|Control|The control group used self-monitoring blood glucose (SMBG) for two weeks with a manual food diary, followed by diet education. They then repeated SMBG with a food diary three months later, with a final follow-up at the 6-month mark.
62245220|NCT05119621|NO_INTERVENTION|Standard pain management|The control group will receive standard pain treatment without any intervention. The group will not receive any other intervention.
62435601|NCT05684250|EXPERIMENTAL|The time course group|The time course of the effect of biofeedback training in young adults wearing MFCLs. Subjects will receive one episode of auditory biofeedback training and accommodation will be measured before the training and after the training on a weekly basis for 3 weeks.
62042373|NCT00675389|EXPERIMENTAL|B|Peer Health Workers and Mobile Phone Intervention
62042374|NCT00675389|NO_INTERVENTION|C|Control
62042375|NCT04832828||COVID+ Group|Patients diagnosed with Covid19 positive in last 7 days
62245221|NCT02979925|EXPERIMENTAL|Active transcutaneous magnetic stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
62245222|NCT02979925|SHAM_COMPARATOR|Sham transcutaneous magnetic stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
62245223|NCT04938830|EXPERIMENTAL|Clesrovimab|Participants will receive intramuscular (IM) injections of clesrovimab and placebo
62245224|NCT04938830|ACTIVE_COMPARATOR|Palivizumab|Participants will receive IM injections.
62823341|NCT06594055|EXPERIMENTAL|Treatment 1|Treatment 1 group used CGM (Freestyle Libre) for two weeks with an AI food camera, followed by diet education. They then repeated CGM for two weeks with an AI food camera three months later, with a final follow-up at the 6-month mark.
62823342|NCT06594055|EXPERIMENTAL|Treatment 2|Treatment 2 group used CGM for two weeks with an AI food camera, followed by diet education, without a repeat three months later. They had a final follow-up at the 6-month mark.
62823343|NCT06590974||Freeze-dried Human Protein C Concentrate (TAK-662)|Participants will be administered Freeze-dried Human Protein C Concentrate (TAK-662) intravenous injection.
62602032|NCT05845450|EXPERIMENTAL|Cohort 6: dMMR/MSI-H status|"Patients selected for the presence of dMMR/MSI-H status and absence of POLE/D1 proof-read domain pathogenic mutation associated with ultra-mutated status will receive a short-course preoperative treatment with the anti-CTLA4 antibody botensilimab 1 mg/kg on day 1.~After receiving the short-course preoperative treatment, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant chemotherapy as per national and international guidelines and according to the suggestion of a central multidisciplinary team. Then, standard follow up will be started as per local guidelines."
62042376|NCT05492266|EXPERIMENTAL|Expiratory Muscle Strength Training + No Maintenance Training|These participants were initially randomized to complete 6-8 weeks of exercises with EMST-150. They had improvement in their speech score of 2 points or more and were randomized to complete 6 months of no maintenance training.
62042377|NCT05492266|NO_INTERVENTION|No Exercises|These participants were initially randomized to 6-8 weeks of no exercises. They ended active study participation after the initial 6-8 weeks of no exercises. They were not eligible to be randomized to maintenance training or no maintenance training.
62042378|NCT05492266|EXPERIMENTAL|Expiratory Muscle Strength Training + Maintenance Training|These participants were initially randomized to complete 6-8 weeks of exercises with EMST-150. They had improvement in their speech score of 2 points or more and were randomized to complete 6 months of maintenance training.
62042379|NCT05492266|EXPERIMENTAL|Expiratory Muscle Strength Training|These participants were initially randomized to complete 6-8 weeks of exercises with EMST-150. They did not have improvement in their speech score of 2 points or more and ended active study participation after the initial 6-8 weeks of exercises.
62245225|NCT06735378|EXPERIMENTAL|Randomization Order 1|"Participants will be randomized into one of the two groups indicating the order in which they will receive the exercise intervention.~Randomization Order 1 will receive the exercise treatment on the first day of the first week of the study. The other three days without exercise will consist of standard dialysis sessions with study procedures."
62823344|NCT06113068|EXPERIMENTAL|Fistura procedure|
62823345|NCT05904704|EXPERIMENTAL|Diagnostic (oxygen-enhanced MRI)|Patients receive supplemental oxygen while undergoing standard of care MRI.
62042380|NCT03527225|EXPERIMENTAL|Music|Patients randomized to the music intervention arm will select a preferred genre of music from an internet based resource.
62245226|NCT06735378|EXPERIMENTAL|Randomization Order 2|"Participants will be randomized into one of the two groups indicating the order in which they will receive the exercise intervention.~Randomization Order 2 will receive the exercise treatment on the first day of the fourth week of the study. The other three days without exercise will consist of standard dialysis sessions with study procedures."
62245227|NCT06107972|EXPERIMENTAL|Launching! to Adulthood (¡Iniciando! la Adultez) program|
62245228|NCT02819076||Painless Children|30 children
62823346|NCT06595849|EXPERIMENTAL|Intervention|This is a single-arm trial, where all participants will be assigned to the intervention group.
62823347|NCT02121223|ACTIVE_COMPARATOR|Control|Patients in control group will receive current standard therapy for STEMI: manual thrombus aspiration + Promus Element stent implantation ( with a pressure less than 12 atm), but not post-dilatation
62823348|NCT02121223|EXPERIMENTAL|Post-dilatation|Patients in this group will receive high pressure post-dilatation with a Quantum Maverick balloon after manual thrombus aspiration + Promus Element stent implantation
62823349|NCT06554873|EXPERIMENTAL|Nicotine Non-Responders|Participants that were not successful in reducing their expired carbon monoxide by the end of week 2 will not continue in the study.
62823350|NCT06554873|EXPERIMENTAL|Nicotine Responders - Group 1|Participants that were successful in reducing their expired carbon monoxide by the end of week 2 will be randomized to continued use of their choice of nicotine products for an additional 10 weeks (12-week total treatment period).
62602033|NCT05845450|EXPERIMENTAL|Cohort 7: dMMR/MSI-H status|"Patients selected for the presence of dMMR/MSI-H status and absence of POLE/D1 proof-read domain pathogenic mutation associated with ultra-mutated status will receive a short-course preoperative treatment with the anti-CTLA4 antibody botensilimab 1 mg/kg on day 1 plus the anti-PD-1 balstilimab 3 mg/Kg on days 1 and 15.~After receiving the short-course preoperative treatment, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant chemotherapy as per national and international guidelines and according to the suggestion of a central multidisciplinary team. Then, standard follow up will be started as per local guidelines."
62602034|NCT05845450|EXPERIMENTAL|Cohort 8: KRAS G12C mutated|Patients selected for the presence of pMMR/MSS status and KRAS G12C mutation will receive a short-course preoperative targeted treatment with the KRAS G12C inhibitor sotorasib 960 mg orally once daily from day 1 to 28 plus the EGFR inhibitor panitumumab 6 mg/kg IV on days 1 and 15.
62602035|NCT02718248|EXPERIMENTAL|CHESS Mobile Health Group|The intervention will be six weekly one hour sessions of face-to-face problem solving therapy combined with the CHESS Mobile Health smart phone application (Comprehensive Health Enhancement Support System - CHESS). The CHESS Mobile Health smart phone application enables users to access relevant resources, create a support network and check in regularly with carers. The intervention will be delivered by Dr. Hatcher, a staff psychiatrist in Liaison Psychiatry at The Ottawa Hospital General Campus.
62602036|NCT03098056|EXPERIMENTAL|PROG2|All subjects will be participating in a lifestyle change program - specifically a high protein, limited carbohydrate food plan (High Phyto-PRO food plan), physical activity and a cognitive behavioral program consisting of 11 group visit. Participants will be recieving nutritional Supplements.
62823351|NCT06554873|EXPERIMENTAL|Nicotine Responders - Group 2|Participants that were successful in reducing their expired carbon monoxide by the end of week 2 will be randomized to continued use of their choice of nicotine products for an additional 22 weeks (24-week total treatment period).
62823352|NCT05849142|EXPERIMENTAL|MRIdian Linac Group|All accrued participants will be enrolled onto the MRIdian Linac Group. Participants will receive adaptive radiotherapy (ART) on the MRIdian Linac. Participants will complete the duration of their radiotherapy regimen on the MRIdian Linac for approximately 7 weeks.
62823353|NCT04599244|EXPERIMENTAL|emergency pulpotomy|intervention arm
62823354|NCT04599244|ACTIVE_COMPARATOR|complete pulp extirpation|control arm
62042381|NCT03527225|NO_INTERVENTION|No Music|These patient's will have no music playing during the first radiotherapy session.
62042382|NCT00413387|EXPERIMENTAL|1|chf1535
62042383|NCT00413387|ACTIVE_COMPARATOR|2|Symbicort
62245229|NCT02819076||Painful Children|70 children
62245230|NCT05008926|EXPERIMENTAL|Naloxegol|"Administration of Naloxegol 25 mg per day by nasogastric tube (NG) or orogastric tube (OG). The administration should be started within the first 24 hours after the patient is admitted to intensive care unit and continued for the duration of the administration of the morphine derivative and until 48 hours after its discontinuation.~Management of constipation and gastroparesis according to the recommendations."
62245231|NCT05008926|PLACEBO_COMPARATOR|Placebo|Administration of the placebo according to the same procedures as the experimental arm.
62245232|NCT06508541||conventional surgery|All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose.
62245233|NCT06508541||Indocyanine green fluorescence-guided surgery|Approximately 0.3 ml of ICG dissolved in 2.5 mg/ml of sterile water was injected submucosally by the endoscopic doctors through colonoscopy at two points around the tumor.All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose using ICG lymphangiography procedure
62245234|NCT06735547|EXPERIMENTAL|Telerehabilitation|Patients will receive telerehabilitation by means of the TRAK mobile tool, collecting data and allowing them to monitor their activity through ROM during exercises (bio-feedback).
62245235|NCT06735547|ACTIVE_COMPARATOR|Conventional Therapy|Patients will be assessed by a professional physiotherapist, who will monitor their progress, by measuring range of motion (ROM), and stability, making corrections if necessary.
62245236|NCT04784715|EXPERIMENTAL|Arm A|Trastuzumab deruxtecan (T-DXd) plus pertuzumab-matching placebo
62245237|NCT04784715|EXPERIMENTAL|Arm B|Trastuzumab deruxtecan (T-DXd) plus pertuzumab
62245238|NCT04784715|ACTIVE_COMPARATOR|Arm C|Standard of care (Taxane (paclitaxel or docetaxel), trastuzumab, and pertuzumab)
62823355|NCT06599359||Pharmacists|Employed Lebanese Pharmacists/Pharmacy Students
62849253|NCT01404936|EXPERIMENTAL|Interferon-2A + Chemotherapy|Interferon-2A 4 (x106 IU/m\^2) subcutaneously Day 1 - 4 + ABVD Chemotherapy on Day 4 (ABVD: Adriamycin 25 mg/m2 intravenous (IV), Bleomycin 10 mg/m\^2 IV, Velban 6 mg/m2 IV, and Dacarbazine 375 mg/m2 IV)
62602037|NCT03976947||Before group|"The before group is the control group. We collect retrospective data in consecutive patients operated before the implementation of lung recruitment maneuvers protocol"
62245239|NCT05836051|EXPERIMENTAL|Hexyl Acetate|E-cigarette liquid containing hexyl acetate, ethyl maltol, propylene glycol, vegetable glycerin and methylbutyl acetate with nicotine salt.
62602038|NCT03976947||After group|We collect data in consecutive patients operated after the implementation of lung recruitment maneuvers protocol. This lung recruitment maneuvers will be realised along the surgery, (After tracheal intubation, per-CPB, post-CPB). Each recruitment maneuver consisted of applying a continuous positive airway pressure of 30 cm of water for 30 seconds
62602039|NCT00697541|EXPERIMENTAL|A|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after four hours
62602040|NCT00697541|ACTIVE_COMPARATOR|B|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
62602041|NCT02120820|ACTIVE_COMPARATOR|Multisensory environment|Multisensory environment (MSE): 30 minutes/session, twice a week for 10 weeks
62602042|NCT02120820|ACTIVE_COMPARATOR|Massage therapy|Massage therapy (MT): 15 minutes/session, twice a week for 10 weeks
62245240|NCT05836051|ACTIVE_COMPARATOR|Ethyl Acetate|E-cigarette liquid containing ethyl acetate, ethyl maltol, propylene glycol, vegetable glycerin and methylbutyl acetate with nicotine salt.
62602043|NCT02120820|OTHER|Control group|Control group: usual care for 10 weeks, with attention and interactions with the caregivers only.
62602044|NCT02120820|ACTIVE_COMPARATOR|Massage in multisensory environment|Participants receive 15 minutes massage therapy in multisensory environment (MT-MSE), twice a week for 10 weeks.
62602045|NCT04064021|EXPERIMENTAL|Acupuncture|Acupuncture 12 sessions over 6 week to be given to pateints
62602046|NCT03811327|EXPERIMENTAL|Treatment group|Zero-time Exercise group
62602047|NCT03811327|NO_INTERVENTION|Waitlist group|
62245241|NCT06442800|EXPERIMENTAL|Alcohol Messages|Participants will view and rate 10 messages shown on alcohol containers.
62435602|NCT05684250|EXPERIMENTAL|The repetition group|Subjects will receive one episode of auditory biofeedback training every week for 3 weeks and accommodation will be measured before the training and after the training on a weekly basis.
62602048|NCT04988477|EXPERIMENTAL|Chronic care for tobacco use|Quarterly brief provider interventions about tobacco and 3 quarterly proactive outreach calls to connect patients to telephone cessation counseling and facilitate obtaining cessation medication.
62602049|NCT01992315|EXPERIMENTAL|Adipose-Derived ECM|
62245242|NCT04045951|EXPERIMENTAL|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SER at 3 years.
62245243|NCT04045951|NO_INTERVENTION|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
62245244|NCT04564976|EXPERIMENTAL|Social Support|
62245245|NCT06181201||Person with rectal cancer|People with locally advanced rectal cancer who are to receive induction chemotherapy with FLOFIRINOX followed or not by neo-adjuvant radio-chemotherapy of the Cap50 type.
62435603|NCT05684250|EXPERIMENTAL|The longer duration group|Subjects will receive one episode of auditory biofeedback training for twice as long every week for 3 weeks and accommodation will be measured before the training and after the training on a weekly basis.
62435604|NCT04193722|EXPERIMENTAL|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy consists of 30-40 treatment sessions (1 session per day during 5 days per week). During the hyperbaric oxygen (HBO) sessions the pressure will be raised to 2.4 atmospheres absolute in a hyperbaric chamber and patients breath in 100% oxygen during 4 times 20 minutes.
62245246|NCT02708095|EXPERIMENTAL|2 mg Baricitinib|Participants received 2 (milligrams) mg of Baricitinib tablet orally once a day for 24 weeks.
62245247|NCT02708095|EXPERIMENTAL|4 mg Baricitinib|Participants received 4 mg of Baricitinib tablet orally once a day for 24 weeks.
62245248|NCT02708095|PLACEBO_COMPARATOR|Placebo|Participants received Placebo orally once daily (QD) for 24 weeks.
62245249|NCT06565442||Study Group|Using the NeuraSignal transcranial doppler robot in a neuro ICU setting to measure cerebral blood flow correlated with arterial blood pressure to generate individualized cerebral autoregulatory curves.
62245250|NCT04475666|ACTIVE_COMPARATOR|Replenish protein group|The subjects randomized to this group will receive the standard amount of proteins (maximum 1.2 g/kg/day) from the primary polymeric formula AND supplemental protein at 1.2 g/kg/day
62245251|NCT04475666|ACTIVE_COMPARATOR|Standard protein group|The subjects randomized to this group will receive standard prescription without supplemental proteins (maximum1.2 g/kg/day) from the primary polymeric formula. No supplemental protein will be allowed
62245252|NCT00935272|EXPERIMENTAL|Treatment|Restylane® Treatment
62245253|NCT00935272|NO_INTERVENTION|Non-Treatment|Non-Treatment Arm
62435605|NCT04193722|NO_INTERVENTION|Usual care|Usual care may consist of physiotherapy, analgetics, edema therapy
62602050|NCT01237249|ACTIVE_COMPARATOR|MPV followed by Revlimid/Low Dose Dexamethasone (Rd)|Melphalan/Prednisone/Velcade (MPV) followed by Revlimid/Low Dose Dexamethasone (Rd)
62602051|NCT01237249|EXPERIMENTAL|Alternating MPV with Revlimid/Low Dose Dexamethasone|Alternating Velcade/Melphalan/Prednisone (MPV) with Revlimid/Low Dose Dexamethasone (Rd)
62602052|NCT06050720|OTHER|Sleep disorder patients|The study participants have been referred by a clinician to the sleep clinic for diagnosis of a sleep disorder, possibly sleep apnoea.
62602053|NCT00976209|EXPERIMENTAL|Phenylephrine Hydrochloride Extended Release Tablets, 30 mg|
62602054|NCT00976209|ACTIVE_COMPARATOR|Phenylephrine Hydrochloride Immediate Release Tablets, 10 mg|
62602055|NCT06649227|OTHER|Experimental group|
62849254|NCT01738477|EXPERIMENTAL|Boostrix Group 2|Healthy male of female subjects, aged 19 to 30 years of age at the time of booster vaccination, who were randomized to the Lot A, Lot B or Lot C groups in study NCT00109330, received a second dose of Boostrix in this study.
62602056|NCT06498089|EXPERIMENTAL|The precise therapy arm|"Patients will be given treatment based on their clinical-molecular phenotype according to a predesigned scheme:~1. Patients in constitutional type will be given treatments with GCs combined with TCZ and MTX.~2. Patients in vascular inflammation type without IL-6 and TNF-α elevation will be given treatments with GCs combined with TOF.~3. Patients in vascular inflammation type with IL-6 elevation will be given treatments with GCs combined with TCZ and MTX.~4. Patients in vascular inflammation type with TNF-α elevation will be given treatments with GCs combined with ADA and MTX."
62602057|NCT06498089|ACTIVE_COMPARATOR|The traditional therapy arm|Patients will be given traditional treatment based on their clinical-molecular phenotype according to a predesigned scheme.
62602058|NCT00274443|EXPERIMENTAL|ABI-007 and Carboplatin|ABI-007 and Carboplatin in patients with Advanced Non-Small Cell Lung Cancer.
62602059|NCT04912219|EXPERIMENTAL|Treatment|
62602060|NCT04912219|NO_INTERVENTION|Control|
62602061|NCT02472743|EXPERIMENTAL|Custom-built phototherapy lamp|"Custom-built phototherapy lamp:~All participants will receive light treatment twice weekly for three weeks (or until ulcer/s healing) to one or both hands (both hands if ulcer/s present bilaterally).~The participant will place their hand within the treatment area of the light-based device (total treatment area approximately 15cm2), aiming to centralise the digital ulcer/s to the centre of the treatment region.~At each treatment study visit (visits 1-6 inclusive), the device will undergo a period of (automatic) calibration before use. All three wavelengths (red, infrared and blue) will be delivered simultaneously in combination, with the fluence of the device set at \[3J/cm2\] (treatment duration approximately 10 to 15 minutes)."
62602062|NCT05351541|EXPERIMENTAL|Psilocybin in combination with Zolpidem and Modafinil|Single dose of Psilocybin (1mg-30mg) in combination with zolpidem and modafinil
62602063|NCT05351541|EXPERIMENTAL|Psilocybin in combination with Zolpidem|Single dose of Psilocybin (1mg-30mg) in combination with zolpidem
62602064|NCT05351541|EXPERIMENTAL|Psilocybin in combination with Modafinil|Single dose of Psilocybin (1mg-30mg) in combination with modafinil
62435606|NCT06331078|EXPERIMENTAL|Square Stepping Exercise Group|The experimental group will have Square Stepping Exercise training twice a week for 4 weeks. Each session will start with a 15-minute warm-up, followed by a 40-minute Square Stepping Exercise workout and ending with a 15-minute cool-down. The Square Stepping Exercise part will start with the Elementary 2 level, which has 30 different patterns. Participants will start with the first pattern at this level. If they can complete it without mistakes within 15 seconds, they'll move on to the next pattern. If not, they'll repeat the pattern until they get it right within the time limit. Each session will have four participants, with two participants working on each of the two mats, which are divided into 40 squares and measure 100cm by 250 cm.
62435607|NCT06331078|ACTIVE_COMPARATOR|Aerobic Exercise Group|Individuals in the aerobic control cohort will partake in a 40-minute treadmill walking session, maintaining their heart rate at 60% of their individual heart rate reserve as calculated using the Karvonen formula. Before and after the aerobic exercise, a 5-minute warm-up session incorporating stretching and calisthenics, as well as a 5-minute cool-down session, will be conducted.
62602065|NCT05351541|EXPERIMENTAL|Psilocybin in combination with Placebo|Single dose of Psilocybin (1mg-30mg) in combination with placebo
62602066|NCT04527211|EXPERIMENTAL|Ivermectin|Oral administration of ivermectin 200 mcg/kg every week for seven weeks
62602067|NCT04527211|PLACEBO_COMPARATOR|Placebo|Oral administration of placebo of similar characteristics every week for seven weeks
62602068|NCT02211963|EXPERIMENTAL|BI 44847|
62823356|NCT06510439|EXPERIMENTAL|Need to be Needed Intervention|Interventionists will meet with participants to discuss supported volunteering concepts and develop an initial plan. This plan will be flexible as it is likely that participants will need multiple opportunities to identify and explore options for voluntarism. Once the plan is developed, interventionist will make weekly contact to support participants in achieving goals. These weekly contacts (3x per month) are expected to be brief (30-40 minutes) and focused on information sharing and supported problem solving. Interventionists will also schedule monthly plan reviews (1x per month) with participants to review and revise supported volunteering individualized plans. Both clients who are achieving goals as well as those falling short of their goals may want to revise or change their plan.
62823357|NCT06510439|ACTIVE_COMPARATOR|Active control group|Participants assigned to the attention control condition will receive printed information on the importance and opportunities for volunteering and will be encouraged to review resources from the TU Collaborative website. They will receive weekly 10-minute non-directive supportive listening sessions via telephone/videoconferencing with a Research assistant. Research assistants are full-time staff members with an undergraduate degree in psychology. Undergraduate students are not involved in performing the weekly check-ins with the control group. The control group will not receive weekly 1:1 support through a trained clinician.
62042384|NCT04001673|ACTIVE_COMPARATOR|Pharmacist's intervention|Evaluation of knowledge and adherence of patients treated by bDMARDs before and after the intervention of a pharmacist that will give information concerning bDMARDs management.
62823358|NCT05367778|EXPERIMENTAL|HS-10370（Phase 1a：Dose Escalation）|Subjects with advanced solid tumors will be enrolled in dose escalation cohorts. Dose escalation of HS-10370 will be done to determine maximum tolerated dose.
62042385|NCT04001673|NO_INTERVENTION|Control|Evaluation of knowledge and adherence of patients treated by bDMARDs who did not receive pharmacist's intervention.
62042386|NCT06578910||640AD|80 patients (105 eyes) implanted with 640AD IOL monocularly or binocularly
62042387|NCT01509222|OTHER|Personalized nurition counseling|Personalized nutrition counseling based on dietary intake and motivation to change.
62042388|NCT01509222|NO_INTERVENTION|Control|No intervention, control group.
62435608|NCT03952910|EXPERIMENTAL|Experimental group|Online pain education program will be accessible by the intervention group
62602069|NCT02211963|PLACEBO_COMPARATOR|Placebo|
62602070|NCT05914038|EXPERIMENTAL|individualized rTMS|Patients will receive individualized repetitive transcranial magnetic stimulation according to lateralization index measured by functional near-infrared spectroscopy
62823359|NCT05367778|EXPERIMENTAL|HS-10370（Phase 1b：Dose Expansion ）|Depending on data obtained from the dose escalation part, dose expansion may proceed with multiple cohorts in subjects with advanced solid tumors having a KRAS G12C mutation.
62823360|NCT05367778|EXPERIMENTAL|HS-10370（Phase 2 ）|Subjects with locally advanced or metastatic KRAS G12C mutant NSCLC will be enrolled in phase 2 part to evaluate the efficacy and sufficient safety of HS-10370 as monotherapy.
62823361|NCT02212015|EXPERIMENTAL|Pazopanib + Paclitaxel|Paclitaxel administered every 28 days at day 1, day 8 and day 15 as a 2h intravenous infusion in a dose of 70mg/m2 in combination with pazopanib in a daily oral dose of 800mg (2x400mg)
62245254|NCT06528691|EXPERIMENTAL|Entrectinib therapy, Cohort 1 and Cohort 2|"Cohort 1: Patients who are younger than 3 years of age diagnosed with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG) will receive therapy as outline in Detailed Description.~Cohort 2: Patients who are younger than 3 years of age diagnosed with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG will receive therapy as outline in Detailed Description."
62042389|NCT03872752|EXPERIMENTAL|Lay leader training in FL intervention|Community lay leaders from pre-existing community frameworks will undergo training in a manualized program that enables lay leaders to effectively disseminate food literacy skills through engaging visual and game-based tools in a food literacy workshop. Post training, lay leaders will implement the food literacy workshop in their communities.
62245255|NCT06735274||Ischemic Stroke (Carotid Circulation)|Patients with ischemic stroke of atherosclerotic, cardioembolic and embolic etiology from an unknown source
62245256|NCT06735274||Ischemic Stroke (Posterior Circulation)|Patients with ischemic stroke of atherosclerotic, cardioembolic and embolic etiology from an unknown source
62245257|NCT06735274||Haemorrhagic Stroke|Patients with intracerebral haemorrhages
62245258|NCT05139849|ACTIVE_COMPARATOR|Intervention|"Adrenaline, vasopressin and steroids arm (intervention)~1. At randomization~   1 ml of vasopressin 20 IU/ml will be administered as soon as possible after adrenaline during the five first cycles of drug administration during CPR.~   1 ml metylprednisolone sodium succinate 40 mg/ml will be administered only during the first cycle of drug administration during CPR~2. In the ICU Hydrocortisone 3 mg/ml At 4 hours post ROSC, and then once daily, surviving patients with post-resuscitation shock will receive an infusion of 100 ml (300 mg hydrocortisone/ d) for ≤ 7 days. From day 8 post ROSC or when vasopressors are not needed the hydrocortisone dos will be reduced daily to 67 ml (200 mg) and 33 ml (100 mg) and then discontinued). Patients with evidence of acute myocardial infarction will receive an infusion of 100 ml (300mg hydrocortisone/ d) for maximum 3 days to prevent retardation of infarct healing."
62245259|NCT05139849|PLACEBO_COMPARATOR|Control|"Adrenaline alone arm (control)~1. At randomization 1 ml sodium chloride 9 mg/ml (placebo) will be administered as soon as possible after adrenaline during the first five cycle of drug administration during CPR 1 ml sodium chloride 9 mg/ml (placebo) will be administered only during the first cycle of drug administration during CPR~b In the ICU sodium chloride 9 mg/ml (placebo) At 4 hours post ROSC, and then once daily, surviving patients with post-resuscitation shock will receive an infusion of 100 ml for ≤ 7 days. From day 8 post ROSC or when vasopressors are not needed the dos will be reduced daily to 67 ml and 33 ml and then discontinued. Patients with evidence of acute myocardial infarction will receive an infusion of 100 ml for 3 days."
62435609|NCT03952910|NO_INTERVENTION|Control group|No intervention for the control group, only one-page simple material related to pain will be provided.
62435610|NCT01956279|EXPERIMENTAL|Pregnenolone (Arm 1)|Pregnenolone
62435611|NCT01956279|PLACEBO_COMPARATOR|Placebo (Arm 2)|Placebo
62823362|NCT05224973|EXPERIMENTAL|speech therapy combined with digital fine motor stimulation|At the beginning of the swallowing rehabilitation session, a fine manual motor training is practiced during the first ten minutes of the session. Training consists of activities requiring increasing precision and different types of grips
62823363|NCT05224973|ACTIVE_COMPARATOR|speech therapy only|standard swallowing rehabilitation session
62042390|NCT00842140|ACTIVE_COMPARATOR|1|This group will receive an oral contraceptive containing 0,03mg ethynylestradiol and 2mg chlormadinone acetate
62042391|NCT00842140|EXPERIMENTAL|2|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
62823364|NCT02314468|ACTIVE_COMPARATOR|negative pressure wound therapy (NPWT)|negative pressure wound therapy (NPWT)
62823365|NCT02314468|ACTIVE_COMPARATOR|Glycerol Preserved Allografts (GPA)|Glycerol Preserved Allografts (GPA)
62823366|NCT06598839|NO_INTERVENTION|Control group|only observation after surgery
62823367|NCT06598839|EXPERIMENTAL|Tα1 group|Tα1 treatment for 3 months after surgery
62602071|NCT05914038|ACTIVE_COMPARATOR|Traditional rTMS|Control group is given traditional rTMS
62823368|NCT01703195|OTHER|Diffusion Weighted Magnetic Resonance Imaging (DWMR)|Patients receive Magnetic Resonance Imaging (MRI) and Diffusion Weighted Magnetic Resonance Imaging (DWMR) imaging pre-treatment and 4-6 weeks post-treatment.
62823369|NCT03732417||Stroke patients|Control group included people with ischemic or haemorragic stroke in Terres de l'Ebre, Spain.
62823370|NCT03732417||Telematic model treatment of patients with Stroke|The intervention group included control and education for the patient's health to promote self-care and empowerment, and enhance pharmacological compliance. The telematic model has been developed through clinical practice guides of primary care and the most recent publications on the subject referenced.
62823371|NCT06307340|EXPERIMENTAL|Adapted STAIR-NT Intervention|
62042392|NCT00842140|EXPERIMENTAL|3|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg metformin.
62042393|NCT06230289|ACTIVE_COMPARATOR|Group B: Transabdominal plane block group|Patients agreeing to participate will be allocated to the control group (Group C, n=25) or the block group (Group B, n=25). The allocation will be randomized using a web-based data entry and randomization platform (by using envelope selection method) by an anesthesiologist not involved in the study. At the end of the surgery, patients in Group B will receive a four-point TAP block.
62245260|NCT05691504|EXPERIMENTAL|Treatment (pelcitoclax, cobimetinib)|Patients receive APG-1252 IV Q7D. Patients also receive cobimetinib PO QD on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy and collection of blood on study and undergo CT and/or MRI throughout the trial. Patients undergo ECHO or MUGA during screening and on study.
62245261|NCT02884154|OTHER|Arm who will undergo EUS-FNB|
62245262|NCT06678373|EXPERIMENTAL|Group A(Ages 6 to 17)|The patient needs to receive 1 dose of inactivated Japanese encephalitis vaccine.
62245263|NCT06678373|EXPERIMENTAL|Group B(Ages 18 to 39)|The patient needs to receive 2 doses of inactivated Japanese encephalitis vaccine, with an interval of 28 days.
62245264|NCT06678373|EXPERIMENTAL|Group C(C1 Age 18-39 years)|The patient needs to receive 2 doses of inactivated Japanese encephalitis vaccine, with an interval of 7 days.
62435612|NCT00401882|ACTIVE_COMPARATOR|Standard Of Care Drug Epinephrine|Additional doses of Epinephrine (1 mg) given as part of standard of care during cardiac arrest
62042394|NCT06230289|NO_INTERVENTION|Group C: Control group with multi-modal analgesia|Patients agreeing to participate will be allocated to the control group (Group C, n=25) or the block group (Group B, n=25). The allocation will be randomized using a web-based data entry and randomization platform (by using envelope selection method) by an anesthesiologist not involved in the study. At the end of the surgery, patients in Group C which will be performed no interventional procedures.
62042395|NCT06191718|EXPERIMENTAL|Tria Mitral Valve|Patients receiving the Foldax Mitral Valve
62245265|NCT06678373|EXPERIMENTAL|Group C(C2 Age 40-59 years)|The patient needs to receive 2 doses of inactivated Japanese encephalitis vaccine, with an interval of 7 days.
62245266|NCT06678373|EXPERIMENTAL|Group C(C3 Age 60 years and above)|The patient needs to receive 2 doses of inactivated Japanese encephalitis vaccine, with an interval of 7 days.
62435613|NCT00401882|ACTIVE_COMPARATOR|IV Metoprolol instead Epinephrine|IV metoprolol 5 mg. up to 2 times (only) during cardiac arrest will be given instead of additional Epinephrine doses
62435614|NCT01846247|PLACEBO_COMPARATOR|Standard Care|Standard stroke unit rehabilitation care
62435615|NCT01846247|EXPERIMENTAL|Standard Care + VEM|Standard stroke unit rehabilitation care in addition to a very early rehabilitation protocol
62435616|NCT05127603|EXPERIMENTAL|Individually tailored physiotherapy; cognitive behavioral intervention|The intervention is offered in accordance with the Neck Pain Guidelines, with a focus on influencing dysfunctional illness perceptions and dysfunctional movement/ pain behavior.
62435617|NCT00670878|EXPERIMENTAL|A|
62435618|NCT00670878|ACTIVE_COMPARATOR|B|
62823372|NCT06307340|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|
62435619|NCT01986842|EXPERIMENTAL|Low protein|Subject will receive a low protein diet (0.7 g/kg BW/day) for 14 days prior to the experimental trial
62435620|NCT01986842|EXPERIMENTAL|High protein|Subjects will receive a high protein diet (1.5 g/kg BW/day) for 14 days prior to the experimental trial
62435621|NCT06353035|EXPERIMENTAL|Rewilding|Private yards of the intervention study subjects will be modified with berry bushes, fruit trees, perennial yard plants, meadow flowers, cultivation boxes, organic mulch materials, decaying deadwood, leaf compost and organic plant growing media with high microbial diversity.
62435622|NCT06353035|NO_INTERVENTION|Control|The control group's yards will not be modified. Control group receives inorganic fertilizers, moss remover and ant control insecticide (Myrr®; active ingredient imidacloprid 0.03 % w/w).
62435623|NCT03090009|ACTIVE_COMPARATOR|Flurbiprofen|Flurbiprofen 100 mg bid.
62602072|NCT03846115|EXPERIMENTAL|Peer-Led Seeking Safety app|This app is designed for Peer-Led Seeking Safety and includes enhanced app features.
62602073|NCT03846115|ACTIVE_COMPARATOR|Control app|This is a basic app that controls for time and attention. The basic app serves as the intervention in this trial.
62602074|NCT04094272||Chronic hepatitis C participants|Participants with a newly started DAA medication for HCV infection were included in the study.
62602075|NCT06021756|EXPERIMENTAL|Intervention: Ketamine|Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.05 mg/kg/hr to 0.30 mg/kg/hr.
62602076|NCT06618612|OTHER|Standard of Care|Standard of Care (SOC)
62823373|NCT05722535|NO_INTERVENTION|Delayed MDPT|Families assigned to the control condition will receive the MDPT after study completion.
62823374|NCT05722535|EXPERIMENTAL|MDPT|Families randomized to the intervention condition will receive the MDPT after they complete the baseline survey.
62823375|NCT06599762|EXPERIMENTAL|Tranexamic Acid|
62435624|NCT03090009|PLACEBO_COMPARATOR|Placebo|Placebo taken bid
62245267|NCT02675023|EXPERIMENTAL|Auto-injector (AI)|M923 administered via AI
62435625|NCT06374381|NO_INTERVENTION|Adherent: Continue Online Resources|Providers who are adherent to parent coaching strategies during the 8 and 16 week timepoints will not be randomized and continue to use the PEACE Online Resources. They will not receive further implementation supports.
62245268|NCT02675023|EXPERIMENTAL|Prefilled syringe (PFS)|M923 administered via PFS
62435626|NCT06374381|PLACEBO_COMPARATOR|Non Adherent: Continue Online Resources|After 8 and 16 weeks, providers with low coaching adherence could be randomized to continue using the PEACE online resources with no further implementation supports.
62435627|NCT06374381|EXPERIMENTAL|Non Adherent: Group Facilitation|After 8 and 16 weeks, providers with low coaching adherence could be randomized to receive weekly group facilitation.
62435628|NCT06374381|EXPERIMENTAL|Non Adherent: Individual Facilitation|After 16 weeks, providers may be randomized to receive individual facilitation with an expert coach if they continue to be non adherent to the use of parent coaching strategies.
62435629|NCT01007981||CRT device|Patients with Cardiac Resynchronization Therapy(CRT) device implanted in the last 5 years will be studied by the new echo modality.Study doesn't involve acute device implantation.
62435630|NCT01987700|ACTIVE_COMPARATOR|FLEX-HD (underlay)|FLEX-HD human acellular dermal matrix applied using an underlay technique
62435631|NCT01987700|ACTIVE_COMPARATOR|FLEX-HD (overlay)|FLEX-HD human acellular dermal matrix applied using an overlay technique
62245269|NCT02874365|EXPERIMENTAL|Crohn disorder|arm composed by 30 patients with Crohn disorder
62245270|NCT02874365|EXPERIMENTAL|FAP (familial adenomatous polyposis )|arm composed by 30 patients with FAP disorder
62245271|NCT02874365|EXPERIMENTAL|ulcerative colitis|arm composed by 30 patients with ulcerative colitis
62245272|NCT02874365|SHAM_COMPARATOR|witness|arm composed by 30 patients with no intestinal disorders
62245273|NCT03116412|NO_INTERVENTION|Routine follow up|Follow up according to national guidelines.
62245274|NCT03116412|EXPERIMENTAL|Radiological assessments|Radiological assessments (CT or PET scans) at 5 occasions during 3 years.
62245275|NCT04985305|EXPERIMENTAL|Intervention Group|"* Educational session for GPs~* Instructed to complete 10-15 home visits at the nursing home with the optimizing antidepressants and other psychotropic drugs~* Instructed to evaluate neuropsychiatric symptoms before and after the visit using a structured form~* Instructed to complete a teaching session at the nursing home with a pre-defined teaching material~* Instructed to contact the nursing home before the home visit to encourage participation of regular staff and relatives in the home visit or, alternatively, to obtain information from regular staff and relatives before the home visit~* Dialogue tool"
62245276|NCT04985305|ACTIVE_COMPARATOR|Control Group|"* Educational session for GPs~* Instructed to complete 10-15 home visits at the nursing home with the optimizing antidepressants and other psychotropic drugs~* Instructed to evaluate neuropsychiatric symptoms before and after the visit using a structured form"
62245277|NCT04333745|EXPERIMENTAL|Controlled Dietary Study|Participants will consume the controlled diet for five days. After one day on the diet, subjects will provide three 24-hour urine collections. On the last dayof the diet, subjects will come in a fasted state to ingest a small amount of carbon-13 oxalate and sucralose, with hourly urine collections and blood samples being taken before and after the ingestion.
62245278|NCT04762888|EXPERIMENTAL|Diagnostic (68Ga-PSMA PET/MRI or PET/CT)|Patients receive 68Ga-PSMA IV over 90 minutes. Patients then undergo PET/MRI over 60 minutes or PET/CT over 30 minutes.
62245279|NCT05017142||Patient population|Children, adolescents and adults diagnosed with an IBrainD from 2005 onward and with disease onset before age 18, who are born, treated or living in Switzerland
62245280|NCT05932017||Patients receiving routine, pre-diagnosed, standard of care procedures.|Single cohort of patients receiving previously prescribed treatment. The only variable will be the modality of visualization utilized on each side of the mouth during the surgical procedure.
62245281|NCT03203499|EXPERIMENTAL|ANS-6637|Single ascending doses of ANS-6637 administered orally
62245282|NCT03203499|PLACEBO_COMPARATOR|Placebo|Placebo administered orally
62245283|NCT06374914||Patients with BCG unresponsiveness and receiving intravesical gemcitabine doxetaxel|
62245284|NCT06374914||Patients with BCG unresponsiveness and radical cystectomy performed|
62245285|NCT06617793|EXPERIMENTAL|YTB323 Cohort 1|Participants will receive one dose of YTB323
62245286|NCT06617793|EXPERIMENTAL|YTB323 Cohort 2|Participants will recieve one dose of YTB323
62245287|NCT06617793|EXPERIMENTAL|YTB323 Cohort 3|Participants will recieve one dose of YTB323
62245288|NCT06617793|EXPERIMENTAL|YTB323 Cohort 4|Participants will recieve one dose of YTB323
62245289|NCT01264653|EXPERIMENTAL|experimental group,control group|Intraocular adrenalin,topical mydriatics, experimental group: Intervention: Procedure:refractive cataract surgery with Intraocular adrenalin, control group:refractive cataract surgery with topical mydriatics
62245290|NCT05958017|EXPERIMENTAL|reSET Group|Participants in this group will use the reSET mobile app for 12 weeks.
62245291|NCT05958017|OTHER|Standard of Care Group|Participants in this group will receive standard of care treatment for 12 weeks.
62245292|NCT00995007|ACTIVE_COMPARATOR|Group 2|Sequential Group (carboplatin followed by vandetanib)
62245293|NCT00995007|ACTIVE_COMPARATOR|Group 1|Combo Group (both drugs together)
62245294|NCT03836755|OTHER|METACOS|Required to do some motor tasks during static and dynamic RSA
62245295|NCT03747978|EXPERIMENTAL|Perindopril and Amlodipine|Fixed dose combination of Perindopril 5mg and Amlodipine 5mg tablets once daily for 6 weeks
62245296|NCT03747978|ACTIVE_COMPARATOR|Perindopril-Indapamide|Fixed-dose combination of Perindopril 5mg and Indapamide 1.25mg tablets once daily for 6 weeks
62245297|NCT06217094|EXPERIMENTAL|NP-101 (3 g)|
62245298|NCT06217094|EXPERIMENTAL|NP-101 (4.8 g)|
62245299|NCT06217094|EXPERIMENTAL|NP-101 (6 g)|
62435632|NCT01987700|ACTIVE_COMPARATOR|Strattice (underlay)|Strattice porcine acellular dermal matrix applied using an underlay technique
62435633|NCT01987700|ACTIVE_COMPARATOR|Strattice (overlay)|Strattice porcine acellular dermal matrix applied using an overlay technique
62435634|NCT02189694|ACTIVE_COMPARATOR|Insulin pump therapy|Glucose levels will be controlled for 3 consecutive nights using insulin pump therapy. Subjects will carry on with their normal conventional insulin pump therapy and will be allowed to freely implement therapeutic adjustments..
62435635|NCT02189694|ACTIVE_COMPARATOR|Single-hormone closed-loop strategy|Glucose levels will be controlled by single-hormone closed-loop strategy for 3 consecutive nights. A member of the research team will be present at the diabetic camp to ensure protocol implementation and patient's safety. Glucose levels will be controlled by single-hormone closed-loop strategy between 22:00 until 7:00 next morning. Glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pump's parameters will then be changed manually to implement the computer generated recommendations.
62823376|NCT06599762|PLACEBO_COMPARATOR|Matching Placebo|
62823377|NCT05002127|EXPERIMENTAL|Phase 2 - Arm A|Evorpacept (ALX148) 30 mg/kg Q2W IV, trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
62042396|NCT02320565|EXPERIMENTAL|3D Laparoscopy|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with 3D Laparoscopic technology.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition 3D telescope. Two additional 5 mm ports are placed under direct visualization. One more 5- mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system"
62245300|NCT05161572|EXPERIMENTAL|Perioperative chemotherapy plus PD-1 antibody plus preoperative chemoradiotherapy|In this arm, patients will receive preoperative chemoradiotherapy (45Gy/25Fractions), two cycles of SOX and three cycles of PD-1 antibody, followed by D2 surgery and three more cycles of SOX and PD-1 antibody. Then PD-1 antibody will be given until one year after surgery.
62823378|NCT05002127|ACTIVE_COMPARATOR|Phase 2 - Arm B|Trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
62245301|NCT05161572|EXPERIMENTAL|Perioperative chemotherapy plus PD-1 antibody|In this arm, patients will receive three cycles of SOX and PD-1 antibody, followed by D2 surgery and three more cycles of SOX and PD-1 antibody. Then PD-1 antibody will be given until one year after surgery.
62245302|NCT06735014||Participants with ALS|Adults with early stage ALS
62245303|NCT06735014||Participants without ALS|Control participants free from neurological disease
62245304|NCT06735937|EXPERIMENTAL|End-tidal controlled|Patients ventilated using end tidal controlled low-flow anesthesia
62245305|NCT06735937|EXPERIMENTAL|Manually controlled|Patients ventilated using manually controlled low flow anesthesia
62245306|NCT05827653|EXPERIMENTAL|Cohort 1_active|Dose 1 NX210c
62245307|NCT05827653|EXPERIMENTAL|Cohort 1_placebo|Placebo
62245308|NCT05827653|EXPERIMENTAL|Cohort 2_active|Dose 2 (TBC) NX210c.
62245309|NCT05827653|EXPERIMENTAL|Cohort 2_placebo|Placebo
62823379|NCT05002127|EXPERIMENTAL|Phase 3 - Arm A|Evorpacept (ALX148) 30 mg/kg Q2W IV, trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
62435636|NCT02189694|ACTIVE_COMPARATOR|Dual-hormone closed-loop strategy|Glucose levels will be controlled by dual-hormone closed-loop strategy for 3 consecutive nights. A member of the research team will be present at the diabetic camp to ensure protocol implementation and patient's safety. Glucose levels will be controlled by dual-hormone closed-loop strategy between 22:00 until 7:00 next morning. Glucose sensor readings will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses. Pumps' parameters will then be changed manually to implement the computer generated recommendations.
62823380|NCT05002127|ACTIVE_COMPARATOR|Phase 3 - Arm B|Ramucirumab 8 mg/kg Q2W IV and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
62042397|NCT02320565|ACTIVE_COMPARATOR|Standard Laparoscopy|Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with standard laparoscopy technology. A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope. Two additional 5 mm ports are placed under direct visualization. One more 5 mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system.
62042398|NCT01508429|ACTIVE_COMPARATOR|misoprostol|800mcg misoprostol (four tablets of 200 mcg administered sublingually)
62042399|NCT01508429|PLACEBO_COMPARATOR|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
62435637|NCT04618835||Emergency presentations|Patients discharged after a presentation to practitioners in the community, primary and secondary care.
62042400|NCT06005805|EXPERIMENTAL|Mastic gum with dietary modification|Mastic gum with dietary modification (for 21 days)
62042401|NCT06005805|PLACEBO_COMPARATOR|Dietary modification|Dietary modification (for 21 days)
62435638|NCT03764410|EXPERIMENTAL|Diabetic group DG|Non-surgical periodontal treatment with scaling and root coronary planing, oral hygiene instructions and removal of biofilm retention factors
62435639|NCT03764410|ACTIVE_COMPARATOR|No diabetic group NG|Non-surgical periodontal treatment with scaling and root coronary planing, oral hygiene instructions and removal of biofilm retention factors
62435640|NCT03654690|NO_INTERVENTION|Control|Participants will receive SMS text message reminders to get tested for HIV in a clinic.
62435641|NCT03654690|ACTIVE_COMPARATOR|Standard Self-Testing|Participants will receive an HIV self-test kit in the mail with no standardized follow-up from counselors.
62823381|NCT04950127|EXPERIMENTAL|Participants receiving linerixibat|
62823382|NCT04950127|EXPERIMENTAL|Participants receiving linerixibat followed by placebo|
62823383|NCT04950127|PLACEBO_COMPARATOR|Participants receiving placebo|
62823384|NCT04950127|EXPERIMENTAL|Participants receiving placebo followed by linerixibat|
62823385|NCT02484248|ACTIVE_COMPARATOR|cross-over of Ketotifen|Patients will begin the active ketotifen treatment first and cross over to placebo.
62823386|NCT02484248|PLACEBO_COMPARATOR|cross-over of Placebo|Patients will begin the placebo treatment first and cross over to the active ketotifen.
62823387|NCT06166732|EXPERIMENTAL|Music-based Mindfulness Group|Participants will receive a music-based mindfulness for 20 minutes.
62823388|NCT06166732|OTHER|Control Group|Participants will receive a information session for 20 minutes.
62849255|NCT01738477|ACTIVE_COMPARATOR|Boostrix Group 1|Healthy male of female subjects, aged 19 to 30 years of age at the time of booster vaccination, who received Massachusetts Public Health Biologic Laboratories combined tetanus and diphtheria vaccine in study NCT00109330, received the first dose of Boostrix in this study.
62849256|NCT00401232|OTHER|Arm 1|
62042402|NCT02782169|ACTIVE_COMPARATOR|Pregabalin|
62602077|NCT06618612|ACTIVE_COMPARATOR|PuraPly AM + SOC|PuraPly Antimicrobial Wound Matrix along with standard of care
62823389|NCT06134518|EXPERIMENTAL|intervention|The intervention group will receive the competency-based education program for 1 month at each PHC, after baseline data collection. The education program will be conducted weekly. This education session will be conducted for 4 hours per session, with 20 health cadres in a group per PHC .The competency level is measured by the researcher developing a competency questionnaire which consists of a knowledge test, skill, and attitude checklist score at the 2nd post-assessment (2 months after being given the education program).
62823390|NCT06134518|EXPERIMENTAL|control|Health cadres in the control group have received the initial orientation from the PHCs. In this study, they take only the competency questionnaires including skill check will be collected following the data collection timeline. After completing the research, the control group will receive the education program material used for the intervention group if they require.
62042403|NCT02782169|PLACEBO_COMPARATOR|Placebo|
62042404|NCT02008890|EXPERIMENTAL|Secukinumab 300mg|"Secukinumab 300mg once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 48.~In order to maintain the blinding beyond the primary endpoint, placebo was administered at Weeks 17, 18 and 19.~For extension period: Secukinumab 300mg at 4-weekly intervals starting Week 52 up to Week 148."
62042405|NCT02008890|EXPERIMENTAL|Secukinumab 150mg|"Secukinumab 150mg once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 48.~In order to maintain the blinding beyond the primary endpoint, placebo was administered at Weeks 17, 18 and 19.~For extension period: Secukinumab 150mg at 4-weekly intervals starting Week 52 up to Week 148."
62042406|NCT02008890|PLACEBO_COMPARATOR|Placebo|Placebo once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 12. Patients who achieved ppPASI 75 at Week 16 remained on placebo treatment Until week 48 and were not eligible to enter the extension. Patients who did not achieve ppPASI 75 at Week 16 were re-randomized to receive Secukinumab 150mg or Secukinumab 300mg from Week 16 onwards up to Week 148.
62042407|NCT06367192|EXPERIMENTAL|Readiness Intervention|"* Attend virtual classroom program sessions- If participants are in the school readiness group, the caregiver, will attend about 8 weeks of sessions virtually with a teacher or social worker and a caregiver of a child with sickle cell, for a total of 8 sessions. The sessions will be during the summer and done in a group. Each session will last about 1 ½ hours and will be video recorded. \> •Complete a caregiver interview-If participants are in the school readiness group, a member of the study team will interview you after the virtual classroom sessions are over. The interview will take about 15-20 minutes and will be audio recorded. Participants will be asked for suggestions and how satisfied you were with the program.~* Complete assessments - Caregiver and participant will complete a set of assessments that evaluate school readiness skills (e.g., early math and reading), child behaviors, and parent-child relationships before and after the intervention."
62042408|NCT06367192|OTHER|Control: Standard school resources|Parents will be provided with information about preschool programs available in the community and age appropriate books for their children
62042409|NCT06647810|EXPERIMENTAL|BI 690517 formulation 1, then BI 690517 formulation 2, then Probenecid + BI 690517 formulation 2|
62042410|NCT06647810|EXPERIMENTAL|BI 690517 formulation 2, then Probenecid + BI 690517 formulation 2, then BI 690517 formulation 1|
62042411|NCT06647810|EXPERIMENTAL|Probenecid + BI 690517 formulation 2, then BI 690517 formulation 1, then BI 690517 formulation 2|
62042412|NCT02181803|EXPERIMENTAL|Part 1 Panel A & B MK-8189 Monotherapy 2-40 mg: Schizophrenic|Participants with schizophrenia will receive monotherapy of MK-8189 in escalating doses starting at 2 mg once daily (QD) up to 40 mg QD, depending on safety and tolerability
62602078|NCT06618612|ACTIVE_COMPARATOR|PuraPly XT + SOC|PuraPly Antimicrobial XT Wound Matrix along with standard of care
62602079|NCT01873300|EXPERIMENTAL|treatment group|Patients undergoing POEM procedure
62602080|NCT02763332|EXPERIMENTAL|Upper trunk group (UTG)|In the UTG, the bandage was applied over the superior fibbers of the trapezious and levator scapulae muscle using a strip in a 'Y' shape. The individuals were asked to remain in an upright sitting position and the base of the strip was attached to the skin beyond the acromion without any tension. Later, we placed the two straps of the bandage with a range of tension from 15 to 25%. The main goal of this shape is achieve muscular relaxation of the trapezius, scapula levator and supraspinatus.
62823391|NCT06603545|EXPERIMENTAL|Digital education for osteoporosis patients (DEOP)|"The participants in the DEOP group will be given access to the DEOP for four months after randomization, and can redo the education multiple times within those four months. Reminders will be sent out using phone text messages monthly for the first 3 months to participants who have not yet started the DEOP.~The experimental group will also be given information, according to standard care, regarding fall prevention, physical activity, diet, and osteoporosis medication according to standard care, by their GP or the physician at the osteoporosis clinics, depending on where they are treated for their osteoporosis."
62823392|NCT06603545|NO_INTERVENTION|No Digital education for osteoporosis patients (DEOP)|The control group will be given information regarding fall prevention, physical activity, diet, and osteoporosis medication according to standard care, by their GP or the physician at the osteoporosis clinics, depending on where they are treated for their osteoporosis.
62042413|NCT02181803|EXPERIMENTAL|Part 2 Panel C MK-8189 Add-on Therapy 2-20 mg: Schizophrenic|Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 2 mg QD up to 20 mg QD, depending on safety and tolerability
62042414|NCT02181803|EXPERIMENTAL|Part 2 Panel C MK-8189 Add-on Therapy 4-20 mg: Schizophrenic|Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 4 mg QD up to 20 mg QD, depending on safety and tolerability
62602081|NCT02763332|ACTIVE_COMPARATOR|Global trunk group (GTG)|In the GTG the bandage was applied parallel to the paravertebral muscles in a 'C' shape. The individuals were sit in the same position with the head in the neutral position. The strip was pasted with approximately 25% of tension all over the paravertebral musculature. The main goal was procuring a global mechanical correction of the superior part of the trunk.
62042415|NCT02181803|EXPERIMENTAL|Part 3 Panel D MK-8189 Monotherapy 2-16 mg: Healthy|Healthy participants will receive monotherapy of MK-8189 in escalating doses starting at 2 mg QD up to 16 mg QD, depending on safety and tolerability
62042416|NCT02181803|PLACEBO_COMPARATOR|Part 1 Panel A & B Placebo Monotherapy: Schizophrenic|Participants with schizophrenia will receive dose-matched placebo to MK-8189 monotherapy
62042417|NCT02181803|PLACEBO_COMPARATOR|Part 2 Panel C Placebo Add-on Therapy: Schizophrenic|Participants with schizophrenia will receive dose-matched placebo to MK-8189 add-on therapy
62042418|NCT02181803|PLACEBO_COMPARATOR|Part 3 Panel D Placebo Monotherapy: Healthy|Healthy participants will receive dose-matched placebo to MK-8189 monotherapy
62042419|NCT06386757|ACTIVE_COMPARATOR|Group Ι Combined Video Laryngoscopy (VL) and Bougie|Group Ι Combined Video Laryngoscopy (VL) and Bougie: Nasal intubation will be performed using a video laryngoscope and a bougie.
62042420|NCT06386757|ACTIVE_COMPARATOR|Group ΙI Direct Laryngoscopy (DL) and Bougie :|Nasal intubation will be performed using a traditional direct laryngoscope and a bougie.
62435642|NCT03654690|EXPERIMENTAL|Enhanced Self-Testing|Participants will receive an HIV self-test kit and will be contacted via telephone for counseling within 24 hours of opening their test.
62042421|NCT05410600|EXPERIMENTAL|Arm Ergometer Smart Trainer Cycling|Participants will participate in an 8-week exercise training program using the smart trainer.
62042422|NCT00649558|EXPERIMENTAL|1|Pioglitazone HCl Tablets 45 mg
62042423|NCT00649558|ACTIVE_COMPARATOR|2|Actos® Tablets 45 mg
62435643|NCT06371716|EXPERIMENTAL|resected PDAC without neoadjuvant chemotherapy treatment|Subgroup A: 10 W (5 patients) Subgroup B: 30 W (5 patients) Subgroup C: 50 W (5 patients)
62435644|NCT06371716|EXPERIMENTAL|resected PDAC with neoadjuvant chemotherapy treatment|Subgroup A: 10 W (5 patients) Subgroup B: 30 W (5 patients) Subgroup C: 50 W (5 patients)
62435645|NCT06371716|EXPERIMENTAL|resected neuroendocrine tumors|Subgroup A: 10 W (5 patients) Subgroup B: 30 W (5 patients) Subgroup C: 50 W (5 patients)
62602082|NCT01870674|EXPERIMENTAL|YH12852|"\<SAD cohort\>~* Experimental: YH12852 1mg/single dose, qd~* Experimental: YH12852 3mg/single dose, qd~* Experimental: YH12852 10mg/single dose, qd~\<FSD cohort\>~* Experimental: YH12852 0.5mg/single dose, qd~* Experimental: YH12852 1mg/single dose, qd~* Experimental: YH12852 2mg/single dose, qd~* Experimental: YH12852 3mg/single dose, qd~\<MAD cohort\>~* Experimental: YH12852 0.5mg/repeat dose, qd~* Experimental: YH12852 1mg/repeat dose, qd~* Experimental: YH12852 2mg/repeat dose, qd~* Experimental: YH12852 3mg/repeat dose, qd~  * Each dosing group(except MAD cohort 0.5mg which has single treatment arm taking YH12852 only) contains 12 subjects. 12 subjects are administered YH12852 or placebo/active comparators.(YH12852:placebo:active=8:2:2)"
62042424|NCT03083587|ACTIVE_COMPARATOR|No intervention|Normal lifestyle. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
62042425|NCT03083587|EXPERIMENTAL|Exercise intervention|Followed by a 1 week normal run in period subjects will undergo a 3 min bout, every half hour between 8 am and 6 pm comprises of simple low-intensity exercise such as moderate walking about or climbing a flight of stairs over a 3-week period. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
62042426|NCT04823377|OTHER|Period A: Usual management|Period of end-of-life care as usual
62042427|NCT04823377|OTHER|Period B: Process of optimization of the medical decision|Period of systematic and iterative use of a device for optimizing the decision to continue an anti-cancer treatment.
62042428|NCT03709355|ACTIVE_COMPARATOR|Elpida® single dose|Single dose of Elpida® (capsule 20 mg)
62245310|NCT06593093|EXPERIMENTAL|phase 1|After completing screening questions and obtaining consent, eligible participants will complete their baseline procedures and measures. All participants will then start the experimental, i.e., bundled intervention, the first week after their ED discharge, including peer support service and buprenorphine treatment with addiction physicians using telehealth. Each participant will be in the study for 3 months. During the study period, participants will be sent survey links to their cell phones and/or emails to complete self-report questionnaires via the Research Electronic Data Capture (REDCap) at 1-month and 3-month for follow-up assessments. Peers will remind the participants to complete the survey.
62245311|NCT06593093|EXPERIMENTAL|phase 2- experimental|Participants will be enrolled the same way as in phase 1. After their enrollment, participants will be randomized to either the experimental (bundled intervention) group or the control (usual care group). Bundled intervention will have the same components as in the phase 1, including peer support, buprenorphine treatment, and telehealth up to 3 months after ED/hospital discharge, and linkage to definitive addiction treatment programs. Participants will be sent survey links to their cell phones and emails to complete self-report questionnaires via REDCap at 1- and 3-month for follow-up assessments. Participants will be reminded via text messages and/or emails to complete the survey twice per day 5 days prior to their follow-up assessments.
62245312|NCT06593093|PLACEBO_COMPARATOR|phase 2- control|Participants who are randomized to the control group will receive the usual care that has been established in the ED at UAB hospital. The current usual care at the UAB ED includes a thorough assessment, buprenorphine initiation as appropriate, peer referral, and a written list of buprenorphine clinics. Participants will also receive information about community-based substance use treatment programs. However, these services are at the participant's own discretion to navigate and attend after ED discharge. Participants will be sent survey links to their cell phones and emails to complete self-report questionnaires via REDCap at 1- and 3-month for follow-up assessments. Participants will be reminded via text messages and/or emails to complete the survey twice per day 5 days prior to their follow-up assessments.
62245313|NCT06715540|EXPERIMENTAL|Cohort 1|Subjects in Cohort 1 will receive BCD-261 at a dose 1 during the Stage 1. Depending on the DLT, the cohort may include 1 to 3 subjects.
62245314|NCT06715540|EXPERIMENTAL|Cohort 2|Subjects in Cohort 2 will receive BCD-261 at a dose 2 during the Stage 1. Depending on the DLT, the cohort may include 3 to 6 subjects.
62245315|NCT06715540|EXPERIMENTAL|Cohort 3|Subjects in Cohort 3 will receive BCD-261 at a dose 3 during the Stage 1. Depending on the DLT, the cohort may include 3 to 6 subjects.
62245316|NCT06715540|EXPERIMENTAL|Cohort 4|Subjects in Cohort 4 will receive BCD-261 at a dose 4 during the Stage 1. Depending on the DLT, the cohort may include 3 to 6 subjects.
62602083|NCT01870674|ACTIVE_COMPARATOR|Prucalopride|\<each cohort\> Prucalopride succinate 1.321mg
62602084|NCT01870674|PLACEBO_COMPARATOR|Placebo|\<each cohort\> Matching Placebo
62602085|NCT03266692|EXPERIMENTAL|ACTR087 in combination with SEA-BCMA|
62042429|NCT03709355|EXPERIMENTAL|Rifampin & Elpida®|Single dose of Rifampin (capsule 150 mg), Rifampin + Elpida® 20mg single dose
62245317|NCT06715540|EXPERIMENTAL|Cohort 5|Subjects in Cohort 5 will receive BCD-261 at a dose 5 during the Stage 1. Depending on the DLT, the cohort may include 3 to 6 subjects.
62449151|NCT00658320|ACTIVE_COMPARATOR|Mycophenolate mofetil (MMF) + Standard dose of cyclosporine|Patients were treated with 1 gram twice a day (2 grams/day) of Mycophenolate mofetil (MMF) and standard dose of cyclosporine for 12 months post renal transplant. Patients were treated with antibody induction therapy using 20 mg basiliximab two hours prior to transplant and 20 mg basiliximab 4 days post transplant or according to local practice. Corticosteroids were administered according to local practice. Patients were treated for 12 months in the core study and 12 months in the extension study.
62602086|NCT06461221|EXPERIMENTAL|Focused Ultrasound Dose #1|Focused Ultrasound will be administered using high frequency stimulation as condition 1. Stimulation will last 1-10 minutes.
62602087|NCT06461221|EXPERIMENTAL|Focused Ultrasound Dose #2|Focused Ultrasound will be administered using medium frequency stimulation as condition 2. Stimulation will last 1-10 minutes.
62602088|NCT06461221|EXPERIMENTAL|Focused Ultrasound Dose #3|Focused Ultrasound will be administered using low frequency stimulation as condition 4. Stimulation will last 1-10 minutes.
62602089|NCT06461221|SHAM_COMPARATOR|Focused Ultrasound Dose #4|Focused Ultrasound will be administered using the sham condition.
62602090|NCT00044707|ACTIVE_COMPARATOR|Pramlintide acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide injection is 0.6 mg/mL
62042430|NCT03709355|EXPERIMENTAL|Rifabutin & Elpida®|Single dose of Rifabutin capsule 150 mg, Rifabutin + Elpida® 20mg single dose
62042431|NCT03709355|EXPERIMENTAL|Clarithromycin & Elpida®|Single dose of Clarithromycin capsule 250 mg, Clarithromycin + Elpida® 20mg single dose
62602091|NCT00044707|PLACEBO_COMPARATOR|Placebo|Placebo solution is the same, sterile preserved formulation, except the active ingredient, pramlintide, is omitted
62042432|NCT03709355|EXPERIMENTAL|Omeprazole & Elpida®|Single dose of Omeprazole capsule 20 mg, Omeprazole + Elpida® 20mg single dose
62042433|NCT03709355|EXPERIMENTAL|Atorvastatin & Elpida®|Single dose of Atorvastatin tablet 80 mg, Atorvastatin + Elpida® 20mg single dose
62823393|NCT03269578||1|Patients with cancer or benign tumors being treated on NCI/DTC studies
62245318|NCT06715540|EXPERIMENTAL|Cohort 6|Subjects in Cohort 6 will receive BCD-261 at a dose 6 during the Stage 1. Depending on the DLT, the cohort may include 3 to 6 subjects.
62245319|NCT06715540|EXPERIMENTAL|Cohort 7|"Subjects in Cohort 7 will receive BCD-261 at a pre-specified proposed therapeautic dose X during the Stage 2. DLT events will not be assesed during the Stage 2.~Cohort 7 will enroll 6 caucasian healthy subjects, who will recieve single subcutaneous injection of BCD-261 solution in vials."
62245320|NCT06715540|EXPERIMENTAL|Cohort 8|"Subjects in Cohort 8 will receive BCD-261 at a pre-specified proposed therapeautic dose X during the Stage 2. DLT events will not be assesed during the Stage 2.~Cohort 8 will enroll 6 caucasian healthy subjects, who will recieve single subcutaneous injection of BCD-261 solution in pre-filled syringes."
62823394|NCT05432856|EXPERIMENTAL|Time-Restricted Eating and Sedentary Time Reduction|Group 1 (Experimental intervention): Participants assigned to this group will receive standard chemotherapy treatment plus a dietary program, and sedentary time reduction strategies, program and a Fitbit monitor. If you are randomized into this group, you will be asked to follow TRE, will receive nutritional education and individualized recommendations on improving diet quality and healthy eating practices, and given to strategies to work towards reducing sedentary time. These components will be gradually introduced over the 24-week program.
62823395|NCT05432856|NO_INTERVENTION|Nutrition and Exercise Guidelines|"Group 2 (Non-experimental intervention): Participants randomized to this group will receive standard chemotherapy treatment plus a single, group-based nutrition during cancer class, as well as a copy of Canada's Food Guide, physical activity guidelines, and a Fitbit monitor. You will be asked to only make dietary changes if they are recommended within the class or by your doctor, and to maintain your usual timing and number of meals consumed per day. Throughout the 24-week period, you will receive seven brief phone calls from a study staff member to ask about your symptoms and provide support. After the end of the study, participants in this group will be offered a one-one-one counselling session with a registered dietitian."
62823396|NCT05279196|EXPERIMENTAL|Muscular response to the training|Epigenetic signature associated with different levels of muscle response induced by 6-month training
62823397|NCT00107198|EXPERIMENTAL|Treatment (surgery, combination chemotherapy, radiotherapy)|"COMBINATION CHEMOTHERAPY: Patients receive doxorubicin hydrochloride IV over 10-30 minutes and cyclophosphamide IV over 1 hour on day 1, vincristine IV over 1 minute on days 1 and 8, and prednisone PO or IV two or three times daily on days 1-7. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve CR after 3 courses of therapy proceed to follow-up. Patients who do not achieve a CR proceed to involved-field radiotherapy.~IFRT: Beginning within 3 weeks after completion of combination chemotherapy, patients undergo IFRT once daily, 5 days a week for 2.8 weeks (14 treatments)."
62823398|NCT06213571|EXPERIMENTAL|Supportive Care (home-based exercise program)|Participants participate in a home-based exercise program with an exercise prescription that will include resistance band and body weight exercises targeting the 5 major large muscle groups along with 3 booklets about exercise and exercise training and attend weekly exercise coaching sessions to report on exercise adherence and to progress exercise over 10 weeks on study.
62245321|NCT06715540|EXPERIMENTAL|Cohort 9|"Subjects in Cohort 9 will receive BCD-261 at a pre-specified proposed therapeautic dose X during the Stage 2. DLT events will not be assesed during the Stage 2.~Cohort 9 will enroll about 10 asian healthy subjects, who will recieve single subcutaneous injection of BCD-261 solution in pre-filled syringes."
62245322|NCT06715540|EXPERIMENTAL|Cohort 10|"Subjects in Cohort 10 will receive BCD-261 at a pre-specified proposed therapeautic dose Y during the Stage 2. DLT events will not be assesed during the Stage 2.~Cohort 10 will enroll about 10 asian healthy subjects, who will recieve single subcutaneous injection of BCD-261 solution in pre-filled syringes."
62245323|NCT06735131|EXPERIMENTAL|Arm 1: 5Gy × 5 , daily|within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
62245324|NCT06735131|EXPERIMENTAL|Arm 2: 8Gy × 5 , daily|within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
62823399|NCT03536104||Controls|"This group will include healthy person."
62823400|NCT03536104||Parkinson's patient|This group will include Parkinsonian patients
62823401|NCT03536104||patients with a related disease.|This group will include patients with a related disease.
62449152|NCT06014632|EXPERIMENTAL|Intervention Group|The study group will be given motor control exercises in addition to the program given to the control group. It will include exercise therapy aimed at improving the motor control of the lumbar spine. These applications will be applied to the patients face-to-face in a clinical setting 2 days a week for 12 weeks. In addition, both groups will be told that they can contact the researcher upon request.
62449153|NCT06014632|ACTIVE_COMPARATOR|Control Group|The control group will receive stretching, strengthening, core stabilization and educational content as usual care.
62449154|NCT03013374||Human milk fed infants|"Infants fed fortified human milk at enrollment~Any intervention is performed. Groups distinction is made according to own mother's milk availability."
62042434|NCT03709355|EXPERIMENTAL|Levonorgestrel+Ethinylestradiol & Elpida®|Single dose of Levonorgestrel 150 µg + Ethinylestradiol 150 µg tablet, Levonorgestrel + Ethinylestradiol + Elpida® 20mg single dose
62823402|NCT06588023||Lille University Hospital|Pre-eclamptic patients undergoing a cesarean section at the maternity ward of Lille University Hospital.
62042435|NCT03709355|ACTIVE_COMPARATOR|Elpida® multiple dose|Elpida® QD dosing for 14 days
62042436|NCT02616874|EXPERIMENTAL|MVA.HIVconsv plus romidepsin|MVA.HIVconsv plus romidepsin
62042437|NCT01372306|EXPERIMENTAL|Galantamine|Galantamine Hydrobromide Tablets of Dr. Reddy's
62042438|NCT01372306|ACTIVE_COMPARATOR|Reminyl|Reminyl 4 mg tablets of Janssen Pharmaceutical Products
62042439|NCT05460416|EXPERIMENTAL|Treatment by acetylsalicylic acid|
62042440|NCT05460416|NO_INTERVENTION|No treatment|
62042441|NCT06580795|EXPERIMENTAL|Participation in the student citizens' assembly|Participants are students participating in the student citizens' assembly
62042442|NCT03626155|EXPERIMENTAL|Seated Control|
62042443|NCT03626155|EXPERIMENTAL|Morning Exercise (walking)|
62042444|NCT03626155|EXPERIMENTAL|Afternoon Exercise (walking)|
62042445|NCT03626155|EXPERIMENTAL|Evening Exercise (walking)|
62245325|NCT06735131|EXPERIMENTAL|Arm 3: 8Gy × 3, every other day|within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
62823403|NCT06588023||Clermont-Ferrand University Hospital|Pre-eclamptic patients undergoing a cesarean section at the maternity ward of Clermont-Ferrand University Hospital.
62823404|NCT01967238|ACTIVE_COMPARATOR|Biologic/Vaccine, Age 18-64 cohort|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
62823405|NCT01967238|ACTIVE_COMPARATOR|Biologic/Vaccine, Age 65-80 cohort|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
62823406|NCT01967238|ACTIVE_COMPARATOR|Vaccine, healthy adults|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
62823407|NCT05229887|ACTIVE_COMPARATOR|Nostril-Tragus-Length|
62823408|NCT05229887|EXPERIMENTAL|Vocal cord markings|
62823409|NCT04466943|EXPERIMENTAL|group A|Moderate neuromuscular blockade (NMB) , defined as a 1±2 twitch response to the train-of four (TOF) by stimulation of the ulnar nerve. The device which will be used is neuromuscular transmission monitor (NMT) to test the depth of muscle relaxation after giving rocuronium which is a muscle relaxant during general anesthesia.
62823410|NCT04466943|EXPERIMENTAL|group B|Deep NMB, defined by (0 twitch count in the TOF, 1±2 twitch responses in the post-tetanic count. The device which will be used is neuromuscular transmission monitor (NMT) to test the depth of muscle relaxation after giving rocuronium which is a muscle relaxant during general anesthesia.
62823411|NCT06598826|ACTIVE_COMPARATOR|Graston technique|This group received Graston technique (IASTM) , in additional to traditional treatment (ROM exercise, strengthening exercise, and stretching exercise) 3 times per week for 1 month
62823412|NCT06598826|ACTIVE_COMPARATOR|Kinesio taping|Group B includes 26 patients who received Kinesiotaping, in addition to traditional treatment (ROM exercise, strengthening exercise, and stretching exercises) 2 times per week for 1 month
62823413|NCT06591065|EXPERIMENTAL|Behavioral: Yoga Flow|The experimental group underwent yoga training conducted by a physiotherapist
62823414|NCT06591065|NO_INTERVENTION|Controlled Group|The control group did not receive any yoga training
62823415|NCT06406595||Older Adults Healthy Control Group|The healthy older adult group is carefully defined to serve as a comparison group against individuals with mental health issues. By selecting participants aged over 60 who do not exhibit mental health issues and demonstrate healthy aging from a cognitive perspective, the investigators establish a baseline for cognitive functioning within the older adult population.
62823416|NCT06406595||Older Adults with Mental Health Issues Group|The older adults with mental health issues group is crucial for examining the impact of Anxiety and/or Depression on cognitive aging. Participants aged over 60 diagnosed with these conditions are included while still demonstrating healthy aging from a cognitive standpoint. This ensures that any observed cognitive differences can be attributed to mental health conditions rather than age-related decline alone.
62042446|NCT02217930|PLACEBO_COMPARATOR|Placebo|"Placebo matched to WCK 2349, oral tablet(s)~Placebo matched to moxifloxacin overencapsulated tablet"
62042447|NCT02217930|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin 400 mg positive control (overencapsulated tablet)
62042448|NCT02217930|EXPERIMENTAL|WCK 2349|WCK 2349 supratherapeutic dose determined in Part 1, oral tablet(s)
62042449|NCT04915573||patients with Cirrhosis|Patient with clinical evidence of liver disease, portal hypertension, ultrasound or computed tomography results, laboratory data will be used to confirm liver disease
62245326|NCT06735131|EXPERIMENTAL|Arm 4: 10Gy × 3, every other day|within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
62245327|NCT06735131|EXPERIMENTAL|Arm 5: 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (8 Gy in total)|on the first 2 days of first 4 cycles of toripalimab and chemotherapy
62245328|NCT05501678|EXPERIMENTAL|Diphenhydramine, then Placebo|"Participants will first receive Diphenhydramine for a 4-week period. A 25 mg dose of Diphenhydramine will be given at bedtime for one week and then will increase to 50 mg if needed and if well tolerated.~Participants will then receive Placebo (fake tablet) for a 4-week period. A 25 mg dose of matching Placebo will be given at bedtime for one week and then will increase to 50 mg if needed and if well tolerated."
62245329|NCT05501678|EXPERIMENTAL|Placebo, then Diphenhydramine|"Participants will first receive Placebo (fake tablet) for a 4-week period. A 25 mg dose of matching Placebo will be given at bedtime for one week and then will increase to 50 mg if needed and if well tolerated.~Participants will then receive Diphenhydramine for a 4-week period. A 25 mg dose of Diphenhydramine will be given at bedtime for one week and then will increase to 50 mg if needed and if well tolerated."
62042450|NCT06488378|EXPERIMENTAL|Axatilimab + Olaparib|"A Bayesian Optimal Interval design will be used to establish the maximum tolerated dose of Axatilimab. Dose reduction and escalation will be per protocol. Participants will complete:~* Baseline visit, tumor biopsy, and imaging~* Imaging every 8 weeks~* Window Phase:~  --Predetermined dose of Olaparib 2x daily, taken 12 hours apart for 14 days~* Combination Treatment Phase:~  * Cycle 1 through Cycle 2:~    * Day 1 of 28 day cycle: Tumor biopsy~   * Days 1 and 15 of 28 day Cycle: Predetermined dose of Axalitimab 1x daily~   * Days 1 through 28 of 28 day cycle Predetermined dose of Olaparib 2x daily, 12 hours apart~   * Tumor biopsy after two weeks of Olaparib and at the end of Cycle 2~ * Cycle 3 through End of Treatment:~    * Days 1 and 15 of 28 Day Cycle: Predetermined dose of Axalitimab 1x daily~   * Predetermined dose of Olaparib 2x daily, taken 12 hours apart~* End of Treatment Visit with imaging~* Follow Up: Every 6 months for 3 years. Imaging will be every 10 weeks."
62042451|NCT02186522||Critical Care Patients|Patients staying in the ICU for at least 48 hours, requiring external support of one or more organs (invasive ventilation, inotropes/vasopressors or renal replacement therapy) and who are not expected to die within 48 hours of study entry.
62042452|NCT05368662|EXPERIMENTAL|Children with home ventilation|
62042453|NCT01146509|EXPERIMENTAL|1|
62042454|NCT05970627|EXPERIMENTAL|Chemotherapy+Toripalimab|"Toripalimab: 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.~Chemotherapy: SOX(S-1+Oxaliplatin) Oxaliplatin,administered as a 2-hour intravenous infusion (130mg/m2) S-1, orally twice daily for 2 weeks followed by a 7-day rest period. The dose of S-1 was 80 mg/day for body surface area less than 1.25 m2, 100 mg/day for body surface area greater than or equal to 1.25 to less than 1.5 m2, and 120 mg/day for body surface area greater than or equal to 1.5 m2 Chemotherapy will be repeated each 21 day for 3 cycles prior to surgery and 3 cycles after surgery."
62042455|NCT04855422||Stable SPK recipients without rejection and/or BKV viremia|All SPK transplant recipients are monitored for routine labs twice a week first month, weekly at 2nd and 3rd month, every 2 weeks between 3-6 months, once a month between 6-12 months and then once every 2 months.
62042456|NCT04855422||Acute T-Cell Mediated Rejection (TCMR )|Kidney and pancreas transplant biopsies will be solely for clinically indicated for increased creatinine, amylase, lipase, blood sugar levels of more than 20% of the baseline, increased spot urine protein/creatinine ratio more than 1 gram/day, and development of donor-specific anti-HLA antibodies.
62245330|NCT02779738|EXPERIMENTAL|Merestinib Fasted|Single dose of merestinib administered in fasted state in one of three periods
62245331|NCT02779738|EXPERIMENTAL|Merestinib Standard Meal|Single dose of merestinib administered with a standard meal in one of three periods
62602092|NCT00317200|ACTIVE_COMPARATOR|1|Paclitaxel + Devacizumab in patients with chemosensitive relapsed small cell lung cancer.
62823417|NCT03970746|EXPERIMENTAL|Cohort A1|PDC\*lung01 Low Dose
62245332|NCT02779738|EXPERIMENTAL|Merestinib High-Fat Meal|Single dose of merestinib administered with a high-fat meal in one of three periods
62245333|NCT05398783||Healthy Volunteers|Male and female volunteers aged 2+ years in good general health as evidenced by medical history
62823418|NCT03970746|EXPERIMENTAL|Cohort A2|PDC\*lung01 High Dose
62245334|NCT05398783||Patients|Male and female patients aged 2+ years diagnosed with diseases thought to alter metabolism or body composition and/or taking medication thought to alter metabolism or body composition
62245335|NCT04016896|EXPERIMENTAL|Widowed Elders' Lifestyle after Loss (WELL)|digital monitoring of sleep, meals, physical activity; motivational health coaching; personalized feedback
62245336|NCT04016896|ACTIVE_COMPARATOR|Enhanced Usual Care|enhanced usual care
62245337|NCT04505865|NO_INTERVENTION|Usual care|Optimally tolerated medical therapy
62245338|NCT04505865|EXPERIMENTAL|Stress reduction|Optimally tolerated medical therapy and stress reduction course for 8 weeks
62449155|NCT03013374||Preterm formula|"Infants fed preterm formula milk at enrollment.~Any intervention is performed. Groups distinction is made according to own mother's milk availability."
62823419|NCT03970746|EXPERIMENTAL|Cohort B1|PDC\*lung01 Low Dose added to SoC, i.e., anti-PD-1 treatment
62823420|NCT03970746|EXPERIMENTAL|Cohort B2|PDC\*lung01 High Dose added to SoC, i.e., anti-PD-1 treatment
62823421|NCT05682430|ACTIVE_COMPARATOR|Heart rate-based HIIT|12 weeks heart-rate based HIIT intervention.
62823422|NCT05682430|EXPERIMENTAL|VIFT speed-based HIIT with mechanical work|12 weeks VIFT speed-based HIIT with mechanical work.
62823423|NCT05328609|ACTIVE_COMPARATOR|Intervention arm|Semaine - The Daily
62245339|NCT06210854|EXPERIMENTAL|Tropis Experimental|Will receive study drug using the Tropis device
62245340|NCT06210854|EXPERIMENTAL|Stratis Experimental|Will receive study drug using the Stratis device
62823424|NCT05328609|NO_INTERVENTION|Control arm|No intervention for the time period
62823425|NCT04265144|EXPERIMENTAL|subjects SSc diagnosed|Patient with systemic scleroderma according to the American College of Rheumatology (ACR) / EULAR 2013 criteria
62602093|NCT04326868|ACTIVE_COMPARATOR|Albendazole|ABZ (400mg)
62602094|NCT04326868|EXPERIMENTAL|Albendazole and Mebendazole|ABZ 400mg + 1 tablet of MBZ (500mg)
62602095|NCT04326868|EXPERIMENTAL|Albendazole and Pyrantel|ABZ (400mg) + Pyr (125 mg)
62823426|NCT05894109|PLACEBO_COMPARATOR|OnabotulinumtoxinA without Zinc Supplementation|Given placebo
62823427|NCT05894109|EXPERIMENTAL|OnabotulinumtoxinA with Zinc Supplementation|Given 50 mg of zinc citrate
62823428|NCT00809185|EXPERIMENTAL|RAD001 (everolimus)|RAD001 (everolimus) at 10mg/day with Bone marrow aspirate/biopsy and other laboratory biomarker analysis
62042457|NCT04855422||Antibody Medicated Rejection (ABMR)|Kidney and pancreas transplant biopsies will be solely for clinically indicated for increased creatinine, amylase, lipase, blood sugar levels of more than 20% of the baseline, increased spot urine protein/creatinine ratio more than 1 gram/day, and development of donor-specific anti-HLA antibodies.
62245341|NCT06210854|PLACEBO_COMPARATOR|Tropis Placebo|Will receive placebo using the Tropis device
62042458|NCT04855422||BKV viremia|All patients will be monitored for BKV viremia monthly after transplantation up to 6 months and at 9, 12 and 24 months. Luminex SAB will be monitored at 1, 3, 12 and 24 months. Spot urine protein and creatinine and HbA1c will be monitored every 3 months after transplantation
62042459|NCT04855422||Follow-up of subjects with acute TCMR, ABMR and BKV viremia after treatment|BKV viremia, Luminex SAB, spot urine protein and creatinine is studied at the time clinically indicated biopsy and/o worsening kidney function and proteinuria.
62042460|NCT04278118|EXPERIMENTAL|Cohort I (hypofractionated radiation therapy)|Patients with benign and radiographically diagnosed intracranial tumors undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 17 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
62042461|NCT04278118|EXPERIMENTAL|Cohort II (hypofractionated radiation therapy)|Patients with pathologically confirmed World Health Organization (WHO) grade 2-3 meningiomas undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 20 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
62245342|NCT06210854|PLACEBO_COMPARATOR|Stratis Placebo|Will receive placebo using the Stratis device
62245343|NCT05257941|ACTIVE_COMPARATOR|IT Injection|an intrathecal (IT) injection in the back in which a small dose duramorph and bupivacaine will be placed into the spinal fluid
62245344|NCT05257941|ACTIVE_COMPARATOR|ESP Block|an erector spinae plane (ESP) block in which bupivacaine and decadron are injected near the nerves under a muscle in the back.
62245345|NCT05987852|EXPERIMENTAL|Hyperbaric Oxygen Therapy|"Participants enrolled in the active intervention group receiving HBOT will undergo compression to 2.4 Atmospheres Absolute (ATA; 100% O2) for 90 minutes with two 5-10 minute air breaks (breathing room air at the 2.4 ATA) during the session. This is done once a day for 5 days."
62435646|NCT03951870|EXPERIMENTAL|Mesolimbic Neurofeedback|"Neuromodulation via fMRI Neurofeedback task: subjects (n=34) will participate in four fMRI-NF sessions, up-regulating activation of three mesolimbic reward nodes:~ventral tegmental area, and bilateral ventral striatum. ROIs are 5 mm spheres around peak activations in funcitonal localizer task (Monetary Incentive delay, reward anticipation contrast), within a predifned meta-analytic anatomical masks of the three regions.~anatomical masks: VTA (Midbrain): -4 -24 -10 \*see below Right Nac: 12 10 -4 Left Nac: -10 10 -6 Oldham, Stuart, et al. Human brain mapping (2018).~\* 23/08/22: Due to VTA complex contours, it was not restricted according to Oldham et al as mentioned above, but via more accurate VTA mask (Murty et al. 2014, NeuroImage). This was mistakenly left out of the original preregistration. It is noteworthy that, to date (23/8/22), ROI analyses haven't been performed.~Hepatitis B vaccination: subjects will receive vaccination against Hepatitis B."
62435647|NCT03951870|ACTIVE_COMPARATOR|Control Neurofeedback|"Neuromodulation via fMRI Neurofeedback task: subjects (n=34) will participate in four fMRI-NF sessions, up-regulating activation of regions comprising one of 4 control networks (5mm spheres around MNI coordinates):~Motor Imagery (Hétu, Sébastien, et al. Neurosci. \& Biobehav Rev (2013)) R. Cerebellum: 32 -62 -28 L. Cerebellum: -32 -56 -30 L. Precentral Gyrus: -26 -2 58; Auditory imagery (McNorgan, Chris.Front in Human Neurosci 6 (2012)) R STG:64 -30 9 L IFG:-48 24 -5 L precentral Gyrus: -52 1 47; Arithmetic processing (Arsalidou, Marie, and Margot J. Taylor. Nuroimage (2011)) R. SPL: 29 -66 49 L. MFG (dlpfc): -45 32 29 L. precuneus: -28 -71 33; Spatial Navigation (Kühn, Simone, and Jürgen Gallinat. Human Brain Map. (2014)) R. hippocampus 26 -35 -11 L. hippocampus -26 -47 -9 L. Post. cingulate -15 -59 19~Hepatitis B vaccination: subjects will receive vaccination against Hepatitis B."
62435648|NCT03951870|OTHER|Natural history|"No brain manipulation (Assesment of natural history immune response).~Hepatitis B vaccination: subjects (n=17) will receive vaccination against Hepatitis B."
62435649|NCT02891564|PLACEBO_COMPARATOR|Control Arm (R 33)|a mobile 3D video game to be used as placebo.
62435650|NCT02891564|EXPERIMENTAL|Intervention Arm (R 33)|a mobile 3D video game (Band Together) that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms.
62435651|NCT04733352|EXPERIMENTAL|proximal acupoints of knees|GB34, SP9, and EX-LE2
62435652|NCT04733352|EXPERIMENTAL|distal acupoints of knees|LI11, HT3, and TE10
62435653|NCT01548950|OTHER|Single-arm study|Preoperatively, sildenafil until development of pulmonary congestion (1-4 weeks). On treatment pulmonary congestion (dyspnea and need for increasing diuretics) occurs when there is a substantial decrease in pulmonary vascular resistance, which may be confirmed noninvasively by Doppler-echocardiography. At that moment, patient will be assigned to surgery. If pulmonary congestion is not observed, bosentan will be added on top of sildenafil, and the patient will be kept on treatment for 10-12 months. In this case, a new cardiac catheterization will be performed before surgery. In both cases (short-term and medium-term treatment) patients will be kept on treatment for six months following surgery, and then re-catheterized.
62435654|NCT00198978|EXPERIMENTAL|Interventional arm|
62435655|NCT00662714|EXPERIMENTAL|1|Repaglinide; oral
62435656|NCT00662714|ACTIVE_COMPARATOR|2|short-acting Insulin (Actrapid)
62435657|NCT02838290|EXPERIMENTAL|Induction|
62435658|NCT02838290|OTHER|Control group|
62042462|NCT01180855|PLACEBO_COMPARATOR|Placebo|Placebo pills prepared by Takeda Pharmaceutical.
62435659|NCT05031871|EXPERIMENTAL|Treatment group A|HR17031 injection dose+INS068 injection dose+SHR20004 injection dose+(INS068+SHR20004) injection dose
62042463|NCT01180855|ACTIVE_COMPARATOR|Rozerem|Rozerem 8mg
62042464|NCT01180855|ACTIVE_COMPARATOR|Rozerem + Multi Component Behavior Therapy|Rozerem 8mg in combination with 4 small group sessions and 2 phone calls of Multi Component Behavior Therapy.
62245346|NCT05987852|SHAM_COMPARATOR|Sham Hyperbaric Air|"This control arm will undergo compression to 1.34 ATA for monoplace chambers and 2.4 ATA for multiplace chambers for the full 90-minute session but 21% oxygen instead of 100% oxygen being administered. These participants will also have two 5-10 minute air breaks to mimic the treatment protocol. Multiplace sham sessions will have modified air breaks to avoid decompression sickness. This will happen once a day for 5 days."
62042465|NCT03683797|EXPERIMENTAL|Post-discharge call|Patients in this arm will receive a call from a clinical care coordinator after they have been discharged from NYU Langone Health.
62435660|NCT05031871|EXPERIMENTAL|Treatment group B|INS068 injection dose+(INS068+SHR20004)injection dose+ HR17031 injection dose +SHR20004 injection dose
62435661|NCT05031871|EXPERIMENTAL|Treatment group C|SHR20004 injection dose+ HR17031 injection dose +(INS 068+SHR20004) injection dose+ INS068 injection dose
62435662|NCT05031871|EXPERIMENTAL|Treatment group D|(INS 068+SHR20004) injection dose+ SHR20004 injection dose+ INS068 injection dose+ HR17031 injection dose
62435663|NCT02678221|ACTIVE_COMPARATOR|Sildenafil citrate with Aspirin|will receive sildenafil citrate 20mg ̸ 8hours plus low dose aspirin 150mg/day
62435664|NCT02678221|OTHER|placebo with Aspirin|will receive placebo plus low dose aspirin 150mg/day
62602096|NCT06483061|EXPERIMENTAL|Ferumoxytol (Feraheme)|Each participant and control will receive Ferumoxytol (Feraheme) 4 mg/kg diluted with 60ml normal saline, administered at 150-200ml/Hr by a registered nurse using a MRI compatible IV infusion pump
62602097|NCT01502397||HBsAg-negative, anti-HBc-positive|HBsAg-negative, anti-HBc-positive subjects undergoing rituximab-containing chemotherapy
62042466|NCT03683797|NO_INTERVENTION|No post-discharge call|Patients in this arm will not receive a call from a clinical care coordinator after they have been discharged from NYU Langone Health.
62042467|NCT06122714|EXPERIMENTAL|Part A1 (healthy participants) Cohort 1|Participants will receive one single ascending dose of AZD4144.
62435665|NCT03455023|EXPERIMENTAL|pharmaceutical care intervention group|Patients will receive individualized pharmaceutical care in addition to usual medical care.
62435666|NCT03455023|NO_INTERVENTION|control group|Patients will receive usual medical care.
62602098|NCT02630849|EXPERIMENTAL|IMF group|intercostal muscle flap and pericostal no-compression suture of the intercostal space
62602099|NCT02630849|ACTIVE_COMPARATOR|IINB group|Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
62245347|NCT04450511|ACTIVE_COMPARATOR|Group 1: Bladder Training (BT)|BT, consisting of four stages, did not contain any PFM training programs in all groups. In these stages, including urgency suppression strategies, it was aimed to delay urination, to inhibit detrusor contraction and to prevent urgency; by squeezing the PFM several times in a row (women were encouraged to pause/stop their work, sit down if possible, relax the entire body and squeeze PFM repeatedly), breathing deeply, giving their attention to another job for a while and self-motivating (I can do it, I can check the urination, etc.).
62245348|NCT04450511|EXPERIMENTAL|Group 2: Bladder Training+Magnetic Stimulation|Patients are told to sit on the chair with a magnetic coil below the chair. When a volume conductor is inserted by this magnetic ﬁeld, an eddy current ﬂow is generated. This eddy current stimulates nerve or muscle of the pelvic ﬂoor. To apply MS, the device was set to generate its maximum stimuli, with a stimulation pulse width of 200 μs and a stimulation repetition cycle of 10 Hz in accordance with the literature. When setting the device at each treatment session, patients were interviewed so that they received stimuli at the maximum stimulation intensity (maximum tolerable stimulation intensity) .
62245349|NCT03369223|EXPERIMENTAL|Part 1A: BMS-986249|
62245350|NCT03369223|EXPERIMENTAL|Part 1B: BMS-986249 + nivolumab (nivo)|
62245351|NCT03369223|EXPERIMENTAL|Part 2A Arm C: BMS-986249 + nivo|Previously untreated unresectable stage III-IV melanoma
62245352|NCT03369223|EXPERIMENTAL|Part 2A Arm D: ipilimumab + nivo then nivo|Previously untreated unresectable stage III-IV melanoma
62245353|NCT03369223|EXPERIMENTAL|Part 2A Arm F: BMS-986249 + nivo|Previously untreated unresectable stage III-IV melanoma
62435667|NCT03706326|EXPERIMENTAL|Treatment with Anti-MUC1 CAR-T cells|Anti-MUC1 CAR-T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
62245354|NCT03369223|EXPERIMENTAL|Part 2B Cohort 1: BMS-986249 + nivo|Advanced or intermediate hepatocellular carcinoma (HCC)
62435668|NCT03706326|EXPERIMENTAL|Combination Therapy: CAR-T combining PD-1 knockout T Cells|Anti-MUC1 CAR-T cells and PD-1 knockout Engineered T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
62823429|NCT06117306|EXPERIMENTAL|Standard Dose|"Non-medicine sessions of PE + One Medicine Session with 3,4-methylenedioxymethamphetamine (MDMA)~PE Non-medicine sessions: 12 sessions~MDMA Medicine session:~Standard Dose: 120 mg MDMA HCl (\~102 mg MDMA)"
62823430|NCT06117306|EXPERIMENTAL|Low Dose|"Non-medicine sessions of PE + One Medicine Session with 3,4-methylenedioxymethamphetamine (MDMA)~PE Non-medicine sessions: 12 sessions~MDMA Medicine session:~Low Dose: 40 mg MDMA HCl (\~34 mg MDMA)"
62823431|NCT06281132|EXPERIMENTAL|Sequence 1|"* Period 1: D956~* Period 2: CKD-341~* Period 3: D956~* Period 4: CKD-341"
62245355|NCT03369223|EXPERIMENTAL|Part 2B Cohort 2: BMS-986249 + nivo|Metastatic castration-resistant prostate cancer (CRPC)
62823432|NCT06281132|EXPERIMENTAL|Sequence 2|"* Period 1: CKD-341~* Period 2: D956~* Period 3: CKD-341~* Period 4: D956"
62823433|NCT06588179|EXPERIMENTAL|Arm：SHR-1501+SHR-2005|
62823434|NCT02900729|EXPERIMENTAL|Renal Denervation plus Medications|Renal denervation procedure after randomization plus maintenance of baseline standardised triple anti-hypertensive medications for 90 days and then medically necessary adjustment of antihypertensive medications for another 90 days
62823435|NCT02900729|ACTIVE_COMPARATOR|Medications|Maintenance of baseline standardised triple antihypertensive medications after randomization for 90 days and then medically necessary adjustment of antihypertensive medications for another 90 days, after which, subjects will be allowed to cross over to perform renal denervation if they still meet the inclusion criteria for the study.
62823436|NCT04877613|EXPERIMENTAL|Cohort 1: single dose of 5x10^7 CART-GFRa4 cells via intravenous infusion|
62823437|NCT04877613|EXPERIMENTAL|Cohort -1: single dose of 2x10^7 CART-GFRa4 cells via intravenous infusion|
62823438|NCT04877613|EXPERIMENTAL|Cohort 2: single dose of 1x10^8 CART-GFRa4 cells via intravenous infusion|
62823439|NCT04877613|EXPERIMENTAL|Cohort 3: single fixed dose of 3x10^8 CART-GFRa4 cells via intravenous infusion|
62245356|NCT03369223|EXPERIMENTAL|Part 2B Cohort 3: BMS-986249 + nivo|Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC)
62245357|NCT03369223|EXPERIMENTAL|Part 2A Arm A: BMS-986249 + nivo then nivo|"* Previously untreated unresectable stage III-IV melanoma~* Enrollment is closed for this Arm"
62245358|NCT03369223|EXPERIMENTAL|Part 2A Arm B: BMS-986249 + nivo|"* Previously untreated unresectable stage III-IV melanoma~* Enrollment is closed for this Arm"
62435669|NCT03706326|EXPERIMENTAL|Treatment with PD-1 knockout Engineered T cells|PD-1 knockout Engineered T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
62823440|NCT06585111|EXPERIMENTAL|Breastfeeding Education|Women in the intervention group received breastfeeding education through six motivational interviews based on the Health Action Process Approach (HAPA) Model (antenatal period 28-38 weeks, postpartum period 1-3 days, postpartum period 1-2 weeks, postpartum period 4-6 weeks, postpartum period 4th month, postpartum period 6th month).
62849257|NCT05034822|EXPERIMENTAL|Ruxolitinib cream|ruxolitinib 1.5% cream will be applied twice daily to all areas of the skin affected by AD
62435670|NCT04318652|OTHER|Methylprednisolone eye drops|Preservative free steroids methylprednisolone 5% eye drops (prepared by dilution of methyleprednisolone 500mg in 10 ml distilled water (Solu-Medrol, Pfizer company) was prepared and given for all enrolled cases by the following regimen 5 times/day for 5 days with gradual decrease every third day over the following 2 weeks
62245359|NCT03369223|EXPERIMENTAL|Part 2A Arm E: Nivo|"* Previously untreated unresectable stage III-IV melanoma~* Enrollment is closed for this Arm"
62245360|NCT01855698||All patients registered|
62245361|NCT06643312|OTHER|Group 1|"* Individuals with SCI that can stand independently~* Will receive TPAD training~* Will undergo standing, posture, sitting, and stepping assessments~* Participation in this group will last about six months"
62245362|NCT06643312|OTHER|Group 2|"* Individuals with SCI that cannot stand independently~* Will receive TPAD training~* Will undergo standing, posture, sitting, and stepping assessments~* Participation in this group will last about 6 months"
62245363|NCT06643312|NO_INTERVENTION|Group 3|"* Individuals with SCI that can stand independently~* Will undergo standing and posture assessments~* Participation in this group will last about 2 weeks"
62042468|NCT06122714|EXPERIMENTAL|Part A1 (healthy participants) Cohort 2|Participants will receive one single ascending dose of AZD4144.
62042469|NCT06122714|EXPERIMENTAL|Part A1 (healthy participants) Cohort 3|Participants will receive one single ascending dose of AZD4144.
62042470|NCT06122714|EXPERIMENTAL|Part A1 (healthy participants) Cohort 4|Participants will receive one single ascending dose of AZD4144.
62042471|NCT06122714|EXPERIMENTAL|Part A1 (healthy participants) Cohort 5|Participants will receive one single ascending dose of AZD4144.
62042472|NCT06122714|EXPERIMENTAL|Part A1 (healthy participants) Cohort 6|Participants will receive one single ascending dose of AZD4144.
62042473|NCT06122714|PLACEBO_COMPARATOR|Part A1 (healthy participants) placebo|Participants will receive matching Placebo.
62245364|NCT06643312|NO_INTERVENTION|Group 4|"* Individuals with SCI that cannot stand independently~* Will undergo standing and posture assessments~* Participation in this group will last about 2 weeks"
62245365|NCT06643312|NO_INTERVENTION|Group 5|"* Individuals without a SCI~* Will undergo standing, posture, and sitting assessments~* Participation in this group will last about 2 weeks"
62245366|NCT00075088|EXPERIMENTAL|Electrocardiogram (ECG) Intervention|Patients randomized to the experimental group had their ECGs printed out in the target ED with an audible voice alarm. Print-out of the pre-hospital ECG in the target ED was the intervention.
62245367|NCT00075088|OTHER|Routine Clinical Practice|Control patients had an ECG conducted after hospital arrival, as was the standard of care in the county.
62245368|NCT06605807|EXPERIMENTAL|Clinician Participants|All clinician participants will undergo the same intervention, an educational session providing a clinical decision framework for managing older adults' chronic conditions during hospitalization.
62245369|NCT05179863||Patient population|Children, adolescents, and adults with a high suspicion, or a confirmed diagnosis of a rare disease who are treated or living in Switzerland.
62435671|NCT04318652|PLACEBO_COMPARATOR|distilled water eyedrops|Distilled water eyedrops instilled 3 times per day for two weeks
62823441|NCT06585111|NO_INTERVENTION|Control|The women in the control group received six follow-ups based on the Health Action Process Approach (HAPA) Model (antenatal period 28-38 weeks, postpartum period 1-3 days, postpartum period 1-2 weeks, postpartum period 4-6 weeks, postpartum period 4th month, postpartum period 6th month).
62435672|NCT04928911||Adults receiving COVID-19 vaccine|Adults about to receive a COVID-19 vaccine fill out a questionnaire of potential predictors of side effect occurrence
62435673|NCT05127811|EXPERIMENTAL|100mg(on empty)|
62435674|NCT05127811|EXPERIMENTAL|200mg(on empty)|
62435675|NCT05127811|EXPERIMENTAL|400mg(on empty)|
62435676|NCT05127811|EXPERIMENTAL|600mg(on empty)|
62042474|NCT06122714|EXPERIMENTAL|Part A2 (healthy Japanese participants) Cohort 1|Participants will receive one single ascending dose of AZD4144.
62042475|NCT06122714|EXPERIMENTAL|Part A2 (healthy Japanese participants) Cohort 2|Participants will receive one single ascending dose of AZD4144.
62042476|NCT06122714|PLACEBO_COMPARATOR|Part A2 (healthy Japanese participants) placebo|Participants will receive matching placebo.
62042477|NCT06122714|EXPERIMENTAL|Part A3 (healthy Chinese participants) Cohort 1|Participants will receive one single ascending dose of AZD4144.
62042478|NCT06122714|PLACEBO_COMPARATOR|Part A3 (healthy Chinese participants) placebo|Participants will receive matching placebo.
62042479|NCT06122714|EXPERIMENTAL|Part B1 (healthy participants) Cohort 1|Participants will receive one multiple ascending dose of AZD4144.
62042480|NCT06122714|EXPERIMENTAL|Part B1 (healthy participants) Cohort 2|Participants will receive one multiple ascending dose of AZD4144.
62042481|NCT06122714|EXPERIMENTAL|Part B1 (healthy participants) Cohort 3|Participants will receive one multiple ascending dose of AZD4144.
62042482|NCT06122714|PLACEBO_COMPARATOR|Part B1 (healthy participants) placebo|Participants will receive matching placebo.
62042483|NCT06122714|EXPERIMENTAL|Part B2 (healthy Japanese participants) Cohort 1|Participants will receive one multiple ascending dose of AZD4144.
62435677|NCT05127811|EXPERIMENTAL|600mg（with a meal）|
62435678|NCT05127811|EXPERIMENTAL|800mg(with a meal)|
62435679|NCT01919957|NO_INTERVENTION|memory outcome|
62435680|NCT02767622||Patient Group|Twenty right handed patients with biopsy-proven liver cirrhosis listed for liver transplantation.
62435681|NCT02767622||Control Group|Twenty age-matched healthy persons. They were similar to the patient group in respect to the number of education years, sex, and handedness.
62602100|NCT02968667|EXPERIMENTAL|Intervention|Intervention group received 6 weeks of empowerment program
62823442|NCT04299464|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to RO7017773 for approximately 12 weeks.
62602101|NCT02968667|NO_INTERVENTION|Treatment as usual|Medications
62245370|NCT05539365|EXPERIMENTAL|Treatment (ST-alpha-DC1, pembrolizumab)|Patients undergo leukapheresis over 90 minutes. Patients then receive ST-alpha-DC1 IT on days 1, 8, and 50 in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV on days 8, 29, 50, and 71 in the absence of disease progression or unacceptable toxicity. Patients who are receiving clinical benefit from treatment at the end of day 85, may continue to receive pembrolizumab IV every 3 weeks beyond the 4 study doses. Patients also undergo tumor biopsies on days 1, 8, and 50 and CT scans at baseline and days 50 and 85.
62245371|NCT05335018|EXPERIMENTAL|Treatment|"total 2years. Glofitamab: Increase from 2.5mg for 8days in 1 cycle to 10mg for 15days. 2cycles 1day 30mg, 30 mg on the 1st day of every week thereafter. Poseltinib: 40mg/day bid orally, administered daily from the 1st to the 21st of every week.~Lenalidomide: 20mg/day bid orally, administered daily from the 1st to the 14st of every week."
62823443|NCT04299464|EXPERIMENTAL|RO7017773 Low Dose|Participants will receive a fixed low dose of RO7017773 for approximately 12 weeks.
62042484|NCT06122714|PLACEBO_COMPARATOR|Part B2 (healthy Japanese participants) placebo|Participants will receive matching placebo.
62245372|NCT05839041|EXPERIMENTAL|Part 1|Participants will receive a single intravitreal injection of AVD-104 at one of 4 escalating doses. All participants will be followed up for safety until Month 3.
62245373|NCT05839041|ACTIVE_COMPARATOR|Part 2: High dose AVD-104|100 participants will be randomized and treated with bimonthly intravitreal injections of high-dose AVD-104 for the first 12 months. They will continue bimonthly injections for months 13-24.
62245374|NCT05839041|ACTIVE_COMPARATOR|Part 2: Low dose AVD-104|100 participants will be randomized and treated with monthly intravitreal injections of low dose AVD-104 for 24 months.
62245375|NCT05839041|ACTIVE_COMPARATOR|Part 2: Avacincaptad|100 participants will be randomized to receive monthly injections of avacincaptad (2 mg. intravitreal)
62245376|NCT02149212|ACTIVE_COMPARATOR|Clinical Treatment|Phlebotonics: Aminaftone 75 mg BID Limb elastic compression support (Elastic stockings: Venosan / Elastic Bandages: Atamed) Unna boot dressing
62602102|NCT05483894|ACTIVE_COMPARATOR|Experimental group|Atorvastatin 10mg once daily for 24 weeks
62602103|NCT05483894|PLACEBO_COMPARATOR|Control group|Placebo once daily for 12 weeks and then Atorvastatin 10mg once daily for 12 weeks
62602104|NCT04197895|EXPERIMENTAL|test group|Socket preservation with APRF
62823444|NCT04299464|EXPERIMENTAL|RO7017773 High Dose|Participants will receive a fixed high dose of RO7017773 for approximately 12 weeks.
62823445|NCT04488679|EXPERIMENTAL|PRF along with MTA|5 ml of the participant blood will be drawn into 10 ml test tubes without an anticoagulant and centrifuged immediately .centrifugation will be done using a tabletop centrifuge for 10:12 min at 2700:3000 rounds per minute. The resultant product will exhibit three layers. platelet-poor plasma at the surface, PRF clot in the middle, and red blood cells at the bottom. Sterile tweezers inserted into a test tube to retrieve the PRF clot. The prepared fibrin membrane will be gently packed over the pulp
62823446|NCT04488679|ACTIVE_COMPARATOR|MTA direct pulp capping|MTA is primarily calcium oxide in the form of tricalcium silicate, dicalcium silicate and tricalcium aluminate. Bismuth oxide is added for radiopacity, MTA is considered a silicate cement rather than an oxide mixture, a so its biocompatibility is due to its reaction products. MTA elevates the expression of transcription factors, induces dentin bridge formation, possesses biocompatibility9, and sustains a high pH for a longer duration and a close physiochemical seal with dentin that forms an insoluble barrier to prevent microleakag
62823447|NCT06329817|EXPERIMENTAL|Supine position|
62823448|NCT06329817|EXPERIMENTAL|Semi- fowler position|
62042485|NCT01368965|EXPERIMENTAL|Ulthera® System treatment|
62042486|NCT04932122|ACTIVE_COMPARATOR|Dorsal wrist ganglion alone (DWG)|Dorsal wrist ganglion excision alone
62042487|NCT04932122|ACTIVE_COMPARATOR|DWG with PIN|Dorsal wrist ganglion excision with posterior interosseus neurectomy (PIN)
62245377|NCT02149212|ACTIVE_COMPARATOR|Iliac vein stenting|Wallstent
62245378|NCT05984277|EXPERIMENTAL|Arm 1|Volrustomig plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via iv infusion
62245379|NCT05984277|ACTIVE_COMPARATOR|Arm 2|Pembrolizumab plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via iv infusion
62245380|NCT04032691|EXPERIMENTAL|Clonidine Pill|0.1 mg by mouth daily at bedtime for one week
62245381|NCT06167317|EXPERIMENTAL|Part A: GS-0201 Monotherapy Dose Escalation|Participants will receive escalating doses of GS-0201 monotherapy, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol or up to 105 weeks, whichever occurs first.
62602105|NCT04197895|ACTIVE_COMPARATOR|control group|natural healing
62602106|NCT04167124|EXPERIMENTAL|multi-sensor lifestyle intervention|
62823449|NCT06342037|EXPERIMENTAL|Tiragolumab and atezolizumab|Tiragolumab 600mg and atezolizumab 1200 mg, both every three weeks
62823450|NCT06342037|EXPERIMENTAL|Tiragolumab and ipilimumab|Tiragolumab 600mg every 3 weeks and ipilimumab 1mg/kg every 3 weeks for the first 4 cycles
62823451|NCT06342037|EXPERIMENTAL|Tiragolumab, atezolizumab and ipilimumab|Tiragolumab 600mg and atezolizumab 1200mg both every 3 weeks, plus ipilimumab 1mg/kg every 3 weeks for the first 4 cycles
62245382|NCT06167317|EXPERIMENTAL|Part B: Cohort B1: GS-0201 Monotherapy Dose Expansion|Participants with selected indications will receive GS-0201 monotherapy at the recommended dose for expansion.
62245383|NCT06167317|EXPERIMENTAL|Part B: Cohort B2: GS-0201 Monotherapy Dose Expansion|Participants with selected indications not included in cohort B1 will receive GS-0201 monotherapy at the recommended dose for expansion.
62245384|NCT06167317|EXPERIMENTAL|Part C: Dose Escalation: GS-0201 + Sacituzumab Govitecan (SG)|Participants will receive escalating doses of GS-0201 in combination with SG, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol or up to 105 weeks, whichever occurs first.
62823452|NCT06090422|EXPERIMENTAL|Intervention group|Ketamine, 0,8 mg/kg body weight, given as four single doses (biweekly for two weeks)
62042488|NCT01891149||Malawian women|Malawian women who present for care at the Fistula Care Centre
62042489|NCT03280173|EXPERIMENTAL|61 mgA tafamidis free acid soft gelatin capsule fed|fasted
62245385|NCT06167317|EXPERIMENTAL|Part D: Cohort D1: Dose Expansion: GS-0201 + SG|Participants with confirmed unresectable locally advanced or metastatic triple negative breast cancer (mTNBC) will receive GS-0201 at the recommended Phase 2 dose (RP2D) in combination with SG.
62245386|NCT06167317|EXPERIMENTAL|Part D: Cohort D2: Dose Expansion: GS-0201 + SG|Participants with confirmed unresectable locally advanced or metastatic HR+/HER2- breast cancer will receive GS-0201 at the recommended Phase 2 dose (RP2D) in combination with SG.
62245387|NCT05443230||patients with sarcopenia|
62435682|NCT04323007|OTHER|Nephrotic syndrome patients|This study is to evaluate Thyroid Hormone profile in patients with Nephrotic syndrome to identify clinical predictor of Thyroid dysfunction in patients with Nephrotic syndrome
62435683|NCT03973996|EXPERIMENTAL|Green Tea|Participants consuming gummy confections with catechin-rich green tea extract daily for 4 weeks
62435684|NCT03973996|PLACEBO_COMPARATOR|Placebo|Participants consuming matched gummy confections formulated without green tea extract daily for 4 weeks
62435685|NCT00270699|EXPERIMENTAL|1|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10\^5 PFU dose) into the deltoid region of either arm.
62435686|NCT00270699|EXPERIMENTAL|2|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10\^3 PFU dose) into the deltoid region of either arm. This arm will enroll after Arm 1.
62435687|NCT00270699|EXPERIMENTAL|3|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10\^1 PFU dose) into the deltoid region of either arm. This arm will enroll after Arms 1 and 2.
62435688|NCT00270699|PLACEBO_COMPARATOR|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
62435689|NCT04134975|EXPERIMENTAL|Scanner Group|lumbar spine surgical procedure with guided pedicle screw placement coupled with intraoperative scanning (BODYTOM, Samsung).
62435690|NCT04134975|ACTIVE_COMPARATOR|fluoroscopy group|lumbar spinal surgery with pedicle screw placement guided by fluoroscopy, a fluoroscopic control being performed with each set screw.
62435691|NCT05482672|EXPERIMENTAL|GetHealthy-OA|The GetHealthy-OA program combines a 6-week mind-body program delivered via live video with the oral supplement fisetin. Oral fisetin will be taken for 2 consecutive days (day 1 and 2), a 28-day wash-out period, and then another 2-day course (days 31 and 32).
62435692|NCT05482672|PLACEBO_COMPARATOR|Minimally Enhanced Usual Care|The minimally enhanced usual care group will be given a health education booklet at the date of baseline testing and will take an oral placebo for 2 consecutive days (day 1 and 2) and then again 28 days later (days 29 and 30).
62435693|NCT01810926|EXPERIMENTAL|MRD-Regimen&Polyclonal antibody|Patients MRD will be randomized to receive Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 \& ATG-Fresenius S® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2
62435694|NCT01810926|SHAM_COMPARATOR|MRD-Regimen|Patients receiving stem cell transplantation from a matched related donors (MRD) will be randomized to receive only Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²) + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 (total dose of 150 mg/m²) after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals (total dose of 8 mg/kg)+ Cyclosporine A iv at a starting dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL (In the absence of GvHD CSA will be tapered after day + 180 and stopped at 9-12 months) + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
62823453|NCT06090422|ACTIVE_COMPARATOR|Control group|Midazolam, 0,8 mg/kg body weight, given as four single doses (biweekly for two weeks)
62823454|NCT04686474|EXPERIMENTAL|Azadirachta indica leaves extract containing ointment intervention.|Azadirachta indica leaves extract containing ointment will be used twice daily for 12 weeks
62823455|NCT06604663|NO_INTERVENTION|Usual Care|Usual Care at AMPATH involves telephoning clients or care supporters the day prior to their appointment (at some clinics) and/or telephoning or making a home visits after appointments are missed. This will be in place at usual care clinics until the date at which the clinic is randomized to receive the CDSS support.
62042490|NCT03280173|EXPERIMENTAL|61 mgA tafamidis free acid soft gelatin capsule fasted|fed
62042491|NCT03280173|EXPERIMENTAL|4 × 20 mg tafamidis meglumine soft gelatin capsules fed|fed
62245388|NCT05443230||patients without sarcopenia|
62042492|NCT03280173|EXPERIMENTAL|4 × 20 mg tafamidis meglumine soft gelatin capsules fasted|fasted
62245389|NCT02060383|EXPERIMENTAL|Incretin based therapy (randomized group)|Participants randomized to the incretin based arm started with sitagliptin once daily. If sitagliptin did not control the participant's hyperglycemia, sitagliptin was stopped and participants switched to liraglutide once daily. If despite treatment with liraglutide, hyperglycemia was not controlled then the participant was eligible for rescue therapy with addition of insulin.
62602107|NCT04349449||Vedolizumab Participants|Participants diagnosed with moderate to severe CD from approximately 20 investigational sites will be observed over a period of 12 months after initiation of treatment with vedolizumab, intravenous infusion under standard clinical care.
62602108|NCT06230666|EXPERIMENTAL|Single-isocenter SBRT|SBRT using a single-isocenter treatment plan
62602109|NCT06230666|ACTIVE_COMPARATOR|Multiple-isocenter SBRT|SBRT using multiple treatment plans
62602110|NCT00705458|EXPERIMENTAL|CTA|Initial EKG-gated computed tomography angiography of the coronary arteries
62602111|NCT00705458|ACTIVE_COMPARATOR|MPI|Initial nuclear stress myocardial perfusion imaging
62849258|NCT03843008|EXPERIMENTAL|Melatonin Group|Participants will receive 3mg of melatonin at 18:00 (+/- one hour) each evening up to seven days or for the duration of his or her hospital stay.
62042493|NCT00507000|ACTIVE_COMPARATOR|A, Cholecalciferol|A Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
62042494|NCT00507000|PLACEBO_COMPARATOR|Vitamin D and Tuberculosis|B, Lactose
62042495|NCT02728557|EXPERIMENTAL|Supportive psychotherapy|Participants will receive supportive therapy.
62245390|NCT02060383|EXPERIMENTAL|Insulin (randomized group)|Participants randomized to the insulin arm started with once daily dose of basal insulin. The dose was up or down titrated at the discretion of the investigator. If blood glucose levels remained uncontrolled on basal insulin, participant switched to basal insulin plus prandial insulin.
62042496|NCT02728557|EXPERIMENTAL|Supportive-expressive psychotherapy|Participants will receive supportive-expressive therapy.
62042497|NCT06732076|EXPERIMENTAL|experimental|web based education
62042498|NCT06732076|NO_INTERVENTION|control|no intervention
62042499|NCT04437940||Covid-19 positive women|Women with nasofarangeal Covid-19 PCR test is positive
62042500|NCT01866228|NO_INTERVENTION|No Consultation Recording|Participant does not receive consultation recording
62449156|NCT01352650|ACTIVE_COMPARATOR|Cohort 1A|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5
62042501|NCT01866228|EXPERIMENTAL|Consultation Recording|Participant receives consultation recording
62602112|NCT04220333|PLACEBO_COMPARATOR|Control|Participants received the instruction: 'please, lie down, relax and pay attention to your breath'. This procedure was carried during 15 minutes. Soon after the experiment, individual assessment was performed blinded to who received intervention using a structured questionnaire and Likert-scales about the degree of relaxation and feelings.
62623398|NCT05680662|EXPERIMENTAL|adjuvant quadruple thearpy of quercetin , zinc, EGCG, metformin for 100 breast cancer cases|experimental study of adjuvant quadruple therapy of quercetin, zinc, EGCG, and metformin for 100 cases of different types of breast cancer women daily dose as follows daily 500 mg orally quercetin OD daily 50 mg zinc sulfate orally OD daily 300 mg EGCG orally OD daily metformin 850 mg orally OD during chemotherapy courses and until last stage of treatment
62042502|NCT02252705||Incident patients|Patients with less than three months from diagnosis to start of the Registry or those who have been diagnosed during the recruitment period.
62042503|NCT02252705||Prevalent patients|Patients who have been diagnosed with more than three months from diagnosis to start of the Registry.
62042504|NCT01803308|EXPERIMENTAL|Experimental Part A|"Experimental: Part A: Part A will use a single ascending dose protocol in small, open-label cohorts to determine the starting dose for Part B in the potentially therapeutic range.~Intervention: SB9200"
62042505|NCT01803308|EXPERIMENTAL|Experimental Part B|"Experimental: Part B: Part B will use a multiple ascending dose protocol to further explore the safety, tolerability, pharmacokinetics and pharmacodynamics of SB9200 over 7-14 days of dosing.~Intervention: SB9200 and Placebo"
62042506|NCT03846648|ACTIVE_COMPARATOR|Cypep-1|"CyPep-1 cream 1% (w/w) will be applied once daily on a 5x5 cm healthy skin area on the upper back and on 1 to max 3 common warts on the (dorsal/palmar) side of the hand.~In Part 1 the dosing will be performed once daily for 7 days. The dose of 200 μL CyPep-1 cream will be applied on a 5x5 cm on the back by clinical staff. In addition, up to 3 common warts will be treated with 20 μL of the CyPep1 cream per day.~In Part 2 subjects will administer 20-30 mg CyPep-1 cream once daily at home after instruction by clinical staff. The total treatment period will be 28 days, possibility of a maximum extension of three days is allowed."
62849259|NCT03843008|NO_INTERVENTION|No Melatonin Group|Participants will receive no melatonin for the length of their hospital stay.
62042507|NCT03846648|PLACEBO_COMPARATOR|Placebo|Placebo cream (the same as that of the drug product CyPep-1 1% (w/w) but without the active substance) will be applied once daily on the same areas as described above.
62042508|NCT01833338|OTHER|Single arm|There is only one arm in this study. All patients undergo MSCT, IVUS and OCT.
62042509|NCT04598867|EXPERIMENTAL|CD-008-0045 40 mg/day|Patients assigned to the CD-008-0045 40 mg/day group will receive 1 capsule of CD-008-0045 (20 mg) before breakfast and before dinner for 32 weeks.
62042510|NCT04598867|PLACEBO_COMPARATOR|Placebo|Patients assigned to the Placebo group will receive 1 placebo capsule before breakfast, and dinner for 8 weeks.
62042511|NCT04598867|ACTIVE_COMPARATOR|Afobazol 30 mg/day|Patients assigned to the Afobazol 30 mg/day group will receive 1 tablet of Afobazol (10 mg) before breakfast, before lunch and before dinner for 8 weeks.
62042512|NCT05309278|EXPERIMENTAL|Physical and cognitive exercise group|Participants will be randomized to receive physical and cognitive training for a period of 12 weeks.
62042513|NCT05309278|ACTIVE_COMPARATOR|Physical exercise only group|Participants will be randomized to receive only physical training for a period of 12 weeks.
62042514|NCT02131779|EXPERIMENTAL|Co-Educational Workshops|Community health advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part health series with men and women dyads. Technical assistance and support will be given as needed to community health advisors. Workshop sessions will include didactic lecture, group discussions, video and group exercises.
62042515|NCT02131779|ACTIVE_COMPARATOR|Men's Workshops|Community health advisors will be trained using traditional/classroom methods and provided with technical assistance/support as needed to deliver 4 part educational sessions to men only groups to relay information about making an informed decision about prostate cancer screening. Workshop sessions will include didactic lecture, group discussions, video and group exercises.
62042516|NCT02747238|ACTIVE_COMPARATOR|Ultrasound|Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started
62042517|NCT02747238|ACTIVE_COMPARATOR|No ultrasound|Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started
62042518|NCT01297231||Breast cancer|This prospective study will recruit patients with stage 0-3 breast cancer who have had or are scheduled for a breast MRI prior to treatment.
62435695|NCT01810926|EXPERIMENTAL|MUD-Regimen & Rituximab|Patients MUD will be randomized to receive Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11 + ATG-Fresenius S ® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 \& Rituximab in a single infusion of 200 mg/m2 on day -1
62042519|NCT04048824|EXPERIMENTAL|Inhibitory Learning-Based Exposure|Participants will receive exposure therapy aimed at increasing inhibitory learning.
62042520|NCT04048824|ACTIVE_COMPARATOR|Habituation-Based Exposure|Participants will receive exposure therapy aimed at reducing fear responding.
62449157|NCT01352650|ACTIVE_COMPARATOR|Cohort 1B|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10
62602113|NCT04220333|EXPERIMENTAL|Intervention|"The intervention protocol was divided in two steps: first, patients spent 5 minutes in the phase of harmonization with five colored stones of a size of a walnut (green, red, yellow, white and black) placed around their bodies.~Second, in accordance to the emotion chosen by the participant, a matching mandala was placed next to the feet, on the abdomen, or next to the head depending on the self-perceived personality type, intuitive, emotive and rational for the remaining 10 minutes (Figure 3B). The researcher also checked the control subjects once during the 15 fifteen minutes of experiment.~Soon after the experiment, individual assessment was performed blinded to who received intervention using a structured questionnaire and Likert-scales about the degree of relaxation and feelings."
62602114|NCT00750412|EXPERIMENTAL|TeenScreen|
62042521|NCT05387941|EXPERIMENTAL|Dexamethasone treated infants|15 infants that receive dexamethasone eye drops for treatment of retinopathy of prematurity will be included, and both serum and saliva samples will be collected in order to find out the pharmacokinetic properties of dexamethasone in eye drops according to a pre-specified sampling scheme specifically designed for this purpose by experts in pediatric pharmacokinetics.
62602115|NCT00750412|NO_INTERVENTION|Treatment As Usual|
62042522|NCT02106299|EXPERIMENTAL|Regen Sling|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a Regen Sling (medprin).
62042523|NCT02106299|ACTIVE_COMPARATOR|tension-free vaginal tape-obturator|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (gynecare™, USA).
62042524|NCT04262544|EXPERIMENTAL|mHealth|Intervention group
62042525|NCT04262544|ACTIVE_COMPARATOR|Usual Care|Control group
62042526|NCT03148223|EXPERIMENTAL|Intervention|Auriculotherapy with application of mustard seeds fixed with adhesive tape at specific points in the auricle during one session per week lasting 20 minutes for 3 consecutive months.
62042527|NCT03148223|PLACEBO_COMPARATOR|Control|Auriculotherapy with tape-only fixation in the auricle, without mustard seeds, following the same stitch protocol used with the intervention group, during a session per week lasting 20 minutes, for three consecutive months.
62042528|NCT06580483|EXPERIMENTAL|A tooth (on one side) supporting complete overdenture|The tooth is prepared to receive a restoration
62245391|NCT02060383|OTHER|Non-Randomized Arm|"This arm represents the non-randomized participants: Cushing's Disease (CD) or Acromegaly participants, who received pasireotide s.c. or LAR (long-acting release) respectively, but who were not randomized to the Incretin or Insulin arms.~For the purpose of analysis, this non-randomized arm is further split into 3 groups:~* Baseline insulin group (BL insulin) includes participants who were receiving insulin at study entry~* Oral antidiabetic drugs (OAD) group includes participants who developed hyperglycemia that was controlled by metformin and/or other background anti-diabetic treatment~* No OAD group includes participants who did not receive any anti-diabetic medication during the core phase of the trial"
62602116|NCT06037694|ACTIVE_COMPARATOR|Free Gingival Graft|A mucogingival surgery where a conventional free gingival graft harvested from the palate is placed on a recipient site prepared to increase the width of KM at implant sites.
62602117|NCT06037694|EXPERIMENTAL|Meshed Free Gingival Graft|A mucogingival surgery where a meshed free gingival graft harvested from the palate is placed on a recipient site prepared to increase the width of KM at implant sites.
62245392|NCT06734468|EXPERIMENTAL|Lifestyle Intervention|All participants will receive an intervention.
62245393|NCT06735521||Univentricle heart, operated with TCPC (total cavo pulmonary connection)|
62245394|NCT06246656|ACTIVE_COMPARATOR|CAD/CAM milled TAD guides|The position guides for orthodontic Temporary Anchorage Devices (TAD) will be produced by CAD/CAM milling.
62245395|NCT06246656|ACTIVE_COMPARATOR|3D printed guides|The position guides for orthodontic Temporary Anchorage Devices (TAD) will be produced by 3D printing technology.
62245396|NCT06556147|EXPERIMENTAL|Stage 1, Day 1, Sequential Cohort 1|Young and older adult participants will receive VXB-241 60 mcg (low dose) or Placebo, intramuscularly (IM), once on Day 1.
62245397|NCT06556147|EXPERIMENTAL|Stage 1, Day 1, Sequential Cohort 2|Young and older adult participants will receive VXB-241 120 mcg (medium dose) or Placebo, IM, once on Day 1.
62245398|NCT06556147|EXPERIMENTAL|Stage 1, Day 1, Sequential Cohort 3|Young and older adult participants will receive VXB-241 240 mcg (medium-high dose) or Placebo, IM, once on Day 1.
62245399|NCT06556147|EXPERIMENTAL|Stage 1, Day 1, Sequential Cohort 4|Young and older adult participants will receive VXB-241 480 mcg (high dose) or Placebo, IM, once on Day 1.
62245400|NCT06556147|EXPERIMENTAL|Stage 2, Day 1, Concurrent Group 1a|Older adult participants will receive VXB-241 60 mcg (low dose), IM, once on Day 1.
62245401|NCT06556147|EXPERIMENTAL|Stage 2, Day 1, Concurrent Group 1b|Older adult participants will receive VXB-241 120 mcg (medium dose), IM, once on Day 1.
62042529|NCT06580483|ACTIVE_COMPARATOR|A tooth (on the other side) supporting complete overdenture|The tooth is prepared to receive another restoration
62245402|NCT06556147|EXPERIMENTAL|Stage 2, Day 1, Concurrent Group 1c|Older adult participants will receive VXB-241 240 mcg (medium-high dose), IM, once on Day 1.
62245403|NCT06556147|EXPERIMENTAL|Stage 2, Day 1, Concurrent Group 1d|Older adult participants will receive VXB-241 480 mcg (high dose), IM, once on Day 1.
62245404|NCT06556147|ACTIVE_COMPARATOR|Stage 2, Day 1, Concurrent Group 2a|Older adult participants will receive Arexvy 120 mcg, IM, once on Day 1.
62245405|NCT06556147|PLACEBO_COMPARATOR|Stage 2, Day 1, Concurrent Group 3a|Older adult participants will receive Placebo, IM, once on Day 1.
62245406|NCT06556147|EXPERIMENTAL|Group 1e: VXB-241 Revaccination in VXB-241 Recipients|Approximately 50% of the older adult participants who received VXB-241 (any dose level), will receive VXB-241, IM, once on Day 364 in the second year of the study.
62245407|NCT06556147|PLACEBO_COMPARATOR|Group 1f: Placebo Revaccination in VXB-241 Recipients|Approximately 50% of the older adult participants who received VXB-241 (any dose level), will receive Placebo, IM, once on Day 364 in the second year of the study.
62245408|NCT06556147|ACTIVE_COMPARATOR|Group 2b: Arexvy Revaccination|All older adult participants who received Arexvy 120 mcg will receive Arexvy 120 mcg revaccination, IM, once on Day 364 in the second year of the study.
62245409|NCT06556147|EXPERIMENTAL|Group 3b: VXB-241|All older adult participants who received Placebo will receive VXB-241, IM, once on Day 364 in the second year of the study.
62602118|NCT04819503|OTHER|Active and then sham repetitive transcranial magnetic stimulation|"Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the leg.~Sham stimulation is delivered with a sham coil placed in the helmet encasing the active rTMS coil. Sham rTMS sessions will use exactly the same parameters of stimulation as active rTMS."
62823456|NCT06604663|EXPERIMENTAL|Clinical decision support, CDSS|When a clinic is assigned to receive the CDSS support intervention two components will be enacted to enable proactive outreach that prevents a missed visit. These patients are considered to be in the active, experimental arm. Please seem the section above on Detailed Description for background and details on how this intervention is implemented.
62245410|NCT02743884|EXPERIMENTAL|Esophageal Cooling Device|Esophageal cooling
62245411|NCT02743884|EXPERIMENTAL|Esophageal Warming|Esophageal warming
62245412|NCT04500041|ACTIVE_COMPARATOR|Casting|Subjects will be treated with serial casting
62245413|NCT04500041|ACTIVE_COMPARATOR|Bracing|Subjects will be treated with full-time orthotics (braces)
62245414|NCT06736548|EXPERIMENTAL|STEP-Together Intervention|"Enrolled participants will complete the educational intervention session (STEP-Together) delivered by an interventionist during an online group videoconference session.~-Up to 12 participants will also take part in a coaching session 1 week after the virtual intervention session."
62245415|NCT04870359|ACTIVE_COMPARATOR|Pre-emptive Treatment (Prednisolone and/or AZA/MMF)|"1. Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks.~2. Adjustment of the 2nd agent would be as follows:~   1. For patients who receive AZA \<75mg/day; increase the dose of AZA to 75 mg/day.~  2. For patients who receive MMF \<1g/day, increase the dose of MMF to 1g/day."
62245416|NCT04870359|NO_INTERVENTION|Control|Current immunosuppressive regimen and dosage should remain unchanged until the development of renal or extra-renal flares which required increase/change in immunosuppression.
62245417|NCT05727384|EXPERIMENTAL|Clazakizumab|Participants received Clazakizumab 5 mg as a subcutaneous injection every 4 weeks for 24 weeks
62245418|NCT05727384|PLACEBO_COMPARATOR|Placebo|Participants received Clazakizumab placebo as a 5 mg subcutaneous injection every 4 weeks for 24 weeks
62823457|NCT01915784|EXPERIMENTAL|Group A|Genuair® (Pressair™) first; Breezhaler® (Neohaler™) second
62823458|NCT01915784|EXPERIMENTAL|Group B|Breezhaler® (Neohaler™) first; Genuair® (Pressair™) second
62042530|NCT06360939|EXPERIMENTAL|Stereotactic body radiation therapy|SBRT within 6 weeks of randomisation guided by previous electrophysiology studies, electrocardiograms and cardiac imaging.
62823459|NCT03702127|EXPERIMENTAL|TMS in patients with intracranial electrodes|We will administer TMS to neurosurgical patients with intracranial electroencephalography in order to better understand the effects TMS has on the human brain. Participants will receive both active and sham stimulation at varying points during the study.
62823460|NCT03773640|EXPERIMENTAL|The study group|Study group (I) consist of patients who were treated with the occlusal splints and radio frequency currents. In the case of application of radiation to the muscle area, the energy was 20 J and 15 J to the area of the masticatory muscles, the frequency was 3 MHz, bipolar technique, the duration of the procedure was 10 minutes, the coupling substance was a gel for ultrasound examinations.
62042531|NCT06360939|ACTIVE_COMPARATOR|Catheter ablation|CA within 6 weeks of randomisation (constituting standard of care for patients with VT and structural heart disease)
62042532|NCT00476216|EXPERIMENTAL|Combination of Arixtra with chemotherapy|Carboplatin 6 AUC q 21 days; Paclitaxel 200 mg/m2 q 21 days. Cohort I: Arixtra 2.5 mg SQ qd x 21 days; Cohort II: Arixtra weight-based dose (D1-2)followed by Arixtra 2.5 SQ q day (D3-21)
62245419|NCT01955447|PLACEBO_COMPARATOR|Reference|no added plant-based ingredients
62245420|NCT01955447|ACTIVE_COMPARATOR|Low level plant-based ingredients|Low level addition of plant-based ingredients
62245421|NCT01955447|ACTIVE_COMPARATOR|Medium level plant-based ingredients|Medium level addition of plant-based ingredients
62823461|NCT03773640|ACTIVE_COMPARATOR|The control group|The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
62823462|NCT02443688|EXPERIMENTAL|50 mg CTX-4430|Once daily oral capsule for 48 weeks
62823463|NCT02443688|EXPERIMENTAL|100 mg CTX-4430|Once daily oral capsule for 48 weeks
62823464|NCT02443688|PLACEBO_COMPARATOR|Matching Placebo|Once daily oral capsule for 48 weeks
62823465|NCT05686603|EXPERIMENTAL|P-MLA|a fractional 1064-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) picosecond laser with MLA handpiece (P-MLA for short)
62042533|NCT00609687|OTHER|A|Patients with suspected sarcoid-related posterior segment inflammation with inconclusive clinical exam findings, ancillary testing, and laboratory results
62042534|NCT05335512||Patients underwent TURBT|Patients undergoing complete TURBT for evaluation of a newly diagnosed bladder lesion in TMH and found to have NMIBC (either low risk or high risk)
62042535|NCT01368367|ACTIVE_COMPARATOR|Intensive exercise group|
62245422|NCT01955447|ACTIVE_COMPARATOR|High level plant-based ingredients|High level addition of plant-based ingredients
62245423|NCT00044551|EXPERIMENTAL|Arm 1|
62245424|NCT03292289|EXPERIMENTAL|Study process|Pre- and post-operative consultations. Stomatherapy consultation. Questionnaires
62435696|NCT01810926|SHAM_COMPARATOR|MUD-Regimen|Patients MUD will be randomized to receive only Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11 + ATG-Fresenius S ® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2
62823466|NCT05686603|SHAM_COMPARATOR|AF-Er|ablative fractional 2940-nm Er:YAG laser (AF-Er for short)
62823467|NCT06597812||group s|Patients receiving sevoflurane
62823468|NCT06597812||Group p|Patients receiving propofol-based total intravenous anesthesia
62042536|NCT01368367|PLACEBO_COMPARATOR|Stretch exercise only|
62042537|NCT01015157|ACTIVE_COMPARATOR|Standard stapling without reinforcement|Standard Echelon 60 linear stapling with GOLD cartridges
62042538|NCT01015157|ACTIVE_COMPARATOR|Seamguard gastric stapling line reinforcement|
62042539|NCT04161508|EXPERIMENTAL|Sugammadex|sugammadex 2 mg/ Kg for the reversal of neuromuscular blockade at the end of surgery
62042540|NCT04161508|ACTIVE_COMPARATOR|Neostigmine|neostigmine 50 mcg/Kg + glycopyrrolate 10 mcg/kg for the reversal of neuromuscular blockade at the end of surgery
62245425|NCT05384379|EXPERIMENTAL|Treated Group|Intubated patients treated with inhaled BZ371B will receive a dose of 12 mg of BZ371B divided in two different nebulizations per day, for three cosnecutive days
62245426|NCT05173142|EXPERIMENTAL|dose escalation phase of HMPL-453 monotherapy or combination therapy|HMPL-453 monotherapy or combination therapy
62245427|NCT05173142|EXPERIMENTAL|indication specific dose expansion phase of HMPL-453 combination therapy|HMPL-453 combined with chemotherapy or anti-PD-1 antibody, in patients with IHCC, G/GEJ, or UC harboring specific FGFR gene alterations
62245428|NCT05874323|EXPERIMENTAL|Type I Diabetes Mellitus|177 patients with Type I Diabetes Mellitus
62042541|NCT03466294|EXPERIMENTAL|Azacitidine and Venetoclax|On day 1 of cycle 1, Azacitidine 75 mg/m2 will be given by injection or infusion, and will continue for 7 days. Azacitidine doses will be given in subsequent cycles for patients who do not achieve response. Venetoclax will be administered orally once daily on days 2 through 28 in cycle 1. Beginning with cycle 2, and each subsequent cycle, venetoclax will be administered Days 1 through 28.
62042542|NCT03551574||Macular involving retinal detachment|Patients with retinal detachments that have developed PVR when the macula has been involved
62823469|NCT01885299||Patients being treated by SRS/SBRT|Patients with a condition being considered for treatment by SRS/SBRT
62823470|NCT01863784|EXPERIMENTAL|JNJ-38518168|
62823471|NCT03177317|EXPERIMENTAL|Elderly patients (>= 70 years of age)|Dexamethasone 8mg intravenously before chemotherapy
62823472|NCT04542837|EXPERIMENTAL|KN046 plus Lenvatinib|
62823473|NCT04927429||Affected participants|Participants with a clinically indicated referral for cardiac MRI
62823474|NCT04927429||Healthy participants|Healthy individuals of various ethnicities to serve as reference ranges
62823475|NCT03727217|EXPERIMENTAL|Pre and postoperative ultrasound|An ultrasound is performed in preoperative and in postoperative.
62823476|NCT04282187|EXPERIMENTAL|Treatment (decitabine, ruxolitinib, fedratinib, pacritinib)|Patients receive decitabine IV QD over 1 hour on days 1-10, and either ruxolitinib PO BID, fedratinib PO daily, or pacritinib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62042543|NCT00676767|EXPERIMENTAL|1|
62042544|NCT00676767|ACTIVE_COMPARATOR|2|
62435697|NCT01107080||Degradation|30 mastectomy, partial mastectomy, and mammoplasty samples will be analyzed to define the effective post-excision time window in which the device must be used before the results can no longer be evaluated. The mammoplasty specimens are necessary to assess normal tissue outcomes.
62042545|NCT00676767|PLACEBO_COMPARATOR|3|
62042546|NCT00584727|ACTIVE_COMPARATOR|senofilcon A/alphafilcon A/etafilcon A|First intervention:senofilcon A toric contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: etafilcon A sphere contact lenses
62042547|NCT00584727|ACTIVE_COMPARATOR|alphafilcon A/etafilcon A/senofilcon A|First intervention: alphafilcon A toric contact lenses Second intervention: etafilcon A sphere contact lenses Third intervention: senofilcon A toric contact lenses
62245429|NCT05874323|OTHER|Control|include 177 Healthy Control Cases.
62435698|NCT01107080||Reproducibility|25 Partial Mastectomy cases will be analyzed to distinguish between different implementation methods of the technology.
62435699|NCT06232863|EXPERIMENTAL|BH009|Every 28 days constitutes a treatment cycle, and administration on day 1, day 8, day 15 of each cycle
62435700|NCT01305317|EXPERIMENTAL|lipitor|atorvastatin 20mg daily
62435701|NCT03622333|EXPERIMENTAL|Familial Carcinoid Tumors|All patients with proven Familial Carcinoid Tumors
62435702|NCT01574599|EXPERIMENTAL|Repetitive Facilitative Exercise|Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
62435703|NCT01574599|NO_INTERVENTION|Conventional Therapy Program|Typical therapy excluding robotics, RFE
62435704|NCT04362033|EXPERIMENTAL|PLR group|"Patients will be submitted to two different fluid responsiveness maneuvers in a cross over randomization:~In PLR arm, patients will be submitted to the PLR maneuver (patient is positioned from 45 grade of semi-recumbent position to dorsal decubitus and the legs are raised at 45 grade) firstly, then PEEP increment maneuver. At the end, all patients will receive a bolus of 500mL of Lactate Ringer's"
62435705|NCT04362033|EXPERIMENTAL|PEEP group|"Patients will be submitted to two different fluid responsiveness maneuvers in a cross over randomization:~In PEEP arm, patients will be submitted to the PEEP maneuver (consisted in increase the PEEP level 5 cmH2O above the mean airway pressure, patient is positioned in 45 grade of semi-recumbent position) firstly, then PLR maneuver. At the end, all patients will receive a bolus of 500mL of Lactate Ringer's"
62435706|NCT01513785|ACTIVE_COMPARATOR|group R20A|All the patients were sent to a penicillin skin test before treatment except they were given penicillin before. The group R20A will receive 14 days of Amoxicillin 1g t.i.d and Rabeprazole 20 mg b.i.d. PPI was taken 30 minutes before meals while antibiotic was taken 30 minutes after meals.
62435707|NCT01513785|ACTIVE_COMPARATOR|group R10A|All the patients were sent to a penicillin skin test before treatment except they were given penicillin before. The group R10A will receive 14 days of Amoxicillin 1g t.i.d and Rabeprazole 10 mg b.i.d. PPI was taken 30 minutes before meals while antibiotic was taken 30 minutes after meals.
62435708|NCT01418729|ACTIVE_COMPARATOR|Sorafenib plus Pravastatin|The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h.
62435709|NCT01418729|PLACEBO_COMPARATOR|Sorafenib plus Placebo|The treatment received will be sorafenib 400 mg/12 h + placebo/24 h.
62435710|NCT00437281|PLACEBO_COMPARATOR|Placebo|
62435711|NCT00437281|EXPERIMENTAL|Pregabalin|
62435712|NCT04728087|EXPERIMENTAL|ACCEL|Participant will be treated with up to 2 bellows (10 grams nominal) of ACCEL®.
62823477|NCT05914090|EXPERIMENTAL|Intervention group|
62823478|NCT05914090|NO_INTERVENTION|Control group|
62823479|NCT02167971|EXPERIMENTAL|Active Coil|The patients assigned to this group will undergo repetitive Transcranial Magnetic Stimulation over 10 sessions (each one with 2,000 pulses) on left dorsolateral prefrontal cortex.
62823480|NCT02167971|SHAM_COMPARATOR|Sham|The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
62042548|NCT00584727|ACTIVE_COMPARATOR|etafilcon A/senofilcon A/alphafilcon A|First intervention: etafilcon A sphere contact lenses Second intervention:senofilcon A toric contact lenses Third intervention: alphafilcon A toric contact lenses
62042549|NCT00584727|ACTIVE_COMPARATOR|senofilcon A/etafilcon A/alphafilcon A|First intervention: senofilcon A toric contact lenses Second intervention: etafilcon A sphere contact lenses Third intervention: alphafilcon A toric contact lenses
62042550|NCT00584727|ACTIVE_COMPARATOR|alphafilcon A/senofilcon A/etafilcon A|First intervention: alphafilcon A toric contact lenses Second intervention: senofilcon A toric contact lenses Third intervention: etafilcon A sphere contact lenses
62042551|NCT00584727|ACTIVE_COMPARATOR|etafilcon A/alphafilcon A/senofilcon A|First intervention: etafilcon A sphere contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: senofilcon A toric contact lenses
62042552|NCT00384267||Neonates|Inpatient
62042553|NCT02607995||low key intervention|for the whole group
62042554|NCT02753049|EXPERIMENTAL|Peer led mHealth adherence intervention|Eligible participants enrolled will receive five, weekly-60 minute, 'ACCESS' sessions, delivered by a peer adherence coach via remote videoconferencing, using smartphones. Cognitive behavioral strategies will be employed to target beliefs about antiretroviral treatment (ART), knowledge of ART, and adherence self-efficacy.
62435713|NCT04728087|ACTIVE_COMPARATOR|Gelfoam or SURGIFOAM|Participant will be treated with up to 12.5 cm x 8.0 cm of Gelfoam® (Absorbable Gelatin Sponge, Pfizer Manufacturer Part Number 0342-01) or SURGIFOAM® (Absorbable Gelatin Sponge, Manufacturer Part Number ETH1974).
62435714|NCT06544772|EXPERIMENTAL|Pivot cigarette smoking cessation program|A commercially available mobile phone app and program for smoking cessation
62435715|NCT00310778|EXPERIMENTAL|1|treatment
62435716|NCT00475852|EXPERIMENTAL|001|Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
62435717|NCT00475852|PLACEBO_COMPARATOR|002|Placebo matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
62602119|NCT04819503|OTHER|Sham and then active repetitive transcranial magnetic stimulation|Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the leg.Sham stimulation is delivered with a sham coil placed in the helmet encasing the active rTMS coil. Sham rTMS sessions will use exactly the same parameters of stimulation as active rTMS.
62849260|NCT04171492||Open Label|Nodify XL2 results will be reported to the investigator and available to the subject.
62849261|NCT04171492||Blinded|Nodify XL2 results will not be available to the investigative site or subject.
62849262|NCT03739034|EXPERIMENTAL|Lifestyle Medicine|Patients presenting for lifestyle medicine treatment to prevent, arrest or reverse chronic lifestyle related diseases.
62042555|NCT01436825||Group 1|
62042556|NCT01426165|EXPERIMENTAL|Magnesium 8 grams over 4 hours|
62042557|NCT01426165|EXPERIMENTAL|Magnesium 8 grams over 8 hours|
62042558|NCT04919265||Mother and Infant|The cohort will be followed for 2 years with 8 follow-up measurement points of the infants until the age of 1 year.
62042559|NCT04917523|EXPERIMENTAL|Aged 3-6 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
62042560|NCT04917523|EXPERIMENTAL|Aged 7-12 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
62042561|NCT04917523|EXPERIMENTAL|Aged 13-17 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
62042562|NCT04917523|ACTIVE_COMPARATOR|Aged ≥18 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
62042563|NCT03311412|EXPERIMENTAL|Sym021 Dose Level 1|Part 1, Sym021 monotherapy dose level 1
62042564|NCT03311412|EXPERIMENTAL|Sym021 Dose Level 2|Part 1, Sym021 monotherapy dose level 2
62435718|NCT05017493|EXPERIMENTAL|Treatment arm|Patients in the Treatment arm received Xagrotin in combination to the standard of care for Covid19.
62435719|NCT05017493|NO_INTERVENTION|Control arm|Patients in the Control arm received the standard of care for Covid19.
62435720|NCT04351282|EXPERIMENTAL|SBRT|4-6 cycles of chemotherapy±immunotherapy and radical radiotherapy for nasopharyngeal tumors were given. SBRT for oligometastatic lesions will be assigned to those who got PR,SD after systemic treatment.
62435721|NCT00911859|EXPERIMENTAL|Part 1: VMP+Siltuximab 11 mg/kg|Siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP (Velcade+Melphalan+Prednisone). Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally (by mouth).
62602120|NCT05640284||Adequate KMT|Keratinized mucosal thicknesses (KMT) on their buccal surfaces are 2 mm and above.
62602121|NCT05640284||inadequate KMT|Keratinized mucosal thicknesses (KMT) on their buccal surfaces are less than 2 mm.
62602122|NCT05640284||adequate KGW|keratinized gingival width (KGW) on their buccal surfaces are 2 mm and above.
62849263|NCT04665089|ACTIVE_COMPARATOR|Erythromycin arm|The erythromycin arm (n=55) receives, in addition to the standard antimicrobial therapy, erythromycin 1 g three times per day intravenously: each gram is diluted in 250 ml of 5% glucose serum to be administered over 1 hour for 5 days.
62042565|NCT03311412|EXPERIMENTAL|Sym021 Dose Level 3|Part 1, Sym021 monotherapy dose level 3
62435722|NCT00911859|EXPERIMENTAL|Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg|Siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP. Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally
62602123|NCT05640284||inadequate KGW|keratinized gingival width (KGW) on their buccal surfaces are less than 2 mm.
62602124|NCT05640284||Peri-implant health|"The absence of signs of inflammation (redness, swelling, bleeding on probing) in the peri-implant soft tissue, probing depth (PD) ≤5 mm with mild force (approximately 0.25 N), and no further bone loss following initial healing are defined as peri-implant health."
62602125|NCT05640284||peri-implant mucositis|"Peri-implant mucositis is defined as clinically observable signs of inflammation (swelling, redness and soft consistency of tissue), bleeding on probing (lines or drops) and/or signs of suppuration in the absence of bone loss greater than 2 mm, the threshold for initial bone remodulation."
62602126|NCT06556277|EXPERIMENTAL|Metyrapone And Hydrocortisone|During one of the study periods, subjects receive hydrocortisone 19.9 mg/d day 1 to day 6 and 12 mg/d on day 7 subcutaneously via a pump in a pulsed fashion (eight times/day) and metyrapone per os (starting with a dose of 750 mg/d, then the dose will be increased on day 3, where 2500mg/d is achieved and reduced on day 7 to 750mg).
62602127|NCT06556277|PLACEBO_COMPARATOR|Placebo|During the other study period, subjects receive placebo (0,9% NaCl solution) the same dose of placebo instead of hydrocortisone subcutaneously via a pump in a pulsed fashion and the same dose of placebo tablets p.o instead of metyrapone.
62602128|NCT03926390|NO_INTERVENTION|Non bovine colostrun|Preterm received preterm formula
62823481|NCT02715609|EXPERIMENTAL|DSF, Cu, Surgery, RT, TMZ (dose escalation)|"* DSF (dose level (DL) 1=125mg, DL 2=250mg, DL 3=375 mg, DL 4=500mg). DSF starts at DL 2 and escalated using the Time-to-Event Continual Reassessment Method~* 3 day lead-in of oral DSF once daily (QD) prior to surgery (optional)~* 2 mg Cu gluconate 3 times daily (TID) on days when DSF is given (optional pre-surgery)~* Surgery performed per routine clinical care.~* After surgery, evaluation to confirm the final pathological diagnosis as GBM (if not the patient will not continue with the 2nd part of the study).~* RT 4-6 weeks following surgery at 60 Gy in 30 daily fractions.~* TMZ from Day 1 of RT to the last day of RT at a daily oral dose for a maximum of 49 days as per standard clinical care.~* DSF QD and Cu TID during chemoradiotherapy as per preoperative dose~* 4-6 weeks after completion of chemoradiotherapy, adjuvant TMZ may be administered for 6 cycles. TMZ on Days 1-5 of every 28-day cycle. Daily DSF of 500mg will be continued with adjuvant TMZ for up to 6 cycles."
62823482|NCT02715609|EXPERIMENTAL|DSF, Cu, Surgery, RT, TMZ (dose expansion)|"* Surgery performed per routine clinical care.~* RT 4-6 weeks following surgery at 60 Gy in 30 daily fractions.~* TMZ from Day 1 of RT to the last day of RT at a daily oral dose for a maximum of 49 days as per standard clinical care.~* DSF QD and Cu TID during chemoradiotherapy as per preoperative dose~* 4-6 weeks after completion of chemoradiotherapy, adjuvant TMZ may be administered for 6 cycles. TMZ on Days 1-5 of every 28-day cycle. Daily DSF of 500mg will be continued with adjuvant TMZ for up to 6 cycles.~* If a patient develops recurrent tumor during follow-up and plans to undergo another resection, he/she may opt for an optional preoperative DSF study prior to salvage surgery."
62823483|NCT06586294|EXPERIMENTAL|The dose escalation and expansion stage of AK129 combined with chemotherapy;|Part 1: The dose escalation stage： 3 dose groups of AK129 were set up, combination with chemotherapy of XELOX,followed by AK129 and capecitabine maintenance; Part 2：The dose expansion stage： Two to three dosing regimens were set for expansion of AK129 in combination with XELOX.
62435723|NCT00911859|ACTIVE_COMPARATOR|Part 2, Arm B: VMP|Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally
62435724|NCT01306461|ACTIVE_COMPARATOR|Timolol and Tafluprost|Concomitant administration of preservative-free timolol and tafluprost eye drops
62602129|NCT03926390|ACTIVE_COMPARATOR|Bovine colostrum group|Preterm received bovine colostrum as trophic feeding
62042566|NCT03311412|EXPERIMENTAL|Arm A: Sym021+Sym022 Dose Level 1|Part 2, Arm A: Sym021 RP2D in combination with dose level 1 of Sym022
62042567|NCT03311412|EXPERIMENTAL|Arm A: Sym021+Sym022 Dose Level 2|Part 2, Arm A: Sym021 RP2D in combination with dose level 2 of Sym022
62245430|NCT00765986||1|Patients with inoperable NSCLC undergoing RT or Chemo-RT
62602130|NCT05587868||Patients who have not received vaccination for COVID-19|This group includes patients who refused or contraindicated to receive vaccination for COVID-19.
62602131|NCT05587868||Patients who had received first dose of vaccination for COVID-19|Regardless of the type of COVID-19 vaccine used (received before or after laboratory-confirmed SARS-CoV-2 infection).
62602132|NCT05587868||Patients who had received second dose vaccination for COVID-19|Regardless of the type of COVID-19 vaccine used, using same type of vaccine as the first dose (received before and/or after laboratory-confirmed SARS-CoV-2 infection).
62602133|NCT05587868||Patients who had received third dose/booster vaccination for COVID-19|Complete cycle of vaccination using same type of vaccine for the first and second dose and a same/different type for the third dose/booster (received before and/or after laboratory-confirmed SARS-CoV-2 infection).
62602134|NCT02425722|EXPERIMENTAL|ASP0456 0.0625mg|oral
62245431|NCT04853355|EXPERIMENTAL|Spironolactone Treatment|Patients with non-responsive Diabetic Macular Edema will be treated with Spironolactone in addition to the regular course of monthly aflibercept (Eylea).
62245432|NCT03920722|EXPERIMENTAL|Rituximab|Experimental regimen: One year Glucocorticoid treatment and Rituximab IV 1 gram on Day 1 and 15
62245433|NCT03920722|PLACEBO_COMPARATOR|Rituximab-Placebo|Standard regimen: One-year Glucocorticoid treatment and Placebo-Rituximab IV on Day 1 and 15
62245434|NCT02428010|EXPERIMENTAL|Treatment|TMVR Implant
62245435|NCT05661227|SHAM_COMPARATOR|C group|Before induction of anesthesia, general anesthesia was performed after ultrasound-guided femoral nerve block
62245436|NCT05661227|EXPERIMENTAL|DEX group|Before induction of anesthesia, general anesthesia was performed after ultrasound-guided femoral nerve block. Dexmedetomidine 0.8μg/kg was pumped intravenously for 10min 15min before induction of anesthesia, and then continued to be infused at 0.5μg/ (kg·h) until 30min before the end of surgery
62823484|NCT06586294|EXPERIMENTAL|The dose escalation and expansion stage of AK129 combined with chemotherapy with cadonilimab|Part 1:The dose escalation stage： 3 dose groups of AK129 were set up, combination with cadonilimab and chemotherapy of XELOX,followed by AK129 and cadonilimab maintenance; Part 2:The dose expansion stage： Two to three dosing regimens were set for expansion of AK129 in combination with cadonilimab and chemotherapy of XELOX.
62042568|NCT03311412|EXPERIMENTAL|Arm A: Sym021+Sym022 Dose Level 3|Part 2, Arm A: Sym021 RP2D in combination with dose level 3 of Sym022
62042569|NCT03311412|EXPERIMENTAL|Arm A: Sym021+Sym022 Dose Level 4|Part 2, Arm A: Sym021 RP2D in combination with dose level 4 of Sym022
62042570|NCT03311412|EXPERIMENTAL|Arm B: Sym021+Sym023 Dose Level 1|Part 2, Arm B: Sym021 RP2D in combination with dose level 1 of Sym023
62042571|NCT03311412|EXPERIMENTAL|Arm B: Sym021+Sym023 Dose Level 2|Part 2, Arm B: Sym021 RP2D in combination with dose level 2 of Sym023
62245437|NCT05661227|EXPERIMENTAL|ERIPC group|Before induction of anesthesia, ultrasound-guided femoral nerve block was performed, and then general anesthesia was performed. After induction of anesthesia, orthopedic tourniquet was tied and inflated to 200 mmHg(1 mmHg=0.133 kPa) for 5 min and deflated for 5 min, and three cycles were repeated
62245438|NCT05661227|EXPERIMENTAL|LRIPC group|An orthopedic pressure tourniquet was placed on the lower extremity 24 h before surgery and inflated to 200 mmHg for 5 min and deflated for 5 min. Three cycles were repeated
62435725|NCT01306461|EXPERIMENTAL|Fixed Dose Combination of tafluprost and timolol|Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops
62245439|NCT06211192||Group 1|"the first group consisted of infants who continued to receive ASM treatment after 12 months of age (referred to as infants still on ASM after 12 months, n=69)"
62435726|NCT03016182|ACTIVE_COMPARATOR|Remote Ischemic Preconditioning(RIPC)|3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg will be given to RIPC
62435727|NCT03016182|PLACEBO_COMPARATOR|Control|Control group without remote ischemic preconditioning
62435728|NCT03569254|EXPERIMENTAL|Neomedlight Phototherapy Blanket|Phototherapy with a fiber-optic device based on LED light administered intermittently for a total of 6 hours with periods of 2 hours in kangaroo position and pauses of 1 hour at the end of each period.
62435729|NCT03569254|ACTIVE_COMPARATOR|Ohmeda-Fiber Optic Phototherapy Blanket|Phototherapy with a fiber-optic device: the Ohmeda fiber optic Phototherapy blanket
62435730|NCT03645070|NO_INTERVENTION|No probe|Twenty patients will be allocated to this group, which will have no esophageal temperature monitoring technique
62435731|NCT03645070|ACTIVE_COMPARATOR|Single probe thermometer|Twenty patients will be allocated in this group, in which there will be monitoring of esophageal temperature during radiofrequency applications in the posterior wall of the left atrium, with unipolar thermometer.
62435732|NCT03645070|ACTIVE_COMPARATOR|Multi-probe|Twenty patients will be allocated in this group, in which there will be esophageal temperature monitoring during radiofrequency applications in the posterior wall of the left atrium, with a multipolar and self expandable thermometer.
62435733|NCT01255228|EXPERIMENTAL|Low glycemic index diet|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
62602135|NCT02425722|EXPERIMENTAL|ASP0456 0.125mg|oral
62823485|NCT06596655|EXPERIMENTAL|Use of single use bronchoscope|
62823486|NCT04268979|EXPERIMENTAL|eSNAP & Caregiver Navigator|eSNAP intervention plus questionnaires
62042572|NCT03311412|EXPERIMENTAL|Arm B: Sym021+Sym023 Dose Level 3|Part 2, Arm B: Sym021 RP2D in combination with dose level 3 of Sym023
62042573|NCT03311412|EXPERIMENTAL|Arm B: Sym021+Sym023 Dose Level 4|Part 2, Arm B: Sym021 RP2D in combination with dose level 4 of Sym023
62245440|NCT06211192||Group 2|"the second group consisted of infants who had stopped ASM treatment before 12 months of age (referred to as infants who had ceased ASM before 12 months, n=88)"
62245441|NCT02303704|ACTIVE_COMPARATOR|multiport antegrade cardioplegia|Patients who received multiport antegrade cardioplegia and continuous controlled warm blood perfusion through vein grafts.
62245442|NCT02303704|ACTIVE_COMPARATOR|Aortic root antegrade cardioplegia|Patients who underwent routine conventional CABG with antegrade aortic root cardioplegia without warm blood perfusion
62245443|NCT00037869|EXPERIMENTAL|MIBG|High Dose I-131 Metaiodobenzylguanidine
62435734|NCT01255228|EXPERIMENTAL|diet intervention|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
62435735|NCT04468087|EXPERIMENTAL|Atazanavir|600 mg (2 capsules) twice daily on the first day and 300 mg (1 capsule) twice daily for the subsequent 9 days.
62042574|NCT03311412|EXPERIMENTAL|Arm B: Sym021+Sym023 Dose Level 5|Part 2, Arm B: Sym021 RP2D in combination with dose level 5 of Sym023
62042575|NCT03311412|EXPERIMENTAL|Sym021+Sym022+Sym023 Dose Level 1|Part 3, Sym021 in combination with Sym022 and Sym023
62245444|NCT00626756|EXPERIMENTAL|LI|arm controled by LIDCO technology
62245445|NCT00626756|NO_INTERVENTION|CA|standard approach
62245446|NCT01438151|EXPERIMENTAL|Remicade|Subjects will begin with receiving infliximab at 5 mg/kg for the first visits. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
62435736|NCT04468087|EXPERIMENTAL|Daclatasvir 60 mg|initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once daily for 9 days.
62602136|NCT02425722|EXPERIMENTAL|ASP0456 0.25mg|oral
62602137|NCT02425722|EXPERIMENTAL|ASP0456 0.5mg|oral
62602138|NCT02425722|PLACEBO_COMPARATOR|Placebo group|oral
62602139|NCT03653949|EXPERIMENTAL|High Intensity Interval Training|The subjects will participate of an educational intervention and a High Intensity Interval Training.
62602140|NCT03653949|ACTIVE_COMPARATOR|Control Group|The subjects will participate of an educational intervention.
62042576|NCT03311412|EXPERIMENTAL|Sym021+Sym022+Sym023 Dose Level 2|Part 3, Sym021 in combination with Sym022 and Sym023
62042577|NCT03311412|EXPERIMENTAL|Sym021+Sym022+Sym023 Dose Level 3|Part 3, Sym021 in combination with Sym022 and Sym023
62602141|NCT06389487|EXPERIMENTAL|Part A: RSV-A-AIR Group|Adult participants, 18-49 YOA, at increased risk (AIR) for RSV disease, receive a single dose of RSVPreF3 OA investigational vaccine at Day 1 and are followed up until end of study (6 months post vaccine dose administration).
62602142|NCT06389487|EXPERIMENTAL|Part A: RSV-OA Group|Older adults (OA) participants, \>=60 YOA, receive a single dose of RSVPreF3 OA investigational vaccine at Day 1 and are followed up until end of study (6 months post vaccine dose administration).
62602143|NCT06389487|EXPERIMENTAL|Part B: RSV-A-AIR Group|Adult participants, 18-49 YOA, at increased risk (AIR) for RSV disease, receive a single dose of RSVPreF3 OA investigational vaccine at Day 1 and are followed up until end of study (6 months post vaccine dose administration).
62435737|NCT04468087|EXPERIMENTAL|Sofusbuvir + Daclatasvir 60 mg|400 mg twice daily (2 capsules) on the first day and 400 mg (1 capsules) once daily for the subsequent 9 days (sofosbuvir) + initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once a day for 9 days (daclastavir)
62435738|NCT04468087|PLACEBO_COMPARATOR|Placebo Atazanavir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
62435739|NCT04468087|PLACEBO_COMPARATOR|Placebo Daclatasvir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
62435740|NCT04468087|PLACEBO_COMPARATOR|Placebo Sofusbuvir + Daclatasvir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
62435741|NCT00657878|EXPERIMENTAL|non platinum based chemotherapy|a non platinum based therapy (corresponding to stealth liposomal doxorubicin, or topotecan, or gemcitabine,or any other drug approved in clinical practice for the treatment of patients with ovarian cancer after previous platinum-based chemotherapy) followed by a platinum based chemotherapy at disease progression
62435742|NCT00657878|ACTIVE_COMPARATOR|platinum based chemotherapy|platinum based chemotherapy (corresponding to the combination of carboplatin + paclitaxel, or carboplatin + gemcitabine for patients with significant but lower than grade 3 neuropathy at baseline) followed by a non platinum based chemotherapy at disease progression
62435743|NCT04675060|EXPERIMENTAL|Cohort 1|TQ-B3139 capsules administered single dose of 600 mg under fasted conditions in day 1 followed by single dose of 600 mg with a high-fat meal in day 5, then TQ-B3139 capsules administered 600mg orally, twice daily.
62435744|NCT04675060|EXPERIMENTAL|Cohort 2|TQ-B3139 capsules administered single dose of 600 mg with a high-fat meal in day 1 followed by single dose of 600 mg under fasted conditions in day 5, then TQ-B3139 capsules administered 600mg orally, twice daily.
62435745|NCT03187483|ACTIVE_COMPARATOR|Flash-free bracket group|Orthodontic treatment with flash-free bracket system
62435746|NCT03187483|ACTIVE_COMPARATOR|Control|Orthodontic treatment with conventional adhesive-coated brackets
62435747|NCT02207647||Patients with syndromes requiring lumbar puncture|
62435748|NCT01502345|EXPERIMENTAL|PUUV DNA Vaccine|This group will receive Puumala Virus DNA Vaccine only
62435749|NCT01502345|EXPERIMENTAL|HTNV + PUUV|This group will receive a 1:1 mixture of HTNV and PUUV DNA Vaccines
62435750|NCT01502345|EXPERIMENTAL|HTNV DNA Vaccine|This group will receive Hantaan Virus DNA Vaccine only
62435751|NCT02947282|ACTIVE_COMPARATOR|Intervention|Educational Workshop
62435752|NCT02947282|NO_INTERVENTION|Control|They will continue regular prenatal care as planned
62435753|NCT05729256|EXPERIMENTAL|Self-Regulation Intervention|Single session motivational intervention on reducing heavy drinking and sexual risk behavior, encouraging consideration of pre-exposure prophylaxis (PrEP), followed by 4 weeks of text messages on content relevant to drinking goals and support for healthy sexual choices
62435754|NCT05729256|ACTIVE_COMPARATOR|Brief Advice and Information|Single session to provide psychoeducation about heavy drinking risks, discussion of barriers to safe sex, information about pre-exposure prophylaxis (PrEP)
62435755|NCT04733235||with endometrial compaction|Participants who have endometrial compaction caused by progesterone effects on undergoing frozen embryo transfer with artificial hormone replacement
62435756|NCT04733235||without endometrial compaction|Participants who have not endometrial compaction caused by progesterone effects on undergoing frozen embryo transfer with artificial hormone replacement
62435757|NCT00190307|EXPERIMENTAL|1|Aspirin:KARDEGIC
62435758|NCT01991977|EXPERIMENTAL|Diagnostic (PET, pMRI, DTI, IMRT, temozolomide)|Patients undergo 18F DOPA-PET, pMRI and DTI within 14 days before radiation therapy, 3-6 weeks after radiation therapy, and during follow-up. Patients also undergo IMRT over 30 fractions and receive temozolomide.
62435759|NCT02292433|EXPERIMENTAL|PF-04937319|PF-04937319 Split dose
62435760|NCT02292433|PLACEBO_COMPARATOR|Placebo|Placebo split dose
62435761|NCT05547815|EXPERIMENTAL|experimental arm|5 doses of rabies vaccine
62435762|NCT03342508|EXPERIMENTAL|Fetal Pillow Inflated (FPI)|"A Fetal Pillow will be inserted vaginally by the obstetrician after catheterization of the bladder (if it has not been previously performed). Once the Fetal Pillow is in place, the woman's legs will be placed flat on the operating table. The anesthesiologist will then inflate the Fetal Pillow. The obstetrician will not be aware to inflation of Fetal Pillow~Cesarean delivery will then be performed~The circulating nurse will deflate the Fetal Pillow following delivery. The obstetrician will remove the Fetal Pillow at the end of the procedure. The obstetrician will then fill out a survey regarding the delivery."
62435763|NCT03342508|NO_INTERVENTION|Fetal Pillow Not Inflated (FPNI)|"A Fetal Pillow will be inserted vaginally by the obstetrician after catheterization of the bladder (if it has not been previously performed). Once the Fetal Pillow is in place, the woman's legs will be placed flat on the operating table. The Fetal Pillow will not be inflated.~Cesarean delivery will then be performed. The obstetrician will continue to be able to use conventional methods for delivery of a second stage arrest including hand from below and reverse breech extraction.~The circulating nurse will deflate the Fetal Pillow following delivery. The obstetrician will remove the Fetal Pillow at the end of the procedure. The obstetrician will then fill out a survey regarding the delivery."
62602144|NCT01243502|EXPERIMENTAL|0.01% CT327 (or placebo)|Six (of eight) subjects received a single topical dose of 0.01% CT327 followed by a 7 day wash-out period. The subjects then received a single topical dose of CT327 on five consecutive days. Two subjects received placebo.
62042578|NCT03311412|EXPERIMENTAL|Sym021+Sym022+Sym023 Dose Level 4|Part 3, Sym021 in combination with Sym022 and Sym023
62042579|NCT03311412|EXPERIMENTAL|Sym021+Sym022+Sym023 Dose Level 5|Part 3, Sym021 in combination with Sym022 and Sym023
62602145|NCT01243502|EXPERIMENTAL|0.001% CT327 (or placebo)|Six (of eight) subjects received a single topical dose of 0.001% CT327 followed by a 7 day wash-out period. The subjects then received a single topical dose of CT327 on five consecutive days. Two subjects received placebo.
62042580|NCT01255982||1|Diagnosed with bipolar I or II disorder, and with an acute episode of bipolar depression at inclusion
62042581|NCT04808804||DM|Patients With Type 2 Diabetes Mellitus without any signs of diabetic retinopathy or with mild non proliferative diabetic retinopathy
62602146|NCT06260046|EXPERIMENTAL|sufentanil group|sufentanil is administered for analgesic during general anesthesia
62042582|NCT04808804||Healthy|healthy controls
62042583|NCT04474002|ACTIVE_COMPARATOR|4L Klean Prep®|Drug: 59g polyethylene glycol, 5.685g Na sulphate, 1.685g Na bicarbonate, 1.465g NaCl, 0.7425g KCl and aspartame 0.0494g
62042584|NCT04474002|EXPERIMENTAL|1L Klean prep® and 2 sachets Picoprep®|Drug: 59g polyethylene glycol, 5.685g Na sulphate, 1.685g Na bicarbonate, 1.465g NaCl, 0.7425g KCl, aspartame 0.0494g, sodium picosulfate 0.01g, magnesium oxide 3.5g, citric acid 12.0g
62042585|NCT00220298|EXPERIMENTAL|Arm 1|
62042586|NCT06490107|EXPERIMENTAL|Durvalumab combined with S-1|Durvalumab combined with S-1
62042587|NCT02291679|EXPERIMENTAL|72 μg linaclotide|72 μg oral linaclotide, once daily for 12 weeks
62245447|NCT05653440|EXPERIMENTAL|Effort-maximized, then accuracy-maximized, then effort-accuracy balanced|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
62245448|NCT05653440|EXPERIMENTAL|Effort-maximized, then effort-accuracy balanced, then accuracy-maximized|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
62245449|NCT05653440|EXPERIMENTAL|Accuracy-maximized, then effort-maximized, then effort-accuracy balanced|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
62245450|NCT05653440|EXPERIMENTAL|Accuracy-maximized, then effort-accuracy balanced, then effort-maximized|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
62602147|NCT06260046|ACTIVE_COMPARATOR|remifentanil group|remifentanil is administered for analgesic during general anesthesia
62602148|NCT00270231|ACTIVE_COMPARATOR|Naltrexone|"All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.~Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg."
62602149|NCT00270231|PLACEBO_COMPARATOR|Placebo|"All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule."
62823487|NCT04268979|NO_INTERVENTION|Waitlist Control Condition|Participants randomly assigned to the waitlist control condition will only complete questionnaires during the 8-week study period. After the 8 weeks, they will then have access to the eSNAP, including completion of questionnaires and 8 weeks of Caregiver Navigator sessions as needed.
62042588|NCT02291679|EXPERIMENTAL|145 μg linaclotide|145 μg oral linaclotide, once daily for 12 weeks
62823488|NCT05199337|EXPERIMENTAL|Treatment Arm|Subjects will receive ZN-d5 orally (PO), once (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62823489|NCT01223534|ACTIVE_COMPARATOR|Arm A, Standard practice, TST|Participants allocated to screening as stablished by current practice (TST)
62823490|NCT01223534|EXPERIMENTAL|Arm B, Experimental, TST plus QFT-IT|Participants allocated to screening with TST, and if positive, followed by QFT-IT to confirm tuberculosis infection.
62823491|NCT00541658|ACTIVE_COMPARATOR|5 mg Before Breakfast|5 mg / Immediate-release Risedronate (At Least 30 Minutes Before Breakfast)
62823492|NCT00541658|EXPERIMENTAL|35 mg After Breakfast|35 mg / Delayed-release Risedronate (Immediately Following Breakfast)
62823493|NCT00541658|EXPERIMENTAL|35 mg Before Breakfast|35 mg / Delayed-release Risedronate (At Least 30 Minutes Before Breakfast)
62823494|NCT06407414|ACTIVE_COMPARATOR|control|classical physiotherapy methods
62823495|NCT06407414|EXPERIMENTAL|exercise|In addition to classical physiotherapy methods, neuromuscular exercise protocol will be applied.
62823496|NCT05962528|EXPERIMENTAL|Type 1 group|Toric soft lens with high sagittal height
62823497|NCT05962528|EXPERIMENTAL|Type 2 group|Toric soft lens with low sagittal height
62602150|NCT02733341|ACTIVE_COMPARATOR|Oral Ticagrelor|Patients in the oral Ticagrelor arm will receive Ticagrelor at a loading dose of 180mg followed by maintenance dose of 90mg twice daily for 12 months.
62823498|NCT05962528|EXPERIMENTAL|Type 3 group|Spherical soft lens with high sagittal height
62042589|NCT02291679|PLACEBO_COMPARATOR|Placebo|matching placebo, once daily for 12 weeks
62042590|NCT00447980|EXPERIMENTAL|1 NT-501 implant|High Dose
62042591|NCT00447980|EXPERIMENTAL|2 NT-501 implant|Low Dose
62042592|NCT00950066|PLACEBO_COMPARATOR|Placebo|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with placebo once a day."
62042593|NCT00950066|ACTIVE_COMPARATOR|Irbesartan 150mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 150 mg once a day."
62602151|NCT02733341|ACTIVE_COMPARATOR|Intravenous Cangrelor|Patients in the intravenous Cangrelor arm will receive Cangrelor as an initial bolus dose given as per body weight followed by an intravenous infusion for no longer than three hours, they will then switch to oral Ticagrelor given at maintenance dose of 90mg twice daily for 12 months
62602152|NCT05465616|NO_INTERVENTION|Placebo|Participants with HbA1c levels between 5.7-8.9% (inclusive) are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
62602153|NCT05465616|EXPERIMENTAL|Viome's Precision Nutrition Program (VPNP)|Participants with HbA1c levels between 5.7-8.9% (inclusive) are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
62602154|NCT06622577|EXPERIMENTAL|dietary management with additional Cysteine supplementation|
62602155|NCT05906186||Pre-test|Standard care: all patients who are starting their first (neo adjuvant or adjuvant) treatment with chemotherapy visit the nurse practitioner. Site effects like constipation will be discussed and the prescription of laxatives is standard care. Participants will keep a stool pattern diary during two months using the Bristol Stool Scale (BSS). During follow up the occurrence of side effect, such as nausea, diarrhea and constipation is assessed.
62602156|NCT05906186||Post-test|After the first four months (pre-test phase) of the study, nurse practitioners are asked, as lifestyle advice, to eat two kiwis per day instead of two pieces of fruit. A similar group of patients undergoing their first (neo-adjuvant or adjuvant) chemotherapy treatment are approached with a request to participate in the study. Participants keep a diary of defecation patterns for two months using the Bristol Stool Scale (BSS). During follow-up, the occurrence of side effects such as nausea, diarrhea and constipation will be assessed.
62602157|NCT02590874|EXPERIMENTAL|Duloxetine group|Active drug group
62602158|NCT02590874|PLACEBO_COMPARATOR|Placebo group|Inactive drug group
62602159|NCT05157620|EXPERIMENTAL|Yoga-based Exercise (YE)|The Yoga-based Exercise (YE) intervention is a series of yoga-based poses that consists of sitting, standing, kneeling, and lying postures as well as breathing exercises. The duration of the intervention will be 12 months. Participants will engage in yoga-based exercise sessions lasting 60 minutes twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in yoga-based exercises once a week. The remainder of the study (6 months), participants will engage in yoga-based exercises once a month.
62823499|NCT05962528|EXPERIMENTAL|Type 4 group|Spherical soft lens with low sagittal height
62823500|NCT05962528|PLACEBO_COMPARATOR|Control group|Traditional spherical soft lens
62823501|NCT05908461|EXPERIMENTAL|Intervention Group|Participants will receive the Early Childhood Friendship project intervention (8x10-min puppet shows, 7x5-min gross motor activities7x5-min passive activities, up to 3x1-hour in-vivo behavioral reinforcement periods).
62823502|NCT05908461|NO_INTERVENTION|Control Group|Participants will not receive the Early Childhood Friendship project intervention.
62823503|NCT00603317|EXPERIMENTAL|1|Order 1 : Firstly Amoxicillin-Acid clavulanic, and Secondly Placebo
62823504|NCT00603317|EXPERIMENTAL|2|Order 2 : Firstly Placebo, and Secondly Amoxicillin-Acid clavulanic
62823505|NCT03664531|EXPERIMENTAL|Gluten, ATIs, nocebo|Participants will start on 1 week of muesli bars with purified gluten followed by 14 days washout. They will then take 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days of washout. Finally, they will have 1 week of nocebo muesli bars (with nothing).
62823506|NCT03664531|EXPERIMENTAL|Gluten, nocebo, ATIs|Participants will start on 1 week of muesli bars with purified gluten followed by 14 days washout. They will then take 1 week of nocebo muesli bars (with nothing) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with non-purified gluten (containing ATIs).
62042594|NCT00950066|ACTIVE_COMPARATOR|Irbesartan 150 mg / Amlodipine 5 mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 150 mg / Amlodipine 5 mg once a day."
62823507|NCT03664531|EXPERIMENTAL|ATIs, gluten, nocebo|Participants will start on 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days washout. They will then take 1 week of muesli bars with purified gluten followed by 14 days of washout. Finally, they will have 1 week of nocebo muesli bars (with nothing).
62042595|NCT00950066|ACTIVE_COMPARATOR|Amlodipine|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Amlodipine 5 mg once a day."
62602160|NCT05157620|ACTIVE_COMPARATOR|Wellness Lifestyle Program (WLP)|The Wellness Lifestyle Program (WLP) is a comprehensive lifestyle program that consists of 30 minutes of educational information covering various topics, such as nutrition, healthy living, stress reduction, and more will be followed by 30 minutes of low-intensity exercise such as walking. The duration of the intervention will be 12 months. Participants will engage in the 60 minute WLP session twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in WLP sessions once a week. The remainder of the study (6 months), participants will engage in WLP sessions once a month.
62042596|NCT00950066|ACTIVE_COMPARATOR|Irbesartan 300 mg|"Active Comparator: Irbesartan~Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 300 mg once a day."
62435764|NCT02725671|OTHER|Cardiogoniometry and ECG Assessment|The same patient will undergo both advanced ECG assessment using cardiogoniometry and standard ECG
62823508|NCT03664531|EXPERIMENTAL|ATIs, nocebo, gluten|Participants will start on 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days washout. They will then take 1 week of nocebo muesli bars (containing nothing) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with purified gluten.
62823509|NCT03664531|EXPERIMENTAL|Nocebo, ATIs, gluten|Participants will start on 1 week of nocebo muesli bars (with nothing) followed by 14 days washout. They will then take 1 week of muesli bars containing non-purified gluten (containing ATIs) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with purified gluten.
62823510|NCT03664531|EXPERIMENTAL|Nocebo, gluten, ATIs|Participants will start on 1 week of nocebo muesli bars (with nothing) followed by 14 days washout. They will then take 1 week of muesli bars with purified gluten followed by 14 days of washout. Finally, they will have 1 week of muesli bars with non-purified gluten (containing ATIs).
62823511|NCT04690686|EXPERIMENTAL|LW-02 device immunopheresis combined with atezolizumab|LW-02 column immunopheresis treatments \~3x/week for 16 weeks plus atezolizumab 1200 milligrams (mg) q3w until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first \[N=8\]
62823512|NCT04690686|EXPERIMENTAL|LW-02 device immunopheresis combined with weekly paclitaxel|LW-02 column immunopheresis treatments \~3x/week for 16 weeks plus paclitaxel 80 mg/m2 /week × 6 followed by 2 weeks rest until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first. \[N=8\]
62823513|NCT04690686|EXPERIMENTAL|LW-02 device immunopheresis|LW-02 column immunopheresis treatments \~3x/week for 16 weeks alone until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first. \[N=8\]
62823514|NCT01527370|EXPERIMENTAL|Zoster Vaccine Live|
62823515|NCT03131024|EXPERIMENTAL|Aerobic exercise|The exercise arm includes a single bout of supervised treadmill walking scheduled such that it would end approximately 24 hours prior to each of the participant's scheduled anthracycline treatment time.
62823516|NCT03131024|EXPERIMENTAL|50% caloric restriction|The caloric restriction arm will restrict their total caloric intake by 50% for 48 hours prior to each anthracycline treatment.
62042597|NCT00950066|ACTIVE_COMPARATOR|Irbesartan 300 mg / Amlodipine 5 mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 300 mg / Amlodipine 5 mg once a day."
62435765|NCT01344408|EXPERIMENTAL|Computer-training|The computer-training program, Move it to improve it was installed in the participants homes using an internet-connected computer with a web camera connected to a cloud-based specifically adapted interactive training program.
62435766|NCT01344408|EXPERIMENTAL|Printed instructions|A training program delivered as printed instructions
62435767|NCT03574246|EXPERIMENTAL|CHXBNZ|Pharyngeal pack moisturized with chlorhexidine gluconate %0,12 benzydamine hydrochloride %0,15 and placed to oropharynx
62823517|NCT03131024|NO_INTERVENTION|Usual care|The usual care arm will be asked to maintain their typical exercise and diet throughout treatment.
62823518|NCT06601309|EXPERIMENTAL|High PD-L1 Expression Group (CPS ≥ 20)|Patients with high PD-L1 expression (CPS ≥ 20) will receive neoadjuvant immunotherapy alone. This treatment consists of serplulimab for 2 cycles.
62823519|NCT06601309|EXPERIMENTAL|Moderate PD-L1 Expression Group (CPS 10-20)|Patients with moderate PD-L1 expression (CPS 10-20) will receive neoadjuvant chemotherapy combined with immunotherapy. This includes paclitaxel and cisplatin along with serplulimab for 2 cycles.
62823520|NCT06601309|EXPERIMENTAL|Low PD-L1 Expression Group (CPS < 10)|Patients with low PD-L1 expression (CPS \< 10) will receive standard neoadjuvant chemoradiotherapy. This includes paclitaxel and cisplatin along with radiotherapy (40 Gy in 20 fractions over 4 weeks).
62435768|NCT03574246|ACTIVE_COMPARATOR|SF|Pharyngeal pack moisturized with %0,9 NaCl and placed to oropharynx
62435769|NCT00889785|ACTIVE_COMPARATOR|1 (Usual Care)|Patients will continue to review usual care in the diabetes clinic. Patients will receive monthly phone calls as an active control condition.
62042598|NCT04616261|EXPERIMENTAL|SET-HIGH|High volume speed endurance training
62823521|NCT03072407|PLACEBO_COMPARATOR|PB-119 injection placebo|totally 8 subjects will have PB-119 injection placebo once per weekly for 4 weeks.
62042599|NCT04616261|EXPERIMENTAL|SET-LOW|Low volume speed endurance training
62823522|NCT03072407|EXPERIMENTAL|PB-119 injection 25ug|totally 8 subjects will have PB-119 injection 25 ug once per weekly for 4 weeks
62042600|NCT01441102|EXPERIMENTAL|Dextromethorphan hydrobromide|
62823523|NCT03072407|EXPERIMENTAL|PB-119 injection 50ug|totally 8 subjects will have PB-119 injection 50 ug once per weekly for 4 weeks
62042601|NCT00591474|EXPERIMENTAL|1|VRE positive patients
62042602|NCT00591474|PLACEBO_COMPARATOR|2|VRE positive patients
62042603|NCT01602887|ACTIVE_COMPARATOR|Reference|This is the reference formulation
62042604|NCT01602887|EXPERIMENTAL|NF1|This is a test formulation
62042605|NCT01602887|EXPERIMENTAL|NF2|This is a test formulation
62042606|NCT01602887|EXPERIMENTAL|SOL|This is a test formulation
62435770|NCT00889785|EXPERIMENTAL|Intervention|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
62823524|NCT03072407|EXPERIMENTAL|PB-119 injection 100ug|totally 8 subjects will have PB-119 injection 100 ug once per weekly for 4 weeks
62042607|NCT04244890||Uninterrupted CPAP|Newborn infants in need of respiratory support directly after birth
62245451|NCT05653440|EXPERIMENTAL|Effort-accuracy balanced, then effort-maximized, then accuracy maximized|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
62823525|NCT03072407|EXPERIMENTAL|PB-119 injection 200ug|totally 8 subjects will have PB-119 injection 200 ug once per weekly for 4 weeks
62823526|NCT05518812|EXPERIMENTAL|Hemabate|Dilute the 250mcg/mL vial with 25mL saline to create a solution of 10mcg/mL, and inject no more than 10mL of diluted solution at the base of the fibroid. The route of administration depends on the location of the fibroid.
62823527|NCT04230759|ACTIVE_COMPARATOR|5FU+Mitomycin C|Radiochemotherapy for anal cancer
62823528|NCT04230759|EXPERIMENTAL|5FU+Mitomycin C+Durvalumab|Radiochemotherapy with Durvalumab for anal cancer
62823529|NCT03481088|OTHER|Functional appliance therapy|"All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.~1. Stage- I (pre-treatment),~2. Stage- II (after pre-functional therapy)~3. Stage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)"
62823530|NCT02453620|EXPERIMENTAL|Treatment (entinostat, nivolumab, ipilimumab)|Patients receive entinostat PO on days -14 and -7 and then weekly, nivolumab IV over 60 minutes on day 1 and then every 2 weeks, and ipilimumab IV over 90 minutes on day 1 and then every 6 weeks for 4 doses. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT as clinically indicated throughout the trial. Patients may undergo PET/CT or bone scan throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
62823531|NCT05943691|EXPERIMENTAL|Hetrombopag plus High-dose Dexamethasone|Hetrombopag 5mg po qd; HD-DEX 40mg qd for 4 days
62823532|NCT05943691|ACTIVE_COMPARATOR|High-dose Dexamethasone|HD-DEX 40mg qd for 4 days
62042608|NCT01398280|EXPERIMENTAL|Aminocaproic Acid (ACA)|Subjects will treat their facial skin twice daily for up to 12 weeks with 5-6 visits and 2 telephone visits. Investigator and subject will be blinded. Tape strip samples will be collected from facial skin at each visit to assess Kallikrein 5 (KLK5) activity.
62042609|NCT01398280|PLACEBO_COMPARATOR|Vehicle cream|Subjects will apply vehicle twice daily for up to 12 weeks with 5-6 visits and 2 telephone visits. Investigator and subject will be blinded. Tape strip samples will be collected from facial skin at each visit to assess Kallikrein 5 (KLK5) activity.
62042610|NCT05840432||Cardiac Surgery Postoperative Patients|Cardiac Surgery Postoperative Patients who are admitted to the intensive care unit after the surgery, from the surgical room
62042611|NCT00729404|EXPERIMENTAL|Arm 1|
62042612|NCT00729404|EXPERIMENTAL|Arm 2|
62042613|NCT01315093|EXPERIMENTAL|Heparin, Low-Molecular-Weight group|LMWH was administered during an IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders. Drug was started at the beginning of the cycle and stopped at the time of pregnancy test if negative, or continued if pregnancy occurred until the 32th weeks of gestation
62042614|NCT01315093|ACTIVE_COMPARATOR|Non Heparin, Low-Molecular-Weight group|IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders.
62042615|NCT00733538|ACTIVE_COMPARATOR|1|patients receiving zometa treatment
62042616|NCT00733538|NO_INTERVENTION|2|No treatment, just follow-up
62042617|NCT05762133|EXPERIMENTAL|ASSET-PPD intervention group|25 parent dyads with a mother who is receiving individual treatment outside of the study and the father is receiving the ASSET-PPD training
62245452|NCT05653440|EXPERIMENTAL|Effort-accuracy balanced, then accuracy-maximized, then effort-maximized|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
62245453|NCT03044886|EXPERIMENTAL|2000IU/day|Subjects took 2000IU vitamin D per day
62245454|NCT03044886|EXPERIMENTAL|1000IU/day|Subjects took 1000IU vitamin D per day
62823533|NCT04895891|EXPERIMENTAL|EOS imaging|For each patient, EOS images are compared with computed tomography \[CT\] images
62245455|NCT03044886|PLACEBO_COMPARATOR|Placebo|Subjects took placebo
62602161|NCT05408325||confirmed COVID 19 ptients|All patients confirmed by RT-PCR, as positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who visited the emergency room and the outpatient clinic in the study period.
62042618|NCT05762133|NO_INTERVENTION|No additional treatment group|25 parent dyads with a mother who is receiving individual treatment outside of the study and the father is not receiving the ASSET-PPD training
62823534|NCT05933941|EXPERIMENTAL|Group 1|This group will perform cervical mobility exercises and exercises with virtual reality glasses. 2 sessions will be held per week with a total of 8 sessions
62042619|NCT04920357||Post-COVID-19|Persons with a verified previous COVID-19 infection
62042620|NCT04920357||COVID-19 naive|Persons that have no history of COVID-19
62042621|NCT04162665|EXPERIMENTAL|Pre-operative adaptive short course radiation therapy|Consenting and eligible patients will receive adaptive short course radiation therapy (SCRT) (25 Gy at in 5 fractions), followed by standard of care total neoadjuvant chemotherapy followed by standard of care gastrectomy or esophagogastrectomy. The recommended SOC chemotherapy options are CAPOX, FOLFOX, or FLOT, but any SOC total neoadjuvant chemotherapy may be given at the discretion of the treating medical oncologist after consultation with the study chair. Patients who are not able to complete their full total neoadjuvant therapy regimen prior to surgery may complete chemotherapy postoperatively at the discretion of the treating physician.
62823535|NCT05933941|ACTIVE_COMPARATOR|Group 2|This group will only perform cervical mobility exercises at two sessions per week with a total of 8 sessions.
62042622|NCT05381155|EXPERIMENTAL|Immediate Treatment|Participants in the immediate treatment group will receive the single-session behavioral intervention on day 15.
62042623|NCT05381155|OTHER|Waitlist|Participants in the waitlist control group will receive the single-session behavioral intervention on day 30.
62042624|NCT05715996|EXPERIMENTAL|mixed reality guided localization group|Application of mixed reality technique for percutaneous lung nodule localization.
62042625|NCT05715996|NO_INTERVENTION|Computerized tomography (CT) guided localization group|Computerized tomography (CT) guided percutaneous lung nodule localization.
62042626|NCT05591508|EXPERIMENTAL|A, Intervention Arm|Ketogenic Diet +Standard care of Status epilepticus according to current guideline of management
62245456|NCT05094336|EXPERIMENTAL|Part 1a, Phase 1: AMG 193 Monotherapy Dose Exploration|"Participants with MTAP-null solid tumors will receive escalating doses of AMG 193 to estimate the MTD and/or the RP2D.~A group of these participants in the United States (US) will have the option to take part in a Drug Substance Particle Size (DSPS) assessment. These participants will receive AMG 193 at a selected dose and a dose of a comparator AMG 193 table(s)."
62245457|NCT05094336|EXPERIMENTAL|Part 1c, Phase 1: AMG 193 Monotherapy Dose Expansion|Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort: MTAP-null or lost MTAP expression NSCLC.
62245458|NCT05094336|EXPERIMENTAL|Part 2a, Phase 1: AMG 193 Dose Exploration + Docetaxel|Participants with MTAP-null NSCLC will receive escalating doses of AMG 193 + a fixed dose of docetaxel to estimate the MTD/RP2D of the combination.
62602162|NCT05408325||healthy subjects|normal healthy volunteers
62823536|NCT05933941|NO_INTERVENTION|Control group|This group will not receive any treatment or perform any type of exercise during the duration of this study.
62823537|NCT06592560||Healthy people|
62823538|NCT06592560||Patients with benign breast lesions|
62823539|NCT06592560||Patients with breast cancer|
62823540|NCT04416217||Topical Steroid Treatment|Pediatric patients with eosinophilic esophagitis scheduled to begin topical steroid treatment for the treatment of their condition. The type of topical steroid is not limited and is at the discretion of the treating physician as are dosing and concomitant treatments.
62823541|NCT03562364|NO_INTERVENTION|Standard of Care|The standard of care group will remain non-weight bearing for 10-12 weeks following definitive fixation and receive physical therapy in accordance with standard practice at the treating center.
62823542|NCT03562364|EXPERIMENTAL|Early Advanced Weight Bearing (EAWB)|The Early Advanced Weight Bearing (EAWB) group will receive early weight-bearing treatment using the antigravity AlterG treadmill. These sessions will begin 14-28 days following definitive fixation and last for a total of 10 weeks
62042627|NCT05591508|NO_INTERVENTION|B, No Intervention Arm|Standard care of Status Epilepticus according to current guidelines of management
62245459|NCT05094336|EXPERIMENTAL|Part 2b, Phase 1: AMG 193 + Docetaxel Dose Expansion|Participants with MTAP-null NSCLC will receive the identified MTD/RP2D of AMG 193 + docetaxel.
62245460|NCT05094336|EXPERIMENTAL|Part 3: AMG 193 Phase 2|Participants with MTAP-null solid tumors will receive AMG 193.
62245461|NCT05094336|EXPERIMENTAL|Part 1e, Phase 1: AMG 193 Monotherapy Dose Expansion|Participants will receive the identified selected dose/MTD of AMG 193 in the following cohort: MTAP-null BTC.
62435771|NCT02962882|EXPERIMENTAL|A. Mepilex Border Sacrum (Safetac)|A dressing that is a flexible, self-adherent, profylactic, absorbent pad in three layers to be used on the sacrum area at pressure points in patients in the ICU, prone to get pressure injuries (PI).
62042628|NCT03258567|EXPERIMENTAL|Nivolumab (A)|Nivolumab, 3mg/kg IV every 2 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment (closed effective with activation of Amendment C)
62042629|NCT03258567|EXPERIMENTAL|Nivolumab (B)|Nivolumab, 480 mg IV every 4 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment
62602163|NCT05581472|ACTIVE_COMPARATOR|Online Acceptance and Commitment Therapy Intervention + Phone Coaching|"This online Acceptance and Commitment Therapy intervention is delivered over 8 weeks, in 8 15-minute modules. Additionally, each participant will receive a weekly call for the duration of the intervention (i.e., 9 phone calls: one introduction phone call, 8 module related phone calls) from a Master's-level clinical student who will serve as the participants phone coach. The intervention includes 8 modules: Away Moves, Letting Go of Control, Noticing Hooks, Stepping Back, Your Values, How You Want to Act, Goal Setting, and Making Commitments). Each module ends with a practice assignment which participants are asked to engage in over the next week.~During the phone coaching calls, the clinical student will be able to help troubleshoot any technical difficulties being experienced, as well as clarify any questions about the material being taught in the intervention."
62602164|NCT05581472|ACTIVE_COMPARATOR|Online Acceptance and Commitment Therapy Intervention without phone coaching|"This online Acceptance and Commitment Therapy intervention is delivered over 8 weeks, in 8 15-minute modules. Additionally, each participant will receive a weekly call for the duration of the intervention (i.e., 9 phone calls: one introduction phone call, 8 module related phone calls) from a Master's-level clinical student who will serve as the participants phone coach. The intervention includes 8 modules: Away Moves, Letting Go of Control, Noticing Hooks, Stepping Back, Your Values, How You Want to Act, Goal Setting, and Making Commitments). Each module ends with a practice assignment which participants are asked to engage in over the next week."
62602165|NCT05581472|NO_INTERVENTION|Waitlist Control|Participants in this arm of the study will complete the same sleep diaries and questionnaires at the same time points as the intervention group, but will not be administered the intervention modules and will not receive any phone coaching. When they have completed the 1-month follow-up they will be offered the intervention.
62823543|NCT06234189|EXPERIMENTAL|Defocus Incorporated Multiple Segment Spectacle Lenses (DIMS)|
62823544|NCT06650709|EXPERIMENTAL|Olaparib-Durvalumab-Bevacizumab|Olaparib 300mg PO BID continuous dosing, Durvalumab 1500mg IV Day 1, Bevacizumab 10mg/kg IV Day 1 and 15 of a 28-day cycle Patients that respond to the therapy following 2 cycles will receive a 1 further cycle with the C3 Day 15 Bevacizumab omitted.
62823545|NCT05558332|EXPERIMENTAL|YST-CHR Group|This group will recieve the new adapted YST treatment (YST-CHR). Clinicians will administer this treatment. Neither group will be blind.
62823546|NCT05558332|NO_INTERVENTION|Treatment as usual|This group will receive their usual therapy/treatment as usual.
62823547|NCT01269203|ACTIVE_COMPARATOR|Curcumin|1000 mg/day Curcumin + 5 -15 mg/day Lenalidomide
62823548|NCT01269203|PLACEBO_COMPARATOR|Placebo|Placebo daily + 5 -15 mg/day Lenalidomide
62823549|NCT04665453|EXPERIMENTAL|Melatonin peroral|0,1mg/kg melatonin will be given in the form of a syrup to the participant before EEG and vital functions monitoring
62823550|NCT04665453|EXPERIMENTAL|Dexmedetomidine intranasally|3 mcg/kg of dexmedetomidine in the form of a nasal spray will be given to the participant before EEG and vital functions monitoring
62823551|NCT04665453|EXPERIMENTAL|Dexmedetomidine sublingually|3 mcg/kg of dexmedetomidine will be given to the participant sublingually before EEG and vital functions monitoring
62823552|NCT06603051|NO_INTERVENTION|Arm A: ACL reconstruction usual care|On the day of surgery, all patients (Group A and Group B) will receive a multi-modal oral pre-operative cocktail and an ultrasound guided adductor canal block. Additionally, an ultrasound guided popliteal or infiltration of the tissue plane between the popliteal artery and the capsule of the knee (iPACK) block will be administered. The pre-operative oral medication cocktail and block medications are as follows: Acetaminophen 975 mg x 1, Celecoxib 400 mg PO x 1, adductor canal block with 133 mg (10 mL) liposomal bupivacaine (EXPAREL) admixed with 0.5% bupivacaine HCl 50 mg (10 mL), popliteal or iPACK nerve infiltration with 133 mg (10 mL) liposomal bupivacaine (EXPAREL) admixed with 0.5% bupivacaine HCl 50 mg (10 mL). 15 mg IV ketorolac at conclusion of the case will be administered.
62823553|NCT06603051|EXPERIMENTAL|Arm B: Usual care plus pre-operative cryoneurolysis|Those randomized to the intervention group (Group B) will receive a standard treatment of Cryoneurolysis to their surgical knee within 7-10 days of their scheduled surgery. Treatment nerves for the procedure will include the anterior femoral cutaneous nerve (AFCN), supra-patellar branch of the saphenous nerve (SPBSN) and infra-patellar branch of the saphenous nerve (IPBSN).
62042630|NCT05744648|EXPERIMENTAL|Group A|Group A will receive composite resin restoration with Titania nanoparticle incorporated bonding agent
62823554|NCT06123338|EXPERIMENTAL|Participants with Esophagogastric Cancer|Participants will have a diagnosis of resectable HER2+ (IHC 3+ or IHC 2+/FISH ratio \>2.0) esophageal, GEJ or gastric cancer.
62042631|NCT05744648|EXPERIMENTAL|Group B|Group B will receive composite resin restoration without Titania nanoparticle incorporated bonding agent
62435772|NCT02962882|EXPERIMENTAL|B. Mepilex Border Heel (Safetac)|A dressing that is a flexible, self-adherent, profylactic, absorbent pad in three layers to be used on the heels (on both left and right heels), in patients in the ICU, prone to get pressure injuries (PI).
62602166|NCT02978859|EXPERIMENTAL|MGCD516|Patients with locally advanced and unresectable or metastatic sarcoma will receive MGCD516 at the discretion of the principal investigator until disease progression, unacceptable toxicity or adverse event(s) or withdrawal of consent.
62042632|NCT01584765||Rechallenge|positive, negative, indeterminate and intermediate rechallenge subtypes
62602167|NCT02998476|EXPERIMENTAL|Group A Parsaclisib (no prior BTK inhibitor)|Parsaclisib in subjects who were not previously treated with a BTK inhibitor.
62849264|NCT04665089|PLACEBO_COMPARATOR|Placebo arm|The placebo arm (n=55) receives, in addition to the standard antimicrobial therapy, isotonic saline, intravenously, 20 ml diluted in 250 ml of 5% glucose serum to be administered over 1 hour for 5 days.
62245462|NCT05094336|EXPERIMENTAL|Part 1f, Phase 1: AMG 193 Monotherapy Dose Expansion|"Participants will receive the identified selected dose/MTD of AMG 193 in the following cohort:~MTAP-null head and neck squamous cell carcinoma (HNSCC)"
62245463|NCT05094336|EXPERIMENTAL|Part 1g, Phase 1: AMG 193 Monotherapy Dose Expansion|"Participants will receive the identified selected dose/MTD of AMG 193 in the following cohort:~MTAP-null pancreatic adenocarcinoma"
62245464|NCT05094336|EXPERIMENTAL|Part 1h, Phase 1: AMG 193 Monotherapy Dose Expansion|Participants will receive the identified selected dose/MTD of AMG 193 in the following cohort: MTAP-null or lost MTAP expression solid tumors (other than lymphoma or primary brain tumor).
62042633|NCT01584765||Severe positive rechallenge|Subtype of positive rechallenge is defined as: ALT≥5 xULN or AP ≥2 xULN and bilirubin ≥2 xULN with one of the following: INR ≥1.5, Ascites, or Encephalopathy where time from liver chemistry elevation to INR≥1.5,ascites, or encephalopathy is less than 26 weeks in the absence of underlying cirrhosis; other organ failure considered due to DILI; liver-related hospitalization
62245465|NCT05094336|EXPERIMENTAL|Part 1i, Phase 1: AMG 193 Dose Optimization|Participants will receive a randomized dose optimization evaluation of AMG 193.
62245466|NCT05094336|EXPERIMENTAL|Part 1j, Phase 1: AMG 193 DSPS Substudy (US Sites Only)|Participants will receive doses of AMG 193 and comparator AMG 193 test tables at different times in a fasted state.
62042634|NCT00935376|EXPERIMENTAL|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP)to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
62245467|NCT05094336|EXPERIMENTAL|Part 1k, Phase 1: AMG 193 Food Effect Substudy (US Sites Only)|Participants will receive AMG 193 once on a fasted state and once after eating a standardized high-fat, high calorie meal.
62245468|NCT05094336|EXPERIMENTAL|Part 1l, Phase 1: AMG 193 Monotherapy Dose Expansion|Participants will receive the identified selected dose/MTD of AMG 193 in the following cohort: MTAP-null esophageal/gastric cancer.
62245469|NCT05094336|EXPERIMENTAL|Part 1m, Phase 1: AMG 193 Monotherapy Dose Expansion|Participants will receive the identified selected dose/MTD of AMG 193 in the following cohort: MTAP-null glioma.
62245470|NCT05949151|ACTIVE_COMPARATOR|Group I|Patients received a complete removable mandibular implant supported overdenture
62245471|NCT05949151|ACTIVE_COMPARATOR|Group II|Patients received implant supported fixed bridge
62435773|NCT04014400|EXPERIMENTAL|Suprathel|Once hemostasis is obtained, the Suprathel material will be handled with a new pair of sterile gloves. It will be cut so that the material extends 1-2 cm beyond the donor site margins, then applied to the donor site. The Suprathel will be secured with a protective layer of Rylon extending 1-2 cms beyond the margins of the Suprathel. The primary dressing will be covered with cotton gauze (4x4 fluff gauze pads) and wrapped with rolled gauze). The outer dressing will be changed 7-10 days post-op. The Suprathel and Rylon will remain in place until they can be easily peeled off. To facilitate the pain-free and easy removal of the primary Suprathel dressing, practioners will apply Vaseline or lotion to saturate and loosen the material. The patients will be followed on average about once per week in an outpatient clinic until the Suprathel (and Rylon) are removed, but they may continue to be seen until the STSG is fully healed.
62602168|NCT02998476|EXPERIMENTAL|Group B Parsaclisib (prior BTK inhibitor)|Parsaclisib in subjects who were previously treated with a BTK inhibitor.
62602169|NCT03204487|EXPERIMENTAL|Patients with glaucoma or ocular hypertension|
62245472|NCT04779190|EXPERIMENTAL|Low-level laser therapy|In the low-level laser therapy group, each patient are going to receive low-level laser therapy and cold-pack therapy and perform a home-based exercise program 5 times a week, once a day for 15 sessions.
62245473|NCT04779190|EXPERIMENTAL|Therapeutic ultrasound|In the therapeutic ultrasound group, each patient are going to receive therapeutic ultrasound and cold-pack therapy and perform a home-based exercise program 5 times a week, once a day for 15 sessions.
62245474|NCT04779190|ACTIVE_COMPARATOR|Control|Participants are going to perform a home-based exercise program and receive cold-pack therapy 5 times a week, once a day for 15 sessions.
62245475|NCT05693168|EXPERIMENTAL|Comparison of ANNE Limb Sensor pulse oximetry measurements to blood gas analysis|
62602170|NCT03589339|EXPERIMENTAL|NBTXR3 activated by SABR followed by anti-PD-1 monotherapy|Intratumoral injection of NBTXR3 followed by SABR followed by monotherapy with nivolumab or pembrolizumab
62602171|NCT02719301||Men/Women between 18 & 85|Accepting both healthy and non-healthy subjects. A portion of the subjects will have a fluid management issue or heart failure.
62602172|NCT00734331||IBD|Inflammatory bowel disease patients
62602173|NCT00734331||Control|Average risk patients undergoing screening colonoscopy
62849265|NCT05960630|EXPERIMENTAL|MIRRORS Protocol|Diagnostic Laparoscopy proceed to either robotic or open Interval cytoreductive surgery with conversion to open at any point should this be required to remove all visible disease.
62042635|NCT00935376|EXPERIMENTAL|Mindfulness Meditation Program|Mindfulness Meditation Program (MMP) is based on Mindfulness-Based Stress Reduction (MBSR), which teaches participants mindfulness skills such as meditation and yoga. Mindfulness may be defined as paying attention in a particular way, on purpose, in the present moment, and nonjudgmentally. The goal of MBSR is to provide participants with experiential tools and mindfulness practices to assist them to become more mindful of themselves, others and their external environment. The techniques are easy to learn and teach individuals to be aware of the present moment, with an open mind in which they can perceive their thoughts, physical sensations, and emotions nonjudgmentally.
62245476|NCT00895141|EXPERIMENTAL|Low saturated fat diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 8%E saturated fat
62245477|NCT00895141|EXPERIMENTAL|High saturated fat diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
62245478|NCT01009827||AMTU Clients|All HIV-infected adolescents and young adults engaged in care at the 15 sites and their affiliates who are between 12 and 24 years of age, inclusive, are aware of their HIV status and understand written and/or verbal English will be eligible for inclusion in the study. In addition, new patients who have their initial clinic visit within the enrollment period will also be eligible for participation.
62245479|NCT03659851||Levosimendan before LVAD implantation|Levosimendan use 24 hrs. before LVAD implantation
62245480|NCT03659851||Dobutamine/milrinone before LVAD implantation|Dobutamine/milrinone use 24 hrs. before LVAD implantation
62245481|NCT06725017|EXPERIMENTAL|SK08 low dose group|1 × 10\^7 CFU \~ 2.5 × 10\^8 CFU/dose, twice daily (BID), taken orally for 8 weeks
62245482|NCT06725017|EXPERIMENTAL|SK08 high dose group|1 × 10\^9 CFU \~ 2.5 × 10\^10 CFU/dose, BID, taken orally for 8 weeks
62435774|NCT04014400|ACTIVE_COMPARATOR|Xeroform|After hemostasis occurs, the Xeroform dressing will be handled with a new pair of sterile gloves and cut so that the material extends 1-2 cm beyond the donor site margins, then applied to the donor site. The primary dressing will be covered with cotton gauze (4x4 fluff gauze pads) and wrapped with rolled gauze (Kerlix). The outer dressing will be changed 7-10 days post-op. The Xeroform will remain in place until it can be easily peeled off. To facilitate the pain-free and easy removal of the Xeroform dressing, practioners may apply Vaseline or lotion to saturate and loosen the material. The patients will be followed on average about once per week in an outpatient clinic until the Xeroform is removed, but they may continue to be seen until the STSG is fully healed.
62435775|NCT02237352||Control|Subjects without diabetic nephropathy
62823555|NCT06588777|EXPERIMENTAL|Modified thoracoabdominal nerve block through perichondrial approach (M-TAPA)|Using the in plane technique A deep angle was given to the costochondral angle at the edge of the 10th costal margin with the probe in the sagittal direction to view the lower surface of the costal cartilage in the midline. A 22-G, 100-mm block needle will be inserted in the cranial direction using the in-plane technique and the needle tip will be moved to the posterior aspect of the 10th costal cartilage. It is noted that the needle tip never crossed the cranial edge of the 10th costal cartilage and 20 mL of 0.25% bupivacaine will be injected into the lower surface of the chondrium to make Modified thoracoabdominal nerve block through perichondrial approach (M-TAPA).
62042636|NCT00935376|ACTIVE_COMPARATOR|Sleep Education Program|The Sleep Education Program (SEP) will serve as the control intervention in which participants will receive classes informing them how to change their habits to improve their sleep, and what to do if they have concerns about their sleep quality.
62245483|NCT06725017|PLACEBO_COMPARATOR|Placebo group|BID, taken orally for 8 weeks.
62245484|NCT03447366|EXPERIMENTAL|Mitral doppler|Mitral doppler before and after vascular filling
62245485|NCT05880940|EXPERIMENTAL|Boost - Moveable wheelchair Arm rest|Movable wheelchair arm rest device group: participants in this group will be provided with a wheelchair equipped with movable wheelchair arm rest device and will be trained by training therapists on how to use the device. Therapists will determine if the participant is capable of using the device in either a stationary mode or overground mode. Afterwards, participants will be allowed to utilize the device within the inpatient facility on their own. The investigators encourage at least 30 minutes per day of device use, although this is not required or limited to 30 minutes. Therapists may adjust the difficulty of the device utilize to provide additional challenge as they deem suitable for the participant. Once participants are discharged from the unit, they will be allowed to keep the movable wheelchair arm rest devices until their 3-month post stroke follow up visit, the last visit of the study.
62435776|NCT02237352||Diabetic nephropathy|Subjects with diabetic nephropathy
62435777|NCT04360603|EXPERIMENTAL|27 gauge system|study group, using 27G vitrectomy system
62435778|NCT04360603|ACTIVE_COMPARATOR|25 gauge system|control group, using 25G vitrectomy system
62602174|NCT04735770|EXPERIMENTAL|LTAP|Patients receive laparoscopically inserted TAP block with levobupivacain and local wound anesthesia injections with saline.
62849266|NCT05960630|ACTIVE_COMPARATOR|Standard Care|Standard Care - Open Interval Cytoreductive Surgery Surgery will proceed directly with standard open interval cytoreductive surgery through an extended midline incision
62245486|NCT05880940|ACTIVE_COMPARATOR|Electronic Arm Exercises|Electronic exercise program designed by training therapists. These exercises will be assigned to the participants electronically using a commercial home exercise program platform commonly used by hospital systems (i.e.: Medbridge). They will be encouraged to exercise for 30 min/day in addition to the regular rehabilitation therapy at Acute Rehab Unit (ARU), although this is not required or limited to 30 minutes. Therapists may adjust the difficulty of exercise program to provide additional challenge as they deem suitable for the participant. Once participants are discharged from the unit, they will be allowed to keep the electronic exercise program until their 3-month post stroke follow up visit, the last visit of the study.
62245487|NCT02718599|ACTIVE_COMPARATOR|Terlipressin|Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
62245488|NCT02718599|PLACEBO_COMPARATOR|CONTROL|Patients receive the same volume of 0.9% saline in place of terlipressin for the same duration(50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours).
62602175|NCT04735770|ACTIVE_COMPARATOR|Local wound analgesia|Patients receive laparoscopically inserted TAP block with saline and local wound anesthesia injections with levobupivacaine.
62602176|NCT01876537|ACTIVE_COMPARATOR|Usual surgery|
62823556|NCT06588777|EXPERIMENTAL|Quadratus lumborum block|"Using the in plane technique the probe will be placed in the mid-axillary line between the lower costal margin and the iliac crest in a transverse plane to view all abdominal layers. The probe will be moved towards the posterior axillary line, to reach a point where all three abdominal muscle layers merge to form aponeurosis.~The aponeurosis will then be followed dorsally until the quadratus lumborum muscle is seen deep to transversalis fascia with its attachment to the transverse process of the L4 vertebral body. A 22 G, 100 mm, blunt, insulated nerve block needle will be inserted 1 cm medial to the probe and advanced using the in-plane technique with ultrasound real-time assessment. The injection site will be the junction of transversalis fascia and the anterolateral border of quadratus lumborum muscle."
62042637|NCT06524349|EXPERIMENTAL|3D printed knee extender device|Participants will utilize a 3D printed knee extender device and an at-home home rehabilitation program designed to be used with the 3D printed knee extender device.
62042638|NCT06524349|NO_INTERVENTION|Standard Rehabilitation|
62042639|NCT03365024|EXPERIMENTAL|Computerized Intervention 1|A web-based program will deliver components of CBT-I on a time and event-based schedule. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
62042640|NCT03365024|ACTIVE_COMPARATOR|Computerized Intervention 2|A web-based program will deliver components of sleep education via an Internet platform. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
62042641|NCT03258749|ACTIVE_COMPARATOR|Formoterol|inhaled formoterol(4.5μg, bid)
62042642|NCT03258749|EXPERIMENTAL|Tiotropium|inhaled Tiotropium(18μg, qd)
62602177|NCT01876537|ACTIVE_COMPARATOR|Hardware wound healing|
62449158|NCT01352650|ACTIVE_COMPARATOR|Cohort 2A|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5
62823557|NCT04820075|OTHER|Process about performance of the preoperative shower|Implementation of a process aimed at improving the preoperative shower in programmed surgery
62823558|NCT05120180|EXPERIMENTAL|Branches Sparing|The patients in this arm will undergo axillary lymph node dissection with preserved axillary vein branches
62602178|NCT02002533|EXPERIMENTAL|Arm I (BBT intervention)|Patients undergo BBT intervention, comprising insomnia education, stimulus control, discouragement of napping and encouragement of exercise, and sleep compression over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6.
62042643|NCT00208416|ACTIVE_COMPARATOR|1|DePuy MI System
62042644|NCT00208416|ACTIVE_COMPARATOR|2|Conventional surgical technique
62042645|NCT00130533|EXPERIMENTAL|Xeloda (capecitabine)|1000 mgrs/m2 twice a day, tablets, 8 cycles
62042646|NCT00130533|NO_INTERVENTION|Observation|Observation. No intervention.
62042647|NCT01939548|EXPERIMENTAL|PF-02545920 (5mg)|
62245489|NCT00115791|EXPERIMENTAL|1|
62042648|NCT01939548|PLACEBO_COMPARATOR|Placebo|
62042649|NCT01939548|EXPERIMENTAL|PF-02545920 (15mg)|
62042650|NCT03853668|ACTIVE_COMPARATOR|aerobic exercise group|"aerobic exercises (intervention) on treadmill for 10 weeks, 3 times/week for duration of 30-45 min/session.~Exercise intensity is 50-65%of maximal heart rate (MHR)"
62245490|NCT00115791|PLACEBO_COMPARATOR|2|
62823559|NCT05120180|ACTIVE_COMPARATOR|None Branches Sparing|The patients in this arm will undergo axillary lymph node dissection without preserved axillary vein branches
62823560|NCT01314183|ACTIVE_COMPARATOR|exercise|Subjects in this arm receive 12 exercise sessions in 9 weeks.
62042651|NCT03853668|EXPERIMENTAL|aerobic and resisted exercise|combined resisted and aerobic exercises (intervention) for 10 weeks (circuit weight training and treadmill training respectively) 2 times/week for a duration of 30-45 min/session Exercise intensity is 50-65%of maximal heart rate (MHR) for aerobic part and 50% of 1 repetition maximum (1RM) for resistance part.
62042652|NCT02136940|EXPERIMENTAL|AMA0076 0.1%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
62245491|NCT01892306|EXPERIMENTAL|Treatment as usual plus UP CBT|Existing psychiatrist-administered psychopharmacotherapy plus weekly transdiagnostic CBT
62245492|NCT01892306|ACTIVE_COMPARATOR|Treatment as usual|Existing psychiatrist-administered psychopharmacotherapy
62245493|NCT01313715|EXPERIMENTAL|160U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 45 children aged 13-60 months old on day0,28
62823561|NCT01314183|ACTIVE_COMPARATOR|exercise + manual therapy|Subjects in this group receive exercise combined with manual therapy techniques for 12 sessions in 9 weeks.
62042653|NCT02136940|EXPERIMENTAL|AMA0076 0.25%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
62042654|NCT02136940|EXPERIMENTAL|AMA0076 0.50%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
62245494|NCT01313715|EXPERIMENTAL|320U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 45 children aged 13-60 months old on day0,28
62245495|NCT01313715|EXPERIMENTAL|640U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 45 children aged 13-60 months old on day0,28
62245496|NCT01313715|EXPERIMENTAL|160U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 45 infants aged 6-12 months old on day0,28
62245497|NCT01313715|EXPERIMENTAL|320U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 45 infants aged 6-12 months old on day0,28
62245498|NCT01313715|EXPERIMENTAL|640U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 45 infants aged 6-12 months old on day0,28
62245499|NCT01313715|PLACEBO_COMPARATOR|0/0.5ml placebo in children|0/0.5ml placebo in 45 children aged 13-60 months old on day0,28
62449159|NCT01352650|ACTIVE_COMPARATOR|Cohort 2B|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 2 decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 4 decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10
62245500|NCT01313715|PLACEBO_COMPARATOR|0/0.5ml placebo in infants|0/0.5ml placebo in 45 infants aged 6-12 months old on day0,28
62245501|NCT03173066|EXPERIMENTAL|Single Arm|Patients with a clinical concern for pulmonary embolus but not able to receive iodinated contrast will be enrolled. Ferumoxytol will be administered as a contrast agent in coordination with magnetic resonance angiography to identify patency of the cardiopulmonary vasculature.
62245502|NCT02462928|EXPERIMENTAL|Abicipar Pegol 2 mg (2Q8)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 8 and every 8 weeks (2Q8) thereafter through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
62602179|NCT02002533|ACTIVE_COMPARATOR|Arm II (control)|Patients undergo HEAL comprising nutritional education and suggestions for symptom management over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6.
62245503|NCT02462928|EXPERIMENTAL|Abicipar Pegol 2 mg (2Q12)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 12, and every 12 weeks (2Q12) thereafter through week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
62245504|NCT02462928|ACTIVE_COMPARATOR|Ranibizumab 0.5 mg (rQ4)|Ranibizumab (Lucentis®) 0.5 mg was administered to the study eye by intravitreal injection every 4 weeks (rQ4) from Day 1 through Week 96.
62245505|NCT02163083|NO_INTERVENTION|Lymphadenectomy using standard Methods|Lymphadenectomy will be performed as a standard procedure
62823562|NCT01314183|EXPERIMENTAL|exercise + booster|subjects in this arm will receive exercise sessions delivered with booster sessions (8 sessions in the first 9 weeks, 2 sessions at 5 months, 1 session at 8 months, and 1 session at 11 months).
62823563|NCT01314183|EXPERIMENTAL|exercise + manual therapy + booster|Subjects in this arm will receive exercise combined with manual therapy techniques and booster sessions.
62823564|NCT06592612|ACTIVE_COMPARATOR|Control Arm|Patients in the control arm will receive second-line systemic therapy until disease progression is confirmed by imaging or until they are unable to continue systemic therapy due to adverse events. The following stipulations apply to the second-line treatment drugs: for patients who received bevacizumab combined with atezolizumab/sintilimab as the first-line treatment, lenvatinib or regorafenib will be used for second-line treatment; for patients who received lenvatinib with or without PD-1 antibody as the first-line treatment, regorafenib combined with another PD-1 antibody will be used for second-line treatment.
62849267|NCT01771341|PLACEBO_COMPARATOR|Pressure support|
62849268|NCT01771341|EXPERIMENTAL|NAVA|
62849269|NCT03764293|EXPERIMENTAL|SHR-1210|SHR-1210+Apatinib
62042655|NCT02136940|PLACEBO_COMPARATOR|Placebo|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
62042656|NCT03899753|EXPERIMENTAL|2-Octyl Cyanoacrylate and mesh|The wound will be closed with 2-Octyl Cyanoacrylate and a mesh
62042657|NCT03899753|ACTIVE_COMPARATOR|2-Octyl Cyanoacrylate|The wound will be closed with just 2-Octyl Cyanoacrylate
62042658|NCT05824065|EXPERIMENTAL|OMA102 1 mg|Ingestion of 1 oral tablet, once a day, immediately before lying down to sleep
62042659|NCT05824065|EXPERIMENTAL|OMA102 2 mg|Ingestion of 1 oral tablet, once a day, immediately before lying down to sleep
62042660|NCT05824065|PLACEBO_COMPARATOR|Placebo|Ingestion of 1 oral tablet, once a day, immediately before lying down to sleep
62042661|NCT03827122|EXPERIMENTAL|Group one|Botx will be injection in masster muscles 20unit Botx (onabotulinumtoxinA) and visual pain scale will be taken before and after in four intervals 2,8,16,48 weeks
62042662|NCT01826474|EXPERIMENTAL|PRO045, cohort 1|0.15 mg/kg until dose-titration
62042663|NCT01826474|EXPERIMENTAL|PRO045, cohort 2|1.0 mg/kg until dose-titration
62042664|NCT01826474|EXPERIMENTAL|PRO045, cohort 3|3.0 mg/kg until dose-titration
62042665|NCT01826474|EXPERIMENTAL|PRO045, cohort 4|6.0 mg/kg until dose-titration
62042666|NCT01826474|EXPERIMENTAL|PRO045, cohort 5|9.0 mg/kg until move to 48 week treatment phase
62042667|NCT01826474|EXPERIMENTAL|PRO045, cohort 6|48 week treatment phase
62042668|NCT03817996||HFNC + hypoperfusion + Responders|"Patients treated with HFNC presenting with any sign of hypoperfusion, in whom volume expansion was planned by the attending physician.~Clinical signs of inadequate tissue perfusion were suspected at the bedside by observing hypotension (systolic blood pressure \<90 mm Hg or the need for norepinephrine), oliguria (urine output \<0.5 mL/kg/hr), and cool, mottled extremities.~Their CO increases \>15% after passive leg raising."
62042669|NCT03817996||HFNC + hypoperfusion + Non-Responders|Same as previous but their CO do not increase \>15% after passive leg raising maneuver.
62042670|NCT01743079|EXPERIMENTAL|Telbivudine|Mother receives telbivudine 600mg per day. Infant receives standard immunoprophylaxis
62042671|NCT01743079|EXPERIMENTAL|Lamivudine|Mother receives lamivudine 100mg per day. Infant receives standard immunoprophylaxis.
62823565|NCT06592612|EXPERIMENTAL|SBRT Arm|Patients in the SBRT arm will also receive second-line systemic therapy until disease progression is confirmed by imaging or until they are unable to continue systemic therapy due to adverse events. The choice and stipulations for second-line systemic therapy drugs are the same as those for the control arm. SBRT will be administered to all oligoprogressive lesions and must begin within 2 weeks after the start of second-line therapy. Systemic therapy will not be paused during SBRT. Patients who do not withdraw from the study will not receive crossover treatment; however, if a patient in the control group withdraws from the study due to tumor progression and is assessed as suitable for SBRT, salvage SBRT will be administered promptly.
62042672|NCT01743079|NO_INTERVENTION|No antiviral treatment|Mother receives no antiviral treatment. Infant receives standard immunoprophylaxis
62042673|NCT01532115|EXPERIMENTAL|BIA 9-1067|
62245506|NCT02163083|EXPERIMENTAL|Lymphadenectomy using ICG|A fluorescent dye (indocyanine green) will be ultrasound-controlled preoperatively injected in the prostate. During robot-assisted radical intervention by DaVinci ® robot the lymphadenectomy is performed using the fluorescence lymphography.
62435779|NCT02808806|ACTIVE_COMPARATOR|real-time audio-visual feedback|real-time audio-visual feedback to caregivers (i.e. both in- and outside the hospital) bringing the patient to the location where IVT/IAT is administered . The real time audio-visual feedback consists in information on the actual TSD for a particular patient and whether or not this exceeds pre-set median time delay. The feedback is provided by handhelds in the ambulance and by pre-set monitors on different locations in the participating hospitals.
62602180|NCT01103947|ACTIVE_COMPARATOR|EcoAnesthesia Mask first|"Both the standard adult facemask (Portex Adult, USA) and the new facemask (EcoAnesthesia Mask, Intersurgical, Inc., Liverpool, NY, USA) will be tested in each patient for three minutes. The order of usage of each mask will be randomly assigned to each patient. This group will receive the EcoAnesthesia Mask first."
62823566|NCT06092723|EXPERIMENTAL|Lactococcus lactis subsp. lactis, LY-66|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
62823567|NCT06092723|EXPERIMENTAL|Lactobacillus plantarum, PL-02|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
62823568|NCT06092723|EXPERIMENTAL|Lactococcus lactis subsp. lactis, LY-66+Lactobacillus plantarum, PL-02|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
62245507|NCT02740296||Healthy controls|Healthy controls
62435780|NCT02808806|NO_INTERVENTION|regular care|no real-time audio-visual feedback
62042674|NCT01532115|PLACEBO_COMPARATOR|Placebo|
62042675|NCT01532115|ACTIVE_COMPARATOR|moxifloxacin|
62042676|NCT04022200||Paclitaxel DCB for De Novo Coronary Lesions|we define de novo coronary artery lesions as the lesions never been treated with any interventional device, such as POBA, stent, rota ablation, laser etc.
62042677|NCT03483987|EXPERIMENTAL|Sof+Ledi+R arm|"Participants with HCV genotype 1,4, 5 or 6 and relapsed with following regimens will be treated with sofosbuvir, ledipasvir and ribavirin combination~1. Sofosbuvir plus velpatasvir with or without ribavirin for 12 weeks~2. Sofosbuvir plus ribavirin with or without pegylated interferon for 12 or 24 weeks~3. Sofosbuvir plus velpatasvir with or without ribavirin for 24 weeks and are not eligible for pegylated interferon"
62042678|NCT03483987|EXPERIMENTAL|Sof+Ledi+R+Peg-IFN arm|Participants with HCV genotype 1,4, 5 or 6, who have relapsed after a 24 weeks treatment regimen of sofosbuvir plus velpatasvir with or without ribavirin combination and are eligible for pegylated interferon, will be treated with a combination of sofosbuvir, ledipasvir, ribavirin plus pegylated interferon
62042679|NCT03483987|EXPERIMENTAL|Sof+Dacla+R arm|"Participants with HCV genotype 2 or 3 and relapsed with following regimens will be treated with a combination of sofosbuvir, daclatasvir and ribavirin~1. Sofosbuvir plus velpatasvir with or without ribavirin for 12 weeks~2. Sofosbuvir plus ribavirin with or without pegylated interferon for 12 or 24 weeks~3. Sofosbuvir plus velpatasvir with or without ribavirin for 24 weeks and are not eligible for pegylated interferon"
62042680|NCT03483987|EXPERIMENTAL|Sof+Dacla+R+Peg-IFN arm|Participants with HCV genotype 2 or 3, who have relapsed after a 24 weeks treatment regimen of sofosbuvir plus velpatasvir with or without ribavirin combination and are eligible for pegylated interferon, will be treated with a combination of sofosbuvir, ledipasvir, ribavirin plus pegylated interferon
62042681|NCT03483987|EXPERIMENTAL|Sof+Velpa+R arm|"Following group of participants will be treated with sofosbuvir, velpatasvir and ribavirin combination~1. who were treated earlier with 12 week treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin or~2. who were earlier treated with a 24 treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin and are not eligible for pegylated interferon"
62435781|NCT02145403|EXPERIMENTAL|Carfilzomib|Carfilzomib will be administered IV over 30 minutes, starting at dose level 1 (20 mg/m2 IV) on Day +1, +2, +6 and +7.
62435782|NCT03065283|ACTIVE_COMPARATOR|Diaphragmatic release|The stretching of the peripheral fibers of the diaphragm
62823569|NCT06092723|PLACEBO_COMPARATOR|Placebo|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
62823570|NCT01183689|NO_INTERVENTION|Control Group|"Self-Guided Behavior Changes. This group will be used to determine average rate of weight gain over 3 years with little intervention. Participants randomized to this group will receive one face-to-face session that will provide general education of self-weighing and information about both the small and large changes approach. Participants will also be provided with quarterly newsletters describing study events and very limited information on health eating."
62823571|NCT01183689|EXPERIMENTAL|Small behavior changes|Participants randomized to this group will be taught to self-weigh daily and report weights regularly. They will be reinforced for maintaining weight below randomization weight and taught that if weight exceeds randomization weight, they should reinstate small changes (e.g., modify diet by approximately 100 kcal, decrease portion sizes or change types of food, increase activity by 2000 steps/day).
62823572|NCT01183689|EXPERIMENTAL|Large behavior changes|Participants randomized to this group will be taught to self-weigh daily and report weights regularly. They will be reinforced for maintaining weight below randomization weight and taught that if weight exceeds randomization weight, they should reinstate large changes (e.g., modify diet to 1200-1500 or 1500-1800 kcal/day with \< 30% fat, increase exercise to 250 minutes/week of moderate intensity activity).
62823573|NCT03894124|OTHER|Study intervention|Pifeltro® (doravirine 100mg) daily dose for 7 days
62823574|NCT01553656|EXPERIMENTAL|Cabozantinib capsules and tablets|Subjects will be enrolled in cohorts at different dose levels in order to determine the maximum tolerated dose of cabozantinib. Initially, subjects enrolled will receive the capsule formulation; other subjects will receive the tablet formulation.
62245508|NCT02740296||RRMS|Relapsing-Remitting Multiple Sclerosis
62823575|NCT02581085|PLACEBO_COMPARATOR|Placebo Vehicle|Subjects will take 2 placebo capsules following AM meal, 2 placebo capsules following PM capsules
62823576|NCT02581085|ACTIVE_COMPARATOR|Tocotrienol supplement|Subjects will take (2) 200 mg TCT capsules following AM meal, (2) 200 mg TCT following PM meal
62823577|NCT05249556|EXPERIMENTAL|GNX|The suspension contains GNX (50 mg/mL), hydroxypropyl methylcellulose, polyvinyl alcohol, sodium lauryl sulfate, simethicone, methylparaben, propylparaben, citric acid, and sodium citrate at pH 3.5 to 4.2, and is sweetened with sucralose and flavored with artificial cherry.
62823578|NCT05249556|PLACEBO_COMPARATOR|Placebo|The PBO suspension consists of titanium dioxide, Avicel® (microcrystalline cellulose and carboxymethylcellulose sodium), sodium lauryl sulfate, simethicone, methylparaben, propylparaben, citric acid, sodium citrate and is sweetened with sucralose and flavored with artificial cherry
62823579|NCT02575963|EXPERIMENTAL|Phase 1 (Completed)|"Cytarabine + Lintuzumab-Ac225 Cytarabine days 1 to 10 of each cycle. Doses were divided into 2 equal fractions with the first fraction given approx. 4-7 days after 1 cycle of low dose cytarabine and the second fraction given 4-7 days after the first fraction, followed by up to 11 more cycles. Furosemide (Phase 1 only) and Spironolactone were administered after Lintuzumab-Ac225.~Experimental: Phase 2~Experimental: Lintuzumab-Ac225 The Phase II dose determined during the Phase I dose escalation was 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8. Spironolactone is administered after Lintuzumab-Ac225."
62823580|NCT06592209|EXPERIMENTAL|Every 30 Minutes Movement Break|Participants in the movement breaks every 30 minutes group complete a 7-day baseline period, followed by 2 weeks of the selected dose condition. Participants are asked to complete movement breaks every 30 minutes during all waking hours on weekdays and weekends (i.e. 7 days a week). Information regarding work productivity, energy and fatigue levels, mood, physical activity, and barriers/facilitators to taking movement breaks are collected via either 5 daily SMS surveys throughout the day (9am, 12pm, 3pm, 6pm, 9pm) or one emailed survey at the end of each day (8pm). Survey delivery method is randomized. Participants also provide feedback regarding the feasibility, acceptability, and appropriateness of the intervention.
62245509|NCT02740296||RRMS+MDD|Relapsing-Remitting Multiple Sclerosis and Major Depressive Disorder
62435783|NCT03065283|PLACEBO_COMPARATOR|Diaphragmatic release control|In both placebo techniques, only the light touching of the contacts of the volunteers' skin
62849270|NCT03764293|ACTIVE_COMPARATOR|Control|Sorafenib
62849271|NCT03689686|EXPERIMENTAL|Patients|Fifteeen children with Acute Respiratory Failure admitted to a PICU, needing noninvasive respiratory support
62849272|NCT01324141|EXPERIMENTAL|1/Chemo + Radiation|Chemo + Radiation
62849273|NCT02692391|PLACEBO_COMPARATOR|Placebo|6 doses, Q8hrs for a total period of 48 hours
62245510|NCT02740296||MDD|Major Depressive Disorder
62245511|NCT05520541|EXPERIMENTAL|Clinical Group|This group will receive clinical-based LSVT-BIG training
62245512|NCT05520541|ACTIVE_COMPARATOR|Home Group|This group will receive home-based LSVT-BIG training
62245513|NCT02959749|ACTIVE_COMPARATOR|Docetaxel, bevacizumab|docetaxel, 75mg/m2, intravenous infusion on day 1. VEGF monoclonal antibody bevacizumab, 7.5 mg/m2, intravenous infusion on day 1, every 21days a cycle，until disease progression, intolerable toxicities, or patient death.
62245514|NCT02959749|EXPERIMENTAL|EGFR TKI|osimertinib 80mg oral once daily，until disease progression, intolerable toxicities, or patient death.
62245515|NCT03869281||PTA|patients who underwent their first deceased donor PTA, or second deceased donor PTA if their first graft was explanted within a week, at the IRCCS San Raffaele Hospital between 2 January 2005 and 31 December 2017
62245516|NCT03869281||Controls|outpatients with T1D attending the Endocrinology Unit at IRCCS San Raffaele Hospital and patients listed for a first deceased donor PTA
62245517|NCT04621734|ACTIVE_COMPARATOR|Nasal bridle to secure feeding tube|The nasal bridle will be used to secure the nasoenteric feeding tube.
62245518|NCT04621734|PLACEBO_COMPARATOR|Adhesive Tape use to secure feeding tube|Adhesive tape will be used as standard of care to secure the nasoenteric feeding tube.
62245519|NCT03724734|EXPERIMENTAL|Adaptive DBS|We will use our custom-built externalized research system (ERS) to deliver adaptive stimulation to the subthalamic nuclei.
62602181|NCT01103947|ACTIVE_COMPARATOR|Standard mask first|"Both the standard adult facemask (Portex Adult, USA) and the new facemask (EcoAnesthesia Mask, Intersurgical, Inc., Liverpool, NY, USA) will be tested in each patient for three minutes. The order of usage of each mask will be randomly assigned to each patient. Patients in this arm will receive the standard mask first."
62823581|NCT06592209|EXPERIMENTAL|Every 60 Minutes Movement Break|Participants in the movement breaks every 60 minutes group complete a 7-day baseline period, followed by 2 weeks of the selected dose condition. Participants are asked to complete movement breaks every 60 minutes during all waking hours on weekdays and weekends (i.e. 7 days a week). Information regarding work productivity, energy and fatigue levels, mood, physical activity, and barriers/facilitators to taking movement breaks are collected via either 5 daily SMS surveys throughout the day (9am, 12pm, 3pm, 6pm, 9pm) or one emailed survey at the end of each day (8pm). Survey delivery method is randomized. Participants also provide feedback regarding the feasibility, acceptability, and appropriateness of the intervention.
62823582|NCT06592209|EXPERIMENTAL|Every 120 Minutes Movement Break|Participants in the movement breaks every 120 minutes group complete a 7-day baseline period, followed by 2 weeks of the selected dose condition. Participants are asked to complete movement breaks every 120 minutes during all waking hours on weekdays and weekends (i.e. 7 days a week). Information regarding work productivity, energy and fatigue levels, mood, physical activity, and barriers/facilitators to taking movement breaks are collected via either 5 daily SMS surveys throughout the day (9am, 12pm, 3pm, 6pm, 9pm) or one emailed survey at the end of each day (8pm). Survey delivery method is randomized. Participants also provide feedback regarding the feasibility, acceptability, and appropriateness of the intervention.
62823583|NCT06246539|EXPERIMENTAL|Intervention - VR Mindfulness|"The intervention group will be given the VR headset for their unrestricted use over the 12 week intervention period. The VR headset is exceptionally easy and intuitive to use. Each participant will have the choice of 20 locations in which to use the mindfulness-based program. Each of the 20 locations/programs are different. They range in length from 5 minutes (introductory) to 20 minutes."
62042682|NCT03483987|EXPERIMENTAL|Sof+Velpa+R+Peg-IFN arm|Participants, who have relapsed after a 24 week treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin and are eligible for pegylated interferon will be treated with sofosbuvir, velpatasvir, ribavirin and pegylated interferon combination
62435784|NCT04440345|EXPERIMENTAL|IBI362|"Participants received dose 1 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 2 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 3 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 4 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 5 level of IBI362 administered as multiple subcutaneous doses."
62435785|NCT04440345|PLACEBO_COMPARATOR|placebo|Participants received matching placebo dose regiments by subcutaneous injection
62435786|NCT06204926||Eyes with SMILE surgeries|Eyes with SMILE surgeries which were performed by surgeons with experiences.
62435787|NCT06502041|EXPERIMENTAL|MARPE with MOP|
62435788|NCT06502041|ACTIVE_COMPARATOR|MARPE without MOP|
62435789|NCT03286647|EXPERIMENTAL|NORMALGRIEF|Oral hygiene instruction
62435790|NCT03286647|EXPERIMENTAL|COMPLICATEDGRIEF|Oral hygiene instruction
62435791|NCT03286647|ACTIVE_COMPARATOR|CONTROLS|Oral hygiene instruction
62435792|NCT01936168|ACTIVE_COMPARATOR|RFA|Radiofrequency Ablation (RFA)
62435793|NCT01936168|EXPERIMENTAL|MOCA|Mechanochemical Endovenous Ablation (MOCA)
62435794|NCT03978702|EXPERIMENTAL|Indication for pancreatectomy|Blood sampling at different time points before and after pancreatectomy
62435795|NCT04252352|ACTIVE_COMPARATOR|Ablative fractional CO2 laser resurfacing|One fractional CO2 laser treatment are performed of acne scars on one side of the face
62435796|NCT04252352|ACTIVE_COMPARATOR|Radio-frequency microneedling|One radio-frequency microneedling treatment are performed of acne scars on one side of the face
62435797|NCT03139747|EXPERIMENTAL|Single Arm|
62823584|NCT06246539|NO_INTERVENTION|Control|The control arm will not have any intervention. However, at the conclusion of the study, all participants from the Control group will be given the VR intervention
62823585|NCT06590506||First line breast cancer metastatic subtype luminal|Women with hormone-positive, HER2-negative breast cancer who will receive CDK4/6 inhibitor plus hormone treatment.
62823586|NCT06590506||First line colon cancer metastatic|Women with colon cancer of any subtype, candidates to receive first-line treatment.
62823587|NCT06590506||First line lung cancer metastatic|Women with lung cancer of any subtype, candidates to receive first-line treatment.
62042683|NCT01384708|EXPERIMENTAL|treatment|imaging with proflavine
62042684|NCT00248781|EXPERIMENTAL|Arm 1|exercise
62435798|NCT05189561|EXPERIMENTAL|Cerebo®|Participants undergoing scanning using NIRS device.
62435799|NCT00276874|EXPERIMENTAL|Aripiprazole|Subjects receive oral aripiprazole.
62435800|NCT00276874|PLACEBO_COMPARATOR|Placebo|Subjects receive oral placebo
62435801|NCT01151787|ACTIVE_COMPARATOR|cyclobenzaprine hydrochloride|
62435802|NCT01151787|PLACEBO_COMPARATOR|placebo|
62435803|NCT03765671|EXPERIMENTAL|Mild Child-Pugh A|Single oral dose of elafibranor 120mg
62435804|NCT03765671|EXPERIMENTAL|Moderate Child-Pugh B|Single oral dose of elafibranor 120mg
62435805|NCT03765671|EXPERIMENTAL|Severe Child-Pugh C|Single oral dose of elafibranor 120mg
62435806|NCT03765671|EXPERIMENTAL|Healthy|Single oral dose of elafibranor 120mg
62435807|NCT04147728|EXPERIMENTAL|SRS Combination With Anlotinib|Stereotactic Radiosurgery Combination With Anlotinib
62435808|NCT05313620|EXPERIMENTAL|Ulcerative colitis patients treated with tofacitinib|Tofacitinib 5 mg/day oral per clinical practice
62435809|NCT05313620|ACTIVE_COMPARATOR|Ulcerative colitis patients treated with an anti-TNFα drug|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice, or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice, or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice
62823588|NCT06600659||Observational|Patients undergo blood sample collection, complete surveys, and have their medical records reviewed on study.
62042685|NCT00248781|OTHER|Arm 2|health education
62042686|NCT04275466|EXPERIMENTAL|necrotic cavity lavage|This arm was performed necrotic cavity lavage after debridement
62042687|NCT04275466|NO_INTERVENTION|non-necrotic cavity lavage|This arm was not performed necrotic cavity lavage after debridement
62042688|NCT00894231|PLACEBO_COMPARATOR|placebo|Sugar tablet
62042689|NCT00894231|ACTIVE_COMPARATOR|Xyzal|
62042690|NCT05718375|EXPERIMENTAL|CU01-1001 (low dose)|1 Tab/3 times/day (CU01-1001 120 mg, Breakfast and Dinner; Placebo 120 mg, Lunch)
62042691|NCT05718375|EXPERIMENTAL|CU01-1001 (high dose)|1 Tab/3 times/day (CU01-1001 120 mg, Breakfast, Lunch, and Dinner)
62602182|NCT02346110|ACTIVE_COMPARATOR|Bupivacaine-adrenalin + sodium chloride|"Single shot saphenous block:~10 mL of 5 mg/mL bupivacaine with 5 μg/mL adrenalin = 50 mg bupivacain and 50 μg adrenalin~1 mL sodium chloride solution"
62823589|NCT05903794|EXPERIMENTAL|EXG102-031|Each participant will receive a single subretinal injection of EXG102-031 in the study eye. Participants will be enrolled into one of four dosage groups sequentially, and the dose administered will be determined based on which study group the participant is enrolled into.
62823590|NCT03641755|EXPERIMENTAL|Dose Level -1: Sapacitabine (100 mg) + Olaparib (300 mg)|"* Olaparib will be administered orally twice daily for each 28-day cycle~* Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle"
62823591|NCT03641755|EXPERIMENTAL|Dose Level 1: Sapacitabine (150 mg) + Olaparib (300 mg)|"* Olaparib will be administered orally twice daily for each 28-day cycle~* Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle"
62823592|NCT03641755|EXPERIMENTAL|Dose Level 2: Sapacitabine (200 mg) + Olaparib (300 mg)|"* Olaparib will be administered orally twice daily for each 28-day cycle~* Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle"
62823593|NCT03641755|EXPERIMENTAL|Dose Level 3: Sapacitabine (250 mg) + Olaparib (300 mg)|"* Olaparib will be administered orally twice daily for each 28-day cycle~* Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle"
62823594|NCT01128374|EXPERIMENTAL|intervention|Therapy
62823595|NCT04077073|EXPERIMENTAL|ReIn-hand and robot|"The participant will practice reach, grasp, retrieve, and release (GR3) a plastic jar for 40 trials per session, with the assistance of ReIn-hand to open their paretic hand and of robot to reduce the shoulder load."
62823596|NCT04077073|ACTIVE_COMPARATOR|ReIn-Hand|"The participant will practice reach, grasp, retrieve, and release (GR3) a plastic jar for 40 trials per session, with the assistance of ReIn-hand to open their paretic hand."
62042692|NCT05718375|PLACEBO_COMPARATOR|Placebo|1 Tab/3 times/day (Placebo, Breakfast, Lunch, and Dinner)
62042693|NCT03860233|EXPERIMENTAL|Visit 1 Randomization|At visit 1subjects will receive one of two interventions: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.
62042694|NCT03860233|EXPERIMENTAL|Visit 2 Crossover Randomization|At visit 2 subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.
62042695|NCT06184672|EXPERIMENTAL|intervention group|the principal investigator will apply the dry needling technique to those allocated to the experimental group on the latent trigger points diagnosed on the selection phase. They will receive just one session following Hongs protocol.
62042696|NCT06184672|NO_INTERVENTION|control group|Subjects in the control group will be asked to wait on the intervention couch for a similar time the ones who received the treatment.
62042697|NCT03496155|EXPERIMENTAL|Intervention Group (Arm 1- Main)|"Will receive the Build Your Teen's Strengths educational pamphlet, health coaching sessions, and provider endorsement."
62042698|NCT03496155|NO_INTERVENTION|Control Group (Arm 1- Main)|Will receive usual care at well-child visit.
62042699|NCT03496155|EXPERIMENTAL|Intervention Group (Arm 1-asthma subgroup)|"Will receive the Build Your Teen's Strengths educational pamphlet, health coaching sessions, and provider endorsement."
62042700|NCT03496155|NO_INTERVENTION|Control Group (Arm 1-asthma subgroup)|Will receive usual care at well-child visit.
62042701|NCT03496155|NO_INTERVENTION|Control Group (Arm 2)|Convenience sample used for a post-hoc, exploratory analysis. Will receive usual care at well-child visit.
62042702|NCT05080946|EXPERIMENTAL|Participants Randomized to Aspirin|Participants randomized to this arm will receive 325mg daily dose aspirin
62042703|NCT05080946|PLACEBO_COMPARATOR|Participants Randomized to Placebo|Participants randomized to this arm will receive a daily dose of a placebo (inactive substance)
62042704|NCT03771976||Over 35 years of age|Primiparous women over 35 years of age.
62823597|NCT06511037|EXPERIMENTAL|Pafolacianine (CYTALUX)|All subjects will receive one single intravenous infusion of 0.025 mg/kg of pafolacianine (CYTALUX) injection prior to anticipated intraoperative imaging planned for cytoreductive surgery.
62849274|NCT02692391|ACTIVE_COMPARATOR|Indomethacin suppository|Loading dose :100mg Maintenance dose: 50 mg, Q8hrs for a total period of 48 hours (5 doses)
62849275|NCT03993067|ACTIVE_COMPARATOR|Standard Treatment|Fibrin glue and Tabotamp on cut surface
62042705|NCT03771976||Between 20-34 years of age|Primiparous women between 20 and 34 years of age.
62042706|NCT06072534|ACTIVE_COMPARATOR|Miva 3|"Mivacurium chloride (Mivacron®) 0.3 mg/kg 3 times effective dose (ED) 95 iv during induction recording intubation condition during rapid sequence intubation within 90 sc monitoring hemodynamic changes during intubation ,time to recover to T1"
62042707|NCT06072534|ACTIVE_COMPARATOR|Miva 4|"Mivacurium chloride (Mivacron®) 0.4 mg/kg 4 times effective dose (ED) 95 iv during induction~recording intubation condition during rapid sequence intubation within 90 sc monitoring hemodynamic changes during intubation,time to recover to T1"
62245520|NCT03724734|ACTIVE_COMPARATOR|Conventional DBS|We will use our custom-built externalized research system (ERS) to deliver continuous stimulation to the subthalamic nuclei.
62245521|NCT01162239|EXPERIMENTAL|Extended Brief Contact|Following standard brief treatment, participants have monthly meetings with medical staff.
62435810|NCT05313620|NO_INTERVENTION|healthy controls|
62602183|NCT02346110|EXPERIMENTAL|Bupivacaine-adrenaline + Dexamethasone|"Single shot saphenous block:~10 mL of 5 mg/mL bupivacaine with 5 μg/mL adrenalin = 50 mg bupivacain and 50 μg adrenalin~1 mL of 4 mg/mL dexamethasone = 4 mg dexamethasone"
62823598|NCT04474080|EXPERIMENTAL|Virtual Peer Support Platform|"The intervention program content will be informed by the BASICS-a guide for supporting resilience against burnout, developed by the Ontario Medical Association Physician Health Program, as well as the Person-Environment-Occupation (PEO) model, a transactive approach to modelling occupational performance issues in the field of Occupational Therapy. The BASICS highlights six fundamental domains will underlie the focus of group therapy sessions, where participants will be encouraged to consider how they may incorporate healthy physical and emotional practices both on their own (Person), and during the practice of medicine (Occupation), in addition to identifying barriers to adopting these practices within the healthcare environment (Environment)."
62823599|NCT04474080|ACTIVE_COMPARATOR|Control period|Residents will continue with their regular academic day activities during the allotted intervention time.
62245522|NCT01162239|EXPERIMENTAL|Extended Health Education|Following standard treatment, participants receive monthly counseling with content based on a health education model.
62435811|NCT00955747|PLACEBO_COMPARATOR|Sugar Substitute Splenda|1.5 g Sugar Substitute Splenda, dissolved in 125 ml of water three times per day. If intestinal problems occur, the dose should be reduced to 1 g dissolved in water tid or additionally reduced to 0.5 g dissolved in 125 ml of water tid if problems still persisted, until patients adapted to treatment.
62823600|NCT00593346|EXPERIMENTAL|Accelerated partial breast brachytherapy|Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
62245523|NCT01162239|EXPERIMENTAL|Extended Relapse Prevention plus varenicline|Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model plus access to ongoing medication treatment with varenicline.
62245524|NCT01162239|EXPERIMENTAL|Extended Relapse Prevention|Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model.
62435812|NCT00955747|EXPERIMENTAL|Tagatose|15 g Tagatose dissolved in 125 ml of water three times a day. The Tagatose dosage will be decreased to 10 g dissolved in 125 ml of water tid or decreased additionally to 5 g Tagatose dissolved in 125 ml of water tid, if needed due to gastrointestinal effects, until patients adapt to the treatment
62602184|NCT06181305|EXPERIMENTAL|Group A (HRT plus letrozole incorporation)|"Exogenous oestradiol in the form of 2 mg oral oestradiol valerate , three times daily will be started on the 2nd or 3rd day of the cycle. Tri-laminar endometrium of ≥ 9 mm will be the targeted cut-off. If the endometrium does not yet reach the target, oestradiol supplementation will be continued with serial US assessment until the targeted cut-off will be reached. Upon reaching the target endometrium, oral letrozole tablets 2.5 mg will be started twice daily for 5 days only with continuation of 6 mg daily oestradiol supplementation. Then, daily intramuscular progesterone in oil (100 mg intramuscular progesterone) will be started once per day with continuation of 6 mg oestradiol~interventions:~Drug:estradiol valertae~Drug :letrozole 2.5 mg tablet"
62245525|NCT01211535|EXPERIMENTAL|OPTI-FREE RepleniSH|OPTI-FREE RepleniSH multipurpose solution used with study contact lenses on a daily wear basis for 14 days
62602185|NCT06181305|ACTIVE_COMPARATOR|Group B (Letrozole mild ovarian stimulation)|"Oral letrozole 2.5-5 mg daily on cycle day(3-7) will be added . TVS will be performed from cycle day 8-10 to make sure that a dominant follicle has been recruited with the endometrium thickness ≥ 7 mm . Upon reaching the dominant follicle (18-20mm) , endometrial thickness will be measured on the day of ovulation trigger and blood sample will be withdrawn from each patient for assessment of E2 , P4 and LH levels. Patients with low LH level , high E2 level , low P4 level (\<1 ng/ml) will continue in the RCT; 10,000unit HCG will be injected as ovulation trigger~intervention :~Drug :letrozole 2.5mg tablet~procedure: on the day of ovulation trigger blood sample will be withdrawn from each patient for assessment of E2 , P4 and LH levels."
62042708|NCT04437251|EXPERIMENTAL|Brain stimulation-induced improvements in leg skill learning|"To examine the degree of stimulation-induced improvements in learning capacity between three groups: stroke group, healthy young group, and healthy older group. Up to date, most studies have investigated the effects of brain stimulation on hand skill improvements in healthy young adults; little is known about stimulation-induced improvement in the leg skill improvement in stroke survivors as well as in older healthy adults. The investigators will answer the question: Do stroke survivors improve leg skill learning at a comparable rate as healthy young and older adults after brain stimulation transcranial direct current stimulation (tDCS)?"
62245526|NCT01211535|ACTIVE_COMPARATOR|ReNu Biotrue|ReNu Biotrue multipurpose solution used with study contact lenses on a daily wear basis for 14 days
62435813|NCT00544557||Patients with Ankylosing Spondylitis|
62435814|NCT00732329|EXPERIMENTAL|A|"optimized home based occupational therapy including:~* diagnostic assessment~* patient-centered definition of targets involving the care giver~* occupational therapy"
62435815|NCT00732329|NO_INTERVENTION|B|treatment according to guidelines of German Society for Psychiatry, Psychotherapy and Nervous Diseases (DGPPN) and German Society of Neurology (DGN) without optimized occupational therapy
62435816|NCT00204750|ACTIVE_COMPARATOR|1|Bougie dilation
62602186|NCT05137535||Children diagnosed with Covid-19|Pediatric patients enrolled by the family pediatricians participating in this study, affected by Covid-19 disease whose diagnosis was confirmed by SARS-Cov-2 molecular test
62602187|NCT01825174|ACTIVE_COMPARATOR|Non-overweight children in ball games program|twice a week different ball games 90min
62823601|NCT06589609|EXPERIMENTAL|Intervention|FlubHPVE6E7
62823602|NCT06588439|EXPERIMENTAL|Cognitive-motor training group|Participants receive 16 sessions of cognitive-motor training.
62245527|NCT02595021|EXPERIMENTAL|Total or Subtotal Colectomy|all patients who underwent total colectomy(removal of the large intestine from ileum to the rectum. After it is removed, the end of the small intestine is sewn to the rectum) or subtotal colectomy(removal of transverse colon, descending colon, sigmoid colon to the rectum. After it is removed, the end of the ascending colon is sewn to the rectum)as part of optimal cytoreductive surgery
62245528|NCT02595021|ACTIVE_COMPARATOR|Other Bowel Resection|all patients who underwent partial intestinal resection as part of optimal cytoreductive surgery
62245529|NCT00096668|EXPERIMENTAL|TOCOSOL Paclitaxel|TOCOSOL Paclitaxel administered weekly at 120mg/mm2
62245530|NCT02564107|EXPERIMENTAL|Ibandronate|Female participants with metastatic bone disease secondary to breast cancer will receive ibandronate for a period of 25 weeks.
62245531|NCT05033665|ACTIVE_COMPARATOR|Euhydrated|Afternoon urine osmolality \< 800 mmol/kg or urine specific gravity \< 1.020.
62435817|NCT00204750|EXPERIMENTAL|2|Needle-knife incision
62435818|NCT03294161|EXPERIMENTAL|Immucillin DI4G|Meglumine Antimoniate by intravenous route at 20mg/kg/day during 20 days + Immucillin DI4G 2% by topical use once a day at the ulcer for 20 days .
62823603|NCT06588439|ACTIVE_COMPARATOR|Control group|Participants receive 16 sessions of conventional physiotherapy.
62823604|NCT05372757|EXPERIMENTAL|Partial Heart Transplantation Arm|
62823605|NCT06513026|ACTIVE_COMPARATOR|Lactose-Containing Milk|Participants will be randomized to lactose-containing milk in strata of age (\<60, ≥60) and sex (female, male). Within each age and sex stratum, 10 participants will be randomized into two intervention groups in a 1:1 ratio
62435819|NCT03294161|ACTIVE_COMPARATOR|Meglumine Antimoniate|Meglumine Antimoniate by intravenous route at 20mg/kg/day during 20 days + placebo for topical use once a day at the ulcer for 20 days.
62435820|NCT04861896|EXPERIMENTAL|"My Guide (psychoeducation & self management program)"|Smartphone-based program plus standard clinical care.
62245532|NCT05033665|EXPERIMENTAL|Underhydrated|Afternoon urine osmolality ≥ 800 mmol/kg or urine specific gravity ≥ 1.020.
62245533|NCT05835089||children and adolescents with chronic kidney diseases|The serum level of LH, FSH, prolactin, Testosterone (in boys), estradiol (in girls) and Kisspeptin levels will be measured for all the study participants.
62245534|NCT05835089||control group of patients|The serum level of LH, FSH, prolactin, Testosterone (in boys), estradiol (in girls) and Kisspeptin levels will be measured for all the study participants.
62823606|NCT06513026|ACTIVE_COMPARATOR|Lactose-Free Milk|Participants will be randomized to lactose-free milk in strata of age (\<60, ≥60) and sex (female, male). Within each age and sex stratum, 10 participants will be randomized into two intervention groups in a 1:1 ratio
62245535|NCT06734156||Colorectal Cancer (CRC)|Participants with a confirmed CRC diagnosis, stratified by age: 40-49, 50-59, 60-64, 65-69, and 70-74 years.
62245536|NCT00051285|EXPERIMENTAL|Enoximone|
62245537|NCT00051285|PLACEBO_COMPARATOR|Placebo|
62245538|NCT04749342|EXPERIMENTAL|Complete Decongestive Therapy|Complete decongestive therapy (CDT) is also known as complex decongestive therapy. It involves a two-stage treatment protocol. The first stage consists of skin care, manual lymph drainage, exercises and compression with multi-layered bandages. The second stage aims to optimize and conserve the volume reduction obtained in stage one. This is achieved by using a low-stretch elastic garment in combination with skin care and exercises
62245539|NCT04749342|EXPERIMENTAL|Compression Bandaging|External compression is the mainstay of management for all stages of lymphedema. The efficacy of compression therapy alone, or combined with MLD, has been supported by randomized clinical trials
62245540|NCT02699957||Atrial Fibrillation|Those patients with the condition of atrial fibrillation.
62823607|NCT02963246|EXPERIMENTAL|Mindfulness group|Mindfulness intervention (12 months). Mindfulness based Cognitive Therapy is an evidence-based psychological program designed to help manage depressive and stress symptoms.
62823608|NCT02963246|NO_INTERVENTION|Control Group|Treatment-as-usual control
62823609|NCT05750823|EXPERIMENTAL|Ruxolitinib Cream|Participants with non-segmental vitiligo with genital involvement will receive ruxolitinib 1.5% cream BID for up to 48 weeks
62042709|NCT04437251|EXPERIMENTAL|Effects of brain stimulation on functional improvements|"To determine the effect of brain stimulation (tDCS) on functional improvements in stroke survivors. Specifically, the investigators will compare stepping reaction time, cortical neuronal activity, peripheral nerve activity, and walking function in the stroke survivors before and after tDCS, and also compared these findings with results from healthy adults. The investigators will answer the question: Do stroke survivors shorten stepping reaction time and improve leg muscle activation and gait performance after tDCS, and these improvements are at a similar rate as compared to data collected from healthy young and older adults?"
62042710|NCT04437251|SHAM_COMPARATOR|Effects of brain stimulation combined with stepping training|After enrolling to the study, participants with chronic stroke will be randomly assigned to one of two groups: anodal tDCS or sham tDCS groups. All subjects will then undergo a total of twelve training sessions over four weeks in which subjects will learn a novel visuomotor stepping task immediately after visuomotor learning training while 20-minute tDCS (anodal or sham stimulation) is delivered over the leg area of primary motor cortex.The investigators will measure changes in brain neuronal activity, peripheral nerve activity, and walking performance before and after a 12-session training program, and will follow up one week later.
62042711|NCT05678764||Conversational Information Collection Tool Referrals|These are patients who refer to talk therapy using the novel information collection tool.
62042712|NCT05678764||Other Referrals|These are patients who refer to talk therapy using other referral methods.
62042713|NCT02262533|EXPERIMENTAL|Treatment A: Apixaban|Apixaban tablet by mouth on specified day
62042714|NCT02262533|EXPERIMENTAL|Treatment B: Atenolol|Atenolol tablet by mouth on specified day
62823610|NCT03768492|EXPERIMENTAL|Caffeine Based Cream|caffeine based cream during and for 4 weeks following radiation
62042715|NCT02262533|EXPERIMENTAL|Treatment C: Apixaban and Atenolol|Apixaban and Atenolol tablets by mouth on specified day
62823611|NCT03768492|PLACEBO_COMPARATOR|Placebo|placebo cream during and for 4 weeks following radiation
62245541|NCT05810831|EXPERIMENTAL|Massage with post isometric relaxation exercises|
62435821|NCT05692921|EXPERIMENTAL|Remote Home Monitoring (RHM)|Remote Home Monitoring Platform (RHM): will be utilized to help tailor education and support for the patient after they have been discharged from the hospital. The platform will provide access to and delivery of health related education and information for continued self-care within the community. The platform will be used to evaluate post discharge symptoms and for health care providers to access the need for continued direct patient care and education through virtual processes.
62042716|NCT03907995|EXPERIMENTAL|Cognitive Behavioral Therapy|The form of treatment will involve 6 group sessions every two weeks about an hour each. Sessions consist of teaching a different coping technique in each session to help cope with disaster or other events.
62042717|NCT01073423|EXPERIMENTAL|Yoga|
62245542|NCT05810831|EXPERIMENTAL|Massage|
62245543|NCT04925986|EXPERIMENTAL|Group 1A: PD-L1 1-49%, Main Study Population|Participants with PD-L1 Tumor Proportion Score (TPS) 1-49% receive Pembrolizumab 200mg intravenous (IV) every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily, beginning on cycle 1 day 1 (C1D1).
62245544|NCT04925986|EXPERIMENTAL|Group 1B: PD-L1 1-49%, Pembrolizumab run-in population|Participants with PD-L1 Tumor Proportion Score (TPS) 1-49% receive Pembrolizumab 200mg intravenous (IV) for one dose alone, beginning on cycle 1 day 1 (C1D1). On Cycle 2 Day 1 (C2D1), participants receive Pembrolizumab 200mg intravenous (IV) once every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily.
62245545|NCT04925986|EXPERIMENTAL|Group 2A: PD-L1 ≥ 50%, Main Study Population|Participants with PD-L1 Tumor Proportion Score (TPS) ≥ 50% receive Pembrolizumab 200mg intravenous (IV) every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily, beginning on cycle 1 day 1 (C1D1).
62245546|NCT04925986|EXPERIMENTAL|Group 2B: PD-L1 ≥ 50%, Pembrolizumab run-in population|Participants with PD-L1 Tumor Proportion Score (TPS) ≥ 50% receive Pembrolizumab 200mg intravenous (IV) for one dose alone, beginning on cycle 1 day 1 (C1D1). On Cycle 2 Day 1 (C2D1), participants receive Pembrolizumab 200mg intravenous (IV) once every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily.
62602188|NCT01825174|EXPERIMENTAL|Overweight children in nutrition counseling program|9 units of 90min each of nutrition counseling
62602189|NCT01825174|PLACEBO_COMPARATOR|Control group overweight children|No intervention during six months
62602190|NCT01825174|EXPERIMENTAL|Overweight children in ball games program|twice a week different ball games 90min
62602191|NCT01825174|EXPERIMENTAL|Overweight children in ball games and nutrition counseling|twice a week different ball games 90min and 9 units of 90min each of nutrition counseling
62602192|NCT01825174|PLACEBO_COMPARATOR|Non-overweight control (no intervention)|
62602193|NCT00150124|EXPERIMENTAL|block-replacement therapy|BRT regimen until 3 months after 131I therapy
62849276|NCT03993067|EXPERIMENTAL|Hemopatch|Hemopatch on cut surface
62823612|NCT05005429|EXPERIMENTAL|Experimental: Bintrafusp alfa (M7824)|"Bintrafusp alfa (M7824): 1200mg, over 60 minutes IV infusion The treatment will start within 1-5 days from enrollment. The treatment will be administered at day 1 of 14-day intervals .~Treatment will be administered until unacceptable toxicity, loss of clinical benefit, disease progression or completion of 2 years of therapy. If the patient has benefit after 2 years, the trial chair and the sponsor must be consulted to evaluate how to continue with the treatment."
62245547|NCT00908583|EXPERIMENTAL|Phase 1, two stages|Patients will receive 1 dose of rituximab, 4 doses of bortezomib and plasmapheresis. Rituximab will be given at a dose of 375 mg/m2 on day 32. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 32, 35, 39, 42. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
62823613|NCT06590701|EXPERIMENTAL|Early dart throwing motion|From the 2nd postoperative week, the 'Dart-Throwing Motion' is started, from radial extension to ulnar flexion.
62245548|NCT00908583|EXPERIMENTAL|Phase 2, two stages|Patients will receive 1 dose of rituximab, 4 doses of bortezomib and plasmapheresis. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 32, 35, 39, 42. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
62435822|NCT05692921|ACTIVE_COMPARATOR|Rapid Response Nursing (RRN)|"Rapid Response Nursing Team (RRN): The RRN will help clients/patients to:~* Understand their current health conditions, treatments, how to manage symptoms and when/who to ask for help; Specifically; they will~* Help clients to understand their hospital discharge plan;~* Support patients during their recovery at home;~* Reinforce and contribute to in-hospital education about heath health and recovering safely at home;~* Review medications to help clients understand the purpose, side effects and how to take prescribed medications correctly, including assisting clients with getting prescriptions filled;~* Connect with their Home Clinic, ensuring everyone has the necessary information for follow-up care;~* Connect clients with a Home Clinic if they do not have one; and~* Access appropriate home supports to help clients remain at home safely for as long as possible."
62435823|NCT05692921|NO_INTERVENTION|Registry|"Registry Arm:~Patients who fit the criteria for study inclusion and choose not to participate in the main study will be provided with an opportunity to consent to the registry arm of the study. The registry arm of the study is an opportunity to establish a standard of care group free from research bias. Patients who enroll in the registry will only need to complete a short questionnaire before they are discharged home which will take approximately 5 minutes. Additionally, research staff will also complete a medical chart review to identify specific medical information related to their demographics, cardiac procedure, hospital stay, recovery, and to identify any re-admissions to hospital that may have occurred after the patient has been discharged home."
62823614|NCT06590701|ACTIVE_COMPARATOR|Mobilisation in anatomical planes|From the 2nd postoperative week, movements are started in the anatomical plane of the hand (standard rehabilitation)
62435824|NCT02278549||Asymptomatic|Individuals between 30 and 50 years old that have had no episode of low back pain in the last two years requiring medical attention
62435825|NCT02278549||Patients with Low Back Pain|Individuals between 30 and 50 years old that present with non-specific low back pain for more than 3 months
62435826|NCT04837625||Myasthenic Crisis Cohort|
62435827|NCT01792258||critical ill patients|The investigator will enroll all the critical ill patients undergoing percutaneous tracheostomy performed in ICU
62435828|NCT06152159||The second parent of a child|The second parent of a child born since minimum 3 months and maximum 6 months.
62435829|NCT05001490|EXPERIMENTAL|Experimental group|
62435830|NCT05001490|NO_INTERVENTION|Control group|
62435831|NCT03779399||Patient with benign ovarian tumor|25 patients with benign ovarian tumor (cystadenoma) were admitted to IInd Department of Gynecology, Lublin Medical University, Lublin, Poland.
62435832|NCT03779399||Patient with borderline tumor|11 women with borderline ovarian tumor were admitted to IInd Department of Gynecology
62435833|NCT03779399||Patient with ovarian cancer|24 women with ovarian cancer were admitted to IInd Department of Gynecology
62435834|NCT03779399||Patient without ovarian pathology|20 patient with unexpleined infertility were admitted to IInd Department of Gynecology
62435835|NCT02555709|PLACEBO_COMPARATOR|Placebo 1|healthy volunteers
62435836|NCT02555709|EXPERIMENTAL|VTP-43742 Dose 1|healthy volunteers
62435837|NCT02555709|EXPERIMENTAL|VTP-43742 Dose 2|healthy volunteers
62435838|NCT02555709|EXPERIMENTAL|VTP-43742 Dose 3|healthy volunteers
62042718|NCT01073423|ACTIVE_COMPARATOR|Music Therapy|
62435839|NCT02555709|EXPERIMENTAL|VTP-43742 Dose 4|healthy volunteers
62435840|NCT02555709|EXPERIMENTAL|VTP-43742 Dose 5|healthy volunteers
62435841|NCT02555709|EXPERIMENTAL|VTP-43742 Dose 6|healthy volunteers
62435842|NCT02555709|EXPERIMENTAL|VTP-43742 Dose 7|healthy volunteers
62435843|NCT02555709|PLACEBO_COMPARATOR|Placebo 2|psoriatic patients
62435844|NCT02555709|EXPERIMENTAL|VTP-43742 Dose 8|psoriatic patients
62435845|NCT02555709|EXPERIMENTAL|VTP-43742 Dose 9|psoriatic patients
62435846|NCT02555709|EXPERIMENTAL|VTP-43742 Dose 10|psoriatic patients
62435847|NCT02555709|EXPERIMENTAL|VTP-43742 Dose 11|psoriatic patients
62435848|NCT02501109|EXPERIMENTAL|Group A|Healthy volunteers will receive Aripiprazole Oral Soluble Film(OSF) 10mg orally a single of dose within 28 days with water.
62042719|NCT03583749||amoxicillin-clavulanate|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
62823615|NCT06587880|ACTIVE_COMPARATOR|Bone Bioactive Liquid|Bone bioactive liquid (BBL) is a saline solution used as a mouthwash that contains calcium chloride (CaCl2) and magnesium dichloride hexahydrate (MgCl2-6H2O) with a net negative charge.
62823616|NCT06587880|ACTIVE_COMPARATOR|Chlorhexidine Gluconate|It is a strong bisbiguanide base, with cationic structure at physiological pH (positively charged), and has a broad-spectrum antibacterial activity that works against Gram-positive and Gram- negative bacteria and certain mycetes.
62823617|NCT06587880|ACTIVE_COMPARATOR|Warm Saline Mouth Rinse|Prescribing WSMR as a prophylactic postoperatively is due to the fact that the heat of the solution results in a therapeutic increase in blood flow to the extraction socket.
62823618|NCT06587880|ACTIVE_COMPARATOR|Hyaluronic Acid mouthwash|It is a high molecular weight non-sulphated polysaccharide. It is biocompatible, non-immunogenic, biodegradable, viscoelastic that make it a preferable biomaterial for medical and pharmaceutical applications without adverse events.
62823619|NCT02662673|OTHER|Localized prostate cancer, Focal treatment.|
62823620|NCT04467437|ACTIVE_COMPARATOR|Intensive Training Only|Physical and gait training that targets rehabilitation of walking function.
62823621|NCT04467437|ACTIVE_COMPARATOR|Intensive Training Combined with Spinal Stimulation|Transcutaneous spinal stimulation combined with physical and gait training that targets rehabilitation of walking function.
62823622|NCT01682239|EXPERIMENTAL|RVAP lead|"Pacemaker lead implantation:~Pacemaker leads will be placed in specific predefined RA and RV sites according to randomization. In this arm pacemaker leads will be placed in the RV apex. The successful lead positioning at its target location will be verified by surface ECG and by fluoroscopy."
62042720|NCT03583749||ceftriaxone|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
62435849|NCT02501109|EXPERIMENTAL|Group B|Healthy volunteers will receive Aripiprazole Oral Soluble Film(OSF) 10mg orally a single of dose within 28 days without water.
62435850|NCT02501109|EXPERIMENTAL|Gruop C|Healthy volunteers will receive the reference drug Abilify tab. 10mg orally a single of dose within 28 days with water.
62435851|NCT01470794|EXPERIMENTAL|Single Arm|Toca 511 vector/Toca FC prodrug
62602194|NCT00150124|ACTIVE_COMPARATOR|methimazole|methimazole stopped 8 days before 131I therapy
62823623|NCT01682239|EXPERIMENTAL|RVSP arm|"Pacemaker lead implantation:~Pacemaker leads will be placed in specific predefined RA and RV sites according to randomization. In this arm pacemaker leads will be placed in the RV septum. The successful lead positioning at its target location will be verified by surface ECG and by fluoroscopy."
62823624|NCT03041740|NO_INTERVENTION|Usual Care (Control) Group|Control subjects will be treated as per standard of care for preterm infants with BPD.
62823625|NCT03041740|ACTIVE_COMPARATOR|Perfluorooctylbromide (PFOB) Group|Subjects in the PFOB group will be administered an initial PFOB treatment dose of 2.5 mL/kg and up to a total intra-pulmonary volume of 25 mL/kg for up to 10 days.
62823626|NCT06359158|EXPERIMENTAL|Digital stethoscope use|"The intervention comprises a comprehensive curriculum titled Respiratory Auscultation with Digital Stethoscopes, designed to enhance the proficiency of medical students in diagnosing respiratory disorders through auscultation. The curriculum utilizes advanced digital stethoscope technology, specifically electronic digital stethoscopes, and the Eko auscultation software platform, to facilitate the visualization and analysis of recorded breath sounds, thereby augmenting traditional auscultation training methods."
62823627|NCT06359158|NO_INTERVENTION|Traditional stethoscope use|The curriculum utilizes a traditional stethoscope.
62042721|NCT03583749||piperacillin-tazobactam|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
62042722|NCT02863068|PLACEBO_COMPARATOR|control|patients will receive placebo and standard of care
62042723|NCT02863068|EXPERIMENTAL|topical sodium nitrite|patients will receive 2% topical sodium nitrite cream and standard of care
62042724|NCT03364751|ACTIVE_COMPARATOR|IQOS arm|\~86 patients, switching from cigarette smoking to IQOS use.
62245549|NCT00908583|EXPERIMENTAL|Phase 3, two stages|Patients will receive 1 dose of rituximab and 4 doses of bortezomib. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 23, 26, 30 and 33. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
62823628|NCT04375891|OTHER|Radiotherapy|Radiotherapy alone
62823629|NCT04375891|OTHER|Radiotherapy plus radiofrequency ablation|Radiotherapy plus radiofrequency ablation / vertebral augmentation(Combination therapy)
62823630|NCT02954536|EXPERIMENTAL|Pembrolizumab, trastuzumab,capecitabine/cisplatin|Pembrolizumab 200 mg IV every 3 weeks, trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) IV every 3 weeks with cisplatin IV every 3 weeks with oral capecitabine 2 weeks on/1 week off. Each cycle consists of 21 days. Treatment will be administered on an outpatient basis. In Cycle 1, patients will initiate therapy with trastuzumab 8 mg/kg IV with pembrolizumab 200 mg IV. CT/MRI scan will be performed after the initial 3 weeks (1 cycle) to determine response to pembrolizumab and trastuzumab combination. With subsequent cycles, all patients will begin systemic chemotherapy with the capecitabine/cisplatin regimen in addition to pembrolizumab 200 mg IV with trastuzumab 6 mg/kg maintenance. Patients will receive cisplatin 80 mg/m2 IV on Day 1, and capecitabine 850mg/m2 twice a day on Days 1 through 14, every 3 weeks.
62823631|NCT02610855|ACTIVE_COMPARATOR|Spinal Fusion Surgery|The surgical participants recruited from the pediatric orthopaedic clinic and have severe scoliosis curves requiring posterior spinal fusion. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified before and one year after spinal fusion surgery.
62823632|NCT02610855|ACTIVE_COMPARATOR|Brace Treatment|The bracing participants have scoliosis curves that require treatment with a spinal brace for at least the next year. All braces will have monitors to record hours of brace wear, as is current standard of care. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified before bracing and after one year.
62823633|NCT02610855|OTHER|Control Arm|The control group are participants who do not have scoliosis. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified at baseline and one year after enrollment.
62849277|NCT06421103|EXPERIMENTAL|Micro-dosing Indocyanine Green (ICG)|Multiple dose levels of intravenous Indocyanine Green (ICG) administered intra-operatively. Starting dose will be 10% of standard (for the study institution) and escalated as per protocol.
62245550|NCT00908583|EXPERIMENTAL|Phase 4, single stage|Patients will receive 1 dose of rituximab and 6 doses of bortezomib. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered during the pre-transplant period on days 1, 4, 8, and 11, 14, and 17. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
62435852|NCT01786811|EXPERIMENTAL|Trained Clinicians|Clinicians randomized into this group will receive training in using the Serious Illness Conversation Guide with their patients. Patients of these clinicians will also be in the intervention arm.
62435853|NCT01786811|NO_INTERVENTION|Non-trained Clinicians|Clinicians randomized into this group will not receive training in using the Serious Illness Conversation Guide with their patients. They will provide usual care. Patients of these clinicians will also be in the control arm.
62435854|NCT01786811|NO_INTERVENTION|Non-volunteer Clinicians|These clinicians do not agree to participate in the study. They will continue to provide usual care. Their patients will be invited to participate and be followed.
62435855|NCT00683150||Endothelial Function Test|Patients scheduled to have major abdominal or thoracic surgery.
62435856|NCT02925065|EXPERIMENTAL|Early-start guitar instruction group|A 6 week twice-weekly non-traditional group guitar instruction will be implemented in addition to usual treatment between weeks 1-6 of the study.
62435857|NCT02925065|EXPERIMENTAL|Delayed-start guitar instruction group|A 6 week twice-weekly non-traditional group guitar instruction will be implemented in addition to usual treatment between weeks 8-13 of the study.
62435858|NCT05925322|EXPERIMENTAL|"Engage & Connect Psychotherapy"|"Engage \& Connect is a remotely-delivered psychotherapy, aimed to increase engagement in rewarding social activities and in turn, reduce suicidality. In Engage \& Connect, depressed middle-aged and older adults with suicidal ideation work with a therapist to develop action plans to pursue rewarding social activities of their choice."
62435859|NCT05925322|ACTIVE_COMPARATOR|Symptom Review and Psychoeducation (SRP)|In this intervention, the therapist will review the participant's symptoms and provide literature-based clinical explanations and clarifications about the symptoms, the course, and the causes of depression and aging processes. In SRP, the therapist reviews the depressed individual's symptoms, and level of information on depression, identifies misconceptions, and guides selection of educational material which could benefit the patient.
62435860|NCT01020305|EXPERIMENTAL|Temsirolimus + Bicalutamide|"Temsirolimus 25 mg administered intravenously (IV) once weekly for 12 weeks~Casodex (bicalutamide) administered 50 mg/day orally (PO)"
62435861|NCT01675908|ACTIVE_COMPARATOR|Metal stent|Patients randomized to one cohort will undergo placement of fully covered self expandable metal stents. The rates (%) of stent dysfunction and complications will be evaluated.
62435862|NCT01675908|ACTIVE_COMPARATOR|Plastic Stent|At ERCP, a 10Fr plastic stent will be placed in the bile duct. The rates (%) of stent dysfunction and complications will be evaluated.
62849278|NCT04423198||Target Condition|Subjects presenting to the Emergency Department (ED) or Urgent Care (UC) with a blunt head trauma
62435863|NCT03387410|EXPERIMENTAL|Intravenous IRDye 800BK|Patients undergoing laparoscopic bowel resection \& laparoscopic donor nephrectomy
62435864|NCT00443352|EXPERIMENTAL|Duloxetine|Duloxetine 120mg daily for 12 weeks.
62435865|NCT01512979|EXPERIMENTAL|linagliptin|patients receive linagliptin tablet once daily
62435866|NCT01512979|EXPERIMENTAL|linagliptin plus metformin|patients receive linagliptin tablet once daily and metformin tablets twice daily
62823634|NCT06493552|EXPERIMENTAL|sEphB4-HSA + Pembrolizumab in MIBC|"sEphB4-HSA shall be started at a dose of 10mg/kg using actual body weight and administered IV over 60 minutes on days 1 and 8 of each cycle as outlined under section 7.1.3.~Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. All trial treatments will be administered on an outpatient basis unless the patient has been admitted for another reason and meets all criteria for further therapy.~Pembrolizumab dose, schedule, delays, and discontinuation of therapy shall be determined by the treating physician in accordance with product label(s), standard of care and institutional policies.~Treatment will continue until the prespecified number of cycle of therapy are completed or until progression of disease or unacceptable toxicities where specified by the protocol for specific cohort(s)."
62823635|NCT06493552|ACTIVE_COMPARATOR|Gemcitabine-Cisplatin (GC) or Pembrolizumab Alone in MIBC|Dose modification, delays and discontinuation of therapy shall be determined by the treating physician in accordance with product label(s), standard of care and institutional policies.
62602195|NCT04649918||mild to moderate COVID 19|patients post-acute mild to moderate COVID 19
62602196|NCT04649918||severe to critical COVID 19|patients post-acute severe to critical COVID 19
62245551|NCT00908583|EXPERIMENTAL|Phase 5, single stage|Phase 5 evaluated even greater bortezomib dosing density by eliminating the inter-cycle dosing interval. Phase 5 evaluated eight consecutive doses of bortezomib with one dose of rituximab. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patient will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, 11, 14, 17, 20, and 23. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
62823636|NCT06493552|EXPERIMENTAL|sEphB4-HSA + Pembrolizumab in Naive mUC|"sEphB4-HSA shall be started at a dose of 10mg/kg using actual body weight and administered IV over 60 minutes on days 1 and 8 of each cycle as outlined under section 7.1.3.~Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. All trial treatments will be administered on an outpatient basis unless the patient has been admitted for another reason and meets all criteria for further therapy.~Pembrolizumab dose, schedule, delays, and discontinuation of therapy shall be determined by the treating physician in accordance with product label(s), standard of care and institutional policies.~Treatment will continue until the prespecified number of cycle of therapy are completed or until progression of disease or unacceptable toxicities where specified by the protocol for specific cohort(s)."
62823637|NCT06493552|ACTIVE_COMPARATOR|Enfortumab Vedotin (EV) + Pembrolizumab in Naive mUC|Dose modification, delays and discontinuation of therapy shall be determined by the treating physician in accordance with product label(s), standard of care and institutional policies.
62849279|NCT04423198||Trauma Control|Subjects presenting to the ED or UC requiring an Xray but do not have a head trauma
62435867|NCT04800055|EXPERIMENTAL|ATSB + VC intervention|Arm 1 will receive ATSBs for up to two years.
62245552|NCT05326425|EXPERIMENTAL|lazertinib(YH25448)|lazertinib 240mg, once a day, oral, before disease progression
62602197|NCT05631522|EXPERIMENTAL|foot reflexology group|Patients who will receive foot reflexology before and throughout the MCDR procedure.
62602198|NCT05631522|NO_INTERVENTION|control group|Patients who will receive the routine ICU care during the MCDR procedure.
62602199|NCT03785613|EXPERIMENTAL|Test Product T1: Buprenorphine patch (9 mg)|"Buprenorphine transdermal patch formulation, containing 9 milligrams buprenorphine in an active surface area of 25 square centimeters. Single application of transdermal patch during 96 hours, on skin in the midclavicular line directly under the clavicle.~Matching placebo patch to T1: simultaneous application for 96 hours on the upper back."
62602200|NCT03785613|EXPERIMENTAL|Test Product T2: Buprenorphine patch (3.8 mg)|"Buprenorphine transdermal patch formulation, containing 3.8 milligrams buprenorphine in an active surface area of 10 square centimeters. Single application of patch during 96 hours, on skin in the midclavicular line directly under the clavicle.~Matching placebo patch to T2: simultaneous application for 96 hours on the upper back."
62602201|NCT03785613|ACTIVE_COMPARATOR|Reference Product R: Transtec patch (20 mg)|"Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters. Single application of transdermal patch during 96 hours, on skin in the midclavicular line directly under the clavicle.~Matching placebo patch to R: simultaneous application for 96 hours on the upper back."
62602202|NCT06623578|EXPERIMENTAL|robotic-assisted surgery|
62602203|NCT06623578|OTHER|Open Surgery|conventional treatment
62245553|NCT06230653||MMG on dominant arm|Mechanomyography-device will be examined on the dominant arm.
62245554|NCT06230653||MMG on non-dominant arm|Mechanomyography-device will be examined on the non-dominant arm.
62245555|NCT04885036|ACTIVE_COMPARATOR|Treatment As Usual|This group will receive treatment as usual within the family unit
62435868|NCT04800055|NO_INTERVENTION|VC only|Arm 2 will receive the standard of care of universal vector control coverage.
62435869|NCT03790085|EXPERIMENTAL|Risperidone|It can be used after schizophrenia is diagnosed. Risperidone affects prolactin and may affect menstruation in young women, so we will try not to use it in such patients. Patients were randomized to a single Risperidone control trial for 8 weeks to evaluate the clinical efficacy of the patients. Risperidone routine daily 2-6 mg, up to 8 mg, can be taken orally twice a day.
62435870|NCT03790085|EXPERIMENTAL|Olanzapine|It can be used after schizophrenia is diagnosed. Olanzapine is not generally used in patients with diabetes and hyperlipidemia. Patients were randomized to a single Olanzapine control trial for 8 weeks to evaluate the clinical efficacy of the patients. Olanzapine is available once or twice a day, starting at 5 mg daily and up to 20 mg daily.
62823638|NCT05846243|EXPERIMENTAL|Group 1 (The first stage): VAC∆6 (10⁷ PFU), Live Smallpox Vaccine (2 months after the vaccination)|"15 volunteers aged 18 to 60 who met the inclusion criteria and who received a single intradermal VAC∆6 dose of 1x10⁷ PFU/0.2ml. Live smallpox vaccine was administered by scarification 2 months after the vaccination.~(The first stage is an open comparative study of the safety, reactogenicity, immunological activity and protective efficacy of VAC∆6 vaccine in two parallel groups)."
62245556|NCT04885036|EXPERIMENTAL|EFST intervention|This group will receive an EFST stand alone treatment consisting of a two days EFST course and 6 individual parental guidance sessions
62245557|NCT00648804|EXPERIMENTAL|1|Ondansetron Orally Disintegrating Tablets 8 mg
62245558|NCT00648804|ACTIVE_COMPARATOR|2|Zofran ODT® Tablets 8 mg
62623399|NCT05680662|EXPERIMENTAL|no adjuvant thearpy for 100 cases of breast cancer breast for this group ( controlled group )|this arm ( 100 cases controlled group not taken adjuvant therapy only was taken the regular chemotherapy as prescription
62245559|NCT04475900||Healthy|Healthy eyes without any signs of ocular diseases
62245560|NCT04475900||Ectasia|ectasia suspects early, moderate and advanced keratoconus
62245561|NCT04475900||Glaucoma|Normal Tension glaucoma Primary Open-Angle Glaucoma
62245562|NCT04199234|EXPERIMENTAL|experimental group|60 mg Encapsulated Iron
62623400|NCT05823103|ACTIVE_COMPARATOR|Hysteroscopic Metroplasty using ESHRE ASRM Classification|
62823639|NCT05846243|EXPERIMENTAL|Group 2 (The first stage): VAC∆6 (10⁶ PFU), Live Smallpox Vaccine (1 month after the vaccination)|"15 volunteers aged 18 to 60 who met the inclusion criteria and who received two intradermal VAC∆6 doses of 10⁶ PFU/0.2ml (given 28 days apart). Live smallpox vaccine was administered by scarification one month after the full vaccination series.~(The first stage is an open comparative study of the safety, reactogenicity, immunological activity and protective efficacy of VAC∆6 vaccine in two parallel groups)."
62823640|NCT05846243|EXPERIMENTAL|Group 3 (The second stage): two intradermal VAC∆6 (10⁶ PFU/0.2 ml) given 28 days apart.|"76 volunteers aged 18 to 60 who met the inclusion criteria and who received two intradermal VAC∆6 doses of 10⁶ PFU/0.2 ml (given 28 days apart).~(The second stage is a Double-blind, Comparative, Randomized, Placebo-controlled study on Immunogenicity, Reactogenicity, and Safety of the VAC∆6 Vaccine in Parallel Groups)."
62823641|NCT05846243|PLACEBO_COMPARATOR|Group 4 (The second stage): two intradermal placebo doses of 0.2 ml (given 28 days apart).|"76 volunteers aged 18 to 60 who met the inclusion criteria and who received two intradermal placebo doses of 0.2 ml (given 28 days apart).~(The second stage is a Double-blind, Comparative, Randomized, Placebo-controlled study on Immunogenicity, Reactogenicity, and Safety of the VAC∆6 Vaccine in Parallel Groups)."
62823642|NCT05846243|EXPERIMENTAL|Group 5 (The second stage) in the FGBUZ MSCH-163: a single intradermal VAC∆6 (10⁷ PFU/0.2 ml).|"60 volunteers aged 18 to 60 who met the inclusion criteria and who received a single intradermal VAC∆6 dose of 10⁷ PFU/0.2 ml.~(The second stage is a Double-blind, Comparative, Randomized, Placebo-controlled study on Immunogenicity, Reactogenicity, and Safety of the VAC∆6 Vaccine in Parallel Groups)."
62823643|NCT05846243|PLACEBO_COMPARATOR|Group 6 (The second stage) in the FGBUZ MSCH-163: a single intradermal placebo dose of 0.2 ml.|"60 volunteers aged 18 to 60 who met the inclusion criteria and who received a single intradermal placebo dose of 0.2 ml.~(The second stage is a Double-blind, Comparative, Randomized, Placebo-controlled study on Immunogenicity, Reactogenicity, and Safety of the VAC∆6 Vaccine in Parallel Groups)."
62823644|NCT05846243|EXPERIMENTAL|Group 7 (The second stage) in the Hospital No. 1: a single intradermal VAC∆6 (10⁷ PFU/0.2 ml).|"16 volunteers aged 18 to 60 who met the inclusion criteria and who received a single intradermal VAC∆6 dose of 10⁷ PFU/0.2 ml.~(The second stage is a Double-blind, Comparative, Randomized, Placebo-controlled study on Immunogenicity, Reactogenicity, and Safety of the VAC∆6 Vaccine in Parallel Groups)."
62823645|NCT05846243|PLACEBO_COMPARATOR|Group 8 (The second stage): in the Hospital No. 1: a single intradermal placebo dose of 0.2 ml.|"16 volunteers aged 18 to 60 who met the inclusion criteria and who received a single intradermal placebo dose of 0.2 ml.~(The second stage is a Double-blind, Comparative, Randomized, Placebo-controlled study on Immunogenicity, Reactogenicity, and Safety of the VAC∆6 Vaccine in Parallel Groups)."
62823646|NCT04172181||UCBT-SCID-Case|SCID patients who underwent cord blood stem cell transplantation.The only curative therapy for SCID is allogeneic hematopoietic stem cell transplantation.
62823647|NCT00456846|EXPERIMENTAL|ABI-007|100 mg/m\^2 ABI-007 was administered by intravenous (IV) infusion over 30 minutes weekly for 3 weeks followed by 1 week rest. Therapy continued until disease progression or unacceptable toxicity.
62823648|NCT06591676|EXPERIMENTAL|administration of DAS in samples of outpatients|
62245563|NCT04199234|ACTIVE_COMPARATOR|control group|60 mg Iron sulphate
62245564|NCT06495242|ACTIVE_COMPARATOR|Direct pulp capping|After caries excavation and pulp exposure, the cavity is disinfected . the capping material is applied and the tooth is restored.
62245565|NCT06495242|ACTIVE_COMPARATOR|Partial pulpotomy|After caries excavation and pulp exposure, 2-3 mm of the exposed pulp are cut . The capping material is applied and the tooth is restored.
62245566|NCT04268043|EXPERIMENTAL|flexible laryngeal airway|
62245567|NCT04268043|EXPERIMENTAL|proseal laryngeal mask airway|
62245568|NCT01870557||Diabetes Mellitus type 1|n=100
62245569|NCT01870557||Diabetes Mellitus type 2|n=100
62245570|NCT03670706|ACTIVE_COMPARATOR|Group A|Exercise training, then crossover to analgesic optimisation
62823649|NCT06591676|EXPERIMENTAL|administration of DAS in samples of students|
62823650|NCT04160117|EXPERIMENTAL|Intervention|Colchicine 0.6 mg p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
62823651|NCT04160117|PLACEBO_COMPARATOR|Control|Matching placebo p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
62245571|NCT03670706|ACTIVE_COMPARATOR|Group B|Analgesic optimisation, then crossover to exercise training
62245572|NCT03670706|NO_INTERVENTION|Group C|Control group
62245573|NCT05206591|EXPERIMENTAL|Secukinumab|Secukinumab 300 mg s.c
62245574|NCT05206591|PLACEBO_COMPARATOR|Placebo|Placebo s.c.
62245575|NCT06723756|EXPERIMENTAL|BGF MDI HFO|Participants will receive single doses (2 inhalations as a single dose) of test formulation BGF MDI HFO
62823652|NCT06379659|ACTIVE_COMPARATOR|Growth hormone|
62823653|NCT06379659|PLACEBO_COMPARATOR|Placebo|
62823654|NCT04005846|OTHER|Active tDCS first / Sham tDCS second|Receiving active tDCS during the first visit followed by sham tDCS on the next visit
62823655|NCT04005846|OTHER|Sham tDCS first / Active tDCS second|Receiving sham tDCS during the first visit followed by active tDCS on the next visit
62823656|NCT00278343|EXPERIMENTAL|Treatment (cediranib maleate)|Patients receive cediranib maleate PO QD every 4 weeks in the absence of disease progression or unacceptable toxicity.
62823657|NCT06593847|OTHER|Positive or Negative Mood Induction via film clips|VR exposure is the only intervention, but the VR intervention is conducted following either positive or negative mood induction.
62823658|NCT04625946|EXPERIMENTAL|Metformin|Standard of care ablation with recommendations for lifestyle modification and metformin.
62823659|NCT04625946|OTHER|Standard of care|Standard of care ablation with recommendations for lifestyle modification.
62823660|NCT06653933||COPD patients with invasive mechanical ventilation in ICU|All patients with COPD who received invasive mechanical ventilation for more than 24 hours in the intensive care unit.
62823661|NCT06595550|EXPERIMENTAL|whey protein|whey protein with suhoor
62245576|NCT06723756|ACTIVE_COMPARATOR|BGF MDI HFA|Participants will receive single doses (2 inhalations as a single dose) of reference formulation BGF MDI HFA
62245577|NCT02681250|EXPERIMENTAL|Titanium-zirconium|Patients receiving titanium-zirconium implants
62245578|NCT02681250|ACTIVE_COMPARATOR|Titanium|Patients receiving titanium implants
62245579|NCT04411953|ACTIVE_COMPARATOR|Reference Product (Treatment A)|"Subjects received Haloperidol Tablets 2 mg Reference Product (Mylan Pharmaceuticals Inc.). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.~A high-fat, high-calorie breakfast was served 30 minute before administration of the IMP."
62435871|NCT03790085|EXPERIMENTAL|Aripiprazole|It can be used after schizophrenia is diagnosed. Aripiprazole has no specific contraindications. Patients were randomized to a single Aripiprazole control trial for 8 weeks to evaluate the clinical efficacy of the patients. Aripiprazole is taken orally once a day, starting at 10 mg daily and up to 30 mg daily.
62623401|NCT05823103|ACTIVE_COMPARATOR|Hysteroscopic Metroplasty using Shawki Septum Scoring System|
62823662|NCT06595550|PLACEBO_COMPARATOR|no whey protein|no whey protein with suhoor
62823663|NCT01684917|EXPERIMENTAL|Life style advice|reduce energy intake by 20% less than estimated energy expenditure.
62823664|NCT01684917|ACTIVE_COMPARATOR|UK background diet|Diet where energy intake will be matched with estimated energy expenditure.
62823665|NCT01684917|OTHER|Metabolomic inquiry|This inquiry took place prior to the randomized controlled trial and include 50 volunteers who will then be asked to volunteers of the weight loss study. Were randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option.
62823666|NCT04115761|OTHER|Investigational Group|ADCV01 is autologous dendritic cells (DCs) stimulated by the patients' own tumor antigens. The total 10 doses (1 mL/dose; 2±0.5 × 10\^7 cell/dose) of ADCV01 will be administered to patients assigned to the investigational group. The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes (half of volume about 0.5 mL of ADCV01) once weekly for the first 4 doses, and the following 2 treatments will be administered bi-weekly. The last 4 treatments will be administered every 4 weeks.
62823667|NCT04115761|OTHER|Control Group|the conventional treatment (RT and chemotherapy) will be given after tumor resection, followed by subsequent evaluations by an approximately 8-week interval.
62849280|NCT04423198||Healthy Control|Subjects that are healthy and not taking any prescription medications
62042725|NCT03364751|ACTIVE_COMPARATOR|Cigarette arm|\~86 patients, continuing cigarette smoking.
62849281|NCT02664571|OTHER|ACA with isolated hemosiderosis|"This group is composed of patients with amyloid cerebral angiopathy (ACA) with isolated hemosiderosis.~Intervention: Pet scan with FBB~Intervention: MRI scan~Intervention: APO E genotyping"
62823668|NCT03756519|EXPERIMENTAL|Exercise|Participants in the exercise intervention arm will receive the usual care protocol plus a standardized, evidence informed exercise intervention provided by trained physiotherapy students. The exercise intervention will begin with a brief assessment to rule out contraindications to exercise and to identify any directional preferences (e.g. pain with lumbar flexion and relief with extension). The PT will then be taught four standardized exercises: the pelvic tilt exercise, a rotational exercise, a tailored graded walking program taking into account the current abilities of the patient, and an exercise based on the directional preference of the individual. These will be re-enforced with a handout including the rationale, instructions and dosage recommendations for the exercises.
62823669|NCT03756519|ACTIVE_COMPARATOR|Usual care|Our usual care protocol was developed based on 30 responses to an 18 item survey of Queen's Department of Emergency Medicine physicians. Three themes emerged as interventions most commonly used. Each of these strategies has evidence for small, but positive treatment effects and low risk of harms: 1) advice to stay active and engaged in usual activities, 2) use of ice or heat to manage pain, and 3) recommendation for analgesia using NSAIDs if needed and appropriate.
62823670|NCT05809934|EXPERIMENTAL|AZD2693 dose 1|Participants will receive AZD2693 dose 1
62823671|NCT05809934|EXPERIMENTAL|AZD2693 dose 2|Participants will receive AZD2693 dose 2
62042726|NCT06732843||Normo-ovarian response patients who undergo an IVF treatment including PGT-A|"Patients will follow the stimulation protocol outlined below:~Initial doses will be based on ovarian reserve parameters, with the starting dosage identical for both stimulation cycles (Gonal-F® or hMG):~Dose adjustments may be made starting from day 6 Antagonist suppression will be fixed from day 5 onwards Final oocyte maturation will be triggered with a dual trigger: 2,500 IU urinary hCG and 0.3 mg Decapeptyl."
62823672|NCT05809934|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive placebo
62823673|NCT06061809|EXPERIMENTAL|Pilot Combination Therapy|Participants will receive N-803 1 mg subcutaneously (SC), PD-L1 t-haNK (\~2 × 10\^9 cells/infusion) intravenously (IV), and Bevacizumab (10 mg/kg IV) combination therapy during 28-day cycles on days 1 and 15 of each cycle. Maximum treatment period is 76 weeks, 19 cycles.
62823674|NCT05665231|EXPERIMENTAL|V3 Mis® implant|Implant with coronal triangular neck
62823675|NCT05665231|ACTIVE_COMPARATOR|C1 MIS® implant|Implant with coronal cylindrical neck (regular)
62823676|NCT04245150||Ductal Carcinoma In Situ (DCIS) or invasive breast cancer|Participants with DCIS or invasive breast cancer
62823677|NCT03603782|EXPERIMENTAL|1|
62435872|NCT03244397|EXPERIMENTAL|PT group|"The participants assigned to this group will receive 16 sessions of physical therapy. Each session will last 45/50 minutes, 2 sessions a week for 8 weeks.~A directly pelvic floor muscle(PFM) training protocol will be applied. Throw vaginal palpation and in lithotomy position, participants will perform PFM exercises per the treatment proposed by the PERFECT scheme. Biofeedback exercises will be also performed in lithotomy position. Hypopressive exercises which are also home daily from the eighth session. Plus educational strategy."
62245580|NCT04411953|EXPERIMENTAL|Test Product (Treatment B)|"Subjects received Haloperidol Tablets 2 mg Test Product (Cycle Pharmaceuticals Ltd). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.~A high-fat, high-calorie breakfast was served 30 minute before administration of the IMP."
62245581|NCT01610687|EXPERIMENTAL|GW-1000-02|Active treatment
62435873|NCT03244397|ACTIVE_COMPARATOR|Control group|Only educational strategy 1 session per week for 6 weeks (every session will last 40/45 minutes). The educational strategy will consist of instruction of printed materials and dimensional anatomical models about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, weight lifting, high impact sports, constipation, smoking, or drinking too much caffeine. They will be also instructed in toilet habits, and will be taught to use the knack maneuver before and during increases of intra-abdominal pressure.
62823678|NCT03603782|EXPERIMENTAL|2|
62823679|NCT03603782|EXPERIMENTAL|3|
62823680|NCT03603782|EXPERIMENTAL|4|
62823681|NCT02877108||Adasuve|These patients will receive Adasuve for treatment of agitation.
62042727|NCT02199028|EXPERIMENTAL|Hyaluronidase, Then Control|"Participants assigned to active treatment arm (Hylenex) for weeks 1 and 3.~On weeks 1 and 3 (Hyaluronidase weeks) subjects injected 1 milliliter (ml) Hyaluronidase (150 units/ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.~On weeks 2 and 4 (control weeks) no Hyaluronidase was administered."
62042728|NCT02199028|EXPERIMENTAL|Control, Then Hyaluronidase|"Participants were first assigned to the control arm. They received active treatment (Hyaluronidase) on weeks 2 and 4.~On weeks 1 and 3 (control weeks) no Hyaluronidase was administered.~On weeks 2 and 4 (Hyaluronidase weeks) subjects injected 1 milliliter (ml) Hyluronidase (150 units/ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear."
62245582|NCT02432313|EXPERIMENTAL|Modified Release Formulation x (MRx)|Various formulations of Modified Release anatabine citrate tablets
62435874|NCT04697511|EXPERIMENTAL|Midazolam and/or M2951|
62435875|NCT01588106||Test group|patients using CONTOUR Next USB
62042729|NCT03339323|NO_INTERVENTION|Control|Standard rehabilitation procedure
62042730|NCT03339323|EXPERIMENTAL|Exercise|Aerobic exercise combined with resistance training; Concentric resistance training; Eccentric resistance training
62435876|NCT01588106||Control group|patients using standard CONTOUR
62435877|NCT05450497|EXPERIMENTAL|Propofol Group|Patient sedation after cardiac surgery at the intensive care unit. Continuous infusion of propofol using a syringe pump at the dose of 1-1.5 mg / kg / h
62823682|NCT02877108||Haloperidol/Lorazepam|These patients will receive haloperidol/lorazepam for treatment of agitation.
62823683|NCT05577247||Before antidepressant treatment|
62823684|NCT05577247||After antidepressant treatment|
62823685|NCT02190253||Organ transplant recipients|Recipients of either liver, kidney, liver and kidney, and small bowel transplants
62042731|NCT00251862|EXPERIMENTAL|Decision aid plus YourDiseaseRisk|Patients viewed the decision aid and completed the Your Disease Risk risk assessment tool prior to visit with their primary care provider.
62042732|NCT00251862|EXPERIMENTAL|Decision aid alone|Patient's viewed decision aid only prior to a visit with their primary care provider.
62042733|NCT00251862|SHAM_COMPARATOR|III|Standard care
62602204|NCT04045132|ACTIVE_COMPARATOR|MoodGym Alone|The MoodGym program is an evidence-based online cognitive behavioral treatment program that has been shown to be effective at reducing depression symptoms in a meta-analysis of 11 trials (g=0.36, 95% CI 0.17-0.56). Moodgym contains five modules with interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files that can be completed online without therapist interaction.
62602205|NCT04045132|EXPERIMENTAL|Parenting Program + MoodGym|The social media-based parenting program consists of 8 weekly sessions using a Facebook platform with the following topics: depression psychoeducation and behavioral activation, infant temperament, play, feeding, safety, sleep, parent-child interactions, and shared book reading. Participants in the experimental arm will also be enrolled in the online depression treatment program, MoodGym.
62823686|NCT02190253||Waitlist patients|Patients on waitlist for liver, kidney or intestinal transplantation
62042734|NCT05942911|EXPERIMENTAL|IHL-675A|150 mg CBD, 200 mg HCQ: two soft gel capsules each containing 75 mg CBD and 100 mg HCQ twice per day for a total daily dose of 300 mg CBD and 400 mg HCQ
62042735|NCT05942911|ACTIVE_COMPARATOR|Cannabidiol|150 mg: two capsules each containing 75 mg CBD twice per day for a total daily dose of 300 mg CBD
62042736|NCT05942911|ACTIVE_COMPARATOR|Hydroxychloroquine|200 mg: two capsules each containing 100 mg HCQ twice per day for a total daily dose of 400 mg HCQ
62042737|NCT05942911|PLACEBO_COMPARATOR|Placebo|Two capsules twice per day
62042738|NCT03498833|OTHER|Test-retest reliability testing|Minimum 50 IKOA will be evaluated with the scale on two occasions within two weeks to establish test retest reliability.
62245583|NCT03005951|EXPERIMENTAL|Lean males|This is a randomized, two-period, cross over design with the intervention of consuming breakfast versus fasting for breakfast to study the effects on hormone responses and cognitive function using CTET in lean and obese male adolescents. These two study groups will be randomized to one of two orders:: (A,B) or (B,A) where A = Yes breakfast and B=No breakfast
62435878|NCT05450497|EXPERIMENTAL|Dexmedetomidine|Patient sedation after cardiac surgery at the intensive care unit. Continuous infusion of Dexmedetomidine using a syringe pump at the dose of 0.5-1.0 mcg/ kg / h
62435879|NCT05450497|EXPERIMENTAL|Dexmedetomidine and propofol|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group DEX+PR:~continuous infusion of propofol using a syringe pump at the dose of 0.5-1.5 mg / kg / h and dexmedetomidine 0.2-0.7 mcg\\kg\\h"
62435880|NCT02154113|ACTIVE_COMPARATOR|Velashape II device|Controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation.
62823687|NCT05795452||Adolescents from the Mothers and Newborns Cohort|
62823688|NCT03777982|EXPERIMENTAL|LHRH Agonist or Antagonist|-LHRH agonist or antagonist should be prescribed per standard of care
62823689|NCT03777982|EXPERIMENTAL|Prednisone+Apalutamide+Abiraterone Acetate +LHRH Agonist|"* LHRH agonist or antagonist should be prescribed per standard of care~* Abiraterone acetate will be taken once daily~* Prednisone will be taken twice daily~* Apalutamide will be taken once daily"
62823690|NCT06037161|EXPERIMENTAL|GPST + CTG|Gingival Pedicle Split Thickness + Connective Tissue Graft procedure
62042739|NCT00158665|EXPERIMENTAL|Subjects receiving vaccine|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine 4 weeks apart.
62042740|NCT01332227|EXPERIMENTAL|Atazanavir/Ritonavir + Raltegravir|Atazanavir + Ritonavir (heat-stable) + Raltegravir
62435881|NCT02154113|ACTIVE_COMPARATOR|Ultrashape|The UltraShape Contour I V3 uses focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption.
62435882|NCT03276910|EXPERIMENTAL|Eprex 20 UI/kg|6 doses at 20 IU/kg in subcutaneous use
62435883|NCT03276910|EXPERIMENTAL|Eprex 50 UI/kg|6 doses at 50 IU/kg in subcutaneous use
62435884|NCT03276910|PLACEBO_COMPARATOR|Placebo|6 injections at 1ml in subcutaneous use of sodium chloride AGUETTANT 0.9%
62435885|NCT03334487|EXPERIMENTAL|Rovalpituzumab tesirine + dexamethasone|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle plus oral dexamethasone 8 mg twice daily on Day -1, Day 1, and Day 2 of 6-week each cycle.
62435886|NCT00435695|ACTIVE_COMPARATOR|GSK163090|one infusion only
62602206|NCT03525028|EXPERIMENTAL|Metformin group|Oral metformin 500 mg once daily for first week, 500 mg twice daily for next 23 weeks. The follow-up treatment according to the participants' condition.
62823691|NCT06037161|ACTIVE_COMPARATOR|CAF + CTG|Coronally Advanced Flap + Connective Tissue Graft procedure
62823692|NCT02470286|EXPERIMENTAL|Cohort 1 (SA001 60mg or Placebo)|6 subjects receiving a single dose of 60mg SA001 and 2 subjects receiving placebo
62823693|NCT02470286|EXPERIMENTAL|Cohort 2 (SA001 120mg or Placebo)|6 subjects receiving a single dose of 120mg SA001 and 2 subjects receiving placebo
62823694|NCT02470286|EXPERIMENTAL|Cohort 3 (SA001 180mg or Placebo)|6 subjects receiving a single dose of 180mg SA001 and 2 subjects receiving placebo
62823695|NCT02470286|EXPERIMENTAL|Cohort 4 (SA001 240mg or Placebo)|6 subjects receiving a single dose of 240mg SA001 and 2 subjects receiving placebo
62823696|NCT02470286|EXPERIMENTAL|Cohort 5 (SA001 300mg or Placebo)|6 subjects receiving a single dose of 300mg SA001 and 2 subjects receiving placebo
62823697|NCT02612272|ACTIVE_COMPARATOR|Corticosteroid|"This arm will receive intra-articular betamethasone.~4cc of 1% lidocaine, 1cc of 0.9% normal saline and 1cc (6 mg) of betamethasone.~An 18 gauge needle connected to a syringe filled with the study drug will be administered. If there is no effusion, a 22 gauge needle with 6cc of the study drug will be injected into the administration site~Please see detailed description of study for further information."
62602207|NCT03525028|PLACEBO_COMPARATOR|Placebo group|Oral placebo 500 mg once daily for first week, 500 mg twice daily for next 23 weeks. The follow-up treatment according to the participants' condition.
62042741|NCT01332227|OTHER|Atazanavir/Ritonavir + Tenofovir/Emtricitabine|"Reference~Atazanavir + Ritonavir (heat-stable) + Tenofovir/Emtricitabine"
62602208|NCT06389292|EXPERIMENTAL|Lisaftoclax (APG-2575) combined with Azacitidine|
62602209|NCT06389292|ACTIVE_COMPARATOR|Placebo combined with Azacitidine|
62602210|NCT03085238|EXPERIMENTAL|M-Trap|
62602211|NCT01378975|EXPERIMENTAL|Cohort 1: Previously Untreated Participants|Participants who had not received previous treatment for brain metastases \[i.e., had never received brain stereotactic radiotherapy (SRT), whole-brain radiotherapy (WBRT), surgery, or any other treatment for their brain metastases\] received Vemurafenib 960 milligram (mg) tablet orally, twice daily (BID) from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant's safety, death, reasons deemed by the investigator, or study termination by the Sponsor.
62823698|NCT02612272|EXPERIMENTAL|Ketorolac|"This arm will receive intra articular ketorolac.~2cc (60 mg) of ketorolac and 4cc of 1% lidocaine~An 18 gauge needle connected to a syringe filled with the study drug will be administered. If there is no effusion, a 22 gauge needle with 6cc of the study drug will be injected into the administration site~Please see detailed description of study for further information."
62042742|NCT02134587|OTHER|Subjects post educational intervention|Multifaceted educational intervention in pharmacovigilance
62823699|NCT04126135|ACTIVE_COMPARATOR|Usual Care Group|Subjects are asked to completely stop smoking on their quit day and use a daily Nicotine Replacement Therapy (NRT) patch for 25 days.
62823700|NCT04126135|EXPERIMENTAL|Treatment Group|Subjects will start a 25-day course of Cytisine tablets started during the four days before the quit date and are asked to reduce smoking during this time.
62042743|NCT03358563|EXPERIMENTAL|Degarelix SC + bicalutamide + docetaxel|Degarelix SC monthly x3 + bicalutamide 50mg orally QD x 14 wks + Docetaxel 75mg/m2 IV q 21 days x 3
62042744|NCT03358563|EXPERIMENTAL|DegarelixSC + bicalutamide + docetaxel + Ferumoxytol enhanced MRI|Degarelix SC monthly x3 + bicalutamide 50mg orally QD x 14 wks + Docetaxel 75mg/m2 IV q 21 days x 3 + Ferumoxytol enhanced MRI within 21 days prior to start of hormonal therapy and second and final ferumoxytol-enhanced MRI at the conclusion of hormone therapy but prior to their prostatectomy.
62042745|NCT03178006||obese plus diabetes,|BMI 30-40kg/m2 and diabetes or pre-diabetes
62042746|NCT03178006||obese|BMI 30-40kg/m2
62602212|NCT01378975|EXPERIMENTAL|Cohort 2: Previously treated Participants|Participants who were previously treated with brain SRT, WBRT, or surgery for their brain metastases and have progressed following this treatment, received Vemurafenib 960 milligram (mg) tablet orally, BID from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant's safety, death, reasons deemed by the investigator, or study termination by the Sponsor.
62602213|NCT02895308|EXPERIMENTAL|Online|The Online psychoeducation is presented on on a webpage.
62602214|NCT02895308|ACTIVE_COMPARATOR|Face-to-face|The face-to-face psychoeducation is provided by psychologist and psychology master students.
62602215|NCT03376347|NO_INTERVENTION|Conventional arm|Institutional Standard of Care with intention to keep MAP\> 65 mmHg. The FlotracIQ will be connected, but fully covered.
62823701|NCT06590220||TAO|
62042747|NCT03178006||control|BMI 20-27,5kg/m2
62042748|NCT03317002|EXPERIMENTAL|AZD5718 Dose A|AZD5718 Dose A once daily
62042749|NCT03317002|EXPERIMENTAL|AZD5718 Dose B|AZD5718 Dose B once daily
62042750|NCT03317002|PLACEBO_COMPARATOR|Placebo|Matching placebo once daily
62042751|NCT06234410||Patients waitlisted for kidney transplantation|Patients who have been placed on the waiting list for a kidney transplant within Scotland
62042752|NCT03128996|EXPERIMENTAL|RIC Prep Regimen & GVHD Prophylaxis|Single arm study. All patients receive the same Reduced Intensity Conditioning (RIC) regimen and GVHD prophylaxis regimen
62435887|NCT03582293|ACTIVE_COMPARATOR|Tranexamic Acid|Tranexamic acid 500mg two times a day orally for a total of 28 days
62602216|NCT03376347|ACTIVE_COMPARATOR|Treatment arm|FlotracIQ with HPI algorithm.
62602217|NCT02913365||Patients presenting with hemoptysis|Patients over 18 years of age presenting with hemoptysis at the Centre Hospitalier Universitaire de Sherbrooke (CHUS) between the periods of 2005 to 2010.
62823702|NCT06212024||MBT-early|See intervention description. Within subject comparison.
62823703|NCT06592950||Quantitative online survey|Across four markets (Canada, France, Spain and Japan)
62823704|NCT06592950||Qualitative interviews|Conducted in Canada
62823705|NCT04142931|ACTIVE_COMPARATOR|filtration of 2X PV|filtration of 2X PV through the ImmunicomAIAC
62823706|NCT04142931|ACTIVE_COMPARATOR|filtration of 2X PV combined with Nivolumab 240mg|filtration of 2X PV through the Immunicom AIAC, and nivolumab 240 mg given every 14 days for 4 times. Nivolumab will be initiated in C2.
62849282|NCT02664571|OTHER|ACA with lobar hematoma(s)|"This group is composed of patients with amyloid cerebral angiopathy (ACA) with lobar hematoma(s).~Intervention: Pet scan with FBB~Intervention: MRI scan~Intervention: APO E genotyping"
62849283|NCT02664571|OTHER|Alzheimer's without ACA|"This group is composed of Alzheimer's type dementia without MRI signs in favor of amyloid cerebral angiopathy (ACA).~Intervention: Pet scan with FBB~Intervention: MRI scan~Intervention: APO E genotyping"
62849284|NCT02664571|OTHER|Healthy volunteers|"This group is composed of healthy volunteers.~Intervention: Pet scan with FBB~Intervention: MRI scan~Intervention: APO E genotyping"
62823707|NCT05432648|EXPERIMENTAL|Short Bowel Syndrome Arm|Patients with SBS will be initiated on green bean purees added to enteral formula recipes, based on kilocalories of enteral formula over 3 weeks. During week 1 subjects will prepare and add 50 mL green bean puree per 1000kcal of enteral feed (5%) to their formula mixture, increasing to 100ml (10%) and 150ml (15%) during weeks 2 and 3, respectively.
62823708|NCT05432648|ACTIVE_COMPARATOR|Control Arm -|Patients without SBS will be initiated on green bean purees added to enteral formula recipes, based on kilocalories of enteral formula over 3 weeks. During week 1 subjects will prepare and add 50 mL green bean puree per 1000kcal of enteral feed (5%) to their formula mixture, increasing to 100ml (10%) and 150ml (15%) during weeks 2 and 3, respectively.
62823709|NCT04353141||Pregnant patients with confirmed COVID-19 infection|
62823710|NCT04353141||Pregnant patients symptomatic for COVID-19|Symptomatic patients suspicious for COVID-19 infection (swab is taken on admission)
62823711|NCT04353141||Pregnant patients asymptomatic for COVID19|Patients asymptomatic for COVID19 with other feto-maternal diseases or who come for delivery or caesarean section
62602218|NCT02288078|ACTIVE_COMPARATOR|Treatment group|"Treatment with regorafenib (160 mg/day, oral administration, 3 weeks on therapy followed by 1 week off therapy), test drug capsule (dexamethasone 2 mg) and proton pump inhibitors (PPIs) will be started within 14 days of enrollment. The protocol treatment period is 4 weeks.~Follow-up treatment for the underlying disease after the 4-week protocol treatment is not specified. The physician in charge will decide whether or not to continue treatment with regorafenib. For the prevention of fatigue/malaise, dexamethasone 2 mg can be used.~General condition, blood pressure, Patient Reported Outcome, clinical findings, hematology/blood chemistry, coagulation and fibrinolysis system, urinalysis, medicatiob check, adverse event, thyroid function test, brain MRI, Contrast-enhanced torso CT"
62823712|NCT03962491|OTHER|Daily Self-Monitoring Surveys|Asked to complete daily self-monitoring surveys.
62823713|NCT03962491|EXPERIMENTAL|Daily Self-Monitoring Surveys + Contingency Management|Asked to complete daily self-monitoring surveys, with opportunity for monetary rewards.
62245584|NCT03005951|EXPERIMENTAL|Obese males|This is a randomized, two-period, cross over design with the intervention of consuming breakfast versus fasting for breakfast to study the effects on hormone responses and cognitive function using CTET in lean and obese male adolescents. These two study groups will be randomized to one of two orders:: (A,B) or (B,A) where A = Yes breakfast and B=No breakfast
62245585|NCT05957354|ACTIVE_COMPARATOR|active cTBS group|active cTBS combined with speech language therapy
62245586|NCT05957354|SHAM_COMPARATOR|sham cTBS group|sham cTBS combined with speech language therapy
62435888|NCT03582293|PLACEBO_COMPARATOR|PLACEBO|Placebo capsules two times a day orally for a total of 28 days
62823714|NCT06597149|EXPERIMENTAL|Stimulation|Subjects are placed supine, ECG electrodes are applied, a butterfly catheter is inserted into a peripheral vein. A 5 ml sample of blood is withdrawn. A TENS device is placed on the cutaneous branch of the auricular branch of the vagus nerve. After a twenty-minute baseline reading, the TENS unit is then turned ON and electrical stimuli are delivered over 40 minutes. A second sample of blood representing the experimental period is drawn at the end of the 40 minutes. The TENS device is then turned to the OFF positon and after twenty minutes a third and final sample of blood is drawn.
62823715|NCT06585839|EXPERIMENTAL|Study|Participants have full access to the investigational device, the Natal Mind mobile application.
62245587|NCT06363669|NO_INTERVENTION|control group|Group with placebo treatment (100 ml of orange-flavored water without any additional substances (0 kcal))
62435889|NCT00756847|EXPERIMENTAL|1|
62435890|NCT00796289|EXPERIMENTAL|GnRH High Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
62435891|NCT00796289|EXPERIMENTAL|GnRH Medium Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a medium target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
62435892|NCT00796289|EXPERIMENTAL|GnRH Low Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a low target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
62435893|NCT00796289|ACTIVE_COMPARATOR|Clomiphene Citrate|Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral 50 mg clomiphene citrate for 5 days
62435894|NCT00796289|PLACEBO_COMPARATOR|Placebo|Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
62823716|NCT06585839|ACTIVE_COMPARATOR|Control|Participants use the investigational device solely for inputting data at predetermined points. They receive standard care without the intervention from the investigational device.
62823717|NCT03969004|EXPERIMENTAL|Cemiplimab|
62823718|NCT03969004|PLACEBO_COMPARATOR|Placebo|
62245588|NCT06363669|EXPERIMENTAL|group with MIPS supplementation|Group with supplementation. Supplement was commercially available and dispensed without a prescription. The dietary supplement contained in one dose (30ml): beta-alanine 3000 mg, taurine 1000 mg, caffeine 290 mg, L-tyrosine 125 mg, and cayenne pepper extract (Capsicum annuum L.) 4.2 mg (of which 8% capsaicin). The supplement was mixed with water; in total, participants were given 100 ml of liquid to drink, 30 minutes before the warm-up for the all-out anaerobic test.
62435895|NCT02344134|EXPERIMENTAL|NBP607|cell culture-derived trivalent inactivated subunit influenza vaccine
62435896|NCT02344134|ACTIVE_COMPARATOR|Agrippal S1|egg-derived trivalent inactivated subunit influenza vaccine
62435897|NCT03372499|EXPERIMENTAL|nutritional management group|diet management strategy for encephalopathy
62435898|NCT03372499|NO_INTERVENTION|control group|Current ordinary guidance for patients after TIPS placement performed by trained nurse in the inpatient department
62435899|NCT02693184||Fragility Fracture Case|Men and women, age \>65 years with a fragility fracture (defined as a fracture sustained after a fall from a standing height or less).
62435900|NCT06539299|NO_INTERVENTION|Control Group|No bone preservation procedure after tooth extraction
62245589|NCT00230438|EXPERIMENTAL|External Beam Radiation Therapy|
62435901|NCT06539299|ACTIVE_COMPARATOR|Socket Preservation - Student|Socket preservation done by a student
62435902|NCT06539299|ACTIVE_COMPARATOR|Socket Preservation - surgeon|Socket preservation done by a surgeon
62435903|NCT02675426|EXPERIMENTAL|Upadacitinib 15 mg|"Period 1: Participants receive upadacitinib 15 mg once daily for 12 weeks.~Period 2: Participants continue to receive upadacitinib 15 mg once daily for an additional 248 weeks."
62435904|NCT02675426|EXPERIMENTAL|Upadacitinib 30 mg|"Period 1: Participants receive upadacitinib 30 mg once daily for 12 weeks.~Period 2: Participants continue to receive upadacitinib 30 mg once daily for an additional 248 weeks or until implementation of Protocol Amendment 6 at which time participants switch to receive upadacitinib 15 mg once daily."
62042753|NCT01898468|ACTIVE_COMPARATOR|Intracostal Closure Technique|Closure involves drilling four evenly spaced holes using a 5-mm bit attached to the end of a Stryker drill into the bed of the sixth rib.
62042754|NCT01898468|ACTIVE_COMPARATOR|Pericostal Closure Technique|Closure involves placing sutures around the ribs in the standard pericostal fashion
62042755|NCT03234205|EXPERIMENTAL|MRI scan during free respiration|
62042756|NCT04643704||FPIES|100 patients
62042757|NCT04643704||IgE mediated food allergy|100 patients
62042758|NCT04643704||Celiac disease|100 patients
62042759|NCT04643704||Control group|100 patients
62042760|NCT05828966|ACTIVE_COMPARATOR|HUMAN CHORIONIC GONADOTROPIN (HCG) Group|H.C.G. will be given in Group A and in a dose of 5000units intramuscular injection followed by a drip of 10,000 units in 500ml of dextrose 5%, at the rate of 20 drops per minute. Half hourly assessment of uterine contractions, maternal vital signs, fetal heart rate monitoring will be done.
62042761|NCT05828966|ACTIVE_COMPARATOR|Magnesium Sulphate(MgSO4) Group|4gm of MgSO4 will be given in Group B as intravenously as continuous dose followed by 2gm/hr till uterine quiescence is achieved.
62042762|NCT05232695||metabolically healthy obese individuals|Individuals who have a body mass index equal or higher than 30 kg/m2, no medication usage, who have only high waist circumference without any other metabolic syndrome criteria.
62823719|NCT02078206|EXPERIMENTAL|Neurocognitive stimulation|Intervention of experimental group consists in a neurocognitive stimulation treatment. Using kinect technology, patient can interact with a virtual environment where different cognitive tasks have to be resolved.
62823720|NCT02078206|NO_INTERVENTION|Treatment as usual|
62042763|NCT05232695||metabolically unhealthy obese individuals|Individuals who have a body mass index equal or higher than 30 kg/m2, no medication usage, who have more than one metabolic syndrome criteria (as defined below) including high waist circumference.
62042764|NCT05191758|NO_INTERVENTION|control|no supplements will be taken
62042765|NCT05191758|EXPERIMENTAL|3 grams of supplements|subjects will take 3 grams of supplements once per day
62042766|NCT05191758|EXPERIMENTAL|6 grams of supplements|subjects will take 3 grams of supplements twice per day
62823721|NCT06594640|EXPERIMENTAL|R-CMOP|"R-CMOP regimen includes rituximab (R), cyclophosphamide (C), mitoxantrone hydrochloride liposome injection (M), vincristine (O), and prednisone (P).~The regimen will be administered every 3 weeks, for a maximum of 6 cycles."
62042767|NCT05191758|EXPERIMENTAL|9 grams of supplements|subjects will take 3 grams of supplements three times per day
62245590|NCT02663284|EXPERIMENTAL|Perineural block|Perineural block with Ropivacaine 0.5%
62245591|NCT04197726|EXPERIMENTAL|sbeIIa/b white bread|sbeIIa/b white bread with high resistant starch content
62245592|NCT04197726|ACTIVE_COMPARATOR|Control white bread|Reference white bread (wild-type)
62245593|NCT00024167|EXPERIMENTAL|Induction regimen A|Doxorubicin IV over 24 hours day 1; Oral ketoconazole 3 x daily on days 1-7 of weeks 1, 3, and 5; Vinblastine IV over 30 minutes Day 1, oral Estramustine 3 x daily on Days 1-7 of weeks 2, 4, and 6.
62823722|NCT04879589|EXPERIMENTAL|SC ATRS-2002|3 different dosages \[25mg (0.13mL) , 75mg (0.4mL) and 200mg (1.05mL)\] will be tested as single SC injection into the abdomen.
62823723|NCT04879589|ACTIVE_COMPARATOR|Oral Abiraterone Acetate|A single dose of 1000mg of commercially available oral formulation of abiraterone acetate will be administered to enrolled participants in Cohort 4
62823724|NCT00761423|EXPERIMENTAL|1|Combination of eccentric exercises and injection of PRP
62823725|NCT00761423|PLACEBO_COMPARATOR|2|Combination of eccentric exercises and physiological saline injection
62823726|NCT06655636|EXPERIMENTAL|Group 1 - Assistance, Sham, Anti-Assistance|Group 1 receives all three interventions in the order of assistance, then sham (slack springs), then anti-assistance. Each intervention corresponds to different settings on the device.
62823727|NCT06655636|EXPERIMENTAL|Group 2 - Sham, Assistance, Anti-Assistance|Group 2 receives all three interventions in the order of sham (slack springs), then assistance, then anti-assistance. Each intervention corresponds to different settings on the device.
62245594|NCT00024167|EXPERIMENTAL|Induction regimen B|Oral Prednisone 2 x daily on days 1-21 (days 1-14 of course 5 only) and Docetaxel IV over 1 hour Day 1.
62245595|NCT00024167|EXPERIMENTAL|Consolidation arm I|Doxorubicin IV over 24 hours once weekly for 6 weeks + Strontium-89 IV once at beginning of chemotherapy.
62435905|NCT02675426|EXPERIMENTAL|Placebo / Upadacitinib 15 mg|"Period 1: Participants receive placebo once daily for 12 weeks.~Period 2: Participants receive upadacitinib 15 mg once daily for 248 weeks."
62042768|NCT06224738|EXPERIMENTAL|human HER2-targeted CAR-M cell|"Recombinant human granulocyte stimulating factor treatment mobilized bone marrow stem cells, when the mononuclear cells rose to more than 8×10\^8/L, the collection of peripheral blood single nuclei cells, the total number of mononuclear cells collected 1.5×10\^9-1.8×10\^9. Intraperitoneal infusion of anti-human HER2 CAR-M cells 3×10\^8 cells/person, in a single administration.According to the principle of 3+3 dose increment, enter dose 2 and dose 3. Dose2: the monocyte rises to more than 9.5×10\^8/L and collect peripheral blood single nucleus cells. Reinfuse anti-human HER2 CAR-M cells 5×10\^8 cells/person, 1 person/bag/dose, 100 ml/bag. Dose3: the mononuclear cell rises to more than 1.3×10\^9/L and collect peripheral blood single nucleus cells. Reinfuse anti-human HER2 CAR-M cells 1×10\^9 cells/person, 1 person/bag/dose, 200 ml/bag."
62435906|NCT02675426|EXPERIMENTAL|Placebo / Upadacitinib 30 mg|"Period 1: Participants receive placebo once daily for 12 weeks.~Period 2: Participants receive upadacitinib 30 mg once daily for 248 weeks or until implementation of Protocol Amendment 6 at which time participants switch to receive upadacitinib 15 mg once daily."
62245596|NCT00024167|EXPERIMENTAL|Consolidation arm II|Doxorubicin as in Consolidation arm I.
62245597|NCT05466812|EXPERIMENTAL|Sr-89 treated group|Sr-89 treatment
62823728|NCT06592196||Cross-sectional study and retrospective cohort study|This research was conducted in two phases. Initially, a cross-sectional study was performed to assess the correlation between statin usage prior to hospital admission and the initial state of liver enzymes among patients. Subsequently, a retrospective cohort study was undertaken, wherein patients who had not been on statins prior to admission were categorized into two groups based on their statin usage post-admission.
62245598|NCT01561495|EXPERIMENTAL|All Participants|Proton Radiotherapy
62245599|NCT05244707|EXPERIMENTAL|Mediterranean style diet|Mediterranean style diet.
62245600|NCT05244707|ACTIVE_COMPARATOR|Standard of care|Standard of care.
62245601|NCT02901873|ACTIVE_COMPARATOR|Thyroid surgery|Electrical Impedance Spectroscopy in Thyroid surgery
62245602|NCT02901873|ACTIVE_COMPARATOR|Parathyroid surgery|Electrical Impedance Spectroscopy in parathyroid surgery
62042769|NCT03952832|EXPERIMENTAL|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62042770|NCT05817448||control group|40 pregnant women with normal placentation having no pregnancy related disorders according to the physical examination and laboratory findings.
62042771|NCT05817448||placenta previa group|"40 pregnant women that will be diagnosed according to the ultrasound diagnostic criteria.~Then according to the histopathological examination, placenta previa group will be subdivided into 2 groups, placenta previa with MAP and placenta previa without MAP"
62042772|NCT05684081|EXPERIMENTAL|INTERVENTION|Refers to the intervention arm i.e. ECASH payment of health workers
62042773|NCT05684081|NO_INTERVENTION|CONTROL|Refers to status Quo or no intervention i.e. payment using cash
62042774|NCT04789096|EXPERIMENTAL|TUGETHER Treatment|"Participants will receive:~* Tucatinib (oral) at a dose of 300 mg BD on day 1-21 of each 21-day cycle~* Pembrolizumab will be administered at a dose of 200 mg IV on day 1 of each 21 day cycle~* Trastuzumab will be given as a loading dose of 8 mg/kg IV (if loading required, otherwise 6 mg/kg) on day 1 followed by 6 mg/kg on day 1 of each 21 day cycle.~Participants registered to PD-L1 negative/unknown cohort prior to Protocol Amendment 2 received Capecitabine 1000 mg/m\^2 day 1-14 of each 21 day cycle."
62042775|NCT01825213||Multispectral CT of the liver|Images of lesions and liver will be compared to histology.
62042776|NCT06580314|ACTIVE_COMPARATOR|Arm I (olaparib, bevacizumab)|Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may also receive bevacizumab IV on day 1 of each cycle. Cycles of bevacizumab repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and CT and/or MRI throughout the study.
62042777|NCT06580314|EXPERIMENTAL|Arm II (olaparib, bevacizumab)|Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients may also receive bevacizumab IV on day 1 of each cycle. Cycles of bevacizumab repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and CT and/or MRI throughout the study.
62042778|NCT00222534|EXPERIMENTAL|Acetazolamide|Acetazolamide 250 mg Three times a day for five days
62435907|NCT01050231|EXPERIMENTAL|Robotic group (Type I)|Type I Robotic Therapy (Functional activities first) Participants in this group will participate in functional/task-oriented multi-joint training with the BONES robot first, followed by individual joint training with the BONES robot. A one-week break was provided between interventions.
62435908|NCT01050231|ACTIVE_COMPARATOR|Robotic group (Type II)|Type II Robotic Therapy (Individual joints first) Participants in this group will participate in individual joint training with the BONES robot first, followed by functional/task-oriented multi-joint training with the BONES robot. A one-week break was provided between interventions.
62042779|NCT00222534|PLACEBO_COMPARATOR|Placebo|Placebo, one tablet Three times a day for five days
62042780|NCT04541810||Participants receiving Upadacitinib|Participants receiving Upadacitinib as prescribed by their physician per local label.
62245603|NCT01475604|ACTIVE_COMPARATOR|Targeted pulsed electromagnetic field|
62435909|NCT00306631|EXPERIMENTAL|1|
62435910|NCT02720315|EXPERIMENTAL|Intensive cryotherapy|Application of ice in a plastic bag wrapped to the patient's site of pain, and kept in place for 20min.
62042781|NCT00156065|ACTIVE_COMPARATOR|Haloperidol/Haloperidol|Haloperidol in original study (NCT00156104) and in current long-term extension.
62042782|NCT00156065|EXPERIMENTAL|Asenapine/Asenapine|Asenapine in original study and asenapine in current long-term extension.
62245604|NCT01475604|SHAM_COMPARATOR|Sham|
62245605|NCT02794454|ACTIVE_COMPARATOR|HeezOn Ultra-1|HeezOn Ultra-1 includes ingredients like Shilajit, Galangal, Fenugreek. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
62042783|NCT00156065|EXPERIMENTAL|Placebo/Asenapine|Double-Blind subjects randomized to only placebo medication for 6 weeks in the short-term 041023 asenapine trial, were randomized (double-blind) into the long-term 041513 asenapine extension trial and received asenapine 5 mg BID for Week 1. After Week 1, subjects received asenapine (either 5 mg BID or 10 mg BID) for the remainder of the 52-week trial.
62602219|NCT02288078|PLACEBO_COMPARATOR|Placebo group|"Treatment with regorafenib (160 mg/day, oral administration, 3 weeks on therapy followed by 1 week off therapy), placebo capsule (lactose) and proton pump inhibitors (PPIs) will be started within 14 days of enrollment. The protocol treatment period is 4 weeks.~Follow-up treatment for the underlying disease after the 4-week protocol treatment is not specified. The physician in charge will decide whether or not to continue treatment with regorafenib. For the prevention of fatigue/malaise, dexamethasone 2 mg can be used.~General condition, blood pressure, Patient Reported Outcome, clinical findings, hematology/blood chemistry, coagulation and fibrinolysis system, urinalysis, medication check, adverse event, thyroid function test, brain MRI, Contrast-enhanced torso CT"
62435911|NCT02720315|NO_INTERVENTION|Control|Existing pain control practice of physicians and nurses, which includes application of a chemical cold pack.
62435912|NCT03986749|EXPERIMENTAL|ARCR-BursaSeries|Tendon healing in the reconstruction of the rotator cuff, taking advantage of augmentation potential of the subacromial bursa.
62435913|NCT00600288|EXPERIMENTAL|1|
62602220|NCT06649448|EXPERIMENTAL|Cohort 1|Small cell lung cancer (SCLC) patients receiving ICI combined with chemotherapy (etoposide + carboplatin/cisplatin).
62602221|NCT06649448|EXPERIMENTAL|Cohort 2|Non-small cell lung cancer (NSCLC) patients receiving ICI combined with chemotherapy (platinum-based/taxane, pemetrexed/platinum).
62602222|NCT06649448|EXPERIMENTAL|Cohort 3|Esophageal squamous cell carcinoma (ESCC) patients receiving ICI combined with chemotherapy (TP, which stands for cisplatin + taxane).
62042784|NCT02615574|EXPERIMENTAL|αDC1 vaccine + CKM|all subjects enrolled in study
62042785|NCT03049410|ACTIVE_COMPARATOR|iRARC|Intracorporeal Robot Assisted Radical Cystectomy
62042786|NCT03049410|ACTIVE_COMPARATOR|Open Radical Cystectomy (ORC)|Open Radical Cystectomy
62602223|NCT03219606|EXPERIMENTAL|education arm|Participants in education arm will have an organized education course of modified Rodnan Skin Scoring.
62042787|NCT04888390|EXPERIMENTAL|Intervention group|The intervention group will receive multi-model exercise intervention 2-3 times per week for 3 months.
62042788|NCT04888390|ACTIVE_COMPARATOR|Usual care group|The Usual care group will receive heart failure disease and exercise-related education.
62042789|NCT02479230|EXPERIMENTAL|vaccine: gemcitabine hydrochloride|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning 3, 7, or 10 days later, patients receive tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine ID followed by a second vaccination 7 days later. Courses may repeat after at least 4 weeks in the absence of disease progression or unacceptable toxicity.
62245606|NCT02794454|ACTIVE_COMPARATOR|HeezOn Ultra-2|HeezOn Ultra-2 includes ingredients like Arjuna, Galangal, Fenugreek. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
62602224|NCT06060106||Endoscopic submucosal dissection|Early esophageal cancer patients treated with ESD
62602225|NCT06060106||Esophagectomy|Early esophageal cancer patients treated with esophagectomy
62602226|NCT02468128|EXPERIMENTAL|SDE 150mg|Single dose, intramuscular, Sebacoyl Dinalbuphine Ester injection 150 mg (2 ml)
62602227|NCT02468128|PLACEBO_COMPARATOR|placebo|Single dose, intramuscular , Sebacoyl Dinalbuphine Ester placebo injection (2mL)
62435914|NCT00600288|PLACEBO_COMPARATOR|2|
62435915|NCT00609778|EXPERIMENTAL|1:Mechanical CPR with LUCAS|A Mechanical device that provides chest compressions
62435916|NCT00609778|ACTIVE_COMPARATOR|2 Manual CPR|Manual chest compressions
62602228|NCT02231593||Acromegalic patients|
62602229|NCT03521817|EXPERIMENTAL|Alcohol|Etoh will have a 30% reduction in calories from weight maintenance and will consume the same percentage of each traditional macronutrient (20% protein, 50% carbohydrate, and 30% fat; (minus the \~240 kcals from ethanol). The Etoh group will consume a 30% energy restriction diet that will also include \~2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila).
62245607|NCT02794454|PLACEBO_COMPARATOR|Placebo|Placebo consists of Micro-crystalline Cellulose. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
62823729|NCT03730649|ACTIVE_COMPARATOR|Sulforaphane without light challenge|Participants with moderate photodamage and moderate intrinsic skin aging will apply sulforaphane (broccoli sprout extract) in jojoba oil nightly (without any UV or visible light irradiation) for up to 6 months and have up to 9 biopsies taken just before treatment and occurring at regular intervals during the study
62823730|NCT03730649|ACTIVE_COMPARATOR|Sulforaphane with light challenge|Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments and biopsies taken before and within 7 days after UV or visible light irradiation; one of the UV/visible light treated areas will be pre-treated with sulforaphane (broccoli sprout extract) for up to 28 consecutive nights and the other UV/visible light treated areas will be pre-treated with jojoba oil.
62823731|NCT06599437|ACTIVE_COMPARATOR|Early same admission laparoscopic cholecystectomy ( group A)|Early laparoscopic cholecystectomy is performed on next day within 24 hours after common bile duct stone removal by ERCP.
62823732|NCT06599437|ACTIVE_COMPARATOR|Late laparoscopic cholecystectomy ( group B)|Late laparoscopic cholecystectomy is performed 6 weeks after common bile duct stones clearance
62823733|NCT05819658|PLACEBO_COMPARATOR|Placebo|Placebo SC injection will be administered once weekly for 4 weeks then every 2 weeks through Week 24 for double blind phase.
62823734|NCT05819658|EXPERIMENTAL|GV1001 0.56 mg|GV1001 0.56 mg SC injection will be administered once weekly for 4 weeks then every 2 weeks through Week 24 for double blind phase.
62823735|NCT05819658|EXPERIMENTAL|GV1001 1.12 mg|GV1001 1.12 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24 for double blind phase.
62823736|NCT06588062|EXPERIMENTAL|Intervention Group I|All the participants of intervention (Group I) will receive conventional oral hygiene instructions in presence of their parents. These instructions will be given on model, showing each surface to be cleaned properly. Tooth brushing with the Horizontal Scrub Technique will be promoted and performance of brushing twice daily for 2 minutes. Moreover, avoidance of sugary diet will also be given. In addition the intervention participants (Group I) will be provided with PECS tool to be utilized during tooth brushing. It will be a set of 10 picture cards depicting brushing sequence and techniques by animated character. The picture will be illustrating brushing of left and right buccal, lingual, labial, and occlusal surfaces of maxillary and mandibular teeth. Each card will be accompanied by the instructions of specific step of technique with clear picture illustration for better understanding. The same instructions will be provided again, one week apart for development of skills.
62823737|NCT06588062|NO_INTERVENTION|Control Group II|All the participants of control (Group II) will receive conventional oral hygiene instructions in presence of their parents. These instructions will be given on model, showing each surface to be cleaned properly. Tooth brushing with the Horizontal Scrub Technique will be promoted and performance of brushing twice daily for 2 minutes. Moreover, avoidance of sugary diet will also be given. However, PECS tool is not used as an intervention in this group. The same instructions will be provided again, one week apart for development of skills.
62245608|NCT01636479|EXPERIMENTAL|SAR405838|SAR405838 in escalating doses
62245609|NCT03178968|EXPERIMENTAL|15 minutes' erosion|Orange juice is administered ex vivo and in vivo for 5 minutes and repeated a total of 3 times
62245610|NCT03178968|EXPERIMENTAL|30 minutes' erosion|Orange juice is administered ex vivo and in vivo for 10 minutes and repeated a total of 3 times
62245611|NCT03178968|EXPERIMENTAL|45 minutes' erosion|Orange juice is administered ex vivo and in vivo for 15 minutes and repeated a total of 3 times
62245612|NCT01289795||first-ever ischemic stroke|first-ever ischemic stroke according to the WHO definition
62245613|NCT01816412|EXPERIMENTAL|LDCB|Paclitaxel Coated Balloon
62823738|NCT05257356|EXPERIMENTAL|Chronic Pain Patients|"All participants perform 1 psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The performance of chronic pain patients will be compared to healthy volunteers to characterize possible alterations in patients. Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of pain, which is assumed to be already increased in patients.~Primary objectives: Show that emotional-motivational components are increased relative to sensory-discriminative components in chronic pain, and that enhanced emotional-motivational pain responses in chronic pain can be decreased by counterconditioning, leading to a normalization of pain perception relative to healthy individuals.~Secondary objective: Assess whether chosen personality traits assessed by questionnaires can explain variations in sensory-discriminative and emotional-motivational pain responses."
62849285|NCT02546700|EXPERIMENTAL|Lebrikizumab: Biomarker-high|Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
62849286|NCT02546700|EXPERIMENTAL|Lebrikizumab: Biomarker-low|Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
62042790|NCT01710176|ACTIVE_COMPARATOR|standard chemotherapy with full-dose epirubicin + ifosfamide|Standard arm foresees 3 cycles of preoperative chemotherapy, each cycle will be repeated every 21 days and includes: epirubicin 60 mg/m2/day, short infusion, days 1 and 2; ifosfamide 3 g/m2/day, days 1, 2, 3
62042791|NCT01710176|EXPERIMENTAL|histotype-tailored chemotherapy according to the histotype|gemcitabine+docetaxel for undifferentiated pleomorphic sarcoma, trabectedin for myxoid liposarcoma with hypercellularity, ifosfamide for synovial sarcoma, ifosfamide+etoposide for malignant peripheral nerve sheath tumor, gemcitabine+dacarbazine for leiomyosarcoma
62602230|NCT03521817|ACTIVE_COMPARATOR|No Alcohol|No Etoh will have a 30% reduction in calories from weight maintenance and will consume the same percentage of each traditional macronutrient (20% protein, 50% carbohydrate, and 30% fat).
62602231|NCT04395612|EXPERIMENTAL|Treatment arm1|niraparib 200mg/day and brivanib 400mg/day
62602232|NCT04395612|EXPERIMENTAL|Treatment arm2|niraparib 200mg/day and toripalimab 240mg/21 days
62602233|NCT05487287||Ischemic stroke patients with functional deficit of the hand|
62602234|NCT05487287||Healthy subjects|
62602235|NCT05373992|EXPERIMENTAL|Screen Time Restricted|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) for the first 72-hours following the initial clinic visit. After the first 72-hours following the initial clinic visit, participants will follow the standard of care as prescribed by their provider. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
62245614|NCT01816412|ACTIVE_COMPARATOR|PTA|Standard Uncoated Balloon Angioplasty Catheter PTA Catheter
62435917|NCT00775983|ACTIVE_COMPARATOR|laminaria|laminaria placed for cervical dilation; usual standard of care in study clinic
62042792|NCT02211326|EXPERIMENTAL|genotype-guided group|Interventions：on day1\~day3, patients received dose according to IWPC formula (PGx-1) included clinical variables and genotype data for VKORC1, CYP2C9\*1, CYP2C9\*2, and CYP2C9\*3; on day4\~day7, patients received dose according to Lenzini formula consisted of clinical variables, VKORC1, CYP2C9\*2, CYP2C9\*3 and previous INR and dosing information (PGx-2); and on day8, the clinicians adjusted the dose according to observed INR.The overall follow-up period is 12 weeks.
62042793|NCT02211326|ACTIVE_COMPARATOR|control group|Interventions：on day1\~day3, patients were given initial dose (2.25mg); and starting from day4, the clinicians began to adjust the dose for patients according to observed INR.The overall follow-up period is 12 weeks.
62042794|NCT00831779|EXPERIMENTAL|Dapagliflozin|
62042795|NCT00831779|PLACEBO_COMPARATOR|Placebo|
62042796|NCT06203106||Affected Subjects|Subjects in this group will have a diagnosis and/or medical history of a condition, disease, genetic background, or trait of interest.
62042797|NCT06203106||Healthy Control|Subjects in this group will serve as healthy controls.
62042798|NCT00860379|PLACEBO_COMPARATOR|Placebo|Placebo
62042799|NCT00860379|EXPERIMENTAL|Selenium1|Subject will receive 2 ug/kg of IV selenium per day
62435918|NCT00775983|EXPERIMENTAL|Dilapan-S|experimental treatment
62042800|NCT00860379|EXPERIMENTAL|Selenium2|Subject will receive 4 ug/kg of IV selenium per day
62042801|NCT01850914||Shunted patients with INPH|Cases: Patients with normal pressure hydrocephalus who have underwent surgery. Controls: Sex- and age-matched community based controls.
62042802|NCT01850914||Populationbased elderly.|A group of populationbased elderly, matched according to age and sex to the patients with INPH. Vascular risk factors studied.
62435919|NCT01165242|EXPERIMENTAL|Group A|Subjects were vaccinated with vaccine GSK134612 Lot A
62435920|NCT01165242|EXPERIMENTAL|Group B|Subjects were vaccinated with vaccine GSK134612 Lot B
62435921|NCT01165242|ACTIVE_COMPARATOR|Group C|Subjects were vaccinated with Menactra®
62435922|NCT02001428|EXPERIMENTAL|Intermittent Screening and Treatment|Infants enrolled at Village health posts will be randomly allocated to receive intermittent screening and treatment (IST) on every scheduled immunization visit at 2, 3, 4 and 9 months of age. Infants in this group will be screened for malaria by Rapid Diagnostic Test (RDT), and if positive, treated with dihydroartemisinin-piperaquine (DHP). Infants will also receive follow up home visits at 6 and 12 months.
62435923|NCT02001428|NO_INTERVENTION|Passive Case Detection|Infants in the control arm will only be checked for malaria if they have fever, or history of fever in the 24 hours prior to the scheduled immunization visit at 2,3,4 and 9 months of age, or at a follow up home visit at 6 and 12 months. Infants with malaria will be treated with DHP once daily for 3 days according to local treatment guidelines.
62042803|NCT06034548|EXPERIMENTAL|diabetes and hypertension self-management|12-week lifestyle and disease self-management
62042804|NCT06034548|NO_INTERVENTION|Control|Wait-list control
62042805|NCT03855449|EXPERIMENTAL|eDECIDE Web-based Intervention Group|Participants randomized to the eDECIDE arm will use the online version of the program through the eDECIDE study portal. Participants in this group will receive bi-weekly calls from their health coach to mark their progress with the program.
62245615|NCT05881967||Uterine sarcoma|Participants were enrolled for the first treatment of uterine sarcoma or secondary operation for recurrence fo uterine sarcoma.
62245616|NCT05881967||Uterine fibroid|Participants were enrolled for surgery of uterine fibroids.
62435924|NCT01859702|EXPERIMENTAL|VIGADEXA|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution, 1 drop instilled in the study eye 2 days before surgery, followed by 1 drop instilled 4 times a day the day before surgery. On the day of surgery, 1 drop was instilled 60 minutes prior to the procedure.
62435925|NCT03564899|NO_INTERVENTION|control|Receive no physical activity intervention (maintain baseline physical activity participation)
62245617|NCT05690945|EXPERIMENTAL|QL1706+chemotherapy|Participants with locally advanced or metastatic NSCLC patients who are PD-L1 negative will receive QL1706, paclitaxel/pemetrexed and carboplatin by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with QL1706 or QL1706 combined with pemetrexed.
62435926|NCT03564899|EXPERIMENTAL|Lighter intensity physical activity|Receive an intervention of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve for 12 weeks.
62435927|NCT03564899|ACTIVE_COMPARATOR|Higher intensity physical activity|Receive an intervention of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve for 12 weeks.
62823739|NCT05257356|EXPERIMENTAL|Healthy Controls|"Substudy 1(b): Participants perform 1 psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. Associative learning by monetary reinforcement is implemented to diminish the pain aversiveness. Substudy2: Participants perform the same task combined with MRI assessing the counterconditioning effects on frontostriatal circuits.~Primary objective: Show that emotional-motivational components are increased relative to sensory-discriminative components in chronic pain (Substudy 1(b)). Assess the neural correlates of the counterconditioning effects on emotional-motivational pain responses, specifically alterations in functional connectivity in frontostriatal networks compared to the unchanged natural state (Substudy 2).~Secondary objective: To assess whether chosen personality traits assessed by questionnaires can explain variations in sensory-discriminative and emotional-motivational pain responses (Substudy1(b)+2)."
62823740|NCT06570447|EXPERIMENTAL|combination therapy of Glofitamab, chidamide|Each subject will be given combination therapy of Glofitamab, chidamide. Glofitamab Injection with 2.5 mg on D8 and 10 mg on D15 in Cycle 1; with 30mg in Cycle 2-12, every 3 weeks.
62823741|NCT04354129||PID/SID Cutaquig Treated Patients|Immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home.
62823742|NCT05222451|EXPERIMENTAL|Dietary Guidelines for Americans|7 days of a diet consistent with the Dietary Guidelines for Americans (DGA).
62823743|NCT05222451|EXPERIMENTAL|Medium Chain Triglyceride Supplemented DGA|7 days of a diet consistent with the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
62245618|NCT05690945|ACTIVE_COMPARATOR|Tiselizumab+chemotherapy|Participants with locally advanced or metastatic NSCLC patients who are PD-L1 negative will receive tiselizumab, paclitaxel/pemetrexed and carboplatin by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with tiselizumab or tiselizumab combined with pemetrexed.
62245619|NCT01919320||CSS Console TAH-t Patients|All TAH-t patients implanted while supported with the CSS Console who were enrolled in the INTERMACS Registry and implanted with the TAH-t on or after June 20, 2012.
62245620|NCT01919320||C2 Driver System TAH-t Patients|200 TAH-t patients implanted while supported by the Companion 2 (C2) Driver System who were enrolled in the INTERMACS Registry and implanted with the TAH-t on or after June 20, 2012.
62245621|NCT01919320||All TAH-t Patient Records|All records for TAH-t patients enrolled in the INTERMACS Registry will be reviewed to support Objective 2 of the protocol.
62245622|NCT05279703|ACTIVE_COMPARATOR|0.03 mcg group|epinephrine infusion will be started after subarachnoid block until 5 minutes after delivery of the baby
62245623|NCT05279703|ACTIVE_COMPARATOR|0.02 mcg group|epinephrine infusion will be started after subarachnoid block until 5 minutes after delivery of the baby
62245624|NCT05279703|ACTIVE_COMPARATOR|0.01 mcg group|epinephrine infusion will be started after subarachnoid block until 5 minutes after delivery of the baby
62245625|NCT03599557|EXPERIMENTAL|Intervention|Arm 1 will receive the STOP-HPV communication intervention
62245626|NCT03599557|NO_INTERVENTION|Control|Arm 2 will receive standard of care
62245627|NCT00526396|ACTIVE_COMPARATOR|A|standard fixed doses
62245628|NCT00526396|EXPERIMENTAL|B|toxicity adjusted dosing
62245629|NCT02119754|EXPERIMENTAL|Plurogel PN|Plurogel PN
62435928|NCT06546436|ACTIVE_COMPARATOR|Low-dose group|Subjects enrolled in this group will received a one-dose injection of CARC-101C, 3×1010 eRBC(engineered Red Blood Cells) in one dose.
62823744|NCT05222451|EXPERIMENTAL|Ketogenic Diet|7 days of a ketogenic diet (KETO).
62823745|NCT04841863|ACTIVE_COMPARATOR|Drug Code Active Patient o DCAP|"Inclusion in the active group involves the use of MyPlan digital health tool that aims to improve clinical-patient communication, enahnce patient empowerment, improve early detection of side effects and allows professionals to individualize interventions.~Patients will receive follow-up by videoconference 48 hours after discharge and in the phase II, at 6 and 12 months after discharge."
62823746|NCT04841863|PLACEBO_COMPARATOR|Standard care|"Inclusion in the control group do not involves the use of MyPlan digital health tool. Patients will receive the standard of care.~Patients will receive follow-up by videoconference 48 hours after discharge and in the phase II, at 6 and 12 months after discharge."
62823747|NCT04088877|EXPERIMENTAL|Exercise and Art Sculpting Class|Participants will take part in a twelve week exercise program twice per week as well as an eight week art sculpting class once a week.
62823748|NCT01400308|ACTIVE_COMPARATOR|Chlorhexidine + Mupirocin|"Will be treated with the protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07, as shown listed in Table 4. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)."
62823749|NCT01400308|EXPERIMENTAL|Prontoderm|Will be treated with the protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.
62245630|NCT04236648|OTHER|Minimally-invasive non-surgical therapy (MINST)|Study treatment
62245631|NCT06197334|EXPERIMENTAL|Healthy volunteers|
62245632|NCT06197334|EXPERIMENTAL|Crohn's disease patients with fibrosis|
62245633|NCT06197334|EXPERIMENTAL|Crohn's disease patients without fibrosis|
62245634|NCT06197334|EXPERIMENTAL|Functional gastrointestinal disorders patients|
62435929|NCT06546436|ACTIVE_COMPARATOR|High-dose group|Subjects enrolled in this group will received a one-dose injection of CARC-101C, 3×1011 eRBC in one dose.
62435930|NCT05377333|EXPERIMENTAL|LY3457263 (Alone)|LY3457263 administered subcutaneously (SC).
62245635|NCT00594321|ACTIVE_COMPARATOR|2|Subjects randomized to the control arm of the study will have a standard vertebroplasty with any FDA-approved bone cement done in accordance with the usual method employed by the treating physician.
62823750|NCT05422443||Chronic pain group|Children with chronic pain
62823751|NCT05422443||Health group|children without chronic pain
62823752|NCT04689139|EXPERIMENTAL|Thoracic aorta surgery patients|Blood samples on proadrenomedullin, presepsin, NT-proBNP, Troponin I, procalcitonin are acquired
62823753|NCT06295185|EXPERIMENTAL|mental health treated with digital intervention app 'Maro'|"Intervention group will use 'Maro app' which was developed to improve mental health for 8weeks.~Through 8weeks intervention group will record their status more than once a day and utilize specific functions in the app.~They will also have meetings once a week in the online chat in order to share their own experience about Maro application use with other employees in the same branch."
62823754|NCT06295185|SHAM_COMPARATOR|Digital Sham App|Control group will use Sham app for 8weeks.
62823755|NCT04424095||Pediatric patients|Recruited pediatric patients will undergo an in-office vascular visit and an echo duplex scan of lower limbs, in order to detect any symptoms or signs related to chronic venous disease.
62823756|NCT06345274|EXPERIMENTAL|Measurement Based Care Implementation|All participating opioid treatment programs will receive this arm.
62823757|NCT03774446|EXPERIMENTAL|Seliciclib|80 mg each day oral seliciclib for 4 weeks
62823758|NCT04335721|EXPERIMENTAL|Voxelot|Voxelotor 1500mg once a day
62823759|NCT04335721|OTHER|Standard of Care (SOC)|Observational while receiving SOC
62823760|NCT02700321|EXPERIMENTAL|High Flow nasal cannula oxygen (HFNC)|"Patients randomized in HFNC group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ®/Airvo® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction."
62245636|NCT00594321|EXPERIMENTAL|1|Subjects randomized to the experimental arm of the study will have a vertebroplasty with the SPACE CpsXL Bone cement (FDA-approved) and SPACE 360 Delivery System (FDA-approved).
62823761|NCT02700321|ACTIVE_COMPARATOR|STANDARD high flow Face Mask (HFFM)|"Patients randomized in Standard face mask group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction."
62823762|NCT05144373|EXPERIMENTAL|Gross motor intervention|Participants will receive a home-based, parent-administered body-weight supported treadmill intervention from about 10 months of age until walking onset.
62823763|NCT05144373|EXPERIMENTAL|Gross and fine motor intervention|"Besides the body-weight supported treadmill intervention as illustrated above, participants will receive additional fine motor intervention using sticky mittens from about 10 months of age for five months."
62823764|NCT05144373|NO_INTERVENTION|Control|Participants will not receive specific intervention.
62823765|NCT02021877||TBI subjects|Unselected adult patients with acute TBI from the Emergency Departments of the recruiting hospitals
62823766|NCT02021877||Control subjects|Acute orthopaedic non-trivial trauma that needs either surgery or conservative measures and clinical follow-up (including mere superficial soft tissue injuries)
62823767|NCT06591052|EXPERIMENTAL|Passive Group|Passive stretching was administered to the hamstring, quadriceps, and calf muscles by the same physiotherapist for participants in the passive group.
62602236|NCT05373992|EXPERIMENTAL|Aerobic Exercise|Participants will be asked to engage in 30-minutes of aerobic exercise (AE) daily for the first 72-hours following the initial clinic visit in the form of a stationary exercise bike, treadmill, or outdoors. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate. After the first 72-hours following the initial clinic visit, participants will follow the standard of care as prescribed by their provider. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
62602237|NCT05373992|EXPERIMENTAL|Screen Time Restricted & Aerobic Exercise|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) as well as engage in 30-minutes of AE in the form of a stationary exercise bike, treadmill, or outdoors, for the first 72-hours following the initial clinic visit. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate. After the first 72-hours following the initial clinic visit, participants will follow the standard of care as prescribed by their provider. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
62602238|NCT05373992|ACTIVE_COMPARATOR|Stretching|Participants will be asked to follow a daily stretching program for the first 72-hours following the initial clinic visit. After the first 72-hours following the initial clinic visit, participants will follow the standard of care as prescribed by their provider. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
62602239|NCT00810017|EXPERIMENTAL|Single arm study|Etoposide 100mg/m2 daily x 3 days Q3W and Trastuzumab 8mg/kg loading dose then 6mg/kg, then single agent until disease progression
62602240|NCT06439628||Rimegepant treatment group|
62602241|NCT00955045|EXPERIMENTAL|istradefylline|
62602242|NCT05756127||All eligible patients|Observational cohort using anonymized patient-level primary care data linked to secondary administrative data; CPRD-GOLD and CPRD-AURUM.
62042806|NCT03855449|ACTIVE_COMPARATOR|DECDIE Traditional Group|Participants randomized to the DECIDE group will receive a copy of the curriculum via mail and will be a self-study group where they go through the curriculum on their own with 4 calls from their health coach.
62602243|NCT01560533|OTHER|Treated by HIPEC|Patients treated by HIPEC for peritoneal cancer
62602244|NCT01560533|OTHER|Standard chemiotherapy|Patients treated by standard chemiotherapy for peritoneal cancer
62602245|NCT03042871|ACTIVE_COMPARATOR|Group A|Group A included 30 patients treated with one 0.5mg intravitreal ranibizumab injection. All patients were followed monthly for 12 months with additional injections performed as needed.
62602246|NCT03042871|ACTIVE_COMPARATOR|Group B|Group B included 30 patients treated with three monthly 0.5mg intravitreal ranibizumab injections. All patients were followed monthly for 12 months with additional injections performed as needed.
62042807|NCT06732050|NO_INTERVENTION|Control group|The control group will undergo standard treatment for laparoscopic endometriosis/adenomyosis surgery at Spital Limmattal. Although the control group will not be using NOL®-monitoring to guide analgesic requirement, the monitor will be installed with a blinded screen to investigate whether our multimodal anesthesia model is in coherence with values between 10 and 25. The anesthesia care team will not be able to see the values during surgery in order to tailor analgesic requirement only by conventional clinical judgement.
62042808|NCT06732050|EXPERIMENTAL|nociception guided treatment|For the nociception level-guided group the same standard narcosis will be applied whilst ensuring that the NOL® level value will be maintained between 10 and 25.
62602247|NCT04053010|EXPERIMENTAL|group 1|234 subjects; simultaneously administration of Sabin-IPV and DTaP at the age of 3/4/5 months old, 0.5 ml each dose, respectively
62042809|NCT00725452||Infliximab|Subjects with plaque psoriasis will receive Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.
62245637|NCT02603471|EXPERIMENTAL|Text Messaging CBT (TXT-CBT)|This condition will receive CBT based text messaging (TXT-CBT). Those assigned to TXT-CBT will also be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have an initial meeting with a CBT clinician to review the Life-Steps concepts. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
62245638|NCT02603471|ACTIVE_COMPARATOR|Informational group|A pamphlet with information about HIV, the importance of ART adherence, and relapse prevention will be provided to participants in this condition.
62602248|NCT04053010|ACTIVE_COMPARATOR|group 2|234 subjects; Sabin-IPV only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
62602249|NCT04053010|ACTIVE_COMPARATOR|group 3|234 subjects; DTaP only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
62602250|NCT03336268|EXPERIMENTAL|POINT|This arm will be offered both POINT services (in addition to standard emergency care) and enrollment in study data collection. If they choose to enroll in POINT, they may choose whether or not to enroll in data collection, as it is not required. Should they enroll in data collection, they will be consented and enrolled in the research study as a participant in the POINT study arm.
62602251|NCT03336268|NO_INTERVENTION|Standard Care|This arm will only be offered enrollment in study data collection, as they will receive standard emergency care. If they choose to enroll, they will be consented in the research study as the Standard Care arm.
62823768|NCT06591052|EXPERIMENTAL|PNF group|"The hold-relax technique, a specialized method within PNF (Proprioceptive Neuromuscular Facilitation), was applied by the same physiotherapist to the hamstring, quadriceps, and calf muscles of the participants in the PNF group."
62042810|NCT05747222|EXPERIMENTAL|Group Action Observation Therapy (G-AOT)|"G-AOT patients will carry out AOT therapy in addition to conventional rehabilitation therapies. In case of bilateral clinical engagement, treatment with AOT will have been conducted on the limb that on motor outcome measures appears less involved.~G-AOT patients will undergo rehabilitation treatment with AOT once a day, 5 days a week. 15 sessions will then be given, for a total duration of 3 weeks of experimental treatment with AOT."
62042811|NCT05747222|ACTIVE_COMPARATOR|Group Conventional (G-CONV)|G-CONV patients will only carry out rehabilitation treatments as per clinical practice.
62435931|NCT05377333|PLACEBO_COMPARATOR|Placebo (Alone)|Placebo administered SC.
62602252|NCT00962091|EXPERIMENTAL|Dose Escalation|A single dose of alisertib 15 mg, oral solution (OS) was administered on Day 1, followed by alisertib 40 mg, powder-in-capsule (PIC), orally, twice a day (BID) on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle. A single dose of alisertib 50 mg PIC, orally, was administered on Cycle 2 Day 1 followed by alisertib 40 mg on Days 3 through 9, followed by a 14-day rest period in Cycle 2 in a 23-day cycle. Subsequent cycles, alisertib 40 or 50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
62602253|NCT00962091|EXPERIMENTAL|Part A: Relative Bioavailability OS/PIC (Sequence A)|A single dose of alisertib 25 mg, OS, administered on Day 1, followed by alisertib 40 mg PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. A single dose of alisertib 50 mg PIC, orally, administered on Cycle 2 Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in a 23-day cycle. Subsequent cycles, alisertib 40-50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
62602254|NCT00962091|EXPERIMENTAL|Part A: Relative Bioavailability PIC/OS (Sequence B)|A single dose of alisertib 50 mg, PIC, orally administered on Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. Cycle 2 Day 1 alisertib 25 mg, OS, once on Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in a 23-day cycle. Subsequent cycles followed by alisertib 40-50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in Cycle 3, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
62823769|NCT03467750|EXPERIMENTAL|Ketorolac|Participants randomized to the ketorolac group will receive 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis has been achieved
62823770|NCT03467750|ACTIVE_COMPARATOR|Standard of Care|Participants randomized to this group will receive the pain management standard of care for the adenotonsillectomy procedure.
62823771|NCT03712813|EXPERIMENTAL|Macrodyne LivMD plate|
62823772|NCT03712813|NO_INTERVENTION|Wait-Listed Control|
62245639|NCT04573751|SHAM_COMPARATOR|Standard therapy|No intracoronary epinephrine and verapamil
62245640|NCT04573751|ACTIVE_COMPARATOR|Epinephrine|Intracoronary bolus epinephrine injection requires two ampoules each of 1:1,000 epinephrine (1 μg/mL) diluted into 100 mL of normal saline solution (to 20 μg/mL epinephrine solution); therefore, a 5-mL syringe contains 100 μg of epinephrine. Intracoronary epinephrine will be administered at a dose of 100 μg and at a lower dose of 80 μg in patients with blood pressure \>160 mmHg
62435932|NCT05377333|EXPERIMENTAL|LY3457263 + Dulaglutide|LY3457263 in combination with dulaglutide administered SC.
62435933|NCT05377333|EXPERIMENTAL|Placebo + Dulaglutide|Placebo in combination with dulaglutide administered SC.
62435934|NCT01740492|EXPERIMENTAL|LDK1: Low dose Ketamine (0.15mg/kg)|"Participants randomized to the first group, LDK1, will receive an intravenous injection of low dose ketamine (0.15mg/kg).~All participants, regardless of the group, will receive a dose of morphine(0.15mg/kg) at the same time the study drug is administered."
62435935|NCT01740492|EXPERIMENTAL|LDK2: Low dose Ketamine (0.3mg/kg)|"Participants randomized to the second group, LDK2, will receive an intravenous injection of low dose ketamine (0.3mg/kg).~All participants, regardless of the group, will receive a dose of morphine(0.15mg/kg) at the same time the study drug is administered."
62823773|NCT04069689|EXPERIMENTAL|EPX-100|Single and multiple doses of 20, 40, 80mg of EPX-100 (Clemizole Hydrochloride)
62245641|NCT04573751|ACTIVE_COMPARATOR|Verapamil|Intracoronary verapamil is administered at a dose of 0.5 mg.
62435936|NCT01740492|PLACEBO_COMPARATOR|0.9% Normal Saline|This group will receive a placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
62435937|NCT02481479|OTHER|Single group -Paired comparison|Saxagliptin 2.5mg or 5mg od
62823774|NCT04069689|PLACEBO_COMPARATOR|Placebo|Single and multiple doses of 20, 40, 80mg of placebo
62823775|NCT01870349||Titanium Implant Abutments|Gingival Crevicular Fluid Sampling
62823776|NCT01870349||Zirconium Implant Abutments|Gingival Crevicular Fluid Sampling
62823777|NCT04853173|EXPERIMENTAL|ambulatory protocol after adult tonsillectomy|prescription of analgesics for outpatient procedure with hospital surveillance
62823778|NCT01190397|EXPERIMENTAL|Blephasteam Arm|
62823779|NCT01190397|ACTIVE_COMPARATOR|warm and moist compresses arm|
62823780|NCT05052996|EXPERIMENTAL|ISL+LEN|"Participants will receive the following for at least 48 weeks:~* Day 1: LEN oral 600 mg (2 x 300 mg) and ISL 2 mg (2 x 1 mg)~* Day 2: LEN only oral 600 mg (2 x 300 mg)~* Day 8 and weekly thereafter (ie, every 7 days): LEN oral 300 mg (1 x 300 mg) and ISL 2 mg (2 x 1 mg)"
62849287|NCT02546700|PLACEBO_COMPARATOR|Placebo: Biomarker-high|Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
62245642|NCT04573751|ACTIVE_COMPARATOR|Epinephrine + verapamil|Intracoronary administration of epinephrine at a dose of 80-100 μg and verapamil at a dose of 0.5 mg.
62245643|NCT03222739|OTHER|Device Arm|This is a single arm study comparing an ultrasound with the industry standard of x-ray to detect and monitor scoliosis curvature.
62449160|NCT01352650|ACTIVE_COMPARATOR|Cohort 3A|Cycle 1: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 3: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5
62245644|NCT02091583|PLACEBO_COMPARATOR|Butter, sunflower and safflower oil|The oil (50g/day) is given in muffin and cookies made with refined wheat flour (3 g/day)daily for 4 weeks.
62245645|NCT02091583|ACTIVE_COMPARATOR|High Oleic Canola Oil and DHA (HOCO-DHA)|The oil (50g/day) is given in muffin and cookies made with refined wheat flour (3 g/day) daily for 4 weeks.
62823781|NCT05052996|EXPERIMENTAL|B/F/TAF|"Participants will receive the following for at least 48 weeks:~* bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg once daily~After 48 weeks, participants will switch from B/F/TAF to ISL+LEN~* Day 1: LEN oral 600 mg (2 x 300 mg) and ISL 2 mg (2 x 1 mg)~* Day 2: LEN only oral 600 mg (2 x 300 mg)~* Day 8 and weekly thereafter (ie, every 7 days): LEN oral 300 mg (1 x 300 mg) and ISL 2 mg~Participants who do not switch from B/F/TAF to ISL+LEN at Week 48 will be discontinued from the study."
62435938|NCT02957786|EXPERIMENTAL|Cytisine plus behavioural support|"12-week course of cytisine capsules (1.5mg), with a decreasing dosing regimen (9mg/day for days 1-3, 7.5mg/day for days 4-12, 6mg/day for days 13-16, 4.5mg/day for days 17-20, 3.0mg/day from days 21-week 12).~Participants will be asked to reduce their smoking over the first four days of treatment so that they are not smoking at all by the fifth day, which will be their designated Quit date.~Participants will also withdrawal-orientated behavioural support (delivered by cessation advisors), in addition to brief cessation advice from the study-specific doctor (at the point that the prescription is provided) and community pharmacist (at the point the participant redeems their prescription)."
62449161|NCT01352650|ACTIVE_COMPARATOR|Cohort 3B|Cycle 1: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 2: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 4: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10
62823782|NCT05920759|PLACEBO_COMPARATOR|Normal sleep|Participants will sleep for 7-9 hours the night prior to the study visit.
62823783|NCT05920759|EXPERIMENTAL|Restricted sleep|Participants will restrict sleep to four hours the night prior to the study visit.
62823784|NCT04717037|EXPERIMENTAL|Study|The olive oil massage will be applied initially at 72 hrs of life then twice daily with a dose of 4ml/kg till 28 days .
62823785|NCT04717037|NO_INTERVENTION|Control|Patients who are assigned to the control group will receive standard care as per unit policies.
62823786|NCT06588959||patients with systemic sclerosis|
62823787|NCT06601920|EXPERIMENTAL|Guided and then self-guided in Taipei Botanical Garden|One group will get guided forest healing activities during the first period of the trial, and then self-guided during the second period in Taipei Botanical Garden.
62823788|NCT06601920|EXPERIMENTAL|Self-guided and then guided in Taipei Botanical Garden|"One group will get self-guided healing activities during the first period of the trial, and then guided forest healing activities during the second period in Taipei Botanical Garden."
62823789|NCT06601920|EXPERIMENTAL|Guided and then self-guided in Chiayi Arboretum.|"One group will get guided forest healing activities during the first period of the trial, and then self-guided healing activities during the second period in Chiayi Arboretum."
62245646|NCT02091583|ACTIVE_COMPARATOR|Barley Beta-glucan|The Barley beta-glucan (3 g/day) is given in muffin and cookies made with a combination of butter, sunflower and safflower oil (50 g/day) daily for 4 weeks.
62823790|NCT06601920|EXPERIMENTAL|Self-guided and then guided in Chiayi Arboretum|"One group will get self-guided healing activities during the first period of the trial, and then guided forest healing activities during the second period in Chiayi Arboretum."
62823791|NCT05058339||Observational (survey)|Patients complete survey over 20 minutes.
62245647|NCT02091583|ACTIVE_COMPARATOR|HOCO-DHA and Barley beta-glucan|The oil and beta-glucan (50g and 3g/day, respectively) is given in muffin and cookies daily for 4 weeks.
62245648|NCT02815917|EXPERIMENTAL|Cohort 1a: Lorazepam; 1b: Perphenazine|"Up to 5 healthy volunteers will participate in a double-blind, placebo controlled serial imaging cohort 1a. Each subject will undergo two dynamic \[18F\]FTP PET/CT brain scans on two separate days. On one scan day the patient will receive an IV injection of normal saline (placebo) prior to the FTP brain scan, on the other scan day the patient will receive an IV injection of lorazepam prior to the planned FTP injection scan. The type of injection (placebo versus lorazepam) will be double-blinded to the patient and the injecting nuclear medicine Authorized User. Up to 5 subjects will participate in Cohort 1b where subjects will undergo two FTP PET/CT with and without perphenazine.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
62245649|NCT02815917|EXPERIMENTAL|Cohort 2: Healthy Volunteer Test/Retest|"Up to 10 healthy volunteers will participate in a serial imaging cohort. Each subject will undergo two dynamic \[18F\]FTP PET/CT brain scans on two separate days.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
62823792|NCT01394237||Operated by laparoscopic sacrocolpopexy|Patients operated at our institution by laparoscopic sacrocolpopexy between 2003 and 2007
62823793|NCT03030586||Alzheimer|400 patients in total, with approximately 200 patients with mild Alzheimer's disease and 200 patients with moderate to severe Alzheimer's disease will be recruited for sampling blood, urine (and other peripheral body fluids: tears and saliva as optional) for validation of biomarkers
62823794|NCT03030586||Non-Alzheimer neurodegenerative disease|"200 patients comprising:~* 75 patients with behavioural variant of Fronto-Temporal Lobe Degeneration (FTD),~* 50 patients with Parkinson's disease dementia (PDD),~* 50 patients with Dementia with Lewy Bodies (DLB) and~* 25 patients with Progressive Supranuclear Palsy (PSP) or cortico-basal degeneration (CBD)"
62823795|NCT03030586||Healthy Controls|200 healthy subjects
62823796|NCT06603948|EXPERIMENTAL|SFI|Spectral Focused Imaging
62823797|NCT06603948|PLACEBO_COMPARATOR|WLI|White Light Imaging
62823798|NCT06131801||Children and Young Adults|Children and Young Adults who are prescribed venetoclax made from crushed tablets as part of their clinical care.
62245650|NCT02815917|EXPERIMENTAL|Cohort 3: Arterial sampling|"Up to 5 cocaine-dependent males who are voluntarily seeking treatment for cocaine dependence will participate in this imaging cohort. Each subject will undergo one dynamic \[18F\]FTP PET/CT brain scan. Patients will have an arterial line placed for blood draws during the scan. This group will be used to determine the arterial blood input and FTP parent to metabolite ratio curves for FTP for a cocaine-dependent patient population for comparison with previously collected data in healthy normal volunteers.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
62245651|NCT02815917|EXPERIMENTAL|Cohort 4: Cocaine-dependent Test/Retest|"Up to 5 cocaine-dependent males who are voluntarily seeking treatment for cocaine dependence will participate in this imaging cohort. Each subject will undergo two dynamic \[18F\]FTP PET/CT brain scans on two separate days. This group will be used to test the variability of the \[18F\]FTP uptake measures in cocaine-dependent patients when scans are done following the consistent procedures with no other interventions.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
62245652|NCT02426528|EXPERIMENTAL|Cultural and Social exposure A|Cultural and Social exposure
62245653|NCT02426528|NO_INTERVENTION|Cultural and Social exposure B|Non Intervention (Control Group)
62602255|NCT00962091|EXPERIMENTAL|Part B: OS Food Effect Fed/Fasted (Sequence A)|Alisertib 35 mg (35 mg = relative bioavailability estimate in Part A as dose of OS that was calculated to yield the area under the concentration time curve of a 50-mg PIC dose): A single dose of alisertib 35 mg oral solution (OS), in fed state, administered on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. Cycle 2 Day 1 alisertib 35 mg administered, OS, in fasted state, once on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 3 onwards, participants received alisertib 40 mg, PIC, orally, BID on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted, based on individual tolerance, followed by a 14-day rest period, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
62823799|NCT05322798|EXPERIMENTAL|HF-SCS|SCS system implantation with high-frequency stimulation availability
62823800|NCT05322798|ACTIVE_COMPARATOR|LF-SCS|Conventional SCS system implantation
62823801|NCT06594224|EXPERIMENTAL|IV Ibuprofen Group|Females in this group (n=40) were given 800 mg Ibuprofen in 200 cc normal saline intravenously at the time of arrival in the ward
62823802|NCT06594224|EXPERIMENTAL|IV Nalbuphine|Patients in this group received 20 mg nalbuphine in 200 cc normal saline IV at the time of arrival in the ward.
62823803|NCT01710982|ACTIVE_COMPARATOR|TZP-101|TZP-101
62823804|NCT01710982|PLACEBO_COMPARATOR|Placebo|Placebo
62245654|NCT00891319|EXPERIMENTAL|CCFES|"CCFES - Contralaterally Controlled Functional Electrical Stimulation~* Electrical stimulator~* Stimulation to finger and thumb extensors only in response to, and with an intensity proportional to, opening of the contralateral unimpaired hand.~* A glove instrumented with sensors and worn on the unimpaired hand detects the degree of hand opening and determines stimulation intensity.~* Therapy sessions are done with the subject being assisted by the CCFES system."
62823805|NCT04669886||endotoxin study group|Patients scheduled for Percutaneous Nephrolithotomy (PCNL) as surgical treatment for their kidney stones will be evaluated for postoperative endotoxin levels as a risk marker for sepsis.
62823806|NCT06378047|EXPERIMENTAL|IRE/Pembrolizumab|Participants will undergo irreversible electroporation (IRE) using the NanoKnife system. About 1 week following IRE, study participants will receive a 200mg dose of pembrolizumab.
62823807|NCT06069193|EXPERIMENTAL|Experimental: Touch Intervention|This group receives professional touch techniques, such as procedural touch.
62245655|NCT00891319|ACTIVE_COMPARATOR|cNMES|"cNMES - Cyclic NeuroMuscular Electrical Stimulation~* Electrical stimulator~* Preprogrammed cycles of finger and thumb extensor stimulation repeatedly and automatically open the hand.~* Subject instructed to not move the contralateral arm/hand during stimulation.~* Therapy sessions are done without the stimulation system."
62245656|NCT05804279|EXPERIMENTAL|BPDO-1603|1 tablet contains memantine 20mg/donepezil 10mg
62245657|NCT05804279|ACTIVE_COMPARATOR|BPDO-16031,BPDO-16033|1 tablet memantine 20mg and 1 tablet donepezil 10mg
62245658|NCT03399097||non-obese|non-obese
62245659|NCT03399097||obese|obese
62602256|NCT00962091|EXPERIMENTAL|Part B: OS Food Effect Fasted/Fed (Sequence B)|A single dose of alisertib 35 mg, OS, in fasted state, administered on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 2 Day 1 alisertib 30 mg, OS administered in fed state, once on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 3 onwards, participants received alisertib 40 mg PIC, orally, BID on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
62823808|NCT06069193|EXPERIMENTAL|Experimental: Control|This group does not receive professional touch techniques and serves as the control for comparison.
62849288|NCT02546700|PLACEBO_COMPARATOR|Placebo: Biomarker-low|Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
62849289|NCT02873117||5 alpha reductase inhibitor|
62849290|NCT02873117||Any other drug for benign prostate hyperplasia|
62245660|NCT03399097||previously obese|previously obese
62245661|NCT00684229|ACTIVE_COMPARATOR|Regional anesthesia and analgesia|Regional anesthesia and analgesia (either epidural or paravertebral anesthesia).
62245662|NCT00684229|ACTIVE_COMPARATOR|general anesthesia followed by opioid analgesia|Subjects randomized to arm 2 will receive general anesthesia followed by opioid analgesia.
62823809|NCT06059664|EXPERIMENTAL|Finerenone|"Participants in this study arm will receive the study drug Finerenone.~Initial Dosing: Dosing regimen of 10 mg or 20 mg once daily (QD), based upon screening eGFR. For eGFR \< 60 mL/min/1.73m\^2, participants will start at 10 mg QD. For eGFR ≥ 60 mL/min/1.73m\^2, participants will start at 20 mg QD.~Dose Titration: Dose will be titrated according to potassium levels. For participants initiated at 10mg, the dose will be up titrated to 20 mg if the potassium level measured after 2 weeks is ≤4.8 meq/L and eGFR has not decreased by \>30 percent of the screening visit value. Study drug dosing may be titrated up or down per the below.~Potassium level: ≤ 4.8~* If on lower dose, up-titrate to higher dose~* If on higher dose, continue on the same dose~Potassium level: 4.9-5.5 = continue same dose~Potassium level: \>5.5 = withhold study drug and recheck potassium within 3 days. Re-initiate study drug at the 10 mg dose once potassium is ≤4.8 meq/L."
62849291|NCT05300438|EXPERIMENTAL|TSN084|
62042812|NCT04934423|EXPERIMENTAL|active tDCS|tDCS active, for 30 minutes for 5 consecutive days, with an anode positioned in the left dorsolateral prefrontal cortex and cathode electrode placed over the right supraorbital area. The EEG International 10-20 system will be taken as a reference. The current intensity will be defined from computational modeling, using Nuclear Magnetic Resonance (MRI) to estimate and individualize a dose to be administered.
62245663|NCT01475682||1|"167 subjects recruited from our previous OSA and metabolic syndrome (OSAMS) cohort from October 2002 to June 2007 will be invited to be reassessed at this time point."
62245664|NCT00943020|ACTIVE_COMPARATOR|Nutricia PreOp + Lipid|Nutricia PreOp + Lipid
62245665|NCT00943020|ACTIVE_COMPARATOR|Nutrica PreOP + Glutamine|Nutrica PreOP + Glutamine
62245666|NCT00943020|EXPERIMENTAL|Nutricia PreOP|Nutricia PreOP: carbohydrate only drink
62245667|NCT00000125|NO_INTERVENTION|Observation|Close Observation.
62245668|NCT00000125|OTHER|Treatment|Participants treated with commercially available topical ocular hypotensive eye drops.
62245669|NCT02811055|EXPERIMENTAL|Administration of Aprepitant|Administration of Aprepitant 80 mg once per day during 14 days; Blood sampling, electrocardiogram, orthostatic test and Blood Pressure Measurement are done after 14 days
62245670|NCT02811055|PLACEBO_COMPARATOR|Administration of placebo|Administration of Placebo once per day during 14 days; Blood sampling, electrocardiogram, orthostatic test and Blood Pressure Measurement are done after 14 days
62245671|NCT04578886|PLACEBO_COMPARATOR|Placebo|Placebo, lactulose monohydrate, encapsulated, once nightly at 2100, for up to 14 day study duration or otherwise indicated by study protocol.
62245672|NCT04578886|EXPERIMENTAL|Guanfacine|Guanfacine immediate-release, 2mg dose, over-encapsulated tablet, once nightly at 2100, for up to 14 day study duration or otherwise indicated by study protocol.
62245673|NCT04515472|ACTIVE_COMPARATOR|Healthy Volunteer Male|Healthy male currently on no testosterone treatment
62245674|NCT04515472|ACTIVE_COMPARATOR|Healthy Volunteer Female|Healthy female currently on no estrogen treatment
62245675|NCT04515472|ACTIVE_COMPARATOR|MTF group|MTF transgender currently on estrogen treatment
62823810|NCT06059664|PLACEBO_COMPARATOR|Placebo|"Participants in this study arm will receive the placebo comparator.~Initial Dosing: Dosing regimen of 10 mg or 20 mg once daily (QD), based upon screening eGFR. For eGFR \< 60 ml/min/1.73m\^2, participants will start at 10mg QD. For eGFR ≥ 60ml/min/1.73m\^2, participants will start at 20 mg QD.~Dose Titration: Dose will be titrated according to potassium levels. For participants initiated at 10 mg, the dose will be up titrated to 20 mg if the potassium level measured after 2 weeks is ≤4.8 meq/L and eGFR has not decreased by \>30 percent of the screening visit value. Study drug dosing may be titrated up or down per the table below.~Potassium level: ≤ 4.8~* If on lower dose, up-titrate to higher dose~* If on higher dose, continue on the same dose~Potassium level: 4.9-5.5 = continue same dose~Potassium level: \>5.5 = withhold study drug and recheck potassium within 3 days. Re-initiate study drug at the 10 mg dose once potassium is ≤4.8 meq/L."
62849292|NCT06027645|EXPERIMENTAL|Crawli Group|Participants from the Crawli Group will benefit from the crawling stimulation intervention with a mini-skateboard (i.e. the crawliskate) in addition to usual care
62849293|NCT06027645|NO_INTERVENTION|Control Group|Control group infants benefit from usual care
62245676|NCT04515472|ACTIVE_COMPARATOR|FTM group|FTM transgender group currently on testosterone treatment
62245677|NCT01714778||e-Cigarette|Smokers attempting to quit with behavioural support and e-Cigarettes.
62245678|NCT00153647|ACTIVE_COMPARATOR|1|Cap-assisted Colonoscopy
62435939|NCT02957786|ACTIVE_COMPARATOR|Varenicline plus behavioural support|"12-week course of Varenicline tablets (0.5mg/1mg), with an increasing dosing regimen (0.5mg/day for days 1-3, 1.0mg/day for days 4-7, 2.0mg/day for day 8-week 12).~Participants will be asked to reduce their smoking over the first four days of treatment so that they are not smoking at all by the fifth day, which will be their designated Quit date.~Participants will also receive withdrawal-orientated behavioural support (delivered by cessation advisors), in addition to brief cessation advice from the study-specific doctor (at the point that the prescription is provided) and community pharmacist (at the point the participant redeems their prescription)."
62435940|NCT02580890|EXPERIMENTAL|tDCS active|"Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline. The stimulator to be used will be the Chattanooga Ionto ISO 13485. Stimulation will be performed for 5 days, one time per day."
62435941|NCT02580890|SHAM_COMPARATOR|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
62435942|NCT03785483|EXPERIMENTAL|Motivation|Using implementation intention techniques such as action planning. Every week, participants state when, where, and what kind of prescribed exercises they will do.
62435943|NCT03785483|ACTIVE_COMPARATOR|Mindfulness|10 minutes of audio recordings daily. Recordings contain: awareness of the breath, acceptation of thoughts and emotions, awareness of postures, awareness during stretching, awareness of a single movement (moving legs up while standing).
62435944|NCT03785483|NO_INTERVENTION|Treatment as usual|Physical activity prescribe 120 minutes per week.
62435945|NCT01841359|NO_INTERVENTION|Baseline|"Baseline Arm/Phase 1, is comprised of study visits 1 and 2. Visit 1: Screening visit. Eligible individuals who provided informed consent were asked to keep a 3-day log of food intake, blood glucose (8 per day), as well as any hypoglycemic symptoms, concurrent with a 3 day period of blinded (masked) continuous glucose monitoring device wear.~Visit 2: a baseline mixed meal tolerance test was performed. Glucose, hormonal responses, and satiety were assessed. Glucose and symptom logs were reviewed."
62245679|NCT00153647|PLACEBO_COMPARATOR|2|Regular Colonoscopy
62245680|NCT04841512|PLACEBO_COMPARATOR|Placebo|Sterile phosphate-buffered saline for injection Single 1mL injection into the facet joint
62245681|NCT04841512|EXPERIMENTAL|XT-150 Dose #1|Lower dose of XT-150 sterile solution for injection Single 1 mL injection into the facet joint
62245682|NCT04841512|EXPERIMENTAL|XT-150 Dose #2|Higher dose of XT-150 sterile solution for injection Single 1 mL injection into the facet joint
62823811|NCT04385277|EXPERIMENTAL|Treatment (temozolomide, irinotecan, dinutuximab)|Patients receive temozolomide PO or via enteral tube daily and irinotecan IV over 90 minutes daily on days 1-5, dinutuximab IV over 10-20 hours daily on days 2-5, sargramostim SC or IV over 2 hours daily on days 6-12, and isotretinoin PO BID on days 8-21. Patients undergo MUGA during screening. Patients also undergo MRI, or CT, I23I-MIBG, or FDG-PET, BM aspiration, and BM biopsy on study. Treatment repeats every 28 days for up to 5 cycles (up to 6 cycles for isotretinoin only) in the absence of disease progression or unacceptable toxicity.
62823812|NCT04634422|EXPERIMENTAL|Plasma Exchange and convalescent Plasma|2 plasma exchange procedures within 24 hours and in addition 2 bags of CCP (equalling 600 ml CCP) infused at the end of the 2nd procedure.
62435946|NCT01841359|EXPERIMENTAL|Pramlintide|"At the end of Visit 2 (following the baseline mixed meal tolerance test), pramlintide was prescribed, with instructions for titration from minimal to maximal dose (15 to 120 µg). During the treatment phase (8 weeks), the participants were asked to keep record of all hypoglycemic symptoms and blood glucose measurements..~Visit 3: (week 4 of treatment) focused on evaluation of symptoms and side effects. Participants again completed a food and glucose diary for 3 days with concurrent wear of a blinded (masked) continuous glucose monitoring device.~Visit 4: (week 8 of treatment), participants received a dose of pramlintide 15 minutes prior to undergoing a repeat mixed meal tolerance test. (the dose administered was the maximally tolerated dose of pramlintide used during the 8 week outpatient treatment phase)."
62435947|NCT04101474|ACTIVE_COMPARATOR|Ketamine group|half of participants will take ketamine
62435948|NCT04101474|NO_INTERVENTION|Placebo group|the other half of participants will not take any drugs
62435949|NCT04344054|EXPERIMENTAL|Arm 1|RV3-BB/TV P2-VP8 boost
62435950|NCT04344054|EXPERIMENTAL|Arm 2|RV3-BB/TV P2-VP8 co-administered
62435951|NCT04344054|EXPERIMENTAL|Arm 3|RV3-BB primed TV P2-VP8
62435952|NCT04344054|EXPERIMENTAL|Arm 4|Rotarix®/TV P2-VP8 Boost
62435953|NCT04344054|EXPERIMENTAL|Arm 5|Rotarix®/TV P2-VP8 co-administered
62435954|NCT04344054|EXPERIMENTAL|Arm 6|TV P2-VP8 alone
62435955|NCT04656951|EXPERIMENTAL|Daratumumab added to VCd in induction, Vd in maintenance and Rd at relapse|"Daratumumab at standard dose of 1800 mg will be administered subcutaneously at weekly intervals in cycles 1-2 and every 2 weeks in cycles 3-6 and every 4 weeks in cycles 7-8 together with VCD using bortezomib weekly s.c. for 8 cycles of 28 days each, cyclophosphamide i.v. at 500 mg/m2 on d1 of every cycle and dexamethasone p.o. at 20 mg per week.~Maintenance will be daratumumab subcutaneously every 4 weeks with bortezomib s.c. and dexamethasone 20 mg every 2 weeks until progression or intolerance.~At relapse/progression treatment will be daratumumab 1800 mg subcutaneously weekly during cycle 1-2, every 2 weeks in cycle 3-6 and every 4 weeks thereafter together with lenalidomide 25 mg p.o. day 1-21 and dexamethasone 20-40 mg weekly."
62435956|NCT06168071|EXPERIMENTAL|taVNS with EEG in healthy children|The investigators will enroll 10 children between 7-18 years of age who are admitted to the hospital for EEG monitoring for spell characterization to receive one session of 30 minutes of taVNS. The investigators will titrate taVNS to below perceptual threshold of stimulation and objectively assess tolerability. The following parameters will be used for taVNS: frequency 25 Hz, pulse width 250 µs, and varying intensities from 0.5 milliampere (mA) to 2 mA. Intensity will be titrated to be a level below perceptual threshold in a patient. The participant will have continuous cardiorespiratory monitoring via pulse oximetry and blood pressure every 5 minutes. EEG data will be compared before, during and after taVNS.
62435957|NCT03256175|EXPERIMENTAL|Oxygen|Patient was give 15L/min of Oxygen via HFM 30 mins before and continue through out the procedure. 6 weeks post procedure, EST was arranged
62435958|NCT03256175|PLACEBO_COMPARATOR|Air|Patient was given Facemask without oxygen through out the procedure. 6 weeks post procedure, EST was arranged
62435959|NCT01188928|EXPERIMENTAL|LEO 80185|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension
62435960|NCT01188928|ACTIVE_COMPARATOR|Betamethasone|Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle
62435961|NCT01188928|ACTIVE_COMPARATOR|Calcipotriol|Calcipotriol 50 mcg/g in the topical suspension vehicle
62435962|NCT01188928|PLACEBO_COMPARATOR|Topical suspension vehicle|The topical suspension vehicle alone
62823813|NCT04634422|NO_INTERVENTION|Control without intervention|Standard care without the use of PLEX or convalescent plasma.
62602257|NCT00962091|EXPERIMENTAL|Part C: ECT Food Effect Fed/Fasted (Sequence A)|Alisertib 50 mg, enteric-coated tablets (ECT), orally, in fed state, once on Day 1, followed by alisertib 40 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle, followed by alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 40 or 50 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 2 in a 23-day cycle. Cycle 3 onwards, participants were administered alisertib 40 mg BID ECT on Days 1-7 with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
62602258|NCT00962091|EXPERIMENTAL|Part C: ECT Food Effect Fasted/Fed (Sequence B)|Alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 40 mg, ECT, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle, followed by alisertib 50 mg, ECT, orally, in fed state, once on Day 1, followed by alisertib 40 or 50 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 2, a 23-day cycle. Cycle 3 onwards participants were administered alisertib 40 mg BID ECT on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
62602259|NCT01440140|EXPERIMENTAL|Closed loop (algorithm)|
62602260|NCT01440140|PLACEBO_COMPARATOR|Open loop|
62602261|NCT04388904|EXPERIMENTAL|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)|Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.
62602262|NCT01589848||von Willebrand women|Referred women who may have von Willebrand Disease
62602263|NCT04978441||Type 1 diabetes mellitus (T1DM)|"1. Males or females above 18 years old~2. Patients with a prior medical history diagnosis of T1DM~3. Patients who are using a continuous glucose monitor (CGM or FGM)"
62602264|NCT03703908|EXPERIMENTAL|Sequential|All enrolled subjects will initially be treated with the active study medication CCX140-B at a dose of 5 mg twice daily. Dose will increase in a step-wise fashion up to 15 mg twice daily.
62602265|NCT01811862|EXPERIMENTAL|Acupuncture|Acupuncture treatment once daily inpatient for 5 consecutive days starting at on the day after chemotherapy plus usual pre- and post-transplantation care.
62602266|NCT01811862|SHAM_COMPARATOR|Sham acupuncture|Sham acupuncture once daily inpatient for 5 consecutive days starting at on the day after chemotherapy plus usual pre- and post-transplantation care.
62602267|NCT05107466||Individuals with Hearing Loss|60 adults (\>18 y/o) with a diagnosis of hearing loss. These participants may use cochlear implant(s), hearing aid(s), or have unaided hearing loss.
62602268|NCT05107466||Individuals with Normal Hearing|40 adults (\>18 y/o) without a diagnosis of hearing loss.
62602269|NCT00560586|EXPERIMENTAL|Budesonide|Budesonide for 6 weeks followed by crossover to placebo
62602270|NCT00560586|PLACEBO_COMPARATOR|Placebo|Placebo for 6 weeks followed by crossover to treatment.
62823814|NCT05964842|NO_INTERVENTION|Standard of care (Control)|Patients in this arm will receive the routine TB care, according to the Uganda Ministry of Health guidelines, that is; i) Patient screened for TB ii) Patient identified as presumptive and registered in the presumptive TB register iii) Patient referred for TB testing iv) Patient expected to return and pick results on their own drive vi) Positive TB patients initiated on treatment.
62435963|NCT02506725|EXPERIMENTAL|Prenatal Care in groups|We will do prenatal care using centering care pregnancy methodology in 10 sessions
62602271|NCT00526565|EXPERIMENTAL|1|TAT (Tapas Acupressure Technique)
62602272|NCT00526565|ACTIVE_COMPARATOR|2|SS (Professionally facilitated social support groups)
62602273|NCT02567409|EXPERIMENTAL|Arm A (berzosertib, gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV over 60 minutes on day 1. Patients also receive berzosertib IV over 60 minutes on days 2 and 9. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
62602274|NCT02567409|EXPERIMENTAL|Arm B (gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride and cisplatin as in Arm A.
62435964|NCT02506725|NO_INTERVENTION|Control Group|We will do in this arm conventional Prenatal care available in the family clinics
62823815|NCT05964842|EXPERIMENTAL|SMS only|In addition to standard of care, participants in this arm will receive three SMS reminders. The first SMS will be sent on day one after enrollment into the study. The second SMS will be sent once participant results are ready. If two days after the second SMS the patient has not returned to complete TB diagnosis, a third SMS will be sent. Messages will be automatically sent in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.
62602275|NCT01027728|EXPERIMENTAL|CCX354-C|
62602276|NCT02332239|EXPERIMENTAL|iDOVE Intervention (ED+text)|"1. In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~2. Eight-week longitudinal tailored CBT-based text-message program"
62602277|NCT02332239|PLACEBO_COMPARATOR|Control (EUC)|"1. In-ED brief session, discussing home safety \& nutrition~2. Eight-week longitudinal home safety \& nutrition text-message program"
62602278|NCT03071731|EXPERIMENTAL|Bronchodilators|Nebulization of ipratropium bromide/salbutamol sulfate (500 µg/2.5 mg) before the administration of the Glittre ADL-test
62602279|NCT03071731|PLACEBO_COMPARATOR|Placebo|Nebulization of a placebo before the administration of the Glittre ADL-test
62602280|NCT04231396|OTHER|HA and CI Users using Audiobooks for Hearing Loss for Auditory Training|"study participants will be seen weekly for 12 weeks and will use the Audiobooks for HL App for the final 6 weeks using the App at least two hours per week on their own. The researcher will conduct 12 weekly in-home visits where the following will be done:~First 6 weeks:~• Partial BKB-SIN will be administered~Final 6 weeks:~* Partial BKB-SIN will be administered~* Conduct a comprehension test.~* Address any usability issues the participant brings up.~* Review and set new weekly goals Final session: Conduct Final Usability survey"
62602281|NCT00735293|OTHER|Treatment|There is only one arm to this study. All patients will receive treatment with the VASER for their axillary hyperhidrosis/bromidrosis
62602282|NCT02834988||SLND Patients|Patients scheduled to have their sentinel lymph nodes removed, as part of standard of care.
62602283|NCT02900495|EXPERIMENTAL|Suprapubic TENS|electrodes, 'transcutaneous electric nerve stimulation' placed onto the lower abdomen in the suprapubic region directly over the bladder
62602284|NCT02900495|EXPERIMENTAL|Posterior Tibial TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the posterior tibial nerve behind the medial malleolus of the ankle and another electrode on the bottom of the foot
62602285|NCT02900495|EXPERIMENTAL|Parasacral TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the S3 foramen on the sacrum on each side of the midline in the lower back/upper buttocks
62602286|NCT02900495|PLACEBO_COMPARATOR|Shoulder TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the scapula on the shoulder/back
62602287|NCT02255318|EXPERIMENTAL|Taurolock|Patients received Taurolock lock for 3 months administration.
62602288|NCT02255318|PLACEBO_COMPARATOR|Placebo|Patients received placebo lock (physiological serum) for 3 months administration.
62435965|NCT05610930|NO_INTERVENTION|Control arm|"Participants received a questionnaire including 3 sets of images of food packaging, (brand blinded), categorized by food groups: 8 cookies, 7 breakfast cereals, and 7 ready-to-eat meals, but without front-of-pack nutritional label (in case the original Nutri-Score was displayed on the product, it was hidden by the investigators). They had the possibility to check the back-of-pack nutrition facts and ingredient information. First, they were asked which product they would intend to purchase in each category, and which product they thought to be the healthiest. Then, participants were asked 1) to rank them according to their nutritional quality by identifying the first, the second and the third products with the best nutritional quality (in this order) and 2) to identify those that were ultra-processed."
62602289|NCT01655849|EXPERIMENTAL|Z160|375mg BID
62602290|NCT01655849|PLACEBO_COMPARATOR|placebo|matching placebo control
62602291|NCT01534208|EXPERIMENTAL|Androxal 12.5 mg|Androxal 12.5 mg daily
62602292|NCT01534208|EXPERIMENTAL|Androxal 25 mg|Androxal 25 mg daily
62602293|NCT01443091|EXPERIMENTAL|Colostrum|
62602294|NCT01443091|PLACEBO_COMPARATOR|Sterile water|
62602295|NCT04341831|EXPERIMENTAL|Group 1|We will be added 200mg teicoplanin powder around instrument for each level.
62602296|NCT04341831|NO_INTERVENTION|Group 2|We will not used any antibiotic powder in this group.
62602297|NCT06619938|ACTIVE_COMPARATOR|Mindfulness Without Biofeedback|
62602298|NCT06619938|EXPERIMENTAL|Mindfulness With Biofeedback|
62602299|NCT01149421|EXPERIMENTAL|1.5 milligram (mg) LY2189265|LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
62602300|NCT01149421|EXPERIMENTAL|0.75 milligram (mg) LY2189265|LY2189265: 0.75 milligram (mg), subcutaneous (SC), once weekly (QW)
62602301|NCT01149421|PLACEBO_COMPARATOR|Placebo|Placebo: subcutaneous (SC), once weekly (QW)
62602302|NCT05821972|EXPERIMENTAL|Nebulized dexmedetomidine and ketamine|Pre-operative nebulization of dexmedetomidine and ketamine
62602303|NCT05821972|ACTIVE_COMPARATOR|Nebulized dexmedetomidine|Pre-operative nebulization of dexmedetomidine
62602304|NCT02956447|EXPERIMENTAL|Intravenous Kisspeptin|Blood sampling every 10 minutes over two 12-hour periods. One 12-hour period without any intervention. One 12-hour period consisting of administration of 10 boluses of kisspeptin 112-121 intravenously (IV).
62602305|NCT02956447|EXPERIMENTAL|Subcutaneous Kisspeptin|Subcutaneous (SC) administration of kisspeptin 112-121 every 90 minutes over eight days.
62602306|NCT06390007|PLACEBO_COMPARATOR|Control group|In the control group, standard analgesic therapy will be administered by the attending physician, and a sham press needle (a patch resembling a press needle without a needle) will be applied.
62602307|NCT06390007|EXPERIMENTAL|Intervention group|In the experimental group, standard analgesic therapy will be administered and press needle acupuncture will be applied at acupuncture points.
62602308|NCT00556634|ACTIVE_COMPARATOR|B|
62602309|NCT00556634|EXPERIMENTAL|A|
62602310|NCT01881880|OTHER|Tomosynthesis|Bilateral mammography with 4 views Tomosynthesis
62602311|NCT00070018|EXPERIMENTAL|CHOP + RT + Zevalin|Patients first receive 3 cycles (21 days each) of CHOP, consisting of: cyclophosphamide 750 mg/m\^2 on day 1, doxorubicin 50 mg/m\^2 on day 1, vincristine 1.4 mg/m\^2 on day 1, and prednisone 100 mg on days 1-5. Patients receive 4000-5000 cGy of radiation therapy in 25 fractions, starting 3 weeks after completion of CHOP. 3-6 weeks after completing RT, patients receive Zevalin, which consists of: rituximab 250 mg/m\^2 on days 1 and 7, 8 or 9; In-111 ibritumomab tiuxetan 5 mCi within 4 hours after rituximab on day 1; and Y-90 ibritumomab tiuxetan 0.4 mCi/kg within 4 hours after rituximab on day 7, 8 or 9.
62602312|NCT00292110|ACTIVE_COMPARATOR|Arm Four|
62602313|NCT00292110|EXPERIMENTAL|Arm One|
62602314|NCT00292110|ACTIVE_COMPARATOR|Arm Three|
62602315|NCT00292110|ACTIVE_COMPARATOR|ArmTwo|
62602316|NCT02528890||preganat women between 34 - 40 weeks|Eligible pregnant women, who meet the inclusion criteria, will have a vaginal/anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
62602317|NCT01695330|EXPERIMENTAL|Subcutaneous bortezomib|
62823816|NCT05964842|EXPERIMENTAL|Phone call only|In addition to standard of care, participants in this arm will receive three phone call reminders to complete TB diagnosis. The first phone call will be made on day one after enrollment into the study. The second phone call will be made once participant results are ready. If two days after the second phone call the patient has not returned to complete TB diagnosis, a third phone call will be made. Phone calls will be made in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.
62823817|NCT05964842|EXPERIMENTAL|SMS and mobile money incentives|"In addition to standard of care, participants in this arm will receive three SMS reminders and a transport refund once they complete TB diagnosis. The first SMS will be sent on day one after enrollment into the study. The second SMS will be sent once participant results are ready. If two days after the second SMS the patient has not returned to complete TB diagnosis, a third SMS will be sent. Messages will be automatically sent in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.~Once participants in this study arm complete TB diagnosis by submitting a sputum sample and collecting back results, a money incentive worth 20,000/= (Twenty thousand shillings only) will be given as a transport refund sent via mobile money."
62823818|NCT05964842|EXPERIMENTAL|Phone call and mobile money incentives|"In addition to standard of care, participants in this arm will receive three phone call reminders and a transport refund once they complete TB diagnosis. The first phone call will be made on day one after enrollment into the study. The second phone call will be made once participant results are ready. If two days after the second phone call the patient has not returned to complete TB diagnosis, a third phone call will be made. Phone calls will be made in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.~Once participants in this study arm complete TB diagnosis by submitting a sputum sample and collecting back results, a money incentive worth 20,000/= (Twenty thousand shillings only) will be given as a transport refund sent via mobile money."
62435966|NCT05610930|EXPERIMENTAL|Experimental arm|"Participants received a questionnaire including 3 sets of images of real food product packaging (brand blinded), categorized by food groups: 8 cookies, 7 breakfast cereals, and 7 ready-to-eat meals, with the Nutri-Score 2.0 displayed on the front-of-pack of each product. First, they were asked which product they would intend to purchase in each category, and which product they thought to be the healthiest. Then, participants were asked 1) to rank them according to their nutritional quality by identifying the first, the second and the third products with the best nutritional quality (in this order) and 2) to identify those that were ultra-processed. Last, a series of questions evaluated how participants of this arm perceived the Nutri-Score 2.0 and whether they found it helpful."
62435967|NCT01507831|PLACEBO_COMPARATOR|Placebo|Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 78 weeks.
62602318|NCT05950581|EXPERIMENTAL|: Modified Twin-Block Appliance with Clear Plates.|Clear plates technique A group of patients in which participants will be undergo to clear plates treatment will be applied to the upper and lower arch 17 hours daily Experimental : Modified Twin-Block Appliance with Clear Plates.
62602319|NCT05950581|EXPERIMENTAL|Traditional Twin-Block appliance|Traditional Twin-Block appliance A group of patients in which participants will undergo to the Traditional Twin-Block appliance Treatment, appliances will be applied to the upper and lower arch 17 hours daily
62602320|NCT04340258|EXPERIMENTAL|Pembrolizumab & Cesium-131|200 mg Pembrolizumab (Day -14 pre-surgery; Every 3 weeks after surgery) + Cesium-131 Seeds to deliver 60-70Gy of radiation (Single dose at the time of salvage surgery)
62602321|NCT02013661||Suture in Periodontal resective surgery|Four types of suture including silk, polypropylene, PGA, and PTFE
62602322|NCT01425970|EXPERIMENTAL|25 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 1
62602323|NCT01425970|EXPERIMENTAL|50 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 2
62602324|NCT01425970|EXPERIMENTAL|100 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 3
62602325|NCT01425970|PLACEBO_COMPARATOR|Placebo + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 4
62602326|NCT01425970|EXPERIMENTAL|100 mg INX-08189 + Ribavirin|PART B Arm 1
62602327|NCT01425970|EXPERIMENTAL|200 mg INX-08189 + Ribavirin|PART B Arm 2
62602328|NCT01425970|EXPERIMENTAL|Daclatasvir + INX-08189 100 mg|PART B Arm 3
62602329|NCT01425970|EXPERIMENTAL|Daclatasvir + INX-08189 200 mg|PART B Arm 4
62602330|NCT01425970|EXPERIMENTAL|Daclatasvir + INX-08189 50 mg + Ribavirin|PART B Arm 5
62602331|NCT03488849|EXPERIMENTAL|SureCRIC|SureCRIC-aided cricothyroid membrane identification
62602332|NCT03488849|ACTIVE_COMPARATOR|Freehand|Freehand cricothyroid membrane identification
62602333|NCT00689559|EXPERIMENTAL|1|AZD3480 + Aripiprazole
62602334|NCT00689559|EXPERIMENTAL|2|Placebo + Aripiprazole
62823819|NCT01945008||Hepatitis-C infected patients|Patients with Hepatitis-C infection untreated at the enrolment
62823820|NCT04847817||Index cases|Patients infected by SARS-Cov2 Polymerase Chain Reaction (PCR) and hospitalized in a referral center for COVID-19 .
62823821|NCT04847817||Households cases|Household contacts of SARS-Cov2 hospitalized COVID-19 patients.
62245683|NCT04147026|EXPERIMENTAL|SinnoTest® software|SinnoTest® is a therapeutic guidance device for patients suffering from rheumatoid arthritis. Prescription of an original or biosimilar biotherapy (rituximab, adalimumab, abatacept) is possible.
62823822|NCT01135277||Sepsis|Patients who have been diagnosed with Sepsis within 24 hours of admission
62823823|NCT01135277||Non-Septic|Patients who have not been diagnosed with sepsis within 24 hours of admission
62245684|NCT04147026|ACTIVE_COMPARATOR|Current practice|Prescription of biotherapy without the SinnoTest® software which corresponds to current practice (all biotherapies).
62435968|NCT01507831|EXPERIMENTAL|Alirocumab|Alirocumab 150 mg Q2W added to stable LMT for 78 weeks.
62435969|NCT00927888|ACTIVE_COMPARATOR|1 - Bupivacaine Block|3 ml of 0.25% Bupivacaine with Epi 1:100,000 (A block)
62435970|NCT00927888|PLACEBO_COMPARATOR|2 - Placebo|Normal saline with Epi 1:100,000 (B block)
62435971|NCT00776633|EXPERIMENTAL|Short triple|6 weeks triple therapy
62435972|NCT00776633|ACTIVE_COMPARATOR|Long triple|6 months triple therapy
62823824|NCT01592734|EXPERIMENTAL|PEG-only|Polyethylene glycol 4000 only (PEG-only).
62823825|NCT01592734|ACTIVE_COMPARATOR|PEG-EL|Polyethylene glycol 3350 with electrolytes (PEG-EL).
62823826|NCT06603324|EXPERIMENTAL|CVVHD treatment in paediatric mode with multiFiltratePRO|Treatment of acute kidney injury paediatric patients with continuous veno-venous haemodiafiltration (CVVHD) in paediatric mode with multiFiltratePRO
62823827|NCT06592352|EXPERIMENTAL|Modafinil Generis 100 mg|Modafinil Generis 100 mg, in a dose of 200mg, once a day, orally.
62245685|NCT00846651|EXPERIMENTAL|colloid, then phenylephrine infusion|colloid administration; with 0.5 L Hydroxyethylstarch solution at a rate of 17 ml/min and completed over 30 min. A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
62245686|NCT00846651|ACTIVE_COMPARATOR|crystalloid, then phenylephrine infusion|crystalloid administration; The patients received 1.5 L Ringer's lactate infusion at a rate of 50 ml/min and completed over 30 min prior to spinal anesthesia for cesarean section. A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
62245687|NCT00437385|ACTIVE_COMPARATOR|1|Continuation-Medication with Antidepressants (after WBS Guidelines)
62245688|NCT00437385|EXPERIMENTAL|2|Continuation-ECT with Antidepressants
62245689|NCT00437385|EXPERIMENTAL|3|"Continuation-Psychotherapy (Cognitive Behavioral Group Psychotherapy including the Situational Analysis of CBASP)"
62435973|NCT01504828|EXPERIMENTAL|Ramipril|Those who are 40 years and older receive an ACE inhibitor to determine if this reduces age-related changes in left ventricular energetics and function
62435974|NCT06177041|EXPERIMENTAL|M108 plus CAPOX|
62435975|NCT06177041|PLACEBO_COMPARATOR|placebo plus CAPOX|
62435976|NCT00868114|EXPERIMENTAL|1|3 weekly injections of intratumoral TNFerade plus radiation and 3 weekly intratumoral injections of dendritic cell vaccine
62435977|NCT00868114|EXPERIMENTAL|2|Radiation Only with 3 weekly intratumoral injections of dendritic cell vaccine
62602335|NCT03925584|EXPERIMENTAL|Music Therapy|Implement standardized nurse-led music therapy for neonates post congenital heart surgery who are admitted to the cardiac intensive care unit.
62823828|NCT06378008|EXPERIMENTAL|Test toothpaste|Participants will dose the toothbrush with a ribbon of toothpaste, across the full brush head and will brush the entire dentition thoroughly for at least 1-timed minute, twice daily (morning and evening), for approximately 56 days making sure to brush the sensitive areas of the two 'test teeth' carefully first. Participants who wish to rinse after brushing will be instructed to rinse with 10 milliliter (ml) water using graduated rinsing cup provided.
62823829|NCT06378008|ACTIVE_COMPARATOR|Reference toothpaste (Negative control)|Participants will dose the toothbrush with a ribbon of toothpaste, across the full brush head and will brush the entire dentition thoroughly for at least 1-timed minute, twice daily (morning and evening) for approximately 56 days. Participants who wish to rinse after brushing will be instructed to rinse with 10 ml water using graduated rinsing cup provided.
62823830|NCT06365697|EXPERIMENTAL|experimental group|Carotid artery stenting with the experimental device
62823831|NCT06365697|ACTIVE_COMPARATOR|control group|Carotid artery stenting with the control device
62823832|NCT03475004|OTHER|Safety run-in|Ten patients will be accrued to stage 1 and treated with standard doses of pembrolizumab, binimetinib and bevacizumab. If the standard doses are not tolerable and 2 or more patients experience a DLT, then patients would be enrolled in dose level -1 which would comprise of standard doses of pembrolizumab and bevacizumab but binimetinib would be at a dose lower of 30 mg PO BID. If 2 or more patients experience a DLT at dose level -1, then patients will be enrolled in dose level -2 which will comprise of standard doses of pembrolizumab and bevacizumab but a lower dose of binimetinib at 15 mg BID. Upon determination of the safety and tolerability of the treatment regimen, the study will proceed to stage 2.
62042813|NCT04934423|SHAM_COMPARATOR|Sham tDCS|The electrodes will be positioned in the same way as in the intervention group. However, individuals in this group will receive a stimulation that will last only 20-30 seconds. Subsequently, the device is switched off, no longer emitting current.
62042814|NCT01477125|EXPERIMENTAL|Flex working memory training|30-40 minutes of working memory training, 5 days a week for 5 weeks
62042815|NCT01477125|PLACEBO_COMPARATOR|Control version of Flex|30-40 minutes of training with a control version of Flex, 5 days a week for 5 weeks.
62042816|NCT06061497|EXPERIMENTAL|Abdomino-diaphragmatic breathing|"There are four consultations with autonomous rehabilitation nursing intervention: abdomino-diaphragmatic breathing.~In addition to adding the health care that is recommended in the Integrated Care Process for Asthma in Children and Adults, of the Portuguese Directorate-General for Health, namely:~Health education:~Inhalation technique Adherence to treatment; Presence of comorbidities; Smoking; Other environmental factors; Promotion of physical activity."
62245690|NCT04441034|EXPERIMENTAL|Anti-convulsant medication|The participants will be randomized to receiving an anti-convulsant medication. Then using a patient centered approach, the participant and their treating pain provider will choose one medication within the class. Participants will continue the medications for at least 6 months provided that they can tolerate the side effects, consider the treatment effective, and are willing to continue the treatment. We are studying two classes of medications and specific names of medications do not apply.
62245691|NCT04441034|EXPERIMENTAL|Anti-depressant medication|The participants will be randomized to receiving an anti-depressant medication. Then using a patient centered approach, the participant and their treating pain provider will choose one medication within the class. Participants will continue the medications for at least 6 months provided that they can tolerate the side effects, consider the treatment effective, and are willing to continue the treatment. We are studying two classes of medications and specific names of medications do not apply.
62245692|NCT06473974|OTHER|Participation Group/Arm.|Experimental: Test cosmetic product Other: Cleanser and sunscreen
62245693|NCT01591317|EXPERIMENTAL|Prasugrel - 60 mg/10 mg|Prasugrel 60 mg loading dose given once orally, followed by 10 mg once a day orally for 10 days
62435978|NCT03974152|EXPERIMENTAL|Own brand cigarette first, then ENDS with protonated nicotine, then ENDS with unprotonated nicotine|In each of the 3 sessions, participants will be instructed to take one puff of the tobacco product (cigarette or Subox Mini C ENDS with 18 mg nicotine) every 30 seconds for 5 minutes followed by a 2nd blood draw (if staffing allows). Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
62602336|NCT02255136|EXPERIMENTAL|Individualized homeopathic medicines|Psorinum, Tuberculinum, Medorrhinum, Calcarea carbonica, Natrum sulphuricum etc. as indicated; Rescue medicines, e.g. Aralea racemosa, Arsenicum album, Histamine hydrochloride, House dust, Ipecacuanha, Antimonium tartaricum, Grindelia robusta etc. as indicated; 5 ml dose of indicated homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; administered twice daily for 1 year
62823833|NCT03475004|EXPERIMENTAL|Cohort A|Patients will start with 7-day run-in of binimetinib on day -7 of cycle 1 only. Pembrolizumab and bevacizumab will then be added to binimetinib on cycle 1 day +1. Cycle 1 will end on day 21. Patients will start treatment with pembrolizumab, binimetinib, and bevacizumab on day 1 of all subsequent cycles.
62245694|NCT01591317|EXPERIMENTAL|Prasugrel - 30 mg/7.5 mg|Prasugrel 30 mg loading dose given once orally, followed by 7.5 mg once a day orally for 10 days
62245695|NCT01591317|EXPERIMENTAL|Prasugrel - 30 mg/5 mg|Prasugrel 30 mg loading dose given once orally followed by 5 mg once a day orally for 10 days
62245696|NCT05903872|EXPERIMENTAL|aromatherapy massage group|For three days, twice a day (15 minutes each), aromatherapy massage was applied with a mixture of lavender, fennel and frankincense essential oils in almond oil as a carrier oil.
62435979|NCT03974152|EXPERIMENTAL|ENDS with unprotonated nicotine first, then ENDS with protonated nicotine, then Own brand cigarette|In each of the 3 sessions, participants will be instructed to take one puff of the tobacco product (cigarette or Subox Mini C ENDS with 18 mg nicotine) every 30 seconds for 5 minutes followed by a 2nd blood draw (if staffing allows). Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
62602337|NCT02255136|PLACEBO_COMPARATOR|Intervention placebo|5 ml dose made up of single drop of rectified spirit in 5 ml distilled water, identical in appearance of homeopathic medicine, to be administered twice daily for 1 year
62823834|NCT03475004|EXPERIMENTAL|Cohort B|Patients will be treated with pembrolizumab, bevacizumab, and binimetinib together on day 1 of all cycles including cycle 1. Patients will start treatment with pembrolizumab, binimetinib, and bevacizumab on day 1 of all subsequent cycles.
62042817|NCT06061497|PLACEBO_COMPARATOR|Usual care|"They will have the care recommended in the Integrated Care Process for Asthma in Children and Adults, of the Portuguese Directorate-General for Health, namely:~Health education:~Inhalation technique Adherence to treatment; Presence of comorbidities; Smoking; Other environmental factors; Promotion of physical activity."
62042818|NCT05756855|EXPERIMENTAL|behavioral intervention|This will involve conducting a 12-week open pilot trial (up to n=16 dyads of EIS clinicians-EIS participants) to test the feasibility and acceptability of the adapted Psychological Interventions for Coping with Anger and Schizophrenia: a study of outcomes (PICASSO) intervention in the OnTrackNY setting.
62042819|NCT01121068||Health care workers|
62042820|NCT03538470|EXPERIMENTAL|Spa treatment|Mineral water cares in Contrexéville thermal cure center, massage, cataplasm.
62042821|NCT05437458||Persistent delirium|People with Parkinson's who have experienced persistent delirium (delirium lasting for ≥14 days) and will also be invited to interview.
62823835|NCT06536101|EXPERIMENTAL|GIM-407 oral dose|"SAD: 4 cohorts of subjects are planned to be orally dosed, ranging from 20 mg to 160 mg~MAD: 4 cohorts of subjects are planned to be orally dosed once daily for 7 consecutive days, ranging from 20 mg to 160 mg"
62042822|NCT05437458||Non-persistent delirium|People with Parkinson's who have experienced non-persistent delirium (delirium lasting \<14 days).
62042823|NCT05437458||No delirium (Control group)|People with Parkinson's who have never experienced delirium
62245697|NCT05903872|ACTIVE_COMPARATOR|back massage group|For three days, twice a day (15 minutes each), back massage was applied using only 1 tablespoon of almond oil (a carrier oil) in order to evaluate the effect of essential oils.
62245698|NCT04465097|EXPERIMENTAL|Tucidinostat and Exemestane|Patients receive exemestane from week 1 to week 26 and Tucidinostat BIW from week 3 to week 26. Courses continue in the absence of disease progression or unacceptable toxicity. If the patient is premenopausal, leuprorelin or goserelin will be prescribed.
62245699|NCT05940922||CIDP GBS hATTR|Adult patients diagnosed and treated at the study centre for chronic inflammatory demyelinating polyneuropathy (CIDP), or Guillain-Barre syndrome (GBS), or heredofamilial amyloidosis (hATTR).
62245700|NCT06407791|EXPERIMENTAL|LymphaVibe Experimental Arm|All patients in this single arm (only arm of the study) will receive both treatment with the LymphaVibe AND the standard of care, thus serving as their own control. Patients will have baseline measurements taken, receive treatment with the LymphaVibe, have their measurements repeated, receive the standard of care, and have their measurements repeated again.
62245701|NCT06730321||Patients underwent robotic thyroidectomy|Patients underwent robotic thyroidectomy without conversion during the study period
62245702|NCT06228651|ACTIVE_COMPARATOR|Tourniquet|The leg with the tourniquet which was inflated during surgery
62245703|NCT06228651|ACTIVE_COMPARATOR|Control|The leg without the tourniquet which was not inflated during surgery
62245704|NCT05912803|EXPERIMENTAL|Simulated Equestrian Therapy|"The treatment group will receive Simulated Equestrian Therapy using 2 horse simulators (wooden and mechanical). Each participant will undergo a warm-up before phase I and cool-down after phase II.~The treatment will be divided into following 2 phases; Phase I The child will be instructed to ride the mechanical simulator in a pre-defined area measuring 10 yards and complete a total of 4 rounds of this area. Rest periods in between and after will be provided to the child when required. Major muscles of the body will be targeted here to strengthen the core.~Phase II The child will be instructed to ride the wooden simulator and a combination of goal directed activates will be performed every week for 12 weeks in the following manner;~0-2 weeks: Practicing catching and throwing.~3-5 weeks: Placing the ball, and rings on the target.~6-8 weeks: Target hitting on a game of dart.~9-12 weeks: Leaning to the head, feet, and tail of the horse"
62602338|NCT00621465|ACTIVE_COMPARATOR|1|Participants will receive standard aftercare and community care services.
62602339|NCT00621465|EXPERIMENTAL|2|Participants will receive usual care and the Critical Time Intervention.
62602340|NCT03375515|EXPERIMENTAL|PCA IV Hydromorphone titration|PCA titration using programmable pump: bolus hydromorphone at 0.5mg (for opioid intolerance) or hydromorphone dose equivalent to 10% to 20% of the total opioid taken in the previous 24 hours with a lockout time 15 min (for opioid tolerance) was administered by the patients educated. No basal infusion was set in the pump.Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. The titration will be done on the patient's request (manipulation by the patient himelf/herself) in 24hrs.
62823836|NCT06536101|PLACEBO_COMPARATOR|Matching placebo oral dose|Placebo
62245705|NCT05912803|ACTIVE_COMPARATOR|Neuro-Motor Therapy|This group will perform overall stability and body balancing exercises to strengthen the core and develop the coordination and balance required for task performance. Each activity will be performed in a set of 2-3, considering the activity level of the child, with 8-12 repetitions attaining the available ROM and flexibility of the child thrice for three weeks. The participants will undergo warm-up before the exercise and cool-down afterwards.
62245706|NCT05439668|EXPERIMENTAL|Classic abdominal exercises Group|This group will carry out an abdominal strengthening exercise program based on the classic abdominal exercises.
62245707|NCT05439668|EXPERIMENTAL|Abdominal hypopresives exercise Group|This group will carry out an abdominal strengthening exercise program based on the abdominal hypopressives exercises.
62245708|NCT05682924||Study group|35 patients with ph-positive chronic myeloid leukemia in the chronic phase, aged 40 to 60 years, receiving bosutinib at a dose of 500 mg / day
62245709|NCT05682924||Comparison group|35 patients with ph-positive chronic myeloid leukemia in the chronic phase, aged 40 to 60 years, receiving nilotinib at a dose of 800 mg / day
62245710|NCT05682924||Control group|35 patients with ph-positive chronic myeloid leukemia in the chronic phase, aged 40 to 60 years, receiving imatinib at a dose of 600 mg / day
62245711|NCT01990092|EXPERIMENTAL|Metanx|Subjects will take 2 Metanx tablets once daily for 48 weeks.
62245712|NCT01990092|PLACEBO_COMPARATOR|Placebo|Subjects will take 2 placebo tablets once daily for 48 weeks.
62245713|NCT02365753|PLACEBO_COMPARATOR|SofPulse nonfunctional device.|The Sofpulse non-functional device is placed over the incision after cesarean delivery and then turned on. The device only appears to be function correctly because the lights turn on, but does not emit a pulsed electromagnetic frequency..
62245714|NCT02365753|ACTIVE_COMPARATOR|Active|The Sofpulse Pulsed electromagnetic frequency device is placed over the incision after cesarean delivery and then turned on. Device appears to be operational and functions correctly.
62823837|NCT03579251|OTHER|Pilot test|12 weeks of behavioral intervention (Black Men's Care), including an in-person session and two-way SMS, with a three-month follow-up period post-intervention.
62042824|NCT05437458||Carers for Qualitative Interview|Carers of people with Parkinson's who have consented to being interviewed.
62042825|NCT06474221|EXPERIMENTAL|Electronic Based Psychosocial Intervention (EBPSI)|Electronic Based Psychosocial Intervention (EBPSI) described as video based telepsychiatry sessions targeted on brief intervention and coping skills; with a total of 5 sessions on days 10, 30, 45, 60 and 90 after baseline intervention.
62602341|NCT03375515|ACTIVE_COMPARATOR|non-PCA IV Hydromorphone titration|Non-PCA titration administered by a nurse or clinician: Initial hydromorphone doses were same with PCA titration. Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. The dose of hydromorphone increased by 50%-100% if pain unchanged or increased, or repeat same dose if pain decrease to 4-6. The titration will be done on the patient's request (manipulation by a nurse) in 24hrs.
62042826|NCT06474221|ACTIVE_COMPARATOR|Treatment as Usual|The Treatment as Usual (TAU) arm shall be a telephonic regular contact: with a total of 5 reminder calls on days 10, 30, 45, 60 and 90 after baseline intervention. The session shall include a reminder for the next planned follow up session and a general query for overall wellbeing.
62602342|NCT02455375||Cases|"Case group = group of patients positive with reference tests including serological (ELISA, IF neutralization) and/or molecular assays:~* detection of PUUV RNA in plasma collected at admission.~* or/and detection of IgM and IgG against PUUV in serum collected at admission,~* or/and detection of a seroconversion in IgG against PUUV from admission and late sera"
62602343|NCT02455375||Controls|Control group = group of patients who do not have the criteria listed above
62602344|NCT00784550|EXPERIMENTAL|ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler|Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID Plus Tiotropium Bromide 18 mcg QD
62602345|NCT00784550|ACTIVE_COMPARATOR|SPIRIVA® HANDIHALER® inhaler|Tiotropium Bromide 18mcg QD plus Placebo DISKUS BID
62602346|NCT06623188|EXPERIMENTAL|Auricular neuromodulation|
62602347|NCT06623188|SHAM_COMPARATOR|Sham auricular neuromodulation|
62602348|NCT02685501||Combat women soldiers|Women soldiers in combat units
62602349|NCT02685501||Non combat women soldiers|Women soldiers in non-combat units
62602350|NCT03546010|EXPERIMENTAL|Oculometric and neuropsychological tests|Oculometric tests and neuropsychological tests
62602351|NCT06211933|EXPERIMENTAL|HIFU intervention|HIFU intervention
62602352|NCT04750733||Multiple Sclerosis|Ambulatory MS patients
62602353|NCT02719353|EXPERIMENTAL|comfilcon A Extended Range test lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
62602354|NCT02719353|ACTIVE_COMPARATOR|comfilcon A control lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
62602355|NCT05400889|EXPERIMENTAL|tofacitinib or baricitinib|Tofacitinib 5mg was taken orally once or twice a day and baricitinib 2mg or 4mg was taken orally once a day for 6 months.
62602356|NCT01527487|EXPERIMENTAL|Eribulin+Cyclophosphamide (ErC)|"Eribulin (Er): 1.4mg/m2 IV (Days 1 and 8) given short (≤1.5 minutes) IV infusion, per institutional standard~Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard"
62602357|NCT01527487|EXPERIMENTAL|Docetaxel+Cyclophosphamide (TC)|"Docetaxel (T): 75 mg/m2 IV (Day 1), given by 1-hour IV infusion~Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard"
62602358|NCT02403349|EXPERIMENTAL|Fimasartan|fimasartan potassium 60mg, 1 tablet by mouth, every day Angiotensin ll receptor blocker
62602359|NCT02403349|ACTIVE_COMPARATOR|Valsartan|valsartan 80mg, 1 tablet by mouth, every day angiotensin II receptor antagonists
62602360|NCT02403349|ACTIVE_COMPARATOR|Atenolol|atenolol 50mg, 1 tablet by mouth, every day beta-blocker
62245715|NCT04640974|EXPERIMENTAL|Cingal|Single injection of Cingal into the ankle joint of subjects diagnosed with osteoarthritis of the ankle.
62245716|NCT02761551|NO_INTERVENTION|Usual Care|Patients in this group will not receive any reminders for influenza vaccine.
62245717|NCT02761551|EXPERIMENTAL|1 notice|Patients in this group will receive one reminder for influenza vaccine across the 2016 influenza season.
62245718|NCT02761551|EXPERIMENTAL|2 notices|Patients in this group will receive up to two reminders for influenza vaccine across the 2016 season.
62042827|NCT02527668|EXPERIMENTAL|Calcifediol Hy.D (25-hydroxyvitamin D)|20 μg Calcifediol Hy.D (25-hydroxyvitamin D) (one capsule) per day for 6 months
62245719|NCT02761551|EXPERIMENTAL|3 notices|Patients in this group will receive up to three reminders for influenza vaccine across the 2016 season.
62435980|NCT03974152|EXPERIMENTAL|ENDS with protonated nicotine first, then Own brand cigarette, then ENDS with unprotonated nicotine|In each of the 3 sessions, participants will be instructed to take one puff of the tobacco product (cigarette or Subox Mini C ENDS with 18 mg nicotine) every 30 seconds for 5 minutes followed by a 2nd blood draw (if staffing allows). Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
62435981|NCT03974152|EXPERIMENTAL|ENDS with protonated nicotine first, then ENDS with unprotonated nicotine, then Own brand cigarette|In each of the 3 sessions, participants will be instructed to take one puff of the tobacco product (cigarette or Subox Mini C ENDS with 18 mg nicotine) every 30 seconds for 5 minutes followed by a 2nd blood draw (if staffing allows). Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
62435982|NCT03974152|EXPERIMENTAL|Own brand cigarette first, then ENDS with unprotonated nicotine, then ENDS with protonated nicotine|In each of the 3 sessions, participants will be instructed to take one puff of the tobacco product (cigarette or Subox Mini C ENDS with 18 mg nicotine) every 30 seconds for 5 minutes followed by a 2nd blood draw (if staffing allows). Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
62435983|NCT03974152|EXPERIMENTAL|ENDS with unprotonated nicotine first, then Own brand cigarette, then ENDS with protonated nicotine|In each of the 3 sessions, participants will be instructed to take one puff of the tobacco product (cigarette or Subox Mini C ENDS with 18 mg nicotine) every 30 seconds for 5 minutes followed by a 2nd blood draw (if staffing allows). Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
62435984|NCT02922959|ACTIVE_COMPARATOR|PTOEND|"PTOEND: Personally-tailored opioid overdose prevention education and naloxone distribution.~Participants in this arm will be given a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment."
62602361|NCT06211738||People with clinical dyspnea|Any intensive care patient undergoing invasive mechanical ventilation deemed suitable for ventilatory weaning test.
62602362|NCT01885767||NF1|Patients meeting clinical and/or genetic criteria for Neurofibromatosis 1
62602363|NCT01885767||NF2|Patients meeting clinical and/or genetic criteria for Neurofibromatosis 2
62602364|NCT01885767||SchW|Patients meeting clinical and/or genetic criteria for Schwannomatosis
62602365|NCT04495816|ACTIVE_COMPARATOR|Omega-3|1,000 mg of omega-3 fatty acid (2 softgels per day for 6 weeks)
62602366|NCT04495816|SHAM_COMPARATOR|Placebo/Control|2 softgels per day for 6 weeks
62602367|NCT02939027|EXPERIMENTAL|Group 1|For the first 20 patients, a total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days week, 3 weeks or lees at least 2 days apart each fraction.
62602368|NCT02939027|EXPERIMENTAL|Group 2|For the next 20 patients a total dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days week 3 weeks or lees at least 2 days apart each fraction.
62602369|NCT06430502|EXPERIMENTAL|Tumor treatment vaccine combined with PD-1/L1 inhibitor for patients with advanced solid tumors|Tumor treatment vaccine(TTV) would be given deep subcutaneously in the arm or near the tumor. Use PD-1/L1 inhibitors in accordance with the drug indication.
62602370|NCT01664949|EXPERIMENTAL|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
62042828|NCT02527668|ACTIVE_COMPARATOR|Vitamin D3 (cholecalciferol)|3200 IU Vitamin D3 (cholecalciferol) (one capsule) per day for 6 months
62042829|NCT02527668|PLACEBO_COMPARATOR|Placebo|1 Placebo capsule per day for 6 months
62042830|NCT01830608||300 patients with AMD|
62042831|NCT01164995|EXPERIMENTAL|MK-1775 and carboplatin|MK-1775: oral capsules. Carboplatin: intravenous infusion in 30 minutes
62245720|NCT04939519|ACTIVE_COMPARATOR|Text-Messaging (TM)|Population health management intervention that analyzes electronic health record data to automatically identify participants who are eligible for the COVID-19 vaccine and proactively reach those participants for vaccine scheduling. This is a bi-directional text messaging system.
62245721|NCT04939519|ACTIVE_COMPARATOR|Text-Messaging plus Patient Navigation|Population health management intervention that includes the same bi-directional text-messaging system as Arm 1 (the text messaging condition) with the addition of patient navigation. Patient navigation includes real-time assistance from a community health worker to address barriers, provide motivation, and assist with logistics of COIVD vaccination.
62245722|NCT04236895|ACTIVE_COMPARATOR|Lantus ® US|Insulin glargine (Lantus®, product approved and marketed in the USA (US RLD)), 100 U/mL in 3 mL pre-filled pens
62245723|NCT04236895|ACTIVE_COMPARATOR|Lantus ® EU|Insulin glargine (Lantus®, product marketed in Germany (EU RP)), 100 U/mL in 3 ml pre-filled pens
62245724|NCT04236895|EXPERIMENTAL|Gan & Lee Insulin Glargine|Insulin glargine 100 U/mL in 3 mL pre-filled pens
62602371|NCT01664949|ACTIVE_COMPARATOR|OPTIVE™|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
62602372|NCT03149289||HCV RNA positive|hemoglobinopathies with hepatites C treated with antiviral drugs
62602373|NCT04072991|ACTIVE_COMPARATOR|Low FODMAP diet|As part of their treatment for IBS participants may be randomised to a low FODMAP diet
62602374|NCT04072991|ACTIVE_COMPARATOR|Gluten Free Diet|As part of their treatment for IBS participants may be randomised to a gluten free diet
62042832|NCT03215836|OTHER|Obese Asthmatics|BMI \>/= 30 and without metabolic syndrome
62245725|NCT04616196|EXPERIMENTAL|Dose Escalation of NKTR-255 with Cetuximab|Establish RP2D, of NKTR-255 with cetuximab.
62245726|NCT04616196|EXPERIMENTAL|Dose Expansion of NKTR-255 with Cetuximab - Cohort A|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with HNSCC.
62245727|NCT04616196|EXPERIMENTAL|Dose Expansion of NKTR-255 with Cetuximab - Cohort B|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with CRC.
62245728|NCT04616196|EXPERIMENTAL|Dose Expansion of NKTR-255 with Cetuximab - Cohort C|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with cSCC.
62042833|NCT03215836|OTHER|Obese Astmatics|BMI \>/= 30 and with metabolic syndrome
62042834|NCT03215836|OTHER|Obese non-asthmatics|BMI \>/= 30
62042835|NCT03215836|OTHER|Non - obese asthmatics|BMI: lean \> 20; Normal \>/= 20 to \<25; overweight \</= 25 to \< 30;
62042836|NCT02549469|EXPERIMENTAL|Naproxen sodium extended release 660 mg, 20% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve (Naproxen sodium) 220 mg tablet
62042837|NCT02549469|EXPERIMENTAL|Naproxen sodium extended release 660 mg, 30% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet
62602375|NCT04072991|ACTIVE_COMPARATOR|British Dietetic Association diet|As part of their treatment for IBS participants may be randomised to the BDA diet
62602376|NCT01688778|EXPERIMENTAL|Telemedicine|Monthly video consultations with a nurse as add-on to standard treatment.
62602377|NCT01688778|NO_INTERVENTION|Standard treatment|Standard diabetes control at a Diabetes Clinic or GP
62602378|NCT03117894|ACTIVE_COMPARATOR|GA with RA|Regional Anesthesia and General Anesthesia.
62042838|NCT02549469|EXPERIMENTAL|Naproxen sodium extended release 660 mg, 40% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet
62042839|NCT02549469|ACTIVE_COMPARATOR|Naproxen sodium 220 mg|Bioequivalence in healthy adult subjects in a fasted state
62245729|NCT04616196|EXPERIMENTAL|Dose Expansion of NKTR-255 with Cetuximab - Cohort D|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with ASCC.
62245730|NCT04616196|EXPERIMENTAL|Dose Expansion of NKTR-255 with Cetuximab - Cohort E|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with cervical cancer.
62602379|NCT03117894|ACTIVE_COMPARATOR|GA without RA|Only General Anesthesia (without a supplemental Regional Anesthesia).
62602380|NCT04109937|NO_INTERVENTION|Surgery Alone|Patients with lower extremity bone metastases will receive surgical fixation/reconstruction but will not receive any post-operative radiation therapy.
62245731|NCT02770443|EXPERIMENTAL|Treatment|Withdrawal of beta blockers and ACE inhibitors
62245732|NCT02770443|PLACEBO_COMPARATOR|control|no withdrawal, standard of care
62245733|NCT02193542||Pregnant patient|Pregnant woman presenting for vaginal or cesarean delivery
62823838|NCT04531085|ACTIVE_COMPARATOR|RCT operative|Procedure of preference is open reduction and internal fixation (ORIF) with cannulated non-resolvable 4.0mm screw with or without washer. If the fracture fragment is too small or fragmented for screw fixation 1.6mm - 1.8mm Kirshner-wires and/or bone anchor are used. Long arm cast for 4 weeks.
62823839|NCT04531085|ACTIVE_COMPARATOR|RCT Non-operative|Non-operative treatment means upper limb immobilization with forearm in neutral pro-supination with a long arm cast for 4 weeks.
62823840|NCT04531085|OTHER|Patient preference operative|Procedure of preference is open reduction and internal fixation (ORIF) with cannulated non-resolvable 4.0mm screw with or without washer. If the fracture fragment is too small or fragmented for screw fixation 1.6mm - 1.8mm Kirshner-wires and/or bone anchor are used. Long arm cast for 4 weeks.
62823841|NCT04531085|OTHER|Patient preference non-operative|Non-operative treatment means upper limb immobilization with forearm in neutral pro-supination with a long arm cast for 4 weeks.
62042840|NCT06732440|EXPERIMENTAL|Balance Plus Motion|Participants enrolled in this arm of the study will participate in balance training, and will receive 20 minutes of passive, subthreshold tilts before each bout of training.
62042841|NCT06732440|SHAM_COMPARATOR|Balance Only|Participants enrolled in this arm of the study will complete balance training immediately following 20 minutes of a sham motion condition (intermittent, small amplitude translations of the motion platform).
62245734|NCT02172287|EXPERIMENTAL|Tiotropium (Ba679 BR)|Tiotropium capsule once daily by oral inhalation
62042842|NCT06732440|ACTIVE_COMPARATOR|Motion Only|Participants enrolled in this arm of the study will participate in 20 minutes of passive, subthreshold whole-body tilts, but not will complete the balance training intervention.
62823842|NCT03884829|EXPERIMENTAL|CYC140 single agent|CYC140 will be administered as a single agent on Day 1 and Day 8 of each 3 week cycle
62245735|NCT02172287|ACTIVE_COMPARATOR|Salmeterol|Salmeterol inhalation aerosol twice daily
62245736|NCT02172287|PLACEBO_COMPARATOR|Placebo|"* Tiotropium (Ba679 BR)- placebo one capsule once daily by inhalation~* Salmeterol- placebo, inhalation aerosol twice daily"
62823843|NCT06592885|ACTIVE_COMPARATOR|Hall Technique in treatment of carious primary molars|The Hall technique, proposed by Norna Hall in the 1980s, involves the placement of preformed metal crowns on primary molars without any tooth preparation or local anesthesia
62042843|NCT06010472|EXPERIMENTAL|anti-CD19 CAR NK cells|To evaluate the safety and effectiveness of anti-CD19 CAR NK cells (KN5501) in patients with moderate to severe refractory SLE. All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by anti-CD19 CAR NK cells infusion.
62245737|NCT01905124|EXPERIMENTAL|Drug: CF101|CF101 1 mg q12 hours
62245738|NCT01905124|PLACEBO_COMPARATOR|Placebo tablets of CF101|Placebo tablets q12 hours
62042844|NCT04649866|EXPERIMENTAL|Test group|Endothelial dysfunction will be tested using Strain-gauge plethysmography to measure forearm blood flow during infusions of acetylcholine \[ACh\] and sodium nitroprusside \[SNP\]
62245739|NCT04699175|EXPERIMENTAL|Treatment group A|
62245740|NCT04699175|EXPERIMENTAL|Treatment group B|
62435985|NCT02922959|EXPERIMENTAL|PTOEND+PI|"PTOEND+PI: Personally-tailored opioid overdose prevention education and naloxone distribution, plus Peer Intervention.~In addition to a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment, participants randomized to this arm will also receive the experimental Peer Intervention."
62823844|NCT06592885|EXPERIMENTAL|Atraumatic Restorative Treatment in treatment of carious primary molars|ART, which took place in Tanzania during the mid-1980s, is a conservative approach involving the removal of carious lesions using hand instruments, followed by the application of a glass ionomer restoration, promoting the preservation of tooth structure.
62042845|NCT04649866|ACTIVE_COMPARATOR|Control group|Endothelial dysfunction will be tested using Strain-gauge plethysmography to measure forearm blood flow during infusions of acetylcholine \[ACh\] and sodium nitroprusside \[SNP\]
62823845|NCT02473848|EXPERIMENTAL|Ingenol mebutate 500 ucg|active arm
62823846|NCT05954858|EXPERIMENTAL|Surgical tissue autograft: TPF flap/pericranial flap|Use of a pedicled autologous piece of tissue called the temporoparietal fascial (TPF) flap or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients
62245741|NCT04699175|PLACEBO_COMPARATOR|Treatment group C|
62245742|NCT01456689|EXPERIMENTAL|LGH447|Eligible patients will be treated with oral LGH447 until disease progression or occurrence of unacceptable toxicity.
62245743|NCT01456689|EXPERIMENTAL|LGH447 and midazolam|Eligible patients will receive midazolam on two separate days, the first dose will be administered prior to the start of LGH447 and the second will be co-administered with LGH447. After that, the patients will continue to be treated with oral LGH447 until disease progression or occurrence of unacceptable toxicity.
62245744|NCT01167751|EXPERIMENTAL|MNC implantation|Implantation of BM derived MNC
62245745|NCT01167751|EXPERIMENTAL|AC 133 implantation|Implantation of BM derived AC 133
62245746|NCT01167751|PLACEBO_COMPARATOR|Control|Injection of cell carrier
62245747|NCT03426826|PLACEBO_COMPARATOR|Arm 1|Placebo Comparator placebo into the jejunum through upper endoscopy.
62245748|NCT03426826|ACTIVE_COMPARATOR|Arm 2|Active Comparator: Donor Stool Transplant Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool into the jejunum through upper endoscopy.
62245749|NCT05894265|EXPERIMENTAL|ActiveMatrix® Dosage A|
62245750|NCT05894265|EXPERIMENTAL|ActiveMatrix® Dosage B|
62245751|NCT05894265|PLACEBO_COMPARATOR|Saline Injection|
62245752|NCT00838214|EXPERIMENTAL|budesonide|3mg capsules 3x/day for 6 months
62245753|NCT00838214|ACTIVE_COMPARATOR|prednisone|5mg tablet, 40mg starting dose titrated to 10mg over 3 months
62245754|NCT00857532|EXPERIMENTAL|Normal cognitive performance|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores of ≥9, indicating normal cognitive performance.
62245755|NCT00857532|EXPERIMENTAL|Mild cognitive deficits|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores between 6 and 8, inclusive, indicating mild cognitive deficits.
62823847|NCT02130817|EXPERIMENTAL|Belatacept|"Belatacept (nujolix):~Tacrolimus withdrawal~Standard of care(SOC) treatment:~Plasmapheresis/Intravenous Immunoglobulin G (IVIG) therapy~Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg starting in the operating room.~Maintenance immunosuppression:~Myfortic: Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.~Steroids: Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30."
62823848|NCT03631940|EXPERIMENTAL|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk the entire length of umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC as we have demonstrated in our previous trials.
62823849|NCT03631940|ACTIVE_COMPARATOR|Early Cord Clamping|This will occur by clamping the umbilical cord as soon as possible. Since both ECC and UCM will occur after a brief assessment, it is important to note that the cord clamping time will be longer than in previously conducted preterm trials (average 20 seconds) which performed the intervention on all subjects regardless of whether or not they were vigorous. In all cases, the cord clamping time will be documented to ensure consistency.
62042846|NCT05885152|EXPERIMENTAL|Whole-body electrical stimulation, Protocol 1|A whole body electrical stimulation session. Symmetrical biphasic current will be used, pulse width of 400µs, frequency of 75Hz, contraction time of five seconds, rest time of 10 seconds, for eight minutes, totaling 32 muscle contractions. During the first two minutes of stimulation, the patient will remain in isometry to become familiar with the electrical current. Then with the use of a stick (for proprioception), a series of biceps exercises and a series of triceps exercises, a series of sit-ups and a squat, a series of step ups and downs, and a series of plantings.
62245756|NCT00857532|EXPERIMENTAL|Severe cognitive impairment|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores below 5, indicating moderate to severe cognitive impairment.
62245757|NCT04357704|EXPERIMENTAL|bilateral cochlear implant recipients|
62245758|NCT04357704|ACTIVE_COMPARATOR|normal hearing listners|
62245759|NCT02488499|ACTIVE_COMPARATOR|Individualized Treatment|Individualized Treatment: 15 sessions of individualized treatment (i.e., parent-child) that target areas of presenting concern identified during assessment. These may include social problem-solving, emotion regulation, parent-child difficulties.
62245760|NCT02488499|EXPERIMENTAL|Coping Power|Coping Power: 15 sessions of concurrent parent and child group treatment. The child group focuses on developing problem-solving and emotion regulation skills. The parent group focuses on developing parenting skills and problem-solving strategies to manage and reduce their children's disruptive behaviour.
62245761|NCT02342366|PLACEBO_COMPARATOR|Placebo|Placebo
62245762|NCT02342366|EXPERIMENTAL|GHB|GHB, Gamma-Hydroxybutyrate, two doses (20 and 35 mg/kg p.o.)
62245763|NCT01122576|EXPERIMENTAL|Crystalens AO|Eligible subjects to undergo small incision cataract surgery and were implanted with the Crystalens AO bilaterally.
62042847|NCT05885152|EXPERIMENTAL|Whole-body electrical stimulation, Protocol 2|A whole body electrical stimulation session. Symmetrical biphasic current will be used, pulse width of 400µs, frequency of 75Hz, contraction time of five seconds, rest time of 10 seconds, for 16 minutes, totaling 64 muscle contractions. During the first two minutes of stimulation, the patient will remain in isometry to become familiar with the electrical current. Then with the use of a stick (for proprioception), a series of biceps exercises and a series of triceps exercises, a series of sit-ups and a squat, a series of step ups and downs, and a series of plantings.
62823850|NCT04294134|ACTIVE_COMPARATOR|MIO-CPP|The 9 month MIO-CPP model will begin with the standard 12 weeks of MIO for each mother, with the CPP assessment and engagement phase embedded during this time. This phase will be followed by the dyadic mother-child phase, the core intervention stage of CPP. If a parent needs additional stabilization, more individual time can be added. During the core phase of dyadic CPP the Child Parent Specialists will continue to build and strengthen parents' reflective functioning by embedding aspects from MIO. The 9 month MIO-CPP model will begin with the standard 12 weeks of MIO for each mother, with the CPP assessment and engagement phase embedded during this time. This phase will be followed by the dyadic mother-child phase, the core intervention stage of CPP. If a parent needs additional stabilization, more individual time can be added.
62823851|NCT04294134|EXPERIMENTAL|MIO-CPP-CRS|"In Phase 2, participants will receive MIO-CPP therapy, as well as support from a CRS. The MIO-CPP model will begin with 6 sessions of MIO for each study participant, with the CPP assessment and engagement phase embedded during this time. This phase will be followed by the dyadic mother-child phase, the core intervention stage of CPP. If a parent needs additional stabilization, more individual time can be added. During the core phase of dyadic CPP the Child Parent Specialists will continue to build and strengthen parents' reflective functioning by embedding aspects from MIO.~Participant dyads will be assigned a Certified Recovery Specialists (CRSs) who will provide services to support them as they transition out of SUD treatment and back into their home communities."
62823852|NCT02900118||Group 1|Patients with breast cancer bone metastasis at the initial diagnosis.
62823853|NCT02900118||Group 2|Patients with breast cancer bone metastasis in a metastatic bone relapse.
62245764|NCT01122576|ACTIVE_COMPARATOR|ReSTOR|Eligible subjects to undergo small incision cataract surgery and were implanted with the ReSTOR IOL bilaterally.
62823854|NCT02900118||Group 3|Patients with breast cancer bone metastasis with a progression of bone metastasis.
62823855|NCT00311675|EXPERIMENTAL|1|
62823856|NCT06053268|EXPERIMENTAL|Single-arm, within-subject pilot: EmbracePlus smartwatch|Prior to engaging in the intervention participants will complete baseline assessments of stress and coping. Participants will then engage in a daily mindfulness practice via the Headspace mobile application. The basic application program includes daily 10-minute sessions in guided mindfulness meditation that include mindful breathing, body awareness, emotion and thought recognition, and attentional control. During the first and fourth week of the intervention, participants will complete EMAs assessing mood, current activity, and intervention engagement. Participants will also wear a wrist-worn device to assess biomarkers of stress. At the completion of the intervention participants will complete follow-up assessments related to intervention and data collection procedures feasibility and acceptability as well as coping behaviors and stress.
62823857|NCT04634071|EXPERIMENTAL|Group 1: Varenicline, Intense Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive varenicline, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
62823858|NCT04634071|EXPERIMENTAL|Group : Varenicline, Intense Counselling|Patients diagnosed with tobacco-related treatment will receive varenicline and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
62823859|NCT04634071|EXPERIMENTAL|Group 3: Varenicline, Minimal Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive varenicline, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
62823860|NCT04634071|EXPERIMENTAL|Group 4: Varenicline, Minimal Counselling|Patients diagnosed with tobacco-related treatment will receive varenicline and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
62823861|NCT04634071|EXPERIMENTAL|Group 5: Buproprion, Intense Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive Buproprion, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
62823862|NCT04634071|EXPERIMENTAL|Group 6: Buproprion, Intense Counselling|Patients diagnosed with tobacco-related treatment will receive Buproprion and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
62823863|NCT04634071|EXPERIMENTAL|Group 7: Buproprion, Minimal Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive Buproprion, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
62823864|NCT04634071|EXPERIMENTAL|Group 8: Buproprion, Minimal Counselling|Patients diagnosed with tobacco-related treatment will receive Buproprion and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
62042848|NCT04133233|EXPERIMENTAL|active treatment|"IL-2 (ILT-101) Sub-cutaneous~1 million UI/j"
62042849|NCT04133233|PLACEBO_COMPARATOR|placebo|placebo Sub-cutaneous The Placebo used is a sterile powder that will be produced by the CMO (AMATSI, France).
62042850|NCT04770922||Pediatric ALL patients on 6-mercaptopurine|Pediatric ALL patients treated with 6-mercaptopurine who did not experience neutropenia.
62245765|NCT01122576|ACTIVE_COMPARATOR|Tecnis Multifocal IOL|Eligible subjects to undergo small incision cataract surgery and were implanted with the Tecnis Multifocal IOL bilaterally.
62245766|NCT01526044|EXPERIMENTAL|Freestyle group|Glucose levels are being monitored with the Freestyle Navigator up to 5 days, or until discharge from the ICU
62435986|NCT01652118|ACTIVE_COMPARATOR|Clarithromycin|Fist group treated with clarithromycin which is include 10 days application.
62042851|NCT04770922||Pediatric ALL patients on 6-mercaptopurine with neutropenia|Pediatric ALL patients treated with 6-mercaptopurine who experienced neutropenia.
62042852|NCT00586911|ACTIVE_COMPARATOR|Cystadane|
62042853|NCT00586911|PLACEBO_COMPARATOR|Identical Placebo|
62042854|NCT06177665|EXPERIMENTAL|Erector Spinae Plane Block|Ultrasound(US)-guided erector spinae plan block(ESP) with 20 ml 0,25% bupivacaine at T4 vertebra level will performe preoperatively to all patients in the ESP group.
62602381|NCT04109937|ACTIVE_COMPARATOR|Surgery and Post-Operative Radiation Therapy|Patients with lower extremity bone metastases will receive surgical fixation/reconstruction and will receive any post-operative radiation therapy.
62823865|NCT04634071|EXPERIMENTAL|Group 9: Nicotine, Intense Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch), counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
62823866|NCT04634071|EXPERIMENTAL|Group 10: Nicotine, Intense Counselling|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch) and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
62823867|NCT04634071|EXPERIMENTAL|Group 11: Nicotine, Minimal Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch), counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
62823868|NCT04634071|EXPERIMENTAL|Group 12: Nicotine, Minimal Counselling|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch) and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
62823869|NCT06142786|EXPERIMENTAL|Individualized alpha neurofeedback|
62823870|NCT06142786|SHAM_COMPARATOR|Sham neurofeedback|
62823871|NCT06502860|EXPERIMENTAL|Experimental Group|The intervention group will receive skin-to-skin contact facilitated by the use of a sling. Immediately after the cesarean section and stabilization, the newborn will be placed against the mother's bare chest using a specially designed sling. This sling will secure the baby in a safe and comfortable position, allowing for continuous close contact. The duration of skin-to-skin contact will be encouraged to last as long as the mother and baby are comfortable, without any set time limits.
62823872|NCT06502860|NO_INTERVENTION|Control Group|The control group will receive standard skin-to-skin contact without the use of a sling. Immediately after the cesarean section and stabilization, the newborn will be placed directly on the mother's bare chest. This traditional method will involve holding the baby manually to maintain skin-to-skin contact. The duration of skin-to-skin contact will be encouraged to last as long as the mother and baby are comfortable, without any set time limits.
62823873|NCT06603727|EXPERIMENTAL|Program 1|Computerized Gaming Rehabilitation Program 1
62602382|NCT02359812||Healthy|Healthy volunteers with no history of neurological disorders
62602383|NCT02359812||Stroke|Patients had a recent stroke, two weeks or earlier prior to enrollment
62602384|NCT04318171||Carotid arteries.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
62823874|NCT06603727|ACTIVE_COMPARATOR|Program 2|Computerized Gaming Rehabilitation Program 2
62823875|NCT06588452||Manual Review Arm|Study staff manually reviews patient eligibility.
62823876|NCT06588452||Artificial Intelligence (AI) Review Arm|AI screens for eligibility, followed by an abbreviated final review by study staff.
62435987|NCT01652118|PLACEBO_COMPARATOR|placebo|Second group treated with salin as same as amount of clarithromycine volume
62602385|NCT04318171||Peripheral arteries.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
62602386|NCT04318171||AVF.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
62823877|NCT06276556|EXPERIMENTAL|ABP-671|
62823878|NCT06276556|ACTIVE_COMPARATOR|Allopurinol|
62602387|NCT04318171||Vein mapping|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
62823879|NCT04300192|EXPERIMENTAL|Group 1: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 4 doses of whole-cell pertussis (wP) vaccine during the first 2 years of life
62823880|NCT04300192|EXPERIMENTAL|Group 2: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 3 doses of wP followed by 1 dose of acellular pertussis (aP) vaccine during the first 2 years of life
62042855|NCT06177665|EXPERIMENTAL|Rhomboid Intercostal Block|Ultrasound(US)-guided rhomboid intercostal block(RIB) with 20 ml 0,25% bupivacaine at T5-T6 vertebra level will performe preoperatively to all patients in the RIB group.
62042856|NCT03583918|EXPERIMENTAL|Highthroughput Micro Coring Device|Skin excision and removal with with Highthroughput Micro Coring device
62435988|NCT03892148|ACTIVE_COMPARATOR|Standard|Use of loop diuretics and thiazide diuretics leaves to the discretion of the responsible physician
62823881|NCT04300192|EXPERIMENTAL|Group 3: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 2 doses of wP vaccine followed by 2 doses of aP vaccine during the first 2 years of life
62823882|NCT04300192|EXPERIMENTAL|Group 4: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 1 dose of wP vaccine followed by 3 doses of aP vaccine during the first 2 years of life
62823883|NCT04300192|EXPERIMENTAL|Group 5: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 4 doses of aP vaccine during the first 2 years of life
62823884|NCT04300192|EXPERIMENTAL|Group 6: Adacel Quadra vaccine (HIV positive)|Adacel Quadra single injection at Day 0 in HIV + participants who received 4 doses of wP vaccine during the first 2 years of life
62823885|NCT04300192|EXPERIMENTAL|Group 7: Adacel Quadra vaccine (HIV positive)|Adacel Quadra single injection at Day 0 in HIV + participants who received 4 doses of aP vaccine during the first 2 years of life
62823886|NCT06599086|ACTIVE_COMPARATOR|Patients with bifid median nerve diagnosed with carpal tunnel syndrome|Each patient will receive 2 cc:(1 cc betamethasone dipropionate+1cc physiological saline) perineural injection into the median nerve under US guidance, for 1 session.
62823887|NCT06599086|ACTIVE_COMPARATOR|Patients with anatomical variations without median nerve diagnosed with carpal tunnel syndrome|Each patient will receive 2 cc:(1 cc betamethasone dipropionate+1cc physiological saline) perineural injection into the median nerve under US guidance, for 1 session.
62245767|NCT01526044|ACTIVE_COMPARATOR|AccuChek group|Glucose levels are being measured by the AccuChek. Patients also get a Freestyle Navigator, which will be blinded. The device will stay on the patient up to 5 days, or until discharge from the ICU.
62245768|NCT02992886|EXPERIMENTAL|preCRT+surgery|Treatment including preoperative chemoradiotherapy (preoperative radiation with concurrent chemotherapy) with Raltitrexed followed by surgery. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy or Volumetric-Modulated Arc Therapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on d1 and d22). Pelvic surgery is planned 6 weeks after completion of CRT based on the decision of MDT.
62245769|NCT03289910|EXPERIMENTAL|Arm A (veliparib, topotecan hydrochloride, carboplatin)|Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62823888|NCT06602284|OTHER|A single arm, full face clinical study.|Dermapen 4 in conjunction with MG-CLR serum
62823889|NCT04945681|EXPERIMENTAL|Mass vaccination|Mass vaccination of children aged 6 weeks to 14 years old with pneumococcal conjugate vaccine. Children 6 weeks to 11 months old receive two doses, spaced 4 weeks apart. All other children receive a single dose. Vaccination is simultaneous, as per a campaign delivery strategy.
62823890|NCT04797585|ACTIVE_COMPARATOR|Laparoscopic supracervical hysterectomy|Minimally invasive procedure to remove a woman's uterus
62823891|NCT04797585|EXPERIMENTAL|Vaginal hysterectomy|Surgical procedure to remove the uterus
62823892|NCT02121158|OTHER|1|ICD implantation in addition to Optimal Medical Therapy
62823893|NCT02121158|ACTIVE_COMPARATOR|2|Optimal Medical Therapy
62823894|NCT06597188|EXPERIMENTAL|TAVR group|TAVR with the study device will be performed in the TAVR group
62823895|NCT06597188|ACTIVE_COMPARATOR|SAVR group|SAVR with a commercially available surgical bioprosthetic valve will be performed in the control group
62245770|NCT03289910|ACTIVE_COMPARATOR|Arm B (topotecan hydrochloride, carboplatin)|Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62245771|NCT04344691|NO_INTERVENTION|Control|5 minutes waiting time
62245772|NCT04344691|EXPERIMENTAL|Stretching|Rectus femoris static stretching during 90' (with three hold-relax progressions until final ROM)
62435989|NCT03892148|EXPERIMENTAL|Protocol|use of loop diuretics and thiazide diuretics according to the CARRESS-HF protocol developed by the Heart Failure Network
62435990|NCT04645238|ACTIVE_COMPARATOR|Static Hamstring Stretching|Static Hamstring Stretching
62435991|NCT04645238|ACTIVE_COMPARATOR|PNF Stretching|PNF Hamstring Stretching (Hold-Relax)
62435992|NCT04166981|ACTIVE_COMPARATOR|Non-instrumented arm|Decompression with concomitant non-instrumented posterolateral fusion with autologous(obtained from the decompression) and allogenic bone graft.
62435993|NCT04166981|EXPERIMENTAL|Instrumented arm|Decompression with concomitant instrumented posterolateral fusion with autologous(obtained from the decompression) and allogenic bone graft and supplementary pedicle screw fixation.
62823896|NCT05773755|EXPERIMENTAL|Deep Brain Stimulation (DBS) for Treatment Resistant Depression|Open label active Deep Brain Stimulation (DBS)
62823897|NCT06604741|EXPERIMENTAL|High volume intensity (HVIMT)|"High-volume intensity inspiratory muscle training (IMT) is a therapeutic approach designed to improve respiratory muscle strength and endurance. In this clinical trial, participants will engage in a structured regimen of inspiratory exercises with high resistance and significant repetition volume.~Participants will perform inspiratory muscle exercises using power breath that provides high resistance, with a focus on both intensity and volume. The protocol involves 3 sessions per day for 6 weeks."
62823898|NCT06604741|EXPERIMENTAL|Low volume intensity LVIMT|"Participants will engage in a structured training program involving inspiratory muscle exercises with high resistance and a high volume of repetitions. The regimen includes multiple sessions per day over several weeks, using specialized inspiratory muscle training devices.~Changes in inspiratory muscle strength (measured by maximal inspiratory pressure) and endurance."
62823899|NCT04559815||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
62823900|NCT04981925|EXPERIMENTAL|MBSR treatment|
62435994|NCT04033133|EXPERIMENTAL|Multiple Sclerosis|People with MS get tDCS with different intensities.
62435995|NCT04033133|ACTIVE_COMPARATOR|Healthy Subjects|Healthy subjects get tDCS with different intensities.
62435996|NCT00520351|ACTIVE_COMPARATOR|1|
62435997|NCT00520351|ACTIVE_COMPARATOR|2|
62042857|NCT05817851|ACTIVE_COMPARATOR|Control group|- Control group (standard treatment): post-cardiac arrest care will be provided, including temperature control, according to current international guidelines and local procedures. Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.
62042858|NCT05817851|EXPERIMENTAL|Experimental group|- Experimental group (IV high-dose vit-C): in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.
62823901|NCT06596512|ACTIVE_COMPARATOR|PARTICS - Non Frequent Nebulizer Users|Participants who use a nebulizer less than once a week are Non Frequent Nebulizer (NFN) Users. Adding the PARTICS strategy - Patient Activated Reliever-Triggered Inhaled CorticoSteroid (PARTICS). Patient will use inhaled corticosteroid at time of reliever inhaler or after reliever nebulizer use.
62245773|NCT00627029|EXPERIMENTAL|Intervention|Care coordination, consisting variously (depending on the demonstration site)--nurse telephonic counseling, nurse in-person home visits, home telemonitoring equipment, and physician education and feedback.
62823902|NCT06596512|ACTIVE_COMPARATOR|PARTICS - Frequent Nebulizer User|"Participants who use a nebulizer once a week or more are Frequent Nebulizer Users. Addition of the PARTICS strategy - Patient Activated Reliever-Triggered Inhaled CorticoSteroid (PARTICS). Patient will use inhaled corticosteroid at time of rescue inhaler or rescue nebulizer use"
62823903|NCT06596512|ACTIVE_COMPARATOR|MART (non frequent nebulizer users) - MART strategy - Maintenance and Reliever Therapy|Participants who use a nebulizer less than once a week are Non Frequent Nebulizer (NFN) Users. MART strategy is a ICS/LABA combination therapy for maintenance and relief.
62245774|NCT00627029|NO_INTERVENTION|Control|Usual care in Medicare fee-for-service from beneficiaries' physicians and other health care providers
62245775|NCT05125068|EXPERIMENTAL|Arm A|AT-1501 10mg/kg Arm A will receive 10 mg/kg of AT-1501 every 3 weeks for up to 93 weeks for a total of 32 infusions.
62245776|NCT05125068|EXPERIMENTAL|Arm B|AT-1501 5mg/kg Arm B will receive 5 mg/kg of AT-1501 every 3 weeks for up to 93 weeks for a total of 32 infusions
62245777|NCT03763669|EXPERIMENTAL|Intervention|Pregnant women randomly assigned to receive (n. 40) diet and folic acid (400 mcg per day) and myo-inositol supplementation
62823904|NCT06596512|ACTIVE_COMPARATOR|MART (frequent nebulizer users)|Participants who use a nebulizer once a week or more are Frequent Nebulizer Users. MART strategy is a ICS/LABA combination therapy for maintenance and relief.
62823905|NCT04791579|ACTIVE_COMPARATOR|Treatment Arm|Ciprofloxacin 500 mg PO every 12 hrs for 3 days following the procedure
62823906|NCT04791579|PLACEBO_COMPARATOR|Placebo Arm|Placebo pill PO every 12 hrs for 3 days following the procedure
62823907|NCT06038864||Intensive group|Patients with lower limb lymphoedema planned for intensive treatment
62823908|NCT06038864||Maintenance group|Patients with stable lower limb lymphoedema who are in the maintenance phase (at least 3 months)
62245778|NCT03763669|PLACEBO_COMPARATOR|Control|Pregnant women randomly assigned to receive (n. 40) only diet and folic acid (400 mcg per day)
62245779|NCT02877862|EXPERIMENTAL|Intervention|Receive 7-day mAGIC app intervention and handout
62245780|NCT02877862|NO_INTERVENTION|Control|Handout only
62823909|NCT03435211|EXPERIMENTAL|INVSENSOR00006|All subjects consented are enrolled into the test group and received the INVSENSOR00006.
62042859|NCT05671562|EXPERIMENTAL|Lycopene|Capsules containing 7mg of lycopene. 2 capsules are swallowed once per day with water for 12 weeks. Looks identical to placebo capsule.
62042860|NCT05671562|PLACEBO_COMPARATOR|Placebo|Placebo capsules containing an inactive ingredient. 2 capsules are swallowed once per day with water for 12 weeks. Looks identical to lycopene capsule.
62245781|NCT05334004|EXPERIMENTAL|Cohort 1: Lopinavir/Ritonavir 200mg/50mg (2 cycles)|Cohort 1 will receive two 5-day cycles of the low dose of the suppository (Lopinavir/Ritonavir (200mg/50mg)) in Weeks 0 and 2
62042861|NCT03035292||Children attending eye clinic|"Children 1 month to 5 years of age attending paediatric ophthalmology clinic with and without cataracts. Children who had previously had intra-ocular surgery were excluded.~One eye of each child was assessed by an inexperienced screener (medical student) by red-reflex assessment using direct ophthalmoscope and infrared-reflex using a new device (CatCam). CatCam is a modified smart phone camera which images the reflection of co-axial infrared light from the ocular fundus. A cataract appears as a black silhouette on the white infrared-reflex imaged by the camera.~Sensitivity and specificity for red-reflex and infrared-reflex assessment compared to gold standard dilated ophthalmic examination by a specialised were compared."
62823910|NCT04555551|EXPERIMENTAL|Targeted MCARH109 CAR Modified T cells|Patients will undergo leukapheresis of peripheral blood for further T cell enrichment; activation and genetic modification using a lentiviral vector encoding a GPRC5D targeted CAR (MCARH109). These T cells will be expanded and after the appropriate number of cells is generated, the modified T cells may be infused fresh or frozen for later use according to standard operation procedures. These modified T cell infusions will be administered 2-7 days following completion of conditioning chemotherapy.
62042862|NCT04752423||PATIENT group|Adult patients shedule for general anesthesia
62042863|NCT04752423||NURSE group|Nurse anesthesist in charge of the corresponding patient
62042864|NCT00868855|EXPERIMENTAL|1|Bradykinin
62042865|NCT00914329|EXPERIMENTAL|Gelsemium 5CH|Globules of Gelsemium sempervirens 5CH
62042866|NCT00914329|EXPERIMENTAL|Gelsemium 15CH|Globules of Gelsemium Sempervirens 15CH
62042867|NCT00914329|PLACEBO_COMPARATOR|Placebo|Globules of placebo
62042868|NCT06523530|EXPERIMENTAL|Goserelin|31 women with histologically confirmed endometriosis will receive goserelin acetate post-surgically.
62042869|NCT06523530|NO_INTERVENTION|Control|31 women with histologically confirmed endometriosis will not receive pharmacological treatment post-surgically.
62042870|NCT03503266|EXPERIMENTAL|[14C] MT-7117|14-C MT-7117
62042871|NCT04210206|EXPERIMENTAL|Diet|
62042872|NCT04210206|NO_INTERVENTION|Control|
62823911|NCT05679388|EXPERIMENTAL|Study Group 1|"All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in.~Study Group 1 will receive:~* Relugolix (360 mg) on Day 1~* Relugolix (120 mg) on Days 2-7"
62823912|NCT05679388|EXPERIMENTAL|Study Group 2a|"All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in.~Study Group 2a will receive:~* Relugolix (360 mg) on Day 1~* Relugolix (120 mg) on Days 2-7~* Itraconazole (200 mg) on Days 1-14"
62823913|NCT05679388|EXPERIMENTAL|Study Group 2b|"All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in.~Study Group 2b will receive:~* Relugolix (360 mg) on Day 1~* Relugolix (120 mg) on Days 2-7~* Ritonavir (100 mg tablets taken by mouth) on Days 1-14"
62823914|NCT05679388|EXPERIMENTAL|Study Group 3a|"All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in.~Study Group 3a will receive:~* Relugolix (360 mg) on Day 1~* Relugolix (120 mg) on Days 2-4~* Itraconazole (200 mg tablets taken by mouth) on Days 1-14"
62042873|NCT02955264|EXPERIMENTAL|D-Galactose|D-Galactose is an oral powdered supplement to be taken by mouth. For the first 6 weeks galactose will be given at the dose 0.5g per kg, then from weeks 7-12 at 1.0g per kg, lastly from weeks 13 to 18 at 1.5g per kg (with a maximum daily dose of 50g).
62042874|NCT02443948||adjuvant/follow up setting|
62042875|NCT02443948||neo-adjuvant setting|
62042876|NCT02443948||advanced disease|
62245782|NCT05334004|EXPERIMENTAL|Cohort 1b: Lopinavir/Ritonavir 200mg/50mg (3 cycles)|Cohort 1b will receive three 5-day cycles of the low dose of the suppository (Lopinavir/Ritonavir (200mg/50mg)) in Weeks 0, 2, and 4 if Cohort 2 has one dose-limiting toxicity (DLT).
62435998|NCT03760510|EXPERIMENTAL|Adhesive Tape|Patients in adhesive tape arm had endotracheal tube secured with adhesive tape
62042877|NCT06641180|EXPERIMENTAL|IIV-HD|Participants will receive a single intramuscular (IM) injection of IIV-HD at Day 1
62042878|NCT06641180|ACTIVE_COMPARATOR|IIV-SD|Participants will receive a single intramuscular (IM) injection of IIV-SD at Day 1
62042879|NCT01896570||Group A: cardioversion at AT|after achievement of AT, pts were cardioverted
62042880|NCT01896570||Group B: ablation to SR|After AT has been achieved, all subsequent AT were ablated with the endpoint of procedural SR termination
62042881|NCT03876834|EXPERIMENTAL|study group (group A)|Group (A) included 30 leukemic patients receiving chemotherapy in addition to training by inspiratory muscle trainer(IMT) for 4 weeks, 5 sessions /week
62823915|NCT05679388|EXPERIMENTAL|Study Group 3b|"All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in.~Study Group 3b will receive:~* Relugolix (360 mg) on Day 1~* Relugolix (120 mg) on Days 2-4~* Ritonavir (100 mg) on Days 1-14"
62042882|NCT03876834|NO_INTERVENTION|control group (B)|Group (B) included 10 leukemic patients receiving chemotherapy only
62823916|NCT04359810|EXPERIMENTAL|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent plasma (1 unit; \~200-250 mL) collected from a volunteer who recovered from COVID-19 disease
62823917|NCT04359810|ACTIVE_COMPARATOR|Non-convalescent Plasma (control plasma)|Non-convalescent plasma (1 unit; \~200-250 mL) of standard plasma collected prior to December 2019
62823918|NCT04638543|EXPERIMENTAL|ABP-671|The study will consist of three sequential groups with escalating total daily ABP-671 doses. Each group is further divided into two dose cohorts with either QD or BID dosing.
62245783|NCT05334004|EXPERIMENTAL|Cohort 2: Lopinavir/Ritonavir 400mg/100mg (2 cycles)|Cohort 2 will receive two 5-day cycles of the higher dose of the suppository (Lopinavir/Ritonavir (400mg/100mg)) in Weeks 0 and 2, if Cohort 1 dose is safe.
62823919|NCT04638543|PLACEBO_COMPARATOR|Placebo|
62823920|NCT05306873|EXPERIMENTAL|MMF|Participants will receive 500 mg mycophenolate mofetil (MMF) bid for 7 days, followed by 500mg and 1,000mg MMF in divided doses for 7 days. They will then continue at a stable dose of 1,000mg MMF bid. Visits to evaluate AEs, vital signs, hematology and chemistry, study medication compliance, medication use, disease status, participant reported outcomes, and to obtain biomarker samples will occur every 4 weeks after randomization
62245784|NCT05334004|EXPERIMENTAL|Cohort 2b: Lopinavir/Ritonavir 400mg/100mg (3 cycles)|Cohort 2b will receive three 5-day cycle of the higher dose of the suppository (Lopinavir/Ritonavir (400mg/100mg)) in Weeks 0, 2 and 4 if Cohort 3 has one DLT.
62823921|NCT05306873|PLACEBO_COMPARATOR|Placebo for MMF|Participants will receive 500 mg corresponding mycophenolate mofetil (MMF) placebo bid for 7 days, followed by 500mg and 1,000mg corresponding MMF placebo in divided doses for 7 days. They will then continue at a stable dose of 1,000mg corresponding MMF placebo bid. Visits to evaluate AEs, vital signs, hematology and chemistry, study medication compliance, medication use, disease status, participant reported outcomes, and to obtain biomarker samples will occur every 4 weeks after randomization
62042883|NCT00349453|EXPERIMENTAL|Deferiprone (L1) monotherapy|Deferiprone (L1) monotherapy
62823922|NCT05306873|EXPERIMENTAL|MMF+ Placebo for Voclosporin|Participants randomized in this arm will receive up to 24 weeks of mycophenolate mofetil (MMF) plus placebo for voclosporin, also during the first 2 weeks of treatment, a single intramuscular injection of 80 mg methylprednisolone acetate may be administered if needed to achieve amelioration of symptoms without meeting the definition of treatment failure in Stage 3 and without a requirement to stop Stage 3 study-provided medication
62042884|NCT00349453|EXPERIMENTAL|Combination therapy|Deferiprone (L1) and desferrioxamine combination treatment
62245785|NCT05334004|EXPERIMENTAL|Cohort 3: Lopinavir/Ritonavir 600mg/150mg (2 cycles)|Cohort 3 will receive two 5-day cycles of the highest dose of the suppository (Lopinavir/Ritonavir (600mg/150mg)) in Weeks 0 and 2, if the Cohort 2 dose is safe.
62245786|NCT05334004|EXPERIMENTAL|Cohort 4: Lopinavir/Ritonavir 600mg/150mg (3 cycles)|Cohort 4 will receive three 5-day cycles of the highest dose of the suppository (Lopinavir/Ritonavir (600mg/150mg)) in Weeks 0, 2, and 4, if the Cohort 3 dose is safe.
62245787|NCT04120610||Healthy|Healthy cohort is an age-matched population (over 40 years old) without history of PAD or suspected PAD. Healthy cohort will receive FlowMet-R measurement, Ankle Brachial Index (ABI), and Toe Brachial Index (TBI) measurements.
62435999|NCT03760510|EXPERIMENTAL|Tube Fastener|Patients in the tube fastener arm had endotrachel tube secured with tube fastener
62042885|NCT06106386|NO_INTERVENTION|Control Group|Conventional root canal treatment is done and irrigation will be done with 2.5% room temperature sodium hypochlorite
62602388|NCT01768845|EXPERIMENTAL|Transplant|After a preparative regimen the patient will receive an infusion of one or two umbilical cord blood unit(s) (UBC). The UBC unit(s) will be thawed according to methods of Rubinstein et al. If two products are used, they will be administered sequentially on the same day 1-6 hours apart. Tacrolimus and mycophenolate mofetil (MMF) will be used for GVHD prophylaxis. On day +30, +60, +100, +180, and +365 the chimeric status of patients will be interpreted by variable number tandem repeat (VNTR) analysis. Immune reconstitution (Digeorge Panel) will also be checked at these time points.
62602389|NCT00847782|OTHER|Blood draw (Group 1)|"Normocholesterolemic Subjects~Normal Healthy Volunteers"
62602390|NCT00847782|OTHER|Blood draw (Group 2)|Hypercholesterolemic Subjects
62602391|NCT00847782|OTHER|Blood draw (Group 3)|Hypercholesterolemic Subjects with Statin Treatment
62602392|NCT01152216|EXPERIMENTAL|Dimebon|
62602393|NCT03485937|EXPERIMENTAL|Pre-Operative Videos + verbal/written instructions|This video contains the same instructions that the patient receives when they arrive at the clinic, as well as a video walk through of the clinic/patient room. Videos will be created by the study team to ensure that the content coincides with what is delivered in the standard-of-care verbal and written instructions.
62602394|NCT03485937|ACTIVE_COMPARATOR|verbal/written instructions|This arm will receive the standard-of-care verbal/written instructions and the pre-operative video explanation. These instructions contain the same content as in the pre-operative videos
62602395|NCT02091375|EXPERIMENTAL|GWP42003-P 20 mg/kg/day Dose|Participants received 20 mg/kg/day of GWP42003-P administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
62602396|NCT02091375|PLACEBO_COMPARATOR|Placebo|Participants received placebo (0 mg/mL CBD), volume-matched to the 20 mg/kg/day dose level, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
62602397|NCT06309420|EXPERIMENTAL|Pixie CO2|Cryogenic treatment of warts (Carbonic ice tablet) Maximum 3 application by the technician in charge of the study Apply 15 seconds for a wart on hand or arm and 40 seconds for a wart on feet or toe
62602398|NCT06309420|ACTIVE_COMPARATOR|Wortie®|Cryogenic treatment of wart (dimethylether-based product) Maximum 3 application by the technician in charge of the study. Apply 20 seconds for a wart on hand or arm and 40 seconds for a wart on feet or toe
62602399|NCT02061683|EXPERIMENTAL|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
62823923|NCT05306873|EXPERIMENTAL|MMF+ Voclosporin|Participants randomized in this arm will receive up to 24 weeks of mycophenolate mofetil (MMF) plus voclosporin, also during the first 2 weeks of treatment, a single intramuscular injection of 80 mg methylprednisolone acetate may be administered if needed to achieve amelioration of symptoms without meeting the definition of treatment failure in Stage 3 and without a requirement to stop Stage 3 study-provided medication
62823924|NCT01564160|EXPERIMENTAL|Arm 1: PCSO-524|PCSO-524
62823925|NCT01564160|ACTIVE_COMPARATOR|Arm 2: Fish Oil|Fish Oil
62823926|NCT06590090|EXPERIMENTAL|400mg Natrunix + MTX weekly|Subjects will receive 400mg Natrunix and MTX weekly
62823927|NCT06590090|EXPERIMENTAL|Placebo+ MTX weekly|Subjects will receive placebo and MTX weekly
62823928|NCT05527015|ACTIVE_COMPARATOR|Single vision spectacles (SVLs)|
62823929|NCT05527015|EXPERIMENTAL|Bifocal spectacles (BFLs)|
62042886|NCT06106386|EXPERIMENTAL|Cryotherapy Group|Root canal treatment is done and irrigation is done with cooled sodium hypochlorite ( 2- 4°C) through out the visits and final flush with 2- 4°C cold saline will be used for 5 minutes.
62823930|NCT06590142||Hirschsprung's - Aganglionic|Bowel specimens will be taken from the aganglionic segment of bowel from children with Hirschsprung's disease
62436000|NCT04460989||standard implant|arthroplasty with a standard implant
62823931|NCT06590142||Hirschsprung's - Ganglionic|Bowel specimens will be taken from the ganglionic segment of bowel from children with Hirschsprung's disease
62042887|NCT06106386|ACTIVE_COMPARATOR|Final Flush group|Root canal treatment is done and irrigation is done with sodium hypochlorite at room temperature through out the visits then final flush with 2- 4°C cold saline will be used for 5 minutes.
62042888|NCT04716179|EXPERIMENTAL|Patients with COVID-19|Patients with confirmed COVID-19 infection
62436001|NCT04460989||personalized implant|arthroplasty with a customized implant
62436002|NCT01400269|EXPERIMENTAL|Pacific Autism Center for Education (PACE)|Behavioral: Pacific Autism Center for Education (PACE) developmentally based parent delivered intervention
62436003|NCT03825952|EXPERIMENTAL|Participants using MERM device|Participants will use an electronic medication monitor to measure their adherence to ART in routine clinical care.
62436004|NCT02832908|OTHER|Patients + parents|Patients with severe head trauma
62436005|NCT01032681|EXPERIMENTAL|Group 1|Dose escalation of EMD 521873 monotheraphy 3 doses per cycle
62436006|NCT01032681|EXPERIMENTAL|Group 2|Low dose CPA + Dose escalation of EMD 521873 three doses per cycle
62436007|NCT01032681|EXPERIMENTAL|Group 3|Dose escalation of EMD 521873 monotheraphy 1 dose per cycle
62436008|NCT03208959|EXPERIMENTAL|Dose level 1|HTI-1090 tablets will be orally administered on an empty stomach,twice daily, BID i.e., dosing will be 12 hours apart and at approximately the same times each day
62823932|NCT06590142||Control|Bowel specimens will be taken from the bowel from children who do not have Hirschsprung's disease who are undergoing bowel surgery
62823933|NCT06007534|OTHER|Adult male patient|Men having Sex with Men on PrEP (pre-Exposition Prophylaxy) regularly taking doxycycline for Sexually Transmitted Infection (STI) prevention or HIV-infected
62823934|NCT02464696|EXPERIMENTAL|Arm A (NIPPV therapy)|Patients undergo intermittent NIPPV, with the recommended schedule comprising 2 hours on NIPPV followed by =\< 2 hours off NIPPV and continuous NIPPV at night or while sleeping for 8 hours per day, for 28 days or until discharged from the hospital.
62823935|NCT02464696|ACTIVE_COMPARATOR|Arm B (high flow oxygen therapy)|Patients continue to receive high flow nasal cannula oxygen therapy using current protocol for titration of high flow oxygen therapy for 28 days or until discharged from the hospital. Patients may receive NIPPV if they develop evidence of accessory muscle use with breathing or at the discretion of the treating physician.
62823936|NCT06313515|EXPERIMENTAL|tSCS paired with arm-crank exercise|"Device: Transcutaneous Spinal Stimulation~Non-invasive electrical stimulation of the spinal cord over the skin.~Other: Arm-crank exercise~Exercise using an arm-bike to target cardiovascular functioning."
62823937|NCT06313515|SHAM_COMPARATOR|Sham stimulation paired with arm-crank exercise|"Device: Sham Stimulation~Non-invasive electrical stimulation of a lower extremity muscle group over the skin.~Other: Arm-crank exercise~Exercise using an arm-bike to target cardiovascular functioning."
62823938|NCT05554133|EXPERIMENTAL|The Active Biopsy Guidance System|This imaging scanning device is made up of 2 parts: the optical mapping scope and the high-resolution microendoscope (HRME):
62042889|NCT04716179|OTHER|Healthy participants|The controlled group with healthy participants without COVID-19 infection.
62042890|NCT06126354|ACTIVE_COMPARATOR|Maintenance hyperinsulinemia (MH) protocol|The basal insulin infusion rate (IIR) necessary to maintain participants' mean basal fasting plasma glucose (mbFPG) will be determined during the basal titration period. Then, during the intervention period, the IIR will remain at 100% of basal for the full duration (225 min). The IIR and resulting insulin levels are expected to be relatively high (cf. hyperinsulinemia) because of dexamethasone-induced insulin resistance.
62042891|NCT06126354|EXPERIMENTAL|Reduction toward euinsulinemia (RE) protocol|The basal insulin infusion rate (IIR) necessary to maintain participants' mean basal fasting plasma glucose (mbFPG) will be determined during the basal titration period. Then, during the intervention period, the IIR will be reduced progressively, at 75-min intervals, to 90%, 75%, and 60% of basal IIR. Thus, the basal hyperinsulinemia expected due to underlying insulin resistance will be reduced toward euinsulinemia.
62042892|NCT02475122|OTHER|open-label study|open-label study
62042893|NCT05959993|EXPERIMENTAL|Intervention group|Intervention group participants underwent six interviews at two-week intervals, during which a hybrid and structured nursing intervention was administered.
62042894|NCT05959993|NO_INTERVENTION|Control group|Control group participants were not subjected to a structured nursing intervention.
62245788|NCT04120610||PAD|PAD cohort is all-comers to the vascular lab that are scheduled to undergo assessment for Peripheral Artery Disease (PAD) or have a planned endovascular or surgical intervention to address PAD. PAD cohort patients will receive FlowMet-R measurement in addition to their routine standard of care.
62245789|NCT05116150|ACTIVE_COMPARATOR|Randomized double blind grape seed extract design|Grape see extract
62823939|NCT04711746|EXPERIMENTAL|Previous proximal unprovoked pulmonary embolism|
62823940|NCT04711746|ACTIVE_COMPARATOR|Previous proximal provoked pulmonary embolism|
62436009|NCT03208959|EXPERIMENTAL|Dose level 2|100% Increment from dose level 1
62042895|NCT05305196|EXPERIMENTAL|Eccentric-focused exercise group|Three eccentric-focused exercises addition to the general treatment group
62042896|NCT05305196|ACTIVE_COMPARATOR|General treatment group|hot pack application on shoulder region upper trapezius massage two stretching exercises (modified sleeper stretch and modified cross-body stretch)
62042897|NCT00057551|EXPERIMENTAL|CBASP|Cognitive Behavioral System of Psychotherapy plus medication (Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine)
62042898|NCT00057551|ACTIVE_COMPARATOR|Brief Supportive Psychotherapy|Brief Supportive Psychotherapy plus medication (Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine)
62042899|NCT00057551|ACTIVE_COMPARATOR|Medication Only|Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine
62042900|NCT02030015|EXPERIMENTAL|Syner-G Therapy Regimen|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet, and daily treatment with orally-administered miglustat, for the duration of the 60-month study.
62042901|NCT05894434|EXPERIMENTAL|Standard Intervention: Multisensory Training|Patients with stable hemianopia (\>6 months) are given multisensory training
62245790|NCT05116150|PLACEBO_COMPARATOR|Randomized double blind placebo design|Placebo
62245791|NCT05217303|EXPERIMENTAL|HL-085|12 mg BID HL-085
62436010|NCT03208959|EXPERIMENTAL|Dose level 3|100% Increment from dose level 2
62436011|NCT03208959|EXPERIMENTAL|Dose level 4|100% Increment from dose level 3
62602400|NCT02250066|OTHER|Study group 1|Received high monounsaturated fat diet
62436012|NCT03208959|EXPERIMENTAL|Dose level 5|50% Increment from dose level 4
62436013|NCT04866485|EXPERIMENTAL|HBM4003+pembrolizumab|HBM4003 combined with pembrolizumab in subjects with advanced NSCLC and other solid tumors
62436014|NCT04468776|ACTIVE_COMPARATOR|Medication (zolpidem or trazodone)|Zolpidem or trazodone, as prescribed by physician
62436015|NCT04468776|ACTIVE_COMPARATOR|Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)|Internet-based CBT-I program
62436016|NCT04468776|EXPERIMENTAL|Combination|Medication (zolpidem or trazodone) as prescribed by physician and Internet-based CBT-I program
62602401|NCT02250066|OTHER|Study group 2|Received high carbohydrate diet
62823941|NCT04298697|EXPERIMENTAL|TDF/FTC for 1 week|The first 10 participants (Arm A) will take TDF/FTC for three consecutive days of one week, taking 2 pills on the first day and one pill on the second and third day, for a total of 4 doses.
62823942|NCT04298697|EXPERIMENTAL|TDF/FTC for 13 weeks|The second 10 participants (Arm B) will take TDF/FTC for three consecutive days for thirteen weeks, taking 2 pills on the first day and one pill on the second and third day of each week, for a total of 52 doses.
62823943|NCT04298697|EXPERIMENTAL|TDF/FTC for 13 weeks with weekly alternating schedule|The third 10 participants (Arm C) will take TDF/FTC for three consecutive days, alternating weeks over a 13-week period, taking 2 pills on the first day and one pill on the second and third day of each dosing week, for a total of 28 doses.
62823944|NCT04298697|EXPERIMENTAL|TDF/FTC for 13 weeks with weekly alternating schedule every two weeks|The fourth 10 participants (Arm D) will take TDF/FTC for three consecutive days over a 13-week period, alternating two weeks of study medication followed by two weeks with no medication, taking 2 pills on the first day and one pill on the second and third day of dosing each week, for a total of 28 doses.
62602402|NCT02250066|NO_INTERVENTION|Control Group|Control group was encouraged to follow the Food Guide Pyramid
62823945|NCT03793946|EXPERIMENTAL|AB-assistant|Use of the AB-assistant app by physicians in intervention wards.
62823946|NCT03793946|NO_INTERVENTION|Standard antimicrobial stewardship|Physicians on these wards will use conventional ways to assess local guidelines to prescribe antimicrobials.
62042902|NCT05894434|ACTIVE_COMPARATOR|Standard Intervention: Unisensory Training|Patients with stable hemianopia (\>6 months) are given auditory training and crossover to multisensory training
62042903|NCT05894434|EXPERIMENTAL|Early Intervention: Multisensory Training|Patients with early hemianopia (\<1 months) are given multisensory training
62042904|NCT05894434|ACTIVE_COMPARATOR|Early Intervention: Unisensory Training|Patients with early hemianopia (\<1 months) are given auditory training and crossover to multisensory training
62042905|NCT04872764||COVID-19 patients with acute kidney injury|COVID-19 patients with acute kidney injury
62042906|NCT04872764||COVID-19 patients without acute kidney injury|COVID-19 patients without acute kidney injury
62602403|NCT03634436|EXPERIMENTAL|Cohort 1|A single subcutaneous injection of SHR-1209 dose 1 versus placebo
62042907|NCT03331718|NO_INTERVENTION|Control|Pancreaticojejunostomy with duct-to-mucosa anastomosis is performed as usual.
62042908|NCT03331718|ACTIVE_COMPARATOR|PGA felt reinforcement|In addition to usual pancreaticojejunostomy, PGA felt is used in duplicate.
62042909|NCT05310474|NO_INTERVENTION|Group C|Upon consent, patients will be randomized to receive standard of care, and not be given the active range of motion monitor (the knee glider) two weeks prior to surgery. All patients enrolled in the study will have access to Force Therapeutics, patient engagement and outcome collection system utilized by OSI Orthopedic \& Sports Medicine.
62042910|NCT05310474|EXPERIMENTAL|Group B|Upon consent, patients will be randomized to receive the active range of motion monitor (the knee glider) close to surgery to use postoperatively (through week 4). All patients enrolled in the study will have access to Force Therapeutics, patient engagement and outcome collection system utilized by OSI Orthopedic \& Sports Medicine.
62823947|NCT01692600||healthy volunteers|Age-matched with the patient group, with no oral pathologies and comorbidities
62042911|NCT05310474|EXPERIMENTAL|Group A|Upon consent, patients will be randomized to receive the active range of motion monitor (the knee glider) Receives Knee Glider 2 weeks prior to surgery to utilize through postoperative week 4. All patients enrolled in the study will have access to Force Therapeutics, patient engagement and outcome collection system utilized by OSI Orthopedic \& Sports Medicine.
62602404|NCT03634436|EXPERIMENTAL|Cohort 2|A single subcutaneous injection of SHR-1209 dose 2 versus placebo
62602405|NCT03634436|EXPERIMENTAL|Cohort 3|A single subcutaneous injection of SHR-1209 dose 3 versus placebo
62602406|NCT03634436|EXPERIMENTAL|Cohort 4|A single subcutaneous injection of SHR-1209 dose 4 versus placebo
62602407|NCT03795025|EXPERIMENTAL|3x10RM + no training|
62602408|NCT03795025|EXPERIMENTAL|6x10RM + no training|
62602409|NCT03795025|EXPERIMENTAL|3x10RM + 6x10RM|
62823948|NCT01692600||Late oral radiation toxicity patients|Head-and-neck cancer patients who had undergone radiation therapy and developed late radiation side ffects
62823949|NCT02965911|ACTIVE_COMPARATOR|UDCA Standard treatment|All subjects will reiceive UDCA at a dose of 13-15mg/kg/d by oral for 12 months, and UDCA will be maintained after 12 months.
62823950|NCT02965911|EXPERIMENTAL|Fenofibrate Combined with UDCA Treatment|All subjects will be treated with UDCA,13-15mg/kg/d, and Fenofibrate, 200mg/d by oral for 12 month,
62823951|NCT06596200|EXPERIMENTAL|Intervention Group - SCS|Patients who are eligible will receive a trial implant for a 3-7 day trial period. If there is at least 50% pain relief in the trial period, the patients will receive the permanent SCS implant and will be followed for 1 year post permanent implant.
62245792|NCT06267287||cases of PJI 2018-2019|All cases of monomicrobial and polymicrobial periprocthetic infection for 2018-2019. Microbiological identification of pathogens of periprosthetic infections and determination of their sensitivity to antibiotics.
62823952|NCT06157515|EXPERIMENTAL|continuous vibrating mesh nebulization (cVMN)|Participants will inhale 2.5 mg salbutamol (from a 0.5 unit dose vial of Saldolin Inhalation Solution, Taiwan FDA approval number 043572) via the commercially available vibrating mesh nebulizer (Microbase, model number MBPN002). The device continuously generates aerosol throughout the respiratory cycle. Participants are encouraged to breathe with normal tidal breathing for up to 5 minutes until no aerosol is visually seen. No repeat or additional dosing is utilized.
62823953|NCT06157515|EXPERIMENTAL|Breath-actuated vibrating mesh nebulizer (bVMN)|Participants will inhale 2.5 mg salbutamol (from a 0.5 unit dose vial of Saldolin Inhalation Solution, Taiwan FDA approval number 043572) via the commercially available vibrating mesh nebulizer (Microbase, model number MBPN002) with trigger module attachment. This device utilizes a microphone and algorithm to detect the inspiration to activate aerosol generation during period of inspiration only. Participants are encouraged to breathe with normal tidal breathing for up to 5 minutes until no aerosol is visually seen. No repeat or additional dosing is utilized.
62823954|NCT06024408|PLACEBO_COMPARATOR|Part A: Placebo|Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
62245793|NCT06267287||cases of PJI 2021-2022|All cases of monomicrobial and polymicrobial periprocthetic infection for 2021-2022. Microbiological identification of pathogens of periprosthetic infections and determination of their sensitivity to antibiotics.
62245794|NCT00302510|PLACEBO_COMPARATOR|immunoadsorption|
62245795|NCT02180620|EXPERIMENTAL|No exercise|participants will remain sedentary during testing
62245796|NCT02180620|EXPERIMENTAL|Meal then exercise|45 min of resistance training will be performed after a standard meal
62602410|NCT03795025|NO_INTERVENTION|Control|This arm includes 3 weeks of testing and 7 weeks of no intervention and post tests, followed by 7 weeks of progressive unilateral strength training 3 times per week for 7 weeks. Both legs exercises individually with 3 sets of 10 maximal repetitions.
62823955|NCT06024408|EXPERIMENTAL|Part A: Low Dose|Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
62823956|NCT06024408|EXPERIMENTAL|Part A: Mid Dose|Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
62823957|NCT06024408|EXPERIMENTAL|Part A: High Dose|Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
62823958|NCT06024408|PLACEBO_COMPARATOR|Part B: Placebo|Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
62823959|NCT06024408|EXPERIMENTAL|Part B : Low Dose|Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
62823960|NCT06024408|EXPERIMENTAL|Part B: Mid Dose|Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
62823961|NCT06024408|EXPERIMENTAL|Part B: High Dose|Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
62823962|NCT06024408|PLACEBO_COMPARATOR|Part C: Placebo (Optional)|Sponsor may elect to enroll participants who are heterozygous for the PNPLA3 rs738409:G risk allele and may be randomized 1:1
62823963|NCT06024408|EXPERIMENTAL|Part C: High Dose (Optional)|Sponsor may elect to enroll participants who are heterozygous for the PNPLA3 rs738409:G risk allele and may be randomized 1:1
62823964|NCT06600113|EXPERIMENTAL|Game playing|Children play a specially designed educational game within one week of their medical procedure. The game informs the child what to expect at the day of the procedure and teaching coping strategies
62245797|NCT02180620|EXPERIMENTAL|exercise then meal|45 min of resistance training will be performed prior to a standard meal
62245798|NCT00576433|EXPERIMENTAL|1|
62602411|NCT02679833|PLACEBO_COMPARATOR|Placebo|A toothpaste, with the same matrix, all components, and appearance like the active arm but not containing vitamin B12.
62245799|NCT01954186|EXPERIMENTAL|intravenous & intramuscular oxytocin|intravenous or intramuscular 10 iu oxytocin
62245800|NCT01954186|ACTIVE_COMPARATOR|after delivery & when anterior shoulder seen|oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered
62245801|NCT06200649|EXPERIMENTAL|Intervention Group|"Massage will be applied to the intervention group by the researcher who has received training in classical massage techniques and has a certificate. The massage will start with effusion (stroking) and will end with effleurage (stroking).~Baby oil will be used during the massage in order to provide slipperiness and to prevent mothers and babies from being affected by the smell. The oil used will be spread on the back by patting. The massage will last 20 minutes. Post-test data will be obtained by re-filling the forms after 3 hours (6 hours after Normal Birth) for the intervention group to whom massage is applied."
62602412|NCT02679833|ACTIVE_COMPARATOR|Cyanocobalamin|A toothpaste with cyanocobalamin 100 µg cyanocobalamin per 1 g.
62823965|NCT06600113|ACTIVE_COMPARATOR|Story telling|Children are read an illustrated story by their parent within one week of their medical procedure. The story informs the child what to expect at the day of the procedure and teaching coping strategies
62823966|NCT06600113|NO_INTERVENTION|Usual care|These children get the usual care, information from their parents or doctor before the medical procedure
62245802|NCT06200649|NO_INTERVENTION|Control group|No intervention will be made to the control group, and the routine nursing practices of the clinic will continue. Pre-test and post-test will be applied.
62245803|NCT05001451|EXPERIMENTAL|GDX012 Suspension for IV Infusion|Allogeneic cell therapy that is enriched for Vδ1+ γδ T cells
62823967|NCT05538741|EXPERIMENTAL|Bolus|Remimazolam bolus injection for 20 seconds
62245804|NCT03289949|OTHER|Project 1: Occupancy of psilocybin/ketanserin|After baseline MRI \& 5-HT2AR PET-imaging, participants will be allocated to undergo either one oral dose of psilocybine or one oral dose of ketanserin. After drug administration, participants will undergo two CIMBI-36 PET scans.
62245805|NCT03289949|OTHER|Project 2: Long term effects of psilocybin|"After baseline MRI \& CIMBI-36 PET-imaging, participants will receive one dose of oral psilocybine intervention. One and 12 weeks after dosing, participants will undergo post-intervention PET-scan.~Subproject B: After baseline MRI \& UCB-J PET-imaging, participants will receive one dose of oral psilocybine intervention. One week after dosing, participants will undergo post-intervention UCB-J PET-scan.~Subproject C: After baseline MR imaging, participants will receive one dose of oral psilocybine (25 mg) or placebo. One month after dosing, participants will undergo a post-intervention MRI scan."
62436017|NCT05866133||Young people with addiction|Both behavioural and drug addiction will be assessed. Participants with scores consistent with an addiction will be included in this group.
62436018|NCT05866133||Young people without addiction|Both behavioural and drug addiction will be assessed. Participants with scores not consistent with an addiction will be included in this group.
62436019|NCT02382978|EXPERIMENTAL|nurse-provided well child care visit|these children will be seen by a nurse only for their regular, pre-scheduled well child care visit
62436020|NCT05061667|ACTIVE_COMPARATOR|Group I|Group I will consist of randomly assigned patients scheduled for thoracic surgery. These patients will recieve paravertebral block which is already proven to be effective in postoperative pain. After applying standart monitors to the patient and proper positioning in the operating room, paravertebral block will be performed at the planned surgical side using high frequency (8-18 MHz) linear probe of GE Logiq S7 (General Electric Healthcare, Little Chalfont, United Kingdom). 20 ml of 0.25% bupivacaine will be administered into the paravertebral space at T5-T6 vertebra levels using a 50 mm 22 G block needle (BBraun, Melsungen, Germany).
62823968|NCT05538741|ACTIVE_COMPARATOR|Continuous|Remimazolam continuous infusion
62602413|NCT04714632||Children with idiopathic scoliosis|Adolescent between 10-18y with diagnosing idiopathic scoliosis
62602414|NCT04714632||Healthy children|Healthy children between 10-18y without any orthopedics problems
62602415|NCT01520142|EXPERIMENTAL|Treatment|
62823969|NCT06322160||No use of PCI-TC in clinical consultations|In this phase we aim to explore the views of the current decision-making process in thyroid cancer treatment. The patients will be approached for interview within 14 days after their consultations where the treatment decisions for their low risk differentiated thyroid cancer are made. There is no time restriction to approach clinicians for interview.
62245806|NCT03289949|OTHER|Project 3: Functional connectivity|After baseline MRI scanning and CIMBI-36 PET, participants will undergo one psilocybine-intervention fMRI scan and one ketanserin-intervention fMRI scan. If P2 shows there are long term effects of psilocybine on 5-HT2AR levels, psilocybine will be fixed as the second intervention. If not, interventions will be randomized.
62042912|NCT01522417|EXPERIMENTAL|Short Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.~Patients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
62042913|NCT01522417|ACTIVE_COMPARATOR|Eptifibatide (Integrilin)|"Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.~Patients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
62042914|NCT01522417|EXPERIMENTAL|Long Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post PCI.~Patients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
62042915|NCT06068855|EXPERIMENTAL|Double-Blind Period: Botox|Participants will receive 6 intramuscular injections of BOTOX to the masseter on Day 1.
62042916|NCT06068855|PLACEBO_COMPARATOR|Double Blind Period: Placebo|Participants will receive 6 intramuscular injections of Placebo to the masseter on Day 1.
62042917|NCT06068855|EXPERIMENTAL|Open-Label Period: Botox|Participants who are eligible for retreatment will be given open-label BOTOX on Day 180 and will be followed for up to 6 months
62042918|NCT06078462||Group A|Fifty physiotherapist females will participate in this group and will be assessed at the beginning of the study and after 6 months of clinical work.
62042919|NCT06078462||Group B|Fifty dentist females will participate in this group and will be assessed at the beginning of the study and after 6 months of clinical work.
62042920|NCT04487093|EXPERIMENTAL|neoantigen vaccine + EGFR-TKI|
62042921|NCT04487093|EXPERIMENTAL|neoantigen vaccine + anti-angioge|
62042922|NCT00979836|EXPERIMENTAL|Calcium Dobesilate|
62042923|NCT00979836|PLACEBO_COMPARATOR|Placebo|The placebo is a capsule with the same presence of experimental drug.
62042924|NCT04072510|EXPERIMENTAL|Case: Self-esteem group + Treatment as Usual|"Self-esteem group is based on a cognitive behavioral model of low self-esteem addressing thoughts, feelings and behaviour. The self-esteem group is designed to be administered in 6 weekly sessions.~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.Treatment as usual occurred alongside the self-esteem group."
62245807|NCT01549626|ACTIVE_COMPARATOR|defatted flaxseed flour|30 grams per day of defatted flaxseed flour
62602416|NCT01520142|PLACEBO_COMPARATOR|Placebo|
62042925|NCT04072510|ACTIVE_COMPARATOR|Control: Treatment as Usual Only|Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.
62042926|NCT05148377|EXPERIMENTAL|Sodium heparin (Heptar)|Sodium heparin (Heptar®) produced by Eurofarma Laboratory,
62042927|NCT05148377|ACTIVE_COMPARATOR|Liquemine®|Roche Lab's Liquemine®
62042928|NCT06524466|EXPERIMENTAL|Experimental arm|After enrollment, patients will immediately begin treatment with Lenvatinib (Len) and Pucotenlimab (Puco). SBRT will be performed within 2-4 weeks after enrollment (with continued Len plus Puco during this period). Six to ten weeks after the completion of SBRT, imaging assessments will be conducted. If there is no sign of tumor progression (PD), surgical resection will be performed within 10-16 weeks after the completion of SBRT. A total of four cycles of Puco treatment must be completed before surgery. The surgical resection should conducted within two weeks after completing the fourth cycle of Puco. Len should be discontinued one week before surgery.
62042929|NCT05850832|ACTIVE_COMPARATOR|Group E|Esmolol group: patients received loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery
62042930|NCT05850832|ACTIVE_COMPARATOR|Group M|Magnesium sulphate group: patients received loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
62042931|NCT03253224|PLACEBO_COMPARATOR|Saline|Patient who received normal saline during the operation
62042932|NCT03253224|EXPERIMENTAL|Magnesium|Patient who received magnesium sulfate during the operation
62042933|NCT05656599||Letermovir Group|HSCT recipients who received letermovir prophylaxis
62602417|NCT05200117||Nulliparous cohort|Cervical stiffness will be measured in the same subject sequentially between days and during the same day and at different gestational ages.
62042934|NCT05656599||Preemptive therapy Group|HSCT recipients who received PCR-guided preemptive therapy
62245808|NCT01549626|ACTIVE_COMPARATOR|golden flaxseed flour|30 grams per day of golden flaxseed flour
62245809|NCT01549626|ACTIVE_COMPARATOR|whole brown flaxseed flour|30 grams per day of whole brown flaxseed flour
62245810|NCT02633410|ACTIVE_COMPARATOR|Transtibial|Transtibial technique used to create femoral tunnel
62245811|NCT02633410|ACTIVE_COMPARATOR|Anteromedial|Anteromedial technique used to create femoral tunnel
62602418|NCT05200117||Multiparous cohort|Cervical stiffness will be measured in the same subject sequentially between days and during the same day and at different gestational ages.
62602419|NCT06624254||Adaptive Pressure Control|On adaptive pressure control mode with acute respiratory failure
62436021|NCT05061667|EXPERIMENTAL|Group II|Group II will consist of randomly assigned patients scheduled for thoracic surgery. These patients will recieve rhomboid block which is being experimented for its efficacy in postoperative pain. After applying standart monitors to the patient and proper positioning in the operating room, rhomboid block will be performed at the planned surgical side using high frequency (8-18 MHz) linear probe of GE Logiq S7 (General Electric Healthcare, Little Chalfont, United Kingdom). 20 ml of 0.25% bupivacaine will be administered into the plane between rhomboid muscle and intercostal muscles, medial to scapula at T5-T6 vertebra levels using a 50 mm 22 G block needle (BBraun, Melsungen, Germany).
62602420|NCT05412225|EXPERIMENTAL|Participants with clinical T4 biopsy-proven breast cancer|Participants with clinical T4 biopsy-proven breast cancer with no evidence of distant metastases who demonstrate a complete or partial response to standard neoadjuvant chemotherapy/NAC and desire immediate autologous reconstruction/IR will be eligible to enroll.
62823970|NCT06322160||User experience of PCI-TC in thyroid cancer outpatient clinic setting|First, the clinicians will be trained on how to use the PCI-TC in their outpatient clinics. A new group of patients will then be identified and recruited for the phase two study. Patients from this new group will be given the PCI-TC in a quiet area just off the waiting area prior to the consultation. They will be asked to tick items on the PCI-TC list which they wish to discuss. The clinicians will conduct the consultation using the ticked PCI-TC as a guide and discuss with patients regarding the treatment plan for their thyroid cancer. The patients will be approached for interview within 14 days after their consultations. The clinicians will be approached for interview after all recruited patients in phase two study have had their consultation regarding their cancer treatment.
62042935|NCT02184611|EXPERIMENTAL|Umeclidinium bromide|Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive UMEC Inhalation Powder 62.5 mcg OD over a period of 24 weeks
62042936|NCT02184611|PLACEBO_COMPARATOR|Placebo|Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive matching placebo of UMEC Inhalation Powder OD over a period of 24 weeks
62823971|NCT03396341||patients receiving a positive BRCA1/2 mutation result|All interested participants will provide a saliva sample for genetic risk modifier testing, and will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system
62823972|NCT05227417|EXPERIMENTAL|Intervention|SMS-based intervention delivered with a web-based system, which will include weekly health check-ins, appointment reminders all delivered via SMS (text messages).
62823973|NCT05227417|NO_INTERVENTION|Control|Standard of care: Those who test positive in both tests receive post-test counseling, including emotional support, and are linked to a facility for antiretroviral (ART) initiation, ideally within one week. During the 1st medical appointment after diagnosis, lab tests are requested including CD4 and viral load. In most cases, ART initiation occurs at the second medical appointment when safety lab results are available. Currently, it is not mandatory to have CD4/VL results available to start ART. It is recommended that patients have CD4 counts and viral load assessed twice during the first year. A one-month supply of ART is provided initially. If clients are adherent, ART is dispensed every 3 months by nurses who also assess adherence. Standard follow-up is performed by nurses when clients visit the center for their appointments.
62823974|NCT01054014|EXPERIMENTAL|001|JNJ-40346527/Placebo Single oral dose of JNJ-40346527 (either 10 50 150 300 600 or 1000mg) or Placebo
62042937|NCT00668954|ACTIVE_COMPARATOR|Pomegranate Juice|
62245812|NCT03100201|ACTIVE_COMPARATOR|Intervention Armeo®Spring|The intervention group will receive conventional occupational- and physiotherapy and an additive robotic-assisted training using the Armeo®Spring robot for three weeks.
62245813|NCT03100201|ACTIVE_COMPARATOR|Control group|The control group will receive conventional occupational- and physiotherapy.
62245814|NCT06692322|EXPERIMENTAL|Mild hepatic impairment (Child-Pugh A)|
62245815|NCT06692322|EXPERIMENTAL|Moderate hepatic impairment (Child-Pugh B)|
62245816|NCT06692322|EXPERIMENTAL|Normal hepatic function|
62436022|NCT03618966|EXPERIMENTAL|Right-real NMMS Group|It will receive a real stimulation (rNMMS) of the right arm and a sham stimulation (sNMMS) of the left arm
62042938|NCT00668954|PLACEBO_COMPARATOR|Placebo Juice (non-Pomegranate)|
62042939|NCT02302443|EXPERIMENTAL|Cohort 1|Very low dose of HM12470 (single dose, subcutaneous injection)
62436023|NCT03618966|ACTIVE_COMPARATOR|Left-real NMMS Group|It will receive a rNMMS of the left arm and a sNMMS of the right arm
62436024|NCT00744510|EXPERIMENTAL|1|Reflexology
62042940|NCT02302443|EXPERIMENTAL|Cohort 2|Low dose of HM12470 (single dose, subcutaneous injection)
62042941|NCT02302443|EXPERIMENTAL|Cohort 3|Intermediate dose of HM12470 (single dose, subcutaneous injection)
62042942|NCT02302443|EXPERIMENTAL|Cohort 4|High dose of HM12470 (single dose, subcutaneous injection)
62042943|NCT02302443|EXPERIMENTAL|Cohort 5|Active comparator and a selected dose of HM12470 (single dose, subcutaneous injection)
62042944|NCT02302443|EXPERIMENTAL|Cohort 6|Active comparator and a selected dose of HM12470 (single dose, subcutaneous injection)
62436025|NCT00744510|NO_INTERVENTION|2|
62436026|NCT02238977|ACTIVE_COMPARATOR|Fluoxetine|Fluoxetine up to 20 mg orally daily for 12 weeks. Flexible dosing between a minimum of 10 mg daily and 20 mg daily as tolerated.
62436027|NCT02238977|EXPERIMENTAL|Bupropion|Bupropion sustained release (SR) 150 mg orally twice per week
62436028|NCT04520035|EXPERIMENTAL|neoadjuvant chemotherapy with camrelizumab|"paclitaxel and cisplatin~Carilizumab 200 mg, every 3 weeks, 2 cycles.~Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles~Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles"
62436029|NCT02280421|OTHER|ASP2151 400mg|ASP2151 400mg + 100mg ciclosporin
62436030|NCT02280421|OTHER|ASP2151 1200mg|ASP2151 1200mg + 100mg ciclosporin
62436031|NCT02609282|EXPERIMENTAL|Prompt group|Following an education session on the health benefits of breaking prolonged sitting, the prompt group will receive hourly prompts on their PC to stand. The prompts will be delivered by Microsoft Outlook and will run for a period of 10 weeks. The messages will be short in length, varied and centre around the key message of breaking prolonged sitting by standing.
62436032|NCT02609282|NO_INTERVENTION|Control group|The control group will receive the same education session as the prompt group, but will receive no prompts on their PC.
62436033|NCT00789802|EXPERIMENTAL|transdermal estradiol|participants will be randomized to transdermal estradiol
62042945|NCT03837912|EXPERIMENTAL|Patient reported safety experiences fed back to PC providers|The intervention will consist in gathering patient-reported experiences and outcomes of the safety of the healthcare patients received in their PC centres during the previous 12 months. This information will be processed and fed back to their healthcare professionals to help them identify potential safety problems, and then target improvements based on problematic areas.
62245817|NCT01764971||chronic itp and cerebral dysfunction|patients with chronic itp and had behavioral and or cognitive dysfunction
62245818|NCT01764971||chronic itp only|chronic ITP patients without cerebral dysfunction
62245819|NCT05023863|ACTIVE_COMPARATOR|Alpha Lipoic Acid Group (intervention group)|35 patients will receive radiation therapy with or without platinum-based chemotherapy in addition to alpha lipoic acid 600 mg tablets twice daily (throughout the radiotherapy period). .
62245820|NCT05023863|PLACEBO_COMPARATOR|Control Group|35 Patients will receive radiation therapy with or without platinum-based chemotherapy in addition to placebo tablets twice daily (throughout the radiotherapy period)
62245821|NCT03719638|ACTIVE_COMPARATOR|D-blade group|Intubation will be done using D-blade of videolaryngoscope in a simulated difficult airway Difficult airway will be simulated with collar.
62245822|NCT03719638|ACTIVE_COMPARATOR|Macintosh group|Intubation will be done using Macintosh videolaryngoscope in a simulated difficult airway Difficult airway will be simulated with collar.
62436034|NCT00789802|EXPERIMENTAL|oral naproxen|participants will be randomized to oral naproxen
62436035|NCT00789802|PLACEBO_COMPARATOR|oral placebo|participants will be randomized to oral placebo
62823975|NCT01054014|EXPERIMENTAL|002|JNJ-40346527/Placebo JNJ-40346527 once daily oral dose for 14 days (either 50 150 300 500 or 750mg) or Placebo
62823976|NCT01054014|EXPERIMENTAL|003|JNJ-40346527 JNJ-40346527 150mg one dose either fasting (or with food) then after 7 days off treatment JNJ-40346527 150mg either with food (or fasting)
62823977|NCT03171402||Low fruit and vegetable consumers|Participants with low F\&V consumption, as defined by 24-hr dietary recall
62823978|NCT03171402||High fruit and vegetable consumers|Participants with high F\&V consumption, as defined by 24-hr dietary recall
62823979|NCT04054557|ACTIVE_COMPARATOR|Arm I (Standard of Care office Visits)|Participants receive standard of care office visits approximately every 3 months (± 2 weeks) for one year.
62823980|NCT04054557|EXPERIMENTAL|Arm II (Standard of Care Office Visits, survey, telehealth)|Patients receive standard of care as in Arm I and 4 automated electronic surveys every 3 weeks (+/- 1 weeks) for a total of 18 electronic surveys over one year. Patients who report severe or very severe side effects, or stopping or are thinking about stopping their ET will have a follow up encounter with a research coordinator.
62823981|NCT04054557|EXPERIMENTAL|Arm III (Smart Pill Bottle, messaging)|Patients receive a wireless smart pill bottle that performs daily time-specific reminders to open the pill bottle and take the medication. Additional messages are triggered by the pill bottle when non-adherence is indicated (lack of bottle opening or no change in remaining pills), as well as when medication is skipped.
62042946|NCT03837912|NO_INTERVENTION|Patient reported safety experiences not fed back to providers|Waiting list: the practices allocated to the control group will receive the intervention (feedback report) after the trial finished (i.e., after post-intervention data collection has been completed).
62042947|NCT04730622||Fragility fracture|Patients who are candidates for hip replacement surgery (endo- and arthroplasty).
62245823|NCT06074991|EXPERIMENTAL|experimental group|Music therapy was applied to the patients in the experimental group with the help of mp3 and headphones for 30 minutes in a position where they felt comfortable. Hüseyni makam was used for music therapy. Posttest-1 data were collected immediately after the end of the music therapy. 30 minutes after the posttest-1 data, the posttest-2 data were collected. The patients in the control group, on the other hand, did not undergo any procedure other than medical intervention. Posttest-1 data were collected 30 minutes after the pretest and posttest-2 data 30 minutes after the posttest-1.
62823982|NCT06139510|OTHER|Individuals living with sickle cell disease|Participants living with sickle cell disease will undergo standardized testing called quantitative sensory testing. Quantitative sensory testing measures changes in sensitivity to different type of sensations that include temperature, touch or pressure.
62823983|NCT04444076|EXPERIMENTAL|REGENETEN Bioinductive Implant|REGENETEN bioinductive Implant,a bovine mesh that will be implanted following supraspinatus tendon repair.
62823984|NCT04444076|NO_INTERVENTION|Standard of Care|Supraspinatus tendon repair.
62823985|NCT03234699|EXPERIMENTAL|Single Group|
62823986|NCT06174246|ACTIVE_COMPARATOR|Pain self-management|Participants will complete an online pain self-management education program by themselves as it is intended.
62823987|NCT06174246|EXPERIMENTAL|Pain self-management with support from a physiotherapist|Participants will complete an online pain self-management education program, and, during the treatment period, will take part in two sessions with a physiotherapist and one group session led by a peer living with chronic MSKP.
62245824|NCT06074991|NO_INTERVENTION|control group|The control group did not receive any therapy, and there was no interaction between the experimental group and the control group during the training period.
62602421|NCT05402124|OTHER|ASA 81mg|Acetylsalicylic acid delayed release tablets (81mg), single tablet taken once per day for 90 days.
62823988|NCT05722860|EXPERIMENTAL|L-Citrulline|L-Citrulline 50 g/day per os for 1 week
62042948|NCT06580457|EXPERIMENTAL|Intervention|Receive the personal causal model with a 1-hour, live clinical feedback session.
62042949|NCT06580457|NO_INTERVENTION|Control|No clinical feedback session. Personal causal models will be provided at the end of the study for those who wish to receive them.
62823989|NCT04200534|EXPERIMENTAL|Group I (centralized care strategy)|Participants receive counseling over the phone to help them quit smoking and learn about lung cancer screening over 15-20 minutes for 6-8 sessions over 8 weeks. Participants may also receive nicotine patches.
62823990|NCT04200534|ACTIVE_COMPARATOR|Group II (usual care)|Participants receive counseling on lung cancer screening and smoking cessation from primary care providers at health care visit.
62823991|NCT03744793|EXPERIMENTAL|Treatment (pemetrexed, avelumab)|Patients receive pemetrexed IV over 10 minutes on day 1. Starting cycle 2, patients also receive avelumab IV over 60 minutes. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62823992|NCT03317158|EXPERIMENTAL|Phase 1: Cohort 1|Durvalumab monotherapy
62823993|NCT03317158|EXPERIMENTAL|Phase 1: Cohort 2|Durvalumab plus BCG
62042950|NCT03719755|ACTIVE_COMPARATOR|50% dextrose|Cystoscopic distention of 40 cc of 50% dextrose plus 300 cc of normal saline washout
62042951|NCT03719755|PLACEBO_COMPARATOR|Normal Saline|Cystoscopic distention media of normal saline.
62823994|NCT03317158|EXPERIMENTAL|Phase 1: Cohort 3|"Durvalumab plus External Beam Radiotherapy (EBRT)~(BCG re-treatment) - Cross-over to Durvalumab Monotherapy"
62823995|NCT03317158|EXPERIMENTAL|Phase 1: Cohort 4|"Durvalumab + Gemcitabine/Intravesical Docetaxel (Gem/Doc)~The sequence of administration is flexible to allow for scheduling of both the infusion and intravesical treatments."
62245825|NCT05715528|EXPERIMENTAL|Obeldesivir|Participants will receive obeldesivir 350 mg twice daily for 5 days.
62436036|NCT02552381||Group I|"Patients without LMWH treatment.~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.~The following assays will be performed for these patients :~* Fibrin Structure measured at baseline and every month using prototype assays~* Other markers activity : sFVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
62823996|NCT03317158|EXPERIMENTAL|Phase 1: Cohort 5|"NOTE: Cohort 5 was abandoned prior to any patients enrolled.~Durvalumab + Tremelimumab + Gem/Doc~The sequence of administration is flexible to allow for scheduling of both the infusion and intravesical treatments. For the intravenous medications, durvalumab should be administered first followed by tremelimumab."
62823997|NCT03317158|EXPERIMENTAL|Phase 1: Cohort 6|Additional Regimens (to be determined)
62245826|NCT05715528|PLACEBO_COMPARATOR|Obeldesivir Placebo|Participants will receive obeldesivir placebo twice daily for 5 days.
62245827|NCT03208751|OTHER|Exercise training|All patients were included in the exercise training group
62042952|NCT04960865|EXPERIMENTAL|Experimental Group|Participants will be applied Kinesio tape with 50% tension.
62436037|NCT02552381||Group II|"Patients with LMWH treatment at prophylactic dose at enrollment only.~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.~The following assays will be performed for these patients :~* Fibrin Structure measured at baseline and every month using prototype assays,~* Anti-FXa activity measured at baseline and every month,~* Other markers activity : FVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
62823998|NCT03317158|EXPERIMENTAL|Phase 2: Cohort 4 Expansion|"Durvalumab + Gemcitabine/Intravesical Docetaxel (Gem/Doc)~The sequence of administration is flexible to allow for scheduling of both the infusion and intravesical treatments."
62602422|NCT01763723|EXPERIMENTAL|IPL after UV-exposure|8 UV-exposures followed by 3 weekly IPL exposures
62823999|NCT04639336||Patients with Pompe disease|
62824000|NCT01841099|EXPERIMENTAL|Mesalamine|Mesalamine. Mesalamine granules. 30 mg/kg/day oral for 7 days followed by 50 mg/kg/day oral for 21 days if tolerated.
62824001|NCT01841099|PLACEBO_COMPARATOR|Placebo granules|Placebo granules
62824002|NCT03645122|EXPERIMENTAL|PCMS REST|PCMS will be triggered while the hand/digits are at rest.
62824003|NCT03645122|ACTIVE_COMPARATOR|SHAM|SHAM stimulation will be triggered when a criterion level of force stability by the hand/digits is achieved.
62824004|NCT03645122|EXPERIMENTAL|PCMS ACTIVE|PCMS will be triggered when a criterion level of force stability by the hand/digits is achieved.
62824005|NCT03537989|EXPERIMENTAL|Restricted group|"Oral fluid to 2 h before surgery. Intra-operatively: Glucose 5% (500 ml - volume drunk during fast); HAES 6% for blood loss volume to volume; IV-medicine in saline 0.9% for anesthesia and antibiotics. Blood products after current rules.~Postoperatively: 1000 ml glucose containing fluid in the recovery room. Free oral intake of fluid and food as well as enteral feeding by tube 500 ml.~In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. If less than 1500 ml fluid pr. mouth supplement with VI-fluid.~Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid. Goal: zero fluid balance with up to 1-kilogram body weight increase.~Urine \< 0.5 ml/kg/h: supplement with fluid. MAP \< 60 and hypovolemia: treat with fluid."
62824006|NCT03537989|ACTIVE_COMPARATOR|Standard group|"Oral fluid to 2 h before surgery. Intra-operatively: Saline 500 ml for fasting; 500 ml HAES 6% for the epidural, Saline for the third space: 7 ml/kg/h first hour, 5 ml/kg/h 2.-3. Hour, 3 ml/kg/h subsequent hours. 1000-1500 ml Saline replaced lost blood up to 500 ml, additional HAES 6% for additional blood loss; IV-medicine in saline.~Postoperatively: 1000-2000 ml isotonic fluid in the recovery room. Free oral fluid and food as well as enteral feeding by tube 500 ml.~In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. Supplemental iv-fluid according to department rules. Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid.~Urine \< 0.5 ml/kg/h: supplement with fluid. MAP \< 60 and hypovolemia: treat with fluid."
62824007|NCT04287218|EXPERIMENTAL|TG-iConquerFear|The participant is guided through the web-based sessions by minimum weekly contact with an experienced therapist (estimated ½ hour/week for 10 weeks). The therapist will motivate, answer questions and give feedback on written material and exercises.
62824008|NCT04287218|ACTIVE_COMPARATOR|Augmented treatment as usual|"The control group is described as augmented treatment as usual (aTAU), since the diagnostic telephone interview exceeds standard treatment. Further more, the participants will be referred to a website with a non-guided, publicly available E-learning program in cancer rehabilitation hosted by the Region of Central Jutland (livogkraeft.rm.dk). In addition to written material the website includes self-help instructions for meditation."
62824009|NCT04998331||Participants With CD30-positive Lymphoma|All participants diagnosed with relapsed/refractory (R/R) cHL, CTCL (mycosis fungoides \[MF\] and cutaneous anaplastic large cell lymphoma \[pcALCL\]) and sALCL with CD30 positive, and who have previously achieved a CR or PR with BV treatment and subsequently experienced disease progression/relapse and were administered BV retreatment will be observed retrospectively from their initiation of BV treatment until participant's inclusion date in the study or until treatment discontinuation due to toxicities or any cause. All study data will be collected retrospectively from the medical records.
62824010|NCT06562790|EXPERIMENTAL|Gamma-PN3|2 doses on Days 1 and 29
62824011|NCT06562790|ACTIVE_COMPARATOR|Prevnar|1 dose on Day 1 and saline placebo on Day 29.
62824012|NCT04929249|EXPERIMENTAL|Inclisiran First|Inclisiran sodium 300 mg 1.5 ml (equivalent to 284 mg of inclisiran) + usual care
62824013|NCT04929249|NO_INTERVENTION|Usual Care|Treating physicians were recommended to treat patients in accordance with the 2018 ACC/AHA guidelines
62042953|NCT04960865|SHAM_COMPARATOR|Sham Group|Participants will be applied Kinesio tape without any tension.
62042954|NCT04960865|PLACEBO_COMPARATOR|Placebo Group|Participants will be applied rigid tape without any tension
62623402|NCT02436499|EXPERIMENTAL|Treatment with Botox and fMRI screening|"Following baseline screening, participants will receive two subsequent treatments with botulinum-A toxin, each separated by 12 weeks. Participants will receive standardized botulinum-A toxin dosing for chronic migraine prophylaxis, comprised of 155 total units given at 31 specified sites across 7 head/neck muscles (protocol to be explicitly described in full protocol). Second dose of botulinum-A toxin will either be maintained at 155 total units as dosed initially, or be increased to 195 total units, depending on response to clinical questionnaires and examination to evaluate response and efficacy (to be described in full protocol, consistent with the Follow-the-Pain Injection Paradigm)."
62042955|NCT01385072|EXPERIMENTAL|Double matched sibling transplantation|"Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.~Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS."
62824014|NCT04353349||Patients operated with an open approach|
62824015|NCT04353349||Patients operated with minimally invasive robotic approach|
62824016|NCT04353349||Patients operated with VATS approach|
62824017|NCT06556121|EXPERIMENTAL|Saddle block with intrathecal morphine Group|"Patients will receive a multimodal analgesic regimen with acetaminophen, NSAIDs and opioids plus a surgeon-administered pudendal nerve block by anatomical landmarks with 50mL of Normal Saline, 30mL of 0.25% Bupivacaine with epinephrine 1:200.000 and 20mL Lidocaine 1%. A volume of 20 mL of this mixture is used for the pudendal nerve block, and infiltration of the surgical incision and bilateral spermatic cord block is performed with an additional 20 mL of the same mixture of local anesthetic. 30ml of the solution is used to soak the vaginal plug made of gauze that is put inside the vaginal canal by the end of the procedure.~Patients who are randomized to the saddle block with intrathecal morphine will receive an injection of 5mg of heavy Bupivacaine 0.75% plus 100mcg of morphine injected in the intrathecal space."
62824018|NCT06556121|SHAM_COMPARATOR|Control Group|"As part of the analgesic plan, all patients will receive a multimodal analgesic regimen with acetaminophen, NSAIDs and opioids plus a surgeon-administered pudendal nerve block by anatomical landmarks with 50mL of Normal Saline, 30mL of 0.25% Bupivacaine with epinephrine 1:200.000 and 20mL Lidocaine 1%. A volume of 20 mL of this mixture is used for the pudendal nerve block, and infiltration of the surgical incision and bilateral spermatic cord block is performed with an additional 20 mL of the same mixture of local anesthetic. 30ml of the solution is used to soak the vaginal plug made of gauze that is put inside the vaginal canal by the end of the procedure.~Patients in this group will receive a non-invasive sham saddle block in addition to the care standard."
62824019|NCT01805011||50 healthy mothers|
62824020|NCT00437112|EXPERIMENTAL|1|"4 week pretreatment phase consists of continuation of usual OAM therapy~24 week treatment period with insulin glargine and OAM continuation followed by 24 week treatment period with HIIP and OAM continuation~8 week follow up period"
62042956|NCT06195540|EXPERIMENTAL|Rivaroxaban arm|
62436038|NCT02552381||Group III|"Patients with LMWH treatment at therapeutic dose.~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.~The following assays will be performed for these patients :~* Fibrin Structure measured at baseline and every month using prototype assays,~* Anti-FXa activity measured at baseline and every month,~* Other markers activity : FVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
62436039|NCT00989079|EXPERIMENTAL|Cohort 1 Sequence 1|Period 1 (fasted) Placebo → Period 2 (fasted) ertugliflozin (E) 10 mg → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
62042957|NCT06195540|ACTIVE_COMPARATOR|Low-molecular-weight heparin arm|"Treatment with LMWH is the standard-of-care in this population of lower limb trauma patients at risk of thrombosis.~The control group is therefore the group of patients who receive prophylactic anticoagulant treatment with LMWH for the duration of immobilization (i.e. until full mobilization with weight-bearing)."
62042958|NCT03295487|ACTIVE_COMPARATOR|Group A|post menopausal female with genuine stress incontinence treated by TVT-O and local estrogen cream for 3 months after surgery
62042959|NCT03295487|ACTIVE_COMPARATOR|Group B|post menopausal female with genuine stress incontinence treated by TVT-O only
62042960|NCT03076099|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine was administered intravenously when tracheal extubation, 1.2μg/kg Dexmedetomidine was mixed with 100 ml normal saline and maintained 4 hours constantly.
62602423|NCT00369200|EXPERIMENTAL|Arm I|"Patients receive AFP464 IV over 3 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.~Cohorts of 2-6 patients receive escalating doses of AFP464 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which ≤ 1 of 6 patients experience dose-limiting toxicity. An additional 10 patients whose tumor is amenable to biopsy are treated at the MTD.~Patients undergo blood collection periodically for pharmacokinetic and pharmacodynamic studies. Patients treated at the MTD also undergo tumor tissue biopsies periodically for additional pharmacodynamic and correlative biomarker studies.~After completion of study treatment, patients are followed for 4 weeks."
62602424|NCT06200415|EXPERIMENTAL|Glucosamine sulphate gel|injecting about 2 mm of glucosamine sulphate gel in the affected periodontal pocket only once
62042961|NCT03076099|PLACEBO_COMPARATOR|Control group|Normal Saline was administered intravenously when tracheal extubation,equal volume of normal saline was mixed with 100 ml normal saline and maintained 4 hours constantly.
62042962|NCT01922115|ACTIVE_COMPARATOR|TROSPIUM CHLORIDE|Those with overactive bladder will be administered either a placebo or Sanctura XR extended release (Trospium chloride) for treatment (60 mg).
62245828|NCT05506826|EXPERIMENTAL|fine motor activities group|Patients in this group will receive conventional therapy for 1 month sixty minutes/day, 5 days/week in addition to performing fine motor exercises like therapy ball exercises, therapy putty exercises, table top exercises, moving beans, stacking pennies and rubber band resistances exercises etc. for 30 minutes
62245829|NCT05506826|ACTIVE_COMPARATOR|control group|Patients in this group will receive conventional therapy for four weeks sixty minutes per day, five days per week. In addition, receive thirty minutes of mirror therapy, which included periodic wrist flexion-extension, flexion and extension exercises of fingers on non paralyzed limb
62602425|NCT06200415|EXPERIMENTAL|ginger gel|injecting about 2 mm of ginger gel in the affected periodontal pocket only once
62602426|NCT01451632|EXPERIMENTAL|Part 1: MM-121 + cetuximab|increasing doses of weekly MM-121 + weekly cetuximab
62042963|NCT01922115|PLACEBO_COMPARATOR|PLACEBO|Subjects may be administered a placebo rather than the Sanctura XR (Trospium Chloride).
62042964|NCT02175355|EXPERIMENTAL|Low dose of Micardis®|
62042965|NCT02175355|EXPERIMENTAL|Medium dose of Micardis®|
62042966|NCT02175355|EXPERIMENTAL|High dose of Micardis®|
62042967|NCT02175355|ACTIVE_COMPARATOR|Hydrochlorothiazide|
62602427|NCT01451632|EXPERIMENTAL|Part 2: MM-121 + cetuximab + irinotecan|increasing doses of irinotecan + the Recommended Phase 2 Dose/Maximum Tolerated Dose (RP2D/MTD) of MM121 + cetuximab as determined in Part 1
62602428|NCT01577849|ACTIVE_COMPARATOR|Vitamin D3|
62602429|NCT01577849|EXPERIMENTAL|DP-R206|
62623403|NCT04831996|EXPERIMENTAL|Treat Group 1 : Normal Renal Function|eGFR: ≥ 90 mL/min/1.73 m\^2
62623404|NCT04831996|EXPERIMENTAL|Treat Group 2 : Mild Renal Impairment|eGFR: 60-89 mL/min/1.73 m\^2
62623405|NCT04831996|EXPERIMENTAL|Treat Group 3 : Moderate Renal Impairment|eGFR: 30-59 mL/min/1.73 m\^2
62042968|NCT02175355|PLACEBO_COMPARATOR|Placebo|
62042969|NCT04481737|EXPERIMENTAL|PDTA-IIMR|
62042970|NCT04481737|ACTIVE_COMPARATOR|Peer support|
62042971|NCT01400503|EXPERIMENTAL|Siltuximab|Siltuximab 11 mg/kg, intravenous infusion, given as a 1-hour infusion every 3 weeks.
62245830|NCT04069754|EXPERIMENTAL|Adapted Passport to Freedom Intervention Arm|The intervention consists of 5 weekly, 90 minute group sessions that cover topics such as mindfulness, health, healthy relationships, family matters, and reflections
62245831|NCT02905253|EXPERIMENTAL|AC-084, single ascending dose (Part A)|AC-084 administered at different single dose levels in a sequential manner, and in a maximum of 7 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
62245832|NCT02905253|PLACEBO_COMPARATOR|Placebo,single ascending dose (Part A)|Matched placebo administered as single ascending doses in parallel to AC-084
62245833|NCT02905253|EXPERIMENTAL|AC-084, multiple ascending dose (Part B)|AC-084 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be between 1 and 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A. Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
62245834|NCT02905253|PLACEBO_COMPARATOR|Placebo,multiple ascending dose (Part B)|Matched placebo administered as multiple ascending doses in parallel to AC-084
62623406|NCT04831996|EXPERIMENTAL|Treat Group 4 : Severe Renal Impairment|eGFR: 15-29 mL/min/1.73 m\^2 and not on Hemo Dialysis
62245835|NCT02905253|EXPERIMENTAL|AC-084, single dose (Part C)|Up to 6 subjects in part C will receive AC-084 administered at a single dose (foreseen to be 100 mg)
62623407|NCT04831996|EXPERIMENTAL|Treat Group 5 : Kidney Failure|eGFR: \< 15 mL/min/1.73 m\^2 on Hemo Dialysis
62245836|NCT03585985||Group 1|10 patients aged above 70 years with typical geriatric multimorbidity or aged above 80 years otherwise, patient in the hospital Franziskushospital Aachen on the ward of geriatric medicine
62245837|NCT03585985||Group 2|10 healthy elderly people above 70 years, healthy
62042972|NCT02212574|OTHER|Chemotherapy|"Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1. Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15. Cisplatin is given directly into a vein over 8 hours on Day 1. This cycle lasts 42 days.~Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2. MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours. Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.This cycle lasts 28 days"
62042973|NCT06185205|EXPERIMENTAL|Accelerated Partial Breast Irradiation (APBI)|7.5 gray (Gy) × 3 fractions via multicatheter brachytherapy
62245838|NCT04100629|PLACEBO_COMPARATOR|Control Group|The control group will receive medical facts and are not meant to support newly licensed nurses and are not known to affect stress, resilience, perceived social support, or Intention To Leave one's job.
62824021|NCT00437112|EXPERIMENTAL|2|"4 week pretreatment phase consists of continuation of usual OAM therapy~24 week treatment period with HIIP and OAM continuation followed by 24 week treatment period with insulin glargine and OAM continuation~8 week follow up period"
62824022|NCT05907785|EXPERIMENTAL|Prepubertal group: Educational intervention|An educational intervention to improve physical activity and promote healthy dietary habits will be carried out in prepubertal (8-10 years) volunteers with normal weight (NW), overweight (OW), and obesity (OB).
62824023|NCT05907785|EXPERIMENTAL|Postpubertal group: Educational intervention|An educational intervention to improve physical activity and promote healthy dietary habits will be carried out in postpubertal (13-15 years) volunteers with normal weight (NW), overweight (OW), and obesity (OB).
62245839|NCT04100629|EXPERIMENTAL|Experimental Group|Texts sent to the experimental group will be based on nurturant support messages and are intended to decrease stress, Intention To Leave, increase resilience, and perceived sense of support.
62245840|NCT00659529|EXPERIMENTAL|1|All subjects will receive oral sildenafil three times per day during the study. Study endpoints will be measured before the treatment period and at the end of the treatment period.
62436040|NCT00989079|EXPERIMENTAL|Cohort 1 Sequence 2|Period 1 (fasted) E 0.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
62436041|NCT00989079|EXPERIMENTAL|Cohort 1 Sequence 3|Period 1 (fasted) E 0.5 mg → Period 2 (fasted) E 10 mg → Period 3 (fasted) Placebo → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
62436042|NCT00989079|EXPERIMENTAL|Cohort 2 Sequence 1|Period 1 (fasted) Placebo → Period 2 (fasted) E 30 mg → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.
62436043|NCT00989079|EXPERIMENTAL|Cohort 2 Sequence 2|Period 1 (fasted) E 2.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.
62436044|NCT00989079|EXPERIMENTAL|Cohort 2 Sequence 3|Period 1 (fasted) E 2.5 mg → Period 2 (fasted) E 30 mg → Period 3 (fasted) Placebo. Each dose of study drug will be separated by a minimum of 7 days.
62436045|NCT06330311|EXPERIMENTAL|Whole-Body Vibration Group|Allocated participants will receive an intervention with Whole-Body vibration (12 - 18 minutes, 12 - 20 hz, 1 - 2 mm progression) added to a physical therapy treatment based on learning and motor control through activities with a defined goal and therapeutic exercises (56 minutes per session) 4 sessions per week for 4 weeks.
62436046|NCT06330311|ACTIVE_COMPARATOR|Control Group|"Physical therapy treatment based on learning and motor control through activities with a defined goal and therapeutic exercises (56 minutes per session) 4 sessions per week for 4 weeks.~In the control group, the same measurements will be made at the same time as the subjects in the experimental group."
62623408|NCT04664907|EXPERIMENTAL|Patients suffering from post traumatic stress disorder|
62824024|NCT06593028|EXPERIMENTAL|Veggie Vouchers pilot intervention|During well-child visits, caregivers received brief education from pediatricians about a Supplemental Nutrition Assistance Program (SNAP) fruit and vegetable incentive program in South Carolina. Following the clinic visit, a free trial for this SNAP fruit and vegetable incentive program was then offered. The free trial consisted of 3 vouchers, each good for one free fruit and vegetable box.
62824025|NCT06601972|EXPERIMENTAL|Giomer|Low-shrinkage bioactive material
62623409|NCT06551298|EXPERIMENTAL|Experimental group|Menggongzi Tibetan Tea Special Drink (50ml/time, taken after breakfast and lunch)+Low fat diet
62824026|NCT06601972|ACTIVE_COMPARATOR|Nanohybrid composite|Universal Nano-hybrid composite
62824027|NCT03779009|EXPERIMENTAL|Tracer injection|
62824028|NCT06600919|EXPERIMENTAL|Intervention Arm: Passive Music Therapy|Participants in the Passive Music Therapy arm will receive preoperative music therapy designed to reduce perioperative anxiety. The intervention will involve listening to calming music via headphones for a 20 minutes before entering the operating room.
62042974|NCT02330133|EXPERIMENTAL|Women's Reproductive Health|Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections
62042975|NCT02330133|ACTIVE_COMPARATOR|Online sexual health content|Online general text-based information about reproductive health issues and STD prevention strategies
62042976|NCT00989768|EXPERIMENTAL|Botulinum toxin type - A|Dysport® compared to Botox®
62245841|NCT02004951|OTHER|Misago RX (Misago RX, Terumo Corp., Tokyo|The Misago RX is a peripheral stent (Misago RX, Terumo Corp., Tokyo, Japan) indicated to treat iliac and femoropopliteal arteries. The Misago RX is a flexible self-expanding nitinol stent that is delivered via a RX monorail delivery catheter.
62042977|NCT04648189|EXPERIMENTAL|Single dose cetuximab prior to surgery|A single dose of cetuximab, 400mg/m2, will be administered 72 to 48 hours prior to surgery
62042978|NCT05350943|EXPERIMENTAL|HAIC+Toripalimab+Donafenib|HAIC(GEMOX)+Toripalimab+Donafenib
62042979|NCT03206320|NO_INTERVENTION|Control|
62042980|NCT03206320|ACTIVE_COMPARATOR|Reference|
62245842|NCT02004951|OTHER|Zilver PTX (Cook Medical, Bloomington, IN, USA)|Zilver PTX (Cook Medical, Bloomington, IN, USA) is a nitinol stent with a polymer-free paclitaxel coating designed to treat the above- the-knee femoropopliteal arteries. The anti-proliferative drug is the paclitaxel, a cytotoxic drug. The Zilver PTX stent is delivered via a over-the-wire system.
62245843|NCT00404066|EXPERIMENTAL|Neoadjuvant Chemotherapy|Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles, followed by docetaxel + lapatinib for four 21-day cycles, followed by surgery. Dexamethasone was administered twice-a-day for 3 days, starting 24 hours before the docetaxel infusions. After surgery +/- radiation, participants may receive trastuzumab (Herceptin) for a year.
62245844|NCT03560947|EXPERIMENTAL|Manual Therapy and Exercise|
62436047|NCT05249010||acupuncture and moxibustion group|The investigators intend to recruit 30 participants who receive acupuncture and then measure the VAS and electric characteristic by the semiconductor analyzer Agilent B1500A first. The investigators add the burned moxa on the acupuncture as a method for moxibustion, and then measure the VAS and electric characteristic again.
62245845|NCT03560947|ACTIVE_COMPARATOR|Usual Care|
62245846|NCT05710926|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Personality Disorder as manualized by Beck, Davis, Freeman and Beck in their book (2016) will be delivered to partecipants in the active control group.
62245847|NCT05710926|EXPERIMENTAL|Evolutionary Systems Therapy for Schizotypy|Evolutionary Systems Therapy for Schizotypy as manualized by Cheli and colleagues in their trial (2023) will be delivered to partecipants in the experimental group.
62436048|NCT03567915||Rice|Group that healthy volunteers eat rice.
62436049|NCT03567915||Noodle|Group that healthy volunteers eat noodle.
62436050|NCT04876833||HC，healthy control|18-65 years old，no smoking history，normal pulmonary function，normal compatible computed tomography.
62436051|NCT04876833||HG，high-risk COPD group|18-60 years old，≥10 pack-years smoking history，normal pulmonary function，normal compatible computed tomography.
62436052|NCT04876833||EG，early COPD group|"18-60 years old，≥10 pack-years smoking history，and with any of the following abnormalities：~1. Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) less than 80%;~2. Compatible computed tomography abnormalities：airway abnormality and/or emphysema，air trapping, or bronchial thickening；~3. FEV1 decline (≥60 mL per year)."
62436053|NCT04876833||MG，mild and moderate COPD group|18-65 years old，FEV1/FVC\<70%，FEV1%predicted ≥50%.
62436054|NCT01745978|EXPERIMENTAL|the knob-tipped knife|the knob-tipped knife using for precut papillotomy in difficult CBD cannulation
62436055|NCT01745978|ACTIVE_COMPARATOR|the needle knife|the needle knife using for precut papillotomy in difficult CBD cannulation
62436056|NCT06340542|EXPERIMENTAL|Exercise Group|Thoracic mobility exercises were given to the participants. Exercises has to be performed with combination of breathing which involve holding time 10 seconds 5 repetition per set, 3 sets Each exercise has to perform 5 days in a week for 2 weeks two times a day.
62436057|NCT06340542|ACTIVE_COMPARATOR|Manual Release technique group|Manual therapy including trigger point release and thoracic mobilization were applied for 3 times a week for two weeks.
62436058|NCT06530485|EXPERIMENTAL|Microbiota-directed food|Children randomized to this group will receive Microbiota-directed food (MDF) daily for 12 weeks. MDF can modulate the gut microbiota and enhance host immunity, growth, and development in malnourished children.
62436059|NCT06530485|ACTIVE_COMPARATOR|Khichuri|Children randomized to this group will receive zinc with Micronutrient powder (MNP) and Khichuri daily for 12 weeks.
62449162|NCT05810766|EXPERIMENTAL|mobilization with movement Group|"Week 1 \& 2: mobilization with movement at glenohumeral joint for improving flexion, abduction internal and external rotation. 3 sets of painless glides of 10 repetitions will be given, with 1 minute rest between sets.~* Week 2 \& 4:MWM at glenohumeral joint and then we will add progression by adding glides at sternoclavicular and acromioclavicular joint.5 sets of painless glides of 10 repetitions will be given, with 3-minute rest between sets.~* Week 3 \& 6:MWM at glenohumeral joint and glides at sternoclavicular, acromioclavicular along with glides at scapulothoracic. 5 sets of painless glides for 10 repetitions were given. Progression can be introduced by increasing the number of repetitions performed exercises for 3 weeks."
62449163|NCT05810766|OTHER|conventional physical therapy|Hot pack for 15 minutes
62042981|NCT03206320|EXPERIMENTAL|New|
62042982|NCT03443882|ACTIVE_COMPARATOR|Astaxanthin formulation #1|capsules
62042983|NCT03443882|ACTIVE_COMPARATOR|Astaxanthin formulation #2|tablets
62042984|NCT03443882|ACTIVE_COMPARATOR|Astaxanthin formulation #3|powder
62042985|NCT03443882|EXPERIMENTAL|Astaxanthin formulations|fast condition
62042986|NCT06580145|EXPERIMENTAL|L-leucine|
62042987|NCT06580145|ACTIVE_COMPARATOR|L-lysine|
62042988|NCT06643351|ACTIVE_COMPARATOR|Standard Intrapartum Glucose Target Range|The goal intrapartum glucose target range will be 70-110mg/dl. Insulin infusion will be initiated when maternal capillary glucose exceeds 110 mg/dL.
62042989|NCT06643351|EXPERIMENTAL|Liberalized Intrapartum Glucose Target Range|The goal intrapartum glucose target range will be 70-160mg/dl. Insulin infusion will be initiated when maternal capillary glucose exceeds 160 mg/dL.
62042990|NCT05711641|EXPERIMENTAL|Lidocaine 10%|The patient is instructed to lie down in lateral decubitus, with the ear in study facing upwards and 10% lidocaine is applied to the external auditory canal, using an eyedropper, until its complete filling (approximate average of 2ml).
62042991|NCT05711641|PLACEBO_COMPARATOR|Placebo|The patient is instructed to lie down in lateral decubitus, with the ear in study facing upwards and distilled water is applied to the external auditory canal, using an eyedropper, until its complete filling (approximate average of 2ml).
62042992|NCT02646228||molecular profiling, patient derived cells|
62042993|NCT01925950|PLACEBO_COMPARATOR|Placebo|Control
62042994|NCT01925950|EXPERIMENTAL|orBec|Investigational drug
62042995|NCT04639128|NO_INTERVENTION|No-Device|No placement of an adductor canal catheter
62436060|NCT03652961|EXPERIMENTAL|Abatacept plus DMARD|"Abatacept will be used concomitantly with standard of care disease-modifying anti-rheumatic drugs (DMARDs), other than tumor necrosis factor (TNF) antagonists or Janus kinase (JAK) inhibitors.~Intravenous (IV) Abatacept will be administered as a 30-minute IV infusion utilizing weight range-based dosing:~1. Less than 60 kg: 500 mg~2. 60 to 100 kg: 750 mg~3. More than 100 kg: 1000 mg~Following the initial IV Abatacept administration, an IV infusion will be given at Weeks 2 and 4 after the first infusion and every 4 weeks thereafter for a total of 7 Abatacept doses.~Abatacept will be discontinued after 6 months in all patients. Patients who have flared or failed to achieve low disease activity at 6 months will exit the trial except for one post-study visit for lab work at 9 months. In patients who have achieved low disease activity, Abatacept will be held for 6 months or until a flare results while DMARD use is continued."
62042996|NCT04639128|EXPERIMENTAL|Device|Placement of an adductor canal catheter
62042997|NCT04437784|ACTIVE_COMPARATOR|Laparoscopic Trans-Abdominal Pre-Peritoneal (Lap TAPP group))|Both hernias were treated by laparoscopic trans-abdominal pre-peritoneal repair using 2 separate meshes fixed by endoscopic tackers
62042998|NCT04437784|ACTIVE_COMPARATOR|Open Pre-Peritoneal Repair ( Open PP group)|Both hernias were treated by open pre-peritoneal single mesh repair with suture fixation
62042999|NCT04437784|ACTIVE_COMPARATOR|Bilateral Lichtenstein repair (LICHT group)|treated by bilateral standard Lichtenstein repair using 2 separate meshes with suture fixation
62043000|NCT02231827|EXPERIMENTAL|Gait analysis|
62043001|NCT03565081|EXPERIMENTAL|PWS elastic band training group|Genetically confirmed diagnosis of PWS participants were recruited. The PWS participants needed to have sufficient command of the Mandarin language to understand the study information and motivated to conduct the training program.
62043002|NCT00642512|EXPERIMENTAL|1|
62043003|NCT00642512|ACTIVE_COMPARATOR|2|
62043004|NCT00642512|OTHER|3|
62043005|NCT00642512|PLACEBO_COMPARATOR|4|
62043006|NCT05412641|OTHER|Intervention - Responsible Fatherhood Programming|Participants receive educational programming to include: 24/7 Dad, Couples Communication I, and a comprehensive program targeting financial literacy/money management. The study features only one group. Participants will receive the intervention described. There is no control group.
62043007|NCT06209879|EXPERIMENTAL|Hyaluronic Acid/Hydroxypropyl Guar arm|Systane Hydration® MD
62043008|NCT00803452|ACTIVE_COMPARATOR|Doxycycline|Oral doxycycline
62043009|NCT00803452|ACTIVE_COMPARATOR|azithromycin|Topical azithromycin daily to the conjunctival culdesac
62043010|NCT03399422|EXPERIMENTAL|i-PRF assisted upper canine retraction|I-PRF assisted upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
62824029|NCT06600919|NO_INTERVENTION|Control Arm: Standard Care (No Music Therapy)|Participants in the Control Arm will receive standard care without the intervention of passive music therapy.
62043011|NCT03399422|EXPERIMENTAL|conventional upper canine retraction|Conventional upper canine retraction will be performed in the other side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
62043012|NCT04840550|EXPERIMENTAL|Tegoprazan 25mg|Tegoprazan 25mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
62043013|NCT04840550|ACTIVE_COMPARATOR|Lansoprazole 15mg|Lansoprazole 15mg capsules will be orally administered, once a day, with NSAIDs, for up to 6 months.
62824030|NCT02759614|EXPERIMENTAL|Bevacizumab and Erlotinib|Bevacizumab 15 mg/kg shall be intravenous infusion on day 1 once every 3 weeks, Erlotinib 150 mg tablets shall be administered orally every day at least one hour before or two hours after the ingestion of food.
62824031|NCT02759614|ACTIVE_COMPARATOR|Erlotinib|Erlotinib 150 mg tablets shall be administered orally every day at least one hour before or two hours after the ingestion of food.
62043014|NCT01473667|ACTIVE_COMPARATOR|Superficial Cervical Plexus Block|
62043015|NCT01473667|ACTIVE_COMPARATOR|Local Infiltration|
62043016|NCT04199858|EXPERIMENTAL|Nocebo induction|Conditioning and evocation of a nocebo response to a sham (inert) medication contained in a blue or a brown jar, controlled within subjects.
62043017|NCT04796441|EXPERIMENTAL|CAR--γδT|Patients will be treated with CAR--γδT cells
62043018|NCT03156790|EXPERIMENTAL|Spectrila®|recombinant L-Asparaginase
62043019|NCT06172972|EXPERIMENTAL|Atraumatic nursing care group|Before the phlebotomy, children in the intervention group were allowed to choose a distracting method (foam balloons, stress balls, musical books) to be occupied with during the procedure. It was ensured that the parent was staying with the child and that the child played with this material during the procedure (making a foam balloon, squeezing the ball with the hand in which the procedure was not carried out and reading the book with the parent
62043020|NCT06172972|NO_INTERVENTION|Control group|The parents of the children in the control group were ensured to stay with their children during the procedure, and the child's attention was distracted by the nurse asking questions about the child's name, age, and what grade the child was in. This is one of the methods frequently used in Turkiye.
62245848|NCT06013657||Liver resection|Patients undergoing liver resection due to hepatocellular carcinoma from 2010 to 2021 in RSCM, Jakarta, an academic tertiary-level national referral hospital in Indonesia.
62245849|NCT02682225|EXPERIMENTAL|Sequence 1: Qualification Session|Participants will receive Treatment A (intravenous placebo and intranasal placebo concurrently) on Day 1 and Treatment B (0.5 milligram per kilogram (mg/kg) of intravenous racemic ketamine and intranasal placebo concurrently) on Day 2.
62043021|NCT02453685|EXPERIMENTAL|BIAsp|
62043022|NCT02453685|ACTIVE_COMPARATOR|IGlar + IAsp|
62043023|NCT02668523|EXPERIMENTAL|Raindrop|A single arm study to evaluate the effectiveness of a 2mm Raindrop Near Vision Inlay for the treatment of presbyopia in pseudophakic subjects. This corneal inlay is placed under a LASIK flap or in a corneal pocket, and is designed to change the anterior curvature of the cornea, resulting in the ability to reduce spectacle dependency for near and intermediate tasks.
62043024|NCT01438502||HyperHAES|
62245850|NCT02682225|EXPERIMENTAL|Sequence 2: Qualification Session|Participants will receive Treatment B (0.5 mg/kg of intravenous racemic ketamine and intranasal placebo concurrently) on Day 1 and Treatment A (intravenous placebo and intranasal placebo concurrently) on Day 2.
62824032|NCT06594536|EXPERIMENTAL|Sulforaphane|"Prostaphane® is a dietary supplement based on SULFODYNE®, a broccoli seed extract standardised in free, stabilised sulforaphane.~Patients will receive treatment for 8 weeks at the following dosage:~* 1 capsule/day up to 50 kg,~* 2 capsules/day from 50.1 to 90 kg;~* 3 capsules/day above 90 kg,~Each capsule contains 10mg of Sulforaphane."
62824033|NCT06594536|PLACEBO_COMPARATOR|Placebo|"Patients will receive treatment for 8 weeks at the following dosage:~* 1 capsule/day up to 50 kg,~* 2 capsules/day from 50.1 to 90 kg;~* 3 capsules/day above 90 kg,~Each capsule contains placebo."
62824034|NCT06275685|ACTIVE_COMPARATOR|Control|The control arm will receive multi-day visualizations of their sensor derived data but not receive SeizureWise
62824035|NCT06275685|EXPERIMENTAL|Personalized seizure risk score|The personalized seizure risk score arm will receive multi-day visualization of their sensor derived data and also SeizureWise, an investigational algorithm which enables forecasting of future seizure probabilities based on the pattern and frequency of previous generalized tonic-clonic seizure (GTCS) events, as well as changes in physiological and behavioral variables
62043025|NCT05081453|EXPERIMENTAL|Pavlik harness treatment group|Application of a pavlik harness for 2 months in position seeking 90º of flexion of both knees and 45º of hip flexion with some abduction. An ultrasound control is performed at 2 and 6 months
62824036|NCT03373123|EXPERIMENTAL|Single arm study|Patients will receive CTA, Endoscopy, and rEndosc per protocol. Intervention: Procedure: Endoscopy
62436061|NCT02447510|OTHER|group 1|bone substitute grafting material applied to the defect site control (n=10)
62043026|NCT05081453|NO_INTERVENTION|Control group without intervention|Control group without intervention. An ultrasound control is performed at 2 and 6 months
62436062|NCT02447510|OTHER|group 2|experimental platelet rich growth factor PRGF applied to the defect site (n=10) G2
62436063|NCT02447510|OTHER|group 3|platelet rich fibrin PRF applied to the defect site (n=10) G3.
62043027|NCT04560491||Frozen section|Patients underwent intraoperative sentinel node examination by frozen section
62043028|NCT04560491||Scrape cytology|Patients underwent intraoperative sentinel node examination by scrape cytology
62436064|NCT00125567|EXPERIMENTAL|1|Stalevo (levodopa/carbidopa/entacapone)
62436065|NCT00125567|ACTIVE_COMPARATOR|2|Levodopa/carbidopa
62436066|NCT04719364||Focus Groups|10 black, 10 Latinx, and 10 white MSM will be recuited in this focus group 'cohort'
62824037|NCT06388512|EXPERIMENTAL|Prototype positioning device|The prototype prone positioning device will be used during neurosurgical procedures utilizing intraoperative MRI.
62824038|NCT06598683|EXPERIMENTAL|Group A|
62043029|NCT02400138|EXPERIMENTAL|Respiratory training|Respiratory training will include training of the inspiratory and expiratory muscles seven times per week over eight weeks, during 40 minutes per day, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve device, regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
62824039|NCT06598683|ACTIVE_COMPARATOR|Group B|
62824040|NCT02439697|EXPERIMENTAL|Darbepoetin alfa (NESP®) same dose|Patients on stable low dose Aranesp® (darbepoetin alfa manufactured by Amgen®) (on 20mcg preparations or on 40mcg every 2 weeks or less) will be converted to the same dose of NESP® (darbepoetin alfa manufactured by Kirin®)
62824041|NCT02439697|EXPERIMENTAL|Extended dosing Darbepoetin alfa (NESP®)|Patients on stable dose of Aranesp® (darbepoetin alfa manufactured by Amgen®) will be converted to higher dose preparation of NESP® (darbepoetin alfa manufactured by Kirin®) 40 or 120 mcg preparations) with extended dosing intervals. The total dose of Darbepoetin alpha remains the same.
62824042|NCT02439697|EXPERIMENTAL|Darbepoetin alfa (NESP®) 120mcg|Patients on Aranesp® 100 mcg preparation (darbepoetin alfa manufactured by Amgen®) will be switched to the NESP® (darbepoetin alfa manufactured by Kirin®)120mcg preparation with slight increase in dosing interval according to the conversion
62043030|NCT02400138|SHAM_COMPARATOR|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring, which will be also concealed. The control group will also attend the weekly sessions and undergo the same procedures, except for the load adjustments. If the training proves to be effective, the control subjects will be informed and have the choice to receive the training with proper loads.
62043031|NCT04650555|EXPERIMENTAL|Single Ascending Dose Cohort 1|500 mg BIO 300 Oral Powder administered as a single dose
62623410|NCT06551298|ACTIVE_COMPARATOR|Positive control group|Atorvastatin Calcium Tablets (20mg, qn)+Low fat diet
62623411|NCT06551298|OTHER|Negative control group|Low fat diet
62623412|NCT01358786|NO_INTERVENTION|no quilting sutures but drains|
62623413|NCT01358786|EXPERIMENTAL|quilting sutures and drains|
62824043|NCT03815929|ACTIVE_COMPARATOR|Standard replacement therapy regimen|100 mcg transdermal estradiol patch (or equivalent oral dose)
62824044|NCT03815929|ACTIVE_COMPARATOR|Titrated replacement therapy regimen|Transdermal estradiol patch (or equivalent oral dose) titrated to achieve pre-menopausal estradiol level
62824045|NCT03815929|NO_INTERVENTION|Timed Control Group|Healthy age-matched subjects not on hormone therapy
62824046|NCT06210724||Study cohort|In addition to standard of care, three faecal samples will be obtained. On as soon as possible after diagnosis, one at three weeks post diagnosis and one at six.
62043032|NCT04650555|EXPERIMENTAL|Single Ascending Dose Cohort 2|1000 mg BIO 300 Oral Powder, if dose escalation criteria met, administered as a single dose
62043033|NCT04650555|EXPERIMENTAL|Single Ascending Dose Cohort 3|2000 mg BIO 300 Oral Powder, if dose escalation criteria met, administered as a single dose
62043034|NCT04650555|EXPERIMENTAL|Single Ascending Dose Cohort 4|Single dose to be determined based on the safety and pharmacokinetic profiles in cohorts 1-3
62043035|NCT04650555|EXPERIMENTAL|Multiple Single Dose Cohort 5|Highest dose or maximum tolerated dose from the Single Ascending Dose study administered as a single dose given daily for 6 consecutive days
62623414|NCT01358786|EXPERIMENTAL|quilting sutures but no drains|
62824047|NCT06603233|EXPERIMENTAL|Deep Learning Models Group|As artificial intelligence models, DeepLabV3+, Mask R-CNN (Detectron2), YOLOv8, U-Net, Super Vision U-net and U-Net Transformer models, which are state-of-the-art in semantic segmentation, were selected.
62623415|NCT00797394|EXPERIMENTAL|Treated|
62623416|NCT00797394|ACTIVE_COMPARATOR|Control|
62623417|NCT02069106|EXPERIMENTAL|Pro-Omega LDL|3 capsules 1000 mg BID for 8 weeks
62623418|NCT02069106|PLACEBO_COMPARATOR|Placebo|3 capsules BID for 8 weeks
62623419|NCT02447341||In patients|
62043036|NCT06732453|EXPERIMENTAL|Seated Yoga Intervention|Two one-hour yoga sessions with home practice administered individually by a yoga interventionist in GI clinic
62043037|NCT01279499|ACTIVE_COMPARATOR|SEVO group|Anaesthesia will be induced with IV Propofol (2 mg/kg TW \[TW = ideal body weight, IBW + 0.4 \* difference to the excess weight\]), Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR \> 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes.If the positive sympathetic response persists, then Nifedipine 10 mg will be administered sublingual, if HR \< 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR \> 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of positive sympathetic stress responses that required pharmacologic intervention will be recorded.
62043038|NCT01279499|ACTIVE_COMPARATOR|SEVO-BIS group|Anaesthesia will be induced with IV Propofol (2 mg/kg TW \[TW = ideal body weight, IBW + 0.4 \* difference to the excess weight\]), Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).Intraoperatively Sevoflurane will be guided by a target BIS of 40 - 50 .Every rise of BP or HR \> 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes. If the positive sympathetic response persists, then Nifedipine 10 mg will be administered sublingual, if HR \< 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR \> 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of positive sympathetic stress responses that required pharmacologic intervention will be recorded.
62043039|NCT01279499|ACTIVE_COMPARATOR|Propo- Remi group|"General Anaesthesia (GA) will be induced with a continuous IV Propofol (P) infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (R, 1 μg/kg IBW) and succinylcholine (1mg/kg IBW). GA will be maintained with continuous intravenous administration of P at 150-300mcg/kg/min (doses based on ideal body weight).~Every rise of BP or HR \> 15% of baseline will be followed by a R bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of R to 1.0 μg/kg/min . If HR \< 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR \> 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of stress responses that required intervention is recorded."
62043040|NCT01279499|ACTIVE_COMPARATOR|Propo-Remi-BIS group|"General Anaesthesia (GA) will be induced with a continuous IV Propofol (P) infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (R, 1 μg/kg IBW) and succinylcholine (1mg/kg IBW). GA will be maintained with continuous intravenous administration of P at 150-300mcg/kg/min (IBW).~The depth of anesthesia will be adjusted to accomplish a BIS score 40 -50. If BP or HR is \> 15% of baseline will a bolus of R IV (1 μg/kg IBW) will be given and an the infusion rate of R will be increased to 1.0 μg/kg/min . If this response persists and HR \< 70/ min, Nifedipine 10 mg will be given s.l. and if HR \> 70/ min Diltiazem 10-20 mg IV will be given, followed by esmolol infusion if no response is observed."
62043041|NCT02456168||SLE|
62043042|NCT02456168||Healthy control|
62245851|NCT02682225|EXPERIMENTAL|Sequence 3: Treatment Phase|Participants in Sequence 3 will receive Treatment A (intravenous placebo and intranasal placebo) on Day 1 of period 1, Treatment D (intravenous placebo and intranasal 112 milligram (mg) of esketamine as 4 devices, each with 28 mg esketamine) on Day 1 of period 2, Treatment B (0.5 mg/kg of intravenous racemic ketamine and intranasal placebo) on Day 1 of period 3, Treatment C (intravenous placebo and intranasal 84 mg esketamine as 3 devices, each with 28 mg esketamine followed by 1 device with placebo) on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
62824048|NCT06603233|ACTIVE_COMPARATOR|The Difference Between The AI Model (U-Net Transformer) and Dentists Group|"Using the prior knowledge (α = 0.05, β = 0.2) and an effect size of 0.61, the actual power of the comparison between the AI model (U-Net Transformer) and dentists on 34 test images is at least 80%, which is deemed sufficient. Therefore, randomly selected 35 images on the test dataset were labeled by three dentists without seeing the ground truth and were predicted by the AI model. Then, the intersection over union (IoU) score of these labeled and predicted images were calculated. The IoU score, which computes the ratio between the intersection and the union of two sets, is commonly used to evaluate the accuracy of prediction on semantic segmentation.~To confirm clinical feasibility, three t-tests, which evaluates the difference between the means of two variables, were applied to IoU scores of dentists and IoU scores of the AI model and a p value \< .05 was considered statistically significant."
62043043|NCT01342874||Inositol group|Inositol dietary exposure 4000 mg/day
62043044|NCT01342874||Control group|folic acid 400 mcg/day
62043045|NCT05441085|ACTIVE_COMPARATOR|Nulliparous|Patients of ASA physical status 2-3 with a singleton pregnancy; gestational age \> 37 weeks; regular uterine contractions occurring at least every 5 min; cervical dilation 2-5 cm; and pain \> 5
62043046|NCT05441085|ACTIVE_COMPARATOR|Multiparous|Patients of ASA physical status 2-3 with a singleton pregnancy; gestational age \> 37 weeks; regular uterine contractions occurring at least every 5 min; cervical dilation 2-5 cm; and pain \> 5
62245852|NCT02682225|EXPERIMENTAL|Sequence 4: Treatment Phase|Participants in Sequence 4 will receive Treatment B on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment C on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
62245853|NCT02682225|EXPERIMENTAL|Sequence 5: Treatment Phase|Participants in Sequence 5 will receive Treatment C on Day 1 of period 1, Treatment B on Day 1 of period 2, Treatment D on Day 1 of period 3, Treatment A on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
62436067|NCT04719364||Quantitative Survey Group|Cross-sectional group of 100 black, 100 Latinx, and 100 white MSM
62449164|NCT03405207|ACTIVE_COMPARATOR|active drug receiving group|the drug is vitamin D3 50000 UNT oral capsule prescribing under Holick's protocol, which is every week for 8 weeks then every month for long life
62623420|NCT02447341||Out patients|
62245854|NCT02682225|EXPERIMENTAL|Sequence 6: Treatment Phase|Participants in Sequence 6 will receive Treatment D on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment B on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
62824049|NCT04238910|EXPERIMENTAL|Maximizing Energy|"The Maximizing Energy (MAX) intervention consists of two weekly 30-minute sessions delivered live via the Internet using web-camera technology for 8 weeks. The interventions are delivered by occupational therapists.~The MAX intervention was developed by combining two active ingredients - Problem Solving Therapy and energy conservation strategy education. Participants engage in two introductory sessions during the first week of the intervention. During the first session in a week, participants practice the steps of MAX Intervention with a fatigue-related problem. At the end of the session, the participants identify a clearly defined action plan for solution implementation. Participants are asked to implement the solution over the next few days. The second session takes place later in the week. The interventionist reviews the problem, the identified solution, and its implementation. Participants use a workbook to support their application of the MAX Intervention."
62824050|NCT04238910|ACTIVE_COMPARATOR|Health Education|consists of two weekly 30-minute sessions delivered live via the Internet using web-camera technology for 8 weeks. The interventionist delivered health education using a variety of health related topics relevant to individuals with TBI (e.g., characteristics and prevalence of fatigue after TBI, diet and nutrition, importance of exercise, energy conservation strategies).Participants use a workbook to follow along with the interventionist during the weekly sessions.
62824051|NCT06599307|EXPERIMENTAL|Intervention|This group will receive Rituximab as follows: initial 1gm divided into 2 doses (500 mg each) given 2 weeks apart then another 1gm will be given after 6 months. Vials will be diluted on 500 ml normal saline 0.9% and will be given as intravenous infusions.
62824052|NCT06599307|PLACEBO_COMPARATOR|Control|This group will receive 500 ml normal saline 0.9% as intravenous infusions. Another dose will be given after 6 months
62824053|NCT05737485|EXPERIMENTAL|RCT1100|Drug: RCT1100 single dose
62824054|NCT02849418|EXPERIMENTAL|GSK1358820 Injection 200 U|Subjects will receive a single treatment with 200 U GSK1358820 injection (30 mL of study drug will be administered as 30 injections, each of 1.0 mL) in the detrusor of bladder, using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents. If the criteria for re-treatment between 12 to 36 weeks after first treatment are met, subjects will receive a second treatment with GSK1358820. Following this, subjects could receive another re-treatment up to 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.
62436068|NCT01816971|EXPERIMENTAL|Treatment (dexamethasone, carfilzomib, lenalidomide)|"INDUCTION THERAPY: Patients receive dexamethasone IV or PO QD on days 1, 8, 15 and 22; carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16; and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity..~TRANSPLANT: Patients undergo autologous stem cell transplant.~CONSOLIDATION THERAPY: Patients receive dexamethasone, carfilzomib, and lenalidomide as in induction. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive dexamethasone and lenalidomide as in induction therapy and carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Treatment repeats every 28 days for 10 courses in the absence of disease progression or unacceptable toxicity."
62623421|NCT02624635|ACTIVE_COMPARATOR|Manual Therapy|The treatment for this group will be manual therapy.
62043047|NCT05069090||Students and academics Universidad La Frontera|The intervention consists of social distancing measures to curb the viral transmission of SARS-CoV-2. The Araucanía region was subject to lockdown in a different moment than the Coquimbo region, creating exogenous variation.
62436069|NCT02324985|ACTIVE_COMPARATOR|Active Arm|S-Ibuprofen Topical Gel 5%
62436070|NCT02324985|PLACEBO_COMPARATOR|Placebo Arm|Vehicle Topical Gel
62436071|NCT04418427|EXPERIMENTAL|1|6E11 vg/eye ADVM-022 +/- aflibercept 2mg IVT
62436072|NCT04418427|EXPERIMENTAL|2|2E11 vg/eye ADVM022 +/- aflibercept 2mg IVT
62436073|NCT04418427|ACTIVE_COMPARATOR|3|Aflibercept 2mg IVT
62436074|NCT06462157|EXPERIMENTAL|Online CMT groups|Online Compassionate Mind Training
62623422|NCT02624635|EXPERIMENTAL|Manual Therapy and Hip Strengthening|It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip.
62043048|NCT05069090||Students and academics Universidad Católica del Norte|The intervention consists of social distancing measures to curb the viral transmission of SARS-CoV-2. The Coquimbo region was subject to lockdown in a different moment than the Araucanía region, creating exogenous variation.
62043049|NCT05426434|ACTIVE_COMPARATOR|SP + DP placebo every 4 weeks|Control arm
62043050|NCT05426434|EXPERIMENTAL|SP + DP given every 4 weeks|Intervention arm
62043051|NCT05938985||with dry eye disease (DED)|DED diagnosis defined by the Dry Eye Workshop (DEWS) II.
62043052|NCT05938985||control (non-DED)|No significant ocular disease other than refractive error and no systemic disease likely to be associated with dry eye. The non-DED group will be sex-matched and age-matched to the DED patients.
62043053|NCT03531424|ACTIVE_COMPARATOR|Angiographic guided PCI|Angiographic guided PCI is coronary revascularization based on stand-alone angiography.
62043054|NCT03531424|EXPERIMENTAL|CTA guided PCI|CTA guided PCI is coronary revascularization based on systematic use of CTA plus coronary angiography.
62043055|NCT06336616|EXPERIMENTAL|Intervention group|All participants will receive an online behavioral intervention for 10 weeks, followed by monthly maintenance sessions for 3 months.
62043056|NCT06733350|ACTIVE_COMPARATOR|Group 1 (AS)|Patients with normal testosterone level undergo standard AS for up to 5 years in the absence of disease progression. Patients undergo blood sample collection and MRI throughout the trial and may undergo prostate biopsy on study.
62043057|NCT06733350|EXPERIMENTAL|Group 2 (TRT, AS)|Patients with low testosterone level associated with hypogonadal symptoms and willing to receive TRT receive testosterone per treating physician discretion via injection, gel, lotion, or transdermal patch and undergo standard AS for up to 5 years in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection and MRI throughout the trial and may undergo prostate biopsy on study.
62043058|NCT06733350|ACTIVE_COMPARATOR|Group 3 (AS)|Patients with low testosterone level with no symptoms, or low testosterone level associated with hypogonadal symptoms but declined TRT undergo standard AS for up to 5 years in the absence of disease progression. Patients undergo blood sample collection and MRI throughout the trial and may undergo prostate biopsy on study.
62043059|NCT03709368|EXPERIMENTAL|RANAS|Hardware CLTS+PHAST RANAS (contextualized)
62436075|NCT06462157|NO_INTERVENTION|Control Group|Treatment as usual
62043060|NCT03709368|EXPERIMENTAL|Mini-RANAS|Hardware CLTS+PHAST mini-RANAS (norms)
62043061|NCT03709368|ACTIVE_COMPARATOR|Control|Hardware CLTS+PHAST Placebo
62043062|NCT02060851|EXPERIMENTAL|Vifor and EPO|intravenous iron and EPO
62043063|NCT02060851|PLACEBO_COMPARATOR|control|no intravenous iron or EPO
62043064|NCT02060851|EXPERIMENTAL|Vifor|intravenous iton but no EPO
62043065|NCT06363929||Neonates with hyperinsulinism|Neonates with a diagnosis of hyperinsulinism will wear a Dexcom G6 continuous glucose monitor placed for 10 days.
62043066|NCT00163579|EXPERIMENTAL|Bryophyllum|
62043067|NCT00163579|PLACEBO_COMPARATOR|Placebo|
62043068|NCT05340881|ACTIVE_COMPARATOR|Bright Light Exposure|Participants are exposed to bright light (1,000 lux at eye level) using light glasses (Luminette Version 3) for a maximum duration of 30 minutes upon awakening each day from Monday to Friday for 6 weeks while wearing an actigraph and periodic completion of questionnaires, cognitive assessments, and lab work.
62436076|NCT06129552||Healthy controls|
62436077|NCT06129552||CRSwNP patients|
62436078|NCT06129552||AR patients|
62623423|NCT01225926|EXPERIMENTAL|Toric T3 - T9|AcrySof IQ Toric IOL surgically implanted in the capsular bag of the eye following cataract removal. Both eyes were implanted, with the second eye implanted at least 1 week after and within 1 month of the first eye.
62043069|NCT05340881|PLACEBO_COMPARATOR|Dim Light Exposure|Participants are exposed to exposed to dim light (equivalent intensity of \<25 lux) using light glasses (Luminette) for a maximum duration of 30 minutes upon awakening each day from Monday to Friday for 6 weeks while wearing an actigraph and periodic completion of questionnaires, cognitive assessments, and lab work.
62043070|NCT05586568|EXPERIMENTAL|XZP-3621 tablet and itraconazole oral liquid|
62043071|NCT05586568|EXPERIMENTAL|XZP-3621 tablet and Rifampicin capsules|
62043072|NCT05586568|EXPERIMENTAL|XZP-3621 tablet and esomeprazole tablet|
62043073|NCT03097705|OTHER|IOP and OCT RNFL measurements|all subjects will undergo ophthalmological exams including IOP and RNFL OCT measurements
62043074|NCT02115633|EXPERIMENTAL|Walkasins ON then OFF|Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a 1 hour rest period they will be retested with Walkasins turned off.
62043075|NCT02115633|EXPERIMENTAL|Walkasins OFF then ON|Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a 1 hour rest period they will be retested with Walkasins turned on.
62043076|NCT03167307|EXPERIMENTAL|Omega-3 fatty acid oil|A daily dose of 500mg EPA/ 250mg DHA in the 8 to \<13 year olds, and 1000mg EPA / 500mg DHA in the 13 to \<18 years olds, respectively, will be added to standardized treatment according to the German S3 Guidelines for the treatment of depression in children and adolescents
62043077|NCT03167307|PLACEBO_COMPARATOR|Placebo oil|Placebo capsules will contain mostly medium chain triglycerides (MCT) and also a small amount of fish oil to mimic the fishy flavour and taste. Placebo will be added to standardized treatment according to the German S3 Guidelines for the treatment of depression in children and adolescents
62043078|NCT06079905||Frail elderly with limited life expectancy that fracture a hip|Frail elderly with limited life expectancy that fracture a hip
62043079|NCT05186948||Breast cancer patients (stages I-IIIA)|200 patients with an initial diagnosis of breast cancer stages I-IIIA and scheduled chemotherapy, fulfilling the eligibility criteria
62043080|NCT05186948||healthy control|Group of 30 healthy control participants, matched for age and sex, with no evidence or history of significant neurodegenerative disorder affecting brain function.
62043081|NCT04460118||screw group|coracoid bone block fixed by the screw
62043082|NCT04460118||button group|coracoid bone block fixed by the suture-button
62043083|NCT04618874|EXPERIMENTAL|ROSE group|Ultrasound-assisted percutaneous needle aspiration with rapid on-site evaluation
62043084|NCT04618874|NO_INTERVENTION|US NAB group|Ultrasound-assisted percutaneous needle aspiration without rapid on-site evaluation
62043085|NCT02254226|EXPERIMENTAL|Salmeterol MDI low|
62043086|NCT02254226|ACTIVE_COMPARATOR|Salmeterol MDI high|
62436079|NCT05165251|EXPERIMENTAL|Amlodipine/atorvastatin|amlodipine/atorvastatin (5mg/10mg QD)
62436080|NCT05165251|ACTIVE_COMPARATOR|Amlodipine|amlodipine (5mg QD)
62436081|NCT05165251|OTHER|Lifestyle intervention|
62436082|NCT04698122||type 1 diabetes|Patients with type 1 diabetes
62436083|NCT04698122||type 2 diabetes|Patients with type 2 diabetes
62436084|NCT04698122||Healthy volunteers|Healthy volunteers
62043087|NCT02254226|EXPERIMENTAL|Salmeterol Diskus low|
62043088|NCT02254226|EXPERIMENTAL|Salmeterol Diskus high|
62043089|NCT01926730|NO_INTERVENTION|Usual diet|Patients will follow a usual diet and consume at least 16 oz of water per day
62043090|NCT01926730|EXPERIMENTAL|Restriction diet|Participants will follow a diet that limits intake of selected food items. Patients will consume at least 16 oz of water per day.
62436085|NCT01040325|EXPERIMENTAL|Active|358 subjects receive a two vaccination regimen with an LT patch
62436086|NCT01040325|PLACEBO_COMPARATOR|Placebo|358 subjects receive a two vaccination regimen with placebo patch
62436087|NCT00263081|EXPERIMENTAL|Lapaquistat Acetate QD|(and current lipid-lowering treatment)
62436088|NCT00263081|PLACEBO_COMPARATOR|Current lipid-lowering treatment|
62436089|NCT06468683|EXPERIMENTAL|Experimental: After preconditioning with chemotherapy, F01 will be evaluated.|Assigned Interventions
62043091|NCT06732362||No peripheral vascular neuropathy|Grouping was performed according to the TCSS grading scale
62602430|NCT06372275|EXPERIMENTAL|Values Clarification Condition|Participants will respond to values clarification writing prompts related to physical exercise once a day over 28 days in addition to a short daily survey. In each session, one writing prompt will be randomly presented from a pool of four categories: hierarchical, conditional, distinction, and perspective-taking. The survey inquires about time spent doing light, moderate, and vigorous exercise the day before, in addition to time spent watching television, using the computer, and sitting. It also includes the 24 item Multidimensional Psychological Flexibility Inventory adapted for ecological momentary assessment and questions asking participants to rate the extent to which they currently feel 8 emotions, their current motivation to exercise, and their stress yesterday. The writing prompt and survey are estimated to take 10 minutes to complete daily. Participants will have the option to review additional educational content about values and their previous written responses.
62602431|NCT06372275|PLACEBO_COMPARATOR|Self-Reflection Condition|Participants in this condition will be asked to respond to one randomly selected self-reflection prompt about physical activity from a library of 28 prompts once a day over 28 days \[4 weeks\]. As with the experimental condition, participants will also complete the same daily survey which includes questions about how many minutes they spent doing light, moderate, and vigorous exercise the day before, in addition to how many hours they spent watching television, using the computer, and sitting. The survey also contains the 24 item Multidimensional Psychological Flexibility Inventory adapted for ecological momentary assessment and questions asking participants to rate the extent to which they are currently feeling 8 emotions, their current motivation to exercise, and their stress the day before. This is estimated to take 10 minutes to complete daily. Participants will have the option to review additional educational content about values clarification and their previous written responses.
62602432|NCT03395717|EXPERIMENTAL|Exoskeleton-Assisted Gait Training|Patients conduct sessions of gait training, each lasting 60 minutes, using the powered wearable exoskeleton (Ekso) in addition to conventional therapy. Before the treatment's beginning, a PT checks the correct alignment of the subject's joints with Ekso and the areas of greater pressure between body's skin and device, to set a proper Ekso fit as to customize the padding as well. The best individualized exoskeleton settings should be verified to plan a tailored robotic treatment. During treatment, subjects are trained to interface with the Ekso, with optimal postural arrangement and weight shifting strategies. No strength is required from the patient; only an appropriate balance and weight shifts are necessary to achieve walking, since steps are triggered by the user's lateral weight shift.
62824055|NCT02849418|PLACEBO_COMPARATOR|Placebo Injection|Subjects will receive a single treatment with placebo (30 injections, each of 1 mL) in the detrusor of bladder, using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents. If the criteria for re-treatment between 12 to 36 weeks after first treatment are met, subjects will receive treatment with GSK1358820. Following this, subjects could receive another re-treatment up to 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment
62623424|NCT01225926|ACTIVE_COMPARATOR|IQ SN60WF|AcrySof IQ IOL surgically implanted in the capsular bag of the eye following cataract removal. Both eyes were implanted, with the second eye implanted at least 1 week after and within 1 month of the first eye.
62623425|NCT00828061|PLACEBO_COMPARATOR|A|placebo
62043092|NCT06732362||Mild peripheral vascular neuropathy|Grouping was performed according to the TCSS grading scale
62824056|NCT03521570|EXPERIMENTAL|Treatment (nivolumab, IMRT)|Patients receive nivolumab IV over 30 minutes on weeks -2, 0, 2, 4, and 6 and undergo IMRT once daily beginning on week 0 for up to 6-6.5 weeks. Beginning week 10, patients receive nivolumab IV over 30 minutes every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
62824057|NCT00966654|PLACEBO_COMPARATOR|Saline|Saline
62824058|NCT00966654|ACTIVE_COMPARATOR|GLP-1|GLP-1 (7-36) amide
62824059|NCT05118945||SWITCH group: Change from Basal IQ to Control IQ|"The patients of the SWITCH group used the X:s insulin pump with the Basal IQ algorithm until the start of the study and switched to the Control IQ algorithm at study start."
62245855|NCT04323826|EXPERIMENTAL|salads with olive oil-water mixture|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g olive oil-water mixture will be provided to consume.
62436090|NCT04340414|EXPERIMENTAL|NCP patient with severe ARDS and/or high ventilator supported|The NCP patient with severe ARDS and/or high ventilator supported condition was eligibilitable for enrollment
62824060|NCT05118945||START group: Change from conservative therapy to Control IQ|"The patients of the START group have a conservative Insulin therapy (MDI = multiple daily injections or CSII = Continuous subcutaneous insulin infusion) until the start of the study, but will switched to the Control IQ algorithm at study start."
62824061|NCT04890860|EXPERIMENTAL|Adults patients undergoing mitral and / or tricuspid valve surgery with cardiopulmonary bypass.|
62824062|NCT05958251||Cicaben|Umbilical cord stump of the newborns was medicated by Cicaben ® (Orsana S.r.l.), a natural topical dermo-protective powder
62043093|NCT06732362||Severe peripheral vascular neuropathy|Grouping was performed according to the TCSS grading scale
62043094|NCT02452723|EXPERIMENTAL|ISC-hpNSC|
62824063|NCT05958251||Standard dry care|Umbilical cord stump of the newborns was medicated by standard dry care
62824064|NCT01694953||Patients with MNGIE|Patients of all races of any gender who are at least 5 years of age with a defect in thymidine phosphorylase may participate in this natural history study.
62824065|NCT02759419|EXPERIMENTAL|BAY63-2521|Single-arm, uncontrolled
62824066|NCT05203302|EXPERIMENTAL|Late Adult Cochlear Implant (LateAdultCI)|Post-lingually implanted adults, 18+ years
62824067|NCT05203302|EXPERIMENTAL|Early Child Cochlear Implant (EarlyChildCI)|Early implanted children, ages 7-17 years
62824068|NCT05203302|EXPERIMENTAL|Early Adult Cochlear Implant (EarlyAdultCI)|Early implanted adults, ages 18 to 35 years
62245856|NCT04323826|EXPERIMENTAL|salads with olive oil-water emulsion|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g olive oil-water emulsion (4% whey protein isolate as emulsifier) will be provided to consume.
62245857|NCT04323826|EXPERIMENTAL|salads with coconut oil-water emulsion|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g coconut oil-water emulsion (4% whey protein isolate as emulsifier) will be provided to consume.
62245858|NCT04323826|EXPERIMENTAL|salads with coconut oil-water mixture|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g coconut oil-water mixture will be provided to consume.
62245859|NCT01621997|EXPERIMENTAL|operation inspection|During retraining the patients performed bag exchange under the supervision of a nurse. The nurse ensured that each error listed in the NAC form should be avoided, thus immediately corrected any wrong steps if only.
62245860|NCT01621997|EXPERIMENTAL|verbal education|"Patients in the oral education group also underwent retraining every 2 months. A nurse would address all items in the NAC form one by one, to remind the patient of the key points of bag exchange. Scores calculated by the sum of error items during the bag exchange for patients in technique inspection group, or by the sum of yes in the interactive quiz for patients in verbal education group."
62824069|NCT05203302|EXPERIMENTAL|Cochlear Implant (CI)|CI children, ages 7-17 years, with aided residual hearing (bimodal/contralateral, electric+acoustic/ipsilateral)
62245861|NCT01621997|EXPERIMENTAL|usual care|Patients in the usual care group did not receive any retraining
62043095|NCT03918655||Patient newly diagnosed with AML (prospectively)|Patient newly diagnosed with AML in Saint Antoine hospital or Tours University hospital
62602433|NCT03395717|NO_INTERVENTION|Traditional Over ground Gait Training|"The Control Group (CG) performs 60 minutes. lasting sessions of Traditional Over ground Gait Training with a senior PT. In the starting phase, the gait task facilitation is allowed by the Pt's assistance or by using aids, such as walkers, tripods etc.~Traditional Over ground Gait Trainings include:~* Sit-to-Stand tasks~* Exercises for upright position control (right/left load shift): these tasks will allow to include people who are unable to walk in the CG.~CG patients will not use any other robots or treadmill for gait training."
62602434|NCT03817034|EXPERIMENTAL|Multimodal Analgesia|
62602435|NCT04038177|EXPERIMENTAL|Superset strength training|This is the experimental group that performs strength training with sets and rest intervals programmed in a superset manner
62602436|NCT04038177|ACTIVE_COMPARATOR|Traditional strength training|This is the comparator group that engages in strength training with sets and rest intervals programmed in accordance with the recommendations from The American College of Sports Medicine
62602437|NCT05964517|NO_INTERVENTION|Control Group|The control group refers to patients with tension-type headache who will not be treated. These patients are only evaluated during follow-up.
62824070|NCT05203302|ACTIVE_COMPARATOR|Normal Hearing Children (NHC)|Ages 7-17 years, Control Group
62824071|NCT05203302|ACTIVE_COMPARATOR|Normal Hearing Adults (NHA)|18+ years, Control Group
62043096|NCT03918655||Patient diagnosed with AML (retrospectively)|Patient diagnosed with AML in Saint Antoine hospital in 2015 to 2019
62602438|NCT05964517|ACTIVE_COMPARATOR|Study Group|Patients with tension-type headache in the study group are treated. Evaluations are made before and after treatment.
62602439|NCT01001598|OTHER|danazol|Subjects with either Fanconi anemia or Dyskeratosis congenita
62824072|NCT06300697|OTHER|Control group Adult|Participation will be approximately 14 days after enrollment.
62824073|NCT06300697|OTHER|Food allergy-only group|Participation will be approximately 14 days after enrollment.
62824074|NCT06300697|OTHER|Food allergy plus atopic dermatitis group|Participation will be approximately 14 days after enrollment.
62824075|NCT06300697|OTHER|Atopic dermatitis without food allergy group|Participation will be approximately 14 days after enrollment.
62824076|NCT06300697|OTHER|Control Group less than 18 years old|Participation will be approximately 14 days after enrollment.
62043097|NCT03909126|EXPERIMENTAL|Montreal Region of Quebec|Vaccination with Boostrix at time of gestational diabetes screening in a hospital setting
62043098|NCT03909126|NO_INTERVENTION|Montérégie|Vaccination with Boostrix of pregnant women receiving routine care at the CLSC or regular clinic
62043099|NCT03909126|EXPERIMENTAL|Maurice Region|Vaccination with Boostrix of pregnant women receiving routine care at high volume clinic
62043100|NCT03909126|NO_INTERVENTION|National Capital|Vaccination with Boostrix of pregnant women receiving routine care at the CLSC or regular clinic
62449165|NCT03405207|PLACEBO_COMPARATOR|placebo receiving group|the same as active comparator unless the drug is the identical placebo oral capsule
62449166|NCT00564525|PLACEBO_COMPARATOR|1|
62043101|NCT04762381|ACTIVE_COMPARATOR|Dexamethasone|24 mg dexamethasone as single dose intravenously peroperatively
62043102|NCT04762381|PLACEBO_COMPARATOR|Placebo|saline infusion intravenously in a single dose
62602440|NCT02250261|EXPERIMENTAL|KÄPY group|Workplaces, which are supported to promote employees' ACW.
62602441|NCT02250261|NO_INTERVENTION|Comparison group|Workplaces, which are not supported to promote employees' ACW but will be offered support to do so after the study.
62602442|NCT00103922|EXPERIMENTAL|Arm 1|
62602443|NCT04146675|EXPERIMENTAL|TRICOT JERSEY VANISE DOUBLE FACE|
62602444|NCT04146675|PLACEBO_COMPARATOR|TRICOT JERSEY SIMPLE|
62602445|NCT04713436||Triple antibiotic paste(TAP)|ciprofloxacin, metronidazole and minocycline
62602446|NCT04713436||Doble antibiotic paste(DAP)|ciprofloxacin and metronidazole
62602447|NCT04713436||Modified triple antibiotic paste(mTAP)|ciprofloxacin, metronidazole and cefaclor
62602448|NCT02556619|NO_INTERVENTION|Standard Therapy|Patients will undergo standard medical care for Hepatocellular Carcinoma diagnosis.Patients however will not be denied early palliative care if requested.
62623426|NCT00828061|ACTIVE_COMPARATOR|B|10 mg prednisone
62623427|NCT00828061|ACTIVE_COMPARATOR|C|25 mg prednisone
62623428|NCT02098395|EXPERIMENTAL|Liraglutide 1.8 mg + insulin|
62623429|NCT02098395|EXPERIMENTAL|Liraglutide 1.2 mg + insulin|
62824077|NCT05116384|ACTIVE_COMPARATOR|Pulmonary vein isolation|Electrical isolation by cryoballoon of all pulmonary veins
62824078|NCT05116384|EXPERIMENTAL|Pulmonary vein isolation + renal artery denervation|After completion of the standard PVI, radiofrequency ablation of bilateral renal arteries
62245862|NCT02287376|EXPERIMENTAL|Diclofenac Potassium|Diclofenac Potassium for Oral Solution 50 mg
62043103|NCT05031364|EXPERIMENTAL|Consultation-Based Training on BIACA|Community mental health clinicians will be given online one-on-one training and consultation in the BIACA (Behavioral Interventions for Anxiety in Children with Autism; e.g., Wood et al., 2020) CBT program. Clinicians will be provided with weekly 30-minute video-conference-based consultation sessions with an expert in BIACA. These consultation sessions are manual-driven and utilize a Practice-Based Coaching format, in which a trained consultant meets weekly with clinicians to provide practice-based feedback (cf. McLeod et al., 2018). Consultation meetings include agenda setting, case material review, planning for the next treatment session, and a meeting summary. Relevant online training materials (e.g., demonstration videos of CBT sessions; corresponding written session materials) developed in the context of a NIMH R34 grant available on meya.ucla.edu (1R34MH110591) will also be provided to clinicians for each upcoming therapy session.
62043104|NCT05031364|ACTIVE_COMPARATOR|Usual Care Augmented by Self-Instruction Resources for CBT for Autism|Community mental health clinicians in this arm will provide any therapy, counseling, and/or behavioral treatment procedures they deem appropriate for each participating child. Clinicians randomized to this arm will be given immediate access to CBT-for-autism self-instruction materials that are already freely available to any clinician at meya.ucla.edu (see Consultation-Based Training on BIACA arm, above), to supplement their usual clinical care, if they so choose, until they complete their Usual Care/Self-Instruction participation and are offered direct training and weekly consultation in BIACA.
62043105|NCT02013622|EXPERIMENTAL|Brexpiprazole|Up to 4 mg/day, once daily dose, tablets, orally
62436091|NCT01070394|EXPERIMENTAL|LDX Treatment|Eligible participants received 12 weeks of open-label treatment. Those on treatment prior to baseline underwent a 7-day (for amphetamine or methylphenidate) or 28-day (for atomoxetine or other medications) washout period prior to initiating LDX treatment. The starting dose was 30mg/day, which could be titrated up by 20mg/day during visits 2-6 (for a maximum dose of 70mg/day). At discretion of investigator, the dose could be down-titrated by 20mg/day during visits 4-6. Once the dose was optimized (after visit 6), the dose was maintained for 8 weeks.
62623430|NCT02098395|EXPERIMENTAL|Liraglutide 0.6 mg + insulin|
62824079|NCT06381765|ACTIVE_COMPARATOR|Serratus plane block|Deep serratus plane block will perform with 20 ml 0,25 %bupivacaine at the midaxillary 5. rib, bilaterally
62824080|NCT06381765|ACTIVE_COMPARATOR|Serratus plane block+pectointercostal plane block|deep serratus plane block (20 ml 0,25 %bupivacaine) at the midaxillary 5.th rib+ pectointercostal plane block (0,25% bupivacaine 15 ml) at 4-5.th intercostal space will perform bilaterally .
62824081|NCT04810091|EXPERIMENTAL|Arm A (telotristat ethyl, SSA)|Patients receive telotristat ethyl PO TID and SSA for 6 months in the absence of disease progression or unacceptable toxicity.
62824082|NCT04810091|ACTIVE_COMPARATOR|Arm B (placebo, SSA)|Patients receive placebo PO TID and SSA for 6 months in the absence of disease progression or unacceptable toxicity.
62824083|NCT03938233|ACTIVE_COMPARATOR|DSME program delivered by community health volunteers|Randomisation will happen in 21 primary care units to offer DSME delivered by lay health workers to those newly diagnosed with diabetes and those having difficulties with self-managing their diabetes.
62824084|NCT03938233|ACTIVE_COMPARATOR|DSME program delivered by nurses|Randomisation will happen in 21 primary care units to offer DSME delivered by nurses (for comparative effectiveness) to those newly diagnosed with diabetes and those having difficulties with self-managing their diabetes.
62824085|NCT03938233|NO_INTERVENTION|Usual care(no DSME program)|Randomisation will happen in 21 primary care units where no DSME will be offered to those newly diagnosed with diabetes and/or those having difficulties with self-managing their diabetes.These patients will continue with usual care and will be assessed as the control group.
62824086|NCT01043302||Surgery+chemotherapy|Primary mass was resected and systemic chemotherapy was performed as an adjuvant treatment
62043106|NCT05786248|OTHER|Impedancemtry|measurement of fluid shift by impedancemetry, recording by polysomnography, measurement of neck, calf and ankle perimeters, at different times: 0 min (T0), 30min (T30), 90min (T90), and the next day on waking
62043107|NCT06734026|EXPERIMENTAL|Cafe Therapy|Participants will be volunteer workers for two hours per day, three days per week for 6-8 weeks, alongside a trained researcher.
62043108|NCT06734026|NO_INTERVENTION|Control Group|No Intervention is administered during the 2 months between Assessments
62043109|NCT01944865|EXPERIMENTAL|Interval Training|The INTV consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, and in the last 30 s of each repetition was performed a maximal sprint, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.
62245863|NCT05221801|ACTIVE_COMPARATOR|angle 5 + 1ml water|The measurement would be done in seat inclination angles of 5 degrees with 1 ml water intake.
62245864|NCT05221801|ACTIVE_COMPARATOR|angle 5 + 5 ml water|The measurement would be done in seat inclination angles of 5 degrees with 5 ml water intake.
62245865|NCT05221801|ACTIVE_COMPARATOR|angle 5 + 5 ml pudding|The measurement would be done in seat inclination angles of 5 degrees with 5 ml pudding intake.
62245866|NCT05221801|ACTIVE_COMPARATOR|angle 15 + 1ml water|The measurement would be done in seat inclination angles of 15 degrees with 1 ml water intake.
62436092|NCT03522740|ACTIVE_COMPARATOR|Decision Aid for Renal Therapy|Usual Care as in the 'no intervention arm' below plus access to an web-based decision aid, the Decision Aid for Renal Therapy to patients and their care-partners
62623431|NCT02098395|PLACEBO_COMPARATOR|Liraglutide placebo 0.3 ml + insulin|
62623432|NCT02098395|PLACEBO_COMPARATOR|Liraglutide placebo 0.2 ml + insulin|
62623433|NCT02098395|PLACEBO_COMPARATOR|Liraglutide placebo 0.1 ml + insulin|
62623434|NCT04704271|ACTIVE_COMPARATOR|Delta-9-Tetrahydrocannabinol (THC)|4 mg vaporized THC will be administered.
62824087|NCT01043302||Chemotherapy|Only treated with chemotherapy
62824088|NCT01829620|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|The Treatment as Usual (TAU) control group will reflect current clinical practices for treating suicidal Soldiers and Marines.
62824089|NCT01829620|EXPERIMENTAL|Continuing Contacts via Text (CCVT)+TAU|The intervention group will receive Continuing Contacts via Text (CCVT) in addition to Treatment as Usual (TAU).
62245867|NCT05221801|ACTIVE_COMPARATOR|angle 15 + 5 ml water|The measurement would be done in seat inclination angles of 15 degrees with 5 ml water intake.
62245868|NCT05221801|ACTIVE_COMPARATOR|angle 15 + 5 ml pudding|The measurement would be done in seat inclination angles of 15 degrees with 5 ml pudding intake.
62824090|NCT06554795|EXPERIMENTAL|Dose Level 1|Enrolled subjects will receive DB-1419 at Dose Level 1
62824091|NCT06554795|EXPERIMENTAL|Dose Level 2|Enrolled subjects will receive DB-1419 at Dose Level 2
62824092|NCT06554795|EXPERIMENTAL|Dose Level 3|Enrolled subjects will receive DB-1419 at Dose Level 3
62824093|NCT06554795|EXPERIMENTAL|Dose Level 4|Enrolled subjects will receive DB-1419 at Dose Level 4
62623435|NCT04704271|PLACEBO_COMPARATOR|Placebo|Inhaled placebo (no active cannabinoids)
62043110|NCT01944865|EXPERIMENTAL|Intermittent Training|The riders completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery (10-15 on the CR100 scale).
62245869|NCT05221801|ACTIVE_COMPARATOR|angle 30 + 1ml water|The measurement would be done in seat inclination angles of 30 degrees with 1 ml water intake.
62623436|NCT03969615|ACTIVE_COMPARATOR|Supplemental oxygen|5lpm of supplemental oxygen via a nasal cannula or face mask
62824094|NCT06554795|EXPERIMENTAL|Dose Level 5|Enrolled subjects will receive DB-1419 at Dose Level 5
62824095|NCT06554795|EXPERIMENTAL|Dose Level 6|Enrolled subjects will receive DB-1419 at Dose Level 6
62824096|NCT06554795|EXPERIMENTAL|Dose Expansion 1|
62824097|NCT06554795|EXPERIMENTAL|Dose Expansion 2|
62824098|NCT06554795|EXPERIMENTAL|Dose Expansion 3|
62824099|NCT06554795|EXPERIMENTAL|Dose Expansion 4|
62824100|NCT06554795|EXPERIMENTAL|Dose Expansion 5|
62824101|NCT06554795|EXPERIMENTAL|Dose Expansion 6|
62043111|NCT02177110||Study|Patients who have fresh frozen and FFPE tissue taken prior to treatment
62043112|NCT02177110||Control|Fresh frozen tissue and FFPE tissue is available
62245870|NCT05221801|ACTIVE_COMPARATOR|angle 30 + 5 ml water|The measurement would be done in seat inclination angles of 30 degrees with 5 ml water intake.
62436093|NCT03522740|NO_INTERVENTION|Usual Care|In-person education as would be done at study sites plus 'Choosing a Treatment for Kidney Failure', an educational booklet published by the National Kidney Foundation
62824102|NCT06554795|EXPERIMENTAL|Dose Expansion 7|
62824103|NCT06554795|EXPERIMENTAL|Dose Expansion 8|
62824104|NCT06186050|ACTIVE_COMPARATOR|High-fat meal with Beetroot Drink|2 sausage egg McMuffins and a hashbrown from McDonalds and 10g of beetroot powder mixed in 250 mL cold tap water drink
62245871|NCT05221801|ACTIVE_COMPARATOR|angle 30 + 5 ml pudding|The measurement would be done in seat inclination angles of 30 degrees with 5 ml pudding intake.
62436094|NCT05684133||Patients with Sepsis|Adult patients (18 years or older) meeting Sepsis-3 criteria within 6 hours of emergency department admission. Patients will be excluded with the following conditions: traumatic injury, cardiac arrest, stroke, comfort measures only.
62436095|NCT00502541|EXPERIMENTAL|Fluocinolone acetonide|Fluocinolone acetonide intravitreal implant
62436096|NCT00502541|ACTIVE_COMPARATOR|Standard of Care|Standard of care
62436097|NCT03989115|EXPERIMENTAL|RMC-4630 and Cobimetinib|RMC-4630 and Cobimetinib for oral administration
62436098|NCT03989115|EXPERIMENTAL|RMC-4630 and Osimertinib|RMC-4630 and Osimertinib for oral administration
62436099|NCT06529640|ACTIVE_COMPARATOR|Subepothelial connective tissue graft (SCTG) group|Subepithelial connective tissue graft from palate then coronally positioning flap to cover root recession
62623437|NCT03969615|EXPERIMENTAL|SuperNO2VA nasal positive airway pressure device|Intervention arm will receive the SuperNO2VA nasal positive pressure device at 10lpm
62824105|NCT06186050|PLACEBO_COMPARATOR|High-fat meal with Placebo Drink|2 sausage egg McMuffins and a hashbrown from McDonalds and Mio water flavouring in 250 mL cold tap water. Trace amounts of sugar and sodium were mixed to match the beetroot supplement
62824106|NCT06186050|SHAM_COMPARATOR|Low-fat meal control|Kelloggs cornflakes (110g), greek yogurt (400g), skim milk (500 mL), and orange juice (250 mL). Energy-matched to the high-fat meal
62043113|NCT05290831|EXPERIMENTAL|Main study group|
62043114|NCT04431466|ACTIVE_COMPARATOR|Standard of care|Standard of care (SOC) treatment
62043115|NCT04431466|EXPERIMENTAL|SOC plus ivermectin 100 mcg/kg|SOC plus ivermectin 100 mcg/kg
62043116|NCT04431466|EXPERIMENTAL|SOC plus ivermectin 200 mcg/kg|SOC plus ivermectin 200 mcg/kg
62245872|NCT05221801|ACTIVE_COMPARATOR|angle 45 + 1ml water|The measurement would be done in seat inclination angles of 45 degrees with 1 ml water intake.
62245873|NCT05221801|ACTIVE_COMPARATOR|angle 45 + 5 ml water|The measurement would be done in seat inclination angles of 45 degrees with 5 ml water intake.
62436100|NCT06529640|ACTIVE_COMPARATOR|Periosteal pedicle flap (PPF) group|periosteal flap elevation and repositioning to the root then coronally positioning flap to cover root recession
62436101|NCT01456052|EXPERIMENTAL|Low Dose Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally once daily (QD).
62449167|NCT00564525|EXPERIMENTAL|2|Amitriptyline given
62824107|NCT01239953|ACTIVE_COMPARATOR|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon (SeQuent Please, B. Braun)
62824108|NCT01239953|ACTIVE_COMPARATOR|Everolimus-eluting stent|Everolimus-eluting stent (Xience Prime, Abbott Vascular)
62824109|NCT02234882|EXPERIMENTAL|Rosuvastatin and BMS-663068|Treatment A: Rosuvastatin, single dose (SD) Treatment B: BMS-663068 administered on specified days Treatment C: Combination BMS-663068 and Rosuvastatin administered on specified days
62824110|NCT05094206|EXPERIMENTAL|Indolent B-cell NHL Dose Level -2: 0.75x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 2.5x10\^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
62824111|NCT05094206|EXPERIMENTAL|Indolent B-cell NHL Dose Level -1: 1x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 2.5x10\^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
62824112|NCT05094206|EXPERIMENTAL|Indolent B-cell NHL Dose Level 0: 2.5x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 2.5x10\^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
62824113|NCT05094206|EXPERIMENTAL|Indolent B-cell NHL Dose Level 1: 5x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 2.5x10\^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
62824114|NCT05094206|EXPERIMENTAL|Indolent B-cell NHL Dose Expansion: CAR20.19.22|The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6 cells/kg.
62043117|NCT04431466|EXPERIMENTAL|SOC plus ivermectin 400 mcg/kg|SOC plus ivermectin 400 mcg/kg
62623438|NCT06252155|NO_INTERVENTION|Control|No intervention will be made to the control group.
62043118|NCT05068817|EXPERIMENTAL|Pilates mat exercises|one hour Pilates exercises with 10 min warm up and 5-10 min cooling down
62043119|NCT05068817|EXPERIMENTAL|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit
62043120|NCT05068817|ACTIVE_COMPARATOR|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program
62245874|NCT05221801|ACTIVE_COMPARATOR|angle 45 + 5 ml pudding|The measurement would be done in seat inclination angles of 45 degrees with 5 ml pudding intake.
62824115|NCT05094206|EXPERIMENTAL|Aggressive B-cell NHL Dose Level -1: .75x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1x10\^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
62043121|NCT00617578|EXPERIMENTAL|1|programming of VF therapy: ATP (antitachycardia pacing) One Shot ON
62449168|NCT05187026||EPIC-26 follow-up|All men will receive EPIC-26 in paper and also an electronic version.
62824116|NCT05094206|EXPERIMENTAL|Aggressive B-cell NHL Dose Level 0: 1x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1x10\^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
62824117|NCT05094206|EXPERIMENTAL|Aggressive B-cell NHL Dose Level 1: 2.5x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1x10\^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
62824118|NCT05094206|EXPERIMENTAL|Aggressive B-cell NHL Dose Level 2: 5x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1.0x10\^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
62824119|NCT05094206|EXPERIMENTAL|Aggressive B-cell NHL Dose Expansion: CAR20.19.22|The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6 cells/kg.
62824120|NCT06013735|ACTIVE_COMPARATOR|sodium fluoride solution|children will rinse with sodium fluoride solution mouth rinse (0.2%).
62245875|NCT02509104|EXPERIMENTAL|Cohort 1 Fasted condition|Each subject will receive both treatments A and B in either of period 1 or 2 with a washout period of 28 days between treatment periods. Subjects will receive the study treatments under fasting conditions.
62824121|NCT06013735|ACTIVE_COMPARATOR|guava leaves|children will rinse with guava leaves aqueous extract mouth rinse (0.5%).
62824122|NCT06013735|ACTIVE_COMPARATOR|pomegranate peel|children will rinse with pomegranate peel aqueous extract mouth rinse (0.5%).
62824123|NCT06013735|PLACEBO_COMPARATOR|Control|children will rinse with distilled water
62824124|NCT02991768|EXPERIMENTAL|Entocort EC|Subjects will take 6mg Entocort EC by mouth daily for 8 weeks.
62824125|NCT02991768|PLACEBO_COMPARATOR|Placebo|Subjects will take 6mg matching placebo pill daily for 8 weeks.
62824126|NCT06595251||Fit2Play Program|
62824127|NCT06591546|EXPERIMENTAL|Telescoping nail|"The implant used in this study is Fassier Duval type of telescoping nail.~The Fassier-Duval rod has certain advantages:~the design is dedicated to minimally invasive, ideally percutaneous, approaches sparing joint cartilage at implant positioning and removal. This reduces the risk of delayed growth and infection, with lower scar impact; instrumentation is much better than the very basic Dubow-Bailey instrumentation; maximum diameter is greater: 6.4 mm, compared to 5 mm for Bailey-Dubow; The length of the female part can be adapted, including intraoperatively. Precutting according to the surgeon's measurement can be adjusted intraoperatively with a dedicated circular saw with a diamond disc."
62824128|NCT04438486|ACTIVE_COMPARATOR|dietary advice|
62824129|NCT04438486|EXPERIMENTAL|dietary advice+ Barely Green|
62824130|NCT05762302|EXPERIMENTAL|Adults with suspected Lower Respiratory Track Infection (LRTI)- The MeMed BV arm|ED and urgent care center patients over the age of 18 years , with clinical suspicion of Lower Respiratory Track Infection. clinician will receive the BV result, this will include a recommendation regarding antibiotic treatment. A telephone FU call will be done at 28 (+/- 3) days after the day of consent to complete a short questionnaire regarding your current illness
62824131|NCT05762302|NO_INTERVENTION|Adults with suspected Lower Respiratory Track Infection (LRTI)- The control arm|ED and urgent care center patients over the age of 18 years , with clinical suspicion of Lower Respiratory Track Infection. clinician will not receive the BV result, and will treat according to standard of care. A telephone FU call will be done at 28 (+/- 3) days after the day of consent to complete a short questionnaire regarding your current illness
62824132|NCT02967991|ACTIVE_COMPARATOR|19 Left|EUS-guided liver biopsy using a19-gauge liver biopsy in the left lobe
62824133|NCT02967991|EXPERIMENTAL|22 Left|EUS-guided liver biopsy using a 22-gauge liver biopsy in the left lobe
62824134|NCT02967991|ACTIVE_COMPARATOR|19 Right|EUS-guided liver biopsy using a 19-gauge liver biopsy in the right lobe
62824135|NCT02967991|EXPERIMENTAL|22 Right|EUS-guided liver biopsy using a 22-gauge liver biopsy in the right lobe
62824136|NCT02569385||spontaneous breathing trials|spontaneous breathing trials in patients with prolonged weaning
62245876|NCT02509104|EXPERIMENTAL|Cohort 2 Fed condition|Each subject will receive both treatment A and B in either of period 1 or 2 with a washout period of 28 days between treatment periods. Subjects will receive the study treatments under fed (high fat breakfast) conditions.
62436102|NCT01456052|EXPERIMENTAL|High Dose Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally three times daily (TID).
62824137|NCT02504593|OTHER|Community health volunteers|The study subjects are all community health volunteers in community units in Kenya (10 community units in Bungoma East and 6 community units in Kiminini) that have been trained to provide community-based malaria diagnosis through rapid diagnostic testing.
62824138|NCT05387564|ACTIVE_COMPARATOR|"All-in"|"In the all-in arm, pediatric primary care physicians receive all toolkit components at once."
62436103|NCT01456052|PLACEBO_COMPARATOR|Placebo|Matching placebo administered orally.
62824139|NCT05387564|ACTIVE_COMPARATOR|"Add-in"|"In the add-in arm, pediatric primary care physicians will have sequential addition of toolkit components in 6 week increments"
62602449|NCT02556619|EXPERIMENTAL|Early Palliative Care/Symptom Control|"Patients will undergo palliative care services at time of Hepatocellular Carcinoma diagnosis.~Palliative care and symptom control services are adapted from the National Consensus Project for Quality Palliative Care.~Early referral, patients meeting inclusion criteria will be enrolled and referred to palliative care within 3 weeks of the index consultation with Medical-Oncology, Surgical-Oncology or Gastroenterology.~Intervention will be:~1. Establish palliative care goals~2. Symptom Assessment and Control~3. End-of-Life Care"
62602450|NCT02952989|EXPERIMENTAL|SGN-2FF|Dose escalation and dose expansion
62824140|NCT02514083|EXPERIMENTAL|Ibrutinib and short-course fludarabine|"* Ibrutinib 420 mg PO daily for the duration of the study~* Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4"
62043122|NCT00617578|ACTIVE_COMPARATOR|2|programming of VF therapy: ATP (antitachycardia pacing) One Shot OFF
62043123|NCT02291731|EXPERIMENTAL|Continuous use of autologous serum|with continuous use of topical autologous serum for an additional 2 weeks after total re-epithelialization.
62824141|NCT06591091|EXPERIMENTAL|Clemastine arm|"Participants in the clemastine arm of the study will receive 5.36 mg PO twice daily for 12 weeks. Based on clinical assessment, participants will also receive one of the following antidepressant medications: SSRI: Fluoxetine, sertraline, citalopram, escitalopram, vilazodone, vortioxetine SNRI: Venlafaxine, desvenlafaxine, duloxetine, levomilnacipran Augmentation: Bupropion and mirtazapine (monotherapy option in addition to first augmentation level), aripiprazole and quetiapine (second augmentation level).~Allowable concomitant medications parallel clinical practice. These can include trazodone (up to 100mg nightly) for insomnia or as-needed use of benzodiazepines for concomitant anxiety, up to a maximum daily dose equivalent to lorazepam 2mg daily. Psychotropic medications used for other indications (such as tricyclics or gabapentin for pain) are allowable. Concomitant psychotherapy is allowed."
62824142|NCT06591091|PLACEBO_COMPARATOR|Placebo arm|"Participants in the placebo arm of the study will receive a placebo capsule PO twice daily for 12 weeks. Based on clinical assessment, participants will also receive one of the following antidepressant medications: SSRI: Fluoxetine, sertraline, citalopram, escitalopram, vilazodone, vortioxetine SNRI: Venlafaxine, desvenlafaxine, duloxetine, levomilnacipran Augmentation: Bupropion and mirtazapine (monotherapy option in addition to first augmentation level), aripiprazole and quetiapine (second augmentation level).~Allowable concomitant medications parallel clinical practice. These can include trazodone (up to 100mg nightly) for insomnia or as-needed use of benzodiazepines for concomitant anxiety, up to a maximum daily dose equivalent to lorazepam 2mg daily. Psychotropic medications used for other indications (such as tricyclics or gabapentin for pain) are allowable. Concomitant psychotherapy is allowed."
62824143|NCT05249582|EXPERIMENTAL|Virtual Reality Condition|Participants will be using a virtual reality headset to engage with a mountain climbing game.
62824144|NCT05249582|ACTIVE_COMPARATOR|Control Condition|Participants will be mimicking hand movements displayed on a television screen.
62824145|NCT05902988|EXPERIMENTAL|Dose Escalation: Dose Escalation Cohorts|Subjects will be enrolled at various doses and/or schedules of VLS-1488. These Dose Escalation Cohorts will be utilized to identify the MTD and to select dose levels for Dose Expansion.
62043124|NCT03556111|EXPERIMENTAL|anterior knife-edge maxilla graft (Without Xenograft Usage)|"The intervention will be a Sticky bone augmentation of defect. It is prepared using particulate autologous graft only along with fibrin glue and growth factors obtained from the patients' blood.~The sample is withdrawn and placed in plastic tubes which are spun twice in a centrifuge at a certain speed and time. The first spin to obtain the fibrin glue and the second to obtain the growth factors. The mixture is added to the harvested autogenous bone to form a semi-solid bone graft that is easily manipulated in the recipient site."
62043125|NCT03556111|EXPERIMENTAL|anterior knife edge maxilla graft (With Xenograft Usage)|"The intervention will be the sticky bone augmentation of the defect using both particulate autogenous and xenograft bovine bone.~The bone will be harvested from the donor, coupled with the bovine bone, the growth factors and the fibrin glue that is obtained from the patient's own blood sample.~The venous blood sample is placed in plastic tubes to be centrifuged at a certain speed and time to obtain the fibrin glue and growth factors.~The mixture is prepared until the bone is sticky and ready to be placed in the recipient defective maxilla"
62043126|NCT02744222|EXPERIMENTAL|BCD-054, 180 mcg, biweekly|Patients of Groups 1 will receive blinded BCD-054 180 mcg intramuscularly once every two weeks for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive). Between every two injections of the active drug, once every 2 weeks, patients will receive intramuscular injections of placebo.From Week 53 until Week 100, patients of Groups 1 will receive open-label BCD-054 180 mcg or 240 mcg intramuscularly once every 2 weeks
62602451|NCT02952989|EXPERIMENTAL|SGN-2FF and Pembrolizumab|Dose escalation and dose expansion
62602452|NCT06158568|EXPERIMENTAL|Percutaneous Electrical Nerve Stimulation|Participants assigned to this group will received four sessions (once per week) of ultrasound guided percutaneous electrical nerve stimulation targeting the axillar and suprascapular nerves for 30 minutes. We will apply a biphasic compensated electrical current at a frequency of 2 Hz, a pulse width of 250 μs and intensity allowed over a pain-free motor threshold (muscle contraction). In addition, they will receive a program of exercises for the shoulder musculature for 3 weeks.
62043127|NCT02744222|EXPERIMENTAL|BCD-054, 240 mcg, biweekly|Patients of Groups 2 will receive blinded BCD-054 240 mcg intramuscularly once every two weeks for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive). Between every two injections of the active drug, once every 2 weeks, patients will receive intramuscular injections of placebo.From Week 53 until Week 100, patients of Groups 2 will receive open-label BCD-054 180 mcg or 240 mcg intramuscularly once every 2 weeks
62043128|NCT02744222|ACTIVE_COMPARATOR|Avonex®, 30 mcg, weekly|Patients of Group 3 (reference group) will receive blinded Avonex® 30 mcgintramuscularly once a week for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive).
62043129|NCT02744222|PLACEBO_COMPARATOR|Placebo, 0,5 ml, weekly|Patients of Group 4 (placebo) will receive blinded placebo once a week for the first 20 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive)
62824146|NCT05902988|EXPERIMENTAL|Dose Escalation: Backfill Cohorts|Additional subjects may be enrolled at any dose level that does not meet de-escalation or elimination rules per the BOIN design. These Backfill Cohorts will be utilized to build additional data to support selection of doses and/or tumor types for further study in Dose Expansion.
62824147|NCT05902988|EXPERIMENTAL|Dose Expansion: Exploration Cohorts|Subjects with a selected single tumor type will be randomized 1:1 into Exploration Cohorts at two or more dose levels of interest. A subset of subjects will have additional assessments to examine the potential for VLS-1488 to interact with other drugs and the effect of food on VLS-1488 absorption.
62824148|NCT05902988|EXPERIMENTAL|Dose Expansion: Development Cohorts|Subjects with other tumor types will be enrolled at a single dose level of interest. These Development Cohorts will be utilized to examine the preliminary efficacy of VLS-1488 in various tumor types.
62824149|NCT06012916||Treatment Resistant Depression + Esketamine Treatment|This is a group of individuals with treatment resistant depression receiving Esketamine treatment as prescribed by their physician during outpatient appointments over several weeks at the Interventional Psychiatry outpatient clinic at University of North Carolina at Chapel Hill (UNC). After signing the informed consent, electroencephalogram (EEG) will be recorded before and after Esketamine administration by the attending physician. The participant will perform a cognitive task before and after the Esketamine administration as well as complete self-scored questionnaire regarding depressive symptoms, treatment expectation and Esketamine side-effects. Clinical information like the duration of episode, medication or clinician-rated depression scores will be retrieved from the charting system.
62824150|NCT01581801|OTHER|Gastric Bypass|60 subjects obese subjects with complications or morbidly obese subjects will be assigned randomly to this arm to undergo gastric bypass
62824151|NCT01581801|OTHER|Sleeve Gastrectomy|60 subjects obese subjects with complications or morbidly obese subjects will be assigned randomly to this arm to undergo sleeve gastrectomy
62824152|NCT06514326|ACTIVE_COMPARATOR|DPT-STD|This is the standard intervention arm
62824153|NCT06514326|EXPERIMENTAL|DPT-TP|This is the enhanced intervention arm
62824154|NCT06303115|ACTIVE_COMPARATOR|Nicotine Pouch P1312914, 4 mg nicotine|Subjects will be switched to exclusive use of their assigned pouch flavor and strength.
62824155|NCT06303115|ACTIVE_COMPARATOR|Nicotine Pouch P1312915, 8 mg nicotine|Subjects will be switched to exclusive use of their assigned pouch flavor and strength.
62824156|NCT06303115|ACTIVE_COMPARATOR|Nicotine Pouch P1013215, 8 mg nicotine|Subjects will be switched to exclusive use of their assigned pouch flavor and strength.
62824157|NCT06303115|ACTIVE_COMPARATOR|Nicotine Pouch P1013218, 10 mg nicotine|Subjects will be switched to exclusive use of their assigned pouch flavor and strength.
62824158|NCT06303115|ACTIVE_COMPARATOR|Nicotine Pouch P1012919, 12 mg nicotine|Subjects will be switched to exclusive use of their assigned pouch flavor and strength.
62824159|NCT06303115|OTHER|Smoking Abstinence|Subjects will not use any tobacco or nicotine containing products.
62824160|NCT06303115|OTHER|Continued UB cigarette smoking|Subjects will continue use of their Usual Brand Cigarettes.
62043130|NCT03393000|EXPERIMENTAL|Trans Sodium Crocetinate plus SOC|Trans Sodium Crocetinate plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
62043131|NCT03393000|ACTIVE_COMPARATOR|Standard of Care (SOC)|Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
62824161|NCT03527420|ACTIVE_COMPARATOR|Exercising|12 weeks of aerobic exercise training
62043132|NCT02939040|EXPERIMENTAL|Positive Activities Intervention|Patients will note at least one positive event each day, write it down on a slip of paper and then deposit this piece of paper in a piggy bank. After approximately 21 days, the participant reads each one the night before surgery.
62824162|NCT03527420|NO_INTERVENTION|Non-exercising|standard of care
62043133|NCT02939040|NO_INTERVENTION|Usual Care Group|The control group will serve to show the relative benefits of the Positive Piggy Bank intervention. These participants will follow the same questionnaire completion procedures.
62043134|NCT01926756|OTHER|Straight catheterization (control)|The control arm is the current practice at our hospital (to perform straight catheterization for short procedures).
62824163|NCT04443413|EXPERIMENTAL|Arm I (x-ray therapy)|Within 12 weeks of the last breast cancer surgery or last dose of adjuvant chemotherapy and no sooner than 14 days since the last chemotherapy, patients undergo x-ray therapy over 25 fractions in the absence of disease progression or unacceptable toxicity. Optionally, patients may then receive a 4-fraction boost of x-ray therapy.
62824164|NCT04443413|EXPERIMENTAL|Arm II (proton beam radiation therapy)|Within 12 weeks of the last breast cancer surgery or last dose of adjuvant chemotherapy and no sooner than 14 days since the last chemotherapy, patients undergo proton beam radiation therapy over 5 fractions in the absence of disease progression or unacceptable toxicity. Optionally, patients may receive a concurrent 5-fraction boost of proton beam radiation therapy.
62824165|NCT06596720|EXPERIMENTAL|Study group|Cognitive assessments for participants in the study group were conducted using the Standardized Mini-Mental State Test, Stroop Test T-BAG Form, Wechsler Digit Span subtest, and Letter Cancellation Test. Participants underwent a thirty-minute session on a moderate-intensity bicycle ergometer. Subsequently, pulse, oxygen saturation, and blood pressure were measured, and the Stroop Test T-BAG Form, Wechsler Digit Span Tests, and Letter Cancellation Tests were repeated.
62824166|NCT06596720|NO_INTERVENTION|Control group|Cognitive assessments for participants in the control group were conducted using the Standardized Mini-Mental State Test, Stroop Test T-BAG Form, Wechsler Digit Span subtest, and Letter Cancellation Test. The control group was left in a quiet room for thirty minutes. After this period, pulse, oxygen saturation, and blood pressure were measured, and the Stroop Test T-BAG Form, Wechsler Digit Span Tests, and Letter Cancellation Tests were repeated
62824167|NCT06088069|EXPERIMENTAL|Group VR|Patients will be virtually immersed into a natural universe and soft music for 15 minutes preoperatively and during surgery.
62824168|NCT06088069|NO_INTERVENTION|Group C|Patients will not receive Virtual reality (VR) experience.
62824169|NCT06058299|EXPERIMENTAL|TBAJ876 25 mg|TBAJ876 25 mg + pretomanid 200 mg + linezolid 600 mg for 8 weeks followed by HR for 7 to 18 weeks
62824170|NCT06058299|EXPERIMENTAL|TBAJ876 50 mg|TBAJ876 50 mg + pretomanid 200 mg + linezolid 600 mg for 8 weeks followed by HR for 7 to 18 weeks
62824171|NCT06058299|EXPERIMENTAL|TBAJ876 100 mg|TBAJ876 100 mg + pretomanid 200 mg + linezolid 600 mg for 8 weeks followed by HR for 7 to 18 weeks
62824172|NCT06058299|ACTIVE_COMPARATOR|BPaL|Bedaquiline 200 mg + pretomanid 200 mg + linezolid 600 mg for 8 weeks followed by bedaquiline 100 mg + pretomanid 200 mg + linezolid 600 mg for 18 weeks
62824173|NCT06058299|ACTIVE_COMPARATOR|2HRZE/4HR|Isoniazid (H) + rifampicin (R) + pyrazinamide (Z), ethambutol (E) for 8 weeks followed by HR for 18 weeks (dose based on participant's weight).
62436104|NCT04485286|EXPERIMENTAL|Lung Cancer or Pancreatic Cancer Subjects Undergoing Radiation Therapy|Lung cancer or pancreatic cancer patients will receive \[68Ga\]CBP8 and undergo PET imaging 1) prior to radiation therapy and 2) 3-6 months after radiation therapy
62824174|NCT04331587||Bronchoscopy|The bronchoscopy procedure and use of both the thin and ultrathin bronchoscopes are considered standard of care and will be performed under moderate sedation in an outpatient bronchoscopy suite as part of each patient's clinical care.
62824175|NCT06587646|ACTIVE_COMPARATOR|Standard Care|Standard care (SC) will be defined as a written MRI report by a qualified radiologist followed by EUA and intervention as per surgeon's findings. Interventions will include one or combinations of: lay open of fistula, insertion of seton into the fistula tract and / or drainage of abscess. This arm is to provide outcome data on standard care for this condition as a comparator to the experimental arm.
62824176|NCT06587646|EXPERIMENTAL|vEUA (Virtual Examination Under Anaesthetic) - 3D MRI imaging|"vEUA-enhanced care will be defined as having a vEUA performed by the radiologist following a MRI using the same unmodified sequence from the standard care (SC) arm (in addition to a written radiology report). The surgeon will then be given unlimited access to the vEUA interactive report via standard PC hardware. The surgeon will then perform the EUA and intervention as per SC but with the additional insight garnered from the vEUA interactive report. We will also monitor the time taken to mark up and produce the vEUA and compare this to the time taken to produce a standard MRI report.~The care in this group will be the same as standard care but with the addition of 3D reconstruction of the MRI scan and review of this by the patient and surgeon."
62824177|NCT05246592||Preponderant lymphatic reflux group|high ratio of axillary lymphatic reflux to axillary vein reflux
62824178|NCT05246592||Preponderant venous reflux group|low ratio of axillary lymphatic reflux to axillary vein reflux
62824179|NCT06047210||A-HLH Patients|Patients diagnosed with A-HLH.
62824180|NCT06047210||Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) Patients|Patients diagnosed with HLH in the context of a malignancy.
62824181|NCT03875378|EXPERIMENTAL|Transdermal estrogen/progesterone|Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) patch applied weekly for 18 months
62824182|NCT03875378|PLACEBO_COMPARATOR|Placebo|Placebo patch applied weekly for 18 months
62824183|NCT06143566|EXPERIMENTAL|Polypill|Participants will take a polypill containing finerenone 10 mg, empagliflozin 12.5 mg, and losartan (50 mg or 100 mg) daily.
62824184|NCT06143566|NO_INTERVENTION|Usual Care|Participants will continue to take normal medications for diabetes and high blood pressure.
62824185|NCT03996824||AAV viral transduction|Collection of inner ear cells during a non-conservative surgical approach (translabyrinthine or transotic).
62824186|NCT06593041||systemic lupus erythematosus patients|
62824187|NCT06596486||All participants|All participants will receive standard care with the addition of extra assessment of block from neuraxial anaesthesia
62824188|NCT03587961|EXPERIMENTAL|Symdeko|Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Symdeko, depending on the in vitro response pattern
62602453|NCT06158568|PLACEBO_COMPARATOR|Placebo Percutaneous Nerve Stimulation|Participants assigned to this group will received four sessions (once per week) of placebo ultrasound guided percutaneous electrical nerve stimulation targeting the axillar and suprascapular nerve. The electrical current will be off and no electrical current will be provided to the patient. In addition, they will receive the same program of exercises for the shoulder than the experimental group for three weeks.
62824189|NCT03587961|EXPERIMENTAL|Ivacaftor|Patients who have mutation response to a potentiator of CFTR function will be given Ivacaftor monotherapy.. Patients with a mutation equivalent to wild type will be given Ivacaftor.
62824190|NCT03587961|EXPERIMENTAL|Orkambi|Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Orkambi, depending on the in vitro response pattern
62824191|NCT04730258|EXPERIMENTAL|1A: Monotherapy escalation and expansion|Dose escalation and expansion arm with CFI-400945
62824192|NCT04730258|EXPERIMENTAL|2A: Combination escalation and expansion|Dose escalation and expansion arm with CFI-400945 and azacitidine
62824193|NCT06602869||Case group MNT +|Cystic fibrosis patients with positive serology and positive culture
62824194|NCT06602869||Control group MNT -|Cystic fibrosis patients with negative serology and negative culture
62824195|NCT06654622||Training Cohort (Recurrence Group)|Stage II-III CRC patients who experienced postoperative recurrence (evaluated by miRNA panel).
62824196|NCT06654622||Training Cohort (Non-Recurrence Group)|Stage II-III CRC patients who did not experience postoperative recurrence (evaluated by miRNA panel).
62824197|NCT06654622||Testing Cohort (Recurrence Group)|Validation of miRNA panel and EMRATI score in independent stage II-III CRC patients who experienced postoperative recurrence.
62824198|NCT06654622||Testing Cohort (Non-Recurrence Group)|Validation of miRNA panel and EMRATI score in independent stage II-III CRC patients who did not experience postoperative recurrence.
62824199|NCT06604611|EXPERIMENTAL|Colchicine Treatment Group|This group is intended to include 100 patients, all of the patients will be given 5mg of once-daily the colchicine treatment on top of the SGLT2i treatment
62824200|NCT06604611|NO_INTERVENTION|Control Group|The group is intended to include 100 patients, all of the patients will be given standard SGLT2i treatment
62824201|NCT05888883||Microbial Keratitis Participants|Up to 50 participants presenting with clinically suspected microbial keratitis will be recruited from the Princess Alexandra Eye Pavilion, NHS Lothian, Edinburgh
62824202|NCT05888883||Healthy Control Participants|Up to 20 participants with no history of microbial keratitis will be recruited.
62824203|NCT05642039|EXPERIMENTAL|Mindfulness Course Group|Participants will participate in the mindfulness course that would last 6 weeks.
62824204|NCT05642039|EXPERIMENTAL|HS Educational Course Group|Participants will participate in the mindfulness course that would last 6 weeks.
62824205|NCT05775367|EXPERIMENTAL|Study Group|This group of children with single-sided deafness will receive a cochlear implant.
62824206|NCT05775367|NO_INTERVENTION|Typical Hearing Control Group (THCG)|This group of five-year-old children will have typical hearing in both ears.
62824207|NCT05775367|NO_INTERVENTION|Single-Sided Deafness Control Group (SSDCG)|This group of five-year-old children will have single-sided deafness and no cochlear implant.
62824208|NCT06628284||Test Group|The study will be conducted as a single-arm trial consisting of participants enrolled in the test group. Each participant will receive a G7 CGM and their blood glucose levels will be continuously transmitted to the Dexcom Clarity cloud system for monitoring and data collection.
62824209|NCT06596057|EXPERIMENTAL|experimental group|
62602454|NCT06158568|ACTIVE_COMPARATOR|Exercise|Participants assigned to this group will receive the same program of exercises for the shoulder than the remaining groups for three weeks.
62824210|NCT06595407||Males with aortic stenosis|Males with mild or greater aortic stenosis (aortic valve area \<1.5 cm2) due to calcific non-congenital aortic stenosis.
62824211|NCT06595407||Control males without aortic stenosis|Males without any diagnosis for aortic stenosis (matched for aortic stenosis group).
62824212|NCT00281463|EXPERIMENTAL|Pushrim Activated Power Assist Wheelchair|Participants will be asked to propel both their own chair and a pushrim activated power assist wheelchair on a computer controlled wheelchair dynamometer.
62824213|NCT05093270|EXPERIMENTAL|Part A Dose Escalation (Single Ascending Dose)|Up to 5 dose levels of BGB-23339 or Placebo
62824214|NCT05093270|EXPERIMENTAL|Part B Dose Escalation (Multiple Ascending Dose)|Up to 4 dose levels of BGB-23339 or placebo based on data collected in Part A
62824215|NCT05093270|EXPERIMENTAL|Part C Dose Escalation (Multiple Ascending Dose in Chinese Subjects Sub-study)|Up to 2 dose levels of BGB-23339 or placebo based on data collected in Part A and B (conducted in China only)
62824216|NCT05093270|EXPERIMENTAL|Part D (Food-Effect Study)|Three single dose levels of BGB-23339 under different feeding conditions
62824217|NCT06194864|EXPERIMENTAL|Part 1|ecopipam 89.6 mg on Days 1 and 9 with repeat doses of itraconazole Days 6-16.
62043135|NCT01926756|ACTIVE_COMPARATOR|No straight catheterization|The experimental arm will void preoperatively and will not be straight catheterized intraoperatively. This is a change from the current practice at our hospital.
62043136|NCT06533033|EXPERIMENTAL|melatonin therapy|
62043137|NCT06533033|ACTIVE_COMPARATOR|topical corticosteroid a|
62043138|NCT03977519|EXPERIMENTAL|MA group|Huatuo Brand needles (0.30×25mm,0.30×40mm or 0.30×75mm) will be used at EX-B8,BL32,SP8,and SP6.
62824218|NCT06194864|EXPERIMENTAL|Part 2|ecopipam 179.2 mg on Days 1 and 13 with repeat doses of rifampicin days 6-20.
62824219|NCT05378165|EXPERIMENTAL|Music group|The music group listened to Acemasiran-type classical Turkish music with a headset from an MP3 player starting at about 10 min before colonoscopy until completion of the procedure.
62043139|NCT03977519|ACTIVE_COMPARATOR|TENS group|Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used to stimulate the area along the lower borders of the ribs and the upper borders of the hip crests on both sides.The parameters of the electric acupuncture apparatus：Continuous wave,the frequency is 100Hz, the current intensity is 2.5mA-5mA.
62824220|NCT05378165|EXPERIMENTAL|Stress ball group|"The stress ball group was given stress balls which was medium hard and made of high-quality silicone approximately 10 minutes before colonoscopy. The patients in stress ball group were instructed to squeeze the balls twice after counting up to five and repeat until the end of the entire procedure."
62043140|NCT05353998|EXPERIMENTAL|Sleep Navigation group|Caregiver-child dyads in this study arm (intervention condition) will participate in the Sleep Navigation program.
62043141|NCT05353998|OTHER|CDS-only group|Caregiver-child dyads in this study arm (control group) will not participate in the Sleep Navigation program, but will be directed to follow up with their primary care clinician as needed.
62043142|NCT04088019||Observational cohort group|"Subjects: idiopathic uveitis with IGRA positive.~Examinations:~* Clinical improvement examinations at day 0, second week, week 8, month 3, month 6 and month 12.~* Blood sampling at day 0, second week, month 6 for analysing type 1 IFN gene expression scoring using RT-qPCR methods."
62043143|NCT05028725|EXPERIMENTAL|Esophageal Squamous Cell Carcinoma (ESCC) Cases|Each study participant will undergo esophageal sponge sampling using the 'EsophaCap' sponge device. Group 1 will include a safety-phase, which will consist of a lead-in cohort of 8 patients with ESCC. Subsequent recruitment of ESCC Cases (Group 1) will not commence until the Data Safety Monitoring Board (DSMB) has deemed the safety lead-in data appropriate for continuation. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.
62043144|NCT05028725|EXPERIMENTAL|Non-ESCC, Esophageal squamous dysplasia (ESD) Cases|Each study participant will undergo (1) Esophagogastroduodenoscopy (EGD) with chromoendoscopic screening and possible biopsy, and (2) esophageal sponge sampling using the 'EsophaCap' sponge device. Pathology from chromoendoscopic screening will be used to categorize non-ESCC study participants as esophageal squamous dysplasia (ESD) cases and controls. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.
62043145|NCT05028725|EXPERIMENTAL|Non-ESCC, Control Group|Each study participant will undergo (1) Esophagogastroduodenoscopy (EGD) with chromoendoscopic screening and possible biopsy, and (2) esophageal sponge sampling using the 'EsophaCap' sponge device. Pathology from chromoendoscopic screening will be used to categorize non-ESCC study participants as esophageal squamous dysplasia (ESD) cases and controls. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.
62043146|NCT06059222|ACTIVE_COMPARATOR|Group 1 - ROMO 12 months, ZOL 12 months|90 patients 12 months of romosozumab (ROMO) followed by 12 months of zoledronate (ZOL)
62043147|NCT06059222|ACTIVE_COMPARATOR|Group 2 - ROMO 6 months, ZOL 12 months, ROMO 6 months|90 patients 6 months of romosozumab followed by 12 months of zoledronate and lastly 6 months of romosozumab.
62043148|NCT06059222|ACTIVE_COMPARATOR|Group 3 - ROMO 6 months, ZOL 18 months|"90 patients 6 months of romosozumab followed by 18 months of zoledronate~."
62043149|NCT04357327|EXPERIMENTAL|Symptomatic patients|Patients with symptoms associated with COVID-19, i.e., dyspnea, cough, fever, etc.
62043150|NCT04357327|ACTIVE_COMPARATOR|Asymptomatic subjects|Asymptomatic patients with low risk phenotype, that means patients with a previous negative swab, no relatives affected by COVID-19 and with reduced social interaction within the last two weeks.
62043151|NCT04250727|EXPERIMENTAL|3mg Nicotine Concentration|15 participants will be randomly assigned to receive ZYN Pouches with 3mg nicotine concentration.
62245877|NCT05411549|EXPERIMENTAL|Mediterranean Diet|Participants enrolled in group 1 will be counselled by a dietician and asked to adopt a Mediterranean diet for a 12-week period from counselling. Participants will complete the Mediterranean Diet Adherence Score, pain questionnaires as well as quality of life questionnaires (EPH-30, SF-36, GIQLI) which have been previously validated. Participants in this group will give a baseline and final visit blood sample and stool samples to assess inflammation biomarkers as well as gut microflora
62824221|NCT05378165|EXPERIMENTAL|Video group|"The patients in the video group allowed to watch a licensed virtual reality application, A walk on the beach, through an Android mobile phone placed in Cardboard Super Flex Goggles, started 10 minute before the colonoscopy until the procedure was completed."
62824222|NCT05378165|OTHER|Control group|Standard colonoscopy was performed on the patients in the control group, without any additional intervention.
62043152|NCT04250727|EXPERIMENTAL|6mg Nicotine Concentration|15 participants will be randomly assigned to receive ZYN Pouches with 6mg nicotine concentration.
62602455|NCT02255552|EXPERIMENTAL|Treated Group|Approximately 80 patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with genetic deletions amenable to treatment by exon 51 skipping will receive 30 mg/kg of eteplirsen weekly for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
62602456|NCT02255552|NO_INTERVENTION|Untreated Group|Approximately 30 DMD patients not amenable to exon 51 skipping will not receive eteplirsen.
62824223|NCT03667378||supportive care visits|A concurrent supportive care intervention (intervention arm) Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).intervention arm will have at least monthly visits with a supportive care clinician
62824224|NCT03667378||without supportive care visits|A concurrent supportive care intervention (intervention arm) Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).intervention arm will have at least monthly visits with a supportive care clinicianTo receive the investigational cancer treatment alone (control arm) no monthly visit with a supportive care clinician.
62824225|NCT06588374|EXPERIMENTAL|Hemorrhoidectomy Only|Hemorrhoids by Hemorrhoidectomy alone
62043153|NCT00363519|PLACEBO_COMPARATOR|P|
62043154|NCT00363519|EXPERIMENTAL|E|
62043155|NCT03298646|EXPERIMENTAL|Lidacaine hydrochloride|"Adding 10 ml of 2% Lidocaine hydrochloride on hysteroscopic saline media during office hysteroscopy to test its efficacy in reducing pain.~22 women."
62602457|NCT03903003|ACTIVE_COMPARATOR|preoxygenation mask applied to the cesarean|In order to protect the mother from hypoxia, preoxygenation is performed with face mask before induction of anesthesia.
62602458|NCT03903003|ACTIVE_COMPARATOR|high flow nasal oxygenation applied to the ceserian|In order to protect the mother from hypoxia, preoxygenation is performed with high flow nasal oxygenation mask before induction of anesthesia.
62602459|NCT00583882|OTHER|1|Change every 6 days, rewire every 6 days
62824226|NCT06588374|EXPERIMENTAL|Hemorrhoidectomy With Lateral Internal Sphincterotomy|hemorroids by lateral internal sphincterotomy and hemorrhoidectomy
62824227|NCT06585995|EXPERIMENTAL|Daily Vitamin D Supplementation Group|This arm of the study involves daily administration of vitamin D to participants, with the dosage adjusted based on body weight and initial vitamin D levels, aiming to to investigate the efficacy of this regimen in improving vitamin D levels and reducing COVID-19 symptoms and IL-6, GPx and Von Willebrand Factor concentration.
62824228|NCT06585995|EXPERIMENTAL|Monthly Bolus Vitamin D Supplementation Group|This arm of the study consists of administering a monthly bolus dose of vitamin D, equivalent to the total daily dose accumulated over the month, divided into 4 daily doses on 4 consecutive days, to investigate the efficacy of this regimen in improving vitamin D levels and reducing COVID-19 symptoms and IL-6, GPx and Von Willebrand Factor concentration.
62824229|NCT03409016||Immune Checkpoint Inhibitor Therapy|Patients starting treatment with ipilimumab, nivolumab, pembrolizumab, or atezolizumab, alone or in combination, for treatment of a metastatic solid tumor cancer will be enrolled. Patients will receive checkpoint inhibitor therapy per standard protocol. There are no study-related medications or interventions beyond blood testing.
62245878|NCT05411549|NO_INTERVENTION|No Diet Modification|Participants enrolled in group 2 will be NOT counselled by a dietician. Participants will complete the Mediterranean Diet Adherence Score, pain questionnaires as well as quality of life questionnaires (EPH-30, SF-36, GIQLI) which have been previously validated. Participants in this group will give a baseline and final visit blood sample and stool samples to assess inflammation biomarkers as well as gut microflora
62602460|NCT00583882|OTHER|2|New site every 6 days
62602461|NCT00583882|OTHER|3|New site every 12 days
62602462|NCT01332279|EXPERIMENTAL|Treatment (enzyme inhibitor and radiation therapy)|Patients receive RAD001 PO and erlotinib hydrochloride PO QD. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo EBRT BID 5 days a week for 5 weeks.
62602463|NCT03794102|ACTIVE_COMPARATOR|Ureteroscopy with water irrigation|Participants meeting medical requirements to undergo ureteroscopy will undergo a routine cystoscopy and ureteroscopy following standard techniques. Water will be used as the irrigation fluid during the ureteroscopy.
62602464|NCT03794102|ACTIVE_COMPARATOR|Ureteroscopy with saline irrigation|Participants meeting medical requirements to undergo ureteroscopy will undergo a routine cystoscopy and ureteroscopy following standard techniques. Saline will be used as the irrigation fluid during the ureteroscopy.
62602465|NCT01497886|ACTIVE_COMPARATOR|Hip Hop Stroke educational program|Hip Hop Stroke is a school-based educational program that incorporates educational hip hop music and two cartoons to communicate stroke knowledge to children.
62043156|NCT03298646|ACTIVE_COMPARATOR|Diclofenac|"100 mg Diclofenac oral tablet is administered 1 hour before the procedure to test its efficacy in reducing pain.~22 women."
62043157|NCT00877331|EXPERIMENTAL|1|Brief intervention using motivational interviewing. One in-person session (30-45 minutes) with a brief phone follow-up one week later.
62602466|NCT01497886|PLACEBO_COMPARATOR|Nutrition Education program|"The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence)."
62602467|NCT05953480|EXPERIMENTAL|Redasemtide Dose A|Redasemtide will be administered as an intravenous (IV) infusion once daily for 5 consecutive days during hospitalization.
62602468|NCT05953480|EXPERIMENTAL|Redasemtide Dose B|Redasemtide will be administered as an IV infusion once daily for 5 consecutive days during hospitalization.
62602469|NCT05953480|PLACEBO_COMPARATOR|Placebo|Placebo will be administered in an amount equivalent to redasemtide, as an IV infusion, once daily for 5 consecutive days during hospitalization.
62602470|NCT03260426|EXPERIMENTAL|Clear Liquid Diet|Clear liquids on postoperative day zero and intestinal rate measured by Abstats
62602471|NCT03260426|EXPERIMENTAL|Regular Solid Diet|Regular diet from postoperative day zero and intestinal rate measured by Abstats
62602472|NCT01494064||Retrospective|Included patients have been no specific nursing practice.
62043158|NCT00877331|NO_INTERVENTION|2|Enhanced care as usual.
62602473|NCT01494064||Prospective|Standardization of nursing supervision of included patients using a grid of appropriate surveillance for the prevention of complications in the ICU
62245879|NCT03930147|EXPERIMENTAL|Passive phase, Pressure-Control Ventilation / ASV order|90 minutes of Pressure-Control Ventilation, change to ASV mode with 15 to 30 minutes of washout, 90 minutes of ASV. Return to Pressure-Control Ventilation mode at the end of the intervention.
62602474|NCT01241617|ACTIVE_COMPARATOR|Duet TRS|Endo GIA with integrated Duet TRS
62602475|NCT01241617|ACTIVE_COMPARATOR|Endo GIA|Endo GIA stapler with Single Use Loading units
62245880|NCT03930147|EXPERIMENTAL|Passive phase, ASV / Pressure-Control Ventilation order|90 minutes of ASV, change to Pressure-Control Ventilation mode with 15 to 30 minutes of washout, 90 minutes of Pressure-Control Ventilation.
62043159|NCT02872701|EXPERIMENTAL|Patients Receiving OTL38|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
62043160|NCT02816138|EXPERIMENTAL|Transdermal nicotine patch|Transdermal nicotine patch, administered on awakening and removed at bedtime (16h/d). Dosing 3.5mg patch/daily, titrated over study to maximum dose of 21mg patch/daily.
62043161|NCT05591339|EXPERIMENTAL|BCG vaccine|"Participants that are randomized in the active arm will receive an adult 0.1 ml dose of BCG vaccine (e.g. BCG-Denmark or BCG-Japan) in the skin covering the left upper deltoid muscle. Two doses will be given, 4 weeks apart.~Intervention: Biological BCG-vaccine."
62043162|NCT05591339|PLACEBO_COMPARATOR|Placebo|Placebo will be 0.1 ml sterile 0.9 % NaCl, which has a similar color as the resuspended BCG vaccine. Two placebo doses will be given, 4 weeks apart.
62245881|NCT03930147|EXPERIMENTAL|Active phase, Pressure-Support / ASV order|90 minutes of Pressure-Support Ventilation, change to ASV mode with 15 to 30 minutes of washout, 90 minutes of ASV. Return to Pressure-Support Ventilation at the end of the intervention.
62245882|NCT03930147|EXPERIMENTAL|Active phase, ASV / Pressure-Support order|90 minutes of ASV, change to Pressure-Support Ventilation with 15 to 30 minutes of washout, 90 minutes of Pressure-Support Ventilation.
62245883|NCT04611438|EXPERIMENTAL|CBD|The patient would be on cannabidiol for 24 weeks and would go through laboratory, electroencephalography, and neuropsychological tests before, during, and after intervention.
62245884|NCT02806154||Elderly cancer patients|Elderly cancer patients treated with chemotherapy will have DEXA
62245885|NCT04276766|EXPERIMENTAL|Beetroot|"Following baseline microcirculatory and blood pressure measurements, as well as the collection of urine and saliva samples, participants on the beetroot group were asked to consume 140ml beetroot juice (James White Drinks Company, Suffolk, UK). The 140 ml of beetroot juice equate to approximately 8.4 mmol of NO3- ."
62245886|NCT04276766|PLACEBO_COMPARATOR|Placebo|"Following baseline microcirculatory and blood pressure measurements, as well as the collection of urine and saliva samples, participants on the placebo group were asked to consume 140 ml nitrate-depleted beetroot juice (James White Drinks Company, Suffolk, UK)."
62245887|NCT04173715||General Group|All those who are over 65 years old and capable of walking by themselves.
62245888|NCT04173715||Low Physical Function Status Group.|All those who present a low physical function status will be included in this group.
62245889|NCT04173715||Medium Physical Function Status Group.|All those who present a medium physical function status will be included in this group.
62245890|NCT04173715||High Physical Function Status Group.|All those who present a high physical function status will be included in this group.
62245891|NCT04319302||Paediatric biliary obstruction|This was a retrospective review of all paediatric patients who had undergone an IVGT graft procedure for biliary tract anatomical obstruction in the past five years. We looked at the indications for surgery, the demographic profile of the patients, outcomes following surgery and outlined the surgical technique used.
62602476|NCT00945204|EXPERIMENTAL|access to intermediate care clinics|
62245892|NCT02241291||All patients|Patients undergoing PCI at Bern University Hospital
62245893|NCT06027567|EXPERIMENTAL|Semaglutide|"Semaglutide up-titration to 2.4 mg for 10 months initially combined with a Very Low Calorie Diet (800 kcal/day) for 8 weeks.~Counselling by dietician Standard medical treatment of intracranial hypertension"
62245894|NCT06027567|ACTIVE_COMPARATOR|Standard care (dietician)|Standard weight loss intervention Counselling by dietician Standard medical treatment of intracranial hypertension
62245895|NCT03915808|EXPERIMENTAL|Conjugated linoleic acid plus lifestyle counselling|supplementation of 3.2 g/day conjugated linoleic acid and receive education sessions regularly
62245896|NCT03915808|PLACEBO_COMPARATOR|Sunflower oil plus lifestyle counselling|supplementation of equivalent sunflower oil, and receive education sessions regularly
62245897|NCT06736496|EXPERIMENTAL|group 1|patients will receive : nalbuphine administered at a dose of 0.2 mg / kg IV bolus dose before induction and intermittent doses of 0.5 mg/kg if MAP and HR greater than 20% of the base line value.
62436105|NCT04514029|EXPERIMENTAL|Simvastatin and Dexamethasone|Simvastatin 40 mg/day will be started at least 5 days prior to apheresis and will be continued until day +30 after infusion. Intrathecal dexamethasone 8 mg will be administered on days (related to CAR-T infusion) -1, +6, +13, (+/- 2 days).
62436106|NCT01696383|EXPERIMENTAL|DuoTrav|One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
62245898|NCT06736496|EXPERIMENTAL|group 2|patients will receive : Dexmedetomidine infusion at rate of 0.5mcg/kg/h initiated 10 min before induction and ketamine iv bolus dose of 0.35 mg/kg and Lidocaine iv bolus dose of 1mg/kg administrated before skin incision.
62436107|NCT04478071|EXPERIMENTAL|vadadustat|
62436108|NCT04478071|PLACEBO_COMPARATOR|placebo|
62245899|NCT02198612|OTHER|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
62245900|NCT06235840|EXPERIMENTAL|Working memory adaptive cognitive training|In the intervention, the n-back task involving working memory in terms of its content updating was applied. This task is based on the continuous presentation of items (letters in this study) that appear and disappear one by one. During each presentation, the participant must judge whether the currently displayed item matches the item presented 'n' trials earlier. The n-back task used in the current study was computerized and was programmed in PsychoPy software. All participants started their training from the 1-back level. The training was adaptive, meaning that, according to the performance accuracy achieved, participants progressed to higher (or dropped to lower) levels of difficulty. The increasing/decreasing difficulty was based on a rise/fall in the 'n' parameter. Participants were involved in 12 sessions, three in each of the four weeks. Each session lasted approximately 45 minutes.
62436109|NCT02905721|EXPERIMENTAL|Spectral cardiac CT scan|All patients will undergo cardiac CT scan with spectral mode acquisition
62436110|NCT01259401|EXPERIMENTAL|SIP group|The Sleep Intervention Program group received a sleep education program based on behavioral principles, delivered in 4 individual sessions carried out within the Adult Day Health Care program.
62436111|NCT01259401|ACTIVE_COMPARATOR|Control group|The Control group received basic sleep education, delivered in 4 individual sessions carried out within the Adult Day Health Care
62436112|NCT03833453|ACTIVE_COMPARATOR|PTSD-EMDR|PTSD treatment
62436113|NCT03833453|EXPERIMENTAL|Integrated DBT-EMDR|Integrated PTSD-PD-treatment
62436114|NCT00756028|EXPERIMENTAL|1|Patients receiving short protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-antagonist (Orgalutran®: Ganirelix)
62436115|NCT00756028|ACTIVE_COMPARATOR|2|Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®: Nafarelin)
62436116|NCT06180967|EXPERIMENTAL|Midazolam (Intravenous [IV] Bolus)|A single IV bolus dose of midazolam will be administered in the morning following a 10-hour fast prior to dosing and a 4-hour fast postdose on Day 1 and Day 15.
62436117|NCT06180967|EXPERIMENTAL|Midazolam Oral|A single oral dose of midazolam will be administered in the morning following a 10-hour fast prior to dosing and a 4-hour fast postdose on Day 3 and Day 17.
62602477|NCT00945204|NO_INTERVENTION|usual care|
62043163|NCT01970462|EXPERIMENTAL|Sitagliptin|Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
62043164|NCT01970462|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo prior to discharge and 6 weeks after discharge.
62043165|NCT01911728|EXPERIMENTAL|Multiple doses of MDV3100|Multiple doses of MDV3100 and a single dose of pioglitazone and a single dose of cocktail containing -warfarin, omeprazole and midazolam
62824230|NCT03409016||Control|An additional 18 patients starting standard chemotherapy will be enrolled as a control population. Patients will receive chemotherapy per standard protocol
62824231|NCT06593873|OTHER|Group 1: Theoretical training only (Control Group)|Group 1 (control group) will receive only theoretical training.
62824232|NCT06593873|OTHER|Group 2: Theoretical training+ Preclinical practical training with typodont-phantom head(Test group)|Group 2 (test group) will receive training with typodont-fantom head in addition to theoretical training.
62824233|NCT05783622|EXPERIMENTAL|Dose Escalation|Subjects will be dosed weekly during each 21-day cycle. Dosage per cohort will increase to determine the maximum tolerable dose.
62043166|NCT03230227|ACTIVE_COMPARATOR|Bupivacaine magnesium|( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
62043167|NCT03230227|ACTIVE_COMPARATOR|bupivacain only|bupivacaine 0.125% infusion in the presternum , for 48 hours
62043168|NCT03508648|PLACEBO_COMPARATOR|Matching Placebo|Subjects previously enrolled in the placebo arm of study G201002.
62436118|NCT06180967|EXPERIMENTAL|Pirtobrutinib|Multiple oral doses of Pirtobrutinib once a day (QD) will be administered on Days 5 through Day 17.
62436119|NCT02599883|EXPERIMENTAL|MulticenterRecruitment|COPD phenotypization by Low-Dose Computed Tomography
62436120|NCT03336632|EXPERIMENTAL|Chidamide|Chidamide, tablets, 5 mg/tablet, 20 mg orally twice weekly from D-7\~+14 Cyclophosphamide: 50 mg/Kg intravenously D+3, +4 Cyclosporine A: intravenously then orally 3 mg/Kg D+5\~D+100
62043169|NCT03508648|ACTIVE_COMPARATOR|1 mg GTx-024|Subjects previously enrolled in the 1 mg GTx-024 arm of study G201002.
62436121|NCT04352491||Patients with liver disease|All people who have shown at Institute of Liver and Biliary Sciences (1st January 2018 - 31st March 2020), will be sent the SMS for participation.
62436122|NCT02935075|EXPERIMENTAL|Reduced dose|Tenofovir 200mg +lamivudine 300mg +efavirenz 400mg PO q.d.
62043170|NCT03508648|ACTIVE_COMPARATOR|3 mg GTx-024|Subjects previously enrolled in the 3 mg GTx-024 arm of study G201002.
62043171|NCT04530448|ACTIVE_COMPARATOR|Standard of Care|Standard of Care treatment
62043172|NCT04530448|ACTIVE_COMPARATOR|Sodium Bicarbonate|Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
62043173|NCT02486484|EXPERIMENTAL|intravitreal ziv-aflibercept|intravitreal ziv-aflibercept
62043174|NCT01746342|ACTIVE_COMPARATOR|Effective CPAP|Continuous positive airway pressure: effective fixed level determined by polysomnographic titration
62043175|NCT01746342|SHAM_COMPARATOR|Sham CPAP|Continuous positive airway pressure device modified by manufacturer to deliver minimal pressure
62043176|NCT03511833|ACTIVE_COMPARATOR|Morphine group|Morphine group will receive IV medication and IN saline.
62436123|NCT02935075|ACTIVE_COMPARATOR|Standard dose|Tenofovir 300mg +lamivudine 300mg +efavirenz 600mg PO q.d.
62436124|NCT04905979|EXPERIMENTAL|AD113|Two oral capsules administered before bed
62436125|NCT04905979|EXPERIMENTAL|Atomoxetine|Two oral capsules administered before bed
62436126|NCT04148183|EXPERIMENTAL|Metformin Group|Metformin (850 mg/day) treatment was administered for 8 weeks
62436127|NCT04148183|EXPERIMENTAL|Rosiglitazone Group|Rosiglitazone (4 mg/day), treatment was administered for 8 weeks
62436128|NCT04148183|PLACEBO_COMPARATOR|Placebo Group|Placebo treatment was administered for 8 weeks
62436129|NCT02565485|NO_INTERVENTION|Standard IV Preload|Patients in this arm will receive 500mL of Lactated Ringer's solution, which is the standard IV fluid preload used on Labor and Delivery at MetroHealth Medical Center
62436130|NCT02565485|EXPERIMENTAL|Volume Replacement IV Preload|Patients in this arm will receive 1500mL of Lactated Ringer's solution
62824234|NCT05783622|EXPERIMENTAL|Backfill Expansion|Subjects will be dosed weekly during each 21-day cycle. Subjects will be dosed at levels previously declared tolerable.
62436131|NCT01498419|EXPERIMENTAL|Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)|Drug Sensitive Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 100 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
62824235|NCT05783622|EXPERIMENTAL|Expansion|Subjects will be dosed weekly during each 21-day cycle. Subjects will be dosed at the preliminary recommended Phase 2 dose (RP2D).
62824236|NCT01821690|EXPERIMENTAL|Buspirone Treatment|starting at 15 mg/day and ending at 60 mg/day as prescribed
62824237|NCT01821690|PLACEBO_COMPARATOR|Buspirone Placebo|placebo tablets as prescribed
62824238|NCT05683028|EXPERIMENTAL|Cognitive control training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
62824239|NCT05683028|ACTIVE_COMPARATOR|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
62043177|NCT03511833|EXPERIMENTAL|Ketamine group|Ketamine group will receive IV saline and IN medication.
62043178|NCT01201148|EXPERIMENTAL|Oscillating or intermittent tDCS|
62824240|NCT05813106|EXPERIMENTAL|Dexmedetomidine group|These patients will receive 0.2 mcg/kg dexmedetomidine intravenously 30 minutes before end
62824241|NCT05813106|PLACEBO_COMPARATOR|Control group|These patients will receive normal saline intravenously 30 minutes before end
62824242|NCT01516905||I124-NM404 brain metastases or GBM imaging|determining appropriate imaging timepoints. Image at 6 hour, 24 hour and 48 hour post injection of I-124NM404
62824243|NCT04700098|EXPERIMENTAL|Internet-based behavioral treatment for insomnia|Internet version of cognitive-behavioral treatment for insomnia
62824244|NCT04700098|EXPERIMENTAL|Online insomnia patient education|Online insomnia patient education
62824245|NCT04249999|EXPERIMENTAL|Intervention|Access to online physical activity platform (www.activonline.com.au) in addition to usual care.
62824246|NCT04249999|NO_INTERVENTION|Control|No access to online physical activity platform. Continue with usual care.
62824247|NCT06592300|EXPERIMENTAL|Tenofovir Alafenamide Film Tablet|Tenofovir Alafenamide 25 mg Film Tablet
62824248|NCT06592300|ACTIVE_COMPARATOR|Vemlidy® film-coated tablets|Vemlidy® 25 mg film-coated tablets
62824249|NCT01243190|EXPERIMENTAL|Ofatumumab|Loading dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).
62824250|NCT03670940||COPD patients|COPD patients without bronchiectasis
62824251|NCT03670940||COPD and bronchiectasis patients|COPD patients with bronchiectasis
62824252|NCT03094416|EXPERIMENTAL|levothyroxine sodium capsules|levothyroxine sodium capsules 88 to 250 mcg/day (depending on individual needs) for 3 months
62824253|NCT03557294|EXPERIMENTAL|1.0mg varenicline b.i.d.|Days 1 through 3: 0.5mg, once daily; days 4 through 7: 0.5mg, twice daily; days 8 through end of treatment: 1mg, twice daily.
62824254|NCT03557294|EXPERIMENTAL|0.5mg varenicline b.i.d.|Days 1 through 3: 0.5mg, once daily; 0.5 mg b.i.d. dose starting at day 4 through the end of the study
62824255|NCT03557294|PLACEBO_COMPARATOR|0.0mg placebo varenicline b.i.d.|Days 1 through 3: 0.0mg placebo once daily; days 4 through 7: 0.0mg placebo twice daily; days 8 through end of treatment: 0.0 mg placebo twice daily.
62824256|NCT03133221|EXPERIMENTAL|Oral Zydelig 150 mg BID|Zydelig given orally at 150 mg twice daily continuously on 28-day cycles starting 30 to 120 days after autologous stem cell transplantation for patients with indolent or transformed indolent B-cell NHL, for up to 1 year maintenance duration. Dose withhold/modification is allowed according to tolerability/toxicity.
62436132|NCT01498419|EXPERIMENTAL|Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)|Drug Sensitive Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 200 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
62436133|NCT01498419|ACTIVE_COMPARATOR|Drug Sensitive: Rifafour|Drug Sensitive Participants: Rifafour was administered orally once daily for 8 weeks according to weight: 30 kg to 37 kg: two tablets; 38 kg to 54 kg: three tablets; 55 kg to 70 kg: four tablets; ≥71 kg: five tablets
62824257|NCT04989751||LGMD patients|
62824258|NCT06392841|EXPERIMENTAL|Initial Treatment (Cycle 1 to Cycle 6)|Androgen Deprivation Therapy (ADT) with a GnRH agonist or antagonist per standard of care. 200 mg niraparib and 1,000 mg abiraterone acetate dual action tablet (DAT, Akeega) once daily, with 5mg prednisone once daily for 24 weeks (6 cycles) unless there is progression or unacceptable toxicity. After 6 cycles, disease evaluation performed.
62824259|NCT06392841|EXPERIMENTAL|Cohort A: prostate specific antigen (PSA) >4 ng/mL without progression at the completion of 24 weeks|"After 6 cycles, there will be an option to:~1. Continue ADT + niraparib/abiraterone acetate plus prednisone in 28-day cycles for a total of 2 years OR until disease progression or unacceptable toxicity. Subsequent therapy will be at the discretion of the investigator per standard of care.~2. Discontinue niraparib. Continue ADT, start abiraterone acetate plus prednisone and docetaxel 75mg/m2 in 21-day cycles. Docetaxel every 3 weeks x 6 doses. At the completion of docetaxel, the subject will move to follow-up per protocol. Niraparib should not be restarted at the completion of docetaxel. Subsequent therapy will be at the discretion of the investigator per standard of care."
62043179|NCT02925611|ACTIVE_COMPARATOR|Isoflurane|Isoflurane as an inhalational anaesthetic ,titrated with BIS ( bispectral index) /entropy monitoring,from start to end of surgery.
62043180|NCT02925611|ACTIVE_COMPARATOR|Desflurane|Desflurane as an inhalational anaesthetic ,titrated with BIS ( bispectral index) /entropy monitoring,from start to end of surgery.
62043181|NCT05612074|EXPERIMENTAL|Nitric Oxide|High dose inhaled nitric oxide (targeting 250 ppm and not exceeding 300 ppm) in a nitrogen-oxygen-air mixture, at two different FiO2 levels (0.21 and 0.8) will be delivered intermittently with a dedicated system and a snug-fitting facemask to healthy volunteers three times per day for 5 days. The subjects will be monitored before, during and after the administration
62043182|NCT02451527|EXPERIMENTAL|Digoxin and PEX168|A single dose of 0.5mg digoxin administered on Day 1 followed by 5 weekly subcutaneous injections of a single dose of 200ug PEX168, followed by a further single dose of 0.5mg digoxin on Day 38.
62043183|NCT05040009|ACTIVE_COMPARATOR|moderate and high risk patient with integrated foot care program|"Integrated foot care program will be applied to moderate and high-risk patients for diabetic foot with follow up after 6-12 months~1. Regular foot care and examination by an adequately trained professional: -~2. Structured education~3. Adequate footwear~4. Foot-related exercises and weight-bearing activity.~5. Foot examination and screening every 4 months in moderate risk and 2 months in high-risk patient for diabetic foot.~6. Instructions about foot self-management"
62436134|NCT01498419|EXPERIMENTAL|Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)|Multi Drug-Resistant Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 200 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
62436135|NCT05181137|EXPERIMENTAL|Part 1 Active Experimental: SHR0302 Dose#1|SHR0302 Oral tablets taken once daily (QD) for 8 weeks SHR0302 Oral tablets taken once daily (QD)
62436136|NCT05181137|PLACEBO_COMPARATOR|Part 1 Placebo Comparator: Placebo|Placebo Oral tablets taken once daily (QD) for 8 weeks
62436137|NCT05181137|EXPERIMENTAL|Part 2 Active Experimental: SHR0302 Dose#2|SHR0302 Oral tablets taken once daily (QD) for 44 weeks
62436138|NCT05181137|PLACEBO_COMPARATOR|Part 2 Placebo Comparator: Placebo|Placebo Comparator: Maintenance Treatment Placebo Comparator: Placebo
62824260|NCT06392841|EXPERIMENTAL|Cohort B: PSA ≤ 4 ng/mL without progression at the completion of 24 weeks|"Continue ADT + niraparib/abiraterone acetate plus prednisone for 1 year unless progression or unacceptable toxicity. At 1 year, disease evaluation will occur.~* PSA ≥ 0.2 ng/mL: ADT + niraparib/abiraterone acetate plus prednisone will continue for 2 years or until progression or unacceptable toxicity. Therapy beyond 2 years will be per standard of care per investigator discretion.~* PSA \< 0.2 ng/mL and PSA not trending up:~  1. Continue ADT + niraparib/abiraterone acetate plus prednisone for 2 years or until progression or unacceptable toxicity. Therapy beyond 2 years will be per standard of care per investigator discretion OR~ 2. STOP ADT + niraparib/abiraterone acetate plus prednisone only IF:~     * C14 PSA \< 0.2 AND not trending up~    * Subjects not eligible that elect to stop ADT + niraparib/abiraterone acetate plus prednisone, will be removed from protocol treatment and move to follow-up. Subsequent therapy re-initiation will be at the discretion per standard of care."
62436139|NCT05181137|EXPERIMENTAL|Part 3 Active Experimental: SHR0302 Dose#2|SHR0302 Oral tablets taken once daily (QD) for 26 weeks
62436140|NCT03780933|NO_INTERVENTION|control group|conventional treatment (corticosteroids, mechanical ventilation)
62436141|NCT03780933|EXPERIMENTAL|test group (vitamin C)|high dose vitamin c iv infusion
62436142|NCT02220140|NO_INTERVENTION|Control|Service as usual
62436143|NCT02220140|EXPERIMENTAL|Intervention group|Participants are offered access to the web based resilience program and are invited to join a short introduction course.
62436144|NCT03281434|ACTIVE_COMPARATOR|Collagen peptide|Supplement will be delivered twice daily (30g per supplement) of hydrolyzed collagen peptides
62436145|NCT03281434|EXPERIMENTAL|Whey protein|Supplement will be delivered twice daily (30g per supplement) of whey protein isolate
62043184|NCT05040009|NO_INTERVENTION|moderate and high risk patient with conventional treatment|conventional treatment will be applied to moderate and high-risk patients for diabetic foot with follow up after 6-12 months.
62043185|NCT04041960|EXPERIMENTAL|SMG|Brain region targeted with transcranial magnetic stimulation: superamarginal gyrus
62043186|NCT04041960|EXPERIMENTAL|MTG|Brain region targeted with transcranial magnetic stimulation: middle temporal gyrus
62043187|NCT04041960|ACTIVE_COMPARATOR|Vertex|Brain region targeted with transcranial magnetic stimulation (none associated): Vertex
62436146|NCT00500409|EXPERIMENTAL|Drug Group|Osteoform
62824261|NCT02474316|EXPERIMENTAL|PegINF plus nucleos(i)de analgoue|Peginterferon alfa-2a 180μg /wk plus nucleos(t)ide analgoue (NA) 1 piece qd for 48 weeks
62824262|NCT02474316|ACTIVE_COMPARATOR|nucleos(t)ide analgoue|nucleos(t)ide analgoue (NA) 1 piece qd for 48 weeks
62436147|NCT00500409|ACTIVE_COMPARATOR|Control group|SHELCAL
62436148|NCT05268731||Extrahepatic bile duct obstruction and failed ERCP|"Patients with extrahepatic bile duct obstruction and obstructive jaundice have received a percutaneous transhepatic biliary drainage.~The choice between an insertion of an external or an external/internal drainage has been made during the procedure depending on whether the guide wire could be accessed to the jejunum/duodenum or not.~The choice between internal/external drainage or a primary metal stent has been made by the investigators preference or was made on the basis of an existing malign bile duct obstruction or not."
62436149|NCT02163811|EXPERIMENTAL|VETPALS|VETPALS is a five session course utilizing adult learning methods to teach self-management for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA Puget Sound clinician in conjunction with a peer facilitator (Veteran with limb loss).
62824263|NCT02903771|EXPERIMENTAL|Part A and Part B|"Part A (Dose Escalation):~Part A is a Dose Escalation study to determine the Maximum Tolerated Dose of Cantrixil as a monotherapy.~The tolerance of Cantrixil in combination with standard chemotherapy agents will also be examined.~Part B (Expansion Cohort):~An expansion cohort of an additional 12 patients will be recruited at the MTD."
62824264|NCT06603272||laparoscopic group|patients underwent laparoscopic gastrectomy
62824265|NCT04865276|ACTIVE_COMPARATOR|Intervention|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system
62043188|NCT01235390|EXPERIMENTAL|5 g of walnuts|
62043189|NCT01235390|EXPERIMENTAL|40 g of walnuts|
62043190|NCT01892059|EXPERIMENTAL|Segmental artery clamping|Patients with Renal tumor are randomized into this group,they will received laparoscopic partial nephrectomy. During operation, the technique of segmental renal artery clamping will performed.
62043191|NCT01892059|ACTIVE_COMPARATOR|Main renal artery clamping|Patients with renal tumor are randomized into this group,they will received laparoscopic partial nephrectomy. During operation, the technique of traditional main renal artery clamping will be performed.
62043192|NCT03311373|EXPERIMENTAL|Treatment Period 1|Test Formulation (Regimen B or D) or Reference Formulation (Regimen A or C)
62043193|NCT03311373|EXPERIMENTAL|Treatment Period 2|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
62043194|NCT03311373|EXPERIMENTAL|Treatment Period 3|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
62043195|NCT03311373|EXPERIMENTAL|Treatment Period 4|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
62043196|NCT01634126|ACTIVE_COMPARATOR|1 FIT kit|
62043197|NCT01634126|ACTIVE_COMPARATOR|2 FIT kit|
62245901|NCT06235840|ACTIVE_COMPARATOR|Multi-domain non-adaptive cognitive training|Non-adaptive multi-domain computerized training included tasks involving: visual-spatial functions, visual and verbal memory, reasoning on visual and verbal material, and calculia. Participants were involved in 12 sessions, three in each of the four weeks. Each session lasted approximately 45 minutes.
62245902|NCT06235840|NO_INTERVENTION|No contact|The passive control group was the no-contact group. Participants had no contact with the researcher for 4 weeks, corresponding to the duration of the intervention (training) in the experimental group.
62436150|NCT02163811|ACTIVE_COMPARATOR|Individual Education Support Program|VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
62824266|NCT04865276|ACTIVE_COMPARATOR|Control|Home visit by a Community Health Worker during which the participant is scheduled to attend the tobacco cessation program at the public health system
62824267|NCT06596837|EXPERIMENTAL|respondents exposed to highly immersive virtual reality (Cold River)|The experimental group will have a virtual reality (VR) application Cold River in the VR headset that will significantly enhance the sense of immersion (e.g., realistic environment, interactive capabilities) during one part of the dressing change.
62245903|NCT04608513|EXPERIMENTAL|ACT-1014-6470 single dose (dose level 1)|Soft capsule for oral administration
62245904|NCT04608513|PLACEBO_COMPARATOR|Placebo single dose (dose level 1)|Soft capsule for oral administration
62245905|NCT04608513|EXPERIMENTAL|ACT-1014-6470 single dose (dose level 2)|Soft capsule for oral administration
62245906|NCT04608513|PLACEBO_COMPARATOR|Placebo single dose (dose level 2)|Soft capsule for oral administration
62245907|NCT04608513|EXPERIMENTAL|ACT-1014-6470 multiple dose (dose level 1)|Soft capsule for oral administration
62245908|NCT04608513|PLACEBO_COMPARATOR|Placebo multiple dose (dose level 1)|Soft capsule for oral administration
62245909|NCT04608513|EXPERIMENTAL|ACT-1014-6470 multiple dose (dose level 2)|Soft capsule for oral administration
62245910|NCT04608513|PLACEBO_COMPARATOR|Placebo multiple dose (dose level 2)|Soft capsule for oral administration
62245911|NCT04608513|EXPERIMENTAL|ACT-1014-6470 multiple dose (dose level 3)|Soft capsule for oral administration
62245912|NCT04608513|PLACEBO_COMPARATOR|Placebo multiple dose (dose level 3)|Soft capsule for oral administration
62245913|NCT04608513|EXPERIMENTAL|ACT-1014-6470 multiple dose (dose level 4)|Soft capsule for oral administration
62245914|NCT04608513|PLACEBO_COMPARATOR|Placebo multiple dose (dose level 4)|Soft capsule for oral administration
62245915|NCT06162000|EXPERIMENTAL|intervention group of nursing students|The group that will use the developed software in case studies
62245916|NCT06162000|NO_INTERVENTION|Control Group of nursing students|Group that will prepare case studies on paper
62245917|NCT04356911|PLACEBO_COMPARATOR|PLACEBO (Negative Control)|The dental elements of this group had no desensitizing treatment. After whitening therapy, a water-soluble placebo gel (KY®, Johnson \& Johnson, SP, Brazil) was applied to dental oral surfaces, then the laser tip was positioned at two points, apical and cervical, without emitting light (placebo), simulating the application of Low Level Laser Therapy (LLLT).
62245918|NCT04356911|EXPERIMENTAL|FBM|The group received the application of a placebo gel associated with LLLT after office bleaching.
62245919|NCT04356911|EXPERIMENTAL|ESTRÔNCIO|After whitening in-office bleaching, the group was treated with desensitization to 10% strontium chloride. Subsequently, a laser tip was positioned at two points (apical and cervical), without emitting light (placebo).
62824268|NCT06596837|OTHER|respondents exposed to low-immersive virtual reality (static images)|The control group will have only static images of a snowy landscape in the virtual reality headset during one part of the dressing change.
62245920|NCT04356911|EXPERIMENTAL|FBM+ESTRÔNCIO|After whitening in the office, the group received a 10% strontium chloride desensitizer associated with low level light therapy.
62245921|NCT03348865|EXPERIMENTAL|Fertility Life Counselling Aid (FeLiCiA)|"Patients to undergo weekly Felicia counselling interventions for 6 weeks; making a total of 6 sessions.~Each session is expected lasts 30 mins to 1 hour."
62245922|NCT03348865|NO_INTERVENTION|Control|Patients are to undergo treatment as usual.
62245923|NCT01889303|ACTIVE_COMPARATOR|Arm A|"chemotherapy regimen:Oxaliplatin 85mg/m2 IV d1,Leucovorin 400mg/m2 IV d1,5-FU 400mg/m2 IV bolus d1 ,then 2400mg/m2 over 46h continuous infusion Q2W for 3 cycles → 5-FU 400 mg/m2 IV and Leucovorin 20 mg/m2 IV on the first four and the last three days of radiotherapy + RT 45Gy (5weeks)→ Rest for 4 weeks →Oxaliplatin 85mg/m2 IV d1,Leucovorin 400mg/m2 IV d1,5-FU 400mg/m2 IV bolus d1 ,then 2400mg/m2 over 46h continuous infusion Q2W for 3 cycles.~Radiation: concurrent chemoradiotherapy with 5-FU/CF.Radiotherapy consisted of 45Gy of radiation at 1.8Gy per day, five days per week for five weeks."
62824269|NCT06596837|NO_INTERVENTION|Changing dressings without the use of virtual reality|In the study, each dressing change, whether in the experimental or control group, will include a part where the participant will not wear a virtual reality (VR) headset. Each participant will have two different sessions, and the part of the dressing change without the VR headset will occur at a different stage of the change in each session.
62824270|NCT02432378|EXPERIMENTAL|Cisplatin + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
62824271|NCT02432378|EXPERIMENTAL|Cisplatin + CKM + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
62824272|NCT04907799|EXPERIMENTAL|Daily Caloric Restriction|The daily caloric restriction group will participate in a 2-year, group-based, behavioral weight loss intervention based on a 30% reduction in caloric intake and increased physical activity.
62824273|NCT04907799|OTHER|Standard Advice Control|The standard advice control group will receive an initial consultation with a registered dietician regarding current clinical recommendations for ADPKD without subsequent counseling sessions.
62824274|NCT02875496||Healthy aging|Subjects meeting criteria for healthy aging No intervention administered
62824275|NCT02875496||Early Alzheimer Disease|Subjects meeting criteria for Early Alzheimer Disease No intervention administered
62824276|NCT02875496||Depression|Subjects meeting criteria for Depression No intervention administered
62824277|NCT02875496||MCI-Mild Cognitive Impairment|Subjects meeting criteria for MCI-Mild Cognitive Impairment No intervention administered
62824278|NCT02875496||General Arm|Subjects not meeting criteria for any of the other arms (Healthy, Early Alzheimer's, Depression, or MCI)
62824279|NCT06588361|EXPERIMENTAL|COPD patients|Experimental group will receive training based on Kolcaba's Comfort Theory once a week for 5 weeks.No interventions will be provided to the control group.
62043198|NCT02058615|EXPERIMENTAL|Male Spouse Transition Toolkit|All participants in this group will be given access to the Male Spouse Transition Toolkit (MaTT). MaTT is a website based application that is designed to help male spouses of women with breast cancer to increase their awareness of the transitions and experiences they have as a husband and caregiver as well as to stay organized and seek help and resources as needed. To do so it consists of six sections: about me; common changes to expect; frequently asked questions; resources; calendar; and, important health information. These sections contain activities and exercises, as well as fillable templates (i.e., resources, calendar) that users can download at their convenience, from their home computer, tablet, or smart phone. They will be asked to use the MaTT for one month.
62043199|NCT02058615|NO_INTERVENTION|Usual Care|Participants in this group will not receive access to the Male Spouse Transition Toolkit, and thus will not receive an intervention. Data collection for outcome variables will be the same as the participants in the experimental arm.
62043200|NCT04080050||RGX-501|Study participants who have received RGX-501 gene therapy in a separate parent trial
62824280|NCT05168839|EXPERIMENTAL|FLUO+|"Experimental arm = surgery with IOFA.~In the experimental arm, cancer resection and anastomosis will be performed after assessment of descending colon perfusion using intravenous injection of indocyanine green 0.1ml/kg."
62043201|NCT03676855|ACTIVE_COMPARATOR|bladder dissection before uterine incision|
62824281|NCT05168839|NO_INTERVENTION|FLUO-|"Control arm = Surgery without IOFA.~In the control arm, cancer resection and anastomosis will be performed without intraoperative fluorescence angiography."
62824282|NCT04263623|EXPERIMENTAL|High Dose (4 mg)|Oral tablet containing 2 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
62824283|NCT04263623|EXPERIMENTAL|Low Dose (2 mg)|Oral tablet containing 1 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
62824284|NCT04263623|PLACEBO_COMPARATOR|Placebo|Oral tablet containing no active drug. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
62043202|NCT03676855|EXPERIMENTAL|bladder dissection after uterine incision|
62043203|NCT02245958||BOTOX®|Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
62043204|NCT02245958||Xeomin®|Retrospective chart review of doses of Xeomin® (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
62043205|NCT00623090|EXPERIMENTAL|1 Website|Participants receive the Login information for the Internet we developed on prostate cancer screening.
62245924|NCT01889303|EXPERIMENTAL|Arm B|"chemotherapy regimen:Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W x 2 cycles → Docetaxel 35mg iv D1,Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy (5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W x 2 cycles~Radiation: concurrent chemoradiotherapy with DC.Radiotherapy consisted of 45Gy of radiation at 1.8Gy per day, five days per week for five weeks."
62824285|NCT06593925|EXPERIMENTAL|Polyoxymethylene telescopic denture|
62824286|NCT06593925|ACTIVE_COMPARATOR|Conventional complex partial denture with clasps|
62824287|NCT03990961|EXPERIMENTAL|Pembrolizumab Treatment|
62824288|NCT01349543|EXPERIMENTAL|Viral Challenge|
62824289|NCT01623570|EXPERIMENTAL|Pergoveris: 150IU r-hFSH+ 75IU r-hLH|This is a prospective randomized study using two in-label treatments for the patient disease: Pergoveris and Menopur. Pergoveris arms can be considered as experimental for the aim of the study, anyway it is standard routine practice for HH women.
62043206|NCT00623090|ACTIVE_COMPARATOR|2 Booklet|Participants receive the education booklet we developed on prostate cancer screening.
62043207|NCT00623090|PLACEBO_COMPARATOR|3 Usual Care|Usual care: participants receive no intervention.
62043208|NCT01831622|EXPERIMENTAL|Behavioral|"Cognitive testing of participants. Asterisk applies for patient group.~Day 1:~* Patient arrives having abstained medication for minimum 20 hours.\*~* Administer either Ritalin or placebo intervention, and wait 60 minutes before computer-testing.\*~* Case Report Form (CRF), ASRS and Wechsler Adult Intelligence Scale (WAIS) subtests.~* Blood sample, if consented.\*~* Computerized testing.~* Administer opposite treatment.\*~Day 2:~* Patient arrives having abstained medication for a minimum of 20 hours.\*~* Administer either Ritalin or placebo intervention (opposite of Day 1), and wait 60 minutes before computer-testing.\*~* CRF 3, ASRS and Edinburgh Handedness Inventory (EHI).~* Blood sample, if consented.\*~* Computerized testing.~* Administer opposite treatment.\*"
62245925|NCT00351416|EXPERIMENTAL|Aromatase inhibitor EFP|"Letrozole administration (20 mg) on day 2-4 (EFP; early follicular phase) of cycle 2 and~Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted."
62245926|NCT00351416|EXPERIMENTAL|Aromatase inhibitor LFP|"Letrozole administration (20 mg daily x 2) at follicle size of \> 16 mm (LFP; late follicular phase) in cycle 2.~Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted."
62602478|NCT01783821|EXPERIMENTAL|Budesonide and Formoterol|Subjects randomized to this arm will receive combined standard aerosolized doses of budesonide (0.5 mg) and formoterol (20 mcg) twice daily, with at least 6 hours between doses, for 5 days for a total of 10 doses or until hospital discharge or death, with the first dose administered as soon as possible following randomization but not later than 4 hours.
62824290|NCT01623570|EXPERIMENTAL|Menopur: hMG-HP (150IU)|This is a prospective randomized study using two in-label treatments for the patient disease: Pergoveris and Menopur. Menopur can be considered as experimental for the aim of the study, anyway it is standard routine practice for HH women
62245927|NCT03984903|ACTIVE_COMPARATOR|Face-to-face Learning Group|
62245928|NCT03984903|EXPERIMENTAL|Multimedia Learning Group|
62245929|NCT05643612||splenic injury group|We retrospectively collected data from patients who underwent contrast-enhanced abdominal CT in the emergency department of Chang Gung Memorial Hospital, Linko, due to trauma and acute abdomen from Jul 2008 to Dec 2017. We identified 300 venous phase scans with splenic injury.
62245930|NCT05643612||control group|We retrospectively collected data from patients who underwent contrast-enhanced abdominal CT in the emergency department of Chang Gung Memorial Hospital, Linko, due to trauma and acute abdomen from Jul 2008 to Dec 2017. We randomly selected 300 additional venous phase scans without splenic injury
62245931|NCT02566577|ACTIVE_COMPARATOR|Fresh RBC transfusion/Storage-aged RBC transfusion|Subjects will receive a transfusion of packed red blood cell (RBC) units of fresh blood (\<10 days old) followed by a transfusion of packed RBC units of storage-aged (\>21 days old) blood.
62602479|NCT01783821|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive normal saline, the quantity, appearance and timing of the doses the same as the intervention arm.
62602480|NCT02760030|EXPERIMENTAL|Treatment (fulvestrant, palbociclib)|Patients receive fulvestrant IM on days 1 and 15. Patients also receive palbociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62602481|NCT05520021|ACTIVE_COMPARATOR|Magnesium sulfate treatment|A total of 30 pregnancies with preterm labor threats will be treated with Magnesium sulfate.
62824291|NCT05446272|EXPERIMENTAL|NIV-NAVA|
62824292|NCT05446272|ACTIVE_COMPARATOR|NS- NIPPV|
62824293|NCT05138757|EXPERIMENTAL|Treatment Group|Subjects who meet inclusion criteria will be randomized 1:1. The treatment group will receive prebiotic therapy for 30 days, then subjects will start peanut oral immunotherapy (POIT) in addition to the prebiotic. Subjects will continue through a prescribed course of POIT for approximately 180 days. After completion of POIT up-dosing, subjects will continue on maintenance POIT plus prebiotic therapy for an additional 180 days at which time they will undergo a DBPCFC. Subjects will then stop prebiotic therapy and continue on maintenance POIT in extended observation for approximately 4 years.
62824294|NCT05138757|PLACEBO_COMPARATOR|Control Group|Subjects who meet inclusion criteria will be randomized 1:1. The control group will receive placebo therapy for 30 days, then subjects will start peanut oral immunotherapy (POIT) in addition to the placebo. Subjects will continue through a prescribed course of POIT for approximately 180 days. After completion of POIT up-dosing, subjects will continue on maintenance POIT plus placebo for an additional 180 days at which time they will undergo a DBPCFC. Subjects will then stop placebo and continue on maintenance POIT in extended observation for approximately 4 years.
62824295|NCT02811068||Venepuncture|Collection of single blood sample to assess antibody persistence over time
62245932|NCT02566577|ACTIVE_COMPARATOR|Storage-aged RBC transfusion/Fresh RBC transfusion|Subjects will receive a transfusion of packed red blood cell (RBC) units of storage-aged (\>21 days old) blood followed by a transfusion of packed RBC units of fresh blood (\<10 days old).
62245933|NCT01871636|ACTIVE_COMPARATOR|endoscopic mucosal resection|Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
62245934|NCT01871636|ACTIVE_COMPARATOR|Waterjet-assisted ESD|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
62245935|NCT01235793|EXPERIMENTAL|DRBEAT Regimen|
62245936|NCT06154655|EXPERIMENTAL|Intervention Group|participants will receive health education on climate change included in their routine antenatal care and also have access to the e-magazine accessible through mobile phones
62245937|NCT06154655|NO_INTERVENTION|Control Group|participants will receive health education on climate change included in their routine antenatal care
62245938|NCT02378220|NO_INTERVENTION|"Controls (not tested)"|Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
62602482|NCT05520021|ACTIVE_COMPARATOR|Nifedipine treatment|A total of 30 pregnancies with preterm labor threats will be treated with Nifedipine.
62602483|NCT05520021|NO_INTERVENTION|Healthy pregnant women|A total of 30 pregnancies without preterm labor threat will be included.
62602484|NCT02918552|EXPERIMENTAL|Treatment|20 or 40 mg sodium nitrite tid
62602485|NCT02918552|PLACEBO_COMPARATOR|Control|20 or 40 mg placebo tid
62602486|NCT00732979|EXPERIMENTAL|A|Infrahepatic inferior vena cava clamping The inferior vena cava is circumferentially dissected below the liver and clamped with a vascular clamp. Patients in this study group will receive intravenous volume for maintenance of fluid hemostasis according to local standards.
62824296|NCT06593509|EXPERIMENTAL|Non-invasive mechanical ventilation|Device: Non-invasive mechanical ventilation Bilevel pressure support through a face mask
62824297|NCT06593509|EXPERIMENTAL|High Flow Conditioned Oxygen Therapy|Device: High Flow Conditioned Oxygen device vapotherm via nasal cannula
62602487|NCT00732979|ACTIVE_COMPARATOR|B|Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below \< 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
62602488|NCT03611231|EXPERIMENTAL|Experimental|chidamide
62245939|NCT02378220|ACTIVE_COMPARATOR|"Intervention (tested)"|"Patients in the tested group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug interactions (DDI), drug-gene interactions (DGI), and drug-drug-gene interactions (DDGI) using YouScript® to provide drug therapy recommendations to prescribers."
62436151|NCT04262310||Study Aims|To obtain normative data (median, 10th and 90th percentile) as well as inter-individual coefficient of variation (COV, assessed by \[SD/mean\]) with approximately 15 participants in each age group: 18-30, 31-45, 46-60, and 60-70 years old. To assess intra-individual COV \[assessed by \[SD/mean\]. To assess effect of standard diets containing 16.25 or 32.5 g fiber/day during the two 24 hour periods before and during the measurement of permeability
62436152|NCT03242122|ACTIVE_COMPARATOR|CHO Control 1 Glucose|25 g glucose
62824298|NCT06593509|ACTIVE_COMPARATOR|Conventional Oxygen Therapy|Device: Conventional Oxygen Therapy conventional Oxygen Therapy with Venturi facial mask.
62824299|NCT05525104|NO_INTERVENTION|Control|In patients randomised to the control group, sevoflurane will be titrated according to a Minimal Alveolar Concentration (MAC) of 0.9 respectively an end tidal sevoflurane concentration of 2.3% based on standard practice in our paediatric anaesthesia department.
62824300|NCT05525104|EXPERIMENTAL|Treatment|In patients randomised to the intervention group of the trial, the anaesthetic agent sevoflurane will be titrated according to the typical DSA pattern for general anaesthesia with sevoflurane, provided by the Narcotrend
62824301|NCT03770546|EXPERIMENTAL|Osteoarthritis - Amnion Injection|BioDRestore Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from human amniotic tissues.
62824302|NCT03770546|ACTIVE_COMPARATOR|Osteoarthritis - Betamethasone Injection|Betamethasone Sodium Phosphate and Betamethasone Acetate injection (To clarify, this is one formulation/injected solution, not separate solutions/interventions)
62824303|NCT03770546|EXPERIMENTAL|Adhesive Capsulitis - Amnion Injection|BioDRestore Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from human amniotic tissues.
62824304|NCT03770546|ACTIVE_COMPARATOR|Adhesive Capsulitis - Betamethasone Injection|Betamethasone Sodium Phosphate and Betamethasone Acetate injection (To clarify, this is one formulation/injected solution, not separate solutions/interventions)
62824305|NCT06599775|EXPERIMENTAL|Adebrelimab and chemotherapy combined with endoscopic resection and simultaneous chemoradiotherapy|Adebelizumab, an innovative PD-L1 inhibitor, combined with chemotherapy followed by endoscopic resection and subsequent concurrent chemoradiotherapy
62824306|NCT05929963||HCV Ab(+）HCVRNA（-）|HCV Ab（+） HCVRNA(-) in pregnant women
62824307|NCT05929963||HCV Ab(+）HCVRNA（+）|HCV Ab(+）HCVRNA（+）in pregnant women
62436153|NCT03242122|EXPERIMENTAL|CHO Experimental 1 Slowly Digested|25 g slowly-digested carbohydrate blend
62436154|NCT03242122|EXPERIMENTAL|CHO Experimental 2 Digestion Resistant|25 g digestion-resistant carbohydrate blend
62436155|NCT03242122|EXPERIMENTAL|CHO Experimental 3 Low Sugar|25 g low sugar carbohydrate blend
62436156|NCT03242122|EXPERIMENTAL|CHO Experimental 4 Maltodextrin|25 g maltodextrin
62602489|NCT03495154|EXPERIMENTAL|Parietene DS Composite Mesh|Patients treated with Parietene DS Composite Mesh
62824308|NCT05929963||HCVAb(-) HCVRNA(-)|HCV Ab(-）HCVRNA（-）in pregnant women
62436157|NCT03242122|ACTIVE_COMPARATOR|CHO Control 2 Glucose|25 g glucose
62436158|NCT00384696||Smoking Cessation|Treatment to help quit smoking, including written self-help materials, counseling, and 4 week supply of nicotine patch plus 5 MD Anderson Visits.
62602490|NCT00477607|EXPERIMENTAL|Arm 1|Receiving alpha-lipoic acid during cisplatin treatment.
62602491|NCT00477607|PLACEBO_COMPARATOR|Arm 2|Receiving placebo during cisplatin treatment
62824309|NCT06410274||Intracerebral Haemorrhage Patients|Patients with a clinical diagnosis of haemorrhagic stroke on CT imaging within 48 hours of onset (for patients waking with a stroke, time of onset will be taken to be the time when the patient was last asymptomatic). This is a non-intervention study so no intervention will be given. However, the investigators will observe changes in cerebral haemodynamics of this group within 48 hours of stroke onset and within 3-7 days post-onset.
62824310|NCT04532528||Standard of care (SOC) only|This group includes Atrial Fibrillation (AF) patients diagnosed within 1 month, under 75 years old, and newly prescribed dabigatran on physician's decision based on local labelling.
62436159|NCT06075914|EXPERIMENTAL|Ketogenic Diet Arm|The goal of the KD is to have participants achieve consistent blood BHB ≥0.5 mM; preferably in the range of \>1 to 3 mM. We will measure ketones daily via finger stick to provide individual feedback and provide a quantitative measure of compliance. The KD will consist of approximately 50 g carbohydrate and 1.5 g/kg reference weight protein. These may be adjusted based on daily BHB readings. Fat will comprise the remaining calories with an emphasis on monounsaturated and saturated sources from whole foods. A wide range of foods will be incorporated including non-starchy vegetables, fruits (berries, olives, tomatoes, lemons/limes), meats (beef, chicken, pork, fish, lamb), nuts and seeds, oils (olive, canola, coconut), cheese, butter, cream, eggs, and fatty fish (salmon, sardines). Nutritional ketosis is associated with natriuresis that will lead to sodium and fluid loss if the extra sodium excreted is not compensated, thus slightly higher sodium and potassium intakes will be required.
62436160|NCT06075914|PLACEBO_COMPARATOR|Mediterranean Diet + Placebo|The MD+PL arm will be modeled after a Mediterranean style eating pattern. It will contain the same amount of protein as the KD, but with slight variations in protein sources, including limiting red meat to 1x/wk. The diet will provide unprocessed, higher-fiber foods with emphasis on vegetables, fruits, nuts and seeds, legumes, tubers, whole grains, and fish and seafood. Poultry, eggs, cheese, and yogurt will be included in moderate amounts. Use of olive oil and other monounsaturated fat sources (e.g., avocados and olives) will be encouraged while keeping added sugars to a minimum and avoiding highly processed foods (refined grains, fruit juice, processed meats). Saturated fat will be \<10% of energy. We will include adequate omega-3 fats (e.g., salmon). No alcohol will be included in both diets, but we will track consumption. This group will also consume two daily doses of placebo.
62436161|NCT06075914|ACTIVE_COMPARATOR|Mediterranean Diet + Ketone Ester|The MD+KE arm will consume the exact same diet as the MD+PL group with the exception they will consume two daily doses of KE instead of the placebo.
62436162|NCT01623830|EXPERIMENTAL|Reactivation + VRE|Virtual reality exposure therapy (VRE) for the fear of flying (FOF) preceded by a reminder of the feared stimulus (a virtual reality clip of a virtual airplane taxiing and taking off) presented in the head mounted display 10 minutes prior to all VR exposure therapy sessions
62436163|NCT01623830|ACTIVE_COMPARATOR|Neutral Cue + VRE|VRE for the FOF preceded by a neutral cue (a virtual reality clip of a virtual living room) presented in the head mounted display 10 minutes prior to all VR exposure therapy sessions.
62436164|NCT03707483|EXPERIMENTAL|Intervention|250 μM of vitamin C will be used with the platelet rich fibrin
62436165|NCT03707483|ACTIVE_COMPARATOR|Comparator|using platelet rich fibrin alone
62436166|NCT04486183|EXPERIMENTAL|Intervention|The data were collected by the researcher at the waiting room of the blood collection unit at a close distance to the lavatory. The capillary first and second blood drop values taken from the patients after fasting and at two hours following OGTT and capillary and venous blood glucose values were compared.
62436167|NCT04791735|EXPERIMENTAL|Laparoscopic approach for liver resection of HCC|
62436168|NCT04791735|EXPERIMENTAL|laparotomy|
62436169|NCT04053881||Certolizumab pegol|Plaque psoriasis patients who have been newly prescribed certolizumab pegol (CZP).
62436170|NCT03028194|EXPERIMENTAL|Curettage|Postpartum uterine curettage performed immediately after delivery of the placenta.
62436171|NCT03028194|PLACEBO_COMPARATOR|Placebo|No procedure performed after delivery of the placenta.
62436172|NCT02512770|EXPERIMENTAL|dilatation|esaphageal dilatation group
62436173|NCT02512770|NO_INTERVENTION|control|control group ( only endoscopy for control)
62436174|NCT04366466|OTHER|suicide attempt patient who will receive sanitory supervision|The control group will establish the health monitoring
62436175|NCT04366466|EXPERIMENTAL|Suicide attempt patient who will participate to PEPS Program|The intervention group will test the program of Promotion of Commitment to Care for the Prevention of Suicidal Recidivism.
62436176|NCT05081674|ACTIVE_COMPARATOR|ALK-translocated|"1. st line Alectinib~2. nd line Carboplatin pemetrexed~3. rd line Docetaxel"
62436177|NCT05081674|ACTIVE_COMPARATOR|EGFR-mutant|"1. st line Erlotinib~2. nd line Carboplatin pemetrexed~3. rd line Docetaxel"
62436178|NCT05081674|ACTIVE_COMPARATOR|PD-L1 >= 50%|"1. st line Pembrolizumab~2. nd line Carboplatin pemetrexed~3. rd line Docetaxel"
62436179|NCT05081674|ACTIVE_COMPARATOR|PD-L1< 50%|"1. st line Carboplatin pemetrexed~2. nd line nivolumab~3. rd line Docetaxel"
62436180|NCT00949390||Phase I and CAM Survey|Complementary and alternative medicine (CAM) in patients with advanced malignancies currently treated on University of Texas MD Anderson Cancer Center Phase I clinical trials.
62436181|NCT00871169|EXPERIMENTAL|Irinotecan, oxaliplatin, and cetuximab|The goal is to administer at least 4 cycles to each patient, but treatment may stop earlier if the treating physician deems stopping to be in the best interest of the patient. Repeated treatment may be given to patients who benefit (either complete or partial response or stabilization of disease)
62436182|NCT03935581|EXPERIMENTAL|ExAblate 4000 System|ExAblate Neuro system to perform AF echo imaging in treatment of Essential Tremor
62436183|NCT01114113|ACTIVE_COMPARATOR|non-trigger meal|"Measurement of intestinal transport eating a non-trigger meal."
62436184|NCT01114113|ACTIVE_COMPARATOR|"trigger meal baseline"|"Measurement of intestinal transport after eating a trigger meal."
62436185|NCT01114113|PLACEBO_COMPARATOR|"trigger meal with placebo"|Measurement of intestinal transport with blinded placebo
62436186|NCT01114113|ACTIVE_COMPARATOR|"trigger meal with enzymes (blinded)"|Measurement of intestinal transport with blinded active enzyme capsule
62436187|NCT05028101|ACTIVE_COMPARATOR|Control (Standard of Care (SOC))|Reconstructive surgical technique, delayed autologous breast reconstruction, and usual local anesthesia and analgesia during hospital stay.
62602492|NCT03438734|ACTIVE_COMPARATOR|Low flow|"Anesthesia was maintained with desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen-air mixture in both groups. While target minimum alveolar concentration (MAC) was 1-1.5 and the flow rate was adjusted to 0.75 L/min. Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.~The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of Bispectral Index (BIS, Bispectral Index, Monitoring System) decreases with the deepening of anesthesia."
62602493|NCT03438734|SHAM_COMPARATOR|Normal flow|"Anesthesia was maintained with desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen-air mixture in both groups. While target minimum alveolar concentration (MAC) was 1-1.5 and the flow rate was adjusted to 1.5 L/min.Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.~The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of Bispectral Index (BIS, Bispectral Index, Monitoring System) decreases with the deepening of anesthesia."
62602494|NCT02039973|EXPERIMENTAL|Task-sharing approach to group therapy|The intervention will consist of problem-solving therapy as well as cognitive behavioral components. Core problem-solving therapy components will involve lay CBHW facilitated discussions to explore symptoms of depression and how problems are related to depression. Core cognitive behavioral components will include lay CBHW facilitated discussions to explain the purpose of the sessions, as well as effect a number of behavioral changes in participants.
62602495|NCT02039973|ACTIVE_COMPARATOR|Enhanced standard of care|The control condition will promote an enhanced standard of care. Clinicians and nurses at MCH clinics included in the study will receive a structured one day re-orientation training consistent with the World Health Organization (WHO) mh-GAP guidelines for assessment as well as basic psychosocial and drug treatment of moderate to severe depression in primary care settings. The training will be consistent with the standard of care for mental health among HIV-positive populations as outlined in Tanzanian health policy. In addition, clinical staff will be trained to encourage women to invite their male partners to accompany them at clinic visits, where psycho-education on perinatal depression for couples will be offered for those opting to participate.
62602496|NCT03578016|EXPERIMENTAL|Circle of Security-Parenting|10 weekly, manualized group sessions at the clinic
62602497|NCT03578016|OTHER|Treatment as Usual (TAU)|TAU consists of clinical assessment and treatment.
62602498|NCT02991417|EXPERIMENTAL|CDVAX|
62602499|NCT04991363|EXPERIMENTAL|Patients|
62602500|NCT02170896|EXPERIMENTAL|Period 1: BIBR1048 MS Capsule A+Pantoprazole|
62602501|NCT02170896|EXPERIMENTAL|Period 1: BIBR1048 MS Capsule B+Pantoprazole|
62602502|NCT02170896|EXPERIMENTAL|Period 1: BIBR1048 MS Capsule C+Pantoprazole|
62602503|NCT02170896|EXPERIMENTAL|Period 1: BIBR1048 MS Capsule D+Pantoprazole|
62602504|NCT02170896|ACTIVE_COMPARATOR|Period 1: BIBR1048 MS solution+Pantoprazole|
62602505|NCT02170896|EXPERIMENTAL|Period 2: BIBR1048 MS Capsule C|
62602506|NCT02170896|EXPERIMENTAL|Period 2: BIBR1048 MS Capsule D|
62602507|NCT02170896|ACTIVE_COMPARATOR|Period 2: BIBR1048 MS solution|
62824311|NCT04532528||SOC with advanced educational intervention|"This group includes Atrial Fibrillation (AF) patients diagnosed within 1 month, under 75 years old, and newly prescribed dabigatran on physician's decision based on local labelling who also received advance educational intervention.~The educational intervention was based on material of the Shared decision making of treatment of New Oral AntiCoagulants (NOAC) in AF patients and Atrial Fibrillation Patient Care in Hospitals. The educational materials were delivered after baseline and at their 3, 6, 9, and 12 months visit."
62824312|NCT06603168|EXPERIMENTAL|Autonomic Recalibration Treatment|"Participant receives Autonomic Recalibration Treatment.~Measurements:~Pre/post shear wave elastography Pre/post myonometry Pre/post motion capture HRV/GSR during ART Pre/post pain ratings Pre/post trigger point log"
62245940|NCT05639413|OTHER|COBRAF|"A 30 mL blood samples (6 mL in each of 5 EDTA tubes) will be collected from each patient at the following timepoints:~* At the starts of cycle 1, 2 and 3,~* At 3 and 6 months after starting of each treatment line, if applicable.~* At disease progression after second-line treatment with encorafenib combined with cetuximab, if applicable.~* At disease progression after immunotherapy-based treatment in dMMR/MSI patients.~At most 390 mL of blood will be collected from each patient during the study."
62245941|NCT05431101|ACTIVE_COMPARATOR|Absorbable sutures|Absorbable sutures Vicryl rapide or Safil quick
62623862|NCT00385827|EXPERIMENTAL|Mitoxantrone+Prednisone+Siltuximab (CNTO 328) (Part 1)|In Part 1, mitoxantrone 12 milligram per square meter (mg/m\^2) will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m\^2) along with siltuximab 6 mg/kilogram (mg/kg) intravenously as a 2 hour-infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year; and prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
62824313|NCT06590545|EXPERIMENTAL|KYV-101, anti-CD19 CAR T-cell immunotherapy.|A dosage of 1x10\^8 KYV-101 CAR+ T cells will be administered intravenously as a single infusion.
62602508|NCT04840420|ACTIVE_COMPARATOR|Intervention|"Inpatient~The WBCs conducts approximately daily visits to:~1. collect demographics and baseline data;~2. co-develop personalised social prescription plan with the participant based on Social Determinants of Health (SDoH) using SBAR4;~3. referring and accompanying the participant to attend inpatient activities that suit the participant's interests and preferences; and~4. informing and seeking the participant's agreement with community assets identified for the participant together with CNS.~About 1-week post-discharge, the WBCs will call to check his/her transition back to community and readiness to start attending community activities or receiving services. For community activities, the WBCs and CNS will visit the participant, accompanying him/her to the activity premise on the first day of the activity session and send the participant home after the session."
62245942|NCT05431101|ACTIVE_COMPARATOR|Non-absorbable sutures|Non-absorbable sutures Ethilon or Flexocrin
62245943|NCT00388505|EXPERIMENTAL|Tobramycin inhalation powder (TIP)|Participants received four 28 mg capsules of tobramycin inhalation powder (TIP) delivered with the T-326 inhaler twice daily for 28 days followed by 28 days off therapy (one cycle) for a total of three cycles.
62245944|NCT00388505|ACTIVE_COMPARATOR|Tobramycin solution for inhalation (TOBI)|Participants received one 300 mg (in 5 mL) ampoule of tobramycin solution for inhalation (TOBI) delivered with a nebulizer twice daily for 28 days followed by 28 days off therapy (one cycle) for a total of three cycles.
62436188|NCT05028101|EXPERIMENTAL|SOC + Functional Medicine|"Reconstructive surgical technique, delayed autologous breast reconstruction, and usual local anesthesia and analgesia during hospital stay.~Perioperative nutrition and lifestyle-based interventions along with select dietary supplements."
62436189|NCT02140489|EXPERIMENTAL|Sequence 1|amosartan → rosuvastatin → amosartan and rosuvastatin
62436190|NCT02140489|EXPERIMENTAL|Sequence 2|rosuvastatin → amosartan and rosuvastatin → amosartan
62436191|NCT02140489|EXPERIMENTAL|Sequence 3|amosartan and rosuvastatin → amosartan → rosuvastatin
62436192|NCT06282796||Anthracycline-Based Breast Cancer Chemotherapy Group|Age ≥18 years, histologically or cytopathologically confirmed stage I-III HER2+ breast cancer, scheduled to receive consecutive anthracycline chemotherapy or subsequent sequential trastuzumab targeted therapy, with a prechemotherapy LVEF≥53%.
62436193|NCT06175702||Complete molecular response and low risk genetics|Patients in Complete Remission and Complete Molecular Response at end Induction therapy will receive consolidation with imatinib (or dasatinib if intolerance) and chemotherapy, unless they show the IKZF1plus genotype, which will imply switch to the not complete molecular response or high-risk genetics (IKZ1plus) group.
62436194|NCT06175702||Not complete molecular response or high-risk genetics (IKZF1plus)|Patients in Complete Remission and without Complete Molecular Response at the end of Induction therapy or showing the IKZF1plus genotype, will receive consolidation treatment with ponatinib and chemotherapy followed by allogeneic stem cell transplantation and maintenance therapy.
62602509|NCT04840420|OTHER|Control|"Usual Care~Inpatient phase For the control group, the interviewer will conduct approximately 2 visits to collect demographics and baseline data. The duration of each visit will range from 15 to 30 minutes.~Community phase For the control group, no intervention will be administered."
62602510|NCT03542331|OTHER|Control group|The control group wille have a mock catheter introduction between day 6 and 8 of the cycle without any Lipiodol flush
62824314|NCT04599010|ACTIVE_COMPARATOR|FFM-indexed feeding|In FFM-indexed feeding, there will be a permissive feeding volume restriction to 150 ± 10 mL/kg (FFM)/day without increasing the milk calorie density or changing the type of formula milk for 2 weeks in the intervention group
62043209|NCT01831622|EXPERIMENTAL|fMRI-arm|"Asterisk applies only for patient group.~Day 1:~* Patient arrives having abstained medication for minimum 20 hours.\*~* Administer either Ritalin or placebo intervention, and wait 60 minutes before MRI testing.\*~* CRF 2, Adult ASRS and WAIS subtests.~* Blood sample, if consented.\*~* Computerized testing.~* Administer opposite treatment to ensure the patients have not been withheld from medication for too long while keeping blind.\*~Day 2 (after 14 - 40 days):~* Patient arrives having abstained medication for a minimum of 20 hours.\*~* Administer either Ritalin or placebo intervention, and wait 60 minutes before testing (opposite of Day 1).\*~* CRF 3, ASRS and EHI.~* Blood sample, if consented.\*~* Computerized testing.~* Administer opposite treatment.\*"
62043210|NCT06152133|EXPERIMENTAL|Telerehabilitation Core stability exercises group|
62043211|NCT06152133|ACTIVE_COMPARATOR|Core stability exercises group|
62436195|NCT01643083|ACTIVE_COMPARATOR|Rifaximin|
62436196|NCT01643083|PLACEBO_COMPARATOR|Placebo|
62436197|NCT05131009||Patients with pulmonary complications following abdominal surgery|
62436198|NCT05131009||Patients without pulmonary complications following abdominal surgery|
62436199|NCT01499927|ACTIVE_COMPARATOR|electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
62436200|NCT01499927|NO_INTERVENTION|no electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents without computerized decision support
62436201|NCT06298279|EXPERIMENTAL|Tunneled Delivery/Standard Resources|"In this arm, participants will be guided through the Self-Guided PSP Wellbeing Course in a predetermined order and using predetermined timing. Future lessons will unlock as previous lessons are completed.~Participants receiving the standard resources will be presented with resources that are typically presented in PSPNET courses. This includes lesson slides case stories, do-it yourself guides, and frequently asked questions pages."
62449169|NCT01290939|EXPERIMENTAL|Arm 1|Lomustine 90 mg/m² every 6 weeks (cap. 160 mg) + bevacizumab 10 mg/kg every 2 weeks (at further progression treatment will be according to investigators discretion). In the absence of hematological toxicity \> grade 1 during the first cycle the dose of lomustine can be escalated to 110 mg/m² (cap 200 mg) in their second cycle.
62602511|NCT03542331|EXPERIMENTAL|Intervention group|The intervention group will undergo endometrial flushing with Lipiodol between day 6 and 8 of the cycle
62043212|NCT05227833|EXPERIMENTAL|Vonoprazan|Vonoprazan (vonaspire 20 mg), tablets, one tablet per day before breakfast for 14 days starting from the day of band ligation.
62436202|NCT06298279|EXPERIMENTAL|Tunneled Delivery/Enhanced Social Learning Resources|"In this arm, participants will be guided through the Self-Guided PSP Wellbeing Course in a predetermined order and using predetermined timing. Future lessons will unlock as previous lessons are completed.~Participants receiving the enhanced social learning resources will receive the same resources offered in the standard conditions (i.e., lesson slides, case stories, do-it-yourself guides, and frequently asked questions pages) and will also receive additional resources. Additional resources will include homework records to accompany the case stories, de-identified quotations from previous clients for each lesson, and a motivational video encouraging them to engage with the course."
62436203|NCT06298279|EXPERIMENTAL|Personalized Delivery/Standard Resources|"In this arm, participants will be able to navigate through the course modules in whichever order and at whatever pace they like. Participants will not have to complete one lesson in order to gain access to the following lesson.~Participants receiving the standard resources will be presented with resources that are typically presented in the course. This includes lesson slides, case stories, do-it yourself guides, and frequently asked questions pages."
62449170|NCT01290939|ACTIVE_COMPARATOR|Arm 2|Lomustine single agent 110 mg/m² every 6 weeks (cap. 200 mg) (at further progression treatment will be according to investigators discretion).
62824315|NCT04599010|ACTIVE_COMPARATOR|Standard feeding|The standard feeding approach will include an oral feeding volume goal of 150 ± 10 mL/kg/day during the 2-week study period
62824316|NCT06596421|EXPERIMENTAL|experiment|abdominal massage
62245945|NCT02605681||septic patients|We recruited the patients admitted to the Department of Critical Care Medicine, Zhongda Hospital, a tertiary hospital, from November 2017 to March 2018. The inclusive criteria were adult patients (age \> 18 years-old and \< 80 years-old) diagnosed with sepsis, according the definition of the Surviving Sepsis Campaign (2016). Exclusive criteria included: 1. age \< 18 years-old or \> 80 years-old; 2. pregnancy or breastfeeding; 3. malignancy; 4. patients with potentially elevated plasma midkine apart from sepsis including acute myocardial infarction, stroke, limb thrombosis, chronic renal dysfunction (baseline plasma creatine ≥2 mg/dL), autoimmune diseases and Alzheimer syndrome; 5. patients deceased or discharge from ICU within 24 hours; or, 6. written consents could not be obtained.
62245946|NCT06387849|EXPERIMENTAL|Aromatherapy group|Two to twelve hours after undergoing C-section, the women enrolled in the experimental arm benefited from aromatherapy with lavender essential oil (EO): The patients were invited to inhale cotton balls, soaked separately with three drops of the EO at a distance of 10 centimeters for 30 minutes.
62245947|NCT06387849|PLACEBO_COMPARATOR|Placebo|Two to twelve hours after undergoing C-section, the women enrolled in the placebo arm were invited to inhale cotton balls, soaked separately with three drops of the distilled water at a distance of 10 centimeters for 30 minutes.
62245948|NCT05245019|EXPERIMENTAL|cardamom group|the pH of saliva will be checked first then they r required to chew cardamom nd after 15 minutes again pH will be checked
62245949|NCT05245019|EXPERIMENTAL|fennel group|the pH of saliva will be checked first then they r required to chew fennel and after 15 minutes again pH will be checked
62245950|NCT03512691|EXPERIMENTAL|Information on CVD risk|Respondents will receive information on the predicted probability of having a heart attack or stroke within 10 years. The predictions will be obtained from the Globorisk tool (www.globorisk.org). All information will be provided within a risk perceptions module of the baseline survey. Only this module will differ across the two treatment groups (information and lottery) and the control group. Information obtained from earlier modules will be retrieved automatically and used to make predictions of CVD risk consistent with the risk factor profile of the respondent.
62245951|NCT03512691|EXPERIMENTAL|Lottery Incentive|Respondents will be offered a ticket for a lottery with a money prize on condition that they visit a specific public health clinic for a checkup. There will be one prize per barangay giving each respondent a one in ten chance of winning P5000 (US$100). The prize is equivalent to approximately 14 days earnings at the regional minimum wage.
62245952|NCT03512691|NO_INTERVENTION|Control|No intervention will be introduced to the participants in this arm.
62245953|NCT03025763||Coronal Nonsyndromic Craniosynostosis, trios|Participants with diagnosis of coronal, nonsyndromic craniosynostosis including affected and unaffected biological parents
62602512|NCT00001656|ACTIVE_COMPARATOR|Olanzapine|
62602513|NCT00001656|ACTIVE_COMPARATOR|Clozapine|
62602514|NCT01659346|EXPERIMENTAL|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3 weeks till eradication
62602515|NCT01659346|ACTIVE_COMPARATOR|Carvedilol|Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
62824317|NCT06596421|NO_INTERVENTION|control|no intervention
62043213|NCT05227833|ACTIVE_COMPARATOR|Pantoprazole|Pantoprazole (Controloc 40 mg OR Antopral 40 mg OR Perloc 40 mg), tablets, one tablet per day before breakfast for 14 days, starting from the day of band ligation.
62602516|NCT04620954|EXPERIMENTAL|Intervention|
62824318|NCT01414803|EXPERIMENTAL|rosuvastatin/fenofibrate combination|rosuvastatin 10 mg/fenofibrate 160 mg per day
62043214|NCT05227833|PLACEBO_COMPARATOR|Placebo|No acid suppressive medications will be described.
62043215|NCT06195982|EXPERIMENTAL|ketone ester|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate, a ketone ester
62043216|NCT06195982|PLACEBO_COMPARATOR|placebo|KE-free solution
62602517|NCT04824755|EXPERIMENTAL|Demographics and clinic characteristics of children in different ages|
62824319|NCT01414803|ACTIVE_COMPARATOR|rosuvastatin monotherapy|rosuvastatin 10 mg per day
62043217|NCT05976282|EXPERIMENTAL|FIT Group|Participants aged 40-65 years will receive the self-administered FIT test by mail including instructions for obtaining and returning their stool specimens. Participants will be in this group for up to 6 months.
62043218|NCT05976282|EXPERIMENTAL|Septin9 Test Group|Participants aged 50-65 years who declined the initial offer of FIT, will complete a 10-15 minute questionnaire about their personal health, quality of life, and health-related to colorectal cancer including screening history and smoking. Participants will be in this group for up to 6 months.
62043219|NCT01936480|EXPERIMENTAL|Moxifloxacin group|Healthy volunteers with QT genotype score in the highest or lowest quintile
62043220|NCT01936480|PLACEBO_COMPARATOR|Placebo group|Healthy volunteers with QT genotype score in the highest or lowest quintile
62436204|NCT06298279|EXPERIMENTAL|Personalized Delivery/Enhanced Social Learning Resources|"In this arm, participants will be able to navigate through the course modules in whichever order and at whatever pace they like. Participants will not have to complete one lesson in order to gain access to the following lesson.~Participants receiving the enhanced social learning resources will receive the same resources offered in the standard conditions (i.e., lesson slides, case stories, do-it-yourself guides, and frequently asked questions pages) and will also receive additional resources. Additional resources will include homework records to accompany the case stories, de-identified quotations from previous clients for each lesson, and a motivational video encouraging them to engage with the course."
62436205|NCT02006966|EXPERIMENTAL|Group L|Intravenous lidocaine infusion group
62436206|NCT02006966|ACTIVE_COMPARATOR|Group C|Intravenous normal saline infusion - control group
62436207|NCT04961229|EXPERIMENTAL|Third dose of BNT162b2 vaccine with Immunosuppression reduction|Third dose of BNT162b2 vaccine with reduction of mycophenolic acid dose
62436208|NCT04961229|EXPERIMENTAL|Third dose of BNT162b2 vaccine without immunosuppression reduction|Third dose of BNT162b2 vaccine without reduction of mycophenolic acid dose
62436209|NCT04961229|EXPERIMENTAL|Third dose of BNT162b2 vaccine|Third dose of BNT162b2 vaccine with no change in immunosuppression for patients that are excluded from the randomised trial
62436210|NCT06541782|EXPERIMENTAL|Dyadic CAT-based Intervention|This arm (n=30) will include dyadic CAT-based intervention only.
62436211|NCT06541782|ACTIVE_COMPARATOR|Psycho-Educational Parent Counseling|This arm (n=30) will include psycho-educational parent counseling only.
62436212|NCT02754791|NO_INTERVENTION|Monthly report|A monthly report will be submitted to department heads describing their departments rate of blood culture contamination and comparing it to blood culture contamination rate in previous months and to blood culture contamination rate of the hospital as a whole
62436213|NCT02754791|EXPERIMENTAL|Steripath|The Steripath device (Magnolia) will be used to take blood cultures in this arm instead of standard methods. This will be in addition to a departmental monthly report (described above).
62436214|NCT02754791|EXPERIMENTAL|Soluprep wipes|In this arm, skin sterilization will be achieved using Soluprep wipes (3M) instead of standard methods (alcohol wipes).This will be in addition to a departmental monthly report (described above).
62436215|NCT03254719|OTHER|Treatment Arm|All participants enrolled in the study will receive chiropractic care consistent with the usual chiropractic procedures for the management of chronic low back pain at the Iowa City VA Health Care System. Participants will also complete study assessments as described in outcomes.
62436216|NCT02991261|EXPERIMENTAL|SPARC001 type I|Treatment type I
62436217|NCT02991261|EXPERIMENTAL|SPARC001 type II|Treatment type II
62436218|NCT02991261|ACTIVE_COMPARATOR|Reference001 type I|Hydrocodone-Acetaminophen
62436219|NCT02991261|ACTIVE_COMPARATOR|Reference type II|Hydrocodone-Acetaminophen
62436220|NCT04523415||patients wiht CT data|all patients with CT data are enrolled with this research, and the classification about proximal humeral fractures are identified.
62436221|NCT03351413|EXPERIMENTAL|Intervention|"LIVE-LiFE to Prevent Falls Among Older Fallers Intervention, which is an individually tailored program at the participant's home spaced across 12 weeks including:~* Home safety assessment and risk reduction strategies; incorporating strength and balance training into daily habits vision screening and referral; and education about fear of falling and falls~* Home repairs, modifications, and low cost assistive devices to address unsafe home environments increasing fall risk~* Medication review and feedback concerning medications with increased fall risk"
62436222|NCT03351413|NO_INTERVENTION|Control|- An individualized fall risk assessment provided to participant and their primary care provider
62436223|NCT05077306|EXPERIMENTAL|music therapy group|Patients receive an individual single session of receptive music therapy in presence.
62436224|NCT05077306|NO_INTERVENTION|Control group|Patients receive standard care
62043221|NCT03031587|EXPERIMENTAL|MRI examination|Each patient coming to the hospital for cardiac MRI examination can participate to the study if he/she meets the eligibility criteria
62043222|NCT01976767||Cohort A|Adults: severe asthmatics on high dose ICS and / or OCS
62436225|NCT04170959|NO_INTERVENTION|A: Observational arm|Radiotherapy as per standard of care without metformin, no additional biomarkers/imaging will be performed
62436226|NCT04170959|OTHER|B: Control arm|Radiotherapy as per standard of care without metformin, with additional biomarkers/imaging
62436227|NCT04170959|ACTIVE_COMPARATOR|C: Interventional arm|Radiotherapy as per standard of care with metformin, with additional biomarkers/imaging
62436228|NCT00206466|ACTIVE_COMPARATOR|One|Taxotere
62436229|NCT02229266|EXPERIMENTAL|NK cells|Infusion of haploidentical NK cells after immunosuppression with cyclophosphamide and fludarabine, followed by immunostimulatory treatment with interleukin-2
62602518|NCT04824755|EXPERIMENTAL|PedEyeQ domain scores|
62602519|NCT04824755|EXPERIMENTAL|Boxes represent first, median, and third quartile values.|
62602520|NCT04824755|EXPERIMENTAL|Parent of kids aged 0-4y and 5-11y PedEyeQ domain scores|
62602521|NCT06301581||Group 1|HiRes Ultra or HiRes Ultra 3D Version V2 newly implanted on this side
62602522|NCT06301581||Group 2|HiRes Ultra or HiRes Ultra 3D Version V2 implanted following an Ultra Version V1 device failure on the same ear
62824320|NCT03162146||Patient admitted to intensive care unit|All patients requiring intensive care unit stay
62602523|NCT05725408|EXPERIMENTAL|Telehealth Group|Participants will be randomized to the telehealth group where they will attend weekly group intervention sessions online through the Zoom platform. Participants will be emailed or mailed materials for session since they will not be attending in-person. Participants will not be asked to attend any sessions or portions of the study in-person.
62602524|NCT05725408|ACTIVE_COMPARATOR|In-Person Group|Participants will be randomized to the in-person group where they will attend weekly group intervention sessions at a building on the Texas A\&M University campus. Participants will be emailed or provided session materials when they arrive for sessions. After the first session, they will not be attending any online sessions.
62602525|NCT05473741||SGA-LAI|Outpatients with schizophrenia treated with second generation long-acting injectable antipsychotics whose psychotic symptoms have remitted.
62602526|NCT00813670|EXPERIMENTAL|Cohort 1: Single dose of XPF-001|
62602527|NCT00813670|EXPERIMENTAL|Cohort 2: Single dose of XPF-001|
62245954|NCT03025763||Coronal, nonsyndromic craniosynostosis|Participants with coronal, nonsyndromic craniosynostosis when biological parents are not available
62245955|NCT03025763||Unaffected controls|Unaffected controls who may have undergone clinically indicated craniofacial surgery for trauma or conditions other than craniosynostosis or bone disease
62043223|NCT01976767||Cohort B|Adults: current smokers or ex-smokers, severe asthmatics on high dose ICS and / or OCS
62245956|NCT02823249|ACTIVE_COMPARATOR|1.56 g L-Tryptophan|"1.56 g L-Tryptophan in 300 mL tap water given via nasogastric tube~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
62245957|NCT02823249|ACTIVE_COMPARATOR|1.56 g L-Leucine|"1.56 g L-Leucine in 300 mL tap water given via nasogastric tube~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
62245958|NCT02823249|ACTIVE_COMPARATOR|50 g Xylitol|50 g Xylitol in 300 mL tap water given via nasogastric tube
62245959|NCT02823249|ACTIVE_COMPARATOR|75 g Erythritol|75 g Erythritol in 300 mL tap water given via nasogastric tube
62245960|NCT02823249|PLACEBO_COMPARATOR|75 g Glucose and mixed liquid meal|"75 g Glucose in 300 mL tap water given via nasogastric tube~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
62245961|NCT02823249|PLACEBO_COMPARATOR|Tap water and mixed liquid meal|"300 mL tap water given via nasogastric tube~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
62245962|NCT02354781|EXPERIMENTAL|Experimental|The vector will be delivered to both limbs via multiple, direct intramuscular injections of rAAV1.CMV.huFollistin344; the number of injections per muscle will depend on the size of the patient. A total dose of 2.4E12 vg/kg (1.2E12vg/kg/limb) will be delivered to the lower limbs of 6 DMD subjects
62436230|NCT02229266|ACTIVE_COMPARATOR|Control Intervention|1 cycle of consolidation chemotherapy with high-dose cytarabine
62436231|NCT04901754|EXPERIMENTAL|Camrelizumab Plus Apatinib|camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally
62436232|NCT03079362||Children|Children who underwent selective dorsal rhizotomy (SDR) including intraoperative neuromonitoring (IOM)
62436233|NCT05936736|EXPERIMENTAL|24 Gy in one fraction, urethral sparing HDR like|Patients with localized prostate cancer - negative PSMA PET CT +/- standard staging exams (bone scan, CT, MRI)-enrolled in this study, will be treated to prostate/prostate seminal vesicles (according to the risk group) to a total dose of 24 Gy delivered in 1 fraction, with a urethral sparing HDR like technique. For unfavorable intermediate and high-risk pts, Androgen Deprivation Therapy (ADT) will be prescribed for 6 and 24 months, respectively. The procedure will be performed in just one day, from fiducials implantation to radiation treatment delivery.
62436234|NCT01535248||All ERCP Patients|All patients that will be approached for this study will be undergoing ERCP as part of their medical care.
62436235|NCT03222167|EXPERIMENTAL|Elbasvir/ Grazoprevir|Elbasvir/ Grazoprevir 50/100 mg fixed dose combination for 12 weeks treatment aimed to evaluate SVR12 in treatment naïve patients with chronic hepatitis C (genotype 1b) infection, associated with metabolic syndrome, with or without severe fibrosis / compensated cirrhosis.
62436236|NCT02872181|EXPERIMENTAL|BMI <30|Pregnant women undergoing C/S with BMI \<30
62436237|NCT02872181|EXPERIMENTAL|BMI 30-40|Pregnant women undergoing C/S with BMI 30-40
62043224|NCT01976767||Cohort C|Adults: non-smokers, mild to moderate asthmatics on regular inhaled corticosteroids (ICS)
62436238|NCT02872181|EXPERIMENTAL|BMI >40|Pregnant women undergoing C/S with BMI \>40
62602528|NCT00813670|EXPERIMENTAL|Cohort 3: Single dose of XPF-001|
62602529|NCT00813670|EXPERIMENTAL|Cohort 4: Single dose of XPF-001|
62602530|NCT00813670|EXPERIMENTAL|Cohort 5: Single dose of XPF-001|
62602531|NCT00813670|EXPERIMENTAL|Cohort A: Repeated doses of XPF-001|
62602532|NCT00813670|EXPERIMENTAL|Cohort B: Repeated doses of XPF-001|
62602533|NCT00813670|EXPERIMENTAL|Cohort C: Repeated doses of XPF-001|
62602534|NCT05062330|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days|
62043225|NCT01976767||Cohort D|Adults: healthy volunteers, non-smokers, non-asthmatic with pre bronchodilator FEV1 \> 80% predicted
62043226|NCT00699959||1|patients with heart failure
62245963|NCT05075395|EXPERIMENTAL|Intervention|The Physical Therapy/Occupational Therapy (PT/OT) provider will assess whether the patient meets eligibility criteria. If the patient is eligible to participate, they will then introduce the study to the patient and their parent or guardian. If the patient is interested in participating, the PI or PI's research assistant (RA) will seek written informed consent. After informed consent is obtained, the PI or RA will begin pretest data collection. Then, the PT/OT provider will begin the therapy session with Paro. The PI or RA will remain in the room during therapy session to record field notes. When the therapy session is complete, the PI or RA will begin posttest data collection. The patient will remain in the study for up to 7 PT/OT sessions or until they are discharged from the PICU. The PT/OT providers will coordinate all subsequent therapy sessions with the PI/RA while the patient remains on the study protocol.
62245964|NCT04042740|EXPERIMENTAL|Glecaprevir/Pibrentasvir (G/P)|"Participants were assigned to receive G/P FDC tablets to be taken orally once daily for 4 weeks (Step 1).~Participants who experienced HCV re-infection, suspected relapse, virologic failure, or undefined post-treatment viremia in Step 1 were offered to enter Step 2 for re-treatment. HCV re-treatment regimens may have included G/P FDC tablets orally once daily for 8-16 weeks, or alternate regimens through clinical care."
62043227|NCT00699959||2|patients without heart failure
62436239|NCT04364165|EXPERIMENTAL|Standard of care messaging|On mobile clinic days randomized to standard of care messaging, participants will receive standard invitation cards distributed at the Tutu Tester containing basic information encouraging HIV testing. Messages will encourage men to come in for HIV testing at the mobile clinic on the same day. A mobile clinic recruiter will deliver the standard invitation card and share a brief script including the standard Tutu Tester message that free HIV testing is available at the Tutu Tester, with no further information or motivation to test.
62436240|NCT04364165|EXPERIMENTAL|U=U messaging|On mobile clinic days randomized to U=U messaging, participants will receive the U=U invitation cards distributed at the Tutu Tester that will seek to assuage the fears of testing HIV positive by conveying the message that HIV treatment makes it possible for HIV positive people to be untransmittable and to live normal lives. Messages will encourage men to come in for HIV testing at the mobile clinic on the same day. A mobile clinic recruiter will deliver the U=U invitation card and share a brief script asking people if they knew they could control HIV and that pills exist that can keep them healthy and ensure they don't transmit the virus to their sex partners, and that free HIV testing is available at the Tutu Tester.
62436241|NCT03349177|EXPERIMENTAL|FEC group|Fluorouracil 500mg/m2 on day 1, epirubicin 100mg/m2 on day 1 and cyclophosphamide 500mg/m2 on day 1 every 3 weeks for six cycles
62436242|NCT03349177|EXPERIMENTAL|EC-T group|Epirubicin 100mg/m2 on day 1 cyclophosphamide 600mg/m2 on day1 every 2 weeks for four cycles followed by docetaxel 100mg/m2 on day 1 every 3 weeks for four cycles
62436243|NCT03349177|EXPERIMENTAL|TC group|Docetaxel 75mg/m2 on day 1 and cyclophosphamide 600mg/m2 on day 1 every 3 weeks for six cycles
62436244|NCT04229303|EXPERIMENTAL|Part 1 - ZP-059 5mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 1: 5mg (1 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
62436245|NCT04229303|EXPERIMENTAL|Part 1 - ZP-059 10mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 2: 10mg (2 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
62436246|NCT04229303|EXPERIMENTAL|Part 1 - ZP-059 20mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 3: 20mg (4 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
62436247|NCT04229303|EXPERIMENTAL|Part 1 - ZP-059 40mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 4: 40mg (8 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
62436248|NCT04229303|EXPERIMENTAL|Part 2 - ZP-059 10mg bid|"Part 2: administration of multiple ascending doses (MAD) of ZP-059 on Days 1 to 10.~Cohort 1: 10mg (2 x 5 mg capsule) ZP-059 twice daily (bid) administered via DPI (RS01 monodose device) for 9 days and once in the morning of Day 10."
62436249|NCT04229303|EXPERIMENTAL|Part 2 - ZP-059 20mg bid|"Part 2: administration of multiple ascending doses (MAD) of ZP-059 on Day 1 to 10.~Cohort 2: 20mg (4 x 5 mg capsule) ZP-059 twice daily (bid) administered via DPI (RS01 monodose device) for 9 days and once in the morning of Day 10."
62602535|NCT05062330|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution administered 7 times over two consecutive days|
62602536|NCT03308318||the supratemporalis approach|patients operated upon with zygomaticofacial or craniofacial fractures using the supratemporalis approach
62043228|NCT04227015|EXPERIMENTAL|Administration of CTA101|Dose escalation follows the standard 3+3 dose escalation design. A total of 2 dose levels are set for subjects.
62043229|NCT02539810|EXPERIMENTAL|Renal artery stenting|"Renal artery angioplasty plus stenting and standardized and optimized medication regimen.~Patients are treated with renal artery stenting plus a standardized optimal medical treatment, including the antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits."
62043230|NCT02539810|ACTIVE_COMPARATOR|standardized and optimized medication regimen|Patients are treated with a standardized optimal medical treatment including the antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
62043231|NCT06579833|OTHER|Histotripsy|Histotripsy is a promising non-invasive technique that uses high-intensity ultrasound waves to disrupt tissue without damaging surrounding structures
62043232|NCT02794376|EXPERIMENTAL|Immediate Treatment Group|Mindfulness course consisting of six weekly two hour mindfulness sessions plus meditation homework assignments.
62043233|NCT02794376|OTHER|Delayed Treatment Group|Waiting period plus Mindfulness course consisting of six weekly two hour mindfulness sessions plus meditation homework assignments after the waiting period has finished.
62043234|NCT01918410|ACTIVE_COMPARATOR|Contact Lens with alginic acid|
62043235|NCT01918410|PLACEBO_COMPARATOR|Contact lens without alginic acid|
62043236|NCT04216810|ACTIVE_COMPARATOR|Exercise group|Exercise group
62043237|NCT04216810|EXPERIMENTAL|Exercise group and dry cupping|Exercise and dry cupping
62043238|NCT03963908|EXPERIMENTAL|Intervention|AtEase is a mobile app designed to promote pain self-management, healthy sleep habits, and effective stress management. It includes a tailored Newsfeed that updates regularly with articles, activities, videos, and quizzes chosen for the user; a chat feature that asks questions and provide tailored feedback; a Message Center; and a Pain Tracker. Users can interact with AtEase as often as they like for six months.
62043239|NCT03963908|ACTIVE_COMPARATOR|Comparison|Chronic Pain Education for Veterans is a VA-endorsed pain management online educational curriculum that provides CBT pain self-management materials. Users randomized to the comparison condition will have unlimited access for 6 months.
62043240|NCT01485042|EXPERIMENTAL|Dose Escalation|This is a Phase 1 dose escalation with an expanded cohort that will enroll at MTD.
62043241|NCT04846959||Pregnant Women Exposed to Risankizumab|Pregnant women of any age in the United States (US) who are diagnosed with plaque psoriasis, psoriatic arthritis, Crohn's disease, or other conditions for which risankizumab is an FDA-approved treatment and exposed to risankizumab at any time during pregnancy.
62436250|NCT04229303|EXPERIMENTAL|Part 2 - ZP-059 40mg qd|"Part 2: administration of multiple ascending doses (MAD) of ZP-059 on Day 1 to 10.~Cohort 3: 40mg (8 x 5 mg capsule) ZP-059 once daily (qd) administered via DPI (RS01 monodose device) on Days 1 to 10."
62436251|NCT04229303|EXPERIMENTAL|Part 3 - ZP-059 / Oral Voriconazole|Crossover treatment period: Single inhaled dose (20 mg) of ZP-059 5mg capsules administered via DPI, and a single dose of oral voriconazole (200 mg Vfend® tablet) on the morning of Day 1 of the respective treatment period with a washout period of at least 96 hours.
62436252|NCT04229303|EXPERIMENTAL|Part 3 - Oral Voriconazole / ZP-059|Crossover treatment period: Single dose of oral voriconazole (200 mg Vfend® tablet), and a single inhaled dose (20 mg) of ZP-059 5mg capsules administered via DPI on the morning of Day 1 of the respective treatment period with a washout period of at least 96 hours.
62436253|NCT04528628|EXPERIMENTAL|MDD with melancholic features|
62436254|NCT04528628|EXPERIMENTAL|MDD with atypical features|
62436255|NCT04528628|EXPERIMENTAL|MDD with anxious distress|
62436256|NCT04528628|EXPERIMENTAL|MDD (overall)|
62436257|NCT04650100|EXPERIMENTAL|PENG group|For the PENG group, the ultrasound-guided PENG block (20 ml of Ropivacaine 4.75 mg/ml) is performed before the surgery.
62436258|NCT04650100|NO_INTERVENTION|Control group|No additional intervention, only standard care
62436259|NCT03751020|EXPERIMENTAL|Expressive Writing (EW)|Expressive Writing (EW) prompts individuals to write about personally stressful events, potentially enabling cognitive processing of unresolved, psychological and physiological stressors.
62436260|NCT03751020|EXPERIMENTAL|Self-Affirmation (SA)|Self-Affirmation (SA) interventions prompt individuals to write advice to a (hypothetical) similarly stigmatized person regarding how best to cope with stigma-related stress. By affirming one's own stigmatized identity through the process of helping another similarly stigmatized person.
62436261|NCT03751020|PLACEBO_COMPARATOR|Control|Participants randomly assigned to the control condition will be asked to write about what they have done since waking up that morning for 20 minutes across 3 consecutive days.
62436262|NCT04711629|EXPERIMENTAL|Smoker COPD|Patients who continue to smoke
62436263|NCT04711629|ACTIVE_COMPARATOR|Ex-smoker COPD|Patients who quit smoking.
62602537|NCT06648525|EXPERIMENTAL|Group A: Adebrelimab+Irinotecan liposomes+5-fluorouracil+calcium folinate+lenvatinib|Adebrelimab in combination with Irinotecan liposomes, 5-fluorouracil, calcium folinate and lenvatinib
62043242|NCT04846959||Pregnant Women Not Exposed to Risankizumab|Pregnant women of any age in the US who are diagnosed with plaque psoriasis, psoriatic arthritis, Crohn's disease, or other conditions for which risankizumab is an FDA-approved treatment and not exposed to risankizumab, but who are exposed to other medications in the same class or line of therapy as risankizumab at any time during pregnancy.
62043243|NCT05741879|EXPERIMENTAL|Gamified online exercise in a family environment|Strength training Resistance training Flexibility training Basic motor skills training Executive function training
62043244|NCT05741879|ACTIVE_COMPARATOR|Standard care Non-supervised daily routines/activities|Non-supervised daily routines/activities
62043245|NCT02919800|EXPERIMENTAL|MOD-5014|MOD-5014 longevity is the result of fusion of three consecutive C-terminal peptide (CTP) domains to the C-terminus of FVII. CTP technology is based on a natural peptide, the C-terminal peptide of the beta chain of human chorionic gonadotropin (hCG), which provides hCG with the required longevity to maintain pregnancy (initial half-life \[t1/2\] \~10 h, terminal t1/2 \~37 h). The beta chain of luteinizing hormone (LH), a gonadotropin that triggers ovulation, is almost identical to hCG but does not include the CTP. As a result, LH has a significantly shorter half-life in blood (initial t1/2 \~1 h, terminal t1/2 \~10 h) (Fares et al., 1992).
62043246|NCT02919800|PLACEBO_COMPARATOR|MOD-5014 Placebo|Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
62043247|NCT03722927|EXPERIMENTAL|Bupivacaine Group|Participants will be randomized to the Bupivacaine Group and receive a bilateral mastectomy with immediate implant based breast reconstruction
62043248|NCT03722927|EXPERIMENTAL|Liposomal Bupivacaine Group|Participants will be randomized to the Liposomal Bupivacaine Group and receive a bilateral mastectomy with immediate implant based breast reconstruction
62436264|NCT01381822|EXPERIMENTAL|TH-302 Dose escalation|The initial dose of TH-302 will be 240 mg/m2. A Dose Level minus 1 and 2 will be built into the study in the event that subjects experience excessive toxicity at Dose Level 1. Dose escalation will continue with approximately 40% increases from the previous dose level; however lower dose increases of 20-39% may be implemented after consultation between the Investigators, Medical Monitor and Sponsor with the percent increase dependent on the current dose level and the cumulative safety data.
62449171|NCT02331537|EXPERIMENTAL|Internet-based cognitive-behavior therapy|The experimental group will go through active internet-based treatment. The treatment is 10 weeks long and is based on the principles of exposure i.e. the participant is instructed to stay with the frightening thought until it is no longer associated with anxiety.
62602538|NCT06648525|EXPERIMENTAL|Group B: Adebrelimab+Irinotecan liposomes+5-fluorouracil+calcium folinate|Adebrelimab in combination with Irinotecan liposomes, 5-fluorouracil and calcium folinate
62824321|NCT06603428|EXPERIMENTAL|Operative and Nonoperative Management in Isolated Greater Tuberosity Fracture of Humerus Bone.|Patients more than 5 ml displacement of GT fracture (3ml in active highly demanded patient) are for internal fixation, others less this are for conservative management.
62824322|NCT06593197|EXPERIMENTAL|Apremilast with phototherapy|
62824323|NCT06593197|ACTIVE_COMPARATOR|Phototherapy alone|
62824324|NCT02231515|EXPERIMENTAL|Pattern laser trabeculoplasty (PLT)|Pattern laser trabeculoplasty
62824325|NCT02231515|ACTIVE_COMPARATOR|Selective laser trabeculoplasty (SLT)|Selective laser trabeculoplasty (SLT)
62824326|NCT04318678|OTHER|CD123-CAR T cell therapy|CD123-CAR T-cell dose and infusion Up to 4 Dose levels will be evaluated with a maximum dose of 2.5 x 10\^8 CAR+ T cells. If dose limiting toxicities (DLTs) are observed on Dose level 1 then the cell dose is de- escalated.
62824327|NCT04611386||rivaroxaban group|20 rivaroxaban using patients
62824328|NCT04611386||apixaban group|20 apixaban using patients
62824329|NCT04611386||edoxaban group|20 edoxaban using patients
62824330|NCT04611386||control group|5 control group patients
62824331|NCT03889223|ACTIVE_COMPARATOR|The LDF neuraxial positioning technique|In the LDF neuraxial positioning technique, fifty participants were planned to lay down the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist. Volunteers jaw touch to chest and legs in abdominal flexion with hands are on the knees. The position is completed with the back curved in the fetal position. Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 7-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 15 weeks.
62602539|NCT01318213||Intervention Arm|The intervention will consist of wearing gloves and gowns for all patient contact in the ICUs that are randomized to receive the intervention. During the intervention phases of the study, all healthcare workers (nurses, physicians, nurse extenders, respiratory therapists, social workers etc.) in the intervention group will be required to wear gloves and gowns for patient contact and when entering any patient room. In essence, healthcare workers will apply the CDC Contact Precautions guidelines for ALL patients.
62043249|NCT02077179|NO_INTERVENTION|Standard of Care|Participants in this arm will receive care as per the usual standards from Kingston General Hospital and their primary care provider.
62043250|NCT02077179|EXPERIMENTAL|HIP Program|Participants in this arm will follow the HIP Program in addition to their usual care from Kingston General Hospital and their primary care provider.
62043251|NCT04547608|OTHER|group PRi|received immediate injection of rocuronium after propofol administration,
62602540|NCT01318213||Non-intervention - Usual Standard of Care|The non-intervention units will follow their present standard of care. For all of these units, this will consist of healthcare workers following Contact Precautions (gloves and gowns) only for patients known to have antibiotic-resistant bacteria such as VRE and MRSA based on previous admission clinical and surveillance cultures or clinical cultures from the present admission. This represents on average 20-25% of patients on Contact Precautions. For the rest of the patients standard precautions will be followed.
62602541|NCT05136144|EXPERIMENTAL|SM-020|Topical Akt Inhibitor SM-020 Gel
62602542|NCT04777669|EXPERIMENTAL|Experiment|Subjects will be tested for their ability to understand speech with and without noise reduction
62602543|NCT00777322|EXPERIMENTAL|Interventional study|Patients with known keratoconus or pellucid marginal degeneration will be invited to join the study. The study is partly a continuation in the management of patients who have had previous keratophakia, who will have near-normal or supra-physiological levels of corneal thickness. It is also intended for patients with relatively mild keratoconus who have sufficient corneal thickness to allow a limited laser ablation whilst still leaving a residual stromal bed of at least 350μ.
62602544|NCT05769621||PA Participants|Participants with PA who meet all eligibility criteria for medical record abstraction.
62602545|NCT05769621||MMA Participants|Participants with MMA who meet all eligibility criteria for medical record abstraction.
62602546|NCT05742568|EXPERIMENTAL|High-dose dual therapy|Esomeprazole Enteric Tablets 40mg, 3 times/day; Amoxicillin Capsules 1000mg, 3 times/day.The course of all drugs is two weeks.
62602547|NCT05742568|ACTIVE_COMPARATOR|Bismuth Quadruple Therapy|Esomeprazole Enteric Tablets 40mg, 2 times/day; Amoxicillin Capsules 1000mg, 2 times/day; Clarithromycin Tablets 500mg, 2 times/day; Colloidal Bismuth Tartrate Capsules 220mg, 2 times/day.The course of all drugs is two weeks.
62602548|NCT02422810||No aspirin|Subjects who have not taken aspirin or other blood thinners in the previous 10 days
62602549|NCT02422810||Aspirin Daily|Subjects who have taken aspirin daily for the previous 10 or more days
62602550|NCT02422810||New to aspirin|Subjects newly started on aspirin during their visit
62602551|NCT01067261|EXPERIMENTAL|TMNS and pelvic floor muscle training|This group will receive both the normal pelvic floor muscle training and the TMNS vibration therapy following their radical prostatectomy. Treatment with TMNS will start before the surgery and continue 6 weeks after the surgery.
62602552|NCT01067261|ACTIVE_COMPARATOR|Pelvic floor muscle training only|This group will receive the normal pelvic floor muscle training after prostatectomy only.
62602553|NCT02549976|EXPERIMENTAL|Evaluation group|"Digestive damage will be assessed on patients by using the methods described in the Lemann index protocol, dependant of Crohn's disease locations.~All patients will have clinical examination and abdominal magnetic resonance imaging analyses. Upper endoscopy, colonoscopy, and pelvic magnetic resonance imaging analyses will be performed according to disease locations :~* Upper tract location : upper endoscopy~* Colorectal location : colonoscopy~* Perianal location : pelvic MRI~* All patients : abdominal MRI"
62602554|NCT00549913|EXPERIMENTAL|1|10 subjects to receive lowest dose of NeoFuse (MPCs)
62602555|NCT00549913|ACTIVE_COMPARATOR|2|4 subjects standard posterolateral spinal fusion with instrumentation
62043252|NCT04547608|OTHER|group PRd|rocuronium injection when bispectral index score became below 60 after propofol administration
62043253|NCT00003500|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62043254|NCT02186210|EXPERIMENTAL|prewarming|prewarming during induction of anesthesia
62602556|NCT00549913|EXPERIMENTAL|3|10 subjects to receive middle dose of NeoFuse
62602557|NCT00549913|ACTIVE_COMPARATOR|4|3 subjects standard posterolateral spinal fusion with instrumentation
62602558|NCT00549913|EXPERIMENTAL|5|10 subjects to receive highest dose of NeoFuse
62602559|NCT00549913|ACTIVE_COMPARATOR|6|3 subjects with standard posterolateral spinal fusion with instrumentation
62602560|NCT04608344|EXPERIMENTAL|Sequence AB|Participants will receive atorvastatin (ATV) 40 mg tablet on Day 1, followed by a washout period of 1 day, and then pravastatin (PRA) 40 mg + rosuvastatin (ROS) 10 mg tablets on Day 3 in Treatment A, Period 1. In Treatment B, Period 2 participants will receive filgotinib 200 mg tablet once daily for 11 days, with ATV 40 mg on Day 12 and PRA 40 mg + ROS 10 mg tablets on Day 14. Period 1 and Period 2 will be separated by a washout period of 3 days.
62043255|NCT02186210|NO_INTERVENTION|control|no prewarming during induction of anesthesia
62043256|NCT03211286|ACTIVE_COMPARATOR|TXA group|Tranexamic acid, a single dose of 1 g intravenous diluted in 100 mL saline solution at the time of surgical incision
62043257|NCT03211286|PLACEBO_COMPARATOR|Control group|Saline solution, 100 mL intravenous at the time of surgical incision
62043258|NCT03610087|OTHER|Low Intensity Intervention|The comparison group (low intensity) receives access to the e-platform and given an educational package with information about nutrition, physical activity, and smoking based on the NAVIGATE program (Mueser et al., 2015); i.e., a comprehensive program for implementing coordinated speciality care) with weekly e-mail reminders for 12 weeks. Participants receive access to online resources and free online webinars about these healthy behaviours.
62043259|NCT03610087|EXPERIMENTAL|High Intensity Intervention|The intervention group (high intensity) receives a technology-enabled CCM intervention. Participants receive access to an online platform and infographic modules to learn more about nutrition, physical activity, and smoking cessation. Also, they are assigned a personal health coach who collaboratively schedules weekly virtual sessions via the platform to discuss the educational materials, goal setting and motivation, and provide support in the 12-week program. The participant's health coach reviews the participant's concerns and goals weekly with a virtual care team (VCT; including a psychiatrist, addictions specialist, nutrition specialist, peer mentor, and recreational therapist), who provides individualized recommendations to include in the participant's treatment plan. Participants have access to online resources and online webinars about nutrition, physical activity and smoking.
62043260|NCT02316795|EXPERIMENTAL|SLN biopsy with ICG injection|"During the SLN biopsy, the patient will undergo injection of ICG around the breast tumor or melanoma per standard techniques. 1.6 mL of 500 micro-molar ICG will be injected periareolarly (for breast cancer) or peri-tumorly (for melanoma). This will be performed after standard of care technetium-colloid injection. Patients will then undergo the standard SLN biopsy procedure.~After gamma-probe identification of the SLN, the surgeon will put on the goggle system to attempt to identify the SLN using fluorescence guidance. After this is performed, the goggle system will be removed and the SLN biopsy will be completed per standard techniques. Findings with the goggles will be recorded but will not change how the SLN biopsy is performed."
62043261|NCT04515459|OTHER|Patients treated for bone or soft-tissue sarcoma of the limbs|
62043262|NCT00885196|EXPERIMENTAL|AEB071 200 mg BID|
62043263|NCT00885196|EXPERIMENTAL|AEB071 400 mg OD|
62043264|NCT00885196|EXPERIMENTAL|AEB071 300 mg BID|
62043265|NCT00885196|PLACEBO_COMPARATOR|Placebo BID|
62043266|NCT01506895|EXPERIMENTAL|darapladib|darapladib dosed at 160 mg once daily
62245965|NCT02237404|NO_INTERVENTION|Hospital monitoring of pacemakers|Patients have to go to the hospital to be monitorized
62245966|NCT02237404|EXPERIMENTAL|Remote monitoring of pacemakers|"Telemedicine System:~Patients have not to go to the hospital to be monitorized"
62602561|NCT04608344|EXPERIMENTAL|Sequence BA|Participants will receive filgotinib 200 mg tablet once daily for 11 days, with ATV 40 mg on Day 6 and PRA 40 mg + ROS 10 mg tablets on Day 8 in Treatment B, Period 1. In Treatment A, Period 2 participants will receive ATV 40 mg tablet on Day 18, followed by a washout period of 1 day and PRA 40 mg + ROS 10 mg tablets on Day 20. Period 1 and Period 2 will be separated by a washout period of 6 days.
62824332|NCT03889223|EXPERIMENTAL|The SCF neuraxial positioning technique|In the SCF neuraxial positioning technique, the same fifty participants were planned to sit on the same part of the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs crossed, forearms of the participants are on the lap and hands are on the knees, and the position is completed with the back curved in the fetal position.Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 7-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 15 weeks.
62043267|NCT01506895|PLACEBO_COMPARATOR|placebo|Placebo to match once daily
62245967|NCT01708291|ACTIVE_COMPARATOR|Mindfulness Based Stress reduction|attending 10 weekly sessions and comprised of an eight week mindfulness intervention program, and completing pre- and postevaluation measures on the first and last sessions
62245968|NCT01708291|PLACEBO_COMPARATOR|No Mindfulness based intervention|completing only re- and post-evaluation measures on the first and last sessions
62245969|NCT00448435|ACTIVE_COMPARATOR|SLM+FP First|SLM(salmeterol) 25mcg + FP(fluticasone propionate) 50mcg twice daily in first intervention period and SFC(salmeterol/fluticasone propionate) 25/50mcg twice daily in second intervention period and (after washout period).
62245970|NCT00448435|ACTIVE_COMPARATOR|SFC First|SFC (Salmeterol/Fluticasone propionate combination) 25/50mcg twice daily in first intervention period and SLM (Salmeterol) 25mcg + FP (Fluticasone Propionate) 50mcg twice daily in second intervention period (after washout period).
62245971|NCT00448435|EXPERIMENTAL|SFC|SFC (salmeterol/fluticasone propionate combination) 25/50mcg twice daily in Extension period (after cross-over period).
62245972|NCT01817283|PLACEBO_COMPARATOR|placebo + cART|combined with antiretroviral therapy, the control group will take placebo 2 tabs tid per day lasting for 6 months and then switch to take Triplitode 2 tabs tid po for anther 6 months
62824333|NCT06194188|EXPERIMENTAL|Low Dose Group|0.06mg/ml/dose, the number of doses administered (no more than 36 doses) will be determined after the area has been assessed by the investigator based on the subject's submental fat accumulation
62824334|NCT06194188|EXPERIMENTAL|High Dose Group|0.08 /ml/dose, the number of doses administered (no more than 36 doses) will be determined after the area has been assessed by the investigator based on the subject's submental fat accumulation
62824335|NCT06194188|PLACEBO_COMPARATOR|Placebo group|0/ml/dose, the number of doses administered (no more than 36 doses) will be determined after the area has been assessed by the investigator based on the subject's submental fat accumulation
62245973|NCT01817283|EXPERIMENTAL|Triptolide + cART|combined antiretroviral therapy, the experimental group will take Triptolide 2 tabs tid po per day for 12 months.
62824336|NCT00998686|EXPERIMENTAL|dutogliptin/PHX1149T|
62824337|NCT00998686|ACTIVE_COMPARATOR|sitagliptin|
62824338|NCT05220436|EXPERIMENTAL|DISCOVER workshop programme|"As this is a case series study, all participants will receive the intervention (i.e. no other arms to the study design).~The DISCOVER workshop programme includes: 1:1 mental health and emotional well-being assessment session with a Clinical Psychologist, a group workshop day, follow-up supportive phone calls and a closing follow-up 1:1 mental health and emotional well-being session with a Clinical Psychologist."
62824339|NCT04838405|EXPERIMENTAL|CT-388|SC dose of CT-388
62824340|NCT04838405|PLACEBO_COMPARATOR|Placebo|SC dose of placebo matching CT-388 dose
62824341|NCT04838405|EXPERIMENTAL|CT-388 Optional|SC dose of CT-388
62245974|NCT03661944||Symptomatic group|There is no intervention in this group, only functional assessments and general physical examinations will be done
62245975|NCT03661944||Healthy control group|There is no intervention in this group, only functional assessments and general physical examinations will be done
62436265|NCT04965610|EXPERIMENTAL|Preoxygenation via THRIVE/High Flow Nasal Cannula|Patients receive preoxygenation for induction of general anaesthesia via High Flow Nasal Cannula for the duration of 5 minutes. After that the induction agents will be given. Now arterial blood gases will be drawn every 2 minutes and the SpO2 will be measured until the 6th apnoeic ABG or if the SpO2 decreases to 92%. After that normal intubation follows.
62436266|NCT04965610|ACTIVE_COMPARATOR|Preoxygenation via face mask (PROX)|Patients receive preoxygenation for induction of general anaesthesia via tight fitting face mask for the duration of 5 minutes. After that the induction agents will be given. Now arterial blood gases will be drawn every 2 minutes and the SpO2 will be measured until the 6th apnoeic ABG or if the SpO2 decreases to 92%. After that normal intubation follows.
62824342|NCT04838405|EXPERIMENTAL|CT-388 MD|SC dose of CT-388
62824343|NCT01969136|EXPERIMENTAL|Experimental: EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
62824344|NCT01969136|EXPERIMENTAL|Experimental: EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
62824345|NCT01969136|PLACEBO_COMPARATOR|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 182
62824346|NCT05805176|EXPERIMENTAL|ADHD Therapy|
62824347|NCT06601725||Phenotype A|Phenotype A was characterized by metabolic syndrome
62245976|NCT01717287|EXPERIMENTAL|Raltegravir Film-coated Tablet|Raltegravir film-coated tablet 400 mg administered orally twice-daily, in combination with other anti-retroviral therapy for 24 weeks
62245977|NCT01717287|EXPERIMENTAL|Raltegravir Chewable Tablet|Raltegravir chewable tablet weight-based dose up to 300 mg administered orally twice-daily, in combination with other anti-retroviral therapy for 24 weeks
62602562|NCT00814944|EXPERIMENTAL|Dose Group 1|
62602563|NCT00814944|EXPERIMENTAL|Dose Group 2|
62824348|NCT06601725||Phenotype B|phenotype B was characterized by the absence of metabolic syndrome
62824349|NCT06601725||Phenotype C|phenotype C was characterized by hyperandrogenism
62245978|NCT04634396|OTHER|Experimental TACTICs|Telephone Acceptance and Commitment Therapy Intervention for Caregivers of adults with dementia (TACICS. Participants will receive a manualized acceptance and commitment therapy intervention delivered via phone in 6 weekly 1 hour sessions by a trained interventionalist
62824350|NCT06601725||Phenotype D|phenotype D was characterized by the absence of hyperandrogenism
62824351|NCT02081677|ACTIVE_COMPARATOR|etafilcon A|Marketed control soft contact lens
62824352|NCT02081677|EXPERIMENTAL|Prototype E1|Investigational soft contact lens
62824353|NCT02081677|EXPERIMENTAL|Prototype E2|Investigational soft contact lens
62824354|NCT02081677|EXPERIMENTAL|Prototype E3|Investigational soft contact lens
62824355|NCT06587061|EXPERIMENTAL|Arm A|HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
62824356|NCT04639245|EXPERIMENTAL|Treatment (FH-MagIC TCR-T cells, atezolizumab)|"LYMPHODEPLETION: Patients receive cyclophosphamide IV and fludarabine IV on days -4, -3, and -2 before each T-cell infusion.~T-CELL INFUSION: Patients receive FH-MagIC TCR-T cells IV over 15-20 minutes. Six to twelve weeks after first T-cell infusion, patients with progressive disease and non-persisting transgenic TCR T cells may receive a second T-cell infusion.~In the Phase 2 portion of the study, atezolizumab will be administered as standard of care beginning 24-72 hours after T-cell infusion. Atezolizumab will be given IV every 3 weeks for at least 1 year in the absence of disease progression or unacceptable toxicity. An alternative PD1 inhibitor may be substituted if atezolizumab (preferred) is not available."
62824357|NCT00705055||1|Normal Males
62824358|NCT00705055||2|Normal Females
62824359|NCT00705055||3|Abnormal Males
62824360|NCT00705055||4|Abnormal Females
62824361|NCT03798951|EXPERIMENTAL|Prehabilitation program|The patients included in the treatment group will follow a prehabilitation program, based on a physiotherapist, nutritionist and psychologist evaluation. All the treatments will be tailored according the characteristics of each single patient. The program will have a duration of, at least, 4 weeks.
62824362|NCT03798951|NO_INTERVENTION|Control|The patients included in this group will, also, receive a basal evaluation by a physiotherapist, a nutritionist and a psychologist. These patients will not receive a tailored prehabilitation program and will be revaluated the day before surgery.
62824363|NCT06591481||Active axSpA patients|Participants diagnosed with axSpA (according to ASAS criteria for axSpA) showing active lesions in their MRI exams.
62824364|NCT06591481||Control|This group is composed by: 1) Participants with buttock or low back pain that not fulfil ASAS criteria for axSpA and 2) axSpA patients that do not show active lesions in their MRI exams.
62824365|NCT01254136|EXPERIMENTAL|Treatment A - INCB007839 300mg BID|This is a single arm, open label study in which all patients will receive a single dose of the investigational product INCB007839 in combination with a standard regimen of trastuzumab and vinorelbine.
62824366|NCT04023669|EXPERIMENTAL|A: prexasertib + cyclophosphamide|"Stratum A: Participants receive combination treatment with cyclophosphamide given intravenously (IV) on days 1 and 15 and prexasertib given intravenously (IV) on days 2 and 16. Cycles repeat every 28 days for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity. They may also receive growth therapy support with filgrastim or peg-filgrastim.~Note: Only if absolutely necessary, cyclophosphamide may be given on day 16 and prexasertib may be given on day 17."
62824367|NCT04023669|EXPERIMENTAL|B: prexasertib + gemcitabine|"Stratum B: Participants receive combination treatment with gemcitabine given intravenously (IV) on days 1 and 15 and prexasertib given intravenously (IV) on days 2 and 16. Cycles repeat every 28 days for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity. They may also receive growth therapy support with filgrastim or peg-filgrastim.~Note: Only if absolutely necessary, gemcitabine may be given on day 16 and prexasertib may be given on day 17."
62043268|NCT04499651|NO_INTERVENTION|Control|All people who are living with HIV who are currently in custody in the Los Angeles County Jail are provided with Transitional Case Management and may also receive Whole Person Care related services regardless of participation in this study. Participants recruited from clinics who do not enroll in the study will be offered HIV/HCV care that follows the national HIV/HCV care guidelines, as provided by participating study clinics. Participants recruited from non-medical community agencies who do not enroll in the study and do not have a regular provider will receive a referral list of HIV/HCV care facilities that follow the national HIV/HCV care guidelines.
62043269|NCT04499651|ACTIVE_COMPARATOR|Navigation|"Participants will be paired with a navigator and will complete the following didactic sessions in one-on-one format:~1. Session 1: Intervention Overview and Basic HIV/HCV Knowledge and Skills Builder~2. Session 2: Rapport Building~3. Session 3: Society and Self and the Role of Disclosure~4. Session 4: Accompaniment 1~5. Session 5: Goal-Setting, Problem-Solving and a Disclosure Toolkit~6. Session 6: Accompaniment 2~7. Session 7: Accompaniment 3 (ONLY if needed)~8. Weekly check-in calls following Session 2 for six months"
62043270|NCT05853887|OTHER|Penn Medicine New Jersey|All sites with be randomized to implement the nudge at different points in time. Prospective data with be compared with each site's respective baseline numbers over a two-year period.
62043271|NCT05853887|OTHER|Penn Medicine Lancaster General Health|All sites with be randomized to implement the nudge at different points in time. Prospective data with be compared with each site's respective baseline numbers over a two-year period.
62043272|NCT05853887|OTHER|Penn Presbyterian Medical Center|All sites with be randomized to implement the nudge at different points in time. Prospective data with be compared with each site's respective baseline numbers over a two-year period.
62043273|NCT03869398|NO_INTERVENTION|Control arm: No pre-op medications|patients undergoing total thyroidectomy are started on calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID immediately postoperatively. No pre-operative medications are given
62043274|NCT03869398|EXPERIMENTAL|Intervention arm: Tums and Calcitriol pre-op|patients start calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
62043275|NCT05073367||Participants with H. Pylori|Participants having evidence of H. pylori infection or having a positive result of H. pylori diagnostic testing recorded at inpatient or outpatient visits using pre-existing electronic medical record data in China will be observed retrospectively for 54 months.
62436267|NCT05751395||Critically ill Patients in severe Multiple Organ Dysfunction|Critically ill Patients in severe Multiple Organ Dysfunction in need of a second Central Venous Catheter (CVC) for e.g. blood purification techniques
62436268|NCT06232356||Study population|The study population will consist of adult subjects (healthy or with respiratory disease - COPD) between 18 and 80 years of age, who will be enrolled in the pulmonary function laboratories of the participating hospitals, from among those listed above, who are attended to a functional respiratory examination.
62436269|NCT04127591||myocardial infarction group|Patients admitted with the diagnosis of myocardial infarction.
62436270|NCT04127591||Blank control group|Patients admitted without the diagnosis of myocardial infarction.
62824368|NCT04701814|ACTIVE_COMPARATOR|group A (controlled group)|received passive range of motion (PROM)/ active assisted range of motion (AAROM)/ active range of motion (AROM) exercises, strengthen of rotator cuff, biceps, shoulder and scapular muscles, ultrasound (5 min. - 1.5 W/c.m2 - 1 MHZ), electrical stimulation ( interferential bipolar technique for 20 min. on shoulder joint). This treatment was repeated three times per weeks with 24 hours rest for 3 weeks.
62824369|NCT04701814|ACTIVE_COMPARATOR|group B(Study group)|All patients in group B received biomechanical scapular mobilization with movement and motor learning and traditional methods.
62436271|NCT06530290|EXPERIMENTAL|Mirtazapine|Mirtazapine (15 mg), once a day, for 12 weeks
62436272|NCT06530290|PLACEBO_COMPARATOR|Placebo|Placebo, once a day, for 12 weeks
62436273|NCT04281056|NO_INTERVENTION|Control|
62436274|NCT04281056|EXPERIMENTAL|Tooth removal|Tooth removal and their replacement by means of a denture Teeth have been removed and replaced by means of dentures for at least one year
62449172|NCT02331537|NO_INTERVENTION|Waitlist|Waitlist control that will get the internet-based treatment when the first group has finished (i.e. Week 10). There are no active treatment for these participants at all.
62602564|NCT00814944|EXPERIMENTAL|Dose Group 3|
62602565|NCT00814944|PLACEBO_COMPARATOR|Dose Group 4|
62602566|NCT03193879||COPD group|COPD patients
62043276|NCT05049408||Group OSCC|Patients with Oral Squamous Cell Carcinoma (OSCC)
62824370|NCT06595433|EXPERIMENTAL|PAPE 90% warm up protocol|performed three repetitions of dip squats with 90% of their one-repetition maximal dip squats and rested for 4 minutes.
62043277|NCT05049408||Group OPMD|Patients with oral potentially malignant disorders (OPMD)
62043278|NCT05049408||Group HC|Healthy Control
62043279|NCT04361565||Individuals diagnosed for COVID-19|
62436275|NCT04335110|OTHER|Intervention|Care Partners and Persons with Dementia. Up to 40 Care Partners and their 40 care-recipients with ADRD will participate in this study. The primary focus of this study is on Care Partners, however, we will gather subjective and objective data on participants with Alzheimer's Disease and Related Dementias (ADRD) to assess the effect of the intervention on Care Partner affective responses to caregiving and quality of life for both. STELLA participants will be recruited from the existing cohort of patients, and their Care Partners, who are enrolled in the Oregon Roybal Center for CAre Support Translational Research Advantaged by Integrating Technology) ORCASTRAIT Life Laboratory (OSLL).
62436276|NCT02775253|EXPERIMENTAL|Chronic cold acclimation group|All patients will be conducted a chronic cold acclimation intervention for 33 days.
62602567|NCT03193879||Asthma group|Asthma patients
62602568|NCT03193879||Health group|Healthy volunteers
62602569|NCT04476121|EXPERIMENTAL|PRF application|Patients with alveolar osteitis in which PRF application was performed.
62602570|NCT04476121|ACTIVE_COMPARATOR|Aspirin application|Patients with alveolar osteitis in which Nipas was used.
62602571|NCT00136435|OTHER|Only Arm for this study|Only Arm for this study
62602572|NCT02790359|ACTIVE_COMPARATOR|Patient group 1|Air
62602573|NCT02790359|ACTIVE_COMPARATOR|Patient group 2|Carbon dioxide
62824371|NCT06595433|EXPERIMENTAL|PAPE 50% warm up protocol|performed three repetitions of dip squats with 50% of their one-repetition maximal dip squats and rested for 4 minutes.
62824372|NCT06595433|OTHER|Unloaded warm-up protocol|They performed the snatch movement with 75% of their maximum snatch weight without pre-warm-up, i.e. without weights, until exhaustion.
62043280|NCT05918705||ONSD / ETD Ratio Correlation With Prognosis of Sepsis Associated Encephalopathy|"* Data on in-hospital mortality will be recorded for all patients.~* Clinical diagnosis of brain death will be also recorded for all patients.~* Morbidity will be assessed both on ICU discharge and 3 months following ICU discharge with the Modified Rankin Scale (mRS), where patients will be assessed at the 3-month follow-up by telephone or face-to-face interviews with the patients or relatives.~According to neurologic outcome on ICU discharge and 3 months following ICU discharge, the included patients will be classified into two groups;~* Good Neurologic Outcome (GNO); mRS 0 - 2.~* Poor Neurologic Outcome (PNO); mRS 3 - 6."
62043281|NCT01552850|EXPERIMENTAL|Oxycodone Formulation A Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
62043282|NCT01552850|EXPERIMENTAL|Oxycodone Formulation B Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
62043283|NCT01552850|EXPERIMENTAL|Oxycodone Formulation C Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
62043284|NCT01552850|EXPERIMENTAL|Oxycodone Formulation D Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
62043285|NCT01552850|EXPERIMENTAL|Oxycodone Oral Solution|40 mg oxycodone oral solution (5 mg/5 ml) under 50 mg naltrexone block
62043286|NCT02652988|ACTIVE_COMPARATOR|Active-tDCs|17 patients will receive Active-tDCS intervention (2mA, 30 min) at home.
62043287|NCT02652988|SHAM_COMPARATOR|Sham-tDCS|17 patients will receive Sham-tDCS intervention (2mA, 30 min) at home.
62043288|NCT06100133|EXPERIMENTAL|Ketone Ester|Up to 100g ketone ester daily for 56 days
62436277|NCT02947373|OTHER|Imaging Arm|Patients will receive a one-time injection of Hyperpolarized Pyruvate prior to a single MR imaging examination that includes the acquisition of HP carbon-13 metabolic data.
62824373|NCT05162781|EXPERIMENTAL|CICT with Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) shaping on IADL and (B) the Cognitive Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis.
62602574|NCT06623370|ACTIVE_COMPARATOR|Group M|In addition to the routine anesthesia protocol, 1 mg/kg of methylprednisolone will be administered after induction.
62602575|NCT06623370|PLACEBO_COMPARATOR|Group C|Routine anesthesia will be administered.
62824374|NCT05162781|EXPERIMENTAL|CICT without Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) shaping on IADL and (B) the Cognitive Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. No follow-up phone calls will be made after treatment ends.
62824375|NCT05162781|ACTIVE_COMPARATOR|BF-HELP with Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) training on relaxation, healthy nutrition, and healthy sleep, and (B) the Healthy Lifestyle Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis.
62824376|NCT05162781|ACTIVE_COMPARATOR|BF-HELP without Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) training on relaxation, healthy nutrition, and healthy sleep, and (B) the Healthy Lifestyle Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. No follow-up phone calls will be made after treatment ends.
62824377|NCT03994081|EXPERIMENTAL|alpha Transcranial alternating current stimulation (tACS).|10 Hz tACS with a zero-to-peak amplitude of 1 mA for 40 minutes.
62824378|NCT03994081|SHAM_COMPARATOR|Sham stimulation|20 seconds of ramp-up, 40 seconds of 10 Hz tACS with zero-to-peak amplitude of 1 mA, and 20 seconds of ramp-down for a total of 80 seconds of stimulation.
62043289|NCT05365893|EXPERIMENTAL|PHL (Paricalcitol, Hydroxychloroquine, Losartan)|Paricalcitol 25 mcg IV administered M-W-F Hydroxychloroquine 600 mg PO BID Losartan 50 mg PO daily
62043290|NCT05365893|ACTIVE_COMPARATOR|Neoadjuvant therapy and surgery only (Control)|Control arm These patients will proceed to surgery at completion of neoadjuvant therapy.
62043291|NCT06732713|EXPERIMENTAL|Swiss ball group|Swiss ball exercises will be done and intervention period will be of 8 weeks with 3 to 4 sessions per week of about 25 to 30 minutes
62043292|NCT06732713|EXPERIMENTAL|Frenkel exercise group|Frenkel exercises will be done and intervention period will be of 8 weeks with 3 to 4 sessions per week of about 25 to 30 minutes
62436278|NCT02977442|EXPERIMENTAL|exercise|12 week exercise program, 5 days/week, 60 min/day
62436279|NCT02977442|NO_INTERVENTION|standard of care|12 week standard of care recommendations
62602576|NCT01732471|EXPERIMENTAL|Kuvan®|
62602577|NCT01404208|ACTIVE_COMPARATOR|D-Cycloserine|
62602578|NCT01404208|PLACEBO_COMPARATOR|Sugar Pill|
62602579|NCT05186038||Population of children and adolescents between 2 and 18 years old|Population of children and adolescents between 2 and 18 years old who are diagnosed with celiac disease or are suspected to suffer the disease.
62043293|NCT03633968|ACTIVE_COMPARATOR|maxillary sinus lift small antrostomy|"local anaesthesia will be given flap will be reflected to expose sinus lateral wall. round diamond bur will be used to make small antrostomy and expose schneiderian membrane.~maxillary sinus lift by using antral membrane balloon elevation without using graft material with simultaneous implant placement"
62824379|NCT04470154|EXPERIMENTAL|Stage I: 0.05 μg/kg|IV HSK21542 0.05 μg/kg solution（active or placebo） administered after each dialysis session within 2h±30 min (3 times/week).
62824380|NCT04470154|EXPERIMENTAL|Stage I: 0.15 μg/kg|IV HSK21542 0.15 μg/kg solution（active or placebo） administered after each dialysis session within 2h±30 min (3 times/week).
62824381|NCT04470154|EXPERIMENTAL|Stage I: 0.30 μg/kg|IV HSK21542 0.30 μg/kg solution（active or placebo） administered after each dialysis session within 2h±30 min (3 times/week).
62043294|NCT03633968|ACTIVE_COMPARATOR|maxillary sinus lift large antrostomy|"local anaesthesia will be given flap will be reflected to expose sinus lateral wall round diamond bur will be used to make large antrostomy and expose schneiderian membrane.~maxillary sinus lift by using antral membrane balloon elevation without using graft material with simultaneous implant placement"
62824382|NCT04470154|EXPERIMENTAL|Stage I: 0.80 μg/kg|IV HSK21542 0.80 μg/kg solution（active or placebo） administered after each dialysis session within 2h±30 min (3 times/week).
62824383|NCT04470154|EXPERIMENTAL|Stage II: 0.3 μg/kg|IV HSK21542 0.3 μg/kg solution（active or placebo） administered after each dialysis session within 10 min (3 times/week).
62824384|NCT04470154|EXPERIMENTAL|Stage II: 0.6 μg/kg|IV HSK21542 0.3 μg/kg solution（active or placebo） administered after each dialysis session within 10 min (3 times/week).
62824385|NCT04769479|EXPERIMENTAL|acoramidis|
62824386|NCT04004234|EXPERIMENTAL|Manganese primed anti-PD-1 antibody plus nPG chemotherapy|Subject received Manganese primed anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
62043295|NCT01474096|EXPERIMENTAL|implementation strategy|determining whether the use of implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding CPG in primary care is more effective than the usual practice of mere circulation.
62043296|NCT01474096|NO_INTERVENTION|Conventional intervention|
62043297|NCT05728723|EXPERIMENTAL|Intervention group|Pharmacy Education with Android Application as a Tool Conducted for Three Months in Hypertensive Patients to Improve Knowledge, Adherence, Outcome Therapy and Quality of Life
62043298|NCT05728723|ACTIVE_COMPARATOR|Pharmacy education|Pharmacy education in hypertensive patients
62043299|NCT05629702|EXPERIMENTAL|Standard Temozolomide with Nabiximols|"* Temozolomide 150mg/m2 for cycle 1, increasing to 200mg/m2 for subsequent cycles, once daily for days 1-5, orally, at the start of each 28 day cycle, up to a maximum of 6 cycles.~* Nabiximols up to 12 oromucosal sprays per day up to a maximum of 6 cycles; self titrated over days 1-14 in cycle 1."
62043300|NCT05629702|PLACEBO_COMPARATOR|Standard Temozolomide with Nabiximols-matched placebo|"* Temozolomide 150mg/m2 for cycle 1, increasing to 200mg/m2 for subsequent cycles, once daily for days 1-5, orally, at the start of each 28 day cycle, up to a maximum of 6 cycles.~* Nabiximols-matched placebo up to 12 oromucosal sprays per day up to a maximum of 6 cycles; self titrated over days 1-14 in cycle 1."
62043301|NCT02248792|EXPERIMENTAL|Group A|Methotrexate 10mg orally once weekly
62043302|NCT02248792|ACTIVE_COMPARATOR|Group B|Methotrexate 25mg orally once weekly
62043303|NCT06731894|EXPERIMENTAL|Arm I (CBD)|Patients receive CBD PO QD on days 1-3 of cycle 1, BID on days 4-6 of cycle 1, and TID on days 7-28 of cycle 1. Patients receive CBD PO TID on days 1-28 of cycle 2. Cycles repeat every 28 days for up to 2 cycles in the absence of unacceptable toxicity. Patients undergo urine collection during screening.
62824387|NCT05412082|EXPERIMENTAL|SMART TNT Plan I|"Participants will initiate therapy with neoadjuvant chemotherapy of either six (6) 14-day cycles of 5-fluorouracil + leucovorin + oxaliplatin (FOLFOX) or four (4) 21-day cycles of capecitabine+oxaliplatin (CAPOX). Participants will then receive chemo-radiation therapy according to Plan I as follows:~Plan I (5 weeks):~* MRI-guided pelvic IMRT to the Planning Tumor Volume (PTV) at a dose of 50 Grays (gy) delivered in 25 fractions (fx) over 5 weeks.~* Concurrent chemotherapy beginning on Day 1 of RT either:~  * 5-FU delivered 5 or 7 days per week.~ * Capecitabine (Xeloda) delivered 5 days per week.~After completing Plan I, participants achieving complete Clinical Response (cCR) after completing Plan I chemo-radiation will forgo the Plan II boost and continue to follow-up. Participants not achieving cCR will begin Plan II, one week after completing Plan I."
62043304|NCT06731894|EXPERIMENTAL|Arm II (THC:CBD)|Patients receive THC:CBD PO QD on days 1-3 of cycle 1, BID on days 4-6 of cycle 1, and TID on days 7-28 of cycle 1. Patients receive THC:CBD PO TID on days 1-28 of cycle 2. Cycles repeat every 28 days for up to 2 cycles in the absence of unacceptable toxicity. Patients undergo urine collection during screening.
62824388|NCT05412082|EXPERIMENTAL|SMART TNT Plan II|"Plan II boost RT (1 week): For participants not achieving cCR after chemo-radiation. Participants will receive MRI-guided accelerated radiation therapy (ART) boost to the primary tumor.~Participants achieving a cCR will continue to follow-up. Participants still showing residual tumor will undergo standard of care treatment including surgery and adjuvant chemotherapy per institutional guidelines during follow-up."
62824389|NCT04144686|ACTIVE_COMPARATOR|Group A|Vestibular participants undertaking a single-task vestibular rehabilitation
62824390|NCT04144686|EXPERIMENTAL|Group B|Vestibular participants undertaking a dual-task vestibular rehabilitation
62824391|NCT04971746|EXPERIMENTAL|GLPG4716 and pirfenidone|
62436280|NCT02451670|EXPERIMENTAL|Prioritized Clinical Decision Support|Patients receiving care in clinics randomized to the intervention arm of the study and their primary care providers were presented with patient-specific written advice as to prioritized treatment and lifestyle changes that could reduce their cardiovascular risk, prompted by an electronic health record-based alert during their primary care visit.
62824392|NCT04971746|EXPERIMENTAL|GLPG4716 and nintedanib|
62824393|NCT04211753|EXPERIMENTAL|Treatment as usual plus mobile app|Those who will receive naturalistic treatment in outpatient setting and also the mobile app
62824394|NCT04211753|ACTIVE_COMPARATOR|Treatment as usual|Those who will receive naturalistic treatment in outpatient setting but not the mobile app
62436281|NCT02451670|NO_INTERVENTION|Usual Care|Patients receiving care in clinics randomized to the usual care arm of the study and their providers were not presented with the prioritized clinical decision support.
62824395|NCT06158399|EXPERIMENTAL|ARCHOP|Azacitidine in combination with R-CHOP
62824396|NCT06588517|EXPERIMENTAL|Group T|"take the tablet under fed condition ,1 tablet at a time, once a day.Test product (T): Pirfenidone Modified-~Release Tablets Strength: 600 mg/tablet Batch No.:~08532 Content: 600 mg/tablet Valid to: January/2025 Storage Conditions: sealed at normal temperature (10-30°C) Manufacturer: Overseas Pharmaceuticals, Ltd."
62824397|NCT06588517|ACTIVE_COMPARATOR|Group R|take the tablet under fed condition ,1 tablet at a time, three times a day.Reference product (R): Pirfenidone Tablets Strength: 200 mg/tablet Batch No.: 0239 Content: 200 mg/tablet Valid to: September 2026 Storage Conditions: sealed at room temperature Manufacturer: Shionogi \& Co., Ltd..
62824398|NCT06591130|EXPERIMENTAL|Y-CMAP + TAU|
62824399|NCT06591130|NO_INTERVENTION|TAU alone|Treatment as usual (TAU) will include standard routine care that participants could potentially be receiving by their treating GP, or from autism centers, such as behavioral therapy, psychoeducation, occupational therapy, sports therapy, and art therapy. We will maintain a detailed record of each participant's routine care.
62824400|NCT00970047||Pregnant females|Women who are pregnant and between 6 and 16 weeks of gestation and who are 18 to 64 years of age.
62824401|NCT06091111|EXPERIMENTAL|Intervention arm|Subjects is randomized to start with either a period of reference product use followed by a cross over to using the study device or the opposite sequence, starting with the study device and then cross over to using the reference device.
62824402|NCT01521117|EXPERIMENTAL|Donepezil, Then Placebo|Donepezil 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6. After a washout period of 4 weeks, placebo 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6.
62824403|NCT01521117|EXPERIMENTAL|Placebo, Then Donepezil|"Placebo 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6.~After a washout period of 4 weeks, donepezil 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6."
62824404|NCT05083741||Chitogel|Chitodex gel plus Kenalog inserted into the middle meatus
62824405|NCT05083741||Nexfoam|NexFoam plus Kenalog inserted into the middle meatus
62824406|NCT05485896|EXPERIMENTAL|Advanced RCC (Locally advanced, regional LN invaded, or M1-NED)|Patients will receive treatment with Pembrolizumab in combination with Lenvatinib every 3 weeks for 3 cycles in the preoperation. In addition, 17 cycles' Pembrolizumab were needed for patients with high risk of recurrence (tumor stage 2 with nuclear grade IV or sarcomatoid differentiation, tumor stage 3 or higher, regional lymph-node metastasis, or stage M1 with no evidence of disease residual).
62436282|NCT05185427||Participants with pulse oximetry readings|The research team will take a reflectance measurement on the same location that the most recent pulse oximetry measurement was taken. In addition, a reflectance measurement will be taken bilaterally for the nailbed, dorsal and ventral side of the digits, dorsal and ventral side of the hand, dorsal and ventral side of the forearm, lower leg, foot, and either side for the ear. The most recent pulse oximetry and arterial oxygen saturation readings will be accessed through the electronic medical records, those readings are generally conducted simultaneously and will provide comparison. The duration anticipated for an individual participant's participation is 1 day.
62436283|NCT05967312||Intervention:|Offered the Minuteful Kidney Test Kit
62043305|NCT06731894|PLACEBO_COMPARATOR|Arm III (placebo)|Patients receive placebo PO QD on days 1-3 of cycle 1, BID on days 4-6 of cycle 1, and TID on days 7-28 of cycle 1. Patients receive placebo PO TID on days 1-28 of cycle 2. Cycles repeat every 28 days for up to 2 cycles in the absence of unacceptable toxicity. Patients undergo urine collection during screening.
62436284|NCT05967312||Control|Continue as standard of care
62436285|NCT06547879|EXPERIMENTAL|Intervention group|One session per week; 20 minutes for the training module and 25 minutes for the awareness practice, a total of 45 minutes each week, for a total of 8 weeks.
62436286|NCT06547879|NO_INTERVENTION|Control group|Usual care.
62824407|NCT00579215|EXPERIMENTAL|1|Enhance Care (EC) will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits.
62824408|NCT00579215|OTHER|2|As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
62824409|NCT05798494|EXPERIMENTAL|Intervention|Intervention group will receive dietary counseling by a trained dietitian from 3 months post-partum of the 1st child until birth of the 2nd child. The mother will receive advice to provide a moderate caloric restriction (-500 to 1000 kcal/d) and attend physical activity sessions to attain a 10 % weight loss according to pre-pregnancy weight. If the father is also overweight or obese, he will receive the same advice.
62824410|NCT05798494|NO_INTERVENTION|Control|The control group will receive standard care and will not receive any dietary advice prior to pregnancy. During pregnancy control subjects will receive dietary advice according to standard care which means no counselling from a dietitian unless there are special needs (e.g., gestational diabetes), then they will receive counseling from a dietitian in accordance with standard care.
62824411|NCT01379898|ACTIVE_COMPARATOR|Phenoxybezamine|Phenoxybenzamine (capsules 10 mg, once to twice daily) is administered orally, starting 2-3 weeks before planned resection of PCC.
62824412|NCT01379898|ACTIVE_COMPARATOR|Doxazosin|Phenoxybenzamine (slow release tablets 4 or 8 mg, once to twice daily) is administered orally, starting 2-3 weeks before planned resection of PCC.
62824413|NCT06581328|EXPERIMENTAL|UC Participants: Vedolizumab|Participants with moderate to severely active UC will receive vedolizumab 300 milligrams (mg), intravenous (IV) infusion at Weeks 0 and 2. Following the first 2 vedolizumab IV doses, participant may be switched to vedolizumab 108 mg subcutaneous (SC) injection at Week 6, to be administered every 2 weeks until Week 50. Treating health care practitioner (HCP) may give an additional dose of vedolizumab IV at Week 6 with mandatory transition by Week 14.
62824414|NCT06581328|EXPERIMENTAL|CD Participants: Vedolizumab|Participants with moderate to severely active CD will receive vedolizumab 300 mg, IV infusion at Weeks 0 and 2. Following the first 2 vedolizumab IV doses, participant may be switched to vedolizumab 108 mg SC injection at Week 6, to be administered every 2 weeks until Week 50. Treating HCP may give an additional dose of vedolizumab IV at Week 6 with mandatory transition by Week 14.
62824415|NCT04986072|EXPERIMENTAL|Sodium Nitroprusside Arm|Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours
62602580|NCT04117074|EXPERIMENTAL|Arm 1: Thoracic Epidural Analgesia with bupivicaine|Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
62824416|NCT04986072|PLACEBO_COMPARATOR|Placebo Arm|5% Dextrose (0.5 μg/kg/min) for 4 hours
62824417|NCT01747447|PLACEBO_COMPARATOR|Vitamin D placebo + fish oil placebo|Daily vitamin D placebo and daily fish oil placebo
62824418|NCT01747447|ACTIVE_COMPARATOR|Vitamin D placebo + fish oil|Daily vitamin D placebo and daily fish oil capsule (1 g/d; EPA + DHA in a 1.2:1 ratio)
62043306|NCT06732219|EXPERIMENTAL|Enhanced Teaching Arm|Participants in this arm will receive a behavioral intervention designed to reduce challenging behaviors and improve skill acquisition. The intervention includes functional communication training (FCT) to teach appropriate communication responses, the use of extinction-correlated stimuli to signal changes in reinforcement conditions, terminal probe schedule thinning to systematically reduce the frequency of reinforcement, competing stimuli to minimize engagement in challenging behaviors during reinforcement delays, and caregiver fading to promote skill generalization and maintenance across naturalistic environments. These strategies will be tailored to individual needs and administered within structured sessions.
62043307|NCT03263429|EXPERIMENTAL|Panitumumab/Irinotecan/CB-839|Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28, panitumumab IV over 60-90 minutes on days 1 and 15, and irinotecan hydrochloride IV over 90 minutes on day 1 and 15 (Phase I only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62824419|NCT01747447|ACTIVE_COMPARATOR|Vitamin D + fish oil placebo|Daily vitamin D (2,000 IU/d) and daily fish oil placebo
62436287|NCT01423838|ACTIVE_COMPARATOR|Solifenacin|Anticholinergic molecule used in the treatment of overactive bladder.
62436288|NCT01423838|ACTIVE_COMPARATOR|Oxybutynin|Anticholinergic molecule used in the treatment of overactive bladder.
62824420|NCT01747447|ACTIVE_COMPARATOR|Vitamin D + fish oil|Daily vitamin D (2,000 IU/d) and daily fish oil capsule (1 g/d; EPA + DHA in a 1.2:1 ratio)
62436289|NCT04072978||Intraocular lens implantation: AC IOL|"Patients who are scheduled to undergo AC IOL (anterior chamber intraocular lens) implantation for any of the following indications:~* primary or secondary aphakia~* primary or secondary lens subluxation or dislocation"
62436290|NCT04072978||Intraocular lens implantation: SF IOL|"Patients who are scheduled to undergo SF IOL (scleral fixated intraocular lens) implantation for any of the following indications:~* primary or secondary aphakia~* primary or secondary lens subluxation or dislocation"
62436291|NCT01557452|EXPERIMENTAL|Givinostat|Patient received the dose of 0.75 mg/kg BID from December 28th, 2011 to January 27th, 2014
62245979|NCT05104021|EXPERIMENTAL|game group|"Children who accepted to participate in the game were taken to the playground with minimum two and maximum four people. After the children were introduced to each other, the rules of the game were explained. Between the children playing, dice were rolled to determine the starting order of the game. The player who scored the highest number had the right to start the game first. With the help of the stopwatch, the playing time was started, and the children played the game in accordance with the rules.~For the child who first reached the square of the world, the time was stopped and recorded in the Child Follow-up Form. The game was played with a maximum game duration of 15 minutes. In the same way, the times of the children who reached the world square in the second, third and fourth places were recorded on the Follow-up Form."
62245980|NCT05104021|NO_INTERVENTION|control group|"Children in the control group were allowed to walk for 15 minutes on a flat surface in the clinic accompanied by the researcher and their parents. As soon as the child came out of his room, the time was started with the help of a stopwatch. The time was stopped when the child went back to bed.~The pain and fear scores of each child who completed the game and mobilization were evaluated separately and simultaneously by the child, parent and researcher with the help of the Visual Analog Scale and the Child Fear Scale, and then the physiological parameter measurements were made by the researcher and the Child Follow-up Form was evaluated after the procedure. and data collection was terminated."
62245981|NCT04633174|EXPERIMENTAL|Sous vide device|The intervention will be the use of a sous vide device to heat the water bath to 38oC, rather than the traditional methods of manual water exchanges or placing the frostbitten tissue under running water.
62245982|NCT01951781|OTHER|NEOCD64|NEOCD64 : dosage of CD64 blood marker in preterm newborn who are suspected of nosocomial infection (blood sample)
62245983|NCT02500667|EXPERIMENTAL|N91115 + Rifampin|N91115 200 mg twice daily (BID) from Study Day 1- 13, Rifampin 600 mg once daily (QD) from Study Day 8 - 12
62436292|NCT00691145|EXPERIMENTAL|1|
62436293|NCT00764803||2|Subjects who meet the indications for use and are implanted with the Encore MJS™ Knee System.
62043308|NCT02652481|OTHER|ImageReady MR Conditional Defibrillation System Group|"Prospective, non-randomized, confirmatory study.Subjects will initially be enrolled into Phase I to undergo a non-diagnostic study required MR Scan. Once Phase I is complete, subjects will be enrolled into Phase II where there is no requirement to undergo a non-diagnostic study required MR scan Up to 37 subjects will be used for an interim analysis. Of these subjects, the first 20 who undergo the study required MRI scan and complete the MRI + 1 Month Visit will be used for this analysis. The second cohort will consist of subjects who will receive the non-diagnostic study required MR scan until 137 CRT-D and 28 VR ( single chamber) ICD subjects undergo the study required MR scan (complete or incomplete).~De novo implants and existing implants may be enrolled in Phase I There will be a non-diagnostic study required MR scan (during the MRI visit) There will be a study required MRI visit and MRI + 1 month visit"
62043309|NCT06489535|EXPERIMENTAL|RETAIN intervention|Participants randomized to the RETAIN intervention will receive Motivational Interviewing targeted to their clinical concerns and personalized support tailored to each participants' specific needs determined by their answers to intake questions.
62245984|NCT03305939|EXPERIMENTAL|Intervention|Participants randomized in to the intervention group will receive group sessions, monthly phone calls, and telephonic prompts (text/voice recording).
62245985|NCT03305939|NO_INTERVENTION|Control|Control group participants will be referred to their usual doctor for ongoing management, with no attempt made to influence this. They will not get any part of the intervention but will receive the usual care (if any exists). Any abnormal OGTT results during the follow-up visits will be provided to the patient and their doctor. This is entirely consistent with current usual care.
62245986|NCT01292447|PLACEBO_COMPARATOR|Control Group|Will receive placement of inert glycerin gel on ectocervix and in cervical canal prior to IUD placement.
62824421|NCT05557110|EXPERIMENTAL|reduced-intensity chemotherapy followed by berintuzumab|"Induction therapy was performed with reduced intensity chemotherapy (including 1 dose of Idarubicin 8 mg/m2, 1 dose of Vindesine 3 mg/m2, and 7 days of Dexamethasone 9 mg/m2/d) followed by 2 weeks of Blinatumomab (9 ug/d d8-14, 28 ug/d d15-21) immediately. Bone marrow evaluation was performed on day 22±2, and consolidation therapy was performed after achieving bone marrow remission (CR/CRh/CRi). If CR/CRh/CRi was not achieved in the first course of induction therapy, Blinatumomab (28ug/d×14d) should be continued and bone marrow evaluation should be evaluated again.~The regimen of consolidation therapy is recommended as multidrug combination chemotherapy (including high-dose Methotrexate or Cytarabine combined with Asparaginase) or alternating with Blinatumomab (28 ug/d×28d). If Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) is not performed, consolidation therapy needs at least 4 courses before 2 years maintenance therapy."
62824422|NCT01646580|EXPERIMENTAL|ciclopirox|
62824423|NCT02971748|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
62824424|NCT04985279|ACTIVE_COMPARATOR|Standard clinical practice|"* Lumbar ultrasound scan will be performed to identify the desired needle insertion site, followed by demarcation using skin markers.~* The angulation of the ultrasound probe will be adjusted to optimise the image of the simulated patient's lumbar spine.~* The ultrasound probe will be removed and needle insertion simulated by touching the tip of a blunt needle to the patient's back, at the desired angle.~* A usability questionnaire regarding the procedure will be completed."
62824425|NCT04985279|EXPERIMENTAL|Position and Angle Marking System (PAMS)|"* PAMS will be attached to the ultrasound probe.~* Lumbar ultrasound scan will be performed to identify the desired needle insertion site, followed by demarcation by gentle pressing PAMS into the simulated patient's back to create skin indentations.~* The angulation of the ultrasound probe will be adjusted to optimise the image of the simulated patient's lumbar spine, and the angle read off a graduated scale.~* The ultrasound probe will be removed and needle insertion simulated by touching the tip of a blunt needle to the patient's back, at the desired angle.~* A usability questionnaire regarding the procedure will be completed."
62436294|NCT00764803||1|Subjects who meet the indications for and are implanted with the Encore 3DKnee™ system.
62436295|NCT00903890||A|Individuals who have previously received radiation therapy and anthracycline chemotherapy for their Hodgkin's or non-Hodgkin's lymphoma.
62436296|NCT01768078|EXPERIMENTAL|with corticoids|
62436297|NCT01768078|OTHER|without corticoids|
62436298|NCT01388686||INABBRA|Participating intensive care units of hospitals in the INABBRA alliance.
62436299|NCT02039310||≥ 65 years / opts for radical cystectomy|
62436300|NCT01797419|EXPERIMENTAL|GS-5806|Single dose, oral liquid, .5 mL/kg
62824426|NCT05172024||Participants with SARS-CoV-2 Infection|
62824427|NCT05172024||Participants without SARS-CoV-2 Infection|
62824428|NCT06604130|EXPERIMENTAL|The experimental arm receiving diagnosis from serum RNA combination|
62043310|NCT06489535|ACTIVE_COMPARATOR|Control|Control arm participants will be offered different videos or podcast episodes that are unrelated to the study topics of infections, substance use, overdose, and medication management.
62602581|NCT04117074|EXPERIMENTAL|Arm 2: Surgical Site Infiltration with Liposomal Bupivacaine|Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
62602582|NCT01537068|EXPERIMENTAL|Desvenlafaxine|Serotonin-norepinephrine reuptake inhibitors (SNRIs) antidepressant drug
62602583|NCT01537068|PLACEBO_COMPARATOR|Placebo|Placebo treatment
62043311|NCT02965365||TTN positive group|The group which subsequently diagnosed as TTN
62043312|NCT02965365||TTN negative group|The group which is not diagnosed as TTN
62043313|NCT04944641|EXPERIMENTAL|A: Routine AED group|Routine and proper antiepileptic drugs group
62602584|NCT02691728|EXPERIMENTAL|Treatment Arm|12 Week treatment with LDV/SOF FDC
62043314|NCT04944641|EXPERIMENTAL|B: AED and education group|Routine, proper antiepileptic drugs and education group
62602585|NCT03026530|EXPERIMENTAL|Pulmonary recruitment maneuver|Ventilator-piloted pulmonary recruitment maneuver at the end of laparoscopic bariatric surgery.
62602586|NCT03026530|ACTIVE_COMPARATOR|Control group|Ordinary ventilation at the end of laparoscopic bariatric surgery.
62436301|NCT01797419|PLACEBO_COMPARATOR|Placebo|Single dose, oral liquid, .5 mL/kg
62602587|NCT05432323||Adolescents|
62602588|NCT05432323||Parents|
62602589|NCT02152553|ACTIVE_COMPARATOR|Hydrocortisone|Near-physiologic doses of Hydrocortisone are being given to subjects. The first day between 09.00 and 12.00 0,024 mg Hydrocortisone/kg per hour. The first day between 12.00 and 20.00 0,012 mg Hydrocortisone/kg per hour. The first day between 20.00 and 24.00 0,008 mg Hydrocortisone/kg per hour. The second day between 00.00 and 11.00 0,030 mg Hydrocortisone/kg per hour. Hydrocortisone infusion: 0,4 ml Solu Cortef 100 mg (50 mg/ml) added in 999,6 ml sodium chloride 0,9% solution (1 mg Solu Cortef/ 50 ml total solution volume).
62602590|NCT02152553|PLACEBO_COMPARATOR|Placebo|The same volume of sodium chloride 0,9% as in the other arm where Hydrocortisone is given in saline 0,9% solution. The given volume of sodium chloride will variate chronically as in Hydrocortisone arm.
62602591|NCT00956631|OTHER|interlaminar decompression|Commercially available product (mild® Device Kit) used to perform interlaminar decompression
62602592|NCT05418972|EXPERIMENTAL|Neoadjuvant immunotherapy +/- Adjuvant immunotherapy|"NEOADJUVANT: All participants will receive neoadjuvant therapy with the fixed dose combination of intravenous relatlimab 160 mg and nivolumab 480 mg x 2 doses on days 1 and 29.~SURGERY: All participants will have sentinel lymph node mapping and biopsy prior to a wide local excision of the primary melanoma between days 43 and 56.~ADJUVANT: Participants with no pathological response or partial pathological response will receive the fixed dose combination of intravenous relatlimab 160 mg and nivolumab 480 mg for a further 11 doses."
62602593|NCT04003545|ACTIVE_COMPARATOR|Active group|Thirty eight patients will be recruited from UNINOVE outpatient units and randomly allocated in the two groups.
62602594|NCT04003545|PLACEBO_COMPARATOR|Placebo group|Thirty eight patients will be recruited from UNINOVE outpatient units and randomly allocated in the two groups.
62602595|NCT05221268|EXPERIMENTAL|downhill|Received downhill walking training.
62824429|NCT06233240|EXPERIMENTAL|Sequence 1-Sitagliptin and Metformin Hydrochloride Tablets test product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg test product, treatment 2= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg reference product.
62824430|NCT06233240|EXPERIMENTAL|Sequence 2-Sitagliptin and Metformin Hydrochloride Tablets reference product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg test product, treatment 2= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg reference product.
62824431|NCT05167409|EXPERIMENTAL|Evorpacept (ALX148) + cetuximab + pembrolizumab|Evorpacept (ALX148) + cetuximab + pembrolizumab. Evorpacept (ALX148) 15 mg/kg IV weekly, cetuximab 400 mg/m2 once then 250 mg/m2 weekly, and pembrolizumab 200 mg every 3 weeks
62602596|NCT05221268|EXPERIMENTAL|Level -walking|Received level walking training.
62602597|NCT02574702|NO_INTERVENTION|Control Group|Patients with primary loop ileostomy closure without drainage of the surgical wound
62043315|NCT03621644|EXPERIMENTAL|Ablative MRIdian SMART|Radiation: Stereotactic MRI-guided On-table Adaptive Radiation Therapy 50 Gy in 5 fractions
62043316|NCT04445636|EXPERIMENTAL|Dexmedetomidine group|A group which will receive dexamedetomidine as an adjunct to bupivacaine used in caudal anesthesia.
62043317|NCT04445636|EXPERIMENTAL|Morphine group|A group which will receive morphine as an adjunct to bupivacaine used in caudal anesthesia.
62043318|NCT04955912|EXPERIMENTAL|Experimental group|Music medicine
62043319|NCT04955912|NO_INTERVENTION|Control group|not routinely do anything to reduce premenstrual symptoms
62043320|NCT03510572|EXPERIMENTAL|Healthy volunteer|Cognitively healthy subjects will receive a single IV injection of \[18F\]PI-2620.
62043321|NCT03510572|EXPERIMENTAL|Alzheimer's Disease|Alzheimer's Disease Subjects will receive a single IV injection of \[18F\]PI-2620.
62043322|NCT03510572|EXPERIMENTAL|Frontotemporal dementia|frontotemporal dementia Subjects will receive a single IV injection of \[18F\]PI-2620.
62043323|NCT03510572|EXPERIMENTAL|Parkinson's disease|Parkinson's disease Subjects will receive a single IV injection of \[18F\]PI-2620.
62245987|NCT01292447|EXPERIMENTAL|Study Group|Will receive placement of 2% lidocaine gel on ectocervix and in cervical canal prior to IUD placement.
62245988|NCT01052896|EXPERIMENTAL|Gabapentin|Half of the 100 patients enrolled will be placed on Gabapentin therapy to determine if they have improved dyspepsia symptoms.
62436302|NCT02281071|EXPERIMENTAL|laterally moved coronally advanced flap microsurgical|For the test group (LMCAF-M), the surgical procedures were performed with the aid of a galilean loupe, under 2.5x magnification vision, microsurgical instruments and microsurgical suture material .
62043324|NCT03270449|EXPERIMENTAL|Multidisciplinary intervention|The 10-week intervention will include twice weekly 1-2 hours sessions with multiple professional team members to undergo education and exercise sessions. The multidisciplinary team will consist of a rheumatologist, rheumatology nurse, dietitian, physiotherapist, a trained exercise therapist, a physiologist who specializes in pain management, a psychiatrist and a mental health clinician. All intervention team members have expertise in working with individuals with chronic pain conditions. General disease information, current best practices and techniques such as self-pain management, pacing, sleep hygiene, approach to a healthy lifestyle and weight loss will be discussed. The total number of hours for the 10 week intervention is 31 hours.
62043325|NCT03270449|NO_INTERVENTION|Usual care|Usual care involves being referred to the local rheumatologist involved in the study. The rheumatologist and the rheumatology nurse will see the control group patients during a one hour one on one consultation appointment. During that time the patient's history will be taken, physical exam performed and investigations analyzed. If a diagnosis of fibromyalgia is confirmed, the rheumatologist and nurse will counsel the patient and provide resources for self directed management. Unless there is a concern of an alternative diagnosis, follow up will not be arranged.
62043326|NCT00293267|EXPERIMENTAL|1|raltegravir potassium
62043327|NCT00293267|PLACEBO_COMPARATOR|2|Placebo
62043328|NCT06463288|EXPERIMENTAL|Jacobson's Technique|"Participant in the group A were instructed to perform the Jacobson relaxation technique.~* Quite place were chosen where there is no disturbance.~* Patients were relax either on the lying position or sitting position with head well-supported.~* Patients were instructed to loosen any tight clothing.~* Patients were educated for muscles of each group emphasis on attention on that muscle group only.~* Repeat this three times, constrict the muscle and then relax, tens the muscle and maintain it for five seconds then relax it lightly and then tense and relax. Constrict the muscle very slightly then relax it. Focus on each muscle group and then decide to relax the target muscle."
62043329|NCT06463288|ACTIVE_COMPARATOR|Pranayama Technique|"Participant in group B were instructed to perform the pranayama relaxation technique.~* Quite place were chosen where there is no disturbance and patient were relaxed in sitting position with spine straight.~* In this technique patients were instructed to perform different type of pranayama techniques.~* Guide the participants to take a steady breath in through your both nostrils. Then inhale until you reach your total lung capacity, maintaining a tall spine.~Treatment was continuous 4 weeks, 3 times in a week for 15 mint. Assessment was done through the tool before and after the treatment."
62043330|NCT03860584|EXPERIMENTAL|MFGM-enriched full-fat dairy milk|Participants in this arm will receive MFGM-enriched full-fat dairy milk (3 servings/d) that contains MFGM at 10% phospholipid (relative to total lipid content) delivering MFGM at \~10-times that in full-fat dairy milk.
62043331|NCT03860584|PLACEBO_COMPARATOR|Soy phospholipid/lecithin milk|Participants in this arm will receive a matched dairy milk that instead contains soy phospholipid/lecithin.
62602598|NCT02574702|EXPERIMENTAL|Drainage Group|"Patients with the application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure.~Intervention: application of a contralateral drainage in surgical wound closure."
62602599|NCT06465134||Group 1|Patients scheduled for AF ablation or cardioversion
62602600|NCT05528198|OTHER|ABC|Administration order: montelukast sodium oral thin films without water, montelukast sodium oral thin films with water, montelukast sodium chewable tablets with water.
62824432|NCT04595968|EXPERIMENTAL|Vestal DM active device|150 subjects randomised to receive active device plus lifestyle intervention for 24 weeks
62824433|NCT04595968|SHAM_COMPARATOR|Vestal DM sham device|150 subjects randomised to receive sham device plus lifestyle intervention for 24 weeks.
62824434|NCT06592274|EXPERIMENTAL|Experimental Group 1|HB0017 higer dose plus longer dose regimen
62824435|NCT06592274|EXPERIMENTAL|Experimental Group 2|HB0017 higer dose plus shorter dose regimen
62824436|NCT06592274|EXPERIMENTAL|Experimental Group 3|HB0017 low dose plus shortest dose regimen
62824437|NCT06598267|EXPERIMENTAL|SASI group|single anastomosis sleeve ileal bypass
62824438|NCT06598267|EXPERIMENTAL|RYGB group|Roux-en-Y gastric bypass
62824439|NCT02608190|EXPERIMENTAL|Active training|Patients will undergo active working memory training (see description of protocol).
62824440|NCT02608190|ACTIVE_COMPARATOR|Passive training|Patients will undergo passive working memory training (see description of protocol).
62602601|NCT05528198|OTHER|BCA|Administration order: montelukast sodium oral thin films with water, montelukast sodium chewable tablets with water, montelukast sodium oral thin films without water.
62824441|NCT06242132|ACTIVE_COMPARATOR|clopidogrel arm|The clopidogrel arm will receive (a 300 mg loading dose during the first 24 hours of stroke onset, followed by 75 mg daily from the 2nd to the 90th day)
62043332|NCT05485805|EXPERIMENTAL|Naproxen sodium/caffeine - Dose 1|Participants will receive a single dose of one tablet of naproxen sodium/caffeine plus one tablet of placebo after extraction of third molars.
62602602|NCT05528198|OTHER|CAB|Administration order: montelukast sodium chewable tablets with water, montelukast sodium oral thin films without water, montelukast sodium oral thin films with water.
62824442|NCT06242132|ACTIVE_COMPARATOR|cilostazol arm|The cilostazol arm will receive (a 200 mg loading dose during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day)
62824443|NCT03828825|EXPERIMENTAL|Patent Foramen Ovale Closure|The percutaneous closure of Patent Foramen Ovale is realized under trans-thoracic echocardiography control. If necessary, the operator will use trans-esophageal echocardiography to implant the prosthesis.
62043333|NCT05485805|EXPERIMENTAL|Naproxen sodium/caffeine - Dose 2|Participants will receive a single dose of two tablets of naproxen sodium/caffeine after extraction of third molars.
62043334|NCT05485805|EXPERIMENTAL|Naproxen sodium|Participants will receive a single dose of one tablet of naproxen sodium plus one tablet of placebo after extraction of third molars.
62043335|NCT05485805|EXPERIMENTAL|Caffeine|Participants will receive a single dose of two tablets of caffeine after extraction of third molars.
62043336|NCT05485805|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of two tablets of matching placebo after extraction of third molars.
62043337|NCT06733870|OTHER|immediate load with provisional restoration|immediate load with PMMA crown on Ti base
62043338|NCT06733870|OTHER|immediate load with one abutment one time concept|immediate ;load with customized final abutment and PMMA crown
62043339|NCT06244277|EXPERIMENTAL|Chinese medicine group|Participants received Suanzaoren Decoction and Huanglian Wendan Decoction orally twice daily for 4 weeks. Subjects who had previously taken Western medicine hypnotics continued to take them, and those who did not take them did not add Western medicine hypnotics.
62602603|NCT01472965|ACTIVE_COMPARATOR|Treatment|Eligible patients with CLABSI will be enrolled within 96 hours of collection of positive blood culture and randomized to blinded treatment with 70% ethanol catheter lock therapy.
62824444|NCT06493578|ACTIVE_COMPARATOR|Low dose VYN201 (1.0%)|Subjects will apply VYN201 1.0% once daily on affected vitiligo areas. The first part of the study will be a 24-week, double-blind, vehicle controlled treatment period. Following, the second part will be a 28-week, double-blind treatment extension period, with a 4-week safety follow-up period after the last investigational medicinal product (IMP) dose. After completion of the Week 24 assessments, subjects randomized to 1.0% will remain and continue on the same dose until Week 52.
62824445|NCT06493578|ACTIVE_COMPARATOR|Mid dose VYN201 (2.0%)|Subjects will apply VYN201 2.0% once daily on affected vitiligo areas. The first part of the study will be a 24-week, double-blind, vehicle controlled treatment period. Following, the second part will be a 28-week, double-blind treatment extension period, with a 4-week safety follow-up period after the last investigational medicinal product (IMP) dose. After completion of the Week 24 assessments, subjects randomized to 2.0% will remain and continue on the same dose until Week 52.
62824446|NCT06493578|ACTIVE_COMPARATOR|High dose VYN201 (3.0%)|Subjects will apply VYN201 3.0% once daily on affected vitiligo areas. The first part of the study will be a 24-week, double-blind, vehicle controlled treatment period. Following, the second part will be a 28-week, double-blind treatment extension period, with a 4-week safety follow-up period after the last investigational medicinal product (IMP) dose. After completion of the Week 24 assessments, subjects randomized to 3.0% will remain and continue on the same dose until Week 52.
62602604|NCT01472965|PLACEBO_COMPARATOR|Control|Eligible patients with CLABSI will be enrolled within 96 hours of collection of positive blood culture and randomized to blinded treatment with heparin-saline placebo catheter lock therapy.
62602605|NCT04829331|EXPERIMENTAL|Restrata with a split-thickness skin graft|
62602606|NCT04829331|NO_INTERVENTION|Split-thickness skin graft alone|
62824447|NCT06493578|PLACEBO_COMPARATOR|Vehicle|Subjects will apply VYN201 vehicle (placebo) once daily on affected vitiligo areas. The first part of the study will be a 24-week, double-blind, vehicle controlled treatment period. Following, the second part will be a 28-week, double-blind treatment extension period, with a 4-week safety follow-up period after the last investigational medicinal product (IMP) dose. After completion of the Week 24 assessments, subjects randomized to vehicle (placebo) will be re-randomized to 1 of the 3 higher VYN201 (active) dose groups (1.0%, 2.0% or 3.0% once daily) in a 1:1:1 ratio while maintaining the blind until Week 52.
62043340|NCT06244277|ACTIVE_COMPARATOR|Western medicine group|Participants received cognitive behavioral therapy, if for various reasons can not accept cognitive behavioral therapy, or have received cognitive behavioral therapy is not effective, according to the doctor to consider drug treatment, taking Zolpidem Tartrate Tablets 0.25mg/kg, the maximum dose was 10mg / day ; according to the doctor 's clinical consideration, anxiety and depression drugs can be added. For patients under 18 years of age, under the careful consideration of the doctor for drug treatment, taking Zolpidem tablets, 10mg / day
62245989|NCT01052896|PLACEBO_COMPARATOR|Placebo|Half of the 100 patients will be placed on placebo look-alike of the gabapentin.
62824448|NCT06654518|EXPERIMENTAL|participants underwent preoperative CBCT measurements to guide the dental implant placement process.|Participants in this arm underwent preoperative Cone Beam Computed Tomography (CBCT) scans to assess bone density and alveolar ridge width. The data obtained from these scans was used to guide dental implant placement, with the primary goal of predicting the primary stability of the implant. The intervention involved using CBCT technology to gather precise anatomical details that help optimize implant placement and ensure adequate bone support for the implant.
62824449|NCT03691376|EXPERIMENTAL|Treatment (autologous NY-ESO-1 engineered T and HSC)|Patients receive melphalan IV over 30 minutes on day -1. Patients then receive autologous NY-ESO-1 CD4-TCR CD34+ HSC IV on day 0 and autologous NY-ESO-1-specific CD8-positive T lymphocytes IV between days 7 and 21. Patients also receive aldesleukin SC BID for 14 days on the following day after the T cell infusion (between days 8 and 22).
62245990|NCT05934162|EXPERIMENTAL|Therapist-supported internet delivered prolonged exposure|Therapist-supported internet delivered prolonged exposure comprising psychoeducation about PTSD, controlled breathing, imaginal exposure including processing, in vivo exposure and relapse prevention. The treatment will be delivered in a digital platform for ten weeks. Participants will have access to a therapist that will guide them through treatment in a text based format.
62436303|NCT02281071|ACTIVE_COMPARATOR|laterally moved coronally advanced flap macrosurgical|For the control group (LMCAF), LMCAF was performed with conventional instruments (detaylı) and materials (stur). Loupe magnification, microsurgical instruments and suture material were not used in the control group.
62436304|NCT00227656|EXPERIMENTAL|Capecitabine + PEG-interferon alfa-2a|Capecitabine 1000 mg/m2 orally twice daily during the first 14 days of each 3-week cycle (2 weeks on, 1 week rest), and PEG-interferon alfa-2a subcutaneously beginning at 180 mcg per week for 21 days.
62824450|NCT02042417|EXPERIMENTAL|INRatio2 and CoaguChek|one measuring per tool, in case of error: one repetiton
62824451|NCT05452486|EXPERIMENTAL|L1 First|All participants will receive both experimental conditions (i.e., test materials in English, test materials in Spanish) in a counterbalanced order. Individuals in this arm receive Spanish materials first, then English test materials.
62824452|NCT05452486|EXPERIMENTAL|L2 First|All participants will receive both experimental conditions (i.e., test materials in English, test materials in Spanish) in a counterbalanced order. Individuals in this arm receive English materials first, then Spanish test materials.
62043341|NCT04711915|ACTIVE_COMPARATOR|0.1 mg/kg DMT|0.1 mg/kg DMT administered intravenously
62043342|NCT04711915|ACTIVE_COMPARATOR|0.3 mg/kg DMT|0.3 mg/kg DMT administered intravenously
62245991|NCT05934162|ACTIVE_COMPARATOR|Therapist-supported CBT|Therapist-supported CBT internet-delivered treatment comprising psychoeducation about PTSD, relaxation techniques and relapse prevention. . The treatment will be delivered in a digital platform for ten weeks. Participants will have access to a therapist that will guide them through treatment in a text based format.
62245992|NCT00356616|EXPERIMENTAL|A|Trizivir+ Tenofovir 2/day
62245993|NCT00356616|NO_INTERVENTION|B|antiretroviral treatment optimizated by genotyp
62245994|NCT04119141|ACTIVE_COMPARATOR|Standard Arm|the first acquisition will be carried out without a tin filter in supine position and the second with tin filter in procubitus.
62436305|NCT06467500|EXPERIMENTAL|Bispecific antibody plus Chemotherapy|
62436306|NCT03400371||Patients diagnosed with JME|People who meet the eligibility requirements and have been diagnosed with juvenile myoclonic epilepsy.
62436307|NCT03400371||Controls|People without a lifetime history of seizures.
62436308|NCT06171997|EXPERIMENTAL|Swaddling after bath group|Newborns in this group will be swaddled safely after bath.
62436309|NCT06171997|NO_INTERVENTION|No swaddling after bath group|No action will be taken after bath.
62602607|NCT01058486|EXPERIMENTAL|Activity-Self Management|
62602608|NCT01058486|NO_INTERVENTION|Usual Care|
62602609|NCT05040620|NO_INTERVENTION|Placebo|controlling group who will receive traditional orthodontic treatment.
62824453|NCT06374238|EXPERIMENTAL|CBT w/ Health Coach|Group will utilize the Presence app to undergo self CBT for EMA, but with addition of peer health coaches.
62824454|NCT06374238|ACTIVE_COMPARATOR|CBT w/o Health coach (self-guided)|Group will utilize the Presence app to undergo self-guided CBT for EMA, but without peer health coaches.
62602610|NCT05040620|EXPERIMENTAL|Olive Oil|experimental group who will receive the local application of Olive Oil five times daily after teeth brushing
62602611|NCT01374932|EXPERIMENTAL|CPAP (see below)|Adult patients with asthma who require treatment with CPAP because of OSAS (RDI\> = 20 events per hour). CPAP will be administered according to SEPAR guidelines and tailored to individual characteristics
62824455|NCT06374238|ACTIVE_COMPARATOR|Usual Care with no access to CBT|Participants in the UC group will have access to CaRISMA app to complete a daily pain and mood e-diary, daily record of opiate use, and weekly assessment of pain via the Painimation tool. All other care will be at the discretion of their treating provider
62824456|NCT06604507||Soldiers or civilians, who underwent an amputation as a result of the 2022 war in Ukraine|The cohort consists of soldiers or civilians, who underwent an amputation as a result of the 2022 war in Ukraine, and will use an app that provides non-pharmaceutical methods to care for the sensations and pains related to amputation.
62824457|NCT06462794|EXPERIMENTAL|CX-801|
62824458|NCT06462794|EXPERIMENTAL|CX-801 + pembrolizumab|
62824459|NCT05764265|EXPERIMENTAL|LTP001|Participants will receive LTP001 orally once daily in the morning for approximately 52 weeks
62824460|NCT06595498|EXPERIMENTAL|SeqSensei™ Solid Cancer IVD Kit (Sysmex)|
62245995|NCT04119141|EXPERIMENTAL|Tin filter Arm|the first acquisition will be carried out with tin filter in supine position and the second without tin filter in procubitus.
62602612|NCT03367559|EXPERIMENTAL|Rotavirus Vaccine|3 dose, interval for each dose is 4 weeks. The first dose will be received at 6-8 weeks of age.
62824461|NCT06595498|ACTIVE_COMPARATOR|cobas® EGFR Mutation Test v2 (Roche)|
62824462|NCT06604702|EXPERIMENTAL|Fat Injection for Rectocele|Participants in this arm will undergo autologous fat injection as a novel treatment for rectocele. Fat grafts will be harvested from the patient's abdomen, processed to purify the fat, and injected into the submucosal layer of the rectocele through the posterior vaginal wall. This procedure aims to reduce the size of the rectocele, alleviate symptoms like vaginal bulge and obstructive defecation, and prevent recurrence.
62824463|NCT03464734|EXPERIMENTAL|Pembrolizumab + nab-paclitaxel|pembrolizumab 200 mg + nab-paclitaxel 125 mg/m2, intravenously
62824464|NCT05403385|EXPERIMENTAL|Part 1, open label|Inupadenant will be given at one or more dose levels to determine the recommended Phase 2 dose (RP2D).
62245996|NCT03794583|EXPERIMENTAL|Inhaled Treprostinil Solution|Inhaled treprostinil solution (0.6 milligrams per milliliter \[mg/mL\], 6 mcg/breath) QID during waking hours.
62824465|NCT05403385|EXPERIMENTAL|Part 2, active treatment|Treatment with inupadenant combined with carboplatin and pemetrexed
62824466|NCT05403385|PLACEBO_COMPARATOR|Part 2, placebo|Treatment with matched placebo combined with carboplatin and pemetrexed
62245997|NCT01528813|ACTIVE_COMPARATOR|Er:YAG + amorolfine lacquer|30 ungual units affected by onychomycosis due to dermatophytes
62245998|NCT01528813|PLACEBO_COMPARATOR|Amorolfine lacquer|30 ungual units affected by onychomycosis due to dermatophytes
62602613|NCT04566133|EXPERIMENTAL|Cohort 1/Arm 1: Trametinib + Hydroxychloroquine (HCQ)|Trametinib + hydroxychloroquine (HCQ)
62824467|NCT06591637|EXPERIMENTAL|intervention group|The intervention group received fertility supportive behavior education based on Watson's Theory of Human Caring and was given a booklet titled 'Fertility-Supporting Health Training' at the onset of treatment. In addition to routine nursing care, the researcher provided detailed intervention and guidance regarding the booklet throughout the treatment period.
62824468|NCT06591637|OTHER|control group|The control group received routine nursing care and was given a booklet titled 'Fertility-Supporting Health Training' at the onset of treatment, but the researcher did not provide any additional intervention or guidance regarding the booklet.
62824469|NCT03837041|ACTIVE_COMPARATOR|Reconditioning Proprioception group|Training Proprioception 1 hour for 2 day a week
62824470|NCT03837041|NO_INTERVENTION|Control group|
62602614|NCT00553852|EXPERIMENTAL|1|The clinical examination will determine anthropometric indexes (weight, height, BMI, waist circumference). The biochemical evaluation will include the measurement of lipid profile, fasting plasma glucose and insulin, liver test function, FT3, FT4, GHRH + Arginine test to detect GHD, plasma IGF-I levels. The instrumental evaluation will include DEXA Total Body and bioimpedance analysis to determine body composition, and liver ultrasounds.
62824471|NCT04169035|EXPERIMENTAL|Odon device|The practitioner providing the woman's care in labour determines that she requires an assisted vaginal birth, and there is no obstetric indication for an alternative method of assiste vaginal birth. Odon trained practitioner available to assist the birth.
62602615|NCT00553852|PLACEBO_COMPARATOR|2|PHASE II: In the medical treatment protocol very severe obese patients with persistent GHD after LASGB will be inclosed. Starting from 15-day, GHD patients were re-evaluated by GHRH + Arginine test. After evaluation, the patients with persistent GHD will be randomized to be treated with Recombinant GH replacement therapy (Group A: Recombinant GH replacement therapy at the initial dose 0.15-0.30 mg/die; dose adjustment will be made according to IGF-I levels; Group B: no GH treatment).
62824472|NCT04169035|ACTIVE_COMPARATOR|Forceps or ventouse|"The practitioner providing the woman's care in labour determines that she requires an assisted vaginal birth, and there is no obstetric indication for an alternative method of assisted vaginal birth.~The woman is unable to have an Odon assisted birth as no Odon trained practitioner is available to assist the birth."
62824473|NCT04367727|EXPERIMENTAL|5 minutes before 1|Light emitting diode applied 5 minutes before fatiguing task
62824474|NCT04367727|PLACEBO_COMPARATOR|5 minutes before 2|Light emitting diode applied 5 minutes before fatiguing task
62824475|NCT04367727|EXPERIMENTAL|1 hour before 1|Light emitting diode applied 1 hour before fatiguing task
62824476|NCT04367727|PLACEBO_COMPARATOR|1 hour before 2|Light emitting diode applied 1 hour before fatiguing task
62824477|NCT04367727|EXPERIMENTAL|5 hours before 1|Light emitting diode applied 5 hours before fatiguing task
62245999|NCT06734052|EXPERIMENTAL|Computer-guided Action Planning to support Physical Activity (CAPPA)|"Participants in the CAPPA Arm receive a Fitbit and health coaching using Computer-guided Action planning. Coaches will utilize the coaching software within www.myactionplans.com to guide the coaching interaction and support physical activity plan development. The emphasis is this arm is to create plans that are person-centered and driven by the participant. The action planning process is grounded in the conversational style of motivational interviewing and follows Brief Action Planning as a self-management support style. Coaches in the CAPPA arm will also have access to a custom Movement Dashboard which that uses Fitbit data to plot daily physical activity. The dashboard is coach-facing and is used to support coach dialogue about physical activity.~There is scheduling flexibility: 4-12 visits over the 12-week period. Participants are strongly encouraged not to have a gap longer than three weeks between visits."
62436310|NCT03990389|NO_INTERVENTION|Usual Care Group|"Subjects will undergo screening including Rapid Estimate of Adult Literacy in Medicine (REALM-R) and Edinburgh Postnatal Depression Scale (EPDS) and a few additional questions.~Eligible subjects randomized to usual care will receive monthly reminder phone calls from a research coordinator. Subjects will receive an email with a link to surveys for the purpose of collecting information on depression severity, medication adherence, self-efficacy, side-effect burden, and maternal functioning.~All participants will be asked to participate in a semi-structured debrief interview upon study completion."
62436311|NCT03990389|EXPERIMENTAL|Chabot Care Group|"Subjects will undergo screening including REALM-R and EPDS and a few additional questions.~Eligible subjects randomized to chatbot care will receive monthly reminder phone calls from a research coordinator. Subjects will receive an email with a link to surveys for the purpose of collecting information on depression severity, medication adherence, self-efficacy, side-effect burden, and maternal functioning.~In addition to the above procedures, eligible subjects randomized to chatbot care will receive weekly messages from the chatbot asking them to complete a depression severity measure and side-effect burden assessments. Within week 1 subjects will receive a check-in call from a study coordinator to answer any questions regarding use of the chatbot.~All participants will be asked to participate in a semi-structured debrief interview upon study completion."
62436312|NCT03990389|NO_INTERVENTION|Provider Subject Cohort|20 provider subjects from each study site will be enrolled to ensure they understand the study and consent to have their patients enrolled in the study
62824478|NCT04367727|PLACEBO_COMPARATOR|5 hours before 2|Light emitting diode applied 5 hours before fatiguing task
62824479|NCT03448406|EXPERIMENTAL|Empagliflozin|
62824480|NCT03448406|ACTIVE_COMPARATOR|Placebo|
62824481|NCT02568267|EXPERIMENTAL|NTRK1/2/3-rearranged NSCLC|Oral entrectinib (RXDX-101)
62824482|NCT02568267|EXPERIMENTAL|ROS1-rearranged NSCLC|Oral entrectinib (RXDX-101)
62436313|NCT04733131||converted to a belatacept based immunosuppression|Belatacept: infusion on Days 1, 15, 29, 43, 57 then every 28 days. All patients received a background maintenance immunosuppressive regimen of mycophenolate mofetil or mycophenolic acid, with adjunctive corticosteroids, according to their immunosuppressive regimen at the time of enrollment.
62824483|NCT02568267|EXPERIMENTAL|ALK- or ROS1-rearranged NSCLC|"with CNS-only progression previously treated with crizotinib (NOTE: The ALK-rearranged portion of this arm is now closed to enrollment.)~Oral entrectinib (RXDX-101)"
62824484|NCT02568267|EXPERIMENTAL|NTRK/1/2/3-rearranged mCRC|Oral entrectinib (RXDX-101)
62824485|NCT02568267|EXPERIMENTAL|ROS1-rearranged mCRC|Oral entrectinib (RXDX-101)
62824486|NCT02568267|EXPERIMENTAL|ALK-rearranged mCRC|Oral entrectinib (RXDX-101)
62824487|NCT02568267|EXPERIMENTAL|NTRK1/2/3-rearranged other solid tumor|Oral entrectinib (RXDX-101)
62824488|NCT02568267|EXPERIMENTAL|ROS1-rearranged other solid tumor|Oral entrectinib (RXDX-101)
62824489|NCT02568267|EXPERIMENTAL|ALK-rearranged other solid tumor|Oral entrectinib (RXDX-101)
62824490|NCT06594341|ACTIVE_COMPARATOR|Simplified treatment|Children will be treated with a simplified protocol prescribing 2 sachets of RUTF to children admitted with a MUAC\<115mm or edema and 1 sachet to children with MUAC 115-124mm. Children admitted with a MUAC\<115mm or edema will be transitioned to receive 1 sachet of RUTF once they have reached a MUAC\>=115mm for 2 consecutive visits. Visit frequency will be weekly for all children regardless of severity or phase.
62602616|NCT04111718|EXPERIMENTAL|Viewing of preparation|The patient will be in the room for the preparation of the PRP and will receive a description of the centrifuge process from the physician administering the injection.
62602617|NCT04111718|SHAM_COMPARATOR|Blinded to preparation|The patient will leave the room after their blood is drawn and will not view the preparation of the PRP, and will also not receive a description of the centrifuge process.
62246000|NCT06734052|ACTIVE_COMPARATOR|Health education|"Participants in Arm 2 receive a Fitbit and health education delivered by a coach. Health education selects topics from the chronic disease self-management program that address common features of living with a chronic condition. Arm 2 avoids making specific plans and avoids discussion of physical activity. The emphasis in this arm is in providing education.~There is scheduling flexibility, 4-12 visits over the 12-week period. Participants are strongly encouraged not to have a gap longer than three weeks between visits to keep the content fresh."
62246001|NCT06292000|EXPERIMENTAL|Crossover - AM first|Crossover design with AM exercise first
62246002|NCT06292000|EXPERIMENTAL|Crossover - PM first|Crossover design with PM exercise first
62246003|NCT05368961|ACTIVE_COMPARATOR|Usual care|Usual care (midazolam) is administered pre-operatively
62602618|NCT02103335|EXPERIMENTAL|Single Group Assignment|Combination Pomalidomide, low-dose Dexamethasone, and Marizomib:
62602619|NCT00038623|EXPERIMENTAL|Yttrium-ibritumomab (Zevalin)|After Rituximab infusion (250 mg/m\^2 intravenous) on Day 1, 111\^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
62602620|NCT03298256||Lenke type 1 AIS|Patients will be given a new prescription for a custom made Boston type thoracic-lumbo- sacral-orthosis (TLSO) braces. All patients will undergo low dose biplanar X-rays using the EOS ® machine system.
62602621|NCT02741791|EXPERIMENTAL|AXS-05|
62824491|NCT06594341|EXPERIMENTAL|Simplified treatment with a reduced visit frequency|"Children will be treated with a simplified protocol prescribing 2 sachets of RUTF to children admitted with a MUAC\<115mm or edema and 1 sachet to children with MUAC 115-124mm. Children admitted with a MUAC\<115mm or edema will be transitioned to receive 1 sachet of RUTF once they have reached a MUAC\>=115mm for 2 consecutive visits. Visit frequency will be weekly for children in the severe phase and fortnightly for children in the moderate phase."
62602622|NCT02741791|ACTIVE_COMPARATOR|Bupropion|
62824492|NCT06594341|EXPERIMENTAL|Simplified treatment without transition period|Children will be treated with a simplified protocol prescribing 2 sachets of RUTF to children admitted with a MUAC\<115mm or edema and 1 sachet to children with MUAC 115-124mm. Children admitted with a MUAC\<115mm or edema will be transitioned to receive 1 sachet of RUTF immediately when they have reach a MUAC\>=115mm. Visit frequency will be weekly for all children regarless of severity or phase.
62246004|NCT05368961|EXPERIMENTAL|Distraction|Distraction (interactive tablet) is given to children pre-operatively
62436314|NCT03953365|NO_INTERVENTION|without mesh|Patients undergo to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy without prophylactic mesh
62602623|NCT01789671|EXPERIMENTAL|Peer Interventionist|Families randomized to this family-based behavioral intervention arm will receive 20 weeks of family-based behavioral pediatric overweight intervention delivered by parents who previously received this treatment (PEER). This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
62602624|NCT01789671|ACTIVE_COMPARATOR|Professional Interventionist|Families randomized to this family-based behavioral intervention arm will receive 20 weeks of family-based behavioral pediatric overweight intervention delivered by behavioral specialists(PROFESSIONAL). This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
62602625|NCT06621082|EXPERIMENTAL|Postoperative drug group|This study started from the recruitment of subjects, confirmed diagnosis by clinical diagnosis and pathological biopsy, preliminary screening according to inclusion and exclusion criteria, and signing of informed consent. Patients who were evaluated as indications for surgical resection and underwent surgical treatment were treated with Smetinib bisulfate capsules. PFS, ORR, and DOR were evaluated after 6 cycles of administration of Simetinib bisulfate capsules (20-50mg bid) daily for 30 days, as individualized by patient body surface area (BSA).
62436315|NCT03953365|OTHER|with mesh|Patients undergo to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with prophylactic mesh
62436316|NCT00947011|PLACEBO_COMPARATOR|Placebo|
62436317|NCT00947011|ACTIVE_COMPARATOR|Januvia|
62246005|NCT02194036|EXPERIMENTAL|Learning oriented physiotherapy|Learning oriented physiotherapy is a treatment approach based on knowledge from neuroscience and particularly aimed to curb physical symptoms and ailments, but also to regain a sense of better physical balance and mental control. Therapy sessions are normally given every 2 weeks with individual homework lessons between. The therapy will last between 6 to 12 months depending on learning process and individual needs.
62246006|NCT02194036|ACTIVE_COMPARATOR|Widely Recognized Psychiatric Treatment|Standard Outpatient Treatment within the Psychiatric clinic
62436318|NCT03503708|EXPERIMENTAL|Intervention Group|All the eligible participants will receive Livitol-17 capsules. It consist of 390 mg of whole herbs and extract of Phyllanthus niruri (Bhumyamalaki), Boerhaavia diffusa (Punarnava) and Picroorrhiza kurroa (Katuki).
62246007|NCT02630446|EXPERIMENTAL|in-home respite care program|During the respite care period, lasting at least five days, a trained or experienced care worker for persons with dementia takes over all caregiving tasks while the informal caregiver is absent. The care worker thus temporary moves into the house of the person with dementia. The care worker also writes down his/her observations in a diary as well as daily experiences and strategies on how to manage the difficult behaviors the caregivers listed before. So additionally to the provision of respite, this program also includes caregiver support and psycho-education. This support enables the caregiver to validate theirs perceptions, to learn how to deal with difficult behaviors and to feel understood by somebody.
62246008|NCT02630446|NO_INTERVENTION|standard dementia care|Control group receiving all types of standard dementia care except in-home respite care of the Baluchon type.
62246009|NCT06734364|EXPERIMENTAL|buddy|
62246010|NCT06734364|ACTIVE_COMPARATOR|splint|
62246011|NCT00233688|EXPERIMENTAL|1|QUANTUM LP™ STENT GRAFT SYSTEM
62436319|NCT06010056|EXPERIMENTAL|Group A|PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1) as postoperative analgesia.
62436320|NCT06010056|ACTIVE_COMPARATOR|Group B|PCA morphine (Pfizer Inc., US) 1 mg ml-1 as postoperative analgesia.
62824493|NCT06594341|EXPERIMENTAL|Simplified treatment with a reduced visit frequency and without a transition period|"Children will be treated with a simplified protocol prescribing 2 sachets of RUTF to children admitted with a MUAC\<115mm or edema and 1 sachet to children with MUAC 115-124mm. Children admitted with a MUAC\<115mm or edema will be transitioned to receive 1 sachet of RUTF immediately once reach a MUAC\>=115mm . Visit frequency will be weekly for children in the severe phase and fortnightly for children in the moderate phase."
62436321|NCT01333176|EXPERIMENTAL|All volunteers have HbA1c test|All candidates receive same procedure
62436322|NCT03618459||Breast-surgery patients|A consecutive cohort of adult patients undergoing breast surgery with a combined anesthesia technique, employing a thoracic single-shot paravertebral block performed before surgery. Operations performed were in all cases unilateral tumor resections, lumpectomies and mastectomies without axillary lymphadenectomy.
62449173|NCT03356587|EXPERIMENTAL|Arm4: Abemaciclib|Abemaciclib represents a selective and potent small molecule CDK4 and CDK6 dual inhibitor with broad antitumor activity in preclinical pharmacology models.(oral class) Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day
62602626|NCT05057897|OTHER|Cohort 1 - immunocompromised participants with solid organ transplant|Previously unvaccinated immunocompromised participants with solid organ transplant will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
62602627|NCT05057897|OTHER|Cohort 2 - immunocompromised participants with hematopoietic stem cell transplant|Previously unvaccinated immunocompromised participants with hematopoietic stem cell transplant will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
62824494|NCT06212362|EXPERIMENTAL|Step-by-Step treatment|
62824495|NCT06212362|ACTIVE_COMPARATOR|Cool Kids treatment|
62824496|NCT05408429|EXPERIMENTAL|2-Dose 20vPnC Group|Pneumococcal conjugate vaccine (2 doses approximately 2 months apart)
62824497|NCT05408429|EXPERIMENTAL|1-Dose 20vPnC Group|Pneumococcal conjugate vaccine
62824498|NCT05408429|ACTIVE_COMPARATOR|13vPnC Group|Pneumococcal conjugate vaccine
62824499|NCT06595485|EXPERIMENTAL|online mindfulness -base intervention|
62824500|NCT06595485|NO_INTERVENTION|waitlist control group|
62824501|NCT02925286|EXPERIMENTAL|Intervention group|Five organizations will get the intervention during fall/winter 2016.
62824502|NCT02925286|NO_INTERVENTION|Wait-list group|Five organizations will be on the waitlist for 12 months and then get the intervention.
62824503|NCT05179785|EXPERIMENTAL|Left vLPFC cTBS/right dlPFC iTBS/left Som cTBS|"A random number sequence will be generated for randomization of the 3 EEG/TBS session order to which each participant is assigned:~left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex) right dlPFC iTBS (iTBS applied to the right dorsolateral prefrontal cortex) left Som cTBS (cTBS applied to the left somatosensory cortex)"
62824504|NCT05179785|EXPERIMENTAL|Left vLPFC cTBS/left Som cTBS/right dlPFC iTBS|"A random number sequence will be generated for randomization of the 3 EEG/TBS session order to which each participant is assigned:~left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex) left Som cTBS (cTBS applied to the left somatosensory cortex) right dlPFC iTBS (iTBS applied to the right dorsolateral prefrontal cortex)"
62246012|NCT00233688|ACTIVE_COMPARATOR|2|Surgical intervention
62449174|NCT05487833|EXPERIMENTAL|insulin|
62246013|NCT02656498|EXPERIMENTAL|Cognitively Healthy Subjects|Cognitively healthy subjects will receive an IV injection, \[18F\]THK-5351 at baseline and also receive an IV injection, \[18F\]THK-5351 at 24 months.
62246014|NCT02656498|EXPERIMENTAL|MCI Subjects|MCI Subjects will receive an IV injection, \[18F\]THK-5351 at baseline and also receive an IV injection, \[18F\]THK-5351 at 24 months.
62246015|NCT02656498|EXPERIMENTAL|AD Subjects|AD Subjects will receive an IV injection, \[18F\]THK-5351 at baseline and also receive an IV injection, \[18F\]THK-5351 at 24 months.
62246016|NCT02656498|EXPERIMENTAL|Subjects with other neurodegenerative disease|Subjects with other neurodegenerative disease will receive an IV injection, \[18F\]THK-5351 at baseline.
62246017|NCT02917668|ACTIVE_COMPARATOR|Group A|15 patients who will receive usual care for 30 minutes and then switch to FreeO2 for another 30 minutes
62824505|NCT05179785|EXPERIMENTAL|left Som cTBS/right dlPFC iTBS/Left vLPFC cTBS|"A random number sequence will be generated for randomization of the 3 EEG/TBS session order to which each participant is assigned:~left Som cTBS (cTBS applied to the left somatosensory cortex) right dlPFC iTBS (iTBS applied to the right dorsolateral prefrontal cortex) left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)"
62246018|NCT02917668|ACTIVE_COMPARATOR|Group B|15 patients who will be oxygenated by FreeO2 for 30 minutes and then switch to usual care for another 30 minutes
62436323|NCT05418478|EXPERIMENTAL|Intervention group|"Study group intervention: 7 sessions of transtheoretical model-based interview (2 in the first month, a total of 7 times, once a month), a structured disease education through transtheoretical model-based telehealth practices, and 6-month follow-up.~* After the participants are included in the study, a health education structured according to the Transtheoretical model will be given to the patients in the study group through tele-health applications.~* The patients in the intervention group will be trained through tele-health practices for at least 25-30 minutes on a transtheoretical basis, every 2 weeks in the first month and once a month in the following months. Tele-health applications include phone monitoring, SMS notification and application applications.~* In the 6-month follow-up, there will be 2 follow-ups as pre-test (1st month) and post-test (6th month).~* Behavioral: 7 sessions of behavior change training based on the transtoerytic model"
62436324|NCT05418478|NO_INTERVENTION|Control|"* No notification will be made to the relatives of the patients in the control group. Control group patients will be called for routine control in line with their usual plans. After a total of 6 months from the beginning, the self-care and treatment compliance levels of the patients in the control group will be examined.~* There will be 2 follow-ups as pre-test (1st month) and post-test (6th month)."
62602628|NCT05057897|OTHER|Cohort 3 - immunocompromised participants with solid organ cancer receiving cytotoxic chemotherapy|Previously unvaccinated immunocompromised participants with solid organ cancer receiving cytotoxic chemotherapy will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
62602629|NCT05057897|OTHER|Cohort 4 - immunocompromised participants with chronic inflammatory disorders|Previously unvaccinated immunocompromised participants with chronic inflammatory disorders will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
62602630|NCT05057897|OTHER|Cohort 5 - immunocompromised participants with primary immunodeficiency|Previously unvaccinated immunocompromised participants with primary immunodeficiency will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
62602631|NCT05057897|OTHER|Cohort 6 - immunocompetent participants|Previously unvaccinated immunocompetent participants will receive a primary vaccination series with 2 IM doses of AZD1222 separated by 4 weeks, followed by a booster dose of AZD1222 administered 6 months after the first dose. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1. Participants will receive a third dose booster 6 months after dose 1 and will continue to be followed to the end of the study.
62602632|NCT00203944||international adopted infants|international adoptees making their first visit to international adoption clinic
62602633|NCT00203944||Control infants|
62824506|NCT05179785|EXPERIMENTAL|left Som cTBS/Left vLPFC cTBS/right dlPFC iTBS|"A random number sequence will be generated for randomization of the 3 EEG/TBS session order to which each participant is assigned:~left Som cTBS (cTBS applied to the left somatosensory cortex) left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex) right dlPFC iTBS (iTBS applied to the right dorsolateral prefrontal cortex)"
62824507|NCT05179785|EXPERIMENTAL|right dlPFC iTBS/left Som cTBS/Left vLPFC cTBS|"A random number sequence will be generated for randomization of the 3 EEG/TBS session order to which each participant is assigned:~right dlPFC iTBS (iTBS applied to the right dorsolateral prefrontal cortex) left Som cTBS (cTBS applied to the left somatosensory cortex) left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)"
62824508|NCT05179785|EXPERIMENTAL|right dlPFC iTBS/Left vLPFC cTBS/left Som cTBS|"A random number sequence will be generated for randomization of the 3 EEG/TBS session order to which each participant is assigned:~right dlPFC iTBS (iTBS applied to the right dorsolateral prefrontal cortex) left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex) left Som cTBS (cTBS applied to the left somatosensory cortex)"
62824509|NCT00144807|EXPERIMENTAL|R-AC|rituximab + doxorubicin + cyclophosphamide + autologous stem cell transplantation
62824510|NCT06601738|EXPERIMENTAL|Group A|
62824511|NCT06601738|ACTIVE_COMPARATOR|Group B|
62824512|NCT06140589||effective group|The tumor size of each diameter of the tumor before and after treatment was measured on magnetic resonance imaging or CT. According to Recist 1.1 criteria, patients who were evaluated as complete remission, partial remission and stable disease were included in the effective group. Patients assessed as having progressive disease were included in the treatment-refractory group.
62824513|NCT06140589||ineffective group|The tumor size of each diameter of the tumor before and after treatment was measured on magnetic resonance imaging or CT. According to Recist 1.1 criteria. Patients assessed as having progressive disease were included in the ineffective group.
62824514|NCT06604585|EXPERIMENTAL|The intervention- an interactive digital parental support program in primary care.|"The intervention group will receive conventional parental support according to the national child health care programme. Additionally, they will have access to the digital parental support program, 'Parenthood - A Journey Together'."
62246019|NCT02366975|NO_INTERVENTION|Eugonadal patients|Patients without hypogonadism has been enrollend but not randomized
62246020|NCT02366975|ACTIVE_COMPARATOR|Hypogonadal patients A|Patients with hypogonadism has been randomized to testosterone gel solution 2%
62246021|NCT02366975|PLACEBO_COMPARATOR|Hypogonadal patients B|Patients with hypogonadism has been randomized to placebo solution gel
62246022|NCT00763971|EXPERIMENTAL|Lisdexamfetamine Dimesylate (LDX)|Overencapsulated LDX 30, 50, or 70mg
62449175|NCT05487833|PLACEBO_COMPARATOR|standard management|
62246023|NCT00763971|ACTIVE_COMPARATOR|Methylphenidate Hydrochloride|Overencapsulated Concerta 18, 36, or 54mg
62246024|NCT00763971|PLACEBO_COMPARATOR|Placebo|Overencapsulated Placebo
62602634|NCT06617351|EXPERIMENTAL|Melatonin|"Participants will receive Melatonin (5mg, 3 times daily with breakfast, lunch and dinner) beginning 24 hours before and ending 48 hours following an acute bout of dynamic high-intensity resistance exercise. On the day of the exercise bout, participants will ingest a single dose of Melatonin prior to arriving at the lab and following all testing procedures.~Melatonin formula: 7.5 kCal, 2 g Carbohydrate, 1.5 g total sugars, 7.5 mg sodium, 5 mg melatonin."
62602635|NCT06617351|PLACEBO_COMPARATOR|Placebo|"Participants will receive Placebo (3 times daily with breakfast, lunch and dinner) beginning 24 hours before and ending 48 hours following an acute bout of dynamic high-intensity resistance exercise. On the day of the exercise bout, participants will ingest a single dose of the placebo prior to arriving at the lab and following all testing procedures.~Placebo formula: 12.5 kCal, 3g Carbohydrate, 1.875 g total sugars, 1.25 mg sodium."
62824515|NCT06604585|NO_INTERVENTION|The control group without access to the digital parental support program.|"The control group will receive conventional parental support according to the national child health care programme, without access to the digital parental support program, 'Parenthood - A Journey Together'."
62824516|NCT06221280|ACTIVE_COMPARATOR|Group E|Patients who underwent erector spinae plane block
62824517|NCT06221280|ACTIVE_COMPARATOR|Group T|Patients who underwent transversus abdominis plane block
62824518|NCT06591351|ACTIVE_COMPARATOR|cilostazol and aspirin|The cilostazol arm will receive (a 200 mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
62824519|NCT06591351|ACTIVE_COMPARATOR|clopidogrel and aspirin|The clopidogrel arm will receive (a 300 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
62824520|NCT06522620|ACTIVE_COMPARATOR|Sciatic saphenous nerve block group (Group S)|Postoperative analgesia using subgluteal approach sciatic nerve block + saphenous nerve block
62602636|NCT01528657|EXPERIMENTAL|Ventricular Pace Suppression (VpS)|The function Ventricular Pace Suppression (VpS) is activated
62602637|NCT01528657|EXPERIMENTAL|Intrinsic Rhythm Support (IRSplus)|The function Intrinsic Rhythm Support (IRSplus) is activated
62602638|NCT03944369|OTHER|Observational Control|The observational control arm is an observational control group.
62602639|NCT03944369|OTHER|KB109|KB109 is a novel glycan.
62602640|NCT03936335||Dupilumab cohort|"Exposed to dupilumab during the relevant exposure window:~* First trimester~* Pregnancy"
62602641|NCT03936335||Other systemic therapy or phototherapy cohort|"Exposed to systemic medications other than dupilumab or to phototherapy during the relevant exposure window:~* First trimester~* Pregnancy"
62602642|NCT03936335||Unexposed cohort|"* Not exposed to systemic medications (including dupilumab) or phototherapy; and~* Received topical prescription therapy, or a second diagnosis for AD on a date that differs from the base population qualifying AD diagnosis date during the relevant exposure window:~* First trimester~* Pregnancy"
62602643|NCT06649500|EXPERIMENTAL|Experimental Sensorized Treadmill|"Patients will carry out treatment with a sensorized treadmill, Walker View. This treadmill gives the possibility to patients to see their image reconstructed in a 3D mode in order to observe the bad aligments that increase the patients balance disorders. The feedback systems are necessary to give continuous stimulation to the patients.~Each patients will carry out 18 treatment sessions and each session will last 30 minutes"
62602644|NCT06649500|ACTIVE_COMPARATOR|Conventional Therapy|"Patients in this arm will carry out treatment with a conventional group therapy, consisting in usual treatment according to current clinical practice.~Each patient will undergo 18 sessions of conventional therapy based on group re-education."
62602645|NCT06649500|NO_INTERVENTION|Clinical monitoring|Patients in this arm will take part in the 'no intervention' part of the study and they will not carry out treatment. Patients will undergo only a clinical monitoring with an educational intervention, which does not elvove treatment or exercises, and they will continue to follow their daily habits.
62824521|NCT06522620|EXPERIMENTAL|Combined posterior femoral cutaneous nerve block group (Group P)|Postoperative analgesia using supragluteal approach sciatic nerve block + posterior femoral cutaneous nerve block + saphenous nerve block
62824522|NCT01221896||Hyperparathyroidism|Patients with hyperparathyroidism, prior to surgery.
62246025|NCT04070755|EXPERIMENTAL|FMX-101|
62602646|NCT05269212|ACTIVE_COMPARATOR|Usual care|
62602647|NCT05269212|ACTIVE_COMPARATOR|Personalized biopsychosocial rehabilitation program|
62824523|NCT05760898|EXPERIMENTAL|Blood pressure intervention arm|The investigators will recruit 25 Black RA patients with HTN for the study. Participants will be provided with a home blood pressure monitor, teaching from nursing staff regarding the correct use of the monitor, and a guide to help interpret normal and elevated blood pressure values. Participants will be instructed to obtain and record blood pressure values at least three times per week over the course of 3 months. Every 2 weeks, these results will be sent to the study team, and participants will complete a brief survey regarding other factors that may influence blood pressure control, including RA disease activity (RAPID3 score), pain, current use of acute RA therapies, anti-hypertensive medication use, anti-hypertensive medication adherence, and current perceived barriers to HTN self-management.
62246026|NCT06735703||Pregnant women after 34 wks with PROM|
62602648|NCT05236231|EXPERIMENTAL|Treatment Sequence ABC|Participants will receive single oral dose of fixed dose combination (FDC) of macitentan/tadalafil under fasting conditions in (test) (Treatment A) Treatment Period 1 followed by single oral dose of FDC of macitentan/tadalafil under fed conditions (test) (Treatment B) in Treatment Period 2 and then single oral dose of macitentan/tadalafil under fasting conditions (reference) (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
62824524|NCT04060498|EXPERIMENTAL|Mindfulness intervention|This arm consists of seven weekly-session mindfulness-based intervention for psychosis (MBI-p). The MBI-p is a protocol-based, low intensity intervention developed to help patients achieve a greater sense of peace and calmness, and facilitates participants in handling everyday stress and conflicts.
62246027|NCT06379048|ACTIVE_COMPARATOR|M-Suture|Episiotomy repair is completed until the skin closure. Interrupted matress suturing technique is applied to this arm.
62824525|NCT04060498|PLACEBO_COMPARATOR|Psychoeducation intervention|This arm consists of seven weekly-sessions of psychoeducation. Topics to be discussed in the sessions include the signs and symptoms of psychosis, aetiology of psychosis, as well as pharmacological and non-pharmacological interventions.
62824526|NCT04386304|EXPERIMENTAL|Dose escalation of (+)-epicatechin|Subjects will receive escalating doses of (+)-epicatechin starting at 75 mg/day and progressing to 150 mg/day and 225 mg/day with 2 months treatment duration for each dose. Subjects will continue treatment on the individual's maximum tolerated dose for another 6 months.
62824527|NCT05887375|EXPERIMENTAL|Sugammadex 2 mg/kg|Sugammadex 2 mg/kg administered as a single intravenous (IV) dose.
62824528|NCT05887375|ACTIVE_COMPARATOR|Neostigmine + Glycopyrrolate|Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose.
62824529|NCT06602505|NO_INTERVENTION|Group B: No-field Block Group|Group B did not receive any field block before institution of subarachnoid block using 27 G Quincke's spinal needle for lower segment Caesarean section.
62824530|NCT06602505|EXPERIMENTAL|Group A: Field Block Group|Patients received field block with 5ml of 2% Lignocaine using a 24 G hypodermic needle before institution of subarachnoid block using 27 G Quincke's spinal needle for lower segment Caesarean section.
62043343|NCT03608930|EXPERIMENTAL|rotary polypectomy snare|All colorectal polyps found are removed using a rotary polypectomy snare (Disposable Polypectomy Snare). The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is used after hot snare polypectomy if removing a flat polyp or bleeding on the wound after treatment.
62246028|NCT06379048|ACTIVE_COMPARATOR|I-Suture|Episiotomy repair is completed until the skin closure. Interrupted primary suturing technique is applied to this arm.
62246029|NCT06379048|ACTIVE_COMPARATOR|SC-Suture|Episiotomy repair is completed until the skin closure. Continious subcutaneous suturing technique is applied to this arm.
62246030|NCT03602274||orthopedic and visceral surgery patients|patient having been subjected to an intervention from the orthopedic or visceral surgery department being prescribed 4 g paracetamol / day
62246031|NCT03602274||Overdosed patients|Patent admitted to hospital with paracetamol overdoses
62436325|NCT03080194|EXPERIMENTAL|paliperidone palmitate group|The subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement.
62602649|NCT05236231|EXPERIMENTAL|Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1 followed by Treatment C in Treatment Period 2 and Treatment A in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
62824531|NCT05403437||Group 1: Pregnant women with PGP and newly diagnosed with GDM|Pregnant women with PGP who were newly diagnosed with Gestational Diabetes Mellitus (GDM) according to routine control examinations and whose treatment for diabetes was not started
62824532|NCT05403437||Group 2: Pregnant women with PGP and diagnosed with GDM|Pregnant women with PGP who were diagnosed with Gestational Diabetes Mellitus (GDM) according to routine control examinations and whose treatment has been already started for diabetes
62824533|NCT05403437||Group 3: Pregnant women with PGP|Pregnant women with PGP who were not diagnosed with GDM according to routine control examinations
62824534|NCT00593216||Healthy|Healthy volunteers devoid of any ear problems
62824535|NCT00593216||Vertigo|Patients with the symptoms of vertigo
62824536|NCT05817058|EXPERIMENTAL|Treatment of escalating doses of AFM28|AFM28 first in human starting dose will be 25 mg i.v.
62824537|NCT03215056|EXPERIMENTAL|PENTHROX® (methoxyflurane)|"PENTHROX® (methoxyflurane) administered as a liquid for inhalation and should be self-administered under supervision of research nurse trained in its administration, using the hand held PENTHROX® inhaler.~One vial of 3 mL PENTHROX® is to be vaporised in a PENTHROX® inhaler. On finishing the 3 mL dose, another 3 mL may be used.~Dose of PENTHROX® should not exceed 6 mL in a single administration.~The patient is instructed to inhale ten successive inhalations of PENTHROX® (methoxyflurane) followed by additional intermittent inhalations as required.~The maximum dose administered will not exceed 6 mL of methoxyflurane."
62246032|NCT02459769|ACTIVE_COMPARATOR|Dyadic Exercise Intervention|Progressive walking and resistance exercise treatment, prescribed to both cancer survivors and their caregivers (daily walking and 3 times/week resistance prescription for 6 weeks). Cancer survivor and caregiver are also asked to discuss ways they can support one another in a) remaining adherent to exercise, and b) dealing with stress, including LGBT-specific minority stress.
62246033|NCT02459769|OTHER|Individual Exercise Intervention|Progressive walking and resistance exercise treatment, prescribed solely to cancer survivors (daily walking and 3 times/week resistance prescription for 6 weeks). The caregiver is told not to change his/her exercise behavior in any way.
62824538|NCT03215056|PLACEBO_COMPARATOR|Normal saline|"Normal saline will be administered as a liquid for inhalation and should be self-administered under supervision of research nurse trained in its administration, using the hand held PENTHROX® inhaler.~One vial of 5 mL of normal saline is to be vaporised in a PENTHROX® inhaler. On finishing the 5 mL dose, another 5 mL may be used.~Dose of normal saline should not exceed 10 mL in a single administration.~In this study, the patient is instructed to inhale ten successive inhalations of placebo followed by additional intermittent inhalations as required.~The maximum dose administered will not exceed 10 mL of placebo (2 × 5 mL)"
62824539|NCT00821795|ACTIVE_COMPARATOR|NPH/Regular 70/30 mix|transition insulin therapy with NPH/Regular 70/30 mix for outpatient glycemic control following a hospitalization for non-critical acute illness
62824540|NCT00821795|ACTIVE_COMPARATOR|Aspart insulin analog biphasic mix|transition insulin therapy with Aspart insulin analog 70/30 mix for outpatient glycemic control following a hospitalization for non-critical acute illness
62824541|NCT04282161|EXPERIMENTAL|Axys EX device|
62824542|NCT02796170|ACTIVE_COMPARATOR|Dapagliflozin|Participants underwent 6 weeks of Dapagliflozin or placebo (washout period for 2 weeks) and then crossed over to 6 weeks of placebo or Dapagliflozin.
62824543|NCT02796170|ACTIVE_COMPARATOR|Placebo|Participants underwent 6 weeks of Dapagliflozin or placebo (washout period for 2 weeks) and then crossed over to 6 weeks of placebo or Dapagliflozin.
62824544|NCT06604637|EXPERIMENTAL|VNS Group|In addition to standard treatment, noninvasive transcutaneous auricular vagus nerve stimulation (taVNS) will be applied to this group.
62824545|NCT06604637|NO_INTERVENTION|Control roup|The control group will receive standard treatment (lifestyle recommendations + pharmacological treatment).
62824546|NCT01843829|EXPERIMENTAL|Carboplatin and Paclitaxel Arm|"2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)~then CRT: Paclitaxel 50mg/m2 Days 1,8,15,22,29 (IV infusion); Carboplatin AUC 2 Days 1,8,15,22,29 (IV infusion) XRT: 45 Gy in 25 fractions~then surgery.~All drugs will be sourced from local stock"
62824547|NCT01843829|EXPERIMENTAL|Oxaliplatin and Capecitabine Arm|"2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)~then CRT: Oxaliplatin 85mg/m2 Days 1, 15, 29 (IV infusion); Capecitabine 625mg/m2 bd (oral) only on days when receiving RT XRT: 45 Gy in 25 fractions\*~then surgery.~All drugs will be sourced from local stock"
62824548|NCT04837716|EXPERIMENTAL|Treatment (ensartinib, carboplatin, pemetrexed, bevacizumab)|"INDUCTION THERAPY: Patients receive ensartinib PO QD on days 1-21, carboplatin IV over 15-60 minutes on day 1, pemetrexed IV over 10 minutes on day 1 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ensartinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
62824549|NCT02002598|EXPERIMENTAL|CFZ with bendamustine and dexamethasone|Subjects will receive Carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days with dose escalation from 27, 36, 45 to 56 mg/ m2 . No matter what target dose the subject will receive, days 1 and 2 doses in the first cycle will always be 20 mg/m2, followed by target dose for all subsequent dates and cycles. Bendamustine will be given IV on days 1 and 2 with dose escalation up to 90 mg/m2 and dexamethasone 20 mg orally or intravenously on 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle. Study treatment will be given until 8 cycles of treatment are completed or until disease progression, whichever comes first.
62246034|NCT00324753|EXPERIMENTAL|Intervention|Communication sheet
62246035|NCT00324753|OTHER|Control|Standard of care brochures
62436326|NCT03080194|ACTIVE_COMPARATOR|control group|The subjects in control group will be applied with oral antipsychotics or other conventional medication.
62602650|NCT05236231|EXPERIMENTAL|Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1 followed by Treatment A in Treatment Period 2 and Treatment B in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
62246036|NCT05371509|EXPERIMENTAL|Myofunctional therapy (MT) nozzle|Subjects diagnosed with mild to moderate obstructive sleep apnea will receive a water bottle with a myofunctional therapy (MT) nozzle to use daily
62436327|NCT01783496|ACTIVE_COMPARATOR|Framed Tip|Treatment with Thermage CPT Framed Tip
62436328|NCT01783496|EXPERIMENTAL|Pattern Tip|Treatment with the Thermage CPT Pattern Tip
62436329|NCT01783496|EXPERIMENTAL|Pattern Tip Group 2|Treatment with the Thermage CPT Pattern tip
62436330|NCT01783496|EXPERIMENTAL|Total Tip|Treatment with the Thermage CPT Total tip
62436331|NCT01783496|EXPERIMENTAL|Framed and Patterned Tip|Split face treatment with the Thermage CPT Framed and Patterned tips
62436332|NCT01783496|EXPERIMENTAL|Total and Patterned Tip|Split face treatment with the Thermage CPT Total and Patterned tips
62602651|NCT05236231|EXPERIMENTAL|Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1 followed by Treatment C in Treatment Period 2 and Treatment B in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
62824550|NCT06599905|EXPERIMENTAL|Group with episodic migraine (EM)|Subjects with episodic migraine (EM) with or without aura according to the International Headache Society (IHS) Classification (3rd edition).
62824551|NCT06599905|EXPERIMENTAL|Group with chronic migraine (EC)|Subjects with chronic migraine (CM) with or without Medication Overuse (MO) according to the International Headache Society (IHS) Classification (3rd edition).
62824552|NCT06599905|OTHER|Control group|Age- and sex-matched controls.
62436333|NCT05791942|NO_INTERVENTION|Holdout Condition: No reminder|Eligible, randomized participants will receive no text message reminder.
62824553|NCT06047561||Aortic Stenosis|Participants with Aortic Stenosis across the spectrum of disease severity
62436334|NCT05791942|EXPERIMENTAL|Control Reminder|Eligible, randomized participants will receive a generic text message reminding them to close their outstanding health gap.
62436335|NCT05791942|EXPERIMENTAL|Anecdote-based Reminder|Eligible, randomized participants will receive a text message reminding them to close their outstanding health gap. This message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings.
62246037|NCT05371509|PLACEBO_COMPARATOR|Placebo nozzle|Subjects diagnosed with mild to moderate obstructive sleep apnea will receive a water bottle with a placebo nozzle to use daily
62246038|NCT02903069|EXPERIMENTAL|Stage 1: Concomitant Treatment|"MRZ + TMZ + RT~Patients who complete Concomitant Treatment may continue on to Adjuvant Treatment."
62436336|NCT05791942|EXPERIMENTAL|Call-to-action Reminder|Eligible, randomized participants will receive a text message reminding them to close their outstanding health gap. This message will prompt people to take care of the health gap right away before it slips their mind.
62436337|NCT03423706|EXPERIMENTAL|new model of haplo-HSCT|use the new model of haplo-HSCT to treat the r/r B-ALL patients matching the inclusion criterion
62602652|NCT05236231|EXPERIMENTAL|Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1 followed by Treatment B in Treatment Period 2 and Treatment A in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
62824554|NCT06047561||Aortic Valve Replacement|Participants who have previously undergone aortic valve replacement
62824555|NCT06047561||Healthy Volunteers|Healthy Volunteers for the purposes of case-control analysis
62824556|NCT03128294||long-term survivors of ovarian cancer|long-term survivors of ovarian cancer
62436338|NCT04881890|EXPERIMENTAL|Low-Carbohydrate Diabetes Prevention Program|At least 20 individuals with prediabetes will participate in a year-long , group-based program.
62436339|NCT04133571|NO_INTERVENTION|Control group|Control group: using normal saline for bladder irrigation
62436340|NCT04133571|EXPERIMENTAL|Study group|Study group: using 0.05% Lidocaine normal saline solution for bladder irrigation
62436341|NCT04476732|EXPERIMENTAL|Paraben-free then Paraben-containing|Paraben free facial lotion is applied twice a day for 1 week and measurements are taken. Then, paraben-containing facial lotion is applied twice a day for 1 week and measurements are taken.
62824557|NCT05773729|EXPERIMENTAL|BD211 Single-Dose group|Route of Administrate: infusion intravenously. Dosage form: injection solution. Dose: 5×10\^6 cells /kg \~ 10×10\^6 cells /kg. Frequency of administration: One dosing intravenously. Intervention: Single dose of BD211
62824558|NCT06599411||Patients|Affected by inflammatory skin disease
62436342|NCT02647554|EXPERIMENTAL|Ulinastatin group|Ulinastain treatment group：400,000 IU ulinastatin will be reconstituted in 10 mL of 0.9% normal saline, and then dissolved in 100 mL of 0.9% normal saline every 8 hours for 10 days in a double-blind fashion.
62436343|NCT02647554|PLACEBO_COMPARATOR|Placebo group|Placebo control group：Matching with medication
62824559|NCT06599411||Controls|Plastic surgery patients who have had any type of surgery resulting in healthy skin remnants
62824560|NCT06596044|EXPERIMENTAL|VA BIC|Patients randomized to VA BIC will receive the VA BIC intervention plus standard care
62824561|NCT06596044|OTHER|Standard Care|Patients randomized to the control arm will receive standard care alone.
62824562|NCT06591104||metabolically healthy non obesity (MHNO)|"According to the NCEP ATP III definition, metabolic syndrome is present if three or more of the following five criteria are met: waist circumference over 40 inches (men) or 35 inches (women), blood pressure over 130/85 mmHg, fasting triglyceride (TG) level over 150 mg/dl, fasting high-density lipoprotein (HDL) cholesterol level less than 40 mg/dl (men) or 50 mg/dl (women) and fasting blood sugar over 100 mg/dl.~Obesity was defined as a BMI of ≥ 25.0 kg/m2 . Patients with a BMI of 18.5-\<23.0 were considered normal weight; for those with a BMI of 23.0-\<25.0 were overweight. The patients with normal weight and those who were overweight were collapsed into the non-obesity group.~so this group of patients are metabolically healthy and non obese with BMI 18.5 - \<25"
62043344|NCT03608930|NO_INTERVENTION|regular polypectomy snare|All colorectal polyps found are removed using a regular polypectomy snare (polypectomy snare, symmetrical). The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the bending section angulation of the colonoscopy as required, advance the snare until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is performed after hot snare polypectomy if a flat polyp or bleeding on the wound after treatment.
62043345|NCT01760850|EXPERIMENTAL|Arm I (Esperanza y Vida)|Participants engage in the Esperanza y Vida educational information session for breast and cervical cancer.
62043346|NCT01760850|ACTIVE_COMPARATOR|Arm II (control)|Participants engage in an educational information session for diabetes.
62043347|NCT04255628||with cancer pain|head and neck and esophageal cancer patients. with cancer pain
62043348|NCT04255628||without cancer pain|head and neck and esophageal cancer patients. without cancer pain=30
62043349|NCT01474733|EXPERIMENTAL|educational intervention|participants undergo a series of educational interventions over 3 years
62043350|NCT05624177|ACTIVE_COMPARATOR|Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum: Chew 5 minutes|Streptococcus salivarius M18 chewing gum 1 billion cfu chewing the gum for 5 minutes duration.
62043351|NCT05624177|ACTIVE_COMPARATOR|Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum: Chew 10 minutes|Streptococcus salivarius M18 chewing gum 1 billion cfu chewing the gum for 10 minutes duration.
62043352|NCT03058211||pneumococcal pneumonia|Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
62043353|NCT03058211||non-pneumococcal pneumonia|Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
62246039|NCT02903069|EXPERIMENTAL|Stage 1: Adjuvant Treatment|MRZ + TMZ
62043354|NCT00446810|ACTIVE_COMPARATOR|A1|Benfotiamine
62043355|NCT00446810|ACTIVE_COMPARATOR|A2|
62436344|NCT04074213||Haematologic malignancies with clozapine|Cases reported in the World Health Organization (WHO) database of patients treated by Clozapine, with a chronology compatible with the drug toxicity
62043356|NCT02432872|EXPERIMENTAL|escalated daunorubicin|Daumorubicin 60mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.
62043357|NCT02432872|ACTIVE_COMPARATOR|standard daunorubicin|Daunorubicin 45mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.
62043358|NCT02432872|EXPERIMENTAL|medium dosage cytarabine|1g/m2 q12h for 3 days as consolidation therapy.
62043359|NCT02432872|ACTIVE_COMPARATOR|standard dosage cytarabine|100mg/m2 cytarabine for 6 days combined with aclacinomycin 20mg per day for 6 days as consolidation therapy.
62043360|NCT05980117|EXPERIMENTAL|Intervention|Patients assigned to the study group will receive Remimazolam.
62043361|NCT05980117|ACTIVE_COMPARATOR|Control|Patients assigned to the control group will receive Midazolam.
62246040|NCT02903069|EXPERIMENTAL|Stage 2: Dose-Expansion|"MRZ + TMZ + RT followed by MRZ + TMZ~In Stage 2 (dose-expansion): a minimum of 12 and up to approximately 18 additional evaluable patients will be enrolled in a cohort in which Concomitant Treatment (MRZ + TMZ + RT) is followed by Adjuvant Treatment (MRZ + TMZ) to confirm the MTD for each treatment regimen as determined in the Dose-Escalation (Stage 1), and to assess preliminary activity of the recommended Phase 2 dose (RP2D)."
62246041|NCT02903069|EXPERIMENTAL|Optune Arm|MRZ + TMZ + Optune
62436345|NCT03796299||1|Patients with bladder cancer
62436346|NCT03796299||2|Patients with upper urinary tract cancer
62436347|NCT03796299||3 (control)|Controls
62436348|NCT02086656|EXPERIMENTAL|open label|Single arm, open label
62436349|NCT06410040||Advanced ALK+ NSCLC Patients with Brain or Meningeal Metastasis|
62602653|NCT05236231|EXPERIMENTAL|Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1 followed by Treatment A in Treatment Period 2 and Treatment C in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
62602654|NCT03301740|EXPERIMENTAL|UF Profiling Phase First|"First treatment phase begins with linear UF profiling during HD.~Participants randomized to starting with the experimental UF profiling phase will receive 9 HD treatments with UF profiling (1st experimental phase). Following a 3 conventional HD treatment wash-out period, participants will then cross over to 9 conventional HD treatments (1st control phase). Following a 2nd 3 conventional HD treatment wash-out period, participants will cross over to 9 HD treatments with UF profiling (2nd experimental phase). Following a 3rd conventional HD treatment wash-out period, participants will cross over to 9 conventional HD treatments (2nd control phase)."
62824563|NCT06591104||metabolically healthy obesity ( MHO )|"According to the NCEP ATP III definition, metabolic syndrome is present if three or more of the following five criteria are met: waist circumference over 40 inches (men) or 35 inches (women), blood pressure over 130/85 mmHg, fasting triglyceride (TG) level over 150 mg/dl, fasting high-density lipoprotein (HDL) cholesterol level less than 40 mg/dl (men) or 50 mg/dl (women) and fasting blood sugar over 100 mg/dl.~Obesity was defined as a BMI of ≥ 25.0 kg/m2 . Patients with a BMI of 18.5-\<23.0 were considered normal weight; for those with a BMI of 23.0-\<25.0 were overweight. The patients with normal weight and those who were overweight were collapsed into the non-obesity group.~so this group of patients are metabolically healthy but they are obese with BMI of ≥ 25.0 kg/m2"
62246042|NCT05762523|EXPERIMENTAL|"Group 1 VAC∆6: оnce at a dose of 10⁶ PFU (plaque-forming units)"|15 healthy volunteers of both sexes aged 18-40 years who had not been vaccinated against smallpox, had no vaccine marks and anti-smallpox virus neutralizing antibodies in their sera as well as those who met the inclusion criteria and did not have any exclusion criteria
62824564|NCT06591104||metabolically unhealthy non obsesity ( MUNO )|"According to the NCEP ATP III definition, metabolic syndrome is present if three or more of the following five criteria are met: waist circumference over 40 inches (men) or 35 inches (women), blood pressure over 130/85 mmHg, fasting triglyceride (TG) level over 150 mg/dl, fasting high-density lipoprotein (HDL) cholesterol level less than 40 mg/dl (men) or 50 mg/dl (women) and fasting blood sugar over 100 mg/dl.~Obesity was defined as a BMI of ≥ 25.0 kg/m2 . Patients with a BMI of 18.5-\<23.0 were considered normal weight; for those with a BMI of 23.0-\<25.0 were overweight. The patients with normal weight and those who were overweight were collapsed into the non-obesity group.~so this group of patients are metabolically unhealthy ( have three or more of metabolic syndrome criteria) and non obese with BMI 18.5 - \<25"
62824565|NCT06591104||metabolically unhealthy obesity ( MUO )|"According to the NCEP ATP III definition, metabolic syndrome is present if three or more of the following five criteria are met: waist circumference over 40 inches (men) or 35 inches (women), blood pressure over 130/85 mmHg, fasting triglyceride (TG) level over 150 mg/dl, fasting high-density lipoprotein (HDL) cholesterol level less than 40 mg/dl (men) or 50 mg/dl (women) and fasting blood sugar over 100 mg/dl.~Obesity was defined as a BMI of ≥ 25.0 kg/m2 . Patients with a BMI of 18.5-\<23.0 were considered normal weight; for those with a BMI of 23.0-\<25.0 were overweight. The patients with normal weight and those who were overweight were collapsed into the non-obesity group.~so this group of patients are metabolically unhealthy but they are obese with BMI of ≥ 25.0 kg/m2"
62824566|NCT04558125|EXPERIMENTAL|Low-dose TNKase and Standard of Care Anticoagulation|"1. TNKase (0.25 mg/kg) bolus Other names: Tenecteplase, TNK~2. Standard of care anticoagulation (heparin or enoxaparin)"
62824567|NCT04558125|ACTIVE_COMPARATOR|Placebo and and Standard of Care Anticoagulation|"1. Placebo bolus (intravenous syringe identical to that of TNK )~2. Standard of care anticoagulation (heparin or enoxaparin)"
62824568|NCT06019754|PLACEBO_COMPARATOR|Control group|patients who will be recruited in the control group will receive general anesthesia only
62824569|NCT06019754|ACTIVE_COMPARATOR|Interventional group|Patients who will be recruited in the Interventional will receive one point combined lumbar and sacral plexus block. then they will receive general anesthesia
62824570|NCT05820932||Participants with prostate cancer, ADT (ADT Cohort)|This group is comprised of adult men with hormone-sensitive prostate cancer who are starting androgen deprivation therapy as part of standard of care prostate cancer (not as part of this protocol).
62824571|NCT05820932||Participants in remission, No ADT (Prostate cancer Control (PC) Cohort))|This group is comprised of adult men who are in remission from prostate cancer who have never received ADT.
62824572|NCT05820932||Partners of Participants|Study partner participants will also be recruited
62824573|NCT04593784|EXPERIMENTAL|Cohort 1|Subjects receive 60 mg edoxaban orally once daily in the morning on Days 1 to 4. On Day 4, approximately 3 hours after administering edoxaban, study drug (ciraparantag or placebo) will be intravenously administered.
62824574|NCT04593784|EXPERIMENTAL|Cohort 2|Subjects receive 10 mg apixaban orally every 12 hours on Days 1 to 3, with a final dose in the morning on Day 4. On Day 4, approximately 4 hours after administering apixaban, study drug (ciraparantag or placebo) will be intravenously administered.
62824575|NCT04593784|EXPERIMENTAL|Cohort 3|Subjects receive 20 mg rivaroxaban orally once daily in the morning on Days 1 to 4. On Day 4, approximately 4 hours after administering rivaroxaban, study drug (ciraparantag or placebo) will be intravenously administered.
62824576|NCT06292260|EXPERIMENTAL|With mHealth app|All healthcare providers will receive the mHealth app (eSkinHealth) to be used in their daily practices.
62824577|NCT03945240|EXPERIMENTAL|Group 1 (Pinnacle, lower dosimetry parameters)|Utilize the Pinnacle Series Laser by Aspen Laser Systems to apply LLLT
62824578|NCT03945240|EXPERIMENTAL|Group 2 (Pinnacle, higher dosimetry parameters)|Utilize the Pinnacle Series Laser by Aspen Laser Systems to apply LLLT
62824579|NCT03945240|EXPERIMENTAL|Group 3 (Phoenix)|Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply LLT.
62043362|NCT00854633|EXPERIMENTAL|1|Talactoferrin
62824580|NCT06497543|EXPERIMENTAL|Cohort 1|Small Cell Lung Cancer patient with Refractory Brain Metastases
62043363|NCT00854633|PLACEBO_COMPARATOR|2|Placebo
62824581|NCT06497543|EXPERIMENTAL|Cohort 2|Small Cell Lung Cancer patient with Leptomeningeal Metastasis
62043364|NCT03490513|PLACEBO_COMPARATOR|Weight loss plus placebo|Participants will take a placebo every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and undergo supervised exercise training program.
62602655|NCT03301740|EXPERIMENTAL|Conventional HD Phase First|"First treatment phase begins with conventional HD.~Participants randomized to starting with the control conventional HD phase will receive 9 conventional HD treatments (1st control phase). Following a 3 conventional HD treatment wash-out period, participants will then cross over to 9 HD treatments with UF profiling (1st experimental phase). Following a 2nd 3 conventional HD treatment wash-out period, participants will cross over to 9 conventional HD treatments (2nd control phase). Following a 3rd conventional HD treatment wash-out period, participants will cross over to 9 HD treatments with UF profiling (2nd experimental phase)."
62602656|NCT04298450|EXPERIMENTAL|Active SMS Intervention|Participants assigned to the experimental arm will receive the active SMS intervention. Participants in the active intervention group who consent to participate will be asked to complete a web-based survey. Based on survey findings, purposive sampling will be used to select a subsample of 12 to 20 participants for qualitative interviews.
62824582|NCT05674656|EXPERIMENTAL|Dolutegravir(DTG)/Rilpivirine (RPV)|
62824583|NCT03873883|EXPERIMENTAL|1A Dose escalation EOS100850|Dose Escalation- EOS100850 Monotherapy: to confirm RP2D
62824584|NCT03873883|EXPERIMENTAL|1B Dose escalation EOS100850 and Pembrolizumab|EOS100850 and Pembrolizumab Combination Therapy: to confirm RP2D as combination
62824585|NCT03873883|EXPERIMENTAL|2A Dose Expansion- EOS100850|Dose Expansion - EOS100850 Monotherapy: to explore safety, PK, PD, and antitumor activity of inupadenant as monotherapy
62824586|NCT03873883|EXPERIMENTAL|2B Dose Expansion - EOS100850 and Pembrolizumab|Dose Expansion - EOS100850 and Pembrolizumab Combination Therapy: to explore safety, PK, PD, and antitumor activity of inupadenant in combination with pembrolizumab in melanoma and CRPC patients
62824587|NCT03873883|EXPERIMENTAL|2D Dose expansion - EOS100850 and Chemotherapy in TNBC|Dose expansion - EOS100850 and Chemotherapy Combination: to explore safety, PK, PD, and antitumor activity of inupadenant in combination with chemotherapy SOC carboplatin and paclitaxel in patients with TNBC
62824588|NCT03873883|EXPERIMENTAL|3 EOS100850 in BMK-H participants|Dose expansion - EOS100850 Monotherapy : to evaluate the safety, PD, and antitumor activity of inupadenant as monotherapy at the mono-RP2D in BMK-H participants in 4 disease-specific cohorts: NSCLC; HNSCC; EC; and other forms of cancer
62824589|NCT03635281|EXPERIMENTAL|PEEP group|In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached)
62824590|NCT03635281|EXPERIMENTAL|RM+PEEP group|"Recruitment maneuvers will be performed as follow Recruitment maneuvers~1. set FIO2 at 1.0~2. Ppeak limit at 45 cmH2O~3. Respiratory rate set at 6~4. I:E set at 1:1~5. Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O~6. If the maximum VT is set without rasing the Pplat, raise PEEP~7. Allow three respiratory cycles with Pplat between 30 and 40 cmH2O~8. End of RM~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached)."
62602657|NCT04298450|SHAM_COMPARATOR|Sham SMS|Participants assigned to the sham comparator will receive the sham SMS intervention. They will not be re-contacted.
62602658|NCT01707251|EXPERIMENTAL|Intravenous Ibuprofen|800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
62602659|NCT01707251|PLACEBO_COMPARATOR|Saline|IV saline every 6 hours starting preoperatively (5 doses).
62602660|NCT03540303|EXPERIMENTAL|CAR19 T cells carrying cytoplasmic activated PD-1|patients with refractory/relapsed B-NHL receive a preconditioning before infusion of CAR T cells.
62602661|NCT03149120|EXPERIMENTAL|Nivolumab|Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
62602662|NCT03149120|EXPERIMENTAL|Nivolumab with Pazopanib|Pazopanib at a dose of 800mg by mouth daily.
62602663|NCT05455190|EXPERIMENTAL|Fit Together|Participants in the intervention arm will receive standard of care obesity treatment from their provider and be able to participate in the Fit Together program and attend activity sessions throughout the duration of their 12 month participation.
62602664|NCT05455190|ACTIVE_COMPARATOR|Control|Participants in the control arm will receive standard of care obesity treatment from their provider and a healthy cooking magazine mailed to them at a regular interval throughout the duration of their 12 month participation
62602665|NCT00122122|OTHER|Arm 1|
62602666|NCT01185509|EXPERIMENTAL|Trastuzumab and Vinorelbine - Cohort A|Cycle 1: Patients received trastuzumab 8 mg/kg intravenously (IV) on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Cycles 2+: Patients received trastuzumab 6 mg/kg IV on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Patients were treated until disease progression or unacceptable toxicity. Eligibility required patients to have HER2 amplification by fluorescence in situ hybridization (FISH) (mean ratio \> 2.0). The CTC tests of the first 11 patients were done at DFCI. The study team then decided to proceed with a different CTC test performed outside of DFCI. Because the method of CTC isolation was different from that performed by DFCI, the first 11 patients were placed into a separate cohort (Cohort A) and the remaining 20 patients represented the main cohort.
62824591|NCT01933737|EXPERIMENTAL|Kinesio Taping Group|The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
62824592|NCT01933737|EXPERIMENTAL|Placebo tape group|The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
62824593|NCT00125255|EXPERIMENTAL|S-Caine Peel|
62824594|NCT00125255|PLACEBO_COMPARATOR|Placebo Peel|
62824595|NCT06586671|EXPERIMENTAL|Nemtabrutinib Form A|Participants receive nemtabrutinib form A orally.
62623863|NCT00385827|EXPERIMENTAL|Mitoxantrone+Prednisone+Siltuximab (Part 2)|In Part 2, mitoxantrone 12 mg/m\^2 will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m\^2) along with siltuximab 6 mg/kg intravenously as a 2-hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year; and prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
62824596|NCT06586671|EXPERIMENTAL|Nemtabrutinib Form B|Participants receive nemtabrutinib form B orally.
62824597|NCT06586671|EXPERIMENTAL|Nemtabrutinib Form C|Participants receive nemtabrutinib form C orally.
62824598|NCT06599164||UNINJURED PLAYERS|Players will be evaluated for isometric strength by electromyography, extensor strength, single leg vertical jump test and ultrasound evaluation, all of which will be measured on all players in the preseason, at 4 months and at the end of the season.
62824599|NCT06599164||INJURED PLAYERS|As for futsal players with ACL injuries, isometric strength is evaluated in pre-operation, at 4 months and at the end of the soccer year by electromyography, extensor strength, single-leg vertical jump test and ultrasound evaluation.
62824600|NCT06227481|ACTIVE_COMPARATOR|Subcision plus platelet rich plasma|3 sessions of scar subcision with platelet rich plasma injection at the same session with one month interval
62824601|NCT06227481|ACTIVE_COMPARATOR|Subcision plus Polydioxanone mono threads|3 sessions of scar subcision followed by the insertion of Polydioxanone mono threads after the last session
62043365|NCT03490513|EXPERIMENTAL|Weight loss plus anastrozole|Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and undergo supervised exercise training program.
62824602|NCT06227481|ACTIVE_COMPARATOR|Subcision plus fractional carbon dioxide laser|3 sessions of scar subcision with Fractional carbon dioxide laser at the same session with one month interval
62824603|NCT01779765|EXPERIMENTAL|PHGG|2.5gr per day for the first week and then 5gr per day for 11 weeks.
62824604|NCT01779765|PLACEBO_COMPARATOR|Maltodextrin|2.5gr per day for the first week and then 5gr per day for 11 weeks.
62824605|NCT04234113|EXPERIMENTAL|Experimental: Part A (nanrilkefusp alfa monotherapy)|Drug: Nanrilkefusp alfa
62824606|NCT04234113|EXPERIMENTAL|Experimental: Part B (nanrilkefusp alfa combined with pembrolizumab)|Drug: Nanrilkefusp alfa Drug: Pembrolizumab
62824607|NCT04234113|EXPERIMENTAL|Experimental: Part A1 (nanrilkefusp alfa divided dosing, monotherapy)|Drug: Nanrilkefusp alfa, twice a day as 2 divided doses (50%:50%)
62824608|NCT04234113|EXPERIMENTAL|Experimental: Part B1 (nanrilkefusp alfa divided dosing, combined with pembrolizumab)|Drug: Nanrilkefusp alfa, twice a day as 2 divided doses (50%:50%) Drug: Pembrolizumab
62824609|NCT04234113|EXPERIMENTAL|Experimental: Part D (nanrilkefusp alfa monotherapy, expansion at the RP2D identified in Part A)|Drug: Nanrilkefusp alfa Indications: Relapsed/refractory advanced/metastatic renal cell carcinoma, relapsed/refractory advanced/metastatic skin squamous-cell carcinoma, relapsed/refractory advanced/metastatic melanoma
62824610|NCT04234113|EXPERIMENTAL|Part D1 (nanrilkefusp alfa divided dosing, monotherapy, expansion at the RP2D identified in Part A1)|Drug: Nanrilkefusp alfa, twice a day as 2 divided doses (50%:50%) Indications: Relapsed/refractory advanced/metastatic renal cell carcinoma, relapsed/refractory advanced/metastatic skin squamous-cell carcinoma, relapsed/refractory advanced/metastatic melanoma
62824611|NCT06597253|EXPERIMENTAL|Lactate Sensor Device Arm|Continuous interstitial fluid lactate monitoring using the non-invasive Nemaura Investigational Lactate Device.
62824612|NCT04065269|EXPERIMENTAL|1A: ceralasertib (AZD6738)|Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with loss of ARID1A expression treated with single agent AZD6738.
62824613|NCT04065269|EXPERIMENTAL|1B: ceralasertib (AZD6738) + olaparib|"In second stage of trial, opening of this cohort depends on response rate in cohort 1A during first stage of trial.~Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with loss of ARID1A expression treated with AZD6738 in combination with olaparib."
62824614|NCT04065269|EXPERIMENTAL|2: ceralasertib (AZD6738) + olaparib|Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with NO loss of ARID1A expression treated with AZD6738 in combination with olaparib.
62824615|NCT04065269|EXPERIMENTAL|3: ceralasertib (AZD6738) + olaparib|Women with other rare relapsed gynaecological cancers (endometrioid ovarian carcinoma, endometrioid endometrial carcinoma, cervical adenocarcinoma, cervical squamous, ovarian carcinosarcoma and endometrial carcinosarcoma) irrespective of ARID1A status, treated with AZD6738 in combination with olaparib.
62824616|NCT04065269|EXPERIMENTAL|4: ceralasertib (AZD6738) + durvalumab|Women with endometrial cancers (serous, clear cell, endometroid, carcinosarcoma) with ARID1A loss.
62824617|NCT04065269|EXPERIMENTAL|5: ceralasertib (AZD6738) + durvalumab|Women with endometrial cancers (serous, clear cell, endometroid, carcinosarcoma) with NO loss of ARID1A.
62824618|NCT06224413||All Participants|Participants with CALD treated with eli-cel in the post marketing setting will be followed in this registry study for up to 15 years after eli-cel infusion to collect real-world longitudinal data, and evaluate the outcomes.
62824619|NCT04410978|EXPERIMENTAL|SAR442168|Dose 1 of oral SAR442168 + placebo to match the teriflunomide tablet once daily
62824620|NCT04410978|ACTIVE_COMPARATOR|Teriflunomide|Oral 14 mg oral teriflunomide + placebo to match the SAR442168 tablet once daily
62824621|NCT06311487|EXPERIMENTAL|TANDEM Exercise|Participants in this arm will engage in morning aerobic exercise while in a fasted state, morning aerobic exercise while in a fed state, evening aerobic exercise while in a fasted state, and evening aerobic exercise while in a fed state in a randomly assigned order
62824622|NCT05727306||People with Alopecia Areata|Children and adults aged 12+ with new onset Alopecia Areata registered with a contributing General practitioner (GP) practice during the study period.
62824623|NCT05727306||People without Alopecia Areata|Children and adults aged 12+ without Alopecia Areata registered with a contributing GP practice during the study period.
62824624|NCT06481163|EXPERIMENTAL|300 mg Telacebec per day|Telacebec will be administered orally with food or within 30 minutes after food once daily for 28 consecutive days.
62824625|NCT01058980|ACTIVE_COMPARATOR|Dormant PV conduction|"After PVI, dormant conduction will be evaluated using intravenous adenosine. If dormant conduction is present, the patients will be randomized to two parallel groups:~* Group 1: No additional ablation~* Group 2: Additional ablation until elimination of dormant conduction."
62824626|NCT01058980|ACTIVE_COMPARATOR|No dormant PV conduction|If no dormant conduction is documented, patients will be selected in a random fashion to be included in a registry (follow-up as planned for group 1 and 2 above). The registry group will allow for further assessment of the role of dormant conduction as a predictor of AF recurrence by comparing the success rate after ablation in patients without dormant conduction with those of Group 1 and 2.
62824627|NCT03081117|EXPERIMENTAL|Insulin, intranasal|Regular insulin, 20 IU intranasal twice a day for 24 weeks; 0.2 mL per dose
62824628|NCT03081117|PLACEBO_COMPARATOR|Placebo, intranasal|Saline solution (placebo), intranasal twice a day for 24 weeks; 0.2 mL per dose
62824629|NCT06596993|EXPERIMENTAL|experimental group|IMU-based balance training
62824630|NCT06596993|OTHER|control group|General health education or exercise training
62824631|NCT04730609|EXPERIMENTAL|Dexmedetomidine|IV administration of Dexmedetomidine, using an Up-Down method utilizing a biased coin design to determine that next patient's dose. Initial dose will be 10mcg.
62824632|NCT03706417|EXPERIMENTAL|Telemedicine|Babies that received telemedicine consult intervention.
62824633|NCT06586944|EXPERIMENTAL|Experimental group|After the research groups were formed, a six-session interview programme was created for the participants included in the experimental group . In the sessions, nursing and psychiatric nursing interventions (psychoeducation, relaxation, awareness, effective coping, cognitive restructuring) based on the Roy Adaptation Model were carried out for the negative situations caused by anxiety and anxiety experienced by individuals. Virtual reality-based intervention was effectively used as an important intervention tool in the implementation of the interventions and in the evaluation of the implemented interventions in four sessions of a total of six sessions. During the application, the participants were asked to evaluate their anxiety in the range of 0-10 as subjective feedback via the 'Amelia VR Platform', and ratings were requested every three minutes during the 15-minute experience of the virtual reality platform, especially at moments when their anxiety increased subjectively.
62602667|NCT01185509|EXPERIMENTAL|Trastuzumab and Vinorelbine - Main Cohort|Cycle 1: Patients received trastuzumab 8 mg/kg intravenously (IV) on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Cycles 2+: Patients received trastuzumab 6 mg/kg IV on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Patients were treated until disease progression or unacceptable toxicity. Eligibility required patients to have HER2 amplification by FISH (mean ratio \> 2.0). The CTC tests of the first 11 patients were done at DFCI. The study team then decided to proceed with a different CTC test performed outside of DFCI. Because the method of CTC isolation was different from that performed by DFCI, the first 11 patients were placed into a separate cohort (Cohort A) and the remaining 20 patients represented the main cohort.
62246043|NCT05762523|EXPERIMENTAL|"Group 2 VAC∆6: once at a dose of 10⁷ PFU"|15 healthy volunteers of both sexes aged 18-40 years who had not been vaccinated against smallpox, had no vaccine marks and anti-smallpox virus neutralizing antibodies in their sera as well as those who met the inclusion criteria and did not have any exclusion criteria
62602668|NCT04944810||Magnetic bariatric surgery|Perform a bariatric surgery using the magnetic device like a second assitant in the steps of the surgery in order to perform the surgery with less incisions and with the same safety
62602669|NCT06273475|EXPERIMENTAL|Intervention|Training facilitated through body weight unloading robotic technology yielding a dynamic unloading force applied to the body centre of mass.
62602670|NCT06273475|ACTIVE_COMPARATOR|Active Control|Training facilitated without the use of body weight unloading robotic technology, thereby only allowing manual assistance from physiotherapists.
62246044|NCT05762523|EXPERIMENTAL|"Group 3 VAC∆6: twice at a dose of 10⁶ PFU"|15 healthy volunteers of both sexes aged 18-40 years who had not been vaccinated against smallpox, had no vaccine marks and anti-smallpox virus neutralizing antibodies in their sera as well as those who met the inclusion criteria and did not have any exclusion criteria
62246045|NCT05762523|EXPERIMENTAL|"Group 4 OspaVir® + live smallpox vaccine"|15 healthy volunteers of both sexes aged 18-40 years who had not been vaccinated against smallpox, had no vaccine marks and anti-smallpox virus neutralizing antibodies in their sera as well as those who met the inclusion criteria and did not have any exclusion criteria
62602671|NCT03426436|OTHER|Test|Obtain two consecutive 15-lead ECGs; The first 15-lead ECG will have an additional three electrodes/stickers on the right side of the chest and the second 15-lead ECG will have an additional three electrodes/stickers on the posterior side.
62602672|NCT03547362|EXPERIMENTAL|Casein|Single oral administration
62602673|NCT03547362|EXPERIMENTAL|Dairy protein blend 1|single oral administration
62824634|NCT06586944|NO_INTERVENTION|Control Group-2|No intervention was made to the participants in the II. Control group except for the completion of the pre-test, post-test and follow-up test.
62824635|NCT06586944|ACTIVE_COMPARATOR|Control Group|For the participants in the control group, a six-session interview programme was created in a way that virtual reality application was not used. In the sessions, nursing and psychiatric nursing interventions (psychoeducation, relaxation, awareness, effective coping, cognitive restructuring) based on the Roy Adaptation Model were carried out for the negative situations caused by anxiety and anxiety experienced by individuals. Subjective goals were determined for the adaptive or maladaptive behaviour, attitude and thought patterns caused by anxiety-inducing stimulus(s) and appropriate interventions from the Nursing Interventions Classification System (NIC) were carried out for these goals.
62824636|NCT03651349|PLACEBO_COMPARATOR|Placebo control|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
62824637|NCT03651349|EXPERIMENTAL|50 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
62824638|NCT03651349|EXPERIMENTAL|100 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
62824639|NCT03651349|EXPERIMENTAL|150 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
62824640|NCT03651349|EXPERIMENTAL|225 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
62824641|NCT03651349|EXPERIMENTAL|300 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
62824642|NCT03651349|EXPERIMENTAL|400 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
62824643|NCT03651349|EXPERIMENTAL|525 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
62824644|NCT05083234|EXPERIMENTAL|Sunflower Seed Oil Group (SSO)|The skin of newborns in the sunflower seed oil group was moisturized with SSO
62824645|NCT05083234|EXPERIMENTAL|Liquid Vaseline Group (LV)|The skin of newborns in the liquid vaseline group was moisturized with LV.
62824646|NCT05083234|EXPERIMENTAL|Control Group|The skin of newborns in the control group was not moisturized.
62436350|NCT02540707|PLACEBO_COMPARATOR|Solifenacin|Women with overactive bladder syndrome will be treated by solifenacin 5 mg qd \* 12 weeks
62436351|NCT02540707|EXPERIMENTAL|Mirabegron|Women with overactive bladder syndrome will be treated by mirabegron 25 mg qd \* 12 weeks
62436352|NCT05255133|EXPERIMENTAL|GEP-NET and lung-NET patients|Liquid biopsies and scans
62436353|NCT04638855|EXPERIMENTAL|Medicurtain®|Treat Medicurtain 5ml prefilled syringe after hysteroscopy surgery
62436354|NCT04638855|SHAM_COMPARATOR|Placebo|No device after hysteroscopy surgery
62602674|NCT03547362|EXPERIMENTAL|Whey protein|Single oral administration
62602675|NCT03547362|EXPERIMENTAL|Dairy protein blend 2|Single oral administration
62602676|NCT03547362|EXPERIMENTAL|Dairy protein blend 3|Single oral administration
62602677|NCT03547362|EXPERIMENTAL|Dairy protein blend 4|Single oral administration
62824647|NCT03363841|EXPERIMENTAL|SCY-078|SCY-078
62824648|NCT04370210||Child without follow-up in child psychiatry|Child enrolled, and their parents, must complete online questionnaires
62824649|NCT04370210||Child with follow-up in child psychiatry|Child enrolled, and their parents, must complete online questionnaires
62436355|NCT00884130||Laparoscopic|Patients having a laparoscopic colorectal resection
62436356|NCT00884130||Open|Patients having an open colorectal resection
62602678|NCT01350648||HBV and HCV Co-infection|HBV and HCV Co-infection
62824650|NCT03502005|EXPERIMENTAL|BIKTARVY®|initiation of single pill once daily bictegravir/emtricitabine/tenofovir alafenamide from prior efavirenz/emtricitabine/tenofovir DF
62824651|NCT05893186|EXPERIMENTAL|STN DBS|Patients with implanted STN DBS leads will be allocated to this group for DBS stimulation of the STN, within FDA-approved limits and labeling, for symptoms of PD.
62824652|NCT05893186|EXPERIMENTAL|GP DBS|Patients with implanted GP DBS leads will be allocated to this group for DBS stimulation of the GP, within FDA-approved limits and labeling, for symptoms of PD.
62824653|NCT05893485|NO_INTERVENTION|Control|No Music Therapy
62824654|NCT05893485|ACTIVE_COMPARATOR|Music Therapy Intervention|Four music therapy sessions provided prior to delivery.
62824655|NCT06586437|EXPERIMENTAL|Neurotypical Youth/Adults|Compared with the sham controls, those receiving the transcutaneous current stimulation will demonstrate alterations in the strength of the sensorimotor cortical activity, spinal cord activity, and corticospinal coherence. Moreover, the extent of the alterations in the sensorimotor cortical activity, spinal cord activity, and corticospinal coherence will be tightly linked with the clinical presentations of persons with CP.
62824656|NCT06586437|EXPERIMENTAL|Cerebral Palsy Youth/Adults|Compared with the sham controls, those receiving the transcutaneous current stimulation will demonstrate alterations in the strength of the sensorimotor cortical activity, spinal cord activity, and corticospinal coherence. Moreover, the extent of the alterations in the sensorimotor cortical activity, spinal cord activity, and corticospinal coherence will be tightly linked with the clinical presentations of controls.
62824657|NCT04981223|EXPERIMENTAL|ExactVu Imaging|"EV29L transducer will be inserted in the subject's rectum. Cine sweeps will be performed to save images of:~1. The entire prostate from posterior to anterior (may require 2 sweeps to cover base and apex)~2. The peripheral zone using the highest zoom setting (30mm depth) on the system (may require 2 sweeps to cover base and apex). Analysis of these images will be performed after surgery but before prostatectomy"
62824658|NCT06559826|EXPERIMENTAL|Ketamine Assisted Psychotherapy (KAP)|KAP sessions will occur once a week for a total of 4 weeks with the potential for a second session the first week for dose-finding purposes. Participants will have a ketamine exposure of at least 0.3 mg/kg and a maximum of 1.0mg/kg, at each treatment session, personalizing dose to patient experience. Each of the treatment sessions will last 120-180 min and will be conducted by a single therapist who has completed the KAP training as specified in the standard operating procedures.
62824659|NCT06559826|ACTIVE_COMPARATOR|Ketamine (KET)|Standard medicalized ketamine administration consisting of twice weekly treatment for 3 weeks, followed by a 4th week with a single ketamine infusion serving as a down-titration period before discontinuation. Participants will have a ketamine exposure of at least 0.3 mg/kg administered via intravenous infusion at each treatment session. Patients may be up-titrated over the course of subsequent treatment sessions, as indicated clinically up to 1.0 mg/kg25. No formal psychotherapy will be provided in the KET arm, though study participants will have matched basic psychoeducation related to depression and treatment with ketamine prior to the first dosing session, during the ketamine treatment period, and post-treatment, in order to match the KAP arm. All individuals will be followed over an eight week follow up period and undergo clinical study assessments.
62824660|NCT04977453|EXPERIMENTAL|GI-101|"Dose escalation: GI-101, multiple ascending doses~Dose expansion:"
62602679|NCT01350648||Hepatitis B|Hepatitis B alone
62043366|NCT05031702|ACTIVE_COMPARATOR|Dietary supplement|Extract from Camellia Sinensis leaf
62043367|NCT05031702|PLACEBO_COMPARATOR|Placebo|Tablets of the same size as the active component
62602680|NCT01350648||Hepatitis C|Hepatitis C alone
62602681|NCT01350648||HIV and HBV and HCV Tri-Infection|HIV and HBV and HCV Tri-Infection
62602682|NCT01350648||HIV and HBV Co-infection|HIV and HBV Co-infection
62436357|NCT02555059||BAYQ3939|Pediatrics patients treated with Ciproxan injection in daily clinical practice.
62436358|NCT03862625|EXPERIMENTAL|a modular adaptive seating system|In the first group, there is home exercises program for scoliosis and a modular adaptive seating system.
62436359|NCT03862625|ACTIVE_COMPARATOR|home exercises for scoliosis|In the second group there is only home exercise program for scoliosis.
62436360|NCT04405934|OTHER|Genomic-sequence informed IPC measures|Cohort follow baseline (no report receipt), then rapid vs standard sequencing report receipt phase, then return to baseline phase (no report receipt)
62602683|NCT01350648||HIV/HCV Co-Infection|HIV and HCV Co-infection
62602684|NCT05561153||Control group|It will consist of healthy individuals between the ages of 18-40 who do not have any pathology related to the knee joint and have not undergone surgery.
62602685|NCT05561153||Study group|Male and female individuals between the ages of 18-40 who were referred to Hacettepe University, Faculty of Physical Therapy and Rehabilitation, Musculoskeletal Physiotherapy and Rehabilitation Department with the diagnosis of patellofemoral pain will be included in the study.
62602686|NCT03595813|EXPERIMENTAL|Patients treated with Immune Checkpoint Blockade|
62602687|NCT03141775||Treatment of CDI|Treatment of CDI for hospitalized patients with Clostridium difficile associated diarrhea
62602688|NCT05750732||Study group|Age range 20-50, BMI range of 25-40 kg/m2
62602689|NCT05750732||Control group|Age range 20-50, BMI range18.5-24.9 kg/m2
62824661|NCT04977453|EXPERIMENTAL|GI-101 + Pembrolizumab|"Dose escalation: GI-101, multiple ascending doses~Dose expansion:"
62824662|NCT04977453|EXPERIMENTAL|GI-101 + Lenvatinib|"Dose optimization:~Dose expansion:"
62246046|NCT01891097|ACTIVE_COMPARATOR|Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, Neiguan PC6, Shenmen HT7, Sanyinjiao SP6, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (ITO ES160, Japan) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.4 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
62824663|NCT04977453|EXPERIMENTAL|GI-101 + Local Radiotherapy|"Dose optimization:~Dose expansion:"
62824664|NCT04977453|EXPERIMENTAL|GI-101A|"Dose escalation: GI-101A, multiple ascending doses~Dose expansion:"
62824665|NCT04977453|EXPERIMENTAL|GI-101A + Pembrolizumab|"Dose escalation: GI-101A, multiple ascending doses~Dose expansion:"
62824666|NCT04119739|EXPERIMENTAL|Median nerve neural mobilization|Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 4 weeks.
62436361|NCT05245773|EXPERIMENTAL|30-day automated hovering + usual care|The intervention arm will get the usual post-discharge call from their practice, typically within 2 business days of discharge. In addition, they will be enrolled in the 30-day automated texting program, wherein they will receive check-in messages on a tapering schedule; they will be free to opt out at any time. They can also message into the platform at any time. Any needs identified through the platform will be escalated to their primary care practice, and they will receive a follow-up phone call from practice staff to address their needs.
62436362|NCT05245773|NO_INTERVENTION|Usual care|The control arm will continue to receive the usual post-discharge call from their practice, typically within 2 business days of discharge.
62436363|NCT05890105|EXPERIMENTAL|Cohort 1|Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo.
62602690|NCT02579343|EXPERIMENTAL|Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants in this group will be treated twice weekly during their follow-up visits with micro-currents of electricity through auricular acupuncture.
62602691|NCT02579343|SHAM_COMPARATOR|Sham Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
62436364|NCT05890105|EXPERIMENTAL|Cohort 2|Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo.
62436365|NCT05890105|EXPERIMENTAL|Cohort 3|Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo.
62436366|NCT02748005|EXPERIMENTAL|Fenugreek seeds extract 500 mg|Fenugreek seeds extract(Furosap) 500 mg
62824667|NCT04119739|ACTIVE_COMPARATOR|Ibuprofen Arginine|Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.
62824668|NCT04119739|NO_INTERVENTION|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
62824669|NCT05602454|EXPERIMENTAL|Digital Heart Failure Medication Titration|The Story Health platform will remotely receive daily vital signs directly from a blood pressure cuff and scale provided to the participant. Participants will also report any symptoms. All of this data will be transmitted, via the platform, to the treating clinician at the site, who will create care plans for medication titration and make clinical decisions. The care plans will be implemented with assistance from health coaches from Story Health Inc.
62824670|NCT05602454|NO_INTERVENTION|Usual Care|Routine clinical care will be followed. Participants will also receive a blood pressure cuff and scale, though the data will not be routinely fed back to the treating clinicians unless requested.
62246047|NCT01891097|EXPERIMENTAL|Acupuncture plus auricular acupuncture|Subjects will be treated with electroacupuncture plus auricular acupuncture for 3 weeks. The acupuncture regimen, is the same as in electroacupuncture group. In additional to electroacupuncture, subjects will receive auricular acupuncture using borneol. The following 6 ear acupoints points will be selected: Ear Shenmen, Heart, Kidney, Liver, Spleen, Occiput, and Subcortex. In each treatment borneol crystals will be attached to the left or right side of the ear in alternation with adhesive plaster in each acupuncture treatment visit. Subjects will be asked to press the borneol crystals lightly for five minutes in the morning, afternoon and evening everyday and reminded them to remove the plaster and borneol crystals after 48 hours. We will check for skin irritation at each treatment visit.
62246048|NCT01891097|NO_INTERVENTION|Waiting-list control|This group will receive no treatment. Subjects will be assessed at baseline and the 4th and 7th week; afterwards, they will be randomized to one of the other two groups in the ratio of 1:1.
62824671|NCT04328792||Prospectively validation group|Two diagnosis methods will be used in the prospective validation section, one is traditional qualitative and quantitative method, the other is artificial intelligence prediction model based on videos to compare the diagnostic efficacy.
62824672|NCT05587777||Mild Cancer Related Fatigue|After treatment(6 months from inclusion) is ended a fVAS \< 50
62824673|NCT05587777||Cancer related Fatigue|After treatment (6 months from inclusion) with fVAS ≥ 50 mm or a rise of fVAS of ≥ 25 mm.
62824674|NCT05587777||Healthy control|"Healthy women matches with age~1. 50-70: women attending the mammography screening~2. 19-50: invitation in newspaper, flyers and posters"
62824675|NCT03793751|EXPERIMENTAL|DEX Group|Receiving Dexmedetomidine injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
62602692|NCT01841567|OTHER|dressing|
62043368|NCT02658864|EXPERIMENTAL|10-mg group|Twelve healthy subjects were administered a single oral dose of 10 mg lafutidine tablets in fasted state.
62246049|NCT02555696||nab-paclitaxel|nab-paclitaxel 260mg/m\^2 in intravenous (IV) infusion every 3 weeks until progression or toxicity
62246050|NCT01777412|EXPERIMENTAL|Bevacizumab|Bevacizumab 10 mg/kg intravenous infusion at onset of exacerbation and, if needed, a second time during the plasma exchange phase.
62246051|NCT06296589|EXPERIMENTAL|trauma Informed Guilt Reduction Therapy|6 session behavioral intervention focused on trauma-related guilt, shame, and moral injury
62436367|NCT06078488|EXPERIMENTAL|Intervention|Individualized and Protocolized Nutrition Care Bundle with Nutritional Supplementation, Education and Support by Nurses trained in Nutritional Management and Dietitians.
62602693|NCT01914575|EXPERIMENTAL|Dipole Density Mapping|
62602694|NCT02429310|NO_INTERVENTION|Supervised Exercise Only|This is the cohort of patients with Intermittent Claudication that will receive standard care of a supervised exercise programme only.
62824676|NCT03793751|PLACEBO_COMPARATOR|CONTROL Group|The Control Group will receive an equal volume placebo infusion of normal saline.
62043369|NCT02658864|EXPERIMENTAL|20-mg group|Twelve healthy subjects were administered a single oral dose of 20 mg lafutidine tablets in fasted state.
62824677|NCT05867407|EXPERIMENTAL|Anumana Low EF AI-ECG Algorithm|Anumana Low EF AI-ECG Algorithm
62824678|NCT05867407|OTHER|Care-as-Usual|Care-as-Usual
62824679|NCT04562389|EXPERIMENTAL|Phase 1a: Cohort 1: Selinexor 40 mg + Ruxolitinib BID|Participants with MF will receive a dose of 40 milligrams (mg) selinexor oral tablets once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with 15 or 20 mg ruxolitinib twice a day (BID) based on the participants baseline platelet count.
62824680|NCT04562389|EXPERIMENTAL|Phase 1a: Cohort 2: Selinexor 60 mg + Ruxolitinib BID|Participants with MF will receive a dose of 60 mg selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle in combination with 15 or 20 mg ruxolitinib BID based on the participants baseline platelet count.
62043370|NCT02658864|EXPERIMENTAL|40-mg group|Twelve healthy subjects were administered a single oral dose of 40 mg lafutidine tablets in fasted state.
62824681|NCT04562389|EXPERIMENTAL|Phase 1b: Selinexor and Ruxolitinib BID|Participants with MF will receive a dose of 40 or 60 mg selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle in combination with 15 or 20 mg ruxolitinib BID based on the participants baseline platelet count.
62824682|NCT04562389|EXPERIMENTAL|Phase 3: Selinexor 60 mg + Ruxolitinib BID|Participants with MF will receive a fixed starting dose of 60 mg selinexor (RD) oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle in combination with a starting dose of 15 or 20 mg ruxolitinib BID based on the participants baseline platelet count.
62824683|NCT04562389|ACTIVE_COMPARATOR|Phase 3: Placebo + Ruxolitinib BID|Participants with MF will receive a matching placebo of selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle in combination with a starting dose of 15 or 20 mg ruxolitinib BID based on the participants baseline platelet count.
62824684|NCT03271086|EXPERIMENTAL|Relaxation breathing training|Dyads of a parent and their child in this group will receive training on how to use breathing to relax with the StressEraser in the pediatric clinic and will then practice the breathing for about 4 weeks They will also complete a baseline questionnaire and two questionnaires one month after the training.
62043371|NCT02219022|ACTIVE_COMPARATOR|Control group|Patient remain with their usual clinical treatment.
62824685|NCT03271086|EXPERIMENTAL|Technology-enhanced relaxation breathing|Dyads of a parent and their child in this group will receive technology-enhanced training on how to use breathing to relax with the StressEraser and the app Breathe2Relax in the pediatric clinic and will then practice the breathing for about 4 weeks and weekly receive weekly reminder text messages to practice their relaxation breathing. They will also complete a baseline questionnaire and two questionnaires one month after the training.
62043372|NCT02219022|EXPERIMENTAL|Experimental group|"Patients in experimental group participated in a 12-week progressive resistance training using a maximum repetition exercise in which patients performed 1 Maximum Repetition with the maximum bearable weight. Once the 1 Maximum Repetitionwas determined, training was divided into the following regimen: 2 series of 8 repetitions, the first with 50% and the second with 70% of 1 Maximum Repetition.~The exercises were knee extension and flexion and hip abduction and adduction, elbow extension and flexion, wrist extension and flexion and shoulder abduction and adduction and spine extension and flexion all performed in machines. The 1 Maximum Repetition load was reevaluated every 6 weeks.~Patient remain with their usual clinical treatment."
62043373|NCT06134349||BLISS candidates|Adult patients with bipolar disorder (BD) type I or II, who have recently started lithium treatment as part of standard care, will be included. At 12-month follow-up, the longitudinal outcome of lithium treatment will be assessed using a validated questionnaire. Based on previous studies, approximately one-third of participants are expected to be classified as full responders at the 12-month follow-up, with another one-third classified as clinical non-responders to lithium treatment.
62246052|NCT06296589|ACTIVE_COMPARATOR|Prolonged Exposure Therapy|12 session behavioral intervention focused on PTSD symptoms
62246053|NCT04752020|EXPERIMENTAL|Netarsudil use|Patients will receive Netarsudil eye drops to use 1 drop nightly in the operative eye after DWEK surgery until corneal clearance
62436368|NCT06078488|EXPERIMENTAL|Control|Nursing Care by Nurses trained in Nutritional Management, with or without Supplements.
62436369|NCT01380314|EXPERIMENTAL|1|Miltefosine 150 mg x day + Imiquimod 5%
62436370|NCT01380314|PLACEBO_COMPARATOR|2|Miltefosine 150 mg x day + Placebo
62436371|NCT04821882|NO_INTERVENTION|Control|Healthy participant
62436372|NCT04821882|EXPERIMENTAL|Dextrose treatment|IC/PBS patients had been treated by intravesical instillations of hyaluronic acid and/or botox for more than 6 months
62436373|NCT03491605||peripheral EBV-DNA load|subjects with high load (\>1×103 copies/ml）of EBV-DNA copies in peripheral blood.
62436374|NCT06455189|OTHER|Group 1|Routine standard of care process will be followed for neurosurgical guidance
62436375|NCT06455189|EXPERIMENTAL|Group 2|The surgeon will have access to advanced MRI and MRF analysis research images during surgery and may use them for guidance, in addition to all routinely used surgical tools.
62436376|NCT04391556|EXPERIMENTAL|Firmagon|120 mg Firmagon subcutaneous injection after a TEP-PSMA
62436377|NCT03361956|EXPERIMENTAL|Part A: Arm 1 (JNJ-56136379 or NA) (open label)|Participants with hepatitis B virus (HBV) currently not being treated and receiving JNJ-56136379 tablet (at a lower dose) orally for 24 weeks, will stop further dosing with JNJ-56136379 and start treatment with nucleos(t)ide analog (NA) (entecavir \[ETV\] or tenofovir disoproxil fumarate \[TDF\]), and enter the 24 week post treatment follow-up phase.
62246054|NCT03426423|EXPERIMENTAL|Intervention|12 weeks smoking cessation intervention tailored to diabetic and gender specificities, delivered by a study nurse.
62246055|NCT03426423|ACTIVE_COMPARATOR|Control|Usual care comprising a unique intervention of 5-10 minutes, non tailored smoking cessation intervention, delivered by a study nurse.
62246056|NCT05803434|EXPERIMENTAL|Cannabidiol treatment|
62436378|NCT03361956|PLACEBO_COMPARATOR|Part A: Arm 2 (Placebo+NA [ETV] or [TDF])|Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
62436379|NCT03361956|EXPERIMENTAL|Part A: Arm 3 (JNJ-56136379 + NA [ETV or TDF])|Participants with HBV currently not being treated will receive JNJ-56136379 along with NA (ETV or TDF) tablet orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
62246057|NCT05351047|EXPERIMENTAL|Cohort 1|Once weekly dosing for 4 weeks (Dosing Days 1, 8, 15 and 22) OR Once weekly dosing for 6 weeks (Dosing Days 1, 8, 15, 22, 29 and 36) randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 1 (6 subjects) or matching placebo (2 subjects).
62246058|NCT05351047|EXPERIMENTAL|Cohort 2|Once weekly for 6 weeks dosing on Days 1, 8, 15, 22, 29 and 36 randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 2 (6 subjects) or matching placebo (2 subjects).
62246059|NCT05351047|EXPERIMENTAL|Cohort 3|Three times weekly for 6 weeks dosing each week on Days 1, 3, and 5 randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 3 (6 subjects) or matching placebo (2 subjects).
62246060|NCT05351047|EXPERIMENTAL|Cohort 4 (optional)|Between one to seven doses each week for 6 weeks randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 4 (6 subjects) or matching placebo (2 subjects).
62246061|NCT05351047|EXPERIMENTAL|Cohort 5 (optional)|Between one to seven doses each week for 6 weeks randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 5 (6 subjects) or matching placebo (2 subjects).
62436380|NCT03361956|PLACEBO_COMPARATOR|Part A: Arm 4 (Placebo + NA [ETV or TDF])|Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
62246062|NCT04692038||Treatment Group|The subjects would receive forceps biopsy combined with puncture biopsy under the guidance of Augmented Reality Navigation and Radial EBUS
62436381|NCT03361956|EXPERIMENTAL|Part A: Arm 5 (JNJ-56136379 + NA [ETV or TDF])|Virologically suppressed participants will receive JNJ-56136379 along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
62436382|NCT03361956|EXPERIMENTAL|Part B: Arm 6 (JNJ-56136379 + NA [ETV or TDF]) (open label)|Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose, orally for 24 weeks. The eligible participants may enter the extension phase and will receive JNJ-56136379 along with NA (ETV or TDF) from Week 24 to Week 48.
62436383|NCT03361956|PLACEBO_COMPARATOR|Part B: Arm 7 (placebo + NA [ETV or TDF])|Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
62436384|NCT03361956|EXPERIMENTAL|Part B: Arm 8 (JNJ-56136379 + NA [ETV or TDF])|Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
62043374|NCT04899050|EXPERIMENTAL|Absence Seizures Treated with Epidiolex|This is a pilot, open-label study consisting of a screening period of up to 28 Days, a 4-week dose-titration treatment period to dose of up to 20 mg/kg/day BID of CBD (EPIDIOLEX ), and a 30-day safety follow-up period following the last dose of study medication.
62246063|NCT04613856|ACTIVE_COMPARATOR|Current Best Practice - 237 mL water bolus|
62246064|NCT04613856|EXPERIMENTAL|New Intervention - 500 mL water bolus|
62246065|NCT00686270|EXPERIMENTAL|1|apricitabine
62246066|NCT04910477|EXPERIMENTAL|Dexmedetomidine|Group D (patients will receive ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
62043375|NCT06381089|EXPERIMENTAL|Robotic Rehabilitation Group (RRG)|"A 6-week protocol will be applied in the study. In addition to the neurological rehabilitation program, robotic rehabilitation will be applied to the RRG group 2 days a week.~Some evaluations will be made by the researcher at two different time periods throughout the study. These time periods will be planned and carried out immediately before the study and after the 6-week treatment."
62043376|NCT06381089|EXPERIMENTAL|Vagal Nerve Stimulation With Robotic Rehabilitation Group (VRRG)|In addition to the neurological rehabilitation program, the VRRG group will receive both robotic rehabilitation and t-VNS 2 days a week. Some evaluations will be made by the researcher at two different time periods throughout the study. These time periods will be planned and carried out immediately before the study and after the 6-week treatment.
62043377|NCT02767115|EXPERIMENTAL|GSE mucoadhesive gel|2%GSE mucoadhesive gel administered in the periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0
62043378|NCT02767115|PLACEBO_COMPARATOR|Control mucoadhesive gel|GSE free mucoadhesive gel administered in the periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0
62043379|NCT00183703||Qualitative Interview|Participants with rapid cycling bipolar disorder (RCBPD)
62043380|NCT00911534|EXPERIMENTAL|1|
62043381|NCT00911534|PLACEBO_COMPARATOR|2|
62246067|NCT04910477|EXPERIMENTAL|Neostigmine/atropine|Group N (patients will receive nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
62043382|NCT01834755|OTHER|single arm|Evaluation of psychological phenotype with several questionnaire (Big Five, EPADV-16), physical activity with a self-administered questionnaire (Baecke) and several test ( SPPB, Handgrip Strengh test, MicroFET 2 Digital Dynamometer)
62246068|NCT04910477|PLACEBO_COMPARATOR|Saline placebo|Group S (patients will receive nebulization of saline placebo in 4 ml)twice daily for three days.
62246069|NCT01375335|EXPERIMENTAL|Dobutamine|
62436385|NCT03361956|PLACEBO_COMPARATOR|Part B: Arm 9 (placebo + NA [ETV or TDF])|Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
62436386|NCT03361956|EXPERIMENTAL|Part B: Arm 10 (JNJ-56136379 + NA [ETV or TDF])|Virologically suppressed participants will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
62436387|NCT02025582|EXPERIMENTAL|Kinesio tape|
62824686|NCT04971642|EXPERIMENTAL|Ultrasound scanning|"The subjects recruited are existing patients of the Orthodontic Clinic - Oral Health Clinic-Dentistry, University of Alberta. An intraoral ultrasound scanning will be done on the buccal side of the upper and lower incisor/canine/premolar/molar teeth for a total of sixteen (16) teeth (four(4) teeth in each of the four quadrants) of these subjects.~The ultrasound scans will be done separately by a research assistant not involved in patient care. The whole procedure for ultrasound scanning and data storage will take about 25-30 min including 3-5 min preparation time and 22-25 min of data acquisition and storage time."
62824687|NCT06602713|ACTIVE_COMPARATOR|Healthy volunteers|Questionnaires and exercices
62043383|NCT06576271|EXPERIMENTAL|Part A: Healthy participants receiving GSK4527363|
62043384|NCT06576271|PLACEBO_COMPARATOR|Part A: Healthy participants receiving placebo matching GSK4527363|
62043385|NCT06576271|EXPERIMENTAL|Part A: Healthy participants receiving belimumab|
62043386|NCT06576271|EXPERIMENTAL|Part B: Participants with SLE receiving GSK4527363|
62043387|NCT06576271|EXPERIMENTAL|Part B: Participants with SLE receiving belimumab|
62043388|NCT06576271|EXPERIMENTAL|Part C: Healthy Japanese participants receiving GSK4527363|
62246070|NCT01434251|ACTIVE_COMPARATOR|Standard care|Infants will be treated according to the treatment policy operative in the Neonatal Intensive Care Unit (NICU) of the Wilhelmina Children's Hospital/University Medical Centre Utrecht (UMCU): anti-hypotensive therapy will be started when the mean blood pressure (in mmHg) is below the gestational age in weeks.
62824688|NCT06602713|EXPERIMENTAL|Patient operated at shoulder by open Latarjet procedure|Questionnaires and exercices
62824689|NCT01423500|OTHER|MSD - Matched Sibling Donor|patients with a MSD receive a conditioning of TBI (12 Gy, 6 fractions) and VP16 60mg/kg for one day (-3)
62246071|NCT01434251|OTHER|Delayed intervention|Anti hypotensive therapy will be started when the mean blood pressure (in mmHg) is \< (gestational age in weeks - 5 mmHg) or when there is clinical or biochemical evidence of impaired tissue perfusion.
62246072|NCT01921855|EXPERIMENTAL|BAY Factor VII (6.5 µg/kg) / Placebo|n = 4, randomized 3:1; 6.5 µg/kg BAY 86-6150 (B0189):Placebo
62043389|NCT06576271|PLACEBO_COMPARATOR|Part C: Healthy Japanese participants receiving placebo matching GSK4527363|
62043390|NCT06576271|EXPERIMENTAL|Part C: Healthy Chinese participants receiving GSK4527363|
62043391|NCT06576271|PLACEBO_COMPARATOR|Part C: Healthy Chinese participants receiving placebo matching GSK4527363|
62043392|NCT06194123|EXPERIMENTAL|Experimental|All subjects will be instructed to use the Crest Daily Whitening Serum for 1 week as described on the label. This product is available for purchase at any pharmacy.
62043393|NCT05449951|EXPERIMENTAL|Dry needling|This intervention was for three weeks in which there are 2 sessions per week. Sterile, disposable dry needles brand of JIAJAN with size of 0.30x40mm were used. Intervention was initiated after palpation of muscles(flexor carpi radials and flexor carpi ulnaris).First cleaning the area through alcohol swabs. There is a point for FCR in medial forearm, to that point 4 cm below and 1 cm medial to the midpoint of crease of elbow was needled. There is a point for FCU at the center of the proximal third segment of a line from the medial epicondyle to the ulnar styloid process was needled.Then, in swift in-and-out motions around 5mm vertical motions without rotation the needle was manipulated .About 1 minute Dry needling was executed for each targeted area, in respect to the patient's level of tolerance. This was monitored by the physiotherapist throughout the session by asking for regular verbal feedback
62043394|NCT05449951|OTHER|Sustained stretching|The second group received sustained stretching protocol along with conventional therapy. Participants undergone the overall treatment sessions for three weeks (3weeks) and 2 sessions per week. The targeted muscles are wrist flexors (flexor carpi radials and flexor carpi ulnaris). Participants received 10 repetition with 30 seconds hold in each session for 10 minutes. Pre and post data in each session was measured through outcome measure tools
62246073|NCT01921855|EXPERIMENTAL|BAY Factor VII (20 µg/kg) / Placebo|n = 4, randomized 3:1; 20 µg/kg BAY 86-6150 (B0189):Placebo
62246074|NCT01921855|EXPERIMENTAL|BAY Factor VII (50 µg/kg) / Placebo|n = 4, randomized 3:1; 50 µg/kg BAY 86-6150 (B0189):Placebo
62246075|NCT01921855|EXPERIMENTAL|BAY Factor VII (90 µg/kg) / Placebo|n = 4, randomized 3:1; 90 µg/kg BAY 86-6150 (B0189):Placebo
62246076|NCT04652713|EXPERIMENTAL|High protein breakfast|Participants will be served a dairy-based protein-rich breakfast meal.
62246077|NCT04652713|EXPERIMENTAL|High carbohydrate breakfast|Participants will be served a carbohydrate-rich breakfast meal
62436388|NCT02578810||Eclampsia|In 24 patients with Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts.
62824690|NCT01423500|OTHER|MD - Matched Donor|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions), VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
62824691|NCT01423500|OTHER|MMD - Mismatched Donor|Patients with a MMD receive stem cells either from cord blood, a haploidentical donor (parent) or from a non-related donor with a match less or equal 8/10
62824692|NCT04448392|OTHER|Neonatal HSV disease requiring suppressive therapy|All subjects enrolled in the study will receive 2 (up to 7) days of valacyclovir 20 mg/kg every 8 hours after completion of standard of care treatment course with acyclovir.
62246078|NCT04652713|EXPERIMENTAL|No breakfast|Participants will be served no breakfast
62246079|NCT00303420|ACTIVE_COMPARATOR|1|Alteplase used by normal dwell procedure
62824693|NCT04827069|EXPERIMENTAL|Arm 1|Clifutinib Besylate:10 mg
62824694|NCT04827069|EXPERIMENTAL|Arm 2|Clifutinib Besylate:20 mg
62824695|NCT04827069|EXPERIMENTAL|Arm 3|Clifutinib Besylate:40 mg
62824696|NCT04827069|EXPERIMENTAL|Arm 4|Clifutinib Besylate:55 mg
62824697|NCT04827069|EXPERIMENTAL|Arm 5|Clifutinib Besylate:70 mg
62824698|NCT04827069|EXPERIMENTAL|Arm 6|Clifutinib Besylate:100 mg
62043395|NCT03256162|EXPERIMENTAL|Ketamine|Participants will receive four once-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
62246080|NCT00303420|EXPERIMENTAL|2|"Alteplase given by an new push protocol"
62246081|NCT03746951|ACTIVE_COMPARATOR|Fascia iliaca compartment block (FICB)|FICB is a local anesthetic nerve block, a type of local anesthesia, used for the hip, thigh, and knee. It is performed by inserting the needle into the groin.
62246082|NCT03746951|ACTIVE_COMPARATOR|Lumbar plexus block (LPB)|LPB is a local anesthetic nerve block, a type of local anesthesia, used for the hip, thigh, and knee. It is performed by inserting the needle into the back.
62824699|NCT06597461|ACTIVE_COMPARATOR|Myofascial release (MR) group|The group that received Graston myofascial application
62824700|NCT06597461|PLACEBO_COMPARATOR|Placebo myofascial release (PMR) group|The group that received placebo Graston myofascial application
62602695|NCT02429310|EXPERIMENTAL|NMES + Supervised Exercise|This cohort of patients with Intermittent Claudication will receive the standard care of supervised exercise plus the use of a Revitive IX neuromuscular electrical stimulation device (Intervention) as per the protocol. The adjunctive benefit of the latter intervention compared to standard treatment alone will then be assessed.
62602696|NCT01908933|EXPERIMENTAL|AeriSeal Emphysematous Lung Sealant Syst|This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
62602697|NCT04794413|EXPERIMENTAL|Pimavanserin|All participants will receive pimavanserin 17mg once daily for 1 week and, if the tics are deemed to be inadequately controlled then increase to 34 mg once daily, taken orally as two 17 mg tablets once daily.
62602698|NCT00900640||ERCP group|All patients who have been scheduled for an ERCP due to medical necessity will be considered for this study.
62602699|NCT05609942|EXPERIMENTAL|Monotherapy|Participants with AdvSM (ASM, SM-AHN, or MCL) will receive BLU-263 monotherapy.
62602700|NCT05609942|EXPERIMENTAL|Combination therapy|Participants with high risk and very high risk systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) of non-MC lineage will receive BLU-263 in combination with azacitidine.
62602701|NCT00157820|ACTIVE_COMPARATOR|SC true|Single chamber Implantable Cardioverter Defibrillator programmed as a Single Chamber.
62602702|NCT00157820|EXPERIMENTAL|SC sim|Dual chamber ICD initially programmed as single chamber (SC simulated) ICD (''SC sim arm'')
62602703|NCT00157820|EXPERIMENTAL|DC true|Dual chamber ICD initially programmed as a DDED (''DC true arm'').
62602704|NCT04972370||Patients with Unilateral Cleft Lip with or without Cleft Palate|
62246083|NCT02304848|EXPERIMENTAL|DBS (Deep Brain Stimulation)|DBS ( Deep Brain Stimulation) ( both high and low frequency deep brain stimulation will be applied to the subthalamic nucleus)
62246084|NCT05218590|ACTIVE_COMPARATOR|Right nostril group|Nasal intubation with video rigid stylet was performed through the right nostril.
62436389|NCT02578810||Control|In 24 control patients without Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts
62246085|NCT05218590|PLACEBO_COMPARATOR|Left nostril group|Nasal intubation with video rigid stylet was performed through the left nostril.
62246086|NCT06727240|EXPERIMENTAL|ReLink®|One or more investigational devices will be added to the infusion line. Standard practise procedure related to PIVC infusions according to hospital norm will be followed. Thereafter the planned IV therapy is initiated until completion.
62246087|NCT06727240|NO_INTERVENTION|Control|Standard practise related to PIVC infusions according to hospital norm will be followed. Thereafter the planned IV therapy is initiated until completion.
62246088|NCT03706404|EXPERIMENTAL|Point-of-care Testing and Ultrasound pathway|
62246089|NCT03706404|NO_INTERVENTION|Classical pathway|
62246090|NCT03916887|EXPERIMENTAL|golf training|10-week golf training program
62436390|NCT05709106||Rimegepant treatment group|this group would use Rimegepant 75mg ODT, use it when needed for 1year
62602705|NCT02744482|EXPERIMENTAL|Risedronate|Patients take an oral tablet of Risedronate 75 mg, 2 consecutive days per month during 18 months.
62602706|NCT02744482|PLACEBO_COMPARATOR|Placebo|Patients take an oral tablet of Placebo, 2 consecutive days per month during 18 months.
62602707|NCT02789956|EXPERIMENTAL|Test: internal connection|Evaluate marginal bone level (MBL) changes at implants that are placed semi-edentulous patient when they are treated with implant level Co/cr Cad/Cam framework.
62602708|NCT02789956|ACTIVE_COMPARATOR|Test: external connection|Evaluate marginal bone level (MBL) changes at implants that are placed semi-edentulous patient when they are treated with abutment level Co/cr Cad/Cam framework.
62602709|NCT00373009|EXPERIMENTAL|Core stabilization and psychosocial education|A core stabilization exercise program (CSEP) is used in this group and has sound biomechanical and anatomical rationale. In addition, a psychosocial education program (PSEP) will be used for this group.
62602710|NCT00373009|ACTIVE_COMPARATOR|Core stabilization exercise only|A core stabilization exercise program (CSEP) is used in this group and has sound biomechanical and anatomical rationale.
62602711|NCT00373009|ACTIVE_COMPARATOR|Psychosocial education class only.|A psychosocial education program (PSEP) will be used in this group.
62602712|NCT00373009|OTHER|Traditional Army training|Traditional Army training will be used in this group.
62602713|NCT00416689||Breast or lung CA pt undergoing chemoTx|
62043396|NCT03256162|ACTIVE_COMPARATOR|Midazolam|Participants will receive four once-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
62043397|NCT05263752||Undergone ERCP with NvisionVLE® Imaging Low Profile System|Undergone ERCP with NvisionVLE® Imaging Low Profile System at MDMC between 10/15/2017 and 10/15/2019
62043398|NCT05786690||Group 1|17 patients with MIC prosthesis,
62043399|NCT05786690||Group 2|17 patients with non-MIC prosthesis,
62043400|NCT03982186|EXPERIMENTAL|Arm 1: JNJ-73763989 (medium dose) + JNJ-56136379 + NA|Participants will receive medium dose of JNJ-73763989 along with JNJ-56136379 and nucleos(t)ide analog (NA) treatment (either entecavir \[ETV\], tenofovir disoproxil fumarate \[TDF\], or tenofovir alafenamide \[TAF\]) up to 48 weeks.
62043401|NCT03982186|EXPERIMENTAL|Arm 2: JNJ-73763989 (high dose) + Placebo + NA|Participants will receive high dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
62043402|NCT03982186|EXPERIMENTAL|Arm 3: JNJ-73763989 (medium dose) + Placebo + NA|Participants will receive medium dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
62043403|NCT03982186|EXPERIMENTAL|Arm 4: JNJ-73763989 (low dose) + Placebo + NA|Participants will receive low dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
62602714|NCT04234295|ACTIVE_COMPARATOR|Lean, Healthy Controls|Subjects with a body mass index (BMI) of 25 or less will have a fat tissue biopsy collected
62824701|NCT06597474|EXPERIMENTAL|Food-Body-Mind intervention|Guided by the Actor-Partner Interdependence Model, the Allostatic Load Model, and the Transactional Theory of Stress and Coping, the proposed 16-week Food-Body-Mind intervention includes: 1) a school-based mindfulness component delivered to equip preschoolers with knowledge and skills in mindful eating and movement (e.g., yoga, deep breathing exercises); 2) a home-based mindfulness component to increase caregivers' skills in practicing mindful eating, movement, and parenting behaviors at home to foster a more positive, mindful, and healthy home environment; and 3) a school learning and home practice connection component to improve caregiver-preschooler relationships.
62043404|NCT03982186|EXPERIMENTAL|Arm 5: Placebo + JNJ-56136379 + NA|Participants will receive placebo for JNJ-73763989 and a fixed dose of JNJ-56136379 along with NA (either ETV, TDF, or TAF) up to 48 weeks.
62043405|NCT03982186|PLACEBO_COMPARATOR|Arm 6 (Control): Placebo + Placebo + NA|Participants will receive placebo for JNJ-73763989 and placebo for JNJ-56136379 along with NA (either ETV, TDF, or TAF) up to 48 weeks.
62043406|NCT04616287|EXPERIMENTAL|dementia with Lewy bodies|
62436391|NCT05624359|EXPERIMENTAL|ropivacaine plus FA|5 mL FA (50 mg; by Beijing Taide Pharmaceutical Co., Ltd) and 15 mL of 1% ropivacaine (Nai Le Pin 10mg/mL; by AstraZeneca AB, Sweden) diluted to a total volume of 30 mL in normal saline
62436392|NCT05624359|ACTIVE_COMPARATOR|ropivacaine alone|15 mL of 1% ropivacaine diluted to a total volume of 30 mL in normal saline
62436393|NCT06272851||diabetics|Type 2 DM patients aged 30 to 80 years
62043407|NCT04616287|ACTIVE_COMPARATOR|Alzheimer disease|
62043408|NCT04616287|SHAM_COMPARATOR|healthy elderly subjects|
62246091|NCT04345081||SRNSM Group|"Under the age of 65 with uni- or bilateral primary breast cancer ( clinical Stage 0-III), needing skin sparing mastectomy, nipple sparing mastectomy or patients require risk reducing mastectomy independently of the axillary surgery, having immediate or delayed-immediate implant based reconstruction.~This Group receive Skin Reducing Nipple Sparing Mastectomy"
62043409|NCT05773976|OTHER|Potential candidates, that according the investigator judgment could be treated with one of IPs|"At V0, as per clinical practice, only one of the below reported IPs products can be dispensed to the enrolled subject, depending on investigator clinical evaluation and decision:~* Afomill Refreshing Soothing~* Afomill Anti-redness Eye Drops~* Iridil"
62043410|NCT05384626|EXPERIMENTAL|Phase 1 dose escalation|NVL-655 oral daily dosing
62436394|NCT06272851||non diabetics|non-diabetic healthy individuals
62436395|NCT04053478|EXPERIMENTAL|Myometrium + Ephedrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine
62436396|NCT04053478|EXPERIMENTAL|Myometrium + Phenylephrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine
62436397|NCT04053478|EXPERIMENTAL|Myometrium + Norepinephrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine
62436398|NCT04053478|EXPERIMENTAL|Myometrium + Vasopressin|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin
62602715|NCT04234295|EXPERIMENTAL|Obese, Non-Diabetic|Subject with a BMI between 30 and 50 kg/m2 will have fat tissue biopsy collected
62602716|NCT02762552|EXPERIMENTAL|Transcranial-holter monitoring|Transcranial doppler in patient with ischemic stroke
62602717|NCT03780803|EXPERIMENTAL|Patients with PAH|home cardiac rehabilitation and respiratory rehabilitation
62602718|NCT03780803|EXPERIMENTAL|Patients with HFREF|home cardiac rehabilitation and respiratory rehabilitation
62602719|NCT03780803|EXPERIMENTAL|Patients with IHD|home cardiac rehabilitation and respiratory rehabilitation
62246092|NCT04345081||SSM Group|"Under the age of 65 with uni- or bilateral primary breast cancer ( clinical Stage 0-III), needing skin sparing mastectomy, nipple sparing mastectomy or patients require risk reducing mastectomy independently of the axillary surgery, having immediate or delayed-immediate implant based reconstruction.~This Group receive Skin Sparing Mastectomy"
62824702|NCT06597474|NO_INTERVENTION|Usual care control|"Like those in the intervention group, preschoolers assigned to the control group will receive usual Head Start activities during the intervention period. After the 12-month follow-up data collection from both intervention and control participants in each year, each control family will receive all intervention supplies including the Tasty Healthy Cookbook, MyPlate plates, and a breathing ball, as well as the program manual on how to use the intervention supplies. These intervention supplies will be distributed to control families at the end of in-person data collection appointments. Moreover, a virtual caregiver meeting on mindful eating, movement, and parenting will be provided to all caregivers who are interested."
62246093|NCT01795300|EXPERIMENTAL|Carbon Ion Radiotherapy|Treatment Schedule Carbon Ion Radiation Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
62246094|NCT01795300|EXPERIMENTAL|Proton Therapy|Treatment Schedule Proton Radiation Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
62246095|NCT01795300|EXPERIMENTAL|Hypofractionated Photon Therapy|Treatment Schedule Photon Radiation 3 Gy E Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
62246096|NCT01795300|ACTIVE_COMPARATOR|Conventional Photon Radiotherapy|Treatment Schedule Photon Radiation 1.8 Gy E Total Dose 57.6 Gy Gy E, 32 fractions, 1.8 Gy E single dose
62436399|NCT04053478|EXPERIMENTAL|Umbilical artery + Ephedrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine
62436400|NCT04053478|EXPERIMENTAL|Umbilical artery + Phenylephrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine
62436401|NCT04053478|EXPERIMENTAL|Umbilical artery + Norepinephrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine
62436402|NCT04053478|EXPERIMENTAL|Umbilical artery + Vasopressin|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin
62436403|NCT04053478|EXPERIMENTAL|Umbilical vein + Ephedrine|The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine
62436404|NCT04053478|EXPERIMENTAL|Umbilical vein + Phenylephrine|The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine
62436405|NCT04053478|EXPERIMENTAL|Umbilical vein + Norepinephrine|The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine
62436406|NCT04053478|EXPERIMENTAL|Umbilical vein + Vasopressin|The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin
62436407|NCT06316947|EXPERIMENTAL|Families|Somali American families with children in the household and at least one adult using shisha at home
62436408|NCT03575559|EXPERIMENTAL|Individual planning|An education and general motivational treatment is provided to each participant. Afterwards, participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form up to three own individual plans. They are not allowed to speak to each other. The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, problem solving (coping planning). Interventions: Behavioral: Individual planning. Behavioral: Education and motivation. Active Comparator: No planning intervention, individual distraction task.
62602720|NCT03780803|NO_INTERVENTION|Control group|No rehabilitation
62602721|NCT01491750|EXPERIMENTAL|GUIDED IMAGERY|
62824703|NCT02694185|EXPERIMENTAL|Experimental Group|This group will undergo the intervention as described in the protocol
62824704|NCT02694185|NO_INTERVENTION|Control Group|This group will not receive the intervention, they will receive usual care
62824705|NCT03351764|OTHER|arm 1|these are within subject repeated measures studies across a number of conditions
62246097|NCT03626584||Cardiac Amyloidosis Patients|Patients with established diagnosis of cardiac amyloidosis.
62602722|NCT01491750|PLACEBO_COMPARATOR|AUDIO BOOK|
62824706|NCT03351764|PLACEBO_COMPARATOR|arm 2|these are within subject repeated measures studies across a number of conditions (which can include sham TMS as a placebo)
62602723|NCT06128291||Posterior colporrhaphy|Medical records of women received concomitant posterior colporrhaphy for their pelvic organ prolapse repairs. Comparison will be made to compare preoperative and postoperative conditions.
62824707|NCT05002868|EXPERIMENTAL|RP12146|RP12146 will be administered orally daily (QD or BID)
62824708|NCT06599372|OTHER|The rTMS method|The treatment lasts 2 weeks with 20 rTMS sessions at a rate of 2 sessions per day. Each session lasts 20 minutes with a one hour break between sessions. The application of rTMS will be done on the left temporo-parietal junction.
62043411|NCT05384626|EXPERIMENTAL|Cohort 2a|Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement who have received 1 prior 2nd-generation ALK TKI (ceritinib, alectinib, or brigatinib). Up to 2 prior lines of chemotherapy and/or immunotherapy are allowed.
62043412|NCT05384626|EXPERIMENTAL|Cohort 2b|Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, who have received 2-3 prior ALK TKIs (crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib). Up to 2 prior lines of chemotherapy and/or immunotherapy are allowed.
62824709|NCT06599372|OTHER|The cTBS method|The treatment lasts 15 days with 45 sessions of cTBS at a rate of 3 sessions per day. The session lasts 40 seconds and consists of 3 pulses at 50Hz repeated every 200 milliseconds (5Hz) to reach a total of 600 pulses, with a 15 minute break between sessions. The application of cTBS will be performed on the left temporo-parietal junction.
62043413|NCT05384626|EXPERIMENTAL|Cohort 2c|Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, who have received lorlatinib as the only prior ALK TKI therapy. Up to one prior line of chemotherapy and/or immunotherapy received prior to lorlatinib is allowed.
62824710|NCT06601855||Cholecystectomy group|Patient in this group received cholecystectomy, whether immediately, or delayed
62436409|NCT03575559|EXPERIMENTAL|Collaborative planning|An education and general motivational treatment is provided to each participant. Afterwards, participants are filling in the planning forms together, referring to their joint physical activity. The friendship dyad forms up to three joint plans about engaging in PA together. The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, problem solving (coping planning). Interventions: Behavioral: Collaborative planning. Behavioral: Education and motivation. Active Comparator: No planning intervention, collaborative distraction task.
62436410|NCT03575559|ACTIVE_COMPARATOR|Individual distraction task|An education and general motivational treatment is provided to each participant. Afterwards, participants have to interpret a short video showing scenes of two different superhero movies. Several questions will be asked about characteristics of the two super heroes in the movie and whether these heroes are comparable. Each participant watches the movie alone and answers all questions by him/herself. Both members of the dyad are not allowed to speak to each other.
62824711|NCT06601855||Non-operative management group|Patients in this group did not receive cholecystectomy during follow up period
62824712|NCT04008745|EXPERIMENTAL|Intervention Group|Patients in the intervention group will perform foot-related exercises described in an educational booklet three times/week at home. In the follow-up period, patients will follow the same schedule set by the project till the end of the study (16-weeks).
62824713|NCT04008745|NO_INTERVENTION|Control Group|Participants in the control group will not receive any specific intervention in addition to the treatment recommended by the health professionals team (doctors, nurses, podiatrists), which includes pharmacological treatment, and self-care recommendations and foot care by international consensus.
62824714|NCT05654259||obese women with normal gestational weight gain|obese women (body mass index ≥30 kg/m2) with weight gain 5-9 kg
62824715|NCT05654259||obese women excessive gestational weight gain|obese women (body mass index ≥30 kg/m2) with weight gain \>9 kg
62602724|NCT02634372|EXPERIMENTAL|EMDR Therapy|EMDR: 20 individual sessions 60 minutes each for 6 months
62246098|NCT03626584||Healthy Volunteers|Healthy volunteer subjects of similar age and gender to patient cohort.
62246099|NCT02086851|EXPERIMENTAL|Lifestyle Intervention plus Parent Motivational Interviewing|Lifestyle intervention + Parent MI
62602725|NCT02634372|ACTIVE_COMPARATOR|Supportive therapy|Supportive therapy: 20 individual sessions 60 minutes each for 6 months.
62602726|NCT01236781|EXPERIMENTAL|Group A: Screening|Group A comprises 500 asymptomatic women with no history of breast cancer who are scheduled for routine screening of the breasts with FFDM.
62824716|NCT05654259||non-obese women with normal gestational weight gain|non-obese women (body mass index 18.5-24.9 kg/m2) with weight gain 11.5-16 kg
62824717|NCT05654259||non-obese women with excessive weight gain|non-obese women (body mass index 18.5-24.9 kg/m2) with weight gain \>16 kg
62824718|NCT05654259||obese women with OSA|obese women (body mass index ≥30 kg/m2) with Obstructive Sleep Apnea (OSA) (Apnea and Hypopnea Index (AHI) ≥5 events/hr
62824719|NCT05654259||obese women without OSA|obese women (body mass index ≥30 kg/m2) without Obstructive Sleep Apnea (OSA) (AHI \<5 events/ hr)
62824720|NCT05654259||non-obese women without OSA|non-obese women without OSA (AHI \<5 events/ hr)
62824721|NCT01929421|EXPERIMENTAL|Gemcitabine/ s-1|
62824722|NCT04834661||inside group|laparoscopic surgery for colorectal and gastric cancer inside the primary registered medical institution
62043414|NCT05384626|EXPERIMENTAL|Cohort 2d|Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, who are naïve to ALK TKI therapy. Up to one prior line of chemotherapy and/or immunotherapy is allowed.
62043415|NCT05384626|EXPERIMENTAL|Cohort 2e|Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, not eligible for other Phase 2 cohorts.
62043416|NCT05384626|EXPERIMENTAL|Cohort 2f|Patients with other solid tumors harboring an ALK rearrangement or activating ALK mutation, who have received ≥1 prior systemic anticancer therapy, or for whom no satisfactory standard therapy exists.
62043417|NCT03657433|EXPERIMENTAL|Ferumoxyltol|"Patients will receive two infusions of Ferumoxyltol, 510mg, intravenously, one week apart.~Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies."
62043418|NCT03657433|ACTIVE_COMPARATOR|Ferrous Sulfate|"Patients will be provided with oral ferrous sulphate, 325mg, to take 2x daily at home.~Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies."
62043419|NCT04501510||HumerusFracture|Patients with humerus fracture
62043420|NCT04501510||RadiusFracture|Patients with radial bone fracture
62043421|NCT02288468|EXPERIMENTAL|STN|"Deep Brain Stimulation of Nucleus subthalamicus with Vercise™ Deep Brain Stimulation System.~The STN will be typically reached with the most distal contacts of the DBS electrode (8 contact). Imaging studies (postop helical CT and re-fusion to planning MRI data) will allow for the identification of contacts located in the STN. We expect the STN to be typically covered by contacts 1-4 of the Vercise™ DBS lead. Typically, only the most superficial contacts (3,4) will be activated after a monopolar review of each contact. In this monopolar review the therapeutic widths of each contact will be tested for its effectiveness in tremor reduction, reduction of rigidity and bradykinesia. Typical settings will be: Frequency 130-180 Hz, pulse width 60-90 us, Amplitude 1-7 mA."
62246100|NCT02086851|ACTIVE_COMPARATOR|Lifestyle Intervention alone|lifestyle intervention alone
62246101|NCT04877795||Cardiac Surgery|Adult Patients undergoing elective on-pump cardiac surgery (i.e. Coronary artery bypass graft surgery (CABG) and/or valvular surgery)
62436411|NCT03575559|ACTIVE_COMPARATOR|Collaborative distraction task|An education and general motivational treatment is provided to each participant. Afterwards, participants have to interpret a short video showing scenes of two different superhero movies together. Several questions ask about the characteristics of the two super heroes in the movie and whether these heroes are comparable. Both members of the dyad watch the movie together and answer the questions conjointly.
62436412|NCT01993433|EXPERIMENTAL|DRM02|DRM02 Topical Gel, 0.25%
62436413|NCT01993433|PLACEBO_COMPARATOR|Vehicle|DRM02 Topical Gel, Vehicle
62436414|NCT01893502|ACTIVE_COMPARATOR|Group 1|Participants will receive weekly proactive and live telephone counselling from Quitline (run by the Health Promotion Board) for one month
62824723|NCT04834661||outside group|laparoscopic surgery for colorectal and gastric cancer outside the primary registered medical institution
62436415|NCT01893502|ACTIVE_COMPARATOR|Group 2|Participants will receive weekly proactive and live telephone counselling from Quitline (run by the Health Promotion Board) for six months
62436416|NCT04182932|EXPERIMENTAL|CJ-40010 EV71 A dose|Inactivated EV71 vaccine(A dose) or placebo in 10 healthy adults (three doses, 28 days interval)
62436417|NCT04182932|EXPERIMENTAL|CJ-40010 EV71 B dose|Inactivated EV71 vaccine(B dose) or placebo in 10 healthy adults (three doses, 28 days interval)
62436418|NCT04182932|EXPERIMENTAL|CJ-40010 CVA16 C dose|Inactivated CVA16 vaccine(C dose) or placebo in 10 healthy adults (three doses, 28 days interval)
62436419|NCT04182932|EXPERIMENTAL|CJ-40010 CVA16 D dose|Inactivated CVA16 vaccine(D dose) or placebo in 10 healthy adults (three doses, 28 days interval)
62824724|NCT06586814|OTHER|Suture|Wound Closure
62824725|NCT06586814|OTHER|Staple|Wound Closure
62824726|NCT03902431|NO_INTERVENTION|Control|CVD risk prior to the patient and clinician training
62824727|NCT03902431|EXPERIMENTAL|Training|CVD risk after the patient and clinician training
62824728|NCT06597162|EXPERIMENTAL|education group|"For participants in the training group, data will be collected face to face in two stages: the pre-test phase and the post-training post-test phase.~A survey will be distributed to the control group simultaneously with the training group and will be collected as pre-test and post-test, but no training will be given to the control group. Only after the study ends will educational materials be shared with the control group."
62824729|NCT06597162|NO_INTERVENTION|Control group|Routine care was given to the control group
62824730|NCT06598917|EXPERIMENTAL|Maintenance chemotherapy with S-1 regimen|Maintenance chemotherapy with S-1 regimen
62824731|NCT06596343|EXPERIMENTAL|Adjuvant Chemotherapy Combined with Traditional Chinese Medicine (TCM) Supportive Therapy|"Patients will sign an informed consent form after surgery but before starting chemotherapy, and those enrolled will receive a combination of chemotherapy and Traditional Chinese Medicine (TCM) supportive therapy.~1. Chemotherapy Regimen:~   * Postoperative adjuvant chemotherapy: A dual-drug concurrent regimen will be used, with each cycle lasting 21 days. On day 1 of each cycle, oxaliplatin will be administered intravenously at a dose of 130 mg/m². From day 1 to day 14 of each cycle, capecitabine will be taken orally at a dose of 1000 mg/m², twice daily. The treatment duration will follow the CSCO 2023 guidelines for colorectal cancer, with chemotherapy lasting for 6 months.~2. TCM Treatment:~   * TCM treatment will be based on syndrome differentiation (Zheng) and guided by the Guidelines for TCM Diagnosis and Treatment of Malignant Tumors."
62436420|NCT04182932|EXPERIMENTAL|CJ-40010 Bivalent E dose|Inactivated EV71/CVA16 vaccine(E dose) or placebo in 10 healthy adults (three doses, 28 days interval)
62436421|NCT04182932|EXPERIMENTAL|CJ-40010 Bivalent F dose|Inactivated EV71/CVA16 vaccine(F dose) or placebo in 10 healthy adults (three doses, 28 days interval)
62436422|NCT03780894|EXPERIMENTAL|Experimental treatment|The active treatment consists of intravenous injection of 2g of fibrinogen concentrate, 1g of tranexamic acid, 2 red bood cells concentrate O Rh(D) negative (Banc de Sang i Teixits, Barcelona, Spain), and crystalloids at pre-hospital phase of care.
62043422|NCT02288468|EXPERIMENTAL|Vim/DRT|"Deep Brain Stimulation of Ventral intermediate nucleus with Vercise™ Deep Brain Stimulation System.~The thalamic target (Vim/DRT) will be typically reached with the proximal contacts. Imaging studies (postop helical CT and re-fusion to planning MRI data) will allow for the identification of contacts located the thalamic target. We expect the thalamic target to be typically covered by contacts 5-8 of the Vercise™ DBS lead. We will perform a monopolar review of each contact. In this monopolar review the therapeutic widths of each contact will be tested for its effectiveness in tremor reduction and the occurrence of side effects (typically capsular e.g. facial contraction). Typical settings will be: Frequency 130-180 Hz, pulse width 60-90 us, Amplitude 1-7 mA."
62043423|NCT02288468|EXPERIMENTAL|STN+Vim/DRT|"Combined Deep Brain Stimulation of Nucleus subthalamicus and Ventral intermediate nucleus with Vercise™ Deep Brain Stimulation System.~STN+Vim/DRT stimulation is essentially a combination of the previously described procedure."
62043424|NCT00854022||Healthy|Healthy adults, of any ethnicity, or sex, and with no previous history of cancer, except for non-melanoma skin cancer
62043425|NCT00854022||RCC|Adult patients with newly diagnosed (diagnosed within the year of enrollment) renal carcinoma (RCC) any ethnicity, or sex, who have not received prior chemotherapy or radiotherapy.
62043426|NCT02191072|EXPERIMENTAL|omalizumab|omalizumab 300mg subcutaneously once
62824732|NCT06604650||Active Older Adults|Body mass index (height and weight), blood pressure and pulse, arm and leg strength and mobility
62824733|NCT00360841|EXPERIMENTAL|A|The subjects in arms A and B will receive auricular acupuncture. The subjects in arms A will receive auricular acupuncture (at 2nd and 4th chemotherapy courses) as well as the sham auricular acupuncture (at the 3rd chemotherapy course).
62043427|NCT00660842|EXPERIMENTAL|A|weekly chemotherapy
62043428|NCT00660842|ACTIVE_COMPARATOR|B|every 3 weeks chemotherapy
62043429|NCT02068755||Cardiac surgery|Patients who have undergone cardiac surgery
62043430|NCT00808275|EXPERIMENTAL|Dairy calcium|Diet with dairy calcium sources
62043431|NCT00808275|EXPERIMENTAL|Non-dairy calcium|Diet with non-dairy calcium sources
62043432|NCT03076970|EXPERIMENTAL|Lasmiditan 200 mg|single oral tablet
62043433|NCT03076970|ACTIVE_COMPARATOR|Sumatriptan 100 mg|single oral tablet
62436423|NCT03780894|ACTIVE_COMPARATOR|Standard treatment|Patients in the control arm will be treated according the existing protocols based on crystalloids and tranexamic acid administration.
62043434|NCT03076970|EXPERIMENTAL|Combination of lasmiditan and sumatriptan|single oral tablet of each
62043435|NCT03256773||Notmal|No lung Disease
62043436|NCT03256773||Cystic Fibrosis|cystic fibrosis Lung Disease
62824734|NCT00360841|SHAM_COMPARATOR|B|The subjects in arms A and B will receive auricular acupuncture. The subjects in arm B will receive the sham auricular acupuncture (at the 2nd and 4th chemotherapy courses) and auricular acupuncture (at the 3rd chemotherapy course).
62824735|NCT00360841|NO_INTERVENTION|C|No treatment received.
62824736|NCT05205031|ACTIVE_COMPARATOR|Intravenous|The intervention will consist of attempts to successfully establish a peripheral intravenous access during the cardiac arrest. The prehospital clinician will be required to attempt the intervention a minimum of two times.
62043437|NCT03256773||PCD|Primary Ciliary Dyskinesia
62824737|NCT05205031|EXPERIMENTAL|Intraosseous|The intervention will consist of attempts to successfully establish an intraosseous access during the cardiac arrest. The prehospital clinician will be required to attempt the intervention a minimum of two times.
62824738|NCT06603610|ACTIVE_COMPARATOR|Intervention|Participants in this arm will receive the intervention.
62824739|NCT06603610|PLACEBO_COMPARATOR|Control|Participants in the control group will receive their usual care, along with a booklet containing information about locally available resources, such as those related to meal preparation, grocery delivery, housekeeping, pharmacies that deliver medicines, home care, and Wheel-Trans. Participants in this arm will also receive telephone follow-up support.
62824740|NCT00791934|EXPERIMENTAL|Stratus Microflow Ethmoid Spacer|Temporary implantation of Ethmoid spacer with Triamcinolone Acetonide for 28 days.
62824741|NCT02357654|EXPERIMENTAL|GnRH agonist|
62824742|NCT02357654|PLACEBO_COMPARATOR|Placebo|
62824743|NCT02603146|EXPERIMENTAL|Hydroxychloroquine Group|Subjects randomized to hydroxychloroquine (HCQ). Subjects will receive 200-400 mg of HCQ (1-2 pills), based upon ideal body weight (IBW), taken daily for 12 months.
62043438|NCT03256773||COPD|Chronic Obstructive Lung Disease
62043439|NCT05566223|EXPERIMENTAL|CISH CRISPR TIL / Phase I Arm|"Dose Escalation/Expansion Cohort~Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +escalating doses of CISH inactivated TIL + high-dose aldesleukin"
62043440|NCT05566223|EXPERIMENTAL|CISH CRISPR TIL plus pembrolizumab / Phase I Arm|"Dose Expansion with Maintenance Therapy Cohort~Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +escalating doses of CISH inactivated TIL + high-dose aldesleukin~Maintenance pembrolizumab during follow-up"
62043441|NCT05566223|EXPERIMENTAL|CISH CRISPR TIL / Phase II Arm PD-L1 Negative Cohort|"Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +recommended phase II dose (from phase I) of CISH inactivated TIL + high-dose aldesleukin~May include maintenance pembrolizumab during follow-up"
62436424|NCT02801448|PLACEBO_COMPARATOR|Placebo|Placebo containing maltodextrine but no active sulforaphane
62436425|NCT02801448|ACTIVE_COMPARATOR|BSE|Broccoli sprout extract once daily for 12 weeks
62824744|NCT02603146|PLACEBO_COMPARATOR|Placebo Group|Subjects randomized to placebo HCQ. Subjects will receive 200 - 400 mg of HCQ placebo (1-2 pills), based upon IBW, taken daily for 12 months.
62043442|NCT05566223|EXPERIMENTAL|CISH CRISPR TIL / Phase II Arm PD-L1 Positive Cohort|"PD-L1 positive is defined as tumors with a PD-L1 Tumor Proportion Score (TPS) ≥ 1%.~Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +recommended phase II dose (from phase I) of CISH inactivated TIL + high-dose aldesleukin~May include maintenance pembrolizumab during follow-up"
62824745|NCT01194830|ACTIVE_COMPARATOR|Linagliptin|1 Tablet PO QD
62824746|NCT01194830|PLACEBO_COMPARATOR|Placebo|1 Tablet PO QD
62824747|NCT06587893||healthy adult volunteer group|hospital workers recruited in intensive care and emergency departments.
62824748|NCT03144427||Burns|Patients with burns to 20% or more of their BSA (body surface area) require resuscitation with intravenous crystalloid fluids in order to avoid organ failure and death
62043443|NCT05119894|EXPERIMENTAL|Brexpiprazole LAI: Dose 1|
62043444|NCT05119894|EXPERIMENTAL|Brexpiprazole LAI: Dose 2|
62436426|NCT03526367|EXPERIMENTAL|hydration plus rosuvastatin therapy|"1. After randomized，hydration（3ml/kg/h, if patients had LVEF\<40%, 1.5 ml/kg/h）last 12 hours;~2. After randomized，a loading dose of rosuvastatin 20mg then 10 mg daily followed for at least 7 days."
62824749|NCT00087152|EXPERIMENTAL|Imatinib Mesylate & Capecitabine|
62824750|NCT05822804|EXPERIMENTAL|experimental group|Vascular Closure Device (Tonbridge)
62824751|NCT05822804|ACTIVE_COMPARATOR|control group|EXOSEAL Vascular Closure Device (Codis Corporation)
62824752|NCT05799820|EXPERIMENTAL|QL1706|
62824753|NCT05799820|EXPERIMENTAL|QL1706 in combination with bevacizumab and XELOX|
62824754|NCT06263010|EXPERIMENTAL|Allo APOE4 carriers|Group of 5 participants who are carriers of the APOE4 gene and will receive allopregnanolone 4mg administered weekly via a 30-min IV infusion for a duration of 12 weeks.
62824755|NCT06263010|ACTIVE_COMPARATOR|Allo APOE4 none-carriers|Group of 5 participants who are none-carriers of the APOE4 gene and will receive allopregnanolone 4mg administered weekly via a 30-min IV infusion for a duration of 12 weeks.
62824756|NCT00412334|EXPERIMENTAL|1|
62043445|NCT05119894|EXPERIMENTAL|Brexpiprazole LAI: Dose 3|
62043446|NCT05119894|EXPERIMENTAL|Brexpiprazole LAI: Dose 4|
62246102|NCT05248451||Normal Renal Function|Patients undergoing inpatient non-cardiac surgery at St. Paul's Hospital with normal preoperative Estimated Glomerular Filtration Rate (eGFR) results. eGFR values considered will be from samples drawn within a one year period preceding surgery. Values from samples drawn within the 7 days immediately preceding surgery will be excluded, in order to avoid introducing bias from acute kidney injuries. All available eGFR values in the 7 to 365 days preceding an individual's surgery will be included, and the average of these values will be used as their preoperative eGFR. Investigators will include all people that have one or more measure. Depending on sample size, investigators may decide to limit inclusion to those that have two or more eGFR estimates.
62436427|NCT03526367|ACTIVE_COMPARATOR|Standard therapy|No statin within 12 h after randomization, hydration at physicians' discretion, but no more than 1ml/kg/h.
62824757|NCT00412334|EXPERIMENTAL|2|
62824758|NCT00412334|EXPERIMENTAL|3|
62824759|NCT00412334|EXPERIMENTAL|4|
62043447|NCT06074705|EXPERIMENTAL|Part 1, Dose Escalation Cohort 1: DS-1471a|Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
62246103|NCT05248451||Renal Dysfunction, Chronic Kidney Disease (CKD)|Patients undergoing non-cardiac surgery with abnormal preoperative Estimated Glomerular Filtration Rate (eGFR). eGFR values considered will be from samples drawn within a one year period preceding surgery. Values from samples drawn within the 7 days immediately preceding surgery will be excluded, in order to avoid introducing bias from acute kidney injuries. All available eGFR values in the 7 to 365 days preceding an individual's surgery will be included, and the average of these values will be used as their preoperative eGFR. Investigators will include all people that have one or more measure. Depending on sample size, investigators may decide to limit inclusion to those that have two or more eGFR estimates. As eGFR is not accurate in the setting of dialysis, patients receiving dialysis for at least 90 days prior to their surgical procedure will also be included as a separate eGFR category.
62824760|NCT06586047|EXPERIMENTAL|PET Imaging|Triple negative breast cancer patients will undergo FDG PET/CT and Pyl PET/Ct
62824761|NCT04953104|EXPERIMENTAL|Treatment (nivolumab & relatlimab)|Participants found to be eligible to take part in this study, you will receive nivolumab and relatlimab by vein over about 30 minutes on Day 1 of every 28-day study cycle (about every 4 weeks).
62043448|NCT06074705|EXPERIMENTAL|Part 1, Dose Escalation Cohort 2: DS-1471a|Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
62043449|NCT06074705|EXPERIMENTAL|Part 1, Dose Escalation Cohort 3: DS-1471a|Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
62043450|NCT06074705|EXPERIMENTAL|Part 1, Dose Escalation Cohort 4: DS-1471a|Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
62043451|NCT06074705|EXPERIMENTAL|Part 1, Dose Escalation Cohort 5: DS-1471a|Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
62043452|NCT06074705|EXPERIMENTAL|Part 1, Dose Escalation Cohort 6: DS-1471a|Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
62824762|NCT06599515|ACTIVE_COMPARATOR|HugoTM Ras (Medtronic) robotic system|The patient is positioned supine position and a tilt of Trendelenburg of 12 degrees is given. A Verres needle insufflation at Palmers' point at the left subcostal margin will be done to achieve a pneumoperitoneum of 12 mmHg. Subsequently, a trocar of 12 mm is placed at the upper margin of the umbilicus using an optical trocar. Two further trocars of 8 mm are placed left and right side at 7 to 8 cm distance from the umbilical trocar and 2 cm caudal from the umbilical trocar. The setup of the arms, tilt and angles are done using the setup guide. The operation is performed using a scope with a 0°-degree angle. As instruments we have a fenestrated bipolar forceps in the left hand and a monopolar curved scissors in the right hand. Mesh used will be DextileTM Anatomical Mesh X-Large of 16x12 cm. There is a left sided and a right sided version and in bilateral hernias the meshes will overlap on the midline. The peritoneum is closed using a barbed suture (V-Loc 3/0) of 15 cm in length.
62436428|NCT06045416||LD_Diff_Diag|LD differential diagnosis cohort: Patients presenting at the ED with differential diagnosis of LD according to the treating physician
62824763|NCT06599515|ACTIVE_COMPARATOR|daVinci Xi (Intuitive Surgical) robotic system|An 8-mm trocar will be placed at the supraumbilical position after creation of pneumoperitoneum using a Verress needle with an intra-abdominal pressure of 12 mmHg. Two additional trocars (8 mm) are placed bilaterally in the flank at the level of the umbilicus under direct vision. The distance between the lateral trocars and the umbilical trocar will be 7 cm at minimum. The Progrip™ Laparoscopic Self-Fixating Mesh of 12×16 cm (anatomic version, Medtronic, Minneapolis, MN, US) will be used. The suture will be a slowly absorbable barbed suture 15 cm in length (V-Loc™ 90, Medtronic, Minneapolis, MN, US). The trocars are docked to the robotic arms, with the endoscope at the umbilicus. Inguinal hernia repair will be performed according to the standard surgical principle.
62824764|NCT03954366|OTHER|Arm A - rucaparib and oral rosuvastatin|
62436429|NCT06045416||Heathy_Control|Previously healthy patients (HC) with routine blood investigations presenting at the ED or PID outpatient department
62436430|NCT04800445||Case group of fullterm neonates with neonatal sepsis|
62436431|NCT04800445||Healthy fullterm neonates|
62436432|NCT02416037|EXPERIMENTAL|Prone Proseva|
62436433|NCT02416037|ACTIVE_COMPARATOR|Prone Talmor|
62436434|NCT02673671||Subjects with unknown POI status consented pre-surgery|Up to 100 subjects may be consented prior to surgery who are planned to undergo gastrointestinal surgery or a planned surgery that does not involve the abdominal cavity. The investigator does not change the routine medical care of study participants.
62436435|NCT02673671||Subjects with known/unknown POI status consented post-surgery|Up to 50 subjects who have undergone gastrointestinal surgery or surgery not involving the abdominal cavity may be consented post- operatively during their hospital stay for this study.The investigator does not change the routine medical care of study participants.
62436436|NCT06281119|EXPERIMENTAL|Cervavac administered as three doses|Recombinant Quadrivalent Human Papillomavirus (Types 6,11 16, 18) Vaccine manufactured by Serum Institute of India Pvt Ltd administered as three doses at day 0, 60 and 180.
62436437|NCT06281119|EXPERIMENTAL|Cervavac administered as two doses|Recombinant Quadrivalent Human Papillomavirus (Types 6,11 16, 18) Vaccine manufactured by Serum Institute of India Pvt Ltd administered as two doses at day 0 and 180.
62436438|NCT06281119|ACTIVE_COMPARATOR|Gardasil administered as three doses|Recombinant Quadrivalent Human Papillomavirus (Types 6,11 16, 18) Vaccine manufactured by MSD administered as three doses at day 0, 60 and 180.
62436439|NCT01434056||Liver transplantation waiting list|Patients waiting for liver transplantation with chronic end staged liver disease
62436440|NCT03335020|PLACEBO_COMPARATOR|Normal|Healthy volunteers. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
62436441|NCT03335020|ACTIVE_COMPARATOR|Fibromuscular Dysplasia (FMD)|Subjects with diagnosis of FMD. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
62436442|NCT03335020|ACTIVE_COMPARATOR|Atherosclerosis|Subjects with diagnosis of atherosclerosis. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
62602727|NCT01236781|EXPERIMENTAL|Group B: Diagnostic Enriched Population|Approximately 50 asymptomatic women with no history of breast cancer who have been informed of positive (abnormal) findings from a recent (within 30 days) FFDM screening will be recruited to Group B prior to their diagnostic imaging (e.g., diagnostic FFDM and/or ultrasound and/or other).
62602728|NCT00093418|EXPERIMENTAL|Arm I|Arm I: Patients receive oral tipifarnib twice daily on days 1-21. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
62043453|NCT06074705|EXPERIMENTAL|Part 2, Dose Expansion (Tumor-specific Cohort 1): DS-1471a|Participants will receive intravenous DS-1471a at the maximum tolerated dose and/or recommended dose for expansion as established in Part 1 Dose Escalation.
62602729|NCT00093418|EXPERIMENTAL|Arm II|Patients receive oral tipifarnib twice daily on days 1-7 and 15-21. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
62246104|NCT06083831||Sequential feeding group|After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) by continuous feeding, continuous feeding was changed into intermittent feeding. The total daily dosage of enteral nutrition was equally distributed during three periods at 7-9:00, 11-13:00 and 17-19:00. The enteral nutritional suspension administered during each period was given at a uniform rate within two hours by an enteral feeding pump. The other times of the day were fasting times.
62246105|NCT06083831||Continuous feeding group|Patients received continous feeding with a constant velocity by an enteral feeding pump over one day.
62246106|NCT02393677|PLACEBO_COMPARATOR|Ropivacaine|amide local anesthetic
62436443|NCT03335020|ACTIVE_COMPARATOR|Spontaneous Coronary Artery Dissection (SCAD)|Subjects with diagnosis of SCAD. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
62436444|NCT03335020|ACTIVE_COMPARATOR|Segmental Arterial Mediolysis (SAM)|Subjects with diagnosis of SAM. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
62436445|NCT04078230|EXPERIMENTAL|Extend LymphAdenectomy|Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors
62436446|NCT04078230|NO_INTERVENTION|Regional LymphAdenectomy|Regional lymph node dissection for intrahepatic cholangiocarcinoma included station 12.
62436447|NCT01653483|EXPERIMENTAL|GSK573719|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
62436448|NCT01653483|PLACEBO_COMPARATOR|GSK573719 matched-placebo|Placebo
62436449|NCT00468923|PLACEBO_COMPARATOR|Rosuvastatin|Rosuvastatin 10 mg vs placebo
62436450|NCT00468923|PLACEBO_COMPARATOR|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 mg vs placebo
62824765|NCT03954366|OTHER|Arm B - rucaparib and oral contraceptives|
62824766|NCT06587620|PLACEBO_COMPARATOR|control group (group c ) : saline|IV infusion of 50 ml saline over 10 min before induction of anesthesia. IV saline infusion immediately after induction till 15 min before the end of surgery.
62824767|NCT06587620|ACTIVE_COMPARATOR|Tranexamic acid group (group T)|Start IV infusion of a loading dose of tranexamic acid 10 mg/kg completed to 50 ml saline over 10 min before induction of anesthesia. IV infusion of tranexamic acid at a dose of 1 mg/kg/h immediately after induction till 15 min before the end of surgery.
62436451|NCT00814658|EXPERIMENTAL|Galantamine + Nimodipine|
62436452|NCT00814658|EXPERIMENTAL|Galantamine + Placebo|
62436453|NCT05707429||Healthy control group|will include patient's relatives or volunteers, who accept to participate in the study through invitation or posters which send or spread it to all staff hospitals about importance of the study.
62436454|NCT05707429||IBD patients inactive group|"IBD patients group: they will be recruited from outpatient clinic and inpatient with CD or UC at the Gastroenterology department at Alrajhi hospital.~CD patients will be assessed by the Crohn's Disease Activity Index a score of less than 150 corresponds to relative disease quiescence (remission); 150 to 219, mildly active disease; 220 to 450, moderately active disease; and greater than 450, severe disease (9)."
62824768|NCT06587620|ACTIVE_COMPARATOR|Dexmedetomidine group (group D).|Start IV infusion of a loading dose of dexmedetomidine 1ug/kg completed to 50 ml saline over 10 min before induction of anesthesia. IV infusion of dexmedetomidine 0.3-0.7 µg/kg/h immediately after induction to maintain Mean Arterial Pressure (MAP) between 60-70 mmHg till 15 min before the end of surgery.
62824769|NCT05983757|ACTIVE_COMPARATOR|Standard of Care Treatment|Standard medical management in patients who suffer a distal medium vessel occlusion
62824770|NCT05983757|EXPERIMENTAL|Endovascular Thrombectomy|Endovascular thrombectomy in patients who suffer a distal medium vessel occlusion.
62824771|NCT03242915|EXPERIMENTAL|Pembrolizumab/Carboplatin/Pemetrexed|Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks
62824772|NCT05826743|EXPERIMENTAL|COLO BT™|Patients receive COLO BT™ during colorectal surgery.
62246107|NCT02393677|ACTIVE_COMPARATOR|Ropivacaine with Dexmedetomidine|combination of amide local anaesthetic and alpha2 agonist
62436455|NCT03955666|EXPERIMENTAL|Cohort A (PRV-3279 or placebo)|Sterile solution for intravenous administration, 3 doses, every 2 weeks
62436456|NCT03955666|EXPERIMENTAL|Cohort B (PRV-3279 or placebo)|Sterile solution for intravenous administration, 3 doses, every 2 weeks
62436457|NCT04621942|EXPERIMENTAL|Training group|12 women after mastectomy. Inertial rehabilitation was performed twice a week (Monday and Thursday, between 5:00 and 8:00 PM) for 6 weeks using Cyklotren device (Inerion, Poland). Moreover, women from training group participated in rehabilitation gymnastics twice a week.
62436458|NCT04621942|ACTIVE_COMPARATOR|Control group|12 women after mastectomy. All women participated in rehabilitation gymnastics twice a week.
62246108|NCT02187679|EXPERIMENTAL|Abobotulinum toxin A|Abobotulinum toxin A Injection
62246109|NCT04621396||Next Generation Cohort|We will follow the children from mothers who either have T2D, GDM, or are controls.
62043454|NCT06074705|EXPERIMENTAL|Part 2, Dose Expansion (Tumor-specific Cohort 2): DS-1471a|Participants will receive intravenous DS-1471a at the maximum tolerated dose and/or recommended dose for expansion as established in Part 1 Dose Escalation.
62043455|NCT06074705|EXPERIMENTAL|Part 2, Dose Expansion (Tumor-specific Cohort 3): DS-1471a|Participants will receive intravenous DS-1471a at the maximum tolerated dose and/or recommended dose for expansion as established in Part 1 Dose Escalation.
62043456|NCT00273312|EXPERIMENTAL|Patupilone|was administered at 10 mg/m2, as a single intravenous infusion over 20 minutes, once every 3 weeks
62602730|NCT00093418|EXPERIMENTAL|Arm III|Patients receive tipifarnib as in arm I, but at a lower dose. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
62824773|NCT05826743|ACTIVE_COMPARATOR|Standard of Care|Patients receive the standard of care, a protective stoma, during colorectal surgery.
62824774|NCT00901836|EXPERIMENTAL|Preoperative Proton Therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
62824775|NCT00901836|ACTIVE_COMPARATOR|Surgery|Standard of care surgery will be performed 4-6 weeks after the completion of radiation.
62436459|NCT05270187|EXPERIMENTAL|Scanning Gorup|"Patients in this group will receive facial massage, facial expression exercises and a Multiwave Locked System Laser with energy density 10 J/cm2. Laser will scan the affected side after calculating the distance and the total energy delivered to the one side of the face.~The average treatment area is 50 cm2. The energy density was 10 J/cm2 with a total energy of 500 J and the treatment time is approximately 15 minutes. The laser probe will be away from the eye region. Both patients and therapist wear a laser googles."
62602731|NCT00093418|EXPERIMENTAL|Arm IV|Patients receive tipifarnib as in arm II, but at a lower dose. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
62824776|NCT06598475|EXPERIMENTAL|Step 1 (3 clinics)-15 months control then 30 months intervention|
62043457|NCT01641393|EXPERIMENTAL|EUR-1008 then Kreon|"* EUR-1008 during Treatment Period 1 (29 days ±2 days) and~* Kreon during Treatment Period 2 (29 days ±2 days)."
62043458|NCT01641393|EXPERIMENTAL|Kreon then EUR-1008|"* Kreon during Treatment Period 1 (29 days ±2 days) and~* EUR-1008 during Treatment Period 2 (29 days ±2 days)."
62043459|NCT02593175|EXPERIMENTAL|Treatment (panitumumab, paclitaxel, carboplatin)|Patients receive panitumumab IV over 30 minutes and paclitaxel IV over 30 minutes on days 1, 8, and 15. Patients also receive carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62623864|NCT00385827|ACTIVE_COMPARATOR|Mitoxantrone+Prednisone (Part 2)|In Part 2, mitoxantrone 12 mg/m\^2 will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m\^2) along with prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
62824777|NCT06598475|EXPERIMENTAL|Step 2 (3 clinics)-21 months control then 24 months intervention|
62824778|NCT06598475|EXPERIMENTAL|Step 3 (3 clinics)-27 months control then 18 months intervention|
62824779|NCT06591845|EXPERIMENTAL|Treatment T (Therapeutic dose)|The subjects will receive a ziresovir 125 mg as single dose on Day 1 (Period 1) or Day 9 (Period 2) or Day 17 (Period 3) or Day 25 (Period 4)
62824780|NCT06591845|EXPERIMENTAL|Treatment ST (Supratherapeutic dose)|The subjects will receive a ziresovir 500 mg as single dose on Day 1 (Period 1) or Day 9 (Period 2) or Day 17 (Period 3) or Day 25 (Period 4)
62043460|NCT01587534|EXPERIMENTAL|pancreatic enzyme replacement therapy|The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
62824781|NCT06591845|PLACEBO_COMPARATOR|Treatment P (Placebo)|The subjects will receive a placebo as single dose on Day 1 (Period 1) or Day 9 (Period 2) or Day 17 (Period 3) or Day 25 (Period 4)
62043461|NCT01587534|NO_INTERVENTION|Placebo|The placebo will match the active drug in appearance, taste, and weight and contained pharmacologically inactive substances.
62043462|NCT02434133||Case (Group A)|Group A (Immunomodulator) currently taking azathioprine or 6- mercaptopurine (Blood Draw)
62824782|NCT06591845|ACTIVE_COMPARATOR|Treatment PC (positive control)|The subjects will receive a moxifloxacin hydrochloride tablet 400 mg as single dose on Day 1 (Period 1) or Day 9 (Period 2) or Day 17 (Period 3) or Day 25 (Period 4)
62824783|NCT00212108|EXPERIMENTAL|Celecoxib and ZD1839|Celecoxib and ZD1839 will be given twice a day and daily respectively for two consecutive weeks prior to further anti-cancer treatment.
62824784|NCT05852119|EXPERIMENTAL|Hemodynamically stable patients with very low risk symptomatic acute pulmonary embolism (PE)|
62824785|NCT05546853|EXPERIMENTAL|Experimental|NP137+ mFOLFIRINOX
62824786|NCT01423175|EXPERIMENTAL|ClAraC|
62824787|NCT01423175|ACTIVE_COMPARATOR|FLAMSA|
62043463|NCT02434133||Case (Group B)|"Group B (Biologic group) currently taking anti-TNF therapy (infliximab, golimumab, adalimumab, or certolizumab).~(Blood Draw)"
62824788|NCT06599801||Anterolateral thigh flap group|Oral squamous cell carcinoma patients received the reconstruction with anterolateral thigh flaps after tumor resection
62824789|NCT06599801||Forearm flap group|Oral squamous cell carcinoma patients received the reconstruction with forearm flaps after tumor resection
62043464|NCT02434133||Case (Group C)|Group C (Combination therapy) currently taking anti-TNF therapy and an immunomodulator (including methotrexate) (Blood Draw)
62043465|NCT02434133||Control|"Individuals will be obtained from patients without an IBD diagnosis coming to Digestive Health Center for endoscopic procedures or clinic visits.~(Blood Draw)"
62043466|NCT04683926|EXPERIMENTAL|Desmetramadol 10 mg, fasted|While fasting a single oral dose of 10 mg desmetramadol under.
62043467|NCT04683926|EXPERIMENTAL|Desmetramadol 20 mg, fasted|While fasting a single oral dose of 20 mg desmetramadol.
62043468|NCT04683926|EXPERIMENTAL|Desmetramadol 30 mg , fasted|While fasting a single oral dose of 30 mg desmetramadol.
62824790|NCT06599801||Latissimus dorsi flap group|Oral squamous cell carcinoma patients received the reconstruction with latissimus dorsi flaps after tumor resection
62824791|NCT06599801||Fibula flap group|Oral squamous cell carcinoma patients received the reconstruction with Fibula flaps after tumor resection
62824792|NCT06599801||Thoracodorsal artery perforator flap group|Oral squamous cell carcinoma patients received the reconstruction with Thoracodorsal artery perforator flaps after tumor resection
62824793|NCT04756427|EXPERIMENTAL|Sodium citrate 4%|All enrolled participants will received the daily sodium citrate 4% locking solution for CLABSI prophylaxis intervention and be observed prospectively for adverse events
62043469|NCT04683926|EXPERIMENTAL|Desmetramadol 30 mg , fed|After feeding a single oral dose of 30 mg desmetramadol.
62043470|NCT02164877|EXPERIMENTAL|pectin|Patients allocated to experiment group will receive standard enteral nutrition formula(Fresubin) supplemented with 15g pectin each day for 4 weeks.
62043471|NCT02164877|PLACEBO_COMPARATOR|control|Patients allocated to control group will receive standard enteral nutrition formula(Fresubin) for 4 weeks
62043472|NCT01314274|EXPERIMENTAL|bevacizumab|submucosal intranasal bevacizumab on day 0
62043473|NCT01314274|PLACEBO_COMPARATOR|placebo|0.9% NaCl intranasal submucosal on day 0
62043474|NCT01712841||Severe NEAMD|Presence of definite central or noncentral geographic atrophy within 3000 microns of the foveal center
62043475|NCT01712841||Moderate/Intermediate NEAMD|Presence of large drusen (\>125µ) and pigmentary changes without geographic atrophy
62043476|NCT01712841||Mild/Early NEAMD|Presence of small or medium drusen without geographic atrophy
62824794|NCT01899521|PLACEBO_COMPARATOR|Placebo zinc and placebo SAMe|Placebo tablet of zinc sulfate once daily and placebo tablet of s-adenosylmethionine twice daily
62824795|NCT01899521|ACTIVE_COMPARATOR|Active zinc and placebo SAMe|Zinc sulfate 220 mg once daily and placebo tablet of s-adenosylmethionine twice daily
62824796|NCT01899521|ACTIVE_COMPARATOR|Placebo zinc and active SAMe|Placebo tablet of zinc sulfate once daily and s-adenosylmethionine 400 mg twice daily
62824797|NCT01899521|ACTIVE_COMPARATOR|Active zinc and active SAMe|Zinc sulfate 220 mg once daily and s-adenosylmethionine 400 mg twice daily
62824798|NCT06234761||patients with nasal polyposis|Patients with nasal polyposis will be treated with dupilumab following the clinical care path available in the hospital
62623865|NCT05535426|EXPERIMENTAL|Tetranite Stabilized Dental Implants with Provisional Crown|Extraction of maxillary anterior teeth followed by immediate insertion and stabilization of dental implants with Tetranite in otherwise non-stable sites. A provisional crown will also be inserted during this surgery.
62824799|NCT05279651|ACTIVE_COMPARATOR|Ivabradine|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive 5mg of oral ivabradine at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive 5mg oral ivabradine twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
62043477|NCT06496178|EXPERIMENTAL|MCLA-158|
62043478|NCT06496178|ACTIVE_COMPARATOR|Investigator's Choice|
62043479|NCT06359210|NO_INTERVENTION|Group A- Complete Responder|Participant is randomized to the no further intervention group.
62043480|NCT06359210|EXPERIMENTAL|Group B- Complete Responder|Participant is randomized to receive monthly physical activity behavior change discussion sessions for 3-months (total of three sessions).
62043481|NCT06359210|EXPERIMENTAL|Group C- Incomplete Responder|Participant is randomized to receive monthly physical activity behavior change discussion sessions for 3-months (total of three sessions).
62043482|NCT06359210|EXPERIMENTAL|Group D- Incomplete Responder|Participant is randomized to receive monthly physical activity behavior change discussion sessions for 3-months (total of three sessions) AND bi-weekly exercise sessions (total of six sessions).
62824800|NCT05279651|PLACEBO_COMPARATOR|Placebo|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive matching placebo at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive matching placebo twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
62824801|NCT01648751|EXPERIMENTAL|Vaginal estrogen|Patients in the experimental group will receive vaginal estrogen cream
62824802|NCT01648751|PLACEBO_COMPARATOR|Placebo cream|Patients in the comparison group will receive placebo vaginal cream
62043483|NCT01981564|EXPERIMENTAL|Asthma Express Intervention|Clinic visit for asthma education + nurse home visits
62043484|NCT01981564|ACTIVE_COMPARATOR|Standard Asthma Education Control group|Standard asthma education during nurse home visits
62043485|NCT01624675|EXPERIMENTAL|Risperidone|Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (\>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing \>= 45 kg was 3.0 mg. For subjects weighing \>=45 kg, the maximum daily dose was 3.0 mg.
62824803|NCT06582901|EXPERIMENTAL|Cognitive Training|Computer Based Cognitive Training (CT) Programs delivered in a group setting using the Neuropsychological Educational Approach to Cognitive Remediation (NEAR) model.
62824804|NCT06582901|ACTIVE_COMPARATOR|Enhanced Treatment as Usual|Enhanced Treatment as Usual (E-TAU) sessions are delivered in a group therapy format and guided by the principles of Cognitive Behavioral Therapy (CBT). The E-TAU sessions focus on helping individuals identify and change negative thought patterns and behaviors that contribute to emotional distress and mental health issues.
62824805|NCT04088149|EXPERIMENTAL|GXNPC1|"There are 2 dose levels Cohort 1: Low dose (1 ± 0.1 × 10\^8 GXNPC1) of IPs will be administered in parallel.~Cohort 2: High dose (2 ± 0.2 × 10\^8 GXNPC1) of IPs will be administered sequentially."
62043486|NCT01624675|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo matching with risperidone orally up to 8 weeks.
62043487|NCT05092321|EXPERIMENTAL|Aquatic Occupational Therapy|Group-based aquatic occupational therapy with 1:1 swim buddy for safety.
62043488|NCT01165775||Threatened pre term labor patients|Patients receiving betamethasone to minimize the complications of prematurity will monitor blood glucose levels using the Dexcom Seven Plus Continuous Glucose Monitoring System.
62043489|NCT01677273|ACTIVE_COMPARATOR|Hydrolyzed casein|Hydrolyzed casein
62043490|NCT01677273|ACTIVE_COMPARATOR|Intact casein|Intact casein
62043491|NCT01677273|ACTIVE_COMPARATOR|Intact whey protein|Intact whey protein
62043492|NCT06732518|EXPERIMENTAL|Fluoride toothpaste|Subjects will brush using a fluoride toothpaste containing 1000 ppm MFP and 1.5% arginine in a PCC/RNCC base and a soft bristle toothbrush
62043493|NCT06732518|ACTIVE_COMPARATOR|Fluoride free toothpaste in a chalk base|Subjects will brush using a fluoride free toothpaste in a chalk base with herbal ingredients and a soft bristle toothbrush
62043494|NCT06732518|ACTIVE_COMPARATOR|Fluoride free toothpaste in a PCC/RNCC base|This is a negative control group in which subjects will brush using a fluoride free toothpaste in a PCC/RNCC base and a soft bristle toothbrush
62602732|NCT03332628|OTHER|Microneedle application|This is the only study arm, which all participants complete. Nine sites on the upper arm will be identified. Baseline measurements of transepidermal water loss, electrical resistance, hydration, and color will be made at each site. The 9 sites will be divided into clusters of 3 sites each. The first cluster will have small microneedle patches applied to at each site. This will only occur on the first study day. Transepidermal water loss and electrical resistance are re-measured immediately after microneedle application. The sites will be covered with a small patch secured with medical tape. The second cluster of sites will not receive microneedle application but will just be covered with patches. The last cluster of sites will not have microneedle application or patches. Electrical resistance will be re-measured at all sites for 4 days after microneedle application. Measurements from the 2nd and 3rd cluster of sites allow each subject to serve as their own control in data analysis.
62602733|NCT00264160|EXPERIMENTAL|AMN107|
62602734|NCT05940129|EXPERIMENTAL|Web-based Intervention Arm (WC-SHE)|Women in computerized WC-SHE arm receives education on healthy relationships the danger assessment and tailored safety planning and list of resources. The intervention also includes assessments of strengths and safety strategies. In addition, husbands and in-laws receive one-on-one health education session that includes topics related to maternal and child health and safety
62602735|NCT05940129|EXPERIMENTAL|WC-SHE +Economic Empowerment|Women in economic empowerment arm receive computerized WC-SHE and are connected with self-help groups. Husbands are also engaged in economic empowerment activities that involve individual psychoeducation, working with spouses in self-help group activities and participating in government economic or vocational training programs. In addition, husbands and in-laws participate in individual sessions on topics related to maternal and child health and safety
62602736|NCT05940129|EXPERIMENTAL|WC-SHE + Enhanced Family Psychoeducation and Advocacy Support Intervention|Women in this arm receive computerized WC-SHE, advocacy and support by a support committee of professionals based on women's priorities and needs, and phone call support by women community resource persons. Husbands and in-laws participate in individual and group sessions that cover topics such as stress, healthy relationships, healthy communication within families and impact of domestic violence on children.
62602737|NCT05869279|EXPERIMENTAL|CARCIK-CD19|Gene therapy product composed of T lymphocytes differentiated according CIK-cell protocol (leading to production of CD3+ cells also expressing CD8 and to a lesser extent CD4 or CD56) that have been genetically modified to express CAR with specificity for targeting CD19 molecule expressed on the surface of B cells. The CARCIK-CD19 contains cells that express the anti-CD19 single chain fragment variable (scFV) linked to an intracellular signaling domain comprising the TCR CD3 ζ chain and tandem costimulatory domains as the CD28 and OX40 (CD19-CD28OX40).
62602738|NCT00923663|EXPERIMENTAL|Lenalidomide|Lenalidomide administered orally at a dose of 25 mg daily
62824806|NCT06141226|EXPERIMENTAL|TQB2450 +Anlotinib+Docetaxel|TQB2450（1200mg intravenous(iv). 3 weeks using a(q3w), day 1(d1)）+Anlotinib administered PO at day 1-14 every 3 weeks+Docetaxel（60mg/square meter intravenous(iv). 3 weeks using a(q3w), day 1(d1)）
62043495|NCT06732518|OTHER|Washout|This is a washout group in which subjects will brush using a fluoride free toothpaste in a PCC/RNCC base and a soft bristle toothbrush for 9 days, between the treatment phases
62043496|NCT06648642|ACTIVE_COMPARATOR|Left dorsolateral prefrontal cortex (L-DLPFC) IR-TMS|Stimulation will be delivered to the L-DLPFC at a depth corrected intensity of 80-95 V/m, using a theta burst stimulation protocol which delivers 1,800 pulses/session. Sessions will be compressed and delivered up to 4 times per day, over the course of 2 weeks.
62043497|NCT06648642|ACTIVE_COMPARATOR|Dorsomedial prefrontal cortex (DMPFC) IR-TMS|Stimulation will be delivered to either the DMPFC at a depth corrected intensity of 80-95 V/m, using a theta burst stimulation protocol which delivers 1,800 pulses/session. Sessions will be compressed and delivered up to 4 times per day, over the course of 2 weeks.
62824807|NCT06141226|PLACEBO_COMPARATOR|TQB2450 +Androtinib Placebo+Docetaxel|TQB2450 Injection（1200mg intravenous(iv). 3 weeks using a(q3w), day 1(d1)）+Anlotinib capsule placebo administered PO at day 1-14 every 3 weeks+Docetaxel Injection（60mg/square meter intravenous(iv),q3w, d1）
62824808|NCT06008314|EXPERIMENTAL|Implementation at Vanderbilt University Medical Center (VUMC) & Vanderbilt Wilson County Hospital|ePNa (the decision support tool) will be implemented at 2 EDs that are part of the Vanderbilt Health system.
62824809|NCT05862220||D-Dimer group|A blood sample was taken before starting the patients on any thrombolytic treatment. The latex agglutination test was used to measure plasma D-dimer level; this was done using a Sysmex CA-7000 automatic coagulation unit. The positivity threshold was above 250 ng/ml.
62824810|NCT05862220||CTPA group|CTPA was performed after performing blood sampling using Siemens Somatom definition AS 24 slice scanners. Non-ionic water-soluble contrast Omnipaque 350 mg I/mg or Visipaque 320 mg I/mg was injected at 4 mm/s maximum dose 100 ml using a Medtron pressure injector.
62824811|NCT06191796|EXPERIMENTAL|Dose-finding Cohort A: Zanzalintinib + AB521|Participants with solid tumors will receive zanzalintinib + AB521
62824812|NCT06191796|EXPERIMENTAL|Dose-finding Cohort B: zanzalintinib + AB521 + nivolumab|Participants with ccRCC will receive zanzalintinib + AB521 + nivolumab
62824813|NCT06191796|EXPERIMENTAL|Expansion Cohort 1: Zanzalintinib + AB521|Participants with ccRCC will receive zanzalintinib + AB521
62824814|NCT06191796|EXPERIMENTAL|Expansion Cohort 2: zanzalintinib + AB521 + nivolumab|Participants with ccRCC will receive zanzalintinib + AB521 + nivolumab
62824815|NCT06596330|EXPERIMENTAL|LLM-generated coaching prompt|
62246110|NCT02903082||Case|Patient hospitalized in intensive care for sepsis evolving for less than 48 hours with two criteria of systemic inflammatory response syndrome
62824816|NCT06596330|ACTIVE_COMPARATOR|10,000 Step Reminder|
62824817|NCT05569044|OTHER|Control Group|No intervention
62824818|NCT05569044|EXPERIMENTAL|Oral Rehydration Solution|ORS with carbohydrate
62824819|NCT05569044|EXPERIMENTAL|Water|Water with flavor
62043498|NCT06648642|ACTIVE_COMPARATOR|Orbitofrontal cortex (OFC) IR-TMS|Stimulation will be delivered to either the OFC at a depth corrected intensity of 80-95 V/m, using a theta burst stimulation protocol which delivers 1,800 pulses/session. Sessions will be compressed and delivered up to 4 times per day, over the course of 2 weeks.
62043499|NCT06525493|EXPERIMENTAL|Group A|Patients receive the large-volume distal adductor canal block (ACB). In this technique, a linear transducer is placed on the medial aspect, approximately one fourth of the distal thigh to identify the Adductor Hiatus, and the injection is performed in-plane near that point using ropivacaine.
62043500|NCT06525493|EXPERIMENTAL|Group B|This arm involves a combination of two regional anesthesia techniques: proximal adductor canal block (ACB) and iPACK. In proximal ACB, the transducer is placed in the middle of the thigh, and the injection is performed in-plane approximately 1-2 cm distal from a specific point. Meanwhile, in iPACK, the curvilinear transducer is positioned on the posteromedial aspect of the distal thigh, and the injection is performed between the popliteal artery and the femur
62246111|NCT02903082||Control|10 Patients hospitalized for a hematologic pathology workup considered normal by two haematologists and 10 patients hospitalized for a preoperative workup.
62246112|NCT06007638|EXPERIMENTAL|LY3876602|Single ascending doses of LY3876602 administered intravenously (IV).
62246113|NCT06007638|PLACEBO_COMPARATOR|Placebo|Placebo administered IV.
62246114|NCT06007638|EXPERIMENTAL|LY3876602 Part B (MAD)|Multiple ascending doses of LY3876602 will be administered intravenously (IV).
62602739|NCT04642677|EXPERIMENTAL|Group A|"Patients and caregivers were received palliative sedation with healthcare provider's recommended communication with sympathy and printed paper, Regardless of the patient's outward consciousness, talk with the patient and express empathy. Hearing will be maintained until the end. three times a day (8, 14 and 20 o'clock)."
62602740|NCT04642677|NO_INTERVENTION|Group B|Patients and caregivers were received palliative sedation without intervention.
62602741|NCT00715728||1: Bair Hugger|Intraoperative warming with Bair Hugger forced air system
62824820|NCT06588387||Siponimod Cohort|Patients who received at least one dose of siponimod during the drug initiation period (April 2021 to September 2022).
62824821|NCT05494190|EXPERIMENTAL|Induction chemotherapy group|"Patients initially receive induction chemotherapy consisting of docetaxel, cisplatin and capecitabine (TPC), q3w, 2-3 cycles in total.~Patients with regional response of complete reaction (CR)/partial reaction (PR)≥50% after induction chemotherapy then receive concomitant chemoradiotherapy for both the primary and regional sites.~Patients with regional response of PR\<50%/stable disease (SD)/progressive disease (PD) after induction chemotherapy then receive surgery for both the primary and regional sites and postoperative concomitant chemoradiotherapy."
62824822|NCT05494190|ACTIVE_COMPARATOR|Surgery group|Patients initially receive surgery for both the primary and regional sites and postoperative concomitant chemoradiotherapy.
62824823|NCT06594822|EXPERIMENTAL|Group A, Probiotic Group|Probiotics were given as an adjunct to standard therapy i.e., NSAIDs, Steroids, DMARDs
62824824|NCT06594822|ACTIVE_COMPARATOR|Group B, Standard treatment group|Standard therapy including NSAIDs, steroids and DMARDs
62824825|NCT01219114||1|
62824826|NCT04971954|EXPERIMENTAL|Nicotine gum|Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication
62824827|NCT04971954|PLACEBO_COMPARATOR|Placebo gum|The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.
62824828|NCT06367933|EXPERIMENTAL|experimental|severe neuromuscolar scoliosis who need surgical correction
62824829|NCT06284005|EXPERIMENTAL|prosthetic group|prosthetic group performs the entire protocol with the prosthesis prototype.
62824830|NCT06599918|PLACEBO_COMPARATOR|Placebo|"Administration of the placebo compound, in the same format as the active compound.~The placebo is composed by microcrystalline Cellulose (Excipient No. 1 for capsules: 98.05% microcrystalline cellulose, 1.95% colloidal silica). Molecular formula: C14H26O11 IUPAC name: methyl 4-O-methyl-hexopyranosyl-(1-\>4)-hexopyranoside Molecular weight: 370.35 g/mol Qualitative and quantitative composition (per capsule): Microcrystalline Cellulose 400 mg Pharmaceutical form: Hard gelatin capsules containing. Dose and route of administration: maximum 2.4 g daily/oral. Raw material suppliers: Fagron and Acofarma. Encapsulation location: Pharmacy Service of HSCSP."
62824831|NCT06599918|ACTIVE_COMPARATOR|Nicotinamide|"Administration of the active compound, the amide form of vitamin B3, Nicotinamide (NAM).~International Nonproprietary Name: Nicotinamide. Molecular formula: C6H6N2O IUPAC name: Pyridine-3-carboxamide. Molecular weight: 122.12 g/mol. Qualitative and quantitative composition (per capsule): Nicotinamide 500 mg. Pharmaceutical form: Hard gelatin capsules. Dose and route of administration: maximum 3 g daily/oral. Raw material suppliers: Fagron and Acofarma. Encapsulation location: Pharmacy Service of HSCSP."
62602742|NCT00715728||2: Hot Dog|Intraoperative warming with Hot Dog resistive heating system
62602743|NCT06205173|NO_INTERVENTION|Control group|According to the traditional care model, no interventions are applied to the hands and feet.
62824832|NCT05328102|EXPERIMENTAL|Part 1A: Plamotamab (lower dose), Tafasitamab, and Lenalidomide|Drug: Plamotamab will be administered at a lower dose in addition to tafasitamab (12 milligrams \[mg\]/kilograms \[kg\] intravenously) plus lenalidomide (25 mg orally). This cohort was planned to enroll sequentially prior to Part 1B.
62824833|NCT05328102|EXPERIMENTAL|Part 1B: Plamotamab (target dose), Tafasitamab, and Lenalidomide|Drug: Plamotamab will be administered at the target dose in addition to tafasitamab (12 mg/kg intravenously) plus lenalidomide (25 mg orally). This cohort was planned to enroll sequentially after Part 1A.
62824834|NCT05328102|EXPERIMENTAL|Part 2A :Plamotamab, Tafasitamab, and Lenalidomide|Drug: Plamotamab will be administered at protocol defined dose in addition to tafasitamab (12 mg/kg intravenously) plus lenalidomide 25 mg (orally).
62824835|NCT05328102|ACTIVE_COMPARATOR|Part 2B: Tafasitamab and Lenalidomide|Drug: Tafasitamab (12 mg/kg intravenously) plus lenalidomide 25 mg (orally).
62824836|NCT05756179|ACTIVE_COMPARATOR|Intervention group|Diosmin 450 mg and Hesperidin 50 mg Combination /tablet/ twice daily for 3 months + Conventional Therapy (Methotrexate)
62043501|NCT02251327||Case detection group|Suspected or confirmed new pulmonary tuberculosis cases who have received anti-tuberculosis drugs for less than 3 (three) days and provide up to two expectorated sputum specimens. One investigational Xpert DST test and one Xpert MTB/RIF test were performed directly on the same sputum specimen; in addition, one smear microscopy test, one mycobacterial liquid culture, and one solid culture were performed after digestion and decontamination of sputum.
62043502|NCT02251327||Drug resistance risk group|Confirmed pulmonary tuberculosis cases with documented rifampin resistance, who have received anti-tuberculosis drugs for 31 days or less and/or history of prior tuberculosis PLUS ongoing signs and/or cases with symptoms of pulmonary tuberculosis PLUS suspected drug resistance and provide up to two expectorated sputum specimens. One investigational Xpert DST test and one Xpert MTB/RIF test were performed directly on the same sputum specimen; in addition, one smear microscopy test, one mycobacterial liquid culture, and one solid culture were performed after digestion and decontamination of sputum.
62043503|NCT02803775|ACTIVE_COMPARATOR|Paced|Paced arm in which the left heart lead electrode is selected utilizing the longest time to when patient right ventricle lead is pacing. The result of the pacing algorithm becomes the patient's pacing location for the study duration (self-assigned algorithm within this cohort).
62043504|NCT02803775|ACTIVE_COMPARATOR|Sensed|Sensed arm is based on the longest time that patient own heart's conduction reaches the left heart lead electrode.The result of the sensing algorithm becomes the patient's pacing location for the study duration (self-assigned algorithm within this cohort).
62043505|NCT06386770|ACTIVE_COMPARATOR|Group Ι Block only (group BO) (control group)|Ultrasound guided erector spinae block will receive 30 ml (28 ml bupivacaine 0.25% +2ml normal saline Na cl 0,9 %) +10ml IV normal saline will be injected over 10 min after 10 min from the induction of general anesthesia
62043506|NCT06386770|ACTIVE_COMPARATOR|Group ΙI (group DL):|Ultrasound guided erector spinae block will receive 30 ml (28 ml bupivacaine 0.25% plus dexmedetomidine (0.5µg/kg) diluted in 2ml normal saline Na cl 0,9%) + 10ml IV normal saline will be injected over 10 min after 10 min from the induction of general anesthesia
62043507|NCT06386770|ACTIVE_COMPARATOR|Group III (group D IV):|Ultrasound guided erector spinae block will receive 30 ml (28 ml bupivacaine 0.25% +2ml normal saline Na cl 0,9%) + dexmedetomidine (0.5µg/kg) diluted with 10 ml normal saline IV infusion by syringe pump over 10 min after 10 min from the induction of general anesthesia
62043508|NCT01222325|ACTIVE_COMPARATOR|swl 3000 impulses- 60 imp/min|patients in this group were submitted to extracorporeal shockwave lithotripsy (SWL) 3000 impulses at 60 impulses per minute under general anesthesia. Unique session
62043509|NCT01222325|ACTIVE_COMPARATOR|swl- 4000 impulses - 90 impulses /min|patients in this group were submitted extracorporeal shockwave lithotripsy (swl) to 4000 impulses at 90 impulses per minute under general anesthesia- unique session
62043510|NCT04905394|EXPERIMENTAL|Treatment with subchondroplasty for bone edema in the knee|Patients treated with subchondroplasty for bone edema of the knee
62043511|NCT00973557||Taking Bevacizumab|Patients who are currently being treated for cancer by the drug Bevacizumab.
62043512|NCT06429566|EXPERIMENTAL|GB001 recombinant peptide spray low dose group|Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times，The dosage of the group is 0.108mg/spray.
62043513|NCT06429566|EXPERIMENTAL|GB001 recombinant peptide spray high dose group|Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times，The dosage of the group is 0.216mg/spray.
62043514|NCT06429566|EXPERIMENTAL|Placebo group|Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, for 8 days.
62824837|NCT05756179|NO_INTERVENTION|Control group|Conventional Therapy (Methotrexate) only
62824838|NCT06497842|EXPERIMENTAL|High-effort|The high-effort protocol will entail performing 3 sets per exercise, 8 repetitions per set, \~2.5 seconds per repetition, with 120 seconds between sets and exercises.
62824839|NCT06497842|EXPERIMENTAL|Low-effort|The low-effort protocol will entail performing 6 sets per exercise, 4 repetitions per set, \~2.5 seconds per repetition, with 60 seconds between sets and exercises.
62824840|NCT06208514|EXPERIMENTAL|Brief pain exposure therapy (BPET)|
62824841|NCT05698485|EXPERIMENTAL|3 Step Skin Care Regimen|3 different skin care products will be applied to the face
62043515|NCT05808049|EXPERIMENTAL|MXP22 (Probiotic and antioxidant capsule)|Dose : NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
62043516|NCT05808049|PLACEBO_COMPARATOR|Placebo (Microcrystalline Cellulose )|Dose : NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once dailybafter lunch for 120 days
62043517|NCT02848248|EXPERIMENTAL|SGN-CD123A|SGN-CD123A every 3 weeks
62043518|NCT04952506|EXPERIMENTAL|R-T1-T2|"1. Period 1: Reference~2. Period 2: Test 1~3. Period 3: Test 2"
62043519|NCT04952506|EXPERIMENTAL|T2-R-T1|"1. Period 1: Test 2~2. Period 2: Reference~3. Period 3: Test 1"
62043520|NCT04952506|EXPERIMENTAL|T1-T2-R|"1. Period 1: Test 1~2. Period 2: Test 2~3. Period 3: Reference"
62043521|NCT04952506|EXPERIMENTAL|T2-T1-R|"1. Period 1: Test 2~2. Period 2: Test 1~3. Period 3: Reference"
62043522|NCT04952506|EXPERIMENTAL|T1-R-T2|"1. Period 1: Test 1~2. Period 2: Reference~3. Period 3: Test 2"
62043523|NCT04952506|EXPERIMENTAL|R-T2-T1|"1. Period 1: Reference~2. Period 2: Test 2~3. Period 3: Test 1"
62043524|NCT01560039|ACTIVE_COMPARATOR|Real EEG-NF|10 EEG based neurofeedback sessions modulating the activity of the primary motor cortex
62602744|NCT06205173|EXPERIMENTAL|Hot compressing group|Temperature control will be maintained within the range of 37-38 degrees Celsius.The application will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection.
62824842|NCT00687193|PLACEBO_COMPARATOR|Placebo|
62824843|NCT00687193|EXPERIMENTAL|CP-690,550, 10mg|
62824844|NCT00687193|EXPERIMENTAL|CP-690,550, 15mg|
62043525|NCT01560039|SHAM_COMPARATOR|Sham EEG-NF|10 sessions of Sham EEG_NF of the motor cortex area
62043526|NCT01560039|ACTIVE_COMPARATOR|Transcrainal Magnetic Stimulation|10 dailt TMS stimulation sessions of M1
62824845|NCT00687193|EXPERIMENTAL|CP-690,550, 1mg|
62824846|NCT00687193|EXPERIMENTAL|CP-690,550, 3mg|
62602745|NCT06205173|EXPERIMENTAL|Cold compressing group|Temperature control will be maintained within the range of 12-18 degrees Celsius.The application will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection.
62824847|NCT00687193|EXPERIMENTAL|CP-690,550, 5mg|
62824848|NCT02459106||Healthy lean insulin-sensitive individuals|This group will be studied by measuring the adipose tissue miRNA release, adipose tissue-released miRNA will be profiled, and these effects will be examined.
62824849|NCT02459106||Obese insulin-resistant individuals|This group will be studied by measuring the effect of adipose tissue-release miRNA on skeletal muscle biology and insulin sensitivity, adipose tissue-released miRNA will be profiled, and these effects will be examined on obese insulin-resistant individuals on skeletal muscle biology and insulin sensitivity.
62824850|NCT02030808|PLACEBO_COMPARATOR|Muscle Relaxants (MR) group|Cisatracurium will be administered
62824851|NCT02030808|ACTIVE_COMPARATOR|Non- Muscle Relaxants (NMR) group|No cisatracurium will be administered
62824852|NCT05888038|EXPERIMENTAL|Intervention - use of VR|
62824853|NCT06473064|OTHER|grade 3 and 4 gynecomastia|To evaluate and determine the posibility of complication of benelli technique for nipple sparing mastectomy in surgical treatment of grade 3and 4 gynecomastia and its cosmetic effect
62824854|NCT06587958|EXPERIMENTAL|Fermented plant-based foods|
62824855|NCT06587958|ACTIVE_COMPARATOR|Non-fermented plant-based foods|
62824856|NCT06587958|OTHER|Habitual diet|
62824857|NCT03341377||Lung cancer surgical patients|Patient-reported symptom assessments in patients undergoing lung cancer surgery.
62824858|NCT02928887|EXPERIMENTAL|Blue light|Exposure to high illuminance (1000 lux), blue spectrum (480nm) light for the 24 hour photoperiod prior to surgery and for the 24 hour photoperiod immediately after surgery
62824859|NCT02928887|NO_INTERVENTION|Ambient light|Exposure to ambient, white fluorescent light
62824860|NCT02199002|OTHER|healthy volunteers|healthy volunteers (no gastric complains)
62824861|NCT02199002|OTHER|PPI responders|proven reflux, good symptom relief upon PPI therapy
62824862|NCT02199002|OTHER|PPI non-responders|proven reflux disease, poor symptom control (less then 50% symptom reduction) upon PPI therapy (2x40mg omeprazole)
62824863|NCT02199002|OTHER|Barrett - no dysplasia|proven barrett with no dysplasia on biopsies
62824864|NCT02199002|OTHER|barrett - high grade dysplasia|proven barrett with high grade dysplasia on biopsies
62824865|NCT05715931|EXPERIMENTAL|Toripalimab plus Trastuzumab with FLOT(5-FU+leucovorin+docetaxel+oxaliplatin)|
62824866|NCT05978193|EXPERIMENTAL|Arm A|PD-1 inhibitor + Paclitaxel + Cisplatin/Carboplatin+ Low-dose radiotherapy (LDRT) + Conventionally fractionated radiotherapy (CFRT)
62824867|NCT05978193|ACTIVE_COMPARATOR|Arm B|PD-1 inhibitor + Paclitaxel + Cisplatin/Carboplatin
62824868|NCT02524925|ACTIVE_COMPARATOR|fast track protocol|Oral fluids intake (0.5 lt) 6 hours after operation Mobilization 4 hours after operation Check discharge criteria the 4th-6th postoperative day
62824869|NCT02524925|NO_INTERVENTION|conventional protocol|Oral intake after bowel mobilization Mobilization after the 1st postoperative day Check discharge criteria the 7th-15th postoperative day
62824870|NCT05473364|EXPERIMENTAL|Acetazolamide - 62.5mg Dose|2-week treatment period with 62.5mg dose of acetazolamide taken twice daily.
62824871|NCT05473364|EXPERIMENTAL|Acetazolamide - 125mg Dose|2-week treatment period with 125mg dose of acetazolamide taken twice daily.
62602746|NCT05680831|EXPERIMENTAL|0.070 ppm ozone concentration|Exposure to 0.070 ppm ozone for 6.6 hours while performing moderate intermittent exercise.
62824872|NCT05473364|EXPERIMENTAL|Acetazolamide - 250mg Dose|2-week treatment period with 250mg dose of acetazolamide taken twice daily.
62824873|NCT06284265|EXPERIMENTAL|Raphamin|"Take orally, do not take with meals. Keep the tablets in the mouth until completely dissolved.~On the first day of treatment, 8 tablets are taken according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day another 1 tablet is taken 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day. The duration of treatment is 10 days."
62824874|NCT06284265|PLACEBO_COMPARATOR|Placebo|Take orally, do not take with meals. Keep the tablets in the mouth until completely dissolved. Placebo is administered according to the Raphamin regimen for 10 days.
62824875|NCT05387239|EXPERIMENTAL|Experimental/treatment arm|
62824876|NCT05387239|PLACEBO_COMPARATOR|Placebo|
62824877|NCT06596915|EXPERIMENTAL|BA1302|
62824878|NCT03904849|ACTIVE_COMPARATOR|Cannabidiol|Cannabidiol 6 mL of 100 mg/mL cannabidiol oral solution per day for 8 days
62824879|NCT03904849|PLACEBO_COMPARATOR|Placebo|Placebo 6 mL oral solution per day for 8 days
62824880|NCT04137068|OTHER|Sedentary to Active|Participants will visit the research laboratory for baseline measurements at visit 1 after wearing a pedometer for one week and maintaining their typical level of physical activity. After the baseline visit, participants will reduce their step count by more than half for two weeks. Participants will visit the laboratory once every week during the 2 week interventional period for a total of 3 visits.
62824881|NCT03205423|PLACEBO_COMPARATOR|Gabapentin 0 mg|once daily at 8am
62824882|NCT03205423|ACTIVE_COMPARATOR|Gabapentin 1800 mg|once daily at 8am
62824883|NCT06001047|EXPERIMENTAL|Group A (acupuncture group)|Treatment patients with residual symptoms after successful manual repositioning by electroacupuncture
62824884|NCT06001047|ACTIVE_COMPARATOR|Group B (betahistine group)|Treatment patients with residual symptoms after successful manual repositioning by oral betahistine
62602747|NCT05680831|EXPERIMENTAL|Clean air (0.0 ppm ozone)|Exposure to clean air (0.0 ppm ozone) for 6.6 hours while performing moderate intermittent exercise.
62602748|NCT00714753|EXPERIMENTAL|Intervention Group|Protocol treatment consists of either two high dose-rate (HDR) brachytherapy implantation sessions or one HDR brachytherapy session followed by external beam radiotherapy (EBRT). Each HDR session consists of two 9.5Gy fractions. After the first HDR session of two fractions, patients express a preference for: (1) a second HDR brachytherapy implantation session, or (2) EBRT. The second HDR session or EBRT will begin 2-4 weeks after the first HDR brachytherapy session.
62602749|NCT05213013|EXPERIMENTAL|Experimental|All registered participants in the control group, will receive inhaler treatment with the toy-type nebulizer in the hospital. Both the parent and the child in the intervention group will be trained on the use of a nebulizer/mask.
62602750|NCT05213013|NO_INTERVENTION|No intervention|No intervention. All registered participants in the control group, will receive inhaler treatment with the standard nebulizer in the hospital. Both the parent and the child in the intervention group will not be trained on the use of a nebulizer/mask.
62602751|NCT00857597|EXPERIMENTAL|EsophyX|
62602752|NCT00857597|ACTIVE_COMPARATOR|Proton Pump Inhibitors|
62602753|NCT04323865||Study 2. Repeatability of FHRV|
62602754|NCT05062824|EXPERIMENTAL|Intervention|Participants in the intervention will have access to Baby Feed
62043527|NCT04259450|EXPERIMENTAL|Phase 1- 14 mg Cohort 1|Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
62043528|NCT04259450|EXPERIMENTAL|Phase 1- 40 mg Cohort 2|Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
62043529|NCT04259450|EXPERIMENTAL|Phase 1- 80 mg Cohort 3|Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
62043530|NCT04259450|EXPERIMENTAL|Phase 1- 160 mg Cohort 4|Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
62602755|NCT05062824|NO_INTERVENTION|Standard Care|Participants in the standard care group will NOT have access to Baby Feed
62602756|NCT02237209|EXPERIMENTAL|RSV LID ΔM2-2 Vaccine|Participants will receive one dose of the RSV LID ΔM2-2 vaccine at study entry, delivered as nose drops.
62043531|NCT04259450|EXPERIMENTAL|Phase 1- 320 mg Cohort 5|Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
62043532|NCT04259450|EXPERIMENTAL|Phase 1- 480 mg Cohort 6|Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
62043533|NCT04259450|EXPERIMENTAL|Phase 1- 720 mg Cohort 7|Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
62043534|NCT04259450|EXPERIMENTAL|Phase 2- CRC 480 mg Cohort A|Subjects with microsatellite stable (MSS) colorectal cancer (CRC) with rat sarcoma gene (RAS) wild-type tumor expressing EGFR who received who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
62602757|NCT02237209|PLACEBO_COMPARATOR|Placebo Vaccine|Participants will receive one dose of placebo at study entry, delivered as nose drops.
62602758|NCT02013856|EXPERIMENTAL|Low Epicatechin and procyanidin|Low epicatechin and procyanidin doses
62602759|NCT02013856|EXPERIMENTAL|High Epicatechin and procyanidin|High epicatechin and procyanidin doses
62602760|NCT02013856|EXPERIMENTAL|High Procyanidin|High procyanidin only
62602761|NCT02013856|PLACEBO_COMPARATOR|Placebo|No epicatechin and procyanidin
62602762|NCT00259974|EXPERIMENTAL|1|Rituximab
62602763|NCT01028430||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
62602764|NCT01228110|ACTIVE_COMPARATOR|Corticosteroid group|This group was entitled to receive hydrocortisone 200 mg loading bolus followed by an intravenous infusion (300 mg in 500 ml 0.9% saline) at a rate of 12.5 mg/hour for 7 days
62602765|NCT01228110|PLACEBO_COMPARATOR|Placebo group|This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug).
62602766|NCT03984227||SLE patient group|SLE diagnosed patients between (18- 60) years old will be enrolled. All participants should met at least four of the American College of Rheumatology criteria (Hochberg, 1997). Disease activity will be assessed in accordance with the SLE Disease Activity Score (SLEDAI 2000 (SLEDAI-2K) (Ward et al., 2000).
62602767|NCT03984227||control group|The control group will include age and sex matched healthy volunteers
62602768|NCT04930510||Group 1 : Elderly 80 years or over patients referred for TAVI with CAD|Elderly 80 years or over patients referred for TAVI with CAD Group 1: Coronary lesion defined as significant (\>50% narrowing) on the coronary angiography performed before TAVI, with or without PCI (decision of the heart team) Description of the coronary lesions included: proximal/non proximal, number of lesions, location of lesion
62602769|NCT04930510||Group 2 : No significant coronary disease group|No significant coronary disease group in the cohort of elderly 80 years or over referred for TAVI
62602770|NCT05542797|EXPERIMENTAL|Micronised progesterone|Micronized progesterone will be given to 70 pregnant women with threated miscarriage.
62043535|NCT04259450|EXPERIMENTAL|Phase 2- ccRCC 480 mg Cohort B|Subjects with clear cell renal cell carcinoma (ccRCC) expressing EGFR who recieved 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
62043536|NCT04259450|EXPERIMENTAL|Phase 2- NSCLC 480 mg Cohort C|Subjects with advanced or metastatic (non-small cell lung cancer) NSCLC with an epidermal growth factor receptor (EGFR) mutation who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
62043537|NCT02937961|EXPERIMENTAL|Early SLED|
62043538|NCT02937961|ACTIVE_COMPARATOR|Late SLED|
62246115|NCT06007638|PLACEBO_COMPARATOR|Placebo: Part B (MAD)|Placebo administered IV
62602771|NCT05542797|EXPERIMENTAL|Dydrogesterone|Dydrogesterone will be given to 70 pregnant women with threated miscarriage.
62602772|NCT03399903|EXPERIMENTAL|Pentasa|40 participants will be randomized to take 1 gram of Pentasa, twice daily for 8 weeks
62602773|NCT03399903|ACTIVE_COMPARATOR|Align|40 participants will be randomized to take Align tablets, once daily for 8 weeks
62602774|NCT01957618||Treatment group|liver cirrhosis group who received indefinite anti-viral treatment
62043539|NCT02112188||Chinese patients with advanced cancer|IMCP intervention to be culturally \& linguistically tailored for Chinese cancer patients. This study will be carried out in 3 phases: 1) formative research \& 2) adaptation. For this application we will continue the formative research (phase 1) by conducting 20 to 30 indepth interviews with Chinese immigrants with advanced cancer to inform the adaptation of the intervention. Results of the patient in-depth interviews will inform how to adapt the IMCP process \& session themes to reflect the needs of the community. In the adaptation phase (phase 2) the Breitbart IMCP research team (including Drs. Breitbart, Lichtenthal, \& Applebaum), Drs. Leng, Gany, \& Ms. Huang will discuss a priori adaptations to the intervention. Potential changes to the process \& content will be discussed. Adaptations will be incorporated in a modified IMCP-Ch treatment manual, therapist checklist/outline \& Treatment Integrity Coding Manual. PHASE 3, 4 Conduct feasibility study of IMCP-Ch for Chinese cancer patients.
62043540|NCT06440291|EXPERIMENTAL|cardioneuroablation|Cardioneuroablation procedure as described in the Methods section of the study
62043541|NCT05117242|EXPERIMENTAL|Arm A|Treatment with acasunlimab once every 21 days for the first 2 cycles and then every 42 days in subsequent cycles
62043542|NCT05117242|EXPERIMENTAL|Arm B|Treatment with acasunlimab + pembrolizumab once every 21 days
62043543|NCT05117242|EXPERIMENTAL|Arm C|Treatment with acasunlimab + pembrolizumab once every 42 days
62043544|NCT02937168|EXPERIMENTAL|Part 1: PET/CT Scan|Healthy participants will have 2 PET/CT scan in Part 1: within 7 days of eligibility being confirmed, and 7 days after the first PET/CT scan. Participants will receive Fluorodeoxyglucose F-18 (FDG) as part of the PET/CT procedures and will provide sputum/blood samples.
62824885|NCT06592807|EXPERIMENTAL|Warm Sock Group|"1. Before surgery, patients are informed about the study and their tympanic body temperatures are measured.~2. The socks that the patient will wear during the surgery are warmed and put on.~3. During the surgery, the operating room temperature is measured and recorded. The patient's tympanic body temperature is also measured and recorded. (Every half hour).~4. When the patient is taken to the postoperative care unit, the socks are changed to new heated socks.~5. After the surgery, patients are given a survey question regarding socio-demographic data. Patients' pain is assessed with VAS (visual analog scale). Patients' thermal comfort is assessed. Patients' shivering is assessed according to the shivering scale. In addition, patients' vital signs are assessed every 15 minutes for one hour."
62824886|NCT06592807|NO_INTERVENTION|Control Group|"1. Before surgery, patients are informed about the study and their tympanic body temperatures are measured.~2. During the surgery, the operating room temperature is measured and recorded. The patient's tympanic body temperature is also measured and recorded. (Every half hour).~3. After the surgery, patients are given a survey question regarding socio-demographic data. Patients' pain is assessed with VAS (visual analog scale). Patients' thermal comfort is assessed. Patients' shivering is assessed according to the shivering scale. In addition, patients' vital signs are assessed every 15 minutes for one hour."
62824887|NCT06595901||Patients|Participants wear ActiGraphs, complete questionnaires via phone call/text message, and participate in interviews remotely on study.
62824888|NCT06595901||Stakeholders|Semi-structured interviews will be conducted with up to 15 key stakeholders (e.g., nurse coordinators, surgical and medical oncologists, physical therapists) at Siteman Cancer Center.
62824889|NCT06541574|SHAM_COMPARATOR|Control Group|receiving no methotrexate
62824890|NCT06541574|EXPERIMENTAL|Injection group|receiving standard surgery without intraoperative methotrexate followed by postoperative 400µg intravitreal methotrexate injections 1, 3, 6, and 10 weeks after surgery.
62824891|NCT06541574|EXPERIMENTAL|Infusion Group|receiving surgery with intraoperative intraocular methotrexate infusion as described above and postoperative sham injections.
62824892|NCT06541574|EXPERIMENTAL|Combined Infusion/Injection group|receiving both intraoperative intraocular methotrexate infusion and postoperative 400µg intravitreal methotrexate injections 1, 3, 6, and 10 weeks after surgery.
62824893|NCT03760718|ACTIVE_COMPARATOR|Preservative free Chloroprocaine Group 1|40 ml of preservative-free 1% chloroprocaine
62824894|NCT03760718|ACTIVE_COMPARATOR|Preservative free Chloroprocaine Group 2|40 ml of preservative-free 2% chloroprocaine
62824895|NCT03760718|ACTIVE_COMPARATOR|Preservative free Chloroprocaine Group 3|40 ml of preservative-free 3% chloroprocaine
62043545|NCT02937168|EXPERIMENTAL|Part 2: Reslizumab|Reslizumab 3.0 milligrams/kilogram (mg/kg) will be administered by intravenous (IV) infusion, over 20 to 50 minutes, at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
62043546|NCT02937168|PLACEBO_COMPARATOR|Part 2: Placebo|Matching placebo will be administered by IV infusion at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
62246116|NCT02966223|EXPERIMENTAL|MRI and HIDA scan|
62824896|NCT02102646|ACTIVE_COMPARATOR|Triptorelin|Triptorelin 22,5mg/24th week intramuscularly
62602775|NCT01957618||Historical control group|Liver cirrhotic patients who were enrolled before 2004 and did not receive treatment during the follow-up
62602776|NCT02784522|EXPERIMENTAL|locking compression plate group|In the experimental group, patients will undergo closed reduction via a lateral approach to the shoulder followed by locking compression plate fixation using a minimally invasive technique.The locking compression plate is purchased from Xiamen Dabo Yingjing Medical Devices Co., Ltd., Xiamen, China.
62602777|NCT02784522|ACTIVE_COMPARATOR|conventional locking plate group|Patients in the control group will be subjected to closed reduction via a lateral approach to the shoulder followed by conventional steel plate fixation using a minimally invasive technique. The conventional locking plate is purchased from Xiamen Dabo Yingjing Medical Devices Co., Ltd., Xiamen, China.
62602778|NCT02170961||acute heart failure (AHF)|patients consulting the emergency department for dyspnea. the diagnosis of AHF was based on clinical, biological (BNP) and echocardiographic data.
62602779|NCT02170961||Non acute heart failure (NAHF)|patients consulting the emergency department for dyspnea. the diagnosis of AHF was based on clinical, biological (BNP) and echocardiographic data.
62602780|NCT01338961|NO_INTERVENTION|Normothermic CPB|Standard management. Patients will be kept at normothermia throughout the procedure (\>36oC).
62602781|NCT01338961|ACTIVE_COMPARATOR|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC.
62824897|NCT02102646|ACTIVE_COMPARATOR|orchiectomy|Androgen deprivation therapy by bilateral subcapsular orchiectomy
62602782|NCT06237413|EXPERIMENTAL|Phase 1 Dose Escalation|"This Phase adopts an open-label design, with an Accelerated Titration(AT) design for the low-dose group (50 mg Bid) and the standard 3+3 design for the high-dose groups（100 mg Bid、50 mg Qd、100 mg Qd、200 mg Qd）."
62602783|NCT06237413|EXPERIMENTAL|Phase 2 Dose Expansion|After the completion of the dose escalation study, RP2D will be selected for dose expansion in advanced solid tumors (such as non-small cell lung cancer, colorectal cancer, pancreatic cancer, etc.) with KRAS mutations that have failed at least the first-line standard treatment
62602784|NCT05992259|ACTIVE_COMPARATOR|Active TENS|It will be performed attached to the tragus of the left ear.
62602785|NCT05992259|SHAM_COMPARATOR|Sham TENS|It will be performed attached to the earlobe of the left ear.
62602786|NCT05737017|EXPERIMENTAL|The ClearCoajet group|During the endoscopic resection procedures, the ClearCoajet will be used for injection and initial hemostasis for intraprocedural bleeding.
62602787|NCT05737017|ACTIVE_COMPARATOR|The control group|During the endoscopic resection procedures, the conventional injector will be used for injection.
62602788|NCT01443351||ITP patients|Patients with refractory ITP eligible for treatment with TPO-ra
62602789|NCT03462459|EXPERIMENTAL|Vancomycin|125 mg, oral capsule by mouth, once daily, for the duration of standard-of-care antibiotic therapy plus 5 days
62246117|NCT03967782|EXPERIMENTAL|cohorte 1|18 adolescents with obesity are involved and will perform the three conditions.
62824898|NCT03696836|EXPERIMENTAL|Trammpolin® meniscus prosthesis|The patients will be implanted with the Trammpolin® meniscus prosthesis
62824899|NCT05030272|EXPERIMENTAL|"Quit on the Go (formerly Learn to Quit)"|A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches and a 5-10 week course of NRT gum (or Nicotine Lozenges if unable to use gum). Participants also receive technical smartphone coaching for the first 4 weeks of the study.
62043547|NCT06562361|EXPERIMENTAL|100 µg [68Ga]Ga-DOTA-Cys-ATH001 (target dose of 200 MBq)|All participants will receive a single, bolus iv injection of up to 100 µg \[68Ga\]Ga-DOTA-Cys-ATH001 (target dose of 200 MBq). At Visit 4, cohort 1b (healthy participants, n=3) and cohort 2b (presumed MASH participants, n=3) will come for a second PET/MR imaging visit within 6 weeks from the first imaging visit where an additional bolus iv injection of up to 100 µg \[68Ga\]Ga-DOTA-Cys-ATH001 will be administered.
62602790|NCT03462459|PLACEBO_COMPARATOR|Placebo|125 mg placebo capsule by mouth, once daily, for the duration of standard-of-care antibiotic therapy plus 5 days
62602791|NCT03102697||Obese individuals|Obese patients submitted to treatment using two consecutively air-filled IGB (Heliosphere® 600 cc and Heliosphere 720 cc) without any interval between the removal of the first and the placement of the second.
62043548|NCT06525324|EXPERIMENTAL|in 10 sites immediate implant will be placed along with T-PRF and xenograft|Immediate implant is placed along with T-PRF and xenograft.
62043549|NCT06525324|ACTIVE_COMPARATOR|in 10 sites immediate implants will be placed with PRF and xenograft|Immediate implant is placed along with PRF and xenograft as control
62436460|NCT05270187|EXPERIMENTAL|Point laser Group|Patients in this group will received facial massage, facial expression exercises and laser at predetermined eight points on the affected side of the facial muscles. the hand piece is positioned perpendicular to 8 points which is located on the superficial roots of the facial nerve of the affected side. Each point will receive an energy density of 10 J/point with total energy delivered to the patient during one session of 80 joules. The time of application 90 sec/point. laser is calibrated by the manufacture company before the starting the experiment and periodically during the sessions. The laser probe will be away from the eye region. Both patients and therapist wear a laser googles.
62043550|NCT04950374|EXPERIMENTAL|Moisturizer Body Lotion and Lip Moisturizer Regimen|All participants will receive and use both products.
62436461|NCT05270187|PLACEBO_COMPARATOR|Control Group|patients in this group will receive only facial massage, facial expression exercises and placebo laser. Facial expression exercises include active graduated strengthening exercises in front of a mirror (active assisted, freedom, and resisted), proprioceptive neuromuscular facilitation exercises for facial muscles, and resisted exercises for neck muscles. Participants are taught to perform massage and exercises correctly by the physiotherapist. All treatment groups are given instruction to repeat the massage and exercises two times a day for at least 6 weeks. The patient or one of his/her family members will confirm that the participant carries out the massage and exercises at home.
62436462|NCT00736619|EXPERIMENTAL|1|"Cetuximab loading dose, 400 mg/m2 intravenously (IV) IMRT, 1 fraction/day, up to total of approximately 70 Gy, over approximately 33 treatment days~* Cetuximab 250 mg/m2 weekly IV X 7 weeks~* Albumin-bound paclitaxel (Abraxane®) weekly IV X 7 weeks, according to dose escalation scheme"
62436463|NCT02419859|EXPERIMENTAL|PaQ® Insulin Delivery Device|The intervention is continuous subcutaneous U 100 Insulin, Asp(B28)-rapid-acting insulin, at a constant basal rate of either 20, 24, 32, 40 or 50 U per day over 3 days and and bolus insulin as needed at meals in 2 U increments.
62436464|NCT03705169|EXPERIMENTAL|Arm A: 1 mg/kg SAR441236|Participants continued on non-study-provided ART and received 1 mg/kg of SAR441236, administered as a single intravenous (IV) infusion on Day 0 (Cohort 1).
62436465|NCT03705169|EXPERIMENTAL|Arm A: 3 mg/kg for SAR441236|Experimental: Arm A: 3 mg/kg SAR441236 Participants continued on non-study-provided ART, and received 3 mg/kg of SAR441236, administered as a single IV infusion on Day 0 (Cohort 2).
62436466|NCT03705169|EXPERIMENTAL|Arm A: 10 mg/kg SAR441236|Participants continued non-study-provided ART and received 10 mg/kg of SAR441236, administered as a single IV infusion on Day 0 (Cohort 3).
62436467|NCT03705169|EXPERIMENTAL|Arm A: 30 mg/kg SAR441236|Participants continued non-study-provided ART and received 30 mg/kg of SAR441236, administered as an IV infusion on Day 0 and then every 12 weeks for a total of four doses (Cohort 4).
62436468|NCT03705169|PLACEBO_COMPARATOR|Arm A: 0 mg/kg SAR441236|"Placebo participants were pooled across those receiving:~* 1 mg/kg dose volume-equivalent administered as a single IV infusion (Cohort 1).~* 3 mg/kg dose volume-equivalent administered as a single IV infusion (Cohort 2).~* 10 mg/kg dose volume-equivalent administered as a single IV infusion (Cohort 3)~* 30 mg/kg dose volume-equivalent administered as an IV infusion on Day 0 and then every 12 weeks for a total of four doses (Cohort 4)~All continued on non-study provided ART."
62436469|NCT03705169|EXPERIMENTAL|Arm B: 1 mg/kg SAR441236|Participants received 1 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment was initiated or re-initiated by Day 28 (Cohort 5).
62436470|NCT03705169|EXPERIMENTAL|Arm B: 30 mg/kg SAR441236|Participants received 30 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment was initiated or re-initiated by Day 28 (Cohort 8).
62436471|NCT03705169|EXPERIMENTAL|Arm C: 0.3 mg/kg SAR441236|Participants continued non-study-provided ART and received 0.3 mg/kg of SAR441236, administered as a subcutaneous (SC) injection(s) on Day 0 (Cohort 10).
62436472|NCT03705169|EXPERIMENTAL|Arm C: 1 mg/kg SAR441236|Participants continued non-study-provided ART and received 1 mg/kg of SAR441236, administered as an SC injection(s) on Day 0 (Cohort 11).
62602792|NCT00860249|NO_INTERVENTION|Usual Care|Usual Care. Participants in this arm will receive Usual care until outcome assessment is performed at 6 months following randomization. At that time, they will be sent a letter reminding them to obtain the ordered preventative service test, however no further outcomes will be assessed. Thus, during the course of the study, all participants in this arm will have solely received usual care.
62602793|NCT00860249|EXPERIMENTAL|Behavioral: Letter Only|Behavioral: Letter Only Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
62602794|NCT00860249|EXPERIMENTAL|Behavioral: Letter and Educational DVD|Behavioral: Letter and Educational DVD Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
62602795|NCT04777448|NO_INTERVENTION|Control|Simple physical activity advices will be given to the 27 patients of the control arm
62246118|NCT06131333||Complex PCI|All consecutive patients with complex coronary artery disease (CAD) were treated with percutaneous coronary intervention (PCI). The complexity of CAD was defined as having at least one of the following characteristics: chronic total occlusion (CTO), lesion length \>40 mm, severe calcification assessed by angiography or intravascular imaging examination, multivessel PCI during the same intervention, or true bifurcation defined as any lesion involving both the main vessel (MV), proximal or distal and the ostium of the side branch (SB) (Medina 1,1,1; 1,0,1; or 0,1,1).
62246119|NCT05232006|EXPERIMENTAL|Niraparib|PARP-inhibitor, Niraparib Dosage : starting 300 mg/day for patients with body weight ≥77kg and platelet counts ≥ 150 000/µl or 200 mg when body weight inferior to 77kg and/or platelet counts ≤ 150 000/µl and \> 100 000/µl Pharmaceutical form : 100 mg capsules Posology : single dose daily Route of administration : oral Administration procedures : oral, daily single dose Duration of treatment : 12 cycles of 28 days each
62246120|NCT06288945|EXPERIMENTAL|Study Group|The educational nursing interventions were individually administered to each participant in the study group in two sessions which were conducted after the assessment phase on the day of the eye examination at the ophthalmology outpatient clinic and after the diagnosis of dry eye syndrome.
62436473|NCT03705169|PLACEBO_COMPARATOR|Arm C: 0 mg/kg SAR441236|"Placebo participants were pooled across those receiving:~* 0.3 mg/kg dose volume-equivalent administered as an SC injection(s) (Cohort 10).~* 1 mg/kg dose volume-equivalent administered as an SC injection(s) (Cohort 11).~All continued on non-study provided ART."
62436474|NCT04458337||SARS-CoV-2 patients undergoing a surgical procedure|The investigators propose to conduct a prospective observational cohort study on all patients suspected or confirmed being infected to SARS-CoV-2, or recovered from SARS-CoV-2, undergoing a surgery.
62436475|NCT03575039|EXPERIMENTAL|Single arm clinical investigation|Subjects in experimental group will be implanted the VitaFlow II Transcatheter Aortic Valve System.
62436476|NCT01718210|EXPERIMENTAL|GM-CSF medium|patient's embryos are incubated after fertilization with mediun supplemented with GM-CSF
62436477|NCT01718210|PLACEBO_COMPARATOR|CONTROL|50 women with recurrent implantation failure (at leat three previous IVF attempts failed with at least 8 good embryos transferred in uterus)that the obtained with IVF are incubated with a standard medium for IVF, and utilized as control group.
62436478|NCT03524937|EXPERIMENTAL|MELATONIN (LOW DOSE)|Daily administration of melatonin by enteral route at 0.3 mg/day (low dose arm), up to 14 days.
62436479|NCT03524937|EXPERIMENTAL|MELATONIN (HIGH DOSE)|Daily administration of melatonin by enteral route at 3 mg/day (high dose arm), up to 14 days.
62246121|NCT06288945|NO_INTERVENTION|Control Group|The control group was selected first and did not receive the educational program for dry eye syndrome
62436480|NCT03524937|PLACEBO_COMPARATOR|PLACEBO|Daily administration of identical placebo up to 14 days.
62436481|NCT03208348|EXPERIMENTAL|Pilot virtual reality|Children with anxiety will have a single visit to test the virtual reality system and measure its affects on their anxiety ratings.
62436482|NCT02130206|ACTIVE_COMPARATOR|Caries Free|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
62436483|NCT02130206|PLACEBO_COMPARATOR|Caries Free - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
62436484|NCT02130206|ACTIVE_COMPARATOR|Caries Active|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
62436485|NCT02130206|PLACEBO_COMPARATOR|Caries Active - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
62436486|NCT02804269||Healthy Volunteer|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
62436487|NCT02804269||Dilated Cardiomyopathy|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
62436488|NCT02804269||Hypertrophic cardiomyopathy|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
62602796|NCT04777448|EXPERIMENTAL|telerehabilitation|Patients in the tele rehabilitation arm will perform 24 1h-telerehabilition sessions (dance, gym, cardio training, yoga, ...)
62436489|NCT02804269||Ischemic heart disease with reduced EF|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
62436490|NCT02804269||Ischemic heart disease with normal EF|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
62602797|NCT03112668|EXPERIMENTAL|Supportive Care (ACT)|Patients and their partners attend 6 weekly ACT sessions over 60-75 minutes. Couples learn skills of acceptance, avoidance, awareness, values and committed action, mindfulness and values in relationships, and handling persistent worries and concerns. Patients and their partners also do homework assignment after each session.
62602798|NCT01297166|EXPERIMENTAL|LEO 27989 ointment|
62602799|NCT06077552|EXPERIMENTAL|experimental group|pyramidal training by treadmill for 40 minutes per session three sessions per week for eight weeks in addition to the diet health advises.
62602800|NCT06077552|NO_INTERVENTION|control group|receive diet health advises.
62043551|NCT01642680|EXPERIMENTAL|Physical activity during chemotherapy|This group will start with a physical activity program 3 months before the end of their chemotherapeutic regimen. After chemotherapy they will continue the PA program for another 3 months.
62246122|NCT02073071||Preterm/low birth weight infants|Preterm infant formula per standard of care
62246123|NCT00467389|EXPERIMENTAL|Oral Placebo First|Three days of daily treatment with oral placebo, followed by three days of daily treatment with 5 mg of donepezil
62602801|NCT01194934|EXPERIMENTAL|Group A|Group A: 2.0 mg/kg NOX-A12 IV every day for 5 days
62246124|NCT00467389|EXPERIMENTAL|Donepezil First|Three days of daily treatment with 5 mg of donepezil, followed by three days of daily treatment with oral placebo.
62246125|NCT02098720|EXPERIMENTAL|Conbercept|Subjects will receive Conbercept injections at a dose of 0.5 mg/eye, once a month for first 3 months. In the next 3 months, the investigator will decide whether repeat injections are needed based on the monthly assessment results.
62246126|NCT02247765|EXPERIMENTAL|Arterial Line|CO-Oximetry value obtained as a comparator. Obtained during motion conditions.
62436491|NCT05209490|OTHER|Femoral nerve blockade under ultrasound control with a peripheral nerve stimulator|
62436492|NCT05209490|OTHER|Femoral nerve blockade under ultrasound control without a peripheral nerve stimulator|
62436493|NCT02706002|ACTIVE_COMPARATOR|hip prosthesis under fluoroscopy|implantation of femoral stem of hip prosthesis in this group of patients are under fluoroscopic guidance for stem size and stem alignment and last rap before original stem implantation will be checked for alignment , lateral and vertical offsets parameters.
62436494|NCT02706002|SHAM_COMPARATOR|hip prosthesis without fluoroscopy|in this group of patients rasping of femoral canal during hip prosthesis is made via anatomic landmarks which confirmed by to senior surgeons and than original stem implanted.
62436495|NCT00787566|EXPERIMENTAL|0.5 mg of TRG (intranasal granisetron)|0.5 mg dose, intranasal powder, single spray, administered once
62436496|NCT00787566|EXPERIMENTAL|1.0 mg of TRG (intranasal granisetron)|1.0 mg dose, intranasal powder, songle spray, administered once
62436497|NCT00787566|EXPERIMENTAL|2.0 mg of TRG (intranasal granisetron)|2.0 mg dose, intranasal powder, single spray, administered once
62436498|NCT03717285|EXPERIMENTAL|Group 1:Under direct vision|Patients in Group 1 insert the UAS under direct vision.In this procedure,the investigators will insert the ureteroscope into urinary bladder beside the guidewire to observe the process of uas insertion into the ureter.
62436499|NCT03717285|ACTIVE_COMPARATOR|Group 2:Under non direct vision|Patients in Group 2 insert the UAS under non direct vision.In this procedure,the investigators will insert the UAS under fluoroscopy control.
62436500|NCT05933525|ACTIVE_COMPARATOR|Travelan|IMM-124E (Travelan) is the investigational product. Travelan 1200mg will be taken orally for 7 days.
62436501|NCT05933525|PLACEBO_COMPARATOR|Placebo|ProMilk 85 milk powder is the placebo. Placebo has been manufactured into tablets using the same manufacturing process as Travelan. 1200mg will be taken orally for 7 days.
62436502|NCT00708630|EXPERIMENTAL|1|Provision of extended symptom side effects information
62436503|NCT00708630|NO_INTERVENTION|2|Standard information on side effects
62436504|NCT06528002||Group 1|type 2 diabetic patients take normal breakfast dose at Iftar and take 50% of dinner dose as short acting insulin at Suhoor with giving metformin dose after Suhoor even if giving once per day.
62436505|NCT06528002||Group 2|patients on regmin as recommendations of IDF take normal breakfast dose at Iftar and Reduce Suhoor dose by 20-50% of dinner premixed dose.
62436506|NCT03082456|OTHER|Three breast screening modalities|Subjects who have had mammography less than two years ago will receive MBI and breast ultrasound only. Other participants will receive three interventions including molecular breast imaging, mammography and breast ultrasound. The interval between each examination will be less than 6 months.
62436507|NCT01314326||Perimetric Glaucoma (PG)|Patients with clinically confirmed abnormal VF and glaucomatous ONH or NFL defect
62436508|NCT01314326||Glaucoma Suspects and Pre-Perimetric Glaucoma (GSPPG) Group|Patients who are at high risk to develop perimetric glaucoma
62436509|NCT01314326||Normal Group|Volunteers with healthy eyes
62602802|NCT01194934|EXPERIMENTAL|Group B|Group B: 4.0 mg/kg NOX-A12 IV every day for 5 days
62602803|NCT01194934|ACTIVE_COMPARATOR|Group C|"The treatment groups will enter the study sequentially. The decision on starting groups C and D will be made after groups A and B have been completed and data are available.~Group C: 5 µg/kg filgrastim SC every day for 5 days"
62602804|NCT01194934|EXPERIMENTAL|Group D|"The treatment groups will enter the study sequentially. The decision on starting groups C and D will be made after groups A and B have been completed and data are available.~Group D: Safe and efficacious dose of NOX-A12 IV in combination with filgrastim SC for 5 days"
62043552|NCT01642680|ACTIVE_COMPARATOR|Physical activity after chemotherapy|This group will start with a physical activity program after the end of their chemotherapeutic regimen. The physical activity program wil take 6 months to complete.
62246127|NCT02247765|EXPERIMENTAL|Motion|The subject has to perform motions during the procedure. This is to verify that device is able to read through motion.
62436510|NCT05451043|EXPERIMENTAL|Pancreatic Cancer|Durvalumab will be administered once every 4 weeks, in combination with gemcitabine + nab-paclitaxel (day 1/8/15) and continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients.
62436511|NCT05451043|EXPERIMENTAL|Hepatocellular Cancer|Durvalumab will be administered once every 4 weeks in combination with continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients.
62436512|NCT05451043|EXPERIMENTAL|Biliary Tract Cancer|Durvalumab will be administered once every 3 weeks, in combination with cisplatin + gemcitabine (day 1/8) and continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients.
62436513|NCT06503042||Chemotherapy combined with immunotherapy group|NSCLC patients undergoing neoadjuvant chemotherapy combined with immunotherapy regimens
62436514|NCT06503042||Chemotherapy group|NSCLC patients undergoing neoadjuvant chemotherapy regimens
62436515|NCT00003782|EXPERIMENTAL|Arm 1: Doxorubicin + Cyclophosphamide, then Docetaxel|Doxorubicin + Cyclophosphamide, then Docetaxel
62436516|NCT00003782|EXPERIMENTAL|Arm 2: Doxorubicin + Docetaxel|Doxorubicin + Docetaxel
62436517|NCT00003782|EXPERIMENTAL|Arm 3: Doxorubicin + Docetaxel + Cyclophosphamide|Doxorubicin + Docetaxel + Cyclophosphamide
62436518|NCT01154153|PLACEBO_COMPARATOR|Placebo|"* placebo during the screening phase and~* placebo during the treatment phase.~All children had the option to take rescue medication, (Claritin®) as needed to relieve symptoms of AR."
62436519|NCT01154153|EXPERIMENTAL|TAA-AQ|"* placebo during the screening phase and~* TAA-AQ (Nasacort AQ) during the treatment phase.~All children had the option to take rescue medication, (Claritin®) as needed to relieve symptoms of AR."
62436520|NCT01146730|EXPERIMENTAL|Workcoping and IPS|CBT based counseling and supported employment
62824900|NCT05030272|OTHER|Brief Advice (Standard of Care)|Brief Advice and Combined Nicotine Replacement Therapy (patches and gum or lozenges) has been recommended by the US Clinical Practice Guidelines for patients with psychiatric illness. Brief Advice will consist of 20 minutes of guidance about the use of nicotine replacement therapy, and strategies to initiate and maintain a quit attempt. The intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches and a 5-10 week course of NRT gum (or Nicotine Lozenges if unable to use gum).
62602805|NCT06623279|EXPERIMENTAL|HG202|The study will enroll up to 3 dose cohorts：Low dose/Middle dose/High dose
62043553|NCT01647490|ACTIVE_COMPARATOR|Right Ventricular Apex (RVA)|In the RVA group the right ventricular pacing lead will be implanted in the apex region of the right ventricle
62436521|NCT01146730|ACTIVE_COMPARATOR|Ordinary care by GP or NAV|Ordinary care by GP or The Norwegian Labour and Welfare Administration (NAV)
62436522|NCT05261425|ACTIVE_COMPARATOR|Monocryl buried|Upper extremity primary surgical wound closure via suture with Monocryl buried
62436523|NCT05261425|ACTIVE_COMPARATOR|Nylon (FDA Approved) not buried|Upper extremity primary surgical wound closure via suture with Nylon(FDA Approved) not buried
62602806|NCT06621953|EXPERIMENTAL|BFR|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff will be inflated to either 40% or 80% of limb occlusion pressure during lower limb strengthening exercises, as determined by Phase One (2318/MODREC/24a). These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
62602807|NCT06621953|ACTIVE_COMPARATOR|Control|Standard residential rehabilitation consists of; (1) exercise-based therapy delivered in group settings and individually to address a variety of physical components relating to their pathology (e.g., balance and co-ordination, cardiovascular endurance, mobility and flexibility, motor control and dynamic stability, and muscular strength), (2) patient education sessions (e.g., activity modification, behavioural change, and focusing on pain management), and (3) one-on-one support sessions (e.g., dietetics, occupational therapy, physiotherapy, podiatry, prosthesis/orthosis specialists, social workers, and speech and language therapists).
62602808|NCT05569928|ACTIVE_COMPARATOR|Homozygous FHBL2 subjects|
62043554|NCT01647490|EXPERIMENTAL|Right Ventricular Septum (RVS)|In the RVS group the right ventricular pacing lead will be implanted in the septal region (mid septum) of the right ventricle
62043555|NCT05661955|EXPERIMENTAL|Cohort A: Previously Treated UC|BGB-A445 Monotherapy
62043556|NCT05661955|EXPERIMENTAL|Cohort B: Previously Treated UC|BGB-A445 and Tislelizumab
62043557|NCT05661955|EXPERIMENTAL|Cohort C: Previously Treated RCC|BGB-A445 Monotherapy
62436524|NCT02168075|EXPERIMENTAL|Group 1|0.25g/kgof 20% mannitol administered at drilling of skull.
62436525|NCT02168075|EXPERIMENTAL|Group 2|0.5g/kg of 20% mannitol administered at drilling of skull.
62436526|NCT02168075|EXPERIMENTAL|Group 3|1.0 g/kg of 20% mannitol administered at drilling of skull.
62436527|NCT02168075|EXPERIMENTAL|Group 4|1.5g/kg of 20% mannitol administered at drilling of skull.
62436528|NCT00595426|EXPERIMENTAL|1. YM150 Dose X, twice daily|
62436529|NCT00595426|EXPERIMENTAL|2. YM150 Dose Y, once daily|
62436530|NCT00595426|EXPERIMENTAL|3. YM150 Dose Y, twice daily|
62436531|NCT00595426|EXPERIMENTAL|4. YM150 Dose Z, once daily|
62436532|NCT00595426|ACTIVE_COMPARATOR|5. Warfarin|various doses
62436533|NCT01032161||Delirium|Delirium was determined by RASS-PAEDS
62602809|NCT05569928|ACTIVE_COMPARATOR|Heterozygous FHBL2 carriers|
62824901|NCT04225195|EXPERIMENTAL|Amphotericin B cholesteryl sulfate complex for injection(ABCD)|"Patients with invasive candidiasis (IC) will only receive intravenous treatment with ABCD. ABCD will be administered once a day at a dose of 3-4 mg/kg.~Patients with invasive aspergillosis (IA) will be treated with ABCD for 4 weeks first, followed by oral administration of voriconazole. ABCD dosing regimen will be the same as that for IC patients."
62436534|NCT01032161||no Delirium|no Delirium was determined by RASS-PAEDS
62436535|NCT04882111|EXPERIMENTAL|Discharged Cancer Patients|25 patients, adults ≥ 18, with stage II - IV solid tumor malignancy discharging from an acute care hospital to a SNF in the metro Denver area who have decisional capacity to consent and are English speaking.
62436536|NCT06012591|OTHER|WHO Standard implementation|
62436537|NCT02036528|EXPERIMENTAL|AppliGel-G with oral Ciprofloxacin and Doxycycline|AppliGel-G (Gentamicin Topical Gel) in conjunction with oral Ciprofloxacin and Doxycycline
62436538|NCT02036528|ACTIVE_COMPARATOR|Oral Ciprofloxacin and Doxycycline only|Ciprofloxacin and Doxycycline
62436539|NCT04545632||Patients|Patients receiving chemotherapy with ethanol-containing docetaxel
62602810|NCT05569928|ACTIVE_COMPARATOR|ANGPTL3 wild-type Campodimele residents|
62602811|NCT04376333|ACTIVE_COMPARATOR|STD+CBT|Standard conservative dental orofacial pain care + cognitive-behavioral coping skills treatment
62043558|NCT05661955|EXPERIMENTAL|Cohort D: Previously Treated RCC|BGB-A445 and Tislelizumab
62824902|NCT04735471|EXPERIMENTAL|ADI-001 Dose Escalation|ADI-001 is administered via infusion with ascending dose levels as a single dose to determine the maximum tolerated dose (MTD) or maximum assessed dose (MAD) of ADI-001 (Part 1a).
62824903|NCT04735471|EXPERIMENTAL|ADI-001 Dose Extension|ADI-001 is administered via infusion at MAD/MTD to evaluate the safety of multiple doses (Part 1b).
62824904|NCT04735471|EXPERIMENTAL|ADI-001 Dose Expansion|Dose Expansion ADI-001 is administered via infusion at the MTD/MAD to confirm recommended phase 2 dose (Part 2).
62824905|NCT05540132|ACTIVE_COMPARATOR|Fast Acting Carbohydrate|Prior to exercise performance test, subject will be randomized to consume 22 grams of fast-acting carbohydrate (maltodextrin) or slow-acting cornstarch based supplement
62824906|NCT05540132|ACTIVE_COMPARATOR|Slow-acting cornstarch supplement|Prior to exercise performance test, subject will be randomized to consume 22 grams of slow-acting cornstarch based supplement or fast-acting carbohydrate (maltodextrin)
62824907|NCT05106647|NO_INTERVENTION|Control|This group would complete a survey that measures stress before and after leisure time with no added instructions.
62824908|NCT05106647|EXPERIMENTAL|Reduce screen time|Participants randomized to the intervention group are encouraged to set up an automated response to emails received during their weekend off, reduce their screen time for duration of leisure time, and uninstall work applications from their mobile device. Surveys are sent prior to and after leisure time.
62824909|NCT06599723|ACTIVE_COMPARATOR|Conventional lumbar steroid injections group|Patients will receive conventional lumbar steroid injections.
62824910|NCT06599723|EXPERIMENTAL|Racz catheter group|Patients will receive lumbar epidural steroid using Racz catheter.
62824911|NCT06591520|EXPERIMENTAL|AK112 + Gemcitabine + Cisplatin|
62824912|NCT06591520|ACTIVE_COMPARATOR|Durvalumab + Gemcitabine + Cisplatin|
62824913|NCT01195701||Anorgasmia (cases)|Women with difficulty or inability to reach sexual climax will be the cases in this study.
62824914|NCT01195701||Normal orgasmic function|Women who report that they usually or always achieve sexual climax will be the controls in this study.
62043559|NCT05661955|EXPERIMENTAL|Cohort E: Previously Treated Melanoma|BGB-A445 Monotherapy
62043560|NCT05661955|EXPERIMENTAL|Cohort F: Previously Treated Melanoma|BGB-A445 and Tislelizumab
62043561|NCT05661955|EXPERIMENTAL|Cohort G: First Line Cisplatin Ineligible UC|BGB-A445 and Tislelizumab
62824915|NCT02623972|EXPERIMENTAL|Arm A: Eribulin > AC|"* Eribulin-Administered via iv, at predetermined dosage and schedule per cycle~* Two research breast biopsies~* Adriamycin (doxorubicin) via iv a predetermined dosage and schedule per cycle~* Cyclophosphamide (AC) via iv a predetermined dosage and schedule per cycle~* Surgical Removal of the breasts (Mastectomy) and axillary lymph node dissection~* Radiation Therapy~* Endocrine Therapy (if applicable)~* Optional 5 Patient-Optional DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans"
62824916|NCT02623972|EXPERIMENTAL|Arm B: AC > Eribulin|"* Adriamycin (doxorubicin) via iv a predetermined dosage and schedule per cycle~* Cyclophosphamide (AC) via iv a predetermined dosage and schedule per cycle~* Two research breast biopsies~* Eribulin-Administered via iv, at predetermined dosage and schedule per cycle~* Surgical Removal of the breasts (Mastectomy) and axillary lymph node dissection~* Radiation Therapy~* Endocrine Therapy (if applicable)~* Optional 5 Patient-Optional DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans"
62043562|NCT05661955|EXPERIMENTAL|Cohort H: First Line Non-mucosal Melanoma|BGB-A445 and Tislelizumab
62043563|NCT05661955|EXPERIMENTAL|Cohort I: Previously Treated Non-mucosal Melanoma|BGB-A445 and Tislelizumab
62602812|NCT04376333|EXPERIMENTAL|STD+IATP|Standard conservative dental orofacial pain care + Individualized Assessment and Treatment Program; a highly individualized coping skills training procedure.
62602813|NCT01231295||Memory problems|Group with clinically validated memory problems
62824917|NCT06597409|ACTIVE_COMPARATOR|Active Comparator|Group A (Standard Pulmonary Rehabilitation)
62602814|NCT01231295||Reference group|Group without memory problems
62043564|NCT04357262|NO_INTERVENTION|Control|No other non-standard of care activities will be performed
62602815|NCT03333902|EXPERIMENTAL|QLB type 2|"Ultrasound-guided, Inject at the point posterior to quadratus lumborum muscle, 0.2% ropivacaine 30mL in each side for a total of 60mL.~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
62602816|NCT03333902|EXPERIMENTAL|QLB type 3|"Ultrasound-guided, Inject at the point between the quadratus lumborum and the psoas major muscle, 0.2% ropivacaine 30mL in each side for a total of 60mL.~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
62602817|NCT03333902|EXPERIMENTAL|QLB type 2+3|"Ultrasound-guided, conduct both QLB type 2 and 3, 0.2% ropivacaine 15mL in each point of injection, for a total of 60mL.~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
62043565|NCT04357262|EXPERIMENTAL|Intervention|Will be signed up for the automated text messaging program (StreaMD)
62043566|NCT00554879|EXPERIMENTAL|1|Acupuncture
62824918|NCT06597409|EXPERIMENTAL|Experimental|Group B (Standard PR + RMS)
62043567|NCT00554879|SHAM_COMPARATOR|2|Sham Acupuncture
62043568|NCT06545760|EXPERIMENTAL|Admission to Kangaroo Mother Care (KMC) ward for > 2 days after discharge from NICU|Following discharge from the neonatal intensive care unit (NICU), preterm mothers and their infants will be discharged to an inpatient kangaroo mother care (KMC) ward for greater than 2 days for continued support.
62623866|NCT03743025|EXPERIMENTAL|Dulaglutide Arm|Participants without a history of DM who are randomized to receive a single injection of dulaglutide (0.75 mg/0.5 mL solution in a single-dose pen) one to three days prior to surgery.
62824919|NCT05233189|EXPERIMENTAL|"With the MOOC Childhood cancer, living well, after"|Quantify the impact of the MOOC's membership on the CCS knowledge about LTFU adapted to the medical history of patients and measure how this MOOC can improve the LTFU care of each CCS.
62824920|NCT05233189|ACTIVE_COMPARATOR|"Without the MOOC Childhood cancer, living well, after"|Quantify the impact of the MOOC's non-membership on the CCS knowledge about LTFU adapted to the medical history of patients and measure how this MOOC can improve the LTFU care of each CCS.
62824921|NCT06596122|ACTIVE_COMPARATOR|Intervention group|In conjunction with the AC-T chemotherapy protocol, individuals in the intervention group who have a vitamin D deficiency will receive vitamin D replacement therapy.
62824922|NCT06596122|NO_INTERVENTION|The control group|only the standard of care will be administered.
62824923|NCT04827407|EXPERIMENTAL|Basic therapy + Efferon LPS|Basic therapy is the institution's routine practice for treating patients with septic shock against a background of abdominal sepsis plus extracorporeal hemoperfusion therapy (Efferon LPS)
62043569|NCT06545760|PLACEBO_COMPARATOR|Admission to Kangaroo Mother Care (KMC) ward for < 2 days after discharge from NICU|Following discharge from the neonatal intensive care unit (NICU), preterm mothers and their infants will be discharged to an inpatient kangaroo mother care (KMC) ward for less than 2 days for continued support.
62043570|NCT01770054||obtention of a blood sample|all Atahualpa residents aged 40 years or more
62043571|NCT01371773|EXPERIMENTAL|Left-sided double lumen tube|
62602818|NCT03333902|ACTIVE_COMPARATOR|epidural anesthesia group (EA)|"Epidural catheter placement was conducted when finishing spinal anesthesia. After surgery, 30 mL saline (placebo) was Injected at the point posterior to the quadratus lumborum in each side for a total of 60mL. We used a single bolus of 0.15% ropivacaine + 2 mg morphine (diluted in 6 ml saline) via epidural cathether.~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
62824924|NCT04827407|NO_INTERVENTION|Baseline therapy|Basic therapy is the institution's routine practice for treating patients with septic shock against a background of abdominal sepsis.
62824925|NCT04959435||Case|Behcet's disease patients
62043572|NCT04003168|EXPERIMENTAL|Human BCMA targeted T Cells Injection|"A single infusion of anti-BCMA CAR transduced T cells administered intravenously at a target dose of 3 to 9 x 10\^6 CAR T +cells/kg. The classic 3+3 dose escalation will be applied."
62043573|NCT04266301|EXPERIMENTAL|MBG453 (Sabatolimab) + Azacitidine|Participants will receive MBG453 plus Azacitidine
62602819|NCT06055244|EXPERIMENTAL|Amantadine|Subjects will be treated with amantadine.
62824926|NCT04959435||Controls|Controls that matched two to two at case according to sex,social status and diet.
62824927|NCT05277766|EXPERIMENTAL|Nal-IRI (Onivyde) - 30mg/m²|PIPAC with Onivyde (30 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
62824928|NCT05277766|EXPERIMENTAL|Nal-IRI (Onivyde) - 45mg/m²|PIPAC with Onivyde (45 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
62824929|NCT05277766|EXPERIMENTAL|Nal-IRI (Onivyde) - 60mg/m²|PIPAC with Onivyde (60 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
62824930|NCT05277766|EXPERIMENTAL|Nal-IRI (Onivyde) - 75mg/m²|PIPAC with Onivyde (75 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
62602820|NCT06055244|PLACEBO_COMPARATOR|Placebo|Subjected received placebo identical to amantadine in appearance.
62602821|NCT02119832|EXPERIMENTAL|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
62602822|NCT01334580|ACTIVE_COMPARATOR|Methadone Drug Counseling|Methadone Drug Counseling is provided by skilled drug counselors over a 12 week period and focuses on cessation of illicit drugs
62246128|NCT05716009|EXPERIMENTAL|Phase 1a Dose Escalation of tagraxofusp-erzs in r/r AML|"Tagraxofusp-erzs and gemtuzumab ozogamicin (GO) will be administered every 4 weeks with 28 days defined as a treatment cycle. Tagraxofusp-erzs dose escalation for cycles 1-4 in combination with fixed dose GO.~This is a dose escalation design . The dose-limiting toxicity (DLT) period will be the 28 days following the first dose of GO. The initial dose level 1 (DL1) cohort will receive GO 3mg/m2 (capped at a maximum dose of 4.5mg) intravenously (IV) on cycle 1 days 1, 4, and 7 and tagraxofusp-erzs at an initial dose of 7μg/kg/day on days 10, 11, 12. For subsequent cycles of DL1, GO will continue to be administered at a dose of 3mg/m2 IV on day 1 and tagraxofusp-erzs will be administered IV at a dose of 7μg/kg/day on days 4,5,and 6. Subsequent escalation dose levels will receive tagraxofusp-erzs doses of 7mcg/kg/day, 9mcg/kg/day or 12mcg/kg/day. Initial cycle doses of tagraxofusp at these levels will be given on Days 5,6 and 7, then in subsequent cycles on days 1,2 and 3."
62246129|NCT05716009|EXPERIMENTAL|Phase 1b recommended Phase 2 dose (RP2D) of tagraxofusp- erzs in r/r AML|This is dose expansion at the RP2D of tagraxofusp. Participants with relapsed or refractory acute myeloid leukemia (r/r AML) will receive the RP2D of tagraxofusp-erzs, as determined in Phase 1a, and gemtuzumab at a dose of 3mg/m2 (max absolute dose of 4.5mg) on days 1,4, and 7 of cycle 1 and day 1 of subsequent cycles.
62246130|NCT01756469|NO_INTERVENTION|Control|non-alcohol related information about nutrition
62246131|NCT01756469|ACTIVE_COMPARATOR|Intervention|Behavioral Intervention for Alcohol Use
62246132|NCT06241209|NO_INTERVENTION|Group 1 (online news)|"Group 1 with an odd number year of birth will be asked to view 15 minutes of online news three days per week for 2 months. LIVE: Canadian News \| Weather \& Traffic - Latest Sports \| Breaking News (globalnews.ca)"
62246133|NCT06241209|ACTIVE_COMPARATOR|Group 2 (PowerPoint program)|Group 2 with an even number year of birth will be asked to view the 15-minute PowerPoint program three days per week for 2 months.
62436540|NCT05064202|EXPERIMENTAL|Impella 5.5|ADHF-CS patients who are in the experimental arm will be treated with an Impella 5.5 (+/- standard of care)
62436541|NCT05064202|OTHER|Standard of care|ADHF-CS patients who are in the control arm will be treated with escalating doses of inotropes (standard of care)
62436542|NCT05252078|EXPERIMENTAL|Anlotinib|"Patients in the study group will receive the following treatment:~21 days as a treatment cycle, Anlotinib 12 mg/day, Orally (D1-D14); TQB 2450 1200 mg, iv (D1).~If anlotinib is not tolerated, the dose can be reduced to 10mg or 8mg, until un-tolerable toxicity again."
62436543|NCT03108079|OTHER|Arm 1|"Women who agree to participate will undergo a standard high resolution, thin slice pelvic floor static/dynamic MRI study, first with a full bladder, and after the bladder is emptied. Bladder filling and drainage will be performed sequentially, using each of the 2 catheter types (Cystosure Urinary Access Catheter and Foley Catheter). During bladder emptying, a cine video scan will be taken at the midsagittal plane to show the dynamics of the bladder fluid and walls during emptying. Each subject will serve as their own control.~Interventions are listed in the Interventions Section."
62436544|NCT05618483|EXPERIMENTAL|Interventional|The participants will receive Xylitol based nasal spray
62436545|NCT05618483|PLACEBO_COMPARATOR|Control|The participants will receive saline based placebo
62436546|NCT04484922|EXPERIMENTAL|Dexmedetomidine|
62436547|NCT04484922|PLACEBO_COMPARATOR|Control|
62436548|NCT03492073|EXPERIMENTAL|Emotional Supportive Mindfulness-based Program|"The program is based on 15/20 minutes sessions of meditative practices in which can participate only the patients, only his/her caregiver, or both.~Number of sessions is an independent outcome, because it depends on the number of days of hospitalization."
62436549|NCT03492073|ACTIVE_COMPARATOR|Emotional Supportive Program|"The program is based on 15/20 minutes sessions based on narrative therapy, in which the patient or his/her caregiver or both can talk about their emotions.~Number of sessions is an independent outcome, because it depends on the number of days of hospitalization."
62436550|NCT01252628|EXPERIMENTAL|PX-866 (SCCHN)|Phase 2 (Squamous Cell Carcinoma of the Head and Neck)
62436551|NCT01252628|ACTIVE_COMPARATOR|Cetuximab (SCCHN)|Phase 2 (Squamous Cell Carcinoma of the Head and Neck)
62436552|NCT01252628|EXPERIMENTAL|PX-866 (CRC)|Phase 2 (Colorectal Carcinoma)
62436553|NCT01252628|ACTIVE_COMPARATOR|Cetuximab (CRC)|Phase 2 (Colorectal Carcinoma)
62436554|NCT02468986||Uncontrolled Rheumatoid Arthritis|"18-75 years old; Rheumatoid arthritis, defined by 1987 American College Rheumatology criteria; Attending clinic at Aston Center for Rheumatology or Parkland Rheumatology Clinic; Uncontrolled: Patients will be labeled as uncontrolled RA if Disease Activity Score (DAS) score is \>3.2 and C-reactive protein (mg/dL) elevated above normal range.~Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP \> 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL\>160) in the past 6 months; Pregnant or nursing."
62043574|NCT04266301|PLACEBO_COMPARATOR|Placebo + Azacitidine|Participants will receive Placebo plus Azacitidine
62602823|NCT01334580|EXPERIMENTAL|Cognitive-Behavioral Therapy for Pain and Opioid Dependence|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
62602824|NCT00175032|EXPERIMENTAL|Lansoprazole 30 mg QD + Naproxen 500 mg BID|(and added aspirin)
62602825|NCT00175032|ACTIVE_COMPARATOR|Celecoxib 200 mg QD|(and added aspirin)
62602826|NCT04351906|OTHER|ECCO2R|ECCO2R in patients with mild to moderate ARDS with/without AKI requiring dialysis.
62602827|NCT03179293|ACTIVE_COMPARATOR|Propofol|propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
62602828|NCT03179293|PLACEBO_COMPARATOR|Control|Normal saline will be administered IV over the next 3 min prior to the patient leaving the OR
62602829|NCT03410082|ACTIVE_COMPARATOR|OAA/S|The patients in the control group will receive MAC titrated according to observer's assessment of anesthesia/sedation(OAA/S) score.
62602830|NCT03410082|ACTIVE_COMPARATOR|BIS|The patients in the control group will receive MAC titrated according to bispectral index(BIS).
62602831|NCT01979471|OTHER|Advanced care|For all the patients randomized to the advanced care group the pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA)
62824931|NCT05277766|EXPERIMENTAL|Nal-IRI (Onivyde) - 90mg/m²|PIPAC with Onivyde (90 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
62436555|NCT02468986||Controlled Rheumatoid Arthritis|18-75 years old; Rheumatoid arthritis, defined by 1987 American College Rheumatology criteria; Attending clinic at Aston Center for Rheumatology or Parkland Rheumatology Clinic; Controlled: Disease activity score (DAS) \<3.2, normal C-reactive protein. Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP \> 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL\>160) in the past 6 months; Pregnant or nursing.
62436556|NCT02468986||Healthy Controls|18-75 years old. Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP \> 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL\>160) in the past 6 months; Pregnant or nursing.
62436557|NCT04846556||venous thromboembolic event related to cancer|Patients admitted for a venous thromboembolic event related to their cancer will be included A data collection will be realized. Patients admitted between 2017 and 2019 at Saint-Etienne University Hospital, Louis-Mourier Hospital (AP-HP) and Amiens University Hospital.
62436558|NCT02308111|EXPERIMENTAL|Obeticholic Acid (OCA) 5 mg to 10 mg|Obeticholic Acid (OCA) 5 mg for a minimum 3 months and then titrating up to a maximum 10 mg for the remainder of the trial (based on tolerability and CP Score).
62436559|NCT02308111|PLACEBO_COMPARATOR|Placebo|
62436560|NCT04511351|EXPERIMENTAL|RT+GDP+Chidamide|IMRT followed by GDP chemotherapy with chidamide during radiation and chemotherapy phase
62246134|NCT04830150|EXPERIMENTAL|supportive interventions group|Supportive and educational nursing interventions about reducing maternal stress levels in the experimental group included the following: the NICU was physically described to mothers on the first day they visited their infants, mothers were introduced to team members, and given information about how to obtain information about their baby, visiting hours and conditions.
62246135|NCT04830150|NO_INTERVENTION|control group|Mothers did not have any other intervention applied by the researchers during routine operation while their infants were in the unit.
62246136|NCT04788576||Patients with heart failure with preserved ejection fraction (HFpEF)|Subject with preserved ejection fraction (ejection fraction \> 50%) and with dyspnea on exertion (NYHA Grade 2 or more) and diagnosed as HFpEF using HFA-PEFF scoring system (HFA-PEFF ≥5 or 2-4 with abnormal stress test or invasive hemodynamic test)
62246137|NCT06735963|ACTIVE_COMPARATOR|conventional therapy control group|The control group will receive conventional therapy alone, including exercises, ultrasound, and transcutaneous electrical nerve stimulation (TENS).
62246138|NCT06735963|EXPERIMENTAL|Experimental VR-based Group|Experimental group receiving VR-based rehabilitation in addition to conventional physical therapy,
62246139|NCT04257383|EXPERIMENTAL|Treatment|Families in the treatment cells will receive the Sugira Muryango treatment immediately after household identification and enrollment.
62246140|NCT04257383|EXPERIMENTAL|Waitlist Control|Families in the control cells will receive the Sugira Muryango treatment following the completion of the 12-month follow up on the original treatment group.
62246141|NCT01843972|EXPERIMENTAL|BI 691751 dose 2 (part I)|single dose given as oral solution
62246142|NCT01843972|EXPERIMENTAL|BI 691751 dose 3 (part I)|single dose given as oral solution
62246143|NCT01843972|EXPERIMENTAL|BI 691751 dose 4 (part I)|single dose given as oral solution
62246144|NCT01843972|EXPERIMENTAL|BI 691751 dose 5 (part I)|single dose given as oral solution
62246145|NCT01843972|EXPERIMENTAL|BI 691751 dose 6 (part I)|single dose given as oral solution
62246146|NCT01843972|EXPERIMENTAL|BI 691751 dose 7 (part I)|single dose given as oral solution
62246147|NCT01843972|EXPERIMENTAL|BI 691751dose 1 (part I)|single dose given as oral solution
62246148|NCT01843972|PLACEBO_COMPARATOR|Placebo (part I)|placebo solution
62246149|NCT01843972|EXPERIMENTAL|BI 691751 tablet (part II)|single dose given as 1 tablet
62246150|NCT01843972|ACTIVE_COMPARATOR|BI 691751 solution (part II)|single dose given as oral solution
62246151|NCT06249724|ACTIVE_COMPARATOR|Active stimulation|Low-intensity focused ultrasound stimulation of dorsal root ganglion involved in pain conduction
62436561|NCT04511351|NO_INTERVENTION|RT+GDP|IMRT followed by GDP chemotherapy without chidamide during radiation and chemotherapy phase
62824932|NCT03446794||patients with NVAF and ESCKD on HD|
62824933|NCT06588348|EXPERIMENTAL|Steroid Treatment|All participants are in the treatment arm. Patients with Esophagogastric Junction Outflow Obstruction (EGJOO) will undergo steroid treatment for 14 days. On the last day of the 14 day treatment, patient will undergo esophageal manometry testing to assess for treatment response. They will also be asked to complete follow-up Eckardt and BEDQ surveys.
62824934|NCT00568295|EXPERIMENTAL|Acetaminophen|Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP
62824935|NCT00568295|ACTIVE_COMPARATOR|Refecoxib 12.5 mg|Rofecoxib: Capsules 12.5 mg, oral, C-904-1A
62824936|NCT00568295|ACTIVE_COMPARATOR|Rofecoxib 12.5 x 2|Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A
62824937|NCT06046118|EXPERIMENTAL|Treatment group|"Two cycles of treatment using continuous and pulsed yellow light followed by continuous and pulsed red light.~Cycle 1 consists of 8 sessions (two sessions per week for 4 weeks) and cycle 2 consists of 6 sessions (two sessions per week for 3 weeks)."
62246152|NCT06249724|SHAM_COMPARATOR|Sham stimulation|Zero-intensity focused ultrasound stimulation of dorsal root ganglion involved in pain conduction
62246153|NCT01130051|EXPERIMENTAL|Colcrys® 0.6 mg intact tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
62246154|NCT01130051|EXPERIMENTAL|Colcrys® 0.6 mg tablet on applesauce|One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
62246155|NCT03536390|PLACEBO_COMPARATOR|Placebo|one chewable tablet once daily in morning.
62246156|NCT03536390|EXPERIMENTAL|Methylphenidate Hydrochloride Extended Release Chewable Tablet|one chewable tablet once daily in morning.
62246157|NCT03707132||Tourniquet Group|'Tourniquet: Folley catheter in the low segment of the uterus
62246158|NCT03707132||Control Group|Standard hysterectomy is performed
62246159|NCT00470236|ACTIVE_COMPARATOR|Arm 1 (Standard WB Fractionation)|Whole Breast RT alone - Standard fractionation schedule (50GY/25 Fractions/35days)
62602832|NCT01979471|NO_INTERVENTION|Usual Care|"Patients randomized to the usual care group will receive:~* Usual pharmacy care with no specific interventions for 3 months~* At the end of the 3 months of the usual care period, all patients will cross over to receive the advanced care outlined above for 3 months"
62043575|NCT02436265|SHAM_COMPARATOR|Group 1 Ropivacaine|Group 1 Ropivacaine Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine
62246160|NCT00470236|EXPERIMENTAL|Arm 2 (Shorter WB Fractionation)|Whole Breast RT alone - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days)
62246161|NCT00470236|ACTIVE_COMPARATOR|Arm 3 (Standard WB fractionation+Boost)|Whole Breast RT + tumor bed boost - Standard fractionation schedule (50 Gy/25 fractions/35 days; Boost 16 Gy/8 fractions/10 days)
62246162|NCT00470236|EXPERIMENTAL|Arm 4 (Shorter WB fractionation + Boost)|Whole breast RT + tumour bed boost - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days; Boost 16 Gy/8 fractions/10 days)
62246163|NCT03176563||Women treated with the herbal drug Uva Ursi|Patients of the clinical trial REGATTA (NCT03151603) who have been randomized in the Uva Ursi arm.
62246164|NCT03176563||Women treated with antibiotics|Patients of the clinical trial REGATTA (NCT03151603) who have been randomized in the fosfomycin arm.
62246165|NCT06706310|ACTIVE_COMPARATOR|TQ-A3334 tablets 0.2mg quaque die (QD), combined with nucleoside (acid) analogs (NAs)|TQA3334 tablets 0.2mg once a day 0.2 mg/time, 1 time/night, 48 weeks of administration; 1 time/day for combined medication, 72 weeks of administration; 72 weeks.
62246166|NCT06706310|PLACEBO_COMPARATOR|0.2mg quaque die (QD) placebo, combined with nucleoside (acid) analogs (NAs)|Placebo tablets 0.2mg once a day,0.2 mg/time, 1 time/night, 48 weeks of administration; 1 time/day for combined medication, 72 weeks of administration; 72 weeks.
62246167|NCT06706310|ACTIVE_COMPARATOR|TQ-A3334 tablets 0.5mg once the next day(QOD), combined with nucleoside (acid) analogs (NAs)|TQA333 tablets 0.5mg once the next day once the next day, administration for 48 weeks; combined medication 1/day, 72 weeks of administration.
62246168|NCT06706310|PLACEBO_COMPARATOR|Placebo 0.5mg once the next day (QOD) , combined with nucleoside (acid) analogs (NAs)|Placebo 0.5mg once the next day, administration for 48 weeks; combined medication 1/day, 72 weeks of administration;
62824938|NCT06046118|SHAM_COMPARATOR|Sham group|"Sham treatment will occur using a sham mask, designed to release a very low level of light, in this way the patient will not be able to distinguish if he is receiving the treatment or not.~Cycle 1 consists of 8 sessions (two sessions per week for 4 weeks) and cycle 2 consists of 6 sessions (two sessions per week for 3 weeks)."
62824939|NCT04967391|EXPERIMENTAL|Tumescence During STSG Harvest|Prior to the split thickness skin graft (STSG) harvest, the tumescence technique will injection of 100-150 mL normal saline with 1:500,000 epinephrine injected into a deep dermal thigh tissue plane with 18-gauge spinal needle on a 60 mL syringe.
62602833|NCT01041976|EXPERIMENTAL|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
62602834|NCT01041976|PLACEBO_COMPARATOR|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
62602835|NCT01319851|EXPERIMENTAL|Alefacept|Pediatric subjects with non-malignant diseases (NMD) will receive pre-conditioning with alefacept 0.5 mg/kg/dose i.v. with the first dose split on days -40 and -39 and the remaining doses given on days -33, -26, -19, and -12 (e.g. weekly for 5 doses).
62602836|NCT01489124|EXPERIMENTAL|0.5 g of imipenem by 0.5-hr infusion|0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
62602837|NCT01489124|EXPERIMENTAL|0.5 g of imipenem by 2-hr infusion|0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
62602838|NCT01489124|EXPERIMENTAL|1 g of imipenem by 2-hr infusion|1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
62623867|NCT03743025|PLACEBO_COMPARATOR|Placebo Arm|Participants without a history of DM who are randomized to receive a single injection of a placebo (saline injection of 0.5 mL pre-drawn solution) one to three days prior to surgery.
62824940|NCT04967391|NO_INTERVENTION|No Intervention|"Patients randomized to no tumescence will have their free flap donor site reconstructed with a split thickness skin graft (STSG) harvested at 0.0175 inches using the dermatome to obtain a graft from the thigh."
62824941|NCT04799964|EXPERIMENTAL|Flow Diverter (Tonbridge)|Treatment with Flow Diverter (Tonbridge)
62824942|NCT04799964|ACTIVE_COMPARATOR|Tubridge (MicroPort)|Treatment with Tubridge (MicroPort)
62824943|NCT05877924|EXPERIMENTAL|NBL-020|"Dose increasing study: The initial dose for the dose escalation study is 0.1 mg/kg administered once every 3 weeks (Q3W), with a pre-set maximum escalation dose of 30 mg/kg Q3W.~Dose expansion study: Based on the results of the dose escalation study, the dosage for the dose extension study will be determined through joint discussion between the sponsor and the investigators."
62824944|NCT06146907|ACTIVE_COMPARATOR|cognitive motor dual task|24 participants
62246169|NCT06706310|ACTIVE_COMPARATOR|TQ-A3334 tablets 0.5mg quaque die (QD), combined with nucleoside (acid) analogs (NAs)|TQA3334 tablets 0.5mg once a day, 1/night, 48 weeks of administration; 1 time/day for combined medication, 72 weeks of administration; 72 weeks.
62246170|NCT06706310|PLACEBO_COMPARATOR|Placebo 0.5mg quaque die (QD) combined with nucleoside (acid) analogs (NAs)|Placebo 0.5mg once a day, 1/night, 48 weeks of administration; 1 time/day for combined medication, 72 weeks of administration; 72 weeks.
62043576|NCT02436265|ACTIVE_COMPARATOR|Group 2 Ropivacaine and Dexamethasone|Group 2 Ropivacaine/dexamethasone Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine and 0.1mg/kg of intravenous dexamethasone immediately after caudal placement
62436562|NCT03518710|EXPERIMENTAL|Children with NF1|"One experimental group of NF1 children with 3 reading levels (1st grade, 2nd grade and 3rd grade). For this research they will pass :~* Neuropsychological evaluation~* Evaluation of the reading assistance technique"
62436563|NCT05499156|EXPERIMENTAL|exosome therapy|placenta-MSCs derived exosomes Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. These vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti-inflammatory properties by using paracrine effects. Exosomes, as a vehicle for signaling, are responsible for a significant part of cell-to-cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC-derived exosome treatment on various fistulas and inflammatory bowel disease. In this study, we aimed to evaluate the safety and effectiveness of PlacentaMSCs derived exosomes in the treatment of patients with complex preanal fistula (Crohn's) in phases I and II of the clinical trial
62436564|NCT05499156|EXPERIMENTAL|placebo|placebo
62824945|NCT06146907|ACTIVE_COMPARATOR|exergaming|24 participants
62436565|NCT01916785|EXPERIMENTAL|A1|Arm A1: Dasatinib dose adjustment based on Cmin ≥3nM value analysed on blood after 7-10 days dasatinib 100mg intake
62436566|NCT01916785|ACTIVE_COMPARATOR|A2|Arm A2: Dasatinib standard dose (100mg/d) with Cmin ≥ 3nM analysed on blood after 7-10 days dasatinib 100mg intake
62436567|NCT01916785|ACTIVE_COMPARATOR|B|Arm B : Dasatinib standard dose with Cmin \< 3nM analysed on blood after 7-10 days dasatinib 100mg intake
62436568|NCT02600169||Patients treated with pemprolizumab|All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma. Patients will be included from all 14 WIN-O (Werkgroep Immunologie Nederland voor Oncologie) centers in the Netherlands. Patients are at least 18 years of age.
62602839|NCT05625191||Control Group- Without Phonotrauma|Videoendoscopy and acoustic recordings using a head-mounted microphone with a voice-specialized SLP for participants without voice disorders, acoustic recordings will involve the five repetitions of three vowels (/ɑ, i, u/) and a standard reading passage (Rainbow Passage) in three voice conditions (breathy, typical, and pressed). For all participants, high-speed videoendoscopy and simultaneous acoustic recording will occur on one repetition of a sustained /i/ in each requested condition.
62602840|NCT05625191||Patients Diagnosed with Phonotrauma|"Videoendoscopy and acoustic recordings using a head-mounted microphone with a voice-specialized SLP for Participants who have a diagnosis of phonotrauma will be instructed to produce five repetitions of the same three vowels but in only two conditions: typical voice and resonant voice following stimulability assessment and with cues. They will be instructed to maintain relatively consistent volume and pitch across conditions. For all participants, high-speed videoendoscopy and simultaneous acoustic recording will occur on one repetition of a sustained /i/ in each requested condition."
62602841|NCT04519788|ACTIVE_COMPARATOR|AT-301B|AT-301B consists of edetate disodium, glyceryl monooleate, polysorbate 80, benzalkonium chloride, microcrystalline cellulose and sodium carboxymethylcellulose (vivapur), trisodium citrate dihydrate, and purified water (HCl to adjust pH to 5.0)
62602842|NCT04519788|PLACEBO_COMPARATOR|AT-301A|AT-301A consists of sodium chloride, benzalkonium chloride and purified water (NaOH/HCl to adjust pH to 5.0)
62602843|NCT06624111||Picture belong to a patient with obesity|Dietitians were randomly assigned to a case study via SurveyMonkey. All the information (demographics, biochemical parameters and diet history physical activity level) about the cases was the same, only their weight and, therefore, their photographs were different. In this case there was a photograph of a woman with obesity
62043577|NCT05944523|ACTIVE_COMPARATOR|Group 1|The group in which preemptive erector spina plane block was applied
62043578|NCT05944523|ACTIVE_COMPARATOR|Group 2|The group in which the end of the surgery was applied to the erector spina plane block
62602844|NCT06624111||Picture belong to a patient with normal-weight|Dietitians were randomly assigned to a case study via SurveyMonkey. All the information (demographics, biochemical parameters and diet history physical activity level) about the cases was the same, only their weight and, therefore, their photographs were different. In this case there was a photograph of a woman with normal weight.
62602845|NCT05908435|EXPERIMENTAL|Dispensers, Flyers, Enhanced Signage + a social media component delivered by teen ambassadors|The DFS+ experimental group is designed to increase utilization of free sunscreen dispensers, applying and reapplying sunscreen, and motivating use of other forms of sun protection by teens in 8 Boston parks and 2 Maine beaches. IMPACT Melanoma will install and maintain free sunscreen dispensers at the study sites. Flyers will be posted at locations at the park/beach to inform people of the availability of free sunscreen and the location of the dispenser. 'Teen enhanced' signage will be present on the dispenser in the intervention parks/beaches. Teen ambassadors will share 3-5 posts to their social media platform over the course of 1 week encouraging sun protection practices and use of the free sunscreen dispenser (when the intervention is occurring at the study site).
62602846|NCT05908435|NO_INTERVENTION|Dispensers, Flyers, Signage|The DFS control group includes dispensers, flyers, and standard signage at 8 Boston parks and 2 Maine beaches. IMPACT Melanoma will install and maintain free sunscreen dispensers at the study sites. Flyers will be posted at locations at the park/beach to inform people of the availability of free sunscreen and the location of the dispenser. Standard signage will be present on the dispenser in the control parks/beaches.
62602847|NCT02815813|EXPERIMENTAL|PeerFIT|PeerFIT is a group-based lifestyle intervention enhanced by mobile health technology and social media designed to achieve clinically significant improvements in weight loss and cardiorespiratory fitness in young adults with serious mental illness.
62602848|NCT02815813|ACTIVE_COMPARATOR|BEAT|BEAT involves basic education in fitness and nutrition supported by a wearable activity tracking device designed to achieve clinically significant improvements in weight loss and cardiorespiratory fitness in young adults with serious mental illness.
62602849|NCT05946577||Patients treated by chemoradiotherapy with high dose of cisplatin|radiotherapy 60-70 Gy in 30-35 fractions with concomitant chemotherapy by cisplatin 100 mg/m2 every 3 weeks (week 1, 3 and 7)
62043579|NCT04823260|ACTIVE_COMPARATOR|Arm A = 300 mg NMN supplement (n = 20)|Subjects who are assigned to 300 mg arm (NMN) will be instructed to take 2 capsules after breakfast once a day with ambient temperature water for 60 days.
62043580|NCT04823260|PLACEBO_COMPARATOR|Arm B = Placebo 300 mg (n=07)|Subjects who are assigned to 300 mg arm (placebo) will be instructed to take 2 capsules after breakfast once a day with ambient temperature water for 60 days.
62043581|NCT04823260|ACTIVE_COMPARATOR|Arm C = NMN Supplement 600 mg (n= 20)|Subjects who are assigned to 600 mg arm (NMN) will be instructed to take 4 capsules after breakfast once a day with ambient temperature water for 60 days.
62043582|NCT04823260|PLACEBO_COMPARATOR|Arm D = Placebo 600 mg (n=07)|Subjects who are assigned to 600 mg arm (Placebo) will be instructed to take 4 capsules after breakfast once a day with ambient temperature water for 60 days.
62043583|NCT04823260|ACTIVE_COMPARATOR|Arm E = NMN Supplement 900 mg (n=10)|Subjects who are assigned to 900 mg arm (NMN) will be instructed to take 6 capsules after breakfast once a day with ambient temperature water for 60 days.
62246171|NCT02370680|EXPERIMENTAL|Durlaza™, 1 capsule|Aspirin run-in, followed with Durlaza™, one capsule QD (quaque die), for 14 ± 4 days and an in-patient visit
62602850|NCT05946577||Patients treated with exclusive radiotherapy or radiotherapy with non-ototoxic chemotherapy|"patient ineligible for chemotherapy with cisplatin:~* exclusive radiotherapy: 60-70 Gy in 30-35 fractions~* radiotherapy with a non-ototoxic chemotherapy (due to contraindication to cisplatin): 60-70 Gy in 30-35 fractions"
62602851|NCT00691899|EXPERIMENTAL|1|
62602852|NCT00691899|PLACEBO_COMPARATOR|2|
62602853|NCT06090097|EXPERIMENTAL|KneeBRIGHT Group|The interventional group will conduct all exercises during the 10-week therapy regimen using the KneeBRIGHT electromyogram sensors and game software.
62602854|NCT06090097|ACTIVE_COMPARATOR|Control Group|The control group will conduct all exercises following a standard physical therapy regimen.
62602855|NCT05862883|EXPERIMENTAL|Target group|201 children 6-18 years old with mild to moderate COVID-19, who were taking Rutan.
62602856|NCT05862883|OTHER|control group|100 children 6-18 years old with mild to moderate COVID-19, who were not taking Rutan.
62602857|NCT05900089|EXPERIMENTAL|SHR0302 Group A|
62602858|NCT05900089|EXPERIMENTAL|SHR0302 Group B|
62602859|NCT05900089|EXPERIMENTAL|SHR0302 Group C|
62602860|NCT03357575|EXPERIMENTAL|Mesenchymal Stem Cells from adipose|Mesenchymal Stem Cells from adipose will be injected.
62602861|NCT03357575|ACTIVE_COMPARATOR|hyaluronic acid|Hyaluronic acid will be injectied.
62602862|NCT00648934|EXPERIMENTAL|1|Topiramate Sprinkle Capsules 25 mg
62602863|NCT00648934|ACTIVE_COMPARATOR|2|Topamax® Sprinkle Capsules 25 mg
62602864|NCT00379808|PLACEBO_COMPARATOR|Placebo|1 lactose-containing capsule daily for 1 month
62602865|NCT00379808|ACTIVE_COMPARATOR|Montelukast 10 mg|1 montelukast 10 mg tablet (masked by capsule) daily for 1 month
62602866|NCT01834716|EXPERIMENTAL|Aerobics exercise|Participants in this group will be randomized to aerobics exercise (the equivalent of walking briskly for 50 minutes three times per week).
62602867|NCT01834716|EXPERIMENTAL|Non-Aerobics Exercise|Participants in this group will be randomized to a non-aerobics (attending classes of toning and stretching a minimum of three times per week) exercise group.
62602868|NCT02071810|EXPERIMENTAL|BIA 9-1067 5 mg|BIA 9-1067 (OPC, Opicapone) 5 mg
62043584|NCT04823260|PLACEBO_COMPARATOR|Arm F = Placebo 900 mg (n=06)|Subjects who are assigned to 900 mg arm (Placebo) will be instructed to take 6 capsules after breakfast once a day with ambient temperature water for 60 days.
62043585|NCT03407794|NO_INTERVENTION|Control|Participants randomized into the control group will be asked to follow their usual diet during the 6 weeks of the intervention.
62043586|NCT03407794|EXPERIMENTAL|Fermented vegetable|Participants randomized into the fermented vegetable group will receive 1/2 cup per day of fermented vegetables, including cabbage, carrots or pickles, for 6 weeks.
62246172|NCT02370680|EXPERIMENTAL|Durlaza™, 2 capsules|in a rollover with 10 subjects from the first arm, an aspirin run-in, followed by Durlaza™, two capsules QD, for 14 ± 4 days and an in-patient visit
62043587|NCT03407794|ACTIVE_COMPARATOR|Non-fermented vegetable|Participants randomized into the non-fermented vegetable group will receive 1/2 cup per day of non-fermented vegetables, including cabbage, carrots or pickles, for 6 weeks.
62043588|NCT01636180|EXPERIMENTAL|Clopidogrel - Repeated Loading Dose|repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
62246173|NCT04961853|EXPERIMENTAL|Cases|
62246174|NCT00749879|EXPERIMENTAL|25 mg AMCC fed|"25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose~Fed State"
62246175|NCT00749879|EXPERIMENTAL|25 mg AMCC fasting|"25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose~Fasting State"
62246176|NCT00749879|EXPERIMENTAL|50 mg AMCC fed|"2, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose~Fed State"
62602869|NCT02071810|EXPERIMENTAL|BIA 9-1067 10 mg|BIA 9-1067 (OPC, Opicapone) 10 mg
62602870|NCT02071810|EXPERIMENTAL|BIA 9-1067 20 mg|BIA 9-1067 (OPC, Opicapone) 20 mg
62602871|NCT02071810|EXPERIMENTAL|BIA 9-1067 30 mg|BIA 9-1067 (OPC, Opicapone) 30 mg
62602872|NCT02071810|EXPERIMENTAL|Placebo|Placebo, PLC
62602873|NCT05375344|ACTIVE_COMPARATOR|Exercise Group|Participants in this group will participate in the home-based exercise group intervention that consists of general balance and strength training, bladder training and urge suppression, and home hazard assessments.
62602874|NCT05375344|NO_INTERVENTION|Control Group|Participants in this group will receive informational booklets on fall prevention and behavioral treatment for Urgency Incontinence.
62602875|NCT04814316||Study group|Patients with gastroesophageal reflux or gastroesophageal reflux disease who will use lansoprazole.
62602876|NCT04814316||Control group|Healty volunteers who will not use lansoprazole.
62602877|NCT03124121|OTHER|Induction cohort|Golimumab induction therapy
62602878|NCT03124121|OTHER|Maintenance cohort|Golimumab maintenance therapy
62602879|NCT05680506|EXPERIMENTAL|Pain neuroscience education group|Pain neuroscience education 10- 15min Hot pack(10 min) TENS Kaltenborn Moilization technique at L4-L5 segment stretchings and stabilization exercises. (5 reps/1 set) Total duration:40 min/session
62602880|NCT05680506|ACTIVE_COMPARATOR|Standard therapy group|Hot pack(10 min) TENS Kaltenborn Mobilization technique at L4-L5 segment stretchings and stabilization exercises (5 reps /1 set) Total duration:30 min/session
62602881|NCT05210101|OTHER|Sotrovimab|Two intravenous (IV) doses of sotrovimab were be administered in total - the first on Treatment Day 1 (500mg) and the second on Treatment Day 2, approximately 8-14 weeks after the first dose, at a higher 2000mg dose, in light of the reduced antiviral susceptibility of the BA.2 subvariant to sotrovimab, with the dosing interval determined by theoretical modeling of the duration of efficacy of sotrovimab as antiviral prophylaxis based on the rising prevalence of the Omicron BA.2 subvariant.
62602882|NCT03409900|EXPERIMENTAL|LPB Unilateral DAA THA|Patients will be randomized to receive either a LPB or QLB for post-operative analgesia. Randomization to either LPB or QLB will occur via block randomization using sealed sequentially numbered opaque envelopes that will correspond to the order with which patients are enrolled. Patients and research assistants will be blinded to their randomization by administration of intravenous sedation (titrated to patient comfort), utilization of ultrasonography to visualize pertinent structures for both blocks, and by the nature of the block technique themselves both being in close proximity on the posterior lower back.
62602883|NCT03409900|EXPERIMENTAL|QLB Unilateral DAA THA|Patients will be randomized to receive either a LPB or QLB for post-operative analgesia. Randomization to either LPB or QLB will occur via block randomization using sealed sequentially numbered opaque envelopes that will correspond to the order with which patients are enrolled. Patients and research assistants will be blinded to their randomization by administration of intravenous sedation (titrated to patient comfort), utilization of ultrasonography to visualize pertinent structures for both blocks, and by the nature of the block technique themselves both being in close proximity on the posterior lower back.
62602884|NCT01491126||examinees undergoing bidirectional endoscopy|Study population will include sequential examinees undergoing bidirectional endoscopy, age\> 18 years
62602885|NCT03840148|EXPERIMENTAL|Cefepime/VNRX-5133 (taniborbactam)|Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period.
62824946|NCT06244628|EXPERIMENTAL|Iguratimod|Oral administration of Iguratimod, 25mg twice daily.
62824947|NCT05511415|ACTIVE_COMPARATOR|Dexmedetomidine|The myometrial samples are bathed in increasing concentrations of dexmedetomidine (from 10 -9M to 10 -4M).
62246177|NCT00749879|EXPERIMENTAL|50 mg AMCC fasting|"2, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose~Fasting State"
62246178|NCT00749879|EXPERIMENTAL|50 mg SMCC fasting|"2, 25 mg Proellex capsules formulated with SMCC microcrystalline cellulose~Fasting State"
62246179|NCT01614821|EXPERIMENTAL|Treatment Arm|PCI-32765; ibrutinib
62246180|NCT04906616|NO_INTERVENTION|Control Comparison|Standard of care, e.g. regular HIV care plus brief advice on alcohol use
62246181|NCT04906616|EXPERIMENTAL|Mlambe Intervention|A couples-based intervention to reduce problematic drinking and improve economic and HIV outcomes.
62246182|NCT02742467|EXPERIMENTAL|1|Perindopril plus Amlodipine at a dose of 4mg/5mg once daily for two months and 8mg/10mg once daily for the remaining four months.
62436569|NCT03911609|EXPERIMENTAL|Isometric (Static) Exercise|Subjects will perform isometric (static) handgrip exercise at submaximal intensity for four minutes. The exercise will be performed while the subject is seated, and the elbow bent at around 90° and unsupported. Subjects will be asked to rate their pain using numerical pain rating scale that ranges from 0 (no pain) to 10 (worst pain), perceived exertion (RPE) from 0 (Nothing at all) to 10 (extremely strong), and perceived stress from 0 (not stressed at all) to 10 (extremely stressed). The ratings of pain intensity, RPE and perceived stress will be provided before, at the middle and at the end of the exercise.
62436570|NCT03911609|EXPERIMENTAL|Cognitive Task|The mental math task, which is also known as serial subtraction test, will be performed for four minutes. Subjects will be asked to rate their pain intensity and perceived stress before, at the middle and at the end of the mental math task.
62436571|NCT06503341||Adult patients|Adult patients with or without cardiovascular diseases.
62436572|NCT02758366|EXPERIMENTAL|Doxorubicin|"Patients are treated with Weller-Stupp protocol: initial radiotherapy (1.8 Gy/die, days 1-5; total dose 54-60 Gy) with concomitant oral temozolomide (75mg/m2/die, days 1-7) per 6 weeks.~At week 10 (4 weeks after the chemo-radiotherapy treatment completion): 1 cycle of oral temozolomide (150-180 mg/m2, days 1-5)~At week 14 (8 weeks after the chemo-radiotherapy treatment completion) 1 cycle of prolonged infusion of Doxorubicin (25mg/m2/die in 24 hours, days 1-4; total cumulative dose 100 mg/m2).~At week 18 (4 weeks after the end of doxorubicin administration): 16 cycles of oral temozolomide (initial dose of 150 mg/m2 increasing to 180 mg/m2 days 1-5, 28-day cycle).~Oral valproic acid (20-30 mg/Kg/die bid) is administered from week 1 until the last treatment day."
62602886|NCT03840148|ACTIVE_COMPARATOR|Meropenem|Meropenem will be administered q8h IV over 30 minutes.
62246183|NCT02742467|ACTIVE_COMPARATOR|2|Perindopril Plus Hydrochlorothiazide at a dose of 4mg/12.5mg and 8mg/25mg once daily for the remaining four months.
62602887|NCT03265548|NO_INTERVENTION|Standard|Usual Direct view laryngoscopy
62602888|NCT03265548|EXPERIMENTAL|Intervention|Video laryngoscopy
62246184|NCT02742467|ACTIVE_COMPARATOR|3|Amlodipine plus Hydrochlorothiazide 5mg/12.5mg for two months and 10mg/25mg for the remaining four months.
62602889|NCT00980174|PLACEBO_COMPARATOR|2|Subjects will receive placebo for denosumab (SC injection every 6 months) for 1 year (double-blind phase) followed by 60 mg denosumab (SC injection every 6 months) for 1 year (open-label phase)
62824948|NCT05511415|ACTIVE_COMPARATOR|Oxytocin|The myometrial samples are bathed in oxytocin 20nM.
62824949|NCT05511415|ACTIVE_COMPARATOR|Dexmedetomidine + Oxytocin|The myometrial samples are bathed in oxytocin at 20nM along with dexmedetomidine (10-9M to 10-4M).
62824950|NCT05511415|ACTIVE_COMPARATOR|Oxytocin pre-treatment followed by Dexmedetomidine|The myometrial samples are pre-treated with oxytocin (10-5M) for 2 hours, and then in increasing concentrations of dexmedetomidine (from 10 -9M to 10 -4M).
62824951|NCT05511415|ACTIVE_COMPARATOR|Oxytocin pre-treatment followed by Oxytocin|The myometrial samples are pre-treated with oxytocin (10-5M) for 2 hours, and then bathed in oxytocin at 20nM.
62824952|NCT05511415|ACTIVE_COMPARATOR|Oxytocin pre-treatment followed by Dexmedetomidine + Oxytocin|The myometrial samples are pre-treated with oxytocin (10-5M) for 2 hours, and then bathed in oxytocin at 20nM along with dexmedetomidine (10-9M to 10-4M)
62824953|NCT06118021|EXPERIMENTAL|HS-20094 5mg|Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.
62824954|NCT06118021|EXPERIMENTAL|HS-20094 10mg|Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.
62824955|NCT06118021|EXPERIMENTAL|HS-20094 15mg|Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.
62043589|NCT01636180|ACTIVE_COMPARATOR|Clopidogrel - standard of care|no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
62246185|NCT03859726||Compliance group|6hLC≥10% NIRS Sublingual microcirculation
62246186|NCT03859726||Non compliance group|6hLC\<10%
62436573|NCT02447484|EXPERIMENTAL|Mujer Segura Siempre|Twice-daily safer-sex and safer-drug-use text messages, 5 days per week, for 24 months. Text message content based on 8 different constructs of behavior-maintenance theory and tailored to specific preferences and motivators provided by participant.
62436574|NCT02447484|ACTIVE_COMPARATOR|General Health Message Texts|Twice-daily text messages, 5 days per week, for 24 months. Text message content centered on general health promotion, including getting regular medical checkups and maintaining good dietary and exercise habits.
62436575|NCT04449159|PLACEBO_COMPARATOR|Placebo|
62436576|NCT04449159|EXPERIMENTAL|Vinh Wellness Collagen|
62436577|NCT03754816|EXPERIMENTAL|Experimental group|The combination of PECS II and parasternal block performed by injecting Levobupivacaine 0.375% 40 ml, injected between minor and major pectoralis muscles, between minor and serratus muscles and between major and intercostal muscles
62436578|NCT01681771|EXPERIMENTAL|Cogntive behaviour therapy|Internet based Cognitive behaviour therapy during 9 weeks
62436579|NCT01681771|ACTIVE_COMPARATOR|Discussion group|Internet moderated discussion group during 9 weeks
62436580|NCT02960815|ACTIVE_COMPARATOR|Intramuscular vaccine|The control intervention consists in the administration of the standard intramuscular influenza vaccine (Mutagrip®), containing 15 μg of each of the three viral strains without imiquimod.
62436581|NCT02960815|EXPERIMENTAL|Imiquimod and intradermal vaccine|In the imiquimod and intradermal vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intradermal influenza vaccine preparations containing 15 μg of each of the three viral strains (Intanza®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.
62436582|NCT02960815|EXPERIMENTAL|Imiquimod and intramuscular vaccine|In the imiquimod and intramuscular vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intramuscular influenza vaccine preparations containing 15 μg of each of the three viral strains (Mutagrip®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.
62436583|NCT04412499||Methylphenidate + parent-training programm|Methylphenidate and participation in a parent-training programme
62436584|NCT04412499||Methylphenidate alone|Methylphenidate alone
62436585|NCT04976868||Pimecrolimus Cream 1% - Elidel®|Elidel® as prescribed within routine clinical practice
62436586|NCT04078919|ACTIVE_COMPARATOR|Low calorie diets with nuts|Low calorie diet in which 20 percent of daily calories will be provided from nuts
62043590|NCT05875948|EXPERIMENTAL|An Open-Label Safety Run-In Part|"Three initial cohorts (Cohort 1, N=3 patients, Cohorts 2 and 3, N=6 patients, each) will be treated with an open-label combination of terlipressin and R2R01 to ascertain the safety of the combination therapy.~A Safety Review Committee (SRC) will review the safety of Cohort 1 patients based on the adverse events and laboratory abnormalities up until Day 14, prior to the start of recruitment of Cohort 2 patients, as well as the safety of Cohorts 1 and 2 patients up until Day 14 prior to the start of recruitment of Cohort 3 patients.~Data from all Cohorts 1, 2, and 3 patients up until Day 14 will be reviewed by the SRC before starting the randomized part of the study (Cohorts 4 and 5), so that the SRC can decide and confirm the most appropriate R2R01 dose schedule for patients in Cohorts 4 and 5. Patients enrolled in Cohorts 1, 2, or 3 will remain in their Cohort until study completion (Day 90) or study discontinuation."
62246187|NCT06735898||Group 1|Basic therapy + Cytoflavin® intravenous solution in the volume of 20 ml per day IV drip in dilution on 100-200 ml of 5-10% dextrose solution or 0.9% sodium chloride solution during 10 days, transition to Cytoflavin® tablets from the next day after the end of intravenous administration during the next 75 days according to the instructions for medical use
62246188|NCT06735898||Group 2|Basic therapy, according to clinical guidelines (clinical practice established within the center) for the treatment of patients in stages 2-3 of rehabilitation.
62246189|NCT05731570|EXPERIMENTAL|Intervention|cognitive rehabilitation programme. 1h session per week x 10 weeks
62246190|NCT05731570|NO_INTERVENTION|Control|The control group receives treatment as usual, this is, participants will carry on with the care they were receiving prior to entry in the study.
62246191|NCT05184998||Hypokalemia group|defined as sK range (0, 3.5\] mmo/L
62246192|NCT05184998||Normokalemia group|defined as sK range (3.5, 5.0\] mmo/L
62246193|NCT05184998||Hyperkalemia group|defined as sK range (5.0, \~) mmo/L
62246194|NCT00727649|ACTIVE_COMPARATOR|Arm 1|Fiber (psyllium) powder
62436587|NCT04078919|PLACEBO_COMPARATOR|Low calorie diet|Low calorie diet
62436588|NCT00863057|EXPERIMENTAL|1|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine and methadone placebo, (Period 2, Weeks 6 to 9) duloxetine placebo and methadone, (Period 3, Weeks 11 to 14) duloxetine and methadone, (Period 4, Weeks 16 to 19) duloxetine placebo and methadone placebo
62436589|NCT00863057|EXPERIMENTAL|2|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine placebo and methadone, (Period 2, Weeks 6 to 9) duloxetine placebo and methadone placebo, (Period 3, Weeks 11 to 14) duloxetine and methadone placebo, (Period 4, Weeks 16 to 19) duloxetine and methadone
62602890|NCT00980174|EXPERIMENTAL|1|60 mg denosumab (SC injection every 6 months) for 1 year (double-blind phase) followed by 60 mg denosumab(SC injection every 6 months) for 1 year (open-label phase). These subjects will be on denosumab for a total of 2 years.
62602891|NCT05596500|EXPERIMENTAL|Blueberry-protein gel|Blueberry polyphenols (1 cup fresh blueberries equivalent) from extract with 20 grams rice-pea protein in a gel.
62246195|NCT00727649|ACTIVE_COMPARATOR|Arm 2|Loperamide
62602892|NCT05596500|ACTIVE_COMPARATOR|Blueberry gel|Blueberry polyphenols (1 cup fresh blueberries equivalent) from extract in a gel.
62043591|NCT05875948|PLACEBO_COMPARATOR|Single-blind Placebo-controlled Randomized period|"After conclusion of the open-label safety run-in part, and after the SRC has determined the appropriate R2R01 dose schedule, approximately 80 patients will receive terlipressin and be randomized 1:1 to either R2R01 (Cohort 4) or placebo (Cohort 5).~At randomization, patients will be stratified by the presence of systemic inflammatory response syndrome (SIRS), since patients with SIRS have shown a better response to terlipressin than patients without SIRS."
62436590|NCT00863057|EXPERIMENTAL|3|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine and methadone, (Period 2, Weeks 6 to 9) duloxetine and methadone placebo, (Period 3, Weeks 11 to 14) duloxetine placebo and methadone placebo, (Period 4, Weeks 16 to 19) duloxetine placebo and methadone
62602893|NCT05596500|PLACEBO_COMPARATOR|Placebo|All proximate matched ingredients except for the blueberry polyphenols and plant protein.
62602894|NCT04932746|EXPERIMENTAL|The dexmedetomidine group:|"An initial dose of 1 mcg / kg 1 dexmedetomidine will be given 10 minutes after the start of anesthesia infusion within 10 minutes, after which the dexmedetomidine infusion is maintained at a dose of 0.4 mcg / kg / hour.~The injection will be stopped before the skin is closed."
62602895|NCT04932746|EXPERIMENTAL|The Placebo group (the control group):|After the same anesthesia, the same amount of Saline solution will be administered, instead of dexmedetomidine, with the same protocol.
62602896|NCT00497848|ACTIVE_COMPARATOR|motivational interviewing|
62602897|NCT00497848|EXPERIMENTAL|The System Orientated Intervention|
62602898|NCT02319720|EXPERIMENTAL|BMA/Cultured Bone Marrow Cells|The subjects in this arm will have fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken. Part of the aspirate will be cultured. Up to three applications of cultured cells will be applied to the wound following the bone marrow biopsy. A single treatment cycle will consist of one application of a freshly obtained bone marrow aspirate and up to three applications of cultured cells derived from that aspirate. If the wound has not healed, up to three additional treatment cycles may be performed. Each bone marrow biopsy will be followed by direct application of fresh bone marrow to the wound and up to three applications of cultured cells (prepared from the most recent bone marrow biopsy).
62043592|NCT05875948|EXPERIMENTAL|An Open-Label Terlipressin Non-Responder Cohort|In Cohort 5, if patients do not respond to terlipressin, they must discontinue Cohort 5. After discontinuation, they will be allowed to enter Cohort 6 (Terlipressin Non-Responder Part) to receive R2R01 with the same dosing and schedule as that for Cohort 4. No patient from any Cohort other than Cohort 5 will be allowed to enter Cohort 6.
62043593|NCT03065868|EXPERIMENTAL|eradictaion|H. pylori eradication group
62824956|NCT06118021|EXPERIMENTAL|HS-20094 20mg|Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.
62043594|NCT03065868|NO_INTERVENTION|non-eradication|H. pylori non-eradication group
62436591|NCT00863057|EXPERIMENTAL|4|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine placebo and methadone placebo, (Period 2, Weeks 6 to 9) duloxetine and methadone, (Period 3, Weeks 11 to 14) duloxetine placebo and methadone, (Period 4, Weeks 16 to 19) duloxetine and methadone placebo
62824957|NCT04398433|EXPERIMENTAL|INO-3107|Participants will be administered one INO-3107 intramuscular (IM) injection followed by electroporation (EP) using CELLECTRA™ 2000 at Day 0, Week 3, Week 6, and Week 9.
62824958|NCT06589232||Food allergy|Threshold dose to pistachio
62043595|NCT06017219|EXPERIMENTAL|within subject control 20mg|spermidine
62043596|NCT06017219|EXPERIMENTAL|within subject control 40mg|spermidine
62043597|NCT06338319|EXPERIMENTAL|BOOST Program|"Parents in the BOOST Program group will receive books to read with their children and send smartphone video recordings of their reading interactions.~To provide support, parents will participate in 3 remote, parent-focused book-sharing intervention sessions"
62824959|NCT05979883|OTHER|Arm A: Standard of care (SOC) treatment planning|Patients randomized to the SOC treatment planning arm will receive a treatment planning computed tomography (CT) scan followed by dosimetric planning with a medical dosimetrist; and the plan will be reviewed by a medical physicist and radiation oncologist. This is the current standard practice for all radiation oncology patients.
62824960|NCT05979883|ACTIVE_COMPARATOR|Arm B: Machine Learning Assisted Planning (MLAP)|Patients randomized to the MLAP arm will receive a treatment planning scan followed by MLAP through the RapidPlan module produced by Varian. Of note, RapidPlan is an FDA cleared module with treatment planning being the approved usage for the program. The RapidPlan module has site specific treatment packages for different disease sites. These separate disease specific packages have different capabilities. For example, the Head and Neck package currently audits dosimetrist-generated plans for possible improvements. The MLAP arm of the trial will leverage the RapidPlan module's full capabilities upwards to the FDA-approved usage.
62824961|NCT05766800|EXPERIMENTAL|Downstaged arm with surgical treatment|In this arm, patients with tumors resectable after chemoimmunotherapy will receive surgical treatment in department of thoracic surgery.
62824962|NCT05766800|ACTIVE_COMPARATOR|Downstaged arm with radiotherapy|In this arm, patients with tumors resectable after chemoimmunotherapy will receive radiotherapy in department of medical oncology.
62824963|NCT05766800|OTHER|Unresectable arm|In this arm, patients with tumors still unresectable after chemoimmunotherapy will receive therapy in department of medical oncology.
62824964|NCT06589856|PLACEBO_COMPARATOR|CTR|
62824965|NCT06589856|EXPERIMENTAL|LAC5|
62824966|NCT06589856|EXPERIMENTAL|LAC10|
62824967|NCT06589856|EXPERIMENTAL|LAC20|
62824968|NCT05572255|EXPERIMENTAL|Treatment A (Reference)|An intact 200 mg cenobamate tablet administered orally.
62824969|NCT05572255|EXPERIMENTAL|Treatment B (Test 1)|A crushed 200 mg cenobamate tablet in suspension administrated orally.
62824970|NCT05572255|EXPERIMENTAL|Treatment C (Test 2)|A crushed 200 mg cenobamate tablet in suspension administered via an NG tube
62824971|NCT04050358|ACTIVE_COMPARATOR|1X dose of NRPT|
62436592|NCT00006721|ACTIVE_COMPARATOR|Arm I (CHOP only)|"Patients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day~1. Patients also receive oral prednisone daily on days 1-5. Treatment continues every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. (Arm I closed to accrual as of 12/15/02)"
62436593|NCT00006721|EXPERIMENTAL|Arm II (CHOP + rituximab)|Patients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on days 8, 29, 50, 71, 92, and 113. Patients also receive oral prednisone daily on days 8-12, 29-33, 50-54, 71-75, and 113-117 and rituximab IV over 4-6 hours on days 1, 6, 48, 90, 134, and 141.
62602899|NCT02319720|EXPERIMENTAL|Cultured Bone Marrow Cells|In this group, the bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound. Up to three applications of cultured cells will be applied to the wound following the bone marrow biopsy. A single treatment cycle will consist of up to three applications of cultured cells derived from a single bone marrow aspiration. If the wound has not healed, up to three additional treatment cycles may be performed. Each bone marrow biopsy will be followed by up to three applications of cultured cells (prepared from the most recent bone marrow biopsy).
62602900|NCT02319720|EXPERIMENTAL|Bone Marrow Aspirate|The subjects in this group will have fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken. A single treatment cycle will consist of one application of a freshly obtained bone marrow aspirate. If the wound has not healed, up to three additional bone marrow biopsies may be performed. If the wound heals at any point during this protocol, no additional bone marrow biopsy procedures will be performed and no additional cells will be applied.
62602901|NCT02319720|ACTIVE_COMPARATOR|Control|In this arm, subjects will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressing and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
62602902|NCT05449938|EXPERIMENTAL|Thick periodontal phenotype|Stage II and stage III periodontitis Patient with thick periodontal phenotype will be enrolled using probe transparency method .
62602903|NCT05449938|ACTIVE_COMPARATOR|Thin periodontal phenotype|Stage II and stage III periodontitis Patient with thin periodontal phenotype will be enrolled using probe transparency method.
62602904|NCT01200732|ACTIVE_COMPARATOR|Tadalafil|
62824972|NCT04050358|PLACEBO_COMPARATOR|Placebo|
62043598|NCT06338319|NO_INTERVENTION|Standard of Care Comparison Group|"Parents in the Standard of Care Comparison Group will receive books to read with their children and send smartphone video recordings of their reading interactions.~Parents in the comparison group will not participate in BOOST intervention sessions."
62436594|NCT00006721|EXPERIMENTAL|Arm III (CHOP + tositumomab)|Patients receive chemotherapy as in arm I and tositumomab (monoclonal antibody anti-B1) IV over 1 hour followed by iodine I 131 tositumomab IV over 20 minutes on days 134 and 141.
62602905|NCT01200732|PLACEBO_COMPARATOR|placebo|
62602906|NCT01966419|ACTIVE_COMPARATOR|Ornithine phenylacetate|Participants receive ornithine phenylacetate for up to 5 days via continuous IV infusion in addition to standard of care (SOC)
62602907|NCT01966419|PLACEBO_COMPARATOR|Placebo|Participants receive matching placebo up to 5 days via continuous IV infusion in addition to SOC
62602908|NCT01103102|ACTIVE_COMPARATOR|Lowest Dose|
62602909|NCT01103102|ACTIVE_COMPARATOR|Intermediate Dose|
62602910|NCT01103102|ACTIVE_COMPARATOR|Highest Dose|
62602911|NCT01103102|PLACEBO_COMPARATOR|Placebo Control|
62602912|NCT06402591|NO_INTERVENTION|single dose cefazolin prophylaxis|prophylaxis according current guidelines single dose 2000mg cefazolin 15-30 minutes before incision
62602913|NCT06402591|EXPERIMENTAL|extended cefazolin prophylaxis|5 days of cefazolin prophylaxis start dose 2000mg followed by 14 doses of 1000mg
62824973|NCT05227196|EXPERIMENTAL|Group 1 Sequence 1|Crossover arm
62043599|NCT00696748|ACTIVE_COMPARATOR|1|Men receiving Nebido
62436595|NCT02967133|ACTIVE_COMPARATOR|Arm A|Nivolumab q 14 days until disease progression/toxicity
62436596|NCT02967133|ACTIVE_COMPARATOR|Arm B|"Nivolumab every 21 days until disease progression~Nab-paclitaxel every 21 days"
62602914|NCT00718380|EXPERIMENTAL|Group 1|Dose escalation from Open label 0.05 to 0.25 mg/kg once a day dosing for 21 days
62602915|NCT00718380|EXPERIMENTAL|Group 2|Open label 0.10 mg/kg once a day dosing after safety evolution of Group 1
62602916|NCT00718380|EXPERIMENTAL|Group 3|Open label 0.20 mg/kg once a day dosing after safety evolution of Group 2
62602917|NCT00718380|EXPERIMENTAL|Group 4|Open label 0.25 mg/kg once a day dosing after safety evolution of Group 3
62602918|NCT01819753|ACTIVE_COMPARATOR|Single access|It was performed only single access standard PCNL in this group.
62602919|NCT01819753|ACTIVE_COMPARATOR|Multiple access|It was performed multiple access standard PCNL in this group
62602920|NCT06119334|EXPERIMENTAL|Experimental|Sixteen weeks of phone-based counselling at a rate of 1 session/week and ongoing access to a online platform (Nex J Connected Wellness) that has health promotion text and videos readily accessed in combination with text messaging exchanges between counselor and participant. Participants receive a Fitbit which is connected to the Nex J Connected Wellness such that counselors can monitor steps/day.
62602921|NCT06119334|NO_INTERVENTION|Wait list control|Participants wait for 16 weeks.
62824974|NCT05227196|EXPERIMENTAL|Group 1 Sequence 2|Crossover arm
62824975|NCT05227196|EXPERIMENTAL|Group 2 Sequence 1|Crossover arm
62824976|NCT05227196|EXPERIMENTAL|Group 2 Sequence 2|Crossover arm
62824977|NCT05227196|EXPERIMENTAL|Group 3 Sequence 1|Crossover arm
62824978|NCT05227196|EXPERIMENTAL|Group 3 Sequence 2|Crossover arm
62824979|NCT03844750|EXPERIMENTAL|Treatment (vactosertib, pembrolizumab, surgery)|Neoadjuvant pembrolizumab will be administered at a fixed dose of 200 mg (IV) for 1 cycle plus 200 mg vactosertib (PO QD, 5 days per week x 2 weeks). Adjuvant pembrolizumab (400 mg IV) + vactosertib (200 mg PO QD Cycle 1, 5 days per week, Cycles 2 and beyond (200 mg BID, 5 days per week) will be administered for up to eight 6-week cycles
62246196|NCT06091761|EXPERIMENTAL|AA + TEA|Auricular acupuncture (AA) every week in eight weeks (eight sessions). Combined with Thread embedding acupuncture (TEA) every two weeks in eight weeks (four sessions).
62246197|NCT06091761|SHAM_COMPARATOR|AA + Sham-TEA|Auricular acupuncture (AA) every week in eight weeks (eight sessions). Combined with Sham Thread embedding acupuncture (Sham-TEA) every two weeks in eight weeks (four sessions).
62246198|NCT00390611|ACTIVE_COMPARATOR|Paclitaxel/Carboplatin/Sorafenib|Paclitaxel 175 mg/m2 1-3 hour IV infusion, Day 1 Carboplatin AUC 6 infused over 20 minutes IV, Day 1 Sorafenib 400mg PO bid
62246199|NCT00390611|ACTIVE_COMPARATOR|Paclitaxel/carboplatin|Paclitaxel 175 mg/m2 1-3 hour IV infusion, Day 1 Carboplatin AUC 6 infused over 20 minutes IV
62246200|NCT02992314|EXPERIMENTAL|Metaqil™ Oral Rinse|"In this arm the test article, Metaqil ™ oral rinse, a proprietary formulation of agents including Monk fruit extract, which can minimize the metallic taste in the mouth caused by the patient's medications.~Subjects rinse twice a day with 10 mL of the oral rinse for 30 seconds for 30 days.~They will note, in the daily oral hygiene diary, the date and time of brushing and rinsing."
62246201|NCT02992314|PLACEBO_COMPARATOR|Placebo Oral Rinse|This arm will use a placebo with out the active ingredients same way the experimental arm do.
62436597|NCT01072032|EXPERIMENTAL|Low-Reward|Low-Reward Anklebot training Group: The low reward-feedback group receives the Anklebot training with only immediate feedback on target successes, without cumulative scores and with minimal social interaction with the research team.
62436598|NCT01072032|ACTIVE_COMPARATOR|High-Reward|High-Reward Anklebot training Group: The high-reward group receives cumulative scores and abundant social interaction and are eligible for prizes during each training session and at completion of the study
62602922|NCT03344965|EXPERIMENTAL|OLAPARIB QD GERMLINE MUTATION|"After the screening procedures confirm eligibility to participate in the research study:~* Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~* Tumor measurement q6 weeks x 24 weeks, then q 12 weeks"
62824980|NCT06598527|EXPERIMENTAL|neoadjuvant SBRT combined with immunochemotherapy|Following admission, intrapulmonary primary stereotactic body radiotherapy (SBRT) was administered at a dosage of 24 Gy across three fractions. Subsequently, within seven days of completing SBRT, two cycles of Tislelizumab in combination with a platinum-based double-agent chemotherapy regimen were initiated. These cycles were repeated every three weeks. Surgical intervention was scheduled to occur 4-6 weeks (±7 days) after the completion of the second chemotherapy cycle
62824981|NCT06598527|ACTIVE_COMPARATOR|neoadjuvant immunochemotherapy|Three cycles of Tislelizumab in conjunction with platinum-based chemotherapy were administered at three-week intervals. Surgical intervention was subsequently scheduled to occur within 4 to 6 weeks (±7 days) following the completion of the third chemotherapy cycle.
62824982|NCT05814666|EXPERIMENTAL|Danvatirsen plus pembrolizumab|"Danvatirsen dosing:~Week 1: Danvatirsen intravenously (IV) on Days 1, 3, and 5~Week 2 and subsequent weeks: Danvatirsen IV weekly~Pembrolizumab dosing:~Pembrolizumab every 3 weeks after the Danvatirsen dose."
62824983|NCT05814666|ACTIVE_COMPARATOR|Pembrolizumab|Pembrolizumab IV every 3 weeks after the Danvatirsen dose.
62824984|NCT06409533|EXPERIMENTAL|Strict Rate Control|Physicians will aim for a resting heart rate of 60 to 80 beats per minute, as recorded by a 12-lead resting ECG after the patient has rested for 15 minutes, with the measurement taken over a one-minute period.
62824985|NCT06409533|ACTIVE_COMPARATOR|Lenient Rate Control|Physicians will aim for a resting heart rate of 81 to 110 beats per minute, as recorded by a 12-lead resting ECG after the patient has rested for 15 minutes, with the measurement taken over a one-minute period.
62824986|NCT05569408||EVUSHELD Arm|Individuals given EVUSHELD for prophylaxis
62824987|NCT05569408||Concurrent Control Arms|Individuals eligible for Evusheld prophylaxis but did not receive EVUSHELD
62824988|NCT06117605|NO_INTERVENTION|No alert|Participants will receive no physician alert or registered nurse (RN) alert.
62824989|NCT06117605|EXPERIMENTAL|Nurse alert|Participants will receive RN alert.
62824990|NCT06117605|EXPERIMENTAL|Prescribing clinician alert|Participants will receive physician alert.
62043600|NCT00696748|PLACEBO_COMPARATOR|2|Men receiving Placebo
62043601|NCT00789438||General Anesthesia|Patients undergoing short-term surgery (30-90 min) under general anesthesia
62043602|NCT00789438||Spinal|Patients undergoing short-term surgery (30-90 min) under spinal anesthesia
62824991|NCT06117605|EXPERIMENTAL|Nurse alert and prescribing clinician alert|Participants will receive physician alert and RN alert.
62824992|NCT04097938|EXPERIMENTAL|GLPG3667 SAD|Single doses of GLPG3667 at up to 6 dose levels in ascending order
62043603|NCT00789438||Spinal + Sedation|Patients undergoing short-term surgery (30-90 min) under spinal anesthesia with sedation
62043604|NCT01444222||Pulmonary Hypertension|
62043605|NCT01444222||pulmonic valve stenosis|
62824993|NCT04097938|PLACEBO_COMPARATOR|Placebo SAD|Single doses of placebo
62824994|NCT04097938|EXPERIMENTAL|GLPG3667 MAD|Multiple doses of GLPG3667 at up to 3 dose levels in ascending order, daily for 13 days
62824995|NCT04097938|PLACEBO_COMPARATOR|Placebo MAD|Multiple doses of placebo
62824996|NCT04097938|EXPERIMENTAL|GLPG3667 FE fasted|Single dose of GLPG3667 in fasted state
62824997|NCT04097938|EXPERIMENTAL|GLPG3667 FE fed|Single dose of GLPG3667 in fed state
62824998|NCT04097938|EXPERIMENTAL|GLPG3667 oral suspension rBA-FE fed|Single dose of GLPG3667 oral suspension in fed state
62824999|NCT04097938|EXPERIMENTAL|GLPG3667 capsules rBA-FE fasted|Single dose of GLPG3667 capsules in fasted state
62825000|NCT04097938|EXPERIMENTAL|GLPG3667 capsules rBA-FE fed|Single dose of GLPG3667 capsules in fed state
62825001|NCT02854345|EXPERIMENTAL|Tomoscintigraphic parathyroid imaging on a CZT camera|Tomoscintigraphic parathyroid imaging on a CZT camera
62825002|NCT05360004|EXPERIMENTAL|CHM+Vc|Participants in CHM+VC group are required to consume vitamin C 1000mg/day and 1 sachet (9 g) of granules daily (1 hour after meal by dissolving 1 sachet of 9g granules in 150 ml of hot water and drink it orally) .
62825003|NCT05360004|PLACEBO_COMPARATOR|Vc|Participants will receive vitamin C 1000mg/day for 14 days
62825004|NCT04089748||Patients enrolled in VESPER study|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort
62602923|NCT03344965|EXPERIMENTAL|OLAPARIB QD GERMLINE MUTATION - EXPANSION|"After the screening procedures confirm eligibility to participate in the research study:~* Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~* Tumor measurement q6 weeks x 24 weeks, then q 12 weeks"
62602924|NCT03344965|EXPERIMENTAL|OLAPARIB QD SOMATIC MUTATION|"After the screening procedures confirm eligibility to participate in the research study:~* Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~* Tumor measurements q6 weeks x 24 weeks, then q 12 weeks"
62602925|NCT03344965|EXPERIMENTAL|OLAPARIB QD SOMATIC MUTATION - EXPANSION|"After the screening procedures confirm eligibility to participate in the research study:~* Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~* Tumor measurements q6 weeks x 24 weeks, then q 12 weeks"
62043606|NCT01444222||pulmonic valve homograft|
62246202|NCT01606020|ACTIVE_COMPARATOR|Sleep deprivation First|"First night D7 :~Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.~Second night D28 :~Overnight, the subjects stay in their homes. No intervention during this night."
62436599|NCT01670461|EXPERIMENTAL|FACE Advance Care Planning|FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
62436600|NCT01670461|OTHER|Standard of Care (SOC) Control|Standard of Care Control: Advance Directive Information Booklet plus Advance Directive Checklist.
62602926|NCT00751257|EXPERIMENTAL|1|2400mg N-acetylcysteine (1200mg b.i.d.) for 4 consecutive weeks
62602927|NCT00751257|PLACEBO_COMPARATOR|2|"Identically appearing placebo pills, packaged in an N-acetylcysteine slurry so that placebo will retain smell similar to active NAC capsules"
62602928|NCT01942499|OTHER|Community Exercise Group|Community-based exercise program for one year
62043607|NCT01444222||pulmonic valve insufficiency|
62246203|NCT01606020|ACTIVE_COMPARATOR|sleep deprivation second|"First night D7 :~Overnight, the subjects stay in their homes. No intervention during this night.~Second night D28 :~Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep."
62246204|NCT05997381|EXPERIMENTAL|BioBrace Augment Group|An arthroscopic rotator cuff repair is performed with the BioBrace Implant fixed on top of the repaired tendon using anchors.
62043608|NCT01444222||atrial septum defect|
62043609|NCT01444222||Ebstein's anomaly|
62043610|NCT01444222||transvalvular right ventricular lead|
62043611|NCT01444222||control|
62043612|NCT05695638||Intention-to-treat cohort|All patients included
62043613|NCT02144064|ACTIVE_COMPARATOR|Group A(heparin group)|Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
62246205|NCT05997381|SHAM_COMPARATOR|Repair Only Group|An arthroscopic rotator cuff repair is performed using standard surgical procedure.
62246206|NCT00955487|EXPERIMENTAL|Inhaled Nitric Oxide (iNO)|Participants will receive a low concentration of iNO until they are 30 weeks corrected gestational age or for 14 days if they were born at 29 weeks or more.
62246207|NCT00955487|PLACEBO_COMPARATOR|Nitrogen (placebo)|Participants will receive nitrogen (placebo) while in the hospital.
62246208|NCT01558427|EXPERIMENTAL|Active clinical surveillance|Active monitoring of patients with low volume metastases with Prostate Specific Antigen (PSA) and sequential imaging.
62246209|NCT01558427|EXPERIMENTAL|Salvage treatment of metastases|Surgical or radiotherapy treatment of metastases.
62246210|NCT06272292|EXPERIMENTAL|Symptomatic CAM-FAI patients|33 patients that exhibit symptomatic CAM-FAI on medical imaging (Alpha angle \>60) and have reduced hip internal rotation (IR\<15). All participants in this group will be males aged between 21 and 35 years old.
62246211|NCT06272292|EXPERIMENTAL|Asymptomatic CAM-FAI patients|33 healthy control that exhibit asymptomatic CAM on x-ray scans (Alpha angle \>60). All participants in this group will be males aged between 21 and 35 years old.
62246212|NCT06272292|EXPERIMENTAL|Healthy controls|33 healthy control that exhibit no symptoms or abnormal morphologies of the proximal femur (Alpha angle \>60 , IR\>15). All participants in this group will be males aged between 21 and 35 years old.
62246213|NCT06177028|EXPERIMENTAL|Lenalidomide|Lenalidomide 10 mg/day taken daily orally for 26 weeks of treatment followed by 4 weeks of washout. The trial will last up to 30 weeks in duration.
62043614|NCT02144064|NO_INTERVENTION|Group B|group B (n = 100) receive no thing
62246214|NCT06177028|PLACEBO_COMPARATOR|Placebo|Placebo taken daily orally for 26 weeks of treatment followed by 4 weeks of washout. The trial will last up to 30 weeks in duration.
62246215|NCT06202404||High risk group|This is a observational study, patients will be assigned to high-risk or low-risk groups (according to a radiomics model) by the investigators. Both the patients and the treating physicians will be blinded to this procedure. No interventions excluding standard treatment procedure executed by the treating physicians.
62602929|NCT01942499|NO_INTERVENTION|Usual Care|
62246216|NCT06202404||Low risk group|This is a observational study, patients will be assigned to high-risk or low-risk groups (according to a radiomics model) by the investigators. Both the patients and the treating physicians will be blinded to this procedure. No interventions excluding standard treatment procedure executed by the treating physicians.
62246217|NCT02827669|EXPERIMENTAL|One Drop Experts Program|Participants will be able to use the One Drop mobile app and One Drop Experts program on their smartphones. The One Drop mobile app is a diabetes management platform that allows users to track and log their blood glucose levels, medications, food, and activities. One Drop Experts is a diabetes education and coaching program delivered entirely through the One Drop mobile application.
62825005|NCT04089748||Patients from St Louis cohort not enrolled in VESPER study|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort
62825006|NCT04907357|ACTIVE_COMPARATOR|rTMS|Participants will receive up to 30 rTMS sessions within the 8-week treatment period.
62825007|NCT04907357|SHAM_COMPARATOR|Sham (Placebo)|Participants will receive up to 30 sham rTMS sessions within the 8-week treatment period.
62825008|NCT00495196|EXPERIMENTAL|1|
62246218|NCT02827669|EXPERIMENTAL|One Drop Experts Program + Apple Watch|An Apple Watch will be provided to study participants in this arm. In addition to using the One Drop mobile app and One Drop Experts program on their smartphones, participants will also be able to engage with the app and program on their Apple Watch.
62246219|NCT01660451|EXPERIMENTAL|Copanlisib (indolent NHL)|Part A: Participants in this arm will be patients with indolent NHL.
62246220|NCT01660451|EXPERIMENTAL|Copanlisib (aggressive NHL)|Part A: Participants in this arm will be patients with aggressive NHL.
62246221|NCT01660451|EXPERIMENTAL|Copanlisib (indolent B-cell NHL)|Part B: Participants in this arm will be patients with indolent B-cell NHL.
62825009|NCT00495196|ACTIVE_COMPARATOR|2|
62825010|NCT05994482||Older adults|Aim 1: Older adults with and without a prior history of precancerous polyps
62825011|NCT05994482||Older adults with prior polypectomy|Aim 2: Older adults with a prior history of precancerous polyps, exposed vs unexposed to surveillance colonoscopy
62825012|NCT05994482||Stakeholders|Aim 3: Veterans, clinical, and policy stakeholders who will provide input and participate in an expert panel to synthesis available evidence on pros/cons of surveillance in older adults.
62825013|NCT06600594|NO_INTERVENTION|KT - Control Group|Cosmetology and physiotherapy students who do not practice any sports
62825014|NCT06600594|EXPERIMENTAL|PT - Beginner Group|"Students joining the Podlasie Song and Dance Ensemble - beginners"
62825015|NCT06600594|ACTIVE_COMPARATOR|DT - Experienced Group|"Young adults trained from the Podlasie team with approximately 2-3 years of experience."
62825016|NCT05356897|EXPERIMENTAL|Treatment (tucatinib, trastuzumab, TAS-102)|Patients receive tucatinib PO BID, trastuzumab IV over 30-90 minutes on days 1 and 15, and TAS-102 PO BID on days 1-5 and 8-12. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62825017|NCT06587243|NO_INTERVENTION|Control|No videos
62602930|NCT01343667|OTHER|GFRS EPD|Carotid artery stenting with Gore Flow Reversal System embolic protection device
62825018|NCT06587243|EXPERIMENTAL|Animation Only|informational animation video only
62043615|NCT04020341|EXPERIMENTAL|Gepotidacin|Participants will be administered oral doses of 1500 milligrams (mg) gepotidacin plus nitrofurantoin matching placebo twice daily (BID); approximately every 12 hours for 5 days
62043616|NCT04020341|ACTIVE_COMPARATOR|Nitrofurantoin|Participants will be administered oral doses of 100 mg nitrofurantoin plus gepotidacin matching placebo BID; approximately every 12 hours for 5 days.
62602931|NCT01343667|OTHER|GEF EPD|Carotid artery stenting with Gore Embolic Filter embolic protection device
62602932|NCT06622096||ICU patients with a predicted length of stay > 24 hours|
62825019|NCT06587243|EXPERIMENTAL|Narrative Only|personal narrative video only
62825020|NCT06587243|EXPERIMENTAL|Narrative Then Animation|personal narrative video followed immediately by the informational animation video
62825021|NCT06587243|EXPERIMENTAL|Animation Then Narrative|informational animation video followed immediately by the personal narrative video
62825022|NCT04824339|EXPERIMENTAL|Immediate Intervention Group|The intervention is an 8-week combined aerobic and resistance program, with virtual, group-based, supervised exercise sessions twice per week (60 min). The intervention also includes optional education on healthy eating.
62825023|NCT04824339|EXPERIMENTAL|Delayed Intervention Group|Usual lifestyle control for 8 weeks and then invited to participate in the exercise intervention.
62602933|NCT01060605|EXPERIMENTAL|Rapamycin pre transplant|Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
62825024|NCT06288997|ACTIVE_COMPARATOR|Active tACS group|In the active group, the intervention is carried out using Hi-tACS with an intensive current of 15mA and a frequency of 77.5 Hz. Each intervention session lasts for 40 minutes, with two sessions conducted daily - one in the morning and one in the afternoon. The intervention is spread over a 10-day period, with sessions taking place five days per week, totaling two weeks.
62825025|NCT06288997|SHAM_COMPARATOR|Sham tACS group|The sham group undergoes sessions with the same technical settings, designed to produce similar scalp sensations but without effective penetration of the electric field into the brain. Each session lasts for 40 minutes, with two sessions conducted daily - one in the morning and one in the afternoon. The intervention is spread over a 10-day period, with sessions taking place five days per week, totaling two weeks.
62825026|NCT05954676|EXPERIMENTAL|CareOrbit - Patients|"Patients will be assigned a username and password to access their CareOrbit account via the internet (caregivers will use the same account information). These patients may designate up to 3 additional individuals who will be participating in the patient's postoperative care to receive the link along with a unique username and password via email. All patients will additionally receive standard pre- and post-operative instructions and care. This will include verbal education by the surgeons at their pre-operative visits.~Patient questionnaires will be distributed at the first and second post-operative visits (typically 1-2 weeks after discharge and 3 months after post-operative clinic visit). At 30 days following discharge, the patients' medical records will be reviewed by the study team to assess for the primary or secondary outcomes. Patients will be contacted by telephone to inquire about ED/UC visits outside of the BJC system."
62043617|NCT00924287|EXPERIMENTAL|Metastatic Cancer|Cancer that has invaded other parts of the body
62043618|NCT06580171|EXPERIMENTAL|Walking and Remembering Group|Only Walking and Remembering Test will be applied to the group.
62436601|NCT02638857|SHAM_COMPARATOR|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization(TACE) treatment:patients will receive lipiodol,Mitomycin (MMC),Epirubicin（EADM） hepatic arterial infusion,3 cycles.
62436602|NCT02638857|EXPERIMENTAL|DC-PMAT cells|After accepting concurrent TACE treatment,patients will receive 3 cycles of Dendritic Cell -Precision Multiple Antigen T (DC-PMAT) cells treatment.
62436603|NCT04857385|ACTIVE_COMPARATOR|Terumo TR Band|Physical standard of care radial hemostasis device.
62602934|NCT06293027||FXS affected individuals|Individuals with genetic diagnosis of FXS.
62602935|NCT06293027||Neurotypical controls|Healthy volunteers without known health or medical issues.
62436604|NCT04857385|EXPERIMENTAL|StatSeal|Potassium-ferrate based chemical hemostasis device.
62436605|NCT04857385|EXPERIMENTAL|Axiostat|Chitosan based biological hemostasis device.
62436606|NCT01004081|EXPERIMENTAL|BIIB021 BID + exemestane|BIIB021 100 mg BID + exemestane 25 mg QD
62436607|NCT01004081|EXPERIMENTAL|BIIB021 TIW + exemestane|BIIB021 450 mg TIW + exemestane 25 mg QD
62602936|NCT04810247|EXPERIMENTAL|Body Project intervention|
62602937|NCT01367600|EXPERIMENTAL|Arm 1|
62436608|NCT04597762|EXPERIMENTAL|right eye: Ciclosporin, left eye: Ciclosporin + Hydrocortisone|Patients receive treatment with Ciclosporin eyedrops for the right eye and Ciclosporin eyedrops + Hydrocortisone eyedrops for the left eye
62436609|NCT04597762|EXPERIMENTAL|left eye: Ciclosporin, right eye: Ciclosporin + Hydrocortisone|Patients receive treatment with Ciclosporin eyedrops for the left eye and Ciclosporin eyedrops + Hydrocortisone eyedrops for the right eye
62436610|NCT01766011|EXPERIMENTAL|study pre-term formula|Pre-term formula with a modified stabilizer system in 2 oz. ready to feed plastic bottles
62436611|NCT01078623|ACTIVE_COMPARATOR|Formoterol 12 μg|Formoterol fumarate 12 μg twice daily
62436612|NCT01078623|PLACEBO_COMPARATOR|Placebo|Placebo twice daily
62602938|NCT06166537|OTHER|EDPTP plus GCS|Control - Extended duration pharmacological thromboprophylaxis (EDPTP) and Graduated compression stockings (GCS).
62825027|NCT05954676|EXPERIMENTAL|CareOrbit - Caregivers|"Patients will be assigned a username and password to access their CareOrbit account via the internet (caregivers will use the same account information). These patients may designate up to 3 additional individuals who will be participating in the patient's postoperative care to receive the link along with a unique username and password via email. All patients will additionally receive standard pre- and post-operative instructions and care. This will include verbal education by the surgeons at their pre-operative visits.~Patient questionnaires will be distributed at the first and second post-operative visits (typically 1-2 weeks after discharge and 3 months after post-operative clinic visit). At 30 days following discharge, the patients' medical records will be reviewed by the study team to assess for the primary or secondary outcomes. Patients will be contacted by telephone to inquire about ED/UC visits outside of the BJC system."
62246222|NCT03829241|EXPERIMENTAL|Troriluzole|"Randomization phase (Weeks 1 through 8): Participants received troriluzole 100 mg capsules twice daily (BID) orally for up to 8 weeks in the double-blind (DB) randomization phase.~Extension phase (Weeks 9 through 56): Participants, who completed the randomization phase and for whom the investigator believed open-label (OL) treatment could offer an acceptable risk-benefit profile, entered the extension phase and received OL troriluzole capsules (continuing on the same dose and regimen that was taken at the end of the randomization phase) for up to additional 48 weeks."
62246223|NCT03829241|PLACEBO_COMPARATOR|Placebo|"Randomization Phase (Weeks 1 through 8): Participants received troriluzole matching placebo capsules BID orally for up to 8 weeks in the DB randomization phase.~Extension Phase (Weeks 9 through 56): Participants, who completed the randomization phase and for whom the investigator believed OL treatment could offer an acceptable risk-benefit profile, entered the extension phase and received OL troriluzole capsules (continuing on the same dose and regimen that was taken at the end of the randomization phase) for up to additional 48 weeks."
62436613|NCT01078623|EXPERIMENTAL|Aclidinium 200 μg / formoterol 12 μg|Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
62602939|NCT06166537|OTHER|EDPTP alone|Intervention - Extended duration pharmacological thromboprophylaxis (EDPTP) alone, no stockings
62602940|NCT04530591||Patient Participants|"This group of participants will complete a survey about their opioid use history and their preferences for a device-based intervention. They will then participate in a semi-structured interview to provide feedback on non-functional, looks-like prototypes of such a device."
62602941|NCT02542241|EXPERIMENTAL|Sodium Chloride [3%]|
62602942|NCT02542241|ACTIVE_COMPARATOR|Sodium Chloride [0.9%]|
62825028|NCT00976183|EXPERIMENTAL|Vorinostat|All study patients will receive the indicated dose of Vorinostat in conjunction with paclitaxel and carboplatin.
62825029|NCT06397079|EXPERIMENTAL|Electric toothbrush|Teach Bass brushing technique and use electric toothbrush
62825030|NCT06397079|ACTIVE_COMPARATOR|Soft bristle toothbrush|Teach Bass brushing technique and use soft bristle toothbrush
62825031|NCT04536909||Non-surgical|A non-surgical group for comparison, they will conduct a training program tailored for the kyphoscoliotic patients. The inclusion criteria is the same as for the surgical group.
62825032|NCT04536909||Surgical|Patients operated with correction of kyphotic- or scoliotic deformity.
62825033|NCT05890729|EXPERIMENTAL|Part A - XTMAB-16: 2 mg/kg every 4 weeks (Q4W) for 12 weeks or Placebo|
62825034|NCT05890729|EXPERIMENTAL|Part A - XTMAB-16: 4 mg/kg every 4 weeks (Q4W) for 12 weeks or Placebo|
62825035|NCT05890729|EXPERIMENTAL|Part A - XTMAB-16: 2 mg/kg every 2 weeks (Q2W) for 12 weeks or Placebo|
62825036|NCT05890729|EXPERIMENTAL|Part A - XTMAB-16: 4 mg/kg every 2 weeks (Q2W) for 12 weeks or Placebo|
62825037|NCT05890729|EXPERIMENTAL|Part B - XTMAB-16 (dose established in Part A) for 24 weeks or Placebo|
62825038|NCT04544917|EXPERIMENTAL|SmartManage Group|Participants in this group will receive ten 90-minute weekly therapist delivered SmartManage group sessions via video conference. Participants will have access to the SmartManage web platform, which will also guide the live intervention sessions.
62825039|NCT04544917|ACTIVE_COMPARATOR|Educational Control Group|Participants in this group will view ten weekly control content video recorded sessions.
62825040|NCT06592599|EXPERIMENTAL|Gemcitabine, Docetaxel and Capecitabine|Patients will receive three q 21-day cycles of gemcitabine 1000 mg/m2 plus docetaxel 75 mg/m2 plus toripalimab 240 mg, followed by radiation to 70 Gy plus concurrent weekly cisplatin, 40 mg/m2 up to 7 doses, followed by adjuvant capecitabine 650 mg/m2 BID for one year plus toripalimab 240 mg q 21 days for 9 doses.
62825041|NCT05860413|EXPERIMENTAL|Intermittent energy restriction (IER)|Intermittent fasting using a very-low energy diet (VLED; 550-800 kcal/d) 2-3 days per week
62825042|NCT05860413|EXPERIMENTAL|Time-restricted eating (TRE)|Intermittent fasting using an 8-hour eating period.
62825043|NCT06596824|EXPERIMENTAL|The treatment group|In addition to the standard-of-care physiotherapy program, the treatment group will additionally receive a training intervention utilizing sensor-based technology that provides 3D avatar training, supported by an accompanying app, to deliver personalized exercise regimens. This intervention aims to correct the pathological knee movement and loading patterns that exacerbate joint inflammation and contribute to the development of knee OA.
62602943|NCT04605393|EXPERIMENTAL|Placebo/THC|Oral placebo followed by inhalation of cannabis containing THC.
62602944|NCT04605393|EXPERIMENTAL|CBD/THC|Oral CBD 1000mg followed by inhalation of cannabis containing THC.
62602945|NCT01007734||1|
62602946|NCT02895646||Beta-lactam antibiotic allergy|Diagnosis based on clinical symptomatology and skin test positive for allergen and negative for other drugs and substances. Skin tests are performed 6 weeks after allergic reaction.
62602947|NCT02895646||Control|No specific clinical investigation for control subjects
62602948|NCT01848743|ACTIVE_COMPARATOR|Tenofovir|All enrolled patients are randomized to tenofovir arm who receives tenofovir 300 mg qd for 36 months
62825044|NCT06596824|NO_INTERVENTION|the control group|Standard-of-care physiotherapy program
62825045|NCT03916770|ACTIVE_COMPARATOR|whole body vibration|WBV(whole body vibration) will be applied to interventional group for 4 weeks, 3 days a week, a total of 12 sessions while standing upright with the WBV powerplate pro5 device.(Vibration frequency: 30Hz, amplitude: 2.2 mm at progressively increasing duration)
62825046|NCT03916770|SHAM_COMPARATOR|Sham whole body vibration|The sham WBV will be applied to the Control group. A WBV device with 99.5% weakened amplitude will be used for sham WBV. (Application duration of the sham WBV will be same as WBV in the treatment group ).
62825047|NCT03789669|EXPERIMENTAL|Investigational|In phase I the investigators will use the investigational Cheetah femtosecond laser and Cheetah patient interface (PI) on one eye to create a LASIK flap (worst seeing eye should be preferred). Refractive correction via corneal ablation with a commercial excimer laser will be performed at the discretion of the investigator.If refractive correction is performed on the study eye, the fellow eye may receive standard LASIK treatment, otherwise, fellow eye will remain untreated.
62825048|NCT03789669|ACTIVE_COMPARATOR|Investigational/Control|"In phase II, both eyes of each subject will be treated. The investigators will use the investigational Cheetah femtosecond laser and Cheetah PI on one eye, and commercial iFS femtosecond laser and PI on the other eye to create a LASIK flap on subjects' corneas. Flap parameters (such as flap depth, flap diameter, and hinge angle) should be the same for both eyes. The eye to receive Cheetah flap will be randomized (ratio of 1:1 for right eye and left eye).~Subjects in phase II will undergo refractive correction via corneal ablation on both eyes using a commercial excimer laser for vision correction (same excimer laser system will be used on both eyes)."
62043619|NCT02446301|EXPERIMENTAL|Period I (reference drug)|Before administration of investigational products, subjects should be fasted for 10 hours. On the dosing day, subjects will be confined after administration and won't be discharged until after completion of sample collections for 24 hours following dosing in Period I (Bain® IM injection).
62043620|NCT02446301|EXPERIMENTAL|Period II (Test drug)|Subjects will be back to the clinical site to join Period II (SDE IM injection) and will be discharged after completion for sample collections for 24 hours post drug administration.
62043621|NCT00956345|EXPERIMENTAL|25U/kg|
62246224|NCT04295616|EXPERIMENTAL|IPV & active breathing training|"Intrapulmonary Percussive Ventilation (IPV) and active breathing exercises, provided by trained speech and language therapists.~This training will be performed in combination with a multidisciplinary rehabilitation programme."
62246225|NCT04295616|ACTIVE_COMPARATOR|Active breathing training only|Active breathing training provided by trained speech therapists. This training will be performed in combination with a multidisciplinary rehabilitation programme.
62436614|NCT01078623|EXPERIMENTAL|Aclidinium 200 μg / formoterol 6 μg|Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
62436615|NCT01078623|EXPERIMENTAL|Aclidinium 200 μg|Aclidinium bromide 200 μg twice daily
62043622|NCT00956345|EXPERIMENTAL|50U/kg|
62043623|NCT00956345|EXPERIMENTAL|100U/kg|
62043624|NCT01981694|EXPERIMENTAL|Single ascending doses|
62436616|NCT02005354|ACTIVE_COMPARATOR|Trans-cutaneous Electrical Nerve Stimulation (TENS)|"The Intervention-TENS group will have 2 electrodes applied proximal to the painful area along neuro-anatomical distribution (electrode-one placed 5cm superior and 2cm medial to the posterior superior iliac spine and electrode-two placed 5cm medial to the posterior superior iliac spine) in the same way as the control-TENS group.~The concealed electrical parameter in this group will be within the therapeutic window, that is, well above the sensory detection threshold but below the pain threshold giving a strong but comfortable sensation. From previous studies, this is likely to be 50-110Hz.~The device will be activated prior to entry into the treatment room and 2 minutes before administration of local anaesthetic and for 2 minutes after removal of the biopsy needle. This will cover the expected duration of pain as assessed in the pilot study.~All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)"
62602949|NCT01848743|PLACEBO_COMPARATOR|lamivudine|All enrolled patients are randomized to lamivudine arm who received lamivudine 100 mg qd for 6 months, followed by tenofovir for another 30 months.
62043625|NCT01981694|EXPERIMENTAL|Measurement of eye blink rate|
62043626|NCT04402866|EXPERIMENTAL|Part 1: TD-0903 - MAD Dose A|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose A
62043627|NCT04402866|EXPERIMENTAL|Part 1: TD-0903 - MAD Dose B|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose B
62043628|NCT04402866|EXPERIMENTAL|Part 1: TD-0903 - MAD Dose C|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose C
62043629|NCT04402866|EXPERIMENTAL|Part 1: Placebo for MAD|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
62043630|NCT04402866|EXPERIMENTAL|Part 2: TD-0903|99 subjects will be randomized to receive TD-0903
62043631|NCT04402866|EXPERIMENTAL|Part 2: Placebo|99 subjects will be randomized to receive Placebo
62246226|NCT03836820|EXPERIMENTAL|Clinical pilates exercise|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
62246227|NCT03836820|EXPERIMENTAL|Aerobic exercise|Progressive aerobic walking exercise will be performed three days in a week. Exercise intensity will be 50- 80% of maximal heart rate and exercises will be performed 45 minutes in per session for 8 weeks.
62043632|NCT04745611||COVID-19 non-ICU patients|Patients who were admitted to one of six recruiting hospitals in the Netherlands due to COVID-19 during the first patient wave (march-june 2020) and who were not admitted to an intensive care unit.
62043633|NCT04745611||COVID-19 ICU patients|Patients who were admitted to one of six recruiting hospitals in the Netherlands due to COVID-19 during the first patient wave (march-june 2020) and who were admitted to an intensive care unit.
62043634|NCT04745611||COVID-19 non-ICU family members|Close family members of patients who were admitted to one of six recruiting hospitals in the Netherlands due to COVID-19 during the first patient wave (march-june 2020) and who were not admitted to an intensive care unit.
62043635|NCT04745611||COVID-19 ICU family members|Close family members of patients who were admitted to one of six recruiting hospitals in the Netherlands due to COVID-19 during the first patient wave (march-june 2020) and who were admitted to an intensive care unit.
62043636|NCT02294890||Fibrosis diathesis|"all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis.~This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis."
62043637|NCT02294890||No fibrosis diathesis|"all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis.~This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis."
62043638|NCT00030693|EXPERIMENTAL|Arm I (recombinant fowlpox-B7.1 vaccine)|Patients receive rF-B7.1 vaccine intratumorally on day 1.
62043639|NCT00030693|EXPERIMENTAL|Arm II (recombinant fowlpox-TRICOM vaccine)|Patients receive fowlpox-TRICOM vaccine intratumorally on day 1.
62246228|NCT03836820|EXPERIMENTAL|Clinical pilates and Aerobic exercise|Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.
62825049|NCT03789669|ACTIVE_COMPARATOR|Control/Investigational|"In phase II, both eyes of each subject will be treated. The investigators will use the commercial Cheetah femtosecond laser and Cheetah two piece PI on one eye, and commercial Cheetah femtosecond laser and investigational Cheetah one piece PI on the other eye to create a LASIK flap on subjects' corneas. Flap parameters (such as flap depth, flap diameter, and hinge angle) should be the same for both eyes. The eye to receive Cheetah flap will be randomized (ratio of 1:1 for right eye and left eye).~Subjects in phase II will undergo refractive correction via corneal ablation on both eyes using a commercial excimer laser for vision correction (same excimer laser system will be used on both eyes)."
62246229|NCT05196425|OTHER|Control group|
62825050|NCT06589869|ACTIVE_COMPARATOR|Standard of Care|Standard of care. Perioperative education for information related to prostatectomy and pelvic floor exercise training. Patient were advice to perform pelvic floor exercise at least 30 times per day
62043640|NCT06514144||Treatment Initiation|Initiation of treatment following exacerbation classified as prompt, delayed or very delayed.
62043641|NCT00680511|ACTIVE_COMPARATOR|1|Family therapy combined with methamphetamine-specific group treatment.
62246230|NCT05196425|ACTIVE_COMPARATOR|MS with optic neuritis|
62246231|NCT05196425|ACTIVE_COMPARATOR|Ms without optic neuritis|
62043642|NCT00680511|ACTIVE_COMPARATOR|2|Family Therapy.
62043643|NCT06219317|EXPERIMENTAL|Cemiplimab|Cemiplimab IV 350 mg every 3 weeks for up to 12 months or until progression or discontinuation
62043644|NCT06219317|PLACEBO_COMPARATOR|Placebo|Placebo (saline solution) IV every 3 weeks for up to 12 months or until progression or discontinuation
62043645|NCT06495619|ACTIVE_COMPARATOR|(1)TAU|treatment-as-usual for weight loss (TAU)
62043646|NCT06495619|ACTIVE_COMPARATOR|(2)TAU+GSH|combined TAU and guided self-help for improving eating behaviors (TAU+GSH)
62246232|NCT00631189|ACTIVE_COMPARATOR|1|Rosuvastatin and Pravastatin
62246233|NCT00631189|ACTIVE_COMPARATOR|2|Rosuvastatin and Atorvastatin
62246234|NCT04528862|EXPERIMENTAL|Nature|
62246235|NCT04528862|SHAM_COMPARATOR|Urban|
62246236|NCT04300582|ACTIVE_COMPARATOR|Standard pharmaco-invasive strategy|Cardiac catheterization 3 to 24 hours after thrombolytic completion in STEMI patients.
62043647|NCT06495619|ACTIVE_COMPARATOR|(3)TAU+GSH+BF|combined TAU, GSH, and biofeedback (TAU+GSH+BF)
62043648|NCT05253872|EXPERIMENTAL|Intervention group|Patients in the intervention arm will receive follow-up conducted by melanoma nurses, where the patients will get tools to cope with the melanoma diagnosis and structured training in skin self-examination
62043649|NCT05253872|NO_INTERVENTION|Control group|Patients in the control arm will receive clinical follow-up according to the current standard of care for their clinical stage.
62043650|NCT01767558|OTHER|Ablation / MRI|"All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.~MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit."
62043651|NCT06220357|EXPERIMENTAL|Group A (5 mg/mL)|This group received 5 mg/mL of ICG or 100% in terms of concentration. The 1 mL of the ICG solution was taken using a 3 mL syringe
62043652|NCT06220357|ACTIVE_COMPARATOR|Group B (2,5 mg/mL)|This group received 2,5 mg/mL of ICG or 50% in terms of concentration. The 0.5 mL of the ICG solution was mixed with 0.5 mL of distilled water using a 1 cc syringe
62246237|NCT04300582|EXPERIMENTAL|Fast pharmaco-invasive strategy|Cardiac catheterization less than 3 hours after thrombolytic completion in STEMI patients.
62825051|NCT06589869|EXPERIMENTAL|EM Chair|Patients who randomised to intervention group (Arm A) will receive HIFEM assisted (BTL EMsella) pelvic floor muscle training for total 6 sessions (2 session per week, 30 minutes per session with modulated intensity) plus standard of care. The intervention will be started within 2 weeks after Foley Catheter removed. Patients will attend follow up for training and at 1, 3 and 6 month post-operatively.
62825052|NCT02780648|EXPERIMENTAL|Stereotactic Body Radiation|Patients will receive 5 fractions of 5 Gy or 6.6 Gy (dose depending upon whether or not they have received prior radiation therapy to the pancreatic region) delivered over a five-day period.
62825053|NCT03041519|EXPERIMENTAL|Zero-fluoroscopy ablation|Zero-fluoroscopy ablation will be performed under the guidance of Ensite NavX for mapping and ablation and fluoroscopy will not be used during the procedure.
62825054|NCT03041519|ACTIVE_COMPARATOR|Conventional fluoroscopy ablation|Conventional fluoroscopy ablation will be performed under fluoroscopic guidance plus Ensite NavX for mapping and ablation during the procedure.
62825055|NCT01664975|EXPERIMENTAL|GDPT regimen|GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen
62043653|NCT06220357|ACTIVE_COMPARATOR|Group C (0,5 mg/mL)|This group received 0,5 mg/mL of ICG or 10% in terms of concentration. The 0.1 mL of the ICG solution was mixed with 0.9 mL of distilled water using a 1 cc syringe
62043654|NCT06205589|ACTIVE_COMPARATOR|Group 1/Phase 2a: ID93+GLA-SE 4 months and 6 months after start of TB treatment|Participants will be enrolled at approximately 4 months after the start of TB treatment, entering the study directly into Step 2, and will be randomized to receive ID93 + GLA-SE immediately. They have no Step 1 observation period from the start of SOC TB treatment to randomization.
62043655|NCT06205589|ACTIVE_COMPARATOR|Group 2/Phase 2a: ID93+GLA-SE 3 months and 5 months after start of TB treatment|Participants will be enrolled at approximately 3 months after the start of TB treatment, entering the study directly into Step 2, and will be randomized to receive ID93 + GLA-SE or placebo immediately. They have no Step 1 observation period from the start of SOC TB treatment to randomization.
62825056|NCT01664975|EXPERIMENTAL|CHOP regimen|CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
62825057|NCT06442943|EXPERIMENTAL|Intervention group|Participants in the intervention group received the digtal multi-domain cognitive intervention. The digital multi-domain cognitive intervention system is used to carry out various intervention activities. The activities include learning about health knowledge once a week; home-based exercise three times per week, for 30 minutes each time; art therapy once a week, for 90 minutes at a time; and cognitive training, which includes memory, attention, executive function, and visuospatial training, conducted three times per week, with each session lasting 30 minutes.
62043656|NCT06205589|ACTIVE_COMPARATOR|Group 3/Phase 2a: ID93+GLA-SE 2 months and 4 months after start of TB treatment|Participants will enter the study within approximately 7 days after starting TB treatment in Step 1, which is an observation period between the start of SOC TB treatment until entering Step 2. In Step 2 they will be randomized to ID93 + GLA-SE at 2 months after study entry/start of TB treatment.
62043657|NCT06205589|ACTIVE_COMPARATOR|Group 4/Phase 2a: ID93+GLA-SE 1 month and 3 months after start of TB treatment|Participants will enter the study within approximately 7 days after starting TB treatment in Step 1, which is an observation period between the start of SOC TB treatment until entering Step 2. In Step 2 they will be randomized to ID93 + GLA-SE 1 month after study entry/start of TB treatment.
62043658|NCT06205589|ACTIVE_COMPARATOR|Group 5/Phase 2b: ID93+GLA-SE schedule based on Group 3 and 4 safety and immunogenicity data|Participants will enter the study within approximately 7 days after starting TB treatment in Step 1, which is an observation period between the start of SOC TB treatment until entering Step 2. The vaccination schedule will be selected from either the Group 3 or Group 4 schedule, following a review of the safety and immunogenicity data after the last participant in Group 4 receives the second vaccination. If both the safety and immunogenicity criteria are met, the Group 4 schedule will be selected and Group 5 will include Group 4 participants. If Group 4 fails to meet both the safety and immunogenicity criteria, the Group 3 vaccination schedule will be selected and Group 5 will include Group 3 participants. If safety and immunogenicity criteria are not met in either Group 3 or 4, then enrollment to Group 5 will not proceed and the phase 2b component of the study will not be undertaken.
62246238|NCT00890929|EXPERIMENTAL|Azacitidine followed by lenalidomide|Dose escalation then dose expansion
62246239|NCT03976791|EXPERIMENTAL|Enlarged internal incision|enlarged the internal incision about 0.4mm
62246240|NCT03976791|PLACEBO_COMPARATOR|Regular 2.2mm incision|regular 2.2mm corneal incision for microincision coaxial phacoemulsification
62043659|NCT06205589|PLACEBO_COMPARATOR|Group 1/Phase 2a: Placebo vaccine 4 months and 6 months after start of TB treatment|Participants will be enrolled at approximately 4 months after the start of TB treatment, entering the study directly into Step 2, and will be randomized to receive placebo immediately. They have no Step 1 observation period from the start of SOC TB treatment to randomization.
62043660|NCT06205589|PLACEBO_COMPARATOR|Group 2/Phase 2a: Placebo vaccine 3 months and 5 months after start of TB treatment|Participants will be enrolled at approximately 3 months after the start of TB treatment, entering the study directly into Step 2, and will be randomized to receive placebo immediately. They have no Step 1 observation period from the start of SOC TB treatment to randomization.
62043661|NCT06205589|PLACEBO_COMPARATOR|Group 3/Phase 2a: Placebo vaccine 2 months and 4 months after start of TB treatment|Participants will enter the study within approximately 7 days after starting TB treatment in Step 1, which is an observation period between the start of SOC TB treatment until entering Step 2. In Step 2 they will be randomized to placebo at 2 months after study entry/start of TB treatment.
62602950|NCT04144036|EXPERIMENTAL|Neihulizumab Dose Escalation, 3 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
62043662|NCT06205589|PLACEBO_COMPARATOR|Group 4/Phase 2a: Placebo vaccine 1 month and 3 months after start of TB treatment|Participants will enter the study within approximately 7 days after starting TB treatment in Step 1, which is an observation period between the start of SOC TB treatment until entering Step 2. In Step 2 they will be randomized to ID93 + GLA-SE or placebo 1 month after study entry/start of TB treatment.
62246241|NCT00717054|ACTIVE_COMPARATOR|Aprepitant and Scopolamine group|Patients receive aprepitant and scopolamine for prevention of postoperative nausea and vomiting then were followed through the post operative period looking for nausea, vomiting, composite, and rescue medication utilization. This was compared to patients receiving aprepitant and scopolamine placebo looking for a difference in incidence of events.
62246242|NCT00717054|PLACEBO_COMPARATOR|Aprepitant and Scopolamine Placebo Group|Patients receiving aprepitant and placebo scopolamine for prevention of postoperative nausea and vomiting then followed through the post operative period looking for signs of nausea, vomiting, composite, and rescue medication utilization. This was compared to patients receiving aprepitant and scopolamine looking for a difference in incidence of events.
62246243|NCT04733339||'Traditional' group|10 stroke patients
62602951|NCT04144036|EXPERIMENTAL|Neihulizumab Dose Escalation, 6 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
62825058|NCT06442943|OTHER|Control group|Participant in the control group reveived the health education , once a week, covering the prevention and treatment of chronic diseases in the elderly, as well as healthy lifestyles for the elderly
62825059|NCT06591273|EXPERIMENTAL|Adult Patients of moderate to severe plaque psoriasis|
62825060|NCT06057766|EXPERIMENTAL|Physical activity tele coaching group|Patients in the experimental group will undertake a 12-week (semi)automated telecoaching program with the aim of enhancing their physical activity. The program uses a Fitbit wearable and a smartphone application that is developed for and tested to be effective for patients with COPD.
62825061|NCT06057766|NO_INTERVENTION|Control group|
62825062|NCT05949736|EXPERIMENTAL|The Clinical Symptom Changes of Music Therapy in a Randomized Controlled Study.|This study investigates the clinical symptom changes of the Music Therapy (MT) group through a randomized controlled trial, aiming to explore the short- and long-term efficacy of MT for individuals experiencing mental sub-health. The study includes one-month and six-month post-treatment follow-ups to assess the lasting effects of MT intervention.
62246244|NCT04733339||'Technology-supported' group|10 stroke patients
62043663|NCT06205589|PLACEBO_COMPARATOR|Group 5/Phase 2b: Placebo vaccine schedule based on Group 3 and 4 safety and immunogenicity data|Participants will enter the study within approximately 7 days after starting TB treatment in Step 1, which is an observation period between the start of SOC TB treatment until entering Step 2. The vaccination schedule will be selected from either the Group 3 or Group 4 schedule, following a review of the safety and immunogenicity data after the last participant in Group 4 receives the second vaccination. If both the safety and immunogenicity criteria are met, the Group 4 schedule will be selected and Group 5 will include Group 4 participants. If Group 4 fails to meet both the safety and immunogenicity criteria, the Group 3 vaccination schedule will be selected and Group 5 will include Group 3 participants. If safety and immunogenicity criteria are not met in either Group 3 or 4, then enrollment to Group 5 will not proceed and the phase 2b component of the study will not be undertaken.
62043664|NCT04222101|OTHER|cardiomyopathy|only one arm, all participants undergo oral glucose tolerance testing and results are used to evaluate association with degree of cardiac dysfunction
62246245|NCT01355146||Fabry's Disease under Replagal|
62246246|NCT05599789|EXPERIMENTAL|Pembrolizumab in Combination with Plinabulin and Docetaxel|Pembrolizumab in Combination with Plinabulin and Docetaxel
62436617|NCT02005354|PLACEBO_COMPARATOR|Trans-cutaneous Electric Nerve Stimulation (TENS)|"Patients in the CT group will have 2 gel-electrodes applied proximal to the sampling area (usually the right posterior superior iliac crest).~The Control-TENS device will be identical in appearance to the Intervention-TENS device with a functioning display panel. The concealed electrical parameter in this group will be titrated to and set at the sensory detection.~All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)"
62246247|NCT01755845|EXPERIMENTAL|Arm 1|Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area. After completion of chemoradiotherapy, patients receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
62246248|NCT01755845|ACTIVE_COMPARATOR|Arm 2|Patients receive chemoradiotherapy as in arm 1.
62246249|NCT00905684||Group 1|
62246250|NCT00905684||Group 2|
62246251|NCT03864445|EXPERIMENTAL|KHK7791|Patients take KHK7791 BID and can down titrate, based on a GI tolerability question.
62246252|NCT03864445|PLACEBO_COMPARATOR|Placebo|Patients take Placebo BID.
62246253|NCT00244972|EXPERIMENTAL|Treatment (sorafenib tosylate, tipifarnib)|Patients receive sorafenib tosylate PO QD or BID on days 1-28 and tipifarnib PO QD or BID on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients may be allowed to continue the treatment after the 12 courses if there is continued clinical response or disease stabilization, and patients do not have significant toxicities.
62436618|NCT04611035||Patient|Patient with first-line gastrointestinal cancers and patient with advanced and refractory GI cancers (\>1 line of treatment), or post-progression biopsy)
62602952|NCT04144036|EXPERIMENTAL|Neihulizumab Dose Escalation, 9 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
62436619|NCT01369251|EXPERIMENTAL|Hygiene with water and soap|
62436620|NCT01369251|ACTIVE_COMPARATOR|Usual alcohol care|
62436621|NCT00803946|ACTIVE_COMPARATOR|Test Product|
62436622|NCT00803946|ACTIVE_COMPARATOR|Reference Product|
62436623|NCT01428024|EXPERIMENTAL|Restylane Lip Volume|Submucosal injections with Restylane Lip Volume. Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 2 and 12.
62602953|NCT04144036|EXPERIMENTAL|Neihulizumab Dose Expansion|Upon determination of the maximum-tolerated dose, an expansion cohort of 4-7 patients will be enrolled so that a total of 10 patients are enrolled at the potential Phase II dose. This will be done to preliminarily assess efficacy.
62825063|NCT05949736|EXPERIMENTAL|The changes of objective markers of the music therapy.|This study examines the changes in objective markers resulting from Music Therapy (MT) intervention. It explores alterations in behavior, biological features, and neuroimaging data to understand the potential biological mechanism underlying the efficacy of music therapy. By analyzing these objective markers, the study aims to gain valuable insights into the impact of MT on individuals' mental well-being.
62246254|NCT06508112||patients diagnosed pulmonary embolism|Patients over the age of 18 who presented to the emergency department of a tertiary care hospital with complaints of cough, dyspnea, chest pain, tachycardia, hemoptysis, and syncope, and were diagnosed with pulmonary embolism (PE) confirmed by pulmonary computed tomographic angiography (CTPA), were included in our study. Informed consent was obtained from the patients who were stable and from the relatives of the patients who were unstable. Plethysmographic variability index (PVI) and Perfusion index (PI) levels were automatically obtained 2 minutes after the device was attached, using a probe placed on the index finger of the hand while the patient was lying supine. PI and PVI measurements and data were collected consecutively by the same individual. The measurements were taken using the Masimo Radical-7® Pulse CO-Oximeter, which is approved by the U.S. Food and Drug Administration.
62246255|NCT05327556|ACTIVE_COMPARATOR|0.5 mcg/kg Dose|Providers use 0.1 mL/kg of 5 mcg/mL epinephrine for target dose 0.5 mcg/kg
62043665|NCT05874557||treatment group|MHD patients who took compound amino acid capsules regularly(2# tid po) for 9 months
62246256|NCT05327556|ACTIVE_COMPARATOR|1.0 mcg/kg Dose|Providers use 0.1 mL/kg of 10 mcg/mL epinephrine for target dose of 1.0 mcg/kg
62246257|NCT05126901|EXPERIMENTAL|1 month to 2 year old subjects (infants)|"Subjects aged 1 month to less than 2 years will enter a Pre-assignment phase: baseline urine samples are collected and subjects will take a single dose of 0.1 ml/kg ferric maltol suspension. Further 3 samples up to 12h will be taken.~Subjects showing evidence of absorption, metabolism and elimination of maltol will enter the treatment phase and be assigned to the ferric maltol arm.~The first 6 subjects screened will perform the pre-assignment PK phase. After review by the investigator, and medical monitors , if Maltol Glucuronide is shown to be adequately eliminated, timepoint 20-24 hrs (+ 4hrs) will not be performed on subsequent subjects.~Subjects will be assigned to receive ferric maltol oral suspension and start the 0.1 ml/kg BID dose on V2 and continue for 7-10 days. On V3 they will perform the same PK assessments as on Pre-assignment PK visit."
62246258|NCT05126901|EXPERIMENTAL|2 to 17 year old subjects - Ferric Maltol|"Subjects aged 2-17 will be randomised 1:1 to receive ferric maltol oral suspension or ferrous sulfate oral liquid.~The first 12 subjects randomised to ferric maltol in each age sub-group (2 - 9 yrs, 10 - 17 yrs respectively) will enter a PK phase with 2 PK days.~Following PK Day 2 subjects will continue until Week 12. Once the 18 subjects in each age subgroup have finished their PK visits, they will continue until week 12.~Ferrous sulfate 125 mg/ml (25 mg elemental iron) or equivalent dose will be used for all children/adolescents. To maximise the iron replenishment for subjects within this group as well; aged 2 - 17 yrs will be dosed 6 mg/kg to the maximum of 4 ml BID.~Subjects randomised to ferrous sulfate oral liquid will not need to complete the PK period."
62436624|NCT01428024|EXPERIMENTAL|Restylane Lip Refresh|Submucosal injections with Restylane Lip Refresh. Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 2 and 12.
62436625|NCT03074279||Cases|Patient with epilepsy who died as a result of confirmed or probable SUDEP and NEAR SUDEP during the study period.
62436626|NCT03074279||Controls|Patient with epilepsy matched by: âge, etiology and type of epilepsy, level of seizure control
62436627|NCT04156191|EXPERIMENTAL|ARQ-151 cream 0.15% or 0.05%|Open-label study of 0.15% or 0.05% active concentration
62436628|NCT00685971|EXPERIMENTAL|Vitamin D|vitamin
62436629|NCT00685971|PLACEBO_COMPARATOR|Placebo|
62436630|NCT03287466|EXPERIMENTAL|SpO2 88-92%|The intervention is targeted oxygen therapy (TO2T) to achieve an arterial haemoglobin oxygen saturation (SpO2) of 88-92%.
62602954|NCT03482076|OTHER|transferrin receptor concentration|Prevelance of iron deficiency in this patients
62602955|NCT06649032||Cohort Incidence|This cohort will comprise subjects recruited from 1st November 2023 to 21st December 2023 and followed from 22nd December 2023 to 30th April 2024 and subjects recruited from 01st November 2024 to 21st December 2024 and followed from 22nd Dec 2024 to 30th April 2025. During the follow-up period, the subjects will be asked to report respiratory tract infections to the investigators (phone calls or study visit).
62602956|NCT06649032||Cohort Respiratory Tract Infections (RTI) positive|Subjects recruited from 1st November 2023 to 21st December 2023, followed from 22nd December 2023 to 30th April 2024 and who developed at least one respiratory tract infection will be also followed from 22nd December 2024 to 30th April 2025 and asked to report respiratory tract infections to the investigators.
62602957|NCT04443621||participants with early stage dementia|Subjects with diagnosed any type of dementia at an early phase (MMSE score 20 - 25 points) - for longitudinal study (three phasis).
62043666|NCT05874557||control group|MHD patients in the control group are selected by PSM with age, sex, dialysis month, baseline BMI, baseline Kt/V and baseline ultrafiltration volume. And they did not take compound amino acid capsules or similar amino acid nutritional supplement for the same 9 months.
62043667|NCT00845390||ICD Patients|ICD patients
62043668|NCT04688242|EXPERIMENTAL|Treatment Arm|Anal dilatation plus probiotics per anus Q3D, starting from 2 weeks after proctectomy until reduction of ileostomy.
62602958|NCT04443621||participants without dementia|Subjects without dementia with MMSE score 26 - 30 points (for validation of ACE-III).
62825064|NCT01849146|EXPERIMENTAL|Arm I (adavosertib, temozolomide, radiation)|"INITIATION CYCLE: Patients receive adavosertib PO on days 1, 3, and 5 or 1-5 weekly and temozolomide PO QD for 6 weeks. Patients also undergo concurrent radiation therapy 5 days per week for 6 weeks.~MAINTENANCE CYCLES: Beginning in week 10, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
62825065|NCT01849146|EXPERIMENTAL|Arm II (adavosertib, temozolomide)|Patients receive adavosertib PO QD on days 1, 3, and 5 or 1-5 weekly, and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62825066|NCT03515486|EXPERIMENTAL|Post-stroke mood disorders evaluation|Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations.
62825067|NCT03052829|EXPERIMENTAL|Physical Activity Counseling|Subjects will be given counseling on the benefits of increasing activity, instructions on how to slowly increase their activity over 12 weeks with walking, record their daily step counts, and have bi-weekly phone calls with study staff to reinforce the training and help them overcome barriers to being physically active.
62825068|NCT03052829|PLACEBO_COMPARATOR|Patient Usual Care|Subjects will undergo usual care without intervention in this study arm
62825069|NCT06597721|EXPERIMENTAL|AMT-754 Dose Escalation|
62825070|NCT06600347|EXPERIMENTAL|DASH diet group|The participants will be treated with the DASH diet and antihypertensive drugs
62825071|NCT06600347|EXPERIMENTAL|Progressive muscle relaxation group|The participants will be treated with progressive muscle relaxation and antihypertensive drugs
62825072|NCT06600347|EXPERIMENTAL|DASH diet and progressive muscle relaxation group|The participants will be treated with DASH diet and progressive muscle relaxation in addition to antihypertensive drugs
62246259|NCT05126901|ACTIVE_COMPARATOR|2 to 17 year old subjects - Ferrous Sulfate|"Subjects aged 2-17 will be randomised 1:1 to receive ferric maltol oral suspension or ferrous sulfate oral liquid.~Ferrous sulfate 125 mg/ml (25 mg elemental iron) or equivalent dose will be used for all children/adolescents. To maximise the iron replenishment for subjects within this group as well; aged 2 - 17 yrs will be dosed 6 mg/kg to the maximum of 4 ml BID.~Subjects randomised to ferrous sulfate oral liquid will not need to complete the PK period."
62246260|NCT01584076|EXPERIMENTAL|Donepezil|
62246261|NCT05351151|EXPERIMENTAL|Loco Regional anesthesia (LRA)|The LRA group is made up of patients benefiting from the V2 and V3 ultrasound-guided LRA technique without mucosal infiltration.
62436631|NCT03287466|ACTIVE_COMPARATOR|Current best practice|The control group will have no specific SpO2 targets. Clinicians will be able to target SpO2 according to parameters they feel are suitable for the patient, according to standard UK practice.
62436632|NCT01608633|EXPERIMENTAL|Spray and stretch|
62825073|NCT06602804|EXPERIMENTAL|Healthy adult participants|Performance criteria will be evaluated in healthy adult participants, who receive radiolabeled, autologous infusions of LR-RBC components after being stored for 42 days at 2-6°C.
62825074|NCT06599268||Pharmacists|Pharmacists/Pharmacy Students working in pharmaceutical companies or communities among others
62825075|NCT04880278|ACTIVE_COMPARATOR|Nabilone|In a randomized, double-blind, placebo-controlled design, we will administer a one-time oral dose of nabilone (1mg) or placebo approximately two hours prior to fMRI scanning and task performance in 60 adults with OCD.
62825076|NCT04880278|PLACEBO_COMPARATOR|Placebo|In a randomized, double-blind, placebo-controlled design, we will administer a one-time oral dose of nabilone (1mg) or placebo approximately two hours prior to fMRI scanning and task performance in 60 adults with OCD.
62043669|NCT04688242|NO_INTERVENTION|Control Arm|No anal dilatation or probiotics per anus was allowed, from 2 weeks after proctectomy until reduction of ileostomy.
62043670|NCT05189808||Group|
62043671|NCT00981981|PLACEBO_COMPARATOR|Control|Wheat bran cereal
62043672|NCT00981981|ACTIVE_COMPARATOR|3g high MW|Cereal containing 3g high molecular weight oat beta glucan
62043673|NCT00981981|ACTIVE_COMPARATOR|4g medium MW|Cereal containing 4g oat beta glucan with medium molecular weight
62043674|NCT00981981|ACTIVE_COMPARATOR|3g medium MW|Cereal containing 3g oat beta glucan with medium molecular weight
62043675|NCT00981981|ACTIVE_COMPARATOR|4g low MW|Cereal containing 4g oat beta glucan with low molecular weight
62043676|NCT03565510|NO_INTERVENTION|Control|Those assigned to the Control group will receive a diet composed of 55% of carbohydrate, 15% of protein, and 30% of lipid (similar to the North American dietary pattern).
62043677|NCT03565510|EXPERIMENTAL|High-Protein Diet|Those assigned to the High-Protein Diet group will receive a diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based total diet replacement.
62246262|NCT05351151|ACTIVE_COMPARATOR|Infiltration|"The Infiltration group is made up of patients who benefit from the infiltration technique by local anesthesia of the incision sites by the surgeon without recourse to ultrasound-guided LRA."
62246263|NCT03398525|ACTIVE_COMPARATOR|Usual care|After patient information, appropriate skin antisepsis according to local procedures, surgical hand antisepsis by the operator, use of sterile drapes, gowns and gloves, insertion of a central venous catheter after after local anesthesia with 2% lidocaine, using ultrasound guidance.
62436633|NCT01608633|NO_INTERVENTION|Control|
62436634|NCT04586790|EXPERIMENTAL|midodrine group|midodrine group will receive midodrine 10 mg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral midodrine
62436635|NCT04586790|EXPERIMENTAL|minirin group|the patients will receive minirin 60 µg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral minirin
62436636|NCT04586790|EXPERIMENTAL|control group|the patients will receive IV nor-adrenaline and are gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
62436637|NCT01306253|EXPERIMENTAL|Elderly|Elderly subjects aged over 60 years
62436638|NCT01306253|EXPERIMENTAL|Adults|Adults from 18 to 60 years old inclusive
62436639|NCT03058497|ACTIVE_COMPARATOR|Temperature-Controlled Laminar Airflow Device Active|Temperature-Controlled Laminar Airflow Device
62436640|NCT03058497|PLACEBO_COMPARATOR|Temperature-Controlled Laminar Airflow Device Placebo|Temperature-Controlled Laminar Airflow Device
62436641|NCT01034137|EXPERIMENTAL|Tocilizumab + Methotrexate|Participants will receive intravenous (IV) TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + oral capsules of MTX 10-30 mg/week in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week. The weekly dose of MTX will be taken on one particular day of the week.
62825077|NCT06588998|EXPERIMENTAL|Xengenic Cortical membranes|
62825078|NCT06588998|ACTIVE_COMPARATOR|connective tissue graft|
62825079|NCT01278225||EEG biofeedback (BF) Group|Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions. After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
62825080|NCT01278225||Wait-List Control (WLC) Group|Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits. After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
62825081|NCT04868786|EXPERIMENTAL|Mycophenolate Mofetil|
62436642|NCT01034137|ACTIVE_COMPARATOR|Tocilizumab + Placebo Methotrexate|Participants will receive IV TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + weekly oral matching placebo MTX capsules in climbing dosages. The weekly dose of placebo MTX will be taken on one particular day of the week.
62436643|NCT01034137|ACTIVE_COMPARATOR|Methotrexate + Placebo Tocilizumab|Participants will receive weekly oral MTX in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week + matching placebo TCZ IV 8 mg/kg every four week for a maximum of 26 infusions. The weekly dose of MTX will be taken on one particular day of the week.
62436644|NCT04312659||Infliximab|Participants with pediatric Crohn's disease (CD) who were treated with Infliximab (IFX) and signed the Informed Consent Form (ICF) for the study will be enrolled case by case. Each participants will be followed up for at least 30 weeks. After 30 weeks, participants continuing IFX treatment will be followed up, with a maximum follow-up period of 102 weeks. The primary data source will be participants medical records for all data entered into the CRF.
62436645|NCT06540729|EXPERIMENTAL|Treatment|Disitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer
62436646|NCT01323998||5ARI monotherapy|Patients with BPH receiving 5ARI monotherapy
62436647|NCT01323998||AB monotherapy|Patients with BPH receiving AB monotherapy
62436648|NCT01323998||Early combination (5ARI + AB) therapy|Patients receiving early initiation of combination therapy with a 5ARI plus AB. Early initiation defined as starting 5ARI therapy within 30 days of initiating AB therapy
62436649|NCT01323998||Delayed combination (5ARI + AB) therapy|Patients receiving delayed initiation of combination therapy with a 5ARI plus AB. Delayed initiation defined as starting 5ARI therapy more than 30 days but less than 6 months after initiating AB therapy
62436650|NCT00367406|EXPERIMENTAL|Treatment with a Gamma 3 nail.|
62436651|NCT03988725|EXPERIMENTAL|Vitamin E intervention|All study participants receive Vitamin E 800 IU once daily for 6 months
62436652|NCT03539315|EXPERIMENTAL|Intervention: ARCHES|All women attending facilities assigned to the intervention arm receive the Addressing Reproductive Coercion within Healthcare Settings (ARCHES) intervention.
62436653|NCT03539315|NO_INTERVENTION|Control|All women attending facilities assigned to the control arm receive the standard of care (no intervention).
62436654|NCT06240845|EXPERIMENTAL|High Level Laser Therapy|This group received High-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
62436655|NCT06240845|EXPERIMENTAL|Low Level Laser Therapy|This group received Low-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
62436656|NCT05250349||Isolated HF Group|Patients with echocardiography - confirmed Heart Failure (HFmrEF and HFrEF) and clinical symptoms (NYHA I-III).
62436657|NCT05250349||HF + CS group|Patients with echocardiography - confirmed Heart Failure (HFmrEF and HFrEF) with NYHA I-III symptoms, who were diagnosed with flow limiting Carotid Stenosis on carotid Doppler ultrasound.
62436658|NCT05250349||Control group|A cohort of patients without Heart Failure or other significant cardiac pathology and without Carotid Stenosis (a paired propensity match will be performed).
62825082|NCT04526340|EXPERIMENTAL|Nutrient day|on the nutrient day the subjects will take the testing food/nutrient capsules with 500 ml water
62825083|NCT04526340|PLACEBO_COMPARATOR|Control day|on the control day the subjects will take 500 ml water without nutrient/food capsules
62436659|NCT05491174|EXPERIMENTAL|DBT-Informed Intervention|The DBT-informed group intervention, known as the 'Managing Emotions Group', will consist of 90-minute sessions, run weekly over 10 weeks.
62436660|NCT05491174|NO_INTERVENTION|Wait-list control|Participants will be placed on a wait-list for up to 18 weeks.
62436661|NCT03518697|EXPERIMENTAL|Exercise Group|"1. First 6 months supervised exercise program with telephone contact every two weeks~2. Second 6 months exercise program without telephone contact~3. Patients should increase habitual daily physical activity for 10-20 minutes per day 5 times per week~4. Activities were chosen according to the preferences, interests, and severity of disease of the patients~5. Activites should improve endurance, strength, coordination and flexibility~6. Every three month regular vistit at the CF care center (medical examination, lung function, exercise testing, counselling and evaluation of activities by acceleometry and if appropirate adaption of exercise program)"
62436662|NCT03518697|NO_INTERVENTION|Control-Group|"1. 12 months usual routine care and habitual exercise in daily life.~2. At start and after 12 month assessment of habitual exercise with accelerometry (Actigraph GTX3)"
62436663|NCT06481696|ACTIVE_COMPARATOR|Resveratrol group|Treatment with resveratrol, folic acid and vitamins B6, B12, D. The duration of treatment will be at least 65 days before the starting of stimulation (from the stage of pre-antral follicles) and until the day of oocyte pick up.
62436664|NCT06481696|ACTIVE_COMPARATOR|Placebo group|Treatment with folic acid only. The duration of treatment will be at least 65 days before the starting of stimulation (from the stage of pre-antral follicles) and until the day of oocyte pick up.
62436665|NCT02573428||Autism Spectrum Disorder|Individuals who receive a clinical diagnosis of Autism Spectrum Disorder
62436666|NCT02573428||Developmental/Psychiatric Controls|Individuals who receive a clinical diagnosis of another developmental or psychiatric disorder
62436667|NCT02573428||Healthy Controls|Individuals who have no specific developmental or psychiatric diagnosis
62825084|NCT03708731||Sickle Cell Disease|All participants who meet eligibility requirements and consent to the study.
62825085|NCT05661643|EXPERIMENTAL|temozolomide treatment|
62825086|NCT02559453|ACTIVE_COMPARATOR|2 operations|Subjects in this arm will receive a maximum of two surgical debridements of their wound.
62825087|NCT02559453|ACTIVE_COMPARATOR|3 or more operations|Subjects in this arm will receive three or more surgical debridements of their wound.
62825088|NCT06106360||3 Cohorts|Cohort 1: Daily from day 2 through the end of treatment cycle (n=34) Cohort 2: Daily days 2-9 then every third day through end of cycle (n=33) Cohort 3: Daily days 2-9 for all symptoms, every third day thereafter regarding 'pain' only through end of cycle (n=33)
62602959|NCT06477835|ACTIVE_COMPARATOR|Test group|"During the placebo-controlled double-blind treatment phase, subjects were randomized 1:1 to the following treatment groups:~• Test group: SIM0718 300 mg SC with loading dose of 600 mg on Day 1.~During the W16-W52 Maintenance Period:~• All subjects were dosed SC at 300 mg SIM0718."
62043678|NCT06369259|EXPERIMENTAL|Safety Run In|"If you are enrolled in the Safety Run In group, the dose of avutometinib you receive will depend on when you join this study. Up to 3 dose levels of avutometinib will be tested, and between 3-6 participants will be enrolled at each dose level.~The first group of participants will receive the planned starting dose level of avutometinib. Then, if no intolerable side effects are seen, a second group of participants will be enrolled to receive a higher dose. If intolerable side effects are seen, the second group will receive a lower dose. One of these 3 doses will be selected as the recommended dose of avutometinib in combination with cetuximab and defactinib."
62043679|NCT06369259|EXPERIMENTAL|Expansion|If you are enrolled in the Expansion, you will receive avutometinib at the recommended dose that was found in Safety Run In.
62043680|NCT06731920||Main study group|Patients undergoing cervical medial branch blocks as part of their usual care.
62602960|NCT06477835|PLACEBO_COMPARATOR|Control group|"During the placebo-controlled double-blind treatment phase, subjects were randomized 1:1 to the following treatment groups:~• Volume-matched placebo SC, placebo loading dose on Day 1.~During the W16-W52 Maintenance Period:~• All subjects were dosed SC at 300 mg SIM0718."
62043681|NCT05356884|EXPERIMENTAL|Diabetes Intervention|12-session behavioral intervention covering diabetes pathology, self-monitoring, medication adherence, identifying and responding to emergency situations, diet, physical activity, health care utilization and maintaining healthy habits.
62043682|NCT05356884|ACTIVE_COMPARATOR|Leadership & Life Skills|12-session leadership and life skills intervention focusing on adolescent self-esteem, self-efficacy, communication skills, mindfulnesss, healthy habits.
62043683|NCT02718274|NO_INTERVENTION|Control|Standard of care.
62043684|NCT02718274|ACTIVE_COMPARATOR|Self-testing|Community-Based Distribution Agents (CBDAs) in the HIV Self-Testing (HIVST) Arm villages will be trained to provide HIVST services as well as reproductive health services.
62825089|NCT04270266|EXPERIMENTAL|Group I (meditation)|Patients attend meditation group sessions over 75 minutes once weekly for up to 5 weeks.
62825090|NCT04270266|ACTIVE_COMPARATOR|Group II (educational)|Patients attend educational group sessions over 75 minutes once weekly for up to 5 weeks.
62602961|NCT00628849||1|This group will have 2 mm plates and screws placed according to Champy principles
62602962|NCT00628849||2|This group will have 2 mm plates placed according to modified Champy principles
62825091|NCT06597630||unilateral primary aldosteronism group|The patient was diagnosed with unilateral primary aldosteronism and underwent total adrenal resection
62043685|NCT02718274|ACTIVE_COMPARATOR|Self-testing + home HIV care home initiation|CBDAs will be trained to provide HIV Self-Testing plus offer home assessment and HIV care initiation (first assessment and first 14 days of HIV care medications), with this additional intervention aimed at facilitating linkage into care.
62825092|NCT06588790|EXPERIMENTAL|Home-based rapid self-testing|Participants randomized to the home-based testing arm will be provided with rapid diagnostic tests (RDTs) for priority conditions (malaria, HIV, pregnancy) that can be used on-demand and without prior approval, if/when indicated. In this study arm, testing will be conducted primarily by the participant. Participants will be taught to use applicable RDTs at the baseline visit and a stock of RDTs with instructions for use will be left in the household.
62825093|NCT06588790|EXPERIMENTAL|Community health worker (CHW)-facilitated rapid testing|Participants who are randomized to the CHW-facilitated rapid testing arm will have access to in-home testing and information through the research team. The research team will include a CHW and/or nurse who has a supply of RDTs and can conduct RDT testing, if/when indicated. This study arm is intended to be similar to local CHW-facilitated healthcare delivery programs, which may vary by country. All testing that is conducted in this arm will be performed by the CHW (or research team).
62825094|NCT06588790|NO_INTERVENTION|Standard of care|Households randomized to the standard of care arm will receive education on indications for testing for priority conditions. Participants will be instructed to seek screening/testing at the local clinic, if/when indicated. This study arm is intended to be similar to local routine health care delivery for those in the household, which may vary by country.
62825095|NCT06589947|ACTIVE_COMPARATOR|Standard BP group|The treatment goal for the standard group is to achieve BP levels \<90th pct.
62436668|NCT04607642|EXPERIMENTAL|A BMX-001|Patients will receive standard of care radiation therapy plus Cisplatin. BMX-001 will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks.
62602963|NCT00628849||3|This group will have larger (2.3 mm or greater) plates and screws placed according to the AO technique
62825096|NCT06589947|EXPERIMENTAL|Intensified BP group|Treatment goal in the intensified group will be lowering BP ≤60th pct.
62825097|NCT06590870|EXPERIMENTAL|Intranasal fentanyl plus standard of care|"One dose of fentanyl 1.5 µg/kg via a mucosal atomization device 10 minutes before the PICC placement.~Standard of care includes sucrose 24% oral solution with or without non-nutritive sucking."
62043686|NCT03520764|EXPERIMENTAL|New infant formula with synbiotics|pHP infant formula with synbiotics (test product)
62043687|NCT03520764|ACTIVE_COMPARATOR|Standard infant formula with prebiotics|Standard (commercial) infant formula with prebiotics (control product)
62043688|NCT03520764|NO_INTERVENTION|human milk|Full breastfeeding for at least 17 weeks
62436669|NCT04607642|PLACEBO_COMPARATOR|B Placebo|Patients will receive standard of care radiation therapy plus Cisplatin. Placebo will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks.
62436670|NCT01510665|EXPERIMENTAL|Magnesium Supplement|Magnesium citrate dietary supplement (300 mg elemental Magnesium daily dose) given week 13 to week 28 (two pills daily)
62436671|NCT01510665|PLACEBO_COMPARATOR|Placebo|Identical appearing pill with inactive ingredients given week 13 to week 28 (two pills daily)
62436672|NCT01510665|ACTIVE_COMPARATOR|Diet|Nutritionist counseling session and advice on following a magnesium rich diet from week 13 to week 28
62043689|NCT04307004|OTHER|Unattended vs Attended Blood Pressure|Participants blood pressure will be measured three times attended and three times unattended using the Microlife WatchBP Office AFIB device. Whether investigators measure blood pressure attended first and then unattended or unattended first and then attended will be assigned using a random number generator. At visit 2, clinic blood pressure will be measured three times attended and three times unattended using the Microlife WatchBP Office AFIB device, as at visit 1, but in the reverse order.
62825098|NCT06590870|PLACEBO_COMPARATOR|Intranasal normal saline plus standard of care|"One dose of normal saline (volume equivalent to fentanyl 1.5 µg/kg) via a mucosal atomization device 10 minutes before the PICC placement.~Standard of care includes sucrose 24% oral solution with or without non-nutritive sucking."
62043690|NCT04307004|OTHER|ABPM vs HBPM|Participants will be fitted with either the Microlife WatchBP O3 ambulatory blood pressure monitoring device or instructed on how to use the Microlife WatchBP Home N home blood pressure device, depending on which they are assigned to complete first. The order in which participants undergo ambulatory or home blood pressure monitoring will be assigned through a random number generator.
62602964|NCT04875312|EXPERIMENTAL|Group USC|Effect of ultrasound cavitation sessions on sex hormones in obese infertile patients with poly cystic ovarian syndrome
62602965|NCT04875312|EXPERIMENTAL|Group EA|Effect of electro acupuncture on sex hormones in obese infertile patients with poly cystic ovarian syndrome
62602966|NCT06648954|EXPERIMENTAL|Multisite HD-tDCS group|"Device:~Constant current will be applied for 20min and the electrodes will be placed over the target area"
62602967|NCT06648954|SHAM_COMPARATOR|Sham stimulation group|The stimulator will be applied for 20 minutes with only 30s ramp-up and ramp-down stimulation delivered. The patients will feel the initial itching sensation at the beginning in order to evaluate the placebo effect.
62602968|NCT06648954|ACTIVE_COMPARATOR|Conventional tDCS Group|Constant current (2mA) will be applied for 20min and the anode will be placed over the standard C3/C4 position.
62602969|NCT01756963||IBD-SL cohort|
62602970|NCT00284427|EXPERIMENTAL|1|Vitamin C
62602971|NCT05863091|EXPERIMENTAL|A group of patients undergoing pulmonary function tests|Patients undergoing pulmonary function tests with spontaneous breathing
62602972|NCT05863091|EXPERIMENTAL|A group of patients on ventilators in an intensive care unit|Among patients who are on a ventilator, those on the Richmond agitation sedation scale -4 to -5 and who do not breathe spontaneously
62602973|NCT00655473|EXPERIMENTAL|Dalcetrapib (RO4607381)|
62602974|NCT00655473|PLACEBO_COMPARATOR|Placebo|
62825099|NCT05978167|EXPERIMENTAL|Methylphenidate then Placebo|20 mg of methylphenidate then matching placebo pill.
62825100|NCT05978167|PLACEBO_COMPARATOR|Placebo then Methylphenidate|Matching placebo pill then 20 mg of methylphenidate.
62602975|NCT03273400|EXPERIMENTAL|Mobilisations|"The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The plinth will rest on force plates to allow the authors to analyse the force placed through the vertebrae. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.~Following the intervention all measure lumbar flexion, hamstring extensibility and sEMG activity will be recorded immediately, 5, 10, 15, 20, 30, 60 minutes post application as a single test."
62602976|NCT03273400|NO_INTERVENTION|Control|All outcome measures (lumbar/hamstring range of motion; EMG activity of the Biceps Femoris and Erector Spinae) will be measured. The control group will then receive no intervention and be asked to lie supine on a plinth for the treatment duration before having the outcome measures reassessed.
62602977|NCT05250687|EXPERIMENTAL|MR guided high intensity focused ultrasound (MR-HIFU)|MRHIFU treatment will be delivered using the ExAblate 2100 System (INSIGHTEC, Tirat Carmel, Israel), which is an FDA-approved device for pain palliation of bone metastases.
62602978|NCT05250687|ACTIVE_COMPARATOR|External beam radiation therapy (EBRT)|Patients will undergo radiotherapy for painful bone metastases.
62602979|NCT06505161|ACTIVE_COMPARATOR|Dry needling group|The dry needling group will recibe a dry needling treatment with the Hong technique.
62602980|NCT06505161|EXPERIMENTAL|Percutaneous electrolysis group|The percutaneous electrolysis grupos will recibe a tratement of galvanic current at 1.5mA, with 3-5 impacts, for 3-5 seconds in the low back multifiud muscles.
62602981|NCT05952804|EXPERIMENTAL|Arm I (therapeutic immune globulin)|Patients receive IGRT with IVIG within 14 days prior to CD19 CAR-T treatment. Patients then undergo CD19 CAR-T therapy. Patients receive IVIG monthly, starting 28 days after CD19 CAR-T therapy for 4 months in the absence of unacceptable toxicity. Patients also undergo blood sample collection throughout the study.
62602982|NCT05952804|PLACEBO_COMPARATOR|Arm II (normal saline)|Patients receive placebo with normal saline IV within 14 days prior to CD19 CAR-T treatment. Patients then undergo CD19 CAR-T therapy. Patients receive normal saline monthly, starting 28 days after CD19 CAR-T therapy for 4 months in the absence of unacceptable toxicity. Patients also undergo blood sample collection throughout the study.
62825101|NCT06589427||Invasively ventilated intensive care unit patients.|Critically ill patients receiving invasive ventilation for various reasons, like ARDS, or AHRF.
62825102|NCT06604182|EXPERIMENTAL|HCV positive|Eligible participants that are HCV infected.
62246264|NCT03398525|EXPERIMENTAL|Musical intervention|"After patient information, appropriate skin antisepsis according to local procedures, surgical hand antisepsis by the operator, use of sterile drapes, gowns and gloves, insertion of a central venous catheter after after local anesthesia with 2% lidocaine, using ultrasound guidance.~In addition, a U-shaped music program (MUSIC CARE, trade mark) will be delivered to the patient through headphones throughout the catheter insertion procedure beginning with the operator's hand washing and ending once the dressing is put on the catheter insertion site."
62825103|NCT06595446|EXPERIMENTAL|Arm A|Early Stent removal
62825104|NCT06595446|ACTIVE_COMPARATOR|Arm B|Late Stent removal
62246265|NCT05487339|ACTIVE_COMPARATOR|upper lumbar ESPB group|Group where ESPB is performed at L2 with local anesthetic mixture 20 ml
62246266|NCT05487339|ACTIVE_COMPARATOR|lower lumbar ESPB group|Group where ESPB is performed at L4 with local anesthetic mixture 20 ml
62825105|NCT06035159|OTHER|online psychotherapy|All participants have access to the psychotherapeutic intervention, which consists of 6 modules. Initially, we want to get information about the feasibility, comprehensibility and satisfaction of the participants with the tool. Secondly, the effectiveness of the intervention will be assessed through a pre-post measurement.
62825106|NCT05981235|EXPERIMENTAL|AZD6422|It is anti-CLDN18.2 CAR-T cell therapy and the study consists of two parts: dose escalation (part 1) and dose expansion (part 2)
62825107|NCT02364700|EXPERIMENTAL|interventional group|This is a single group, interventional pilot study. All participants will receive 6-week hand training on the HOH device.
62825108|NCT00811590|EXPERIMENTAL|All patients|All participants enrolled.
62246267|NCT00628173|EXPERIMENTAL|1|patients with refractory glaucoma who were candidate for AGV implantation allocated in superior site
62246268|NCT00628173|EXPERIMENTAL|2|patients with refractory glaucoma who were candidate for AGV implantation allocated in inferior site
62246269|NCT04964570|EXPERIMENTAL|Video and behavioral change module (BCM) + booster|Participants will watch the video and read the BCM twice (day 1 and day 14)
62246270|NCT04964570|EXPERIMENTAL|Video and behavioral change module (BCM)|Participants will watch the video and read the BCM once (day 1 only)
62246271|NCT04964570|NO_INTERVENTION|Control|This arm will recieved the same length video with a content that is not related to mental health and no BCM
62246272|NCT05273957|EXPERIMENTAL|Case Manager|Patients are followed up by a case manager
62246273|NCT05273957|ACTIVE_COMPARATOR|Standard-of-care|Patients are followed up only by the neurologist
62246274|NCT00631501|PLACEBO_COMPARATOR|2|
62246275|NCT00631501|EXPERIMENTAL|Doxycycline|100 mg twice daily
62246276|NCT01506960|EXPERIMENTAL|Coronary stenting with OCT, NIRS/IVUS|All subjects will have Near Infrared Spectroscopy/Intravascular Ultrasound Imaging performed.
62246277|NCT00894686|EXPERIMENTAL|All subjects|Assessment of seropersistence of TBE antibodies at yearly intervals from approximately 3 years (38 months) to 10 years (118 months) after the first booster vaccination (in Study 700401), as well as antibody response to a second booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5 mL, depending on the subject´s age. Timing of the second booster vaccination will depend on the level of serum TBE antibodies detected at the defined assessment time points. Subjects who are not protected against TBE for an entire further season (NT titer \<= 20 and/or ELISA value \<=126 VIE U/mL) will be invited to receive the second booster vaccination at either the 40, 48, 60, 72, 84, 96, 108, or 120-month time point.
62246278|NCT02888665|EXPERIMENTAL|Treatment (pembrolizumab, doxorubicin hydrochloride)|Patients receive pembrolizumab IV over 30 minutes on day 1 and doxorubicin hydrochloride IV over 1-3 hours on day 1 of courses 2-7 only. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62246279|NCT03882242|EXPERIMENTAL|Intervention Program Facilitators|"Participants will learn about and deliver (facilitate) a prevention program In favor of Myself to school-children"
62246280|NCT04900558||Radical Cystectomy|Patients who underwent radical cystectomy for bladder cancer in our centre
62825109|NCT00844701||Non-smoker|Non-smoking control
62043691|NCT04668885|EXPERIMENTAL|Primary refractory/relapsed AML|Lower dose CPX-351 in participants with primary refractory/relapsed AML. Participants will receive an induction and maintenance phase of CPX-351
62043692|NCT04668885|EXPERIMENTAL|MDS after HMA failure|Lower dose CPX-351 in participants with MDS after HMA failure. Participants will receive an induction and maintenance phase of CPX-351
62246281|NCT00247936|ACTIVE_COMPARATOR|1|Combined Thoracoscopic and Laparoscopic Esophagectomy
62246282|NCT00247936|ACTIVE_COMPARATOR|2|Hand-Assisted Transhiatal Esophagectomy
62246283|NCT02032602|ACTIVE_COMPARATOR|1, CG: Active MTrP|a single session of physical therapy intervention which will be consisted on Deep Dry Needling of the active MTrP most hyperalgesic to palpation of the infraspinatus muscle homolateral to painful shoulder
62246284|NCT02032602|EXPERIMENTAL|2, EG: Active+Latent MTrPs|The same treatment described above for the Control Group, combined with the Deep Dry Needling of the most hyperalgesic latent MTrP, both located in the infraspinatus muscle homolateral to the painful shoulder.
62246285|NCT06710613||control group|conventional nasal cannula oxygen group
62825110|NCT00844701||Nicotine Dependent Smoking Group|current smokers
62825111|NCT02952508|EXPERIMENTAL|Iopofosine I 131, intravenous administration WM|Iopofosine I 131 in Waldenstroms Macroglobulinemia
62825112|NCT02952508|EXPERIMENTAL|Iopofosine I 131, intravenous administration MM|Iopofosine I 131 in Multiple Myeloma
62825113|NCT02952508|EXPERIMENTAL|Iopofosine I 131, intravenous administration CNS Lymphoma|Iopofosine I 131 in Central Nervous System Lymphoma
62043693|NCT04578990|EXPERIMENTAL|Walking intervention group|It will consist of performing the Treadmill training progression for 36-72 sessions. 3 sessions of 60 minutes, will be held weekly.
62043694|NCT04578990|EXPERIMENTAL|Strength intervention group|The training program consists of performing a training program with resistance exercises for 36-72 weeks.
62043695|NCT04578990|EXPERIMENTAL|Concurrent intervention group|The training program consists of alternating strength and resistance stimuli in the same session for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied for 35 minutes and to complete the 60 minutes, the same guidelines will be followed as in the walking exercise, applying resistance stimuli.
62043696|NCT04578990|NO_INTERVENTION|Control group|It will receive standard advice consisting of the recommendation to perform aerobic exercise at the lower limbs level.
62602983|NCT03565263||FGID-IBD|"* Patients aged 9-18 years~* with inflammatory bowel disease (Crohns, ulcerative colitis or indeterminate colitis)~* in remission (defined as: Physician's global assessment = remission, no nocturnal stools, no blood in stools, \< or = 3 stools/day, C-reactive-protein \< 10 mg/L, Erythrocyte sedimentation rate \< 20 mm, no flare of disease or change of treatment in the last 3 months, no ongoing corticosteroid therapy~* followed for IBD for at least 1 year~* with at least one Functional Gastrointestinal disorder according to the Fr-qPGS questionnaire (Rome III criteria)"
62043697|NCT02436330|EXPERIMENTAL|Exergaming and Didactic health teaching|Participation of child and parent/guardian in 6 months of weight management programming consisting of exergaming combined with didactic teaching.
62043698|NCT02436330|ACTIVE_COMPARATOR|Didactic health teaching|Participation of child and parent/guardian in 6 months of weight management programming consisting only of didactic teaching.
62043699|NCT06198465|EXPERIMENTAL|adebrelimab combined with chemotherapy|
62043700|NCT01416870|EXPERIMENTAL|Active 1|34 subjects will receive ICI176,334-1without water
62246286|NCT06710613||experimental group|high flow nasal cannula oxygen group
62246287|NCT02946593|EXPERIMENTAL|Treatment|Participants in the treatment group will attend a once a week 7-week outdoor fall prevention program that includes didactic presentations, group discussions/problem solving, practice in strategy use, and action planning for safe community mobility.
62246288|NCT02946593|ACTIVE_COMPARATOR|Control|Participants in the control group will receive written information about preventing outdoor falls.
62246289|NCT00232583|ACTIVE_COMPARATOR|Metfomin and Insulin|Metformin 1000mg/BID and Insulin Novolog 70/30 per protocol titration
62436673|NCT02557672|ACTIVE_COMPARATOR|Fresh frozen plasma|After cardiopulmonary bypass, patients will receive protamine at dose 0.01 mg/unit of heparin given with target activated clotting time (ACT) within 10% of baseline value. After protamine administration the ACT, complete blood count (CBC), prothrombin time (PT)/ international normalized ratio (INR), activated partial thromboplastin time (APTT), and fibrinogen, will be collected via preexisting arterial access. If ACT \>10% baseline additional protamine will be given at the anesthesiologists discretion. Evaluation and determination of excessive microvascular bleeding in the surgical field will occur 10 minutes after return of ACT to within 10% of baseline. Patients with clinical evidence of excessive microvascular bleeding in the surgical field as determined by the surgical team, along with a PT \>16.6 sec/ INR \>1.6 sec will receive fresh frozen plasma as this is standard therapy per our institutional algorithm at a dose of 10-15 mL/kg rounded up to the nearest unit.
62043701|NCT01416870|EXPERIMENTAL|Active 2|34 subjects will receive ICI176,334-1 with water
62043702|NCT01416870|EXPERIMENTAL|Active 3|34 subjects will receive Casodex 80 mg tablet
62043703|NCT02565043|EXPERIMENTAL|RENASYS TOUCH Negative Pressure Wound Therapy Device|"Active Device: RENASYS TOUCH NPWT device administered to all patients using the intermittent/variable therapy mode, for up to 28 days of therapy."
62246290|NCT00232583|ACTIVE_COMPARATOR|Metformin, Pioglitazone and Glyburide|Metformin 1000mg/BID, Pioglitazone 45 mg and glyburide per protocol titration
62246291|NCT05743504|EXPERIMENTAL|Immunotherapy with CCRT before surgery|Tiragolumab and Atezolizumab with CCRT before surgery
62246292|NCT05613166|EXPERIMENTAL|everolimus 1h|The study participants will orally receive everolimus within 1 hour and placebo at 8-9 hours after each seizure event, but with intervals longer than 24 hours.
62246293|NCT05613166|EXPERIMENTAL|everolimus 8-9h|The study participants will orally receive placebo within 1 hour and everolimus at 8-9 hours after each seizure event, but with intervals longer than 24 hours.
62246294|NCT05613166|PLACEBO_COMPARATOR|placebo|The study participants will orally receive placebo both within 1 hour and at 8-9 hours after each seizure event, but with intervals longer than 24 hours.
62246295|NCT00419120|EXPERIMENTAL|Neo-bladder construction|Surgical implantation of autologous neo-bladder construct
62246296|NCT05087160||semester pre pandemia in sub sectors of public health care in Uruguay|all birth in sub sectors of public health care between march 15 and September 30 of 2019, pre pandemia
62246297|NCT05087160||semester pre pandemia in sub sectors of private health care in Uruguay|all birth in sub sectors of private health care between march 15 and September 30 of 2019, pre pandemia
62246298|NCT05087160||semester with mitigation measures against COVID 19 in sub sectors of public health care in Uruguay|all birth in sub sectors of public health care between march 15 and September 30 of 2020, with mitigation measures against COVID- 19
62246299|NCT05087160||semester with mitigation measures against COVID 19 in sub sectors of private health care in Uruguay|all birth in sub sectors of private health care between march 15 and September 30 of 2020, with mitigation measures against COVID- 19
62436674|NCT02557672|EXPERIMENTAL|Prothrombin complex concentrate|After cardiopulmonary bypass, patients will receive protamine at dose 0.01 mg/unit of heparin given with target ACT within 10% of baseline value. After protamine administration the ACT, CBC, PT/ INR, APTT, and fibrinogen, will be collected via preexisting arterial access. If ACT \>10% baseline additional protamine will be given at the anesthesiologists discretion. Evaluation and determination of excessive microvascular bleeding in the surgical field will occur 10 minutes after return of ACT to within 10% of baseline. Patients with clinical evidence of excessive microvascular bleeding in the surgical field as determined by the surgical team, along with a PT \>16.6 sec/ INR \>1.6 sec will receive Prothrombin complex concentrate (Human) 15 units/kg.
62436675|NCT00653653||Group A|Recruited patients will be prospectively observed as one cohort with genotyping/medication interaction analysis after 3 months, followed up by a further 3 month observational period.
62436676|NCT03125057|EXPERIMENTAL|low light dose|PDT is applied to the patients at low light dose : power density of 60mW/cm2 for 20 minutes
62436677|NCT03125057|EXPERIMENTAL|high light dose|PDT is applied to the patients at high light dose : power density of 75mW/cm2 for 20 minutes
62623868|NCT05635877|EXPERIMENTAL|Experimental:Esmolol|The treatment group was given esmolol 0.5mg/kg load, 10μg /kg/min continuous pump; Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was \>3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.
62825114|NCT02952508|EXPERIMENTAL|Iopofosine I 131 intravenous administration NHL [CLOSED]|Iopofosine I 131 in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Diffuse Large B-Cell Lymphoma
62825115|NCT03955146|EXPERIMENTAL|Main Study Cohort: Pamrevlumab|Participants will receive pamrevlumab 30 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion every 3 weeks for up to 48 weeks in the DB period.
62825116|NCT03955146|PLACEBO_COMPARATOR|Main Study Cohort: Placebo|Participants will receive placebo matching to pamrevlumab by IV infusion every 3 weeks for up to 48 weeks in the DB period.
62825117|NCT03955146|EXPERIMENTAL|Japan Extension Cohort: Pamrevlumab|Participants will receive pamrevlumab 30 mg/kg by IV infusion every 3 weeks for up to 48 weeks.
62825118|NCT03955146|PLACEBO_COMPARATOR|Japan Extension Cohort: Placebo|Participants will receive placebo matching to pamrevlumab by IV infusion every 3 weeks for up to 48 weeks.
62825119|NCT03955146|EXPERIMENTAL|OLE Period: Pamrevlumab/Pamrevlumab|Participants who receive pamrevlumab in the DB period will continue to receive the same dose of pamrevlumab for up to 48 weeks in the OLE period or until pamrevlumab is commercially available for the indication of IPF, or the sponsor decides to end the OLE period, whichever occurrs first.
62825120|NCT03955146|EXPERIMENTAL|OLE Period: Placebo/Pamrevlumab|Participants who receive placebo matching to pamrevlumab in the DB period, will receive pamrevlumab 30 mg/kg by IV infusion every 3 weeks for up to 48 weeks in the OLE period or until pamrevlumab is commercially available for the indication of IPF, or the sponsor decides to end the OLE period, whichever occurrs first.
62043704|NCT02565043|ACTIVE_COMPARATOR|RENASYS TOUCH Negative Pressure Wound Therapy System|"Active Device: RENASYS TOUCH NPWT device administered to all patients using the continuous therapy mode for up to 28 days of therapy."
62246300|NCT02308007|ACTIVE_COMPARATOR|Terconazole vaginal gel|One applicator full at bedtime
62246301|NCT02308007|ACTIVE_COMPARATOR|Metronidazole vaginal gel|One applicator full at bedtime
62246302|NCT02308007|ACTIVE_COMPARATOR|Terconazole/metronidazole vaginal gel|One applicator full at bedtime
62246303|NCT05638022||Newborns|Newborns matching inclusion criteria
62246304|NCT05661058||Total number of participants|As this is not an intervention study, the investigators only have one group which the investigators will follow at two-time points to map the context of sedentary behaviour.
62246305|NCT00369785|EXPERIMENTAL|Arm I - Donepezil|Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day
62246306|NCT00369785|PLACEBO_COMPARATOR|Arm II - Control|Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day
62246307|NCT05455710|EXPERIMENTAL|VigiApp|"the intervention group, which will use the mobile application to detect SSI. The Vigi-App application will be installed on the Smartphone of the selected patients, who will receive training on how to use the application; should access it on days seven, 14, 21 and 30 after the surgical procedure, they will additionally be evaluated in person in an outpatient consultation, according to the hospital routine.~The patients in the intervention group will receive notices the day before, through reminders issued by the application, reminding them that they must access and complete the requested information. If the patient presents signs and symptoms of infection on dates other than filling out the application, he can access the application and send his data normally as an extra access."
62436678|NCT03187054|ACTIVE_COMPARATOR|POPQ-based surgery|will undergo anterior or posterior colporrhaphy for all of anterior or posterior vaginal prolapse stage 2 or greater (i.e. point Ba or Bp ≥-1 on the POPQ examination)
62043705|NCT06731972|ACTIVE_COMPARATOR|Group 1 (Routine treatment)|Routine treatment (classical massage, stretching, functional exercises, electrical modalities, thermal agents, home exercises, etc.) will be applied.
62043706|NCT06731972|EXPERIMENTAL|Group 2 (Routine treatment + mobile game)|The routine treatment plus mobile game group will receive routine treatment along with 20-30 minutes of mobile application games (such as Temple Run, Flappy Bird, Angry Birds, etc.) daily as part of their home exercise program.
62043707|NCT03152383|EXPERIMENTAL|Autism Spectrum Disorder|Children diagnosed as having autism spectrum disorder
62436679|NCT03187054|EXPERIMENTAL|Simulated apical support-based surgery|will undergo anterior or posterior colporrhaphy only for the prolapse unresolved under simulated apical support (i.e. point Ba or Bp ≥-1 under simulated apical support)
62825121|NCT06448559||Patients with Chronic obstructive pulmonary disease (COPD)|Patients who have joined a long-term and remote Maintenance Pulmonary Rehabilitation Programmes (M-PRP) No intervention Semi-directive interview
62825122|NCT06448559||Informal caregivers|Informal caregivers designated by patients who participated in M-PRP No intervention Semi-directive interview
62825123|NCT06448559||Care-managers|Health professionals who have carried out the mission of monitoring coordinator (care-manager) within the framework of a M-PRP No intervention Semi-directive interview
62825124|NCT06594666|EXPERIMENTAL|VR/AR visual training group|Wear glasses for correction combined with VR/AR visual training in the first 6 months, and terminate the training for follow-up observation in the last 6 months. Regular follow-up every 3 months, with a total follow-up time of 1 year.
62825125|NCT06594666|NO_INTERVENTION|control group|No intervention, simply wearing glasses for correction, followed up every 3 months for a total of 12 months.
62825126|NCT03861897|EXPERIMENTAL|Intervention KRP-NI + KM|Realization of Non instrumental pleural chest physiotherapy and Mobilization physiotherapy sessions (KRP-NI)
62043708|NCT03152383|ACTIVE_COMPARATOR|Typically developing|Children who are typically developing
62825127|NCT03861897|ACTIVE_COMPARATOR|Control KM|Realization of mobilization physiotherapy sessions (KM)
62825128|NCT03598842|EXPERIMENTAL|Malnourished without lung parasites|Thirty study participants, household contacts of an index TB case, who are malnourished and do not have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and will be given a vegan meal plan.The consented household contact will also receive a daily multivitamin.
62825129|NCT03598842|EXPERIMENTAL|Malnourished with lung parasites|Thirty study participants, household contacts of an index TB case, who are malnourished and have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and will be given a vegan meal plan. The consented household contact will also receive a daily multivitamin. These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.
62825130|NCT03598842|ACTIVE_COMPARATOR|Well-nourished with lung parasites|These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.
62043709|NCT03152383|ACTIVE_COMPARATOR|Other Developmental Delay|Children diagnosed with a developmental delay other than autism spectrum disorder
62825131|NCT03598842|NO_INTERVENTION|Well-nourished without lung parasites|These thirty study participants will serve as the control.These participants will be well-nourished and not have a parasite infection; therefore, they will not receive the nutritional supplementation or treatment for parasite infection.
62825132|NCT06104462|EXPERIMENTAL|Cortical hemodynamic variability of iTBS and its courses|"A group of healthy adults shall undergo repeated experimental visits with concurrent TBS/fNIRS (3≤repetition≤15). An interval of at least two days (48 hours) between the visits is required to minimize carry-over effects from the iTBS protocols.~Inter- (age, gender, personality inventory, etc.) and intra-individual factors (daily mood, daily sleep quality, physical activity levels, etc.) that are potentially moderating iTBS-induced excitability changes will be explored."
62825133|NCT04272086|PLACEBO_COMPARATOR|Bupivacaine TAP|TAP block with 30 mL 0.25% bupivacaine mixed with 10 mL normal saline for a total of 40 mL per side
62825134|NCT04272086|EXPERIMENTAL|Liposomal bupivacaine TAP|TAP block with 10mL liposomal bupivacaine, 20mL 0.25% bupivacaine, and 10mL normal saline for a total of 40 mL per side
62246308|NCT05455710|SHAM_COMPARATOR|telephone call|the called control, consisting of the standard infection surgical site post-discharge surveillance the developed infection of the surgical site procedure, by means of a telephone call. You will receive guidance on phone calls; will follow the standard SSI post-discharge surveillance procedure, by means of a telephone call on days seven, 14, 21 and 30 after the date of surgery, being asked about the presence of signs and symptoms of infection according to the instrument previously validated in previous investigation and will be evaluated in person in an outpatient consultation, according to the hospital routine.
62436680|NCT05907200|EXPERIMENTAL|Treatment Group|It received rehabilitation treatment consisting of a combination of manual therapy (McMennel joint manipulation, pumping and connective tissue massage) and US water immersion.
62825135|NCT05155280|EXPERIMENTAL|Anorexia Nervosa patients|"30 patients with anorexia nervosa = 15 with moderate to high anxiety (STAI YB anxiety (STAI YB \> 51) and 15 with low anxiety (STAI YB\<51).~A TOBII eye tracker will be realised at Day 1. PET and MRI scans will be acquired at Day 2."
62825136|NCT05155280|PLACEBO_COMPARATOR|Controls|15 healthy volunteers (control group) and a low level of anxiety trait (\< 51) A TOBII eye tracker will be realised at Day 1. PET and MRI scans will be acquired at Day 2.
62825137|NCT05742542|EXPERIMENTAL|High intensity interval training with high time spent near VO2max|"Participants performed high intensity interval training with high time spent near VO2max three times a week for two weeks.~All training sessions consisted of five times 2 minutes of work and 1 minute of passive recovery. The work intensity was adjusted at 85% and 87% of power output achieved at the end of incremental test for the first and second week, respectively.~The training sessions were performed using cycle ergometer.~Findings were compared to high intensity interval training with low time spent near VO2max, which followed the same exercise frequency, intensity and total duration."
62825138|NCT05742542|EXPERIMENTAL|High intensity interval training with low time spent near VO2max|"Participants performed high intensity interval training with low time spent near VO2max three times a week for two weeks.~All training sessions consisted of ten times 1 minutes of work and 30 seconds of passive recovery. The work intensity was adjusted at 85% and 87% of power output achieved at the end of incremental test for the first and second week, respectively.~The training sessions were performed using cycle ergometer.~Findings were compared to high intensity interval training with high time spent near VO2max, which followed the same exercise frequency, intensity and total duration."
62825139|NCT05766592|EXPERIMENTAL|LGBTQ-affirmative CBT|Individuals assigned to LGBTQ-affirmative cognitive behavioral therapy will receive 16 weekly individually-delivered sessions, directly after baseline assessment, delivered via telehealth. Based on the Unified Protocol, sessions will address minority stress mechanisms underlying sexual and gender minority mental health disparities.
62825140|NCT05766592|EXPERIMENTAL|ABFT-SGM|Individuals assigned to attachment-based family therapy for sexual and gender minorities will receive a 16-session sequence of family-based therapy delivered via telehealth. This sequence will include sessions with sexual and/or gender minority adult children alone, adult children and parent(s), and parent(s) alone. Sessions will address the quality parent-child relationship in relation to child sexual orientation and gender identity to target mental health disparities.
62825141|NCT02451722|ACTIVE_COMPARATOR|Healthy subjects|"Kyboot shoes will be administered to the healthy subjects.~Pressure distribution and gait parameters will be recorded in comparison with their normal footwear."
62825142|NCT02451722|ACTIVE_COMPARATOR|Diabetic patients|"Kyboot shoes will be administered to the diabetic patients.~Pressure distribution and gait parameters will be recorded in comparison with their normal footwear."
62825143|NCT05173194|EXPERIMENTAL|Telematic Exercise|A remotely supervised resistance exercise program will be carried out for 8 weeks, with three weekly sessions lasting approximately 60 minutes each. Training will be performed in groups of four patients, according to their lung function/physical fitness. The first training session will be on site (University) for familiarization, planning and adjustment of the exercises, and the following sessions will be performed online. Each session is divided into: (i) Warm-up and joint mobility; (ii) main part: strength exercises for different muscle groups; and (iii) cool down: stretching and breathing exercises.
62825144|NCT05173194|NO_INTERVENTION|Control|Control group will follow routine recommendations from the multidisciplinary CF team.
62825145|NCT05398172|EXPERIMENTAL|treatment|3 treatments once a month
62825146|NCT03418389||Pediatric-onset Hypophosphatasia|
62043710|NCT01186029|ACTIVE_COMPARATOR|EMEND Added to the Treatment Regimen for Post-Discharge and Post-Operative Nausea and Vomiting|The addition of Aprepitant (Emend), an antiemetic, to 2 drugs that are already used as a standard of care for post-operative nausea and vomiting and post-discharge nausea and vomiting.
62246309|NCT05214170|EXPERIMENTAL|Electroanatomic mapping with NeuTrace System|Patients with arrhythmias undergo electroanatomic mapping with the NeuTrace System.
62436681|NCT05907200|PLACEBO_COMPARATOR|Control Group|It received rehabilitation treatment consisting of manual therapy alone
62825147|NCT03481400|EXPERIMENTAL|Calcitonin gene-related peptide|Calcitonin gene-related peptide infusion (1.5 micrograms/min for 20 mins)
62825148|NCT03481400|EXPERIMENTAL|Placebo|Infusion with placebo (isotonic saline)
62825149|NCT06206564|EXPERIMENTAL|Artesunate|
62825150|NCT06206564|PLACEBO_COMPARATOR|Placebo ointment|
62825151|NCT03003026|EXPERIMENTAL|Novel task-specific program|Intervention arm - see detailed intervention group description below
62825152|NCT03003026|ACTIVE_COMPARATOR|Parent-led home-based program|Comparison arm - see detailed comparison group description below
62825153|NCT03432676|EXPERIMENTAL|Treatment (pembrolizumab, epacadostat)|Participants receive pembrolizumab IV over 30 minutes on day 1 and epacadostat PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unaccepted toxicity.
62825154|NCT03819192||neonates with signs of EONS|
62825155|NCT03819192||neonates without signs of EONS|
62825156|NCT03819192||pregnant women with PPROM|
62825157|NCT04218526|EXPERIMENTAL|Vercise DBS Group|All participants will have the Vercise DBS system implanted.
62825158|NCT06429917|OTHER|Periodontitis with bruxism|All the participants will undergo subgingival instrumentation with hand scalers, curettes and ultrasonic scaler. Parameters will be recorded at baseline and two, three and six months of time points after subgingival instrumentation.
62825159|NCT03724136|ACTIVE_COMPARATOR|Arm 1|Intravenous Bone Marrow Stem Cell (BMSC) Fraction
62043711|NCT01186029|NO_INTERVENTION|Standard Treatment Regimen for Post-Discharge and Post-Operative Nausea and Vomiting|No addition of Aprepitant (Emend), an antiemetic, to 2 drugs that are already used as a standard of care for post-operative nausea and vomiting and post-discharge nausea and vomiting.
62043712|NCT01196338|ACTIVE_COMPARATOR|Non-weightbearing no ROM|"Patients will be placed in a back slab post-op and will remain non-weight bearing with crutches with no range of motion for a total of 6 weeks.~After 6 weeks post-op, they will be placed in a boot orthosis and permitted to weight-bear as tolerated."
62043713|NCT01196338|EXPERIMENTAL|Early weight-bearing and ROM|"Patients will be placed in a back slab post-operatively. At 2 weeks post op they will have the back slab removed and placed in a boot orthosis. At this time they will be permitted to weight-bear as tolerated and perform limited ankle range of motion exercises.~After 6 weeks post op they will start to wean from the boot orthosis."
62825160|NCT03724136|ACTIVE_COMPARATOR|Arm 2|Intravenous Bone Marrow Stem Cell (BMSC) Fraction combined with Near Infrared Light exposure .
62825161|NCT03724136|ACTIVE_COMPARATOR|Arm 3|Intravenous Bone Marrow Stem Cell (BMSC) Fraction combined with Intranasal topical Bone Marrow Stem Cell (BMSC) Fraction.
62043714|NCT01982240|ACTIVE_COMPARATOR|Plecanatide 3.0 mg|Plecanatide tablets 3.0 mg QD for 12 weeks
62043715|NCT01982240|ACTIVE_COMPARATOR|Plecanatide 6.0 mg|Plecanatide tablets 6.0 mg QD for 12 weeks
62043716|NCT01982240|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets QD for 12 weeks
62246310|NCT06495502||patients|i. be in a well-identified care path ii. Age: 12-25 years old iii. have experienced CSA iv. Child \& adolescent psychiatry treatment prior to majority and after CSA, regardless the reason for this treatment v. No acute symptoms
62246311|NCT06495502||Parents|i. child on a well-identified care path ii. child victim of CSA iii. Child disclosure during child \& adolescent psychiatry treatment iv. not being the perpetrator in case of intrafamilial CSA perpetrated by the mother or the father (the other parent could be included).
62246312|NCT06495502||child & adolescent mental health professionals|i. have experienced, directly or indirectly, at least one situation of CSA disclosure by a minor patient.
62246313|NCT00839709||depletion immunosuppression|
62436682|NCT02152787|EXPERIMENTAL|1) propofol 1.0mg/kg group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
62043717|NCT01982240|OTHER|Bisacodyl|Rescue medication
62043718|NCT05732233|EXPERIMENTAL|Ultivision AI colonoscopy (CADe Arm)|Ultivision AI is used to aid in real-time detection of adenomas.
62246314|NCT00839709||no depletion immunosuppression|
62246315|NCT03763851|EXPERIMENTAL|Cannabis group|"Delta-9 Tetrahydrocannabidiol (THC) /Cannabidiol (CBD) ratio 1:1 capsule~These capsules contain different cannabis formulations with low-dose and high-dose preparations according to the treatment group:~* Cannabis group low-dose capsule contains THC 1mg CBD 1mg~* Cannabis group high-dose capsule contains THC 2.5mg CBD 2.5mg"
62246316|NCT03763851|PLACEBO_COMPARATOR|Placebo group|"The placebo capsule will have no cannabis, it will look identical to the active treatment capsule, and it will also be prepared in low-dose and high-dose presentations."
62246317|NCT02695849||NSCLC Participants|Participants with non-squamous NSCLC will be enrolled in this study.
62246318|NCT05370612|EXPERIMENTAL|Arm 1: Continuous Glucose Monitor (CGM)|CGM for duration of pregnancy.
62436683|NCT02152787|EXPERIMENTAL|2) propofol 0.5mg/kg group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
62436684|NCT02152787|PLACEBO_COMPARATOR|3) normal saline group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
62825162|NCT00055393|ACTIVE_COMPARATOR|Subjects receivng Bupropion|The active arm subjects in this study (n = 18) received flexibly dosed bupropion in this randomized 12-week double-blind trial.
62825163|NCT00055393|PLACEBO_COMPARATOR|Subjects receiving Placebo|The inactive arm subjects in this randomly controlled study (n = 21) received a placebo.
62825164|NCT05635019|ACTIVE_COMPARATOR|Behavioral weight loss counseling (BWL) alone|BWL counseling alone
62825165|NCT05635019|EXPERIMENTAL|BWL+VOUCHER|BWL counseling and gift cards to grocery stores
62825166|NCT05635019|EXPERIMENTAL|BWL+HOME|BWL counseling and home-delivered boxes of groceries
62043719|NCT05732233|ACTIVE_COMPARATOR|Standard colonoscopy (Control Arm)|Patients will undergo standard colonoscopy without AI.
62825167|NCT04410900|EXPERIMENTAL|Experimental (anti-rabies vaccine, collection of blood)|"BOLUS COHORT: Patients receive the inactivated rabies vaccine IM on day 1 and 6-10 weeks later. Patients also undergo a blood collection prior to each vaccine, and at approximately 1, 2, and 4 weeks after each vaccination. A final blood collection occurs 6 months after the first immunization.~FRACTIONAL DOSE COHORT: Patients receive the inactivated rabies vaccine fractionated primary dose IM on days 1, 3, 7, 10, 14, and 17 and the second dose 6-10 weeks later. Patients also undergo a blood collection prior to each vaccine, and at approximately 1, 2, and 4 weeks after each vaccination. A final blood collection occurs 6 months after the first immunization."
62825168|NCT04410900|ACTIVE_COMPARATOR|Control (anti-rabies vaccine, collection of blood)|Patients receive anti-rabies vaccine IM on day 1 and 6-10 weeks later. Patients also undergo collection of blood samples at baseline, and at approximately 1, 2, and 4 weeks after each vaccination. There will be an additional blood draw 6 months (+/- 14 days) after the first immunization.
62825169|NCT03005444|EXPERIMENTAL|Anticoagulation|Rivaroxaban：10mg/d for 2 years
62825170|NCT03005444|NO_INTERVENTION|Non-anticoagulated|No anticoagulants will be used.
62043720|NCT06188572||Diabetes Mellitus|The study group included individuals aged 48-78 (min-max) years, diagnosed with type 2 DM in the treatment units of Harran University Training and Research Hospital.
62043721|NCT06188572||Healthy|Age and sex homogenous healthy individuals without a diagnosis of DM were included in the control group
62043722|NCT01081093|EXPERIMENTAL|Biventricular pacing|
62246319|NCT05370612|ACTIVE_COMPARATOR|Arm 2: Point of Care Glucose Testing (POCT)|"Point of care finger sticks for glucose monitoring.~At two time points during the study - at time of enrollment and at 28-32 weeks gestation, CGM sensor will be placed and remain in place for 10 days. Participant and Physician will be blinded to CGM data."
62825171|NCT04489173|EXPERIMENTAL|Treatment|Treatment with TAS102
62825172|NCT06600984|EXPERIMENTAL|physical therapy group|Control group: received a designed physical therapy program
62825173|NCT06600984|EXPERIMENTAL|whole body vibration group|experimental group: received a designed physical therapy program in addition to WBV for 12 weeks
62825174|NCT02456415|EXPERIMENTAL|K-MET™ Bioresorbable Bone screw|The K-MET™ Bioresorbable Bone Screw, intended to be used for trauma therapy, consists of Cortex screws, Cannulated headless screws. For Headless screw and Cannulated headless screws, the design is similar to normal headless compression screws but the compression function was achieved by using different lengths for the front and rear pitches. These screws are dynamic and allow therewith the fracture at the Carpal, metacarpal, and small hand bone.
62825175|NCT05074056|EXPERIMENTAL|Ketorolac|A double-blinded number of children will get one dose of intravenous 0.5 mg/kg (max dose 30mg) ketorolac intraoperatively.
62825176|NCT05074056|PLACEBO_COMPARATOR|Placebo|A double-blinded number of children will get one dose of intravenous placebo intraoperatively.
62825177|NCT03312231|EXPERIMENTAL|Group 1|3.75 mcg of H7N9 vaccine with PBS diluent plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
62043723|NCT02495051||single group-study|
62043724|NCT06732635|NO_INTERVENTION|Conventional|
62043725|NCT06732635|EXPERIMENTAL|ERAS|Enhanced recovery after surgery (ERAS) programs are designed to achieve early recovery after surgery and a shorter length of stay (LOS) at hospital.
62043726|NCT03130751|EXPERIMENTAL|Mobile application|
62043727|NCT04477928||Study Group|Children receiving routine care at a Sanford facility
62043728|NCT03009279||The MS group|Patients with metabolic syndrome(MS).
62043729|NCT03009279||The non-MS group|Patients without metabolic syndrome(MS).
62043730|NCT01596582|NO_INTERVENTION|Standard Care|Subjects randomized to the control arm will review the web-based decision aid (http://www.colorectalcancerscreening4u.com) just prior to a scheduled visit with their provider.
62043731|NCT01596582|EXPERIMENTAL|Risk Assessment|Subjects randomized to the experimental arm will complete the ACNI risk assessment tool after reviewing the web-based decision aid (http://www.colorectalcancerscreening4u.com) just prior to a scheduled office visit with their provider.
62825178|NCT03312231|EXPERIMENTAL|Group 2|7.5 mcg of H7N9 vaccine plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
62825179|NCT03312231|EXPERIMENTAL|Group 3|15 mcg of H7N9 vaccine plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
62825180|NCT03312231|EXPERIMENTAL|Group 4|15 mcg of unadjuvanted H7N9 vaccine on days 1 and 22, n=50 (19-64 years old) and n=30 (65 and older)
62825181|NCT03312231|EXPERIMENTAL|Group 5|45 mcg of unadjuvanted H7N9 vaccine on days 1 and 22, n=50 (19-64 years old) and n=30 (65 and older)
62602984|NCT03565263||No FGID-IBD|"* Patients aged 9-18 years~* with inflammatory bowel disease (Crohns, ulcerative colitis or indeterminate colitis)~* in remission (defined as: Physician's global assessment = remission, no nocturnal stools, no blood in stools, \< or = 3 stools/day, C-reactive-protein \< 10 mg/L, Erythrocyte sedimentation rate \< 20 mm, no flare of disease or change of treatment in the last 3 months, no ongoing corticosteroid therapy~* followed for IBD for at least 1 year~* not a single Functional Gastrointestinal disorder according to the Fr-qPGS questionnaire (Rome III criteria)"
62825182|NCT05516446|EXPERIMENTAL|DEB for de Novo Lesions|"1. Preparation of the lesion by pre-dilation or another technique using a balloon undersized by 0.5 mm compared to the reference diameter of the artery and, if necessary, by a second balloon with a balloon/artery ratio of 0.8-1 inflated to 16-18 atm for best results.~2. when obtaining a stent-like result and in the absence of a major dissection less than grade C, a flow TIMI less than 3 and a residual stenosis of more than 30%, an angioplasty by a drug eluting balloon will be performed for an inflation of 30 seconds at 8-10 atm.~3. Otherwise, an angioplasty using a drug eluting stent will be proceeded.~4. Before removing the intracoronary guide, the operator will evaluate by Quantitative Coronary Arteriography (QCA)~   * The post-procedural TIMI flow.~  * the minimal post-procedural luminal diameter in mm."
62825183|NCT05516446|ACTIVE_COMPARATOR|DES for de Novo Lesions|"1. The preparation of the lesion and the post dilation will be left to the discretion of the operator.~2. Angioplasty with Drug eluting balloon after pre dilatation will be performed.~3. Before removing the intracoronary guide, the operator will evaluate by Quantitative Coronary Arteriography (QCA)~   * The post-procedural TIMI flow.~  * the minimal post-procedural luminal diameter in mm."
62825184|NCT06431594|EXPERIMENTAL|Part 1: Dose Escalation|
62825185|NCT06431594|EXPERIMENTAL|Part 2: Dose Expansion|
62602985|NCT05591612|EXPERIMENTAL|50% NaCl and 50% MSG Seasoning Mix|Participants received cooking demonstrations and nutrition education, and were asked to use the seasoning provided (50% NaCl and 50% MSG Seasoning Mix) on vegetables and foods prepared. Then they recorded their food intake to compare vegetable intake to other groups.
62825186|NCT01735422|EXPERIMENTAL|r-hLH (825 International Units [IU])|
62043732|NCT03661411|EXPERIMENTAL|Aspirin+ clopidogrel|aspirin 100mg qd and clopidogrel 75mg（300mg in the first day）qd with a total of 10-14 days, then oral aspirin 100mg or clopidogrel 75mg qd lasting for 90 days.
62043733|NCT03661411|ACTIVE_COMPARATOR|Alteplase|intravenous alteplase (0.9 mg/kg and maximal dose of 90 mg) was given, and followed by antithrombotic protocol 24 hours after thrombolysis based on clinical guideline.
62043734|NCT05098093|ACTIVE_COMPARATOR|Standardized botanical extract|
62043735|NCT05098093|ACTIVE_COMPARATOR|Dry botanical extract|
62043736|NCT05098093|ACTIVE_COMPARATOR|Botanical powder|
62449176|NCT06408909|NO_INTERVENTION|Control Group|Group in which only observation is made by the clinical pharmacist For patients in this group, no intervention (i.e. recommendation) will be made to physicians by the clinical pharmacist. Within the intervention group, patient characteristics such as the underlying conditions, and the appropriateness of prescribed medications were evaluated for the patients who received levothyroxine treatment for thyroid diseases and met the inclusion criteria. The participant will take standard treatment. Evaluations will be recorded.
62825187|NCT01735422|EXPERIMENTAL|r-hLH (2750 IU)|
62825188|NCT01735422|EXPERIMENTAL|r-hLH (5500 IU)|
62825189|NCT01735422|EXPERIMENTAL|r-hLH (11000 IU)|
62825190|NCT01735422|EXPERIMENTAL|r-hLH (22000 IU)|
62825191|NCT01735422|ACTIVE_COMPARATOR|u-hCG (5000 IU)|
62825192|NCT04436354|EXPERIMENTAL|vaginoscopic office hysteroscopy in the trendelenburg position|
62043737|NCT04568135||survey|
62043738|NCT01903850|EXPERIMENTAL|spray cryotherapy|spray cryotherapy: 4 -5 second sprays at Baseline (possible additional tx. to be determined at follow up)
62043739|NCT01900782|EXPERIMENTAL|Dosing Regimen 1|Subcutaneous injection
62043740|NCT01900782|ACTIVE_COMPARATOR|Active Comparator|Subcutaneous injection
62246320|NCT03684642|EXPERIMENTAL|Efpeglenatide 4 mg|Participants received Efpeglenatide subcutaneous (SC) injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 2 mg once weekly and increased every 2 weeks to the maximum of 4 mg once weekly for the treatment duration.
62246321|NCT03684642|EXPERIMENTAL|Efpeglenatide 6 mg|Participants received Efpeglenatide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 2 mg once weekly and increased every 2 weeks to the maximum of 6 mg once weekly for the treatment duration.
62246322|NCT03684642|ACTIVE_COMPARATOR|Dulaglutide 1.5 mg|Participants received Dulaglutide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 0.75 mg once weekly and increased after 2 weeks to 1.5 mg once weekly for the treatment duration.
62246323|NCT05531487||Medical students|Undergraduate medical students at one Medical University.
62246324|NCT00936403|EXPERIMENTAL|NNC126-0083|
62246325|NCT00936403|ACTIVE_COMPARATOR|Norditropin NordiFlex®|
62436685|NCT04108481|EXPERIMENTAL|Y90-RE in combination with immunotherapy (durvalumab)|"The treatment phase starts of with the immunotherapy drug (durvalumab) - priming doses every 2 weeks prior to patient getting mapped and ready for treatment with Y90-RadioEmbolization.~Post-Y90-RE, treatment is approximately 2 months in combination with fixed doses (750 mg) of durvalumab. The number and timing of doses of durvalumab each patient will receive will depend on the dose level the patient is assigned to (range 2-5 doses of immunotherapy).~A single patient will be treated per dose level until the first dose limiting toxicity (DLT) is recorded. Once the first DLT is recorded, two additional patients are treated at the same dose level and the trial reverts to a standard 3+3 design. Up to 6 patients will be treated at each dose level. The maximum tolerated dose (MTD) will be defined as the highest dose level for which at most 1 out of 6 patients experience a DLT."
62436686|NCT02561988|EXPERIMENTAL|Avapritinib (also known as BLU-285)|Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.
62436687|NCT00718965|EXPERIMENTAL|25 mg/day AVE5530|
62825193|NCT04436354|EXPERIMENTAL|vaginoscopic office hysteroscopy in lithotomy position|
62043741|NCT01900782|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection
62436688|NCT00718965|EXPERIMENTAL|50 mg/day AVE5530|
62436689|NCT00718965|PLACEBO_COMPARATOR|Placebo|
62436690|NCT03824210||Stage 1|School children age 11-18 (from two nominated schools) and young carers 11-18
62436691|NCT03824210||Stage 2|Young carers from Young Carers in Herts 11-18
62436692|NCT04324879|EXPERIMENTAL|TQ-B3525 tablet|TQ-B3525 tablet administered orally.
62246326|NCT06734377|EXPERIMENTAL|TMS to Mid-dlPFC followed by TMS to PMd|Participants would receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over mid-dlPFC region on the scalp. In their second session, the TMS coil will be placed over the PMd region on the scalp. During every session, participants receive Delta TMS (2.2 Hz), Theta TMS (6.5 Hz), and Arrhythmic TMS.
62246327|NCT06734377|EXPERIMENTAL|TMS to PMd followed by TMS to Mid-dlPFC|Participants would receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over PMd region on the scalp. In their second session, the TMS coil will be placed over the mid-dlPFC region on the scalp. During every session, participants receive Delta TMS (2.2 Hz), Theta TMS (6.5 Hz), and Arrhythmic TMS.
62436693|NCT01159769|EXPERIMENTAL|Olopatadine 0.2%|1 drop self-administered in each eye once daily in the morning for 7 days
62436694|NCT02198677|EXPERIMENTAL|AP|Anterior to posterior pressures 5x10 seconds per set with 10 seconds rest between each set
62246328|NCT02613689|EXPERIMENTAL|Scheduled Gradual Reduction (SGR)|Subjects will receive the Scheduled Gradual Reduction (SGR) intervention, as well as SMS support text messages.
62246329|NCT02613689|ACTIVE_COMPARATOR|Control Group|Subjects will receive SMS support text messages
62246330|NCT06227273|ACTIVE_COMPARATOR|H2 Standard Dose|This condition will schedule 1-5 glasses of hydrogen water a day for 16 weeks.
62246331|NCT06227273|ACTIVE_COMPARATOR|H2 Standard Dose followed by Higher Dose H2|This condition will schedule 1-5 glasses of hydrogen water a day for 8 weeks followed by 4-5 glasses of hydrogen water for 8 weeks.
62246332|NCT01383096|ACTIVE_COMPARATOR|Cohort 1 - Treatment A: OZ439 800mg PIB, fed|OZ439 800 mg (as free base) as powder in a bottle (PIB)for reconstitution in a suspension prior to administration. Administered 30 minutes after a standard fatty breakfast.
62436695|NCT02198677|EXPERIMENTAL|Lateral glides|Lateral glides 5x10 seconds per set with 10 seconds rest between each set
62436696|NCT02525328||CT subjects|blood or saliva specimen
62825194|NCT06596434|ACTIVE_COMPARATOR|Group A: 4-aminopyridine|Dalfampridine (generic) 10 mg capsule PO every 12 hours
62825195|NCT06596434|PLACEBO_COMPARATOR|Group B: Placebo|Placebo - 1 capsule PO every 12 hours
62043742|NCT01900782|EXPERIMENTAL|Dosing Regimen 2|Subcutaneous injection
62043743|NCT05451654|PLACEBO_COMPARATOR|Placebo + SoC (N=30)|"This arm is composed by 30 patients.~* Placebo: administration of 2 mL twice a day (morning and evening) by depositing 1 mL in the gingivo-jugal groove of each cheek with the graduated pipette.~* Standard of care"
62246333|NCT01383096|EXPERIMENTAL|Cohort 1 - Treatment D: OZ439 800 mg Prototype F1 fasted|OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered fasted.
62246334|NCT01383096|EXPERIMENTAL|Cohort 2 - Treatement H: OZ439 800 mg Prototype F2 fasted|OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered fasted.
62246335|NCT01383096|EXPERIMENTAL|Cohort 3 - Treatement K: OZ439 400mg Prototype F1 fasted|Best Prototype Solution - OZ439 400 mg as prototype solution formulation 1. Administered fasted.
62246336|NCT01383096|EXPERIMENTAL|Cohort 1 - Treatement B: OZ439 800mg PIB fasted|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.
62246337|NCT01383096|EXPERIMENTAL|Cohort 1 - Treatment C:OZ439 800mg PIB with milk|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.
62825196|NCT06654687|ACTIVE_COMPARATOR|Crystalloid group|"Transthoracic Echocardiography will be used to measure the changes in stroke volume and cardiac output.~Patients will receive 1000 mL of Ringer's lactate solution over 15 minutes."
62825197|NCT06654687|ACTIVE_COMPARATOR|Combination group|"Transthoracic Echocardiography will be used to measure the changes in stroke volume and cardiac output.~Patients will receive 250 mL of human albumin 5% over 10 minutes and 750 mL of Ringer's lactate solution over 15 minutes."
62246338|NCT01383096|EXPERIMENTAL|Cohort 3 - Treatment J: OZ439 800mg Prototype F1 fasted|Best Prototype Solution - OZ439 800 mg (as free base) as prototype solution formulation 1. Administered fasted.
62825198|NCT03850899||Cases|Heavy drinkers with alcoholic hepatitis
62825199|NCT03850899||Controls|Heavy drinkers without significant liver disease
62825200|NCT03850899||Donor|Healthy non-drinkers
62043744|NCT05451654|EXPERIMENTAL|NanoManganese® + SoC (N=90)|"This arm is composed by 90 patients.~NanoManganese® + standard of care group:~* NanoManganese®: administration of 2 mL twice a day (morning and evening) by depositing 1 mL in the gingivo-jugal groove of each cheek with the graduated pipette.~* Standard of care"
62246339|NCT01383096|EXPERIMENTAL|Cohort 1 - Treatement E: OZ439 800mg Prototype F1 with milk|OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered with milk.
62246340|NCT01383096|EXPERIMENTAL|Cohort 2 - Treatement F: OZ439 800 mg PIB fasted|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.
62246341|NCT01383096|EXPERIMENTAL|Cohort 2 - Treatement G: OZ439 800mg PIB with milk|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.
62246342|NCT01383096|EXPERIMENTAL|Cohort 2 - Treatement I: OZ349 800mg Prototype F2 with milk|OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered with milk.
62043745|NCT03496506|EXPERIMENTAL|Sequential treatment arm|Subjects receive 1 tablet of selexipag twice daily from Day 1 to Day 9 and 1 tablet in the morning of Day 10. In the morning of Day 4 and 1 hour before the administration of selexipag, they receive 4 tablets of clopidogrel. Then from Day 5 to Day 10, 1 hour before the morning administration of selexipag, they receive 1 tablet of clopidogrel .
62043746|NCT04454658|EXPERIMENTAL|Segment A: ABBV-744 Dose Identification and Optimization|Participants who have been previously treated with Janus Kinase inhibitor(s) (JAKi) and stopped such therapy, will receive different dosing regimens and schedules of ABBV-744 to identify the safe dosing regimen and schedule.
62246343|NCT04495010|EXPERIMENTAL|Neoadjuvant treatment + Adjuvant treatment|
62246344|NCT04495010|EXPERIMENTAL|Adjuvant treatment|
62246345|NCT04495010|EXPERIMENTAL|Neo treat with patho response-driven Adju treat or observation|Neoadjuvant treatment with pathologic response-driven Adjuvant treatment or observation
62246346|NCT00612261|EXPERIMENTAL|1|The group 1 patients receive AV sheathotomy for macular edema secondary to branch retinal vein occlusion.
62246347|NCT00612261|ACTIVE_COMPARATOR|2|The group 2 patients receive IVTA.
62246348|NCT06723457|EXPERIMENTAL|Treatment (epcoritamab, lenalidomide)|Patients receive epcoritamab SC weekly during cycle 1 and on days 1, 8, 15, and 22 of cycles 2-3, and day 1 of cycles 4-12. Patients also receive lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT and collection of blood samples throughout the study and may undergo MRI during screening.
62246349|NCT04695392|EXPERIMENTAL|Intervention|R2 Bundle
62246350|NCT04695392|NO_INTERVENTION|Baseline|Usual care
62246351|NCT01223521|EXPERIMENTAL|Immediate intrauterine contraception|IUD (either Cu-IUD or LNG-IUS) inserted immediately after abortion.
62246352|NCT01223521|NO_INTERVENTION|Control group|Post-abortal contraception is prescribed by the hospital but on the responsibility of the patient.
62246353|NCT01910350|EXPERIMENTAL|Cancer prevention intervention|Cancer prevention intervention: Experimental group receives intensive 2 hour education in each breast and cervical cancer risks and prevention intervention, and face to face reading of post intervention surveys by an community health worker.
62246354|NCT01910350|ACTIVE_COMPARATOR|Control group receives standard care|The control group receives reading materials and brochures on breast and cervical cancer such as one would receive in a doctors office and post condition surveys. All materials are read by the participant without the interaction or assistance of the community health worker.
62436697|NCT02525328||subjects without CT|blood or saliva specimen
62825201|NCT05655299|EXPERIMENTAL|VTX958 Dose A|
62825202|NCT05655299|EXPERIMENTAL|VTX958 Dose B|
62825203|NCT05655299|EXPERIMENTAL|VTX958 Dose C|
62825204|NCT05655299|EXPERIMENTAL|VTX958 Dose D|
62825205|NCT05655299|PLACEBO_COMPARATOR|Placebo|
62825206|NCT06058910||Newborn|This study will include newborn pediatric patients under 2-weeks of age who are necessary to conduct this study and are representative of the target population for use with this device.
62825207|NCT04327154|EXPERIMENTAL|Digital nerve repair|There is no comparator for this study. All patients are in the treatment allocated group for digital nerve repair with the TISSIUM™ Nerve Coaptation Device.
62825208|NCT01761877|EXPERIMENTAL|Sulindac (Clinoril)|Women taking aromatase inhibitors for adjuvant therapy for their breast cancer will receive 150 mg of sulindac twice daily for 12 months. They will receive up to 4 MRI within 12 months.
62825209|NCT01761877|NO_INTERVENTION|Observational|Women taking aromatase inhibitors for adjuvant therapy for their breast cancer will continue their treatment will be monitored with MRI and standard of care tests every 6 months for up to 12 months.
62043747|NCT04454658|EXPERIMENTAL|Segment A: ABBV-744 Monotherapy|Participants will receive the identified safe dosing regimen of ABBV-744 as monotherapy.
62043748|NCT04454658|EXPERIMENTAL|"Segment B: Ruxolitinib + ABBV-744 Add on Therapy"|"Participants whose disease (myelofibrosis) is inadequately controlled by ongoing ruxolitinib therapy will receive ruxolitinib and ABBV-744 as add-on therapy."
62043749|NCT04454658|EXPERIMENTAL|Segment C: ABBV-744 + Navitoclax|Participants who have previously been exposed to JAKi, and stopped such therapy, will receive ABBV-744 and navitoclax.
62043750|NCT04454658|EXPERIMENTAL|Segment D: ABBV-744 + Ruxolitinib|Participants who have never received JAKi will receive ABBV-744 and ruxolitinib.
62043751|NCT05597254|EXPERIMENTAL|Probiotic with niacin and berry extract|
62043752|NCT05597254|ACTIVE_COMPARATOR|Probiotic without niacin and berry extract|
62043753|NCT05597254|PLACEBO_COMPARATOR|Placebo|
62043754|NCT06265077|ACTIVE_COMPARATOR|Intervention|(intervention group) patients who will receive filgrastim plus oral famotidine 20 mg once daily and loratadine 10 mg once daily for the full filgrastim treatment period.
62043755|NCT06265077|PLACEBO_COMPARATOR|Control|(control group) patients who will receive placebo plus filgrastim.
62043756|NCT00302796|EXPERIMENTAL|Group A, Antibiotic|1 antibiotic tablet 45 patients Group
62246355|NCT00892619|EXPERIMENTAL|ILM forceps|Using ILM forceps to initiate and complete peel
62043757|NCT00302796|PLACEBO_COMPARATOR|Group B: 1 placebo|1 placebo tablet
62043758|NCT00302796|EXPERIMENTAL|Group C: Antibiotics|2 antibiotic tablets 45 patients
62246356|NCT00892619|ACTIVE_COMPARATOR|Other|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
62246357|NCT00774813|ACTIVE_COMPARATOR|A|Nexalin 1.3mA device + placebo antidepressant
62246358|NCT00774813|ACTIVE_COMPARATOR|B|Nexalin 15mA device + placebo antidepressant
62246359|NCT00774813|PLACEBO_COMPARATOR|C|Placebo device + SSRI (Citalopram or similar)
62602986|NCT05591612|EXPERIMENTAL|70% NaCl and 30% MSG Seasoning Mix|Participants received cooking demonstrations and nutrition education, and were asked to use the seasoning provided (70% NaCl and 30% MSG Seasoning Mix) on vegetables and foods prepared. Then they recorded their food intake to compare vegetable intake to other groups.
62602987|NCT05591612|EXPERIMENTAL|NaCl seasoning|Active Control Participants received cooking demonstrations and nutrition education, and were asked to use table salt on vegetables and foods prepared. Then they recorded their food intake to compare vegetable intake to other groups.
62043759|NCT00302796|PLACEBO_COMPARATOR|Group D, Placebo|2 placebo tablets 36 patients
62043760|NCT02207010|EXPERIMENTAL|AZD1775|Patients will receive a single dose (either 100 mg, 200 mg or 400 mg) of AZD1775, an oral agent, prior to surgery for resection of GBM
62043761|NCT05721534||Care home residents|The intervention was offered to new residents and residents that had not yet attended a consultation focusing on pharmacological treatment in The Chronic Care Model.
62043762|NCT05721534||Community-dwelling patients with chronic disease|Patients were invited for the consultation focusing on pharmacological treatment in the month of their birthday and, thereby, included randomly and consecutively throughout the study period.
62043763|NCT03274869||Scrub typhus without cardiovascular complications|Any participants with the scrub typhus infection without cardiovascular complication will be enrolled as a positive control group during admission and clinically followed by 1 year after discharge
62246360|NCT03308942|EXPERIMENTAL|Stage 1 (Cohort 1): Niraparib plus Pembrolizumab|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/programmed death-ligand 1 (PD-L1) inhibitor treatment and whose tumors have high PD-L1 expression (tumor proportion score \[TPS\]: \>= 50 percent \[%\]) will receive combination of niraparib and a PD-1 inhibitor; pembrolizumab.
62246361|NCT03308942|EXPERIMENTAL|Stage 1 (Cohort 2): Niraparib plus Pembrolizumab|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment and whose tumors have PD-L1 expression (TPS: 1% to 49%) will receive combination of niraparib and a PD-1 inhibitor; pembrolizumab.
62623869|NCT05635877|PLACEBO_COMPARATOR|Placebo Comparator:normal saline(0.9%)|The control group received the same volume of 0.9% normal saline, which was continuously pumped until the end of the operation before extubation.Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was \>3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.
62602988|NCT05307185|EXPERIMENTAL|Tritordeum-based Food (TBD)|A controlled TBD will be provided to each patient. The daily menu will be breakfast, mid-morning snacks, lunch, afternoon snacks, and dinner. This intervention diet implies that each patient in the study has to consume flour, bread, breakfast biscuits, taralli, and pasta prepared exclusively with Tritordeum. The diets will be designed by matching basal metabolism and daily energy consumption with anthropometric data of all patients to assign suitable and tailored dietary regimens. The software utilized to assess the daily intake of macronutrients (50% carbohydrates, 30% lipids, and 20% proteins) will be the same as LFD.
62602989|NCT05307185|ACTIVE_COMPARATOR|Low-FODMAPs diet (LFD)|A personalized LFD will be assigned after reviewing a food diary and having a one-on-one personal consultation with a nutritionist. Diet will match the basal metabolic rate and daily energy expenditure. A detailed weekly structured menu based on three meals (breakfast, lunch, and dinner) and two snacks (morning and afternoon) will be provided. Patients also will receive a booklet detailing what foods are allowed, which foods to avoid and which foods to reduce based on the classifications used by Monash University and cut-off values for each FODMAPs subgroup. Nutritionists have already created a leaflet for patients in the study with details on where to buy specific products. Besides, nutritionists will guarantee adequate fiber intake, also offering advice on cooking without onions and garlic and other high-FODMAP foods. Drinking alcohol will not be recommended, although it is not high in FODMAPs.
62602990|NCT05307185|ACTIVE_COMPARATOR|Specific dietary advice for IBS|"According to NICE BDA Irritable bowel syndrome dietary advice, a controlled diet will be provided. All the food items (bread, pasta, taralli - local salty biscuits, and breakfast biscuits) will be prepared using durum wheat flour commercially available and anonymized to guarantee masking. Dietary recommendations include eating slowly, limiting alcohol, spicy food and fatty foods, caffeine, carbonated drinks; avoiding chewing gums and sweeteners containing polyols; small and frequent meals, stressful conditions."
62043764|NCT03274869||Scrub typhus with cardiovascular complication|Any participants with the scrub typhus infection with cardiovascular complication will be enrolled as a comparison group during admission and clinically followed by 1 year after discharge
62043765|NCT04306198|ACTIVE_COMPARATOR|Lag Screw|Device: Trochanteric Fixation Nail (TFN) whit lag screw Surgical stabilization of intertrochanteric hip fractures using two different proximal fixation implants
62043766|NCT04306198|ACTIVE_COMPARATOR|Helical Blade|Device: Trochanteric Fixation Nail (TFN) whit helical blade Surgical stabilization of intertrochanteric hip fractures using two different proximal fixation implants
62043767|NCT01559844|EXPERIMENTAL|SOF+RBV|Sofosbuvir plus ribavirin for up to 48 weeks or until time of transplant, whichever occurs first.
62043768|NCT00627484||Group 1: GBP non-diabetic|Non-diabetic subjects scheduled to receive gastric bypass
62602991|NCT02812134||anorexic|
62602992|NCT03701698|EXPERIMENTAL|combination therapy|"There is only 1 arm. Combination therapy arm includes ruxolitinib and methylprednisolone.~1. Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.~2. Ruxolitinib oral tablet, 5\~10mg bid orally, for at least 28 days."
62602993|NCT04622423||PDAC liver-MTS|Adult patients with clinical /radiological diagnosis/suspicious of PDAC metastatic to the liver, with subsequent cytological/histological confirmation (stage IV disease, AJCC) from liver resection/metastasectomy or core liver biopsy.
62825210|NCT06586801||Cohort I|400 ALK-positive locally advanced or metastatic NSCLC patients who are treated with Alectinib
62602994|NCT04622423||CRC liver-MTS|Adult patients with histologically or cytologically confirmed diagnosis of CRC metastatic to the liver with indication to surgical resection (upfront or after neoadjuvant therapy).
62623870|NCT00396474||SGA patients|Infants born small for SGA who either received GH, no GH, or growth within normal ranges.
62825211|NCT06586801||Cohort II|200 ALK-positive locally advanced or metastatic NSCLC patients who are treated with Lorlatinib
62825212|NCT06586801||Cohort III|200 ALK-positive locally advanced or metastatic NSCLC patients who are treated with other ALK-TKIs except for Alectinib and Lorlatinib
62825213|NCT00926237|EXPERIMENTAL|Sham followed by active 1Hz, then active 10Hz rTMS|Subjects assigned to this arm received sham rTMS followed by active rTMS at 1Hz and then active rTMS at 10 Hz. Each treatment consisted of a four-day trial with no less than 21 days separating each condition. Subjects receive sham stimulation first to prevent carry forward effects of the active treatment condition into the sham condition.
62825214|NCT00926237|EXPERIMENTAL|Sham followed by active 10Hz and active 1Hz rTMS|Subjects assigned to this arm received sham rTMS followed by active rTMS at 10 Hz and then active rTMS at 1 Hz. Each treatment consisted of a four-day trial with no less than 21 days separating each condition. Subjects receive sham stimulation first to prevent carry forward effects of the active treatment condition into the sham condition.
62246362|NCT03308942|EXPERIMENTAL|Stage 1 (Cohort 3): Niraparib|Participants with locally advanced and metastatic squamous NSCLC who have been previously treated with both platinum and either PD-1 or PD-L1 inhibitor will receive single agent niraparib.
62043769|NCT00627484||Group 2: BND non-diabetic|Non-diabetic subjects scheduled to receive gastric banding
62043770|NCT00627484||Group 3: GBP diabetic|Diabetic subjects scheduled to receive gastric bypass
62043771|NCT00627484||Group 4: VLCD diabetic|Diabetic subjects scheduled to receive very low calorie diet
62043772|NCT00627484||Group 5: SG diabetic|Diabetic subjects scheduled to receive sleeve gastrectomy
62043773|NCT03830593||Group 1|laparoscopic adrenalectomy group 1: tumor size as \< 6 (group1)
62043774|NCT03830593||Group 2|Laparoscopic adrenalectomy group2: tumor size ≥ 6 cm (group2)
62043775|NCT03830593||Learning Curve|The patients, underwent laparoscopic adrenalectomy, were also classified into group A (1-25), B (26-50), C (51-75), and D (76-102) according to the chronological order of their surgery in order to evaluate the learning curve.
62602995|NCT04622423||Primary non-MTS PDAC|Adult patients with clinical/radiological diagnosis of primary non-metastatic PDAC, candidates for surgical resection with radical intent of the primary tumor (upfront surgery or after neoadjuvant therapy). These patients will be monitored for early diagnosis of metachronous hepatic PDAC MTS by follow up testing.
62436698|NCT04460352|ACTIVE_COMPARATOR|Control arm (A)|"Neoadjuvant chemoradiotherapy followed by esophagectomy.~Radiotherapy: 1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.~Chemotherapy: Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting on the first day of radiotherapy.~Esophagectomy: Within 8 weeks of termination of chemoradiotherapy,"
62602996|NCT04622423||Healthy volunteers|Negative control for the clinical study.
62602997|NCT02624388|EXPERIMENTAL|Arm A: Genistein followed by Placebo|Genistein daily throughout chemotherapy cycles 1 and 2, and placebo daily during chemotherapy cycles 3 and 4
62602998|NCT02624388|EXPERIMENTAL|Arm B: Placebo followed by Genistein|Placebo daily throughout chemotherapy cycles 1 and 2, and genistein daily during chemotherapy cycles 3 and 4
62602999|NCT01971762||Patients diagnosed bacteremia by S. aureus|
62825215|NCT04379414|EXPERIMENTAL|Newly Diagnosed Automatic Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.~* Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.~* YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.~* Surveys will be sent once every 6 months for the first 3 years, then annually.~* Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
62246363|NCT03308942|EXPERIMENTAL|Stage 2 (Cohort 1A): Niraparib plus TSR-042 (Dostarlimab)|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment and whose tumors have high PD-L1 expression (TPS: \>= 50%) will receive combination of niraparib and a PD-1 inhibitor; TSR-042 (Dostarlimab).
62246364|NCT03308942|EXPERIMENTAL|Stage 2 (Cohort 2A): Niraparib plus TSR-042 (Dostarlimab)|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment and whose tumors have PD-L1 expression (TPS: 1% to 49%) will receive combination of niraparib and a PD-1 inhibitor; TSR-042 (Dostarlimab).
62246365|NCT03262792|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose
62449177|NCT06408909|EXPERIMENTAL|Intervention Group|Group to which the clinical pharmacist makes recommendations For patients in this group, intervention (i.e. recommendation) will be made to physician in charge by the clinical pharmacist. Within the intervention group, patient characteristics such as the underlying conditions, and the appropriateness of prescribed medications were evaluated for the patients who received treatment for thyroid diseases and met the inclusion criteria. Through medication reviews, evaluations were made to identify drug-related problems and provide solutions to these problems. The clinical pharmacist provided recommendations to the physicians regarding significant clinically important problems.
62603000|NCT03194711||Patients with stable CAD|
62603001|NCT04380012|EXPERIMENTAL|Single drug group|Pyrotinib: 400 mg, po, qd, 21d for a treatment cycle
62603002|NCT04380012|EXPERIMENTAL|Dual-targeted drug group|Pyrotinib: 400 mg, po, qd, 21d for one treatment cycle; Trastuzumab: first dose 8 mg/kg, then 6 mg/kg, iv, q3w, 21d for one treatment cycle
62603003|NCT04789928|EXPERIMENTAL|Patients with uncomplicated LTIVC-related BSI and eligible|Patients included in this study will receive daily injection of genta-EDTA-Na2 lock associated with systemic antibiotics.
62603004|NCT04104217||patients|Participate in 30-60 minute interviews after each music therapy session.
62603005|NCT04104217||caregivers|Participate in 30-60 minute interviews after each music therapy session (ideally within 3 days).
62603006|NCT04104217||nurses|Participate in 10-15 minute interviews after initial music therapy session.
62603007|NCT04104217||music therapists|Music therapist will notify the researcher if he/she has provided music therapy for a patient who is identified as having delirium. Music therapists will also be interviewed about the clinical process after initial and follow up music sessions.
62603008|NCT05493813|ACTIVE_COMPARATOR|Intubated Sevoflurane-GA group|After preoxygenation for 3 minutes with 100% oxygen, anesthesia is induced with intravenous injection of propofol (1.5-2 mg/kg), remifentanil infusion (Ce value around 1-1.5 ng/kg), and cisatracurium (0.15-0.2 mg/kg), and followed by endotracheal intubation. General anesthesia is maintained with cisatracuirum (0.03 mg/kg every 45-50 min), remifentanil (Ce value around 1-1.5 ng/kg) and sevoflurane inhalation. Sevoflurane concentration will be adjusted to keep BIS value within the range of 40-60. Mechanical ventilation will be processed at volume-controlled mode with fraction of inspired oxygen (FiO2) 60%, tidal volume 6 ml/kg, and respiratory rate 9-12/min to keep normocapnia and avoid desaturation during the EVT procedure.
62603009|NCT05493813|ACTIVE_COMPARATOR|Non-intubated TIVA-propofol group|With the application of Optiflow nasal high flow set at a flow rate of 20 L/min and 60% FiO2, total intravenous anesthesia is induced with target-controlled infusion of propofol (effect site (Ce) concentration around 1.5-2 μg/ml) and remifentanil (Ce value around 1.0-1.5 ng/ml), and adjusted as required.
62043776|NCT02369055||Stroke survivors in North Norway|Patients with ischemic or heamorrhagic stroke admitted to stroke units in UNN Tromso, Narvik or Harstad (Norway), and living in the defined geographic area of these 3 hospitals.
62246366|NCT03262792|ACTIVE_COMPARATOR|Andrographis Paniculata 150|Andrographis Paniculata 150 mg
62246367|NCT03262792|ACTIVE_COMPARATOR|Andrographis Paniculata 300|Andrographis Paniculata 300 mg
62246368|NCT00184236|ACTIVE_COMPARATOR|Aerobic interval training|Aerobic interval training (AIT)
62246369|NCT00184236|ACTIVE_COMPARATOR|Multitreatment approach|multitreatment approach (MTG)
62246370|NCT04092517|ACTIVE_COMPARATOR|Control Corn Soya Diet|Control Corn Soya Diet will be prepared to a formulation for Corn Soya Blend (SUPER CEREAL) product adopted by the WFP as complementary food for children over than 6 months.
62246371|NCT04092517|EXPERIMENTAL|Test Corn Moringa Diet|Test Corn Moringa Diet will be prepared to the same formulation as Corn Soya Blend, but the Soya content will be replaced with Moringa and no micronutrient premix will be added.
62825216|NCT04379414|EXPERIMENTAL|Newly Diagnosed Trigger Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.~* Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.~* YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.~* Surveys will be sent once every 6 months for the first 3 years, then annually.~* Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
62825217|NCT04379414|EXPERIMENTAL|Metastatic Automatic Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.~* Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.~* YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.~* Surveys will be sent once every 6 months for the first 3 years, then annually.~* Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
62825218|NCT04379414|EXPERIMENTAL|Metastatic Trigger Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.~* Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.~* YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.~* Surveys will be sent once every 6 months for the first 3 years, then annually.~* Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
62043777|NCT02369055||Stroke survivors in Denmark|Patients with ischemic og heamorrhagic stroke admitted to a stroke unit in Aarhus University Hospital and living in the municipalities of Randars or Favrskov in Central Denmark Region
62043778|NCT01955954|EXPERIMENTAL|Canary Breathing System|Treatment with Canary Breathing System
62246372|NCT03178708|ACTIVE_COMPARATOR|Group A amantadine sulfate|the patients will receive amantadine sulfate infusion using the dose 200 mg slowly I.V 3 hours prior to the surgery
62246373|NCT03178708|PLACEBO_COMPARATOR|Group B ringer lactate|the patients will receive 500 ml ringer lactate infusion slowly i.v 3 hours prior to surgery.
62246374|NCT00640055|ACTIVE_COMPARATOR|1|Coordinator (non-physician)
62246375|NCT00640055|PLACEBO_COMPARATOR|2|Physician
62246376|NCT05235399||Preterm infants who are born before 32 weeks of gestation.|The study aims to recruit preterm infants who are born before 32 weeks of gestation.
62246377|NCT02737540||Major depressive episode|This study population consists of patients over 60 years of age with or without a personal history of suicide attempts, hospitalized in the Nîmes University Hospital psychiatry department or the Sophoras clinic for a major depressive episode.
62246378|NCT02737540||Healthy subjects|Healthy subjects over 60 years, not depressed and without personal history of severe mental illness or suicide attempts will be recruited.
62623871|NCT01954953||no intervention|
62825219|NCT06592534||Infants and children with Hirschsprung's Disease|Children under the age of 7 years with Hirschsprung's Disease.
62825220|NCT02839096|OTHER|Once Daily Dosing|Randomized to 325mg of ferrous sulfate in the morning and placebo in the evening
62825221|NCT02839096|OTHER|Twice Daily Dosing|Randomized to 325mg of ferrous sulfate in the morning and 325mg of ferrous sulfate in the evening
62825222|NCT02941081|EXPERIMENTAL|IHAT|IHAT arm: novel iron supplement - 1 dose/day single IMP containing IHAT (iron hydroxide adipate tartrate) powder bioequivalent to 12.5 mg elemental iron (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to ferrous sulphate)
62825223|NCT02941081|ACTIVE_COMPARATOR|ferrous sulphate|Ferrous sulphate arm: clinical standard of oral iron supplementation - 1 dose/day single IMP containing ferrous sulphate (FeSO4 ) powder equivalent to 12.5 mg elemental iron
62825224|NCT02941081|PLACEBO_COMPARATOR|placebo|Placebo arm: 'no iron' arm - 1 dose/day containing saccharose powder
62825225|NCT06602765|ACTIVE_COMPARATOR|tooth-brushing|In Control arm, tooth brushing with fluoride toothpaste using pea-sized toothpaste, using bass technique.
62825226|NCT06602765|ACTIVE_COMPARATOR|tooth-brushing and dietary counselling|In intervention arm 1, tooth brushing with fluoride toothpaste using pea-sized toothpaste, using the bass technique, and dietary counselling.
62043779|NCT04803981|EXPERIMENTAL|Standard diet with daily SpoonfulONE|Participants will receive one serving of SO (one of three possible forms of SO: mix-ins, puffs, or crackers) daily in addition to a standard diet. The SO form fed on a given day will be at the discretion of the parent/guardian.
62043780|NCT04803981|NO_INTERVENTION|Standard diet|Participants will feed on a standard diet only, with no intervention, and complete questionnaires
62246379|NCT06262854|EXPERIMENTAL|Calcium-sulphate granules with tobramicina+vancomicina|
62449178|NCT02347579||Patients with CRPS|Patients with Complex Regional Pain Syndrome, Type I
62449179|NCT02347579||Patients with CLBP|Patients with chronic low back pain
62825227|NCT06602765|ACTIVE_COMPARATOR|tooth-brushing , dietary counselling and fissure sealing of 1st permanent molar|In the intervention arm 2, tooth brushing with fluoride toothpaste using pea-sized toothpaste, using the bass technique, dietary counseling, and application of fissure sealant on a permanent first molar.
62623872|NCT00202098|EXPERIMENTAL|1|ALI/ARDS patients
62825228|NCT05146882|EXPERIMENTAL|belcesiran|Participants who completed the DCR-A1AT-201 treatment period will receive open-label belcesiran administered subcutaneously
62825229|NCT05146882|NO_INTERVENTION|Observational|Participants who completed the DCR-A1AT-201 Conditional Follow-up period will enter DCR-A1AT-202 for continued follow-up (will not receive open-label belcesiran)
62825230|NCT05232682|EXPERIMENTAL|Probiotic Arm|Probiotic arm
62825231|NCT02637245||Patients with Diabetic Macular Edema|Patients with Diabetic Macular Edema. There will be no intervention in this cohort, only observation of standard of care.
62825232|NCT06592872|EXPERIMENTAL|LifeSkills for Elementary School (Intervention)|Approximately 1500 students in the 3rd grade (100 students per school) will complete pre-tests, post-tests, and 12- and 24-month follow-ups. Students whose school is randomized to the intervention condition (15 schools) will receive the LifeSkills Training standard curriculum plus bullying/cyberbullying classroom and serious game.
62825233|NCT06592872|NO_INTERVENTION|LifeSkills for Elementary School (Control)|Approximately 1500 students in the 3rd grade (100 students per school) will complete pre-tests, post-tests, and 12- and 24-month follow-ups. Students whose school is randomized to the control condition (12 schools) will not receive the LifeSkills Training intervention, but will receive the health education content normally provided by their schools.
62825234|NCT06602687|NO_INTERVENTION|Standard ICSI|ICSI performed using standard sperm selection methods.
62825235|NCT06602687|EXPERIMENTAL|PICSI|ICSI performed using sperm selected based on hyaluronan binding (PICSI® dish, Cooper Surgical).
62825236|NCT00631514|NO_INTERVENTION|1|Hypertensive persons taking either lisinopril/hydrochlorothiazide fixed combination or amlodipine all the time.
62825237|NCT00631514|EXPERIMENTAL|2|Intervention: NSAID. Hypertensives with osteoarthritis taking already amlodipine (5-10 mg o.d. per os) were randomized to the following drug interventions: to take either acetaminophen (1000 mg t.i.d. per os), piroxicam (10-20 mg o.d. per os) or ibuprofen (400-600 mg t.i.d. per os) for 1 month
62825238|NCT00631514|EXPERIMENTAL|3|Hypertensives with osteoarthritis taking already lisinopril/hydrochlorothiazide (20/12.5 mg o.d. per os), were sequentially randomized to the following drug interventions: acetaminophen (1000 mg t.i.d.), ibuprofen (400-600 mg t.i.d.) or piroxicam (10-20 mg o.d.), for 1 month each
62825239|NCT05873751||Trumenba +MenACWY Vaccinated|Exposure Cohort that received at least one dose of Trumenba and MenACWY vaccine
62825240|NCT05873751||MenACWY Only Vaccinated|Non-exposure (reference cohort) that received at least one dose of MenACWY vaccine and no Trumenba vaccine.
62825241|NCT06407726|EXPERIMENTAL|participants will receive Virtual Reality intervention with conventional treatment,|Participants will receive 40-minute sessions five days per week for six weeks of Virtual Reality intervention and conventional therapy.
62825242|NCT06407726|ACTIVE_COMPARATOR|participants will receive Vestibular Exercises with conventional treatment.|Participants will receive 40-minute sessions five days per week for six weeks of Vestibular Exercises and conventional therapy.
62825243|NCT06604572|EXPERIMENTAL|Transabdominal preperitoneal approach surgery group|The enrolled patients were treated with Transabdominal preperitoneal approach
62825244|NCT06604572|OTHER|Open tension-free hernia repair group|The enrolled patients were treated with open tension-free hernia repair
62825245|NCT06654804|EXPERIMENTAL|Contrast-enhanced ultrasound in traumatic spinal cord injury|A bolus IV injection of Perflutren lipid contrast agent will be given. Continuous imaging will be obtained.
62825246|NCT05701748|EXPERIMENTAL|EEG SEF95 values in response to stimuli|EEG SEF95 values that correspond to the three stimuli being applied, separately enrolled and analyzed for the 3-12mo and 13-24 age groups.
62825247|NCT05076006|PLACEBO_COMPARATOR|Placebo|Tablets without active ingredients
62825248|NCT05076006|EXPERIMENTAL|PF-06700841|tablets containing active drug (a combined TYK/JAK inhibitor)
62825249|NCT05462951||Radiochemotherapy followed by brachytherapy|Standard daily radiotherapy plus weekly cisplatin followed by brachytherapy
62825250|NCT06292351|EXPERIMENTAL|DMB-I (Dimebon) + Placebo|
62043781|NCT00809887|PLACEBO_COMPARATOR|1|ALT with placebo with systemic Micafungin therapy
62043782|NCT00809887|EXPERIMENTAL|2|ALT with Micafungin and heparin with systemic Micafungin therapy
62043783|NCT06174714|EXPERIMENTAL|MI and Indo-SURFT|once a week motivational interviewing/motivational enhancement therapy (MI) for 4 weeks, followed by once a week CBT using Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT) for 8 weeks.
62043784|NCT02538731|OTHER|Dilation-assisted group|Dilation-assisted group:Dilation-assisted stone extraction
62043785|NCT02538731|OTHER|laser lithotripsy group|laser lithotripsy group:laser lithotripsy
62043786|NCT02131272|EXPERIMENTAL|Insulin detemir and diet/exercise|Current OADs i.e. metformin or other OADs are continued unchanged
62043787|NCT02131272|ACTIVE_COMPARATOR|Insulin NPH and diet/exercise|Current OADs i.e. metformin or other OADs are continued unchanged
62043788|NCT02413580|EXPERIMENTAL|IGIV-C Treatment|In this arm, subjects with myasthenia gravis exacerbations were treated with an IV dose of 2 g/kg of IGIV-C, which was administered over 2 consecutive days at a dose of 1 g/kg per day.
62246380|NCT06262854|SHAM_COMPARATOR|Calcium-sulphate granules without antibioitcs|
62246381|NCT02183155|EXPERIMENTAL|Meloxicam - low|
62246382|NCT02183155|EXPERIMENTAL|Meloxicam - medium|
62246383|NCT02183155|EXPERIMENTAL|Meloxicam - high|
62449180|NCT02347579||Healthy controls|
62825251|NCT06292351|EXPERIMENTAL|DMB-I (Dimebon)|
62043789|NCT00571454|EXPERIMENTAL|1|Telephone depression care management + treatment as usual
62825252|NCT06292351|PLACEBO_COMPARATOR|Placebo|
62825253|NCT01977547|ACTIVE_COMPARATOR|Short storage|Red blood cells storage duration of equal to or less than 7 days.
62825254|NCT01977547|ACTIVE_COMPARATOR|Standard issue|Red blood cells storage duration of 2 to 42 days with an expected average length of storage of about 17-21 days.
62825255|NCT01033019|EXPERIMENTAL|LDE225 0.75%|Participants topically applied 0.75% LDE225 cream twice daily for 6 weeks.
62825256|NCT01033019|PLACEBO_COMPARATOR|Vehicle|Participants topically applied matching placebo cream twice daily for 6 weeks.
62825257|NCT03003325|ACTIVE_COMPARATOR|Phlebotomies + ASA|Conventional treatment based on phlebotomies and low dose (100 mg) of acetylsalicylic acid (ASA)
62825258|NCT03003325|EXPERIMENTAL|Phlebotomies + ASA + AOP2014|Conventional treatment based on phlebotomies, low dose (100 mg) of acetylsalicylic acid (ASA) plus the addition of 100 µg of Pegylated Proline-Interferon alpha-2b (AOP2014) once every 14 days (subcutaneously).
62825259|NCT05856721|ACTIVE_COMPARATOR|cases group|One hundred patients with liver cirrhosis and GIT complaints
62825260|NCT05856721|ACTIVE_COMPARATOR|control group|One hundred patients with GIT complaints but not have any cormobidity
62825261|NCT06326411|EXPERIMENTAL|Part A Dose Escalation and Part B Dose Expansion|"Part A will evaluate the safety of NST-628 with advanced solid tumors and determine the recommended dose for expansion of NST-628.~Part B will evaluate the objective tumor response rate in subjects with advanced solid tumors harboring specified genetic alterations receiving NST-628 and evaluate the safety of NST-628 in subjects with advanced solid tumors in cohorts defined below:~i. Melanoma Cohorts~1. Activating NRAS mutations~2. Select BRAF alterations~ii. Non-Melanoma Cohorts:~1. Solid tumors with NRAS activating mutations~2. Solid tumors with KRAS activating mutations~3. Solid tumors with select BRAF alterations~4. Glioma with BRAF alterations"
62825262|NCT00736541|EXPERIMENTAL|2|
62825263|NCT04701827|EXPERIMENTAL|Intervention group|AWARE intervention
62825264|NCT04701827|NO_INTERVENTION|Control group|Treatment as usual (consisting of the standard out-patient mental health service routines in The Capital Region of Denmark)
62825265|NCT05908916|EXPERIMENTAL|Therapeutic arm|AtezoBev with combined radiotherapy
62825266|NCT05601232|EXPERIMENTAL|Boron Neutron Capture Therapy (BNCT)|
62825267|NCT06290336|EXPERIMENTAL|Intervention group|Pre-operative exercise therapy and education before knee replacement surgery
62825268|NCT06290336|OTHER|Control group|Standard care
62825269|NCT02876510|EXPERIMENTAL|IMA101 product only (Cohort 1)|"* Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~* Infusion of the IMA101 T-cell product(s)~* Post-infusion administration of low-dose recombinant human interleukin-2"
62825270|NCT02876510|EXPERIMENTAL|IMA101 product + atezolizumab (Cohort 2)|"* Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~* Infusion of the IMA101 T-cell product(s)~* Post-infusion administration of low-dose recombinant human interleukin-2~* Treatment with atezolizumab every 3 weeks after IMA101 product infusion, for 1 year"
62825271|NCT06592326|EXPERIMENTAL|9MW2821+Toripalimab|9MW2821+Toripalimab
62043790|NCT00571454|NO_INTERVENTION|2|Treatment as usual
62825272|NCT06592326|ACTIVE_COMPARATOR|Gemcitabine+Cisplatin/Carboplatin|Gemcitabine+Cisplatin/Carboplatin
62825273|NCT03589846|EXPERIMENTAL|Muscle stimulation|Consented participants who meet eligibility will have a drug induced sleep endoscopy (DISE) and the Grass S88 muscle stimulator.
62825274|NCT02345447|ACTIVE_COMPARATOR|Herbal-based Medication|"Trade Name of active comparator: Otovowen® Substances: Aconitum napellus Dil. D6; Capsicum annuum Dil. D4; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum Dil. D6; Hydrastis canadensis Dil. D4; Iodum Dil. D4; Natrium tetraboracicum Dil. D4; Sambucus nigra; Sanguinaria canadensis.~Manufacturer: Weber \& Weber, Inning/Ammersee Dose: Three times daily 7 drops Mode of Application: orally Duration of Treatment: at first signs of Upper respirtory tract infection until symptoms resolve (maximally 8 weeks of continuous application)."
62825275|NCT02345447|PLACEBO_COMPARATOR|Placebo|Placebo Substance: Aqueous ethanol solution non-distinguishable from verum. Manufacturer: Weber \& Weber, Inning/Ammersee Dose: Three times daily 7 drops Mode of Application: orally Duration of Treatment: at first signs of URI until symptoms resolve (maximally 8 weeks of continuous application).
62825276|NCT06236802|EXPERIMENTAL|ProVee treatment|ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
62043791|NCT03546881|EXPERIMENTAL|Arm with fusion imaging guidance technology|arm with fusion imaging guidance technology to perform the endovascular surgery, in addition to the traditional 2D X-ray screen system.
62043792|NCT03546881|ACTIVE_COMPARATOR|Arm without fusion imaging guidance technology|arm without fusion imaging guidance technology, using the traditional 2D X-ray screen system, to perform the endovascular surgery.
62043793|NCT05562882|EXPERIMENTAL|Intervention|Daratumumab once a week x 8 doses
62246384|NCT02183155|PLACEBO_COMPARATOR|Placebo|
62825277|NCT02891447|EXPERIMENTAL|Treatment (mitomycin, cisplatin)|Patients undergo HIPEC comprised of mitomycin and cisplatin given intraperitoneally over 60 minutes during standard of care cytoreduction and gastrectomy.
62825278|NCT06218056|ACTIVE_COMPARATOR|Cannabidiol (CBD) 400 mg or 800 mg|Sixty participants who meet all eligibility criteria will be randomized to receive CBD (ATL5; Ananda Scientific) at a dose of 400 mg or 800 mg.
62825279|NCT06218056|PLACEBO_COMPARATOR|Placebo|Sixty participants who meet all eligibility criteria will be randomized to receive placebo.
62825280|NCT03036098|EXPERIMENTAL|Arm A: Investigational immunotherapy|
62825281|NCT03036098|ACTIVE_COMPARATOR|Arm B: Standard of care chemotherapy|
62825282|NCT03036098|EXPERIMENTAL|Arm C: Investigational immunotherapy|
62825283|NCT03036098|ACTIVE_COMPARATOR|Arm D: Standard of care chemotherapy|
62043794|NCT03749564|EXPERIMENTAL|SMT Only|All patients receive 2 SMT sessions in the first week.
62043795|NCT03749564|EXPERIMENTAL|SMT extended|All patients receive 2 SMT sessions in the first week. This arm also involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
62043796|NCT03749564|EXPERIMENTAL|SMT with Activation Exercises|"All patients receive 2 SMT sessions in the first week.~This arm receives 6 additional sessions of activation exercises."
62043797|NCT03749564|EXPERIMENTAL|SMT with Mobilizing Exercises|"All patients receive 2 SMT sessions in the first week.~This arm involves 6 additional sessions of mobilizing exercise."
62043798|NCT03749564|EXPERIMENTAL|SMT with Mobilizing and Activation Exercises|"All patients receive 2 SMT sessions in the first week.~This arm involves 6 additions sessions including both activation and mobilizing exercises."
62043799|NCT03749564|EXPERIMENTAL|SMT extended with Mobilizing Exercises|"All patients receive 2 SMT sessions in the first week.~This arm includes 6 additional sessions including both SMT and mobilizing exercises."
62043800|NCT03749564|EXPERIMENTAL|SMT extended with Activation Exercises|"All patients receive 2 SMT sessions in the first week.~This arm includes 6 additional sessions including both SMT and activation exercises."
62043801|NCT03749564|EXPERIMENTAL|SMT extended with Mobilizing and Activation Exercises|"All patients receive 2 SMT sessions in the first week.~This arm includes 6 additional sessions including SMT, activation and mobilizing exercises."
62043802|NCT01764165|ACTIVE_COMPARATOR|oxygen|nocturnal oxygen of 2 L/min
62043803|NCT01764165|EXPERIMENTAL|High Flow of room air|Warm and humidified air at a rate of 20 L/min through a small nasal cannula (similar to oxygen cannula)
62043804|NCT06580405|EXPERIMENTAL|KNP-1000 Apheresis System|Participants are to be treated with the system up to 2 times per week, continuing through delivery or 34 weeks of pregnancy, whichever comes first.
62043805|NCT04824482|EXPERIMENTAL|Robot-assisted treadmill gait training (RTGT)|Locomotor training guided by the robotic device (Lokomat Hocoma) according to a pre-programmed gait pattern with the help of robot-driven exoskeleton orthoses. The process of gait training is automated and controlled by a computer under supervision of a physiotherapist.
62043806|NCT04824482|ACTIVE_COMPARATOR|Therapist-assisted treadmill gait training (TTGT)|Locomotor training via a repetitive execution of walking movements manually guided by a physiotherapist during treadmill gait training.
62043807|NCT00343928|EXPERIMENTAL|1|
62043808|NCT00377403|EXPERIMENTAL|Intervention Arm|Amoxicillin 500mg three times a day (tid) for 10 days in addition to symptomatic treatments
62043809|NCT00377403|PLACEBO_COMPARATOR|Symptomatic treatments only|Placebo for 10 days in addition to symptomatic treatments
62043810|NCT01845740|EXPERIMENTAL|Milatuzumab SC 250 mg|Milatuzumab 250 mg will be administered subcutaneously once weekly for 4 weeks.
62043811|NCT01845740|EXPERIMENTAL|Milatuzumab 150 mg SC|Milatuzumab 150 mg will be administered subcutaneously once weekly for 4 weeks.
62043812|NCT01845740|PLACEBO_COMPARATOR|Placebo SC|Placebo will be administered subcutaneously once weekly for 4 weeks.
62043813|NCT03057353||lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
62043814|NCT03544892|EXPERIMENTAL|Experimental: Low carbohydrate diet|
62246385|NCT02183155|ACTIVE_COMPARATOR|Extended-release indomethacin|
62603010|NCT05621369||Participants with Psoriasis|People who report a diagnosis of Psoriasis. Participants are invited via the Psorcast mobile application to complete the following assessments: Participant self-assessment surveys, skin assessments (Psoriasis Area Draw and Psoriasis Area Photo) and musculoskeletal assessments (Finger/Toe Photos, Joint Count, Digital Jar Open, 30s Walk).
62043815|NCT03544892|ACTIVE_COMPARATOR|Experimental: Standard of care diet|
62043816|NCT05314036|EXPERIMENTAL|Acute Postprandial Blood Sampling|Two-hour postprandial blood sampling following administration of a standardized test meal
62043817|NCT01763710|ACTIVE_COMPARATOR|Arm A|Paclitaxel 80 mg/m2 days 1, 8 and 15
62043818|NCT01763710|EXPERIMENTAL|Arm B|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
62043819|NCT01763710|EXPERIMENTAL|Arm C|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
62043820|NCT01763710|EXPERIMENTAL|Arm D|Nab-paclitaxel 150 mg/m2 days 1 and 15
62043821|NCT00439712|EXPERIMENTAL|Treatment Group 1|
62043822|NCT00439712|PLACEBO_COMPARATOR|Treatment Group 2|
62623873|NCT04718805|EXPERIMENTAL|Treatment A|Participants will receive Treatment A (a single dose of darunavir \[DRV\]/cobicistat \[COBI\] as one fixed dose combination \[FDC\] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence AB or BA). A washout period of at least 7 days will be maintained between each treatment period.
62043823|NCT01024426|EXPERIMENTAL|Health Facility intervention|In the clusters randomized to enhanced health facility-based care, the intervention is designed to address these barriers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
62246386|NCT03627767|EXPERIMENTAL|PF-04965842 100 mg QD|Double-blind randomized treatment following open label run-in period.
62246387|NCT03627767|EXPERIMENTAL|PF-04965842 200 mg QD|Double-blind randomized treatment following open label run-in period.
62246388|NCT03627767|PLACEBO_COMPARATOR|Placebo QD|Double-blind randomized treatment following open label run-in period.
62246389|NCT04513262||Video-assisted surgery|Patients undergoing video-assisted major abdominal surgery (VAS) in Trendelenburg position. The decision regarding the type of VAS was made by the attending surgeon prior to study inclusion. Twenty-five consecutive patients undergoing classic laparoscopic surgery and twenty-five patients undergoing robotic-assisted surgery will be included in the study.
62246390|NCT04158921|OTHER|The Control:Diabetes mobile app for Diabetes self-management.|This is a single arm open label pilot clinical trial that will assess patient-reported blood glucose levels before and after using the Control:Diabetes mobile app.
62043824|NCT01024426|OTHER|Standard of care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
62246391|NCT01475929|ACTIVE_COMPARATOR|Probiotic low|Lower dose of probiotic supplement
62043825|NCT03369548|EXPERIMENTAL|Apple/ Polyphenol|Participants will be asked to consume 2 Renetta Canada apples (with skin) and 2 placebo capsules every day for 8 weeks.
62043826|NCT03369548|EXPERIMENTAL|Oats / Prebiotic|Participants will be asked to consume 40g jumbo rolled oats with semi-skimmed milk and 2 placebo capsules every day for 8 weeks.
62246392|NCT01475929|PLACEBO_COMPARATOR|Placebo|
62246393|NCT01475929|ACTIVE_COMPARATOR|Probiotic high|Higher dose of probiotic supplement
62043827|NCT03369548|EXPERIMENTAL|Lactobacillus reuteri NCIMB 30242 / Probiotic|Participants will be asked to consume 2 probiotic capsules and 40g cornflakes with semi-skimmed milk every day for 8 weeks.
62246394|NCT01713751|ACTIVE_COMPARATOR|Interrupted suturing Group|Includes women who have their skin closed with interrupted mattress stitches using non-absorbable polypropylene \[Prolene®\]
62246395|NCT01713751|ACTIVE_COMPARATOR|Subcuticular suturing Group|Includes women who have their skin closed with subcuticular stitches using non-absorbable polypropylene \[Prolene®\].
62246396|NCT00909350||No treatment|genetic research project; to meet inclusion criteria, participants must have normal upper GI tract upon upper endoscopy, for study biopsies to be taken
62246397|NCT01472380|ACTIVE_COMPARATOR|Efavirenz 600mg alone|efavirenz 600mg by mouth taken on Day 1
62246398|NCT01472380|ACTIVE_COMPARATOR|Efavirenz co-administered with fenofibric acid|co-administered oral doses of efavirenz 600 mg and fenofibric acid 105 mg taken on Day 31
62043828|NCT03369548|PLACEBO_COMPARATOR|Placebo / cornflakes|Participants will be asked to consume 40g cornflakes with semi-skimmed milk and 2 placebo capsules every day for 8 weeks.
62043829|NCT05675657|PLACEBO_COMPARATOR|Control group|Patients will be operated under general anesthesia.
62246399|NCT05698823|EXPERIMENTAL|Study group|"A complete clinical intraoral examination shall be performed for all subjects. Same demographic and clinical data will be obtained from subjects in both arms. The study group shall receive the Lumoral treatment -device, Lumorinse -tablets and instructions for their use.~All subjects shall receive standard oral hygiene instructions for the use of an electric toothbrush, interdental brush, and dental floss."
62246400|NCT05698823|NO_INTERVENTION|Control group|A complete clinical intraoral examination shall be performed for all subjects. Same demographic and clinical data will be obtained from subjects in both arms. All subjects shall receive standard oral hygiene instructions for the use of an electric toothbrush, interdental brush, and dental floss.
62043830|NCT05675657|ACTIVE_COMPARATOR|Quadratus Lumborum Block Group|Patients will receive ultrasound-guided quadratus lumborum block type III bilaterally with 30 ml of bupivacaine 0.25% on each side, totally 60 ml of bupivacaine 0.25% followed by general anesthesia.
62043831|NCT05675657|ACTIVE_COMPARATOR|Erector Spinae Plane Block Group|Patients will receive ultrasound-guided erector spinae plane block bilaterally with 30 ml of bupivacaine 0.25% on each side, totally 60 ml of bupivacaine 0.25% followed by general anesthesia.
62043832|NCT05907824||Parenchyma-sparing Resections|Parenchyma-sparing resections, including open, laparoscopic, or robotic pancreatic enucleation, duodenum-preserving pancreatic head resection, middle segment pancreatectomy, and spleen-preserving distal pancreatectomy, without standard lymph node dissection.
62246401|NCT02598609|OTHER|Cluster A|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster A. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 4 months. The intervention is implemented during 4 months. The length of the post interventional period is 12 months.
62246402|NCT02598609|OTHER|Cluster B|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster B. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 8 months. The intervention is implemented during 4 months. The length of the post interventional period is 8 months.
62246403|NCT02598609|OTHER|Cluster C|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster C. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 12 months. The intervention is implemented during 4 months. The length of the post interventional period is 4 months.
62246404|NCT04162496|EXPERIMENTAL|Treatment with Restylane Refyne Group 1|Treat right side with Restylane Refyne with a cannula and left side with a needle
62623874|NCT04718805|ACTIVE_COMPARATOR|Treatment B|Participants will receive Treatment B (a single dose of DRV/COBI as separate tablets under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence BA or AB). A washout period of at least 7 days will be maintained between each treatment period.
62043833|NCT05907824||Oncologic Resections|Oncologic resections, including open, laparoscopic, or robotic pancreaticoduodenectomy or distal pancreatectomy, with standard lymph node dissection.
62043834|NCT05461222|EXPERIMENTAL|Fetal Endoscopic Tracheal Occlusion (FETO)|FETO is performed in-utero and the balloon is removed prior to delivery, and children will have follow-up visits until the age of 2
62825284|NCT02388269|ACTIVE_COMPARATOR|gammaCore®-G|"The user/operator applies the gammaCore®-G device to the skin on the right side and left side of the neck. The 2 stimulations should be performed on the same side of the neck before stimulating the other side. This is also applies with the doses increase in the open label phase. The user applies conductive gel to the stimulation surfaces to maintain an uninterrupted conductive path from the stimulation surfaces to the skin.~The device is capable of delivering multiple patient treatments (doses). Each dose consists of 90 seconds of stimulation; for each dose, the device is active for 120 seconds before automatically stopping stimulation.The extra 30 seconds allows ."
62043835|NCT05142592|EXPERIMENTAL|Cohort 1|1\~6 subjects in this cohort will receive IPG7236 50 mg bid orally.
62043836|NCT05142592|EXPERIMENTAL|Cohort 2|3\~6 subjects in this cohort will receive IPG7236 100 mg bid orally.
62246405|NCT04162496|EXPERIMENTAL|Treatment with Restylane Refyne Group 2|Treat left side with Restylane Refyne with a cannula and right side with a needle
62246406|NCT00872664|ACTIVE_COMPARATOR|formula with added carotenoids|Both arms are double-blinded. Infant will be assigned to receive preterm formula with added carotenoids. If infant is receiving human milk then the study formula will only be used as a supplement.
62043837|NCT05142592|EXPERIMENTAL|Cohort 3|3\~6 subjects in this cohort will receive IPG7236 150 mg bid orally.
62825285|NCT02388269|SHAM_COMPARATOR|gammaCore®-G sham|"The sham device is a hand-held portable device that appears identical to the gammaCore®-G, in look, weight, visual and audible feedback, user application and control. It passes a low frequency (0.1 Hz) biphasic DC signal into the tissue, which can be felt as a tingling sensation but does not stimulate the vagus nerve or cause muscle contraction. Similar to the active device, the sensation becomes more pronounced as the amplitude is increased, until it is uncomfortable, at which point the amplitude is decreased slightly until tolerable.~Like the active device, the sham device is a multi-use device capable programmed to deliver up to 150, 90-second treatments with a 30-second margin for set-up and operator adjustment of the stimulation intensity."
62043838|NCT05142592|EXPERIMENTAL|Cohort 4|3\~6 subjects in this cohort will receive IPG7236 200 mg bid orally.
62043839|NCT05142592|EXPERIMENTAL|Cohort 5|3\~6 subjects in this cohort will receive IPG7236 250 mg bid orally.
62623875|NCT01662271||adolescents with extreme obesity|BMI ≥35kg/m2
62825286|NCT04383600|NO_INTERVENTION|Conventional side|Canine retraction was commenced without micro-osteoperforations.
62043840|NCT05142592|EXPERIMENTAL|Cohort 6|3\~6 subjects in this cohort will receive IPG7236 300 mg bid orally.
62043841|NCT00234052|EXPERIMENTAL|Treatment Arm|Carboplatin + pemetrexed + bevacizumab
62825287|NCT04383600|EXPERIMENTAL|Mops side|Canine retraction was commenced with micro-osteoperforations.
62825288|NCT06591156|EXPERIMENTAL|Procedure with PRF membranes|Root coverage procedure. One group received PRF membranes.
62043842|NCT01808950|EXPERIMENTAL|0.06% Resiquimod Gel - A|"* 60 mg gel~* Once daily prior to normal sleeping hours~* 5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation"
62043843|NCT01808950|EXPERIMENTAL|0.06% Resiquimod Gel - B|"* 100 mg gel~* Once daily prior to normal sleeping hours~* 5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation"
62043844|NCT01808950|EXPERIMENTAL|0.06% Resiquimod Gel - C|"* 100 mg gel~* Once daily prior to normal sleeping hours~* 5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation~* The BCC will be pretreated. A shave biopsy (curettage or scraping off the tissue in a broad, superficial, tangential way) will be performed"
62043845|NCT00781391|ACTIVE_COMPARATOR|Warfarin/placebo edoxaban|Warfarin tablets plus placebo Edoxaban tablets
62043846|NCT00781391|EXPERIMENTAL|high dose edoxaban/placebo warfarin|Edoxaban tablets (60mg) plus warfarin placebo tablets
62043847|NCT00781391|EXPERIMENTAL|low dose edoxaban/placebo warfarin|Edoxaban tablets (30mg) plus warfarin placebo tablets
62043848|NCT03176420|EXPERIMENTAL|Interventional arm|Endovascular treatment of occluded carotids
62246407|NCT00872664|ACTIVE_COMPARATOR|formula without added carotenoids|Both arms are double-blinded. This arm will use preterm formula as it is currently available, which is without any carotenoids. If the infant is receiving human milk, then the formula will be used as a supplement as needed.
62246408|NCT05817253|EXPERIMENTAL|Early Letter + Portrait Arm|Early Letter + Portrait Arm received a Portrait + Therapeutics Letter with the initial mailing (September 23, 2021). At the delayed mailing (March 28, 2022), Early Letter + Portrait Arm received nothing.
62246409|NCT05817253|EXPERIMENTAL|Delayed Control Arm|Delayed Control Arm received nothing with the initial mailing (on September 23, 2021). At the delayed mailing (March 28, 2022), Delayed Control Arm received a Portrait +Therapeutics Letter.
62623876|NCT01662271||adolescents with obesity|BMI 30-34.9kg/m2
62825289|NCT06591156|ACTIVE_COMPARATOR|Control group|Coronally advanced flap only without any graft or biomaterial
62246410|NCT05817253|EXPERIMENTAL|Early Letter Arm|Early Letter Arm received a Therapeutics Letter only with the initial mailing (September 23, 2021). At the delayed mailing (March 28, 2022), Early Letter Arm received a Portrait + Therapeutics Letter
62246411|NCT00614705|EXPERIMENTAL|1|
62246412|NCT00614705|PLACEBO_COMPARATOR|2|
62825290|NCT06600698|EXPERIMENTAL|INM176 Dose Escalation and Tolerability Assessment in phase I and efficacy assessment in phase II|"Phase I evaluates the safety and tolerability of INM176 using a dose escalation design. Participants will receive INM176 at the following dose levels: Dose Level -1 (400 mg/day), Dose Level 0 (800 mg/day), Dose Level +1 (1200 mg/day), and Dose Level +2 (1600 mg/day). The trial starts with 3 subjects at Dose Level 0. If none experience dose-limiting toxicity (DLT), 3 more subjects will be escalated to Dose Level +1. If one subject at Dose Level 0 experiences DLT, 3 additional subjects will be enrolled at the same level. Dose Level -1 is considered the maximum tolerated dose if 2 or more of 6 subjects experience DLT at Dose Level 0. The recommended Phase II dose (RP2D) may be the MTD or Dose Level +2 if no DLT is observed.~Phase II measures changes in Prostate-Specific Antigen (PSA) levels from baseline to after 6 cycles of treatment at the Recommended Phase II Dose (RP2D). PSA level declines from baseline or stays same will be recorded as a positive responder to INM176."
62246413|NCT02529267||Experienced abuse|Experienced IPV in the past 12 months
62246414|NCT02529267||Did not experience abuse|Did not experience IPV in the past 12 months.
62246415|NCT04998487|EXPERIMENTAL|LY3471851 (Abdomen)|LY3471851 administered subcutaneously (SC) into the abdomen.
62246416|NCT04998487|EXPERIMENTAL|LY3471851 (Thigh)|LY3471851 administered SC into the thigh.
62246417|NCT00446238|EXPERIMENTAL|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
62246418|NCT00446238|ACTIVE_COMPARATOR|Standard of Community Care Treatment|Standard of Community Care Treatment
62246419|NCT01754857|EXPERIMENTAL|Bendamustine, rituximab, lenalidomide|"INDUCTION: Bendamustine 90mg/m2 IV D1\&2 and rituximab IV D1 (up to day 5 of course 1) every 28 days for 6 cycles. Patients with objective response move to maintenance therapy. Patients with objective response after 4 courses are eligible to for maintenance therapy if ongoing induction therapy is associated w/unacceptable toxicity.~MAINTENANCE: At 6-12 wks post induction therapy, patients receive rituximab IV on day 1 of odd-numbered cycles for 24 cycles; lenalidomide 5mg PO daily on days 1-21 of each cycle (28 day cycles). Dose escalation to 10mg daily on days 1-21 allowed at start of cycle 2 or at start of subsequent cycles in subjects w/acceptable toxicities. Lenalidomide dose escalation only allowed at start of a new cycle up to a max dose of 10 mg/day on days 1- 21. Subjects entering maintenance with CrCl ≥40 \& \<60mL/min will begin dosing at 5mg every other day on days 1-21. Patients with excessive toxicity from lenalidomide may continue maintenance therapy with rituximab alone."
62246420|NCT06716671||Type 2 diabetes and continuous glucose monitoring Tarragona|People with type 2 diabetes and intensive insulin therapy who are using a continuous glucose monitoring sensor for the first time in the Camp de Tarragona health region.
62246421|NCT04651010|EXPERIMENTAL|Multimodal MRI|
62436699|NCT04460352|EXPERIMENTAL|Experimental arm (B)|"Definitive chemoradiotherapy followed by surveillance, and esophagectomy only in case of residual or recurrent locoregional cancer.~Radiotherapy: Two alternative schemes:~1. 1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy.~2. 2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy.~Chemotherapy: Three alternative regimens:~1. Platin-Taxane Regimen: Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy.~2a. Platinum-Fluoropyrimidine Regimen: Cisplatin 75mg/m2 weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion weeks 1 and 5.~2b. FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion weeks 1, 3 and 5."
62043849|NCT03176420|NO_INTERVENTION|medical arm|maximal medical therapy of occluded carotids
62246422|NCT00473551|EXPERIMENTAL|Anti-Third Party T Lymphocytes + Nonmyeloablative SCT|"Anti-Third Party CTL (Cytolytic T-lymphocytes) with Nonmyeloablative SCT (Stem Cell Transplantation)~Rituximab 375 mg/m\^2 intravenously over several hours on Day -13, followed by 1000 mg/m\^2 intravenously on Days -6, 1, and 8; + Cyclophosphamide 50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine; + Fludarabine 40 mg/m\^2 intravenously over 30 minutes once per day for 4 days, starting Day -6; + Radiation 2Gy Total body radiation day before transplantation + Stem Cell Transplantation + Intravenous infusion of Anti-third Party CTLs."
62043850|NCT05641558|EXPERIMENTAL|611 dose 1 plus placebo|One subcutaneous injections of 611 150 mg on Day 1, followed by a 4-week observation period. Two subcutaneous injections of 611 150 mg (for a total of 300 mg) as a loading dose on Week 0 Day 29, followed by one 150 mg injection quaque week (QW) from Week 1 to Week 15 (15 cycles).
62043851|NCT05641558|EXPERIMENTAL|611 dose 2 plus placebo|Two subcutaneous injections of 611 150 mg (for a total of 300 mg) on Day 1, followed by a 4-week observation period. Four subcutaneous injections of 611 150 mg (for a total of 600 mg) as a loading dose on Week 0 Day 29, followed by one 300 mg injection quaque 2 week (Q2W) from Week 1 to Week 15 (8 cycles).
62043852|NCT05641558|EXPERIMENTAL|611 dose 3 plus placebo|Four subcutaneous injections of 611 150 mg (for a total of 600 mg) on Day 1, followed by a 4-week observation period. Four subcutaneous injections of 611 150 mg (for a total of 600 mg) as a loading dose on Week 0 Day 29, followed by one 300 mg injection QW from Week 1 to Week 15 (15 cycles).
62043853|NCT02514629|PLACEBO_COMPARATOR|Placebo|Placebo for 52 weeks
62246423|NCT02827305|EXPERIMENTAL|group 1|scaling and Gotukola mouthwash intervention- 1.Scaling 2.Gotukola mouthwash , 10ml twice daily to be rinsed for 60 seconds
62825291|NCT02723708|EXPERIMENTAL|Self activation of VTA bold signal|Participants meeting study inclusion will then be scheduled for 4 fMRI sessions to assess and manipulate the ability to self-stimulate VTA activation. Each session will contain the same tasks and instructions. The experimental imaging task sessions will be done 24-72 hours apart and will consist of two types of runs: Test Runs (one pre-test and post-test each) and three Training Runs. Participants will be instructed to achieve heightened state of motivation using personally relevant thoughts and imagery.
62825292|NCT02105740|EXPERIMENTAL|Hypnosis|Use of hypnosis in the reduction of the levels of pain, depression and anxiety.
62825293|NCT02105740|ACTIVE_COMPARATOR|Control|Comparison of the effects of hypnosis between the control group and the experimental group regarding pain, anxiety and depression with the application of the scales.
62825294|NCT03365102|EXPERIMENTAL|anodal tDCS over the rIFG,|anodal tDCS over the rIFG,
62825295|NCT03365102|EXPERIMENTAL|anodal tDCS over the lOFC|anodal tDCS over the lOFC
62825296|NCT03365102|PLACEBO_COMPARATOR|sham tDCS stimulation|sham tDCS stimulation
62825297|NCT06584968|EXPERIMENTAL|Training with visual feedback|The students in the study group will do monofilament applications on a precision scale. They will be provided with visual feedback by comparing the value of the monofilament with the pressure value of the monofilament applied on the precision scale in grams. In this way, the students will visually experience whether they can provide the appropriate level of pressure during the application. The practice on the precision scale will continue for 15-20 minutes with the monofilaments in the Semmes-Weinstein Monofilament Test kit.
62043854|NCT02514629|EXPERIMENTAL|Metformin|Metformin 850 mg tablets twice daily for 52 weeks
62043855|NCT02514629|EXPERIMENTAL|Testosterone|Testosterone Undecanoate 1000 mg/4ml im injection each 12 weeks for 52 weeks
62043856|NCT02514629|EXPERIMENTAL|Metformin + Testosterone|Metformin 850 mg tablets twice daily + Testosterone Undecanoate 1000 mg/4ml im injection each 12 weeks for 52 weeks
62043857|NCT00785291|ACTIVE_COMPARATOR|Arm A (Paclitaxel)|Patients receive 90 mg/m\^2 paclitaxel IV over 1 hour on days 1, 8, and 15. Patients may receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15.
62246424|NCT02827305|ACTIVE_COMPARATOR|group 2|Scaling
62246425|NCT02827305|ACTIVE_COMPARATOR|group 3|Intervention- Gotukola mouthwash only is advised to be used two times a day, each time 10ml rinsed for 60 seconds (morning and evening ) after the food.
62246426|NCT05948475|EXPERIMENTAL|Tinengotinib 8 mg QD|Tinengotinib will be administered in 28-day cycles.
62436700|NCT05898282||anesthesia professionals|anesthetists working at teaching and referral hospitals of north west Ethiopia
62246427|NCT05948475|EXPERIMENTAL|Tinengotinib 10 mg QD|Tinengotinib will be administered in 28-day cycles.
62436701|NCT06318481|EXPERIMENTAL|Treatment Group|Patients will be provided ticagrelor twice daily for first 30 days after primary PCI.
62246428|NCT05948475|ACTIVE_COMPARATOR|Physician's Choice|Physician's Choice treatments include FOLFOX or FOLFIRI
62825298|NCT06584968|ACTIVE_COMPARATOR|Classical learning|The students in the control group will do practical applications with the classical learning method, where one of the researchers plays the patient role. They will do application trials with the monofilaments in the Semmes-Weinstein Monofilament Test kit for 15-20 minutes.
62043858|NCT00785291|EXPERIMENTAL|Arm B (Nab-paclitaxel)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Patients may also receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15.
62246429|NCT03570372|EXPERIMENTAL|Intervention group|18 week internet-based CBT with therapist support. Regular online group discussions.
62246430|NCT03570372|ACTIVE_COMPARATOR|Control group|Reads 2 books about Autism Spectrum Disorder (ASD)
62825299|NCT05271643|EXPERIMENTAL|CF-CBT-A intervention|Participants will meet with a therapist, a mental health provider on their cystic fibrosis care team who has received training in CF-CBT-A, for a baseline interview and introduction plus 9 weekly sessions of CF-CBT-A.
62825300|NCT02258737|EXPERIMENTAL|transitional case management|
62825301|NCT02258737|ACTIVE_COMPARATOR|standard care|
62043859|NCT00785291|EXPERIMENTAL|Arm C (Ixabepilone)|Patients receive ixabepilone IV over 60 minutes on days 1, 8, and 15. Patients may also receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. (closed to accrual as of 7/18/11)
62246431|NCT04801134|OTHER|Food insecurity|Food insecure families will be assigned education and community resources needed.
62246432|NCT06178965|OTHER|Abdominal Wall Component Release with Contemporary Onlay Mesh Fixation|Abdominal Wall Component Release with Contemporary Onlay Mesh Fixation in patients with incisional hernia
62246433|NCT05029466|EXPERIMENTAL|Immediate treatment|Participants will commence psilocybin treatment immediately upon study enrollment.
62246434|NCT05029466|EXPERIMENTAL|Delayed treatment|Participants will commence psilocybin treatment two weeks after study enrollment.
62246435|NCT02427880|EXPERIMENTAL|Acetazolamide|Each patient receives 250 mg of acetazolamide and 50 mg of hydrochlorothiazide daily for 1 week. Then they are prescribed 40 mg of furosemide daily for 2 weeks.
62246436|NCT02427880|ACTIVE_COMPARATOR|Furosemide|Each patient is prescribed 40 mg of furosemide and 50 mg of hydrochlorothiazide daily for 1 week. Then they receive 40 mg of furosemide daily for 2 weeks.
62246437|NCT05197413|EXPERIMENTAL|Arrae Bloat supplement|"The Bloat capsules are a blend of 5 herbs and a fruit-based digestive enzyme that target the cause for IBS symptoms."
62246438|NCT04564144|EXPERIMENTAL|Volunteers receiving the prepared orodispersible tablets|6 human volunteers will receive the prepared orodispersible tablets plus a commercial one all containing Meclizine HCl in a parallel manner.
62825302|NCT06016114||HIV-1 positive individuals (non-pregnant)|
62825303|NCT06016114||Pregnant HIV-1 positive/negative individuals|
62825304|NCT06472427|PLACEBO_COMPARATOR|1 session with normoxic post-exercise recovery, supplemented with placebo (NPL)|Normoxic training, followed by normoxic recovery with placebo supplements
62825305|NCT06472427|EXPERIMENTAL|1 session with normoxic post-exercise recovery, supplemented with ketones (NKE)|Normoxic training, followed by normoxic recovery with ketone supplements
62825306|NCT06472427|EXPERIMENTAL|1 session with hypoxic post-exercise recovery, supplemented with placebo (HPL)|Normoxic training, followed by hypoxic (simulated altitude of 3000m) recovery with placebo supplements
62825307|NCT06472427|EXPERIMENTAL|1 session with hypoxic post-exercise recovery, supplemented with ketones (HKE)|Normoxic training, followed by hypoxic (simulated altitude of 3000m) recovery with ketone supplements
62825308|NCT00751296|EXPERIMENTAL|Lenalidiomide|Lenalidomide target dose of 10 mg PO OD X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28-day cycle.
62825309|NCT06591260||Arrhythmic (A)|"Arrhythmic Group. To oversimplify, specific subgroups of patients will be considered.~Group 1: major ventricular arrhythmias (haemodynamically unstable VT, hu-VT; ventricular fibrillation, VF).~Group 2: other ventricular arrhythmias (high-burden premature ventricular complexes = hb-PVC; nonsustained VT = NSVT; haemodynamically stable VT = hs-VT).~Group 3: bradyarrhythmias (2nd type II or 3rd degree atrioventricular block = advanced AVB; critical sinus pauses = SND).~Group 4: supraventricular arrhythmias (atrial fibrillation = AF; atrial flutter = AFlu; atrial tachycardia = AT)."
62246439|NCT02507622|OTHER|gas concentration|Gaz concentration of C02, CO and NH4, 3 exhaled in weightlessness and normal gravity.
62246440|NCT01320982|ACTIVE_COMPARATOR|minocycline|minocycline
62246441|NCT01320982|ACTIVE_COMPARATOR|pramipexole|pramipexole
62825310|NCT06591260||Nonarrhythmic (NA)|"Nonarrhythmic Group. To oversimplify, specific subgroups of patients will be considered.~1. Heart failure presentation (and subtypes)~2. Chest pain presentation (and subtypes)~3. Asymptomatic presentation/screening (and subtypes)"
62246442|NCT01320982|ACTIVE_COMPARATOR|acetylsalicylic acid|acetylsalicylic acid
62246443|NCT01320982|PLACEBO_COMPARATOR|Placebo|Placebo
62246444|NCT03574441|ACTIVE_COMPARATOR|TegadermTM only|
62825311|NCT06591260||Subgroups|"For specific study aims, different patient subgroups will be compared. The main groups are hereby reported:~A. Arrhythmic myocarditis subgroups (1-4). B. Non-arrhythmic myocarditis subgroups (i.e.: fulminant, acute coronary syndrome-like, pericarditis-like, heart failure, nonischaemic dilated /hypokinetic cardiomyopathies of unknown aetiology...).~C. Infectious vs. autoimmune vs. toxic myocarditis. D. Myocarditis treated by aetiology-based treatment vs. isolated cardiac medical treatment.~E. Myocarditis at different disease stages: acute, hyperacute, fulminant, chronic active, post-inflammatory, or active vs. previous vs. non-myocarditis.~F. Myocarditis presenting as organ-specific diseases vs. in the context of a genetic disorder or systemic disease.~G. Myocarditis vs. peri-myocarditis/myo-pericarditis. H. Other subgroups"
62825312|NCT04008472|EXPERIMENTAL|Telemedecine|Patients benefiting from telemedicine
62825313|NCT04008472|NO_INTERVENTION|Control|routine care without telemedecine
62825314|NCT04253691|EXPERIMENTAL|Virtual Reality Based Relaxation Therapy|This is a pilot trial with one treatment condition (VR mediation).
62825315|NCT04003701|ACTIVE_COMPARATOR|Usual care group (control group)|Within the usual care, no one of the attendees in the room will have specific interaction with the child during this procedure, with the exception of normal/necessary interaction by the nurse and/or parent. Only minimal distraction is allowed. The child will sit down on the treatment table with the legs stretched out in front of him and the puncture-side arm in a 90-90 position next to the head or stretched out and lying down along the body, with the nurse at the puncture side and the parent at the other side standing next to him. The researcher is also present in the room, within the child's field of vision. At the end of the procedure, the nurse tells the child that he/she did very well.
62825316|NCT04003701|EXPERIMENTAL|Robot-assisted puncture procedure (experimental group)|During the experimental intervention, the child, a nurse, one of the parents/guardians, a researcher and the humanoid robot NAO (H25 Academic Edition, Aldebaran Robotics, Paris, France) will be present in the same room. The child will sit down in the same position as with the usual care. Next to the patient a humanoid robot of three-foot tall will sit on eye level on a slanted reading table, at the non-puncture side. The nurse will carry out the puncture procedure as performed as usual. The robot is programmed to distract the child during the entire procedure (before, during and after the puncture) by playing a game with the child based on his/her interests. The child can therefore choose between a number of games in different themes. In the end the robot tells the child that he/she did very well. During the whole intervention, the robot will be re-activated for each phase only when the child and the nurse are ready.
62825317|NCT05910073||Lamina curved plate|Use of a Lamina Curved plate (Osteobiol® Laboratory) in the treatment of OAC
62246445|NCT03574441|ACTIVE_COMPARATOR|Dressing with TegadermTM plus Steri-StripTM bands|
62436702|NCT06318481|ACTIVE_COMPARATOR|Control Group|Patients will be provided clopidogrel twice daily for first 30 days after primary PCI.
62246446|NCT03574441|EXPERIMENTAL|Dressing with TegadermTM plus catheter support pad.|
62246447|NCT06416735|EXPERIMENTAL|patients carrying the wild-type (GG) genotype of ADD1 rs4961|The protocol involves a test of oral administration of a single dose of Amiloride (5 or 10 mg based on body weight) to 20 patients carrying the wild-type (GG) genotype of ADD1 rs4961
62246448|NCT06416735|EXPERIMENTAL|patients carriers of variant T (GT or TT)|The test involves the administration of a single dose of 5 or 10 mg of Amiloride to 20 hypertensive carriers of the T variant (GT or TT)
62246449|NCT01600976|EXPERIMENTAL|Group 1|10 patients with moderate hepatic impairment (CPB \[Child-Pugh score 7 to 9\])
62246450|NCT01600976|EXPERIMENTAL|Group 2|10 healthy control patients with normal hepatic function. Each healthy control patient is matched to a patient in Group 1 with respect to sex, age (± 5 years) and body mass index (BMI) (± 15%)
62246451|NCT01600976|EXPERIMENTAL|Group 3|up to 4 patients with severe hepatic impairment (CPC \[limited to Child Pugh score 10 to 12\])
62436703|NCT03564756|EXPERIMENTAL|Iron + Vitamin C|One iron tablet once a day plus a 500 mg vitamin C tablet twice a day until delivery.
62436704|NCT03564756|NO_INTERVENTION|Iron + Placebo|One iron tablet once a day plus a placebo tablet twice a day until delivery.
62246452|NCT05221723|EXPERIMENTAL|Exercise Group|In this single group design, all participants will be provided with 6 months of twice weekly supervised group exercise.
62246453|NCT05691517|EXPERIMENTAL|Treatment (CBX-12)|Aatients receive CBX-12 IV, over 60 minutes, on days 1, 8, 15 and 22 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy and CT scans on study and undergo blood sample collection throughout the trial.
62825318|NCT06597669|EXPERIMENTAL|Conventional Technique|A stainless steel crown will place on a carious primary molar after preparation
62825319|NCT06597669|EXPERIMENTAL|Hall technique|A stainless steel crown will place on a carious primary molar without local anesthesia caries removal or any preparation
62246454|NCT05327621|EXPERIMENTAL|Pamiparib|Tablets 20mg per os : 40 mg / bid every day in continuous. Patients will be treated with Pamiparib. Cycles are defined in 28-day periods. Disease response will be assessed every 8 weeks (RECIST 1.1). Safety will be assessed continuously.
62246455|NCT01226823|PLACEBO_COMPARATOR|Placebo|obstetrical monitoring plus placebo
62825320|NCT05472779|ACTIVE_COMPARATOR|Intravaginal Estrogen Application|Intravaginal application of 1 gram estradiol cream at bedtime twice a week for 6 months
62825321|NCT05472779|EXPERIMENTAL|Periurethral Estrogen Application|Periurethral application of 0.5 gram estradiol cream at bedtime twice a week for 6 months
62825322|NCT04379700|EXPERIMENTAL|Embolization Group|23 participants who are aged between 30 to 75 years old, with grade 2 or 3 knee OA on the most recent knee radiographs obtained within 6 months of intervention. Each individual participant will be enrolled for approximately 13 months to complete all study visits from the initial screening visit to last follow up at 12-months post intervention.
62825323|NCT04021719||OnTrackNY LHS Participants and Stakeholders|OnTrackNY participants and stakeholders, including past participants, family members, clinicians, administrators, payors, and state leadership
62825324|NCT02241824|ACTIVE_COMPARATOR|Elastic abdominal binder|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen after an intervention of an elastic abdominal binder.
62825325|NCT02241824|NO_INTERVENTION|No brace|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen with no brace (control).
62825326|NCT02241824|EXPERIMENTAL|In-elastic lumbar brace|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen after an intervention of an in-elastic lumbar brace.
62825327|NCT00509977|EXPERIMENTAL|1|Light therapy
62825328|NCT00509977|EXPERIMENTAL|2|Laser Treatment
62825329|NCT06116045|EXPERIMENTAL|Group A - BZ371A, then Placebo|Participants will first receive topical BZ371A 7.5 mg for daily use for 2 weeks. After a washout period of 2 weeks, they will receive topical Placebo to be used daily for 2 weeks.
62825330|NCT06116045|EXPERIMENTAL|Group B - Placebo, then BZ371A|Participants will first receive topical Placebo for daily use for 2 weeks. After a washout period of 2 weeks, they will receive topical BZ371A 7.5 mg to be used daily for 2 weeks.
62825331|NCT06116045|EXPERIMENTAL|Group C - BZ371A, then Placebo|Participants will first receive topical BZ371A 5.0 mg for daily use for 2 weeks. After a washout period of 2 weeks, they will receive topical Placebo to be used daily for 2 weeks.
62825332|NCT06116045|EXPERIMENTAL|Gorup D - Placebo, then BZ371A|Participants will first receive topical Placebo for daily use for 2 weeks. After a washout period of 2 weeks, they will receive topical BZ371A 5.0 mg to be used daily for 2 weeks.
62825333|NCT06116045|EXPERIMENTAL|Group E - BZ371A, then Placebo|Participants will first receive topical BZ371A 2.5 mg for daily use for 2 weeks. After a washout period of 2 weeks, they will receive topical Placebo to be used daily for 2 weeks.
62825334|NCT06116045|EXPERIMENTAL|Group F - Placebo, then BZ371A|Participants will first receive topical Placebo for daily use for 2 weeks. After a washout period of 2 weeks, they will receive topical BZ371A 2.5 mg to be used daily for 2 weeks.
62825335|NCT06599645|EXPERIMENTAL|Group A|CST+BFR+Tai Chi+Education
62825336|NCT06599645|EXPERIMENTAL|Group B|CST+BFR+Education
62825337|NCT06599645|EXPERIMENTAL|Group C|Tai Chi +BFR+Education
62825338|NCT06599645|OTHER|Group D|CST+Education
62825339|NCT04298047|EXPERIMENTAL|Intervention group|The participants in the Intervention group will be participants of the MMFA participatory art-based activity.
62825340|NCT04298047|NO_INTERVENTION|Control Group|The Control arm will be composed of older community dwellers matched on age and sex compared to the Intervention group but who will not be participants at the MMFA participatory art-based activity.
62246456|NCT01226823|EXPERIMENTAL|Ursodeoxycholic acid|obstetrical monitoring plus active drug
62246457|NCT02755168|OTHER|External Pop-Out Cesarean Section|
62246458|NCT02755168|OTHER|Classic technique|
62246459|NCT02679599|OTHER|Cardiac rehabilitation as usual|Participants will receive cardiac rehabilitation as usual (i.e., as offered in the clinical setting).
62246460|NCT02679599|EXPERIMENTAL|Cardiac rehabilitation plus B-MOBILE-CARDIAC smartphone app|Participants will receive cardiac rehabilitation as usual, plus access to the B-MOBILE-CARDIAC smartphone application through 4 weeks post-rehabilitation.
62436705|NCT05639387|EXPERIMENTAL|Group of healthy volunteers (part I)|Participants will undergo active tVNS.
62436706|NCT05639387|SHAM_COMPARATOR|Group of healthy volunteers (part II)|Participants will undergo sham tVNS.
62436707|NCT04164485|EXPERIMENTAL|Functional collagen scaffold transplantation|
62436708|NCT04164485|EXPERIMENTAL|Autologous adipose cell transplantation|
62825341|NCT06258200|EXPERIMENTAL|Intervention group|Participants in this arm will receive behavioral interventions, including household visits, participation in couples discussion groups, and messaging from community leaders.
62825342|NCT06258200|EXPERIMENTAL|Comparison|Participants in this arm will not receive any interventions.
62825343|NCT06284382|OTHER|Presence of early trauma|"In the presence of early trauma arm, 15 participants are recruited based on a high Childhood Trauma Questionnaire total score."
62825344|NCT06284382|OTHER|Absence of early trauma|"In the absence of early trauma arm, 15 participants are recruited based on a low Childhood Trauma Questionnaire total score."
62825345|NCT03271762|EXPERIMENTAL|MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW Device|MitraClip NT System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
62825346|NCT03271762|ACTIVE_COMPARATOR|cardiac surgery|mitral valve repair in first intervention, valve replacement if repair not feasible
62043860|NCT05236686|EXPERIMENTAL|Hepato-celiac lymphadenectomy|This single-arm, single-center, phase II trial is to evaluate the safety and effectiveness of hepato-celiac lymphadenectomy in the treatment of ovarian cancer with hepato-celiac lymph nodes metastases, in the circumstance of primarily diagnosed advanced epithelial ovarian cancer (primary debulking surgery or interval debulking surgery) and of platinum-sensitive recurrent ovarian cancer (no more than 4 lines of therapy).
62043861|NCT03375983|EXPERIMENTAL|Blood-stage infection of P.vivax|This is a single arm study that plans to enroll 20 patients and each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1.0 × 10\^7 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.
62043862|NCT01059981||1|Dialysis patients
62043863|NCT01059981||2|Trauma patients
62043864|NCT01059981||3|Patients with carbon monoxide poisoning
62043865|NCT03927469||Hospitalisation group|The patients who were hospitalized in the hospital between January 2015 and July 2018, according to ICD 10 code; hemiplegia (G81), flaccid hemiplegia (G81.0), hemiplegia, unspecified (G81.9), Spastic hemiplegia (G81.1) scanned from the hospital database.
62043866|NCT03927469||Re-hospitalisation group.|The patients who were re-hospitalized in the hospital between January 2015 and July 2018, according to ICD 10 code; hemiplegia (G81), flaccid hemiplegia (G81.0), hemiplegia, unspecified (G81.9), Spastic hemiplegia (G81.1) scanned from the hospital database.
62436709|NCT03574883|EXPERIMENTAL|In-phase tACS|6 Hz stimulation (1000 μA) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator. The phase difference between the two stimulation sites will be 0°.
62436710|NCT03574883|ACTIVE_COMPARATOR|Anti-phase tACS|6 Hz stimulation (1000 μA) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator. The phase difference will be 180°,
62825347|NCT05491811|EXPERIMENTAL|Ensartinib and Bevacizumab|Ensartinib 225 mg oral once daily with Bevacizumab 7.5mg/kg intravenous every 3 weeks
62825348|NCT01651026||rectal cancer|
62825349|NCT06585956||Communication Group|Physician-Patient Communication Group
62825350|NCT06585956||Non-Communication Group|Physician-Patient Non-Communication Group
62825351|NCT06588049|EXPERIMENTAL|Nitrate Mouth Rinse|Nitrate suspension with approximately 50-100mg nitrates formulated with water swished in mouth for 30 seconds and then expectorated once daily for 14 consecutive days.
62825352|NCT06588049|PLACEBO_COMPARATOR|Water Mouth Rinse|Water mouth rinse swished in mouth for 30 seconds and then expectorated once daily for 14 consecutive days.
62825353|NCT04106557|EXPERIMENTAL|OV101 once daily (weight-based dosing) Other Name:Gaboxadol|OV101 (gaboxadol), oral, provided once daily at bedtime for 12 week duration
62825354|NCT04106557|PLACEBO_COMPARATOR|Placebo once daily|Matching placebo,oral, provided once daily at bedtime for 12 week duration
62825355|NCT06597786|EXPERIMENTAL|Exercise therapy|Exercise therapy will comprise individualized treadmill walking delivered up to 5 times weekly (over a 7-day period) to achieve a weekly cumulative dose of 225 minutes per week. The minimum treatment period will be 3 weeks. Exercise therapy will be administered via a patient-centric, decentralized platform: Digital Platform for Exercise (DPEx). DPEx will permit all study procedures to be conducted remotely in patients' homes.
62825356|NCT04971161|EXPERIMENTAL|allo-APZ2-CVU (dose group 1: 1 x 10e6 cells/cm²)|Application of IMP on patients wound
62825357|NCT04971161|PLACEBO_COMPARATOR|Placebo|Application of IMP on patients wound
62825358|NCT04971161|EXPERIMENTAL|allo-APZ2-CVU (dose group 2: 3 x 10e6 cells/cm²)|Application of IMP on patients wound
62825359|NCT04971161|EXPERIMENTAL|allo-APZ2-CVU (dose group 3: 6 x 10e6 cells/cm²)|Application of IMP on patients wound
62825360|NCT04946851||non-treatment-seeking individuals|Participants across the spectrum of drinking (from non-drinkers to heavy drinkers) who are not interested in treatment for alcohol use disorder
62825361|NCT04946851||treatment-seeking individuals with alcohol use disorder|Volunteers with an AUD diagnosis who are seeking treatment for the condition
62246461|NCT03904745|EXPERIMENTAL|Atosiban used before embryo transfer|the patients in this group will be administered 6,75mg atosiban intravenously.
62246462|NCT03904745|NO_INTERVENTION|Control group|the patients in this group will not be administered atosiban before embryo transfer.
62825362|NCT04973449|EXPERIMENTAL|Primary Vaccination Cohort:- AZD1222 (4)|Previously unvaccinated participants received intramuscular (IM) AZD1222 5\*10\^10 viral particles (vp) on Days 1 and 29 (4-week dosing interval).
62825363|NCT04973449|EXPERIMENTAL|Primary Vaccination Cohort:- AZD2816 (4)|Previously unvaccinated participants received IM AZD2816 5\*10\^10 vp on Days 1 and 29 (4-week dosing interval).
62825364|NCT04973449|EXPERIMENTAL|Primary Vaccination Cohort:- AZD1222 + AZD2816 (4)|Previously unvaccinated participants received IM AZD1222 5\*10\^10 vp on Day 1 and IM AZD2816 5\*10\^10 vp on Day 29 (4-week dosing interval).
62825365|NCT04973449|EXPERIMENTAL|Primary Vaccination Cohort:- AZD2816 (12)|Previously unvaccinated participants received IM AZD2816 5\*10\^10 vp on Days 1 and 85 (12-week dosing interval).
62825366|NCT04973449|EXPERIMENTAL|Booster Cohort:- AZD1222:AZD1222|Participants, who previously received 2 doses of AZD1222 vaccine according to the authorized dose and dosing regimen, with second dose administered at least 90 days prior to study treatment, received booster dose of IM AZD1222 5\*10\^10 vp on Day 1.
62825367|NCT04973449|EXPERIMENTAL|Booster Cohort:- AZD1222:AZD2816|Participants, who previously received 2 doses of AZD1222 vaccine according to the authorized dose and dosing regimen, with second dose administered at least 90 days prior to study treatment, received booster dose of IM AZD2816 5\*10\^10 vp on Day 1.
62825368|NCT04973449|EXPERIMENTAL|Booster Cohort:- mRNA:AZD1222|Participants, who previously received 2 doses of approved mRNA based vaccine according to the authorized dose and dosing regimen, with second dose administered at least 90 days prior to study treatment, received booster dose of IM AZD1222 5\*10\^10 vp on Day 1.
62825369|NCT04973449|EXPERIMENTAL|Booster Cohort:- mRNA:AZD2816|Participants, who previously received 2 doses of approved mRNA based vaccine according to the authorized dose and dosing regimen, with second dose administered at least 90 days prior to study treatment, received booster dose of IM AZD2816 5\*10\^10 vp on Day 1.
62825370|NCT06604364|NO_INTERVENTION|control|pre-surgery sedation
62825371|NCT06604364|EXPERIMENTAL|VR|virtual reality sedation
62825372|NCT03130738|ACTIVE_COMPARATOR|7-Day Miconazole Oil (Miconazole 2%)|7 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
62436711|NCT03574883|SHAM_COMPARATOR|Sham tACS|The stimulation (anti-phase) will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation.
62436712|NCT03574883|EXPERIMENTAL|Active tDCS|1000 μA tDCS stimulation will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator
62436713|NCT03574883|SHAM_COMPARATOR|Sham tDCS|The stimulation will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation.
62436714|NCT03569319|EXPERIMENTAL|"Group 1: THINK-MED resource (baseline)"|"The THINK-MED resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline (n=10)"
62436715|NCT03569319|EXPERIMENTAL|"Group 2: THINK-MED resource (staged)"|"This group of participants will receive the THINK-MED resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian (n=10)"
62436716|NCT03569319|PLACEBO_COMPARATOR|Group 3: Control|"Participants will receive the THINK-MED resource after their final 6 month study visit (i.e. delayed intervention) (n=10)"
62436717|NCT00062309|ACTIVE_COMPARATOR|CIMRT|76 Gy in 38 fractions
62436718|NCT00062309|EXPERIMENTAL|HIMRT|70.2 Gy in 26 fractions
62436719|NCT05299229||Heart and vascular function|All study participants will have echocardiography and non-invasive monitoring by chest/back sensors and a finger cuff to determine the best method of monitoring heart and vascular function in preeclampsia.
62436720|NCT01361399|EXPERIMENTAL|Arm 1|
62436721|NCT01361399|ACTIVE_COMPARATOR|Arm 2|
62436722|NCT01361399|ACTIVE_COMPARATOR|Arm 3|
62436723|NCT01361399|PLACEBO_COMPARATOR|Arm 4|
62436724|NCT05557578|EXPERIMENTAL|Experimental arm|Tislelizumab combined with GEMOX (GOT) regimen
62436725|NCT03010202|EXPERIMENTAL|Induction phase: Rituximab+Dexamethasone|Open-label, intravenous infusions of rituximab 1000 mg and oral dexamethasone 20 mg daily for 4 days given on day 1 and day 15.
62436726|NCT03010202|NO_INTERVENTION|Induction phase: Rituximab|Open-label, intravenous infusions of rituximab 1000 mg given on day 1 and day 15.
62603011|NCT05621369||Participants with Psoriatic Arthritis|People who report a diagnosis of Psoriatic Arthritis. Participants are invited via the Psorcast mobile application to complete the following assessments: Participant self-assessment surveys, skin assessments (Psoriasis Area Draw and Psoriasis Area Photo) and musculoskeletal assessments (Finger/Toe Photos, Joint Count, Digital Jar Open, 30s Walk).
62603012|NCT05621369||Participants without Psoriasis or Psoriatic Arthritis|People who report no prior diagnosis of Psoriasis or Psoriatic Arthritis. Participants are invited via the Psorcast mobile application to complete the following assessments: Participant self-assessment surveys, skin assessments (Psoriasis Area Draw and Psoriasis Area Photo) and musculoskeletal assessments (Finger/Toe Photos, Joint Count, Digital Jar Open, 30s Walk).
62603013|NCT01838434|ACTIVE_COMPARATOR|lenalidomide (Phase II)|Lenalidomide will be administered orally at 20 mg daily on days 1-21, repeated every 28 days for a maximum of 12 cycles (48 weeks). (Phase II)
62825373|NCT03130738|ACTIVE_COMPARATOR|14-Day Miconazole Oil (Miconazole 2%)|14 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
62825374|NCT03130738|PLACEBO_COMPARATOR|14-Day Placebo - Oil Vehicle|14 days of 2x per day of treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
62825375|NCT06203327||OLGA 0-I|
62825376|NCT06203327||OLGA II|
62825377|NCT06203327||OLGA III-IV|
62825378|NCT06591936||genetic of alpha thalathemia|
62825379|NCT06540261|EXPERIMENTAL|ONO-7913＋ONO-4538＋FOLFOX＋Bev|
62825380|NCT06540261|EXPERIMENTAL|ONO-7913＋ONO-4538＋FOLFOX＋Cet|
62043867|NCT01760239|EXPERIMENTAL|Clinical Decision Support (CDS)|The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR during any visit to a family practice or pediatric clinic (including both preventive care and sick visits, excluding prenatal and postpartum visits). The algorithm will be embedded in the EHR. In most cases, when a normal BP \<90% and \<120/80 mm Hg is entered, no alerts will be triggered. In some cases, clinical staff may receive up to two alerts, either to measure height or to repeat a first elevated BP reading. In cases with confirmed elevated BP measures, providers will receive a single CDS message summarizing that patient's current BP status and recommending specific clinical actions.
62825381|NCT03712696|EXPERIMENTAL|DIGNICAP™|DigniCap® System
62825382|NCT06553703|EXPERIMENTAL|Acceptance and commitment therapy based group psychoeducation|Acceptance and commitment therapybased group psychoeducation to be carried out with the experimental group is planned as 8 sessions. The sessions are planned to be held in 3 groups of 9 people each. The duration of a session is planned to be approximately 90 minutes. Group psychoeducation with the experimental group will be carried out face-to-face every week. The appropriate day for the sessions will be decided together with themembers of each group. The same group session will be held on the same day and time every week.
62825383|NCT06553703|NO_INTERVENTION|No Intervention: Waiting list group|"After the follow-up tests were completed, it was planned to apply the 8-session group psychoeducation applied to the intervention group in the same way to the control group, upon their request.~Intervention: Acceptance and commitment therapy-based group psychoeducation aimed at increasing students' psychological flexibility and reducing their somatic symptoms."
62043868|NCT01760239|NO_INTERVENTION|Control|Patients in this group will receive usual care from their clinic. The CDS tool will not be activated.
62603014|NCT01838434|EXPERIMENTAL|lenalidomide and idelalisib (Phase II)|Lenalidomide will be administered orally and daily on days 1-21, repeated every 28 days for a maximum of 12 cycles (48 weeks). Idelalisib will be orally administered for continuous 28-day cycles until progression, intolerance, or patient/physician discretion. Dosing will be determined by the Phase I portion of the study. (Phase II)
62603015|NCT00454818|EXPERIMENTAL|MYDICAR Very Low Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 \[AAV1\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1.4x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) only.
62603016|NCT00454818|EXPERIMENTAL|MYDICAR Low Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 \[AAV1\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
62825384|NCT05584514|EXPERIMENTAL|Arm 1|"The study is a within-subjects 2 x 3 factorial design. All participants are exposed to all experimental conditions or interventions"
62825385|NCT05271604|EXPERIMENTAL|Cohort M1|Monotherapy BA3021 Q2W dosing regimen
62436727|NCT03010202|EXPERIMENTAL|Maintenance phase: Rituximab|Patients who respond to rituximab in the induction phase will be proceed into the maintenance phase and randomized to rituximab infusion of 500 mg in week 1 and week 24, or
62436728|NCT03010202|NO_INTERVENTION|Maintenance phase: Placebo|Infusion of normal saline 0,9% in week 1 ande week 24 in second randomization.
62436729|NCT05126875|EXPERIMENTAL|Treatment arm|Treatment with stereotactic radiosurgery
62825386|NCT05271604|EXPERIMENTAL|Cohort M2|Monotherapy BA3021 2Q3W dosing regimen
62825387|NCT05271604|EXPERIMENTAL|Cohort N1|Neoadjuvant/induction setting combination therapy of BA3021 2Q3W dosing regimen, pembrolizumab Q3W dosing regimen, and BA3071 Q3W dosing regimen prior to surgery.
62825388|NCT05271604|EXPERIMENTAL|Cohort C1|Combination therapy of BA3021 2Q3W dosing regimen, pembrolizumab Q3W dosing regimen, and BA3071 Q3W dosing regimen
62825389|NCT05271604|EXPERIMENTAL|Cohort C2|Combination therapy of BA3021 2Q3W dosing regimen, and pembrolizumab Q3W dosing regimen
62825390|NCT05271604|EXPERIMENTAL|Cohort C3|Combination therapy of BA3021 2Q3W dosing regimen and cetuximab QW dosing regimen
62825391|NCT03011918||Observational Single Event Faller|one documented fall as an in-patient. It is hypothesized that the nutrition factors present prior to the first fall may be related to fall frequency. Data on exposure to nutrition supplementation will be collected for future analysis. Subpopulation alalysis of individuals with dementia will also be conducted
62825392|NCT03011918||Observational Multiple event faller|multiple falls documented during in-patient stay It is hypothesized that frequent fallers will demonstrate statistically greater weight decline, Hgb decline, Vitamin D deficiency and Higher C-Reactive Protein values prior to the first fall. Data on exposure to nutrition supplementation will be collected for future analysis.. Subpopulation analysis of individuals with dementia will also be conducted.
62043869|NCT01789554|EXPERIMENTAL|MLS dispatch for bystander CPR|When an alarm call of a suspected OHCA suspected is received by the EMS dispatch operator a Mobile positioning system (MPS) is activated. The MPS uses the mobile phone network to geographically locate all lay volunteers connected to a tailored mobile phone service called mobile life saver (MLS). The MPS then locates all lay volunteers within a pre defined radius from the suspected OHACA an alerts them with a computer generated voice call and an sms containing data about were about were the suspected OHCA is located. A map is also sent in order to make route finding easy.
62603017|NCT00454818|EXPERIMENTAL|MYDICAR Mid Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 \[AAV1\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3x10e12 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study).
62825393|NCT03924050|EXPERIMENTAL|Group TORIPALIMAB combined with standard chemotherapy|
62825394|NCT03924050|PLACEBO_COMPARATOR|Group Placebo combined with standard chemotherapy|
62825395|NCT04562870|EXPERIMENTAL|Arm S: Selinexor|Participants with MF who had previously received at least 6 months of treatment with JAK 1/2 inhibitor will receive a dose of selinexor 80 mg for first 2 cycles followed by selinexor 60 mg once weekly (QW) in subsequent cycles orally on Days 1, 8, 15, and 22 of each 28-day cycle to participants on Arm S.
62825396|NCT04562870|ACTIVE_COMPARATOR|Arm PC: Physician's Choice Treatment|Participants with MF who had previously received at least 6 months of treatment with JAK 1/2 inhibitor will receive Physician's choice treatment which will be administered as per clinical practice.
62825397|NCT05781906|EXPERIMENTAL|HMPL-523|HMPL-523 Tablet 300 mg QD7 days followed by a single oral dose of \[14C\]HMPL-523 suspension
62825398|NCT01315925||Newly disgnosed AML|Adult and pediatric patients with newly diagnosed acute myeloid leukemia, both eligible and not eligible for intensive chemotherapy. Since this is a non-interventional study, therapeutic strategies remains related to local guidelines. Will be treated as cases all patients with acute leukemia in first induction developing an Invasive Fungal Infection according to international EORTC criteria for possible/probable/proven infections. Patients who do not develop the infection will be used as a control group.
62825399|NCT04501042||Obese patients tissue proved NASH|age \>20，morbid obesity who will receive bariatric surgery, tissue proved NASH
62825400|NCT04501042||Obese patients tissue proved NAFL|age \>20，morbid obesity who will receive bariatric surgery, tissue proved NAFL
62043870|NCT01789554|NO_INTERVENTION|NO MLS dispatch for bystander CPR|No activation of mobile positioning system to locate and recruit lay responders to nearby OHCAs
62825401|NCT04501042||NASH (before bariatric surgery)|age \>20，morbid obesity receiving bariatric surgery and was proved NASH histologically. Data collected before bariatric surgery.
62043871|NCT05382312|EXPERIMENTAL|Participants receiving GSK3036656+bedaquiline|
62043872|NCT05382312|EXPERIMENTAL|Participants receiving GSK3036656+delamanid|
62825402|NCT04501042||NASH (after bariatric surgery)|age \>20，morbid obesity receiving bariatric surgery and was proved NASH histologically. Data collected after bariatric surgery.
62825403|NCT02064946|ACTIVE_COMPARATOR|Vitamin D3|Vitamin D3 50,000 IU: Patients will be assigned to receive weekly high-dose vitamin D (50,000 IU/week) along with a daily multivitamin (600 IU/day vitamin D + 210 mg/day calcium) and calcium supplements (1,000 mg/day calcium) for a period of 24 weeks.
62825404|NCT02064946|PLACEBO_COMPARATOR|Control|Control: Patients will be assigned to receive a weekly vitamin D placebo along with a daily multivitamin (600 IU/day vitamin D + 210 mg/day calcium)and calcium supplements (1,000 mg/day calcium) for a period of 24 weeks.
62825405|NCT01391962|EXPERIMENTAL|Part I - Cediranib (30 mg) or Sunitinib Malate (37.5 mg) Orally|Patients will be randomized to receive cediranib (30 mg) or sunitinib malate (37.5 mg) orally, once a day in 28-day cycles.
62043873|NCT05382312|EXPERIMENTAL|Participants receiving bedaquiline+delamanid|
62043874|NCT05382312|EXPERIMENTAL|Participants receiving RIFAFOUR e-275|
62043875|NCT05382312|EXPERIMENTAL|Participants receiving GSK3036656+BTZ-043|
62043876|NCT02565914|EXPERIMENTAL|TEZ/IVA|"Part A: Participants who received either TEZ/IVA, IVA monotherapy or Placebo in parent studies 103,106,107,108,109 and 111 were administered TEZ 100 milligram (mg)/IVA 150 mg fixed-dose tablet in the morning and IVA 150 mg mono tablet in the evening for 96 weeks.~Part B: Participants who received either TEZ/IVA, IVA monotherapy or Placebo in parent studies 106,108,109,112 and 114 were administered TEZ 100 mg/IVA 150 mg fixed-dose tablet in the morning and IVA 150 mg mono tablet in the evening for 96 weeks.~Part C: Participants who received TEZ/IVA, IVA monotherapy or Placebo in parent studies 106,108, and 114 were administered TEZ 100 mg/IVA 150 mg fixed dose tablet in the morning and IVA 150 mg mono tablet in the evening for 192 weeks."
62825406|NCT01391962|EXPERIMENTAL|Part II - Cross Over|At the time of disease progression, patients will cross over to the other treatment arm after a 2-week wash-out period.
62825407|NCT03115866|EXPERIMENTAL|FRUVED|Individuals that are at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet with 50% fruit and vegetables.
62043877|NCT00477230|EXPERIMENTAL|1|Single ablation procedure with Endoscopic Ablation System
62043878|NCT00477230|ACTIVE_COMPARATOR|2|Medication
62043879|NCT05832450||No intervention|Perioperative data of patient undergoing elective brain tumor resection without requirements of red cell concentrate transfusion.
62603018|NCT00454818|EXPERIMENTAL|MYDICAR High Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 \[AAV1\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1x10e13 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study).
62603019|NCT00454818|PLACEBO_COMPARATOR|Placebo infusion|A single dose of placebo (Sodium Chloride Injection, USP) administered by antegrade epicardial coronary artery infusion.
62825408|NCT03115866|EXPERIMENTAL|FRUVED + LRC|Individuals at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet of 50% fruit and vegetables plus low refined carbohydrates.
62043880|NCT05089617|EXPERIMENTAL|SAD Cohort 1|5 mg YG1699 or Placebo
62043881|NCT05089617|EXPERIMENTAL|SAD Cohort 2|25 mg YG1699 or Placebo
62043882|NCT05089617|EXPERIMENTAL|Multiple Doses Cohort 1|20 mg YG1699 or Placebo
62043883|NCT04208516|ACTIVE_COMPARATOR|Continuous nerve blocks|A total of 30 subjects equally distributed to either continuous Erector Spinae Plane block for unilateral thoracic surgery , or continuous Quadratus Lumborum block for major abdominal surgery. Patients in this group will receive 20ml 0.5% ropivacaine per block performed after positioning of the needle followed by continuous perineural infusion of 0.25% lidocaine (10ml/hr) beginning in the post-anesthesia care unit (PACU) and continued for 72 hours or until 12 hours prior to patient discharge, whichever comes first, which is standard of care at this institution.
62246463|NCT04401748|EXPERIMENTAL|Arm 1: Venetoclax + Azacitidine (AZA)|Participants will receive venetoclax once daily (QD) (Days 1-14) in combination with AZA QD (7 days of the first 9 days) of each 28 day cycle.
62246464|NCT04401748|ACTIVE_COMPARATOR|Arm 2: Placebo + Azacitidine|Participants will receive placebo once daily (QD) (Days 1-14) in combination with AZA QD (7 days of the first 9 days) of each 28 day cycle.
62603020|NCT03738800|EXPERIMENTAL|CD5789 Cream 200 µg/g|CD5789 200 µg/g, topical, 50g
62825409|NCT03115866|EXPERIMENTAL|FRUVED + LF|Individuals at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet of 50% fruit and vegetables plus low fat.
62043884|NCT04208516|EXPERIMENTAL|Single nerve blocks plus IV lidocaine infusion|A total of 30 subjects equally distributed to either Erector Spinae Plane block for unilateral thoracic surgery, or Quadratus Lumborum block for major abdominal surgery, will be included . Patients in this group will receive 20ml 0.5% ropivacaine, 4mg dexamethasone, and 20mcg dexmedetomidine (30mcg if only one block is performed) per block after proper positioning of the Tuohy needle. Upon patient arrival in the recovery room a continuous infusion of IV lidocaine 50 mg /hr will be started and continued for 72 hours or until 12 hours prior to patient discharge, whichever comes first, which is standard of care at this institution.
62825410|NCT05035862|EXPERIMENTAL|Infusion of γMSCs|Escalating doses Dose escalation design with two dose levels. The low dose level involves a single intravenous infusion of γMSCs at 2x106 cells/kg. The high dose level involves a single intravenous infusion of γMSCs at 5x106 cells/kg.
62043885|NCT04000295|EXPERIMENTAL|Apatinib and Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
62043886|NCT04000295|ACTIVE_COMPARATOR|Weekly Paclitaxel|Weekly Paclitaxel (80 mg/m2, d1, d8, d15, q3w) until disease progression or intolerable toxicity
62043887|NCT06733168|ACTIVE_COMPARATOR|EIT-PEEP setting|Patients will have PEEP settings determined by EIT guidance following a stepwise decremental PEEP trial
62043888|NCT06733168|PLACEBO_COMPARATOR|ARDSNet-PEEP setting|PEEP will be adjusted using the low FiO2-PEEP table to achieve oxygenation targets: SpO2 between 88% and 95% and PaO2 between 55 mmHg and 80 mmHg
62436730|NCT04890275|EXPERIMENTAL|BFR|Participants will participate in a supervised low load lower body blood flow restriction resistance exercise program twice a week for 12 weeks
62436731|NCT04890275|ACTIVE_COMPARATOR|NON-BFR|Participants will participate in a supervised low load lower resistance exercise program twice a week for 12 weeks (matched training volume as experimental arm but without BFR)
62603021|NCT03738800|EXPERIMENTAL|CD5789 Cream 100 µg/g|CD5789 100 µg/g, topical, 50g
62603022|NCT03738800|PLACEBO_COMPARATOR|CD5789 Cream Vehicle|CD5789 Cream Vehicle, topical, 50g
62603023|NCT03356899|ACTIVE_COMPARATOR|Low dose bupivacaine 0.5% (8mg)|Bupivacaine 0.5% for spinal anesthesia
62603024|NCT03356899|ACTIVE_COMPARATOR|High dose bupivacaine 0.5% (10mg)|Bupivacaine 0.5% for spinal anesthesia
62825411|NCT02689635|ACTIVE_COMPARATOR|Sodium Restricted Diet|Low Salt (cardiac) diet
62825412|NCT02689635|ACTIVE_COMPARATOR|Regular Diet|Non-Cardiac diet
62825413|NCT01710501|EXPERIMENTAL|Grazoprevir 25 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 25 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by Response Guided Therapy (RGT). Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their Hepatitis C virus ribonucleic acid (HCV RNA) level at Treatment Week (TW) 4.
62825414|NCT01710501|EXPERIMENTAL|Grazoprevir 50 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 50 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.
62825415|NCT01710501|EXPERIMENTAL|Grazoprevir 100 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 100 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.
62825416|NCT06326060|EXPERIMENTAL|Dosing scheme a: NNC0519-0130|Participants will receive NNC0519-0130 at 1 dose level subcutaneously (s.c.) once-weekly up to 36 weeks.
62825417|NCT06326060|PLACEBO_COMPARATOR|Dosing scheme a: Placebo|Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
62436732|NCT06463938|ACTIVE_COMPARATOR|Active Comparator|would include patients (n=30) who will be given CPP-ACP paste application only
62436733|NCT06463938|EXPERIMENTAL|Experimental|would consist of patients (n=30) who will be given diode laser therapy only
62436734|NCT06463938|OTHER|Combination|would include patients (n=30) who will be given a combination of CPP-ACP paste \& Laser therapy.
62436735|NCT06463938|OTHER|Control|would be a control group
62436736|NCT03016585|EXPERIMENTAL|Tai Chi Training|Tai Chi exercises 3 times per wk for 12 weeks
62436737|NCT03016585|NO_INTERVENTION|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 weeks.
62436738|NCT04897971||Spine implant associated infection cohort|Adult patients undergoing revision spine surgeries with suspected infection of previous instrumentation.
62825418|NCT06326060|EXPERIMENTAL|Dosing scheme b: NNC0519-0130|Participants will receive NNC0519-0130 at 2 dose levels s.c. once-weekly up to 36 weeks.
62825419|NCT06326060|PLACEBO_COMPARATOR|Dosing scheme b: Placebo|Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
62825420|NCT06326060|EXPERIMENTAL|Dosing scheme c: NNC0519-0130|Participants will receive NNC0519-0130 at 3 dose levels s.c. once-weekly up to 36 weeks.
62043889|NCT02943057|EXPERIMENTAL|2% guttae Ganciclovir|2% guttae Ganciclovir 5 times a day for 6 weeks
62825421|NCT06326060|PLACEBO_COMPARATOR|Dosing scheme c: Placebo|Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
62043890|NCT01292876|OTHER|Extracellular Matrix|Implantation of Extracellular Matrix
62043891|NCT05519579|EXPERIMENTAL|Intrathecal chemotherapy before blinatumomab|
62436739|NCT05455970|EXPERIMENTAL|Rhythmic auditory stimulation (RAS) group|Physical therapy including stretching and strengthening exercise and ambulation training with rhythmic auditory stimulation.
62603025|NCT03870776|PLACEBO_COMPARATOR|Placebo group A|Patients will receive the placebo during 42 days.
62825422|NCT06326060|EXPERIMENTAL|Dosing scheme d: NNC0519-0130|Participants will receive NNC0519-0130 at 4 dose levels s.c. once-weekly up to 36 weeks.
62825423|NCT06326060|PLACEBO_COMPARATOR|Dosing scheme d: Placebo|Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
62825424|NCT06326060|EXPERIMENTAL|Dosing scheme e: NNC0519-0130|Participants will receive NNC0519-0130 at 5 dose levels s.c. once-weekly up to 36 weeks.
62043892|NCT02904408|EXPERIMENTAL|Experimental|experimental group (receiving psychotherapy and medical/surgical treatment)
62043893|NCT02904408|NO_INTERVENTION|Control|control group (awaiting group) (receiving medical/surgical treatment)
62043894|NCT05002569|EXPERIMENTAL|Arm A: Nivolumab Plus Relatlimab|Combination
62043895|NCT05002569|EXPERIMENTAL|Arm B: Nivolumab|Monotherapy
62043896|NCT02413164|EXPERIMENTAL|Physical intervention group|12 weeks of groupal sessions of individualised multimodal physiotherapy programme of therapeutic exercises with education healthy-style-of-life based, 2 times for week.
62043897|NCT02413164|NO_INTERVENTION|Control group|This group will receive usual care and will be in wait list status for the duration of study, later the intervention will be offered to this group.
62043898|NCT03768479|EXPERIMENTAL|FES-Fulvestrant|Patients with ER positive breast cancer receive Fulvestrant as the first line treatment enrolled in the study would receive 18F-FES-PET/CT imaging before and after cycle 1 treatment with the first line Fulvestrant.
62043899|NCT01159054|EXPERIMENTAL|This study has only one arm.|Blood sample and scan results to be compared before and after intervention in each subject.
62043900|NCT03185481|EXPERIMENTAL|1 mg QD to 15 mg QD PF-06649751|Up titration from 1 mg QD to 15 mg QD PF-06649751
62603026|NCT03870776|EXPERIMENTAL|MAP4343 group B|Patients will receive daily dose 1 during 42 days.
62043901|NCT03185481|EXPERIMENTAL|3 mg QD to 15 mg QD PF-06649751|Up titration from 3 mg QD to 15 mg QD PF-06649751
62043902|NCT03185481|EXPERIMENTAL|7 mg QD to 15 mg QD PF-06649751|Up titration from 7 mg QD to 15 mg QD PF-06649751
62043903|NCT03185481|EXPERIMENTAL|15 mg QD PF-06649751|15 mg QD PF-06649751 remains at 15 mg QD PF-06649751
62436740|NCT05455970|NO_INTERVENTION|Conventional group|Conventional physical therapy including stretching exercise, strengthening exercise and ambulation training.
62436741|NCT00902824|ACTIVE_COMPARATOR|Group A|"ADVAX at 0,1 and 2 months followed by TBC-M4 at 6 months~Number of volunteers: 12"
62436742|NCT00902824|ACTIVE_COMPARATOR|Group B|"TBC-M4 at 0,1,6 months~Number of volunteers: 12"
62603027|NCT03870776|EXPERIMENTAL|MAP4343 group C|Patients will receive daily dose 2 during 42 days.
62825425|NCT06326060|PLACEBO_COMPARATOR|Dosing scheme e: Placebo|Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
62825426|NCT06326060|EXPERIMENTAL|Dosing scheme f: NNC0519-0130|Participants will receive NNC0519-0130 at 6 dose levels s.c. once-weekly up to 36 weeks.
62825427|NCT06326060|PLACEBO_COMPARATOR|Dosing scheme f: Placebo|Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
62825428|NCT06326060|ACTIVE_COMPARATOR|Dosing scheme g: Tirzepatide|Participants will receive tirzepatide at 6 dose levels s.c. once weekly up to 36 weeks.
62825429|NCT05636228|EXPERIMENTAL|INV-102 0.7% Three Times per Day (TID)|INV-102 ophthalmic solution administered for about 1 week
62825430|NCT05636228|PLACEBO_COMPARATOR|Vehicle TID|INV-102 ophthalmic solution administered for about 1 week
62825431|NCT01029275|EXPERIMENTAL|Arm A|pre-operative medical treatment with Sandostatin
62825432|NCT01029275|NO_INTERVENTION|Arm B|pituitary surgery as a first line treatment
62825433|NCT04665141||Standard of care|Patients with severe asthma being treated with non-biological standard therapies, mainly systemic corticosteroids.
62436743|NCT00902824|PLACEBO_COMPARATOR|Placebo|Both Groups A and B will have 4 volunteers each (8 total) that will receive a placebo.
62603028|NCT04659629|EXPERIMENTAL|Part 1: NL-201 Monotherapy Dose Escalation|NL-201 given as monotherapy by intravenous administration testing ascending doses and two different schedules.
62603029|NCT04659629|EXPERIMENTAL|Part 2: NL201 Monotherapy Expansion Cohorts|NL-201 given as monotherapy by intravenous administration in indication specific cohorts at a dose and schedule determined in Part 1.
62603030|NCT04659629|EXPERIMENTAL|Part 3: NL-201 in Combination with Pembrolizumab Dose Escalation|NL-201, in combination with a set Pembrolizumab dose, testing ascending doses and two different schedules
62603031|NCT04659629|EXPERIMENTAL|Part 4: NL-201 in Combination with Pembrolizumab Expansion Cohorts|NL-201 in combination with Pembrolizumab in indication specific cohorts at a dose and schedule determined in Part 3
62603032|NCT01712893|EXPERIMENTAL|Zoladex combined with chemotherapy|After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the test group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,all patients will receive Tamoxifen after chemotherapy
62603033|NCT01712893|ACTIVE_COMPARATOR|Zoladex after chemotherapy|After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the control group should use Zoladex 3.6mg once a month up to 2-3 years after chemotherapy,all patients will receive Tamoxifen after chemotherapy
62603034|NCT01734252|NO_INTERVENTION|Standard Treatment|If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be contin-ued and, if necessary increased. Hereby the maximum heparin dose is 1.500 IU per hour.
62603035|NCT01734252|EXPERIMENTAL|Treatment with Argatroban|If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be stopped and Argatroban will be given and adjusted until the target aPTT-range is achieved.
62603036|NCT01193075||CMT1B|Families/patients with genetically confirmed CMT1B
62603037|NCT01193075||CMT2A|Families/patients with genetically confirmed CMT2A
62603038|NCT01193075||CMT4A|Families/patients with genetically confirmed CMT4A
62603039|NCT01193075||CMT4C|Families/patients with genetically confirmed CMT4C
62603040|NCT01193075||All other CMT|Families/patients with all other forms of CMT or CMT that has not yet been genetically identified
62603041|NCT04134065|PLACEBO_COMPARATOR|Control group|The physical properties such as appearance, size, color, dosage form, weight, taste and odor of placebo should be as much as possible as the test drug, but should not contain the Vitamin D (such as tablets containing lactose).
62603042|NCT04134065|EXPERIMENTAL|Vitamin D group|Liquid cholecalciferol supplementation (OsteVit DTM, Key Pharmaceuticals, Macquarie Park, NSW, Australia), supplied in 50 mL bottles (5000 units in 1 mL)
62603043|NCT04403659|EXPERIMENTAL|Intervention|Use of a telemonitoring/telemedicine suite (including a sphygmomanometer, pulse oximeter, weight scale, thermometer, glucometer, electrocardiograph) as a support to the routine clinical care
62603044|NCT04403659|NO_INTERVENTION|Control|Routine clinical care, following European Society of Cardiology 2016 Guidelines on Heart failure and Good Clinical Practice guidelines
62603045|NCT02941796|EXPERIMENTAL|Sequence 1|"T → R~T : HCP1105 4cap R : HGP0918 4cap + HGP0816 4tab"
62603046|NCT02941796|EXPERIMENTAL|Sequence 2|"R → T~T : HCP1105 4cap R : HGP0918 4cap + HGP0816 4tab"
62603047|NCT06547242|EXPERIMENTAL|BC-T4CYS 150 µg tablet (Berlin-Chemie AG)|BC-T4CYS 150 µg tablet (Berlin-Chemie AG), oral single dose administration of 4 tablets (600 µg levothyroxine-sodium)
62603048|NCT06547242|ACTIVE_COMPARATOR|Letrox® 150 µg tablet (Berlin-Chemie AG),|Letrox® 150 µg tablet (Berlin-Chemie AG), oral single dose administration of 4 tablets (600 µg levothyroxine-sodium)
62603049|NCT01582659|NO_INTERVENTION|No ekstra counseling|Standardized information about childhood constipation is given and the child receives PEG 3350. No additional follow up appointments are made.
62603050|NCT01582659|ACTIVE_COMPARATOR|2 counseling sessions|Standardized information about childhood constipation is given and the child receives PEG 3350. 2 additional follow up appointments by telephone are made.
62603051|NCT01582659|ACTIVE_COMPARATOR|Web access|Standardized information about childhood constipation is given and the child receives PEG 3350. No additional follow up appointments are made but the family are given access to a website with information about childhood constipation.
62603052|NCT05056792|EXPERIMENTAL|Participants in this group will receive isometric strength training.|Isometric strength training of the quadriceps femoris muscle for 8 weeks.
62603053|NCT05056792|SHAM_COMPARATOR|Participants in this group will receive plyometric training.|Participants in this group will receive plyometric training for 8 weeks.
62825434|NCT04665141||Biological therapies|Patients with severe asthma being treated with omalizumab, mepolizumab, reslizumab, benralizumab, or dupilumab.
62825435|NCT05559710||DMD Group|Children with Duchenne Muscular Dystrophy (DMD) between the ages of 7 and 18 who have been diagnosed with DMD as a result of genetic testing
62825436|NCT05559710||Healthy Controls|Helathy children with similar physical characteristics between the ages of 7 and 8
62825437|NCT05260736|ACTIVE_COMPARATOR|Group Costoclavicular Lateral (CL)|Patients anesthetized with costoclavicular lateral infraclavicular brachial plexus block.
62603054|NCT05583500|EXPERIMENTAL|Single group: excentric exercise protocol|Excentric exercise protocol will be performed for all subjets, consisted of 10 sets of 20 repetitions of squats, jumping from a height of 50 cm
62603055|NCT06618521|ACTIVE_COMPARATOR|Anti-hypertensive drug|It consists of 23 pregnant women. They will take Anti-hypertensive drug (Methyldopa 250 mg according to physician instructions).
62603056|NCT06618521|EXPERIMENTAL|Anti-hypertensive drug + Pilates exercise|It consists of 23 pregnant women. They will be engaged in Pilates exercise for 40 minutes/day, 3 days/week, for 12 weeks, in addition to Anti-hypertensive drug (Methyldopa 250 mg according to physician instructions.
62603057|NCT06618521|EXPERIMENTAL|Anti-hypertensive drug + Circuit exercise training|It consists of 23 pregnant women. They will be engaged in a supervised circuit training exercises for 40 minutes/ day, 3 days/week, for 12 weeks, in addition to Anti-hypertensive drug (Methyldopa 250 mg according to physician instructions.
62825438|NCT05260736|ACTIVE_COMPARATOR|Group Costoclavicular Medial (CM)|Patients anesthetized with costoclavicular medial infraclavicular brachial plexus block.
62043904|NCT03185481|EXPERIMENTAL|1 mg to 7 mg QD PF-06649751|Up titration from 1 to 7 mg QD PF-06649751 if de-escalated in parent study
62043905|NCT03185481|EXPERIMENTAL|3 mg QD to 7 mg QD PF-06649751|Up titration from 3 to 7 mg QD PF-06649751 if de-escalated in parent study
62043906|NCT03185481|EXPERIMENTAL|7 mg QD to 7 mg QD PF-06649751|7 mg QD remains at 7 mg QD PF-06649751 if de-escalated in parent study
62436744|NCT02110706|PLACEBO_COMPARATOR|Placebo|The placebo group will receive a vehicle control infusion
62603058|NCT00503451|EXPERIMENTAL|LBH589|
62825439|NCT05260736|ACTIVE_COMPARATOR|Group Lateral Sagittal (LS)|Patients anesthetized with lateral sagittal infraclavicular brachial plexus block.
62825440|NCT05373537|EXPERIMENTAL|Home-based|home- based CBT-Insomnia intervention
62825441|NCT05373537|EXPERIMENTAL|web-based|web-based CBT-Insomnia intervention
62825442|NCT06470555|ACTIVE_COMPARATOR|Manual compression with 4-hours of bed rest|Femoral haemostasis using manual compression. Bed rest duration of 4 hours following initial haemostasis.
62825443|NCT06470555|EXPERIMENTAL|A figure-of-eight suture secured with a three-way tap with 4-hours of bed rest;|"Femoral haemostasis using a figure-of-eight suture secured with a three-way tap.~Bed rest duration of 4 hours following initial haemostasis."
62825444|NCT06470555|EXPERIMENTAL|A figure-of-eight suture secured with a three-way tap with 2-hours of bed rest;|"Femoral haemostasis using a figure-of-eight suture secured with a three-way tap.~Bed rest duration of 2 hours following initial haemostasis."
62825445|NCT06602778|EXPERIMENTAL|T2DM-BMI0|
62825446|NCT06602778|EXPERIMENTAL|T2DM-BMI1|
62043907|NCT03185481|EXPERIMENTAL|15 mg to 7 mg QD PF-06649751|15 mg QD de-escalated to 7 mg QD in parent study B7601003 remain at 15 mg QD PF-06649751
62043908|NCT06301412|NO_INTERVENTION|EVT group|standard endovascular treatment (EVT) for large vessel occlusion (LVO) without hypothermia
62043909|NCT06301412|ACTIVE_COMPARATOR|EVT group plus hypothermia group|standard endovascular treatment (EVT) for large vessel occlusion (LVO) combined with hypothermia
62825447|NCT06602778|EXPERIMENTAL|T2DM-BMI2|
62825448|NCT06602778|EXPERIMENTAL|T2DM-BMI3|
62043910|NCT06130826|EXPERIMENTAL|Treatment (SBRT, M5A-IL2 ICK)|Patients undergo SOC SBRT over 3 fractions on days 1, 3, and 5, followed by M5A-ICK SC on days 8, 9, and 10 once daily for a single cycle on study. Patients undergo CT or PET/CT as well as blood sample collection throughout the trial. Patients may undergo magnetic resonance imaging or bone scan as clinically indicated on the trial. Additionally, patients may optionally undergo tissue biopsy during screening and on study.
62043911|NCT01054768|EXPERIMENTAL|alpha-lipoic acid and acetyl-L-carnitine|alpha-lipoic acid and acetyl-L-carnitine1400 mg tablet twice a day for 6 months.
62043912|NCT01054768|PLACEBO_COMPARATOR|Placebo|1400 mg placebo tablet twice a day for 6 months.
62043913|NCT00003508|EXPERIMENTAL|Arm: Experimental: Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62603059|NCT02062996|EXPERIMENTAL|ENT - full strength|Full strength oxymetazoline pledgets packed in the nose (total volume 20 ml).
62603060|NCT02062996|EXPERIMENTAL|ENT - 1/2 strength|½ strength oxymetazoline pledgets packed in the nose (total volume 20 ml).
62436745|NCT02110706|EXPERIMENTAL|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
62436746|NCT06447220||The malnourished undergoing washed microbiota transplantation|patients undergoing washed microbiota transplantation who were diagnosed as malnutrition according to weight loss or low BMI
62436747|NCT02362854|ACTIVE_COMPARATOR|Conventional peri-implantitis treatment|Peri-implantitis treatment according to the Cumulative interceptive supportive (CIST) therapy.
62603061|NCT02062996|EXPERIMENTAL|DENTAL - Full strength 1.0 mL|Full strength oxymetazoline 1.0 mL to each naris (total =1000 mcg).
62603062|NCT02062996|EXPERIMENTAL|DENTAL - Full strength 0.5 mL|Full strength oxymetazoline 0.5 mL to each naris (total = 500 mcg).
62825449|NCT05911724||Group I|60 Healthy Subjects.
62825450|NCT05911724||Group II|60 Patients with Stable Angina.
62825451|NCT05911724||Group III|60 Patients with Heart Failure.
62825452|NCT06594900|NO_INTERVENTION|Control|This group receives no training programme and just continues its life and physical activity as it used to do.
62825453|NCT06594900|EXPERIMENTAL|Resistance training intervention|"The participants in the intervention group take part in a 20-week strength training programme in which they train twice a week for 60 min. The training programme focuses on strengthening the knee extensor muscles. Each training session consists of three phases: Warm-up, resistance training and coordination exercises.~In the warm-up as well as coordination phase, full-body games are played to activate and challenge the children. The strength training phase forms the core of each session and includes exercises such as squats, lunges and step-ups. These exercises are performed in four sets of 8-12 repetitions, with the intensity being increased over time. The aim is to perform the exercises with great effort, but not to the point of complete exhaustion."
62825454|NCT06181240|EXPERIMENTAL|Bolt IVL System|Lithotripsy is a medical procedure that uses shock waves to modify intravascular calcium.
62043914|NCT00998608|EXPERIMENTAL|HR|risperidone 2mg/d + haloperidol 2mg/d
62436748|NCT02362854|EXPERIMENTAL|DL application in peri-implantitis|Adjunct Diode Laser application.
62436749|NCT04908722|EXPERIMENTAL|Group 1: Ad26.COV2.S Dose Level 1|Participants in the main study and sub study will receive intramuscular (IM) injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 1 on Days 1 and 57.
62603063|NCT02062996|EXPERIMENTAL|DENTAL - ½ strength 0.5 mL|½ strength oxymetazoline 0.5 mL to each naris (total = 250 mcg).
62825455|NCT04701762|EXPERIMENTAL|videolaryngoscopy|Initial intubation performed using GlideScope videolaryngoscope.
62825456|NCT04701762|ACTIVE_COMPARATOR|conventional direct laryngoscopy|Initial intubation performed using direct laryngoscopy.
62603064|NCT06451289||postictal children|Postictal children aged one to 18 years who presented to the pediatric emergency department underwent head CT according to the Pediatric Emergency Care Applied Research Network (PECARN) guidelines. The seizures were observed by a health worker or directly with home videos.
62603065|NCT06451289||the healthy controls|Previously healthy children admitted to the emergency department and having head CT without space-occupying/incidental lesions were determined as a control group.
62825457|NCT04029883|NO_INTERVENTION|Control Group|The Control group will receive care as usual, as well as a MEMS-cap and a leaflet explaining the importance of pill-taking routines and how to establish them. The study coordinator will spend approximately ten minutes with them to go over the leaflet and answer questions. Control group participants also spend time with the study coordinator at each clinic visit where contact information is updated, and any MEMS-cap problems are resolved. These procedures, which we successfully applied in previous studies, minimize the possibility that results are confounded by differences in attention or other non-specific effects between groups.
62825458|NCT04029883|ACTIVE_COMPARATOR|Message Group|The Message group will receive the same brief information session as the Control group but also receive daily text messages reinforcing the information provided for 3 months. A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time. To keep the importance of routinizing pill- taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform. These messages will reinforce the information provided at recruitment, and remind participants of their personalized routinization strategy. Messages will be tailored and refreshed based on patient-specific factors including BP control, prior adherence, and current medication regimen.
62043915|NCT03102814|ACTIVE_COMPARATOR|Current rehabilitation program|The control group will receive the rehabilitation program currently provided at each participating centre at the start of the study.
62246465|NCT00551551|EXPERIMENTAL|Rééducation|Standardized pelvic floor muscle training program with a physiotherapist in 8 sessions (20-30 minutes each) between 24 and 36 weeks of gestation AND Written instructions about personal (Kegel) pelvic floor exercises
62436750|NCT04908722|EXPERIMENTAL|Group 2: Ad26.COV2.S Dose Level 2|Participants will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 2 on Days 1 and 57 in the main study.
62043916|NCT03102814|EXPERIMENTAL|BRIDGE rehabilitation program|In intervention phase, the BRIDGE program will be added to the current program.
62043917|NCT05042778|EXPERIMENTAL|Auriculotherapy|Indwelling fixed semipermanent needles embedded in a skin-colored adhesive tape will be used in active points around the vagus nerve stimulation area.
62043918|NCT05042778|NO_INTERVENTION|No intervention|No auriculotherapy will be applied.
62043919|NCT03436329|EXPERIMENTAL|Vein ligation first|During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.
62043920|NCT03436329|ACTIVE_COMPARATOR|Artery ligation first|During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.
62043921|NCT03270605||CS with myomectomy|Women having uterine myoma with pregnancy and subjected to myomectomy during delivery by CS
62436751|NCT04908722|EXPERIMENTAL|Group 3: Ad26.COV2.S Dose Level 3|Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 3 on Days 1 and 57.
62436752|NCT04908722|EXPERIMENTAL|Group 4: Ad26.COV2.S Dose Level 4|Participants will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 4 on Days 1 and 57 in the main study.
62043922|NCT03270605||CS without myomectomy|Women having uterine myoma with pregnancy and delivered by CS without myomectomy
62043923|NCT06579209|NO_INTERVENTION|Pre-testing prior to intervention|Prior to receiving the supplement, either Nicotinamide adenine dinucleotide or the placebo, participants will undergo cognitive testing and a blood draw.
62043924|NCT06579209|NO_INTERVENTION|Post-testing after intervention|After receiving the supplement, either Nicotinamide adenine dinucleotide or the placebo, participants will undergo cognitive testing and a blood draw.
62043925|NCT06579209|EXPERIMENTAL|Intervention|For four weeks, the participant will consume an oral supplement, either Nicotinamide adenine dinucleotide or a placebo.
62043926|NCT06012734|EXPERIMENTAL|LB-100 plus atezolizumab|LB-100 IV over 15 minutes on day 1 and day 3 Atezolizumab IV over 30-60 minutes on day 1 Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity
62043927|NCT06723314|EXPERIMENTAL|Vestibular Subperiosteal Tunnel Access|Vestibular Subperiosteal Tunnel Access
62043928|NCT06723314|ACTIVE_COMPARATOR|Coronally Advanced Flap|Coronally Advanced Flap
62043929|NCT05581550|OTHER|PET imaging|
62043930|NCT00363675|EXPERIMENTAL|All study participants|Children with hand burns
62246466|NCT00551551|ACTIVE_COMPARATOR|Control|Written instructions about personal (Kegel) pelvic floor exercises
62246467|NCT05146804|OTHER|BroccoCress/Affilla Cress|Potential participants will be screened after showing their interest to participate to the study. When they are considered eligible to participate (after a phone call with the executing researcher), participants will be randomized into one of the two groups in this study: either consuming the broccoli sprouts on day one (visit 1) and the placebo product in the second visit, or the other way around (placebo product on day 1 and the intervention during the second visit). Both days, participants will consume the PhenFlex, the challenge product with the high caloric load. This will allow for analyzing the effectiveness of the intervention on different biomarkers of chronic, low-grade inflammation, with the main objective being on endothelial activation.
62603066|NCT01523210||upper limb spasticity|patients suffering from upper limb spasticity and are treated with botulinum toxin
62603067|NCT02651519|SHAM_COMPARATOR|Control|All patients undergoing breast cancer operation will be the treatment intervention with general anesthesia as an adjunct to stellate-ganglion block with saline.
62603068|NCT02651519|EXPERIMENTAL|stellate-ganglion block|All patients undergoing breast cancer operation will be the treatment intervention with general anesthesia as an adjunct to stellate-ganglion block with 0.25% ropivacaine hydrochloride.
62825459|NCT04029883|EXPERIMENTAL|Incentive Group|The Incentive group will receive the same information and text messages, but in addition have a chance of winning small, intermittent rewards for taking their medication at the time coinciding with their anchoring strategy. In this group, participants will be eligible for a prize drawing if they take their medication within +/- 1 hour of the time they carry out their existing routine behavior on at least 80% of days between clinic visits. When the participants return for their monthly visit, the study coordinator will download their MEMS-cap data and check whether this eligibility criteria was satisfied. MEMS software can be easily customized to display this information. If the patient qualifies, s/he is invited to draw one of three laminated cards with numbers 0, 25, and 50 out of a bag. The client receives the corresponding amount in USD in the form of a gift card immediately after the drawing.
62825460|NCT06583876|EXPERIMENTAL|Coriofix treatment|
62825461|NCT06586502|NO_INTERVENTION|Control Group|We will compare outcomes of a historical control group, matched for child age and diagnosis, as closely as possible to identify any significant differences between groups that may be attributed to the RECOVER Model of care.
62825462|NCT06586502|EXPERIMENTAL|Intervention Group|The intervention group in the RECOVER study consists of cancer survivors aged 15-39 years who have completed treatment, along with their carers or parents, and health professionals. The survivors will undergo a comprehensive health assessment, including both physical and psychological aspects, to inform the development of a personalized care plan. Carers or parents, who must be able to read and understand English or work with an interpreter, will be actively involved in the assessment process and subsequent consultations to help shape the care plan. Health professionals, including doctors, nurses, and allied health providers from Queensland Health public hospitals, will participate in multidisciplinary team meetings, review health assessments, and contribute to the creation and implementation of the care plan. These groups together form the core of the intervention, engaging in both the application and evaluation of the RECOVER Model of Car
62825463|NCT04345796|ACTIVE_COMPARATOR|carvedilol+empagliflozin|Patients will receive carvedilol SR 16mg and empagliflozin 10mg qd.
62825464|NCT04345796|ACTIVE_COMPARATOR|carvedilol alone|Patients will receive carvedilol SR 16mg alone.
62825465|NCT04345796|ACTIVE_COMPARATOR|empagliflozin alone|Patients will receive empagliflozin 10mg and matching placebo of carvedilol.
62825466|NCT04345796|PLACEBO_COMPARATOR|placebo|Patients will receive matching placebo of carvedilol.
62825467|NCT06600373|EXPERIMENTAL|Experimental group|Conduct approximately 10 minutes of mindful walking after the 110-minute regular physical education group class.
62825468|NCT06600373|ACTIVE_COMPARATOR|Control group|120 minutes regular physical education group class.
62825469|NCT05349214|EXPERIMENTAL|Arm A|ianalumab exposure level 1
62825470|NCT05349214|EXPERIMENTAL|Arm B|ianalumab exposure level 2
62825471|NCT05349214|PLACEBO_COMPARATOR|Arm C|placebo
62436753|NCT04908722|EXPERIMENTAL|Group 5: Ad26.COV2.S Dose Level 5|Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 5 on Days 1 and 57.
62436754|NCT04908722|EXPERIMENTAL|Group 6: Ad26.COV2.S Dose Level 6|Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 6 on Days 1 and 57.
62436755|NCT05514847|NO_INTERVENTION|1 Control Group|Control Group (Group 1): These patients will be screened negative for both the ACOG screening test and the FMF preeclampsia screen. These women will receive no aspirin.
62436756|NCT05514847|ACTIVE_COMPARATOR|2 Randomized Group 1|Group 2: These patients will be screened negative for the ACOG screening test but positive for the FMF preeclampsia screen. These women will be randomized to either 81mg or 162 mg aspirin.
62436757|NCT05514847|OTHER|3 Standard of Care Group|Group 3: These patients will be screened positive for the ACOG screening test but negative for the FMF preeclampsia screen. These women will be offered 81 mg aspirin, which is the standard of care.
62436758|NCT05514847|ACTIVE_COMPARATOR|Group 4 Randomized Group 2|Group 4: These patients will be screened negative for the ACOG screening test and positive for the FMF preeclampsia screen. These women will be randomized to either 81mg or 162 mg aspirin.
62436759|NCT03704779|EXPERIMENTAL|Multimodal Mindfulness Activity Program|Students assigned to the intervention will receive 8 weeks of the mindfulness activity intervention.
62436760|NCT03704779|NO_INTERVENTION|Control Group|Students assigned to the control group will not receive any intervention.
62825472|NCT05561478||Test device (Synthesis Plus Toric)|Requiring bilateral cataract surgery with pre-existing astigmatism
62825473|NCT05561478||Control device (Synthesis Plus)|Requiring bilateral cataract surgery
62825474|NCT02956395|ACTIVE_COMPARATOR|Integrated care group|Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care in three healthcare sectors: Barcelona-Esquerra, Lleida and Badalona.
62825475|NCT02956395|NO_INTERVENTION|Conventional care group|Patients assigned to the control group will be from other healthcare sectors in Catalonia with similar characteristics.
62825476|NCT06598865|NO_INTERVENTION|control|after initial APA training, patients will be asked to implement APA sessions on their own for the duration of the study. They will then be asked to return to the investigating center for a visit at 3 months (Visit 3) to assess the effect of the APA carried out during this period.
62825477|NCT06598865|EXPERIMENTAL|experimental|"after initial APA training, patients will receive regular support from an APA teacher, and will be asked to carry out 3 APA sessions a week, if possible in a Sport-Santé centre close to their home, for the duration of the study. The content of additional APA sessions (up to 2 additional sessions per week) can be discussed with the APA teacher.~They will also be asked to return to the investigating center for a visit at 3 months (Visit 3) to assess the effect of the APA carried out during this period."
62825478|NCT05967585|EXPERIMENTAL|Phase I and Phase II|Phase 2: Implementation processes for assessing vaping behaviors and referring patients to a vaping cessation intervention (This is Quitting-TIQ) developed in Phase 1 will be tested within oncology survivorship clinics. Participants who opt to enroll in TIQ will also be asked to answer acceptability and applicability questions about their experience with the program.
62043931|NCT03611348|ACTIVE_COMPARATOR|Microneedling + latanoprost|patient will receive topical application of latanoprost 0.005% eye drops solution twice daily for 3 months preceded by microneeding in sessions by dermapen every 2 weeks for 3 months (totally 6 sessions).
62603069|NCT00461760|ACTIVE_COMPARATOR|1|Women with normal cytology at recruitment will be recalled for their next routine screen at 2 years and if negative again, for their exit screen at 4 years, all according to current provincial guidelines.
62246468|NCT05146804|OTHER|Affilla Cress/Broccocress|Potential participants will be screened after showing their interest to participate to the study. When they are considered eligible to participate (after a phone call with the executing researcher), participants will be randomized into one of the two groups in this study: either consuming the broccoli sprouts on day one (visit 1) and the placebo product in the second visit, or the other way around (placebo product on day 1 and the intervention during the second visit). Both days, participants will consume the PhenFlex, the challenge product with the high caloric load. This will allow for analyzing the effectiveness of the intervention on different biomarkers of chronic, low-grade inflammation, with the main objective being on endothelial activation.
62603070|NCT00461760|ACTIVE_COMPARATOR|2|Women with abnormal cytology at recruitment or at the 2 year screen will be followed according to provincial guidelines based on their cytology results.
62603071|NCT02669082|EXPERIMENTAL|Ramelteon 8 mg|Ramelteon 8 mg, tablet, orally, once daily at bedtime for 8 weeks.
62603072|NCT04660708|EXPERIMENTAL|Pregnant women|"Physical assessment for women 20-34 weeks gestation including evaluating pain, back and hip range of motion, strength of hip and abdominal muscles, diastasis recti, and strength, amount of scar tissue from previous pregnancies / deliveries, level of muscle overactivity, and the extent of any prolapse of pelvic floor muscles.~Treatment: internal and external myofascial release of the pelvic floor muscles, pelvic floor stretching, and instruction diaphragmatic breathing and exercises for postpartum recovery to perform at home. Exercises include: Pelvic floor stretching: happy baby stretch, deep squat, butterfly stretch; Belly breathing; transverse abdominis contraction, transverse abdominis march, bridge, shoulder blade; Instruction and education on perineal massage and posture."
62603073|NCT03447652|NO_INTERVENTION|Control Group|Each patient in the control group did not perform any rehabilitation exercises. Over the intervention time frame, the patient was required to check in with a member of the research team each week to discuss any changes in their ankle or report any injury incidence.
62603074|NCT03447652|EXPERIMENTAL|Resistance Band Group|Each session, patients completed resistance training using a resistance band in 4 directions of ankle motion (plantarflexion, dorsiflexion, inversion and eversion). Patients would complete 3 sets of 10 repetitions during each session. Every 3 sessions, the band resistance would increase.
62825479|NCT01708200|EXPERIMENTAL|Memory Intervention|Two types of memory protocols (psychoeducational vs computerized) will be compared in a population of individuals with mental illness.
62825480|NCT01854411||analgesic dose measure|breastfeeding mother who will take analgesics
62825481|NCT04771806||Observational (MRI)|Patients undergo MRI with and without contrast immediately before radiotherapy (for radiation planning) and at mid treatment (week 3). Patients also undergo MRI without contrast on weeks 1, 2, 4, 5, and 6 of radiotherapy. Patients may also undergo neurocognitive function testing over 70 minutes before treatment, at the end of each week of treatment, and at 3 and 6 months after completion of treatment.
62825482|NCT06603311|EXPERIMENTAL|Adults with compensated liver disease and HDV with prior Bulevirtide treatment|Adults with compensated liver disease who have been treated for chronic HDV infection with bulevirtide (BLV) for at least 48 weeks and reached HDV RNA below 100 IU/ml for at least 24 weeks will finite their BLV treatment. Patients will be followed up for 48 weeks to identify promising biomarkers associated with HDV control after stopping BLV and to evaluate the safety of the novel concept of finite BLV treatment in this group of patients
62246469|NCT05339321|EXPERIMENTAL|SCG101|SCG101 will be given via Intravenous (IV) infusion.
62825483|NCT06595836|EXPERIMENTAL|polyisoprene condoms lubricated with a silicone lubricant|polyisoprene condoms lubricated with a silicone lubricant
62825484|NCT06595836|ACTIVE_COMPARATOR|commercial latex condoms with a silicone lubricant|commercial latex condoms with a silicone lubricant
62825485|NCT06591026|ACTIVE_COMPARATOR|SH Only|Participants receive standard helpline component only
62825486|NCT06591026|EXPERIMENTAL|SH+CST|Participants receive the standard helpline component and the cognitive coping skills component.
62825487|NCT06591026|EXPERIMENTAL|SH+ATM|Participants receive the standard helpline component and the automated messaging component.
62246470|NCT05339321|EXPERIMENTAL|SCG101 + PD1/PD-L1 checkpoint inhibitor|SCG101 will be given via Intravenous (IV) infusion. The PD-1/PD-L1 checkpoint inhibitor will be given per product label.
62246471|NCT06006325|EXPERIMENTAL|Electroacupuncture (EA)|"The acupoints were Deqi, and the electroacupuncture stimulator was connected and energized."
62246472|NCT06006325|SHAM_COMPARATOR|Sham electroacupuncture (SHAM-EA)|"No Deqi operation was performed on non-acupuncture points, and the electroacupuncture stimulator was connected and not energized."
62246473|NCT01418651|EXPERIMENTAL|Milnacipran|Drug
62246474|NCT05301673||Adults with ADHD|
62436761|NCT01773694|ACTIVE_COMPARATOR|Early Water Exposure|The Intervention group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.
62436762|NCT01773694|NO_INTERVENTION|Standard Care|The Standard Care group will receive standard wound care instructions and verbal education by the staff to keep the dressing dry and intact for 48 hours.
62436763|NCT01742325|OTHER|Lifestyle counseling|To test an intervention program (two 20-minute sessions of walking around the nurse's station daily, five days a cycle) to reduce the symptoms of fatigue and pain and increase quality of sleep.
62825488|NCT06591026|EXPERIMENTAL|SH+CST+ATM|Participants receive the standard helpline component, the cognitive coping skills component, and the automated messaging component.
62825489|NCT06591026|EXPERIMENTAL|SH+MI|Participants receive the standard helpline component and the motivational interviewing component.
62825490|NCT06591026|EXPERIMENTAL|SH+MI+CST|Participants receive the standard helpline component, the motivational interviewing component, and the cognitive coping skills component.
62825491|NCT06591026|EXPERIMENTAL|SH+MI+ATM|Participants receive the standard helpline component, the motivational interviewing component, and the automated messaging component.
62825492|NCT06591026|EXPERIMENTAL|SH+MI+CST+ATM|Participants receive the standard helpline component, the motivational interviewing component, the coping skills component, and the automated messaging component.
62043932|NCT03611348|ACTIVE_COMPARATOR|latanoprost|Patient will receive topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months (active control side).
62043933|NCT05872568|EXPERIMENTAL|Imitation EC-MPS(Ruiyirong)|
62043934|NCT05872568|ACTIVE_COMPARATOR|Original EC-MPS（myfortic）|
62043935|NCT05588726|ACTIVE_COMPARATOR|Sleep Hygiene|
62043936|NCT05588726|EXPERIMENTAL|Mindfulness|
62043937|NCT02565654||Rifaximin group|Patients are treated with rifaximin (Alfa Wassermann Pharmaceutical Co., Ltd. Italy) for 14 days at a daily dosage of 1200 mg (400 mg, three times daily)
62246475|NCT05301673||Partner, family member or close friend of the individuals with ADHD|
62436764|NCT04189094|EXPERIMENTAL|Sintilimab + CRT arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) plus Sintilimab induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions). After PCI, Sintilimab maintenance therapy will be administered once every 3 week for 13 cycles.
62436765|NCT04189094|ACTIVE_COMPARATOR|CRT arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).
62436766|NCT01261325|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets administered twice daily
62436767|NCT01261325|EXPERIMENTAL|Brivaracetam 100 mg/ day|Brivaracetam 50 mg/ day administered twice daily.
62436768|NCT01261325|EXPERIMENTAL|Brivaracetam 200 mg/ day|Brivaracetam 100 mg/ day administered twice daily
62436769|NCT04694040||healthy adult volunteers showing no signs of temporomandibular disorders|
62436770|NCT06529029|EXPERIMENTAL|RUL LAP-ST (Low-Amplitude Pulse Seizure Therapy - Right Unilateral)|Low Amplitude Pulse Seizure Therapy RUL ECT at 600mA (or 700mA)
62436771|NCT06529029|ACTIVE_COMPARATOR|RUL ECT (Electroconvulsive Therapy)|RUL Conventional pulse amplitude Electroconvulsive Therapy (ECT)
62436772|NCT00551486||1|Patients with thyroid incidentaloma underwent ultrasound-guided fine needle aspiration biopsy
62436773|NCT06052878||General anesthesia|Children whose mothers underwent general anesthesia for non-obstetric surgery during pregnancy.
62436774|NCT06052878||Locoregional anesthesia|Children whose mothers underwent regional anesthesia for non-obstetric surgery during pregnancy.
62436775|NCT06052878||Control|Children whose mothers did not undergo any surgical intervention during pregnancy.
62436776|NCT03358394|EXPERIMENTAL|Intervention group|The intervention group will be asked to complete the outcomes measures anxiety, depression and mindfulness questionnaires at baseline, a week before the start of the intervention and at the end of the intervention time period(i.e., after five weeks).
62436777|NCT03358394|EXPERIMENTAL|Control group|"The control group will be asked to complete the outcomes measures anxiety, depression and mindfulness questionnaires at baseline, a week before the start of the intervention and at the end of the intervention after six weeks.~At the end of the pilot trial, control group will receive the full intervention. They would be sent the materials week by week as same as the intervention group."
62436778|NCT06021262||control group|healthy individuals without previous acute or chronic exposure to organophosphates
62436779|NCT06021262||chronic exposure group|patients with chronic occupational or environmental exposure to organophosphates
62246476|NCT00800683|EXPERIMENTAL|BI 1356|patient to receive a tablet containing BI 1356 once daily
62436780|NCT06021262||acute exposure group|patients with acute exposure to organophosphates in accidental or suicidal settings
62436781|NCT04387110||Ocrelizumab|Women receiving treatment for multiple sclerosis with ocrelizumab infusion between 2 and 36 weeks postpartum.
62436782|NCT02450942|EXPERIMENTAL|18F-FDS injection and PET/CT scan|The patients were intravenously injected with 18F-FDS and underwent PET/CT scan 1 h after the injection.
62436783|NCT04807127||ICI-pneumonitis|Cancer patients experiencing ICI-pneumonitis
62436784|NCT04807127||Radiotherapy induced pneumonitis|Cancer patients experiencing RT-pneumonitis
62436785|NCT04807127||TKI-induced pneumonitis|Cancer patients experiencing TKI-induced pneumonitis
62436786|NCT04155788|EXPERIMENTAL|Food Exposure|
62246477|NCT00800683|PLACEBO_COMPARATOR|placebo|patient to receive a tablet identical to BI 1356 once daily
62825493|NCT04158362|EXPERIMENTAL|Standard Chemotherapy regimen|"\* Paclitaxel: administrated at the dose of 80 mg/m² as a 1-hour intravenous infusion every week (i.e., D1, D8 and D15) of a 3-week cycle.~OR~\* Capecitabine: given orally at a dose of 2000 to 2500 mg/m² daily for 14 days followed by a 7-day rest period every 3 weeks."
62043938|NCT02938598|EXPERIMENTAL|A|Engagement On - Problem Solving High - Motivation On
62043939|NCT02938598|EXPERIMENTAL|B|Engagement On - Problem Solving Low - Motivation On
62043940|NCT02938598|EXPERIMENTAL|C|Engagement On - Problem Solving High - Motivation Off
62043941|NCT02938598|EXPERIMENTAL|D|Engagement On - Problem Solving Low - Motivation Off
62043942|NCT02938598|EXPERIMENTAL|E|Engagement Off - Problem Solving High - Motivation On
62043943|NCT02938598|EXPERIMENTAL|F|Engagement Off - Problem Solving Low - Motivation On
62043944|NCT02938598|EXPERIMENTAL|G|Engagement Off - Problem Solving High - Motivation Off
62043945|NCT02938598|EXPERIMENTAL|H|Engagement Off - Problem Solving Low - Motivation Off
62043946|NCT05766514|EXPERIMENTAL|Arm A (investigational arm): cladribine, cytarabine, and decitabine|
62043947|NCT05766514|ACTIVE_COMPARATOR|Arm B (control arm): azacitidine with venetoclax or decitabine with venetoclax|
62246478|NCT00521053|EXPERIMENTAL|PV-10|
62246479|NCT05444751|EXPERIMENTAL|SA + ESP Block|Spinal Anesthesia: Patients will be provided with iv sedation, if desired, to facilitate placement of spinal anesthetic. Midazolam (2-5mg, iv), ketamine (up to 20 mg, lv) and/or propofol (0.1-0.2 mg/kg) will be permitted.
62449181|NCT01325207|EXPERIMENTAL|intravenous trastuzumab infusions|A Phase I single dose study (H0407g) of intravenous trastuzumab infusions ranging from 10-500 mg resulted in dose-dependent pharmacokinetics (PK) with serum clearance of trastuzumab decreasing with an increasing dose at doses \<250 mg. PK modeling of trastuzumab concentration-time data from 7 patients that were administered doses of 250 mg and 500 mg had in a mean halflife of 5.8 days (range 1-32 days).
62436787|NCT00661674|EXPERIMENTAL|Sequence 1: Placebo, Combo, Palonosetron|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Placebo~Week 2: Palonosetron + Hydroxyzine Combo~Week 3: Palonosetron"
62603075|NCT03447652|EXPERIMENTAL|Biomechanical Ankle Platform System|The Biomechanical Ankle Platform System board is an oval shaped board that utilizes a half-sphere on the bottom of the board to allow the patient to train on an unstable surface. A one legged stance on their involved limb was performed on the Biomechanical Ankle Platform System board while clockwise and counterclockwise circles were completed. The initial rotation of direction was selected by the patient and changed every 10 seconds of the 40-second trial. Five 40-second trials were completed with 1-minute rest intervals in between the trials. Progression was determined by the supervising clinician and was based on the patient's ability to make smooth transitions between direction changes and completion of smooth circular rotations in both directions.
62603076|NCT03447652|EXPERIMENTAL|Combination Group|Patients completing the combination protocol completed both the resistance band and Biomechanical Ankle Platform System board protocols during each session. The order of exercise completion was counterbalanced for each session.
62603077|NCT05659511||healthy control group|Healthy people neither in insomnia group nor in MCI group.
62436788|NCT00661674|EXPERIMENTAL|Sequence 2: Palonosetron, Combo, Placebo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron~Week 2: Palonosetron + Hydroxyzine Combo~Week 3: Placebo"
62603078|NCT05659511||insomnia|Pittsburgh sleep quality index (PSQI)\>5, Epworth Sleepiness Scale (ESS)\>9 ，Insomnia Severity Index (ISI)\>8.
62436789|NCT00661674|EXPERIMENTAL|Sequence 3: Combo, Placebo, Palonosetron|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron + Hydroxyzine Combo~Week 2: Placebo~Week 3: Palonosetron"
62436790|NCT00661674|EXPERIMENTAL|Sequence 4: Placebo, Palonosetron, Combo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Placebo~Week 2: Palonosetron only~Week 3: Palonosetron + Hydroxyzine Combo"
62603079|NCT05659511||insomnia-MCI|Pittsburgh sleep quality index(PSQI)\>5 ,Epworth Sleepiness Scale(ESS)\>9 ，Insomnia Severity Indeex(ISI)\>8; 20\< MoCA\<26.
62603080|NCT06649279||Group H|High Flow Anesthesia Group
62603081|NCT06649279||Group M|Minimal Flow Anesthesia Group
62603082|NCT01238718|ACTIVE_COMPARATOR|lidocaine|
62603083|NCT01238718|PLACEBO_COMPARATOR|normal saline|
62603084|NCT02781181|OTHER|CAS with CPD|CAS performed under neuroprotection
62603085|NCT02781181|ACTIVE_COMPARATOR|CAS without CPD|CAS without neuroprotection
62603086|NCT03283059|EXPERIMENTAL|Octohydroaminoacridine Succinate Tablet|Octohydroaminoacridine Succinate Tablet 4mg P.O. tid
62603087|NCT03283059|ACTIVE_COMPARATOR|Aricept|Aricept 5mg/day P.O.
62603088|NCT03283059|PLACEBO_COMPARATOR|Placebo|Placebo P.O. tid
62043948|NCT00837174|EXPERIMENTAL|Combination Vorinostat + Bortezomib|Six cycle combination therapy with vorinostat and bortezomib.
62043949|NCT00722891|ACTIVE_COMPARATOR|Purevision Lens with ReNu|Purevision Lenses with ReNu Multiplus Solution
62043950|NCT00722891|ACTIVE_COMPARATOR|Purevision Lenses with RepleniSH|Purevision Lenses with Optifree RepleniSH Solution
62603089|NCT02839564|EXPERIMENTAL|Adhesiolysis group|Patients underwent laparoscopic adhesiolysis
62603090|NCT02839564|PLACEBO_COMPARATOR|Placebo group|Patients underwent diagnostic laparoscopy alone
62603091|NCT00622336|EXPERIMENTAL|Lenalidomide 25mg (CC-5013)|Oral 25mg daily on Days 1-21 every 28 days
62825494|NCT04158362|EXPERIMENTAL|Standard Endocrine therapy (ET) regimen + Abemaciclib|"\* Letrozole: continuous orally administration of 2.5 mg/day (1 tablet/day) OR anastrozole continuous orally administration of 1 mg/day (1 tablet/day) in combination with oral abemaciclib 150 mg (BID: twice a day) continuous for patients NSAI naïve or relapsing \>1 year after the end of adjuvant ET.~OR~\* Fulvestrant: 500 mg intramuscular on D1-D15-D29 (loading dose). Then 500 mg every 28 days (maintenance dose) with oral abemaciclib 150 mg BID continuous for patients relapsing on adjuvant or less than one year after completion of adjuvant NSAI.~For women with a non-menopausal status at inclusion, a concomitant Luteinizing hormone-releasing hormone (LH-RH) agonist will be administered in combination with ET every 28 days. The LH-RH agonist drug to be used will be left to the investigator's choice."
62825495|NCT06583980|EXPERIMENTAL|Intervention group|Each participant is assigned a coordinating rheumatology nurse. Based on an initial bio-psycho-social assessment, the nurse and the participant define up to five activities using the Patient Specific Functional Scale (PSFS) and agree on goals based on shared decision-making. The coordinating nurse provides self-management support in face-to-face, telephone or online consultations depending on the participant's needs during the following six months. At each face-to-face consultation with the nurse, the PSFS activities and the goals are evaluated. Each participant can get up to 2.5 hours of support from the nurse, up to 4 hours a physiotherapist and or occupational therapist, and 1 hour from a social worker. In addition, the coordinating nurse helps identify relevant offers in the participant's municipality. The coordinating nurse can plan up to two conferences with involved professionals. A final consultation with the coordinating nurse is held after the six-month intervention.
62436791|NCT00661674|EXPERIMENTAL|Sequence 5: Combo, Palonosetron, Placebo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron + Hydroxyzine Combo~Week 2: Palonosetron only~Week 3: Placebo"
62436792|NCT00661674|EXPERIMENTAL|Sequence 6: Palonosetron, Placebo, Combo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron only~Week 2: Placebo~Week 3:Palonosetron + Hydroxyzine Combo"
62436793|NCT05969795|OTHER|Study Group|Intermittent ultrasound scans to monitor follicular growth and serial measurements of serum LH, E2 and P4 levels throughout the cycle to determine ovulation. Embryo transfer (ET) will be scheduled on the fifth day after ovulation. Blood for P4 measurement will be drawn upon admission to the clinic for the ET procedure. P4 will be measured on day 5 or day 6 after the ET procedure and together with the hCG 10 days after ET procedure.
62436794|NCT05969795|OTHER|Control Group|Intermittent ultrasound scans to monitor follicular growth and serial measurements of serum LH, E2 and P4 levels throughout the cycle to determine ovulation. Embryo transfer (ET) will be scheduled on the fifth day after ovulation. Administer on FET day 200 mg of P4 and increase to 300 mg/day from the day after the ET onwards until the pregnancy test. Blood for P4 measurement will be drawn before starting LPS in form of vaginal progesterone. P4 will be measured on day 5 or day 6 after the ET procedure and together with the hCG 10 days after ET procedure. In case of an implantation, vaginal P4 will be continued until 7 weeks of pregnancy.
62436795|NCT02060656|ACTIVE_COMPARATOR|Control: R-GEM-P|Rituximab,Gemcitabine, Methylprednisolone,Cisplatin.
62436796|NCT02060656|EXPERIMENTAL|Experimental: LR-GEM|Lenalidomide, Rituximab, Gemcitabine, Methylprednisolone
62436797|NCT03037684||chronic pain|individuals suffering from chronic pain
62436798|NCT03037684||neuropathic pain|individuals suffering from neuropathic pain
62825496|NCT06583980|NO_INTERVENTION|Usual care|Usual care consists of planned consultations every 6-12 months by a rheumatologist or a rheumatology nurse and access to support from a rheumatology nurse by telephone. The planned consultations encompass review of blood tests, joint examinations, review of completed answers to questionnaires in DANBIO, adherence and evaluation of whether pharmacological adjustment is necessary. In addition, the planned nursing consultations sporadically encompass education in relation to management of the disease, symptoms and the pharmacological treatment. At the outpatient departments at the Danish Hospital for Rheumatic Diseases, Rigshospitalet-Glostrup and Frederiksberg Hospital, patients who have specific challenges can be offered an additional nursing consultation for non-pharmacological support. At Rigshospitalet-Glostrup it is also possible to refer a patient to see a physiotherapist and/ or an occupational therapist in the outpatient department.
62825497|NCT04793360||LiverCare Surveillance|Participants undergoing orthotopic liver transplant (de-novo or re-transplant) will be considered for this study
62825498|NCT03069937|EXPERIMENTAL|Docetaxel + Degarelix|Docetaxel (TAXOTERE) will be given for up to 6 cycles every 21 days. During the 5th and 6th cycles, degarelix (Firmagon) will be administered on Cycle 5 day 1 and cycle 6 day 8. After cycle 6, degarelix will continue to be given every 28 days for a 5 more doses, for a total of 7 doses.
62825499|NCT06589336|OTHER|Intervention Group|"Weeks 1-8: The intervention group will receive Instacart groceries (voucher + delivery fees), access to the Mid-Ohio Farmacy Program, behavioral nutrition counseling, and social needs screening and referrals.~Weeks 9-16: The intervention group will receive Instacart groceries (delivery fees only), access to Mid-Ohio Farmacy program, behavioral nutrition counseling and social needs screening and referrals.~Weeks 17-24: The intervention group will receive Instacart access (no financial support), access to the Mid-Ohio Farmacy Program and social needs screening and referrals."
62825500|NCT06589336|OTHER|Control Group|"Weeks 1-8: The control group will receive Instacart groceries (voucher + delivery fees) and access to the Mid-Ohio Farmacy program.~Weeks 9-16: The control group will receive Instacart groceries (delivery fees only) and access to the Mid-Ohio Farmacy program.~Weeks 17-24: The control group will receive Instacart access (no financial support) and access to the Mid-Ohio Farmacy program."
62825501|NCT05886621|EXPERIMENTAL|Smiling instead of Smoking - HIV|"Participants will be onboarded to the smartphone app Smiling instead of Smoking - HIV (SiS-H), and will be asked to use it for 8 weeks while they quit smoking."
62825502|NCT05886621|ACTIVE_COMPARATOR|QuitGuide|"Participants will be onboarded to the smartphone app QuitGuide (QG), and will be asked to use it for 8 weeks while they quit smoking."
62825503|NCT01285323|PLACEBO_COMPARATOR|Placebo|Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
62043951|NCT01215292|PLACEBO_COMPARATOR|Acyline & T Gel & Placebo Ketoconazole|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel (T gel) 5 gm daily Days 1-10, + placebo tab PO 1x daily, Day 3-10
62043952|NCT01215292|EXPERIMENTAL|Acyline & T Gel & Ketoconazole 400|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Days 1-10, + ketoconazole 400mg PO 1x daily, Days 3-10
62043953|NCT01215292|EXPERIMENTAL|Acyline & T gel & Ketoconazole 800|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + ketoconazole 800mg PO 1x daily, Days 3-10
62043954|NCT01215292|EXPERIMENTAL|Acyline & T gel & Dutasteride|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + dutasteride 2.5 mg PO 1x daily, Days 3-10
62043955|NCT01215292|EXPERIMENTAL|Group 5: anastrazole|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + anastrazole 1 mg PO 1x daily, Days 3-10
62436799|NCT03272867|EXPERIMENTAL|Intervention group|One group of volunteers will ingest a powder with dose of 6.1 g ProManna twice a day for a period of 2 weeks
62436800|NCT03272867|PLACEBO_COMPARATOR|Control group|Another group of volunteers will ingest a powder with the same amount of a placebo twice a day for a periode of 2 weeks
62436801|NCT01312779|OTHER|All subjects receive implant|Subjects serve as own control
62436802|NCT00424814|EXPERIMENTAL|1|Kaletra (lopinavir/ritonavir)
62436803|NCT00424814|ACTIVE_COMPARATOR|2|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)
62436804|NCT02910310|NO_INTERVENTION|Baseline period|The baseline period will involve data collection on study outcomes before uterine balloon tamponade (UBT) is introduced at study sites.
62436805|NCT02910310|EXPERIMENTAL|Uterine balloon tamponade|The UBT period will involve data collection on study outcomes after providers at sites are trained on UBT use and UBT is introduced into PPH management practice at study sites.
62436806|NCT06523088|EXPERIMENTAL|PN20 group|subcutaneous injections, a single dose
62436807|NCT06523088|PLACEBO_COMPARATOR|Placebo group|subcutaneous injections, a single dose
62436808|NCT02938806||Obese/overweight children with T1D|No intervention
62436809|NCT02938806||Normal weight children with T1D|No intervention
62436810|NCT02938806||Obese/overweight children, no diabetes|No intervention
62043956|NCT06444906|ACTIVE_COMPARATOR|Dermacyte Matrix|Dermacyte Matrix will be applied topically in conjunction with SOC on a weekly frequency and dosed by square centimeters to match the ulcer surface area.
62436811|NCT02938806||Healthy, normal weight children|No intervention
62436812|NCT02624518|EXPERIMENTAL|Diagnostic (68Ga-RM2 PET/MRI)|Patients receive 68Ga-RM2 IV and beginning 45 minutes later undergoing PET/MRI scan. The 68Ga-RM2 PET/MRI may be repeated at the completion of treatment to evaluate response to therapy, if requested by the treating physician. Imaging with PET/MRI is the intervention.
62436813|NCT04706871|EXPERIMENTAL|taVNS group|
62436814|NCT04706871|PLACEBO_COMPARATOR|tnVNS group|
62603092|NCT05695105|EXPERIMENTAL|Vibration Group|For primary and permanent teeth that will receive only toothbrush vibration treatment.
62436815|NCT00706706|EXPERIMENTAL|sunitinib|single agent sunitinib, single arm
62436816|NCT02658682|EXPERIMENTAL|ABM +|Attention Bias Modification
62436817|NCT02658682|SHAM_COMPARATOR|ABM -|Sham Attention Bias Modification
62436818|NCT03813485|ACTIVE_COMPARATOR|Dry needling in upper trapezius|"Patients receive dry needling in latent myofascial trigger point in upper trapezius. The needle was penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
62603093|NCT05695105|EXPERIMENTAL|Vibration and Mini-implant Group|For permanent teeth that will receive mini-implant treatment followed by failed toothbrush vibration treatment.
62603094|NCT00046917|EXPERIMENTAL|Treatment (chemotherapy)|Patients are stratified according to the number of prior treatment regimens (0 or 1 vs more than 1). Patients receive irinotecan hydrochloride IV over 30 minutes followed immediately by cisplatin IV over 30 minutes followed 7 hours later by alvocidib IV over 1-4.5 hours weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62603095|NCT03788668|ACTIVE_COMPARATOR|Hyoid suspension with barbed reposition pharyngoplasty|
62246480|NCT05444751|ACTIVE_COMPARATOR|GA + ESP Block|General anesthesia: induction of general anesthesia to facilitate endotracheal intubation: fentanyl (up to 2μg.kg.min-1), propofol (1-2 mg.kg-1), vecuronium (1-2 mg.kg-1).
62246481|NCT06073236|EXPERIMENTAL|Intervention group|The intervention group will receive what came out of the co-creation sessions with preschoolers' teachers and parents.
62436819|NCT03813485|EXPERIMENTAL|Dry needling in lower trapezius|"Patients receive dry needling in latent myofascial trigger point in lower trapezius. The needle was penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
62436820|NCT02439606|ACTIVE_COMPARATOR|Glide Rite Rigid Stylet group|Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.
62436821|NCT02439606|EXPERIMENTAL|Parker-Flex-It Directional Stylet group|Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It Directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
62436822|NCT04253925|EXPERIMENTAL|global postural correction exercises|global postural correction exercises in addition to Kegel exercises
62436823|NCT04253925|ACTIVE_COMPARATOR|Kegel exercises|only Kegel exercises
62436824|NCT04932733|EXPERIMENTAL|Elderly isometric exercise|Quadriceps isometric exercise.
62436825|NCT04932733|ACTIVE_COMPARATOR|Young isometric exercise|Quadriceps isometric exercise.
62436826|NCT04270669|EXPERIMENTAL|RC28-E 0.5mg|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 0.5mg RC28-E every 4 weeks, for 3 consecutive times; In the PRN phase (from week 12 to week 48), the study eye will receive the same dose on an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
62436827|NCT04270669|EXPERIMENTAL|RC28-E 1.0mg|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 1.0 mg RC28-E every 4 weeks, for 3 consecutive times; In the PRN phase (from week 12 to week 48), the study eye will receive the same dose on an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
62436828|NCT04270669|EXPERIMENTAL|RC28-E 2.0mg|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 2.0 mg RC28-E every 4 weeks, for 3 consecutive times; In the PRN phase (from week 12 to week 48), the study eye will receive the same dose on an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
62436829|NCT05600179||patients with diabetic macular edema|
62436830|NCT05600179||healthy patients|
62246482|NCT06073236|NO_INTERVENTION|Control group|No intervention will be given in the control group, but they will receive the intervention after follow-up. Afterwards, teachers and parents can keep the intervention materials as an incentive.
62246483|NCT00420017|EXPERIMENTAL|Amiodarone|Intravenous amiodarone
62246484|NCT00420017|OTHER|Control|Control
62436831|NCT02058810|OTHER|Conventional nasal Oxygen|Conventional nasal Oxygen as needed
62436832|NCT02058810|OTHER|Nasal high flow|Nasal high flow therapy with FiO2 40% and flow of 40l/min for at least 48h
62436833|NCT02809534|EXPERIMENTAL|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62436834|NCT02368522||Patients treated with and without exposure|
62436835|NCT04503252||Study population: patients with CSAI caused by MSSA|Inpatients with CSAI caused by MSSA treated or intended to receive cefazolin within the next 24-48 hours (at least 10 (maximum of 20) critically-ill patients, at least 10 (maximum of 20) patients with an estimated glomerular filtration rate of \<60ml/min, at least 10 patients with BSI).
62436836|NCT04503252||Sub-study: Torque Teno virus (TTV) viremia|TTV viral load may indicate the immunological status of the host. The TTV sub-study is to to describe the viral kinetics of TTV in CSAI patients.
62436837|NCT04503252||Sub-study: cefazolin concentrations in sweat|Out of the study population (patients with CSAI) a total of 15 CSAI patients will be included for the substudy investigating cefazolin concentrations in sweat as a non-invasive therapeutic drug monitoring.
62043957|NCT06444906|OTHER|Standard of Care|SOC therapy will consist of weekly debridement of nonviable tissue as clinically indicated, saline-moistened non-occlusive dressing, weight off-loading to decrease pressure on extremity, aggressive treatment of infection and arterial revascularization if indicated.
62043958|NCT06273644|EXPERIMENTAL|60-65 E% Carbohydrates|Diet plan A with 60-65 E% Carbohydrates in 4 weeks
62043959|NCT06273644|ACTIVE_COMPARATOR|40-45% Carbohydrates|Diet plan B with 40-45 E% Carbohydrates in 4 weeks
62043960|NCT03491176|EXPERIMENTAL|Diagnostic (MRI, blood sample collection)|Patients undergo MRI scans and collection of blood samples for biomarker testing pre-radiation therapy, weekly during radiation therapy, and at 2-3 months post-radiation therapy.
62043961|NCT01811082|EXPERIMENTAL|Coenzyme A 400mg|Coenzyme A 400mg per day
62043962|NCT01811082|ACTIVE_COMPARATOR|Pantethine 600mg|Pantethine 600mg per day.
62043963|NCT02085148|EXPERIMENTAL|Sequential dosing schedule|Expansion phase: Schedule B - Sequential dosing schedule: Of a 21-day cycle, regorafenib will be dosed sequentially, following administration of VI: Vincristine：intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 8 to Day 21.
62043964|NCT02085148|EXPERIMENTAL|Concomitant dosing schedule|Expansion phase: Schedule A - Concomitant dosing schedule: Of a 21-day cycle, regorafenib will be concomitantly administered with vincristine and irinotecan (VI): Vincristine: intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50 mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 1 to Day 14.
62246485|NCT02471950||Elective Cardiac surgery|Those patients scheduled for elective heart surgery requiring cardiopulmonary bypass who will be given 2.5% isoflurane while on bypass.
62825504|NCT01285323|EXPERIMENTAL|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
62825505|NCT06065449|EXPERIMENTAL|Arm 1 - Standard Dose|Participants will receive either 1 radiation treatment a day for 3 days in a row (not counting weekends or holidays), or Participants will receive 1 radiation treatment given on 1 day.
62825506|NCT06065449|EXPERIMENTAL|Arm 2 - High Dose|Participants will receive either 1 radiation treatment a day for 5 days, or 1 radiation treatment given on 1 day.
62825507|NCT04750915||AARP|Members of AARP, aged 50-71 years and who resided in one of six states or in two metropolitan areas in the United States
62825508|NCT05913232|EXPERIMENTAL|H-1337 0.6% Ophthalmic Solution b.i.d.|One drop H-1337 twice daily in the study eye for 28 days
62436838|NCT02544633|EXPERIMENTAL|Arm 1|MGCD265 in patients with MET activating mutations in tumor tissue
62436839|NCT02544633|EXPERIMENTAL|Arm 2|MGCD265 in patients with MET gene amplifications in tumor tissue
62825509|NCT05913232|EXPERIMENTAL|H-1337 1.0% Ophthalmic Solution b.i.d.|One drop H-1337 twice daily in the study eye for 28 days
62825510|NCT05913232|EXPERIMENTAL|H-1337 1.0% Ophthalmic Solution q.a.m. and H-1337 Placebo q.p.m.|One drop H-1337 every morning and matching placebo every evening in the study eye for 28 days
62825511|NCT05913232|ACTIVE_COMPARATOR|Timolol 0.5% Ophthalmic Solution b.i.d.|One drop Timolol twice daily in the study eye for 28 days
62436840|NCT02544633|EXPERIMENTAL|Arm 3|MGCD265 in patients with MET activating mutations in blood (circulating tumor DNA)
62436841|NCT02544633|EXPERIMENTAL|Arm 4|MGCD265 in patients with MET gene amplifications in blood (circulating tumor DNA)
62436842|NCT01475656||Levetiracetam as first line|Babies who receive levetiracetam as a first line drug for seizures
62436843|NCT01475656||Phenobarbital as first line|Babies who receive phenobarbital as a first line drug for seizures and levetiracetam as a second line drug
62436844|NCT01362114|EXPERIMENTAL|Sihogayonggolmoryeo-tang extract|"* name of product: 'SIHOGAYONGGOLMORYU TANG EXTRACT GRAN'~* standard code for item: 200005676~* shape, type: extract(brown)~* usage, content: adults;three times a day, each taken before or between meals~* dose, standard: 2.5g for each sack, capsulated~* storage : airtight container, stored in room temperature~* expiration date : 36months after manufacture~* macufacturing company: KyungBangnShinYak inc."
62043965|NCT02085148|EXPERIMENTAL|Dose escalation|Dose escalation phase: This phase of the study has been completed
62603096|NCT03788668|NO_INTERVENTION|barbed reposition pharyngoplasty|
62603097|NCT03466125||Adult patients who underwent cardiac surgery in Massachusetts|No interventions. A retrospective cohort study of patients who underwent cardiac surgery in Massachusetts in calendar years 2012 - 2016.
62603098|NCT01481584|EXPERIMENTAL|Canola protein|Canola protein (Brassica juncea; incorporated in a drink)
62825512|NCT05316597|EXPERIMENTAL|Terpenes On|"Forest bathing intervention with no filtration of terpenes from inhaled air using PAPR with particle-only filter (terpenes on)"
62825513|NCT05316597|ACTIVE_COMPARATOR|Terpenes Off|"Forest bathing intervention with filtration of terpenes from inhaled air using PAPR with activated charcoal filter (terpenes off)"
62825514|NCT04475458||LANDMARK|The children who underwent circumcision received general anesthesia plus dorsal penis nerve block performed by the surgeon with a landmark technique.
62043966|NCT03974542|EXPERIMENTAL|telephone outreach|
62246486|NCT00916149|ACTIVE_COMPARATOR|Levetiracetam|12 individuals with epilepsy, 6 of whom experience infrequent focal epileptiform discharges and 6 of whom experience frequent focal discharges. These individuals will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.
62603099|NCT01481584|ACTIVE_COMPARATOR|Reference protein|Reference Protein (soy protein isolate; incorporated in a drink)
62603100|NCT01481584|NO_INTERVENTION|Wash out|Wash out (four weeks without any intervention between interventional periods)
62603101|NCT01481584|NO_INTERVENTION|Run-in|Run-in period (three days before intervention, defined diet)
62603102|NCT01718834|ACTIVE_COMPARATOR|prophylactic vaccine|6 monthly doses each of 648 ug of prophylactic vaccine subcutaneously injected to healthy volunteers
62246487|NCT00916149|ACTIVE_COMPARATOR|Lamotrigine|12 individuals with epilepsy, 6 of whom experience infrequent generalized discharges and 6 of whom experience frequent generalized discharges. These individuals will be treated with lamotrigine (LMT). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LMT on discharge frequency, discharge duration, and cognitive task performance.
62603103|NCT01718834|ACTIVE_COMPARATOR|therapeutic vaccine|6 monthly doses each of 648 ug subcutaneously injected to chronic HCV patients
62603104|NCT01801358|EXPERIMENTAL|Arm A|AEB071 and MEK162 combined
62603105|NCT01801358|EXPERIMENTAL|Arm B|MEK162 alone
62825515|NCT04475458||ULTRASOUND|The children who underwent circumcision received sedation (in spontaneous breathing) plus ultrasound-guided dorsal penis nerve block.
62825516|NCT00385216|ACTIVE_COMPARATOR|Nicotine nasal spray|In one sitting the subject will receive a nicotine nasal spray, 3 mg, one application.
62043967|NCT03974542|NO_INTERVENTION|control|
62043968|NCT02609217||Multiparous|12 multiparous women and their partners, planned to undergo elective term cesarean section.
62043969|NCT02609217||Nulliparous|12 nulliparous women and their partners, planned to undergo elective term cesarean section.
62246488|NCT00916149|NO_INTERVENTION|No treatment|15 healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.
62246489|NCT06494007|ACTIVE_COMPARATOR|Diltiazem monotherapy|The Diltiazem monotherapy
62246490|NCT06494007|ACTIVE_COMPARATOR|Diltiazem with 90 mg calcium|Diltiazem with 90 mg calcium
62246491|NCT06494007|ACTIVE_COMPARATOR|The Diltiazem with 180 mg calcium|Diltiazem with 180 mg calcium
62603106|NCT01305005||patients with active-fluidics system|patients who underwent phacoemulsification surgery using active-fluidics system
62603107|NCT01305005||patients with gravity-fluidics system.|patients who underwent phacoemulsification surgery using gravity-fluidics system
62603108|NCT03552224|EXPERIMENTAL|Subjects with no hearing loss|Subjects referred for cerebellopontine angle surgery with no hearing loss with recording of auditory nerve activity by contact electrode
62603109|NCT03552224|EXPERIMENTAL|Subjects with hearing loss|Subjects referred for cerebellopontine angle surgery with hearing loss with recording of auditory nerve activity by contact electrode
62603110|NCT02611128||Peripubertal girls|Peripubertal girls with varying androgen concentrations will have careful phenotype/genotype assessment, primarily to assess the relationship between urinary exosomal DENND1A.V2 and serum free testosterone concentrations.
62603111|NCT02068170||patients treated with a potentional QT-prolonging drug|
62603112|NCT02638259|EXPERIMENTAL|50mg GP2015|Group 1 will receive treatment with 50mg GP2015 by subcutaneous injection every week up to 24 weeks (Treatment Period 1) after which patients achieving at least a moderate clinical response continue treatment with 50mg GP2015 subcutaneous injection every week up to 48 weeks (Treatment Period 2).
62603113|NCT02638259|ACTIVE_COMPARATOR|50mg EU-authorized Enbrel|Group 2 will receive treatment with 50mg EU-authorized Enbrel by subcutaneous injection every week up to 24 weeks (Treatment Period 1) after which patients achieving at least a moderate clinical response will be switched to 50 mg GP2015 subcutaneous injection every week up to 48 weeks (Treatment Period 2).
62603114|NCT01157650|EXPERIMENTAL|Autologous mesenchymal stem cells|Fistulizing Crohn's disease
62825517|NCT00385216|PLACEBO_COMPARATOR|Placebo spray|In one sitting the subject will receive a placebo nasal spray (0 mg), one application.
62825518|NCT05255900||metyrapone treatment|hypercortisolemic patients taking metyrapone since less than a week (usually 250 mg/day, maximum dose 6000 mg/day)
62603115|NCT01461252|OTHER|Cryoablation combined with radiation|All subjects will have cryoablation combined with radiation on one or two painful metastatic bone tumors.
62603116|NCT02115074|EXPERIMENTAL|Fluvastatine Celebrex|dose escalation for Fluvastatine
62603117|NCT06295887|EXPERIMENTAL|Test group|The test group wears an HMD (head-mounted display) and participates in a simulation program using VR. They experience both easy and difficult cases using VR. After the simulation session, a debriefing session will be provided.
62603118|NCT06295887|ACTIVE_COMPARATOR|Control group|"The control group participates in simulation training using Sim-man, and the scenarios are the same in both the control and the test groups (easy cases and difficult cases).~After the simulation session, a debriefing session will be provided."
62603119|NCT05267925|EXPERIMENTAL|Intervention|All participants will be asked to take the dietary herbal supplement CuraLin for the duration of the study. All participants will take 2 capsules orally, three times per day following meals for 12 weeks.
62825519|NCT06235775|EXPERIMENTAL|GV1001 1.12 mg|"In GV1001-PSP-CL2-011 study, subjects who were in the trial group (Study Group 1(GV1001 0.56 mg/day), Study Group 2(GV1001 1.12 mg/day) is alternately administered High-dose test drug(GV1001 1.12 mg/day) and placebo once a week from Ex-Visit 1(Visit 16, Week 26) to Ex-Visit 5(Visit 20, Week 30) and High-dose test drugs(GV1001 1.12 mg/day) are administered from Ex-Visit 6 (Visit 21, Week 32) to Ex-Visit 26(Visit 41, Week 72) every two weeks.~In the GV1001-PSP-CL2-011 study, subjects who were in the placebo group are administered placebo at Ex-Visit 1 (Visit16, Week26), the first visit of the extension study, and Ex-Visit 2 (Visit17, Week27) to Ex-Visit 5 (Visit 20, Week 30), High-dose test drugs(GV1001 1.12 mg/day) are administered once a week and High-dose test drugs (GV1001 1.12 mg/day) are administered from Ex-Visit 6 (Visit 21, Week 32) to Ex-Visit 26(Visit 41, Week 72) every two weeks."
62825520|NCT04286984||Pre-upPBM|Patients with a diagnosis of gastric cancer before the upPBM implementation in their attending center
62825521|NCT04286984||Post-upPBM|Patients with a diagnosis of gastric cancer after the upPBM implementation in their attending center
62825522|NCT02479399||Suglat group|Tablets
62825523|NCT04295148|ACTIVE_COMPARATOR|Semitendinosus graft|Participants receive the Semitendinosus Graft technique during ACL reconstruction.
62825524|NCT04295148|ACTIVE_COMPARATOR|Quadriceps tendon-bone graft|Participants receive the Quadriceps Tendon-Bone Graft technique during ACL reconstruction.
62825525|NCT06589206|ACTIVE_COMPARATOR|conventional twin block|Growing patients with class II skeletal discrepancy due to mandibular deficiency will be treated with the conventional design of twin block previously introduced by Clark.
62825526|NCT06589206|EXPERIMENTAL|Vacuum formed twin block appliance with sagittal blocks|Growing patients with class II skeletal discrepancy due to mandibular deficiency will be treated with a modified design of twin block formed of vacuum sheets with sagittal blocks.
62825527|NCT06592898|ACTIVE_COMPARATOR|Control group: straight leg raise|The patient was supine position, one knee angle was 90°, the foot was flatted on the ground. The ankle was flexed to contract the quadriceps on the other side. Then straighten the knee joint and the hip was 30° and lift the thigh, the heel was about 20cm away from the ground, and put down the lower limb after 2 seconds. Ten times are in a group, each practice has 5 groups, rest between the groups is 1 minute. Practice 5 times a week, practice on both sides, take uniform respiration without holding breath.
62825528|NCT06592898|EXPERIMENTAL|Experimental group A: wall squat|The subjects' upper body was upright, the distance between feet was same as width of shoulder, and hands were placed on each side of the body or above the thighs. Tiptoes were towards the front, and perpendicular to the wall. The distance between the wall and heel was about a foot long, and the back was close to the wall, squatted slowly.
62825529|NCT06592898|EXPERIMENTAL|Experimental group B: direct squat|The subjects stood on the flat ground, the upper body was upright, the distance between feet was same as width of shoulder, and tiptoes were towards the front. The trunk was adjusted forward according to the Angle of static squat. The specific method is to adjust the trunk position to the line of the shoulder joint and knee joint perpendicular to the ground. Knee joint can bend at a large angle.The center of gravity was between the feet, put hands in front of body.The angle was set at 30° for the first two weeks, increased to 45° after two weeks, and set at 60° for the last two weeks.
62825530|NCT06592898|EXPERIMENTAL|Experimental group C: wall squat assisted by elastic bands|Based on wall squat, subjects put elastic band of 20 pounds between the thighs, open thighs and feet at a low speed, so that the elastic bands were slightly deformed and sence of resistance was obvious on the outside of the thighs.The angle was set at 30° for the first two weeks, increased to 45° after two weeks, and set at 60° for the last two weeks.
62825531|NCT03845205|EXPERIMENTAL|Integrated AUD Treatment (IAT)|IAT will include computer-delivered CBI in the hospital, nurse-delivered clinical monitoring and treatment adherence counseling, and at-home participation in web-based, 7-session computerized cognitive-behavioral therapy (CBT4CBT), supplemented by tailored text messages. Alcohol pharmacotherapy will be added to behavioral treatments as needed.
62825532|NCT03845205|NO_INTERVENTION|Treatment As Usual|All LT patients receive physician instructions to not drink alcohol. Consistent with current discharge procedures, AH patients are encouraged to engage in alcohol treatment services. Patients receive regular blood draws for monitoring of liver function, and regular phone calls for post-operative monitoring.
62825533|NCT06602973|EXPERIMENTAL|Rest, Fed Exercise, Fasted Exercise|"At Study Visit 2, participants will eat breakfast and rest (abstain from exercise).~At Study Visit 3, participants will eat breakfast and exercise. At Study Visit 4, participants will abstain from breakfast and will engage in exercise."
62825534|NCT06602973|EXPERIMENTAL|Rest, Fasted Exercise, Fed Exercise|"At Study Visit 2, participants will eat breakfast and rest (abstain from exercise).~At Study Visit 3, participants will abstain from breakfast and will engage in exercise.~At Study Visit 4, participants will eat breakfast and exercise."
62825535|NCT06602973|EXPERIMENTAL|Fed Exercise, Rest, Fasted Exercise|"At Study Visit 2, participants will eat breakfast and exercise. At Study Visit 3, participants will eat breakfast and rest (abstain from exercise).~At Study Visit 4, participants will abstain from breakfast and will engage in exercise."
62825536|NCT06602973|EXPERIMENTAL|Fed Exercise, Fasted Exercise, Rest|"At Study Visit 2, participants will eat breakfast and exercise. At Study Visit 3, participants will abstain from breakfast and will engage in exercise.~At Study Visit 4, participants will eat breakfast and rest (abstain from exercise)."
62603120|NCT05137340|EXPERIMENTAL|NCPAP group|Participants enrolled spontaneously breathing preterm infants born between 24 and 29.9 weeks' gestational age with signs of respiratory distress syndrome. The initial respiratory support mode of premature infants assigned to NCPAP group was NCPAP. Patients diagnosed with NRDS on NCPAP were given a therapeutic dose of pulmonary surfactant via MISA within 120 minutes after birth. NCPAP group ventilator parameter setting: PEEP 6cmH2O (adjustment range 6-8cmH2O), FiO2 adjustment range 0.21-0.40, in order to achieve postnatal target oxygen saturation.
62825537|NCT06602973|EXPERIMENTAL|Fasted Exercise, Fed Exercise, Rest|"At Study Visit 2, participants will abstain from breakfast and will engage in exercise.~At Study Visit 3, participants will eat breakfast and exercise. At Study Visit 4, participants will eat breakfast and rest (abstain from exercise)"
62043970|NCT00738946|EXPERIMENTAL|2|Amodiaquine+pyrimethamine versus placebo
62603121|NCT05137340|ACTIVE_COMPARATOR|NIPPV group|Participants enrolled spontaneously breathing preterm infants born between 24 and 29.9 weeks' gestational age with signs of respiratory distress syndrome. The initial respiratory support mode of premature infants assigned to NIPPV group was NIPPV. Patients diagnosed with NRDS on NIPPV were given a therapeutic dose of pulmonary surfactant via MISA within 120 minutes after birth. The initial ventilator parameters of NIPPV group were as follows: PEEP 6cmH2O (adjustment range 6-8cmH2O), PIP15cmH2O (regulation range 15-20cmH2O), inspiratory time 0.3s (regulation range 0.3-0.4s), respiratory rate 30 beats/min (regulation range 20-40 beats/min), and FiO2 regulation range 0.21-0.40 in order to achieve postnatal target oxygen saturation.
62603122|NCT02203851|EXPERIMENTAL|Risankizumab 90 mg|Participants entered the study receiving risankizumab 90 mg by subcutaneous (SC) injection and had achieved ≥90% improvement in Psoriasis Area and Severity Index (PASI90) Score at Week 12 continued to receive open-label (OL) risankizumab 90 mg by SC injection at Week 12 and every 12 weeks for approximately 4 years from the first dose in either the lead-in or extension study.
62603123|NCT02203851|EXPERIMENTAL|Risankizumab 180 mg|Participants entered the study receiving risankizumab 90 mg by subcutaneous (SC) injection and had achieved \<90% improvement in Psoriasis Area and Severity Index (PASI90) Score at Week 12 switched to open-label (OL) risankizumab 180 mg by SC injection at Week 12 and every 12 weeks for approximately 4 years from the first dose in either the lead-in or extension study.
62603124|NCT00874328|EXPERIMENTAL|study arm|Irinotecan /IV D1 Cisplatin 60mg/m2 iv D1 S-1 bid, P.o. D1 \~ 14 q 3 weeks until maximum 6 cycles
62603125|NCT05939115|ACTIVE_COMPARATOR|Left unilateral aTBS|Participants who are randomly assigned to this group will receive iTBS (intermittent theta burst stimulation) to the left dorsolateral prefrontal cortex (LDLPFC) determined using Beam method for 1800 pulses with an intertreatment interval of fifty minutes. Stimulation was at 90% of resting motor threshold. Patients received ten sessions every day for five consecutive days for a total of fifty sessions (90,000 pulses).
62603126|NCT05939115|ACTIVE_COMPARATOR|Sequential bilateral aTBS|Participants who are randomly assigned to this group will receive ten sessions daily for five consecutive days for a total of fifty sessions. During each session continuous theta burst stimulation (cTBS) in which (1800 pulses) are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDLPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDLPFC) with using beam method for target localization. Stimulation was at 90% of resting motor threshold.
62603127|NCT06143254|EXPERIMENTAL|Symbolic Gesture Training Group|Caregivers of children who are assigned to the SGT group will participate in three caregiver training meetings to learn how to use infant signing in combination with verbal training to promote the speech and language development of their child. These meetings will take place 1 month (meeting 1), 2 months (meeting 2) and 3 months (meeting 3) after baseline assessments are performed (T0). Each meeting will take two hours. After the first training session (meeting 1), caregivers will start using the symbolic gestures to support verbal in- and output at home with their child.
62603128|NCT06143254|ACTIVE_COMPARATOR|Verbal Training Group|Caregivers of children who are assigned to the VT group will participate in three caregiver training meetings to learn how to use verbal training to promote the speech and language development of their child. These meetings will take place 1 month (meeting 1), 2 months (meeting 2) and 3 months (meeting 3) after baseline assessments are performed (T0). Each meeting will take two hours. After the first training session (meeting 1), caregivers will start using supporting verbal in- and output at home with their child.
62825538|NCT06602973|EXPERIMENTAL|Fasted Exercise, Rest, Fed Exercise|"At Study Visit 2, participants will abstain from breakfast and will engage in exercise.~At Study Visit 3, participants will eat breakfast and rest (abstain from exercise).~At Study Visit 4, participants will eat breakfast and exercise."
62825539|NCT01381939||Induction of labor in ICP|Induction of laborin women with ICP
62825540|NCT01381939||Induction of labor in women with no ICP|No ICP
62825541|NCT01381939||ICP and spontanius delivery|
62825542|NCT06593262|EXPERIMENTAL|app-based digital cognitive behavioral therapy for insomnia with AI chatbot|
62825543|NCT06593262|ACTIVE_COMPARATOR|app-based digital cognitive behavioral therapy for insomnia without AI chatbot|
62825544|NCT03995134||Propofol and Remifentanil|Procedural sedation in Dentistry provided by a Target Controlled Infusion pump using propofol as the sedative/hypnotic agent and Remifentanil as the opioid analgesic agent.
62825545|NCT05736380|ACTIVE_COMPARATOR|Unilateral cerebellar rTMS|
62825546|NCT05736380|SHAM_COMPARATOR|Sham cerebellar rTMS|
62825547|NCT05400967|EXPERIMENTAL|68Ga-FAPI PET/CT for scan and 177Lu-EB- FAPI for therapy|All patients diagnosed with metastatic tumors underwent 68Ga-FAPI PET/CT scan. If the PET/CT showed high FAPI expression in tumor lesions of some patients, they would intravenously injected with the dose about 2.22GBq (60 mCi) of 177Lu-EB-FAPI for therapy.
62825548|NCT06593301|ACTIVE_COMPARATOR|classical learning group|"PRELIMINARY Introductory Information Form, Secure Blood And Blood Products Transfusion Self-Efficacy Scale, Skill Observation Form Routine Applications~. Theoretical Education; Face in the Classroom Face to Face Training (PPt presentation, verbal lecture, question and answer, discussion, case study etc.)"
62825549|NCT06593301|EXPERIMENTAL|Flipped classroom model group|PRELIMINARY Introductory Information Form, Secure Blood And Blood Products Transfusion Self-Efficacy Scale, Skill Observation Form
62043971|NCT05338723|NO_INTERVENTION|control-group|This group will include 25 patients who will receive doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy.
62043972|NCT05338723|ACTIVE_COMPARATOR|rosuvastatin-group|This group will include 25 patients who will receive doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy in addition to 20 mg of oral rosuvastatin 24 hours prior to the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months).
62043973|NCT00997087|PLACEBO_COMPARATOR|Sugar Pill, Placebo|
62043974|NCT00997087|ACTIVE_COMPARATOR|Flumazenil|
62043975|NCT02489396||Grocery Customers|All customers who shop on the Rosie site during the intervention period.
62043976|NCT05603468|EXPERIMENTAL|Platelet Rich Plasma group|patients rejected with platelet rich plasma
62043977|NCT05603468|ACTIVE_COMPARATOR|Corticosteroid group|patients rejected with corticosteroid
62043978|NCT05603468|PLACEBO_COMPARATOR|Normal saline group|patients rejected with normal saline
62246492|NCT06442865||Retrospective data|"Subjects with a diabetic neuropathic or neuroischemic wounds, anywhere on the leg, ranging in size between 2 cm2 and 16 cm2, that has not healed at least 20% after the 6 weeks of the standard of care (SoC) with the known therapeutic history ≥ 6 weeks and ≤ 104 weeks prior to clinical trial inclusion.~Retrospective data will contain information about the subject's history and wound treatment by SoC."
62246493|NCT06442865||Prospective data|"Subjects with a diabetic neuropathic or neuroischemic wounds, anywhere on the leg, ranging in size between 2 cm2 and 16 cm2, that has not healed at least 20% after the 6 weeks of the standard of care (SoC) with the known therapeutic history ≥ 6 weeks and ≤ 104 weeks prior to clinical trial inclusion.~Prospective data will contain information about wound treatment by AMNIODERM+®."
62246494|NCT06494787|EXPERIMENTAL|Aliya PEF Plus Pembrolizumab|This is an open label, phase 2 using Aliya PEF energy and Pembrolizumab 200 mg i.v. over 30 minutes every 3 weeks.
62043979|NCT06248619|EXPERIMENTAL|Teprotumumab|Teprotumumab administered SC
62043980|NCT06248619|PLACEBO_COMPARATOR|Placebo|Placebo for teprotumumab administered SC
62043981|NCT04397042||recurrent pregnancy loss|Group 1 included thirty women admitted to our clinic for termination of pregnancy due to absence of fetal cardiac activity or absence of fetal pole on ultrasonographic examination. Patients with a history of two or more unexplained first trimester miscarriages and no live births were included in the study
62043982|NCT05829655|EXPERIMENTAL|Suvorexant (20mg/day)|Double blind administration of suvorexant once per day during residential stay until discharge
62043983|NCT05829655|PLACEBO_COMPARATOR|Placebo|Double blind administration of placebo once per day during residential stay until discharge
62043984|NCT00378989|ACTIVE_COMPARATOR|Intervention|A letter with personal feedback of the results of a health risk appraisal and invitation to a consultation at the occupational health services.
62043985|NCT00378989|NO_INTERVENTION|Control|Care as usual
62043986|NCT06038656|EXPERIMENTAL|Experimental|Participants will receive 10 g of GOS daily for 6 weeks. Fractional iron absorption will be determined pre- and post the 6-week intervention from 3 conditions: 1) after a period of rest; 2) three hours after an acute resistance exercise bout without GOS and 3) three hours after an acute resistance exercise bout, co-administered with 10 g GOS.
62043987|NCT00345982|EXPERIMENTAL|A|Sertindole 16 mg
62043988|NCT00345982|PLACEBO_COMPARATOR|B|Placebo
62043989|NCT02264704|EXPERIMENTAL|High intensity exercise|High intensity exercise Participants will exercise at high intensity (70% VO2 peak) intermittently (30 seconds on, 30 seconds off) for 15 minutes, twice weekly for 15 weeks.
62043990|NCT02264704|EXPERIMENTAL|Moderate intensity exercise|Participants exercise at moderate intensity (35% VO2 peak) continuously for 15 minutes, twice weekly for 15 weeks.
62043991|NCT02264704|NO_INTERVENTION|Usual Care|Participants receive usual medical care.
62043992|NCT01049113|EXPERIMENTAL|ON 013105|ON 013105 administered intravenously as 2-hour infusion once a week for 3 weeks of 3-week cycles. This is dose escalation study; starting dose is 17 mg.
62043993|NCT02195986|EXPERIMENTAL|Estradiol Vaginal Cream|Estradiol Vaginal Cream, 0.01%, administered once daily for 7 days.
62043994|NCT02195986|ACTIVE_COMPARATOR|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream, administered once daily for 7 days.
62246495|NCT02414568|EXPERIMENTAL|PVAB regimen|Prednisone 40 mg/m2 (PO) Days 1-5 ; Vinblastine 6 mg/m2 (IV) Day 1 ; Doxorubicin 40 mg/m2 (IV) Day 1 ; Bendamustine 120 mg/m2 (IV) Day 1
62246496|NCT05877222|EXPERIMENTAL|Treatment A (5 × 10 mg daridorexant)|Participants will receive a single oral dose of 5 × 10 mg daridorexant.
62246497|NCT05877222|EXPERIMENTAL|Treatment B (5 × 25 mg daridorexant)|Participants will receive a single oral dose of 2 × 25 mg daridorexant.
62246498|NCT06326892||Natural Orifice Specimen Extraction (NOSE)|Patients with low rectal cancer who underwent rectal resection with Natural Orifice Specimen Extraction (NOSE)
62246499|NCT06326892||Controls|Patients with low rectal cancer who underwent rectal resection with traditional specimen extraction
62246500|NCT01909427|PLACEBO_COMPARATOR|Placebo/CNTO 6785 200 mg+Methotrexate (MTX)|
62825550|NCT02170376|EXPERIMENTAL|Group 1|Placebo once-daily for 11 days 200 mg entacapone concomitantly with levodopa/carbidopa on Day 12
62043995|NCT02195986|PLACEBO_COMPARATOR|Placebo Vaginal Cream|Placebo Vaginal Cream, administered once daily for 7 days.
62043996|NCT00262587|PLACEBO_COMPARATOR|Placebo|Placebo inhaler (sugar powder)
62043997|NCT00262587|ACTIVE_COMPARATOR|Seretide|Seretide inhaler
62603129|NCT06143254|NO_INTERVENTION|No Intervention Control Group|Standard clinical care at this moment at the Cleft Palate Teams of the University Hospitals of Ghent and Leuven includes providing information to caregivers about speech-language development and encouraging caregivers to communicate with their children. This information will be orally provided by an SLP during a standard clinical appointment at the cleft team at the age of 12 months. A brochure including this information will be provided. Caregivers of children who will be assigned to group C will have the opportunity to receive the most effective intervention (SGT or VT) after finishing the study.
62043998|NCT05237050|EXPERIMENTAL|Sound therapy associated with relaxation|
62043999|NCT05237050|ACTIVE_COMPARATOR|Relaxation alone|
62603130|NCT04100915||Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)|Patients diagnosed with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
62603131|NCT01902758|EXPERIMENTAL|ambrisentan and theophylline|ambrisentan (5mg) once daily for 2 consecutive days theophylline (400mg) once daily for 2 consecutive days
62825551|NCT02170376|EXPERIMENTAL|Group 2|25 mg BIA 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
62825552|NCT02170376|EXPERIMENTAL|Group 3|50 mg 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
62044000|NCT05497440|EXPERIMENTAL|All'InCath CBC 035M Balloon Dilatation Catheter|All participants will undergo the same intervention. Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography.
62044001|NCT03763422|EXPERIMENTAL|Early Treatment arm|Radiotherapy + Temozolomide
62044002|NCT03763422|ACTIVE_COMPARATOR|Active surveillance arm|Treatment as per local practice
62044003|NCT01510275|EXPERIMENTAL|Intervention|Combined use of RESPIVOL® and RESPILIFT® (with resistive load)
62044004|NCT01510275|SHAM_COMPARATOR|Control|Combined use of RESPIVOL® and RESPILIFT® (without resistive load)
62044005|NCT01618864|OTHER|Luxe|
62044006|NCT01346748|EXPERIMENTAL|Statin|
62044007|NCT02087631|EXPERIMENTAL|Quetiapine|Extended-release quetiapine fumarate up to 300mg once daily for 4 weeks
62044008|NCT02818712||Patients with IPF|
62044009|NCT04198805|ACTIVE_COMPARATOR|Vitamin E (1000 mg)|Vitamin E (1000 mg) once daily for 6 months (1 capsule) and matching placebos (2 matched capsules) for 6 months.
62044010|NCT04198805|ACTIVE_COMPARATOR|DHA EE (1.89 g)|DHA EE (1.89 g) once daily for 6 months (2 capsules) and matching placebo for DHA EE (1 matched capsule for 6 months).
62044011|NCT04198805|ACTIVE_COMPARATOR|DHA EE (1.89 g) and Vitamin E (1000 mg)|DHA EE (1.89 g) once daily for 6 months and Vitamin E (1000 mg) once daily for 6 months.
62044012|NCT04198805|PLACEBO_COMPARATOR|Placebo|Matching soybean oil placebo (3 capsules) of all arms daily for 6 months.
62246501|NCT01909427|EXPERIMENTAL|CNTO 6785 200 mg+MTX|
62825553|NCT02170376|EXPERIMENTAL|Group 4|75 mg 9-1067 once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
62825554|NCT02170376|PLACEBO_COMPARATOR|Group 5|placebo once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
62825555|NCT05726305|EXPERIMENTAL|Live donor uterus transplantation|Transplantation of uterus from a living donor. Immunosuppression with tacrolimus.
62825556|NCT05726305|EXPERIMENTAL|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor. Immunosuppression with tacrolimus.
62044013|NCT01284426||Chronic urticaria|Chronic urticaria, Natural history
62246502|NCT01909427|EXPERIMENTAL|CNTO 6785 100 mg+MTX|
62246503|NCT01909427|EXPERIMENTAL|CNTO 6785 50 mg+MTX|
62246504|NCT01909427|EXPERIMENTAL|CNTO 6785 15 mg+MTX|
62246505|NCT01098812|ACTIVE_COMPARATOR|Control IOL|Approved Intraocular control lens
62603132|NCT01902758|PLACEBO_COMPARATOR|placebo|matched placebo tablets wil be given at the same time to the comparison group as the medications to the experimental group
62603133|NCT00733083|ACTIVE_COMPARATOR|1|0,1 mg/kg of oxycodone
62603134|NCT00733083|ACTIVE_COMPARATOR|2|0,1 mg/kg of morphine
62603135|NCT00733083|ACTIVE_COMPARATOR|3|0,5 mg/kg dexamethasone (max 24 mg
62603136|NCT00733083|PLACEBO_COMPARATOR|4|NaCl 0,9%
62603137|NCT05729542|ACTIVE_COMPARATOR|Arthrex Tightrope|Syndesmosis fixation performed with ARthrex Tightrope device. This is a high-tension suture fixation with a button based anchor system.
62044014|NCT00975312|EXPERIMENTAL|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand.
62044015|NCT04739501||TACE in HCC group 1|the patient did undergo tace
62603138|NCT05729542|EXPERIMENTAL|Synthes Fibulink|Syndesmosis fixation perforemd with Synthes Fibulink device. This is a high-tension fixation with a screw based anchor system.
62603139|NCT01905501|ACTIVE_COMPARATOR|Total intravenous anesthesia|Total intravenous anaesthesia
62825557|NCT04716764||Case Group|The study will include female individuals aged 19-64 years who applied to Necmettin Erbakan University Meram Medical Faculty General Surgery and Medical Oncology Departments and were diagnosed with breast cancer for the first time and volunteering to participate in the study. Patients with breast cancer will be followed up before surgery, before chemotherapy, and in the sixth and twelfth months after starting chemotherapy.
62825558|NCT04716764||Healthy (Control) participants|The control group consists of healthy adult women who applied to the Internal Diseases (Internal Medicine) outpatient clinic of Necmettin Erbakan University Meram Medical Faculty Hospital, who are at the same age as the case group, and who have not been diagnosed with any disease by the doctor, and who are willing to participate in the study. Healthy individuals will be interviewed once. The obtained data will be compared with the preoperative data of breast cancer patients.
62825559|NCT01767090|PLACEBO_COMPARATOR|Placebo|Applicable to first 12 week period (Part One); subjects in this arm will be randomized to one of the ASP1707 dose levels for the second 12 week period (Part Two)
62246506|NCT01098812|EXPERIMENTAL|Toric IOL|Investigational Toric IOL
62246507|NCT01098812|EXPERIMENTAL|Higher Cylinder Toric IOL|Investigational Toric IOLs with higher cylinder powers.
62825560|NCT01767090|EXPERIMENTAL|ASP1707 lowest dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
62246508|NCT02604225|EXPERIMENTAL|Penthrox|Methoxyflurane
62436845|NCT01362114|PLACEBO_COMPARATOR|Placebo; corn flour,|"* raw material: total contents(500㎎); cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)~* shape, type: extract(brown)~* usage, dose: adults: three times a day, 1 sack before or between meals~* dose, standard: 2.5g for each sack, capsulated~* storage : airtight container, stored in room temperature~* expiration date : 36 months after manufacture~* manufacturing company: KyungBangnShinYak inc."
62044016|NCT03951454|EXPERIMENTAL|Conexiones|5 telephone sessions of Conexiones, with each session delivered 2 weeks apart across a total period of 8 weeks
62044017|NCT03951454|OTHER|Taking Time|1 telephone session consisting of a scripted protocol guiding participants through the NCI's Taking Time Booklet.
62044018|NCT06580444|NO_INTERVENTION|Placebo|A 0.9% bag of sodium chloride will be administered intravenously. Participant will be given a self-administered alcoholic drink of their choice that is individually calculated, and they will receive money up to $15 for every minute they resist drinking.
62044019|NCT06580444|ACTIVE_COMPARATOR|90mcg/kg/h dose of Brexanolone|Brexanolone will be diluted with sterile water and 0.9% sodium chloride and will be administered intravenously. Participant will be given a self-administered alcoholic drink of their choice that is individually calculated, and they will receive money up to $15 for every minute they resist drinking.
62246509|NCT02604225|PLACEBO_COMPARATOR|Placebo|Saline 0.9%
62246510|NCT04165993|EXPERIMENTAL|Concurrent chemotherapy and KN026|KN026 combined with docetaxol
62246511|NCT04165993|EXPERIMENTAL|KN026 monotherapy|KN026 monotherapy
62246512|NCT04165993|EXPERIMENTAL|A combination treatment of KN026 and KN046|KN026 combined with KN046
62246513|NCT03931967||MR-proADM|
62436846|NCT01182714|OTHER|removal of catheter|
62603140|NCT01905501|EXPERIMENTAL|Balanced anesthesia|
62246514|NCT05125289|EXPERIMENTAL|experimental intervention group 1|Graston technique group
62246515|NCT05125289|EXPERIMENTAL|Experimental :interventional group II|Active release technique group
62246516|NCT05125289|EXPERIMENTAL|experimental group III|Proprioceptive Neuromuscular Facilitation stretching group
62246517|NCT01103245|ACTIVE_COMPARATOR|HCTZ plus ALI 150 then ALI 300|"Hydrochlorothiazide (HCTZ) 12.5mg daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 150 mg (ALI 150) daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 300mg ((ALI 300) for 1 month"
62044020|NCT06580444|ACTIVE_COMPARATOR|60mcg/kg/h dose of Brexanolone|Brexanolone will be diluted with sterile water and 0.9% sodium chloride and will be administered intravenously. Participant will be given a self-administered alcoholic drink of their choice that is individually calculated, and they will receive money up to $15 for every minute they resist drinking.
62825561|NCT01767090|EXPERIMENTAL|ASP1707 low dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
62825562|NCT01767090|EXPERIMENTAL|ASP1707 medium dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
62246518|NCT01103245|ACTIVE_COMPARATOR|HCTZ plus ALI 150 then ALI 150 and SPL 25|"HCTZ 12.5mg daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 150 mg daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 150 mg daily and Spironolactone 25mg (SPL 25) daily for one month"
62044021|NCT06580444|ACTIVE_COMPARATOR|30mcg/kg/h dose of Brexanolone|Brexanolone will be diluted with sterile water and 0.9% sodium chloride and will be administered intravenously. Participant will be given a self-administered alcoholic drink of their choice that is individually calculated, and they will receive money up to $15 for every minute they resist drinking.
62044022|NCT05217342|EXPERIMENTAL|PVP-Guided|Peripheral venous pressure guided therapy arm
62044023|NCT05217342|ACTIVE_COMPARATOR|Control|Standard medical therapy arm
62044024|NCT03162575|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2.5 hours
62246519|NCT01103245|ACTIVE_COMPARATOR|HCTZ plus SPL 25 then SPL 50|"HCTZ 12.5mg daily for 1 month~then HCTZ 12.5mg daily plus Spironolactone 25 mg (SPL 25) daily for 1 month~then HCTZ 12.5mg daily plus Spironolactone 50 mg daily for one month"
62825563|NCT01767090|EXPERIMENTAL|ASP1707 high dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
62825564|NCT01767090|ACTIVE_COMPARATOR|Leuprorelin acetate|Subjects in this arm will be treated with leuprorelin acetate for a total of 24 weeks
62825565|NCT06596109|EXPERIMENTAL|honey intake and lifestyle changes|Twenty fatty liver (non-alcoholic from) patients with obesity are included as 20 patients who will receive honey intake (orally, as a daily total dose of 2 g/kg, this dose will be divided to three equal subdoses, every dose will be administered before meal), low calorie diet, and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
62246520|NCT01103245|ACTIVE_COMPARATOR|HCTZ plus SPL 25 then ALI 150 and SPL 25|"HCTZ 12.5mg daily for 1 month~then HCTZ 12.5mg daily plus Spironolactone 25 mg daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 150 mg daily and Spironolactone 25 mg daily for one month"
62246521|NCT03432351||Children: 0-36mo|EEG sensor will be placed on the subject's forehead to observe and record EEG activity. No other applicable intervention.
62246522|NCT02191020|EXPERIMENTAL|Total glucosides of paeony & Acitretin Capsules|During the first week，0.6g，oral，b.i.d.During the other weeks，0.6g，oral，t.i.d
62825566|NCT06596109|ACTIVE_COMPARATOR|lifestyle changes|Twenty fatty liver (non-alcoholic from) patients with obesity are included as 20 patients who will receive low calorie diet, and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
62825567|NCT01915810|EXPERIMENTAL|Arm I (pre-quit physical activity)|Participants receive telephone-based cessation counseling over 15-20 minutes 1-2 weeks before assigned quit date and nicotine patch for 6 weeks. Beginning 2 weeks before the assigned quit date, participants receive a Walking Program guide and engage in the SCwPA comprising brisk, self-paced walking with a goal of 150 minutes of exercise activity per week for 5 weeks.
62825568|NCT01915810|EXPERIMENTAL|Arm II (quit day physical activity)|Participants receive telephone-based cessation counseling over 15-20 minutes 1-2 weeks before assigned quit date and nicotine patch for 6 weeks. Beginning on the assigned quit date, participants receive a Walking Program guide and engage in the SCwPA comprising brisk, self-paced walking with a goal of 150 minutes of exercise per week for 5 weeks.
62044025|NCT03162575|NO_INTERVENTION|Waiting List Control|Patients assigned to the waiting list condition will receive no intervention for three months and afterwards will receive MBCT
62044026|NCT02382198|ACTIVE_COMPARATOR|Active Group|This arm will receive the study drug glycopyrrolate.
62044027|NCT02382198|PLACEBO_COMPARATOR|Placebo Group|Control arm to receive placebo
62044028|NCT03355638|ACTIVE_COMPARATOR|aflibercept monotherapy|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata
62044029|NCT03355638|EXPERIMENTAL|aflibercept plus pranoprofen|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients also self- administered one drop of pranoprofen (Pranoflog; Sifi SpA, Aci Sant'Antonio, CT, Italy) three times a day for 12 months. All patients were followed up for 12 months.
62044030|NCT03355638|EXPERIMENTAL|aflibercept plus nutraceutical|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients were given daily tablets of Omega-3 supplementation (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).
62825569|NCT01915810|ACTIVE_COMPARATOR|Arm III (no physical activity)|Participants quit smoking on an assigned date and receive telephone-based cessation counseling over 15-20 minutes 1-2 weeks before assigned quit date and nicotine patch for 6 weeks.
62825570|NCT04232358|EXPERIMENTAL|Corticosteroid injections + resistance training|Corticosteroid injections every 4 weeks until symptoms resolve with a maximum of 3 injections + resistance training at home instructed via a smart phone training app and avoidance of pain aggravating activities for 3 months
62246523|NCT02191020|ACTIVE_COMPARATOR|Acitretin Capsules|20mg/day oral,when subject's weight less than 70kg;otherwise,30mg/day oral.
62825571|NCT04232358|PLACEBO_COMPARATOR|Local anesthesia injections + resistance training|Local anesthesia injections every 4 weeks until symptoms resolve with a maximum of 3 injections + resistance training at home instructed via a smart phone training app and avoidance of pain aggravating activities for 3 months
62825572|NCT04386291|ACTIVE_COMPARATOR|Anxiety Reduction Training (A.R.T.)|Participants will received biweekly on-line lessons that provide education and strategies to reduce stress and disturbing thoughts and improve healthy coping and sleep. .
62825573|NCT04386291|EXPERIMENTAL|ART and Kundalini Yoga|This combines ART with a daily 30 minute practice of Kundalini Yoga (stretching, guided breathing, and meditation). Accessible by smart phone, tablet or computer.
62825574|NCT04386291|EXPERIMENTAL|ART and Meditation|This combines ART with a daily 15 minute meditation with stress reduction techniques and guided breathing.
62825575|NCT04792645|PLACEBO_COMPARATOR|Placebo|10mg once daily of placebo for two weeks, then 20mg for the remaining six weeks
62044031|NCT00769548|EXPERIMENTAL|Arm 1|Neoadjuvant total androgen suppression (TAS) given 2 months before and during radiation therapy (RT) to the whole pelvis followed by a prostate boost.
62246524|NCT01210690||Patients, 1 - 11 months old, prescribed Keppra® oral solution|Epileptic patients who have been prescribed Keppra® (Levetiracetam) oral solution and who are between 1 and 11 months old. The patients will be followed as per current clinical practices for their condition. The choice of medical treatment, including the concomitant use of other antiepileptic drugs, is made independently by the physician in the regular course of practice and is not influenced by the study protocol.
62246525|NCT01017588|EXPERIMENTAL|back exercise|strengthening back exercise
62246526|NCT05556278||Intervention|An electroneurography and an ultrasound study will be performed to patients with clinical suspicion of CTS and fulfilling the inclusion/exclusion criteria.
62246527|NCT05378854|EXPERIMENTAL|LifeChamps Platform|Participants will be asked to use the LifeChamps platform and will be provided with the study equipment.
62825576|NCT04792645|EXPERIMENTAL|Memantine|10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks
62825577|NCT06597500|EXPERIMENTAL|Treatment Period 1: GSK3923868|Participants will receive GSK3923868 on Day 1.
62825578|NCT06597500|EXPERIMENTAL|Treatment Period 2: GSK3923868 + Itraconazole|Participants will receive itraconazole from Days 1 to 10 and GSK3923868 on Day 5.
62825579|NCT01951443|EXPERIMENTAL|Ginseng|Encapsulated 400mg Rg3-KRG extract
62246528|NCT03967379|EXPERIMENTAL|Mobile app plus enhanced standard care|"* Patients will received enhanced standard care in addition to access to the sexual health mobile app.~* The app will also prompt patients to engage their partners with specific exercises."
62825580|NCT01951443|PLACEBO_COMPARATOR|Wheat Bran|400mg Wheat Bran capsule
62825581|NCT06600724|ACTIVE_COMPARATOR|Standard of Care|Standard of care will be cleaning, debridement, ulcer moisture balance, and offloading.
62825582|NCT06600724|EXPERIMENTAL|EPIEFFECT|EPIEFFECT® is a PURION processed lyophilized human placental tissue allograft that includes the amnion layer, intermediate layer, and chorion layer of the amniotic membrane. The product is intended for use as a barrier to provide a protective environment in acute and chronic wounds.
62246529|NCT03967379|OTHER|Enhanced Standard Care|"* Patients will receive Enhanced Standard Care~* Patients will meet with a transplant clinician for a brief medical examination to assess the need for medications for erectile dysfunction, vaginal atrophy, or vulvovaginal GVHD~* Patients will not have access to the sexual health mobile app"
62603141|NCT04462523|EXPERIMENTAL|Group 1 Pre-surgery Dextenza insert|Ten patients will receive the dexamethasone intracanalicular insert pre-operatively (1 week to 1 days prior to vitreo-retinal surgery). All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
62603142|NCT04462523|EXPERIMENTAL|Group 2 Surgery Day Dextenza insert|Ten patients will receive dexamethasone intracanalicular insert on the day of surgery. All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
62825583|NCT06600724|EXPERIMENTAL|EPIXPRESS|EPIXPRESS™ is a PURION processed lyophilized human placental tissue allograft that includes the amnion layer, intermediate layer, and chorion layer of the amniotic membrane. The product is intended for use as a barrier to provide a protective environment in acute and chronic wounds. EPIXPRESS is fenestrated to help facilitate fluid movement and can be used on wounds that produce copious amounts of exudate.
62825584|NCT06596733|EXPERIMENTAL|Vit-A-Vision|Application of Vit-A-Vision ointment
62825585|NCT02181777|EXPERIMENTAL|GRASP|GRoup trAining for Social skills in Psychosis
62825586|NCT02181777|ACTIVE_COMPARATOR|Standard care|Treatment as usual as provided by care team
62825587|NCT06594939|EXPERIMENTAL|Mosum-Pola-SD-CHP|"Each cycle is 28 days and consists of one A treatment on Day 1 and one B treatment on Day 15 for six cycles.~Day 1 (A part of cycle) Polatuzumab Vedotin 1.8 mg/kg Intravenous (IV); Mosunetuzumab (Cycle 1A) 5 mg Subcutaneous (SC); Cyclophosphamide 375 mg/m\^2 IV; Doxorubicin 25 mg/m\^2 IV; Prednisone 50 mg Orally~Day 2 (A part of cycle) Pegfilgrastim 6 mg SC~Day 8 (A part of cycle) Mosunetuzumab 45 mg SC~Day 15 (B part of cycle) Mosunetuzumab (Cycle 1B-6B) 45 mg SC; Cyclophosphamide 375 mg/m\^2 IV; Doxorubicin 25 mg/m\^2 IV; Prednisone 50 mg Orally~Day 16 (B part of cycle) Pegfilgrastim 6 mg SC"
62825588|NCT06326450|EXPERIMENTAL|Experimental: Augmented Reality Enhanced Simulation (Treatment group)|Participants will experience augmented simulations with a holographic mixed-reality setting based on different workplace scenarios such as medical crisis via Augmented Reality (AR) headset.
62825589|NCT06326450|NO_INTERVENTION|Traditional In Situ Simulation (Control group)|Participants will experience in-person simulations of different workplace scenarios such as medical error and workplace harassment
62825590|NCT06563700|PLACEBO_COMPARATOR|Group A|single vision lens
62825591|NCT06563700|EXPERIMENTAL|Group B|one of ZEISS BD spectacle lens designs 1 to 5
62825592|NCT06563700|EXPERIMENTAL|Group C|one of ZEISS BD spectacle lens designs 1 to 5
62825593|NCT06563700|EXPERIMENTAL|Group D|one of ZEISS BD spectacle lens designs 1 to 5
62825594|NCT06563700|EXPERIMENTAL|Group E|one of ZEISS BD spectacle lens designs 1 to 5
62825595|NCT06563700|EXPERIMENTAL|Group F|one of ZEISS BD spectacle lens designs 1 to 5
62825596|NCT03103542|EXPERIMENTAL|Recombinant coagulation factor VIII Fc (rFVIIIFc)|Participants will receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 60 Weeks during the ITI Period. Participants who meet the criteria for ITI success will enter a tapering period of 16 weeks where the dose will be tapered down until a prophylactic dose, as judged by the Investigator, is achieved and thereafter a follow-up period of 32 weeks where the patient will continue to receive prophylactic treatment with rFVIIIFc.
62825597|NCT01490151|EXPERIMENTAL|TTR controller|The intervention will consist of using the TTR controller (Medtronic) for post-prandial glucose control following high and low glycemic meals
62825598|NCT05885438|EXPERIMENTAL|Intervention|Participants in the intervention group will receive the ACT workshop
62825599|NCT05885438|NO_INTERVENTION|Waitlist Control|Participants in the waitlist control group will not receive the intervention until all members of the intervention group have received the workshop. Once all members of the intervention group have received the workshop, participants in the waitlist control group will be able to receive the workshop if they so desire.
62825600|NCT04522388|EXPERIMENTAL|Treatment|Nutritional shakes, Ensure Enlive, twice per day orally in patients awaiting lung transplant
62825601|NCT06591663|EXPERIMENTAL|implementation of culturally adapted Urdu version of the Cognitive Therapy Rating Scale (CTRS)|
62825602|NCT06362824|EXPERIMENTAL|De Pie Intervention|The De Pie intervention program receives a sedentary behavior reduction and physical activity promotion intervention centered on two steps: Step 1) reduce sitting time and move more throughout the day; Step 2) if cleared by a safety assessment and blood pressure check, participants can work towards adding structured bouts of exercise into their day.
62436847|NCT00686478|EXPERIMENTAL|interferon alpha 2b (Intron A)|1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
62436848|NCT00686478|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously once a day for 7 days, then three times a week for 23 weeks.
62603143|NCT04462523|EXPERIMENTAL|Group 3 Post op Day 1 Dextenza insert|Ten patients will receive DEXTENZA insert Day 1 post-operatively. All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops
62603144|NCT04462523|ACTIVE_COMPARATOR|Group 4 Topical steroid|Ten patients will be prescribed standard of care ophthalmic drops, Prednisolone Acetate, and no dexamethasone insert (control group). All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
62603145|NCT00421824|EXPERIMENTAL|A|
62603146|NCT00421824|EXPERIMENTAL|B|
62603147|NCT03866733|ACTIVE_COMPARATOR|Narcotics group (group N)|intervention: injection of boluses of intra venous Narcotics (fentanyl) in the dose of (3-5 mcg/kg) during the surgery after induction of anesthesia. morphine 0.5mg/kg as rescue analgesia will be started upon arrival till 48 hours after surgery. NSAID every 12 hrs if there is no contraindication and iv acetaminophine igm/6hrs.
62246530|NCT01368809|ACTIVE_COMPARATOR|Fentanyl|Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
62246531|NCT01368809|PLACEBO_COMPARATOR|Saline Solution|Saline Solution 2 ml at induction, 1-2 ml boluses as needed
62603148|NCT03866733|EXPERIMENTAL|Erector spinea block group (group B)|intervention: after induction our intervention will be the performance of ultrasound guided bilateral continous Erector spinea block with insertion of catheters then 15 ml of 0.25% bupivacaine will be injected in each of the catheters followed by a continuous infusion of 0.125% plain bupivacaine at the rate of 8 ml/h. morphine 0.5mg/kg as rescue analgesia will be started upon arrival till extubation and iv acetaminophine igm/6hrs.
62825603|NCT06362824|ACTIVE_COMPARATOR|HALT-AD Active Comparison Group|Those randomized to HALT-AD (Healthy Actions and Lifestyles to Avoid Dementia) will receive one phone call to introduce them to preventing cognitive decline through various lifestyle behaviors (e.g. stress reduction, healthy diet, healthy sleep) other than physical activity. They will be encouraged by the Health Coach upon randomization to complete one module approximately every week (there are 10 modules in total).
62825604|NCT06590831|ACTIVE_COMPARATOR|Group A: (lactoferrin Group)|About 133 anemic pregnant women will be treated with lactoferrin only (pravotin 100mg ) twice daily for 4 weeks.
62825605|NCT06590831|ACTIVE_COMPARATOR|Group B: (Amino acid chelated iron Group)|About 133 anemic pregnant women will be treated with amino acid chelated iron only (phara fero 27) once daily for 4 weeks.
62825606|NCT06590831|ACTIVE_COMPARATOR|Group C: (lactoferrin with amino acid chelated iron Group)|About 133 anemic pregnant women will be treated with lactoferrin with amino acid chelated iron (phara fero 27 plus ) once daily for 4 weeks
62825607|NCT06603740|EXPERIMENTAL|Partial meniscectomy using the Arthrex Nanoscope|
62825608|NCT06603740|OTHER|Partial meniscectomy using conventional arthroscopy equipment|
62825609|NCT06597422|EXPERIMENTAL|Single Low Dose Arm|Low dose of STSP-0902 ophthalmic solution to study eye. Single dose.
62246532|NCT03971994|ACTIVE_COMPARATOR|Young adults|Participants aged between 18 and 40 years old.
62246533|NCT03971994|ACTIVE_COMPARATOR|Healthy old adults|Participants aged between 65 and 95 years old.
62246534|NCT03971994|EXPERIMENTAL|Patients with Alzheimer's Disease|Participants aged between 65 and 95 years old with a diagnosis of Alzheimer's Disease.
62246535|NCT05366920|ACTIVE_COMPARATOR|conventional diathermy hook|Laparoscopic cholecystectomy made with diathermy hook starting from Calot´s triangle Intervention: Procedure: dissection of gallbladder in laparoscopic cholecystectomy
62825610|NCT06597422|EXPERIMENTAL|Single Middle Dose Arm|Middle dose of STSP-0902 ophthalmic solution to study eye. Single dose.
62825611|NCT06597422|EXPERIMENTAL|Single High Dose Arm|High dose of STSP-0902 ophthalmic solution to study eye. Single dose.
62246536|NCT05366920|ACTIVE_COMPARATOR|5 mm suction irrigation blunt dissection|Laparoscopic cholecystectomy made with 5mm suction irrigation blunt dissection starting from gallbladder fundus Intervention: Procedure: dissection of gallbladder in laparoscopic cholecystectomy
62246537|NCT01288222|EXPERIMENTAL|Unrelated Donor Transplant Patients|Patients with acute myeloid leukemia who have received KIR genotype from an unrelated donor transplant.
62436849|NCT04426071||SCI, brain injury, stroke Participants|Those 18 years of age and older, diagnosed with a stroke, spinal cord injury (traumatic and non-traumatic), or acquired brain injury (of all severities, including concussion) living in the community will be included. Additionally, only those the cognitive capacity to understand and complete the measures will be included. Those who consent will complete an online survey on enrollment into the study, and subsequently at 3 and 6 months.
62436850|NCT04296383|EXPERIMENTAL|Azithromycin plus Xiyanping injection group|
62825612|NCT06597422|EXPERIMENTAL|Single Control Dose Arm|STSP-0902 Placebo to study eye. Single dose.
62436851|NCT04296383|ACTIVE_COMPARATOR|Azithromycin group|
62825613|NCT06597422|EXPERIMENTAL|Multiple Low Dose Arm|Low dose of STSP-0902 ophthalmic solution to study eye. Three times daily for a total of 8 days.
62825614|NCT06597422|EXPERIMENTAL|Multiple Middle Dose Arm|Middle dose of STSP-0902 ophthalmic solution to study eye. Three times daily for a total of 8 days.
62825615|NCT06597422|EXPERIMENTAL|Multiple High Dose Arm|High dose of STSP-0902 ophthalmic solution to study eye. Three times daily for a total of 8 days.
62825616|NCT06597422|EXPERIMENTAL|Multiple Highest Dose Arm|Middle dose of STSP-0902 ophthalmic solution to study eye. Six times daily for a total of 8 days.
62825617|NCT06597422|EXPERIMENTAL|Multiple Control Dose Arm|STSP-0902 Placebo to study eye. Multiple doses.
62825618|NCT06597422|EXPERIMENTAL|Tear PK study Arm|STSP-0902 ophthalmic solution to both eyes. Single dose.
62825619|NCT06490289|NO_INTERVENTION|Group A (Control Group)|No intervention was done
62825620|NCT06490289|EXPERIMENTAL|Group B|Denpro oral gel (Gennec Health Sciences PVT, LTD, Karachi, Pakistan) was administered.
62825621|NCT06601777|EXPERIMENTAL|intervention group|The Smart Homespital system can be applied for the first 3 months (12 weeks), and then the primary and secondary variables will be evaluated at 3, 6, 9months.
62825622|NCT06601777|EXPERIMENTAL|attention-waitlist control group|The waiting list-control group will receive general medical services for the first 3 months and will receive the Smart Homespital system for 3-6 months. Primary and secondary variables will be evaluated between 3, 6, and 9 months.
62436852|NCT01121900|EXPERIMENTAL|Trazodone HCl OAD|OAD: Once A Day
62436853|NCT01121900|ACTIVE_COMPARATOR|Trazodone HCl (Apotex Corp.)|
62825623|NCT03560297|EXPERIMENTAL|SeRenade Program|Parent-Child Music Class Program (parent training, peer inclusion, musical play)
62825624|NCT03560297|EXPERIMENTAL|Delayed/Waitlist Program|Participants do not participate in the program for a time period
62825625|NCT06597864|OTHER|Psychotherapy group|Single arm of participants receiving a phenomenologically oriented psychotherapeutic intervention
62825626|NCT06588764|EXPERIMENTAL|Study group|Modified deep lateral and/or medial wall decompression in Moderate-to-severe Graves' Orbitopathy
62825627|NCT04852224||Androgen Deprivation Therapy (ADT+)|Men diagnosed with prostate cancer and scheduled to receive greater than or equal to 6-months of treatment with androgen deprivation therapy
62603149|NCT06440733|EXPERIMENTAL|Older adults with frailty and cognitive impairment|In this study, an 8-week multicomponent exercise program will be carried out focused on improving the general physical condition and balance of older adult subjects, in order to try to reduce the risk of falls and improve the quality of life of a group. of older adults made up of 17 participants.
62825628|NCT04852224||Prostate Cancer Surveillance (ADT-)|Men diagnosed with prostate cancer under active surveillance (i.e., not receiving active treatment for prostate cancer)
62603150|NCT05207852||0.5 h group|Blood samples were taken 0.5 h after dexamethasone administration
62603151|NCT05207852||2 h group|Blood samples were taken 2 h after dexamethasone administration
62603152|NCT05207852||4 h group|Blood samples were taken 4 h after dexamethasone administration
62603153|NCT05207852||6 h group|Blood samples were taken 6 h after dexamethasone administration
62603154|NCT05207852||12 h group|Blood samples were taken 12 h after dexamethasone administration
62603155|NCT05207852||24 h group|Blood samples were taken 24 h after dexamethasone administration
62603156|NCT05207852||36 h group|Blood samples were taken 36 h after dexamethasone administration
62825629|NCT04852224||Non-cancer Control (PCa-)|Age-matched men without a history of cancer
62825630|NCT03175367|EXPERIMENTAL|Group A: dosing regimen 1|SC Evinacumab QW for 16 weeks
62825631|NCT03175367|EXPERIMENTAL|Group A: dosing regimen 2|SC Evinacumab Q2W for 16 weeks (alternating with matching placebo on opposite weeks)
62825632|NCT03175367|EXPERIMENTAL|Group A: dosing regimen 3|SC Evinacumab QW for 16 weeks
62825633|NCT03175367|EXPERIMENTAL|Group A: matching placebo|Placebo SC QW for 16 weeks
62825634|NCT03175367|EXPERIMENTAL|Group B: dosing regimen 1|Intravenous (IV) Evinacumab Q4W for 24 weeks
62825635|NCT03175367|EXPERIMENTAL|Group B: dosing regimen 2|IV Evinacumab Q4W for 24 weeks
62825636|NCT03175367|EXPERIMENTAL|Group B: matching placebo|Placebo IV Q4W for 24 weeks
62825637|NCT06202521|EXPERIMENTAL|SARS-CoV-2 domain: CX-4945 (400 mg BID for 5 days) +SOC|Notes: The SOC within the SARS-CoV-2 domain is defined as the medications in use at each respective site for the treatment of CAP related to SARS-CoV-2 infection.
62825638|NCT06202521|PLACEBO_COMPARATOR|SARS-CoV-2 domain: Placebo + SOC|Notes: The SOC within the SARS-CoV-2 domain is defined as the medications in use at each respective site for the treatment of CAP related to SARS-CoV-2 infection.
62825639|NCT06202521|EXPERIMENTAL|Influenza virus domain: CX-4945 (400 mg BID for 5 days) +SOC|Notes: The SOC within the influenza virus domain is defined as the medications in use at each respective site for the treatment of CAP related to influenza virus infection.
62825640|NCT06202521|PLACEBO_COMPARATOR|Influenza virus domain: Placebo + SOC|Notes: The SOC within the influenza virus domain is defined as the medications in use at each respective site for the treatment of CAP related to influenza virus infection.
62825641|NCT05532189|EXPERIMENTAL|ACL reconstruction with internal brace augmentation (suture tape)|This group will receive a standard ACL reconstruction using a BTB autograft with suture tape augmentation on the graft to strengthen it during the surgical procedure.
62825642|NCT05532189|ACTIVE_COMPARATOR|ACL reconstruction without internal brace augmentation|This group will only receive a standard ACL reconstruction using a BTB autograft. No suture tape will be added to the graft during the surgical procedure.
62825643|NCT06604039||Subject|Needing a vascular access device for therapy or diagnosis
62825644|NCT06169839|ACTIVE_COMPARATOR|Skill training with Low Realism Simulation|the theoretical part of the TYD and OED training with Participation Certificate, the curriculum of which is created by the Ministry of Health, will be explained (by the Researcher). (2 hours) Skill training with Low Realism Simulation (1 hour) Basic CPR Manikin (classical training provided by the Ministry of Health),
62603157|NCT05207852||48 h group|Blood samples were taken 48 h after dexamethasone administration
62603158|NCT02687906|EXPERIMENTAL|Single dose IV meropenem-vaborbactam|"Vabomere (meropenem-vaborbactam) for IV injection will be administered as a single dose diluted in normal saline infused IV over 3 hours~* Cohort 1 (n=8): 12 to \< 18 years of age (40 mg/kg)~* Cohort 2 (n=8): 6 to \< 12 years of age (40 mg/kg)~* Cohort 2b (n=4): 6 to \< 12 years of age (60 mg/kg)~* Cohort 3 (n=8): 2 to \< 6 years of age (60 mg/kg)~* Cohort 4 (n=8): 3 months to \< 2 years of age (60 mg/kg)~* Cohort 5 (n=24): Birth to \< 3 months of age (dose TBD)~  * Group A: Gestational Age (GA) \< 32 weeks, Postnatal Age (PNA) \< 2 weeks (n=6)~ * Group B: GA \< 32 weeks, PNA \> 2 weeks (n=6)~ * Group C: GA \> 32 weeks, PNA \< 2 weeks (n=6)~ * Group D: GA \> 32 weeks, PNA \> 2 weeks (n=6)~* Cohort 6 (n=7): 2 to \< 12 years of age and ≤ 35 kg of weight (80 mg/kg)"
62825645|NCT06169839|EXPERIMENTAL|Skills training with High Reality Simulation|the theoretical part of the TYD and OED training with Participation Certificate, the curriculum of which is created by the Ministry of Health, will be explained (by the Researcher). (2 hours) Skills training with High Reality Simulation (1 hour) SimMan® 3G (Laerdal medical)
62825646|NCT06169839|EXPERIMENTAL|Skill training will be given with Virtual Reality Application Supported Simulation|the theoretical part of the TYD and OED training with Participation Certificate, the curriculum of which is created by the Ministry of Health, will be explained (by the Researcher). (2 hours) Skill training will be given with Virtual Reality Application Supported Simulation (1 hour) and application training will be given with 3D MedSim.
62825647|NCT06036225|EXPERIMENTAL|Receiving the prehabilitation intervention|All participants will receive the prehabilitation intervention.
62825648|NCT01350947|EXPERIMENTAL|All patients|All participants enrolled.
62825649|NCT06590714|EXPERIMENTAL|Experimental(Acelex cap 2mg)|"Experimental Arm (Polmacoxib (Acelex cap 2mg) + Non-NSAID Non-Opioid or Opioid Analgesics(ULTRACET ER SEMI TAB))~1. Polmacoxib (preventive Acelex cap 2mg) administration, Method: One tablet orally once daily, regardless of meals."
62044032|NCT00769548|EXPERIMENTAL|Arm 2|Neoadjuvant TAS given 2 months before and during RT to the prostate only.
62825650|NCT06590714|ACTIVE_COMPARATOR|Active Comparator(NSAIDs-excluded non-opioid or opioid analgesics)|"Control Group (Administration of Non-NSAID Non-Opioid or Opioid Analgesics(ULTRACET ER SEMI TAB))~1. Non-NSAID Non-Opioid or Opioid Analgesics(ULTRACET ER SEMI TAB), Administration Method: PRN"
62825651|NCT00603408|EXPERIMENTAL|Cisplatin + Radiation + Recommended Surgery|"Cisplatin 75 mg/m\^2 IV Day 1 Week 1, Day 1 Week 2, Day 1 Week 7, Day 1 Week 10~Radiation = Total dose to breast or chest wall will be 50-60 Gy in 1.8-2.0 Gy daily fractions. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks.~Surgery (recommended) mastectomy with/without axillary lymph node dissection"
62825652|NCT06600516|ACTIVE_COMPARATOR|Stimulus Control|Stimulus control.45 People with insomnia may fail to associate the bedroom with sleep, and instead may associate it with worrying, planning, or recreation. Stimulus control includes the following instructions: (1) go to bed only when sleepy; (2) only use your bed or bedroom for sleep (or sex); (3) if you do not fall asleep quickly (i.e., 15 minutes), leave the bed, do something in another room, and return to bed only when you feel a strong sleep urge; (4) if you do not fall asleep quickly upon returning to bed, repeat instruction 3; (5) use your alarm to awaken at the same time every morning regardless of duration of sleep obtained; and (6) do not take long naps.
62825653|NCT06600516|ACTIVE_COMPARATOR|Sleep Restriction|Sleep restriction.46 People with insomnia often spend too much time awake in bed. Sleep restriction modifies the participant's sleep window so total time in bed is no more than 30 minutes beyond their average total sleep time to consolidate sleep, thus improving depth, continuity, and consistency. As the participant's sleep efficiency improves with treatment (i.e., the percentage of total time spent asleep within the sleep window), their sleep window is also increased. However, the shortened sleep window often causes increased anxiety.
62436854|NCT04283760||Healthy Group|"1. Demographic Information~2. Mental Chronometry Test~3. Movement Imagination Questionnaire- Revised Second~4. Beck Depression Inventory"
62044033|NCT00769548|EXPERIMENTAL|Arm 3|RT to the whole pelvis followed by a boost to the prostate followed by 4 months of TAS.
62044034|NCT00769548|EXPERIMENTAL|Arm 4|RT to the prostate only followed by 4 months of TAS.
62044035|NCT04674241|ACTIVE_COMPARATOR|DEX group|The DEX group will receives dexmedetomidine intraoperative.
62044036|NCT04674241|PLACEBO_COMPARATOR|Placebo group|The placebo group will receives 0.9% saline intraoperative.
62044037|NCT04979559|EXPERIMENTAL|mHealth apps|The participants in this arm will receive information regarding mobile health applications used for screening and early intervention of the prediabetic states.
62436855|NCT04283760||Acute Stroke Patients|"1. Demographic Information~2. Mental Chronometry Test~3. Movement Imagination Questionnaire- Revised Second~4. Beck Depression Inventory~5. Trail Making Test~6. Barthel Index~7. Motor Assessment Scale~8. Trunk Impairment Scale~9. Mini Mental Test~10. Glaskow Coma Scale"
62603159|NCT02322502|EXPERIMENTAL|desflurane|Suprane® Dose: 0.8 MAC / 4-5 vol. % Mode of administration: inhalation with laryngeal mask One application
62246538|NCT01067755||Bronchoscopy, lung neoplasm|Patients who have been recommended for bronchoscopy for the purpose of obtaining a biopsy sample of a central or peripheral pulmonary lesion, diagnosing mediastinal or hilar lymphadenopathy or for lung fiducial placement.
62246539|NCT05672472|EXPERIMENTAL|Sivelestat sodium|The patients in the test group were given 0.2 mg/kg. h of sivelestat sodium (0.1 g/tube, Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.) (the daily dose was added to 250 ml of 0.9% sodium chloride) intravenously for 24 hours and 5 consecutive days.
62436856|NCT02685605|EXPERIMENTAL|Experimental Arm (A)|Standard surgery plus intraoperative radiotherapy (20-30 Gy) followed by radiochemotherapy (EBRT: 60 Gy, 75 mg/m2/d temozolomide) and adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
62436857|NCT02685605|ACTIVE_COMPARATOR|Control Arm (B)|Standard surgery followed by radiochemotherapy (EBRT: 60 Gy, 75 mg/m2/d temozolomide) and adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
62436858|NCT04543045||Stage 1|20 patients will be interviewed once, which will be approximately 60 minutes in duration. The interviews will be audio recorded.
62436859|NCT04543045||Stage 2|Five patients who participated in stage 1 will take part in a cognitive interview, which will be approximately 60 minutes in duration.The interviews will be audio recorded.
62436860|NCT05326152|EXPERIMENTAL|IntralesionaL Hepatitis B vaccine|0.2 ml of hepatitis B vaccine injected in the largest wart and repeated every 2 weeks till clearance of warts or for a maximum of 5 sessions
62825654|NCT06600516|ACTIVE_COMPARATOR|Sleep Compression|Sleep compression.47,48 Sleep compression encourages time-in-bed restrictions. Unlike sleep restriction, sleep compression allows a gradual reduction in time-in-bed over the course of multiple weeks. Typically, average total sleep time and total time in bed values are calculated from one or more weeks of daily sleep diaries. The difference between these two values is then divided by the number of weeks remaining and the allotted time in bed duration is compressed by this calculated value weekly, by delaying bedtime or advancing wake time.
62436861|NCT05326152|EXPERIMENTAL|Intramuscular Hepatitis B vaccine|"0.5 ml injected in the deltoid muscle for those who were younger than 19 years at the time of study and 1 ml for those who were 20 years and older at the time of study.~Three injections were done at 0, 1, and 4 months."
62825655|NCT06600516|NO_INTERVENTION|Waitlist Control|Waitlist Control. Those randomly assigned to the WLC group will be told that they must wait 4 weeks for treatment, which is a fraction of the typical wait period in routine clinical care. During this time the participants are asked to maintain their regular schedule. At the end of 4 weeks, they will complete the baseline assessments again, which will serve as the post-waitlist assessment and then scheduled with a clinician to receive CBTi.
62436862|NCT05326152|PLACEBO_COMPARATOR|Intralesional saline|0.2 ml of saline injected in the largest wart and repeated every 2 weeks till clearance of warts or for a maximum of 5 sessions
62603160|NCT02322502|ACTIVE_COMPARATOR|sevoflurane|"Sevoflurane:~Dose: 0.8 MAC / 1.2-1.4 vol.% Mode of administration: inhalation with laryngeal mask One application"
62603161|NCT02322502|ACTIVE_COMPARATOR|propofol|Propofol Dose: 5-7 mg kg-1 h-1 to maintain a BIS index value between 40 and 60 Mode of administration: intravenous One application
62246540|NCT05672472|PLACEBO_COMPARATOR|sodium chloride|The patients in the control group were given 250 ml 0.9% sodium chloride (250ml/bag, Jilin Dubang Pharmaceutical Co., Ltd.) by intravenous pump for 24 hours and 5 consecutive days.
62246541|NCT02798822|ACTIVE_COMPARATOR|RME on upper first permanent molars|Intervention/Procedure: Rapid maxillary expansion. When RME was in situ, patients started the screw activation (Snap-lock expander screw, Forestadent, Pforzheim, Germany) of one-quarter turn a day (0.22 mm) until overcorrection was achieved (ie, the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp), and the RME remained in place for 10 months. The screw was turned for 35 ± 6 days for Gr6, and the average treatment time was 12 ± 1.3 months.
62436863|NCT06189261||Patients with stage 1/2 malignant melanoma|During the study, two intervention consultations will take place 1 and 3 months after the initial clinical team meeting, where each participant's case will be discussed. At the start of each intervention consultation, patients will be asked to complete the intervention questionnaire. The recorded information will be passed to their nurse specialist, who will identify the participant's needs and offer tailored advice and support to meet these needs. Throughout the study, participants will also be asked to complete a set of questionnaires in the clinic (months 1 and 3) or at home (months 2 and 4) to explore potential effects of the intervention.
62436864|NCT00303992|EXPERIMENTAL|Trastuzumab and Irinotecan|
62436865|NCT01186783|NO_INTERVENTION|standard treatment|All patients receive established medical therapy according to current guidelines and therapeutic standards.
62436866|NCT01186783|ACTIVE_COMPARATOR|ivabradine (add-on)|Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.
62436867|NCT02140073|EXPERIMENTAL|omeprazole+domperidone SR|patients with GERD receive omeprazole 20mg + domperidone SR 30mg , 2 capsules in the morning
62825656|NCT06240260|EXPERIMENTAL|TENS unit|Patients who choose to use a TENS unit for their IUD insertion procedure
62246542|NCT02798822|ACTIVE_COMPARATOR|RME on upper second deciduous molars|Intervention/Procedure: Rapid maxillary expansion. When RME was in situ, patients started the screw activation (Snap-lock expander screw, Forestadent, Pforzheim, Germany) of one-quarter turn a day (0.22 mm) until overcorrection was achieved (ie, the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp), and the RME remained in place for 10 months. The screw was turned for 41 ± 8 days, and the average treatment time was 12 ± 1.3 months.
62436868|NCT02140073|ACTIVE_COMPARATOR|omeprazole|omeprazole 40mg in the morning
62436869|NCT01422733|EXPERIMENTAL|hydrocortisone, dexamethasone, Cosyntropin (ACTH), rhCG|12 weeks hydrocortisone, dexamethasone, and Cosyntropin (ACTH) to perform standardized adrenal stimulation testing; dexamethasone, and rhCG to perform standardized ovarian stimulation testing
62436870|NCT02162329|OTHER|Healthy Control Group|Healthy participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete. Electroencephalography (EEG) and magnetic resonance imaging (fMRI) scan performed. These should take a total of about 90 minutes to complete.
62436871|NCT02162329|EXPERIMENTAL|Tibetan Meditation Group|Participants fill out several questionnaires at baseline, at completion of meditation classes, and at follow up visit. The forms should take about 30 minutes to complete. Participants complete computer tests to check memory and concentration taking about 20 minutes to complete. Electroencephalography (EEG) performed at baseline, at completion of classes, and at follow up visit. Participants have magnetic resonance imaging (fMRI) scan of brain at baseline, at completion of meditation classes, and at follow up visit. Tests, EEG, and fMRI should take a total of about 90 minutes to complete. Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
62436872|NCT02162329|OTHER|Wait-List Group|"Participants fill out several questionnaires at baseline and at follow up visit. The forms should take about 30 minutes to complete. Participants complete computer tests to check memory and concentration taking about 20 minutes to complete. Tests, EEG, and fMRI should take a total of about 90 minutes to complete. Participants receive the standard of care for cancer patients.~After 8 week follow up visit, Wait-List Group offered meditation program."
62436873|NCT05809583||ozanimod|Patients with UC starting ozanimod therapy as part of their clinical care
62436874|NCT01672372|PLACEBO_COMPARATOR|Placebo Max Stress B|oil/water emulsion with food coloring to simulate actual product
62436875|NCT01672372|EXPERIMENTAL|Max Stress B|whole-nutrient natural source extract from probiotic colonies that contains vitamins B1, B2, B5, B6, B12, and folate, PABA, biotin, inositol, purified water and certified organic alcohol.
62436876|NCT00384891|EXPERIMENTAL|Synergo + MMC|Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
62436877|NCT00384891|ACTIVE_COMPARATOR|Bacillus Calmette-Guérin|Intravesical instillation with BCG (Bacillus Calmette-Guérin)
62436878|NCT05903599|EXPERIMENTAL|Group A|anodal Transcranial direct current stimulation with saline soaked sponges will be used on electrodes, for 20 mins in addition to the 60 mins of conventional treatment.
62436879|NCT05903599|SHAM_COMPARATOR|Group B|A sham stimulation will be given. It will be comprised 20 min of sham TDCS followed by 60 mins of conventional treatment for postural stability in sub-acute stroke
62436880|NCT05946642|EXPERIMENTAL|Sulphadoxine-Pyrimethamine/Amodiaquine (SPAQ)|"SPAQ treatment will be given according to child's age. Dispersible tablets of sulphadoxine-pyrimethamine (SP) will be given on day 1 only.~Dispersible tablets of amodiaquine (AQ) which will be given once a day for 3 days.~The full 3-day course will be administered each month under directly observed therapy (DOT)."
62436881|NCT05946642|EXPERIMENTAL|Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM)|"DP will be available as tablets of 320/40mg and 160/20mg piperaquine/dihydroartemisinin per tablet. DP will be given once daily for 3 days and according to body weight.~IVM will be given at 300-400μg/kg/day over 3 days (to the nearest whole tablet). IVM will also be taken on an empty stomach with water.~Ivermectin will be available as 3 mg or 6 mg tablets to be administered at the doses of 300- 400μg/kg/day for 3 days (to the nearest whole tablet). IVM should also be taken with water on an empty stomach."
62825657|NCT06240260|ACTIVE_COMPARATOR|Standard care|Patients who decline to use a TENS unit for their IUD insertion procedure
62825658|NCT06585397||Upper extremity evaluation of children with quadriparetic CP|Within the framework of ICF, the Modified Ashworth Scale, the Manual Ability Classification System and the Functional Independence Measure for Children will be applied to 20 quadriparetic children with CP.
62825659|NCT06100809|ACTIVE_COMPARATOR|Control|No coaching provided. Nutrional handout only
62825660|NCT06100809|EXPERIMENTAL|Intervention|Coaching provided. Nutrition handout also provided
62825661|NCT05458128|OTHER|Pitolisant|Week 1: 8.9 mg pitolisant administered once daily in the morning upon wakening; Week 2: 17.8 mg pitolisant administered once daily in the morning upon wakening; Weeks 3 through end of treatment: 17.8 mg to 35.6 mg pitolisant administered once daily in the morning upon wakening.
62044038|NCT04979559|ACTIVE_COMPARATOR|Standard care|The participant in this arm will receive regular practice or standard care of screening and early intervention of prediabetic state.
62044039|NCT02123108|EXPERIMENTAL|Basiliximab|Tacrolimus with Basiliximab induction
62044040|NCT02123108|ACTIVE_COMPARATOR|Tacrolimus Group|Tacrolimus (without basiliximab induction); standard of care group
62044041|NCT04818580|EXPERIMENTAL|Right-Sided Progressive Tension Sutures|
62044042|NCT04818580|ACTIVE_COMPARATOR|Left-Sided Progressive Tension Sutures|
62246543|NCT02619968|EXPERIMENTAL|Experimental group|"Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application.~Application of the tourniquet Will be held in conjunction with exercises for the experimental group.~Tennis ball: will initially be 3 sets, where one series with 10 grips, increasing 5 grips every week, 60 seconds rest every series.~Halter: are performed with load of 1 kg, 2 kg and 3 kg. Handgrip: they will be performed 3 sets of dynamic manual hold exercises in the intensity of 40% of MVC.~Home program: at home will be performed isometric exercises with tennis ball on the same frequency as in performing ambulatory without applying the tensiometer."
62246544|NCT02619968|SHAM_COMPARATOR|Group control|Will be held the same isometric and isotonic concentric ambulatory and home with the same duration, frequency and intensity, except is not to apply the tourniquet.
62246545|NCT04569409|EXPERIMENTAL|ALLO-ASC-DFU|Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
62246546|NCT04569409|PLACEBO_COMPARATOR|Vehicle sheet|Hydrogel sheet without allogenic mesenchymal stem cell
62825662|NCT02780843|EXPERIMENTAL|Computerized Tomography|Patients will be examined with Computerized Tomography (CT) at admission
62246547|NCT04697043|EXPERIMENTAL|systemic therapy followed by surgery|"ُThe main intervention is surgery. After the diagnosis of primary distant metastatic breast cancer, patients will be randomly allocated into two groups: A. systemic therapy followed by surgery if the disease is not progressive; B. Systemic therapy Patient selection criteria~The eligibility criteria for the study are:~- primary distant metastatic breast cancer (M1); - an anticipated survival of at least 6 months; - a histologically proven diagnosis of the breast tumor; - a known hormonal and HER2Neu status; - TNM classification: T1-T3, resectable T4 status, and N0-N3; - performance status and comorbidity should allow surgery and/or systemic therapy; - age ≥ 18 years;- written informed consent."
62246548|NCT04697043|NO_INTERVENTION|Systemic therapy|"After the diagnosis of primary distant metastatic breast cancer, patients will be randomly allocated into two groups: A. systemic therapy followed by surgery if the disease is not progressive; B. Systemic therapy Patient selection criteria~The eligibility criteria for the study are:~- primary distant metastatic breast cancer (M1); - an anticipated survival of at least 6 months; - a histologically proven diagnosis of the breast tumor; - a known hormonal and HER2Neu status; - TNM classification: T1-T3, resectable T4 status, and N0-N3; - performance status and comorbidity should allow surgery and/or systemic therapy; - age ≥ 18 years;- written informed consent."
62436882|NCT05946642|NO_INTERVENTION|Control|The control/standard of care arm will consist of the standard malaria control measures provided by the malaria programme, including case management and long-lasting insecticidal nets (LLINs).
62825663|NCT02780843|EXPERIMENTAL|Magnetic Resonance Imaging|Patients will be examined with Magnetic Resonance Imaging (MRI) at admission
62825664|NCT05972317|NO_INTERVENTION|Non-IBS|Participants which are not suffering from IBS symptoms.
62825665|NCT05972317|EXPERIMENTAL|IBS -low FODMAP|individuals that are diagnosed with IBS according to Rome IV criteria
62825666|NCT05972317|NO_INTERVENTION|FODMAP graduates|Individuals who have practiced a low-FODMAP diet in the past
62825667|NCT06603935|NO_INTERVENTION|Standard Care (STC) group|Participants in this arm will receive the current standard of care for managing allergic rhinitis, which includes clinical evaluations, diagnosis, and treatments based on the healthcare provider's assessment. Treatment options may include medications such as intranasal corticosteroids, antihistamines, or decongestants, as typically prescribed for allergic rhinitis management. The standard care group will not have access to the digital tools provided in the experimental arm, but their care will follow established guidelines and practices for allergic rhinitis management.
62825668|NCT06603935|EXPERIMENTAL|Standard Care plus Digital Tools (QHSLab with AME and ARIS) group|Participants in this arm will receive the standard care for managing allergic rhinitis, which includes regular clinical evaluations and treatments as determined by their healthcare provider. In addition, they will be provided access to the QHSLab digital platform, which includes the Allergy Management Evaluation (AME) and Allergic Rhinitis Intervention Steps (ARIS) tools. These tools will offer continuous symptom monitoring, medication reminders, and personalized feedback based on patient-reported data. The intervention aims to improve symptom management, medication adherence, and quality of life over the 12-month follow-up period.
62825669|NCT06246084|EXPERIMENTAL|Group A: Endocrine Therapy Education Intervention|"Participants will complete:~* Baseline visit.~* Educational video once a week for 6 weeks.~* 6-week survey.~* 3-month survey."
62825670|NCT06246084|NO_INTERVENTION|Group B: Wait-List Control Group|"Participants will complete:~* Baseline visit.~* 6-week survey.~* 3-month survey.~* Access to intervention educational videos.~* 2-week post video survey."
62825671|NCT06593015||Prospective cohort: Department of Translational and Precision Medicine, Sapienza University of Rome|The prospective cohort in this study consists of patients with cirrhosis who were prospectively enrolled from 26 different centres across Italy (EpatoSarco groups) between January 2019 and January 2020. The cohort includes a total of 447 patients aged between 40 and 75 years, who underwent abdominal CT scans for various clinical indications. The results of the original study were already published in May 2024.
62044043|NCT01206998|EXPERIMENTAL|Vaginal progesterone gel|
62044044|NCT01206998|PLACEBO_COMPARATOR|Placebo vaginal gel|
62246549|NCT00002920|ACTIVE_COMPARATOR|Tamoxifen alone|Tamoxifen alone x 5 years
62246550|NCT00002920|EXPERIMENTAL|Tamoxifen plus MPA|Tamoxifen Plus Medroxyprogesterone Acetate (MPA) x 5 years
62246551|NCT03948633|EXPERIMENTAL|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/fear/fainting mitigation interventions from CARD during vaccination).
62603162|NCT00602433||questionnaire and laboratory biomarker analysis|Subjects with advanced non-small cell lung cancer and take erlotinib as part of their anticancer therapy for at least 3 months. Subjects have had some changes in hair growth, acne or menses (periods) that might be a side effect of erlotinib. Subjects will complete a questionnaire and blood collected for biomarker analysis.
62603163|NCT02823834||PROFEMUR® Gladiator Plasma Femoral Stems|Single study group either previously implanted with the following combination of components: PROFEMUR® Gladiator Plasma Femoral Stems, PROCOTYL® L Beaded Acetabular Shells, Polyethylene or Ceramic Liners, and Metal or Ceramic Femoral Heads.
62603164|NCT01771601||Near-infrared spectroscopy sensors|Term infants born by elective Caesarean section
62603165|NCT06197412|NO_INTERVENTION|control group 1|The optimal clinical treatment scheme was used to treat the wound of progressive infection period patients for 2 weeks
62603166|NCT06197412|EXPERIMENTAL|powder group 1|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder was used to treat the wound of progressive infection period patients for 2 weeks
62603167|NCT06197412|EXPERIMENTAL|ointment group 1|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao ointment was used to treat the wound of progressive infection period patients for 2 weeks
62603168|NCT06197412|NO_INTERVENTION|control group 2|The optimal clinical treatment scheme was used to treat the wound of granulation period patients for 2 weeks
62825672|NCT06593015||Retrospective group: University of Alberta, Edmonton, Alberta, Canada|The retrospective cohort in this study comprises patients with cirrhosis who were evaluated for liver transplantation (LT) at the University of Alberta Hospital in Canada. This cohort includes 1,104 patients who underwent CT imaging as part of their LT evaluation between January 2000 and August 2021. After applying specific exclusion criteria, 863 patients were ultimately included in the analysis. The results of the original study were already published in Apr 2022
62825673|NCT05030155|EXPERIMENTAL|Patients with FFS=0 - Mepolizumab|Mepolizumab 300mg every 4 weeks until D336
62825674|NCT05030155|PLACEBO_COMPARATOR|Patients with FFS=0 - Placebo|Placebo of Mepolizumab every 4 weeks until D336
62246552|NCT03948633|NO_INTERVENTION|Control|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting).
62246553|NCT02946632|EXPERIMENTAL|Triple combination therapy group|Xigduo (metformin 1000mg + dapagliflozin 10mg), saxagliptin 5mg once daily for 104 weeks
62246554|NCT02946632|ACTIVE_COMPARATOR|Stepwise add-on therapy group|"* Participants were started on metformin 1000mg once daily after screening \& assignment~* At each visits, FPG and HbA1c are measured. Sequential add-on therapy regimen is described"
62603169|NCT06197412|EXPERIMENTAL|powder group 2|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder was used to treat the wound of granulation period patients for 2 weeks
62603170|NCT06197412|EXPERIMENTAL|ointment group 2|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao ointment was used to treat the wound of granulation period patients for 2 weeks
62603171|NCT02189018|ACTIVE_COMPARATOR|Control|Ad lib activity at home
62603172|NCT02189018|EXPERIMENTAL|Active Exercise|Active exercise on treadmill
62603173|NCT02189018|EXPERIMENTAL|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
62603174|NCT02189018|EXPERIMENTAL|Weight loss and active exercise|Weight loss plus active exercise on treadmill
62603175|NCT06532136|ACTIVE_COMPARATOR|Deucravacitinib|Participants receiving 6mg deucravacitinib once daily for 8 weeks. Participants previously randomized to deucravacitinib will continue to receive deucravacitinib for an additional 8 weeks until Week 16.
62603176|NCT06532136|ACTIVE_COMPARATOR|Placebo then Deucravacitinib|Participants receiving placebo once daily for 8 weeks. At week 8, those participants originally randomized to placebo will initiate dosing with 6mg deucravacitinib once daily for 8 weeks until Week 16.
62603177|NCT00595114||MIA 1|Participants from the MIA trial who are polymerase chain reaction (PCR) negative and have received treatment with placebo
62603178|NCT00595114||MIA 2|Participants from the MIA trial who are PCR negative and have received treatment with the antibiotic clarithromycin
62603179|NCT00595114||MIA 3|Participants from the MIA trial who are PCR positive and have received treatment with placebo
62603180|NCT00595114||MIA 4|Participants from the MIA trial who are PCR positive and have received treatment with the antibiotic clarithromycin
62603181|NCT00595114||LEUKO 1|Participants from the LEUKO trial who have received treatment with placebo
62603182|NCT00595114||LEUKO 2|Participants from the LEUKO trial who have received treatment with zileuton
62603183|NCT02811588||Phase1:Screening phase: normocapnic group|Normocapnic COPD patients
62825675|NCT05030155|EXPERIMENTAL|Patients with FFS≥1 - Mepolizumab|Mepolizumab 300mg every 4 weeks until D336 and placebo of Azathioprine 1mg/kg/day from D126 until D360 and placebo of cyclophosphamide/mesna at D1, D15, D28, D56, D84 and D112
62825676|NCT05030155|PLACEBO_COMPARATOR|Patients with FFS≥1 - Placebo|Placebo of Mepolizumab every 4 weeks until D336, cyclophosphamide and mesna at D1, D15, D28, D56, D84 and D112 and Azathioprine 1mg/kg/day from D126 until D360
62603184|NCT02811588||Phase1;Screening phase: hypercapnic group|Hypercapnic COPD patients
62825677|NCT02938299|EXPERIMENTAL|Arm 1: neoadjuvant + surgery|"Patients in Arm 1 will receive multiple intratumoral administrations into all injectable cutaneous, subcutaneous, and nodal tumors of a mixture of L19IL2 and L19TNF once weekly for up to 4 weeks (or until all injectable tumors have disappeared, or intolerance to study treatment or in the opinion of the investigator immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first).~Newly occurring injectable melanoma lesions within the 4 weeks treatment period will also be treated as described. Surgical resection of all existing metastases will follow within 4 weeks after end of treatment. Surgery will be performed after the safety evaluation carried out at week 5 and, if indicated, may be carried out on the same day of the safety evaluation."
62825678|NCT02938299|ACTIVE_COMPARATOR|Arm 2: surgery alone|Patients in Arm 2 will receive directly surgical resection of melanoma tumor lesions within 4 weeks after randomization.
62246555|NCT06499025|EXPERIMENTAL|targeted AML1-ETO neoantigen cytotoxic T cells (CTL)|The escalating doses of cells (CTL) in this study will be 5\*10\^7 cells and 1\*10\^8 cells.
62246556|NCT06302647||Questionnaire for subjects|Questionnaire will be provided to general subjects anonymously to gain knowledge on their willigness to use a platform to look for early phase clinical trials.
62246557|NCT06302647||Questionnaire for pharma/biotech industry|Questionnaire will be provided to Pharma/biotech industry anonymously to gain knowledge on their willigness to use a platform to promote the recruitment in early phase clinical trials.
62246558|NCT06302647||Questionnaire for doctors|Questionnaire will be provided to Pharma/biotech industry anonymously to gain knowledge on their willigness to use a platform to have information and promote the recruitment in early phase clinical trials.
62436883|NCT05474612|EXPERIMENTAL|kinesiology taping with conventional therapy|"Patients in group A is treated with conventional treatment (include stretching exercises of SCM, Scaleni and upper fibers of trapezius followed by strengthening (isometrics) of Neck flexors (SCM, rectus capitis, anterior and longus capitis) and then with kinesiology taping.~Two pieces of the tape cutted in a Y-shape. Applied on deep cervical extensors and upper fibers of trapezius."
62825679|NCT06491238|EXPERIMENTAL|Light intensity Exercise|Aerobic intensity levels: Heart rate reserve (HRR) 30-39%, 9-11 Borg Rate of Perceived Exertion (RPE) Strength intensity levels: %One Repetition Max (1RM) 40-50%, OMNI RPE 1-4
62246559|NCT02367066|EXPERIMENTAL|AR-C165395XX + placebo|1st period AR-C165395XX 2nd period placebo
62825680|NCT06491238|EXPERIMENTAL|Moderate intensity Exercise|Aerobic intensity levels: HRR 40-59%, 12-13 Borg RPE Strength intensity levels: %1RM 60-80%, OMNI RPE 5-6
62246560|NCT02367066|PLACEBO_COMPARATOR|Placebo + AR-C165395XX|1st period Placebo for AR-C165395XX 2nd period AR-C165395XX
62246561|NCT02887872|EXPERIMENTAL|Pilot data|Four participants with chronic stroke participated in a 45-minute combined electrical stimulation-dynamic hand orthosis regimen using the affected upper extremity (UE) 5X/week for 6 weeks.
62246562|NCT05933161||Left Ventricular Assist Device (LVAD) supported Type 2 Diabetes Mellitus (T2DM) Subjects|Subjects diagnosed with T2DM who have a LVAD will be provided a Freestyle Libre 3 CGM.
62246563|NCT05558306|OTHER|Treatment protocol|All patients were treated according to the treatment protocol with cast for minimally displaced fractures and surgery for displaced fractures.
62825681|NCT06594952||minor anomalies group|pregnant women with minor fetal structural anomaly detected by ultrasound.
62825682|NCT06594952||major anomalies group|pregnant women with major fetal structural anomaly detected by ultrasound
62825683|NCT06594952||Control Group|Pregnant women with normal ultrasound.
62825684|NCT06166992|EXPERIMENTAL|BI 1291583 alone (not radio-labelled, low dose) then [14C]-BI 1291583 (radio-labelled)|
62825685|NCT06166992|EXPERIMENTAL|BI 1291583 alone (not radio-labelled, high dose) then [14C]-BI 1291583 (radio-labelled)|
62825686|NCT00289653|EXPERIMENTAL|single open-label treatment arm|Adult smokers willing to quit were treated with escalating doses of transdermal nicotine patch (Nicoderm) and brief counselling if they continued to smoke over a 9-week treatment period.
62825687|NCT00570115||A|The subjects for this group are matched for age, gender, body mass index. The presence of obstructive sleep apnea will divide the cohort in 02 subgroups: non-Obstructive Sleep Apnea and Obstructive Sleep Apnea
62825688|NCT04919109|PLACEBO_COMPARATOR|Placebo comparator|Administered as nose drops
62246564|NCT02208297|EXPERIMENTAL|Loteprednol Etabonate Gel (BID)|Loteprednol Etabonate Gel 0.38% administered two times daily (BID)
62436884|NCT05474612|ACTIVE_COMPARATOR|Instrument Assisted Soft Tissue Mobilization with Conventional therapy|"Patients in group B is treated with conventional treatment (stretching exercises of SCM, Scaleni and upper fibers of trapezius followed by strengthening (isometrics) of Neck flexors (SCM, rectus capitis, anterior and longus capitis) and then with Instrument Assisted soft tissue mobilization technique.~IASTM using tools over the length of targeted muscles (SCM, descending fiber of trapezius, suboccipitalis muscles) in a multidirectional stroking fashion applied to the skin at 30°- 60° for 5 minutes."
62825689|NCT04919109|EXPERIMENTAL|Experimental: CodaVax-RSV 10^6 PFU|Respiratory syncytial virus live attenuated vaccine against RSV administered as nose drops
62825690|NCT04919109|EXPERIMENTAL|Experimental: CodaVax-RSV 10^5 PFU|Respiratory syncytial virus live attenuated vaccine against RSV administered as nose drops
62449182|NCT02918162|EXPERIMENTAL|Pembrolizumab|"All study subjects will receive standard of care chemotherapy regimen for 3 cycles prior to and 3 cycles following surgery in combination with Pembrolizumab with an additional cycle of Pembrolizumab (4 total) in the pre-operative period. Additionally subjects will complete 12 months of maintenance Pembrolizumab (14 additional doses to complete 17 post-operative cycles) following completion of post-operative chemotherapy.~Standard of care combination chemotherapy regimen has a 21-day cycle."
62825691|NCT04919109|EXPERIMENTAL|Experimental: CodaVax-RSV 10^4 PFU|Respiratory syncytial virus live attenuated vaccine against RSV administered as nose drops
62246565|NCT02208297|PLACEBO_COMPARATOR|Vehicle Gel (BID)|Vehicle gel administered two times daily (BID)
62246566|NCT02434445||Hepatorenal syndrome group|Patients with advanced cirrhosis who develope hepatorenal syndrome
62246567|NCT02434445||Non-hepatorenal syndrome group|Patients with advanced cirrhosis who do not hepatorenal syndrome
62436885|NCT01538706|EXPERIMENTAL|Hospital-based home care|Patients were included if below the age of 18, had been diagnosed with any type of cancer at least one month prior to inclusion, on intravenous anticancer therapy with a curative intent, and the parent was fluent in speaking and reading Danish. Patients living within a radius of 50 kilometres from the hospital were assigned to the home care program. Moreover, patients were assigned to one of three groups according to the geographical distance from the hospital and timing of the inclusion period: (1) home care group if participating in the program, (2) historical standard care group for an eight-month period before the program started regardless of their residence distance from the hospital, and (3) concurrent standard care group if living more than 50 km from the university hospital.
62436886|NCT00072033|ACTIVE_COMPARATOR|Arm A|Docetaxel and Cisplatin chemo- and radiochemotherapy followed by surgery
62825692|NCT04919109|EXPERIMENTAL|Experimental: CodaVax-RSV 10^3 PFU|Respiratory syncytial virus live attenuated vaccine against RSV administered as nose drops
62825693|NCT06345690||VIA Disc NP|Patients meeting study criteria receiving Vivex VIA Disc NP injection as treatment
62436887|NCT03872271|EXPERIMENTAL|Experimental|ileal pouch-anal anastomosis without diverting loop ileostomy
62825694|NCT04662021|EXPERIMENTAL|Exercise group|
62436888|NCT03872271|ACTIVE_COMPARATOR|Control|ileal pouch-anal anastomosis with diverting loop ileostomy
62246568|NCT01560923|EXPERIMENTAL|Sipuleucel-T + Oral Indoximod|Oral Indoximod will be self-administered by mouth twice daily (1200 mg) for 6 months starting after the last (3rd) infusion of sipuleucel-T. Indoximod is a sterile tan powder compounded in capsule form of 200 mg.
62246569|NCT01560923|PLACEBO_COMPARATOR|Sipuleucel-T + Placebo|Placebo is identical-looking to Indoximod and provided in the same manner.
62246570|NCT01290705|EXPERIMENTAL|high exercise|High dose, high repetition exercise therapy, 3 times weekly in 12 weeks
62246571|NCT01290705|EXPERIMENTAL|low exercise|low dose, low repetition exercise therapy, 3 times weekly in 12 weeks
62246572|NCT01573078||Crohn's disease patient|Outpatients who carry a diagnosis of Crohn's disease made by a gastroenterologist.
62825695|NCT04662021|EXPERIMENTAL|Cognitive therapy group|
62825696|NCT06598501|EXPERIMENTAL|rTMS and CBT|During 5 weeks of therapy, the subjects will undergo 12 CBT sessions (30-40 minutes) combined with 15 rTMS procedures (20 minutes).
62825697|NCT02792686|EXPERIMENTAL|ABX464|50, 100, 150 or 200 mg once a day / Single Administration
62825698|NCT00546806|EXPERIMENTAL|1|"AVIVA Soft Tissue Injury Care Model"
62246573|NCT04775225|ACTIVE_COMPARATOR|Hip denervation group|This group will receive Lidocaine 2% block of the femoral and obturator genicular branches.
62246574|NCT04775225|PLACEBO_COMPARATOR|control group|this group will receive saline injection subcutaneously at the same places.
62246575|NCT04775225|ACTIVE_COMPARATOR|Steroid|This group with receiving an intra-articular injection of 80mg triamcinolone
62246576|NCT06494930|EXPERIMENTAL|F-IMT Group|Participants in this group will perform functional IMT under supervision 5 days a week. In functional IMT, the core stabilization exercise protocol will be applied at the same time as the participants practice the breathing exercise with the device.
62246577|NCT06494930|ACTIVE_COMPARATOR|Control Group|Participants in this group will also apply a core stabilization exercise protocol under supervision 5 days a week.
62246578|NCT05334017|ACTIVE_COMPARATOR|Xylometazoline|Xylometazoline 0,1% as nasal solution given immediately prior to nasal intubation
62246579|NCT05334017|ACTIVE_COMPARATOR|Cocaine|Cocaine 4% as nasal solution given immediately prior to nasal intubation
62246580|NCT00493220|EXPERIMENTAL|HYLENEX SC, Placebo SC, IV|subcutaneous HYLENEX and ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention
62825699|NCT00546806|EXPERIMENTAL|2|Pre-approved Framework Guideline for Grade I and II Whiplash Associated Disorders (PAF)
62825700|NCT00546806|ACTIVE_COMPARATOR|3|Physician-based Education and Activation
62825701|NCT05521607|OTHER|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|There is only one arm in this study which is to enable high qualitative estimation of bilirubin levels in the blood of new-borns, independent of skin color, using Picterus JP.
62044045|NCT02481310|EXPERIMENTAL|Treatment (combination chemotherapy, rituximab, ixazomib)|"INDUCTION:~Patients receive ixazomib citrate PO on day 1 and day 8 or 15; etoposide IV, vincristine sulfate IV, and doxorubicin hydrochloride IV continuously over 96 hours on days 1-4; prednisone PO BID on days 1-5; rituximab IV should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr on day 1; and cyclophosphamide IV over 90 minutes on day 5.~CNS PROPHYLAXIS:~Patients with a negative LP receive methotrexate IT once per course. Patients with a positive LP receive methotrexate IT or intraventricularly OR cytarabine IT or intraventricularly OR methotrexate IT or intraventricularly, cytarabine IT or intraventricularly, and therapeutic hydrocortisone IT or intraventricularly.~MAINTENANCE:~Patients not treated with consolidative SCT, receive ixazomib citrate PO BID on days 1, 8, and 15. Treatment repeats every 28 days for up to one year in the absence of disease progression or unacceptable toxicity."
62044046|NCT02366910|EXPERIMENTAL|omafilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
62044047|NCT02366910|ACTIVE_COMPARATOR|delefilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
62044048|NCT05524974|EXPERIMENTAL|Camrelizumab combined with Oxplatin and S-1 for Immune Genotypes|
62044049|NCT05524974|ACTIVE_COMPARATOR|Oxplatin and S-1 for Immune Genotypes|
62044050|NCT05524974|EXPERIMENTAL|Apatinib Mesylate combined with Oxplatin and S-1 for Mesenchymal Genotypes|
62044051|NCT05524974|ACTIVE_COMPARATOR|Oxplatin and S-1 for Mesenchymal Genotypes|
62044052|NCT05524974|EXPERIMENTAL|Nab-paclitaxel combined with Oxplatin and S-1 for Classic Genotypes|
62044053|NCT05524974|ACTIVE_COMPARATOR|Oxplatin and S-1 for Classic Genotypes|
62044054|NCT05524974|ACTIVE_COMPARATOR|Oxplatin and S-1 for Metabolic Genotypes|
62044055|NCT02824133|EXPERIMENTAL|AZD4547|AZD4547: intake of 80mg bd (160mg/day), on a continuous schedule.
62044056|NCT05330221|EXPERIMENTAL|Intervention Group|"PAL2 Intervention~Drug Therapy"
62044057|NCT05330221|NO_INTERVENTION|Usual Care Group|Participants that are randomized into usual care will be assisted with arrangement of follow-up, either with existing primary care provider (PCP) or a Wayne Health provider. All subsequent medical treatment will be at the discretion of the PCP.
62044058|NCT02481544|EXPERIMENTAL|Gratitude Journaling Plus Standard of Care|"The most often used gratitude intervention consists of journaling, writing lists of things for which the individual is grateful. This technique was first employed and found to be effectual for enhancing wellbeing by Emmons and McCullough and has been suggested to be as effective as methods frequently used in clinical therapy. We are proposing an 8-week intervention in which the participant records 3-5 things for which they are grateful most days of the week. A longer intervention was chosen because Emmons and McCullough (2003) suggest that healthy behavior changes only occurred in a prolonged multi-week intervention. To ensure some conformity in the intervention, instructions that will be used will be similar to Emmons and McCullough (2003): There are many things in our lives, both large and small, that we might be grateful about. Think back over your day (week) and write down on the lines below up to five things in your life that you are grateful or thankful for."
62603185|NCT02811588||Phase1:Treatment phase: control group|Hypercapnic COPD patients in whom NIV is not indicated or who have contraindication(s) for, or refuse, NIV treatment.
62825702|NCT06592859|EXPERIMENTAL|NMN Arm|NMN Arm participants took one capsule (containing 350mg NMN) with breakfast daily for one year.
62603186|NCT02811588||Phase1:Treatment phase: non-invasive ventilation group|Hypercapnic COPD patients in whom NIV is indicated and who accept NIV treatment.
62825703|NCT06592859|PLACEBO_COMPARATOR|Placebo Arm|Placebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.
62825704|NCT06084611|EXPERIMENTAL|Provox Life HME|Use of Provox Life HMEs and attachment
62825705|NCT06084611|NO_INTERVENTION|Control - No HME|Control group is current standard of Care in Brazil, which is not using an HME
62825706|NCT02698696|EXPERIMENTAL|ECo program|Objective: to inform the patient about cognitive impairments and their repercussions; to train the patient in problem-solving skills through exercises; to implement strategies in daily life Duration: three months Frequency: two one-hour individual sessions and one hour of at-home training per week Modalities: pen and paper exercises, tools (tokens, cards, maps, chessboard) Modules: Psychoeducation, Attention, Memory, Executive Functions, Functional Impairments
62044059|NCT02481544|SHAM_COMPARATOR|Memorable Events Journaling Plus Standard of Care|"In the sham control condition, individuals will record memorable events with methods identical to the gratitude journaling condition: Patients will be asked to record 3-5 memorable events in a given day, on most days of the week. Patients will be contacted once per week to remind them to continue with the memorable events journal. Patients will be given 2 journals during their first testing session (one journal is for the first four weeks and the second is for the second four weeks of journaling). Patients will be contacted once per week to remind them to continue with gratitude journal writing. Patients will be instructed to record the date of each journal entry next to each new day of journaling Patients will be provided with materials to return their first journal by mail and will and return their second journal at the T2 laboratory testing session."
62044060|NCT02481544|NO_INTERVENTION|Standard of Care|SOC consists of medical care that is included in post-MI treatment, such as physician visits and medication adjustments and cardiac rehabilitation. These patients will not have any active intervention, but will undergo the same testing routine as the gratitude intervention group. These patients will be given the opportunity to participate in the gratitude journaling intervention after they have completed the study. Patient records will be evaluated at each timepoint for changes in medications and medical treatment.
62044061|NCT04365764||Exposed to the treatment|Exposure variable will be studied treatment
62044062|NCT04365764||Not exposer to the treatment (control group)|
62436889|NCT02832297|OTHER|Vectra DA (Arm A)|Treatment intensification with non-biologic DMARDS guided by Vectra DA
62825707|NCT02698696|EXPERIMENTAL|CRT program|Objective: problem-solving skills training through exercises, in order to use strategies in daily life Duration: three months Frequency: two one-hour individual sessions and one hour of at-home training per week Modalities: pen and paper exercises Modules: Cognitive Flexibility, Working Memory, Planning
62603187|NCT03470428||Pediatric Fontan Patients|Participants ages 10 to 18 who have had Lateral Tunnel or Extracardiac Fontan procedures.
62044063|NCT02571517|EXPERIMENTAL|Glucocorticoids|"methylprednisolone intravenous administration of 2mg/kg/day (divided in two doses) and/or oral prednisolone 2,5 mg/kg/day (in two divided doses) during 7 days.~Patients younger than 2 year, who required hospitalization, affected by moderate or severe bronchiolitis"
62603188|NCT03470428||Adult Fontan Patients|Participants ages 18 to 60 who have had Lateral Tunnel or Extracardiac Fontan procedures.
62603189|NCT00489515||patients with gastrointestinal cancer scheduled for surgery|
62603190|NCT02428374|ACTIVE_COMPARATOR|rosuvastatin plus clopidogrel|rosuvastatin 40 mg and clopidogrel 75 mg
62603191|NCT02428374|ACTIVE_COMPARATOR|Rosuvastatin plus ticagrelor|Rosuvastatin 40 mg plus ticagrelor 90 mg bid
62603192|NCT02428374|ACTIVE_COMPARATOR|simvastatin plus clopidogrel|Simvastatin 40 mg plus clopidogrel 75 mg
62603193|NCT02428374|ACTIVE_COMPARATOR|Simvastatin plus ticagrelor|Simvastatin 40 mg plus ticagrelor 90 mg bid
62825708|NCT02698696|ACTIVE_COMPARATOR|Supportive psychotherapy|Individual psychotherapy sessions focussing on autonomy in daily life, management of mood disorders' cognitive and functional impact, social skills, and the regulation of sleep and daily activities.
62825709|NCT06588478|ACTIVE_COMPARATOR|Pirtobrutinib Standard Dose (Dose 1)|Pirtobrutinib administered orally.
62825710|NCT06588478|EXPERIMENTAL|Pirtobrutinib Dose 2|Pirtobrutinib administered orally.
62044064|NCT02571517|PLACEBO_COMPARATOR|Placebo|"will receive iv/oral glucose 5% solution as placebo of 2mg/kg/day and/or 2,5 mg/kg/day (divided in two doses) during 7 days.~Patients younger than 2 year, who required hospitalization, affected by moderate or severe bronchiolitis."
62436890|NCT02832297|OTHER|Usual care (Arm B)|Treatment intensification by usual care without using Vectra DA
62603194|NCT05217511|EXPERIMENTAL|NMSE Group|Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points starting on the first day of randomization.The subjects also receive conventional physical therapy, which included gross motor therapy and respiratory therapy twice a day every day during their stay in the ICU.
62603195|NCT05217511|NO_INTERVENTION|CPT group|The subjects only receive conventional physical therapy, which included gross motor therapy and respiratory therapy twice a day every day during their stay in the ICU.
62603196|NCT04303754|EXPERIMENTAL|Diabetes-Specific Formula|Diabetes-Specific Formula
62603197|NCT04303754|EXPERIMENTAL|Bread and Spread|White bread with spread
62603198|NCT04303754|EXPERIMENTAL|Rice Porridge|Rice Porridge
62603199|NCT01350440|EXPERIMENTAL|IVIG|Intravenous Immune Globulin
62603200|NCT05509764||group 0|control group
62603201|NCT05509764||group 3|3 Lt/min Oxygen therapy via nasal cannula
62603202|NCT05509764||group 6|6 Lt/min Oxygen therapy via Simple face mask
62603203|NCT04469673|EXPERIMENTAL|JS002|Participants received one of 3 dose regimens of JS002 administered as multiple subcutaneous doses.
62603204|NCT04469673|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo dose regimens by subcutaneous injection.
62603205|NCT02014220|EXPERIMENTAL|Atlantic Western chips|deep fried potato chips
62603206|NCT02014220|EXPERIMENTAL|Dakota Pearl chips|deep fried potato chips
62603207|NCT02014220|EXPERIMENTAL|Andover Ontario chips|deep fried potato chips
62603208|NCT02014220|EXPERIMENTAL|white bread with margarine|energy control
62603209|NCT02014220|EXPERIMENTAL|white bread|control
62603210|NCT04482244|EXPERIMENTAL|Cannabidiol|"After screening procedures confirm participation in the research study, participants will be randomized one of two groups:~* Participants in the experimental arm will complete questionnaires and then receive a single dose of CBD prior to diagnostic CT scan or positron emission tomography (PET) .~* Cannabidiol: Oral, per protocol dosage, single dose~* Additional questionnaires 2 hours post scan and follow up via phone call 1 week regarding experience"
62603211|NCT04482244|PLACEBO_COMPARATOR|Placebo|"After the screening procedures confirm participation in the research study, participants will be randomized one of two groups:~* Participants in the placebo arm will complete questionnaire and then receive a single dose of placebo prior to diagnostic CT scan or positron emission tomography (PET) .~* Placebo: Oral, per protocol dosage, single dose~* Additional questionnaires 2 hours post scan and follow up via phone call 1 week regarding experience"
62603212|NCT06228079|NO_INTERVENTION|The control group|Patients in the control group would go through observation and follow-up after recurrent endoscopic surgery.
62603213|NCT06228079|EXPERIMENTAL|The experimental group|Patients in the experimental group would be implemented with adjuvant therapy including chemotherapy and immunotherapy after endoscopic surgery.
62603214|NCT02026336|NO_INTERVENTION|enose|Electronic nose can discriminate the inflammatory asthma phenotypes, supporting their potential as a non-invasive alternative tool to induced sputum.
62603215|NCT04198285|EXPERIMENTAL|Retrograde filled|This arm will contain patients who had retrograde bladder filling upon completion of surgery with 200 milliliters (mL) of sterile saline.
62603216|NCT04198285|NO_INTERVENTION|Control|This arm will contain patients who simply had the urinary catheter removed upon completion of surgery, and were left with an empty bladder.
62825711|NCT06588478|EXPERIMENTAL|Pirtobrutinib Dose 3|Pirtobrutinib administered orally.
62603217|NCT03229629|EXPERIMENTAL|Maternal BCC only|Mothers with child under 20 months or pregnant will receive Behavior Change Communication (BCC)
62603218|NCT03229629|EXPERIMENTAL|Maternal BCC & Paternal BCC|"1. Mothers with child under 20 months or pregnant will receive BCC~2. Husband/partner of the enrolled mother will receive BCC \*BCC: Behavior Change Communication"
62603219|NCT03229629|EXPERIMENTAL|Food voucher|"1. Mothers or fathers with child under 20 months or pregnant will receive monthly food voucher worth 200 birr(\~$10)~2. Within household, recipient of voucher (mother or father) will be randomly selected.~   * Food voucher"
62603220|NCT03229629|EXPERIMENTAL|Maternal BCC & Food Voucher|"1. Mothers with child under 20 months or pregnant will receive BCC~2. Mothers or fathers with child under 20 months or pregnant will receive monthly food voucher worth 200 birr(\~$10)~3. Within household, recipient of voucher (mother or father) will be randomly selected.~   * BCC: Behavior Change Communication"
62825712|NCT06590857|EXPERIMENTAL|Dose Escalation|"RYZ101 Dose Level -1~RYZ101 Dose Level 1~RYZ101 Dose Level 2~RYZ101 Dose Level 3"
62825713|NCT06590857|ACTIVE_COMPARATOR|Randomization|"RYZ101 RP2D~RYZ101 RP2D + Pembrolizumab"
62825714|NCT06590857|EXPERIMENTAL|Expansion|RYZ101 RP2D Regimen
62825715|NCT04494672|EXPERIMENTAL|Intramedullary nailing with ADAPT system (arm-A)|A commercial product, namely ADAPT will be used as investigation product in arm-A
62044065|NCT00387582|EXPERIMENTAL|I|Lucentis injections for the first three months of the study and then per the protocol for the duration of the trial.
62044066|NCT00387582|ACTIVE_COMPARATOR|II|Argon Laser treatment at enrollment and then per the protocol for the duration of the study.
62044067|NCT01080508||group 1|asa 1\&2 patients
62044068|NCT01080508||group 2|asa 1\&2 patients
62825716|NCT04494672|ACTIVE_COMPARATOR|Intramedullary nailing without ADAPT system (arm-B)|No aid in performing intramedullary nailing for proximal femoral fractures will be implemented in arm-B
62825717|NCT06009939||Healthy men aged 20-30 years old|"Foot: 10 minutes of baseline measurement, 5 minutes of occlusion and 5 minutes of Post-occlusive reactive hyperemia (PORH) measurement.~Arm: 10 minutes of baseline measurement, 5 minutes of occlusion and 5 minutes of Post-occlusive reactive hyperemia (PORH) measurement."
62825718|NCT06009939||Healthy women aged 20-30 years old|"Foot: 10 minutes of baseline measurement, 5 minutes of occlusion and 5 minutes of Post-occlusive reactive hyperemia (PORH) measurement.~Arm: 10 minutes of baseline measurement, 5 minutes of occlusion and 5 minutes of Post-occlusive reactive hyperemia (PORH) measurement."
62246581|NCT00493220|EXPERIMENTAL|HYLENEX SC, IV, Placebo SC|subcutaneous HYLENEX and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention
62436891|NCT01494220||Living donor liver transplantation|Patients undergoing living donor liver transplantation in the Mansoura University Liver Transplantation Program from 2007 to 2010
62436892|NCT01207063|EXPERIMENTAL|Radiotherapy|
62436893|NCT04036578|OTHER|Pelvic Floor Dysfunction With and Without POP|group 1(Pelvic Floor Dysfunction Without POP Stage I\~II) and group 2(Pelvic Floor Dysfunction With POP Stage I\~II)
62436894|NCT03493698|EXPERIMENTAL|Treatment A: Midazolam|All subjects will receive a single oral dose of 2 mg Midazolam on Day 1
62825719|NCT06009939||Healthy men aged 50-60 years old|"Foot: 10 minutes of baseline measurement, 5 minutes of occlusion and 5 minutes of Post-occlusive reactive hyperemia (PORH) measurement.~Arm: 10 minutes of baseline measurement, 5 minutes of occlusion and 5 minutes of Post-occlusive reactive hyperemia (PORH) measurement."
62825720|NCT06009939||Healthy women aged 50-60 years old|"Foot: 10 minutes of baseline measurement, 5 minutes of occlusion and 5 minutes of Post-occlusive reactive hyperemia (PORH) measurement.~Arm: 10 minutes of baseline measurement, 5 minutes of occlusion and 5 minutes of Post-occlusive reactive hyperemia (PORH) measurement."
62436895|NCT03493698|EXPERIMENTAL|Treatment B and C: Inarigivir|All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3, Day 6-18
62436896|NCT03493698|EXPERIMENTAL|Treatment D: Inarigivir with Midazolam|All subjects will receive a single oral dose of 400 mg Inarigivir coa administered with a single oral dose of 2 mg Midazolam on Day 19
62825721|NCT01600326|ACTIVE_COMPARATOR|Tenotomy Group|Subject enrolled in this arm will receive treatment for tendinitis and pain evaluation of pain pre and post treatment.
62825722|NCT01600326|ACTIVE_COMPARATOR|Plasma Injection Group|Treatment is Ultrasound guided platelet rich plasma injection.
62825723|NCT01341834|EXPERIMENTAL|LBH589-RAD001|LBH589-RAD001, single arm dose finding study
62825724|NCT04976231||Treatment Naive|Subjects who are naïve to ERT and start treatment with idursulfase
62825725|NCT04976231||Treatment less than 3 years|Subjects who have received ERT for \<3 years
62825726|NCT04976231||Treatment over 3 years|Subjects who have received ERT for 3 or more years
62825727|NCT06252038|EXPERIMENTAL|Group Video Diabetes Prevention Program|Participants randomized to the group video DPP for 12-months.
62246582|NCT00493220|EXPERIMENTAL|Placebo SC, HYLENEX SC, IV|subcutaneous placebo and ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention
62246583|NCT00493220|EXPERIMENTAL|Placebo SC, IV, HYLENEX SC|subcutaneous placebo and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention
62246584|NCT00493220|EXPERIMENTAL|IV, HYLENEX SC, Placebo SC|IV ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention
62825728|NCT06252038|ACTIVE_COMPARATOR|Self Directed Diabetes Prevention Program|Participants randomized to the self directed DPP for 12-months.
62436897|NCT04525690|EXPERIMENTAL|HCV Screening Default-1 Hospital Crossed Over|Upon entering the admission order set in the EHR clinicians will receive a default order for HCV screening for eligible patients. Clinicians will have the opportunity to opt-out and not order screening
62436898|NCT04525690|EXPERIMENTAL|HCV Screening Default-2 Hospitals Crossed Over|Upon entering the admission order set in the EHR clinicians will receive a default order for HCV screening for eligible patients. Clinicians will have the opportunity to opt-out and not order screening.
62825729|NCT04091555|OTHER|Adult patients who suffer from symptoms of tension headaches|Patients will begin taking the capsules at the onset of headache symptoms.
62246585|NCT00493220|EXPERIMENTAL|IV, Placebo SC, HYLENEX SC|IV ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention
62246586|NCT03268733|EXPERIMENTAL|Treatment group|45 PCOS patients will receive 5 mg folic acid
62246587|NCT03268733|NO_INTERVENTION|control group|45 PCOS patients will receive no folic acid
62246588|NCT05555355|PLACEBO_COMPARATOR|Group 1 (control)|Retrospective control of patients who did not use Prevena following spine surgery.
62246589|NCT05555355|ACTIVE_COMPARATOR|Group 2 (Prevena)|Prospective group of patients receiving spine surgery who will have Prevena applied to incision area.
62436899|NCT01860482|EXPERIMENTAL|Newrabell single arm|Newrabell® Tablet 10mg b.i.d PO during 8 weeks
62436900|NCT00548990|EXPERIMENTAL|1|a 10-month moderate aerobic exercise training program
62436901|NCT00548990|PLACEBO_COMPARATOR|2|flexibility/balance control group
62436902|NCT05479968||Tissue Spectrometry group|The experimental group is subjected to testing the Specrocor Investigational Device.
62436903|NCT01724359|EXPERIMENTAL|Paliperidone ER|
62436904|NCT02436135|EXPERIMENTAL|Cohort A, Idelalisib + Ruxolitinib|Idelalisib 50 mg once daily in participants receiving ruxolitinib.
62436905|NCT02436135|EXPERIMENTAL|Cohort B, Idelalisib + Ruxolitinib|Idelalisib 50 mg twice daily in participants receiving ruxolitinib.
62436906|NCT02436135|EXPERIMENTAL|Cohort C, Idelalisib + Ruxolitinib|Idelalisib 150 mg once daily in participants receiving ruxolitinib.
62436907|NCT02436135|EXPERIMENTAL|Cohort D, Idelalisib + Ruxolitinib|Idelalisib 150 mg twice daily in participants receiving ruxolitinib.
62436908|NCT00686803|EXPERIMENTAL|PL3994 Dose A|PL3994 Dose A
62436909|NCT00686803|EXPERIMENTAL|PL3994 Dose B|PL3994 Dose B
62436910|NCT00686803|EXPERIMENTAL|PL3994 Dose C|PL3994 Dose C
62436911|NCT00686803|EXPERIMENTAL|PL3994 Dose D|PL3994 Dose D
62436912|NCT00686803|EXPERIMENTAL|PL3994 Dose E|PL3994 Dose E
62436913|NCT00686803|PLACEBO_COMPARATOR|Placebo|Placebo
62436914|NCT04656522|EXPERIMENTAL|Participatory Comic Intervention|This is a pre-test/post-test trial, therefore all participants will participate in the participatory comic intervention.
62436915|NCT04116346|NO_INTERVENTION|Fasting group|Fasting for both solids and fluids for up to 6 hours pre-procedure
62436916|NCT04116346|EXPERIMENTAL|Non Fasting group|Usual meal on the day of the procedure and allowed to drink as usual
62436917|NCT00747747|NO_INTERVENTION|Control|No coadiuvant treatment. The subject is treated with the antibiotic only and forbidden to take any coadiuvant medicine as a remedy for the symptoms during the period of the study.
62436918|NCT00747747|ACTIVE_COMPARATOR|Saline solution|Saline solution sprayed according to the product indication. Only one brand/specific product has been selected.
62436919|NCT00747747|EXPERIMENTAL|Sinuclean treatment|Sinuclean DM Spray.
62436920|NCT00595660|ACTIVE_COMPARATOR|1|Needle 21 for FNA
62436921|NCT00595660|ACTIVE_COMPARATOR|2|22 needle for FNA
62436922|NCT00595660|ACTIVE_COMPARATOR|3|23 needle for FNA
62436923|NCT00595660|ACTIVE_COMPARATOR|4|24 needle for FNA
62436924|NCT03716102|EXPERIMENTAL|Svelte DES|Stent: A mounted Cobalt Chromium (Co-Cr) alloy based stent Polymer coating: Polyesteramide (PEA) Sirolimus drug
62436925|NCT03628352|EXPERIMENTAL|Tricaprilin|Approximately 5 mL liquid of tricaprilin using various flavoring agents (swish and expectorate) up to 20 times. Dose will not be ingested.
62436926|NCT04101136|ACTIVE_COMPARATOR|Atorvastatin 20 mg|Study pharmacist will make code (A and B) for atorvastatin and placebo, then save the code in safe place. Pharmacist will record each subject as participant received A or B intervention.
62436927|NCT04101136|PLACEBO_COMPARATOR|Placebo 20 mg|The placebo tablets will be prepared by Cipto Mangunkusumo hospital pharmacist, were composed of starch and were similar to atorvastatin tablets in size, shape, and colour.
62436928|NCT02513459|EXPERIMENTAL|Risankizumab|Maintenance treatment with risankizumab 180 mg administered subcutaneously (SC) every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
62436929|NCT01785875|EXPERIMENTAL|Etelcalcetide|Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.
62436930|NCT05510713|NO_INTERVENTION|the treatment-as-usual group|we used the single-cannula in femoral venous blood purification therapy in the following patients with vena cava disconnection or severe obstruction
62436931|NCT05510713|EXPERIMENTAL|intervention group|we used the dual-cannula in jugular-femoral venous blood purification therapy in the following patients with vena cava disconnection or severe obstruction
62436932|NCT04988945|EXPERIMENTAL|Durvalumab + Tremelimumab|1500mg Durvalumab administered IV over 60 minutes on Day 1 of each immunotherapy treatment every 4 weeks until disease progression (PD) and 300mg Tremelimumab administered over 60 minutes on Day 1 of cycle 1.
62436933|NCT03455179|EXPERIMENTAL|Slow-speed traditional resistance training|Resistance training with variable resistances (elastic band) at high intensity and slow-speed (2s of concentric contraction and 2s of eccentric contraction) twice a week over 20 weeks.
62436934|NCT03455179|EXPERIMENTAL|High-speed resistance training|Resistance training with variable resistances (elastic band) at low intensity and high-speed (''as fast as possible´´ for the concentric contraction, pause for 1 second and 2-3 seconds for the eccentric contraction) twice a week over 20 weeks.
62436935|NCT03455179|EXPERIMENTAL|Multicomponent training|Training sessions with balance, resistance, aerobic, flexibility and coordination components twice a week over 20 weeks.
62436936|NCT03455179|NO_INTERVENTION|Control|Participants randomized into the CONTROL group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet.
62436937|NCT03944785||Parkinson's Disease Patients|PD patients who have been newly prescribed safinamide (XADAGO) for the treatment of OFF episodes as described in the XADAGO Package Insert
62603221|NCT03229629|EXPERIMENTAL|Maternal BCC&Paternal BCC &Food Voucher|"1. Mothers with child under 20 months or pregnant will receive BCC~2. Husband/partner of the enrolled mother will receive BCC~3. Enrolled participants will receive monthly voucher worth 200 birr(\~$10)~4. Within household, recipient of voucher (mother or father) will be randomly selected.~   * BCC: Behavior Change Communication"
62603222|NCT03229629|NO_INTERVENTION|Control|Control group
62825730|NCT06597240||AMCOR|Patients \>18 years with locally advanced head anc neck cancer requiring chemoradiotherapy with curative intent.
62825731|NCT04945733|EXPERIMENTAL|Amivantamab: Gastric Cancer (GC) Cohorts|Participants in Phase 2a GC cohorts will receive intravenous (IV) infusion of weight-based dose of amivantamab in 28-day cycles. Participants with body weight less than (\<) 80 kilograms (kg) will receive IV infusion of amivantamab 1,050 milligrams (mg) and participants with body weight greater than or equal to (\>=) 80 kg will receive IV infusion of amivantamab 1,400 mg once weekly in Cycle 1 and then every 2 weeks in subsequent cycles (on Days 1 and 15 of each cycle), followed by additional dosing based on body weight if recommended by clinical trial management team (CTMT) (amivantamab 1750 mg for body weight \<80 kg and 2100 mg for body weight \>=80 kg as IV infusion) every 2 weeks on Days 1 and 15 of 28 day cycle. Phase 2b GC expansion cohorts will be initiated if activity is observed within Phase 2a cohorts.
62825732|NCT04945733|EXPERIMENTAL|Amivantamab: Esophageal Cancer (EC) Cohorts|Participants in Phase 2a EC cohorts will receive IV infusion of weight-based dose of amivantamab in 28-day cycles. Participants with body weight \<80 kg will receive IV infusion of amivantamab 1,050 mg and participants with body weight \>=80 kg will receive IV infusion of amivantamab 1,400 mg once weekly in Cycle 1 and then every 2 weeks in subsequent cycles (on Days 1 and 15 of each cycle) followed by additional dosing based on body weight if recommended by CTMT (amivantamab 1750 mg for body weight \<80 kg and 2100 mg for body weight \>=80 kg as IV infusion) every 2 weeks on Days 1 and 15 of 28 day cycle. Phase 2b EC expansion cohorts will be initiated if activity is observed within Phase 2a cohorts.
62246590|NCT05223751|EXPERIMENTAL|HRV4 + Breathing and Humming Training|On a biweekly basis, and with the other members of their subgroup within the cohort, participants will meet with the Meo Health breathing coach on Zoom for approximately 30 minutes. These sessions will encourage participants to complete their daily exercises and provide additional respiratory training.
62246591|NCT05223751|NO_INTERVENTION|HRV4 Only|Control participants will complete the daily heart rate variability (HRV) reading using the HRV4Training application.
62246592|NCT03239483|EXPERIMENTAL|Dapivirine gel|Participants will receive a single dose of dapivirine gel rectally, followed by 7 daily doses of dapivirine gel to be administered under direct observation in the clinic.
62246593|NCT03239483|PLACEBO_COMPARATOR|Placebo gel|Participants will receive a single dose of placebo gel rectally, followed by 7 daily doses of placebo gel to be administered under direct observation in the clinic.
62603223|NCT04907331|ACTIVE_COMPARATOR|Corminaty twice|The participants receive Comirnaty twice 3-7 weeks apart
62603224|NCT04907331|ACTIVE_COMPARATOR|Vaxzevria twice|The participants receive Vaxzevria twice 12 weeks apart.
62603225|NCT04907331|EXPERIMENTAL|Heterologous|The recipients receive Vaxzevria followed by Comirnaty 12 weeks apart
62603226|NCT00671775||Bariatric surgery patients|
62603227|NCT00671775||Weight loss programs|
62603228|NCT03509870|OTHER|mesenchymal stromal cells|mesenchymal stromal cells in collagen scaffold
62603229|NCT02747797|EXPERIMENTAL|Advanced cancer with lucitanib-targeting biomarker(s)|Lucitanib 10 mg orally daily
62603230|NCT04682262|EXPERIMENTAL|Cervical dilatation|Patients receive cervical dilatation up to 10 millimeter Hegar dilator under general anaesthesia. Patient undergo standard hysteroscopy operation.
62603231|NCT04682262|NO_INTERVENTION|Expectant|Patients are scheduled for follow-up.
62603232|NCT03408249|EXPERIMENTAL|IBD patients|IBD patients performing IBDoc calprotectin test and ease-of-use questionnaires
62603233|NCT06621498|EXPERIMENTAL|Ridge preservation with dense polytetrafluoroethylene membrane|Tooth extraction and ridge prservation with dense PTFE membrane to cover the socket was used in this group.
62603234|NCT06621498|EXPERIMENTAL|Ridge preservation with dense polytetrafluoroethylene membrane and platelet-rich plasma|Tooth extraction and ridge prservation with dense PTFE membrane and autologous PRP was used in this group.
62603235|NCT06621498|EXPERIMENTAL|Ridge preservation with free gingival grafts|Tooth extraction and ridge prservation with autologous free gingival grafts as a method for socket sealing was used. Donor sites were the hard palate and the maxillary tuberosity.
62603236|NCT06621498|NO_INTERVENTION|Control group|Tooth extraction without ridge preservation.
62825733|NCT00497094|ACTIVE_COMPARATOR|1|Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin irrespective of the baseline cholesterol level) and clopidogrel (75mg daily). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations. Additionally patients will undergo carotid artery stenting using a filter wire protection device.
62825734|NCT00497094|NO_INTERVENTION|2|Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin daily irrespective of the baseline cholesterol level) and clopidogrel (75mg daily). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations
62825735|NCT01786005|SHAM_COMPARATOR|Sham|Imitation of stimulation.
62825736|NCT01786005|EXPERIMENTAL|High-frequency stimulation|High-frequency stimulation
62825737|NCT01786005|EXPERIMENTAL|TBS Theta burst stimulation|TBS Theta burst stimulation
62603237|NCT02407132|ACTIVE_COMPARATOR|Standard DSME|Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
62825738|NCT01786005|EXPERIMENTAL|Low-frequency stimulation|Low-frequency stimulation
62825739|NCT03493997|EXPERIMENTAL|Radiotherapy+Ialuril®+Ialuril Soft Gels®|Radiotherapy+Ialuril®+Ialuril Soft Gels®
62825740|NCT03493997|ACTIVE_COMPARATOR|Radiotherapy only|Radiotherapy only
62825741|NCT03205709|ACTIVE_COMPARATOR|Training Group 1|Computerized Cognitive Training
62246594|NCT00640484|EXPERIMENTAL|A|CHF 4226 (carmoterol) 2 μg once a day, in the morning
62246595|NCT00640484|EXPERIMENTAL|B|CHF 4226 (carmoterol) 4 μg once a day, in the morning
62246596|NCT00640484|PLACEBO_COMPARATOR|C|placebo once a day, in the morning
62603238|NCT02407132|EXPERIMENTAL|Adapted DSME|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
62603239|NCT04429204|EXPERIMENTAL|Basic science (cryoablation, tissue collection)|At the time of standard of care pleural biopsy, patients undergo cryoablation over 30 minutes, then a sample of tissue from the ablated region and a non-ablated (tumor negative control) region are collected.
62825742|NCT03205709|PLACEBO_COMPARATOR|Training Group 2|Crossword puzzles
62825743|NCT02472821|ACTIVE_COMPARATOR|Interactive Lesson|Subjects will receive a community-based face-to-face interactive youth educational program on hearing health
62825744|NCT02472821|ACTIVE_COMPARATOR|Interactive lesson + Web-based booster|Subjects will receive a community-based face-to-face interactive youth educational program on hearing health followed by an Internet-based educational booster
62825745|NCT02472821|NO_INTERVENTION|No-intervention control|No interventions; pre- and post- measures only.
62825746|NCT00027534|EXPERIMENTAL|TRICOM-CEA(6D)|Subjects receiving TRICOM-CEA(6D)
62246597|NCT00640484|ACTIVE_COMPARATOR|D|salmeterol 50 μg twice daily, in the morning and in the evening
62246598|NCT03184324|EXPERIMENTAL|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily
62603240|NCT00426140|EXPERIMENTAL|EPO906|
62603241|NCT04738136|NO_INTERVENTION|Standard of Care (SOC)|Subjects will only receive standard of care treatment for moderate severity COVID19 bronchiolitis/pneumonia.
62603242|NCT04738136|EXPERIMENTAL|Standard of Care(SOC) + S-1226 at either 4% 8% or 12% CO2|Subjects will receive SOC plus the highest tolerated dose of S-1226 at either 4% 8% or 12% CO2 twice daily for up to 5 consecutive days.
62603243|NCT01726036|ACTIVE_COMPARATOR|Gomco Circumcision Clamp|Gomco circumcision clamp used for neonatal circumcision.
62825747|NCT06596070||Intestinal barrier dysfunction group|
62825748|NCT06596070||Non-intestinal barrier dysfunction group|
62603244|NCT01726036|ACTIVE_COMPARATOR|Mogen Circumcision Clamp|Mogen circumcision clamp used for neonatal circumcision.
62603245|NCT03251794||threatened preterm labor|women presented to the reception unit from 28-37 weeks by regular contractions and opened cervix
62603246|NCT04463732||Healthy group|Subjects are above 20 years old. Their condition is healthy with no history of inspiratory disease. They can cooperate with the measurements of this study.
62825749|NCT06592027|PLACEBO_COMPARATOR|Group A|this group will receive single dose of dexmedetomidine 0.5 mcg /kg in 50 ml normal saline over 10 min IV infusion
62825750|NCT06592027|ACTIVE_COMPARATOR|Group B|this group will receive single dose of dexmedetomidine 1 mcg /kg in 50 ml normal saline over 10 min IV infusion
62825751|NCT04775381|EXPERIMENTAL|Vitamin D|During preoperative visit (Month -2) patients will receive a cholecalciferol supplementation added to a fruit juice.
62246599|NCT03184324|EXPERIMENTAL|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily
62246600|NCT03184324|EXPERIMENTAL|DWP14012 80mg|DWP14012 40mg\*2, tablet, orally, once daily
62246601|NCT03184324|ACTIVE_COMPARATOR|Esomerpazole 40mg|Esomerpazole 40mg, tablet, orally, once daily
62603247|NCT01928797|NO_INTERVENTION|Control group|The care provider will use blood pressure and heart rate data to administer vasopressor use. In the control group, vasopressors (phenylephrine and ephedrine) will be used as considered appropriate to maintain BP within 20% of baseline. The CO data is measured and blinded to the anesthesiologists in the control group, therefore the anesthesiologist choice of ephedrine or phenylephrine is based on the individual anesthesiologist standard of care preference
62603248|NCT01928797|EXPERIMENTAL|Study group|The care provider will use the cardiac output monitor data (intervention) to guide vasopressors (Phenylephrine and ephedrine) in addition to blood pressure and heart rate data based on a standardized protocol in addition to the blood pressure and heart rate data available in the control group.
62603249|NCT01980810|EXPERIMENTAL|albumin-bounded paclitaxel plus S-1|arm 1:albumin-bounded paclitaxel 200mg iv d1 and S-1 80mg/m2/d po d1-10, repeated every 2 weeks,up to 9 cycles,then S-1 as single agent to treat to disease progression
62603250|NCT00393263|EXPERIMENTAL|1|pimecrolimus
62603251|NCT00393263|ACTIVE_COMPARATOR|2|clobetasol
62603252|NCT06619028|EXPERIMENTAL|Intervention Group (IG)|During the intervention period, the participants will be exposed to an external load, by means of a weighted vest of 10% of their body weight, for a minimum of 8 hours per day for 4 weeks. In the first phase of the study, participants will be followed without changes in their lifestyle as a control. During the intervention they will be instructed to perform their usual activities with the vest, without further alterations in their lifestyle. This will be followed by a 4-week follow-up period without the use of the weighted vest.
62603253|NCT04948554|EXPERIMENTAL|Cohort 1: MK-2225|Participants in Cohort 1 will receive MK-2225 at 0.25 mg/kg once every two weeks (Q2W) plus standard of care (SOC) for 12 weeks.
62603254|NCT04948554|PLACEBO_COMPARATOR|Cohort 1: Placebo|Participants in Cohort 1 will receive placebo Q2W plus SOC for 12 weeks.
62603255|NCT04948554|EXPERIMENTAL|Cohort 2: MK-2225|Participants in Cohort 2 will receive MK-2225 at 0.5 mg/kg (or lower) Q2W plus SOC for 12 weeks.
62603256|NCT04948554|PLACEBO_COMPARATOR|Cohort 2: Placebo|Participants in Cohort 2 will receive placebo Q2W plus SOC for 12 weeks.
62246602|NCT05829590|EXPERIMENTAL|with Artificial intelligence assistant system|Endoscopists would complete the colonoscopy report with the assistance of the artificial intelligence system.
62603257|NCT04948554|EXPERIMENTAL|Cohort 3: MK-2225|Participants in Cohort 3 will receive MK-2225 at 1.0 mg/kg (or lower) Q2W plus SOC for 12 weeks.
62603258|NCT04948554|PLACEBO_COMPARATOR|Cohort 3: Placebo|Participants in Cohort 3 will receive placebo Q2W plus SOC for 12 weeks.
62603259|NCT04948554|EXPERIMENTAL|Cohort 4: MK-2225|Participants in Cohort 4 will receive MK-2225 at ≤2.0 mg/kg Q2W if needed plus SOC for 12 weeks.
62603260|NCT04948554|PLACEBO_COMPARATOR|Cohort 4: Placebo|Participants in Cohort 4 will receive placebo Q2W plus SOC for 12 weeks.
62603261|NCT04948554|EXPERIMENTAL|Cohort 5: MK-2225|Participants in Cohort 5 will receive MK-2225 (no more frequent than Q2W) ≤2.25 mg/kg Q2W or ≤4.5 mg/kg Q4W if needed plus SOC for 12 weeks.
62825752|NCT04775381|NO_INTERVENTION|Fruit juice|During preoperative visit (Month -2) patients will receive only fruit juice.
62246603|NCT05829590|NO_INTERVENTION|without Artificial intelligence assistant system|Endoscopists would complete the colonoscopy report without special prompts.
62246604|NCT01159613||Non Responders|Non Responders
62246605|NCT01159613||RESPONDERS|
62246606|NCT00252304|EXPERIMENTAL|Zinc|Zinc sulphate 10 or 20 mg per day
62246607|NCT00252304|PLACEBO_COMPARATOR|Placebo|Placebo
62246608|NCT03512639|ACTIVE_COMPARATOR|Study|Patients in the study group were given homeopathic medication (Arnica montana C30 and Bellis perennis C30) .
62246609|NCT03512639|PLACEBO_COMPARATOR|control|Patients in the control group were given placebo medication. The placebos and the active medication were indistinguishable in appearance, taste and smell
62246610|NCT06493487|EXPERIMENTAL|integrated neuromuscular inhibition technique|integrated neuromuscular inhibition in addition to conventional treatment
62246611|NCT06493487|EXPERIMENTAL|instrument assisted soft tissue mobilization|instrument assisted soft tissue mobilization technique (IASTM) in addition to conventional treatment
62246612|NCT06493487|PLACEBO_COMPARATOR|conventional treatment|(home education program, therapeutic ultrasound, plantar fascia stretching, intrinsic muscle strengthening of foot, Self stretching of calf muscle using a towel and Ice Massage using frozen bottle).
62436938|NCT02307409||Decompensated Chronic Liver Disease|Decompensated Chronic Liver Disease patients will be enrol
62436939|NCT02307409||Healthy Controls|Healthy Controls will be enrol
62436940|NCT02052128|EXPERIMENTAL|onapristone 10 mg BID mg|onapristone 10 mg BID extended-release tablets
62603262|NCT04948554|PLACEBO_COMPARATOR|Cohort 5: Placebo|Participants in Cohort 5 will receive (no more frequent than Q2W) placebo plus SOC for 12 weeks.
62603263|NCT04948554|EXPERIMENTAL|Cohort 6: MK-2225|Participants in Cohort 6 will receive MK-2225 (no more frequent than Q2W) ≤2.25 mg/kg Q2W or ≤4.5 mg/kg Q4W if needed plus SOC for 12 weeks.
62044069|NCT06079463|EXPERIMENTAL|Diabetic patients undergoing progressive relaxation exercise|"After the purpose of the study was explained and their verbal and written consents were obtained, a questionnaire including the Beck Anxiety Scale, which includes the socio-demographic characteristics, and the World Health Organization Quality of Life Scale, were applied to the patients in the experimental and control groups. will participate in the research, will be asked, and will be filled in face to face by the responsible researcher. After the progressive relaxation exercise training is given to the experimental group patients, the voice recording containing the commands for the application of the progressive relaxation exercise will be sent to the phone of the patient and/or their relatives. Patients in the experimental group spent an average of 25-30 minutes each day for four weeks. Ongoing exercises will be conducted and followed up. At the end of the fourth week, Beck Anxiety Scale and World Health Organization Quality of Life Scale will be applied."
62044070|NCT06079463|NO_INTERVENTION|Diabetic patients not applied progressive relaxation exercise|After explaining the purpose of the study and obtaining their verbal and written consents, a questionnaire form including the Beck Anxiety Scale and the World Health Organization Quality of Life Scale, in which the socio-demographic characteristics of the experimental and control group patients who will participate in the research, are asked, will be filled in face to face by the principal researcher.Then, a voice recording containing the commands for the application of the progressive relaxation exercise will be sent to the phone of the volunteer patients in this group and/or their relatives, and they will be informed about how to apply it.
62044071|NCT03371082|EXPERIMENTAL|Gan & Lee Insulin Glargine Injection|Gan \& Lee Insulin Glargine Injection for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0-mL pre-filled Gan \& Lee injector pen. Subjects randomized to the Gan \& Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
62044072|NCT03371082|ACTIVE_COMPARATOR|Lantus®|Lantus® (insulin glargine injection) solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL pre-filled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
62044073|NCT00474695||1|Active approved treatment
62044074|NCT01786369||Admitted Patients with Acute Psychosis|Patients 18 years of age or older with a documented diagnosis of schizophrenia, schizoaffective disorder, or bipolar 1 disorder who are admitted to an inpatient psychiatric unit at Zucker Hillside Hospital for a psychotic compensations. Patients must have been in the outpatient setting for at least one month prior to admission on a regimen including risperidone, olanzapine, quetiapine, paliperidone or aripiprazole.
62044075|NCT05560048|EXPERIMENTAL|treatment to placebo|Participants should eat rice protein RP-80NY once a day for 28 days, then exchange the treatment sample to placebo after 14 days of wash-out. The dosage of the rice protein RP-80NY or placebo is 0.053 g/kg body weight.
62044076|NCT05560048|EXPERIMENTAL|placebo to treatment|Participants should eat placebo once a day for 28 days, then exchange the treatment sample to rice protein RP-80NY after 14 days of wash-out. The dosage of the rice protein RP-80NY or placebo is 0.053 g/kg body weight.
62044077|NCT02839551|EXPERIMENTAL|Simplified drug provocation test|Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
62044078|NCT05782764|EXPERIMENTAL|single arm|Recombinant human endostatin (CIV72h, D1-D3, 14 tubes) was administered by continuous intravenous infusion every 3 weeks. The drug was discontinued until disease progression or intolerable side effects.
62044079|NCT04332796|ACTIVE_COMPARATOR|Chorhexidine scrub|Chorhexidine scrub was given to patients for 4 weeks
62044080|NCT04332796|ACTIVE_COMPARATOR|ZnO-NPs socks|ZnO-NPs socks to patients for 4 weeks
62044081|NCT04332796|ACTIVE_COMPARATOR|Combination of chorhexidine scrub and ZnO-NPs socks|Chorhexidine scrub and ZnO-NPs socks to patients for 4 weeks
62044082|NCT01371214|EXPERIMENTAL|Group 1|PLIÉ exercise program 30-45 minutes, 2-3 days/week for 18 weeks followed by 18 weeks of usual care (20-minutes of chair-based exercises 2-5 days/week).
62044083|NCT01371214|ACTIVE_COMPARATOR|Group 2|Usual care (20 minutes of chair-based exercises 2-5 days/week) for 18 weeks followed by the PLIÉ exercise program 30-45 minutes/day, 2-3 days/week for 18 weeks.
62044084|NCT02191267|EXPERIMENTAL|Presumed CTE Group|Interventions administered to the Presumed CTE Group include: \[F-18\]-T807 PET Scan, \[F18\]-Florbetapir PET Scan, MRI/MRS Scans, and Genetic Analysis for Genetic Risk Score for Tau.
62044085|NCT02191267|EXPERIMENTAL|Control Group|Interventions administered to the Control Group include: \[F-18\]-T807 PET Scan, \[F18\]-Florbetapir PET Scan, and MRI/MRS Scans.
62246613|NCT05985642||Observational PIC Destination Cohort|"Step 1: Continued analytical treatment interruption (ATI) - During Step 1, PICs will be monitored for safety (including liver function, creatinine, pregnancy, and STI testing), viral, immune, neuropsychological, and socio-behavioral outcomes for up to 96 weeks of continued ATI.~Step 2: ART Restart - Participants will begin Step 2 if they meet ART restart criteria or reach week 96. Participants will be monitored for safety (including liver function, creatinine, and pregnancy), immune, viral, neuropsychological, and socio-behavioral outcomes through 48 weeks after ART restart."
62246614|NCT01073241|ACTIVE_COMPARATOR|transurethral prostatic resection|The patients' prostate was resected with the conventional Nesbit TURP.
62246615|NCT01073241|EXPERIMENTAL|ventral wall of urethra-preserving enucleation of prostate|The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.
62436941|NCT02052128|EXPERIMENTAL|onapristone 20 mg BID|onapristone 20 mg BID extended-release tablets
62436942|NCT02052128|EXPERIMENTAL|onapristone 30 mg BID|onapristone 30 mg BID extended-release tablets
62436943|NCT02052128|EXPERIMENTAL|onapristone 40 mg BID mg|onapristone 40 mg BID mg extended-release tablets
62436944|NCT02052128|EXPERIMENTAL|onapristone 50 mg BID|onapristone 50 mg BID extended-release tablets
62825753|NCT04009408|EXPERIMENTAL|EMST therapy|Participants use the EMST device as per study protocol, set to 50% of the patient's maximal expiratory pressure, as measured by handheld manometer.
62825754|NCT04009408|SHAM_COMPARATOR|Sham EMST therapy|Participants use a sham EMST device that has the spring removed as per study protocol, with no significant airflow resistance.
62825755|NCT05135000|EXPERIMENTAL|LTP001|Participants will receive LTP001 orally once daily in the morning for approximately 24 weeks
62825756|NCT05135000|PLACEBO_COMPARATOR|Placebo|Participants will receive LTP001 placebo capsules matching LTP001 orally once daily in the morning for approximately 24 weeks
62825757|NCT04524949|EXPERIMENTAL|IMCY-0098, low dose|The dose A (Cohort 1) will consist of subcutaneous administrations of 450 µg of the peptide in two separate injections of 225 µg each (500 µL each).
62044086|NCT02191267|EXPERIMENTAL|AD Dementia Group|Interventions administered to the AD Dementia Group include: \[F-18\]-T807 PET Scan, \[F18\]-Florbetapir PET Scan, MRI/MRS Scans
62044087|NCT01394900|EXPERIMENTAL|CNU intervention|African American/Black men who have sex with men (MSM) in same sex intimate relationships in which at least one partner is illicitly using psychostimulants and/or psychoactive substances will receive 4 sessions of CNU intervention
62044088|NCT01394900|ACTIVE_COMPARATOR|WP intervention|African American/Black men who have sex with men (MSM) in same sex intimate relationships in which at least one partner is illicitly using psychostimulants and/or psychoactive substances will receive 4 sessions of general wellness promotion (WP) intervention
62044089|NCT02398929|OTHER|Bisoprolol 2.5 mg|Bisoprolol 2.5 mg will be given once daily following run-in placebo for 2 weeks
62044090|NCT05273632|ACTIVE_COMPARATOR|Oxytocin|Pre- Operative Oxytocin is given intravenously 5-10 minutes slowly before skin incision
62044091|NCT05273632|ACTIVE_COMPARATOR|Tranexamic acid and Etamsylate|Tranexamic acid and Etamsylate are slowly given intravenously 10 minutes before start of Cesarean Delivery
62044092|NCT05273632|PLACEBO_COMPARATOR|Saline|Normal saline (about 200 ml) is given intravenously 10 minutes before start of Cesarean Section
62044093|NCT02310529|EXPERIMENTAL|Interpersonal Psychotherapy|Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group). IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected. Intervention will be delivered by trained clinical psychologists.
62044094|NCT02310529|NO_INTERVENTION|Treatment as usual|Patients including in this group will be taking only treatment as usual (in Pakistan it means that participants attending in outpatients' clinic at regular intervals and may or may not be taking prescribed medication).
62044095|NCT01379833||Subjects|Subjects are patients with CIDP
62044096|NCT01379833||Controls|Controls are age-matched people without CIDP
62436945|NCT02052128|EXPERIMENTAL|onapristone 100 mg QD|onapristone 100 mg QD immediate-release tablets
62825758|NCT04524949|EXPERIMENTAL|IMCY-0098, high dose|The dose B (Cohort 2) will consist of subcutaneous administrations of 1350 µg of the peptide in two separate injections of 675 µg each (500 µL each).
62825759|NCT04524949|PLACEBO_COMPARATOR|Placebo|Participants randomized to placebo will receive subcutaneous administrations of identical volumes of placebo solution to maintain study blind.
62825760|NCT05891379||Exposed group|intravenous Intravenous methylprednisolone (IVMP) plus intravenous inebilizumab
62825761|NCT05891379||Non-exposed group|IVMP plus oral immunosuppressant (Mycophenolate Mofetil or Azathioprine)
62825762|NCT04552301|EXPERIMENTAL|Cognitive Processing Therapy and Targeted Asthma Education|Intervention group - Cognitive Processing Therapy and Targeted Asthma Education
62044097|NCT03687190|EXPERIMENTAL|Tai chi|participants in this group accepted Tai chi exercise and conventional medicine.
62044098|NCT03687190|ACTIVE_COMPARATOR|controlled group|participants were not received Tai chi exercise, but only routine conventional medicine
62044099|NCT03585582||PARDS survivors|"1. Children \<18 years~2. diagnosed with PARDS, as defined by PALICC~3. admitted to the ICU at the CHUSJ, a pediatric tertiary care center"
62044100|NCT04738526|ACTIVE_COMPARATOR|natural tooth|
62044101|NCT04738526|EXPERIMENTAL|lithium disilicate (IPS e-max) ceramic crown|monolithic lithium disilicate (IPS e-max) ceramic crown for crowns in esthetic zone
62044102|NCT04738526|EXPERIMENTAL|New gradient technology zirconia (5Y-TZP\ 3Y-TZP) IPS e.max ZirCad Prime ceramic crown|
62825763|NCT04552301|ACTIVE_COMPARATOR|Psychotherapy and General Asthma Education|Control group - Psychotherapy and General Asthma Education
62825764|NCT06603389||Observation Group|Scales are used to get primary indicator and secondary indicators. The sample size should be set at 5 to 10 times the number of items, with a minimum total sample of 200. Additionally, an extra sample should be calculated to account for a potential 10-20% attrition rate, mitigating the impact of possible data loss. Given that the initial version scale consisted of 55 items, the minimum required sample size is 330.
62825765|NCT06596395|EXPERIMENTAL|Caffeine + Beetroot Juice|70 mL of concentrated NO3--rich (BJ, 6.5 mmol NO3-) + 3 mg/kg of caffeine
62825766|NCT06596395|EXPERIMENTAL|Beetroot Juice|70 mL of concentrated NO3--rich (BJ, 6.5 mmol NO3-) + 3 mg/kg of placebo (maltodextrin)
62044103|NCT01174095||Follow-up Group|"Subjects who received AdGVVEGF121cDNA in either IRB protocol #0794-894 entitled Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Diffuse Coronary Artery Disease or IRB protocol #0297-693 entitled Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Diffuse Coronary Artery Disease Via Minimally Invasive Surgery."
62044104|NCT03432364|EXPERIMENTAL|ST-400 Investigational product|ST-400 Investigational product is composed of autologous CD34+ hematopoietic stem/progenitor cells that are genetically modified ex vivo at the erythroid-specific enhancer of the BCL11A gene
62044105|NCT04329754|OTHER|iPure|"A new single-piece hydrophobic acrylic IOL (IPure IOL). The study IOL is a one-piece aspheric acrylic hydrophobic glistening-free lens, with a 4.9% water content, a 360 square posterior edge design, and a 5 haptic angulation, providing UV and blue-light filtration.~Patient were allocated into two groups. The study group received the iPure lens while the control group received Tecnis ZCB00. Randomisation was done with a binomial law, using random.org. The surgeon was masked to IOL allocation until shortly before implantation. Examiners were masked to IOL allocation."
62436946|NCT03280537|EXPERIMENTAL|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
62044106|NCT04329754|OTHER|ZCB00|"A standard IOL (ZCB00).The control IOL, is a one-piece hydrophobic acrylic IOL with a biconvex aspheric optic and 360 continuous square posterior optic edge with a UV filter and an offset, stepped haptic design.~Patient were allocated into two groups. The study group received the iPure lens while the control group received Tecnis ZCB00. Randomisation was done with a binomial law, using random.org. The surgeon was masked to IOL allocation until shortly before implantation. Examiners were masked to IOL allocation."
62044107|NCT00108602|OTHER|1|
62044108|NCT03664869|ACTIVE_COMPARATOR|Group A|"BCG instillation therapy with induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG~Dosage of Bacillus of Calmette-Guerin (BCG) is dependent on the preferred brand of BCG by the participating institution. Either 2 x 10\^8 - 3 x 10\^9 for BCG-MEDAC, 2-8 x 10\^8 colony forming unit for OncoTICE or, 81mg for ImmuCYST and TheraCys. The investigators will nominate which BCG brand is used."
62246616|NCT00417040|OTHER|(Internet-based STAR database)|"Patients are registered into the STAR database, obtain a password, undergo STAR training, and complete a patient-STAR questionnaire after seeing their clinician (baseline self-report) on day 1 of course 2\* of chemotherapy. Patients are reminded to complete online STAR questionnaire before seeing their clinician on day 1 of courses 3, 4, 5, and 6\* of chemotherapy. Clinicians review these patient reports before creating their own assessment. Patients also complete a patient feedback survey on day 1 of course 4\* of chemotherapy. Clinicians complete feedback survey at study completion.~NOTE: \*All time points are based on scheduled therapy with clinical trial CALGB-90401, CALGB-30607, CALGB-30704, CALGB-40601, CALGB-40603, CALGB-40502, CALGB-70604, CALGB-80405, or CALGB-40503."
62044109|NCT03664869|EXPERIMENTAL|Group B|"Sequential BCG and EMDA mitomycin C treatment with nine weekly instillations of BCG, BCG, EMDA-MMC x3 followed by nine monthly instillations of EMDA-MMC, EMDA-MMC, BCG x3~Dosage of Bacillus of Calmette-Guerin (BCG) is dependent on the preferred brand of BCG by the participating institution. Either 2 x 10\^8 - 3 x 10\^9 for BCG-MEDAC, 2-8 x 10\^8 colony forming unit for OncoTICE or, 81mg for ImmuCYST and TheraCys. The investigators will nominate which BCG brand is used.~Mitomycin C dosage is 40 mg of MMC with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water"
62044110|NCT05550142|EXPERIMENTAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine 50μg|Two doses were administered by intramuscular injection, 28 days apart
62044111|NCT05550142|EXPERIMENTAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine 100μg|Two doses were administered by intramuscular injection, 28 days apart
62044112|NCT01403896|ACTIVE_COMPARATOR|Plerixafor Group|
62044113|NCT01403896|EXPERIMENTAL|Plerixafor + G-CSF group|
62044114|NCT02692326|EXPERIMENTAL|Intervention: Cyclic parenteral nutrition Cohort|All newborn who were included in the study to receive cyclic parenteral nutrition (within 24 hours). The parenteral nutrition was stopped for one hour the first day until 4 hours in preterm infants and 6 hours in term neonates.
62044115|NCT02692326|NO_INTERVENTION|Control: Continuous parenteral nutrition|All newborn who were included in the study to receive continuous parenteral nutrition (24 hours). The parenteral nutrition was given by a central line in 24 hours with a basal flow
62044116|NCT03538951|EXPERIMENTAL|Cohort 1|10% VDA-1102
62044117|NCT03538951|EXPERIMENTAL|Cohort 2|20% VDA-1102
62044118|NCT05288010|OTHER|Active Group|Patients of the clinic receiving cannabis treatment for non cancer chronic pain, who have been invited to join the study and have agreed and consented to join study.
62044119|NCT03204916||Observational (cancer care delivery analysis)|"CHART REVIEW: Patient medical record data is abstracted and treatment plans are reviewed for consistency to NCCN guidelines. For each patient, induction and post-induction care is recorded as either concordant with NCCN guidelines or non-concordant with NCCN guidelines.~SITE QUESTIONNAIRE: Participating sites complete a questionnaire which is designed to capture facility-oriented data.~FOCUS GROUPS: Healthcare providers participate in focus groups over 2-3 hours to discuss facilitators and barriers to AYA ALL guideline concordance. Participants provide responses which will be recorded on a flip-chart or white board, followed by discussion of the ideas for clarification"
62825767|NCT06596395|EXPERIMENTAL|Caffeine|70 mL of NO3--depleted (BJ, 0.04 mmol NO3-) + 3 mg/kg of caffeine
62825768|NCT06596395|PLACEBO_COMPARATOR|Placebo|70 mL of NO3--depleted (BJ, 0.04 mmol NO3-) + 3 mg/kg of placebo (maltodextrin)
62044120|NCT01792180|NO_INTERVENTION|Control group|No intervention besides weekly telephone calls from the computerized falls telephone system
62044121|NCT01792180|EXPERIMENTAL|Intervention group|Weekly use of the mobility feedback device, use of instruction book with every day exercises, use of activity diary in intervention group.
62044122|NCT03742700|EXPERIMENTAL|T-smokers|T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.
62044123|NCT03742700|EXPERIMENTAL|E-smokers|E-smokers were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
62044124|NCT03742700|EXPERIMENTAL|T/E-smokers|T/E-smokers (dual users) were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
62044125|NCT03742700|PLACEBO_COMPARATOR|Control subjects|The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
62825769|NCT02828826|EXPERIMENTAL|telephone coaching|"Patients randomized to the experimental group will benefit from the telephone coaching , with 5 phone calls programmed by the physiotherapist according to the most convenient times for the patient, due to appointments per month.~The telephone coaching conducted by the physiotherapist with patients is to assess the number of exercises performed, the number of falls may have occurred, assess the fear of falling and overall assessment of the patient's general condition and a self-assessment of their physical ability (one leg balance, fear of falling, FTSST). With this information, the therapist may encourage patients to practice more diligently exercises can even strengthen the practice of some based on its evaluation.~Data from the telephone coaching will be recorded in the eCRF."
62246617|NCT06544694|EXPERIMENTAL|0.003% AR-15512|One drop in each eye twice daily for 90 days (treatment period)
62603264|NCT04948554|PLACEBO_COMPARATOR|Cohort 6: Placebo|Participants in Cohort 6 will receive (no more frequent than Q2W) placebo plus SOC for 12 weeks.
62603265|NCT01602432||High Risk Group|"Defined as patients whose primary malignancy is located in the brain, bladder, lung, testicle, stomach, pancreas and lymphatic system and whose risk score before the beginning of anticancer treatment is ≥ 2 according to the Risk Stratification Method proposed by Khorana et al. (2008).~Based on this method, the model includes 5 predictive variables as follows:~1. Site of cancer: classified as very high-risk (+2 points) or high-risk (+1 point).~2. Platelet count: (\>350 x 109/L) (+1 point)~3. Hemoglobin level (\<100 g/L) and/or use of erythropoiesis stimulating agents (+1 point)~4. Leukocyte count (\> 11 x 109/L)(+1 point).~5. body mass index (≥ 35 Kg/m2) (+1 point)."
62436947|NCT03280537|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
62436948|NCT01179633|ACTIVE_COMPARATOR|Oplon Active Patch|
62436949|NCT01179633|PLACEBO_COMPARATOR|Placebo patch|
62436950|NCT04549259|EXPERIMENTAL|Social Support + Stigma Reduction + SBCM + Tech Detailing|
62603266|NCT01602432||Low high Risk Group|"Defined as patients whose primary malignancy is located in the brain, bladder, lung, testicle, stomach, pancreas and lymphatic system and whose risk score before the beginning of anticancer treatment is \< 2 according to the Risk Stratification Method proposed by Khorana et al. (2008).~In order to confirm the patient low risk status, we will draw a blood sample to determine serum levels of D- dimer and soluble P selectin in patients of this low risk group according to Ay et al. (2010). If levels of D-dimer are ≥ 1.44 µg/mL and/or soluble P selectin ≥ 53.1 ng/mL, we will add one point for each one of the increased biochemical marker and the total score recalculated."
62603267|NCT01846221|EXPERIMENTAL|Clonidine|Participants randomized to this arm of the study receive 100 micrograms clonidine with the bupivacaine in their epidural when requesting pain relief in advanced labor
62603268|NCT01846221|EXPERIMENTAL|Fentanyl|Participants randomized to this arm of study will receive 100 mcg fentanyl with the bupivacaine in their epidural when requesting pain relief in advanced labor
62603269|NCT01168310|EXPERIMENTAL|1|
62603270|NCT01168310|EXPERIMENTAL|2|
62825770|NCT02828826|NO_INTERVENTION|Without telephone coaching|
62436951|NCT04549259|EXPERIMENTAL|Social Support + Stigma Reduction + SBCM|
62603271|NCT01168310|EXPERIMENTAL|3|
62825771|NCT00497458|PLACEBO_COMPARATOR|Arimidex|Arimidex 1 mg plus placebo
62825772|NCT00497458|ACTIVE_COMPARATOR|Arimidex test 40mg|Arimidex 1mg and testosterone 40mg
62825773|NCT00497458|ACTIVE_COMPARATOR|Arimidex plus test 80mg|Arimidex 1mg and testosterone 80mg
62825774|NCT02933008|EXPERIMENTAL|aNMT Biofeedback|Participants randomized to receive a neuromuscular training intervention that incorporates biofeedback training.
62825775|NCT02933008|SHAM_COMPARATOR|Sham Biofeedback|Participants randomized to receive a neuromuscular training intervention with sham feedback training.
62246618|NCT06544694|ACTIVE_COMPARATOR|Artificial Tears|One drop in each eye twice daily for 90 days (treatment period)
62246619|NCT02376608|ACTIVE_COMPARATOR|Pronova Pure 150:500 EE EU|2 × PronovaPure 150:500 EE EU
62436952|NCT04549259|EXPERIMENTAL|Social Support + Stigma Reduction + Technology Detailing|
62436953|NCT04549259|EXPERIMENTAL|Social Support + Stigma Reduction|
62436954|NCT04549259|EXPERIMENTAL|Social Support + SBCM + Technology Detailing|
62436955|NCT04549259|EXPERIMENTAL|Social Support + SBCM|
62436956|NCT04549259|EXPERIMENTAL|Social Support + Technology Detailing|
62436957|NCT04549259|EXPERIMENTAL|Social Support|
62436958|NCT04549259|EXPERIMENTAL|Stigma Reduction + SBCM + Technology Detailing|
62436959|NCT04549259|EXPERIMENTAL|Stigma Reduction + SBCM|
62603272|NCT01168310|EXPERIMENTAL|4|
62603273|NCT01168310|EXPERIMENTAL|5|
62603274|NCT01168310|ACTIVE_COMPARATOR|6|
62603275|NCT01168310|PLACEBO_COMPARATOR|7|
62603276|NCT06404060|EXPERIMENTAL|Cardiopulmonary Rehabilitation (Exercise Intolerance)|Participants assigned to Cardiopulmonary Rehabilitation will undergo a 12-week personalized cardiopulmonary rehabilitation intervention with a follow-up period of 3 months (total study duration of 6 months).
62603277|NCT06404060|ACTIVE_COMPARATOR|Education|Participants in this group will receive two general education sessions at the start of the intervention with weekly phone/virtual follow-ups from site study staff.
62603278|NCT03688958|PLACEBO_COMPARATOR|Early Cancer placebo|"The daily supplement of a vegetable colored water solution (drops) for 7 to 35 days in early breast cancer diagnosticated woman.~Placebo: vegetable colored water solution (drops). Evaluate the activity of placebo on tumor size, and molecular tumor response, as well as side effects attenuation"
62603279|NCT03688958|EXPERIMENTAL|Early Cancer Iodine|The daily supplement of an iodine solution (drops, 5 mg/day) for 7 to 35 days in early breast cancer diagnosticated woman
62246620|NCT02376608|ACTIVE_COMPARATOR|Pronovum PRF-037|2 × Pronovum PRF-037
62246621|NCT02376608|ACTIVE_COMPARATOR|Pronovum PRF-041|2 × Pronovum PRF-041
62246622|NCT02376608|ACTIVE_COMPARATOR|Eskimo-3|3 × Eskimo-3
62246623|NCT01514136|EXPERIMENTAL|One arm|The arm consists of two periods: in period one, products are tested in the order A, B, C, D, and in period two, products are tested in the order A\*, B\*, C\*, D\*.
62246624|NCT05484570||Diagnosed|Patients who are diagnosed with a DNA Repair Disorder
62825776|NCT06586385|EXPERIMENTAL|Experimental group|The sample will consist of 30 women who are taking a course in the field of handicraft technology at the Public Education Center affiliated to the Erzincan Provincial Directorate of National Education and who are assigned through simple randomization to meet the conditions for inclusion in the study and who voluntarily consent to participate.
62825777|NCT06586385|NO_INTERVENTION|Control group|The sample will consist of 30 women who are taking a course in the field of handicraft technology at the Public Education Center affiliated to the Erzincan Provincial Directorate of National Education and who are assigned through simple randomization to meet the conditions for inclusion in the study and who voluntarily consent to participate.
62825778|NCT05179135|ACTIVE_COMPARATOR|Control|Standardized meal, without exercise
62825779|NCT05179135|EXPERIMENTAL|Low-intensity walking|
62825780|NCT05179135|EXPERIMENTAL|Moderate-intensity cycling (MOD)|
62246625|NCT05484570||Control|Healthy family members of enrolled diagnosed participants.
62246626|NCT01054950|EXPERIMENTAL|Education and counseling|Phone calls using behavioral techniques
62603280|NCT03688958|PLACEBO_COMPARATOR|Advanced Cancer FEC/TE placebo|"The daily supplement of an vegetable colored water solution (drops) within 4 to 6 cycles of chemotherapy with FEC/TE in advanced breast cancer diagnosticated woman.~Placebo: vegetable colored water solution (drops). Evaluate the adjuvancy of placebo in FEC/TE treatment on tumor size and molecular tumor response, as well as side effects attenuation."
62603281|NCT03688958|EXPERIMENTAL|Advanced Cancer FEC/TE + Iodine|"The daily supplement of an iodine solution (drops, 5 mg/day) within 4 to 6 cycles of chemotherapy with FEC/TE in advanced breast cancer diagnosticated woman Drug: Iodine solution (5 mg/day). Evaluate the adjuvancy of I2 on FEC/TE treatment on tumor size and molecular tumor response, as well as side effects attenuation.~Other Name: evaluating the adjuvancy of iodine supplement in FEC/TE treatment"
62603282|NCT01656278|ACTIVE_COMPARATOR|Conventional biochemical and clinical examinations|Biochemical and clinical examinations
62603283|NCT01656278|EXPERIMENTAL|Conventional biochemical and clinical examinations and MRI.|Biochemical and clinical examinations and MRI.
62603284|NCT01653860|EXPERIMENTAL|The Brøset anger management model|Group treatment
62603285|NCT01653860|ACTIVE_COMPARATOR|ordinary group treatment|Group treatment
62603286|NCT03101722|EXPERIMENTAL|Huperzine A intervention|Huperzine A intervention: Huperzine A with a dose 0.1\~0.2 mg/time, 2 times/day. BTHE：basic treatment and health education
62825781|NCT05179135|EXPERIMENTAL|High-intensity interval exercise (HIIT)|
62825782|NCT05179135|EXPERIMENTAL|Intermittent high-intensity exercise (IHE)|
62825783|NCT05902416||RIC regimen,Elderly,Haplo-HSCT,PFS,OS,TRM|
62825784|NCT06592976|EXPERIMENTAL|Women with endometriosis|
62825785|NCT05876442|EXPERIMENTAL|Group A: ESWT plus HILT in addition to Traditional Physical Therapy Exercise .|patients will receive Extraporeal Shock wave therapy at the area of the wrist for 5 minutes 1 time a week for 2 months, then High-intensity laser therapy at the site of the carpal bones for 5 minutes 2 times a week. Then a program of traditional physical therapy exercises for post-burn carpal tunnel syndrome for 30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. Followed by strengthening exercises for the wrist flexors, extensors, radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercise, and instructed to wear a wrist splint at night.
62246627|NCT01054950|PLACEBO_COMPARATOR|Control|Single phone call
62825786|NCT05876442|EXPERIMENTAL|Experimental: Group B: ESWT plus Traditional Physical Therapy Exercise .|Patients will receive Extraporeal Shock wave therapy at the area of the wrist for 5 minutes 1 time a week for 2 months, Then a traditional physical therapy exercise program for the post-burn carpal tunnel syndrome for 30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. They were followed by strengthening exercises for the wrist flexors, extensors, and radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercise, and instructed to wear a wrist splint at night
62825787|NCT05876442|EXPERIMENTAL|Experimental: Group C:HILTplus Traditional Physical Therapy Exercise.|patients will receive High-intensity laser therapy at the area of the carpal bones for 5 minutes 2 times a week for 2 monthes. Then a program of traditional physical therapy exercises for post-burn carpal tunnel syndrome for 30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. Followed by strengthening exercises for the wrist flexors, extensors, and radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercises, and instructed to wear a wrist splint at night
62825788|NCT05876442|ACTIVE_COMPARATOR|Traditional Physical Therapy Exercise.|patients will receive a program of traditional physical therapy exercise for post-burn carpal tunnel syndrome for 30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. They were followed by strengthening exercises for the wrist flexors, extensors, and radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercise, and instructed to wear a wrist splint at night.
62436960|NCT04549259|EXPERIMENTAL|Stigma Reduction + Technology Detailing|
62246628|NCT04959955||AECOPD group|
62246629|NCT04959955||CAP group|
62246630|NCT04389190|ACTIVE_COMPARATOR|Standard Protocol|This is the fluoroscopy protocol used routinely in most catheterization labs in the region. This includes fluoroscopy and cine image acquisition at 15 frames per second (FPS) at 8-inch mode. Virtual collimation and last image hold (LIH) will be used as needed. This protocol will be implemented for 6 weeks.
62246631|NCT04389190|EXPERIMENTAL|Low frame rate protocol|This will have fluoroscopy and cine image acquisition at 7.5 FPS at 8-inch mode with all other settings on factory default. Virtual collimation and LIH will be used as needed. This protocol will be implemented for 6 weeks as well.
62436961|NCT04549259|EXPERIMENTAL|Stigma Reduction|
62436962|NCT04549259|EXPERIMENTAL|SBCM + Technology Detailing|
62436963|NCT04549259|EXPERIMENTAL|SBCM|
62436964|NCT04549259|EXPERIMENTAL|Technology Detailing|
62436965|NCT04549259|NO_INTERVENTION|HIV Information Only|This arm will not receive any of the 4 intervention components but will receive information on successfully aging with HIV.
62436966|NCT05664191|EXPERIMENTAL|LEVOSIMENDAN|Experimental : Levosimendan group
62436967|NCT05664191|PLACEBO_COMPARATOR|PLACEBO|Placebo : Comparator group
62436968|NCT04648293||Improvement in Hemodynamics|Over the course of a patient's hospitalization, data will be collected on patients from the initiation to completion of hemodynamic monitoring with the Starling monitor in a wide variety of clinical settings, and for different diagnoses. Improvement in hemodynamics is exhibited by an increase in both Cardiac Output and Stroke Volume observed at 12 hour intervals from time of monitoring until completion.
62436969|NCT04648293||No Improvement in Hemodynamics|Over the course of a patient's hospitalization, data will be collected on patients from the initiation to completion of hemodynamic monitoring with the Starling monitor in a wide variety of clinical settings, and for different diagnoses. No Improvement in hemodynamics is exhibited by no increase in both Cardiac Output and Stroke Volume observed at 12 hour intervals from time of monitoring until completion.
62436970|NCT03107949|EXPERIMENTAL|Lungpacer Diaphragm Pacing Therapy (DPTS)|The LIVE Catheter will be temporarily inserted (LIVE Catheter will be inserted into every patient enrolled and can stay in place for up to 30 days) into the left subclavian vein and connected to the Lungpacer Control Unit in order to perform diaphragm pacing to stimulate the phrenic nerves and activate the diaphragm 3 x a day on all patients until extubated/removed from mechanical ventilation or until day 30 whichever comes first.
62449183|NCT05700591|EXPERIMENTAL|rhPro-UK|Recombinant Human Pro-urokinase (rhPro-UK)
62044126|NCT02566018||experimental intervention|A greater degree of initial displacement is tolerated to allow for conservative, non-operative treatment in more simple fracture patterns. Two-part fractures with marked displacement including two part patterns with a non-displaced greater or minor tuberosity fracture (formally three part fractures) are treated with a proximal humerus nail; and displaced three and four part fractures are primarily managed with a reverse total shoulder arthroplasty. Proximal Humeral Internal Locking System (PHILOS)-plates are only used exceptionally in this group of patients.
62603287|NCT03101722|SHAM_COMPARATOR|control|Participants in the BTHE group will receive advice regarding lifestyle modification, avoiding alcohol and cigarette consumption.
62825789|NCT06473181|OTHER|Core stability exercises that is part of physiotherapy rehabilitation|Physical therapy including core stability exercises and improving developmental milestones to improve children development
62044127|NCT02566018||control intervention|"Since May 2013 we have changed our treatment algorithm for the treatment of fractures of the humeral head in the elderly. Before this change in algorithm we used PHILOS plates extensively and rarely Inverse Shoulder prostheses.~In general all proximal humerus fractures were operated except minimally or undisplaced."
62825790|NCT04602663|EXPERIMENTAL|follow up every week|Variceal Band ligation every week.
62246632|NCT04389190|EXPERIMENTAL|Customized Protocol|This will have varying settings based on three weight based groups. Small (\<60 kg), medium (60-85 kg), large (\>85 kg). The variables changed are fluoroscopy dose per frame, fluoroscopy frame rate, image acquisition frame rate, thickness of the spectral beam filters, peak tube voltage and peak cathode current. Additional features will also be utilized including live zoom (1.4 factors with 12 inch field of view, FOV), fluoro store and Spot fluoroscopy. Virtual collimation and LIH will be used as needed. This protocol will be applied for 12 weeks.
62603288|NCT05755386|EXPERIMENTAL|iptacopan 200mg b.i.d|iptacopan 200mg b.i.d
62825791|NCT04602663|EXPERIMENTAL|follow up every 2 weeks|Variceal Band ligation every 2 weeks
62825792|NCT04602663|EXPERIMENTAL|follow up every 3 weeks|Variceal Band ligation every 3 weeks
62825793|NCT04602663|EXPERIMENTAL|follow up every 4 weeks|Variceal Band ligation every 4 weeks
62825794|NCT06166147||Cancer arm|Participants with new diagnosis of pancreatic cancer, from whom a peripheral blood sample will be collected.
62246633|NCT02376556||Blepharoplasty|patients undergoing upper eyelid blepharoplasty
62246634|NCT02376556||blepharoplasty and muller muscle resection|patients undergoing a combined blepharoplasty and muller muscle resection surgery
62246635|NCT02462213||Amyloidosis|Patients being managed for amyloidosis without prior history of cardiac involvement
62246636|NCT02462213||Cardiac amyloidosis|Patients being managed for cardiac amyloidosis
62246637|NCT00655447||1|all women having a hysterectomy with oophorectomy
62436971|NCT04727944|EXPERIMENTAL|MEG and EEG recordings on Healthy volunteers|"All subjects can participate in experiment 1 and/or 2. All analyses are intra-subject (no analyses are between-subject).~* Experiment 1 will test the functional role of beta bursts in naturalistic action preparation, using a combined anatomical MEG-MRI approach which will be conducted in 2 sessions.~* Experiment 2 will study the relationship between beta bursts and naturalistic action preparation using EEG."
62436972|NCT03729752|ACTIVE_COMPARATOR|Healthy Volunteer|Four serial PET-MR scans over 120 hours following a single, bolus injection of \[89\]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
62436973|NCT03729752|EXPERIMENTAL|Viremic HIV-infected|Four serial PET-MR scans over 120 hours following a single, bolus injection of \[89\]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
62436974|NCT03729752|EXPERIMENTAL|Suppressed HIV-infected|A PET-MR scan following a single, bolus injection of \[89\]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
62603289|NCT05755386|PLACEBO_COMPARATOR|Placebo to iptacopan 200mg b.i.d.|Placebo to iptacopan 200mg b.i.d.
62825795|NCT06166147||Benign disease arm|Participants with benign pancreatic diseases, from whom a peripheral blood sample will be collected.
62825796|NCT06197997|EXPERIMENTAL|Title 1 schools receive the Chicago Parent Program intervention|The experimental group from Title 1 or Community Schools across two Maryland school districts (Baltimore City Public Schools and Cecil County Public Schools) will receive the Chicago Parent Program intervention.
62449184|NCT05700591|ACTIVE_COMPARATOR|rt-PA|Alteplase(rt-PA)
62449185|NCT02914795||non-resuscitated myocardial infarction|diagnostic analysis of platelet function of a matched historical cohort of the ATLANTIS-ACS trial
62603290|NCT04891211|ACTIVE_COMPARATOR|Pediatric endocrinologist|Patient selection by pediatric endocrinologist on the basis of vitamin D
62603291|NCT04891211|NO_INTERVENTION|Ophthalmologist|"1. Evaluation of the results by 2 different retina specialists during the examination of patients~2. Interpretation of the results without knowing the vitamin D level of patients"
62246638|NCT00655447||2|all women having a hysterectomy without removal of ovaries
62246639|NCT00334945||Growth Hormone|Patient ages 3-14 years receiving growth hormone for growth hormone deficiency or short stature
62449186|NCT02914795||resuscitated myocardial infarction|diagnostic analysis of platelet function of the patient cohort included according to the inclusion criteria
62449187|NCT06486324|EXPERIMENTAL|Treatment Group|Crossbite Side
62449188|NCT06486324|EXPERIMENTAL|Positive Control Group|Non-cossbite Side
62603292|NCT00101075|EXPERIMENTAL|XELOX|"* Oxaliplatin 130 mg/m2 day 1 every 3 weeks~* Capecitabine 1700 mg/m2/day days 1-14 every 3 weeks. -- Patients will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
62603293|NCT00663897|EXPERIMENTAL|1|Treatment with lansoprazole (30 mg) once daily for 14 days
62825797|NCT06197997|NO_INTERVENTION|Title 1 schools receive the usual school practice|The control group from Title 1 or Community Schools across two Maryland school districts (Baltimore City Public Schools and Cecil County Public Schools) will receive the usual school practice.
62825798|NCT05431933|EXPERIMENTAL|Safety group|Three doses of Eupolio will be administered at 6, 10 and 14 weeks of age. Only safety will be evaluated for this arm.
62825799|NCT05431933|EXPERIMENTAL|Immunogenicity group 1 (4 Eupolio including 1 boosting dose)|Three doses of Eupolio will be administered at 6, 10 and 14 weeks of age, and additional single dose of Eupolio will be administered one year after the three primary vaccinations.
62825800|NCT05431933|EXPERIMENTAL|Immunogenicity group 2 (3bOPV+2 Eupolio)|bOPV will be administered at 6, 10 and 14 weeks of age, and Eupolio will be administered at 14 and 40 weeks of age.
62246640|NCT00334945||Healthy Children|Children with normal stature ages 3-18 years.
62246641|NCT03247426||Evaluation individuals with exercise|Individuals who work in sitting position and do regular exercises will be recruited.
62825801|NCT05965258||Optimize mGDMT|NICM patients referred for mGDMT optimization
62246642|NCT03247426||Evaluation individuals without exercise|Individuals who work in sitting position and do not perform regular exercises will be recruited.
62825802|NCT05965258||MitraClip and mGDMT|NICM patients who are fully medically optimized with significant FMR at the time of the baseline CMR and are referred for Mitraclip treatment
62825803|NCT01542047|EXPERIMENTAL|Carboplatin AUC5 + escalating pazopanib|Carboplatin AUC5 IV Day 1 Pazopanib in escalating dosages, 200 mg to 800 mg starting on days 2 or 3 and ending on days 19 or 21
62825804|NCT05411016|PLACEBO_COMPARATOR|Placebo|
62825805|NCT05411016|EXPERIMENTAL|KK4277|
62825806|NCT02866786|ACTIVE_COMPARATOR|OCP only arm|OCP containing 35 microgram ethinyl estradiol and 2 milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill. OCP to be taken for 6 months.
62246643|NCT01237340|EXPERIMENTAL|Saizen®|
62246644|NCT00956267|EXPERIMENTAL|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
62246645|NCT00956267|ACTIVE_COMPARATOR|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
62246646|NCT00524849|ACTIVE_COMPARATOR|conventional Zometa|Zometa 4mg IV q4w, in combination with other antitumor agents one month after the initial dosing.
62246647|NCT00524849|EXPERIMENTAL|weekly Zometa|Weekly Zometa in combination with other antitumor agents one month after the initial dosing.
62246648|NCT06727110|EXPERIMENTAL|PILP Cement|PILP cement placement prior to tooth restoration.
62246649|NCT06727110|EXPERIMENTAL|PILP Conditioner|PILP conditioner application prior to tooth restoration.
62246650|NCT06727110|NO_INTERVENTION|No intervention|Placement of traditional dental restoration without additional intervention.
62246651|NCT06724978|EXPERIMENTAL|Part 1 (Single Ascending Dose)|Participants will receive S-740792 or placebo.
62246652|NCT06724978|EXPERIMENTAL|Part 2 (Multiple Ascending Dose)|Participants will receive S-740792 or placebo, in addition to midazolam.
62449189|NCT02765321|EXPERIMENTAL|Physical activity and healthy eating promotion|
62449190|NCT02046421|EXPERIMENTAL|Treatment (mifepristone, carboplatin, gemcitabine)|Patients receive mifepristone PO QD on days 0, 1, 7, and 8, and carboplatin IV over 30 minutes and gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62603294|NCT00663897|ACTIVE_COMPARATOR|2|Treatment with mosapride (5 mg) thrice daily for 14 days
62825807|NCT02866786|ACTIVE_COMPARATOR|Metformin arm|Metformin 500mg bid in morning and evening after meals to be taken for 6 months.
62825808|NCT00870740|EXPERIMENTAL|Group 1: DAC HYP 150 mg|Participants who received placebo in 205MS201 receive DAC HYP 150 mg subcutaneous (SC) injection every 4 weeks for a total of 13 doses.
62825809|NCT00870740|EXPERIMENTAL|Group 1: DAC HYP 300 mg|Participants who received placebo in 205MS201 receive DAC HYP 300 mg SC injection every 4 weeks for a total of 13 doses.
62825810|NCT00870740|EXPERIMENTAL|Group 2: Washout then DAC HYP 150 mg|Participants who received DAC HYP 150 mg SC injection in 205MS201 undergo a washout period (placebo SC every 4 weeks for a total of 5 doses) and then receive DAC HYP 150 mg SC every 4 weeks for a total of 8 doses.
62825811|NCT00870740|EXPERIMENTAL|Group 2: DAC HYP 150 mg|Participants who received DAC HYP 150 mg SC injection in 205MS201 receive DAC HYP 150 mg SC every 4 weeks for a total of 13 doses.
62825812|NCT00870740|EXPERIMENTAL|Group 3: Washout then DAC HYP 300 mg|Participants who received DAC HYP 300 mg SC in 205MS201 undergo a washout period (placebo SC every 4 weeks for a total of 5 doses) and then receive DAC HYP 300 mg SC every 4 weeks for a total of 8 doses.
62246653|NCT01767051||Children born from mothers who are diagnosed with PCOS|Children at the age of 2.5-4 years or at the age of 6-8 years born from mothers who are diagnosed with PCOS at the University Medical Centre in Utrecht (UMCU) in the period 2004-2012 (n=891) will be asked to participate. Children who were born before the diagnosed PCOS of their mothers at the UMCU will be asked to participate too. All mothers have been diagnosed with PCOS according to standardised extensive diagnostic work-up and have given informed consent to be approached for future research purposes.
62603295|NCT02657577||WIC staff|WIC staff is eligible to complete the WIC staff online survey if the individual is at least 18 years of age and have been employed at a WIC Clinic or DHH in Louisiana for at least 6 months in the past 2 years.
62603296|NCT02657577||WIC clients|WIC client is eligible to complete the WIC client online survey if the individual is at least 18 years of age and received WIC services during pregnancy or postpartum or have had a child who received WIC services in the past 2 years.
62825813|NCT00870740|EXPERIMENTAL|Group 3: DAC HYP 300 mg|Participants who received DAC HYP 300 mg SC in 205MS201 receive DAC HYP 300 mg SC every 4 weeks for a total of 13 doses.
62825814|NCT06482944|NO_INTERVENTION|Whole Foods Counseling Group (Control)|Participants randomized to the control group will receive a single dietetic counseling session (weeks 1-2) on the 2020-2025 Dietary Guidelines for Americans (DGA) which is considered a healthy diet pattern for prediabetes. Diet adherence will be assessed with a 7-day food diary in the first week and then a 3-day food diary in weeks 2-12. Study personnel and/or the study RDN will follow up with the participants during the study to review the food diaries.
62825815|NCT06482944|EXPERIMENTAL|Whole Foods Healthy Eating Group (Intervention)|"The 12-week whole foods intervention consists of 2 phases. The feeding phase (weeks 1-8) is comprised of an intensive 2-week controlled feeding period followed by a 6-week partial feeding period. This diet intervention will encourage the consumption of a whole foods dietary pattern. The maintenance phase (weeks 9-12) is a 4-week free-living period to assess intervention feasibility without food provision or dietetic support."
62825816|NCT01556022|EXPERIMENTAL|ADRCs processed by the Celution System|400,000 adipose-derived regenerative cells (ADRCs) per kilogram (kg) of body weight not to exceed 40,000,000 cells.
62825817|NCT01556022|PLACEBO_COMPARATOR|Lactated Ringers and Subject's blood|Sterile Lactated Ringers Solution (3mL) mixed with ≤ 0.10 ml of the study Subject's own freshly drawn blood.
62825818|NCT00385671|ACTIVE_COMPARATOR|Pregabalin|Pregabalin (PGB) 50 milligram (mg) three times a day (TID) (US \& Germany) or 75 mg twice daily (BID) (Canada), orally (PO) for 2 weeks, then PGB 100 mg TID (US \& Germany) or 150 mg BID (Canada), PO for 10 weeks.
62825819|NCT00385671|EXPERIMENTAL|Duloxetine|Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then DLX 60 mg QD, PO for 11 weeks.
62825820|NCT00385671|EXPERIMENTAL|Gabapentin + Duloxetine|Stable Gabapentin (GAB) + Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then stable GAB + DLX 60 mg QD, PO for 11 weeks.
62825821|NCT06603714|EXPERIMENTAL|Treated segment - stretched|Instrument assisted soft tissue mobilization will be completed with the calf muscles in a shortened position (30° knee flexion and full ankle plantar flexion).
62603297|NCT01312714|ACTIVE_COMPARATOR|Cholecalciferol|
62825822|NCT06603714|EXPERIMENTAL|Treated segment - shortened|Instrument assisted soft tissue mobilization will be completed with the calf muscles in a lengthened position (full knee extension and approximately 0° ankle dorsiflexion).
62825823|NCT03651752|OTHER|Diphenylcyclopropenone (DPCP) Ointment|All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks
62825824|NCT05048134|EXPERIMENTAL|Treatment group A|
62825825|NCT05048134|EXPERIMENTAL|Treatment group B|
62825826|NCT05048134|EXPERIMENTAL|Treatment group C|
62603298|NCT01312714|PLACEBO_COMPARATOR|Placebo|
62825827|NCT05048134|EXPERIMENTAL|Treatment group D|
62603299|NCT05545020|ACTIVE_COMPARATOR|Trivalent chromium|A dietary supplement already available in market one of its known uses is to control diabetes.
62825828|NCT05048134|EXPERIMENTAL|Treatment group E|
62825829|NCT03563014||Radium-223 (Xofigo, Bay88-8223)|Belgium patients with a diagnosis of mCRPC (no known visceral metastases) and who were treated with Radium-223 for this indication
62825830|NCT01668784|EXPERIMENTAL|Arm 1: Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
62825831|NCT01668784|ACTIVE_COMPARATOR|Arm 2: Everolimus|Everolimus 10 mg tablets by mouth daily until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
62246654|NCT01767051||Children who participated in the WHISTLER study|Children who participated in the WHISTLER 3 (11-163) and WHISTLER/Cardio study (10-194) in 2002-2012. The children were born from mothers with a regular cycle prior to conception who conceived naturally. The children were examined at the age of 2.5-4 years or at the age of 7-8 years. The data of the WHISTLER 3 and WHISTLER/Cardio study have already been collected.
62603300|NCT05545020|ACTIVE_COMPARATOR|Immunesuppressants|Synthetic and/ or biological DMARDs
62603301|NCT02090621|EXPERIMENTAL|Extracorporeal Photopheresis|Extracorporeal Photopheresis
62825832|NCT06603090|EXPERIMENTAL|Text message influenza and COVID-19 vaccine reminders|Text message reminders for both influenza and COVID-19 vaccinations
62825833|NCT06603090|EXPERIMENTAL|Text message influenza vaccine reminders|Text message reminders only for influenza vaccination
62825834|NCT06603090|EXPERIMENTAL|Text message COVID-19 vaccine reminders|Text message reminders only for COVID-19 vaccination
62825835|NCT06603090|NO_INTERVENTION|Usual Care|Usual care has no text message
62825836|NCT00910650|EXPERIMENTAL|F5 TCR transgenic cells|F5 TCR transgenic cell adoptive transfer therapy
62825837|NCT06590272||TECNIS PCB00 IOL (A)|The patients in this groups underwent cataract surgery with TECNIS PCB00 IOL
62825838|NCT06590272||HumanOptics Diff-Aay IOL (B)|The patients in this groups underwent cataract surgery with HumanOptics Diff-Aay IOL
62825839|NCT06590272||TECNIS Symfony ZXR00 IOL (C)|The patients in this groups underwent cataract surgery with TECNIS Symfony ZXR00 IOL
62603302|NCT06647082|EXPERIMENTAL|Pediatric Knee Exoskeleton|N=5 patient participants will undergo 5 sessions of experimental therapeutic rehabilitation sessions with the exoskeleton and the visual biofeedback game. Participants will use the device for a maximum of 2 hours per session for 5 sessions.
62825840|NCT06590272||ZEISS AT LISA tri 839MP IOL (D)|The patients in this groups underwent cataract surgery with ZEISS AT LISA tri 839MP IOL
62825841|NCT01495949|ACTIVE_COMPARATOR|etomidate|
62825842|NCT01495949|ACTIVE_COMPARATOR|thiopentone|
62825843|NCT05657340|EXPERIMENTAL|seasickness susceptible|43 seasickness susceptible maritime crewmembers underwent video-head impulse test
62825844|NCT05657340|OTHER|seasickness non-susceptible|43 seasickness non-susceptible maritime crewmembers underwent video-head impulse test
62825845|NCT05043454|EXPERIMENTAL|Vascular Density Improvement in Hypertensive Participants|Participants will undergo baseline visits and follow-up visits to include neurocognitive testing, VO2 max testing (graded exercise test), blood draws, and retinal scans. Potential subjects must pass an exercise stress test with 12-lead ECG, and training sessions (exercise protocol). Standardized neurocognitive tests assessing functions such as memory and attention will be administered and retinal scans will be conducted. The at-home exercise intervention will be supervised via the Polar beat/flow applications by study personnel. Subjects will engage in cardiovascular exercise with heart rate monitoring on 4 days per week for a total of 10 weeks.
62825846|NCT06283355|EXPERIMENTAL|Single NMT|Swab parent nares then insert swab directly into neonate nares once.
62825847|NCT06283355|EXPERIMENTAL|Repeat NMT|Swab parents nares then insert swab directly into neonate nares multiple times.
62825848|NCT06283355|PLACEBO_COMPARATOR|Placebo|Insert a sterile swab into neonate nares.
62825849|NCT04401813|EXPERIMENTAL|IBI310|An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma
62825850|NCT01426100|EXPERIMENTAL|CKD-828 40/2.5mg|
62825851|NCT01426100|EXPERIMENTAL|CKD-828 40/5mg|
62825852|NCT01426100|ACTIVE_COMPARATOR|Telmisartan 80mg|
62825853|NCT06448117|EXPERIMENTAL|"Mind Nutrition Nutritional counseling"|The intervention arm includes five dietary counseling sessions during 6 months.
62825854|NCT06448117|NO_INTERVENTION|Control|The control arm does not include any intervention.
62825855|NCT06324162|EXPERIMENTAL|2-slot brackets|50 patients treated with 2-slot brackets.
62825856|NCT06324162|EXPERIMENTAL|Twin brackets|50 patients treated with traditional twin brackets.
62825857|NCT02419495|EXPERIMENTAL|Arm A (selinexor, carboplatin) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
62825858|NCT02419495|EXPERIMENTAL|Arm B (selinexor, paclitaxel)|Patients receive selinexor PO twice weekly (e.g. Monday/Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) on days 1-14. Patients then receive selinexor PO on days 1, 3, 8 and 10 and paclitaxel IV over 3 hours on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After 8 cycles of combination treatment, patients can continue single agent selinexor until disease progression.
62825859|NCT02419495|EXPERIMENTAL|Arm C (selinexor, eribulin)|Patients receive selinexor PO on days 1, 8, and 15 and eribulin IV over 1 hour on days 1 and 8. Combination treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
62825860|NCT02419495|EXPERIMENTAL|Arm D (selinexor, doxorubicin, cyclophosphamide) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15, doxorubicin IV over 90 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
62825861|NCT02419495|EXPERIMENTAL|Arm E (selinexor, carboplatin, paclitaxel) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Treatment repeats every 21 days for up to 8 cycles depending con cancer type (6 cycles for non-small cell lung cancer, up to 8 cycles for ovarian cancer and other histological malignancies) in the absence of disease progression or unacceptable toxicity. After 6 to 8 cycles, patients can continue single agent selinexor until disease progression.
62825862|NCT02419495|EXPERIMENTAL|Arm F (selinexor, carboplatin, pemetrexed) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and carboplatin IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
62825863|NCT02419495|EXPERIMENTAL|Arm G (selinexor, topotecan hydrochloride) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and topotecan hydrochloride IV over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. After 8 cycles, patients can continue single agent selinexor until disease progression.
62044128|NCT00916032|ACTIVE_COMPARATOR|1|One infusion using a 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent followed by a second infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total)
62246655|NCT05312489||Upper extremity arterial trauma|Vascular traumatic injuries of the arterial system of the upper limbs.
62603303|NCT03444051||20-gauge Procore®|"Between March and December 2017, 68 EUS-FNB were consecutively performed in our unit for a pancreatic or peripancreatic mass. The choice of the needle depended upon the availability at the time of admission:~34 punctures were performed with a 20-gauge Procore® during the period study"
62603304|NCT03444051||22-gauge Acquire®|"Between March and December 2017, 68 EUS-FNB were consecutively performed in our unit for a pancreatic or peripancreatic mass. The choice of the needle depended upon the availability at the time of admission:~34 punctures were performed with a 22-gauge Acquire® during the period study"
62603305|NCT03449992|EXPERIMENTAL|Intervention group|Participants in this group ingested nitrate-rich beetroot juice for 15 days
62603306|NCT03449992|PLACEBO_COMPARATOR|Placebo group|Participants in this group ingested a placebo drink for 15 days
62603307|NCT05148403|EXPERIMENTAL|Experimental group|Glibenclamide was given orally or through nasogastric tube, 1.25 mg every 8 hours for 7 days
62603308|NCT05148403|NO_INTERVENTION|Control group|No glibenclamide treatment
62603309|NCT00091637|PLACEBO_COMPARATOR|1|Placebo infusion
62603310|NCT00091637|EXPERIMENTAL|2|Pexelizumab infusion
62603311|NCT02953106|ACTIVE_COMPARATOR|Azelastine-Fluticasone Nasal|137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate per actuation. 1 squirt twice daily
62603312|NCT02953106|PLACEBO_COMPARATOR|Placebos|contains the same components as Dymista nasal spray with the exception of the active ingredients. 1 squirt twice daily.
62603313|NCT02610829|EXPERIMENTAL|Gamma Tocopherol|Subjects will ingest 1400 mg gamma tocopherol, orally administered in 3 doses separated by 12 hours.
62603314|NCT04045184||B-FED|Clients of the Birmingham AIDS Outreach Food and Education Delivery (B-FED) program who are also patients at the 1917 Clinic.
62825864|NCT02419495|EXPERIMENTAL|Arm H (selinexor, FOLFIRI) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, 15 and 22, irinotecan hydrochloride IV over 90 minutes, fluorouracil IV continuously over 48 hours and leucovorin calcium IV over 2 hours on days 1 and 15. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
62825865|NCT02419495|EXPERIMENTAL|Arm I (selinexor, irinotecan hydrochloride) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8 and 15 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. After 8 cycles, patients can continue single agent selinexor until disease progression.
62825866|NCT02419495|EXPERIMENTAL|Arm J (selinexor, capecitabine, oxaliplatin) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8 and 15, capecitabine PO twice daily (BID) on days 1-14 and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. After 8 cycles, patients can continue single agent selinexor until disease progression.
62825867|NCT02419495|EXPERIMENTAL|Arm K (selinexor, olaparib) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, 15, and 22 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62825868|NCT02419495|EXPERIMENTAL|Arm L (selinexor, pembrolizumab)|Patients receive selinexor PO twice weekly (e.g. Monday/Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62044129|NCT00916032|ACTIVE_COMPARATOR|2|One infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total) followed by a second infusion of one 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent
62603315|NCT04045184||non B-FED|Patients at the 1917 Clinic who have chosen not to participate in B-FED at this time.
62603316|NCT01044511|EXPERIMENTAL|Home visit|After SEMS placement, 2 home visits and a phonecall are made by a specialist nurse
62825869|NCT02419495|EXPERIMENTAL|Arm M (selinexor, nivolumab|Patients receive selinexor PO twice weekly (e.g. Monday/Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62044130|NCT05900726|EXPERIMENTAL|Pelvipower chair|
62603317|NCT01044511|ACTIVE_COMPARATOR|Standard|Standard contact via Hotline and traditional referring methods
62603318|NCT00126100|EXPERIMENTAL|1|Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
62603319|NCT00126100|PLACEBO_COMPARATOR|2|Patients were randomly assigned to receive subcutaneously a daily dose of placebo for 5 days.
62603320|NCT00734695|EXPERIMENTAL|1|Baruch Pade Medical Center
62603321|NCT00734695|ACTIVE_COMPARATOR|2|Rambam Medical Center
62603322|NCT00734695|ACTIVE_COMPARATOR|3|Soroka Medical Center
62603323|NCT06355167|OTHER|1 dose: 1 capsule of Bacopa monnieri (400mg)|Group A: 400mg/d of Bacopa monnieri
62603324|NCT06355167|OTHER|2 doses: 2 capsules of Bacopa monnieri (800mg)|Group B: 800 mg/d of Bacopa monnieri
62044131|NCT05900726|SHAM_COMPARATOR|Sham stimulation|
62603325|NCT00196339|EXPERIMENTAL|Cyproterone acetate 5 mg ( DR-2031)|1 tablet daily
62603326|NCT00196339|EXPERIMENTAL|Cyproterone acetate 15 mg ( DR-2031)|1 tablet daily
62603327|NCT00196339|EXPERIMENTAL|Cyproterone acetate 25 mg ( DR-2031)|1 tablet daily
62603328|NCT00196339|PLACEBO_COMPARATOR|Placebo|1 tablet daily
62603329|NCT03104426|ACTIVE_COMPARATOR|Darbepoetin alfa group|Group treated with darbepoetin alfa (Aranesp) 10microg/kg once a week for a period of 8 weeks.
62603330|NCT03104426|NO_INTERVENTION|Control group|"Standard care which involves close monitoring of hemoglobin levels and if necessary, top-up red cell transfusion."
62603331|NCT05356962|EXPERIMENTAL|Interventional group|The surgeons will undergo a multi-module training on how to use the StOP?-protocol and perform the StOP?-protocol during all their operations during a 4-month period.
62603332|NCT05356962|NO_INTERVENTION|Control group|Surgeons in the control group will not be trained to the StOP?-protocol and will communicate as usual during their operations.
62825870|NCT02419495|EXPERIMENTAL|Arm P (selinexor, nivolumab, ipilimumab)|Patients receive selinexor PO on days 1, 8, 15, 22, 29, and 36, nivolumab IV over 30 minutes on days 1, 15, and 29, and ipilimumab PO QD on day 1. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62825871|NCT02419495|EXPERIMENTAL|Arms N and O (selinexor, nivolumab, ipilimumab)|Patients receive selinexor PO on days 1, 8, and 15, nivolumab IV over 30 minutes on day 1, and ipilimumab PO QD on day 1. Cycles repeat every 3 weeks for 4 cycles. Starting cycle 5, patients receive selinexor PO on days 1, 8, 15, and 22 and nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62825872|NCT04447807|EXPERIMENTAL|Group A: Metacognitive Training Intervention|"Participants of this group will undergo Metacognitive Training (MCT) in group format for the duration of 9 weeks. The intervention will be held once a week, with an estimated duration of 1-2 hours. The MCT intervention focuses on rehabilitating Social Cognition and teaching skills of interpersonal relations, as well as functional remediation aspects.~We estimate a total of 26 participants in this group."
62825873|NCT04447807|EXPERIMENTAL|Group B: Treatment as Usual|Participants of this group will continue to receive medical attention in the Bipolar Disorder Program -PROMAN- part of the University of São Paulo Medical School, although they will not be part taking in any group rehabilitation format We estimate a total of 26 participants in this group.
62825874|NCT00794716|EXPERIMENTAL|NRL972|2 mg NRL972 IV
62825875|NCT06604208|EXPERIMENTAL|Binaural Beats|
62825876|NCT06604208|SHAM_COMPARATOR|Placebo|
62825877|NCT06591143|EXPERIMENTAL|ART|Atraumatic restorative treatment
62825878|NCT06591143|EXPERIMENTAL|Hall technique|Stainless steel crown placement without tooth preparation
62825879|NCT05056415|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|"In the involved municipalities, TAU mainly consists of short-term efforts, such as Occupational Therapist (OT) prescribing technical aids, often initiated by the housing staff (HS). Daily support provided by HS varies, depending on the approach and commitment of individual staff and the norms that prevail in different housing units, as well as variations between municipalities. Co-planning on long-term rehabilitation efforts does not exist or is weak, and collaboration between OT and HS is, as described by staff from both parties, difficult to achieve.~After a control-period of 6 month, house facilities within the TAU-group will also be offered ELR."
62825880|NCT05056415|EXPERIMENTAL|Everyday Life Rehabilitation (ELR) plus TAU|"ELR is a model for long-term, outreach, and personalized rehabilitation for persons with SPD living in sheltered or supported housing facilities, in close collaboration between resident, OT, and HS.~ELR includes personcentred, motivational-, recovery- and activity-based methods, built on certain process steps. The focus is to promote personal recovery, while targeting meaningful daily activities, through person-driven goals, negotiated expectations, exploration and activity-training in real-life situations, and a maintenance phase. ELR includes a web-based educational package, and devices for reflective collaborative learning.~ELR consists of a weekly session with an OT, followed by regular collaboration with HS, who support the resident on a daily basis, in line with guidance given by the OT and input shared from the HS. The intervention period will last for 6 months.~Prior to the intervention, OT, HS, and HM will partake in web-based training, with associated manuals, and tools."
62825881|NCT01459211|OTHER|Lenalidomide & Dexamethasone|Lenalidomide, 5mg daily, increased to 10mg after 1st cycle. Dexamethasone, 20mg days 1-4 each cycle
62825882|NCT06284343||Patients affected by Gynecologic Cancer undergoing systemic antineoplastic treatment|Study population will consist of subsequent patients prospectively enrolled at the time of prescription of a new line of systemic antineoplastic treatment for a gynecologic oncological disease, defined as ovarian, tubal, uterine, cervical, vaginal, or vulvar neoplasm
62825883|NCT06590194|EXPERIMENTAL|75mg, QD|PH009-1 75mg QD orally administered, receive a single dose orally, followed by a 4-day washout period. Then, the same dose of PH009-1 will be administered QD, every 21 days a cycle until disease progression or not tolerated
62825884|NCT06590194|EXPERIMENTAL|150mg, QD|PH009-1 150mg QD orally administered, receive a single dose orally, followed by a 4-day washout period. Then, the same dose of PH009-1 will be administered QD, every 21 days a cycle until disease progression or not tolerated
62825885|NCT06590194|EXPERIMENTAL|300mg, QD or 150mg, BID|PH009-1 300mg QD or 150mg BID orally administered, receive a single dose orally, followed by a 4-day washout period. Then, the same dose of PH009-1 will be administered QD, every 21 days a cycle until disease progression or not tolerated
62825886|NCT06590194|EXPERIMENTAL|450mg, QD or 225mg, BID|PH009-1 450mg QD or 225mg BID orally administered, receive a single dose orally, followed by a 4-day washout period. Then, the same dose of PH009-1 will be administered QD, every 21 days a cycle until disease progression or not tolerated
62825887|NCT06590194|EXPERIMENTAL|600mg, QD or 300mg, BID|PH009-1 600mg QD or 300mg BID orally administered, receive a single dose orally, followed by a 4-day washout period. Then, the same dose of PH009-1 will be administered QD, every 21 days a cycle until disease progression or not tolerated
62825888|NCT06590194|EXPERIMENTAL|750mg, QD or 375mg, BID|PH009-1 750mg QD or 375mg BID orally administered, receive a single dose orally, followed by a 4-day washout period. Then, the same dose of PH009-1 will be administered QD, every 21days a cycle until disease progression or not tolerated
62044132|NCT01803074|EXPERIMENTAL|Part A-Group 1: BMS-955176 (5 mg) or Placebo|"BMS-955176 5 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
62603333|NCT02342548|EXPERIMENTAL|20 mg BID PF-02545920 non-titrated|Subjects who received 20 mg BID in completed study A8241021 will continue to receive 20 mg BID PF-02545920
62825889|NCT06601348|OTHER|Nutrition education, physical activity interventions, and a health promoting school|"The intervention programme will be implemented for 6 months. Nutrition education is developed through piloting a health promoting school model, the content will combine the government programme healthy school and WHO cartoon pamphlets distributed to each school/student in the intervention school. Nutrition and health education was provided 6 times for students, and 2 times for parents and 4 times for teachers and UKS officers. Physical activity intervention School-based physical activity programme for students called Happy in school children Other forms of physical activity included games, dance or rhythmic gymnastics, such as jumping rope, and squatting, or by adjusting the curriculum. And piloting the health promoting school (HPS) model, the expected outcome of the health promoting school (HPS) model is health literacy."
62825890|NCT06417216|EXPERIMENTAL|Head Cancelled|Study tasks performed in head-cancelled conditions
62825891|NCT06417216|NO_INTERVENTION|Normal|Study tasks performed in normal conditions.
62825892|NCT05754645||110 women|60 women with a BMI between 18,5-25 kg/m2, of which 10 preconceptional 60 women with a BMI \> 30 kg/m2, of which 10 preconceptional
62825893|NCT06474455|EXPERIMENTAL|SHR-9839 combined with SHR-A2009|
62825894|NCT06474455|EXPERIMENTAL|SHR-9839 combined with SHR-A1921|
62603334|NCT02342548|EXPERIMENTAL|20mg BID PF-02545920 titrated|Subjects who received either Placebo or 5mg BID of PF-02545920 in completed study A8241021 will be titrated up to 20 mg with 5mg increment per week, over 4 weeks (5mg increment/wk)
62825895|NCT06474455|EXPERIMENTAL|SHR-9839 combined with pemetrexed + carboplatin|
62825896|NCT06474455|EXPERIMENTAL|SHR-9839 combined with Almonertinib|
62603335|NCT02232854|EXPERIMENTAL|Depression training/supervision program|"A complex intervention, which will include:~* Primary Health Care team training in depression~* A focus group, after training~* Telephone monitoring of patients~* Web-based supervision of clinicians"
62603336|NCT02232854|NO_INTERVENTION|Usual Care|Patients in the control group will receive all the interventions that are guaranteed for persons with depression in Chile: treatment in Primary Health Care clinics with the Primary Health Care team and referral to the regional specialized psychiatric service.
62825897|NCT04074720|OTHER|Standard of Care|patients will have tissue procured after a standard of care procedure, a one time blood draw performed, and optional rectal swab
62825898|NCT06070506||HFrEF group|Heart failure patients with LVEF persistently ≤40%.
62825899|NCT06070506||HFimpEF group|Heart failure patients with previous LVEF ≤40% and a follow-up LVEF of more than 40%.
62825900|NCT05450679||Cervical Radiofrequency Ablation (RFA)-treated group|Only patients who have already been deemed candidates by their primary pain physician for cervical RFA will be recruited to the study. During the cervical RFA procedure, all patients will undergo sensory and motor stimulation testing prior to receiving radiofrequency lesioning, which is a standard and recommended practice.
62825901|NCT05714410|ACTIVE_COMPARATOR|PHGG fiber|Partially Hydrolyzed Guar Gum (PHGG) in powder formulation, is to be consumed orally adding water or juice. One serving per day.
62825902|NCT05714410|PLACEBO_COMPARATOR|Placebo Maltodextrin|Maltodextrin in powder formulation is to be consumed orally adding water or juice. One serving per day.
62825903|NCT06595641|ACTIVE_COMPARATOR|strength training program group|"In Group I, fifteen patients will undergo a 3-week exercise program, with sessions lasting 35-45 minutes, three times a week. Each session includes five exercises, each performed for three sets of 10 repetitions:~Shoulder Retraction - Strengthens muscles between shoulder blades. Shoulder Scaption - Improves stability and range of motion. Shoulder External Rotation from Side Lying - Targets rotator cuff muscles. Shoulder Protraction - Enhances shoulder blade function. Shoulder Extension - Strengthens posterior shoulder muscles."
62825904|NCT06595641|EXPERIMENTAL|Experimental TECAR Group|"In the experimental group, fifteen patients will follow a three-week program that combines targeted exercises with Transfer Energy Capacitive and Resistive (TECAR) therapy. Each session of the exercise program, conducted three times a week, will include a series of five shoulder exercises: retraction, scaption, external rotation from a side-lying position, protraction, and extension.~Alongside these exercises, patients will receive TECAR therapy, which involves applying high-frequency electromagnetic energy to the affected shoulder. During the therapy, a capacitive electrode will first be used for ten minutes to target the soft tissues near the biceps. Following this, the therapy will switch to the resistive mode for another ten minutes, focusing on the deeper tissues around the T1-T9 vertebrae. Each TECAR session will last for a total of twenty minutes, and patients will undergo this treatment nine times over the course of the study, with three sessions each week."
62825905|NCT06597123|NO_INTERVENTION|Control Group|The control group (CG) will provide survey data and complete role plays with standardized patients for motivational interviewing (MI) assessment at designated project intervals. Premier Physician Network data for these primary care providers (PCPs) will also be obtained at these intervals.
62825906|NCT06597123|ACTIVE_COMPARATOR|BASIC AI-Augmented Motivational Interviewing Training|The Basic intervention group will provide survey data and complete role plays with standardized patients for motivational interviewing (MI) assessment at designated project intervals. Premier Physician Network data for these primary care providers (PCPs) will also be obtained at these intervals. Basic PCPs will participate in a didactics session on MI, and subsequently complete two AI (artificial intelligence)-augmented MI training sessions that involve role-play practice of MI.
62825907|NCT06597123|ACTIVE_COMPARATOR|PLUS AI-Augmented Motivational Interviewing Training|The Plus intervention group will provide survey data and complete role plays with standardized patients for motivational interviewing (MI) assessment at designated project intervals. Premier Physician Network data for these primary care providers (PCPs) will also be obtained at these intervals. Plus intervention group PCPs will participate in a didactics session on MI, and subsequently complete four AI (artificial intelligence)-augmented MI training sessions that involve role-play practice of MI.
62825908|NCT00770263|EXPERIMENTAL|Dose Level 1A|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 10 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 10 mg IV on days 8, 15, and 22 during subsequent cycles."
62825909|NCT00770263|EXPERIMENTAL|Dose Level 1|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 15 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 15 mg IV on days 8, 15, and 22 during subsequent cycles."
62246656|NCT05312489||Lower extremity arterial trauma|Vascular traumatic injuries of the arterial system of the lower limbs.
62449191|NCT03688230|EXPERIMENTAL|Abituzumab + Cetuximab + FOLFIRI|"Cetuximab:~400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min~* (60 min \[± 5 min\] after completion of the cetuximab infusion) Abituzumab 1000 mg: every 2 weeks for 60 min~* (60 min \[± 5 min\] after completion of the abituzumab infusion) FOLFIRI: every 2 weeks Irinotecan 180 mg/m² IV, 30 - 90 min day 1 Folinic acid (racemic) 400 mg/m² IV, 120 min day 1 5-FU 400 mg/m² bolus day 1 5-FU 2400 mg/m² IV over a period of 46 h day 1-2"
62603337|NCT03541954|OTHER|Patient with pelvic or perineal pain with sensitization|Patients with chronic pelvic or perineal pain with sensitization (Convergences PP criteria \> 5)
62603338|NCT03541954|OTHER|Patient with pelvic or perineal pain without sensitization|Patients with chronic pelvic or perineal pain without sensitization (Convergences PP criteria \< 5)
62246657|NCT00407654|EXPERIMENTAL|Arm I|Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
62603339|NCT01632150|EXPERIMENTAL|Elotuzumab + Thalidomide + Dexamethasone + Cyclophosphamide|
62603340|NCT04909268||Patients with positive pneumococcal antigenuria|
62603341|NCT02603562|EXPERIMENTAL|ATYR1940|Participants received ATYR1940 intravenous (IV) infusion at doses of 0.3, 1.0, and 3.0 milligrams/kilograms (mg/kg) once weekly using intraparticipant dose escalation for 12 weeks.
62603342|NCT05738122|EXPERIMENTAL|Intervention (Journal Group)|Participants in the Intervention group are provided with the 60-day self-guided emotion regulation journals upon enrolment in the study. These participants complete surveys at 2 weeks, 1 month, and 2 months. After the 60-day period, these participants also complete an exit interview and a follow-up survey.
62825910|NCT00770263|EXPERIMENTAL|Dose Level 2|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 20 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 20 mg IV on days 8, 15, and 22 during subsequent cycles."
62825911|NCT00770263|EXPERIMENTAL|Dose Level 3|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 25 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 25 mg IV on days 8, 15, and 22 during subsequent cycles."
62825912|NCT00770263|EXPERIMENTAL|Dose Expansion Phase|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 25 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 25 mg IV on days 8, 15, and 22 during subsequent cycles."
62825913|NCT02023086||FABRY group|"* contrast sensitivity measurement~* slit lamp assessment and intra-ocular pressure measurement~* ocular coherence tomography at the optic nerve head~* visual field testing~* OSOME (oxygen flow at the optic nerve head measurement)~* Tropicamide"
62246658|NCT04987567|ACTIVE_COMPARATOR|Antioxidant docosahexaenoic acid (DHA)|"Antioxidant docosahexaenoic acid (Tridocosahexaenoin-AOX ® 70%) 50mg/kg/day:~50mg/kg/day so:~* \> = 13-17kg: 2 pearls (700mg DHA) every day, once or twice daily (od or bd)~* \> = 18-24kg: 3 pearls (1050mg DHA) every day, od or bd~* \> = 25-30kg: 4 pearls (1400mg DHA) every day, bd (2-0-2)~* \> = 31-36kg: 5 pearls (1750mg DHA) every day, bd (2-0-3)~* \> = 37-43kg: 6 pearls (2100mg DHA) every day, bd (3-0-3)~* \> = 44-49kg: 7 pearls (2450mg DHA) every day, three times a day (td) (3-1-3)~* \> = 50kg: 8 prearls (2800mg DHA) every day, td (3-2-3)."
62825914|NCT02023086||CONTROL group (Historical database)|"* contrast sensitivity measurement~* slit lamp assessment and intra-ocular pressure measurement~* ocular coherence tomography at the optic nerve head~* visual field testing~* oxygen flow at the optic nerve head measurement (OSOME)~* Under tropicamide"
62825915|NCT05523453|ACTIVE_COMPARATOR|Processing of Positive Memories Technique (PPMT)|Participants receive 5 60-minute Processing of Positive Memories Technique (PPMT) sessions for PTSD following the treatment procedures as outlined in PPMT therapy manual.
62825916|NCT05523453|ACTIVE_COMPARATOR|Supportive Counseling (SC)|Participants receive 5 60-minute supportive counseling (SC) sessions. SC includes a discussion of the daily monitoring diary and exploration of current issues and concerns.
62825917|NCT06650527|EXPERIMENTAL|Group 1: Empathy Training|"Participants will be randomly assigned to the empathy training or control condition for 6 months. During the first phase of the study, participants in Group 1 will receive the photo captioning intervention.~At the 6-month time point, participants in Group 1 will crossover to control.~Assessments will be collected at baseline, 10-day (immediate post-training), 6-month (crossover), 6-month and 10-day (immediate post-crossover) and 12-month (completion)"
62825918|NCT06650527|OTHER|Group 2: Control Condition|"During the first phase of the study, participants in Group 2 are controls. At the 6-month time point, participants in Group 2 will crossover and initiate the intervention.~Assessments will be collected at baseline, 10-day (immediate post-training), 6-month (crossover), 6-month and 10-day (immediate post-crossover), and 12-month (completion)"
62825919|NCT05818085|EXPERIMENTAL|ABP-671|
62825920|NCT05818085|ACTIVE_COMPARATOR|Allopurinol|
62825921|NCT05818085|PLACEBO_COMPARATOR|Placebo|
62825922|NCT04351334||Patients with ALK-positive NSCLC|
62825923|NCT05444855|EXPERIMENTAL|Peer Leader and Friend Network Participants|"All adolescents enrolled as friends of peer leaders will have access to activities and materials shared by the peer leaders.~All adolescents will be asked to complete an eligibility screening survey and baseline survey online or in-person. They will complete short surveys at 2, 4 and 6 months via Twilio text, call, or email.~Peer Leaders~Investigators will enroll up to 40 Peer Leaders. In addition to the above activities (under intervention trial participant), if a teen is a peer leader they will attend a training session in-person or online with our study team to learn about sexual and mental health information and how to share information with their friends (like text or social media). The peer leaders will answer the same surveys described above and will be asked about their Peer Leader experience and how they are sharing the study health information."
62603343|NCT05738122|NO_INTERVENTION|Control (Waitlist Group)|Participants in the Waitlist group complete a 2-week, 1-month and 2-month survey. After the 60-day period, they receive access to the 60-day self-guided emotion regulation journal for their own use.
62825924|NCT01411345|OTHER|Phase 3 - Arm I: Standard Salvage Radiation Treatment (SSRT)|"Phase 3 total dose of 68 Gy will be delivered in 34 fractions to the Clinical Target Volume (CTV), 51 Gy in 34 fractions can be given to the pelvic nodes.~this arm is closed"
62603344|NCT05249283|EXPERIMENTAL|Patients|Patients with acute or chronic otoneurological disorders, presenting or having experienced dizziness and / or balance disorders
62603345|NCT05249283|OTHER|Control subjects|
62603346|NCT05836857||Cannabis (Marijuana) and Cannabidiol (CBD)|This is a survey to determine the number of cancer pain patients who use and/or used Marijuana and/or CBD for pain or other symptom burdens.
62603347|NCT03254823||Severe ME/CFS patients|patients with a clinical diagnosis of ME/CFS and are house or bed bound.
62603348|NCT03254823||Household controls|Healthy human participants who are either related/non-related to, living in the same household or in close proximity to, or providing care to the severe ME/CFS patient they are paired with. They are used as an environmental control.
62603349|NCT02660606||Group 1: Opioid abusers|
62603350|NCT02660606||Group 2: Abusers of other substances|
62603351|NCT02660606||Group 3: Non-opioid abusers|
62603352|NCT02660606||Group 4: Non-opioid users|
62246659|NCT04987567|PLACEBO_COMPARATOR|Placebo|"Olive oil 50mg/kg/day so:~* \> = 13-17kg: 2 pearls every day, once or twice daily (od or bd)~* \> = 18-24kg: 3 pearls every day, od or bd~* \> = 25-30kg: 4 pearls every day, bd (2-0-2)~* \> = 31-36kg: 5 pearls every day, bd (2-0-3)~* \> = 37-43kg: 6 pearls every day, bd (3-0-3)~* \> = 44-49kg: 7 pearls every day, three times a day (td) (3-1-3)~* \> = 50kg: 8 prearls every day, td (3-2-3)."
62246660|NCT06502106|EXPERIMENTAL|Condensed Internet delivered prolonged exposure (CIPE)|Condensed Internet delivered prolonged exposure (CIPE) for three weeks with therapist support.
62246661|NCT00127868|ACTIVE_COMPARATOR|1|oral griseofulvin and selenium sulfide shampoo 1%
62246662|NCT00127868|ACTIVE_COMPARATOR|2|oral griseofulvin and ciclopirox shampoo
62246663|NCT00127868|ACTIVE_COMPARATOR|3|oral griseofulvin and ketoconazole shampoo 2%
62246664|NCT00127868|PLACEBO_COMPARATOR|4|oral griseofulvin and baby shampoo
62246665|NCT01491295|ACTIVE_COMPARATOR|Lamivudine plus adefovir|Continue lamivudine/adefovir add on treatment (standard treatment)
62246666|NCT01491295|EXPERIMENTAL|Tenofovir|Switch from lamivudine/adefovir add on threatment to tenofovir monotherapy
62246667|NCT03715153|EXPERIMENTAL|BUMETANIDE (S95008) followed by Open-Label S95008|Participants will receive S95008 for 6 months, 26 weeks, and then they will begin an open-label 6 month treatment period with S95008.
62246668|NCT03715153|PLACEBO_COMPARATOR|PLACEBO followed by Open-Label S95008|Participants will receive placebo for 6 months, 26 weeks, and then they will begin an open-label 6 month treatment period with S95008.
62246669|NCT05362383|EXPERIMENTAL|Experimental group|transcutaneous electrical nerve stimulation (TENS) is applied
62246670|NCT05362383|NO_INTERVENTION|Control group|no intervention
62246671|NCT04338828|EXPERIMENTAL|Treatment Group|Inhaled nitric oxide
62246672|NCT04338828|PLACEBO_COMPARATOR|Control Group|Inhaled supplemental oxygen
62246673|NCT00909181|EXPERIMENTAL|Oxybutynin Gel 56 mg/day|
62246674|NCT00909181|EXPERIMENTAL|Oxybutynin Gel 84 mg/day|
62246675|NCT00909181|PLACEBO_COMPARATOR|Placebo Gel|
62246676|NCT05737706|EXPERIMENTAL|Phase 1/1B|Dose Escalation/Evaluation
62246677|NCT05737706|EXPERIMENTAL|Phase 2|MRTX1133 recommended Phase 2 dose administered to separate cohorts of patients with selected solid tumor malignancies with KRAS G12D mutation to include the following: NSCLC, PDAC, CRC, Other Solid Tumors
62246678|NCT03533413|ACTIVE_COMPARATOR|Interventional:Combined CT-fluroscopy|Combined CT-fluroscopic radiofrequency ablation of thoracic dorsal root ganglia.
62825925|NCT01411345|EXPERIMENTAL|Phase 3 - Arm II: Mapped Tumor Salvage RT (MTSRT)|"Phase 3 Patients will receive the same treatment to the CTV of 68 Gy in 34 fractions and the Gross Tumor Volume (GTV) defined by functional imaging will receive 2.25 Gy per day for a total of 76.5 Gy (biological equivalent to 80 Gy in 2.0 Gy fractions assuming an α/β ratio of 3).~this arm was continues as single arm phase 2"
62246679|NCT03533413|ACTIVE_COMPARATOR|Interventional: standard fluroscopy|Fluroscopic radiofrequency ablation of thoracic dorsal root ganglia.
62825926|NCT01411345|EXPERIMENTAL|Phase 2: Mapped Tumor Salvage RT (MTSRT)|Phase 2 Patients will receive the same treatment to the CTV of 68 Gy in 34 fractions and the Gross Tumor Volume (GTV) defined by functional imaging will receive 2.25 Gy per day for a total of 76.5 Gy (biological equivalent to 80 Gy in 2.0 Gy fractions assuming an α/β ratio of 3).
62825927|NCT06478186|ACTIVE_COMPARATOR|TA-ER|Name: ZILRETTA (triamcinolone acetonide extended-release injectable suspension; TA-ER) Active ingredient: Extended-release formulation of TA in 75:25 poly (lactic-co-glycolic) acid (PLGA) microspheres Dosage: Nominal 32 mg TA, intra-articular (IA) injection, administered as a 5 mL injection Mode of Administration: IA Knee Injection
62825928|NCT06478186|ACTIVE_COMPARATOR|TA-IR|Name: Kenalog®-40 (triamcinolone acetonide injectable suspension) Active Ingredient: Triamcinolone Acetonide- Immediate Release (TA-IR) Dosage: 40 mg/mL, IA, administered as a 1 mL Injection: TA-IR Mode of Administration: IA Knee Injection
62825929|NCT06604455|EXPERIMENTAL|Integrative medicine single-modality|Acupressure/relaxation only
62825930|NCT06604455|EXPERIMENTAL|Integrative medicine multi-modality|Acupressure/relaxation with acupuncture
62825931|NCT05349591|NO_INTERVENTION|Control|The Participants in this arm receive islet transplant only and no cePolyTregs.
62825932|NCT05349591|EXPERIMENTAL|Treatment|Participants will receive cePolyTregs (target 400-1600 million, with a minimal acceptable dose of 100 million) two weeks post islet transplant and will be followed for 1 year after cePolyTregs infusion to assess the safety and preliminary efficacy of cePolyTregs therapy.
62825933|NCT06589349|EXPERIMENTAL|kangaroo care group|Kangaroo care will be performed twice a day, in the morning and evening, for three days, between 10:00 in the morning and 22:00 in the evening, 1 hour after the treatment and care practices applied to the baby. To measure breast milk cortisol levels, breast milk samples will be collected by the researcher by expressing breast milk at 12.00 on the 1st, 2nd and 3rd days of the experimental and control groups.
62825934|NCT06589349|NO_INTERVENTION|Control Group|Babies in the control group will be followed routinely in an incubator/cotton. It will be monitored for 70 minutes without any procedure or application, and as in the experimental group, stimuli that will disturb the baby during this period will be tried to be controlled. If mothers in this group want to do kangaroo care, they will be encouraged, not prevented. However, mothers in this group who start giving kangaroo care at least twice a day for three days will be excluded from the study. To measure breast milk cortisol levels, samples of mothers in the control group will be collected by expressing breast milk at 12:00
62825935|NCT06590948||HCC|
62825936|NCT06590948||non-HCC|
62825937|NCT05939453|SHAM_COMPARATOR|Sham Light|
62825938|NCT05939453|EXPERIMENTAL|Light Therapy|
62825939|NCT06598748|EXPERIMENTAL|Mechanical Interface Mobilisation Technique|In the mechanical interface group, five techniques, including; wrist distraction (3 sets for 3 minutes), rhythmic and gentle stretching of the transverse carpal ligaments, release of palmar hand fascia, gliding of the finger flexor tendons (using oscillatory flexion-extension movement of metacarpophalangeal joint), and release of the upper forearm muscle and fascia will be applied. To release the upper forearm muscle as demonstrated for pronator teres muscle in, the therapist applied a firm pressure on the origin of the muscle by one thumb and concurrently moved the forearm into extension and supination (17).
62825940|NCT06598748|ACTIVE_COMPARATOR|Exercise Therapy|"Participants in this group will perform myofascial stretching of the carpal ligament, 3 days per week for four weeks along with isometric exercises at wrist joint as demonstrated by the physiotherapist.~The participants will be instructed to perform gentle, pain-free isometrics of the wrist and hand musculature (25). Exercise would be performed with 5-10-second hold, with 10 repetitions (26)."
62246680|NCT05425069||Dexmedetomidine with minimal concentration of propofol (D-P)|"Intravenous infusion with Dexmedetomidine for 10 minutes at 0.8 ug/kg/hr and so on, then induction with Propofol TCI Target 2.0 ug/ml (Schnider model) and Remifentanil TCI 4.5 ng/ml. 3 minutes after LOC Propofol will be reduced to 0.5 ug/ml. intubate using Remifentanil 4.5 ng/ml and Rocuronio 0.5 mg/kg.~Anesthesia will be dynamically adjusted to maintain SEF95 remains at minimum values at 10 Hz for the rest of the surgery. Sedline will be maintained for up to 60 min post-op. in the recovery room. Data will be retrieved via pen drive stick from SEdline"
62449192|NCT03688230|PLACEBO_COMPARATOR|Placebo + Cetuximab + FOLFIRI|"Cetuximab:~400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min~* (60 min \[± 5 min\] after completion of the cetuximab infusion) Placebo: every 2 weeks for 60 min~* (60 min \[± 5 min\] after completion of the placebo infusion) FOLFIRI: every 2 weeks Irinotecan 180 mg/m² IV, 30 - 90 min day 1 Folinic acid (racemic) 400 mg/m² IV, 120 min day 1 5-FU 400 mg/m² bolus day 1 5-FU 2400 mg/m² IV over a period of 46 h day 1-2"
62825941|NCT06653907|PLACEBO_COMPARATOR|Placebo|The target participants are women who undergo thyroid function and TPOAb testing in early pregnancy. Among these pregnant women, TSH 2.5mIU/L-ULRR and TPOAb negative pregnant women will be selected. Then, participants were randomly assigned 1:1 (based on age and BMI) to an oral placebo group during pregnancy. Participants in our study will determine the dosage of medication based on their weight.
62825942|NCT06653907|ACTIVE_COMPARATOR|Levothyroxine|The target participants are women who undergo thyroid function and TPOAb testing in early pregnancy. Among these pregnant women, TSH 2.5mIU/L-ULRR and TPOAb negative pregnant women will be selected. Then, participants were randomly assigned 1:1 (based on age and BMI) to an active comparator group of oral Levothyroxine (L-T4) during pregnancy. Participants in our study will determine the dosage of medication based on their weight.
62246681|NCT05425069||Propofol TCI fine titrated (P)|"Basal frontal EEG with eyes opened and closed (90 sec each) The previous bolus of Lidocaine in a 20 mg intravenous dose, TCI Propofol Induction (Schnider Model) is initiated starting 8 mg/kg/h until clinical unconsciousness (LOC loss of response to the call and to moderate stimulus in the shoulder) and then it is passed to TCI to keep the Ce calculated to the LOC.~After LOC, we proceed to intubate using Remifentanil 4.5 ng/ml and Rocuronio. Anesthesia will be dynamically adjusted to maintain Sedline SEF 95 value of minimum at 10Hz. Sedline will be maintained for up to 60 min post LOC in the recovery room.~Data will be retrieved via pen drive stick."
62246682|NCT00932425|EXPERIMENTAL|Outpatient cardiac monitoring|Patients will be assigned to wear a portable outpatient cardiac telemetry device for 21 days
62246683|NCT00932425|NO_INTERVENTION|Control|Patients will be discharged home with standard clinical follow-up
62603353|NCT01484093|EXPERIMENTAL|R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.|This is a phase I/phase II multi-institution trial. The phase I part of the trial will determine the MTD of cytarabine. The phase II part of the trial will examine the efficacy of the proposed regimen by evaluating the 3-year event-free survival (EFS) in patients with untreated mantle cell lymphoma. All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR.
62603354|NCT00558896|EXPERIMENTAL|Relapsed Myeloma (<4 Prior Regimens)|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
62603355|NCT00558896|EXPERIMENTAL|Lenalidomide Refractory Myeloma|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
62603356|NCT00558896|EXPERIMENTAL|Bortezomib/Lenalidomide Refractory/Relapsed Myeloma|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
62825943|NCT06476106|EXPERIMENTAL|Flight Thigh Cuff Crew Participants|Participants will participate in 2 preflight study sessions consisting of a VTC fit check and a baseline data collection without and with the VTC donned. Participants will also participate in 3 inflight study sessions: a VTC fit check on flight day 30 (FD30) and two separate data collection sessions on flight day 45 (FD45) and 45 days before landing (R-45). During the two in-flight data collection days, participants will be studied before and for up to 6 hours after donning the VTC.
62603357|NCT00558896|EXPERIMENTAL|Bortezomib/Lenalidomide Relapsed/Refractory Myeloma|"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
62603358|NCT00558896|EXPERIMENTAL|Relapsed Myeloma (< 4 Prior Regimens)|"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
62603359|NCT00558896|EXPERIMENTAL|Relapsed/Refractory Myeloma|"Pomalidomide: 4 mg orally once daily, days 1-21 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
62603360|NCT00558896|EXPERIMENTAL|Relapsed Amyloidosis|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
62246684|NCT03632109|EXPERIMENTAL|Single Arm|Men who have sex with men (MSM) with pharyngeal gonorrhea will be treated with 360mg intramuscular gentamicin x 1.
62246685|NCT01412554||Longitudinal Insulin Sensitivity|The participants were examined using the hyperinsulinaemic isoglycaemic glucose clamp technique which is the gold standard to assess insulin sensitivity.
62246686|NCT02125305|EXPERIMENTAL|Metformin|Metformin 750mg(D1), Metformin 500mg(D2)
62246687|NCT02994420||Lean women|BMI 18-25, weight in kg / height in m2
62449193|NCT04262830||All Study Participants|This is an observational study where all study participants are within a single group.
62603361|NCT02132975|EXPERIMENTAL|With motorised probe handler|The surgeon use the motorised probe handler to do the biopsy
62044133|NCT01803074|EXPERIMENTAL|Part A-Group 2: BMS-955176 (10 mg) or Placebo|"BMS-955176 10 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
62246688|NCT02994420||Obese women|BMI 30-35, weight in kg / height in m2
62603362|NCT02132975|EXPERIMENTAL|Without motorised probe handler|The surgeon do the biopsy as he usually do.
62603363|NCT01570881||Delirium,Nondelirium|those with delirium and those without delirium
62603364|NCT05731869||Control group|The group measured without the use of orthoses and tapes
62246689|NCT01956825|PLACEBO_COMPARATOR|water|just water
62246690|NCT01956825|EXPERIMENTAL|"L-CARNITINE AND MAGNESIUM (slim water product)"|"The experimental arm will receive a product slim water, which contains 150 mg magnesium lactate and 2000 mg L-carnitine. The purpose is to follow the patients and examine several metabolic parameters over time (liver function test, lipid profile, liver fat content, etc.) and by that to show and prove the positive effect of the experimental treatment over placebo."
62603365|NCT05731869||Epicondylitis Band Group|Group measured with epicondylitis band
62603366|NCT05731869||Wrist Orthosis Group|Group measured with wrist orthosis
62603367|NCT04064164|EXPERIMENTAL|Treatment|The treatment NHs will received immediate feedback from the Speeko App after each recording sessions
62603368|NCT04064164|NO_INTERVENTION|Control|The Control NHs will not receive app feedback until all recording sessions are complete.
62603369|NCT03067675||Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device
62603370|NCT05308602|EXPERIMENTAL|SCTV01C|
62603371|NCT05308602|EXPERIMENTAL|SCTV01E|
62603372|NCT05308602|ACTIVE_COMPARATOR|mRNA vaccine manufactured by Pfizer or Moderna|
62603373|NCT05308602|ACTIVE_COMPARATOR|Sinopharm inactivated COVID-19 vaccine|
62825944|NCT06473857|EXPERIMENTAL|Mental Health Literacy intervention|Mental health literacy interventions delivered online for adolescents and young adults on, 3 modalities : webconferences, build battle, serious games
62044134|NCT01803074|EXPERIMENTAL|Part A-Group 3: BMS-955176 (20 mg) or Placebo|"BMS-955176 20 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
62246691|NCT00832117|EXPERIMENTAL|Escalation and Expansion|
62044135|NCT01803074|EXPERIMENTAL|Part A-Group 4: BMS-955176 (40 mg) or Placebo|"BMS-955176 40 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
62603374|NCT02913027|NO_INTERVENTION|Observational|ARM: Normal Pelvic Exam Exposures: External Exam followed by speculum exam, followed by bimanual exam
62246692|NCT01873716|EXPERIMENTAL|Injection of Indocyanine Green|Injection of Indocyanine Green prior to carotid endarterectomy surgery. Collection of specimen during surgery with subsequent carotid tissue analysis.
62246693|NCT01873716|NO_INTERVENTION|No injection|No injection prior to carotid endarterectomy surgery. Collection of specimen during surgery with subsequent carotid tissue analysis.
62246694|NCT06035991|EXPERIMENTAL|Patients with end-stage Heart Failure|
62246695|NCT05611788|EXPERIMENTAL|Structure Learning Training|The intervention group will receive structure learning training that tap on their ability to extract patterns from prior stimuli presentations to make predictions. Participants will be presented with visual sequences of symbols determined by frequency statistics and upon mastery, more complex context-based statistics. No feedback will be provided and participants are trained in an adaptive manner
62246696|NCT05611788|NO_INTERVENTION|Passive Control|The passive control group will not receive any intervention but will receive the same pre-post cognitive-behavioural and neuroimaging intervention assessments.
62246697|NCT04874181|EXPERIMENTAL|Silverfit 3D|The subject will use SIlverfit 3D for rehabilitation of his/her shoulder/knee strength post stroke.
62246698|NCT05778188|EXPERIMENTAL|RLS-0071|Doses of RLS-0071 to be administered every 8 hours (q8h), for a total of 10 doses over 72 hours.
62436975|NCT02571725|EXPERIMENTAL|Olaparib and Tremelimumab|"Each cycle is 28 days:~Olaparib at 300 mg, orally, twice daily + Tremelimumab at 10 mg/kg, intravenously, every 4 weeks for the first 6 doses, then every 12 weeks until disease progression or unacceptable toxicity.~* If 1 of the first 3 patients experiences a regimen-limiting toxicity (RLT), 3 more patients will be treated with 10 mg/kg Tremelimumab in Phase 1. If 2 or more of 6 patients experience RLT, then 6 mg/kg Tremelimumab will be tested~* If at 6 mg/kg, 1 or more of 3 patients experience RLT, 3 patients will be treated at 3 mg/kg Tremelimumab~* If at 3 mg/kg, 1 or more patients experience RLT, the study will be discontinued for safety purposes~In Phase 2, patients will receive doses of Olaparib and Tremelimumab determined in the Phase 1 portion as described above, based on tolerability."
62436976|NCT03233282|OTHER|Cognitive Fatigability|
62436977|NCT03233282|OTHER|Physical Fatigability|
62436978|NCT02926378|EXPERIMENTAL|Acupuncture Intervention|Every participant will receive six acupuncture treatments across a three to four-week period. The treatments will last a total of about one hour, including a 10 minute initial assessment, needling, and 45 min of lying down with the needles. Two treatments a week will be performed by Dr. Siminovich-Blok, the PI of this study and a NYS licensed acupuncturist at NYU Langone Medical Center (NYULMC) Ambulatory Care Center. Each acupuncture treatment will consist of 1) a combination of a fixed set of points suggested by the literature, and 2) an individualized set of points based on the evaluation by the licensed acupuncturist. The first set of points will consist of 4 acupoints used consistently in the treatment of stroke through the literature.
62436979|NCT01671384|ACTIVE_COMPARATOR|Valproate, levocarnitine|"The patients will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)"
62436980|NCT01671384|PLACEBO_COMPARATOR|Placebo|"All patients will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)"
62436981|NCT04513340|EXPERIMENTAL|Treatment A|Treatment A will be given under fed conditions by intra-oral single dose administration
62436982|NCT04513340|EXPERIMENTAL|Treatment B|Treatment B will be given intra-orally and orally under fed conditions by single dose administration
62436983|NCT04513340|EXPERIMENTAL|Treatment C|Treatment C will be given orally under fed conditions by single dose administration
62436984|NCT04513340|EXPERIMENTAL|Treatment D|Treatment D will be given orally under fasting conditions by single dose administration
62436985|NCT02687477|SHAM_COMPARATOR|Sham procedure|Patients in the sham group will take sham procedure like PADN.
62603375|NCT02913027|ACTIVE_COMPARATOR|Experimental Pelvic Exam|Arm: Changing the order of Pelvic Exam Intervention: External exam, Bimanual Exam, Speculum Exam
62603376|NCT01222377|EXPERIMENTAL|Arm I|Patients undergo endoscopic breast surgery.
62603377|NCT04160572|EXPERIMENTAL|Morning-evening sleep schedule|
62825945|NCT06473857|OTHER|Other topic intervention - not related to mental health|Other topics online interventions for adolescents and young adults, 3 modalities : webconferences, build battle, serious games
62044136|NCT01803074|EXPERIMENTAL|Part B-Group 5: BMS-955176 + Atazanavir|"BMS-955176 40 mg solution by mouth once daily for 28 days~Atazanavir 2 x 200 mg capsules by mouth once daily for 28 days"
62246699|NCT05778188|PLACEBO_COMPARATOR|Placebo|Doses of sterile saline (sodium chloride, 0.9%) to be administered every 8 hours (q8h), for a total of 10 doses over 72 hours.
62246700|NCT00809523|EXPERIMENTAL|Inactivated negative ion generator|Equivalent exposure to inactivated Negative Ion Generator
62246701|NCT00809523|EXPERIMENTAL|LED light treatment device|Light-emitting photodiode light treatment device, used for 30 min before 8 am
62246702|NCT02684513|ACTIVE_COMPARATOR|Oral Carbohydrate Beverage Group|Subjects assigned to this group will receive 710 mL of a preoperative beverage the evening prior to surgery and 355 mL the morning of surgery.
62449194|NCT05898451|EXPERIMENTAL|Independent use of Refnot|Refnot is administered at a dose of 400,000 IU subcutaneously 3 times a week for 4 weeks. 4 weeks constitute 1 course of treatment with Refnot. In the absence of progression of the disease - an additional 4 weeks.
62603378|NCT04160572|ACTIVE_COMPARATOR|Evening-morning sleep schedule|
62603379|NCT02361554|EXPERIMENTAL|Deep Brain Stimulation Implant|Unblinded treatment arm, deep brain stimulation of the substantia nigra pars reticulata for treatment resistant schizophrenia.
62825946|NCT05600634||Kidney and skin transplataiton|
62436986|NCT02687477|EXPERIMENTAL|Pulmonary Arterial Denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
62603380|NCT00985959|EXPERIMENTAL|Phase I: JNJ-26866138 0.7 mg/m2|JNJ-26866138 0.7 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles.
62603381|NCT00985959|EXPERIMENTAL|Phase I: JNJ-26866138 1.0 mg/m2|JNJ-26866138 1.0 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
62436987|NCT06530381|EXPERIMENTAL|Group 1|Pilates Exercises Applied With Face-to-Face
62825947|NCT03052270|EXPERIMENTAL|Vaginal progesterone and Pessary|"1. Short cervical length equal or less than 20 mm~2. Singleton pregnant women between 18 -24 weeks with no prior history of preterm deliveries.~3. 18 years or older at the time of enrollment.~4. Consent to participate in the study~Vaginal progesterone as standard of care plus Arabin pessary"
62436988|NCT06530381|EXPERIMENTAL|Group 2|Pilates Exercises Applied With Telerehabilitation
62436989|NCT02042690|ACTIVE_COMPARATOR|chemotherapy|"Drugs:~Drug:Methotrexate 1g/m2 d1,IV (in the vein) , used in cycle 1,3,5 Drug:arabinoside 2-3g/m2,q12h, d2-3, IV, used in cycle 1,3,5 Drug:cyclophosphamide:300mg/m2 q12h, d1-3, IV,used in cycle 2,4,6 Drug:Epirubicin 60mg/m2.d，d4,used in cycle 2,4,6 Drug:Vindesin 4mg/d，d4，d11, IV,in cycle 2,4,6 Drug:dexamethasone 40mg/d，d1-4，d11-14, IV, in cycle 2,4,6 Drug:Methotrexate 20 mg/m2/w,po, during maintenance treatment for 2 years Drug:6-mercaptopurine 60 mg/m2/d，po，d1-d28,during maintenance treatment for 2 years Drug:Vindesin 4mg/d，Predisone:1mg/kg, d1-7, every month during maintenance treatment for 2 years"
62436990|NCT02042690|EXPERIMENTAL|Haplo-identical HSCT|Haplo-identical HSCT Protocol:G, donor treatment with recombinant granulocyte colony-stimulating factor (rhG-CSF); I, intensified immunologic suppression; A, antihuman thymocyte immunoglobulin (ATG) for the prevention of GVHD; C, combination of peripheral blood stem cell transplantation (PBSCT), and bone marrow transplantation (BMT)，named GIAC regimen. Graft versus-host disease(GVHD) prevention regimen: CSA/MMF/MTX, cyclosporine A(CSA) 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HSCt and then gradually tapered. Every 12h, 0.5g mycophenolate mofetil (MMF)(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. Methotrexate (MTX) was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
62436991|NCT02595333|EXPERIMENTAL|Group SF1|primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
62825948|NCT03052270|ACTIVE_COMPARATOR|Vaginal progesterone only|"1. Short cervical length equal or less than 20 mm~2. Singleton pregnant women between 18 -24 weeks with no prior history of preterm deliveries.~3. 18 years or older at the time of enrollment.~4. Consent to participate in the study~Vaginal progesterone as standard of care"
62825949|NCT04328805|EXPERIMENTAL|Ibuprofen Arginine|Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.
62825950|NCT04328805|NO_INTERVENTION|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
62825951|NCT06588036|ACTIVE_COMPARATOR|Intervention Group|: Group 1 receiving zinc and probiotic supplementation, Group 2 receiving zinc, probiotic, and prebiotics. Group 3 receiving zinc, probiotics, and anti-secretory agents, and Group 4 receiving zinc, probiotic, anti-secretory agents, and adsorbents.
62825952|NCT06588036|ACTIVE_COMPARATOR|Duration of diarrhea|This will showcase the duration of diarrhea that the pediatric population had before receiving treatment.
62825953|NCT06598020|EXPERIMENTAL|Enhanced competency curriculum-based training|Trainees allocated to this arm undergo practical training, based on the five-item competency curriculum adapted from the list of knowledge, skills, and ability-related competencies recommended by the Society for Integrative Oncology.
62825954|NCT06598020|EXPERIMENTAL|Standard training arm|Trainees in this arm will observe from the side practitioner-patient interaction in integrative oncology setting of care
62825955|NCT06413355|EXPERIMENTAL|FAPI-74 PET/CT Scan|Head and neck cancer (up to 5 subjects), post tubercular lung disease (PTLD, up to 10 subjects) and exploratory (up to 10 subjects) with fibrosis-inducing medical conditions that are known or suspected to cause tissue fibrosis (e.g. cancer-associated, postinfection, post-radiation, pre/post-transplant, cardiac, liver, kidney or pulmonary fibrosis).
62825956|NCT05444348|EXPERIMENTAL|ACT intervention|Participants will receive the ACT intervention
62825957|NCT05444348|NO_INTERVENTION|control|Participants will receive no intervention only usual care.
62825958|NCT05920889|ACTIVE_COMPARATOR|Semaglutide Group|Prescribe study drug: Patients randomized into the semaglutide group will receive 0.5mg subcutaneous injection of the drug before or during EVT, and 7 days after the procedure. i.e. semaglutide group will receive a total of 2 injections.
62825959|NCT05920889|NO_INTERVENTION|Standard of care|Standard medical therapy
62825960|NCT04589741|EXPERIMENTAL|toripalimab combined with CAV/IE regimen|toripalimab combined with CAV/IE regimen in patients with advanced or unresectable bone and soft tissue sarcomas who failed standard treatment
62825961|NCT04589741|PLACEBO_COMPARATOR|CAV/IE chemotherapy alone|CAV/IE chemotherapy alone in patients with advanced or unresectable bone and soft tissue sarcomas who failed standard treatment
62825962|NCT06331299|EXPERIMENTAL|UGN-103|Patients will receive UGN-103 (75 mg mitomycin) once weekly for 6 weeks (a total of 6 doses).
62825963|NCT02992288|EXPERIMENTAL|Neladenoson bialanate (BAY1067197) (5 mg)|Chronic heart failure with reduced ejection fraction
62436992|NCT02595333|EXPERIMENTAL|Group S1|primary cesarean section+postoperative analgesia with sufentanil group
62825964|NCT02992288|EXPERIMENTAL|Neladenoson bialanate (BAY1067197) (10 mg)|Chronic heart failure with reduced ejection fraction
62603382|NCT00985959|EXPERIMENTAL|Phase I: JNJ-26866138 1.3 mg/m2|JNJ-26866138 1.3 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
62044137|NCT01803074|EXPERIMENTAL|Part B-Group 6: BMS-955176 + Atazanavir + Ritonavir|"BMS-955176 40 mg solution by mouth once daily for 28 days~Atazanavir 1 x 300 mg capsules by mouth once daily for 28 days~Ritonavir 1 x 100 mg tablet by mouth once daily for 28 days"
62246703|NCT02684513|ACTIVE_COMPARATOR|Rehydration Beverage Group|Subjects assigned to this group will receive 710 mL of re-hydration beverage the evening prior to surgery and 355 mL the morning of surgery.
62246704|NCT02684513|NO_INTERVENTION|Fasted Controls|Subjects assigned to this group will fast for ≥8 hours prior to surgery.
62603383|NCT00985959|EXPERIMENTAL|Phase II: JNJ-26866138 1.3 mg/m2|JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5-9 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
62603384|NCT05968027||Onco'nect pre-deployment|- Onco'nect pre-deployment (12 months): period covering the year prior to the actual implementation of the solution in each centre; patients receiving I.V. chemotherapy during the first 6 months of the period will be included, in order to assess the 6-month follow-up.
62603385|NCT05968027||Onco'nect post-deployment|-Onco'nect post-deployment (12 months): period covering the year following the implementation of the solution within the centre (installation, interoperability and parameterisation validated); patients with I.V. chemotherapy implemented during the first 6 months of the period will be included, in order to be able to evaluate the 6-month follow-up.
62825965|NCT02992288|EXPERIMENTAL|Neladenoson bialanate (BAY1067197) (20 mg)|Chronic heart failure with reduced ejection fraction
62825966|NCT02992288|EXPERIMENTAL|Neladenoson bialanate (BAY1067197) (30 mg)|Chronic heart failure with reduced ejection fraction
62825967|NCT02992288|EXPERIMENTAL|Neladenoson bialanate (BAY1067197) (40 mg)|Chronic heart failure with reduced ejection fraction
62825968|NCT02992288|PLACEBO_COMPARATOR|Placebo|Chronic heart failure with reduced ejection fraction
62825969|NCT06591442||Elderly group patients (60-74 years).|
62825970|NCT06591442||Advanced age group patients (≥75 years)|
62825971|NCT00364637|ACTIVE_COMPARATOR|Total intravenous anesthesia|
62825972|NCT00364637|EXPERIMENTAL|sevoflurane|
62825973|NCT06609460|EXPERIMENTAL|CD388 Low Dose|Participants are randomized to receive a low dose of CD388 by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
62825974|NCT06609460|EXPERIMENTAL|CD388 Medium Dose|Participants are randomized to receive a medium dose of CD388 by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
62825975|NCT06609460|EXPERIMENTAL|CD388 High Dose|Participants are randomized to receive a high dose of CD388 by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
62825976|NCT06609460|PLACEBO_COMPARATOR|Placebo|Participants are randomized to receive placebo by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
62044138|NCT01803074|EXPERIMENTAL|Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine|"Atazanavir 1 x 300 mg capsule by mouth once daily for 28 days~Ritonavir 1 x 100 mg tablet by mouth once daily for 28 days~Tenofovir 1 x 300 mg tablet by mouth once daily for 28 days~Emtricitabine 1 x 200 mg capsule once daily for 28 days"
62246705|NCT05370716|EXPERIMENTAL|Group A|Pregabalin + Polmacoxib
62246706|NCT05370716|ACTIVE_COMPARATOR|Group B|Polmacoxib
62044139|NCT01803074|EXPERIMENTAL|Part C-Group 8: BMS-955176 (40 mg) or Placebo|"BMS-955176 40 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
62246707|NCT05370716|ACTIVE_COMPARATOR|Group C|Pregabalin
62246708|NCT06404268|EXPERIMENTAL|Study group - Wearable ankle robot rehab|Wearable rehab robot with motor relearning with real-time feedback, passive stretching under intelligent control; Active movement training with robotic assistance
62603386|NCT03994614|EXPERIMENTAL|the TEAS intervention group|Patients in this group will be given TEAS treatment for 12 weeks prior to COS.
62825977|NCT06594081|NO_INTERVENTION|Control|No application will be made.
62825978|NCT06594081|EXPERIMENTAL|Intervention|Training was provided via podcast.
62825979|NCT06425458|EXPERIMENTAL|Co-Designed Strengths-Based Leadership Program|"Young people transitioning out of homelessness will attend a four-week, strengths-based leadership program.~Two four-week leadership programs (15 youth per program) will be led by coaches from the research team's current TYOH 2.0 study with youth advisors participating as paid leadership interns."
62825980|NCT03077971|EXPERIMENTAL|ACT Self-Help|Participants in this arm will receive a self-help book based on Acceptance and Commitment Therapy (ACT). Participants will receive chapters each week, either electronically or by post, for 8 weeks.
62825981|NCT03077971|EXPERIMENTAL|ACT Self-Help with Telephone Support|Participants in this arm will receive a self-help book based on Acceptance and Commitment Therapy (ACT). Participants will receive chapters each week, either electronically or by post, for 8 weeks. In addition to this, participants will have weekly telephone calls to support the use of the book.
62825982|NCT03077971|NO_INTERVENTION|Treatment As Usual|Participants in this arm will have no intervention as part of the trial.
62246709|NCT06404268|ACTIVE_COMPARATOR|Control group - Limited wearable ankle robot rehab|The same wearable robot used by the study group will be used for the control group but in a limited way: no motor relearning training under real-time feedback; passive movement in the joint middle range of motion instead of passive stretching; active movement training with no robotic assistance
62436993|NCT02595333|EXPERIMENTAL|Group SF2|repeated cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
62603387|NCT03994614|NO_INTERVENTION|No intervention group|Patients in this group will not be given any interventions for 12 weeks prior to COS.
62603388|NCT02872857|PLACEBO_COMPARATOR|Placebo|
62603389|NCT02872857|EXPERIMENTAL|8mg galantamine twice daily|
62603390|NCT02872857|EXPERIMENTAL|12mg galantamine twice daily|
62603391|NCT03619759||Sugammadex|Patients who used sugammadex Sugammadex 1 vial (200mg) intravenous, at the end surgery, before extubation
62603392|NCT03619759||Non-sugammadex|Patients who didn't use sugammadex Pyridostigmine 15\~20mg intravenous, at the end of surgery, before extubation
62246710|NCT00978835|EXPERIMENTAL|Nurse case management|Telephone calls by a nurse every two months to assess adherence to diet, physical activity, and pill-taking regimens. The nurse will then identify barriers to adherence to these recommendations and use motivational interviewing approaches to offer solutions to the barriers identified. No changes to medication are made.
62436994|NCT02595333|EXPERIMENTAL|Group S2|repeated cesarean section+postoperative analgesia with sufentanil group
62436995|NCT01531348|EXPERIMENTAL|BM-MSC|Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
62436996|NCT04563078|EXPERIMENTAL|Transcranial Magnetic Stimulation (TMS)|TMS is a noninvasive treatment that uses magnetic fields to induce a small electric current in specific brain regions.
62603393|NCT02835950|EXPERIMENTAL|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
62603394|NCT04543318|EXPERIMENTAL|Deep temporal nerves group|this group will use deep temporal nerves for reactivation of affected upper facial nerve branch
62603395|NCT04543318|ACTIVE_COMPARATOR|Masseteric nerve group|this group will use masseteric nerve for reactivation of affected upper facial nerve branch (gold standard)
62603396|NCT02203318||control|healthy children with normal bilateral testis
62603397|NCT02203318||undescended palpable testis|patient whose affected testis is not descended to the normal position but palpable and exist intact in the upper area
62603398|NCT02203318||non-paplpable testis|patient whose affected testis is not palpable during the physical examination
62603399|NCT04104932||Surgical group|Patients with isolated minor rib fractures received surgical stabilization.
62603400|NCT04104932||Conservative group|Patients with isolated minor rib fractures received conservative treatment, such as NSAIDs.
62603401|NCT05135884||Cohort|
62825983|NCT06539832||Monoclonal gammopathy patients without concurrent infection|"(I) Inclusion criteria:~1. Age 45 years or older;~2. Patients screened positive for monoclonal protein by MALDI-TOF MS;~3. No symptoms of infection, with normal infection indicators (whole blood hs-CRP, serum IL-6, PCT);~4. Adequate remaining whole blood, plasma and stool samples available, and relevant case data can be provided.~(II) Exclusion criteria:~1. History of intestinal tumors, irritable bowel syndrome or inflammatory bowel disease, or diagnosed during hospitalization;~2. Received antibiotic treatment in the past one month;~3. Insufficient sample volume, or presence of severe hemolysis, lipemia, jaundice or other unqualified sample conditions."
62603402|NCT02980510|EXPERIMENTAL|A=Experimental group|FOLFIRINOX + Panitumumab oxaliplatin 85 mg/m² IV infusion over 2 hours immediately followed by folinic acid 400 mg/m² given as a 2-hour intravenous (IV) infusion with the addition, after 30 minutes of irinotecan 150 mg/m² given as a 90-minute intravenous infusion through a Y-connector immediately followed by fluorouracil 400 mg/m² IV bolus then 5-fluoruracil (5-FU) 2400 mg/m² over 46 hours continuous infusion.
62603403|NCT02980510|ACTIVE_COMPARATOR|B=Control group|mFOLFOX6 + Panitumumab mFOLFOX6 every 2 weeks: oxaliplatin 85 mg/m² IV infusion over 2 hours immediately followed by folinic acid 400 mg/m² IV infusion over 2 hours followed by fluorouracil 400 mg/m² IV bolus then 5-FU 2400 mg/m² over 46 hours continuous infusion.
62825984|NCT06539832||Monoclonal gammopathy patients with concurrent infection|"(I) Inclusion criteria:~1. Age 45 years or older;~2. Patients screened positive for monoclonal protein by MALDI-TOF MS;~3. Presence of infection symptoms, with abnormal infection indicators (whole blood hs-CRP, serum IL-6, PCT);~4. Adequate remaining whole blood, plasma and stool samples available, and relevant case data can be provided.~(II) Exclusion criteria:~1. History of intestinal tumors, irritable bowel syndrome or inflammatory bowel disease, or diagnosed during hospitalization;~2. Received antibiotic treatment in the past one month;~3. Insufficient sample volume, or presence of severe hemolysis, lipemia, jaundice or other unqualified sample conditions."
62825985|NCT06539832||Healthy control group|"(I) Inclusion criteria:~1. Age 45 years or older;~2. Patients screened negative for monoclonal protein by MALDI-TOF MS;~3. No symptoms of infection, with normal infection indicators (whole blood hs-CRP, serum IL-6, PCT);~4. Adequate remaining whole blood, plasma and stool samples available, and relevant case data can be provided.~(II) Exclusion criteria:~1. History of intestinal tumors, irritable bowel syndrome or inflammatory bowel disease, or diagnosed during hospitalization;~2. Received antibiotic treatment in the past one month;~3. Severe systemic diseases including malignant tumors;~4. Insufficient sample volume, or presence of severe hemolysis, lipemia, jaundice or other unqualified sample conditions."
62603404|NCT00655681|EXPERIMENTAL|A recieveds pamidronate 1mg/kg once|Receives pamidronate 1mg/kg once
62603405|NCT00655681|PLACEBO_COMPARATOR|B: placebo group recieves saline|receives saline injection 10 cc/kg over 4 hours once post operatively
62603406|NCT00691873|PLACEBO_COMPARATOR|1|Placebo will be compared to Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
62603407|NCT00691873|EXPERIMENTAL|2|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
62825986|NCT05562999|EXPERIMENTAL|Deep neuromuscular blockade|Participant will receive deep neuromuscular blockade (PTC 1-2)
62825987|NCT05562999|ACTIVE_COMPARATOR|Moderate neuromuscular blockade|Participant will receive moderate neuromuscular blockade (TOF 1-2)
62603408|NCT05744037|EXPERIMENTAL|CAR-T Cell Infusion|After FC regimen (fludarabine (25mg/m2/d) on days -5 to -3 and cyclophosphamide (750mg/m2) on days -5) were pretreated, Anti-CD19 CAR T cells were transfused on day 0. The dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. Intravenous drip/push at a constant rate for 30 minutes; Ibrutinib, a BTK inhibitor, was enrolled with a standard dose of 560mg qd.
62603409|NCT04481191|EXPERIMENTAL|Concomitant RotaTeq and IPV|Participants will receive RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular \[IM\] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 \[Day 1\]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
62603410|NCT04481191|ACTIVE_COMPARATOR|Staggered RotaTeq and IPV|Participants will receive RotaTeq (2 mL oral dose) at Visit 1 (Day 1), Visit 3 (30 to 42 days after Visit 1), and Visit 5 (30 to 42 days after Visit 3); and IPV (0.5 mL IM injection) at Visit 2 (15 to 21 days Visit 1), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
62603411|NCT06622707|EXPERIMENTAL|kinesio taping group|Kinesio taping will be applied to this group.
62603412|NCT06622707|EXPERIMENTAL|control group|Participants in this group will not receive any intervention other than routine clinical care.
62603413|NCT03769675|EXPERIMENTAL|Spinal Cord Stimulator Implant|Spinal Cord Stimulator implant
62603414|NCT01170637|ACTIVE_COMPARATOR|Ibuprofen 200 mg|Oral administration as a fixed dose combination tablet (RhinAdvil(R))
62825988|NCT05484635|ACTIVE_COMPARATOR|Diagnostic laparoscopy|Minimally invasive incisions will be made, and a diagnostic laparoscopy will be performed. The surgeon will evaluate the mesh configuration, ensuring proper positioning, perform adhesiolysis if indicated for bowel involvement with the mesh and assess the abdomen for alternative sources of chronic pain.
62246711|NCT00978835|ACTIVE_COMPARATOR|Nurse Education|Didactic, non-interactive education by a nurse on general health topics.
62246712|NCT03686956|EXPERIMENTAL|Experimental group|"The therapy lasted two months, at a rate of two sessions per week, with a duration of 45 minutes per session. The program consisted of pelvic floor exercises assisted by manometric biofeedback, which were performed in supine position for 20 minutes. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.~Together with the treatment at the clinic, patients were asked to perform a series of exercises at home, consisting in: 8-12 sustained contractions of 6 seconds, with a subsequent rest period of double the work-time, followed by 3-5 fast contractions of 2 seconds with maximum intensity, resting double the work-time. Domiciliary exercises were performed in supine, siting and standing position."
62603415|NCT01170637|ACTIVE_COMPARATOR|Pseudoephedrine-HCl 30 mg|Oral administration as a fixed dose combination tablet (RhinAdvil(R))
62603416|NCT01170637|ACTIVE_COMPARATOR|Ibuprofen 200 mg BI|Oral administration as a fixed dose combination tablet (BI product)
62603417|NCT01170637|ACTIVE_COMPARATOR|Pseudoephedrine-HCl 30 mg BI|Oral administration as a fixed dose combination tablet (BI product)
62603418|NCT04398654|NO_INTERVENTION|Control Group|Monitoring and therapy adjustment within the scope of the basic care described in the clinical trial plan.
62603419|NCT04398654|ACTIVE_COMPARATOR|Intervention Group|As in control group. In addition, in the intervention arm the CardioMEMSTM HF sensor implanted.
62603420|NCT00800813||open, laparoscopic, or robotic-assisted lap|Patients will also be assessed for penile length and the presence of Peyronie's Disease at these specified times.
62603421|NCT02707471|EXPERIMENTAL|SM-AET|a self-management intervention for enhancing skills to improve adherence and reduce symptom interference (SM-AET) (active intervention group)
62603422|NCT02707471|OTHER|general health education Intervention|general health education Intervention (control group)
62246713|NCT03686956|NO_INTERVENTION|Control group|The control group received an information brochure with recommendations, including the same program of pelvic floor exercises taught to the patients in the experimental group, but without carrying out any kind of supervision by the physiotherapist.
62044140|NCT01803074|EXPERIMENTAL|Part A-Group 9: BMS-955176 (80 mg) or Placebo|"BMS-955176 80 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
62246714|NCT03653104|EXPERIMENTAL|Melodica Intervention|An 8-week group intervention including twice-weekly sessions. Each session will last one hour in duration with approximately 20 minutes for instruction, 30 minutes in group music-making, and 10 minutes allocated for educational information about COPD, tobacco cessation, and pulmonary rehabilitation.
62246715|NCT03653104|ACTIVE_COMPARATOR|Education Control|A single 90-120 minute education session including the same educational information about COPD, tobacco cessation, and pulmonary rehabilitation provided to the melodica intervention group.
62246716|NCT03653104|NO_INTERVENTION|Usual Care Control|Usual care at Richard L. Roudebush VA Medical Center.
62246717|NCT03653104|NO_INTERVENTION|Interview Only|Semi-structured interviews will be conducted with Veterans who meet eligibility criteria, but who do not agree to participate in the intervention, to identify potential barriers to participation
62246718|NCT02615704||Active APP with MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using active APP with MEMS
62603423|NCT00846703|ACTIVE_COMPARATOR|Protocol A (MM)|
62603424|NCT00846703|EXPERIMENTAL|Protocol B (MM/VD)|
62603425|NCT00250458|EXPERIMENTAL|1|Rizatriptan (MK0462)10 mg orally disintegrating tablet/oral lyophilisate
62603426|NCT00250458|PLACEBO_COMPARATOR|2|matching placebo
62603427|NCT04494763|EXPERIMENTAL|Propanolol|Dose: 1 to 8 mg/kg/day in 1 to 2 divided doses adjusted to achieve target reduction in resting heart rate by 25% from baseline Frequency: once to Twice daily Route of Administration: Oral Duration: 18 months
62603428|NCT04494763|PLACEBO_COMPARATOR|Placebo|Placebo in a similar manner
62603429|NCT03639805|ACTIVE_COMPARATOR|non interventional arm|Standard Of Care
62603430|NCT03639805|EXPERIMENTAL|interventional arm|Standard of Care + music therapy program MUSIC CARE®
62603431|NCT06011460||Patients' name|Diagnosis of treatment-resistant depressive episode in the course of bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders-5. Age from 18 to 65 years old.
62603432|NCT04303936|OTHER|Patients with severe HA under FVIII concentrates prophylaxis|
62603433|NCT06526650|OTHER|Aim 3: Community Level Intervention|Aim 3 is community-driven, supports the overall goal of the PILI 'Āina project, allows all members of the community to benefit, and is strongly promoted within the community. The investigators will design and implement 'Ai Pono, a community-level component that can operate in tandem with PILI 'Āina. This component will not be tested in the group-randomized trial. Instead, all 7 communities will implement 'Ai Pono for the full study period.
62603434|NCT05997823|ACTIVE_COMPARATOR|home exercises|
62246719|NCT02615704||Active APP without MEMs|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using active APP without MEMS
62603435|NCT05997823|EXPERIMENTAL|sham-KT and home exercises|
62603436|NCT05997823|EXPERIMENTAL|dorso-volar KT and home exercises|
62603437|NCT06620822|ACTIVE_COMPARATOR|Sintilimab|
62603438|NCT06620822|EXPERIMENTAL|LM-108+Sintilimab|
62603439|NCT06620822|EXPERIMENTAL|IBI310+Sintilimab|
62825989|NCT05484635|EXPERIMENTAL|Laparoscopic mesh removal|Minimally invasive incisions will be made, and a diagnostic laparoscopy will be performed. The surgeon will evaluate the mesh configuration, ensuring proper positioning, perform adhesiolysis if indicated for bowel involvement with the mesh and assess the abdomen for alternative sources of chronic pain. If randomized to mesh removal, laparoscopic or robotic preperitoneal mesh removal.
62825990|NCT06235190|EXPERIMENTAL|Felix NeuroAI Wristband|
62825991|NCT06235190|SHAM_COMPARATOR|Sham Device|
62246720|NCT02615704||Control APP with MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using control APP with MEMS
62603440|NCT06620822|EXPERIMENTAL|IBI363|
62603441|NCT05884424|EXPERIMENTAL|PARO Therapy Robot|Participants allocated to the PARO Therapy Robot group will undergo three group robot therapy sessions per week for 12 weeks, in addition to continuing their standard care.
62603442|NCT05884424|NO_INTERVENTION|Control|Participants in the control group will maintain their standard care, participating in those activities previously assigned in their individual care plan.
62603443|NCT03243344|EXPERIMENTAL|Surgiflo|Using Surgiflo® (Absorbable Gelatin Hemostatic) for the post-operative haemostasis in endonasal surgery.
62246721|NCT02615704||Control APP without MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using control APP without MEMS
62246722|NCT00427089|EXPERIMENTAL|1|2L gut cleansing solution
62246723|NCT00427089|ACTIVE_COMPARATOR|2|
62246724|NCT02232620|EXPERIMENTAL|BBI503|
62246725|NCT05919290|OTHER|HNSCC patients|Up to 100 HNSCC patients receiving CT-based radiation therapy will receive up to weekly non-contrast MRI scans during treatment.
62436997|NCT04563078|SHAM_COMPARATOR|Sham Transcranial Magnetic Stimulation (TMS)|Sessions of Sham Transcranial Magnetic Stimulation (TMS) will be conducted.
62603444|NCT03243344|EXPERIMENTAL|Floseal|Using Floseal® (Absorbable Gelatin Hemostatic) containing human thrombin for the post-operative haemostasis in endonasal surgery
62603445|NCT03243344|EXPERIMENTAL|Algosteril|Using Algosteril® (Hemostatic Sterile Wick) for the post-operative haemostasis in endonasal surgery
62603446|NCT03243344|NO_INTERVENTION|Abstention|Not using device for the post-operative haemostasis in endonasal surgery
62603447|NCT02495194|EXPERIMENTAL|Active Horticultural Therapy|15 sessions of Horticultural Therapy program teaching the elderly about gardening techniques and for them to benefit from the therapeutic effects of the parks
62603448|NCT02495194|OTHER|Waitlist Control Group|Participants will receive the same horticultural therapy program at the end of the assessments
62603449|NCT03916731|EXPERIMENTAL|STARgraft AV|Participants will be implanted with 6mm diameter STARgraft AV grafts as an upper arm Brachial Artery to Axillary Vein shunt for hemodialysis access.
62603450|NCT03916731|ACTIVE_COMPARATOR|Control (ePTFE)|Participants will be implanted in the same upper arm location with standard 6mm diameter ePTFE dialysis access grafts. All other aspects of this study arm are identical to the Experimental one.
62603451|NCT04692766|EXPERIMENTAL|RPH-104 80 mg|subjects will receive RPH-104 at a dose of 80 mg subcutaneously once every 2 weeks
62603452|NCT04692766|PLACEBO_COMPARATOR|Placebo|subjects will receive placebo subcutaneously once every 2 weeks
62603453|NCT01346540|EXPERIMENTAL|BIBF 1120|VEGF inhibitor
62603454|NCT01346540|PLACEBO_COMPARATOR|Placebo|BIBF 1120 placebo
62603455|NCT05850390||Diagnosed asthma patients|Adults aged 18 and above who have been diagnosed with persistent asthma or allergy with asthma as a co-morbidity and are prescribed a controller medication.
62825992|NCT03085862||Lung ultrasound and EVLW|This prospective study involved 60 patients without known cardiac or pulmonary diseases admitted to the intensive care unit at our hospital after elective abdominal or vascular surgery. The inferior vena cava collapsibility index (IVCcl), PaO2/FiO2 ratio, and appearance of B-lines ≤7 mm were determined upon admission to the intensive care unit and at 6, 12, and 24 h later. Fluid overload was defined as IVCcl ≤ 40% and the presence of B-lines ≤7 mm. Tissue oxygenation impairment was defined as a PaO2/FiO2 ratio \< 200.
62825993|NCT06594978|EXPERIMENTAL|dual-site anodal tDCS over the M1|
62825994|NCT06594978|EXPERIMENTAL|dual-site anodal tDCS over the DLPFC|
62825995|NCT06594978|SHAM_COMPARATOR|sham tDCS|
62436998|NCT02521948|EXPERIMENTAL|MANTA Vascular Closure Device|The MANTA device, developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
62436999|NCT03171714|EXPERIMENTAL|Derma-Stent|The novel silicon packing device made of a nonabsorbent material to pack a drained abscess for healing.
62825996|NCT06119048|EXPERIMENTAL|Genetic Carriers and Non-Carriers of PKU|
62825997|NCT01950182|ACTIVE_COMPARATOR|Palliative chemotherapy|Chemotherapy combined with trastuzumab. Chemotherapy could use the following drugs such as capecitabine , Vinorelbine, or Gemcitabine.
62246726|NCT05919290|OTHER|Healthy volunteers and HNSCC patients|"Cohort A - Up to 20 healthy volunteers will undergo non-contrast MRI at two time points.~Cohort B - Up to 53 patients planned to receive curative (chemo) radiotherapy for HNSCC will undergo two baseline MRI scans, one MRI in week 2 and week 4, and final MRI scan 6-8 weeks after completion of treatment."
62246727|NCT00457873|EXPERIMENTAL|A|0.9% saline in 5% dextrose (intravenous)
62825998|NCT01950182|EXPERIMENTAL|Palliative endocrine therapy|Endocrine therapy combined with trastuzumab. Endocrine therapy could use tamoxifen or aromatase inhibitors including anastrozole, letrozole, or exemestane.
62825999|NCT06504992|EXPERIMENTAL|Treatment|Powdered, intrawound vancomycin 1000 mg at the time of definitive surgery for open fracture fixation in addition to the current best practice of intravenous antibiotics with irrigation and debridement
62826000|NCT06504992|NO_INTERVENTION|Control|Intravenous antibiotics with irrigation and debridement alone.
62826001|NCT06177080|OTHER|Definitions of active phase angle of progression, head symphysis distance and examination findings|Definitions of active phase AOP and HSD and examination findings measured in each period according to the type of birth
62246728|NCT00457873|ACTIVE_COMPARATOR|B|0.45% saline in 5% dextrose (intravenous)
62246729|NCT05949996|EXPERIMENTAL|Implementation condition|Under implementation condition, a nurse-led symptom distress screening program will be implemented using 5 implementation strategies including training, audit and feedback, facilitation and adaptable workflow.
62437000|NCT03171714|ACTIVE_COMPARATOR|Usual Care, cotton gauze packing|Standard of care to pack a drained abscess for healing.
62449195|NCT05898451|EXPERIMENTAL|The use of Refnot in combination with chemotherapy|Refnot is administered at a dose of 400,000 IU subcutaneously 3 times a week for 4 weeks. 4 weeks constitute 1 course of treatment with Refnot. In the absence of progression of the disease - an additional 4 weeks. Chemotherapy may be used after 4-8 weeks of Refnot use.
62603456|NCT06416020|ACTIVE_COMPARATOR|Hub Clinic MOUD with buprenorphine only (HC-MOUD Only)|Participants will receive MOUD with buprenorphine prescribed by providers based at participating hub clinics. MOUD treatment with buprenorphine will follow standard guidelines for induction and maintenance using a sublingual buprenorphine formulation. Hub clinic buprenorphine providers and participants may shift to long acting injection buprenorphine formulations after initial induction with sublingual buprenorphine. If telemedicine prescribing of MOUD with buprenorphine is part of the usual standard of care at the clinic, participants assigned to HC-MOUD Only may be prescribed buprenorphine via telemedicine, following the clinic's usual guidelines. Participants may not receive telemedicine services at the community spokes or Recovery Guiding, which are available only to participants assigned to BTMOUD. All study participants, however, may have access to any services that are routinely provided as part of the MOUD with buprenorphine treatment-as-usual care in the hub clinic.
62826002|NCT03413891|PLACEBO_COMPARATOR|Control Group|10mL water as mouthwash with white cherry flavor in oral syringes. Once before tooth extraction and 3 times daily during 3 days post-extraction (starting day after extraction).
62826003|NCT03413891|EXPERIMENTAL|Tranexamic Acid Group|10mL tranexamic acid mouthwash 10% in oral syringes. Once before tooth extraction and 3 times daily during 3 days post-extraction (starting day after extraction).
62826004|NCT04089787|EXPERIMENTAL|Intervention group|Shortened antibiotic treatment of 5 days
62826005|NCT04089787|ACTIVE_COMPARATOR|Control group|Antibiotic treatment of 7 days or longer at the discretion of the treating physician
62826006|NCT06589141|EXPERIMENTAL|Metformin|Metformin (500 to 2000 mg orally)
62826007|NCT06589141|EXPERIMENTAL|Glyburide|Glyburide (2.5 mg to 20 mg orally)
62826008|NCT05074979|OTHER|control group|While other groups continue their exercise program for 6 weeks, this group will only be informed after COVID 19.
62826009|NCT05074979|EXPERIMENTAL|home exercise program group|this group will implement COVID 19 home exercise program.
62826010|NCT05074979|EXPERIMENTAL|telerehabilitation group|this group will implement COVID 19 telerehabilitation program.
62826011|NCT03712358|EXPERIMENTAL|Cohort 0 (PVSRIPO)|A single dose of PVSRIPO into a single lesion.
62826012|NCT03712358|EXPERIMENTAL|Cohort 1 (PVSRIPO)|A single dose of PVSRIPO into 2 different lesions, 21 days apart, when applicable per dose escalation guidelines.
62826013|NCT03712358|EXPERIMENTAL|Cohort 2 (PVSRIPO)|A single dose of PVSRIPO into 3 different lesions, 21 days apart, when applicable per dose escalation guidelines.
62826014|NCT03712358|EXPERIMENTAL|Cohort 3 (PVSRIPO)|A single dose of PVSRIPO into 3 different lesions, 21 days apart, when applicable per dose escalation guidelines.
62603457|NCT06416020|EXPERIMENTAL|Recovery Guiding / Better Together Medications for Opioid Use Disorder (BT-MOUD) procedures|Better Together Medications for Opioid Use Disorder (BT-MOUD) includes HC-MOUD plus access to telemedicine provision of MOUD with buprenorphine at a nonmedical community organization spoke, plus manual-guided Recovery Guiding provided onsite at the spoke, and plus any other services available at the community organization spoke. Recovery Guiding is a manualized, highly structured, stepwise intervention that uses educational and behavioral tools to provide pragmatic guidance for patients beginning buprenorphine treatment and to address the key recovery misconceptions and dysfunctional behaviors that frequently interfere with recovery efforts of patients initiating medication for opioid use disorder (MOUD) treatment.
62603458|NCT03633799|EXPERIMENTAL|VeraCept|VeraCept™ Intrauterine Contraceptive
62044141|NCT01803074|EXPERIMENTAL|Part A-Group 10: BMS-955176 (120 mg) or Placebo|"BMS-955176 120 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
62246730|NCT05949996|NO_INTERVENTION|Control condition|The control condition is the usual clinical outpatient operation without the specific implementation program (i.e. applying the five implementation strategies including training, audit and feedback, facilitation and adaptable workflow) for standardized routine symptom distress screening. Prior to the start of the first 4-month control condition, we will meet each study unit and brief the staff about the purpose of this implementation study, as well as the introduction of the symptom distress screening tool. The symptom distress screening tool and referral forms will be given to the study sites. The staff are encouraged to screened and referred all eligible patients to JCICC, a local cancer care centre. In contrast to the intervention condition, there will be no half-day skill training workshop and no weekly audit and feedback report delivered and discussed with the site facilitator. We will keep the recording of the briefing session for fidelity assessment.
62246731|NCT02137122|EXPERIMENTAL|Cognitive Training + Active tDCS|Participants will undergo up to 10 hours of cognitive training. Cognitive training will involve computerized games that stress elements of cognition. The group will undergo active transcranial direct current stimulation.
62603459|NCT02559726|EXPERIMENTAL|O-HCM|20 patients with Hypertrophic Cardiomyopathy with outflow-tract obstruction
62826015|NCT03712358|EXPERIMENTAL|Cohort 4 (PVSRIPO)|A single dose of PVSRIPO into a single lesion, followed by PVSRIPO injected into up to 6 lesions at Day 10 and every 21 days thereafter.
62603460|NCT02559726|EXPERIMENTAL|NO-HCM|20 patients with Hypertrophic Cardiomyopathy without outflow-tract obstruction
62603461|NCT02559726|OTHER|healthy volunteers|20 healthy volunteers
62826016|NCT04475978|EXPERIMENTAL|IVUS group|
62246732|NCT02137122|SHAM_COMPARATOR|Cognitive Training + Sham tDCS|Participants will undergo up to 10 hours of cognitive training. Cognitive training will involve computerized games that stress elements of cognition. The group will undergo sham transcranial direct current stimulation.
62603462|NCT01131884|ACTIVE_COMPARATOR|Fosamax|Fosamax at 70 mgs q weekly by mouth for the duration of the study.
62603463|NCT01131884|PLACEBO_COMPARATOR|Placebo Sugar Pill|Double blind study using Fosamax versus placebo. Placebo is an inactive drug.
62603464|NCT01232530||Safety Active Surveillance Group|For the active surveillance, all age groups, including children less than 5 years of age, will be identified from the census database and encouraged to attend the health facility whenever sick. Those with a diagnosis of malaria and treated with an antimalarial drug will be actively monitored for AEs.
62603465|NCT01232530||Safety Passive Surveillance Group|For the people under passive surveillance, sick subjects attending the health facilities, diagnosed with malaria and treated with an antimalarial drug will be identified from the census database. The treatment administered will be recorded in a drug exposure log book and the patients will be encouraged to report passively any AE/ADR.
62603466|NCT01232530||Early Pregnancy Exposure to ACTs Group|All the pregnant women identified during the repeat surveys will be included in a pregnancy cohort. At the time the pregnant woman is identified, her possible exposure to ACTs will be extracted from the drug exposure log book or elicited by history. Births identified through the repeat surveys or any other outcome of pregnancy will be retrospectively matched with antimalarial treatment exposure, particularly during the first trimester of the pregnancy.
62826017|NCT04475978|PLACEBO_COMPARATOR|Angio group|
62246733|NCT00680823|EXPERIMENTAL|Ropivacaine Injections|Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of 0.5% ropivacaine on each side.
62826018|NCT03098875|ACTIVE_COMPARATOR|Sevoflurane|"General anesthesia using sevoflurane as a hypnotic agent, and remifentanil as an analgesic.~Two steady state periods of 10 minutes each, one with a steady bispectral index at 25 +/- 5, the other with a steady bispectral index at 55 +/- 5. Continuous recording of heart rate during the last minute of each steady-state. Off-line spectral analysis of heart rate variability."
62826019|NCT03098875|ACTIVE_COMPARATOR|Propofol|"General anesthesia using propofol as a hypnotic agent, and remifentanil as an analgesic.~Two steady state periods of 10 minutes each, one with a steady bispectral index at 25 +/- 5, the other with a steady bispectral index at 55 +/- 5. Continuous recording of heart rate during the last minute of each steady-state. Off-line spectral analysis of heart rate variability."
62826020|NCT06317051|ACTIVE_COMPARATOR|Dapagliflozin 10mg + pitavastatin 4mg|Dapagliflozin 10mg + pitavastatin 4mg given as daily tablets for 48 weeks
62044142|NCT01803074|EXPERIMENTAL|Part A-Group 11 (Optional): BMS-955176 (≤120 mg) or Placebo|"BMS-955176 ≤120 mg solution by mouth once daily for 14 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 14 days"
62826021|NCT06317051|ACTIVE_COMPARATOR|Dapagliflozin 10mg + rosuvastatin 10mg/ezetimibe 10mg|Dapagliflozin 10mg + rosuvastatin 10mg/ezetimibe 10mg given as daily tablets for 48 weeks
62044143|NCT01803074|EXPERIMENTAL|Part B-Group 12: BMS-955176 (80 mg) + Atazanavir|"BMS-955176 80 mg solution by mouth once daily for 28 days~Atazanavir 2 x 200 mg capsules by mouth once daily for 28 days"
62603467|NCT01232530||ACT Effectiveness Monitoring Group|"Besides monitoring AEs and ADRs, data on the effectiveness of ACTs when used in real life conditions and on a large scale will be collected in the active surveillance area. For patients with a microscopically confirmed diagnosis of malaria, clinical symptoms and a blood sample for thick and thin blood smears, will be collected before antimalarial treatment, at day 28 after treatment and at any unscheduled visit. Treatment administration will not be supervised."
62603468|NCT06287866|NO_INTERVENTION|Second Intention Wound Healing|
62603469|NCT06287866|EXPERIMENTAL|Pinch Grafting|
62603470|NCT01455246|EXPERIMENTAL|Daptomycin + Meropenem|30 patients with cirrhosis and nosocomial SBP
62603471|NCT01455246|ACTIVE_COMPARATOR|Ceftazidime|30 patients with cirrhosis and nosocomial SBP
62603472|NCT05020405|EXPERIMENTAL|ARS with GBR and SMV|alveolar ridge splitting in combination with the use of GBR with SMV with immediate implant placement
62603473|NCT05020405|ACTIVE_COMPARATOR|alveolar ridge splitting with GBR|alveolar ridge splitting in combination with the use of GBR without SMV with immediate implant placement
62603474|NCT01626625|EXPERIMENTAL|stem cells|stem cells + hydroxy apatite
62603475|NCT01626625|ACTIVE_COMPARATOR|autograft|
62603476|NCT05409079|EXPERIMENTAL|Abilitech Assist|The Abilitech™ Assist device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
62603477|NCT02948010|ACTIVE_COMPARATOR|Auto CPAP + comfort feature A|Auto CPAP with comfort feature A using Fisher \& Paykel Healthcare CPAP Device
62603478|NCT02948010|ACTIVE_COMPARATOR|Auto CPAP with comfort feature B|Auto CPAP with comfort feature B using Fisher \& Paykel Healthcare CPAP Device
62603479|NCT02948010|ACTIVE_COMPARATOR|Auto CPAP with no comfort feature|Auto CPAP with no comfort feature using Fisher \& Paykel Healthcare CPAP Device
62603480|NCT02948010|ACTIVE_COMPARATOR|Auto CPAP with comfort feature A+B|Auto CPAP with comfort feature A+B using Fisher \& Paykel Healthcare CPAP Device
62603481|NCT02948010|ACTIVE_COMPARATOR|CPAP with comfort feature A|CPAP with comfort feature A using Fisher \& Paykel Healthcare CPAP Device
62603482|NCT02948010|ACTIVE_COMPARATOR|CPAP with comfort feature B|CPAP with comfort feature B using Fisher \& Paykel Healthcare CPAP Device
62603483|NCT02948010|ACTIVE_COMPARATOR|CPAP with no comfort feature|CPAP with no comfort feature using Fisher \& Paykel Healthcare CPAP Device
62603484|NCT02948010|ACTIVE_COMPARATOR|CPAP with comfort feature A + B|CPAP with comfort feature A + B using Fisher \& Paykel Healthcare CPAP Device
62603485|NCT02948010|ACTIVE_COMPARATOR|CPAP at Sub therapeutic level|CPAP at Sub therapeutic level using Fisher \& Paykel Healthcare CPAP Device
62603486|NCT04518969|NO_INTERVENTION|Control|Standard medical therapy (ie: control group) : Adult intensive care patient admit in acute respiratory distress needing intubation with suspicion of under the CT Scan of Covid 19 confirmed by positive antigen or PCR technology N =12 -Mechanical ventilation, prone position if needed,fluid challenge if needed , vasopressors if needed, inotropic support in needed......
62603487|NCT04518969|EXPERIMENTAL|Cytosorb|"CytoSorb therapy (ie: study group): Adult intensive care patient admit in acute respiratory distress needing intubation with suspicion of under the CT Scan of Covid 19 confirmed by positive antigen or PCR technology N =12 -Mechanical ventilation, prone position if needed,fluid challenge if needed , vasopressors if needed, inotropic support in needed...... Plus patients will be on CRRT with CytoSorb.Nevertheless , patients will be uniquely in CVVHD mode in order to measure only the CytoSorb Effect.~First 24 h : the CytoSorb should be changed after 12 h as we forecast a huge cytokine storm in the first 24 hours.~After the initial 24 h, cartridge change will occur every 24 hours up a maximum of 96 h in total in the inflammation storm persist."
62826022|NCT06317051|PLACEBO_COMPARATOR|Placebo + pitavastatin 4mg|Placebo + pitavastatin 4mg given as daily tablets for 48 weeks
62603488|NCT01981343|EXPERIMENTAL|A-F Betafood|Two A-F Betafood tablets taken with a meal, 3 times daily for 12 weeks
62603489|NCT01981343|PLACEBO_COMPARATOR|Placebo|2 Placebo tablets taken with a meal, 3 times daily for 12 weeks
62603490|NCT05591924||ESTABLISH|Adults over 18 years of age admitted to the ICU within 48 hours and whose presentation to the Emergency Department was within 72h of ICU admission.
62603491|NCT05591924||Healthy Controls|Adults over 18 years of age with no infectious symptoms, interaction with the health care system, or antimicrobial use in the past 14 days and no history of immunosuppression.
62603492|NCT01907061|ACTIVE_COMPARATOR|600 mg N-acetylcysteine or placebo IV|600 mg N-acetylcysteine or placebo IV perfused over 15 minutes during the transplant procedure, prior to reperfusion,
62603493|NCT01907061|ACTIVE_COMPARATOR|600 mg N-acetylcysteine or placebo NG|600 mg NAC or placebo administered via NG tube starting at 12 hrs + 30 min post O.R. infusion,
62603494|NCT01907061|ACTIVE_COMPARATOR|N-acetylcysteine or placebo q 12 hour|600 mg NAC or placebo administered via NG tube every 12 hrs + 30 min for 3 additional doses (at 24, 36 and 48 hrs post O.R. infusion). The total administration will be 3000 mg over a 48 hr period.
62603495|NCT01976468||SCC metastasis|organ transplant recipients
62603496|NCT02827643|ACTIVE_COMPARATOR|TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement|Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study
62603497|NCT02827643|OTHER|TDF/3TC or FTC/EFV|the subjects in this arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.
62603498|NCT02544295|EXPERIMENTAL|Clinical interview-Virtual reality task:1|Healthy controls will be assessed by a clinical interview by a psychiatrist, once, 1 day-duration and Virtual reality task, once, 1 day-duration
62603499|NCT02544295|EXPERIMENTAL|Clinical interview-Virtual reality task:2|Patients will be assessed by a clinical interview by a psychiatrist, once, 1 day-duration and Virtual reality task, once, 1 day-duration
62826023|NCT06317051|PLACEBO_COMPARATOR|Placebo + rosuvastatin 10mg/ezetimibe 10mg|Placebo + rosuvastatin 10mg/ezetimibe 10mg given as daily tablets for 48 weeks
62826024|NCT03193255|ACTIVE_COMPARATOR|No daily lens rubbing|Daily lens disinfection with OPHTECS cleadew GP without lens rubbing
62826025|NCT03193255|ACTIVE_COMPARATOR|Daily rubbing|Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with cleadew GP
62246734|NCT00680823|PLACEBO_COMPARATOR|Normal Saline Injections|Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of normal saline on each side.
62603500|NCT03714854|ACTIVE_COMPARATOR|Deep brain stimulation ON|Patients will undergo every experimental tasks with their DBS stimulator in ON and OFF positions. Order of ON/OFF conditions will be counterbalanced between patients.
62603501|NCT03714854|PLACEBO_COMPARATOR|Deep brain stimulation OFF|Patients will undergo every experimental tasks with their DBS stimulator in ON and OFF positions. Order of ON/OFF conditions will be counterbalanced between patients.
62826026|NCT03193255|ACTIVE_COMPARATOR|Daily rubbing with separate cleaner|Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with a daily lipid cleaner
62826027|NCT03193255|ACTIVE_COMPARATOR|Daily rubbing and weekly protein removal|Daily lens disinfection with OPHTECS cleadew GP after daily lipid cleaner followed by weekly protein removal treatment
62826028|NCT06599151|EXPERIMENTAL|Pain Patients With Spinal or Peripheral Nerve Origin|Individuals suffering from nerve pain that is of spinal or peripheral nerve origin and undergo a \[18F\]FTC-146 PET/MRI scan.
62826029|NCT06599151|EXPERIMENTAL|Healthy Volunteers|Individuals who do not have pain and undergo a \[18F\]FTC-146 PET/MRI scan.
62826030|NCT01742026||High Risk Oncohematological Patients|Detection Aspergillus PCR technique and Aspergillus AGA technique
62826031|NCT06271993|OTHER|Collagen wound dressing with positive and negative controls|Application of test dressing, histamine, and saline with glycerin to volar forearm skin
62246735|NCT00680823|NO_INTERVENTION|Observation|Observation for 30 minutes.
62826032|NCT02003924|SHAM_COMPARATOR|Placebo|Sugar pill manufactured to mimic enzalutamide 40 mg capsule
62044144|NCT01803074|EXPERIMENTAL|Part C-Group 13: BMS-955176 (120 mg) or Placebo|"BMS-955176 120 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
62246736|NCT06117371|EXPERIMENTAL|Monotherapy group 1|BEBT-607 tablets, 100mg/day,50mg each time, are administered once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days. 28 days is as a treatment cycle.
62246737|NCT06117371|EXPERIMENTAL|Monotherapy group 2|BEBT-607 tablets, 200mg/day,100mg each time, are administered once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days. 28 days is as a treatment cycle.
62246738|NCT06117371|EXPERIMENTAL|Monotherapy group 3|BEBT-607 tablets, 300mg/day,150mg each time, are administered once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days. 28 days is as a treatment cycle.
62826033|NCT02003924|EXPERIMENTAL|Enzalutamide|160 mg by mouth once daily
62826034|NCT04815876|ACTIVE_COMPARATOR|Transrectal|Patients will receive a transrectal MRI-guided prostate biopsy.
62826035|NCT04815876|ACTIVE_COMPARATOR|Transperineal|Patients will receive a transperineal MRI-guided prostate biopsy.
62603502|NCT03058224|EXPERIMENTAL|IGN-ES001|Polyclonal avian immunoglobulin IgY containing specific IgY against E. coli F18ab and S. typhimurium in partially delipidated avian egg yolk powder
62603503|NCT03058224|PLACEBO_COMPARATOR|Placebo|Polyclonal avian immunoglobulin IgY containing unspecific IgY in partially delipidated avian egg yolk powder
62603504|NCT04492605|PLACEBO_COMPARATOR|Placebo|Placebo
62603505|NCT04492605|EXPERIMENTAL|TCI378 Probiotics|TCI378 Probiotics
62246739|NCT06117371|EXPERIMENTAL|Monotherapy group 4|BEBT-607 tablets, 400mg/day,200mg each time, are administered once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days. 28 days is as a treatment cycle.
62246740|NCT06117371|EXPERIMENTAL|Monotherapy group 5|BEBT-607 tablets, 600mg/day,300mg each time, are administered once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days. 28 days is as a treatment cycle.
62603506|NCT04492605|EXPERIMENTAL|TCI507 Probiotics|TCI507 Probiotics
62603507|NCT00843037|EXPERIMENTAL|Open label - Sunitinib|Sunitinib, 50mg daily, once daily for 4 weeks followed by a 2-week break
62603508|NCT01546168|EXPERIMENTAL|esophageal deviation|esophageal deviation with IDE device during AF ablation
62826036|NCT05452863|ACTIVE_COMPARATOR|Automatic oxygen supply|Oxygen will be supplied by the O2matic device
62826037|NCT05452863|PLACEBO_COMPARATOR|Manual oxygen supply|Oxygen will be supplied by nurse adjustments in the usual way
62826038|NCT06595927|EXPERIMENTAL|Participants with chronic neck pain|"Both groups will receive the same experimental procedure, divided in 2 parts.~Part 1: a first cervical MRI is done, followed by a cervical extensor endurance test during 3 minutes and the second cervical MRI.~Part 2 : several clinical tests will be done:~* tandem stand balance test (eyes closed, firm ground)~* cranio-cervical flexion test~* head lift test~* cervical joint position error sense test in 4 directions"
62826039|NCT06595927|ACTIVE_COMPARATOR|Participants free of neck pain|the same experimental procedure than the other group
62826040|NCT06318143|NO_INTERVENTION|Education|provision of information about task sharing
62826041|NCT06318143|EXPERIMENTAL|TASSH|replicable evidence-based task-sharing strategy,TAsk-Strengthening Strategy for Hemoglobinopathies (TASSH)
62044145|NCT06497452||Observational Cohort|
62246741|NCT06117371|EXPERIMENTAL|Monotherapy group 6|BEBT-607 tablets, 800mg/day,400mg each time, are administered once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days. 28 days is as a treatment cycle.
62246742|NCT06117371|EXPERIMENTAL|Monotherapy group 7|BEBT-607 tablets, 300mg/day,150mg each time, are administered twice a day (only once on day 1 and day 28 of the first cycle), continuous administration for 28 days. 28 days is as a treatment cycle.
62603509|NCT01546168|NO_INTERVENTION|temperature monitoring|luminal esophageal temperature monitoring, standard temperature monitoring alone
62246743|NCT06117371|EXPERIMENTAL|Monotherapy group 8|BEBT-607 tablets, 400mg/day,200mg each time, are administered twice a day (only once on day 1 and day 28 of the first cycle), continuous administration for 28 days. 28 days is as a treatment cycle.
62826042|NCT06587542|EXPERIMENTAL|HIV-positive patients with anogenital warts|Injection of protein purified derivative
62826043|NCT06587542|EXPERIMENTAL|HIV-negative patients with anogenital warts|
62826044|NCT06518239|EXPERIMENTAL|PEEP Belt|PEEP belt will be placed on the patient intraoperatively. All patients will be monitored using anesthesia machines as standard of care.
62826045|NCT06590649|EXPERIMENTAL|Household Participants|The household participants will be analyzed alongside the index participants to determine household-level effects from the intervention. Household participants must live in an index participant's household. Index participants are allowed to have up to 3 household participants.
62826046|NCT00688987|ACTIVE_COMPARATOR|1|Subjects with AI will be randomized to each of three doses of hydrocortisone for 4 months on each dose.
62826047|NCT00688987|ACTIVE_COMPARATOR|2|isocaloric diet
62826048|NCT04047602|EXPERIMENTAL|Reduced Dose Stereotactic Radiosurgery|Subjects will receive one stereotactic radiosurgery (SRS) treatment at a reduced dose based on the brain tumor size concurrently with their standard of care immunotherapy. Subjects will undergo follow up with clinical exams and brain MRI scans at 1, 3, 6, 9, and 12 months post SRS treatment
62826049|NCT02249663|EXPERIMENTAL|Investigational Test Product|Azelastine hydrochloride and Fluticasone propionate Nasal Spray, 137/50 mcg
62826050|NCT02249663|ACTIVE_COMPARATOR|Reference Listed Drug|Dymista™ (azelastine hydrochloride/fluticasone propionate) Nasal Spray, 137/50 mcg
62826051|NCT02249663|PLACEBO_COMPARATOR|Placebo|Placebo Nasal Spray
62826052|NCT06594991|EXPERIMENTAL|Refractory melanoma after PD-1 monotherapy (Cohort A)|All patients will receive intravenous Fianlimab and Cemiplimab every three weeks continuously. Ipilimumab will be given every 6 weeks continuously.
62044146|NCT01542606|EXPERIMENTAL|color status|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
62246744|NCT06117371|EXPERIMENTAL|Monotherapy group 9|BEBT-607 tablets, 600mg/day,300mg each time, are administered twice a day (only once on day 1 and day 28 of the first cycle), continuous administration for 28 days. 28 days is as a treatment cycle.
62246745|NCT01852682|EXPERIMENTAL|PA21|
62246746|NCT04643314|EXPERIMENTAL|Guided video-based self-evaluation|"In addition to their usual residency training, participants randomized to this group will undergo the following interventions:~The participants will be asked to review their own operating room recordings (of each of the 5 consecutive submitted laparoscopic cholecystectomy cases that the participant acted as the primary operator) and to assess themselves (within 72 hours (3 days) of the procedure) using validated intra-operative assessment tools. The completion of the self-evaluations is to guide and document video-based self-reflection. The duration of self-assessment/reflection session will be up do the participant. Residents in this group will have unlimited access to their recordings through the web-based platform. On the other hand, they will not be able to access the battery of assessment forms after the third day following the procedure."
62246747|NCT04643314|NO_INTERVENTION|Traditional intraoperative teaching|"Subjects randomized to this group will undergo their usual residency training.~The recordings of the 5 submitted consecutive laparoscopic cholecystectomy procedures performed by the participant as the primary operator will be stored. However participants in this arm of the study will not have access to the uploaded videos until the end of the study."
62603510|NCT06532604|EXPERIMENTAL|SSRI treated patients|MDD patients treated with Selective Serotonin Reuptake Inhibitors (SSRIs) the day after the inclusion visit.
62603511|NCT06532604|EXPERIMENTAL|Alpha-2 antagonists treated patients|MDD patients treated with alpha-2 adrenergic receptor antagonists (alpha-2 antagonists) the day after the inclusion visit.
62603512|NCT01877382|EXPERIMENTAL|Part 1, Milademetan Alone|Participants receive milademetan alone with different dose schedules.
62603513|NCT01877382|EXPERIMENTAL|Part 2, Milademetan Alone|Participants with advanced melanoma and diffuse large B cell lymphoma (DLBCL) receive milademetan alone with different dose schedules.
62826053|NCT06594991|EXPERIMENTAL|Refractory melanoma after combined PD-1 and LAG-3 blockade (Cohort B)|All patients will receive intravenous Fianlimab and Cemiplimab every three weeks continuously. Ipilimumab will be given every 6 weeks continuously.
62826054|NCT05438849||Women Veterans receiving primary care in VISN-7 of the VA Healthcare Administration (VHA)|This project will include English-speaking, community-dwelling women Veterans 20 years or older with a diagnosis of UI (all types) and access to the internet via a mobile device or computer. Women Veterans who are currently pregnant or less than 12 weeks postpartum will be excluded. PURSUIT utilizes a mobile health application, called MyHealtheBladder, to connect patients with nonsurgical treatment options.
62044147|NCT04207827|EXPERIMENTAL|xSmoker app|"The xSmoker app was developed with European Commission funding. xSmoker is a digital health coaching mobile app that helps individuals stop smoking and remain smoke free. The initial version of the xSmoker application was received from the developers and translated into Romanian by the research team. The content has been divided into three main sections: Daily Tips (approximately 630 items), which includes information on the beneficial effects of quitting smoking, Panic Tips (approximately 100 items), which can be accessed at that time when risk of smoking relapse is high, as well as a section called Library (about 120 items), where detailed information on the topics included in the first two sections is provided."
62246748|NCT00121693|EXPERIMENTAL|Music Listening 1|Intervention: Listen to Music type 1
62246749|NCT00121693|EXPERIMENTAL|Music Listening 2|Intervention: Listen to Music type 2
62246750|NCT00121693|EXPERIMENTAL|Music LIstening 3|Intervention: Listen to Music type 3
62437001|NCT04009967|EXPERIMENTAL|Prostate Cancer|Participants will receive 3 cycles of pembrolizumab regardless of PD-L1 status. After completion of the second cycle of pembrolizumab treatment, and just before the third injection of pembrolizumab an 18FDG-PET/CT scan will be performed to assess a potential metabolic response. Then between 2 to 4 weeks after the third treatment, subjects will undergo radical prostatectomy. Subjects will be followed every 3 months during the first year post-surgery and according to physician decision during the following years.
62437002|NCT01169649|EXPERIMENTAL|islet cell carcinomas and carcinoid tumors|This is an open label phase II study of MK-2206 administered to patients with metastatic neuroendocrine tumors.
62246751|NCT00121693|NO_INTERVENTION|Control|Intervention: Listen to White noise
62246752|NCT01062945|PLACEBO_COMPARATOR|Placebo|
62246753|NCT01062945|ACTIVE_COMPARATOR|Doxazosin|
62246754|NCT02320955||Reimplantation of cryoconserved bone flap|All patients who receive reimplantation of a cryoconserved autologous bone flap
62246755|NCT05812040|OTHER|MRD + HR-MRD|
62437003|NCT05938153||geriatrics individuals|
62246756|NCT06736028|EXPERIMENTAL|Ketogenic Diet|During the first six weeks, participants will follow a low-energy diet aiming at inducing a minimum of 5% weight loss. This will be followed by a 2-week refeeding and weight stabilization phase. Then, this group will follow an eucaloric ketogenic diet (5% CHO: 70% fat; 25% protein) for 4 weeks aiming at weight loss maintenance.
62246757|NCT06736028|ACTIVE_COMPARATOR|Low-Fat Diet|During the first six weeks, participants will follow a low-energy diet aiming at inducing a minimum of 5% weight loss. This will be followed by a 2-week refeeding and weight stabilization phase. Then, this group will follow an eucaloric low-fat diet (50% CHO: 25% fat: 25% protein) for 4 weeks aiming at weight loss maintenance.
62246758|NCT01566682||Indeterminate Pulmonary Lesions|Patients with Pulmonary Lesions as seen by CT
62437004|NCT04805281|ACTIVE_COMPARATOR|Lithium Disilicate IPS e.max crowns in posterior teeth|
62437005|NCT04805281|EXPERIMENTAL|Monolithic Zirconia (5Y-TZP/3-YTZP) crowns in posterior teeth|
62437006|NCT02514187|OTHER|Evaluation of hyperthyroidism|For the evaluation of hyperthyroidism each research subject will undergo imaging using both cyclotron-produced 99mTc and the current standard method used at the site for thyroid imaging (either 123I or generator-produced 99mTc). Each study will be performed on a separate day, with flexibility to schedule either study first.
62826055|NCT05438849||Health care providers in community-based outpatient clinics in VISN-7 of the the VHA|Community-Based Outpatient Clinics (CBOCs) from VA Integrated Service Network (VISN) 7 will be targeted, spanning the states of Alabama, Georgia, and South Carolina. VISN 7 CBOCs, serving at least 50 women Veterans with primary care services, will be recruited.
62826056|NCT00762164|ACTIVE_COMPARATOR|1Vytorin 10/80 divided into 4|Vytorin 10/80 divided into 4
62826057|NCT00762164|ACTIVE_COMPARATOR|Simvastatin|Simvastatin 20 milligrams
62826058|NCT01533207|EXPERIMENTAL|Arm I (chemotherapy)|Patients receive adjuvant gemcitabine hydrochloride IV over 70-90 minutes on days 1 and 8 and docetaxel IV over 30-60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo CT and/or MRI. Patients with no evidence of disease receive doxorubicin hydrochloride IV every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim SC on days 2-8 or pegfilgrastim SC on day 2 or 3.
62826059|NCT01533207|OTHER|Arm II (no treatment)|Patients undergo clinical observation.
62826060|NCT01391416||CKD stage 3-4|CKD stage 3-4 from Thai SEEK study
62826061|NCT01391416||hyperhomocysteine group|CKD stage 3-4 from Thai SEEK study
62826062|NCT05135533|EXPERIMENTAL|Portable Neuromodulation Stimulator|
62826063|NCT05135533|SHAM_COMPARATOR|Sham|
62603514|NCT00176436|ACTIVE_COMPARATOR|active|Atomoxetine titrated up to 120 mg/day by week 8 and continues at 120 mg/day through week 24. Diet support group, group counseling and exercise.
62246759|NCT05137496|EXPERIMENTAL|Ruxolitinib+methylprednisolone|Ruxolitinib and methylprednisolone administered as the first-line therapy
62246760|NCT01903291||dimethyl fumarate|To be taken according to the United States Prescribing Information (USPI)
62246761|NCT01672034||Obese, BMI > 35|
62246762|NCT04597814||interstitial lung disease patients|interstitial lung disease patients who need lung transplantation
62246763|NCT04597814||non- interstitial lung disease patients|non- interstitial lung disease patients who need thoracic surgery to remove pneumatocele
62603515|NCT00176436|PLACEBO_COMPARATOR|Placebo|Placebo medication, diet support group, group counseling and exercise
62826064|NCT06593795||Group ECV|Pregnant women with a fetus in breech presentation at term of pregnancy undergoing an external cephalic version (ECV) maneuver. This procedure is aimed to induce fetal cephalic position allowing vaginal delivery instead of cesarean section
62603516|NCT06622954|OTHER|Protein- and Calorie restriction group|This group will receive the dietary intervention.
62826065|NCT03841461||Academicians|The academicians working in any program of any higher education institution
62826066|NCT01980017|NO_INTERVENTION|Wait-Listed Control Group|Usual care for smoking cessation
62603517|NCT06622954|NO_INTERVENTION|Control Group|This group will not receive any intervention.
62603518|NCT02143791|EXPERIMENTAL|Burst and Tonic stimulation|All subjects were required to receive BurstDR stimulation therapy for the first 3 months after permanent implant. Thereafter the stimulation mode could be changed to tonic stimulation depending on patient's preference or physician's discretion.
62603519|NCT03604770||Women seeking fertility treatment|Women aged 18-45 who are seeking fertility treatment at Bethesda Fertility Center will be provided a survey and food diary to complete.
62603520|NCT00993759|NO_INTERVENTION|No treatment|
62826067|NCT01980017|EXPERIMENTAL|Ottawa Model for Smoking Cessation|Ottawa Model for Smoking Cessation
62826068|NCT05536635|EXPERIMENTAL|breathing techniques|The patients in the intervention group will be taught and practiced breathing technique. Breathing techniques will be taught face-to-face by the researcher to the patients in the intervention group. The participant will breathe through one nostril at a natural rate and depth, while the other nostril will be closed with the thumb or forefinger. After the act of breathing, it will open the closed nostril, close the open nostril and breathe naturally. As explained later, they will continue the cycle with the act of breathing. This process is described as a loop.
62826069|NCT05536635|NO_INTERVENTION|treatment as usual|The control group will continue his/her usual treatment as advised by the physician.
62826070|NCT03566290|EXPERIMENTAL|Open-Label Extension, 3 mg GTx-024|Eligible subjects from G201002
62826071|NCT00771277|EXPERIMENTAL|Arm 1|Use of volunteer support teams to provide services
62246764|NCT03384914|ACTIVE_COMPARATOR|Dendritic Cell (DC1) Vaccine|"The vaccine will be administered in two phases: a vaccination phase and a booster phase.~Approximately 6 months from the initiation of the first vaccine, patients will receive the first of 3 booster vaccines."
62246765|NCT03384914|ACTIVE_COMPARATOR|pUMVC3-IGFBP2-HER2-IGF1R (WOKVAC)|"The vaccine will be administered in two phases: a vaccination phase and a booster phase.~Approximately 6 months from the initiation of the first vaccine, patients will receive the first of 3 booster vaccines."
62246766|NCT02872077|ACTIVE_COMPARATOR|Auricular Acupuncture|Study subjects randomized to this group will receive auricular acupuncture: the investigator will evaluate the infant using an ear point locator to determine active sites, and will place acupuncture needles in the active sites found in one ear. Acupuncture sites will be alternated every 3 days between right and left ear.
62246767|NCT02872077|NO_INTERVENTION|Control|The subjects randomized to the control group will have NO interventions, and will continue to receive routine care for NAS, pharmacologic and non-pharmacologic, per NICU protocol.
62246768|NCT03565276|EXPERIMENTAL|Experimental: TXA|Intravenous Tranexamic Acid beginning at 5mg/kg administered as part of a dose-escalation design.
62246769|NCT00578786|EXPERIMENTAL|Ambrisentan|2.5, 5 or 10 mg ambrisentan
62246770|NCT01655927|EXPERIMENTAL|Tranexamic Acid|15 mg/Kg Tranexamic Acid IV after anesthesic induction,and continues with a dose of 1mg/kg/h intraoperatory
62246771|NCT01655927|PLACEBO_COMPARATOR|Saline (Placebo)|15 mg/Kg of Saline IV after anesthesic induction,and continues with a dose of 1mg/kg/h intraoperatory
62246772|NCT02236884|EXPERIMENTAL|no-scar transanal TME|no-scar transanal total mesorectal excision(TME) of rectal cancer
62246773|NCT06006663|ACTIVE_COMPARATOR|group 1|ibuprofen as intracanal medicament
62603521|NCT00993759|EXPERIMENTAL|3804-250A lotion|
62603522|NCT01528943|EXPERIMENTAL|Prostacyclin|Treatment with prostacyclin
62603523|NCT01528943|PLACEBO_COMPARATOR|Isotonic saline|Treatment with isotonic saline
62603524|NCT01252862|EXPERIMENTAL|Two iStents devices|Two iStents devices will be implanted
62603525|NCT01886742|ACTIVE_COMPARATOR|Control group|Standard dose group (2 g intravenous (IV) cefazolin dose for patients \<120 kg, and 3 g IV cefazolin for patients \>120 kg)
62603526|NCT01886742|EXPERIMENTAL|Treatment group|Weight-based dose group (30 mg/kg cefazolin IV)
62826072|NCT06545188|EXPERIMENTAL|Mortality salience trigger|Mortality Attitudes Personality Survey (MAPS, Rosenblatt et al. 1998) will be administered (two open questions about death and mortality)
62826073|NCT06545188|OTHER|Dental pain questions (control condition)|Two open questions about a dental treatment will be administered
62826074|NCT06597708|ACTIVE_COMPARATOR|participants committed to keto diet|The experimental intervention consisted of a KD without caloric restriction over a period of 4 weeks. Prior to the study period, the participants were instructed by a dietitian. The participants were provided with online brochure describing the main aspects of a KD and given a list of suitable foods with a very low carbohydrate content. They were advised to eat ad libitum but to limit their carbohydrate intake to a maximum of 20-40 g/day to derive at leasut 75%, 15-20%, and 5-10% of total energy from fats, protein, and carbohydrates, respectively. The participants were allowed to vary the food according to their preferences within the framework of the KD.
62826075|NCT06597708|ACTIVE_COMPARATOR|participants committed to intermittent fasting with calorie restriction|The 16/8 TRF group was asked to consume their daily calorie intake during an 8-hour window during the daytime and then fast for the remaining 16 hours each day throughout the intervention period. During the 16 hours fasting, they were able to drink water, coffee and tea without sugar. Participants are encouraged to drink 6-8 glasses of water per day. They were free to arrange the 8-hour eating window based on personal preferences. This flexibility was expected to help the participants adapt to their individual lifestyles and to facilitate compliance with the dietary intervention.
62826076|NCT00894816|ACTIVE_COMPARATOR|1|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19) 10E8 CFU per serving
62603527|NCT02678000|EXPERIMENTAL|LHW090|"For Part 1, patients will receive 3 doses of LHW090 once daily with escalating doses every 4 days for a total 12 days of treatment.~For Part 2, patients will receive LHW090 once daily for 4 weeks."
62603528|NCT02678000|PLACEBO_COMPARATOR|Placebo|For Part 1, patients will receive matching placebo once daily for 12 days. For Part 2, patients will receive matching placebo once daily for 4 weeks.
62603529|NCT01648088||Pre-op THA and TKA patients|Patients who are scheduled for total joint arthroplasty
62826077|NCT00894816|PLACEBO_COMPARATOR|2|Placebo (infant cereals without any additions)
62826078|NCT06602882|EXPERIMENTAL|Intervention group|"Participants in the intervention group will engage with a chatbot-delivered screening and brief intervention (SBI) over a 30-minute period on the chatbot webpage.~The SBI chatbot involves screening individuals for alcohol consumption by AUDIT before recruitment and then providing a brief intervention comprising personalised feedback. Its delivery is fully automated via a smartphone app."
62826079|NCT06602882|EXPERIMENTAL|Waitlist control group|All participants in the waitlist control will receive the SBI chatbot 4 weeks later. The intervention has the same content for both intervention and waitlist control groups.
62826080|NCT06596980|EXPERIMENTAL|Interventional arm|Use of the medical device Poppins Clinical 5 times per weeks (20 minutes training sessions)
62246774|NCT06006663|ACTIVE_COMPARATOR|group 2|modified triple antibiotic paste as intracanal medicament
62246775|NCT06006663|ACTIVE_COMPARATOR|group 3|curcumin as intracanal medicament
62246776|NCT06006663|ACTIVE_COMPARATOR|group 4|olive leaves as intracanal medicament
62437007|NCT02514187|OTHER|Evaluation of altered osteogenesis by bone scintigraphy|For the evaluation of altered osteogenesis by bone scintigraphy each research subject will serve as his/her own control, and undergo imaging using both generator- and cyclotron-produced 99mTc. Each study will be performed on a separate day, with flexibility to schedule either study first.
62826081|NCT03234595|EXPERIMENTAL|single arm|There is 1 treatment arm with 4 dose cohorts in Phase I and 1 treatment arm in Phase IIa.
62826082|NCT05424081|EXPERIMENTAL|EMBER|Self-help tool to increase weight management engagement
62826083|NCT05424081|ACTIVE_COMPARATOR|Control|List of treatments
62826084|NCT06603129||Delirium Group|group that developed delirium within 3 days postoperatively
62826085|NCT06603129||Non Delirium Group|group that did not develop delirium within 3 days postoperatively
62826086|NCT01838694|PLACEBO_COMPARATOR|Placebo|Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes.
62246777|NCT04272541|ACTIVE_COMPARATOR|Psychoeducation program|The intervention program consists of psychopharmacology (standard intervention in mental health services) + individual psychoeducation (individual treatment including learning of Healthy Lifestyle). This program is implemented for three months, allocated in several sessions.
62246778|NCT04272541|ACTIVE_COMPARATOR|Habitual intervention|Intervention program consists of psychopharmacology (standard intervention in mental health services). This program is implemented for three months.
62246779|NCT01129726|EXPERIMENTAL|Intubation|Transillumination-guided Fiberoptic Intubation
62246780|NCT05656625||group distal nerve block(DNB)|Radial, median and ulnar nerve blocks were used alone or in combinations as a method of anesthesia for patients who had undergone hand and wrist surgery.
62246781|NCT05656625||group brachial plexus block(BPB)|Brachial plexus blocks (infraclavicular, axillary etc.) was applied to patients who were going to undergo hand and wrist surgery.
62246782|NCT02900183|EXPERIMENTAL|ARC-AAT Injection|Intravenous administration of ARC-AAT Injection (4 mg/kg or 6 mg/kg) every 28 days for a total of 7 doses
62246783|NCT03517189|EXPERIMENTAL|Aorta no-touch|Aorta no-touch off-pump coronary artery bypass surgery.
62437008|NCT01429402|EXPERIMENTAL|study group I|For primary lip surgery, immediately after primary lip repair will received botulinum toxin injection (1-2U/kg, at 25U/mL) into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site
62826087|NCT01838694|EXPERIMENTAL|Ala-Cpn10|Recombinant minimally modified Chaperonin10 (Cpn10) Multiple doses in the range 10mg twice weekly to 100mg twice weekly administered intravenously by infusion over 60 minutes.
62826088|NCT05168202|EXPERIMENTAL|CC-95251 monotherapy|
62826089|NCT05168202|EXPERIMENTAL|CC-95251 + azacitidine|
62826090|NCT05168202|EXPERIMENTAL|CC-95251 + azacitidine + venetoclax|
62826091|NCT04464317||Patient who has had cardiovascular surgery|Undergone an elective, urgent, and/or emergent cardiovascular surgery via endovascular or open (sternotomy and/or extended thoracotomy) technique at the University of Florida Health.
62826092|NCT06654479||The study included neonates treated in the neonatal intensive care unit.|In the newborns in the study, changes in body temperatures during routine nursing interventions of the nurses of the clinic were examined.
62603530|NCT04132089|NO_INTERVENTION|Control|This was the control group for the messaging component of the study (push notifications). These participants only received the mobile health application called capABILITY without messages.
62603531|NCT04132089|OTHER|Facilitator Message Group|This group of participants received the mobile health application called capABILITY and received three facilitator messages per week. Facilitator messages are designed to help people who lack ability to do something.
62603532|NCT04132089|OTHER|Spark Trigger Group|This group of participants received the mobile health application called capABILITY and received three spark messages per week. Spark messages are designed to help people who lack ability to do something.
62603533|NCT03931408|EXPERIMENTAL|Gentamicin|Participants will be randomized into one of three groups. In this arm, participants will perform bladder instillations using a 50ml solution of gentamicin mixed with saline, 2 times per day. A formulation derived from 480 mg gentamicin sulfate diluted in 1 L normal saline will be used for instillation. Participants will be blinded during the study and will not know if they are receiving gentamicin or placebo (saline alone).
62603534|NCT03931408|PLACEBO_COMPARATOR|Placebo instillation (saline alone)|Participants will be randomized into one of three groups. In this arm, participants will perform bladder instillations using a 50ml solution of saline alone. Participants will be blinded during the study and will not know if they are receiving gentamicin or placebo (saline alone).
62603535|NCT03931408|OTHER|No instillation|Participants will be randomized into one of three groups. In this arm participants will not receive an instillation of gentamicin or saline alone, but instead will continue standard of care. Participants will be assessed at the pre-, mid- and post-intervention time points.
62246784|NCT01290055|EXPERIMENTAL|Group 1a - Drink deuterated water on days 0 - 14 post-vaccination|Participants testing positive for human leukocyte antigen-A2 (HLA-A2) will be enrolled into one of the three Group 1 study arms. To assess the life span and decay of effector CD8+T cells, participants in group 1a will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water for 2 weeks, on Days 0 through 14 post-vaccination.
62437009|NCT01429402|EXPERIMENTAL|Study Group II|For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room.
62437010|NCT01429402|PLACEBO_COMPARATOR|Control Group I|Similar amount as group I (in C.C.) of normal saline will be injected after primary lip surgery at 3 months of age.
62437011|NCT01429402|PLACEBO_COMPARATOR|Control II|Similar amount (in C.C.) as Study Group II of normal saline will be injected after revision lip surgery (secondary cleft lip repair).
62437012|NCT04236310|EXPERIMENTAL|SHR6390+Anastrozole+Pyrotinib+Trastuzumab±Ovarian Suppression|
62437013|NCT01365845|ACTIVE_COMPARATOR|1|Conventional photon plan
62437014|NCT01365845|EXPERIMENTAL|2|3D-Proton/Conventional plan or 3D-proton only
62603536|NCT05146063||Polycystic ovary syndrome patients with insulin resistance|
62603537|NCT05146063||Polycystic ovary syndrome patients without insulin resistance|
62603538|NCT01432821|EXPERIMENTAL|Apomorphine|"After randomization healthy volunteers or patients with idiopathic generalized epilepsy receive:~-sequence A: 1 mg/kg and then 5 mg/kg of apomorphine"
62603539|NCT01432821|PLACEBO_COMPARATOR|Saline|"After randomization healthy volunteers or patients with idiopathic generalized epilepsy receive:~sequence B: 2 injections of saline"
62603540|NCT04489381|ACTIVE_COMPARATOR|Nitazoxanide|Two nitazoxanide 300 mg tablets orally twice daily for 5 days
62246785|NCT01290055|EXPERIMENTAL|Group 1b - Drink deuterated water on days 14 - 28 post-vaccination|Participants testing positive for HLA-A2 will be enrolled into one of the three Group 1 study arms. To assess the life span and decay of effector CD8+T cells, participants in group 1b will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water for 2 weeks, on Days 14 through 28 post-vaccination.
62603541|NCT04489381|PLACEBO_COMPARATOR|Placebo|Two placebo tablets orally twice daily for 5 days
62603542|NCT00688311|EXPERIMENTAL|Synbiotic|Ingestion of synbiotic dietary supplement
62603543|NCT00688311|PLACEBO_COMPARATOR|Placebo|Ingestion of the Placebo
62603544|NCT06619470|EXPERIMENTAL|binaural beat group|Binaural Beats added to music and mental training sessions
62603545|NCT06619470|SHAM_COMPARATOR|music therapy group|music and mental training sessions
62603546|NCT04787796|EXPERIMENTAL|The Self-built-in M-ECG recorders have passed the electrical.|We shall conduct this prospective clinical study to define the specific patterns of multichannel ECG change in adults with suspected CAD or ACS. For multichannel ECG (M-ECG) examination, the signal will be recorded with a Self-built-in ECG recorder.
62437015|NCT01783483|ACTIVE_COMPARATOR|Suture Wire|The closure technique should be per surgeon and institutional preference, with documentation of the wiring technique including the wiring configuration and number of wires used. A minimum of 6 wires that cross the midline sternotomy should be used (e.g. 6 simple wires, 3 double wires, 3 figure of 8 wires, etc.).
62449196|NCT02339909|ACTIVE_COMPARATOR|Control|"The intervention for the Control group consists of the standard invitation letter from the Screening service. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
62044148|NCT04207827|EXPERIMENTAL|xSmoker app + SMSs|The xSmoker app + phone text messages with content based on the Motivation and Problem Solving approach and informed by our prior work. The investigators developed six categories of messages sent to participants: (1)Importance and trust, (2)Fear of relapse, (3)Partner support, (4)Breastfeeding, (5)The need to smoke, and (6)Relapse. Four major objectives were established based on the content of the SMS text messages, with the help of the literature: (1)supporting motivation, (2)supporting self-efficacy, (3)supporting dyadic effectiveness, and (4)developing problem-solving skills. The messages were delivered using Textit, a platform for visually building interactive SMS applications (htpps://textit.in). All the messages were uploaded in the platform and different flows and sub-flows were created for every day of the intervention to automatize the process of SMS delivery. A combination of trigger words and skip patterns was used in order to tailor the messages.
62044149|NCT04207827|OTHER|Control|Usual postnatal care
62603547|NCT06647875|EXPERIMENTAL|Intervention Group|During their infants' 6-month check-up, parents will be administered a demographic survey, the Karitane Parental Self-Efficacy Scale, the Behavioral Pediatric Feeding Assessment Scale, the Edinburgh Postnatal Depression Scale, and the Generalized Anxiety Disorder-7 scale. The Father-Infant Bonding Scale will be administered exclusively to fathers during the same visit. Subsequently, both mothers and fathers in this group will receive complementary feeding education.
62044150|NCT06289075||ICU patients|All ICU patients in different countries worldwide from 2005-2023
62044151|NCT02934074||Unilateral Lower Limb Loss|Individuals with unilateral lower limb loss will be participants of the group.
62044152|NCT01746004|EXPERIMENTAL|[^14C]-LY2157299|Single 150 mg oral dose of LY2157299 monohydrate containing 100 micro curies of \[\^14C\] labeled drug
62044153|NCT06579924|EXPERIMENTAL|Mini-PCNL with disposable scope|PCNLs carried out using disposable scope
62044154|NCT06579924|ACTIVE_COMPARATOR|Mini-PCNL using re-usable scope|Mini-PCNLs carried out using re-usable scope
62044155|NCT00765596||1 RYGB|Subjects undergoing RYGB with gastric tube placement
62044156|NCT00765596||2 Matched controls|Subjects matched by BMI, age, gender to RYGB group
62044157|NCT01232608|EXPERIMENTAL|Exercise|12 months of exercise training
62044158|NCT01232608|NO_INTERVENTION|Control|Normal follow-up by primary physician
62603548|NCT06647875|ACTIVE_COMPARATOR|Control Group|During their infants' 6-month check-up, parents will be administered a demographic survey, the Karitane Parental Self-Efficacy Scale, the Behavioral Pediatric Feeding Assessment Scale, the Edinburgh Postnatal Depression Scale, and the Generalized Anxiety Disorder-7 scale. The Father-Infant Bonding Scale will be administered exclusively to fathers during the same visit. Subsequently, only mothers in this group will receive complementary feeding education.
62826093|NCT06586242|EXPERIMENTAL|penpulimab combined with anlotinib hydrochloride plus albumin paclitaxel and oxaliplatin|penpulimab：200mg, intravenous infusion, 30-60 minutes per infusion, once every 3 weeks, administered on the first day of each cycle anlotinib hydrochloride：Body weight \<60kg, 8mg Po, body weight ≥ 60kg, 10mg Po, D 1-14, q3w Albumin paclitaxel: 260mg/m2, intravenous infusion, 30 minutes per infusion, once every 3 weeks, d 1 medication per week oxaliplatin：130mg/m2, i.v., administered after albumin paclitaxel, on day 1 of each week; Three weeks is a treatment cycle.
62826094|NCT06586242|ACTIVE_COMPARATOR|penpulimab combined with anlotinib hydrochloride plus albumin paclitaxel and lobaplatin|penpulimab：200mg, intravenous infusion, 30-60 minutes per infusion, once every 3 weeks, administered on the first day of each cycle anlotinib hydrochloride：Body weight \<60kg, 8mg Po, body weight ≥ 60kg, 10mg Po, D 1-14, q3w Albumin paclitaxel: 260mg/m2, intravenous infusion, 30 minutes per infusion, once every 3 weeks, d 1 medication per week lobaplatin：50mg/m2, i.v., administered after albumin paclitaxel, on day 1 of each week; Three weeks is a treatment cycle.
62044159|NCT05477758||CASPER|A multi-centred, pragmatic, two-arm parallel open RCT. Participants with Subthreshold depression were individually randomised (1:1) to receive either collaborative care focusing on behavioural activation or usual GP care
62246786|NCT01290055|EXPERIMENTAL|Group 1c - Drink deuterated water on days 0 - 28 post-vaccination|Participants testing positive for HLA-A2 will be enrolled into one of the three Group 1 study arms. To assess the life span and decay of effector CD8+T cells, participants in group 1c will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water for 4 weeks, on Days 0 through 28 post-vaccination.
62246787|NCT01290055|EXPERIMENTAL|Group 2a - Drink deuterated water 2 months post-vaccination|To assess the homeostatic proliferation of Memory CD8 T cells, participants in group 2a will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water 2 months post-vaccination.
62603549|NCT04323267|EXPERIMENTAL|Digital Home Exercise Program|Limber Digital Application Device (3 x a week for 8 weeks)
62826095|NCT06586034|EXPERIMENTAL|Impacto|This is the mobile application to be developed and evaluated in this project.
62826096|NCT03858179|EXPERIMENTAL|PBMT + training/ PBMT + detraining|PBMT applied before the strength training sessions (12 weeks, 2 times a week) and PBMT applied during the detraining period (4 weeks, 2 times a week).
62603550|NCT04323267|ACTIVE_COMPARATOR|Physical therapy|Therapy prescription 2 x a week for 8 weeks (specified by physician)
62826097|NCT03858179|EXPERIMENTAL|PBMT + training/ placebo + detraining|PBMT applied before the strength training sessions (12 weeks, 2 times a week) and placebo applied during the detraining period (4 weeks, 2 times a week).
62826098|NCT03858179|EXPERIMENTAL|Placebo + training/ PBMT + detraining|Placebo applied before the strength training sessions (12 weeks, 2 times a week) and PBMT applied during the detraining period (4 weeks, 2 times a week).
62826099|NCT03858179|PLACEBO_COMPARATOR|Placebo + training/ placebo + detraining|Placebo applied before the strength training sessions (12 weeks, 2 times a week) and placebo applied during the detraining period (4 weeks, 2 times a week).
62826100|NCT03951103||Hemophili A patients|Patients treated with rFVIIIFc for ITI
62826101|NCT06599294|EXPERIMENTAL|intraoral photogrammetry scanning|
62826102|NCT06599294|ACTIVE_COMPARATOR|Intra oral scanning|
62826103|NCT06586840||Adductor Canal Block|For Group I, after patients are placed in the supine position, a linear ultrasound probe (13-6 MHz) will be used to identify the superficial femoral artery in the short axis, lateral to the Sartorius muscle, and anterior to the adductor magnus muscle in the adductor canal. A 22-gauge × 100 mm needle (Braun® Stimuplex) will be inserted in-plane laterally to medially under sterile conditions, and 20 mL of 0.5% bupivacaine will be injected after negative aspiration.
62826104|NCT06586840||Adding an IPACK Block to the Adductor Canal Block|For Group II, 20 mL of 0.25% bupivacaine will be injected into the Adductor Canal after spinal anesthesia. With the knee flexed, a convex probe (3.5-6 MHz) will be placed in the popliteal region to identify the popliteal artery in the short axis. The ultrasound probe will be moved distally after the common peroneal and tibial nerves are identified. The probe will be gradually moved towards the popliteal fossa until the popliteal vessels are identified superficially. The ultrasound probe will be moved to the level where the femoral condyles merge with the femoral shaft. The popliteal artery, tibial and peroneal nerves will be visualized to identify the space between the femur and the popliteal artery. In the area known as iPACK, a 22-gauge × 100 mm needle (Braun® Stimuplex) will be inserted in-plane laterally to medially, and 20 mL of 0.25% bupivacaine will be injected after negative aspiration.
62826105|NCT04456504|EXPERIMENTAL|Healthcare worker|Healthcare worker who has previously received at least 5 doses of hepatitis B vaccine with aluminum adjuvant (Recombivax B or Engerix B) and has an antibody to the hepatitis B surface antigen (antiHBs) that is less than 10 mIU/ml.
62826106|NCT01751698|ACTIVE_COMPARATOR|JASP-EMT|JASP-EMT (Joint Attention, Symbolic Play and Enhanced Milieu Teaching) focuses on creating a context for joint engagement within naturally occurring child-led play routines. There is evidence of the effects of these interventions with children with ASD, and pilot data showing effects with minimally verbal children.
62246788|NCT01290055|EXPERIMENTAL|Group 2b - Drink deuterated water 6 months post-vaccination|To assess the homeostatic proliferation of Memory CD8 T cells, participants in group 2b will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water 6 months post-vaccination.
62246789|NCT01290055|EXPERIMENTAL|Group 3 - Drink deuterated water for up to 8 weeks without vaccination|To assess homeostatic turnover of CD8+ T lymphocytes in general, unvaccinated participants will be asked to drink deuterium (70% enriched 2H2O) labeled water for up to 8 weeks.
62044160|NCT05477758||CASPER+|A multi-centred, pragmatic, two-arm parallel open RCT. Participants with Major depression were individually randomised (1:1) to receive either collaborative care focusing on behavioural activation or usual GP care
62603551|NCT06391593|EXPERIMENTAL|ALTO-203 25 μg|"Drug: ALTO-203 25 μg~Single-Dose Treatment Period: Single Dose, ALTO-203 25 μg~Multi-Dose Treatment Period: ALTO-203 25 μg, administered orally, once daily for 28 days"
62044161|NCT05477758||SHARD|A multi-centred, pragmatic, two-arm parallel open RCT. Participants with Subthreshold depression were individually randomised (1:1) to receive the self-help booklet based on the principles of behavioural activation or usual GP care
62826107|NCT01751698|ACTIVE_COMPARATOR|DTT|CORE-DTT (discrete trial training for core features of ASD) emphasizes didactic adult-led instruction and is considered the current evidenced-based 'standard of care' for children with autism (NRC, 2001).
62826108|NCT06597903|EXPERIMENTAL|NRL994 low dose bowel prep (LDBP)|Patients given two doses of NRL994, one on the evening before and one on the morning of their scheduled colonoscopy. Degree of gut cleansing was rated by the colonoscopist and an independent reviewer. Volume of fluid aspirated during colonoscopy and weight of stools/volume of urine from start of cleansing to start of colonoscopy were also measured. Number of patients who reached clear effluent evaluated.
62044162|NCT02351219|EXPERIMENTAL|FOLFOXIRI|
62044163|NCT04521855||Caregivers|Caregivers (family environment or close entourage) for adults and children with cerebral palsy.
62044164|NCT06362512|EXPERIMENTAL|dual-task group|patients receive three dual motor-cognitive exercise training per week for six weeks.
62044165|NCT06362512|ACTIVE_COMPARATOR|single-task group|Patients receive three separate cognitive and mobility exercises per week for six weeks.
62044166|NCT06362512|ACTIVE_COMPARATOR|control group|Patients receive three upper limb muscle strengthening exercise with muscle stretching per week for six weeks.
62246790|NCT01290055|EXPERIMENTAL|Group 4a - Drink deuterated water on days 0 - 7 post-vaccination, with fine needle aspirate|To assess homeostatic turnover of monocytes participants in group 4a will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water on Days 0 through 7 post-vaccination. Participants will undergo two fine needle aspirate (FNA) procedures to examine the immune response in the lymph nodes.
62603552|NCT06391593|EXPERIMENTAL|ALTO-203 75 μg|"Drug: ALTO-203 75 μg~Single-Dose Treatment Period: Single Dose, ALTO-203 75 μg~Multi-Dose Treatment Period: ALTO-203 75 μg, administered orally, once daily for 28 days"
62603553|NCT06391593|PLACEBO_COMPARATOR|Placebo|"Drug: Placebo~Single-Dose Treatment Period: Single Dose, Placebo~Multi-Dose Treatment Period: Placebo, administered orally, once daily for 28 days"
62826109|NCT06598618|ACTIVE_COMPARATOR|Graston technique+ Conventional PT|
62826110|NCT06598618|OTHER|Muscle energy technique + Conventional PT|
62826111|NCT01003977||Xience V|Patients treated with a Xience V everolimus-eluting stent
62826112|NCT01361230|EXPERIMENTAL|Protocol|Using sedation monitoring and protocol
62044167|NCT03599349|EXPERIMENTAL|Microfocused ultrasound w/ visualization|Each subject to receive a full face and neck area treatment using a standard 800 line treatment with set energy levels (0.90 joules for the 4-4.5mm transducer, 0.30 joules for the 7-3.0mm/7-3.0N transducers and 0.75 joules for the 7-4.5mm transducer)
62044168|NCT01620866|EXPERIMENTAL|EMDR|
62044169|NCT01620866|NO_INTERVENTION|TAU|Treatment as usual (TAU)
62044170|NCT03246282|EXPERIMENTAL|Treatment Group|"Polychromatic light emitting diode system is a non-significant risk device that administers low-dose light generated by light emitting diode(s). A small adapter attaches directly to a standard 20-guage catheter that threads a small fiber optic through the distal end of the catheter. The optic terminates at the proximal end of the catheter. Polychromatic light is emitted to illuminate the catheter near the site of catheter entrance. Concurrently, normal saline flows through the optic adapter, into and through the 20-gauge catheter.~Device: UVL1000 Treatment Station Drug: Normal Saline 0.9% Infusion Solution Bag Device: Peripheral Catheterization"
62044171|NCT04605796|EXPERIMENTAL|Single Arm|"Experimental group:~Toripalimab combined with Bevacizumab"
62044172|NCT05906602|EXPERIMENTAL|Ischemic Conditioning|While seated, a rapid inflation cuff, similar to those used to measure blood pressure, will be placed around the paretic thigh to perform real ischemic conditioning. The pressure of the cuff will be increased for 5 minutes followed by no pressure for 5 minutes, repeated 5 times for a total of 50 minutes.
62044173|NCT05906602|SHAM_COMPARATOR|Sham Ischemic Conditioning|While seated, a rapid inflation cuff, similar to those used to measure blood pressure, will be placed around the paretic thigh to perform sham or fake ischemic conditioning. The pressure of the cuff will be increased for 5 minutes followed by no pressure for 5 minutes, repeated 5 times for a total of 50 minutes.
62044174|NCT01197196|EXPERIMENTAL|Behavioral weight loss|
62044175|NCT01197196|ACTIVE_COMPARATOR|Migraine Education|
62044176|NCT00677352|EXPERIMENTAL|1|
62246791|NCT01290055|EXPERIMENTAL|Group 4b - Drink deuterated water for 7 days without vaccination|To assess homeostatic turnover of monocytes participants in group 4b, unvaccinated participants will will be asked to drink deuterium (70% enriched 2H2O) labeled water for 7 days post enrollment.
62246792|NCT05135026|NO_INTERVENTION|Control Group (CG)|Usual care
62826113|NCT01361230|NO_INTERVENTION|Control|Standard practice
62044177|NCT00677352|ACTIVE_COMPARATOR|2|
62044178|NCT01686555|EXPERIMENTAL|Single Dose|Subjects enrolled in the Single Ascending Dose (SAD) part of the study will receive a single dose of study drug or placebo. (Groups 1, 2, 3, 4, 5 and 6).
62044179|NCT01686555|EXPERIMENTAL|Multiple Dose|Subjects enrolled in the Multiple Ascending Dose (MAD) part of the study will receive multiple doses of study drug or placebo. (Groups 7, 8, 9, 10 and 11)
62044180|NCT03098134|EXPERIMENTAL|VR-Video-Exposure|
62044181|NCT03098134|ACTIVE_COMPARATOR|Education-Video-|
62603554|NCT01763138|OTHER|pamphlet and reminder|pictorial oral health pamphlet comprising of instructions on child's oral hygiene and feeding practices and a oral health education reminder phone call after a period of one month.
62603555|NCT01763138|OTHER|pamphlet only|oral health education pictorial pamphlet would be provided to mothers however there will be no reminder phone calls.
62603556|NCT01763138|NO_INTERVENTION|control|no oral health education or reminder phone calls will be provided to mothers.
62603557|NCT05273775|EXPERIMENTAL|single arm|HRS5091 + probe drugs (Midazolam Maleate Tablets+Warfarin Sodium Tablets+ Omeprazole Enteric Capsules+ Digoxin Tablets+ Rosuvastatin Calcium) + Vitamin K1 Tablets
62603558|NCT02570139|EXPERIMENTAL|Cavilon Advanced Skin Protectant|Product applicator contains liquid barrier applied on buttocks/thighs with it drying rapidly to durable barrier film. It's applied 3x/per week.
62603559|NCT02570139|ACTIVE_COMPARATOR|ConvaTec Sensi-Care Protective Barrier|Marketed product applied following manufacturer's recommendation. The product is 15% zinc oxide with petrolatum.
62603560|NCT02292186|EXPERIMENTAL|Revusiran (ALN-TTRSC)|
62044182|NCT04131608||diabetic foot ulcer (1and2)with iron defic|"50 diabetic patients with diabetic foot ulcer grade (1and2) with iron deficiency anemia will be applied TO~1. cbc~2. ferritin~3. HBA1C~4. ankle brachial index by duplex"
62044183|NCT04131608||diabetic foot ulcer grade(1and2)without iron deficiency anemia|"50 patients with diabetic foot ulcer grade (1and2) without iron deficiency anemia will be applied to~1. CBC~2. Ferritin,~3. HBA1C~4. ankle brachial index by duplex"
62246793|NCT05135026|EXPERIMENTAL|Intervention Group (IG)|In the intervention hospitals, we will perform USG additional 2 times during the 3rd visit of 24-26 weeks and 5th visit of 34 weeks (2 USG and even more USG if needed + additional 4 ANC + Health education; pictorial flip chart showing danger sign during pregnancy and potential risks for unnecessary caesarean delivery to increase awareness for safe delivery) for all the enolled pregnant mothers.
62437016|NCT01783483|EXPERIMENTAL|SternaLock Blu closure system|"Patients will receive treatment option for sternal closure with the SternaLock Blue closure system at a minimum of 2 X plates on the sternal body and 1 L plate (or equivalent) on the manubrium. This technique is the standard configuration for this study, and is intended to ensure that at least 3 plates are used to achieve adequate fixation and stability, while allowing for variations in the plating configuration as a result of patient anatomy and surgeon preference. Various Sternal Blu plates may be used on the manubrium as described below, as can an additional plate on the sternal body."
62437017|NCT01753479|EXPERIMENTAL|Test subject|
62246794|NCT05097729|EXPERIMENTAL|Stimulation Modality 1|Repetitive TMS will be applied at 100% resting motor threshold intensity to a region of interest located in the parietal cortex, that will be determined based on its connectivity with the hippocampus.
62246795|NCT05097729|SHAM_COMPARATOR|Stimulation Modality 2|Parameters will be identical to the modality 1, except that the coil will be flipped over.
62246796|NCT05097729|ACTIVE_COMPARATOR|Stimulation Modality 3|The stimulation will be delivered over the motor cortex contralateral to the predominant painful region, i.e., right motor cortex stimulation if left knee pain. The stimulation intensity will be set at 80% of the resting motor threshold.
62246797|NCT06387121|EXPERIMENTAL|low-dose chemotherapy, Venetoclax combined with immuno-targeted drugs|The cycle of induction therapy is administered with immuno-targeted drugs (including Inotuzumab ozogamicin and/or Blinatumomab), a combination of low-dose chemotherapy (including vincristine, cyclophosphamide, dexamethasone, methotrexate and cytarabine) and Venetoclax (VEN).
62246798|NCT06387121|EXPERIMENTAL|low-dose chemotherapy combined with Venetoclax|The cycle of induction therapy is administered with a combination of low-dose chemotherapy and VEN.
62437018|NCT04063566|OTHER|Total cohort|The study will consist of one group, one arm, all receiving the same screening procedures.
62437019|NCT01189240|EXPERIMENTAL|Phase I Dose Finding|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
62437020|NCT01189240|EXPERIMENTAL|Phase II Stage I|"Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15.Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
62437021|NCT01189240|EXPERIMENTAL|Phase II Stage II Arm 1|"Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
62603561|NCT03145662|ACTIVE_COMPARATOR|high pressure balloon|randomized to have dialysis fistula or AV graft treated with high pressure balloon
62603562|NCT03145662|ACTIVE_COMPARATOR|cutting balloon|randomized to have dialysis fistula or AV graft treated with cutting balloon
62603563|NCT00659698|EXPERIMENTAL|1|received programmed infusions of insulin determined by the control algorithm of the artificial pancreas
62603564|NCT00659698|NO_INTERVENTION|2|glucose levels were controlled using a manual injection of insulin according to the commonly used sliding scale
62603565|NCT06619795|SHAM_COMPARATOR|CogS|The participants underwent cognitive treatment while receiving sham tDCS stimulation.
62603566|NCT06619795|SHAM_COMPARATOR|MotS|The participants underwent motor treatment while receiving sham tDCS stimulation
62044184|NCT01950949|EXPERIMENTAL|change respiratory parameters, volume expanding|
62044185|NCT03365882|EXPERIMENTAL|Arm I (pertuzumab, trastuzumab)|Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62437022|NCT01189240|ACTIVE_COMPARATOR|Phase II Stage II Arm 2|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
62603567|NCT06619795|EXPERIMENTAL|CogA|The participants underwent cognitive treatment while simultaneously receiving anodal stimulation with tDCS.
62603568|NCT06619795|EXPERIMENTAL|MotA|The participants underwent motor treatment while simultaneously receiving anodal stimulation with tDCS.
62246799|NCT01131949|EXPERIMENTAL|Lamotrigine (chewable, dispersible)|Lamotrigine Tablets (chewable, dispersible),25 mg of Dr. Reddy's Laboratories Limited
62246800|NCT01131949|ACTIVE_COMPARATOR|Lamictal|Lamictal Tablets 25 mg of Glaxo SmithKline
62044186|NCT03365882|EXPERIMENTAL|Arm II (cetuximab, irinotecan hydrochloride)|Patients receive cetuximab IV over 60-120 minutes and irinotecan hydrochloride IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may optionally crossover to Arm I.
62246801|NCT03015519|EXPERIMENTAL|Albiglutide cohort 1: Part A|Approximately 12 eligible subjects, aged between 14 to 18 years, will receive a single dose of 30 mg albiglutide post-randomization.
62437023|NCT01189240|EXPERIMENTAL|Phase I Dose Finding - Level 1 5mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 5mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
62246802|NCT03015519|PLACEBO_COMPARATOR|Placebo cohort 1: Part A|Approximately 3 eligible subjects, aged between 14 to 18 years, will receive a single dose of matching placebo post-randomization.
62826114|NCT03307109||Patients having prosthetic joint infection|The primary aim is to measure the evolution of quality of life in patients having prosthetic joint infection during their medical care and possibly psychologic assistance in the Infectious and Tropical Diseases Department of Croix-Rousse Hospital.
62044187|NCT03878732||Caucasian female|
62044188|NCT03878732||Hispanic female|
62246803|NCT03015519|EXPERIMENTAL|Albiglutide cohort 2: Part A|Approximately 12 eligible subjects, aged between 10 to 14 years, will receive a single dose of 30 mg albiglutide post-randomization.
62437024|NCT01189240|EXPERIMENTAL|Phase I Dose Finding - Level 2 10mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 10mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
62437025|NCT01189240|EXPERIMENTAL|Phase I Dose Finding - Level 3 20mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 20mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
62437026|NCT06417957|EXPERIMENTAL|Experimental|Experimental group (Education group)
62437027|NCT06417957|NO_INTERVENTION|Control group|Control group
62437028|NCT05826106||R anastomosis|
62437029|NCT03601247|OTHER|All patients|Split-face study: patients undergoing bilateral eye surgery will have the sides of their face randomized to receive either placebo or silicone gel.
62246804|NCT03015519|PLACEBO_COMPARATOR|Placebo cohort 2: Part A|Approximately 3 eligible subjects, aged between 10 to 14 years, will receive a single dose of matching placebo post-randomization.
62246805|NCT03015519|EXPERIMENTAL|Albiglutide: Part B|Approximately 120 eligible subjects, aged between 10 to 18 years, will receive albiglutide 30 mg once weekly post-randomization.
62246806|NCT03015519|PLACEBO_COMPARATOR|Placebo: Part B|Approximately 60 eligible subjects, aged between 10 to 18 years, will receive matching placebo once weekly post-randomization.
62246807|NCT06022783|EXPERIMENTAL|with VR-G|The nurses in this procedure were asked to watch a relaxing video with using VR-G for 20 minutes at their break time.
62246808|NCT06022783|NO_INTERVENTION|no VR-G|The nurses in this procedure did not watch any video and completed their routine working shift and break times.
62246809|NCT00644553|ACTIVE_COMPARATOR|A|
62246810|NCT00644553|ACTIVE_COMPARATOR|B|
62246811|NCT03482687|EXPERIMENTAL|Me & You: Building Healthy Relationships|Me \& You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid.
62246812|NCT03482687|NO_INTERVENTION|Comparison Group|No intervention was provided, only usual care.
62246813|NCT06147570|EXPERIMENTAL|HS-10365|160 mg BID of HS-10365
62246814|NCT01530412|NO_INTERVENTION|Control Group|Patients are randomized to the control group and are assessed pre rehabilitation and post rehabilitation after which they proceed to the intervention group.
62246815|NCT01530412|EXPERIMENTAL|Pulmonary Rehabilitation|Patients undergo an active seven week pulmonary rehabilitation programme. Assessments occur pre rehabilitation, post rehabilitation, at three months and at one year.
62246816|NCT00587392||A|Active NDO Endoscopic Full-thickness Plicator Procedure
62246817|NCT06179329|OTHER|Radial - Anterolateral / Saphenous - RCA|"Radial artery graft for the anterolateral wall, and no-touch saphenous vein graft for the right coronary artery territory"
62437030|NCT02509871|OTHER|Body composition measurement|DXA, impedance
62437031|NCT06527495|EXPERIMENTAL|Sorafenib|Sorafenib 200 - 400 mg twice daily
62437032|NCT06338228||patients managed for Acetabular fracture|collect the data for all the patients managed and operated on between 01/01/2020 AND 31/01/2022 for Acetabular fracture
62603569|NCT01777295|EXPERIMENTAL|HBsAg/AS Group|Subjects in this group received 1 dose of Placebo at Day -30 followed by 2 doses of HBsAg/AS, at Day 0 and Day 30.
62246818|NCT06179329|OTHER|Radial - RCA / Saphenous - Anterolateral|"Radial artery graft for the territory of the right coronary artery and no-touch saphenous vein for the anterolateral wall."
62044189|NCT06485076|EXPERIMENTAL|Early Palliative Care|Participants in the intervention/early palliative care arm will be invited to attend a consultation (in-person or via Microsoft Teams) in the outpatient palliative care clinic alongside ongoing care from their hematologist. The intervention will comprise of a comprehensive interdisciplinary assessment from a specialist palliative care nurse and a physician within 1 week of referral and monthly follow-up visit for 3 months. This will include an assessment of physical symptoms, psychological distress, social supports and advance care planning, as well as 24/7 telephone support between visits, community-based resources, and access to the acute palliative care unit, if required.
62044190|NCT06485076|NO_INTERVENTION|Usual Care|Participants in the usual care arm will receive care from their hematologist as usual, with referral to the outpatient palliative care clinic at the discretion of the hematologist or upon patient request
62044191|NCT03553004|EXPERIMENTAL|Niraparib Treatment|"* Niraparib 300 milligrams (mg) by mouth daily for 28 days (1 cycle = 28 days)~* (Dose reduced to 200mg dose for participants whose baseline weight is less than 77 kilograms (kg) \[169.756 pounds (lbs)\] or baseline platelet count is less than 150,000 microliters (µL))."
62044192|NCT04205630|EXPERIMENTAL|SYD985|SYD985, Intravenous, every 3 weeks (Q3W)
62044193|NCT02960100|EXPERIMENTAL|Arm I (mHealth HPV vaccine intervention)|Participants receive targeted HPV vaccine narrative-style video via the mobile-friendly website. Participants also receive monthly HPV vaccination reminders via email or by text message.
62044194|NCT02960100|ACTIVE_COMPARATOR|Arm II (standard HPV information and HPV VIS)|Participants receive standard information with the HPV Vaccine Information Statement via the mobile-friendly website.
62044195|NCT06461130|EXPERIMENTAL|Double leg dual duty aerobic exercise group|During double-leg cycling training, people were made to do dual tasks. Dual-task: aerobic training on a bicycle ergometer + serial sevens In the dual-task condition, participants completed the exercise while simultaneously performing a series of sevens cognitive tasks. Specifically, participants were instructed to serially subtract sevens from a prescribed three-digit number (range 100-300) and read the calculations aloud while performing aerobic exercise.
62246819|NCT04662398|ACTIVE_COMPARATOR|Case (Testes shocker device)|The shocker will be used in delivering the current gradually on the testes and penis to improve the blood flow and stimulates the sexual activity among males.
62246820|NCT04662398|SHAM_COMPARATOR|Control (non testes shocker device)|These groups will not given the shocks, shame device will be used instead and then compare the two results.
62437033|NCT01396759|EXPERIMENTAL|bubble CPAP|Children will receive bubble CPAP Bubble-CPAP, which requires a source of gas flow (typically 6-8 L/ minute in a neonate), an air-oxygen blender, a humidifier and a T-piece. The expiratory arm is inserted in a bottle of water and the level of CPAP delivered is equivalent to the length of the expiratory tubing that remains under water. Robust equipment is now available at a fraction of the cost of mechanical ventilators. Bubble-CPAP has potential advantages over the mechanical ventilation, such as lower cost, ease of application by nursing staff, lower risk of complications, and has been proposed as an inexpensive method of delivering CPAP in developing countries.
62246821|NCT01766726||Healthy control subjects|Historical healthy control subjects matched to HIV+ patients on traditional cardiovascular risk factors will be studied at baseline with respect to arterial inflammation and coronary atherosclerotic plaque. Prospectively recruited healthy control subjects matched to HIV+ patients on traditional cardiovascular risk factors will be studied at baseline with respect to lipid and immune function.
62246822|NCT01766726||ART-naïve HIV+ patients starting QUAD/Stribild|ART-naïve HIV+ patients who are about to be started QUAD/Stribild by their treating clinicians will be studied at baseline and 6 months after initiating QUAD/Stribild therapy.
62246823|NCT06428981|OTHER|spine surgery|The inclusion criteria consisted of patients over the age of 20 who were diagnosed with degenerative cervical diseases, including herniation of the intervertebral disc, ossification of the posterior longitudinal ligament, and spinal stenosis, resulting in cervical radiculopathy, or degenerative cervical myelopathy, and were scheduled to undergo anterior discectomy with fusion surgery.
62044196|NCT06461130|ACTIVE_COMPARATOR|Double leg standard aerobic exercise group|In double leg cycling training, both legs; Exercise was performed on the bicycle ergometer, starting with a 5-minute warm-up (25% labor force) on the ergometer before the application, lasting a total of 20 minutes, and continuously training at 70% intensity. Finished with 5 minutes of cooling. Individuals were allowed to maintain a pedaling frequency of 50 rpm, set externally with a metronome.
62246824|NCT00581685|PLACEBO_COMPARATOR|2|Prospective, single center, randomized, double-blinded, placebo controlled study
62246825|NCT02952040|EXPERIMENTAL|ASP1517 alone period preceding group|Subjects will receive a single oral dose of ASP1517 alone in period 1, then subjects will receive a single oral dose of ASP1517 with lanthanum carbonate hydrate in period 2.
62246826|NCT02952040|EXPERIMENTAL|ASP1517+lanthanum period preceding group|Subjects will receive a single oral dose of ASP1517 with lanthanum carbonate hydrate in period 1, then subjects will receive a single oral dose of ASP1517 alone in period 2.
62437034|NCT01396759|EXPERIMENTAL|High flow air/ oxygen mix|High flow air/ oxygen mix is useful in reducing the indication of mechanical ventilation (4); however, there is a lack of randomized studies comparing it with bubble CPAP or with standard flow O2 supplementation by nasal prongs. High flow air/oxygen mix uses flows of 2 litre per kg per minute of blended air / oxygen mix, usually with a low fraction of inspired oxygen (say 25-40%).
62437035|NCT01396759|ACTIVE_COMPARATOR|Standard O2 supplementation by nasal prongs|Standard O2 supplementation by nasal prongs @ 0.5-2.0 litre per minute
62437036|NCT05987657|OTHER|Salivary and blood progesterone dosage|IVF patients with fresh embryo transfer having a dosage of progesterone, salivary and blood, on triggering day
62437037|NCT01567371|EXPERIMENTAL|LiDCO rapid monitor|
62437038|NCT04368052|OTHER|Observation|preoperative and postoperative cognitive functions of 33 patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels.
62437039|NCT04497324|EXPERIMENTAL|Experimental group|Administration of 1 to 2 units of convalescent plasma (200 ml to 250 ml, each), within 48 hours, plus standard of care.
62437040|NCT04497324|NO_INTERVENTION|Control group|Standard of care
62044197|NCT02377154|OTHER|Opthalmologically healthy individuals|Slit lamp, Autorefractor, IOLMaster 500, Pentacam HR, LenStar LS900, VERION Image Guided System
62044198|NCT00411593|EXPERIMENTAL|Avastin® + Bortezomib|"Phase I - 3 \* 3 design, enrolling patients to receive Avastin® at a fixed dose of 15 mg/kg every 3 weeks and Bortezomib dosed at 1.6 mg/m2 weekly for 2 weeks out of 3.~Phase II - The MTD for Bortezomib from the weekly schedule that is chosen will be combined with Avastin® to estimate the rate of progression-free survival."
62044199|NCT03628287|ACTIVE_COMPARATOR|Original Care Coordination Program|Specific intervention components include: 1) outreach for initial case finding and after any missed appointment; 2) case management, including social services and benefits assessments; 3) multidisciplinary care team communication and decision-making via case conferences; 4) patient navigation, including appointment reminders, assistance with scheduling appointments, transportation resources, and accompaniment to primary care visits; 5) antiretroviral treatment adherence support, including directly observed therapy for individuals with greatest need; and 6) structured health promotion, for which clients are assigned to program tracks (determining their frequency of health promotion visits: weekly, monthly or quarterly), depending on their level of assessed need.
62044200|NCT03628287|EXPERIMENTAL|Revised Care Coordination Program|"The revised model includes the original intervention components without program track assignments or the three-month induction period of weekly visits. Program additions include a set of tools for assessment and counseling around client HIV self-management capacity; allowance of video chat for delivery of some services; and optional immediate antiretroviral therapy (iART: ensuring the client has a filled prescription within 4 days of enrollment or diagnosis). Other changes include greater guidance on recruiting individuals with unsuppressed VL and a switch from per-member-per-day reimbursement to fee-for-service reimbursement that accounts for resource demands, such as staff travel to clients' homes, and offers higher rates for meeting performance standards."
62044201|NCT04235335|OTHER|Wait List Control|Participants receive intervention after 12 week delay
62044202|NCT06579001|EXPERIMENTAL|Dex group|at least 20 min before the introduction of anesthesia, the patient takes the sitting position, the head is slightly tilted forward, and the product is kept upright. Insert the nostril at the same Angle as the nasal cavity. Press down on the spray pump evenly with the index and middle fingers at the same time, and press the pump to the bottom at one time for 1 spray (25ug). After 1 spray on both nostrils, tilt your head back slightly and inhale gently. After staying for about 30 s, 1 spray was applied to each nostril on both sides for a total of 4 sprays (100ug).
62603570|NCT01777295|ACTIVE_COMPARATOR|Engerix-B Group|Subjects in this group received 1 dose of Placebo at Day -30 followed by 3 doses of Engerix-B at Day 0, Day 30 and Day 180.
62044203|NCT06579001|PLACEBO_COMPARATOR|Saline group|Normal saline packaged in the same appearance was used
62246827|NCT04559204|EXPERIMENTAL|experimental group|408 subjects from experimental group will be simultaneously administrated with one dose of IIV (0.5 ml) and one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
62246828|NCT04559204|ACTIVE_COMPARATOR|control group A|408 subjects from control group A will be only administrated with one dose of IIV (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
62437041|NCT01203774|ACTIVE_COMPARATOR|Pen-administered vs syringe-admnistered Glargine|SoloSTAR pen-administered Glargine insulin then syringe-administered Glargine insulin
62603571|NCT02847182|EXPERIMENTAL|Cord Blood Infusion (best source)|Subjects will be randomized to receive a cord blood infusion at the baseline or 6 month visit. The cord blood will be autologous (if available) or unrelated cord blood.
62603572|NCT02847182|PLACEBO_COMPARATOR|Placebo Infusion|Subjects will be randomized to receive a placebo infusion at the baseline or 6 month visit. The placebo is an acellular media product similar in both appearance and odor.
62826115|NCT06597032|EXPERIMENTAL|Resilience Challenge|The Resilience Challenge Study is an online program containing a series of positive emotion skills for individuals experiencing stress and distress during their everyday life. The online program specifically targets positive emotion and offers an array of skills in a self-guided online delivery platform. Participants will, over the course of 6-8 weeks, access weekly skill lessons, daily homework, and daily emotion reporting. The skill lessons will include: positive events, savoring, gratitude, everyday mindfulness, mindfulness meditation, positive reappraisal, self-compassion, personal strengths, and attainable goals.
62826116|NCT01932593|EXPERIMENTAL|Infusion of autologous bone marrow|Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
62826117|NCT01932593|PLACEBO_COMPARATOR|Placebo|
62826118|NCT04162418|OTHER|Intervention|Treatment with Temporary Spur Stent System and a commercially available, limus-base, drug coated balloon
62826119|NCT06599242|EXPERIMENTAL|Basic Body Awareness Therapy Group ( BBATG)|Basic Body Awareness Therapy Exercises American football team training
62246829|NCT04559204|ACTIVE_COMPARATOR|control group B|408 subjects from control group B will be only administrated with one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
62603573|NCT01764997|EXPERIMENTAL|Adalimumab Open Label run-in|Adalimumab 40 mg every 2 weeks (Q2W) for 16 weeks added to stable dose of MTX.
62044204|NCT05131880|EXPERIMENTAL|Experimental|"The experimental group will participate in a physiotherapy program with the addition of the Fisior Tapestry Method physiotherapy program, three sessions per week, for 12 weeks.~An initial assessment will be made at the beginning of the study, another one at the end of the intervention, and another one at follow-up."
62044205|NCT05131880|ACTIVE_COMPARATOR|Control|The control group will participate in a physiotherapy program three sessions per week for 12 weeks.
62044206|NCT05298150|EXPERIMENTAL|Dynamic cycling|The cycling parameters will change according to motor performance of the participants. Motor performance will be measured by assessing the change in tremor and movement speed.
62246830|NCT04414371|EXPERIMENTAL|Group 1 - Yoga Group|Learn online yoga practices and practice daily for 12-weeks
62246831|NCT04414371|OTHER|Group 2 - Control Group|waist-list control for 4-week, cross-over to yoga practice for 8-week
62246832|NCT02416752||remifentanil group|Group received intra op remifentanil infusion
62437042|NCT01203774|ACTIVE_COMPARATOR|Syringe-administered vs pen-administered Glargine|Syringe-administered Glargine insulin and then pen-administered Glargine insulin
62603574|NCT01764997|ACTIVE_COMPARATOR|Etanercept + MTX (Randomized)|Etanercept 50 mg in combination with Placebo for sarilumab Q2W and etanercept 50 mg on alternating weeks for 24 weeks added to stable dose of MTX.
62603575|NCT01764997|EXPERIMENTAL|Sarilumab 150 mg + MTX (Randomized)|Sarilumab 150 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
62603576|NCT01764997|EXPERIMENTAL|Sarilumab 200 mg + MTX (Randomized)|Sarilumab 200 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
62603577|NCT01764997|EXPERIMENTAL|Sarilumab 150 mg + MTX Open Label Sub-study|Sarilumab 150 mg Q2W for 52 weeks added to stable dose of MTX.
62603578|NCT01100892|NO_INTERVENTION|Control group|Observation only. Does not receive once-daily insulin detemir.
62603579|NCT01100892|EXPERIMENTAL|Once-daily insulin detemir|Once-daily insulin detemir
62603580|NCT06623786||Double immune checkpoint inhibitor|"* Histologically or cytologically confirmed stage IV NSCLC without EGFR sensitizing mutations or ALK translocations OR~* Histologically or cytologically confirmed advanced, malignant pleural mesothelioma~* Eligible for double immune checkpoint inhibition with an anti PD1/L1 inhibitor and a CTLA-4 inhibitor with or without chemotherapy according to current guidelines and SmPC"
62826120|NCT06599242|ACTIVE_COMPARATOR|Control Group|American football team training
62826121|NCT06184516|EXPERIMENTAL|Reproductive organ sparing radical cystectomy|
62437043|NCT04262375|EXPERIMENTAL|Durvalumab and Oleclumab|A single dose level for oleclumab and durvalumab will be used, comprising of Oleclumab 3000 mg IV Q2W for 4 doses, then Q4W AND Durvalumab 1500 mg IV Q4W
62603581|NCT06623786||Immunotherapy with PD1/L1 inhibitor|"* Histologically or cytologically confirmed stage IV NSCLC without EGFR sensitizing mutations or ALK translocations~* Eligible for treatment with an anti-PD-1/L1 inhibitor with or without chemotherapy according to current guidelines and SmPCs"
62826122|NCT06184516|ACTIVE_COMPARATOR|Radical cystectomy|
62246833|NCT02416752||conventional opioid gropup|Group received only conventional opioids and No infusion of remifentanil
62246834|NCT04263012||Patients with an implanted LVAD|Patients which received an implantation of a left ventricular assist device (LVAD) at the University Hospital Basel since 2014
62246835|NCT04062773|EXPERIMENTAL|TRF|Eating restricted to between midday and 6pm.
62246836|NCT04062773|PLACEBO_COMPARATOR|Normal timing of food intake.|Eating between 8am and 11pm.
62246837|NCT03583450|EXPERIMENTAL|Perioperative virtual reality headset|Perioperative virtual reality headset with mobile app and routine anesthetic care
62246838|NCT03583450|NO_INTERVENTION|Control|Routine anesthetic care
62246839|NCT05336916|EXPERIMENTAL|Blended MBCT|"The blended MBCT consists of four 2,5 hour group sessions through videoconference (session 1, 3, 5 and 8), taught by experienced mindfulness trainers. The other sessions (2, 4, 6 and 7) are delivered online and are individual. Mindfulness trainers will provide online feedback to participants for these sessions. The sessions include meditation exercises, psycho-education, and group discussion. In addition to the sessions, participants are instructed to do daily home practice 45 minutes a day. The regular MBCT program was adapted to fit the needs of the target group and, for instance includes psycho-education about grief and cancer-related fatigue.~Online sessions were built around a specific theme. Participants are provided with information, audio files of meditations, and recording assignments around the theme of the session through a personal, secure webpage. The sessions look appealing and persuasive technologies such as reminders and videos are used."
62437044|NCT03952156|EXPERIMENTAL|Cohort 1|Dose Level 1 of HMI-102 delivered intravenously one time
62437045|NCT03952156|EXPERIMENTAL|Cohort 2|Dose Level 2 of HMI-102 delivered intravenously one time
62437046|NCT03952156|EXPERIMENTAL|Cohort 3|Dose Level 3 of HMI-102 delivered intravenously one time
62437047|NCT03952156|EXPERIMENTAL|Delayed Treatment Control|Delayed Treatment Control Arm
62437048|NCT03952156|EXPERIMENTAL|Expansion Phase First Dose level|Expansion Phase First Dose Level of HMI-102 delivered intravenously one time
62437049|NCT03952156|EXPERIMENTAL|Expansion Phase Second Dose level|Expansion Phase Second Dose Level of HMI-102 delivered intravenously one time
62437050|NCT00287287|EXPERIMENTAL|Lenalidomide (Revlimid)|Treatment will be initated at 25 mg/day taken in the morning. Dose adjustments may be made to alleviate toxicities.
62437051|NCT03348982|EXPERIMENTAL|Intervention group|The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session) in a hall/gymnasium of each participating school.Each intervention session will be conducted in the morning by a trained research assistant assisted by student helpers. Each intervention session will be conducted in an identical format, comprising three activities: warm-up (5 min), jogging (20 min), and cool-down (5 min). In the jogging activity, participants will be asked to jog side-by-side with the research staff around an activity circuit (57m x 50m) marked with 4 red cones.
62437052|NCT03348982|NO_INTERVENTION|Control group|Participants in the control group will receive no physical intervention and will be required to follow their daily routine without participating in any additional physical activity/exercise program throughout the whole study period (T1-T3).
62437053|NCT06530069||Case Group|this group consists of patients who have been diagnosed with otomycosis.Observational exposures: Ear cleaning, swimming, wearing earphones, diabetes, immunosuppression, antibiotic ear drops, narrowing of the external auditory canal, etc.
62437054|NCT06530069||Control Group|This group includes healthy individuals who have not been diagnosed with otomycosis during medical examinations.Observational exposures: Ear cleaning, swimming, wearing earphones, diabetes, immunosuppression, antibiotic ear drops, narrowing of the external auditory canal, etc.
62437055|NCT05483439|EXPERIMENTAL|Immunotherapy and neoadjuvant therapy|Traditional herbal medicine twice daily combined with neoadjuvant therapy recommended by the guidelines every 3 weeks, for 6 or 8 cycles.
62437056|NCT05483439|OTHER|neoadjuvant therapy|Only received neoadjuvant therapy recommended by the guidelines every 3 weeks, for 6 or 8 cycles.
62437057|NCT06089135|ACTIVE_COMPARATOR|Intravascular Lithotripsy|
62437058|NCT06089135|ACTIVE_COMPARATOR|Cutting Balloon|
62437059|NCT03032991||Control|Children at 8 years old born from healthy pregnancies
62437060|NCT03032991||GDM|Children at 8 years old born from mothers with gestational diabetes during pregnancy
62437061|NCT02100449|OTHER|Lung ultrasound and Doppler, pneumonia|In this group, a lung ultrasound examination using pulsed-wave Doppler will be performed in patients with high clinical suspicion of pneumonia on Day 0. A bronchoalveolar lavage will also be performed on Day 0.
62437062|NCT02100449|OTHER|Lung ultrasound and Doppler, atelectasis|Patients without clinically active pulmonary disease but presenting a consolidation of suspected atelectatic nature. Fever, hypothermia, leucocytosis and leucopenia will not be present. Tracheal secretions will remain unchanged. There will be no deterioration of oxygenation. In this group, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0.
62437063|NCT02277314|OTHER|Low Cost Treatment for Cataracts|Low cost, manual small incision cataract surgery performed in an educational environment. All costs covered by subjects.
62603582|NCT06623305|NO_INTERVENTION|Retrospective Arm|Retrospective data review of patients who did not receive light therapy
62044207|NCT05298150|ACTIVE_COMPARATOR|Forced cycling|The cycling parameters will not change regardless of the motor performance. Motor performance will be measured by assessing the change in tremor and movement speed.
62246840|NCT05336916|EXPERIMENTAL|Unguided online MBCT|"Participants in the unguided online arm receive access to the 8 online mindfulness sessions (same intervention as blended MBCT arm), but no mindfulness trainer will be involved.~Each online session was built around a specific theme, for instance automatic pilot, communication or self-care. Participants are provided with information, audio files of meditations, and recording assignments around the theme of the session through a personal, secure webpage. Participants are encouraged to read the information and do the assigned meditations and recording assignments within one week. The sessions will look appealing and persuasive technologies such as reminders and video's will be used."
62437064|NCT03453359|EXPERIMENTAL|BIS|Group of patients (90) in whom sedation is adjusted using as main parameters the information obtained by the BIS sedation monitor (BIS VISTA, Aspect Medical Systems, USA).
62437065|NCT03453359|ACTIVE_COMPARATOR|Ramsay|Group of patients (90) in whom sedation is based on subjective monitoring of the level of sedation, using the Ramsay scale as a reference.
62437066|NCT00994032|ACTIVE_COMPARATOR|vertebroplasty|
62437067|NCT00994032|ACTIVE_COMPARATOR|Medical Treatment|
62437068|NCT02659267|EXPERIMENTAL|Interventions Group=|Group of change behavior including physical activity and healthy eating habits promotion.
62437069|NCT02659267|NO_INTERVENTION|Control Group=|Group that will not receive the VAMOS program as intervention, only participate in the Health Academy Program Activities.
62437070|NCT03310203|EXPERIMENTAL|Obese women: central obesity|OGTT with iron
62437071|NCT03310203|EXPERIMENTAL|Obese women: peripheral obesity|OGTT with iron
62437072|NCT03310203|EXPERIMENTAL|Lean women|OGTT with iron
62437073|NCT01001897|EXPERIMENTAL|misoprostol|400 micrograms of misoprostol inserted buccally or vaginally prior to IUD insertion
62437074|NCT01001897|PLACEBO_COMPARATOR|Placebo|Troches identical to experimental drug inserted buccally or vaginally prior to IUD insertion
62437075|NCT02099968|EXPERIMENTAL|Comprehensive Lifestyle Modification|
62437076|NCT02099968|ACTIVE_COMPARATOR|Standard Lifestyle Modification / modified DASH|
62437077|NCT00957957||1|Participants having elective Roux-en-Y gastric bypass surgery (RYGBP)
62437078|NCT00957957||2|Participants having elective gastric banding surgery (GB)
62437079|NCT04621890|EXPERIMENTAL|LOAN2DOSE|From one-week post-randomization to the 12-week study visit, youth randomized to this treatment arm will receive personalized feedback via monetary deductions from a virtual bank of $210 for missed doses of insulin at mealtimes. According to the methodology for calculating BOLUS(1) breakfast will be 0600-1000, lunch will be 1100-1500, and dinner will be 1600-2000. Thus, we will deduct $0.50 per mealtime with at least one meal-associated (carbohydrate-associated) insulin bolus missed (maximum -$1.50/day). Youth can also lose an additional amount of up to $5.00/week for weeks during which they don't achieve at least 5 days of 3 mealtime insulin boluses. Finally, we will deduct the virtual account up to $2.00 per week for failing to share their insulin use data at least two times per week with the study team during the three-month treatment phase (maximum deduction of $24.00). Maximum total deductions is $210.
62437080|NCT04621890|EXPERIMENTAL|COIN2DOSE|From one-week post-randomization to the 12-week study visit, youth randomized to this treatment arm will receive personalized feedback via monetary incentives for dosing insulin at mealtimes. Mealtimes will be defined based on hour of the day and the presence of a carbohydrate entry associated with the insulin bolus. Breakfast will be 0600-1000, lunch will be 1100-1500, and dinner will be 1600-2000. Thus, we will reimburse youth up to $0.50 per mealtime with at least one meal-associated (carbohydrate-associated) insulin bolus completed (maximum $1.50/day). We will offer the opportunity for youth to earn a bonus reimbursement of up to $5.00/week for weeks during which they achieve at least 5 days of 3 mealtime insulin boluses. Finally, we will pay youth up to $2.00 per week for sharing their insulin use data at least two times per week with the study team during the three-month treatment phase (maximum $24.00). Therefore, maximum total incentive available is $210.
62437081|NCT04621890|NO_INTERVENTION|Control|This group will engage have usual diabetes care without intervention. They will fill out all questionnaires, attend clinic visits and provide A1C samples at the same times as the participants in the other groups.
62044208|NCT02603081|PLACEBO_COMPARATOR|Placebo|0 mg SPI-1005 bid po x 21d
62044209|NCT02603081|ACTIVE_COMPARATOR|Low dose|200 mg SPI-1005 bid po x 21d
62044210|NCT02603081|ACTIVE_COMPARATOR|Mid dose|400 mg SPI-1005 bid po x 21d
62044211|NCT02603081|ACTIVE_COMPARATOR|High dose|600 mg SPI-1005 bid po x 21d
62044212|NCT00986206||Biomarker testing|Collect serum for biomarker testing for LAP and HE4 and discovery of new biomarkers.
62437082|NCT03001609|EXPERIMENTAL|AC0010|each participant will be given a single dose of 14C-labeled AC0010
62437083|NCT03720795|OTHER|Stepped Care CBT|Stepped Care CBT consists of two main steps. Step One involves 4 parent-led, therapist-assisted treatment sessions, up to 45 minutes each, over an 8-week period. Participants who do not show significant improvement in symptom severity at the end of Step One, are then 'stepped up' to receive Step Two, which involves 12 weekly, therapist-led, parent-assisted treatment sessions, up to 60 minutes each.
62437084|NCT01847183|EXPERIMENTAL|Click City®: Alcohol|Receive the Click City®: Alcohol program as part of their school curriculum.
62437085|NCT01847183|NO_INTERVENTION|Usual Curriculum|Students receive their usual alcohol curriculum
62603583|NCT06623305|ACTIVE_COMPARATOR|Prospective Arm|Prospective data review of patients who receive light therapy
62603584|NCT00767039|ACTIVE_COMPARATOR|1|Surfactant (beractant, Survanta initial dose 100 mg/kg and subsequent doses 100 mg/kg phospholipids every 6-12 hours, as needed for up to 4 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation
62603585|NCT00767039|EXPERIMENTAL|2|Surfactant (poractant, Curosurf initial dose 200 mg/kg and subsequent doses 100 mg/kg phospholipids every 12-24 hours as needed for up to 3 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation
62044213|NCT06370026|EXPERIMENTAL|KSD-101|Biological: Dendritic Cell Vaccine.Autologous monocyte-derived DCs pulsed with EBV antigen.
62246841|NCT05336916|NO_INTERVENTION|Treatment As Usual|Not offered the mindfulness program, treatment as usual
62826123|NCT02505607|NO_INTERVENTION|Standard Care Group|In this group, subjects will receive standard counseling regarding Overactive Bladder.
62826124|NCT02505607|EXPERIMENTAL|Care Plan Group|"In this group, subjects will receive counseling regarding Overactive Bladder using a printed Overactive Bladder Plan of Care information sheet."
62437086|NCT02025309|ACTIVE_COMPARATOR|Group Methylprednisolone|Patient in this group received general anaesthesia for surgical procedures. During the anesthesia management methylprednisolone was administered intravenously (1mg/kg) to the patients in this group. Also neuromuscular monitorisation was performed to assess the train of four ratio at the end of the procedure, after the reversal of neuromuscular block. All patients were followed during the recovery period from general anaesthesia and the time needed to regain a full neuromuscular recovery was noted. For that, the train of four ratio was followed up and the ratio of 0.9 was recorded.
62437087|NCT02025309|PLACEBO_COMPARATOR|Group Control|Patients who received general anaesthesia and endothracheal entubation but who did not recieved methyprednisone during general anaesthesia were enrolled in the study as control group. Neuromuscular monitorisation was performed to assess the train of four ratio at the end of the procedure, after the reversal of neuromuscular block. All patients were followed during the recovery period from general anaesthesia and the time needed to regain a full neuromuscular recovery was noted. For that, the train of four ratio was followed up and the ratio of 0.9 was recorded.
62603586|NCT05194267|EXPERIMENTAL|Active tDCS|Will be receiving active intensive tDCS treatment
62603587|NCT03816644|EXPERIMENTAL|5-Cog|The 5-Cog coupled with a decision tree is a simple, 5-minute procedure that will identify older persons with cognitive impairment in primary care settings, and flag them for further evaluation. The 5-Cog includes the Picture Memory Impairment Screen (PMIS), Motoric Cognitive Risk syndrome (MCR), and the Symbol Match test. The 5-Cog will be given after randomization and before the patients sees the physician. The 5-Cog will sort patients with 'cognitive impairment' from those with 'no cognitive impairment'. After completing the 5-Cog, the non-physician tester will send a message through the Electronic medical record (EMR) system to provide the physician with the 5-Cog results and guide the them through the follow-up based on the results.
62437088|NCT03646253||Patients with proximal humerus fracture|
62437089|NCT02608359||Abiraterone Acetate (Zytiga) Post-marketing Surveillance (PMS)|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
62246842|NCT04052529|EXPERIMENTAL|Intervention|Participants are instructed to use a popular dietary self-monitoring application on their smartphone for one month.
62437090|NCT06482710|EXPERIMENTAL|Pinwheel Group|Children in the intervention group with CF were given pinwheel breathing exercises.
62603588|NCT03816644|ACTIVE_COMPARATOR|Health Literacy & Grip Assessment|The 5 minute assessment includes the Short Assessment of Health Literacy (SAHL) and a grip assessment measured using a handgrip dynamometer. After completing the SAHL and grip assessment, the non-physician tester will send a message through the EMR to provide the physician with the results from the assessments and guide the them through the follow-up based on the results.
62603589|NCT03968224|EXPERIMENTAL|Metformin/Dapagliflozin|Metformin 1,700 mg/day and Dapagliflozin 10 mg/day for a year.
62603590|NCT03968224|ACTIVE_COMPARATOR|Metformin|Metformin 1,700 mg/day
62044214|NCT00402181|EXPERIMENTAL|Treatment Plan A|Siltuximab 6 milligram per kilogram (mg/kg) as intravenous (directly into the vein) infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days (if participant have complete or partial response) along with dexamethasone (starting from Cycle 2, If participant do not have complete or partial response) 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles.
62246843|NCT04052529|NO_INTERVENTION|Control|Participants are not asked to use the smartphone application.
62246844|NCT02920424|EXPERIMENTAL|Part A: JNJ-56022473 or Placebo (4:1)|Subjects will receive 3 subcutaneous (SC) administrations of the same dose level of JNJ-56022473 Dose 1, Dose 2, or Dose 3 or placebo every 2 weeks (in the ratio of 4:1 \[4 active: 1 placebo\]).
62246845|NCT02920424|EXPERIMENTAL|Part B: JNJ-56022473 or Placebo (5:1)|Subjects will receive 3 SC administrations of the same dose level of JNJ-56022473 or placebo every 2 weeks (in the ratio of 5:1 \[5 active: 1 placebo\]). The dose level(s) will be based upon an interim analysis (IA) of the Part A data.
62246846|NCT03827772|EXPERIMENTAL|Intervention Arm: Fecal microbiota transplantation|30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
62437091|NCT06482710|NO_INTERVENTION|Control Group|The children in the control group were not given pinwheel breathing exercises and continued with their own breathing exercise routines.
62437092|NCT01753531||Flu Symptoms|
62603591|NCT04533191||Subjects treated with LAL lens|Subjects that underwent standard of care cataract surgery and LAL IOL placement.
62603592|NCT01729533|ACTIVE_COMPARATOR|ICSI|In this arm, patients will be provided with standard intracytoplasmic sperm injection (ICSI), in which sperm selection is performed under an overall magnification of x400.
62826125|NCT05881304|EXPERIMENTAL|Immediate SREC provision (iSREC)|Those randomized to the iSREC group will be provided a free 8-week supply of standardized research e-cigarettes (SRECs) and asked to try to switch completely to the SREC.
62826126|NCT05881304|ACTIVE_COMPARATOR|Delayed SREC provision waitlist control (WLC)|Those in the WLC condition will receive SREC provision after an 8-week delay.
62826127|NCT03020251|ACTIVE_COMPARATOR|control group (C group)|patient will receive preoperative chest physiotherapy (standard supportive care)
62826128|NCT03020251|EXPERIMENTAL|rehabilitation group (R group)|patient will receive preoperative chest physiotherapy and a preoperative rehabilitation program at home (exercise training)
62246847|NCT03827772|OTHER|Control Arm|Nutritional supplementation, supportive management
62246848|NCT04952740|EXPERIMENTAL|Ischemic postconditioning|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.) + immediate post-ischemic adaptation: 30 seconds balloon inflation and 30 seconds deflation for 3 cycles
62246849|NCT04952740|ACTIVE_COMPARATOR|No Ischemic postconditioning|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.)
62826129|NCT06010160|EXPERIMENTAL|Advocacy Training Intervention|6 weekly group sessions of advocacy training for cervical cancer screening
62044215|NCT00402181|EXPERIMENTAL|Treatment Plan B|Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks along with dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles (duration of each cycle is 28 days) after that on Day 1 to 4 up to 12 cycles.
62044216|NCT03700138|EXPERIMENTAL|Privigen|TThe treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 6 weeks, with a total of 3 perfusions administered (W0, W4, W8).
62437093|NCT00955032|EXPERIMENTAL|High-Frequency Repetitive Transcranial Magentic Stimulation|High-Frequency repetitive transcranial magnetic stimulation patients randomized to this treatment will receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of Motor Evoked Potential (MEP) threshold, respectively.
62603593|NCT01729533|EXPERIMENTAL|IMSI|In this arm, patients will be provided with a modified intracytoplasmic sperm injection (ICSI) procedure, the IMSI, in which sperm selection is performed under an overall magnification of x6600.
62603594|NCT04268498|EXPERIMENTAL|Arm A - Bortezomib, Lenalidomide and Dexamethasone (VRD)|Participants in this group will receive Bortezomib, Lenalidomide and Dexamethasone on a 21 day treatment cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.
62044217|NCT03700138|PLACEBO_COMPARATOR|Placebo|The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
62044218|NCT00561210|EXPERIMENTAL|I|Total enteral tube feeding
62044219|NCT00561210|ACTIVE_COMPARATOR|II|Total enteral tube feeding
62044220|NCT01146496|ACTIVE_COMPARATOR|Storage container|Ultraviolet light resistant plastic in-ground pesticide storage container
62044221|NCT01146496|NO_INTERVENTION|Control|
62044222|NCT01777659|EXPERIMENTAL|TENS CABG|Eligible patients will be randomized to a transcutaneous electrical nerve stimulation program (TENS; n = 20) or to placebo-TENS (P-TENS; n = 18). All patients were followed by their own physicians, received routine nursing assistance, and were visited daily by one of the investigators, but P-TENS group will be not exposed to any specific electrical stimulation or motor physical intervention.
62437094|NCT00955032|SHAM_COMPARATOR|Sham Repetitive Transcranial Magentic Stimulation|Sham repetitive transcranial magnetic stimulation patients randomized to receive the sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
62603595|NCT04268498|EXPERIMENTAL|Arm B - Carfilzomib, Lenalidomide and Dexamethasone (KRD)|Participants in this group will receive Carfilzomib, Lenalidomide and Dexamethasone on a 28 day cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.
62044223|NCT01777659|PLACEBO_COMPARATOR|P-TENS CABG|Patients will be treated with placebo-TENS (P-TENS) condition for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). P-TENS device underwent modifications in its internal programming: the control capacitor of the time constant was changed and the active time between pulses was modified from 330 milliseconds to 33 seconds, in order to prevent an analgesic effect (33).
62044224|NCT03195868|EXPERIMENTAL|Photobiomodulation|All patients will be treated similarly in this study
62044225|NCT04979455||Exertional heat illness|Participants who experience an atypical elevation in thermal strain or an EHI undergoing strenuous physical exercise.
62044226|NCT04979455||Control|Participants who do not experience an atypical elevation in thermal strain or an EHI undergoing strenuous physical exercise.
62044227|NCT05283967||Adults and children, U.S.|A prospective, observational study of the pharmacokinetics of first-line anti-TB drugs (isoniazid, rifampin, and pyrazinamide) among TB patients (i.e. patients with active TB disease) will be conducted.
62044228|NCT05283967||Tanzanian children|A prospective, observational study of the pharmacokinetics of first-line anti-TB drugs (isoniazid, rifampin, and pyrazinamide) among TB patients (i.e. patients with active TB disease) will be conducted.
62044229|NCT00844025|EXPERIMENTAL|Pharmacist intervention|Patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including medication review, medication reconciliation, patient education and recommended actions.
62246850|NCT02912416|EXPERIMENTAL|Probiotics|Capsule with probiotics
62246851|NCT02912416|PLACEBO_COMPARATOR|Placebo|Capsule with placebo
62044230|NCT00844025|NO_INTERVENTION|Usual care|Patients randomized to usual care group will receive routine review of medication by ward-based pharmacist and nurse.
62044231|NCT05875519|EXPERIMENTAL|Anaesthesia with vasocontrictor|
62603596|NCT04268498|EXPERIMENTAL|Arm C- Carfilzomib, Lenalidomide and Dexamethasone with Daratumumab (DKrd)|Participants in this group will receive Carfilzomib, Lenalidomide, Dexamethasone with Daratumumab, Acetaminophen, Diphenhydramine and Montelukast on a 28 day cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.
62603597|NCT05821790||patients treated for meningioma|Samples required for the study will be obtained from surgical waste of patients who underwent meningioma resection.
62044232|NCT05875519|ACTIVE_COMPARATOR|Anaesthesia without vasocontrictor|
62437095|NCT00077428|EXPERIMENTAL|Treatment (bortezomib, doxorubicin hydrochloride)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression continue to receive bortezomib as above and doxorubicin IV over 2-5 minutes on days 1 and 8. Treatment repeats every 21 days for up to 14 courses in the absence of further disease progression or unacceptable toxicity.
62603598|NCT00743938|EXPERIMENTAL|A1|
62603599|NCT00743938|ACTIVE_COMPARATOR|B2|
62603600|NCT04612413|PLACEBO_COMPARATOR|Cohort 1|Single IV dose of placebo solution
62603601|NCT04612413|EXPERIMENTAL|Cohort 2|Single IV dose of 5x10\^9 Allocetra-OTS cells in suspension
62603602|NCT04612413|EXPERIMENTAL|Cohort 3|Single IV dose of 10x10\^9 Allocetra-OTS cells in suspension
62603603|NCT04612413|EXPERIMENTAL|Cohort 4|Single or two doses of 10x10\^9 Allocetra-OTS cells in suspension
62603604|NCT03108937|EXPERIMENTAL|Dexmedetomidine|Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.
62603605|NCT03108937|PLACEBO_COMPARATOR|saline|Same amount of saline will be administrated.
62826130|NCT06010160|NO_INTERVENTION|Usual care control|usual care (no intervention); control participants will be offered the chance to receive the intervention at the conclusion of month 12 follow-up data collection
62044233|NCT04718428||psoriatic arthritis|Patients with psoriatic arthritis who met the CASPAR criteria and were 18-70 years old were included. Participants with infection of the nails to be examined, loss of nails, trauma history of the nails, having the habit of nail biting, peripheral neuropathy, peripheral vascular disease, another rheumatological disease, systemic infection, and pregnancy were excluded.
62044234|NCT04718428||healthy controls|A gender- and age-matched healthy controls were included. They were recruited from the healthy relatives of the hospital staff. Participants with infection of the nails to be examined, loss of nails, trauma history of the nails, having the habit of nail biting, peripheral neuropathy, peripheral vascular disease, any rheumatological disease, systemic infection, and pregnancy were excluded.
62044235|NCT03141424|NO_INTERVENTION|Group A|Usual care. Unchanged asthma medication during the entire study period.
62044236|NCT03141424|EXPERIMENTAL|Group B|Tapering of ICS over 8 weeks. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
62437096|NCT04038151|EXPERIMENTAL|Condition A: Hybrid Leg|Subject will be trained on use of the experimental device, the Hybrid Leg.
62437097|NCT04038151|OTHER|Condition B: Passive Leg|Subject will use their currently prescribed home passive prosthesis
62437098|NCT06370299||patients screened for MDR gram negative bacilli with positive detection|This group has risk factors for acquisition of multidrug resistant gram negative bacilli (e.g hospital admission outside of Scandinavia), and are therefore screened. They have a detection of ESBL producing Enterobacterales (EPE), Carbapenemase producing Enterobacterales (CPE), Carbapenem resistant A.baumannii (CRAB) and/or carbapenem resistant P.aeruginosa (CRPA).
62437099|NCT06370299||patients screened for MDR gram negative bacilli with negative detection|This group has also similar risk factors for acquisition of multidrug resistant gram negative bacilli (e.g hospital admission outside of Scandinavia), and are therefore screened, but they do not have a detection of EPE, CPE, CRAB and/or CRPA.
62437100|NCT03548714|EXPERIMENTAL|PT150 with alcohol consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times.
62437101|NCT03548714|PLACEBO_COMPARATOR|PT150 with placebo consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times.
62437102|NCT04873674||ASD group|240 ASD patients (aged 4-25 years)
62437103|NCT04873674||Unaffected siblings of ASD|60-100 unaffected siblings of ASD probands
62603606|NCT06225154|NO_INTERVENTION|No intervention|Periodontally healthy subjects with type 2 diabetes mellitus or systemically healthy didn't have an initial periodontal treatment
62603607|NCT06225154|EXPERIMENTAL|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed in a quadrant-wise manner at 1-week intervals for periodontitis patients systemically healthy or with type 2 diabetes mellitus.
62603608|NCT02938949|ACTIVE_COMPARATOR|Alirocumab|Alirocumab (150 mg) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
62603609|NCT02938949|PLACEBO_COMPARATOR|placebo|Placebo (sterile saline) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
62826131|NCT03162926|EXPERIMENTAL|Single-group|Up to six (6) VC-02-20 implants
62826132|NCT01140529|EXPERIMENTAL|Dexmedetomidine|
62826133|NCT01140529|ACTIVE_COMPARATOR|Haloperidol|
62826134|NCT01140529|PLACEBO_COMPARATOR|Placebo|
62826135|NCT06588972|PLACEBO_COMPARATOR|Group 1|placebo (solution of Medium Chain Triglycerides, without any active ingredient)
62603610|NCT05599672|EXPERIMENTAL|Alcohol-targeted Brief Intervention-Medication Therapy Management|Alcohol-targeted Brief Intervention-Medication Therapy Management (ABI-MTM) intervention is a pharmacy-based medication management intervention, combined with Screening, Brief Intervention, and Referral to Treatment
62603611|NCT05599672|ACTIVE_COMPARATOR|Standard medication counseling|Standard Medication Counseling (SMC) (1) will offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present, and (4) discuss generic substitution. Following this session, in the second SMC component, participants will be emailed/mailed (according to participant preference) safety information about co-use of alcohol and opioids
62044237|NCT01229631|PLACEBO_COMPARATOR|Supplementation with non-active|Subjects will be supplemented with placebo capsules (3 capsules am \& 3 capsules pm)
62437104|NCT04873674||TD group|120 age-, and sex matched TDC from the same geographic areas of the ASD group via referral by teachers, or advertisement at college or community.
62603612|NCT02153658|NO_INTERVENTION|Arm 1|Subjects followed the current hygiene instructions, standard washing in a shower with soap.
62603613|NCT02153658|ACTIVE_COMPARATOR|Arm 2|Subjects cleaned the foreskin with soapy water using a syringe once a day.
62603614|NCT02153658|ACTIVE_COMPARATOR|Arm 3|Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.
62603615|NCT03705000|EXPERIMENTAL|Slit Stent II|The Slit Stent II (investigational) device is created by modifying an existing FDA cleared lacrimal stent (BIKA, manufactured by FCI Opthalmics) by adding additional 3 mm and 35 mm long slits of equal depth.
62603616|NCT03705000|ACTIVE_COMPARATOR|BIKA for DCR|The BIKA for DCR is a sterile, single-use device, and is an FDA cleared device.
62603617|NCT06376591|EXPERIMENTAL|Sucrosomial® B12 (Center 1)|Participants will receive an oral single dose of 1000 mcg Sucrosomial® B12 supplement for 7 days.
62603618|NCT06376591|ACTIVE_COMPARATOR|B-SUB® B12 (Center 1)|Participants will receive oral single dose of 1000 mcg B-SUB® B12 supplement for 7 days.
62603619|NCT06376591|EXPERIMENTAL|Sucrosomial® B12 (Center 2)|Participants will receive an oral single dose of 1000 mcg Sucrosomial® B12 supplement for 7 days.
62826136|NCT06588972|EXPERIMENTAL|Group 2|C. sativa extract with a THC:CBD ratio of 1:10 (2mg:20mg/day)
62437105|NCT05863156|EXPERIMENTAL|intervention 1|electro fetal monitoring
62603620|NCT06376591|ACTIVE_COMPARATOR|Mecogen SL® B12 (Center 2)|Participants will receive an oral single dose of 1000 mcg Mecogen SL® B12 supplement for 7 days.
62603621|NCT06376591|EXPERIMENTAL|Sucrosomial® B12 (Center 3)|Participants will receive an oral single dose of 1000 mcg Sucrosomial® B12 supplement for 7 days.
62603622|NCT06376591|ACTIVE_COMPARATOR|Evermin® B12 (Center 3)|Participants will receive an oral single dose of 1000 mcg Evermin® B12 supplement for 7 days.
62603623|NCT06376591|ACTIVE_COMPARATOR|Neuromax® B12 (Center 3)|Participants will receive an oral single dose of 1000 mcg Neuromax® B12 supplement for 7 days.
62603624|NCT00146900|EXPERIMENTAL|Prolonged Exposure (CBT)|Twelve 1.5 hours weekly sessions of Prolonged Exposure cognitive behavioral therapy
62603625|NCT00146900|ACTIVE_COMPARATOR|Cognitive Therapy|Twelve 1.5 hours weekly sessions of Cognitive Therapy without exposure to traumatic reminders.
62826137|NCT06588972|EXPERIMENTAL|Group 3|C. sativa extract with a THC:CBD ratio of 1:10 (4 mg:40 mg/day)
62826138|NCT04206124|EXPERIMENTAL|Single Arm Study Group|Includes all consented patients, male and female, undergoing anterior cervical spine surgery, parathyroidectomy or thyroidectomy (18-60 years old), without history of diabetes mellitus and not pregnant or incarcerated.
62826139|NCT06586970|NO_INTERVENTION|Arm 1: Meals only|"ARM 1: Meals only. Participants randomized to receive meals only will receive 7-14 frozen meals, delivered 1x/week, for 3-months. Participants will be provided with a menu of 42 meal options and instructions for how to select their meals and change weekly meal selections (if desired). Participants in this arm will also receive nutrition education and fall prevention handouts. Nutrition education handouts will indicate which of LifeCare Alliance's meals are considered to be heart healthy as well as diabetic-friendly. Participants will have the autonomy to select their own meals according to their preferences and their ability to self-manage their own health conditions (e.g., diabetes, cardiovascular disease). Fall prevention education handouts will provide guidance on how to reduce fall risk at home and modify the home environment to eliminate fall hazards."
62826140|NCT06586970|ACTIVE_COMPARATOR|Arm 2: Meals + RD services|"ARM 2: Meals + registered dietitian services. Participants randomized to receive meals + RD only will receive 7-14 frozen meals, delivered 1x/week, for 3-months. In addition to receiving nutrition education and fall prevention handouts, participants in this arm will have a telephone-based nutrition assessment completed by one of LifeCare Alliance's registered dietitians who will assign participants a nutrition diagnosis (e.g., overconsumption of carbohydrates) within 60 days of study enrollment."
62044238|NCT01229631|ACTIVE_COMPARATOR|Dietary supplementation with Juice plus+|Subjects will be supplemented with Juice plus+ capsules (3 capsules am \& 3 capsules pm)
62044239|NCT01844284|EXPERIMENTAL|Absorb™ BVS|Subjects receiving Absorb™ BVS
62603626|NCT00146900|EXPERIMENTAL|SSRI (escitalopram)|Twenty milligrams daily of escitalopram (blinded capsules)
62603627|NCT00146900|PLACEBO_COMPARATOR|Placebo|Two concealed placebo pills resembling 10mg escitalopram tablets
62603628|NCT00146900|NO_INTERVENTION|Waiting List|Twelve weeks of waiting list no intervention group
62603629|NCT00371644|EXPERIMENTAL|Arm 1|Participants receive 12 biweekly sessions of Cognitive Processing Therapy (CPT).
62044240|NCT01844284|ACTIVE_COMPARATOR|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
62437106|NCT05863156|EXPERIMENTAL|intervention 2|electro fetal monitoring
62437107|NCT05863156|EXPERIMENTAL|control group|electro fetal monitoring
62437108|NCT01280799|EXPERIMENTAL|Active Treatment|
62437109|NCT05053178|EXPERIMENTAL|Intervention group|Mindfulness-based mandala activity was applied to the intervention group via the zoom online program. Students will be divided into groups of 6-10 and mandala activities will be carried out. 3 weeks of mandala activity, breathing exercises, affirmations, etc. a therapeutic application program was created and implemented.
62603630|NCT00371644|ACTIVE_COMPARATOR|Arm 2|Participants receive 12 biweekly sessions of Present Centered Therapy (PCT).
62603631|NCT01733043|EXPERIMENTAL|Dexmedetomidine infusion|Dexmedetomidine 0.5 mcg/kg loading dose administered over 20 minutes, followed by 0.6 mcg/kg/hr infusion for 1 hour and 40 minutes
62603632|NCT01733043|PLACEBO_COMPARATOR|Placebo|Normal saline infusions will be administered over 4 hours at rates mimicking the DEX infusion rate
62826141|NCT06586970|ACTIVE_COMPARATOR|Meals + OT services|ARM 3: Meals + occupational therapy services. Participants randomized to this arm will receive 7-14 frozen meals, delivered 1x/week, for 3-months and be able to make weekly meal selections from LifeCare Alliance's full list of 40 meals. In addition to receiving nutrition education and fall prevention handouts, participants in this arm will be contacted (within 30 days of study enrollment) by one of Lifecare Alliance's occupational therapists to complete a phone screen to determine each participant's occupational therapy needs (e.g., home safety/fall risk hazards, need for durable medical equipment).
62826142|NCT06586970|ACTIVE_COMPARATOR|Arm 4: Meals + RD + OT services|ARM 4: Meals + registered dietitian services + occupational therapy services. Participants in this arm will receive 7-14 frozen meals, delivered 1x/week, for 3-months as well as the same nutrition education and fall prevention handouts as provided in Arms 1-3. Additionally, participants will receive the combination of dietitian and OT services as provided in Arms 2 and 3 and have the same autonomy to make their own weekly meal selections from a curated list provided by the dietitian.
62826143|NCT05349487|EXPERIMENTAL|SpeakFree Hands Free Heat Moisture Exchanger (HEM) Valve Group|Participants will be fitted to use a hand free HME device over their stoma in order to communicate with a voice prosthesis for one month. The participants will also serve as their own control performing voicing and speech tasks using digital occlusion and digital depression HME.
62826144|NCT04167657|EXPERIMENTAL|Arm1|Sintilimab monotherapy every 3 weeks, after a radiation targeting a single location no less than dose 30Gy( 6 Gy × 5, or other ), or the planned dose could reach 30 Gy.
62826145|NCT06595056|EXPERIMENTAL|Intervention|Participants will receive a one-on-one counseling session and access to an individually tailored multi-media website. Key intervention components will be reinforced through text messaging to aid goal setting, a physical activity tracker (Fitbit) to set goals, track and log activity, and access to a study Instagram account to reinforce exposure to web content.
62826146|NCT06595056|NO_INTERVENTION|Control|Participants will receive a physical activity tracker (Fitbit) only.
62826147|NCT05927935|EXPERIMENTAL|Supervised strength exercise intervention|Group 1
62826148|NCT05927935|ACTIVE_COMPARATOR|Usual care|Group 2
62044241|NCT06011941|EXPERIMENTAL|modified laparoscopic transcystic biliary drainage|A 7-Fr triple-lumen 30-cm central venous catheter was adopted to replace conventional 5-Fr ureteral catheter. Then we developed a continued suture and circling manner by the V-Loc closure device, which simultaneously covered and anchored the C-tube. Furthermore, the catheter was introduced through the abdominal wall located at 3 cm below the costal margin on the midaxillary line/the posterior axillary line, which was traditionally performed at the point below the midclavicular line on the right side.
62044242|NCT04540705|EXPERIMENTAL|Part 1A (Part 1): Nivolumab + Axitinib|
62826149|NCT02675465|EXPERIMENTAL|ATB200|In Stage 1, safety, tolerability, and PK will be evaluated following sequential single ascending doses of intravenously infused ATB200 for 3 dosing periods.
62437110|NCT05053178|NO_INTERVENTION|Control group|For the students in the control group, the standard support program given by the school administration and course instructors will be applied for clinical problems. At the end of the study, it is planned to apply mandala activities among the students in the control group
62603633|NCT00005817|EXPERIMENTAL|Arm I (becatecarin)|Patients receive rebeccamycin analogue IV over 60 minutes on day 1.
62044243|NCT04540705|EXPERIMENTAL|Part 1B (Part 1): Nivolumab + Cabozantinib|
62437111|NCT01428726|PLACEBO_COMPARATOR|Placebo|
62603634|NCT00005817|EXPERIMENTAL|Arm II (becatecarin)|Patients receive rebeccamycin analogue IV over 60 minutes on days 1-5.
62603635|NCT01455181|EXPERIMENTAL|NPSP558|
62437112|NCT01428726|EXPERIMENTAL|NT-KO-003 low dose|
62603636|NCT02060266|EXPERIMENTAL|Semaglutide|
62603637|NCT03212066|EXPERIMENTAL|Intervention|Master Mind is a 25-lesson elementary school, mindfulness education substance abuse prevention program for 4th and 5th grade classrooms.
62603638|NCT03212066|NO_INTERVENTION|Wait-List Control|Business as usual
62603639|NCT03321461|EXPERIMENTAL|TMTP1|The TMTP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. Then TMTP1-ICG spray was applied thoroughly to the ectocervix for 30 minutes. After cleaned by NS, fluorescent detected sites will be removed.
62603640|NCT03321461|ACTIVE_COMPARATOR|ICG|The ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. ICG spray was applied thoroughly to the ectocervix for 30 minutes. After cleaned by NS, fluorescent detected sites will be removed.
62603641|NCT01498705||Hemmorhagic Stroke|"* Hospitalization for an admitting diagnosis of hemorrhagic stroke admitted to the neurosurgical intensive care unit~* Age greater than 18 years~* No evidence of ischemic cerebrovascular injury"
62603642|NCT03011983||Adolescents With Concussion|Adolescents with a concussion (n=120) will undergo neuroimaging (MEG and MRI) and neuropsychology assessments at two time points in the acute and chronic periods after injury, respectively. Brain imaging injury measures will be compared to a control normative database we will create. These brain measures will also be associated with cognitive and clinical outcomes.
62246852|NCT04229511||Infection caused by CRKp|Group 1 cases are constituted by one BSI episode or non-bactereamic invasive infection episode (eg. pneumonia, intra-abdominal infection or urinary tract infection) with CRKp and a positive rectal swab screening or invasive infection (e.g. pneumonia, urinary tract infection and BSI) with CRKp within 90 days before identification of index BSI or other invasive infection with CRKp
62826150|NCT02675465|EXPERIMENTAL|ATB200 + AT2221|In Stage 2, safety, tolerability, and PK will be evaluated following single- and multiple-ascending dose combinations of ATB200 co-administered with AT2221 (Miglustat) In Stage 3, long term safety and efficacy will be assessed following 24 month treatment of ATB200 co-administered with AT2221 (Miglustat)
62246853|NCT04229511||Infection caused by any other bacteria|Group 2 cases who are colonized with CRKp or had invasive infection (e.g. pneumonia, urinary tract infection and BSI) with CRKp within 90 days before identification of index BSI or other types of invasive infection with any bacteria other than CRKp and develop subsequent BSI or non-bactereamic invasive infection with these bacteria
62246854|NCT04229511||No infection|Group 3 cases involve the colonized patients with CRKp who do not develop subsequent BSI or other invasive infections with CRKp or any other bacteria
62246855|NCT03477513|EXPERIMENTAL|Single Arm|Dose-escalated radiation therapy
62246856|NCT03505385|EXPERIMENTAL|Co-created intervention|"The Get Ready (GR) intervention was delivered one-to-one with the care home resident and a relevant family member during a 12-week period:~1. The familiarisation stage aimed to build a rapport with two long-term achievement goals to sit less and move more with the resident and the family member and consisted of two sessions, one in week 1 (50-60minutes) and the other in week 3 (30-40 minutes).~2. The ramping up stage aimed to review the rapport and reach an achievable consensus with the resident and the family member. It consisted of two sessions, one in week 5 and the other in week 7 (20-30 minutes each).~3. The maintenance stage aimed at integrating behaviours and included two sessions, one in week 9 and the other at week 12 (20-30 minutes each). Sessions 5 and 6 were used to understand how the resident was getting on with their short-term GR goals, facilitating some problem-solving discussions."
62246857|NCT03505385|NO_INTERVENTION|Usual care|
62826151|NCT05732311|EXPERIMENTAL|active treatment|600 pulses of iTBS per day with 120% resting motor threshold applied five days in one week; tapering interval over 8 months (three treatments with breaks of three weeks; two treatments with breaks of five weeks; one last treatment after eight weeks)
62826152|NCT05732311|ACTIVE_COMPARATOR|active treatment 2|600 pulses of iTBS per day with 120% resting motor threshold applied five sessions in one day (three treatments with breaks of three weeks; two treatments with breaks of five weeks; one last treatment after eight weeks)
62246858|NCT03841695|EXPERIMENTAL|Treatment Group|Experimental group received Robot Assisted Training (RMTC finger-hand robot (Mirror Hand)) and traditional occupation therapy (Conventional OT) for 1 hour and forty minutes.
62246859|NCT03841695|ACTIVE_COMPARATOR|Control Group|Control group received traditional occupation therapy (Conventional OT) for 1 hour and forty minutes.
62826153|NCT06145321|EXPERIMENTAL|Experimental Group|G-CSF at a dose of 5 mcg/kg/day intravenously infused for 4 hours
62246860|NCT05354076|EXPERIMENTAL|liposomal doxorubicin|According to the clinical diagnosis and treatment norms, it is suitable for patients with advanced malignant tumors diagnosed by histopathology with doxorubicin hydrochloride liposome injection chemotherapy.
62246861|NCT03965078||CMO without epiretinal membrane|Subject diagnosed with CMO within 12 weeks of cataract surgery without evidence of epiretinal membrane at the time of diagnosis.
62437113|NCT01428726|EXPERIMENTAL|NT-KO-003 high dose|
62826154|NCT06145321|OTHER|Control Group|G-CSF at a dose of 5 mcg/kg/day intravenously bolus
62246862|NCT03965078||CMO with epiretinal membrane|Subject diagnosed with CMO within 12 weeks of cataract surgery with evidence of epiretinal membrane at the time of diagnosis.
62246863|NCT03339869|EXPERIMENTAL|blood sample group|Adult patient hospitalized in intensive care unit and treated for infection.
62246864|NCT02501382||Patients with NSTI treated with HBOT|NSTI definition: An infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection causing necrosis in subcutis, muscle and/or fascia.
62246865|NCT04085796||Older patients|Older patients who received the ICCI while in the hospital's A\&E
62246866|NCT04085796||ICCI Professional|The member of staff who delivers the ICCI at the site
62437114|NCT03476356|EXPERIMENTAL|Group L|This group will receive oral clomiphene citrate (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle plus oral carnitine supplementation (Carnivita Forte, Eva Pharma, Egypt) (1g tablet, three times per day) from the third day of the cycle until the day of the pregnancy test.
62826155|NCT04421898||group 1|group 1 : infants with congenital muscular torticollis
62826156|NCT04421898||group 2|group 2 : healthy , without congenital muscular torticollis
62826157|NCT03496311||Pregnant Women|Pregnant women with gestational age \> 35 weeks undergoing spinal anesthesia for elective cesarean section.
62826158|NCT03496311||Control Group|Fertile, non-pregnant women undergoing spinal anesthesia for elective surgery.
62826159|NCT04645355|EXPERIMENTAL|New-onset guttate psoriasis|Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.
62044244|NCT00994981|EXPERIMENTAL|magnesium|Using a table of random numbers, the patients were randomized to receive magnesium solution or normal saline. Allocation concealment was ensured using sequentially numbered, sealed opaque envelopes. Immediately after patient's arrival in the operating room, an anesthesiologist who was not involved in this study opened the envelopes and prepared the study solution outside the operating room.
62246867|NCT00514774|EXPERIMENTAL|A|
62246868|NCT00514774|EXPERIMENTAL|B|
62246869|NCT00514774|PLACEBO_COMPARATOR|C|
62437115|NCT03476356|ACTIVE_COMPARATOR|Group C|This group will receive oral clomiphene citrate only (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle.
62437116|NCT02881476|EXPERIMENTAL|Allogeneic WJ-MSCs injection|Intervention: Biological: Cell-based therapy of allogeneic Wharton's jelly-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects.
62826160|NCT04645355|EXPERIMENTAL|Chronic plaque psoriasis|Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.
62044245|NCT00994981|PLACEBO_COMPARATOR|normal saline|Using a table of random numbers, the patients were randomized to receive magnesium solution or normal saline. Allocation concealment was ensured using sequentially numbered, sealed opaque envelopes. Immediately after patient's arrival in the operating room, an anesthesiologist who was not involved in this study opened the envelopes and prepared the study solution outside the operating room.
62044246|NCT04977050|EXPERIMENTAL|Intervention Site|All miners in the New Mexico intervention mine site who will be administered nasal swabs for antigen testing every other work shift, and serological testing 3 months.
62044247|NCT04977050|NO_INTERVENTION|Controled site|All miners in the Wyoming Control mine site who will be administered serological testing 3 months.
62044248|NCT05327387|EXPERIMENTAL|model-based electrical brain stimulation|
62044249|NCT01579734|PLACEBO_COMPARATOR|Placebo|1 tablet day for 5 years
62044250|NCT01579734|ACTIVE_COMPARATOR|Tamoxifen|Tamoxifen 5 mg, (1 tablet) day for 5 years
62603643|NCT03011983||Adolescents Without Concussion|Age- and gender-matched healthy controls (n=160) will be recruited to establish a normative database of whole-brain slow-wave maps from MEG resting-state data as well as white-matter diffusion measures from MRI.
62603644|NCT00946894|EXPERIMENTAL|Total thyroidectomy|Patients who underwent total thyroidectomy
62603645|NCT00946894|EXPERIMENTAL|Dunhill operation|Patients who underwent unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
62603646|NCT00946894|ACTIVE_COMPARATOR|Bilateral subtotal thyroidectomy|Patients who underwent bilateral subtotal thyroidectomy
62826161|NCT06596265||Fit2 Lead Cohort 1-2|Fit2Lead runs September through June at no charge, and provides daily academic support, sports and recreation, meditation, stress resilience, and life skills-focused workshops. Participants who reach age 15 years and are awaiting an internship placement can remain in phase 1 until a position opens or can be transferred to another internship program within the MDPROS.
62826162|NCT05169541||Recurrent pregnancy loss after spontaneous conception|Minimum three consecutive losses from pregnancies achieved after spontaneous conception
62044251|NCT00762320|EXPERIMENTAL|Low dose Kaletra tablets|Patients will serve as their own controls as they are switched from the baseline treatment with liquid Kaletra to the study intervention treatment with Low Dose Tablet Kaletra (100mg/25mg)
62044252|NCT05651854|EXPERIMENTAL|Bhramari pranayama breathing|Bhrāmarī Prāṇāyāma breathing involves inhalation through both nostrils and producing humming sound of a bee while exhaling (Nivethitha et al., 2016).
62044253|NCT05651854|EXPERIMENTAL|Sheetali pranayama breathing|Sheetali pranayama involve inhalation through extension of the tongue outside the mouth and roll the sides of the tongue up so that it would form a tube. At the end of inhalation, the tongue is drawn in, mouth is closed and exhale through the nose (Thanalakshmi et al., 2014).
62044254|NCT03942133|EXPERIMENTAL|entrance placement of adductor canal catheter|
62044255|NCT03942133|EXPERIMENTAL|middle point placement of adductor canal catheter|
62044256|NCT00808379|OTHER|Arm 2 (Radiation + boost )|"Radiation dose to pelvis will be delivered at 1.8 Gy per day, five days per week, to give a total of 25 fractions over a period of five weeks for a total of 45 Gy.~Boost Field - Will be given to all the patients in the radiotherapy alone followed by surgery arm.~The boost will be given with by 3dimensional conformal radiotherapy to a dose of 15-20 Gy. After 45Gy the boost will be planned on the original tumor volume."
62044257|NCT00808379|ACTIVE_COMPARATOR|Arm 1 (standard) Chemoradiation|"The Radiation dose will be delivered at 1.8 Gy per day, five days per week, to give a total of 25 fractions over a period of five weeks for a total of 45 Gy.~Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles."
62044258|NCT03377543|EXPERIMENTAL|Control Sleep/Non-Active Placebo or 81mg Aspirin Pill|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
62044259|NCT03377543|EXPERIMENTAL|Sleep Restriction/81mg Aspirin Pill|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
62044260|NCT03377543|EXPERIMENTAL|Sleep Restriction/Non-Active Placebo|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
62044261|NCT04815525||Normal finding|Colonoscopy finding normal
62044262|NCT04815525||Hyperplastic polyps|Colonoscopy finding of hyperplastic polyps
62437117|NCT03770871|ACTIVE_COMPARATOR|IPT using Dycal (TM )|Indirect pulp treatment; IPT using Dycal (TM ); (2 paste system) by partial caries removal
62437118|NCT03770871|EXPERIMENTAL|IPT using Vitrebond (TM )|Indirect pulp treatment; IPT using Vitrebond (TM );(powder and liquid) by partial caries removal
62437119|NCT06112535|EXPERIMENTAL|TORS with Versius|
62437120|NCT00613847|ACTIVE_COMPARATOR|1|Patients with invasive solid tumors
62603647|NCT04147624|EXPERIMENTAL|Treatment Group|Participants in the treatment group will receive 125 mL of Souvenaid taken by mouth, once daily, for 6 consecutive months.
62603648|NCT04147624|PLACEBO_COMPARATOR|Placebo Group|Participants in the treatment group will receive 125 mL of iso-caloric placebo taken by mouth, once daily, for 6 consecutive months.
62603649|NCT03362138||Dermoscopy|Dermoscopic imaging of a lesion decided to be biopsied
62603650|NCT06507631||Blended care pirate group|During the 8-week pirate group, children will receive two times three hour training sessions. Additionally, parents are advised to practise with their child at home for three hours per week.
62603651|NCT00868491|EXPERIMENTAL|induction chemotherapy plus chemo-immuno-radiotherapy|TPF induction chemotheraopy, radiotehrapy, concomitant cisplatin and cetuximab
62603652|NCT04561024||RT-PCR Positive Patients|RT-PCR confirmed patients positive for SARS-CoV-2
62044263|NCT04815525||Low-risk adenomas|Colonoscopy finding of low-risk adenomas
62044264|NCT04815525||High-risk adenomas|Colonoscopy finding of high-risk adenomas
62044265|NCT04168554||Phase 1 and Phase 2|"20 patients studied in the emergency room with a pediatrician not presen in the ER performing the telemedicine examination from a distance (ie an office down the hall) followed directly by a face-to-face~20 patients included in the general practitioners office, telemedicine is performed from within the hospital to the GPs office.~Patient is then still referred to the hospital in order to check whether the telemedicine and face-to-face examination are somewhat similarce physical examination"
62044266|NCT05924542|EXPERIMENTAL|Intervention Group|"Participants had access to the Kelaa Mental Resilience App for 4 weeks. Thus, participants in the intervention group could complete a maximum of 28 sessions and track a maximum of 28 nights. It was completely left to the user to what extent s/he wanted to engage with the app. The app seeks to translate insights from scientific research on psychology, sleep medicine, and neuroscience into an action-based program. It draws on the tenets of clinical, health, positive, cognitive, biological, and social psychology to foster recovery and growth. Kelaa aims to reduce stress and increase well-being of the user, specifically in the workplace. Users learn new behaviors and best practices through different means, for example, based on CBT and mindfulness based cognitive therapy. The app is designed to implement lifestyle changes through (1) measuring behavior, cognitions, and emotions (tracking module) and (2) providing psycho-educational content (intervention module)."
62044267|NCT05924542|NO_INTERVENTION|Wait-list Control Group|"Participants in the waitlist control group received no intervention and no tracking opportunity for the duration of the trial (6 weeks), yet they had unrestricted access to treatment as usual within their companies. Upon completion of the trial, participants in the waitlist control group received access to the Kelaa app."
62044268|NCT01821261|EXPERIMENTAL|Mouth Rinse 19668-012|Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner, rinse mouth with water, and then rinse with 20 ml of mouth rinse 19668-012 for 30 seconds and spit it out - do not swallow.
62044269|NCT01821261|ACTIVE_COMPARATOR|Mouth Rinse 500347078842|"Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner, rinse mouth with water, and then rinse with 10 ml of mouth rinse 500347078842 for 60 seconds and spit it out - do not swallow.~Attention: Toothpastes can stop mouth rinse from working. Rinse your mouth thoroughly with water and wait 5 minutes after brushing your teeth before using the mouth rinse. You can also use the mouthwash at a different time of day."
62044270|NCT01821261|OTHER|Toothpaste 035000513007|Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner. Subjects in this arm will not use any mouth rinse.
62044271|NCT00445679|EXPERIMENTAL|A|DVS SR 50mg/day
62044272|NCT00445679|EXPERIMENTAL|B|DVS SR 100mg/day
62044273|NCT00445679|EXPERIMENTAL|C|DVS SR 200mg/day
62044274|NCT00445679|ACTIVE_COMPARATOR|D|Paroxetine 20mg/day
62044275|NCT05552651|EXPERIMENTAL|Envafolimab plus chemotherapy|
62044276|NCT04605562|EXPERIMENTAL|IC+CCRT with palbociclib|If patients were non-Immune Subtype.
62044277|NCT04605562|EXPERIMENTAL|IC+CCRT with galunisertib and PD-1 blocking antibody|If patients were Evaded Immune Subtype.
62603653|NCT04561024||Negative patients|RT-PCR confirmed patients negative for SARS-CoV-2 or patients with CXR performed before the emergence of COVID-19 pandemic
62826163|NCT05169541||Recurrent pregnancy loss after assisted reproductive treatment|Minimum three consecutive losses from pregnancies achieved after assisted reproductive treatment (ART), which includes in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and frozen embryo transfer (FER).
62437121|NCT00613847|ACTIVE_COMPARATOR|2|Patients with advanced solid tumors that express HER2 with tumors that are HER2 1+ by IHC or FISH.
62603654|NCT01619540|OTHER|acute heart failure|control arm
62603655|NCT01619540|EXPERIMENTAL|COPD exacerbation|COPD exacerbation
62044278|NCT04605562|EXPERIMENTAL|IC+CCRT with PD-1 blocking antibody|If patients were Active Immune Subtype.
62044279|NCT03536000||Healthy women|"* 200 Pregnant women~* Over 18 years~* Healthy~* With the ability to understand and sign the informed Consent~* With the ability to attend the established controls~* Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
62044280|NCT03536000||Intrauterine Growth restriction|"* Pregnant women~* Over 18 years~* Intrauterine Growth Reestriction(IUGR): fetuses with percentile Growth \<p3 or \<p10 with vascular Doppler alteration.~* With the ability to understand and sign the informed Consent~* With the ability to attend the established controls~* Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
62246870|NCT00617136|EXPERIMENTAL|III|Prewarming by HotDog
62246871|NCT00617136|ACTIVE_COMPARATOR|I|Intraoperative warming by Bair Hugger
62603656|NCT05415371|ACTIVE_COMPARATOR|Standard Care|Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
62603657|NCT05415371|EXPERIMENTAL|Standard Care + Financial Incentives|Financial Incentives participants will receive standard care plus incentives for completing counseling calls and abstinence.
62246872|NCT00617136|ACTIVE_COMPARATOR|II|Intraoperative warming by HotDog
62603658|NCT06452745||Colorectal Cancer|Diagnosed colorectal cancer after histopathological analysis of biopsy and polypectomy pieces taken within a colonoscopy.
62603659|NCT06452745||Adenomatous high risk polyps|Diagnosed adenomatous high risk polyps after histopathological analysis of biopsy and polypectomy pieces taken within a colonoscopy. With = or \> 10 adenomas or serrated polyps and/or any sessile or flat lesion of = or \>20 mm (pediculated = or \>20 mm are not high risk).
62826164|NCT05169541||Recurrent implantation failure|Minimum three consecutive embryo transfers (ET) of good quality embryos with no hCG production. The patient must not have experienced any clinical pregnancies (i.e. evidence of pregnancy on an US or by histopathological examination) after IVF or spontaneous conception. Biochemical pregnancies after spontaneous conception, which terminated before evidence of a gestational sac on an ultrasonic scan (US) could be visualized and before the series of RIF occurred, are accepted.
62246873|NCT04611620||Breast Cancer and Colorectal Cancer Survivors|The purpose of this study is to explore the factors related with cognitive concerns and other symptoms in breast and colorectal cancer survivors.
62826165|NCT04474834||PRS|Providing polygenic risk score (PRS)
62826166|NCT05804136|OTHER|Duramesh|"Laparotomy closure is associated with the occurrence of Surgical Site Events (SSEs) such as wound dehiscence and incisional hernias. Abdominal wall closure can also cause pain and discomfort, or can lead to intestinal obstruction.~Standard sutures can cut through otherwise intact tissue due to the presence of a sharp leading edge leading to repair failure. Meshes distribute forces and allow for tissue ingrowth. Duramesh combines the desirable principles of a mesh repair with the placement precision of a suture. It is the world's first device that both approximates tissue and allows ingrowth for a strong early repair.~Consequently, the expected clinical benefit is the reduced occurrence of Surgical Site Events such as incisional hernias. Additional benefits may include reduced pain and improved quality of life due to durable closure of the abdominal wall with Duramesh. This will be evaluated in this randomized study.~Size 1 Duramesh is used in this RCT. Duramesh is CE-marked."
62826167|NCT05804136|OTHER|Standard suture|2-0, 0, or Number 1 polydioxanone suture (PDS) is used as comparator.
62826168|NCT01694940||Mitochondrial Disease Patients|Patients with possible or known mitochondrial disorders. Patients who are known carriers of mitochondrial or nuclear DNA mutations involved in mitochondrial function.
62826169|NCT03435250|EXPERIMENTAL|AG-270|AG-270 will be administered on Days 1 to 28 of each 28-day cycle. Treatment will continue until disease progression or unacceptable toxicity.
62826170|NCT03435250|EXPERIMENTAL|AG-270/docetaxel|AG-270 will be administered daily, starting 1 week prior to docetaxel infusion. Starting on Cycle 1 Day 1, docetaxel (by intravenous infusion \[IV\]) will be administered once during each 21-day cycle. Treatment with AG-270 and docetaxel will continue until disease progression or unacceptable toxicity.
62246874|NCT03870516|PLACEBO_COMPARATOR|Valve replacement according to guideline parameters|One group will be referred for surgery according according to indications for mitral valve replacement in European guidelines for valvular heart diseases published in 2017 and will have speckle tracking echocardiography before surgery and 6 months later for comparison.
62246875|NCT03870516|ACTIVE_COMPARATOR|Early valve replacement|The other group will include patients with severe asymptomatic mitral regurgitation who have left atrial or left ventricular dysfunction according to speckle tracking echocardiography and will be referred to surgery, then speckle tracking echo will be performed 6 months later.
62449197|NCT02339909|EXPERIMENTAL|Fixed Incentive|"The intervention for the fixed incentive group consists of the standard invitation letter from the Screening service, with additional text offering a fixed financial incentive (£10) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
62603660|NCT06452745||Adenomatous medium risk polyps|Diagnosed adenomatous medium risk polyps after histopathological analysis of biopsy and polypectomy pieces taken within a colonoscopy. With 5 to 9 non-advanced serrated adenomas or polyps and/or at least 1 advanced lesion (adenoma \>10mm and/or hairy component and/or high-grade dysplasia or serrated polyp \>10mm and/or dysplasia).
62603661|NCT06452745||Adenomatous low risk polyps|Diagnosed adenomatous low risk polyps after histopathological analysis of biopsy and polypectomy pieces taken within a colonoscopy. With 1 to 4 non-advanced adenomas (\<10mm, without hairy component or high-grade dysplasia) or non-advanced serrated polyps (\<10mm, without dysplasia).
62603662|NCT06452745||Healthy|No luminal lesions are observed during the colonoscopy.
62603663|NCT06441760|EXPERIMENTAL|Teleconsultation video arm with PEM physicians|Emergency Medical Services (EMS) providers randomized into this arm will receive video teleconsultation with Pediatric Emergency Medicine (PEM) physicians.
62826171|NCT03435250|EXPERIMENTAL|AG-270/nab-paclitaxel/gemcitabine|AG-270 will be administered daily, starting 1 week prior to nab-paclitaxel and gemcitabine infusion. Starting on Cycle 1 Day 1, nab-paclitaxel and gemcitabine IV will be administered on Days 1,8, and 15 during each 28-day cycle. Treatment with AG-270, nab-paclitaxel, and gemcitabine will continue until disease progression or unacceptable toxicity.
62826172|NCT05424406|EXPERIMENTAL|Active light condition|Timed bright light exposure will be delivered in a controlled laboratory setting (10,000 lux) designed to delay the DLMO to 4 am or later. This would shift the circadian nadir (e.g., the period of maximal sleepiness) into the typical daytime sleep period after the nightshift (i.e., circadian nadir at \~10am). Bright light will be delivered in a controlled lab environment using a full spectrum light-box with UV filter (Sunbox Sunray II) to achieve a robust reduction of circadian misalignment. The light schedule will be tailored to each individual nightshift worker, determined by: 1) their baseline circadian phase, and 2) the human phase response curve adjusted to the individual's baseline circadian phase.
62826173|NCT05424406|ACTIVE_COMPARATOR|Control light condition|Shift workers randomized to the control condition will receive less intense light that still has a perceptible alerting effect (100 photopic lux). However, light will occur during a portion of the phase response curve with minimal phase shifts.
62826174|NCT05424406|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT) condition|The CBT condition will probe sleep reactivity using validated CBT strategies over 6 sessions in accordance with the two-factor theory of emotion. Behavioral strategies will be used to reduce physiological arousal (e.g., relaxation training, breathing) and to strengthen behavioral cues for sleep (e.g., sleep hygiene and sleep scheduling). Sleep times will be scheduled to align with the reduced circadian misalignment (compromised phase position, i.e., maintaining a slightly delayed sleep period on offwork days). Cognitive strategies will identify stressors (e.g., dysfunctional beliefs about sleep) and intervene on worry and rumination with cognitive reappraisal and active coping. Sessions will be conducted by a trained behavioral sleep medicine provider via telemedicine to increase accessibility.
62826175|NCT05424406|ACTIVE_COMPARATOR|Sleep education control condition|"This condition will use an established sleep education control protocol modified for nightshift workers based on the Plain Language about Shiftwork published by the National Institute for Occupational Safety and Health (NIOSH). Sleep duration recommendations will be equivalent to the CBT group (8 hours of sleep opportunity) to ensure that outcomes are not confounded by time in bed. Materials in the sleep education control condition will be separated into weekly electronic materials monitored for engagement and completion."
62437122|NCT06450600|EXPERIMENTAL|Therapeutic Education Program for Multiple Sclerosis Patients|Participants in this arm will receive a comprehensive therapeutic education program designed specifically for individuals diagnosed with multiple sclerosis. The program includes individual assessments to identify patient needs and concerns, followed by targeted educational workshops. These workshops cover a wide range of topics, including disease understanding, bladder and sphincter management, fatigue management, and psychological well-being. The intervention is delivered by a multidisciplinary team, including physiotherapists, neurologists, psychologists, urologists, occupational therapists, nurses, and nutritionists, aiming to improve participants' quality of life by enhancing their disease management skills and overall well-being.
62437123|NCT03103009|EXPERIMENTAL|pasireotide|Interventions - One patient will be given a drug, pasireotide (Signifor), on a compassionate use basis for treatment of post-gastric bypass hypoglycemia. The minimal dose will be 0.3 mg subcutaneous daily and the maximal dose will be 0.6 mg subcutaneous twice daily. The patient may continue treatment with pasireotide indefinitely unless the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued at the discretion of the treating physician or Novartis or withdrawal of consent.
62437124|NCT03873519|EXPERIMENTAL|Cold North|Group A: Cold color scheme, room facing North
62603664|NCT06441760|ACTIVE_COMPARATOR|Audio support arm with EM physicians|EMS providers randomized into this arm will receive audio support by usual care Emergency Medicine (EM) physicians.
62603665|NCT03035006|EXPERIMENTAL|Lipotecan based chemoradiotherapy|Patients will receive Lipotecan based CCRT. Lipotecan will be given as a 30-minute (±3 minutes) iv infusion qw for 6 weeks at the predefined dose level for each cohort. A total of 6 doses of Lipotecan will be administered to each patient in conjunction with RT at 3.5 Gy per fraction for 16 fractions. During CCRT period, Lipotecan should be given within 2 hours prior to the start of RT, and the Lipotecan and RT should be delivered on the same day, unless any conditions fulfils with the dose interruption standards. Radiotherapy treatment, at the allocated dose level, is only permitted if the normal tissue dose constrain criteria are maintained
62603666|NCT02059434|EXPERIMENTAL|LAS190792 Dose 1 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
62603667|NCT02059434|EXPERIMENTAL|LAS190792 Dose 2 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
62603668|NCT02059434|EXPERIMENTAL|LAS190792 Dose 3 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
62603669|NCT02059434|EXPERIMENTAL|LAS190792 Dose 4 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
62826176|NCT06588881|OTHER|ENDONEB|The sterile device and gamma rays, latex free and disposable consists of the following components: a steel canister, a catheter 2m hose, one attack base located at the proximal end of the catheter, one unit at the end back, two needles and two syringes. The device must always be stored in the original packaging. Store only in one place Temp temperature not exceeding 30°C(86°)Application procedure: The device must be pr repaired and activated adequately in order to ensure its correctness operation. See instructions for assembly and indoor use of the package.
62826177|NCT00023959|EXPERIMENTAL|Treatment (hydroxyurea, fluorouracil, bevacizumab, radiation)|Patients receive oral hydroxyurea every 12 hours on days 1-6, fluorouracil IV continuously on days 1-5, and bevacizumab IV over 90 minutes on day 1. Patients also undergo radiotherapy once daily on days 1-5. Patients receive G-CSF subcutaneously on days 6-12. Treatment repeats every 2 weeks for up to 7 courses in the absence of disease progression or unacceptable toxicity.
62826178|NCT03167749||Patients group|Male patients with liver cirrhosis of any etiology and severity. Laboratory tests will be done
62826179|NCT03167749||Control group|Healthy males without history or features of liver disease. Laboratory tests will be done
62603670|NCT02059434|EXPERIMENTAL|LAS190792 Dose 5 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
62826180|NCT01060332||diabetics|
62603671|NCT02059434|EXPERIMENTAL|LAS190792 Dose 6 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
62044281|NCT03536000||Preeclampsia|"* Pregnant women~* Over 18 years~* Preeclampsia: elevated blood pressure + Ratio Prot/Creatinin in urine\> 30 mg / mmol creatinin~* With the ability to understand and sign the informed Consent~* With the ability to attend the established controls~* Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
62044282|NCT03536000||Diabetes Mellitus type 1|"* Pregnant women~* Over 18 years~* Diabetes mellitus type1~* With the ability to understand and sign the informed Consent~* With the ability to attend the established controls~* Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
62603672|NCT02059434|PLACEBO_COMPARATOR|Placebo (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
62437125|NCT03873519|EXPERIMENTAL|Cold South|Group B:Cold color scheme, room facing South
62603673|NCT02059434|EXPERIMENTAL|LAS190792 Dose 1 (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
62044283|NCT06580418||Ulcerative colitis (UC)|20 patients with moderate to severe UC under endoscopic surveillance for their disease
62044284|NCT06580418||Crohn's Disease (CD)|20 patients with moderate to severe CD under endoscopic surveillance for their disease
62044285|NCT03689335|ACTIVE_COMPARATOR|Operative|Surgical fixation of the humeral shaft fracture
62044286|NCT03689335|ACTIVE_COMPARATOR|Non-operative|Conservative treatment of the humeral shaft fracture, using a humeral brace
62044287|NCT03665610||Mandatory Safety Population|All subjects who enrolled in studies RPC01-1912, RPC01-1913, or RPC01-1914 and received at least one dose of ozanimod or IP (per parent studies), excluding subjects who discontinued during Period 1 of study RPC01-1913.
62437126|NCT03873519|EXPERIMENTAL|Warm North|Group C: Warm color scheme, room facing North
62603674|NCT02059434|EXPERIMENTAL|LAS190792 Dose 2 (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
62603675|NCT02059434|ACTIVE_COMPARATOR|Tiotropium 18 μg|Single dose, oral inhalation by HandiHaler® single-dose DPI
62603676|NCT02059434|ACTIVE_COMPARATOR|Indacaterol 150 μg|Single dose, oral inhalation by Breezhaler® single-dose DPI
62603677|NCT02059434|PLACEBO_COMPARATOR|Placebo (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
62603678|NCT03407183||spastic neurogenic bladder|intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) in patients with spastic neurogenic bladder is 200 U of onabotulinumtoxinA once, then follow up after three months.
62603679|NCT06079762|EXPERIMENTAL|AGE SELF CARE group visit program|Participants will take part in 8 weekly 90-minute virtual group visit program sessions
62603680|NCT01503398|EXPERIMENTAL|Olanzapine Tablets, 5 mg|Olanzapine Tablets, 5 mg of Dr. Reddy's Laboratories Limited
62603681|NCT01503398|ACTIVE_COMPARATOR|Zyprexa|Zyprexa Tablets, 5 mg of Eli Lilly and company
62826181|NCT05902260|EXPERIMENTAL|Nutritional intervention|Subjects should consume two 200 mL bottles of study product per day
62437127|NCT03873519|EXPERIMENTAL|Warm South|Group D: Warm color scheme, room facing South
62044288|NCT03665610||Optional pharmacokinetic(s) and pharmacodynamics(s) population|Subjects in study RPC01-1913 have completed the study at least through Period 2 and completed the 7 ± 2 days postdose follow-up assessments; or subjects in study RPC01-1914 have completed the study through the 7 ± 2 days postdose follow-up and had no major protocol violations in the parent studies that are deemed to impact PK or PD assessments.
62044289|NCT02453581|EXPERIMENTAL|OZ439 100mg|OZ439 100mg Powder for Oral Suspension
62044290|NCT02453581|EXPERIMENTAL|OZ439 200mg|OZ439 200mg Powder for Oral Suspension
62437128|NCT05953922|ACTIVE_COMPARATOR|treatment group|The treatment group will engage in transcutaneous electrical stimulation (TENS) and core stability exercises for three sessions each week for four weeks.
62437129|NCT05953922|NO_INTERVENTION|control group|The transcutaneous electrical stimulation nerve stimulation will be administered to the control group just for three sessions each week for four weeks.
62437130|NCT02756000|EXPERIMENTAL|complete PCI at initial hospitalization|Staged, complete revascularization of all non-culprit significant lesions in a single PCI session during initial hospitalization for ST elevation myocardial infarction
62437131|NCT02756000|EXPERIMENTAL|complete PCI after 30 days|Staged, complete revascularization of all non-culprit significant lesions in a single PCI session after 30 days from initial hospitalization for ST elevation myocardial infarction
62826182|NCT06589011|ACTIVE_COMPARATOR|Pressure support|The initial pressure support ventilation setting was a driving pressure of 7 cm H2O, PEEP of 5 cm H2O, and safety backup ventilation of 12 breaths/min (safety backup ventilation setting, VT, 8 ml/kg of predicted body weight; and PEEP, 5 cm H2O). The flow trigger and end of breath were set at 2 l/min and 30% of peak flow, respectively.
62603682|NCT06521580|EXPERIMENTAL|open reduction and internal fixation|Open reduction and internal fixation (ORIF) is a common surgical technique used to treat fractures by realigning and stabilizing the broken bones with hardware such as plates, screws, or rods. In the context of osteopetrosis, ORIF can be particularly challenging due to the sclerotic nature of the bone, which makes drilling and hardware placement difficult, and the poor vascularity, which can impede healing and increase the risk of complications such as nonunion or infection.
62603683|NCT05125952|EXPERIMENTAL|Acute Respiratory Failure|Patients with acute respiratory failure managed with pressure-support ventilation.
62603684|NCT06623669|EXPERIMENTAL|MORPH|MORPH participants will attend one weekly group-mediated session alongside a group of their peers plus individual coaching calls. Participants will aim to increase daily steps by moving often throughout the day, using an activity monitor and mHealth app to view feedback and set goals. Participants will also aim to weight via healthy eating while reducing daily calories by \~400kcal/day below weight maintenance needs to achieve approximately 6% weight loss in 6 months and 10% over 18 months.
62603685|NCT06623669|ACTIVE_COMPARATOR|Measurement Only|Measurement-only participants will receive an activity monitor and wireless weight scale to account for the effect of these self-monitoring technologies and activity behavior.
62826183|NCT06589011|PLACEBO_COMPARATOR|control group|The emergence process was led by the discretion of the attending anesthesiologist. The basic strategy was to allow the patient to breathe spontaneously and only help respiration if necessary, with intermittent manual assistance.
62826184|NCT01156428||Control Subjects (normal volunteers)|"Control kidney specimens will be obtained from donor transplant kidneys or nephrectomy specimens performed on patients undergoing nephrectomy for the clinical indication of an identified renal mass.~In the case of donor transplant kidneys, the renal biopsy will be conducted during the act of living donor nephrectomy and transplantation.~In the case of renal mass nephrectomies, representative normal tissue will be obtained from the nephrectomized kidney at a site distant from the renal mass."
62826185|NCT01156428||Renal Disease Subjects|Patients who require a renal biopsy based upon clinical indications such as proteinuria, hematuria, acute renal failure (ARF) of unclear etiology, chronic kidney disease of unclear etiology, nephrotic syndrome, nephritic syndrome, suspected lupus nephritis or any other medically warranted indication for a biopsy.
62826186|NCT02626312|EXPERIMENTAL|Treatment (radiation therapy)|Patients undergo radiation therapy 5 days a week for a total of 15 or 25 fractions in the absence of disease progression or unacceptable toxicity.
62826187|NCT04883281|ACTIVE_COMPARATOR|Involved Nodal Radiotherapy with conventional margins w or w/o chemotherapy|If a patient loses a significant amount of weight on treatment, or the tumor contour changes substantially, repeat CT simulation and re-planning is allowed in the CM arm. However, the gross tumor volume may not be reduced due to tumor shrinkage. The original extent of disease must be included in the replanned GTV.
62826188|NCT04883281|EXPERIMENTAL|Involved Nodal Radiotherapy with marginless Daily Adaptive Radiotherapy w or w/o chemotherapy|Patients in the ML/DART Arm will have their radiation plan adapted with every fraction. The adaptation process will be performed automatically on the Varian Ethos adaptive therapy software under the supervision of the treating physician.
62826189|NCT06268704|EXPERIMENTAL|Non-Particulate Steroid|Patients in this arm will receive an injection of 1 milliliter of 2% lidocaine with 10 milligrams of dexamethasone to one or both sacroiliac joints. If participants initially achieve relief from the injection but then have a return of pain they may be offered a second injection with the same drug at the same dose.
62826190|NCT06268704|ACTIVE_COMPARATOR|Particulate Steroid|Patients in this arm will receive an injection of 1 milliliter of 2% lidocaine with 40 milligrams of methylprednisolone to one or both sacroiliac joints. If participants initially achieve relief from the injection but then have a return of pain they may be offered a second injection with the same drug at the same dose.
62826191|NCT06595745|EXPERIMENTAL|Release sites|Traditional mosquito control will be applied, followed by weekly release of Wolbachia wAlbB-infected Aedes aegypti males to induce sterile mating with wild female mosquitoes.
62826192|NCT06595745|ACTIVE_COMPARATOR|Control sites with traditional mosquito control only|Traditional mosquito control will be applied but no mosquito release will occur in the control sites
62437132|NCT02756000|ACTIVE_COMPARATOR|Dobutamine stress testing|Revascularization by PCI or deferral of revascularization of non-culprit coronary artery lesions based on ischemia testing using Dobutamin stress echocardiography
62826193|NCT05708053|EXPERIMENTAL|Metformin Group|"Patients will receive pre-treatment standard and post treatment of care to the procedure plus metformin 500 mg twice daily 7 days before and 6 months after the PCI procedure.~Metformin will be stopped on the same day of the procedure and restored 3 hours after the procedure."
62826194|NCT05708053|NO_INTERVENTION|Comparator|Patients will receive pre-treatment and post treatment standard of care to the procedure
62044291|NCT02453581|EXPERIMENTAL|OZ439 500mg|OZ439 500mg Powder for Oral Suspension
62044292|NCT02657031|ACTIVE_COMPARATOR|Control Arm|This arm uses standard of care treatment of prochlorperazine 10 mg IV along with diphenhydramine 25 mg IV plus Normal Sailine 500 cc bolus
62044293|NCT02657031|EXPERIMENTAL|Study Arm|This arm uses stud drug regime of Ketamine 0.3 mg/kg along with Ondansetron 4 mg IV plus Normal Saline 500 cc bolus.
62044294|NCT01719835|EXPERIMENTAL|Chemotherapy GEM-P|Gemcitabine, Methylprednisolone, Cisplatin
62044295|NCT01719835|ACTIVE_COMPARATOR|Chemotherapy CHOP|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone
62044296|NCT00314314|EXPERIMENTAL|1|
62044297|NCT00314314|PLACEBO_COMPARATOR|2|
62437133|NCT02179684|EXPERIMENTAL|Early surgery|Patienst with Bell´s Palsy with an early surgical intervention (\< 3month), according to 'baby-sitter' method
62437134|NCT02179684|ACTIVE_COMPARATOR|Conventional treatment and follow-up|Patienst with Bell´s Palsy treated with conventional treatment and standardized physiotherapy according to Jaqueline Diels model.
62437135|NCT00824460|EXPERIMENTAL|1.25 g PA21|
62044298|NCT01562210|EXPERIMENTAL|Olaparib, radiation +/- Cisplatin|Olaparib and radiotherapy with or without Cisplatin
62437136|NCT00824460|EXPERIMENTAL|5.0 g PA21|
62437137|NCT00824460|EXPERIMENTAL|7.5 g PA21|
62437138|NCT00824460|EXPERIMENTAL|10.0 g PA21|
62437139|NCT00824460|EXPERIMENTAL|12.5 g PA21|
62437140|NCT00824460|EXPERIMENTAL|Sevelamer hydrochloride - active control|
62603686|NCT03168919|EXPERIMENTAL|Chemoradiation with MRI assessment|This study has only one arm. The eligible subjects will receive standard of care fractionated radiation therapy along with concomitant temozolomide, which will NOT be changed based on the MRI scans obtained as a part of this study. There is no control or sham group.
62044299|NCT05600348|EXPERIMENTAL|0 oz Pork|Participants receive 0 oz pork and 6 oz 50:50 blend of chicken and beef per day
62044300|NCT05600348|EXPERIMENTAL|3 oz Pork|Participants receive 3 oz pork and 3 oz 50:50 blend of chicken and beef per day
62044301|NCT05600348|EXPERIMENTAL|6 oz Pork|Participants receive 6 oz pork and 0 oz 50:50 blend of chicken and beef per day
62826195|NCT02063724|EXPERIMENTAL|HER-2 Pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
62044302|NCT04158050||anti-IL5/IL5R-therapy group|Asthma patients, asthma and rhinitis, asthma and nasal polyps and anti-IL5/IL5R
62044303|NCT04158050||anti-IgE-therapy group|Asthma patients, asthma and rhinitis, asthma and nasal polyps and anti-IgE-therapy
62044304|NCT01949779||TransForm™ Occlusion Balloon Catheter|TransForm™ Occlusion Balloon Catheter
62246876|NCT06346184|EXPERIMENTAL|Arm 1|"* Period1 : RLD2302 + RLD2102~* Period2 : HCP2303"
62246877|NCT06346184|EXPERIMENTAL|Arm 2|"* Period1 : HCP2303~* Period2 : RLD2302 + RLD2102"
62437141|NCT00036777|EXPERIMENTAL|Treatment (carboplatin, 7-hydroxystaurosporine)|"Patients receive carboplatin IV over 1 hour followed by UCN-01 IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of carboplatin and UCN-01 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
62826196|NCT06060925||Active myofascial pain syndrome|Subjects that experience spontaneous pain
62437142|NCT03040076|EXPERIMENTAL|Cognitive Bias Treatment|Intervention condition
62826197|NCT06060925||Latent myofascial pain syndrome|Subjects that elicit pain only when palpated and disturbed.
62044305|NCT03861013|EXPERIMENTAL|Intervention group|Participation in a multidimensional stress prevention program (GeDStress).
62044306|NCT03861013|NO_INTERVENTION|Wait-list control group|Participants on the wait-list control group will not receive any treatment between the baseline and last follow-up. After the study has ended, they have the option to participate in the program.
62044307|NCT05019092|EXPERIMENTAL|Screening|Ultrasound (US) examination of lower limbs 48 hours after admission and again after 3-5 days (5-7 days after the admission)
62044308|NCT05019092|NO_INTERVENTION|Control|Ultrasound (US) examination according to the clinical evaluation of risk factors for deep vein thrombosis (DVT) and life-threatening bleeding, based on the standard of care (SOC) of the enrolling institution.
62437143|NCT03040076|ACTIVE_COMPARATOR|Relaxation Condition|Active control condition
62826198|NCT06060925||Subjects without pain|No symptoms of chronic pain.
62826199|NCT06596408|EXPERIMENTAL|High Myopes of spherical error -6 and more .|About 50 participants with high myopia will undergo evaluation of their macular vascular density using OCTA and also central macular thickness using OCT.
62826200|NCT05430178|EXPERIMENTAL|NAFLD|Participants in the pediatric NAFLD clinic
62826201|NCT05430178|EXPERIMENTAL|Ob control|Participants with obesity, without NAFLD
62826202|NCT05430178|EXPERIMENTAL|NW control|Participants in the normal range for body weight, without NAFLD
62826203|NCT05430178|EXPERIMENTAL|Liver control|Participants undergoing liver biopsy or liver surgery, without NAFLD
62826204|NCT05834634||Group 1|Patients with parkinsonism
62044309|NCT04684121|EXPERIMENTAL|Granexin gel|"Within-subject comparison of Granexin® Gel versus vehicle gel (placebo).~Granexin® gel 200 μM will be applied daily over ten days. Granexin® will be applied to one of two selected target burns."
62044310|NCT04684121|PLACEBO_COMPARATOR|Vehicle Gel|"Within-subject comparison of Granexin® Gel versus vehicle gel (placebo).~Vehicle gel will be applied daily over ten days. Vehicle will be applied to one of two selected target burns."
62044311|NCT00526266|EXPERIMENTAL|1|
62044312|NCT00526266|PLACEBO_COMPARATOR|2|
62044313|NCT00526266|NO_INTERVENTION|3|No Treatment
62044314|NCT05391854|ACTIVE_COMPARATOR|Pep2dia|
62044315|NCT05391854|PLACEBO_COMPARATOR|Placebo|
62044316|NCT05527379|EXPERIMENTAL|CIP procedure under virtual reality|CIP procedure under virtual reality
62044317|NCT04857931|ACTIVE_COMPARATOR|Colchicine 0.5 mg die|Colchicine 0.5 mg die
62246878|NCT05687903|EXPERIMENTAL|TAK-861 Dose 1|Participants will receive TAK-861 dose 1, orally, from Day 1 up to Weeks 8 or 12.
62246879|NCT05687903|EXPERIMENTAL|TAK-861 Dose 2|Participants will receive TAK-861 dose 2, orally, from Day 1 up to Weeks 8 or 12.
62437144|NCT03231527||Total Arterial coronary CABG|Total Arterial revascularization
62044318|NCT04857931|ACTIVE_COMPARATOR|Colchicine 0.5 mg bid|Colchicine 0.5 mg bid
62044319|NCT04857931|PLACEBO_COMPARATOR|Placebo|Placebo
62044320|NCT00500942||1|Patients having a standard procedure performed in Interventional Radiology.
62044321|NCT00994877||Septic Patients|
62246880|NCT05687903|EXPERIMENTAL|TAK-861 Dose 3|Participants will receive TAK-861 dose 3, orally, from Day 1 up to Weeks 8 or 12.
62246881|NCT05687903|EXPERIMENTAL|TAK-861 Dose 4|Participants will receive TAK-861 dose 4, orally, from Day 1 up to Weeks 8 or 12.
62246882|NCT05687903|PLACEBO_COMPARATOR|Placebo|Participants will receive TAK-861 matching placebo tablets, orally, from Day 1 up to Weeks 8 or 12.
62437145|NCT03231527||Saphenous vein based CABG|Saphenous vein based revascularization
62437146|NCT01990885|EXPERIMENTAL|Cohort A|Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion
62603687|NCT05131087|EXPERIMENTAL|Cadence|Cadence procedure
62826205|NCT05834634||Group 2|Healthy age and sex matched controls
62826206|NCT05510583||Group 1|Pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2013 and 30/06/2015. Patients received traditional paper-based blood glucose monitoring.
62826207|NCT05510583||Group 2|Pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2021 and 31/12/2021. Patients received remote monitoring with myDiabby Healthcare
62246883|NCT01388231|ACTIVE_COMPARATOR|Manualized CBT Group|The present group is comprised of clinical practitioners performing cognitive-behavioral therapy (CBT) on social phobic patients after receiving structured clinical training on the treatment of social phobia based on the Clark and Wells (1995) model.
62246884|NCT01388231|ACTIVE_COMPARATOR|CBT Group -Treatment as Usual|The present group is comprised of clinical practitioners performing cognitive-behavioral therapy (CBT) on social phobic patients, while receiving no structured training in the treatment of social phobia.
62246885|NCT00323908||1|Women at high risk for developing breast cancer
62826208|NCT01484119|ACTIVE_COMPARATOR|Investigational Drug|ACT-129968
62826209|NCT01484119|PLACEBO_COMPARATOR|Comparative Drug|matching placebo tablets and capsules
62826210|NCT01484119|ACTIVE_COMPARATOR|Reference Drug|Cetirizine
62826211|NCT06331013|EXPERIMENTAL|CyberKnife SBRT treatment|CyberKnife ultra-hypofractionated SBRT for localized Prostate cancer with dose-escalation to the dominant intraprostatic lesion
62826212|NCT06085664|EXPERIMENTAL|REGN5678 (anti-PSMAxCD28)|"Participants will receive REGN5678 by vein over about 2 hours the first time you receive it.~Participants will be admitted to the hospital, where participants will be monitored for side effects. Other doses may be given over 30-90 minutes depending on how you handle the dose.~Participants will receive REGN5678 weekly for 6 weeks."
62826213|NCT05641337|EXPERIMENTAL|group with new combination therapy|The hypoglycemic scheme of the experimental group was that the initial dose of Insulin Degludec and Insulin Aspart was 0.3U/kg multiplied by the patient's weight, plus 5 mg of linagliptin and 0.5 g of metformin three times a day.
62246886|NCT03610399|OTHER|Primaquine Regular Dose Unsupervised|This is the regular primaquine dose Brazil without directly observed therapy.
62246887|NCT03610399|ACTIVE_COMPARATOR|Primaquine Regular Dose Supervised|This is the regular primaquine dose in Brazil but with directly observed therapy.
62437147|NCT01990885|EXPERIMENTAL|Cohort B|Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion
62437148|NCT01990885|EXPERIMENTAL|Cohort C|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from Cohorts A and B) in a randomized double-blind fashion
62437149|NCT01990885|EXPERIMENTAL|Cohort D|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion
62246888|NCT03610399|ACTIVE_COMPARATOR|Primaquine Double Dose Unsupervised|This is the double total primaquine dose (14 days) in Brazil with directly observed therapy.
62246889|NCT04055181|ACTIVE_COMPARATOR|rTMS in schizophrenia patients|In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of motor threshold (MT) for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
62246890|NCT04055181|SHAM_COMPARATOR|rTMS in schizophrenia Controls|In sham rTMS, all procedures were identical to 10Hz Schizophrenia group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
62246891|NCT04055181|ACTIVE_COMPARATOR|rTMS in major depressive disorders patients|In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
62826214|NCT05641337|ACTIVE_COMPARATOR|group with intensive insulin therapy|group was treated with intensive insulin therapy.The initial total amount of insulin is 0.5U/kg, of which 40% is basal insulin and 20% is aspart insulin before three meals
62826215|NCT02080806|ACTIVE_COMPARATOR|Mechanical insufflation exsufflation|Application of cough assist machine as part of the regular physiotherapy
62826216|NCT02156843|EXPERIMENTAL|Pyridorin|Pyridorin (pyridoxamine dihydrochloride) 300 mg oral BID (twice daily, every 12 hours) Capsule
62826217|NCT02156843|PLACEBO_COMPARATOR|Placebo|Placebo Oral Capsule taken BID (twice daily, every 12 hours)
62826218|NCT03868995|SHAM_COMPARATOR|Sham injection|Dextrose water injection to subcutaneous layer at tender point
62826219|NCT03868995|EXPERIMENTAL|Tendon injection|Dextrose water injection to injured tendon
62826220|NCT06604468||Patient with congestive heart failure|Patients with a diagnosis of congestive heart failure
62044322|NCT00994877||Healthy Control|
62044323|NCT00820833|PLACEBO_COMPARATOR|1|Standard infant formula
62044324|NCT00820833|EXPERIMENTAL|2|Test formula
62044325|NCT00820833|NO_INTERVENTION|3|Breastfeeding reference group
62246892|NCT04055181|SHAM_COMPARATOR|rTMS in major depressive disorders controls|In sham rTMS, all procedures were identical to 10Hz depression group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
62437150|NCT01990885|EXPERIMENTAL|Cohort E|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion
62437151|NCT02708290||Test arm|The test group included participants who completed more than one thousand exercises and made no more than one error per exercise.
62044326|NCT00224874|EXPERIMENTAL|Etanercept|Enroll within 48 hours of new onset acute GVHD and randomize to Etanercept
62437152|NCT02708290||Control arm|The control group included the rest of participants. The test group participants were matched to the control group by age, gender, expressive language, receptive language, sociability, cognitive awareness, and health at the 1st evaluation.
62437153|NCT02762565|EXPERIMENTAL|breast scanner|
62437154|NCT02792413|EXPERIMENTAL|Denosumab|Denosumab 60 mg, subcutaneous injection every 6 months for 24 months
62826221|NCT02183662|EXPERIMENTAL|BI 224436|
62826222|NCT02183662|PLACEBO_COMPARATOR|Placebo|
62246893|NCT01236664|EXPERIMENTAL|Memory Training|
62246894|NCT01236664|ACTIVE_COMPARATOR|Control workshop|
62246895|NCT03779919|EXPERIMENTAL|High Energy|Extracorporeal shock wave therapy with 0.3 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
62246896|NCT03779919|EXPERIMENTAL|Low Energy|Extracorporeal shock wave therapy with 0.05 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
62437155|NCT02792413|PLACEBO_COMPARATOR|Placebo|NaCl 0.9% (1 mL), subcutaneous injection every 6 months for 24 months
62437156|NCT04036227|EXPERIMENTAL|GS-248|"Part I (SAD): Single doses of 1 mg, 5 mg, 25 mg, 75 mg, 225 mg and 450 mg (planned doses)~Part II (MAD): Multiple ascending doses for 10 days in four cohorts with planned doses of 25 mg, 75 mg, 225 mg and 450 mg. The doses will be finally selected based on results from Part I."
62739032|NCT02216968|EXPERIMENTAL|HA - Increase vegetable intake|"60 Hispanic-American (HA) preschool children will participate in the Intervention Group. 60 HA children will belong to the Control Group.~6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
62044327|NCT00224874|EXPERIMENTAL|Mycophenolate Mofetil|Enroll within 48 hours of new onset acute GVHD and randomize to Mycophenolate Mofetil
62044328|NCT00224874|EXPERIMENTAL|Denileukin Diftitox|Enroll within 48 hours of new onset acute GVHD and randomize to Denileukin Diftitox
62246897|NCT03779919|PLACEBO_COMPARATOR|Sham|Extracorporeal shock wave therapy with 0 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
62246898|NCT03000088||60° angle group|intubate using McGrath Videolaryngoscope with 60° angled stylet
62246899|NCT03000088||90°angle group|intubate using McGrath Videolaryngoscope with 90° angled stylet
62246900|NCT01681628|EXPERIMENTAL|Thought Field Therapy|Thought Field Therapy delivered by trained community leaders.
62246901|NCT01681628|OTHER|Wait list|"Delayed intervention.~No intervention prior to assessment after one week (pre-test 2). Then treated with Thought Field Therapy, and re-assessed after a further week (post-test)."
62246902|NCT04327830||Older adults and their caregivers|Older adults who have received or are receiving home care services and their caregivers
62246903|NCT04327830||Interdisciplinary health and social care providers|Interdisciplinary health and social care providers who provide home care services to older adults
62246904|NCT03351881|ACTIVE_COMPARATOR|Opt Out|
62246905|NCT03351881|ACTIVE_COMPARATOR|Opt In|
62437157|NCT04036227|PLACEBO_COMPARATOR|Placebo|Matching placebo oral solution
62739033|NCT00706108||1|Simulation of anesthesia induction with critical incidents: Analysis of technical and non-technical performance (15 Teams)
62739034|NCT00706108||2|Analysis of technical and non-technical performance in live anesthesia inductions (40 teams)
62739035|NCT00706108||3|Simulation of anesthesia inductions with advanced simulated critical incidents or events and analysis of technical and non-technical performance (max. 50 teams)
62739036|NCT04483193||Critically ill patients|Critically ill patients hospitalised at the intensive care unit.
62739037|NCT04974827|EXPERIMENTAL|Camrelizumab , Cisplatin or Carboplatin|Participants will be given intravenous administration of Camrelizumab (200mg) ,Cisplatin(40mg/m²) or Carboplatin(AUC 2) and Radiotherapy. After completing 5 cycles of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until one year.
62739038|NCT04787783|EXPERIMENTAL|Web based assessment|Participants will be leaded through preoperative period on a web based application. Participants will be addressed to either virtual or traditional face to face outpatient consultation on the basis of the information registered in the web based preoperative questionnaire that the application incorporates. Virtual assessment will be the performed by evaluating both the filled web based questionnaire together with participants´ electronic records. Face to face assessment will be performed in the traditional way by means of an interview with the participant together with the consultation of participant´s previous electronic records.
62044329|NCT00224874|EXPERIMENTAL|Pentostatin|Enroll within 48 hours of new onset acute GVHD and randomize to Pentostatin
62044330|NCT01655290|EXPERIMENTAL|Gadobutrol|first session gadobutrol second session gadobenate dimeglumin
62044331|NCT01655290|EXPERIMENTAL|Demeglumin|first session gadobenate dimeglumin second session gadobutrol
62246906|NCT03351881|ACTIVE_COMPARATOR|Opt Neutral|
62603688|NCT03803228|EXPERIMENTAL|DUOSTIM|(stim 1) flexible antagonist protocol with pre-treatment with estrogen (S1 between J1 and J8 under E2) and stimulation with Fertistartkit® 300 IU / d; triggering by rHCG (Ovitrelle®250μg) and puncture at 36h; oocyte freezing; (stim 2) resumption of stimulation only by Fertistratkit® 300 IU / day from the day after the puncture; introduction of Progestan® 7 days later to avoid menstruation during the second puncture; triggering with rHCG and second puncture at 36h associated with the devitrification of stim 1 oocytes, with sperm collection and embryonic vitrification. Transfer of frozen embryos to the subsequent cycle in the natural cycle (without HCG) and until the frozen embryos are exhausted.
62739039|NCT04787783|NO_INTERVENTION|Traditional face to face assessment|"Participants will be leaded through preoperative period following traditional institutional standards of care.~Face to face assessment will be performed in the traditional way by means of an interview with the participant together with the consultation of participant´s previous electronic records."
62044332|NCT04367584||Subjects with inflammatory AV lesions|Clinical examination Laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
62044333|NCT04367584||Subjects with non inflammatory AV lesions|Clinical examination Laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
62437158|NCT00254397|EXPERIMENTAL|gp100 + Leuprolide|Group IA: HLA-A\*0201 positive/HLA-DP4 negative treated with gp100 (1.0 ml subcutaneous injection in extremities) + Leuprolide (3-month 11.25 mg sustained-release formulation administrated intramuscularly then again 12 weeks later (2 injections)).
62044334|NCT01345721|EXPERIMENTAL|MenACWY (2 primary + 1 booster dose)|Subjects who had previously received two primary doses of MenACWY-CRM vaccine (at 6-8 months and 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
62437159|NCT00254397|EXPERIMENTAL|gp100 - No Leuprolide|Group IB: HLA-A\*0201 positive/HLA-DP4 negative treated with gp100 (1.0 ml subcutaneous injection in extremities) - No Leuprolide
62437160|NCT00254397|EXPERIMENTAL|gp100 + MAGE-3 + Leuprolide|Group IIA: HLA-A\*0201positive/HLA-DP4 positive treated with gp100 (1.0 ml subcutaneous injection in extremities) + MAGE-3 (1.0 ml subcutaneous injection in extremities) + Leuprolide (3-month 11.25 mg sustained-release formulation administrated intramuscularly then again 12 weeks later (2 injections)).
62437161|NCT00254397|EXPERIMENTAL|gp100 + MAGE-3 - No Leuprolide|Group IIB: HLA-A\*0201positive/HLA-DP4 positive treated with gp100 (1.0 ml subcutaneous injection in extremities) + MAGE-3 (1.0 ml subcutaneous injection in extremities) - No Leuprolide
62437162|NCT05197010|EXPERIMENTAL|Home-based exercise program|The subjects will receive 6 weeks of the home exercise program via a smartphone application. The home exercise program sets the exercise intensity to 3 levels (low, medium, and high) according to the disease and consists of 2 stretches, 3 strengthening and/or functional exercises, and a cool-down exercise. The exercise group applies a daily home exercise program (30min/day, 7days/week for 6 weeks).
62437163|NCT05197010|NO_INTERVENTION|Exercise brochure|This group will be offered a brochure including number of exercises for back or knee.
62437164|NCT01483976|ACTIVE_COMPARATOR|Oral medical nutritional supplement without AN777|orally over a three hour period
62437165|NCT01483976|EXPERIMENTAL|Experimental oral medical nutritional supplement with AN777|orally over a three hour period
62044335|NCT01345721|EXPERIMENTAL|MenACWY (1 primary + 1 booster dose)|Subjects who had previously received one primary dose of MenACWY-CRM vaccine (at 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
62044336|NCT01345721|EXPERIMENTAL|MenC (1 primary dose)+MenACWY (1 booster dose)|Subjects who had previously received one primary dose of the comparator MenC vaccine (at 12 months of age) in parent study, were administered one booster dose MenACWY-CRM vaccine in this extension study.
62044337|NCT01471054|EXPERIMENTAL|Ozurdex|Patients will be followed at 1 week after Ozurdex insertion (0.7 mg) and then at 1,2, 3,4, 5, and 6 months. Following the 6-month visit, patients will be seen every 2 months. At each visit patients will be checked for side effects of treatment, measurement of best-corrected visual acuity (BCVA), complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Each eye in the Ozurdex group can have a maximum total of three Ozurdex insertions at minimum of 4-month intervals in the first year after enrolling into the study.
62246907|NCT05491252|NO_INTERVENTION|Control Group (CG)|The subjects in the Control Group (CG) will receive usual care as being received in study hospitals. Usual care at study hospitals involve consultaion with the physician which encompasses history taking, blood glucose measurement, prescription and provision of general education regarding lifestyle modification verbally or in the form of pamphelets.
62437166|NCT06482866||Control group|Patients underwent septoconchoplasty with or without turbionplasty. Surgeons didn't use nasal splits.
62437167|NCT06482866||Study group|Patients underwent septoconchoplasty with or without turbionplasty. Surgeons used nasal splits.
62437168|NCT01102777|OTHER|Usual Care|Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
62437169|NCT01102777|OTHER|Internet-mediated Walking Program|"participants in the intervention arm are asked to participate in a walking program~automated internet-mediated walking program: intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress"
62437170|NCT01336010|EXPERIMENTAL|Group A - 8 weeks therapy|8 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 2 weeks of therapy.
62437171|NCT01336010|EXPERIMENTAL|Group B - 16 weeks therapy|16 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 4 weeks of therapy.
62437172|NCT01336010|EXPERIMENTAL|Group C - 24 weeks therapy|24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 6 weeks of therapy.
62739040|NCT04896619|EXPERIMENTAL|Daily dose of Kori-tofu mixed in 3 slices of bread|Kori tofu as part of bread
62044338|NCT01471054|ACTIVE_COMPARATOR|Bevacizumab|Patients will be followed at 1 week after the initial bevacizumab injection and then at 1,2, 3,4, 5, and 6 months after implant. Following the 6-month visit, the patients will be examined every 4-8 weeks depending on the status of their macular edema. At each visit patients will be checked for side effects of treatment, measurement of BCVA, complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Eyes in the Bevacizumab group can have a maximum total of twelve (12) bevacizumab injections at minimum of 4-week intervals in the first year after enrolling into the study.
62603689|NCT03803228|ACTIVE_COMPARATOR|Conventional stimuli|"(stim 1) flexible antagonist protocol with pre-treatment with estrogen (S1 between J1 and J8 under E2) and stimulation with Fertistartkit® 300 IU / d; triggering by rHCG (Ovitrelle®250μg) and puncture at 36h; fresh embryonic transfer if satisfactory endometrial conditions with luteal phase support by vaginal micronized progesterone Progestan® 600 mg / d; otherwise embryonic freezing and transfer of frozen embryos to the subsequent cycle in the natural cycle until the frozen embryos are exhausted.~(stim 2) ditto starting on the next cycle if possible or the next one. Hormonal Controls + Ultrasound During Stimulation: Blocking / S1 - S5 / S6 - S8 / S9 - SHCG / SHCG-1"
62826223|NCT03772886|EXPERIMENTAL|Peanut Ball Arm|Study participants randomized to the Peanut Ball Arm will have the peanut ball placed during labor. Study participants will be required to use the peanut ball for a minimum of 30 minutes of each hour until they reach complete dilation. Peanut ball use time will be noted in the patient's chart.
62044339|NCT03493048|EXPERIMENTAL|Cetuximab Plus FOLFOXIRI|Cetuximab Plus FOLFOXIRI Patients will receive Cetuximab Plus FOLFOXIRI every 14 days: Cetuximab 500mg/m2 ivd over 90 minutes on Day 1; Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1; Irinotecan 130 mg/m2 ivd over 90 minutes on Day 1; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
62044340|NCT03493048|ACTIVE_COMPARATOR|Cetuximab Plus FOLFOX|Patients will receive Cetuximab Plus FOLFOX every 14 days: Cetuximab 500mg/m2 ivd over 90 minutes on Day 1; Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
62044341|NCT02651766|NO_INTERVENTION|Waiting List control group|No treatment within the study period, were allowed to continue physiotherapy and medication. Were offered the treatment after finishing the study
62044342|NCT02651766|EXPERIMENTAL|Cupping massage treatment|Received the 5 cupping treatments, application twice a week on the upper back and neck
62246908|NCT05491252|EXPERIMENTAL|Intervention Group (IG)|The subjects in the Intervention Group (IG) will receive usual care as well as a nurse-led PAtient CEntered Self-Management Intervention (PACE-SMI). PACE-SMI will be delivered for eight weeks duration comprising eight face to face individual and group educational, couselling and behavioral (ECB) training sessions in addition to telephonic reminders and a home visit by Principal Investigator (PI) and Research Assistants (RA). Outcome variables will be measured at three points in time (at baseline, at completion of intervention and lastly, after three months follow-up).
62246909|NCT01829360|EXPERIMENTAL|Standard then Alternative: High Dose|Children in this arm are assigned to the standard treatment for the first round of intervention (dose 6 x dose frequency 6) and then the alternative treatment that maximizes dose (dose 9 x dose frequency 4)
62246910|NCT01829360|EXPERIMENTAL|Alternative: High Dose then Standard|Children in this arm are assigned to the alternative treatment that maximizes dose (dose 9 x dose frequency 4) in the first round of intervention and then to the standard treatment for the second round of intervention (dose 6 x dose frequency 6)
62246911|NCT01829360|EXPERIMENTAL|Alternative: High Dose Frequency then Standard|Children in this arm are assigned to the alternative treatment that maximizes dose frequency (dose 4 x dose frequency 9) in the first round of intervention and then to the standard treatment for the second round of intervention (dose 6 x dose frequency 6)
62246912|NCT01829360|EXPERIMENTAL|Standard then Alternative: High Dose Frequency|Children in this arm are assigned to the standard treatment for the first round of intervention (dose 6 x dose frequency 6) and then the alternative treatment that maximizes dose frequency (dose 4 x dose frequency 9)
62246913|NCT01603329|EXPERIMENTAL|Comprehensive incentives + comprehensive communication|Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
62246914|NCT01603329|EXPERIMENTAL|Comp incentives + comp communication + non-white paper|Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication, and their patient reports are printed on non-white bright colored paper.
62246915|NCT01603329|EXPERIMENTAL|Focused incentives + focused com for oral diabetes medication|Physicians are given financial incentives for improving patient medication adherence for oral diabetes medication.
62246916|NCT01603329|EXPERIMENTAL|Foc incentives + foc comm for Diabetes + non-white paper|Physicians given financial incentives for improving patient medication adherence for oral diabetes medication and patient reports are printed on bright non-white paper.
62246917|NCT01603329|EXPERIMENTAL|Focused incentives + focused comm for hypertension meds|Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication.
62246918|NCT01603329|EXPERIMENTAL|Foc incentives + comm for hypertension meds + non-white paper|Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication with patient reports on non-white paper.
62246919|NCT01603329|EXPERIMENTAL|Focused incentives + focused comm for cholesterol meds|Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication.
62246920|NCT01603329|EXPERIMENTAL|Foc incentives +comm for cholesterol meds + non-white paper|Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication and patient reports are printed on non-white paper.
62044343|NCT05454150|EXPERIMENTAL|TAVI with balloon-expandable valve (Sapien 3/Ultra, Edwards Lifesciences©)|
62044344|NCT05454150|ACTIVE_COMPARATOR|TAVI with self-expanding valve (Evolut R/Pro, Medtronic©)|
62044345|NCT01800968|ACTIVE_COMPARATOR|Liraglutide|Increasing dose from 0.6mg, 1.2mg to 1.8mg SQ daily.
62044346|NCT01800968|PLACEBO_COMPARATOR|Placebo|Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg SQ daily.
62246921|NCT01603329|EXPERIMENTAL|Comprehensive communiation|Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
62603690|NCT00497978|ACTIVE_COMPARATOR|1|taurine will be given per capsule
62603691|NCT00497978|PLACEBO_COMPARATOR|2|placebo capsules containing microcrystalline cellulose will be given
62603692|NCT00339196|EXPERIMENTAL|1|5-azacytidine VALPROIC acid and ATRA
62603693|NCT01818206|EXPERIMENTAL|Cystic fibrosis (CF) patients|Cystic fibrosis patients whom induced sputum is collected in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
62603694|NCT03425357|EXPERIMENTAL|Low Load Exercises|An exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction.
62603695|NCT04237558|ACTIVE_COMPARATOR|Vaginal hysterectomy|Removal of uterus through vagina in absence of prolapse
62603696|NCT04237558|ACTIVE_COMPARATOR|Laparoscopic hysterectomy|Key hole surgery through small incisions of the abdomen
62603697|NCT01045083|EXPERIMENTAL|1|
62603698|NCT05105828||post Hepatitis C patients with hepatocellular carcinoma|post Hepatitis C patients with hepatocellular carcinoma above 18 years
62603699|NCT05105828||control group|post Hepatitis C patients without hepatocellular carcinoma above 18 years
62603700|NCT04489875|EXPERIMENTAL|Chewing gum|the patients in this arm will receive the post-operative oral feeding along with chewing gum which they'll be required to chew for at least 15 minutes before their meal 3 times a day
62603701|NCT04489875|NO_INTERVENTION|No chewing gum|The patients in this arm will only receive the post-operative oral feeding
62603702|NCT01272401||Breast cancer patients and survivors|
62603703|NCT01157000|EXPERIMENTAL|001|Canagliflozin On Day 1 all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
62603704|NCT06385691|EXPERIMENTAL|use of myDIET tool for nutritional management|Patients will be followed up at regular intervals during neoadjuvant chemotherapy, perioperatively and up to 6 months after the date of surgery (after completion of postoperative chemotherapy).
62603705|NCT04116723|EXPERIMENTAL|Flexible brace|The design of the flexible brace incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) artificial hinge bone for the strategical application and fixation of corrective panel, 3) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
62603706|NCT02262598|EXPERIMENTAL|Telmisartan/HCTZ fixed dose|
62603707|NCT02262598|ACTIVE_COMPARATOR|Telmisartan and HCTZ monocomponents|
62044347|NCT01832428|OTHER|Transfer of autologous MNC intrathecally|Intra thecal transplantation of autologous stem cells 100 Millions per dose in 3 divided doses at interval of 7days.
62044348|NCT00955669|ACTIVE_COMPARATOR|Symptoms and Objective Examination|
62044349|NCT04139564|EXPERIMENTAL|EaseVRx group|Each subject will be asked to complete a 56-day program using the EaseVRx virtual reality headset with assigned modules each week. Each week, subjects will be asked to complete 7 modules (one per day), each approximately 5 minutes in duration, for a total of 56 modules across the program.
62246922|NCT01603329|EXPERIMENTAL|Comprehensive communication + non-white paper|Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication and patient reports are printed on non-white paper.
62246923|NCT01603329|EXPERIMENTAL|Control Arm|Physicians and their patient adherence is tracked, but they receive no intervention.
62246924|NCT02939989|EXPERIMENTAL|Glecaprevir/Pibrentasvir + SOF + RBV for 12 weeks|Participants without cirrhosis who had non-genotype 3 infection and were naïve to protease inhibitor (PI) and/or nonstructural viral protein 5A inhibitor (NS5Ai) prior to participation in AbbVie HCV parent study received daily treatment with glecaprevir/pibrentasvir (GLE/PIB) 300 mg/120 mg plus sofosbuvir (SOF) 400 mg plus twice-daily weight-based ribavirin (RBV) 600 mg - 1200 mg daily total for 12 weeks.
62603708|NCT04543097|NO_INTERVENTION|Usual care|Participants randomised to the usual care arm will continue to receive care as usual for their health and vocational needs. For most patients, this will comprise usual clinical care, without formal vocational advice.
62603709|NCT04543097|EXPERIMENTAL|Usual care plus vocational support|Vocational support following a stepped care model based on the principles of case management in addition to usual primary care.
62044350|NCT04139564|ACTIVE_COMPARATOR|Active control group VR Sham|Each subject will be asked to complete a program accessible via VR that includes 2d visual wildlife scenes similar to some EaseVRx content
62603710|NCT06230029|EXPERIMENTAL|Music Listening|"The presentation of the music listening session will be standardized and will be as follows: Make yourself comfortable; we will first choose the musical style; then adjust the volume; put on the headphones; then the mask; let us know if something is wrong; we can take off the headphones or the mask at any time if you wish; we will stay by your side.~The following data will be collected just before the headset is put on and just after its removal:~* heart rate using a previously disinfected chest belt (PolarH10®)~* blood pressure~* level of anxiety (according to the validated SFQ and VAS scales)~Music listening session will last 15 minutes, at the end of which the headphones will be removed before the patient is transferred to the operating room."
62739041|NCT04896619|ACTIVE_COMPARATOR|Daily dose of whey protein, soy oil and maltodextrin mixed in 3 slices of bread|Whey protein, soy oil and maltodextrin as part of bread
62739042|NCT06032104|EXPERIMENTAL|Bean smoothie then usual diet|Participants first receive 2 weeks of adding bean smoothie to usual diet before colonoscopy. After colonoscopy, they receive usual diet for 2 weeks
62739043|NCT06032104|EXPERIMENTAL|Usual diet then bean smoothie|Participants first receive 2 weeks of usual diet before colonoscopy. After colonoscopy, they add bean smoothie to usual diet for 2 weeks
62246925|NCT02939989|EXPERIMENTAL|Glecaprevir/Pibrentasvir + SOF + RBV for 16 weeks|Participants with genotype 3, and/or compensated cirrhosis, and/or experience with PI and/or NS5Ai prior to participation in Abbvie HCV parent study received daily treatment with GLE/PIB 300 mg/120 mg plus SOF 400 mg plus twice-daily weight-based RBV 600 mg - 1200 mg daily total for 16 weeks.
62246926|NCT03934255|EXPERIMENTAL|Constant Routine Protocol|Participants will be kept in constant conditions for 30 hours to observe circadian physiology in the absence of light, physical activity, and meals.
62044351|NCT04058353|ACTIVE_COMPARATOR|Control: IVA or TEZ/IVA|Following an IVA or TEZ/IVA run-in period of 4 weeks, participants either received IVA 150 milligrams (mg) every 12 hours (q12h) or TEZ 100 mg once daily (qd)/IVA 150 mg q12h in the treatment period for 8 weeks.
62044352|NCT04058353|EXPERIMENTAL|TC: ELX/TEZ/IVA|Following an IVA or TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 8 weeks.
62044353|NCT04029129|EXPERIMENTAL|High exposure|Ambient air was allowed freely into the room.
62044354|NCT04029129|EXPERIMENTAL|Medium exposure|Limited air filtration was used to partially reduce levels of pollution in the room relative to outside.
62246927|NCT00643526|EXPERIMENTAL|Injection Site: First Thigh Then Abdomen|Participants will self inject subcutaneously placebo using auto injector at thigh followed by self injection of placebo subcutaneously at abdomen on Day 1.
62246928|NCT00643526|EXPERIMENTAL|Injection Site: First Abdomen then Thigh|Participants will self inject subcutaneously placebo using auto injector at abdomen followed by self injection of placebo subcutaneously at thigh on Day 1.
62246929|NCT06086093|PLACEBO_COMPARATOR|placebo|Take 1 sachet(5g) 4 times daily.
62246930|NCT06086093|EXPERIMENTAL|RespireAid|Take 1 sachet(5g) 4 times daily.
62739044|NCT01162954|EXPERIMENTAL|DA-6034|
62044355|NCT04029129|EXPERIMENTAL|Low exposure|Doors and windows were closed and sealed and full filtration was used to maximally reduce pollution in the room.
62044356|NCT01512901|EXPERIMENTAL|1|
62044357|NCT01512901|EXPERIMENTAL|2|
62246931|NCT03407404|EXPERIMENTAL|Ketamine-midazolam|Continous intravenous sedation with a colorless drug mixture in 50ml syringe containing 900mg ketamine and 36mg midazolam.
62246932|NCT03407404|ACTIVE_COMPARATOR|Morphine-Midazolam|Continous intravenous sedation with a colourless drug mixture in 50ml syringes containing 54mg morphine and 36mg midazolam.
62246933|NCT00847184|ACTIVE_COMPARATOR|1. Airtraq|Intubation with the use of the Airtraq technique
62246934|NCT00847184|ACTIVE_COMPARATOR|2. MacIntosh|Intubation using the standard MacIntosh blade
62246935|NCT02123316|ACTIVE_COMPARATOR|Pangramin Plus D. pteronyssinus|Pangramin Plus D. pteronyssinus 100% for subcutaneous injection
62044358|NCT01512901|SHAM_COMPARATOR|3|
62044359|NCT06354179|ACTIVE_COMPARATOR|Standard of care|
62044360|NCT06354179|EXPERIMENTAL|Test 1|
62044361|NCT06354179|EXPERIMENTAL|Test 2|
62246936|NCT02123316|PLACEBO_COMPARATOR|Placebo|Placebo for subcutaneous injection
62246937|NCT00691990|ACTIVE_COMPARATOR|A|Classic thyroidectomy with drains
62246938|NCT00691990|ACTIVE_COMPARATOR|B|Classic thyroidectomy without drains
62246939|NCT00146081|EXPERIMENTAL|A|Family Program: Participants who have identified at least 1 family member or friend to enroll in SHARE with them, who are randomly assigned to program A, are invited to bring their enrolled family member or friend (co-participant) with them to the study intervention group sessions as their supportive team member.
62739045|NCT01162954|PLACEBO_COMPARATOR|Placebo|
62739046|NCT06607445||Lusitania|Primary health care
62739047|NCT06607445||Celtici|Oncology
62739048|NCT06607445||Vettonia|Mental health
62739049|NCT06607445||Turdulia|Internal medicine
62739050|NCT06607445||Lácara|Nephrology
62739051|NCT06607445||Tartessos|Neurology
62739052|NCT06607445||Cancho Roano|Emergencies
62739053|NCT06607445||Oretania|Cardiology
62739054|NCT06607445||Carpetania|Rheumatology
62739055|NCT06607445||Baeturia|Transplants
62739056|NCT06607445||Endovélico|Infectious
62739057|NCT06607445||Sirona|Clinical pharmacology
62739058|NCT06607445||Gaudeamus|University of extremadura
62739059|NCT06607445||Sucellus|Urology
62739060|NCT06607445||Mnemosyne|Neurology-Vascular
62739061|NCT06607445||Paidos|Pediatrics
62739062|NCT06607445||Turuñuelo|Pneumology
62739063|NCT05719857|EXPERIMENTAL|Portal hypertension patients with TE ≤ 20 kPa.|All patients included will undergo HVPG measurement and US-guided percutaneous liver biopsy. The exams will be performed in sequence, in the laboratory of hepatic hemodynamics. Within 4 to 8 weeks, a multiparametric magnetic resonance imaging of the abdomen with elastography will be performed, concluding the protocol.
62739064|NCT03573206|EXPERIMENTAL|Treatment Arm|Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
62739065|NCT03702062|EXPERIMENTAL|Observational Arm|Participants will be asked to measure self-assessed 6 minute walk test via the smart phone application twice a week for 2 months after discharge from a heart failure hospitalization, and weekly thereafter for 6 months.
62739066|NCT00698750||Copeland™ Humeral Resurfacing Head|Copeland™ Humeral Resurfacing Head
62246940|NCT00146081|ACTIVE_COMPARATOR|B|Coach Program: Participants who identify 1 or 2 family members or friends to enroll in SHARE with them, who are randomly assigned to program B, are invited to attend the study intervention group sessions without their enrolled family or friend (co-participants). The co-participants receive the same written materials, but act as supportive team members outside of the group sessions only. They are invited to attend special field workshops and personal counseling sessions with their co-participants.
62246941|NCT00146081|EXPERIMENTAL|C|Team Program: Participants who do not identify 1 or 2 family or friend co-participants, and are randomly assigned to program C, are paired with other unrelated enrollees in their group sessions as supportive team members.
62044362|NCT01959451|ACTIVE_COMPARATOR|Prasugrel|Prasugrel 5 mg or 10mg daily for 12 months.
62246942|NCT00146081|ACTIVE_COMPARATOR|D|Individual Program: Participants who do not identify 1 or 2 family members or friends to enroll in SHARE with them, and are randomly assigned to program D, attend group sessions as individuals.
62044363|NCT01959451|EXPERIMENTAL|Prasugrel/Clopidogrel|Day 0 - 7 Prasugrel 5 or 10mg Day 8 - 14 Clopidogrel 75mg q/d. On Day 14 platelet function testing Patients with HPR will be switched to Prasugrel the others will remain on Clopidogrel for 11 1/2 months
62246943|NCT03892512|ACTIVE_COMPARATOR|dexmedetomedine|The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex .Pfizer CO ) .
62246944|NCT03892512|ACTIVE_COMPARATOR|esmolol|Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride . Baxter CO ).
62246945|NCT02611661|OTHER|Stratum 1: Observe|"* PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~* No further treatment just observation"
62246946|NCT02611661|EXPERIMENTAL|Stratum 2: Percutaneous ablation|"* PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~* Percutaneous ablation can be radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation"
62246947|NCT02611661|EXPERIMENTAL|Stratum 3: SBRT|"* PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~* The planned SBRT dose will be 30 Gy in 5 fractions of 6 Gy each. It is recommended that each fraction be separated by a minimum of 12 hours and a maximum of 8 days."
62603711|NCT06230029|NO_INTERVENTION|No Music|"Heart rate variability monitoring while NOT listening to music. The presentation for the patients included in the group without music will be as follows: Make yourself comfortable; we will first put on the headphones but there will be no music; let us know if anything is wrong; we can remove the headphones or mask at any time if you wish; we will stay by your side.~The following data will be collected just before the headset is put on and just after its removal:~* heart rate using a previously disinfected chest belt (PolarH10®)~* blood pressure~* level of anxiety (according to the validated SFQ and VAS scales)~The session will last 15 minutes, at the end of which the headphones will be removed before the patient is transferred to the operating room."
62603712|NCT06083688|EXPERIMENTAL|Intermittent Preventive Treatment with dihydroartemisinin-piperaquine (IPT-DP)|All students are treated at each intervention. Treatment will be with DP (females less than 13 years old and all males) or chloroquine (females 13 years old or older).
62603713|NCT06083688|EXPERIMENTAL|Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine (IPT-SPAQ)|All students are treated at each intervention. Treatment will be with SP and AQ (females less than 13 years old and all males) or chloroquine (females 13 years old or older).
62603714|NCT06083688|NO_INTERVENTION|Control|Students will not receive preventive treatment.
62603715|NCT05519059|EXPERIMENTAL|Patients With Advanced or Metastatic Breast Cancer|Patients will receive Pelareorep with Paclitaxel for 8 cycles (28 days/cycle).
62603716|NCT03717051|EXPERIMENTAL|Intervention|The intervention group will receive nicotine replacement therapy (NRT) sampling and medication counseling. The nurse will help the subject to decide which NRT product (patch or gum) he/she can use and advise how to use the NRT based on his/her smoking habit and amount of cigarette consumption. In addition, the nurse will deliver medication counselling which addresses five main components: (1) the benefits for using NRT in quitting, (2) withdrawal symptoms due to smoking cessation, (3) side effects of NRT, (4) instructions for using NRT, and (5) making appointments for TWGHs SC clinics. Afterwards, the participant will receive 1-week free NRT, an education card about NRT and a one-page leaflet provided by the SC clinics.
62603717|NCT03717051|ACTIVE_COMPARATOR|Control|The control group subjects will receive medication counseling. They will be advised to obtain free NRT by enrolling in the smoking cessation services, but will not be given the sampling. The same one-page leaflet will be provided by the SC clinics.
62437173|NCT01336010|EXPERIMENTAL|Group D - 32 weeks (gt1) or 24 weeks (gt 2/3)|32 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 8 weeks of therapy (genotype 1) or 24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 8 weeks of therapy.
62044364|NCT02642250|EXPERIMENTAL|Entoban Capsules|Entoban is the combination of Holarrhena antidysenterica, Berberis aristata, Symplocos racemosa, Querecus infectoria and Helicteres isora.
62044365|NCT02642250|EXPERIMENTAL|Metronidazole DS|Metronidazole DS(400 mg) is commonly used to treat diarrhea.It eliminates bacteria and other microorganisms that cause infections of the reproductive system, gastrointestinal tract, skin, vagina, and other areas of the body.
62044366|NCT03001297|EXPERIMENTAL|MEDI5884 Dose 1|Participants will receive single dose of MEDI5884 Dose 1 injection SC on Day 1.
62044367|NCT03001297|PLACEBO_COMPARATOR|Placebo|Placebo will be administered subcutaneously (SC).
62044368|NCT03001297|EXPERIMENTAL|MEDI5884 Dose 2|Participants will receive single dose of MEDI5884 Dose 2 injection SC on Day 1.
62044369|NCT03001297|EXPERIMENTAL|MEDI5884 Dose 3|Participants will receive single dose of MEDI5884 Dose 3 injection SC on Day 1.
62044370|NCT03001297|EXPERIMENTAL|MEDI5884 Dose 4|Participants will receive single dose of MEDI5884 Dose 4 injection SC on Day 1.
62044371|NCT03154801|EXPERIMENTAL|Paramedical care|paramedical early detection of sexual dysfunction and sexual health counseling
62603718|NCT02535351|ACTIVE_COMPARATOR|A: TKIs|sunitinib 50 mg orally 4 weeks on/ 2 weeks off or pazopanib 800 mg orally continuously
62603719|NCT02535351|EXPERIMENTAL|B: TKIs + Cytoreductive Nephrectomy|Cytoreductive nephrectomy + sunitinib 50 mg orally 4 weeks on/ 2 weeks off or pazopanib 800 mg orally continuously
62826224|NCT03772886|NO_INTERVENTION|Control Arm|Study participants randomized to the Control Arm will labor without the peanut ball.
62246948|NCT02611661|EXPERIMENTAL|Stratum 4: SBRT + Percutaneous Ablation|"* PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~* Percutaneous ablation can be radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation~* The planned SBRT dose will be 30 Gy in 5 fractions of 6 Gy each. It is recommended that each fraction be separated by a minimum of 12 hours and a maximum of 8 days."
62246949|NCT02611661|NO_INTERVENTION|Stratum 5: Referral for systemic therapy|"* PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~* Referred for further systemic therapy and are not candidates for further locoregional therapy on study."
62246950|NCT02975492|EXPERIMENTAL|Cholecalciferol sequential dose|cholecalciferol : 100 000 Unit International (UI), sequential dose (2 mL)
62246951|NCT02975492|EXPERIMENTAL|Cholecalciferol daily dose|cholecalciferol : 1000 UI, daily dose during 28 days (0.1 ml by day)
62603720|NCT06270017|EXPERIMENTAL|Colon cancer|Tumour tissue from each patients tumour will be implanted in zebrafish embryos and evaluated regarding growth and response to chemotherapy
62603721|NCT00825526|EXPERIMENTAL|Early Intervention, MBSR therapy|Group that receives Mindfulness Based Stress Reduction Therapy immediately after randomization
62603722|NCT00825526|ACTIVE_COMPARATOR|Delayed Treatment Arm, MBSR Therapy|Group that receives Mindfulness Based Stress Reduction Therapy within 3 months of randomization
62603723|NCT04622761|NO_INTERVENTION|control|Immediate surgery (radical prostatectomy) (standard care)
62603724|NCT04622761|EXPERIMENTAL|treatment|"14 days prior to starting Cabazitaxel patients will take 50mg Bicalutamide once daily for 21 days.~7 days prior to starting Cabazitaxel patients will be given 3 months LHRH treatment via injection. The entire dose will be administered via one injection 7 days prior to starting Cabazitaxel. This may be either leuprorelin or goserelin acetate and should be given as per local practice.~At least 30 minutes prior to each administration of Cabazitaxel, patients will be administered IV premedication consisting of:~50mg Ranitidine 10mg Chlorphenamine 8mg Dexamethasone Daily from Day 1 until end of Cabazitaxel treatment patients will take 10mg Prednisolone once daily from Day 1 until end of Cabazitaxel treatment Day 1 of each cycle - Patients will receive Cabazitaxel 25 mg/m2 intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles."
62603725|NCT00648505|EXPERIMENTAL|1|Glipizide and Metformin HCl Tablets 5 mg/500 mg
62603726|NCT00648505|ACTIVE_COMPARATOR|2|Metaglip® Tablets 5 mg/500 mg
62603727|NCT02018354|ACTIVE_COMPARATOR|ACL Reconstruction|Standard ACL reconstruction only.
62603728|NCT02018354|EXPERIMENTAL|ACL + LET|Anatomic ACL reconstruction following the same procedure as the active comparator group with an added lateral extra-articular tenodesis (LET).
62603729|NCT02696447||Cancer treated by radiotherapy|Patient with a solid cancer (all locations) treated with radiation therapy and/or brachytherapy as curative intent
62603730|NCT02106702|ACTIVE_COMPARATOR|FAP counseling|Control arm utilizing the standard of care: access to services provided by the Forensic AIDS Project for up to 90 days after release
62603731|NCT02106702|EXPERIMENTAL|Navigator enhanced case-management|Experimental arm: access to Navigator enhanced case-management services for one year after release
62603732|NCT04908904|ACTIVE_COMPARATOR|Cafestol|12 mg cafestol
62603733|NCT04908904|PLACEBO_COMPARATOR|Placebo|Placebo
62603734|NCT06128785|EXPERIMENTAL|Electroacupuncture group|The acupuncture will be performed within 6 hours after surgery Acupoint: bilateral Hegu (LI4), Zhigou (SJ6), Zusanli (ST36), Shangjuxu (ST37), All acupoints will be taken by tonifying method after obtaining qi, and unilaterally connected to an electroacupuncture instrument for electrical stimulation with a continuous wave frequency of 5 Hz and a stimulation intensity as tolerated by the patient for 30 min each time. Acupuncture stimulation was given every 12 h. The duration of treatment was from postoperative to the fourth postoperative day (d0-d4) or until the patient's first postoperative anal discharge or until the fourth day.
62603735|NCT06128785|SHAM_COMPARATOR|Sham EA group|In order to achieve maximum patient blindness, both groups will use adhesive pads, and the sham acupuncture needle will have the same appearance as the traditional needle, with a blunt tip (Suzhou Medical Supplies Factory, specification 0.25×40mm), lifting and inserting and twisting, but not piercing the adhesive pad. The output wire of the special sham electroacupuncture apparatus is cut in the middle, and the appearance is as usual; that is, the electroacupuncture apparatus shows an on state, but is not actually energized; the electroacupuncture points, acupuncture time points, frequency, retention time, and duration of treatment are the same as the intervention group, and the patients are informed that it is an effective light current input and may not feel stimulation, but the current is output. All study patients will be treated independently and separately to ensure that patients will not come into contact with each other.
62603736|NCT06128785|NO_INTERVENTION|Conventional control group|Routine perioperative management will be given, postoperative fluid and nutritional support, correction of acid-base imbalance, electrolyte disorders, anti-infection, hemostasis and other symptomatic management.
62603737|NCT03256292||testosterone, diet, and increased physical activity|Group receiving standard of care consisting of diet and regular exercise counseling + testosterone replacement therapy
62246952|NCT01049243|OTHER|Fluocinonide Cream 0.1%|Fluocinonide Cream 0.1% open label
62826225|NCT05783141|EXPERIMENTAL|Experimental formula group|Follow-on formula supplemented with a novel prebiotic combination
62246953|NCT05065931||Before|before CDSS on-line
62826226|NCT05783141|PLACEBO_COMPARATOR|Control formula group|Follow-on formula not supplemented
62826227|NCT06262815||Patients with nasogastric tube treatment|Adult patients with diagnosed small bowel obstruction in the Emergency Department for a nasogastric tube was placed
62246954|NCT05065931||After|after CDSS on-line
62246955|NCT04603365|EXPERIMENTAL|Treatment (pamiparib, temozolomide)|Patients receive PO BID on days 1-28 and temozolomide PO QD on days 1-7. Cycles repeat every 28 days for up to 36 months in the absence of disease progression or unacceptable toxicity.
62603738|NCT00081731|ACTIVE_COMPARATOR|Optimal Medical Therapy|Optimal anti-hypertensive therapy
62603739|NCT00081731|EXPERIMENTAL|Stenting|Stent procedure plus optimal anti-hypertensive therapy
62826228|NCT06262815||Patients without nasogastric tube treatment|Adult patients with diagnosed small bowel obstruction in the Emergency Department for no nasogastric tube was placed
62826229|NCT06262815||Patients living with frailty|Subgroup of patients, with small bowel obstruction in the Emergency Department over 65 years of age with a clinical frailty score of \&gt;4.
62826230|NCT06262815||Patients not living with frailty|Subgroup of patients, with small bowel obstruction in the Emergency Department over 65 years of age with a clinical frailty score of \&lt;5.
62826231|NCT06589401|EXPERIMENTAL|INP12|"In Part A (dose escalation), INP12 will be administered for 3 consecutive weeks (Days 1, 8, and 15) based on 28-day cycles. At least 3 patients will be included in each dose level. Each patient will be evaluated for dose-limiting toxicity (DLT) throughout the first cycle (28 days).~In Part B (dose expansion), once the MTD is reached (or the highest protocol-defined dose in the absence of exceeding the MTD), an expanded cohort will be evaluated with the dose level of the MTD, or an intermediate one."
62826232|NCT04215731|EXPERIMENTAL|mFOLFOXIRI Plus Bevacizumab|Patients will receive neoadjuvant mFOLFOXIRI plus bevacizumab once every two weeks for 4 cycles and the same mFOLFOXIRI for 2 cycles. After completing all 6 cycles chemotherapy, the patient will have an MRI scan to examine the tumor. If MRI restaging is ycT4a/b, or MRF involved, the patient will receive concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks). If MRI restaging is ycT0-3 and MRF negative, then the patient will proceed directly to surgery.
62826233|NCT04215731|ACTIVE_COMPARATOR|Induction FOLFOX Followed by Concomitant Chemoradiotherapy|Patients will receive induction FOLFOX chemotherapy for 4 cycles and followed by concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks), then the patient will proceed to surgery.
62826234|NCT05405062|ACTIVE_COMPARATOR|Carboxytherapy|Six carboxytherapy sessions with an interval of 2 weeks. Five ccs will be injected at each point with a depth of 7mm. Between each point and the other is 5 cm.
62826235|NCT05405062|ACTIVE_COMPARATOR|Short pulsed 1064 nm Nd-YAG laser combined with subcision|Twenty-five joules/cm2, 2.2Hz combined with subcision with an interval of 1 month.
62826236|NCT06654882|ACTIVE_COMPARATOR|Second TNFi (Tumor Necrosis Factor inhibitor) medication|Adalimumab originator or biosimilar; etanercept originator or biosimilar depending on which TNFi the participant had failed.
62826237|NCT06654882|ACTIVE_COMPARATOR|Abatacept|The 50 mg, 87.5 mg and 125 mg SQ doses will be available for weight-based dosing. All participants randomized to abatacept in the first or second stage randomization will receive abatacept SQ weekly at a dosage based on the participant's body weight
62826238|NCT06654882|ACTIVE_COMPARATOR|Tocilizumab originator or biosimilar|Tocilizumab will be provided in prefilled syringes (162 mg tocilizumab/0.9 mL solution). All participants randomized to tocilizumab in the first or second stage randomization will be receiving 1 prefilled syringe (162 mg) with a dosing interval based on the body weight criteria.
62826239|NCT06654882|ACTIVE_COMPARATOR|Tofacitinib|Tofacitinib will be provided as oral tablets (tofacitinib citrate 5 mg) and as an oral solution (1 mg/mL). All participants randomized to tofacitinib in the first or second stage randomization will receive tofacitinib oral tablets or oral solution twice daily, approximately 12 hours apart, in the morning and evening, at a dosage based on the participant's body weight .
62826240|NCT02011906|ACTIVE_COMPARATOR|CAD, OMEGA 3|patients with CAD who receive 4 gr/day omega 3 in the form of 4 softgels each of them contains 1000 mg omega 3 and a softgel contains placebo of vitamin E
62826241|NCT02011906|ACTIVE_COMPARATOR|CAD, omega 3 and vitamin E|patients with CAD who receive 4 gr/day omega 3 in the form of 4 softgels each of them contains 1000 mg omega 3 and a softgel contains 400 IU vitamin E
62826242|NCT02011906|PLACEBO_COMPARATOR|CAD, placebo|patients with CAD who receive 4 softgels/day each of them contains placebo of omega 3 and a softgel/day contains placebo of vitamin E
62246956|NCT06494384|ACTIVE_COMPARATOR|Problem Solving Treatment as usual (PST as usual)|Participants in this arm will receiving training in PST as usual.
62246957|NCT06494384|EXPERIMENTAL|Problem Solving Treatment Aid (PST-Aid)|Participants in this arm will receiving training in PST with PST-Aid.
62603740|NCT02631746|EXPERIMENTAL|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 46 courses in the absence of disease progression or unacceptable toxicity.
62603741|NCT01904318|EXPERIMENTAL|IDP-73152 mesylate 40 mg|
62603742|NCT01904318|EXPERIMENTAL|IDP-73152 mesylate 80 mg|
62603743|NCT01904318|EXPERIMENTAL|IDP-73152 mesylate 160 mg|
62603744|NCT01904318|EXPERIMENTAL|IDP-73152 mesylate 320 mg|
62246958|NCT02022085|EXPERIMENTAL|Baha Attract System|"This transcutaneous solution is based on a magnet coupling using magnets on both side of the skin;~* One implant magnet~* One external magnet on which a sound processor is attached, i.e. the Sound Processor magnet (SP magnet)"
62603745|NCT01904318|EXPERIMENTAL|IDP-73152 mesylate 640 mg|
62603746|NCT01904318|EXPERIMENTAL|IDP-73152 mesylate 1280 mg|
62603747|NCT01904318|PLACEBO_COMPARATOR|Placebo|
62603748|NCT03207074|OTHER|All patients|Single study arm. All patients who participate in the study will receive conventional histological diagnosis and diagnosis with the new technology (iKnife)
62603749|NCT04660318|EXPERIMENTAL|Experimental: remote photoplethysmography for physiological parameters Monitor Readings|
62603750|NCT04660318|OTHER|Control: rstandard acquisition system for physiological parameters Monitor Readings|
62603751|NCT01272141|EXPERIMENTAL|Arm A: Lapatinib plus Everolimus|
62603752|NCT05542667|ACTIVE_COMPARATOR|Giomer varnish|PRG coat barrier by SHOFU is varnish based on a new technology named Giomer by incorporating pre-reacted glass ionomer particles, so varnish contains GI particles embedded in a resin matrix, it should be applied once per year since it is the only varnish in the market that is light cured so it is more durable than others.
62246959|NCT05989802|EXPERIMENTAL|Evaluation of various novel TB triage and diagnostic tests|The investigators will conduct evaluation of novel TB triage and diagnostic tests in a cohort of children with presumed TB. The investigators aim to enroll 250 participants per year at each of three enrollment sites for evaluation of various novel TB triage and diagnostic tests and 30 health workers to assess test usability. Novel test evaluations will be conducted on a rolling basis as new tests ready for field evaluation are identified.
62246960|NCT03575078|EXPERIMENTAL|Maximum tolerated dose of ARQ761 in combination with Olaparib.|ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
62246961|NCT02786134|EXPERIMENTAL|low-dose methotrexate (LDM)|Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dipyridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.
62603753|NCT05542667|ACTIVE_COMPARATOR|Fluoroide varnish|Bifluorid 10 by VOCO is a varnish containing 5% sodium fluoride and 5 % calcium fluoride, it should be applied once each 6 months by a professional dentist and it tends to decrease the hypersensitivity of the teeth as well as decrease the risk of caries.
62603754|NCT05044949|ACTIVE_COMPARATOR|Low dose L reuteri capsules|Subjects will be asked to consume 2 capsules with high dose L reuteri per day in 28 days.
62603755|NCT05044949|ACTIVE_COMPARATOR|High dose L reuteri capsules|Subjects will be asked to consume 2 capsules with a low dose L reuteri per day in 28 days.
62603756|NCT05044949|PLACEBO_COMPARATOR|Placebo capsules|Subjects will be asked to consume 2 capsules with placebo powder per day in 28 days.
62603757|NCT03191136|EXPERIMENTAL|Group1|taking YHD1119 (pregabalin 300mg) in fasted state at Period 1
62603758|NCT03191136|EXPERIMENTAL|Group2|taking YHD1119 (pregabalin 300mg) in fed state at Period 1
62603759|NCT02386930|EXPERIMENTAL|Behavrioal Lifestyle modification|
62603760|NCT02386930|NO_INTERVENTION|Control|
62603761|NCT06240533||Historical baseline|Patients with LBP in a retrospective register based study of health care quality indicators covering historical time series data from regional health care databases in Sweden before dissemination by publication of the P3C pathway (January 2013-June 2023).
62826243|NCT04322890|EXPERIMENTAL|Cohort A: EGFR mutation|Lung Cancer with EGFR mutation including EGFR exon19del, exon 21L858R, etc.
62826244|NCT04322890|EXPERIMENTAL|Cohort B: ALK fusion|Lung Cancer with ALK fusion.
62826245|NCT04322890|EXPERIMENTAL|Cohort C: ROS1 fusion|Lung Cancer with ROS1 fusion.
62826246|NCT04322890|EXPERIMENTAL|Cohort D: MET alterations|Lung Cancer with MET alteration including amplification, exon 14 skipping and met fusion etc.
62826247|NCT04322890|EXPERIMENTAL|Cohort E: RET fusion|Lung Cancer with RET fusion.
62826248|NCT04322890|EXPERIMENTAL|Cohort F: KRAS mutation|Lung Cancer with KRAS mutation.
62044372|NCT05460494|NO_INTERVENTION|Usual Care|Usual care for AD/ADRD care partners consists of a screen for burden, and potential referral to AD/ADRD social workers and the AD helpline.
62246962|NCT02786134|EXPERIMENTAL|placebo|Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dypridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.
62246963|NCT01444014|EXPERIMENTAL|YF476|
62603762|NCT06240533||Dissemination|Patients with LBP in a prospective register based study of health care quality indicators for phase 1 (January 2013-June 2023) compared to phase 2 (June 2023- February 2024) after dissemination by publication of the P3C pathway for LBP.
62603763|NCT06240533||Single-faceted implementation|Patients with LBP in a prospective register based study of health care quality indicators for phases 1+2 (January 2013-February 2024) compared to phase 3 (March 2024-February 2026) after single-faceted implementation (health care practitioner workshop) of the P3C pathway for LBP. Health care practitioner confidence in managing LBP and perspectives regarding barriers and facilitators determining implementation P3C pathway success will also be investigated via questionnaires and qualitative interviews directly after and 1 year prospectively the implementation intervention.
62603764|NCT06240533||Multi-faceted implementation|Patients with LBP in a prospective register based study of health care quality indicators for phases 1+2+3 (January 2013-February 2026) compared to phase 4 (March 2026-December 2027) after multi-faceted implementation (repeated health care practitioner workshops and follow-up) of the P3C pathway for LBP.
62603765|NCT02622841|EXPERIMENTAL|BLEND|Combination of stereotactic bodyradiotherapy and surgical stabilization within 48 hours for the treatment of unstable spinal metastases.
62603766|NCT01058759|EXPERIMENTAL|Arm B: Enoxaparin|
62826249|NCT04322890|EXPERIMENTAL|Cohort G: uncommon mutation|Cohort G mainly includes all identified lung cancer mutations except EGFR mut, ALK fusion, ROS1 fusion, MET alterations, KRAS mut and RET fusion. These include: BRAF V600E and non-V600E, NRG fusion, NTRK fusion, ERBB2 amp and mut，NRAS mut, MAP2K1 mut，RIT1 mut, RAF1 mut, FGFR fusion, ARAF mut, HRAS mut etc.
62826250|NCT03324100||Allergic Rhinitis Patients|
62826251|NCT03324100||Healthy Controls|
62826252|NCT01481844|EXPERIMENTAL|sequential treatment|1.drugs experimental-Sequential -PPI( Lansoprazole 30mg x2/day) + amoxicillin 1gx2/day for 5days, followed by 5 days of PPI(Lansoprazole 30mg x2/day) + ( Clarithromycin500mg x2/day and Tinidazole 500mg x2/day )
62826253|NCT01481844|ACTIVE_COMPARATOR|quadruple therapy|Quadruple drug regimen (i.e.-14 days of PPI (Lansoprazole 30mg x2/day) + Bismuth Subsalicylate 525mg X4/day + Metronidazole 500mg x3/day + Tetracycline 500mg x4/day )-is standard of care as second line treatment in eradication of H pylori
62044373|NCT05460494|EXPERIMENTAL|Intervention Arm 1|MCP videos alone. Care partners randomized to intervention arm 1 during Step 2 randomization will receive usual care + RELOAD-C, consisting of: 1) 6 brief (\~5 minute) videos of Dr. Allison Applebaum introducing concepts from MCP for care partners of persons with AD/ADRD; and 2) written content associated with the videos, such as directions for homework assignments. The tab with links to the virtual group meetings will be removed. Participants in this arm use RELOAD-C on their own and do not have interaction with other care partners while using the platform. One video will become available for viewing each week for the first 6 weeks after randomization, and each care partner will have a unique user ID/login.
62603767|NCT01058759|ACTIVE_COMPARATOR|Arm A: No Enoxaparin|
62044374|NCT05460494|EXPERIMENTAL|Intervention Arm 2|"MCP videos + MCP-focused virtual groups. In addition to the components that the intervention arm 1 participants receive (6 MCP videos, written text), the RELOAD-C platform for the intervention arm 2 participants will include links to the virtual group meetings (7 in total). The first 6 group meetings will occur weekly. Each of the first 6 group meetings will facilitate discussion of the MCP concepts introduced in that week's video, as participants receive access to each video \~3 days prior to the group meeting. The 7th virtual meeting will be used as a booster in week 9, and will focus on sharing how participants are using the MCP concepts in their daily lives. All meetings will be facilitated by our social worker, Katherine Henthorne, LCSW."
62603768|NCT02340611|EXPERIMENTAL|Cediranib and Olaparib|Cediranib, 20 mg , orally, once a day, every day. Olaparib, 150 mg or 200 mg (depending on previous treatment dose), orally, once a day, every day.
62603769|NCT01454843|ACTIVE_COMPARATOR|Wavefront-guided LASIK - Allegretto|Wavefront-guided LASIK using the Allegretto excimer laser.
62603770|NCT01454843|ACTIVE_COMPARATOR|Wavefront-guided LASIK - AMO|Wavefront-guided LASIK using AMO CustomVue excimer laser.
62603771|NCT03161249|EXPERIMENTAL|Experimental group|Mobile psychotherapy (5 modules) plus treatment as usual
62826254|NCT06586554|EXPERIMENTAL|SS Group|SS group received a static stretching on the hamstring muscle
62826255|NCT06586554|ACTIVE_COMPARATOR|MFR Group|The MFR group received a myofascial release on the hamstring muscle
62826256|NCT03206814|ACTIVE_COMPARATOR|Group 1 - Usual care|Standard strategy for management of hypertension, based on three-monthly visits at the referral centre.
62826257|NCT03206814|EXPERIMENTAL|Group 2 - POST-strategy|Patient Optimal Strategy for Treatment (POST) for management of hypertension, based on on three-monthly visits at the referral centre + providing the patients with the ESH-CARE APP system to communicate home blood pressure measurements to the referral centre, and the referral centre with an online platform to monitor the patients' status.
62826258|NCT04574271|EXPERIMENTAL|Intensive dietary advice and exercise prescription|Personalized dietary advice and exercise prescription according to nutritional status.
62826259|NCT04574271|ACTIVE_COMPARATOR|Usual dietary advice and exercise prescription|Generalized dietary advice and exercise prescription in elder subjects.
62826260|NCT01484704||No treatment|
62826261|NCT01484704||MRI|
62826262|NCT02214797|OTHER|Presbyopic group - Low Add|"40 years and over Add of less than +1.50D~Control lens : Lotrafilcon B and Senofilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion. Each lenses will be worn for a week with a minimum 2 day washout period between the lens types. Each lens will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
62826263|NCT02214797|OTHER|Presbyopic group - Med Add|"40 years and over Add of +1.50D to +1.75D~Control lens : Lotrafilcon B and Senofilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
62826264|NCT02214797|OTHER|Presbyopic group - High Add|"40 years and over Add of +2.00D to +2.50D~Control lens : Lotrafilcon B and Senofilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
62826265|NCT02214797|OTHER|Non-presbyopic group|"18 to 39 years old No Add~Control lens : Lotrafilcon B and Etafilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
62826266|NCT00904982|OTHER|1 Usual Care Group/Control|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication. The MM can display messages to the participant and can confirm when medication is taken correctly.
62826267|NCT00904982|EXPERIMENTAL|2Med-eMonitor/Reminder|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication and will be set on active mode for this group. The MM will display messages of encouragement to participants and education on the importance of taking their warfarin medication. The Med-eMonitor also features an alarm that will sound to remind participants to take their medication as scheduled.
62826268|NCT00904982|EXPERIMENTAL|3 Incentive Group/Lottery|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication. The MM can display messages to the participant. This group will also be entered into a daily lottery in which he/she can win money. On any given study day, participants have a 1 in 10 chance of winning $10 and 1 in 100 chance of winning $100 when taking their warfarin as prescribed. Participants must take their dose correctly in order to be eligible for the daily lottery.
62826269|NCT00904982|EXPERIMENTAL|4 Combined Group/Lottery and Reminder|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication and will be set on active mode for this group. The MM will display messages of encouragement to participants and education on the importance of taking their warfarin medication. The Med-eMonitor also features an alarm that will sound to remind participants to take their medication as scheduled. Participants in this group will also be entered into a daily lottery. On any given study day, participants have a 1 in 10 chance of winning $10 and 1 in 100 chance of winning $100 when taking their warfarin medication as prescribed. Participants must take their dose correctly in order to be eligible for the daily lottery.
62826270|NCT00665652|EXPERIMENTAL|Lenalidomide|
62826271|NCT06273800|OTHER|Blood sample|Collection of serum blood sample at day of start neo adjuvant treatment
62826272|NCT04340752|EXPERIMENTAL|Group 1:ICG 7.5 mg|Subjects in this group are randomized to receive 7.5 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
62437174|NCT01336010|EXPERIMENTAL|Group E - 48 weeks (gt 1) or 24 weeks (gt 2/3)|48 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 12 weeks of therapy (genotype 1) or 24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 12 weeks of therapy (genotype 2/3).
62826273|NCT04340752|EXPERIMENTAL|Group 2:ICG 12.5 mg|Subjects in this group are randomized to receive 12.5 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
62826274|NCT04340752|EXPERIMENTAL|Group 3: ICG 25 mg|Subjects in this group are randomized to receive 25 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
62246964|NCT02316184|PLACEBO_COMPARATOR|Brief Advice|Participants in this arm will receive brief advice about alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
62246965|NCT02316184|ACTIVE_COMPARATOR|MI|Participants in this arm will receive a talking intervention designed to explore their interest in reducing/eliminating alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
62246966|NCT05440396||Patient|"Patients will be recruited independently in each of the centers participating in the study, according to the specific organization of each service (hospital and home). Patients will be selected based on the study inclusion/non-inclusion criteria. The included patients will receive oral information about the study. The informed consent will be obtained before any investigation.~Each photograph will focus on the intravascular catheter. The investigators will respect the main non-inclusion criterion: not to show any peripheral identification sign close to the insertion point of the catheter that cannot be masked when the photograph is taken. In this context, jewellery, clothing, tattoos, scars, and birthmarks represent identifying features. Individual access accounts with secure, randomly generated passwords will be provided to investigators.~The photographs will be anonymous, and any identification of the person concerned will be impossible."
62246967|NCT06087887||tumor size 0-1cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 0-1 cm.
62246968|NCT06087887||tumor size 1-2 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 1-2 cm.
62246969|NCT06087887||tumor size 2-3 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 2-3 cm.
62246970|NCT06087887||tumor size 3-4 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 3-4 cm.
62826275|NCT04311099|EXPERIMENTAL|Ultrasound-guided TAP|Ultrasound-guided TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and laparoscopic assisted injection of 20 ml saline (placebo) bilaterally at the beginning of surgery
62246971|NCT06087887||tumor size 4-5 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 4-5 cm.
62826276|NCT04311099|EXPERIMENTAL|Laparoscopic assisted TAP|Laparoscopic assisted TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery
62826277|NCT04311099|PLACEBO_COMPARATOR|Placebo|Laparoscopic assisted injection of 20 ml saline (placebo) bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery
62246972|NCT06087887||tumor size 5-6 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 5-6 cm.
62246973|NCT06087887||tumor size 6-7 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 6-7 cm.
62437175|NCT01336010|NO_INTERVENTION|Untreated Group|Observation only. No treatment for hepatitis C administered. Subjects who have undetectable HCV RNA at baseline, do not wish to commence treatment or are ineligible for treatment.
62826278|NCT04445285|EXPERIMENTAL|Treatment Arm|Patient will receive 2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.
62826279|NCT04445285|PLACEBO_COMPARATOR|Placebo Arm 0.9% sodium chloride|Patient will receive 2.5ml of Sodium Chloride 0.9% aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.
62826280|NCT05179928|ACTIVE_COMPARATOR|Group E (n=30)|Erector Spinae Plane Block
62826281|NCT05179928|ACTIVE_COMPARATOR|Group R (n=30)|Rectus Sheath Block
62826282|NCT04543708|ACTIVE_COMPARATOR|Incision drainage|"Adult with clinical suspicion of tonsillar abscess who underwent a CT-scan confirming the abscess will be randomly assigned to one arm or the other. Incision drainage arm will benefit from drainage of the tonsillar abscess under local anesthesia and then be hospitalized for intravenous antibiotics. If the incision drainage fails, they will get a tonsillectomy under general anesthesia."
62246974|NCT06087887||tumor size 7-8 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 7-8 cm.
62246975|NCT06087887||tumor size 8-9 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 8-9 cm.
62246976|NCT06087887||tumor size 9-10 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 9-10 cm.
62246977|NCT06087887||tumor size >10 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of \>10 cm.
62437176|NCT05954078|EXPERIMENTAL|mFOLFIRINOX adjuvant chemotherapy|Patients will receive mFOLFIRINOX once every two weeks for 6 cycles as adjuvant chemotherapy, after which a blood test is conducted to check the status of ctDNA. If the ctDNA remains positive, the treatment continues for another 6 cycles. If the ctDNA becomes negative, then maintenance chemotherapy with single-agent capecitabine is given once every 21 days for 4 cycles.
62437177|NCT05954078|ACTIVE_COMPARATOR|mFOLFOX6/XELOX adjuvant chemotherapy|Patients will receive mFOLFOX6 once every two weeks for 6 cycles or XELOX once every three weeks for 4 cycles as adjuvant chemotherapy. After the treatment, a blood test is conducted to check the status of ctDNA. If the ctDNA remains positive, the treatment continues with another 6 cycles of mFOLFOX 6 or 4 cycles of XELOX given once every 21 days. If the ctDNA becomes negative, then maintenance chemotherapy with single-agent capecitabine is given once every 21 days for 4 cycles.
62437178|NCT05300932|EXPERIMENTAL|Baricitinib 4mg|4mg of oral Baricitinib everyday for 48 weeks.
62437179|NCT05300932|ACTIVE_COMPARATOR|Cyclophosphamide|Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period. Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
62437180|NCT00581594|OTHER|1|Posterior repair with graft augmentation.
62603772|NCT03161249|OTHER|Control group|"Control group: Treatment as usual~The description of this group, the control group, corresponds to the treatment to receive the usual treatment that is received on a regular basis, we will not perform any additional intervention"
62603773|NCT01192113|EXPERIMENTAL|Group A: Diabetic Peripheral Neuropathy (IV)|
62603774|NCT01192113|EXPERIMENTAL|Group B: Diabetic Peripheral Neuropathy (IM)|
62603775|NCT01192113|EXPERIMENTAL|Group C: Idiopathic Peripheral Neuropathy|
62603776|NCT01192113|EXPERIMENTAL|Group D: Nutritional & Metabolic Peripheral Neuropathy|
62826283|NCT04543708|ACTIVE_COMPARATOR|Tonsillectomy|"Adult with clinical suspicion of tonsillar abscess who underwent a CT-scan confirming the abscess will be randomly assigned to one arm or the other. Tonsillectomy arm will benefit from tonsillectomy under general anesthesia and then be hospitalized for intravenous antibiotics."
62826284|NCT06586723|ACTIVE_COMPARATOR|PBIS|Positive Behavioral Interventions and Supports (PBIS) is an evidence-based, multi-tiered, problem-solving, and team-based framework designed to build a continuum of supports to promote all students' social emotional behavioral health.
62826285|NCT06586723|EXPERIMENTAL|HELM|Helping Educational Leaders Mobilize Evidence (HELM) is an implementation strategy for promoting building-level implementation leadership, implementation climate, and high-fidelity delivery of evidence-based practices
62826286|NCT05208060|EXPERIMENTAL|MV130|Suspension of 6 inactivated whole bacteria concentrates, that contains 90% of Gram positive bacteria (V104 S. pneumoniae 60%, V102 S. aureus 15%, V101 S. epidermidis 15%) and 10% of Gram negative bacteria (V113 K. pneumoniae 4%, V105 M. catarrhalis 3%, V103 H. influenzae 3%), at a concentration of 300 FTU/mL, equivalent to \~ 10\^9 bacteria/mL.
62826287|NCT05208060|PLACEBO_COMPARATOR|Placebo|Sodium chloride 9 mg/mL and water for injection s.q. f 1 mL.
62044375|NCT06305949|EXPERIMENTAL|Optimized transcranial Direct Current Stimulation|Patients receive optimized stimulation obtained from an individualized T1 MRI-based simulation of transcranial direct current stimulation for 30 minutes, once a day for 4 weeks, for a total of 20 sessions.
62044376|NCT06305949|SHAM_COMPARATOR|Sham transcranial Direct Current Stimulation|Patients receive sham stimulation for 30 minutes, once a day for 4 weeks, for a total of 20 sessions.
62044377|NCT03406728|ACTIVE_COMPARATOR|PDSAFEX GROUP|Parkinson's Disease Sensory Attention Focused Exercise (PDSAFEX) is an exercise intervention developed in light of research which focuses on utilizing sensory integration and proprioception to improve balance. This intervention will be administered to one group of my participants. The protocol will be followed and led by trained volunteers.
62044378|NCT03406728|ACTIVE_COMPARATOR|CONTROL GROUP|The control group in this study will be asked to maintain their daily lifestyle as closely as possible for the 12-week duration of the study.
62044379|NCT03406728|EXPERIMENTAL|VIRTUAL REALITY GROUP|Virtual reality intervention will be assigned to this group. They will complete activities aimed at improving their dynamic balance. These activities are specifically developed based on previous literature and geared towards mirroring day to day activities/scenarios that individuals with PD may come into contact with.
62044380|NCT04419948|EXPERIMENTAL|Control|100g white bread plus 40ml butter
62044381|NCT04419948|EXPERIMENTAL|Positive control|100g white bread plus 40ml butter and 400mg ibuprofen
62044382|NCT04419948|EXPERIMENTAL|Refined olive oil|100g white bread plus 40ml refined olive oil
62044383|NCT04419948|EXPERIMENTAL|EVOO with moderate concentration of oleocanthal|100g white bread plus 40ml EVOO containing 250 mg/kg oleocanthal
62044384|NCT04419948|EXPERIMENTAL|EVOO with high concentration of oleocanthal|100g white bread plus 40ml EVOO containing 500 mg/kg oleocanthal
62437181|NCT00581594|OTHER|2|Posterior repair without graft augmentation.
62437182|NCT01955603|EXPERIMENTAL|Dose level 1|
62603777|NCT01192113|EXPERIMENTAL|Group E: Compression Peripheral Neuropathy|
62603778|NCT01060878|EXPERIMENTAL|Dose I|
62603779|NCT01060878|EXPERIMENTAL|Dose II|
62603780|NCT01060878|EXPERIMENTAL|Dose III|
62603781|NCT01060878|PLACEBO_COMPARATOR|Placebo|
62603782|NCT01952080|EXPERIMENTAL|teduglutide|Open label teduglutide, subcutaneously injected.
62603783|NCT01952080|NO_INTERVENTION|Standard of Care|
62603784|NCT01200459|EXPERIMENTAL|Social/Mobile Intervention|Theory-based intervention to promote weight loss utilizing web, mobile phone and social media.
62603785|NCT01200459|NO_INTERVENTION|Control|"Participants randomized to this group will have access to usual care health information via the SMART study website. This arm will be compared to our intervention group."
62603786|NCT02124759|PLACEBO_COMPARATOR|Placebo|Placebo: maltodextrin, 6 g three times a day
62603787|NCT02124759|ACTIVE_COMPARATOR|Sevelamer|Sevelamer: (1.6 g sevelamer + 4.4 g maltodextrin three times a day)
62603788|NCT02124759|ACTIVE_COMPARATOR|Synbiotic|Synbiotic: 5g Oligofructose + 4x1010 Bifidobacterium longum CFU 3x daily during diet
62826288|NCT03651310|NO_INTERVENTION|Control Group|waiting in preoperative area without music listening.
62044385|NCT02002403|PLACEBO_COMPARATOR|Placebo|
62044386|NCT02002403|EXPERIMENTAL|Optina Low Dose|Optina, 15 mg orally, twice daily
62603789|NCT01018381|ACTIVE_COMPARATOR|Conventional Therapy|Conventional therapy is given, including PEIT, TOCE, PEIT + TOCE, TOCE + RFA for hepatocellular carcinoma or Entecavir for hepatitis B virus.
62603790|NCT01018381|EXPERIMENTAL|Conventional Therapy plus MGN-3|
62603791|NCT02278367|EXPERIMENTAL|Flortaucipir PET Scans|
62603792|NCT04875026|EXPERIMENTAL|5-fluorouracil 4% (Tolak) + Dexeryl|This group will apply 5-FU once daily for 4 weeks, and Dexeryl once daily for 8 weeks.
62603793|NCT04875026|OTHER|5-fluorouracil 4% (Tolak)|This group will only apply 5-FU once daily for 4 weeks.
62603794|NCT01135069|ACTIVE_COMPARATOR|Generic|treatment of acne for 12 weeks
62603795|NCT01135069|ACTIVE_COMPARATOR|Brand|Treatment of acne for 12 weeks
62603796|NCT01135069|PLACEBO_COMPARATOR|Placebo|Treatment if acne for 12 weeks as placebo
62826289|NCT03651310|ACTIVE_COMPARATOR|Music Listening Group|The music listening group will be given a set of noise canceling headphones and an MP3 player with multiple tracks representing different music genres to use while in preoperative area.
62826290|NCT06596161|EXPERIMENTAL|Study Group|Receiving Iron
62044387|NCT02002403|EXPERIMENTAL|Optina - High Dose|Optina, 45 mg orally, twice daily
62246978|NCT05259579|EXPERIMENTAL|Anti-reflux mucosal ablation|This technique creates an anti-reflux mechanism by performing mucosal ablation at the gastric cardia and inducing cicatrisation, and thereby rebuilds the flap valve at the gastric cardia
62826291|NCT06596161|PLACEBO_COMPARATOR|Control Group|Receiving Placebo
62826292|NCT05703607|EXPERIMENTAL|SubStudy A (SSA): Group 1|Candidate 1, Dose Level 1, lyophilized, 0, 2 months schedule
62826293|NCT05703607|EXPERIMENTAL|SSA: Group 2|Candidate 1, Dose Level 2, lyophilized, 0, 2 months schedule
62826294|NCT05703607|EXPERIMENTAL|SSA: Group 3|Candidate 1, Dose Level 3, lyophilized, 0, 2 months schedule
62826295|NCT05703607|EXPERIMENTAL|SSA: Group 4|Candidate 1, Dose Level 2, frozen, 0, 2 months schedule
62826296|NCT05703607|EXPERIMENTAL|SSA: Group 5|Candidate 1, Dose Level 2, Frozen, 0, 6 months schedule
62826297|NCT05703607|EXPERIMENTAL|SSA- Group 6|Candidate 2, frozen, 0, 2 months schedule
62826298|NCT05703607|EXPERIMENTAL|SSA: Group 7|Candidate 3, Frozen, 0, 2 months schedule
62826299|NCT05703607|ACTIVE_COMPARATOR|SSA: Group 8|Shingrix, 0, 2 months schedule
62246979|NCT04549727||infants with surgical NEC|Infants who undergo surgery for NEC disease
62246980|NCT04549727||Infants with GI surgical diseases other than NEC|Infants who undergo surgery for other GI diseases than NEC
62826300|NCT05703607|ACTIVE_COMPARATOR|SSA: Group 9|Shingrix, 0, 6 months schedule
62826301|NCT05703607|EXPERIMENTAL|SSA: Group 10|Candidate 1, Dose level 4, lyophilized, 0, 6 months schedule
62826302|NCT05703607|EXPERIMENTAL|SSA: Group 11|Candidate 2, Dose level 2, lyophilized, 0, 2 months schedule
62826303|NCT05703607|EXPERIMENTAL|Substudy B (SSB): Group 1|Selected Vaccine candidate/dose-level/dosing schedule
62044388|NCT03104764|ACTIVE_COMPARATOR|Scalpel|Frenotomy performed with conventional scalpel
62044389|NCT03104764|EXPERIMENTAL|Er:YAG laser|Frenotomy performed with Er:YAG laser
62044390|NCT04405518|ACTIVE_COMPARATOR|Control group|"The doses of fibrinogen will be calculated acording to the formula based on previous study (AJT2017), rounded to the higher value according to the presentation format of the drug. Study medication will be stored at the hospital pharmacy.~Formula: 8mm - A10FIBTEM registered in mm) x 1.1 = fibrinogen dose required"
62437183|NCT01955603|EXPERIMENTAL|Dose level 2|
62437184|NCT01955603|EXPERIMENTAL|Dose level 3|
62437185|NCT06547905|EXPERIMENTAL|Leakage Detection System arm|Participants will utilize the leakage detection system
62603797|NCT00756600|ACTIVE_COMPARATOR|1|Regional Anesthesia
62603798|NCT00756600|ACTIVE_COMPARATOR|2|General Anesthesia
62603799|NCT05882695|EXPERIMENTAL|Experimental Part 1: Active SPG302 to be administered to healthy volunteers (SAD)|8 participants will be randomized in a 3:1 ratio to active or placebo. Study intervention will be administered orally once. Randomization to each SAD cohort will be done in a staggered manner; initially 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed and after a safety evaluation period after the dose without clinically significant adverse events (AEs) and investigator approval, then, 6 additional participants will be randomized and dosed (5 active and 1 placebo) at the discretion of the Investigator according to the randomization schedule
62603800|NCT05882695|PLACEBO_COMPARATOR|Placebo Comparator Part 1: Placebo comparator to be administered to healthy volunteers (SAD)|8 participants will be randomized in a 3:1 ratio to active or placebo. Study intervention will be administered orally once. Randomization to each SAD cohort will be done in a staggered manner; initially 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed and after a safety evaluation period after the dose without clinically significant adverse events (AEs) and investigator approval, then, 6 additional participants will be randomized and dosed (5 active and 1 placebo) at the discretion of the Investigator according to the randomization schedule
62603801|NCT05882695|EXPERIMENTAL|Experimental Part 2: Active SPG302 to be administered to healthy volunteers (MAD)|8 participants will be randomized in a 3:1 ratio to active or placebo. Participants will receive study intervention QD over 5 days and will be discharged on Day 6. A follow-up safety visit will be conducted on Day 12 (±3 days).
62603802|NCT05882695|PLACEBO_COMPARATOR|Placebo Comparator Part 2: Placebo comparator to be administered to healthy volunteers (MAD)|8 participants will be randomized in a 3:1 ratio to active or placebo. Participants will receive study intervention QD over 5 days and will be discharged on Day 6. A follow-up safety visit will be conducted on Day 12 (±3 days).
62826304|NCT05703607|ACTIVE_COMPARATOR|SSB: Group 2|Shingrix
62826305|NCT05703607|EXPERIMENTAL|SSA: Group 12|Candidate 2, Dose level 3, lyophilized, 0, 2 months schedule
62826306|NCT05703607|EXPERIMENTAL|SSA: Group 13|Candidate 2, Dose level 4, lyophilized, 0, 2 months schedule
62826307|NCT05703607|ACTIVE_COMPARATOR|SSA: Group 14|Shingrix, 0, 2 months schedule
62826308|NCT01744262|ACTIVE_COMPARATOR|Inhalational anesthesia group|
62826309|NCT01744262|EXPERIMENTAL|Total intravenous anesthesia group|
62826310|NCT04422184|EXPERIMENTAL|SEN GROUP|Sensodyne Repair and Protect - NOVAMIN technology
62826311|NCT04422184|EXPERIMENTAL|REG GROUP|Dentalclean Daily Regenerator - REFIX technology
62603803|NCT05882695|EXPERIMENTAL|Experimental Part 3: Active SPG302 to be administered to participants with ALS|Participants with ALS will be randomized to receive SPG302 or placebo at a 3:1 ratio. Study intervention will be administered QD over 28 days. A follow-up safety visit will be conducted 30 days after last dose (±7 days). Participants who complete Part 3 may be offered to participate in an open-label extension.
62044391|NCT04405518|EXPERIMENTAL|intervention group|"The doses of fibrinogen will be calculated acording to the formula based on previous study (AJT2017), rounded to the higher value according to the presentation format of the drug. Study medication will be stored at the hospital pharmacy.~Formula: 11mm - A10FIBTEM registered in mm) x 1.1 = fibrinogen dose required"
62246981|NCT05041023||Relative volunteers|For each situation of death of a patient in ICU following a decision to withdraw LST and for which OD has been discussed with the relatives, a relative can be included after information and acceptance of the study. One relative per situation can be included : the most involved personn in the relationship with the resuscitation team.
62437186|NCT02914366|EXPERIMENTAL|Ambroxol high dose (1050 mg)|Participants randomized to the 1050 mg/day group will begin with a dose of 225mg (3 mg/kg/day), increasing bi-weekly by \~3mg/kg to a dose of 1050 mg/day (\~l5 mg/kg/day).
62603804|NCT05882695|PLACEBO_COMPARATOR|Placebo Comparator Part 3: Placebo comparator to be administered to participants with ALS|Participants with ALS will be randomized to receive SPG302 or placebo at a 3:1 ratio. Study intervention will be administered QD over 28 days. A follow-up safety visit will be conducted 30 days after last dose (±7 days). Participants who complete Part 3 may be offered to participate in an open-label extension.
62603805|NCT05882695|EXPERIMENTAL|Experimental Part 3: Open Label Extension - Active SPG302 administered to participants with ALS|Participants with ALS will be randomized to receive SPG302 or placebo at a 3:1 ratio. Study intervention will be administered QD over 28 days for up to 3 cycles in the USA and up to 12 cycles in Australia. A follow-up safety visit will be conducted 30 days after last dose (±7 days).
62603806|NCT01472757|PLACEBO_COMPARATOR|Placebo|
62603807|NCT01472757|ACTIVE_COMPARATOR|Dose 1|
62603808|NCT01472757|ACTIVE_COMPARATOR|Dose 2|
62603809|NCT01472757|ACTIVE_COMPARATOR|Dose 3|
62603810|NCT02934087|ACTIVE_COMPARATOR|Retrograde Gate Cannulation|All patients undergoing elective EVAR with a standard commercially available stent graft will be randomized after informed consent obtained; gate cannulation method will be attempted for a period of 15 minutes. If unsuccessful during this time a crossover to the alternative method (snare) will be attempted. The study will be terminated at 15 minutes in the crossover arm if still unsuccessful.
62739067|NCT05351177|EXPERIMENTAL|High-Intensity Interval Training Group|Participants in the High-Intensity Interval Training (HIIT) group will complete 8 weeks of twice-weekly HIIT of 30 minutes in duration. Heart rate, ratings of perceived exertion, affect and enjoyment will be assessed. This will include a five minute warm-up on a cycle ergometer, followed by 10 x 60 second repetitions on the cycle ergometer interspersed with 60 seconds rest. A five minute cooldown will follow on the cycle ergometer.
62826312|NCT04422184|EXPERIMENTAL|REGK GROUP|Dentalclean Daily Regenerator - REFIX technology + potassium citrate
62826313|NCT00796939|ACTIVE_COMPARATOR|Green Light Mask|
62826314|NCT00796939|PLACEBO_COMPARATOR|Red light mask|
62044392|NCT04373538|EXPERIMENTAL|Memory Support Intervention|
62044393|NCT06367205|EXPERIMENTAL|Goal-Directed Fluid Therapy (GDFT) group|Following anesthesia induction, patients will be connected to the FlowTrac/Vigileo monitoring system to facilitate the recording of pertinent hemodynamic parameters, including stroke volume variation (SVV), stroke volume, and cardiac output. Then, Norepinephrine Infusion Combined with Goal-directed Fluid Therapy will be administered. Efforts are made to sustain a mean arterial pressure (MAP) of ≥ 80 mmHg.
62044394|NCT06367205|ACTIVE_COMPARATOR|Regular Fluid Therapy group|Patients will not undergo monitoring with the FlowTrac/Vigileo system throughout the whole procedure. Anesthesiologists will rely on their clinical expertise and intraoperative circulatory hemodynamic assessment to regulate fluid infusion rates and administer medications as necessary to sustain a mean arterial pressure (MAP) of ≥ 80 mmHg until the conclusion of the surgical procedure.
62246982|NCT05041023||Caregivers|For each situation of death of a patient in ICU following a decision to withdraw LST and for which OD has been considered, 2 to 3 caregivers who are present at the time the WLST is initiated can be included (1 physician and 1 or 2 paramedics).
62437187|NCT02914366|PLACEBO_COMPARATOR|Placebo|Participants receive capsules visually identical to the experimental groups but without active ingredients.
62437188|NCT01402583||PEG IFN/Ribavirin|Subjects with Hepatitis C undergoing PEG IFN/Ribavirin treatment
62437189|NCT04070456|EXPERIMENTAL|Intervention sites-Tablet-based SDH tool|All clinicians and primary care teams at a practice that are randomized to the intervention will receive the tablet-based SDH tool.
62826315|NCT05500794|EXPERIMENTAL|MBSR (Mindfulness-Based Stress Reduction) group|MBSR (Mindfulness-Based Stress reduction) program : 1 weekly session of 2 hours and a half for 8 weeks, (first and last session: 3 hours) and an optional day of intensive practice of 6 hours, supervised by an MBSR instructor.
62437190|NCT04070456|NO_INTERVENTION|Control sites|Care as usual, no tablet-based SDH tool.
62437191|NCT00216944|ACTIVE_COMPARATOR|1|Premedication with atropine and morphine
62437192|NCT00216944|ACTIVE_COMPARATOR|2|Premedication with glycopyrronium, thiopental, suxamethonium and remifentanil
62437193|NCT04372433|EXPERIMENTAL|Dose Escalation of IO-202|Dose cohorts treated with intravenous (IV) IO-202 monotherapy in ascending doses.
62437194|NCT04372433|EXPERIMENTAL|Dose Escalation of IO-202 Plus Azacitidine|AZA Dose cohorts treated with intravenous (IV) IO-202 in ascending doses plus Azacitidine (IV or SC) on days 1-7 of each 28-day cycle.
62826316|NCT05500794|NO_INTERVENTION|Standard group|No intervention in this group which will be followed according to the standard care
62826317|NCT04800276|EXPERIMENTAL|APA with consideration of ischemia localization|
62437195|NCT04372433|EXPERIMENTAL|Dose Expansion of IO-202 plus Azacitidine AML|To enroll high LILRB4 expression monocytic AML patients refractory to or relapsed after available therapies known to be active in AML.
62437196|NCT04372433|EXPERIMENTAL|Dose Expansion of IO-202 plus Azacitidine CMML|To enroll hypomethylating-agent naive CMML patients.
62826318|NCT04800276|EXPERIMENTAL|APA without consideration of ischemia localization|
62826319|NCT02993107|OTHER|Group 1 (Placebo Crossovers)|Subjects who complete the placebo arm of ARC003 and consent to enroll in ARC004 (Group-1) will cross over to active treatment with AR101 using the same dosing regimen used in ARC003 in open-label fashion. Group 1 subjects may also be assigned to cohorts which test the gradual lengthening of dosing intervals. Following the completion of their longest tested dosing interval, Group 1 subjects will undergo an exit double-blinded placebo-controlled food challenge (DBPCFC).
62826320|NCT02993107|OTHER|Group 2 (Active Rollovers)|Subjects who successfully complete the active arm of ARC003 and consent to enroll in ARC004 (Group-2) will consecutively enter treatment with AR101 in one of three cohorts which will test alternate dosing intervals. There will be a DBPCFC at the completion of the subject's longest tested dosing interval.
62826321|NCT05835284||Single Arm|Enrolled subjects will receive a non-diagnostic CT scan on the pre-market, investigational Edge-on Silicon Photon Counting CT device.
62826322|NCT03564808|EXPERIMENTAL|Fat graft enriched with MSCs|Adipose tisse derrived MSCs
62826323|NCT03564808|EXPERIMENTAL|Fat graft only|Fat graft withiut enrichment with MSCs
62826324|NCT02372604|ACTIVE_COMPARATOR|Group1 : Regulatory dosage|"In a first time, every day, one tablet of 5 mg of levocetirizine is taken the morning and a second tablet of placebo is taken the evening, during 5 weeks (between visit 2 and 3).~In a second time,and after primary endpoint assessment, every day, one tablet of 10 mg of levocetirizine is taken the morning and a second tablet of 10 mg of levocetirizine is taken the evening, during 5 weeks (between visit 3 and 4)."
62826325|NCT02372604|EXPERIMENTAL|Group 2 : fourfold dosage|"In a first time, every day, one tablet of 10 mg of levocetirizine is taken the morning and a second tablet of 10 mg of levocetirizine is taken the evening, during 5 weeks (between visit 2 and 3).~In a second time, every day, one tablet of 5 mg of levocetirizine is taken the morning and a second tablet of placebo is taken the evening, during 5 weeks (between visit 3 and 4)."
62826326|NCT05383937|EXPERIMENTAL|intensive arm|The children included in this arm will receive two weeks of daily care during which two daily speech therapy sessions of one hour each will be performed. This will be done between M2 and M4 of inclusion in order to avoid potential measurement bias. These sessions will be carried out by a state-qualified speech therapist employed at the CRRF of Bregille. They will guide the intensive rehabilitation of dyslexic children by focusing the exercises on their main difficulties.
62826327|NCT05383937|ACTIVE_COMPARATOR|classic arm or gold standard|"The speech therapy session will be provided only by private practitioners, with a weekly consultation of 30 minutes. The private speech therapist who initially referred the patient for inclusion in the research protocol will be responsible for his or her classic rehabilitation. The therapy will continue during the 6 months of research."
62826328|NCT01586546|EXPERIMENTAL|Face-to-Face MBM Skills Group|
62826329|NCT01586546|EXPERIMENTAL|Online MBM Skills Group|
62826330|NCT01586546|OTHER|Waitlist Control I|This group will be given the option to participate in a face-to-face MBM skills group intervention after conclusion of study.
62826331|NCT01586546|OTHER|Waitlisted Control II|This group will be given the option to participate in an Online MBM skills group intervention after conclusion of study.
62246983|NCT04546568|EXPERIMENTAL|Servo control - Leoni plus CLAC|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% as per standard practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
62437197|NCT04372433|EXPERIMENTAL|Dose Expansion of IO-202 plus Azacitidine + Venetoclax (Ven)|To enroll newly diagnosed high LILRB4 expression AML patients who are unfit for intensive induction chemotherapy.
62826332|NCT06253442|ACTIVE_COMPARATOR|Patients will receive Supra scapular nerve block and Axillary nerve block.|ultrasound guided suprascapular nerve block combined with ultrasound guided axillary nerve block will be provided to the patient
62826333|NCT06253442|ACTIVE_COMPARATOR|Patients will receive Interscalene block.|ultrasound guided interscalene brachial plexus block will be provided to the patient
62826334|NCT04377126|ACTIVE_COMPARATOR|Unacylated ghrelin|Participants randomized to unacylated ghrelin will self-administer 20 ug/kg unacylated ghrelin daily. Study drug is dispensed in syringes labeled with the participant's name, date of birth, expiration date, and instructions for administration. Syringes will NOT be labeled with the group assignment, ensuring that both the research team collecting data and study participants are blinded to group assignment (i.e. double blinded status). Study drug is stored and handled according to the University of Chicago Research Pharmacy Standard Operating Procedure (SOP).
62437198|NCT03826381||Study 1: DM2 + normal kidney function|"Number of patients: 54~Patients in this group are diagnosed with Diabetes type 2. Kidney function: eGFR is \> 60, absence of clinical proteinuria.~Inclusion- and exclusion criteria are listed under section Eligibility. Examinations performed in this group are listed under the section Groups and Interventions and the same as in the other group.~The patients are examined once."
62826335|NCT04377126|PLACEBO_COMPARATOR|Placebo|Participants randomized to placebo will self-administer an identical-appearing solution of bacteriostatic saline daily.
62826336|NCT03459755|EXPERIMENTAL|Lifestyle Intervention|Patients assigned to the Physical Activity arm will undergo exercise testing protocol and have supervised physical activity interventions while on study. Patients will also complete questionnaires and have research blood drawn.
62826337|NCT03459755|NO_INTERVENTION|Usual care|Patients will complete questionnaires and have research blood drawn.
62044395|NCT02495025|EXPERIMENTAL|Telephone-based screening|Families randomized to the intervention arm will be connected with 211 Los Angeles for completion of developmental screening over the phone. Screening will consist of three structured, validated, parent-report tools: the Parental Evaluation of Developmental Status (PEDS), the PEDS Developmental Milestones (PEDS:DM), and the Modified Checklist for Autism in Toddlers (M-CHAT). If any developmental or behavioral concerns are present, the care coordinator at 211 Los Angeles will make appropriate referrals for developmental evaluation and intervention services. A copy of the care plan generated from 211 will be sent to the child's primary care provider and included in the medical record.
62437199|NCT03826381||Study 1: DM2 + CKD stage 3-5|"Number of patients: 54~Patients in this group are all diagnosed with diabetes type 2. Furthermore, the patients have chronic kidney disease stage 3-5 (eGFR \<60).~Inclusion- and exclusion criteria are listed under section Eligibility. Examinations performed in this group are listed under the section Groups and Interventions are the same as in the other group.~The patients are examined once."
62437200|NCT04823000|EXPERIMENTAL|Repeated MSCs treatment in MS patients|Treatment with intrathecal and intravenous injection of autologous MSC (1 million cells per Kg of body weight)
62044396|NCT02495025|NO_INTERVENTION|Usual care|Children randomized to the control group will report for their well-child care visits as scheduled, and will receive clinic-based developmental screening and care coordination. Any developmental or behavioral concerns will be directed to the child's pediatrician, as is the current clinical recommendation.
62044397|NCT05806229|ACTIVE_COMPARATOR|Group I|(Mid transverse process to pleura block ) : Patients will receive midpoint transverse process to pleura block with bupivacaine 0.5% (DBK Pharmceutical) (20ml) and dexamethazone 4 mg (SIGMATEC) (1ml) total volume 21 ml
62044398|NCT05806229|SHAM_COMPARATOR|Group II|Patients will receive midpoint transverse process to pleura block with 2ml normal saline subcutaneously (shamblock)
62044399|NCT03148470|EXPERIMENTAL|intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) + Sham iTBS
62044400|NCT03148470|EXPERIMENTAL|continuous theta burst stimulation|continuous theta burst stimulation (cTBS) + Sham cTBS
62044401|NCT01172002|EXPERIMENTAL|leflunomide group|
62044402|NCT01172002|ACTIVE_COMPARATOR|Azathioprine group|
62437201|NCT05737329|OTHER|Transdermal estradiol gel 0.1% 1.5mg/ day|Patient will be given Hormone Replacement Therapy (HRT) in the form of: Transdermal estradiol gel 0.1% 1.5mg (Gel sachet) in continuous daily regimen. The progesterone component of HRT (200mg micronized progesterone administered vaginally) will be given for 14 days, starting from day 14 through day 28 of each cycle.
62437202|NCT05737329|OTHER|Transdermal estradiol gel 0.1% 2.0mg/ day|Patient with insufficient effect from previous treatment estradiol gel 0.1% 1.5mg will be given HRT in the form of: Transdermal estradiol gel 0.1% 2.0mg (Gel sachet) in continuous daily regimen. The progesterone component of HRT (200mg micronized progesterone administered vaginally) will be given for 14 days, starting from day 14 through day 28 of each cycle.
62437203|NCT05583175|EXPERIMENTAL|Venetoclax plus RIC|Administration with oral Venetoclax plus RIC regimen for allo-HSCT in the elderly patients with myeloid malignancies.
62437204|NCT05678985|EXPERIMENTAL|Choose to Move|"CTM (Phase 4) is a 3-month, flexible, choice-based program for low active older adults that can be delivered in-person or online.~CTM includes~* One-on-One Consultation: Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop an action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~* Group Meetings: Over the 3-months, participants will attend eight, 1-hour group-based meetings (up to 12 participants total) led by their activity coach. Meetings cover a discussion topic (health-related) and provide time and space for social connection between participants. Group meetings are held in person or online as public health restrictions and community preference dictate."
62437205|NCT02854683|EXPERIMENTAL|Normal Saline|Subjects will receive 1 liter of intravenous normal saline over 1 hour and on an alternate day Subjects will drink ORS solution 1 liter total by mouth over 20 minutes.
62437206|NCT02854683|EXPERIMENTAL|Oral rehydration solution|Subjects will receive 1 liter of intravenous normal saline over 1 hour and on an alternate day Subjects will drink ORS solution 1 liter total by mouth over 20 minutes.
62826338|NCT02603887|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62826339|NCT05625126|EXPERIMENTAL|Rumination Invervention - 3 week baseline|"Baseline measures will be collected weekly for 3 weeks.~All participants will then receive a one-session online Rumination Intervention for PTSD with a follow-up call to clarify/solidify learning."
62044403|NCT04239040|EXPERIMENTAL|Relapsed or Refractory High Risk Neuroblastoma|"Tissue Collection of Cancerous cells during primary or clinically indicated surgical resection.~Manufacture and cryopreservation of vaccine. Treatment with vaccine, nivolumab and ipilimumab.~* Vaccine injected weekly over initial 21 day cycle, biweekly for cycles 2-4 of 21 day cycle duration and cycles 5 and subsequent of 28 day cycle duration until vaccine supply is exhausted.~* Intravenous infusion of nivolumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days~* Intravenous infusion of ipilimumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days~* Intravenous infusion of nivolumab biweekly for cycle 5 and subsequent of 28 day cycle duration. Subsequent 28 day cycles will last up to 2 years."
62044404|NCT00575926|ACTIVE_COMPARATOR|A: Lingzhi extract|Oral 300mg capsules containing Lingzhi extract (4 to 6 capsules per day as dosed by patients' age)
62437207|NCT01545687|EXPERIMENTAL|Arm I|Patients dissolve in mouth 1 lozenge of Lactobacillus bevis CD2 every 2-3 hours (total of 6 per day) daily during CRT (comprising cisplatin and radiotherapy \[RT\]) and for 4 weeks after, including weekends.
62044405|NCT00575926|PLACEBO_COMPARATOR|B: Placebo|Starch with same appearance and taste as LingZhi
62437208|NCT01545687|PLACEBO_COMPARATOR|Arm II|Patients dissolve in mouth 1 lozenge of placebo every 2-3 hours (total of 6 per day) daily during CRT and for 4 weeks after, including weekends.
62437209|NCT00526773|OTHER|1|Telephone management plus a motivational intervention
62826340|NCT05625126|EXPERIMENTAL|Rumination Invervention - 5 week baseline|"Baseline measures will be collected weekly for 5 weeks.~All participants will then receive a one-session online Rumination Intervention for PTSD with a follow-up call to clarify/solidify learning."
62826341|NCT01488890|EXPERIMENTAL|CYD Dengue vaccine: Group 1|Participants received 3 doses of CYD dengue vaccine; one each at 0, 6 and 12 months.
62826342|NCT01488890|EXPERIMENTAL|CYD Dengue vaccine: Group 2|Participants received 3 doses of CYD dengue vaccine; one each at 0, 2 and 6 months.
62826343|NCT01488890|EXPERIMENTAL|CYD Dengue and Yellow Fever vaccine: Group 3|Participants received 3 doses of CYD dengue vaccine; one each at 0, 2 and 6 months, and single dose of YF vaccine at Day 0.
62044406|NCT03212157|EXPERIMENTAL|GT1|Optimsation of glucose infusion protocol outside the Magnetic Resonance Imaging (MRI) scanner in healthy volunteers. To establish an optimised bolus and safety of infusion protocol of intravenous glucose to maximise exchange sensitive MRI signal.
62044407|NCT03212157|EXPERIMENTAL|GT2|Optimsation of glucose infusion protocol inside the Magnetic Resonance Imaging (MRI) scanner in patient volunteers. To assess the reproducibility of these techniques and initial proof-of-concept study in cancer patients
62044408|NCT03212157|EXPERIMENTAL|GT3|Use of glucoCEST technique in staging of head and neck SCC, lymphoma and gliomas and correlating diagnostic potential with standard imaging such as FDG PET. To apply exchange-sensitive MRI in selected cancer types to assess its diagnostic potential. To study of non-glucose endogenous exchange sensitive MRI signals in (a) Prostate Cancer and (b) high grade Glioma patients.
62044409|NCT01821742||Children requiring fluid bolus on PICU|
62044410|NCT03361436|EXPERIMENTAL|Treatment (eribulin mesylate, IMRT, surgery)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8 and undergo intensity-modulated radiation therapy QD 5 days a week beginning on day 8 of cycle 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may undergo surgery within 3-10 weeks after radiation therapy.
62044411|NCT03786731|EXPERIMENTAL|TranS-C Group|Transdiagnostic Sleep and Circadian Treatment
62044412|NCT03786731|NO_INTERVENTION|CAU group|Care-As-Usual group
62044413|NCT02038530||No Ultrasound|Low Clinical Pretest Probability and D-dimer \< 1000 ug/L; Moderate Clinical Pretest Probability and D-dimer \< 500 ug/L
62044414|NCT02038530||Ultrasound Required|Low Clinical Pretest Probability and D-dimer 1000 - 3000 ug/L; Moderate Clinical Pretest Probability and D-dimer 500 - 3000 ug/L; High Clinical Pretest Probability
62044415|NCT00559650|PLACEBO_COMPARATOR|Arm 1|
62826344|NCT01488890|ACTIVE_COMPARATOR|Yellow Fever vaccine: Group 4|Participants received single dose of YF vaccine at Day 0.
62826345|NCT03880097||Research Biopsy|"The research biopsy is the same procedure as a standard of care percutaneous biopsy. A core (hollow) needle is inserted into the tumour tissue in order to collect tissue samples. The procedure is called a research biopsy as it is an additional procedure to the standard of care, used purely to collect tissue samples for research purposes."
62826346|NCT01001026|OTHER|1|Adults: One doses of H1N12009 vaccine
62044416|NCT00559650|EXPERIMENTAL|Arm 2|
62044417|NCT01298999|EXPERIMENTAL|YF476|YF476 (gastrin-receptor antagonist)
62044418|NCT01298999|PLACEBO_COMPARATOR|Placebo|Placebo pill (identical in appearance to YF476 pills)
62044419|NCT01735890|EXPERIMENTAL|CJ Amlodipine/Valsartan 10/160mg|
62044420|NCT01735890|ACTIVE_COMPARATOR|Novartis Exforge 10/160mg|
62044421|NCT01718925||Inflammatory Bowel Disease|Ulcerative Colitis and Crohns's disease patients will be recruited from sqeduled outpatient follow-up
62044422|NCT01718925||Irritable Bowel Syndrome|Irritable Bowel patients will be recruited from sqeduled outpatient follow-up
62044423|NCT01718925||Rheumatoid Arthritis|Rheumatoid Arthritis patients will be recruited from sqeduled outpatient follow-up
62437210|NCT00526773|OTHER|2|Telephone management with standard patient education
62437211|NCT04269278||0 ng/ml|Blood specimen which was added 0 ul of dexmedetomidine
62437212|NCT04269278||0.5 ng/ml|Blood specimen which was added 0.25 ul of dexmedetomidine
62437213|NCT04269278||1.0 ng/ml|Blood specimen which was added 0.5 ul of dexmedetomidine
62437214|NCT04269278||1.5 ng/ml|Blood specimen which was added 0.75 ul of dexmedetomidine
62437215|NCT03031899||Rose Bengal positive lesion and biopsy|Lesions that were stained positive with rose bengal were biopsied and assessed for dysplasia
62437216|NCT03031899||Toluidine blue positive lesion and biopsy|Lesions that were stained positive with toluidine blue were biopsied and assessed for dysplasia
62437217|NCT04546906|EXPERIMENTAL|CD22 CAR-T|Patients will be treated with CD22 CAR-T cells
62826347|NCT01001026|OTHER|2|Children: Two doses of H1N12009 vaccine given 3 weeks apart
62826348|NCT05343182|ACTIVE_COMPARATOR|Modified Vestibulectomy|
62826349|NCT05343182|ACTIVE_COMPARATOR|Traditional Vestibulectomy|
62246984|NCT04546568|ACTIVE_COMPARATOR|Servo control - IntellO2 Precision Flow, Vapotherm|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
62603811|NCT02934087|ACTIVE_COMPARATOR|Snare Technique|"All patients undergoing elective EVAR with a standard commercially available stent graft were randomized after informed consent obtained; gate cannulation method was attempted for a period of 15 minutes. If unsuccessful during this time a crossover to the alternative method (retrograde gate cannulation) was attempted. The study will be terminated at 15 minutes in the crossover arm if still unsuccessful.~Antegrade or crossover cannulation involves passing a guidewire from the ipsilateral limb to the contralateral limb gate of the endograft, which can be accomplished with a curved catheter. The wire may be retrieved on the contralateral limb using a snare device."
62246985|NCT02468596|EXPERIMENTAL|Patients|Patients suffering from anti-MAG neuropathy
62246986|NCT04450563|ACTIVE_COMPARATOR|Placebo + closed-loop insulin system|
62246987|NCT04450563|EXPERIMENTAL|Empagliflozin 2.5 mg + closed-loop insulin system|
62246988|NCT04450563|EXPERIMENTAL|Empagliflozin 5 mg + closed-loop insulin system|
62246989|NCT01776736|EXPERIMENTAL|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
62044424|NCT01718925||Diabetes Mellitus|Diabetes mellitus patients will be recruited from sqeduled outpatient follow-up
62044425|NCT06384417|EXPERIMENTAL|Hello for Cancer game|"For this arm, individuals will play the modified Hello game (Hello for Cancer). This game was modified to be better suited for individuals with cancer and their loved ones, and those modifications are now being tested. This game will include questions related to a variety of topics around an individual's cancer experience and medical decision making related to their cancer diagnosis.~After playing the game, individuals will be asked to reflect on the game questions and provide feedback to inform further modifications."
62246990|NCT03286049||Healthy children (HC)|10 healthy children
62246991|NCT03286049||Children with non allergic rhinitis (NAR)|10 children with non allergic rhinitis
62246992|NCT03286049||Rhinitis children, perennial allergy (PAR)|10 rhinitis children, sensitized to perennial allergens
62246993|NCT03286049||Rhinitis children, seasonal allergy, outside season (OSR)|10 rhinitis children sensitized to seasonal allergens, observed outside the allergen season
62044426|NCT06384417|PLACEBO_COMPARATOR|Table Topics game|For this arm, individuals will play commercially available Table Topics game during the research event. This game asks a variety of conversation starting questions, not particularly related to medical decision making.
62246994|NCT03286049||Rhinitis children, seasonal allergy, within season (WSR)|10 rhinitis children sensitized to seasonal allergens, observed during the allergen season
62246995|NCT00741325||G-CSF plus plerixafor|Participants in Study AMD3100-3101 (NCT00103610)underwent mobilization with granulocyte colony-stimulating factor (G-CSF)and received plerixafor, prior to undergoing apheresis.
62246996|NCT00741325||G-CSF plus placebo|Participants in Study AMD3100-3101 (NCT00103610)underwent mobilization with granulocyte colony-stimulating factor (G-CSF)and received placebo, prior to undergoing apheresis.
62246997|NCT02572791|EXPERIMENTAL|Periodic personal decolonization|All household participants will perform chlorhexidine body washes twice weekly for 3 months and apply mupirocin ointment to the anterior nares twice daily for five consecutive days each month for 3 months.
62246998|NCT02572791|EXPERIMENTAL|Household environmental hygiene|In addition to their usual cleaning, households will be asked to perform targeted household hygiene focusing on sources known to harbor S. aureus and serve as reservoirs for transmission.
62437218|NCT02449603|EXPERIMENTAL|Exenatide|Exenatide (Colorless transparent liquid, comes in a prefilled pen.5ug/10ug, AstraZeneca) should be initiated, 60 minutes pre-breakfast and pre-supper, at 5ug twice a day for 4 weeks and then titrated up at 10ug twice a day until the completion of the study.
62437219|NCT02449603|ACTIVE_COMPARATOR|Biphasic insulin Aspart 30|Biphasic insulin Aspart 30 (Colorless transparent liquid, 100u/mL, 3ml each, Novo Nordisk), subcutaneous injection, starting at a dose of 0.2-0.4 IU/kg, or 10～12 IU/d assigned in pre-breakfast and pre-supper in a 1:1 ratio. The adjustment of insulin dose is instructed to achieve an optimal balance between glycaemic control and risk of hypoglycaemia as dictated by best clinical practice, titrated to glucose targets of fasting plasma glucose (FPG) and pre-supper \<7 mmol/L.
62437220|NCT01835132|EXPERIMENTAL|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
62603812|NCT00703287|SHAM_COMPARATOR|A2|Generic physiotherapy
62603813|NCT00703287|EXPERIMENTAL|A1|Specialized Physiotherapy
62603814|NCT03417024||All Subjects|All subjects will undergo scanning with both Automated Breast Ultrasound and Digital Breast Tomosynthesis devices.
62246999|NCT02572791|EXPERIMENTAL|Integrated personal/household hygiene|Participants in households randomized to this arm will perform the Periodic Personal Decolonization plus the Household Environmental Hygiene, described above in arms 1 and 2.
62247000|NCT03987724|EXPERIMENTAL|Experimental group|The experiment consists of a supine bicycle exercise in a positron emission tomography (PET) scanner. Each subject will perform the experiment as well as serve as their own control (tumor blood flow at rest vs. blood flow during exercise).
62603815|NCT04747951|EXPERIMENTAL|total neoadjuvant therapy|Total neoadjuvant therapy consisted chemoradiotherapy with capecitabine and nine weeks of consolidation chemotherapy with XELOX prior to surgery and adjuvant therapy if necessary.
62826350|NCT06595914|EXPERIMENTAL|Clinicians|Clinician participants will all have access to any clinical implementation strategies that are developed and disseminated in the project.
62826351|NCT06595914|NO_INTERVENTION|Patients-Survey Cohort|Patient participants will be observationally followed via survey during the study to monitor patient-reported outcomes.
62247001|NCT00703053|EXPERIMENTAL|Group 1|25 subjects: Day 0, A/Vietnam/04 90 mcg; Day 7, A/Vietnam/04 90 mcg.
62247002|NCT00703053|EXPERIMENTAL|Group 9|100 subjects: Day 0, A/Vietnam/04 90 mcg; Day 28, A/Vietnam/04 90 mcg.
62247003|NCT00703053|EXPERIMENTAL|Group 8|100 subjects: Day 0, A/Vietnam/04 90 mcg.
62247004|NCT00703053|EXPERIMENTAL|Group 7|50 subjects: Day 0, A/Indonesia/05 90 mcg; Day 180, A/Indonesia/05 90 mcg.
62247005|NCT00703053|EXPERIMENTAL|Group 6|50 subjects: Day 0, A/Vietnam/04 90 mcg; Day 180, A/Indonesia/05 90 mcg.
62247006|NCT00703053|EXPERIMENTAL|Group 5|50 subjects: Day 0, A/Vietnam/04 45 mcg + A/Indonesia/05 45 mcg; Day 28, A/Vietnam/04 45 mcg + A/Indonesia/05 45 mcg.
62437221|NCT02730065|ACTIVE_COMPARATOR|Structured Aerobic Dance Training Group|Active intervention will last for 24 weeks and consists of 60-minute/session, which includes 10 minutes warm-up, 40 minutes of dancing and 10 minutes of cool down. In groups of 5, participants will practice the dance led by a physiotherapist once per week for the first 2 months and twice per week for 3rd to 6th month.
62437222|NCT02730065|PLACEBO_COMPARATOR|Stretching plus education|Participants in the control group will receive a weekly 3-hour group-based (group of 5 participants) programme containing stretching exercise, stress reduction and health education on dementia and stroke prevention for 6 months. The programme consists of low-intensity seated stretching, psychoeducation on stress management, various relaxation methods with practice as well as education on the causes, identification, treatment and prevention of stroke and dementia. Benefits of physical exercise will also be discussed but will its weight will be evenly balanced with other forms of evidence-based preventive strategies.
62247007|NCT00703053|EXPERIMENTAL|Group 4|50 subjects: Day 0, A/Vietnam/04 90 mcg; Day 28, A/Indonesia/05 90 mcg.
62247008|NCT00703053|EXPERIMENTAL|Group 3|50 subjects: Day 0, A/Indonesia/05 90 mcg; Day 28, A/Indonesia/05 90 mcg.
62247009|NCT00703053|EXPERIMENTAL|Group 2|25 subjects: Day 0, A/Vietnam/04 90 mcg; Day 14, A/Vietnam/04 90 mcg.
62247010|NCT03086265|EXPERIMENTAL|THRIVE|high flow nasal oxygen
62247011|NCT03086265|ACTIVE_COMPARATOR|Endotracheal tube|tracheal intubation
62247012|NCT04914325|EXPERIMENTAL|Intervention arm :copings veneered with CAD/CAM composite resin|
62247013|NCT04914325|ACTIVE_COMPARATOR|Control arm : copings veneered with manual layering|
62247014|NCT04343248|ACTIVE_COMPARATOR|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily for 6 weeks
62247015|NCT04343248|PLACEBO_COMPARATOR|Placebo|Two placebo tablets orally twice daily for 6 weeks
62437223|NCT03459326||control group|men in relation
62603816|NCT04747951|ACTIVE_COMPARATOR|standard therapy|Standard therapy (neoadjuvant chemoradiotherapy, surgery, adjuvant chemotherapy)
62603817|NCT00759889||wound biopsy|diabetic foot,venous leg ulcer, decubitus ulcer
62603818|NCT01942031|EXPERIMENTAL|structured collegial feed back|Structured feed back and information about stroke to the primary care center, to physicians and head of the center
62826352|NCT06595914|NO_INTERVENTION|Patients-Chart Review Only|Patients who are not in the survey study but who meet other eligibility criteria will undergo chart review to provide electronic health record-based outcomes.
62247016|NCT04462341|ACTIVE_COMPARATOR|Manual brushing only|Participants brushed with a manual toothbrush and fluoridated toothpaste twice a day for 6 weeks
62437224|NCT03459326||FIV group|men whose couple taken care of fecundation in vitro
62247017|NCT04462341|EXPERIMENTAL|Manual brushing + water flossing|Participants brush twice a day and water flossed once a day for 6 weeks.
62437225|NCT03459326||ICSI group|men whose couple taken care of intracytoplasmic injection
62437226|NCT03459326||IUI group|men whose couple taken care of intrauterine insemination
62603819|NCT01942031|NO_INTERVENTION|Control group|No structured feed back on stroke prevention. Ordinary educational activities only.
62603820|NCT04568525|ACTIVE_COMPARATOR|COVID - 19 patients|
62247018|NCT02882490|EXPERIMENTAL|Parent training (PT)|The PT arm receives a 10-week therapist-guided behavioral group treatment. The treatment is based on existing literature for training parents in child behavior management skills (Barkley 1999). Parents attend weekly sessions, which last 90 minutes and are held at the Hospital Clinic of Barcelona. Parents are given homework assignments to complete between sessions.
62247019|NCT02882490|EXPERIMENTAL|Supportive Therapy (ST)|The ST arm receives a 10-week supportive group treatment. Parents are invited to discuss relevant problems that have occurred during the previous week. A therapist moderate the discussion but does not provide information about the behavioral techniques included in the PT group. Parents attend weekly sessions, which last 90 minutes and are held at the Hospital Clinic of Barcelona. Parents are given homework assignments to complete between sessions.
62603821|NCT04568525|ACTIVE_COMPARATOR|COVID - 19 and pneumonia patients|
62603822|NCT04568525|ACTIVE_COMPARATOR|Health patients|
62247020|NCT05163470|EXPERIMENTAL|On Fi.RE. framework|Men football professional players
62247021|NCT05163470|ACTIVE_COMPARATOR|Traditional rehabilitation|Men football professional players
62437227|NCT00200395|EXPERIMENTAL|OSI-774 (Tarceva)|Oral treatment with OSI-774 (Tarceva) will be given as a 150 mg tablets daily for 14 days. On day 15 and if there are no adverse effects the dose will be increased to 200 mg.
62437228|NCT06543823|SHAM_COMPARATOR|Study group|The wound bed is left bare after the tonsillectomy procedure
62826353|NCT06591624||elective adult neurosurgical patients succesfully extubation after neurosurgery|succesfully extubation after neurosurgery
62826354|NCT06591624||elective adult neurosurgical patients prolonged mechanical ventilation|prolonged mechanical ventilation
62826355|NCT01774721|EXPERIMENTAL|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing.
62826356|NCT01774721|ACTIVE_COMPARATOR|gefitinib|Gefitinib is provided as 250 mg tablets, continuous oral daily dosing.
62826357|NCT06592638|EXPERIMENTAL|Dose Escalation|
62826358|NCT06590155|EXPERIMENTAL|to delineate the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathy|Erythropoietin was administered in the first weeks of life at different multiple doses between 259-1000 UI/KG/D for 3 days
62826359|NCT06590155|OTHER|Role of Erythropoietin in neonate hypoxic ishemic encephalopathy|EPO reduces the need for blood transfusions in premature infants. To cross the blood-brain barrier
62044427|NCT02538185|PLACEBO_COMPARATOR|Vaccine injected ID with classical syringe|"Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);~Left forearm, ID with classical syringe filled with vaccine (0.1mL);~Non-dominant deltoid, Intramuscular (IM) with classical syringe filled with placebo (0.5mL)."
62437229|NCT06543823|EXPERIMENTAL|SupraTHEL 250 group|The SupraTHEL 250 membrane is suture ionto the wound bed after the tonsillectomy procedure
62437230|NCT00425659|ACTIVE_COMPARATOR|3|
62437231|NCT00425659|EXPERIMENTAL|1|
62437232|NCT00425659|OTHER|2|usual practice
62437233|NCT04390139|EXPERIMENTAL|Treatment A|Wharton-Jelly mesenchymal stromal cells on D1 and D3
62437234|NCT04390139|PLACEBO_COMPARATOR|Treatment B|Placebo on D1 and D3
62437235|NCT00510549|ACTIVE_COMPARATOR|1, PD|Peritoneal Dialysis
62603823|NCT03757637|NO_INTERVENTION|General module|"Control group will be case manager care only group. Eligible patients will also invite and receive their first time assessment as baseline during hospitalization. The usual cancer care group will receive routine cancer care in the inpatient wards through OPD visits."
62826360|NCT06590155|NO_INTERVENTION|Role of Erythropoietin in neonatal hypoxic ischemic encephalopathy|prevent apoptosis of erythroid progenitor cells and to enhance their maturation and proliferation
62437236|NCT00510549|ACTIVE_COMPARATOR|2, HD|Hemodialysis
62826361|NCT02491684|PLACEBO_COMPARATOR|Placebo (matching)|Placebo, once daily inhalation for 14 days
62826362|NCT02491684|EXPERIMENTAL|Interferon beta-1a|Interferon beta-1a, 24 μg (metered dose) once daily inhalation for 14 days
62826363|NCT05731986|ACTIVE_COMPARATOR|Optimal stimulation (for a blood pressure response)|Stimulation will be applied during an orthostatic sit-up challenge, using the profile (stimulation site and parameters) that was chosen in the mapping sessions, for optimal modulation of systolic blood pressure.
62826364|NCT05731986|SHAM_COMPARATOR|Sham stimulation|Sham stimulation will be applied during an orthostatic sit-up challenge. Sham stimulation will be delivered at a predetermined spinal location. Stimulation parameters, however, will be different from those chosen for the optimal stimulation, and sensation may be different as well.
62826365|NCT05128916|ACTIVE_COMPARATOR|Intralesional PRP|Patients with onychomycosis will receive intralesional injections of PRP.
62826366|NCT05128916|ACTIVE_COMPARATOR|Oral terbinafine|Patients with onychomycosis will receive oral terbinafine 250 mg daily
62826367|NCT05128916|ACTIVE_COMPARATOR|Intralesional PRP + Oral terbinafine|Patients with onychomycosis will receive intralesional PRP in addition to oral terbinafine 250 mg daily.
62044428|NCT02538185|ACTIVE_COMPARATOR|Vaccine injected ID with NanoJect device (DebioJect™)|"Right forearm, ID with NanoJect device (DebioJect™) filled with vaccine (0.1mL);~Left forearm, ID with classical syringe filled with placebo (0.1mL);~Non-dominant deltoid, IM with classical syringe filled with placebo (0.5mL)."
62247022|NCT05443893||Normal subjects|Gait analysis with artificial intelligence and traditional methods
62247023|NCT05443893||Subjects with abnormal gait|Gait analysis with artificial intelligence and traditional methods
62247024|NCT02765620||drug|Early treatment response assessment: using baseline data and early follow-up data Evaluate treatment response: using baseline data, early follow-up data and final data Compare PERCIST to RECIST criteria: correlation analysis Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot
62247025|NCT02765620||radiation|Early treatment response assessment: using baseline data and early follow-up data Evaluate treatment response: using baseline data, early follow-up data and final data Compare PERCIST to RECIST criteria: correlation analysis Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot
62437237|NCT03392376|EXPERIMENTAL|Haloperidol injection|"Haloperidol 2,5mg x 3 daily, with additional as needed doses to a maximum of 20mg/daily.~Other name: Serenase"
62437238|NCT03392376|PLACEBO_COMPARATOR|Normal Saline|Saline (0,9%)
62437239|NCT03107351|SHAM_COMPARATOR|repeatability measures|In this arm, healthy subjects will undergo repeated measures at different times of the day.
62826368|NCT03592186|EXPERIMENTAL|Parenting Wisely+|Parenting Wisely+ consists of access to the Parenting Wisely computer program (www.parentingwisely.com), paired with engagement strategies: up to four in-person coaching sessions, daily text messages, and access to an online networking forum.
62603824|NCT03757637|EXPERIMENTAL|NLSCP|NLSCP group will receive 5 section of NLSCP. Contents of scheduled intervention will be developed baed on the literature mentioned above. Ex 1 group, patients will receive at least 3 times face-to-face NLSCP, and two times by telephone calls for following up.
62826369|NCT03592186|ACTIVE_COMPARATOR|Treatment as Usual|"The active comparator is defined as residential treatment services as usual.~At short-term facility, average length of stay was 6-10 days. At long-term facility, average length of stay was 30-45 days."
62826370|NCT02541175||All study participants|In order to cover a wide variety of common arrhythmias but keeping the number of subjects needed low (pilot study), the subjects are pre-selected according to following 4 categories: 1) 4 patients with intermitting or persisting atrial fibrillation. 2) 4 patients with atrial flutter 3) 6 patients with frequent atrial or ventricular extra-systoles. 4) 6 cardiac healthy subjects.
62603825|NCT03757637|EXPERIMENTAL|ICT supported HAP|The ICT supported HAP group will receive information or counseling through mobile phone App as the schedule intervention time. For this group, patients will receive two face to face interventions in the first two sections (pre-discharge from hospital and 5th week post-op). It will be delivered by research nurse to intervene patients and help them to build up the App system. Research nurse will also help patients to be familiar with the operation system. The rest parts of the intervention will all through Apps in the scheduled time. Patients can raise their questions and concerns through APPs. Patients in the HAP can raise their concerns or questions through APP and receive interventions or answers through App interactively.
62826371|NCT01071304|EXPERIMENTAL|All Participants|In Part 1, all participants received a single oral dose of 2 mg midazolam on Day -2. On Days 1-5, all participants received daily single oral doses of ridaforolimus 40 mg ( 4 x 10 mg tablets). On Day 5, all participants received a single oral dose of 2 mg midazolam coadministered with the dose of ridaforolimus. Participants had the option to continue into Part 2 of this study.
62437240|NCT03107351|EXPERIMENTAL|Contractility changes measures|In this arm, healthy subjects will have their cardiac contractility increased in a controlled way and assessed with both HK and echocardiography.
62603826|NCT06618807|ACTIVE_COMPARATOR|Active group|The active group will undergo a 8-week trial of home-use tPBM using the active Neuro RX Gamma (v2) device, 6 days/week, 20 minutes per session.
62826372|NCT06595355|EXPERIMENTAL|Case: Intravitreal injection of bevacizumab with oral curcumin|"Intravitreal injection of bevacizumab with oral curcumin Inclusion criteria: Patients with center-involving macular edema with macular center thickness of more than 300 microns in OCT 2-Patients who did not receive intravitreal bevacizumab in the last 3 months and intravitreal corticosteroids in the previous 6 months.~3- The amount of BCVA should not be \<20/400. 4-Consent to participate in the study"
62826373|NCT06595355|PLACEBO_COMPARATOR|Control: Intravitreal injection of bevacizumab with oral placebo|Intravitreal injection of bevacizumab with oral placebo
62826374|NCT06588270|EXPERIMENTAL|Virtual reality-based therapy|"The intervention group will receive a VR experience with a treatment software. The aim is to immerse the patient in an interactive environment that invites him/her to explore and complete goal-directed activities with sensory, visual and/or auditory rewards.~The therapy will be delivered with the support of a therapist once per week for 12 consecutive weeks. Each therapy session will last approximately 20 minutes."
62247026|NCT03359525|EXPERIMENTAL|Group A|Group A: Intravenous Tranexamic acid at a dose of 1 gram administered 30 min prior to skin incision and 1 gram 3 hours after the procedure. (Total dose administered is 2 grams)
62437241|NCT01119729||HIV-infected Outpatients|
62437242|NCT03124381|ACTIVE_COMPARATOR|Acne Mask|Cleanser, Acne Mask
62603827|NCT06618807|SHAM_COMPARATOR|Sham group|The sham group will undergo a 8-week trial of home-use PBM using the sham Neuro RX Gamma (v2) device, 6 days/week, 20 minutes per session.
62826375|NCT06588270|SHAM_COMPARATOR|Sham -VR|Control group's patients will continue pharmacological and non pharmacological usual treatment. Additionally, these patients will attend to VR sessions without the software created activities for treatment (sham-VR). Sessions will be the same length and quantity as the intervention group's sessions.
62826376|NCT06591117|EXPERIMENTAL|Vizio Treatment|single-arm clinical study
62044429|NCT02538185|PLACEBO_COMPARATOR|Vaccine injected IM with classical syringe|"Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);~Left forearm, ID with classical syringe filled with placebo (0.1mL);~Non-dominant deltoid, IM with classical syringe filled with vaccine (0.5mL)."
62044430|NCT01443819|OTHER|Lumbar Transforaminal Epidural Corticosteroid Injection|
62826377|NCT06322186|EXPERIMENTAL|Ready-Heat Blanket|Two Ready-Heat 4-panel half blankets applied indirectly (as per manufacturer's directions) with two flannel blankets placed under them.
62437243|NCT03124381|EXPERIMENTAL|Gel-Cream + Acne Mask|Cleanser, Gel-Cream, Acne Mask
62437244|NCT02400710|EXPERIMENTAL|Clinician-Supported PTSD Coach|Four 20-minute sessions (2 in-person, 2 by phone) focused on instructions for use, setting symptom reductions goals, and assigning specific PTSD Coach activities (i.e., assessments, management strategies, psycho-educational readings) for the participant to complete on their own.
62437245|NCT02400710|ACTIVE_COMPARATOR|Self-Managed PTSD Coach|One in-person 10-minute session that provides instructions on how to use the PTSD Coach app.
62437246|NCT05641272|EXPERIMENTAL|Group I: sublingual allergoid-mannan conjugates (MM09 at 3.000 UTm/mL)|Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 3.000 UTm/mL for sublingual immunotherapy. The dose is 2 sprays daily applied to the sublingual mucosa for 6 months.
62044431|NCT01443819|OTHER|Physical Therapy|
62044432|NCT01443819|OTHER|Cohort observational|
62044433|NCT00606775|EXPERIMENTAL|Carvedilol|
62044434|NCT00606775|NO_INTERVENTION|Control|
62044435|NCT00994357|EXPERIMENTAL|Real-time Continuous Glucose Monitoring|Real-time Continuous Glucose Monitoring at five times for up to 6 days during pregnancy, and during delivery, in addition to standard monitoring and treatment.
62247027|NCT03359525|EXPERIMENTAL|Group B|Group B: Topical Tranexamic acid at a dose of 1 gram injected in to the periarticular tissues prior to closure and 1 gram injected into the joint through the drain following wound closure. (Total dose administered is 2 grams)
62247028|NCT03359525|EXPERIMENTAL|Group C|Group C: Combined Intravenous 1 gram given intravenous 30 min prior to skin incision and topical tranexamic acid (1 gram) injected in to the periarticular tissues prior to closure. (Total dose administered is 2 grams)
62044436|NCT00994357|ACTIVE_COMPARATOR|Control group|Standard monitoring and treatment of diabetic patients during pregnancy.
62247029|NCT02015325|NO_INTERVENTION|Control|Control schools were included if they did not have any ongoing water and sanitation hygiene initiative.
62247030|NCT02015325|EXPERIMENTAL|Planet Water Program Intervention|School were included that were receiving the Planet Water Foundation's Program (PWP) providing a school-based program focusing on three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. Children will have access to safe water in the schools provided through the use of an AquaTower, and a 4 week educational program.
62044437|NCT02771743|EXPERIMENTAL|High risk neuroblastoma|"1. Nine cycles of induction chemotherapy with cisplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen~2. Upfront surgery or surgery after 6 cycles of chemotherapy~3. Peripheral stem cell mobilization after 7 cycles of chemotherapy~4. Tandem high dose chemotherapy with autologous stem cell transplantation (Tandem HDCT/auto-SCT)~   * Dose of chemotherapeutic agents of 1st HDCT is tailored according to the residual positron emission tomography (PET)/Metaiodobenzylguanidine (MIBG) uptake before 1st HDCT~  * Dose of MIBG of 2nd HDCT is tailored according to the residual PET/MIBG uptake before 2nd HDCT~5. Radiotherapy after tandem HDCT~6. Immunotherapy and differentiation therapy with Interleukin-2/isotretinoin"
62044438|NCT04931927|ACTIVE_COMPARATOR|Control|Participants are randomized to treatment as usual (TAU)
62044439|NCT04931927|EXPERIMENTAL|MCI-T|Participants are randomized to the Making Connections Intervention-Telehealth (MCI-T) plus treatment as usual (TAU)
62826378|NCT06322186|ACTIVE_COMPARATOR|Warmed blankets/FAWB|Two warmed blankets (current standard of care) will be applied to the patient.
62437247|NCT05641272|EXPERIMENTAL|Group II: sublingual allergoid-mannan conjugates (MM09 at 9.000 UTm/mL)|Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 9.000 UTm/mL for sublingual immunotherapy.. The dose is 2 sprays daily applied to the sublingual mucosa for 6 months.
62437248|NCT05641272|PLACEBO_COMPARATOR|Group III: sublingual placebo|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.The dose is 2 sprays daily applied to the sublingual mucosa for 6 months.
62437249|NCT02688127|EXPERIMENTAL|tranexamic acid group|tranexamic acid given as 1 gram intravenous dose dilute in 500 cc of ringer lactate 20 minute before cesarean section
62437250|NCT02688127|PLACEBO_COMPARATOR|placebo group|the control group will receive 500 cc of ringer lactate 20 minute before cesarean section
62437251|NCT05574582|EXPERIMENTAL|Arthroscopic assisted Cancellous chips graft reconstruction|"The arthroscopic technique is potentially less invasive with minimal donor site morbidity and potentially faster time to union because of minimal trauma to the ligament structures, joint capsule, and the tenuous blood supply. It may also have advantageous osteogenic properties compared to a structural graft.~Currently, studies have reported similar union rates, patient reported outcomes score, and functional score compared to open graft technique. Results in patients with gross deformity are debated with some studies favoring conventional open structural graft and other found no difference in outcome between the techniques."
62437252|NCT05574582|ACTIVE_COMPARATOR|Open cancellous graft reconstruction|Convention open technique with debridement of the nonunion side, insertion of cancellous graft from the iliac crest and osteosynthesis with compression screw is currently commonly applied in scaphoid nonunion.
62437253|NCT06497023||maligant|female patients with maligant breast masses who underwent biopsy and/or surgical resection.
62826379|NCT01152255|EXPERIMENTAL|Panel A - MK6186 40 mg|MK6186 40 mg
62826380|NCT01152255|PLACEBO_COMPARATOR|Panel A - Placebo|placebo
62826381|NCT01152255|EXPERIMENTAL|Panel B - MK6186 150 mg|MK6186 150 mg
62826382|NCT01152255|PLACEBO_COMPARATOR|Panel B - Placebo|placebo
62826383|NCT01152255|EXPERIMENTAL|Panel C - MK6186 <=150 mg|MK6186 \<=150 mg
62826384|NCT01152255|PLACEBO_COMPARATOR|Panel C - Placebo|placebo
62826385|NCT01152255|EXPERIMENTAL|Panel D - MK6186 <=150 mg|MK6186 \<=150 mg
62826386|NCT01152255|PLACEBO_COMPARATOR|Panel D - Placebo|placebo
62826387|NCT02167698|EXPERIMENTAL|Airway pressure release ventilation arm|"This group of children would be ventilated using the Airway pressure release ventilation (APRV) mode.~Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups."
62826388|NCT02167698|ACTIVE_COMPARATOR|Low-tidal volume ventilation arm|Low-tidal volume ventilation using pressure-regulated volume control mode with target tidal volume of 6 ml/kg or less and other lung-protective strategies. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups
62826389|NCT02855125|ACTIVE_COMPARATOR|TAS-114 + S-1|Participants received 400 milligrams (mg) of TAS-114 tablets orally twice daily (BID) along with 30 milligrams per meter square (mg/m\^2) of S-1 capsule BID for 2 weeks (Day 1 to 14), followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 51 weeks).
62826390|NCT02855125|ACTIVE_COMPARATOR|S-1 (Monotherapy)|Participants received 30 mg/m\^2 of S-1 capsules BID for 2 weeks (Day 1 to 14) followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 38 weeks).
62044440|NCT00316082|EXPERIMENTAL|Saxagliptin 2.5 mg QAM (A)|PLUS open-label metformin (as needed as rescue medication)
62044441|NCT00316082|EXPERIMENTAL|Saxagliptin 2.5 mg titrated to 5 mg QAM (B)|PLUS open-label metformin (as needed as rescue medication)
62044442|NCT00316082|EXPERIMENTAL|Saxagliptin 5 mg QAM (C)|PLUS open-label metformin (as needed as rescue medication)
62437254|NCT06497023||benign|female patients with benign breast masses who underwent biopsy and/or surgical resection.
62826391|NCT02920632|EXPERIMENTAL|Online cognitive training 1|Eight-week, three times a week during 45 minutes cognitive training
62826392|NCT02920632|ACTIVE_COMPARATOR|Online cognitive training 2|Eight-week, three times a week during 45 minutes cognitive activities
62603828|NCT00329641|EXPERIMENTAL|Treatment (carboplatin, paclitaxel, sorafenib)|"Patients receive carboplatin IV and paclitaxel IV once on day 1 and oral sorafenib twice daily on days 2-19. Treatment repeats every 21 days for up to 6 courses.\* After 6 courses, patients continue to receive oral sorafenib alone twice daily in the absence of disease progression or unacceptable toxicity.~\[Note: \*If sorafenib is discontinued prior to course 6, patients may continue to receive carboplatin and paclitaxel for up to 6 courses; if carboplatin and paclitaxel are discontinued prior to course 6, patients may continue to receive sorafenib alone twice daily on days 1-21 of each course in the absence of disease progression or unacceptable toxicity. \]"
62044443|NCT00316082|EXPERIMENTAL|Saxagliptin 5 mg QPM (D)|PLUS open-label metformin (as needed as rescue medication)
62044444|NCT00316082|PLACEBO_COMPARATOR|Placebo (E)|PLUS open-label metformin (as needed as rescue medication)
62044445|NCT05671874|EXPERIMENTAL|Web-based Decision Aid + Communication (DA+C) tool|Surrogate(s) will read/click through the DA+C tool prior to the clinician-family meeting and complete the integrated worksheet. Surrogate(s) will have unlimited access to the DA+C tool and may return to the tool and edit the worksheet at any time.
62044446|NCT05671874|NO_INTERVENTION|Usual Care|No decision aid
62044447|NCT05540925||Low-risk for MVI|Using the sequencing data of cfDNA, a nomogram to predict MVI was constructed using genomic mutations. We designed to stratify early-stage HCC into two sub-stages with nomogram-estimated high or low risks of MVI, respectively, using an optimal cutoff value of 90. The MVI low-risk group refers to patients with score ≤ 90.
62044448|NCT05540925||High-risk for MVI|Using the sequencing data of cfDNA, a nomogram to predict MVI was constructed using genomic mutations. We designed to stratify early-stage HCC into two sub-stages with nomogram-estimated high or low risks of MVI, respectively, using an optimal cutoff value of 90. The MVI low-risk group refers to patients with score \> 90.
62044449|NCT01676337|NO_INTERVENTION|Control|Patients randomized to the control arm will not receive text message reminder regarding their upcoming appointment.
62044450|NCT01676337|EXPERIMENTAL|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
62044451|NCT01507805|EXPERIMENTAL|EA preconditioning|electroacupuncture five days pre-operation
62044452|NCT01507805|SHAM_COMPARATOR|Sham EA preconditioning|Patients treated with sham EA preconditioning Intervention
62044453|NCT01535820|EXPERIMENTAL|Treatment sequence AB|
62044454|NCT01535820|EXPERIMENTAL|Treatment sequence BA|
62603829|NCT04437472||CareSignal|-Participants will undergo a single training session on how to use the CareSignal software no more than 4 weeks before starting standard of care therapy. After the training session, patients will be encouraged by the treatment team to complete the baseline symptom report once they receive the questions via SMS prior to starting any therapy and to complete the weekly reports during therapy and in follow up.
62044455|NCT00689221|EXPERIMENTAL|Cilengitide + Temozolomide + Radiotherapy|
62603830|NCT06424600||S-form users|Smoke- form users
62826393|NCT02920632|NO_INTERVENTION|Healthy control subjects|Reference group to compare cognitive training effects to
62826394|NCT05526885|EXPERIMENTAL|Approach 1 - CAD4TB screening|Participants with a CAD4TB version 7 (Delft Imaging, NL) score above the overall threshold (as defined for study approach 1) are eligible for Xpert MTB/RIF Ultra testing.
62044456|NCT00689221|ACTIVE_COMPARATOR|Temozolomide + Radiotherapy|
62044457|NCT04188977|OTHER|Usual Practice|OTPs are able to request from state and federal health department officials to utilize interim methadone treatment to address admission delays in their OTP.
62044458|NCT04188977|EXPERIMENTAL|Implementation Facilitation|Implementation Facilitation (IF) will consist of educational outreach to OTP staff, identification of local champions, training, performance feedback, and learning collaborative for OTP staff and state health department officials.
62044459|NCT06497244|EXPERIMENTAL|micro osteo-perforation side|the patient will receive micro osteo-perforation in one side Computer generated random numbers will generated using Microsoft Office Excel sheet by a person who was not involved in the clinical trial. Because of the split mouth design, the right sides of patients will randomly be assigned to one of the two groups (MOPs or control). Then, the left sides will automatically be assigned to the alternative group.
62044460|NCT06497244|NO_INTERVENTION|no micro osteo-perforation side|the other side without micro osteo-perforation
62044461|NCT01688466|EXPERIMENTAL|0.5 mg/day with Dose Escalation|0.5 mg/day with Dose Escalation by 0.5 mg/day increments every 2 weeks to a maximum of 2.0 mg/day
62044462|NCT01688466|EXPERIMENTAL|0.5 mg/day without Dose Escalation|0.5 mg/day without Dose Escalation
62044463|NCT05422417|EXPERIMENTAL|Prolonged intermittent theta-burst(iTBS)-DMPFC|This active group will receive prolonged intermittent theta-burst(iTBS) on the dorsomedial prefrontal cortex(DMPFC)
62247031|NCT06155838|EXPERIMENTAL|EASE Intervention|"The intervention consists of four fundamental themes that have empirical support, structured across seven group sessions for adolescents and three group sessions for their parents or guardians. The sessions for teenagers will be conducted in person, spanning seven weeks with one session per week, each lasting 90 minutes. Similarly, three sessions are scheduled for parents.~In accordance with WHO guidelines (2016), the intervention will be administered by non-specialist co-facilitators(class teachers) who possess at least 16 years of education (undergraduate degree). These co-facilitators will undergo a ten-day training program, demonstrating mock sessions as part of this training. During the intervention delivery, they will also benefit from weekly supervision provided by a specialist, who will be a graduate psychologist or trained nurse in mental health."
62603831|NCT06424600||E-form users|E-Cigarette users
62603832|NCT06424600||D-form users|Dual-Form users
62603833|NCT03024528||CAM-ICU (+)|Delirious patients.
62044464|NCT05422417|EXPERIMENTAL|20Hz rTMS-DMPFC|This active group will receive 20Hz rTMS on the DMPFC
62044465|NCT05422417|SHAM_COMPARATOR|Sham prolonged iTBS-DMPFC or 20Hz rTMS-DMPFC|Patients in the sham group will receive the same prolonged iTBS or 20Hz rTMS performed by a sham coil.
62044466|NCT05009303||Participants|Thirty healthy individuals and seventy patients suffering from chronic pain or disability in one or both of their lower extremities
62044467|NCT01268748|OTHER|4 ports laparoscopic cholecystectomy|
62044468|NCT01268748|OTHER|One port transumb. laparoscopic surgery|
62044469|NCT01698294|EXPERIMENTAL|Group I (flaxseed)|"Participants receive flaxseed PO daily for 6 weeks. After a usual diet washout period of 8 weeks, patients crossover to Group II."
62603834|NCT03024528||CAM-ICU (-)|Non-delirious patients
62826395|NCT05526885|EXPERIMENTAL|Approach 2 - CAD4TB screening with POC-CRP triage testing|Participants with a CAD4TB version 7 (Delft Imaging, NL) score within the threshold window (between lower and upper limit threshold as defined for study approach 2), a POC-CRP LumiraDx (LumiraDx Limited, UK) test will follow as a triage test. If CRP is above the determined threshold as defined for approach 2, Xpert MTB/RIF Ultra will be performed. If the CAD4TB score is above the upper limit threshold as defined for approach 2, Xpert MTB/RIF Ultra will be performed (without further CRP testing).
62826396|NCT03406377|PLACEBO_COMPARATOR|Placebo|Water for injection, Sorbitol, L-Methionine, Sodium Acetate Trihydrate
62826397|NCT03406377|EXPERIMENTAL|OPK-88003|70 mg/vial (extractable volume 1 mL) (20mg for 4 weeks, 40 mg for 4 weeks and 70 mg for 22 weeks)
62826398|NCT00144547|EXPERIMENTAL|1|
62826399|NCT04080648|OTHER|Standard of case - guselkumab|Patients will continue to receive guselkumab according to the standard dosing schedule; subcutaneous injection of 100 mg at weeks 0 and 4 and then every 8 weeks
62826400|NCT00726063|EXPERIMENTAL|Nanotite implant|Nanotite dental implant
62826401|NCT00726063|ACTIVE_COMPARATOR|Osseotite implant|Osseotite dental implant
62044470|NCT01698294|ACTIVE_COMPARATOR|Group II (usual diet)|"Participants maintain a usual diet for 6 weeks. After a usual diet washout period of 8 weeks, patients crossover to Group I."
62044471|NCT04629703|ACTIVE_COMPARATOR|Fostamatinib (150 mg twice daily for 14 days) + Standard of Care|Fostamatinib (150 mg twice daily for 14 days) + Standard of Care
62437255|NCT02850523|EXPERIMENTAL|Experimental|After an initial assessment, the experimental group will receive 6 weekly sessions (2 hours long) of group Cognitive Behavioural Therapy for Perinatal Anxiety (n=6 per group) for perinatal anxiety. They will then be re-assessed at post-treatment and 3 months post-treatment to determine the effectiveness of the treatment and whether these effects are maintained 3 months after treatment.
62826402|NCT04909996|EXPERIMENTAL|Group A: Sentinox treatment performed 3 times/day for 5 days (as add-on to the standard therapy)|
62044472|NCT04629703|PLACEBO_COMPARATOR|Placebo (twice daily for 14 days) + Standard of Care|Placebo (twice daily for 14 days) + Standard of Care
62044473|NCT01156948|ACTIVE_COMPARATOR|vaginal misoprostol|vaginal misoprostol was administered to this group of nulliparous women
62044474|NCT01156948|EXPERIMENTAL|oral misoprostol|oral misoprostol
62044475|NCT01903538|EXPERIMENTAL|Cathodal transcranial direct current stimulation|
62044476|NCT01903538|SHAM_COMPARATOR|Sham transcranial direct current stimulation|
62044477|NCT01788865|EXPERIMENTAL|cSEMS|Patients with malignant ureteral obstruction have cSEMS(Covered self-expandable dual-layered metal stent) implant
62437256|NCT02850523|NO_INTERVENTION|Waitlist Control|After an initial assessment, the wait-list control group will not receive any treatment for 6 weeks. They will then be re-assessed after 6 weeks and this data will be used to compare this group to the experimental group to determine the effectiveness of the treatment. After this re-assessment they will be offered the same treatment as the experimental group: 6 weekly sessions (2 hours long) of group Cognitive Behavioural Therapy for Perinatal Anxiety
62437257|NCT03668028|EXPERIMENTAL|TPX-114|Subjects undergo arthroscopic rotator cuff repair with TPX-114.
62044478|NCT00319748|EXPERIMENTAL|Intent-To-Treat|Patients treated with at least one dose - 852A subcutaneous injection.
62044479|NCT00319748|EXPERIMENTAL|Evaluable Cohort|Patients who received all 24 doses of 852A per protocol.
62044480|NCT03945188|EXPERIMENTAL|Etrasimod 2 mg|
62044481|NCT03945188|PLACEBO_COMPARATOR|Placebo|
62044482|NCT06086327|EXPERIMENTAL|68Ga-Pentixafor, PET/CT|Inject 68Ga-Pentixafor and then perform PET/CT scan.
62044483|NCT04588961|ACTIVE_COMPARATOR|Control group|Patients undergoing trapeziectomy with suspensionplasty for primary basal thumb osteoarthritis
62044484|NCT04588961|ACTIVE_COMPARATOR|Study group|Patients undergoing joint alloplasty using prothesis for primary basal thumb osteoarthritis
62044485|NCT03391674|EXPERIMENTAL|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
62044486|NCT03391674|NO_INTERVENTION|Observational|Observational
62437258|NCT03668028|PLACEBO_COMPARATOR|Placebo|Subjects undergo arthroscopic surgery for rotator cuff repair without TPX-114.
62437259|NCT02529800|EXPERIMENTAL|Sequence 1|High fat diet+HGP0412 → High fat diet+HIP1402 → fasted state+HIP1402
62437260|NCT02529800|EXPERIMENTAL|Sequence 2|High fat diet+HIP1402 → fasted state+HIP1402 → High fat diet+HGP0412
62826403|NCT04909996|EXPERIMENTAL|Group B: Sentinox treatment performed 5 times/day for 5 days (as add-on to the standard therapy)|
62826404|NCT04909996|NO_INTERVENTION|Group C: no Sentinox treatment; only the standard therapy will be performed|
62826405|NCT04546711||Ketogenic Diet|"* Baseline Assessments~* Ketogenic diet intervention~* 3 and 6 month Assessments"
62826406|NCT05518097||Conventional Physical Therapy Program|Patients with knee osteoarthritis underwent a conventional physical therapy program including hotpack, US, TENS and exercise.
62437261|NCT02529800|EXPERIMENTAL|Sequence 3|fasted state+HIP1402 → High fat diet+HGP0412 → High fat diet+HIP1402
62437262|NCT00006170|EXPERIMENTAL|Bupropion and Weight Concerns intervention|Bupropion SR and a weight concerns psychosocial intervention
62437263|NCT00006170|ACTIVE_COMPARATOR|Placebo and Weight Concerns|A matched placebo administered on same schedule as bupriopion and a weight concerns psychosocial intervention for smoking cesstion
62603835|NCT02744027|OTHER|Dynamic Contrast Enhanced Magnetic Contrast Imaging|Dynamic Contrast Enhanced Magnetic Resonance (MR) Lymphangiogram and heavy T2 Magnetic Resonance imaging data will be evaluated for abnormal lymphatic perfusion of the lung parenchyma. Abdominal and thoracic lymphatic malformations will be characterized by location, number, size, relationship to other organs and perfusion patterns in order to create a basis of imaging classification of lymphatic abnormalities (LA). Subjects will undergo both Dynamic Contrast Enhanced Magnetic Resonance Lymphangiogram (DCMRL) and Heavy Weighted T2 Imaging.
62603836|NCT00653302|EXPERIMENTAL|1|Lantus once a day plus Glucophage 1000mg, twice a day per os
62826407|NCT06600529|EXPERIMENTAL|Control Group|"Standard Care:~Procedure: Routine conventional Applied Behavioral Analysis (ABA) management and interventions for ASD, as per current clinical guidelines."
62826408|NCT06600529|EXPERIMENTAL|Experimental Group|The Group may be provided with three interventions and then compared with the control group in order to evaluate the effects of the said interventions.
62826409|NCT05387200|EXPERIMENTAL|Masibone S|Masibone S (alendronate sodium trihydrate 70mg, oral solution) 1 bottle weekly and cholecalciferol 1000U/calcium 100mg 1T daily for 48 weeks
62826410|NCT05387200|ACTIVE_COMPARATOR|Fosamax|Fosamax (aledronate sodium 70mg, oral tablet) 1T weekly and cholecalciferol 1000U/calcium 100mg 1T daily for 48 weeks
62247032|NCT06155838|NO_INTERVENTION|control/ wait list|Throughout the study, participants in the control group will continue to receive standard treatment. Nevertheless, following the conclusion of the trial, all control group participants will undergo the EASE intervention over a seven-week period, which will also involve three sessions for their parents and guardians. This approach ensures that the control group is not placed at a disadvantage, in alignment with ethical principles.
62603837|NCT03111199|PLACEBO_COMPARATOR|Control Placebo Group|The subjects of this group will be submitted to TENS bound in placebo mode in the lumbar spine.
62437264|NCT00006170|ACTIVE_COMPARATOR|Bupropion and standard smoking cessation|Bupropion SR and a time and attention controlled smoking cessation intervention
62826411|NCT03868514||TiLOOP Bra Pocket|Medical Device
62826412|NCT06594185|EXPERIMENTAL|Subjects bilaterally implanted with enVista Aspire EA or Aspire Toric ETA IOLs|
62826413|NCT00651742|EXPERIMENTAL|S-1 30 mg/m^2|Participants received 30 milligrams per meter square (mg/m\^2) of S-1 orally twice daily (BID) for 2 weeks (i.e., Day 1 to 14), followed by 1 week recovery period (i.e., Day 15 to 21; one cycle equaled 21 days), treatment was repeated every 3 weeks until death, progression of disease, occurrence of intolerable side effects, withdrawal of consent, or removal by Investigator, whichever comes first.
62603838|NCT03111199|EXPERIMENTAL|Cryotherapy Group|The subjects of this group will be submitted to Cryotherapy in the lumbar spine.
62603839|NCT03111199|EXPERIMENTAL|TENS Burst Group|The subjects of this group will be submitted to TENS Burst in the lumbar spine.
62826414|NCT05766813|EXPERIMENTAL|Lenrispodun 30 mg|Lenrispodun 30 mg tablets administered orally, once-daily.
62826415|NCT05766813|PLACEBO_COMPARATOR|Placebo|Matching tablets administered orally, once daily.
62826416|NCT06600191|EXPERIMENTAL|Implant|"Participants who pass all screening criteria will undergo a percutaneous procedure for the implantation of a permanent mitral valve replacement device.~Participants will be followed for 5 years to evaluate safety and feasibility of Capstan Medical TMVR System for mitral valve replacement in humans with predominantly regurgitant mitral valves who are symptomatic and who are not good surgical candidates."
62044487|NCT04133727|EXPERIMENTAL|Intervention|Intervention group will wear a simulation suit in which will mimic the physical limitations experienced by older adults. In addition, they will participate in a polypharmacy workshop which allows them to communicate with older adults
62826417|NCT06600204||Patients who underwent a single or multiple segmentectomy|Patients who underwent a single or multiple segmentectomy in the thoracic surgery department of the Nancy University Hospital between April 2021 and July 2023
62826418|NCT04908631|OTHER|tDCS during auditory training|Use of tDCS during completion of the auditory training program
62826419|NCT01010828|ACTIVE_COMPARATOR|Tri-Vector Approach|
62826420|NCT01010828|EXPERIMENTAL|Mini Mid-Vastus Approach|
62826421|NCT04115306|EXPERIMENTAL|Oral PMD-026 in combination with fulvestrant|Daily dosing of PMD-026 with fulvestrant dosing according to package insert
62826422|NCT05919186|EXPERIMENTAL|EmrbyORP continued at high O2|Antioxidants supplementation Every 12 hours (3.5 μL)
62826423|NCT05919186|EXPERIMENTAL|EmrbyORP at baseline with high O2|Antioxidants supplementation At baseline only (6.5 μL)
62044488|NCT04133727|ACTIVE_COMPARATOR|Control|This group will participate in a polypharmacy workshop which allows them to communicate with older adults
62437265|NCT00006170|PLACEBO_COMPARATOR|Placebo and standard smoking cessation|A matched placebo administered on same schedule as bupriopion and a time and attention controlled smoking cessation intervention
62437266|NCT01871987|EXPERIMENTAL|fasted group|receiving FK949E in fasted condition
62437267|NCT01871987|EXPERIMENTAL|low fat group|receiving FK949E after low fat meal
62603840|NCT03111199|EXPERIMENTAL|TENS Burst and Cryotherapy Group|The subjects of this group will be submitted to TENS Burst and Cryotherapy in the lumbar spine.
62826424|NCT05919186|EXPERIMENTAL|EmrbyORP continued at low 02|Antioxidants supplementation Every 12 hours (3.5 μL)
62826425|NCT05919186|EXPERIMENTAL|EmrbyORP at baseline with low o2|Antioxidants supplementation At baseline only (6.5 μL)
62826426|NCT02587637|OTHER|Single device arm|
62826427|NCT06448676|ACTIVE_COMPARATOR|OnabotulinumtoxinA: 20 units|20 units (4-4-4-4-4) Commercial Name: Botox® Producing Company: Allergan, an AbbVie company Location: Dublin, Ireland Additional Commercial Names: Vistabel® (in some regions, especially Europe)
62044489|NCT06432517|EXPERIMENTAL|Moderate to high intensity exercise|BMI≥18.5, age between 18-40 years old, 81subjects.
62044490|NCT02676102|ACTIVE_COMPARATOR|Control Group|Participant will watch an educational video produced in partnership with the community of black men including customers, employers and owners of BOBs.
62826428|NCT06448676|ACTIVE_COMPARATOR|IncobotulinumtoxinA: 20 units|20 units (4-4-4-4-4) Commercial Name: Xeomin® Producing Company: Merz Pharmaceuticals Location: Frankfurt, Germany Additional Commercial Names: Bocouture® (for aesthetic use in some regions)
62826429|NCT06448676|ACTIVE_COMPARATOR|AbobotulinumtoxinA: 50 (Speywood) units|50 units (10-10-10-10-10) Commercial Name: Dysport® Producing Company: Ipsen Biopharmaceuticals, Inc. Location: Paris, France Additional Commercial Names: Azzalure® (for aesthetic use in some regions)
62044491|NCT02676102|ACTIVE_COMPARATOR|Targeted Intervention|Participants will watch an educational video produced in partnership with the community of black men including customers, employees, and owners of BOBs. Video production was informed by entertainment education models and produced with experts including an Academy Award winning filmmaker.
62044492|NCT02676102|ACTIVE_COMPARATOR|Tailored Intervention|Participants will watch videos with content individualized to participant's pre-intervention ODBI scores representing their organ donation beliefs
62044493|NCT05330065|EXPERIMENTAL|Bevacizumab and Camrelizumab for Malignant Pleural Effusion|
62044494|NCT03156660|EXPERIMENTAL|Weight gain prevention (Group 1)|Small Changes weight stability intervention
62044495|NCT03156660|EXPERIMENTAL|Weight loss intervention (Group 2)|Look AHEAD weight loss intervention
62044496|NCT03156660|ACTIVE_COMPARATOR|Self-guided intervention (Group 3)|Self-guided weight management with the EatingWell Diet book
62044497|NCT01067170|EXPERIMENTAL|Pneumatic compression stockings|
62044498|NCT05685459|EXPERIMENTAL|Intervention|The students involved in the intervention group were divided into subgroups, and the simulation was carried out using standardized patients. Each subgroup consisted of two students. Students were asked to practice supine and lateral recumbent positions in each scenario.
62044499|NCT05685459|NO_INTERVENTION|Control|The students in the control group were divided into subgroups and practised the supine position and the lateral recumbent position with a high-fidelity manikin. Each subgroup consisted of two students. The applications lasted 5-10 minutes for each group, and after the applications, the debriefing phase was conducted, which lasted 20 minutes.
62044500|NCT02044991|ACTIVE_COMPARATOR|Treatment|Participants randomized to this arm will receive a corticosteroid. This is 40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
62044501|NCT02044991|PLACEBO_COMPARATOR|Placebo|Participant's randomized to this condition will receive a placebo injection once weekly
62044502|NCT00109538|EXPERIMENTAL|Lonafarnib|Lonafarnib 200 mg twice daily, oral, continuously
62044503|NCT00109538|PLACEBO_COMPARATOR|Placebo|Placebo, BID, oral
62044504|NCT00530855|EXPERIMENTAL|Lacosamide|Lacosamide tablets for dosing 100 -800 mg/day
62826430|NCT06448676|ACTIVE_COMPARATOR|AbobotulinumtoxinA: 60 (Speywood) units|60 units (12-12-12-12-12) Commercial Name: Dysport® Producing Company: Ipsen Biopharmaceuticals, Inc. Location: Paris, France Additional Commercial Names: Azzalure® (for aesthetic use in some regions)
62826431|NCT06448676|ACTIVE_COMPARATOR|PrabotulinumtoxinA 20 units|20 units (4-4-4-4-4) Commercial Name: Jeuveau® Producing Company: Evolus, Inc. Location: Newport Beach, California, USA Additional Commercial Names: Nuceiva® (for aesthetic use in some regions)
62826432|NCT06448676|ACTIVE_COMPARATOR|Excluded: DaxibotulinumtoxinA 20 units (reason for exclusion: not available in the EU)|20 units (4-4-4-4-4) Commercial Name: Daxxify® Producing Company: Revance Therapeutics, Inc. Location: Nashville, Tennessee, USA
62826433|NCT06448676|ACTIVE_COMPARATOR|Excluded: LetibotulinumtoxinA-wlbg: 20 units (reason for exclusion: not available in the EU).|Arm Description: 20 units (4-4-4-4-4) Commercial Name: Letybo® Producing Company: Hugel Inc. Location: Chuncheon-si, South Korea
62826434|NCT06597110|NO_INTERVENTION|control group|participants with no ASMR intervention
62826435|NCT06597110|EXPERIMENTAL|intervention group A|participants engaged in pre-sleep ASMR listening sessions lasting 10 mins
62826436|NCT06597110|EXPERIMENTAL|intervention group B|participants engaged in pre-sleep ASMR listening sessions lasting 20 mins
62044505|NCT05134181|ACTIVE_COMPARATOR|Group MTP|will receive ultrasound-guided intra-articular SIJ injection with 40 mg of methylprednisolone with a uniform dose of 2 mL of 2% lidocaine hydrochloride.
62044506|NCT05134181|ACTIVE_COMPARATOR|- Group TMC|will receive ultrasound-guided intra-articular SIJ injection with 40 mg of Triamcinolone acetonide with a uniform dose of 2 mL of 2% lidocaine hydrochloride .
62247033|NCT04764851|OTHER|Cohort 1|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 1 Probe Cocktail given on 2 separate days:~* midazolam: 1 µg infused IV~* caffeine: 200 mg oral tablet~* omeprazole: two 20 mg oral tablets~* dextromethorphan: 1.6mL (containing \~10 mg) oral solution"
62247034|NCT04764851|OTHER|Cohort 2|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 2 Probe Cocktail given on 3 separate days:~* midazolam: 10 µg/mL given as 1mL oral solution.~* dabigatran: 375 µg/mL and pitavastatin: 10 µg/mL given as 1mL oral solution~* rosuvastatin: 25 µg/mL and atorvastatin: 50 µg/mL given as 2mL oral solution"
62437268|NCT01871987|EXPERIMENTAL|high fat group|receiving FK949E after high fat meal
62826437|NCT06597110|EXPERIMENTAL|intervention group C|participants engaged in pre-sleep ASMR listening sessions lasting 30 mins
62826438|NCT06492733|EXPERIMENTAL|FastWire System - Peripheral|This study is to assess the safety and efficacy of the FastWire System. It is intended to assess that the FastWire System can facilitate the intra-luminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions (CTOs).
62826439|NCT00635206|ACTIVE_COMPARATOR|1|Auto M series device set to Bi Flex
62826440|NCT00635206|ACTIVE_COMPARATOR|2|Set to standard CPAP
62826441|NCT06602531|EXPERIMENTAL|Low dose of ARCT-2304, Schedule 1, Young Adults|"Low dose of ARCT-2304 administered through intramuscular injection in the deltoid muscle.~Interventions: 2-dose regimen, schedule 1 Investigational Vaccine: ARCT-2304"
62826442|NCT06602531|EXPERIMENTAL|Mid dose of ARCT-2304, Schedule 1, Young Adults|"Mid dose of ARCT-2304 administered through intramuscular injection in the deltoid muscle.~Interventions: 2-dose regimen, schedule 1 Investigational Vaccine: ARCT-2304"
62247035|NCT04764851|OTHER|Cohort 3|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 3 Probe Cocktail given on 2 separate days:~- bupropion: 100mg oral tablet"
62247036|NCT04668651||diabetic|diabetic patients
62247037|NCT04668651||non diabetic|non-diabetic patients
62247038|NCT04031820|ACTIVE_COMPARATOR|unipolar cup|550 patients will receive a total hip arthroplasty with a unipolar cup.
62437269|NCT06377358|EXPERIMENTAL|Obese patients|Twenty obese patients treated by tecar therapy
62826443|NCT06602531|EXPERIMENTAL|High dose of ARCT-2304, Schedule 1, Young Adults|"High dose of ARCT-2304 administered through intramuscular injection in the deltoid muscle.~Interventions: 2-dose regimen, schedule 1 Investigational Vaccine: ARCT-2304"
62826444|NCT06602531|ACTIVE_COMPARATOR|Control, Schedule 1, Young Adults|"Control Vaccine (dose 1) and placebo (dose 2) administered through intramuscular injection in the deltoid muscle.~Interventions: 2-dose regimen, schedule 1 Investigational Vaccine: Comparator vaccine younger adult and saline placebo vaccine"
62826445|NCT06602531|EXPERIMENTAL|Low dose of ARCT-2304, Schedule 1, Older Adults|"Low dose of ARCT-2304 administered through intramuscular injection in the deltoid muscle.~Interventions: 2-dose regimen, schedule 1 Investigational Vaccine: ARCT-2304"
62826446|NCT06602531|EXPERIMENTAL|Mid dose of ARCT-2304, Schedule 1, Older Adults|"Mid dose of ARCT-2304 administered through intramuscular injection in the deltoid muscle.~Interventions: 2-dose regimen, schedule 1 Investigational Vaccine: ARCT-2304"
62826447|NCT06602531|EXPERIMENTAL|High dose of ARCT-2304, Schedule 1, Older Adults|"High dose of ARCT-2304 administered through intramuscular injection in the deltoid muscle.~Interventions: 2-dose regimen, schedule 1 Investigational Vaccine: ARCT-2304"
62826448|NCT06602531|ACTIVE_COMPARATOR|Control, Schedule 1, Older Adults|"Older Adults Control Vaccine (dose 1) and placebo (dose 2) administered through intramuscular injection in the deltoid muscle.~Interventions: 2-dose regimen, schedule 1 Investigational Vaccine: Comparator vaccine older adult and saline"
62826449|NCT06602531|EXPERIMENTAL|Low dose of ARCT-2304, Schedule 2, Young Adults|"Low dose of ARCT-2304 administered through intramuscular injection in the deltoid muscle.~Interventions: 2-dose regimen, schedule 2 Investigational Vaccine: ARCT-2304"
62826450|NCT06602531|EXPERIMENTAL|Mid dose of ARCT-2304, Schedule 2, Young Adults|"Mid dose of ARCT-2304 administered through intramuscular injection in the deltoid muscle.~Interventions: 2-dose regimen, schedule 2 Investigational Vaccine: ARCT-2304"
62826451|NCT06602531|EXPERIMENTAL|High dose of ARCT-2304, Schedule 2, Young Adults|"High dose of ARCT-2304 administered through intramuscular injection in the deltoid muscle.~Interventions: 2-dose regimen, schedule 2 Investigational Vaccine: ARCT-2304"
62826452|NCT06602531|ACTIVE_COMPARATOR|Control, Schedule 2, Young Adults|"Young Adults Control Vaccine (dose 1) and placebo (dose 2) administered through intramuscular injection in the deltoid muscle.~Interventions: 2-dose regimen, schedule 2 Investigational Vaccine: Comparator vaccine younger adult and saline placebo vaccine"
62826453|NCT06602531|EXPERIMENTAL|Low dose of ARCT-2304, Schedule 2, Older Adults|"Low dose of ARCT-2304 administered through intramuscular injection in the deltoid muscle.~Interventions: 2-dose regimen, schedule 2 Investigational Vaccine: ARCT-2304"
62826454|NCT06602531|EXPERIMENTAL|Mid dose of ARCT-2304, Schedule 2, Older Adults|"Mid dose of ARCT-2304 administered through intramuscular injection in the deltoid muscle.~Interventions: 2-dose regimen, schedule 2 Investigational Vaccine: ARCT-2304"
62826455|NCT06602531|EXPERIMENTAL|High dose of ARCT-2304, Schedule 2, Older Adults|"High dose of ARCT-2304 administered through intramuscular injection in the deltoid muscle.~Interventions: 2-dose regimen, schedule 2 Investigational Vaccine: ARCT-2304"
62826456|NCT06602531|ACTIVE_COMPARATOR|Control, Schedule 2, Older Adults|"Older Adults Control Vaccine (dose 1) and placebo (dose 2) administered through intramuscular injection in the deltoid muscle.~Interventions: 2-dose regimen, schedule 2 Investigational Vaccine: Comparator vaccine older adult and saline placebo vaccine"
62826457|NCT04298320|EXPERIMENTAL|SHR-1210 + AIN457|SHR-1210 was administered 200mg iv every 2 weeks in combination with AIN457 150mg or 300mg ih every 2 weeks
62826458|NCT04003467|EXPERIMENTAL|EBP05 1.5mg|subjects will be randomly assigned to receive 3 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
62826459|NCT04003467|EXPERIMENTAL|Placebo for EBP05 0.5mg (1, 2, 3 or 5)|subjects will be randomly assigned to receive 3 or 5 tablets of matching EBP05 placebo orally each day for 6 months
62826460|NCT04003467|EXPERIMENTAL|EBP05 2.5mg|subjects will be randomly assigned to receive 5 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
62826461|NCT04003467|EXPERIMENTAL|EBP05 0.5mg|subjects will be randomly assigned to receive 1 tablet of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
62826462|NCT04003467|EXPERIMENTAL|EBP05 1.0mg|subjects will be randomly assigned to receive 2 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
62826463|NCT06598904|EXPERIMENTAL|Group 1: single-note lavender essential oil|Aroma diffuser with single-note lavender essential oil.
62826464|NCT06598904|EXPERIMENTAL|Group 2: single-note orange essential oil|Aroma diffuser with single-note orange essential oil
62826465|NCT06598904|PLACEBO_COMPARATOR|Group 3: deionized water|Aroma diffuser with deionized water.
62826466|NCT05527977|NO_INTERVENTION|Baseline Period|Run-in non-incentivized period for all participants.
62247039|NCT04031820|ACTIVE_COMPARATOR|Dual Mobility cup|550 patients will receive a total hip arthroplasty with a dual mobility cup.
62247040|NCT02492477|EXPERIMENTAL|6 months|evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase
62247041|NCT02492477|EXPERIMENTAL|12 months|evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase
62437270|NCT05093777|EXPERIMENTAL|Intervention group|"Half of the study participants will be randomized to the intensive habilitation program the first year of program. The second year of program this group of participants will be offered habilitation as usual."
62603841|NCT01465633|ACTIVE_COMPARATOR|with iodine|
62044507|NCT03343223|EXPERIMENTAL|Intervention Group|"1. Public health personnel identify PrEP-eligible clients.~2. PrEP-eligible clients are given a list of PrEP providers in Iowa and a brochure with info on getting PrEP. Clients are referred to a PrEP navigator, who facilitates linkage to clients' choice of TelePrEP or to community PreP providers.~3. Public health clients choosing TelePrEP complete a video visit with the tele-pharmacist and obtain PrEP relevant lab tests.~4. PrEP medication is mailed to the client and follow up video visits and lab testing are performed.~5. Within 7 days of enrollment, the subject will complete a survey regarding PrEP beliefs (20 minutes).~6. 30 to 40 days after enrollment, the subject will complete a second survey with 4 questions about initiation of PrEP since study enrollment (10 minutes).~7. 6 months following enrollment, a study team member will obtain medical records for the subject from PrEP providers in Iowa to determine if the subject has initiated and been retained in PrEP."
62247042|NCT00376584|PLACEBO_COMPARATOR|Placebo → MK-0524A 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A Placebo for 5 days (drug holiday) followed by MK-0524A 2 g for the remainder of the study (7 days).
62247043|NCT00376584|ACTIVE_COMPARATOR|Placebo → Extended Release (ER)-Niacin 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A Placebo for 5 days (drug holiday) followed by ER-Niacin 2g for the remainder of the study (7 days)
62247044|NCT00376584|EXPERIMENTAL|MK-0524A 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A 2g for the remainder of the study (approximately 2 weeks).
62603842|NCT01465633|EXPERIMENTAL|without iodine|
62603843|NCT00606840|EXPERIMENTAL|1|One arm is a large changes group in which participants will be asked to make periodic large changes in their eating and activity, aimed at producing initial weight loss, in order to prevent weight gain over time.
62603844|NCT00606840|EXPERIMENTAL|2|The second arm is a small changes group in which participants will be asked to make small changes to their eating and activity and maintain these changes forever in order to prevent weight gain.
62603845|NCT01550016||Febrile Patients|Observation of patients with possible dengue fever in the early phase of disease
62826467|NCT05527977|EXPERIMENTAL|Incentivized Period|3 month period during which time clinicians will receive compensation incentives for their performance in the program to improve clinical documentation.
62826468|NCT05986955|EXPERIMENTAL|Specified Diet 1 - Microbial Diet|Participants provided with a typical Australian diet including all food groups as described by the Australian Guide to Healthy Eating without any dietary exclusions. Meals have been designed by researchers and dietitians and prepared by professional chefs.
62826469|NCT05986955|ACTIVE_COMPARATOR|Specified Diet 2 - Non-microbial Diet|Diet provided to participants is identical to Specified Diet 1 however after cooking and packaging, food for this arm will be sterilised by irradiation in line with International Organisation for Standardisation (ISO) standards and Australian code of good manufacturing practice.
62826470|NCT00730717|EXPERIMENTAL|1|Patients who are not concurrently receiving methotrexate treatment for pyoderma gangrenosum
62247045|NCT03912181||Familial chylomicronaemia syndrome (FCS)|"* Patient homozygous or compound heterozygous mutation in lipoprotein lipase (LPL) gene~* Patient homozygous or compound heterozygous mutation in any Apolipoprotein A5 (Apo A5), glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 (GPI HBP1), lipase maturation factor 1 (LMF1), Apolipoprotein C2 (ApoC2), genes and heterozygous (het) mutation in LPL gene"
62603846|NCT06648161|EXPERIMENTAL|Experiment|In the second stage of labor, the birth mirror will be used to allow the mother to see her own perineum.
62603847|NCT06648161|NO_INTERVENTION|Control|During the birth process, she will receive routine midwifery care and no intervention will be made.
62603848|NCT00929474|EXPERIMENTAL|QuickOpt|
62603849|NCT00929474|ACTIVE_COMPARATOR|Control|
62826471|NCT00730717|EXPERIMENTAL|2|Patients who are receiving concurrent methotrexate for pyoderma gangrenosum
62603850|NCT06500923||Ø2.9mm (Test)|Test patients have received a 2.9 Ø dental implant
62603851|NCT06500923||Ø3.3mm (Control)|Control patients have received a 3.3 Ø dental implant
62603852|NCT04561297|EXPERIMENTAL|Biopsied Patients|Patients scheduled for a breast biopsy will have breast tissue dielectric constant measurements made prior to the biopsy
62603853|NCT01897610|NO_INTERVENTION|control group|The study subjects randomly assigned to the control group is given Nexavar chemotherapy according to the clinical test plans.
62603854|NCT01897610|EXPERIMENTAL|Immuncell-LC group|The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after baseline by administering Nexavar chemotherapy same as control group with Immuncell-LC (10 times).
62826472|NCT05854368|OTHER|Patients with gastric lesion|"Patients with:~* Gastric epithelial dysplasia~* Glandular atrophy of the gastric mucosa~* Intestinal metaplasia of the gastric mucosa~* Proximal gastric adenocarcinoma~* Distal gastric adenocarcinoma"
62826473|NCT05854368|OTHER|Control|Healthy Volunteers
62826474|NCT04225585|EXPERIMENTAL|Coping Skills Training for Persistent Post-Surgical Pain|novel pain coping skills training intervention designed specifically for people with persistent pain (PP) following breast cancer surgery
62826475|NCT04225585|ACTIVE_COMPARATOR|General health education with a coach|general health education intervention
62247046|NCT03912181||Multifactorial chylomicronemia syndrome|"* Patient with heterozygous mutation in lipoprotein lipase (LPL) , Apolipoprotein A5 (Apo AV), GPI HBP1, LMF1, ApoC2 genes and any additional combination of functional variant~* Patient with any additional combination of functional variant in LPL gene Apo AV, glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 (GPI HBP1), lipase maturation factor 1 (LMF1), Apolipoprotein C2 (ApoC2) genes"
62603855|NCT01617772|EXPERIMENTAL|Atorvastatin|20mg atorvastatin daily
62603856|NCT01617772|EXPERIMENTAL|Carnitine|1000mg L-carnitine daily
62603857|NCT01617772|EXPERIMENTAL|Atoral|1000mg L-carnitine and 20mg atorvastatin
62603858|NCT01617772|PLACEBO_COMPARATOR|Placebo|Identically looking placebo
62603859|NCT01117675|OTHER|Arm I|Arm I: HIV-infected patients controlled through Virtual Hospital
62603860|NCT01117675|OTHER|Arm II|Arm II: HIV-infected patients controlled through Standard Care
62603861|NCT03248518|ACTIVE_COMPARATOR|Usual Care alone|Participants receive written information about fatigue which is designed as self-management guide.
62603862|NCT03248518|ACTIVE_COMPARATOR|CBA + usual care|In addition to usual care, participants receive a talking therapy using a cognitive behavioural approach. The talking therapy will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 8 sessions over a period of 6 months.
62826476|NCT04225585|ACTIVE_COMPARATOR|Self-guided health education|general health education intervention
62247047|NCT02442726|ACTIVE_COMPARATOR|Thermal Injury|A first degree heat injury is induced by a contact thermode (12.5 cm2; 47C; 420 s) applied at the skin at the lower leg. CO2-Laser stimulation (Laser Stimulation Device, SIFEC)
62247048|NCT02442726|SHAM_COMPARATOR|Sham Injury|"A sham injury is induced by a contact thermode (12.5 cm2; 38C; 420 s) applied at the skin at the lower leg. CO2-Laser stimulation (Laser Stimulation Device, SIFEC) is used to assess"
62603863|NCT03248518|ACTIVE_COMPARATOR|PEP + usual care|In addition to usual care, participants receive a personalised exercise programme. After an initial face-to-face assessment, the remaining programme will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 7 sessions over a period of 6 months.
62603864|NCT05500482|EXPERIMENTAL|Vaccinated arm|Typhoid Conjugate Vaccine (TyphiBEV) 0.5 ml as a single dose given intramuscularly to consenting, eligible residents of vaccine clusters
62603865|NCT05500482|NO_INTERVENTION|Control arm|No vaccination in the control clusters
62603866|NCT04676685|EXPERIMENTAL|Part A, Cohort 1: E2730 20 Milligram (mg) or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 20 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
62603867|NCT04676685|EXPERIMENTAL|Part A, Cohort 2: E2730 40 mg or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 40 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
62603868|NCT04676685|EXPERIMENTAL|Part A, Cohort 3: E2730 60 mg or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 60 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
62603869|NCT04676685|EXPERIMENTAL|Part A, Cohort 4: E2730 80 mg or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 80 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
62603870|NCT04676685|EXPERIMENTAL|Part B, E2730 80 mg: Fasted + Fed|Participants will receive a single treatment of E2730 (80 mg capsule) in fasted condition on Day 1 treatment period 1 followed by E2730 80 mg capsule in fed condition on Day 1 of treatment period 2. A washout period of at least 21 days will be maintained between the 2 treatments.
62826477|NCT06591221|EXPERIMENTAL|Chuna maintenance therapy group|This group will receive chuna therapy determined by the clinician based on the subject's symptoms, degree of improvement, etc. (1 time/2 weeks, total 20 weeks)
62603871|NCT04676685|EXPERIMENTAL|Part B, E2730 80 mg: Fed + Fasted|Participants will receive a single treatment of E2730 80 mg capsule in fed condition on Day 1 of treatment period 1 followed by E2730 80 mg capsule in fasted condition on Day 1 of treatment period 2. A washout period of at least 21 days will be maintained between the 2 treatments.
62603872|NCT03157739|EXPERIMENTAL|Evaluation of Optimized Prototype|Patients and parents will use MigraineManager to complete assessment measures at baseline and post-treatment (i.e., 2 months after baseline). Answers to these measures will determine what interventions each participant will receive. Data obtained in this phase will be used to make final modifications to MigraineManager for large scale testing.
62603873|NCT00585715|EXPERIMENTAL|Candela DCD with cooling|Laser treatment with Candela DCD cooling which produces a cryogenic fluid that cools the epidermis prior to each laser pulse. Treatment will be conducted on either the left or the right thigh, which will also be randomly determined. The contra-lateral side will not be treated and will serve as a control. The laser system to be used in is Candela GentleYAG, a 1064nm Nd:YAG laser. This arm will receive a coolant during the laser procedure.
62603874|NCT00585715|ACTIVE_COMPARATOR|Candela DCD without Cooling|Laser treatment without cooling before each laser pulse. Treatment will be conducted on either the left or the right thigh, which will also be randomly determined. The contra-lateral side will not be treated and will serve as a control. The laser system to be used in is Candela GentleYAG, a 1064nm Nd:YAG laser. This arm will not receive a coolant during the laser procedure.
62603875|NCT05447676|ACTIVE_COMPARATOR|Dalfampridine (4-AP)+STDP+training|The effects of the functional recovery of the lower-limb muscles will be determined after 10 sessions of 4-AP, STDP stimulation and training.
62826478|NCT06591221|OTHER|Lifestyle management & self-exercise group|This group will perform lifestyle management and daily self-exercise. The exercise education will be performed per 4 weeks for total 20 weeks.
62826479|NCT06589635|EXPERIMENTAL|ADC-189 and itraconazole|"Part 1: Single dose of ADC-189~Part 2: Itraconazole with single dose of ADC-189"
62826480|NCT01748747|EXPERIMENTAL|Arm I (MART-1 antigen, Gag:267-274 peptide vaccine)|Patients receive MART-1 antigen and Gag:267-274 peptide vaccine emulsified in Montanide ISA 51 VG SC on day 1.
62247049|NCT02709590|EXPERIMENTAL|Group A|oral diclofenac potassium plus lidocaine anesthetic cream placed into their cervix immediately before HSG
62247050|NCT02709590|PLACEBO_COMPARATOR|Group B|oral placebo tablets plus placebo cream placed into their cervix immediately before HSG
62437271|NCT05093777|OTHER|Control group|"Half of the study participants will be randomized to treatment as usual the first year of program, then offered the intensive program during the second year (stepped wedge design)."
62247051|NCT01701999|EXPERIMENTAL|Vaccine|
62247052|NCT04261504|EXPERIMENTAL|Integrative Body Mind Training (IBMT)|mindfulness
62247053|NCT04261504|ACTIVE_COMPARATOR|Relaxation Training (RT)|relaxation
62247054|NCT04048395||Follicular lymphoma arm|The analysis will involve patients diagnosed with follicular lymphoma who received induction chemotherapy and then experienced a worsening of disease within 24 months from the start date of the treatment.
62247055|NCT00125762|EXPERIMENTAL|Single Arm undergoing FibroScan|Single arm active comparison of biopsy to vibration controlled elastography
62437272|NCT03651661|ACTIVE_COMPARATOR|nasal insulin|160 U of human insulin as nasal spray
62437273|NCT03651661|PLACEBO_COMPARATOR|nasal placebo|placebo as nasal spray
62437274|NCT03417622|EXPERIMENTAL|Post-treatment volume-resection margin|Lumpectomy is performed with resection margin of the clinically / radiologically identifiable post-treatment tumor.
62437275|NCT03417622|ACTIVE_COMPARATOR|Pre-treatment volume-resection margin|Lumpectomy is performed with resection margin of the bracketed tissue.
62437276|NCT05515809|EXPERIMENTAL|interventional arm|the experimental arm will receive the parasternal block with injection of locoregional anesthesia
62437277|NCT05515809|ACTIVE_COMPARATOR|control arm not requiring loco-regional anesthesia.|the control arm will receive a standard treatment, without locoregional anesthesia
62437278|NCT06528587||narrow diameter implant|Patients who have performed computer-guided implant surgery for the rehabilitation of single edentulism in the anterior region with lack of adequate bone thickness or mesio-distal space using implants with narrow diameter.
62437279|NCT05079893||Cases|The cases will be the patients suffering from low back pain for at least three months and referred by an orthopedic doctor or general physician.
62437280|NCT05079893||Controls|The controls will be the patients matched for age, sex, handedness who had no complaints of lower back pain
62603876|NCT05447676|PLACEBO_COMPARATOR|Placebo+STDP+training|The effects of the functional recovery of the lower-limb muscles will be determined after 10 sessions of placebo drug, STDP stimulation and training.
62247056|NCT00911625|ACTIVE_COMPARATOR|0.5 units/kg|Participants randomized to this arm will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
62247057|NCT00911625|EXPERIMENTAL|0.25 units/kg|Participants randomized to this arm will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
62247058|NCT02290860|OTHER|Intervention|Type 2 diabetes diagnosis test.
62247059|NCT04915651|EXPERIMENTAL|Gallbladder Cryoablation|High-risk patients who undergo gallbladder cryoablation
62247060|NCT05859750|EXPERIMENTAL|AK104 6mg/kg and AG|
62247061|NCT05859750|EXPERIMENTAL|AK104 10mg/kg and AG|
62437281|NCT05802095|EXPERIMENTAL|Experimental group|The babies in the experimental group are fed 3 meals from the day after the decision to switch to oral feeding, with supplemental feeding tube device(SFTD) (09:00-12:00-15:00) and other meals with a bottle.
62437282|NCT05802095|NO_INTERVENTION|Control|The babies in the control group, on the other hand, will be fed 3 meals a day (09:00-12:00-15:00) after the decision to switch to oral feeding, which is the routine feeding method of the intensive care unit, and with a bottle for other meals in the same way.
62437283|NCT03641118||Lower gastrointestinal cancer|All lower gastrointestinal neoplasms including rectal
62437284|NCT03641118||Upper gastrointestinal cancer|All upper gastrointestinal neoplasms
62437285|NCT03641118||Hepatobiliary cancers|All liver, pancreas, biliary cancer
62437286|NCT06178679|EXPERIMENTAL|ST-100-002|ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Bilaterally twice daily for 7 weeks (49 days)
62437287|NCT06178679|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution Bilaterally twice daily for 7 weeks (49 days)
62437288|NCT04376723|EXPERIMENTAL|Assisted self-guidance|Participants will be asked to use the app for five weeks and will be contacted via telephone once a week by a researcher to provide a rationale for using the app, or to offer any information about the app itself. This will not be used to provide therapeutic intervention.
62437289|NCT01353924|ACTIVE_COMPARATOR|Bet v 1aF1 + Bet v 1aF2 -Alum|
62437290|NCT01353924|PLACEBO_COMPARATOR|Alum-Placebo|
62437291|NCT04050332|EXPERIMENTAL|Stair Walking|Participants in this arm will engage in four minutes of stair walking while being tracked by radio frequency identification equipment.
62437292|NCT04050332|NO_INTERVENTION|Control|Participants in this arm will stand in the stairwell for four minutes while being tracked by radio frequency identification equipment.
62603877|NCT05447676|EXPERIMENTAL|Dalfampridine (4-AP)+STDP+training for extended sessions|The long-term effects of the functional recovery of the lower-limb muscles will be determined after 40 sessions of 4-AP, STDP stimulation and training.
62603878|NCT01087580|EXPERIMENTAL|Chemotherapy alone, no radiation therapy|"A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days~B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel"
62603879|NCT01087580|EXPERIMENTAL|Chemotherapy with Radiation Therapy|"A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel~GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index \< 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week."
62603880|NCT00322361|EXPERIMENTAL|1|Modified Process Hepatitis B Vaccine
62603881|NCT00322361|ACTIVE_COMPARATOR|2|Recombivax HB™
62603882|NCT03449394|ACTIVE_COMPARATOR|Delusions (Tx)|
62603883|NCT03449394|NO_INTERVENTION|Delusions (TAU)|
62603884|NCT03449394|ACTIVE_COMPARATOR|Depression (Tx)|
62826481|NCT01748747|EXPERIMENTAL|Arm II (MART-1 antigen, resiquimod, Montanide ISA 51 VG)|Patients receive MART-1 antigen emulsified in Montanide ISA 51 VG SC followed by resiquimod applied topically on day 1.
62826482|NCT01748747|EXPERIMENTAL|Arm III (MART-1 antigen, Gag:267-274 peptide, resiquimod)|Patients receive MART-1 antigen and Gag:267-274 peptide vaccine peptide vaccine emulsified in Montanide ISA 51 VG SC followed by resiquimod applied topically on day 1.
62826483|NCT06592625|EXPERIMENTAL|SHR-A1811 plus Adebrelimab|
62826484|NCT02203396|EXPERIMENTAL|Severe Aplastic Anemia|Drug: rabbit ATG, Cyclosporine, Levamisole
62826485|NCT06604052|EXPERIMENTAL|Reduced-Port Fusion Surgery Group|Recive preoperative trocar/stoma fusion positioning and intraoperative trocar/stoma fusion surgery
62826486|NCT06604052|ACTIVE_COMPARATOR|Traditional surgery group|Recive traditional preoperative stoma positioning and traditional stoma surgery
62826487|NCT06503614|EXPERIMENTAL|Cohort A: Durvalumab and Monalizumab for CIS +/- high grade papillary urothelial cancer|Durvalumab 1500mg IV and monalizumab 1500mg IV will be administered to all patients once every 4 weeks. A cycle is equal to 4 weeks. This will continue until disease progression, unacceptable toxicity, or for a maximum of 1 year.
62603885|NCT03449394|NO_INTERVENTION|Depression (TAU)|
62603886|NCT03556293|ACTIVE_COMPARATOR|Technical Assistance (No ASR)|Technical Assistance (TA). Intervention: TA will be offered to the 4 teams randomized to the TA condition without automated surveillance reporting and will receive the AKI Prevention Toolkit plus monthly technical calls independently
62603887|NCT03556293|ACTIVE_COMPARATOR|Virtual Learning Collaborative (No ASR)|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams without automated surveillance reportingand will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator \[CAC\] and Systems Redesign).
62603888|NCT03556293|ACTIVE_COMPARATOR|Technical Assistance with ASR|Technical Assistance (TA). Intervention: TA will be offered to the 4 teams randomized to the TA condition with automated surveillance reporting (ASR) and will receive the AKI Prevention Toolkit plus monthly technical calls independently and monthly ASR dashboard.
62603889|NCT03556293|ACTIVE_COMPARATOR|Virtual Learning Collaborative with ASR|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams with automated surveillance reporting (ASR) and will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites with the and monthly ASR dashboard. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator \[CAC\] and Systems Redesign).
62826488|NCT06503614|EXPERIMENTAL|Cohort B: Durvalumab and Monalizumab for high grade papillary urothelial cancer without CIS|Durvalumab 1500mg IV and monalizumab 1500mg IV will be administered to all patients once every 4 weeks. A cycle is equal to 4 weeks. This will continue until disease progression, unacceptable toxicity, or for a maximum of 1 year.
62826489|NCT00919217||Relapsing-remitting multiple sclerosis|Females with relapsing-remitting multiple sclerosis
62826490|NCT03146585||Patients on artificial ventilation|
62826491|NCT03146585||Patients on renal replacement therapy|
62826492|NCT03146585||Patients with targeted temperature management|
62826493|NCT06053307|EXPERIMENTAL|Acceptance commitment therapy via a mobile-application|The arm will pilot a behavioral intervention to treat psychosocial distress in patients with glaucoma using acceptance commitment therapy (ACT) delivered via a mobile-application. The intervention will be developed and refined using qualitative feedback from glaucoma patients and healthcare stakeholders.
62826494|NCT05348538|EXPERIMENTAL|Medication review with follow up or MaJ? for the acronym in french|All the pharmacists accepting to participate in the study will perform the intervention.
62826495|NCT05187689|EXPERIMENTAL|Virtual reality and mental health literacy intervention|This arm will participate in an interactive virtual reality experience to learn and practice mental health literacy and psychological first aid skills, supplemented by mhealth SMS with informational bidirectional messages.
62247062|NCT05859750|EXPERIMENTAL|AK104 and mFOLFIRINOX|
62247063|NCT05859750|EXPERIMENTAL|AK104 and NALIRIFOX|
62247064|NCT01827579|EXPERIMENTAL|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10\^5 /kg at day 30 post-SCT, 3 x 10\^5 /kg at day 60 and 10\^6 /kg at day 90 post transplant
62247065|NCT01827579|NO_INTERVENTION|Control (normal HSCT)|Patients randomised to the control arm with undergo stem cell transplantation according to site local practice.
62044508|NCT03343223|NO_INTERVENTION|Control Group|"1. Public health personnel identify PrEP-eligible.~2. Public health personnel give PrEP-eligible clients a list of PrEP providers in Iowa, and a brochure with information on getting PrEP.~3. The client initiates contact with a PrEP provider in Iowa and schedules an appointment.~4. PrEP medication is mailed to the client and follow up video visits and lab testing are performed.~5. Within 7 days of enrollment, the subject will complete a survey regarding PrEP beliefs (20 minutes).~6. 30 to 40 days after enrollment, the subject will complete a second survey with 4 questions about initiation of PrEP since study enrollment (10 minutes).~7. 6 months following enrollment, a study team member will obtain medical records for the subject from PrEP providers in Iowa to determine if the subject has initiated and been retained in PrEP."
62044509|NCT02191553|ACTIVE_COMPARATOR|Control Group: Relaxation Techniques|Relaxation techniques which do not involve either formal or informal mindfulness training. Subjects in this group practice Jacobson's progressive muscular relaxation, emotional imagining and Schultz's autogenic training.
62437293|NCT04525742|OTHER|Parents who have a disabled child or children|Parents having disabled child or children will be included in the research and it will be wanted to complete the survey questionary
62437294|NCT03086239|EXPERIMENTAL|Part A: Rovalpituzumab tesirine|Part A Dose Escalation: Rovalpituzumab tesirine intravenous (IV) (various doses and dose regimens) on Day 1 of each 6-week cycle
62437295|NCT03086239|EXPERIMENTAL|Part B: Rovalpituzumab tesirine|Part B Dose Expansion: Rovalpituzumab tesirine dosed at regimen(s) previously demonstrated in Part A to not to exceed the maximum tolerated dose (MTD).
62437296|NCT01597895|ACTIVE_COMPARATOR|Maraviroc|
62437297|NCT01597895|EXPERIMENTAL|Maraviroc + Boceprevir|
62437298|NCT01597895|EXPERIMENTAL|Maraviroc + Telaprevir|
62437299|NCT02909725|EXPERIMENTAL|Limit accumulation of sedentary time|Group 1 (SR): Participants will be asked to limit the accumulation of prolonged bouts ( \>50 minutes) of sedentary time.
62437300|NCT02909725|EXPERIMENTAL|Walk 30 minutes most days of the week|Group 2 (WALK): Participants will be asked to walk 30 minutes per day on most days of the week.
62437301|NCT02909725|ACTIVE_COMPARATOR|Normal daily routine; Usual Care|Group 3 (UC): Participants will be asked to continue on with their normal daily routine. The usual care group will receive no form of intervention.
62437302|NCT02048254|EXPERIMENTAL|brachytherapy|Iodine-125 radioactive seeds permanent interstitial implantation brachytherapy
62437303|NCT02048254|ACTIVE_COMPARATOR|IMRT|IMRT (intensity-modulated radiation therapy), 6 Millivolt (MV)-x fractionated irradiation, 1 time/day, 5 times a week, till the end. Add up to 33 times.
62044510|NCT02191553|EXPERIMENTAL|Loving Kindness Meditation (Metta)|Loving-kindness meditation following Kristin Neff protocol
62044511|NCT02191553|EXPERIMENTAL|Body Scan|Body scan as described in standard MBSR protocol
62044512|NCT02191553|EXPERIMENTAL|Sitting Practice|Sitting practice as mindfulness meditation described in standard MBSR protocols.
62044513|NCT02579252|EXPERIMENTAL|AADvac1|"AADvac1 is a suspension for subcutaneous injection. AADvac1 is provided in single-use vials. Dosage: 40 µg Axon peptide 108 (coupled to keyhole limpet haemocyanin (KLH)) using aluminium hydroxide (containing 0.5 mg Al3+) as adjuvant, in a phosphate buffer.~Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses."
62437304|NCT04663880|EXPERIMENTAL|Asthmatic subjects allergic to house dust mite|24 subjects were randomized in a doubleblinded manner into six subgroups. All were exposed first to placebo then in cross over to three different Der p1 concentrations, respectively 15, 25, and 46 ng/m3.
62437305|NCT04663880|ACTIVE_COMPARATOR|Asthmatic subjects not allergic to house dust mite|13 subjects were exposed first to placebo then to Der p1 concentration of 25 ng/m3.
62437306|NCT04636749|ACTIVE_COMPARATOR|Erbium laser|Treatment with Erbium laser
62437307|NCT04636749|SHAM_COMPARATOR|Sham laser|Treatment with sham laser
62437308|NCT05548933||HP|Chronic periodontitis (stage III/IV) patients with hyperlipidemia
62437309|NCT05548933||CP|Chronic periodontitis(stage III/IV) patients without hyperlipidemia
62437310|NCT06529718|EXPERIMENTAL|Experimental|Experimental treatment under study
62437311|NCT06529718|ACTIVE_COMPARATOR|Control|Standard of care second-line treatment for advanced biliary tract cancer
62603890|NCT05595564|EXPERIMENTAL|Hypoxia|Participant developed running activity on a treadmill in hypoxic condition, submitted or not to photobiomodulation therapy.
62603891|NCT05595564|ACTIVE_COMPARATOR|Normoxia|Participant developed treadmill running activity in normoxic condition, submitted or not to photobiomodulation therapy.
62437312|NCT01901991|EXPERIMENTAL|Radioactive seed localization (RSL)|"Patients are randomised for preoperative lesion localization with either radioactive seed localization (RSL) or wire-guided localization (WGL).~In this arm 205 patients will have RSL performed. The radioactive seed is introduced through a gauge needle using standard ultrasound guidance. Once guided to the nonpalpable breast lesion, the seed is deployed into the breast tissue by advancing a stilette in the needle. The exact location is confirmed by mammography. The nonpalpable lesion is located during the operation with a handheld gamma probe, identical to the one used for the sentinel node procedure. The surgical specimen is orientated and examined at the Department of Radiology and Pathology in accordance with the existing guidelines of WGL."
62603892|NCT01627301|EXPERIMENTAL|Device-guided Breathing (DGB)|Participants randomized to the DGB group use a device to guide their breathing to a slow breathing rate.
62437313|NCT01901991|ACTIVE_COMPARATOR|Wire-guided localization (WGL)|"Patients are randomised for preoperative lesion localization with either radioactive seed localization (RSL) or wire-guided localization (WGL).~In this arm 205 patients will have WGL performed. Guided by ultrasound or mammography a flexible wire is introduced into the breast by the radiologist just before the operation. The tip of the wire must mark the nonpalpable lesion, and correct localization is verified by mammography. The surgeon uses the wire and mammography as a guide during the operation. The surgical specimen is orientated and examined at the Department of Radiology and Pathology in accordance with the existing guidelines of WGL."
62826496|NCT05187689|EXPERIMENTAL|Group Problem Management+ and VR/mental health literacy|This arm will participate in an interactive virtual reality experience to learn and practice mental health literacy and psychological first aid skills, supplemented by mhealth SMS with informational bidirectional messages. This arm will also participate in an 5-week Group Problem Management Plus intervention, a group based problem solving intervention.
62826497|NCT05187689|NO_INTERVENTION|Control|This is a waitlist control. After Arms 1 and 2 are complete, the waitlist will receive the Group Problem Management Plus 5 week intervention on its own.
62826498|NCT06211361|EXPERIMENTAL|Intervention|Participants will be included in a cardiac rehabilitation program.
62826499|NCT01887327|PLACEBO_COMPARATOR|Placebo|Participants receive placebo and phototherapy
62826500|NCT01887327|EXPERIMENTAL|Stannsoporfin 3.0 mg/kg|Participants receive stannsoporfin (3.0 mg/kg) and phototherapy
62044514|NCT02579252|PLACEBO_COMPARATOR|Placebo|Placebo is a suspension for subcutaneous injection. Placebo is provided in single-use vials. Dosage: aluminium hydroxide (containing 0.5 mg Al3+), in a phosphate buffer. Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses.
62044515|NCT02693275|OTHER|Quotient® System iPad Test|The Quotient® System iPad Test is a test specifically designed to provide clinicians with objective measures in ability to maintain seated stillness, sustained attention to a monotonous task and inhibiting incorrect impulsive responses. The attention task with motion analyses provides a number of objective measures for detailed assessment of the subject's movements and attentiveness.
62247066|NCT01979224|NO_INTERVENTION|treatment and routine counseling|Parents attend regular consultation and receive regular medical guidance
62437314|NCT02660385|EXPERIMENTAL|Cognitive Behavioral Therapy|Cognitive behavioral therapy for insomnia (CBT-I) will be provided in a group format, led by an interventionist. CBT-I includes strategies for modifying thoughts and behaviors about sleep. Participants will be instructed on and practice methods for modifying their thoughts and behaviors about sleep and insomnia. Participants will participate in four sessions, conducted every other week for 8 weeks. They will receive a call from the interventionist on intervening weeks.
62437315|NCT02660385|ACTIVE_COMPARATOR|Heart Failure Self-Management Education|Heart Failure Self-management education is an intervention that will be provided by a nurse in a group format. This includes standard components, such as education about fluid and sodium management, heart failure medications, diet and physical activity. Participants will participate in four sessions, conducted every other week for 8 weeks. They will receive a call from the interventionist on intervening weeks.
62437316|NCT01084603|EXPERIMENTAL|Oral Nicotine 1|One oral administration of 1 mg nicotine
62437317|NCT01084603|EXPERIMENTAL|Oral Nicotine 2|Two oral administrations of 1 mg nicotine
62437318|NCT01084603|EXPERIMENTAL|Oral Nicotine 4|Four oral administrations of 1 mg nicotine
62437319|NCT01084603|ACTIVE_COMPARATOR|NiQuitinTM Nicotine Lozenge 4 mg|One 4 mg marketed nicotine lozenge
62603893|NCT01627301|SHAM_COMPARATOR|Sham DGB|Participants randomized to the sham DGB group use a device identical to the DGB device but respiratory rates are not guided lower than the physiological rate.
62826501|NCT01887327|EXPERIMENTAL|Stannsoporfin 4.5 mg/kg|Participants receive stannsoporfin (4.5 mg/kg) and phototherapy
62247067|NCT03038750||EDNRA Sub-study|"Study population will be split into two groups defined by the allele of EDNRA the participant possesses:~Participants Homozygous for the A-allele of EDNRA, are assigned to the 'case' group.~Participants that are Homozygous for the G-allele will be assigned to the 'control' group.~20 participants will be recruited to each group, 40 in total."
62437320|NCT01084603|ACTIVE_COMPARATOR|Nicorette® Gum 4 mg|One marketed Nicorette® nicotine gum 4 mg chewed for 30 minutes
62437321|NCT00481247|EXPERIMENTAL|Dasatinib|
62437322|NCT00481247|ACTIVE_COMPARATOR|Imatinib|
62437323|NCT03000400|EXPERIMENTAL|Intervention group|Patient and family members receiving the 8 week family centered intervention, The Traumatic Brain Injury Family System Intervention.
62437324|NCT03000400|ACTIVE_COMPARATOR|Control group|Family members attend one ongoing psycho-educational group session provided by Oslo University Hospital (OUH).
62603894|NCT01627301|EXPERIMENTAL|Transcutaneous Vagal Nerve Stimulation (tVNS)|Participants randomized to use a tVNS device to deliver mild electrical stimulation to the vagal nerve.
62826502|NCT06593444|EXPERIMENTAL|Thalamic Ventral Intermediate-DBS group|Participants will undergo Thalamic Ventral Intermediate-DBS ON with the individual stimulation parameters determined in the parameter determination period, then continue to receive stimulation for the remainder of the study.
62826503|NCT01751529|EXPERIMENTAL|Contrast-enhanced Ultrasound|
62826504|NCT06589037|EXPERIMENTAL|experimental group|A group of 24 people receive shock waves along the leg to treat their plantar fasciitis.
62603895|NCT01627301|SHAM_COMPARATOR|Sham tVNS|Participants randomized to use the sham tVNS device which vibrates but does not stimulate the vagal nerve.
62603896|NCT00115037|EXPERIMENTAL|Phase 1 Liberal Response|From the start of baseline subjects were randomly assigned to this arm which defined relapse/non-responder as having 5 or heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.
62603897|NCT00115037|EXPERIMENTAL|Phase 1 Stringent Response|From the start of baseline subjects were randomly assigned to this arm which defined relapse/non-responder as having 2 or heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.
62603898|NCT00115037|EXPERIMENTAL|Phase 2 nalt and tele for responders|Phase 2: Naltrexone and telephone counseling for responders.
62603899|NCT00115037|EXPERIMENTAL|Phase 2 nalt, MM and CBI for NR|Phase 2: naltrexone, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR).
62603900|NCT00115037|PLACEBO_COMPARATOR|Phase 2 placebo, MM and CBI for NR|Phase 2: placebo, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR)
62603901|NCT00115037|EXPERIMENTAL|Phase 2 naltrexone for responders|Phase 2: Naltrexone and TAU for phase 1 responders.
62603902|NCT02163616|EXPERIMENTAL|PPH Treatment|800mcg sublingual misoprostol
62603903|NCT02268747|EXPERIMENTAL|Dacomitinib|"Patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade \<2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).~If the highest skin toxicity will be grade \>2, then the patient will interrupt the treatment following the criteria for dose reduction."
62603904|NCT03125187|EXPERIMENTAL|Sodium heparin UQ First|The participants will receive the Sodium heparin UQ intravenous drug administration at first period and the Sodium heparin FK intravenous drug administration at second period
62603905|NCT03125187|EXPERIMENTAL|Sodium Heparin FK First|The participants will receive the Sodium heparin FK intravenous drug administration at first period and the Sodium heparin UQ intravenous drug administration at second period
62603906|NCT02212548|EXPERIMENTAL|Hydrogel|The patient will be in the dorsal lithotomy position and prepared and draped. A transrectal ultrasound (TRUS) will be used for alignment of the needle and to ensure safe delivery. The hydrogel precursor and accelerator solutions will be mixed and connected to the Y connector that has been flushed with saline and to a syringe holder that ensures both syringe barrels are injected at the same time. After aspirating to ensure the tip of the needle is not intravascular, the perirectal space will be adequately dissected from the apex to midgland by injecting saline into the space between denonvilliers fascia and the anterior rectal space under TRUS guidance. Maintaining the needle position and angulation, the saline syringe is disconnected and the hydrogel system connected. After aspirating to ensure the needle tip is not in a blood vessel and under TRUS guidance, the 'PEG Hydrogel (SpaceOAR) is injected in a smooth, continuous technique.
62603907|NCT00334802|EXPERIMENTAL|A|
62603908|NCT04893356||Dacarbazine treated sarcoma patients|"Approximately 75 patients with histological diagnosis of Leiomyosarcoma (SCL) and Solitary Fibrous Tumor(SFT), previously treated with dacarbazine alone or associated with anthracyclines, will be enrolled, diagnosed from 2010 to 2020.~From formalin fixed tumor samples, DNA will be extracted and MGMT expression and MGMT promoter methylation analyzed."
62603909|NCT02870842|PLACEBO_COMPARATOR|Control|Perform recruitment maneuver with fraction of inspired oxygen (FiO2) of 1.0 after intubation under lung ultrasound guidance and maintain FiO2 of 0.6 during the general anesthesia.
62603910|NCT02870842|ACTIVE_COMPARATOR|Low FiO2|Perform recruitment maneuver with low FiO2 of 0.3 after intubation under lung ultrasound guidance and maintain FiO2 of 0.3 during the general anesthesia.
62603911|NCT06090617||PA group 1|"conclusive diagnosis of unilateral PA by the four corners criteria:~1. Biochemical evidence of PA~2. Lateralization of aldosterone secretion at adrenal venous sampling.~3. Correction of biochemical values and fall of blood pressure after adrenalectomy.~4. Immunohistochemical demonstration of CYP11B2 positive nodule(s)"
62247068|NCT03038750||PNPLA3 Sub-study|"Study population will be split into two groups defined by the allele of PNPLA3 the participant possesses:~Participants Homozygous for the G-allele of PNPLA3, are assigned to the 'case' group.~Participants that are Homozygous for the C-allele of PNPLA3 will be assigned to the 'control' group.~60 participants will be recruited to each group, 120 in total."
62603912|NCT06090617||PA group 2|Presumed diagnosis of bilateral PA, defined as above but without evidence of lateralized aldosterone excess.
62603913|NCT06090617||PH Group|Primary (essential) Hypertension (PH): conclusively ascertained high blood pressure and exclusion of secondary hypertension
62603914|NCT06090617||Non Hypertensive Control Group|comprising patients submitted to surgery but free of hypertension
62603915|NCT02903524|ACTIVE_COMPARATOR|control group|Pirarubicin combination with cyclophosphamide,4 cycles (each cycle is 21days) of chemotherapy
62603916|NCT02903524|EXPERIMENTAL|Experimental group|Doxorubicin Hydrochloride Liposome Injection combination with cyclophosphamide, 4 cycles (each cycle is 21 days) of chemotherapy
62603917|NCT00969956||Group A|150 Type 1 Diabetes, duration of 15 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 2 years (+/- 2 years) (50% women / men)
62603918|NCT00969956||Group B|150 Type 1 Diabetes, duration of 20 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 7 years (+/- 2 years) (50% women / men)
62603919|NCT00969956||Group C|150 Type 1 Diabetes, duration of 25 years (+/- 2 years) and 150 Type 2 Diabetes duration of 12 years (+/- 2 years) (50% women / men)
62044516|NCT05189366|EXPERIMENTAL|Experimental arm : Speech therapy + Sophrology|"In the experimental arm, patients will receive 6 sessions of sophrology. The sessions are individual and last approximately 50 minutes.~In addition to the sophrology sessions, patients will benefit from two speech therapy sessions per week for 6 months, lasting from 30 minutes to 1 hour depending on the patient's general condition."
62044517|NCT05189366|ACTIVE_COMPARATOR|Control arm : Speech therapy|Patients will benefit from two speech therapy sessions per week for 6 months, lasting from 30 minutes to 1 hour depending on the patient's general condition.
62247069|NCT03038750||PROCR Sub-study|"Study population will be split into two groups defined by the allele of PROCR the participant possesses:~Participants Homozygous for the G-allele of PROCR, are assigned to the 'case' group.~Participants that are Homozygous for the A-allele of PROCR will be assigned to the 'control' group.~30 participants will be recruited to each group, 60 in total."
62247070|NCT04587011|EXPERIMENTAL|T1|Tegoprazan A mg or placebo
62603920|NCT00969956||Group D|50 LADA (Late Autoimmune Diabetes in Adults), debut after 35 years of age, duration of 5-10 years (50% women / men)
62603921|NCT03008993|EXPERIMENTAL|Post-Intervention|The HQIS comprises three phases: 1) clinician training - to improve communication-relational skills and to instruct on the project; 2) center support - 4 on site visits by experts of the project team, aimed to introduce the project and boost motivation, instruct staff on how to implement recommendations, help with context analysis and identification of solutions; assess actual implementation in the center; 3) implementation of EBM recommendations.
62603922|NCT03008993|NO_INTERVENTION|Control|
62826505|NCT06589037|ACTIVE_COMPARATOR|Control group|A group of 24 people receive shock waves on the sole of the foot to treat their plantar fasciitis
62826506|NCT06058923|ACTIVE_COMPARATOR|Minimally Invasive Surgical Technique (MIST)|Double flap minimally invasive surgery for the access of intrabony defects
62826507|NCT06058923|EXPERIMENTAL|Modified Minimally Invasive Surgical Technique (M-MIST)|Single flap minimally invasive surgery for the access of intrabony defects
62826508|NCT06655675|EXPERIMENTAL|Ultrasound - patients without hypertensive disorders of pregnancy|Ultrasound will be used to measure velocimetric index of the umbilical artery.
62826509|NCT06655675|EXPERIMENTAL|Ultrasound - patients with diagnosed hypertensive disorders of pregnancy|Ultrasound will be used to measure velocimetric index of the umbilical artery.
62826510|NCT06596876|EXPERIMENTAL|HRG2010 and Sustained-release Carbidopa/Levodopa administered placebo|
62826511|NCT06596876|ACTIVE_COMPARATOR|Sustained-release Carbidopa/Levodopa and HRG2010 placebo|
62826512|NCT06598215|ACTIVE_COMPARATOR|group A hybrid Duckett urethroplasty|
62826513|NCT06598215|ACTIVE_COMPARATOR|group B modified Duckett urethroplasty|
62826514|NCT00523510|EXPERIMENTAL|Feasibility Study|HIV positive women \[and a smaller number of HIV negative/unknown status (1 for every 3 infected women)\] to avoid stigmatizing home-based counseling will be recruited at 1-2 postpartum and provided enhanced home-based infant feeding counseling by community health workers to exclusively breastfeed for 6 months. Mothers will also be told about the option to Flash-heat breastmilk during and after the transition from exclusive breastfeeding. Mothers who choose to Flash-heat will be provided continued home-based counseling and support. Feasibility data will be collected during the time mothers Flash-heat.
62044518|NCT03362567|EXPERIMENTAL|SNAGS Group|Subjects in SNAGS group were treated with application of sustained natural apophyseal glides, twice weekly for six weeks
62247071|NCT04587011|EXPERIMENTAL|T2|Tegoprazan B mg or placebo
62247072|NCT04587011|EXPERIMENTAL|T3|Tegoprazan C mg or placebo
62247073|NCT04587011|EXPERIMENTAL|T4|Tegoprazan D mg or placebo
62826515|NCT00523510|EXPERIMENTAL|Pilot efficacy|We will collect infant health data to monitor and compare health outcomes among 3 groups of infants who had exclusive breast feeding (EBF) for the first months and then either: 1) fed Flash-heated breast milk and complementary foods (n=30), or 2) weaned to replacement foods and NO breast milk (n=15; per standard WHO recommendation for rapid cessation), or 3) continued feeding at the breast and providing other foods and/or fluids, i.e. mixed feeds (n=15; per WHO consensus that breastfeeding continue if replacement feeding is not AFASS94). We will collect infant growth and morbidity data. Infant health outcomes will be compared for the 3 groups noted above. These data will be collected primarily to pilot an efficacy trial.
62826516|NCT02589938|ACTIVE_COMPARATOR|Standard Oral Hygiene|All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.
62247074|NCT06343428||NET G3 patients|Histological diagnosis of well-differentiated neuroendocrine tumor G3 performed or reviewed by a NEN-dedicated pathologist.
62603923|NCT03415659|EXPERIMENTAL|HWH340 monotherapy|HWH340 tablet, oral administration
62603924|NCT03838406|EXPERIMENTAL|BRCA1 positive|"FOLFOX or CAPOX Chemotherapy~FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
62603925|NCT03838406|ACTIVE_COMPARATOR|BRCA1 negative|"FOLFOX or CAPOX Chemotherapy~FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + 5-FU 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
62603926|NCT05463900||Ulcerative Colitis (UC)|Individuals with an ICD-10 diagnosis of Ulcerative Colitis.
62603927|NCT05463900||Crohn's Disease (CD)|Individuals with an ICD-10 diagnosis of Crohn's Disease.
62603928|NCT03957811|NO_INTERVENTION|Controls|Subjects under treatment for diabetes will receive the standard treatment for their condition.
62603929|NCT03957811|EXPERIMENTAL|Intervention|Subjects under treatment for diabetes not diagnosed for diabetic foot will receive the standard treatment plus exercise on a vibrator platform for a period of 12 weeks.
62603930|NCT04954716|EXPERIMENTAL|Deep Neck Flexor Massage|INTERVENTIONAL GROUP(DEEP Neck FLEXOR MASSAGE)
62603931|NCT04954716|ACTIVE_COMPARATOR|Post-Isometric Relaxation Technique|CONTROL GROUP (POST-ISOMETRIC RELAXATION TECHNIQUE)
62603932|NCT00847392|EXPERIMENTAL|Ultrasound|Bladder ultrasound prior to catheterization
62603933|NCT00847392|NO_INTERVENTION|Standard catheterization|No ultrasound prior to bladder catheterization
62603934|NCT01498224|ACTIVE_COMPARATOR|Suture|Suture application
62603935|NCT01498224|EXPERIMENTAL|ReSure Sealant|Sealant application
62603936|NCT05192408|EXPERIMENTAL|Multi-component intervention|"Individual intervention will comprise:~1. Cognitive- behavioral therapy (CBT) which includes: - Behavioural activation, cognitive restructuring, promotion of safety, relaxation techniques~2. Exercise recommendation utilizing current Exercise in older adults Patient Education Materials (PEMs) and videos, tailored based on frailty level and readiness to progress - Components include balance and strength~3. Use of motivational interviewing (MI) techniques for goal setting~There will be 4 sessions in total. Initial sessions will be carried out face to face or via videoconferencing platform if participant prefers due to ongoing COVID-19 pandemic. Subsequent sessions will be carried out via telephone.~Initial sessions will last around 30 minutes and subsequent sessions will last 15 to 30 minutes."
62603937|NCT05192408|OTHER|Usual Care|"Patient Education Materials (PEMs) on:~1. Exercise in older adults (Stay Active, Stay Strong and Stay Steady) - 3 different levels tailored to frailty level and for progression~2. Falls prevention~3. FoF"
62603938|NCT05081557||Participants Receiving Upadacitinib|Participants receiving upadacitinib for atopic dermatitis.
62603939|NCT02707588|EXPERIMENTAL|Pembrolizumab and radiotherapy|200 mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy
62603940|NCT02707588|ACTIVE_COMPARATOR|Cetuximab and radiotherapy|Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.
62044519|NCT03362567|EXPERIMENTAL|MCT Group|subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks
62247075|NCT00918047|EXPERIMENTAL|SPN-804O 150mg/Day|Subjects who weighed 15.0 to 29.9 kg dosed with SPN-804O 150mg/Day
62044520|NCT03594565|EXPERIMENTAL|Local steroids prior to CGMS insertion|"topical spraying of fluticasone propionate nasal spray (nsFP) on the skin area of CGMS placement prior to sensor insertion in a group of pediatric T1D patients who had mild to severe local skin reactions to CGMS adhesives.~Dosage: 2 puffs."
62247076|NCT00918047|EXPERIMENTAL|SPN-8040 300mg/Day|Subjects who weighed 30.0 to 44.9 kg dosed with SPN-8040 300mg/Day
62603941|NCT05074446|EXPERIMENTAL|intensivist in the experimental group|Stereotype threat manipulation will be performed on the intensivist in the experimental group just before they are taken into the testing room.
62603942|NCT05074446|NO_INTERVENTION|intensivist in the control group|The intensivist in the control group will not be given any prior information.
62603943|NCT05074446|EXPERIMENTAL|non-intensivist in the experimental group|Stereotype threat manipulation will be performed on the non-intensivist in the experimental group just before they are taken into the testing room.
62603944|NCT05074446|NO_INTERVENTION|non-intensivist in the control group|The non-intensivist in the control group will not be given any prior information.
62603945|NCT03675295|ACTIVE_COMPARATOR|Comparator: Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
62603946|NCT03675295|ACTIVE_COMPARATOR|Saline|Injection 10 cc saline injection as a median nerve hydro-dissection
62603947|NCT05572177|EXPERIMENTAL|Asthma SMART|Subjects randomized to the intervention arm will be provided with the app to download to their personal iPhone or Android smartphone. Subjects will be asked to use the app every day for 6 months.
62603948|NCT05572177|NO_INTERVENTION|Standard of care|Subjects randomized to the standard-of-care arm will continue to receive regular care for their condition.
62603949|NCT04709705|EXPERIMENTAL|Cryopreserved platelets|Cryopreserved platelets to be given intraoperatively or post operatively up to 3 units post-heparin reversal
62603950|NCT04709705|ACTIVE_COMPARATOR|Liquid stored platelets|Liquid stored platelets to be given intraoperatively or post operatively up to 3 units post-heparin reversal
62603951|NCT06107270|EXPERIMENTAL|Group A|(n=15) will be treated by Post Isometric Relaxation, infrared radiation and continuous ultrasound for 12 sessions (3 sessions per week for four weeks).
62603952|NCT06107270|EXPERIMENTAL|Group B|(n=15) will be treated by DNF training, infrared radiation and continuous ultrasound for 12 sessions (3 sessions per week for four weeks)
62247077|NCT00918047|EXPERIMENTAL|SPN-8040 450mg/Day|Subjects who weighed 45.0 to 59.9 kg dosed with SPN-8040 450mg/Day
62247078|NCT00918047|EXPERIMENTAL|SPN-8040 600mg/Day|Subjects who weighed 60.0 kg and above dosed with SPN-8040 600mg/Day
62603953|NCT06107270|EXPERIMENTAL|Group C|(n=15) will be treated by Post Isometric Relaxation combined DNF training, infrared radiation and continuous ultrasound for 12 sessions (3 sessions per week for four weeks)
62603954|NCT04543721||24-h-ABPM|
62437325|NCT03392090|EXPERIMENTAL|More Good Days video&brief questionnaire|"* Participants will watch the More Good Days video and will be given a brief questionnaire and wallet card to help identify their goals and preferences about information and care~* The More Good Days video is developed to help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments.~* The 3-page brief questionnaire is designed to help patients identify their preferences about information and care and to help encourage a conversation between patients and their doctors and health care team about their goals and preferences~* The wallet card will help patients think about questions they may want to ask their providers when considering treatments."
62437326|NCT01605461|EXPERIMENTAL|BI 207127 NA|Single oral solution dose of BI 207127 NA combined with \[14C\]-BI 207127 NA
62437327|NCT04379661|EXPERIMENTAL|Online support group|Online weekly 1-hour moderated support group sessions for 12-weeks; participants complete surveys at baseline and 12-week follow-up
62603955|NCT03089671|EXPERIMENTAL|Vitamin B|Vitamin B: Patients in this arm will receive 100mg of riboflavin (vitamin B2) 60 to 120 minutes prior to surgery for the purpose of turning the urine bright yellow to see if this helps with detection of ureteric jets during cystoscopy which will be done using normal saline.
62603956|NCT03089671|ACTIVE_COMPARATOR|D5W (5% dextrose in water)|5% Dextrose in Water: Patients in this arm will receive a placebo in the pre-operative area (for the purpose of blinding the surgical team) 60 to 120 minutes prior to surgery. Intraoperative cystoscopy will then be performed using D5W to see if this helps with detection of ureteric jets.
62603957|NCT00715104|EXPERIMENTAL|Sipuleucel-T with Booster|Subjects were to receive 3 infusions of sipuleucel-T 12 weeks prior to RP, and then an additional booster infusion 13 weeks following RP.
62826517|NCT02589938|EXPERIMENTAL|Standard Oral Hygiene + True Acupuncture|"All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.~The True acupuncture points will be at 3 sites on each ear, a site on the chin, on each forearm, a site on each hand, a site on each leg, and one placebo needle for a total of 14 sites. All sites will be applied for 20 minutes."
62437328|NCT04379661|NO_INTERVENTION|Treatment as usual|Inactive control group of participants who complete surveys at baseline and 12-weeks later
62437329|NCT06401200|ACTIVE_COMPARATOR|group 1: milled cobalt chromium bar|10 completely edentulous patients received two implants at canine region bilaterally (3.7mm diameter- 13mm length), within two weeks after surgery (following early loading protocol), an open tray impression technique was made for bar construction which was designed according to randomization patient enrollment
62437330|NCT06401200|EXPERIMENTAL|group 2: Selective laser melted cobalt chromium bar|10 completely edentulous patients received two implants at canine region bilaterally (3.7mm diameter- 13mm length), within two weeks after surgery (following early loading protocol), an open tray impression technique was made for bar construction which was designed according to randomization patient enrollment
62437331|NCT05986071|EXPERIMENTAL|study arm|administration of M1774 in combination with fulvestrant
62603958|NCT00715104|EXPERIMENTAL|Sipuleucel-T without Booster|Subjects were to receive 3 infusions of sipuleucel-T 12 weeks prior to RP, with no further sipuleucel-T treatment.
62603959|NCT03247764||patients with the comorbidity of epilepsy and depression|the clinical data, psychological assessment, and drug treatments will be investigated in patients with the comorbidity of epilepsy and depression
62603960|NCT02089100|EXPERIMENTAL|stereotactic body radiation therapy|The SBRT of all metastases should start in maximum 4 weeks after randomization. Beginning of systemic treatment will take place before 2 and 7 days after SBRT completion. All metastases lesions should be treated every 48h.
62603961|NCT02089100|ACTIVE_COMPARATOR|no specific treatment|no specific treatment to the oligometastatic sites except for palliation (pain, compression, hemorrhage)
62603962|NCT01366859|EXPERIMENTAL|Whey Protein (Immunocal®)|The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
62603963|NCT01366859|PLACEBO_COMPARATOR|Placebo: Rice Protein|The control or placebo study arm will consist of thirty children who will receive a dose of 0.5 g/kg of weight a day up to 18 kg of weight a day or a dose of 10 g/day for those over 18 kg for three months.
62437332|NCT02741271|EXPERIMENTAL|MF/F MDI 100/10 mcg BID|Eligible participants will be assigned randomly to receive double-blinded MF/F MDI 100/10 mcg BID for 24 weeks.
62437333|NCT02741271|ACTIVE_COMPARATOR|MF MDI 100 mcg BID|Eligible participants will be assigned randomly to receive double-blinded MF MDI 100 mcg BID for 24 weeks.
62437334|NCT02189876|EXPERIMENTAL|FemAALES|Females of African American Legacy Empowering Self Intervention. A nine session, theoretically grounded small group intervention.
62437335|NCT02189876|ACTIVE_COMPARATOR|Standard of Care|A one-time STD/family planning testing and counseling session provided to all study participants.
62437336|NCT05023954||A|A longitudinal observational study looking at the pregnancy journey of 200 women Bloods taken for sepsis biomarkers including a genomic sepsis-test throughout the pregnancy journey
62437337|NCT05023954||B|A consecutive collection of data from 100 pregnant women with suspected sepsis Bloods taken for Sepsis Biomarkers including a genomic sepsis-test throughout the sepsis episode
62437338|NCT01879800|NO_INTERVENTION|Treatment As Usual/Waitlist|Treatment As Usual/Waitlist
62603964|NCT02666898|EXPERIMENTAL|Obinutuzumab and Ibrutinib CLL treatment|"3 parts~PART 1: 6 cycles of GA101 + Ibrutinib 420mg PO/ 28 days:~GA101:~C 1 D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v C 2 to 6 :D1 1000 mg i.v~Ibrutinib:~D3 Month 1 to Day 30 Month 15: 420mg daily PO~PART 2: 4 cycles / 28 days~After evaluation at D1 month 9:~* patients in CR with BM MRD \< 10-4, Ibrutinib 420mg daily~* patients with BM MRD \>10-4 or PR 4 courses of GA101 + FC/ 28-day + Ibrutinib PO until M16 Cycle 1 to 4 - GA101: 1000 mg i.v on day 1~* Fludarabine : 40 mg/m² per os, days 2-4, / 28 days~* Cyclophosphamide : 250 mg/m² per os, days 2-4, / 28 days~* Ibrutinib 420mg/day PO~PART 3 (only in GAI-FC+Ibru arm) :~After evaluation at D1 of M16:~* patients CR with BM MRD\< 10-4, treatment stopped~* patients CR with BM MRD \>10-4, Ibrutinib continued until PD or PB MRD becomes negative."
62603965|NCT00642109|OTHER|TVT|Tension-free Vaginal Tape (TVT)
62603966|NCT00642109|OTHER|TOT|Transobturator Tape outside-in (TOT Monarc)
62603967|NCT00642109|OTHER|TVT-O|Transobturator Tape inside-out (TVT-O)
62437339|NCT01879800|EXPERIMENTAL|Acceptance and Commitment Therapy plus Illness Management|Acceptance and Commitment Training plus Illness Management (ACT-IM) Patients in the ACT-IM group will attend a 1-day group workshop. Three broad areas will be covered: 1) Illness Management will cover the importance of physical and psychological self-care for the management of co-morbid depression/anxiety and vascular problems 2) Behavioral Change Training will involve i) teaching patients how to recognize ineffective patterns of behavior and habits, ii) exploring and setting life goals and those related to mental and physical health, and iii) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 3) Mindfulness and Acceptance Training will emphasize new ways of managing troubling thoughts, feelings, and physical sensations .
62437340|NCT00698178||NERD|patients with typical gastro-reflux symptoms but no erosions were discernible on upper gastrointestinal endoscopy
62437341|NCT00698178||EE|Patients with both typical gastroesophageal reflux symptoms and characteristic flam-like erosions as demonstrated on upper gastrointestinal endoscopy
62437342|NCT00698178||FD|Patients report no typical reflux symptoms but fulfill diagnostic criteria of functional dyspepsia, whose upper gastrointestinal endoscopy are negative.
62826518|NCT02589938|OTHER|Standard Oral Hygiene + Sham Acupuncture|"All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.~The Sham acupuncture points will be given according to the same schedule as the active acupuncture points, except the Sham needles will be placed below, above or between true active points."
62826519|NCT06597214|EXPERIMENTAL|AVACore Technologies, Inc. warmUP Sleeve|AVAcore Technologies's warmUP (WU-20) Temperature Management System was developed based on work with the Aquarius Medical Acrotherm device and prior human hypothermic subject data showing a rewarming rate of \~1ºC in 5 minutes when heat and vacuum application was tested. AVAcore Technologies received FDA acceptance of its Section 510(k) premarket notification for the warmUP (vH1) Temperature Management System in 2005. This product was used on over 100 patients in the US in 2005-2006 timeframe.
62437343|NCT01612156|ACTIVE_COMPARATOR|2% lidocaine gel|Subjects in this arm will have all urethral catheters and urethral cotton tipped swabs prepared with 2% lidocaine gel before use in the examination.
62826520|NCT03011320|EXPERIMENTAL|Cohort 1|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) \[20 to 25 millicuries (mCi)\] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 4 mg/m2 EC1456 at \<8 hours prior to surgery"
62826521|NCT03011320|EXPERIMENTAL|Cohort 2|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) \[20 to 25 millicuries (mCi)\] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 4 mg/m2 EC1456 at 48±4 hours prior to surgery"
62437344|NCT01612156|ACTIVE_COMPARATOR|water based lubricant|Subjects in this arm will have all urethral catheters and urethral cotton tipped swabs prepared wtih water based lubricant before use in the pelvic floor examination.
62437345|NCT01352247|EXPERIMENTAL|Unicompartmental Knee Replacement|"TOPKAT will be pragmatic in terms of implant selection for the knee replacement operation. Providing the inclusion criteria are met, surgeons will be entirely free to use an implant of their choice or will use the current implants used at their institution. Implant type used on each patient will be recorded.~A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure."
62603968|NCT03244618|EXPERIMENTAL|CSSP Toothpaste|Toothpaste containing Calcium Silicate and Sodium Phosphate
62603969|NCT03244618|PLACEBO_COMPARATOR|Fluoride Toothpaste|Toothpaste containing Sodium monofluorphosphate
62603970|NCT01625208|EXPERIMENTAL|Combined nerve block|Participants in this group will receive a supraclavicular brachial plexus block plus a median or ulnar nerve block.
62603971|NCT01625208|ACTIVE_COMPARATOR|Single nerve block|Participants in this group will receive a supraclavicular brachial plexus block only.
62437346|NCT01352247|EXPERIMENTAL|Total Knee Replacement|"TOPKAT will be pragmatic in terms of implant selection for the knee replacement operation. Providing the inclusion criteria are met, surgeons will be entirely free to use an implant of their choice or will use the current implants used at their institution. Implant type used on each patient will be recorded.~A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position."
62437347|NCT06458725|OTHER|Volunteers|Single arm of volunteers.
62437348|NCT06047158||Fish oil group|"The patients in this group were treated with omega-3 fish oil fat emulsion at a dose of 100ml/ per person per day for 5 days and added to a three-liter bag (containing water, glucose, amino acids, sodium chloride, vitamins, etc.) except fish oil.~Drug introduction:~Full name: omega-3 fish oil fat emulsion. Common name: Juventus. Specification: 100ml / 10g"
62437349|NCT06047158||Non-fish oil group|Do not use omega-3 fish oil fat emulsion (no omega-3 fish oil fat emulsion is added to the three-liter bag, other substances are the same)
62437350|NCT01097161|EXPERIMENTAL|Speech treatment on prosodic basis|Patients receive 20 therapy sessions over a course of 3 months, with one double session per week.
62603972|NCT04331067|ACTIVE_COMPARATOR|Arm A: Neoadjuvant chemo + nivolumab|-Neoadjuvant chemotherapy consists of paclitaxel and carboplatin. Paclitaxel will be given intravenously (IV) at a dose of 80 mg/m\^2 on a weekly basis for 12 weeks. Carboplatin will be given IV at a dose of AUC 5 every 3 weeks for 12 weeks. Nivolumab will be given IV at a dose of 240 mg every 2 weeks for 12 weeks. Nivolumab will be administered first, followed by carboplatin, followed by paclitaxel.
62603973|NCT04331067|EXPERIMENTAL|Arm B: Neoadjuvant chemo + nivolumab + cabiralizumab|"As of Amendment #7 IRB approved 10/13/2022: The study will no longer enroll to Arm B. Cabiralizumab will no longer be given.~* Neoadjuvant chemotherapy consists of paclitaxel and carboplatin. Paclitaxel will be given intravenously (IV) at a dose of 80 mg/m\^2 on a weekly basis for 12 weeks. Carboplatin will be given IV at a dose of AUC 5 every 3 weeks for 12 weeks. Nivolumab will be given IV at a dose of 240 mg every 2 weeks for 12 weeks. Nivolumab will be administered first, followed by carboplatin, followed by paclitaxel.~* Cabiralizumab will be given IV at a dose of 4 mg/kg every 2 weeks for 12 weeks."
62826522|NCT03011320|EXPERIMENTAL|Cohort 3|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) \[20 to 25 millicuries (mCi)\] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 8 mg/m2 EC1456 at \<8 hours prior to surgery"
62826523|NCT03011320|EXPERIMENTAL|Cohort 4|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) \[20 to 25 millicuries (mCi)\] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 8 mg/m2 EC1456 at 48±4 hours prior to surgery"
62826524|NCT00000385|EXPERIMENTAL|1|Lithium 600 mg to 2700 mg per day
62826525|NCT00000385|PLACEBO_COMPARATOR|2|Matching placebo
62826526|NCT06413992|EXPERIMENTAL|Camrelizumab with Fluzoparib as maintainance therapy|"The treatment period mainly includes:~1. Injection of Paclitaxel (Albumin-bound) at a dose of 260mg/m\^2 administered intravenously every 3 weeks as one treatment cycle, for 6 cycles.~2. Injection of Carboplatin (AUC=5) administered intravenously every 3 weeks as one treatment cycle, for 6 cycles.~3. Injection of Camrelizumab at a dose of 200mg administered intravenously every 3 weeks as one treatment cycle, for 6 cycles.~4. Radiation therapy: Not mandatory.~Maintainance therapy period mainly includes:~1. Injection of Camrelizumab at a dose of 200mg administered intravenously every 3 weeks as one treatment cycle until disease progression, intolerable toxicity, death, or up to a maximum of 2 years.~2. Oral administration of Fluzoparib capsules at a dose of 150mg, once in the morning and once in the evening until disease progression, intolerable toxicity, death, or up to a maximum of 2 years."
62044521|NCT06313580|EXPERIMENTAL|Intervention Arm - Yogurt with added Spices|Consumption of twice daily yogurt with added spices for four weeks.
62044522|NCT06313580|SHAM_COMPARATOR|Sham Arm - Yogurt without added Spices|Consumption of twice daily yogurt without added spices for four weeks.
62044523|NCT02271256|EXPERIMENTAL|Functional intimate apparel|A functional intimate apparel will be provided to patient to wear it 8 hours daily. Monitoring and observation will be provided during the 6-9 months wearing period.
62044524|NCT02271256|NO_INTERVENTION|Control|Monitoring and observation will be provided during the 6-9 months wearing period.
62044525|NCT06111651|EXPERIMENTAL|Intervention|parents will participate in a multicomponent parenting intervention
62044526|NCT06111651|NO_INTERVENTION|Control|parents will receive information about healthy eating habits
62044527|NCT02803268|EXPERIMENTAL|MT-8554 low dose|Patients who meet eligibility criteria will be administered once daily either low dose of MT-8554 or a matching Placebo from Day 1 to 14.
62247079|NCT02091661|ACTIVE_COMPARATOR|Radical retropubic prostatectomy|The surgery arm underwent radical retropubic prostatectomy, performed by a technique described by Walsh.surgery started with dissection of the pelvic lymph nodes. If there were no signs of metastasis in frozen sections, the operation was continued with retropubic radical prostatectomy. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible. The degree to which the surgeon preserve the nerves is categorized as non-nerve-sparing, unilateral nerve-sparing, or bilateral nerve-sparing.The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 6 to 9 days to facilitate bladder emptying.
62826527|NCT06413992|ACTIVE_COMPARATOR|Camrelizumab without Fluzoparib as maintainance therapy|"Treatment period mainly include:~1. Injection of Paclitaxel (Albumin-bound) at a dose of 260mg/m\^2 administered intravenously every 3 weeks as one treatment cycle, for a total of 6 cycles.~2. Injection of Carboplatin (AUC=5) administered intravenously every 3 weeks as one treatment cycle, for a total of 6 cycles.~3. Injection of Camrelizumab at a dose of 200mg administered intravenously every 3 weeks as one treatment cycle, for a total of 6 cycles.~4. Radiation therapy: Not mandatory. Whether to combine radiation therapy is determined by the principal investigator based on the patient's condition. Radiation therapy includes external beam radiation and brachytherapy.~Maintainance therapy period mainly includes:~a) Injection of Camrelizumab at a dose of 200mg administered intravenously every 3 weeks as one treatment cycle until disease progression, intolerable toxicity, death, or up to a maximum of 2 years."
62826528|NCT05530252|EXPERIMENTAL|AMP Group|scaling and root planning and subgingival application of antimicrobial peptide gel
62826529|NCT05530252|ACTIVE_COMPARATOR|Perio Group|scaling and root planning and subgingival application of minocycline hydrochloride ointment
62826530|NCT05530252|OTHER|SRP Group|scaling and root planning
62044528|NCT02803268|EXPERIMENTAL|MT-8554 middle dose|Patients who meet eligibility criteria will be administered once daily either middle dose of MT-8554 or a matching Placebo from Day 1 to 14.
62044529|NCT02803268|EXPERIMENTAL|MT-8554 high dose|Patients who meet eligibility criteria will be administered once daily either high dose of MT-8554 or a matching Placebo from Day 1 to 14.
62044530|NCT02183987|EXPERIMENTAL|Active Knowledge Translation Group|CKD clinics receiving the active knowledge translation intervention.
62044531|NCT02183987|NO_INTERVENTION|Passive Knowledge Translation Group|Clinics will have access to the Canadian Society of Nephrology (CSN) guidelines on the optimal timing of dialysis initiation (current practice). These guidelines have been published in the Canadian Medical Association Journal (CMAJ) and have been recently presented at the annual meeting of the Canadian Society of Nephrology.
62044532|NCT04983550|EXPERIMENTAL|Group A: SG001 + doxorubicin hydrochloride liposome injection|Two-thirds of the patients will be randomly assigned to group A to receive SG001 240 mg, IV, every 2 weeks (1 cycle every 4 weeks), and doxorubicin hydrochloride liposome injection 40 mg/m\^2, IV, every 4 weeks (1 cycle).
62044533|NCT04983550|ACTIVE_COMPARATOR|Group B: doxorubicin hydrochloride liposome injection|One-third of the patients will be randomly assigned to group B to receive doxorubicin hydrochloride liposome injection 40 mg/m\^2, IV, every 4 weeks (1 cycle).
62437351|NCT01563432|EXPERIMENTAL|febuxostat (TR)|
62437352|NCT01563432|EXPERIMENTAL|febuxostat (RT)|
62826531|NCT00536744|ACTIVE_COMPARATOR|Active PACE application - 4 applications|Application of acoustical pulse energy (extracorporeal shockwaves) to target ulcer + standard of care
62826532|NCT00536744|SHAM_COMPARATOR|Inactive, non-energy application|Non-energized (inactive - Sham)) application + standard of care
62826533|NCT04909047|EXPERIMENTAL|Parasacral transcutaneous electrostimulation outpatient|electrostimulation device
62826534|NCT04909047|EXPERIMENTAL|transcutaneous tibial electrostimulation outpatient|electrostimulation device
62826535|NCT04909047|EXPERIMENTAL|home parasacral electrostimulation|electrostimulation device
62826536|NCT01651156|PLACEBO_COMPARATOR|placebo|Frequency: once per day Duration: 7days
62826537|NCT01651156|EXPERIMENTAL|Tolvaptan|Tolvaptan tablet Frequency: once per day Duration: 7days
62826538|NCT01062932|PLACEBO_COMPARATOR|Placebo|
62826539|NCT01062932|ACTIVE_COMPARATOR|Cycloserine|
62826540|NCT05733546|EXPERIMENTAL|25 mg COMP360 Psilocybin|25 mg COMP360 Psilocybin
62044534|NCT06015867|ACTIVE_COMPARATOR|Control Bread: Wholemeal Yeast Bread|Wholemeal bread, containing mainly of wholemeal flour, water and bakers' yeast will be used as the control test bread.
62044535|NCT06015867|ACTIVE_COMPARATOR|Wholemeal Sourdough Bread|Wholemeal sourdough bread, containing mainly of wholemeal flour, water and added sourdough co-culture (consisting of W.anom.+ C.crust strain).
62826541|NCT05733546|EXPERIMENTAL|10 mg COMP360 Psilocybin|10 mg COMP360 Psilocybin
62044536|NCT04949659|EXPERIMENTAL|Low pressure pneumoperitoneum|Use of low pressure pneumoperitoneum during laparoscopic appendectomy
62044537|NCT04949659|EXPERIMENTAL|Medium pressure pneumoperitoneum|Use of medium pressure pneumoperitoneum during laparoscopic appendectomy
62044538|NCT02367755|EXPERIMENTAL|Propofol|propofol infusion at a rate of 3 mg/kg/hr during TH.
62044539|NCT02367755|ACTIVE_COMPARATOR|Lorazepam|lorazepam infusion at a rate of 0.5 mg/kg/hr during TH.
62044540|NCT01785303|ACTIVE_COMPARATOR|Model A|Model A consists of a 4 session CBT-I in phase I and CPAP for OSA in Phase II.
62044541|NCT01785303|ACTIVE_COMPARATOR|Model B|Model B consists of 4 weeks of monitoring using sleep diaries in Phase I. Phase II consists of concurrent initiation of CBT-I and CPAP for OSA.
62044542|NCT01785303|OTHER|Model C|Model C consists of 4 weeks of monitoring with sleep diaries in Phase I. Phase II consists of CPAP for OSA.
62044543|NCT06273098|EXPERIMENTAL|Bladder Health Education|Participants in this arm will receive the intervention
62044544|NCT06273098|NO_INTERVENTION|No Bladder Health Education|Participants in this arm will not receive the intervention
62044545|NCT05432076||experimental group|In the study, sleep bands and white noise will be used for sleep for the babies in the experimental group
62603974|NCT04331067|EXPERIMENTAL|Unrandomized Arm: Neoadjuvant Chemo + Nivolumab|"* As of Amendment #7 IRB approved 10/13/2022: The study will no longer enroll to Arm B. Cabiralizumab will no longer be given. Remaining patients will be enrolled in single arm study.~* Neoadjuvant chemotherapy consists of paclitaxel and carboplatin. Paclitaxel will be given intravenously (IV) at a dose of 80 mg/m\^2 on a weekly basis for 12 weeks. Carboplatin will be given IV at a dose of AUC 5 every 3 weeks for 12 weeks. Nivolumab will be given IV at a dose of 240 mg every 2 weeks for 12 weeks. Nivolumab will be administered first, followed by carboplatin, followed by paclitaxel."
62603975|NCT00415597|EXPERIMENTAL|ALO-01|Doses given once or twice daily
62603976|NCT05661630|EXPERIMENTAL|EX-PLISSIT|
62603977|NCT05661630|NO_INTERVENTION|CONTROL|
62044546|NCT05432076||control group|while the control group will not be interfered with
62044547|NCT06580236|EXPERIMENTAL|Arm 1 - doze 1|B11-FC 0,06 mg/kg single infusion - 5 subjects
62044548|NCT06580236|EXPERIMENTAL|Arm 2 - doze 2|B11-FC 0,3 mg/kg single infusion - 5 subjects
62247080|NCT02091661|ACTIVE_COMPARATOR|External beam radiotherapy|External beam radiotherapy is carried out with intensity-modulated radiation technique. The treatment is designed to maximize the radiation dose to the prostate and seminal vesicles and minimize exposure to surrounding structures, including the bladder and rectum. Radiation to the prostate was delivered in fractionated doses divided over multiple treatments (180 to 200 centigray (cGy) daily fractions, 5 days per week) for a total dose to the prostate of 68 to 77 gray (Gy), prescribed at 90% to 100% of the isodose line.
62247081|NCT02863627|EXPERIMENTAL|Newborn Care Pathway|two telephone interviews conducted after the emergency department visit will be used to gather data to meet the objectives of this study.
62437353|NCT01555606||Moderate to severe plaque psoriasis patients|The group includes adult patients (either male or female) diagnosed with plaque psoriasis for at least 6 months prior to screening with PGA value of greater than or equal to 3. The patients in the group needed are currently receiving treatment with conventional systemic agents, topical therapy and/or phototherapy or biologic therapy
62603978|NCT02169206|OTHER|shoulder radiography|Bilateral shoulder AP standard plain x-ray in 0 and 90 degrees of arm abduction. Non-affected shoulder is used to be compared with the affected shoulder.
62603979|NCT02191176|EXPERIMENTAL|Dextromethorphan syrup - low dose|
62603980|NCT02191176|EXPERIMENTAL|Dextromethorphan syrup - high dose|
62603981|NCT02191176|PLACEBO_COMPARATOR|Placebo|
62603982|NCT01323153|EXPERIMENTAL|Dalcetrapib|
62437354|NCT00629486|EXPERIMENTAL|cytokines were determined|prevalence of genetic polymorphisms of interleukin 1B was measured in HBV-related hepatocellular carcinoma
62603983|NCT01323153|PLACEBO_COMPARATOR|Placebo|
62603984|NCT00353548||1-Anorexia Nervosa|Women ages 16-50 who meet DSM-IV criteria for anorexia nervosa
62603985|NCT00353548||2-Bulimia Nervosa|Women age 16-50 who meet DSM-IV criteria for bulimia nervosa
62603986|NCT00353548||3-Binge Eating Disorder|Women with binge eating disorder
62603987|NCT00353548||4-Healthy Controls|Healthy control subjects ages 16-50 of normal weight
62044549|NCT06580236|EXPERIMENTAL|Arm 3 - doze 3|B11-FC 0,6 mg/kg single infusion - 5 subjects
62247082|NCT02111460|EXPERIMENTAL|Radiotherapy|Systemic Chemotherapy Combined with Loco-regional Radiotherapy
62247083|NCT02111460|ACTIVE_COMPARATOR|Chemotherapy|Chemotherapy alone without Loco-regional Radiotherapy
62437355|NCT02109926||Cases: testicular cancer patients|
62437356|NCT02109926||Group A controls|Sperm donors and husbands of women with fertility disorders All controls must have a normal spermogram
62603988|NCT00353548||5-Obese Controls|Healthy obese control subjects
62044550|NCT06580236|ACTIVE_COMPARATOR|Arm 4 - selected doze|B11-FC 0,6 mg/kg single infusion + botulinum neurotoxin - 5 subjects
62044551|NCT06580236|PLACEBO_COMPARATOR|Arm 5 - placebo|Placebo + botulinum neurotoxin - 5 subjects
62044552|NCT06580236|ACTIVE_COMPARATOR|Arm 6 - selected doze - patients with confirmed botulism|B11-FC 0,6 mg/kg single infusion - 10 subjects
62437357|NCT02109926||Group B controls|Husbands of women with a pathological pregnancy
62437358|NCT00851045|ACTIVE_COMPARATOR|Arm 1|Irinotecan/5-Fluorouracil (bolus)/5-Fluorouracil (infusional)/Leucovorin calcium/CT-322
62603989|NCT06621264|EXPERIMENTAL|Exercise group|"Patients enrolled in this group will receive a detailed 6-month exercise prescription aimed at providing in-home low fatiguingwalking training (at light-moderate intensity, or 2-3 out of 10 of the CR10 Borg's scale). The program consists of a two daily 10-minute interval walking sessions (1 minute walking : 1 minute resting) at a prescribed speed controlled by a digital metronome (https://www.youtube.com/watch?v=ki8YX_t-0jA). The training speed will be set up according to the patients baseline walking capacity (approximately 50% lower than the habitual gait speed) and will be weekly increased until reaching the habitual gait speed. The training time will be maintained constant throughout the entire program.~Exercise prescription will be updated during two intermediate hospital visits at the 1st and 3rd months. Patients will be provided with a digital application properly developed to keep pacing and to record the correct training execution."
62603990|NCT06621264|PLACEBO_COMPARATOR|Control group|Patients enrolled in the Co group will receive standard CKD-PAD care, including optimal medical therapy and nutritional advices
62603991|NCT05656703|EXPERIMENTAL|Bis Guided light anesthesia|Patients are monitored by bispectral index and held under light anesthesia (BIS level 45 to 60)
62603992|NCT05656703|PLACEBO_COMPARATOR|Standard of Care|Patients receive standard of care anesthesia, BIS monitor was covered with a blind
62603993|NCT05749068|EXPERIMENTAL|Experimental|Open label experimental arm
62044553|NCT05965011|EXPERIMENTAL|Intervention (Nordic walking)|"Nordic walking training. These coaching principles will focus on highlighting the participants' strengths and resourcefulness, setting goals, and utilizing solution-focused problem-solving techniques to achieve those goals during practice and related activities . This group sessions will be conducted biweekly to ensure appropriate progression and adherence to the guidelines set by the International Nordic Walking Federation.~In addition to the supervised group sessions, participants will also receive supervised NW training from a certified NW instructor. Participants will be encouraged to set goals and develop strategies to facilitate independent practice for at least three 30-minute sessions per week over a period of 10 weeks. These unsupervised sessions aim to encourage participants to engage in regular practice outside of the group sessions."
62044554|NCT05965011|NO_INTERVENTION|Control (phone calls)|"The control group will receive regular contact to control for attention and maintain participant engagement throughout the study. Over the course of the 10 weeks, participants in this group will receive 5 biweekly phone calls from the study's graduate research assistant (RA).~During each phone call, the RA will engage in discussions with participants about leading a healthy lifestyle in general, covering topics such as proper nutrition and adequate sleep. Additionally, the RA will gather safety-related data, including information on any falls that may have occurred. The phone calls will also serve as reminders for participants about upcoming assessments and their importance in the study. The investigators will provide a training session to the control group following the completion of the study if they are interested."
62044555|NCT02123862||Prostate Cancer|
62044556|NCT02123862||Breast Cancer|
62044557|NCT02123862||Colorectal Cancer|
62044558|NCT02123862||Solid Tumor|
62044559|NCT02123862||Benign Condition|
62044560|NCT04833387|EXPERIMENTAL|PD-1 antibody + capecitabine + radiation|
62247084|NCT06013592|EXPERIMENTAL|Healthy adults without obesity|Liquid meals with different caloric sizes (0, 600, 900, 1200 kcal) in within-participant cross-over design
62247085|NCT06013592|EXPERIMENTAL|Healthy adults with obesity|Liquid meals with different caloric sizes (0, 600, 1200, 1800 kcal) in within-participant cross-over design
62247086|NCT04260412|EXPERIMENTAL|Interventional arm - MCO dialysis membrane|4 weeks of dialysis with MCO membrane, then dialysis for 4 weeks with MCO membrane and increased fiber intake
62247087|NCT04260412|ACTIVE_COMPARATOR|Control arm - high-flux membrane haemodiafiltration|4 weeks of high-flux membrane haemodiafiltration and 4 weeks of high-flux membrane haemodiafiltration and increased fiber intake
62247088|NCT01546974|EXPERIMENTAL|HME filter|
62247089|NCT01546974|EXPERIMENTAL|Heated humidificator MR 730 Fisher & Paykel|
62437359|NCT00851045|ACTIVE_COMPARATOR|Arm 2|Irinotecan/5-Fluorouracil(bolus)/5-Fluorouracil(infusional)/Leucovorin calcium /Bevacizumab/Bevacizumab Placebo(saline solution)
62247090|NCT05603884|EXPERIMENTAL|treatment arm|2 cycles of VCA regimens followed by 2 cycles of D-MAG regimens, and then repeat the above four courses of treatment once
62044561|NCT03984799|EXPERIMENTAL|Bronchoscopy|Research bronchoscopy
62247091|NCT05300321|EXPERIMENTAL|Single Vision Lens|The sunbjects were randomized to allocate in single vision lens group.
62247092|NCT05300321|EXPERIMENTAL|Defocus Incorporated Multiple Segments (DIMS) Lens|The sunbjects were randomized to allocate in Defocus Incorporated Multiple Segments (DIMS) Lens group.
62437360|NCT01951183|PLACEBO_COMPARATOR|Placebo|
62437361|NCT01951183|EXPERIMENTAL|RO6811135|
62044562|NCT01391221|EXPERIMENTAL|Duloxetine treatment|Subjects with major depression will be entered into the trial and treated with open label duloxetine
62044563|NCT03390205||Patients|
62044564|NCT03390205||Controls|
62247093|NCT05889455|EXPERIMENTAL|Sildenafil|
62247094|NCT05889455|PLACEBO_COMPARATOR|Placebo|
62247095|NCT05546294|EXPERIMENTAL|RA patients receiving aerobic and home exercise|A total of 20 sessions of aerobic exercises using bicycle ergometer, five times a week and once a day for four weeks, were applied to the patients. Then the patients were showed a daily home exercise program to apply once a day at their home.
62247096|NCT05546294|ACTIVE_COMPARATOR|RA patients receiving only home exercise|The patients were showed only a daily home exercise program to apply once a day at their home.
62437362|NCT00140556|EXPERIMENTAL|ChemoRadiotherapy|Radiation Therapy concurrent with cisplatin chemotherapy, Avastin and Tarceva
62437363|NCT00418782|ACTIVE_COMPARATOR|1|
62437364|NCT00418782|EXPERIMENTAL|2|
62437365|NCT00418782|PLACEBO_COMPARATOR|3|
62437366|NCT05305183|ACTIVE_COMPARATOR|Alendronate Sodium Tablets and Minodronate Tablets -matching placebo|subjects received 70 mg alendronate sodium tablet weekly and a minodronate tablet matching placebo monthly for 48 weeks.
62437367|NCT05305183|EXPERIMENTAL|Minodronate Tablets and Alendronate Sodium Tablets-matching placebo|subjects received 50mg minodronate tablets monthly and an alendronate sodium tablets -matching placebo weekly for 48 weeks.
62437368|NCT02804828|ACTIVE_COMPARATOR|Arm 1|
62437369|NCT02804828|SHAM_COMPARATOR|Arm 2|
62437370|NCT02915510|EXPERIMENTAL|GMP|Single arm designed, 3 day baseline, 28day on GMP
62826542|NCT05733546|ACTIVE_COMPARATOR|1 mg COMP360 Psilocybin|1 mg COMP360 Psilocybin
62247097|NCT05546294|OTHER|Healthy control group|There is no intervention to this group.
62437371|NCT01556685|ACTIVE_COMPARATOR|Group 1 Avonex|Approximately 90 subjects treated with IFN beta 1a IM 30μg
62826543|NCT05383196|EXPERIMENTAL|DOSE ESCALATION ONVANSERTIB + PACLITAXEL|"In the phase 1b, dose escalation/de-escalation will be managed using a BOIN design to identify the RP2D.~The study is divided into three time periods: a screening period; a treatment period; and a post-treatment follow-up period.~The names of the study interventions involved in this study are:~* Onvansertib~* Paclitaxel"
62826544|NCT05383196|EXPERIMENTAL|DOSE EXPANSION RP2D ONVANSERTIB + PACLITAXEL|"The study is divided into three time periods: a screening period; a treatment period; and a post-treatment follow-up period.~The names of the study interventions involved in this study are:~* Onvansertib~* Paclitaxel"
62247098|NCT01731535||Prior bisphosphonate users|Patients with record of using bisphosphonate medication
62247099|NCT06212635||Non-acute decompensated liver círrhosis|Refractory ascites, low grade encephalopathy but manages to stay at home and only come in ofr check-ups.
62247100|NCT06212635||Acute decompensated liver cirrhosis|Acute event causing further decompensation and the need for in-patient care
62247101|NCT06212635||Acute on chronic liver failure|ACLF 1-3 accordic to criterias established through the Cannonic study.
62247102|NCT06212635||Controls|Healthy individuals
62247103|NCT03343392|EXPERIMENTAL|acetam/ketoro tromet group|One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
62247104|NCT03343392|PLACEBO_COMPARATOR|Placebo group|One hour before in-office bleaching patients received either placebo.
62247105|NCT00057356|PLACEBO_COMPARATOR|1|
62044565|NCT02982694|EXPERIMENTAL|Atezolizumab and Bevacizumab|Atezolizumab will be administered intravenously at 1200 mg on Day 1 every 3 weeks. The dose of bevacizumab in this study is 7.5 mg/kg administered by IV infusion every 3 weeks on Day 1 of each 21 days cycle. Atezolizumab will be administered first, followed by Bevacizumab, with a minimum of 5 minutes between dosing. The interval between cycle infusions must not be \< 10 days.
62044566|NCT00645164|EXPERIMENTAL|Xenaderm|Subject serves as own control
62044567|NCT06060977|EXPERIMENTAL|IMG-007 Dose 1|IMG-007 Dose 1 will be administered intravenously 3 times over 4 weeks
62044568|NCT06060977|EXPERIMENTAL|IMG-007 Dose 2|IMG-007 Dose 2 will be administered intravenously 3 times over 4 weeks
62044569|NCT00331643|EXPERIMENTAL|Treatment (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.
62044570|NCT05840172|EXPERIMENTAL|Test condom A (NRL condom with 5% benzocaine paste)|Following randomization, each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
62044571|NCT05840172|EXPERIMENTAL|Test condom B (NRL condom with 3% benzocaine paste)|Following randomization, each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
62437372|NCT01556685|ACTIVE_COMPARATOR|Group 2 Jumtab|Approximately 90 subjects treated with IFN beta 1a IM biosimilar
62437373|NCT04147481|EXPERIMENTAL|Group Abdominal Nerve Block|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.2% ropivacaine
62437374|NCT04147481|PLACEBO_COMPARATOR|Group control|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.9% saline.
62437375|NCT00205075||Case|
62437376|NCT00205075||Control|
62437377|NCT04999228|EXPERIMENTAL|Infliximab treatment group|For newly diagnosed moderate to severe Pediatric ulcerative colitis, infliximab will be used as first-line treatment
62437378|NCT04999228|ACTIVE_COMPARATOR|Corticosteroid treatment group|For newly diagnosed moderate to severe Pediatric ulcerative colitis, corticosteroids will be used as first-line treatment
62826545|NCT03956849||Professionals working with children|The studypopulation for this mixed-methods study is consisting of healthcareprofessionals working with children (with overweight or obesity), such as pediatric residents, paediatricians and youth health care professionals. Also other professionals working with children, not working in the field of healthcare, such as teachers, can be included in the study population.
62826546|NCT03992560|NO_INTERVENTION|Standard CRT implantation|
62826547|NCT03992560|EXPERIMENTAL|MRI guided CRT implantation|
62826548|NCT05910684|NO_INTERVENTION|Control Group|These participants will complete their online simulations and treat their real-life patients without access to the Aegis test.
62826549|NCT05910684|EXPERIMENTAL|Educational Materials and Test Access|These participants will complete their online simulations and treat their real-life patients with access to educational materials and the Aegis test results. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
62826550|NCT04046367|EXPERIMENTAL|Intervention|Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, with specific training aimed at increasing physical activity, functional capacity and conditioning of the respiratory musculature (prehabilitation by a physiotherapist)
62826551|NCT04046367|ACTIVE_COMPARATOR|Control|Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, as well as standard instructions to increase physical activity.
62826552|NCT00394017|ACTIVE_COMPARATOR|Intervention group|Reminder letters and usual implementations vs. usual implementation
62437379|NCT06182007||No Pneumothorax|Patients with no pneumothorax reported from the first chest imaging after hospital admission.
62437380|NCT06182007||Pneumothorax|Patients with a pneumothorax reported from the first chest imaging after hospital admission.
62437381|NCT01475188|PLACEBO_COMPARATOR|placebo|20 patients with intermittent allergic rhinitis sensitized to grass pollen allergens
62826553|NCT00394017|NO_INTERVENTION|Control group|usual implementations
62603994|NCT00783224|PLACEBO_COMPARATOR|Mometasone Furoate Placebo (PLAMF)|Placebo to mometasone furoate nasal spray, made to be indistinguishable from mometasone furoate nasal spray
62044572|NCT05840172|PLACEBO_COMPARATOR|Control NRL condom|Following randomization, each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
62603995|NCT00783224|PLACEBO_COMPARATOR|Fluticasone Propionate Placebo (PLAFP)|Placebo to fluticasone propionate nasal spray, made to be indistinguishable from fluticasone propionate nasal spray
62044573|NCT04305314||Group 1: PRI > 70%|Compliance with the Enhanced Revovery protocol higher than 70%
62437382|NCT01475188|ACTIVE_COMPARATOR|Specific subcutaneous immunotherapy|21 symptomatic patients with intermittent allergic rhinitis sensitized to grass pollen allergens
62437383|NCT04916171||Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome|"The diagnosis of endometriosis will be made by the presence of ovarian endometrioma and/or a deep infiltrating endometriosis nodule determined by transvaginal ultrasonography or by palpation of the endometriotic nodule on pelvic examination or surgical confirmation.~The diagnosis of adenomyosis will be made by transvaginal ultrasonography or surgical confirmation."
62437384|NCT04916171||Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis|For the diagnosis of polycystic ovary syndrome, Rotterdam Criteria will be used.
62603996|NCT00783224|EXPERIMENTAL|Mometasone Furoate (MF)|Mometasone furoate nasal spray 200 μg/day(QD)
62603997|NCT00783224|ACTIVE_COMPARATOR|Fluticasone Propionate (FP)|Fluticasone Propionate nasal spray 200 μg/day, twice per day (BID)
62603998|NCT01914159|EXPERIMENTAL|Ranibizumab|
62603999|NCT06052540|ACTIVE_COMPARATOR|Probiotics|Probiotic supplement: Mix of probiotic strails. Administration: 1 stick per day or 5 drops per day. Study duration for each patient: 14 days.
62044574|NCT04305314||Group 2: PRI < 70%|Compliance with the Enhanced Revovery protocol lower than 70%
62044575|NCT00712868|EXPERIMENTAL|1|Lactic Acid once a day during 21 days
62044576|NCT02327754|ACTIVE_COMPARATOR|Active comparator|Topiroxostat, (Oral daily dosing for 28 weeks)
62247106|NCT00057356|EXPERIMENTAL|2|Low dose
62247107|NCT00057356|EXPERIMENTAL|3|Middle dose
62247108|NCT00057356|EXPERIMENTAL|4|High dose
62247109|NCT00598260|EXPERIMENTAL|1- study group|study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
62247110|NCT00598260|NO_INTERVENTION|2 - control group|control group
62247111|NCT03248583|EXPERIMENTAL|Default|
62247112|NCT03248583|ACTIVE_COMPARATOR|Psychoeducation|
62247113|NCT03248583|ACTIVE_COMPARATOR|Incentive|
62247114|NCT01516658|EXPERIMENTAL|Hydrogel coil group|use Hydrogel Coil as much as be able to use
62247115|NCT01516658|ACTIVE_COMPARATOR|Bare platinum coil group|use only bare platinum coil
62247116|NCT06157957|OTHER|Active smokers|We do a CT scan in active smokers and ex-smokers plus an spirometry combined to a tobacco cessation programme in active smokers
62247117|NCT01969097|EXPERIMENTAL|Dual tDCS + motor training|Motor training of the affected upper extremity combined with dual transcranial direct current stimulation (tDCS).
62247118|NCT01969097|ACTIVE_COMPARATOR|Anodal tDCS + motor training|Motor training of the affected upper extremity combined with anodal tDCS.
62247119|NCT01969097|SHAM_COMPARATOR|Sham tDCS + motor training|Motor training of the affected upper extremity combined with sham tDCS.
62247120|NCT02615470|EXPERIMENTAL|Enhanced immunization delivery model|Pharmacist-technician pairs employed by community pharmacies that are assigned to this arm will receive a) immunization update training, b) training by immunization experts to enhance immunization delivery model and foster practice change at the beginning of 6-month and c) regular feedback and clinical support for the period of 6 months.
62247121|NCT02615470|ACTIVE_COMPARATOR|Immunization update|Pharmacist-technician pairs employed by community pharmacies that are assigned to the control arm will receive an immunization update training. They will not receive a training by immunization experts nor regular feedback and clinical support.
62247122|NCT03787524||Dysphagia group|Acute stroke patients who will be diagnosed dysphagia according to VFSS results.
62247123|NCT03787524||No dysphagia group|Acute stroke patient who showed no dysphagia according to VFSS results.
62247124|NCT00345189|OTHER|Dosing Schedule 1|Starting dose of 25 mg, with dosing twice a week for 3 weeks out of a 4-week course (Schedule 1). Dosing for schedule 1 is currently closed.
62247125|NCT00345189|OTHER|Dosing Schedule 2|Starting dose of 600 mg, with dosing twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).
62247126|NCT02944253|EXPERIMENTAL|Low energy diet 70 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 70 gram carbohydrates for 8 weeks.
62604000|NCT06052540|PLACEBO_COMPARATOR|Placebo|Placebo: Medium Chain Triglycerides. Administration: 1 stick per day or 5 drops per day. Study duration for each patient: 14 days.
62604001|NCT02930161|EXPERIMENTAL|Runihol 2 tablets x 2 times a day|Intake of 1 tablet of Runihol and 1 placebo tablet orally, with drinking 100 ml of water, 30 minutes before meals three times a day (morning, afternoon and evening) for 84 days (12 weeks).
62604002|NCT02930161|EXPERIMENTAL|Runihol 1 tablet x 3 times a day|Intake of Runihol, 2 tablets orally, with drinking 100 ml of water, 30 minutes before meals, 2 times a day (morning and evening) for 84 days (12 weeks), and 2 placebo tablets orally, with drinking 100 ml of water, 30 minutes before meals, 1 time a day (afternoon) for 84 days (12 weeks).
62604003|NCT02930161|PLACEBO_COMPARATOR|Placebo|Two placebo tablets orally, with drinking 100 ml of water, 30 minutes before meals three times a day (morning, afternoon and evening) for 84 days (12 weeks).
62604004|NCT05548998||High flow cohort (HFA)|Patients, whose maintenance phase of anesthesia is managed with a fresh gas flow ≥ 1L/min, were included in this cohort.
62604005|NCT05548998||Low flow cohort (LFA)|Patients, whose maintenance phase of anesthesia is managed with a fresh gas flow \< 1L/min, were included in this cohort.
62604006|NCT06010420|EXPERIMENTAL|flat sole|Weighted-unweighted in navicular drop test 10 mm or more pronation
62826554|NCT02718404|EXPERIMENTAL|MR-HIFU Treatment|"The Philips MR-HIFU Sonalleve System integrates a high intensity phased array focused ultrasound transducer with a 3 Tesla Magnetic Resonance (MR) imaging system and electromechanical transducer positioning system to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively.~At HIFU day (day 0) before treatment patient will be performed a bone lesion MRI and a functional brain MRI.~During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.~Following the MR-HIFU procedure, a set of MR images of the target region will be acquired with the use of a MR contrast agent, together with a functional brain MRI."
62826555|NCT06597136|EXPERIMENTAL|Diaphragmatic kinesiology taping|"The taping on the diaphragm from the abdomen was performed when the participant was standing and breathed-out and the body was in extension. The base of the tape was about 1 inch below the xiphoid process area. Then the arms were lifted above the head and, with maximum deep inspiration and after maximum rib cage expansion, the tails were applied with 10% tension on the rib cage. Diaphragmatic kinesiology taping will be applied in addition to conventional treatment for 3 days.~To evaluate the effectiveness of the application, vital signs, respiratory muscle strength, grip strength, blood gas analysis, dyspnea and fatigue will be evaluated. Additionally, Richmond Agitation Sedation Scale (RASS), Non-Verbal Pain Scale, Glaskow coma scale, Physical Function Test in Intensive Care (PFIT)- CPax (Chelsea Critical Care Physical Assessment Tool) scales will be used."
62437385|NCT02002156|EXPERIMENTAL|BCG at birth and routine vaccines|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
62247127|NCT02944253|EXPERIMENTAL|Low energy diet 100 gram carbohydrates|isocaloric (4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 100 gram carbohydrates for 8 weeks.
62247128|NCT02944253|EXPERIMENTAL|Low energy diet 130 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 130 gram carbohydrates for 8 weeks.
62437386|NCT02002156|EXPERIMENTAL|BCG at 3 months old and routine vaccines|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
62437387|NCT02002156|EXPERIMENTAL|Routine vaccines|NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
62437388|NCT01527539|EXPERIMENTAL|BIAsp 30|
62437389|NCT02885935|EXPERIMENTAL|Recommended protein intake|Subjects consumed diets with a macronutrient distribution of 10% protein, 55% carbohydrates, and 35% fat for 4 weeks.
62044577|NCT02327754|PLACEBO_COMPARATOR|Placebo comparator|Placebo, (Oral daily dosing for 28 weeks)
62044578|NCT00630110|ACTIVE_COMPARATOR|docetaxel|docetaxel (75 mg/m2)
62604007|NCT06010420|EXPERIMENTAL|normal base|Weighted-unweighted in navicular drop test difference between measurement 5-9 mm is normal
62604008|NCT06010420|EXPERIMENTAL|high sole|Weighted-unweighted in navicular drop test 4 mm or less is considered supination. are being
62604009|NCT04571801|ACTIVE_COMPARATOR|1|Standard diagnostics
62604010|NCT04571801|EXPERIMENTAL|2|Standard diagnostics + NGS
62604011|NCT01524783|EXPERIMENTAL|Everolimus + BSC|Participants received everolimus 10 mg once daily plus best supportive care (BSC) throughout the study
62604012|NCT01524783|PLACEBO_COMPARATOR|Placebo + BSC|Participants received matching placebo once daily plus best supportive care (BSC) during the blinded period. Participants were allowed to crossover to treatment with everolimus 10mg once daily plus BSC during the open-label period.
62826556|NCT06597136|EXPERIMENTAL|Accessory respiratory muscle kinesiology taping|Tapings of the accessory inspiratory muscles were applied in a sitting posture. Sternocleidomastoideus taping was applied when the neck of the participant was in lateral flexion to the opposite side to be taped and in rotation to the same side; and anterior and medius scalene tapings were applied when the neck of the participant was in the lateral flexion position to the opposite side to be taped. Tapings were repeated on the opposite side.Taping was applied to accessory expiratory muscles in the supine position. While the participant was supporting one leg in the hip and knee flexion position on the bed, the other leg was extended from the bed and the hip was kept in the extension position. The obliquus externus muscle was taped on the side with hip-knee flexion and the obliquus internus muscle was taped on the side with hip extension.In addition to conventional treatment, kinesiology taping will be applied to the accessory respiratory muscles for 3 days.
62826557|NCT06597136|SHAM_COMPARATOR|Sham kinesiology taping|"Sham kinesiology taping will be applied for 3 days. Sham KT was performed with the same taping material. A 2-blocked I strip was applied vertically to the sternum. The same procedures were followed.~To evaluate the effectiveness of the application, vital signs, respiratory muscle strength, grip strength, blood gas analysis, dyspnea and fatigue will be evaluated. Additionally, Richmond Agitation Sedation Scale (RASS), Non-Verbal Pain Scale, Glaskow coma scale, Physical Function Test in Intensive Care (PFIT)- CPax (Chelsea Critical Care Physical Assessment Tool) scales will be used."
62826558|NCT06597136|NO_INTERVENTION|Control Group|Conventional treatment will be applied in the control group. Participants' vital signs, respiratory muscle strength, grip strength, blood gas analysis, dyspnea and fatigue will be evaluated. Additionally, Richmond Agitation Sedation Scale (RASS), Non-Verbal Pain Scale, Glaskow coma scale, Physical Function Test in Intensive Care (PFIT)- CPax (Chelsea Critical Care Physical Assessment Tool) scales will be used.
62826559|NCT05961722||Group 1|Group receiving preoperative and intraoperative saline infusion.
62826560|NCT05961722||Group 2|The group receiving preoperative dextrose and intraoperative saline infusion.
62044579|NCT00630110|EXPERIMENTAL|NPI-2358 + docetaxel|NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
62044580|NCT06574815|EXPERIMENTAL|SIS-EL|Guided bone regeneration (GBR) with an SIS membrane and early implant loading
62437390|NCT02885935|EXPERIMENTAL|Elevated protein intake|Subjects consumed diets with a macronutrient distribution of 20% protein, 45% carbohydrates and 35% fat for 4 weeks.
62437391|NCT03237611|EXPERIMENTAL|low dose aprepitant or fosaprepitant|In addition to standard prophylactic antiemetics (Ondansetron 16mg and Dexamethasone 20mg) patients will be given aprepitant 125mg orally or 115mg fosaprepitant intravenously prior to the first cycle of carboplatin-based chemotherapy. No medications will be given afterwards
62437392|NCT01847196|EXPERIMENTAL|Angel® Catheter|All eligible subjects will receive an Angel® Catheter.
62437393|NCT03368495|EXPERIMENTAL|Co-administration of MMR/YF|Participants randomized to this arm will receive both MMR and yellow fever vaccines on Day 0.
62437394|NCT03368495|ACTIVE_COMPARATOR|MMR followed by YF|Participants randomized to this arm will receive MMR vaccine on Day 0 followed by yellow fever vaccine on Day 28.
62437395|NCT03368495|ACTIVE_COMPARATOR|YF followed by MMR|Participants randomized to this arm will receive YF vaccine on Day 0 followed by MMR vaccine on Day 28.
62437396|NCT04027010|EXPERIMENTAL|"Healthy U tablet application"|Healthy U is a self-administered intervention implemented through a tablet app with interactive learning experiences, including videos, digital games, quizzes, and role-plays. Healthy U takes youth 3-4 hours to complete. The goals of Healthy U are to: 1) Increase male youth's perception of vulnerability to unplanned fatherhood, STDs and HIV; 2) Increase male youth's self-efficacy for negotiating condom use with their partners; 3) Increase male youth's self-efficacy for using condoms correctly and consistently every time they have sex; and 4) Increase male youth's engagement with goals and dreams for their future.
62437397|NCT04027010|NO_INTERVENTION|Treatment as usual|The counterfactual condition for the study is a business-as-usual condition. OYA does not provide much programming to youth in its facilities related to sexual health and pregnancy prevention.
62437398|NCT01201954|ACTIVE_COMPARATOR|sucrose|0,5 ml/kg of sucrose administered 2 minutes prior the procedure
62437399|NCT01201954|PLACEBO_COMPARATOR|sterile water|0,5 ml/kg of sterile water administered 2 minutes prior the procedure
62437400|NCT04235647|EXPERIMENTAL|Study group|Older, sedentary adults (age 50-75 years) with and least one other cardiovascular risk-factor
62604013|NCT03160001|PLACEBO_COMPARATOR|Placebo and etanercept|Placebo lactose 500mg cap twice daily with etanercept 50mg weekly for 8 weeks
62044581|NCT06574815|ACTIVE_COMPARATOR|Gide-EL|Guided bone regeneration (GBR) with a Bio-Gide membrane and early implant loading
62437401|NCT04235647|ACTIVE_COMPARATOR|Control group|Older, sedentary adults (age 50-75 years) with and least one other cardiovascular risk-factor
62604014|NCT03160001|EXPERIMENTAL|Niclosamide and etanercept|Niclosamide cap 500 mg twice daily with Etanercept 50mg weekly for 8 weeks
62604015|NCT06623877|EXPERIMENTAL|Group A: biopcy proven glomerulonephritis patients not started specific treatement|agroup of Biopcy proven glomerulonephritis patients not started specific treatement will undergo for renal shear wave elastography
62604016|NCT06623877|EXPERIMENTAL|Group B : healthy persons|A group of healthy persons will undergo for renal shear wave elastography
62437402|NCT04985214||Oral therapy|Patients included in the PK-E3i clinical study or patients with hemopathies starting treatment with oral therapy.
62437403|NCT02257632|EXPERIMENTAL|Group 1|6 monthly intravitreal injections of 0.5 mg ranibizumab
62437404|NCT02257632|EXPERIMENTAL|Group 2|3 monthly intravitreal injections of 2 mg aflibercept followed by 3 monthly intravitreal injections of 0.5 mg ranibizumab
62437405|NCT03031457||1|Patients undergo primary fascial closure of abdominal donor-site
62604017|NCT05177900|ACTIVE_COMPARATOR|Biphasic pulse without interphase gap|
62604018|NCT05177900|EXPERIMENTAL|Biphasic pulse with interphase gap|
62826561|NCT05961722||Group 3|The group receiving preoperative and intraoperative dextrose infusion.
62247129|NCT04687813|EXPERIMENTAL|Single Ascending Doses 100mg|Drug: FTP-198, single dose 100mg Drug: Placebo, single dose Placebo matched to FTP-198, tablet
62826562|NCT06598280|EXPERIMENTAL|SDD Group|Following successful venipuncture, one or two PPS are deployed at the discretion of the operator prior to catheter insertion for catheter sheath sizes ≥ 9 French. Another PPS is deployed after catheter removal if the sheath size is \< 9 French. All sheaths are removed at the end of the ablation procedure. Hemostasis should be achieved by delivery of the suture. Protamine may be administered according to institutional standards. A vertical mattress suture (Donati suture) is applied superficially to conform to the skin tissue. The suture is removed on the first day after PVI.
62826563|NCT06598280|EXPERIMENTAL|ONS Group|Once the PVI block is confirmed, a figure-of-eight suture is placed at the femoral access site. The sheaths are removed and haemostasis should be achieved by manual compression at the discretion of the operator. Protamine may be administered according to institutional standards. A tourniquet is applied for a minimum of 30 minutes and the patient should remain supine.
62826564|NCT06464601||Cohort 1:neoadjuvant treatment|
62826565|NCT06464601||Cohort 2:conversion treatment|
62826566|NCT04502030|EXPERIMENTAL|Panzyga|
62826567|NCT04502030|PLACEBO_COMPARATOR|Placebo|
62826568|NCT04465344|EXPERIMENTAL|IOL implantation experimental|Experimental arm: Trifocal intraocular lens Isatis TF
62826569|NCT04465344|ACTIVE_COMPARATOR|IOL implantation active comparator|Comparator arm: Monofocal intraocular lens Isatis
62826570|NCT01955135|ACTIVE_COMPARATOR|sedation|The sedation group (Group S, n=30), received 1 mg/kg ketamine and 1 mg/kg propofol as a bolus for induction. The patients then received an infusion of 100-150 mcg/kg/min propofol and 0.25mg/kg/h of ketamine for maintenance.
62826571|NCT01955135|ACTIVE_COMPARATOR|general anesthesia|In the general anesthesia group (Group G, n=30), anesthesia was induced using 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen; endotracheal intubation was facilitated without use of a neuromuscular blocker agent. Anesthesia was maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen.
62826572|NCT03674411|EXPERIMENTAL|FLU, CY, TBI + MGTA-456 infusion|
62826573|NCT06590363|EXPERIMENTAL|Music|Corresponded to patients and doctors subjected to the period of listening to zen music in the appointment.
62826574|NCT06590363|NO_INTERVENTION|Non-Music|Corresponded to patients and doctors not subjected to the period of listening to zen music.
62826575|NCT06069843|EXPERIMENTAL|Treatment|Single dose of IV ketamine administered at the standard dose used for depression treatment (0.5 mg/kg)
62826576|NCT00906204|EXPERIMENTAL|Single-dose Thymoglobulin|Biological/Vaccine Single-dose rabbit Anti-thymocyte Globulin induction, 6 mg/kg IV infusion
62826577|NCT00906204|ACTIVE_COMPARATOR|Divided-dose Thymoglobulin|Biological/Vaccine Divided-dose rabbit Anti-thymocyte Globulin induction, 1.5 mg/kg IV infusion QD x 4
62826578|NCT04484077|EXPERIMENTAL|hCT-MSC infusion|A single, intravenous infusion of hCT-MSCs. Targeted dose is 2x10\^6 cells/kg with a maximum dose of 10 x 10\^7 cells/kg.
62826579|NCT02015260|PLACEBO_COMPARATOR|placebo|placebo 0% nitrite cream and placebo 0% citric acid cream
62247130|NCT04687813|EXPERIMENTAL|Single Ascending Doses 300mg(food-impact)|Drug: FTP-198, single dose 300mg Drug: Placebo, single dose Placebo matched to FTP-198, tablet 2-X: fasting (Period 1) ; 2-Y:Postprandial (Period 1) 2-X:Postprandial (Period 2); 2-Y:fasting (Period 2)
62247131|NCT04687813|EXPERIMENTAL|Single Ascending Doses 400mg|Drug: FTP-198, single dose 400mg Drug: Placebo, single dose Placebo matched to FTP-198, tablet
62247132|NCT06267989|ACTIVE_COMPARATOR|Extraction|Extraction of the primary canine
62826580|NCT02015260|ACTIVE_COMPARATOR|Topical NO Dose A|3% sodium nitrite + 4.5% citric acid twice daily
62826581|NCT02015260|ACTIVE_COMPARATOR|Topical NO Dose B|6% sodium nitrite + 9% citric acid once daily
62826582|NCT02015260|ACTIVE_COMPARATOR|Topical NO Dose C|6% sodium nitrite + 9% citric acid twice daily
62826583|NCT04323124|EXPERIMENTAL|Treatment|PF-07059013 assignment
62247133|NCT06267989|EXPERIMENTAL|Expansion|Rapid maxillary expansion without extraction of the primary canine
62247134|NCT06267989|NO_INTERVENTION|Control|No intervention during the observation period (18 months)
62826584|NCT04323124|PLACEBO_COMPARATOR|Placebo|Placebo assignment
62826585|NCT06587828||Inflammatory Bowel Diseases- Crohn's Disease and Ulcerative Colitis|"Group A: IBD-Treatment Naïve Crohn's: Patients that are scheduled to have an endoscopic procedure to confirm a suspected diagnosis of Crohn's disease and are not currently on any Crohn's directed treatment.~Group B: IBD-On-Treatment Crohn's: Patients with an established diagnosis of Crohn's disease and are only on treatments that are allowed under this protocol (see Inclusion and Exclusion criteria) and consent to have extra biopsies obtained from inflamed and normal colon for research purposes during a planned endoscopy for their standard clinical care.~Group C: IBD-Ulcerative Colitis: Patients with established or suspected diagnosis of ulcerative colitis who may be on treatments that are allowed under this protocol (see Inclusion and Exclusion criteria).~Interventions: Companion blood samples with colonoscopy and biopsies for participants with Crohn's Disease or Ulcerative Colitis"
62826586|NCT06587828||Celiac Disease: Small intestine endoscopic biopsies obtained during endoscopy|"Group A Celiac Disease: Excess small intestine biopsies obtained during endoscopy from patients with celiac disease or from patients who are suspected to have celiac disease. A companion blood sample will be drawn on or around the same day.~Group B Celiac Disease: Patients who are suspected to have celiac disease or are known to have celiac disease and who undergo a research endoscopy of the small intestine to obtain biopsy samples from the small intestine. A companion blood sample will be drawn on or around the same day.~Interventions: Companion blood samples with upper endoscopy and biopsies."
62826587|NCT06587828||Ankylosing spondylitis or non-radiographic axial spondyloarthritis (nr-axSpA) (HLA-B27 positive)|"Group A ankylosing spondylitis- arthrocentesis: HLA-B27 positive patients with known or suspected ankylosing spondylitis or nr-axSpA with inflammatory joint involvement who consent to arthrocentesis done for research purposes. A blood sample drawn on or around the same day of the procedure is also required. A minimum of 2 mL and up to 10 mL of joint aspiration fluid is required.~Group B ankylosing spondylitis- surgery: HLA-B27 positive patients with known or suspected ankylosing spondylitis or nr-axSpA planned for surgery for their standard clinical care who consent to have excess materials from their resected joint tissues used for research purposes. Bone, joint or biologic materials from the surgical resection is acceptable. A blood sample drawn on or around the same day of the procedure is also required.~Interventions: Companion blood samples with arthrocentesis"
62044582|NCT06574815|SHAM_COMPARATOR|Gide-DL|Guided bone regeneration (GBR) with a Bio-Gide membrane and delayed implant loading
62044583|NCT00377325|EXPERIMENTAL|1|Participants will receive full dose cyclosporin.
62044584|NCT00377325|EXPERIMENTAL|2|Participants will receive active drug full dose until cleared, then one dose every 4 days.
62044585|NCT00377325|PLACEBO_COMPARATOR|3|Participants will receive active drug full dose until clear, then full dose every 4 days with placebo on the intervening days.
62604019|NCT03083769||Cohort 1|The retrospective cohort consists of about 839 kidney transplant recipients from Nanfang Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be recorded.
62604020|NCT03083769||Cohort 2|The retrospective cohort consists of about 663 kidney transplant recipients from Guilin No. 924 Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be recorded.
62826588|NCT06587828||Multiple Sclerosis. Excess CSF collected during lumbar puncture|"A. Multiple Sclerosis Group A: Extra CSF from standard clinical procedure in patients diagnosed with multiple sclerosis and have a planned lumbar puncture for standard clinical care where extra CSF may be obtained for standard of care. A blood sample drawn on or around the same day is required. CSF in excess of clinical laboratory requirements will be used for study purposes. 2 mL to 10 mL of CSF is required. Up to 20 patients will be recruited into research procedure group.~B. Multiple Sclerosis Group B: Research CSF collection - Patients will have CSF collected during a lumbar puncture that is not required for standard clinical care and will also have a companion blood sample collected. The patient will consent to a research lumbar puncture and will be enrolled into the research CSF collection cohort. 2 mL to 10 mL of CSF is required. Up to 10 patients will be recruited into this group.~Interventions: Companion blood samples with lumbar puncture"
62044586|NCT00952822|EXPERIMENTAL|1|ADVATE reconstituted in 2 mL sterile water for infusion
62044587|NCT00952822|ACTIVE_COMPARATOR|2|ADVATE reconstituted in 5 mL sterile water for infusion
62247135|NCT02878551|EXPERIMENTAL|Prehabilitation program|Multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
62604021|NCT05726942|EXPERIMENTAL|Healthi|
62604022|NCT05726942|NO_INTERVENTION|Control|
62826589|NCT06587828||Scleroderma. Skin tissue biopsy|"A. Scleroderma Group A: Excess Tissue - Excess skin tissue obtained during a planned skin tissue biopsy and with a companion blood sample. A minimum sample of a a single 3 mm punch biopsy is required and up to 3 punch biopsies will be allowed. Up to 10 patients will be recruited into this group.~B. Scleroderma Group B: Research Skin Biopsy - Patients that agree to a research skin tissue biopsy, not otherwise clinically indicated and obtained at any one point in time, and with a companion blood sample. For skin biopsies, a minimum sample of a single 3 mm punch biopsy is required and up to 3 punch biopsies will be allowed. Up to 10 patients will be recruited into this group.~Interventions: Companion blood samples with skin biopsy"
62826590|NCT06587828||Systemic Sclerosis with pulmonary involvement|"Patients would consent to have excess materials from their bronchoscopy, bronchoalveolar lavage fluid or thoracoscopy done for standard of care purposes. Patients should not undergo these procedures unless required for standard clinical care. There is no minimum tissue requirement for this cohort. Up to 10 patients will be recruited into this group.~Interventions: Companion blood samples with biopsy"
62044588|NCT06580977|EXPERIMENTAL|cardiovascular training|The experimental group will perform a cardiovascular training three times a week over 12 weeks.
62044589|NCT06580977|ACTIVE_COMPARATOR|stretching|The active control group will perform a stretching training three times a week over 12 weeks.
62044590|NCT01420848|ACTIVE_COMPARATOR|Auriculotherapy Group|"The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.~Two points were chosen to treat stress and anxiety (Shenmen and Brainstem)."
62044591|NCT01420848|PLACEBO_COMPARATOR|Placebo Group|Auriculotherapy by sham, at the fist and outer ear points. These points aren't indicated for stress and anxiety.
62044592|NCT01420848|NO_INTERVENTION|Control Group|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
62826591|NCT06587828||Other Autoimmune Disease such as psoriasis, vitiligo, type 1 diabetes and others|"A. Other Autoimmune Group A: Excess Biologic Material - Excess material sourced from a part of the body exhibiting clinical symptoms of autoimmune disease +/- nearby normal biologic materials, and with a companion blood sample. While there is no minimum tissue requirement for this cohort, tissue requirements from other autoimmune diseases described above may be used to guide tissue collection sample amounts.~B. Other Autoimmune Group B: Research Biologic Material - Research skin tissue biopsy, other tissue biopsy or biologic materials collected from an affected part of the body +/- normal healthy biologic materials, and with a companion blood sample. In the instance of a skin biopsy, a minimum of a single 3 mm punch biopsies, and up to three, 3 mm punch biopsies, will be obtained."
62044593|NCT03531320|EXPERIMENTAL|Part 1:Dose-Escalation Phase|40 mg D07001-softgel capsules 60 mg D07001-softgel capsules 80 mg D07001-softgel capsules 120 mg D07001-softgel capsules 160 mg D07001-softgel capsules
62044594|NCT03531320|EXPERIMENTAL|Part 2: Dose-Expansion Phase (Phase 2)|higher dose-expansion of D07001-softgel capsules lower dose-expansion of D07001-softgel capsules
62044595|NCT02115594|EXPERIMENTAL|Fulvestrant + Entinostat|Arm A: Fulvestrant (500 mg on C1D1, C1D15, C2D1, and on Day 1 of each subsequent cycle) plus entinostat (5 mg PO once weekly)
62044596|NCT02115594|ACTIVE_COMPARATOR|Fulvestrant + Placebo|Arm B: Fulvestrant (500 mg on C1D1, C1D15, C2D1, and on Day 1 of each subsequent cycle) plus placebo (5 mg PO once weekly)
62044597|NCT03064516|EXPERIMENTAL|Endocrown|Restorations with ceramic endocrown in endodontically treated teeth
62044598|NCT03064516|ACTIVE_COMPARATOR|Onlay and fiber pin|Restorations with onlay ceramic and glass fiber pin in endodontically treated teeth
62604023|NCT04208321|EXPERIMENTAL|Cohort 1|40 mg (1 tablet of 40 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
62044599|NCT05047198|ACTIVE_COMPARATOR|Control|Catheter Ablation using invasive mapping
62604024|NCT04208321|EXPERIMENTAL|Cohort 2|80 mg (2 tablets of 40 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
62044600|NCT05047198|EXPERIMENTAL|Treatment|Radio-ablation using non-invasive mapping
62044601|NCT05691257|EXPERIMENTAL|Roxadustat group|Roxadustat group: patients with heart failure and chronic kidney disease and anemia treated with roxadustat and other anemia correction drugs.
62044602|NCT05691257|OTHER|Control group|Control group: patients with heart failure and chronic kidney disease and anemia who were treated with other drugs include: Recombinant human eythropoietin (RH-EPO), iron agents (ferrous succinate, polysaccharide iron complex, iron sucrose, etc.)
62044603|NCT04679090|EXPERIMENTAL|Participant|Participants will answer a series of questionnaires, wear a physical activity tracker (pedometer) and do functional tests (six minute walk test, chair stand test, balance, back scratch, sit and reach, leg strength and hand strength) pre and post.
62044604|NCT06336668|ACTIVE_COMPARATOR|Bovine based-HMF|The infant will fed human milk fortified with bovine-based HMF.
62247136|NCT03708172|ACTIVE_COMPARATOR|rTMS + Cognitive Training|Participants will receive repetitive transcranial magnetic stimulation (rTMS) in an open label fashion. In addition, participants will receive active cognitive training (CT) which consists of completing computer-based tasks designed to enhance executive function.
62604025|NCT04208321|EXPERIMENTAL|Cohort 3|160 mg (4 tablets of 40 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
62826592|NCT06587828||Evolving autoimmune disease|Serial sampling of excess materials, with companion blood samples, can be obtained at intervals consistent with excess materials collected for clinical care.
62604026|NCT04208321|EXPERIMENTAL|Cohort 4|320 mg (4 tablets of 80 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
62604027|NCT04208321|EXPERIMENTAL|Cohort 5|640 mg (8 tablets of 80 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
62604028|NCT04208321|EXPERIMENTAL|Cohort 6|160 mg (4 tablets of 40 mg) of VT-1598 administered orally as a single dose, n=6, or matching placebo, n=2, after high-calorie, high-fat meal on Day 1 in a double-blind manner.
62604029|NCT00850096|PLACEBO_COMPARATOR|Placebo for Nasulin|Placebo for Nasulin Spray
62826593|NCT06587828||Previously cryopreserved, dissociated tissue obtained from a biobank or tissue repository|These samples will have been collected from patients with autoimmune diseases, at any one time point after diagnosis and with a companion blood sample.
62826594|NCT03435796|OTHER|Participants exposed to Gene-modified (GM) T cell therapy|
62826595|NCT03606369|EXPERIMENTAL|Palonosetron|"Early emesis: Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV.~Delayed emesis: Dexamethasone 8 mg orally on days 2, 3 and 4."
62826596|NCT03606369|ACTIVE_COMPARATOR|Ondansetron|"Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV.~Delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs."
62826597|NCT06601153||Retrospective cohort of 561 patients with suspected CAD|All patients with suspected CAD with available blood samples stored in bio-banks and interpretable CCT stored in imaging repositories.
62826598|NCT06601153||Prospective cohort od 400 patients with suspected CAD|All patients with suspected CAD in whom with blood samples will be collected and stored in bio-banks and CCT will be acquired and stored in imaging repositories.
62826599|NCT06595732|EXPERIMENTAL|1PFMT + Abd Group|Participants in this group will perform pelvic floor muscle training in conjunction with abdominal muscle training. It is believed that abdominal contraction will lead to an increase in abdominal pressure, which will serve as additional load for pelvic floor muscle training.
62826600|NCT06595732|EXPERIMENTAL|AHG Group|Participants in this group will perform Hypopressive Abdominal Gymnastics exercises (Caufriez, 1997). It is believed that these exercises reduce the pressure on the pelvic floor muscles and help tone this musculature without causing harm.
62826601|NCT06595732|ACTIVE_COMPARATOR|PFMT Group|Participants of PFMT group will perform specific exercises for the pelvic floor muscles, with maximum contraction and without involvement of other muscle groups. This arm is considered the control group because it is the treatment that has been proven to effectively treat urinary incontinence, as demonstrated in over 50 clinical trials.
62826602|NCT06592430||Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers|
62826603|NCT06592430||Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers|
62826604|NCT04202601|EXPERIMENTAL|Neoadjuvant therapy group|
62826605|NCT04202601|EXPERIMENTAL|first-line therapy group|
62826606|NCT04202601|EXPERIMENTAL|≥second-line therapy group|
62826607|NCT06593002|EXPERIMENTAL|Experimental: Therapeutic play|Children in the experimental group received a therapeutic video game intervention in addition to the pre-treatment routine.
62826608|NCT06593002|NO_INTERVENTION|Control group|Children in the control group underwent routine clinical practice. No other intervention was performed.
62826609|NCT03173248|EXPERIMENTAL|AG-120 + Azacitidine|Participants received AG-120 500 mg orally, once daily (QD) in combination with azacitidine 75 milligrams per square meter per day (mg/m\^2/day) subcutaneously (SC) or intravenously (IV), on Days 1-7, or on Days 1-5 and 8-9, of each 28-day cycle for a minimum of 6 cycles until death, disease relapse, disease progression, development of unacceptable toxicity (adverse event), confirmed pregnancy, withdrawal by participant or protocol violation.
62826610|NCT03173248|PLACEBO_COMPARATOR|Placebo + Azacitidine|Participants received AG-120 matching placebo orally, QD in combination with azacitidine 75 mg/m\^2/day SC or IV, on Days 1-7, or on Days 1-5 and 8-9, of each 28-day cycle for a minimum of 6 cycles until death, disease relapse, disease progression, development of unacceptable toxicity (adverse event), confirmed pregnancy, withdrawal by participant or protocol violation .
62604030|NCT00850096|ACTIVE_COMPARATOR|Nasulin|Nasulin (intranasal insulin spray 1%)
62604031|NCT04319081||Uncontrolled patients with hypercholesterolemia|Patients that meet criteria inclusions and they have just started to take Alirocumab or Evolocumab
62604032|NCT04927871|EXPERIMENTAL|Hybridized Lyfestile Intervention|The participants will receive three interventions including Total Diet Replacement, Medical Nutrition Therapy, and the Diabetes Prevention Program
62826611|NCT04760808||AIS group|
62044605|NCT06336668|EXPERIMENTAL|Human milk-based HMF|The infant will be fed human milk fortified with human milk-based HMF.
62044606|NCT00683644|EXPERIMENTAL|1 - zinc placebo|Zinc sulfate (50 mg elemental zinc) taken once daily for 4 months. Washout 1 month. Placebo oral capsule taken once a day for 4 months.
62044607|NCT00683644|EXPERIMENTAL|2 - placebo zinc|Placebo oral capsule taken once a day for 4 months. Washout 1 month. Zinc sulfate (50 mg elemental zinc) taken once daily for 4 months.
62604033|NCT04927871|ACTIVE_COMPARATOR|Only Diabetes Prevention Program|The comparison group will receive only the Diabetes Prevention Program
62044608|NCT02822222|EXPERIMENTAL|RMJH-111b|Four (4) RMJH-111b (magnesium citrate, tribasic anhydrous) soft gelatin capsules (110 mg elemental magnesium/capsule) orally bid for 7 days
62044609|NCT02822222|PLACEBO_COMPARATOR|Placebo|Four (4) placebo soft gelatin capsules (0 mg elemental magnesium/capsule) orally bid for 7 days
62044610|NCT00825266|ACTIVE_COMPARATOR|bosentan|Bosentan 62.5 twice daily for 4 weeks, then 125 mg twice daily.
62044611|NCT00825266|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration of the study.
62044612|NCT03157518|EXPERIMENTAL|Treatment Arm|Patients enrolled will receive probiotic supplementation following the first bronchoscopy for four weeks. A second bronchoscopy will be performed following probiotic administration.
62044613|NCT03978234|EXPERIMENTAL|Single group|Single group
62044614|NCT04219605||Symptomatic vaginitis patients|Symptomatic patients evaluated in the clinic for vulvovaginal symptoms.
62044615|NCT04578327|EXPERIMENTAL|Aim 1|Data from Specific Aim 1 will be used to test the following hypotheses: H1a. The body-powered prosthetic devices are embodied more than passive and myoelectric prosthetic devices. H1b. Passive cosmetic devices are embodied less than actuated cosmetic devices (agency). H1c. Body-powered terminal devices are embodied less than myoelectric terminal devices (agency).
62044616|NCT04578327|EXPERIMENTAL|Aim 3|Data from Specific Aim 3 will be used to test the following hypotheses: H3a. The maximum number of channels elicits more embodiment than the minimum number. H3b. The sensory feedback from passive spatial locations of the hand increases the embodiment compared to sensory feedback just from the grasping spatial locations.
62044617|NCT01298960|EXPERIMENTAL|rGH Group|
62044618|NCT01298960|NO_INTERVENTION|Non rGH group|
62044619|NCT04727151|EXPERIMENTAL|TAC01-HER2|Lymphodepletion followed by TAC01-HER2 as a single IV infusion, with a potential for a second dose administration.
62044620|NCT04727151|EXPERIMENTAL|TAC01-HER2 plus pembrolizumab|Lymphodepletion followed by TAC01-HER2 as a single IV infusion, followed by pembrolizumab administration.
62044621|NCT05944965|EXPERIMENTAL|Atomoxetine-plus-Oxybutynin (AtoOxy)|80mg atomoxetine and 5mg of oxybutynin administered to participant, 30 min prior to bed.
62044622|NCT05944965|ACTIVE_COMPARATOR|Atomoxetine|80mg atomoxetine and placebo administered to participant, 30 min prior to bed.
62044623|NCT05944965|PLACEBO_COMPARATOR|Placebo|Placebo plus placebo administered to participant, 30mins prior to bed
62604034|NCT01916161||IBD patients|Ambulatory patients attending IBD clinics at Leeds Teaching Hospitals
62604035|NCT05450926|NO_INTERVENTION|healthy volunteers|Two Algology Specialists will record the localization and number of cervical spinal nerve, transverse process cornes and surrounding vascular structures at cervical C4-5-6-7 levels in healthy volunteers by Doppler USG.
62604036|NCT05450926|ACTIVE_COMPARATOR|patients with cervical radicular pain|Two Algology Specialists will apply cervical root block to patients with cervical radicular pain guided by Doppler USG, and pain scores of the patients will be evaluated with VAS (visual analog scale) before and after the procedure.
62604037|NCT05450926|OTHER|human cadavers|Seven formalin-containing human cadavers will be examined by 3 anatomy doctors at Ankara University Faculty of Medicine, Department of Anatomy to determine the morphology of the spinal nerve, vertebral artery, assending and deep arteries in the cervical foraminal region, as well as the radicular arteries.
62604038|NCT02050568||Anterior genital prolapse|Women with anterior genital prolapse ≥ grade 2, who are awaiting genital prolapse surgery.
62826612|NCT04760808||Control Group|
62044624|NCT01241357||Observation only|This study has a single arm and no intervention.
62044625|NCT01441739||NEC suspected - Final diagnosis NEC|
62044626|NCT01441739||NEC suspected - Final diagnosis no NEC|
62044627|NCT01441739||Controls|
62044628|NCT01696487|EXPERIMENTAL|Healthy Volunteers|Volunteers will be challenged with oral 150g Fructose per day for 28 days.
62044629|NCT01696487|NO_INTERVENTION|NAFLD|Patients with confirmed fatty liver (imaging positive) will be compared at baseline with other arms.
62044630|NCT01696487|NO_INTERVENTION|NASH|Patients with confirmed non-alcoholic steatohepatitis (biopsy proven) will be compared at baseline with other arms.
62044631|NCT01696487|NO_INTERVENTION|Hepatitis C genotype 1 (HCV-GT1)|Patients with confirmed hepatitis C genotype 1 will be compared at baseline with other arms and act as different liver disease control group
62044632|NCT04380922||Active IBD|"Active Inflammatory Bowel Diseases defined as :~For Crohn's disease :~* Harvey Bradshaw Index ≥ 4~* Associated with fecal calprotectin rate \> 250 µg/g within 3 months OR CRP ≥ 6mg /L OR the presence of ulcerative and/or inflammatory lesions in endoscopy or in imaging within 3 months For Ulcerative colitis~* Partial Mayo score ≥ 2~* Associated with fecal calprotectin rate \> 250 µg/g within 3 months OR CRP ≥ 6mg /L OR the presence of ulcerative and/or inflammatory lesions in endoscopy within 3 months"
62044633|NCT04380922||Non-active IBD|Non-active Inflammatory Bowel Diseases
62044634|NCT04512521||eosinophilic asthma|
62247137|NCT03708172|SHAM_COMPARATOR|rTMS + Sham Cognitive Training|Participants will receive repetitive transcranial magnetic stimulation (rTMS) in an open label fashion. In addition, participants will receive sham cognitive training (CT) which consists of completing computer-based tasks.
62604039|NCT02050568||Posterior genital prolapse|Women with posterior genital prolapse ≥ grade 2, who are awaiting genital prolapse surgery.
62826613|NCT03249207|ACTIVE_COMPARATOR|IL-1Ra twice daily|
62826614|NCT03249207|PLACEBO_COMPARATOR|Placebo twice daily|
62826615|NCT05206565|EXPERIMENTAL|Autologous with TRAM/DIEP flaps, with neurotization|Autologous with TRAM/DIEP flaps, with neurotization
62604040|NCT05359770|EXPERIMENTAL|Experimental|Experimental: Experimental Group/ Active HD-tDCS Patients randomly enrolled in this group will receive 10 sessions of anodal HD-tDCS stimulation on cortical representation zone of left diaphragmatic motor cortex associated to respiratory training; for 20 minutes (each session) with a 2mA intensity. The electrical current will be delivered with a ramp-up time of 30 s, held at 3mA for 20 min, and then ramped down over 30 s.
62826616|NCT05206565|NO_INTERVENTION|Autologous with TRAM/DIEP flaps, without neurotization|Autologous with TRAM/DIEP flaps, without neurotization
62826617|NCT02529072|EXPERIMENTAL|Group I|Patients will receive nivolumab 3 mg/kg IV every 2 weeks for 8 weeks followed by surgery. Following resection, nivolumab and DC vaccine will be administered every 2 weeks (± 1) for a total of 3 vaccines, followed by biweekly treatment with nivolumab and monthly DC vaccinations for a total of 5 more vaccines. Patients will continue to receive nivolumab every 2 weeks until progression.
62826618|NCT02529072|EXPERIMENTAL|Group II|Patients will initially receive the fourth cycle of nivolumab then receive nivolumab 3 mg/kg IV and DC vaccine every 2 weeks for a total of 3 vaccines, and then surgery. Subsequent to surgery, the patient will resume biweekly treatment with nivolumab and monthly DC vaccinations for a total of 5 more vaccines. Patients will continue to receive nivolumab every 2 weeks until progression.
62826619|NCT02345135|ACTIVE_COMPARATOR|Ataxia Telangiectasia|All A-T patients presented for 3 study visits. In all visits patients had a clinical examination, a blood collection and a lung function measurement. Furthermore symptom diaries were distributed and collected on these visits.
62826620|NCT02345135|ACTIVE_COMPARATOR|Healthy Control|All healthy controls presented for 3 study visits. In all visits patients had a clinical examination and a lung function measurement. Furthermore symptom diaries were distributed and collected on these visits.
62826621|NCT02488915|EXPERIMENTAL|EmboTrap® Revascularization Device|Mechanical Thrombectomy with EmboTrap
62826622|NCT06586463|ACTIVE_COMPARATOR|conventional treatment|(Control group) receives conventional therapy (cervical, and scapular stabilization exercises, stretching exercises for the pectoralis minor, sternocleidomastoid, scalene muscles and hot pack )
62826623|NCT06586463|EXPERIMENTAL|kinetic control training|"takes the same as the control group plus kinetic control. Correction of Low cervical flexion UCM Initially, position the lower and upper cervical spine in neutral with the head supported. the person is trained to perform independent upper cervical flexion (nodding). The upper cervical spine can flex only so far as there is no low cervical flexion. As the ability to control upper cervical extension gets easier and the pattern of dissociation feels less unnatural the exercise can be progressed.~Correction of scapula and glenohumeral ( UCM) the arm flexion is performed unsupported through the partial range that can be controlled well. This is eventually progressed throughout the full benchmark range with the elbow straight. With visual, auditory and kinaesthetic cues the person becomes familiar with the task of flexing the glenohumeral joint to 90° without scapula movement or glenohumeral translation."
62826624|NCT02708836|ACTIVE_COMPARATOR|ETT only|Endotracheal tube intubation after induction of anesthesia. Ventilation with ETT until emergence.
62826625|NCT02708836|EXPERIMENTAL|Combined ETT/LMA technique|Placement of LMA after induction of anesthesia. Intubation of trachea with ETT via LMA with fiberoptic bronchoscope. Ventilation with ETT throughout case. Removal of ETT while deeply anesthetized. Ventilation with LMA until emergence.
62826626|NCT06500338|NO_INTERVENTION|Preflight Seated|Preflight control at 1 Gravity level (G), seated. Data collection of Internal Jugular Vein (IJV) area, IJV pressure, and Doppler blood flow.
62826627|NCT06500338|NO_INTERVENTION|Preflight Supine|Preflight control at 1 Gravity level (G), supine. Data collection of Internal Jugular Vein (IJV) area, IJV pressure, and Doppler blood flow.
62826628|NCT06500338|EXPERIMENTAL|inflight reduced gravity measures|inflight experimental at 0 Gravity levels (G), 0.25G, 0.5G, and 0.75G. Data collection of Internal Jugular Vein (IJV) area, IJV pressure, and Doppler blood flow.
62826629|NCT06486025|ACTIVE_COMPARATOR|Magnesium Sulphate 1g/hr|Women in this group will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 1 g/h.
62826630|NCT06486025|ACTIVE_COMPARATOR|Magnesium Sulphate 2g/hr|Women in this group will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 2 g/h.
62826631|NCT05121064|EXPERIMENTAL|Arm A- Alcohol Brief Intervention|Following enrollment and randomization, participants will receive a single session of alcohol brief intervention (BI). Further, standard of care antiretroviral therapy (ART) adherence counseling will be provided as per local guidelines.
62247138|NCT01326078|EXPERIMENTAL|propofol nanoemulsion|3-4 mg/kg of propofol nanoemulsion will be administered by 1mL per 5 seconds, adjustment dose can be given.
62247139|NCT01326078|ACTIVE_COMPARATOR|propofol lipid emulsion|3-4 mg/kg will be administered by 1 ml per 5 seconds.
62604041|NCT05359770|SHAM_COMPARATOR|Sham Comparator|Sham Comparator: Control Group / Sham Group In the sham condition, the device will provide a 30-second ramp-up followed immediately by a 30-second ramp down in HD-tDCS associated with inspiratory muscle training for 20 minutes
62604042|NCT00123617|EXPERIMENTAL|Phase III cardiac rehabilitation|Phase III group-based cardiac rehabilitation classes, weekly
62604043|NCT00123617|NO_INTERVENTION|Monitoring|Normal daily living, no extra visits to study centre
62604044|NCT05471570|ACTIVE_COMPARATOR|anodal tDCS|20 minutes of one mA anodal High-Definition tDCS (HD-tDCS) over right IFG combined with 40 minutes of naming therapy for five consecutive days in week 1
62247140|NCT06656364|EXPERIMENTAL|Esprit BTK System|This device, manufactured by Abbott Medical, is intended to be used for improving luminal diameter in infrapopliteal lesions in patients with CLTI.
62826632|NCT05121064|EXPERIMENTAL|Arm B- Alcohol Brief Intervention plus Common Elements Treatment Approach|Following enrollment and randomization, participants will receive a single session of alcohol brief intervention (BI) and then will be referred to receive Common Elements Treatment Approach (CETA). Further, standard of care antiretroviral therapy (ART) adherence counseling will be provided as per local guidelines. For CETA, a specially trained counselor will contact the participant within 2 weeks of enrollment to arrange for CETA sessions, which occur approximately weekly. Participants will receive 6 to 12 sessions of CETA with the number of sessions based on symptoms and response to therapy.
62826633|NCT05121064|ACTIVE_COMPARATOR|Arm C- Standard of Care|Following enrollment and randomization, participants will receive ART adherence counseling, which is the standard of care at the clinics.
62437406|NCT01956357|EXPERIMENTAL|Aquatic exercise|"The aquatic aerobic training had a duration of 12 weeks and adopted the interval-training method, with intensities ranging between 85 and 100% of second ventilatory threshold (VT2) and total duration of 45 minute per session.~The sessions consisted of warm up, main part and calm down. The warm-up consisted of a walk in deep water at low intensity for three minutes. The main part was intended to aerobic training in deep water, in which subjects walked and / or ran, depending on your fitness level found in pre-training test. The calm down consisted of walking in deep water at low intensity for two minutes and stretching standardized, emphasizing the muscles worked in the main part of the session, with a total duration of approximately five minutes."
62044635|NCT02681913|NO_INTERVENTION|standard cardioplegia|"Delivery of cardioplegic solutions will be according to the standard protocol (Amphia hospital, Breda, the Netherlands). Oxygenated blood and cardioplegic maintenance solution is delivered in a 20:1 ratio. Cardioplegic solutions will be administered at 20-minutes intervals. The flow of the cardioplegia must be at 300 ml/min, the duration is approximately 1 minute.~The cardioplegic maintenance solution consists of a 500 ml normal saline (0.9% NaCl) infusion bag. Potassiumchloride (20 mmol) and magnesiumsulphate (1000 mg) is added according to standard protocol.~This arms receives standard intermittent 20:1 diluted warm blood cardioplegic solution.~Intervention: n/a"
62044636|NCT02681913|EXPERIMENTAL|adenosine enriched cardioplegia|"Delivery of cardioplegic solutions will be according to the standard protocol (Amphia hospital, Breda, the Netherlands). Oxygenated blood and cardioplegic maintenance solution is delivered in a 20:1 ratio. Cardioplegic solutions will be administered at 20-minutes intervals. The flow of the cardioplegia must be at 300 ml/min, the duration is approximately 1 minute.~The cardioplegic maintenance solution consists of a 1000 mg = 500 ml adenosine infusion bag (2 mg/ml). Potassiumchloride (20 mmol) and magnesiumsulphate (1000 mg) is added according to standard protocol.~This arms receives adenosine enriched, intermittent 20:1 diluted warm blood cardioplegic solution.~Intervention: Drug: Adenosine"
62044637|NCT03236298|ACTIVE_COMPARATOR|PIEB speed of infusion 250 ml/hr|The programmed intermittent bolus of 10ml will be administered every 40 minutes, at a speed of 250 ml/hr by the CADD-Solis Ambulatory Infusion System.
62044638|NCT03236298|ACTIVE_COMPARATOR|PIEB speed of infusion 125 ml/hr|The programmed intermittent bolus of 10ml will be administered every 40 minutes, at a speed of 125 ml/hr by the CADD-Solis Ambulatory Infusion System.
62247141|NCT02347488|EXPERIMENTAL|ETT holder and bite guard|Participants will have endotracheal tubes secured with tape prior to having surgery, which is the current standard of care. Following the traction test and measurement of displacement, participants will have endotracheal tubes secured with a combined Haider ETT Tube Holder and Bite Guard.
62247142|NCT00217243||Pain study Netherlands|20 healthy subjects 20 patients with a traumatic unilateral peripheral nerve injury 20 patients with CRPS I
62437407|NCT01956357|EXPERIMENTAL|Land exercise|"The land aerobic training had a duration of 12 weeks and adopted the interval-training method, with intensities ranging between 85 and 100% of second ventilatory threshold (VT2) and total duration of 45 minute per session.~The sessions consisted of warm up, main part and calm down. The warm-up consisted of a walk in athletic track at low intensity for three minutes. The main part was intended to aerobic training in athletic track, in which subjects walked and / or ran, depending on your fitness level found in pre-training test. The calm down consisted of walking in athletic track at low intensity for two minutes and stretching standardized, emphasizing the muscles worked in the main part of the session, with a total duration of approximately five minutes."
62437408|NCT02494245|ACTIVE_COMPARATOR|Intervention|128 participants will take part in the STARFISH intervention
62437409|NCT02494245|NO_INTERVENTION|Control|Participants allocated to the control group will be given a booklet with general advice on physical activity.
62826634|NCT02530515|EXPERIMENTAL|Treatment (ex vivo autologous lymph node lymphocytes)|Patients receive infusion of ex vivo-activated autologous lymph node lymphocytes IV over 10-30 minutes on day 0.
62826635|NCT03645824|EXPERIMENTAL|Pacritinib treatment befor allo-SCT|The effect of pacritinib treatment during 3 to 4 cycles before allo-SCT on engraftment 6 months (day +180) post allo-SCT in MF patients.
62826636|NCT03365271|EXPERIMENTAL|drainage|A drainage will be applied in this group.
62604045|NCT05471570|SHAM_COMPARATOR|sham tDCS|20-minutes sham HD-tDCS with 40-minutes therapy of naming therapy for five consecutive days in week 1
62604046|NCT04529512|EXPERIMENTAL|Receiving DEXTENZA® 1-3 days prior to surgery|Participants to receive DEXTENZA® 1-3 days prior to surgery
62604047|NCT04529512|EXPERIMENTAL|Receiving DEXTENZA® 1-2 weeks prior to surgery|Participants to receive DEXTENZA® 1-2 weeks prior to surgery
62604048|NCT04529512|EXPERIMENTAL|Receiving DEXTENZA® 1 month prior to surgery|Participants to receive DEXTENZA® 1 month prior to surgery
62044639|NCT00846872|ACTIVE_COMPARATOR|Low dose GHRP-3|Subjects will receive the infusion for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
62247143|NCT02102334||Unilateral osteoarthritis|Patients operated with a total hip replacement due to unilateral osteoarthritis of the hip. Radiographic measurements of the postoperative radiographs.
62604049|NCT04529512|NO_INTERVENTION|Not receiving the DEXTENZA® implant|Participants will not receive the DEXTENZA® implant
62604050|NCT05290480|EXPERIMENTAL|Expiratory muscle training|participant performed expiratory muscle training with threshold device
62604051|NCT05290480|EXPERIMENTAL|Insentive spirometry|participant performed deep breathing exercise with insentive spirometry device
62604052|NCT02482064|NO_INTERVENTION|Traditional Obturators|Patients will use traditional obturators which are going to be made from ordinary heat-activated acrylic resin.
62247144|NCT02843763|OTHER|Renal transplant with 1rst cancer|"Renal transplant patients with first cancer (all cancer excepting skin cancer including in group 2).~Intervention : blood sample"
62437410|NCT03196791|EXPERIMENTAL|Deep neuromuscular block group|Sugammadex sodium 4mg/kg/IV after operation
62604053|NCT02482064|EXPERIMENTAL|Flexible Obturators|Patients will use the new obturators made from flexible resin.
62604054|NCT01690910|ACTIVE_COMPARATOR|Front Wheeled Walker|The Front Wheeled Walker is a standard walker that is used to assist patients while walking.
62604055|NCT01690910|ACTIVE_COMPARATOR|Rifton Gait Trainer|The Rifton Gait Trainer is used to assist patients while walking. It includes a harness to support the patient and prevent falls.
62604056|NCT03047096|EXPERIMENTAL|HA & CS group|hyaluronic acid and corticosteroids
62604057|NCT03047096|EXPERIMENTAL|HA group|hyaluronic acid
62604058|NCT02909881|EXPERIMENTAL|Endurance trained male cyclists|8 male endurance trained male cyclist will consume varying amounts (0, 1, 1.5 and 2 g/min) of PhytoSpherix (sweet-corn derived sugar) during a 150 min . cycling exercise
62604059|NCT00624559|EXPERIMENTAL|Celebrex; Low sodium|Subject completes a normal sodium diet (3 days), a low salt diet (7 days), followed by a high salt diet (7 days) while taking a celebrex pill (100 mg twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
62604060|NCT00624559|EXPERIMENTAL|Celebrex, High Sodium|Subject completes a normal sodium diet (3 days), a high salt diet (7 days), followed by a low salt diet (7 days) while taking a celebrex pill (100 mg twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
62604061|NCT00624559|PLACEBO_COMPARATOR|Placebo, Low Sodium|Subject completes a normal sodium diet (3 days), a low salt diet (7 days), followed by a high salt diet (7 days) while taking a placebo pill (twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
62604062|NCT00624559|PLACEBO_COMPARATOR|Placebo, High Sodium|Subject completes a normal sodium diet (3 days), a high salt diet (7 days), followed by a low salt diet (7 days) while taking a placebo pill (twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
62604063|NCT06620341|EXPERIMENTAL|Pharmacist medication education group|Pharmacists give emergency doctors medication education every month about how to use antibiotic infusion reasonably
62604064|NCT06620341|NO_INTERVENTION|No pharmacists' education on antibiotics|Following routine clinical practices, with no pharmacists' education on rational use of antibiotics
62604065|NCT03376217|NO_INTERVENTION|Control|IPTp delivered at antenatal clinic
62604066|NCT03376217|EXPERIMENTAL|Intervention|IPTp delivered by HSAs
62604067|NCT05818410|EXPERIMENTAL|New prosthesis|20 participants will be fitted with the Lunaris foot and follow the protocol
62604068|NCT05818410|ACTIVE_COMPARATOR|Standard prosthesis|20 participants will be fitted with the SACH foot and follow the protocol
62604069|NCT05818410|OTHER|Control group of able-bodied individuals|20 able-bodied individuals will be recruited to enable comparison with both groups of participants with lower limb amputation
62604070|NCT03258008|EXPERIMENTAL|Utomilumab + ISA101b|"Utomilumab by vein every 4 weeks for up to 12 doses beginning on Cycle 1 Day 1.~ISA101b as an injection under the skin every 4 weeks for 3 doses. Participants receive 2 injections each time."
62247145|NCT02843763|OTHER|Renal transplant patients without cancer|"Renal transplant patients without cancer matched for age, transplantation duration and CMV/EBV status.~Intervention : blood sample"
62437411|NCT03196791|EXPERIMENTAL|Moderate neuromuscular group|Sugammadex sodium 2mg/kg/IV after operation
62437412|NCT04969952|EXPERIMENTAL|Group A|Group A had watching educational module plus ACP brochure
62604071|NCT05468749|EXPERIMENTAL|CTP-543 Treatment|
62604072|NCT01537016|EXPERIMENTAL|Promogran and High EPA|Wound with high EPA will be treated with promogran and covered with a secondary dressing that is standard of care
62604073|NCT01537016|EXPERIMENTAL|Promogran and Low EPA|Wounds with low EPA will be treated with Promogran and covered with a secondary which is standard of care
62437413|NCT04969952|ACTIVE_COMPARATOR|Group B|Group B ACP brochure only
62826637|NCT03365271|ACTIVE_COMPARATOR|without drainage|Non-drainage will be applied in this group.
62826638|NCT06655168|OTHER|Video laryngoscopy|
62247146|NCT02843763|NO_INTERVENTION|Patient with cancer|Patient with cancer from oncology departement matched for cancer type and stade and CMV/EBV status.
62604074|NCT01537016|ACTIVE_COMPARATOR|High EPA and standrad of care|Wounds with high EPA will get standard of care as in line with current practice as they is no other test currently available for EPA
62604075|NCT01537016|ACTIVE_COMPARATOR|Low EPA and standard of care|Low EPA wounds will be treated with the standard of care for diabetic foot ulcers.
62247147|NCT02843763|OTHER|Renal transplant with first skin cancer|Renal transplant patients with first epidermoid skin cancer. Intervention : blood sample
62437414|NCT02622074|EXPERIMENTAL|Cohort A: KNp / KAC|Participants receive pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m\^2 in Cycles 2-5 on Days 1, 8 and 15 (once each week; QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m\^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m\^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via intravenous (IV) infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
62437415|NCT02622074|EXPERIMENTAL|Cohort B: KNpCb (Regimen 1) / KAC|Participants first receive KNpCb Regimen 1 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m\^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at Area Under the Curve (AUC) 6 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m\^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m\^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
62437416|NCT02622074|EXPERIMENTAL|Cohort C: KNpCb (Regimen 2) / KAC|Participants first receive KNpCb Regimen 2 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 125 mg/m\^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at AUC 5 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m\^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m\^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
62437417|NCT02622074|EXPERIMENTAL|Cohort D: KNpCb (Regimen 3) / KAC|Participants first receive KNpCb Regimen 3 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 125 mg/m\^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at AUC 2 in Cycles 2-5 on Days 1, 8 and 15 (QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 PLUS doxorubicin (A) 60 mg/m\^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m\^2 in Cycles 6-9 on Day 1 (Q3W) in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
62437418|NCT02622074|EXPERIMENTAL|Cohort E: KTCb (Regimen 1) / KAC|Participants first receive KTCb Regimen 1 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS paclitaxel (T) starting at 80mg/m\^2 in Cycles 2-5 on Days 1, 8, and 15 (QW) PLUS carboplatin (Cb) starting at AUC 5 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m\^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m\^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
62437419|NCT02622074|EXPERIMENTAL|Cohort F: KTCb (Regimen 2) / KAC|Participants first receive KTCb Regimen 2 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS paclitaxel (T) starting at 80mg/m\^2 in Cycles 2-5 on Days 1, 8, and 15 PLUS carboplatin (Cb) starting at AUC 2 in Cycles 2-5 on Days 1, 8 and 15 (QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m\^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m\^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
62437420|NCT00313053|EXPERIMENTAL|Human mAb 216|
62437421|NCT00728559|EXPERIMENTAL|1|preemptive trocar site analgesia
62437422|NCT00728559|EXPERIMENTAL|2|trocar site pre skin closure analgesia
62437423|NCT00728559|NO_INTERVENTION|3|control
62604076|NCT00600405|EXPERIMENTAL|I|Subjects randomized to the experimental group receive ibuprofen, oxycodone, and tamsulosin 0.4 mg orally daily for ten days.
62604077|NCT00600405|OTHER|II|Standard therapy arm: subjects randomized to standard therapy receive ibuprofen and oxycodone alone.
62604078|NCT03176615|EXPERIMENTAL|Group A (Cross-over Group 1)|Subjects randomly assigned to two experimental diets. This arm will receive high-fat meals first, followed by a washout period of two-seven days and then low-fat meals.
62604079|NCT03176615|EXPERIMENTAL|Group B (Cross-over Group 2)|Subjects randomly assigned to two experimental diets. This arm will receive low-fat meals first, followed by a washout period of two-seven days and then high-fat meals.
62604080|NCT04520334|OTHER|Zhineng Qigong|Zhineng Qigong intervention
62604081|NCT03264378|EXPERIMENTAL|PEI-GTO-ThAI|Physical exercise intervention (PEI) supported by the GTO-ThAI Implementation Model
62604082|NCT03264378|ACTIVE_COMPARATOR|PEI-Standard|Physical exercise intervention (PEI) supported by the standard governmental administrative procedures
62247148|NCT02843763|OTHER|RT with several skin cancer|Renal transplant patients with several epidermoid skin cancer. Intervention : blood sample
62247149|NCT02843763|OTHER|Rt patients without cancer apparied to RT skin cancer|"Renal transplant patients without cancer matched for age, transplantation duration and CMV/EBV status with renal transplant patients with skin cancer.~Intervention : blood sample"
62247150|NCT00860951|OTHER|Brain Computer Interface Keyboard|What effect does the environment (BCI, AT device, Computer) have on the accuracy of typing using a BCI keyboard?
62247151|NCT04873050|EXPERIMENTAL|Semaglutide Pen Injector (Ozempic)|Weekly injections of semaglutide for 8 months total (2 months of titration; 6 months of full dose- 1mg/week)
62826639|NCT06655168|OTHER|Direct laryngoscopy|
62826640|NCT06585813|EXPERIMENTAL|Fibrogide group|we are comparing the grafting of fibrogide(VCMX) with the connective tissue graft on multiple implant placement
62826641|NCT06585813|EXPERIMENTAL|Connective Tissue graft Group|
62604083|NCT01294371||Leuprorelin|"Patients with genital endometriosis received leuprorelin (Lucrin Depot®) in accordance with the respective marketing authorization/manufacturer's directions. All participants received leuprorelin for up to 6 months intramuscularly at a dose of 3.75 mg once a month. If intramuscular administration was not possible, leuprorelin was injected subcutaneously at a dose of 3.75 mg once a month. The first injection was to be carried out on the 3rd day of a menstrual period.~Accepted options for add-back therapy included: monophasic combined low-dose products for hormonal replacement therapy; combined oral contraceptives; and, if use of hormones was not possible, phytoestrogens with calcium products."
62044640|NCT00846872|ACTIVE_COMPARATOR|High dose GHRP -3|Subjects will receive the infusion for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
62247152|NCT04873050|SHAM_COMPARATOR|Placebo|Weekly injections of placebo for 8 months total
62247153|NCT00580710||conventionally treated|conventionally treated, relatively poorly controlled patients with type 1 diabetes
62247154|NCT00580710||intensively treated|intensively treated, well controlled patients with type 1 diabetes
62247155|NCT00580710||lean healthy|age- and sex- matched non-diabetic, normal weight (BMI \> or = 18.5 but \< or = 25 kg/m2) control subjects
62247156|NCT00580710||obese subjects|obese individuals defined as BMI \> or = 30kg/m2
62247157|NCT00580710||type 2 diabetics|Type 2 diabetics on diet only or diet and Metformin
62437424|NCT02732587|EXPERIMENTAL|125 mg Saracatinib|125 mg Saracatinib once daily for 8-11 days
62437425|NCT03111147|EXPERIMENTAL|0 degrees humeral component version|Reverse Total Shoulder Arthroplasty with humeral component positioned in 0 degrees of version
62437426|NCT03111147|EXPERIMENTAL|30 degrees humeral component retroversion|Reverse Total Shoulder Arthroplasty with humeral component positioned in 30 degrees of retroversion
62437427|NCT01430182|EXPERIMENTAL|Methadone 0.2 mg/kg|0.2 mg/kg methadone by actual body weight, administered over ten minutes, initiated after induction of anesthesia and endotracheal intubation complete.
62437428|NCT01430182|ACTIVE_COMPARATOR|Morphine 0.2 mg/kg|0.2 mg/kg morphine by actual body weight, administered over ten minutes, initiated after induction of anesthesia and endotracheal intubation complete.
62437429|NCT01606137|EXPERIMENTAL|GW-1000-02|Active treatment
62437430|NCT06107088|EXPERIMENTAL|Test product1|1 capsule 'lactase-bacterial strain combination' and 1 capsule placebo, once a day, one week
62437431|NCT06107088|EXPERIMENTAL|Test product2|1 capsule lactase and 1 capsule bacterial strain, once a day, one week
62437432|NCT06107088|ACTIVE_COMPARATOR|Comparator|1 capsule lactase and 1 capsule placebo, once a day, one week
62437433|NCT06107088|PLACEBO_COMPARATOR|Placebo|2 capsules placebo, once a day, one week
62437434|NCT03201471|EXPERIMENTAL|treatment group|In this group, the patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1; CTX 750mg/m2, ivgtt,d2; EPI 70mg/m2, ivgtt,d2; VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2, PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18; one cycle every 21 days； abbreviation： CTX： cyclophosphamide；EPI：etoposide；VCR： vincristine；Pred：prednisone； R-CHOP：the chemo-therapy regimen composed of Rituximab, cyclophosphoamide; etoposide, vincristine and prednisone.
62437435|NCT01677910|EXPERIMENTAL|250 mg Telotristat Etiprate|Following a 3 to 4-week run-in period on stable-dose somatostatin analog (SSA) therapy (octreotide or lanreotide) participants were randomized to receive one 250 mg telotristat etiprate tablet plus one placebo-matching telotristat etiprate tablet administered three times daily for 12 Weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
62437436|NCT01677910|EXPERIMENTAL|500 mg Telotristat Etiprate|Following a 3 to 4-week run-in period on stable-dose SSA therapy (octreotide or lanreotide) participants were randomized to receive, one telotristat etiprate 250 mg plus one placebo-matching telotristat etiprate tablet administered 3 times daily for 1 week, followed by two telotristat etiprate (250 mg) tablets administered three times daily for 11 weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
62437437|NCT01677910|PLACEBO_COMPARATOR|Placebo|Following a 3 to 4-week run-in period on stable-dose SSA therapy (octreotide or lanreotide) participants were randomized to receive two placebo-matching telotristat etiprate tablets administered three times daily for 12 weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
62247158|NCT00580710||type 1 diabetes unaware|Type 1 diabetics unaware of hypoglycemic symptoms
62247159|NCT00580710||type 1 diabetes aware|Type 1 diabetics aware of hypoglycemic symptoms
62247160|NCT02877940|ACTIVE_COMPARATOR|ProSeal Laryngeal mask airway|ProSeal will be inserted in mechanically ventilated patients undergoing elective surgeries.
62247161|NCT02877940|ACTIVE_COMPARATOR|Laryngeal Tube Suction- Disposable|LTS-D will be inserted in mechanically ventilated patients undergoing elective surgeries.
62247162|NCT02877940|ACTIVE_COMPARATOR|Group I|i-gel will be inserted in mechanically ventilated patients undergoing elective surgeries..
62247163|NCT01212978|NO_INTERVENTION|Delayed Intervention|These subjects will neither receive a pedometer or access to the motivational software until completion of the study.
62247164|NCT01212978|ACTIVE_COMPARATOR|Pedometer only|Participants in the this arm will receive a pedometer with instructions to reach a goal of 10,000 steps/day but will not receive access to the motivational software.
62247165|NCT01212978|EXPERIMENTAL|Pedometer + Motivational Software|In this arm, subjects will receive access to both a pedometer and motivational software
62247166|NCT06178250|OTHER|placenta, fetal liver, sectional ductus venosus volumes between 24-29 weeks pregnant women|The placenta, fetal liver and ductus venosus volumes of 46 patients diagnosed with GDM and 93 patients without a GDM diagnosis between 24-29 weeks were evaluated with 3D ultrasound.
62247167|NCT02649049||Patients with NAFLD|Patients with NAFLD are the cases.
62247168|NCT02649049||control group|Healthy people without NAFLD are controls.
62604084|NCT05084365|EXPERIMENTAL|sulforaphane|The goal of the study is to investigate whether adding sulforaphane will benefit cognitive function in individuals who have PD.
62604085|NCT05084365|PLACEBO_COMPARATOR|placebo|The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
62604086|NCT00772122|EXPERIMENTAL|Granulocyte colony stimulating factor|The G-CSF group of 35 women, underwent a daily sub-cutaneous administration of the filgrastim (Neupogen, Dompe', Italy), the recombinant G-CSF, at a dosage of 1 micro gram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
62604087|NCT00772122|PLACEBO_COMPARATOR|placebo (saline solution)|The placebo group consisting of 33 subjects, was given a treatment with saline solution at the 0.2ml/day subcutaneously/, from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
62604088|NCT05548868|EXPERIMENTAL|Experimental Arm|Patients will receive standard dietary counselling and use of E4W mobile app
62604089|NCT05548868|ACTIVE_COMPARATOR|Control Arm|Patients will receive standard dietary counselling. No use of E4W.
62604090|NCT06499012|ACTIVE_COMPARATOR|All-plant Protein Booster Product Group|Containing ingredients: Soy protein Isolate, Soybean peptide, wheat protein, pea protein, Pea peptide, Aloe Vera powder, Sweetener (Maltitol) Anti-caking (Silicon Dioxide) Thickener (guar gum, arabic gum)
62604091|NCT06499012|PLACEBO_COMPARATOR|Placebo Group|Containing ingredients: Aloe Vera powder, Sweetener (Maltitol) Anti-caking (Silicon Dioxide) Thickener (guar gum, arabic gum)
62604092|NCT00526331|EXPERIMENTAL|Study Group|FloTrac Sensor + Vigileo Monitor used to decide how much fluid to give during surgery.
62604093|NCT00526331|EXPERIMENTAL|Control Group|FloTrac Sensor + Vigileo Monitor only used for data collection during surgery; Standard of Care to decide fluid amount.
62604094|NCT02750605|EXPERIMENTAL|Drug eluting balloon angioplasty|Intervention with DEB angioplasty in long lesions of crural arteries
62604095|NCT02750605|ACTIVE_COMPARATOR|Plain old balloon angioplasty|Intervention with plain old balloon angioplasty POBA in long lesions of crural arteries
62604096|NCT02680184|EXPERIMENTAL|Part 1: Dose-Escalation - CMP-001 and Pembrolizumab|Participants will receive up to 5 escalating dose levels (1 milligram \[mg\], 3 mg, 5 mg, 7.5 mg and 10 mg) of CMP-001 via intratumoral injection according to one of 2 schedules (Schedule A: once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued; Schedule B: once weekly for 2 weeks, followed by every 3 weeks thereafter until participant is discontinued) in combination with pembrolizumab at its labelled dose and schedule.
62604097|NCT02680184|EXPERIMENTAL|Part 1: Dose-Expansion - CMP-001 and Pembrolizumab|Participants will receive CMP-001 10 mg via intratumoral injection by Schedule A (once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued) in combination with pembrolizumab at its labelled dose and schedule. As of 05 October 2018, the dose and schedule for Part 1 Dose Expansion Phase was selected based on all available safety, efficacy and pharmacodynamic data from the Part 1 Dose Escalation Phase. Participants who were enrolled prior to 05 October 2018 to receive CMP-001 doses less than (\<) 10 mg will have the option to receive CMP-001 doses up to 10 mg on Schedule A in combination with pembrolizumab.
62604098|NCT02680184|EXPERIMENTAL|Part 2: CMP-001 Monotherapy and Crossover to Combination|Participants will receive CMP-001 10 mg via intratumoral injection by Schedule A (once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued). Participants who were enrolled prior to 05 October 2018 to receive CMP-001 doses \<10 mg will have the option to receive CMP-001 doses up to 10 mg on Schedule A. Participants with documented progression while on CMP-001 monotherapy treatment will have the option to crossover to the combination treatment of CMP-001 10 mg plus pembrolizumab, at the discretion of the Investigator.
62604099|NCT06648980|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose
62604100|NCT06648980|ACTIVE_COMPARATOR|Phytoglycogen|Phytoglycogen
62604101|NCT04588727|EXPERIMENTAL|AZD3366 Dose 1 Part A|Randomized healthy subjects will receive Dose 1 of AZD3366.
62604102|NCT04588727|EXPERIMENTAL|AZD3366 Dose 2 Part A|Randomized healthy subjects will receive Dose 2 of AZD3366.
62604103|NCT04588727|EXPERIMENTAL|AZD3366 Dose 3 Part A|Randomized healthy subjects will receive Dose 3 of AZD3366.
62604104|NCT04588727|EXPERIMENTAL|AZD3366 Dose 4 Part A|Randomized healthy subjects will receive Dose 4 of AZD3366.
62604105|NCT04588727|EXPERIMENTAL|AZD3366 Dose 5 Part A|Randomized healthy subjects and healthy Japanese subjects will receive Dose 5 of AZD3366.
62604106|NCT04588727|EXPERIMENTAL|AZD3366 Dose 6 Part A|Randomized healthy subjects and healthy Japanese subjects will receive Dose 6 of AZD3366.
62604107|NCT04588727|EXPERIMENTAL|AZD3366 Dose 7 Part A|Randomized healthy subjects, healthy Japanese subjects, and healthy Chinese subjects will receive Dose 7 of AZD3366.
62604108|NCT04588727|PLACEBO_COMPARATOR|Placebo Part A|Randomized healthy subjects, healthy Japanese subjects, and healthy Chinese subjects will receive Placebo matched to AZD3366.
62604109|NCT04588727|EXPERIMENTAL|AZD3366 Dose X Part B|Randomized healthy subjects will receive Dose X of AZD3366 in conjunction with concomitant administration of ticagrelor and ASA.
62604110|NCT04588727|PLACEBO_COMPARATOR|Placebo Dose X Part B|Randomized healthy subjects will receive Dose X of placebo in conjunction with concomitant administration of ticagrelor and ASA.
62604111|NCT04586335|EXPERIMENTAL|CYH33 in Combination with Olaparib|CYH33 in Combination with Olaparib; 20 mg CYH33 QD in combination with olaparib 300 mg BID. Additional dose levels of CYH33 at20 and 30 mg QD and CYH33 at 40 mg QD in combination with olaparib 200 mg BID will be evaluated.
62604112|NCT02360475|EXPERIMENTAL|RSV vaccine formulation 1 Group|Subjects in this group will receive a single dose of formulation 1 of the RSV vaccine
62604113|NCT02360475|EXPERIMENTAL|RSV vaccine formulation 2 Group|Subjects in this group will receive a single dose of formulation 2 of RSV vaccine
62604114|NCT02360475|EXPERIMENTAL|RSV vaccine formulation 3 Group|Subjects in this group will receive a single dose of formulation 3 of RSV vaccine
62604115|NCT02360475|ACTIVE_COMPARATOR|Boostrix Group|Subjects in this group will receive a single dose of Boostrix
62604116|NCT06074887|EXPERIMENTAL|İntervention group|
62604117|NCT06074887|NO_INTERVENTION|Control group|
62604118|NCT06527222|EXPERIMENTAL|Ranolazine low dose|Participants receive Ranolazine 500mg orally twice daily for 24 weeks.
62247169|NCT01157520||Cesarean|Women scheduled for elective Cesarean section under spinal anesthesia
62044641|NCT00846872|PLACEBO_COMPARATOR|Saline Infusion|Subjects will receive Placebo for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
62044642|NCT01758354|EXPERIMENTAL|Pompe disease newborn screening|newborns will be tested if they were affected by Pompe disease
62604119|NCT06527222|EXPERIMENTAL|Ranolazine high dose|Participants receive Ranolazine 1000mg orally twice daily for 24 weeks.
62826642|NCT06587594|EXPERIMENTAL|SFBT intervention|Behavioral: Solution-focused Brief Therapy (SFBT) A behavioral health intervention designed to help autistic adults to make a positive change in their life using strength-based approach.
62826643|NCT03379181|EXPERIMENTAL|Propranolol 80 mg|Patients receive a single dose of 80 mg propranolol p.o.
62044643|NCT05609084|OTHER|Control|Patients will have speech therapy assessment in addition to standard care.
62826644|NCT03931941|EXPERIMENTAL|Active|RBX2660 is an enema of a microbiota suspension
62437438|NCT01677910|EXPERIMENTAL|Telotristat Etiprate Open-Label Extension|Patients previously assigned to 250 mg or 500 mg three times daily of telotristat etiprate were administered two 250 mg telotristat etiprate tablets three times daily in a 36 week open-label extension (OLE) period. Patients previously assigned to placebo were administered one 250 mg telotristat etiprate tablet plus one placebo-matching tablet three times daily for one week, followed by two 250 mg telotristat etiprate tablets three times daily for 35 weeks.
62437439|NCT00877682|EXPERIMENTAL|Cryotherapy|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
62044644|NCT05609084|EXPERIMENTAL|Experimental|Patients will have speech therapy assessment and intensive speech rehabilitation
62437440|NCT02922114|EXPERIMENTAL|Ultrasonography|B-mode and power Doppler Ultrasonography examination
62437441|NCT06544577||ELacestrant|Subjects in this cohort will receive elacestrant
62437442|NCT03876756||PAUR (postpartum acute urinary retention)|patients presenting postpartum acute urinary retention.
62437443|NCT03876756||Control|patients without postpartum acute urinary retention. This group was selected randomly, respecting a 1:1 matching criteria, including the year of delivery and the age of the patient at delivery.
62437444|NCT05175456|EXPERIMENTAL|Bedjet arm|All participants will complete a baseline study period of 4 weeks and then will be provided the Bedjet system.
62437445|NCT04177810|EXPERIMENTAL|Cemiplimab and Plerixafor|All participants will receive Cemiplimab and Plerixafor.
62826645|NCT00517387|ACTIVE_COMPARATOR|1|All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
62604120|NCT06527222|PLACEBO_COMPARATOR|Placebo|Participants receive Ranolazine placebo orally twice daily for 24 weeks.
62247170|NCT00430482|EXPERIMENTAL|1|Cognitive Behavioral Therapy
62604121|NCT05400031|NO_INTERVENTION|Control|In this group, the researcher will provide the participants with routine care.
62604122|NCT05400031|PLACEBO_COMPARATOR|placebo group|In this group, the researcher will provide the participants with a propolis vehicle
62604123|NCT05400031|ACTIVE_COMPARATOR|propolis group|In this group, the researcher will provide the participants with a propolis solution.
62604124|NCT00719914|ACTIVE_COMPARATOR|1|Intracoronary injection of eptifibatide
62044645|NCT01204801|EXPERIMENTAL|Thermochemotherapy|Preoperative Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy.
62044646|NCT01204801|ACTIVE_COMPARATOR|Chemotherapy (control)|Preoperative Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs
62044647|NCT01190696|OTHER|hip spica casting|Patients in the spica cast group treated with skeletal traction and spica cast applied for them
62044648|NCT01190696|OTHER|titanium elasting nailing|For patients in the Titanium Elasting Nailing group, the nail applied retrogradely in femoral shaft fracture
62044649|NCT00381966|EXPERIMENTAL|Robotic placement device|The intervention involves use of a robotic template to assist in placement of needles for prostate brachytherapy.
62044650|NCT00962195|EXPERIMENTAL|purple sweet potato juice|Daily oral intake of 3x 125 ml of PSP-juice for a period of 8 weeks
62044651|NCT00962195|PLACEBO_COMPARATOR|Control juice|Daily oral intake of 3x 125 ml of control juice for a period of 8 weeks
62044652|NCT03369717|EXPERIMENTAL|Antibiotics|To receive postoperative antibiotics
62437446|NCT01501383|ACTIVE_COMPARATOR|VX-765 Dose 1 Part A|
62437447|NCT01501383|ACTIVE_COMPARATOR|VX-765 Dose 2 Part A|
62437448|NCT01501383|ACTIVE_COMPARATOR|VX-765 Dose 3 Part A|
62437449|NCT01501383|ACTIVE_COMPARATOR|VX-765 Dose 4 Part A|
62437450|NCT01501383|PLACEBO_COMPARATOR|Placebo Dose Part A|Placebo
62437451|NCT01501383|ACTIVE_COMPARATOR|VX-765 Dose Part B|
62437452|NCT04725526|NO_INTERVENTION|usual clinical practice|A group of pluripatological patients with heart failure and complex needs of health will be tratad per standard of care on site
62437453|NCT04725526|EXPERIMENTAL|mHealth intervention plus usual clinical practice|A group of pluripatological patients with heart failure and complex needs of health will be tratad per standard of care plus mHealth intervention on site
62826646|NCT04968002|EXPERIMENTAL|Preoperative neoadjuvant therapy for patients with stage IIa-IIIa non-small cell lung cancer.|No EGFR mutation or ALK gene translocation was found in the untreated patients with NSCLC stage IIa-IIIb diagnosed by imaging, histopathology or cytology. After informed consent is signed by the patients. The patients were treated according to the protocols.
62826647|NCT06588465|EXPERIMENTAL|treatment group A|We plan to enroll 72 volunteer patients with microalbuminuria. After 1 week waiting period (as the waiting list group), the patients will be randomized to treatment group A or group B.
62826648|NCT06588465|EXPERIMENTAL|treatment group B|We plan to enroll 72 volunteer patients with microalbuminuria. After 1 week waiting period (as the waiting list group), the patients will be randomized to treatment group A or group B.
62826649|NCT06559683||Deep Parasternal|Patients scheduled for open-heart surgery will receive a deep parasternal intercostal plane block preoperatively, and sensory block status will be evaluated 30 minutes later using small ice tubes.
62826650|NCT06559683||Superficial Parasternal|Patients scheduled for open-heart surgery will receive a superficial parasternal intercostal plane block preoperatively, and sensory block status will be evaluated 30 minutes later using small ice tubes.
62826651|NCT01099267||Lenalidomide|No intervention was given during this extension study which gathered survival information on participants of study NCT00065156 (Celgene study CC-5013-MDS-003). During the CC-5013-MDS-003 study, participants initially took a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle. The study was amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.
62826652|NCT01456884|EXPERIMENTAL|Live - Vibroacoustic|Treatment order A: live guitar and vocal music therapy on day one, vibroacoustic music therapy on day two.
62826653|NCT01456884|EXPERIMENTAL|Vibroacoustic - Live|Treatment order B: vibroacoustic music therapy live guitar on day one, and vocal music therapy on day two.
62826654|NCT05163080|ACTIVE_COMPARATOR|Arm A|Peptide Vaccine (SurVaxM) in emulsion with Montanide given together with locally administered Sargramostim plus adjuvant oral Temozolomide
62044653|NCT03369717|NO_INTERVENTION|No antibiotics|Will not receive any postoperative antibiotics
62437454|NCT03787485||LINKS Participants|Study participants who took part in the LINKS intervention.
62437455|NCT03787485||Electronic Medical Record Controls|The principal analytical strategy is propensity score matching, which will lead to the generation of a natural control group from the health centers existing electronic medical records. Propensity matching is highly effective in addressing selection bias of known confounders and enables causal inferences when randomization is not possible, feasible or appropriate, by creating matched groups with similar covariate distributions. Matched controls will be extracted from the electronic medical record from the participating clinics.
62437456|NCT01875445|PLACEBO_COMPARATOR|Placebo|Matched dosage of inositol daily.
62437457|NCT01875445|ACTIVE_COMPARATOR|Inositol|Powder form, 2g TID up to 6g TID
62437458|NCT05767255|ACTIVE_COMPARATOR|basal group bolus|"* Insulin Glargine required on an in-hospital basis~* Insulin Aspart required on an in-hospital basis"
62437459|NCT05767255|EXPERIMENTAL|insulin degludec + liraglutide ( ideglira)|16 Units once a day
62826655|NCT05163080|PLACEBO_COMPARATOR|Arm B|Saline-Montanide emulsion with locally administered saline (instead of sargramostim) plus adjuvant oral temozolomide
62826656|NCT04633265|EXPERIMENTAL|ECG-I Mapping and Ablation of drivers|ECG-I Mapping will be performed and drivers will be ablated as directed by ECG-I.
62044654|NCT03912844||Liver resection/liver transplantation after SIRT|The cohort consist of patients that, after decision of a multidisciplinary tumor board have received a SIRT/TARE or will receive a SIRT/TARE to make them later eligible for following liver resection or liver transplantation.
62247171|NCT00430482|ACTIVE_COMPARATOR|2|Individual Counseling
62044655|NCT06292156|EXPERIMENTAL|Theta treatment group|In active tACS, the target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 6 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3 consecutive weeks.
62044656|NCT06292156|ACTIVE_COMPARATOR|Alpha active control group|In active tACS, the target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 10 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3 consecutive weeks.
62044657|NCT06292156|SHAM_COMPARATOR|Sham control group|In sham group, Sham stimulation lasted 30 s (15 s of ramp- up and 15 of ramp-down) .
62044658|NCT02985866|EXPERIMENTAL|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump, study continuous glucose monitor (CGM), and a study glucometer. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
62044659|NCT02985866|ACTIVE_COMPARATOR|Sensor Augmented Therapy|Subjects will continue to use their personal insulin pump with a study continuous glucose monitor (CGM) and study glucometer.
62044660|NCT02881723|EXPERIMENTAL|Treatment for oropharyngeal cancer by surgery|Disease-free patients treated for locally advanced oropharyngeal cancer for over 12 months by surgery
62044661|NCT02881723|EXPERIMENTAL|Treatment for oropharyngeal cancer by radio-chemotherapy|Disease-free patients treated for locally advanced oropharyngeal cancer for over 12 months by radio-chemotherapy
62044662|NCT03705208|EXPERIMENTAL|Youth First Curriculum|"The full Youth First curriculum provides holistic training of both emotional resilience and adolescent health concepts. The curriculum is comprised of a 15-session emotional resilience curriculum and a 10-session adolescent health program. The resilience curriculum aims to increase both internal assets (such as self-esteem, coping skills, health knowledge, and conflict-resolution skills) and external assets (such as positive bonds with peers and family).~The adolescent health curriculum provides in-depth training in physical health and wellness topics such as sexual and reproductive health, common diseases, nutrition, gender equality, and substance use.~The curriculum is imparted by school teachers are trained and certified by CorStone."
62044663|NCT03705208|NO_INTERVENTION|School as usual|This arm is comprised of students attending school as usual and receiving the established government-designed curriculum.
62044664|NCT00801008|EXPERIMENTAL|Exercise and Relaxation Intervention|Participants in this arm will receive a 12 week exercise and relaxation intervention
62044665|NCT00801008|NO_INTERVENTION|Wait List Control Condition|Participants in this arm will be offered the exercise and relaxation intervention after a 12 week delay.
62044666|NCT00654810|EXPERIMENTAL|1|Low intensity group (40% of maximal exercise capacity)
62044667|NCT00654810|EXPERIMENTAL|2|High intensity group (80% of maximal exercise capacity)
62044668|NCT02870140|EXPERIMENTAL|SUPRAFLEX|Percutaneous Coronary Intervention with the SUPRAFLEX Sirolimus Eluting Bioabsorbable Polymer Coronary Stent System. It is a balloon expandable sirolimus eluting stent with an bioabsorbable polymer coating.
62044669|NCT02870140|ACTIVE_COMPARATOR|XIENCE|Percutaneous Coronary Intervention with the XIENCE EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating.
62044670|NCT02723864|EXPERIMENTAL|M6620 (VX-970)|M6620 will be administered intravenous (IV) on Days 2 and 9 of each 21-day cycle; Veliparib will be administered orally twice a day (BID) Days 1-3 and 8-10 of each cycle; Cisplatin will be administered at 40 mg/m\^2 IV Day 1 (and Day 8 from dose level 3 onwards) of each cycle
62044671|NCT03520166|PLACEBO_COMPARATOR|Group-A|No treatment
62044672|NCT03520166|EXPERIMENTAL|Group-B|Medium frequency electrotherapy (interferential currents)
62044673|NCT05941754|EXPERIMENTAL|high omega-3 group|A single dose of 4.0g EPA was given orally
62044674|NCT05941754|EXPERIMENTAL|low omega-3 group|A single dose of 2.0g EPA was given orally
62044675|NCT05941754|PLACEBO_COMPARATOR|placebo group|A single dose of 4.0g corn oil was given orally
62044676|NCT05941754|NO_INTERVENTION|healthy control group|no intervention. assessement of cognitive performance twice.
62044677|NCT05638399|EXPERIMENTAL|Denosumab|denosumab (60 mg subcutaneously, per 6 month)
62044678|NCT05638399|ACTIVE_COMPARATOR|zoledronate|zoledronate (5mg, intravenous infusion once a year)
62044679|NCT04064151|EXPERIMENTAL|"My Guide (psychoeducation & self-management program)"|Smartphone-based program plus standard clinical care.
62044680|NCT04064151|NO_INTERVENTION|Standard Medical Care|Standard clinical care with no smartphone intervention.
62044681|NCT05649111|ACTIVE_COMPARATOR|Group A|will receive Difluprednate 4 times per day for 1 week, then twice per day for 1 week and then once per day for 5 days starting 24 hours after the operation
62247172|NCT05290688|OTHER|Untreated RRMS patients|Untreated RRMS patients with a 50 ml blood sample during their routine care
62247173|NCT05144568|EXPERIMENTAL|experimental group|Nutrition education will be given to participants with PMS in the experimental group.
62247174|NCT05144568|NO_INTERVENTION|Control group|
62437460|NCT02454972|EXPERIMENTAL|lurbinectedin (PM01183)|lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
62437461|NCT01737177|EXPERIMENTAL|Bendamustina, Lenalidomide, Rituximab|1 arm for all patients
62604125|NCT00719914|PLACEBO_COMPARATOR|2|Intra-coronary injection of normal saline.
62437462|NCT06285721|EXPERIMENTAL|Standardized treatment arm|Standardized tACS will be applied with 2.0 mA (peak-to-peak) intensity for 30 minutes, with a 10 Hz frequency. Two 5x5 cm saline-soaked electrodes located at the frontal and occipito-parietal part of the scalp will be utilized (corresponding to 10-20 EEG electrode locations POz-Oz and AFz), including in the stimulation field the DLPFC, precuneus and posterior cingulate cortex. At the beginning of stimulation, the intensity will ramp up for 30 seconds to 2.0 mA peak-to-peak, while at the end of stimulation, the intensity will ramp down for 30 seconds.
62826657|NCT05534165|EXPERIMENTAL|Tecovirimat|Tecovirimat (TPOXX®) Capsules, 200 mg (as tecovirimat monohydrate) administered as 600 mg (three 200 mg capsules) taken twice daily orally, every 12 hours, within 30 minutes after a full meal of moderate or high fat (approximately 25 g of fat) for 14 days
62826658|NCT05534165|PLACEBO_COMPARATOR|Placebo|Identical placebo supplied by SIGA Technologies Inc.
62826659|NCT06601205|EXPERIMENTAL|Flutamide|1 tablet 250 mg daily until the day before surgery
62449198|NCT02339909|EXPERIMENTAL|Probabilistic Incentive|"The intervention for the probabilistic incentive group consists of the standard invitation letter from the Screening service, with additional text offering a probabilistic financial incentive (entry into a lottery offering at least a 1 in 100 chance to win £1000) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
62604126|NCT02271711|EXPERIMENTAL|Treatment (autologous ex vivo-expanded NK cells)|Patients receive autologous expanded NK cells IV into the ventricle over 3 minutes once weekly on weeks 1-3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may continue treatment at the discretion of the treating physician if pseudo-progression or benefit of slowed progression is suspected.
62604127|NCT06077149|EXPERIMENTAL|Long-term care facility residents|Licensed RSV vaccine IM x 1. Specific product to be determined availability at the facility as SOC
62826660|NCT06601205|EXPERIMENTAL|Finasteride|1 tablet 5 mg daily until the day before surgery
62826661|NCT06601205|PLACEBO_COMPARATOR|Placebo|1 tablet daily until the day before surgery
62826662|NCT06590766|EXPERIMENTAL|Integrative oncology single-modality|Acupressure/relaxation only
62826663|NCT06590766|EXPERIMENTAL|Integrative oncology multi-modality|Acupressure/relaxation with acupuncture
62826664|NCT06590766|ACTIVE_COMPARATOR|Palliative nursing counseling|Patients choosing to undergo a palliative nursing consultation only.
62826665|NCT03682419|EXPERIMENTAL|VKA Patients|Single Arm - blood collection by venepuncture and fingerstick in patients undergoing Warfarin Therapy
62826666|NCT03682419|EXPERIMENTAL|non-Vka Patients|Single Arm - blood collection by venepuncture and fingerstick in patients not undergoing Warfarin Therapy
62826667|NCT05447052|EXPERIMENTAL|Bio-MIMICS Stent|Helical shaped BioMimics 3D Stent
62826668|NCT05447052|ACTIVE_COMPARATOR|Innova Stent|Conventional: Nitinol Stent
62826669|NCT03814603||African Americans|
62826670|NCT03814603||Non-Hispanic Whites|
62604128|NCT06077149|ACTIVE_COMPARATOR|community dwelling adults|Licensed RSV vaccine IM x1. The proportion of specific products will be matched to the LTCF cohort
62044682|NCT05649111|ACTIVE_COMPARATOR|Group B|will receive Difluprednate 3 times per day for 4 days, then twice per day for 4 days and then once per day for 4 days starting 4 hours after the operation
62044683|NCT04946968|EXPERIMENTAL|Dacomitinib|Oral Dacomitinib tablets, once daily.
62044684|NCT06213948|EXPERIMENTAL|Healthy|
62044685|NCT06213948|EXPERIMENTAL|Functional Dyspepsia|
62044686|NCT06457555||nurses working in adult intensive care units|"In the research, parallel data type was used in the convergent parallel mixed design (convergent parallel) in order to obtain meticulous, valid and reliable data through survey questions and individual interviews. In the quantitative dimension of the research, nurses working in internal medicine, neurology, cardiology and surgical intensive care clinics of a public hospital were examined.~While determining their level of knowledge regarding the prevention of pressure ulcers, it is also aimed to determine their experiences regarding practices to prevent pressure ulcers in a qualitative dimension."
62044687|NCT06560047|OTHER|Catheter Ablation|Patients randomized to the intervention will undergo early catheter ablation with pulmonary vein isolation as treatment for AF. Catheter ablation should be conducted within 6 weeks of randomization.
62044688|NCT06560047|NO_INTERVENTION|Standard treatment|Patients randomized to standard treatment will receive standard guideline directed treatment for AF and HF. Treatment will be initiated at the baseline visit and further clinical follow-up will be conducted at the patients local hospital. Patient will be treated with either rhythm (excluding catheter ablation) or rate control. The choice of treatment strategy will be at the discretion of the treating physician according to current guideline recommendations. If rate control is chosen, patients should have a resting heart rate \< 110 beats per minutes. Rate control can be obtained by medical treatment with digoxin, beta-blockers and if needed amiodarone, in combination or as single treatment. Rhythm control will be conducted through cardioversion and/or medical treatment with amiodarone. Catheter ablation will not be part of the treatment choices in the standard treatment arm.
62044689|NCT02522936|EXPERIMENTAL|Biotene|Participants will be given Biotene oral spray to use as needed when taking oxybutynin.
62044690|NCT02522936|NO_INTERVENTION|Routine care|Participants will be given routine care.
62044691|NCT03928080||Experimental cohort|Primary study to assess diagnostic accuracy
62044692|NCT03928080||Confirmation cohort|Second cohort to confirm results from the first study on independent population
62044693|NCT02925676|EXPERIMENTAL|hyposafe H02|All subjects included are assigned to hyposafe H02-testing
62604129|NCT05602129|EXPERIMENTAL|HSK36273 Continuous infusion|Drug:HSK36273 Administration mode:Continuous infusion
62044694|NCT03818282|EXPERIMENTAL|Paclitaxel for injection (albumin-bound)|
62044695|NCT03833882|EXPERIMENTAL|MAF1217/Cationorm|
62044696|NCT03833882|EXPERIMENTAL|Cationorm/MAF1217|
62044697|NCT03910413|OTHER|Dual Energy CT|
62044698|NCT01093612|EXPERIMENTAL|Arm I|PART ONE: Patients are randomized to 1 of 3 dose levels. Patients undergo a PET scan 24-48 hours after injection of copper Cu 64-DOTA-trastuzumab. PART TWO: Patients undergo a PET scan 24-48 hours after injection of copper Cu 64-DOTA-trastuzumab.
62044699|NCT04171102|ACTIVE_COMPARATOR|Short term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 3-5 weeks post implantation
62604130|NCT05602129|EXPERIMENTAL|HSK36273 Bolus+Continuous infusion|Drug:HSK36273 Administration mode:Bolus+Continuous infusion
62604131|NCT05602129|ACTIVE_COMPARATOR|Heparin sodium|Drug:Heparin sodium Administration mode:Bolus+Continuous infusion
62604132|NCT05582369|EXPERIMENTAL|Affective Rewards Messages|Throughout the study, each week participants will be asked to plan two exercise sessions for the upcoming week, and will be asked to report on how they did with those plans at the end of the day when they planned to exercise. At the very beginning of the time window when they planned to exercise participants will be randomized with 40% probability to receive no message, 20% probability to receive a reminder to fill out the study questionnaire at the end of the day, and 40% probability to receive one of two types of affective rewards messages (active intervention). The two types are: 1) low-reflection messages written by participants at the beginning of the study, about the affective rewards of exercise they have previously experienced; and 2) high-reflection messages that prompt participants to reflect on the affective rewards of exercise and text back a response.
62604133|NCT01479192|EXPERIMENTAL|Fenretinide|100mg: 2cps/day for 5 years followed by
62604134|NCT01479192|PLACEBO_COMPARATOR|Placebo|matched placebo 2 cps/day for 5 years
62604135|NCT02110940|ACTIVE_COMPARATOR|Conservative Physiotherapy|Subjects will be referred to the physiotherapy department to receive conventional physiotherapy treatment.
62044700|NCT04171102|ACTIVE_COMPARATOR|Mid term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 3-4 months post implantation
62044701|NCT04171102|ACTIVE_COMPARATOR|Long term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 6-8 months post implantation
62044702|NCT01429129|EXPERIMENTAL|Nicotine Replacement Therapy|
62044703|NCT01429129|NO_INTERVENTION|Control|
62044704|NCT06063304||Healthy Volunteers|This group consists of healthy volunteers with no history of knee joint pain (refer to inclusion/exclusion criteria for more details). They will be scanned once and their scans will be used as the baseline to compare the early knee osteoarthritis patient data with. 10 healthy volunteers will be recruited.
62044705|NCT06063304||Knee Osteoarthritis Patients|This group consists of early knee osteoarthritis patients (refer to inclusion/exclusion criteria for more details). They will be scanned 4 times over a period of 2 years (at enrolment, 6 months, 12 months and 24 months after enrolment) to see how the disease progresses. Their scans will be compared with the baseline healthy volunteer scans to check for any differences in anatomy and tissue properties. 60 knee osteoarthritis patients will be recruited.
62044706|NCT04636970|NO_INTERVENTION|Control group|Patients randomised to control group will get usual recommendations regarding physical activity after a discharge from inpatient cardiac rehabilitation.
62044707|NCT04636970|EXPERIMENTAL|Intervention group|Patients randomised to intervention group will continue home exercise training that will last 12 weeks and consists of endurance, flexibility, balance and cardiovascular resistance training performed with low to moderate intensity, in 20-60 minutes sessions, five times a week. Study participants will be asked to wear wrist and chest unobtrusive devices during active day time or at least during the training session and two hours before and after. Study participants well receive telephone calls every other week and were asked to answer questions regarding their health and physical activity.
62044708|NCT00744484|EXPERIMENTAL|B1|B1 - training in water
62437463|NCT06285721|EXPERIMENTAL|Personalized treatment arm|Personalized tACS will be applied with 2.0 mA (peak-to-peak) intensity for 30 minutes with a 30 second ramp up and ramp down. Treatment will be personalized based on a delirium neural mass model. After fitting the model to the individual EEG, a virtual tACS trial allows for optimization of treatment parameters for each individual patient. Treatment optimization will take place through changing stimulation location and/or frequency. After determining the optimal individual treatment strategy, settings of the personalized stimulation will remain constant during the treatment phase.
62437464|NCT06285721|SHAM_COMPARATOR|Sham treatment arm|At the beginning and end of this 30-minute protocol, the tACS device will ramp up to 2.0 mA peak-to-peak intensity for 30 seconds, stimulate for 60 seconds and ramp down for 30 seconds, which mimics the sensation of actual tACS stimulation and improves blinding.
62437465|NCT04479657|EXPERIMENTAL|QingFei Granule+Cefuroxime group|Cefuroxime：30mg/kg/d,bid QingFei Granule: tid
62437466|NCT04479657|ACTIVE_COMPARATOR|Cefuroxime group|Cefuroxime：30mg/kg/d,bid
62044709|NCT00744484|EXPERIMENTAL|S1|S1 - training on land
62044710|NCT06056375|OTHER|Waitlist Control|Waitlist control; all participants receive the treatment but are in a control condition prior to the treatment
62247175|NCT05644457||Patients receiving systemic therapies for cancers of the head and neck|Patients undergoing systemic therapy for recurrent, metastatic, or locally advanced cancer of the head and neck not suitable for treatment with curative intent. A biological research study involving the collection of blood, tumour tissue, saliva, and other body fluids routinely examined during cancer care (e.g. cerebrospinal fluid (CSF), ascites, urine, stool or pleural fluids).
62247176|NCT03764150||PaCO2> 45 mmHg|Diurnal hypercapnia defined by PaCO2\> 45 mmHg
62247177|NCT03764150||PaCO2 <45 mmHg|PaCO2 diurnal within the limits of normal (PaCO2 \<45 mmHg)
62604136|NCT02110940|EXPERIMENTAL|Neurodynamic mobilization exercise|"The experimental group will be given three neurodynamic mobilization exercises which focus more on lower limbs and the major innervating cutaneous nerves - saphenous nerve, sciatica nerve and femoral nerve.~Subjects will be instructed to practice everyday, each action repeat for 10 times."
62604137|NCT01519297|OTHER|Single arm intervention|Irbesartan 150 mg orally for one dose
62604138|NCT03685292||Group A|Subject(s): A Subgroup
62604139|NCT03685292||Group B|Subject(s): B Subgroup
62604140|NCT03685292||Group C|Subject(s): C Sub Group
62604141|NCT03909854|ACTIVE_COMPARATOR|Adaptive Pressure Control|The Adaptive Pressure Control arm is the baseline mode/protocol for medical intensive care unit mechanical ventilation
62604142|NCT03909854|ACTIVE_COMPARATOR|Assist Volume Control|The assist volume control arm is the new protocol that will be implemented and tested for feasibility
62604143|NCT05600283|EXPERIMENTAL|Self-collected vaginal swab samples|Subjects will self-collect a vaginal swab (Evalyn brush) and complete a scheduled standard of care clinician-collected cervical swab
62604144|NCT02028403|EXPERIMENTAL|Cohort 1A: single dose 0.3 mg/kg BMS-936559|Participants will receive 0.3 mg/kg of BMS-936559, administered as a single infusion once at study entry.
62044711|NCT05482360|EXPERIMENTAL|PrEP Optimization Strategies|Up to 12 facilities will be assigned one of three intervention groups (4 facilities per group). The strategies have no yet been identified but will be through other activities in the PrEPARE study.
62044712|NCT05482360|NO_INTERVENTION|Comparator|Up to 4 facilities will be assigned to the comparator group.
62044713|NCT04406948|EXPERIMENTAL|MGCND00EP1|"Participants who will assigned to receive add on MGCND00EP1 will receive carrier oil containing THC and CBD in ratio 20:1, (10% of cannabidiol and 0.5 % and (-)-trans-Δ9-tetrahydrocannabinol) .~Titration Dose: 1 to 2 mg/kg body weight/day. dose will be increased every week by 2 mg/kg body weight/day up to a maximum 25 mg/kg body weigh/day or maximum daily dose 800 mg (the smaller of those 2 values) (divided into two daily doses).~After titration, patients will be receiving a stable maintenance dose of IMP (up to 25 mg/kg BW per day or maximum daily dose 800 mg (whichever smaller)) for 6 weeks period.~During forth treatment period participants will commence a 2 weeks down-titration taper period, followed by 4 weeks observational follow up period of previous standard AE treatment without IMP."
62247178|NCT00351442||1|Inidividuals who have been exposed to HIV but remain uninfected.
62044714|NCT04406948|PLACEBO_COMPARATOR|PLACEBO|"Participants who are assigned to receive add on PLACEBO will be administered the carrier oil (without the active ingredients).~Titration Dose: 1 to 2 mg/kg body weight/day. dose will be increased every week by 2 mg/kg body weight/day up to a maximum 25 mg/kg body weigh/day or maximum daily dose 800 mg (the smaller of those 2 values) (divided into two daily doses).~After titration, patients will be receiving a stable maintenance dose of IMP (up to 25 mg/kg BW per day or maximum daily dose 800 mg (whichever smaller)) for 6 weeks period.~During forth treatment period participants will commence a 2 weeks down-titration taper period, followed by 4 weeks observational follow up period of previous standard AE treatment without IMP."
62044715|NCT01804920|EXPERIMENTAL|D-serine adjuvant treatment|"Random assignment, parallel group, double blind, placebo controlled 8 weeks trial.~First arm: D-serine adjuvant treatment, up to 4 g/day Second arm: Placebo adjuvant treatment"
62044716|NCT01804920|PLACEBO_COMPARATOR|Placebo adjuvant treatment|"Random assignment, parallel group, double blind, placebo controlled 8 weeks trial.~First arm: D-serine adjuvant treatment, up to 4 g/day Second arm: Placebo adjuvant treatment"
62044717|NCT01263951|EXPERIMENTAL|Everolimus and sorafenib|All patients will receive everolimus and sorafenib daily.
62044718|NCT04375748||Patients treated for symptoms of acute myocarditis.|Patients treated in intensive coronary care unit (ICCU) or intensive care unit (ICU), in one of the participating hospitals, for symptoms of acute myocarditis confirmed by a myocardial MRI and/or a CT scan and/or a myocardial biopsy.
62044719|NCT04835155|EXPERIMENTAL|experimental group|The researcher applied Premature Infant Oral Motor Intervention to the experimental group for 5 minutes per day for 14 consecutive days, 15-20 minutes before a sheduled feeding at either the 09:00 or 12:00 feeding. On the first day, the baseline sucking capacity of babies in experimental group was measured before any intervention. On the following 8th, 11th and 14th days, the measures of sucking capacity were repeated and followed by oral feeding trials. Growth measures were collected on the 1st and 14th days and the day of disharge.
62044720|NCT04835155|NO_INTERVENTION|control grup|The researcher did not apply any intervention. On the first day, the baseline sucking capacity of babies in control group was measured before any intervention. On the following 8th, 11th and 14th days, the measures of sucking capacity were repeated and followed by oral feeding trials.
62044721|NCT06286150|EXPERIMENTAL|single-port robot group|
62604145|NCT02028403|PLACEBO_COMPARATOR|Cohort 1B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
62604146|NCT02028403|EXPERIMENTAL|Cohort 2A: single dose 1 mg/kg BMS-936559|Participants will receive 1 mg/kg of BMS-936559, administered as a single infusion once at study entry.
62044722|NCT02660710|EXPERIMENTAL|R-CHOP|We will enroll 40 adult patients age 18-60 years (20 HIV-infected with CD4 count ≥ 100 cells/µL, 20 HIV-uninfected) who will receive a maximum of 6-8 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) over 18-24 weeks
62044723|NCT01799564|EXPERIMENTAL|Micropulse|Micropulse laser will be applied to the inferior hemiretina next to the area of atrophy in a randomly selected eye in 1, 2 or 3 occasions
62044724|NCT01799564|NO_INTERVENTION|Control|The fellow eye does not receive any treatment
62044725|NCT00616187|ACTIVE_COMPARATOR|interferon|
62247179|NCT00351442||2|HIV infected regular sexual partners of Group 1 participants.
62247180|NCT00351442||3|HIV uninfected individuals or couples who have not been exposed to HIV.
62437467|NCT03100578|EXPERIMENTAL|PLASTIC STENT|"Endoscopic double pigtail plastic stent, with formal indication on pancreatic collection, according to the instruction forms of the manufacturer.~Interventions associated:~EUS-guided transmural drainage of pancretic collection: PLASTIC STENT."
62604147|NCT02028403|PLACEBO_COMPARATOR|Cohort 2B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
62604148|NCT02028403|EXPERIMENTAL|Cohort 3A: single dose 3 mg/kg BMS-936559|Participants will receive 3 mg/kg of BMS-936559, administered as a single infusion once at study entry.
62044726|NCT00616187|SHAM_COMPARATOR|untreated|
62247181|NCT00626249|EXPERIMENTAL|T Inhalation powder in diabetic subjs w/ normal renal func|T inhalation powder in diabetic subjects with normal renal function, Single dose, 30 units
62437468|NCT03100578|ACTIVE_COMPARATOR|SELF EXPANDABLE METALLIC STENT|"Lumen apposing metal stent with formal indicaction on pancreatic collection, according to the manufacturer instruction forms.~Interventions associated:~EUS-guided transmural drainage of pancretic collection: METALLIC STENT."
62604149|NCT02028403|PLACEBO_COMPARATOR|Cohort 3B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
62604150|NCT02028403|EXPERIMENTAL|Cohort 4A: single dose 10 mg/kg BMS-936559|Participants will receive 10 mg/kg of BMS-936559, administered as a single infusion once at study entry.
62044727|NCT00970879|EXPERIMENTAL|cotrimoxazole (high)|CD4 cell count≥350/mm3
62044728|NCT00970879|ACTIVE_COMPARATOR|mefloquine|CD4 cell count≥350/mm3
62044729|NCT00970879|EXPERIMENTAL|cotrimoxazole (low)|CD4 cell count\<350/mm3
62247182|NCT00626249|EXPERIMENTAL|T Inhalation powder diabetic subj w/mild or moderate nephrop|T Inhalation powder in diabetic subjects w/mild or moderate nephropathy - Single dose, 30 units
62247183|NCT00961753|EXPERIMENTAL|Optimized Ibuprofen|
62247184|NCT00961753|ACTIVE_COMPARATOR|Standard Ibuprofen|
62437469|NCT04797715|EXPERIMENTAL|AXS-05|Up to 26 weeks in double-blind period
62437470|NCT04797715|PLACEBO_COMPARATOR|Placebo|Up to 26 weeks in double-blind period
62437471|NCT01308281|EXPERIMENTAL|PCI with IVUS guidance|PCI(percutaneous coronary intervention) with IVUS(IntraVascular UltraSound) group
62437472|NCT01308281|ACTIVE_COMPARATOR|PCI without IVUS guidance|PCI(percutaneous coronary intervention) group
62437473|NCT06382181|EXPERIMENTAL|Music Therapy|Through listening to songs, singing, dancing, guided relaxation with music and instrumental group performance, the enjoyment and expression of feelings will be encouraged.
62437474|NCT06382181|EXPERIMENTAL|Health education|Health education workshops
62437475|NCT06382181|EXPERIMENTAL|Physical exercise|Physical exercise adapted to the physical conditions of each participant
62437476|NCT05949281|ACTIVE_COMPARATOR|Colchicine|Colchicine tablet 0.5 mg once-daily
62437477|NCT05949281|PLACEBO_COMPARATOR|Placebo|Placebo tablet once-daily
62604151|NCT02028403|PLACEBO_COMPARATOR|Cohort 4B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
62604152|NCT03929250|EXPERIMENTAL|2g CAW Dose|2g of Centella asiatica water extract in a standardized product.
62604153|NCT03929250|EXPERIMENTAL|4g CAW Dose|4g of Centella asiatica water extract in a standardized product.
62247185|NCT04711148|PLACEBO_COMPARATOR|placebo|"The Core Part：Participants receive placebo~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
62437478|NCT00754195|ACTIVE_COMPARATOR|1|Insertion distance of thoracic epidural catheter: 3 cm
62826671|NCT05893888|EXPERIMENTAL|Arm 1: Pathologically proven and clinically confirmed Tis/CIS of the lip or oral cavity|PRV111 Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Situ (CIS) (WHO 2017)
62247186|NCT04711148|EXPERIMENTAL|orelabrutinib(low dose)|"The Core Part：Participants receive low dose orelabrutinib~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
62437479|NCT00754195|ACTIVE_COMPARATOR|2|Insertion distance of thoracic epidural catheter: 5 cm
62437480|NCT00754195|ACTIVE_COMPARATOR|3|Insertion distance of thoracic epidural catheter: 7 cm
62437481|NCT04562025|EXPERIMENTAL|UC-MSCs treatment group|"Conventional treatment plus UC-MSCs:~Participants will receive conventional treatment plus 3 times of UC-MSCs (1\*10E6 UC-MSCs/kg body weight/100mL intravenously at week 1, week 2，week3)."
62604154|NCT01736605|ACTIVE_COMPARATOR|Massage|Daily massage for 20 minutes the first 3 days following surgery.
62604155|NCT01736605|ACTIVE_COMPARATOR|Massage combined with meditation|Daily massage for 20 minutes combined with meditation the first 3 days following surgery.
62604156|NCT06620627||Participants at average risk for colorectal cancer|Participants 40 years of age or older at time of consent, planning or intending to undergo asymptomatic screening colonoscopy.
62604157|NCT02660879|PLACEBO_COMPARATOR|Written Education|These patients were video taped before they had any inhaler education using their own inhalers. They were then given written educational materials, and given 5 minutes to read these materials. They were then re-taped for their inhaler technique.
62604158|NCT02660879|EXPERIMENTAL|Online Video Education|These patients were video taped before they had any inhaler education using their own inhalers. They were then given online video education located at use-inhalers.com, and were asked to complete the education (took on average 5 minutes). They were then re-taped for their inhaler technique.
62604159|NCT01752153|EXPERIMENTAL|Silymarin (Legalon)|Patients who were unable or unwilling to use desferrioxamine or had stopped desferrioxamine treatment for at least 6 months, were received only silymarin.
62826672|NCT05893888|EXPERIMENTAL|Arm 2: Pathologically proven and clinically confirmed T1-T3, Nx, M0 of the lip or oral cavity|Arm 2 PRV211 Intraoperative Locoregional Delivery Placed into the Resected Tumor Bed Primary Endpoint: Safety Primary Objective: Determine Safety of PRV211 in intraoperative setting
62044730|NCT00970879|ACTIVE_COMPARATOR|mefloquine & cotrimoxazole|CD4 cell count\<350/mm3
62044731|NCT01459510|EXPERIMENTAL|multi media intervention|Play Nicely Program
62247187|NCT04711148|EXPERIMENTAL|orelabrutinib(medium dose)|"The Core Part ：Participants receive medium dose orelabrutinib~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
62247188|NCT04711148|EXPERIMENTAL|orelabrutinib (high dose)|"The Core Part：Participants receive high dose orelabrutinib~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
62437482|NCT04562025|PLACEBO_COMPARATOR|Placebo control group|"Conventional treatment plus Placebo:~Without UC-MSCs therapy but conventional treatment should be received. Participants will receive conventional treatment plus 3 times of Placebo intravenously at week 1, week 2，week3."
62437483|NCT02046785|OTHER|0.9% saline solution|comparing values obtained before and after administration of 500 ml of 0.9% saline
62437484|NCT05425108|ACTIVE_COMPARATOR|CP1 device|
62437485|NCT05425108|NO_INTERVENTION|Control|
62437486|NCT06252194|EXPERIMENTAL|Group A|Metformin 500 mg twice daily along with topical retinoids for 12 weeks
62437487|NCT06252194|ACTIVE_COMPARATOR|Group B|Doxycycline 100 mg twice daily along with topical retinoids for 12 weeks
62437488|NCT04716959|EXPERIMENTAL|Prepectoral Prosthetic Breast Reconstruction|
62604160|NCT01752153|EXPERIMENTAL|Combined therapy (Deaferrioxamine+Silymarin (Legalon)|In combined therapy group, patients continued desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy) was added to desferrioxamine regimen at the dose of 140 mg, taken orally, three times a day, 7 days a week.
62044732|NCT01459510|NO_INTERVENTION|Routine primary care|Routine primary care
62044733|NCT02683850|EXPERIMENTAL|Omega-3 SPM|"Intervention: Study participants will be instructed to take 3 Omega-3 SPM™ softgel supplements in the morning and 3 Omega-3 SPM™ soft gel supplements in the evening for two weeks.~At weeks two participants whose PROMIS-43 Pain Intensity score indicates a reduction in pain levels weeks, will take 2 Omega-3 SPM™ soft gel supplements in the morning and 2 in the evening for the remaining 2 weeks of the study.~Participants whose PROMIS-43 Pain Intensity score remained the same after two weeks, or increased will take 4 Omega-3 SPM™ soft gel supplements in the morning and 4 SPM™ softgels in the evening for the remaining two weeks of the study."
62604161|NCT02223156||MediYoga|
62044734|NCT06515379||Renal Infarction|Patients diagnosed with renal infarction using data obtained from the hospital system have been reviewed and evaluated. Laboratory, clinical and imaging data ahve been registered and statistical analyses have been conducted
62437489|NCT04716959|ACTIVE_COMPARATOR|Subpectoral Prosthetic Breast Reconstruction|
62604162|NCT02223156||Music relaxation|
62604163|NCT02223156||No treatment|
62044735|NCT05361226|EXPERIMENTAL|s-CAIS (static computer aided implant surgery)|For the s-CAIS group, Cone Beam Computed Tomography (CBCT) and full-arch optical scan were performed to provide digital information for implant planning software (coDiagnostix 9, Dental Wings GmbH, Chemnitz, Germany). The virtual implant was set on a three dimensional (3D) virtual jaws according to the prosthetically driven protocol by one postgraduate dentist and was confirmed by one experienced dentist. Static surgical template covering on occlusal part of 4 teeth anteroposteriorly was then fabricated via 3D printing machine (surgical guide resin, Form 2, Formlabs, Somerville, Massachusetts, USA). This surgical template would be used during surgery.
62247189|NCT02530372|EXPERIMENTAL|UriCap-F|"The UriCap-F is an FDA cleared Class I device intended for urinary management in women.~The device is comprised of a multiple use unit and a single use unit. The multiple use unit is intended to be reused by the same patient for up to 30 days. It is removed every 24 hours, rinsed under running water, dried and re-applied.~The UriCap is held in position by means of a single-use medically approved adhesive tape."
62437490|NCT00752856|EXPERIMENTAL|1 - Kaletra + Isentress taken twice daily|Kaletra (lopinavir/ritonavir 400/100 mg) + Isentress (Raltegravir 400 mg) twice-daily
62437491|NCT00752856|ACTIVE_COMPARATOR|2 - Atripla taken once daily|Sustiva (EFV 600 mg), Viread (TDF 300 mg) and Emtriva (FTC 200 mg) taken as Atripla® once-daily
62437492|NCT05605028|EXPERIMENTAL|Mental Health lifestyle intervention|The intervention will focus on identifying risk factors for depression and anxiety and will quantitate the educational component of the POWER Obesity group intervention delivered by mental health professionals that are currently presenting for 30 min during the Monday session to address the root causes of obesity as well as to encourage positive lifestyle changes (e.g. sleep, diet, sun exposure, circadian rhythms, and addictions). The previously published hypothesis identifies triggers, that combined, could cause mental health problems. The 10 groups of triggers are: (1) Genetic, (2) Developmental, (3) Lifestyle, (4) Circadian Rhythm, (5) Addiction, (6) Nutrition, (7) Toxic, (8) Social/Complicated Grief, (9) Medical Condition, and (10) Frontal Lobe. Each of these factors will be dealt with in the lifestyle intervention.
62437493|NCT05605028|ACTIVE_COMPARATOR|Dietitian-led|A group of participants that visit a dietitian will be the control.
62449199|NCT04337996|EXPERIMENTAL|experimental arm|These are patients whose diagnosis of SARS-Cov-2 infection was made on the Gold-Standard: combined history/clinical examination, PCR and CT scan and requiring hospitalization at Tourcoing Hospital.
62604164|NCT03679286||All subjects|No intervention
62604165|NCT05524220|ACTIVE_COMPARATOR|Group A: Standard care with a facemask.|
62604166|NCT05524220|EXPERIMENTAL|Group B: SuperNO2VA™EtCO2|
62604167|NCT05366413|EXPERIMENTAL|Pain management strategies|"Participants will receive early referral to an anesthesia-trained interventional pain management specialist evaluated for pain management strategies.~Participants will complete surveys every 2 months and will have the option of tracking their pain at home using a secure smartphone application.~Participants will be followed on the study for 4 months."
62604168|NCT00005604|EXPERIMENTAL|Treatment (rhIl-12, IL-2)|Patients receive interleukin-12 (IL-12) IV on days 1 and 4 for 6 weeks. Beginning on day 4 of the third week, patients receive interleukin-2 (IL-2) subcutaneously 1 hour before and 20 hours after each dose of IL-12. On subsequent courses, IL-2 and IL-12 are administered on days 1 and 4 of each week. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease response may continue treatment until complete response or disease progression.
62604169|NCT03897933||Erector spinae plane block group (ESP)|Single- shot ultrasound guided ESP block with 30 ml 0.25% bupivacain at the T10 vertebral level was performed preoperatively to patients in the ESP group (Group I).
62604170|NCT03897933||non- blocked Group|consists of the patient group without any procedure
62604171|NCT01667939|EXPERIMENTAL|pregnancy diet|Healthy Eating Index (HEI) in supervised pregnancies
62604172|NCT01667939|NO_INTERVENTION|unsupervised pregnancy|women attending the obstetrics unit who did not follow a supervised diet
62604173|NCT00943670|EXPERIMENTAL|T-DM1 / T-DM1 + pertuzumab|"Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg.~From Cycle 4, participants with early progressive disease (demonstrated prior to the end of Cycle 6) could receive combined pertuzumab and trastuzumab emtansine. Pertuzumab was administered after trastuzumab emtansine by IV infusion at a loading dose of 840 mg on Day 1, starting at the cycle after tumor progression was determined, followed by 420 mg IV infusion every 3 weeks in subsequent cycles.~Participants who met criteria for ongoing clinical benefit were allowed to continue study treatment in the absence of disease progression or unacceptable toxicity for up to 1 year."
62604174|NCT06454422|EXPERIMENTAL|Wuqinxi|"including observation of disease progression and complications, oxygen inhalation, medication guidance, rest and diet nursing, daily activity guidance, psychological guidance, and follow-up after discharge.~Patients mimicked precise Wuqinxi movements and breathing patterns while exercising."
62247190|NCT05018767|EXPERIMENTAL|Treatment Group|Single intravenous infusion of 100 million cells
62247191|NCT05315362|EXPERIMENTAL|Intervention group - intradermal vaccination with patch|Participants will receive 20 µg of mRNA-1273 vaccine through the intradermal route using a solid micro needle delivery system
62604175|NCT06454422|NO_INTERVENTION|general nursing routines|including observation of disease progression and complications, oxygen inhalation, medication guidance, rest and diet nursing, daily activity guidance, psychological guidance, and follow-up after discharge.
62826673|NCT05154786|EXPERIMENTAL|Early Mobilization and endurance training|Early Mobilization and endurance training for prolonged mechanical ventilator
62826674|NCT05154786|ACTIVE_COMPARATOR|Usual care|Weaning protocols, bed exercise, and early mobilization.
62826675|NCT03198715|EXPERIMENTAL|DS-1040b 0.6 mg|Participants receive DS-1040b 0.6 mg by intravenous infusion over six hours
62826676|NCT03198715|EXPERIMENTAL|DS-1040b 1.2 mg|Participants receive DS-1040b 1.2 mg by intravenous infusion over six hours
62826677|NCT03198715|EXPERIMENTAL|DS-1040b 2.4 mg|Participants receive DS-1040b 2.4 mg by intravenous infusion over six hours
62826678|NCT03198715|EXPERIMENTAL|DS-1040b 4.8 mg|Participants receive DS-1040b 4.8 mg by intravenous infusion over six hours
62826679|NCT03198715|PLACEBO_COMPARATOR|Placebo|Participants receive saline by intravenous infusion over six hours
62826680|NCT06188637|EXPERIMENTAL|Open- label ozanimod|All patients will receive open-label ozanimod
62826681|NCT03264326|EXPERIMENTAL|BFR Group|Blood Flow Restriction Training with Eccentric Exercise Protocol
62247192|NCT05315362|ACTIVE_COMPARATOR|Control group - intramuscular vaccination with standard needle|Participants will receive 20 µg of mRNA-1273 vaccine through the intramuscular route
62437494|NCT06091774||"Group with the medical device iATROS"|"Patients are subsequently assigned to one of the two groups in a 1:1 randomization.~The treatment to be carried out in the intervention group is the use of the therapy control for the treatment of CHD, which is played out via the iATROS medical device. At the start of the digital treatment, the patients receive suitable measuring devices for recording their vital parameters in the home environment. With the completion of the visit in month 9, the active phase of the study has ended. Patients will now use the iATROS medical device for another 9 months, after which the stability of the intervention effects will be determined."
62449200|NCT03916653|EXPERIMENTAL|Test group|Osseous resection using piezoelectric device
62449201|NCT03916653|ACTIVE_COMPARATOR|Control group|Osseous resection using conventional rotary instruments
62604176|NCT02670733||high responsiveness of ICP to PEEP|After increasing positive end-expiratory pressure (PEEP) from 5 cmH2O to 15 cmH2O, intracranial pressure (ICP) increases above the median for the study population.
62247193|NCT01431274|EXPERIMENTAL|tiotropium+olodaterol low dose FDC|Once daily 2 puffs solution for inhalation Respimat
62247194|NCT01431274|EXPERIMENTAL|tiotropium+olodaterol high dose FDC|Once daily 2 puffs solution for inhalation Respimat
62247195|NCT01431274|ACTIVE_COMPARATOR|olodaterol|Once daily 2 puffs solution for inhalation Respimat
62247196|NCT01431274|ACTIVE_COMPARATOR|tiotropium low dose|Once daily 2 puffs solution for inhalation Respimat
62247197|NCT01431274|ACTIVE_COMPARATOR|tiotropium high dose|Once daily 2 puffs solution for inhalation Respimat
62247198|NCT03602404||St. Petersburg: School aged children|Generally healthy 9 to 12 years old children
62826682|NCT03264326|SHAM_COMPARATOR|Sham BFR Group|Sham Blood Flow Restriction Training with Eccentric Exercise Protocol
62826683|NCT06340802|EXPERIMENTAL|VNS Treatment|Vagus nerve stimulation is started 2-week after the implantation.
62826684|NCT03255122|EXPERIMENTAL|Immediate treatment|Individuals in this condition will immediately receive I-CALM treatment, which draws on videoconferencing to remotely deliver real time cognitive-behavioral therapy for early child anxiety to families in their home.
62826685|NCT03255122|OTHER|Waitlist|Individuals in Waitlist will participate in an initial waitlist condition, and then after post-waitlist assessment will be offered the I-CALM intervention. Accordingly families in this condition receive Delayed I-CALM.
62826686|NCT02835378||Bilateral upper limb amputation|Bilateral upper limb amputees, with amputation from the short transverse hand (hand completely non-functional) to complete arm, whatever their age
62826687|NCT05803252|EXPERIMENTAL|FACT Group|4-6 FACT consultation sessions, one weekly session, 45-60 mins per session. These sessions will be using online video conferencing platforms.
62826688|NCT05803252|OTHER|Waitlist Control Group|The waitlist control group participants will commence their intervention trial immediately after they complete their follow-up assessment.
62826689|NCT05156567||routine physicians|
62826690|NCT05156567||DLS|
62826691|NCT03460795|EXPERIMENTAL|Conventional plus MSC and Tregs treatment|
62826692|NCT06597305|EXPERIMENTAL|CBT-20-AN|The single CBT-20-AN arm of this study is experimental, consisting of 20 weekly sessions and one-month, three-month, and six-month follow-ups.
62044736|NCT05361226|ACTIVE_COMPARATOR|c-LIS (conventional laboratory-guided implant surgery)|"For the c-LIS group, a radiographic template (ORTHO Plast, prominent®, Chonburi, Thailand) was fabricated covering on occlusal part of 4 teeth anteroposteriorly according to diagnostic wax-up on the study model. A radiographic marker (gutta percha) was then filled in the created hole of the template and for used while taking CBCT image to verify marker position.~Next, a study model was scanned by laboratory surface scan (D900m, 3Shape, Copenhagen, Denmark). The STL file was imported to 3D printing devices and the resin model was fabricated (Dental LT clear resin, Form 2, Formlabs, Somerville, Massachusetts, USA).~Next, the same template that had been used for CBCT was used to place implant replicas in a resin model. The position of the implant replicas in the models were assumed as pre-operative planned implant position."
62044737|NCT05279781|ACTIVE_COMPARATOR|Root canal treatment group|This group will receive complete root canal therapy
62044738|NCT05279781|ACTIVE_COMPARATOR|Pulpotomy group|This group will receive full pulpotomy
62044739|NCT00119548|OTHER|Arm 1|Randomized, controlled trial with three intervention models: Model A (traditional counseling/testing);
62044740|NCT00119548|OTHER|Arm 2|Model B (nurse-initiated screening, traditional counseling/testing);
62044741|NCT00119548|OTHER|Arm 3|Model C (nurse-initiated screening, streamlined counseling/rapid testing).
62044742|NCT01813474|EXPERIMENTAL|olaparib tablet monotherapy|olaparib tablet
62044743|NCT03748290|EXPERIMENTAL|People with a SCI who will receive Lyrica 75mg for 12 weeks|
62044744|NCT03748290|PLACEBO_COMPARATOR|People with a SCI who will receive Placebo for 12 weeks|
62044745|NCT01841346||PCI patients|Patients undergoing PCI for elective or ACS will be enrolled.
62247199|NCT03602404||St. Petersburg: Women of reproductive age|Generally healthy non-pregnant, non-lactating women between 18 and 44 years of age
62247200|NCT03602404||Papua New Guinea: School aged children|Generally healthy 9 to 12 years old children
62604177|NCT02670733||low responsiveness of ICP to PEEP|After increasing positive end-expiratory pressure (PEEP) from 5 cmH2O to 15 cmH2O, the level of intracranial pressure (ICP) increases below the median for the study population.
62826693|NCT06590129|ACTIVE_COMPARATOR|Only Rehabilitation|Evaluated with the Boston questionnaire and the Visual Analogue Scale (VAS), then te patients were enroled to a 15-20 sessions in rehabilitation area with physical media: paraffin glove (10 coats for 15min), mobilizations of wrist and fingers, strectching of wrist and fingers tendons/muscles, muscle stregthening whit isometric or isotonic excercises to intrinsic muscles of the hand an forearm, and occupational therapy with techniques for sensory return, nerve and tendon sliding techniques, activities aimed at improving basic hand functions and work simulation activities.
62247201|NCT03186118|EXPERIMENTAL|Cohort A|Participants will receive CD19-targeting CAR T cells. Participants who have a total CD19 antigen load in bone marrow of \<15% will be assigned to Cohort A, to receive up to 6 T-APC treatments.
62247202|NCT03186118|EXPERIMENTAL|Cohort B|Participants will receive CD19-targeting CAR T cells. Participants for whom laboratory testing on Study Day 14 indicates they are at risk for early loss of CAR T cells will be assigned to Cohort B to receive up to 6 T-APC treatments. If laboratory testing prior to planned T-APC treatment indicates loss of CAR-T cells, participants may move to Cohort C.
62247203|NCT03186118|EXPERIMENTAL|Cohort C|Participants will receive CD19-targeting CAR T cells. Participants for whom laboratory testing shows loss of CAR T cells within 6 months will be assigned to Cohort C. They will receive another CAR T cell infusion followed by up to 6 T-APC treatments.
62247204|NCT03186118|EXPERIMENTAL|Cohort D|Participants will receive CD19-targeting CAR T cells. Participants who do not meet assignment rules for Cohorts A, B, or C will be followed after CAR T cell infusion in Cohort D.
62604178|NCT02865603|EXPERIMENTAL|PAX Good Behavior Game|The intervention is delivered by teachers within the normal school curriculum. Teachers from intervention classes completed 3-day training and were supported by the mentor, who visited their class during the 2016/17 school year and provided counseling via e-mail and phone. During the second year (2017/18) teachers could use the PAX GBG methods, but they did not receive additional support from the mentors.
62044746|NCT04085783|EXPERIMENTAL|endometrial PRP|In study group (75 patients), intrauterine infusion of PRP was done 48 hrs. before ET. PRP was prepared from autologous blood and it was made by using two steps centrifuge process. All Blastocyst transfers were performed under ultrasound guidance by one expert gynecologist with infertility fellowship. ET was performed according to American Society for Reproductive Medicine (ASRM) guidelines 2013 (Two or three embryos for each participant). On PRP infusion day, 17.5 ml of peripheral venous blood was drawn into a syringe that contains 2.5 ml of Acid Citrate and centrifuged immediately at 1200 rpm for 12 min to separate red blood cells, then plasma was centrifuged again at 3300 rpm for 7 min to obtain PRP that contained platelet 4-5 times more than peripheral blood. 0.5- 1 ml of PRP was infused into the uterine cavity with embryo transfer catheter (Wallace - Smiths, UK). On the other side, No PRP was done in control group. Pregnancy tests were done 12 days after ET.
62044747|NCT01625351|EXPERIMENTAL|Treatment|"Participants to undergo transplantation. They receive alemtuzumab, fludarabine, sirolimus, busulfan, melphalan, and stem cells.~Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy.~Cells for infusion are prepared using the CliniMACS System."
62044748|NCT03545867|EXPERIMENTAL|Seated control (CON)|Participants remain seated in their habitual wheel chair for \~45 min (duration of exercise performed in other arms). Following the intervention they are fed.
62044749|NCT03545867|EXPERIMENTAL|Circuit resistance training (CRT)|Participants complete upper extremity resistance maneuvers (lifts) interspersed with low-load/high-speed arm cycling for a combined 30 repetitions of 6 lifts and \~20 min of arm cycling. During this time energy expenditure is measured via open-circuit indirect calorimetry. Following the intervention they are fed.
62604179|NCT02865603|NO_INTERVENTION|Waitlist control group|Control group continue their normal activities without intervention. After a post-test assessment in spring 2018 the control group teachers will be trained and supported to implement PAX GBG.
62044750|NCT03545867|EXPERIMENTAL|Moderate intensity continuous (MICT)|Participants complete continous arm cycling at a steady-state power output (intensity) matched to the energy expenditure (kcal/min) and duration of exercise (min) response during CRT. Following the intervention they are fed.
62044751|NCT03545867|EXPERIMENTAL|High intensity interval training (HIIT)|"Participants complete interval arm cycling at power output that varies between 2 min active and two min recovery periods. This interval exercise is matched to the total energy expenditure (accumulated kcals) response during CRT. Following the intervention they are fed."
62044752|NCT01093118|EXPERIMENTAL|TMI-358|Active treatment
62247205|NCT05490173|EXPERIMENTAL|Intranasal exosomes administration|ELWB newborns who will receive intranasal exosomes
62247206|NCT05490173|NO_INTERVENTION|Control|ELWB newborns who will not receive intranasal exosomes
62247207|NCT03919929|ACTIVE_COMPARATOR|Diet Intervention|Weight loss with dietary intervention
62044753|NCT01093118|PLACEBO_COMPARATOR|MMI-467|
62044754|NCT01281644|NO_INTERVENTION|No Laser Treatment|
62044755|NCT01281644|ACTIVE_COMPARATOR|45-60 J Diode Laser Therapy|Diode laser therapy will be initiated at 45-60 J for 30 ms to 100 ms.
62247208|NCT03919929|EXPERIMENTAL|GLP-1 Intervention|Participants will take a daily oral tablet of semaglutide for 4 months.
62247209|NCT01157013|EXPERIMENTAL|Advanced Hepatocellular Carcinoma|Hepatocellular carcinoma patients not candidates to local and/or curative treatment and an expected overall survival of at least three months and who are susceptible of receiving sorafenib therapy.
62449202|NCT04258241|ACTIVE_COMPARATOR|Local infiltration analgesia with local anesthetic (LIA+)|Local infiltration analgesia will be performed at the end of the surgery by injection of 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline.
62449203|NCT04258241|PLACEBO_COMPARATOR|Local infiltration analgesia without local anesthetic (LIA-)|Local infiltration analgesia will be performed at the end of the surgery by injection of 0.3 mg of epinephrine and 120 ml of normal saline.
62449204|NCT00194740|EXPERIMENTAL|1|
62449205|NCT06101654||Healthy Adult Volunteers|Minimum of ten (10) subjects meeting the eligibility criteria.
62449206|NCT04121806|EXPERIMENTAL|Ulcerative colitis patients with mild to moderate activity|Participants will be followed for 14 days on their traditional diet followed by an 8 week intervention with the specially designed and provided treatment diet.
62449207|NCT00513968|EXPERIMENTAL|I|HB-110 2mg, 4mg or 8mg combined with Adefovir
62449208|NCT00513968|ACTIVE_COMPARATOR|II|Adefovir
62449209|NCT02324465|ACTIVE_COMPARATOR|King Vision Video Laryngoscope|The patient would be randomized to intubation via use of the King Vision VL
62449210|NCT02324465|ACTIVE_COMPARATOR|Glidescope Video Laryngoscope|The patient would be randomized to intubation via use of the Glidescope VL
62449211|NCT05637281|PLACEBO_COMPARATOR|convention|patients in convention arm receive conventional management according to AP guidelines of International Association of Pancreatology and the Chinese Society of Gastroenterology, including goal-directed fluid resuscitation, oxygen supply even mechanical ventilation, and nutritional support if necessary.
62449212|NCT05637281|EXPERIMENTAL|convention + indometacin|Besides the conventional treatment,patients in convention + indometacin arm receive 50-mg indomethacin suppositories at intervals of 12 hours for a total of 6 doses.
62826694|NCT06590129|EXPERIMENTAL|Median nerve ultrasound guided hidrodissection + rehabilitation|"Evaluated with the Boston questionnaire and the Visual Analogue Scale (VAS), then an ultrasound guided hidrodissection of the median nerve with 4.5ml of glucosade solution was performed.~The patients were enrolled into 15-20 sessions in rehabilitation área with the same protocolo of the control group."
62044756|NCT03032055||VOC|"Patients who won't develop a secondary Acute chest syndrome during a vaso occlusive crisis within 15 days after admission.~Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate and chest pain or decreased breath sounds .~A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults. It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries."
62044757|NCT03032055||2°ACS|"Patients who will develop a secondary acute chest syndrome during a vaso occlusive crisis within 15 days after admission.~Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate AND chest pain or decreased breath sounds .~A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults.It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries."
62437495|NCT06091774||"Group without the medical device iATROS"|"All patients in the control group will receive standard-of-care treatment in the 9 months after randomization. There will be no further intervention during this phase. Similarly, treatment is not influenced or restricted in terms of free choice of medical care or medical treatment.~Subsequently, they also receive access to the iATROS medical device. Patients will receive suitable measuring devices for recording their vital parameters in the home environment. The effects of the intervention will be recorded after 9 months."
62604180|NCT02898324|EXPERIMENTAL|KiVa program full|The schools allocated in this arm will receive the Chilean adaptation of KiVa program with all its universal and indicated actions.
62604181|NCT02898324|EXPERIMENTAL|KiVa program w/o the digital component|The schools allocated in this arm will receive the Chilean adaptation of KiVa program without the digital component (online game)
62604182|NCT02898324|NO_INTERVENTION|Control group|The schools allocated in this arm will not receive the KiVa program. If successful, these schools will receive the program the following academic year.
62604183|NCT03147300|ACTIVE_COMPARATOR|Östergötland region - Control group|
62604184|NCT03147300|EXPERIMENTAL|Östergötland region - Intervention group|
62604185|NCT00727090|EXPERIMENTAL|1|Conivaptan in addition to usual care at the discretion of the attending medical staff
62247210|NCT04219813|OTHER|Patients affected with Non-celiac Gluten/Wheat Sensitivity|The researchers will deliver to each patient 10 kits for the analysis of the GIP and they will ask them to use them two times per week, for 5 weeks. Furthermore, the patients will test urine GIP in the event of symptoms/signs that they attribute to the accidental intake of gluten, within the same 5 weeks. Both gastrointestinal and extra-intestinal symptoms which the patients will attribute to the accidental intake of gluten, will be considered.
62247211|NCT01147198|ACTIVE_COMPARATOR|Ready to Use Supplementary Food|Ready to Use Supplementary Food treatment
62247212|NCT01147198|ACTIVE_COMPARATOR|Premix|Premix Corn Soy Blend-oil treatment
62247213|NCT03210103|ACTIVE_COMPARATOR|Arm 1, Radiation +/- Chemotherapy|Standard Treatment (Radiation +/- Chemotherapy)
62247214|NCT03210103|EXPERIMENTAL|Arm 2, TOS + Neck Dissection|Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)
62247215|NCT03817866||BRAHMS CgA II KRYPTOR|Adult patients with well defined grade 1 and grade 2 GEP-NETs. Serial serum samples from all patients will be analyzed using the BRAHMS CgA II KRYPTOR Assay.
62604186|NCT00727090|NO_INTERVENTION|2|Usual care by the attending physician staff
62247216|NCT04384393|EXPERIMENTAL|ThisCART19 cells injections|In this study, allogeneic anti-CD19 CAR T Cells(ThisCART19 cells) is used to treat patients with refractory or relapsed CD19 positive B cell malignancies.
62437496|NCT01402115|EXPERIMENTAL|Polycan|Polycan 150mg for 12 weeks
62437497|NCT01402115|PLACEBO_COMPARATOR|Placebo|Placebo 15mg for 12 weeks
62437498|NCT02023632|EXPERIMENTAL|Similar-Age-Same-Gender (SASG)|Participants in this trial arm will be of similar age (65+) and of the same gender (i.e., separate groups for male older adults and female older adults).
62604187|NCT00335959|EXPERIMENTAL|Chemotherapy, Chemoradiation, Surgery|"Chemotherapy: Oxaliplatin, 130 mg/m2, 2 hour IV infusion on Days 1 and 22; Capecitabine 850 mg/m2/dose, PO q 12 hours on Days 1-14 and 22-35 Chemoradiation: Capecitabine 650 mg/m2/dose, PO q 12 hours on days 43-77; Radiation therapy 180 cGy/day, 5 days/week beginning on Day 43.~Surgery: Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy"
62604188|NCT04576065|NO_INTERVENTION|Usual Care|Patients randomized to usual care will follow-up with primary care providers and specialists as recommended by hospital providers, or seek medical care as needed after hospital discharge.
62604189|NCT04576065|EXPERIMENTAL|Intervention|Patients randomized to intervention will have 6 months of access after hospital discharge for telehealth visits with a nurse practitioner and an activity tracker providing data to the nurse practitioner about subject's daily level of activity.
62604190|NCT01044953||Soccer Players|German professional soccer players
62604191|NCT02806544|EXPERIMENTAL|Tamoxifen|Tamoxifen 20mg by mouth daily
62044758|NCT02357251|ACTIVE_COMPARATOR|Enhanced recovery protocol|Aspects of perioperative care will be standardized. Specific protocol for pre-operative, intra-operative, and post-operative care will be followed in this group.
62044759|NCT02357251|NO_INTERVENTION|Standard of care|Treating physicians will determine all aspects of patients' perioperative care. Specifically, the individual surgeon, nurse, resident, fellow, and anesthesiologist caring for the patient will determine the patients' pre-operative counseling, bowel preparation, postoperative nausea and vomiting prophylaxis, IV fluid replacement, use of drains, timing of urinary catheter removal, mobilization, post-operative nutrition, pain medication, and bowel stimulation.
62044760|NCT06526117|EXPERIMENTAL|Low or Moderate Dose Hydroxyurea|Initial treatment with Hydroxyurea at 10 mg/kg/day (range 7 to 15 mg/kg/day) for primary stroke prevention. Subsequent treatment with moderate-dose hydroxyurea (20 mg/kg/day (range 17.5 - 26 mg/kg/day)) based after at least two severe pain events requiring physician contact during the trial.
62044761|NCT04125368|EXPERIMENTAL|Intervention|A\&T intervention areas: intensified maternal nutrition behavior change interventions during antenatal care delivered through government health facilities and in the community
62604192|NCT02210169|NO_INTERVENTION|Intermittent infusion of vancomycin|Vancomycin will be administered intravenously over 1 hour. Doses will be given from one to four times a day according to corrected gestational age.
62604193|NCT02210169|ACTIVE_COMPARATOR|Continuous infusion of vancomycin|A loading dose of vancomycin will be given over 1 hour followed by a continuous infusion of vancomycin over a 24 hour period.
62826695|NCT05964218|EXPERIMENTAL|Food-Body-Mind Intervention|Guided by the Actor-Partner Interdependence Model, the Allostatic Load Model, and the Transactional Theory of Stress and Coping, the pilot 5-week Food-Body-Mind intervention includes: 1) a school-based mindfulness component delivered to equip preschoolers with knowledge and skills in mindful eating and movement (e.g., yoga, deep breathing exercises); 2) a home-based mindfulness component to increase caregivers' skills in practicing mindful eating, movement, and parenting behaviors at home to foster a more positive, mindful, and healthy home environment; and 3) a school learning and home practice connection component to improve caregiver-preschooler relationships.
62826696|NCT05388110||Healthy controls|
62826697|NCT05388110||Depressed adolescents|
62826698|NCT05740254|EXPERIMENTAL|Early Time Restricted Eating|early-day TRE (7:00 to 15:00 h)
62826699|NCT05740254|EXPERIMENTAL|Late Time Restricted Eating|late TRE (12:00 to 20:00 h)
62826700|NCT04335006|EXPERIMENTAL|Experimental A|Subjects receive Carelizumab in combination with Nab-paclitaxel plus Apatinib,each 4-week cycle
62826701|NCT04335006|EXPERIMENTAL|Experimental B|Subjects receive Carelizumab in combination with Nab-paclitaxel,each 4-week cycle
62826702|NCT04335006|ACTIVE_COMPARATOR|Comparator C|Subjects receive nab-paclitaxel intravenously each 4-week cycle.
62826703|NCT06591247|ACTIVE_COMPARATOR|Double Balloon Catheter induction|A Double balloon catheter will be inserted for 12 hours in this group of women
62826704|NCT06591247|ACTIVE_COMPARATOR|Membrane stripping|This group of women will undergo membrane stripping twice (every 4-6 hours) over a period of 12 hours
62826705|NCT04901793|EXPERIMENTAL|Virtual Reality Intervention Group|Patient is fitted with a Virtual Reality headset and handheld remote control. Subject is able to play an interactive game during the duration of the in-office procedure.
62826706|NCT04901793|NO_INTERVENTION|Control Group|standard of care
62826707|NCT04865770|EXPERIMENTAL|Semaglutide 1.0 mg OW|Once-weekly (OW) Semaglutide administered subcutaneously (s.c., under the skin).
62826708|NCT04865770|PLACEBO_COMPARATOR|Placebo (Semaglutide) 1.0 mg OW|Once-weekly (OW) placebo (Semaglutide) administered subcutaneously (s.c., under the skin).
62826709|NCT02940795|EXPERIMENTAL|Coke cola|Exclusively lactating mothers with infants between 4-6 weeks were investigated. Lactating mothers will be consume a 20 ounce bottle of coke cola.
62826710|NCT02940795|EXPERIMENTAL|Diet Rite|Exclusively lactating mothers with infants between 4-6 weeks were asked to consume a 12 ounce bottle of diet rite.
62826711|NCT06600048|EXPERIMENTAL|Hyperbaric prilocaine group|Patients will receive 1.5 ml (30 mg) 0.5% hyperbaric prilocaine.
62044762|NCT04125368|NO_INTERVENTION|Control|Comparison areas: standard antenatal care services delivered at government health facilities and in the community
62044763|NCT02328833|EXPERIMENTAL|Active Implementation of Guidelines|Primary Care Centers where the experimental strategies of guidelines implementation will be done
62044764|NCT02328833|NO_INTERVENTION|No Active Implementation of Guidelines|Primary Care Centers where the experimental strategies of guidelines implementation not will be done
62604194|NCT05236894|EXPERIMENTAL|Aim 1: Arm I (lower dose nicotine pouch)|Patients receive lower dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
62604195|NCT05236894|EXPERIMENTAL|Aim 1: Arm II (higher dose nicotine pouches)|Patients receive higher dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
62826712|NCT06600048|ACTIVE_COMPARATOR|Hyperbaric bupivacaine group|Patients will receive 1.5 ml (7.5 mg) 0.5% hyperbaric bupivacaine.
62826713|NCT06600178|EXPERIMENTAL|Active Drug Group|Dapagliflozin 10mg oral tablet
62826714|NCT06600178|PLACEBO_COMPARATOR|Placebo Group|placebo tablet
62826715|NCT03882294|EXPERIMENTAL|Probiotics|Subjects in probiotic group will receive fermented milk containing live cultures Lactobacillus casei Shirota (LcS), 3 x 10\^10 CFU/bottle (80 ml)
62826716|NCT03882294|PLACEBO_COMPARATOR|Placebo|Subjects in placebo group will receive milk drink without LcS (80 ml).
62826717|NCT03476486|EXPERIMENTAL|Treatment|The hand that was subject to thread carpal tunnel release surgery
62826718|NCT03476486|NO_INTERVENTION|Control|The hand that was not treated
62826719|NCT06594276|NO_INTERVENTION|Needle aspiration with systemic antibiotics|
62826720|NCT06594276|ACTIVE_COMPARATOR|Needle aspiration with local instillation of antibiotics|
62044765|NCT01496833|EXPERIMENTAL|Endovascular|Total endovascular arch reconstruction
62044766|NCT01515748|OTHER|Surgery + Adjuvant Chemotherapy (SC)|Participants underwent surgery within 2 weeks after randomization followed by adjuvant chemotherapy with S-1 \[(Gimeracil) + Oxo (Oteracil)\] 40 milligrams per square meter (mg/m\^2) administered orally twice daily, from Day 1 to 28 of each cycle for 1 year, and were followed-up after End-of-Treatment (EOT) until disease progression or death or study cut-off date, whichever comes first (maximum duration: up to 10 years).
62044767|NCT01515748|EXPERIMENTAL|Neoadjuvant Chemotherapy +Surgery +Adjuvant chemotherapy (CSC)|Participants received neo-adjuvant chemotherapy with Docetaxel 50 mg/m\^2 intravenously (IV) for greater than or equal to (\>=)1 hour (hr) on Day 1 of each treatment cycle plus Oxaliplatin 100 mg/m\^2 IV for \>=2 hr on Day 1 of each treatment cycle plus S-1 \[(Gimeracil) + Oxo (Oteracil)\] 40 mg/m\^2 administered orally twice daily from Day 1 to 14, of each treatment cycle followed by surgery approximately 1-3 weeks after completion of neo-adjuvant chemotherapy and adjuvant chemotherapy with S-1 \[(Gimeracil) + Oxo (Oteracil)\] 40 mg/m\^2 administered orally twice daily, from Day 1 to 28 of each cycle for 1 year, and were followed-up after EOT until disease progression or death or study cut-off date, whichever comes first (maximum duration: up to 10 years).
62604196|NCT05236894|ACTIVE_COMPARATOR|Aim 1: Arm III (cigarette smoking)|Patients smoke usual brand of cigarettes, taking one puff every 30 seconds over 5 minutes at visits 1, 2, and 3.
62604197|NCT05236894|EXPERIMENTAL|Aim 2: Arm I (3mg NP)|Patients receive nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
62604198|NCT05236894|EXPERIMENTAL|Aim 2: Arm II (3mg NP)|Patients receive nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
62604199|NCT05236894|EXPERIMENTAL|Aim 2: Arm III (3mg NP)|Patients receive nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
62604200|NCT05730153|ACTIVE_COMPARATOR|group 1|
62604201|NCT05730153|SHAM_COMPARATOR|group 2|
62604202|NCT06507904|EXPERIMENTAL|Part 1 Sequence 1 - Palatability|Participants will receive 4 preparations (Treatments A, B, C, D) of osivelotor pellet/granules at least 2 hours apart on Day 1 which they will put in their mouth and then spit it out.
62604203|NCT06507904|EXPERIMENTAL|Part 1 Sequence 2 - Palatability|Participants will receive 4 preparations (Treatments B, C, D, A) of osivelotor pellet/granules at least 2 hours apart on Day 1 which they will put in their mouth and then spit it out.
62604204|NCT06507904|EXPERIMENTAL|Part 1 Sequence 3 - Palatability|Participants will receive 4 preparations (Treatments C, D, A, B) of osivelotor pellet/granules at least 2 hours apart on Day 1 which they will put in their mouth and then spit it out.
62604205|NCT06507904|EXPERIMENTAL|Part 1 Sequence 4 - Palatability|Participants will receive 4 preparations (Treatments D, A, B, C) of osivelotor pellet/granules at least 2 hours apart on Day 1 which they will put in their mouth and then spit it out.
62604206|NCT06507904|EXPERIMENTAL|Part 2 Pharmacokinetics - Treatment E|Participants will receive 1 preparation (Treatment E) of osivelotor pellet/granules on Day 1 which they will put in their mouth and swallow.
62604207|NCT06507904|EXPERIMENTAL|Part 2 Pharmacokinetics - Treatment F|Participants will receive 1 preparation (Treatment F) of osivelotor pellet/granules on Day 1 which they will put in their mouth and swallow. They might have a dose on Day 7 which they will put in their mouth and then spit it out; afterwards they will complete the taste questionnaire.
62604208|NCT06507904|EXPERIMENTAL|Part 2 Pharmacokinetics - Treatment G|Participants will receive 1 preparation (Treatment G) of osivelotor pellet/granules on Day 1 which they will put in their mouth and swallow.
62604209|NCT06507904|EXPERIMENTAL|Part 2 Pharmacokinetics - Treatment H|Participants will receive famotidine and afterwards preparation (Treatment H) of osivelotor pellet/granules on Day 1 which they will put in their mouth and swallow.
62604210|NCT06507904|EXPERIMENTAL|Part 2 Pharmacokinetics - Treatment I|Participants will receive 1 preparation (Treatment I) of osivelotor pellet/granules on Day 1 which they will put in their mouth and swallow.
62604211|NCT06507904|EXPERIMENTAL|Part 2 Pharmacokinetics - Treatment J|Participants will receive 1 preparation (Treatment J) of osivelotor pellet/granules on Day 1 which they will put in their mouth and swallow. They might have a dose on Day 7 which they will put in their mouth and then spit it out; afterwards they will complete the taste questionnaire.
62604212|NCT06507904|EXPERIMENTAL|Part 2 Pharmacokinetics - Treatment K|Participants will receive 1 preparation (Treatment K) of osivelotor pellet/granules on Day 1 which they will put in their mouth and swallow.
62604213|NCT03410810||Infant Control Group|The control arm (term born Infants) will receive an MRI at neonatal age and neurodevelopmental follow-up assessments, investigators will then compare significant morphological and diffusion properties within the brain to those of a Preterm brain.
62604214|NCT03410810||Infant Preterm Group|The experimental group will consist of preterm infants, who will receive an MRI at neonatal age and neurodevelopmental assessments. This groups scans will then be compared to those of the control arm. Significant biomarkers will then be identified.
62604215|NCT03410810||Childhood Control Group|The experimental group will consist of preterm born children aged 6-8 years, who received an MRI at neonatal age and will be called back for a neuropsychological assessment. This groups scans will then be compared to those of the children control arm. Significant biomarkers will then be identified.
62604216|NCT03410810||Childhood Preterm Group|The experimental group will consist of term born children aged 6-8 years, who received an MRI at neonatal age and will be called back for a neuropsychological assessment. This groups scans will then be compared to those of the children preterm group. Significant biomarkers will then be identified.
62604217|NCT00958607|ACTIVE_COMPARATOR|Self-Directed Program|
62604218|NCT00958607|ACTIVE_COMPARATOR|Stroke Support Person|
62604219|NCT00958607|NO_INTERVENTION|Standard Care|"Participants in this arm receive Standard Care which consists of being given a copy of the Heart\& Stroke Foundation's stroke resource titled Let's Talk About Stroke"
62604220|NCT02515994|EXPERIMENTAL|senofilcon C|JJVCI investigational contact lens daily wear replacement.
62604221|NCT02515994|ACTIVE_COMPARATOR|comfilcon A|Marketed contact lens daily wear replacement.
62044768|NCT04102202|EXPERIMENTAL|BOL-DP-o-05|
62044769|NCT04102202|PLACEBO_COMPARATOR|Placebo|
62044770|NCT04184193||Pulmonary Rehabilitation|
62247217|NCT03163979|ACTIVE_COMPARATOR|PET/CT and Comet assay guided IMRT|18F-FDG PET/CT and Comet assay guide IMRT Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
62604222|NCT01549041|EXPERIMENTAL|asenapine 10 mg daily in the evening|Patients will receive their entire daily dose of asenapine as a single dose in the evening
62604223|NCT01549041|ACTIVE_COMPARATOR|asenapine 5 mg twice daily|Patients will receive asenapine 5 mg daily in the morning and 5 mg daily in the evening
62604224|NCT05787366|OTHER|Usual care|usual care and follow-up by a nurse: control group receiving conventional management, i.e. referral to a specialist(s) according to symptoms, as well as nursing follow-up.
62604225|NCT05787366|EXPERIMENTAL|Intervention group|usual care and Personalized Multifactorial Intervention: group benefiting from the Personalized Multifactorial Intervention coordinated by a nurse
62604226|NCT01384019|EXPERIMENTAL|DP-TA|distal protection and thrombus aspiration during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)
62044771|NCT02707354|EXPERIMENTAL|Probe based confocal laser endomicroscopy (Cellvizio)|intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console.
62044772|NCT02154633|EXPERIMENTAL|Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes
62044773|NCT02154633|ACTIVE_COMPARATOR|Delayed Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes
62604227|NCT01384019|PLACEBO_COMPARATOR|c-PCI|conventional PCI without DP-TA during primary percutaneous coronary intervention for ST-elevation myocardial infarction
62604228|NCT02745912|EXPERIMENTAL|Metformin + Naltrexone/Bupropion|Metformin (850 mg, immediate release tablet, orally, once on Day 1 and Day 14) naltrexone/bupropion (8/90 mg/mg, extended-release tablets, orally, twice daily from Day 3 through Day 5 and 16/180 mg/mg, twice daily from Day 6 through Day 15.
62604229|NCT01280682|EXPERIMENTAL|rituximab|patients who had newly diagnosed type 1 diabetes are assigned to receive infusions of rituximab of 125mg/m\^2 day1 day8 day15 day22 repeat after six months (only day1 and day8) besides insulin
62604230|NCT01280682|NO_INTERVENTION|parallel control|patients who had newly diagnosed type 1 diabetes only use insulin
62044774|NCT06088940|EXPERIMENTAL|Probiotic Group (Group 1: Experimental intervention)|Participants will be given a 12-week supply of the probiotic supplement and asked to take 1 capsule daily by mouth at the same time as their first meal of the day.
62247218|NCT03163979|ACTIVE_COMPARATOR|PET/CT and Comet assay guided RapidArc|"18F-FDG PET/CT and Comet assay guide RapidArc:~1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment."
62604231|NCT06519409|EXPERIMENTAL|Photodynamic therapy|After debridement photodynamic therapy was performed by applying indocyanine green photo sensitizer to furcation defect sites for 1 min. A diode laser with the wavelength of 810 nm and 100 mW 0f power output in the continuous mode was applied to this site. The indocyanine dye has high absorption in the infrared spectrum with an absorption peak near 810 nm, which is close to the emission of diode lasers. This dye has low toxicity, a rapid elimination time and is a good photo sensitizer. The furcation defects then received the graft hydrated with sterile saline. The graft material compacted into the bone defect was similar to the control site.
62604232|NCT06214702||Study group|Patients with diastolic blood pressure (DBP) after the 20th GW up ≥140 or 90 mmHg without proteinuria.
62604233|NCT06214702||Control Group|Patients were normotensive at the 20th GW.
62604234|NCT04441476||ICU staff|
62604235|NCT03647774|EXPERIMENTAL|Extended release naltrexone|Extended release naltrexone 380 mg as an intramuscular injection every 4 weeks.
62604236|NCT03647774|NO_INTERVENTION|Treatment As Usual (TAU)|Daily sublingual buprenorphine in flexibel dose according to the patients need and ART guidelines.
62044775|NCT06088940|PLACEBO_COMPARATOR|Placebo Group (Group 2: Control condition)|Participants will be given a 12-week supply of the placebo capsules and asked to take 1 capsule daily by mouth at the same time as their first meal of the day.
62044776|NCT03278015|EXPERIMENTAL|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
62044777|NCT03278015|EXPERIMENTAL|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
62044778|NCT03278015|EXPERIMENTAL|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
62044779|NCT05534347||Juvenile Idiopathic Arthritis|Patients seen in a specialized rheumatology consultation for the management of juvenile idiopathic arthritis in an adult service, after information and collection of their non-opposition.
62044780|NCT00225433|ACTIVE_COMPARATOR|1|Follitropin beta
62044781|NCT00225433|ACTIVE_COMPARATOR|2|Ganirelix acetate
62604237|NCT05514210|EXPERIMENTAL|real-time heart team group|Patients randomized to this group will be accessed and discussed by multidisciplinary specialists during the coronary angiography process
62604238|NCT05514210|ACTIVE_COMPARATOR|conventional heart team group|Patients randomized to this group will be accessed and discussed offline and face-to-face by multidisciplinary specialists after the coronary angiography process
62604239|NCT05827575|EXPERIMENTAL|taVNS|selected cavum conchae of the two ears for 25hz electrical stimulation
62604240|NCT05827575|SHAM_COMPARATOR|sham-taVNS|selected scapha of the two ears for 25hz electrical stimulation
62604241|NCT01807416|ACTIVE_COMPARATOR|standard platform , standard abutment|implant insertion and abutment connection Osseointegrated implants with regular collar connected to standard designed prosthetic abutments
62604242|NCT01807416|ACTIVE_COMPARATOR|standard platform, flat abutment|implant insertion and abutment connection Osseointegrated implants with regular collar connected to flat designed prosthetic abutments
62044782|NCT02943408|EXPERIMENTAL|person-centered mental health intervention (PCMHI)|We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.
62826721|NCT06598111|EXPERIMENTAL|Amplified Benefits and Consequences|On the first day of the study (day 0), participants in the Amplified Benefits \& Consequences condition write a brief, detailed narrative describing a day in their future if they did not restrict their caloric intake and were not concerned about their body weight or shape. Participants type their responses and provide a recording of themselves reading their narrative aloud. On each subsequent day (day 1 through day 6), participants are provided with their written narrative and asked to create a new recording of themselves reading it aloud. After completing their recording and surveys, participants complete a modified version of the Pros and Cons of Anorexia Scale.
62044783|NCT02943408|ACTIVE_COMPARATOR|health and wellness|The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
62437499|NCT02023632|ACTIVE_COMPARATOR|Similar-Age-Mixed-Gender (SAMG)|This group will include participants of both genders who are similar aged (65+).
62604243|NCT01807416|ACTIVE_COMPARATOR|switching platform, standard abutment|implant insertion and abutment connection Osseointegrated implants with switched platform collar connected to standard designed prosthetic abutments
62826722|NCT06598111|EXPERIMENTAL|Amplified Benefits|On the first day of the study (day 0), participants in the Amplified Benefits condition write a brief, detailed narrative describing a day in their future if they did not restrict their caloric intake and were not concerned about their body weight or shape. Participants type their responses and provide a recording of themselves reading their narrative aloud. On each subsequent day (day 1 through day 6), participants are provided with their written narrative and asked to create a new recording of themselves reading it aloud.
62826723|NCT06598111|EXPERIMENTAL|Amplified Consequences|On each day of the study, participants in the Amplified Consequences condition complete the modified Pros and Cons of Anorexia scale and are presented with blurbs about the consequences of restrictive eating.
62826724|NCT06598111|PLACEBO_COMPARATOR|Control|Participants in the control condition write a brief narrative considering a future free of concern about finances. As with the active conditions, participants type their narrative on day 0 and record themselves reading it aloud each day.
62604244|NCT01807416|ACTIVE_COMPARATOR|switching platform, flat abutment|implant insertion and abutment connection Osseointegrated implants with switched platform collar connected to flat designed prosthetic abutments
62604245|NCT03034473|OTHER|Blood and tissue samples during therapy|Collection of blood and tissue samples during preoperative multimodal treatment (Radiochemotherapy (RCTx) followed by total mesorectal excision (TME) and Chemotherapy (CT)) in rectal cancer.
62604246|NCT01801280|ACTIVE_COMPARATOR|Mycophenolate mofetil (C)|Mycophenolate mofetil (C) b.i.d. every 12 hours for 2 weeks.
62604247|NCT01801280|OTHER|Mycophenolate mofetil+Pantoprazole (C+P)|Mycophenolate mofetil b.i.d and Pantoprazole o.m. for 2 weeks.
62604248|NCT01801280|OTHER|Mycophenolate sodium (M)|Mycophenolate sodium (M) b.i.d. every 12 hours for 2 weeks.
62604249|NCT01801280|OTHER|Mycophenolate sodium+Pantoprazole (M+P)|Mycophenolate mofetil b.i.d and Pantoprazole 40mg o.m. for 2 weeks.
62604250|NCT02680613|EXPERIMENTAL|Motivational SMS|This arm will receive 15 motivational SMS about cervical cancer and screening.
62044784|NCT03653455|EXPERIMENTAL|Pre- and post-operative discussion group|Patients will discuss with their care provider their health outcomes before and at 6-months after their surgery. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
62044785|NCT03653455|EXPERIMENTAL|Incentivised group|Patients will receive up to $30 in amazon gift cards as an incentive if they complete their forms before surgery, as well as at 6-months and 1-year after surgery. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
62044786|NCT03653455|EXPERIMENTAL|Control group|Patients will only receive email reminders to complete their forms, if they haven't done so.
62044787|NCT04164992|EXPERIMENTAL|not resectable pancreatic cancer patients|Patients with not-resectable pancreatic adenocarcinoma will be treated with endoscopic ultrasound radio frequency ablation
62044788|NCT01380951|EXPERIMENTAL|telbivudine|
62044789|NCT01295450|ACTIVE_COMPARATOR|Vitamin Complex|A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
62044790|NCT01295450|EXPERIMENTAL|Apevinat BC|"Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily."
62044791|NCT01248832|EXPERIMENTAL|Telephone Counseling|Telephone Counseling
62044792|NCT01248832|ACTIVE_COMPARATOR|Self-help Materials|Self-help Materials
62044793|NCT03509649|EXPERIMENTAL|Experienced - Positive|Participants will receive cervical spine manipulation after being given a positive description of the technique from an experienced clinician
62044794|NCT03509649|EXPERIMENTAL|Experienced - Negative|Participants will receive cervical spine manipulation after being given a negative description of the technique from an experienced clinician
62044795|NCT03509649|ACTIVE_COMPARATOR|Novice - Positive|Participants will receive cervical spine manipulation after being given a positive description of the technique from a novice clinician
62044796|NCT03509649|ACTIVE_COMPARATOR|Novice - Negative|Participants will receive cervical spine manipulation after being given a negative description of the technique from a novice clinician
62044797|NCT00240487|ACTIVE_COMPARATOR|Nitric oxide first|Subjects will be randomized to receive Nitric Oxide (NO) immediately after study entry, given at 10 parts per million (ppm) for the first 4 hours of study participation. Blood gases will be monitored once an hour for 4 hours. After the first 4 hours of study participation, the nitric oxide (NO) will be turned off and subjects will receive no intervention (no nitric oxide) for the next 4 hours of study participation. During this time, all subjects will receive standard clinical are. Blood gases will be monitored once an hour for 4 hours.
62044798|NCT00240487|ACTIVE_COMPARATOR|Delayed nitric oxide|Subjects will be randomized to receive no intervention (no nitric oxide) for he first 4 hours of study participation. During this time, all subjects will receive standard clinical care. Blood gases will be monitored once an hour for 4 hours. After the first 4 hours of study participation, the nitric oxide will be turned on and subjects will receive 10 ppm of nitric oxide for the next 4 hours of study participation. Blood gases will be monitored once an hour for 4 hours.
62044799|NCT00137566|EXPERIMENTAL|1 Paracetamol|Paracetamol as per protocol
62044800|NCT00137566|PLACEBO_COMPARATOR|2 Placebo|Inactive placebo as per protocol.
62044801|NCT06333054|EXPERIMENTAL|Silcap Shampoo|Subjects with head lice were treated with Silcap Shampoo at visit 1 (day 0) and at visit 3 (day 7).
62044802|NCT06333054|ACTIVE_COMPARATOR|Goldgeist® Forte|Subjects with head lice were treated with Goldgeist® Forte at visit 1 (day 0) and at visit 3 (day 7).
62044803|NCT00036881|EXPERIMENTAL|zinc sulfate|"Patients receive oral zinc sulfate 3 times daily beginning the first week of radiotherapy.~Treatment continues daily during and for 1 month after radiotherapy in the absence of unacceptable toxicity.~Quality of life is assessed at baseline, weekly during treatment, and then at 1, 2, 3, and 6 months after the completion of treatment.~Patients are followed at 1, 2, 3, and 6 months after the completion of treatment and then every 6 months for 1 year."
62044804|NCT00036881|PLACEBO_COMPARATOR|placebo|"Patients receive oral placebo 3 times daily beginning the first week of radiotherapy.~Treatment continues daily during and for 1 month after radiotherapy in the absence of unacceptable toxicity.~Quality of life is assessed at baseline, weekly during treatment, and then at 1, 2, 3, and 6 months after the completion of treatment.~Patients are followed at 1, 2, 3, and 6 months after the completion of treatment and then every 6 months for 1 year."
62044805|NCT06057142|EXPERIMENTAL|Fun activities for reciting Tang poems|The students will participate in three weekly sessions of Tang poem classes and one session of performance show. Each session lasts for 1.5 hours. Parents can sit in the class. A total of six poems will be taught by two experienced Chinese teachers.
62044806|NCT03961789||cohorte 1|patients undergoing opioid replacement therapy
62044807|NCT01735565||Post bone marrow transplant|Patients who are undergoing bone marrow transplant, as well as patients who have completed a bone marrow transplant within the previous year.
62247219|NCT03163979|ACTIVE_COMPARATOR|RapidArc|"RapidArc:~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used."
62437500|NCT02023632|SHAM_COMPARATOR|Mixed-Age-Mixed-Gender (MASG)|This group is used as the 'standard' group based exercise course; including those of mixed age and mixed gender.
62044808|NCT03999879||Cognitively Normal|having 30 participants with normal cognition
62044809|NCT03999879||Amnesic MCI|aMCI Group having 15 participants with a CDR of 0.5-1 and a Mini-Mental State Examination (MMSE) of 20-25.
62247220|NCT03163979|SHAM_COMPARATOR|7f-IMRT|seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
62247221|NCT02921568|OTHER|All patients|All patients will be imaged on the P200TE and Spectral OCT/SLO devices.
62604251|NCT02680613|EXPERIMENTAL|Travel Voucher|This arm will receive a voucher covering return transport from the screening clinic. This arm will also receive identical 15 motivational SMS about cervical cancer and screening as the Motivational SMS arm.
62604252|NCT02680613|NO_INTERVENTION|Control|This arm will receive standard sensitization during study period (church announcements, screening promotion by key community leaders and posters in community, as well as sensitization by the research assistants conducting the door-to-door household recruitment) during the study and follow-up period. They will also receive one SMS message with the location of screening services during the study period. At the conclusion of the study, participants in the arm will receive identical motivational SMS as the other two arms.
62826725|NCT01084655|EXPERIMENTAL|Phase 1: Orteronel 200 mg BID + Docetaxel + Prednisone|Orteronel (TAK-700) 200 milligram (mg), tablets, orally, twice daily (BID) starting from Day 1 along with docetaxel 75 milligram per square meter (mg/m\^2), infusion, intravenously over 1 hour on Day 1 and prednisone 5 mg, tablets , orally, twice daily from Day 8 up to Day 21 of each treatment cycle. Cycle 1 of Phase 1 consisted of a 28-day treatment period and subsequent cycles consisted of 21-day treatment periods.
62826726|NCT01084655|EXPERIMENTAL|Phase 1: Orteronel 400 mg BID + Docetaxel + Prednisone|Orteronel (TAK-700) 400 mg, tablets, orally, twice daily starting from Day 1 along with docetaxel 75 mg/m\^2, infusion, intravenously over 1 hour on Day 1 and prednisone 5 mg, tablets , orally, twice daily from Day 8 up to Day 21 of each treatment cycle. Cycle 1 of Phase 1 consisted of a 28-day treatment period and subsequent cycles consisted of 21-day treatment periods.
62604253|NCT03721588||Major depressive disorder|MDD; patients with diagnosis of major depressive disorder, Clinical interviews, psychometric scales were applied.
62604254|NCT03721588||MDD and ADHD|MDD; major depressive disorder ADHD; attention deficit hyperactivity disorder, Clinical interviews, psychometric scales were applied.
62604255|NCT05563402|EXPERIMENTAL|Treatment arm|"Therefore, the investigators propose an, open, non-randomized study. This study protocol includes 12 one-hour RAGT training sessions for 4 weeks, three times a week, under the supervision of a qualified rehabilitation team.~Informed consent will be obtained from patients before inclusion in the study, which will be carried out in accordance with the Declaration of Helsinki.~With the aim of describing Usability as the main objective, and Safety as a secondary objective and functional changes at the level of balance, walking speed and quality of life."
62604256|NCT01573416|PLACEBO_COMPARATOR|Control group|
62044810|NCT00989248|EXPERIMENTAL|comparation VE/VO2 and VE/VCO2|
62044811|NCT04605848|EXPERIMENTAL|BAT group|"Patients will be divided in two groups for statistical analysis:~* patients with detectable BAT by PET-CT (BAT+)~* patients with no detectable BAT by PET-CT (BAT-)"
62044812|NCT05943457|EXPERIMENTAL|Intervention (MK7) Arm|This corresponds to the sub-group of subjects who will receive the supplement (vitamin K2 or Menaquinone-7).
62044813|NCT05943457|PLACEBO_COMPARATOR|Control Arm|This corresponds to the sub-group of subjects who will receive placebo.
62044814|NCT04189718|EXPERIMENTAL|osseodensification protocol|Experimental: In the test group, osteotomy site preparation was performed using Osseodensification technique at 1100 rpm and implant was placed
62044815|NCT04189718|ACTIVE_COMPARATOR|conventional implant site preparation protocol|Control: in the control group, osteotomy site was prepared using conventional drilling protocol at 1100 rpm and implant was placed.
62044816|NCT01489995|EXPERIMENTAL|Reference|Fasted
62044817|NCT01489995|EXPERIMENTAL|Glucose Drink|Fed
62044818|NCT01489995|EXPERIMENTAL|Before High Fat Meal|Fed
62044819|NCT01489995|EXPERIMENTAL|Before Light Meal|Fed
62044820|NCT01489995|EXPERIMENTAL|After Light Meal|Fed
62247222|NCT06234150|EXPERIMENTAL|Aerobic dance|50 minutes of moderate-intensity aerobic dance three times a week
62247223|NCT06234150|EXPERIMENTAL|Fast-walking|50 minutes of moderate-intensity fast walking three times a week
62437501|NCT03763331|SHAM_COMPARATOR|Sham treatment|Participants were dressed in water-circulating trousers that are connected to a pump. Water at 91.4 degrees F was circulated through the pants for 90 minutes daily for 8 weeks..
62604257|NCT01573416|ACTIVE_COMPARATOR|Intervention group|
62604258|NCT05715047|EXPERIMENTAL|CBT for Fatigue Program|"Screening for eligibility will use the Fatigue Symptoms Inventory (FSI) average severity item over the prior week. Scores of ≥4 of 0-10 will be invited to participate. 30 participants will be enrolled and will complete study procedures as outlined:~* Baseline questionnaires.~* 10 intervention sessions.~* Questionnaires and surveys 3 and 5 months after enrollment."
62604259|NCT05715047|ACTIVE_COMPARATOR|Usual Care|"Screening for eligibility will use the Fatigue Symptoms Inventory (FSI) average severity item over the prior week. Scores of ≥4 of 0-10 will be invited to participate. 30 participants will be enrolled and will complete study procedures as outlined:~* Baseline questionnaires.~* Receive adapted material from the MGH Bone Marrow Transplant Survivorship program outlining common contributors to fatigue after transplant and recommendations for management.~* Questionnaires and surveys 3 and 5 months after enrollment."
62826727|NCT01084655|EXPERIMENTAL|Phase 2: Orteronel 400 mg BID + Docetaxel + Prednisone|Orteronel (TAK-700) 400 mg, tablets, orally, twice daily starting from Cycle 1 Day 15 along with docetaxel 75 mg/m\^2, infusion, intravenously over 1 hour on Day 1 and prednisone 5 mg, tablets, orally, twice daily from Day 1 up to Day 21 of each 21-day treatment cycle until disease progression or end of treatment (EOT).
62826728|NCT06281925|EXPERIMENTAL|Cryotherapy|Patients receiving oxaliplatin who are randomized to the Interventional (Cryotherapy) Arm will wear a pair of gloves that has removable ice packs throughout their treatment, starting 15 minutes before and ending 15 minutes after completion of oxaliplatin. These ice packs will be replaced every 30 minutes. The total wearing time of the cryotherapy will be approximately 2 hours.
62826729|NCT06281925|NO_INTERVENTION|Control|Patients receiving oxaliplatin who are randomized to the Control Arm will not receive the gloves with removable ice packs throughout their treatment.
62247224|NCT06234150|NO_INTERVENTION|Usual care|Maintain the usual lifestyle and receive medical treatment as normal as the rest of the group.After the baseline evaluation, participants in the control group are asked to maintain their regular lifestyle, including their level of physical activity, and to continue receiving medical treatment and care by standard procedures for 12 weeks. The control group did not receive any encouragement from the researcher to increase the time they spent exercising because, at the time of patient data collection, they were not routinely informed about the benefits of exercise during chemotherapy. Control patients were allowed to engage in the same experimental exercise condition after the 24-week study cycles; if they declined, the study would be stopped.
62247225|NCT02113579|EXPERIMENTAL|KOX|"After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.~Fluoride Toothpaste / Crest® Cavity Protection Regular and Experimental Mouth Rinse 12027-033"
62247226|NCT02113579|PLACEBO_COMPARATOR|PLA|"After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.~Fluoride Toothpaste/Crest® Cavity Protection Regular and Placebo Mouth Rinse"
62437502|NCT03763331|ACTIVE_COMPARATOR|Heat Therapy|Participants were dressed in water-circulating trousers that are connected to a pump. Water at 110 degrees F will be circulated through the pants for 90 minutes daily for 8 weeks.
62437503|NCT03812068|EXPERIMENTAL|Long-distance developmental behavioral intervention|Long-distance learning program combined parent-mediated developmental behavioral intervention
62437504|NCT03812068|ACTIVE_COMPARATOR|Developmental behavioral intervention|only parent-mediated developmental behavioral intervention
62247227|NCT00962390|EXPERIMENTAL|150mg S-equol|
62437505|NCT02123459|EXPERIMENTAL|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods
62437506|NCT02123459|ACTIVE_COMPARATOR|Cephalexin (Test)|Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods
62247228|NCT00962390|EXPERIMENTAL|50mg S-equol|
62826730|NCT06445530|EXPERIMENTAL|MFeast ENHANCED|MFeast ENHANCED (a hybrid MTF intervention with a patient-activated transition from prepared meal to fresh food delivery, adaptations for postpartum people, structural and nutritional lactation support, cultural adaptations for engagement and adherence, and food provision for dependents)
62826731|NCT06445530|ACTIVE_COMPARATOR|MFeast Usual Care|MFeast Usual Care (prepared medically tailored meals only).
62826732|NCT01724346|EXPERIMENTAL|Chlorambucil|Participants who received chlorambucil 0.5 mg/kg (to maximum 0.8 mg/kg) Days 1 and 15 of 28-day cycle up to 12 cycles in Study 1115. In Study 1116, participants had the option to crossover to next-line ibrutinib 420 mg/day after disease progression (PD).
62247229|NCT00962390|EXPERIMENTAL|10 mg S-equol|
62247230|NCT00962390|PLACEBO_COMPARATOR|Placebo|
62437507|NCT01475669|EXPERIMENTAL|Fibrinogen Concentrate (Human)|
62437508|NCT01475669|PLACEBO_COMPARATOR|Placebo|
62437509|NCT04898985||500 patients in the LLS COVID-19 Registry with no/limited antibody response|Five hundred (500) patients participating in the LLS COVID-19 Registry, who have shown either no antibody or limited antibody response by way of the Spike Antibody test to one of the vaccinations authorized for emergency use (EUA) by FDA will participate in this Research Study.
62437510|NCT04898985||500 patients also participating in the LLS COVID-19 Registry with antibody response|500 patients with similar blood cancer diagnosis, also participating in the LLS COVID-19 Registry, who have shown full Spike antibody response to one of the vaccinations authorized for emergency use (EUA) by FDA will also be enrolled in this Research Study for comparison (as a control arm) and will also be followed for at least 10 years (in the COVID-19 Registry).
62826733|NCT01724346|EXPERIMENTAL|Ibrutinib|Participants who received ibrutinib 420 mg daily in Study 1115 received ibrutinib orally once daily. Participants continuing in first-line ibrutinib therapy entered Study 1116 at the ibrutinib dose tolerated in Study 1115.
62044821|NCT03198026|EXPERIMENTAL|Treatment (ibrutinib, obinutuzumab)|"Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab intravenously (IV) on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2 months after cycle 6, patients with stable disease will continue to receive obinutuzumab every 2 months for a total of 12 doses.~After completion of study treatment, patients are followed up monthly for 1 year, every 3-6 months for 4 years, and then annually for up to 2 years."
62044822|NCT04725344|EXPERIMENTAL|ACTIV'DOS group|ACTIV'DOS is a smartphone application of self rehabilitation. There are 7 muscular exercices. Patients going to exercices during 15 minutes per day, during 6 weeks.
62437511|NCT02683733|ACTIVE_COMPARATOR|Treatment Arm|"Patients will receive 5-Aminosalicylic acid as per their current treatment regimen and will also take Bio-enhanced curcumin twice daily after meals as per the following regimen:~Starting dose: 50 mg BID of Bio-enhanced Curcumin Soft Gelatin Capsule Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
62044823|NCT04725344|EXPERIMENTAL|Control group|This group uses a sheet of paper for self-rehabilitation exercise. The self-rehabilitation program is the same as the ACTIV'DOS group. Patients have to exercise during 15 minutes per day, during 6 weeks.
62044824|NCT03115892|EXPERIMENTAL|intervention arm|Green Tea With Aloe Vera mouthwash twice daily for one week
62247231|NCT01541579|EXPERIMENTAL|Treatment Arm|Cx601 is a cell suspension in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given at a dose of 120 million cells (5 million cells / mL) for intralesional injection.
62247232|NCT01541579|PLACEBO_COMPARATOR|Placebo-control group|Placebo (saline solution) will be given also for intralesional injection at the same quantity (volume, 24 mL) and following the same schedule.
62247233|NCT01326208|EXPERIMENTAL|Acute Lung Injury / ARDS|Patient under mechanical suffering from ALI or ARDS
62247234|NCT05745051|EXPERIMENTAL|Evaluate the safety and effectiveness of CVA-FLOW Software Device for acute ischemic stroke|The purpose of this study is to demonstrate the effectiveness and safety of CVA-FLOW, a digital health AI based Telestroke system developed by CVAID Ltd. Company aims to assist certified medical staff to triage acute ischemic stroke patients using dedicated algorithms in order to support application for market approval for CVA-FLOW device.
62247235|NCT04014036|EXPERIMENTAL|1|30 subjects receive ESWT (LM-IASO, Litemed Co., Taiwan) for 6 courses in 3 weeks (0.05mJ/mm2, 3000 pulses). Thereafter, the two groups are cross over.
62247236|NCT04014036|SHAM_COMPARATOR|2|30 subjects receive Sham therapy for 3 weeks (the machine turning on but the energy is zero). Thereafter, the two groups are cross over.
62247237|NCT04121611|EXPERIMENTAL|Optical coherence tomography confirmed residual thrombus|Early antithrombotics
62247238|NCT04121611|NO_INTERVENTION|Optical coherence tomography confirmed no residual thrombus|Best medical management
62247239|NCT04180150|EXPERIMENTAL|TQ-A3334 combined with entecavir|Subjects receive TQ-A3334 (1.2 mg QW) and entecavir (0.5 mg qd) in 24 weeks
62437512|NCT02683733|PLACEBO_COMPARATOR|Control Arm|Patients will receive 5-Aminosalicylic acid as per their current treatment regimen and will also take a placebo pill twice daily after meals
62437513|NCT01025193|EXPERIMENTAL|Belimumab|Belimumab will be administered intravenously at a dose of 10mg/kg on days 0, 14, 28 and every 28 days for up to 52 weeks to normalize alloantibody levels in sensitized patients awaiting kidney transplantation. Subjects who are not able to undergo transplantation before the end of the treatment period will have final follow-up evaluation 8 weeks after the last dose of belimumab is administered.
62604260|NCT02557373|PLACEBO_COMPARATOR|Vitamin A|Randomized participants will receive a one-dose of vitamin A supplementation (100,000 IU) at the beginning of the trial.
62247240|NCT04180150|PLACEBO_COMPARATOR|Placebo combined with entecavir|Subjects receive placebo (0 mg QW) and entecavir (0.5 mg qd) in 24 weeks
62247241|NCT03858790|EXPERIMENTAL|Experimental|Subjects' PINS spinal cord stimulator randomized to this arm is on always
62247242|NCT03858790|SHAM_COMPARATOR|Control|Subjects' PINS spinal cord stimulator randomized to this arm is off for a week
62247243|NCT01050504||Ancillary-correlative (blood and tissue collection)|Patients undergo collection of blood and tissue samples for analysis via mutation mapping, DNA sequencing, gene expression microarray, and gene profiling.
62247244|NCT05378646|EXPERIMENTAL|Experimental|Patients received Ingaron 500,000 IU subcutaneously once a day, every other day. The course of treatment is 7 injections. The first injection was given on the first day of active therapy. Subsequent injections were given every other day. The period of active therapy was 14 days.
62247245|NCT05378646|NO_INTERVENTION|Control|Patients received standard treatment for chronic prostatitis. The period of active therapy was 14 days.
62247246|NCT00617539|EXPERIMENTAL|irinotecan and temozolomide|
62247247|NCT00789750|EXPERIMENTAL|Colesevelam|Participants receive six colesevelam tablets (3.8 grams/day) in addition to pioglitazone-based therapy (30 mg or 45 mg)
62247248|NCT00789750|PLACEBO_COMPARATOR|Placebo|Participants receive six placebo tablets in addition to pioglitazone-based therapy (30 mg or 45 mg)
62247249|NCT05749536||Asthma|With positive asthma test
62247250|NCT05749536||Healthy|With no signs of asthma
62247251|NCT02838082|EXPERIMENTAL|Sleep Hygiene Protocol|Participants in this arm will undergo a 4 week sleep hygiene protocol
62449213|NCT02687204|ACTIVE_COMPARATOR|Enoxaparin prophylaxis|All enrolled patients will receive twice daily enoxaparin prophylaxis. Patients with identified out of range peak anti-Xa levels will receive real time dose adjustment and will be considered as the experimental arm.
62604261|NCT02557373|EXPERIMENTAL|Rice Bran + Vitamin A|Randomized participants will receive a one-dose of vitamin A supplementation (100,000 IU) at the beginning of the trial plus consume a measured dose of rice bran daily.
62604262|NCT02608255|EXPERIMENTAL|acute coronary syndromes|
62604263|NCT01314105|EXPERIMENTAL|BIBF 1120 L+ Carboplatin + PLD|BIBF 1120 (100 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL\*min) + PLD (30 mg/m2)
62604264|NCT01314105|EXPERIMENTAL|BIBF 1120 M + Carboplatin + PLD|BIBF 1120 (150 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL\*min) + PLD (30 mg/m2)
62604265|NCT01314105|EXPERIMENTAL|BIBF 1120 H + Carboplatin + PLD|BIBF 1120 (200 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL\*min) + PLD (30 mg/m2)
62604266|NCT03605940|EXPERIMENTAL|Experimental group|corticosteroids + ECP
62604267|NCT03605940|ACTIVE_COMPARATOR|Contrôl group|corticosteroids alone
62604268|NCT01939626|EXPERIMENTAL|Single-step medium|embryos will be cultured in a single-step medium for 5 days with no change
62826734|NCT03216525|ACTIVE_COMPARATOR|Oral Alvimopan|Oral Alvimopan (Entereg, Merck) 12 mg between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
62826735|NCT03216525|PLACEBO_COMPARATOR|Matching Placebo|Matching placebo between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
62044825|NCT03115892|ACTIVE_COMPARATOR|control arm|Chlorhexidine Mouthwash twice daily for one week
62437514|NCT05585502|EXPERIMENTAL|Training group|T2D patients and controls in the experimental group will undergo 50 telemedicine MOS sessions (15 minutes/day, 5 days/week, 10 weeks). Before the training period all subjects will participate to three different experimental sessions: during the first session a blood sample will be withdrawn and a skin biopsy will be taken; during the second session, muscle-tendon stiffness and muscle function will be evaluated; during the third session, the energy cost of walking will be determined at different speeds. After the training period and 5 weeks after the end of the training period, all subjects will repeat the second and the third sessions.
62437515|NCT05585502|NO_INTERVENTION|Control group|T2D patients and controls in the control group will not perform any specific training. However, they will participate to the same three sessions as the experimental group.
62437516|NCT02971410|EXPERIMENTAL|Treatment (simvastatin)|Patients receive standard of care chemotherapy for up to 3 courses and simvastatin (PO) daily 2 days before the first dose of chemotherapy for up to 2 days after the last dose of chemotherapy. Treatment with simvastatin continues in the absence of disease progression or unacceptable toxicity.
62437517|NCT04873349|ACTIVE_COMPARATOR|Olive leaf capsules|Non-hospitalized COVID-19 patients who have positive PCR results and show mild to moderate clinical manifestations and symptoms (20-30 patients) will receive a 50% standardized olive leaf capsule 750 mg (700 mg oleuropein/day; the active principle in olive leaf) two times daily for a period of ten days alongside with the Egyptian protocol medications. All the active comparator participants should be adults, with no chronic diseases (except hypertension and diabetes), non addict or alcoholics.
62437518|NCT04873349|PLACEBO_COMPARATOR|Starch capsules|Non-hospitalized COVID-19 patients who have positive PCR results and show mild to moderate clinical manifestations and symptoms (20-30 patients) will receive a placebo starch capsules (750 mg) two times daily for a period of ten days alongside with the Egyptian protocol medications. All the placebo comparator participants should be adults, with no chronic diseases (except hypertension and diabetes), non addict or alcoholics.
62604269|NCT01939626|OTHER|Control|Embryos cultured in two Culture media for 5 Days.
62604270|NCT04836481||LEV8|Levetiracetam 1000 mg every 8 hours
62604271|NCT04836481||LEV12|Levetiracetam 1000 mg every 12 hours
62604272|NCT00771511|EXPERIMENTAL|1|Capsaicin cream applied to cervix after lidocaine gel
62604273|NCT00771511|PLACEBO_COMPARATOR|2|only lidocaine applied to the cervix
62604274|NCT06623903||Early breast cancer patients initiating endocrine therapy|Patients with estrogen receptor-positive breast cancer initiating adjuvant endocrine therapy (either tamoxifen or aromatase inhibitors).
62826736|NCT06402656|EXPERIMENTAL|Customized facemask|
62826737|NCT06402656|ACTIVE_COMPARATOR|Standard facemask|
62826738|NCT01615484|EXPERIMENTAL|Ex-vivo lung perfusion (EVLP) with STEEN Solution™|The perfusion of the lungs will be performed using STEEN Solution™. The lungs will be physiologically assessed during ex vivo perfusion with STEEN Solution™ perfusate.
62044826|NCT05240105||Departments for Psychosomatic Medicine at University Clinics|no study interventions, observational group
62604275|NCT02172586|EXPERIMENTAL|Telmisartan|
62044827|NCT05240105||Clinics specialized in Psychosomatic Medicine|no study interventions, observational group
62044828|NCT05240105||Departments for Psychosomatic Medicine at general hospitals|no study interventions, observational group
62044829|NCT05240105||Departments for Psychosomatic Medicine at psychiatric hospitals|no study interventions, observational group
62604276|NCT02172586|EXPERIMENTAL|Telmisartan + Hydrochlorothiazide|
62604277|NCT02172586|ACTIVE_COMPARATOR|Losartan|
62604278|NCT02172586|ACTIVE_COMPARATOR|Losartan + Hydrochlorothiazide|
62604279|NCT04764084|EXPERIMENTAL|Treatment group|Niraparib-Anlotinib combination therapy
62604280|NCT05299372|OTHER|Telemonitoring via Careportal®|Participants will be prompted by the device to answer two sets of questions every week: 10 items (1 nested) in the morning and 16 items (4 nested) in the evening. Also on a weekly basis, patients will be prompted to perform overnight oximetry test, and upload patient-ventilator interaction data (PVI) via Careportal®.
62604281|NCT02195427|EXPERIMENTAL|TEOSYAL RHA Global Action/Juvederm Ultra XC|Split-face injection of TEOSYAL® RHA Global Action into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
62604282|NCT02195427|EXPERIMENTAL|TEOSYAL RHA Deep Lines/Juvederm Ultra XC|Split-face injection of TEOSYAL® RHA Deep Lines into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
62826739|NCT01615484|NO_INTERVENTION|Lung transplant from conventional brain-dead organ donor|No experimental procedures will be carried out.
62826740|NCT05512884|EXPERIMENTAL|Speeded anomia therapy|21h of anomia therapy
62826741|NCT05512884|NO_INTERVENTION|Standard care|Participants' typical daily routine
62826742|NCT05671146|EXPERIMENTAL|Graded weight-bearing exercise|participants will perform exercises using an anti-gravity treadmill
62826743|NCT05671146|ACTIVE_COMPARATOR|Closed kinetic chain exercise|Exercises will be achieved in a weight-bearing position, with or without support, besides other exercises to improve knee flexors and extensors strength.
62826744|NCT05671146|SHAM_COMPARATOR|open kinetic chain exercise|Exercises including stretching and strengthening exercises for knee flexors and extensors
62826745|NCT05525325|ACTIVE_COMPARATOR|General Anesthesia Group|Patients randomized to the GA arm are intubated after anesthetic induction.
62826746|NCT05525325|EXPERIMENTAL|Procedural Sedation Group|After randomization into the PS arm, the need for analgesics or sedatives are evaluated clinically.
62826747|NCT03361761||experimental|therapeutic coordination apartments with formalized/official Health education program
62044830|NCT06472596||cases ( asthmatic patients)|asthmatics investigated by serum creatinine , GFR calculation , ESR,CRP,ABG,CBC , serum electrolytes , interleukin6, tumor necrotic factor alpha
62826748|NCT03361761||active comparator|therapeutic coordination apartments without formalized/official Health education program
62826749|NCT06594835|EXPERIMENTAL|Better Together|Better Together (BT) is a 90-min, an age-appropriate, culturally relevant prevention intervention to prevent substance use among Black youth experiencing household challenges (ages 11-13) by addressing the multilevel influences of substance use.
62044831|NCT06472596||control (healthy persons)|healthy persons investigated by same investigations and compare results with asthmatics
62044832|NCT05559034||Healthy adults|The study will comprise only one group of healthy adults subject to a same behavioral and cognitive intervention.
62044833|NCT03589079||Monogenic Disorder|Participants exhibiting clinical phenotypes suggestive of an underlying novel monogenic disorder, with/without the presence of familial recurrence of the phenotype and/or parental consanguinity will be included. Sanger and/or Next generation Sequencing (NGS) - Panel/WES/WGS approaches will be used to facilitate identification of de novo/inherited variants in the child/proband.
62044834|NCT06473662|EXPERIMENTAL|75iu|Capsule containing 75iu recombinant human insulin administered two times per day
62437519|NCT01850069||Intracranial hypertension|Patients with raised intracranial pressure
62437520|NCT03215485|EXPERIMENTAL|Intervention Group|"All intervention youth participants will receive three components:~1. Nutrition lessons~2. Virtual World learning environment~3. Newsletters"
62437521|NCT03215485|ACTIVE_COMPARATOR|Comparison|"All comparison youth participants will only receive one component:~1) Newsletters"
62437522|NCT03615456|ACTIVE_COMPARATOR|Conventional thyroidectomy|Thyroidectomy with ligation and division of thyroid vessels
62044835|NCT06473662|EXPERIMENTAL|150iu|Capsule containing 150iu recombinant human insulin administered two times per day
62826750|NCT06594835|ACTIVE_COMPARATOR|Control|Control group participants received a media education program
62826751|NCT04733469|EXPERIMENTAL|Multimedia Psychoeducational Intervention + Enhanced Usual Care|Intervention participants receive the Multimedia Psychoeducational Intervention in addition to Enhanced Usual Care
62826752|NCT04733469|OTHER|Enhanced Usual Care|Control participants receive Enhanced Usual Care
62826753|NCT06590103|EXPERIMENTAL|Physically Active Lessons.|Physically Active Learning: consists of incorporating physical activity (usually of moderate-vigorous intensity) into the educational content taught in non-physical education academic classes.
62826754|NCT06590103|NO_INTERVENTION|Control group|The control group will receive the usual academic classes without any methodological modification during the intervention period.
62826755|NCT06150391|EXPERIMENTAL|Group GA-E. Patients without previous occlusion o penalization treatment - Experimental|"GA-E volunteers (experimental) will be prescribed home therapy using computer-based exercises (Visionary) for 12 weeks, five days week, ½ half hour per day. Visionary target frequencies will be adjusted, considering BCVA, each three weeks. Contrast of Gabor patch frequencies will be adjusted to match patient contrast sensitivity thresholds.~In case BCVA does not improve at least 2 lines in two consecutive visits (6 weeks), patients will change to GA-C."
62826756|NCT06150391|ACTIVE_COMPARATOR|Group GA-C. Patients without previous occlusion o penalization treatment - Control|"GA-C patients (control) will be prescribed occlusion following Pediatric Eye Disease Investigation Group (PEDIG) criteria: 2 hours for mild and moderate amblyopia or 6 hours for severe amblyopia. Patients will receive a calendar to track patching accomplishment.~In case BCVA does not improve at least 2 lines in two consecutive visits (6 weeks), patients will change to GA-E."
62437523|NCT03615456|ACTIVE_COMPARATOR|Harmonic scalpel thyroidectomy|Thyroidectomy with sealing of thyroid vessels using harmonic scalpel
62437524|NCT00003102|EXPERIMENTAL|Cohort 1 50cGy radiation|"On day 1, patients received a single dose of 131I-cG250 (5 mCi/5 mg) administered as an intravenous infusion over 10 minutes.~Therapeutic doses of 131I-cG250 were administered the following week as fractionated outpatient doses, starting with 30 millicurie (mCi)/5 mg 131I-cG250. Subsequent doses of 131I-cG250 were administered at 2-3 day intervals with the total amount of 131I-cG250 administered based on the calculated clearance of the initial dose administered on day 1. Whole body activity was maintained at no more than 30 mCi iodine-131.~In the absence of disease progression and after recovery from toxicity, patients could be re-treated beginning 8 weeks after the last treatment of the initial series, for a total of not more than 3 treatments."
62437525|NCT00003102|EXPERIMENTAL|Cohort 2 75cGy radiation|"On day 1, patients received a single dose of 131I-cG250 (5 mCi/5 mg) administered as an intravenous infusion over 10 minutes.~Therapeutic doses of 131I-cG250 were administered the following week as fractionated outpatient doses, starting with 30 millicurie (mCi)/5 mg 131I-cG250. Subsequent doses of 131I-cG250 were administered at 2-3 day intervals with the total amount of 131I-cG250 administered based on the calculated clearance of the initial dose administered on day 1. Whole body activity was maintained at no more than 30 mCi iodine-131.~In the absence of disease progression and after recovery from toxicity, patients could be re-treated beginning 8 weeks after the last treatment of the initial series, for a total of not more than 3 treatments."
62437526|NCT00003102|EXPERIMENTAL|Cohort 3 100cGy radiation|"On day 1, patients received a single dose of 131I-cG250 (5 mCi/5 mg) administered as an intravenous infusion over 10 minutes.~Therapeutic doses of 131I-cG250 were administered the following week as fractionated outpatient doses, starting with 30 millicurie (mCi)/5 mg 131I-cG250. Subsequent doses of 131I-cG250 were administered at 2-3 day intervals with the total amount of 131I-cG250 administered based on the calculated clearance of the initial dose administered on day 1. Whole body activity was maintained at no more than 30 mCi iodine-131.~In the absence of disease progression and after recovery from toxicity, patients could be re-treated beginning 8 weeks after the last treatment of the initial series, for a total of not more than 3 treatments."
62437527|NCT00739479|ACTIVE_COMPARATOR|1|Patients will be randomized to receive PHWP. Since sex and baseline weight can influence the response, randomization will be stratified according to these variables.
62437528|NCT00739479|PLACEBO_COMPARATOR|2|Patients will be randomized to receive PHG. Since sex and baseline weight can influence the response, randomization will be stratified according to these variables.
62437529|NCT03872960|EXPERIMENTAL|Intervention Arm: Expedited transfer to a CAC|The intervention arm consists of activation of the pre-hospital triaging system currently in place for post-arrest STE patients. This involves pre-alert of the CAC and strategic delivery of the patient to the catheter laboratory (24 hours a day, 7 days a week). Patients will receive definitive post-resuscitation care: intubation and ventilation, where necessary, targeted temperature management, and goal directed therapies including evaluation and identification of underlying cause of arrest with access to immediate reperfusion if necessary. Prognostication will occur no earlier than 72 hours post-cardiac arrest to prevent premature withdrawal of life-sustaining treatment. Transfer times estimated from the 40-patient pilot are anticipated to be 100 minutes (median; IQR 75 to 113) from time of arrest to the designated centre.
62437530|NCT03872960|NO_INTERVENTION|Control Arm: Current standard of care|The control arm comprises the current standard of pre-hospital advanced life support (ALS) care management for patients with ROSC following cardiac arrest of suspected cardiac aetiology. The patient is conveyed to the geographically closest emergency department. Management thereafter will be as per standard hospital protocols however as in the intervention arm, prognostication is to be delayed in trial patients until at least 72 hours post arrest.
62449214|NCT02687204|EXPERIMENTAL|Real time dose adjustment|Patients with identified out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment
62826757|NCT06150391|EXPERIMENTAL|Group GB-E. Patients with previous occlusion o penalization treatment - Experimental|"GB-E volunteers will receive occlusion following PEDIG criteria and will be prescribed home therapy using Visionary. Patients will receive a calendar to track patching accomplishment.~Visionary target frequencies will be adjusted, considering BCVA, each three weeks."
62044836|NCT06473662|EXPERIMENTAL|300iu|Capsule containing 300iu recombinant human insulin administered two times per day
62044837|NCT01616901|EXPERIMENTAL|Spontaneous breathing trial|
62826758|NCT06150391|ACTIVE_COMPARATOR|Group GB-C. Patients with previous occlusion o penalization treatment - Control|"GB-C volunteers will receive occlusion following PEDIG criteria and will be prescribed home therapy using Visionary. Patients will receive a calendar to track patching accomplishment.~Visionary target frequencies will always be low, no matter patient VA.~In case BCVA does not improve at least 2 lines in two consecutive visits (6 weeks), patients will be move to GB-E."
62437531|NCT04639687|EXPERIMENTAL|Immediate intervention|If randomized to this group, household of child and participating caregiver receives 12 weekly deliveries of vegetables plus added whole grains, along with text messages containing links to cooking instruction videos
62437532|NCT04639687|OTHER|Wait list control (delayed intervention)|If randomized to this group, participants do not get any intervention activities for the first 12 weeks, and their outcome data at V2 contribute as controls. For ethical reasons, this low-income population ultimately gets the intervention (food)later, and data after they receive the intervention contributes to follow-up data only.
62826759|NCT01981408|EXPERIMENTAL|[^14C]-LY2801653|Single oral dose of LY2801653 containing 100 micro curies of radioactivity
62437533|NCT04193059|ACTIVE_COMPARATOR|PANSY-1: EC-T|4 cycles of EC (epirubicin 90 mg/m\^2 ivgtt d1+ cyclophosphamide 600 mg/m\^2 iv d1, 21 days per cycle), followed by 4 cycles of T (docetaxel 100 mg/m\^2 ivgtt d1, 21 days per cycle)
62437534|NCT04193059|EXPERIMENTAL|PANSY-1: PCb|6 cycles of weekly PCb (paclitaxel 80 mg/m\^2 ivgtt d1, d8, d15+ carboplatin Area Under Curve (AUC)=2 ivgtt d1, d8, d15, 28 days per cycle)
62437535|NCT04193059|ACTIVE_COMPARATOR|PANSY-2: EC-TH(P)|4 cycles of EC (epirubicin 90 mg/m\^2 ivgtt d1+cyclophosphamide 600 mg/m\^2 iv d1, 21 days per cycle), followed by 4 cycles of TH(P) (docetaxel 100 mg/m\^2 ivgtt d1 + trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle, with pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle for participants receiving dual-targeted therapy). After 8 cycles of chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks), with pertuzumab (420mg ivgtt every 3 weeks) for participants receiving dual-targeted therapy.
62437536|NCT04193059|EXPERIMENTAL|PANSY-2: PCbH(P)|6 cycles of weekly PCbH(P) (paclitaxel 80 mg/m\^2 ivgtt d1, d8, d15 + carboplatin AUC=2 ivgtt d1, d8, d15 + trastuzumab 2 mg/kg (loading dose 4mg/kg, w1) ivgtt d1, d8, d15, d22, 28 days per cycle, with pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle for participants receiving dual-targeted therapy). Participants may also choose to receive trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle with chemotherapy. After 6 cycles of chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks), with pertuzumab (420mg ivgtt every 3 weeks) for participants receiving dual-targeted therapy.
62437537|NCT00325494|EXPERIMENTAL|Cohort 1|MORAb-009 weekly dose of 12.5 mg/m\^2
62437538|NCT00325494|EXPERIMENTAL|Cohort 2|MORAb-009 weekly dose of 25 mg/m\^2
62437539|NCT00325494|EXPERIMENTAL|Cohort 3|MORAb-009 weekly dose of 50 mg/m\^2
62437540|NCT00325494|EXPERIMENTAL|Cohort 4|MORAb-009 weekly dose of 100 mg/m\^2
62437541|NCT00325494|EXPERIMENTAL|Cohort 5|MORAb-009 weekly dose of 200 mg/m\^2
62437542|NCT00325494|EXPERIMENTAL|Cohort 6|MORAb-009 weekly dose of 400 mg/m\^2
62437543|NCT05448859||3-4 hours denudation|oocytes with 3-4 hours denudation time
62437544|NCT05448859||4-5 hours denudation|oocytes with 4-5 hours denudation time
62437545|NCT05448859||5-6 hours denudation time|oocytes with 5-6 hours denudation time
62437546|NCT05448859||6-7 hours denudation time|oocytes with 6-7 hours denudation time
62437547|NCT05448859||more than 7 hours denudation time|oocytes with more than 7 hours denudation time
62437548|NCT02081170|EXPERIMENTAL|autologous platelet concentrate|
62437549|NCT02352740|EXPERIMENTAL|Healthy subjects with 'hypertriglyceridemic waist'|"Subjects with overweight, elevated waist circumference and elevated fasting triglyceridemia.~Intervention : A form arginine and B form arginine"
62437550|NCT02352740|EXPERIMENTAL|Healthy subjects|"Control subjects, i.e. without overweight, elevated waist circumference and elevated fasting triglyceridemia.~Intervention : A form arginine and B form arginine"
62437551|NCT04400695|EXPERIMENTAL|RC48-ADC|RC48-ADC common name：Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection Dosage form：Lyophilized powder injection specification：60 mg / piece Medication plan：Every 2 weeks Expiration date：18 months HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.
62437552|NCT04400695|ACTIVE_COMPARATOR|Physician's Choice|"Physician's Choice:~HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.~Physician's choice from the following options:~Paclitaxel Injection Docetaxel Injection Vinorelbine Tartrate Injection Capecitabine Tablets"
62437553|NCT04678453|EXPERIMENTAL|Cohort 1 - Low dose SNK01|SNK01 (low dose) administered once every three weeks (Q3W) for four cycles.
62437554|NCT04678453|EXPERIMENTAL|Cohort 2 - Medium dose SNK01|SNK01 (medium dose) administered Q3W for four cycles.
62437555|NCT04678453|EXPERIMENTAL|Cohort 3 - High dose SNK01|SNK01 (high dose) administered Q3W for four cycles.
62437556|NCT04678453|EXPERIMENTAL|Cohort 4 - SNK01 at Maximum Tolerated Dose (MTD) / Recommended Phase 2 Dose (RP2D)|SNK01 (at MTD/RP2D) administered Q3W for four cycles.
62437557|NCT04582227||The ETT group|Oral endotracheal intubation via direct laryngoscopy will be performed. The ETT cuff will be inflated to 25 cmH2O using a manometer.
62437558|NCT04582227||The LMA group|The Ambu aura-i LMA size will be chosen and inserted using the recommended single-handed rotational technique. Subsequently, a manometer was used to inflate the cuff to 60 cm H2O.
62437559|NCT05508451|ACTIVE_COMPARATOR|paracetamol|
62437560|NCT05508451|ACTIVE_COMPARATOR|tenoxicam|
62437561|NCT05508451|ACTIVE_COMPARATOR|tenoxicam+paracetamol|
62437562|NCT05508451|PLACEBO_COMPARATOR|placebo|
62449215|NCT01886274|EXPERIMENTAL|tDCS|The experimental group received tDCS to the occipital cortex in 12 sessions, 3 days per week.
62044838|NCT01835210||Quality of life|Teenager with acne vulgaris This is an observational study, in which the disease of interest is acne vulgaris.
62044839|NCT02781402|EXPERIMENTAL|4 weeks of Aerobic Training for normal BMI group|4 weeks of aerobic training on treadmill 3 times per week.
62044840|NCT02781402|EXPERIMENTAL|4 weeks of Aerobic Training for overweight BMI group|4 weeks of aerobic training on treadmill 3 times per week.
62826760|NCT06593223||Acute heart failure (AHF) patients|For acute heart failure (AHF) patients：NIFP test were conducted 2-3 times during the hospital stay. The first test is supposed to be conducted close to the time of admission. In the same day of each NIFP test a physical examination is performed to the patient and clinical congestion score (CCS) is recorded. If available, the Nt-proBNP test result in the same day of NIFP test is recorded. Echocardiography examination is scheduled for most of patients and Ejection Fraction (EF), E/A, and E/e' ratio are recorded as well.
62826761|NCT06593223||Stabilized outpatient chronic heart failure patients|For stabilized outpatient chronic heart failure patients：NIFP test was conducted and if Nt-proBNP test result is available in the same day it will be recorded as well.
62826762|NCT03546309|EXPERIMENTAL|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.They will also accept medication treatment by professional neurologists.
62247252|NCT02838082|ACTIVE_COMPARATOR|Standard of Care Protocol|Participants will undergo 4 weeks of current inpatient standard of care procedures in a rehabilitation facility
62247253|NCT04262635|EXPERIMENTAL|ArmA Cetuximab plus Capecitabine|Maintenance therapy with Cetuximab as intravenous (IV) infusion at the dose of 500 mg/m2, given every 2 weeks (Q2W); plus capecitabine in 2-week cycles until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
62247254|NCT04262635|ACTIVE_COMPARATOR|ArmB Cetuximab|Maintenance therapy with Cetuximab as intravenous (IV) infusion at the dose of 500 mg/m2, given every 2 weeks (Q2W) until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
62247255|NCT01512563|EXPERIMENTAL|Paclitaxel ElutingCovered Metal Stent|
62247256|NCT01512563|ACTIVE_COMPARATOR|Covered Metal Stent|
62247257|NCT03767036|ACTIVE_COMPARATOR|Tramadol|Each participant received an oral dose of tramadol hydrochloride 25 mg (A1, one capsule) under fasting conditions with 250 milliliters (mL) of water.
62247258|NCT03767036|ACTIVE_COMPARATOR|Ketorolac|Each participant received an oral dose of ketorolac 10 mg (A2, one tablet) under fasting conditions with 250 mL of water.
62449216|NCT01886274|SHAM_COMPARATOR|control|The control group received sham stimulation to the occipital cortex in 12 sessions, 3 days per week.
62247259|NCT03767036|EXPERIMENTAL|Tramadol and ketorolac|Each participant received an oral dose of tramadol hydrochloride 25 mg and ketorolac 10 mg simultaneously (A3 = one capsule of A1 + one tablet of A2, test medication) under fasting conditions with 250 mL of water.
62247260|NCT04255147|EXPERIMENTAL|Mesenchymal Stromal Cell Therapy|Patients are enrolled into one of three escalating dose panels based on the time of enrolment. The first three patients will receive 1 million cells/kg of body weight, the next three patients will receive 3 million cells/kg of body weight, and the final three patients will receive 10 million cells/kg of body weight. Progression through the escalating dose panels is subject to review by an independent Data Safety Monitoring Committee.
62247261|NCT01221727|OTHER|Midazolam|All 27 subjects will receive midazolam.
62247262|NCT01221727|ACTIVE_COMPARATOR|Denosumab|Eighteen (18) subjects will receive denosumab.
62247263|NCT00041080|EXPERIMENTAL|Arm I (thalidomide)|Patients receive oral thalidomide once daily on days 1-28.
62247264|NCT00041080|EXPERIMENTAL|Arm II (tamoxifen)|Patients receive oral tamoxifen twice daily on days 1-28.
62247265|NCT01069250||Brain injury|Patients after traumatic brain injury or spontaneous intracranial bleeding
62247266|NCT03407651|EXPERIMENTAL|Part 1a|Coagulation Factor VIIa variant, 18 µg/kg by intravenous route
62449217|NCT01886274|NO_INTERVENTION|healthy subjects|This group was submitted to one evaluation session of cortical excitability.
62247267|NCT03407651|EXPERIMENTAL|Part 1b|Coagulation Factor VIIa variant, 30 µg/kg by subcutaneous route
62449218|NCT02785913|EXPERIMENTAL|Arm I (GDC-0032)|Patients receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62044841|NCT04292249||Elective on-pump cardiac surgery patients|Adult patients (≥18 years) undergoing elective on-pump cardiac surgery (isolated coronary artery bypass graft (CABG), single and multiple valvular procedures, combined CABG and valvular surgery, and others).
62044842|NCT02104622|EXPERIMENTAL|ReWalk training|
62044843|NCT06577636|ACTIVE_COMPARATOR|Dream Group|Dream Group (n=21) will be subjected to an anesthetic protocol resulting in dream experiences during anesthesia.
62044844|NCT06577636|SHAM_COMPARATOR|No-Dream Group|No-Dream Group (n=21) will be subjected to an anesthetic protocol resulting in no dream experiences during anesthesia.
62044845|NCT02892812|EXPERIMENTAL|LBVE013|13-valent pneumococcal conjugate vaccine
62044846|NCT02892812|EXPERIMENTAL|LBVE014|14-valent pneumococcal conjugate vaccine
62044847|NCT02892812|ACTIVE_COMPARATOR|Prevnar13|13-valent pneumococcal conjugate vaccine
62044848|NCT01769300|NO_INTERVENTION|Control practices|Practices that do not use the ADHD clinical decision support
62044849|NCT01769300|EXPERIMENTAL|Clinical decision support|Electronic health record-based clinical decision support for ADHD medication titration.
62044850|NCT01733108|EXPERIMENTAL|Canagliflozin (JNJ-28431754) + glyburide|Each volunteer will receive a single dose of glyburide on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of glyburide in combination with a single dose of canagliflozin.
62604283|NCT04375904|EXPERIMENTAL|Radiation|Treatment will be delivered via image-guided (IG)-SABR in 8 fractions of 7.5Gy. OAR constraints must be respected but minimum dose coverage of 75% to 95% of the PTV will be allowed and minimum dose of 75% to 99% of the GTV will be allowed. The minimums are chosen to represent at least an equivalent BED to the RT standard fractionation of 55 Gy in 20 fractions based on actual treatment dose of 7.5Gy in 8 fractions. A total of 60 evaluable patients will be required for the study. The sample size was calculated using continuous monitoring for toxicity, up to one year post RT, using a Pocock-type boundary. Accrual will be halted if excessive numbers of ≥ Grade 3 TxR-AEs are seen. The regime will not be considered to be safe if \>25% of evaluable patients experience a ≥ Grade 3 treatment-related adverse event (TxR-AE) by the end of 1-year post-RT. This study will be considered adequately safe if ≤ 25% of evaluable patients experience ≥ Grade 3 TxR-AE by the end of 1 year post-RT.
62604284|NCT02697565|EXPERIMENTAL|Train-the-Trainers Arm|Intervention Arm receives the Healthy Caregivers- Healthy Children Toolkit (healthy lifestyle role modeling intervention) via a nutritional gate keeper. The toolkit reinforces center health and activity policy standards.
62604285|NCT02697565|OTHER|Attention Control Arm|Control Arm that receives an attention control safety curriculum.
62604286|NCT00672841|ACTIVE_COMPARATOR|2|Standard care/empiric therapy group
62604287|NCT00672841|EXPERIMENTAL|1|Active surveillance/ preemptive therapy group
62604288|NCT01502137|EXPERIMENTAL|ESRD patients|
62604289|NCT01502137|EXPERIMENTAL|Healthy subjects|
62604290|NCT04077138||Focus Groups|"Ten focus groups with transgender women and transgender men will be conducted. . The structure of the focus groups will utilize an interactive Rapid Approach, which differs from traditional focus groups by asking fewer questions and tightly focusing on specific areas of inquiry."
62604291|NCT04077138||In-Depth Interviews|Participants for the IDIs, 10-15 TW and TM, will be selected from among Phase 1 participants. We will create a purposive sample that represents a range of experiences that occurred during Phase 1.
62044851|NCT00859079|ACTIVE_COMPARATOR|GLP-1|Intravenously administered GLP-1
62044852|NCT00859079|ACTIVE_COMPARATOR|Insulin intravenously|Insulin intravenously according to the Munich registry
62044853|NCT00253968|EXPERIMENTAL|Eplivanserin|Eplivanserin 5 mg/day
62044854|NCT00253968|PLACEBO_COMPARATOR|Placebo|Placebo of Eplivanserin 5 mg /day
62044855|NCT01204827|EXPERIMENTAL|CHBV Sebivo|
62604292|NCT03486002|OTHER|Cleansweep closed suction system|
62247268|NCT03407651|EXPERIMENTAL|Part 2|Coagulation Factor VIIa variant, 30, 60, 90, 120 µg/kg by subcutaneous route
62604293|NCT03486002|OTHER|Halyard closed suction system|
62604294|NCT01572311|EXPERIMENTAL|Exercise Intervention Group|For 26 weeks, attend Canadian Centre for Activity and Aging combined classes (75-minute or 60-minute classes, 2 to 3 days/week) and also complete 45 minutes of dual-task gait training (15 minutes for 3 days/week or 22.5 minutes for 2 days/week)
62604295|NCT01572311|ACTIVE_COMPARATOR|Exercise Control group|For 26 weeks, attend Canadian Centre for Activity and Aging combined classes (75-minute or 60-minute classes, 2 to 3 days/week) and also complete 45 minutes of gait training (15 minutes for 3 days/week or 22.5 minutes for 2 days/week). Note: no dual-task challenges during gait training
62604296|NCT01070836||natalizumab|US participants with relapsing MS receiving commercial natalizumab
62826763|NCT03546309|OTHER|Medication group|Patients allocated to the medication group will accept medication treatment by professional neurologists.
62044856|NCT05199818|EXPERIMENTAL|Palonosetron HCl Buccal Film|Palonosetron HCl Buccal Film 0.5 mg 1 hr before administration of moderately emetogenic chemotherapy and normal saline injection 30 minutes before administration of moderately emetogenic chemotherapy
62044857|NCT05199818|ACTIVE_COMPARATOR|Palonosetron IV Injection|Placebo buccal film 1 har before administration of moderately emetogenic chemotherapy and Palonosetron HCl Injection 0.25 mg 30 min before administration of moderately emetogenic chemotherapy
62044858|NCT06448351|EXPERIMENTAL|Phase 1, Arm 1 (High, Nic, S)|Participants are randomized to vape one out of the eight study e-liquids in a 10-puff vaping session over 5 minutes using the e-cig study device and then in an ad libitum puffing session over 60 minutes. The 8 e-liquids vary in nicotine concentration (low \[20 mg/g\] or high \[50 mg/g\]), form (Nic or NicH+), and isomer (S-nicotine or R/S nicotine).
62044859|NCT06448351|EXPERIMENTAL|Phase 1, Arm 2 (High, Nic, R/S)|Participants are randomized to vape one out of the eight study e-liquids in a 10-puff vaping session over 5 minutes using the e-cig study device and then in an ad libitum puffing session over 60 minutes. The 8 e-liquids vary in nicotine concentration (low \[20 mg/g\] or high \[50 mg/g\]), form (Nic or NicH+), and isomer (S-nicotine or R/S nicotine).
62247269|NCT05398887|ACTIVE_COMPARATOR|Low dose Chest CT scan|"Underwent low dose chest CT with 30% lower radiation dose~Interventions:~Radiation: Low radiation dose CT Other: Image quality analysis"
62247270|NCT05398887|EXPERIMENTAL|Ultra low dose CT scan with Artificial Intelligence|"Interventions:~Radiation: Low radiation dose CT Image quality Other: Deep-learning based contrast boosting algorithms"
62247271|NCT05782322|EXPERIMENTAL|PD-RAS|training involving RAS
62247272|NCT05782322|ACTIVE_COMPARATOR|PD-noRAS|training without the aid of RAS
62247273|NCT05782322|EXPERIMENTAL|HC-RAS|training involving RAS
62247274|NCT05782322|ACTIVE_COMPARATOR|HC-noRAS|training without the aid of RAS
62604297|NCT02333383||Participants with Ankylosing Spondylitis|Adalimumab 40 mg every other week by subcutaneous (SC) injection for 52 weeks
62826764|NCT04730804|EXPERIMENTAL|Cohort 1: ALXN1830 Single Dose 1/Placebo|Participants will receive a single SC dose of ALXN1830 or placebo.
62826765|NCT04730804|EXPERIMENTAL|Cohort 2: ALXN1830 Single Dose 2/Placebo|Participants will receive a single SC dose of ALXN1830 or placebo.
62826766|NCT04730804|EXPERIMENTAL|Cohort 3: ALXN1830 Multiple Dose 1/Placebo|Participants will receive multiple SC doses of ALXN1830 or placebo.
62826767|NCT04730804|EXPERIMENTAL|Cohort 4: ALXN1830 Multiple Dose 2/Placebo|Participants will receive multiple SC doses of ALXN1830 or placebo.
62044860|NCT06448351|EXPERIMENTAL|Phase 1, Arm 3 (Low, Nic, S)|Participants are randomized to vape one out of the eight study e-liquids in a 10-puff vaping session over 5 minutes using the e-cig study device and then in an ad libitum puffing session over 60 minutes. The 8 e-liquids vary in nicotine concentration (low \[20 mg/g\] or high \[50 mg/g\]), form (Nic or NicH+), and isomer (S-nicotine or R/S nicotine).
62826768|NCT04730804|EXPERIMENTAL|Cohort 5: ALXN1830 Multiple Dose 3/Placebo|Participants will receive multiple SC doses of ALXN1830 or placebo.
62826769|NCT04730804|EXPERIMENTAL|Cohort 6: ALXN1830 /Placebo in Japanese Population|Japanese participants will receive multiple SC doses of ALXN1830 (HTD) or placebo.
62044861|NCT06448351|EXPERIMENTAL|Phase 1, Arm 4 (Low, Nic, R/S)|Participants are randomized to vape one out of the eight study e-liquids in a 10-puff vaping session over 5 minutes using the e-cig study device and then in an ad libitum puffing session over 60 minutes. The 8 e-liquids vary in nicotine concentration (low \[20 mg/g\] or high \[50 mg/g\]), form (Nic or NicH+), and isomer (S-nicotine or R/S nicotine).
62247275|NCT03764163|EXPERIMENTAL|Study Participants|Pulmonary Function Test, Questionnaires, CT scans, perfusion scan, ventilation scan, Xenon gas ventilation CT scan with hyperpolarized 3-Helium MRI Scan.
62247276|NCT04454697|EXPERIMENTAL|Intervention|Patient receive personalized 3D-printed GWR
62247277|NCT04454697|ACTIVE_COMPARATOR|Control|Patient receive standardized radiation protection tooth splints
62826770|NCT06375161|EXPERIMENTAL|anti-CD19-CAR-T Cells|"anti-CD19-CAR-T cell infusion. Infusion doses: The planned infusion doses are as follows: the first dose group at 1×10\^5 cells/kg; the second dose group at 3×10\^5 cells/kg; the third dose group at 1×10\^6 cells/kg. Infusion doses refer to the number of CAR-positive cells.~Administration route: anti-CD19-CAR-T cells are administered via intravenous drip at a rate of approximately 2 to 5 mL/minute using an infusion pump, with a recommended infusion time of less than 30 minutes."
62826771|NCT04983680|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is an 8-week group intervention (1.5-hour weekly sessions) that combines cognitive-behavioral therapy and mindfulness training to treat emotional problems.
62826772|NCT06199843|EXPERIMENTAL|Rifaximin|Rifaximin 550 mg BD
62826773|NCT06199843|ACTIVE_COMPARATOR|Norfloxacin|Norfloxacin 400 mg OD
62826774|NCT06084026||Neuromuscular Disease|Patients with confirmed neuromuscular disease
62826775|NCT06084026||Control|Participants who do not have or are not expected to have neuromuscular disease
62247278|NCT01174511|EXPERIMENTAL|A-1 COOL cream|"A research product - A-1 COOL cream contain herbal medicine plants basically :~1. WATER PETROLATUM~2. WILD YAM (DIOSCOREA VILLOSA) EXTRACT~3. SORBITAN SESQUIOLEATE~4. CALENDULA OFFICINALIS EXTRACT~5. MINERAL OIL~6. ARNICA MONTANA EXTRACT~7. MICROCRYSTALLINE WAX~8. LICORICE (GLYCYRRHIZA GLABRA) EXTRACT~9. DECYL OLEATE~10. DICOCOYL PENTAERYTHRITYL DISTEARYL CITRATE~11. BEESWAX~12. ALUMINUM STEARATES"
62247279|NCT01174511|PLACEBO_COMPARATOR|Vaselin ointment|Using the study as placebo.
62247280|NCT00684450|ACTIVE_COMPARATOR|1|in vivo protamine titration in cardiac surgery. The titration is done during administration of protamine each 3 minutes to reach 2 consecutive ACT defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds. .The protamine is stopped when this values are obtain. Follow-up is done 15 minutes and 3 hours post-protamine
62247281|NCT00684450|ACTIVE_COMPARATOR|2|standard protamine administration ACT is done during administration of protamine each 3 minutes the values are recorded but the totality of protamine is given. Follow-up is done 15 minutes and 3 hours post-protamine
62449219|NCT01917409|EXPERIMENTAL|conventional laryngoscopy|experimental conventional laryngoscopy group: laryngoscope is used to assist for nasotracheal intubation.
62826776|NCT01131507|EXPERIMENTAL|EUR-1008 (APT-1008)|
62826777|NCT02947321|EXPERIMENTAL|RFA Group|A genicular nerve RFA will be performed prior to planned total knee arthroplasty.
62826778|NCT02947321|SHAM_COMPARATOR|Control Group|A sham genicular nerve RFA will be performed prior to planned total knee arthroplasty.
62826779|NCT04278599|EXPERIMENTAL|Test group|The patients will be administered Zinc Acetate tablets (equivalent to 30 mg of elemental zinc/day) for 6 weeks from the baseline. Topical corticosteroid paste will be prescribed according to the intensity of the lesion.
62826780|NCT04278599|PLACEBO_COMPARATOR|Control group|The patients will be administered Placebo tablets for 6 weeks from the baseline. Topical corticosteroid paste will be prescribed according to the intensity of the lesion.
62044862|NCT06448351|EXPERIMENTAL|Phase 1, Arm 5 (High, NicH+, S)|Participants are randomized to vape one out of the eight study e-liquids in a 10-puff vaping session over 5 minutes using the e-cig study device and then in an ad libitum puffing session over 60 minutes. The 8 e-liquids vary in nicotine concentration (low \[20 mg/g\] or high \[50 mg/g\]), form (Nic or NicH+), and isomer (S-nicotine or R/S nicotine).
62044863|NCT06448351|EXPERIMENTAL|Phase 1, Arm 6 (High, NicH+, R/S)|Participants are randomized to vape one out of the eight study e-liquids in a 10-puff vaping session over 5 minutes using the e-cig study device and then in an ad libitum puffing session over 60 minutes. The 8 e-liquids vary in nicotine concentration (low \[20 mg/g\] or high \[50 mg/g\]), form (Nic or NicH+), and isomer (S-nicotine or R/S nicotine).
62044864|NCT06448351|EXPERIMENTAL|Phase 1, Arm 7 (Low, NicH+, S)|Participants are randomized to vape one out of the eight study e-liquids in a 10-puff vaping session over 5 minutes using the e-cig study device and then in an ad libitum puffing session over 60 minutes. The 8 e-liquids vary in nicotine concentration (low \[20 mg/g\] or high \[50 mg/g\]), form (Nic or NicH+), and isomer (S-nicotine or R/S nicotine).
62826781|NCT06065670|EXPERIMENTAL|Clemastine 12 mg, then clemastine 8 mg, then Placebo|Group 1 will receive the treatment (clemastine) for the first 90 days. They will receive clemastine 12 mg for 14 days followed by clemastine 8 mg for 76 days, and then switch to the placebo (a sugar pill) for the remaining 90 days
62826782|NCT06065670|EXPERIMENTAL|Placebo, then Clemastine 12 mg, then Clemastine 8 mg|Group 1 will receive the placebo for the first 90 days. Then, they will switch to clemastine (treatment) for 90 days. They will receive clemastine 12 mg for 14 days followed by clemastine 8 mg for the remaining 76 days.
62826783|NCT02242604||Not treatment|Patients with the age of 70 years or above, that have a serum sodium of below 130 mmol/L on admission. All patients will be routinely evaluated at admission with a standardized multidimensional geriatric assessment (MGA) consisting of a battery of validated assays.
62247282|NCT02066623||Implantation of ABSORB Scaffold|Patients suffering from coronary artery stenosis with an indication for implantation of ABSORB scaffold
62247283|NCT03155373||A|Asymptomatic/mild symptomatic patients with normal pre-operative left ventricular function (defined as left ventricular ejection fraction \>60%)
62826784|NCT05544019|EXPERIMENTAL|Dose Escalation|Up to 9 dose levels in total will be evaluated across two dosing schedules. Eligible patients will be assigned to a dose level cohort according to an accelerated titration design that will transition to a traditional 3+3 dose escalation.
62826785|NCT03549936|ACTIVE_COMPARATOR|Low lactose formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula which arrives from milk lab labeled as formula A or formula B."
62044865|NCT06448351|EXPERIMENTAL|Phase 1, Arm 8 (Low, NicH+, R/S)|Participants are randomized to vape one out of the eight study e-liquids in a 10-puff vaping session over 5 minutes using the e-cig study device and then in an ad libitum puffing session over 60 minutes. The 8 e-liquids vary in nicotine concentration (low \[20 mg/g\] or high \[50 mg/g\]), form (Nic or NicH+), and isomer (S-nicotine or R/S nicotine).
62044866|NCT06448351|EXPERIMENTAL|Phase 2, Arm 1 (High, 5%, S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62044867|NCT06448351|EXPERIMENTAL|Phase 2, Arm 2 (High, 5%, R/S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62247284|NCT03155373||B|Symptomatic patients with normal pre-operative left ventricular function (defined as left ventricular ejection fraction greater than or equal to 60%)
62247285|NCT03155373||C|Patients with impaired pre-operative left ventricular function (defined as left ventricular ejection fraction \<60%)
62247286|NCT05921396|EXPERIMENTAL|Nasal patency before and after pituitary adenoma surgery|Nasal patency in patients with pituitary adenoma indicated to endoscopic transnasal extirpation of the pituitary adenoma.
62247287|NCT00900523||Known or suspected ovarian cancer|Women who have a diagnosis of ovarian cancer or who are suspected of having ovarian cancer
62437563|NCT01016860|EXPERIMENTAL|OSI-906 and/or irinotecan|Dose Escalation Phase: Treatment for Cycle 1 will commence on Day -3 of a 21-day cycle (3 weeks) when a single dose OSI-906 is given with full pharmacokinetics(PK) sampling at predetermined time points. Irinotecan will be administered intravenously over 90 minutes on Day 1 and Day 8 with full PK sampling on Day 1. The institution of oral dosing of OSI-906 2-4, 8-10, 15-17 (for cycle 1 only) will be given followed by full PK sampling of both drugs on Day 8. Pre-dose samples of OSI-906 will be drawn on Cycle 1 Days 8, 10, 15, 17 and Cycle 2 Days 1, 8, 10, 15 and 17. For Cycle 2 and thereafter, both drugs will be administered starting on Day 1.
62437564|NCT03521999|ACTIVE_COMPARATOR|AboutFace|Veterans in the AboutFACe arm will receive access to an online peer-to-peer digital storytelling resource for Veterans with PTSD
62437565|NCT03521999|PLACEBO_COMPARATOR|Enhanced Usual Care (eUC)|Veterans in the Enhanced Usual Care (eUC) arm will receive an education brochure for PTSD
62437566|NCT04086706||Consecutive Patients with complete colonoscopy|Inclusion criteria were as follows: Patients older than 18 years, with a complete colonoscopy, for CRC screening or post-polypectomy surveillance or diagnostic assessment. Exclusion criteria precluded patients with previous colectomy or an abdominal surgery in the last 6 months, patients with polyposis syndromes or inflammatory bowel diseases and if they were unfit for polypectomy or the polyp specimen was not retrieved for histology.
62247288|NCT01710683||Control group|Median age 45 years, 18-63.
62247289|NCT01710683||Intervention group|Median age 46 years, 18-62.
62247290|NCT00528983|EXPERIMENTAL|Subcutaneous (SC) Azacitidine and Oral Azacitidine|Cycle 1 subjects receive SC Azacitidine for first 7 days of 28 day cycle. For Cycle 2 and beyond subjects receive Oral Azacitidine (experimental) for first 7 days of 28 day cycle.
62437567|NCT05989282||Exposure to structural conditions|Using a survey, we will measure participant exposure to organizational: access policies, transition programs, culture, support for social determinants of health and specialized services.
62437568|NCT01090128|EXPERIMENTAL|All patients|All participants enrolled.
62449220|NCT01917409|EXPERIMENTAL|video-stylet|experimental video-stylet group:video-stylet is used to guide nasotracheal tube into trachea
62044868|NCT06448351|EXPERIMENTAL|Phase 2, Arm 3 (Low, 5%, S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62044869|NCT06448351|EXPERIMENTAL|Phase 2, Arm 4 (Low, 5%, R/S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62044870|NCT06448351|EXPERIMENTAL|Phase 2, Arm 5 (High, 25%, S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62044871|NCT06448351|EXPERIMENTAL|Phase 2, Arm 6 (High, 25%, R/S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62826786|NCT03549936|ACTIVE_COMPARATOR|Regular formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive regular formula which arrives from milk lab labeled as formula A or formula B"
62044872|NCT06448351|EXPERIMENTAL|Phase 2, Arm 7 (Low, 25%, S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62044873|NCT06448351|EXPERIMENTAL|Phase 2, Arm 8 (Low, 25%, R/S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62826787|NCT05759026|EXPERIMENTAL|control condition|The patient will be randomized so that the kind of intervention will be determined in a random way.
62826788|NCT05759026|EXPERIMENTAL|with VR|The patient will be randomized so that the kind of intervention will be determined in a random way.
62826789|NCT05759026|EXPERIMENTAL|with VR personalised|The patient will be randomized so that the kind of intervention will be determined in a random way.
62826790|NCT00003475|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62826791|NCT01630369|EXPERIMENTAL|Human Insulin|Dosage of human insulin (Insuman Basal/Comb/Rapid) will be individually adjusted in accordance with the Summary of Product Characteristics (SmPC). Patients will follow the titration algorithm recommended by the physician.
62826792|NCT05879354|EXPERIMENTAL|Active Cycle Of Breathing Techniques Group|Patients in the intervention group will be provided with video-guided Active Cycle of Breathing Techniques twice a day for 28 days.
62826793|NCT05879354|NO_INTERVENTION|Control group|No intervention will be given to the patients in the control group.
62826794|NCT05823480|EXPERIMENTAL|Treatment (magrolimab, azacitidine)|Patients undergo allo HCT per standard of care. Patients then receive magrolimab IV and azacitidine IV on study. Patients undergo ECHO or MUGA during screening and blood sample collection and bone marrow biopsy and aspirate throughout the study.
62826795|NCT06604013|ACTIVE_COMPARATOR|mild periodontitis (first stage, grade B)|mild periodontitis (first stage, grade B) manifesting CAL ≥ 1-2 mm, in corporation with percentage of bone loss level divided by age was 0.25-1% very year. patients received non-surgical full-mouth periodontal therapy without using adjunct disinfectants.
62826796|NCT06604013|ACTIVE_COMPARATOR|moderate periodontitis (second stage, grade B)|moderate periodontitis (second stage, grade B) manifesting CAL ≥ 3-4mm in corporation with percentage of bone loss level divided by age was 0.25-1% very year. patients received non-surgical full-mouth periodontal therapy without using adjunct disinfectants.
62826797|NCT06604013|ACTIVE_COMPARATOR|severe periodontitis (third stage, grade B)|severe periodontitis (third stage, grade B) manifesting CAL ≥ 5mm , in corporation with BoP increased than (30%), percentage of bone loss level divided by age was 0.25-1% very year. patients received non-surgical full-mouth periodontal therapy without using adjunct disinfectants
62826798|NCT06604013|ACTIVE_COMPARATOR|very severe periodontitis (forth stage, grade C)|very severe periodontitis (forth stage, grade C) manifesting CAL ≥ 5mm in corporation of percentage of bone loss level divided by age more than 1% very year. patients received non-surgical full-mouth periodontal therapy without using adjunct disinfectants
62247291|NCT00528983|EXPERIMENTAL|Oral Azacitidine|Subjects receive Oral Azacitidine (experimental) QD or BID for the first 14 or 21 days of 28 day cycle.
62247292|NCT03684590|ACTIVE_COMPARATOR|Standard opioid administration|Intraoperative opioid will be administered by guiding standard practice
62247293|NCT03684590|EXPERIMENTAL|ANI-guided opioid administration|Intraoperative opioid will be administered based on the analgesia nociceptive index (ANI)
62826799|NCT04764799||Patients that need emergency rapid sequence inductions|"Patients of all ages who need emergency rapid sequence inductions due to their medical condition performed by the staff of the Department of Anaesthesiology and Pain Medicine at the Bern University Hospital.~We defined emergency as a non scheduled intervention with immediate (or maximum up to 6 hours after announcement) need of general anaesthesia (e.g. trauma patients with need for emergency surgery) and therefore appropriate fastening is not possible."
62247294|NCT04465448||healthy volunteers|
62247295|NCT04465448||group case|
62247296|NCT02180971|EXPERIMENTAL|Positive CAG with EG test|A positive finding for coronary angiography with an ergonovine provocation test is defined as transient, total, or sub-total occlusion (\>90% stenosis) with signs/symptoms of myocardial ischemia (chest pain and ischemic ECG change).
62247297|NCT02180971|EXPERIMENTAL|Negative CAG with EG test|Negative test: less than 70% luminal narrowing, without chest pain or ST-segment changes after ergonovine coronary injection
62247298|NCT00929656|EXPERIMENTAL|Real rTMS|Real rTMS + unimanual paretic UE training
62044874|NCT06448351|EXPERIMENTAL|Phase 2, Arm 9 (High, 45%, S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62044875|NCT06448351|EXPERIMENTAL|Phase 2, Arm 10 (High, 45%, R/S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62044876|NCT06448351|EXPERIMENTAL|Phase 2, Arm 11 (Low, 45%, S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62044877|NCT06448351|EXPERIMENTAL|Phase 2, Arm 12 (Low, 45%, R/S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62044878|NCT06448351|EXPERIMENTAL|Phase 2, Arm 13 (High , 65%, S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62044879|NCT06448351|EXPERIMENTAL|Phase 2, Arm 14 (High , 65%, R/S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62044880|NCT06448351|EXPERIMENTAL|Phase 2, Arm 15 (Low, 65%, S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62604298|NCT01959698|EXPERIMENTAL|Treatment (carfilzomib, rituximab, chemotherapy)|Patients receive carfilzomib IV over 10-30 minutes on days 1, 2, 8, and 9; rituximab IV over 3-8 hours on day 3; etoposide IV over 1 hour on days 4-6; carboplatin IV over 1 hour on day 5; and ifosfamide IV over 24 hours on day 5. Treatment repeats every 21-28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62604299|NCT06288269||Control of Hypertension or/and Type 2 Diabetic|Control disease of HT Control disease of DM2 Control disease of HT plus DM2
62604300|NCT06288269||Uncontrol of Hypertension or/and Type 2 Diabetic|Uncontrol disease of HT Uncontrol disease of DM2 Uncontrol disease of HT plus DM2
62604301|NCT03391804|EXPERIMENTAL|ALLN-177|ALLN-177 7,500 units (2 capsules)
62604302|NCT04407429||Health care workers|Physicians, Nursing staff, Midwives, Medical-technical assistants (including medical, therapeutic and diagnostic healthcare staff, and medical and nursing assistants), administrative personnel with patient contact
62604303|NCT04407429||Patients|Patients admitted for non-COVID related symptoms to the Vienna General Hospital with available residual serum samples.
62604304|NCT04122664|ACTIVE_COMPARATOR|RayOne® Hydrophilic lens 600C|Patients will be randomly selected to receive the monofocal, acrylic, RayOne® Hydrophilic lens 600C
62044881|NCT06448351|EXPERIMENTAL|Phase 2, Arm 16 (Low, 65%, R/S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62044882|NCT06448351|EXPERIMENTAL|Phase 2, Arm 17 (High, 85%, S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62044883|NCT06448351|EXPERIMENTAL|Phase 2, Arm 18 (High, 85%, R/S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62247299|NCT00929656|ACTIVE_COMPARATOR|Sham rTMS|Sham rTMS + unimanual paretic UE training
62247300|NCT06159023|NO_INTERVENTION|Thick scope + BAL|In this arm, participants with suspected pulmonary TB will be received bronchoscopic procedure using thick (5.9mm diameter) conventional bronchoscope and bronchoalveolar lavage (BAL).
62247301|NCT06159023|EXPERIMENTAL|Thin scope + BW|In this arm, participants with suspected pulmonary TB will be received bronchoscopic procedure using thin (4.0mm diameter) bronchoscope and bronchial washing (BW).
62247302|NCT06033157|ACTIVE_COMPARATOR|Training|A 12 week physiotherapist supervised training program
62604305|NCT04122664|ACTIVE_COMPARATOR|RayOne® Hydrophobic lens 800C|Patients will be randomly selected to receive the monofocal, acrylic, RayOne® Hydrophobic lens 800C
62247303|NCT06033157|NO_INTERVENTION|No-training|A short consultation with a designated orthopedic surgeon and a folder with general advice on how to avoid further dislocations and to relieve pain from the shoulder.
62437569|NCT02059733|EXPERIMENTAL|18F-DTBZ for Parkinson's Disease and parkinsonism|"This study will compare the brain uptake of 18F- DTBZ in 20 patients with PD, 20 patients with MSA, 20 patients with PSP, 20 patients with CBS, and 20 patients with VaP, 20 patients with ET, and 10 patients with DT.~Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
62437570|NCT02260765|ACTIVE_COMPARATOR|HCP dTMS|this arm will receive dTMS treatment
62437571|NCT02260765|NO_INTERVENTION|HCP TAU|this arm will continue with the same drugs that they are using usually, which mean treatment as usual
62604306|NCT04453800|EXPERIMENTAL|Group A ：low dose sofadil|500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
62604307|NCT04453800|EXPERIMENTAL|Group B: Medium dose group|750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
62604308|NCT04453800|EXPERIMENTAL|Group C: high dose group|1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
62604309|NCT04453800|PLACEBO_COMPARATOR|Group D: placebo group|Saline was administered intravenously
62247304|NCT05662696|EXPERIMENTAL|Telemonitoring Program for Pregnant Women at High Risk for Preeclampsia in Pakistan|The study intervention includes a telemonitoring program for high-risk pregnant women, which will be delivered using the telemonitoring platform. The trial will administer the telemonitoring program to 50 pregnant women at high risk for preeclampsia. The intervention will enable pregnant women to take daily blood pressure readings at home with a provided Bluetooth-enabled home blood pressure monitor, to report if participants have symptoms, and to receive automated alerts and self-care messages (e.g., instructing patients to repeat blood pressure readings, call a medical officer, visit the emergency department, etc.). A healthcare provider (medical officer) will receive alerts from the telemonitoring system if the patient's blood pressure trends are out of the target or if the patient is reporting symptoms.
62247305|NCT00713817|EXPERIMENTAL|Sativex|
62604310|NCT03309826|EXPERIMENTAL|PAP Treatment Arm|Automated positive airway pressure titration then treatment with fixed PAP.
62044884|NCT06448351|EXPERIMENTAL|Phase 2, Arm 19 (Low, 85%, S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62247306|NCT00713817|PLACEBO_COMPARATOR|Placebo|
62604311|NCT03309826|ACTIVE_COMPARATOR|Nasal Dilator Strip|Nightly use of nasal dilator strip
62604312|NCT02617719||Primary care|Staff, patients aged 75 years and older and their carers associated with a single, participating United Kingdom primary care practice.
62604313|NCT00840242|EXPERIMENTAL|Nicotine gum|Nicotine gum
62044885|NCT06448351|EXPERIMENTAL|Phase 2, Arm 20 (Low, 85%, R/S)|Participants vape 20 different study e-liquids varying in concentration (low \[20 mg/g\] or high \[50 mg/g\]), freebase nicotine percentage (5%, 25%, 45%, 65%, or 85%), and isomer (S-nicotine or R/S nicotine) using the e-cig study device during a single visit lasting up to 6 hours.
62247307|NCT05967117|ACTIVE_COMPARATOR|Chest CT evaluation (Administrate contrast media for CECT)|Patients who are planned chest contrast enhanced CT scan ; Conventional concentration iodine contrast agents with the conventional tube voltage
62247308|NCT05967117|EXPERIMENTAL|Chest CT evaluation (Experimental 1)|Patients who are planned chest contrast enhanced CT scan ; Conventional concentration iodine contrast agents with the low tube voltage
62247309|NCT05967117|EXPERIMENTAL|Chest CT evaluation (Experimental 2)|Patients who are planned chest contrast enhanced CT scan ; Low concentration iodine contrast agents with the low tube voltage)
62044886|NCT02160717||Turner Syndrome|Female with Turner Syndrome
62044887|NCT02160717||Healthy Controls|Healthy Female
62044888|NCT00553930|EXPERIMENTAL|G 2/3|Patients with chronic hepatitis or compensated cirrhosis by hepatitis C virus, genotypes 2 or 3, and HIV-coinfected.
62247310|NCT05967117|EXPERIMENTAL|Chest CT evaluation (Experimental 3)|Patients who are planned chest contrast enhanced CT scan; Ultra Low concentration iodine contrast agents with the low tube voltage)
62247311|NCT06232928|EXPERIMENTAL|1-Early group|for the early group, patients were instructed to wear immediate light short Class II elastics from upper canines to lower second premolars for 24 hours except while eating and change the elastics every 12 hours.
62247312|NCT06232928|ACTIVE_COMPARATOR|2-Conventional group|for the conventional group, conventional class II elastics were used on rigid stainless steel arch wires. patients were instructed to wear Class II elastics from upper canines to lower first molars for 24 hours except while eating and change the elastics every 12 hours.
62247313|NCT00512746|OTHER|Surveillance|Screened arm
62247314|NCT00512746|ACTIVE_COMPARATOR|Control|Control arm
62247315|NCT01379573|EXPERIMENTAL|Pregnant women with previous child with cardiac neonatal lupus|400 mg/day Hydroxychloroquine
62604314|NCT00840242|PLACEBO_COMPARATOR|Placebo gum|Placebo gum
62604315|NCT00840242|ACTIVE_COMPARATOR|Nicotine inhaler|Nicotine inhaler
62604316|NCT00840242|PLACEBO_COMPARATOR|Placebo inhaler|Placebo inhaler
62604317|NCT01704001|EXPERIMENTAL|Renal impairment grade 0|
62604318|NCT01704001|EXPERIMENTAL|Renal impairment grade 1|
62604319|NCT01704001|EXPERIMENTAL|Renal impairment grade 2|
62044889|NCT04629482||Children with attention deficit hyperactivity disorder with developmental delays|Children with attention deficit hyperactivity disorder with developmental delays
62604320|NCT01704001|EXPERIMENTAL|Renal impairment grade 3|
62826800|NCT04764799||Patients that need scheduled rapid sequence inductions|"Patients of all ages who need scheduled rapid sequence inductions due to their medical condition performed by the staff of the Department of Anaesthesiology and Pain Medicine at the Bern University Hospital.~Patients of this cohort have a scheduled intervention and therefore can fasten meals for at least 6 hours before induction of general anaesthesia."
62044890|NCT04629482||Children with typical development|Children with typical development
62247316|NCT03762720|EXPERIMENTAL|Physium treatment|Patients will receive five sessions of physium therapy at 80 millibars in 30 minutes for a month
62247317|NCT01791647|ACTIVE_COMPARATOR|myo-inositol|1500 mg/day myoinositol
62247318|NCT01791647|ACTIVE_COMPARATOR|metformin|1500 mg/day of metformin
62449221|NCT06202157|EXPERIMENTAL|LMB (LipoMicel Berberine)|
62604321|NCT06499974||IDA|patients with iron-deficiency anemia
62604322|NCT06499974||ACD/AI|patients with anemia of chronic disease/anemia of inflammation
62604323|NCT06499974||Combined anemia|patients with IDA and ACD/AI
62604324|NCT05961475|EXPERIMENTAL|First product order: order not stated to protect study blinding|Participants will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7 day wash-out period before beginning the next product in the sequence
62604325|NCT05961475|EXPERIMENTAL|Second product order: order not stated to protect study blinding|Participants will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7 day wash-out period before beginning the next product in the sequence
62044891|NCT06236750|EXPERIMENTAL|Patients with Non-Ischemic Chronic Wounds|Patients with intractable diabetic foot ulcer or venous leg ulcer that have not decreased in surface area by at least 50% after 4 weeks of conventional therapies.
62604326|NCT05961475|EXPERIMENTAL|Third product order: order not stated to protect study blinding|Participants will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7 day wash-out period before beginning the next product in the sequence
62604327|NCT05961475|EXPERIMENTAL|Fourth product order: order not stated to protect study blinding|Participants will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7 day wash-out period before beginning the next product in the sequence
62044892|NCT02716389|OTHER|Mask on|
62044893|NCT02716389|OTHER|Mask off|
62604328|NCT05961475|EXPERIMENTAL|Fifth product order: order not stated to protect study blinding|Participants will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7 day wash-out period before beginning the next product in the sequence
62604329|NCT02898558|EXPERIMENTAL|Magnification hand size|magnifying lenses used for 30 minutes daily for 14 days while completing a jigsaw puzzle
62604330|NCT04390763|EXPERIMENTAL|Safety Run-in|Combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel
62604331|NCT04390763|EXPERIMENTAL|Randomized Arm 1|Combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel
62604332|NCT04390763|EXPERIMENTAL|Randomized Arm 2|Combination of NIS793 + gemcitabine + nab-paclitaxel
62604333|NCT04390763|ACTIVE_COMPARATOR|Randomized Arm 3|gemcitabine + nab-paclitaxel
62604334|NCT01944670|EXPERIMENTAL|Internal Joint Stabilizer Group|Patients implanted with the Internal Joint Stabilizer - Elbow (IJS-E)
62604335|NCT03774225|EXPERIMENTAL|Manual and verbal guidance (MVG)|The MVG Group will be done by experimental group with the manual and verbal guidance of a physiotherapist using four games of X-Box Kinect system®
62604336|NCT03774225|EXPERIMENTAL|No manual and verbal guidance (NMVG)|The NMVG Group will be done by experimental group using four games of X-Box Kinect system® in the presence of a physiotherapist that will care about the safety of the participants without interfere in their moviment pattern.
62044894|NCT02808936|EXPERIMENTAL|RIPC group|remote ischemic conditioning group with three cycles of ischemia (5 min) / reperfusion (5 min) of upper or lower limb available with automated RIPC machine using blood pressure cuff
62044895|NCT02808936|SHAM_COMPARATOR|Control group|No remote ischemic conditioning, but blood pressure cuff applied to the upper or lower limb available
62044896|NCT01722968|ACTIVE_COMPARATOR|Arm A|Arm A and feasibility phase: Bevacizumab 15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly.
62044897|NCT01722968|ACTIVE_COMPARATOR|Arm B|Arm B: Paclitaxel 80mg/m2 iv weekly.
62044898|NCT04356404||Prospective group|Patients will be followed up until development of hepatitis flare or at 2 years after study recruitment. We plan to recruit 150 patients for the prospective cohort.
62044899|NCT01577576||Upper-body athletes|This group includes swimmers, rowers or kayakers with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.
62044900|NCT01577576||Lower-body athletes|This group includes runners (marathon or trail) and cyclists with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.
62044901|NCT01577576||Sedentary volunteers|This group of healthy volunteers does not participate in athletic activity for more than two hours per week. They are matched by age and sex with the athletic groups.
62044902|NCT01218126|EXPERIMENTAL|losmapimod 2.5 mg|losmapimod 2.5 mg
62044903|NCT01218126|PLACEBO_COMPARATOR|placebo|
62044904|NCT01218126|EXPERIMENTAL|losmapimod 7.5 mg|losmapimod 7.5 mg
62604337|NCT03774225|ACTIVE_COMPARATOR|Physical Therapy|The Control Group will be trained by conventional Physical Therapy exercises.
62044905|NCT01218126|EXPERIMENTAL|losmapimod 15 mg|losmapimod 15 mg
62044906|NCT03696017||Group 1|Patients either newly admitted to Substance Use Disorder treatment in Wayne County, or in treatment longer but are using opioids (40 patients per group).
62604338|NCT00803205|EXPERIMENTAL|Ataluren|Participants will receive ataluren 3 times per day (TID): 10 milligrams (mg)/kilogram (kg) of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total daily dose 40 mg/kg). Treatment will continue for 48 weeks, after which participants will be followed for 4 weeks.
62604339|NCT00803205|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo TID: 10 mg/kg of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total daily dose 40 mg/kg). Treatment will continue for 48 weeks, after which participants will be followed for 4 weeks.
62044907|NCT03696017||Group 2|Patients either newly admitted to Substance Use Disorder treatment in Wayne County, or in treatment longer but are using benzodiazepines (BZD) (40 patients per group).
62604340|NCT03423966|EXPERIMENTAL|Self Objective Mobility Evaluation|Usual Care Plus a Smartphone pedometer App
62604341|NCT03423966|NO_INTERVENTION|Usual Care (UC)|Usual Care of obesity
62604342|NCT05248334|EXPERIMENTAL|Ranibizumab group|"The Ranibizumab group was treated with one intravitreal injection of 0.5 mg/0.05 ml ranibizumab (Lucentis, Basel, Novartis) at baseline. While additional panretinal photocoagulation was performed if there was sufficient space and view to fill in the previously untreated areas, if needed. Repeated injections will be given after 4 weeks when the clearing of VH was incomplete (for a maximum of two injections).~If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed."
62604343|NCT05248334|ACTIVE_COMPARATOR|PPV group|Vitrectomy to remove vitreous hemorrhage and take additional panretinal photocoagulation. If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/tractive retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed.
62739068|NCT05351177|EXPERIMENTAL|Concurrent Training Group|Participants in the Concurrent Training (CT) group will complete 8 weeks of twice-weekly CT of 30 minutes in duration. Heart rate, ratings of perceived exertion, affect and enjoyment will be assessed. This will include a five minute warm-up on a cycle ergometer, followed by two sets of four then eight repetitions of deadlift, squat, bench press and shoulder press resistance exercises. Thereafter, 5 x 60 second HIIT cycling intervals will be completed on a cycle ergometer, after which a five minute cooldown will ensue.
62044908|NCT03696017||Group 3|Patients either newly admitted to Substance Use Disorder treatment in Wayne County, or in treatment longer but are using BZD/opioid (40 patients per group).
62044909|NCT02062268||Urban area in South Jiangsu Province|health education \& law enforcement
62044910|NCT02062268||urban area in Middle Jiangsu Province|health education \& law enforcement
62044911|NCT02062268||urban area in North Jiangsu Province|health education \& law enforcement
62044912|NCT02062268||rural area in South Jiangsu Province|health education \& law enforcement
62739069|NCT05135585|OTHER|Adults vaccinated with a complete COVID-19 vaccine regimen|Adults of Melanesian, Polynesian, European, and other communities vaccinated with a complete COVID-19 vaccine regimen, residing in New Caledonia.
62044913|NCT02062268||rural area in North Jiangsu Province|health education \& law enforcement
62449222|NCT06202157|EXPERIMENTAL|DHB (Dihydroberberine)|
62044914|NCT01570426||Bipolar Disorder|Children, 7- 17 years-old, who meet diagnostic criteria for bipolar disorder, Type 1
62044915|NCT01570426||ADHD/ADD|Children, 7-17 years-old, who meet diagnostic criteria for attention deficit/hyperactivity disorder (ADHD) OR attention deficit disorder (without hyperactivity)
62826801|NCT00015210|ACTIVE_COMPARATOR|Nefazodone|Nefazodone 100 mg tablet, titrated to a maximum of 200 mg administered twice daily by treatment day 10. Drug tapered over 7 days at the conclusion of the treatment period. Treatment was administered for 8 weeks.
62044916|NCT01570426||Generalized Anxiety Disorder (GAD)|Children, 7-17 years-old, who meet diagnostic criteria for Generalized Anxiety Disorder (GAD)
62044917|NCT01570426||Health Controls|Children, ages 7-17 years-old, without a history of psychiatric diagnosis
62044918|NCT04459390||COVID19 with comorbidities|"Patients with COVID19 with at least one of the following comorbidities:~1. Hypertension~2. Diabetes~3. Cardiovascular disease~4. Chronic pulmonary disease~5. Obesity~6. Chronic liver disease~7. Chronic kidney disease~8. Collagen vascular disease~9. Autoimmune disease~10. Malignancy"
62044919|NCT04459390||COVID19 without comorbidities|Patients with COVID19 without any of the previously mentioned comorbidities
62044920|NCT03365076|EXPERIMENTAL|Physical aerobic intervention|The exercise program will be varying between different aerobic activities indoor or outdoor as walking uphill and in stairs in intervals that will differ from session to session to build up the load and progression for these patients. In total, each session will be lasting approximately 45-60 minutes and a physiotherapist or personal trainer will supervise each session. Depending on the participants starting point, there will be 3 supervised session per week and two sessions where the participants do activity with low intensity (walk) by themselves and keep a log with duration (time) and intensity (using Borg scale).
62247319|NCT03640468|ACTIVE_COMPARATOR|Ketamine group|This group will receive induction of anesthesia using ketamie full dose 1 mg/kg, midazolam 0.05 mg/Kg, and normal saline 10 mL.
62247320|NCT03640468|EXPERIMENTAL|Lidocaine-ketamine group|This group will receive induction of anesthesia using Ketamie half dose 0.5 mg/kg, midazolam 0.05 mg/Kg, and lidocaine 1 mg/Kg.
62247321|NCT01923350|EXPERIMENTAL|Weight Reduction Intervention|
62247322|NCT01923350|ACTIVE_COMPARATOR|Weight Reduction Control Arm|
62247323|NCT01923350|ACTIVE_COMPARATOR|Tested for diabetes|
62826802|NCT00015210|PLACEBO_COMPARATOR|Matched Placebo Tablet|Matched placebo tablet, titrated up to 2 tablets twice daily by day 10 and tapered over 7 days at the conclusion of the study. Treatment period lasted 8 weeks.
62044921|NCT03365076|NO_INTERVENTION|Controls|These patients will be acting as controls by not been instructed to physical activity. We will not monitor their activity either as this has been shown to increase activity by itself.
62044922|NCT02633800|EXPERIMENTAL|Patritumab|All participants receive patritumab with cetuximab plus platinum-based therapy (cisplatin or carboplatin)
62044923|NCT02633800|PLACEBO_COMPARATOR|Placebo|All participants receive placebo with cetuximab plus platinum-based therapy (cisplatin or carboplatin)
62247324|NCT01923350|ACTIVE_COMPARATOR|Not tested for diabetes|
62247325|NCT05915520|EXPERIMENTAL|group A|the 20-geriatric group will receive 5-session per-week 40-minute baduinjuin for 8 weeks plus the daily dose of pantoprazole (40 mg orally administered tablet drug)
62247326|NCT05915520|OTHER|group B|this 20-geriatric group will receive the daily dose of pantoprazole (40 mg orally administered tablet drug for 8 weeks .
62247327|NCT03373981|EXPERIMENTAL|intervention|rTMS
62247328|NCT04329481|ACTIVE_COMPARATOR|mycodigest supplement|"Mycodigest is a dietary supplement which consists of traditional medicinal mushrooms, as essences and grounded powder. These include Shiitake, Maitake, Trametes Coriolus Versicolor, Agaricus.~Compliance to treatment will be considered as taking 80% of supplement/placebo treatment, and will be monitored by telephone calls and emails to patients during the study phase, and by counting the pills which were not taken at the end of the trial.~Treatment with Mycodigest supplement will initiate with 2 pills/day for 7 days, and gradually rise to 4 pills/day for 7 days, 6 pills/day for 42 days. Thus, the full dose of the treatment will be administered for 6 weeks."
62449223|NCT06145178|EXPERIMENTAL|Group 1|Low dose SPYVLP01 alone
62826803|NCT05075980|EXPERIMENTAL|Arm A (IMPT, IMRT, cisplatin)|Patients undergo IMPT or IMRT for 18 sessions over 24 days in the absence of disease progression or unacceptable toxicity. Patients may receive cisplatin IV over 1-2 hours per standard of care. Patients undergo CT or MRI and PET/CT or PET/MRI during screening and follow-up. Patients may also undergo blood sample collection throughout the trial.
62044924|NCT04295005||All patients who started an Empagliflozin therapy|All participants who met the inclusion criteria and none of the exclusion criteria of this study, who had at least two outpatient diagnoses and/or one inpatient diagnosis of Type 2 diabetes mellitus (T2DM) and received at least one outpatient prescription with Empagliflozin (EMPA) between 2015 - 2018 from the Gesellschaft für Qualität und Wirtschaftlichkeit bei Krankenkassen (GWQ) dataset.
62826804|NCT05075980|EXPERIMENTAL|Arm B (IMPT, cisplatin)|Patients undergo IMPT for 15 sessions over 19 days in the absence of disease progression or unacceptable toxicity. Patients may receive cisplatin IV over 1-2 hours per standard of care. Patients undergo CT or MRI and PET/CT or PET/MRI during screening and follow-up. Patients may also undergo blood sample collection throughout the trial.
62044925|NCT04295005||All patients who started a DPP-4 inhibitor (specifically Sitagliptin) therapy|All participants who met the inclusion criteria and none of the exclusion criteria of this study, who had at least two outpatient diagnoses and/or one inpatient diagnosis of Type 2 diabetes mellitus (T2DM) and received at least one outpatient prescription with Dipeptidyl peptidase 4 (DPP-4) inhibitor (DPP-4i) (specifically Sitagliptin) between 2015 - 2018 from the Gesellschaft für Qualität und Wirtschaftlichkeit bei Krankenkassen (GWQ) dataset.
62044926|NCT04295005||All patients who started a GLP-1 receptor agonist therapy|All participants who met the inclusion criteria and none of the exclusion criteria of this study, who had at least two outpatient diagnoses and/or one inpatient diagnosis of Type 2 diabetes mellitus (T2DM) and received at least one outpatient prescription with Glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1-RA) between 2015 - 2018 from the Gesellschaft für Qualität und Wirtschaftlichkeit bei Krankenkassen (GWQ) dataset.
62044927|NCT06104033||Hybrid strategy|The patient undergoes percutaneous coronary intervention with drug-coated balloons and drug-eluting stents or drug-coated balloons only in the coronary artery lesion.
62044928|NCT06104033||DES only|The patient undergoes percutaneous coronary intervention with drug-eluting stents only in the coronary artery lesion.
62247329|NCT04329481|PLACEBO_COMPARATOR|placebo|"will be be identical in size, shape and color to Mycodigest Treatment with Mycodigest placebo will initiate with 2 pills/day for 7 days, and gradually rise to 4 pills/day for 7 days, 6 pills/day for 42 days. Thus, the full dose of the treatment will be administered for 6 weeks."
62044929|NCT06456632|NO_INTERVENTION|Control Group|Group not receiving Su Jok Therapy
62044930|NCT06456632|EXPERIMENTAL|Intervention Group|Group receiving Su jok therapy
62247330|NCT05671783||Post-induction hypotension|Post-induction hypotension (pIOH) is a decrease during the first 20 min after anesthesia induction
62044931|NCT05304338|ACTIVE_COMPARATOR|Chlorhexidine|
62044932|NCT05304338|EXPERIMENTAL|Coconut Oil|
62247331|NCT05671783||Maintenance intraoperative hypotension|maintenance intraoperative hypotension (mIOH) when there is a decrease of blood pressure 20th min after induction, with or without pIOH
62247332|NCT05671783||Normotensive patients|Patients with normotension during surgery.
62247333|NCT05145335|EXPERIMENTAL|Autoregulated cuff|two sessions in which an autoregulated cuff will be used to adapt the pressure in order to keep the total pressure given constant. First session will be within a 30-15-15-15 reps protocol, the second session will be performed until max fatigue.
62449224|NCT06145178|EXPERIMENTAL|Group 2|High dose SPYVLP01 alone
62044933|NCT05304338|EXPERIMENTAL|Black Cumin Oil|
62044934|NCT05304338|EXPERIMENTAL|Terebinth Oil|
62604344|NCT05583279|EXPERIMENTAL|Phase 2|Cohort 1 and 2 youth will then complete baseline assessments (see 4.5) and Cohort 2 will continue receiving TAU while Cohort 1 begins receiving DBT-A (randomized by facility to either in-person or via telehealth delivery) for the next six months while Cohort 1 staff continue consultation with DBT-A. After six months, Phase 2 of this study will conclude with the youth of Cohorts 1 and 2 completing their first follow-up assessment. The implementation plan will be altered accordingly based on feedback from stakeholders prior to the start of Phase 2. The modified implementation plan will be used in the training of the staff in DBT-A at the second four facilities prior to the launch of Phase 3.
62044935|NCT05304338|PLACEBO_COMPARATOR|Distilled Water|
62044936|NCT02250105|ACTIVE_COMPARATOR|ARI-3037MO|ARI-3037MO 3g bid orally for 12 weeks
62044937|NCT02250105|PLACEBO_COMPARATOR|Placebo|Matching placebo 3g bid orally for 12 weeks
62044938|NCT01433354|EXPERIMENTAL|AFQ056 Treatment|All patients will initiate treatment with AFQ056 at a starting dose of 25 mg b.i.d. The dose will be titrated from 25 mg b.i.d to 50 mg b.i.d., 75 mg b.i.d. and 100 mg b.i.d. at weekly intervals. Dose adjustments (up- and down-titrations) will be permitted as needed to manage any tolerability issues and to ensure that patients reach their highest tolerated dose, not to exceed 100 mg b.i.d.
62044939|NCT02774070|OTHER|Symptomatic atlantoaxial joint affection|Undergo plain X-ray and magnetic resonance imaging
62044940|NCT02774070|OTHER|Asymptomatic atlantoaxial joint aff.|Undergo plain X-ray and magnetic resonance imaging
62044941|NCT06216522|EXPERIMENTAL|Intervention|5 drops/0.25mls of 100% sesame oil will be applied to the IV cannula site, from 3cm above the insertion point to 10cm along the vein, with a width of 2cm on either side, every 12 hours for 72 hours.
62044942|NCT06216522|PLACEBO_COMPARATOR|Control|5 drops/0.25mls of liquid paraffin oil will be applied to the IV cannula site, from 3cm above the insertion point to 10cm along the vein, with a width of 2cm on either side, every 12 hours for 72 hours.
62437572|NCT01882400|EXPERIMENTAL|Bisphosphonate treatment|Add a weekly bisphosphonate to adequate doses of calcium and vitamin D supplements
62604345|NCT05583279|ACTIVE_COMPARATOR|No intervention|Cohort 2 will not receive any treatment during Phase 2 of the study, which is the first part of the clinical trial. They will serve as a comparison group for Cohort 1.
62739070|NCT05209620|EXPERIMENTAL|Orelabrutinib Combined with Pemetrexed|"Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration, Pemetrexed, 500mg/m2, Intravenous administration on day 5 of each 3-week cycle (Total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle)."
62739071|NCT04103151||Febrile infants|Febrile Infants less than 3 months presenting to the emergency department with a temperature of ≥ 38oC.
62739072|NCT04103151||Afebrile infants|Afebrile Infants less than 3 months presenting to the emergency department
62739073|NCT00922376|ACTIVE_COMPARATOR|T+ Intervention|The intervention group patients will use the T+ telemedicine application whilst completing repeated measures aiming to compare them to a control group receiving standard care.
62739074|NCT00922376|NO_INTERVENTION|Usual care|The control group will be receiving the standard care offered by the NHS to patients suffering from diabetes.
62739075|NCT03548025|EXPERIMENTAL|Treatment Group|Treated group of subjects, serves as its own control
62044943|NCT04912648||Women age 18 years and older|"* baseline anthropometry~* bloods for metabolic phenotype; targeted and nontargeted Metabolomics~* saliva and urine for steroid Metabolomics~* bioimpedance~* muscle biopsy for transcriptomics"
62044944|NCT06457633|EXPERIMENTAL|Experiential FW|Group treatment protocol of 12 weekly 120 minute sessions (outdoor intervention) based in no-responder predictive analysis and co-creating process
62044945|NCT06457633|ACTIVE_COMPARATOR|Traditional FW|Group treatment protocol of 12 weekly 120 minute sessions (outdoor intervention)
62044946|NCT06457633|ACTIVE_COMPARATOR|Online FW|Group treatment protocol of 12 weekly 60 minute sessions (virtual intervention)
62437573|NCT03476447|ACTIVE_COMPARATOR|High dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a high dose per daily oral feeding
62739076|NCT04989556|ACTIVE_COMPARATOR|Arm I (standard symptom management)|Patients receive standard symptom management by palliative care team once every 4 weeks for 12 weeks. Patients and caregivers also may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
62739077|NCT04989556|EXPERIMENTAL|Arm II (weekly provider-initiated remote contact)|Patients in Phase I immunotherapy trials will receive in-person clinic visits or standard remote care encounters at least once every 4 weeks and the e-ESAS and PC provider-initiated remote contact every week. Patients and caregivers may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
62739078|NCT04989556|EXPERIMENTAL|Arm III (weekly provider-initiated remote contact)|Patients in Phase I non-immunotherapy clinical trials will receive in-person clinic visits or standard remote care encounters at least once every 4 weeks and the e-ESAS and PC provider-initiated remote contact once a week. Patients and caregivers may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
62739079|NCT04817475||Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of patients with a out-of-hospital cardiac arrest will be performed with tele-supervision.
62739080|NCT03299205|EXPERIMENTAL|Exercise|Aerobic exercise program using treadmill.
62739081|NCT04102800|OTHER|Treatment|Benralizumab 30mg by subcutaneous injection, 18 months treatment for the first 75 participants enrolled, 12 months treatment for participants 76-150
62739082|NCT05306665|EXPERIMENTAL|ACT intervention|Participants assigned to this arm will complete a 1-day ACT workshop followed by a telephone booster after surgery
62739083|NCT05306665|NO_INTERVENTION|Treatment As Usual|Participants assigned to this arm will receive treatment as usual.
62739084|NCT06619392|EXPERIMENTAL|Treatment at dose level 1|
62739085|NCT06619392|EXPERIMENTAL|Treatment at dose level 2|
62739086|NCT06619392|EXPERIMENTAL|Treatment at dose level 3|
62739087|NCT06619392|EXPERIMENTAL|Treatment at dose level 4|
62739088|NCT06619392|EXPERIMENTAL|Treatment at dose level 5|
62739089|NCT01201824|OTHER|1|
62739090|NCT00602225|EXPERIMENTAL|Arm I|See Detailed Description
62826805|NCT05075980|EXPERIMENTAL|Arm C (IMRT, cisplatin)|Patients undergo IMRT for 15 sessions over 19 days in the absence of disease progression or unacceptable toxicity. Patients may receive cisplatin IV over 1-2 hours per standard of care. Patients undergo CT or MRI and PET/CT or PET/MRI during screening and follow-up. Patients may also undergo blood sample collection throughout the trial.
62044947|NCT01952496|OTHER|Force-measuring platform|"A force-measure platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.~Intervention: Assisted Standing Treatment Program. Assisted standing treatment program will include at least 2 hours a day, 5 days a week (a total of at least 10 hours a week) for a period of \~9 months."
62044948|NCT01437826|EXPERIMENTAL|antioxidants|tablets composed of 200 mcg selenium \[as l-selenomethionine\], 30 mg zinc, 2 mg vitamin A \[retinol\], 180 mg vitamin C \[ascorbic acid\] and 30 mg vitamin E \[D-α-tocopherol acetate\]
62044949|NCT01437826|PLACEBO_COMPARATOR|Sugar pill|placebo had an identical appearance as intervention
62247334|NCT05145335|ACTIVE_COMPARATOR|non-autoregulated cuff|two sessions in which an non-autoregulated cuff will be used. In these two sessions, the pressure will not be adapted. Consequently, during each muscle contraction the pressure will rise because the cuff is not autoregulated. First session will be within a 30-15-15-15 reps protocol, the second session will be performed until max fatigue.
62247335|NCT04612452||Lighthouse Trust in Lilongwe|
62437574|NCT03476447|ACTIVE_COMPARATOR|Medium dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a medium dose per daily oral feeding
62437575|NCT03476447|ACTIVE_COMPARATOR|Low dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a low dose per daily oral feeding
62826806|NCT03745014|ACTIVE_COMPARATOR|Pheno|
62826807|NCT03745014|ACTIVE_COMPARATOR|Standard of Care|
62826808|NCT06603870|EXPERIMENTAL|Apixaban|2.5 mg twice daily
62826809|NCT05023551|EXPERIMENTAL|Single arm DSP-0390|Arm Description \[\*\] DSP-0390 by oral administration
62826810|NCT00359645|NO_INTERVENTION|Control|Annual auto questionnaire
62826811|NCT00359645|EXPERIMENTAL|Screening|Annual screening of Head and Neck cancer
62826812|NCT06577610|EXPERIMENTAL|Feedback group|The feedback group will be notified of the colonoscopy performances.
62826813|NCT06577610|NO_INTERVENTION|Control group|The control group will not be notified of the colonoscopy performances.
62826814|NCT04965818|EXPERIMENTAL|Futibitanib in combination with binimetinib|"Dose escalation: Futibitanib in combination with binimetinib in patients with advanced cancer disease.~Dose expansion: Futibatinib in combination with binimetinib at the RP2D in patients with advanced KRASmt NSCLC"
62826815|NCT05697328|EXPERIMENTAL|Pseudoephedrine|over the counter pseudoephedrine
62826816|NCT05697328|PLACEBO_COMPARATOR|Placebo|pharmacy created placebo capsule
62826817|NCT01412502||Brain death with organ donation|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death includes brain death with multiple organ donation +/- tissues."
62826818|NCT01412502||Limitation/cessation of active treatment|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death includes limitation/cessation of active treatment without brain death."
62826819|NCT01412502||Sudden death|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death was sudden death of a previously healthy patient (no physical or mental limitations; MacCabe score = 0) within 3 days of admission to ICU without LATA nor brain death."
62826820|NCT00992108|ACTIVE_COMPARATOR|Lidocaine|lidocaine injection group
62247336|NCT04612452||CIDRZ in Lusaka|
62247337|NCT01507467|ACTIVE_COMPARATOR|Accl. RT|Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
62247338|NCT01507467|EXPERIMENTAL|Accl. RT + Nimorazole|Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week + Nimorazole
62247339|NCT02361944|EXPERIMENTAL|Normoxia|Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
62247340|NCT02361944|ACTIVE_COMPARATOR|Hyperoxia|Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
62437576|NCT03476447|PLACEBO_COMPARATOR|Lactose Placebo|10 participants will receive powdered lactose per daily oral feeding
62826821|NCT00992108|EXPERIMENTAL|Botulinum|
62826822|NCT05024539||Regorafenib group|Patients were given only regorafenib orally
62826823|NCT05024539||Joint group|The patient was treated with regorafenib orally and in combination with other medications
62826824|NCT06474026|EXPERIMENTAL|Sham+Active arm|Visit 2-1(Sham procedure), Visit 2-2(7±2 days after applying sham device): evaluate safety and effectiveness for SHAM devices, Active procedure
62826825|NCT06474026|EXPERIMENTAL|Active arm:|Visit 2(Active procedure)
62247341|NCT03641495|EXPERIMENTAL|Pain education plus exercise therapy (PE + ET)|"Pain education according to the book Explain Pain written by Lorimer Moseley and David Butler~Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations."
62247342|NCT03641495|ACTIVE_COMPARATOR|Exercise therapy (ET)|Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations.
62247343|NCT01831921|EXPERIMENTAL|Lifestyle Weight-Loss|Participants in the Behavioral: Lifestyle Weight Loss arm will take part in a group program aimed at achieving modest weight loss (5-7%) through promoting healthy eating and increasing physical activity. The intervention sessions will take place at churches and other community locations and will be coordinated and facilitated by Latino Health Advisors (LHAs). The lifestyle intervention will be delivered in 2 phases: Phase 1 will last for 6 months and consist of weekly group meetings; Phase 2 will last for 18 months and consist of one LHA-led group session or one telephone contact from the LHA per month. Participants in this treatment arm will also receive individual visits with a registered dietitian during months 1, 3, and 6 of phase 1. All participants will be seen for assessment visits as baseline, 6, and 12 months. Some participants will also complete 18 and 24 month visits, depending on the date of randomization.
62604346|NCT05583279|ACTIVE_COMPARATOR|Phase 3|Phase 3 will begin with making any modifications to the treatment protocol based on a review of feedback from stakeholder interviews from Phase 2. Cohort 2 facilities will be randomized to delivering DBT-A in-person or via telehealth (one long-term and one short-term facility will be assigned to each condition). Staff in Cohort 2 will receive training and consultation in DBT-A and implement either telehealth or in-person delivered DBT-A in their facilities. Cohort 1 facilities will cross-over from in-person delivery of DBT-A to telehealth delivery, or vice-versa, thereby facilitating a within-facility comparison of DBT-A delivery methods. After six months, Phase 3 will conclude with the youth of Cohorts 1 and 2 completing their second follow-up assessment and all stakeholders of Cohorts 1 and 2 completing stakeholder interviews.
62604347|NCT00623597|EXPERIMENTAL|1|
62604348|NCT00344591|EXPERIMENTAL|Tailored SET program|tailored SET program for reducing sexual and drug-related HIV transmission risk factors and increasing HIV treatment adherence in HIV infected men who have recently been released from prison
62604349|NCT00344591|ACTIVE_COMPARATOR|Individually focused therapy|Individually focused therapy program for reducing sexual and drug-related HIV transmission risk factors and increasing HIV treatment adherence in HIV infected men who have recently been released from prison
62247344|NCT01831921|ACTIVE_COMPARATOR|Enhanced Usual Care|Participants in the Behavioral: Counseling arm will receive two individual sessions with a registered dietitian and monthly newsletters that focus on existing community resources.All participants will be seen for assessment visits as baseline, 6, and 12 months. Some participants will also complete 18 and 24 month visits, depending on the date of randomization.
62437577|NCT00796484|EXPERIMENTAL|1|
62604350|NCT04759859||Carotid Endarterectomy (CEA)|70 participants undergoing CEA
62604351|NCT04759859||Other Peripheral Vascular Surgery|30 participants undergoing other peripheral vascular surgical procedures
62604352|NCT01300208|EXPERIMENTAL|Cohort 1|CC-11050 (50 milligrams twice per day and Placebo)
62604353|NCT01300208|EXPERIMENTAL|Cohort 2|CC-11050 (100 milligrams twice per day and Placebo)
62604354|NCT01300208|EXPERIMENTAL|Cohort 3|CC-11050 (200 milligrams twice per day and Placebo)
62604355|NCT02014922|NO_INTERVENTION|Control|Participants randomized to the control group will be allowed to continue using their habitual artificial tears, and / or additional habitual concurrent dry eye treatments.
62604356|NCT02014922|EXPERIMENTAL|Treatment|"Participants in the study treatment group will receive all four products:~* TheraTears® Lubricant Eye Drop (15mL) - Dosage: Ophthalmic, 1 or 2 drops, prn~* TheraTears® preservative-free single-use containers (32-pack, 0.6mL each) - Dosage: Ophthalmic, 1 or 2 drops, prn~* TheraTears® Nutrition (90 pack) - Dosage: Oral, 3 capsules QD~* TheraTears® TheraLid® Eyelid Cleanser (48mL) - Dosage: Ophthalmic, 1 or 2 application OU, QD"
62604357|NCT02252471|EXPERIMENTAL|Choices-Teen Intervention|A three session intervention with two counseling sessions with a master's level therapist and a counseling session with a physician. The counseling with the master's level therapist utilizes a motivational interviewing approach to encourage changes in alcohol use, contraceptive use, smoking and HIV risk behaviors. This part of the intervention (a) provides norms-based-but personalized-feedback; (b) encourages participating in the smoking cessation program; (c) increases motivation to change each of the target behaviors; (d) decreases temptation to engage in risk behaviors; (e) increases confidence to avoid risk behaviors; and (f) develops a personalized, tailored change plan. The physician session provides individualized contraception and HIV risk reduction counseling.
62826826|NCT05479877|EXPERIMENTAL|(Experimental group) collagen based Pulpotomy|(sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India)
62826827|NCT05479877|ACTIVE_COMPARATOR|(Control group) Biodentine pulpotomy|Biodentine (Septodont, Saint-Maur-des-Fossés, France)
62826828|NCT06585917|EXPERIMENTAL|7F Sheath Intervention Group|Participants in this arm will undergo coronary intervention using a 7F thin-walled sheath via distal radial artery access. This group will be used to assess the efficacy and safety of the 7F sheath compared to the 6F sheath.
62044950|NCT03227679|ACTIVE_COMPARATOR|Metabolism-Informed Care (MIC)|Smoking Cessation Pharmacotherapy (varenicline, bupropion, and nicotine patch) recommendations were guided by Nicotine Metabolism as measured by the Nicotine Metabolite Ratio. Ultimately, after being educated about smoking cessation medication efficacy and side-effects, the participant could decide to take any medication for which they were medically cleared, but the recommendation was made based on rate of Nicotine Metabolism.
62044951|NCT03227679|ACTIVE_COMPARATOR|Guideline-Based Care (GBC)|Smoking Cessation Pharmacotherapy (varenicline, bupropion, and nicotine patch) was co-selected from those they were medically able to receive after educating participants about smoking cessation medication efficacy and side-effects.
62044952|NCT06202833|EXPERIMENTAL|Tongyuan acupuncture|Point selection of Tongyuan acupuncture group: baihui, zhongwan, guanyuan, qihai, tianshu (double).The method of lifting, inserting and twisting was used once a day, 5 days a week for 4 consecutive weeks. Twenty days in total. Consciousness levels were assessed before intervention, at 1, 2, 3, and 4 weeks of treatment, and 4 weeks after discharge.
62247345|NCT01968850|NO_INTERVENTION|no bone anti-resorptive therapy|(standard of care)
62247346|NCT01968850|EXPERIMENTAL|24-week tx of alendronate/vitamin D|Concomitant initiation of a 24 week course of co-formulated alendronate/vitamin D
62247347|NCT01968850|EXPERIMENTAL|Delayed 24-week tx of alendronate/vitamin D|a 24 week delay in initiation of a 24 week course of alendronate/vitamin D
62247348|NCT00792454|EXPERIMENTAL|exercise training/renal rehabilitation|Experimental arm will undergo 12 weeks of training in exercise, meditation, and nutrition education.
62247349|NCT00792454|NO_INTERVENTION|control|Control co-hort will receive usual chronic kidney disease care and no exercise, meditation or dietary education intervention.
62247350|NCT04453436||Virologic failure|Viral load above detection limits at window period
62247351|NCT04453436||Virologic Success|Viral load bellow detection limits at window period
62247352|NCT00482443|EXPERIMENTAL|1|To assess the efficacy of a Diabetes Interactive Diary in Diabetes Management.
62247353|NCT00482443|ACTIVE_COMPARATOR|2|Control Arm. Patients will receive standard education programme.
62247354|NCT01965977|EXPERIMENTAL|Bortezomib|bortezomib 1.3mg/m2 subcutaneous on day 1 and15
62247355|NCT02844621|EXPERIMENTAL|Healthy subjects|
62247356|NCT05197036||LEGION Porous CR with Hydroxyapatite|Patients who have already received or a due to receive a Porous Tibia + LEGION Porous CR with HA femoral component (min 117 subjects)
62247357|NCT05197036||LEGION Porous CR without Hydroxyapatite|Patients who have already received or a due to receive a Porous Tibia + LEGION Porous CR without HA femoral component (min 117 subjects)
62247358|NCT00702325|EXPERIMENTAL|1|
62247359|NCT00702325|ACTIVE_COMPARATOR|2|
62247360|NCT06159855|OTHER|Control Group: Data Collection|"1. PRE-TEST~   a) Who is decided to have a colonoscopy, using the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~2. ROUTINE APPLICATION~   1. Patients who are planned to undergo colonoscopy and are included in the control group will be trained according to the bowel preparation protocol routinely applied by the clinical nurse.~  2. The Procedure Compliance Survey, which is routinely used as a clinical procedure, is given to the patient/patient's relative after the training of the clinical nurse.~3. FINAL TEST~   1. Immediately after the procedure, data will be collected again with the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~  2. After the procedure, the cleanliness of the intestines will be evaluated by the physician with the Ottawa Bowel Preparation Scale.~  3. The control group will be given training and a booklet after all data collection is completed."
62604358|NCT03786692|EXPERIMENTAL|Arm A|Arm A: Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab Maintenance: Pemetrexed + Bevacizumab + Atezolizumab
62604359|NCT03786692|ACTIVE_COMPARATOR|Arm B|Arm B: Carboplatin + Pemetrexed + Bevacizumab Maintenance: Pemetrexed + Bevacizumab
62044953|NCT06202833|SHAM_COMPARATOR|Sham acupoint acupuncture|In the sham-acupoint group, acupuncture treatment was carried out 1cm beside the selected points of the experimental group, once a day, 5 days a week, for 4 consecutive weeks. Twenty days in total. Consciousness levels were assessed before intervention, at 1, 2, 3, and 4 weeks of treatment, and 4 weeks after discharge.
62044954|NCT05347264|EXPERIMENTAL|massage gun|15 to 20 minutes along with hot pack.
62044955|NCT05347264|EXPERIMENTAL|transverse friction massage|15 to 20 minutes along with hot pack.
62044956|NCT04369014|EXPERIMENTAL|etomidate|
62044957|NCT04369014|EXPERIMENTAL|propofol|
62044958|NCT00372281|EXPERIMENTAL|Cliavist|
62247361|NCT03591354|EXPERIMENTAL|Closed Loop Control (CLC)|"Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology \& Dexcom G6 Continuous Glucose Monitor (CGM) for 3 months.~Objective 1: This arm is participants who had 6 months of CLC in the primary trial (DCLP3 Pivotal Trial)~Objective 2: This arm is participants who had 6 months of sensor-augmented pump (SAP) in the primary trial (DCLP3 Pivotal Trial)~Objective 3: This arm is participants who had 3 months of CLC in the extension trial (DCLP3 Extension) will continue use of the Control-IQ Technology \& Dexcom G6 CGM until the product is commercially available."
62247362|NCT03591354|ACTIVE_COMPARATOR|Predictive-Low Glucose Suspend (PLGS)|"Participants randomized to Predictive-Low Glucose Suspend (PLGS) will use the t:slim X2 with Basal-IQ \& Dexcom G6 CGM for 3 months.~Objective 1: This arm is participants who had 6 months of PLGS in the primary trial (DCLP3 Pivotal Trial)~Objective 2: This arm is not applicable to objective 2~Objective 3: This arm is participants who had 3 months of PLGS in the extension trial (DCLP3 Extension) will continue use of the Control-IQ Technology \& Dexcom G6 CGM until the product is commercially available."
62604360|NCT03799406|ACTIVE_COMPARATOR|Intervention group|cholecalciferol at dose of 100 IU/Kg/day
62604361|NCT03799406|PLACEBO_COMPARATOR|Placebo group|placebo
62826829|NCT06585917|ACTIVE_COMPARATOR|6F Sheath Control Group|Participants in this arm will undergo coronary intervention using a 6F thin-walled sheath via distal radial artery access. This group will serve as the control to compare the outcomes against those of the 7F sheath group.
62826830|NCT06503874|EXPERIMENTAL|Attention Training|The computer based APT-3 intervention will be delivered in a hybrid model that will combine in-person therapy sessions at Shirley Ryan AbilityLab and practice sessions which will be completed remotely. The dosing of each intervention training will be 30 minutes per day, 5 days a week, for 4 weeks (10 hours total over 4 weeks). The difficulty of the tasks in both interventions will increase progressively as the participants improve in their skills. APT-3 treatment will be administered by a trained and certified speech-language pathologist.
62826831|NCT06503874|EXPERIMENTAL|Music Program|This group will receive an enhanced music experience. They will listen to pre determined music for 30 minutes per day, 5 days a week, for 4 weeks (10 hours total over 4 weeks). This will be delivered in a hybrid model that will combine, in person, remote, and independent sessions, similar to the Attention Training group. Once they complete the music program, they will have the option to complete the Attention Training.
62247363|NCT04076254|EXPERIMENTAL|albumin|albumin 5%
62247364|NCT04076254|ACTIVE_COMPARATOR|fluid|Ringer Lactate
62247365|NCT02722876|EXPERIMENTAL|Contralateral rehabilitation|8-weeks of resistance training of the non-operative limb following ACL reconstruction
62247366|NCT02722876|PLACEBO_COMPARATOR|Placebo flexibility exercise|8-weeks of 'placebo' flexibility training of the upper limb
62247367|NCT00472173|ACTIVE_COMPARATOR|Calcium hydroxide|
62247368|NCT00472173|EXPERIMENTAL|MTA|
62437578|NCT06334926||Colon cancer patients|Retrospective data analysis of the subgroup of patients suffering from colon carcinoma
62604362|NCT03347344|EXPERIMENTAL|RILUZOLE|Riluzole PMCS 50 mg is presented as a round, biconvex, 8 mm diameter nearly white film-coated tablet. The tablets will be held under a blister of 20 tablets.
62044959|NCT03175770||Patients with benign or malign tumor in the oropharynx|Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
62604363|NCT03347344|PLACEBO_COMPARATOR|PLACEBO|The placebo PMCS 50 mg is presented as a round, biconvex, 8 mm diameter nearly white film-coated tablet matching the appearance of the Riluzole used in this study
62604364|NCT05990959||HCC_surg|HCC surgical patients who would receive surgical interventions based on clinical judgment and would donate biospecimen for research after signing informed consent permission.
62604365|NCT00550862|EXPERIMENTAL|INT-747 10 mg|INT-747 10 mg once daily in combination with URSO for 12 weeks.
62604366|NCT00550862|EXPERIMENTAL|INT-747 25 mg|INT-747 25 mg once daily in combination with URSO for 12 weeks.
62604367|NCT00550862|EXPERIMENTAL|INT-747 50 mg|INT-747 50 mg once daily in combination with URSO for 12 weeks.
62604368|NCT00550862|PLACEBO_COMPARATOR|Placebo|Placebo once daily in combination with URSO for 12 weeks.
62044960|NCT06329492|EXPERIMENTAL|Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP)|Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) is produced by filtering Platelet Poor Plasma (PPP), a Platelet Rich Plasma byproduct, through a hemoconcentrator filter. (PPP) is frequently used in clinical practice to increase volume of PRP or Bone Marror Aspirate Concentrate (BMAC) injectate, and it is occasionally injected in isolation for some indication
62437579|NCT06334926||Rectal cancer patients|Retrospective data analysis of the subgroup of patients suffering from rectal carcinoma
62604369|NCT03479593||CMR and OCT in NSTEMI patients with MVD|NSTEMI patients with multi vessel disease
62604370|NCT05173818|EXPERIMENTAL|HBO at 1.5 Atmosphere absolute|Participants in this group will be exposed to hyperbaric oxygen at 1.5 atmosphere absolute (ATA) for 60 minutes per session. Each participant will complete 40 sessions, five sessions per week within 3 months from randomization
62604371|NCT05173818|SHAM_COMPARATOR|Sham control initially at 1.2 then changed to 1.0 ATA|Participants in this group will be exposed to hyperbaric oxygen at 1.2 atmosphere absolute (ATA) during the first 5 to 7 minutes and the chamber pressure will be reduced to 1.0 ATA for the remaining 53 - 57 minutes for a total of 60 minutes per session. Each participant will complete 40 sessions, five sessions per week within 3 months from randomization
62604372|NCT06620588||PREPARE|"Patients will receive the routine preoperative physiotherapy assessment, nutrition education, exercise instructions, and inspiratory muscle training if their maximal inspiratory pressure (MIP) is less than100 cmH2O. These sessions, lasting 20 to 40 minutes, will include physiotherapy education and instructions for a home-based, unsupervised exercise program.~Additionally, patients will undergo study-related measurements of baseline MIP using a handheld digital manometer, the 6-minute walk test (6MWT), handgrip strength (HGS) of the dominant hand, and 30-second and 1-minute Sit-To-Stand (STS) tests."
62604373|NCT05922527|EXPERIMENTAL|Combined regenerative technique|Open flap debridement combined with Amnion Chorion Membrane and DFDBA
62604374|NCT05922527|ACTIVE_COMPARATOR|Open flap debridement|Open flap debridement
62604375|NCT01671566|EXPERIMENTAL|Home based interval training|12 weeks home based interval training
62044961|NCT02361515|ACTIVE_COMPARATOR|Moderate Hypofractionated radiotherapy (62Gy)|20 fractions of 3.1Gy
62044962|NCT02361515|EXPERIMENTAL|Stereotactic radiotherapy (37.5Gy)|5 fractions of 7.5Gy)
62247369|NCT06100653|EXPERIMENTAL|BCG for therapeutic use clinical trial group|Ten patients with non-muscular invasive bladder cancer ≥14 days after surgery were included.
62247370|NCT02744300|EXPERIMENTAL|BABI-2 Lifestyle Intervention|Participants in this group will take part in the web-based lifestyle intervention which includes access to the lifestyle intervention website and personalized coaching from a Lifestyle Coach.
62437580|NCT04200703|EXPERIMENTAL|Intervention|Implementation of the Adult and Survivor Centered Approach.
62437581|NCT04200703|NO_INTERVENTION|Comparison|No implementation of intervention.
62437582|NCT03681106|EXPERIMENTAL|Kinesiotape|Kinesio Tex taping treatment for 10 days + usual care
62437583|NCT03681106|NO_INTERVENTION|Control|usual care
62604376|NCT01671566|NO_INTERVENTION|Control group|No structured exercise training.
62604377|NCT00699231|ACTIVE_COMPARATOR|Group A1|Non-responders to vaccination after at least 7 previous injections
62604378|NCT00699231|EXPERIMENTAL|Group A2|Non-responders to vaccination after at least 7 previous injections
62604379|NCT00699231|ACTIVE_COMPARATOR|Group B1|Vaccine-responders requiring a booster dose
62604380|NCT00699231|EXPERIMENTAL|Group B2|Vaccine-responders requiring a booster dose
62604381|NCT00699231|ACTIVE_COMPARATOR|Group C1|Volunteers participating in the hospital's vaccination program
62604382|NCT00699231|EXPERIMENTAL|Group C2|Volunteers participating in the hospital's vaccination program
62604383|NCT00699231|ACTIVE_COMPARATOR|Group D1|Unvaccinated haemodialysis patients
62604384|NCT00699231|EXPERIMENTAL|Group D2|Unvaccinated haemodialysis patients
62604385|NCT00140530|EXPERIMENTAL|1|Due to randomisation patients got a Paclitaxel-eluting stent
62044963|NCT05982769|EXPERIMENTAL|Endurance Arm|
62044964|NCT05982769|EXPERIMENTAL|Resistance|
62044965|NCT05982769|ACTIVE_COMPARATOR|Standard of Care|
62044966|NCT04434560|NO_INTERVENTION|Standard of Care (no neoadjuvant immunotherapy)|Patients will proceed to surgical resection with no nivolumab/ipilimumab given prior to surgery.
62437584|NCT02607761|EXPERIMENTAL|Intervention Group|2 minutes video with information and images on age-related fertility, infertility definitions, infertility risk factors, probabilities of fecundity according to age and cycle.
62437585|NCT02607761|NO_INTERVENTION|Control|No intervention
62437586|NCT02607761|ACTIVE_COMPARATOR|Control 1|2 minutes video with same images but information on work-family balance.
62437587|NCT01223196|PLACEBO_COMPARATOR|Placebo|One arm of the study subjects will be treated with Placebo only, once a day, for 6 months
62437588|NCT01223196|ACTIVE_COMPARATOR|Pioglitazone|One arm of the study subjects will be treated with Pioglitazone, 15mg, once a day, for 6 months
62437589|NCT05824312||TKI group|patients with LATC receiving Tyrosine kinase inhibitor drugs.
62437590|NCT05824312||Controlled group|patients with LATC receiving other treatment.
62604386|NCT00140530|EXPERIMENTAL|2|Due to randomization patients got a Rapamycin-eluting stent.
62604387|NCT04723563|EXPERIMENTAL|Nebulized Heparin|Heparin 5,000 units/mL Dose: 25,000 units Frequency: Four times per day Duration: until hospital discharge
62604388|NCT04723563|PLACEBO_COMPARATOR|Placebo|0.9% Sodium Chloride Dose: 5 mL Frequency: Four times per day Duration: until hospital discharge
62604389|NCT04791605|EXPERIMENTAL|Gait analysis of cemented total hip|Gait analysis of acute collum femoris fracture patient randomized to cemented stem
62247371|NCT02744300|NO_INTERVENTION|Post-GDM Follow-up Group|Participants in this group will have access to a separate website containing links to information about diabetes prevention.
62826832|NCT06503874|NO_INTERVENTION|Delayed Attention Training|This group will not be provided any program for the initial 4 weeks. After they complete the week 5 assessments, they will have the option to complete the Attention Training.
62826833|NCT01773044|ACTIVE_COMPARATOR|alkalinized lidocaine & lidocaine|
62826834|NCT01773044|ACTIVE_COMPARATOR|alkalinized lidocaine &Placebo|
62826835|NCT05371626|OTHER|Suture-less entropion technique|suture-less technique for cicatricial entropion
62826836|NCT03850756||1: No smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers Predisposition to kidney injury biomarkers"
62437591|NCT03909321|NO_INTERVENTION|Control group|The Control group will not be submitted to intervention and will be instructed not to engage in any kind of structured physical exercise training and to keep the life activities identified at baseline.
62437592|NCT03909321|EXPERIMENTAL|Beach tennis training group|The Beach Tennis (BT) group will perform two sessions per week of the Beach Tennis training. This intervention will last 12 weeks.
62437593|NCT01723787||Infantile Spasms|Participants retrospectively identified to have been treated with ACTH according to FDA-approved protocol for Infantile Spasms
62437594|NCT01723787||biological parents|Biological parents of participants retrospectively identified to have been treated with ACTH according to FDA-approved protocol for Infantile Spasms
62437595|NCT02143206||Exercise Method|Patients attend exercise 80 minute exercise sessions of which 30 minutes includes aerobic exercise on a NuStep and Biodex elliptical machine. Patients pain levels are scored when using the NuStep then when using the Biodex and these scores are compared to determine which machine give the best outcome for pain management
62437596|NCT04211298|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine will be used for sedation during bronchoscopy
62826837|NCT03850756||2: No smokers with risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers"
62826838|NCT03850756||3: Smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers Predisposition to kidney injury biomarkers~Also tobacco consumption will be measured"
62826839|NCT03850756||4: Smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers~Also Tobacco consumption will be measured"
62826840|NCT05743491|EXPERIMENTAL|Standard Care|Cancer survivors assigned to this condition continued with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS©® program gratis after completing all study requirements.
62826841|NCT05743491|EXPERIMENTAL|YOCAS©®|YOCAS©® is a standardized yoga program designed specifically for use by cancer patients and survivors. The YOCAS©® program is a low to moderate intensity mode of exercise that draws from two basic types of yoga: gentle Hatha and Restorative yoga. The program includes 18 specific physical postures (asanas) and mindfulness exercises focused on breathing (pranayama) and meditation (dhyana). The program is designed to be delivered by certified yoga instructors in community settings, two times a week for 75 minutes over four weeks.
62247372|NCT04297501||All participants|All enrolled participants in this study
62247373|NCT02276664|NO_INTERVENTION|Study 1 - Focus Groups|Using focus group methodology, investigators will identify and explore new content topics for inclusion in smoking cessation booklets and gather feedback about the existing Stop Smoking for Good booklets regarding tone and message design. Results will be used to modify and adapt the existing cessation intervention.
62437597|NCT04211298|PLACEBO_COMPARATOR|Propofol|Propofol will be used for sedation during bronchoscopy
62437598|NCT03213561|EXPERIMENTAL|Stable and Independent Communication Brain-computer Interfaces|Each arm will receive the same intervention.
62437599|NCT02951663|EXPERIMENTAL|Protein Supplement|Ready to drink blinded protein supplement
62437600|NCT02951663|NO_INTERVENTION|Control|Control group
62437601|NCT01205698|PLACEBO_COMPARATOR|Group 1 - Control A|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
62437602|NCT01205698|EXPERIMENTAL|Group 2 - Experimental A|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
62437603|NCT01205698|PLACEBO_COMPARATOR|Group 3 - Control B|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
62437604|NCT01205698|EXPERIMENTAL|Group 4 - Experimental B|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
62449225|NCT06145178|EXPERIMENTAL|Group 3|Low dose + Alhydrogel
62826842|NCT03521128|EXPERIMENTAL|the radiological tubal blockage group|
62826843|NCT03521128|ACTIVE_COMPARATOR|the laparoscopic salpingectomy group|
62826844|NCT02403128|EXPERIMENTAL|Patients with macular edema from RAM|Intravitreal aflibercept 2.0 mg injection for eyes meeting eligibility criteria will be administered at baseline. Reinjection of the drug for protocol-defined criteria at least two months after previous injection.
62044967|NCT04434560|EXPERIMENTAL|Neoadjuvant Immunotherapy|Patients will receive a single dose of neoadjuvant nivolumab and ipilimumab 7 days (± 3 days) prior to surgical resection.
62044968|NCT04535947|PLACEBO_COMPARATOR|Vehicle|Vehicle
62247374|NCT02276664|EXPERIMENTAL|Study 2 - Self-Help Intervention (SHI)|The SHI arm will receive the intervention developed in Study I.
62437605|NCT00217412|EXPERIMENTAL|Arm I|Group 1 (solid tumor or lymphoma patients): Patients receive oral SAHA once daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients may be treated at the MTD.
62437606|NCT00217412|EXPERIMENTAL|Arm II|Group 2 (leukemia patients): Patients receive SAHA as in group 1 at the MTD.
62437607|NCT00217412|EXPERIMENTAL|Arm III|Group 3 (select solid tumor patients): Patients receive oral isotretinoin twice daily on days 1-14. Patients also receive SAHA once daily on days 1-28 OR once on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.The MTD of SAHA is determined as in group 1. An additional 6 patients may be treated at the MTD.
62437608|NCT03251183||Main group|Blood sampling Comprehensive Cardiovascular magnetic resonance (CMR) Transthoracic echocardiography (TTE) (EchoErgo) Invasive pressure-volume (PV) Loops Left ventricular (LV) biopsy
62044969|NCT04535947|EXPERIMENTAL|SDP-4 Ophthalmic Solution (1.0%)|Active
62044970|NCT04843930|EXPERIMENTAL|AKL-T01 Intervention|Participants in the experimental group will complete 6 weeks of the AKL-T01 intervention. Participants enrolled in the intervention arm will play the game via an iPad application for 20-25 minutes daily for at least 5 days a week (but up to 7 days a week). Participants will also have weekly check-in visits via phone or a secure HIPAA compliant videoconferencing platform (Zoom) with a care manager, who will monitor mood symptoms and gameplay adherence.
62044971|NCT04843930|NO_INTERVENTION|Waitlist Control|Participants in the Waitlist Control arm will not be engaging in any active control condition. Participants in the waitlist control arm will continue any ongoing self- or provider-based cognitive intervention (or no intervention) during the initial 6-week waitlist period. Participants will also have weekly check-in visits via phone or a secure HIPAA compliant videoconferencing platform (Zoom) with a care manager, who will monitor mood symptoms. The control arm will be offered the intervention at the end of 6 weeks waitlist period to ensure all participants ultimately have access to the intervention.
62247375|NCT02276664|ACTIVE_COMPARATOR|Study 2 - Usual Care (UC)|The UC arm will receive the existing Clearing the Air smoking-cessation manual.
62247376|NCT03307434|EXPERIMENTAL|experimental group|experimental group is composed of athletes will be followed the Athletics Injury Prevention Program
62247377|NCT03307434|ACTIVE_COMPARATOR|control group|control group is composed of athletes will be continued their regular training
62437609|NCT03251183||Reproducibility group|Stress-perfusion Cardiovascular magnetic resonance (CMR)
62437610|NCT03251183||Age/gender matched control group|Blood sampling Stress-perfusion Cardiovascular magnetic resonance (CMR) TTE (EchoErgo)
62826845|NCT06603454|ACTIVE_COMPARATOR|Preoperative CT|Contrast-enhanced computed tomography of the aorta including the femoral arteries.
62826846|NCT06603454|NO_INTERVENTION|No preoperative CT|
62437611|NCT03251183||Healthy volunteers|Blood sampling Stress-perfusion Cardiovascular magnetic resonance (CMR) TTE (EchoErgo)
62437612|NCT05151978||(glasgow coma scale) 9 _15|No Secondary Neurological deterioration
62437613|NCT05151978||(glasgow coma scale) 9_15|Secondary Neurological deterioration
62449226|NCT06145178|EXPERIMENTAL|Group 4|High dose + Alhydrogel
62247378|NCT05093322|EXPERIMENTAL|Part 1- Dose escalation|Dose escalation study with sequential dose escalation of surufatinib in combination with gemcitabine. Patients with any recurrent or refractory solid tumors or lymphoma, who have a known or expected dysfunction of VEGFR-1, -2, and -3; FGFR-1; or CSF-1R pathways may be enrolled.
62437614|NCT01492257|NO_INTERVENTION|SDM Control|The control arm will consist of usual care, patients will receive existing educational materials.
62826847|NCT01995708|EXPERIMENTAL|Arm 1 Vaccine|This is a prospective, two-arm phase I randomized trial. Patients will be accrued only from and treated at MSKCCand The Rockefeller University/Center for Clinical \& Translational Science . The study will assess autologous LCs presenting CT7, MAGE-A3, and WT1 after electroporation with CT7, MAGE-A3, and WT1 mRNA. Twenty patients will accrue to the study and ten will receive vaccines at 9x10\^6 LCs per dose (i.e., combination of 3x10\^6 CT7 mRNA-electroporated LCs + 3x10\^6 MAGE-A3 mRNA-electroporated LCs + 3x10\^6 WT1 mRNA-electroporated LCs) and another ten who will not receive any LC vaccines but will otherwise undergo identical cytoreduction, ASCT, and standard supportive care. At approximately 3 months after ASCT and as deemed clinically appropriate, patients will start lenalidomide maintenance therapy, which is now standard to delay disease progression.
62826848|NCT01995708|ACTIVE_COMPARATOR|Arm 2 control|Patients receive standard of care treatment after autologous stem cell transplant
62437615|NCT01492257|EXPERIMENTAL|SDM Intervention|RCT intervention will include a package of decision and communication aids question-asking, and information recall. The intervention includes digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
62437616|NCT02102581||short time tourniquet|60 patients were randomly divided into 2 groups (30 cases/group): group A using the tourniquet throughout the operation, and group B using the tourniquet starting from the implantation of prosthesis to the completion of the operation(short time).
62826849|NCT03010449|EXPERIMENTAL|Intra-bronchial valve and blood|Bronchoscopic lung volume reduction using intra-bronchial valves combined with autologous blood instillation.
62826850|NCT06590597|EXPERIMENTAL|GRUPO EXPERIMENTAL|GROUP RECEIVING EDUCATIONAL INTERVENTION
62437617|NCT01585233|EXPERIMENTAL|Cohort 1|ASKP1240 lowest dose
62826851|NCT06590597|NO_INTERVENTION|GRUPO CONTROL|GROUP RECEIVING USUAL CARE
62826852|NCT04407754|PLACEBO_COMPARATOR|Control Arm|This group will receive placebo powder twice daily.
62826853|NCT04407754|ACTIVE_COMPARATOR|Inositol Arm|This group will receive myo-inositol (2,000mg) plus d-chiro-inositol (50mg) supplement powder twice daily.
62826854|NCT01185236|EXPERIMENTAL|simvastatin/ezetimibe (vytorin) group|vytorin 10/20mg po once daily for 12weeks
62826855|NCT01185236|ACTIVE_COMPARATOR|atorvastatin group|atorvastatin 20mg po once daily for 12weeks
62437618|NCT01585233|EXPERIMENTAL|Cohort 2|ASKP1240 low dose
62437619|NCT01585233|EXPERIMENTAL|Cohort 3|ASKP1240 high dose
62437620|NCT01585233|EXPERIMENTAL|Cohort 4|ASKP1240 highest dose
62437621|NCT01585233|PLACEBO_COMPARATOR|Placebo|
62437622|NCT01264393|ACTIVE_COMPARATOR|Shape Up Rhode Island + Online weight loss program + groups|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an internet-based weight loss program, and the option of attending face-to-face group sessions
62437623|NCT01264393|ACTIVE_COMPARATOR|Shape Up Rhode Island + Online Weight Loss Program|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention in addition to an internet-based weight loss program
62437624|NCT01264393|ACTIVE_COMPARATOR|Shape Up Rhode Island + Internet Resources|Participants in this arm will receive the Standard Shape Up Rhode Island statewide intervention plus access to internet resources
62437625|NCT04965220|EXPERIMENTAL|ATC|HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)
62826856|NCT05170919|EXPERIMENTAL|Olanzapine|
62826857|NCT05170919|EXPERIMENTAL|Mirtazapine|
62826858|NCT01891253||ventilated patients|ventilated patients in an internal medicine ICU with existing PiCCO invasive hemodynamic monitoring
62437626|NCT04965220|EXPERIMENTAL|Primary brain tumor|HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)
62437627|NCT04965220|EXPERIMENTAL|CRC(KRAS mutant)|HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)
62437628|NCT04965220|EXPERIMENTAL|other solid tumor|HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)
62437629|NCT05362058|EXPERIMENTAL|Insulin Efsitora Alfa|Participants will receive insulin efsitora alfa subcutaneously (SC) once weekly.
62826859|NCT00283296|EXPERIMENTAL|Endeavor Wheelchair|Participants will receive an introduction to the Endeavor wheelchair, and will complete the Activities of Daily Living Course with their own personal wheelchair and with the Endeavor chair.
62826860|NCT04217525||Spinal Disorders|This group includes patients with any spinal deformity or disorder coming in for treatment.
62826861|NCT04217525||Spinal Tumors|This group includes patients with spinal tumors or metastasis of the spine, coming in for treatment.
62826862|NCT00551642|ACTIVE_COMPARATOR|Inhaled Nitric Oxide (INO)|INO administered by nasal continuous positive airway pressure, nasal cannula or face mask at 5 parts per million (ppm) for between 7 and 21 days
62826863|NCT00551642|PLACEBO_COMPARATOR|Placebo|Placebo gas administered by nasal continuous positive airway pressure, nasal cannula or face mask, for a maximum of 21 days.
62826864|NCT06586177||Cohort 1 (C1; basic cohort)|Participants will be seen every 6 months up until month 24, then every 12 months. The following parameters will be collected: demographic data, disease characteristics incl. EDSS and MRI data, serum samples, and PBMCs. Furthermore, SF-36 and FSMC are documented.
62247379|NCT05093322|EXPERIMENTAL|Part 2 - Dose expansion|Once the MTD/RP2D has been determined in the part 1 portion of the study, the part 2 disease specific cohorts for patients with refractory or recurrent osteosarcoma, Ewing Sarcoma, and RMS and NRSTS will open for enrollment.
62604390|NCT04791605|EXPERIMENTAL|Gait analysis of non-cemented total hip|Gait analysis of acute collum femoris fracture patient randomized to non-cemented stem
62604391|NCT02663752|OTHER|Deferasirox|All patients are already on commercial deferasirox before entering the study.
62604392|NCT05890430||Patients with microvascular inflammation|Patients presenting with microvascular inflammation on kidney allograft biopsy
62826865|NCT06586177||Cohort 2 (C2; in-depth cohort)|In addition to the parameters collected for C1, participants of C2 will receive: clinical evaluation incl. EDSS and sampling of serum and PBMCs at months 1 and 3, MFSC every 6 months, and OCT as well as NPT every 12 months.
62826866|NCT00524511|EXPERIMENTAL|1|Women receiving Dermabond for skin closure
62044972|NCT06136390|ACTIVE_COMPARATOR|Oxytocin|The patients received a spray of the synthetic oxytocin (24 I.U. Syntocinon®) in combination with mindfulness-based group therapy (MBGT) over 4 weeks once a week. Due to an effect latency of 30-80 mins after intranasal administration of oxytocin on social behavior, the dose was administered 45 min before the 50-min session.
62437630|NCT05362058|ACTIVE_COMPARATOR|Insulin Degludec|Participants will receive insulin degludec SC once daily
62437631|NCT04106596||Patients with antibodies against LGI1|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
62437632|NCT04106596||Patients with antibodies against CASPR2|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
62449227|NCT06145178|EXPERIMENTAL|Group 5|Low dose + Matrix-M
62449228|NCT06145178|EXPERIMENTAL|Group 6|High dose + Matrix-M
62449229|NCT02573909|EXPERIMENTAL|Oxycodone intravenously|Oxycodone 0,1 mg/kg IV
62604393|NCT05890430||Patient without microvascular inflammation|Patients presenting without microvascular inflammation on kidney allograft biopsy
62604394|NCT04481113|EXPERIMENTAL|Treatment (abemaciclib, niraparib)|Patients receive abemaciclib PO BID and niraparib PO QD. Treatment repeats every 28 days for up to 2-4 cycles in the absence of disease progression or unacceptable toxicity. Patients who complete 4 cycles undergo standard of care mastectomy or lumpectomy. Patients demonstrating progressive disease after only 2 cycles are switched to receive standard of care chemotherapy prior to undergoing mastectomy or lumpectomy.
62604395|NCT02205905|EXPERIMENTAL|14C PER977|Open-label, single-dose, non-randomized study of 14C PER977 in six healthy male subjects
62247380|NCT05355779||Interviewees|Paediatric cancer survivors, their parent/caregiver and health care professionals will be invited to express their views and perspectives in an interview with the researcher
62247381|NCT04374643||Confined patients|General population
62623439|NCT06252155|EXPERIMENTAL|Music Group|Mothers will listen to music for 30 minutes every day for 2 postpartum days. The type of music to be used in this study will be Turkish music . Turkish music will be preferred in the study because it is a part of the culture in which the study will be conducted. This type of music was preferred because it evokes feelings of happiness, laughter, joy, power, courage and heroism in the human soul. In deciding the type of music listened to in the study, expert opinion was taken from a faculty member teaching music therapy at a state university. During the music session, the mother will take a comfortable position on the sofa or bed. She will also be asked to close her eyes and imagine where she wants to be. She will also be asked to breathe slowly and deeply to regulate her breathing.
62826867|NCT00524511|ACTIVE_COMPARATOR|2|Women receiving standard surgical skin staples
62826868|NCT05130528|NO_INTERVENTION|Usual Care|Infants randomly assigned to this arm will not receive any study intervention but will continue with any intervention in the community recommended by their health care team.
62044973|NCT06136390|PLACEBO_COMPARATOR|Placebo|The patients received a spray of placebo (24 I.U. Syntocinon®) in combination with mindfulness-based group therapy (MBGT) over 4 weeks once a week. Due to an effect latency of 30-80 mins after intranasal administration of oxytocin on social behavior, the dose was administered 45 min before the 50-min session.
62604396|NCT04240860|EXPERIMENTAL|platelet rich plasma preparation|"* About 15 ml of autologous blood from the patient was collected slowly in 20 ml syringe containing 1.5 ml anticoagulant citrate dextrose solution A (ACDA) under complete aseptic precautions.~  2- Blood was mixed by swinging the syringe slowly. 3- By using 18G needle, the gathered blood was transfused into tube maintaining a slope of 45°.~  4- The centrifugation step was then done by using non digital angle type centrifuge :the tube was put with water tube on the opposite side to achieve centrifuge balance.~  5- The centrifugation occurred in one step by power 3600 RPM for 6 minutes. 6- The buffy coat was elevated up to the buffy coat line (Figure 1). 7- the buffy coat (2-3 ml PRP) was extracted from slim neck by tornado technique so that sunk platelets can be floated and drawn easily.~  8- the remaining platelet poor plasma(PPP) was drawn using 5 cc syringe. then inserted by ovum pick up needle into subendometrium"
62604397|NCT04240860|ACTIVE_COMPARATOR|endometrial scratch|using scissor of hysteroscopr 3 snips was done in the fundus
62604398|NCT04191941|EXPERIMENTAL|Novel CAR-T|Novel CAR-T cells will be administered intravenously
62604399|NCT05356975|EXPERIMENTAL|Superset|This group will perform three strength circuit training. Each circuit training consists of three exercises (lower, middle, and upper body exercises) performed in a supersets fashion. This order makes it less complex, which is important given the characteristics of the population.
62604400|NCT05356975|ACTIVE_COMPARATOR|Concurrent|This group will perform six resistance exercises in a traditional fashion (three exercises for the lower body, three exercises for the upper body) and three aerobic exercises (floor tap squat, jumping jacks, and skaters).
62604401|NCT05220059|EXPERIMENTAL|Polyphenol extract low dose|156mg single dose
62604402|NCT05220059|EXPERIMENTAL|Polyphenol extract medium dose|222mg single dose
62604403|NCT05220059|EXPERIMENTAL|Polyphenol extract high dose|333mg single dose
62604404|NCT05220059|PLACEBO_COMPARATOR|Placebo|Maltodextrin single dose
62604405|NCT02947542|EXPERIMENTAL|BLK catheter|Coronary angiography will be performed with the BLK catheter (one-catheter concept).
62604406|NCT02947542|EXPERIMENTAL|Tiger catheter|Coronary angiography will be performed with the Tiger catheter (one-catheter concept).
62604407|NCT02947542|ACTIVE_COMPARATOR|Judkins catheter|Coronary angiography will be performed with the Judkins catheter (standard catheter).
62604408|NCT00698074|EXPERIMENTAL|1|Cardiac Resynchronisation Therapy
62604409|NCT03245697||Lactating mothers|Lactating mothers recruited in Galicia (NW Spain)
62604410|NCT02382796|EXPERIMENTAL|Dacomitinib|3 dose strengths (45 mg, 30 mg, and 15 mg), continuous oral daily dosing
62604411|NCT00401544|EXPERIMENTAL|Darbepoetin alfa 300 μg plus IV Iron|Darbepoetin alfa 300 μg subcutaneous injection plus intravenous (IV) iron 400 mg, every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
62604412|NCT00401544|EXPERIMENTAL|Darbepoetin alfa 300 μg|Darbepoetin alfa 300 μg subcutaneous injection every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
62604413|NCT00401544|EXPERIMENTAL|Darbepoetin alfa 500 μg|Darbepoetin alfa 500 μg subcutaneous injection every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
62604414|NCT00401544|ACTIVE_COMPARATOR|Darbepoetin alfa 500 μg plus IV Iron|Darbepoetin alfa 500 μg subcutaneous injection plus intravenous (IV) iron 400 mg, every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
62604415|NCT01833936|ACTIVE_COMPARATOR|Group 1- Compex® muscle stimulator|Group 1 will receive an active muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will use the stimulator for three 20 minute sessions per day.
62604416|NCT01833936|SHAM_COMPARATOR|Group 2 -(inactive) muscle stimulator|Group 2 will receive a placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
62604417|NCT03619551|EXPERIMENTAL|Low Dose Busulfan|"Busulfan based preparative regimen targeted at area-under-the-curve (cAUC) exposure of 25-35 mg\*h/L .~Randomization between the two dose levels will be done separately in each genotype stratum (RAG1/RAG2 and IL2RG/JAK3), using permuted blocks."
62604418|NCT03619551|EXPERIMENTAL|Medium Dose Busulfan|"Busulfan based preparative regimen targeted at area-under-the-curve (cAUC) exposure of 55-65 mg\*h/L.~Randomization between the two dose levels will be done separately in each genotype stratum (RAG1/RAG2 and IL2RG/JAK3), using permuted blocks."
62604419|NCT01777568|EXPERIMENTAL|30% oxygen|Inspired oxygen will be maintained at 30%.
62826869|NCT05130528|EXPERIMENTAL|Sensorimotor Intervention|Infants randomly assigned to this arm will participate in the sensorimotor intervention starting in the hospital and lasting for 6 months. This intervention includes 10 visits with a physical or occupational therapist and parent working together to advance an intervention program and 6 months of parent daily intervention. In addition, this arm will continue with any intervention in the community recommended by their health care team.
62044974|NCT00232492|PLACEBO_COMPARATOR|Placebo males|Saline physiological placebo males
62044975|NCT00232492|ACTIVE_COMPARATOR|Ketamine 0,1 mg/kg males|0,1 mg/kg ketamine males
62604420|NCT01777568|EXPERIMENTAL|80% oxygen|Inspired oxygen will be maintained at 80%.
62604421|NCT01471509|PLACEBO_COMPARATOR|Control|240 ml water
62826870|NCT02998463|EXPERIMENTAL|Snuby® users|This group receives the Snuby® skin-to-skin facilitating garment to use in the first six weeks following birth with their baby. The use of the Snuby® garment is participant led, and used for as long and as often as they wish in the six week period.
62044976|NCT00232492|ACTIVE_COMPARATOR|Ketamine 0,3 mg/kg males|0,3 mg/kg ketamine males
62044977|NCT00232492|ACTIVE_COMPARATOR|Ketamine 0,5 mg/kg males|0,5 mg/kg ketamine males
62044978|NCT00232492|PLACEBO_COMPARATOR|Placebo females|Saline physiological as placebo females
62044979|NCT00232492|ACTIVE_COMPARATOR|Ketamine 0.1 mg/kg females|0,1 mg/kg ketamine females
62044980|NCT00232492|ACTIVE_COMPARATOR|Ketamine 0,3 mg/kg females|0,3 mg/kg ketamine females
62044981|NCT00232492|ACTIVE_COMPARATOR|Ketamine 0,5 mg/kg females|0,5 mg/kg ketamine females
62044982|NCT04791982|EXPERIMENTAL|Experimental group|
62044983|NCT04791982|NO_INTERVENTION|Control group|
62604422|NCT01471509|ACTIVE_COMPARATOR|glucose|50 g glucose
62449230|NCT02573909|EXPERIMENTAL|Oxycodone epidurally|Oxycodone 0,1 mg/kg epidurally
62604423|NCT01471509|ACTIVE_COMPARATOR|Amino acid|1 mmol amino acid/kg lean body mass
62604424|NCT01471509|ACTIVE_COMPARATOR|amino acid plus glucose|50 g glucose plus 1 mmol amino acid/kg lean body mass
62604425|NCT02713438|EXPERIMENTAL|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
62604426|NCT02713438|EXPERIMENTAL|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad, the child. The parent is actively participating in forming plans by the child.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
62826871|NCT02998463|NO_INTERVENTION|Conventional Care|This group does not receive any intervention, and collects data on the research outcomes when having conventionally facilitated skin-to-skin contact, using a towel, blanket, or clothing as preferred. Skin-to-skin contact frequency and duration is dictated by the participant.
62826872|NCT01318577|EXPERIMENTAL|Investigational Solution|Hydrogen peroxide system for cleaning, protein removal, disinfecting and storing of contact lenses.
62826873|NCT01318577|ACTIVE_COMPARATOR|Clear Care Solution|Hydrogen peroxide system for cleaning, protein removal, disinfecting and storing of contact lenses
62044984|NCT01795430|EXPERIMENTAL|Treatment (radiation therapy/chemotherapy, stem cell infusion)|"BLOCK I: Patients receive etoposide IV over 1-2 hours and ifosfamide IV over 1 hour on days 1-5. Patients also undergo WB-MRI-guided intensity-modulated radiation therapy BID, 5 days a week, for approximately 4 weeks. Patients may also undergo 4 fractions of SRT QOD, 3-8 fractions of SBRT QOD, or 10 fractions of 3D RT daily to sites of metastatic disease.~BLOCK II: Patients receive high-dose chemotherapy comprising topotecan hydrochloride IV continuously over 24 hours on days -8 to -4, busulfan IV over 2 hours every 6 hours on days -8 to -4, and melphalan IV over 30 minutes on days -3 and -2. Patients undergo autologous peripheral blood or bone marrow stem cell infusion on day 0."
62044985|NCT02226913|EXPERIMENTAL|lidocaine & sodium bicarbonate|2% lidocaine with 1: 80,000 epinephrine buffered with 0.18 mL of 8.4% sodium bicarbonate
62044986|NCT02226913|ACTIVE_COMPARATOR|lidocaine & placebo|2% lidocaine with 1:80,000 epinephrine with 0.18 mL of sterile distilled water
62044987|NCT04052464||endometrium biopsy only|In these cases, only endometrium biopsy is investigated for the selected biomarkers gene expression profile.
62044988|NCT04052464||endometrium lavage followed by endometrium tissue biopsy|In these cases before the endometrium tissue biopsy, an endometrial lavage is performed and from both samples, the selected biomarkers gene expression profile are investigated.
62044989|NCT04052464||serial endometrium lavage followed by endometrium biopsy|In these cases before the endometrium tissue biopsy, at different days endometrial lavage samples are taken. From all samples, the selected biomarkers gene expression profile are investigated.
62247382|NCT05971862|EXPERIMENTAL|SKI-G-801(Denfivontinib) 100mg QD|Administered orally
62826874|NCT05127954|EXPERIMENTAL|Ubrogepant Dose A (12 to 17 Years Old)|Participants will receive oral tablets of ubrogepant Dose A for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, at least 2 hours after initial dose for headache of any intensity.
62826875|NCT05127954|EXPERIMENTAL|Ubrogepant Dose B (6 to 11 Years Old)|Participants will receive the highest dose of oral tablets of ubrogepant tested in Study 3110-305-002 for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, at least 2 hours after initial dose for headache of any intensity.
62826876|NCT05329948|EXPERIMENTAL|haptonomy application|The data will be obtained by applying a pre-test to the pregnant women and their spouses included in the experimental group before the application. After the pre-test data are collected, 5 sessions of haptonomy will be applied to the couples in the experimental group. Each session (Breath awareness and diaphragm breathing 5 minutes, Feminine energy attunement and heart-looking energy work 5 minutes, Physical communication with the baby in the womb with touches 10 minutes, meditation from the heart to the uterus 15 minutes, awareness of the environment, closing breath and feedback 5 minutes) It will be 40 minutes. For the effectiveness and continuity between each session, planning will be made for 3 days to 7 days. The final test will be applied 1 week after the hapatonomy application (after 5 sessions are completed).
62826877|NCT05329948|NO_INTERVENTION|Control|no application will be made
62826878|NCT05342155||Focus Group|For the focus group, the participant will be asked to review the potential platform the investigators are developing to better describe risks of health are developing to better describe risks of health issues in childhood cancer survivors. The focus group session will last approximately 2 hours.
62826879|NCT05342155||Campus and Home Assessments|"For the campus and home assessments, the participant will be engaged in the research activities over 108 weeks (approximately 2 years).~DatStat Connect app-Throughout participation in this research study, the participant will use a personal compatible device, such as smartphone or tablet, to report information about their health and respond to questionnaires using a website app called DatStat Connect.~The wrist monitor (Actigraph) and heart monitor (CorSense) will also transmit information to DatStat Connect. The wrist monitor and heart monitor will connect to a compatible personal device via Bluetooth.~The wrist monitor and heart CorSense device and St Jude Life study visit St Jude LIFE study visit: the participant will be asked to complete a St Jude LIFE research study assessment on the St Jude campus at three timepoints: initial visit (Week 0),approximately end of Year 1 (Week 60), and approximately end of Year 2 (Week 108)."
62826880|NCT05689372||Participants with type 2 diabetes|Participants will be treated with Ozempic (solution for injection 1.34 milligrams per milliliter \[mg/ml\] (Semaglutide subcutaneous \[s.c.\]) according to routine clinical practice conditions for 26 weeks. The physician will determine the dose of Ozempic in accordance with the Korean package insert (K-PI).
62826881|NCT04951921|EXPERIMENTAL|Hyperpolarized 13C pyruvate DNP-MRI scan|Patients receive hyperpolarized 13C pyruvate through IV injection less than 1-2 minute then undergo MRI over 3-5 minutes at baseline and 2 weeks after CCRT treatment. Total 2 times of MRI scan.
62826882|NCT00433173|PLACEBO_COMPARATOR|1|1) Group 1: Placebo
62826883|NCT00433173|ACTIVE_COMPARATOR|2|2) Group 2: Depot GnRH agonist (Zoladex) + Testosterone + placebo
62826884|NCT00433173|ACTIVE_COMPARATOR|3|3) Group 3: (Zoladex + Testosterone + aromatase inhibitor (anastrozole)
62826885|NCT06591000||Allograft tricuspid valve replacement|Patients underwent mitral allograft implantation for primary tricuspid valve disease
62826886|NCT06591000||Stented biological tricuspid valve replacement|Patients underwent biological stented valve replacement for primary tricuspid valve disease
62247383|NCT05971862|EXPERIMENTAL|SKI-G-801(Denfivontinib) 150mg QD|Administered orally
62247384|NCT05971862|EXPERIMENTAL|SKI-G-801(Denfivontinib) 225mg QD|Administered orally
62449231|NCT01386346|EXPERIMENTAL|All subjects|"Azacitidine Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.~Oxaliplatin on Day 1 130mg/m2 Epirubicin on Day 1 50mg/m2 Capecitabine 625 mg/m2"
62826887|NCT05030337|NO_INTERVENTION|Manual oxygen control|Standard ventilation with inspired oxygen concentration adjusted manually as per unit's protocol.
62826888|NCT05030337|OTHER|Closed-loop automated oxygen control|Ventilation with Oxygenie software (closed-loop automated oxygen control system), adjusted by clinical staff as necessary
62044990|NCT02953301|EXPERIMENTAL|resminostat|3 x 200 mg tablets p.o., 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
62044991|NCT02953301|PLACEBO_COMPARATOR|Placebo|3 tablets p.o. matching verum, 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
62044992|NCT03113474|EXPERIMENTAL|Palatable-neutral|Participants are exposed to palatable food in the first test session, and to the neutral food in the second test session.
62044993|NCT03113474|EXPERIMENTAL|Neutral-palatable|Participants are exposed to neutral food in the first test session, and to the palatable food in the second test session.
62247385|NCT05971862|EXPERIMENTAL|SKI-G-801(Denfivontinib) 300mg QD|Administered orally
62247386|NCT05971862|EXPERIMENTAL|SKI-G-801(Denfivontinib) 400mg QD|Administered orally
62247387|NCT05971862|EXPERIMENTAL|SKI-G-801(Denfivontinib) 500mg QD|Administered orally
62247388|NCT03526354|EXPERIMENTAL|Experimental|Brexpiprazole 4mg daily for 12 weeks
62247389|NCT03526354|ACTIVE_COMPARATOR|Treatment as Usual|Stay on current antipsychotic medication for 12 weeks
62826889|NCT04567628||TDM Cohort|Participants diagnosed with inflammatory bowel disease (IBD) (UC or CD) within Takeda Canada Patient Support Program (PSP) group who received treatment with vedolizumab 300 milligram (mg), infusion, intravenously, at Weeks 0, 2, and 6, and every 8 weeks thereafter as per product Health Canada Product Monograph, or every 4 or 6 weeks thereafter as per standard clinical practice between the year 2015 to 2020 along with the biomarker testing and TDM at pre-specified intervals during their treatment were observed retrospectively.
62826890|NCT04567628||Historical Cohort|Participants diagnosed with IBD (UC or CD) within Takeda Canada PSP group who received treatment with vedolizumab 300 mg, infusion, intravenously, at Weeks 0, 2, and 6, and every 8 weeks thereafter as per product Health Canada Product Monograph, or every 4 or 6 weeks thereafter as per standard clinical practice between the year 2015 to 2020 but did not undergo biomarker testing or TDM during their treatment were observed retrospectively.
62247390|NCT00411281|EXPERIMENTAL|Group I|Patients receive very low-dose cytarabine subcutaneously twice daily on days 1-7. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or complete or hepatic clinical remission undergo observation.
62826891|NCT05666739||healthy controls|General public population, including females and males, who are over the age of 18, with a mixture of races and ethnicities representative of North Carolina
62044994|NCT04830072|EXPERIMENTAL|AR group|Brief AWARD advice + active referral + leaflet + 3 months chat-based support with AR pictures
62044995|NCT04830072|ACTIVE_COMPARATOR|Control group|Brief AWARD advice + active referral + leaflet + 3 months chat-based support
62604427|NCT02713438|EXPERIMENTAL|Collaborative Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad (child and parent). Physical activity may be performed jointly by both persons in the dyad.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
62826892|NCT03043872|EXPERIMENTAL|Arm 1|durvalumab+tremelimumab+EP (carboplatin or cisplatin + etoposide)
62826893|NCT03043872|EXPERIMENTAL|Arm 2|durvalumab+EP (carboplatin or cisplatin + etoposide)
62826894|NCT03043872|ACTIVE_COMPARATOR|Arm 3|EP (carboplatin or cisplatin + etoposide)
62826895|NCT03059134|EXPERIMENTAL|Mirabegron 25mg for 12 weeks|Mirabegron 25mg once-daily for 4 weeks, and continue the same dose of mirabegron for another 8 weeks
62826896|NCT03059134|ACTIVE_COMPARATOR|Mirabegron 25mg followed by 50mg|Mirabegron 25mg once-daily for 4 weeks, and increase the dose to 50mg for another 8 weeks
62826897|NCT03059134|ACTIVE_COMPARATOR|Mirabegron 25mg followed by solifenacin|Mirabegron 25mg once-daily for 4 weeks, and shift to solifenacin 5mg for another 8 weeks
62826898|NCT03059134|ACTIVE_COMPARATOR|Mirabegron 25mg add-on solifenacin|Mirabegron 25mg once-daily for 4 weeks, and add-on solifenacin 5mg for another 8 weeks,
62826899|NCT02516137|EXPERIMENTAL|Dry needling group|Subjects with tight hamstrings will receive dry needling to the hamstrings with the needle inserted into the muscle tissue in addition to a standard hamstring stretching exercise program.
62826900|NCT02516137|SHAM_COMPARATOR|Sham dry needling group|Subjects with tight hamstrings will receive sham dry needling to the hamstrings with the needle inserted into the subcutaneous tissue in addition to a standard hamstring stretching exercise program.
62826901|NCT02516137|PLACEBO_COMPARATOR|No needling group|Subjects with tight hamstrings will receive no needling but have the tip of a blunt needle handle placed on the skin over the hamstrings in addition to a standard hamstring stretching exercise program.
62826902|NCT00101179|EXPERIMENTAL|Arm I|"Patients receive azacitidine subcutaneously on days 1-10 and oral MS-275 on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses\* of MS-275 until the maximum tolerated dose (MTD) is determined. Patients receive adjusted doses of azacitidine based on clinical response. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 9 additional patients are treated at the MTD."
62826903|NCT01550003|EXPERIMENTAL|Certolizumab Pegol|Active treatment with Certolizumab Pegol; dose adjustment is based on weight.
62826904|NCT05585905|EXPERIMENTAL|Virtual Reality|The virtual reality system being used for research purposes is the RelievRx by AppliedVR which is an immersive virtual reality device that includes a goggle headset and remote control. The VR experience will be an immersive experience where the child will interact with the system and navigate their way through a game that will involve bright colors, cartoon-like characters, and settings with age-appropriate content.
62826905|NCT05585905|ACTIVE_COMPARATOR|Basic Behavior Guidance Techniques|The control sample will include basic behavior guidance techniques and is standard of care. The use of basic behavior guidance techniques is common in pediatric dentistry and is not unique to this study.
62044996|NCT06347302|ACTIVE_COMPARATOR|Retinal detachment Group|
62044997|NCT06347302|PLACEBO_COMPARATOR|Control group|
62044998|NCT03603080|EXPERIMENTAL|Medication arm|
62044999|NCT03603080|NO_INTERVENTION|No medication arm|
62045000|NCT00550485|OTHER|1|Healthy subjects with a single nucleotide polymorphism (SNP) of the ABCB1-gene (Genotype A)
62045001|NCT00550485|OTHER|2|Healthy subjects with a single nucleotide polymorphism (SNP) of the ABCB1-gene (Genotype B)
62045002|NCT01799265|ACTIVE_COMPARATOR|Transcend followed by REMstar|The patient will receive treatment with Transcend during the first night sleep study, followed by treatment with the REMstar on the second night.
62045003|NCT01799265|ACTIVE_COMPARATOR|REMstar followed by Transcend|The patient will receive treatment with REMstar during the first night sleep study followed by treatment with Transcend on the second night.
62045004|NCT00845663|ACTIVE_COMPARATOR|Pre-filled Syringe|pre-filled syringe (reference)
62247391|NCT00411281|OTHER|Group II|Patients are observed. If symptoms of intermediate- or high-risk disease develop, patients may crossover to group I.
62045005|NCT00845663|EXPERIMENTAL|Auto-injection Device|Auto-injection device (test)
62045006|NCT00361140|EXPERIMENTAL|AUC 6000|"Busulfan AUC Level 1: 6000 +/- 600 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
62247392|NCT02101515|PLACEBO_COMPARATOR|Usual Labor|Immediate delivery after 3 hours with epidural or 2 hours without epidural
62604428|NCT02713438|ACTIVE_COMPARATOR|Education|The education group received extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participant, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
62045007|NCT00361140|EXPERIMENTAL|AUC 7500|"Busulfan AUC Level 2: 7500 +/- 750 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
62045008|NCT00361140|EXPERIMENTAL|AUC 9000|"AUC Level 3: 9000 +/- 900 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
62604429|NCT02637713|EXPERIMENTAL|Radiofrequency Energy to the Lower Esophageal Sphincter (LES)|All patients that have undergone sleeve gastrectomy as treatment for obesity that have developed severe reflux symptoms will be treated with Stretta (FDA approved device for the management of GERD) and evaluated prospectively for resolution/improvement of reflux symptoms.
62604430|NCT02222831|EXPERIMENTAL|Day 0 - Study arm|"Day 0 denudation and time lapse culture on IVF-oocytes.:~After insemination the oocytes will subsequently be denuded and cultured in the EmbryoScope (day 0).~The embryo culture media will be collected at day 2-5."
62604431|NCT02222831|NO_INTERVENTION|Day 1 - control arm|"After insemination oocytes in the control group will be incubated in a standard incubator overnight. On day 1 the oocytes in the will be denuded and further cultured in the EmbryoScope.~The embryo culture media will be collected at day 2-5."
62826906|NCT04267354|EXPERIMENTAL|Arm cycling|Participants will perform arm cycling using a table-top arm cycler. Cadence and resistance of the exercise will be determined as per each individual's tolerance. All exercise will be supervised by the neuromuscular specialist physio, to ensure it is completed safely. Participants will be able to have plenty of breaks during the assessments.
62826907|NCT06597318||multimorbid patients in general internal medicine divisions of all five Swiss university hospitals|
62604432|NCT02581228||Training Set|The objective of the Training stage is to assess the predictive potential of ML-PrediCare for melanoma patients' response to Ipilimumab, Pembrolizumab and Nivolumab.
62045009|NCT00107250|EXPERIMENTAL|AZD2171 + Standard chemotherpay regimens|
62045010|NCT04365582|EXPERIMENTAL|Azithromycin|Azithromycin
62045011|NCT04365582|EXPERIMENTAL|Hydroxychlororquine|Hydroxychlororquine
62045012|NCT04365582|EXPERIMENTAL|Lopinavir/Ritonavir|Lopinavir/Ritonavir
62045013|NCT04365582|NO_INTERVENTION|standards of care|SoC
62045014|NCT03750006|EXPERIMENTAL|HIIT intervention|Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
62045015|NCT05890443|EXPERIMENTAL|Group exercised via mobile application|Individuals aged 40 and over with COPD were included in the study, while individuals with communication, mental, neurological and cognitive problems and unable to exercise were excluded from the study. Among those who met the inclusion criteria, those who had a smart-phone were assigned to the experimental group.
62045016|NCT05890443|NO_INTERVENTION|The group not included in the exercises via the mobile application.|Individuals aged 40 and over with COPD were included in the study. The individuals with communication, mental, neurological and cognitive problems and unable to exercise were excluded from the study. Those who did not have a smart-phone were assigned to the control group.
62045017|NCT03498508||Healthcare professionals in Dalarna County Council|Healthcare professionals working in-hospital at the hospitals in Mora, Avesta and Falun, Sweden, n=1473.
62604433|NCT02581228||Validation Set|The objective of the Validation stage is to test the predictive power of ML -PrediCare in an independent set of patients diagnosed with melanoma.
62604434|NCT01871766|EXPERIMENTAL|Low-Risk, Subset 1|"Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin and cyclophosphamide). They are then evaluated to determine how the tumor responded to treatment. Twelve additional weeks of chemotherapy (vincristine and dactinomycin) is given, followed by evaluation for tumor response. No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.~Participants also receive \^1\^1C-methionine as described in the intervention section."
62826908|NCT02092610|ACTIVE_COMPARATOR|Standard Implant BI300|The product was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
62045018|NCT03498508||Healthcare professionals in Region Västmanland|Healthcare professionals working in-hospital at the hospital in Västerås, Region Västmanland, Sweden, n=1571.
62045019|NCT05439902|EXPERIMENTAL|Tamsulosin|
62045020|NCT05439902|PLACEBO_COMPARATOR|Placebo|
62623440|NCT01815502|EXPERIMENTAL|Dobutamine + Sildenafil|Sildenafil will be given an one time dose 30 to 90 minutes prior to cardiac catheterization. Sildenafil will be given at a dose 1 milligram per kilogram with a maximum of 20 milligrams. During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
62045021|NCT04592445|ACTIVE_COMPARATOR|Axon Treatment Arm|Subjects will receive treatment with the Satera Ablation System following administration of anesthesia access to the R GSN and ablation of the GSN at 1-2 levels will occur.
62045022|NCT04592445|SHAM_COMPARATOR|Sham Control Arm|Following administration of anesthesia subjects will have femoral vein access only. Procedure choreography to mimic procedure steps and length.
62247393|NCT02101515|EXPERIMENTAL|Extended|"Immediate delivery after 4 hours with an epidural or 3 hours without an epidural~Intervention: one additional hour for the second stage of labor~Length of second stage in extended arm is 3 hours without epidural and 4 hours with epidural."
62826909|NCT02092610|EXPERIMENTAL|Novel Implant BI300|The product was the novel titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
62826910|NCT06586853||Hemodialysis patients in Horus hospital|250 patients will be studied for complications and outcome of regular hemodialysis sessions in Horus hospital
62045023|NCT02923804|EXPERIMENTAL|Omega-3|3 capsules of 1g concentrated omega-3 taken daily for 6 months
62045024|NCT02923804|PLACEBO_COMPARATOR|Olive oil|3 capsules of 1g olive oil taken daily for 6 months
62045025|NCT04932629|EXPERIMENTAL|Experimental Group|The eligible patients will undergo corneal transplant surgery, when the central corneal epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration of 0.5x106 cells/µl diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma.
62045026|NCT00416182|EXPERIMENTAL|Pulmozyme|2.5 mg Pulmozyme (dornase alfa) delivered intranasally once daily
62045027|NCT00416182|PLACEBO_COMPARATOR|placebo|2.5 mg/2mL placebo administered intranasally once daily
62604435|NCT01871766|EXPERIMENTAL|Low-Risk, Subset 2|"Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated to determine how it responded to treatment. Radiation therapy and/or surgical resection is performed to destroy or remove the remaining tumor. Twelve additional weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is given, followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants then receive 16 weeks of additional chemotherapy (vincristine, dactinomycin and cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor will be given if needed.~Participants also receive \^1\^1C-methionine as described in the intervention section."
62247394|NCT05665491|EXPERIMENTAL|Interpretation bias manipulation|The primary component of the interpretation bias manipulation is the Word Sentence Association Paradigm (WSAP) delivered by the HabitWorks smartphone app. Users complete 50 trials in each exercise (approximately 5 min) and are prompted to complete 3 exercises per week (12 total over 4 weeks). The WSAP incorporates repetitive and quick practice, increasing individuals' awareness of their cognitive biases and shifting of their automatic responses.
62604436|NCT01871766|EXPERIMENTAL|Intermediate-Risk|"Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated for treatment response. Radiation therapy and/or surgical resection is done. Twelve weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants receive 16 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) followed by 12 weeks of maintenance treatment (bevacizumab, sorafenib, oral cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.~Participants also receive \^1\^1C-methionine as described in the intervention section."
62247395|NCT05665491|PLACEBO_COMPARATOR|Self-Assessment|Parents will complete the same repeated assessments, including EMA of parent behavior and weekly symptom surveys, but they will not complete the WSAP.
62247396|NCT03800290|EXPERIMENTAL|Clenbuterol hydrochloride|"Subjects will ingest clenbuterol hydrochloride capsules (20 microgram/each) twice daily (40 microgram/day) for a maximum of 14 days.~Subjects that received the clenbuterol hydrochloride capsules (at random) in the first study period will receive the placebo capsules during the second study period."
62247397|NCT03800290|PLACEBO_COMPARATOR|Placebos|"Subjects will ingest placebo capsules matching the clenbuterol hydrochloride capsules one time per day for a maximum of 14 days.~Subjects that received the placebo capsules (at random) in the first study period will receive the clenbuterol hydrochloride capsules during the second study period."
62623441|NCT01815502|PLACEBO_COMPARATOR|Dobutamine + placebo|Patients will be given a one time dose of sugar pill 30 to 90 minutes prior to cardiac catheterization.During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
62739091|NCT04834193|EXPERIMENTAL|WET-SUCTION|The stylet will be removed and the needle will be pre-flushed with 1-2mL of saline. The lesion will then be punctured, and suction will be applied using a 10-mL pre-vacuum syringe. The sample collected will be pushed into a formalin vial with saline.
62045028|NCT04616508|EXPERIMENTAL|Behavioral testing|
62247398|NCT03862365||Polyneuropathy with pain|Clinical and diagnostic test evaluation for the establishment of polyneuropathy with pain.
62247399|NCT03862365||Polyneuropathy without pain|Clinical and diagnostic test evaluation for the establishment of polyneuropathy without pain.
62045029|NCT05807243|EXPERIMENTAL|Group 1 (Traditional → Digital)|"Participants in both groups will be monitored for a month while following an hypocaloric diet for healthy weight-loss.~The first group (n=50) will start collecting data via questionnaires (traditional method) for the first two weeks, and switch to the digital data-collection method for the last two weeks."
62247400|NCT03862365||Diabetic polyneuropathy with pain|Clinical and diagnostic test evaluation for the establishment of diabetic polyneuropathy with pain.
62247401|NCT03862365||Diabetic polyneuropathy without pain|Clinical and diagnostic test evaluation for the establishment of diabetic polyneuropathy without pain.
62739092|NCT04834193|ACTIVE_COMPARATOR|SLOW-PULL|After puncturing the lesion, the stylet will be slowly and gradually withdrawn for at least 40cm. The sample will be pushed into formalin using the stylet.
62739093|NCT05331300|EXPERIMENTAL|LASN01 - Parts A and B [Healthy Volunteers]|Completed/Closed to enrollment
62739094|NCT05331300|PLACEBO_COMPARATOR|Placebo - Parts A and B [Healthy Volunteers]|Completed/Closed to enrollment
62739095|NCT05331300|EXPERIMENTAL|LASN01 - Part C [Pulmonary Fibrosis]|Closed to enrollment
62739096|NCT05331300|PLACEBO_COMPARATOR|Placebo - Part C [Pulmonary Fibrosis]|Closed to enrollment
62045030|NCT05807243|EXPERIMENTAL|Group 2 (Digital → Traditional)|"Participants in both groups will be monitored for a month while following an hypocaloric diet for healthy weight-loss.~The second group (n=50) will start with the digital data-collection method for the first two weeks and switch to the data collection via questionnaires (traditional method) for the last two weeks.~n=100)"
62604437|NCT01871766|EXPERIMENTAL|High-Risk|"Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 6 weeks (2 cycles) chemotherapy (vincristine and irinotecan). The tumor is evaluated for treatment response. 3 cycles of chemotherapy \[vincristine, doxorubicin, cyclophosphamide/ifosfamide, etoposide (or etoposide phosphate) (VDC/IE)\] are given. Dexrazoxane is given prior to each dose of doxorubicin. Radiation therapy begins at week 4 or 20 (depending on tumor location) while receiving vincristine and irinotecan. 2 cycles of VDC/IE, 4 cycles of modified vincristine, dactinomycin, cyclophosphamide (VAC), then 2 cycles of modified vincristine/irinotecan (total of 54 weeks). High risk participants also receive additional maintenance therapy beginning week 55 with anti-angiogenic chemotherapy (bevacizumab, sorafenib, cyclophosphamide). Myeloid growth factor is given as needed.~Participants also receive \^1\^1C-methionine as described in the intervention section."
62604438|NCT01765829|ACTIVE_COMPARATOR|Antipsychotic treatment|"Antipsychotic treatment according to common clinical practice~Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine, Pipotiazine, Flufenazine, Periciazine, Clozapine, Pimozide, Perfenazine, Sertindole, Levomepromazine, Amisulpride, Asenapine, Tiapride, Droperidol, Ziprasidone."
62604439|NCT01765829|EXPERIMENTAL|Discontinuation antipsychotic treatment|Dose reduction of antipsychotic treatment (25% every 4 weeks).
62604440|NCT03364517|EXPERIMENTAL|Experimental group SPIA|The regulator will be asked to systematically use the tool Predictor score of the imminence of a childbirth (SPIA). This tool is used to evaluate the means to be sent following a call for imminent delivery outside the hospital.
62604441|NCT03364517|NO_INTERVENTION|Control group|The classic care will be made according to the usual practices of the doctor and the center.
62604442|NCT05838950|EXPERIMENTAL|5s HIIT|5s HIIT group will perform one bout of sprint running for 5-seconds followed by 25-second, resting of total 40 repetition.
62604443|NCT05838950|EXPERIMENTAL|10s HIIT|10s HIIT group will perform one bout of sprint running for 10-seconds followed by 50-second, resting of total 20 repetition.
62247402|NCT03862365||Carpal tunnel syndrome with pain|Clinical and diagnostic test evaluation for the establishment of carpal tunnel syndrome with pain.
62247403|NCT03862365||Carpal tunnel syndrome without pain|Clinical and diagnostic test evaluation for the establishment of carpal tunnel syndrome without pain.
62045031|NCT05807243|NO_INTERVENTION|Group 3 - Young healthy population|n=100) Descriptive part: Data capture (clinical, anthropometric, lifestyle, genetic, biochemical, metabolomic and lipidomic data, among others) and comparison with the other groups.
62247404|NCT05986513|ACTIVE_COMPARATOR|OA-PF|Individuals with knee OA without knee or bodily pain. All participants will complete the same study protocol with pre- post-perturbation MRI scans and pain assessment questionnaires, as well as breath samples collected at multiple time points during the study visit.
62604444|NCT05838950|EXPERIMENTAL|20s HIIT|20s HIIT group will perform one bout of sprint running for 20-seconds followed by 100-second, resting of total 10 repetition.
62604445|NCT05838950|EXPERIMENTAL|Control|Control group
62604446|NCT06226792||Ankylosing Spondylitis|"Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), Rivermead Mobility Index (RMI) will be evaluated.~Vastus Lateralis, Tibialis Anterior, Lateral Gastrocnemius and Medial Gastrocnemius ultrasonography will be performed to evaluate muscle thickness, pennation angle and fascicle length.~Isometric knee extension, isometric ankle dorsiflexion and isometric ankle plantar flexion strength will be evaluated with hand held dynamometer."
62739097|NCT05331300|EXPERIMENTAL|LASN01 - Part D [Thyroid Eye Disease]|Closed to enrollment
62739098|NCT05331300|PLACEBO_COMPARATOR|Placebo - Part D [Thyroid Eye Disease]|Closed to enrollment
62739099|NCT00763295||HIV infection|
62604447|NCT06226792||Volunteers|"Voluntary participants will be admitted to this group. Vastus Lateralis, Tibialis Anterior, Lateral Gastrocnemius and Medial Gastrocnemius ultrasonography will be performed to evaluate muscle thickness, pennation angle and fascicle length.~Isometric knee extension, isometric ankle dorsiflexion and isometric ankle plantar flexion strength will be evaluated with hand held dynamometer."
62604448|NCT03001505||Patients with pancreatic cancer|Patients diagnosed with pancreatic cancer evaluated at this institution.
62247405|NCT05986513|EXPERIMENTAL|OA-Knee|Individuals with knee OA with localized knee pain. All participants will complete the same study protocol with pre- post-perturbation MRI scans and pain assessment questionnaires, as well as breath samples collected at multiple time points during the study visit.
62247406|NCT05986513|EXPERIMENTAL|OA-Knee+Body|Individuals with knee OA with localized knee pain and widespread bodily pain. All participants will complete the same study protocol with pre- post-perturbation MRI scans and pain assessment questionnaires, as well as breath samples collected at multiple time points during the study visit.
62604449|NCT01289249||Children receiving meropenem|Children aged from 3 months to 18 years that receive treatment with meropenem.
62826911|NCT06586853||Hemodialysis patients in Isis hospital|50 patients will be studied for complications and outcome of regular hemodialysis sessions in Isis hospital
62045032|NCT05807243|NO_INTERVENTION|Group 4 - Senior population|n=100) Descriptive part: Data capture (clinical, anthropometric, lifestyle, genetic, biochemical, metabolomic and lipidomic data, among others) and comparison with the other groups.
62247407|NCT06085027|EXPERIMENTAL|The Epifaith® syringe|
62247408|NCT06085027|ACTIVE_COMPARATOR|The plastic syringe|
62604450|NCT04423627|EXPERIMENTAL|Clonidine|0.2 mg/day oral
62604451|NCT04423627|ACTIVE_COMPARATOR|Hydrochlorothiazide|37.5 mg/day oral
62604452|NCT04423627|PLACEBO_COMPARATOR|Placebo|Placebo
62604453|NCT03787303|EXPERIMENTAL|Triiodothyronine (T3)|Following discontinuation of L-thyroxine (T4), triiodothyronine (T3) will be initiated at a 3:1 ratio. The dose will be titrated by the investigator to maintain levels of free T4 \< 50% of normal range while maintaining a euthyroid state. Triiodothyronine (T3) tablets for oral administration will be prescribed once or twice daily depending on the total dose. Treatment duration will be approximately 9 months during which time the subjects will continue to be treated and monitored as usual for their metastatic breast cancer. During the study period and at the conclusion of the study period, there will be continuous evaluations of the disease status and thyroid status with the option of resuming the original thyroid replacement or continuation of the triiodothyronine (T3).
62739100|NCT01766297|EXPERIMENTAL|Proton Radiotherapy|Proton Radiotherapy 4.0 Gy (RBE) x10 fractions to 40 Gy (RBE) Total Dose
62826912|NCT04953858|OTHER|Social Network Strategy|All study participants will receive social network strategy intervention as linkage method to receive HIV testing and care
62826913|NCT03377608||Depo-Provera|
62045033|NCT05807243|NO_INTERVENTION|Group 5 - Oncological population|(n=100) Descriptive part: Data capture (clinical, anthropometric, lifestyle, genetic, biochemical, metabolomic and lipidomic data, among others) and comparison with the other groups.
62247409|NCT05000541||Armolipid-L/Armolipid Plus-L|Armolipid-L used for participants in Germany and Poland Armolipid Plus-L used for participants in Austria
62247410|NCT00814567|ACTIVE_COMPARATOR|Arm I (control)|Patients undergo standard whole breast radiotherapy once daily on days 1-5 for 3 weeks.
62247411|NCT00814567|EXPERIMENTAL|Arm II|Patients undergo reduced whole breast radiotherapy and standard partial breast radiotherapy once daily on days 1-5 for 3 weeks.
62247412|NCT00814567|EXPERIMENTAL|Arm III|Patients undergo standard partial breast radiotherapy once daily on days 1-5 for 3 weeks.
62739101|NCT01147250|PLACEBO_COMPARATOR|Placebo|Placebo matched to lixisenatide once daily (QD) up to end of treatment.
62739102|NCT01147250|EXPERIMENTAL|Lixisenatide|Lixisenatide 10 mcg QD for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to end of treatment.
62739103|NCT02951403|EXPERIMENTAL|Operative treatment|Patients to whom the elbow arthroscopy will be performed.
62739104|NCT02951403|OTHER|Conservative treatment|Patients to whom special physiotherapy will be advised.
62739105|NCT05619094|EXPERIMENTAL|Corrective Exercise|Selective corrective exercise program, 8 weeks
62739106|NCT05619094|NO_INTERVENTION|Control|Training for proper posture
62045034|NCT05807243|NO_INTERVENTION|Group 6 - COVID-19 population|(n=100) patients who developed severe forms of COVID-19 or persistent COVID-19. Descriptive part: Data capture (clinical, anthropometric, lifestyle, genetic, biochemical, metabolomic and lipidomic data, among others) and comparison with the other groups.
62045035|NCT02605629|EXPERIMENTAL|CG428|Patients will self-administer the study product twice per day (morning, evening) for 6 months, for the efficacy assessment
62045036|NCT02605629|PLACEBO_COMPARATOR|Placebo|Patients will self-administer the study placebo twice per day (morning, evening) for 6 months, for the efficacy assessment
62045037|NCT04231708|PLACEBO_COMPARATOR|placebo stressor, sham rTMS|Placebo stressor (lactose) + sham (inactive) rTMS over the left dlPFC
62045038|NCT04231708|EXPERIMENTAL|placebo stressor, active rTMS|Placebo stressor (lactose) + active 10Hz rTMS over the left dlPFC
62045039|NCT04231708|EXPERIMENTAL|active stressor, sham rTMS|Stressor (yohimbine 54mg + hydrocortisone 20mg) + sham (inactive) rTMS over the left dlPFC
62045040|NCT04231708|EXPERIMENTAL|active stressor, active rTMS|Stressor (yohimbine 54mg + hydrocortisone 20mg) + active 10Hz rTMS over the left dlPFC
62045041|NCT03993548|EXPERIMENTAL|Wellness Intervention|KickStart30 is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
62045042|NCT05030948|EXPERIMENTAL|Tiempo Juntos Intervention|"If assigned to this group, participants will take part in weekly 1-hour group sessions twice a week for 3 months. The sessions will be with a trained Community Health Worker that will involve group (5-6 participants) moderate-intensity walking. They will take place at community partner sites during times when all participants can attend. In case of adverse weather, indoor locations are available through community partners. Walks will reflect participant goals and abilities, initially lasting 10 minutes, with 5-minute stretching warm-up and 5-minute cool down exercises, for a total of 20 minutes. Walk duration will increase by 5 minutes/week to at least 30 minutes with program content delivery time decreasing to accommodate increased walk times within the 1-hour session. Upon completing the 3 months of physical activity sessions, for the next 3 months, they will receive motivational booster sessions delivered every other week via phone calls/text messaging."
62045043|NCT05030948|NO_INTERVENTION|Attention Control|"If assigned to this group, participants will take part in 1-hour group (5-6 participants) sessions delivered twice a week for 3 months. The sessions will be with a trained Community Health Worker or qualified staff that will involve reviewing education topics in Spanish related to adult health. They will take place at community partner sites or remotely during times when all participants can attend. In case of adverse weather, indoor locations, or remote options will be available. Upon completing the 3 months of education sessions, for the next 3 months, they will receive educational booster sessions delivered every other week via phone calls/text messaging."
62045044|NCT01877408|ACTIVE_COMPARATOR|Open surgical circumcision|The open surgical technique, which is commonly used for circumcision in South Africa, requires good surgical skills and minor complications are common.
62045045|NCT01877408|EXPERIMENTAL|Unicirc device with tissue adhesive|Coupling removal of the foreskin using the disposable Unicirc device with wound sealing using tissue adhesive results in a procedure that can be performed by generalist doctors with minimal training.
62826914|NCT03377608||Non-hormonal contraception|
62826915|NCT05222334|EXPERIMENTAL|Intrafascial interscalene brachial plexus block group|The patients will receive 10 ml of 0.5% bupivacaine for intrafascial interscalene brachial plexus block group
62826916|NCT05222334|EXPERIMENTAL|Extrafascial interscalene brachial plexus block group|The patients will receive 10 ml of 0.5% bupivacaine for extrafascial interscalene brachial plexus block group
62826917|NCT03708900|EXPERIMENTAL|LCI699 (osilodrostat)|Subjects with cushing's disease taking LCI699 (osilodrostat)
62826918|NCT06594003|ACTIVE_COMPARATOR|three genicular nerves raiofrequency ablation|
62826919|NCT06594003|ACTIVE_COMPARATOR|eight genicular nerves radiofrequency ablation|
62826920|NCT03013998|EXPERIMENTAL|BAML-16-001-S1 (Closed)|This is an open-label Phase 1b/2 clinical study of Samalizumab given in addition to standard induction chemotherapy/consolidation, followed by Samalizumab maintenance, in newly diagnosed acute myeloid leukemia. Patients that are marker negative, as defined based on the Beat AML Master Protocol assignment or with CBF karyotype/interphase cytogenetics/molecular testing defined by presence of t(8;21)(q22;q22) or the molecular equivalent RUNX1/RUNX1T1 fusion transcript or inv(16)(p13q22) or t(16;16)(p13;q22) or the molecular equivalent CBFB/MYH11 fusion transcript based on the Beat AML will receive Samalizumab in combination with induction therapy followed by Samalizumab maintenance.
62826921|NCT03013998|EXPERIMENTAL|BAML-16-001-S2 (Closed)|"This is an open-label Phase 1b/2 clinical study of BI 836858 given in combination with azacitidine, followed by BI 836858 plus azacitidine maintenance, in newly diagnosed acute myeloid leukemia. The target population is assigned by the Beat AML Master Protocol (the umbrella study). Eligible patients will have previously untreated acute myeloid leukemia, age greater than or equal to 60, with any 1 of the following: mutated TET2, IDH1, IDH2, or WT1, or marker negative as defined by the overall Beat AML umbrella protocol."
62826922|NCT03013998|EXPERIMENTAL|BAML-16-001-S3 (Closed)|This is a phase 2 clinical trial to assess the feasibility and efficacy of a stepwise approach to the treatment of IDH2-mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH2 inhibitor AG-221 for IDH2 R140 and R172-mutant patients. The dosing will be based on phase 1 experience of AG-221, which has established 100 mg daily as a safe and tolerated dose, with preliminary suggestion of efficacy. These will be administered continuously in 28 day cycles. Hydroxyurea will be allowed for the purposes of cytoreduction.
62826923|NCT03013998|EXPERIMENTAL|BAML-16-001-S4 (Closed)|This is a 2 cohort phase 1b/2 clinical trial to assess the feasibility and efficacy of entospletinib (ENTO) stepwise approach to the treatment of patients with balanced translocations of MLL identified cytogenetically (Cohort 1) and patients with MLL-partial tandem duplications identified molecularly (Cohort 2). All enrolled participants will be initiated on monotherapy with ENTO 400 mg PO BID. This dose will be administered continuously in 28 day cycles.
62045046|NCT02329054|EXPERIMENTAL|Favipiravir|Favipiravir (oral administration, 200 mg light yellow, round-shaped, coated divisible tablets that can be crushed and mixed with liquid)
62247413|NCT05426642|EXPERIMENTAL|Intervention group|Receive the e-health video and brochure as the intervention
62247414|NCT05426642|OTHER|Control group|Receive brochure as the intervention
62604454|NCT06253741|ACTIVE_COMPARATOR|PARAVERTEBRAL BLOCK|After induction of general anesthesia and endotracheal intubation in the operating room, following the positioning of the patient for surgery, ultrasound-guided paravertebral block (PVB) will be routinely performed in our clinic using 0.25% bupivacaine solution at a dose of 0.5 ml/kg.
62604455|NCT06253741|ACTIVE_COMPARATOR|RHOMBOID INTERCOSTAL AND SUBSERRATUS PLANE BLOCK|After induction of general anesthesia and endotracheal intubation in the operating room, following the positioning of the patient for surgery, rhomboid intercostal block with sub-serratus plane block (RISS) will be routinely performed in our clinic using 0.25% bupivacaine solution at a dose of 0.5 ml/kg under ultrasound guidance.
62604456|NCT06253741|PLACEBO_COMPARATOR|PLACEBO|The group without any peripheral block application will be included
62045047|NCT00789087|ACTIVE_COMPARATOR|1. Videothoracoscopic talc poudrage (VT)|
62247415|NCT05871255||Genitourinary syndrome of menopause (GSM) patients|Patients will apply the vaginal gel (ZG) for a total of 150 days of treatment. The application was daily for the first 12 days, then every 48 hours until the end of the study. Patients will be examined at baseline (T0), after 12 (T1), 57 (T2) and 150 (T3) days of treatment. Examination will include (1) Filling of a Female Sexual Distress Scale (FSDS) questionnaire and (2) Gynecology examination with colposcopy and pH test to evaluate vaginal elasticity, vaginal secretions, pH, mucosal epithelium, and vaginal hydration to calculate the Vaginal Health Index (VHI).
62247416|NCT02771314|EXPERIMENTAL|AZD9291|AZD9291
62247417|NCT02410655|ACTIVE_COMPARATOR|Conventional standard of care|Traditional administration of oxytocin at Lutheran Medical Center involves the use of two 20 IU / 1000 mL bags hung sequentially at a flow rate of 125 mL / hour each after the delivery of the anterior shoulder. This will total no more than 16 hours.
62247418|NCT02410655|ACTIVE_COMPARATOR|Evidence based protocol|The proposed evidence based protocol involves utilizing a single 30IU / 500mL bag of oxytocin. After the delivery of the anterior shoulder, an initial rapid infusion bolus of 50mL of the 30IU / 500mL at 999mL / hour. Three minutes after rapid infusion, uterine tone should be assessed. If inadequate uterine tone persists, a second rapid infusion at the same dose and rate as above should be given. If inadequate uterine tone persists, a third rapid infusion may be given. If adequate uterine tone is achieved after any rapid infusion, the remainder of the bag should be administered at a rate of 100mL / hour until finished. If adequate tone is not achieved, the remainder of the bag should be administered at 100mL / hour and additional uterotonic agents should be considered.
62247419|NCT03635814|EXPERIMENTAL|YD312 drug treatment|From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
62247420|NCT03635814|PLACEBO_COMPARATOR|YD312 placebo drug treatment|From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
62247421|NCT04039854|ACTIVE_COMPARATOR|Volatile anaesthetics arm|Patients randomised to receive volatile anaesthetics will receive either isoflurane, sevoflurane or desflurane during the surgical procedure.
62247422|NCT04039854|ACTIVE_COMPARATOR|Propofol anaesthetics arm|Patients randomised to receive propofol will not receive any volatile anaesthetics during the surgical procedure.
62247423|NCT04992325||Patients with type 2 diabetes mellitus|The patients with previous diagnosis of type 2 diabetes mellitus, without signs of diabetic retinopathy
62247424|NCT04992325||Healthy subjects|Healthy subjects without actual and previous ocular diseases
62045048|NCT00789087|ACTIVE_COMPARATOR|2. Talc slurry through a chest tube (DT)|
62045049|NCT01245010|EXPERIMENTAL|Water|Water and education provision
62045050|NCT01245010|ACTIVE_COMPARATOR|Control|Education only
62045051|NCT05321719|EXPERIMENTAL|Experimental: BeReady2Smile Video, App, & Coach|This arm will test the feasibility of the BeReady2Smile Video and App to promote dental health of young children with a parent education program.
62045052|NCT05321719|EXPERIMENTAL|Assess the Contributions of BRS2 Components|Outcomes of video, app, and coach
62045053|NCT01263834|ACTIVE_COMPARATOR|Mitomycin c|Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
62045054|NCT01263834|EXPERIMENTAL|Bevacizumab|Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
62045055|NCT03102723|EXPERIMENTAL|Cangrelor|Cangrelor (single intravenous bolus followed by a 120-minute infusion) initiated prior to PPCI.
62045056|NCT03102723|PLACEBO_COMPARATOR|Placebo|Matching normal saline placebo (single intravenous bolus followed by a 120-minute infusion) initiated prior to PPCI.
62045057|NCT04745481|EXPERIMENTAL|Trunk stabilization training device|Participants will receive conventional rehabilitation and use trunk stabilization training device 30min each daily, 20 times for 4weeks.
62045058|NCT04745481|ACTIVE_COMPARATOR|Conventional rehabilitation|Participants will receive conventional rehabilitation 60min daily, 20times for 4weeks.
62045059|NCT05933031|EXPERIMENTAL|Tegoprazan 50 mg|Tegoprazan 50 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
62045060|NCT05933031|EXPERIMENTAL|Tegoprazan 100 mg|Tegoprazan 100 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
62045061|NCT05933031|ACTIVE_COMPARATOR|Lansoprazole|Lansoprazolee/Clarithromycin/ Amoxicillin BID peroral, 14 days
62045062|NCT06246604|EXPERIMENTAL|Screening|"Patients will receive an ultrasound screening for DVT between 48 to 96 hours after the admission to the intensive care. In case of negative ultrasound:~* if the pharmacological thromboprophylaxis is NOT possible, ultrasound is repeated after 48-96 hours;~* if the pharmacological thromboprophylaxis is possible, re-evaluation is warrant only in case of clinical changes.~In case of positive ultrasound:~* if the DVT is proximal, it must be treated according to guidelines. Re-evaluation is warranted only in case of clinical changes;~* if the DVT is distal and a full or intermediate anti-thrombotic treatment is possible, re-evaluation is warrant only in case of clinical changes;~* if the DVT is distal and a full or intermediate anti-thrombotic treatment is NOT possible, the ultrasound is repeated after 48-96 hours."
62045063|NCT06246604|ACTIVE_COMPARATOR|Standard-of-care|Ultrasound examination are performed according to clinical risk of DVT
62045064|NCT01826227|EXPERIMENTAL|Positron Emission Tomography|This is a pilot study to determine the ability of intraoperative PET probe to detect and localize recurrent disease. Patients with evidence for a first recurrence of ovarian, fallopian tube or primary peritoneal carcinoma, with evidence of 18F-FDG avid disease on 18F-FDG PET/CT and who are able to undergo secondary CRS are eligible. 20 patients will be studied. All patients will undergo secondary cytoreduction guided by intraoperative PET probe survey. Intraoperative count levels as well as exvivo counts of the resected specimens will be done. Specimens detected with probe only will be labeled so and will be submitted to pathology for histopathologic confirmation.
62045065|NCT02577666|EXPERIMENTAL|Ecologically-Based Therapy + TAU|receives Ecologically-Based Therapy which includes the Community Reinforcement Approach, Strengths-Based Case Management (6 months) and rental assistance for housing (3 months) + TAU
62045066|NCT02577666|EXPERIMENTAL|Housing Only + TAU|receives 3 months of rental assistance for housing only + TAU
62045067|NCT02577666|OTHER|treatment as usual (TAU)|receives usual treatments/interventions (TAU) within in the community
62247425|NCT03452514||Cohort 1 - Low Dose CT (LDCT) Scan|Individuals undergoing their first or subsequent annual LDCT screening study
62247426|NCT03452514||Cohort 2 - Diagnostic CT Scan|Individuals referred for a follow-up diagnostic chest CT scan due to a lung-RADS category 3 or 4 result on a previous LDCT scan
62826924|NCT03013998|EXPERIMENTAL|BAML-16-001-S5 (Closed)|This is a phase 2 clinical trial to assess the feasibility and efficacy of a stepwise approach to the treatment of patients with TP53 mutations (identified molecularly) with/without complex karyotype (Cohort A) or complex karyotype (3 or greater metaphase abnormalities without TP53) (Cohort B). All enrolled participants will be initiated on entospletinib 400 mg orally twice daily. This dose will be administered continuously in 28 day cycles.
62045068|NCT03683147|EXPERIMENTAL|Control (online sessions, content manual, CD after 6 weeks)|Participants randomized to the wait-list control condition complete the online intervention as in the intervention arm after the initial 6-week period has ended.
62045069|NCT03683147|EXPERIMENTAL|Intervention (online sessions, content manual, relaxation CD)|Participants receive online group sessions over 60 minutes for 6 weeks, including 15 minutes of practice on that session's topic and daily meditation or yoga for 45 minutes. At the conclusion of the study period participants participate in mindfulness meditation over 3 hours. Participants also receive a content manual and relaxation CD.
62437633|NCT04106596||Patients with antibodies against GAD|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
62045070|NCT03284788|EXPERIMENTAL|ABT Weight Loss Intervention|Adolescent girls will attend healthy lifestyle sessions that include nutritional education and physical activity education and build skills in the areas of values clarification, mindfulness, self-regulation skills, acceptance of uncomfortable states, goal-setting, problem solving, and self-monitoring.
62437634|NCT01577537|EXPERIMENTAL|VivaGel|
62437635|NCT01577537|PLACEBO_COMPARATOR|HEC Placebo|
62437636|NCT04450290|EXPERIMENTAL|single arm - treatment|All subjects will be implanted with the investigational device.
62437637|NCT00811200|ACTIVE_COMPARATOR|1: Lucentis|
62437638|NCT00811200|ACTIVE_COMPARATOR|2: Kenalog|
62437639|NCT00811200|SHAM_COMPARATOR|3: No treatment|
62604457|NCT01741506|EXPERIMENTAL|Dalteparin (Fragmin®)|Dalteparin (Fragmin®) 5000 IU (International Unit) once daily
62045071|NCT05257772|ACTIVE_COMPARATOR|Optimum Right Ventricular Pacing On|AV Delay Optimised RV Pacing. Subjects will remain in this arm for 3 months before being crossed-over.
62045072|NCT05257772|NO_INTERVENTION|Optimum Right Ventricular Pacing Off|Subjects will remain in this arm for 3 months before being crossed-over. The pacemaker will be programmed to minimum ventricular pacing \& dynamic AV delay will be programmed off.
62045073|NCT01057238|EXPERIMENTAL|Intensive Communication|regular family meeting every 5 days.
62045074|NCT01057238|NO_INTERVENTION|Control|usual care
62045075|NCT04640532|EXPERIMENTAL|Cohort 1 (R/R MF), Dose Level 1|"TL-895 at 200 mg once a day (QD) continuously starting on Cycle 1 Day 1 in a 28-day cycle.~KRT-232 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
62045076|NCT04640532|EXPERIMENTAL|Cohort 1 (R/R MF), Dose Level 2|"TL-895 at 300 mg once a day (QD) continuously starting on Cycle 1 Day 1 in a 28-day cycle.~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
62437640|NCT06440811|ACTIVE_COMPARATOR|FLOT+PD-1 antibody|Patients in the FLOT group received 4 cycles of standard FLOT chemotherapy, the FLOT chemotherapy cycle consists of: day 1: intravenous 5-FU 2600 mg/m² inserted through a peripherally inserted central catheter (PICC) for 24 hours intravenous folic acid 200 mg/m2 intravenous OXA 85 mg/m² intravenous TXT 50 mg/m². The next cycle of chemotherapy was repeated on day 15. PD-1 antibody: 360 mg every 3 weeks.
62437641|NCT06440811|EXPERIMENTAL|SOX+PD-1 antibody|Patients in the SOX group received 3 cycles of S-1 + OXA chemotherapy prior to radical gastrectomy.The SOX chemotherapy cycle consists of: day 1: intravenous OXA 130 mg/m² days 1-14: oral S-1 80 mg/m², 2 times/Day. Repeat next chemotherapy on day 22. PD-1 antibody: 360 mg every 3 weeks.
62437642|NCT00583596|EXPERIMENTAL|implant to close PDA|
62604458|NCT01741506|NO_INTERVENTION|No treatment|No treatment
62437643|NCT00563303|EXPERIMENTAL|H|Hydrocortisone
62437644|NCT00563303|PLACEBO_COMPARATOR|P|Treatment by NaCl (placebo)
62437645|NCT05357560|EXPERIMENTAL|Group 1 - Infants R21 delayed 3rd dose|11 volunteers (infant 5-17 months) given 50 µg of Matrix-M in combination with 5µg R21 at months 0, 1 and 6 via intramuscular (IM) injection in the anterolateral thigh
62437646|NCT05357560|EXPERIMENTAL|Group 2 - Infants R21 standard regimen|11 volunteers (infant 5-17 months) given 50 µg of Matrix-M in combination with 5µg R21 at months 0, 1 and 2 via intramuscular (IM) injection in the anterolateral thigh
62604459|NCT01741506|OTHER|Open surgery arm|Dalteparin (Fragmin®) 5000 IU once daily
62437647|NCT05357560|EXPERIMENTAL|Group 3 - Adults RH5.2 low dose, standard regimen|10 volunteers (adult 18-45 years) given 50 µg of Matrix-M in combination with 10µg RH5.2 VLP at months 0, 1 and 2 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
62437648|NCT05357560|EXPERIMENTAL|Group 4 - Adults RH5.2 high dose, standard regimen|10 volunteers (adult 18-45 years) given 50 µg of Matrix-M in combination with 50µg RH5.2 VLP at months 0, 1 and 2 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
62437649|NCT05357560|EXPERIMENTAL|Group 5 - Adults RH5.2 and R21 low dose, standard regimen|10 volunteers (adult 18-45 years) given 50 µg of Matrix-M in combination with 10µg RH5.2 VLP and 10µg R21 at months 0, 1 and 2 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
62437650|NCT05357560|EXPERIMENTAL|Group 6 - Infants RH5.2 standard regimen|11 volunteers (infant 5-17 months) given 50µg of Matrix-M in combination with 5µg RH5.2 VLP at months 0, 1 and 2 via intramuscular (IM) injection in the anterolateral thigh
62437651|NCT05357560|EXPERIMENTAL|Group 7 - Infants RH5.2, delayed 3rd dose|11 volunteers (infant 5-17 months) given 50µg of Matrix-M in combination with 5µg RH5.2 VLP at months 0, 1 and 6 via intramuscular (IM) injection in the anterolateral thigh
62604460|NCT04861116|EXPERIMENTAL|Intervention program for test anxiety|12 weekly ICT-delivered individual sessions.
62826925|NCT03013998|EXPERIMENTAL|BAML-16-001-S6 (Closed)|The study is an open-label phase 2 study of entospletinib in younger and older AML patients with NPM1+/FLT3ITD-AML. It includes patients age ≥18 years who are able and willing to receive 7 + 3 intensive chemotherapy. Entospletinib is administered daily with IV daunorubicin (days 1-3 for Cycle 1) and cytarabine (days 1-7 for Cycle 1). If a second induction is required, it is given with IV daunorubicin (days 1-2 for Cycle 2) and cytarabine (days 1-5 for Cycle 2).
62826926|NCT03013998|EXPERIMENTAL|BAML-16-001-S9 (Closed)|This is an open-label phase 2 clinical trial of a stepwise approach to the treatment of patients with TP53 mutation AML. On day 1, all enrolled participants will be initiated on therapy with pevonedistat (20 mg/m2) day 1, 3 and 5 together with azacitidine (75 mg/m2 days 1-7 or day 1-5 then day 8, 9) every 28 days. During cycle 1, patients with rapidly progressive disease or severe organ dysfunction, not correctable by hydroxyurea cytoreduction will not be eligible to continue. Those patients who achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 4 will continue on pevonedistat and azacitidine until disease progression, unacceptable toxicity, or 12 cycles of therapy. After 12 months of combined therapy, pevonedistat will be continued until progression of disease, unacceptable toxicity, or up to 2 years of total therapy.
62826927|NCT03013998|EXPERIMENTAL|BAML-16-001-S16 (Closed)|This is an open-label phase 2 clinical study to assess the feasibility and efficacy of a combination based approach to the treatment of IDH1 mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH1 inhibitor AG-120 given daily together with azacitidine (days 1-5 and 8-9 or 7 consecutive days 1-7) in 28 day cycles for IDH1 mutant patients. Those patients who have achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 6, will continue on combination therapy for a total of 12 cycles and then patients will go onto receive monotherapy with AG-120 until disease progression or unacceptable side effects that mandate discontinuation of therapy. Patients who cannot complete 12 cycles of azacitidine may proceed onto monotherapy with AG-120.
62826928|NCT03013998|EXPERIMENTAL|BAML-16-001-S8 (Closed)|This is an open-label Phase 1b/2 clinical study of gilteritinib monotherapy, gilteritinib in combination with decitabine, or gilteritinib in combination with decitabine and venetoclax in untreated FLT3 mutated AML with high and low variant allele frequency. Initially, the combination of gilteritinib and decitabine was tested (Group 1); however, subsequently the combination of decitabine and venetoclax was shown to be a highly effective therapy for older AML patients, so the triple combination of gilteritinib in combination with decitabine and venetoclax (Group 2) is now being evaluated in this study.
62045077|NCT04640532|EXPERIMENTAL|Cohort 2 (R/R MF), Dose Level 1|"TL-895 at 100 mg twice a day (BID) continuously starting on Cycle 1 Day 1 in a 28-day cycle.~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
62045078|NCT04640532|EXPERIMENTAL|Cohort 2 (R/R MF), Dose Level 2|"TL-895 at 150 mg twice a day (BID) continuously starting on Cycle 1 Day 1 in a 28-day cycle.~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
62045079|NCT04640532|EXPERIMENTAL|Cohort 3 (JAKi Intolerant MF)|KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.
62045080|NCT02940366|EXPERIMENTAL|Pitavastatin 4 mg orally daily|
62045081|NCT02940366|PLACEBO_COMPARATOR|Atorvastatin 20 mg orally daily|
62045082|NCT02162784|EXPERIMENTAL|Budesonide/procaterol 180/10mcg X1|HFA MDI, oral inhalation, 180/10mcg, one puff
62045083|NCT02162784|EXPERIMENTAL|Budesonide/Procaterol, 180/10mcg X2|HFA MDI, oral inhalation, two puffs
62826929|NCT03013998|EXPERIMENTAL|BAML-16-001-S10 (Closed)|This is a phase 1b/2 clinical trial to assess the safety and efficacy of the combination of AZD5153 and venetoclax. In a phase 1b component, safety and tolerability of the combination will be assessed in relapsed/refractory AML patients ≥ 18 years of age. Following determination of the recommended Phase 2 dose (RP2D), newly diagnosed, marker negative patients age ≥ 60 will be enrolled in the phase 2 component; these patients will be treated at the previously identified RP2D for the combination. The RP2D will be the highest dose level with ≤ 1 out of 6 patients with dose limiting toxicity and defined as the maximum tolerated dose.
62045084|NCT02162784|ACTIVE_COMPARATOR|Albuterol HFA MDI 100 mcg X2|HFA MDI, oral inhalation, 100mcg, two puffs
62045085|NCT04081467|EXPERIMENTAL|bed rest condition|Bed rest condition without any additional intervention
62045086|NCT03222648|EXPERIMENTAL|Structured Responsive Exercise Training|8 week twice weekly supervised structured responsive static-cycle based exercise training. Training protocol used the same as Loughney et al. 2016
62045087|NCT03222648|ACTIVE_COMPARATOR|Standard of Care Arm|Completion of outcome measures only
62247427|NCT02914054|ACTIVE_COMPARATOR|Conventional Prednisone receiving group|Patients in PDN arm received PDN
62604461|NCT04861116|NO_INTERVENTION|Control|Waiting list that will have access to the intervention program after the 6-month follow-up assessment.
62045088|NCT05362890|EXPERIMENTAL|Patients with obstructive sleep apnea|Patients with OSAS who have been previously examined by a neurologist for sleep disorders, have undergone polysomnography, and have been diagnosed with moderate severe obstructive sleep apnea according to the AHI index
62045089|NCT05362890|NO_INTERVENTION|Control Group|The control group will consist of subjects in whom specific questionnaires excluded the existence of obstructive sleep apnea.
62247428|NCT02914054|ACTIVE_COMPARATOR|Dxamethasone receiving group|In HD-DXM arm, DXM was administered
62247429|NCT02910765|ACTIVE_COMPARATOR|M methylene blue and ozone|intravenous methylene blue and blood mixed with ozone ozone injection in early sepsis patients
62247430|NCT02910765|PLACEBO_COMPARATOR|P Placebo|saline and oxygen mixed blood injection in early sepsis patients
62604462|NCT06521255|EXPERIMENTAL|Tafasitamab and lenalidomide in combination with gemcitabine and oxaliplatin|
62604463|NCT06521255|ACTIVE_COMPARATOR|Rituximab in combination with gemcitabine and oxaliplatin|
62604464|NCT06298513||Patient after first acute myocardial infarction|
62045090|NCT01484548|EXPERIMENTAL|Vaccine: 20 ug LEISH-F3 + 2 ug GLA-SE|Low dose of adjuvant.
62045091|NCT01484548|EXPERIMENTAL|Vaccine: 20 ug LEISH-F3 + 5 ug GLA-SE|Higher dose of adjuvant.
62045092|NCT01484548|ACTIVE_COMPARATOR|20 ug LEISH-F3 alone|20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
62045093|NCT04310553|EXPERIMENTAL|Arm 1|This project plans to enroll 40 patients receiving nanoknife treatment, our center enrolls 20 patients, and the other two centers will enroll 10 patients each. The number of patients expected to participate in the study is 240.
62247431|NCT04084106|EXPERIMENTAL|phenoximethylpenicillin|phenoximethylpenicillin, tablet, 1 g 3 times daily for 5 days.
62247432|NCT04084106|ACTIVE_COMPARATOR|amoxicillin|amoxicillin, tablet, 500 mg 3 times daily for 5 days.
62247433|NCT04084106|ACTIVE_COMPARATOR|amoxicillin-clavulanic acid|amoxicillin-clavulanic acid tablet, 500/125 mg 3 times daily for 5 days.
62247434|NCT04084106|NO_INTERVENTION|No intervention|No intervention
62247435|NCT03053258||Diagnostic Breath Analysis: VAP|Collection of exhaled breath samples
62604465|NCT02167815|ACTIVE_COMPARATOR|Standard care|standard care ( such as alginate, hydrofiber or other treatment)
62604466|NCT02167815|EXPERIMENTAL|Intervention ( Mepilex XT)|
62247436|NCT06470009|SHAM_COMPARATOR|Arm 1|administration of translingual neurostimulation.
62604467|NCT00291161|EXPERIMENTAL|Partners in Dementia Care|"PDC is telephone-based care consultation intervention jointly delivered by care consultants in the VA and local Alzheimer's Association. The steps in care consultation included 1) Assessment of medical and non-medical care needs; 2) Development of a care plan that addresses needs of patients and caregivers; 3) on-going monitoring of the status, progress, and barriers encountered; and 4) Reassessment of care needs for patients and caregivers.~PDC assisted families by: 1) providing disease-related education and information, 2) offering emotional support and coaching, 3) linking families to medical and non-medical services and resources, and 4) mobilizing and organizing the informal care network."
62247437|NCT06470009|ACTIVE_COMPARATOR|Arm 2|administration of translingual neurostimulation.
62247438|NCT04200495||Healthy Controls|No sleep-wake disorder present
62437652|NCT05357560|EXPERIMENTAL|Group 8 - Infants RH5.2 and R21, standard regimen|11 volunteers (infant 5-17 months) given 50µg of Matrix-M in combination with 5µg RH5.2 VLP and 5µg R21 at months 0, 1 and 2 via intramuscular (IM) injection in the anterolateral thigh
62437653|NCT05357560|EXPERIMENTAL|Group 9 - Infants RH5.2 and R21, delayed 3rd dose|11 volunteers (infant 5-17 months) given 50µg of Matrix-M in combination with 5µg RH5.2 VLP and 5µg R21 at months 0, 1 and 6 via intramuscular (IM) injection in the anterolateral thigh
62437654|NCT01203683|EXPERIMENTAL|Active Computer-Based Program|Putatively therapeutic computer program.
62437655|NCT01203683|PLACEBO_COMPARATOR|Placebo computer-based program|Inert computer program.
62437656|NCT00194818|ACTIVE_COMPARATOR|1|Asacol 6 tablets BID (4.8 grams/day)
62437657|NCT00194818|ACTIVE_COMPARATOR|2|Asacol 4 tablets TID (4.8 grams/day)
62437658|NCT05692674|EXPERIMENTAL|adjuvant hypofractionated intensity-modulated proton radiotherapy|CTV1: chest wall ± regional lymph drainage area, proton therapy.
62437659|NCT06263309||Good Functional Score|Harris hip score \> 80
62045094|NCT03330223||Clopidogrel|clopidogrel 75mg qd;aspirin 100mg qd, n=30
62045095|NCT03330223||Ticagrelor|ticagrelor 90mg bid; aspirin 100mg qd, n=30
62045096|NCT05077150||PCP cases|"Any allogeneic HSCT recipient who, during the 1-year study period, underwent a BAL from the day of transplant, and whose BAL fluid was positive for PcP: either by qPCR alone, or positive cytology or IF, irrespectively of clinical presentation, imaging, co-infection and PcP treatment. Only first episode of PcP will be included (incident cases).~Due to the lack of standardization, qPCR on sputum only will not be taken in account for the diagnosis of PcP."
62247439|NCT04200495||Active Sleep-Wake Disorder|Presence of Sleep-Wake Disorder
62247440|NCT03580239|EXPERIMENTAL|Everolimus & Best Supportive Care|Everolimus will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
62247441|NCT03580239|PLACEBO_COMPARATOR|Placebo & Best Supportive Care|Placebo will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
62247442|NCT02896829||Imatinib treatment ending|Interruption of the treatment by Imatinib
62247443|NCT04236063||Haematological malignancy|Patients with haematological malignancy
62247444|NCT00199602|NO_INTERVENTION|lack of drug prophylaxis|
62247445|NCT00199602|EXPERIMENTAL|HBPM 2500 UI anti Xa in one subcutaneous injection per day|
62437660|NCT06263309||Bad Functional Score|Harris Hip score \< 80
62437661|NCT04705909|EXPERIMENTAL|Pitavastatin group|For the intended neoadjuvant treatment period, participants will receive -in addition to standard chemotherapy protocol - Pitavastatin tablets 2 mg once daily.
62437662|NCT04705909|PLACEBO_COMPARATOR|Placebo group|For the intended neoadjuvant treatment period, participants will receive -in addition to standard chemotherapy protocol - Placebo tablets matching pitavastatin orally once daily.
62437663|NCT03821324|OTHER|Intervention|Device: Venus Viva
62247446|NCT00199602|EXPERIMENTAL|warfarine 1mg daily|
62437664|NCT05752305|EXPERIMENTAL|Methylprednisolone group|Preoperative administration of 40mg of methylprednisolone via submucosa
62437665|NCT05752305|EXPERIMENTAL|Dexamethasone group|Preoperative administration of 8mg of dexamethasone via submucosa
62437666|NCT01928914|PLACEBO_COMPARATOR|Group 1|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on three consecutive days of dosing
62437667|NCT01928914|EXPERIMENTAL|Group 2|Subjects in group 2 receive 400mg of tafenoquine and placebo for moxifloxacin on three consecutive days of dosing
62437668|NCT01928914|ACTIVE_COMPARATOR|Group 3|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for tafenoquine and 400mg moxifloxacin.
62045097|NCT05077150||Controls|Controls are matched to case on Centre and HSCT date and if possible on gender and date of birth.
62045098|NCT04779970|EXPERIMENTAL|STOP: Caucasian patients|Cessation of treatment
62247447|NCT05486026|ACTIVE_COMPARATOR|Duloxetine tablet|Patient in the first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals for 13 weeks .
62045099|NCT04779970|EXPERIMENTAL|STOP: non-Caucasian patients|Cessation of treatment
62045100|NCT04779970|NO_INTERVENTION|Control group|Standard of care follow-up
62045101|NCT03071055|ACTIVE_COMPARATOR|ranibizumab|ranibizumab 0.5mg in commercially available vial
62045102|NCT03071055|EXPERIMENTAL|ranibizumab pre filled-syringe|ranibizumab 0.5mg in soon to be available pre-filled syringe
62045103|NCT02992990|OTHER|Bladder tumor biopsy|All subjects will undergo a bladder tumor biopsy followed by transurethral resection.
62247448|NCT05486026|ACTIVE_COMPARATOR|NSAID(non steroidal anti inflammatory)|patient in the second group will receive NSAID(non-steroidal anti inflammatory) drugs for 13 weeks
62247449|NCT03862157|EXPERIMENTAL|Treatment (venetoclax, azacitidine, pevonedistat)|Patients receive venetoclax PO QD on days 1-28, azacitidine IV or SC on days 1-7, and pevonedistat IV over 60 minutes on days 1, 3, and 5. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62247450|NCT03463798||Patients|Patients with a suspicion of diaphragmatic dysfunction
62247451|NCT03463798||Healthy volunteers|Subjects without any medical condition
62247452|NCT01824680|EXPERIMENTAL|obesity|
62247453|NCT01855451|ACTIVE_COMPARATOR|Radiation Therapy + Cetuximab|RT (70 Gy in 35 fractions, 5 days a week over 7 weeks) with weekly Cetuximab (400 mg/m2 loading dose IV prior to radiation, followed by weekly cetuximab 250 mg/m2 for the duration of the radiotherapy)
62247454|NCT01855451|ACTIVE_COMPARATOR|Radiation Therapy + Cisplatin|RT(70 Gy in 35 fractions, 5 days a week over 7 weeks) with weekly Cisplatin (40 mg/m2 IV for the duration of the radiotherapy)
62247455|NCT02649296|OTHER|Treatment with Skanlab Bodywave|Treatment with Skanlab Bodywave twice a week for four weeks at the affected knee.
62247456|NCT02649296|NO_INTERVENTION|No treatment|Treatment with Skanlab Bodywave without function twice a week for four weeks.
62247457|NCT01886313|ACTIVE_COMPARATOR|Civamide Nasal Spray|Civamide Nasal Spray 0.01% 20ug/dose (20ul), 10ul in each nostril, twice daily, for 6 weeks
62437669|NCT01928914|EXPERIMENTAL|Group 4|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for moxifloxacin and 300mg of tafenoquine
62826930|NCT03013998|EXPERIMENTAL|BAML-16-001-S14 (Closed)|The study is an open-label Phase 1b/2 clinical study of TP-0903 given in addition to decitabine in patients ≥ 60 years with newly diagnosed, previously untreated AML with TP53 mutations and/or complex karyotype. The Phase 1b portion of this study will use a standard 3 + 3 design with dose escalation based upon dose limiting toxicities. The maximum tolerated dose will be defined as the highest dose where at most 1 patient in 6 experiences dose-limiting toxicity, and this is generally the recommended Phase 2 dose (RP2D). Once the RP2D is determined from Phase 1b, patients will be enrolled at this dose level to initiate the Phase 2 portion of the study.
62247458|NCT01886313|PLACEBO_COMPARATOR|Placebo Nasal Spray|Placebo Nasal Spray 10ul in each nostril, twice daily, for 6 weeks
62437670|NCT01928914|EXPERIMENTAL|Group 5|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for moxifloxacin and 600mg of tafenoquine
62437671|NCT05823311|EXPERIMENTAL|GPLET (Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin)|Intravenous injection: gemcitabine and cisplatin (CG)+ tislelizumab； Oral administration: lenvatinib.
62437672|NCT05823311|PLACEBO_COMPARATOR|CG (Gemcitabine and Cisplatin)|Intravenous injection: gemcitabine and cisplatin (CG)+placebo； Oral administration: placebo.
62247459|NCT05593666|EXPERIMENTAL|LXE408 short regimen|LXE408 once daily for seven days (followed by 7 days of placebo).
62045104|NCT05199779|EXPERIMENTAL|Self-Compassion Intervention (SCI)|First, participants will be taught to implement a 20-second self-compassion induction via video recording. Second, participants will be taught to choose a cue that will precede their daily use of the self-compassion induction. Participants will document the cue they chose, and will be emailed a record of their selected cue, along with the recording and transcript of the self-compassion induction that they can refer back to for reference. Third, participants will be asked to use the self-compassion induction as much as they can and at least once during their daily routine following exposure to their chosen cue.
62045105|NCT05199779|ACTIVE_COMPARATOR|Finger-Tapping Active Control (AC)|The active control will receive the same procedures as described above, except for receiving a different video containing different instructions describing a finger-tapping exercise. The videos will be virtually identical in length, quality, instructor/their outfit, and lighting.
62045106|NCT04719091|EXPERIMENTAL|HA formulation Oral Spray|The Study Examiner and staff will screen for subjects that meet the enrollment criteria. Subjects will be randomly assigned to one of two treatment groups. Oral soft and hard tissue examinations will be conducted at each visit. Following an initial 3-5 minute evaluation of resting salivary flow, subjects will wait 10 minutes and then use their assigned spray. They will then swallow, and unstimulated saliva will be collected for 3-5 minutes. They will then remain in the study center for 60 min to evaluate xerostomia relief by questionnaire at 5, 15, 30, 45 and 60 min. after the use of Experimental mouth spray. They will then be given their assigned product to use twice daily for one week
62247460|NCT05593666|EXPERIMENTAL|LXE408 long regimen|LXE408 once daily for 14 days
62247461|NCT05593666|ACTIVE_COMPARATOR|Standard of care|AmBisome® 10 mg/kg IV single dose (SDA)
62247462|NCT00533026|ACTIVE_COMPARATOR|A|Subjects received warfarin QD, PO for approximately 12 days. Subjects with stabilized INR after approximately 12 days continued to receive warfarin QD, PO for an additional 14 days and also received duloxetine 60mg QD, PO for the 14 days. Duloxetine doses were tapered, subjects received 30mg QD, PO for 4 days. No warfarin was received during the taper phase.
62437673|NCT01705210||Diabetes mellitus type 2 (DM2)|
62437674|NCT01705210||metabolic syndrome (MetS)|
62437675|NCT01705210||healthy controls|
62437676|NCT00373685|EXPERIMENTAL|Celecoxib|dosing as per USPI label
62437677|NCT00373685|ACTIVE_COMPARATOR|NSAIDs|
62437678|NCT03052166||Cohort A|The group of asymptomatic subjects who have been given BI-RADS 1 or 2 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan.
62437679|NCT03052166||Cohort B|The group of asymptomatic women who have been given BI-RADS categories 4 or 4a, 4b, 4c or 5 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan.
62437680|NCT03052166||Cohort C|The group of women who have been given BI-RADS categories 1, 2, 3, 4 or (4a, 4b, 4c), 5 or 6 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan. Subjects are assigned to Cohort C when it has been determined they cannot be assigned to Cohort A or Cohort B.
62437681|NCT03840811|EXPERIMENTAL|Group 1|Subjects (n = up to 8) will receive a bacterial inoculum containing only the isogenic mutant N. gonorrhoeae strain
62437682|NCT03840811|EXPERIMENTAL|Group 2|Subjects (n = up to 8) will receive a bacterial inoculum containing only the wild-type (WT) N. gonorrhoeae strain.
62437683|NCT03840811|EXPERIMENTAL|Group 3|Subjects (n= up to 16) will receive a bacterial inoculum containing a mixture of equivalent numbers the isogenic mutant and WT strain
62437684|NCT05844683|EXPERIMENTAL|Chlorhexidine Bath|All patients in the randomized to the intervention arm will receive baths using a 2% chlorhexidine digluconate solution
62437685|NCT05844683|ACTIVE_COMPARATOR|usual bath|All patients in the randomized to the intervention arm will receive baths using soap and water according to the current practice
62437686|NCT02982382|EXPERIMENTAL|Manipulative Treatment|Subjects will receive Manipulative Therapy
62437687|NCT02982382|SHAM_COMPARATOR|Pain Education|Subjects will receive Pain Education and manual contact over lumbar region
62437688|NCT02383147|EXPERIMENTAL|Tomographic Neurofeedback (TONF)|15x Neurofeedback Trainings, 1-2 times per week
62437689|NCT02383147|ACTIVE_COMPARATOR|Non Tomographic Neurofeedback (NTE)|15x Neurofeedback Trainings, 1-2 times per week
62437690|NCT00632320||S, 1, A|group (success or failure), case number, measurement method
62437691|NCT02141386|EXPERIMENTAL|Treatment A|plasticity-based, adaptive, computerized cognitive remediation (PACR)
62826931|NCT03013998|EXPERIMENTAL|BAML-16-001-S18 (Closed)|This is an open-label Phase 1b clinical study of AZD5991 + azacitidine in patients aged ≥60 years with newly diagnosed, previously untreated, hypermethylated and marker-negative AML. The phase 1b1 study will adopt a standard 3+3 design with dose escalation based upon dose limiting toxicities. The recommended Phase 2 dose (RP2D) is defined in this study as the highest dose level where less than 2 dose limiting toxicities (DLT) are observed out of 6 patients. Once the RP2D is defined, patients will be enrolled into 2 separate cohorts (hypermethylation and marker negative group) for the phase 1b2 expansion. These 2 groups will both be treated at the RP2D determined from phase 1b1.
62826932|NCT03013998|EXPERIMENTAL|BAML-16-001-S17|This is an open-label Phase 1b dose escalation and expansion clinical trial to determine the safety and recommended dose of SNDX-5613 combined with azacitidine and venetoclax in newly diagnosed, untreated AML patients age ≥ 60 years who are not candidates or do not wish to pursue intensive induction therapy and who have NPM1 mutated or MLL-rearranged disease. After determination of the recommended dose of SNDX-5613, the study will have an expansion cohort to be treated at the recommended dose in combination with azacitidine and venetoclax in the same patient population.
62826933|NCT03013998|ACTIVE_COMPARATOR|BAML-16-001-S12 (Arm A)|This is an open label phase 2 randomized study in which eligible AML patients will be randomly assigned (1:1) to receive either the FDA label-approved regimen of 28-day Venetoclax + Azacitidine (Arm A) or the 14-day regimen of Venetoclax + Azacitidine (Arm B). Newly diagnosed acute myeloid leukemia (AML) patients ≥ 60 years will be enrolled.
62826934|NCT03013998|EXPERIMENTAL|BAML-16-001-S12 (Arm B)|This is an open label phase 2 randomized study in which eligible AML patients will be randomly assigned (1:1) to receive either the FDA label-approved regimen of 28-day Venetoclax + Azacitidine (Arm A) or the 14-day regimen of Venetoclax + Azacitidine (Arm B). Newly diagnosed acute myeloid leukemia (AML) patients ≥ 60 years will be enrolled.
62045107|NCT04719091|PLACEBO_COMPARATOR|Placebo Oral Spray|The Study Examiner and staff will screen for subjects that meet the enrollment criteria. Subjects will be randomly assigned to one of two treatment groups. Oral soft and hard tissue examinations will be conducted at each visit. Following an initial 3-5 minute evaluation of resting salivary flow, subjects will wait 10 minutes and then use their assigned spray. They will then swallow, and unstimulated saliva will be collected for 3-5 minutes. They will then remain in the study center for 60 min to evaluate xerostomia relief by questionnaire at 5, 15, 30, 45 and 60 min. after the use of placebo mouth spray. They will then be given their assigned product to use twice daily for one week
62045108|NCT05925907||Handsurgery patients|patients recruited from trauma handsurgery outpatient clinic in an academic teaching hospital, level 1 trauma unit.
62045109|NCT05925907||Medicolegal patients|Medicolegal patients that are examined in order to asses their personal injury claim.
62045110|NCT03369379|ACTIVE_COMPARATOR|D3 Vitamin|In this group subjects will receive 1 vitamin D3 capsule of 50,000 units, each week, for 12 weeks.
62045111|NCT03369379|PLACEBO_COMPARATOR|Placebo|In this group the subjects will receive 1 placebo capsule each week for 12 weeks.
62045112|NCT04995679|OTHER|Patient whit osteoarthritis of the knee|Patients with osteoarthritis of the knee undergoing total knee replacement surgery with metaphyseal sleeves
62045113|NCT06130150||High-risk|This group includes pregnant women with the risk factors determined in the study
62045114|NCT06130150||Normal|This group includes pregnant women with no risk
62045115|NCT04523896|EXPERIMENTAL|HDR brachytherapy + SABR|"High-Dose-Rate prostate brachytherapy: a single fraction of 15 Gy to the whole prostate.~Between 2-4 weeks after the brachytherapy session, SABR treatment will be delivered:~5 sessions of 5 Gy in consecutive days (i.e monday to friday) to a total dose of 25 Gy to the whole prostate."
62045116|NCT00737555|EXPERIMENTAL|1|Once daily oral administration of CHR-2797 ( escalating dose groups) in solid tumour patients receiving paclitaxel infusion every three weeks
62045117|NCT05969574||AMH <1.3, at least 1 pregnancy or at least 1 miscarriage|Participants will not undergo any additional intervention compared to normal clinical assessment and routine testing of the ovarian reserve, which includes AMH and AFC. Investigators will follow standard stimulation protocols and medications.
62247463|NCT00533026|ACTIVE_COMPARATOR|B|Subjects received warfarin QD, PO for approximately 12 days. Subjects with stabilized INR after approximately 12 days continued to receive warfarin QD, PO for an additional 14 days and also received duloxetine 60 mg QD, PO for 4 days followed by duloxetine 120 mg QD, PO for 10 days. Duloxetine doses were tapered, subjects received 60mg QD, PO for 4 days followed by 30mg QD, PO for 4 days. No warfarin was received during the taper phase.
62045118|NCT05969574||AMH <1.3, at least 1 pregnancy and no miscarriage|Participants will not undergo any additional intervention compared to normal clinical assessment and routine testing of the ovarian reserve, which includes AMH and AFC. Investigators will follow standard stimulation protocols and medications.
62045119|NCT05969574||AMH ≥ 1.3, at least 1 pregnancy or at least 1 miscarriage|Participants will not undergo any additional intervention compared to normal clinical assessment and routine testing of the ovarian reserve, which includes AMH and AFC. Investigators will follow standard stimulation protocols and medications.ons.
62045120|NCT05969574||AMH ≥1.3, at least 1 pregnancy and no miscarriage|Participants will not undergo any additional intervention compared to normal clinical assessment and routine testing of the ovarian reserve, which includes AMH and AFC. Investigators will follow standard stimulation protocols and medications.
62045121|NCT02668224|EXPERIMENTAL|Vibrasens : Test group|Training programme: vibration training 3/week from Day 1 to Day 60 + Usual activities from day 60 to Day 75.
62437692|NCT02141386|ACTIVE_COMPARATOR|Treatment B|"Ordinary Computer Games (an active control condition)"
62437693|NCT01830413||Stenting|cerebral artery stenting for systematic Intracranial artery stenosis
62045122|NCT02668224|ACTIVE_COMPARATOR|Control group|Control: Usual activities from day 1 to Day 75.
62045123|NCT04220164||Dyslipidemic patients|Patients who meet the criteria of high-risk category according to 2017 Taiwan Lipid Guideline for High-Risk Patients have a abnormal serum LDL-C level
62045124|NCT01313286|EXPERIMENTAL|LY2608204 Reference, LY2608204 Test|Single oral 80 mg dose of LY2608204 reference formulation in period 1; single oral 80 mg dose of LY2608204 test formulation in period 2. There is a washout period of at least 14 days between dosing periods.
62045125|NCT01313286|EXPERIMENTAL|LY2608204 Test, LY2608204 Reference|Single oral 80 mg dose of LY2608204 test formulation in period 1; single oral 80 mg dose of LY2608204 reference formulation in period 2. There is a washout period of at least 14 days between dosing periods.
62045126|NCT06449040|ACTIVE_COMPARATOR|Group Anfo12mg/kg|Liposomal amphotericin B (AmBisome®) - 3mg/kg twice a week; total dose of 12 mg/kg
62247464|NCT06310954|EXPERIMENTAL|Ketogenic Diet plus Conventional Treatment Group|This arm of the trial explores the efficacy of an early initiation of the ketogenic diet in conjunction with conventional antiepileptic drugs (AEDs) for children with refractory epilepsy. The intervention aims to evaluate the impact on seizure frequency, and inflammatory markers, and identify patient characteristics predicting a better response to the ketogenic diet, to improve overall therapeutic response rates in refractory epilepsy.
62247465|NCT06310954|PLACEBO_COMPARATOR|Control Group: Conventional Treatment Group|Participants in this arm will receive a standard diet without any ketogenic restrictions, alongside conventional antiepileptic drugs. This comparator aims to assess the standard care's efficacy against the experimental intervention, focusing on seizure control, inflammatory markers, and identifying patient characteristics associated with treatment responsiveness.
62247466|NCT05623397||Breast cancer patients administered ribociclib.|Prospective cohort of consecutive breast cancer patients requiring ribociclib for their standard of care at the clinically indicated dose, as per treating physician prescription (600mg to 200mg/day for 21 days per 28 days cycle). Association with other hormone-derived therapeutics will be allowed.
62437694|NCT06286566|EXPERIMENTAL|Diabetics group|Group of subjects with diabetes who will be inserted implants with a new implant surface called SOI
62826935|NCT03013998|EXPERIMENTAL|BAML-16-001-S21|This is a Phase 1, open-label, multicenter, dose escalation, and dose optimization study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE46-0134 in adult patients with relapsed or refractory AML with FLT3-ITD and/or FLT3-TKD mutations. Patients with AML that are out-patients or hospitalized due to their AML can be enrolled in the study. The study will be run in 2 parts: Part 1 will be dose escalation and determination of the maximum tolerated dose, and Part 2 will be dose expansion.
62826936|NCT06593678|EXPERIMENTAL|Intervention Group. Asynchronous telerehabilitation|Receive a home-based rehabilitation program via an asynchronous digital telerehabilitation platform.
62826937|NCT06593678|ACTIVE_COMPARATOR|Control Group. Booklet-based rehabilitation|Receive a booklet-based rehabilitation program at home through a detailed printed guide (explanatory booklet).
62826938|NCT05324566||Patients with ECG-capable Apple Watch|Patients who own an Apple Watch series 4 or later willing to record and upload personal ECGs to our study App
62826939|NCT03011099|EXPERIMENTAL|Robotic exoskeleton training|During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.
62826940|NCT03011099|ACTIVE_COMPARATOR|Conventional Physical Therapy|During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
62826941|NCT04900324|EXPERIMENTAL|MRI guidance|Injections of botulinum toxin performed using MRI guidance
62826942|NCT04900324|EXPERIMENTAL|Ultrasound guidance|Injections of botulinum toxin performed using ultrasound guidance
62826943|NCT05050331|EXPERIMENTAL|Muscle Energy Technique (MET) Group|The MET protocol consisted of post-isometric relaxation applied to the gastrocnemius and soleus muscles, with 5 repetitions per set, 3 times a week, for 4 weeks
62045127|NCT06449040|ACTIVE_COMPARATOR|Group Anfo18mg/kg|Liposomal amphotericin B (AmBisome®) - 3mg/kg twice a week; total dose of 18 mg/kg
62045128|NCT06449040|ACTIVE_COMPARATOR|Group Anfo24mg/kg|Liposomal amphotericin B (AmBisome®) - 3mg/kg twice a week; total dose of 24 mg/kg
62045129|NCT01273233|EXPERIMENTAL|Group 1: 200U EV71 vaccine|12 adults received 3 doses of 200U EV71 vaccine 14 days apart
62045130|NCT01273233|EXPERIMENTAL|Group 2: 400U EV71 vaccine|12 adults received 3 doses of 400U EV71 vaccine 14 days apart
62045131|NCT01273233|PLACEBO_COMPARATOR|Group 1: Placebo|6 adults received 3 doses of placebo 14 days apart
62045132|NCT01273233|PLACEBO_COMPARATOR|Group 2: Placebo|6 adults received 3 doses of placebo 14 days apart
62247467|NCT00314249|PLACEBO_COMPARATOR|Placebo|Placebo, oral administration, twice daily for 12 weeks
62247468|NCT00314249|EXPERIMENTAL|Milnacipran|Milnacipran 100mg/day (50mg BID \[twice a day\])
62247469|NCT01033656|EXPERIMENTAL|Anakinra|experimental drug of study
62247470|NCT01033656|ACTIVE_COMPARATOR|comparator|comparators:methotrexate, azathioprine, leflunomide or supfasalazine
62826944|NCT05050331|EXPERIMENTAL|Trigger Point Release Group|The gastrocnemius muscle was subjected to trigger point release therapy, 3 sessions per week, over a period of 4 weeks
62604468|NCT00291161|NO_INTERVENTION|Usual Care|Patients and caregivers at the three control VA settings were given a packet of educational materials on dementia and usual-care community resources.
62604469|NCT02553434|EXPERIMENTAL|Pigtail catheter (case)|Inserting 14 French pigtail catheter
62437695|NCT06286566|ACTIVE_COMPARATOR|Healthy Group|Group of helthy subjects who will be inserted implants with a new implant surface called SOI to compare them with the group of diabetic subjects
62826945|NCT05327296|EXPERIMENTAL|Isoflurane|Inhaled isoflurane administered via Sedaconda ACD-S
62247471|NCT02334787|EXPERIMENTAL|0.3% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned0.3% OPA-15406 ointment assessed until 48 hours postdose.
62437696|NCT01724970|EXPERIMENTAL|PLMA|ProSeal
62826946|NCT05327296|ACTIVE_COMPARATOR|Propofol|Propofol administered as intravenous infusion
62826947|NCT05498571||Schizophrenia Patients|We collect relevant information, review cardiovascular events in schizophrenia patients.
62826948|NCT06595420||Outpatient CF Cohort|Not hospitalized CF group: Diagnosis of CF, age \>30 y, with ongoing care at one of the 3 CF Centers (Dartmouth, UAB, UVA).
62826949|NCT06595420||Inpatient CF Cohort|Hospitalized CF cohort: Diagnosis of CF, age \>7 y, being admitted for intravenous antibiotic treatment of pulmonary exacerbation.
62247472|NCT02334787|EXPERIMENTAL|1% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1% OPA-15406 ointment assessed until 48 hours postdose.
62437697|NCT01724970|EXPERIMENTAL|SLMA|Supreme LMA
62437698|NCT06405776|EXPERIMENTAL|Lidocaine group|Patients in the lidocaine group, lidocaine 1.5mg/kg/h is continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg) diluted to 200ml with saline until 72h after surgery.
62604470|NCT02553434|NO_INTERVENTION|Chest tube|inserting 32-36 French chest tube
62604471|NCT00331513|ACTIVE_COMPARATOR|Arm I (vorinostat, idarubicin)|Patients receive oral SAHA three times daily on days 1-14 and idarubicin IV over 15 minutes once daily on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy or who reach the maximum cumulative dose of idarubicin or an equivalent anthracycline and achieve clinical benefit may continue treatment with SAHA alone 3 times daily on days 1-14 of each course, in the absence of disease progression or unacceptable toxicity.
62604472|NCT00331513|ACTIVE_COMPARATOR|Arm II (vorinostat, idarubicin)|Patients receive oral SAHA three times daily and idarubicin IV over 15 minutes once daily on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy or who reach the maximum cumulative dose of idarubicin or an equivalent anthracycline and achieve clinical benefit may continue treatment with SAHA alone 3 times daily on days 1-14 of each course, in the absence of disease progression or unacceptable toxicity.
62826950|NCT06595420||Healthy Controls|Healthy Volunteers without CF
62826951|NCT05664737|EXPERIMENTAL|Transfusion Dependent (TD): Luspatercept + Best supportive care (BSC)|
62826952|NCT05664737|PLACEBO_COMPARATOR|Adult TD Cohort: Placebo + BSC|
62826953|NCT05664737|EXPERIMENTAL|Non-transfusion Dependent (NTD): Luspatercept + BSC|
62826954|NCT05664737|PLACEBO_COMPARATOR|Adult NTD Cohort: Placebo + BSC|
62826955|NCT03518853|EXPERIMENTAL|Short-course Radiation Therapy|Short-course Hypofractionated Once-weekly Radiation Therapy: 35Gy in 5 fractions delivered once a week.
62826956|NCT04495023||Group 1 (Kidney transplanted patients)|Group 1: Kidney transplanted patients requiring oncologic or non-oncologic left elective colectomy All kidney transplanted patients requiring oncologic or non-oncologic left elective colectomy between 01 January 2004 and 31 December 2015.
62826957|NCT04495023||Group 2 (Non-transplanted patients)|Group 2 : Non-transplanted patients requiring oncologic or non-oncologic left elective colectomy Non-transplanted patients requiring oncologic or non-oncologic left elective colectomy between 01 January 2004 and 31 December 2015.
62826958|NCT03574233||patients who are ready to wean ventilator off|
62826959|NCT01825460|EXPERIMENTAL|Manual Therapy Protocol|A protocol with five techniques on thoracic area applied twice a week.
62247473|NCT02334787|EXPERIMENTAL|3% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3% OPA-15406 ointment assessed until 48 hours postdose.
62247474|NCT02334787|PLACEBO_COMPARATOR|Placebo in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned placebo ointment assessed until 48 hours postdose.
62247475|NCT02334787|EXPERIMENTAL|0.3% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
62247476|NCT02334787|EXPERIMENTAL|1% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
62247477|NCT02334787|EXPERIMENTAL|3% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
62604473|NCT04385875|EXPERIMENTAL|Vaccine group|ATI_extension will keep allocation from AELIX-002 for a separate description of the results.
62045133|NCT02954523|EXPERIMENTAL|Phase I- Dasatanib Dose Level 1|"Osimertinib (AZD9291) will be given at a 80mg/day dose taken orally across all levels of the dose escalation schedule.~Dasatinib is taken orally and will be given at up to 4 dose levels. Level 1 (the starting dose - 50 mg twice daily).~Dose escalation will only include 2 dose levels (Levels 1 and 2); in addition there will be 2 dose levels below the starting dose level if dose reductions are necessary (Levels -1 and -2).~There is no limit to the number of cycles a patient can receive."
62045134|NCT02954523|EXPERIMENTAL|Phase I- Dasatanib Dose Level 2|"Osimertinib (AZD9291) will be given at a 80mg/day dose taken orally across all levels of the dose escalation schedule.~Dasatinib is taken orally and will be given at up to 4 dose levels. Level 2 (70 mg twice daily).~Dose escalation will only include 2 dose levels (Levels 1 and 2); in addition there will be 2 dose levels below the starting dose level if dose reductions are necessary (Levels -1 and -2).~There is no limit to the number of cycles a patient can receive."
62045135|NCT02954523|EXPERIMENTAL|Phase I- Dasatanib Dose Level -1|"Osimertinib (AZD9291) will be given at a 80mg/day dose taken orally across all levels of the dose escalation schedule.~Dasatinib is taken orally and will be given at up to 4 dose levels. Level -1 (70 mg once daily).~Dose escalation will only include 2 dose levels (Levels 1 and 2); in addition there will be 2 dose levels below the starting dose level if dose reductions are necessary (Levels -1 and -2).~There is no limit to the number of cycles a patient can receive."
62045136|NCT02954523|EXPERIMENTAL|Phase I- Dasatanib Dose Level -2|"Osimertinib (AZD9291) will be given at a 80mg/day dose taken orally across all levels of the dose escalation schedule.d~Dasatinib is taken orally and will be given at up to 4 dose levels. Level -2 (50 mg once daily).~Dose escalation will only include 2 dose levels (Levels 1 and 2); in addition there will be 2 dose levels below the starting dose level if dose reductions are necessary (Levels -1 and -2).~There is no limit to the number of cycles a patient can receive."
62045137|NCT02954523|EXPERIMENTAL|Phase II- Maximum tolerated dose|The phase II portion of the study will use the maximum tolerated dose of dasatinib determined in the phase I portion. Osimertinib (AZD9291) will be given at the same 80mg dose as the phase I portion. There is no limit to the number of cycles a patient can receive.
62437699|NCT06405776|PLACEBO_COMPARATOR|Placebo group|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2μg/kg, granisetron 12mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.
62045138|NCT03228056|EXPERIMENTAL|uniportal VATS lobectomy|"* uniportal VATS lobectomy~* thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)~* ketoprofene 100 mg i.v every 12 hours~* paracetamol 1000 mg i.v every 8 hours~* rescue doses of morphine in PCA system (bolus dose 2 mg i.v)~* pain intensity measured in VAS scale"
62045139|NCT03228056|ACTIVE_COMPARATOR|two-ports VATS lobectomy|"* two-ports VATS lobectomy~* thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)~* ketoprofene 100 mg i.v every 12 hours~* paracetamol 1000 mg i.v every 8 hours~* rescue doses of morphine in PCA system (bolus dose 2 mg i.v)~* pain intensity measured in VAS scale"
62247478|NCT02334787|EXPERIMENTAL|Placebo in the multiple administration period|In the multiple administration period, same subjects were treated with assigned OPA-15406 ointment placebo twice daily for 14 days and assessed until 48 hours post dose.
62437700|NCT05551728|EXPERIMENTAL|Intervention group|12, 1-hour ESDM-informed caregiver coaching sessions, delivered by non-specialists. Intervention materials and approach have been adapted for the South African context.
62437701|NCT05551728|NO_INTERVENTION|Delayed intervention control group|Usual care.
62437702|NCT01279642|EXPERIMENTAL|ultrasound|Use of ultrasound to PICC placement
62437703|NCT01279642|ACTIVE_COMPARATOR|Control group|PICC placement by inspection and visualization of site
62604474|NCT04385875|PLACEBO_COMPARATOR|Placebo group|ATI_extension will keep allocation from AELIX-002 for a separate description of the results.
62437704|NCT06530537|EXPERIMENTAL|Cilostazol Group|Cilostazol 100mg twice daily
62437705|NCT06530537|ACTIVE_COMPARATOR|Aspirin Group|Aspirin 100mg once daily
62826960|NCT01825460|ACTIVE_COMPARATOR|Two manual techniques|Two manual therapies on thoracic area applied twice a week.
62437706|NCT05617820|EXPERIMENTAL|Estradiol vaginal inserts, 4 mcg|Estradiol vaginal inserts, 4 mcg. Insert vaginally once daily for 14 days.
62437707|NCT05617820|ACTIVE_COMPARATOR|IMVEXXY® (estradiol vaginal inserts) 4 mcg|IMVEXXY® (estradiol vaginal inserts) 4 mcg. Insert vaginally once for 14 days.
62604475|NCT04948034|EXPERIMENTAL|Treatment Arm|"A total of 68 metastatic colorectal cancer patients who have failed the first-line standard treatment will receive multisite SABR followed by Fruquintinib and Tislelizumab within two weeks from completion.~The dosing of Tislelizumab will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal."
62604476|NCT04291456|EXPERIMENTAL|Minocycline|Minocycline 100 mg oral twice daily for up to 24 month
62604477|NCT02602613|EXPERIMENTAL|AMEND|
62045140|NCT03228056|ACTIVE_COMPARATOR|three-ports VATS lobectomy|"* three-ports VATS lobectomy~* thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)~* ketoprofene 100 mg i.v every 12 hours~* paracetamol 1000 mg i.v every 8 hours~* rescue doses of morphine in PCA system (bolus dose 2 mg i.v)~* pain intensity measured in VAS scale"
62045141|NCT00414817|EXPERIMENTAL|Automated Phone-Based Refill Reminders|Intervention Arm: Participants randomly assigned to this study arm may receive up to 8 automated phone calls from the BREATH EASY Medication Reminder Program over the course of the 19 month intervention period.
62045142|NCT00414817|NO_INTERVENTION|Usual Care|"Usual Care: Participants randomly assigned to this arm received the same introductory letter as those in the intervention arm, giving them the opportunity to opt out, but were subsequently selected to be in the usual care study arm, and therefore, receive no intervention."
62826961|NCT06597227|EXPERIMENTAL|Proximal radical gastrectomy group|Patients with locally advanced upper gastric cancer were enrolled for 4 cycles of SOX combined with anti-PD-1 neoadjuvant therapy. After the completion of neoadjuvant therapy, the efficacy was evaluated, and the patients were divided into two groups according to the remission of lesions: (1) PD (Progressive disease) and SD (Stable disease) patients were replaced with conservative treatment or surgical treatment after MDT (Multi-disciplinary Treatment) discussion; (2) For PR (Partial response) and CCR (Clinical complete response) patients, if the patients met the criteria for proximal gastric radical surgery, the enrolled patients were randomly divided into 2 cohorts, which were divided into experimental group : the group of proximal gastric radical surgery; Four cycles of SOX combined with anti-PD-1 adjuvant therapy continued after surgery, and anti-PD-1 adjuvant therapy lasted for 1 year.
62045143|NCT02880800|EXPERIMENTAL|Analgesia, patient controlled|Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of either morphine or hydromorphone.
62045144|NCT02880800|ACTIVE_COMPARATOR|Analgesia, as per needed|Patients will receive intravenous (IV) opioids as per needed.
62045145|NCT01273948|EXPERIMENTAL|Bavituximab 3 mg/kg|Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
62045146|NCT01273948|EXPERIMENTAL|Bavituximab 0.3 mg/kg|Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
62045147|NCT01273948|ACTIVE_COMPARATOR|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
62045148|NCT01494337|ACTIVE_COMPARATOR|HOLEP|HOLEP In the first arm, holmium laser enucleation of the prostate will be done
62045149|NCT01494337|ACTIVE_COMPARATOR|PVEP/XPS|PVEP/XPS green light photoselective Vapo-Enucleation of prostate using XPS 180W machine will be used in the second arm
62437708|NCT05617820|PLACEBO_COMPARATOR|Placebo vaginal inserts|Placebo vaginal inserts. Insert vaginally once for 14 days.
62437709|NCT05447585|EXPERIMENTAL|Coronary Atherectomy System|Subjects in experimental arm will be treated with the Coronary Atherectomy System manufactured by Shanghai Microport Rhythm Co. Ltd.
62437710|NCT05447585|ACTIVE_COMPARATOR|Rotablator Rotational Atherectomy System|Subjects in control arm will be treated with Rotablator Rotational Atherectomy System manufactured by Boston Scientific Corporation
62045150|NCT06127290||HIV-1 patients naive to therapies|HIV-1 patients naive to therapies with sub subtype A6 treated in first line with INSTI
62045151|NCT02219048|PLACEBO_COMPARATOR|Placebo|Matched blinded placebo
62045152|NCT02219048|EXPERIMENTAL|PF-03715455|PF-03715455
62045153|NCT05433870||PRES group|patients in PE or E with PRES
62045154|NCT05433870||NON-PRES group|patients in PE or E without PRES
62045155|NCT00678314|ACTIVE_COMPARATOR|Group A|
62045156|NCT00678314|ACTIVE_COMPARATOR|Group B|
62045157|NCT00678314|PLACEBO_COMPARATOR|Group C|
62045158|NCT02454101|OTHER|cord milking|milking of the umbilical cord 5 times toward the neonate
62045159|NCT02454101|OTHER|delayed cord clamping|delayed cord clamping for 120 seconds
62045160|NCT03810625|EXPERIMENTAL|Sequence AB|D-0502 Dose Patients will get D-0502 single agent once in the fasted state and once in the fed state.
62247479|NCT03210272|EXPERIMENTAL|Single rising dose part|Group of healthy male volunteers receive rising single doses of BI 1358894
62826962|NCT06597227|ACTIVE_COMPARATOR|Total radical gastrectomy group|Patients with untreated, operable locally advanced upper gastric cancer who signed informed consent and met the screening criteria were enrolled for 4 cycles of SOX combined with anti-PD-1 neoadjuvant therapy. After the completion of neoadjuvant therapy, the efficacy was evaluated, and the patients were divided into two groups according to the remission of lesions: (1) PD and SD patients were replaced with conservative treatment or surgical treatment after MDT discussion; (2) For PR and CCR patients, if the patients met the criteria for proximal gastric radical surgery, the enrolled patients were randomly divided into 2 cohorts, Cohort 2 (control group) : total radical gastrectomy group. Four cycles of SOX combined with anti-PD-1 adjuvant therapy continued after surgery, and anti-PD-1 adjuvant therapy lasted for 1 year.
62247480|NCT03210272|EXPERIMENTAL|Food effect part|Group of healthy male volunteers receive single doses of BI 1358894 with and without food
62437711|NCT03058939|EXPERIMENTAL|Paclitaxel|Investigators plan to treat patients with paclitaxel weekly for a total of approximately 16 weeks (8 weeks before ultrasonography for response assessment and 8 weeks before surgery in good responders). Paclitaxel 80mg/m2 will be given on days 1, 8, 15 and so on for a total of 8 doses.
62437712|NCT03058939|OTHER|Carboplatin|After first 8 weeks of paclitaxel, those with progressive disease (based on breast US assessment) or partial response but inoperable will have carboplatin added to their regimen. Patients will receive 8 cycles of weekly paclitaxel and carboplatin (PC).
62045161|NCT03810625|EXPERIMENTAL|Sequence BA|D-0502 Dose Patients will get D-0502 single agent once in the fed state and once in the fasted state.
62247481|NCT03899363|EXPERIMENTAL|surgery|
62247482|NCT03899363|ACTIVE_COMPARATOR|custom thermoplastic orthosis|
62247483|NCT05755945|EXPERIMENTAL|Custom Phone eHealth Application|Subjects diagnosed with migraine headaches and have had a positive response to prevention treatments for migraine, will wear an Apple Watch whenever possible (including during sleep) and complete application questionnaires on the eHealth application daily.
62247484|NCT06335108||Control Group|Surgery carried out according to clinical routine under general anaesthesia.
62247485|NCT06335108||Local Anaesthesia Group|Surgery carried out under local tumescent anaesthesia. Procedure
62247486|NCT03618186|EXPERIMENTAL|Normal control|Cognitively normal volunteers
62247487|NCT03618186|EXPERIMENTAL|Mild Cogntive impairment|Person with cognitive impairment that meet Peterson Criteria
62247488|NCT03618186|EXPERIMENTAL|Demented|Patient's that meet dementia criteria
62437713|NCT03058939|OTHER|Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)|Patients with poor response to 8 courses of paclitaxel followed by 8 courses of PC based on ultrasound assessment will be regarded as failing to respond to treatment. These patients will receive 4 cycles of 3-weekly FEC and will be followed up.
62604478|NCT05776316|EXPERIMENTAL|IHRI|Integrated harm reduction intervention (IHRI) program tailored specifically for highly marginalized Black and Latinx people who use drugs (PWUDs). The IHRI lasts 8 weeks in duration, with the first 4 weeks consisting of weekly education lessons provided by the IHRI care coordinator. The subsequent 4 weeks will involve individualized identification of vulnerabilities in the social determinants of health (SDOH) for the purposes of making informed referrals to relevant partnering social service organizations. Participants will also be exposed to service encounters through mobile vans in which staff offer information to PWUD on syringe exchange, clean user kits, naloxone use, and fentanyl strip distribution.
62604479|NCT05776316|NO_INTERVENTION|HR SAU|Harm reduction services as usual (HR SAU). Participants will be exposed to service encounters through the mobile vans in which staff offer information to PWUD on syringe exchange, clean user kits, naloxone use, and fentanyl strip distribution.
62604480|NCT06595459|EXPERIMENTAL|3mg Nicotine Pouches|Participants will use 3mg nicotine pouches
62604481|NCT06595459|EXPERIMENTAL|6mg Nicotine Pouches|Participants will use 6mg nicotine pouches
62604482|NCT06595459|EXPERIMENTAL|Nicotine Mini Lozenges|Participants will use mini lozenges with dosing based on time to first cigarette (2mg - 4mg)
62604483|NCT06595459|NO_INTERVENTION|No Study Product|Participants randomized to this arm will not receive any intervention
62826963|NCT06242574||Adults with Alzheimer's disease and related dementia|75 patients with ADRD
62826964|NCT06242574||Care partners of Adults with Alzheimer's disease and related dementia|75 care partners for adults with ADRD
62826965|NCT06242574||Clinicians who treat patients with Alzheimer's disease and related dementia|25 healthcare practitioners
62826966|NCT02195518|EXPERIMENTAL|Tenofovir Disoproxil Fumarate|All enrolled subjects will receive open label TDF at a dose of 300 milligram (mg) orally once daily during the study period.
62826967|NCT04911140|ACTIVE_COMPARATOR|Photobiomodulation twice a week|This group will receive the application of photobiomodulation (PBM) twice a week for 4 weeks.
62826968|NCT04911140|ACTIVE_COMPARATOR|Photobiomodulation three times a week|This group will receive the application of photobiomodulation (PBM) three times a week for 4 weeks.
62826969|NCT04911140|PLACEBO_COMPARATOR|Simulated Photobiomodulation|This group will receive the application of simulated photobiomodulation (PBM) twice a week for 4 weeks.
62826970|NCT06593392|EXPERIMENTAL|Single arm|
62826971|NCT06269432|EXPERIMENTAL|Precision Antiplatelet Therapy Trial Group|Platelet function testing guides antiplatelet drug selection
62826972|NCT06269432|ACTIVE_COMPARATOR|Traditional Antiplatelet Therapy Control Group|Aspirin 100mg orally once a day
62826973|NCT06133179|EXPERIMENTAL|Cohort group|Routine care + transtemporal ultrasound examination with contract product during hospitalization
62826974|NCT04812210||case: children with congenital heart disease aged 2 to 4 years.|case: children with congenital heart disease aged 2 to 4 years.
62826975|NCT04812210||control children recruited in kindergartens and schools aged 2 to 4 years|control children recruited in kindergartens and schools aged 2 to 4 years
62826976|NCT00685412|EXPERIMENTAL|0.6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 0.6mg DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
62826977|NCT00685412|EXPERIMENTAL|2mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 2mg of DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
62045162|NCT01805492|EXPERIMENTAL|Intervention|Dr. Dean Ornish Program for Reversing Heart Disease
62045163|NCT01805492|NO_INTERVENTION|Control|Non-intervention controls retrospectively matched to intervention participants
62045164|NCT04911790|EXPERIMENTAL|Experimental Group|Participant will receive two doses inactivated SARS-CoV-2 vaccine . Vaccine will given by intramuscular injection on day 0 and day 28.
62045165|NCT02348814||normal weight|BMI 20-25
62045166|NCT02348814||overweight|BMI 25-30
62045167|NCT02348814||obese|BMI 30-35
62045168|NCT02348814||morbidly obese|BMI \> 35
62045169|NCT02348814||non-diabetic|HgbA1c (\<5.7%) and blood glucose (65-99 mg/dL) within normal range as defined at UCLA Clinical Lab
62045170|NCT02348814||diabetic|HgbA1c (\>6.5%) and blood glucose (\>100 mg/dL) as defined at UCLA Clinical Lab
62826978|NCT00685412|EXPERIMENTAL|6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
62045171|NCT02348814||non-cirrhotic|Normal liver function tests (AST/SGOT, ALT, SGPT, alkaline phosphatase, bilirubin) as defined at UCLA Clinical Lab
62045172|NCT02348814||dyslipidemic|Abnormal lipid profile (Total cholesterol \>170 mg/dL, LDL \>100 mg/dL, HDL \>130 mg/dL, triglycerides \>150 mg/dL) as defined at UCLA Clinical Lab
62045173|NCT05564013|NO_INTERVENTION|Phase 1 - Patient feedback and needs analysis|To facilitate the development of virtual reality application that is suitable for perioperative care management, a survey will be conducted in 100 subjects to gather patient preference and feedback with needs analysis.
62247489|NCT06418217|EXPERIMENTAL|Physiotherapist-led exercise|Physiotherapy-led exercise of patients with lateral hip pain
62437714|NCT03058939|OTHER|LHRH (luteinizing hormone-releasing hormone)|All Premenopausal patients will receive LHRH agonist for two years for contraception and fertility preservation.
62826979|NCT04672863|NO_INTERVENTION|Standard of Care Group|Subjects will participate in a standardized Transplant Nutrition class between day 21-40 as per institutional protocol and will be counseled as per the Mayo Clinic standard of care vis a vis dietary intervention, standard aerobic and resistance exercise recommendations (consistent with AASLD guidelines) and other lifestyle interventions.
62826980|NCT04672863|EXPERIMENTAL|Behavioral: Structured Modified Mediterranean Diet|Subjects will participate in a one-on-one counselling session with a dietician, as opposed to attending the standardized Transplant Nutrition class. Counselling will be provided on the elements of the modified Mediterranean diet which emphasizes consumption of fruits, vegetables, whole grains, beans and nuts, in addition to low salt, moderate amounts of lean protein (primarily fish and poultry) in addition to low to moderate quantities of monounsaturated fats.
62826981|NCT01452438||MenACYW-CRM vaccinated children|All children between the age of 2 to 10 years old who have received of MenACYW-CRM vaccine during the study period.
62045174|NCT05564013|EXPERIMENTAL|Phase 2 - Evaluation of prototype efficacy|Comparison of pre-operative anxiety and post-operative pain in 60 patients before and after intervention using the developed virtual reality application.
62247490|NCT00886704|ACTIVE_COMPARATOR|Convenience drink with EPA and DHA|Daily consumption of 200 ml convenience drink, containing 0.5 g EPA and DHA (Omega-3 Fatty Acids)
62247491|NCT00886704|PLACEBO_COMPARATOR|Convenience drink without EPA and DHA|Daily consumption of 200 ml convenience drink, not containing 0.5 g EPA and DHA (Omega-3 Fatty Acids), but containing 1.0 g of Omega-6 Fatty Acids (e.g. corn oil)
62247492|NCT01156233|EXPERIMENTAL|Cuff palpation technique|Cuff palpation by the investigator's finger.
62045175|NCT04851483|EXPERIMENTAL|Group 1_BAY2328065 _male participants|Approximately 6 participants will be randomly assigned to one of the 2 study intervention sequences (Group 1 or Group 2).
62045176|NCT04851483|EXPERIMENTAL|Group 2_BAY2328065 _male participants|Approximately 6 participants will be randomly assigned to one of the 2 study intervention sequences (Group 1 or Group 2).
62045177|NCT04851483|EXPERIMENTAL|Group 3_BAY2328065 _male participants|Approximately 8 participants will be assigned to the study intervention with one fixed sequence.
62045178|NCT04851483|EXPERIMENTAL|Group 4_BAY2328065 _female participants|Approximately 9 participants will be randomly assigned to receive BAY2328065.
62045179|NCT04851483|PLACEBO_COMPARATOR|Group 4_Placebo _female participants|Approximately 3 participants will be randomly assigned to receive placebo.
62045180|NCT01316510|ACTIVE_COMPARATOR|Bifidobacteria infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge (whichever happens first)
62045181|NCT01316510|PLACEBO_COMPARATOR|Placebo|A dilute formulation of the elemental formula Nutramigen (diluted to look like the probiotic arm).
62045182|NCT04846452|EXPERIMENTAL|NSCLC patients with negative driver genes|Patients with negative driver genes advanced or metastatic NSCLC will receive sintilimab combined with anlotinib hydrochloride and platinum-containing dual-agent chemotherapy regimens as first-line treatment.
62247493|NCT01156233|EXPERIMENTAL|Withdrawing tube technique|Identification of the tube by withdrawing until good quality breath sounds
62826982|NCT05427422||High Recovery|Effective recovery rate defined as difference between Fugl-meyer scores in the 6 weeks after stroke onset (eF) and in the enrollment (sF) normalized by (total score-sf) would be used to indicate the recovery Level of a patients, i.e., (eF-sF)/ (total score-sf). A previously reported recovery rate, i.e., proportional recovery((eF-sF)/(total score-sf)=0.7) was chosen as a standard of a high recovery. Patients with effective recovery rate higher than 0.7 at the T1 time point (6 weeks after stroke onset) would be assigned to group with high recovery rate
62826983|NCT05427422||Low Recovery|The Low Recovery group indicates that patients with effective recovery rate lower than 0.7
62826984|NCT05427422||Healthy Control|Age/sex matched healthy subjects enrolled to compare with group of patients.
62826985|NCT03391362|EXPERIMENTAL|Stereotactic Radiation|"* Stereotactic radiation will begin within 14 days of the MRI used for radiation planning~* Lesions \<2 cm in maximum diameter will be treated with stereotactic radiosurgery, generally 20 Gy in 1 fraction~* Lesions between 2.0 and 3.0 cm in maximum diameter will generally be treated to 18 Gy in 1 fraction~* Lesions \>3 cm will be generally be treated with stereotactic radiotherapy to 30 Gy in 5 fractions"
62826986|NCT06025032|EXPERIMENTAL|HG205|Method of Administration: Once Unilateral intracochlear injection/subject; The duration of the study for each subject includes a screening period, enrollment visit, treatment visit, a 26-week follow-up period, and a 5-year long-term safety follow-up after the injection
62247494|NCT04680442|ACTIVE_COMPARATOR|Control Group|Recommendations for continuing or holding trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) for the control group are guided by an adaptation of the 2008 Canadian recommendations.
62247495|NCT04680442|EXPERIMENTAL|Intervention Group|The intervention group will continue to receive trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) in the setting of asymptomatic decline in LVEF up to an LVEF of 40% as outlined in the criteria listed in Table 3. For reasons of practicality, in the intervention group, the first dose of trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) after randomization can be administered up to 3 weeks late. This will allow time for the participant to be reviewed by a cardiologist and to receive ACE-I/angiotensin receptor blocker and/or beta-blocker, and for dose titration.
62247496|NCT02478970|EXPERIMENTAL|Corneal endotheliopathy|Patients with primary corneal endotheliopathies, such as posterior polymorphous dystrophy, congenital hereditary endothelial dystrophy, Fuchs' dystrophy, iridocorneal endothelial syndrome will be evaluated with the NIDEK CEM-350 and Konan SP4000
62247497|NCT02478970|PLACEBO_COMPARATOR|Normal|Patients without corneal endotheliopathies will be evaluated with the NIDEK CEM-350 and Konan SP4000
62247498|NCT00565591|PLACEBO_COMPARATOR|Dose escalation|
62247499|NCT04634981||Group general anesthesia (G)|patients will positioned with pelvic wedge on operating table and preoxygenated. Then rapid sequence induction with precalculated doses of propofol (2 mg/kg) and rocuronium (0.9 mg/kg) will followed by endotracheal intubation. After delivery of the baby, fentanyl will be administered. Later, anesthesia will be maintained with isoflurane (1%).
62247500|NCT04634981||Group Spinal anesthesia (S)|all parturients will co-loaded with 500 ml of colloid solution. In the left lateral position, the patients' back will be cleaned with povidone iodine. In the meantime, the spinal anesthetic drug and local anesthetic drug will be prepared. After wiping povidone iodine with alcohol, a rapid single shot of 2.5 ml of 0.5% hyperbaric bupivacaine will be administered intrathecally using 22 G spinal needle. Oxygen will be administered using simple face mask till the delivery of the baby.
62247501|NCT02747953|EXPERIMENTAL|afatinib|
62247502|NCT04812067|EXPERIMENTAL|TTHX1114 weekly x 5|TTHX1114 via IC injection weekly x 5
62247503|NCT01519934||Ulthera-treated subjects|All enrolled subjects will have received an Ulthera treatment prior to enrollment.
62247504|NCT02435342|EXPERIMENTAL|30ug dalazatide|12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks.
62247505|NCT02435342|EXPERIMENTAL|60ug dalazatide|12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks.
62247506|NCT03311321|PLACEBO_COMPARATOR|Placebo-Control|The placebo-control group will take four placebo softgel capsules (similar in taste and appearance to the vitamin K2 supplements) every day for 8 weeks.
62247507|NCT03311321|EXPERIMENTAL|Vitamin K2 (360-mcg/d)|The experimental group will take four 90-mcg of vitamin K2 (menaquinone-7; 360-mcg) softgel capsules every day for 8 weeks.
62247508|NCT04993833||Patients|Patients with risk of cerebral edema.
62247509|NCT04993833||Healthy Control|Staff/Faculty who interact with patients at the enrolling site.
62247510|NCT04354298|EXPERIMENTAL|Fall 2019 ID Class|The ID group participated in a 12-week IMPROVment® intervention, which consists of weekly ID classes that progress according to a standardized method, from September 2019-December 2019.
62247511|NCT04354298|EXPERIMENTAL|Fall 2020 ID Class|The ID group will participate in a 12-week IMPROVment® intervention, which consists of weekly ID classes that progress according to a standardized method, from September 2020-December 2020.
62826987|NCT05826639||Temperature-sensitive RFA prior to biliary stenting|Data will be collected on subjects undergoing endoscopic retrograde cholangiopancreatography (ERCP) with temperature-sensitive RFA prior to biliary stenting for treatment of malignant biliary strictures as part of clinical care.
62604484|NCT05872100|EXPERIMENTAL|RESPONSE GROUP|Mindfulness-based psycho-education program will be applied to the students in the experimental group. After the end of the study, the mindfulness-based psychoeducation program given in the experimental group will also be applied to the control group. A 45-minute training and preliminary information will be given to the student group. Participants will meet for the first session. After the trainer, who is a clinical psychologist, introduces himself and meets the participants, 10 minutes will be given to ensure that all participants meet and look at each other. Then, the aim of the research will be discussed by sharing the content of the three-week program. After three weeks, post-tests will be administered.
62826988|NCT05826639||Non-RFA biliary stenting for malignant biliary obstruction|Retrospective participants that have undergone non-RFA biliary stenting for malignant biliary obstruction from a historical cohort will serve as controls.
62826989|NCT06654167|EXPERIMENTAL|Low temperature (16℃) group|Subjects in the exposure group will be exposed to low temperature (16℃) for about 2 hours in a chamber.
62826990|NCT06654167|EXPERIMENTAL|Moderate temperature (22℃) group|Subjects in the exposure group will be exposed to moderate temperature (22℃) for about 2 hours in a chamber.
62826991|NCT04262388|EXPERIMENTAL|Window|"Within each cancer type, 40 patients will be enrolled (for a total of 120 patients on study): 20 patients will be enrolled with locally advanced disease (window) and treated with durvalumab 1500 mg given by IV x 1 dose and oleclumab 3000 mg x 2 doses every 2 weeks prior to definitive therapy (e.g. surgery)."
62826992|NCT04262388|EXPERIMENTAL|Metastatic|"Within each cancer type, 40 patients will be enrolled (for a total of 120 patients on study): 20 patients will be enrolled with recurrent/metastatic (metastatic) disease and treated with durvalumab 1500 mg given by IV every 4 weeks and oleclumab 3000 mg given by IV every 2 weeks x 4 doses then IV every 4 weeks till disease progression, toxicity, withdrawal of subject consent, or another discontinuation reason."
62826993|NCT02574117|EXPERIMENTAL|flap with corticotomy and bone allograft|Maxillary expansion with quad helix appliance was applied to posterior teeth with cross bite. Then corticotomy surgical procedure associated with addition of commercially available bone allograft; demineralized freeze-dried bone allograft on the buccal surface of maxillary 1st premolar, 2nd premolar and 1st molar areas.
62437715|NCT03058939|OTHER|Tamoxifen or letrozole|Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors and according to the state of primary menopause at the onset of the study.
62826994|NCT05975203|NO_INTERVENTION|Standard care|After delivery the infant will be separated from the mother and placed on a primary care unit in another room to monitor the cardiopulmonary adaption for at least 20 minutes.
62826995|NCT05975203|EXPERIMENTAL|skin-to-skin contact|After delivery the infant will be put skin-to-skin on the mother's breast in comfort position for 60 minutes. The cardiopulmonary adaption will be monitored and supervised by the attending neonatologist and nurse.
62045183|NCT04434989|EXPERIMENTAL|Stereotactic Body Radiation Therapy|SBRT is defined as a special radiotherapy technique. The high dose of radiotherapy is accurately injected into the tumor lesion in one to several times using external irradiation technique. Then the tumor is exposed to high dose and the surrounding normal tissue to low dose.
62437716|NCT03058939|OTHER|Herceptin SC and Perjeta|Patients with HER2-positive disease (see glossary and section 10.3) will receive 5 three-weekly courses of trastuzumab (Herceptin SC) with pertuzumab (Perjeta). After that pts will continue receiving trastuzumab to complete total of 18 doses within 1 year of treatment.
62437717|NCT01748500|EXPERIMENTAL|Pantoprazole, Docetaxel, Prednisone|
62437718|NCT03058536|ACTIVE_COMPARATOR|Progesterone|400 mg micronized vaginal progesterone daily from randomization to 36 weeks
62437719|NCT03058536|ACTIVE_COMPARATOR|Arabin Pessary and Progesterone|"Arabin Pessary and Natural Micronized Progesterone~400 mg micronized vaginal progesterone daily from randomization to 36 weeks~The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) in combination with vaginal progesterone."
62826996|NCT06594874|EXPERIMENTAL|Arm A: HS-10370 dose 1 + Adebrelimab|Participants will receive HS-10370 dose 1 administered orally plus Adebrelimab given as a 20 mg/kg intravenous infusion(IV) once every 21-day cycle up to a total of 35 cycles. Participants may continue to receive treatment until discontinuation criteria are met.
62826997|NCT06594874|EXPERIMENTAL|Arm B: HS-10370 dose 2 + Adebrelimab|Participants will receive HS-10370 dose 2 administered orally plus Adebrelimab given as a 20 mg/kg intravenous infusion(IV) once every 21-day cycle up to a total of 35 cycles. Participants may continue to receive treatment until discontinuation criteria are met.
62437720|NCT03058536|ACTIVE_COMPARATOR|Arabin Pessary|The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) without vaginal progesterone use.
62604485|NCT05872100|NO_INTERVENTION|control group|A pre-test will be applied to the control group. No intervention will be made. The final test will be applied.
62604486|NCT04794829||Vaccinated|Received influenza and/or SARS-CoV-2 vaccine
62045184|NCT04434989|ACTIVE_COMPARATOR|Radiofrequency Ablation|Percutaneous radiofrequency ablation to the tumor
62045185|NCT02149251||Pre-genetic diagnosis|Women in this group had ICSI and PGD to exclude genetically affected children or for sex selection
62045186|NCT02149251||Control group|This group will include women who had IVF without PGD
62247512|NCT04354298|NO_INTERVENTION|Control Group|Participants are pre- and post-tested 12-14 weeks apart after not having changed anything drastic in their daily life.
62247513|NCT04216186|ACTIVE_COMPARATOR|Atomoxetine and Coenzyme Q|Atomoxetine and Coenzyme Q
62437721|NCT03058536|NO_INTERVENTION|No intervention|Expectant management
62437722|NCT01806597|EXPERIMENTAL|secukinumab 150mg|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects assigned to secukinumab 150 mg were dosed weekly for the first five weeks, then every four weeks up to and including Week 128. To maintain blinding, subjects received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment were administered by sub-cutaneous injections.
62826998|NCT06594874|EXPERIMENTAL|Arm C: HS-10370+ Adebrelimab + Pemetrexed and Platinum|Participants will receive HS-10370 administered orally in plus with Adebrelimab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met
62826999|NCT06594874|EXPERIMENTAL|Arm D: HS-10370+ Adebrelimab + Pemetrexed|Participants will receive HS-10370 administered orally in plus with Adebrelimab and pemetrexed administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
62827000|NCT06594874|EXPERIMENTAL|Arm E: HS-10370+ Pemetrexed and Platinum|Participants will receive HS-10370 administered orally in plus with pemetrexed and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
62827001|NCT01682434|ACTIVE_COMPARATOR|Wavefront-guided LASIK|One eye will be randomized to wavefront-guided treatment. The other receives conventional LASIK.
62827002|NCT01682434|ACTIVE_COMPARATOR|Conventional LASIK|One eye will receive wavefront-guided LASIK. The other eye receives conventional treatment.
62247514|NCT04216186|PLACEBO_COMPARATOR|Placebo and Atomoxetine|Placebo and Coenzyme Q
62247515|NCT00836251||H218O and 2H2O|schizophrenia
62247516|NCT00656773|EXPERIMENTAL|1|
62247517|NCT00656773|ACTIVE_COMPARATOR|2|
62247518|NCT04434196|EXPERIMENTAL|CC-99282 + obinutuzumab|Escalating doses of CC-99282 administered orally once daily on intermittent schedules with obinutuzumab IV infusion 1000 mg up to 2 years in Part A. CC-99282 administered orally once daily at MTD or alternative tolerating dosing schedule with obinutuzumab IV infusion 1000 mg up to 2 years in Part B.
62247519|NCT02489136|OTHER|Spirit Pass|It is a transfusion of psychic energies. Laying of hands to be in front of the incubator or on bed, at a distance at around 10 to 15 cm, during 10 minutes. Evaluate the effects of spirit passe in newborn and adults before and after ten minutes for 3 days.
62247520|NCT02489136|PLACEBO_COMPARATOR|laying of hands by workes|Laying of hand by workers and volunteers, not belonging to Spiritism.Laying of hands to be in front of the incubator or on bed, at a distance at around 10 to 15 cm, during 10 minutes. Evaluate the effects of spirit passe in newborn and adults before and after ten minutes for 3 days.
62247521|NCT02489136|NO_INTERVENTION|No intervention|No intervention during, in adults before and after ten minutes for 3 days.
62247522|NCT01062048||All participants|Participants administered Januvia up to 100 mg once daily as monotherapy or combination therapy with a sulfonylurea or with insulin during the re-examination period (up to 6 years)
62247523|NCT03985475||Person with a skin infection|For each person included in the study, skin sampling performed as part of the medical management of skin infections will be performed, associated with the contralateral healthy skin sampling.
62247524|NCT02714257|NO_INTERVENTION|Enhanced Usual Care - control group|Participants will receive enhanced usual care by reviewing three printed pamphlets on fall risks and recommendation to exercise. In addition, to maximize patient safety, the investigators will communicate the baseline bone density results (measured by Dual-energy X-ray absorptiometry, DXA) to the patient's primary care provider, and any critical values of a baseline measure.
62247525|NCT02714257|EXPERIMENTAL|Enhanced Usual Care plus Exercise Coaching Intervention|Participants will receive the three printed pamphlets on fall risks and exercising in groups (same as the controls) plus: (1) an exercise program that includes strength, balance, and aerobic exercises; (2) an exercise coach that provides in-person and telephone support/feedbacks to enhance participation in the exercise program; and (3) regular progress reports sent by coaches by fax/Electronic Health Records every 4 months, to communicate the patient's progress.
62827003|NCT03481777|ACTIVE_COMPARATOR|Remote Ischemic Conditioning|"Remote ischemic conditioning (RIC) is applied in the hyperacute prehospital phase using an automated RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg; but if initial systolic blood pressure is above 175 mmHg, the cuff is automatically inflated to 35 mmHg above the systolic blood pressure.~* Initial remote ischemic conditioning: prehospital phase, all included patients~* Remote ischemic conditioning at +6 hours: In-hospital, only patients with AIS and ICH, all centres~* Remote Ischemic Postconditioning (twice daily for 7 days): In-hospital/rehabilitation, Only patients with AIS and ICH and only at Aarhus University Hospital~Usual care with or without acute reperfusion therapy"
62827004|NCT03481777|SHAM_COMPARATOR|Sham - Remote Ischemic Conditioning|"Sham remote ischemic conditioning (Sham-RIC) is applied in the hyperacute prehospital phase using an automated Sham-RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be always be 20 mmHg.~* Initial Sham remote ischemic conditioning: prehospital phase, all included patients~* Sham Remote ischemic conditioning at +6 hours: In-hospital, only patients with AIS and ICH, all centres~* Sham Remote Ischemic Postconditioning (twice daily for 7 days): In-hospital/rehabilitation, Only patients with AIS and ICH and only at Aarhus University Hospital~Usual care with or without acute reperfusion therapy."
62827005|NCT06598488|EXPERIMENTAL|Nitrate rich beetroot juice|4 days of nitrate rich beetroot juice ingestion (Beet it)
62827006|NCT06598488|PLACEBO_COMPARATOR|Nitrate depleted beetroot juice|4 days of nitrate depleted beetroot juice ingestion (Beet it)
62247526|NCT00882310|EXPERIMENTAL|Gemcitabine, Docetaxel, Capecitabine GTX|GTX - A two week regimen of Gemcitabine at 600 mg/m2 on days 4 and 1, infused over 60 minutes, Docetaxel at 30 mg/m2 on days 4 and 11, infused over 60 minutes and Capecitabine at 1000 mg/m2 (capped at 1000 mg BID days 1-14) followed by one week off for a total of a 21 day cycle. This is repeated for a total of 6 months.
62247527|NCT03197857|EXPERIMENTAL|Control|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~* Control~* Control + protein supplementation~* Training in aquabike~* Training in aquabike + protein supplementation~* Bicycle training~* Bicycle training + protein supplementation"
62247528|NCT03197857|EXPERIMENTAL|Control + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~* Control~* Control + protein supplementation~* Training in aquabike~* Training in aquabike + protein supplementation~* Bicycle training~* Bicycle training + protein supplementation"
62045187|NCT06472466|EXPERIMENTAL|Intervention group - VR scenario|Virtual reality immersive intervention: 1-week virtual reality self-help exposure-based intervention. Participants will be asked to use the assigned virtual environment for a minimum of three times in total over the week, at home.
62045188|NCT06472466|ACTIVE_COMPARATOR|Control condition|Participants will all have access to self-help written materials.
62827007|NCT01955252|EXPERIMENTAL|Azithromycin|"All participants older than 2 months (population 18,000) will be offered a single oral dose of oral azithromycin (tablets) 30 mg per Kg up to a maximum dose of 2g.~Women who tell the investigators they are pregnant and people with known allergy to macrolides will be offered benzathine benzylpenicillin.~This will be a single arm study. Study participants who met the inclusion criteria and agree to sign the consent form will be managed with proposed drug and systematically observed to measure outcomes of interest."
62827008|NCT06185816|ACTIVE_COMPARATOR|Active Treatment|"ACTIVE treatment will be conducted by the study PIs, who are licensed pain physicians, Participants will receive 3 treatments, once weekly, for three weeks. Treatments are about 20 minutes long. The Stimpod being used is FDA cleared and is commercially available.~The treatment is a non-invasive pulsed radio frequency current that emits a high frequency magnetic field. It has a pulse width of 0.2ms, a pulse rate of 2Hz and an intensity between 0 - 30ma. There is a 'beep' sound as the pulses occur. There are 2 electrodes used - one is the indifferent electrode that is placed on the skin at a suitable distance away from the active electrode and the other, an active electrode - is a probe that is applied to the target nerve to treat the mononeuropathy"
62045189|NCT01324271|EXPERIMENTAL|Tympanostomy tube placement|placement of tympanostomy tube under local anesthesia in office/clinic setting
62045190|NCT04901650||Inpatient population|A survey will be administered to find out the prevalence of pain in hospitalized patients for any cause and its intensity. The medical history will be reviewed to assess the presence of pain medications and their impact on the pain perception and patients' satisfaction.
62247529|NCT03197857|EXPERIMENTAL|Training in aquabike|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~* Control~* Control + protein supplementation~* Training in aquabike~* Training in aquabike + protein supplementation~* Bicycle training~* Bicycle training + protein supplementation"
62247530|NCT03197857|EXPERIMENTAL|- Training in aquabike + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~* Control~* Control + protein supplementation~* Training in aquabike~* Training in aquabike + protein supplementation~* Bicycle training~* Bicycle training + protein supplementation"
62247531|NCT03197857|EXPERIMENTAL|Bicycle training|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~* Control~* Control + protein supplementation~* Training in aquabike~* Training in aquabike + protein supplementation~* Bicycle training~* Bicycle training + protein supplementation"
62247532|NCT03197857|EXPERIMENTAL|- Bicycle training + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~* Control~* Control + protein supplementation~* Training in aquabike~* Training in aquabike + protein supplementation~* Bicycle training~* Bicycle training + protein supplementation"
62247533|NCT01092975|EXPERIMENTAL|1.25 mg phenylephrine|
62247534|NCT01092975|EXPERIMENTAL|2.5 mg phenylephrine|
62247535|NCT01092975|EXPERIMENTAL|5.0 mg phenylephrine|
62247536|NCT01092975|EXPERIMENTAL|10.0 mg phenylephrine|
62247537|NCT01092975|EXPERIMENTAL|20.0 mg phenylephrine|
62247538|NCT01092975|EXPERIMENTAL|40.0 mg phenylephrine|
62247539|NCT01092975|EXPERIMENTAL|60.0 mg phenylephrine|
62247540|NCT01092975|EXPERIMENTAL|80.0 mg phenylephrine|
62604487|NCT01758978|EXPERIMENTAL|Treatment Group AB|"Subjects in this group will receive study drug in the following sequence:~* Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference)~* Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test)."
62045191|NCT02532673||Hyperbilirubinemia Cohort|Patients will be included who have evidence of hyperbilirubinemia (laboratory test of grade 2 or greater or \> 2 medical claims with an International Classification of Diseases, Ninth Revision, Clinical Modification code of 782.4 or 277.4 in any position) in the first 90 days after initiating Atazanavir therapy.
62247541|NCT01759004|ACTIVE_COMPARATOR|patient with lipoedema|"Lipedema group:~* diagnosed with lipedema following the criteria of Wold~* women~* age ≥ 18 years~clinimetrics: volume, muscle strength, physical condition, BMI"
62045192|NCT02532673||Non-hyperbilirubinemia cohort|Patients will be included who have no evidence of hyperbilirubinemia (no laboratory test of grade 2 or greater or any medical claims with an International Classification of Diseases, Ninth Revision, Clinical Modification of 782.4 or 277.4 in any position) in the 12-month follow-up period.
62045193|NCT00698490|EXPERIMENTAL|Group A|HSV-seronegative subjects
62045194|NCT00698490|EXPERIMENTAL|Group B|HSV-seropositive subjects
62247542|NCT01759004|ACTIVE_COMPARATOR|patients with obesity|"Obesity group:~* BMI ≥ 30~* women~* age ≥ 18 years~clinimetrics: volume, muscle strength, physical condition, BMI"
62045195|NCT00698490|EXPERIMENTAL|Group C|HSV-seronegative subjects
62247543|NCT05110339|EXPERIMENTAL|Ropivacaine plus Dexmedetomidine|In addition to standard general anesthesia, patients receive erector spinae block with ropivacaine at a dose of 0.5% plus dexmedetomidine at 0.3 mcg / kg corrected in a volume of 20 ml at the level of thoracic vertebra number 4, guided with ultrasound and under sterile technique, the date and time of application are recorded on the data collection sheet.
62247544|NCT05110339|ACTIVE_COMPARATOR|Control group|In addition to standard general anesthesia, patients receive erector spinae block with ropivacaine at a dose of 0.5% in a volume of 20 ml at the level of thoracic vertebra number 4, guided with ultrasound and under sterile technique, the date and time of application are recorded on the data collection sheet.
62437723|NCT01806597|EXPERIMENTAL|secukinumab 300 mg|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects assigned to secukinumab 300 mg were dosed weekly for the first five weeks and then every four weeks up to and including Week 128. In order to maintain the blinding, subjects received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment were administered by sub-cutaneous injections.
62247545|NCT03300167|EXPERIMENTAL|CE-marked coronary artery catheter|use of a novel CE-marked coronary artery catheter to obtain spatially-separated intravascular samples for laboratory measurement.
62604488|NCT01758978|EXPERIMENTAL|Treatment Group BA|"Subjects in this group will receive study drug in the following sequence:~* Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test).~* Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference)."
62247546|NCT00606450|EXPERIMENTAL|20 mg Apremilast daily|20 mg of CC-10004 daily
62247547|NCT00606450|EXPERIMENTAL|20mg Apremilast twice daily|CC-10004 twice daily
62247548|NCT00606450|PLACEBO_COMPARATOR|Placebo|Placebo arm
62827009|NCT06185816|SHAM_COMPARATOR|Non-Active Treatment|"Participants enrolled in the non-active arm will receive 3 treatments, once weekly, for three weeks. After the trial is completed, participants will be offered three free treatments.~The placebo device will be inert with nil current emitted however the device will look and be used in exactly the same way. There will also be a 'beep' sound emitted and only the investigator will know the difference. The placebo device will not deliver any electrical stimulation."
62247549|NCT03139708|EXPERIMENTAL|Alphagan plus|Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.
62247550|NCT03139708|EXPERIMENTAL|Tropicamide and Phenylephrine plus|Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.
62247551|NCT03139708|ACTIVE_COMPARATOR|Tropicamide and Phenylephrine only|Tropicamide and Phenylephrine only arm is given one drop of each times one.
62247552|NCT01017068|EXPERIMENTAL|A1 (glaucoma)|
62247553|NCT01017068|EXPERIMENTAL|A2 (glaucoma)|
62247554|NCT01017068|EXPERIMENTAL|A3 (glaucoma)|
62247555|NCT01017068|EXPERIMENTAL|A1 (normals)|
62247556|NCT01017068|EXPERIMENTAL|A2 (normals)|
62247557|NCT01017068|EXPERIMENTAL|A3 (normals)|
62247558|NCT01826851|EXPERIMENTAL|Exparel|266 mg Exparel, single-dose injection.
62247559|NCT01826851|PLACEBO_COMPARATOR|Placebo|0.9% Normal saline, single-dose injection.
62247560|NCT04415658|EXPERIMENTAL|Thyroxine|Intravenous thyroxine infusion
62247561|NCT04415658|PLACEBO_COMPARATOR|Saline Placebo|Intravenous saline infusion
62247562|NCT02761824|EXPERIMENTAL|Camp Discovery|One week activity based camp.
62247563|NCT05119218||Stunted subject|The population is all children under five aged 3-5 years in the stunting locus village. Subjects in this study were taken with a sampling quota of 100 stunting toddlers toddlers in each area.
62247564|NCT05119218||Normal subject|The population is all children under five aged 3-5 years in the stunting locus village. Subjects in this study were taken with a sampling quota of 100 non-stunted toddlers in each area.
62247565|NCT03819062|EXPERIMENTAL|Refractory Constipation with LLLT|Low level laser therapy (LLLT) will be administered to patients with severe refractory chronic constipation
62604489|NCT00420277|EXPERIMENTAL|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
62247566|NCT04156503|EXPERIMENTAL|Test fat: Palm olein|One high fat muffin will be serves together with a glass of low fat milk shake.
62247567|NCT04156503|EXPERIMENTAL|Test fat: Lard|One high fat muffin will be serves together with a glass of low fat milk shake.
62247568|NCT04468620|EXPERIMENTAL|ASSET Intervention|13-session group intervention
62827010|NCT00728689|ACTIVE_COMPARATOR|Group ST-246 Form I (followed by Form V)|Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.
62247569|NCT03615235||Recipients of a Kidney Transplant|APOLLO will prospectively assess transplant outcomes in recipients of kidneys from eligible living and deceased donors at all transplant programs in the United States including Puerto Rico.
62247570|NCT03615235||Living Kidney Donors|APOLLO will prospectively assess post-donation renal outcomes in eligible living kidney donors at all transplant programs in the United States including Puerto Rico.
62247571|NCT05151471|EXPERIMENTAL|MT-1186 - Group 1|Oral edaravone administered once daily for up to 48 weeks or until the drug is commercially available in that country.
62437724|NCT01806597|PLACEBO_COMPARATOR|Placebo|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects on placebo were dosed weekly for 5 weeks then once every 4 weeks. At Week 16, ppIGA responders continued to receive placebo weekly for 5 weeks starting at Week 16, then every 4 weeks up to and including Week 76 while ppIGA non-responders were randomized in a 1:1 ratio to secukinumab either 150 mg or 300mg weekly for 5 weeks, starting at Week 16, then every 4 weeks up to and including Week 128. At Week 80, subjects on placebo were either terminated their participation, if ppIGA responders, or randomized in a 1:1 ratio to secukinumab either 150 mg or 300 mg once every 4 weeks until Week 128 inclusive. All doses of study treatment were administered by sub-cutaneous injections.
62437725|NCT01017679|EXPERIMENTAL|1|Oral Drug gefitinib(Iressa) 500 mg Everyday
62437726|NCT01017679|ACTIVE_COMPARATOR|2|Oral Drug gefitinib(Iressa) 250 mg Everyday
62437727|NCT00800098|PLACEBO_COMPARATOR|Placebo|Placebo cream matched on consistency, color, and smell
62437728|NCT00800098|ACTIVE_COMPARATOR|Active|AARP active arthritis cream
62247572|NCT05151471|EXPERIMENTAL|MT-1186 - Group 2|Oral edaravone administered for 10 days followed by 18-day placebo (regimen denoted as on/off) for up to 48 weeks or until the drug is commercially available in that country.
62247573|NCT02449681|EXPERIMENTAL|TH-4000 (Tarloxotinib)|TH-4000 150 mg/m2 will be administered by IV infusion over 60 minutes on Days 1, 8, 15 and 22 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
62437729|NCT02499354|ACTIVE_COMPARATOR|Oral Iron|Ferrous Sulfate 325mg (oral) tabs morning and evening
62437730|NCT02499354|ACTIVE_COMPARATOR|IV Iron|Ferumoxytol intravenous (IV) 1020 mg - 2 vials of 510 mg (IV push, 2-3 mins) each given 2-7 days apart
62437731|NCT01432132||Head & Neck Patients|Patients undergoing surgical treatment for head and neck cancer.
62437732|NCT01432132||Clinicians|Clinical staff who care for head and neck surgical participants during active treatment.
62437733|NCT02159859|EXPERIMENTAL|Ertapenem|Subjects with end stage renal disease (ESRD) who undergo hemodialysis three times a week and without infection will be administered one gram of ertapenem once over five minutes through infusion access after a hemodialysis session, and will have blood drawn at time 0, 0.5, 1, 2, 6, and 12 hours after the ertapenem administration and once prior to the next hemodialysis session
62437734|NCT05842395|EXPERIMENTAL|Participants with distal radius fractures taking vitamin c supplementation.|Participants who give informed consent and successfully pass the eligibility criteria will take 1g of oral vitamin C daily for three months.
62437735|NCT05842395|PLACEBO_COMPARATOR|Participants with distal radius fractures taking a placebo.|Participants who give informed consent and successfully pass the eligibility criteria will take a placebo daily for three months.
62437736|NCT00852085|EXPERIMENTAL|Group MI|Four group counseling sessions and a directed observational visit to the emergency department of a busy urban hospital
62437737|NCT00852085|ACTIVE_COMPARATOR|Enhanced community service|
62437738|NCT01690065|EXPERIMENTAL|Nilotinib+AD induction|"Nilotinib plus AD induction chemotherapy~* AD regimen : Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)~* Nilotinib 400mg bid PO (continuous without interruption from D8 of induction chemotherapy)~* Re-induction chemotherapy AD regimen : Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 5 days (D 1-5) plus Daunorubicin 45 mg/m2/day iv daily for 2 days (D 1-2)"
62437739|NCT03676374|EXPERIMENTAL|Prucalopride|Prucalopride 2mg once a day as add-on for PPI 2x/d
62437740|NCT03676374|PLACEBO_COMPARATOR|Placebo|Placebo once a day as add-on for PPI 2x/d
62437741|NCT04274192|EXPERIMENTAL|Alternating between Synchronized and Continuous HFNC at 6 and 8 LPM (starting with synchronized)|Subjects will first receive HFNC synchronized to his/her own efforts via NAVA at 6 LPM followed by continuous HFNC at 6 LPM and then HFNC synchronized to his/her own efforts via NAVA at 8 LPM followed by continuous HFNC at 8 LPM
62437742|NCT04274192|ACTIVE_COMPARATOR|Alternating between Synchronized and Continuous HFNC at 6 and 8 LPM (starting with continuous)|Subjects will first receive continuous HFNC at 6 LPM followed by HFNC synchronized to his/her own efforts via NAVA at 6 LPM. Next, subjects will receive continuous HFNC at 8 LPM followed by HFNC synchronized to his/her own efforts via NAVA at 8 LPM.
62437743|NCT04383002|NO_INTERVENTION|Standard of Care (control)|Patients will receive standard of care therapy
62437744|NCT04383002|EXPERIMENTAL|Inhaled Nitric Oxide|
62247574|NCT06041620|EXPERIMENTAL|VGB-Ex01|Each subject will accept one dose of VGB-Ex01.
62247575|NCT03743883||Low-dose ASA cohort|A person is identified as newly exposed to low-dose ASA, he/she will become member of new user low-dose ASA cohort and that date will be the start date for outcome follow-up.
62827011|NCT00728689|ACTIVE_COMPARATOR|Group ST-246 Form V (followed by Form I)|Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.
62437745|NCT00950833|ACTIVE_COMPARATOR|AP-AP Group|subjects from the AP-AP group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in study NCT00496015, receiving an additional dose of pneumococcal conjugate vaccine GSK1024850A for immune memory assessment
62827012|NCT00743834|OTHER|A|Effectiveness of Luvox CR plus Web-based CBT for OCD
62827013|NCT03278275|EXPERIMENTAL|uPAR PET/CT|One injection of the radioligand 68Ga-NOTA-AE105
62827014|NCT04643210|EXPERIMENTAL|F2F MoB EI and access to MoB Digital Platform (MoB DP) group|"The design of the face-to-face Management of my Bipolarity educational intervention (F2F MoB EI) will rely on the Colom \& Vieta model, Cognitive- Behavioural techniques and the results of the relevant literature review and data acquired in the qualitative research of bipolar disease patients' educational needs. A textbook will be devised explaining in detail the step-by-step process and the techniques of the experimental educational method of the MoB F2F EI.~This group will also receive the technology-based intervetion, which regards access to the MoB DP. This is an ecosystem where the participants will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile."
62827015|NCT04643210|ACTIVE_COMPARATOR|The MoB DP group|This group will receive the technology-based intervention, which regards access to the MoB DP. The structure of the MoB DP has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.
62827016|NCT05932238|EXPERIMENTAL|Systane Hydration Preservative Free (PF)|1-2 drops in each eye four times a day for 30 days
62827017|NCT05932238|EXPERIMENTAL|Systane Hydration Preserved|1-2 drops in each eye four times a day for 30 days
62827018|NCT03457896|EXPERIMENTAL|Arm 1|"Guardant360 test on blood from select patients with known HER2 status.~Prior to assignment to Arm 1, HER2 test on blood obtained from Quadruple Wild-Type patients who received anti-EGFR therapy. Patients with HER2 amplified, HER2 Wild-Type or HER2 mutated will recieve:~• Neratinib daily + Trastuzumab weekly until disease progression"
62827019|NCT03457896|EXPERIMENTAL|Arm 2|"Patients with HER2 Wild Type or HER2 amplified with no prior anti-EGFR therapy will receive:~• Neratinib daily + Cetuximab weekly until disease progression"
62247576|NCT03743883||Comparison unexposed cohort|When a member of new user low-dose ASA cohort is confirmed, one comparison member will be confirmed also from the source population not yet censored on that day (start date) and with the same distribution of matching factors (age, sex, time interval since entry date and number of PCP visits in the year prior to start date) of its low-dose ASA pair with the only difference of being free of ASA on start date.
62247577|NCT02955420|EXPERIMENTAL|BC 007 (15, 50, 150, 300, 450, 750, 1350, 1200 mg)|"Part A:~BC 007 at doses of 15, 50 and 150 mg or matching placebo administered as i.v. bolus + infusion of 20 min (Cohorts 1 to 4). The sentinel pair of each cohort will be dosed without bolus.~NaCl 0.9% (matching placebo) administered as i.v. bolus + infusion of 20 min (Part A: Cohorts 1 to 4).~Part B:~BC 007 at doses of 50 and 150 mg administered (Cohort 1) or a single dose \< 50 mg or 150 mg (Cohort 2) as i.v. bolus + infusion of 20 min is administered to GPCR autoantibody positive subjects. The first subject in each dosing period of Cohort 1 will be dosed without bolus.~Part C:~BC007 administered at doses of 300 mg (Cohort 1), 450 mg (Cohort 2), 750 mg (Cohort 3), 1350 mg (Cohort 4) as i.v. bolus + infusion of 40 min to GPCR autoantibody positive subjects. The first three subjects in each dosing period of Cohort 1-4 will be dosed without bolus. In Cohort 5 BC007 dose of 1200 mg will be administered as a continuous infusion of 20 min."
62827020|NCT05309070|ACTIVE_COMPARATOR|Study group|female patients with primary burning mouth syndrome
62827021|NCT05309070|PLACEBO_COMPARATOR|Control group|female patients with primary burning mouth syndrome
62827022|NCT06375551|ACTIVE_COMPARATOR|ORCA-A|Decision Makers receiving automated facilitation to accompany ORCA
62827023|NCT06375551|ACTIVE_COMPARATOR|ORCA-L|Decision Makers receiving live facilitation to accompany ORCA
62827024|NCT03820843|EXPERIMENTAL|Art therapy|Art therapy and standard orthophonic rehabilitation
62827025|NCT03820843|NO_INTERVENTION|Control group|Only standard orthophonic rehabilitation
62827026|NCT05771987|EXPERIMENTAL|HCM patients with LVOT obstruction|Patients with obstructive HCM are considered for this study if 1) symptomatic, 2) refractory to optimized medical therapy and 3) not or poorly\* eligible for septal myectomy or with an indication to implant a pacing device (pacemaker or ICD) independent on the ventricular obstruction.
62247578|NCT04667910|EXPERIMENTAL|601 1.25mg|
62247579|NCT04667910|EXPERIMENTAL|Ranibizuman 0.5 mg|
62247580|NCT00201968|OTHER|FES training|Arm 1 receives functional electrical stimulation while walking on body weight suspension training.
62247581|NCT00201968|OTHER|Control Group training|Aerobic and resistance training program
62437746|NCT00950833|ACTIVE_COMPARATOR|NAP-pre Group|subjects from the NAP-pre group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in study NCT00496015 receiving an additional dose of pneumococcal conjugate vaccine GSK1024850A for immune memory assessment
62604490|NCT00420277|ACTIVE_COMPARATOR|Control|Voluven (HES 130/0.4)
62604491|NCT00326781|ACTIVE_COMPARATOR|Nicotine Nasal Spray|
62827027|NCT00807508|EXPERIMENTAL|1|daily leucine supplementation
62604492|NCT00326781|ACTIVE_COMPARATOR|Transdermal Nicotine patch|
62827028|NCT00807508|PLACEBO_COMPARATOR|2|daily placebo supplementation
62827029|NCT00915252|EXPERIMENTAL|5-azacytidine|Patients enrolled in this arm will receive standard induction and consolidation chemotherapy preceded by 5-azacytidine. These patients will additionally receive maintenance therapy with 5-azacytidine for one year after start of induction therapy.
62827030|NCT00915252|ACTIVE_COMPARATOR|standard chemotherapy|Patients enrolled in this arm will receive standard chemotherapy treatment.
62827031|NCT04951947|EXPERIMENTAL|Arm A|Treatment arm
62827032|NCT01783613|EXPERIMENTAL|Docosahexaenoic acid administration|50 patients will receive docosahexaenoic acid
62827033|NCT01783613|PLACEBO_COMPARATOR|placebo|50 patients will receive placebo
62827034|NCT06601062|NO_INTERVENTION|Treatment as usual|Clinicians will deliver cognitive behavioral therapy as usual, as consistent with routine clinic practices, to patients receiving telehealth services
62827035|NCT06601062|EXPERIMENTAL|Tele-BE|Clinicians will deliver cognitive behavioral therapy as usual, as consistent with routine clinic practices, with the support of the Tele-BE platform, to patients receiving telehealth services
62827036|NCT01186289|EXPERIMENTAL|atorvastatin|high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
62437747|NCT00950833|ACTIVE_COMPARATOR|Unprimed Group|Age-matched subjects from the unprimed group of the NCT00496015 study, not previously vaccinated with any pneumococcal vaccine, receiving two doses of pneumococcal conjugate vaccine GSK1024850A
62827037|NCT01186289|PLACEBO_COMPARATOR|placebo|
62827038|NCT05207488|EXPERIMENTAL|Exercise + Prebiotic|The Exercise + Prebiotic intervention group will consume 10 g/d of fructo-oligosaccharides (FOS). Additionally, they will perform 6 wk. of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk).
62827039|NCT05207488|PLACEBO_COMPARATOR|Exercise + Placebo|The Exercise + Placebo group will consume 10 g/d of a placebo (maltodextrin) powder every day. Additionally, they will perform 6 wk. of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk).
62437748|NCT04434859||Patients with tinnitus|Patients (over 18 years old) seen at the medical center due to tinnitus, lasting at least 3 months.
62247582|NCT01282281||Individuals aged 14-18 and 19-65 with a diagnosis of BD|
62827040|NCT00967746|EXPERIMENTAL|ENG-MIUS low|Low dose: ENG-MIUS containing 38 mg ENG with a skin thickness of approximately 350 μm
62247583|NCT05067426|EXPERIMENTAL|HIIT-HV|"HIIT-HV - high intensity interval training high volume~Participants complete a total of 10 HIIT sessions over a 7-day period consisting of 5 x 4-minute intervals at an intensity of 90-95% of their individual maximum heart rate (HRmax), interspersed with a 2.5-minute active recovery period. Each training session is followed by 30 minutes of low-intensity training (total of 300 minutes of additional low-intensity training during this period)."
62247584|NCT05067426|EXPERIMENTAL|HIIT-LV|"HIIT- LV - high intensity interval training low volume~Participants complete a total of 10 HIIT sessions over a 7-day period consisting of 5 x 4-minute intervals at an intensity of 90-95% of their individual maximum heart rate (HRmax), interspersed with a 2.5-minute active recovery period."
62247585|NCT05067426|NO_INTERVENTION|Control group|Participants continue with their regular training program.
62247586|NCT01580150|EXPERIMENTAL|Berry meal|Carbohydrate meals with berries
62247587|NCT01580150|ACTIVE_COMPARATOR|Reference meal|Carbohydrate meals without berries
62247588|NCT02129205|EXPERIMENTAL|PF-06650808|
62247589|NCT01191541|ACTIVE_COMPARATOR|DNR+Ara-c(Ara-C group)|patients in this group were treated with DNR+Ara-C in consolidation
62437749|NCT02947932|EXPERIMENTAL|Pre-ERCP group Oral resveratrol in in all patients.|Oral resveratrol was administrated within 1hour before ERCP in all patients.
62437750|NCT02947932|ACTIVE_COMPARATOR|Post-ERCP rectal Indomethacin in high-risk patients.|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
62437751|NCT04189276|ACTIVE_COMPARATOR|Group1|T101+ETV(Entecavir) /TDF(Tenofovir)
62437752|NCT04189276|ACTIVE_COMPARATOR|Group2|T101+ETV/TDF
62827041|NCT00967746|EXPERIMENTAL|ENG-MIUS intermediate|Intermediate dose: ENG-MIUS containing 61 mg ENG with a skin thickness of approximately 140 μm
62827042|NCT00967746|EXPERIMENTAL|ENG-MIUS high|High dose: ENG-MIUS containing 72 mg ENG with a skin thickness of approximately 50 μm
62827043|NCT00967746|ACTIVE_COMPARATOR|Multiload|Multiload-cu 375®
62827044|NCT00852683|ACTIVE_COMPARATOR|A|
62827045|NCT00852683|PLACEBO_COMPARATOR|B|
62247590|NCT01191541|EXPERIMENTAL|DNR(No Ara-C group)|patients in this group were treated with DNR alone in consolidation
62247591|NCT04939662|EXPERIMENTAL|Olaparib+Bevacizumab to SCLC patients|"Regimen and administration:~Administration of olaparib Olaparib 300 mg bid per os every 12 hours D1-21 administered in each cycle days. One cycle consists of 21 days. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Administration of bevacizumab Bevacizumab 15 mg/kg via IV administered on Day1 of each cycle. One cycle is consisted of 21 days.~The subject's body weight criterion is based on C1D1 (first dose date), and if more than 10% of BW is increased and decreased, the drug dose is changed to that BW."
62247592|NCT02873650|EXPERIMENTAL|Group 1 - Control group|
62247593|NCT02873650|EXPERIMENTAL|Group 2-Moderate hepatic impairment|
62247594|NCT02873650|EXPERIMENTAL|Group 3-Severe hepatic impairment|
62247595|NCT05488210||Malnourished DM2 patients|Diabetic patients who present malnutrition through the GLIM criteria
62247596|NCT01115530|NO_INTERVENTION|1|Control inpatient GEM rehabilitation and continue twice weekly low level walking/stretching to control for time/interaction with intervention/exercise groups
62247597|NCT01115530|EXPERIMENTAL|2|Resistance exercise (2x/week)
62247598|NCT01115530|EXPERIMENTAL|3|Nutritional (amino acid metabolite) supplement twice daily
62247599|NCT01115530|EXPERIMENTAL|4|Resistance exercise (2x/week) and nutritional (amino acid metabolite) supplement twice daily
62247600|NCT05138666|EXPERIMENTAL|biological sample|respiratory and blood sample
62247601|NCT03319407|OTHER|Observation|All participants will be monitored with EPAD system
62247602|NCT00868426|EXPERIMENTAL|1|Budesonide/Formoterol Batch 1
62437753|NCT04189276|ACTIVE_COMPARATOR|Group3|ETV or TDF
62437754|NCT04189276|ACTIVE_COMPARATOR|Group4|Peg-IFNα-2b+ETV/TDF
62827046|NCT06592183|EXPERIMENTAL|Intervention|Participants in the intervention group will use a speech therapy application, a software designed for post-stroke dysarthria speech therapy and provided in the form of a mobile application. The application provides intensive speech treatment, including respiration, phonation, resonance, prosody, and articulation exercises. The system analyzes patients' voices collected while using the application and delivers the results through real-time visual and summary feedback, increasing patients' ability to self-monitor.
62827047|NCT06592183|NO_INTERVENTION|Waitlist control|
62827048|NCT03085095|EXPERIMENTAL|Relugolix|Relugolix for 48 weeks
62827049|NCT03085095|ACTIVE_COMPARATOR|Leuprolide Acetate|Leuprolide acetate for 48 weeks
62827050|NCT06602843|EXPERIMENTAL|Experimental|Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
62437755|NCT05077852||Cystoscopy Bladder Cancer|Patients diagnosed with primary bladder cancer at the base, trigone or neck of the bladder by cystoscopy.
62437756|NCT05077852||Cystoscopy IPP|Patients diagnosed with intravesical prostate protrusion (IPP) at the base, trigone or neck of the bladder by cystoscopy.
62437757|NCT02212431|EXPERIMENTAL|Cysteamine|"Dosing will be in accordance with licensed use of cysteamine for cystinosis, i.e. 450mg qds.~Dose will be escalated:~450mg od for one week 450mg bd for one week 450mg tds for one week 450mg qds for two weeks"
62437758|NCT02580578||All Participants|Female patients who are diagnosed and treated for symptoms associated with their uterine fibroids per routine clinical practice. No intervention is administered in this study.
62437759|NCT03154528||healthy control group|serum level of Vitamin D is going to be checked by ELISA in 30 healthy control volunteers
62437760|NCT03154528||case study group|serum level of Vitamin D is going to be checked by ELISA in 60 Androgenetic Alopecia patients.
62437761|NCT02158910||Aricept Group 1|Subjects starting at 5 mg Aricept and increasing their dose to 10 mg Aricept
62437762|NCT02158910||Aricept Group 2|Subject starting at 10 mg Aricept and increasing their dose to 23 mg Aricept
62437763|NCT01893866|EXPERIMENTAL|A|
62437764|NCT01893866|EXPERIMENTAL|B|
62827051|NCT06602843|ACTIVE_COMPARATOR|Comparator|chemoradiotherapy followed by surgery
62827052|NCT01968200|EXPERIMENTAL|Enalapril concomitant|Enalapril started concomitantly to AC-containing treatments
62827053|NCT01968200|EXPERIMENTAL|Enalapril after injury|Enalapril prescribed to selected patients showing laboratory evidences of injury after chemotherapy at follow-up visits.
62827054|NCT05813236|EXPERIMENTAL|Novosyn®|Novosyn® Quick is available in a range of gauge sizes and lengths, non-needled or attached to stainless steel needles of varying types and sizes: Novosyn® Quick sutures are available undyed in sizes USP 2 (5 metric) through USP 6-0 (0.7 metric).
62827055|NCT05813236|ACTIVE_COMPARATOR|Monosyn®|Monosyn® Quick is a sterile, synthetic, absorbable, monofilament surgical suture material made from a triblock copolymer comprising glycolide (72 %), ε-caprolactone (14 %) and trimethylene carbonate (14 %), which is only available undyed.
62827056|NCT06592287|EXPERIMENTAL|Frontline has received treatment with immune checkpoint inhibitors|"Previously received first-line treatment with immune checkpoint inhibitors, and first-line PFS\>7m~Adebrelimab 1200 mg, iv. q3w~Apatinib 250 mg po qd~Lrinotecan liposome 80mg/m2, iv. q3w~Continue medication until disease progression, toxicity intolerance, initiation of new anti-tumor treatment, withdrawal of knowledge, or continuous medication for at least 2 years."
62437765|NCT04898725|EXPERIMENTAL|Vit D Group (randomized)|Subjects will be randomly assigned to receive a daily vitamin D supplementation (4800IU daily) for 8 weeks
62437766|NCT04898725|NO_INTERVENTION|Control Group (randomized)|Subjects will be randomly assigned to receive a placebo for 8 weeks.
62437767|NCT04898725|EXPERIMENTAL|Preference Vit D Group (non-randomized)|Subjects with a strong preference to receive a daily vitamin D supplementation (4800IU daily) for 8 weeks.
62437768|NCT04898725|NO_INTERVENTION|Preference no Vit D Group (non-randomized)|Subjects with a strong preference to receive usual care (not receiving vitamin D supplements) for 8 weeks.
62437769|NCT02785133|EXPERIMENTAL|Treatment group|Polychromatic light emitting diode system is a non-significant risk device that administers low-dose light generated by a light emitting diode. Small adapter attaches directly to a standard 20-gauge catheter that threads a small fiber optic through the distal end of the catheter. The optic terminates at the distal end of the catheter. Polychromatic light is emitted to illuminate the catheter and site of catheter entrance. Concurrently, normal saline flows through the optic adapter and through into the 20-gauge catheter.
62437770|NCT01074021|EXPERIMENTAL|Nimotuzumab plus chemoradiotherapy|
62437771|NCT01074021|PLACEBO_COMPARATOR|placebo plus chemoradiotherapy|
62437772|NCT03741218|EXPERIMENTAL|1|All subjects will receive a high-fat breakfast and a medium-fat lunch twice. They will consume together with the breakfast the placebo (PLA) the first time and grape (GRAP) the second time.
62437773|NCT03741218|EXPERIMENTAL|2|All subjects will receive a high-fat breakfast and a medium-fat lunch twice. They will consume together with the breakfast grape (GRAP) the first time and the placebo (PLA) the second time.
62437774|NCT03645083|EXPERIMENTAL|Telephone call|Participants receive a telephone call reminder three days after their initial visit
62437775|NCT03645083|EXPERIMENTAL|Text message|Participants receive a text message reminder three days after their initial visit
62437776|NCT03645083|NO_INTERVENTION|Control|Participants do not receive any intervention after their initial visit
62437777|NCT03982056||Main study group|"Assessments performed:~* Height~* Mass~* Body fat density~* Bone density~* Lean muscle density~* Lung volume measurements~* Floating technique~* Buoyancy"
62437778|NCT03982056||Validation group|"Assessments performed:~* Height~* Mass~* Body fat density~* Bone density~* Lean muscle density~* Lung volume measurements~* Floating technique~* Buoyancy"
62437779|NCT04246970|NO_INTERVENTION|Control group|Conventional medical care
62437780|NCT04246970|EXPERIMENTAL|Prehabilitation group|Conventional medical care and 8 weeks of a Prehabilitation supervised program
62437781|NCT04246970|EXPERIMENTAL|Prehabilitation and posttransplant training group|Conventional medical care, 8 weeks of a Prehabilitation supervised program and a posttransplant training program.
62604493|NCT02703506|EXPERIMENTAL|Experimental. Pain Education Program|Ten group sessions of treatment with a patient education pain for chronic neck pain (biopsychosocial approach). The group sessions of 60-120 minutes twice a week with a maximum of 10 participants.
62604494|NCT02703506|ACTIVE_COMPARATOR|Control|"The control group: individualized session of physical therapy (TENS and exercise).~Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises ."
62827057|NCT06592287|EXPERIMENTAL|Previously not received immune checkpoint inhibitor treatment|"those who have received standard systemic chemotherapy~Adebrelimab 1200 mg, iv. q3w~Apatinib 250 mg po qd~Lrinotecan liposome 80mg/m2, iv. q3w~Continue medication until disease progression, toxicity intolerance, initiation of new anti-tumor treatment, withdrawal of knowledge, or continuous medication for at least 2 years."
62827058|NCT05322655||infants living in low-income neighborhoods of Nairobi|62 infants between 0 and 12 months age
62827059|NCT05322655||infants living in middle-income neighborhoods of Nairobi|62 infants between 0 and 12 months age
62827060|NCT05322655||infants living in low-income neighborhoods of Kisumu|62 infants between 0 and 12 months age
62827061|NCT05322655||infants living in middle-income neighborhoods of Kisumu|62 infants between 0 and 12 months age
62827062|NCT06595537||Ultrasound control of air insufflation in tracheobronchial suction catheter, oesofagus and stomach|Patients will receive a gastric feeding tube. At mid-esophagus level and at gastric level, placement of the gastric feeding tube will be controlled through doppler-ultrasound after air-insufflation. Ultrasound control after air insufflation will also take place after placing a suction catheter through the endotracheal tube in the trachea. Finally the gastric feeding tube placement will be confirmed with chest X-ray.
62827063|NCT02266368|NO_INTERVENTION|Control group|This arm will include patients with non-coated stents
62247603|NCT00868426|EXPERIMENTAL|2|Budesonide/Formoterol Batch 2
62247604|NCT00868426|EXPERIMENTAL|3|Budesonide/Formoterol Batch 1 and charcoal
62247605|NCT04505904|EXPERIMENTAL|Syntocinon First|Crossover design, all participants received experimental condition at either visit one or visit two, and the placebo at the other visit. This arm designates those who received syntocinon at visit one and placebo at visit two. Syntocinon is 24 IU dose administered intranasally in spray form.
62437782|NCT02770716|EXPERIMENTAL|Terlipressin|Participants receive terlipressin intravenously as a bolus injection, followed by a saline flush. Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol.
62437783|NCT02770716|PLACEBO_COMPARATOR|Placebo|Participants receive matching placebo intravenously as a bolus injection, followed by a saline flush. Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol.
62437784|NCT05527210|ACTIVE_COMPARATOR|Active Study Med|Participants randomized to active study medication will mix 4g of powder prebiotic with water, 3 times a day for 12 weeks.
62437785|NCT05527210|PLACEBO_COMPARATOR|Placebo|Participants randomized to active study medication will mix 4g of powder placebo with water, 3 times a day for 12 weeks.
62437786|NCT05631899|EXPERIMENTAL|KRAS-EphA-2-CAR-DC plus anti-PD-1 antibody and anti-CTLA4 antibody|"In the priming phase, a conditioning chemotherapy regimen of Abraxane and cyclophosphamide is administered three days before vaccination, and KRAS-EphA-2-CAR-DC vaccine is infused on Day 0 and Day 7 in Week 1.~In the boost phase, KRAS-EphA-2-CAR-DC vaccine is infused one dose every 8 weeks since Week 5.~Anti-PD-1 antibody and anti-CTLA4 antibody are administered 2 days after the first dose of KRAS-EphA-2-CAR-DC vaccine in the boost phase (Day 3 in Week 5) and every 3 weeks afterwards for four doses, followed by anti-PD-1 antibody once every 3 weeks, until:~1. Unacceptable toxicity occurred or disease progression; or~2. Reactive T cells are undetected repeatedly after the last vaccine dose; or~3. Vaccine exhaustion."
62437787|NCT05631899|EXPERIMENTAL|KRAS-EphA-2-CAR-DC plus anti-PD-1 antibody|"In the priming phase, a conditioning chemotherapy regimen of Abraxane and cyclophosphamide is administered three days before vaccination, and KRAS-EphA-2-CAR-DC vaccine is infused on Day 0 and Day 7 in Week 1.~In the boost phase, KRAS-EphA-2-CAR-DC vaccine is infused one dose every 4 weeks since Week 5 for a total of 6 to 8 doses, then maintenance vaccination is given one dose every 8 weeks.~Anti-PD-1 antibody is administered 2 days after the first dose of KRAS-EphA-2-CAR-DC vaccine in the boost phase (Day 3 in Week 5) and every 4 weeks afterwards, until:~1. Unacceptable toxicity occurred or disease progression; or~2. Reactive T cells are undetected repeatedly after the last vaccine dose; or~3. Vaccine exhaustion."
62604495|NCT05809024|EXPERIMENTAL|single Arm|Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy，if ki67 was higher than 10% after two weeks,CDK4/6 Inhibitor was added.
62604496|NCT02653170|NO_INTERVENTION|Usual Care|Patients in this group will receive the hospitals' usual transitional care approach.
62604497|NCT02653170|EXPERIMENTAL|SCM|"One intervention is provided:~1. SCM (Stroke Case manager): a trained social worker who provides in-home case management services."
62827064|NCT02266368|ACTIVE_COMPARATOR|Antimicrobeal group|This arm will include patients with antimicrobeal coated stents
62827065|NCT06442046|EXPERIMENTAL|Intervention|Enrolled subjects will provide the study team with email, mobile, work phone, physical contact address, and contact numbers for two or more close contacts. Families will be contacted monthly by the case manager assist with additional supports they might need. Quarterly, patients and families will be contacted and patients will be asked to complete VPET and other measures. The intervention group will receive active case management to connect affected youth to community services.
62827066|NCT06442046|ACTIVE_COMPARATOR|Treatment as Usual|The comparison group will receive treatment as usual which consists of a list of community resources and a recommendation that youth not already connected with a community service provider be connected.
62247606|NCT04505904|PLACEBO_COMPARATOR|Placebo First|Crossover design, all participants received experimental condition at either visit one or visit two, and the placebo at the other visit. This arm designates those who received placebo at visit one, and syntocinon at visit two.
62604498|NCT02653170|EXPERIMENTAL|SCM and VSSP|"Two interventions are provided:~1. SCM (Stroke Case manager): a trained social worker who provides in-home case management services. Plus:~2. VSSP (Virtual Stroke Support Portal): Access and training in the use of the VSSP: a purpose-built, online, patient-centered information and support resource."
62604499|NCT00556205|ACTIVE_COMPARATOR|1|Bevacizumab monotherapy 10 mg/kg IV q2 weeks
62604500|NCT00556205|ACTIVE_COMPARATOR|2|Combination Sunitinib \& Bevacizumab Bevacizumab 10 mg/kg IV q2 weeks Sunitinib 50 mg PO QD on 4/2 schedule
62604501|NCT02672007|OTHER|Included patients|All included patients will have respiratory rates measured by a research assistant using a criterion standard approach, by the SensiumVitals device and by the ward staff.
62604502|NCT01577615|EXPERIMENTAL|Patterned Experience Group|Infants in the patterned experience group will receive a patterned feeding experience with all feedings through discharge. They will receive a touch intervention at each gavage feeding. Once oral feedings are initiated, they will be offered an oral feeding at every scheduled feeding. They will be held for feedings. They will be observed twice a week utilizing the computer data acquisition system. Follow up visits will occur at 2,6 amd 24 months corrected age.
62604503|NCT01577615|NO_INTERVENTION|Usual Care Group|In the usual care group infants usually are not held or contained during gavage feeding. Infants in the usual care group are orally fed at the discretion of the nurses or medical team. Once oral feedings are initiated, infants will be observed twice a week using the computer data acquisition system. Follow up visits will occur at 2,6 and 24 months corrected age.
62827067|NCT05323227||Group 1|Patients with Lp(a) \<60mg/dL
62247607|NCT05563922|EXPERIMENTAL|Neoadjuvant concurrent Chemoradiotherapy plus consolidation chemotherapy followed by TEM|All the patients will receive neoadjuvant chemoradiotherapy ( CapOx + radiotherapy) for 2 cycles, one week after chemoradiotherapy, the first evaluation including MRI, colonoscopy, digital rectal examination and serum CEA will be conducted. Patients without tumor progression will continue 4 cycles of chemotherapy （CapOx） until next imaging and serum assessment. After the second assessment, for patients with tumor regression and suitable for TEM will receive local resection otherwise TME. Following treatment strategy will be made base on the final pathology evaluation after surgery, patients with good pathological response (ypT 0-1 without neural vascular invasion) will enter into the follow-up period, otherwise TME will be operated.
62247608|NCT04160351|EXPERIMENTAL|MCO Dialyser|12 treatments (4 weeks) with Medium Cut-Off Dialyzer
62604504|NCT04288336|EXPERIMENTAL|Prevention (intermittent fasting)|Beginning when patients' PSA is detectable up to 24 months after surgery, patients follow a daily intermittent fasting routine consisting of restricting the daily eating period to 8 hours (e.g. between 1PM-9PM) followed by 16 hours of prolonged nightly fasting for up to 1 year or until secondary therapy commences.
62827068|NCT05323227||Group 2|Patients with Lp(a) ≥60 mg/dL
62827069|NCT06436131|EXPERIMENTAL|IBPMS|The exercise program of the experimental group consisted of exercises based on in-phase bilateral movements of the upper and lower limbs, which they were adapted to different sport activities and to fitness functional exercises. The specific exercise program was organized in a group circuit training, performed simultaneously on each session from all the participants of the experimental group, considering the MS exercise recommendations. Specifically, the program included sports activities of basic technical skills of basketball (e.g., different types of passing, catching and throwing the ball) and volleyball (e.g., different types of passing and receiving the ball), whereas the fitness exercises included the diagonal movements from proprioceptive neuromuscular facilitation technique, by the use of a resistance bands.
62827070|NCT06436131|ACTIVE_COMPARATOR|Controls|The participants of the active control group, underwent an exercise program based on conventional exercises, such as strengthening of the major muscle groups of the trunk, resistance exercises for the upper and lower limbs and body weight support treadmill exercise. All participants of the active control group performed the specific types of exercises individually, as opposed with the experimental group which was organized as a group training. Controls performed the specific type exercises once a week, for 12 consecutive weeks.
62247609|NCT04160351|ACTIVE_COMPARATOR|High Flux Dialyser|12 treatments (4 weeks) with High Flux Dialyzer
62247610|NCT02543827|EXPERIMENTAL|MV140 I|The subjects will receive daily dose of MV140 during 6 months
62247611|NCT02543827|EXPERIMENTAL|MV140 II|The subjects will receive daily dose of MV140 during 3 months and placebo during 3 months
62247612|NCT02543827|PLACEBO_COMPARATOR|Placebo|The subjects will receive daily dose of placebo during 6 month
62247613|NCT01803477|ACTIVE_COMPARATOR|Picato® 0.05% gel|once daily for two consecutive days
62437788|NCT05631899|EXPERIMENTAL|KRAS-EphA-2-CAR-DC|"In the priming phase, a conditioning chemotherapy regimen of Abraxane and cyclophosphamide is administered three days before vaccination, and KRAS-EphA-2-CAR-DC vaccine is infused on Day 0 and Day 7 in Week 1.~In the boost phase, KRAS-EphA-2-CAR-DC vaccine is infused one dose every 4 weeks since Week 5 for a total of 6 to 8 doses, then maintenance vaccination is given one dose every 8 weeks, until:~1. Unacceptable toxicity occurred or disease progression; or~2. Reactive T cells are undetected repeatedly after the last vaccine dose; or~3. Vaccine exhaustion."
62437789|NCT05443490|EXPERIMENTAL|Probiotic group|Probiotic mixture
62437790|NCT05443490|PLACEBO_COMPARATOR|Placebo group|Maltodextrine
62437791|NCT03492983|NO_INTERVENTION|Control group|No intervention
62437792|NCT03492983|EXPERIMENTAL|Intervention group|Addition of 10 g/day of high cocoa content chocolate to the usual diet for six months
62437793|NCT02040428|EXPERIMENTAL|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
62437794|NCT02040428|ACTIVE_COMPARATOR|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
62827071|NCT02220920|EXPERIMENTAL|Canagliflozin (TA-7284) ＋insulin|
62827072|NCT02220920|PLACEBO_COMPARATOR|Placebo＋insulin|
62827073|NCT05957380|EXPERIMENTAL|Treatment group|
62045196|NCT00698490|EXPERIMENTAL|Group D|HSV-seronegative subjects
62437795|NCT05567757|EXPERIMENTAL|Investigational|Study subjects implanted with a TRUE AVC as an arteriovenous conduit for hemodialysis
62437796|NCT01521728|ACTIVE_COMPARATOR|Resistance Exercise|Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
62437797|NCT01521728|ACTIVE_COMPARATOR|Endurance Exercise|Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
62604505|NCT00326170|EXPERIMENTAL|VPA + 5-aza + ATRA|Daily for 7 days, Valproic acid (VPA) starting dose 75 mg/m\^2 subcutaneously in combination with 5-azacytidine (5-aza) 50 mg/kg orally; and all-trans retinoic acid (ATRA) 45 mg/m\^2 orally daily (in two divided doses) for 5 days starting on day 3.
62827074|NCT05957380|EXPERIMENTAL|Reference group|
62827075|NCT02151058|OTHER|Negative Control, 035000513007|Colgate® Regular Cavity Protection
62827076|NCT02151058|EXPERIMENTAL|Experimental Mouth Rinse, 19545-118|
62827077|NCT02151058|ACTIVE_COMPARATOR|Active Comparator: Mouth Rinse 037000089872|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint
62045197|NCT00698490|EXPERIMENTAL|Group E|HSV-seronegative subjects
62827078|NCT06279234|EXPERIMENTAL|Part A|Multiple doses of PF 06954522 or placebo daily for up to 8 weeks in adult participants with T2DM in up to 7 cohorts.
62827079|NCT06279234|EXPERIMENTAL|Part B (Optional)|Multiple doses of PF 06954522 or placebo daily for up to 8 weeks in non-diabetic adult participants with obesity in up to 3 cohorts.
62604506|NCT05939791|EXPERIMENTAL|Exercise training|Children previously diagnosed and treated for acute lymphoblastic leukemia in remission between 1 and 3 years with physical exercise intervention
62604507|NCT05939791|NO_INTERVENTION|Passive|Children previously diagnosed and treated for acute lymphoblastic leukemia in remission between 1 and 3 years without physical exercise intervention
62604508|NCT00347594|EXPERIMENTAL|Next Generation Diagnostic Instrument|Next Generation Diagnostic Instrument (NGDI)
62827080|NCT06279234|EXPERIMENTAL|Part C (Optional)|An 8-period multiple-dose assessment of the effect of PF-06954522 on rosuvastatin, midazolam, and omeprazole PK in healthy adult participants for up to 14 weeks in healthy adult participants.
62604509|NCT00347594|ACTIVE_COMPARATOR|Zyoptix Diagnostic Workstation|Zyoptix Diagnostic Workstation (ZDW)
62604510|NCT00947024|EXPERIMENTAL|1|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.
62604511|NCT00947024|ACTIVE_COMPARATOR|3|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.
62827081|NCT03085043|EXPERIMENTAL|Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)|Participants undergo standard of care bone scan, CT of the abdomen and pelvis, and pelvic MRI. Participants also undergo magnetic resonance WB-DWI over 20-30 minutes.
62827082|NCT06536673|OTHER|Retrospective control group|This is the PD population sample from before January 2020.
62827083|NCT06536673|EXPERIMENTAL|Prospective study group|It will be the incident patients in PD who will receive the educational intervention contained in this project and whose results will be compared with the control group.
62827084|NCT06604351|EXPERIMENTAL|group 1|Bronchial endoscopic cryoablation
62827085|NCT01085227||Patients carrier of a LRRK2 mutation|
62827086|NCT01085227||Asymptomatic relatives of LRRK2 patients|
62827087|NCT05609487|OTHER|Control group|"Step in control group This stepped wedge study does not use two parallel treatment arms. The stepped wedge design allows each center to be its own control group and then, after implementation of the practice by the research team, to become a intervention group.~The characteristics of these two phases are detailed below. Patients included in the control phase, i.e. without intervention, will be asked not to oppose participation in the research, after having received the presentation of the study and the information notice. The data collection will be similar to the data collection during the intervention period."
62827088|NCT05609487|OTHER|Protection plan group|"The intervention consists of making the protection plan in a co-constructed process with the care user. This tool is built in 6 steps, is written and takes 20 to 40 minutes to complete.~These 6 steps allow to identify the first signs of a suicidal crisis and to identify different strategies to face it. They are constructed in an ascending order, with the aim of being used by the care user in an autonomous situation."
62827089|NCT05162976|EXPERIMENTAL|Treatment (CC-486, nivolumab)|Patients receive azacitidine PO QD on days 1-7 and nivolumab IV over 30 minutes on day 8. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62827090|NCT05324462||IDegLira|Adult patients with T2D who have initiated treatment with IDegLira a minimum of 26 weeks
62827091|NCT04223479|EXPERIMENTAL|Probiotic Formula Capsule|In this intervention arm, the patients will receive oral viable capsules of probiotic contain (1\*10 10 colony-forming unit (CFU)/g) of lactobacillus (Lactobacillus rhamnosus , Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus plantarum) and bifidobacteria (Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis) species three times a per day
62827092|NCT04223479|PLACEBO_COMPARATOR|Placebos|In this intervention arm Placebo arm received three oral viable capsules daily, containing polysaccharides, without any viable probiotics matching the probiotic capsules in appearance, smell, and taste.
62827093|NCT05274997|EXPERIMENTAL|YY-20394|Administer linperlisib (YY-20394) 80 mg (4 tablets) orally with water, once daily, in a 28-day cycle.
62827094|NCT04230629|ACTIVE_COMPARATOR|Vivinex XY1|Implantation of an intraocular lens Hoya Vivinex XY1
62247614|NCT01803477|EXPERIMENTAL|ingenol mebutate vehicle formulation 1|once daily for two consecutive days
62247615|NCT01803477|EXPERIMENTAL|ingenol mebutate vehicle formulation 2|once daily for two consecutive days
62247616|NCT01803477|EXPERIMENTAL|ingenol mebutate vehicle formulation 3|once daily for two consecutive days
62247617|NCT02807051|EXPERIMENTAL|Pacritinib and Clarithromycin|Single 400-mg (four 100-mg capsules; lot number 21341) oral doses of pacritinib were administered in the fasted state on Days 1 and 12. Twice daily, 500-mg (1 tablet) oral doses of clarithromycin were administered with or without food on Days 8 through 11 and in the fasted state on the morning of Day 12
62247618|NCT01412749||eHNS Participant Registry|Participants diagnosed with head and neck cancer who are candidates for definitive surgical resection of the primary tumor and who are candidates for eHNS.
62827095|NCT04230629|ACTIVE_COMPARATOR|Vivinex XY1A|Implantation of an intraocular lens Hoya Vivinex XY1A
62247619|NCT01892514|EXPERIMENTAL|Demineralized Bone Marrow (DBM)|core decompression of necrotic area and graft with a biological product based on Demineralized Bone Matrix (DBM), Platelet-Rich-Fibrin (PRF) and Concentrated Bone Marrow (CBM)
62247620|NCT01892514|EXPERIMENTAL|Lyophilized Bone Chips (LBC)|core decompression of the necrotic area and graft with a biological product based on homologous Lyophilized Bone Chips (LBC), Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
62247621|NCT03765242||Patient initiating warfarin|
62247622|NCT03765242||Patient initiating apixaban|
62247623|NCT04784897|EXPERIMENTAL|Brilacidin + SoC|Brilacidin IV infusion, 3 days and up to 5 days, in addition to Standard of Care
62827096|NCT00828594|EXPERIMENTAL|Phase 1: RAD001 plus sorafenib|
62827097|NCT04862585|ACTIVE_COMPARATOR|Arm I (paclitaxel, pre-medications)|Patients continue on pre-medications (dexamethasone, diphenhydramine, famotidine/ranitidine/cimetidine) with all future doses of paclitaxel.
62604512|NCT00947024|EXPERIMENTAL|2|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.
62604513|NCT02768441|EXPERIMENTAL|Study group|Participants receiving Dexamphetamine 60 mg SR
62604514|NCT05259410|EXPERIMENTAL|Time restricted eating|Participants will eat all food within the same self selected 8 hour window daily.
62604515|NCT05259410|NO_INTERVENTION|Standard care|Current standard care is to eat enough calories and protein to maintain weight and lean mass.
62604516|NCT05259410|EXPERIMENTAL|Med TRE|Participants will eat a mediterranean style diet within the same self selected 8 hour window daily.
62604517|NCT02101359|EXPERIMENTAL|T2380|"Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.~At the beginning of surgery, 200 μL of T2380 were administrated intracamerally."
62604518|NCT02101359|ACTIVE_COMPARATOR|Mydriatics and anesthetic|"Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.~Topical Mydriatic treatments were instilled three times before surgery."
62604519|NCT02387775|EXPERIMENTAL|Esophageal temperature control|The Esophageal Cooling Device (ECD) will be inserted and utilized for temperature control for up to 36 hours in this arm. The ECD will be used for all three phases of therapeutic hypothermia; induction, maintenance, and rewarming. Conventional cooling or warming techniques (e.g. cold saline, ice packs, cooling or warming blankets) will still be made available to the treating ICU team to be used at their discretion.
62827098|NCT04862585|EXPERIMENTAL|Arm II (paclitaxel)|Patients discontinue premedications (dexamethasone, diphenhydramine, famotidine/ranitidine/cimetidine) with all future doses of paclitaxel, unless patient develops a subsequent infusion HSR.
62437798|NCT01521728|ACTIVE_COMPARATOR|Stretching/Range-of-Motion Exercise|"In ALS, stretching and range of motion are routinely recommended for the prevention of frozen shoulder syndrome and contractures resulting from weakness. The problem is compounded in ALS where upper motor neuron dysfunction may result in spasticity and incapacitating contractures with pain. Therefore, maintaining an aggressive program for stretching and range of motion exercise is widely accepted as a standard of care for ALS management."
62437799|NCT06253468|EXPERIMENTAL|mild to moderate melasma|adult patients suffering from mild to moderate melasma (Investigator's Global Assessment (IGA) 1 or 2)
62437800|NCT06253468|EXPERIMENTAL|mild to moderate acne induced PIHP|adult patients suffering from mild to moderate acne-induced PIHP (IGA) 1 or 2) without active acne (i.e., less than 10 inflammatory lesions)
62437801|NCT06253468|EXPERIMENTAL|solar lentigo|adult patients suffering from solar lentigo with a pigmentation score \> 5
62437802|NCT04967716||Peroneal muscular atrophy|Peroneal muscular atrophy (Charcot-Marie-Tooth, CMT) is a group of genetic diseases that invade the peripheral nervous system with very high genetic heterogeneity. It was proposed by Charcot, Marie of France and Tooth of the United Kingdom in 1886. The prevalence is about 1/2500-4000. It is the most common hereditary peripheral neuropathy. Inheritance includes all forms of Mendelian inheritance. The typical clinical manifestations are progressive, length-dependent limb weakness and atrophy, accompanied by hypoesthesia and weakened tendon reflexes.
62437803|NCT06286839|EXPERIMENTAL|30 mg twice per day|The 30mg dose will be consumed in 2 capsules twice per day, for 3 days and an extra 18 capsules in case of loss of study product
62437804|NCT06286839|EXPERIMENTAL|120 mg twice per day|120mg dose will be consumed in 8 capsules twice per day for 3 days and an extra 12 capsules in case of loss of study product
62437805|NCT01360450|EXPERIMENTAL|Treatment|Interventions: Infants will receive intravenous or oral clonidine(Duraclon) for the treatment of pain and sedation: Duration: (Clonidine HCL) 1 mcg/kg/dose q4 either iv or po.
62437806|NCT01360450|PLACEBO_COMPARATOR|Control|Intervention: Infants will receive place (saline) (if receiving it IV) or orally (sterile water) if receiving it orally
62604520|NCT01223066||Women treated with Macrolane in the breasts|
62604521|NCT00800956|EXPERIMENTAL|Single oral dose of [14C]-esreboxetine|
62604522|NCT01043562||Pediatric ICD pts|Inclusion criteria for study participants included: 1) weight ≤60 kg, 2) new or existing ICD system, and 3) clinically necessary assessment of the defibrillation efficacy of the ICD system. Transvenous systems utilized a high-voltage ICD coil with active-fixation lead attached to the right ventricular endocardial surface, whereas non-transvenous systems depended upon a high-voltage shocking coil placed within the pericardial, subcutaneous or pleural space. To be included in the post-shock pacing portion of the study, adequate sinus and AV node function had to be present at baseline. Exclusion criteria included 1) tenuous hemodynamic status felt to warrant abbreviation of the defibrillation efficacy testing or 2) inability to induce fibrillation during defibrillation threshold testing (DFT).
62045198|NCT03602651||MAGZEN®|All patient will be treated with MAGZEN® and will be evaluated with the Hamilton-anxiety scale (HAM-A)
62437807|NCT02468557|EXPERIMENTAL|Idelalisib 150 mg|Participants were administered with idelalisib (IDL) 150 mg tablets orally, twice daily (morning and evening) for 8 weeks.
62437808|NCT02468557|EXPERIMENTAL|Idelalisib + nab-paclitaxel|Participants will receive escalating doses of idelalisib at a dose level of up to 150mg + nab-paclitaxel.
62437809|NCT02468557|EXPERIMENTAL|Idelalisib + mFOLFOX6|Participants will receive escalating doses of idelalisib at a dose level of up to 150mg + mFOLFOX6.
62437810|NCT04868409|ACTIVE_COMPARATOR|Rocuronium group|Rocuronium 1 mg/kg
62437811|NCT04868409|ACTIVE_COMPARATOR|Suxamethonium group|Suxamethonium 1 mg/kg
62437812|NCT01907737|ACTIVE_COMPARATOR|Active tDCS and active PNS|1 session of active transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and active peripheral nerve stimulation (PNS)
62604523|NCT01786824|EXPERIMENTAL|Bicarbonate|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy containing sodium bicarbonate.~Intervention: Hydration strategy using sodium bicarbonate Intervention: Coronarography"
62604524|NCT01786824|ACTIVE_COMPARATOR|Saline|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy using sodium chloride solution.~Intervention: Hydration strategy using saline Intervention: Coronarography"
62604525|NCT01786824|EXPERIMENTAL|Bicar + L-Carnitine|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy containing sodium bicarbonate. They will also receive an oral L-carnitine solution on days -1, 0, 1 to 7.~Intervention: Hydration strategy using sodium bicarbonate Intervention: L-carnitine Intervention: Coronarography"
62827099|NCT06603779|EXPERIMENTAL|Integrated Neuromuscular Inhibition Group|This group will receive the Integrated Neuromuscular Inhibition Technique which consists of ischemic compression, strain counter strain, and muscle energy technique
62827100|NCT06603779|EXPERIMENTAL|Cervical and Scapular Stabilization exercises Group|This group will receive a group of exercises for the neck and scapula which will strengthen both of them
62827101|NCT06603779|PLACEBO_COMPARATOR|Ultrasound Therapy Group|This group will receive ultrasound Therapy
62827102|NCT06591962||Individuals diagnosed with diabetes mellitus|Individuals with diabetes mellitus admitted to the internal medicine outpatient clinic of a university hospital. A questionnaire will be applied for diabetes mellitus.
62045199|NCT00279201|ACTIVE_COMPARATOR|Insulin glargine|Initiation Phase: Insulin glargine for 24 weeks Maintenance: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.
62247624|NCT04784897|PLACEBO_COMPARATOR|Placebo + SoC|Placebo IV infusion, 3 days and up to 5 days, in addition to Standard of Care
62247625|NCT02537548|EXPERIMENTAL|Treatment (RPLND)|Patients undergo RPLND.
62247626|NCT04066660|EXPERIMENTAL|Treatment & Oligo Fucoidan|4.4 g Oligo Fucoidan powder by six months, BID
62247627|NCT04066660|PLACEBO_COMPARATOR|Treatment & Placebo|4.4 g Placebo powder by six months, BID
62247628|NCT04555161|EXPERIMENTAL|Aria CV Pulmonary Hypertension System|Treatment with the Aria CV Pulmonary Hypertension System
62437813|NCT01907737|OTHER|Active tDCS and sham PNS|1 session of active transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and sham peripheral nerve stimulation (PNS)
62604526|NCT01786824|EXPERIMENTAL|Saline + L-carnitine|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy using sodium chloride solution. They will also receive an oral L-carnitine solution on days -1, 0, 1 to 7.~Intervention: Hydration strategy using saline Intervention: L-carnitine Intervention: Coronarography"
62604527|NCT02526875|EXPERIMENTAL|night|Telminuvo®Tab. 40/2.5mg ,Once daily, from 6 pm to 10 pm, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
62604528|NCT02526875|ACTIVE_COMPARATOR|morning|Telminuvo®Tab. 40/2.5mg ,Once daily, from 6 am to 10 am, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
62604529|NCT00977704|ACTIVE_COMPARATOR|Restylane and Perlane|Restylane and Perlane administered by injection. Recommended volume of 6.0 mL. Injection on study day 1 with an optional touch up on study day 14.
62604530|NCT00657306|EXPERIMENTAL|1|Hydrocortisone, 50 mg/6 h per day
62604531|NCT00657306|PLACEBO_COMPARATOR|2|dextrose solution 5%
62827103|NCT06591962||Individuals without a diagnosis of diabetes mellitus|Individuals without diabetes mellitus admitted to the internal medicine outpatient clinic of a university hospital. A questionnaire will be applied for without diabetes mellitus.
62827104|NCT03842527|ACTIVE_COMPARATOR|Standard Fasting Group|Ultrasound scan of gastric antrum 1 hour prior to procedure. Patients assigned to this group will follow standard fasting procedures of no eating or drinking 8 hours prior to C-section.
62045200|NCT00279201|EXPERIMENTAL|Lispro Low Mix|Initiation Phase: Lispro Low Mix (LM) for 24 weeks Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.
62247629|NCT03838198|OTHER|Safety plan + booster text messages + booster call (Group A)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group A: Participants will receive the in-person MI-enhanced safety plan (individual meeting with the adolescent and a family meeting) during hospitalization -- focused on developing a personalized list of coping strategies and enhancing adolescents' motivation and self-efficacy to utilize these strategies-- which will be followed by 4 weeks of daily post-discharge booster text messages and a phone booster call.
62247630|NCT03838198|OTHER|Safety plan + booster text messages (Group B)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group B: Participants will receive the in-person MI-enhanced safety plan during hospitalization followed by 4 weeks of daily booster text messages post discharge.
62247631|NCT03838198|OTHER|Safety plan + booster call (Group C)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group C: Participants will receive the in-person MI-enhanced safety plan during hospitalization followed by a post-discharge booster call.
62247632|NCT03838198|OTHER|Safety plan (Group D)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group D: Participants will receive the in-person MI-enhanced safety plan during hospitalization.
62247633|NCT04688723|ACTIVE_COMPARATOR|Dabigatran/Clopidogrel|Patiënt receive standard care, with dabigatran + clopidogrel 75mg once daily up to 12 months.
62604532|NCT01758198|EXPERIMENTAL|Group 1: Abatacept + Methotrexate (MTX)|"Abatacept 10 mg/kg solution intravenous (IV) infusion, once monthly for 12 months~Methotrexate ≥6 mg/week for 12 months"
62827105|NCT03842527|EXPERIMENTAL|Carbohydrate Loading Group|"Ultrasound scan of gastric antrum 1 hour prior to procedure.~Patients assigned to this group must stop eating 8 hours prior to their scheduled C-section time.~The night before their C-section they must drink 800mL of 100% apple juice (not from concentrate) OR 800mL of cranberry juice cocktail, not both~The day of their C-section, starting 3 hours before surgery and to be finished 2 hours before surgery time, patients must drink 400mL of 100% apple juice OR 400mL of cranberry juice cocktail, not both~Please note:~* The apple juice must be 100% juice, not from concentrate~* The cranberry juice cocktail must not be plain cranberry juice"
62437814|NCT01907737|OTHER|Sham tDCS and active PNS|1 session of sham transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and active peripheral nerve stimulation (PNS)
62827106|NCT00570986|PLACEBO_COMPARATOR|1|Arm #1 is used for entire study. At week 12, arm is rerandomized.
62437815|NCT01907737|SHAM_COMPARATOR|Sham tDCS and sham PNS|1 session of sham transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and sham peripheral nerve stimulation (PNS)
62247634|NCT04688723|EXPERIMENTAL|Dabigatran/Ticagrelor|Patiënt receive standard care, with dabigatran + ticagrelor 90mg twice daily up to 12 months.
62247635|NCT02542384|ACTIVE_COMPARATOR|CR845 IV 1 mcg/kg|CR845 IV solution will be supplied in 2 mL glass vials.Study drug will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
62247636|NCT02542384|ACTIVE_COMPARATOR|CR845 IV 0.5 mcg/kg|CR845 solution will be supplied in 2 mL glass vials. Study drug will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
62247637|NCT02542384|PLACEBO_COMPARATOR|Placebo IV|Placebo will be supplied in matched vials containing the same volume of buffer but with no active drug. It will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
62437816|NCT05863988|ACTIVE_COMPARATOR|Functional Electrical Stimulation &upper limb loading exercises|The group A Will receive functional electrical stimulation and conservative treatment 30-45 min session 5 days per week for 8 weeks.
62437817|NCT05863988|ACTIVE_COMPARATOR|Functional Electrical Stimulation & Upper Limb Loading Exercises|The group B will receive upper limb loading exercises and conservative treatment 30-45 min session 5 days per week for 8 weeks.
62437818|NCT00571922|ACTIVE_COMPARATOR|Acamprosate|
62437819|NCT00571922|PLACEBO_COMPARATOR|Placebo|
62437820|NCT04398394|EXPERIMENTAL|Group 1|Individuals with healthy retina, 18 to 50 years old.
62437821|NCT04398394|EXPERIMENTAL|Group 2|Individuals with healthy retina and presenting with myopia, 18 to 50 years old.
62437822|NCT04398394|EXPERIMENTAL|Group 3|Individuals with healthy retina, over the age of 50.
62437823|NCT04398394|EXPERIMENTAL|Group 4|Patients with early and intermediate AMD, over the age of 50.
62827107|NCT00570986|ACTIVE_COMPARATOR|2|Arm #2 is used for entire study. At week 12, arm is rerandomized.
62827108|NCT00570986|ACTIVE_COMPARATOR|3|Arm #3 is not used for weeks 0-11. At week 12, arm is rerandomized.
62827109|NCT05657002|ACTIVE_COMPARATOR|accurate problem list, then inaccurate problem list|"in round 1, the participants will use the patient record of patient A, with an accurate problem list and answer the question: can the patient be prescribed Medication X and Y where medication X is a control question and medication Y is related to a contraindicated diagnosis (on problem list)~In round 2, the participants will use the patient record of patient B, with an inaccurate problem list and answer the question: can the patient be prescribed Medication X and Y where medication X is a control question and medication Y is related to medical history (not on problem list)"
62247638|NCT03419338|EXPERIMENTAL|Test group|Surgical alveolus + maxillary sinus lift with inorganic bovine bone + newly forming bone + collagen membrane
62437824|NCT04398394|EXPERIMENTAL|Group 5|Patients with other retinopathies than AMD, over the age of 18.
62437825|NCT03676023||Pulmonary Hemorrhage|Patients treated for pulmonary hemorrhage with inhaled Transexamic Acid
62437826|NCT02763579|EXPERIMENTAL|Atezolizumab + Carboplatin + Etoposide|Participants received intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) followed by etoposide 100 milligrams per square meter (mg/m\^2) on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m\^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) atezolizumab 1200 mg on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
62604533|NCT01758198|PLACEBO_COMPARATOR|Group 2: Placebo matching with Abatacept + Methotrexate|"Placebo matching with Abatacept 0 mg/kg solution, intravenous (IV) infusion once monthly for 12 months~Methotrexate ≥6 mg/week for 12 months"
62604534|NCT01505738||bacterial cultures|Bacterial samples are collected preoperatively from urine, nose and possible lower limb ischaemic wounds, perioperatively from inguinal area and wound edges, and twice postoperatively. In addition, in case of a wound infection, bacterial samples are taken for diagnosis as usual.
62604535|NCT03326284|EXPERIMENTAL|15g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 15g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
62604536|NCT03326284|EXPERIMENTAL|35g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 35g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
62604537|NCT03326284|EXPERIMENTAL|60g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 60g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
62604538|NCT03326284|EXPERIMENTAL|35g protein energy balanced diet|Following a 5-day energy balanced diet the subjects (n=10) will ingest 35g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
62045201|NCT00279201|EXPERIMENTAL|Lispro Mid Mix prior Lispro Low Mix addendum|Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.
62045202|NCT00279201|EXPERIMENTAL|Lispro Low Mix prior Glargine addendum|Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Low Mix for 24 weeks in the Intensification Addendum Phase
62437827|NCT02763579|ACTIVE_COMPARATOR|Placebo + Carboplatin + Etoposide|Participants received intravenous infusions of placebo in combination with carboplatin to achieve an initial target AUC of 5 mg/mL/min followed by etoposide 100 mg/m\^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m\^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) placebo on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
62449232|NCT01430741|OTHER|Implementation as Usual Case Management|"Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition):MISSION-Vet has been developed to target mental health, substance abuse and related issues faced by homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources.~Implementation as Usual (IU) - standard training on the MISSION model via a 1.5 hour webinar"
62604539|NCT00771329|EXPERIMENTAL|1|BIIB023
62604540|NCT00771329|PLACEBO_COMPARATOR|2|
62604541|NCT03216148|EXPERIMENTAL|FET-PET|All participating patients will receive a FET PET-scan with intravenous O-(2-\[18F\]Fluoroethyl)-L-Tyrosine parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
62604542|NCT03981965|EXPERIMENTAL|Focus guidelines|"Participants enrolled in a 2-phase physical activity program divided in 2 phases as described above. Briefly, The activity consisted in a 1-h set of exercises twice per week. The first 12-week phase was performed in group under the direct supervision of a health monitor. The second 12-week phase was autonomous, and consisted of the same physical performance while maintaining virtual link through a social network based on the mobile phone.~The FOCUS guidelines provided 2 features, the participation in monthly health talks provided by the principal investigator and the availability of a virtual mailbox to transmit any comment or suggestion."
62045203|NCT00279201|ACTIVE_COMPARATOR|Basal bolus prior Lispro Low Mix addendum|Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.
62045204|NCT00279201|ACTIVE_COMPARATOR|Basal bolus prior Glargine addendum|Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.
62045205|NCT04014764||Single group|"Documented hematologic malignancy in need of starting an active anti-cancer therapy.~This is a non-interventional study."
62045206|NCT06099067||CANVAS Canagliflozin|CANVAS expousre Group
62045207|NCT06099067||CANVAS DPP4i|CANVAS reference Group
62045208|NCT06099067||LEADER Liraglutide|LEADER exposure Group
62045209|NCT06099067||LEADER DPP4i|LEADER reference Group
62045210|NCT06099067||SAVOR-TIMI Saxagliptin|SAVOR-TIMI exposure Group
62045211|NCT06099067||SAVOR-TIMI 2nd generation Sulfonylurea|SAVOR-TIMI reference Group
62045212|NCT04114734|EXPERIMENTAL|Park Rx|Participants will be given a park prescription as part of their treatment plan
62045213|NCT04114734|NO_INTERVENTION|No Park Rx|Usual care only
62045214|NCT02368808|EXPERIMENTAL|Abangane Support Group|Bereavement support group for adolescents
62045215|NCT02368808|NO_INTERVENTION|Wait List|Wait-listed adolescents will be able to participate in Abangane at the close of the study.
62045216|NCT02535104|EXPERIMENTAL|Treatment group|1 mg/ml solution of ranpirnase applied twice daily
62437828|NCT05776966|EXPERIMENTAL|Gender-specific digital intervention plus treatment as usual (GSDI+TAU)|GSDI + TAU includes the addition of a gender-specific digital intervention (GSDI) to treatment as usual. The GSDI has a web-based component and a mobile component. The web-based portion of the GSDI includes: (1) gender-specific psychoeducation on substance use disorders, (2) specific education on opioid use disorder, including information about medication treatment for opioid use disorder, and (3) information on relapse-prevention skills. Participants complete the web-based portion immediately after completing baseline assessments. The mobile component includes three parts: (1) weekly self-report surveys of opioid and other substance use and medication adherence, (2) weekly skills-practice exercises, and (3) daily motivational messages encouraging self-care. Participants engage with the mobile component after completing the web-based portion until the end of the study (12 weeks).
62247639|NCT03419338|ACTIVE_COMPARATOR|Control group|Maxillary sinus lift with inorganic bovine bone + collagen membrane
62247640|NCT02422407||Subgroup 1|Healthy Volunteers - subset of which 10 will receive salivary gland biopsy.
62604543|NCT03981965|ACTIVE_COMPARATOR|Active group|Participants enrolled in a 2-phase physical activity program divided into 2 phases as described above. This group lacked the monthly talks and did not have access to the virtual mailbox.
62604544|NCT03981965|NO_INTERVENTION|Inactive|Women of similar clinical characteristic who did not participate in the PA program.
62604545|NCT05112289|OTHER|Migraine cohort|Women with migraine and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.
62604546|NCT05112289|OTHER|Small vessel ischemic (SVI) disease cohort|Women diagnosed with SVI disease and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.
62604547|NCT05112289|OTHER|Multiple sclerosis (MS) cohort|Women diagnosed with MS and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.
62045217|NCT02535104|PLACEBO_COMPARATOR|Control|Vehicle - innert gel
62045218|NCT03175302||Surgical group|Baseline preoperative digital cognitive testing performance in adults to predict frequency and severity of clinician reported outcomes within the first three months post-surgery.
62045219|NCT03175302||Control|Non-surgery matched peers with the same testing.
62045220|NCT02166424|ACTIVE_COMPARATOR|Omega-3 polyunsaturated fatty acids|1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily
62045221|NCT02166424|PLACEBO_COMPARATOR|olive oil|2880mg olive oil daily
62045222|NCT04897984|EXPERIMENTAL|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, 2 hours
62247641|NCT02422407||Subgroup 2|Diagnosis of pSS based on the criteria of the American-European Consensus Criteria for Sjögren's Syndrome (AECCSS) with positive biopsy result.
62604548|NCT01090154|EXPERIMENTAL|Cimzia|Treatment with open label Cimzia (certolizumab pegol)
62604549|NCT05304689|OTHER|test system for the determination of interleukins|test system for the determination of interleukins
62604550|NCT05754658||Breast Cancer|Female patients
62604551|NCT05754658||Prostate Cancer|Male patients
62604552|NCT00785434|EXPERIMENTAL|Active|Active escitalopram
62604553|NCT00435019|EXPERIMENTAL|insulin detemir|insulin detemir + insulin aspart
62604554|NCT00435019|EXPERIMENTAL|NPH insulin|NPH insulin + insulin aspart
62045223|NCT01417689|ACTIVE_COMPARATOR|Open-eyes|Patients in this arm are encourage to attempt eye drop instillation using the most commonly used technique that involves looking up, pulling inferior lid down and putting the drop in the inferior cul de sac.
62045224|NCT01417689|EXPERIMENTAL|Closed-eyes|Patients in this group are encouraged to attempt eye drop instillation with both eyes closed near the medial canthal region. After feeling contact with the drop on the skin the drop is expected to enter the eye when opening the eye and resuming blinking.
62045225|NCT00998179|ACTIVE_COMPARATOR|Acu-TENS|Application of Acu-TENS prior to exercise
62045226|NCT00998179|PLACEBO_COMPARATOR|Placebo-TENS|Application of Acu-TENS (without electrical output from the machine) prior to exercise
62045227|NCT02401581|EXPERIMENTAL|rate of early removal of the catheter|In our study, we propose to evaluate the failure rate of an early removal of the catheter 3 hours post-operative after a PVP procedure with GL 180 W/XPS in selected patients on general anesthesia or spinal anesthesia for limiting autonomic effects on the bladder and ensure fastest possible recovery of voiding .
62604555|NCT03616561||Apremilast|The cohort will be recruited in Hospital General de Granollers and Hospital Moises Broggi
62045228|NCT02639260|EXPERIMENTAL|Cohort A|3,000 mg/day
62045229|NCT02639260|EXPERIMENTAL|Cohort B|10,000 mg/day
62045230|NCT02258139|EXPERIMENTAL|Study Group 1|1st overnight visit with no contact lens; 2nd overnight visit randomized to either left or right eye for B\&L Investigational Contact Lens
62045231|NCT01121042|ACTIVE_COMPARATOR|Ondansetron|Ondansetron oral capsule 8mg daily
62827110|NCT05657002|ACTIVE_COMPARATOR|inaccurate problem list, then accurate problem list|"in round 1, the participants will use the patient record of patient A, with an inaccurate problem list and answer the question: can the patient be prescribed Medication X and Y where medication X is a control question and medication Y is related to a contraindicated diagnosis (not on problem list)~In round 2, the participants will use the patient record of patient B, with an accurate problem list and answer the question: can the patient be prescribed Medication X and Y where medication X is a control question and medication Y is related to medical history (on problem list)"
62045232|NCT01121042|PLACEBO_COMPARATOR|Placebo|Placebo (100% lactose) matched oral capsule
62247642|NCT02422407||Subgroup 3|Diagnosis of pSS based on the criteria of the American-European Consensus Criteria for Sjögren's Syndrome (AECCSS) with negative biopsy result.
62247643|NCT02422407||Subgroup 4|Presenting with sicca but not satisfying the criteria of the AECCSS for diagnosis of pSS.
62604556|NCT00835679|EXPERIMENTAL|Cohort A (no systemic neoadjuvant therapy)|Patients receive no systemic neoadjuvant therapy between enrollment and the time of definitive surgical resection of liver metastases. Liver biopsies were performed at surgery since this cohort received no systemic therapy.
62604557|NCT00835679|EXPERIMENTAL|Cohort B (cetuximab)|Patients receive 400 mg/m\^2 cetuximab IV over 120 minutes on day 1 and 250 mg/m\^2 cetuximab IV over 60-120 minutes on day 8. Definitive surgical resection of liver metastases will take place on day 15.
62827111|NCT05839964|ACTIVE_COMPARATOR|CHI-560: Total daily dose: 20 mg CBN|2 units (i.e., 2 gummies). Each gummy: 10 mg CBN
62604558|NCT00835679|EXPERIMENTAL|Cohort C (dasatinib)|Patients receive dasatinib 100 mg orally once daily on days 1-14. Definitive surgical resection of liver metastases will take place on day 15.
62827112|NCT05839964|ACTIVE_COMPARATOR|CHI-563: Total daily dose: 20 mg CBN + 10 mg CBD|2 units (i.e., 2 gummies). Each gummy: 10 mg CBN + 5 mg CBD
62827113|NCT05839964|ACTIVE_COMPARATOR|CHI-564: Total daily dose: 20 mg CBN + 20 mg CBD|2 units (i.e., 2 gummies). Each gummy: 10 mg CBN + 10 mg CBD
62827114|NCT05839964|ACTIVE_COMPARATOR|CHI-565: Total daily dose: 20 mg CBN + 100 mg CBD|2 units (i.e., 2 gummies). Each gummy: 10 mg CBN + 50 mg CBD
62827115|NCT05839964|PLACEBO_COMPARATOR|CHI-660: Placebo|2 units (i.e., 2 gummies). Each gummy: Placebo
62827116|NCT03149562||plasma transfusions|The critical ill neonates with plasma transfusions
62827117|NCT03149562||non-plasma transfusions|The critical ill neonates without plasma transfusions
62827118|NCT06210568||Infertile Male Patients|
62827119|NCT06210568||Fertile males|
62827120|NCT02946723|EXPERIMENTAL|US group|lead implantation surgery for SNM using ultrasound guided technique
62827121|NCT02946723|SHAM_COMPARATOR|X-ray group|lead implantation surgery for SNM using X-ray guided technique
62827122|NCT05742685|EXPERIMENTAL|Reinforcement Learning Intervention Arm|Up to daily, tailored text messages.
62827123|NCT05742685|NO_INTERVENTION|Control Arm|Up to daily, untailored text messages.
62045233|NCT03502655|OTHER|Intervention message (first phase)|Standardized message The intervention will consist in the delivery of a message with a positive content regarding the insertion of the peripheral venous catheter. The message will be delivered through an audio record
62045234|NCT03502655|ACTIVE_COMPARATOR|Control message (first phase)|Standardized message The intervention will consist in the delivery of a control message, whose content is based upon the usual caregiver-patient communication prior to the insertion of a peripheral venous catheter. The message will be delivered through an audio record.
62045235|NCT03502655|OTHER|Intervention message (second phase)|Standardized message The intervention will consist in the delivery of message with a positive content regarding the insertion of the peripheral venous catheter. The message will be delivered by the health providers themselves before inserting the catheter.
62045236|NCT03502655|ACTIVE_COMPARATOR|Control message (second phase)|Standardized message In this arm, the patient will be delivered a control message, which content is based upon the usual caregiver-patient communication prior to the insertion of a peripheral venous catheter. The message will be delivered by the caregivers themselves before inserting the catheter.
62045237|NCT02470546|ACTIVE_COMPARATOR|Metformin|Patients receiving metformin
62045238|NCT02470546|PLACEBO_COMPARATOR|Placebo|Patients receiving placebo
62045239|NCT06097754|EXPERIMENTAL|Ketone group|Ketone esters will be provided
62045240|NCT06097754|PLACEBO_COMPARATOR|Control|Ketone placebo will be provided
62247644|NCT00621231|PLACEBO_COMPARATOR|1|
62247645|NCT00621231|EXPERIMENTAL|2|
62045241|NCT05961358||General anesthesia Patients|Subjects experiencing general anesthesia
62045242|NCT02347020|EXPERIMENTAL|Normal Sleep/ Normal Meal|sleep 0000-0800 h, meals at 1, 5, 11, and 12.5 (snack) h after awakening
62247646|NCT01849497|EXPERIMENTAL|Evolocumab PFS|Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled syringe (PFS). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
62604559|NCT00835679|EXPERIMENTAL|Cohort D (cetuximab, dasatinib)|Patients receive 400 mg/m\^2 cetuximab IV over 120 minutes on day 1 and 250 mg/m\^2 cetuximab IV over 60-120 minutes on day 8 AND dasatinib 100 mg orally once daily on days 1-14. Definitive surgical resection of liver metastases will take place on day 15.
62604560|NCT03825068|ACTIVE_COMPARATOR|ESP block group|patients receive ESP Bock with local anaesthetics
62827124|NCT00914849|EXPERIMENTAL|Arm 1 - Donor|"* Day 1~  * AMD3100 320 ug/kg IV~ * Leukopheresis~* Day 2 (if peripheral blood stem cell (PBSC) collected is not sufficient)~  * AMD3100 320 ug/kg IV~ * Leukopheresis"
62045243|NCT02347020|EXPERIMENTAL|Normal Sleep/ Late Meal|Ns/Lm: sleep 0000-0800 h, meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening
62247647|NCT01849497|EXPERIMENTAL|Evolocumab AI/pen|Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled autoinjector/pen (AI/pen). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
62604561|NCT03825068|PLACEBO_COMPARATOR|control group|general anaestesia
62604562|NCT04611737|EXPERIMENTAL|Experimental group|The researcher interviews with participants for 3 times.
62604563|NCT04611737|NO_INTERVENTION|Control group|The participants receive usual care.
62827125|NCT00914849|EXPERIMENTAL|Arm 2 - Recipient|"Standard of care and physician choice myeloablative or non-myeloablative chemotherapy with or without total body irradiation (permitted = cyclophosphamide and single dose total body irradiation (TBI) / fludarabine and busulfan / fractionated TBI and cyclophosphamide / fractionated TBI, etoposide, and cyclophosphamide / busulfan and cyclophosphamide / fludarabine, busulfan, and ATGAM~Day 0 = Stem Cell Transplant"
62827126|NCT04222309|EXPERIMENTAL|Laparoscopically harvested omental free flap|"1. Standard neurosurgical removal of recurrent GBM,~2. Removal of fat from the abdomen called omentum using a camera (laparoscopically),~3. Lining the brain tumor cavity with the piece of omentum,~4. Joining the blood vessels of the omentum to blood vessels in the scalp or neck to ensure that it maintains good blood flow."
62827127|NCT05801120|EXPERIMENTAL|Ketogenic food products one time|Dietary Supplement: Ketogenic food products Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
62827128|NCT05801120|EXPERIMENTAL|Experimental: Ketogenic food products two times|Dietary Supplement: Ketogenic food products Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
62827129|NCT05801120|EXPERIMENTAL|Experimental: Ketogenic food products three times|Dietary Supplement: Ketogenic food products Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
62827130|NCT01635166|OTHER|Delta Motion|A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement
62827131|NCT04856046||Observational (biospecimen collection, medical record review)|Patients undergo collection of blood samples at 4-6 weeks prior to surgery/ablation and at 12 weeks, 6, 12, 18 and 24 months after surgery/ablation. Patients' previously collected tissue samples are analyzed. Patients' medical records are also reviewed at baseline, 4-6 weeks prior to surgery/ablation, 12 weeks, 6, 12, 18 and 24 months after surgery/ablation, and then every 6 months for 3 years.
62827132|NCT04895839|EXPERIMENTAL|Intervention Arm|
62827133|NCT05440942|EXPERIMENTAL|Part 1 Schedule A: TR^2 Dose Escalation/De-Escalation|"Participants in this group will receive Trametinib, Ruxolitinib and Retifanlimab in a dose escalation/de-escalation design to determine the maximum tolerated dose (MTD). Participants will receive Trametinib and Ruxolitinib for two weeks on (Days 1-14) and two weeks off (Days 15-28) and Retifanlimab on Day 8 of a 28-day cycle. Doses will be administered as follows:~* Dose Level -1A: Trametinib 1 mg orally (PO), Ruxolitinib 5 mg PO, Retifanlimab 500 mg intravenously (IV);~* Starting Dose Level 1A: Trametinib 1.5 mg PO, Ruxolitinib 10 mg PO, Retifanlimab 500 mg IV;~* Dose Level 2A: Trametinib 2 mg PO, Ruxolitinib 10 mg PO, Retifanlimab 500 mg IV;~* Dose Level 3A: Trametinib 2 mg PO, Ruxolitinib 15 mg PO, Retifanlimab 500 mg IV."
62045244|NCT02347020|EXPERIMENTAL|Late Sleep/ Normal Meal|sleep 0330-1130 h, meals at 1, 5, 11, and 12.5 (snack) h after awakening
62045245|NCT02347020|EXPERIMENTAL|Late Sleep/ Late Meal|sleep 0330-1130 h, meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening
62045246|NCT01175915|ACTIVE_COMPARATOR|Western therapy|
62045247|NCT01175915|EXPERIMENTAL|Reduning Injection|
62247648|NCT00932984|EXPERIMENTAL|Dermacyd Silver Floral (Lactic Acid)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
62247649|NCT02292966|EXPERIMENTAL|Hepatitis C treatment|12 weeks of DCV/ASV/BCV therapy.
62604564|NCT02187575|EXPERIMENTAL|UHAC 62 XX tablet|
62604565|NCT02187575|ACTIVE_COMPARATOR|UHAC 62 XX capsule|
62827134|NCT05440942|EXPERIMENTAL|Part 1 Schedule B: TR^2 Alternate Schedule|Participants in this group will receive the MTD determined in Part 1 Schedule A on a continuous dosing cycle: Trametinib and Ruxolitinib on Days 1-28 and Retifanlimab on Day 8 of a 28-Day Cycle.
62045248|NCT01175915|EXPERIMENTAL|Reduning Injection plus western therapy|
62045249|NCT06415357|EXPERIMENTAL|Standard ART counseling, mHC, and MTM|Participants in this arm will receive standard ART counseling, followed by two mHealth interventions (mHC and MTM) to improve PrEP uptake and adherence.
62045250|NCT06415357|EXPERIMENTAL|Standard ART counseling and mHC|Participants in this arm will receive standard ART counseling, followed by one mHealth intervention (mHC) to improve PrEP uptake and adherence.
62247650|NCT04490395|EXPERIMENTAL|Engage PA|
62247651|NCT04490395|OTHER|Treatment as usual plus fitness tracker|
62247652|NCT01641237|EXPERIMENTAL|Low ppm fluoride dentifrice|Low ppm fluoride as sodium fluoride in a silica base dentifrice
62247653|NCT01641237|EXPERIMENTAL|Medium ppm fluoride dentifrice|Medium ppm fluoride as sodium fluoride in a silica base dentifrice
62247654|NCT01641237|EXPERIMENTAL|High ppm fluoride dentifrice|High ppm fluoride as sodium fluoride in a silica base dentifrice
62247655|NCT01641237|PLACEBO_COMPARATOR|No fluoride dentifrice|no added fluoride in a silica base dentifrice
62247656|NCT04615104||Pelvic Ring Fracture|Patients with pelvic ring fractures.
62247657|NCT04615104||Acetabular Fracture|Patients with acetabular fractures.
62247658|NCT05804760||General population (i)|All participants of the study, including any periodontal condition.
62247659|NCT05804760||Periodontally healthy patients with history of periodontitis (ii)|Patients whose current periodontal condition is healthy but who have developed periodontitis in the past.
62604566|NCT00527644|OTHER|Spring Clips|Subjects will undergo laparoscopic cholecystectomy with commercially available 5 mm spring clips utilized for the ligation of the cystic duct and artery.
62827135|NCT05440942|EXPERIMENTAL|Part 2: TR^2 Expansion Cohort|Participants in this group will receive Trametinib, Ruxolitinib and Retifanlimab at the most appropriate dose and schedule determined in Part 1. Participants will continue to receive treatment as long as receiving clinical benefit or until disease progression.
62604567|NCT03586479|EXPERIMENTAL|Low Testing|Children will receive 0 testing (talking) exposures and 6 listening exposures for a total of 6 exposures to each word. This is a listening only condition with minimal testing.
62827136|NCT05778604|EXPERIMENTAL|Physio-fEedback Exercise pRogram (PEER) Group|In week 1 participants will receive the first technology-based physio-feedback, cognitive reframing based on the fall risk appraisal matrix and develop a personal goal setting and action plan. From week 1 to week 8, participants will receive tailored exercise training. Participants will perform peer-led exercises (60 mins/week) and individual exercise at home for at least 30 minutes twice per week. Exercise training consists of four sets of exercise: a) warm-up (seated); b) strength upper and lower body (seated and standing); c) balance (standing and moving); and d) stretch lower and upper body. Participants will receive an exercise booklet (English or Spanish version) with illustrations that highlight steps for each set of exercise and provide a wide variety of exercises to integrate into daily activity such as cooking. Finally, in week 8, participants will receive the second physio-feedback and printed BTracks Balance System (BBS) results.
62827137|NCT05778604|EXPERIMENTAL|Attention Control (AC) Group|Participants in the AC group will receive an information pamphlet about falls, Simple Exercises for Improving Balance and Preventing Falls in Older Adults, (English or Spanish version) that was developed by the CDC Stopping Elderly Accidents, Deaths, and Injuries (STEADI)-Older Adult Fall Prevention. The topics contain information on fall risk, how to prevent falls, check for safety, postural hypotension and chair rise exercise included what you can do to prevent falls, check for safety, postural hypotension, and chair rise exercise. The control group will be encouraged to discuss fall prevention with a primary care provider and continue normal activities (treatment-as-usual) for 6 months. Participants will be offered the PEER intervention when the study concludes.
62827138|NCT03136744|EXPERIMENTAL|Sit Less with MS|The Sit Less with MS program is based on Social Cognitive Theory (SCT) and consists of strategies that will enable people with MS to 'sit less' by frequently interrupting sitting and 'move more' by replacing sitting with light-intensity activity during waking hours.
62827139|NCT06588231|ACTIVE_COMPARATOR|the control group|The patients in the control group were treated with routine rehabilitation nursing, while those in the control group were treated with routine antiplatelet drugs and lipid-lowering drugs after operation. Professional salesmen, according to the specific physical conditions of the patients, formulate corresponding recipes to ensure that the patients have a light diet, low salt, low fat and high nutritional value, and prohibit tobacco and alcohol.
62827140|NCT06588231|EXPERIMENTAL|the exercise group|The exercise group was given individualized rehabilitation training intervention on the basis of the control group. After 2 weeks of adaptive exercise training, there were no adverse events and voluntarily continued the participants. Under the guidance of the specialist, the exercise group received moderate and high intensity interval training, 3 times a week, 30-40 minutes each time, including the beginning of 5 minutes of warm-up and the last 5 minutes of cooling-off period.
62827141|NCT05515965|EXPERIMENTAL|Kinesiotape|The patients in the Kinesiotape group were taped with the mechanical correction method.
62827142|NCT05515965|SHAM_COMPARATOR|Control|In the patients in the Control group were taped with tensionless gluing of the I tape.
62827143|NCT00723736||Pediatric Patients|Those with allergic rhinitis or chronic idiopathic urticaria.
62827144|NCT02234167|OTHER|Risk behaviour and infectious diseases|.(among IDU)
62827145|NCT00217399|EXPERIMENTAL|Treatment|"PHASE I: Patients receive oral sorafenib twice daily and oral anastrozole once daily on days 1-28.~Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of sorafenib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD.~PHASE II: Patients receive sorafenib at the MTD and anastrozole as in phase I."
62827146|NCT06207461||massage group|patients with gastrointestinal function injury caused by medical diseases or with high risk of malnutrition who got massage
62827147|NCT06207461||non-massage group|patients with gastrointestinal function injury caused by medical diseases or with high risk of malnutrition who got no massage
62247660|NCT05804760||Periodontally healthy patients without history of periodontitis (iii)|Patients whose current periodontal condition is healthy, who have also not had periodontitis in the past.
62247661|NCT01335009|EXPERIMENTAL|MORAb-004, 2 mg/kg|Biologic (monoclonal antibody)
62247662|NCT01335009|EXPERIMENTAL|MORAb-004, 4 mg/kg|Biologic (monoclonal antibody)
62247663|NCT01318954||Subjects on allergen immunotherapy|Measurements of Nitric Oxide by NIOX MINO. This device is now FDA approved.
62247664|NCT01255969|NO_INTERVENTION|Control|
62247665|NCT01255969|EXPERIMENTAL|Exercise|Patients in this arm will undergo to personalized exercise program.
62247666|NCT00697450||All participants|
62604568|NCT03586479|EXPERIMENTAL|Mid Testing|Children will receive 2 testing (talking) exposures and 4 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly listening.
62604569|NCT03586479|EXPERIMENTAL|High Testing|Children will receive 4 testing (talking) exposures and 2 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly talking.
62604570|NCT03541330|OTHER|siblings|Brother or sister of a child has malignant haemopathy and follow-up in the pediatric hematology department
62604571|NCT03133091|ACTIVE_COMPARATOR|PIEB (Patient Intermittent Epidural Bolus)|"PIEB: The boluses are programmed every 30 minutes. The patient can ask for another extra bolus in between if she wishes.~The dosis per hour are equivalent to the PCEA. We make a comparison between PCEA vs PIEB."
62604572|NCT03133091|ACTIVE_COMPARATOR|PCEA (Patient continuous Epidural Analgesia)|"PCEA: There is a continuous infusion and the patient can order extra boluses every 15 minutes.~The dosis per hour are equivalent to the other arm to the PIEB. We make a comparison between PCEA vs PIEB."
62449233|NCT01430741|OTHER|Implementation as Usual Veterans|"Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition):MISSION-Vet has been developed to target mental health, substance abuse and related issues faced by homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources.~Implementation as Usual (IU) - standard training on the MISSION model via a 1.5 hour webinar. Staff then deliver MISSION to Veterans."
62604573|NCT00842075|EXPERIMENTAL|1 Symlin|Subcutaneous injection of pramlintide prior to each meal with reduction of mealtime bolus insulin
62827148|NCT03404193|EXPERIMENTAL|Treatment (decitabine, venetoclax)|Participants receive decitabine IV over 1 hour on days 1-10 and may also receive decitabine on days 1-5 after achieving complete remission/complete remission with incomplete count recovery during consolidation/maintenance. Participants also receive venetoclax PO daily on days 1-28 of cycle 1 and on days 1-21 of subsequent cycles. Treatment repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62827149|NCT01089101|EXPERIMENTAL|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience a sustained objective response from selumetinib on the phase I or phase II portions of the trial, and who have completed 2 years of treatment and stopped study drug may be enrolled on the re-treatment study after progression/recurrence. Patients in the re-treatment study may continue treatment indefinitely in the absence of disease progression or unacceptable toxicities. Patients undergo blood sample collection on study.
62827150|NCT06601049|ACTIVE_COMPARATOR|ResArgin|A resveratrol-based supplement. Participants will receive a daily oral dose of ResArgin containing \[50 mg/d\] of trans-Resveratrol for 90 days.
62827151|NCT06601049|PLACEBO_COMPARATOR|placebo|Placebo consists of oat hull. Participants receive a daily oral dose of a placebo matching the appearance and dosage form of ResArgin for 90 days.
62827152|NCT03840018|NO_INTERVENTION|Control|Sending doctors the lists of patients that meet the inclusion criteria to have their treatment reviewed
62827153|NCT03840018|OTHER|Letter by post to patients|Patients were sent a letter explaining the risks of using PPIs at long-term high doses and encouraging them to visit their doctor
62827154|NCT02454088|ACTIVE_COMPARATOR|Triamcinolone acetate|Injection of Calcium hydroxylapatite with Triamcinolone acetate
62827155|NCT02454088|PLACEBO_COMPARATOR|Placebo|Injection of Calcium hydroxylapatite with a placebo
62827156|NCT02786017|SHAM_COMPARATOR|Conventional therapy|
62247667|NCT02379767||Patients|Subjects aged between 18 and 60 years suffering from unipolar severe depression, who did not respond to conventional pharmacological antidepressant treatment (at least two adequate trials with antidepressants of different pharmacological classes over a minimum period of one month, equivalent to 150mg of tricyclic antidepressants). Concomitant psychotropic medication will be accepted during study participation, however, medication should remain stable throughout the study. Patients will undergo 6 to 14 ECT sessions in accordance with recent consensus statements and based on standard operation procedures (SOPs) of the Department of Psychiatry and Psychotherapy.
62045251|NCT06415357|EXPERIMENTAL|Standard ART counseling and MTM|Participants in this arm will receive standard ART counseling, followed by one mHealth intervention (MTM) to improve PrEP uptake and adherence.
62045252|NCT06415357|ACTIVE_COMPARATOR|Standard ART counseling|Participants in this arm will receive standard ART counseling.
62045253|NCT06370988|SHAM_COMPARATOR|Sham iTBS Stimulation|Administered once daily over 30 days, using a sham coil that reproduces auditory and tactile sensations of stimulation and has an identical external appearance. Each session will deliver 600 pulses of sham iTBS in triplet 50Hz bursts, repeated at 5Hz 2s on 8s off for a total time of \~3 minutes, 9 seconds at a target intensity of 120% of the subject's resting motor threshold.
62045254|NCT06370988|EXPERIMENTAL|Active iTBS Stimulation|Administered once daily over 30 days. Each session will deliver 600 pulses of active iTBS in triplet 50Hz bursts, repeated at 5Hz 2s on 8s off for a total time of \~3 minutes, 9 seconds at a target intensity of 120% of the subject's resting motor threshold.
62045255|NCT04766762|EXPERIMENTAL|Acupuncture combined with placebo group|Patients in this group will receive acupuncture combined with placebo.
62247668|NCT02379767||Healthy subjects|Subjects will be age- and sex-matched to the patients and should present no psychiatric, or major neurological or internistic illness.
62247669|NCT03415126|EXPERIMENTAL|ASN007 ascending doses|Patients will receive escalating doses of ASN007 to identify the best dose.
62247670|NCT03415126|EXPERIMENTAL|ASN007 RD: KRAS mutant Melanoma|Patients with BRAF mutant metastatic melanoma will receive the recommended dose from Part A.
62827157|NCT02786017|EXPERIMENTAL|Injectable Collagen Scaffold + HUC-MSCs|
62827158|NCT00630838|EXPERIMENTAL|1|VSL#3 probiotic
62045256|NCT04766762|OTHER|Sham acupuncture combined with medication group|Participants in this group will receive sham acupuncture plus flunarizine hydrochloride.
62045257|NCT00828984|EXPERIMENTAL|Arm A (high-dose PEG 3350)|Patients receive high-dose macrogol 3350-based oral osmotic laxative PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
62045258|NCT00828984|EXPERIMENTAL|Arm B (low-dose polyethylene glycol)|Patients receive low-dose macrogol 3350-based oral osmotic laxative PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
62045259|NCT00828984|PLACEBO_COMPARATOR|Arm C (placebo)|Patients receive placebo PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
62604574|NCT00842075|NO_INTERVENTION|2 Usual Regimen|Usual bolus insulin dose at each meal
62604575|NCT02777944|EXPERIMENTAL|Intervention|Access to Motivate: a web-based intervention, in addition to Usual Care
62604576|NCT02777944|NO_INTERVENTION|Control|Usual Care
62604577|NCT04984317|EXPERIMENTAL|Botox Injection|One-time injection of 100U BOTOX (onabotulinumtoxin A) into the fundus of the bladder under direct visualization via cystoscopy.
62604578|NCT02425761|ACTIVE_COMPARATOR|Anterior Entry SIte|"Anterior entry site is defined as shunt surgery with catheter entry into the brain from an opening near the coronal suture, on the top of the head and near the front. Specifically, anterior entry is defined as ventricular catheter entry less than 1 centimeter anterior to the coronal suture near the mid-pupillary line.~Subjects randomized to this arm will undergo ventriculoperitoneal shunt insertion surgery using an anterior entry site."
62827159|NCT00630838|PLACEBO_COMPARATOR|2|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
62827160|NCT00389610|EXPERIMENTAL|Previously Vaccinated With GVAX Pancreas Vaccine|Participants receive booster vaccination every 6 months, given intradermally.
62827161|NCT00389610|EXPERIMENTAL|GVAX Pancreas Vaccine Naive|Participants will receive GVAX pancreas priming vaccinations once every month for a total of 3 months and every 6 months after that, given intradermally.
62045260|NCT01417507||Supportive care (neurocognitive assessment and MRI)|"Patients undergo neurocognitive assessment using the CogState Test battery (the DET, the IDN, the OCLT, and the GMLT) at baseline\* and at 12, 24, 36, 42, 48, 54, and 60 months. Patients also complete the EORTC QOL-30, the BCM20, and the EQ-5D questionnaires at baseline\*, at 12, 24, 36, 48, and 60 months afterwards, and before undergoing any further treatment. Patients are instructed to complete a seizure and medication diary during study.~Patients undergo MRI scans at baseline\*, at 12, 24, 36, 48, and 60 months, and at the time of radiological, clinical, or neurological failure."
62045261|NCT05873608|OTHER|Interview|Patients and providers undergo observation during a conversation about immunotherapy. Then participate in an interview over 20 minutes.
62045262|NCT05873608|OTHER|Aim 4 tests an educational video|The participants watch a video and their comprehension is tested in a pre and post methodology
62045263|NCT02980055|EXPERIMENTAL|Test: collagen matrix|Root coverage using collagen matrix
62247671|NCT03415126|EXPERIMENTAL|ASN007 RD: NRAS mutant Melanoma|Patients with NRAS and HRAS mutant solid tumors will receive the recommended dose from Part A.
62437829|NCT05776966|OTHER|Treatment as usual (TAU)|TAU for opioid use disorder consists of a mix of medication treatment and individual and group therapy services across various levels of care: inpatient, residential, and outpatient. Residential treatment is for adults who have completed detoxification and require additional treatment in a structured environment. Inpatient treatment includes short-term care and detoxification treatment and incorporates a combination of group, family, and individual therapy targeted at medical stabilization, reducing the severity of the patient's symptoms, and providing resources and ongoing support to prevent relapse. Outpatient treatment is focused on comprehensive evaluation and stabilization.
62437830|NCT01779947|EXPERIMENTAL|Estradiol Vaginal Insert 10 mcg|Estradiol Vaginal Insert 10 mcg - Test Product
62437831|NCT01779947|ACTIVE_COMPARATOR|Vagifem Tablets 10 mcg|Vagifem® (Estradiol Vaginal Tablets) 10 mcg - Reference Listed Drug
62437832|NCT01779947|PLACEBO_COMPARATOR|Placebo|Placebo for the test product Estradiol Vaginal Tablets 10 mcg
62827162|NCT05931419||Robot assisted radical prostatectomy (RARP)|Robot-assisted radical prostatectomy, potentially as part of multimodality therapy with adjuvant radiotherapy or with (neo)adjuvant androgen deprivation therapy. Pelvic lymph node dissection (PLND) may be performed for staging purposes. The presence of positive lymph nodes (pN1) upon PLND is not a reason for exclusion and may be followed by adjuvant treatment such as lymph node irradiation.
62827163|NCT05931419||External beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT)|External beam radiotherapy (hypofractionated or conventionally fractionated) at a biologically effective dose converted to 2Gy fractions (α/β:1.5) of at least 76Gy. EBRT may be combined with a brachytherapy boost and PLND may be performed for staging purposes. The presence of positive lymph nodes (pN1) upon PLND is not a reason for exclusion and lymph node irradiation may be performed. Patients should receive ADT for at least 6 months.
62827164|NCT02376998|EXPERIMENTAL|Valiant™ endoluminal procedure|Data from early and long term complications following endoluminal stent-graft placement for thoracic endovascular aortic repair (TEVAR) procedure (Valiant™ endoluminal procedure) will be collected.
62827165|NCT04165577|EXPERIMENTAL|OCD, Active TMS|Participants with OCD who receive active rTMS
62045264|NCT02980055|ACTIVE_COMPARATOR|Control: connective tissue graft|Root coverage using connective tissue graft
62045265|NCT01124760|EXPERIMENTAL|1|AZD9742
62045266|NCT02923843|EXPERIMENTAL|intervention|Comprehensive Geriatric Assessment
62045267|NCT02923843|NO_INTERVENTION|control|Standard care
62045268|NCT01267513||normal volunteers|Normal individuals, aged 18 -75
62045269|NCT01267513||Hospitalized patients|Pulmonary and cardiac ICU, Trauma
62247672|NCT03415126|EXPERIMENTAL|ASN007 RD: KRAS mutant metastatic CRC|Patients with KRAS mutant CRC will receive the recommended dose from Part A
62247673|NCT03415126|EXPERIMENTAL|ASN007 RD: KRAS mutant NSCLC|Patients with KRAS mutant NSCLC will receive the recommended dose from Part A
62247674|NCT03415126|EXPERIMENTAL|ASN007 RD: Metastatic Pancreatic Cancer|Patients with pancreatic adenocarcinoma will receive the recommended dose from Part A
62437833|NCT02381509||IVC Filter|IVC filter for the prevention of PE
62437834|NCT04202900|OTHER|Phototherapy protocol|"Pretest：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs.~Intervention：LED light therapy for 6 weeks, 2-3 times a week, every 30 minutes. Post test：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs."
62437835|NCT06524024|EXPERIMENTAL|Treatment|Biological: DC-CTL DC combined with CTL
62437836|NCT03818490|EXPERIMENTAL|Bergamot Aromatherapy|Patients in this group inhaled bergamot essential oil for 15 minutes at the start of their medical office visit.
62437837|NCT03818490|NO_INTERVENTION|Control|Patients in this group did not experience an intervention.
62045270|NCT02331862|EXPERIMENTAL|UTI treated with Methylprednisolone|UTI treated with Methylprednisolone in addition to the effective antibiotics
62045271|NCT02331862|NO_INTERVENTION|UTI not treated with Methylprednisolone|UTI treated with effective antibiotics only
62045272|NCT01107860||Group I|
62827166|NCT04165577|SHAM_COMPARATOR|OCD, Sham TMS|Participants with OCD who receive sham rTMS
62045273|NCT01107860||Group II|
62045274|NCT02257268|EXPERIMENTAL|Change behavior group|Change behavior group = Group of change behavior including physical activity and healthy habits promotion.
62045275|NCT02257268|NO_INTERVENTION|Control group|Control group = Group that will not receive the VAMOS program as intervention.
62045276|NCT05753150||Tafenoquine (TQ)|Patients aged ≥16 years, G6PD activity ≥ 6.1 U/gHb, not pregnant or breastfeeding, will receive single-dose TQ in addition to chloroquine, the standard blood schizonticidal drug.
62045277|NCT05753150||Daily primaquine (PQ) for 14 days|Patients aged ≥16 years, G6PD activity ≥ 4.1 U/gHb, not pregnant or breastfeeding, will receive 14-day PQ in addition to chloroquine, the standard blood schizonticidal drug.
62045278|NCT05753150||Weekly primaquine (PQ) for 8 weeks|Patients aged ≥16 years, G6PD activity ≤ 4.0 U/gHb, not pregnant or breastfeeding, will receive 14-day PQ in addition to chloroquine, the standard blood schizonticidal drug.
62045279|NCT05801211||primary surgical tumor resection with anastomosis or only tumor resection without anastomosis|"primary surgical tumor resection with a primary colorectal anastomosis (associated or not with a diverting loop ileostomy) or without a primary anastomosis (Hartmann's procedure)"
62247675|NCT03415126|EXPERIMENTAL|ASN007 RD: MEK, All BRAF, BRAF-fusion cancers|Patients with solid tumors will receive the recommended dose from Part A
62827167|NCT04165577|OTHER|Healthy Control, Active TMS|Healthy control participants who receive active rTMS
62827168|NCT04165577|OTHER|Healthy Control, Sham TMS|Healthy control participants who receive sham rTMS
62045280|NCT05801211||endoscopic stent positioning|staged resection after endoscopic stenting with Self-expandable Metallic Stent (SEMS)
62045281|NCT00500877|ACTIVE_COMPARATOR|Mood Management Phone counseling|Mood management phone counseling for smoking cessation
62045282|NCT00500877|PLACEBO_COMPARATOR|Phone Counseling Standard|Phone counseling standard
62045283|NCT00745810||1|sequential changes before and after cardiopulmonary bypass including ROS, antioxidant status, leukocyte elastase, complements, inflammatory cytokines
62045284|NCT04582474|EXPERIMENTAL|Dengue module and rapid diagnostic tests|
62045285|NCT04467554|EXPERIMENTAL|Measurements and T-chair training|This group will receive three measurements sessions and training with a new developed device (15 therapy sessions in total).
62827169|NCT04165577|OTHER|Healthy Control, Active TMS (1 session)|Healthy control participants who receive 1 session of active, open-label rTMS
62827170|NCT04165577|OTHER|Healthy Control, Active TMS (3 sessions)|Healthy control participants who receive 3 sessions of active, open-label rTMS
62045286|NCT04467554|NO_INTERVENTION|Measurements|This group will receive three measurements sessions.
62045287|NCT02946333||Patient with MM who are not candidates for ASCT|Patients with newly diagnosed MM who are not candidates for ASCT and who are going to start drug treatment for the study disease and patient who is capable of understanding and filling in the study questionnaires At least 450 patients will be enrolled in a 2-year period. Patients must meet all of the inclusion criteria and none of the exclusion criteria and must have previously granted their informed consent in writing.
62045288|NCT04215042|ACTIVE_COMPARATOR|Standard hydration|All patients received standard intravenous saline hydration (0.9% sodium chloride, 1 ml/kg/h for 12 hours before and 6 hours after procedure
62045289|NCT04215042|EXPERIMENTAL|Short hydration|All patients received shot intravenous saline hydration (3 ml/kg for 1 hour before the procedure and after 1ml/kg/h for 6 hours)
62045290|NCT04858958|EXPERIMENTAL|treated subjects will receive Furmonertinib 160mg/day,|treated subjects will receive Furmonertinib 160mg/day, QD, PO, under fasted state, until progressive disease, death or intolerability.
62045291|NCT04858958|EXPERIMENTAL|treated subjects will receive Furmonertinib 240mg/day,|treated subjects will receive Furmonertinib 160mg/day, QD, PO, under fasted state, until progressive disease, death or intolerability.
62247676|NCT04304976|EXPERIMENTAL|Training with ROBERT® Passive|Training performed with ROBERT® in passive mode, resulting in active assistive training.
62827171|NCT04165577|OTHER|OCD, Active TMS (3 session)|Participants with OCD who receive 3 sessions of active, open-label rTMS
62045292|NCT04858958|EXPERIMENTAL|treatment-naïve subjects will receive Furmonertinib 240mg/day|Treatment naïve patients with EGFR exon 20 insertion mutation positive NSCLC
62045293|NCT04278625||Cyanotic CHD|Cyanotic congenital heart disease (CHD) patients presenting for Fontan palliation.
62045294|NCT04278625||Acyanotic CHD|Acyanotic congenital heart disease (CHD) patients presenting for repair via median sternotomy.
62247677|NCT04304976|EXPERIMENTAL|Training with ROBERT® Active|Traning performed with ROBERT® in Active mode, resulting in active resistive training.
62827172|NCT03831152|EXPERIMENTAL|Experimental ADV7103|All patients receive ADV7103 at their individualized dose
62827173|NCT02984813|EXPERIMENTAL|GlaucoHealth|2 pills once daily in the morning for 3 months
62247678|NCT02933736|EXPERIMENTAL|Administration of ribociclib|"Subjects will be administered ribociclib prior to surgical resection of their tumor. All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurring at one of 3 following intervals before brain tumor resection:~Cohort 1: last ribociclib dose 2-4 hours prior to craniotomy for tumor resection~Cohort 2: last ribociclib dose 6-8 hours prior to craniotomy for tumor resection~Cohort 3: last ribociclib dose 23-25 hours prior to craniotomy for tumor resection"
62827174|NCT02984813|EXPERIMENTAL|GlaucoSelect|2 pills once daily in the morning for 3 months
62827175|NCT02984813|PLACEBO_COMPARATOR|Placebo|2 pills once daily in the morning for 3 months
62045295|NCT01207102|EXPERIMENTAL|Abraxane, Carboplatin|Abraxane 100mg/m2 IV days 1, 8 and 15 of a 28 day cycle Carboplatin area under the concentration curve, (AUC)2 IV days 1,8, and 15 of a 28 day Cycle
62045296|NCT03093831|EXPERIMENTAL|Ibrutinib|
62045297|NCT03701984|EXPERIMENTAL|lidocaine infusion arm|The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
62604579|NCT02425761|ACTIVE_COMPARATOR|Posterior Entry Site|"Posterior entry site is defined as shunt surgery with catheter entry into the brain from an opening near the lambdoid suture, on the back of the head. Specifically, posterior entry is defined as ventricular catheter entry 4 to 7 centimeters above the external occipital protuberance (inion), near the mid-pupillary line.~Subjects randomized to this arm will undergo ventriculoperitoneal shunt insertion surgery using a posterior entry site."
62604580|NCT01258075|EXPERIMENTAL|Colesevelam|High-dose colesevelam suspended in a drink for oral administration once daily with dinner
62827176|NCT05458713|EXPERIMENTAL|PC6 High Energy group|The participants of this group will be irradiated with a 4mm probe for 60 seconds with an output power of 100mW on PC6 (acupoint Neiguan).
62437838|NCT02539095|EXPERIMENTAL|Cartizol, collagen injection|Their eligibility to participate in the study is checked, and they are randomized either into the intra-articular collagen injection group based on a randomization table.
62827177|NCT05458713|EXPERIMENTAL|PC6 Low Energy group|The participants of this group will be irradiated with a 4mm probe for 20 seconds with an output power of 100mW on PC6 (acupoint Neiguan).
62827178|NCT05458713|PLACEBO_COMPARATOR|PC6 Placebo group|The participants of this group will be irradiated with a 4mm probe for 0 seconds with an output power of 100mW on PC6 (acupoint Neiguan).
62827179|NCT05458713|ACTIVE_COMPARATOR|BL65 High Energy group|The participants of this group will be irradiated with a 4mm probe for 60 seconds with an output power of 100mW on BL65 (acupoint Shugu).
62045298|NCT03701984|ACTIVE_COMPARATOR|tramadol arm|will be administered with an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
62247679|NCT05902377|EXPERIMENTAL|68Ga-NY104 PET/CT|Each patient will receive one dose of 68Ga-NY104 by intravenous route. Dedicated whole-body PET/CT imaging will be performed.
62247680|NCT00455013|EXPERIMENTAL|belatacept, mycophenolate mofetil (MMF)|thymoglobulin 1.5mg/kg for 4 days;IV belatacept: 10 mg/kg Days 1 and 5, then every other week through Month 3 (Weeks 2,4,6,8,10,12), and then every 4 weeks through Month 6 (Weeks 16, 20, 24),after 6 months, 5 mg/kg every 4 weeks until 12 months; MMF 1g twice daily(bis in die, BID)
62247681|NCT00455013|EXPERIMENTAL|belatacept, sirolimus|thymoglobulin 1.5mg/kg for 4 days;IV belatacept: 10 mg/kg Days 1 and 5, then every other week through Month 3 (Weeks 2,4,6,8,10,12), and then every 4 weeks through Month 6 (Weeks 16, 20, 24),after 6 months, 5 mg/kg every 4 weeks until 12 months;sirolimus 5 mg/day on Day 1 (day of transplant)and continued through Day 2, dosing to be adjusted to keep pre-dose C0 levels at 7-12 ng/mL for first 6 months, followed by 5 - 10 ng/mL until 12 months.
62437839|NCT02539095|PLACEBO_COMPARATOR|Normal Saline injection|Their eligibility to participate in the study is checked, and they are randomized either into the (placebo) injection group based on a randomization table.
62437840|NCT03717610|EXPERIMENTAL|Complete cytoreductive surgery plus HIPEC with cis-platinum100mg/m2 for 90 min|
62437841|NCT02373475|EXPERIMENTAL|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
62827180|NCT05458713|ACTIVE_COMPARATOR|BL65 Low Energy group|The participants of this group will be irradiated with a 4mm probe for 20 seconds with an output power of 100mW on BL65 (acupoint Shugu).
62827181|NCT05458713|SHAM_COMPARATOR|BL65 Sham group|The participants of this group will be irradiated with a 4mm probe for 0 seconds with an output power of 100mW on BL65 (acupoint Shugu).
62827182|NCT02273479|EXPERIMENTAL|Asasantin®|
62827183|NCT02273479|PLACEBO_COMPARATOR|Placebo|
62827184|NCT00222612|ACTIVE_COMPARATOR|A or B with 2DI|3 or 4 drug induction plus 2 delayed intensifications
62247682|NCT00455013|OTHER|tacrolimus, MMF|(IMPs as comparator regimen)thymoglobulin 1.5mg/kg for 4 days; oral tacrolimus 0.1 mg/kg/day in 2 divided doses with initial targeted trough level of 8-12 ng/mL for Days 1 - 30 with dose reduction to achieve 12 hour trough target of 5-10 ng/mL for 12 months; MMF (mycophenolate mofetil) 1g BID.
62437842|NCT02373475|ACTIVE_COMPARATOR|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
62437843|NCT04022070|OTHER|Dynamic Tape|To evaluate the evolution of this symptomatology prior to and thereafter the application of Dynamic Tape® bandage in a sample of subjects affected by plantar fasciitis.
62604581|NCT01258075|EXPERIMENTAL|Placebo proxy|Low-dose colesevelam suspended in a drink for oral administration once daily with dinner
62604582|NCT04104113|EXPERIMENTAL|XBYRT decoction|Participants assigned to receive the modifed Xiang Bei Yang Rong Tang granules
62604583|NCT04104113|PLACEBO_COMPARATOR|Placebo|Participants assigned to receive placebo (contains 5% of XBYRT) granules
62604584|NCT03909113|EXPERIMENTAL|amino acid based formula|amino acid based formula
62045299|NCT03701984|PLACEBO_COMPARATOR|placebo group|will be administered with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
62604585|NCT03059706|EXPERIMENTAL|RegenoGel-OSP™|
62604586|NCT03059706|PLACEBO_COMPARATOR|Placebo|
62604587|NCT02795520|EXPERIMENTAL|OTS167IV|
62604588|NCT02811497|EXPERIMENTAL|Azacitidine and Durvalumab|"Azacitidine will be given by mouth at a fixed dose of 300 mg daily for 14 consecutive days of every 28 day cycle for 3 cycles.~Durvalumab will be given intravenously (by vein) at a fixed dose of 1500 mg (over 1 hour) on Day 1 of every 28 day cycle for 12 months or until disease progression."
62827185|NCT00222612|EXPERIMENTAL|C plus 2DI|Intensified treatment including Capizzi maintenance
62827186|NCT00222612|EXPERIMENTAL|A or B with 1DI|Reduced intensity treatment
62827187|NCT00265603|EXPERIMENTAL|1 Arm|The investigators plan to have approximately 16 persons participate in the study of transimmunization. Transimmunization uses a device, called a UVAR-XTS instrument, to remove a portion of blood, part of which is returned, and part of which is incubated overnight before being returned to the bloodstream the next day
62827188|NCT03480581|EXPERIMENTAL|Reverse First ICARE Training|Participants will engage in 12-sessions in the reverse direction followed by 12-sessions in the forward direction.
62827189|NCT03480581|EXPERIMENTAL|Forward First ICARE Training|Participants will engage in 12-sessions in the forward direction followed by 12-sessions in the reverse direction.
62604589|NCT05467618|EXPERIMENTAL|Intra-Oral Surgical approach|The mandibular fracture was reduced using an intra-oral surgical approach.
62604590|NCT05467618|EXPERIMENTAL|Extra-Oral Surgical approach|An External/Facial approach was used to reduce the mandibular bone fracture.
62604591|NCT04721704|EXPERIMENTAL|Group A|Group A will be given Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI based triple regimen
62604592|NCT04721704|EXPERIMENTAL|Group B|Group B will be given Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI based triple regimen
62604593|NCT01825083|ACTIVE_COMPARATOR|Ketamine|Ketamine administered 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.
62045300|NCT00886340|ACTIVE_COMPARATOR|Enhanced standard care|
62604594|NCT01825083|PLACEBO_COMPARATOR|Placebo|Saline group will received the same volume in saline as the ketamine dose
62827190|NCT05867368|ACTIVE_COMPARATOR|Standard HABIT|Children will receive hand arm bimanual intensive therapy the way it is typically delivered. Children will receive 40 hrs of one-on-one bimanual therapy, delivered as play. Activities will be self-selected, but all options will require both hands to succeed.
62827191|NCT05867368|EXPERIMENTAL|HABIT-VR|Children will receive hand arm bimanual intensive therapy, however, it will be through the use of custom virtual reality games. Children will receive 40 hrs of one-on-one bimanual therapy, delivered through the virtual reality games. Activities will be self-selected, but all games have a task constraint, requiring both hands to succeed.
62827192|NCT06593548|EXPERIMENTAL|AK112 combined with CapeOX and radiotherapy|Participants will receive Ivosidenib in combination with CapeOX chemotherapy and radiotherapy. Participants will first receive Ivosidenib in combination with CapeOX during the first cycle, followed by radiotherapy starting 2 weeks after medication.
62827193|NCT03184688|EXPERIMENTAL|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
62045301|NCT00886340|EXPERIMENTAL|Lifestyle counseling|
62045302|NCT01442948||Acute coronary syndrome|
62045303|NCT01442948||Stable Angina|
62045304|NCT03376581|EXPERIMENTAL|Prospective treatment|
62045305|NCT04658407||all patients diagnosed with a severe hepatic failure|Retrospective cohort using only data already entered in the Health data warehouse of the APHP (Public Paris Hospital)
62045306|NCT01423630|EXPERIMENTAL|Probiotics and fruit fibre|Probiotics and fruit fibre
62604595|NCT02604550|ACTIVE_COMPARATOR|Femoral Nerve Block|Subjects undergoing anterior cruciate ligament (ACL) surgery will be randomized to receive 20 mL of ropivacaine 0.5% in the femoral nerve. Subjects will also receive standard of care Percocet 7.5/325 and naprosyn following surgery.
62604596|NCT02604550|ACTIVE_COMPARATOR|Adductor Canal Block|Subjects undergoing anterior cruciate ligament surgery will be randomized to receive 20 mL of ropivacaine 0.5% in the adductor canal. Subjects will also receive standard of care Percocet 7.5/325 and naprosyn following surgery.
62604597|NCT02910570|EXPERIMENTAL|Liraglutide 3 mg|Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.
62604598|NCT02910570|PLACEBO_COMPARATOR|Liraglutide 3 mg placebo|Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
62604599|NCT03416634|ACTIVE_COMPARATOR|App Alone|Participants randomized to use the Microsoft Band app to track daily activity
62604600|NCT03416634|EXPERIMENTAL|App Plus Automated Motivational Message|Participants randomized to use the Microsoft Band app to track daily activity, and to receive automated, motivational text messages
62827194|NCT03184688|PLACEBO_COMPARATOR|Normal saline|Normal saline for hydrodissection
62437844|NCT02532777|EXPERIMENTAL|Prednisone & Cyclophosphamide|"Drug: prednisone \& cyclophosphamide \& Angiotensin-converting enzyme inhibitor(ACEI).~Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.~cyclophosphamide: 0.1mg/kg. Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
62827195|NCT04693767||Patients with ischemic stroke|
62437845|NCT02532777|EXPERIMENTAL|Prednisone & Mycophenolate mofetil|"Drug: prednisone \& mycophenolate mofetil \& Angiotensin-converting enzyme inhibitor(ACEI).~Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.~mycophenolate mofetil: 25mg/kg/d bid (the maximum dose is 1.5g/d). Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
62437846|NCT02532777|EXPERIMENTAL|Prednisone & Leflunomide|"Drug: prednisone \& leflunomide \& Angiotensin-converting enzyme inhibitor(ACEI). Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.~Leflunomide: give patients the induction dose 1mg/kg/d for three days (the total dose is under 40mg/kg)，then give the maintaining dose 0.5mg/kg/d.~Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
62827196|NCT04693767||Patients with intracranial hematoma|
62827197|NCT03599674|EXPERIMENTAL|Family Bridge Program|Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
62437847|NCT00900809|EXPERIMENTAL|Neukoplast™ (NK-92)|Neukoplast™ will be infused in three doses.1 x 10e9 cells/m2 dose, 3 x 10e9 cells/m2 dose, 5 x 10e9 cells/m2 dose.
62437848|NCT04422847|EXPERIMENTAL|intervention group (3D protective obturator)|Patients enrolled in the intervention group will have an intraoral scan of the palate, alveolar arch, and upper vestibular area before surgery. Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer, in cooperation with the Faculty of Mechanical Engineering (Department of Mechanics of Bodies, Mechatronics and Biomechanics) of Brno University of Technology. For the production of the obturator, a silicone certified for use in the oral cavity will be used.
62437849|NCT04422847|NO_INTERVENTION|control group|The standard procedure without the 3D obturator.
62437850|NCT01190306|EXPERIMENTAL|CXL Treatment|Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light.
62437851|NCT01190306|ACTIVE_COMPARATOR|Sham Control|Eyes in the control group will be treated with riboflavin only.
62437852|NCT06542042||NAS group|In this group, the investigators will detect the number of pathogen in alveolar lavage fluid, blood and peritoneal drainage by using NAS.
62437853|NCT06542042||NGS group|In this group, the investigators will detect the number of pathogen in alveolar lavage fluid, blood and peritoneal drainage by using NGS.
62437854|NCT06542042||Lab Tests group|In this group, the investigators will detect the number of pathogen in alveolar lavage fluid, blood and peritoneal drainage by using laboratory tests.
62604601|NCT03416634|EXPERIMENTAL|App Plus Personalized Motivational Message|Participants randomized to use the Microsoft Band app to track daily activity, and to receive personalized, motivational text messages
62604602|NCT03416634|ACTIVE_COMPARATOR|Wearable Device Alone|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity
62827198|NCT06603584||group A|Bronchial Asthma
62827199|NCT06603584||group B|Chronic Aspiration
62827200|NCT06603584||group C|Primary Ciliary Dyskinesia
62827201|NCT06603584||group D|Cystic Fibrosis
62827202|NCT06592391|OTHER|expert schools|These schools developed their own dynamic school day over the past 5 - 10 years without using the educational innovation.
62045307|NCT01834885|EXPERIMENTAL|QVA149|QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.
62604603|NCT03416634|EXPERIMENTAL|Wearable Device Plus Automated Motivational Message|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity, and to receive automated, motivational text messages
62827203|NCT06592391|EXPERIMENTAL|Cohort 1|These schools will start the development of a tailored dynamic school day using the educational innovation in September 2024. The educational component consists of a number of face-to-face meetings. The implementation of the local plans will start September 2025.
62827204|NCT06592391|EXPERIMENTAL|Cohort 2|these schools will start the development of a tailored dynamic school day using the e-learning version of the educational innovation in September 2025. The implementation of the local plans will start September 2026.
62827205|NCT03561220|ACTIVE_COMPARATOR|IMRT (Photon)|As this trial is pragmatic, all treatment will be standard of care.
62827206|NCT03561220|ACTIVE_COMPARATOR|Proton Therapy Standard of Care|As this trial is pragmatic, all treatment will be standard of care.
62827207|NCT03561220|EXPERIMENTAL|Standard Proton Therapy|78.0 Gy (RBE) in 39 fractions. This is Arm 1 of the embedded randomized trial.
62827208|NCT03561220|EXPERIMENTAL|Hypofractionated Proton therapy|60.0 Gy (RBE) in 20 fractions This is Arm 2 of the embedded randomized trial.
62449234|NCT01430741|EXPERIMENTAL|Getting to Outcomes Case Management|Getting To Outcomes (GTO) is used to strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. In GTO, staff receive ongoing technical assistance using the GTO implementation platform.
62604604|NCT03416634|EXPERIMENTAL|Wearable Device Plus Personalized Motivational Message|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity, and to receive personalized, motivational text messages
62827209|NCT06592573|EXPERIMENTAL|CBT_ONLINE|10-12 sessions of cognitive behavioural therapy conducted online.
62827210|NCT06592573|ACTIVE_COMPARATOR|CBT_IN PERSON|10-12 sessions of cognitive behavioural therapy conducted in-person.
62827211|NCT06598085|EXPERIMENTAL|Robot-assisted surgery|Robot-assisted laparoscopic wide total hysterectomy
62827212|NCT01466712|EXPERIMENTAL|Tiotropium+formoterol/beclomethasone|run-in of 4 weeks with thiotropium cross-over after first treatment period of 4 weeks
62827213|NCT01466712|SHAM_COMPARATOR|tiotropium+placebo|cross-over cfr arm1
62437855|NCT03575429|ACTIVE_COMPARATOR|Engagement Intervention|Family navigators will engage families to access resources and support when they first learn their child has signs of autism spectrum disorder (ASD) using an intervention that integrates motivational interviewing (MI) and problem-solving education (PSE). The family navigator will meet with parents for up to 6 individual MI+PSE sessions for each 3-month stage of intervention.
62437856|NCT03575429|ACTIVE_COMPARATOR|Engagement + Coaching Intervention|Family navigators will engage families to access resources and support when they first learn their child has signs of autism spectrum disorder (ASD) using an intervention that integrates MI+PSE. Family navigators will also coach families to embed intervention strategies for toddlers with ASD in everyday activities using the Early Social Interaction (ESI) model. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places. The family navigator will meet with parents for 12 weekly home visits for each 3-month stage of intervention.
62827214|NCT00561925|EXPERIMENTAL|nevirapine XR|400 mg QD
62604605|NCT05900817|EXPERIMENTAL|antivet arm|Teeth treated will be isolated first then Vaseline will be placed on gingival sulcus before placing dental dam., patient will be seated at a 45 degree angle. Five drops of Antivet in the plastic mixing well that comes. Then ANTIVET solution will be applied over the tooth's surface using a well condensed cotton pellet (approximately a 3 mm diameter). When the cotton pellet is pigmented by the tooth's staining, it will be changed for a new one. This process may take about 1 to 5 minutes per tooth, It should take no longer than 15 minutes from the moment the solution contacts the tooth's surface
62604606|NCT05900817|ACTIVE_COMPARATOR|opulsture arm|They were isolated with a rubber dam and then a fine-grit, water-cooled diamond bur was applied to the stained and white opaque enamel region for five to 10 seconds to enable penetration of the gel into the enamel. An approximately 1-mm- thick layer of 6.6% hydrochloric acid slurry with silicone carbide microparticles (Opalustre, Ultradent Products Inc, South Jordan, UT, USA) was applied to the affected tooth surfaces.
62827215|NCT00561925|ACTIVE_COMPARATOR|nevirapine IR|200 mg BID
62827216|NCT05098834|EXPERIMENTAL|PICU and PCICU Patients|Patients younger than 17 years of age receiving mechanical ventilation for an acute respiratory illness will be approached to participate prior to initiation of an ERT for clinical purposes.
62827217|NCT05397925|EXPERIMENTAL|ADSProgram|"This is the experimental arm of the study. This includes receiving the novel/experimental ADSProgram. Therapy description withheld to protect the integrity of the study.~Intervention: ADSprogram"
62827218|NCT05397925|ACTIVE_COMPARATOR|Treatment as usual|"This is the control arm of the study. This includes receiving the standard of care on nursing Consultations on a medication-based program and multidisciplinary regular care. Therapy description withheld to protect the integrity of the study.~Intervention: Nursing Consultation"
62827219|NCT06653075|ACTIVE_COMPARATOR|traditional anchorage|Skeletal class II patients treated by Herbst Appliance with traditional dental anchorage
62827220|NCT06653075|EXPERIMENTAL|skeletal anchorage|Skeletal class II patients treated by Herbst Appliance with skeletal anchorage
62827221|NCT06652893||Fifty consecutive patients who met the inclusion criteria participated in the study|Consecutive patients with knee osteoarthritis and with a medical indication for viscosupplementation with hybrid hialuronic acid (HA) who fulfilled the inclusion criteria were recruited for the study. The inclusion criteria were: a medical indication for viscosupplementation therapy with hybrid HA; patients aged between 45 and 80 years; diagnosis of femorotibial gonarthrosis associated with femoro-patellar arthrosis or isolated, gonarthrosis symptoms for at least 6 months; patients who failed to respond to analgesics and/or regular NSAIDs, or were proved to be intolerant to the regular use of analgesics, NSAIDS, or weak opioids; grade 2 to 3 OA in the Kellgren-Lawrence grading scale ; pain when walking measured by the Visual Analog Scale of at least 40 mm on the targeted knee; and contralateral knee pain when walking with aVAS of less than 10 mm. The exclusion criteria were: inability to understand the aim of the study, inability to provide acceptable consent, pregnancy, serious ps
62827222|NCT02512822|EXPERIMENTAL|Participants|Noninvasive Radiofrequency
62827223|NCT01051895|EXPERIMENTAL|HPV testing|Women randomized to this arm will undergo high risk HPV DNA testing using Hybrid Capture 2®.
62827224|NCT01051895|ACTIVE_COMPARATOR|Routine colposcopy|Women will be followed in the colposcopy clinic as usual, with no standardized protocol, tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
62827225|NCT06601816|ACTIVE_COMPARATOR|Reamer Group|The group in which the lateral window was created with conventional rotary instrument burs
62827226|NCT06601816|ACTIVE_COMPARATOR|Piezo surgery with Surgical Guide Group|The group in which the lateral window was created using piezo surgery and surgical guide
62827227|NCT06601816|ACTIVE_COMPARATOR|Conventional Group|The group in which the lateral window was created with conventional rotary instrument burs
62827228|NCT05270759||Hospitalized patients receiving hemodialysis/hemodialfiltration|"Adult patients hospitalized in the intensive care unit (ICU) or general ward receiving hemodiafiltration or hemodiafiltration treatments as least 3 times per week with ≥1L of fluid removal per session~Exclusion criteria:~* Planned hospital discharge, death, or transition to comfort care within 48 hours according to the attending physician~* End of active care (awaiting hospital discharge)"
62827229|NCT01811992|EXPERIMENTAL|Dose escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L|"This protocol is a dose escalation study of Ad-hCMV-TK and Ad-hCMV-Flt3L infused at the time of surgical resection followed by systemic oral administration of valacyclovir in addition to current standard of care with temozolomide and radiotherapy. Eligible subjects will be enrolled in six sequential dosing cohorts:~* A= Ad-hCMV-TK: 1x10\^10 vp and Ad-hCMV-Flt3L: 1x10\^9 vp~* B= Ad-hCMV-TK: 1x10\^11 vp and Ad-hCMV-Flt3L: 1x10\^9 vp~* C= Ad-hCMV-TK: 1x10\^10 vp and Ad-hCMV-Flt3L: 1x10\^10 vp~* D= Ad-hCMV-TK: 1x10\^11 vp and Ad-hCMV-Flt3L: 1x10\^10 vp~* E= Ad-hCMV-TK: 1x10\^10 vp and Ad-hCMV-Flt3L: 1x10\^11 vp~* F= Ad-hCMV-TK: 1x10\^11 vp and Ad-hCMV-Flt3L: 1x10\^11 vp~Subjects will be treated sequentially with a minimum of 21 days before treatment of new subjects within a cohort or before dose escalation."
62827230|NCT06600607|OTHER|Schedule A|participants receive pregabalin 300mg in treatment period 1, and receive placebo in treatment period 2
62827231|NCT06600607|OTHER|Schedule B|participants receive placebo in treatment period 1, and receive pregabalin 300mg in treatment period 2
62827232|NCT00830882|EXPERIMENTAL|1:levosalbutamol|2 puffs four times a day for 2 weeks
62247683|NCT04620850|EXPERIMENTAL|Acupressure|Acupressure after cesarean section 3 hr and then next 3 hr (duration 10 min per time) Acupressure at below knee the point ai locate about4 finger spcae below patella on the lateral side of tibia bone
62437857|NCT00162383|EXPERIMENTAL|Cocktail|
62827233|NCT00830882|ACTIVE_COMPARATOR|2: racemic salbutamol|2 puffs four times a day for 2 weeks
62827234|NCT00830882|PLACEBO_COMPARATOR|3: Placebo|2 puffs four times a day for 2 weeks
62247684|NCT04620850|NO_INTERVENTION|No acupressure|Standard post-operative care
62247685|NCT01859468|EXPERIMENTAL|Amorphous calcium carbonate|200 mg elemental calcium tablets, 2 in the morning and 2 in the evening, after a meal
62247686|NCT01859468|PLACEBO_COMPARATOR|StarLac|Tablets containing 300 mg StarLac (starch cellulose and lactose blend) to be used as placebo, 2 tablets in the morning and 2 tablets in the evening, after a meal.
62247687|NCT00108186|OTHER|Arm 1|Celecoxib is an FDA approved drug for other indications such as osteoarthritis. It is not FDA approved for non-small cell lung cancer.
62247688|NCT00590044|EXPERIMENTAL|Insulin glargine+glulisine|Daily insulin glargine + glulisine before meals
62247689|NCT00590044|ACTIVE_COMPARATOR|Split-mixed NPH + Regular insulin|Split-mixed NPH + Regular insulin twice daily
62247690|NCT02715713||testosterone deficiency group|Men between the ages of 40 to 80-years-old with testosterone deficiency
62247691|NCT02715713||prostate cancer group|Men between the ages of 40 to 80-years-old with prostate cancer that will result in testosterone deficiency due to surgical or pharmacological castration.
62437858|NCT00623025|EXPERIMENTAL|1|
62437859|NCT00623025|PLACEBO_COMPARATOR|2|
62437860|NCT02934269|EXPERIMENTAL|CC-90006; Dose Level 1|CC-90006 will be administered by subcutaneous injection in the abdomen
62437861|NCT02934269|EXPERIMENTAL|CC-90006; Dose Level 2|CC-90006 will be administered by subcutaneous injection in the abdomen
62437862|NCT02934269|EXPERIMENTAL|CC-90006; Dose Level 3|CC-90006 will be administered by subcutaneous injection in the abdomen
62437863|NCT02934269|EXPERIMENTAL|CC-90006; Dose Level 4|CC-90006 will be administered by subcutaneous injection in the abdomen
62045308|NCT01834885|ACTIVE_COMPARATOR|fluticasone/salmeterol|Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.
62827235|NCT00578539|EXPERIMENTAL|Stem Cell Transplant|All patients will receive Ara C IV every 12 hours for 6 doses starting at 1400 hours on day -8. Cyclophosphamide IV once daily on day -7 and day -6 starting at 1400 hours. MESNA will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide. Campath 1h will be given on day -4, day -3, day -2 and day-1. TBI (Total Body Irradiation) will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1. Stem cell Infusion are infused on day 0.
62827236|NCT04501523|EXPERIMENTAL|A|ctDNA positive, non-pCR Intervention: Tislelizumab(anti-PD1 antibody) combined with capecitabine
62827237|NCT04501523|ACTIVE_COMPARATOR|B|ctDNA positive, non-pCR Intervention: capecitabine(standard care)
62827238|NCT04501523|EXPERIMENTAL|C|ctDNA positive, pCR Intervention: capecitabine
62827239|NCT04501523|NO_INTERVENTION|D|Follow up(standard care)
62827240|NCT05370196|EXPERIMENTAL|Test Product|Synthetic Male Condom
62827241|NCT05370196|ACTIVE_COMPARATOR|Control Product|Latex Male Condom
62827242|NCT04362241|EXPERIMENTAL|Dextenza|Sustained release Dexamethasone 0.4mg
62827243|NCT04362241|ACTIVE_COMPARATOR|Prednisolone Acetate 1%|Prednisolone Acetate Ophthalmic drops
62827244|NCT02317900|EXPERIMENTAL|TV005 and rDEN2∆30-7169|Participants will receive one injection of TV005 at study entry (Day 0). On Day 180, participants will receive one injection of rDEN2∆30-7169.
62827245|NCT02317900|PLACEBO_COMPARATOR|Placebo and rDEN2∆30-7169|Participants will receive one injection of placebo at study entry (Day 0). On Day 180, participants will receive one injection of rDEN2∆30-7169.
62827246|NCT01176682||1|Adult patients treated with NSAID therapy for diagnosed OA, RA or AS, and with GI risk factors
62827247|NCT06347380|EXPERIMENTAL|Subjects receiving FemPulse System|Subjects will receive the Ring for the treatment of their OAB symptoms
62827248|NCT06590896|EXPERIMENTAL|Cenobamate|
62827249|NCT05433181|EXPERIMENTAL|ACE2 Chewing Gum|
62827250|NCT05433181|PLACEBO_COMPARATOR|Placebo Chewing Gum|
62827251|NCT02473536|EXPERIMENTAL|Stereotactic ablative radiation therapy|SABR
62045309|NCT02311530|EXPERIMENTAL|Test|Felodipine Extended Release Tablets USP 10 mg
62045310|NCT02311530|ACTIVE_COMPARATOR|Reference|Plendil® Extended release tablets 10 mg
62247692|NCT05031988||University Students|To assess the determinants of physical activity and mental health among university students during and after Covid-19 lockdown.
62247693|NCT06239298|EXPERIMENTAL|Dose Exploration|The first stage is a dose-exploration study of ZG005 combined with Donafenib to evaluate the safety and tolerability of different dose combinations in patients with advanced solid tumors who have failed standard therapy.
62247694|NCT06239298|EXPERIMENTAL|Dose Expansion|The second stage is a dose-expansion study to further evaluate the safety and initial efficacy of the combination regimen in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and other potentially beneficial solid tumors.
62247695|NCT05030454|EXPERIMENTAL|CT-guided stereotactic adaptive radiotherapy|-Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.
62827252|NCT06038643|EXPERIMENTAL|Intervention|Social motivation intervention, self-transcendence daily messages, and daily accelerometry.
62827253|NCT06038643|ACTIVE_COMPARATOR|Active Control|Daily accelerometry.
62827254|NCT06654817||experimental group|"ofatumumab combined with corticosteroids versus corticosteroids~To compare the efficacy and safety of two treatment strategies: ofatumumab combined with corticosteroids versus corticosteroids along with azathioprine, in pemphigus patients.~A prospective cohort study was conducted, following patients for 36 weeks from January 1, 2023, to April 30, 2024. Patients meeting the diagnostic criteria were nonrandomly grouped based on screening results. The primary endpoints were time to disease control and skin healing. Secondary endpoints included complete remission rates, relapse rates, corticosteroid doses, pemphigus disease area index (PDAI), dermatology life quality index (DLQI), visual analogue scale (VAS) pain scores, CD19+ B cell percentages, desmoglein-specific antibodies, and adverse events."
62827255|NCT06654817||control group|the standard treatment of corticosteroids plus azathioprine
62827256|NCT02671708|EXPERIMENTAL|IDA+BUCY|For intermediate-risk AML undergoing auto-HSCT，IDA+BUCY conditioning regimen was IDA 15mg/m2/day on days -12 and -10；BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
62045311|NCT00921752||Patients at high cardiovascular risk|
62045312|NCT02553525|EXPERIMENTAL|Therapeutic Stimulation Patterns|This group will receive temporal patterns of stimulation that are designed to suppress oscillatory neural activity at theta- or beta-frequencies. These patterns are hypothesized to alleviate motor symptoms.
62045313|NCT02553525|EXPERIMENTAL|Symptogenic Stimulation Patterns|This group will receive symptogenic patterns of stimulation that are designed to exacerbate oscillatory neural activity at theta- or beta-frequencies. These patterns are hypothesized to exacerbate motor symptoms.
62247696|NCT05503862|EXPERIMENTAL|Arm A|At home semen testing via the YoSperm device
62247697|NCT05503862|NO_INTERVENTION|Arm B|Standard of Care
62827257|NCT02671708|ACTIVE_COMPARATOR|BUCY|"For intermediate-risk AML undergoing auto-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days~-3 and -2."
62827258|NCT01167075|ACTIVE_COMPARATOR|Fresubin Original|
62827259|NCT01167075|EXPERIMENTAL|Intestamin plus Fresubin Original|
62827260|NCT05106426|EXPERIMENTAL|HC2 intervention Group|Participants in this group will receive the Healthy Caregivers-Healthy Children (HC2) intervention for 24 months
62827261|NCT05106426|ACTIVE_COMPARATOR|Jump Start Control Group|Participants in this group will receive the Jump Start intervention for 24 months
62045314|NCT01850979|ACTIVE_COMPARATOR|tacrolimus|tacrolimus 0,03% eye drops (olive oil as vehicle) every 12/12 hours for 3 months placebo as olive oil eye drops every 12/12h hours for 3 months
62247698|NCT04869254||Hematopoietic stem cells transplantation|patients undergone allogeneic or autologous bone marrow transplant who received immunomodulatory therapy with Thymoglobulin
62604607|NCT02851056|EXPERIMENTAL|Survivin Vaccine and Autologous HCT|Dendritic Cell Survivin Vaccine (DC:AdmS) and Autologous Hematopoietic Cell Transplantation (HCT). Participants will receive 1 pre-transplant survivin vaccine, 7-30 days prior to stem cell apheresis collection. After the first survivin vaccination, participants will be mobilized with Granulocyte-colony Stimulating Factor (G-CSF). A second survivin vaccine will be administered on day +21 (between day+20 and +34) after HCT. All participants will be co-immunized with Prevnar 13 at each time they receive the survivin vaccine.
62827262|NCT05106426|NO_INTERVENTION|Parents/Caregivers of Participants receiving HC2 intervention|Parents/caregivers of participants receiving the HC2 program will not be receiving any intervention.
62247699|NCT04044183|EXPERIMENTAL|Active Brains|Active Brains uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The Active Brains sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal \& coping, and growth enhancement). The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a digital monitoring device (i.e., Fitbit) for recording of physical activity.
62437864|NCT02934269|EXPERIMENTAL|CC-90006; Dose Level 5|CC-90006 will be administered by subcutaneous injection in the abdomen
62437865|NCT02934269|EXPERIMENTAL|Placebo|Placebo will be administered by subcutaneous injection in the abdomen
62437866|NCT02793063||BBD Consortium Contact Registrants|Osteogenesis Imperfecta patients who have self-registered at the Brittle Bone Disorders Consortium (BBD) Consortium Contact Registry, a web-based contact registry developed and supported by the Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Consortium (RDCRN), located at the University of South Florida.
62437867|NCT03202628|EXPERIMENTAL|Treatment (ixazomib, pomalidomide, dexamethasone, ASCT)|"INDUCTION (COURSES 1-4): Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days (courses 1-3) and 56 days (course 4) for up to 4 courses in the absence of disease progression or unacceptable toxicity.~TRANSPLANTATION (COURSE 5): Between 2-4 weeks following Induction, patients undergo ASCT.~CONSOLIDATION (COURSES 6-9): Beginning 60-120 days following ASCT, patients receive ixazomib citrate, pomalidomide, and dexamethasone as in Induction. Treatment repeats every 28 days (courses 6-8) and 56 days (course 9) for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE (COURSES 10+): Beginning 0-4 weeks following Consolidation, patients receive ixazomib citrate as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62437868|NCT03740100|OTHER|Open single arm|Bimiralisib capsules orally
62604608|NCT01569750|EXPERIMENTAL|Ibrutinib|"Part 1 (Dose Escalation): Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) until maximum tolerated dose is achieved.~Part 2: Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP."
62604609|NCT03956615|OTHER|Clinically Suspected or Pathologically Confirmed Multiple Myeloma.|Patients with a clinically suspected or pathologically confirmed multiple myeloma.
62827263|NCT05106426|NO_INTERVENTION|No Intervention: Parents/Caregivers of participants receiving Jump Start Intervention|Parents/caregivers of participants receiving the Jump Start program will not be receiving any intervention.
62827264|NCT00284947|EXPERIMENTAL|Maintenance immunosuppression|"40mg Simulect i.v, once every 28 days for 24 weeks (treatment periods)~* 1g MMF or 720mg EC-MPS p.o twice daily~* Oral corticosteroids"
62827265|NCT04596267|EXPERIMENTAL|Pitolisant|Subjects will take an 8.9 mg dose (two 4.45 mg pills) of pitolisant once per day on day 1 through 4. On day 5, 8.9 mg will be taken in front of staff prior to an alcohol self administration trial.
62437869|NCT05803278|EXPERIMENTAL|Children positive to screening test|"Children positive to the online test InTempo, which includes standardized and scientifically validated tests in the following areas: Metaphonology, Reading and Writing"
62437870|NCT01849939|EXPERIMENTAL|Fludarabin|
62437871|NCT06267599||Bladder suture group|This group consisted of patients in whom we could not open the bladder and uterine cervix by dissection, so we had to open the bladder. In this group, the bladder dome was opened and a special suture was passed through the bladder to control bleeding. This procedure was performed to control bleeding.
62437872|NCT06267599||Control group|For the patients in this group, the vascular structures between the bladder and cervix were coagulated one by one. The bladder was not opened during this procedure.
62437873|NCT03724721|EXPERIMENTAL|pneumothorax drainage|Pneumothorax drainage with vacuum bottle plus intercostal catheter
62604610|NCT00745511|ACTIVE_COMPARATOR|1|
62827266|NCT04596267|PLACEBO_COMPARATOR|Placebo|Subjects will take an placebo once per day on day 1 through 4. On day 5, a placebo will be taken in front of staff prior to an alcohol self administration trial.
62045315|NCT01850979|PLACEBO_COMPARATOR|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
62045316|NCT04913844||Skiers group|"The skiers group was formed from licensed ski athletes (17 male, 17 female) who have been active in sports for at least the last 2 years.~There will be no interventions. Physical performance tests and observational assessments will be conducted."
62604611|NCT00745511|ACTIVE_COMPARATOR|2|
62604612|NCT00745511|PLACEBO_COMPARATOR|3|
62604613|NCT05189496|EXPERIMENTAL|hyperbaric oxygen therapy group|30-40 times hyperbaric oxygen therapy
62604614|NCT05189496|NO_INTERVENTION|control group|No hyperbaric oxygen therapy
62437874|NCT01998685|EXPERIMENTAL|Balanced (BAL) anaesthesia|In the BAL group anaesthesia is induced with midazolam 0.1mg kg-1 and fentanyl 1.5 μg kg- 1 Anaesthesia is maintained with sevoflurane 2.0% , oxygen 40% and air 70% with positive pressure ventilation in a circle system, in order to achieve normocapnia.
62827267|NCT01207414|EXPERIMENTAL|iloperidone gradual switch|"Participants taking risperidone, olanzapine or aripiprazole gradually decreased the dose they were taking: 50% of original dose on Day 1, 25% of original dose after the first week and the total discontinuation of the drug after the second week.~On Day 1 participants began taking iloperidone orally twice a day (bid) in the morning and in the evening beginning at a dose of 1 mg and increasing to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg bid on consecutive days over a 7-day period to achieve a total dose of 12-24 mg/day for 12 weeks."
62827268|NCT01207414|EXPERIMENTAL|iloperidone immediate switch|"Participants taking risperidone, olanzapine or aripiprazole discontinued the drug immediately.~On Day 1 participants began taking iloperidone orally twice a day (bid) in the morning and in the evening beginning at a dose of 1 mg and increasing to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg bid on consecutive days over a 7-day period to achieve a total dose of 12-24 mg/day for 12 weeks."
62827269|NCT06588985|EXPERIMENTAL|Emotion Coaching Treatment Group|Parents of the parent-child dyad in this group, will attend 1 3-hour parent workshop on emotion coaching. Followed by 2 biweekly phone consultations with a clinical psychologist.
62827270|NCT06588985|ACTIVE_COMPARATOR|Waitlist Control Group|In this group, questionnaires/data will be collected, but no treatment will be given. Only after they have submitted all data, then they will be invited to participate in the above Emotion Coaching parent workshop and phone consultations.
62827271|NCT03138369|EXPERIMENTAL|Vestibular nerve stimulation|Usage of wearable vestibular nerve stimulator that non-invasively stimulates the vestibular nerves by administering a small electrical current through the skin behind the ears. Should be worn up to one hour a day and at least 5 hours a week.
62827272|NCT03138369|SHAM_COMPARATOR|Sham vestibular nerve stimulation|Usage of wearable control device that appears identical to active device. Instead of stimulating the vestibular nerves this device will discharge its battery into an internal resistor. Should be worn up to one hour a day and at least 5 hours a week.
62827273|NCT01796808|OTHER|Pathway A|"Screening visit followed by pedal fat grafting procedure with local anesthetic and visits at:~1. 1 week~2. Post op study visit 2 (1 month)~3. Post op study visit 3 (2 month)~4. Post op study visit 4 (6 month)~5. Post op study visit 5 (12 month)~6. Crossover to standard podiatry visits~7. Study visit 6 (18 months)~8. Study visit 7 (24 months)"
62827274|NCT01796808|OTHER|Pathway B|"Screening visit followed by:~1. Study visit 1 (6months)~2. Study Visit 2 (12 months)~3. Crossover to Pathway A~pedal fat grafting procedure and local anesthetic and visits at:~1. 1 week~2. Post op study visit 2 (1 month post procedure)~3. Post op study visit 3 (2 month post procedure)~4. Post op study visit 4 (6 month post procedure)~5. Post op study visit 5 (12 month post procedure)"
62827275|NCT04670302|ACTIVE_COMPARATOR|Control group (Tendon repair)|The control group will undergo tendon repair procedure only (without augmentation)
62827276|NCT04670302|EXPERIMENTAL|Experimental group (Tendon repair augmented with AAdMSC-HAM composite)|The experimental group will undergo tendon repair procedure augmented with AAdMSC-HAM composite
62827277|NCT05383118|EXPERIMENTAL|Education Intervention|"Participants in the intervention group will be provided e-learning about dementia prevention and promoting brain health, consisting of following components:~1. One multimedia e-learning lesson on promoting brain health and preventing dementia;~2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~3. Curated resources related to dementia risk factors"
62827278|NCT05383118|ACTIVE_COMPARATOR|Education Control|"Participants in the control group will be provided e-learning about mild cognitive impairment, consisting of following components:~1. One multimedia e-learning lesson on mild cognitive impairment;~2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~3. Curated resources related to mild cognitive impairment"
62827279|NCT04662489|ACTIVE_COMPARATOR|Control arm. Pulmonary vein isolation|Pulmonary vein isolation with ablation.
62827280|NCT04662489|EXPERIMENTAL|Treatment arm. Radial ablation|Pulmonary vein isolation plus radial ablation of rotational activity sites.
62827281|NCT04506229||COVID-19 positive|
62827282|NCT04506229||COVID-19 negative|
62827283|NCT02561884|EXPERIMENTAL|AB|Olostar Tab. followed by Olmetec and Crestor
62827284|NCT02561884|EXPERIMENTAL|BA|Olmetec and Crestor followed by Olostar Tab.
62827285|NCT02364375|EXPERIMENTAL|Full Face|Participants will trial the same mask type/variant (full face, nasal, pillows) as the variant they are using as part of their current treatment. Participants in this arm will trial the Menai mask (full face) and Comparison Menai Standard mask (full face) for 7 nights each.
62827286|NCT02364375|EXPERIMENTAL|Nasal|Participants will trial the same mask type/variant (full face, nasal, pillows) as the variant they are using as part of their current treatment. Participants in this arm will trial the Menai mask (nasal) and Comparison Menai Standard mask (nasal) for 7 nights each.
62437875|NCT01998685|ACTIVE_COMPARATOR|Totally Intravenous Anesthesia (TIVA-TCI)|In the TIVA-TCI group anaesthesia is induced with propofol 6 microg ml-1 and remifentanyl 0.4-1 microg kg-1 min, simultaneously administered using two separate modules of a continuous computer-assisted TCI system. Anaesthesia is maintained with propofol 4 microg ml-1 and remifentanil 0.25 microg Kg-1 min. This infusion is modified by 0.05 microg kg-1 min steps according to analgesic needs.
62045317|NCT04913844||Control group|"The control group was composed of non-athletic and age-matched participants (17 male, 17 female) with no skiing experience.~There will be no interventions. Physical performance tests and observational assessments will be conducted as in the Skiers Group."
62437876|NCT04256993||Ra-223 initiators|"Patients diagnosed with mCRPC (Metastatic Castration-Resistant Prostate Cancer) who start treatment with Ra-223. Patients will be identified from the Patient-overview Prostate Cancer (PPC), a sub-registry of the Prostate Cancer data Base Sweden (PCBaSe) data set."
62437877|NCT04256993||Initiators of other standard of care|The comparator cohort will be patients using standard of care other than Ra-223.
62045318|NCT02918110|EXPERIMENTAL|Cytotec|orally administrated solution of misoprostol (Cytotec®)
62604615|NCT04428203|EXPERIMENTAL|single arm|A Phase I/Ib on the Safety of Epidiolex in Patients with Prostate Cancer with Rising PSA after Localized Therapy with either Surgery or Radiation
62604616|NCT04844905|EXPERIMENTAL|Ivermectin Mass Drug Administration|Ivermectin and Dihydroartemisinin-piperaquine MDA will be given to all eligible participants in each cluster (island) in addition to the standard national malaria control programme interventions.
62604617|NCT04844905|PLACEBO_COMPARATOR|Placebo Mass Drug Administration|Placebo and Dihydroartemisinin-piperaquine MDA will be given to all eligible participants in each cluster (island) in addition to the standard national malaria control programme interventions.
62604618|NCT01623037|EXPERIMENTAL|CoolSculpting Treatment Group|The single arm will include all subjects treated on each flank with the CoolSculpting System and CoolCurve+ applicator. Treatment temperature and duration are defined in the protocol.
62604619|NCT00189852|EXPERIMENTAL|Docobo|telemonitoring at home system for heart failure
62604620|NCT00189852|NO_INTERVENTION|Control|No telemonitoring system in place
62604621|NCT03672448||Neurocognitive disorder|Dementias
62604622|NCT03672448||Normal Aging|Normal Aging with normal cognitive function
62604623|NCT05673161||anemia, treatment|anemic patients who had iron therapy
62604624|NCT05673161||anemia, no treatment|anemic patients who had no therapy
62604625|NCT01058902|PLACEBO_COMPARATOR|Negative control|Not on aspirin pre operatively, but refuse to enter trial or have a contraindication to aspirin
62604626|NCT01058902|EXPERIMENTAL|Aspirin treatment|group randomised to aspirin
62827287|NCT02364375|EXPERIMENTAL|Pillows|Participants will trial the same mask type/variant (full face, nasal, pillows) as the variant they are using as part of their current treatment. Participants in this arm will trial the Menai mask (pillows) and Comparison Menai Standard mask (pillows) for 7 nights each.
62827288|NCT04911296|OTHER|Swallow Group|
62827289|NCT04939714|EXPERIMENTAL|Psychoeducational Intervention|Caregivers receiving the psychoeducational intervention immediately.
62045319|NCT02918110|EXPERIMENTAL|Misodel|vaginal slow release misoprostol (Misodel®)
62604627|NCT01058902|EXPERIMENTAL|No aspirin treatment|Randomised to no aspirin
62604628|NCT01058902|ACTIVE_COMPARATOR|Positive control|Already on aspirin. just observational limb
62604629|NCT03652948|EXPERIMENTAL|Meru Health Ascend Program|"The Meru Health Ascend Program is an 8-week mobile application (app) based intervention that teaches cognitive-behavioral and mindfulness skills. The intervention also includes a group discussion board with the other participants in the intervention group and therapist support via chat within the app.~Study 2 is examining a revised version of the Meru Health Ascend Program that is 12 weeks long and incorporates sleep and nutrition information in addition to the 8-week program."
62604630|NCT04907227|EXPERIMENTAL|Pembrolizumab+Docetaxel|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to a maximum of 35 cycles (approximately 2 years) PLUS docetaxel 75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle (Q3W) for a maximum of 10 cycles (approximately 7 months). Participants also concomitantly receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours, and 1 hour prior to docetaxel administration and prednisone 5 mg by oral tablets twice daily during each 21-day docetaxel cycle.
62604631|NCT04907227|PLACEBO_COMPARATOR|Placebo+Docetaxel|Participants receive placebo by IV infusion on Day 1 of each 21-day cycle (Q3W) for up to a maximum of 35 cycles (approximately 2 years) PLUS docetaxel 75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle (Q3W) for a maximum of 10 cycles (approximately 7 months). Participants also concomitantly receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours, and 1 hour prior to docetaxel administration and prednisone 5 mg by oral tablets twice daily during each 21-day docetaxel cycle.
62604632|NCT05578105||Autoimmune polyendocrine syndrome type II|patients with autoimmune polyendocrine syndrome type II
62604633|NCT04210375|ACTIVE_COMPARATOR|JK07|Single dose of JK07 administered by intravenous infusion over 60 minutes
62604634|NCT04210375|PLACEBO_COMPARATOR|Matching Placebo|Single dose of placebo administered by intravenous infusion over 60 minutes
62604635|NCT04489849|EXPERIMENTAL|Apixaban|Apixaban 2.5mg BID
62604636|NCT04489849|ACTIVE_COMPARATOR|Control|Other treatment except oral anticoagulant
62604637|NCT03871816||Participants with Metastatic Prostate Cancer|Participants with metastatic prostate Cancer (PC) will be evaluated for the prevalence of DNA-repair gene defects (DRDs) and will be assessed for biomarker eligibility status for niraparib interventional studies. Participants will be consented to saliva, blood, and/or archival tumor tissue testing for the presence or absence of DNA-repair gene defects.
62604638|NCT05409313|EXPERIMENTAL|EBP and SDM training group|A total of 36 nurses will be received EBP and SDM training program.
62604639|NCT05409313|ACTIVE_COMPARATOR|SDM training group|A total of 36 nurses will be received SDM training alone.
62604640|NCT04198584|EXPERIMENTAL|VC-CBCS Intervention|The VC-CBCS intervention was delivered via WebEx videoconferencing technology and included 14, 2-hour long sessions that involved group-based psychoeducation, cognitive and behavioral skills training, stress management, relaxation practice and healthy lifestyle habits to support overall health and liver health. Intervention materials included a hard copy Patient Workbook and audio-recorded relaxation techniques.
62604641|NCT04198584|NO_INTERVENTION|Standard of Care (SC)|Participants randomized to SC received no intervention and were followed by medical providers in clinic per clinical practice guidelines and clinicians discretion.
62604642|NCT00711828|EXPERIMENTAL|Treatment (R-CYBOR-D)|Patients receive rituximab IV on day 1and cyclophosphamide PO, bortezomib IV, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62604643|NCT06510387||Correct placement group|The research resident will perform ultrasonography using suprasternal and subxiphoid methods to confirm the correct placement of the endotracheal tube.
62604644|NCT06510387||Incorrect placement group|The research resident will perform ultrasonography using suprasternal and subxiphoid methods.
62604645|NCT01329718|EXPERIMENTAL|CRC Group|
62827290|NCT04939714|NO_INTERVENTION|Waitlist|Caregivers on a waitlist to receive the psychoeducational intervention after a waiting period of 8 weeks.
62827291|NCT06587815|NO_INTERVENTION|Control Group|Children in the control group were received standard care of the clinic
62827292|NCT06587815|EXPERIMENTAL|Intervention Group|Children in the intervention group received musical starry sky projector during the sleep time.
62247700|NCT04044183|PLACEBO_COMPARATOR|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback, and interventionist support/feedback. The original HEP was adapted to provide population-specific information on chronic pain and MCI/MRP symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight, and Medical appointments). The HEP program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The HEP is conducted in the same format as Active Brains-Fitbit but are not taught the mind-body, walking, or cognitive-behavioral skills. HEP participants are encouraged to set lifestyle goals instead of quota-based walking goals aided by the Fitbit as in the Active Brains-Fitbit condition."
62247701|NCT02830763|EXPERIMENTAL|Medium-chain Fatty Acid (CNT-02)|
62247702|NCT01980420|OTHER|Sleeve gastrectomy|All patients will undergo sleeve gastrectomy
62604646|NCT05523141|EXPERIMENTAL|ASC10|"Part 1: Participants will be randomized to receive 100 to 1600 mg ASC10 (including 6 cohorts) in an double-blind manner~Part 2: Participants will be randomized to receive two single 800 mg doses (fed or fasted)"
62604647|NCT05523141|PLACEBO_COMPARATOR|Placebo|Part 1: Participants will be randomized to receive placebo
62827293|NCT01046396|ACTIVE_COMPARATOR|Differin® Cream 0.1%|Adapalene Cream 0.1% - apply once daily on one side of the face for 3 weeks
62827294|NCT01046396|ACTIVE_COMPARATOR|Differin® Lotion 0.1%|Adapalene Lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
62247703|NCT01318252|EXPERIMENTAL|AL-54478|AL-54478 0.005%, single dose, followed 7 days later with 14 days of once daily dosing
62247704|NCT01318252|ACTIVE_COMPARATOR|Latanoprost|Latanoprost 0.005%, single dose, followed 7 days later with 14 days of once daily dosing
62247705|NCT01318252|PLACEBO_COMPARATOR|Vehicle|AL-54478 Vehicle, single dose, followed 7 days later with 14 days of once daily dosing
62247706|NCT04411628|EXPERIMENTAL|LY3819253|Participants received single doses of 700 milligrams (mg), 2800 mg or 7000 mg LY3819253 administered as intravenous infusion.
62247707|NCT04411628|PLACEBO_COMPARATOR|Placebo|Participants received single dose of Placebo as intravenous infusion.
62247708|NCT04353466|EXPERIMENTAL|Trial to asses impact of Elelyso on bone involvement in patien|The infusions will be administered at the selected medical center or in the home care setup. The dose of intravenous (IV) infusions of Elelyso will be the same dose of the other ERTs . Bone parameters QCSI and BMD will be assessed at baseline, 12 months and 24 months.
62247709|NCT05837351|EXPERIMENTAL|Exercise -Running|
62247710|NCT03506737|EXPERIMENTAL|Conventional exercise protocol|Conventional global exercise
62604648|NCT00871442|ACTIVE_COMPARATOR|No Basal Infusion|"PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml~Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)"
62045320|NCT04802941|EXPERIMENTAL|Neoadjuvant Chemotherapy by CDSS|
62247711|NCT03506737|EXPERIMENTAL|Cycle ergometer exercise protocol|Stationary cycle ergometer exercise
62247712|NCT05648058|EXPERIMENTAL|nefopam|administration of intravenous nefopam to prevent Rituximab Transfusion Reaction
62247713|NCT05648058|ACTIVE_COMPARATOR|diphenhydramine|administration of intravenous diphenhydramine to prevent Rituximab Transfusion Reaction
62247714|NCT05470946|OTHER|Enteroscopy|Double balloon enteroscopy
62247715|NCT06274008|EXPERIMENTAL|Exparel|Adductor Canal Block with Bupivacaine Liposome Injectable Suspension Admixture bupivacaine 0.5 % 10 cc with Bupivacaine Liposome Injectable Suspension 10cc total 20
62247716|NCT06274008|NO_INTERVENTION|Standard ACB with bupivacaine|Standard Adductor Canal Block (ACB) with Bupivacaine Standardized amount of 0.5% bupivacaine 20 cc
62247717|NCT02790125|EXPERIMENTAL|Dose Panel 1|"BMS-986166 or Placebo matching BMS-986166~Single oral dose of solution as specified"
62247718|NCT02790125|EXPERIMENTAL|Dose Panel 2|"BMS-986166 or Placebo matching BMS-986166~Single oral dose of solution as specified"
62247719|NCT02790125|EXPERIMENTAL|Dose Panel 3|"BMS-986166 or Placebo matching BMS-986166~Single oral dose of solution as specified"
62247720|NCT02790125|EXPERIMENTAL|Dose Panel 4|"BMS-986166 or Placebo matching BMS-986166~Multiple ascending solid dose formulation as specified"
62247721|NCT02790125|EXPERIMENTAL|Dose Panel 5a/b/c|"BMS-986166~Single oral solid dose formulation under fasting/fed/fasting with famotidine conditions"
62604649|NCT00871442|ACTIVE_COMPARATOR|Basal Infusion|"PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml~Group 2: Basal Infusion: 10 ml/hr; Bolus 5 ml q 30min prn (5ml demand dose with 30min lockout)"
62604650|NCT03211143|EXPERIMENTAL|A|"TR group~Period 1: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days~Period 2: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days"
62604651|NCT03211143|EXPERIMENTAL|B|"RT group~Period 1: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days~Period 2: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days"
62604652|NCT03621540|ACTIVE_COMPARATOR|Verum arm|25 min anodal tDCS + adaptive working memory training
62827295|NCT06586775|EXPERIMENTAL|diabetic group|complete pulpotomy will be performed in teeth with irreversible pulpitis in diabetic patients.
62827296|NCT06586775|ACTIVE_COMPARATOR|Healthy group|complete pulpotomy will be performed in teeth with irreversible pulpitis in systemically healthy patients.
62827297|NCT05036863||Patients with multiple myeloma|
62827298|NCT04836650|PLACEBO_COMPARATOR|Flat Insole (no metatarsal bar)|Postural stability and electromyographic activity in the dominant leg will be assessed with the subject shod (closed clog) and with 1.2 millimeters flat polyester resin insoles.
62827299|NCT04836650|EXPERIMENTAL|Flat Insole (with 2 millimeters metatarsal bar)|Postural stability and electromyographic activity in the dominant leg will be assessed with the subject shod (closed clog) and with 1.2 millimeters flat polyester resin insoles with a 2 millimeters polyester resin metatarsal bar.
62827300|NCT05036018|ACTIVE_COMPARATOR|Group 1|Patients treated with the ACURATE neo2 valve using a minimalist approach
62827301|NCT05036018|ACTIVE_COMPARATOR|Group 2|Patients treated with the ACURATE neo2 valve under standard of care
62604653|NCT03621540|SHAM_COMPARATOR|Sham arm|sham tDCS + adaptive working memory training
62604654|NCT05448287|EXPERIMENTAL|Intervention|Suaahara interventions span health and family planning; nutrition; agriculture/homestead food production; and water, sanitation and hygiene (WASH). Diverse social and behavior change communication interventions are used, primarily to generate demand for access to improved services and to motivate households to adopt optimal health, nutrition, and WASH practices. All Suaahara interventions are supported by a crosscutting theme of gender equality and social inclusion (GESI), in part by targeting women and disadvantaged groups and conducting activities that address GESI-related barriers to optimal health, nutrition, and WASH behaviors.
62045321|NCT04802941|ACTIVE_COMPARATOR|Neoadjuvant Chemotherapy in General practice|
62247722|NCT02614391|EXPERIMENTAL|Active distraction using a tablet|Children were admitted in a comfortable room with a parent and started to play with a videogame suitable for their age three minutes before procedure. They continued to play the videogame during venipuncture. The use of a computer tablet permitted to play with one hand only.
62247723|NCT02614391|ACTIVE_COMPARATOR|Passive distracion|Children were admitted in a comfortable room with a parent and received various kinds of passive distractions: nurses singing a song, reading a book, blowing bubbles and playing a puppet show. The technique that most engaged the child, was continued during procedure.
62247724|NCT02450604|OTHER|Patients with chronic pains of unknown aetiology|
62604655|NCT05448287|NO_INTERVENTION|Comparison|Usual care.
62604656|NCT05207618|EXPERIMENTAL|IBS PATIENTS|Natural specific tannin, chestnut
62604657|NCT05907161|EXPERIMENTAL|SRP|The SRP group will receive non-surgical periodontal therapy using an ultrasonic device and curettes in two sessions.
62827302|NCT05036018|ACTIVE_COMPARATOR|Group 3|Patients treated with the Evolut Pro or Pro+ valve using a minimalist approach
62827303|NCT05036018|ACTIVE_COMPARATOR|Group 4|Patients treated with the Evolut Pro or Pro+ valve under standard of care
62604658|NCT05907161|ACTIVE_COMPARATOR|SRP+LASER|The SRP+LASER group will receive non-surgical periodontal therapy using an ultrasonic device and curettes in two sessions. After session 2, irradiation with a diode laser (Dentsply Sirona - SIROLaser Blue) will be applied intrasulcular to all sites with PD ≥ 4mm.
62827304|NCT00648063|EXPERIMENTAL|1|Letrozole Tablets 2.5 mg
62827305|NCT00648063|ACTIVE_COMPARATOR|2|Femara® Tablets 2.5 mg
62827306|NCT03276338|EXPERIMENTAL|Intervention|Participation in the HOLA intervention designed to prevention HIV
62827307|NCT03276338|NO_INTERVENTION|Delayed-intervention|Delayed intervention with participation in HOLA intervention after follow-up data have been collected
62827308|NCT06604312|EXPERIMENTAL|Sacroiliac Joint Manipulation Group|Sacroiliac joint manipulation was performed in lateral decubitis position.
62827309|NCT06604312|NO_INTERVENTION|Control Group|The control group did not undergo any treatment.
62045322|NCT04320628|EXPERIMENTAL|Experimental|Target ulcer cleansed with NaOCl. After cleansing the wound a second MiX is performed. The subject is given a four-week supply of NaOCl.
62045323|NCT04320628|PLACEBO_COMPARATOR|Control|Target ulcer cleansed with NSS. After cleansing the wound a second MiX is performed. The subject is given a four-week supply of NSS.
62827310|NCT03711968|ACTIVE_COMPARATOR|Treatment group|"Rehabilitative treatment protocol:~Therapeutic exercise 8 mono-weekly sessions, 5 patients per group, duration 60 minutes and two sessions of single treatment, duration 60 minutes (duration of treatment about two months, considering also any recovery sessions)"
62827311|NCT03711968|NO_INTERVENTION|Waiting list|Intervention: The WL patients will be taken into the same treatment at the end of the experimental protocol, after T2 evaluation. In this period they act like a control group.
62827312|NCT01524575|NO_INTERVENTION|ERCC1 high expression|Patients with ERCC1 high expression tumors will be treated at discretion of investigator
62827313|NCT01524575|EXPERIMENTAL|ERCC1 low expression|Patients with ERCC1 low expression will be treated with gemcitabine and oxaliplatin
62604659|NCT05907161|ACTIVE_COMPARATOR|SRP+HA|The SRP+HA group will receive non-surgical periodontal therapy using an ultrasonic device and curettes in two sessions. After session 2, a gel containing hyaluronic acid (Regedent, HyaDENT Cross linked hyaluronic acid gel) will be applied intrasulcular to all sites with PD ≥ 4mm.
62604660|NCT05660824|EXPERIMENTAL|SVF (Stromal vascular fraction)|"Patients will receive a venepuncture to obtain PRP, and a lipoaspirate to obtain SVF. Then an ultrasonographic guided PRP+SVF injection will be performed.~Patients will consecutively receive two monthly PRP injections."
62604661|NCT05660824|ACTIVE_COMPARATOR|PRP (Platelet-rich plasma)|"Patients will receive a venepuncture to obtain PRP, and a sham lipoaspirate. Then an ultrasonographic guided PRP injection will be performed.~Patients will consecutively receive two monthly PRP injections."
62604662|NCT05771818|EXPERIMENTAL|Falls Prevention training|The intervention consists of 10 sessions. One session a week consists of obstacle course training. The other session consists of falls strategies and walking and balance exercises. Each session lasts approximately 1.5 hours
62604663|NCT03469180|ACTIVE_COMPARATOR|Control Group|Childrens in this group will receive treadmill training, three times a week for 8 weeks. Each season will be supervised and last 45 minutes.
62604664|NCT03469180|EXPERIMENTAL|Training Group|İn addition to treadmill training, childrens in this group (after a rest for 5 minutes) will also receive whole body vibration training for 15 minutes.
62604665|NCT00058084|EXPERIMENTAL|Arm I|Patients receive ixabepilone (BMS-247550) IV over 3 hours on day 1.
62604666|NCT00058084|EXPERIMENTAL|Arm II|Patients receive mitoxantrone IV over 30 minutes on day 1 and oral prednisone twice daily on days 1-21. In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62045324|NCT02821403|EXPERIMENTAL|Young adults|adults without presbyopia who aged 18-35 years
62247725|NCT05132270|EXPERIMENTAL|Combination of hydroxyurea and thalidomide|Hydroxyurea was continued at a dose of 10-20 mg/kg/day for 6 months and then thalidomide was added orally at a dose of 2-5mg/kg/day for 6 months.
62247726|NCT03202784|EXPERIMENTAL|BCX7353 API in capsule|fasted administration of BCX7353 API in capsule
62247727|NCT03202784|EXPERIMENTAL|BCX7353 blend in capsule|fasted administration of BCX7353 blend in capsule
62437878|NCT03158428|EXPERIMENTAL|CSD170202AA, CSD170202AB Use Group|Use of product CSD170202AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170202AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
62437879|NCT03158428|EXPERIMENTAL|CSD170202AB, CSD170202AA Use Group|Use of product CSD170202AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170202AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
62437880|NCT03899337|ACTIVE_COMPARATOR|Standard of Care Arm (CHOP-R)|"Arm in the randomised trial. CHOP-R chemoimmunotherapy will continue for up to 6 cycles (each cycle is 21 days), and will be given according to the following schedule:~Rituximab, 375 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Cyclophosphamide, 750 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Doxorubicin, 50 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Vincristine, 1.4 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Prednisolone, 40 mg/m2, PO, OD, 6 cycles, days of cycle: 1-5"
62437881|NCT03899337|EXPERIMENTAL|Experimental Arm (CHOP-R + Acalabrutinib)|"Arm in the randomised trial. CHOP-R chemoimmunotherapy will continue for up to 6 cycles (each cycle is 21 days), and will be given according to the following schedule:~Rituximab, 375 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Cyclophosphamide, 750 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Doxorubicin, 50 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Vincristine, 1.4 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Prednisolone, 40 mg/m2, PO, OD, 6 cycles, days of cycle: 1-5~Acalabrutinib 100 mg, PO, BD will be taken on days 6-21, of each cycle - up to cycle 6. Acalabrutinib treatment will be continuous thereafter until disease progression toxicity, patient choice or death."
62437882|NCT03899337|EXPERIMENTAL|Cohort 1 - Acalabrutinib Monotherapy - Platform Trial|Registration arm in platform study. Patients registered to Cohort 1 will receive 100 mg acalabrutinib monotherapy, twice daily, continuously from day 1 until disease progression, toxicity, patient choice or death.
62437883|NCT03899337|EXPERIMENTAL|Cohort 2 - CHOP-R + Acalabrutinib - Platform Trial|"Registration arm in platform study. CHOP-R chemoimmunotherapy will continue for up to 6 cycles (each cycle is 21 days), and will be given according to the following schedule:~Rituximab, 375 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Cyclophosphamide, 750 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Doxorubicin, 50 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Vincristine, 1.4 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Prednisolone, 40 mg/m2, PO, OD, 6 cycles, days of cycle: 1-5~Acalabrutinib 100 mg, PO, BD will be taken on days 6-21, of each cycle - up to cycle 6. Acalabrutinib treatment will be continuous thereafter until disease progression toxicity, patient choice or death."
62604667|NCT00248976|NO_INTERVENTION|1|This is the control group, which will be monitor. No intervention will be delivered to this group.
62604668|NCT00248976|EXPERIMENTAL|2|This group received the experimental intervention. This is an intervention based on feedback of individualized risk profiles framed as the opportunity to reduce one's biologic age. Net-present value of individual health behaviors in years.
62604669|NCT04445506||SARS-CoV2 patients that received dexamethasone|
62604670|NCT05525234|EXPERIMENTAL|Thalidomide group|Thalidomide tablets, 50mg/day, increase or decrease dose according to itch score. The maximum dose is 100mg/day.
62045325|NCT02821403|EXPERIMENTAL|Middle-aged adults|adults with presbyopia who aged over 40 years
62247728|NCT03202784|EXPERIMENTAL|BCX7353 blend in capsule with food|administration of BCX7353 blend in capsule following high-fat meal
62247729|NCT01219049|EXPERIMENTAL|Tyrosine 1000 mg / day|Patients receive 1000 mg tyrosine per day.
62247730|NCT01219049|EXPERIMENTAL|Tyrosine 2000 mg / day|Patients receive 2000 mg tyrosine per day.
62247731|NCT01219049|PLACEBO_COMPARATOR|Placebo|Patients receive placebo daily.
62247732|NCT03312348|EXPERIMENTAL|Infrared Imaging undertaken|Infrared imaging of Region Of Interest in study participants
62437884|NCT01129154|EXPERIMENTAL|panitumumab|Patients will receive six infusions of panitumumab every 2 weeks for the first cycle.
62604671|NCT05525234|PLACEBO_COMPARATOR|Placebo group|Palacebo tablets, 50mg/day, increase or decrease dose according to itch score. The maximum dose is 100mg/day.
62604672|NCT01658449|EXPERIMENTAL|group A|
62437885|NCT04421794|EXPERIMENTAL|NMES group|For the NMES group one portable stimulator (Compex 2, Medicompex SA, Ecublens, Switzerland) will deliver NEMS (15 min; 75 EMS contractions completed during the training session; rise time = 0.25 s and descending time = 0.75 s). In order to maximize muscle tension without accompanying detrimental effects on fatigue onset, biphasic symmetric regular-wave pulsed currents (85 Hz) lasting 400 μs will be delivered. Each 4-s steady tetanic stimulation will be followed by pause lasting 8-s, during which subjects will be submaximally stimulated at 4 Hz on the medial arch muscles. According to the recommendations, the two electrodes are placed behind the head of the first metatarsal to stimulate the medial arch intrinsic muscles. The goal is to attain the highest tolerable level of muscle contraction without discomfort during the 15 minutes and to provide a full tetanic contraction of the intrinsic foot muscles during the contraction time.
62437886|NCT04421794|PLACEBO_COMPARATOR|Control group|For the control group the one portable stimulator (Compex 2, Medicompex SA, Ecublens, Switzerland) will be used to apply a stimulation of 15 minutes considered by TENS at the lowest intensity detectable by the participant in order to not influence the outcomes of interest. Our aim is to strengthen IFM which is not the role of TENS. The two electrodes will be placed on the dominant foot, at the same place than those for the NMES group.
62437887|NCT05806333|EXPERIMENTAL|suspicious focal liver mass without FDG avidity|Experimental: 18F-FAPI PET/CT Imaging was performed 30-60 minutes after injection of 2-4mci 68Ga-FAPI tracer
62437888|NCT00213954|OTHER|interscalene block|Locoregional anesthesia selection
62437889|NCT00213954|OTHER|axillary block|Locoregional anesthesia selection
62437890|NCT00213954|OTHER|lumbar block|Locoregional anesthesia selection
62437891|NCT00213954|OTHER|parasacral plexus block|Locoregional anesthesia selection
62437892|NCT00650559|EXPERIMENTAL|1|Experimental surgical intervention.
62827314|NCT04238923|EXPERIMENTAL|Topical Gentamicin and Vancomycin|Immediately prior to closure of the incision, 1g of vancomycin will be mixed in 4mL of normal saline and applied as a paste directly to the muscle, fascia and subcutaneous tissue. Gentamicin-eluting collagen sponges will be cut to the appropriate size to cover the defect and applied after application of vancomycin. Following closure, the surgical site will be covered with a sterile dressing and left in place for 48hrs.
62827315|NCT04238923|NO_INTERVENTION|Control|The surgical wound is closed in the standard fashion with 3 layer closure with staples for skin. Following closure, the surgical site will be covered with a sterile dressing and left in place for 48hrs.
62827316|NCT00207077|EXPERIMENTAL|A|
62827317|NCT06651450||Patients who underwent laparoscopic cholecystectomy surgery|Effects of increasing IAB on frontal plane QRS-T angle, QT and QTc in ECG at different stages of surgery
62827318|NCT00937313||Champagne wine|
62827319|NCT00937313||Placebo|alcohol with sparkling mineral water
62827320|NCT06414590|EXPERIMENTAL|Neoadjuvant Tebentafusp in Patients Locally Advanced, Unresectable Primary Uveal Melanoma|Tebentafusp administration: 20mcg on Day 1, 30mcg on Day 8, 68 mcg on Day 15, and weekly doses of 68 mcg thereafter. Eye evaluations including clinical examination, ophthalmic ultrasound, optical coherence tomography, and wide-angle fundus imaging will be performed at baseline, Cycle 1 day 1, Cycle 1 day 8, Cycle 2 day 1, prior to definitive treatment for primary uveal melanoma (post-Tebentafusp), and at post-eye treatment evaluation at 3 months. Additionally optical coherence tomography angiography, autofluorescence, fluorescein angiography and MRI orbit will be performed at baseline, post-tebentafusp, and at post-eye treatment evaluation. Blood circulating tumor-derived DNA will be performed at baseline, Cycle 2 day 1, post-Tebentafusp, and at post-eye treatment evaluation at 3 months. Primary eye tumor biopsy (collected by fine-needle aspiration) and aqueous circulating tumor-derived DNA will be performed at baseline and post-Tebentafusp.
62827321|NCT05558527|EXPERIMENTAL|Social support from a romantic partner|Participants will hold the hand of their romantic partner
62827322|NCT05558527|ACTIVE_COMPARATOR|Social support from a stranger|Participants will hold the hand of a stranger
62827323|NCT05558527|NO_INTERVENTION|No social support|Participants will hold a stress ball
62827324|NCT02594124|EXPERIMENTAL|Group 1|Participants transitioned from ISIS 396443-CS3B (NCT02193074)
62827325|NCT02594124|EXPERIMENTAL|Group 2|Participants transitioned from ISIS 396443-CS4 (NCT02292537)
62827326|NCT02594124|EXPERIMENTAL|Group 3|Participants transitioned from ISIS 396443-CS12 (NCT02052791)
62827327|NCT02594124|EXPERIMENTAL|Group 4|Participants transitioned from ISIS 396443-CS3A (NCT01839656)
62827328|NCT02594124|EXPERIMENTAL|Group 5|Participants transitioned from 232SM202 (NCT02462759)
62827329|NCT04395976|NO_INTERVENTION|Control Group|Participants randomised into the control group receive conventional standard care given by recommended guideline.
62827330|NCT04395976|EXPERIMENTAL|Ayurveda|Treatment includes a tailored combination of herbs based on individual constitution (based on Ayurveda) nutritional advice, specific consideration of selected food items, specific lifestyle advice, yoga advice along with standard recommendations.
62045326|NCT01691833|EXPERIMENTAL|Vitamin D|Patients that are deficient in Vitamin D will be assigned to the randomized arm of the study. They will be randomly chosen to receive either the Vitamin D supplement or the placebo.
62437893|NCT02393534|NO_INTERVENTION|Usual Care|Eligible patients that are randomized to the usual care arm will have a standard in-person clinic visit with their primary care provider.
62604673|NCT01658449|EXPERIMENTAL|group B|
62827331|NCT01988155|ACTIVE_COMPARATOR|Eccentric Exericse|
62827332|NCT01988155|EXPERIMENTAL|Astym|
62604674|NCT02268370|OTHER|Dasatinib|"This research is being done because dasatinib has been shown to achieve a deep molecular response in patients as compared to imatinib.~Patients in this study will continue to take their own supply of imatinib for three months to ensure they have achieved a stable response to the drug. Once this has been confirmed, imatinib will be stopped and the patients in this study will then be monitored to see if their CML relapses. This period can last up to 2.5 years.~If the participant has a relapse, they will be started on dasatinib and will continue to receive dasatinib for up to 2 years.~If after one year they achieve a response, they will continue on dasatinib for one more year. If the participant maintains this response, they will have the option of discontinuing dasatinib."
62827333|NCT03056222|ACTIVE_COMPARATOR|HeartLight® EGLA|Participants will be treated with the endoscopically guided laser ablation catheter
62045327|NCT01691833|PLACEBO_COMPARATOR|Placebo|Patients that are deficient in Vitamin D will be assigned to the randomized arm of the study. They will be randomly chosen to receive either the Vitamin D supplement or the placebo.
62247733|NCT02654366|EXPERIMENTAL|Community Supported Risk Reduction Group|Six weekly sessions will be scheduled during daytime and evening hours to accommodate the daily schedules of BNEP registrants and their CSPs. Each session meets for 60 minutes. Groups will consist of 5-6 BNEP registrant-CSP dyads (10-12 individuals). While BNEP registrants and CSPs attending the group together will receive an attendance incentive, BNEP registrants attending without a CSP will not earn one. The group leader will follow a manual that includes a structured outline. The group manual content combines risk reduction / treatment readiness and community outreach approaches. Following the introduction, each group session is divided into two components: 1) Risk Reduction and Treatment Readiness (30 min) and 2) Community Outreach skills (20 min).
62247734|NCT04607928|PLACEBO_COMPARATOR|Placebo|No anti-fibrotic treatment. Patients in placebo and treatment arm may be on corticosteroid treatment
62247735|NCT04607928|EXPERIMENTAL|Treatment|Pirfenidone
62247736|NCT06113484|EXPERIMENTAL|DIET + EXERCISE|This group engages in physical exercise plus a nutritional intervention. Monthly individual nutrition consultations are conducted. Additionally, this group also benefits from a group culinary workshop.
62247737|NCT06113484|OTHER|WITHOUT DIET + EXERCISE|This group engages in physical exercise; however, it is not the target of the nutritional intervention. Only a group educational session is conducted.
62247738|NCT06113484|NO_INTERVENTION|WITHOUT DIET + WHITOUT EXERCISE (CONTROL)|This group does not engage in physical exercise, nor is it the target of the nutritional intervention. Only a group educational session is conducted.
62247739|NCT01161056||Healthy Control Group|
62247740|NCT05394220||Parapneumonic effusion|Patients with parapneumonic effusion
62247741|NCT05394220||Non-parapneumonic effusion|Patients with pleural effusion but not parapneumonic in nature
62247742|NCT01753583|EXPERIMENTAL|10 patients with corneal abrasions|
62437894|NCT02393534|EXPERIMENTAL|Telephone visit|Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
62437895|NCT06226454|EXPERIMENTAL|Part A: Single Ascending Dose (SAD)|Participants will be randomized to receive a single dose of different dose levels of VX-993.
62827334|NCT03056222|ACTIVE_COMPARATOR|Contact Force Sensing Irrigated RF ablation|Participants will be treated with a contact force sensing irrigated radiofrequency ablation catheter
62827335|NCT02596867|EXPERIMENTAL|open label single arm, drug propanolol|all subjects will receive the experimental drug
62827336|NCT03877510|EXPERIMENTAL|Open Label IPX203|All participants received oral administration of extended-release capsules IPX203 dosing regimen that was determined at the end of the IPX203 dose conversion period of Study IPX203-B16-02 (NCT03670953) for nine months of open-label therapy. The dose and dosing frequency was determined by the investigator to achieve the optimal balance of efficacy and safety.
62827337|NCT00411684|EXPERIMENTAL|CDB-2914|A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of CBD-2914 as Emergency Contraception When Taken Between 48 Hours and 120 Hours of Unprotected Intercourse
62827338|NCT00566670||Observation (all participants)|Stage 5 Chronic Kidney Disease and hemodialysis patients
62827339|NCT00928408||Cinacalcet|
62045328|NCT01691833|NO_INTERVENTION|Normovitaminosis|Patients with normovitaminosis( levels greater than or equal to 30ng/ml) will receive no intervention.
62247743|NCT01753583|EXPERIMENTAL|10 patients with corneal infiltrates|
62247744|NCT01448239|EXPERIMENTAL|alirocumab SAR236553 (REGN727) - Dose A|A single subcutaneous injection of Dose A
62247745|NCT01448239|EXPERIMENTAL|alirocumab SAR236553 (REGN727) - Dose B|A single subcutaneous injection of Dose B
62247746|NCT03459118|EXPERIMENTAL|Function Focused Care|FFC-AL-EIT is implemented by a Research Nurse Facilitator working with the champion and stakeholders using our four step approach: (I) Environment and Policy Assessments; (II) Education; (III) Establishing Resident Function Focused Care Service Plans; and (IV) Mentoring and Motivating.
62247747|NCT03459118|PLACEBO_COMPARATOR|Education Only|Education only sites are exposed to Step II of the Four step approach described under the treatment arm. They receive baseline education of staff.
62247748|NCT05834309|NO_INTERVENTION|Control group|Patients in this group will receive clinical usual care.
62247749|NCT05834309|EXPERIMENTAL|Exercise training group|An individualized multicomponent exercise program including resistance, aerobic, balance and flexibility exercises.The duration of the sessions will be 45 minutes, and the duration of the whole program will be 6 weeks, equivalent to 12 sessions.
62247750|NCT03858036|ACTIVE_COMPARATOR|Epi-OFF CXL|The Epi-ON treatment will be performed without removal of the corneal epithelium. Ricrolin+will be used as the riboflavin formulation for the pre-treatment and irradiation steps of the Epi-ON treatments. The VEGA UV-A light will be used during the irradiation steps of the Epi-ON treatment.
62247751|NCT03858036|ACTIVE_COMPARATOR|Epi-ON CXL|The Epi-OFF treatment will be performed with removal of the corneal epithelium before the first dose of riboflavin is administered. Ricrolin+ will be used as the riboflavin formulation for the pre-treatment and irradiation steps of the Epi-OFF treatments. The VEGA UV-A light will be used during the irradiation steps of the Epi-OFF treatment.
62247752|NCT03887845||Open gastrointestinal surgery|All patients enrolled in this group would undergo open gastric and colorectal resection surgery.
62437896|NCT06226454|PLACEBO_COMPARATOR|Part A: Placebo|Participants will be randomized to receive placebo matched to VX-993.
62437897|NCT06226454|EXPERIMENTAL|Part B: Multiple Ascending Dose (MAD)|Participants will be randomized to receive multiple doses of different dose levels of VX-993. The dose levels will be determined based on the data from Part A.
62437898|NCT06226454|PLACEBO_COMPARATOR|Part B: Placebo|Participants will be randomized to receive placebo matched to VX-993.
62437899|NCT01357356|EXPERIMENTAL|SER120 (750 ng/day)|SER120 (750 ng/day)
62437900|NCT01357356|EXPERIMENTAL|SER120 (1000 ng/day)|SER120 (1000 ng/day)
62437901|NCT01357356|EXPERIMENTAL|SER120 (1500 ng/day)|SER120 (1500 ng/day)
62045329|NCT01803048||TBI|30 individuals who will be tested at two weeks post-TBI; 30 individuals who will be tested at one month post-TBI; 30 individuals who will be tested at three months post-TBI; 30 individuals who will be tested at six months post-TBI; 30 individuals who will be tested at 12 months post-TBI.
62045330|NCT01803048||Healthy Control|30 healthy individuals with no history of TBI
62045331|NCT02219126|EXPERIMENTAL|Homogenized and pasteurized milk|Milk that has undergone homogenization ans pasteurization treatment
62827340|NCT05997290|EXPERIMENTAL|SSA: Group 1|Participants 12 years of age and older, COVID-19 vaccine-experienced will receive 30 µg of BNT162b2 (Omi XBB.1.5) at Visit 1.
62247753|NCT03887845||Laparoscopic gastrointestinal surgery|All patients enrolled in this group would undergo laparoscopic gastric and colorectal resection surgery.
62827341|NCT05997290|EXPERIMENTAL|SSB: Group 2|Participants 12 years of age and older who were previously exposed to SARS-CoV-2 and are COVID-19 vaccine-naïve will receive 30 μg of BNT162b2 (Omi XBB.1.5) at Visit 1
62827342|NCT05997290|EXPERIMENTAL|SSC: Group 3|Cohort 1 - Participants 18 years of age and older will receive 30 µg of BNT162b2 (Omi JN.1) at Visit 1.
62827343|NCT05997290|EXPERIMENTAL|SSC: Group 4|Cohort 2 - Participants 12 years of age and older will receive 30 µg of BNT162b2 (Omi JN.1) at Visit 1.
62827344|NCT05997290|EXPERIMENTAL|SSC - Group 5|Cohort 3 - Participants 18 years of age and older who will receive 30 µg of BNT162b2 (Omi KP.2) at Visit 1.
62827345|NCT06594419|EXPERIMENTAL|Healthy Mother Healthy Baby Toolkit|297 women will be enrolled in this arm.
62045332|NCT02219126|EXPERIMENTAL|Nonhomogenized and nonpasteurized milk|Unhomogenized and unpasteurized milk (raw milk)
62045333|NCT04508439|EXPERIMENTAL|Prophylactic enexaparin|Enoxaparin dose of 1mg / kg / dose twice daily
62045334|NCT04508439|ACTIVE_COMPARATOR|Therapeutic Enoxaparin|Enoxaparin dose of 1mg / kg / dose daily
62247754|NCT01802489|ACTIVE_COMPARATOR|Amiloride|Amiloride capsules 10mg once per day for 5 months
62437902|NCT01357356|PLACEBO_COMPARATOR|Placebo|Placebo
62437903|NCT02619994|ACTIVE_COMPARATOR|Control Arm|"Regimen is the locally-used WHO-approved MDR-TB regimen in Korea based on 2014 Korean guideline of TB management.~* Intensive phase regimen consists of four effective second-line anti-TB drugs (including injectables) and pyrazinamide.~* Treatment duration: for at least 20 months"
62827346|NCT06594419|ACTIVE_COMPARATOR|Standard of Care|297 women will be enrolled in this arm.
62827347|NCT01948206||Prolonged paced QRS group|Patients with implantable cardioverter-defibrillators with Prolonged Paced(\>=150ms) QRS duration
62827348|NCT01948206||Narrow paced QRS group|Patients with Implantable Cardioverter-Defibrillators with Narrow Paced(\<150ms) QRS duration
62827349|NCT01972217|ACTIVE_COMPARATOR|Olaparib|200 mg or 300 mg bid
62827350|NCT01972217|PLACEBO_COMPARATOR|Placebo|placebo to match olaparib bid
62827351|NCT05134584|EXPERIMENTAL|linaclotide|Patients in linaclotide group were given with oral, once daily 290 μg linaclotide for consecutively 4 weeks, along with once daily 20 mg omeprazole, three times daily 50 mg Itopride, for the first ten days of the treatment.
62045335|NCT02279043|EXPERIMENTAL|Intervention|IUC users and non-IUC user participants randomized to the intervention arm will take part in small intervention groups in an online community called Birth Control Connect for twelve days. There will be up to 35 intervention groups with 9 members each. Non-IUC users in these groups will receive the intervention of Interaction with users of IUC and non-IUC users in the context of the online community. About 50% of participants in intervention groups will be current IUC users, and 50% will not be current IUC users. We will measure the attitudes and behaviors of those who do not have IUC before and after the intervention, considering social exposure to IUC users as a possible predictor of changes in knowledge, attitude and behavior.
62045336|NCT02279043|PLACEBO_COMPARATOR|Control|Participants randomized to the control arm will take part in Birth Control Connect control groups identical to those in the intervention arm, except no participants in the control arm will be current IUC users. Therefore, participants in the control arm will have interaction with non-IUC users only. We will measure these participants' attitudes and behavior related to IUC use before and after the twelve-day study period, and compare results to those of participants in the intervention arm. There will be up to 35 control groups of 9 members each.
62247755|NCT01802489|PLACEBO_COMPARATOR|Placebo|Placebo capsules one per day for 5 months
62247756|NCT03778853|EXPERIMENTAL|Anlotinib Hydrochloride|Anlotinib Hydrochloride p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
62247757|NCT06476236|EXPERIMENTAL|M4C Treatment|Single arm study with nutraceutical M4C treatment. Proprietary blend of amino acids, fatty acids, vitamins, and minerals. 1 tbsp in 12 oz of water with two algae oil capsules taken by mouth one to two times daily.
62827352|NCT05134584|ACTIVE_COMPARATOR|lactulose|Patients in Lactulose group were given with oral, once daily 20 mL Lactulose for 4 weeks, along with once daily 20 mg omeprazole, three times daily 50 mg Itopride, for the first ten days of the treatment.
62827353|NCT06595511|ACTIVE_COMPARATOR|Alzheimer's Disease Treatment Group|The group will engage with the 40 Hz sensory entrainment-integrated cognitive game kit for one hour a day, five days a week, for three months.
62827354|NCT06595511|NO_INTERVENTION|Alzheimer's Disease Control Group|
62827355|NCT06595511|NO_INTERVENTION|Healthy Older Adult Group|
62827356|NCT01245530|ACTIVE_COMPARATOR|Aricept|Intervention: Drug: Aricept
62247758|NCT05377190|EXPERIMENTAL|For patients followed in a heart failure clinic (HFC), intervention HFC-IN|Use of the full Continuum solution: remote patient monitoring and digital therapeutics over a period of 12 weeks
62247759|NCT05377190|PLACEBO_COMPARATOR|For patients followed in a HFC, control HFC-IN|Standard of care for the follow-up, no use of remote monitoring or digital therapeutics for the first 12 weeks. After 12 weeks, option is given to the patient to use the full Continuum solution for another period of 12 weeks.
62604675|NCT03398863|ACTIVE_COMPARATOR|Cleaning of uterine cavity|Cleaning of uterine cavity: participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
62247760|NCT05377190|EXPERIMENTAL|For patients not followed in a HFC, intervention HFC-OUT|Use of part of the Continuum solution: the patient will use a mobile application to enter her/his data but no remote monitoring is performed. Digital therapeutics are used for the healthcare professionals.
62045337|NCT02279043|NO_INTERVENTION|IUC users|IUC users will be recruited to populate intervention groups. Interaction with IUC users will be the intervention for non-IUC users randomized to the intervention arm. IUC users will receive no intervention.
62437904|NCT02619994|EXPERIMENTAL|Experimental Arm|"Regimen consists of only oral medication using delamanid, linezolid, levofloxacin, and pyrazinamide, for nine or twelve months depending on the time of sputum culture conversion to negative.~* Delamanid (100 mg bid for the entire treatment period)~* Linezolid (600mg/day for 2 months and 300mg/day afterwards until the end of treatment)~* Levofloxacin (750 \~1000 mg/day)~* Pyrazinamide (1000\~ 2000 mg/day)"
62604676|NCT03398863|NO_INTERVENTION|Not cleaning of uterine cavity|These participants will have their uterine cavities left alone after complete delivery of the placenta. The placenta will be inspected after delivery to make sure it is complete, including the membranes.
62604677|NCT04237129|EXPERIMENTAL|Gan & Lee Insulin Aspart|100 units/mL, 3 ml prefilled pen
62604678|NCT04237129|ACTIVE_COMPARATOR|NovoRapid® Insulin Aspart|"Product approved and marketed in the EU~FlexPen100 units/mL prefilled pen"
62604679|NCT04237129|ACTIVE_COMPARATOR|NovoLog® Insulin Aspart|"Product approved and marketed in the US~FlexPen100 units/mL prefilled pen"
62604680|NCT02848989|EXPERIMENTAL|Qigong Mind-Body Exercise (QMBE)|"After the screening procedures confirm that you are eligible to participate in the research study:~* Breast cancer survivors with persistent post-surgical pain (PPSP) into a 12-week program of Qigong mind-body exercise (QMBE).~* Outcome assessments related to pain, function, and quality of life"
62247761|NCT05377190|PLACEBO_COMPARATOR|For patients not followed in a HFC, control HFC-OUT|Standard of care for the follow-up, no use of a mobile application or digital therapeutics for the first 12 weeks. After 12 weeks, option is given to the patient to use the mobile app and digital therapeutics are activated for another period of 12 weeks.
62247762|NCT03768505|EXPERIMENTAL|Zandelisib (ME-401) open label|Subjects with relapsed/refractory FL or MZL will be administered 60 mg of ME-401 orally, once a day on an intermittent schedule (IS).
62437905|NCT04605952||SARS-CoV-2 IgG antibody positive between 28th June to 15th July 2020|As a serosurveillance measure, 3296 asymptomatic employees of an industrial workforce Jamshedpur (India) were tested for SARS-CoV-2 IgG antibodies specific for the spike subunit antigen by the ErbaLisa COVID-19, Erba Corporate Services (United Kingdom) between 28th June and 15th July 2020. All those who initially tested SARS-CoV-2 IgG antibody positive were retested at 45-65 days
62604681|NCT02833935|EXPERIMENTAL|Physical Activity Intervention Group|Participants will complete a baseline questionnaire (week 1) about their demographic information, self-determination theory variables, their current physical activity, and other psychological indicators. They will complete the same questionnaire at two additional time points. First, about halfway through the intervention (week 6), and then at the end (week 10). Participants in the physical activity intervention group will also receive 8 1-hour physical activity sessions over 2 months (1/week) with a trained physical activity counselor through a video-based internet platform.
62604682|NCT02833935|NO_INTERVENTION|Control Group|Control Group: For participants assigned to the control group, they will be asked to continue with their regular routine for the next two months. Otherwise, the participants in this group will be asked to complete the follow-up baseline questionnaires at 6 and 10 weeks post-baseline. They will be contacted by a physical activity counsellor at the end of the 10-week period.
62247763|NCT05744336|EXPERIMENTAL|Group 1 Immersive Virtual Reality (VR)|Participants in Group 1 Immersive Virtual Reality (VR) will wear the device covering their eyes. The viewing experience will include calming nature sounds for between 15-20 minutes before their planned plain clinic procedure.
62247764|NCT05744336|PLACEBO_COMPARATOR|Group 2 control group|Group 2 control group has no preprocedural intervention. Standard clinic waiting conditions for 15-20 minutes before their planned pain clinic procedure.
62247765|NCT05594316|OTHER|single group|Trichloroacetic acid
62604683|NCT05046431|ACTIVE_COMPARATOR|EU Simponi|
62827357|NCT01245530|EXPERIMENTAL|INM-176|Intervention: Drug: INM-176
62827358|NCT02302599|EXPERIMENTAL|Umbilical cord mesenchymal stem cells|Patients receive Umbilical cord mesenchymal stem cells intravenous infusion for three times with an interval of 4 weeks in the absence of disease progression or unacceptable toxicity
62045338|NCT05721131||Temperature measurement|Each subject will have their temperature measured by both the NC° Thermometer (Gen 3) and the reference clinical thermometer.
62045339|NCT05759416|ACTIVE_COMPARATOR|Gp I(Melatonin gp)|Group I: included 20 chronic periodontitis patients, treated by conventional periodontal therapy SRP combined with intra- pocket application of Melatonin gel once weekly for 1 month begin application at the second week after initial therapy.
62604684|NCT05046431|EXPERIMENTAL|BAT2506|
62604685|NCT04169438|PLACEBO_COMPARATOR|Vehicle Cream Base Emulsion Moisturizer + Petrolatum|Vehicle Cream Base Emulsion Moisturizer + Petrolatum
62604686|NCT04169438|EXPERIMENTAL|FS2 Emulsion Moisturizer + Petrolatum|FS2 Emulsion Moisturizer + Petrolatum
62604687|NCT01428687|ACTIVE_COMPARATOR|Increase Sleep Gradually|Subjects in this condition are taught to increase their sleep by 30 minutes per night during week 1 of the intervention; 60 minutes during week 2; and 90 minutes during week 3. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
62604688|NCT01428687|ACTIVE_COMPARATOR|Increase Sleep Immediately|Subjects in this condition are taught to increase their sleep by 90 minutes per night starting in week 1. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
62045340|NCT05759416|PLACEBO_COMPARATOR|Gp II(placebo gp)|Group II: included 20 chronic periodontitis patients, treated by SRP combined with the injection of placebo, weekly for one month
62045341|NCT04777045|EXPERIMENTAL|Diltiazem|When signs of vascular dysfunction with the coronary function test.
62045342|NCT04777045|PLACEBO_COMPARATOR|Placebo|When signs of vascular dysfunction with the coronary function test.
62045343|NCT05461781|EXPERIMENTAL|distal radial artery|Distal radial aretry for primary percutaneous coronary intervention in STEMI patients
62247766|NCT01115842|EXPERIMENTAL|Vitamin D|The patients will be given Vitamin D - 4000IU per day for 5 days (Day 1 through 5)
62045344|NCT05461781|ACTIVE_COMPARATOR|proximal radial artery|Proximal radial aretry for primary percutaneous coronary intervention in STEMI patients
62045345|NCT01381796|ACTIVE_COMPARATOR|Treatment A - NP101|
62045346|NCT01381796|ACTIVE_COMPARATOR|Treatment C - oral sumatriptan succinate|
62045347|NCT01381796|EXPERIMENTAL|Treatment B - NP101B|
62247767|NCT01115842|NO_INTERVENTION|control|
62247768|NCT06224309||18F-BL40 PET/CT scan|Each subject will have two PET/CT scans, one using 18F-BL40 and the other using 18F-FDG. The 18F-BL40 radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 18F-FDG is considered standard care and has been approved by Health Canada.
62247769|NCT03327441|EXPERIMENTAL|Almonds|
62247770|NCT03327441|ACTIVE_COMPARATOR|Omelette|
62247771|NCT03480412||Follicular Phase|
62247772|NCT03480412||Luteal Phase|
62247773|NCT05144074||Non-filtered platelet concentrates (NF-PC group).|In NF-PC group, 90 whole blood units were collected with Tripple blood bags, Six NF-PCs were pooled together and stored in a horizonal shaker at 20 ± 2C for 5 days .
62247774|NCT05144074||leukocyte-depleted platelet concentrates (LD-PC group).|In LD-PC group, another 90 whole blood units were collected using Whole Blood Filter Saving Platelets (WB-SP) bags with an integrated leukoreduction filter
62604689|NCT01428687|ACTIVE_COMPARATOR|No Intervention: Control Group|This group is told to make no changes in their sleep habits. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
62604690|NCT02370667|EXPERIMENTAL|Biomechanical Exercise (BE)|The participants in this arm will be asked to attend 3 group classes per week for 12 weeks at a local yoga studio taught by a certified yoga instructor. Four class times will be offered per week. These classes will include a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes will include clinical mobility; muscle and fat volumes, and cartilage morphology using MRI; pain; isometric leg strength; cardiovascular fitness; and gait analysis.
62827359|NCT02302599|EXPERIMENTAL|Controlled suspension liquid|Patients receive Controlled suspension liquid
62045348|NCT01381796|EXPERIMENTAL|Treatment D - NP101D|
62045349|NCT02173548|ACTIVE_COMPARATOR|Anakinra|Anakinra 100 mg given subcutaneously once daily for 12 weeks
62045350|NCT02173548|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62045351|NCT01673906|EXPERIMENTAL|Diagnostic work up|The patients enrolled in the study (see below), with a consistent clinical suspicion of a primary duodenal-pancreatic NET.
62045352|NCT02248298|EXPERIMENTAL|2h-AFL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
62045353|NCT02248298|ACTIVE_COMPARATOR|3hr-AFL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
62045354|NCT02248298|ACTIVE_COMPARATOR|3hr-MAL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
62045355|NCT05988996||African American and Black|One cohort includes families that identify as Black, African American, or African attending the racially concordant peer group sessions.
62045356|NCT05988996||Latino English Preferred|One cohort includes families that identify as Latino, Hispanic, Chicano and language preference of English attending the ethnically concordant peer group sessions.
62247775|NCT02053909|ACTIVE_COMPARATOR|Aspirin|One aspirin 81 mg capsule 2 times per day
62247776|NCT02053909|ACTIVE_COMPARATOR|Ticagrelor|One ticagrelor 90 mg capsule 2 times per day
62247777|NCT03792386|ACTIVE_COMPARATOR|Ultrasound guidance with fluoroscopic confirmation|Patients in which the intervention will be performed using ultrasound guidance with fluoroscopic confirmation
62247778|NCT03792386|ACTIVE_COMPARATOR|Fluoroscopic guidance with ultrasonographic confirmation.|Patients in which intervention will be performed using fluoroscopic guidance with ultrasonographic confirmation.
62827360|NCT03625349||PLM participants|Participants who undergo passive leg movement, with and without LNMMA.
62604691|NCT02370667|ACTIVE_COMPARATOR|Traditional Exercise (TE)|The participants in this arm will be prescribed an aerobic and strengthening exercise program often prescribed to those with knee OA. The program will include 15 minutes of walking per class, closed kinetic chain strengthening exercises on machines, and a cool down consisting of stretching. Participants will be asked to come to class 3 times per week for 12 weeks. Certified Kinesiologists as well as student volunteers will be available during all class times for program completion and progression.
62045357|NCT05988996||Latino Spanish preferred|One cohort includes families that identify as Latino, Hispanic, Chicano and language preference of Spanish attending the ethnically and linguistically concordant peer group sessions.
62604692|NCT02370667|OTHER|Meditation Control (M)|The participants in this arm will be asked to attend 3 meditation classes per week for 12 weeks taught by a certified yoga instructor with a specialization in meditation. This will take place at an alternate yoga studio to avoid contamination. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the control group will be offered a free exercise pass following completion of the study.
62604693|NCT01279564|EXPERIMENTAL|ETview|ETview TVT endotracheal tube
62604694|NCT01279564|SHAM_COMPARATOR|Control|Endotracheal tube
62437906|NCT02613065|EXPERIMENTAL|Eggwhite protein shake|Participants drink a NOW Foods protein shake (\~20% daily energy requirements) at the beginning of each of the three daily meals. Kcals/meal are dependent upon participant's baseline Resting Metabolic Rate value.
62437907|NCT02613065|ACTIVE_COMPARATOR|Maltodextrin carbohydrate shake|Participants drink a NOW Foods carbohydrate shake (\~20% daily energy requirements) at the beginning of each of the three daily meals. Kcals/meal are dependent upon participant's baseline Resting Metabolic Rate value.
62437908|NCT06016933|PLACEBO_COMPARATOR|oral hygiene instructions and SRP of all teeth plus placebo gel.|
62437909|NCT06016933|ACTIVE_COMPARATOR|oral hygiene instructions and SRP of all teeth, followed by insertion of the spirulina gel.|
62604695|NCT02519634|OTHER|Group 1|Patients in Group 1 undergo Super-Mini Percutaneous Nephrolithotomy
62604696|NCT02519634|OTHER|Group 2|Patients in Group 2 undergo Retrograde Intrarenal Surgery
62045358|NCT01319266|EXPERIMENTAL|Normal Renal Function|Subjects with normal renal function
62045359|NCT01319266|EXPERIMENTAL|Mild Renal Impairment|Subjects with mild renal impairment (defined by an estimated creatinine clearance of \> 50 and up to 80 mL/min)
62045360|NCT01319266|EXPERIMENTAL|Moderate Renal Impairment|Subjects with moderate renal impairment (defined by an estimated creatinine clearance of 30-50 mL/min)
62045361|NCT01319266|EXPERIMENTAL|Severe Renal Impairment|Subjects with severe renal impairment (defined by an estimated creatinine clearance of less than 30 mL/min)
62045362|NCT01319266|EXPERIMENTAL|End Stage Renal Disease (ESRD)|Subjects with ESRD (defined as being on hemodialysis for at least 6 months prior to enrollment and be receiving standard in-center dialysis treatments three times a week)
62437910|NCT05774106|EXPERIMENTAL|Participatory Action Research (PAR).|"Two circular spirals following Kemmis \& Mctaggart PAR principles. Each spiral includes the following stages: planning, action, observation and reflection.~Four discussions groups and two reflective diaries will be carried out in total.~Note: the PAR process will be conducted only with case managers."
62437911|NCT05774106|NO_INTERVENTION|Regular Practice|The other group will continue working as usual in their daily practice.
62437912|NCT05907395|EXPERIMENTAL|PF-07293893 and Placebo (Cohort 1)|Single dose administration of PF-07293893 and placebo; Within a cohort, participants will receive up to 4 doses of PF-07293893 and up to 2 doses of placebo.
62437913|NCT05907395|EXPERIMENTAL|PF-07293893 and Placebo (Cohort 2)|Single dose administration of PF-07293893 and placebo; Within a cohort, participants will receive up to 4 doses of PF-07293893 and up to 2 doses of placebo.
62437914|NCT05907395|EXPERIMENTAL|PF-07293893 and Placebo (Cohort 3)|Single dose administration of PF-07293893 and placebo; Within a cohort, participants will receive up to 4 doses of PF-07293893 and up to 2 doses of placebo.
62604697|NCT02353884||MCIp,MCIs|progressive MCI：those convert to AD in two years, stable MCI
62604698|NCT02353884||MCI，HC|mild cognitive impairment, healthy control
62604699|NCT01844206|ACTIVE_COMPARATOR|Epidural Morphine|Group receiving 3mg epidural morphine, 24 hours after the initial dose
62604700|NCT01844206|PLACEBO_COMPARATOR|Epidural Saline|Group receiving epidural saline 6ml, 24 hours after receiving epidural morphine 3mg.
62604701|NCT00854919|EXPERIMENTAL|CBT|All subjects received cognitive-behavioral therapy (CBT) during the study period.
62604702|NCT00854919|EXPERIMENTAL|1|Drug; Paroxetine (30-50mg/D)or Fluvoxamine (150-250mg/D), 1-year administration
62604703|NCT00854919|ACTIVE_COMPARATOR|2|Either risperidone (1-5mg/D), olanzapine (1-5mg/D) or quetiapine (25-100mg/D) was added to ongoing SSRI, the combination trial was continued at least for half a year.
62604704|NCT02237924|EXPERIMENTAL|endostar + IMRT|
62604705|NCT02237924|ACTIVE_COMPARATOR|DDP + IMRT|
62604706|NCT02186847|ACTIVE_COMPARATOR|Chemoradiation|60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
62604707|NCT02186847|EXPERIMENTAL|Metformin + Chemoradiation|Metformin plus 60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
62623442|NCT06045611|EXPERIMENTAL|Isolated Pea Protein/Isolated Whey Protein/Isolated Faba Bean Protein/Placebo|"* Study day 1: 0.6g isolated pea protein/kg/body weight + 400 ml water~* Study day 2: 0.6g isolated whey protein/kg/body weight + 400 ml water~* Study day 3: 0.6g isolated faba bean protein/kg/body weight + 400 ml water~* Study day 4: 400 ml water~The fat and energy content of the drinks will be adapted using a plant based oil"
62045363|NCT03577587|EXPERIMENTAL|Verum|Silitidil for 21 days
62045364|NCT03577587|PLACEBO_COMPARATOR|Placebo|Placebo for 21 days
62045365|NCT03577587|NO_INTERVENTION|Reference group|Non-randomized healthy volunteering mothers after term birth receiving no intervention
62045366|NCT02813070|EXPERIMENTAL|Healthy volunteers|185 MBq \[18F\] Flutemetamol
62045367|NCT02813070|EXPERIMENTAL|Mild cognitive impairment|185 MBq \[18F\] Flutemetamol
62045368|NCT02813070|EXPERIMENTAL|Alzheimer's Disease|185 MBq \[18F\] Flutemetamol
62045369|NCT05667220|ACTIVE_COMPARATOR|Sitagliptin monotherapy group (Group A)|
62045370|NCT05667220|EXPERIMENTAL|Sitagliptin combined with Beidougen capsule treatment group (Group B)|
62827361|NCT04788316|EXPERIMENTAL|Intervention|A computerized brief intervention (CBI) followed by six months of personalized text messaging
62247779|NCT03519685|EXPERIMENTAL|Contraceptive Training and Education|Colleges assigned to this arm receive a one-day UCSF Continuing Medical Education (CME # MMC18087) accredited training on contraceptives and technical assistance. The training is for staff at the student health center and local health centers where they refer for contraceptive services. Students attending colleges assigned to this arm receive education about contraceptive methods and how to access services.
62247780|NCT03519685|PLACEBO_COMPARATOR|Nutrition Education|Students attending colleges assigned to this arm receive nutrition education about the impacts of sugar on health.
62247781|NCT04665336|EXPERIMENTAL|Intervention Group Lifestyle counseling|"Obese individuals with evening chronotype will be trained on sleep hygiene in order to create behavioral changes in line with circadian rhythms and an intervention program called Circadian Timing Program which was created by the researcher in line with the relevant literature will be implemented for 12 weeks. This program includes sleep hygiene recommendations and regulation of daylight exposure, sleep, meal, caffeine intake and exercise times. To determine participants' sleep times they will be asked to keep a sleep diary and sleep records will be taken with the smart bracelet. Participants will be given a password to access the research website. The website of the study will be used for the training, control, motivation and communication of the Participants."
62247782|NCT04665336|NO_INTERVENTION|Control group|Participants will be asked to follow their normal daily lifestyle, maintain normal sleep and eating habits and no further instructions or suggestions will be provided during the study.
62247783|NCT02678143|EXPERIMENTAL|Recipients|"* The recipient of one antigen mismatch unrelated HSCT will begin the preparative regimen on Day -7. Alemtuzumab on Days -7, -6, -5, -4, and -3, cyclophosphamide on Days -4 and -3, and 300 cGy of total body irradiation (TBI) on Day -2.~* The recipient of haplo-SCT will begin the preparative regimen on Day -7. Alemtuzumab on Days -7, -6, -5, -4, and -3, fludarabine on Days -7, -6, -5, -4, and -3, cyclophosphamide on Days -4 and -3, and 400 cGy of TBI on Day -2.~* For both types of HSCT, the frozen peripheral blood stem cells will be thawed and infused on Day 0 per institutional guidelines. GVHD prophylaxis will consist of cyclophosphamide on Days +3 and + 4, mycophenolate mofetil (MMF) three times a day on Days +5 through +35 then tapered off over 1 week provided there is no evidence of GVHD, and sirolimus starting on Day +5 and continuing for one year. Sirolimus can be tapered at one year only if donor T-cell chimerism reaches more than 50% in the absence of GVHD."
62247784|NCT00918853|EXPERIMENTAL|resection for adenocarcinoma|quality standard resection for adenocarcinoma of the head of the pancreas
62247785|NCT02607449|EXPERIMENTAL|A|Standard TB treatment+ treatment regiment with FS-1 drug. Study drug was given to the patients orally once per day in dose of 2.5 mg/kg along with other prescribed TB drugs.
62437915|NCT00003966|EXPERIMENTAL|Arm A Lower dose|"This is a randomized, multicenter study. All patients initially receive the same dose of defibrotide IV over 2 hours every 6 hours on day 1. On day 2, patients are randomized to 1 of 2 doses of defibrotide.~- Arm I: On days 2-14, patients receive a lower dose of defibrotide IV over 2 hours every 6 hours.~In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity"
62827362|NCT04788316|NO_INTERVENTION|Control|Treatment as usual
62827363|NCT00857012||All patients|treated with Anastrozole as per SPC
62827364|NCT02633163|EXPERIMENTAL|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal Stem Cells (MSCs) 1 x 10\^6 cells/kg in Plasma-Lyte A solution
62045371|NCT06458205|EXPERIMENTAL|Intervention arm|For all townships within the intervention arm, we have constructed a pay-for-population mechanism to incentivize all medical practitioners to care for population health within each township. For smokers, we will provide a multi-component intervention: (1) NicQuit, a CBT-based digital health intervention for those who use intelligent mobile phones; (2) community-based pulmonary function test; (3) health education and encouragement to seek medication in superior hospitals for those spirometry-defined COPD patients; (4) CBT-based health education to the abnormal BMI; (5) health education to smoking cessation; (6) Active recruitment of smokers with high blood pressure or high blood glucose measurement. Intensive follow-ups will be at month 3, 6, and 12.
62247786|NCT02607449|PLACEBO_COMPARATOR|B|Standard TB treatment + treatment regiment with a placebo. Instead of study drug the placebo was given to the patients orally once per day along with other prescribed TB drugs (in quntity equal to study drug).
62247787|NCT01150825||STEMI|Patients with ST segment elevation myocardial infarction, verified by elevated troponin levels
62247788|NCT01150825||NSTEMI|Patients with non-ST segment elevation myocardial infarction, verified by elevated levels of troponin
62247789|NCT02082899|ACTIVE_COMPARATOR|Active Comparator EBI-005 5 mg/mL|Administered 3 times per day
62247790|NCT02082899|PLACEBO_COMPARATOR|Placebo Comparator|Administered 3 times per day
62827365|NCT02633163|EXPERIMENTAL|High Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal Stem Cells MSCs 5 x 10\^6 cells/kg in Plasma-Lyte A solution
62827366|NCT02633163|PLACEBO_COMPARATOR|Plasma Lyte A Solution|Placebo Infusion (Plasma-Lyte A solution only)
62827367|NCT06382597||Nordic Hamstring Exercise|The subjects will be randomly divided into two research groups. The first research group will undergo a 4-week Nordic Hamstring Exercise training, the second research group will be a control group performing traditional exercises.
62247791|NCT00515957|EXPERIMENTAL|Patients|Patients with Nasopharyngeal Carcinoma in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV-genome or antigens have been demonstrated in tissue biopsies
62437916|NCT00003966|EXPERIMENTAL|Arm B Higher Dose|"This is a randomized, multicenter study. All patients initially receive the same dose of defibrotide IV over 2 hours every 6 hours on day 1. On day 2, patients are randomized to 1 of 2 doses of defibrotide.~- Arm II: On days 2-14, patients receive a higher dose of defibrotide IV over 2 hours every 6 hours.~In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity"
62437917|NCT03985501||newborn screening for sickle cell disease|Newborns with a targeted neonatal screening for sickle cell disease carried out at the University Hospital of Lyon
62827368|NCT06600789|EXPERIMENTAL|Module 1 Part A (Dose Escalation)|Experimental: Module 1 Part A (Dose Escalation) In Part A of Module 1, a minimum of 3 participants and maximum 6 evaluable participants with locally advanced or metastatic solid tumor malignancies will receive CT7439 capsules daily in ascending dose cohorts (maximum 6 cohorts) to identify the minimally biologically active dose (MBAD), maximum tolerated dose (MTD) and/or maximum feasible dose (MFD).
62827369|NCT01713816||Elderly control|Healthy elderly subjects age and gender matched to the AD cohort, predominantly male
62827370|NCT06601400|EXPERIMENTAL|Group A (Test)|Immediate implant placement with Xenograft mixed with Erythropoietin
62827371|NCT06601400|ACTIVE_COMPARATOR|Group B (Control)|Immediate implant placement with Xenograft alone
62827372|NCT05733286|ACTIVE_COMPARATOR|Suvorexant Arm|
62827373|NCT05733286|PLACEBO_COMPARATOR|Placebo Arm|
62437918|NCT02528578|EXPERIMENTAL|healthy volunteers|
62437919|NCT05446090||Asthma Attack patients.|Patients admitted with Asthma Attacks.
62437920|NCT03607006|EXPERIMENTAL|Patient specific PEEK sheets|Patient specific PEEK sheets will be fixed with titanium screws and act as containment system for the mixed autogenous/xenogenic bone graft that will fill the gap between the sheets and the ridge .
62827374|NCT06592118||FTC|Pediatric and Adolescent Patients with Follicular Thyroid Carcinoma
62827375|NCT06592118||PTC|Pediatric and Adolescent Patients with Papillary Thyroid Carcinoma
62827376|NCT04592939|OTHER|Group 1: immediate weight bearing|
62827377|NCT04592939|OTHER|Group 2: 6 week toe touch weight bearing|
62827378|NCT04411641|EXPERIMENTAL|SAR442168|Dose 1 of oral SAR442168 once daily
62827379|NCT04411641|PLACEBO_COMPARATOR|Placebo|Placebo tablet to match SAR442168 once daily
62827380|NCT00667199|EXPERIMENTAL|Radium-223 dichloride (Xofigo, BAY88-8223)-5kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (5kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
62437921|NCT03607006|ACTIVE_COMPARATOR|Autogenous bone shell technique|Bone shells will be fixed with titanium screws to the ridge and mixed autogenous/xenogenic bone graft will fill the gap between the shells and the ridge .
62827381|NCT00667199|EXPERIMENTAL|Radium-223 dichloride (Xofigo, BAY88-8223)-25 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (25kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
62827382|NCT00667199|EXPERIMENTAL|Radium-223 dichloride (Xofigo, BAY88-8223)-50 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (50kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
62604708|NCT06339216|EXPERIMENTAL|Adebrelimab+Apatinib+Paclitaxel for Injection(Albumin Bound)|Adebrelimab injection was started on Day 1 of each cycle, followed 30 minutes later by intravenous drip of Paclitaxel for Injection(Albumin Bound). Combined treatment for 6 to 8 weeks, after efficacy evaluation, the investigator decides the subsequent treatment regimen, or until disease progression, toxicity intolerance, initiation of new anti-tumor therapy, withdrawal of informed consent, or the investigator judges that the subject needs to withdraw from the study treatment. Following RECISTv1.1 defined progression (as assessed by the investigator), study drug may continue if the investigator assesses that the subject is still receiving clinical benefit and tolerates study treatment.
62604709|NCT03055468|EXPERIMENTAL|Peer Support|Participants in this group will receive peer support as well as antidepressant medications comprised of either Fluoxetine 20mg O.D or Imipramine 75mg nocte.
62604710|NCT03055468|ACTIVE_COMPARATOR|No Peer support|Participants will only receive antidepressant medications comprised of either Fluoxetine 20mg O.D or Imipramine 75mg nocte.
62437922|NCT02287337|EXPERIMENTAL|Manipulation|Patients will receive cervical manipulation on 2 visits and then a further 3 visits of therapeutic exercises
62604711|NCT01738841||Cohort Group|Children aged 12 months to 12 years will receive Priorix-Tetra as prescribed by the physician.
62827383|NCT00667199|EXPERIMENTAL|Radium-223 dichloride (Xofigo, BAY88-8223)-100 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (100kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
62437923|NCT02287337|OTHER|Exercise|Patients will receive 5 visits of therapeutic exercises
62437924|NCT03047382|ACTIVE_COMPARATOR|Worthing Hospital site|AKI Care bundle instituted at Worthing site
62604712|NCT03635905|EXPERIMENTAL|Gabapentin|Gabapentin (Neurontin)- 600 mg oral administered pre-operatively at the time of cervical preparation
62604713|NCT03635905|PLACEBO_COMPARATOR|Placebo|
62604714|NCT00438802|EXPERIMENTAL|alefacept|Determine both the maximum tolerated dose level as well as the optimal immunologic dose and toxicity.
62604715|NCT04507893||SARS-COV-2 PNEUMONIA CONFIRMED BY PCR ON NASOPHARYNGEAL SWAB|Hospitalized patients affected by COVID-19 interstitial pneumonia (with positive PCR on naso-pharyngeal swab)
62827384|NCT06595069||Inclisiran Cohort|Chinese adult patients who received at least one treatment with inclisiran.
62827385|NCT05313971|EXPERIMENTAL|Intervention|3-week recruitment period of portuguese medical students wanting to attend the 28-hour online course
62827386|NCT05313971|NO_INTERVENTION|Control|The control group was recruited in order to match the age, gender, academic year and teaching faculty variables with the intervention group and people with these characteristics were invited to participate.
62045372|NCT06458205|NO_INTERVENTION|Control Arm|We will notify smokers with high-risk COPD to seek further diagnoses in superior hospitals. We provide a face-to-face survey to smokers with high-risk COPD. No other specified interventions will be given, they will be always accessible to usual care within the study period.
62045373|NCT00838955|EXPERIMENTAL|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
62437925|NCT03047382|NO_INTERVENTION|Chichester Hospital site|Continues standard care
62437926|NCT06526897|EXPERIMENTAL|Arm A (CXR)|Patients undergo CXR every 3 months for years 1-2, and every 6 months years 3-5. Patients with a suspicious or new nodule undergo a CT and may undergo a biopsy on study.
62437927|NCT06526897|EXPERIMENTAL|Arm B (CT)|Patients undergo chest CT every 3 months for years 1-2, and every 6 months years 3-5. Patients with a suspicious or new nodule may undergo a biopsy on study.
62437928|NCT05148546|EXPERIMENTAL|A: Neoadjuvant nivolumab|Neoadjuvant 2 cycles of nivolumab 360mg every 3 weeks
62437929|NCT05148546|EXPERIMENTAL|B: Neoadjuvant nivolumab + ipilimumab|Neoadjuvant 2 cycles of nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks
62604716|NCT04507893||NEGATIVE SARS-COV-2 PNEUMONIA|Hospitalized patients affected by negative COVID-19 interstitial pneumonia (with negative PCR on naso-pharyngeal swab)
62604717|NCT00928941|EXPERIMENTAL|Arm 1|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units.
62247792|NCT00210184|EXPERIMENTAL|Irinotecan associated to fluorouracil and leucovorin|"On D1, as a single 90-minute intravenous infusion diluted in 250 ml of saline (sodium chloride a 9 ‰), or isotonic glucose, at a dose of 180 mg/m2. Dosage adjustments are provided in case of severe toxicity.~Then 5FU/ folinic acid: 400 mg/m2 of 5-FU as an IV bolus followed by a continuous 2400 mg/m2 infusion over 46 hours with 400 mg/m2 of folinic acid or 200 mg/m2 of l-folinic acid as a 2-hour infusion before 5-FU administration.~Doses of 5-FU are adjusted according to clinical tolerance. Resume on D15 for 6 months"
62604718|NCT00928941|ACTIVE_COMPARATOR|Arm 2|A computer game control condition will be implemented for 3-4 training exercises a week for 40 hours.
62604719|NCT05347875|NO_INTERVENTION|Control Group|Activities of Daily Living App
62604720|NCT05347875|EXPERIMENTAL|Experimental Group|ICanWALK© App
62604721|NCT06533852|EXPERIMENTAL|Fecal Microbiome Transplantation (FMT)|A first dose of 24 capsules of FMT at baseline and a second dose of 24 capsules of FMT at 3 months. Each dose (24 capsules) contains approximately 50g of stool.
62045374|NCT02073799||Photoselective vaporization of the prostate|Patients who underwent photoselective vaporization of the prostate for prostatic hyperplasia and in whom 12-months follow-up data were available
62045375|NCT02073799||Holmium laser enucleation of the prostate|Patients who underwent holmium laser enucleation of the prostate for prostatic hyperplasia and in whom 12-months follow-up data were available
62045376|NCT04893486|EXPERIMENTAL|Active|
62045377|NCT04893486|PLACEBO_COMPARATOR|Vehicle|
62045378|NCT06072378|EXPERIMENTAL|Value-manipulation|Participants with epilepsy will complete a behavioral task in which they use a laptop computer to do a decision-making and memory task.
62247793|NCT02807649|PLACEBO_COMPARATOR|Placebo|Placebo: Methyl cellulose and dextrose
62604722|NCT06533852|PLACEBO_COMPARATOR|FMT Placebo|A first dose of 24 capsules of FMT placebo at baseline and a second dose of 24 capsules of FMT placebo at 3 months. Each dose (24 capsules) contains in total 6 g of microcrystalline cellulose or equivalent.
62604723|NCT01264354|EXPERIMENTAL|1|Clevudine 30mg
62247794|NCT02807649|ACTIVE_COMPARATOR|Low dose|This blend contains Ginko at 120 mg/day and Cistanche at 300 mg/day
62247795|NCT02807649|ACTIVE_COMPARATOR|High dose|This blend contains Ginko at 180 mg/day and Cistanche at 450 mg/day
62604724|NCT01264354|EXPERIMENTAL|2|Clevudine 20mg+Adefovir dipivoxil 10mg
62604725|NCT01264354|EXPERIMENTAL|3|Clevudine 20mg
62045379|NCT04052204|EXPERIMENTAL|Combination A|Avelumab + Bempegaldesleukin (NKTR-214) for treatment of locally recurrent (not amendable for treatment with curative intent) or metastatic squamous cell carcinoma of the head and neck
62247796|NCT00591825|PLACEBO_COMPARATOR|Non-Phobic Control - Placebo|Participants without phobia will be given one placebo administration.
62247797|NCT00591825|ACTIVE_COMPARATOR|Non-Phobic Control - DCS|Participants without phobia will be given one D-cycloserine (DCS) administration of 100mg.
62247798|NCT00591825|PLACEBO_COMPARATOR|Spider-phobic Placebo|Participants with phobia will be given one placebo administration.
62604726|NCT05998434|EXPERIMENTAL|the digital therapy|The participants randomly assigned to the intervention group will receive home-based exercise training with human key-point detection.They will be instructed to complete a minimum of three sports training sessions per week at their preferred time and location.The exercise prescription will be formulated based on previous comprehensive studies, encompassing exercises targeting strength, balance, flexibility, and mobility.Human key point detection technology accurately estimates 25 key points of the human body in pictures or videos using visual detection.
62045380|NCT04052204|EXPERIMENTAL|Combination B|Avelumab + Bempegaldesleukin (NKTR-214) + Talazoparib for treatment of metastatic castration-resistant prostate cancer (mCRPC). Phase 2 will focus on enrolling participants with DDR defect positive mCRPC.
62045381|NCT04052204|EXPERIMENTAL|Combination C|Combination C: Avelumab + Bempegaldesleukin (NKTR-214) + Enzalutamide for Treatment of mCRPC
62045382|NCT06579521|EXPERIMENTAL|Alcohol|
62247799|NCT00591825|EXPERIMENTAL|Spider-phobic DCS|Participants with phobia will be given one D-cycloserine (DCS) administration of 100mg.
62604727|NCT05998434|ACTIVE_COMPARATOR|traditional exercise therapy|The participants randomly assigned to the control group will receive traditional face-to-face exercise instruction. An experienced therapist( 10 years of experience) will be arranged to provide the subjects with 20-30 minutes of exercise instruction three times a week for four weeks. The training sessions were scheduled to start at 4 p.m. on Monday, Wednesday, and Friday of each week. The exercise training content selected for the control group will be consistent with that of the intervention group.
62604728|NCT00936130||Lifestyle counseling|This group will be comprised of participants on a low calorie diet program.
62604729|NCT00936130||Weight Loss Surgery|This group will be comprised of participants having weight loss surgery: Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy.
62604730|NCT05112094|EXPERIMENTAL|peripheral magnetic stimulation|peripheral magnetic stimulation (50-80% output, 20-40Hz, pulse duration 3-5 seconds, for 15 minutes) + physical therapy (shoulder range of motion exercise and stretching 30-40 minutes per day)
62045383|NCT06579339|EXPERIMENTAL|Chewing gum with xylitol|Chewing gum with xylitol was chewed 3 times a day for 15 minutes. A new chewing gum was chewed by the researcher in each chewing period, chewing gum was stopped at the end of 15 minutes and each quadrant was listened for 15 seconds. The onset of bowel movement was evaluated and all information was recorded in the patient information form and follow-up form. Patients who were discharged without stool output were telephoned and their stool output was questioned. Gum chewing was performed at the 2nd hour, 4th hour and 6th hour postoperatively (due to the opening of the oral cavity at 6 hours) and the collection of patient data was continued by telephone until discharge and afterwards.
62247800|NCT00255762|EXPERIMENTAL|Treatment (carboplatin, paclitaxel, bevacizumab)|Patients receive carboplatin IV over 30 minutes on day 1, paclitaxel IV over 1 hour on days 1, 8, and 15, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62247801|NCT06036251||Prior oncology participants|Oncology patients at University of California, San Francisco who participated in the previous study which evaluated the additional stressors imposed by COVID-19 (i.e., social isolation, loneliness) and ongoing general and disease specific stress on the symptom burden of cancer patients and survivors.
62247802|NCT05452811||Open Burch Colposuspension|The retropubic space was entered through a laparotomy Pfannenstiel incision, and two permanent sutures were placed on each side lateral to the urethra, one set at the level of the mid urethra and the other set at the level of the bladder neck.
62247803|NCT05452811||Laparoscopic Burch Colposuspension|After a pneumo peritoneum was established entrance to the retropubic space began with a transverse incision of the anterior peritoneum using sharp dissection and electrocautery. The space was developed using blunt and sharp dissection to identify clearly the retropubic anatomy, including the pubic symphysis, bladder neck, and Cooper's ligaments. The bladder neck was identified and the paraurethral tissue was exposed. A no. 0 permanent suture then was introduced through the 10-mm port and was grasped with a laparoscopic needle driver. With the surgeon's hand in the vagina to elevate the paraurethral tissue, two figure-of-eight sutures incorporating full-thickness vagina excluding epithelium were placed on each side, one set lateral to the mid urethra and the other set lateral to the bladder neck. Each of these sutures then was passed through the ipsilateral Cooper's ligament and was secured with a series of extracorporeal knots using an endoscopic knot pusher.
62827387|NCT06655103|EXPERIMENTAL|Group shown educational movie with virtual reality glasses|Measurements will be performed in three stages. In the first measurement; electrodermal activity, pulse, respiration and oxygen (O2) saturation values together with fear and pain scales 30 minutes before IT chemotherapy treatment without any intervention, in the second measurement; Electrodermal activity, pulse, respiration and O2 saturation values together with fear and pain scales after the application of virtual reality goggles 15 minutes before IT chemotherapy, and in the third measurement, electrodermal activity, pulse, respiration and O2 saturation values together with fear and pain scales will be evaluated within 30-60 minutes after IT chemotherapy treatment (when the sedation effect is over).
62045384|NCT06579339|PLACEBO_COMPARATOR|Chewing gum with non-xylitol|Chewing gum with non-xylitol was chewed 3 times a day for 15 minutes. A new chewing gum was chewed by the researcher in each chewing period, chewing gum was stopped at the end of 15 minutes and each quadrant was listened for 15 seconds. The onset of bowel movement was evaluated and all information was recorded in the patient information form and follow-up form. Patients who were discharged without stool output were telephoned and their stool output was questioned. Gum chewing was performed at the 2nd hour, 4th hour and 6th hour postoperatively (due to the opening of the oral cavity at 6 hours) and the collection of patient data was continued by telephone until discharge and afterwards.
62247804|NCT00105144|EXPERIMENTAL|1|lower dose
62247805|NCT00105144|EXPERIMENTAL|2|higher dose
62045385|NCT06579339|NO_INTERVENTION|Control group|to standardize the control group patients, all the procedures applied in the intervention group were applied, only the gum was not chewed.
62045386|NCT02605005||GA|general anesthesia
62045387|NCT02605005||ISB|interscalene block
62247806|NCT00105144|ACTIVE_COMPARATOR|3|
62604731|NCT05112094|PLACEBO_COMPARATOR|physical therapy only|regular physical therapy (shoulder range of motion exercise and stretching 30-40 minutes per day)
62045388|NCT00910442|EXPERIMENTAL|Patient Group|Dietary supplement:N-acetylcysteine 1g/day and Glutamine 20g/day for 7 consecutive days. The dietary supplements were intermediated by 7 days of washout with usual diet.
62045389|NCT00910442|ACTIVE_COMPARATOR|Control Group|Healthy HIV negative subjects submitted to the same dietary supplement than experimental group: N-acetylcysteine 1g/day and Glutamine 20g/day for 7 consecutive days. The dietary supplements were intermediated by 7 days of washout with usual diet.
62247807|NCT03255850||Adolescents with CHD|Adolescents with CHD are required to complete the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES)
62045390|NCT00691080||ASD children|"ASD children as defined by:~1. Age greater than or equal to 4 or less than or equal to 9 years~2. Diagnosis of Autism Spectrum Disorder; supported by ADOS and the ADI or SCQ (subjects).~3. No current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.)~4. No current or use within the last 1 month of beta-blockers or melatonin~5. No current use of sleep aids~6. No presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD)~(6) No blindness."
62045391|NCT00691080||"Healthy control children"|"Healthy control children as defined by:~1. Age greater than or equal to 4 or less than or equal to 9 years~2. A SCQ score of less than 10 without parental or physician concern for another neurodevelopmental disorder will be used to define normal children.~3. No current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.)~4. No current or use within the last 1 month of beta-blockers or melatonin~5. No current use of sleep aids;~6. No presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD)~(6) No blindness. (7) No current or past diagnosis of ADHD, depression, anxiety or with any other psychiatric conditions.~(8) No sibling with a diagnosis of Autism Spectrum Disorder."
62827388|NCT06655103|EXPERIMENTAL|Group watching cartoons with virtual reality glasses|Measurements will be performed in three stages. In the first measurement; electrodermal activity, pulse, respiration and oxygen (O2) saturation values together with fear and pain scales 30 minutes before IT chemotherapy treatment without any intervention, in the second measurement; Electrodermal activity, pulse, respiration and O2 saturation values together with fear and pain scales after the application of virtual reality goggles 15 minutes before IT chemotherapy, and in the third measurement, electrodermal activity, pulse, respiration and O2 saturation values together with fear and pain scales will be evaluated within 30-60 minutes after IT chemotherapy treatment (when the sedation effect is over).
62827389|NCT06655103|NO_INTERVENTION|The group that received routine clinical care without any intervention|Measurements will be performed in three stages parallel to the treatment groups. In the first measurement; electrodermal activity, pulse, respiration and O2 saturation values together with fear and pain scales 30 minutes before IT chemotherapy treatment without any intervention, in the second measurement; In the second measurement, electrodermal activity, pulse, respiration and O2 saturation values together with fear and pain scales 15 minutes before IT chemotherapy, and in the third measurement, electrodermal activity, pulse, respiration and O2 saturation values together with fear and pain scales will be evaluated within 30-60 minutes after IT chemotherapy treatment (when the sedation effect is over).
62247808|NCT03255850||Healthy control|Data of healthy control who completed the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES) are retrieved from previous studies.
62437930|NCT05148546|EXPERIMENTAL|C: Neoadjuvant nivolumab + relatlimab|Neoadjuvant 2 cycles of nivolumab 360mg + relatlimab 360mg every 3 weeks
62827390|NCT05074992|EXPERIMENTAL|Ipilimumab|3mg/kg Ipilimumab IV infusion (day 1) given as a 21 day cycle for 2 cycles.
62247809|NCT03255850||Childhood cancer survivors|Data of childhood cancer survivors who completed the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES) are retrieved from previous studies.
62247810|NCT05327374||AHF-group|patients with AECOPD and acute heart failure
62247811|NCT05327374||non AHF-group|patients with AECOPD without acute heart failure
62247812|NCT05597865|OTHER|Control Arm|Control arm will received Alcohol and Drug Use Risk Reduction Sessions
62604732|NCT02503072|ACTIVE_COMPARATOR|Prizes conditional on adherence|Participants in this group are eligible for a prize drawing if they come on their scheduled clinic day. They receive the intervention 'Behavioral: Small lottery prizes based on adherence'.
62604733|NCT02503072|ACTIVE_COMPARATOR|Prizes conditional on clinic visits|Participants in this group are eligible for a prize drawing if they show 95% adherence or higher based on their MEMS-cap measured adherence. They receive the intervention 'Behavioral: Small lottery prizes based on timely clinic visits'.
62827391|NCT06591312|ACTIVE_COMPARATOR|Ticagrelor and aspirin arm|The ticagrelor arm will receive (a 180 mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90 mg twice daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
62247813|NCT05597865|EXPERIMENTAL|Intervention|Participants in the intervention arm will receive four (4) Financial Literacy (FL) training sessions and receive a Youth Development Savings account (YDA) at a financial institution accredited by the Bank of Uganda for long-term savings. Each YDA account will be opened in the name of the participant. Savings will be matched at a 1:1 rate with money from the program.
62247814|NCT02493504|EXPERIMENTAL|Heparin|75 patients were randomly assigned to receive 100units/kg of heparin after dissection prior to anastomosis.
62247815|NCT02493504|NO_INTERVENTION|Control|75 received no intraoperative heparin injection.
62247816|NCT04457076|EXPERIMENTAL|LevoCept|LevoCept™ Intrauterine Contraceptive
62247817|NCT01200238|EXPERIMENTAL|STA-9090: Cohort A|"Cohort A participants received STA-9090 200 mg/m2 given intravenously (IV) over 1 hour once weekly (d1, 8, 15 of a 28 day cycle).~Participants were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal."
62604734|NCT05612802|OTHER|IGF|Creatinine and NGAL have been used successfully in the follow-up of acute kidney injury. In our study, in order to show the effect of pneumoperitoneum on acute kidney injury in patients scheduled for laparoscopic surgery, NGAL and IGF-1 values will be measured before, after and 24 hours after pneumoperitoneum, and these values will be compared.
62827392|NCT06591312|ACTIVE_COMPARATOR|clopidogrel and aspirin arm|The clopidogrel arm will receive (a 300 mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
62827393|NCT02536976|EXPERIMENTAL|Active treatment|mirabegron
62604735|NCT01907217|ACTIVE_COMPARATOR|Bilateral ECT Mecta 5000M|Modified bilateral ECT (bitemporal electrode positions) twice weekly at 1.5 times the seizure threshold. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0mg/kg) for muscle relaxation.
62604736|NCT01907217|EXPERIMENTAL|High-dose unilateral ECT Mecta 5000M|High-dose right modified unilateral ECT twice weekly at 6 times the seizure threshold. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0mg/kg) for muscle relaxation.
62604737|NCT00460707|EXPERIMENTAL|Cohort 1|All subjects in Cohort 1 will receive ketoconazole 400 milligrams (mg) once daily on Day 1 to 9 and oral casopitant 150 mg on Day 4 and 50 mg on Day 5 and Day 6 of treatment period 1. After a washout period of 21 days, subjects will be administered oral casopitant 150 mg on Day 1 and 50 mg on Day 2 and Day 3 of treatment period 2.
62604738|NCT00460707|PLACEBO_COMPARATOR|Cohort 2, Group A|Subjects will receive placebo once daily on Day 1 to Day 3 in treatment period 1. Subjects will receive ketoconazole 400 mg once daily on Day 1 to Day 9 and oral placebo once daily on Days 4, 5 and 6 in treatment period 2. There will be a 14-day washout period between treatment periods 1 and 2.
62604739|NCT00460707|EXPERIMENTAL|Cohort 2, Group B|In treatment period 1, subjects will receive oral casopitant 150 mg on Day 1 and 50 mg on Days 2 and 3. In treatment period 2, they will be administered ketoconazole 400 mg once daily on Day 1 to Day 9 and oral casopitant 150 mg on Day 4 and 50 mg on Days 5 and 6. There will be a 14-day washout period between treatment periods 1 and 2.
62604740|NCT03494972|ACTIVE_COMPARATOR|drain|Tetracyclin drain
62604741|NCT03494972|SHAM_COMPARATOR|No-drain|No drain
62604742|NCT03284645||ART Before or Early in Pregnancy|HIV positive pregnant women who started antiretroviral therapy (ART) before or early in pregnancy for prevention of mother-to-child transmission of HIV and for their own health.
62604743|NCT03284645||ART Started Third Trimester|HIV positive pregnant women starting antiretroviral therapy (ART) during the third trimester of pregnancy for prevention of mother-to-child transmission of HIV and for their own health.
62604744|NCT03284645||ART Started Postpartum|HIV positive women starting antiretroviral therapy (ART) after delivery for prevention of mother-to-child transmission of HIV and for their own health.
62604745|NCT05565144||cerebral amyloid angiopathy (CAA)|Patients with CAA treated with intravenous thrombolysis
62604746|NCT02432859|ACTIVE_COMPARATOR|Electrical stimulation|In the electrical stimulation group, group who received direct current ES at sensory threshold intensity for 1 h/day, 3 days/week, for 4 weeks (12 sessions)
62604747|NCT02432859|PLACEBO_COMPARATOR|Placebo|In the placebo group, the treatment procedure was the same as that the ES group, but the current intensity was zero
62604748|NCT04339803|EXPERIMENTAL|mirror therapy|lower limb mirror therapy using ankle exercise
62604749|NCT06408064|EXPERIMENTAL|Live music|It is performed by a music therapist using the guitar as the only musical instrument. Instrumental lullabies are used, selected by the patient's legal guardian.
62604750|NCT06408064|EXPERIMENTAL|Pre-recorded music|Pre-recorded music of the lullaby genre, instrumental type, using a speaker placed inside the patient's incubator.
62604751|NCT06408064|NO_INTERVENTION|Control|There will be no musical intervention.
62604752|NCT06298357|EXPERIMENTAL|Immediate Start|Program starts in the hospital and lasts for 8 weeks after hospital discharge.
62247818|NCT01200238|EXPERIMENTAL|STA-9090: Cohort B|"Cohort B participants received STA-9090 150 mg/m2 given intravenously over 1 hour (IV) twice weekly (d1, 4, 8, 11, 15, 18 of a 28 day cycle).~Participants were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal."
62247819|NCT05881174|ACTIVE_COMPARATOR|Newly untreated diagnosed PTSD patients without medications|Newly untreated diagnosed PTSD patients who have not yet received any PTSD treatment for a 2-week therapy of acupuncture
62604753|NCT06298357|ACTIVE_COMPARATOR|Waitlist Control|After 8 weeks after hospital discharge, these participants start the 8 week intervention.
62604754|NCT01255410|EXPERIMENTAL|Healthy Adults (Group 1)|Healthy adults will receive a single dose of 10\^6 plaque forming unit (PFU) rHMPV-Pa vaccine intranasally.
62604755|NCT01255410|EXPERIMENTAL|Seropositive Children-Vaccine (Group 2)|Seropositive children will receive a single dose of 10\^6 PFU rHMPV-Pa vaccine intranasally.
62247820|NCT05881174|ACTIVE_COMPARATOR|Newly diagnosed PTSD patients on pharmacological therapy|Newly diagnosed PTSD patients on pharmacological therapy for a 2-week therapy of acupuncture
62247821|NCT05881174|ACTIVE_COMPARATOR|Newly diagnosed PTSD patients with or without medications with mild traumatic brain injury|Newly diagnosed PTSD patients with or without medications having mild traumatic brain injury for a 2-week therapy of acupuncture
62604756|NCT01255410|PLACEBO_COMPARATOR|Seropositive Children-Placebo (Group 2)|Seropositive children will receive a single dose of placebo vaccine intranasally.
62604757|NCT01255410|EXPERIMENTAL|Seronegative Infants and Children-Vaccine (10^5) (Group 3)|Seronegative infants and children will receive a single dose of 10\^5 PFU rHMPV-Pa vaccine intranasally.
62604758|NCT01255410|PLACEBO_COMPARATOR|Seronegative Infants and Children-Placebo (Group 3)|Seronegative infants and children will receive a single dose of placebo vaccine intranasally.
62247822|NCT04429854|EXPERIMENTAL|Convalescent Plasma|"4 units of convalescent plasma:~* 2 units of plasma are administered within 12h after randomization, but preferably as soon as practically possible~* 2 units of plasma should be administered between 24h and 36h after the first infusion"
62247823|NCT04429854|OTHER|Standard of Care|Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive. Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.
62247824|NCT02848950|ACTIVE_COMPARATOR|treatment|drug: metformin
62247825|NCT02848950|NO_INTERVENTION|control|without metformin
62437931|NCT06270030|EXPERIMENTAL|LNZ101 (Aceclidine /Brimonidine) ophthalmic solution|Drug: Aceclidine/Brimonidine ophthalmic solution Other Names: LNZ101
62604759|NCT01255410|EXPERIMENTAL|Seronegative Infants and Children-Vaccine (10^6) (Group 4)|Seronegative infants and children will receive a single dose of 10\^6 PFU rHMPV-Pa vaccine intranasally.
62604760|NCT01255410|PLACEBO_COMPARATOR|Seronegative Infants and Children-Placebo (Group 4)|Seronegative infants and children will receive a single dose of placebo vaccine intranasally.
62604761|NCT02870205|EXPERIMENTAL|GSP 301 NS|
62437932|NCT06270030|EXPERIMENTAL|LNZ100 (Aceclidine) ophthalmic solution|Drug: Aceclidine ophthalmic solution Other Names: LNZ100
62247826|NCT02177721|EXPERIMENTAL|Raxibacumab arm|"This is an open-label, single arm study. The study will be implemented for subjects who receive FDA-approved raxibacumab as part of medical treatment of anthrax or for post-exposure prophylaxis.~Intervention: Sampling of subjects or use of subjects salvaged standard of care samples may be considered for the following assessments (if available/applicable): pregnancy test, pharmacokinetics (PK) sampling, protective antigen, toxin neutralizing antibody (TNA), anti-raxibacumab antibodies."
62437933|NCT06270030|PLACEBO_COMPARATOR|Placebo (Vehicle) ophthalmic solution|Drug: Placebo (Vehicle) ophthalmic solution Other Names: NA
62437934|NCT05141578|EXPERIMENTAL|Luci Intervention|Participants enrolled in this group will receive the Luci intervention for a 24-week period.
62827394|NCT02536976|PLACEBO_COMPARATOR|Placebo|Matching placebo
62045392|NCT01826864|EXPERIMENTAL|Arm I (sargramostim and sentinel lymph node biopsy)|Patients receive sargramostim SC 3-5 days prior to undergoing sentinel lymph node biopsy.
62045393|NCT01826864|ACTIVE_COMPARATOR|Arm II (hypertonic saline and sentinel lymph node biopsy)|Patients receive hypertonic saline SC 3-5 days prior to undergoing sentinel lymph node biopsy.
62437935|NCT05141578|NO_INTERVENTION|Wait-list Control|Participants in the waiting-list control group will not receive any intervention during the study. They will be invited to participate to the program at the end of the trial.
62604762|NCT02870205|ACTIVE_COMPARATOR|GOM-NS|
62604763|NCT02870205|ACTIVE_COMPARATOR|GMM-2 NS|
62604764|NCT02870205|PLACEBO_COMPARATOR|GSP 301 placebo NS|
62045394|NCT05955703|EXPERIMENTAL|Using the experimental group as a result of the training based on PPM|"The training sessions planned within the scope of PPM were applied to the patients, who were divided into groups of six according to the bed order, for 15-20 minutes for eight weeks, when the patients felt well, through training booklets and power point presentations. When the trainings started, the posters prepared were hung in the waiting room while the intervention group was undergoing hemodialysis. The person providing the care of the patient was included in each training. During the trainings, it was requested that the training booklets be with the patients and the power point presentations continued in parallel with the training booklets.~* Post-test was applied to intervention group~* three months after the post-test application, follow-up test was applied to the intervention group in order to evaluate the impact."
62045395|NCT05955703|NO_INTERVENTION|Using the control group as a result of the training based on PPM|After the follow-up test, training was given to the patients in the control group and a model-based training booklet was distributed.
62045396|NCT02281799|EXPERIMENTAL|Open label|"10 patients diagnosed with IBD, treated previously with thiopurines and ceased treatment due to suspected thiopurine-induced pancreatitis.~Patients will be commenced on an alternative thiopurine to that used initially,. The medications will be commenced at standard dose (ie Azathioprine 2.5mg/kg/day, 6-MP 1.5mg/kg/day)."
62604765|NCT02570672|EXPERIMENTAL|Metformin|Subjects will be randomized to metformin (titrated up to 1000 mg twice daily, as tolerated)
62827395|NCT02859220|OTHER|group 1|group 1 : Roche Elecsys intact PTH
62827396|NCT02859220|OTHER|group 2|group 2 : PTH 1-84 complete (PAC) report and CAP / PTH 7-84 (CIP), Duo PTH IRMA Scantibodies
62045397|NCT01704313|EXPERIMENTAL|Interrupted|Interrupted suturing technique used around heel of anastomosis
62045398|NCT01704313|ACTIVE_COMPARATOR|Continuous|Continuous suturing technique used for the anastomosis
62045399|NCT04270214|OTHER|Dysport|Single arm study, all participants will receive Dysport injections
62437936|NCT04119583|EXPERIMENTAL|U-shape Automatic Electric Toothbrush|
62437937|NCT04119583|ACTIVE_COMPARATOR|Usual home toothbrushing procedure|
62437938|NCT04119583|NO_INTERVENTION|No toothbrushing|
62437939|NCT04119583|ACTIVE_COMPARATOR|Conventional Electric Toothbrush|
62437940|NCT01244815|EXPERIMENTAL|Asenapine 2.5 mg twice daily (BID)|Participants receive asenapine 2.5 mg BID for 21 days.
62604766|NCT02570672|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to metformin (titrated up to 1000 mg twice daily, as tolerated) vs. placebo.
62604767|NCT05995405|EXPERIMENTAL|GTX-104|GTX-104 is a sterile concentrate of 10 mg nimodipine/5 mL (2 mg/mL), to be diluted in normal saline to obtain a dosing solution composed of dispersed micelles containing nimodipine for IV infusion. It will be administered as a continuous IV infusion of 0.15 mg/hour and a 30-minute IV bolus of 4 mg every 4 hours for up to 21 days
62604768|NCT05995405|ACTIVE_COMPARATOR|Oral nimodipine|Oral nimodipine is a soft gelatin capsule. The dose is 60 mg (two 30 mg capsules) every 4 hours for up to 21 consecutive days.
62827397|NCT06474338||detection by artificial intelligence|The patient with bladder lesion confirmed by cystoscopy, these bladder lesion(s) are detected by artificial intelligence algorithm.
62827398|NCT06474338||detection by urologists.|The patient with bladder lesion confirmed by cystoscopy, these bladder lesion(s) are detected by urologist.
62827399|NCT04214821|ACTIVE_COMPARATOR|Levofloxacin -1 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
62827400|NCT04214821|ACTIVE_COMPARATOR|Levofloxacin-2 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
62437941|NCT01244815|EXPERIMENTAL|Asenapine 5.0 mg BID|Participants receive asenapine 2.5 mg BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive asenapine 5.0 mg BID for the remainder of the 21-day treatment period.
62247827|NCT02437617||Control Group #1|Participants who have had tumor molecular analysis performed with the similar clinical characteristics and genomic aberrations but who receive therapy not matched to their aberrations, or who have received results from Foundation Medicine that fail to demonstrate any molecular alteration.
62247828|NCT02437617||Control Group #2|Participants from historical archives of MD Anderson, no older than two years, who received therapy not matched to their aberrations and are matched not only on the basis of the clinical characteristics, but also, as much as possible, on the basis of genomic aberrations.
62604769|NCT06486649||single group|"The routine consultation process was performed first: according to the process recommended by the 2023 edition of the Chinese Expert Consensus on the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction, the attending cardiologist completed the subject's clinical criteria assessment and performed the HFpEF diagnosis (yes/no).~During the attending physician's checkup visit, the multimodal large language model screening system (MedGuide-72B) collected routine visit data, recorded relevant data and indicators during the patient's communication with MedGuide-72B and made the diagnosis."
62827401|NCT04214821|ACTIVE_COMPARATOR|Levofloxacin-4 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
62827402|NCT04214821|ACTIVE_COMPARATOR|Levofloxacin-6 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 6-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection
62827403|NCT04214821|ACTIVE_COMPARATOR|Moxifloxacin-1 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
62247829|NCT02437617||Matched Targeted Therapy Group|Participants with tumor aberrations who received matched targeted therapy.
62247830|NCT02567539|EXPERIMENTAL|Recurrent high grade glioma|IMRT with or without radiosensitive therapy
62247831|NCT03368950|EXPERIMENTAL|Intervention|Participants in this arm are invited to undertake an 8-week online mindfulness course
62247832|NCT03368950|ACTIVE_COMPARATOR|Wait list|Participants in this arm are informed they are on a wait list and are required to wait 8 weeks, before being invited to take part in the intervention itself (an 8-week online mindfulness course).
62247833|NCT01296984||Extralevator APR|The perineal part of the APR is done with the intent to create a cylindrically shaped specimen thus removing part of or the entire levator muscle with the specimen.
62247834|NCT01296984||Traditional APR|The perineal part of the APR is performed with the intent to remove the tumour with CRM free of tumour and the levator left in place.
62247835|NCT06427291|EXPERIMENTAL|Herpes virus T3011 injection|T3011 with the dose of 5 x 10\^7 PFU, 5 x 10\^8 PFU or 2 x 10\^9 PFU is administered via intravesical instillation, once a week (QW) for the first 12 weeks and then every 2 weeks (Q2W) until 12 months.
62045400|NCT06099301|NO_INTERVENTION|Waitlist control (WC)|The WC group will not receive treatment from the research team during the assessment period. But they will be notified their evaluation results (mild to moderate depression) after they complete the baseline assessment. They will receive the information about mental health hotline services for general public (e.g. Social Welfare Department: 2343 2255; Caritas Family Crisis Support Centre: 18288; Joyful Mental Health Foundation: 2301 2303). The intervention group will receive the hotline information as well. If they want to consult a family doctor, information about the primary care provider/directory for mental health care and counselling services will be provided in their preferred district. Their treatment or help-seeking of the formal mental health services will not be intervened. The mobile app list will be provided to the WC group after the assessment period. The instruction session will be delivered to the WC group and provide necessary assistance.
62045401|NCT06099301|EXPERIMENTAL|Brief advice of a list of mobile apps|In the instruction session, the participants will be introduced with the concept of self-care, a list of four mobile apps with high quality and suitability, and the main functions of these apps. Participants will be instructed to use at least one of the apps for 10 min each day for 30 days. They have freedom to choose which one app to use, or a mix of two or three apps. For each app they choose, they will create user accounts by themselves but be reminded to protect privacy. Two reminders will be sent to the participants at the 2nd and 3rd week. The message will include reminders to use the suggested mobile apps, self-care concept, and tips of using the provided apps. If they have not accessed to any of the mobile apps, the project coordinator will discuss the reasons and work together with the participants to overcome the problems.
62045402|NCT02200913|EXPERIMENTAL|core stabilization exercise|core stabilization exercise 2 times/week 10 weeks
62045403|NCT02200913|EXPERIMENTAL|general trunk strengthening exercise|general trunk strengthening exercise, 2 times/week, 10 weeks
62604770|NCT01686698|ACTIVE_COMPARATOR|VSL#3 (Original De Simone formulation)|VSL#3 (Original De Simone formulation) sachets containing 450 x 109 bacteria, 1 sachet every 12 hours during 3 months (n=20).
62045404|NCT04207346|EXPERIMENTAL|TMS|transcranial magnetic stimulation delivered to the right dorsolateral prefrontal cortex at 1 Hz
62045405|NCT04207346|SHAM_COMPARATOR|Sham|sham transcranial magnetic stimulation delivered to the right dorsolateral prefrontal cortex
62827404|NCT04214821|ACTIVE_COMPARATOR|Moxifloxacin-2 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
62045406|NCT04567108|ACTIVE_COMPARATOR|Maintain SSBs (Control)|Instruction to maintain baseline intake of SSBs (months 0-6); then switch to water only (months 6-12)
62604771|NCT01686698|PLACEBO_COMPARATOR|Placebo|Placebo sachets, 1 sachet every 12 hours during 3 months (n=20).
62827405|NCT04214821|ACTIVE_COMPARATOR|Moxifloxacin-4 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
62247836|NCT02713035|NO_INTERVENTION|Usual|Receive standard medical therapy for eczema
62247837|NCT02713035|EXPERIMENTAL|Treatment|Receive standard medical therapy for eczema plus behavioral self help intervention
62827406|NCT04214821|ACTIVE_COMPARATOR|Moxifloxacin-6 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 6-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
62247838|NCT00608296||1|Study subjects on lithium
62247839|NCT00608296||2|study subjects on quetiapine
62437942|NCT01244815|EXPERIMENTAL|Asenapine 10.0 mg BID|Participants receive asenapine 2.5 mg BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. On Day 5 and 6 participants receive asenapine 5.0 mg BID. On Day 7 participants receive asenapine 5.0 mg in the morning and 10.0 mg in the evening. Participants receive asenapine 10.0 mg BID for the remainder of the 21-day treatment period.
62437943|NCT01244815|PLACEBO_COMPARATOR|Placebo|Participants receive placebo BID for 21 days.
62437944|NCT02314533|EXPERIMENTAL|fenofibrate|Fenofibrate 200mg capsule will be administered orally with breakfast once daily according to the Chinese prescription information of Lipanthyl, while previous type and dose of statin will be administered in the evening.
62437945|NCT01741480|PLACEBO_COMPARATOR|Routine care|General hospital ward patients will receive routine care.
62437946|NCT01741480|EXPERIMENTAL|Intervention arm|The intervention with early warning system monitoring is to have the rapid response team assess the patients real-time.
62437947|NCT02912013|EXPERIMENTAL|Me mini|Subjects treated with Me mini device
62437948|NCT05245981|EXPERIMENTAL|BRI.MAG 2|Patients presenting with dislocated isolated or combined fracture of the medialis malleolus are eligible to receive the investigational device.
62437949|NCT04835766||Symptomatic group|These patients had bladder injury during PAS surgery and had Lower urinary tract symptoms
62623443|NCT06045611|EXPERIMENTAL|Isolated Whey Protein/Placebo/Isolated Pea Protein/Isolated Faba Bean Protein|"* Study day 1: 0.6g isolated whey protein/kg/body weight + 400 ml water~* Study day 2: 400 ml water~* Study day 3: 0.6g isolated pea protein/kg/body weight + 400 ml water~* Study day 4: 0.6g isolated faba bean protein/kg/body weight + 400 ml water~The fat and energy content of the drinks will be adapted using a plant based oil"
62827407|NCT00732056|EXPERIMENTAL|1|3+3 cohort dose escalation
62827408|NCT06600295||patients with cancer of the oral cavity/oropharynx|115 patients with cancer of the oral cavity/oropharynx
62827409|NCT06600295||colon cancer patients|123 colon cancer patients
62827410|NCT06600295||patients with liver cancer|68 patients with liver cancer
62827411|NCT03998306|EXPERIMENTAL|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive probiotic lozenge before falling asleep for12 weeks. They will receive hygienic and dietetic instructions. examination will be conducted before study and after 12 weeks.
62827412|NCT03998306|SHAM_COMPARATOR|CONTROL|no intervention
62045407|NCT04567108|EXPERIMENTAL|Substitute Aspartame ASBs (participants randomized through 8/31/2023)|Instruction/guidelines to eliminate SSBs and replace, where possible with beverages artificially sweetened with aspartame (months 0-6); then switch to water only (months 6-12)
62827413|NCT04587336||Aim 0 - Cognitive Interview|Cognitive Interviews: Examine the understanding and interpretation of diabetes distress and the Diabetes Distress Scale in Veterans with T2D.
62045408|NCT04567108|EXPERIMENTAL|Substitute Sucralose ASBs (participants randomized through 8/31/2023)|Instruction/guidelines to eliminate SSBs and replace, where possible with beverages artificially sweetened with sucralose (months 0-6); then switch to water only (months 6-12)
62827414|NCT04587336||Aim 1 - Baseline Survey|Conduct Baseline Survey: Examine the association of psychosocial factors (depression, PTSD), environmental factors (finances, support), self-management behaviors, and HbA1c with DD.
62827415|NCT04587336||Aim 3a- TARDIS Photo Elicitation|TARDIS Photo Elicitation: To further understand Diabetes Distress by expanding on what we have learned thus far in cognitive and semi-structured interviews with Veterans. Visual-based qualitative methods will help identify and more robustly describe DD in Veterans.
62827416|NCT04587336||Aim 3b - TARDIS Pilot|TARDIS Intervention: Design \& pilot test an innovative, tailored self-management information and supportive services intervention for Veterans with T2D, to promote engagement in self-management behaviors
62827417|NCT01503203|EXPERIMENTAL|Wii Group|This group will do the same training of the Prime Group. However will do also Physical Virtual Training using Nintendo Wii and Wii Balance Board. The physical virtual training going to applied during thirty minutes.
62827418|NCT01503203|ACTIVE_COMPARATOR|Prime Group|This group will do strength exercises and core training.
62827419|NCT06646614|NO_INTERVENTION|Usual Care|The patient will continue to receive as normal and usual. The participants will be interviewed which is expected to last 20-30 min. Surveys will last 15-20 min. The total possible time is 1 hour and 40 min. for both baseline and post over 8 week period.
62827420|NCT06646614|EXPERIMENTAL|Group Advance Care Planning|The participant will engage in 2 hours of educational sessions regarding advance care planning and goals of care. They will be interviewed which is expected to last 20-30 min and surveys will last 15-20 min. The total involvement will be no more than 3 hours and 40 min over 8 weeks.
62827421|NCT06144619||Intermediate risk group (no-surgery)|Participants diagnosed with pre-biopsy mpMRI.
62827422|NCT06144619||High-risk group (surgery)|Participants who had radical prostatectomy (RP) with (or with-out) mpMR imaging.
62045409|NCT04567108|EXPERIMENTAL|Substitute Water|Instruction/guidelines to eliminate SSBs and replace with water (months 0-12)
62827423|NCT05179226|EXPERIMENTAL|Ferric Derisomaltose|"All subjects (a total of 200) will be treated with Ferric Derisomaltose. 12 subjects (half of the 24 subjects participating in the PK-part of the trial) will be treated with 10mg/kg while the remaining subjects will be treated with 20 mg/kg.~."
62623444|NCT06045611|EXPERIMENTAL|Isolated Faba Bean Protein/Isolated Pea Protein/Placebo/Isolated Whey Protein|"* Study day 1: 0.6g isolated faba bean protein/kg/body weight + 400 ml water~* Study day 2: 0.6g isolated pea protein/kg/body weight + 400 ml water~* Study day 3: 400 ml water~* Study day 4: 0.6g isolated whey protein/kg/body weight + 400 ml water~The fat and energy content of the drinks will be adapted using a plant based oil"
62827424|NCT01113255|ACTIVE_COMPARATOR|CHRONIC REPIRATORY FAILURE|
62827425|NCT01113255|ACTIVE_COMPARATOR|ACUTE RESPIRATORY FAILURE|
62827426|NCT03480048|EXPERIMENTAL|Breastfeeding and weight loss support|Participants receive a combination of in-person, phone, and online support for breastfeeding and postpartum weight management.
62827427|NCT03480048|NO_INTERVENTION|Usual care|Participants receive usual care from their prenatal care provider.
62827428|NCT04734691|EXPERIMENTAL|Experimental Arm|
62827429|NCT04734691|ACTIVE_COMPARATOR|Control Arm|
62827430|NCT03493464|EXPERIMENTAL|Treatment|Subjects will receive a single dose of BR55 at 0.03 mL/kg or 0.05 mL/kg.
62827431|NCT02289586|ACTIVE_COMPARATOR|hypoxemia, central airway stenosis.|"Inclusion Criteria:~* (a)patients with central airway stenosis need interventional bronchoscopy (b) partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio less than 300;~Exclusion Criteria:~* (a) facial deformity sufficient to preclude mask fitting; (b) upper gastrointestinal bleeding; (c) upper airway obstruction; (d) acute coronary syndromes; (e) tracheostomy or endotracheal intubation(ETI) before admission; (f) need for urgent ETI due to cardiac or respiratory arrest."
62827432|NCT02289586|EXPERIMENTAL|hypoxemia, central airway stenosis|"Inclusion Criteria:~* (a)patients with central airway stenosis need interventional bronchoscopy (b) partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio less than 300;~Exclusion Criteria:~* (a) facial deformity sufficient to preclude mask fitting; (b) upper gastrointestinal bleeding; (c) upper airway obstruction; (d) acute coronary syndromes; (e) tracheostomy or endotracheal intubation(ETI) before admission; (f) need for urgent ETI due to cardiac or respiratory arrest."
62827433|NCT04451044|EXPERIMENTAL|physiologically-guided arm|Physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy
62827434|NCT04451044|ACTIVE_COMPARATOR|angiographically-guided arm|Standard of care angiographically-guided PCI for determining the PCI strategy
62045410|NCT04567108|EXPERIMENTAL|Substitute ASBs (participants randomized on or after 9/1/2023)|Instruction/guidelines to eliminate SSBs and replace, where possible with beverages artificially sweetened with choice of non-nutritive sweeteners such as sucralose or aspartame
62045411|NCT05674396|EXPERIMENTAL|Traditional Palliation|Participant will be randomized to standard radiation
62827435|NCT04885907|ACTIVE_COMPARATOR|Experimental group|Participants will receive a one dose of mRNA-1273 vaccine 0.5mL i.m. in deltoid muscle
62827436|NCT04885907|PLACEBO_COMPARATOR|Comparator Group|Participants will receive one dose of normal saline injection 0.5mL i.m. in deltoid muscle
62827437|NCT06595524|EXPERIMENTAL|online mindfulness -base intervention|
62045412|NCT05674396|EXPERIMENTAL|Stereotactic body radiotherapy (SBRT)|Participants will be randomized to receive (SBRT) Stereotactic body radiotherapy.
62045413|NCT02471092|PLACEBO_COMPARATOR|Water Control|Skim milk products. Water and permeate control; 250mL serving.
62827438|NCT06595524|NO_INTERVENTION|waitlist control group|
62827439|NCT01999881|EXPERIMENTAL|Arm A (aerobic and exercise training)|Patients and their support persons undergo a supervised combined aerobic exercise comprising walking, cycling, or video-based aerobics and strength training using resistance bands for 40 minutes 2 days a week at the UWHC and 3 days a week at home over 8 weeks.
62827440|NCT01999881|ACTIVE_COMPARATOR|Arm II (usual care)|Patients and their support persons undergo the usual care over 8 weeks.
62827441|NCT06604390|PLACEBO_COMPARATOR|Arm 1: Catechin Group Arm 2: Placebo Group|"Arm 1: Catechin Group. Participants in this group received one capsule of gambir catechin daily, with a dosage of 224 mg.~Arm 2: Placebo Group. Participants in this group received one placebo capsule daily, with a dosage of 224 mg."
62827442|NCT06604390|EXPERIMENTAL|Effects of Gambier Catechin Supplementation on Cognitive Function, APP, MAPT,|Gambir purified with a minimum of 90% (+)-Catechin content. Dosage of 224 mg catechin per capsule, once daily.
62827443|NCT04267380||Corrona US RA Registry 11 mg|patients with RA who have been exposed to tofacitinib 11 mg QD tablet
62827444|NCT04267380||Corrona US RA Registry 5 mg|patients with RA who have been exposed to tofacitinib 5 mg BID tablet
62827445|NCT05153967||Pediatric Myeloablative allo-HSCT|Participants ages 4 to 17 years old with SCD who underwent or are scheduled to undergo myeloablative allo-HSCT.
62827446|NCT05153967||Pediatric Standard Disease-Modifying Therapy|Participants ages 4 to 17 years old with SCD who receive standard therapy.
62827447|NCT05153967||Adult Non-Myeloablative allo-HSCT|Participants ages 18 to 65 years old with SCD who underwent or are scheduled to undergo non-myeloablative allo-HSCT.
62827448|NCT05153967||Adult Standard Disease-Modifying Therapy|Participants ages 18 to 65 years old with SCD who receive standard therapy.
62827449|NCT06052579|EXPERIMENTAL|study group|the patients included in the study group underwent Wiltse TLIF
62827450|NCT06052579|ACTIVE_COMPARATOR|control group|the patients included in the control group underwent traditional posterior -TLIF
62045414|NCT02471092|ACTIVE_COMPARATOR|Skim Milk|Skim milk products. Skim milk (regular 80:20 protein ratio); 250mL serving.
62045415|NCT02471092|EXPERIMENTAL|High Protein Milk|Skim milk products. High protein milk (regular 80:20 protein ratio); 250mL serving.
62045416|NCT02471092|EXPERIMENTAL|High Protein Milk (Modified Ratio)|Skim milk products. High protein milk with modified protein ratio (40:60 ratio); 250 mL serving.
62437950|NCT04835766||Asymptomatic group|These patients had bladder injury during PAS surgery and had no Lower urinary tract symptoms
62045417|NCT02471092|EXPERIMENTAL|Skim Milk (Modified Ratio)|Skim milk products. Skim milk with modified protein ratio (40:60 ratio); 250 mL serving.
62827451|NCT05516381|OTHER|Restricted Invers Kinematic Knee Alignment Technique|Restricted Invers Kinematic Knee Alignment Technique
62827452|NCT05516381|OTHER|Mechanical Knee Alignment Technique|Mechanical Knee Alignment Technique
62247840|NCT01768897|EXPERIMENTAL|Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)|"Patients receive CPI-613 IV over 2 hours on days 1-5, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 3, and mitoxantrone hydrochloride IV over 15 minutes after the 1st, 3rd, and 5th doses of cytarabine. Treatment repeats every 14 days for up to 2 courses\* in the absence of disease progression or unacceptable toxicity.~NOTE: \*Patients undergoing a second course of therapy receive CPI-613 IV over 2 hours on days 1-3, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 2, and mitoxantrone hydrochloride IV over 15 minutes after the 1st and 3rd doses of cytarabine."
62045418|NCT03609567|EXPERIMENTAL|Aromatherapy|Aromatherapy using essential oils
62045419|NCT03609567|PLACEBO_COMPARATOR|Placebo|Aromatherapy using odorless placebo
62247841|NCT02294682|EXPERIMENTAL|GSK2140944 1500 mg|Subjects will receive single oral dose of GSK2140944 1500 mg.
62247842|NCT02294682|EXPERIMENTAL|GSK2140944 3000 mg|Subjects will receive single oral dose of GSK2140944 3000 mg.
62437951|NCT05608590|EXPERIMENTAL|Direct HSG during fertility work-up|Tubal flushing at HSG with Lipiodol® (oil-based contrast medium) (max. 15mL) incorporated in the fertility work-up
62437952|NCT05608590|ACTIVE_COMPARATOR|Delayed HSG 6 months after completing fertility work-up|Tubal flushing at HSG with Lipiodol® (oil-based contrast medium) (max. 15mL) after a 6 months waiting period after completion of fertility work-up
62437953|NCT03154333|EXPERIMENTAL|diacerein 1% ointment|diacerein 1% ointment will be used for 8 weeks
62827453|NCT03783572|EXPERIMENTAL|Stroke patients|40 stroke patients : Injection of the TBA and the investigator will compare the measure of spastic cocontraction index (ICCS) during different movement before versus 4 weeks after injection of TBA : Clinical evaluation and Instrumental evaluation TBA injections are performed as part of routine care
62827454|NCT03783572|ACTIVE_COMPARATOR|Control Group|The control group : Clinical evaluation consists in the search for criteria of non-inclusion and manual laterality score The will ha an Instrumental review just like the patient : concomitant evaluation of the 3D kinematics of the dominant upper limb, EMG of the triceps brachii muscles, biceps brachii, brachio-radial, brachial; associated with EEG recording, during active extension and elbow flexion movements, of the dominant upper extremity, at spontaneous and maximal speed Clinical evaluation
62827455|NCT05320445|EXPERIMENTAL|Supportive-expressive group therapy|The SEGT is a six-module program where each session is approximately one hour, and is held twice a week over a three-week period. It is framed within social cognitive theory, whereby resilience to adversity (NMSK trauma in this instance) relies on personal enablement. Enablement serves to equip the individual with the personal resources to cultivate their self-efficacy and mastery and to select and construct environments that promote successful adaption.
62827456|NCT05320445|NO_INTERVENTION|Treatment as usual|The treatment as usual group will receive standard care only (which may include an individual psychiatric consultation).
62827457|NCT02427308||miltefosine patients that become pregnant|
62827458|NCT04828681||Patients with Angio-IMR>40 Unit|Patients with angio-IMR\>40U in the culprit vessel after successful primary PCI.
62827459|NCT04828681||Patients with Angio-IMR≤40 Unit|Patients with angio-IMR≤40U in the culprit vessel after successful primary PCI.
62827460|NCT00602602|EXPERIMENTAL|GemOx and Bev, then chemoradiation, then surgery|"Gemcitabine 1000 mg/m2 over 100 min on day 1 every 2 weeks~Oxaliplatin 85 mg/m2 over 2 hours on day 2 every 2 weeks~Bevacizumab 10 mg/kg over 90 minutes on day 1 every 2 weeks. Infusion duration may be shortened in subsequent courses if tolerated.~One cycle is 2 weeks. Chemoradiation to begin prior to 4 weeks from last dose of Gem. Between 4 and 6 weeks following chemoradiotherapy, patients will undergo re-staging with CT or MRI and CA 19-9. If there is no evidence of disease progression, the patient will be referred to the surgeon for re-evaluation and consideration of surgical intervention"
62827461|NCT01241721|EXPERIMENTAL|Positron Emission Mammography (PEM)|Positron Emission Mammography (PEM)
62827462|NCT04372381|ACTIVE_COMPARATOR|Supra-Annular transcatheter heart valve|Medtronic Evolut Pro Valve implantation
62827463|NCT04372381|ACTIVE_COMPARATOR|Annular transcatheter heart valve|Edwards Sapien 3 Ultra implantation
62827464|NCT01569191|NO_INTERVENTION|No Treatment|Exposure to grass pollen only
62827465|NCT01569191|ACTIVE_COMPARATOR|Artificial Tear Supplement|Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006
62827466|NCT01569191|ACTIVE_COMPARATOR|Cold compress|Cooled gel eye mask http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
62827467|NCT01569191|ACTIVE_COMPARATOR|Anti-allergic Medication|ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis
62827468|NCT04861103|EXPERIMENTAL|Factor Xa levels in pregnant women with therapeutic Lovenox divided into three times a day dosing|Therapeutic Lovenox dosing split into three times a day dosing for 5 day. Xa levels a measured.
62045420|NCT03733405|EXPERIMENTAL|Postpartum Visit 6 Weeks|Participants will have a postpartum visit scheduled 6 weeks after birth
62045421|NCT03733405|EXPERIMENTAL|Postpartum Visit 2 and 6 Weeks|Participants will have postpartum visits scheduled 2 and 6 weeks after birth
62045422|NCT04118348|NO_INTERVENTION|Passive Control|Will consist of no alerts and will serve to examine lipid panel screening rates given the current standard of care. After 6 months, providers in this (and other conditions) will receive the alert(s) with the best demonstrated success in increasing screening rates.
62045423|NCT04118348|EXPERIMENTAL|Best Practice Alert (BPA-only)|Will consist of a BPA that fires for providers during a visit with an eligible 9-11 year-old patient. This is an active opt-in alert wherein the provider must respond, either confirming the prescription of a lipid panel or opting out with an acknowledgment/reason for declining the test. The BPA will include a recommendation to administer the screen in combination with existing scheduled bloodwork.
62247843|NCT00962156|EXPERIMENTAL|HES 130/0.4|Volume expansion
62247844|NCT00962156|ACTIVE_COMPARATOR|Ringer acetate|Volume expansion
62247845|NCT04332224|EXPERIMENTAL|Non-shivering cooling group|Cooling devices
62247846|NCT00993954|EXPERIMENTAL|Nurse Reduction|Patients randomized to reduction by nurse.
62045424|NCT04118348|EXPERIMENTAL|Health Maintenance Topic (HMT-only)|Will consist of an HMT in Epic that is present for providers at their visit with an eligible patient. The HMT will be highlighted for enhanced visibility, until or unless action is taken.
62045425|NCT04118348|EXPERIMENTAL|BPA+HMT|Will consist of both the BPA and HMT presented simultaneously in Epic.
62045426|NCT01631084|EXPERIMENTAL|JADE|Patients randomized to the JADE group will be followed according to protocol-driven diabetes care based on their individual risk levels, using a web-based disease management program. In addition to their annual comprehensive assessments at baseline, year 1 and year 2, all subsequent follow-up visits will be documented and entered into the JADE portal, which will then issue reports to both patients and doctor to promote sharing of information and informed decisions.
62045427|NCT01631084|ACTIVE_COMPARATOR|DIAMOND|Patients will receive a comprehensive assessment at baseline, year 1 and year 2. In the interim between these time points patients will be managed according to 'usual care' procedures.
62045428|NCT05895032|EXPERIMENTAL|Exercise|12-week exercise intervention
62045429|NCT05895032|ACTIVE_COMPARATOR|Usual care|Participants will continue to receive their usual care as prescribed by the haematologist, physiotherapist and other members of the healthcare team.
62045430|NCT04941040|EXPERIMENTAL|Opioid free anesthesia|patients are going to receive intraoperative analgesics other than opioids
62045431|NCT04941040|ACTIVE_COMPARATOR|Opioid anesthesia|patients are going to receive intraoperative opioid analgesics
62045432|NCT06579612|NO_INTERVENTION|Control arm|Patient in the control arm will beneficiate from commun practice
62045433|NCT06579612|EXPERIMENTAL|Experimental arm|Patient in the control arm will beneficiate from a personalized follow-up and support after a pulmonary rehabilitation program
62045434|NCT02047045|EXPERIMENTAL|Electro-acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 min, 5 times/week for the first 2 weeks, and 3 times/week for the next 6 weeks.
62604772|NCT02897427||Screening (specimen collection, HPV testing)|"STAGE I: Participants fill out a survey and undergo collection of blood and oral rinse samples.~STAGE II: Participants complete a head and neck exam by using brushing of the oropharyngeal mucosa, a thorough oropharyngeal exam including narrow band imaging, collection of oral rinse sample, transcervical ultrasonography of the neck lymph nodes and oropharynx, anoscopy, penile exam, and complete Papanicolaou/HPV testing. Participants undergo repeat oropharyngeal screening, oral HPV DNA test, oral HPV integration testing, ultrasound, and blood sample collection once every year for 5 years. Select participants will provide oral rinse sample by mail every six months."
62604773|NCT04984759|EXPERIMENTAL|Primaquine in colostrum and transitional milk (mother-neonate pairs)|12 women who are breast feeding neonates ≤5 days old will be recruited into the primaquine arm. They will receive primaquine 0.5 mg/kg daily for 14 days directly observed in the clinic.
62604774|NCT04984759|EXPERIMENTAL|Tafenoquine in mature milk (mother-child pairs)|24 women who are breast feeding infants or young children \> 14 days will be recruited into Arm 2. They will receive a single 300 mg dose of tafenoquine directly observed in the clinic. Investigators will begin with recruiting 2-4 women breastfeeding young children ≥12 months old.
62045435|NCT02047045|ACTIVE_COMPARATOR|Prucalopride|Prucalopride Succinate taken orally, 2mg/day in the morning before breakfast
62045436|NCT02592382|EXPERIMENTAL|Xylitol spray|Xylitol nasal spray ( Xlear ltd which contains 10% of Xylitiol) given 3 times a day (one puff for each nostril) for three months period.
62045437|NCT04685902||Adult patients with tracheostomy|Adult patients who currently have a tracheostomy and receive an order for one-way speaking valve trial
62045438|NCT06263621|EXPERIMENTAL|"Intervention Standard"|"The smaller entree is labeled Standard and the larger entree is labeled Large."
62045439|NCT06263621|NO_INTERVENTION|"Control Small"|"The smaller entree is labeled Small and the larger entree is labeled Large."
62045440|NCT03151005|EXPERIMENTAL|Metformin-GLP-1 Receptor Agonist|Metformin-GLP-1 Receptor Agonist Therapy: metformin 0.5 g/time by mouth, 3 times per day, with 5 ug exenatide subcutaneous injection twice per day, for 4 weeks, then change to 10ug exenatide subcutaneous injection twice per day for 8 weeks; or metformin 0.5 g/time by mouth, 3 times per day, with 0.6mg liraglutide subcutaneous injection once per day, for 1 weeks, then change to 1.2-1.8 mg liraglutide subcutaneous injection according to patient's blood glucose condition, twice per day for 8 weeks.
62045441|NCT03151005|ACTIVE_COMPARATOR|Metformin-Oral Contraceptive(OC)|Metformin-Oral Contraceptive(OC) Therapy: metformin 0.5 g/ time by mouth, 3 times per day, with Diane 35(OC) 1 piece per day by mouth, for 12 weeks.
62247847|NCT00993954|ACTIVE_COMPARATOR|Physician Reduction|Patients randomized to treatment by Emergency Department Physician in traditional ED manner
62247848|NCT02941653|ACTIVE_COMPARATOR|Control: Potassium Nitrate 2% gel|The patient will receive the application of potassium nitrate 2% gel on vestibular surface teeth, for 10 minutes.
62604775|NCT04984759|EXPERIMENTAL|Tafenoquine in colostrum and transitional milk (mother-neonate pairs)|12 women who are breast feeding neonates ≤ 5 days old will be recruited into Arm 3. They will receive a single 300 mg dose of tafenoquine directly observed in the clinic.
62045442|NCT04962425||The case group|Trastuzumab for the treatment of breast cancer patients with cardiotoxicity.
62045443|NCT04962425||The control group|Trastuzumab is used to treat patients with breast cancer who do not present with cardiotoxicity
62604776|NCT01860742|ACTIVE_COMPARATOR|Interferon alpha-2b|Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day until progression or unacceptable adverse event from a clinical or a patient point of view.
62604777|NCT01860742|ACTIVE_COMPARATOR|177Lu-DOTATATE|intravenous injection of 177Lu-octreotate with simultaneous infusion of an aminoacid solution
62604778|NCT05940896|EXPERIMENTAL|Dose escalation|DV is given intravenously once every 2 weeks, (dose escalation plan: 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg). DV will be administered at least 2 times during the treatment, and the final DV dose needs to be completed before the last radiotherapy.
62604779|NCT04477044|NO_INTERVENTION|No GoPro|No GoPro Hero4 to be mounted on the participant's head while he/she performs intubation on a manikin.
62604780|NCT04477044|EXPERIMENTAL|GoPro|GoPro Hero4 to be mounted on the participant's head while he/she performs intubation on a manikin.
62604781|NCT00597506|EXPERIMENTAL|Bevacizumab and Everolimus|10 mg Everolimus(RAD001) daily by mouth, days 1-28 10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle
62247849|NCT02941653|EXPERIMENTAL|Intervention: Potassium Oxalate 5% gel|The patient will receive the application of potassium oxalate 5% gel on vestibular surface teeth, for 10 minutes.
62827469|NCT04228523|EXPERIMENTAL|Therapeutic education workshop|Two group receive therapeutic education workshop already existing in Toulouse University Hospital
62604782|NCT04857918|EXPERIMENTAL|Social identity informed virtual running group|Participants will join running groups of six people (males and females) for eight weeks. Each running group will be given the group goal/challenge to collectively run/brisk walk the distance across the province of British Columbia (940 km) over the course of the eight week intervention (Estabrooks et al., 2008), and encouraged to complete 150 minutes of moderate-to-vigorous exercise per week. Participants can record other moderate-to-vigorous exercise to contribute to the group goal. Running groups will be created on the fitness application Strava, and participants will record/post their runs on the Strava app so that members of their running group can provide 'kudos' and words of encouragement. Running groups will have a weekly a coffee chat (via Zoom) to socialize and discuss their experiences running/exercising and progress and challenges associated with meeting the group goal. Participants will also be provided running tip videos, phone armbands, and t-shirts with the study logo.
62604783|NCT04857918|ACTIVE_COMPARATOR|Attention control group|This group of participants will act as an attention control condition. This group will be asked to download the fitness application Strava to their smartphone, and track all of their runs and walks on Strava. Similar to the intervention group, participants will be provided with phone armbands to carry their phone during a run or walk so they can record the run or walk on Strava, and will be asked to try participating in 150 minutes of moderate-to-vigorous exercise per week.
62604784|NCT05021289|EXPERIMENTAL|Guided İmagery|• participants were given one session of guided imagery.
62604785|NCT05021289|NO_INTERVENTION|control group|No intervention was applied on the control group patients.
62604786|NCT02149316|EXPERIMENTAL|RIPC+RIPostC|
62604787|NCT02149316|SHAM_COMPARATOR|control|
62604788|NCT02749864||A: Age 20-34 yr|No intervention Cohort of subjects aged 20-34 years old.
62604789|NCT02749864||B: Age 35-49 yr|No intervention Cohort of subjects aged 35-49 years old.
62604790|NCT02749864||C: Age 50-79 yr|No intervention Cohort of subjects aged 50-79 years old.
62604791|NCT03657940|EXPERIMENTAL|Exercise intervention|multicomponent exercise training program \[VIVIFRAIL\],
62604792|NCT03657940|NO_INTERVENTION|Usual Care|Participants randomly assigned to the usual care group will receive normal outpatient care, which includes physical rehabilitation when needed.
62604793|NCT04220749|ACTIVE_COMPARATOR|Arm 1, Radiation +/- Chemotherapy|Standard Treatment (Radiation +/- Chemotherapy)
62827470|NCT04228523|OTHER|Speaking Therapy|One group receive speaking therapy already existing in Toulouse University Hospital
62827471|NCT03264677|EXPERIMENTAL|Group 1|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
62827472|NCT03264677|EXPERIMENTAL|Group 2|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
62247850|NCT00571233||1|Group one consists of children 1 month - 6 years old who have structurally normal hearts, no heart failure, and a patent ductus arteriosus (PDA).
62437954|NCT03154333|PLACEBO_COMPARATOR|vehicle ointment|vehicle ointment will be used for 8 weeks
62827473|NCT03264677|EXPERIMENTAL|Group 3|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
62045444|NCT00710138|ACTIVE_COMPARATOR|1|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma) given as a single intramuscular injection. The syringe is covered so it is impossible to see whether or not it contains any substance.
62045445|NCT00710138|SHAM_COMPARATOR|2|"The controls receive an intramuscular injection, however, it is only an introduction of the needle into the muscle, but no injections are given. The syringe is covered so it is impossible to see whether or not it contains any substance."
62045446|NCT05602636|ACTIVE_COMPARATOR|interscalene analgesia (Group ISBPB)|"All patients will receive a supraclavicular block as their primary anesthetic. Brachial plexus blocks will be performed at the supraclavicular fossa using 20 to 30 mL of 0.5% bupivacaine under ultrasound guidance.~The C5 to C7 or C5 to C8 nerve roots between the anterior scalene and middle scalene muscles will be visualized in the absence of the subclavian artery and 10 mL 0.125% bupivacaine will be injected around the nerve roots of the brachial plexus. The needle trajectory will be adjusted to facilitate the even distribution of the local anesthetic around each nerve root."
62247851|NCT00571233||2|Group two consists of children 1 month - 6 years old who have single ventricle physiology. Children with and without heart failure may participate.
62247852|NCT05696275|EXPERIMENTAL|exercise|combine walking and elastic band exercise
62604794|NCT04220749|EXPERIMENTAL|Arm 2, TOS + Neck Dissection|Trans-oral Surgery (TOS) + Neck Dissection (plus radiation is required)
62827474|NCT02761330|ACTIVE_COMPARATOR|Etomidate + ECT|General anesthesia for ECT will be induced with etomidate, approximately 0.2 mg/kg (0.1-0.6 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
62827475|NCT02761330|EXPERIMENTAL|Ketamine + ECT|General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
62827476|NCT02761330|SHAM_COMPARATOR|Ketamine alone|General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, no ECT charge will be administered.
62604795|NCT00567749||A, Observational|
62827477|NCT06413121|EXPERIMENTAL|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV for active immunization of infants, as a 3 dose regimen (6, 10 \& 14 weeks) for primary vaccination and booster dose at the age of 12-24 months.
62247853|NCT05696275|NO_INTERVENTION|usual care|as usual care
62247854|NCT02975193|ACTIVE_COMPARATOR|Control group|"Healthy adults ages 18-90 without movement disorders, psychiatric disorders, or dementia. They will complete computer games and questionnaires at one time point.~Specific interventions: Computer task assessing cognition, Impulsive-Compulsive Disorders in Parkinson's Disease, Montreal Cognitive Assessment"
62247855|NCT02975193|ACTIVE_COMPARATOR|Parkinson's disease group with DBS|"Parkinson's disease patients who have elected to receive DBS for treatment of their side effects of PD consent to complete computer games and questionnaires at baseline, computer games during deep brain stimulation, and computer games and questionnaires up to 2 years after surgery.~Specific interventions: Computer task assessing cognition, Impulsive-Compulsive Disorders in Parkinson's Disease, Montreal Cognitive Assessment"
62247856|NCT03404089|EXPERIMENTAL|pharmacokinetic device|MON4STRAT system
62247857|NCT06308432|EXPERIMENTAL|22 degrees, 40% humidity and 50% intensity|"The room in which the 30-minute test will be performed will be at 22 degrees Celsius and 40% humidity.~The subject should perform the test at 50% of the power at which he reached his VO2max."
62604796|NCT06618053||stapes surgery performed under local anesthesia|
62604797|NCT06618053||stapes surgery performed under general anesthesia|
62604798|NCT06501495|EXPERIMENTAL|young adults, older adults without cognitive deficits, prodromal Alzheimer's Disease|young adults, older adults without cognitive deficits, prodromal Alzheimer's Disease
62827478|NCT06413121|ACTIVE_COMPARATOR|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV for active immunization of infants, as a 3 dose regimen (6, 10 \& 14 weeks) for primary vaccination and booster dose at the age of 12-24 months.
62827479|NCT05371717|EXPERIMENTAL|Trial Group|Domiciliary use of Biorepair Total Protection + Biorepair Shock Treatment application
62827480|NCT05371717|ACTIVE_COMPARATOR|Control group|Domiciliary use of Biorepair Total Protection
62827481|NCT01036646||BSTE-0125-Original Protocol|
62604799|NCT06515392||TIA group|patients presenting with transient ischemic attack will be recorded and TIA scores and NIHSS score will be calculated, after 30 days follow-up, recurrent TIA and stroke rates will be determined
62604800|NCT00742508|EXPERIMENTAL|SK&F-105517-D group|SK\&F-105517-D 10-80 mg/day
62604801|NCT00742508|OTHER|Carvedilol-IR group|Carvedilol-IR 5-20 mg/day
62604802|NCT00888602|EXPERIMENTAL|MM1 - Meal|3.4g psyllium served with a meal
62604803|NCT00888602|EXPERIMENTAL|MM2 - Meal|6.8 g psyllium served with a meal
62604804|NCT00888602|EXPERIMENTAL|MM2 (no Meal)|6.8 g psyllium consumed with no meal
62827482|NCT01036646||BSTE-0125.a-Amended Protocol|
62827483|NCT00265993|EXPERIMENTAL|1|enoxaparin
62604805|NCT00888602|SHAM_COMPARATOR|Meal Only|meal only
62604806|NCT00598611|ACTIVE_COMPARATOR|1|desloratadine 20 mg
62604807|NCT00598611|ACTIVE_COMPARATOR|2|desloratadine 20 mg
62604808|NCT02071082|EXPERIMENTAL|HIV treatment-naive and HBV treatment-naive|HIV/HBV coinfected participants who are HIV treatment-naive and HBV treatment-naive will receive E/C/F/TAF for 48 weeks.
62604809|NCT02071082|EXPERIMENTAL|HIV-suppressed|HIV/HBV coinfected participants who are HIV-suppressed will receive E/C/F/TAF for 48 weeks.
62604810|NCT03863327||Acute Coronary Occlusion or near-occlusion (TIMI 0-1)|a. Acute occlusion proven on angiogram (an acute culprit lesion with TIMI 0-1 flow, or description of acute total thrombotic occlusion) b. Acute culprit lesion (any TIMI score) with Peak cTNI \> 10 ng/mL or cTnT \> 1.0 ng/mL c. If no catheterization performed (contraindicated, not compatible with goals of care, etc), then highly elevated troponin as above plus a new/presumed new focal wall motion abnormality on echocardiography d. Positive ECG findings (by any criteria) with death occurring before attempted emergent coronary angiography and autopsy confirming ACO. For cases with positive ECG findings and death before cath but NO autopsy, these will be marked and saved in a separate group, not to be used in the primary analysis.
62827484|NCT04412512|EXPERIMENTAL|VATS approach|patients treated by VATS technique.
62827485|NCT04412512|ACTIVE_COMPARATOR|Thoracotomy approach|patients treated by Thoracotomy technique
62827486|NCT06603337||Retrospective cohort|Patients treated with IBD from January 2015 to June 2024 will be included
62827487|NCT06603337||Prospective cohort|"Consecutive patients with IBD who are starting, from clinical practice, new biologic/small molecule therapies, failure (already exposed) to a mechanism of action (for anti TNF-alpha, multiple molecules are allowed), and who belong to the Lazio Regional Health System will be enrolled."
62827488|NCT06189521|ACTIVE_COMPARATOR|Extracorporeal shock wave group|"Patients were randomized into three groups by a physiotherapist with sealed envelopes. The researchers were blinded to the patient's groups. The same physiotherapy program was applied to all groups. The physiotherapy program consisted of hot packs and TENS for 10 minutes and stretching and eccentric strengthening exercises were given to all groups. All exercises were done under the supervision of the same physiotherapist.~In addition to the ten-day of physiotherapy program, in the first group one day for a week a total of 3 sessions of ESWT was applied at 1.8 bar, 10.0 Hz, 2000 beats (Elmed Vibrolith Ortho)."
62827489|NCT06189521|ACTIVE_COMPARATOR|ultrasound group|In addition to the ten-day of physiotherapy program, in the second group, ten days of ultrasound applied at 1.5 watt/cm2, continuous mode to the painful area for 5 minutes, 5 days a week for two weeks (Chattanooga Intelect Advanced).
62827490|NCT06189521|ACTIVE_COMPARATOR|dexamethasone iontophoresis group|In addition to the ten-day of physiotherapy program, in the third group ten days of dexamethasone iontophoresis therapy was applied. 10 days for 10 minutes. 0,1% dexamethasone ophthalmic pomade was applied to the anodal electrode and placed on the lateral epicondyle and 0.1-0.2 milliampere/cm2 galvanic current was applied in each session (ES-522; ITO Physiotherapy and Rehabilitation).
62827491|NCT01074502|EXPERIMENTAL|apremilast|apremilast 20 mgs twice a day for 12 weeks
62045447|NCT05602636|ACTIVE_COMPARATOR|The intercostobrachial nerve block ( Group ICBN)|"All patients will receive a supraclavicular block as their primary anesthetic. Brachial plexus blocks will be performed at the supraclavicular fossa using 20 to 30 mL of 0.5% bupivacaine under ultrasound guidance.~The ICBN block will be performed with 10 mL of 0.5% bupivacaine in the plane deep to the pectoralis minor and/or serratus anterior muscle over the second and third intercostal space."
62827492|NCT05580653|EXPERIMENTAL|1) Beef then half beef and half pinto bean then pinto bean|
62827493|NCT05580653|EXPERIMENTAL|2) Half pinto bean and half beef then pinto bean then beef|
62045448|NCT05602636|ACTIVE_COMPARATOR|Patient-Controlled Analgesia (Group PCA)|All patients will receive a supraclavicular block as their primary anesthetic. Brachial plexus blocks will be performed at the supraclavicular fossa using 20 to 30 mL of 0.5% bupivacaine under ultrasound guidance.
62045449|NCT02606903|EXPERIMENTAL|BI 695501 prefilled syringe|
62045450|NCT02606903|EXPERIMENTAL|BI 695501 autoinjector|
62045451|NCT01592370|EXPERIMENTAL|Nivolumab monotherapy (Dose Escalation)|"Nivolumab solution intravenously as specified~Non-randomized~Enrollment is closed for this cohort"
62045452|NCT01592370|EXPERIMENTAL|Nivolumab + Ipilimumab|"Nivolumab and Ipilimumab solution intravenously as specified~Non-randomized~Enrollment is closed for this cohort"
62045453|NCT01592370|EXPERIMENTAL|Nivolumab + Lirilumab|"Non-randomized~Nivolumab: 3 mg/kg given every 2 weeks Lirilumab: 3 mg/kg given every 4 weeks~Enrollment is closed for this cohort"
62045454|NCT01592370|EXPERIMENTAL|Nivo + Dara + Pom + Dexa vs. Nivo + Dara|"Randomized~Nivolumab:~Cycle 1: 240 mg Day 15 Cycle 2-6: 240 mg Days 1, 15 Cycle 7 \& beyond: 480 mg Day 1~Daratumumab:~Cycle 1-2: 16 mg/kg Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg Days 1, 15 Cycle 7 \& beyond: 16 mg/kg Day 1~Pomalidomide:~4 mg po (by mouth) daily on Days 1 - 21 of each 28-day cycle~Dexamethasone:~Weeks without daratumumab dosing:~* 40 mg po daily (Days 1, 8, 15, 22) of each 28-day cycle for participants ≤ 75 years old~* 20 mg po daily (Days 1, 8, 15, 22) of each 28-day cycle for participants \> 75 years old~Weeks with daratumumab dosing:~* 20 mg iv before the daratumumab infusion and 20 mg po after the daratumumab infusion in participants ≤ 75 years old~* 16 mg iv before the daratumumab infusion and 4 mg po after the daratumumab infusion in participants \> 75 years old~Enrollment is closed for this cohort"
62045455|NCT01592370|EXPERIMENTAL|Daratumumab vs. Nivolumab + Daratumumab|"Randomized~Nivolumab:~Cycle 1: 240 mg Day 15 Cycle 2 \& beyond: 480 mg Day 1~Daratumumab:~Cycle 1-2: 16 mg/kg Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg Days 1, 15 Cycle 7 \& beyond: 16 mg/kg Day 1"
62045456|NCT02115880|EXPERIMENTAL|Prevention programme|
62045457|NCT02115880|NO_INTERVENTION|Control (treatment as usual)|
62045458|NCT00033358|EXPERIMENTAL|Arm I (medroxyprogesterone)|Patients receive medroxyprogesterone intramuscularly once on day 1. Approximately 90 days after the injection, patients undergo a repeat transvaginal ultrasound and endometrial biopsy.
62247858|NCT06308432|EXPERIMENTAL|35 degrees, 40% humidity and 50% intensity|"The room in which the 30-minute test will be performed will be at 35 degrees Celsius and 40% humidity.~The subject should perform the test at 50% of the power at which he reached his VO2max."
62247859|NCT06308432|EXPERIMENTAL|35 degrees, 65% humidity and 50% intensity|"The room in which the 30-minute test will be performed will be at 35 degrees Celsius and 65% humidity.~The subject should perform the test at 50% of the power at which he reached his VO2max."
62827494|NCT05580653|EXPERIMENTAL|3) Pinto Bean then Beef then half pinto bean and half beef|
62827495|NCT05580653|EXPERIMENTAL|4) Egg then half Egg and half black bean then black bean|
62827496|NCT05580653|EXPERIMENTAL|5) Half egg and half black bean, then black bean then egg|
62827497|NCT05580653|EXPERIMENTAL|6) Black bean then egg then half black bean and half egg|
62827498|NCT02629718|EXPERIMENTAL|A(NACT)|Neoadjuvant Chemotherapy followed by Radical Surgery
62827499|NCT02629718|ACTIVE_COMPARATOR|B(RS)|Radical Surgery alone
62827500|NCT05318313||Telerehabilitation only|Participants choose to have all of their physical therapy provided virtually throughout the length of the study
62827501|NCT05318313||In-person only|Participants choose to have all of their physical therapy provided in-person throughout the length of the study
62247860|NCT06308432|EXPERIMENTAL|22 degrees, 40% humidity and 60% intensity|"The room in which the 30-minute test will be performed will be at 22 degrees Celsius and 40% humidity.~The subject should perform the test at 60% of the power at which he reached his VO2max."
62827502|NCT05318313||Hybrid 1|The TR PT evaluation and follow-up visits in the initial 6 weeks will be performed via Zoom software and subsequent follow-up visits will switch to in person after 6 weeks
62827503|NCT05318313||Hybrid 2|The PT evaluation and follow-up visits in the initial 6 weeks will be performed in person and will switch to TR via Zoom software after 6 weeks
62827504|NCT06051890|EXPERIMENTAL|Transition to Extended-Release Buprenorphine (XRB)|Participants randomized to transition to treatment with XRB.
62827505|NCT06051890|ACTIVE_COMPARATOR|Sublingual Buprenorphine (SLB) Maintenance|Participants randomized to remain on-treatment with SLB.
62827506|NCT05815147|EXPERIMENTAL|Study Group|Participants will be asked to take study product.
62827507|NCT04006587|EXPERIMENTAL|IS intervention|patients were instructed how to use the IS in a seated or semi-seated position, and to maintain sustained maximal inspiration for 3-5 seconds before exhalation, ten times per hour, and for at least eight hours a day.
62827508|NCT04006587|NO_INTERVENTION|control|standard care without IS intervention
62827509|NCT02418169||retrospective, severe traumatic brain injury|All patients in 2010-2014 with severe traumatic brain injury admitted to Turku University Central Hospital (TUCH)
62827510|NCT02418169||retrospective, craniofacial fracture|All patients in 2010-2014 with craniofacial fracture admitted to TUCH.
62827511|NCT02418169||prospective, severe traumatic brain injury|All patients in 2015-2017 with severe traumatic brain injury admitted to Turku University Central Hospital (TUCH)
62827512|NCT02418169||prospective, craniofacial fracture|All patients in 2015-2017 with craniofacial fracture admitted to TUCH.
62827513|NCT05897658|EXPERIMENTAL|Seizure Prophylaxis (Levetiracetam)|Levetiracetam 1 g taken orally twice a day for 7 days
62827514|NCT05897658|PLACEBO_COMPARATOR|Placebo|Placebo taken orally twice a day for 7 days
62045459|NCT00033358|EXPERIMENTAL|Arm II (ethinyl estradiol, norgestrel)|Patients receive OCP comprising ethinyl estradiol and norgestrel once daily on days 1-21. Treatment repeats every 28 days for 3-4 courses (3-4 packs of OCP) in the absence of unacceptable toxicity. Approximately 1 week after starting the fourth pack of OCP, patients undergo a repeat transvaginal ultrasound and endometrial biopsy.
62045460|NCT04304664|EXPERIMENTAL|Mindfulness- Based Intervention (MBI)|In MBI arm, patients received mindfulness- based intervention, a psychological mind- body intervention, focusing on stress reduction,. the intervention was led by a licensed clinical therapist and mindfulness specialist, who was trained in MBSR at Bangor University.
62247861|NCT06308432|EXPERIMENTAL|35 degrees, 40% humidity and 60% intensity|"The room in which the 30-minute test will be performed will be at 35 degrees Celsius and 40% humidity.~The subject should perform the test at 60% of the power at which he reached his VO2max."
62247862|NCT06308432|EXPERIMENTAL|35 degrees, 65% humidity and 60% intensity|"The room in which the 30-minute test will be performed will be at 35 degrees Celsius and 65% humidity.~The subject should perform the test at 60% of the power at which he reached his VO2max."
62437955|NCT05378087|ACTIVE_COMPARATOR|Image staging group|Standard chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
62247863|NCT05543278|EXPERIMENTAL|Amiodarone Arm|In addition to the regular care provided to cardiac surgery patients, those in the Amiodarone Arm will also receive the amiodarone regimen.
62623445|NCT06045611|EXPERIMENTAL|Placebo/Isolated Faba Bean Protein/Isolated Whey Protein/Isolated Pea Protein|"* Study day 1: 400 ml water~* Study day 2: 0.6g isolated faba bean protein/kg/body weight + 400 ml water~* Study day 3: 0.6g isolated whey protein/kg/body weight + 400 ml water~* Study day 4: 0.6g isolated pea protein/kg/body weight + 400 ml water~The fat and energy content of the drinks will be adapted using a plant based oil"
62623446|NCT02950922|EXPERIMENTAL|RVT-501 0.2% ointment|RVT-501 0.2% ointment BID x 28 days (30 adults, 20 adolescents)
62045461|NCT04304664|NO_INTERVENTION|Wait- List Controls (WL)|Patients in wait- list control arm received no active treatment during their 10-weeks waiting period. At the end of that period received the exact intervention as the study group.
62247864|NCT05543278|NO_INTERVENTION|Standard of Care Arm|Patients randomized to the Standard of Care Arm will receive the regular care provided to cardiac surgery patients.
62247865|NCT03244748||Group 1|Patients underwent ablation and continued having amiodarone after the procedure
62247866|NCT03244748||Group 2|Patients underwent ablation and not having amiodarone after the procedure
62247867|NCT04597957|EXPERIMENTAL|Fresh Rx Intervention group|The Fresh Rx intervention group will receive up to 8 visits to the community based farmers market with $10 incentive for fruits and vegetables at each visit.
62247868|NCT04597957|ACTIVE_COMPARATOR|Diabetic Standard of Care Control group|Diabetic standard of care control group will receive no incentive for the community based farmers market.
62247869|NCT02556125||Cervical SCI|Participants with acute, traumatic cervical spinal cord injuries (C-SCIs), classified according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) as A-C (complete SCI (A); motor complete SCI (B); motor incomplete with minimal motor function (C)), affecting C1-C6 spinal cord segments, and who have been scheduled to undergo implantation of a diaphragm pacer, or who have recently received (in past 5-days) implantation of intramuscular diaphragm pacing electrodes due to severe respiratory impairments and dependence on mechanical ventilation.
62247870|NCT01789762|ACTIVE_COMPARATOR|Historical control arm|Patients transfused with platelet concentrates re-suspended in autologous plasma
62247871|NCT01789762|ACTIVE_COMPARATOR|Control arm|Patients transfused with platelets prepared in additive solution
62437956|NCT05378087|EXPERIMENTAL|Surgery staging group|Open/minimally invasive para-aortic lymph node dissection followed by chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
62437957|NCT02807766|EXPERIMENTAL|Sensory Integration Training|Behavior modification and Sensory Integration Training
62437958|NCT02807766|EXPERIMENTAL|applied behavioral analysis|Behavior modification and applied behavioral analysis.
62437959|NCT02807766|EXPERIMENTAL|TEACCH|Behavior modification and TEACCH.
62437960|NCT02807766|OTHER|Behavior modification|Behavior modification.
62437961|NCT02807766|NO_INTERVENTION|healthy control group|No intervention.
62827515|NCT00842114|EXPERIMENTAL|R+CVP+IFN|8 cycles of Rituximab plus CVP chemotherapy (Bagley's et al) associated with Interferon for 12 weeks
62827516|NCT05459363|EXPERIMENTAL|Varsity Athletes|Healthy adults recruited from the University of Kentucky varsity tennis programs.
62827517|NCT05321901|ACTIVE_COMPARATOR|Experimental Group: Telerehabilitation assisted exercise program|"The telerehabilitation-assisted exercise program included a Biopsychosocial Exercise Therapy approach (BETY).~The approaches that make up the BETY innovation are grouped under 4 headings: Patient education on chronic pain, functional body stabilization exercises (mind-body information management), dance therapy-authentic movement (emotion-state information management), and sexual information management.~Tele-rehabilitation group participated in the sessions that lasted for one and a half hours, 3 days a week for 8 weeks, over the Whatsapp group.~The investigators, who provided supervision during the sessions, also participated in the exercises simultaneously."
62045462|NCT04230044||Fycompa® (perampanel)|Fycompa® (perampanel) (oral tablets) treatment will be initiated at 2 milligram (mg) once daily according to the approved package insert, as an add-on drug in addition to other anti-epileptic drugs (AEDs) as prescribed by physician. The dose will be increased based on clinical response and tolerability (by increments of 2 mg/day to a maintenance dose of 4 to 12 mg/day) and participants will be enrolled and observed prospectively for up to 54 Weeks.
62045463|NCT01785680|ACTIVE_COMPARATOR|Current protocol|These treatment arm is the standard care for moderate malnutrition. This includes a fortified cereal supplement treatment until the child reaches MUAC of above 12.5. Currently, MAM and SAM are treated separately, overseen by different agencies. Breastfeeding is often overlooked.
62045464|NCT01785680|EXPERIMENTAL|Integrated Protocol|Integrated protocol for treatment of children with MAM and SAM in humanitarian emergencies has the potential to result in a more streamlined, cost-effective program, higher recovery, and higher program coverage, allowing easier access to malnourished children, thus curing more children of malnutrition and preventing its lifelong effects.
62045465|NCT02077166|EXPERIMENTAL|Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)|Ibrutinib 560 mg administered orally (PO) once daily (QD) beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered intravenously (IV) on Day 1 of each 28-day cycle for 6 cycles.
62247872|NCT01789762|EXPERIMENTAL|Experimental arm|Patients transfused with platelets treated by pathogen reduction process
62247873|NCT00732251|EXPERIMENTAL|Allopurinol|Using an open label, naturalistic design, subjects will continue with their current psychiatric medications during the study. Allopurinol will be given at a fixed dose of 300 mg/day for the first week and then 600mg/d for the remainder of the study. Subjects who cannot tolerate the 600mg dose will be given a dose of 300mg/d. Subjects will participate in monthly follow up visits for 24 months. Subjects who develop a substance abuse or substance dependence disorder during the study will be terminated from the study. Also, subjects who develop a medical condition which can affect their mood stability will be terminated from the study.
62247874|NCT00247741|ACTIVE_COMPARATOR|lidocaine|
62247875|NCT00247741|EXPERIMENTAL|articaine|
62247876|NCT06325618||Turner Syndrome|Women with karyotype verified Turner Syndrome n=100
62827518|NCT05321901|OTHER|Control Group|The control group participants were those who did not want to receive exercise treatment with telerehabilitation and took their routine medications during the 8 weeks period.
62827519|NCT03871777|ACTIVE_COMPARATOR|Vegetarians|Healthy vegetarians (vegans and lacto-ovo vegetarians) 18 and 50 years formed this arm.
62827520|NCT03871777|SHAM_COMPARATOR|Omnivores|Healthy omnivores with similar characteristics of vegetarians (age, body mass index, gender and physical activity levels) formed this arm
62827521|NCT03398317|EXPERIMENTAL|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection
62247877|NCT06325618||Female controls|Healthy, age-matched controls n=50
62437962|NCT04756141|EXPERIMENTAL|CGM Use|Determine CGM accuracy when compared with POC (point of care) glucometers.
62827522|NCT03398317|ACTIVE_COMPARATOR|MACS|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with annexin V microbeads followed by separation on MACS Column, the eluted fraction contains non apoptotic sperm suitable for Oocyte injection.
62827523|NCT03292926|ACTIVE_COMPARATOR|Adductor Canal Block (ACB)|The adductor canal block will be ultrasound-guided sonosite. The anesthesiologist will administer 15 cc bupivacaine 0.5% with 2 mg preservative-free dexamethasone with a 22 gauge (G)/4 inch Chiba needle to the mid-thigh of the surgical limb while subject lays in the supine position post IV sedation.
62604811|NCT03863327||Acute Coronary Occlusion or near-occlusion (TIMI 0-2)|a. Acute occlusion proven on angiogram (an acute culprit lesion with TIMI 0-2 flow, or description of acute total thrombotic occlusion) b. Acute culprit lesion (any TIMI score) with Peak cTNI \> 10 ng/mL or cTnT \> 1.0 ng/mL c. If no catheterization performed (contraindicated, not compatible with goals of care, etc), then highly elevated troponin as above plus a new/presumed new focal wall motion abnormality on echocardiography d. Positive ECG findings (by any criteria) with death occurring before attempted emergent coronary angiography and autopsy confirming ACO. For cases with positive ECG findings and death before cath but NO autopsy, these will be marked and saved in a separate group, not to be used in the primary analysis.
62623447|NCT02950922|EXPERIMENTAL|RVT-501 0.5% ointment|RVT-501 0.5% ointment BID x 28 days (30 adults, 20 adolescents)
62045466|NCT02077166|EXPERIMENTAL|Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)|De-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 10 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
62827524|NCT03292926|ACTIVE_COMPARATOR|Adductor Canal Block & IPACK (ACB/IPACK)|"The adductor canal block will be ultrasound-guided. The anesthesiologist will administer 15 cc bupivacaine 0.5% with 2 mg preservative-free dexamethasone with a 22G/4 inch Chiba needle to the mid-thigh of the surgical limb while subject lays in the supine position post IV sedation.~The IPACK will be ultrasound-guided with c60 sonosite probe (5-2Hz). While laying in the prone or supine, frog-leg position the IPACK will be administered using a 22G/4inch Chiba needle. The anesthesiologist will identify the popliteal artery at the popliteal crease and move cephalad just beyond the femoral condyles at the confluence with the femur. Then the anesthesiologist will identify the space between the femur and the popliteal artery and moving from medial to lateral place the needle in between the popliteal artery and femur with the tip ending 2-3 cm lateral to the artery and inject 25 cc bupivacaine 0.25% with 2 mg preservative-free dexamethasone."
62045467|NCT02077166|EXPERIMENTAL|Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)|Re-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
62045468|NCT02077166|EXPERIMENTAL|Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)|Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
62045469|NCT02077166|EXPERIMENTAL|Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)|Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
62827525|NCT03817216|EXPERIMENTAL|Prostatic Urethral Lift (PUL) post-EBRT|Prostatic Urethral Lift (PUL) following External Beam Radiotherapy (EBRT)
62045470|NCT02077166|EXPERIMENTAL|Phase 2: Enrolled at Lenalidomide Dose 20 mg|Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
62045471|NCT02077166|EXPERIMENTAL|Phase 2: Enrolled at Lenalidomide Dose 25 mg|Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
62045472|NCT02863679|EXPERIMENTAL|Tetracaine hydrochloride gel group|Patients in getracaine hydrochloride gel group were covered with a gauze with tetracaine hydrochloride gel on the cervix after hysteroscopic insertion of utrauterine balloon stent.
62045473|NCT02863679|PLACEBO_COMPARATOR|Control group|Patients in control group were covered with a gauze with saline on the cervix after hysteroscopic insertion of utrauterine balloon stent.
62045474|NCT05327881||Septic shock patients|"Adult patients on vasopressors for greater than 6 hours to maintain a mean arterial pressure greater than or equal to 65 mm Hg. Inclusion criteria: age over 18, urinary catheter in situ, anticipated stay \>24 hours, and signed informed consent by patient or next-of-kin.~Septic shock was defined as persistent hypotension (defined as the need for vasopressors to maintain mean arterial pressure ≥ 65 mm Hg, and a serum lactate level \> 18 mg/dL \[2 mmol/L\] despite adequate volume resuscitation"
62045475|NCT04274673|OTHER|low (less 10ng/dl)|Patients who have low cotinine levels (less 10ng/dl)
62045476|NCT04274673|OTHER|medium (10-500ng/dl)|Patients who have medium cotinine levels (less 10-500ng/dl)
62045477|NCT04274673|OTHER|high (more 500ng/dl)|Patients who have high cotinine levels (less 10-500ng/dl)
62045478|NCT04209075|EXPERIMENTAL|Placebo then Prebiotic|Participant will take Placebo during Period 1 and Prebiotic during Period 2
62045479|NCT04209075|EXPERIMENTAL|Prebiotic then Placebo|Participant will take Prebiotic during Period 1 and Placebo during Period 2
62827526|NCT03817216|EXPERIMENTAL|Prostatic Urethral Lift (PUL) pre-BT|Prostatic Urethral Lift (PUL) preceding Brachytherapy (BT)
62045480|NCT04833764|EXPERIMENTAL|Rosuvastatin|Subjects will receive 20 mg daily dose of rosuvastatin for at least 3 months
62045481|NCT06265545|EXPERIMENTAL|Arm 1|"With IDH1 gene mutation(up to 2 cycles available):IVA :~Ivosidenib 500mg d1-28 Azacitidine 75mg/m2/d d1-7 Venetoclax100mg d1,200mg d2,400mg d3-21 400mg ;d22-28(If the proportion of 21st bone marrow blasts is greater than 5%)"
62827527|NCT03817216|ACTIVE_COMPARATOR|Prostatic Urethral Lift (PUL) post-BT|Prostatic Urethral Lift (PUL) following Brachytherapy (BT)
62827528|NCT01723982|EXPERIMENTAL|A. FE 200440|Barusiban (FE 200440) Solution for Injection for Subcutaneous use
62827529|NCT01723982|PLACEBO_COMPARATOR|B. Placebo|Placebo Solution for Injection for Subcutaneous use
62045482|NCT06265545|EXPERIMENTAL|Arm 2|"FLT3/ITD or FLT3/TKD gene mutation (up to 2 cycles available)~GV :~Gilteritinib 120mg, d1-28 Venetoclax 100mg d1, 200mg d2, 400mg d3-21 400mg d22-28 (if the proportion of 21st bone marrow blasts are greater than 5%)"
62045483|NCT06265545|EXPERIMENTAL|Arm 3|For R/R AML patients without IDH1 or FLT3 mutations who have not been exposed to Venecra in the last 3 months, the investigators will determine whether they are fit patients based on physical status and comorbidivities, and if they are, they can be randomly assigned to Arm3 or Arm4 DAV/IAV/MAV Cytarabine 100mg/m2/d, d1-5 Daunorubicin 60mg/m2/d, d1-2, or Idarubicin 12mg/m2/d, d1-2, or mitoxantrone 8mg/m2/d d1-2 Venetoclax 100mg d3, 200mg d4, 400mg d5-11;
62045484|NCT06265545|EXPERIMENTAL|Arm 4|"HAV :~Cytarabine 100mg/m2/d, d1-5 Homoharringtonine 2mg/m2 d1-5 Venetoclax 100mg d3, 200mg d4, 400mg d5-11"
62449235|NCT01430741|EXPERIMENTAL|Getting to Outcomes Veterans|Getting To Outcomes (GTO) is used to strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. In GTO, staff receive ongoing technical assistance using the GTO implementation platform, that guides staff while delivering MISSION to Veterans.
62449236|NCT03401905|EXPERIMENTAL|Low frequency|Percutaneous electrical nerve stimulation with frequency of 2 Hz and 120 microseconds of pulse width will be applied.
62827530|NCT05650736|EXPERIMENTAL|Abrocitinib 200 mg daily|6 months of treatment with abrocitinib 200 mg daily
62827531|NCT01871012||non-diabetes mellitus group|Subjects undergoing Total Knee Replacement are not diagnosed with diabetes mellitus.
62045485|NCT06265545|EXPERIMENTAL|Arm 5|"A patient with R/R AML without IDH1 or FLT3 mutation who has not been exposed to Venetoclax in the last 3 months but who is judged by the investigators to be unfit based on physical fitness and comorbidivities is unfit to enter Arm5.~Arm5: (up to 4 cycles available)~VA :~Azacytidine 75mg/m2/d d1-7 Venetoclax 100mg d1, 200mg d2, 400mg d3-21 400mg d22-28 (if the proportion of 21st bone marrow blasts are greater than 5%)"
62045486|NCT06265545|EXPERIMENTAL|Arm 6|"Patients with R/R AML without IDH1 or FLT3 mutations who have been exposed to Vinecra within the last 3 months may be enrolled in the exploratory protocol group based on a comprehensive assessment of local drug availability and patient status:~Arm6:~The Investigator's choice (IC) option involves a range of drugs such as clatabine, PI3K inhibitors, histone deacetylase inhibitors, celinisol, and novel liposomes."
62045487|NCT06265545|EXPERIMENTAL|Arm 7|According to the patient's condition and physical condition, evaluate whether there is a suitable new drug clinical trial to be enrolled. If there is, enter the Arm 7 (new drug clinical trial).
62045488|NCT01492023||control|control group: no intervention
62045489|NCT01492023||neuropsychological rehabilitation|intervention group: neuropsychological rehabilitation (13 times 60 minutes, once per week, during 13 weeks) control group: no intervention
62623448|NCT02950922|PLACEBO_COMPARATOR|Vehicle ointment|Vehicle ointment BID x 28 days (30 adults, 20 adolescents)
62623449|NCT03928275|EXPERIMENTAL|Intralesional IL-2 Treatment|CMM patients will received 4 treatments of intralesional Interleukin-2 two weeks apart over an eight week period.
62045490|NCT01846793|EXPERIMENTAL|Open Label Injection of NX-1207|Intraprostatic injection of 2.5 mg NX-1207
62045491|NCT03716609|EXPERIMENTAL|Magnesium supplement group|Subjects receive citrate acid drinks with additional magnesium citrate (300mg magnesium)
62045492|NCT03716609|PLACEBO_COMPARATOR|placebo group|Subjects receive citrate acid drinks without additional magnesium
62045493|NCT01437748|EXPERIMENTAL|Indacaterol maleate|Indacaterol 300 mcg via Breezehaler Inhaler will be administered by a third independent investigator not involved in the performing of any of the tests decribed, following a randomization list
62045494|NCT01437748|ACTIVE_COMPARATOR|Tiotropium bromide|Tiotropium 18 mcg, via HandiHaler inhaler will be administered by a third independent investigator not involved in the performing of any of the tests decribed, following a randomization list
62045495|NCT01951625|EXPERIMENTAL|Vericiguat (BAY1021189) (10 mg)|2.5 mg orally once daily for 2 weeks, up-titration to 5 mg orally once daily for 2 weeks, up-titration to 10 mg orally once daily for 8 weeks
62247878|NCT02408107|EXPERIMENTAL|Physical activity intervention|Received a 30 min physical activity counselling session which employed motivational interviewing to encourage the adoption of current recommended physical activity guidelines. This arm also received 3 support phone calls (1 at the end of months 1, 2 and 3) and a physical activity reminder postcard on months 4 and 5.
62247879|NCT02408107|NO_INTERVENTION|Usual care|This arm received usual care (i.e. no physical activity counselling, support phone calls or post-cards).
62045496|NCT01951625|EXPERIMENTAL|Vericiguat (BAY1021189) (5 mg)|2.5 mg orally once daily for 2 weeks, then 5 mg orally once daily for 10 weeks (with sham titration)
62045497|NCT01951625|EXPERIMENTAL|Vericiguat (BAY1021189) (2.5 mg)|2.5 mg orally once daily for 12 weeks (with sham titrations)
62045498|NCT01951625|EXPERIMENTAL|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg orally once daily for 12 weeks (with sham titrations)
62045499|NCT01951625|PLACEBO_COMPARATOR|Placebo|Orally once daily for 12 weeks (with sham titrations)
62045500|NCT02118129|EXPERIMENTAL|Behavioural intervention|Behavioural intervention consisting of an educational video component and use of a handheld mobile app to track vitamin D intake.
62045501|NCT02118129|PLACEBO_COMPARATOR|Control group|Wait-list control group
62247880|NCT01946451||Idiophatic ERMs|
62247881|NCT01946451||Secondary ERMs|
62247882|NCT04769050||First-line patients|First-line treatment of HER2-positive metastatic breast cancer patients
62247883|NCT04769050||Second-line patients|Second-line treatment of HER2-positive metastatic breast cancer patients
62247884|NCT03706495|EXPERIMENTAL|The Group I|The Group I Postural exercise will receive postural exercise for 60 min/day 2 times/week for 8 weeks.
62449237|NCT03401905|ACTIVE_COMPARATOR|High frequency|Percutaneous electrical nerve stimulation with frequency of 120 Hz and 200 microseconds of pulse width will be applied.
62449238|NCT05412732||group A low risk of infection|
62449239|NCT05412732||group B high risk of infection|
62449240|NCT02806232|EXPERIMENTAL|Part 1, Cohort 1: Biltricide (racemate praziquantel) 20 mg/kg|Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.
62449241|NCT02806232|EXPERIMENTAL|Part 1, Cohort 2: Biltricide (racemate praziquantel) 40 mg/kg|Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
62449242|NCT02806232|EXPERIMENTAL|Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg|Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
62827532|NCT01871012||diabetes mellitus group|subjects have been diagnosed diabetes mellitus mora than three years without serious nerve system complications.
62045502|NCT02245932|EXPERIMENTAL|Resveratrol supplementation|150 mg of resveratrol for 4 weeks (split over two doses of 75 mg/day)
62827533|NCT04404413|EXPERIMENTAL|PARTICIPANTS|A single-group crossover design was used to compare the effects of 2x8 weeks of high-intensity interval training without (HIIT) or with (HIIT+IF) intermittent fasting caloric restriction (20% reduction in weekly energy intake) on body composition and performance. There were two weeks in the middle of both phases in which they did not carry out programmed activity, in order not to alter the experimental phase.
62827534|NCT03836313|EXPERIMENTAL|cryoneurolysis treatment|TKA patients randomized to receive preoperative rehabilitation and cryoneurolysis treatment with the iovera° device (n=70)
62045503|NCT02245932|PLACEBO_COMPARATOR|Placebo supplementation|Placebo for 4 weeks (split over two doses per day)
62045504|NCT04120233|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62045505|NCT04120233|EXPERIMENTAL|Dose 1|Participants will receive 10 mg of MW151.
62045506|NCT04120233|EXPERIMENTAL|Dose 2|Participants will receive 20mg of MW151.
62045507|NCT04120233|EXPERIMENTAL|Dose 3|Participants will receive 40mg of MW151.
62045508|NCT04120233|EXPERIMENTAL|Dose 4|Participants will receive 80mg of MW151.
62045509|NCT04120233|EXPERIMENTAL|Dose 5|Participants will receive 160mg of MW151.
62045510|NCT00500903|EXPERIMENTAL|PIC Dose Escalation|Alisertib 5, 10, 20, 40, 80, 110 or 150 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 7 to 21 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 51 cycles).
62045511|NCT00500903|EXPERIMENTAL|ECT Dose Escalation|Alisertib 10 or 20 mg, Enteric-coated Tablet (ECT) formulation, orally, once daily (QD) for 7 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 2 cycles).
62045512|NCT00500903|EXPERIMENTAL|Relative Bioavailability|Alisertib 40 mg ECT or PIC formulation, orally, twice daily (BID) for 7 days followed by a 14--day recovery period in cycle 1, followed by alisertib 40 mg in the opposite formulation (PIC or ECT) orally, twice daily (BID) for 7 days followed by a 14--day recovery period in cycle 2, followed by alisertib 50 mg PIC formulation orally, twice daily (BID) for 7 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 9 cycles).
62045513|NCT04455789|EXPERIMENTAL|conventional mechanical ventilation|routine mechanical ventilation will be adjusted based on conventional mechanical ventilation settings with tidal volume of 8 ml/kg and PEEP level of 5
62045514|NCT04455789|EXPERIMENTAL|mechanical ventilation adjusted according to driving pressure|routine mechanical ventilation adjusted based on driving pressure during lateral position. After patients are put to lateral position incremental increase in PEEP will be applied and the driving pressures will be recorded for each PEEP level and the patients will be ventilated with this PEEP during anesthesia. the other setting will be same with conventional group. tidal volume of 8 ml/kg
62045515|NCT01189279|EXPERIMENTAL|Part 1: bimatoprost Formulation A|bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
62045516|NCT01189279|EXPERIMENTAL|Part 1: bimatoprost Formulation B|bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
62045517|NCT01189279|EXPERIMENTAL|Part 2: bimatoprost Formulation C|bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
62045518|NCT03548298|EXPERIMENTAL|GERD without hiatal hernia|Participants with GERD without hernia hiatal will receive ARAT
62045519|NCT02341001|NO_INTERVENTION|Standard care|Patients are discharged from the bariatric service at 18 months after surgery.
62045520|NCT02341001|EXPERIMENTAL|Standard care with text message support|Patients are discharged from the bariatric service at 18 months after surgery but receive a daily text message for one year.
62045521|NCT04570436|EXPERIMENTAL|gabapentin 600 mg|single dose
62045522|NCT04570436|ACTIVE_COMPARATOR|diazepam 20 mg|single dose
62045523|NCT04570436|PLACEBO_COMPARATOR|placebo|single dose
62045524|NCT04570436|EXPERIMENTAL|gabapentin 1200 mg|single dose
62045525|NCT04570436|EXPERIMENTAL|gabapentin 1800 mg|single dose
62045526|NCT00479245|OTHER|1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
62045527|NCT04719689|EXPERIMENTAL|Dry needling|Dry needling, hot pack, stretching exercises.
62045528|NCT04719689|EXPERIMENTAL|Dry Cupping|Dry cupping, hot pack, stretching exercises.
62045529|NCT05445648|EXPERIMENTAL|patients treated with immunotherapy-based bladder preservation therapy|Neoadjuvant immunotherapy + TURBT + postoperative adjuvant radiotherapy combined with immunotherapy.
62045530|NCT02559752||Arm 1: NIH Toolbox Cognitive Battery testing|"* This study will use the NIH Toolbox Cognitive Battery computer testing software to investigate the cognitive outcomes in children with CNS tumors receiving PBRT.~* Participants recruited for the study will complete one 45-minute testing session prior to the completion of the first week of radiation therapy.~* They will then complete serial tests 6-12 months after the completion of PBRT and then yearly thereafter."
62045531|NCT03369522||Construction|100 recordings that will be used for the algorithm development
62045532|NCT03369522||Validation|100 recordings for the validation of the algorithm
62045533|NCT04159480|EXPERIMENTAL|Experimental - Cogito Companion|Those allocated to Experimental arm will have access the Cogito Companion for a three-month period post-consent. Passive data collection will also occur during this period. As a secure, privacy-compliant mobile app, the Cogito Companion facilitates the non-invasive collection, transfer, integration, analysis, and reporting of objective behavioral indicators. The Cogito mobile sensing platform passively gathers behavioral information through an individual's normal smartphone usage. Measurements of location, call, and text patterns are recorded.
62604812|NCT03863327||Acute severe 3-vessel disease or critical left main stenosis|"1. Severe 3-vessel disease: \>/=75% stenosis in all three major coronary vessels (or equivalents in the case of anatomic variants or preexisting bypass) with an acute culprit lesion (TIMI\<3) or~2. Left main stenosis \> 50% (see Smith review paper for reference): acute left main culprit of any TIMI score, or any lesion of the left main with TIMI\<3 or~3. Any other cardiac catheterization findings prompting initiation of emergent coronary artery bypass grafting within the next 120 hours"
62604813|NCT03863327||No evidence of acute coronary occlusion|"1. At least three sequential negative cardiac biomarkers within 24 hours of presentation~2. cardiac catheterization showing no culprit lesion.~3. Angiogram showing an acute culprit lesion but both no occlusion (TIMI 2 or greater) and troponins not exceeding the cutoff above~4. If positive troponin values present but no angiography, then the patient must have echocardiography showing no wall motion abnormality and troponin values less than the above cutoff~5. If the patient has insufficient data to classify into one of these categories, the patient must be excluded from the study as they cannot be classified as ACO or non-ACO. For example, patients with extremely high troponin but no culprit seen on cath may have acute occlusion with complete autolysis of thrombus, myocarditis, spasm, etc. Thus the investigators cannot classify them as NO ACO when the possibility of ACO remains and cannot be disproven."
62827535|NCT03836313|NO_INTERVENTION|no cryoneurolysis treatment (standard of care)|TKA patients randomized to receive preoperative rehabilitation only (no cryoneurolysis treatment) (n=70)
62045534|NCT04159480|ACTIVE_COMPARATOR|Active Control|Participants randomized to the Active Control group will download MyCAP and have access to resources housed within this app for a three-month period post-consent. Participants will be provided information regarding the mHealth Tool apps, and provided basic information on how to download the apps. As noted above, participants will be provided biweekly surveys .
62045535|NCT04852016|EXPERIMENTAL|Digital Educational Platform|Study participants randomized to the DEP+SVC group (intervention) will be presented with an iPad with a link to an interactive DEP module discussing the indications for LC, alternatives, risks, complications, expectations and anticipated recovery. They will be asked to review the DEP module at their own pace and will be required to confirm understanding of all of the material presented on the DEP. Upon completion of the module, a member of the surgery team will ask the patient if they have any additional questions or require further clarification regarding the LC procedure, indications for surgery, alternatives, risk, complications, expectations and anticipated recovery. Once all of participant's questions are answered, an informed paper-based consent form for LC will be signed.
62045536|NCT04852016|ACTIVE_COMPARATOR|Standard Verbal Consent|Study participants randomized to the SVC group (control) will discuss the LC procedure, indications for surgery, alternatives, risk, complications, expectations and anticipated recovery with a member of the surgery team. The study participant will be given the opportunity to ask questions and once all of the questions have been answered, an informed paper-based consent form for LC will be signed.
62045537|NCT00969475|NO_INTERVENTION|Control|Half of each subject's wound will not be treated.
62045538|NCT00969475|EXPERIMENTAL|Laser resurfacing|Half of each subject's wound will be treated with a fractional CO2 laser.
62247885|NCT03706495|EXPERIMENTAL|The Group II|The Schroth method three-dimensional exercise therapy program consists of individual exercise programs combined with correction patterns. It is based on sensorimotor and kinesthetic principles. Goals of this exercise are to facilitate the correction of the asymmetric posture and to maintain the correct posture in the daily activities of the patient. The Group II receive Schroth method based on three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.
62247886|NCT06165822|EXPERIMENTAL|Itraconazole drug-durg interaction (DDI)|Itraconazole capsules, 0.2g once daily from Day 3 to Day 10 TQB3909 tablets, single oral dose on Day 1 and Day 8.
62247887|NCT06165822|EXPERIMENTAL|Rifampicin DDI|Rifampicin capsule, 0.6g once daily from Day 3 to Day 11. TQB3909 tablets, single oral dose on Day 1 and Day 10.
62437963|NCT05202691|EXPERIMENTAL|Group 1 (Physical Therapy+Magnetic Field Therapy)|"Physical Therapy Protocol plus Magnetic Field Therapy~A protocol of physical therapy treatment including:~* Manual therapy techniques for inhibition of piriformis, quadratus lumbaris, and paravertebral muscles in prone position and bilaterally.~* 2 functional techniques applied to the sacrum in prone position.~* A myofascial release of ligaments inserted to the sacrum in prone position and bilaterally.~* Manual therapy technique for inhibition of psoas-iliacus muscle in supine position and bilaterally.~* Stretching techniques of piriformis, gluteal and paravertebral muscles in supine position and bilaterally.~* Active gluteus maximus contraction in supine position bilaterally.~To this protocol, a 15 minutes of Magnetic Field Therapy using the Zimmer EmfieldPro device (Zimmer MedizinSysteme, Germany) applied to the lumbosacral region in prone position is added."
62449243|NCT02806232|EXPERIMENTAL|Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg|Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
62604814|NCT01238562|EXPERIMENTAL|YPEG-Filgrastim, 10mcg/kg|
62604815|NCT01238562|EXPERIMENTAL|YPEG-Filgrastim, 20mcg/kg|
62604816|NCT01238562|EXPERIMENTAL|YPEG-Filgrastim, 30mcg/kg|
62604817|NCT01238562|EXPERIMENTAL|YPEG-Filgrastim, 45mcg/kg|
62604818|NCT01238562|EXPERIMENTAL|YPEG-Filgrastim, 60mcg/kg|
62604819|NCT03161002||wild genotype|Through next generation sequencing, distinguish wild genotype of ticagrelor
62604820|NCT03161002||mutant genotype|Through next generation sequencing, distinguish mutant genotype of ticagrelor
62827536|NCT06655454|EXPERIMENTAL|Supplemental Postoperative Bupivacaine|An additional injection, 1 carpule (1.8 mL) of 0.5% bupivacaine with 1:200,000 epinephrine, will be given to patients in this treatment arm, after their standard endodontic procedure is complete.
62827537|NCT06655454|PLACEBO_COMPARATOR|Mock/Placebo Injection|If assigned to this arm, the patient will be shown the removal of a needle cap for an anesthetic syringe. The tip will be bent and placed in the patient's mouth, but no tissue penetration will occur. No solution of anesthetic will be delivered.
62437964|NCT05202691|ACTIVE_COMPARATOR|Group 2 (Physical Therapy)|"Physical Therapy Protocol alone:~The same Physical Therapy Treatment protocol with a sham magnetic intervention applying in the same region with a disconnected Zimmer EmfieldPro device (Zimmer MedizinSysteme, Germany) during 15 minutes."
62437965|NCT05272098|EXPERIMENTAL|Group A|myofascial release therapy
62827538|NCT06655454|NO_INTERVENTION|No Additional Injection|After standard endodontic procedure, no additional injection will be given.
62827539|NCT04144608|EXPERIMENTAL|Toripalimab Combined With Platinum-containing Dual-agent|Toripalimab combined with platinum-containing dual-agent as a neoadjuvant Therapy for Non-small Cell Lung Cancer
62827540|NCT02132962|ACTIVE_COMPARATOR|Healthy controls|Amino acid infusion
62827541|NCT02132962|ACTIVE_COMPARATOR|Cirrhosis|Amino acid infusion
62247888|NCT06033885|EXPERIMENTAL|4-week control period + 4-week intervention period|Prior to the intervention a 4-week control period, where the non-instrumented standing frame is used according to current practice, will be carried out. Subsequently, a 4-week intervention period, where the standing frame is instrumented (PONDUS®) allowing continued adjustments of the force and position within and between sessions will be conducted.
62437966|NCT05272098|ACTIVE_COMPARATOR|Group B|endurance training of the trunk extensor muscles
62604821|NCT00990665|EXPERIMENTAL|CRT-D and LV lead|
62604822|NCT01702194|EXPERIMENTAL|TD-1211 IV [C14]|TD-1211 IV \[C14\]
62604823|NCT01702194|EXPERIMENTAL|TD-1211 PO [C14]|TD-1211 PO \[C14\]
62827542|NCT02264730|EXPERIMENTAL|Clot Foam|Application of Clotfoam
62827543|NCT05082610|EXPERIMENTAL|Part 1 - Dose Escalation Phase (Monotherapy)|HMBD-002 administered as a 60-minute IV infusion as a monotherapy. HMBD-002 will be administered on Days 1, 8, and 15 of a 21-day cycle.
62827544|NCT05082610|EXPERIMENTAL|Part 1 - Dose Escalation Phase (Combination Therapy)|"HMBD-002 administered as a 60-minute IV infusion at escalating doses in combination with pembrolizumab KEYTRUDA®. HMBD-002 will be administered on Days 1, 8, and 15 of a 21-day cycle.~The treatment pembrolizumab KEYTRUDA® will be administered as a 30-minute IV infusion at a dose of 200 mg on Day 1 of every 21-day cycle."
62827545|NCT05082610|EXPERIMENTAL|Part 2 - Dose Expansion (Monotherapy)|HMBD-002 administered at the MTD/RP2D as a 60-minute IV infusion as a monotherapy in patients with TNBC or NSCLC.
62604824|NCT01376466||patients with acute appendicitis|Patients who have been clinically diagnosed to have acute appendicitis
62604825|NCT05992961||Patients not undergoing troponin I surveillance|Patients undergoing acute high-risk abdominal surgery during the period February 1, 2018, to February 28, 2019. No troponin I measurements were made.
62604826|NCT05992961||Patients undergoing troponin I surveillance|Patients undergoing acute high-risk abdominal surgery during the period March 1, 2019, to February 28, 2021 as well as postoperative troponin I surveillance .
62623450|NCT03928275|EXPERIMENTAL|Combination therapy: Intralesional IL-2 and BCG Treatment|CMM patients will receive 4 treatments of combination therapy intralesional Interleukin-2 and Bacillus Calmette Guerin two weeks apart over an eight week period.
62045539|NCT00818961|OTHER|Hematopoietic Stem Cell Transplantation|All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on donor type
62045540|NCT03412682|EXPERIMENTAL|Budesonide (6 mg)|
62045541|NCT03412682|EXPERIMENTAL|Budesonide (9 mg)|
62045542|NCT03412682|ACTIVE_COMPARATOR|Mesalazine (3,600 mg)|
62045543|NCT03439774||Adults 18 years old or older|
62045544|NCT00462215|EXPERIMENTAL|1|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
62045545|NCT00462215|EXPERIMENTAL|2|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
62247889|NCT05757336|EXPERIMENTAL|combined treatment group|"Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab GC regimen: up to the results of safety run-in stage~* Dose A: gemcitabine 1000mg/m2, paclitaxel for injection (albumin-bound) 125mg/m2 iv Q3W~* Dose B: gemcitabine 800mg/m2, paclitaxel for injection (albumin-bound) 100mg/m2 iv Q3W~Sintilimab: 200mg, iv, d1, q3w Bevacizumab: 7.5mg/kg, d1, q3w"
62247890|NCT05716750|OTHER|Osteomalasia|Our study, which is the only group planned prospectively, aims to compare clinical and laboratory data and serum prolidase activity and leptin levels in 38 patients diagnosed with osteomalacia after and before 8 weeks of 50,000 IU D vit treatment.
62247891|NCT01387165||Patients|males and females between 18 and 75 years of age who been diagnosed with T2DM as defined by the American Diabetes Association
62247892|NCT00710736|EXPERIMENTAL|ARRY-334543 + capecitabine|
62247893|NCT01009892|ACTIVE_COMPARATOR|Codeine Sulfate, 30 mg|tablet
62827546|NCT05082610|EXPERIMENTAL|Part 2 - Dose Expansion (Combination Therapy)|HMBD-002 administered at the MTD/RP2D as a 60-minute IV infusion in combination with pembrolizumab KEYTRUDA® at the standard labeled dose in patients with TNBC or NSCLC.
62247894|NCT01009892|ACTIVE_COMPARATOR|Codeine Sulfate, 60 mg|tablet
62604827|NCT02554318|EXPERIMENTAL|Intervention|"TB standard therapy with fixed dose combination :~once per day by mouth for 2 months Fixed dose combination = RHZE (150mg/75mg/400mg/275mg) R=rifampicin, H=isoniazid, Z=pyrazinamide, E=ethambutol,~Patients with body weight: 30 - 37 kg = 2 tablets, 38 - 54 kg = 3 tablets, 55 - 70 kg = 4 tablets, and ≥71 kg = 5 tablets~and 166.5 grams cooked fermented soybean (tempeh) daily for two months"
62604828|NCT02554318|ACTIVE_COMPARATOR|Control|"TB standard therapy with fixed dose combination :~once per day by mouth for 2 months Fixed dose combination = RHZE (150mg/75mg/400mg/275mg) R=rifampicin, H=isoniazid, Z=pyrazinamide, E=ethambutol,~Patients with body weight: 30 - 37 kg = 2 tablets, 38 - 54 kg = 3 tablets, 55 - 70 kg = 4 tablets, and ≥71 kg = 5 tablets"
62247895|NCT01009892|ACTIVE_COMPARATOR|Codeine Sulfate, 15 mg|tablet
62247896|NCT02104154||symptoms of liver disease|Device: Samsung LABGEO PT10 Hepatic Panel
62247897|NCT01025024||POAG group|Elevated intraocular pressure normal open angle glaucomatous optic nerve head abnormality glaucomatous visual field defect
62247898|NCT01025024||Normal control|Normal intraocular pressure No optic disc abnormality No visual field defect No significant ocular and systemic disease
62247899|NCT04087278|ACTIVE_COMPARATOR|Metabotype A|Taking treatment
62247900|NCT04087278|ACTIVE_COMPARATOR|Metabotype B|Taking treatment
62247901|NCT04087278|ACTIVE_COMPARATOR|Metabotype 0|Taking treatment
62045546|NCT00462215|EXPERIMENTAL|3|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
62045547|NCT00462215|EXPERIMENTAL|4|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
62045548|NCT00462215|EXPERIMENTAL|5|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
62045549|NCT00462215|EXPERIMENTAL|6|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
62247902|NCT04087278|PLACEBO_COMPARATOR|Placebo|Taking matching placebo
62247903|NCT05275426|EXPERIMENTAL|Ewing sarcoma|Participants have a diagnosis of Ewing sarcoma as molecularly defined by an EWSR1 fusion with an ETS-transcription factor family member including FLI1, ERG, ETV1, ETV4, and FEV
62247904|NCT01105091|ACTIVE_COMPARATOR|1|ACT-385781A (Actelion Epoprostenol)
62247905|NCT01105091|ACTIVE_COMPARATOR|2|Flolan®
62247906|NCT02022345|ACTIVE_COMPARATOR|PCI at pilot hospitals|Percutaneous Coronary Interventions performed at pilot hospitals which do not have onsite cardiac surgery.
62604829|NCT04382144|ACTIVE_COMPARATOR|Levobupivacaine arm|Patients will receive a single injection of 10 mL of 0.5% (5 mg/mL) levobupivacaine into the common extensor origin.
62045550|NCT06029309|EXPERIMENTAL|Zanu-Tafa Phase 1 Group|"Participants in this group will receive combination therapy of Zanubrutinib (Zanu) and Tafasitamab (Tafa) for up to 24 cycles, followed by maintenance therapy with Zanubrutinib until progression. Each cycle is 28 days in length. Combination therapy will be administered via induction phases as follows:~1. Early induction - cycles 1 to 3 (12 weeks)~2. Late induction - cycles 4 to 12 (36 weeks)~3. Extended induction - cycles 13-24 (48 weeks)~Subsequent maintenance Zanu therapy may last up to 2 years. Total study participation is up to four (4) years."
62045551|NCT06029309|EXPERIMENTAL|Zanu-Tafa Phase 2 Group|"Participants in this group will receive the combination therapy of Zanubrutinib (Zanu) at the recommended phase 2 dose (RP2D) determined during Phase 1, and Tafasitamab at standard doses, followed by maintenance therapy with Zanubrutinib until progression.. Combination therapy will be administered via induction phases as follows:~1. Early induction - cycles 1 to 3 (12 weeks)~2. Late induction - cycles 4 to 12 (36 weeks)~3. Extended induction - cycles 13-24 (48 weeks)~Subsequent maintenance Zanu therapy may last up to 2 years. Total study participation is up to four (4) years."
62045552|NCT00693251|EXPERIMENTAL|bifurcation stent technique|crush technique
62045553|NCT00693251|ACTIVE_COMPARATOR|bifurcation stent techniqe|provisional T stenting
62045554|NCT02630134|EXPERIMENTAL|Baeta|These patients receive the Baeta device and take it home.
62827547|NCT01317472|EXPERIMENTAL|Dexlansoprazole|Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC).
62045555|NCT00291148|ACTIVE_COMPARATOR|Paroxetine|
62827548|NCT01317472|PLACEBO_COMPARATOR|Sugar pill|Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC) or 1 tablet of placebo QAM (1 hour AC).
62827549|NCT00904449|EXPERIMENTAL|Open Label|
62827550|NCT04762095|EXPERIMENTAL|The Effect of mindfulness stress reduction program Quality of Life|mindfulness stress reduction program reduces menopausal complaints.
62827551|NCT04762095|EXPERIMENTAL|The Effect of mindfulness stress reduction program Menopausal Symptoms|mindfulness stress reduction program improves the quality of life of women in the menopausal period.
62827552|NCT02552043|EXPERIMENTAL|Nintendo Wii exercise program group|The EG will perform a domiciliary Pulmonary Rehabilitation program of 30-60 min exercise, 5 days/week during 6 weeks using a Nintendo Wii platform with the game EA SPORTS ACTIVE 2. The exercise activities were loaded into each participant´s console during the clinical interview and adjusting the exercises according to their age in 2 groups (\>12 years and \<13 years). The program consisted of 6 different workouts (1st and 2nd weeks: legs exercises; 3rd week: upper limb exercises; 4th week: thorax exercises; 5th and 6th weeks: cardio exercises), so the patients had a gradual increase reaching the maximum load at the end of training.
62827553|NCT02552043|NO_INTERVENTION|Control group|The CG carried out their routine patient management
62827554|NCT02871986||Individuals with hypogonadism|Individuals with hypogonadism requiring pubertal induction. Participants will receive oestrogen therapy in the form of transdermal oestrogen patch, which is standard care.
62827555|NCT02318316||EBC level|Exhaled breath condensate level of allogeneic stem cell transplantation patients
62827556|NCT04148625||atrial fibrillation, persistent|Subjects with documented symptomatic persistent or longstanding persistent AF (\> than 3 months and \< 3 years continuous AF duration) who has failed a previous PVI catheter ablation procedure and/or needs LAA exclusion; and catheter ablation or minimally surgical approach is planned.
62045556|NCT00291148|ACTIVE_COMPARATOR|pregabalin|
62045557|NCT00276640|ACTIVE_COMPARATOR|vincristine, carboplatin|standard chemotherapy group
62827557|NCT05715099|ACTIVE_COMPARATOR|mild-moderate ulcerative colitis for low dose|2 low dose (25 mg \\dose) per day N= 20
62827558|NCT05715099|ACTIVE_COMPARATOR|mild-moderate ulcerative colitis for high dose|2 high dose (50 mg \\dose) per day N=20
62827559|NCT05715099|ACTIVE_COMPARATOR|healthy subjects for low dose|2 low dose (25 mg \\dose) per day N= 10
62827560|NCT05715099|ACTIVE_COMPARATOR|healthy subjects for high dose|2 high dose (50 mg \\dose) per day N=10
62045558|NCT00276640|ACTIVE_COMPARATOR|vincristine, carboplatin, etoposide|intensified induction chemotherapy group
62247907|NCT02022345|ACTIVE_COMPARATOR|PCI at non-pilot hospitals|Percutaneous Coronary Intervention performed at non-pilot hospitals which have onsite cardiac surgery or perform only primary PCIs for STEMI patients.
62247908|NCT01480921|EXPERIMENTAL|home based exercise training|
62045559|NCT00276640|ACTIVE_COMPARATOR|radiation|radiation therapy group
62045560|NCT00276640|NO_INTERVENTION|Control|Control group: wait and see strategy
62247909|NCT01480921|ACTIVE_COMPARATOR|supervised exercise training|
62827561|NCT05715099|PLACEBO_COMPARATOR|mild-moderate ulcerative colitis for placebo|2 dose placebo per day N=20
62827562|NCT05715099|PLACEBO_COMPARATOR|healthy subjects for placebo|2 dose placebo per day N=10
62827563|NCT00485979|EXPERIMENTAL|Arm A1|Cohort 1: Her2-ve breast cancer
62827564|NCT00485979|ACTIVE_COMPARATOR|Arm B1|Cohort 1: Her2-ve breast cancer
62827565|NCT00485979|EXPERIMENTAL|Arm A2|Cohort 2: Her2+ve breast cancer
27793553|NCT03738982|EXPERIMENTAL|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
62437967|NCT06172010|ACTIVE_COMPARATOR|Oral rifampicin-based combination therapy|rifampicin 450mg BID + levofloxacin 500mg BID in the oral treatment phase with a total duration of antibiotics of 12 weeks
62437968|NCT06172010|EXPERIMENTAL|Oral monotherapy with clindamycin|clindamycin 600mg TID in the oral treatment phase with a total duration of antibiotics of 12 weeks
62604830|NCT04382144|EXPERIMENTAL|Liposomal Bupivacaine arm|Patients will receive a single injection of 10 mL (133mg) of liposomal bupivacaine into the common extensor origin.
62827566|NCT00485979|ACTIVE_COMPARATOR|Arm B2|Cohort 2: Her2+ve breast cancer
62604831|NCT03040427|EXPERIMENTAL|AL or TTR type amyloidosis|The participants will undergo F-18 florbetapir PET scan.
62604832|NCT05098067|EXPERIMENTAL|Intervention group|Participants will receive IV fluid bolus of 1000cc of lactated ringers, metoclopromide 10mg IV and will have 5g of 0.075% capsaicin cream applied to their abdomen. Participants will indicate the severity of their symptoms immediately prior to administration of metoclopromide, at time 0 and every 30 minutes for a total of 120 minutes after administration of the first medications (or discharge) using a 10 cm visual analogue scale (VAS)11,12. The scale will be provided in English or Spanish as appropriate. If at the 90-minute time mark the patient does not report improvement of their symptoms, odansetron 8mg IV will be administered.
62604833|NCT05098067|PLACEBO_COMPARATOR|Placebo group|Participants will receive IV fluid bolus of 1000cc of lactated ringers, metoclopromide 10mg IV and will have 5g of placebo cream applied to their abdomen. Participants will indicate the severity of their symptoms immediately prior to administration of metoclopromide, at time 0 and every 30 minutes for a total of 120 minutes after administration of the first medications (or discharge) using a 10 cm visual analogue scale (VAS). The scale will be provided in English or Spanish as appropriate. If at the 90-minute time mark the patient does not report improvement of their symptoms, odansetron 8mg IV will be administered.
62604834|NCT03808025|EXPERIMENTAL|education|The teaching arm would consist of a standardized dialogue the surgeon will complete with the patient in order to familiarize the patient with the risks of over-prescribing opioid medication and set patient expectations regarding the clinic's opioid prescribing pattern protocol, in an effort to minimize the number of opioid pills prescribed or refills required, the amount actually used, and the untoward side effects of opioid use (e.g. respiratory depression, nausea, sedation, restriction from driving, and access to and use by those the medication was not intended).
62604835|NCT03808025|NO_INTERVENTION|no education|Standard preoperative care without dedicated teaching regarding opioid use and risks
62604836|NCT02225327|ACTIVE_COMPARATOR|Fluad alone|56 Fluad recipients: one vaccine injection administered on Day 0
62604837|NCT02225327|ACTIVE_COMPARATOR|Fluad and PPV23 on the different arms|56 concomitant Fluad-PPV23 recipients on the different arms: one dose of each vaccine administered on Day 0
62827567|NCT03593369|EXPERIMENTAL|KLOX BioPhotonic System (single treatment)+SOC|KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered twice weekly in association with SOC (10 patients)
62827568|NCT03593369|EXPERIMENTAL|KLOX BioPhotonic System (consecutive treatments)+SOC|KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered in two consecutive treatments (twice weekly on the first two weeks then once weekly) in association with SOC (10 patients)
62827569|NCT03593369|ACTIVE_COMPARATOR|Standard of Care|SOC only (5 patients)
62827570|NCT06593080|NO_INTERVENTION|Standard of Care|"The District Hospitals and Primary Health Centres in study districts will implement TB diagnosis for children as per the current Standard of Care (control) in both countries . In Mozambique, the SOC is based on local algorithms which include: TB symptoms screening (TB contact history), HIV testing, Xpert testing on induced sputum (and stool), and a tuberculin skin test. Urine Lipoarabinomannan (LAM) is indicated for Children Living with HIV (CLHIV). No CXR is performed.~In Zambia, the SOC is based on the Union desk guide algorithm which includes: TB symptom screening (TB contact history), HIV testing and Xpert testing on respiratory or stool samples. Urine LAM is indicated for CLHIV,Severe Acute Malnutrition, sepsis, immune-suppression; chronic kidney diseases and cancer. CXRs are performed depending on the facilities. Other tests and imaging are advised in presumed extrapulmonary TB cases. A confirmed TB diagnosis is made based on a positive Xpert or LAM test."
62827571|NCT06593080|EXPERIMENTAL|The comprehensive TDA based approach|Children will benefit from the country SOC as described in the control arm, plus the study intervention
62827572|NCT06591208|OTHER|single group 20 patients subjected PDL on one randomized side and carboxytherapy on the other side|
62827573|NCT03043417|EXPERIMENTAL|CHC's given the intervention|Three CHC sites where all staff receive all components of the intervention. Training, Media, Art workshops, and a Policy analysis as well as survey completion.
62827574|NCT03043417|NO_INTERVENTION|CHC's with NO intervention|Three CHC sites where all staff and a selection of clients complete surveys but receive no intervention.
62604838|NCT02225327|ACTIVE_COMPARATOR|Fluad and PPV23 on the same arm|56 concomitant Fluad-PPV23 recipients on the same arm with 1 inch distance: one dose of each vaccine administered on Day 0
62604839|NCT02225327|ACTIVE_COMPARATOR|PPV23 alone|56 PPV23 recipients: one vaccine injection administered on Day 0
62827575|NCT00430014|EXPERIMENTAL|Atiprimod|
62437969|NCT02208583|ACTIVE_COMPARATOR|AR dependent CRPC|"Assignment to Treatment Group based on druggable gene mutations analysis:~CRPC patients without druggable gene mutations: Docetaxel \& Prednisone; CRPC patients with druggable gene mutations: DP \& Targeted drugs"
62437970|NCT02208583|ACTIVE_COMPARATOR|AR independent CRPC|"Assignment to Treatment Group based on druggable gene mutations analysis:~CRPC patients without druggable gene mutations: cisplatin \& Etoposide; CRPC patients with druggable gene mutations: EP \& Targeted drugs"
62437971|NCT04426526|EXPERIMENTAL|Biceps circumference reduction|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of biceps brachii.
62045561|NCT03900702|ACTIVE_COMPARATOR|Active Intervention|Gaze-driven games, played at home on PC with eye-tracker, to train resistance to attention distraction and speed of processing.
62045562|NCT03900702|NO_INTERVENTION|Wait List Control|Wait list then cross over to active intervention.
62045563|NCT04787601|EXPERIMENTAL|Cognitive training|Cognitive-based neuromuscular exercises will be applied to the experimental group for a total of 8 weeks.
62045564|NCT04787601|OTHER|Control|The control group will only do the classic training.
62045565|NCT02568748|EXPERIMENTAL|CIK with TACE for HCC stage B|HCC patients stage B treated with TACE and CIK as adjuvant therapy.
62045566|NCT02568748|EXPERIMENTAL|TACE only for HCC stage B|HCC patients stage B treated with TACE without receiving CIK cells infusion
62045567|NCT02568748|EXPERIMENTAL|CIK in HCC stage C or D|HCC stage C or D will receive supportive treatment in addition to CIK cells infusion
62045568|NCT02568748|NO_INTERVENTION|Supportive treatment in HCC stage C or D|HCC stage C or D will receive supportive treatment only .
62045569|NCT02401568|OTHER|Normal subjects|"No morphologic changes in carpal ligaments or clinical signs of wrist instability.~Dynamic CT of the wrist will be performed before and after arthrography."
62045570|NCT02401568|OTHER|Wrist instability|Morphologic ligament changes (e.g. partial or complete rupture) Dynamic CT of the wrist will be performed before and after arthrography.
62045571|NCT02081573|EXPERIMENTAL|Brief CBT|During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
62247910|NCT02648516|EXPERIMENTAL|Conventional plus AAIT|Participants will receive ART plus a dose of allogenic adoptive immune transfusion (3 times of MNCs transfusions) from day 0 through the week 2 study visit.
62247911|NCT05646212|NO_INTERVENTION|Standard of Care|Standard of care (with SSRI medications provided for free).
62247912|NCT05646212|EXPERIMENTAL|SOC+ECHO|Standard of care (with SSRI medications provided for free), plus Project ECHO facilitation (an evidence-based tele-education intervention) for physicians
62247913|NCT05646212|EXPERIMENTAL|SOC+ECHO+P4P|Standard of care (with SSRI medications provided for free), plus Project ECHO facilitation (an evidence-based tele-education intervention) for physicians, plus Payment for Performance intervention
62437972|NCT04426526|EXPERIMENTAL|Triceps circumference reduction|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of triceps brachii.
62247914|NCT05053516|OTHER|the intervention group|The intervention group will participate in the training program of this study, while the control group will receive the existing routine training program.
62247915|NCT05053516|OTHER|the control group|The intervention group will participate in the training program of this study, while the control group will receive the existing routine training program.
62247916|NCT04722770||Pediatric patients with possible ear infections|Pediatric patients presenting with otitis media (acute otitis media or otitis media with effusion) will be imaged with the PhotoniCare OtoSight.
62247917|NCT03752008|EXPERIMENTAL|Active Play (AP)|This arm received the Active Play curriculum intervention (described in following section).
62247918|NCT03752008|EXPERIMENTAL|Outdoor Play (OP)|This arm received the Outdoor Play curriculum intervention (described in following section).
62437973|NCT04426526|EXPERIMENTAL|Lower limb circumference reduction|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of muscles in lower limbs.
62247919|NCT03597971|EXPERIMENTAL|Part A: experimental|Subjects will receive HMPL004-6599 or matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule. Dose levels may be repeated, or reduced if deemed appropriate by the Safety Monitoring Committee (SMC).
62247920|NCT03597971|PLACEBO_COMPARATOR|Part A: placebo|Subjects will receive matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule.
62437974|NCT04426526|EXPERIMENTAL|Oblique muscles toning|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of oblique muscles.
62437975|NCT05058859|EXPERIMENTAL|Study Drug|The study drug is Dapagliflozin
62437976|NCT04881526|ACTIVE_COMPARATOR|Ketone ester drink|
62045572|NCT03044483||18-34 year olds|Healthy adults aged 18-34 years old
62045573|NCT03044483||35-54 year olds|Healthy adults aged 35-54 years old
62045574|NCT03044483||55 and over year olds|Healthy adults aged 55 years old and over
62045575|NCT02798510|EXPERIMENTAL|Arm 1|Patients in arm 1 will receive adjuvant chemotherapy followed by concurrent chemoradiotherapy. Patients will receive four cycles of gemcitabine (1,000mg/m2 intravenously on days 1 and 8) and capecitabine (1,500mg/m2 per day on days 1 to 14) every 21 days followed by concurrent capecitabine (1,330mg/m2 per day) and radiotherapy (50.4Gy/28fx to regional lymphatics with or without tumor bed)
62045576|NCT02798510|ACTIVE_COMPARATOR|Arm 2|Patients in arm 2 will receive six cycles chemotherapy of gemcitabine (1,000mg/m2 intravenously on days 1 and 8) and capecitabine (1,500mg/m2 per day on days 1 to 14) every 21 days
62045577|NCT03872921|EXPERIMENTAL|norUrsodeoxycholic acid|norUrsodeoxycholic acid 250mg capsules, 6 capsules/day for 2 years
62045578|NCT03872921|PLACEBO_COMPARATOR|Placebo to norUrsodeoxycholic acid|norUrsodeoxycholic acid 250mg Placebo-capsules, 6 capsules/day for 2 years
62247921|NCT04394481|EXPERIMENTAL|DMD|Ropivacaine: perinervous injection (interscalene block) Dexamethasone: IV injection Dexmedetomidine: IV injection (1µg/kg)
62247922|NCT04394481|ACTIVE_COMPARATOR|Control|Ropivacaine: perinervous injection (interscalene block) Dexamethasone: IV injection
62247923|NCT00771641|ACTIVE_COMPARATOR|Standard Fractionation|Standard Fractionation: 2 Gy/Fx, Q.D. 5 Days/wk, Total Dose: 70 Gy/35 Fx x 7 wks
62247924|NCT00771641|EXPERIMENTAL|Hyperfractionation|Hyperfractionation: 1.2 Gy/Fx, b.i.d. (\> 6 hours apart, 5 days/wk) Total Dose: 81.6 Gy/68 Fx/7 weeks
62247925|NCT00771641|EXPERIMENTAL|Accelerated Hyperfractionation with split|Accelerated Hyperfractionation with split: 1.6 Gy/Fx b.i.d. (\> 6 hours apart), 5 days/wk, Total Dose: 67.2 Gy/42 Fx/6 wks with a 2 week rest after 38.4 Gy
62247926|NCT00771641|EXPERIMENTAL|Accelerated fractionation with concomitant boost|Accelerated fractionation with concomitant boost
62247927|NCT04741386||Cohort A|Patients with CKD stages 4 and 5
62247928|NCT04741386||Cohort B|Patients on hemodialysis and peritoneal dialysis
62247929|NCT04741386||Cohort C|Kidney Transplant Recipients
62247930|NCT04741386||Cohort D|Controls
62247931|NCT04830592|EXPERIMENTAL|Part A|NG-641 monotherapy
62247932|NCT04830592|EXPERIMENTAL|Part B|NG-641 and pembrolizumab
62247933|NCT02010606|EXPERIMENTAL|Cohort A: Patients with newly diagnosed glioblastoma|Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy
62247934|NCT02010606|EXPERIMENTAL|Cohort B: Patients with recurrent glioblastoma|Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
62247935|NCT00779922|EXPERIMENTAL|group 1 to 5|
62247936|NCT02069925|EXPERIMENTAL|Early Detection (ED)|This intervention consists of educational campaigns directed at patients \& families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
62247937|NCT02069925|ACTIVE_COMPARATOR|Usual Detection|This intervention will provide equivalent best practice care without the benefit of an early detection campaign
62247938|NCT01493557|OTHER|Pradaxa (dabigaran etexilate)|Patients with non valvular atrial fibrillation for whom Pradaxa is indicated in accordance with the current local label, not previously treated with Pradaxa, will be provided 3 months of treatment for the prevention of stroke and systemic embolism. Patients who report gastrointestinal symptoms (GIS) will be randomized to one of two management strategies, and data documenting the intensity and duration of the GIS will be collected.
62247939|NCT01493557|ACTIVE_COMPARATOR|Pradaxa and pantoprazole|Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal
62247940|NCT01493557|ACTIVE_COMPARATOR|Pradaxa, 30 minutes after a meal|Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal
62247941|NCT00550654|EXPERIMENTAL|Radiation Therapy in Metastatic Cancer|Patients undergo hypofractionated highly conformal radiotherapy with helical tomotherapy once every other day over 5 days for a total of 3 fractions.
62247942|NCT02465385|EXPERIMENTAL|Intervention|Linaclotide 290mcg
62247943|NCT01669967|PLACEBO_COMPARATOR|Diphenhydramine(Benadryl)|
62247944|NCT01669967|ACTIVE_COMPARATOR|Lidocaine|
62247945|NCT05446428||Any SLE Disease Activity|
62247946|NCT05446428||Moderate to severe SLE Disease Activity|
62247947|NCT02345304|EXPERIMENTAL|Treatment 3|single dose of midazolam + BI drug
62247948|NCT02345304|EXPERIMENTAL|Treatment 4|single dose of probe drugs + BI drug
62247949|NCT02345304|EXPERIMENTAL|Treatment 5|single dose of digoxin + BI drug
62247950|NCT02345304|EXPERIMENTAL|Treatment 1|single doses of probe drugs
62247951|NCT02345304|EXPERIMENTAL|Treatment 2|single dose of digoxin
62247952|NCT01961661|EXPERIMENTAL|probiotic|Lactobacillus rhamnosus GG 5x10\^9 colony forming units (CFU)per day
62247953|NCT01961661|PLACEBO_COMPARATOR|placebo|maltodextrins
62247954|NCT05573659|EXPERIMENTAL|video-assisted capillary refill time.|
62045579|NCT03382782|ACTIVE_COMPARATOR|Behavioral Weight Loss Intervention|"Participants will enroll in the BWLI program for 12 months. BWLI consists of a 8-month initial intervention phase followed by 4-month maintenance phase. The initial intervention phase comprises four types of contact:~* 1-hour to 1-hour, 30 minute group weight-management class led by facilitator (once per week; 26 classes followed by a one week break and an additional 8 weight management review classes)~* 45 minute, physical activity led by facilitator (one-two times per week);~* 20 minute, monthly individual visit with facilitator to address barriers to goals and appropriate skills; and~* weigh-in during weight management group and individual visits (once each week)."
62827576|NCT02365025|EXPERIMENTAL|Experimental group|"Step 1: Patients and parents enrolment. Step 2: The parents of the children assigned to the experimental group will fill a questionaire related to familial and social background, electronic media exposure and sleep characteristics of their children.~Step 3: Parents of the children assigned to this group will participate in 6 meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.~Step 4: Re evaluation by questioners after the 6 meetings participation. Step 5: 3 months follow up after the intervention (Meetings)."
62827577|NCT02365025|NO_INTERVENTION|Control group|"Step 1: Patients and parents enrolment. Step 2: The parents of the children assigned to the control group will fill a questionaire related to familial and social background, electronic media exposure and sleep characteristics of their children.~Step 3: Parents of the children assigned to this group will not participate in the meetings as described in the experimental group.~Step 4: Re evaluation by questioners after the time that the experimental group participated in the meetings.~Step 5: 3 months follow up."
62045580|NCT03382782|EXPERIMENTAL|BWLI & Peer Navigator|"Participants randomly assigned to this condition will begin simultaneously with BWLI and run concurrently across the eight months of the intervention. Peer navigators will meet individually and face-to-face with research participants in time and places convenient to the person as needed. Specific practices are determined by the research participant with the peer navigator and may include:~* partnering with participant on BWLI homework;~* meeting with participant and BWLI facilitator individually;~* attending all other health care appointments; and~* partnering on tasks that arise out of those appointments."
62045581|NCT03382782|ACTIVE_COMPARATOR|Integrated Care (Treatment as Usual)|Participants in this arm will receive integrated care from their usual provider, which is treatment as usual. Integrated care is mental health specialty and general medical care providers working together to address the physical and behavioral health care needs of patients. One-third of research participants will be randomized to integrated care alone.
62247955|NCT05573659|ACTIVE_COMPARATOR|visual capillary refill time.|
62247956|NCT01937572|EXPERIMENTAL|Computer-aided TKA|The Visionaire system is a computer-aided system utilizing MRI of the knee prior to TKA surgeries. This technology achieves accurate rotational and A-P position. All of the commonly-referred anatomical landmarks (AP axis, epicondylar axis) are analyzed pre-operatively, allowing for the proper positioning of the implant for each patient.
62827578|NCT01128933|EXPERIMENTAL|Hypertensive patients|Hypertensive patients with at least moderate renal artery stenosis
62247957|NCT01937572|OTHER|Conventional TKA|A conventional TKA utilizes a jig system based on either intra-medullary or extra-medullary guides. No knee MRI is utilized for a conventional TKA.
62247958|NCT00851682|OTHER|Radical prostatectomy patients|Patients who have been diagnosed with prostate cancer and are scheduled to undergo radical prostatectomy and have not received any preoperative treatment for prostate cancer.
62247959|NCT00851682|OTHER|Brachytherapy patients|Patients who have been diagnosed with prostate cancer and are scheduled to undergo brachytherapy and have not received any preoperative treatment for prostate cancer.
62437977|NCT04881526|PLACEBO_COMPARATOR|Placebo drink|
62449244|NCT02806232|EXPERIMENTAL|Part 1, Cohort 5: Levo Praziquantel 30 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.
62827579|NCT04794777|EXPERIMENTAL|Experimental arm|Individualised therapy based on results of the PSMA PET/CT.
62827580|NCT04794777|ACTIVE_COMPARATOR|Control arm|Standard salvage therapy. Results of PSMA PET/CT blinded.
62827581|NCT05164003|EXPERIMENTAL|CORETOX®|
62827582|NCT05164003|ACTIVE_COMPARATOR|BOTOX®|
62045582|NCT02633137|EXPERIMENTAL|Chemotherapy|Lenalidomide + R-CHOP x 4 cycles R-HiDAC x 2 cycles R-Len maintenance x 6 months. Patients will be followed on active follow up for three years after completion of therapy. After the active followup period, survival, relapse, and new anti-lymphoma therapy information will be collected via telephone calls, patient medical records, and/or clinic visits approximately every 6 months until death, loss to follow up or consent withdrawal, whichever comes first.
62827583|NCT01152268||Adolescent Male Participants|"Self-report questionnaire data will be collected one time, between Days 1-7 post initiation of cancer therapy(e.g. Days 2-8 of being on-treatment for cancer) among eligible participants and their families who enroll on the study. Patients who agree to participate will be asked to complete a battery of paper and pencil questionnaires (which will also be available on-line if preferred) that assess risk/protective factors for sperm banking. When the banking recommendation is Yes or further assessment required, the profiling and referral tool will be given to the family and instructions for completion will be provided. The tool will include a list of key items which will be based on the most influential barriers to banking sperm."
62827584|NCT04847804||Positive case|The sample will be tested by microfluidic device and shows positive
62827585|NCT04847804||Negative control|The sample will be tested by microfluidic device and shows negative
62827586|NCT05683457|EXPERIMENTAL|mRNA-1647|Participants will receive mRNA-1647 by intramuscular (IM) injection on Day 42, Day 67, and Day 92, and a booster dose on Day 180.
62827587|NCT05683457|PLACEBO_COMPARATOR|Placebo|Participants will receive mRNA-1647 matching placebo by IM injection on Day 42, Day 67, and Day 92, and a booster dose on Day 180.
62827588|NCT06651541|EXPERIMENTAL|BZ371A group|The medication will be administered at least twice a week (according to demand), followed by sexual encounters, for 8 weeks
62827589|NCT06651541|PLACEBO_COMPARATOR|Placebo Group|The medication will be administered at least twice a week (according to demand), followed by sexual encounters, for 8 weeks
62827590|NCT04984746|EXPERIMENTAL|No Intervention: (control group)|No Intervention: (control group) The control group was assigned to lettuce without any biofortification but with the same characteristic of bioforticated lettuce(soil, water, harvesting time).
62827591|NCT04984746|EXPERIMENTAL|Experimental: intervention group|Experimental: intervention group To the intervention group was assigned the biofortificated Molibdenum lettuce and Iodine lettuce.
62827592|NCT01553084|EXPERIMENTAL|Effectiveness of Nicotine patch only|
62827593|NCT01553084|EXPERIMENTAL|Effectiveness of Combination NRT|
62827594|NCT01553084|EXPERIMENTAL|Effectiveness of Varenicline [Chantix]|
62827595|NCT05122975|EXPERIMENTAL|S48168 (ARM210) once daily for 28 days|Oral dose of S48168 (ARM210) once daily on top of standard of care regimen for 28 days.
62827596|NCT05122975|PLACEBO_COMPARATOR|Matching Placebo once daily for 28 days|Oral dose of placebo once daily on top of standard of care regimen for 28 days.
62045583|NCT04173455|EXPERIMENTAL|HZ-A-018|"In the dose-escalation part, the 3+3 design will be applied. If the subject does not have a DLT during the first 28-day cycle, those who with stable or remission of disease may continue to receive treatment until disease progression, intolerable toxicity or the subject no longer benefits.~In the dose-expansion part, HZ-A-018 will be administered for several 28-day cycles until disease progression, intolerable toxicity or the subject no longer benefits."
62045584|NCT04813627||Participants with R0 resected Stage II (high risk) or Stage III CRC|The participants eligible for this epidemiological study are those with completely resected Stage II (high risk)/III CRC (per the American Joint Committee on Cancer (AJCC) 8th revised edition staging system) due to receive standard of care chemotherapy for at least 3 months following surgery.
62827597|NCT03895203|EXPERIMENTAL|Bimekzumab dosage regimen|Subjects randomized to this arm will receive assigned bimekizumab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
62045585|NCT00922285|EXPERIMENTAL|Art Therapy|
62045586|NCT01760096|EXPERIMENTAL|Levamisole+cyclosporin A+Glucocorticoids|Levamisole+cyclosporin A+Glucocorticoids
62045587|NCT01760096|ACTIVE_COMPARATOR|cyclosporin A+Glucocorticoids|cyclosporin A+Glucocorticoids
62045588|NCT01760096|ACTIVE_COMPARATOR|Glucocorticoids|Glucocorticoids
62045589|NCT04473131||COVID-19 positive|"Inclusion criteria:~1. Male or female aged over 18 years~2. Admitted patients to ICU with a suspicious COVID19 infection~3. Tested positive for SARS-CoV-2~Exclusion criteria:~1. Burn and trauma~2. Any immunological diseases, or immunosuppressive medications~3. Other immune-related conditions (cancer, hematological malignancies, bone marrow diseases or transplant)~Sample collection time points: 4 to 5 (day 1-3, day 7, day 14, day 21, discharge day from ICU -between day 30-60- if possible)"
62247960|NCT02336841|EXPERIMENTAL|Intervention|Participants in this condition will receive the guided self-help intervention.
62247961|NCT02336841|ACTIVE_COMPARATOR|Control|Participants in this condition will not receive the guided self-help intervention. They will receive treatment as usual and weekly feedback on their eating disorder symptoms for a period of 6 weeks.
62827598|NCT03895203|ACTIVE_COMPARATOR|Adalimumab dosage regimen|Subjects randomized to this arm will receive the assigned adalimumab dosage regimen during the Treatment Period.
62827599|NCT03895203|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and will be reallocated to receive bimekizumab dosage regimen during the Maintenance Period.
62827600|NCT04992312|EXPERIMENTAL|3 milligram (mg) Nasal Glucagon|Participants received a single dose of 3 mg glucagon powder administered intranasally on day 1.
62827601|NCT05310955|EXPERIMENTAL|Control group|daily rehabilitation interventions
62827602|NCT05310955|EXPERIMENTAL|Interventional group|daily rehabilitation interventions and shen-based Qigong exercise
62827603|NCT01948596|EXPERIMENTAL|Omega-3 polyunsaturated fatty acids|1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily
62827604|NCT03520998|EXPERIMENTAL|GRF6019 Low Dose|Subjects will receive a low dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.
62827605|NCT03520998|EXPERIMENTAL|GRF6019 High Dose|Subjects will receive a high dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.
62827606|NCT04450238||Study Group|"All participants are inpatients at the clinic Stillachhaus in Germany. They are receiving treatment for a variety of psychological disoders, mostly depressive disoders."
62045590|NCT04473131||COVID-19 negative|"Inclusion criteria:~1. Male or female aged over 18 years~2. Admitted patients to ICU~3. Tested negative for SARS-CoV-2~Exclusion criteria:~1. Burn and trauma~2. Any immunological diseases, or immunosuppressive medications~3. Other immune-related conditions (cancer, hematological malignancies, bone marrow diseases or transplant)~Sample collection time points: 4 to 5 (day 1-3, day 7, day 14, day 21, discharge day from ICU -between day 30-60- if possible)"
62247962|NCT06465693|EXPERIMENTAL|Group1|After consent, screening, and a 10-day run-in period, eligible participants will be randomly assigned to unblinded CGM plus nutrition therapy
62247963|NCT06465693|ACTIVE_COMPARATOR|Group 2|After consent, screening, and a 10-day run-in period, eligible participants will be randomly assigned to nutrition therapy only
62247964|NCT02427230|ACTIVE_COMPARATOR|Pelvic floor muscle training (PFMT)|Pelvic floor muscle training daily during 12 weeks.
62827607|NCT02389296||Forensic Psychiatric Nurses in Mental Health Centers|Psychiatric nurses working in forensic wards in mental health centers
62827608|NCT02389296||Psychiatric Nurses in General Hospitals|Psychiatric nurses working in general hospitals
62827609|NCT04699617|EXPERIMENTAL|Active arm|The active arm will include 3 days a week of training with the Dolphin 2.0 for 12 consecutive weeks. Each session will have the duration of 60 minutes.
62827610|NCT04699617|ACTIVE_COMPARATOR|Delayed-start control arm|The delayed-start control arm will have six-weeks of physiotherapy specialized for PD (3 times/week, 60 minutes/session) and six-weeks of 3 days a week of training with the Dolphin 2.0, with sessions of 60 minutes.
62247965|NCT02427230|ACTIVE_COMPARATOR|PFMT and electrical stimulation|Pelvic floor muscle training and intravaginal neuromuscular electrical stimulation daily during 12 weeks.
62247966|NCT02654249|OTHER|THD and mucopexy|Patients will undergo to transanal hemorrhoidal dearterialization with mucopexy (THD)‪ under generla anesthesia.
62827611|NCT04103138|EXPERIMENTAL|EEG-Guided Anaesthesia|Patients will have Sedline EEG sensor placed and anaesthesia guided by the EEG characteristics, patient state index (PSI) and suppression ratio (SR), in addition to routine clinical parameters.
62827612|NCT04103138|ACTIVE_COMPARATOR|Routine Care|Patients will have Sedline EEG sensor placed but the monitor is concealed so the clinician is blinded to the EEG response. Anaesthesia is guided by routine clinical parameters.
62827613|NCT05406817|EXPERIMENTAL|Revumenib|"Participants will be administered a single dose of revumenib (containing \~100 microcuries \[14C\]-revumenib) in the AME part of the study.~Each dose administered after the first dose in the AME part of the study will be nonradiolabeled revumenib. revumenib may continue to be administered following completion of the AME part of the study. Doses will be administered in continuous 28-day cycles until either PD or unacceptable toxicity."
62604840|NCT04486170|NO_INTERVENTION|Control group: Current hospital education practices|The control group will receive standard of care postpartum educational materials provided by the nursing and resident physician staff. The will be asked to complete a brief questionnaire to determine if they would be interested in receiving education in a video formal.
62604841|NCT04486170|EXPERIMENTAL|Intervention group: Standardized video and pamphlet|The subjects enrolled in the invention group will be shown a 5 minute educational video on hypertension in the postpartum period. The patients will be shown the video on the ipad while they are in the comfort of their room. They will also be provided with a pamphlet with similar information that was discussed in the video. They will also be asked to complete a brief, anonymous survey to assess patient satisfaction with the video shown, no patient identifiers will be collected.
62604842|NCT06730906|EXPERIMENTAL|Intervention Group|Participants will utilize the PACTAID app for 8 weeks.
62604843|NCT02782299|NO_INTERVENTION|Control|This group will not be exposed to the decision aid. Patients will complete the same surveys, and will be followed for the same length of time.
62604844|NCT02782299|EXPERIMENTAL|Decision Aid|This group will be exposed to the decision aid before the patients appointment with the surgeon. Patients will also complete the same outcome surveys, and will be followed for the same length of time.
62045591|NCT04473131||Heathy volunteers|"Inclusion criteria:~1. Male or female aged over 18 years~2. Normal clinical examination~Exclusion criteria:~1. Person with an infectious syndrome during the last 90 days~2. Extreme physical stress within the last week~3. Person receiving within the last 90 days, a treatment based on: antivirals; antibiotics; antiparasitics; antifungals; non-steroidal anti-inflammatory drugs; immunosuppressive therapy; corticosteroids; therapeutic antibodies; chemotherapy~4. Person with history of: innate or acquired immune deficiency; hematological disease; solid tumor; severe chronic disease; surgery or hospitalization within the last 2 years; pregnancy within the last year; participation to a phase I clinical assay during the last year; participation to a phase I clinical assay during the last year; pregnant or breastfeeding women; a person with restricted liberty or under legal protection~Sample collection time points: 1 (day of blood sample donation)"
62045592|NCT04550988||Adult patients with severe haemophilia A or B|"* Adult patients (≥ 18 years of age) suffering from severe haemophilia A or B~* No professional medical background~* Submitted written consent to participate in the study and to use their study related pseudonymised data"
62045593|NCT03584932|EXPERIMENTAL|Intervention arm|Subjects participate in a youth service navigation intervention and are eligible to receive contingency management incentives.
62045594|NCT03584932|NO_INTERVENTION|Control arm|Standard of care as set forth by the national HIV care guidelines.
62045595|NCT02432105|EXPERIMENTAL|EXE844 for 7 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops, twice daily (BID) in each ear for 7 days after Tympanostomy Tube Insertion
62045596|NCT02432105|EXPERIMENTAL|EXE844 for 3 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops BID in each ear for 3 days after Tympanostomy Tube Insertion
62045597|NCT02432105|ACTIVE_COMPARATOR|Tubes Only|Bilateral myringotomy and tympanostomy tube insertion
62045598|NCT01936025|ACTIVE_COMPARATOR|Sitagliptin|Placebo dextromethorphan + sitagliptin 100 mg
62045599|NCT01936025|EXPERIMENTAL|Dextromethorphan 30 mg + sitagliptin|Dextromethorphan 30 mg + sitagliptin 100 mg
62045600|NCT01936025|EXPERIMENTAL|Dextromethorphan 60 mg + sitagliptin|Dextromethorphan 60 mg + sitagliptin 100 mg
62045601|NCT01936025|EXPERIMENTAL|Dextromethorphan 90 mg + sitagliptin|Dextromethorphan 90 mg + sitagliptin 100 mg
62045602|NCT01936025|EXPERIMENTAL|Dextromethorphan 30 mg + placebo|Dextromethorphan 30 mg + placebo (sitagliptin)
62045603|NCT01936025|EXPERIMENTAL|Dextromethorphan 60 mg + placebo|Dextromethorphan 60 mg + placebo (sitagliptin)
62045604|NCT01936025|EXPERIMENTAL|Dextromethorphan 90 mg + placebo|Dextromethorphan 90 mg + placebo (sitagliptin)
62045605|NCT01936025|PLACEBO_COMPARATOR|Placebo|Placebo (dextromethorphan)+ placebo (sitagliptin)
62045606|NCT03973008|EXPERIMENTAL|Adujvant CT+CRT|Four to six weeks after D2 radical surgery, adjuvant chemotherapy was initiated with SOX regimen , repeated every three weeks, and adjuvant radiotherapy was started at the end of two cycles of adjuvant chemotherapy , with synchronous tegiol single drug chemotherapy. And the original SOX regimen was continued for 4 cycles after 3-4 weeks of radiotherapy.
62045607|NCT03973008|ACTIVE_COMPARATOR|Adujvant CT|The adjuvant chemotherapy was started 4-6 weeks after D2 radical operation. The SOX regimen was repeated every 3 weeks for 8 cycles.
62247967|NCT02654249|ACTIVE_COMPARATOR|Ligasure hemorroidectomy|Patients will undergo to Ligasure™ hemorroidectomy under generla anesthesia.
62247968|NCT05024305|EXPERIMENTAL|Dose Escalation Cohort|Four dose levels of TWP-102 injection will be tested by BOIN study design.
62247969|NCT05024305|EXPERIMENTAL|Dose Expansion Cohort|Once the effective doses have been determined, two expansion cohorts will be opened to evaluate the efficacy and safety in one or two tumors.
62247970|NCT04466644||The regulars of IVF clinics in the USA|Mainly asymptomatic individuals composed by patients who are attending their regular medical consultation and/ clinic staff of the participant sites, located in two areas of the USA with different pandemic status, and undergoing PCR and ELISA tests for diagnosis of COVID-19 before initiating the work after the lockdown.
62604845|NCT05766618|EXPERIMENTAL|injection site|it is the arm where the patients will receive the PRF injection intraligamentally in distobuccal, and distopalatal areas of the distal surface of the canine also submucosal injection will be given buccally and palatially (0.25mm) for each side in either the right or left side of the arch.
62604846|NCT05766618|NO_INTERVENTION|control site|it is the arm where the patients will not receive any injection with the same method of retraction as the intervention side.
62604847|NCT01914211||Acute Normovolemic Hemodilution|Patients that receive acute normovolemic hemodilution prior to surgery.
62604848|NCT01914211||Tranexamic Acid|Patients that receive tranexamic acid during surgery.
62604849|NCT04978805|EXPERIMENTAL|Progressive Relaxation Exercise|A total of 56 sessions of progressive relaxation were performed, 7 days a week for 8 weeks. Each session is set as fifty minutes
62604850|NCT04978805|NO_INTERVENTION|Control group|Routine maintenance will be applied
62604851|NCT04398186||Study group 1|Hiperandrogenism + ultrasonographic PCO
62604852|NCT04398186||Study group 2|Menstruel cycle irregular + ultrasonographic PCO
62604853|NCT04398186||Study group 3|Menstruel cycle irregular + ultrasonographic PCO + hyperandrogenism
62045608|NCT05748912|EXPERIMENTAL|Therapeutic bronchoscopy for removal of mucus plugs|Protocol A: This protocol will study 10 patients with asthma who have CT (Computed Tomography) evidence of mucus plugs in their airways. Screening data will be reviewed to determine participant eligibility. Participants who meet all eligibility criteria will participate in a bronchoscopy done on one lung for the first 5 participants, and if single lung mucus removal is well tolerated then we will perform bronchoscopies on both lungs for the next 5 participants.
62045609|NCT05759195|OTHER|Biomolecular tumor analysis|NGS, IHC, methylome and other molecular studies
62247971|NCT03352700|PLACEBO_COMPARATOR|3L PEG|only used 3L PEG
62604854|NCT04398186||Control group|Do not have PCOS
62604855|NCT05654272||Normal|Normal volunteers \>=18 years older
62604856|NCT05654272||Cardiovascular Disease Patient|\>=18years older with known prior cardiovascular disease
62604857|NCT05168384|EXPERIMENTAL|Group A (ECP + SoC Group)|Extracorporeal photopheresis (ECP) plus Multiple Sclerosis (MS) standard of care
62604858|NCT05168384|ACTIVE_COMPARATOR|Group B (SoC Group)|MS standard of care alone (SoC, defined by Disease-modifying Therapy -DMT, recommended by the American Academy of Neurology -AAN
62604859|NCT02635542|ACTIVE_COMPARATOR|Group CIS|Continual neuromuscular blockade (standard therapy) during general anesthesia will be provided with cisatracurium (CIS), with 0.2mg/kg IV given as an initial dose and repeated dosing determined by neuromuscular blockade monitoring (peripheral nerve stimulator maintained at 1-2 twitches).
62604860|NCT02635542|EXPERIMENTAL|Group SUX|A single dose of neuromuscular blockade (experimental group) will be provided at the start of anesthesia with succinylcholine (SUX), with 1mg/kg IV given as an initial dose and no repeat dosing.
62604861|NCT05353972|EXPERIMENTAL|Cohort 1|Single dose of IMG or placebo solution, intravenously administered
62827614|NCT05122806|OTHER|Bioexalk cohort|All patients included in Explore ALK GFPC 03-2019 study who agree to participate in Bioexalk.
62827615|NCT00325897|ACTIVE_COMPARATOR|Azithromycin, 250 mg|Macrolide Antibiotic (Azithromycin)
62827616|NCT00325897|PLACEBO_COMPARATOR|Placebo|Inactive
62604862|NCT05353972|EXPERIMENTAL|Cohort 2|Single dose of IMG or placebo solution, intravenously administered
62604863|NCT05353972|EXPERIMENTAL|Cohort 3|Single dose of IMG or placebo solution, intravenously administered
62827617|NCT00655902|EXPERIMENTAL|1|
62827618|NCT00655902|PLACEBO_COMPARATOR|2|
62827619|NCT03432598|EXPERIMENTAL|Non-squamous NSCLC|"Day 1 of each 21-day (3 weeks) cycle: Tislelizumab + pemetrexed + cisplatin 75 mg/m²/day IV (or carboplatin AUC 5).~Pemetrexed plus cisplatin (or carboplatin) should be given for up to 4 cycles.~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate. Pemetrexed maintenance after completion of doublet chemotherapy is permitted."
62604864|NCT05353972|EXPERIMENTAL|Cohort 4|Single dose of IMG or placebo solution, intravenously administered
62604865|NCT05353972|EXPERIMENTAL|Cohort 5|Single dose of IMG or placebo solution, intravenously administered
62604866|NCT05353972|EXPERIMENTAL|Cohort 6|Single dose of IMG or placebo solution, intravenously administered
62604867|NCT05353972|EXPERIMENTAL|Cohort 7|Single dose of IMG or placebo solution, intravenously administered
62604868|NCT02607306|EXPERIMENTAL|Insulin degludec/liraglutide OD|
62045610|NCT01249248||Male basketball players|
62247972|NCT03352700|EXPERIMENTAL|3L PEG+Dyclonine Hydrochloride Mucilage|used 3L PEG+Dyclonine Hydrochloride Mucilage
62247973|NCT00068588|EXPERIMENTAL|Treatment (GTI-2040, capecitabine)|Patients receive GTI-2040 IV continuously on days 1-15 of the first course and days 1-14 of all subsequent courses. Patients also receive oral capecitabine twice daily on days 2-15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62247974|NCT00992979|EXPERIMENTAL|Therapeutic Massage|
62604869|NCT02607306|ACTIVE_COMPARATOR|Insulin degludec OD|
62604870|NCT02607306|ACTIVE_COMPARATOR|Liraglutide OD|
62604871|NCT06384456|EXPERIMENTAL|Topical TRanexamic Acid|10mL of 100mg/mL TXA in addition to the standard care
62604872|NCT06384456|PLACEBO_COMPARATOR|Placebo|10mL of 100mg/mL normal saline in addition to the standard care
62604873|NCT00835627|ACTIVE_COMPARATOR|sertraline|flexible dose sertraline
62604874|NCT00835627|ACTIVE_COMPARATOR|CBT-ip|cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual, 1 hour therapy sessions
62604875|NCT00835627|ACTIVE_COMPARATOR|Combined (sertraline + CBT-ip)|flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12 individual, 1 hour therapy sessions
62604876|NCT00835627|ACTIVE_COMPARATOR|Standard care|community care / treatment as usual: routine follow up with existing providers
62827620|NCT03432598|EXPERIMENTAL|Squamous NSCLC Cohort A|"Tislelizumab every 3 weeks (Q3W) + paclitaxel + cisplatin (or carboplatin), Q3W.~Paclitaxel plus cisplatin (or carboplatin) will be administered for 4-6 cycles.~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate."
62604877|NCT00311103|NO_INTERVENTION|Care in the Control Group (CG)|Care in the Control Group (CG): was that provided by the General Practitioners, with basic diagnostic and therapeutic procedures without specified protocols.
62604878|NCT00311103|EXPERIMENTAL|Early Intervention Programa (IG)|Early Intervention Programa (IG): Patients assigned to the intervention group after the randomization were offered an immediate appointment. Patients, who voluntarily accepted, were attended by 2 rheumatologists. The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
62604879|NCT01099774|EXPERIMENTAL|Bimatoprost 0.03% Formulation B Ophthalmic Solution|Bimatoprost 0.03% Formulation B Ophthalmic Solution
62604880|NCT01099774|ACTIVE_COMPARATOR|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% Ophthalmic Solution
62604881|NCT03054064|EXPERIMENTAL|All Enrolled Subjects|All enrolled subjects will receive gait training with the Indego.
62045611|NCT01249248||Female basketball players|
62045612|NCT01249248||Baseball players|
62604882|NCT06455124|EXPERIMENTAL|Arm1|Patients will receive short course radiotherapy and four cycles of CapeOx and PD-1 inhibitor.
62045613|NCT01249248||Softball players|
62045614|NCT01249248||Football players|
62604883|NCT00480493|EXPERIMENTAL|Parent mentor contact|Parent mentor provides face-to-face social support
62604884|NCT00480493|ACTIVE_COMPARATOR|Control Arm|Parent is given a phone contact
62604885|NCT02990351||HCC patients|29 HCC patients who had loco regional therapies for HCC were analyzed. Twenty patients met the Milan criteria (68.97%) \& 4 (13.8%) were beyond Milan but met UCSF criteria and 5 were exceeding UCSF criteria (17.2%).All patients underwent preoperative LRTs, The protocol of bridging/down staging, methods, duration of follow up, the number of the patients who were successfully down-staged before LT and their outcomes after LT were recorded.
62604886|NCT02454075|EXPERIMENTAL|Eligible patients|The dose will be 100 mg YF476 once daily. When 6 patients have completed 12 weeks' treatment with that dose, it may be increased to 150 or 200 mg once daily. Patients will have type II gastric carcinoids and/or ECL cell hyperplasia/dysplasia.
62045615|NCT01249248||Female vollyball players|
62045616|NCT01249248||Male soccer players|
62045617|NCT01249248||Female soccer players|
62045618|NCT02792465|EXPERIMENTAL|Cohort A|CFI-402257 capsules will be taken orally, once a day, every day.
62604887|NCT03819959||Intensive Care Patients|Polytrauma patients who have been admitted to intensive care
62604888|NCT00501059|EXPERIMENTAL|Acetylsalicylic acid (Aspirin, BAYE4465)|Participants received 1 tablet of enteric-coated acetylsalicylic acid \[100 milligram (mg)\] orally once daily.
62604889|NCT00501059|PLACEBO_COMPARATOR|Placebo|Participants received 1 tablets of matching placebo orally once daily.
62827621|NCT03432598|EXPERIMENTAL|Squamous NSCLC Cohort B|"Tislelizumab Q3W on Day 1 + gemcitabine on Day 1 and Day 8 + cisplatin IV (or carboplatin) on Day 1.~Gemcitabine plus cisplatin (or carboplatin) will be administered for 4-6 cycles.~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate."
62045619|NCT02792465|EXPERIMENTAL|Cohort B|CFI-402257 capsules will be taken orally, once a day, every day.
62045620|NCT02792465|EXPERIMENTAL|Cohort C|CFI-402257 capsules will be taken orally, once a day, every day + Fulvestrant injection on day 1 and day 15 of every 28 day cycle
62045621|NCT02010125||Acute ACL injury|"Subjects with acute ACL injury will be recruited and enrolled within 28 days of injury Serum, urine, and synovial fluid will be collected at baseline, 6wks post-injury or post-surgery, 6 months, and 1 year Patients will have a quantitative MRI on both knees 7 days after initial visit, then at 6 months and 1 year.~Patients may or may not opt for ACL reconstruction Patients will have functional testing (One-legged hop tests and Star excursion balance test) at 6 months and 1 year Patients will fill out questionnaires (Knee Osteoarthritis Outcome Survey, Veteran Rand-12, Lysholm, International Knee Documentation Committee, Marx Questionnaire) at baseline, 6 weeks, 6 months, and 1 year"
62045622|NCT00976599|EXPERIMENTAL|CP-690,550 + methotrexate|
62045623|NCT00976599|PLACEBO_COMPARATOR|Placebo + methotrexate|
62045624|NCT05776030|EXPERIMENTAL|Ergonomic Wheelchair Gear Testing|This study has two aims. The first aim will have participants use a single speed ergonomic wheelchair to test three different gear ratio set ups (3:2, 1:1, 2:3).
62045625|NCT05776030|EXPERIMENTAL|Multispeed Testing - Ergonomic Wheelchair|The second aim will have participants compared to the participant's standard wheelchair to a multi-speed (2 gear ratios) ergonomic wheelchair.
62604890|NCT05810506||Healthy|Healthy individuals; they were required to sign the voluntary consent form, not consume alcohol, be between 30-64 years old, and not have any acute or chronic diseases. Individuals outside these criteria were not included in the study. In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.
62437978|NCT02903433|EXPERIMENTAL|High Intake Group|"Throughout the entire study, this group will be provided with 14 avocados per week and will receive 12 bi-weekly home visits over a 6-month period during which they will receive specific brochures offering diet tips. This group will be given specific advice on avocado consumption. Each month throughout the study, we will provide opportunities for families to visit the study kitchen at the SYHC to observe the staff preparing recipes with avocado, participate in preparing recipes, and taste recipes."
62437979|NCT02903433|ACTIVE_COMPARATOR|Low Intake Group|"This group will receive 3 avocados per week, as well as 12 bi-weekly home visits over a 6-month period during which they will be provided with the same educational materials (i.e., Diet Tips) as those assigned to the High intake group. Participants in this group will be encouraged to improve the quality of their diets, but will not be given specific advice on avocado consumption. However, each month throughout the study, we will provide opportunities for families to visit the study kitchen at the SYHC to observe the staff preparing recipes with avocado, participate in preparing recipes, and taste recipes."
62604891|NCT05810506||NAFLD|NAFLD patients included in the study should sign a voluntary consent form, do not consume alcohol, be between 30-64 years old, have been diagnosed with NAFLD by applying to the gastroenterology outpatient clinic, have no other diseases, and should not use medication. In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.
62604892|NCT05721677|EXPERIMENTAL|Tissue adhesive|Tissue adhesive application at the CVL exit-site, on all CVLs, PICCs during the patient LOS. Regular CLABSI preventive protocol. Regular preventive CVL dressings (Chlorhexidine \>2mo).
62604893|NCT05721677|NO_INTERVENTION|Control group|Regular CLABSI preventive protocol. Regular preventive CVL dressings (Chlorhexidine \>2mo).
62604894|NCT01031745|EXPERIMENTAL|Contingency|
62604895|NCT01031745|ACTIVE_COMPARATOR|Control|
62604896|NCT00785213|ACTIVE_COMPARATOR|Rosiglitazone Alone|Baseline rosiglitazone pharmacokinetics.
62604897|NCT00785213|EXPERIMENTAL|Rosiglitazone with Steady State Quinine Sulfate|Rosiglitazone pharmacokinetics in the presence of steady state quinine sulfate.
62604898|NCT04355806||Vaccinated NSCLC group|This group contains 100 NSCLC patients receiving PD-1/PD-L1 inhibitors for more than 6 months, who will be intramuscularly injected one dose of inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
62437980|NCT03013166||Cohort 1|IR hydrocortisone
62247975|NCT00992979|ACTIVE_COMPARATOR|Relaxation Control|Relaxation Control Session
62247976|NCT04216251|EXPERIMENTAL|AMR101|"Study procedures include screening for eligibility and study treatment including ARM101 Lifestyle questionnaire, Nutritional survey. Flexible sigmoidoscopy (24 biopsies of normal colorectal mucosa, one stool sample),blood, evaluations, and follow up visits.~- AMR101-oral predetermined protocol dosage, daily for a minimum of 8 weeks and maximum of 12 weeks"
62437981|NCT03013166||Cohort 2|IR prednisolone
62604899|NCT04355806||Vaccinated Health group|This group contains 30 healthy participants without immunosuppressive diseases, who will be intramuscularly injected one dose of inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
62604900|NCT04355806||Unvaccinated NSCLC group|This group contains 30 NSCLC patients receiving PD-1/PD-L1 inhibitors for more than 6 months without intramuscular injection of any inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
62604901|NCT02174705|EXPERIMENTAL|Sucrose|Sucrose prior to vaccine injections
62604902|NCT02174705|ACTIVE_COMPARATOR|Rotavirus|Rotavirus prior to vaccine injections
62604903|NCT02134353|EXPERIMENTAL|Experimental arm A|Active treatment. Inhaled Mannitol
62604904|NCT02134353|PLACEBO_COMPARATOR|Arm B - Control|Arm B
62604905|NCT06339203|EXPERIMENTAL|Irrisept|The experimental arm will receive irrigation solution Irrisept administered through a proprietary bottle (jet lavage) following the closure of the fascia in Cesarean section.
62604906|NCT06339203|ACTIVE_COMPARATOR|Normal Saline|The active comparator arm will receive the standard of care irrigation solution, normal saline, administered via standard pour over following the closure of the fascia in Cesarean section.
62604907|NCT02464891|EXPERIMENTAL|CCX168|Study medication will be administered as hard gelatin capsules containing 10 mg CCX168. Patients will take 30 mg CCX168, given as 3 x 10 mg capsule, twice daily for 15 days.
62247977|NCT00627302|ACTIVE_COMPARATOR|2|Systane
62247978|NCT00627302|ACTIVE_COMPARATOR|1|PEG-400
62247979|NCT04440189|PLACEBO_COMPARATOR|Placebo|Subjects will receive an injection of Lactated Ringers in their index knee
62247980|NCT04440189|EXPERIMENTAL|Stromal Vascular Fraction (SVF)|Subjects will receive an injection of Stromal Vascular Fraction in their index knee
62247981|NCT05709236|EXPERIMENTAL|Completely edentulous maxillary arch digital impression|treated with Maxillary screw-retained prosthesis with digital full-arch impression
62247982|NCT05709236|ACTIVE_COMPARATOR|Completely edentulous maxillary arch conventional impression|treated with Maxillary screw-retained prosthesis with conventional full-arch impression
62437982|NCT03013166||Cohort 3|MR hydrocortisone
62437983|NCT03013166||Cohort 4|IR to MR hydrocortisone
62449245|NCT02806232|EXPERIMENTAL|Part 1, Cohort 6: Levo Praziquantel 45 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.
62604908|NCT02456038|EXPERIMENTAL|Asfotase Alfa (ALXN1215)|Asfotase Alfa (ALXN1215) is administered 6mg/kg in total per week, divided into 3 times.
62604909|NCT06215300||genotype GG|GG
62604910|NCT06215300||genotype AG/АА|AG/АА
62604911|NCT06172348|EXPERIMENTAL|Treatment Sequence 1|Ritlecitinib 100 mg solution (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule 1 (fasted, Period 2), followed by ritlecitinib 100 mg MR capsule 2 (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 1 (fed, Period 4)
62604912|NCT06172348|EXPERIMENTAL|Treatment Sequence 2|Ritlecitinib 100 mg MR capsule 1 (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule 2 (fasted, Period 2), followed by ritlecitinib 100 mg solution (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 1 (fed, Period 4)
62604913|NCT06172348|EXPERIMENTAL|Treatment Sequence 3|Ritlecitinib 100 mg MR capsule 2 (fasted, Period 1), followed by ritlecitinib 100 mg solution (fasted, Period 2), followed by ritlecitinib 100 mg MR capsule 1 (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 1 (fed, Period 4)
62604914|NCT06172348|EXPERIMENTAL|Treatment Sequence 4|Ritlecitinib 100 mg solution (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule 1 (fasted, Period 2), followed by ritlecitinib 100 mg MR capsule 2 (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 2 (fed, Period 4)
62604915|NCT06172348|EXPERIMENTAL|Treatment Sequence 5|Ritlecitinib 100 mg MR capsule 1 (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule 2 (fasted, Period 2), followed by ritlecitinib 100 mg solution (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 2 (fed, Period 4)
62604916|NCT06172348|EXPERIMENTAL|Treatment Sequence 6|Ritlecitinib 100 mg MR capsule 2 (fasted, Period 1), followed by ritlecitinib 100 mg solution (fasted, Period 2), followed by ritlecitinib 100 mg MR capsule 1 (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 2 (fed, Period 4)
62827622|NCT03432598|EXPERIMENTAL|SCLC|"Tislelizumab Q3W on Day 1, etoposide on Days 1, 2, and 3 + cisplatin (or carboplatin) on Day 1.~Etoposide and cisplatin (or carboplatin) will be administered for 4-6 cycles.~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate."
62247983|NCT00726622|ACTIVE_COMPARATOR|Arm 1: Open laparotomy and rectal resection|Patients undergo open laparotomy and rectal resection. The standard form of surgery is open laparotomy rectal resection. During open laparotomy, the surgeon makes a large incision or cut in the abdomen, and goes in through that cut to remove the tumor and lymph nodes from the rectum.
62827623|NCT05951933|EXPERIMENTAL|Strenghtening + a-TES real|Protocol of therapeutic exercises + real transcranial electrical stimulation of 8 weeks duration (24 supervised sessions). The program will consist of exercises to strengthen the RM and the scapulothoracic muscles, but the EG will perform the RM strengthening exercises while receiving real a-tDCS.
62827624|NCT05951933|SHAM_COMPARATOR|Strenghtening + a-TES placebo|Protocol of therapeutic exercises + placebo transcranial electrical stimulation of 8 weeks duration (24 supervised sessions). The program will consist of exercises to strengthen the RM and the scapulothoracic muscles, but the CG will perform the RM strengthening exercises while receiving placebo a-tDCS.
62827625|NCT05240820|PLACEBO_COMPARATOR|Vicryl+Prolene|wound closure using polyglactin 910 (Vicryl®, Ethicon, Johnson and Johnson Ltd., NJ, USA) and polypropylene (Prolene®, Ethicon)
62045626|NCT05776030|EXPERIMENTAL|Multispeed Testing - Standard Wheelchair|The second aim will have participants compared to the participant's standard wheelchair to a multi-speed (2 gear ratios) ergonomic wheelchair.
62045627|NCT02455648|EXPERIMENTAL|ESD/EMR plus Cell Sheet|Patients receive both mucosal buccal biopsy and insertion of cell sheets during/after ESD/EMR
62045628|NCT02455648|SHAM_COMPARATOR|ESD/EMR|patients receive both mucosal biopsy but no placement of cell sheets during/after ESD
62247984|NCT00726622|EXPERIMENTAL|Arm 2: Laparoscopic-assisted rectal resection|Patients undergo laparoscopic-assisted rectal resection. Laparoscopic-assisted rectal resection is performed using small instruments on long handles introduced into the abdomen through small ports called trocars in 3 - 6 positions on the abdomen through incisions measuring 5 -10 mm, under the guidance of a video camera. The abdominal wall is held up with carbon dioxide under pressure. The piece of bowel or intestine is removed through another incision (about 8 centimeters), and the ends of the intestine are reconnected to provide normal bowel function.
62045629|NCT05989217|EXPERIMENTAL|Occlusal Splint|"Participants allocated will receive therapy with a stabilizing plate made by the simplified technique. This plate is made of an acetate plate, plasticized in a plaster model, and individualized by acrylic resin. This technique allows the professional to make and install the plate in a short time, without the laboratory step, and is also more economical.~After the plate installation and adjustments, the participant will be instructed to use the device every night during sleep. Weekly adjustments will be performed for 4 weeks, and in these sessions information regarding the research parameters will be collected."
62247985|NCT04047160|EXPERIMENTAL|OP-724|"Dose: 140, 280, 380 mg/m2/4 hrs~Administration method:~\[Level 1\] 140 mg/m2/4 hours \[Level 2\] 280 mg/m2/4 hours (starting dose) \[Level 3\] 380 mg/m2/4 hours Continuous intravenous administration will be done for 4 hours twice a week. This procedure will be as one cycle and 12 cycles (12 weeks in total) will be conducted. On 7 days prior to the first cycle administration, a dose scheduled in the first cycle will be administered with continuous intravenous for 4 hours and the safety and pharmacokinetics on the day of administration to the next day after administration will be evaluated."
62604917|NCT01284387|EXPERIMENTAL|3 μg ACC-001 / QS-21 50 μg IM dose 1|3 μg ACC-001 / QS-21 50 μg IM
62604918|NCT01284387|EXPERIMENTAL|10 μg ACC-001 / QS-21 50 μg IM dose 2|10 μg ACC-001 / QS-21 50 μg IM
62604919|NCT01284387|NO_INTERVENTION|Placebo - Phosphate buffered saline (PBS) IM dose|Placebo - Phosphate buffered saline (PBS) IM
62604920|NCT01397786|EXPERIMENTAL|OPC-34712|
62827626|NCT05240820|ACTIVE_COMPARATOR|PDS+Dermabond|wound closure using polydioxanone (StratafixTM Spiral PDS® Plus) and combination of 2-octyl cyanoacrylate and polyester mesh (Dermabond Prineo®)
62604921|NCT03119623|ACTIVE_COMPARATOR|Sacubitril/Valsartan|Sacubitril/valsartan 100mg (Dose Level 1) titrated up if tolerated to 200 mg twice daily (Dose Level 2)
62604922|NCT03119623|ACTIVE_COMPARATOR|Enalapril|Enalapril 5mg (Dose Level 1) titrated up if tolerated to 10mg twice daily (Dose Level 2)
62623451|NCT04776577|OTHER|Study arm|"Group 1 and group 2 will be recruited and assessed in parallel at the discretion of the treating physician, based on the characteristics of the patient. Group 3 will be recruited from suitable patients in group 1 and 2.~Simultaneous measurements study (group 1) Regular study group (group 2) Echocardiography-CFR group (group 3)"
62623452|NCT05195099|ACTIVE_COMPARATOR|control group|
62623453|NCT05195099|EXPERIMENTAL|respiratory treatment|
62623454|NCT02064699||CMV infection|Renal transplant recipient immunized against the Cytomegalovirus
62827627|NCT04046497|EXPERIMENTAL|Smartphone App|artificial intelligence (AI) smartphone app to provide support for medication adherence
62827628|NCT04046497|ACTIVE_COMPARATOR|Usual Care|Usual care provided at CSC clinic
62045630|NCT05989217|EXPERIMENTAL|Laser Therapy|"All participants will be examined and pain trigger points will be identified, if any. The laser will be applied at predetermined points and at specific trigger points identified during the clinical examination. The application of the laser will be symmetrical, i.e. on both sides of the face, with the same number of points, regardless of whether it is a trigger point or not.~The equipment to be used and the parameters for the applications have the following characteristics: 808 nm wavelength, 100 mW of useful emitter power, 105 J/cm2 of energy density, spot area 0.028 cm2, Energy/point 3 J, 1 application per week for 4 weeks."
62045631|NCT05989217|EXPERIMENTAL|Occlusal Splint + Laser Therapy|The therapies will be associated during the same period as the other groups, ensuring the same application and evaluation protocols.
62247986|NCT01098981|EXPERIMENTAL|Target group|A combined treatment with transcranial US and systemic tPA
62045632|NCT03059901|EXPERIMENTAL|More App Notifications|Participants receive more notifications than the Active Comparator group from the Caminamos app to walk.
62045633|NCT03059901|ACTIVE_COMPARATOR|Normal App Notifications|Participants receive less notifications than the Experimental group from the Caminamos app to walk.
62045634|NCT00135005|EXPERIMENTAL|AMN107 + STI571|
62247987|NCT01098981|ACTIVE_COMPARATOR|Control group|Systemic tPA alone
62247988|NCT01852240||erectile dysfunction|"Inclusion criteria:~* male patients with ED defined by an IIEF-5 score of ≤ 21~* age between 18-45a~Exclusion criteria:~* systemic diseases (e.g. diabetes mellitus, heart disease, hypertension, neurological disorders etc.)~* pure psychogenic (non-organic) ED with good spontaneous / nightly erections~* periodontal treatment within the last 3 months~* antibiotic intake within the last 3 months"
62247989|NCT02626468||Normal|Participants with no diagnosis of respiratory disease between the ages of 0 and 80
62247990|NCT02626468||COPD|Patients from different diagnostic groups between the ages of 0 and 80
62437984|NCT05118282|EXPERIMENTAL|Combined coping skills + asthma management arm|The combined coping skills + asthma management arm is a family-based coping skills + asthma management intervention that is bilingual and culturally relevant for Latino families. This program is manualized with video-guided and interactive content to improve coping with stress and asthma management behaviors for both children and their parents. Coping strategies taught include primary and secondary control coping. Asthma management content is interactive and culturally tailored.
62437985|NCT05118282|ACTIVE_COMPARATOR|Standard asthma management arm|The standard asthma management (AM) arm is an asthma management intervention covering standard asthma self-management content (e.g., symptom recognition, self-monitoring). AM is manualized and is matched in length, time, and number of sessions to the experimental arm.
62437986|NCT04283383|EXPERIMENTAL|Intervention training|A structured training process oriented to the clinical practice of the family physician, Primary Care Clinical Ultrasound Classroom (AECAP) will be carried out, and the improvement of knowledge and skills will be evaluated, as well as the improvement of quality of care based on clinical indicators.
62437987|NCT04283383|NO_INTERVENTION|control|
62437988|NCT00285545||Good blood flow|Group with normal blood flow to small intestine
62437989|NCT00285545||Poor blood flow|Group with partial ischemia to small intestine
62437990|NCT04520854|EXPERIMENTAL|2-week Telehealth Protocol|Participants randomized to this arm will receive 5 live-video sessions. The first 2 live-video sessions will occur during the first week, last 20 minutes each and separated by 48-72 hours. The last 3 live-video sessions will occur during the second week, last 30-minutes each and separated by 24-48 hours.
62437991|NCT04520854|ACTIVE_COMPARATOR|2-week Usual Care|The usual care group will be used to reflect the current care provided to patients after discharged from the emergency department for an ankle sprain.
62437992|NCT06528483|EXPERIMENTAL|Sacituzumab Govitecan + Zimberelimab|patients will be treated with Sacituzumab Govitecan 1,8q21 plus + Zimberelimab q21 for 3 cycles then radiological imaging and TURB will be repeated and patients with Stability of disease or down staging will continue Zimberelimab until disease progression, or unacceptable toxicities or completion of treatment (16 cycles). Patients with progressive disease after 3 cycles of study intervention will be treated as per clinical practice.
62437993|NCT01042977|EXPERIMENTAL|1|dapagliflozin 10 mg tablet
62437994|NCT01042977|PLACEBO_COMPARATOR|2|matching placebo tablet
62045635|NCT03960905||Children with the usage of anti-infective drugs|in conformity with the clinical practice
62247991|NCT02698748|EXPERIMENTAL|Chloroquine|Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
62247992|NCT02698748|PLACEBO_COMPARATOR|Placebo|Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain.
62247993|NCT05830578||Cohort 1|Subjects enrolled into Cohort 1 must have no known medical history of AFib and in normal sinus rhythm at the time of screening.
62247994|NCT05830578||Cohort 2|Subjects enrolled into Cohort 2 must have a known diagnosis of persistent or permanent AFib and be in AFib at the time of screening.
62247995|NCT01887639||Unipolar major depression|Outpatients Individuals between 18 and 75 years old with a current episode of non-psychotic unipolar major depression that are treated with an antidepressant drug according to physician´s current and usual practice.
62437995|NCT04011085||Group1|Patients currently undergoing treatment for early breast cancer (either targeted HER2 therapy and chemotherapy OR targeted HER therapy alone)
62437996|NCT04011085||Group2|Patients with early breast cancer who have completed treatment and are in disease-free survival (i.e. no longer receiving locoregional treatment, chemotherapy or targeted HER2 therapy; patients may still be receiving hormone therapy)
62437997|NCT04011085||Group3|Patients receiving treatment for metastatic breast cancer
62437998|NCT03145883|NO_INTERVENTION|Control group|Control group
62827629|NCT02495506|EXPERIMENTAL|Cold stored platelets|Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery
62045636|NCT04481490||Home-based|Cardiac rehabilitation (including exercise training) delivered in a home-based setting, facilitated remotely by Mayo Clinic staff.
62045637|NCT04481490||Center-based|Cardiac rehabilitation (including exercise training) delivered in a center-based setting, facilitated in person by Mayo Clinic staff.
62045638|NCT03208023|ACTIVE_COMPARATOR|Standard intraoperative care- no interventions|Standard intraoperative hemodynamic monitoring and treatment at Vanderbilt University Medical Center - No study interventions
62045639|NCT03208023|EXPERIMENTAL|RESIPI|Intraoperative implementation of RESIPI management strategy, a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical).
62045640|NCT04097457|EXPERIMENTAL|Parent mediated intervention (PMI) group|A short term parent training protocol based on behavioral principles, which is delivered by trained therapists. The protocol includes eleven core sessions, a home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered to parents in an outpatient and home settings. The protocol is administered to groups of 4 families.
62045641|NCT04097457|EXPERIMENTAL|Waitlist control|Families will be recruited and will fill out measure for 3 months prior to participation and will then join the active intervention
62247996|NCT02923089|EXPERIMENTAL|Small Green Lentil Muffin|Muffin: 25g available carbohydrate from small green lentil
62247997|NCT02923089|EXPERIMENTAL|Split Red Lentil Muffin|Muffin: 25g available carbohydrate from split red lentil
62437999|NCT03145883|EXPERIMENTAL|Home-based Aerobic Exercise|Participants will be prescribed weekly exercise goals starting with 75 minutes a week (e.g., 15 minutes per day, 5 days a week) and progressed to 200 minutes a week (e.g., 40 minutes per day, 5 days a week) by week 12. Exercise will consist of participant preference of mobility exercises, most likely walking. Aerobic exercise, similar to a brisk walk, will be recommended as the primary mode of exercise.
62604923|NCT03806231|EXPERIMENTAL|Outpatient Cervical Ripening|Patients randomized to the outpatient cervical ripening arm will come in for a scheduled visit in Labor and Delivery prior to her scheduled induction. A research nurse will examine her and place the Cervidil insert into the posterior vaginal fornix. The patient will be monitored for 2 hours and sent home after a the following are present: (1) reactive non-stress test (NST) (2) category 1 tracing x 2 hours (3) no vaginal bleeding (4) normal maternal vital signes (5) intact bag of water (BOW) and (6) less than 1 contraction every 10 minutes at the time of discharge. The patient will remove the insert the following morning prior to her scheduled induction.
62827630|NCT02495506|ACTIVE_COMPARATOR|Room temperature platelets|Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery
62827631|NCT01586364|EXPERIMENTAL|Ospemifene 60 mg Oral Tablet|Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.
62827632|NCT06396884||Control Group|Elderly patients over 65 years of age who underwent surgery for femoral fracture under spinal anesthesia. These patients underwent oscillometric intermittent (5 mins) noninvasive blood pressure monitoring during the surgical procedure and received intraoperative hemodynamic management based on a liberal fluid therapy protocol.
62827633|NCT06396884||ClearSight Group|Elderly patients over 65 years of age who will undergo surgery for femoral fracture under spinal anesthesia. These patients will undergo continuous and non-invasive blood pressure monitoring using the ClearSight system, and fluid management according to a hemodynamic optimization protocol based on goal-directed fluid therapy
62827634|NCT02077010|EXPERIMENTAL|Inhaled nebulized milrinone|Inhaled nebulized milrinone 60mg/4ml every 8 hours using a jet nebulizer
62827635|NCT03673800|EXPERIMENTAL|Cognitive Training|Online Cognitive training on the Scientific Brain Training® (SBT®) platform with optional guidance by phone
62827636|NCT03673800|SHAM_COMPARATOR|Online sensorial program|Online sensorial program on the Scientific Brain Training® (SBT®) platform with optional guidance by phone
62827637|NCT04314284|OTHER|Historical Control Survey|-The investigators will conduct a historic control survey of 80-100 recently diagnosed gynecologic, colorectal, and lung cancer patients. They can complete the survey in-person, over the phone, or online. The survey will take approximately 15 minutes to complete. It will ask about their knowledge of health insurance and confidence communicating about care costs.
62827638|NCT04314284|EXPERIMENTAL|I Can PIC|-Approximately 80-100 participants will use I Can PIC. This will take approximately 10-15 minutes. After their next appointment with their provider, they will complete a brief survey about their knowledge of health insurance and confidence communicating about care costs. This will take about 10 mins. Patient participants who choose to complete the study in person may view I Can PIC on a tablet provided in the clinic or at the office. Then after their appointment, they can complete the survey on a tablet provided in the clinic or at the office. If they choose to complete it over the phone, the investigators will email them the link to I Can PIC and then call them when it is time to complete the survey. If they wish to complete it online, the investigators will email them the link to I Can PIC, and then the survey after their appointment. After 3-6 months, participants will receive a 5-10 minute follow-up survey which they can complete in-person, online, or over the phone.
62827639|NCT02744053|EXPERIMENTAL|Diagnostic (DCE-MRI, MBI)|Patients undergo DCE-MRI over 45-60 minutes. Patients receive technetium Tc-99m sestamibi via injection, and after 5 minutes patients undergo MBI scan over 1 hour. Both DCE-MRI and MBI are performed at the time of enrollment, at the end of anthracycline therapy, and at the conclusion of NAC before surgery. All patients also undergo standard of care imaging with DM and US (at the same time points if the treating doctor chooses to do so).
62827640|NCT02496286|EXPERIMENTAL|Eligible patients requiring paracentesis for symptom control|
62045642|NCT04097457|EXPERIMENTAL|Individual|A short term parent training protocol based on behavioral principles, which is delivered by trained therapists. The protocol includes eleven core sessions, a home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered to parents in an outpatient and home settings. In this arm the protocol is administered individually to families.
62045643|NCT05347979|EXPERIMENTAL|Dabigatran Etexilate (NIMP) and Relacorilant (IMP)|Following an overnight fast, participants will receive 75 mg dabigatran etexilate on Day 1, 400 mg dose of relacorilant QD on Days 3 to 13, and 75 mg dabigatran etexilate on Day 12. On Day 12, dabigatran etexilate will be dosed at approximately the same time as the relacorilant dose.
62247998|NCT02923089|PLACEBO_COMPARATOR|Wheat Muffin|Muffin: 25g available carbohydrate from wheat
62247999|NCT02923089|EXPERIMENTAL|Small Green Lentil Soup|Soup: 25g available carbohydrate from small green lentil
62045644|NCT05888506|EXPERIMENTAL|Ketone Ester|Participants will consume the supplement prior to bedtime. Nocturnal blood pressure, heart rate, and sleep characteristics will be assessed
62045645|NCT05888506|PLACEBO_COMPARATOR|Placebo Supplement|Participants will consume the supplement prior to bedtime. Nocturnal blood pressure, heart rate, and sleep characteristics will be assessed
62045646|NCT06338982|EXPERIMENTAL|Test group with interoperative wisdom tooth removal in conjunction with BSSO|
62045647|NCT06338982|NO_INTERVENTION|Control group with wisdom tooth removal at least 6 months before BSSO|
62604924|NCT03806231|ACTIVE_COMPARATOR|Inpatient Cervical Ripening|The patient will be admitted into the Labor and Delivery unit prior to her scheduled induction. A research nurse will examine her and place the Cervidil insert into the posterior vaginal fornix. The patient will be watched with continuous fetal monitoring for 2 hours. The patient remains hospitalized and the following morning the induction will be started per Intermountain Healthcare protocol.
62604925|NCT06620523|ACTIVE_COMPARATOR|Group A: CoQ10 1200 mg orally with Glutathione 1000 mg orally|White-colored CoQ10 400 mg capsules will be dispensed AND White colored L-Glutathione 500 mg capsules will be dispensed.
62045648|NCT03113643|EXPERIMENTAL|SL-401+ Azacitidine|SL-401 will be administered every 4 weeks, on a 28 day cycle; SL-401 will be given intravenously; Azacitidine will be administered every 4 weeks, on a 28 day cycle; Azacitidine will be given intravenously or subcutaneously
62438000|NCT00377026|EXPERIMENTAL|lifestyle|participants receive lifestyle intervention
62604926|NCT06620523|PLACEBO_COMPARATOR|Group B: Placebo CoQ10 orally and Placebo Glutathione orally|A placebo to exactly match the CoQ10 will be made with white gelatin empty capsules containing cellulose AND a placebo to exactly match the L-Glutathione will be made with white gelatin empty capsules containing cellulose.
62604927|NCT04007224|ACTIVE_COMPARATOR|Oxytocin|Intranasal Oxytocin
62438001|NCT06527989|EXPERIMENTAL|ceftriaxone 2 grams|Single dose 2grams of ceftriaxone in 1st 24 hr Postoperative
62604928|NCT04007224|EXPERIMENTAL|Autologous umbilical cord blood|Intravenous administration of autologous umbilical cord blood
62623455|NCT02194894|ACTIVE_COMPARATOR|NAFLD patients|Twenty patients with NAFLD will take 3g of APAP daily for 14 days. Serum liver chemistries and trough acetaminophen (APAP) concentrations will be measured on treatment days 0, 2, 4, 7, 9, 11, 14 and on follow up day 17
62045649|NCT03113643|EXPERIMENTAL|SL-401+ Azacitidine + Venetoclax|SL-401 will be administered every 4 weeks, on a 28 day cycle; SL-401 will be given intravenously; Azacitidine will be administered every 4 weeks, on a 28 day cycle; Azacitidine will be given intravenously or subcutaneously; Venetoclax will be administered for 21 days on a 28 day cycle; Venetoclax will be taken orally
62045650|NCT04791761|EXPERIMENTAL|Opioid pain control|Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the pain diary or by email/mail if no appointment was scheduled. Families will receive an opioid disposal education document.
62045651|NCT04791761|EXPERIMENTAL|Opioid pain control + Disposal Pouch|Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the pain diary or by email/mail if no appointment was scheduled. Half of the families randomized to the opioid group will be further randomized to receive an opioid disposal bag + an opioid disposal education document. The pouch is a drug deactivation disposal pouch to dispose the opioid at home.
62045652|NCT04791761|ACTIVE_COMPARATOR|Non-opioid pain control|Patients in this group will be receiving therapy for pain control with acetaminophen and ibuprofen only. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the diary or by email/mail if no appointment was scheduled.
62248000|NCT02923089|EXPERIMENTAL|Split Red Lentil Soup|Soup: 25g available carbohydrate from split red lentil
62248001|NCT02923089|PLACEBO_COMPARATOR|Potato Soup|Soup: 25g available carbohydrate from potato
62438002|NCT06527989|EXPERIMENTAL|ceftriaxone 10 grams|Multiple doses 2 grams of ceftriaxone every 24 hrs for 5 days
62438003|NCT04365283|EXPERIMENTAL|New Bioactive Restorative Material|ACTIVA Presto restorative material
62438004|NCT04365283|ACTIVE_COMPARATOR|High Viscosity Glass Hybrid Reinforced Glass Ionomer|EQUIA Forte restorative material
62438005|NCT01179178||COPD-patients|
62438006|NCT01179178||Older adults (65-81 y)|
62438007|NCT01167855|EXPERIMENTAL|Intervention|"* Telemedicine asthma education sessions~* Asthma health assessment via telemonitoring~* Provider treatment prompts~* School absenteeism~* Prescription filling profile"
62623456|NCT02194894|ACTIVE_COMPARATOR|Healthy controls|Twenty healthy controls will take 3g of APAP daily for 14 days. Serum liver chemistries and trough acetaminophen (APAP) concentrations will be measured on treatment days 0, 2, 4, 7, 9, 11, 14 and on follow up day 17
62623457|NCT01018745|EXPERIMENTAL|BMS-907351 (XL184)|
62045653|NCT00857207|EXPERIMENTAL|Arm 1: Treatment Goal Management Training|Treatment Goal Management Training
62604929|NCT05678400|EXPERIMENTAL|Hypopressive abdominal techniques|All subjects were instructed by a registered physiotherapist on how to correctly perform the hypopressive abdominal techniques (HAT) in two familiarisation sessions of 45 minutes each before any action was taken. After the two sessions, all subjects who did not learn the exercise correctly were dropped from the study. The HAT training consisted of asking subjects in a standing position to perform a spinal elongation with neutral pelvis and scapular muscle activation for three normal respiratory cycles with slow and deep exhalation, and on the last breath, an expiratory apnoea with rib expansion and elevation was requested. In this session, following the guidelines described in the familiarisation sessions, two series of four dynamic HATs in standing position were performed: dynamic HATs in right tilt, dynamic HATs in left tilt, dynamic HATs in right rotation and dynamic HATs in left rotation.
62604930|NCT05678400|ACTIVE_COMPARATOR|Stretching of proprioceptive neuromuscular facilitation|The therapist straddled that leg, and raised the other leg by placing the heel on the shoulder. The therapist then flexed the participant's hip, maintaining knee extension, to the point of discomfort indicated by the patient or the therapist's perceived end of range. In this position the leg was held straight for 10 seconds and immediately afterwards the participant was asked to perform a maximum isometric contraction for 5 seconds using the therapist's shoulder as counter resistance, thus keeping the leg straight at the same point. As soon as the contraction stops, the therapist flexes the hip again until a new range limit is reached, repeating the same protocol again. The total duration is 60 seconds, consisting of 4 passive stretches of 10 seconds each and 4 isometric contractions against resistance of 5 seconds each.
62045654|NCT00857207|NO_INTERVENTION|Arm 2: Control-Brain Health Workshop|Control-Brain Health Workshop
62045655|NCT02813837|EXPERIMENTAL|single arm|Experimental: CD19 CART cell.The target dose range administered in this study is 1x10e5-1x10e7 CART-19 cells/kg.
62045656|NCT01531166||Chronic hepatitis B|
62045657|NCT04494893||Cohort 1|Exposed to coronavirus disease
62438008|NCT01795703|EXPERIMENTAL|Abiraterone|Abiraterone 1000 milligram (mg) oral tablets will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
62438009|NCT04719247|EXPERIMENTAL|Turmeric|Turmeric extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
62438010|NCT04719247|EXPERIMENTAL|Thymus Vulgaris|Thymus Vulgaris extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
62438011|NCT04719247|EXPERIMENTAL|Nigella Sativa|Nigella Sativa extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
62438012|NCT04719247|EXPERIMENTAL|Aloe Vera|Aloe Vera extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
62438013|NCT04719247|ACTIVE_COMPARATOR|Formocresol|Formocresol will be used as a dental pulp dressing material after pulpotomy to be compared with other materials.
62604931|NCT06441032||Precious metal|Single-tooth cast restorations made of precious metal.
62604932|NCT06441032||Non-precious metal|Single-tooth cast restorations made of non-precious metal
62604933|NCT02970019|EXPERIMENTAL|K0706|K0706 will be administered once a day
62604934|NCT02970019|EXPERIMENTAL|Placebo|Placebo will be administered once a day
62604935|NCT05651308|EXPERIMENTAL|Intervention|The intervention group will assign care coordinators to PLWD based on perceived need for assistance with care coordination. Perceived need will be measured through a proxy's responses to a previously validated telephone survey on perceptions of care coordination.
62604936|NCT05651308|ACTIVE_COMPARATOR|Control|Usual care assigns patients to care coordinators in response to a discharge from a hospital or a direct referral from a physician.
62248002|NCT02923089|EXPERIMENTAL|Small Green Lentil Chili|Chili: 25g available carbohydrate from small green lentil
62438014|NCT04115449|EXPERIMENTAL|Dexa group|"Spinal anaesthesia will be performed through the L3-4 interspace in the sitting position. After dural puncture with a 25 G Quincke needle, 3.5 ml of hyperbaric bupivacaine 0.5% solution with fentanyl 20 μg will be injected intrathecally. Than manintance dose of dexmedetomidine will be titrated from (0.2- 0.6 mcg /kg/ min) according to the patient discomfort.~After turning the patient supine, level of sensory block will be assessed by the pinprick test using a 24-gauge hypodermic needle, while the motor block level will be assessed by the modified Bromage scale. Insufflation of gas will be done at the rate of 1.5 liters/min and the maximum abdominal pressure will be kept at 12 mmHg. Supplementary oxygen at 4 liters/min will be given with face mask."
62604937|NCT05901350|NO_INTERVENTION|Levodopa Reduction Group After STN-DBS|Patients in this group started to reduce levodopa dose 1 months after STN-DBS
62045658|NCT04494893||Cohort 2|Active coronavirus disease
62045659|NCT04494893||Cohort 3|Recovered from coronavirus disease
62045660|NCT03994068|EXPERIMENTAL|VIVO mapping pre-procedure|15 patients with structurally normal heart and indication for PVC/VT catheter ablation, who will undergo pre-procedural non invasive mapping with VIVO mapping system.
62045661|NCT01402141|EXPERIMENTAL|Chungkookjang|
62604938|NCT05901350|EXPERIMENTAL|Levodopa non-Reduction Group After SNT-DBS|Patients in this group did not reduce levodopa dose until 12 months after STN-DBS
62045662|NCT01402141|PLACEBO_COMPARATOR|Placebo|
62045663|NCT00540124|EXPERIMENTAL|Tadalafil|
62045664|NCT00540124|PLACEBO_COMPARATOR|Placebo|
62045665|NCT00540124|ACTIVE_COMPARATOR|Tamsulosin|
62045666|NCT05038241||Active VKC|All females and males of pubertal age with active VKC undergo a blood sample for the determination of serum hormone levels, an allergological evaluation and an endocrinological evaluation. All is done at the time of enrollment.
62045667|NCT05038241||Previous active VKC|All females and males of pubertal age who suffered of VKC undergo a blood sample for the determination of serum hormone levels, an allergological evaluation and an endocrinological evaluation. All is done at the time of enrollment.
62248003|NCT02923089|EXPERIMENTAL|Split Red Lentil Chili|Chili: 25g available carbohydrate from split red lentil
62248004|NCT02923089|PLACEBO_COMPARATOR|Rice Chili|Chili: 25g available carbohydrate from rice
62248005|NCT04872452|EXPERIMENTAL|Gastrointestinal dysmotility participants|
62248006|NCT04872452|OTHER|Healthy participants|
62604939|NCT03499275|SHAM_COMPARATOR|Sham NMES|Sham neuromuscular electrical stimulation plus home exercise programme and advice on breathlessness management
62045668|NCT05311202|EXPERIMENTAL|low-volume moderate-intensity group|Participants will attend the trainer-supervised resistance exercise program for 30 minutes
62604940|NCT03499275|EXPERIMENTAL|Active NMES|Neuromuscular electrical stimulation plus home exercise programme and advice on breathlessness management
62604941|NCT01629823|SHAM_COMPARATOR|CPAP less than 1 cm H₂O|
62827641|NCT02783534|EXPERIMENTAL|Verum acupuncture|Participants will receive verum acupuncture plus usual care. Participants will receive acupuncture treatment start from the 5th or 7th day before the estimated first day of menstrual cycle, and for each cycle, participants will receive one session of treatment each day for 5 consecutive days, totally be treated with 15 sessions.Verum needles will be inserted into the skin and manipulated manually until deqi occurs. The needles are retained for 30 min in each session. During the treatment, the acupuncturist inquires the patient about deqi sensations and manipulates the needles to maintain the intensity of deqi. Participants will receive the same usual care as those in the usual care group.
62827642|NCT02783534|SHAM_COMPARATOR|Sham acupuncture|Participants will receive sham acupuncture plus usual care. The Streitberger placebo needle will be placed at non-acupuncture points which are distant from the meridian parts and not located on the same neuromuscular segments as the prescribed points used in the VA group, so as to minimize any therapeutic and segmental effects. The same acupuncture schedule as that in the verum acupuncture group will be applied. The needles are retained for 30 min in each session. During the treatment, the acupuncturist inquires the patient about deqi sensations and pretends to manipulate the needles but deqi is not sought.Participants will receive the same usual care as those in the usual care group.
62045669|NCT05311202|EXPERIMENTAL|moderate-volume moderate-intensity group|Participants will attend the trainer-supervised resistance exercise program for 40 minutes
62045670|NCT05311202|EXPERIMENTAL|high-volume moderate-intensity group|Participants will attend the trainer-supervised resistance exercise program for 50 minutes
62827643|NCT02783534|PLACEBO_COMPARATOR|Usual care|Participants will not receive acupuncture treatment besides health education as a control group.
62827644|NCT02211846|EXPERIMENTAL|Mirabegron|Administered under fed and fasted conditions
62827645|NCT05535946|PLACEBO_COMPARATOR|ABX464 50mg - Responder subjects at the end of induction|Subjects will be orally dosed during 44 weeks
62045671|NCT05311202|EXPERIMENTAL|moderate-volume low-intensity group|Participants will attend the trainer-supervised resistance exercise program for 45 minutes
62827646|NCT05535946|PLACEBO_COMPARATOR|ABX464 25mg - Responder subjects at the end of induction|Subjects will be orally dosed during 44 weeks
62827647|NCT05535946|PLACEBO_COMPARATOR|Placebo - Responder subjects at the end of induction|Subjects will be orally dosed during 44 weeks
62045672|NCT05311202|EXPERIMENTAL|Control group|Reading for 40 minutes
62045673|NCT04530890|EXPERIMENTAL|One arm only|Only one arm with blood samples
62045674|NCT05786716|EXPERIMENTAL|Treatment Arm 04: trastuzumab in combination with pertuzumab|This trastuzumab and pertuzumab treatment arm is for adult, TYA and paediatric participants with malignancies with HER2 amplification or activating mutations.
62045675|NCT03786029|EXPERIMENTAL|A (Acetaminophen)|22 children will receive 320mg (10ml) 30 minutes before the local anesthesia injection.
62045676|NCT03786029|PLACEBO_COMPARATOR|B (Placebo)|22 children will receive 10ml 30 minutes before the local anesthesia injection.
62045677|NCT03786029|EXPERIMENTAL|C (Ibuprofen)|22 children will receive 200mg (10ml) 30 minutes before the local anesthesia injection.
62248007|NCT03808688|OTHER|Netarsudil Ophthalmic Solution 0.02%|
62449246|NCT02806232|EXPERIMENTAL|Part 1, Cohort 7: Levo Praziquantel 60 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
62045678|NCT01454206|NO_INTERVENTION|Treatment as Usual|
62045679|NCT01454206|EXPERIMENTAL|iSBIRT|Participants will receive the internet-facilitated screening, brief intervention and referral to treatment (iSBIRT intervention)
62045680|NCT02132364|OTHER|optimised follow-up|optimised follow-up will be done by nursing personnel associated with a caregiving member of his social circle.
62045681|NCT02132364|NO_INTERVENTION|typical follow-up|no intervention
62248008|NCT03663881|EXPERIMENTAL|P2Et extract|P2Et extract daily doses. Dosage scaling will be performed according to the 3 + 3 standard design.
62248009|NCT05929703|ACTIVE_COMPARATOR|Hospital Elder Life Program (HELP)|Hospital Elder Life Program (HELP) is built upon multicomponent, non-pharmacologic strategies that target delirium risk factors to optimize cognitive and clinical function during hospitalization.
62449247|NCT02806232|EXPERIMENTAL|Part 2, Cohort 8: Levo Praziquantel 50 mg/kg|Participants aged 13-24 months months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
62449248|NCT02806232|EXPERIMENTAL|Part 2, Cohort 9: Levo Praziquantel 50 mg/kg|Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
62449249|NCT02895529|EXPERIMENTAL|Itraconazole|
62449250|NCT02895529|ACTIVE_COMPARATOR|Caspofungin|
62449251|NCT00406757|ACTIVE_COMPARATOR|Pediatric Arm 1|"Cycle 1: Nelarabine 400mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.~Cycle 2 and subsequent Cycles: Nelarabine 650mg2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose."
62449252|NCT00406757|ACTIVE_COMPARATOR|Pediatric Arm 2|Cycle 1 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.
62449253|NCT00406757|ACTIVE_COMPARATOR|Adult Arm 1|"Cycle 1: Nelarabine 1000mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose."
62449254|NCT00406757|ACTIVE_COMPARATOR|Adult Arm 2|Cycle 1 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.
62449255|NCT00406757|ACTIVE_COMPARATOR|Pediatric Arm 3|Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
62449256|NCT02190461|EXPERIMENTAL|Early Respiratory Rehabilitation|Starting the Early Respiratory Rehabilitation programme during the admission and continues it at home immediately after discharge for a period of 3 months.
62604942|NCT01629823|EXPERIMENTAL|CPAP 10cm H₂O|
62604943|NCT01629823|EXPERIMENTAL|CPAP 5cm H₂O|
62604944|NCT05049928|EXPERIMENTAL|Experimental arm|Patients in the experimental group will be treated with CPAP (PRISMA, LOWENSTEIN®) and will have access to the m-Rehab® telerehabilitation program.
62449257|NCT02190461|ACTIVE_COMPARATOR|Conventional Respiratory Rehabilitation|Started a conventional Respiratory Rehabilitation programme at home one month after discharge from hospital and continues for 3 months.
62604945|NCT05049928|NO_INTERVENTION|Control arm|Patients in the experimental group will be treated with CPAP (PRISMA, LOWENSTEIN) and will receive the usual advice on adapted physical activity and nutrition during the initial consultation.
62604946|NCT02787733|EXPERIMENTAL|Citrus flavonoid|Citrus peel extract containing \>90% flavonoids
62604947|NCT02787733|PLACEBO_COMPARATOR|Placebo|Identical looking placebo
62604948|NCT03399682||Incidence of Post Cystography Urinary Tract Infections|all children less than 16 years having cystography
62449258|NCT05361278|EXPERIMENTAL|Chlorhexidine irrigation solution|CHx 2% solution will be used.
62604949|NCT03762928|EXPERIMENTAL|midazolam/efavirenz|
62604950|NCT03762928|EXPERIMENTAL|PF-06651600/midazolam/efavirenz|
62827648|NCT05535946|EXPERIMENTAL|ABX464 50mg - Non responder subjects at the end of induction|Subjects will be orally dosed during 44 weeks
62045682|NCT05226455|EXPERIMENTAL|venetoclax + azacitidine +/- donor lymphocyte infusion|"Venetoclax + azacitidine +/- donor lymphocyte infusion (maximum 12 cycles). Venetoclax: on D1 to D14 of 28 days cycle ; Phase I: 4 dose levels: 50, 100, 200, 400 mg/d, starting dose at 100 mg ; Phase II: dose defined in the phase I.~Azacitidine 75 mg/m²/d or 50 mg/m²/d (if allohematopoietic stem cell transplantation relapse \< 4 months) x 5 days (on D1 to D5 of 28 days cycle)."
62248010|NCT05929703|ACTIVE_COMPARATOR|Family-Augmented Hospital Elder Life Program (FAM-HELP)|The FAM-HELP program will incorporate a family member and/or care partner, who will play a central role with providing bedside support for delirium risk reduction. Family members and care partners will provide social and emotional support along with augmentation of HELP-based protocols.
62604951|NCT03964467|EXPERIMENTAL|Experimental|Transcranial Direct Current Stimulation.1) Scalp measurements of the scalp will be taken using the 10-20 EEG measurement system to determine anode and cathode placement. 2) One 1x1 Bicarbon electrode with wires attached will be placed in the center of each 5 cm x 7 cm sponge electrode dampened with 8 ml of saline. 3) One sponge electrode will be placed over the ipsilesional PMd (F3) and the other sponge electrode over the contralesional supraorbital region(Fp2). 4) Each sponge electrode will be secured under the plastic EZ strap 5) The current from the Actividose II will be turned up to 2 MA. The current will ramp up/down in 15 seconds. We will observe for adverse effects and hit the pause button, then turn the machine off, if a participant does not tolerate the stimulation. Individuals in this arm will have the stimulation stay in current until the full dose is delivered. Each participant will then engage in the UE TRT as outlined below.
62623458|NCT01440985|EXPERIMENTAL|Nicotine Gum|After being randomized to the gum or tablet, dosage will be based on baseline level of nicotine dependence. Highly dependent smokers will receive nicotine 4 mg gum, while low nicotine-dependent smokers will receive nicotine 2 mg gum to help them quit. Subjects will be advised to use the treatment frequently, according to the product labeling, in order to minimize or avoid symptoms of tobacco withdrawal. Study medication will be used for 12 weeks.
62827649|NCT05535946|EXPERIMENTAL|ABX464 25mg - Non responder subjects at the end of induction|Subjects will be orally dosed during 44 weeks
62827650|NCT05535946|EXPERIMENTAL|Long Term Extension|At the end of the maintenance phase (week 44), subjects can continue their allocated treatment for up to 4 years. Once the maintenance phase is unblinded, subjects receiving placebo in the maintenance phase will be allocated to obefazimod 25 mg or can terminate the study.
62045683|NCT03469323|EXPERIMENTAL|Nonintubated VATS succinylcholine|Nonintubated VATS using mini-dose succinylcholine in the beginning of open pneumothorax
62248011|NCT02690220|OTHER|surgical mesh implantation|Standard method to implant the TiLOOP® PRO A surgical mesh transvaginally. Women with a symptomatic genital descensus: at least stage II (ICS-classification according Pelvic Organ Prolapse Quantification System (POP-Q system)). This applies to primary as well as recurrent intervention.
62045684|NCT03469323|PLACEBO_COMPARATOR|Nonintubated VATS placebo|Nonintubated VATS not using succinylcholine in the beginning of open pneumothorax
62045685|NCT01732068|EXPERIMENTAL|Corifollitropin alfa+hMG|
62449259|NCT05361278|EXPERIMENTAL|Activated chlorhexidine irrigation solution|CHx 2% solution will be used with ultrasonic activation.
62449260|NCT05361278|EXPERIMENTAL|Chlorhexidine irrigation gel|CHx 2% gel will be used.
62449261|NCT05361278|EXPERIMENTAL|Activated chlorhexidine irrigation gel|CHx 2% gel will be used with ultrasonic activation.
62449262|NCT05361278|OTHER|Sodium hypochlorite irrigation solution|NaOCl 5,25% solution will be used.
62449263|NCT04843670||patients operated for pancreas tumors|duodenopancreatectomy for head of the pancreas tumors
62449264|NCT01479881|EXPERIMENTAL|001|a single 100-mg dose of cyclosporine, and after a wash out period of at least 10 days, TMC435 150 mg once daily (q.d.) for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7.
62449265|NCT01479881|EXPERIMENTAL|002|TMC435 150 mg once daily (q.d.) for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7 and after a wash out period of at least 10 days, a single 100-mg dose of cyclosporine.
62449266|NCT01479881|EXPERIMENTAL|003|a single 2-mg dose of tacrolimus on Day 1. After a wash out period of at least 10 days, participants will receive TMC435 150 mg q.d. for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7.
62449267|NCT01479881|EXPERIMENTAL|004|TMC435 150 mg q.d. for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7. After a wash out period of at least 10 days, participants receive a single 2-mg dose of tacrolimus.
62449268|NCT01884025|EXPERIMENTAL|Get Moving and Get Well|Walking class developed for Veterans with serious mental illness and administered as part of the PRRC
62449269|NCT01884025|SHAM_COMPARATOR|Health and Humor Class|Equally engaging attention control condition
62827651|NCT02170623|EXPERIMENTAL|Period 1: BIBR 1048 MS with Pantoprazole|"Three treatments of different formulations of 50 mg BIBR 1048 MS (bid for 3 days) with 40 mg Pantoprazole (bid). Randomised sequence.~1. BIBR 1048 MS Capsule I with pantoprazole (bid for 3 days);~2. BIBR 1048 MS Capsule K with pantoprazole (bid for 3 days);~3. BIBR 1048 MS Drinking solution with Pantoprazole (bid for 3 days)"
62827652|NCT02170623|EXPERIMENTAL|Period 2: BIBR 1048 MS|"Three treatments of different formulations of 50 mg BIBR 1048 MS (bid for 3 days) without Pantoprazole. Fixed sequence.~1. BIBR 1048 MS Capsule K (bid for 3 days);~2. BIBR 1048 MS Drinking solution (bid for 3 days)"
62827653|NCT05733351|EXPERIMENTAL|Cohort A (Vudalimab, Abiraterone)|Patients receive vudalimab IV on days 1 and 15 plus abiraterone PO QD of 4-week cycles on study. Patients also undergo PSMA PET and FDG PET scans during screening. Patients also undergo CT and/or MRI scans, bone scans, and blood sample collection throughout the study.
62827654|NCT05733351|EXPERIMENTAL|Cohort B (Vudalimab, Enzalutamide)|Patients receive vudalimab IV on days 1 and 15 plus enzalutamide PO QD of 4-week cycles on study. Patients also undergo PSMA PET and FDG PET scans during screening. Patients also undergo CT and/or MRI scans, bone scans, and blood sample collection throughout the study.
62827655|NCT05733351|EXPERIMENTAL|Cohort C (Vudalimab, Docetaxel, Abiraterone)|Patients receive vudalimab IV on days 1 and 15, docetaxel IV on days 1 and 22 plus abiraterone PO QD of 6-week cycles on study. Patients also undergo PSMA PET and FDG PET scans during screening. Patients also undergo CT and/or MRI scans, bone scans, and blood sample collection throughout the study.
62045686|NCT02396654||normal pregnant women|Normal pregnant women between 37 and 42 weeks gestation.
62248012|NCT04757441|EXPERIMENTAL|Group A: Conventional Treatment + Elongation Longitudinaux Decoaption of Osteo-Articulaire (ELDOA)|Participants will receive conventional treatment along with ELDOA stretching exercises protocol at L5, S1.
62827656|NCT05056935|EXPERIMENTAL|LB1148|active
62248013|NCT04757441|OTHER|Group B: Conventional treatment|Participants will receive only conventional treatment (Control)
62827657|NCT05056935|PLACEBO_COMPARATOR|Placebo|placebo
62827658|NCT05721456|ACTIVE_COMPARATOR|PCV10 (Synflorix®)|
62827659|NCT05721456|ACTIVE_COMPARATOR|PCV13 (Prevenar13®)|
62827660|NCT05721456|EXPERIMENTAL|12-Valent Pneumococcal Conjugate Vaccine|
62827661|NCT02143804|EXPERIMENTAL|CG0070|oncolytic virus genetically modified to express GM-CSF
62827662|NCT05614817|EXPERIMENTAL|[Treatment Period 1]Group 1-Dose1|CBP-201 600 mg (4 mL) SC on Day 1 (Week 0 visit) visit followed by 300 mg (2 mL) SC Q2W starting at Week 2 with the last dose at Week 14.
62827663|NCT05614817|PLACEBO_COMPARATOR|[Treatment Period 1]Goup 2-Placebo1|Placebo (4 mL) SC on Day 0 (Week 0) visit followed by placebo (2 mL) SC Q2W starting at Week 2 with the last dose at Week 14
62827664|NCT05614817|EXPERIMENTAL|[Treatment Period 2] Group 1-Dose2|CBP-201 300 mg SC Q2W starting at Week 16 with the last dose at Week 50 Treatment Period 2 (Group 1 Dose 1 responder pts that rerandomize to Dose 2, Dose 3, or PBO 2)
62827665|NCT05614817|EXPERIMENTAL|[Treatment Period 2] Group 1-Dose3|CBP-201 300 mg SC Q4W starting at Week 16, alternating with placebo SC Q4W starting at Week 18 with the last dose of CBP-201 at Week 48 and placebo at Week 50
62827666|NCT05614817|PLACEBO_COMPARATOR|[Treatment Period 2] Group 1-Placebo2|Placebo Q2W SC starting at Week 16 with the last dose at Week 50
62045687|NCT01687257|EXPERIMENTAL|SOF+RBV|Participants will receive SOF+RBV for 48 weeks.
62045688|NCT01687257|EXPERIMENTAL|Observation, then SOF+RBV|Participants will undergo 24 weeks of observation and then receive SOF+RBV for 48 additional weeks.
62045689|NCT02235350|EXPERIMENTAL|Action Observation Treatment (AOT)|Conventional physiotherapy + Action Observation Treatment
62045690|NCT02235350|SHAM_COMPARATOR|Observation of videos with no motor content (MNO)|Conventional physiotherapy + Observation of videos with no motor content (MNO)
62827667|NCT05614817|PLACEBO_COMPARATOR|[Treatment Period 2] Group 2-Placebo|PBO 1 pts responders that continue PBO 1
62045691|NCT03263884|EXPERIMENTAL|Real treatment group|"Transcranial magnetic stimulation (TMS) is used to stimulate small regions of the brain. During a TMS procedure, a magnetic field generator, or coil, is placed near the head of the person receiving the treatment. The coil produces small electric currents in the region of the brain just under the coil via electromagnetic induction.~The protocol used in this research includes 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses."
62045692|NCT03263884|SHAM_COMPARATOR|Sham treatment group|Sham coil is used to mimic the clicking sound of the TMS coil and skin stimulation
62045693|NCT04465019||TBI Group|Subjects in the TBI group included patients who suffered a TBI and who used the EKSO® bionic exoskeleton during their rehabilitation treatment from 01/01/2017 to 04/30/2020.
62045694|NCT04465019||CVA Group|Subjects in the CVA group included all patients in the hospital that used the EKSO® during their rehabilitation process during their rehabilitation treatment from 01/01/2017 to 04/30/2020.
62045695|NCT01605929|EXPERIMENTAL|Retroclavicular Brachial Plexus Block|
62045696|NCT05855330|ACTIVE_COMPARATOR|L-arginine loading dose + standard dose|L-arginine loading dose (200 mg/kg IV) + standard dose (100 mg/kg IV TID).
62045697|NCT05855330|ACTIVE_COMPARATOR|Standard dose|Standard dose (100mg/kg IV TID).
62248014|NCT04745013|EXPERIMENTAL|PRIORITY|Patients randomized to the hybrid exercise intervention (PRIORITY) will receive a personalized exercise prescription generated by the EXPERT tool which will then be person-tailored by the physiotherapist during one-on-one physical activity consultation. Over a period of one year, patients will participate in 18 supervised center-based exercise sessions in adjunct to a remotely monitored and guided home-based exercise intervention.
62604952|NCT03964467|SHAM_COMPARATOR|Control|Individuals in this arm will have the stimulation cycled off after 2-3 minutes. All will be part of the Circuit-Based, UE Task Related Training. Each participant will engage in the training program for 1.5 hours; rotating through 5 stations at about 15 minute intervals, participating in standing as tolerated, but stations can be adapted to sitting. The goal is for each participant perform \> 225 movements with the affected arm per session, at the highest functional level. Rest breaks given as needed. Examples of stations are: Reach-to-grasp tasks to objects of various weight, texture and dimension at different distances and table heights. Practice opening simulated locks and containers. Shoulder wheel involving grasping plastic plates with varied grip patterns and sliding them up and over the wheel from the unaffected to the affected side encouraging shoulder abduction, external rotation and supination. Bimanual/unimanual ball toss: catching, releasing.
62604953|NCT01029171|EXPERIMENTAL|1|OEP (Otago Exercise Program; home-based balance and strength retraining program)
62248015|NCT04745013|PLACEBO_COMPARATOR|Usual care|The usual care group will receive from the physiotherapist a personalized written exercise prescription that includes an individually tailored recommendation on frequency, intensity, type, time and volume of exercise. This exercise prescription will be generated by means of the EXPERT tool. No counselling or guidance on objective measures of physical activity by means of wearables or platform will be provided.
62604954|NCT01029171|ACTIVE_COMPARATOR|2|CON (control; usual care)
62045698|NCT05855330|ACTIVE_COMPARATOR|Low dose|Low dose (25mg/kg IV TID).
62045699|NCT06211660|EXPERIMENTAL|AI-based AR training system|The AI-empowered AR training system will be used.
62045700|NCT06211660|EXPERIMENTAL|Hand scanner and Video training|Both hand scanner results and a training video will be provided.
62045701|NCT01091155|EXPERIMENTAL|ColonRing TM|
62045702|NCT04962555||Meniscus Suture|The patient underwent meniscus suture surgery
62045703|NCT04962555||Partial meniscus resection|The patient underwent partial meniscus resection
62248016|NCT02906345|NO_INTERVENTION|Control Group|Patients with septic shock, no therapeutic plasma exchange, BMC standard treatment
62248017|NCT02906345|ACTIVE_COMPARATOR|TPE-Filtration Group|Patients with septic shock, therapeutic plasma exchange, plasma separation using a filter (Fresenius MultiFiltrate, Kit 16 MPS P2 dry), BMC standard treatment
62604955|NCT01501773|EXPERIMENTAL|Autologous bone marrow stem cell|
62604956|NCT01501773|NO_INTERVENTION|Control|
62827668|NCT05614817|EXPERIMENTAL|[Treatment Period 2] Group 3-Dose|Dose 1 and PBO 1 Non-responders, and Group 1 and 2 Non-responders that get open-label Dose 4 or 5 (LD 300 mg or 600 mg, biweekly 300 mg thereafter)
62827669|NCT03911167||RG|RG: robotic group
62827670|NCT03911167||LG|LG:laparoscopic group,
62827671|NCT03911167||OG|OG：open group
62604957|NCT01254851|ACTIVE_COMPARATOR|goal-augmented post-operative care.|Patients in this group will be given a goal number of steps to take on each post-operative day.
62827672|NCT03586661|EXPERIMENTAL|Treatment (niraparib, copanlisib)|Patients receive niraparib PO daily on days 1-28 and copanlisib IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62827673|NCT00279175|EXPERIMENTAL|BMC|Intracoronary infusion of autologous bone marrow derived cells
62827674|NCT00279175|PLACEBO_COMPARATOR|Placebo|Intracoronary infusion of Placebo medium
62827675|NCT01713920|EXPERIMENTAL|SEVIKAR|Subjects who are eligible for the inclusion and exclusion criteria will be treated with Sevikar 5/20mg for 4 weeks. If subjects fail to reach the SBP threshold of SeSBP≥ 140mmHg after 4-week treatment, they will receive Sevikar 5/40mg for 4 weeks. At the end of 4-week treatment, subjects who fail to reach SBP threshold will receive Sevikar 10/40mg for 4 weeks. Subjects who can reach SBP threshold will continue to treat with current dose until 12 weeks.
62827676|NCT05902910|ACTIVE_COMPARATOR|Experimental Scheme : A,B,C|The phase B treatment (1.5 hours a day, 5/7 days of conventional rehabilitation and 30mn a day, 5/7 days of treatment with the robot) is scheduled before phase C (2 hours a day, 5/7 days of conventional rehabilitation). The duration of phase B is randomized between 6 and 11 evaluations (2 to 3.5 weeks).
62827677|NCT05902910|ACTIVE_COMPARATOR|Experimental Scheme : A,C,B|The phase C treatment (2 hours a day, 5/7 days of conventional rehabilitation) is scheduled before phase B (1.5 hours a day, 5/7 days of conventional rehabilitation and 30mn a day, 5/7 days of treatment with the robot). The duration of phase C is randomized between 6 and 11 evaluations (2 to 3.5 weeks).
62827678|NCT01067053|EXPERIMENTAL|bevacizumab, capecitabine, oxaliplatin|"6 cycles (3 weeks each one) of:~* bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.~* capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.~* oxaliplatin: 130/mg/m2(iv),1st day of each cycle.~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine"
62045704|NCT04962555||Subtotal meniscus resection|The patient underwent Subtotal meniscus resection
62438015|NCT04115449|PLACEBO_COMPARATOR|Control group|"Normal Saline as a placebo will be infused over a period of ten minutes then spinal anaesthesia will be performed through the L3-4 interspace in the sitting position. After dural puncture with a 25 G Quincke needle, 3.5 ml of hyperbaric bupivacaine 0.5% solution with fentanyl 20 μg will be injected intrathecally. Then the placebo will be titrated according to patient discomfort.~After turning the patient supine, level of sensory block will be assessed by the pinprick test using a 24-gauge hypodermic needle, while the motor block level will be assessed by the modified Bromage scale.Insufflation of gas will be done at the rate of 1.5 liters/min and the maximum abdominal pressure will be kept at 12 mmHg. Supplementary oxygen at 4 liters/min will be given with face mask."
62438016|NCT05481060|EXPERIMENTAL|Screen-based simulation|Screen-based simulation about intimate partner violence against women prepared by researchers will apply to nursing students.
62438017|NCT05481060|NO_INTERVENTION|Control group|Online didactic education about intimate partner violence against women prepared by researchers will apply to nursing students.
62438018|NCT04182750|EXPERIMENTAL|Intervention group|Pharmacist consultation in early pregnancy (gestation week \<12)
62438019|NCT04182750|NO_INTERVENTION|Control group|Standard care.
62438020|NCT04317781|EXPERIMENTAL|Treatment (tagraxofusp-erzs)|Within day 45 and 180 after stem cell transplant, patients receive tagraxofusp-erzs IV over 15 minutes on days 1-3 of cycles 1-4 and days 1-2 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62438021|NCT03028883||buprenorphine dose adjustments|To determine if a relationship exists between buprenorphine dose adjustments and gestational age in opioid-maintained pregnant women
62438022|NCT03456869|EXPERIMENTAL|PSI group|The patient specific implant (PSI) is used to completed the genioplasty.
62438023|NCT02657720|OTHER|Healthy volunteers|Respiration rate will be measured using several medical devices: Radical-7, Capnostream20p and PTAF2 (flow meter)
62438024|NCT01402661||Rheumatoid Arthritis|Pts presenting to enrolling sites across the US are invited to enroll if eligible.
62438025|NCT03422783|EXPERIMENTAL|Included patients|There is only one arm in this study. Intervention will be electrical forearm stimulus under general anesthesia and the response of NOL index following this stimulus and its correlation with postoperative parameters such as pain and opioid consumption in post anesthesia care unit.
62438026|NCT01224210|OTHER|Ambrisentan (24 Weeks), Extension (4 Weeks)|Open Label Ambrisentan
62438027|NCT03536676|ACTIVE_COMPARATOR|Traditional School Breakfast Program|The breakfasts for the 3-week program will adhere to the United States Department of Agriculture nutrition requirements for Grades 6-8.
62438028|NCT03536676|EXPERIMENTAL|'Egg-Cellent' Breakfast in the Classroom|The breakfasts for the 3-week program will adhere to the United States Department of Agriculture nutrition requirements for Grades 6-8 but will include an additional 2 large eggs/breakfast.
62438029|NCT02274467|ACTIVE_COMPARATOR|Uniport catheter|19 gauge uniport epidural catheter
62438030|NCT02274467|ACTIVE_COMPARATOR|Multiport catheter|19 gauge multiorifice epidural catheter
62438031|NCT03263520|EXPERIMENTAL|Group 1: nandrolone and corticosteroid|the patient will receive an application of anabolic nandrolone decanoate at a dose of 50 mg (males) and 25 mg (females), intra-muscular form, in the first and fifteenth days. In addition to the anabolic steroid, the patient will use corticosteroids (dexamethasone) at home at a dose of 4 mg daily by mouth on the morning for both sexes for 30 days.
62438032|NCT03263520|ACTIVE_COMPARATOR|Group 2: corticosteroid|Patient will take corticosteroids ( 4 mg of dexamethasone) per oral, QD at morning for 30 days
62438033|NCT02801591||GH AQ|
62604958|NCT01254851|NO_INTERVENTION|Usual care|routine post-operative ambulation
62604959|NCT05309473|EXPERIMENTAL|Subjects Who Received Acoustic Stimulation|Following 40 hours of deprivation participants will sleep for approximately a four hour recovery sleep period and receive acoustic stimulation via the Philips SmartSleep during slow-wave sleep. They will then sleep for second night of four hour recovery sleep and receive acoustic stimulation via the Philips Smart Sleep device during slow-wave sleep again.
62438034|NCT02424565|EXPERIMENTAL|Test|2 ± 0.2 g of product will be gently rubbed for 15 seconds on the affected knee joint.
62604960|NCT05309473|SHAM_COMPARATOR|Subjects Who Received Sham (no Acoustic Stimulation)|Following 40 hours of deprivation participants will sleep for approximately a four hour recovery sleep period and receive Sham (no acoustic stimulation) via the Philips SmartSleep during slow-wave sleep. They will then sleep for second night of four hour recovery sleep and receive Sham (no acoustic stimulation) via the Philips Smart Sleep device during slow-wave sleep again.
62604961|NCT03873909|ACTIVE_COMPARATOR|Fruit Smoothie|Post-prandial study feeding 155-200 g mamey sapote mesocarp, 6 g of soybean oil , crushed ice and 150-200 g of water to reach a total volume of 450 mL. (845 µg sapotexanthin, 1.21-1.51 mg cryptocapsin).
62604962|NCT03873909|ACTIVE_COMPARATOR|Matrix-Free Shake|Post-prandial study feeding 2 g of carotenoid powder formula (845 µg sapotexanthin, 1.21-1.51 mg cryptocapsin), 37.5 g of sugar, 75 µg of citric acid, 6 g of soybean oil emulsified into 300 g of water using 3 g of soy lecithin as well as ca. 100 g of crushed ice, yielding a shake volume of 450 mL.
62604963|NCT05964114|EXPERIMENTAL|Starting dose of vancomycin standard vs MIPD|Comparison of vancomycin initial dosing via standard of care (flat dose adjusted for renal function) versus model informed precision dosing (starting dose adjusted using pharmacokinetic models).
62604964|NCT06730087||2 groups which will compare cardiometry with ultrasound|patients will be divided into two groups: Group 1 patients with blood pressure less than 90/60 to assess fluid responsiveness and group 2 patients with sonographic finding of increase extravascular lung water in the form of interstitial edema or pulmonary edema or by electrical cardiometry (increase thoracic fluid content).
62604965|NCT03640481|EXPERIMENTAL|Arm A: belumosudil 200 mg, QD, adult arm|Eligible subjects randomized to arm A will take belumosudil 200 mg once daily
62604966|NCT03640481|EXPERIMENTAL|Arm B: belumosudil 200 mg, BID, adult arm|Eligible subjects randomized to arm B will take belumosudil 200 mg twice daily
62604967|NCT03640481|EXPERIMENTAL|Adolescent arm A: belumosudil 200 mg QD|Eligible subjects randomized to arm A will take belumosudil 200 mg once daily
62248018|NCT02906345|ACTIVE_COMPARATOR|TPE-Centrifugation|Patients with septic shock, therapeutic plasma exchange, plasma separation using a centrifuge (Fresenius COM-TEC, PL1 Erythrozytapherese/Plasmabeutel Set) BMC standard treatment
62248019|NCT03156348|EXPERIMENTAL|Intervented|The intervention group will receive in addition to the usual care, it will receive the Clinical Pharmacist Care during hospitalization, discharge and during 2 months post-discharge, through a home visit at 30 ± 5 days post-discharge and a telephone call at 60 ± 5 days.
62438035|NCT02424565|PLACEBO_COMPARATOR|Placebo|2 ± 0.2 g of product will be gently rubbed for 15 seconds on the affected knee joint.
62438036|NCT01181856|EXPERIMENTAL|Group A|Intramuscular immunisation
62604968|NCT03640481|EXPERIMENTAL|Adolescent arm B: belumosudil 200 mg BID|Eligible subjects randomized to arm B will take belumosudil 200 mg twice daily
62604969|NCT01925235||Control|patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure
62604970|NCT01925235||RIPC|patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure plus ischemic preconditioning (intermittent arm ischemia through 4 cycles of 5-minute inflation and 5-minute deflation of a blood pressure cuff)
62438037|NCT01181856|EXPERIMENTAL|Group B|Intradermal immunisation
62438038|NCT00568269|ACTIVE_COMPARATOR|Lichtenstein|
62604971|NCT00628095|EXPERIMENTAL|Active|
62604972|NCT00628095|PLACEBO_COMPARATOR|Placebo|
62604973|NCT02307084|EXPERIMENTAL|Pre-operative ultrasound imaging|Subjects that are randomly allocated to this group will have ultrasound imaging assessment of the long saphenous vein in both legs. This will allow assessment of the suitability of the long saphenous vein and marking of the distribution prior to heart bypass surgery to allow targeted harvesting of a bypass conduit.
62604974|NCT02307084|NO_INTERVENTION|Current protocol|This group will not undergo pre-operative ultrasound imaging of the long saphenous vein in accordance with current Trust protocols.
62604975|NCT04554212|ACTIVE_COMPARATOR|Standard Physical Therapy with Sham BFRT|Participants will undergo 8 weeks of sham blood flow restriction training with cuff inflated to less than 10% occlusion.
62438039|NCT00568269|EXPERIMENTAL|TEP|
62438040|NCT00326885|EXPERIMENTAL|Catumaxomab|
62438041|NCT02568995|EXPERIMENTAL|LIA|Local infiltration analgesia using a combination of ropivacaine 300 mg + ketorolac 30 mg + adrenaline 0.5 mg
62438042|NCT02568995|ACTIVE_COMPARATOR|Femoral nerve block|Ultrasound guided 3-in-1 block using 30 ml of 0.75% ropivacaine
62045705|NCT04962555||Complete meniscectomy|The patient underwent complete meniscectomy
62045706|NCT04134156|ACTIVE_COMPARATOR|Sleeve gastrectomy|5-port standard sleeve gastrectomy was conducted
62045707|NCT04134156|ACTIVE_COMPARATOR|one anastomosis gastric bypass|5-port standard one-anastomosis gastric bypass was performed
62045708|NCT01372657||cataract patients|cataract patients
62045709|NCT03592511|EXPERIMENTAL|Intervention|WGPF-burger group
62045710|NCT03592511|PLACEBO_COMPARATOR|Control|Control-burger group
62045711|NCT05698446||Open Modified Broström +Suture tape augmentation group|Patients who accept a modified Broström +Suture tape augmentation operation
62045712|NCT05698446||Anatomic reconstruction operation group|Patients who accept an anatomic reconstruction
62045713|NCT02026089|NO_INTERVENTION|Sero-positive for varicella at least 5 years prior|No treatment
62604976|NCT04554212|ACTIVE_COMPARATOR|Standard Physical Therapy with BFRT|Participants will undergo 8 weeks of blood flow restriction training with cuff inflated to 60% occlusion.
62045714|NCT02026089|ACTIVE_COMPARATOR|Varicella vaccine|One dose varicella vaccine (Varivax).
62604977|NCT05103839|EXPERIMENTAL|Yoga for Caregivers and Persons With Dementia|Persons With Dementia and their caregivers will participate in up to 20 group yoga classes.
62827679|NCT03846492|EXPERIMENTAL|Active tDCS|The direct current will be delivered at 2 mA intensity via rubber electrodes in saline- soaked sponges for 30 min per day for 2 weeks, 5 days/week. Inhibitory stimulation will be delivered to the frontal lobes.
62604978|NCT02105389|EXPERIMENTAL|Individualized Yoga Intervention|Individualized Yoga Intervention sessions will be administered by a trained yoga instructor three times weekly (or up to a maximum of five times per week) for three consecutive weeks. There will be a common structure for all sessions that will include relaxation and breathing exercises as well as a series of poses focused on strengthening, flexibility, and balance. There will be low, moderate and high intensity regimens prescribed depending on the wishes and abilities of the child and parent and the judgment of the yoga instructor.
62827680|NCT03846492|SHAM_COMPARATOR|sham tDCS|Sham tDCS will use the same parameters except that the device will automatically turn off after a certain duration.
62827681|NCT03541551|EXPERIMENTAL|CTT with ologen® Collagen Matrix|Experimental: Trabeculotomy with trabeculectomy with ologen implant
62827682|NCT03541551|ACTIVE_COMPARATOR|Trab Trab|Active Comparator: Trabeculotomy with trabeculectomy
62827683|NCT01670084|EXPERIMENTAL|Treatment (nilotinib, combination chemotherapy)|See Detailed Description
62827684|NCT05078047|EXPERIMENTAL|Experimental arm|"Reduced dose intensity of IO:~IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision"
62827685|NCT05078047|NO_INTERVENTION|Control arm|"Standard IO:~Continuation of IO at the same dose levels and rhythmicity until disease progression, unacceptable toxicity, death or patient's choice."
62045715|NCT04069000|ACTIVE_COMPARATOR|Regular grade 3 classrooms|Students in this condition will participate in the regular grade 3 program. Educators will use their usual teaching methods to meet educational outcomes, including standards for social-emotional learning.
62045716|NCT04069000|EXPERIMENTAL|First time MindUP participants|Students in this condition will participate in MindUP for the first time. Their classroom teachers will receive training and implement the program during the school year.
62604979|NCT06448858||Obese|Patients with BMI more than 30
62604980|NCT06448858||Overweight|Patients with BMI 25-30
62604981|NCT06448858||Control|Patients with BMI less than 25
62604982|NCT04616105|EXPERIMENTAL|Cohort 1|Single ascending subcutaneous (SC) dose 1 of REGN6490 or matching placebo
62604983|NCT04616105|EXPERIMENTAL|Cohort 2|Single ascending subcutaneous (SC) dose 2 of REGN6490 or matching placebo
62827686|NCT00746382|ACTIVE_COMPARATOR|1|Roflumilast cream 0.5%
62827687|NCT00746382|PLACEBO_COMPARATOR|2|Placebo cream
62827688|NCT04311021||Diabetes type 1|
62045717|NCT04069000|EXPERIMENTAL|Repeat MindUP participants|Students in this condition are in schools where MindUP has been implemented since they were in kindergarten (although some students may not have participated in those first three years, depending on when they moved to the school). Their classroom teachers will receive training and implement the program during the school year.
62045718|NCT02354664||Pompe subjects|These subjects will receive a thoracic MRI, spirometry, inspiratory load compensation, maximal inspiratory pressure, resting breathing pattern, respiratory muscle endurance test.
62045719|NCT02354664||Control subjects|These subjects will receive a thoracic MRI, spirometry, inspiratory load compensation, maximal inspiratory pressure, resting breathing pattern, respiratory muscle endurance test.
62827689|NCT04760782|EXPERIMENTAL|Treatment group|Daily self-administered injection of 80 mcg abaloparatide (8 weeks) + hard collar immobilization (12 weeks)
62827690|NCT04760782|ACTIVE_COMPARATOR|Historical control group|Patients who received only 12 weeks of hard collar immobilization
62827691|NCT01347112|ACTIVE_COMPARATOR|Varenicline|varenicline 1.0 mg twice daily for 12 weeks
62827692|NCT01347112|PLACEBO_COMPARATOR|Sugar Pil|Varenicline look alike sugar pill twice daily for 12 weeks
62045720|NCT01919242||with morbidity|patients who suffered from any type of morbidity after surgery
62045721|NCT01919242||without morbidity|patients who did not suffer from any type of morbidity after surgery
62827693|NCT06586580||Metastatic melanoma|Metastatic melanoma refractory to immunotherapy
62045722|NCT03067038|ACTIVE_COMPARATOR|Single incision LC|Single incision laparoscopic cholecystectomy (SILC) performed through a single infra-umbilical incision using a single port device or three ports closely placed.
62045723|NCT03067038|SHAM_COMPARATOR|Three port LC|Three port laparoscopic cholecystectomy (TPLC) performed through three different placed trocars
62045724|NCT06374446|EXPERIMENTAL|Classical Treatment|Upper and lower extremity exercises + breathing exercises
62827694|NCT05728437|EXPERIMENTAL|Study group|This group includes 30 burned patients who will receive resistance exercises 8 weeks (3times/week) by using dumbbells and sand bags in addition to their physical therapy program (splinting, stretching ex. and ROM ex.) and medical treatment.
62604984|NCT04616105|EXPERIMENTAL|Cohort 3|Single ascending subcutaneous (SC) dose 3 of REGN6490 or matching placebo
62604985|NCT04616105|EXPERIMENTAL|Cohort 4|Single ascending intravenous (IV) dose 4 of REGN6490 or matching placebo
62604986|NCT01210495|EXPERIMENTAL|A|Participants in this group received axitinib + best supportive care. Participants with Child-Pugh Class A disease (score 5 or 6) were enrolled into the randomized portion at a starting axitinib dose of 5 mg BID orally. Participants with Child-Pugh Class B disease (score 7) were to begin enrollment into the randomized portion of the study following determination of the recommended axitinib starting dose in the non-randomized portion. Study treatment was administered in cycles of 4 weeks in duration
62827695|NCT05728437|NO_INTERVENTION|Control group|This group includes 30 burned patients who will receive their physical therapy program (splinting, stretching ex., strengthening ex. and ROM ex.) and medical treatment.
62827696|NCT03908801|EXPERIMENTAL|Intervention|Specialized water dance intervention
62827697|NCT03908801|NO_INTERVENTION|Control|No intervention
62827698|NCT06587932|EXPERIMENTAL|Group A (exprimental group)|18 subjects received brain gym exercises for 15-30 minutes per day, three times a week, for eight consecutive weeks (Elbanna et al., 2023). And traditional treatment in form of balance exercise included standing on one leg, standing in tandem mode, walking in a tandem mode (one foot in front of the other), walking on toes and heels, side walk, standing while one upper extremity and the opposite lower extremity were up, rotating the head from side to side, walking backwards for four steps, and shifting weight from one foot to the other. Periodic exercises were frequently performed for 45 min for 4 sessions per week for 8 weeks (Rojhani-Shirazi et al., 2016)
62827699|NCT06587932|ACTIVE_COMPARATOR|Group B (balance exercise):|18 subjects will receive traditional treatment in form of balance exercise included standing on one leg, standing in tandem mode, walking in a tandem mode (one foot in front of the other), walking on toes and heels, side walk, standing while one upper extremity and the opposite lower extremity were up, rotating the head from side to side, walking backwards for four steps, and shifting weight from one foot to the other. Periodic exercises were frequently performed for 45 min for 4 sessions per week for 8 weeks (Rojhani-Shirazi et al., 2016)
62438043|NCT04249206|EXPERIMENTAL|Hydraulic Sealer Group|"The single-cone obturation technique is based on a master cone of gutta-percha in conjunction with a hydraulic sealer.~Hydraulic endodontic cements exhibit excellent hydraulic properties, biocompatibility and bioactivity."
62438044|NCT04249206|ACTIVE_COMPARATOR|Zinc oxide-eugenol Sealer Group|The continuous wave of condensation of gutta-percha and a zinc oxide-eugenol (ZOE) sealer is a gold standard in endodontic obturation.
62438045|NCT02625766|EXPERIMENTAL|Operative|Patients enrolled in the operative treatment group will undergo surgical intervention for their pelvic fracture. The surgeon will decide the best surgical technique as per standard of care for the patient's injury. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments to determine if the injury is healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
62438046|NCT02625766|EXPERIMENTAL|Non-operative|Patients enrolled in the non-operative treatment group will not undergo surgical intervention for their pelvic fracture. They will mobilize as per the surgeon's instructions according to standard of care of for this injury. X-rays will be taken at follow-up clinic appointments to determine if the injury is healing properly or if the pelvis has shifted and may warrant surgical intervention. If complications arise and/or surgery is required, crossover will be allowed and recorded within study follow-up forms.
62438047|NCT05161104||left ventricular systolic dysfunction(LVSD)|
62438048|NCT05161104||left ventricular diastolic dysfunction(LVDD)|
62438049|NCT05161104||right ventricular dysfunction(RVD)|
62438050|NCT05161104||diffuse ventricular dysfunction|
62438051|NCT05161104||hyperdynamic state left ventricular function|
62438052|NCT05161104||Normal|
62438053|NCT02166242|EXPERIMENTAL|experimental|patients pathologic diagnosis advanced non-small cell lung cancer who had received more than two lines standard treatment, according to NCCN Non-small cell lung cancer guideline, there were no standard treatment scheme for these patients. Approximately 40 patients will be included in the study, patients will received oral ethaselen dispersible tablet, 600 mg bid dose, patients may quit the study whenever they would like or investigator evaluate that progression disease has developed, or any grade of SAE developed during the study.
62438054|NCT00424606|EXPERIMENTAL|1|
62438055|NCT00424606|EXPERIMENTAL|2|
62438056|NCT03705351|EXPERIMENTAL|Treatment|Patients will receive trimodal therapy consisting of tumor treating fields therapy with the Optune device concurrent with temozolomide and radiation therapy.
62438057|NCT01142297|OTHER|dental implant|standard SLA surface and chemically modified surface
62604987|NCT01210495|PLACEBO_COMPARATOR|B|Participants in this group received placebo + best supportive care. Treatment was administered in cycles of 4 weeks in duration. The starting dose of placebo for participants with Child Pugh Class A disease (score 5 or 6) was chosen as 5 mg BID. Participants with Child-Pugh Class B, score 7 received placebo that was determined from the non-randomized portion of the study until the recommended starting dose was determined, participants with Child-Pugh Class B, score 7, were not permitted to enter the randomized portion of the study
62438058|NCT03339791|ACTIVE_COMPARATOR|Sleeve|Morbid obese patients, 65 years old or more, submitted to Sleeve Gastrectomy
62438059|NCT03339791|ACTIVE_COMPARATOR|Bypass|Morbid obese patients, 65 years old or more, submitted to Gastric Bypass
62438060|NCT00472498||1|"Case:~Patients resuscitated after 2001"
62438061|NCT00472498||2|"Control:~Patients who suffer cardiac arrests after 2001."
62438062|NCT06234046|ACTIVE_COMPARATOR|group (1)|Group (1) included 40 cases received Rifaximin as 550 mg twice daily dose for a six-months period.
62045725|NCT06374446|EXPERIMENTAL|Virtual Reality Combined with Classical Treatment|Upper and lower extremity exercises + breathing exercises+virtual reality
62045726|NCT06374446|EXPERIMENTAL|Virtual Reality Group|Virtual reality
62604988|NCT03343249|EXPERIMENTAL|Study Visits|"The Short form of the Rapid Estimate of Adult Literacy in Medicine (REALM) will be administered to ensure that all participants are able to read at \> sixth grade level. Expired carbon monoxide (CO) will be measured.~Assessment: Participants will complete self-report questionnaires; and expired CO, weight, and height will be measured. Participants will be provided with a Samsung Galaxy Light Android smart phone and instructed on how to: 1) use the phone features, 2) complete EMAs, and 3) use the adjunctive Smart-T phone based treatment. Participants will receive 4 random prompts and 1 daily diary prompt during their normal waking hours each day for three consecutive weeks. Random assessments will take approximately 1 min to complete and daily diary assessments will take approximately 5 mins to complete."
62604989|NCT01746797||Women currently taking antidepressants|Women who have selected to stay on antidepressant medication while undergoing infertility treatment.
62827700|NCT06164106|EXPERIMENTAL|Virtual Crisis Response Planning|The virtual crisis response planning (CRP) session will last between 30 minutes to 1-hour and be conducted via doxy.me with a trained study therapist. The virtual CRP is primarily text-based, instead of verbal, and utilizes the chat feature on doxy.me. CRP involves the following standard suicide intervention strategies: supportive listening, provision of crisis resources, and referral to a mental health professional (if not already established). The CRP active component involves a collaborative process in which the therapist invites the participant to share the events, symptoms, and contextual factors leading up to and surrounding their suicidal crisis. Next, the participant identifies their personal warning signs, self-management coping skills, reasons for living, and sources of social support. The participant types the components on a template via the white board feature on doxy.me. The CRP will be saved and serve as a concrete reference for participants in the real-world.
62827701|NCT06164106|ACTIVE_COMPARATOR|In-Person Crisis Response Planning|The in-person crisis response planning (CRP) session will last between 30 minutes to 1-hour. The in-person CRP will follow the same protocol and include the same treatment components as the virtual CRP. However, it will occur face-to-face, instead of on doxy.me, with a trained study therapist. The treatment components, outlined under the virtual CRP arm description, are written by the participant on an index card. The index card serves as a concrete reference for participants in the real-world.
62604990|NCT01746797||Women not on antidepressants|Women who decided to discontinue their antidepressants while undergoing fertility treatments.
62827702|NCT06164106|ACTIVE_COMPARATOR|Virtual Crisis Risk Counseling|The crisis risk counseling session will last between 30 minutes to 1-hour. It will occur virtually on doxy.me with a trained study therapist. It will include the following standard suicide intervention strategies: supportive listening, provision of crisis resources, and referral to a mental health professional (if not already established). The therapist will conduct a semi-structured suicide risk assessment interview, after which participants will complete a self-guided safety plan worksheet via the white board feature. The worksheet will take approximately 10-minutes to complete and will be done independently.
62827703|NCT06654908|EXPERIMENTAL|Group A: (Study group) who have insulin resistance and who will receive resisted exercise|This group includes 34 patients who have insulin resistance and who will receive resisted exercise
62827704|NCT06654908|NO_INTERVENTION|Group B: (Control group) who have insulin resistance and who will receive routine medical treatment.|This group includes 34 patients who have insulin resistance and who will receive routine medical treatment.
62827705|NCT04969926||Patients with confirmed, suspected or at risk of developing parathyroid disorder|Parathyroid (and related disorders) will be evaluated and their biospecimens collected to define the molecular signature and clinical spectrum of their disorder
62827706|NCT04400877||SARS-CoV-2 pos|Patients who have been tested positive for SARS-CoV-2 virus by either nasopharyngeal swab PCR or antibody testing.
62827707|NCT04400877||SARS-CoV-2 neg|Patients without symptoms for SARS-CoV-2 infection who haven't been tested for the virus or patients with symptoms who have been tested negative for SARS-CoV-2 virus by either nasopharyngeal swab PCR or antibody testing.
62827708|NCT06594029|EXPERIMENTAL|Community Navigator Intervention|Weekly meetings between participant and a peer specialist. The peer specialist will help participants identify participation interests, set participation goals, and to achieve those goals while increasing confidence and competence in community participation. Initially, participants will develop a plan for community participation which includes a list of meaningful activities, identifying potential barriers and facilitators to participation. At each weekly meeting, the peer specialist will work with participants to determine what aspects of the plan are working and modify it based on any newly identified barriers, opportunities, or changes to the participants' interests or motivation. The sessions are designed to meet the participants where they are on their journey towards participating in the community. Each successive session will encourage growth and independence through peer support that is tailored to each participant's particular needs and ability.
62827709|NCT06594029|ACTIVE_COMPARATOR|Active control group|Receive information on community participation for adults with your health condition
62438063|NCT06234046|ACTIVE_COMPARATOR|group (2)|Group (2) included 40 cases received Ciprofloxacin as 750 mg once weekly dose for a six-months period.
62045727|NCT06374446|EXPERIMENTAL|Control Group|A brochure with home program explaining the importance of exercise will be given
62045728|NCT03776955|EXPERIMENTAL|Oral Carvedilol|6.25 mg or 12.5 mg if tolerated
62045729|NCT03776955|PLACEBO_COMPARATOR|Oral Placebo|
62438064|NCT01196481|EXPERIMENTAL|Carvedilol+VSL#3|Tablet Carvedilol 6.25 mg BD + VSL#3
62438065|NCT01196481|ACTIVE_COMPARATOR|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3-4 weeks till variceal ligation
62604991|NCT04470284|ACTIVE_COMPARATOR|SMBP_only|Standard treatment with SMBP
62604992|NCT04470284|EXPERIMENTAL|SMBP_mobile_app|SMBP with mobile App based feed-back algorithm
62604993|NCT01273740|EXPERIMENTAL|External support|Bypass graft with external support
62604994|NCT01273740|EXPERIMENTAL|No external support|Bypass with graft without external support
62438066|NCT04647344|EXPERIMENTAL|Nonsquamous NSCLC|
62438067|NCT04647344|EXPERIMENTAL|Squamous NSCLC|
62438068|NCT01002157|EXPERIMENTAL|Vitamin K2 supplementation|
62604995|NCT06302088|NO_INTERVENTION|Waitlist Control Arm|Control Arm engages in baseline, 6-and-12-month surveys, as well as baseline interviews and 24-month interviews. They engage in standard operating procedures and do not take part in the intervention
62604996|NCT06302088|EXPERIMENTAL|SAINTS program Intervention Arm|Intervention arm engages in baseline, 6-and-12-month surveys, as well as baseline interviews and 24-month interviews. They engage in safety training programs and quality improvement cycles during the duration of the intervention.
62604997|NCT03013296|PLACEBO_COMPARATOR|Placebo|Saline
62604998|NCT03013296|OTHER|GIP-A|Infusion of GIP-A alone as study tool.
62604999|NCT03013296|OTHER|GLP-1 receptor antagonist Exendin[9-39]|Infusion of GLP-1 receptor antagonist Exendin\[9-39\] alone as study tool.
62605000|NCT03013296|OTHER|GIP-A + Exendin[9-39]|Infusion of GIP-A + GLP-1 receptor antagonist Exendin\[9-39\] together as study tools.
62605001|NCT03199612|ACTIVE_COMPARATOR|Sildenafil|Baseline blood samples and study measurements will be acquired. Then 20 mg of the study drug will be administered. Then BP will be recorded every 30 minutes for two hours. If BP is stable (drop is \< 5 mmHg after 2 hours and patient is asymptomatic), patient will proceed to take 20 mg of the study drug every 8 hours. The patient will return to clinic on day 8 and 20 mg of the study drug will be administered. After 2 hours blood samples and study measurements will be collected and the patient will resume 20 mg of the study for the next two doses. The patient will return for a third clinic visit on the next day and if BP is in the acceptable range, 40 mg of the study drug will be administered. If BP remains stable for 2 hours, then the patient will continue taking 40 mg every 8 hours. The patient will return to clinic on day 15 for a final study visit and will be given the last 40 mg dose of the study drug and after 2 hours blood samples and study measurements will be taken.
62605002|NCT03199612|PLACEBO_COMPARATOR|Placebo Oral Tablet|Negative control to understand the potential changes in platelet activation and aggregation in comparison to sildenafil.
62605003|NCT05956353|EXPERIMENTAL|Stories for Change: Prevention (S4C) intervention|Participants who are due or overdue for cancer screening will receive the digital storytelling intervention and complete a cross-sectional survey to assess intervention acceptability, socio-behavioral constructs, and theory-based constructs.
62605004|NCT05167175|EXPERIMENTAL|Intervention/Treatment|Subjects will receive a regimen of Olaparib tablets 300 mg twice daily in combination with Abiraterone acetate 1000 mg plus Prednisone 5mg once daily until radiographic disease progression (assessed by the investigator according to RECIST1.1 and PCWG3) or intolerable adverse events (assessed by the investigator according to the actual clinical situation).
62827710|NCT01167777||male/female|Symtomatic and asymptomatic males and females attending STD, family planning, public health and women's health clinics, or other applicable centers, who are being screened for CT or GC.
62827711|NCT01106612|EXPERIMENTAL|Initial coronary CT angiography|EKG-gated, computed tomography angiography of the coronary arteries during heart rate control
62827712|NCT01106612|ACTIVE_COMPARATOR|Initial nuclear stress test|Stress radionuclide myocardial perfusion imaging
62438069|NCT01002157|PLACEBO_COMPARATOR|Placebo control|
62438070|NCT03172585|OTHER|High Resolution computed tomography|Patients will be included in the study when High resolution chest computed tomography without contrast enhancement is ordered by the primary physician. Before the High resolution chest computed tomography scan, a Trans thoracic ultrasonography will be performed.
62438071|NCT04767490|ACTIVE_COMPARATOR|BPD-DS|Biliopancreatic diversion with Duodenal Switch (BPD-DS), with Sleeve gastrectomy, including a 100cm common channel and 150cm stric alimentary limb
62438072|NCT04767490|EXPERIMENTAL|SADI|Single-Anastomosis Duodeno-Ileal anastomosis (SADI) with Sleeve Gastrectomy, including a 250cm common channel
62438073|NCT04370626||Registry Group|Patients who sustain and present with a PLI injury will have two options for participating in the study. This first arm will evaluate clinical presentations, patient demographic, treatment methods and baseline patient-rated and radiographic outcomes. However, no research-related follow up visits will be conducted. Ongoing data from these participants will be collected from chart reviews of clinical follow-ups alone.
62438074|NCT04370626||Prospective Group|Participants who choose to enroll in the prospective arm will experience the same baseline data collection as those in the registry, with the addition of research-related follow up appointments that will allow research staff to measure and assess patient-rated and clinical outcomes, such as questionnaires and range of motion data.
62438075|NCT04370626||Retrospective Group|In this group, a chart review will be conducted to identify previously treated patients with perilunate injuries. Once identified, the patient will be contacted and ask if they are willing to come in for a long-term follow up visit where clinical, patient-rated, and radiographic data will be collected. If patients are unwilling to attend a long-term visit, our analysis will still include data collected from their chart reviews and electronic questionnaires.
62438076|NCT05921084|PLACEBO_COMPARATOR|Control arm|Usual medical care (including general dietary advice).
62438077|NCT05921084|ACTIVE_COMPARATOR|MIND diet intervention arm|Usual medical care plus the MIND diet intervention.
62438078|NCT05923177|EXPERIMENTAL|The tested injected doses of [123I] I-(HE)3-G3 3000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 3000 μg.~Subjects withdrawn from the study for any reason will be replaced"
62438079|NCT00676585|PLACEBO_COMPARATOR|2|Normal Saline
62438080|NCT00676585|EXPERIMENTAL|1|Hydrocortisone 100mg every 8 hours.
62438081|NCT05044403|ACTIVE_COMPARATOR|Conventional treatment|Patients receiving conventional treatment for multiorganic dysfunction syndrome from septic origin.
62438082|NCT05044403|EXPERIMENTAL|Extracorporeal support with haemoperfusion treatment|Patients receiving extracorporeal support with haemoperfusion for multiorganic dysfunction syndrome from septic origin.
62438083|NCT06382467|EXPERIMENTAL|Combination group|Combination regimen (remimazolam plus propofol)
62438084|NCT06382467|ACTIVE_COMPARATOR|Propofol group|Propofol monotherapy
62438085|NCT02186808|OTHER|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
62605005|NCT06258187|EXPERIMENTAL|Pedi-Cap|A Pedi-Cap will be connected to the T-piece resuscitator in between the T-piece and face mask. With effective gas exchange, carbon dioxide (CO2) is detected by the Pedi-cap and will demonstrate gold color change with each exhalation. If there is no CO2 gas exchanged, the Pedi-Cap color will remain purple. The color change will be used as one of the tools for the resuscitation team to determine if the infant has effective non-invasive positive pressure ventilation (PPV) during delivery room resuscitation. Other ways, in addition to the Pedi-Cap, to determine effective PPV include a rise in heart rate, improved infant color, chest rise, and improvement in oxygen saturation.
62605006|NCT06258187|NO_INTERVENTION|No Pedi-Cap|There will be no Pedi-Cap attached to the t-piece resuscitator. Effective non-invasive positive pressure ventilation (PPV) during delivery room resuscitation will be assessed by a rise in heart rate, improved infant color, chest rise, and improvement in oxygen saturation.
62605007|NCT00581542|ACTIVE_COMPARATOR|Moxifloxacin Opthalmic solution|
62827713|NCT04083612|OTHER|Standard of care - ixekizumab|Patient will continue to receive ixekizumab according to standard of care dosing regimen, i.e. loading dose first (160 mg) at week 0; 80 mg every 2 weeks until week 12, then 80 mg every 4 weeks
62827714|NCT02929394|ACTIVE_COMPARATOR|investigational treatment|Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity.
62827715|NCT02929394|NO_INTERVENTION|observation|Observation through clinical and radiological follow-up until disease progression (RECIST 1.1).
62827716|NCT02497534||Affected with Friedreich's ataxia|Friedreich's ataxia patients aged 8 to 70 (inclusive). Assessments will include collection of genetic mutation reports, cardiac and exercise MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), exercise testing with a recombinant bike and/or hand ergometer, pulmonary function testing, and gait analysis. Optional labs include a blood draw, skin biopsy, and/or muscle biopsy.
62827717|NCT02497534||Healthy controls|Health controls aged 8 to 70 (inclusive). Assessments will include cardiac and exercise MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), exercise testing, hand ergometer for exercise testing, pulmonary function testing, gait analysis, and an optional blood draw.
62827718|NCT02497534||Carriers of Friedreich's ataxia|An obligate carrier aged 18 to 70 (inclusive) of the abnormal Friedreich's ataxia gene by being a parent of a child with Friedreich's ataxia. No assessments are to be conducted. Optional labs include a blood draw, skin biopsy, and/or muscle biopsy.
62827719|NCT06651853|EXPERIMENTAL|Treatment arm|Large fraction radiation therapy plus GM-CSF, Lenalidomide, and Glofitamab
62827720|NCT06602609|OTHER|Control Group|The control group adheres to the best standard of care as per current practice.
62827721|NCT06602609|ACTIVE_COMPARATOR|Remote Monitoring Group|Those in the remote monitoring group will be given four devices, which will help the research team make decisions about their health condition based on the data collected. The active arm group will wear the continuous ECG device for 72 hours from discharge and will be instructed to acquire a daily 12-lead ECG and record vital signs until day 7 of hospital discharge. Additionally, participants will utilise 12-lead ECG and vital signs will be measured only when experiencing symptoms.
62827722|NCT04970485|EXPERIMENTAL|Talking Matters intervention|Talking Matters is a group-level, two-pronged intervention for Black and African American 14 to 19 year old adolescents recruited from school- and community-based settings in Philadelphia, PA. Goals are to reduce teens' risk for unplanned pregnancy, sexually transmitted infections, and HIV, and to strengthen protective factors to improve health. The two prongs include (1) an adolescent-focused five-session, group-level intervention called We Get to Choose (WGTC) covering sexual and reproductive health (SRH) knowledge and skills, decision making and self-worth, healthy relationships, substance use and mental health; and (2) an adult-focused three-session, group-level training called Let's Talk Real Talk (LTRT) to build SRH knowledge and skills to communicate with teens about SRH. An opportunity to connect WGTC participants to trusted adults who completed LTRT is provided during one facilitated session conducted each quarter. LTRT participants are not human subjects of the study.
62827723|NCT04970485|NO_INTERVENTION|Control Group|Business as usual
62827724|NCT06326814|EXPERIMENTAL|SAR443809 and placebo dose 1 Arm|6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 1
62827725|NCT06326814|EXPERIMENTAL|SAR443809 and placebo dose 2 Arm|6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 2
62438086|NCT06417606|EXPERIMENTAL|Lenvatinib and Adebrelimab Combined With GEMOX（Gemcitabine and oxaliplatin）|Lenvatinib（oral，12mg once daily if body weight ≥60Kg; Body weight \< 60Kg, 8mg/ day）； Adebrelimab（intravenous drip，1200mg once every 3 weeks）； GEMOX（intravenous drip，Gemcitabine 1000mg/m2, 2 times every 3 weeks d1+d8; intravenous drip，Oxaliplatin, 100mg/m2, was given every 3 weeks）
62605008|NCT00581542|ACTIVE_COMPARATOR|Polymyxin B-trimethoprim opthalmic solution|
62438087|NCT04450498|EXPERIMENTAL|Walvax MPV ACYW® vaccine group|
62438088|NCT04450498|ACTIVE_COMPARATOR|Sanofi Pasteur Menactra® vaccine group|
62438089|NCT02182011|EXPERIMENTAL|Tenecteplase|Single i.v. bolus followed by infusion, weight adjusted
62438090|NCT02182011|ACTIVE_COMPARATOR|Alteplase|Single i.v. bolus followed by infusion
62605009|NCT01406184|EXPERIMENTAL|Durham Connects Eligible Group|From July 1, 2009 - December 31, 2010, all even-birth-date residential births in Durham County, North Carolina were randomly assigned to receive the Durham Connects nurse home visiting program.
62605010|NCT01406184|NO_INTERVENTION|Control Group|From July 1, 2009 - December 31, 2010, all odd-birth-date residential births in Durham County, North Carolina were randomly assigned to a control group condition. These families were assigned to receive services as usual and served as the randomized comparison group for evaluating Durham Connects program impact.
62827726|NCT06326814|EXPERIMENTAL|SAR443809 and placebo dose 3 Arm|6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 3
62827727|NCT06326814|EXPERIMENTAL|SAR443809 and placebo dose 4 Arm|6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 4
62827728|NCT06326814|EXPERIMENTAL|SAR443809 and placebo dose 5 Arm|6 participants receiving SAR443809 and 2 receiving placebo, subcutaneous administration dose 5
62045730|NCT01927432||Regular menstrual cycles|Adult women will be assigned to this category if they report a history of regular menstrual cycles.
62045731|NCT01927432||Irregular menstrual cycles|Adult women will be assigned to this category if they report a history of irregular menstrual cycles, including women with a pre-existing diagnosis of PCOS.
62045732|NCT01592331|PLACEBO_COMPARATOR|Placebo|
62605011|NCT03796338||Critically ill patients|age \> 18 years
62605012|NCT03066245|EXPERIMENTAL|MSC-PLGA|The lesion will be treated with curettage then 1 million of bone marrow derived MSC seeded on 5x5 mm2 PLGA scaffold will be engrafted in the cyst of ABC patient.
62605013|NCT04417140|EXPERIMENTAL|Treatment Arm-dHACM|Patients enrolled in this arm will have a thin sheet of dHACM placed as an overlay over the length of the closed incisions. dHACM is Dehydrated Human Amniotic-Chorion Membrane. It is a FDA registered healing adjunct that has been applied in a broad range of diseases including wounds, plantar fasciitis and burns.
62827729|NCT06326814|EXPERIMENTAL|SAR443809 and placebo dose 6 Arm|Optional: 6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 6
62827730|NCT06326814|EXPERIMENTAL|SAR443809 and placebo dose 7 Arm|Optional: 6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 7
62045733|NCT01592331|EXPERIMENTAL|RO5508887|
62605014|NCT04417140|NO_INTERVENTION|Control Arm|Patients enrolled in this arm will have routine closure.
62605015|NCT03533881|ACTIVE_COMPARATOR|Arom Digest Slim and nutritional changes|Subjects take collagen and follow minimal nutritional changes.
62827731|NCT02874521|EXPERIMENTAL|Intra-dialytic LF-EMS|Performed twice weekly whilst seated on a standard dialysis chair. Delivered by adhesive electrodes in a neoprene garment, applied bilaterally to the quadriceps and hamstrings. Cardiovascular stimulus via rapid, rhythmical, sub-tetanic contractions. Short bursts of four pulses repeatedly delivered by stimulator at a frequency of 4Hz. Current amplitude adjustable from 40 - 200 mA with inbuilt controller. Conducted for one hour at the maximum tolerable intensity. Five minute warm-up and cool down at a lower frequency (3 Hz).
62827732|NCT02874521|EXPERIMENTAL|Intra-dialytic cycle training|Semi-recumbent cycling performed twice weekly whilst seated on a standard dialysis chair. Performed for up to one hour per session, initially at a workload (Watts) equivalent to that achieved at 40-60% VO2 reserve during cardiopulmonary exercise test. Exercise intensity regulated using a combination of heart rate and rating of perceived exertion (12-14). Workload adjusted weekly and controlled with a combination of pedal resistance and cadence to provide a personalised exercise prescription. Five minute warm-up and cool down each session.
62827733|NCT02874521|NO_INTERVENTION|Usual care|Continuation of dialysis treatment without the addition of an intra-dialytic exercise intervention.
62045734|NCT03948048||septic shock|The critically ill children with septic shock (ss group)
62045735|NCT03948048||refractory septic shock with ECMO|The critically ill children with refractory septic shock with ECMO treatment
62045736|NCT03948048||refractory septic shock without ECMO|The critically ill children prediction model th refractory septic shock without ECMO treatment
62045737|NCT03249155|EXPERIMENTAL|AO - plus sonification|patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture.
62438091|NCT02182011|ACTIVE_COMPARATOR|Streptokinase|I.V. infusion
62605016|NCT03533881|ACTIVE_COMPARATOR|Nutritional changes|Subjects only follow minimal nutritional changes
62605017|NCT01813513|EXPERIMENTAL|Group A: IDX719 then IDX719/Simeprevir|Healthy participants take IDX719 150 mg once daily (QD) on Days 1-7 and IDX719 150 mg QD + simeprevir 150 mg QD on Days 8-14.
62605018|NCT01813513|EXPERIMENTAL|Group B: Simeprevir then IDX719/Simeprevir|Healthy participants take simeprevir 150 mg QD on Days 1-7 and IDX719 150 mg QD + simeprevir 150 mg QD on Days 8-14.
62605019|NCT01813513|EXPERIMENTAL|Group C: IDX719|Healthy participants take IDX719 150 mg QD on Days 1-14.
62605020|NCT01813513|EXPERIMENTAL|Group D: IDX719/Simeprevir|Participants from Groups A and B will be asked to return for Group D. Participants take IDX719 and simeprevir QD on Days 1-7 to determine the impact of food on single-dose (on Day 1) and steady state (Day 7) PK.
62605021|NCT01813513|EXPERIMENTAL|Group E: High-Fat then Low-Fat PK|Participants from Group C will return to determine the PK of IDX719 after high-fat (Day 1) and low-fat (Day 7) meals (Days 2-6 are drug-free washout).
62605022|NCT01813513|EXPERIMENTAL|Group F: Low-Fat then High-Fat PK|Participants from Group C will return to determine the PK of IDX719 after low-fat (Day 1) and high-fat (Day 7) meals (Days 2-6 are drug-free washout).
62605023|NCT02750007|EXPERIMENTAL|Experimental|Weekly-dose titration from 0.04mg/day HS-20004 to the maximum tolerable dose or of the ultimate 0.18mg/day
62605024|NCT03794505|ACTIVE_COMPARATOR|Shoulder infiltration|Shoulder infiltration using 2 ml of Lidocaine 2% Injectable Solution and methylprednisolone acetate 40 mg
62605025|NCT03794505|EXPERIMENTAL|Suprascapular nerve block|Suprascapular nerve block ultrasound guided using 25 mg of Ropivacaine HCl Inj 7.5 MG/ML and methylprednisolone acetate 40 mg
62605026|NCT05294991|EXPERIMENTAL|Wellness app intervention #1|Participants assigned to this group will be asked to engage with the app a minimum of 10 minutes per day (70 minutes per week), at any time of day they choose for at 8-week period. There is a recommended program to follow for the 8-week period, but participants are also welcome to engage with other features and content within the app.
62605027|NCT05294991|ACTIVE_COMPARATOR|Wellness app intervention #2|Participants assigned to this group will be asked to engage with the app a minimum of 10 minutes per day (70 minutes per week), at any time of day they choose for at 8-week period. There is a recommended program to follow for the 8-week period, but participants are also welcome to engage with other features and content within the app.
62605028|NCT01485445|EXPERIMENTAL|Fluticasone Furoate (single strip configuration)|400mcg, administered as 2 inhalations of 200mcg
62605029|NCT01485445|EXPERIMENTAL|Fluticasone Furoate (two strip configuration)|400mcg, administered as 2 inhalations of 200mcg. Second strip contains lactose and magnesium stearate
62605030|NCT01485445|EXPERIMENTAL|Fluticasone Furoate/Vilanterol|400/50mcg, administered as 2 inhalations of 200/25mcg
62045738|NCT03249155|ACTIVE_COMPARATOR|CUE - visual and auditory|patients re-learn 8 motor gestures practicing a traditional protocol combining visual and auditory cues.
62605031|NCT02156375|EXPERIMENTAL|Ustekinumab 90 mg/mL|
62605032|NCT02156375|EXPERIMENTAL|Ustekinumab 5 mg/mL|
62605033|NCT02326298|EXPERIMENTAL|CZP 200 mg|"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~Treatment received from Week 16-48 is based on initial treatment and response to treatment:~* PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.~* PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~* PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study."
62605034|NCT02326298|EXPERIMENTAL|CZP 400 mg|"CZP 400 mg every two weeks (Q2W) through Week 14.~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~* PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.~* PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~* PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W."
62605035|NCT02326298|PLACEBO_COMPARATOR|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~* PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.~* PASI75 responders at Week 16 continue to receive Placebo.~* PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~* PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W."
62605036|NCT04505605||Patient hospitalized without being transferred in the ICU|A blood sample on a dry tube with 5 ml separating gel in addition to the blood test made on the basis of the usual medical care, will be taken on D1 (day of the enrollment = the day of hospitalization in the healthcare institution). The total volume of blood collected as part of the research is therefore 5 ml.
62605037|NCT04505605||Patient directly hospitalized in the ICU|A blood sample on a dry tube with a 5 ml separating gel in addition to the blood test made on the basis of the usual medical care, will be taken on D1 and D3 of the admission to intensive care. The total volume of blood collected for research is therefore 10 ml.
62605038|NCT04505605||Patient transferred from an other hospital service to the ICU|A blood sample on a dry tube with 5 ml separating gel in addition to the blood test that will be taken at D1 and D3 of the patient's admission to the intensive care unit, even if it has already been included in the study during the patient's admission to the unit (D1 hospitalization). The total volume of blood collected for the research is therefore 15 ml.
62045739|NCT03263754|EXPERIMENTAL|Intervention|
62045740|NCT03263754|ACTIVE_COMPARATOR|Control|
62045741|NCT04184726|EXPERIMENTAL|MBCT-vision|8 x once weekly group sessions, and home practice between sessions
62045742|NCT00166296|EXPERIMENTAL|Escitalopram|Escitalopram, 15 mg/day
62248020|NCT03156348|NO_INTERVENTION|Control|"The control group will receive hospital care and discharge from a clinical team previously trained in geriatric clinical pharmacology, which includes epicrisis, indications that the physician deems pertinent to the discharge and prescriptions if necessary and a medical control at 15 days post-discharge.~Information will be collected that allows the characterization:~* Sociodemographic~* Morbid~* Pharmaco-therapeutic~* Functionality before (baseline), during and after hospitalization~A physician, a pharmacist and an occupational therapist, blind to the treatment assignment, will collect the records using a specially designed record. Post-discharge evaluations will be conducted through telephone interviews at 30, 60 and 90 days after hospital discharge."
62248021|NCT02247154|EXPERIMENTAL|Vigam® Liquid|
62248022|NCT00791336|EXPERIMENTAL|Nelfinavir|
62827734|NCT06286202|EXPERIMENTAL|Cognitive Remediation: Adapted Neuropsychological and Education Approach to Remediation (NEAR)|NEAR consists of using carefully selected computer cognitive games to restore cognitive functioning through rehearsal and strategy learning. It will be delivered 3 times a week for 12 weeks at the center. The duration of each session within the week is as follows: 1) First session: 45 min computer-assisted cognitive exercises + 30 min bridging group; 2) Second session: 30 min computer-assisted cognitive exercises + 45 min bridging group; 3) Third session: 45 min computer-assisted cognitive exercises. Computer-assisted cognitive exercises are sessions where participants engage in cognitive games that target different cognitive domains. In addition, the Multicontext Treatment Approach to strategy learning will be carried out. The metacognitive framework of self-evaluation and activity mediation will also be utilized. Bridging groups are conducted twice a week, to aid transfer of learning from the computer game sessions to the participants' everyday life.
62827735|NCT06286202|OTHER|Standard Psychiatric Rehabilitation at Anglican Care Centers|Participants in the control arm will attend their scheduled activities at their respective Anglican Care Centers. The Anglican Care Centers run a variety of activities to provide psychosocial rehabilitation for clients with serious mental illness. These may include vocational training such as training in a retail shop or café, instrumental activities of daily living training (eg: taking public transport, money management), psychoeducation, social skills training etc. Participants in the control arm will not be enrolled into the cognitive remediation.
62827736|NCT01032538||Patients with knee osteoarthritis|Patients with knee osteoarthritis that are about to get an operation with oxford unicondylar knee
62827737|NCT03761992|ACTIVE_COMPARATOR|Gingko Biloba Extract|Gingko Biloba Extract 240 mg.
62827738|NCT03761992|PLACEBO_COMPARATOR|Placebo|Placebo Pill
62827739|NCT02012140|EXPERIMENTAL|Ticagrelor|As per ACC/AHA and ESC guidelines 180 mg is the recommended LD. The ticagrelor 90 mg BID dose, following the loading dose, has been selected for the clopidogrel naïve patients with stable angina, NSTEMI and STEMI patients undergoing PCI as the maintenance dose for this study since it is the FDA recommended dose.
62827740|NCT06590740|EXPERIMENTAL|Budesonide-Formoterol treatment|Budesonide 160 μg/formoterol 4.5 μg, 1 inhalation, BID
62827741|NCT02586298|EXPERIMENTAL|ICSI with mitochondria|Half of the Metaphase II oocytes retrieved after the controlled ovarian stimulation will be randomized to this group and autologous mitochondria from the patient's ovarian cortex will be introduced into the oocyte during the intracytoplasmic sperm injection in the vitro fertilization treatment.
62827742|NCT02586298|ACTIVE_COMPARATOR|Control ICSI without mitochondria|The other half of the metaphase II oocytes retrieved after the controlled ovarian stimulation will be randomized to this group and will not receive autologous mitochondria during the intracytoplasmic sperm injection (ICSI) in the vitro fertilization treatment. Control Group
62827743|NCT06452563|ACTIVE_COMPARATOR|Ketoanalogs Supplementation Group|Participants will receive daily a total of six tablets of Ketoanalogs Supplementation divided into three doses for three months .
62827744|NCT06452563|ACTIVE_COMPARATOR|Ketoanalogs Supplementation and intradialytic exercise group|Participants will receive daily a total of six tablets of Ketoanalogs Supplementation divided into three doses for three months in addition to doing intradialytic exercise .
62827745|NCT06452563|ACTIVE_COMPARATOR|Intradialytic exercise group|Participants will be asked to do intradialytic exercise only
62827746|NCT06452563|NO_INTERVENTION|Control group|Participants will not receive drug or do exercises
62605039|NCT02134002|EXPERIMENTAL|Disulfiram|disulfiram 250 mg/day
62827747|NCT04293575||In list group|patients on active heart transplantation (HTx) list with a low likelihood to receive a donation shortly (e.g. for body weight or blood group)
62827748|NCT04293575||"Bridge to decision BTD group"|patients suitable for HTx, but that were still waiting for clinical decision
62045743|NCT00166296|PLACEBO_COMPARATOR|Placebo pill|Placebo
62248023|NCT02827123|EXPERIMENTAL|Mcgrath group|Orotracheal intubation with McGrath MAC videolaryngoscopy
62248024|NCT02827123|PLACEBO_COMPARATOR|Macintosh group|Orotracheal intubation with Macintosh laryngoscopy
62605040|NCT02134002|PLACEBO_COMPARATOR|Placebo|Placebo
62045744|NCT05902832|EXPERIMENTAL|Experimental group - Autistic children|"60 7-10-years-old autistic children, from special education classes integrated in regular schools.~this group will receive EmotiPlay's intervention in the curriculum."
62045745|NCT05902832|NO_INTERVENTION|Control group- Autistic children|"60 7-10-years-old autistic children, from special education classes integrated in regular schools.~this group will be wait-listed and receive treatment as usual."
62605041|NCT02521532|EXPERIMENTAL|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
62605042|NCT02521532|PLACEBO_COMPARATOR|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
62605043|NCT06366139|ACTIVE_COMPARATOR|radiofrequency thermocoagulation group|Trigeminal ganglion radiofrequency thermocoagulation for trigeminal neuralgia
62605044|NCT06366139|ACTIVE_COMPARATOR|pulsed radiofrequency group|Maxillary mandibular nerve pulsed radiofrequency for trigeminal neuralgia
62605045|NCT02971540|EXPERIMENTAL|bupivacaine, LA, solution|an a local anesthetic administered for local wound infiltration on each side in a single dose of 10 ml of 0,2% solution per segment of vertrebral columne with potential duration time of up to 8 hours according to manufacturers data
62605046|NCT02971540|EXPERIMENTAL|ropivacaine, LA, solution|an a local anesthetic administered for local wound infiltration on each side in a single dose of 10 ml of 0,2% solution per segment of vertrebral columne with potential duration time of up to 8 hours according to manufacturers data
62438092|NCT05840003|EXPERIMENTAL|Patients undergoing Ultra-Low-Dose scan plus conventional standard dose thoraco-abdominopelvic scan|All adult patients (except pregnant women) presenting to the imaging department of the Institut de Cancérologie du Gard for a thoraco-abdominopelvic scan as part of an oncology follow-up will under a standard-dose can as well as an ultra-low-dose scan.
62438093|NCT02986152|EXPERIMENTAL|CDC Mobile App Treatment|Subjects who are randomized to the CDC mobile app treatment arm will be asked to perform the app's full suite of intervention tools such as learning about PTSD, assessment, finding support, and mind/body exercises (e.g., guided imagery, meditation, and relaxation exercises) over the entire 8-week study period.
62438094|NCT02986152|OTHER|CDC Mobile App Wait-List Control|Subjects who are randomized to the CDC mobile app wait-list control arm will be asked to perform only the learning about PTSD, assessment, and finding support activities for the first 4 weeks. Following completion of the Week-4 questionnaires, subjects will then be asked to additionally perform the mind/body exercises (e.g., guided imagery, meditation, and relaxation exercises) for the duration of the 8-week study period.
62438095|NCT00624403|ACTIVE_COMPARATOR|1|LMA ProSeal
62438096|NCT00624403|EXPERIMENTAL|2|I-Gel
62438097|NCT01294592|ACTIVE_COMPARATOR|Dutasteride plus tamsulosin|Dutasteride plus tamsulosin arm + lifestyle advice
62605047|NCT02971540|EXPERIMENTAL|metamizol, analgesic, solution|an analgesic drug administered intravenously for pre-emptive analgesia in a initial dose of 1-1,25g with potential duration time of up to 6 hours according to manufacturers data
62605048|NCT02971540|EXPERIMENTAL|tramadol, analgesic, solution|a half-opioid drug administered intravenously for pre-emptive analgesia in a initial dose of 2 mg per kg of body weight with potential duration time of up to 6 hours according to manufacturers data
62827749|NCT04293575||"(Bridge to candidacy BTC group)"|patients who could not be yet in list for HTx because of concomitant, potentially reversible, contraindications such as severe pulmonary hypertension, elevated pulmonary-vascular-resistance, unsatisfactory response to vasodilator challenge or other causes resulting in a prohibitive peri-procedural risk (as pre-transplant body mass index \[BMI\] \>35 kg/m2, severe renal dysfunction with creatinine clearance \<30 mL/min) and other reasons (current alcohol, tobacco or drug abuse, poor social support, non-residents)
62827750|NCT06597201|EXPERIMENTAL|experimental group|Subjects were treated with 1 bag of amino acid (15) peritoneal dialysate (2L) once every morning, and then with conventional glucose peritoneal dialysate (lactate).
62827751|NCT06597201|ACTIVE_COMPARATOR|control group|Subjects received conventional treatment with glucose peritoneal dialysis solution (lactate), which must include 1.5% glucose peritoneal dialysate (lactate) (2L) once.
62438098|NCT01294592|EXPERIMENTAL|Watchful waiting with escalation to tamsulosin|Watchful waiting with escalation to tamsulosin
62438099|NCT05438290|EXPERIMENTAL|DPCP|0.4% ointment
62438100|NCT05559554|EXPERIMENTAL|AK104 (after the change)|Drug: AK104 (after the change) Dose 1 and dose 2, will be administrated intravenously in 60±10 minutes.
62438101|NCT05559554|ACTIVE_COMPARATOR|AK104 (before the change)|Drug: AK104 (before the change) Dose 1 and dose 2, will be administrated intravenously in 60±10 minutes.
62438102|NCT02858856|EXPERIMENTAL|A group|Take Sipjeondaebo-tang on 0\~2 week, 3\~5 week of clinical trial period, total of 4 weeks
62438103|NCT02858856|EXPERIMENTAL|B group|Take Sipjeondaebo-tang on 6\~8 week, 9\~11 week of clinical trial period, total of 4 weeks
62438104|NCT00756132||Bloods Only (B)|Women aged 18-65 years with a newly diagnosed locally advanced or high risk operable breast cancer
62438105|NCT00756132||A-Cog|Women aged 18-65 years newly diagnosed with LABC/high risk who are willing and able to complete cognitive testing.
62438106|NCT00756132||Control (C)|Healthy women aged 18-65 years who are willing and able to complete cognitive testing.
62605049|NCT02971540|EXPERIMENTAL|control group|no pre-emptive analgesia will be used.
62605050|NCT06731582|EXPERIMENTAL|Nicotinamide|1.5 grams/day (2 tablets of 750 mg each)
62605051|NCT06731582|PLACEBO_COMPARATOR|Placebo|2 tablets
62605052|NCT04303533|EXPERIMENTAL|EFP-NF|
62605053|NCT01458717|EXPERIMENTAL|Neoadjuvant|Neoadjuvant - operation - maintenance chemotherapy
62605054|NCT01458717|ACTIVE_COMPARATOR|Upfront surgery|Operation - adjuvant chemoradiation - maintenance chemotherapy
62605055|NCT01637766|EXPERIMENTAL|Selective intra-arterial chemotherapy|Subjects recruited to this study will receive intra-arterial injections of chemotherapy (melphalan) in the branches of the arteries feeding the metastatic spinal tumor. Subjects will receive general anesthesia or conscious sedation. A catheter will be guided using X-ray from the femoral artery at the top of the leg to the arteries of the spine. A dye will be injected through the catheter to show the arteries in greater detail. The chemotherapy is then injected into the tumor. We will inject the maximum systemic dose adjusted to white blood count and platelet count. Subjects will undergo three cycles of chemotherapy three to six weeks apart.
62605056|NCT01670838||subarachnoid haemorrhage|nontraumatic subarachnoid haemorrhage
62605057|NCT06287775|EXPERIMENTAL|Phase I (iadademstat, atezolizumab, durvalumab)|Patients in Phase I receive iadademstat PO on days 1, 8, 15, and 22 or days 1 and 15 of each cycle. Patients also continue receiving their initial ICI treatment, either atezolizumab IV over 30-60 minutes on day 1 of each cycle or durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MUGA or ECHO, brain MRI or brain CT during screening, and CT scans and blood and urine sample collection throughout the trial. Patients may also undergo an optional tumor biopsy on study.
62605058|NCT06287775|ACTIVE_COMPARATOR|Phase II Arm II (atezolizumab, durvalumab)|Patients in Phase II Arm II continue receiving their initial ICI treatment, either atezolizumab IV over 30-60 minutes on day 1 of each cycle or durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MUGA or ECHO, brain MRI or brain CT during screening, and CT scans and blood and urine sample collection throughout the trial. Patients may also undergo an optional tumor biopsy on study.
62605059|NCT06287775|EXPERIMENTAL|Phase II, Arm I (iadademstat, atezolizumab, durvalumab)|Patients in Phase II Arm I receive iadademstat PO on days 1, 8, 15, and 22 or days 1 and 15 of each cycle. Patients also continue receiving their initial ICI treatment, either atezolizumab IV over 30-60 minutes on day 1 of each cycle or durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MUGA or ECHO, brain MRI or brain CT during screening, and CT scans and blood and urine sample collection throughout the trial. Patients may also undergo an optional tumor biopsy on study.
62605060|NCT04803591|EXPERIMENTAL|A: Tranexamic Acid group|Patients in the Tranexamic Acid (TXA) group (arm-A) will be administered with 2 doses of intravenous tranexamic acid (cumulative dose 10ml=1g) as follows: the first dose 10 minutes before the surgical incision (1 vial of 5 ml = 0,5g by slow intravenous injection(=1ml/minute)), and the second 3 hours after the start of surgery (1 vial of 5 ml = 0,5g, by slow intravenous injection).
62605061|NCT04803591|NO_INTERVENTION|B : No treatment group|In the control group, will not be administered TXA or any other drugs.
62605062|NCT01585324|EXPERIMENTAL|Single Arm|
62605063|NCT03652116|ACTIVE_COMPARATOR|Bupivacaine Group|Patients delivered by cesarean section followed by wound infiltration by bupivacaine.
62605064|NCT03652116|ACTIVE_COMPARATOR|Pethidine Group|Patients delivered by cesarean section followed by wound infiltration by pethidine.
62605065|NCT02877719||Children from low-income families|Children from low-income families were invited to fill in a set of questionnaires.
62605066|NCT02877719||Children from high income families|Children from high-income families were invited to fill in a set of questionnaires.
62605067|NCT03176667|EXPERIMENTAL|ESP for VATS|Erector Spinae plane (ESP) block
62605068|NCT03176667|ACTIVE_COMPARATOR|ICB for VATS|Intercostal block (ICB)
62605069|NCT02595281|EXPERIMENTAL|Study arm|
62605070|NCT02035774|ACTIVE_COMPARATOR|LSIB +SSNB|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml)
62605071|NCT02035774|PLACEBO_COMPARATOR|LSIB + placebo|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml) + SSNB (4 ml saline)
62605072|NCT04601103|EXPERIMENTAL|Comparator: No SLS Toothpaste|3M Oral Rinse in combination with no SLS toothpaste (A)
62605073|NCT04601103|EXPERIMENTAL|Comparator: Medium SLS Toothpaste|3M Oral Rinse in combination with medium SLS toothpaste (B)
62605074|NCT04601103|EXPERIMENTAL|Comparator: High SLS Toothpaste|3M Oral Rinse in combination with high SLS toothpaste (C)
62605075|NCT04550351|EXPERIMENTAL|Population I|Population I has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population I is intramuscular injection of deltoid muscle of upper arm with low dose of vaccine.
62605076|NCT04550351|EXPERIMENTAL|Population II|Population II has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population II is a high-dose vaccine intramuscular injection of deltoid muscle of the upper arm.
62605077|NCT04550351|PLACEBO_COMPARATOR|Population Ⅲ|Population Ⅲ has 10 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅲ is a placebo intramuscular injection of deltoid muscle of the upper arm.
62605078|NCT01130155||Mwanza Region|Households, and patients presenting at public health facilities in Mwanza Region
62605079|NCT01130155||Mbeya Region|Households, and patients presenting at public health facilities in Mbeya Region
62605080|NCT01130155||Mtwara Region|Households, and patients presenting at public health facilities in Mtwara Region
62605081|NCT01985139|EXPERIMENTAL|Obese patients|Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
62605082|NCT01985139|EXPERIMENTAL|Normal-weight healthy volunteers|Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
62605083|NCT03014713|ACTIVE_COMPARATOR|Control Group|Patients in this group receive intravenous Patient-Controlled Analgesia(PCA) pump after surgery.The intravenous PCA protocol is dezocine 0.01mg/kg/h,flubiprofen 0.05mg/kg/h.
62605084|NCT03014713|EXPERIMENTAL|Dexmedetomidine Group|Patients in this group receive intravenous Patient-Controlled Analgesia(PCA) pump after surgery.The intravenous PCA protocol is dezocine 0.01mg/kg/h,flubiprofen 0.05mg/kg/h,dexmedetomidine 0.1μg/kg/h.
62605085|NCT05276622||Subjects with newly diagnosed multiple myeloma|Forty subjects with newly diagnosed multiple myeloma.
62605086|NCT05276622||Care partners of the subjects with newly diagnosed multiple myeloma|Thirty care partners of the subjects with newly diagnosed multiple myeloma.
62605087|NCT06269016|EXPERIMENTAL|control group no intervention|no intervention for 3 months with assessment for maximum vaginal squeeze pre and post experiment using bio feedback device and urinary distress inventory UDI-6 short form.
62605088|NCT06269016|EXPERIMENTAL|study group hip muscles strengthening exercise.|hip muscles exercises (hip abductors, adductors and gluteus maximus) for 3 months with assessment for maximum vaginal squeeze pre and post experiment using bio feedback device and urinary distress inventory UDI-6 short form.
62605089|NCT06269016|EXPERIMENTAL|study group hip muscles strengthening exercise combined with pelvic floor muscles exercise.|hip muscles exercises (hip abductors, adductors and gluteus maximus) combined with pelvic floor muscles exercises for 3 months with assessment for maximum vaginal squeeze pre and post experiment using bio feedback device and urinary distress inventory UDI-6 short form.
62605090|NCT06269016|EXPERIMENTAL|study group pelvic floor muscles exercise.|pelvic floor muscles exercises for 3 months with assessment for maximum vaginal squeeze pre and post experiment using bio feedback device and urinary distress inventory UDI-6 short form.
62605091|NCT01289756|EXPERIMENTAL|CYP2D6 EM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
62605092|NCT01289756|EXPERIMENTAL|CYP2D6 IM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
62605093|NCT01289756|EXPERIMENTAL|CYP2D6 PM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
62605094|NCT01289756|EXPERIMENTAL|CYP2D6 UM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
62605095|NCT03269084||Children at HLA-conferred risk for T1D|
62605096|NCT04205149||Pre-ERAS implementation arm|
62605097|NCT04205149||Post-ERAS implementation arm|
62605098|NCT04005144|EXPERIMENTAL|Treatment (brigatinib, binimetinib)|Patients receive brigatinib PO QD and binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62605099|NCT01757730||Altered Stiffness|Tissue stiffness will be evaluated in subjects those with disease conditions where stiffness changes from normal. These studies will be repeated for reproducibility.
62605100|NCT01757730||Healthy Volunteers|Tissue stiffness will be evaluated in normal subjects to determine the normal values. These studies will be repeated for reproducibility.
62605101|NCT02160847|EXPERIMENTAL|DRIVE program|Participants in the experimental group will receive the DRIVE curriculum (15 sessions) via weekly sessions conducted in their home by a DRIVE provider.
62605102|NCT02160847|NO_INTERVENTION|Control Group|"The parents in the control group will be mailed information on nutrition, physical activity, and parent-child interactions. Information on nutrition will include guidelines provided by the MyPlate website (http://www.choosemyplate.gov/preschoolers.html) in addition to information on proper nutrition and suggest levels of physical activity for preschoolers. Lastly, parents will be provided with the free publication, Adventures in Parenting: How responding, Preventing, Monitoring, Mentoring, and Modeling Can Help You Be A Successful Parent, authored by National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development. Information covered in this document includes effective parenting strategies for children at specific ages."
62605103|NCT02106663|ACTIVE_COMPARATOR|Circumferential Pulmonary Vein Ablation|Contiguous ablation lesions will be performed to encircle the two left and right pulmonary veins (PVs), guided by 3D electroanatomic mapping (Carto, Biosense Webster, Inc. or ESI NavX, St. Jude, Inc.) with a 3D LA geometry created either by using the roving mapping catheter or by importing a pre-recorded 3D CT image of the left atrium. After completion of the circumferential ablation, PV isolation will be confirmed by the mapping catheter, and further focal ablation performed as required until electrical PV isolation is confirmed (entrance block at a minimum).
62605104|NCT02106663|ACTIVE_COMPARATOR|Segmental Pulmonary Vein Isolation|Electrical potentials recorded in the pulmonary vein (PV) ostium using a circular mapping catheter, representing myocardial connections between the left atrium and PVs will be ablated at or just proximal to the PV ostium in the PV antrum. Ablation will be performed segmentally at multiple sites guided by the mapping catheter around the PV ostium or antrum, until mapping demonstrates elimination of all PV potentials (entrance block at a minimum).
62605105|NCT01593280|ACTIVE_COMPARATOR|TAP catheter|Indwelling TAP catheter placed at the end of c-section. It will be dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen OnQ C-block pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The catheters will run at 7cc/hr/side for 50 hrs.
62605106|NCT01593280|ACTIVE_COMPARATOR|intrathecal morphine|0.3 mg of intrathecal morphine
62248025|NCT02607553|EXPERIMENTAL|Experimental: G-202|G-202 administered by intravenous infusion on 3 consecutive days of a 28-day cycle
62248026|NCT05838404|EXPERIMENTAL|MOMS on the Bayou Intervention Group|Participants complete intervention protocol.
62248027|NCT03978221|EXPERIMENTAL|diaphragmatic tissue doppler evaluation|A tissue Doppler evaluation, using a sectorial probe, will be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration randomly assessed in spontaneous breathing with Venturi Mask and in Non-invasive ventilation with a helmet or facial mask
62248028|NCT02525393|EXPERIMENTAL|tDCS+rTMS|Stroke patients were treated with an initial two weeks of transcranial direct current stimulation and after six months with two weeks of repetitive transcranial magnetic stimulation.
62605107|NCT01013623|ACTIVE_COMPARATOR|Best Medical Therapy|The best medical therapy group will not initially undergo surgery, but will be treated with the therapy that medical oncologists or surgeons feel is best for the patient. This treatment may include standard or experimental therapies.
62827752|NCT06588244||INOCA|Patients presenting with symptoms or signs of myocardial ischemia with non-obstructing coronary artery disease
62605108|NCT01013623|ACTIVE_COMPARATOR|Surgery Alone|The surgery alone group will undergo complete resection (surgical removal) of all known disease, if possible. After surgery, patients will be followed regularly and monitored for disease recurrence.
62827753|NCT02404935|EXPERIMENTAL|Arm A cetuximab|cetuximab 500 mg/m2 (every 2 weeks) until progression
62827754|NCT02404935|OTHER|Arm B observation|observation until progression
62827755|NCT00460161|ACTIVE_COMPARATOR|1|true acupuncture
62438107|NCT00756132||A1-Cog|Women newly diagnosed locally advanced or high risk breast cancer that qualify for cognitive testing but have a condition related to elevated serum levels of cytokines or other inflammatory markers.
62438108|NCT05080777|EXPERIMENTAL|Tele-Savvy Group|The participants will be enrolled into the Tele-Savvy group. Software analytics monitor caregivers' use of asynchronous material each week.
62827756|NCT00460161|PLACEBO_COMPARATOR|2|placebo/sham acupuncture
62827757|NCT01135173|ACTIVE_COMPARATOR|Arm A|Motivational and educational intervention, delivered by a trained physician from the SCTS plus written self-help materials.
62827758|NCT01135173|EXPERIMENTAL|Arm B|"Behavioral counseling intervention conducted by a trained physician at the SCTS cessation clinic. Subjects complete homework before the session to facilitate this process. Subjects are asked to identify high-risk situations and difficulties in previous cessation attempts and are walked through a series of suggestions in the event of a slip. Three brief (approximately 10 minute) phone calls are provided to subjects during the 90 day follow-up period. These calls are used to identify early relapse, encourage participants, and provide support. In addition, they are used to review materials and information provided during the sessions."
62438109|NCT05080777|ACTIVE_COMPARATOR|Attention Control Group|The participants will be enrolled in the Caregiving During Crisis program. Software analytics monitor caregivers' use of asynchronous material each week.
62438110|NCT04382456|EXPERIMENTAL|acacia gum|
62605109|NCT01013623|ACTIVE_COMPARATOR|Surgery + BCG|The Surgery + BCG group will first have a complete resection (surgical removal) of all known disease, if possible. After recovery from surgery, two doses of BCG will be given two weeks apart. Each dose is given as 8 separate injections into the skin (called intradermal injections).
62827759|NCT06079112|EXPERIMENTAL|9MW2821+Toripalimab|
62827760|NCT06590168|EXPERIMENTAL|intervention Vestibular Socket Preservation for socket preservation|
62827761|NCT06590168|ACTIVE_COMPARATOR|ice cream cone technique for socket preservation|
62827762|NCT04100083|ACTIVE_COMPARATOR|Group 1|Patients taking 50mg Spironolactone
62248029|NCT02525393|EXPERIMENTAL|rTMS+tDCS|Stroke patients were treated with an initial two weeks of repetitive transcranial magnetic stimulation and after six months with two weeks of transcranial direct current stimulation.
62827763|NCT04100083|ACTIVE_COMPARATOR|Group 2|Patients taking 100mg Spironolactone
62248030|NCT02525393|SHAM_COMPARATOR|Sham stimulation|Stroke patients were treated with two weeks of sham transcranial direct current stimulation.
62248031|NCT02973087|EXPERIMENTAL|All Study Participants|Participants will receive prophylaxis with rVWF in two cohorts: on-demand (OD) cohort (previously treated with OD) and pdVWF switch cohort (participants switching from prophylactic treatment with pdVWF).
62438111|NCT03110952|EXPERIMENTAL|TDENV-PIV x2|2 doses of TDENV-PIV on Day 0 and Day 28
62438112|NCT03110952|EXPERIMENTAL|TDENV-F17/TDENV-PIV|1 dose TDENV-F17 on Day 0 and 1 dose TDENV-PIV on Day 28
62438113|NCT03110952|EXPERIMENTAL|TDENV-PIV/TDENV-F17|1 dose TDENV-PIV on Day 0 and 1 dose TDENV-F17 on Day 28
62438114|NCT03110952|PLACEBO_COMPARATOR|Placebo|2 doses placebo (phosphate buffered saline) Day 0 and Day 28
62438115|NCT01877759|OTHER|Mesenchymal stem cell|hUMAN MESENCHYMAL STEM CELLS
62438116|NCT04121000|EXPERIMENTAL|Erector Spinae Block for VATS Group|40 patients who had VATS will receive erector spinae block for postoperative pain management. All patients will receive IV Midazolam (0.05mg/kg) premediacation. Standard monitorization of EKG, non- invasive blood pressure and pulsoximeter will be done and recorded in every 5 minutes. After sedation and standard monitorization, 20 minutes before the induction and in the prone positon the ESB procedure will be done. 10 % povidon- iodin will be used for sterilization and the USG probe will be covered with sterile sheath. The block will be done at the 8th thoracic vertebra line. The USG probe will be replaced 2-3 cm lateral to the spinous process in sagittal plane. When the erector spinae muscle is identified in the USG the needle will be guided caudally.0.5-1 ml local anesthetics will be given in order to confirm the needle is in the right place. After confirmation with 20 mL %0.25 bupivacaine the procedure will be performed.
62438117|NCT04121000|EXPERIMENTAL|Patient - Controlled Analgesia for VATS Group|40 patients who had VATS will receive IV PCA for postoperative analgesia managemnet.
62827764|NCT04100083|ACTIVE_COMPARATOR|Group 3|Patients taking 200mg Spironolactone
62248032|NCT03371758|EXPERIMENTAL|vitiligo patients|
62605110|NCT05697250|EXPERIMENTAL|Group 1 - low power laser settings|4-6 Watts, short pulse mode. 0.4 - 0.6 J at 10 Hz.
62605111|NCT05697250|EXPERIMENTAL|Group 2 - high power laser settings|16-18 Watts, short pulse mode. 0.4 J / 40 Hz, 0.6 J / 30 Hz or 0.8 J / 20 Hz.
62605112|NCT05285722|OTHER|dental anxiety group|"Children,~* Aged 5-15 years~* Having dental anxiety but not having negative experiences during dental treatment in childhood or adolescence~* Without any systemical and mental diasabilities~* Who volunteered to participate in the study and whose parental consent was obtained."
62605113|NCT04747873|EXPERIMENTAL|e-CBT|12 weekly sessions with approximately 30 slides and interactive content, delivered through OPTT designed to mirror in-person standard CBT. Participants go through the content and complete homework at the end of the session. Homework is submitted through OPTT and reviewed by the therapist assigned to the participant, who will provide personalized feedback within three days of submission. Therapists have access to pre-designed session-specific feedback templates to use as a basic structure to write their feedback. By doing so, the time needed to respond to each patient is reduced and therefore the number of patients each therapist can handle increases. On average, developing this feedback takes a therapist 15-20 minutes per patient. In addition to the weekly feedback, participants have the option to message their therapist through the platform throughout the week regarding any questions or concerns they may have.
62605114|NCT04747873|EXPERIMENTAL|e-CBT + Stepped Care|"1 - Participant will receive message from assigned care provider on OPTT who check-in with them about strategies and techniques they have discussed and remind them of weekly homework due date.~2.- Participant will receive phone call from therapist who will check-in on them, remind them of therapy strategies, and verbally remind them of weekly homework due date.~3 - Participant will receive phone call from assigned care provider who will check-in on them, remind them of some therapy strategies and techniques and weekly session due date, and provide CBT summary of previously reviewed CBT concepts.~4 - articipant will receive video call (Microsoft Teams) from their therapist who will check-in on them, remind them of weekly session due date, and provide CBT content support to participant.~5 - Participant will receive CBT sessions in live video call (Microsoft Teams) with research psychiatrist involved in care."
62827765|NCT03736590|EXPERIMENTAL|Intervention - Financial Coaching Plus Social Needs Screening|Families in this intervention arm will receive financial coaching at each well child visit, in addition to clinic-based social needs screening and referral.
62248033|NCT03371758|EXPERIMENTAL|healthy controls|
62248034|NCT00904293|EXPERIMENTAL|Genotype-guided warfarin dosing|A dosing algorithm including clinical factors and genotype information (VKORC1 and CYP2C9) will be used to determine initial warfarin doses.
62248035|NCT00904293|ACTIVE_COMPARATOR|Non-genotype guided warfarin dosing|Initial warfarin dosing will be determined using the same algorithm as in the experimental group, but only including the clinical factors and not including the genotype information
62248036|NCT01910051||Generally healthy|Generally healthy
62438118|NCT00411697|EXPERIMENTAL|Group A|
62605115|NCT01701297|ACTIVE_COMPARATOR|Co-trimoxazole|Co-trimoxazole 960mg daily po
62248037|NCT01910051||Type 2 diabetes mellitus|Type 2 diabetes mellitus
62248038|NCT01785667||Young Danish adults with type 1 diabetes|This is an observational study with no interventions.
62248039|NCT00789867|EXPERIMENTAL|20ml pGM169/GL67A|Received a nebulized dose 20ml via an breath-actuated nebulizer
62248040|NCT00789867|EXPERIMENTAL|10ml pGM169/GL67A|Received a nebulized dose 10ml via an breath-actuated nebulizer
62248041|NCT00789867|EXPERIMENTAL|5ml pGM169/GL67A|Received a nebulized dose 5ml via an breath-actuated nebulizer
62248042|NCT04787094|EXPERIMENTAL|Yoga Group|The sessions will begin with breathing exercises in standing, sitting, supine and prone positions, and these exercises will be applied for about 10 minutes. After the breathing exercises, the sudden relaxation technique, which will take 2-3 minutes, firstly contracting the whole body from the feet to the head and then completely relaxing it.
62248043|NCT04787094|EXPERIMENTAL|Spinal Stabilization Exercise Group|"Spinal stabilization exercises will be applied to the individuals in this group for 8 weeks / 2 days a week, approximately 50-60 minutes a day under the supervision of a physiotherapist.~Spinal stabilization exercises will be progressed in 3 phases by gradually increasing the difficulty."
62248044|NCT04029116|EXPERIMENTAL|Ibrexafungerp|Oral Fluconazole 150 mg every 72 hours for 3 doses followed by Oral Ibrexafungerp 300 mg BID (one day) every 4 weeks for a total of 6 dosing days
62605116|NCT01701297|EXPERIMENTAL|VSL#3 active|VSL#3 active 2 sachets/daily
62827766|NCT03736590|ACTIVE_COMPARATOR|Control - Social Needs Screening and Referral|Families in this active control arm will receive social needs screening and referral to community resources to address identified social needs.
62248045|NCT04029116|PLACEBO_COMPARATOR|Placebo|Oral Fluconazole 150 mg every 72 hours for 3 doses followed by Oral Placebo BID (one day) every 4 weeks for a total of 6 dosing days
62248046|NCT06394596||Kidney transplant patients|Patients who underwent kidney transplantation at a single center
62248047|NCT00724919||1|
62248048|NCT01099163|EXPERIMENTAL|3g CLA|3 g CLA (50:50%) AND other diabetes medication currently prescribed to participant, 100 IU vitamin E
62248049|NCT01099163|ACTIVE_COMPARATOR|3 g CLA|3 g CLA (50:50%) AND other diabetes medication currently prescribed to participant, vitamin E placebo
62248050|NCT01099163|NO_INTERVENTION|3 g MCT + vit E placebo|3 g MCT AND other diabetes medication currently prescribed to participant, 100 IU vitamin E placebo
62248051|NCT00357214|ACTIVE_COMPARATOR|potassium bicarbonate|Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
62248052|NCT00357214|ACTIVE_COMPARATOR|Sodium bicarbonate|Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
62248053|NCT00357214|ACTIVE_COMPARATOR|Potassium chloride|Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.
62248054|NCT00357214|PLACEBO_COMPARATOR|microcrystalline cellulose|Participants will receive placebo is microcrystalline cellulose. This compound has no other name.
62438119|NCT03307512|EXPERIMENTAL|Dance 501|Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
62438120|NCT03307512|ACTIVE_COMPARATOR|Insulin Lispro|Insulin Lispro (Humalog®) will be administered by subcutaneous injection
62045746|NCT05902832|NO_INTERVENTION|Control group-Neurotypical|30 6-10-years-old children, from regular education match in cognitive and linguistic abilities.
62045747|NCT00310219|EXPERIMENTAL|Arm 1|Two radiation oncologists are randomly assigned to develop either a 3DCRT plan using CT only, or a 3DCRT plan using fused PET/CT
62045748|NCT04584164|NO_INTERVENTION|Control arm|This arm involves patients applying the basic hygiene rules (with mouthwashes) without the sialendoscopy method.
62045749|NCT04584164|EXPERIMENTAL|Sialendoscopy arm|This arm involves patients applying the hygiene rule and benifiting in addition a sialendoscopy treatment with a local injection of corticostéroïdes (at the end of the procedure) in the treatment for Xerostomia.
62045750|NCT04595448||Patients|Patients suffering from moderate tricuspid valve regurgitation
62045751|NCT04595448||Controls|Cardiovascular healthy, age, gender and weight matched controls.
62045752|NCT01422408|EXPERIMENTAL|Supportive care (fluocinonide cream)|Patients apply topical fluocinonide cream BID in weeks 1-2 and QD in weeks 3-4.
62438121|NCT03504332|EXPERIMENTAL|Calcium Hydroxide in revascularization|Revascularization of necrotic anterior teeth: canals disinfection step. Pure Calcium Hydroxide powder mixed with saline will be placed as intra-canal medication in the 1st visit of dental pulp revascularization.
62827767|NCT02072668|OTHER|Rivaroxaban for 4 wks, Placebo for 4 wks|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
62827768|NCT02072668|OTHER|Placebo for 4 wks, rivaroxaban for 4 wks|Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
62827769|NCT03027609|EXPERIMENTAL|AR-105|One intravenous infusion of AR-105 20mg/'kg
62827770|NCT03027609|PLACEBO_COMPARATOR|Control|Matching placebo
62827771|NCT03692598|EXPERIMENTAL|MIA Surgical|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Surgical from an open surgical approach
62045753|NCT06280703|EXPERIMENTAL|Part A: LY3938577|Single dose of LY3938577 administered intravenously (IV) in healthy participants.
62045754|NCT06280703|PLACEBO_COMPARATOR|Part A: Placebo|Single dose of Placebo administered intravenously (IV) in healthy participants.
62045755|NCT06280703|EXPERIMENTAL|Part B: LY3938577|For each euglycemic and hyperglycemic clamps participants with T1DM will receive single doses of LY3938577 administered intravenously (IV) with Insulin Lispro administered at a constant low rate to cover individual participant's basal (fasting) insulin demand to maintain a stable glucose level.
62045756|NCT06280703|ACTIVE_COMPARATOR|Part B : Insulin Degludec|For each euglycemic and hyperglycemic clamps participants with T1DM will receive single doses of Insulin Degludec administered intravenously (IV) with Insulin Lispro administered at a constant low rate to cover individual participant's basal (fasting) insulin demand to maintain a stable glucose level.
62045757|NCT06280703|EXPERIMENTAL|Part C: LY3938577|During 3-step clamp and a hyperglycemic clamp with hypoglycemia provocation participants with T1DM will receive LY3938577 by continuous infusion. Insulin Lispro will be administered intravenously to maintain a stable glucose level before administration of LY3938577.
62045758|NCT06280703|ACTIVE_COMPARATOR|Part C: Insulin Degludec|During 3-step clamp and a hyperglycemic clamp with hypoglycemia provocation participants with T1DM will receive Insulin Degludec by continuous infusion. Insulin Lispro will be administered intravenously to maintain a stable glucose level before administration of Insulin Degludec.
62438122|NCT03504332|ACTIVE_COMPARATOR|Di-antibiotic paste in revascularization|Revascularization of necrotic anterior teeth: canals disinfection step. Mix 1:1 ciprofloxacin: metronidazole to a final concentration of 0.1 mg/ml, placed as intra-canal medication in the 1st visit of dental pulp revascularization.
62045759|NCT05017922|EXPERIMENTAL|combined group|unresectable hepatocellular carcinoma patients who received TACE plus endoscopic therapy
62045760|NCT05017922|OTHER|control group|unresectable hepatocellular carcinoma patients who only received TACE
62045761|NCT06185257||Patient with chronic kidney disease under dialysis|
62045762|NCT06185257||Patients with nephrotic syndrome|
62045763|NCT06185257||C. Normal control group|
62827772|NCT03692598|EXPERIMENTAL|MIA Percutaneous|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Percutaneous from a transcatheter approach
62827773|NCT05356377||PKU Palynziq Group|Individuals with PKU who have previously completed baseline (pre-Palnyziq) neurocognitive and neuroimaging evaluations and have since demonstrated a significant and prolonged Phe response to Palynziq (as reflected by at least 3 consecutive months of Phe levels below 360 μmol/L).
62827774|NCT06434519|EXPERIMENTAL|Metronidazole cream + Cetaphil moisturizer|Apply Cetaphil (glycerin (humectant) and petrolatum (occlusive)) moisturizer followed by metronidazole cream. Tape striping will occur at 1 hours and 4 hours post metronidazole application.
62827775|NCT06434519|EXPERIMENTAL|Metronidzole cream + CeraVe moisturizer|Apply CeraVe (glycerin/hyaluronic acid (humectant), ceramides (intercellular lipid component), and dimethicone/petrolatum (occlusive)) moisturizer followed by metronidazole cream. Tape striping will occur at 1 hours and 4 hours post metronidazole application.
62827776|NCT06434519|EXPERIMENTAL|Metronidzole cream + Eucerin Healing Lotion moisturizer|Apply Eucerin Healing Lotion (mineral oil (occlusive) and sorbitol/propylene glycol (humecants)) followed by metronidazole cream. Tape striping will occur at 1 hours and 4 hours post metronidazole application.
62605117|NCT01701297|PLACEBO_COMPARATOR|VSL#3 placebo|VSL#3 placebo 2 sachets/daily
62605118|NCT03041103|EXPERIMENTAL|Adult|Food Product 1:50 grams of fortified nutritious product from legumes administered to adults, for 2 weeks
62605119|NCT03041103|EXPERIMENTAL|Children|Food Product 1: 50 grams of fortified nutritious product from legumes administered to children 9-13 years of age, for 1 weeks
62605120|NCT06245967|EXPERIMENTAL|Experimental|True FSM (Concussion protocol) with symptom management medication
62605121|NCT06245967|SHAM_COMPARATOR|Sham-control|Sham FSM (no protocol) with symptom management medication
62827777|NCT06434519|EXPERIMENTAL|Metronidazole cream + Aveeno Calm and Restore Oat Gel moisturizer|Apply Aveeno Calm and Restore Oat Gel (glycerin (humectant) and dimethicone (occlusive) and oat kernel flour based gel moisturizer) moisturizer followed by metronidazole cream. Tape striping will occur at 1 hours and 4 hours post metronidazole application.
62827778|NCT01283139|EXPERIMENTAL|Sifalimumab 200 milligram (mg)|Sifalimumab 200 milligram (mg) will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
62827779|NCT01283139|EXPERIMENTAL|Sifalimumab 600 mg|Sifalimumab 600 mg will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
62827780|NCT01283139|EXPERIMENTAL|Sifalimumab 1,200 mg|Sifalimumab 1,200 mg will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
62827781|NCT01283139|PLACEBO_COMPARATOR|Placebo|Placebo matching to sifalimumab will be administered intravenously at a fixed dose every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
62827782|NCT00628420|OTHER|1|Patients recieved single low dose of ACP-104
62827783|NCT00628420|OTHER|2|Patients recieved a high dose of ACP-104
62827784|NCT00628420|OTHER|3|Patients recieved a placebo
62827785|NCT06599385|ACTIVE_COMPARATOR|Low-threshold|
62827786|NCT06599385|EXPERIMENTAL|High threshold|
62827787|NCT01484587|EXPERIMENTAL|001|
62827788|NCT01484587|PLACEBO_COMPARATOR|002|
62438123|NCT03495193|ACTIVE_COMPARATOR|Exercise Group|Subjects randomized to the exercise training group will complete 16 weeks of exercise training. Exercise training will be performed 3x/week.
62827789|NCT01416220|EXPERIMENTAL|Lithium|Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l).
62827790|NCT01416220|ACTIVE_COMPARATOR|Paroxetine|Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or Paroxetine.Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7.At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines.
62827791|NCT04796155||labour arrest|Pregnant women whose labour progress is delayed and suspected or diagnosed as labour arrest according to the NICE guidelines. Intrapartum ultrasound will be performed at the suspicion of labour arrest in the active phase of the first and second stage of labour. Amniotomy will be performed as routine obstetric care according to the local clinical protocols in accordance with the NICE guideline. Later, diagnosis of labour arrest will be made in slow progress following amniotomy (\<1cm cervical dilatation in 2 hours) where a sonographic examination will be repeated.
62827792|NCT03666754|ACTIVE_COMPARATOR|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with the deferred treatment of superficial reflux (usually once the ulcer has healed)
62827793|NCT03666754|EXPERIMENTAL|Early endovenous glue embolization arm|Early endovenous glue embolization of superficial venous reflux within 2 weeks in addition to standard compression therapy
62827794|NCT00307801|EXPERIMENTAL|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|A blister consists of 28 tablets taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo.
62827795|NCT00307801|PLACEBO_COMPARATOR|Placebo|Matching placebo to be taken orally daily.
62827796|NCT01457508|EXPERIMENTAL|Group A|Subjects will receive one single injection of DTPa-HBV-IPV vaccine mixed with Hib vaccine.
62605122|NCT03141983|ACTIVE_COMPARATOR|Anakinra|"Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1 alpha and IL-1 beta by competitively binding to the interleukin-1 type I receptor (IL-1RI). Anakinra is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra).~Anakinra will be supplied in pre-filled syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe will contain 100 mg in 0.67 ml solution (pH 6.5) containing disodium EDTA (0.12 mg), sodium chloride (5.48 mg), sodium citrate (1.29 mg), and polysorbate 80 (0.70 mg) in Water for Injection, USP."
62605123|NCT03141983|PLACEBO_COMPARATOR|Placebo|Saline (0.9%) will be used as the placebo, supplied in pre-filled syringes as a sterile, clear, colorless-to-white, preservative free solution.
62605124|NCT05311566|EXPERIMENTAL|Patients with primary IB2-IIIB cervical cancer|Patients with primary IB2-IIIB cervical cancer, including squamous carcinoma, adenocarcinoma, and adenosquamous carcinoma.
62605125|NCT01211483|EXPERIMENTAL|Part A: U3-1287 (high dose) + Erlotinib|U3-1287 (high dose) intravenously (IV) every three weeks (Q3W) + Erlotinib 150 mg/day orally (PO) until cancer gets worse, side effects become unacceptable or participant withdraws consent
62605126|NCT01211483|EXPERIMENTAL|Part B: U3-1287 (low dose) + Erlotinib|U3-1287 (low dose) IV Q3W + Erlotinib 150 mg/day PO until cancer gets worse, side effects become unacceptable or participant withdraws consent
62827797|NCT01457508|ACTIVE_COMPARATOR|Group B|Subjects will receive two separate injections of DTPa-HBV-IPV and Hib vaccine.
62827798|NCT04382950|EXPERIMENTAL|Experimental: rbACE2 group plus Aerosolized Isotretinoin|rbACE2 0.4 mg/kg IV BID for 7 days (unblinded) plus Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
62827799|NCT04382950|NO_INTERVENTION|No Intervention: Control group|Standard of care; no placebo
62045764|NCT04341506||Participant ECG|The study has one arm, I.e., we will collect daily ECGs in 100 participants and track their ECG over three months. We will then compare ECGs pre and post COVID-19 diagnosis in any participant diagnosed with COVID-19 to assess for any early ECG changes that may aid with diagnosing.
62045765|NCT01812655|EXPERIMENTAL|Virtual Reality|Virtual reality using a software program designed for burn patients during burn wound care
62605127|NCT01211483|PLACEBO_COMPARATOR|Part B: Placebo + Erlotinib|Placebo matching U3-1287 IV Q3W + Erlotinib150 mg/day PO until cancer gets worse, side effects become unacceptable or participant withdraws consent
62438124|NCT03495193|ACTIVE_COMPARATOR|No Exercise Group|Subjects randomized to the no-Ex group will receive a handout with tips for improving sleep hygiene. Additionally, study staff will provide the title page for a book on sleep relaxation techniques that is recommended for persons with sleeping difficulty.
62827800|NCT06598657|ACTIVE_COMPARATOR|Mobilization with Movement MWM of Talocrural joint + Conventional PT|
62827801|NCT06598657|OTHER|Conventional PT|
62827802|NCT04591483||Affected|Patients with Stargardt-like macular dystrophy 3 who are \>= 10 years of age.
62827803|NCT00821548|EXPERIMENTAL|1|Electrostimulation of the muscles of the scapular belt and the femoris quadristocks
62827804|NCT05628064|EXPERIMENTAL|1C70 to Pro-Flex XC|Transtibial amputees randomized to start with 1C70 and cross over to Pro-Flex XC
62827805|NCT05628064|EXPERIMENTAL|Pro-Flex XC to 1C70|Transtibial amputees randomized to start with Pro-Flex XC and cross over to 1C70
62827806|NCT06654063|ACTIVE_COMPARATOR|non-surgical periodontal therapy (SRP)|"* The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA) where, conventional scaling and root planning (SRP) to the bottom of the pocket of 4 mm or more~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage."
62827807|NCT06654063|EXPERIMENTAL|non-surgical periodontal therapy (SRP)+ Omega-3|"* The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA)~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.~* Patients will start taking Omega-3 supplements on the day of SRP procedure."
62827808|NCT06654063|EXPERIMENTAL|non-surgical periodontal therapy (SRP)+ Vitamin D|"* Patients will start taking Omega-3 supplements on the day of SRP procedure.~* Serum vitamin D levels will be assessed at baseline and 6 weeks after intervention in all groups."
62827809|NCT03278249|EXPERIMENTAL|Modified Atkins Ketogenic Diet|Modified Atkins Ketogenic Diet in combination with Temodar and Radiation
62827810|NCT00888173|EXPERIMENTAL|Treatment (brivanib alaninate)|Patients receive brivanib alaninate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62827811|NCT02546518|EXPERIMENTAL|Moniri Otovent|A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to ambu bag balloon. A safety valve is used to prevent too high air pressure. The ambu bag balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. During the first week day, a low pressure balloon is used, then it is changed with a higher pressure balloon. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one month.
62827812|NCT02546518|ACTIVE_COMPARATOR|Tympanostomy tube in the ear drum|Operation for insertion of tympanostomy tube under general anesthesia.
62438125|NCT01004120|PLACEBO_COMPARATOR|MDn|
62438126|NCT01004120|ACTIVE_COMPARATOR|B-GOS|
62605128|NCT03713840|EXPERIMENTAL|Healthy Beverages in Child Care|Child care centers in the experimental arm received 12-week intervention that promoted consumption of healthy beverages (water, unsweetened low-fat milk) and discouraged consumption of unhealthy beverages (juice, sugar-sweetened beverages, high-fat or sweetened milk). The multi-pronged intervention was delivered via child care centers, targeted children, parents, and child care staff, and included education, environmental changes, and policies.
62827813|NCT03484754|EXPERIMENTAL|corrugator|single injection of 10 Units of botulinum toxina in the corrugator and procerus
62827814|NCT03484754|ACTIVE_COMPARATOR|orbicularis oculi|single injection of 10 Units of botulinum toxina in the lateral muscle orbicularis oculi (involved in crow's feet wrinkles)
62045766|NCT01812655|ACTIVE_COMPARATOR|Passive distraction|watching a movie
62045767|NCT01812655|NO_INTERVENTION|UC provided by the nurses|
62045768|NCT06490250|EXPERIMENTAL|Inspiratory Muscle Training (IMT) Group|The inspiratory muscle training group will participate in the respiratory exercise program with the IMT device.
62045769|NCT06490250|EXPERIMENTAL|Baduanjin Exercise Group|The Baduanjin group will participate in the Baduanjin exercise program, which includes 8 movements.
62045770|NCT06490250|NO_INTERVENTION|Control Group|The control group will not receive any intervention.
62045771|NCT00303862|EXPERIMENTAL|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 4 weeks. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
62045772|NCT04565171|EXPERIMENTAL|Participants with renal impairment|Participants with End-stage renal disease will receive a single dose of Yimitasvir Phosphate Capsule.
62438127|NCT00593333|ACTIVE_COMPARATOR|1, A|Standard femoral intramedullary nail that utilizes a piriformis fossa portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur.
62438128|NCT00593333|EXPERIMENTAL|2, B|Trigen Trochanteric Femoral Nail (Smith \& Nephew, Memphis)using a trochanteric insertion portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur
62045773|NCT04565171|EXPERIMENTAL|Participants with normal renal function|Participants with normal renal function will receive a single dose of Yimitasvir Phosphate Capsule.
62605129|NCT03713840|NO_INTERVENTION|Control|Child care centers in the control arm received access to intervention materials at a later date.
62605130|NCT05220345|OTHER|colonoscopy with a combined BFT and CADe assisted approach|This multicenter single-arm colonoscopy trial will compare colonoscopy assisted by both balloon-BFT visualizing and CADe to CADe-only assisted colonoscopy in diagnostic, screening (non-iFOBT based)), or surveillance colonoscopy. The latter group will be selected from the interventional arm from the Discovery II trial, using corresponding participating centers. All subjects in this trial will undergo the same treatment, i.e., combined balloon and CADe-assisted colonoscopy.
62605131|NCT05432050||Remimazolam anesthesia|General anesthesia will be induced and maintained by remimazolam and the depth of anesthesia will be monitored with both the bispectral index and patient state index at the same time.
62605132|NCT03635385|ACTIVE_COMPARATOR|Plasma exchange (PE) technic patient group|
62045774|NCT02935491||Transcatheter Aortic Valve Implantation|Lyon and Paris cohorts : 900 patients will be used to test the prognostic value of aortic calcifications and to propose a risk score Clermont and Rouen cohorts (700 patients) will be used to test in an independent group, the predictive value of the risk score
62248055|NCT05547282|OTHER|Low-dose radiotherapy combined with conventional radiotherapy after immunotherapy failure|"The chest, abdomen and pelvis were located by enhanced CT, and the target area was delineated. The lesions were visible lymph nodes with short diameter ≥1cm, and there were metastases confirmed by two associate chief physicians by enhanced MR and PET/CT examination results.~The primary lesion, the largest metastatic lesion or the lesion causing symptoms were selected and divided into 1.8-2Gy/F,40Gy-60Gy. For the remaining lesions, at least one easily evaluated and measurable lesion was selected as the observation lesion, and the unselected lesions (≤10 lesions) were given 1.6Gy/f, 1f/w, 4-6 times.~Immunotherapy regimens are administered according to the specific dose and interval of the original immunization regimen, such as concurrent chemotherapy or antiangiogenic drug therapy regimens. He used Nivolumab, Pembrolizumab, Troripalimab and Camrelizumanb.~Immunotherapy was performed at a frequency of 3 weeks in combination with radiotherapy until progression."
62605133|NCT03635385|ACTIVE_COMPARATOR|Immunoadsorption technic patient group|
62605134|NCT05615610|EXPERIMENTAL|spine TENS|The participants will be received eighteen 45-minute sessions of intervention, 3 sessions per week for 6 weeks.
62605135|NCT05615610|EXPERIMENTAL|tVNS|The participants will be received eighteen 45-minute sessions of intervention, 3 sessions per week for 6 weeks.
62605136|NCT05615610|PLACEBO_COMPARATOR|Control|The participants will be received eighteen 45-minute sessions of intervention, 3 sessions per week for 6 weeks.
62605137|NCT01113138|NO_INTERVENTION|Baseline|
62045775|NCT01382628||Preulcerative plantar foot lesion|An area on the plantar foot, usually at the location of a bony prominence, that presents with erythema, significant hyperkeratosis, or thin, shiny skin.
62045776|NCT01382628||Plantar ulcer no history of amputation|Plantar ulceration without a history of amputation or require an amputation.
62045777|NCT01382628||Plantar ulcer and digital amputation|Plantar ulceration who will be undergoing a digital amputation.
62045778|NCT01382628||Plantar ulcer and transmet amputation|Plantar ulceration who will be undergoing a transmetatarsal amputation.
62248056|NCT00862303|PLACEBO_COMPARATOR|IL-2/IFN-α|
62248057|NCT00862303|EXPERIMENTAL|DC-CIK|
62248058|NCT06154551||Group A|fifteen patients with OPMLs (lichen planus, leukoplakia)
62248059|NCT06154551||Group B|fifteen patients with OSCC
62605138|NCT01113138|ACTIVE_COMPARATOR|Mablet|
62045779|NCT01382628||Plantar ulceration and choparts|Plantar ulceration who will be undergoing Chopart's or more proximal amputation.
62045780|NCT00175825|PLACEBO_COMPARATOR|Placebo|Matching Placebo tablets administered twice a day
62827815|NCT05323812|EXPERIMENTAL|TW001|
62827816|NCT05323812|PLACEBO_COMPARATOR|Placebo|
62827817|NCT06588543||Intracranial aneurysms|Patients with at least one intracranial aneurysm that has been coiled
62827818|NCT06588543||Arteriovenous malformations|Patients with a cerebral arteriovenous malformation that has been treated by endovascular embolisation
62827819|NCT05936580|EXPERIMENTAL|Nuwiq|All patients receiving Nuwiq (recombinant FVIII). Nuwiq will be administered intravenously in accordance with the relevant prescribing information. Treatment will be repeated as necessary every 8-24 hours until adequate wound healing, then - if required - for at least another 7 days to maintain FVIII plasma levels of 30-60 IU/dL.
62045781|NCT00175825|EXPERIMENTAL|Brivaracetam 5 mg/day|Brivaracetam 5 mg/day, 2.5 mg administered twice a day
62045782|NCT00175825|EXPERIMENTAL|Brivaracetam 20 mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day
62045783|NCT00175825|EXPERIMENTAL|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
62045784|NCT00550914||Control arm|The conventional therapy arm will undergo debridement with either a powered microdebrider or cold instrumentation excision as per the preference of the individual surgeon. Debridement will be deemed complete after removal of gross papilloma to the extent that the individual surgeon feels can be safely accomplished. Standard microsurgical principles of the larynx will guide debridement in that no opposing mucosal surfaces of the true vocal folds, laryngeal ventricle or inter-arytenoid space will be simultaneously debrided
62248060|NCT06154551||Group C|fifteen systemically healthy control subjects
62248061|NCT03245567|EXPERIMENTAL|Pre, post, delayed test|Participants will not do the PLM, but will perform a pretest, a posttest and a delayed test at 6 months
62605139|NCT01113138|ACTIVE_COMPARATOR|Magnesium sulfate|
62605140|NCT06622525|EXPERIMENTAL|Intervention Group|This group will receive 100 mEq of sodium bicarbonate diluted in one liter of saline solution, administered at a rate of 100 ml/h, with the goal of maintaining a urinary pH greater than 6.5.
62827820|NCT01178047|ACTIVE_COMPARATOR|Rasagiline|
62827821|NCT01178047|PLACEBO_COMPARATOR|Placebo|
62827822|NCT06586203|ACTIVE_COMPARATOR|Informed|Intervention group tested and informed of the Polygenic risk score test result at the start of the study
62827823|NCT06586203|NO_INTERVENTION|Not initially informed|Control group: tested but not informed of the Polygenic Risk Score test result at the start of the study.
62827824|NCT06587295|EXPERIMENTAL|Escalation|
62827825|NCT06587295|EXPERIMENTAL|Expansion|
62827826|NCT01188343|EXPERIMENTAL|Group 1|Participants will receive the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 0 and Measles, mumps, and rubella live attenuated virus vaccine (MMR) on Day 42
62827827|NCT01188343|EXPERIMENTAL|Group 2|Participants will receive Measles, mumps, and rubella live attenuated virus vaccine (MMR) on Day 0, and the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 42.
62827828|NCT01188343|EXPERIMENTAL|Group 3|Participants will receive the Measles, mumps, and rubella live attenuated virus vaccine (MMR) and the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 0
62827829|NCT06596278|EXPERIMENTAL|Memesto Intervention|Memesto device intervention
62827830|NCT06586333|NO_INTERVENTION|Control Group|Involved GICU patients as the standard care services observation group (OG). Stress ulcer prophylaxis were only observed and no intervention done
62827831|NCT06586333|EXPERIMENTAL|Intervention|In the EICU, patients were identified as part of the recruiting guideline group (GG), and in addition to receiving usual care, they were managed for SUP according to the ASHP stress ulcer prophylaxis guidelines
62827832|NCT06035016||cohort A|Pyrotinib 400mg, qd, po, day 1-21, q3w, Capecitabine 1000mg/m2, bid po d1-14, q3w
62827833|NCT06035016||cohort B|treatment of physician's choice
62827834|NCT03384615|EXPERIMENTAL|Compassion-focused therapy|
62827835|NCT03384615|NO_INTERVENTION|Waitlist control group|
62827836|NCT06161246|EXPERIMENTAL|Treatment Group|Subjects will be treated for correction of glabellar lines with Dysport and comfort intervention on one side and Dysport only on the other side depending on pre-determined randomization. Subjects will complete the study assessments and end the study.
62827837|NCT00817843|EXPERIMENTAL|First Simva 80mg then Simvai/Eze10/10mg|First 6 weeks of Simvastatin 80mg, then 6 weeks of Simvastatin/Ezetimibe 10/10mg after 6 weeks of placebo washout
62827838|NCT00817843|EXPERIMENTAL|First Simva/Eze 10/10mg then Simva 80mg|First 6 weeks of Simvastatin/Ezetimibe 10/10mg, then 6 weeks of Simvastatin 80mg after 6 weeks of placebo washout
62827839|NCT05068297|EXPERIMENTAL|Germanium-Embedded Knee Brace|Following surgery the patients effected limb would be placed in an Germanium-Embedded Knee Brace
62449270|NCT00352495|EXPERIMENTAL|Vinblastine sulfate and carboplatin|The MTD of vinblastine in combination with a monthly dose of carboplatin will be determined during the first cycle of therapy. Each 4-week cycle will consist of carboplatin once every 4 weeks on day 1. Vinblastine will be given once a week for 3 weeks followed by a one week break. Doses of carboplatin and vinblastine sulfate will be assigned at study enrollment. Patients may receive eleven additional four week cycles, barring tumor progression or unacceptable toxicity. The total duration of therapy will be approximately 48 weeks.
62449271|NCT00922532|EXPERIMENTAL|Inhaled Nitric Oxide|Inhaled Nitric Oxide
62605141|NCT06622525|ACTIVE_COMPARATOR|Control Group|This group will be manage with the usual care that is given to patients with heat stroke in this hospital.
62605142|NCT02505451|EXPERIMENTAL|Type 2 diabetic patients|Regional myocardial function will be assessed during dobutamine stress echocardiography in asymptomatic patients with type II diabetes (according to the American Diabetes Association, 2012) free of coronary diseases.
62605143|NCT02505451|EXPERIMENTAL|Metabolic syndrom|Regional myocardial function will be assessed during dobutamine stress echocardiography in asymptomatic patients with the Metabolic syndrome (according to Alberti et al 2009) free of diabetes and coronary diseases.
62605144|NCT02505451|EXPERIMENTAL|controls|Regional myocardial function will be assessed during dobutamine stress echocardiography in healthy subjects.
62605145|NCT05149378|EXPERIMENTAL|Venetclax combined with azacitidine|Relapsed or refractroy acute lymphoblastic leukemia patients reveive venetclax combined with azacitidine regimen treatment.
62605146|NCT01551719|NO_INTERVENTION|Standard Procedure (phase I)|Antibiotic prescription following in vitro sensitivity test according to each surgeon's will.
62827840|NCT05068297|ACTIVE_COMPARATOR|Replica Knee Brace|Following surgery the patients effected limb would be placed in a replica knee brace
62248062|NCT03245567|EXPERIMENTAL|PLM group (pre, post, delayed test, PLM)|Participants will do a pretest, the PLM, a posttest and a delayed test at 6 months
62248063|NCT01557933||ECT|All study subjects have consented to receive ECT.
62248064|NCT05171946|EXPERIMENTAL|Cohort 1|Low-Dose, 1mg, 3 doses 21 days apart
62248065|NCT05171946|EXPERIMENTAL|Cohort 2|Mid-Dose, 2 mg, 2 doses 21 days apart
62248066|NCT05171946|EXPERIMENTAL|Cohort 3|High-Dose, 4 mg, 2 doses 21 days apart
62248067|NCT00619528|EXPERIMENTAL|1|No separate arms: All Enrolled Receive Same Treatment
62248068|NCT00408395|EXPERIMENTAL|1: Trivalent Seasonal Influenza Vaccine|
62248069|NCT00408395|EXPERIMENTAL|2: Adjuvanted Trivalent Seasonal Influenza Vaccine|
62248070|NCT05545605|EXPERIMENTAL|Intervention group|Subjects randomized to the trial group will receive sodium oligomannate 450mg twice daily for 24 weeks.
62248071|NCT05545605|PLACEBO_COMPARATOR|Control group|Subjects randomized to the control group will receive a 450mg placebo capsule twice daily for 24 weeks that has exactly the same appearance and smell as the Intervention group.
62248072|NCT02785679|NO_INTERVENTION|Exclusive breast feeding|Exclusive breast feeding
62248073|NCT02785679|NO_INTERVENTION|Exclusive CMF feeding|Exclusive CMF feeding
62248074|NCT02785679|ACTIVE_COMPARATOR|Breast feeding with small amount of CMF|Breast feeding with addition (as intervention) of 20 cc of cow's milk formula (CMF) per day
62248075|NCT02785679|ACTIVE_COMPARATOR|Breast feeding with one meal of CMF|Breast feeding with addition (as intervention) of one meal per day of cow's milk formula (CMF)
62248076|NCT04830033|EXPERIMENTAL|ENO Breathe group|Participation in the online ENO Breathe programme for 6 weeks.
62248077|NCT04830033|NO_INTERVENTION|Usual Care Group|Participants continue with usual care.
62248078|NCT00798135|EXPERIMENTAL|itraconazole|Patients will receive oral itraconazole 200mg a day until disease progression.
62248079|NCT03138811|EXPERIMENTAL|CSJ117|low dose, medium dose, or high dose administered as a once daily inhaled dose
62248080|NCT03138811|PLACEBO_COMPARATOR|Placebo|placebo comparator administered as once daily inhaled dose
62248081|NCT03998176|EXPERIMENTAL|B/F/TAF|Participants will receive B/F/TAF for 48 weeks
62248082|NCT04891341|EXPERIMENTAL|Technology Supported Task-Oriented Circuit Therapy Group|Ten workstations, which are frequently used in the literature and determined according to the clinical experience of the research team, have been created. Each workstation will be applied for a total of 1 hour, in the form of 5 minutes of training and 1 minute of rest.
62248083|NCT04891341|ACTIVE_COMPARATOR|Home-based Telerehabilitation Group|To the telerehabilitation group; A home program consisting of strengthening, balance and coordination exercises determined according to the needs of volunteers with MS will be given. A session will be applied in the home program under the guidance of a physiotherapist. The exercise will take 1 hour. The exercise participation status of the patient will be monitored with a mobile (smartphone) application. Exercises will be constantly updated according to the needs of the patient, the updated exercises will be sent to the mobile application via video, and the patient will be able to communicate with the physiotherapist via video conference whenever he / she wishes. Progress and complication of the treatment program will be achieved by increasing the weights used, changing the ground characteristics and support surface during balance exercises and increasing the complexity of coordination exercises.
62605147|NCT01551719|EXPERIMENTAL|Implemented procedure|Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection, according to each surgeon's will.
62605148|NCT00948506|PLACEBO_COMPARATOR|1% topical cidofovir|1% topical cidofovir to one side of the face and placebo to the other side of the face
62605149|NCT00948506|PLACEBO_COMPARATOR|3% topical cidofovir|3% topical cidofovir to one side of the face and placebo to the other side of the face
62605150|NCT03284372|EXPERIMENTAL|Intervention 1|Text Message Only
62605151|NCT03284372|EXPERIMENTAL|Intervention 2, Incentive|Text message + Incentive
62605152|NCT03284372|NO_INTERVENTION|Cohort|For the cohort multiple randomized controlled trial (cmRCT), investigators will recruit 130 participants (the base cohort) ages 15-19. The base cohort allows investigators to measure normative food allergy self-management practices, while also serving as a control for experiments in Interventions 1 and 2.
62605153|NCT03284372|NO_INTERVENTION|Control|The baseline cohort serves as the control group in this cmRCT. Participants will not receive text message reminders (during Intervention 1) or incentives (during Intervention 2). However, they will participate in all data collection points, including text message check-ins to assess epinephrine-carrying. Participants in the base cohort will receive usual care.
62605154|NCT03284372|NO_INTERVENTION|Adolescent Allergy Advisors|We will pilot the text messages to be used in Interventions 1 and 2 through interviews and cognitive testing among 20 Adolescent Allergy Advisors, who will critique message content, framing, and language. These advisors will not be part of the cohort multiple randomized controlled trial.
62605155|NCT03754634|EXPERIMENTAL|drugs|Eltrombopag and Diacerein
62605156|NCT04837599|NO_INTERVENTION|Pentax i 10|Patient gets normal colonoscopy without Endocuff or activation of artifical intelligence
62605157|NCT04837599|ACTIVE_COMPARATOR|Pentax i 10 with artificial intelligence Discovery TM|Normal Pentax i 10 colonoscope with on the special monitor acitvated artificial intelligence
62605158|NCT04837599|ACTIVE_COMPARATOR|Pentax i 10 with Endocuff TM|Endocuff cap is mounted on the tip of the endoscope a cheap assistance device proven in former studies to increase adenoma detection rate.
62605159|NCT04837599|ACTIVE_COMPARATOR|Pentax i 10 with Endocuff TM and artificial intelligence Discovery TM|Endocuff cap is mounted on the tip of the endoscope and artificial intelligence is activated on the monitor. hypothesis is that probably artificial intelligence and Endocuff combined potentiate their effect.
62438129|NCT03309410||Pre-study|In the pre-study, venous samples were collected in paired 2 mL ABG syringes and 4.5 mL tubes from each of the 10 patients, to determine which blood collection method was preferred. VBG samples were collected via a butterfly needle with a three-way stopcock in conjunction with routine venous blood sampling upon admission. VBG samples were collected by the biomedical laboratory technician in the same manner as PVB samples in the normal clinical setting. Results from the pre-study were used to determine the preferred blood collection method in the main study. In this study, paired ABG and VBG samples were collected simultaneously from each of the 20 patients. The ABG samples were collected by the responsible physician. Allocation to either the pre-study or the main study was performed by simple quasi-random allocation in order of admission.
62438130|NCT03309410||Main study|In this study, paired ABG and VBG samples were collected simultaneously from each of the 20 patients. The ABG samples were collected by the responsible physician. Allocation to either the pre-study or the main study was performed by simple quasi-random allocation in order of admission. The clinical indication for ABG analysis was decided by the responsible physician in the ED upon patient admission and based on national guidelines and criteria.
62438131|NCT01899157||Survey|"1. Thai naive HIV-infected patients~2. Thai HIV-infected patient reciering highly active antiretroviral therapy"
62438132|NCT04986696|EXPERIMENTAL|Dose escalation of FLASH therapy in skin metastases of small volume (≤ 30 cc)|7 dose levels (22 Gy; 24 Gy; 26 Gy; 28 Gy, 30 Gy, 32 Gy and 34 Gy)
62438133|NCT04986696|EXPERIMENTAL|Dose escalation of FLASH therapy in skin metastases of large volume (> 30 and ≤ 100 cc)|7 dose levels (22 Gy; 24 Gy; 26 Gy; 28 Gy, 30 Gy, 32 Gy and 34 Gy)
62438134|NCT04596449|EXPERIMENTAL|healthy volunteers|
62605160|NCT01885715|PLACEBO_COMPARATOR|Rocuronium-placebo|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
62605161|NCT01885715|ACTIVE_COMPARATOR|Rocuronium-neostigmine 10 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0."
62605162|NCT01885715|ACTIVE_COMPARATOR|Rocuronium-neostigmine 20 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
62827841|NCT06101784|ACTIVE_COMPARATOR|Avenanthramide tablet single oral dose|adaptive dose levels
62827842|NCT06101784|PLACEBO_COMPARATOR|Placebo to match Avenanthramide tablet single oral dose|adaptive dose levels
62827843|NCT06101784|ACTIVE_COMPARATOR|Avenanthramide tablet multiple oral dose|adaptive dose levels
62438135|NCT03807154|EXPERIMENTAL|Internet-based cognitive behavioral therapy (ICBT)|A nine-week long ICBT intervention with therapist support.
62438136|NCT03807154|EXPERIMENTAL|Internet-based Interpersonal Therapy (IIPT)|A nine-week long intervention based in interpersonal psychotherapy with therapist support.
62438137|NCT03807154|NO_INTERVENTION|Wait-list|Wait-list control group
62827844|NCT06101784|PLACEBO_COMPARATOR|Placebo to match Avenanthramide tablet multiple oral dose|adaptive dose levels
62605163|NCT01885715|ACTIVE_COMPARATOR|Rocuronium-neostigmine 40 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
62605164|NCT01885715|PLACEBO_COMPARATOR|Cisatracurium-placebo|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
62605165|NCT01885715|ACTIVE_COMPARATOR|Cisatracurium-neostigmine 10 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
62605166|NCT01885715|ACTIVE_COMPARATOR|Cisatracurium-neostigmine 20 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
62045785|NCT00550914||Experimental Arm|Patients enrolled into the conventional therapy plus PDL treatment arm will undergo debridement of the supraglottis and subglottis via conventional techniques as per the individual surgeons preferences followed by therapy to anterior commissure, true vocal folds, laryngeal ventricle and inter-arytenoid space with the pulsed dye laser. Standard laser settings will be a 450 microsecond pulse width, 5 J per pulse maximum of 1Hz, 1 mm spot fiber, 1-2 mm spot size and fluences of 38-255 J/cm2.
62045786|NCT00914004|EXPERIMENTAL|1|Desipramine HCl 50 mg Tablets Cord Laboratories
62045787|NCT00914004|ACTIVE_COMPARATOR|2|Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc
62045788|NCT02297568|ACTIVE_COMPARATOR|Calciferol,1800 IU/d supplement|The lactating mothers and their breastfed infants with maternal 25 Hydroxy-vitamin D (25OHD) levels of 10-30 ng/ml in third trimester were randomly assigned to 1,800 IU/d .
62438138|NCT01496027||term newborns|
62438139|NCT01496027||Preterm Newborns (32-37 GA)|
62605167|NCT01885715|ACTIVE_COMPARATOR|Cisatracurium-neostigmine 40 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
62605168|NCT01601457|EXPERIMENTAL|Activated recombinant human factor VII|
62605169|NCT01601457|PLACEBO_COMPARATOR|Placebo|
62605170|NCT04812340|ACTIVE_COMPARATOR|High intensity Circuit training|Intervention will consist of 6 series with 3 minutes rest period between the series. The series will consist of burpees, skipping, 1 legged squats, leg levers, and push-ups. the exercise volume will be increased progressively over 8 weeks.
62045789|NCT02297568|PLACEBO_COMPARATOR|Placebo|The lactating mothers and their breastfed infants with maternal 25 Hydroxy-vitamin D (25OHD) levels of 10-30 ng/ml in third trimester were randomly assigned to receive placebo.
62045790|NCT05989100|EXPERIMENTAL|Favourate taste stimulation|The swab will be immersed in sugar, salt, citric acid, or paprika mixed with water, and be placed in -18℃ refrigerator. Select the swabs of the participant favourate taste to brush oral cavity and tounge. The stimulation will last two to three minutes one time, and twice for a rehabilitation session, once per day and six days every week, three weeks totally. Swallowing rehabilitation also include standard training that carried out in the department.
62045791|NCT05989100|ACTIVE_COMPARATOR|Sour stimulation|Using sour swab to brush oral cavity and tounge of the participant. The treatment duration and other training method is as same as mentioned above.
62045792|NCT05989100|PLACEBO_COMPARATOR|Thermal stimulation|Only ice-water swab to brush oral cavity and tounge. The treatment duration and other training method is as same as mentioned above.
62045793|NCT03023592|EXPERIMENTAL|Iguratimod|Patients are treated with Iguratimod 25 mg Twice a day for 24 weeks.
62045794|NCT01261026||Ectopic pregnancy, extra-uterine pregnancy|Ectopic pregnancy, control
62045795|NCT01261026||Abnormal intrauterine pregnancy|
62248084|NCT00533468|EXPERIMENTAL|Active Drug|Active 4% Lidocaine topical cream (LMX4 cream) applied under occlusive dressing
62438140|NCT03376074|EXPERIMENTAL|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 2 hours
62438141|NCT03376074|ACTIVE_COMPARATOR|Conventional cold storage|
62438142|NCT06529822|EXPERIMENTAL|Cohort 1: Muscle Invasive Bladder Cancer (PCV)|The schedule for vaccination will be Days 1, 4, 8, 15, 29, 57, 85, 113, 141, and 169. All study injections will be given intramuscularly and co-administered with poly-ICLC by a trained healthcare provider. It is anticipated that the PCV will be administered concurrently with nivolumab in patients enrolled in Cohort #1 Muscle Invasive Bladder Cancer. Adjuvant nivolumab is considered standard of care in this patient population. Concurrent administration with adjuvant nivolumab is anticipated but not required.
62605171|NCT04812340|ACTIVE_COMPARATOR|Low intensity interval training|the intervention will consist of 4 series of Low-intensity exercises with 3 minutes of rest. the series will comprise of jogging and walking. the Exercise volume will be increased gradually.
62605172|NCT03968250|EXPERIMENTAL|Cognitive Behavioral Therapy for Treating Fatigue|This is the patient group that receives the intervention (IG), i.e., the cognitive behavioral therapy for reducing fatigue.
62827845|NCT04909463|NO_INTERVENTION|Unilateral rib fractures only, no device intervention|Unilateral rib fractures only, no device intervention
62827846|NCT04909463|EXPERIMENTAL|Unilateral rib fractures, device intervention|Unilateral rib fractures, will receive device intervention
62827847|NCT04909463|NO_INTERVENTION|Bilateral rib fractures, no device intervention|Bilateral rib fractures, no device intervention
62045796|NCT06462911|EXPERIMENTAL|Spanish speaking participant with self-reported epilepsy and cognitive and memory dysfunction|"Participants will receive the HOBSCOTCH intervention (in Spanish) consisting of 1:1 sessions delivered once per week including:~1 pre-HOBSCOTCH Session (on webcam or by phone)~1 educational session (on webcam) 6 HOBSCOTCH intervention sessions (webcam or phone)~1 wrap-up session (webcam or phone)"
62045797|NCT01337895|ACTIVE_COMPARATOR|Lifestyle counselling|These participants will be assigned to a 500 kcal/day energy-restricted diet that is low in dairy products (no more than 1 serving per day).
62605173|NCT02063048|NO_INTERVENTION|Usual Care for Weight Loss|Patients randomized to this arm will not receive text messages or any other weight-loss support besides usual care provided at Denver Health. They will receive a weight loss educational packet and be asked to follow up with their primary care provider to further discuss their efforts at weight loss with additional follow-up as directed by their provider. They will be contacted periodically to be weighed. Providers will not be made aware that their patients are participating in the study's control arm.
62605174|NCT02063048|EXPERIMENTAL|Text Message Based Weight Loss Support|Patients will receive the same weight loss educational packet as those randomized to usual care. Patients will be assisted in choosing a self-management goal related to exercise and to eating behaviors. They will receive text messages at a frequency up to 1x daily; input from focus groups will guide text message frequency.
62605175|NCT03118791|PLACEBO_COMPARATOR|Placebo|Capsules containing maltodextrin
62045798|NCT01337895|EXPERIMENTAL|High dairy|These participants will be assigned a 500 kcal/day energy-restricted diet that is high in dairy (4 or more servings per day).
62045799|NCT05892068|EXPERIMENTAL|Patients already on Tucatinib|Cohort A: This is a non-interventional study patients who will enter while already on Tucatinib . Patients in cohort A who are already on Tucatinib at a dose reduction (i.e., for toxicity) will continue the same dose.
62045800|NCT05892068|EXPERIMENTAL|Patients with documented radiological and/or clinical CNS progression with no prior tucatinib|Cohort B: Is to administer Tucatinib at standard dose of 300mg orally twice daily for 4 days prior to surgery (day -4 to 0).
62248085|NCT00533468|PLACEBO_COMPARATOR|Placebo|Placebo Cream made on same run at factory but without active Lidocaine 4% drug
62605176|NCT03118791|ACTIVE_COMPARATOR|80 mg ACN|Capsules containing 80 mg anthocyanins
62605177|NCT03118791|ACTIVE_COMPARATOR|160 mg ACN|Capsules containing 160 mg anthocyanins
62827848|NCT04909463|EXPERIMENTAL|Bilateral rib fractures, device intervention|Bilateral rib fractures, will receive device intervention
62827849|NCT06597981|EXPERIMENTAL|Dyadic empowerment-based sport stacking group|
62827850|NCT06597981|ACTIVE_COMPARATOR|Basic education group|
62827851|NCT05696288|EXPERIMENTAL|Arm A: investigational device (Respiratory Gas Delivery System)|Patients ventilated with the Optiflow™ system, a nasal high flow oxygenation system (NHFO) while undergoing a panendoscopy
62827852|NCT05696288|ACTIVE_COMPARATOR|Arm B: standard nasal oxygenation device|Patients ventilated according to the standard technique while undergoing a panendoscopy
62827853|NCT02320084||HT-1 patients on Orfadin treatment|HT-1 patients on Orfadin (nitisinone) treatment
62827854|NCT06520033|EXPERIMENTAL|Intervention group|"The intervention group will receive a hydration plan executed by a humanoid robot.~Healthcare personnel will receive reminders from the robot to record fluid intake through it."
62827855|NCT06520033|ACTIVE_COMPARATOR|Control group with|The control group will receive the center's usual hydration plan. The health personnel will make the fluid intake record in paper format and at the end of the shift, as usual.
62827856|NCT06173323|EXPERIMENTAL|Basic social support + communication + patient psychoeducation|2 in-person/telephone weekly sessions on providing social support and tips for good communication for caregiver participants and 2 sessions of social support, decision aids, and tips for good communication for patient participants and a single monthly follow-up call for both participants.
62827857|NCT06173323|EXPERIMENTAL|Basic social support + communication|2 in-person/telephone weekly sessions on providing social support and tips for good communication for caregiver participants and a single monthly follow-up call for caregiver participant
62827858|NCT06173323|EXPERIMENTAL|Basic social support + patient psychoeducation|1 in-person/telephone weekly sessions on providing social support for caregiver participants and 2 sessions of social support, decision aids, and tips for good communication for patient participants and a single monthly follow-up call for both participants.
62248086|NCT03422172|EXPERIMENTAL|Subjects receiving CAB|Eligible subjects will receive oral doses of CAB 30 milligrams (mg) tablets once daily for 4 weeks followed by IM injectable suspension of CAB LA 600 mg at Week 5, Week 9, Week 17, Week 25 and Week 33. There will be an approximately 1-week washout period between the last oral dose and the first injection of CAB at Week 5.
62438143|NCT02265952|EXPERIMENTAL|Open-label|Open-label REGN1500
62438144|NCT05004857|EXPERIMENTAL|Patient arm|The subject population will be newborn infants admitted to the Newborn Nursery (NN) at Tulane Lakeside Hospital. The investigators are anticipating some mothers can be recruited from the prenatal clinics who expect to deliver at Tulane Hospital during pregnancy as well.
62605178|NCT03118791|ACTIVE_COMPARATOR|240 mg ACN|Capsules containing 240 mg anthocyanins
62605179|NCT03118791|ACTIVE_COMPARATOR|320 mg ACN|Capsules containing 320 mg anthocyanins
62605180|NCT03118791|ACTIVE_COMPARATOR|480 mg ACN|Capsules containing 480 mg anthocyanins
62605181|NCT00664794|ACTIVE_COMPARATOR|without acromioplasty|
62605182|NCT00664794|ACTIVE_COMPARATOR|with acromioplasty|
62605183|NCT01436331|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|
62605184|NCT01436331|EXPERIMENTAL|TAU+CBT for pts+Family Intervention+CM|
62605185|NCT04251962|EXPERIMENTAL|Bupivacaine|Epidural solution containing 0.1% bupivaacaine in normal saline
62605186|NCT04251962|EXPERIMENTAL|Bupivacaine + Fentanyl|Epidural solution containing 0.1% bupivacaine and 3 mcg/ml of fentanyl in normal saline
62605187|NCT02075775||MOON Shoulder Instability|Patients indicated for Shoulder Instability surgery
62605188|NCT05199896|EXPERIMENTAL|All protocols (behavioral and EEG and fMRI)|If participants accepts (non-sighted participants and Healthy volunteers), they will carry out the behavioral protocol and the EEG protocol and fMRI protocol.
62045801|NCT05892068|EXPERIMENTAL|HER2+ esophagogastric, lung, or colon cancer brain metastases and HER2 mutant breast cancer|Cohort C: Is to administer Tucatinib at standard dose of 300mg orally twice daily for 4 days prior to surgery (day -4 to 0).
62827859|NCT06173323|EXPERIMENTAL|Basic social support|1 in-person/telephone weekly sessions on providing social support for caregiver participants a single monthly follow-up call for the caregiver participant.
62827860|NCT06173323|EXPERIMENTAL|Advanced social support + communication+ patient psychoeducation|4 in-person/telephone weekly sessions on providing social support and tips for good communication for caregiver participants and 2 sessions of social support, decision aids, and tips for good communication for patient participants and a single monthly follow-up call for both participants.
62827861|NCT06173323|EXPERIMENTAL|Advanced social support + communication|4 in-person/telephone weekly sessions on providing social support and tips for good communication for caregiver participants and a single monthly follow-up call for caregiver participant
62827862|NCT06173323|EXPERIMENTAL|Advanced social support + patient psychoeducation|3 in-person/telephone weekly sessions on providing social support for caregiver participants and 2 sessions of social support, decision aids, and tips for good communication for patient participants and a single monthly follow-up call for both participants.
62827863|NCT06173323|EXPERIMENTAL|Advanced social support|3 in-person/telephone weekly sessions on providing social support for caregiver participants and a single monthly follow-up call for caregiver participant
62248087|NCT02626286|OTHER|HIV quarterly global care|HIV quarterly global care including i) data collection on health status, symptoms of sexually transmitted infections (STI) and sexual behavior, ii) a clinical examination, iii) STI diagnosis and treatment, iv) prevention counselling adapted for MSM, v) the provision of condoms and lubricants, and vi) HIV screening test at each quarterly visit for HIV-negative MSM or immediate support of HIV infection including antiretroviral therapy for HIV-positive MSM.
62438145|NCT01208142|ACTIVE_COMPARATOR|Standard of care|25 Control subjects will only receive SOC (a weekly standardized physical therapy and daily wear of an AFO).
62438146|NCT01208142|EXPERIMENTAL|Dynasplint|25 Patients will receive the standard of care as well as an Ankle Flexion Dynasplint
62438147|NCT05158491|ACTIVE_COMPARATOR|180 mg/mm2|Subjects will be dosed at 180 mg/mm2 level.
62438148|NCT05158491|ACTIVE_COMPARATOR|220 mg/mm2|Subjects will be dosed at 220 mg/mm2 level.
62438149|NCT05158491|ACTIVE_COMPARATOR|260 mg/mm2|Subjects will be dosed at 260 mg/mm2 level.
62827864|NCT00092417|EXPERIMENTAL|1|Higher Potency Dose
62827865|NCT00092417|EXPERIMENTAL|2|Lower Potency Dose
62827866|NCT00247663|EXPERIMENTAL|Letrozole|
62827867|NCT00700479|EXPERIMENTAL|A|Aldosterone plus low salt diet
62827868|NCT00700479|EXPERIMENTAL|B|Aldosterone plus high sodium diet
62827869|NCT00700479|PLACEBO_COMPARATOR|C|Placebo plus low sodium diet
62438150|NCT05158491|ACTIVE_COMPARATOR|300 mg/mm2|Subjects will be dosed at 300 mg/mm2 level.
62438151|NCT05972850|EXPERIMENTAL|Vivo Heart|This virtual intervention will include weekly group exercise sessions with a Vivo trainer (2 times/week), weekly health education classes with a registered dietitian (RD) (1 time/week), and two individual meetings with the RD over the course of 12 weeks. Participants will also be asked to complete a weekly aerobic exercise session on their own (1 time/week).
62827870|NCT00700479|PLACEBO_COMPARATOR|D|placebo plus high sodium diet
62827871|NCT02599571|OTHER|Very low nicotine content cigarettes|Reduced nicotine content cigarettes.
62827872|NCT02599571|OTHER|Conventional nicotine content cigarettes|Conventional nicotine content cigarettes.
62449272|NCT00922532|PLACEBO_COMPARATOR|Nitrogen|Nitrogen Placebo
62827873|NCT02700061|EXPERIMENTAL|Induced Constraint Therapy - ICT|Physical rehabilitation with Induced Constraint Therapy as part of the occupational therapy. Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
62248088|NCT02041260|EXPERIMENTAL|Open Label Cabozantimib|
62248089|NCT00074581|EXPERIMENTAL|1|Participants will begin ART in addition to receiving HIV primary care
62248090|NCT00074581|EXPERIMENTAL|2|"Participants will receive HIV primary care. When the CD4 count in these participants reaches 200 to 250 cells/mm3, drops below 200 cells/mm3, or develops an AIDS-defining illness, they will initiate ART.~Note: Per LoA#5, on the Data and Safety and Monitoring Board (DSMB) recommendation, as of May 10, 2011, all HIV-infected participants in Arm 2 who have not already initiated ART will be offered ART as soon as possible."
62827874|NCT02700061|EXPERIMENTAL|Robotic occupational therapy|Physical rehabilitation with Robotic occupational therapy. Robotic Occupational Therapy three times a week for twelve weeks.
62827875|NCT06193096|EXPERIMENTAL|Experimental group|Probiotic formula, 1 stick/day
62827876|NCT06193096|PLACEBO_COMPARATOR|Control group|Placebo formula, 1 stick/day
62827877|NCT02968758|EXPERIMENTAL|Accuracy Testing|Comparison between GenePOC PCR and Reference Method
62248091|NCT01927328|NO_INTERVENTION|Control|Standard Care as determined by the clinical team
62248092|NCT01927328|ACTIVE_COMPARATOR|Iron isomaltoside 1000|Intravenous Iron Isomaltoside 1000 (Monofer®)will be administered in line with the summary of product characteristics.
62827878|NCT02084992|EXPERIMENTAL|Expanded technology disease management|After an initial visit where the program is introduced and education regarding adherence, methods for self-monitoring and early reporting of changes in status are reviewed, patients randomized to this arm will be given tablet computers with a web-based heart failure disease management application. Patients will be asked to interact with the system daily with transmission of weight, heart rate, blood pressure and symptom reports to the nurse manager. A nurse manager will check the data daily and contact patients if any parameters exceed pre-specified parameters. Nurse managers will also touch base with the participants at regular intervals as in the control arm. In addition, educational modules will be placed onto individual tablet computers and given to each patient.
62248093|NCT04409899||Urological surgical patients during COVID-19 pandemic|During the COVID-19 pandemic, the urological patients in the need of a surgical intervention have been screened on the basis of the underline conditions, the priority of surgery, and risk-benefit assessment. A pre-surgical work-out was performed in the selected patients, with some of them being detected of COVID-19 at RT-PCR or suspected for it according to the risk-assessment survey. Enhanced blood tests and X-rays of the thorax were performed as baseline assessments. In case of development of post-surgical unspecific symptoms, clinical and laboratory work-out were performed before to expedite a new RT-PCR, which would have required preventive isolation of a patient in a COVID-19 ward. We evaluated the impact of COVID-19 in this selected cohort and the complications eventually associated with the viral infection.
62248094|NCT02389647||Endovascular group|Subjects undergoing elective endovascular catheterization for coiling of unruptured cerebral aneurysms. Four blood draws of 5mL each: (1) prior to initiation of procedure; (2) at the time of catheterization of major cerebral vessels, (3) immediately after the procedure, and (4) 24-hours after the procedure.
62605189|NCT05199896|EXPERIMENTAL|Behavioral protocol and EEG protocol|"Participants who agree to participate in only one of the experiments (EEG or MRI) will be randomly (by a randomization list) assigned to either the EEG or fMRI type of study in each subgroup.~All participants (non-sighted participants and Healthy volunteers) will do the behavioral session and at least one EEG or MRI session depending on randomization."
62605190|NCT05199896|EXPERIMENTAL|Behavioral protocol and fMRI protocol|"Participants who agree to participate in only one of the experiments (EEG or MRI) will be randomly (by a randomization list) assigned to either the EEG or fMRI type of study in each subgroup.~All participants (non-sighted participants and Healthy volunteers) will do the behavioral session and at least one EEG or MRI session depending on randomization."
62827879|NCT02084992|ACTIVE_COMPARATOR|telephonic disease management|After an initial visit where the program is introduced and education regarding adherence, methods for self-monitoring and early reporting of changes in status are reviewed, the nurse manager will telephone participants weekly for the first month followed by either every two weeks or monthly calls depending on clinical status with the goal of transitioning all participants to monthly calls. During these phone calls the nurse manager will focus on identifying changes in clinical condition and education reinforcement. Participants will be instructed to check and record their weight, heart rate and blood pressure daily and will be encouraged to call if there are any changes in their clinical status.
62827880|NCT00595088|EXPERIMENTAL|20 mg of BC-819/PEI|Six intravesical instillations of 20 mg of plasmid DNA (BC-819) complexed with PEI into the bladder of patients with intermediate-risk superficial bladder cancer \[recurrent stages Ta (low or high grade) and T1 (low grade) TCC\] who have failed prior intravesical therapies including BCG and/or chemotherapy.
62827881|NCT06591299|ACTIVE_COMPARATOR|cilostazol and aspirin|The cilostazol arm will receive (a 200 mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
62827882|NCT06591299|ACTIVE_COMPARATOR|clopidogrel and aspirin|The clopidogrel arm will receive (a 300 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
62605191|NCT02939976|ACTIVE_COMPARATOR|Single Vessel Disease|Standard of care comparator for those subjects with single vessel coronary artery disease. Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
62827883|NCT04734028||PTRG-DES registry|After DES implantation, CAD patients were treated with DAPT with clopidogrel and aspirin. During hospitalization, their platelet function, genotype and inflammation biomarker were evaluated.
62827884|NCT04906811|ACTIVE_COMPARATOR|Fat grafting with the AuraGen 1-2-3 with AuraClens System|Patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. Lipoaspirate processed with the AuraGen 1-2-3 with AuraClens system.
62827885|NCT04906811|ACTIVE_COMPARATOR|Fat grafting with the Revolve System|Patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. Lipoaspirate processed with the Revolve System.
62827886|NCT03331315|ACTIVE_COMPARATOR|Ketorolac|Patients receiving scheduled ketorolac postoperatively
62827887|NCT03331315|EXPERIMENTAL|Celecoxib|Patients receiving celebrex preoperative and postoperatively for 7 days
62827888|NCT05902364|EXPERIMENTAL|Systane Ultra Preservative-Free|1-2 drops in each eye four times a day for 30 days
62827889|NCT06346717|NO_INTERVENTION|Control Group|"No intervention will be made to the patients in the control group (n = 30). Patients in the control group will receive standard care and discharge education provided by the hospital. Discharge training consists of verbal information about the postoperative period. The MMD Scale will be applied to patients who meet the criteria 1 day before the surgery. Patients with a BCS Scale ≥ 89 will be included in the study. Patients will be interviewed face to face and written consent will be obtained. Sociodemographic and descriptive data will be obtained with the Descriptive Patient Form. Discharge day after surgery (3rd day); Functional status level will be measured with KOOS. 3rd and 6th weeks after surgery; Functional status and self-care ability levels will be measured using the KOOS and Self-Care Power Scale, respectively."
62605192|NCT02939976|EXPERIMENTAL|Multi-vessel Disease, Culprit Vessel Only|Subjects randomized to revascularization of infarct related artery only. Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
62045802|NCT03544346||Retired professional rugby players|"Rugby Players will Provide detailed demographic information Provide detailed overall health information Questionnaires Provide information on athlete's playing career; age of debut, career duration, number of seasons participated in. Provide information on concussion history. Be given a general health screen including- heart rate, blood pressure, body composition and height weight ratio.~Perform a battery of neuropsychological tests (Sound-induced flash illusion and CANTAB, NART) Provide a sample of blood."
62045803|NCT03544346||Retired professional rowers|"Rowers will Provide detailed demographic information Provide detailed overall health information Questionnaires Provide information on athlete's playing career; age of debut, career duration, number of seasons participated in. Provide information on concussion history. Be given a general health screen including- heart rate, blood pressure, body composition and height weight ratio.~Perform a battery of neuropsychological tests (Sound-induced flash illusion and CANTAB, NART) Provide a sample of blood."
62045804|NCT01512420||Cohort|
62248095|NCT02389647||Ischemic stroke group|Subjects who present to the emergency department with ischemic infarcts of \<6 hours. Four blood draws of 5mL each: (1) at time of enrollment but prior to tPA, (2) 6 hours post-tPA, (3) 12 hours post-tPA, and (4) 24 hours post-tPA.
62248096|NCT02389647||Intracranial hemorrhage|Subjects who present to the emergency department with intracranial hemorrhage. One 5mL blood draw within 24 hours of onset.
62248097|NCT00981513|ACTIVE_COMPARATOR|Influenza vaccination|Live attenuated influenza vaccine (seasonal and pandemic strains) by nasal spray
62248098|NCT00981513|PLACEBO_COMPARATOR|Saline placebo|Saline nasal spray
62248099|NCT06104982|EXPERIMENTAL|SiFES group|The investigators applied FES to the abdominal muscles of the SiFES group bilaterally, using 2 units of NeuroTrac MyoPlus Pro single-channel electromyography biofeedback electrotherapy devices. The investigators conducted electrical stimulation for a total of 10 minutes per session, with 5 minutes dedicated to bilateral rectus abdominis (RA) and 5 minutes to bilateral obliques externus (OE), obliques internus (OI), and transversus abdominis (TA) muscles three days a week, a period of four weeks. The investigators triggered the initial contraction of the abdominal muscles by instructing the patient to slightly flex their head before the application of electrical stimulation. During this process, the contraction was detected by the surface EMG present in the FES device, and the abdominal muscles were stimulated with electrical impulses.
62248100|NCT06104982|ACTIVE_COMPARATOR|Control group (TE group)|The investigators administered isometric strengthening to the TE groups, three days a week, with three sets per session, a period of four weeks.
62605193|NCT02939976|EXPERIMENTAL|Multi-vessel Disease, Complete Revascularization|Subjects randomized to complete revascularization. Complete revascularization of all diseased arteries with Medtronic Resolute family of stents; Use of Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology to determine which arteries to stent; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
62605194|NCT03042416|EXPERIMENTAL|18F-DOPA scan|18F-DOPA (4 MBq/kg, minimum 110 MBq, maximum 600 MBq) intravenous. Single-dose 20-80 minutes prior to PET/CT scan of brain or whole body (depending on specific imaging protocol for patient).
62605195|NCT02306694|EXPERIMENTAL|Open label|Everyone receives Advate (antihemophilic factor) on Day 1 and 3.
62827890|NCT06346717|EXPERIMENTAL|Experimental Group|"Patients assigned to the intervention group (n=30) will receive Knee Prosthesis-M mobile application service for iOS and Android devices, in addition to standard treatment. The MMD Scale will first be applied to patients who meet the criteria 1 day before the surgery. Patients with a BCS Scale ≥ 89 will be included in the study. Patients will be interviewed face to face and written consent will be obtained. Sociodemographic and descriptive data will be obtained with the Descriptive Patient Form. The intervention group will also use the Knee Prosthesis-M mobile application for 6 weeks, starting from the 1st day of the surgery. Discharge day after surgery (3rd day); The level of functional status will be measured using the KOOS. At the 3rd and 6th weeks after surgery, functional status and self-care skills will be measured using the KOOS and Self-Care Power Scale, respectively."
62827891|NCT06389422|EXPERIMENTAL|Radiotherapy and Pembrolizumab|Moderate-dose hypofractionated intensity-modulated radiotherapy with a gross tumor dose of 25Gy/5f and a maximum dose of 35Gy/5f at the tumor center concurrent with Pembrolizumab, followed Pembrolizumab±lenvatinib for maintenance.
62827892|NCT06262321|EXPERIMENTAL|Prophylactic Palliative Radiotherapy|Prophylactic Palliative Radiotherapy
62827893|NCT05833763|EXPERIMENTAL|Study Treatment|"This study design involves 3 phases:~1. Treatment Ramp-Up~   1. Pre-Phase (7 days): Obinutuzumab (1000mg) will be administered intravenously (IV) on D-7 and a second dose administered between Day 6 and Day 1.~  2. Cycle 1: An initial dose level of Glofitamab will evaluate step-up dosing. If excessive dose-limiting toxicity is observed, including cytokine release syndrome (CRS), a lower initial dose of 1.25mg of glofitamab will be evaluated at dose level -1.~   i. Dose level 1 (14 days):~  * 2.5mg Glofitamab by IV on Day 1~  * 10mg Glofitamab by IV on Day 8 ii. Dose level -1 (21 days):~  * 1.25mg Glofitamab by IV on Day 2~  * 2.5mg Glofitamab by IV on Day 8~  * 10mg Glofitamab by IV on Day 15 c. Cycle 2 (21 days): 30mg Glofitamab by IV on Day 1~2. Fixed course combination phase: Cycles 3-12 (21 days per cycle): 30mg of Glofitamab by IV on day 1~3. Maintenance phase: Cycles 13+ (21 days per cycle): Glofitamab discontinued. 200mg oral daily"
62045805|NCT00487409|OTHER|Group A|Standard of Care
62045806|NCT00487409|OTHER|Group B|Standard of Care
62248101|NCT00445523|EXPERIMENTAL|1|TroVax® alone
62248102|NCT00445523|EXPERIMENTAL|2|TroVax® plus IFN-α
62248103|NCT04440787||Three point cuff palpation and Blck mark line technique|"In Three point cuff palpation technique the cuff will be palpated just below the cricothyroid membrane,at the level of suprasternal notch and below the suprasternal notchand the tube is re-positioned in case of any discrepancy between the black mark line technique and three point cuff at three different over the trachea."
62605196|NCT04984681|EXPERIMENTAL|Mindfulness-based Stress Reduction|Mindfulness-based stress reduction sessions received by the treatment group will include an orientation, approximately 8 intervention sessions, and an exit interview.
62605197|NCT04984681|OTHER|Usual Care|The control condition will continue receiving usual care or standard of care.
62605198|NCT04151238|EXPERIMENTAL|Exercise intervention|The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home. Data on training at home and other items of physical activity is recorded in a diary.
62605199|NCT01540136|EXPERIMENTAL|Nedaplatin|Nedplatin combine with IMRT
62605200|NCT01540136|ACTIVE_COMPARATOR|Cisplatin|Cisplatin combine with IMRT
62605201|NCT01778699|EXPERIMENTAL|Lozenges with Lactobacillus brevis CD2|During the treatment phases subjects will use 2 lozenges a day.
62605202|NCT01778699|PLACEBO_COMPARATOR|Lozenges|During the treatment phases subjects will use 2 lozenges a day.
62605203|NCT02258334|EXPERIMENTAL|Fluzone® Quadrivalent vaccine Group 1|Adults 18 to \< 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® Quadrivalent vaccine
62827894|NCT00853307|EXPERIMENTAL|Alisertib 50 mg|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).
62827895|NCT06450899|EXPERIMENTAL|Prochlorperazine Maleate|This arm will be the interventional/experimental arm receiving prochlorperazine maleate, further described in experimental arm section.
62248104|NCT01516151|ACTIVE_COMPARATOR|Group A|0.5g total CaPre™ from baseline to week 4 and 1.0g total CaPre™ from week 4 to week 8
62248105|NCT01516151|ACTIVE_COMPARATOR|Group B|1.0g total CaPre™ from baseline to week 4 and 2.0g total CaPre™ from week 4 to week
62605204|NCT02258334|EXPERIMENTAL|Fluzone® Intradermal vaccine Group 2|Adults 18 to \< 65 years of age randomly assigned to receive an intradermal injection of Fluzone® Intradermal vaccine
62605205|NCT02258334|EXPERIMENTAL|Fluzone® Quadrivalent vaccine Group 3|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® Quadrivalent vaccine
62605206|NCT02258334|EXPERIMENTAL|Fluzone® High-Dose vaccine Group 4|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® High-Dose vaccine
62827896|NCT06450899|PLACEBO_COMPARATOR|Placebo|The placebo arm individuals will receive a non-identical placebo.
62827897|NCT05129345||Aim 1|People living with HIV who are at least 35 years of age and who have one or more of the following conditions: hypertension, dyslipidemia, or type 2 diabetes. All genders, races and ethnicities will be included in this study. Subjects will have a telephone visit including being consented electronically and complete a demographic survey, a photography training visit and an interview visit.
62605207|NCT06478602|EXPERIMENTAL|Fecal microbiota transplantation (FMT) in patients with liver cirrhosis|The experimantal group will receive fecal transplantation from a healthy donor. The study results will be obtained from analyzing the progression observed in imaging and laboratory tests (blood and fecal matter) as well as the patients clinical condition - compared to the initial phase and the control group. Patients will undergo fecal transplantation using a minimum of 70 grams of material collected and tested from a healthy donor. The fecal matter will be transferred into the cecum using a colonoscope.
62605208|NCT06478602|NO_INTERVENTION|Control|The control group will include patients who will be monitored for their progress while receiving standard treatment.
62045807|NCT05090709|EXPERIMENTAL|Experimental A - Mobilisation Intervention|Participants receive 4 separate treatment sessions of the 30 minute spinal mobilisation intervention.
62045808|NCT05090709|ACTIVE_COMPARATOR|Experimental B - General Massage|Participants receive 4 separate treatment sessions of the 30 minute general massage.
62045809|NCT03076255|EXPERIMENTAL|Supportive care (MID)|Patients undergo Computed Tomography (CT) simulation with thermoplastic mask and maskless immobilization device (MID) for radiation therapy (RT) planning on day 1. Patients undergo standard of care RT using thermoplastic mask only and cone-beam computed tomography (CBCT) imaging with thermoplastic mask and MID on day 8 and 15.
62248106|NCT01516151|ACTIVE_COMPARATOR|Group C|2.0g total CaPre™ from baseline to week 4 and 4.0g total CaPre™ from week 4 to week 8
62248107|NCT01516151|OTHER|Group D|Standard of care
62248108|NCT01516151|ACTIVE_COMPARATOR|Group E|4.0g total CaPre™ from baseline to week 8
62248109|NCT01865396|EXPERIMENTAL|early palliative care|Interventional palliative care, after diagnosis and once a month.
62248110|NCT01865396|ACTIVE_COMPARATOR|Standard care|Patients will receive the standard oncologic care.
62827898|NCT05129345||Aim 2|People living with HIV who are at least 35 years of age and who have one or more of the following conditions: hypertension, dyslipidemia, or type 2 diabetes. All genders, races and ethnicities will be included in this study. Subjects will have a telephone visit and be electronically consented to study and complete an electronic survey.
62045810|NCT01843374|EXPERIMENTAL|Tremelimumab|Tremelimumab
62045811|NCT01843374|PLACEBO_COMPARATOR|Placebo|Placebo
62438152|NCT01777425||rhinosinusitis patients|patients having undergone endoscopic sinus surgery (ESS) for bilateral inflammatory sinonasal disease from January 2008 until December 2010.
62605209|NCT02277158|EXPERIMENTAL|Chemoradiotherapy|There are four dose levels and one arm only. Level 1: S-1, 50 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 2: S-1, 65 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 3: S-1, 80 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 4: S-1, 90 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks
62605210|NCT02440321|EXPERIMENTAL|parent-child interactive program|The parent-child interactive program is designed by three phase: precontemplation/ contemplation stage, preparation stage, and action/maintenance stage. In phase 1, the main focus is to promote motivation through information providing and being aware of children's perception toward ETS and smoking. In phase 2, the main focus is strengthening parents/children's ability to plan and implement smoke-free home. In phase 3, intervention focus is on maintaining behavioral change and smoke-free home by continuously strengthening implementing ability, identifying and eliminating barriers, and reinforcing successful experience. Parent-child interaction is designed through three phases, and parents perceive children's feedback through all phases.
62605211|NCT02440321|ACTIVE_COMPARATOR|written materials|The mailed materials included information on ETS and its adverse effects, smoking behavior that causes ETS at home, and a workbook for smoking cessation.
62605212|NCT02490748|NO_INTERVENTION|RFA alone|Patients undergo radiofrequency ablation alone.
62827899|NCT05129345||Aim 3|Group composed of 10 willing participants recruited from the participating clinics and community based organizations and may include, HIV providers, nurses, pharmacists, people living with HIV who have cardiometabolic disorders, and representatives of the community advisory boards, and any other key stakeholders. There will be 3 one hour meetings over 3 months.
62045812|NCT05617690|EXPERIMENTAL|Cyclopol group|
62045813|NCT05617690|ACTIVE_COMPARATOR|Propofol group|
62045814|NCT03489304|OTHER|Zaleplon|Open-label zaleplon 5-10mg daily
62045815|NCT04953390|EXPERIMENTAL|Experimental|All study participants wearing study devices and evaluating three different microphone settings in simulated noise environments in lab, and using study devices during home trial period.
62045816|NCT03355417|EXPERIMENTAL|OT-SI|Occupational therapy using a sensory integration approach
62438153|NCT02297906|EXPERIMENTAL|Intranasal ketorolac|Ketorolac 0.5 mg/kg, maximum single dose = 30 mg. Administered once by intranasal route using a mucosal atomization device.
62045817|NCT00746590|EXPERIMENTAL|1|
62045818|NCT06577623|EXPERIMENTAL|MINDful TIME group|8-week mindfulness-based intervention for adolescents with ASD and their caregivers. Weekly meetings will be held in-person and will last approximately 2-hours. Adolescents and their caregivers will be asked to engage in home practice outside of group meetings
62248111|NCT03229408|EXPERIMENTAL|Salsalate-Treated Lean PCOS without IR|n=15
62248112|NCT03229408|PLACEBO_COMPARATOR|Placebo-Treated Lean PCOS without IR|n=15
62248113|NCT03229408|EXPERIMENTAL|Salsalate-Treated Lean PCOS with IR|n=15
62248114|NCT03229408|PLACEBO_COMPARATOR|Placebo-Treated Lean PCOS with IR|n=15
62438154|NCT02297906|ACTIVE_COMPARATOR|Intravenous ketorolac|Ketorolac 0.5 mg/kg, maximum single dose = 30 mg. Administered once by intravenous route.
62438155|NCT01446913|ACTIVE_COMPARATOR|Standard Intervention group|This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.
62438156|NCT01446913|ACTIVE_COMPARATOR|Enhanced CPAP intervention|This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.
62605213|NCT02490748|EXPERIMENTAL|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
62605214|NCT01131065|EXPERIMENTAL|Hepatitis B immune globulin|Treatment group (newly liver transplanted subjects due to HBV induced liver disease)
62438157|NCT01446913|NO_INTERVENTION|Usual Care|This group usual care after TIA/stroke and a sleep study at the end of the study.
62438158|NCT00891683|PLACEBO_COMPARATOR|Placebo|4 Capsules of Placebo
62438159|NCT00891683|ACTIVE_COMPARATOR|100 mg|One 100 mg capsule and 3 placebo capsules of AEG33773
62438160|NCT00891683|ACTIVE_COMPARATOR|200 mg|Two 100 mg capsules and two placebo capsules
62438161|NCT00891683|ACTIVE_COMPARATOR|400 mg|Four 100 mg AEG33773 capsules
62438162|NCT03323632|EXPERIMENTAL|MyndMove|The MyndMove system is a neuromodulation device that delivers short electrical pulses to stimulate muscle contractions and enhance motor recovery following Stroke or Spinal Cord Injury. MyndMove delivers therapeutic stimulation sequences called protocols, which are coded therapeutic algorithms which assist muscle movement allowing the brain and central nervous system to be retrained restoring voluntary reaching and grasping functions lost following neurological injury. The MyndMove system comprises the hardware device, stimulation electrodes and cables, hand and foot switches, and integrated software.
62045819|NCT05005780|EXPERIMENTAL|µ-alpha oscillation coupled ipsilesional 100 Hz triplet bursts|µ-rhythm (The µ rhythm frequency band is defined by activity falling between 8 and 13 Hz and recorded by scalp electrodes over the sensorimotor cortex during waking neural activity) negative peak triggered TMS of ipsilesional primary motor cortex, consisting of 400 triple pulses at 100 Hz, delivered at a mean inter-triple pulse interval of 3.0 s. Stimulation intensity: 100% resting motor threshold.
62045820|NCT05005780|ACTIVE_COMPARATOR|contralesional 1 Hz rTMS|1200 stimuli to the contralesional primary motor cortex at 1 Hz. Stimulation intensity: 115% resting motor threshold.
62248115|NCT03229408|EXPERIMENTAL|Salsalate-Treated Obese PCOS|n=15
62248116|NCT03229408|PLACEBO_COMPARATOR|Placebo-Treated Obese PCOS|n=15
62248117|NCT03881228|EXPERIMENTAL|Intervention|"1. at enrollment, caretakers will receive an educational booklet for caretakers explaining why IPT needs to be given~2. at enrollment and weekly for 24 weeks, caretakers will receive a children's storybook, with weekly installments, over the 6-month course of IPT as a non-monetary incentive~3. weekly, caretakers will receive short messages services (SMS) reminders delivered to the caretaker for the weekly pick-up."
62248118|NCT03881228|NO_INTERVENTION|Standard of care|Routine care at the health facility
62248119|NCT06461182|EXPERIMENTAL|Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma|Indolent B-cell Lymphoma such as marginal-zone B-cell lymphoma、Waldenstrom macroglobulinemia lymphocytic lymphoma、CLL/SLL、mantle cell lymphoma.
62438163|NCT05559294|EXPERIMENTAL|Professional development|"The intervention consists of a nine months long professional development program with an interchange between three e-learning modules and three group workshops starting with an e-learning module and ending with a workshop. Each workshop is 3 hours with approximately 100 participants. The e-learning modules are completed individually by ECEC staff. Between workshops, each day nursery and/or kindergarten center will receive a two-hour supervisory visit from UCL staff to support professional development. The daily leader at the day nursery and/or kindergarten center sets the theme for each supervisory visit to enhance development as much as possible.~The intervention is being designed as a collaboration between UCL and Odense municipality"
62248120|NCT05823025||Hypertension|Hypertensive patient
62248121|NCT05823025||Sleep apnea or COPD|Patient having sleep apnea or COPD (Chronic obstructive pulmonary disease)
62248122|NCT04562987|ACTIVE_COMPARATOR|Core Component (tele-coaching, emails, smartphone app & Fitbit)|All participants will receive the Core component, which includes access to weekly tele-coaching, weekly emails from the interventionist, a smartphone app, and a Fitbit monitor. Tele-coaching will include discussion of general cancer-related and wellness topics, and the smartphone app will have basic activity monitoring features.
62248123|NCT04562987|EXPERIMENTAL|Move (tele-coaching calls, smartphone app & Move goals & badges)|Tele-coaching calls for Move participants will be based in social cognitive theory to encourage behavior adoption and goal setting focused on reducing prolonged sitting. Smartphone app features include activity monitoring that visualizes progress toward Move-based goals and goal achievement badges specific to Move.
62438164|NCT05559294|ACTIVE_COMPARATOR|Usual professional development|Education and Care as Usual entails a standing offer from the municipality of Odense for Usual Competence development within the area of nature, outdoor life and natural phenomena visits from a learning consultant to support the ECEC staff's work with digital technology at the day nursery and/or kindergarten center. It is up to the day nursery and/or kindergarten center if the use the offer or not. This offer is extended to all day nursery and/or kindergarten centers.
62605215|NCT03526926||Vyxeos|A minimum of 50 patients who receive at least one infusion of prescribed VYXEOS.
62605216|NCT04447495||SARS-CoV-2 positive|We will enroll patients within a larger clinical validation study of the iAMP® test against the gold standard (the CDC-recommended test) until we have prospectively collected a total of 100 positive cases.
62605217|NCT04447495||Controls|Current SARS-CoV-2 positivity in the region is approximately 20%, therefore, approximately 400 negative control samples will be needed.
62605218|NCT02538692|EXPERIMENTAL|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a classic formula of traditional Chinese medicine for IBS-D. It is composed of 4 herbs: Radix Paeoniae Alba, Ledebouriella seseloides Wolff, pericarpium citri reticulatae and Rhizoma Atractylodis Macrocephalae. The granules will be administrated for thrice daily at a dose of 15g per time. The total duration of treatment is 4 weeks.
62605219|NCT02538692|PLACEBO_COMPARATOR|Placebo|It is a placebo that made with similar appearance and taste as the Tong-Xie-Yao-Fang granules.
62605220|NCT06266156||Firts Dental Visit|Dental anxiety level, heart rate and oxygen saturation of participants in first dental visit.
62605221|NCT06266156||Second dental visit|Dental anxiety level, heart rate and oxygen saturation of participants in second dental visit.
62605222|NCT04497350|EXPERIMENTAL|Transcranial Magnetic Stimulation|All patients are required to have an advanced MRI of the brain including a structural T1, volume measurements of various brain regions, ASL, and BOLD sequences. Patients will also undergo an in-scanner task designed to activate key neurofunctional regions of interest.
62605223|NCT04497350|EXPERIMENTAL|Theta Burst Stimulation|All patients are required to have an advanced MRI of the brain including a structural T1, volume measurements of various brain regions, ASL, and BOLD sequences. Patients will also undergo an in-scanner task designed to activate key neurofunctional regions of interest.
62605224|NCT04978428|EXPERIMENTAL|Epidiolex|Epidiolex (2.5 mg/kg twice daily for one week) followed by Epidiolex (5mg/kg twice daily for two weeks)
62605225|NCT06496022||cohort|Patients will be divided into 2 groups: pre-frailty and frailty using Frail Scale.
62827900|NCT06473740|EXPERIMENTAL|Observation group|Best endovascular treatment + Introduction Neovasculgen (International nonproprietary or group name: deoxyribonucleic acid plasmid supercoiled pCMV-VEGF165). Dosage form: Lyophilisate for the preparation of a solution for intramuscular administration in the form of a white powder. Composition for 1 bottle: Active ingredient: supercoiled plasmid deoxyribonucleic acid pCMV-VEGF165 1.2 mg. Excipients: dextrose monohydrate - 60.0 mg, sodium hydrogen phosphate dodecahydrate - 3.94 mg, sodium dihydrogen phosphate dihydrate - 0.16 mg. Description: White lyophilisate. Administer 1 bottle diluted in 20-50 ml of saline on days 7 and 21 after endovascular intervention intramuscularly along the affected vessel.
62827901|NCT06473740|NO_INTERVENTION|Standart of Care|Arterial stenting with stent grafts or balloon angioplasty
62827902|NCT01547923|EXPERIMENTAL|A : pre-therapeutic screening for DPD deficiency|Prior to treatment by fluoropyrimidines,a DPD deficiency is identified by a joint phenotypic-pharmacogenetic approach.
62827903|NCT01547923|OTHER|B : no pretherapeutic research of DPD deficiency|For patients included in this arm, a blood sample will be taken prior to treatment by fluoropyrimidines but not analysed. If grade 3 or 4 toxicity levels are encountered during treatment, DPD deficiency will be detected.
62827904|NCT03823521|EXPERIMENTAL|Cardioplexol™- Cardioplegia Solution|Cardioplexol™ will be used as cardioplegic solution in cardiac surgery
62827905|NCT06394050||Breast cancer patients after neoadjuvant treatment|
62827906|NCT04030143|EXPERIMENTAL|Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder|Participants with schizophrenia or bipolar I disorder received aripiprazole 2 month (2M) long-acting injection (LAI) 960 milligrams (mg) for a total of 4 injections administered every 56 days (± 2 days) over the course of 32 weeks.
62827907|NCT04030143|EXPERIMENTAL|Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder|Participants with schizophrenia or bipolar I disorder received aripiprazole IM 400 mg, for a total of 8 injections administered every 28 days (± 2 days) over the course of 32 weeks.
62827908|NCT04069234|EXPERIMENTAL|Ticagrelor|ticagrelor 60mg BID for 30 Days and ASA 75 - 150 mg once daily
62827909|NCT04069234|ACTIVE_COMPARATOR|Clopidogrel|clopidogrel 75mg OD for 30 Days and ASA 75 - 150 mg once daily
62827910|NCT02949336||Group 1: Traditional UKA|Patients with a traditional Medial Unicompartmental Knee Arthroplasty, SIGMA® High Performance Partial Knee System (functional ACL and tibial posterior slope matching the native bone) will undergo observational use of fluoroscopy to analyze joint kinematics
62827911|NCT02949336||Group 2: ACL deficient UKA|Patients with the same medial UKA implant (SIGMA® High Performance Partial Knee System) in an ACL deficient knee, where the UKA was implanted at a 50% reduced tibial posterior slope relative to the native knee will undergo observational use of fluoroscopy to analyze joint kinematics.
62438165|NCT02201433||medical staff and member of an association|"members of medical staff and member of an association of parents of premature infants.~This cohort is necessary to build protocol interview for part 2 of the study"
62605226|NCT06620250|EXPERIMENTAL|Digital Prevention and control of myopia|"two articles per month were sent to the parent/primary caregiver for acceptance of the intervention, and one month after the intervention began, anExpert said video intervention was added, at the beginning of each month, a video was posted for them to learn; three months after the start of the intervention, the wechat message intervention was added, and relevant knowledge about myopia prevention and control was sent to the wechat group every Tuesday morning; nine months after the start of the intervention, increase the text message intervention, send text messages every Friday evening to remind children of the weekend outdoor activities. In addition, live broadcasts will be held in March September and June 6 to answer parents' questions and concerns."
62605227|NCT06620250|NO_INTERVENTION|Control Group|No intervention of any kind
62605228|NCT05864053|ACTIVE_COMPARATOR|Ketamine|Ketamine 0.5mg/kg 45 minute infusion x 1
62827912|NCT05469386|PLACEBO_COMPARATOR|Placebo|Placebo capsule administered in the morning
62827913|NCT05469386|EXPERIMENTAL|Methylphenidate ER (.3 mg/kg dose)|Methylphenidate ER (.3 mg/kg dose)administered in the morning
62827914|NCT05469386|ACTIVE_COMPARATOR|General Classroom|General classroom procedures
62827915|NCT05469386|EXPERIMENTAL|Positive Behavior Support Classroom|Positive Behavior Support Classroom procedures
62827916|NCT05469386|EXPERIMENTAL|Academic accommodations|Academic accommodations are used during seat work and quiz
62827917|NCT01801163|EXPERIMENTAL|Sorafenib plus Stereotactic Radiotherapy|Single agent Sorafenib x 2 weeks followed by Stereotactic Radiotherapy, then Sorafenib until disease progression.
62605229|NCT05864053|EXPERIMENTAL|(2R,6R)-hydroxynorketamine|(2R,6R)-hydroxynorketamine 0.5mg/kg 45 minute infusion x 1
62605230|NCT05864053|PLACEBO_COMPARATOR|Saline|Saline 45 minute infusion x 1
62605231|NCT05479591||Participants with type 2 diabetes (T2D)|Participants with T2D previously treated with premix insulin for at least 12 weeks (3 months) based on local clinical guidelines will initiate treatment with IDegLira at the treating physician's discretion according to the approved IDegLira label in Croatia.
62248124|NCT04562987|EXPERIMENTAL|Exercise (tele-coaching calls & smartphone app)|Tele-coaching calls for Exercise participants will be based in social cognitive theory to encourage behavior adoption and goal setting focused on engaging in 30 minutes of moderate-intensity physical activity per day (in 10+ minute bouts). Smartphone app features include activity monitoring that visualizes progress toward Exercise-based goals and goal achievement badges specific to Exercise.
62248125|NCT04562987|EXPERIMENTAL|Combo (Move+Exercise)|Includes tele-coaching that encourages behavior adoption and goal setting focused on reducing prolonged sitting and engaging in 30+ minutes of physical activity per day. Participants are able to visualize progress toward Move and Exercise goals and are eligible to receive achievement badges for Move and Exercise.
62827918|NCT00664443||Potential cardiac arrest calls|All 9-1-1 calls for unconscious patients will be included over the timeframe January 2008 and October 2009 in the participating communities to determine cardiac arrest diagnostic accuracy by 9-1-1 call takers
62827919|NCT02124369|OTHER|Abraxane & gemictabine|Abraxane, IV, 125mg/m2 and gemcitabine, IV, 1000mg/m2, on days 1,8 \& 15 per 28 day cycle, up to a maximum of 6 cycles.
62827920|NCT01843621|EXPERIMENTAL|Total vaccinated|The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003
62827921|NCT05413759|EXPERIMENTAL|Pharmaceutical care in multiprofessional collaboration|Medication reconciliation (hospital admission and discharge), disease-modifying antirheumatic drugs (DMARD) treatment information interview and 2 motivational interviews (after discharge, at 2 months and 6 months after the inclusion).
62827922|NCT05413759|NO_INTERVENTION|Control group (usual practices group)|Usual follow-up during the 12-month follow-up.
62605232|NCT01116713|ACTIVE_COMPARATOR|Dexamethasone group|This group of patients received intravenous dexamethasone (8 mg) 60 minutes before skin incision.
62605233|NCT01116713|PLACEBO_COMPARATOR|Placebo group|Patients of these group received homologated placebo 60 minutes before skin incision.
62827923|NCT01001221|EXPERIMENTAL|Cabazitaxel + gemcitabine|"Cabazitaxel and gemcitabine on Day 1 then gemcitabine alone on Day 8 every 3 weeks until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision.~On Day 1, cabazitaxel was given either first followed by gemcitabine (part 1a) or after gemcitabine with 1 hour gap between the two infusions (part 1b). Required premedication with antihistamine, corticosteroid and H2 antagonist was administered intravenously 30 minutes before each dose of cabazitaxel."
62827924|NCT05710224|EXPERIMENTAL|V181|Participants will receive a single 0.5 mL subcutaneous (SC) injection of V181 on Day 1.
62827925|NCT05710224|EXPERIMENTAL|Butantan-DV|Participants will receive a single 0.5 mL SC injection of Butantan-DV on Day 1.
62827926|NCT03056092|OTHER|AMD/RVO/DME|Patients presenting to St. Michael's Hospital retina clinic with neovascular age related macular degeneration, macular edema secondary to RVO and diabetic macular edema treated with intravitreal ranibizumab in a variable dosing regimen.
62827927|NCT03479255|EXPERIMENTAL|Smartphone-enabled structured exercise therapy (SE-SET)|"This arm involves a smartphone app Movn - rehabilitation platform based on MULTIFIT, a case-management system for secondary prevention and patient surveillance after acute MI.~The key features of the smartphone app include daily reminders to exercise, virtual diary for patients to enter data on exercise sessions, two-way secure messaging with the health coach, and educational videos on heart and vascular health."
62827928|NCT03479255|ACTIVE_COMPARATOR|Standard exercise therapy|Self-directed, unsupervised exercise as prescribed by the patient's physician.
62827929|NCT02991222|EXPERIMENTAL|SPARC001 type I|Treatment type I
62827930|NCT02991222|EXPERIMENTAL|SPARC001 type II|Treatment type II
62827931|NCT02991222|ACTIVE_COMPARATOR|Reference001 type I|Treatment type I
62605234|NCT03873441|EXPERIMENTAL|Computer Games-Aided Balance Training Group|The participants in CGR group will be asked to sit or stand (as per the screening result) on fixed \& compliant surfaces; to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects using bi-manual grip gradually progressing to head rotations (mouse mounted on a cap worn by participant); finally using trunk movements as a part of experimental therapy protocol. While performing CGR; children will be standing on a thin pressure mat (placed over fixed or compliant surface). This will allow us to record the information of COP displacement \[body sway\] while CGR intervention implementation. This information will be used to quantify therapy dosage. The CGR Group will receive a 45-60 minutes of session thrice a week for 12 weeks.
62827932|NCT02991222|ACTIVE_COMPARATOR|Reference type II|Treatment type II
62827933|NCT00620451|EXPERIMENTAL|Larazotide acetate 4 mg|larazotide acetate capsules 4 mg TID
62827934|NCT00620451|EXPERIMENTAL|Larazotide acetate 8 mg|Larazotide acetate capsules 8 mg TID
62248126|NCT05712135||supine|The patient group whose cuff pressure was measured in the supine position in neurosurgery
62605235|NCT03873441|ACTIVE_COMPARATOR|Conventional Balance Training Group|The control group will be receiving the conventional balance training for static and dynamic balance function improvement. The therapy will be provided in sitting or standing (as per the screening result) in a graded manner progressing from fixed surfaces to movable compliant surfaces. The Conventional Balance Training Group will receive a 45-60 minutes of session thrice a week for 12 weeks.
62827935|NCT00620451|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62605236|NCT06071182|EXPERIMENTAL|Task-oriented therapy|Traditional physiotherapy for 30 minutes a day, twice a week for 4 weeks (Passive upper extremity Normal Joint Movements, 3-way and 1 set of 10 repetitions passive stretches for the shoulder (bilateral), 2-way, 1 set of 10 repetitions passive stretches at the elbow level) + 2 times a week a day Fruit ninja game on tablet in 20 minutes
62045821|NCT00033696|EXPERIMENTAL|chemotherapy + radiation therapy|"Induction therapy: Patients receive paclitaxel IV over 3 hours on days 1 and 22, oral topotecan on days 2-4 and 23-25, and oral etoposide on days 5-7 and 26-28. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on days 8 and 29 and continuing until blood counts recover.~Consolidation therapy: Patients receive carboplatin IV over 1 hour on days 43, 64, and 85 and etoposide IV over 1 hour on days 43-45, 64-66, and 85-87. Patients undergo radiotherapy daily 5 days per week beginning on day 43 and continuing for 6-7 weeks.~Patients with rapid disease progression discontinue study therapy.~Patients are followed at least every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years."
62045822|NCT04018326||Compliant patients|The compliant patient was defined as a patient who did not miss any follow-up visit until the end of the study period.
62045823|NCT04018326||Loss to follow-up (LTFU)|LTFU was defined as missing any follow-up visit for any interval exceeding 6 months provided that patients eventually resumed care before the end of the study period (time zero was defined as the date of the missed follow-up visit).
62045824|NCT04844580|PLACEBO_COMPARATOR|Standard Treatment + Placebo|Standard medical treatment, as deemed appropriate by physicians, is going to be according to the Turkish Republic COVID-19 (SARS-CoV-2 INFECTION) ADULT PATIENT TREATMENT GUIDELINES published by the Ministry of Health, General Directorate of Public Health. The management of all additional complications and / or symptoms that develop in patients will be managed in the same way as specified in these guidelines. If these guidelines are changed by the Turkish Republic Ministry of Health General Directorate of Public Health, a protocol amendment will be planned. The necessary changes within the scope of urgent security measures will be reflected in the standard treatment in accordance with the necessary regulations.
62605237|NCT06071182|SHAM_COMPARATOR|Sham-controlled|Same time traditional therapy + 5 minutes sham intervention
62605238|NCT03126565|EXPERIMENTAL|Group A|This group will include a cohort of 185 participants who will be monitored by the CareSage risk assessment platform. Tailored interventions, using a Stepped-Care Approach, will be targeted to patients flagged as high risk for emergency transport during the 6-month intervention period.
62605239|NCT03126565|NO_INTERVENTION|Group B|This group will include a cohort of 185 participants where study staff will not see if patients are flagged by the CareSage risk assessment platform as being at high or low risk for emergency transport during the 6-month intervention period. Patients will continue to receive care as usual.
62827936|NCT03706755|ACTIVE_COMPARATOR|A|group A: will receive 1 mcg/Kg of Norepinephrine intravenously
62827937|NCT03706755|ACTIVE_COMPARATOR|B|group B: will receive 0.5 mcg/Kg of Norepinephrine intravenously
62827938|NCT04475367|EXPERIMENTAL|hypertensive patients using HyperCrossApp|"Interdisciplinary health care~+ HyperCross App"
62827939|NCT04475367|ACTIVE_COMPARATOR|hypertensive patients without using HyperCrossApp|Interdisciplinary health care
62605240|NCT03134716||Clinical follow-up|Clinical follow-up of MS-patients for 5 years. PET imaging data with PK11195 and TMSX only in baseline and with UCB-J at 5 years
62605241|NCT03134716||Healthy controls|comparison of healthy controls' and MS patients' PET imaging data with PK11195 and TMSX only in baseline and with UCB-J at 5 years
62605242|NCT00508937|ACTIVE_COMPARATOR|1|
62827940|NCT01451112|EXPERIMENTAL|Treated|
62827941|NCT06577155|ACTIVE_COMPARATOR|E|Spinal levobupivacaine
62827942|NCT06577155|ACTIVE_COMPARATOR|N|Spinal levobupivacaine plus nalbuphine
62248127|NCT05712135||prone|The patient group whose cuff pressure was measured in the prone position in neurosurgery
62248128|NCT05712135||semi-fowler|The patient group whose cuff pressure was measured in the semi-fowler position in neurosurgery
62248129|NCT04347850||Patient with Covid-19 confirmed (middle form)|Covid-19 confirmed: middle form
62248130|NCT04347850||Patient with Covid-19 confirmed (severe form)|Covid-19 confirmed : severe form
62248131|NCT04347850||Patient with Covid-19 not confirmed|Covid-19 not confirmed
62605243|NCT00508937|EXPERIMENTAL|2|
62605244|NCT00508937|EXPERIMENTAL|3|
62827943|NCT03299166|EXPERIMENTAL|Troriluzole|
62827944|NCT03299166|PLACEBO_COMPARATOR|Placebo|
62827945|NCT06602245||Hemoperfusion and antibiotic tratment groups|"The trial will be conducted in one group of patients. Patients who are undergoing antibiotic therapy and hemoperfusion will be included in the study.~Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity. All patients included undergo a single extracorporeal blood purification for 4-12 hours in the form of isolated hemoperfusion using the Efferon LPS device in combination with antibiotic therapy.~The hemoperfusion must be started no later than 30 minutes after the end of the antibacterial drug administration, otherwise the patient will be excluded from the study.~Antibacterial drugs are administered by infusion according to the instructions for use:~* Meropenem within 30 minutes~* Vancomycin within 60 minutes~* Linezolid within 60 minutes."
62605245|NCT00508937|EXPERIMENTAL|4|
62605246|NCT00508937|EXPERIMENTAL|5|
62605247|NCT03330067|SHAM_COMPARATOR|Cold and dry CO2 pneumoperitoneum|Pneumoperitoneum is created by insufflation of standard cold (19-21°C) and nonhumidified (0%) CO2 directly from a standard CO2 tank or wall source.
62605248|NCT03330067|EXPERIMENTAL|Warm and humidified CO2 pneumoperitoneum|The humidification and warming device to be used is the Insuflow Synergy Port (Lexion Company, FDA approved) which is a specialized 5 mm port that delivers warmed (95° F) and humidified (95% relative humidity) CO2, the source of which is a standard CO2 tank or wall source.
62605249|NCT04236167|NO_INTERVENTION|Control half of scar|one half of the scar will receive standard scar treatment with topical products and pressure garments, but no ablative fractional CO2 laser
62827946|NCT02835248||Primary|Older adult study participants will be recruited from the cohort of participants in the STRIDE Study at the Boston trial site (http://www.stride-study.org/).
62605250|NCT04236167|EXPERIMENTAL|Laser treatment half of scar|The other half of the scar will receive standard scar treatment with topical products and pressure garments and, in addition, will receive ablative fractional CO2 laser treatment
62605251|NCT01139099|OTHER|Arm|There is no arm in this study.
62605252|NCT03079037||Stimulation|Traditional deep brain stimulation
62605253|NCT02167048|EXPERIMENTAL|Normal-dose Psychostimulant, Low-dose|Normal-dose: Dose participants are currently taking as part of their prescription (on more than or equals to 20 mg/day of Psychostimulants) Low-dose: Half the normal dose
62605254|NCT02167048|ACTIVE_COMPARATOR|Low-dose Psychostimulants, Normal-dose|Normal-dose: Dose participants are currently taking as part of their prescription (on more than or equals to 20 mg/day of Psychostimulants) Low-dose: Half the normal dose
62605255|NCT02167048|NO_INTERVENTION|No intervention, No intervention|This arm is completely no intervention, and is ONLY for healthy volunteers. We are testing healthy volunteers of the same age to give us an estimate of order effects to help us correct for better performance in the 2nd session due simply to taking the same tests twice (note: the tests are Version A and B).
62605256|NCT04989972|EXPERIMENTAL|Intervention arm|participants will take the active intervention PSIL428
62045825|NCT04844580|EXPERIMENTAL|Standard Treatment + Inhaled Aviptadil|In addition to the standard medical treatment mentioned above, patients randomized to this arm will be given Inhaled Aviptadil 2 times a day, 30 minutes apart. Aviptadil treatment is aimed to be a minimum of 7 days and a maximum of 14 days. Aviptadil will be discontinued in patients who do not heal after 14 days. The dose of inhaled Aviptadil was determined by evaluating the results of the Phase 1 and Phase 2 studies.
62605257|NCT04989972|EXPERIMENTAL|placebo arm|participants will take the intervention 1 mg Oyster mushrooms
62605258|NCT04989972|EXPERIMENTAL|open label|all participants will take the active intervention PSIL428
62605259|NCT04546113|ACTIVE_COMPARATOR|Paravertebral Block|If the patient is randomized to group Paravertebral Block, the anesthesiologist performs TPVB before induction of general anesthesia. The patient is positioned in lateral décubitus position. The anesthetist performs the bilateral paravertebral block with ultrasound identification of the paravertebral space at the T4-T5 level. Slow injection of 0.3 to 0.35 ml / kg of ropivacaine on each side (diluted to 3.75 mg / ml = dilution in a 20 ml syringe with 10 ml of ropivacaine 7.5 mg / ml and 10 ml of NaCl 0.9%) after aspiration test.
62605260|NCT04546113|EXPERIMENTAL|Erector Spinae Plane Block|"If the patient is randomized to group Erector Spinae Plane Block, the anesthesiologist performs the ESPb block before induction of general anesthesia. The patient is positioned in a right lateral decubitus position. The anesthesiologist performs the erector block of the spine ESP with ultrasound identification at the T4-T5 level (identify the 1st rib on ultrasound then the space T4 to T5). Slow injection of 20 ml of ropivacaine on each side (diluted to 3.75 mg / ml = dilution in a 20 ml syringe with 10 ml of ropivacaine 7.5 mg / ml and 10 ml of 0.9% NaCl) after aspiration test.~The patient is then turned in left lateral decubitus position and the contralateral block is performed according to the same procedure."
62605261|NCT03801824|ACTIVE_COMPARATOR|Standard Nutrition Therapy|Subjects in this group receive a standard nutrition therapy based on local guidelines that is usually high in fibre with moderate to high glycemic index food
62605262|NCT03801824|EXPERIMENTAL|Low Glycemic Index|Subjects in this group receive intervention on low glycemic index foods
62605263|NCT00757029|OTHER|open label|
62605264|NCT05437588|OTHER|MDD Participant|Participants with MDD will return at six weeks for a second blood draw and assessments
62605265|NCT04101032|EXPERIMENTAL|eBEfree|eBEfree is a ICT-delivery version of BEfree - eBEfree that comprises 12 online sessions, based on mindfulness,values and compassion components for women with Binge Eating.
62605266|NCT04101032|NO_INTERVENTION|Waiting List|Participants will remain in a waiting list. After 12 weeks, they will be offered the same intervention.
62605267|NCT00503997|EXPERIMENTAL|drug therapy|
62605268|NCT03944733|ACTIVE_COMPARATOR|Iron Intervention|IDA mothers will receive a 65 mg of iron (ferrous sulfate) daily for 4.5 months in the postpartum period (6 weeks to 6 months post delivery).
62605269|NCT03944733|PLACEBO_COMPARATOR|Placebo|IS mothers will receive 600 mg of gelatin daily for 4.5 months in the postpartum period (6 weeks to 6 months post delivery).
62605270|NCT04743323||Study Participants|"Participants will be recruited whilst hospitalized for an acute episode of pancreatitis. They will be interviewed about their health behaviors including alcohol consumption during the two weeks immediately preceding the onset of pancreatitis. Blood and urine bio-specimens will be collected at this time.~Following discharge from hospital (5-26 weeks) the same participant will be interviewed again during an asymptomatic control period and blood and urine bio-specimens will be collected. This study will compare the participant's exposure immediately preceding the onset of pancreatitis to that of an asymptomatic control period from the same participant.~Participants will be followed for 24 months via review of their medical records every 6 months to assess any recurrent disease or progression of disease."
62827947|NCT03629977||early RRT|A patient where initiation of RRT is started without the absolute indications
62045826|NCT00990080|ACTIVE_COMPARATOR|Group 1|Pediacel® at 2 and 4 months of age followed by Infanrix™-IPV/Hib at 6 months.
62045827|NCT00990080|ACTIVE_COMPARATOR|Group 2|Infanrix™-IPV/Hib at 2 months of age followed by Pediacel® at 4 and 6 months.
62045828|NCT05979753|ACTIVE_COMPARATOR|EFFECTS OF HIGH INTENSITY INTERVAL TRAINING IN SPRINTERS|The aim of this is study is to assess the effect of High Intensity Interval Training on Sprinter's speed and explosive strength.
62438166|NCT02201433||fathers|fathers of preterm newborns
62605271|NCT02405975|NO_INTERVENTION|Control|These participants will not receive the educational intervention
62605272|NCT02405975|EXPERIMENTAL|Intervention|"These participants will receive the online educational intervention SCRIPT"
62605273|NCT04402281||suPAR algoritm control|Control arm (Meilahti hospital): Samples are collected and suPAR measured but no algorithm is implemented.
62827948|NCT03629977||late RRT|"CRRT based on absolute indications.~Absolute indications:~1. hyperkalemia (serum potassium≥6 mEq/L),~2. severe acidosis (pH≤7.15),~3. plasma urea\>36 mmol/L (equals BUN=100.8 mg/dl),~4. oliguria or anuria (urine output\<0.3 ml/kg per hour for ≥24 hours or anuria for ≥12 hours), and~5. fluid overload with pulmonary edema as defined by the presence of all the following factors: (a) \>10% fluid accumulation (cumulative fluid balance/baseline weight\>10%), (b) oliguria (urine output\<0.5 ml/kg per hour for ≥12 hours), and (c) severely impaired oxygenation (PaO2/FiO2\<200 indicated by respiratory Sequential Organ Failure Assessment \[SOFA\] score≥3)"
62605274|NCT04402281||suPAR algoritm intervention|"Intervention arm (Jorvi Hospital).~According the algorithm when admitting a patient with suPAR below 3 ng/ml, physician should answer the following question~Are you sure it is the right decision to admit this patient? Please discuss this with a senior physician.~If discharging a patient with suPAR above 6 ng/ml, physician should answer the following question~Are you sure it is the right decision to discharge this patient? Please discuss this with a senior physician."
62827949|NCT03629977||never RRT|RRT is never started, matched against early RRT group.
62827950|NCT00696072|ACTIVE_COMPARATOR|A1|
62827951|NCT00696072|ACTIVE_COMPARATOR|A2|
62827952|NCT02017405|OTHER|5g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 5.0 g total daily dose of SBI on Day 1 followed by 5.0 g Placebo on Day 2 or a 5.0 g total daily dose of Placebo on Day 1 followed by 5.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 2.5g SBI will be taken two times a day for 14 days during the open-label phase."
62827953|NCT02017405|OTHER|10g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 10.0 g total daily dose of SBI on Day 1 followed by 10.0 g Placebo on Day 2 or a 10.0 g total daily dose of Placebo on Day 1 followed by 10.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 5.0 g SBI will taken two times a day for 14 days during the open-label phase."
62827954|NCT02017405|OTHER|20g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 20.0 g total daily dose of SBI on Day 1 followed by 20.0 g Placebo on Day 2 or a 20.0 g total daily dose of Placebo on Day 1 followed by 20.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 20.0 g SBI will be taken two times a day for 14 days during the open-label phase."
62827955|NCT02017405|OTHER|Matching Placebo|Placebo will be taken either on Day 1 or on Day 2 based on the randomization during the double-blind, crossover phase.
62827956|NCT05855798|ACTIVE_COMPARATOR|control group|Erector spinae plane block with 20 mL 0.5% bupivacaine
62827957|NCT05855798|ACTIVE_COMPARATOR|magnesium group|Erector spinae plane block with 20 mL 0.5% bupivacaine+150 mg magnesium sulphate
62827958|NCT05855798|ACTIVE_COMPARATOR|ketamine group|Erector spinae plane block with 20 mL 0.5% bupivacaine+2 mg/kg ketamine
62605275|NCT05733026||1|Breast cancer patients who developed cardiotoxic side effects in response to Doxorubicin treatment
62605276|NCT05733026||2|Breast cancer patients who did not develope cardiotoxic side effects in response to Doxorubicin treatment
62605277|NCT02906033|EXPERIMENTAL|Intervention group|New perioperative practice model.
62827959|NCT00004563|EXPERIMENTAL|Cylophosphamide|Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
62827960|NCT00004563|PLACEBO_COMPARATOR|Placebo|Matching gel caps at a dose of 25 mg
62827961|NCT03960749|EXPERIMENTAL|Sprotte 25G needle, stylet reinserted|
62827962|NCT03960749|EXPERIMENTAL|Sprotte 25G needle, stylet not reinserted|
62827963|NCT03960749|EXPERIMENTAL|Sprotte 22G needle, stylet reinserted|
62827964|NCT03960749|EXPERIMENTAL|Sprotte 22G needle, stylet not reinserted|
62827965|NCT03960749|EXPERIMENTAL|Spinocan 25G needle, stylet reinserted|
62827966|NCT03960749|EXPERIMENTAL|Spinocan 25G needle, stylet not reinserted|
62827967|NCT06603025|EXPERIMENTAL|Intervention group|Preoperative intervention group patients will chew sugarless gum for at least 30 minutes 30-60 minutes before surgery. The gum will be removed before going to the operating room.
62827968|NCT06603025|NO_INTERVENTION|Control group|standard care (no chewing gum)
62605278|NCT02906033|NO_INTERVENTION|Control group|Traditional practice model.
62605279|NCT06328504|EXPERIMENTAL|Cashew Immunotherapy|Children with cashew allergy receiving OIT (OIT-oral immunotherapy).
62827969|NCT02799446|EXPERIMENTAL|Reslizumab|Reslizumab will be administered intravenously every 4 weeks at a dose of 3mg/kg.
62045829|NCT05979753|ACTIVE_COMPARATOR|EFFECTS OF HIGH INTENSITY INTERVAL TRAINING ON SPEED AND EXPLOSIVE STRENGTH|The aim of this is study is to assess the effect of High Intensity Interval Training on Sprinter's speed and explosive strength.
62045830|NCT01718327|EXPERIMENTAL|open label, single arm|single arm: sunitinib until progresion or unacceptable toxicity
62248132|NCT04026061|EXPERIMENTAL|FMA group|Receiving the FMA training and tool
62248133|NCT04026061|PLACEBO_COMPARATOR|control group|Receiving a simple tablet training and some websites
62248134|NCT01613495|PLACEBO_COMPARATOR|Placebo|Normal Saline
62605280|NCT06328504|NO_INTERVENTION|Cashew avoidance|Children with cashew allergy not receiving OIT (OIT-oral immunotherapy).
62605281|NCT05362240|EXPERIMENTAL|Four corner fusion|Scaphoid excision and fusion between lunate , capitate , hamate and triquetrum using k.wires
62827970|NCT02799446|PLACEBO_COMPARATOR|Placebo|Matching placebo.
62827971|NCT04123470|EXPERIMENTAL|Treatment|Delolimogene mupadenorepvec plus atezolizumab
62827972|NCT04207814|EXPERIMENTAL|Cases|
62827973|NCT03745612|EXPERIMENTAL|TRF|Time restricted feeding
62827974|NCT03745612|ACTIVE_COMPARATOR|CER|continuous energy restriction
62827975|NCT06593782|EXPERIMENTAL|HSK21542-A|
62827976|NCT06593782|EXPERIMENTAL|HSK21542-B|
62827977|NCT06593782|ACTIVE_COMPARATOR|Dolasetron|
62827978|NCT06597084|EXPERIMENTAL|Group A|ESL 800 mg
62827979|NCT06597084|PLACEBO_COMPARATOR|Group B|Placebo
62827980|NCT04423666|EXPERIMENTAL|Intervention|"Will receive:~1. education~2. a wireless pedometer with set up~3. nurse coaching via text message, email or telephone based on participant preference and at frequency determined by the participant"
62827981|NCT04423666|EXPERIMENTAL|Control|"Will receive:~1. education~2. a wireless pedometer with set up"
62605282|NCT05362240|EXPERIMENTAL|Three corner fusion without triquetrum excision|Scaphoid excision with fusion between lunate , capitate and hamate with preservation of triquetrum
62605283|NCT00940680|EXPERIMENTAL|amlodipine/losartan 5/100mg|
62605284|NCT00940680|ACTIVE_COMPARATOR|losartan 100mg|
62827982|NCT00736021|EXPERIMENTAL|A|Single arm (open label study): Provide twelve weeks of treatment with high does (40 mg daily) of escitalopram to trauma survivors with chronic PTSD.
62827983|NCT06602310|EXPERIMENTAL|Preanestes@s2.0: web-based non-face-to-face preoperative assessment. Telematic group.|Participants will be leaded through preoperative period on a web based application. Participants will be addressed to either virtual or telephone POA on the basis of the information registered in the web based preoperative questionnaire that the application incorporates. Virtual assessment will be performed by evaluating both the filled web based questionnaire together with participants´ electronic medical records. Telephone assessment will also incorporate a telephone call for further clarifications.
62827984|NCT06602310|NO_INTERVENTION|Traditional face-to-face preoperative assessment|Participants will be leaded through preoperative period following traditional institutional standards of care. Face to face assessment will be performed in the traditional way by means of an interview with the participant together with the consultation of participant´s previous electronic records.
62827985|NCT05132556|EXPERIMENTAL|Nitrate-rich beetroot juice (~12.8 mmol)|Participants will have blood pressure, arterial stiffness, and blood samples (from venipuncture) assessed before and after the nitrate-rich beetroot juice (\~12.8 mmol).
62827986|NCT05132556|PLACEBO_COMPARATOR|Beetroot juice with nitrate removed|Participants will have blood pressure, arterial stiffness, and blood samples (from venipuncture) assessed before and after the beetroot juice with nitrate removed.
62827987|NCT03852056|PLACEBO_COMPARATOR|MFP Fluoride toothpaste|Commercially available, monofluorophosphate (MFP) toothpaste. Fluoride level is 0.76%
62605285|NCT03567512|EXPERIMENTAL|Intervention group|The Intervention administered to this group will focus on Quit Smoking of parental and household smokers and Reduction of Secondhand Smoke Exposure among the Children.
62827988|NCT03852056|EXPERIMENTAL|Stannous Fluoride Toothpaste|New toothpaste containing 0.454% stannous fluoride.
62827989|NCT06599788|ACTIVE_COMPARATOR|Self-paced work first|The order of the interventions is self-paced work first, followed by the other interventions in a permuted block randomization design.
62827990|NCT06599788|EXPERIMENTAL|Reduced-pace work first|The order of the interventions is reduced-pace work first, followed by the other interventions in a permuted block randomization design.
62827991|NCT06599788|EXPERIMENTAL|Increase-paced work first|The order of the interventions is increased-pace work first, followed by the other interventions in a permuted block randomization design.
62827992|NCT06599788|EXPERIMENTAL|Additional rest breaks first|The order of the interventions is additional rest breaks first, followed by the other interventions in a permuted block randomization design.
62827993|NCT02807402||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, and was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
62827994|NCT02085967|EXPERIMENTAL|E2006 Part A|E2006 10-mg tablets alone and in combination with rifampin 600 mg or itraconazole 200 mg
62827995|NCT02085967|EXPERIMENTAL|E2006 Part B|E2006 10-mg tablets alone and in combination with midazolam 2 mg plus bupropion 75 mg
62827996|NCT03013231||s/p ACLR|Patients having undergone ACL Reconstruction Surgery with goal of returning to sport. 6 months post-op, patients will complete the BRS survey as a method of evaluating resilience.
62605286|NCT03567512|PLACEBO_COMPARATOR|Control group|The placebo intervention will be administered in this group.
62605287|NCT05062252|EXPERIMENTAL|Mirror group|Mirror Medacta Shoulder System
62827997|NCT06595966||experimental group|The results of CA15-3, CEA, color Doppler ultrasound and other traditional postoperative monitoring examinations for breast cancer, as well as 5ml of peripheral venous blood, were collected on the day of enrollment/the 7th day after adjuvant treatment/the 3rd, 6th, 9th, 12th, 15th, 18th, 21st, 24th, 30th and 36th months after surgery.
62605288|NCT05062252|ACTIVE_COMPARATOR|Historical Control group|Total shoulder arthroplasty system
62605289|NCT06331195|PLACEBO_COMPARATOR|DICA-FH + placebo|Participants allocated into this arm (n= 75) will receive the DICA Br adapted to FH (DICA-FH) plus placebo of both phytosterol and krill oil during 120 days.
62438167|NCT02201433||fathers or médical staff|This cohort is build for data validation. We will include fathers who have experienced this situation. Caregivers of NICU who are not participating in the first part
62605290|NCT06331195|EXPERIMENTAL|DICA-FH + phytosterol|Participants allocated into this arm (n= 75) will receive the DICA Br adapted to FH (DICA-FH) plus 2g/day of phytosterol and placebo of the krill oil during 120 days.
62605291|NCT06331195|EXPERIMENTAL|DICA-HF + krill oil|Participants allocated into this arm (n= 75) will receive the DICA Br adapted to FH (DICA-FH) plus 2g/day of krill oil and placebo of phytosterol during 120 days.
62605292|NCT06331195|EXPERIMENTAL|DICA-HF + phytosterol + krill oil|Participants allocated into this arm (n= 75) will receive the DICA Br adapted to FH (DICA-FH) plus 2g/day of phytosterol and 2g/day of krill oil during 120 days.
62827998|NCT01342861|SHAM_COMPARATOR|Observational period|A first period of follow-up on the 400 patients was designed to survey and evaluate current nutrition administration policy
62827999|NCT01342861|EXPERIMENTAL|Intervention period|The second period of follow-up on the 400 patients was designed to evaluate the impacts of adding milky food to the breakfast and of educating health care professionals on the early detection of undernutrition.
62828000|NCT05625113|EXPERIMENTAL|neuroprosthesis|This is a prospective, monocentric, real-life, feasibility case series, succeeding to the PREHENS-STROKE study, aimed at assessing the feasibility, acceptability, tolerance, efficacy and organizational impact of the use of a gripping neuroprosthesis at home (innovative medical device) in a population of vascular hemiparetic patients. The study consists of an initial phase of inclusion and evaluation (T1 and T2), an intermediate phase (T3 to T9) of learning and use of the gripping neuroprosthesis at home by the patient and a final phase (T10 and T11) of evaluation of the impact of the use of the neuroprosthesis. Each patient is their own control (self-matching).
62828001|NCT03544749|EXPERIMENTAL|Ambu® AuraGain™ group|
62828002|NCT03544749|ACTIVE_COMPARATOR|I-gel group|
62828003|NCT00896077|ACTIVE_COMPARATOR|Subcutaneous|Subcutaneous administration of LSF
62828004|NCT00896077|ACTIVE_COMPARATOR|IV|IV administration arm
62828005|NCT02086578|EXPERIMENTAL|Group 1|Physical examination by MD, optional Breast MRI, Breast-Q© at baseline (after permanent implant exchange, physical exam and Breast-Q© may be done after the initiation of IMRT), 12 ± 2 months and 24 ± 2 months post- IMRT. Total length of the follow-up time will be 24 ± 2 months post-IMRT. A subset of 10 left-sided patients will receive 13N-NH3 PET scans within the radiation simulation session. A CT for coronary calcium scoring and a low-dose CT for attenuation correction will also be obtained at this time. Myocardial blood flow will be measured during rest and at peak stress with 13N-NH3 as a perfusion tracer. A follow-up 13N-NH3 PET study with low-dose CT for attenuation correction will be obtained 12-18 months (± 6 months) post-IMRT.
62828006|NCT02086578|EXPERIMENTAL|Group 2|Physical examination by MD, optional Breast MRI, Breast-Q © at baseline (after permanent implant exchange and after IMRT), 18 ± 2 months and 30 ± 2 months post-IMRT, as these patients will undergo exchange of the temporary expander for the permanent implant approximately 4-8 months following the completion of radiation (at the discretion of the treating plastic surgeon). Total length of the follow-up time will be 30 ± 2 months post-IMRT
62828007|NCT00464633|EXPERIMENTAL|Alvocidib|Cycles with 4-week treatment with alvocidib followed by 2-week rest period for up to a maximum of 6 cycles
62828008|NCT04777331|EXPERIMENTAL|Prasinezumab|"Participants will receive an IV infusion of prasinezumab every 4 weeks (Q4W).~Participants will enter into the optional Open Label Extension (OLE) once the double-blind treatment period has completed."
62828009|NCT04777331|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo as an IV infusion Q4W.
62828010|NCT06587945|EXPERIMENTAL|Nicotinamide Riboside|Oral Nicotinamide Riboside intake from date of presentation: 2g daily for 4 weeks followed by 1g daily for 16 weeks postoperatively
62438168|NCT02175966|EXPERIMENTAL|Arm 1: DCV/ASV/BMS-791325+Sofosbuvir|"Initial Therapy:~Daclatasvir/Asunaprevir/BMS-791325 \[30 mg (as the free base)/200 mg/75 mg (as the free base)\] film coated Fixed Dose Combination tablet twice daily orally for 4 weeks~Sofosbuvir 400 mg tablet once daily orally for 4 weeks"
62828011|NCT06587945|PLACEBO_COMPARATOR|Placebo|
62828012|NCT05122338|PLACEBO_COMPARATOR|Normal saline in transversus abdominis plane block|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side.
62828013|NCT05122338|ACTIVE_COMPARATOR|Ropivacaine in transversus abdominis plane block|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side.
62045831|NCT06295770|EXPERIMENTAL|Obinutuzumab in Treatment of Fibrillary Glomerulonephritis|Patients with biopsy proven fibrillary GN who have \>1 gram/24 hour of proteinuria and eGFR ≥ 20 ml/min/BSA will be treated with Obinutuzumab.
62438169|NCT02175966|EXPERIMENTAL|Arm 2: DCV/ASV/BMS-791325 + Sofosbuvir|"Initial Therapy~Daclatasvir/Asunaprevir/BMS-791325 \[30 mg (as the free base)/200 mg/75 mg (as the free base)\] film coated Fixed Dose Combination tablet twice daily orally for 6 weeks~Sofosbuvir 400 mg tablet once daily orally for 6 weeks"
62438170|NCT02175966|EXPERIMENTAL|Rescue Therapy: Arm 1:DCV/ASV/BMS-791325+RBV±PegIFNα-2a|"Daclatasvir/Asunaprevir/BMS-791325 \[30 mg (as the free base)/200 mg/75 mg (as the free base)\] film coated Fixed Dose Combination tablet twice daily orally for 12 weeks~Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks~With or without Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks"
62438171|NCT02175966|OTHER|Rescue Therapy: Arm 2: Sofosbuvir + RBV + PegIFNα-2a|"Sofosbuvir 400 mg tablet once daily orally for 12 weeks~Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks~Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks"
62828014|NCT05122338|ACTIVE_COMPARATOR|Compound lidocaine in transversus abdominis plane block|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side.
62828015|NCT05122338|ACTIVE_COMPARATOR|Compound lidocaine and esketamine in transversus abdominis plane block|Before the induction of anesthesia, 0.4% compound lidocaine and 0.4mg/kg esketamine are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side.
62438172|NCT00048971||Group 1|Patients undergo collection of blood specimens for polymerase chain reaction and restriction fragment length polymorphism analysis. Genotyping assays are performed to determine UGT1A1 promoter genotyping, UGT1A1 coding polymorphisms, TS promoter polymorphisms, and MTHFR polymorphisms.
62438173|NCT01403883|ACTIVE_COMPARATOR|Standard care|standard care of patient with psychological and enterostomal therapy clinic if necessary
62828016|NCT06591832|EXPERIMENTAL|Experimental Gorup|Routine nursing practice will be performed and Virtual reality based progressive relaxation exercise will be applied
62045832|NCT03357874|EXPERIMENTAL|Clopidogrel group|
62045833|NCT03357874|EXPERIMENTAL|Ticagrelor group|
62045834|NCT05038384||Observational (survey)|Participants complete a survey over 20 minutes.
62605293|NCT02427438|ACTIVE_COMPARATOR|Video Home Program Education|Subjects in this group will complete the same 8 weeks of home program exercises for lumbar instability. The home program exercises will be completed using a video with verbal instruction for guidance of proper technique and repetitions.
62438174|NCT01403883|EXPERIMENTAL|Optimal care|Optimal care of patient with systematic and repeated psychological and enterostomal therapy follow up
62605294|NCT02427438|ACTIVE_COMPARATOR|Handout Home Program Education|Subjects will complete the same 8 weeks of home program exercises for lumbar instability. The home program exercises will be completed using a handout with two dimensional pictures and written instructions for guidance of proper technique and repetitions.
62605295|NCT02300350|EXPERIMENTAL|Treatment A|0.5 mg single-dose oral digoxin administration
62605296|NCT02300350|EXPERIMENTAL|Treatment B|400 mg oral LX4211 qd administration
62605297|NCT02300350|EXPERIMENTAL|Treatment C|0.5 mg single-dose oral digoxin administration + 400 mg oral LX4211 qd administration
62248135|NCT01613495|ACTIVE_COMPARATOR|Octreotide|They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
62438175|NCT05956197||Acute Decompensation of Cirrhosis|Acute Decompensation of Cirrhosis
62438176|NCT06504108|EXPERIMENTAL|calcium silicate-based sealer|Performing full pulpotomy of permanent mandibular and maxillary molar teeth using calcium silicate-based sealer as a capping agent.
62605298|NCT03890627||Thoracic bio-reactance measurement of cardiac output|
62605299|NCT00362713|EXPERIMENTAL|A|3 mg/kg or 10 mg/kg
62605300|NCT02422550||participants undergoing radiation therapy & normal volunteers|Protocol participation will consist of one or more research MRI or CT exams not to exceed 45 minutes.
62828017|NCT06591832|NO_INTERVENTION|Control Group|Routine nursing practice will be performed
62828018|NCT06519942||T2DM DNP+|type 2 diabetes with diabetic neuropathy
62828019|NCT06519942||T2DM DNP-|type 2 diabetes without diabetic neuropathy
62828020|NCT06519942||HC|healthy controls
62438177|NCT06504108|ACTIVE_COMPARATOR|Premixed calcium silicate-based putty|Performing full pulpotomy of permanent mandibular and maxillary molar teeth using premixed calcium silicate-based putty as a capping agent.
62605301|NCT01397539|EXPERIMENTAL|BIIB037|A single dose of BIIB037 by intravenous infusion.
62438178|NCT06504108|EXPERIMENTAL|combination between calcium silicate-based sealer and premixed calcium silicate-based putty|Performing full pulpotomy of permanent mandibular and maxillary molar teeth using a combination of calcium silicate-based sealer and premixed calcium silicate-based putty as a capping agent.
62438179|NCT01206712||T2DM patients treated with LANTUS + MET|T2DM patients treated with LANTUS + Metformin(MET) in their routine antidiabetic therapy. These patients do not receive any study specific medication.
62605302|NCT01397539|PLACEBO_COMPARATOR|Placebo|A single dose of placebo matching BIIB037 by intravenous infusion.
62605303|NCT03978013|EXPERIMENTAL|Pomegranate|
62605304|NCT03978013|ACTIVE_COMPARATOR|Apple|
62605305|NCT03784118|EXPERIMENTAL|Children|Children who are followed up after arterial catheterization for evaluation of complications, using ultrasonography
62605306|NCT01361269|EXPERIMENTAL|Fosmidomycin and clindamycin treatment|All the subject will be given fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
62828021|NCT03865979|ACTIVE_COMPARATOR|Intervention Arm|"Subject CT images assessed by Viz RECRUIT software in real time analysis All subjects in which the Viz RECRUIT software is utilized will be identified per cohort described below per PI confirmation of ENRICH Trial status/Study ID.~Cohort A: Subjects with imaging data Cohort B: Subjects with imaging data and ultimately enrolled as part of the ENRICH Trial"
62605307|NCT00256321|EXPERIMENTAL|Celecoxib/Oxaliplatin/Capecitabine|"Oxaliplatin 70mg/m2 IV on Days 1 and 8. Capecitabine 1000mg/m2 PO BID from Days 1 through 14. Celecoxib 400mg PO BID from Days 1 through 21.~1 Cycle = 21 days."
62605308|NCT03524352|EXPERIMENTAL|fecal microbiota|
62605309|NCT03524352|PLACEBO_COMPARATOR|placebo|
62605310|NCT02466217||1: AID groups|Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus/Antiphospholipid Syndrome, FMF, Cryopyrin-Associated Periodic Syndromes (CAPS)/TNF-receptor Associated Periodic Syndrome (TRAPS), Vasculitis, Uveitis, Myositis, Crohn's Disease, Ulcerative colitis, Type 1 Diabetes
62605311|NCT02466217||2: Control groups|knee arthritis, hip arthritis, muscular dystrophy, healthy subject
62828022|NCT03865979|NO_INTERVENTION|Control Arm|Subjects enrolled as part of the ENRICH Trial prior to Viz RECRUIT software activation
62828023|NCT00307710|EXPERIMENTAL|A: Trivalent Subvirion Vaccine|Group A: Trivalent subvirion vaccine - standard inactivated influenza vaccine by intramuscular injection.
62828024|NCT00307710|EXPERIMENTAL|B: Vaccine 15 μg|Group B: Trivalent rHA0 vaccine 15 μg per rHA0 (total 45 μg rHA0)
62828025|NCT00307710|EXPERIMENTAL|C: Vaccine 45 μg|Group C: Trivalent rHA0 vaccine 45 μg per rHA0 (total 135 μg rHA0)
62828026|NCT00307710|EXPERIMENTAL|D: Vaccine 135 μg|Group D: Trivalent rHA0 vaccine 135 μg per rHA0 (total 405 μg rHA0)
62828027|NCT06594861||Individuals with autoantibodies against Ro/SSA and/or La/SSB|
62828028|NCT06594861||Individuals without autoantibodies against Ro/SSA and/or La/SSB|
62605312|NCT01915654||Study population|The study involves patients operated in the cardiothoracic and cardio-vascular surgery department of Besançon University Hospital between December 2008 and May 2009 (study population) or between December 2007 and May 2008 and between December 2009 and May 2010 (reference population).
62605313|NCT01915654||Reference population|The study involves patients operated in the cardiothoracic and cardio-vascular surgery department of Besançon University Hospital between December 2008 and May 2009 (study population) or between December 2007 and May 2008 and between December 2009 and May 2010 (reference population).
62605314|NCT05864573|EXPERIMENTAL|ZGGS15|
62605315|NCT04108988|EXPERIMENTAL|InvestiDate Intervention|One Night Stan will be adapted as a multiplayer videogame called InvestiDate based on the card game prototype with a focus on a slightly younger age group.
62605316|NCT04108988|PLACEBO_COMPARATOR|Non-Health Related Game|Participants in the non-health related game group will play a multiplayer game unrelated to the content of InvestiDate.
62605317|NCT03165474|ACTIVE_COMPARATOR|Control Arm|In the control group, children and parents will receive didactic health information and resources by email and/or text. The delivery mode of the health messages will be based on based on personal preference.
62605318|NCT03165474|EXPERIMENTAL|Intervention Arm|In the intervention group, children will have access to a web-based interactive nutrition comic and receive health messages from comic characters by email and/or text, while parents will receive weekly newsletters related to nutrition and health by email and/or text.
62605319|NCT06618040|EXPERIMENTAL|Sleep Health Education Program for Caregivers|The BTS-C is an online sleep health education program that is located on a mobile application. The BTS-C utilizes asynchronous avatar-based interactive learning and educational content and videos that are tailored to the caregivers' goals and expectations, paired with targeting messages for change surrounding principles of sleep health practices. The modules will be completed over the course of 6 weeks.
62605320|NCT04491305||Women with pathohistological confirmation|Women aged between 18 and 50 with surgically proven endometriosis.
62605321|NCT02505334|EXPERIMENTAL|Liraglutide 1.8 mg|The total trial duration for the 1.8 mg/day treatment arm will be approximately 67 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week main treatment period, a safety extension period of 26 weeks and a follow-up visit.
62605322|NCT02505334|ACTIVE_COMPARATOR|Liraglutide 0.9 mg|The total trial duration for the 0.9 mg/day treatment arm will be approximately 41 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week treatment period, and a follow-up visit.
62605323|NCT05919914|EXPERIMENTAL|Wrist extensor exercise with Blood Flow Restriction|"Blood flow restriction training. Patients will execute a wrist extension exercise on standing position with the elbow extended. The load (dumbbells) will be set according to a pain monitoring approach ( exercise should not provoke pain \>2/10) during wrist extension. Load is increased by 0.5 to 1kg. We will allow a 30 sec break. The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France).~An 40% occlusion pressure is set and subjects perform 4 sets of wrist extension (30-15-15-15 reps)."
62605324|NCT05919914|ACTIVE_COMPARATOR|Wrist extensor exercise without Blood Flow Restriction|Patients will execute a wrist extension exercise on standing position with the elbow extended. The load (dumbbells) will be set according to a pain monitoring approach ( exercise should not provoke pain \>2/10) during wrist extension. Load is increased by 0.5 to 1kg. We will allow a 30 sec break.
62605325|NCT06263270|ACTIVE_COMPARATOR|Active Treatment Arm (CYT-108)|One intra articular (IA) injection of 5mL at 5mg/mL into one target knee with mild to moderate OA for total of 25mg CYT-108 on Days 1 and 85 (2 injections \[50 mg\] in total).
62605326|NCT06263270|PLACEBO_COMPARATOR|Placebo Control Arm (Phosphate Buffered Saline)|Equivalent volume 5mL of phosphate buffer saline, PBS (equal volume to the active treatment arm injection) at the same time intervals as the treatment arm.
62605327|NCT05395897||New users|Users without any reimbursement for psychotropic drugs before the beginning of the coronavirus crisis.
62605328|NCT05395897||Actual or former users|Users without at least one reimbursement for psychotropic drugs before the beginning of the coronavirus crisis.
62605329|NCT04587739|EXPERIMENTAL|Experimental group|
62605330|NCT02712021|EXPERIMENTAL|Cerebral Palsy-Study group|The intervention consisted of wearing a lycra suit, with shoulder, trunk and pelvis coverage, for more than 4 hours per day for 6 months. The motor function assessments will be performed without the Lycra suit, whereas the static balance assessments were performed with and without the suit.
62605331|NCT02712021|ACTIVE_COMPARATOR|Cerebral Palsy-Control Group|Children with clinical characteristics similar to the study group; they will be assessed using the same protocol but with no use of lycra garments
62605332|NCT04051099|EXPERIMENTAL|bilateral cervical plexus block|bilateral superficial cervical plexus block with 0.25% bupivacaine 8 ml each (total 0.25% bupivacaine 16 mg)
62605333|NCT04051099|EXPERIMENTAL|General anesthesia|General anesthesia with endotracheal intubation under total intravenous anesthesia (TIVA)
62605334|NCT04599933|EXPERIMENTAL|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
62438180|NCT01206712||T2DM patients treated with SU + MET|T2DM patients treated with Sulfonylurea (SU) + Metformin(MET)in their routine antidiabetic therapy. These patients do not receive any study specific medication.
62605335|NCT04599933|PLACEBO_COMPARATOR|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
62438181|NCT01206712||T2DM patients treated with DPP-4 + MET|T2DM patients treated with Dipeptidylpeptidase 4 inhibitors (DPP-4) + Metformin(MET) in their routine antidiabetic therapy. These patients do not receive any study specific medication.
62438182|NCT01206712||Healthy subjects|healthy volunteres who do not receive any antidiabetic medication in their routine therapie.
62605336|NCT04940520|ACTIVE_COMPARATOR|Control group|Group A: control group, drug recommended by the Brazilian Society of Dermatology
62605337|NCT04940520|ACTIVE_COMPARATOR|Alpha-bisabolol and laser|Group B: alpha bisabolol-based product associated with low-level laser therapy
62605338|NCT04940520|ACTIVE_COMPARATOR|Alpha bisabolol|Group C: alpha bisabolol based product
62605339|NCT04788225||Patients with ATFL repair by arthroscopic method|Patients who have passed at least 1 year after the operation Unilateral arthroscopic ATFL repair Between the ages of 18-65 Volunteer to participate in the study Without any orthopedic conditions, neuromuscular disease, balance disorder, cognitive disorder No history of fracture and surgical operation of the lower extremity
62605340|NCT04788225||Control group|Between the ages of 18-65 Volunteer to participate in the study Healthy individuals with no disease
62605341|NCT06277154|EXPERIMENTAL|MASCT-I+ Doxorubicin+ Ifosfamide|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells. DC cells injection will be given via subcutaneous injection, and T cells injection will be given via Intravenous (IV) infusion. Doxorubicin and Ifosfamide will be given per protocol.
62605342|NCT06277154|ACTIVE_COMPARATOR|Doxorubicin+ Ifosfamide|Doxorubicin and Ifosfamide will be given per protocol.
62828029|NCT06204757||women|women who have given birth to a healthy baby
62828030|NCT06204757||midwives|
62828031|NCT06585852|ACTIVE_COMPARATOR|Control Group|Xenograft alone with split-crest technique by ultrasonic bone surgery and implant placement.
62605343|NCT02332564||Coronary Artery Disease|Patient with significant coronary artery disease
62828032|NCT06585852|EXPERIMENTAL|Study Group|Xenograft mixed with RGD with split-crest technique by ultrasonic bone surgery and implant placement.
62605344|NCT02332564||No Coronary Artery Disease|Patient without significant coronary artery disease
62828033|NCT03546686|EXPERIMENTAL|Treatment Arm|"Pembrolizumab + Core Biopsy/Cryoablation + Breast Surgery +Post Surgery pembrolizumab~OR~Ipilimumab and Nivolumab + Core Biopsy/Cryoablation + Breast Surgery +Post Surgery Nivolumab"
62828034|NCT01374438|EXPERIMENTAL|MSDC-0160 capsules|MSDC tablets contained in #00 capsules
62045835|NCT03819140|ACTIVE_COMPARATOR|Continuous OCP Therapy|Participants randomly assigned to this arm will receive 8 packs of a 21 day oral contraceptive pills (OCP) called Yasmin (3 mg Drospirenone/0.03 mg Ethinyl estradiol) which comes in a formulation of 21 days of active hormone and 7 days of sugar pills. In this arm, participants will only be expected to take active hormone pills (colored pills) for the 6 months straight without stopping or taking the sugar pills in each pack.
62045836|NCT03819140|ACTIVE_COMPARATOR|Cyclical OCP Therapy|Participants randomly assigned to this arm will receive 6 packs of a 21 day oral contraceptive pill (OCP) called Yasmin (3 mg Drospirenone/0.03 mg Ethinyl estradiol) which has 21 days of active hormone and 7 days of sugar pills. Participants will take one pill daily for 6 months and be expected to take the sugar pills at the end of each monthly pack prior to starting a new pack.
62605345|NCT05988905|EXPERIMENTAL|robot assisted gait training|RAGT enables training of automatically programmed normal gait pattern. Patients underwent 30 min of RAGT using SUBAR® and conventional exercise rehabilitation each for 30 min once a day for 5 days a week for 8 weeks.
62605346|NCT05988905|ACTIVE_COMPARATOR|conventioanl training|The conventional training group focused on gait training such as active range of motion (ROM) exercise, weight bearing training, manual lymphatic drainage, and hypertrophic scar care for 60 min once a day for 5 days a week for 8 weeks.
62605347|NCT04120454|EXPERIMENTAL|Treatment (ramucirumab, pembrolizumab)|Patients receive ramucirumab IV over 60 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
62605348|NCT05265156|OTHER|Plant based formula for young children|The study is designed with a single arm, so all subjects will receive the study product.
62828035|NCT01374438|PLACEBO_COMPARATOR|Placebo capsules|Placebo tablets contained in #00 capsules
62828036|NCT03583892||Group A|In the Group A, a single-dose of 600mg gabapentin was used as part of a multimodal analgesic technique.
62828037|NCT03583892||Group B|In the group B gabapentin was not administered.
62828038|NCT02431637|EXPERIMENTAL|Piperaquine Phosphate after infected blood malaria challenge|Volunteers will receive a dose of 480 mg piperaquine phosphate (PQP) approx. 7 days after a challenge with P. falciparum infected red blood cells. The effects of PQP on gametocyte carriage (assessed by PCR) and infectivity to mosquitos after direct and indirect feeding on blood from volunteers will be assessed.
62828039|NCT03051178|EXPERIMENTAL|Subjects with Essential Tremor|This cohort will receive deep brain stimulation (DBS) therapy responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.
62828040|NCT06125041|EXPERIMENTAL|treatment group|"Administration regimen: adebelizumab 1200mg, IV, Q3W+ carboplatin AUC 5 d1+ etoposide 100mg/m2 D1, 2, 3; 21 days is a treatment cycle. After 4-6 cycles, patients with imaging evaluation CR/PR/SD (according to tumor RECIST1.1 standard) receive adebelizumab maintenance therapy and radiotherapy at the same time. Patients with imaging evaluation PD (according to tumor RECIST1.1 standard) can receive adebelizumab maintenance therapy combined with radiotherapy according to the clinical practice, or they can change other treatment schemes and continue to follow up.~After the induction treatment, the participants will continue to receive adebelizumab (20mg/kg, IV, Q3W) combined with concurrent radiotherapy (conventional radiotherapy SBRT chest lesions (2Gy\*25f), brain (3Gy\*10f)/ bone (3Gy\*10f)/ suprarenal gland (3Gy\*10-15f)/ liver (3YX)."
62828041|NCT06587022||group 1|Group 1(small target delineation)：The target bolume only includes local tumor.
62828042|NCT06587022||group 2|Group 2(small target delineation)：The target bolume includes local tumor and adjacent vertebral area.
62828043|NCT04125927|EXPERIMENTAL|Open-label arm|
62828044|NCT04084236|ACTIVE_COMPARATOR|Active TENS|
62828045|NCT04084236|SHAM_COMPARATOR|Sham TENS|
62828046|NCT01941810|EXPERIMENTAL|Supportive care (bovine lactoferrin supplement)|Patients receive bovine lactoferrin supplement PO TID for 1 month.
62248136|NCT00003370|EXPERIMENTAL|Arm I|"If the dose limiting toxicity is myelosuppression in stratum 1, then stratum 1 is closed and stratum 2 opens.~Stratum 2 consists of the following: patients receiving no more than 2 prior chemotherapy regimens; patients who have not received prior central axis radiation or bone marrow transplantation; and patients with no known bone marrow involvement. Patients receive intravenous 6-hydroxymethylacylfulvene over 10 minutes daily for 5 days. The course is repeated every 28 days unless disease progression or unacceptable toxic effects are observed. Patients with stable or responding disease may receive up to 1 year of therapy. If dose limiting toxicity occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and the next lower dose is declared the maximum tolerated dose. Dose escalation will not occur until all patients within a cohort have been observed for 28 days from day 1 of therapy. Patients are followed until death."
62248137|NCT03530917|EXPERIMENTAL|Single Ascending Dose (SAD): Placebo|In SAD Cohorts 1-4, there will be eight participants in total receiving placebo, two in each cohort.
62248138|NCT03530917|EXPERIMENTAL|SAD: Cohort 1|Eight participants will be administered 40mg RO7020531 orally on Day 1.
62248139|NCT03530917|EXPERIMENTAL|SAD: Cohort 2|Eight participants will be administered 100mg RO7020531 orally on Day 1.
62248140|NCT03530917|EXPERIMENTAL|SAD: Cohort 3|Eight participants will be administered 140mg RO7020531 orally on Day 1.
62248141|NCT03530917|EXPERIMENTAL|SAD: Cohort 4|Eight participants will be administered 170mg RO7020531 orally on Day 1.
62248142|NCT03530917|EXPERIMENTAL|Multiple Ascending Dose (MAD): Placebo|In MAD Cohorts 1-3, there will be six participants in total receiving placebo, two in each cohort.
62605349|NCT01511718|EXPERIMENTAL|Ondansetron Hydrochloride Tablets 8 mg|Ondansetron Hydrochloride Tablets 8 mg of Dr. Reddy's Laboratories Limited
62605350|NCT01511718|ACTIVE_COMPARATOR|Zofran Tablets 8 mg|Zofran Tablets 8 mg of GlaxoSmithKline
62605351|NCT04251728|EXPERIMENTAL|Exercise plus AMPS group (AMPS-G)|Physical exercise and automated mechanical peripheral stimulation (AMPS) with intensity at the pain threshold, performed two times a week for 12 weeks.
62605352|NCT04251728|SHAM_COMPARATOR|Exercise plus SHAM group (Exercise-G)|Physical exercise and simulated automated mechanical peripheral stimulation (AMPS) with intensity at the sensory threshold performed two times a week for 12 weeks.
62605353|NCT06621667|EXPERIMENTAL|study group|
62828047|NCT02749422|ACTIVE_COMPARATOR|Healthy Subjects|
62828048|NCT02749422|EXPERIMENTAL|Temporal Lobe Epilepsy Patients|
62828049|NCT04900116|ACTIVE_COMPARATOR|Group 1|In this group, US guided PENG block will be performed with 20 ml 0.5% bupivacaine using a 22 gauge 10 mm block needle.
62828050|NCT04900116|ACTIVE_COMPARATOR|Group 2|In this group, US guided PENG block will be performed with 20 ml 0.25% bupivacaine using a 22 gauge 10 mm block needle.
62828051|NCT04900116|ACTIVE_COMPARATOR|Group 3|In this group, US guided PENG block will be performed with 20 ml 0.125% bupivacaine using a 22 gauge 10 mm block needle.
62828052|NCT04900116|PLACEBO_COMPARATOR|Group 4|In this group, US guided PENG block will be performed with 20 ml saline solution (%0.9 NaCl) using a 22 gauge 10 mm block needle.
62828053|NCT05574387|NO_INTERVENTION|Control Group|This group will take mesalamine 1 g three times daily
62828054|NCT05574387|ACTIVE_COMPARATOR|Metformin group|This group will take mesalamine 1 g three times daily plus metformin 500 mg two times daily
62828055|NCT05788770|EXPERIMENTAL|FEops HEARTGuide|Device selection using FEops HEARTGuide: 3D anatomical analysis and simulation of transcatheter aortic valve prosthesis prior to procedure based on computed tomography.
62605354|NCT06621667|ACTIVE_COMPARATOR|control group|
62828056|NCT05788770|NO_INTERVENTION|Standard transcatheter aortic valve implantation (no FEops HEARTGuide)|Control: standard of care, CT based device selection.
62045837|NCT04517396|EXPERIMENTAL|Fenofibrate + Usual Care|The randomized intervention will be Fenofibrate, in combination with usual care. Dosing: 145 mg of Tricor or a dose-equivalent preparation
62605355|NCT04586634|ACTIVE_COMPARATOR|Peristeen|Subjects to use newly developed Peristeen cone catherter device
62045838|NCT04517396|PLACEBO_COMPARATOR|Placebo + Usual Care|The randomized intervention will a matching placebo, in combination with usual care.
62045839|NCT00815295|EXPERIMENTAL|Cetuximab + sorafenib|Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly. Sorafenib will be given at 200mg/m2 twice daily.
62045840|NCT00572195|EXPERIMENTAL|Evaluation Group (stimulation ON)|Group of subjects that have an RNS® System implanted, completed the RNS® System Pivotal or Feasibility study, and elected to continue to receive RNS® System responsive stimulation for the long term.
62045841|NCT03595579|EXPERIMENTAL|AXS-05|
62045842|NCT03595579|ACTIVE_COMPARATOR|Bupropion|
62045843|NCT06215014|EXPERIMENTAL|Handgrip training|Participants will perform isometric handgrip training 3 days per week for a month.
62438183|NCT05924971|EXPERIMENTAL|Standard blood pressure control plus aspirin 81 mg|Standardized postpartum blood pressure control Aspirin 81 mg by mouth x 1 week post-delivery
62438184|NCT05924971|NO_INTERVENTION|Standard blood pressure control|Standardized postpartum blood pressure control
62828057|NCT03530215||Adverse Events with Antineoplastic and immunomodulating agents|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Antineoplastic and immunomodulating agents, with a chronology compatible with the drug toxicity
62828058|NCT06422819|EXPERIMENTAL|Experimental group (HRV-BFB training)|Participants assigned to the experimental group will undergo HRV Biofeedback training using the Inner Balance Coherence Plus® software. This software incorporates a Bluetooth plethysmograph ear sensor, which will transmit cardiac pulse data to the Inner Balance Coherence Plus smartphone app, where the EmWave Pro® Plus software will extract HRV in real-time. This software will display the participant's HRV-BFB curve on their smartphone. The installation of the program and necessary instructions for its use will be provided at the first visit (V1). Fractional training sessions of 8 minutes will be recommended, twice daily for 30 days (during the period V1-V2 or the period V2-V3). Respiratory instructions will differ between the two interventions. During the HRV-BFB intervention, participants will be instructed to maximize their HRV.
62438185|NCT03063632|EXPERIMENTAL|Group I (pembrolizumab, interferon gamma-1b)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unexpected toxicity. Patients also receive interferon gamma-1b SC 3 times per week for 12 weeks, and then follow 3 weeks on and 3 weeks off schedule for up to 2 years in the absence of disease progression or unexpected toxicity.
62438186|NCT03063632|EXPERIMENTAL|Group II (pembrolizumab, interferon gamma-1b)|Patients pembrolizumab IV over 30 minutes on day 1 and interferon gamma-1b SC once a week. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unexpected toxicity.
62438187|NCT03760133|ACTIVE_COMPARATOR|with Probiotics|Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
62438188|NCT03760133|NO_INTERVENTION|without Probiotics|Participants included in this group will not be taken probiotics for 1 month after bowel preparation for colonoscopy.
62438189|NCT01840683|EXPERIMENTAL|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|A total of 8 apheresis therapies with the H.E.L.P. Plasmat Futura System will be performed over a period of 12 weeks.
62438190|NCT02903927|EXPERIMENTAL|CT LUCIA|
62438191|NCT02903927|ACTIVE_COMPARATOR|Acrysof IQ Sn60WF|
62438192|NCT05586620|ACTIVE_COMPARATOR|3-snip punctoplasty|
62045844|NCT06215014|NO_INTERVENTION|Control|Participants will not perform isometric handgrip training for a month.
62045845|NCT06240325|EXPERIMENTAL|Sleep Promotion Program|Participants will receive the Sleep Promotion Program (SPP), consisting of 2 individual sessions with a clinician via telehealth (or in-person if desired), about 2 weeks apart, and web-based intervention components.
62045846|NCT06240325|ACTIVE_COMPARATOR|Sleep Psychoeducation|Participants will receive Sleep Psychoeducation (SPE), a 20-minute discussion with a clinician via telehealth (or in person).
62438193|NCT05586620|ACTIVE_COMPARATOR|3-snip punctoplasty with mitomycin C|
62045847|NCT01911377|ACTIVE_COMPARATOR|Arm 1: Botulinum Toxin Type A|"200 units of Botulinum Toxin Type a will be administered intradermally to the allodynic area chosen for study.The allodynic area will be mapped, and the number of injections needed to cover the allodynic area without exceeding 40 injection sites will be determined.~All participants will receive a cream formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes before the injections to minimize any discomfort caused by the injections."
62045848|NCT01911377|PLACEBO_COMPARATOR|Arm 2: Normal Saline for Injection|Normal saline for intradermal injection will be prepared by the Investigational Pharmacy in a manner as to be indistinguishable from active drug. The allodynic area will be mapped so as to determine the number of injections needed to cover the whole allodynic area without exceeding 40 injection sites. All participants will receive a cream formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes before the injections to minimize any pain caused by the injections.
62045849|NCT01235403|EXPERIMENTAL|Lacosamide|Flexible dosing between 200mg/day and 400mg/day
62045850|NCT05681806|EXPERIMENTAL|Treatment High Dose|Subjects consuming 1000mg LMP Creatine + 500mg Carnipure crystalline 1x/day
62045851|NCT05681806|EXPERIMENTAL|Treatment Low Dose|Subjects consuming 500mg LMP Creatine + 500mg Carnipure crystalline 1x/day
62045852|NCT05681806|ACTIVE_COMPARATOR|Active Control|Subjects consuming 5g creatine monohydrate 1x/day
62438194|NCT02904200|EXPERIMENTAL|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
62438195|NCT02904200|ACTIVE_COMPARATOR|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
62438196|NCT01113710||Neupro®|Routine treatment in accordance with the local marketing authorization for Neupro® in RLS
62438197|NCT04517006|NO_INTERVENTION|Track activities|For three weeks research subjects will be keeping track of the things they do without altering their routine in any way.
62438198|NCT04517006|EXPERIMENTAL|Self-focused acts|"For three weeks research subjects will be treating themselves by doing things that they enjoy. These acts don't have to be large or costly, but they should be over and above what they typically do. They are asked to do one (or more) things they enjoy each day for the first three days of each week and report them."
62438199|NCT04517006|EXPERIMENTAL|Prosocial acts|For three weeks research subjects are asked to perform acts of kindness, meaning behaviors that benefit someone else and are over and above what they typically do (i.e., they are not expected of them). These acts should also involve some sacrifice by them (e.g., in effort, energy, time, or money) and be completed for the first three days of each week.
62828059|NCT06422819|PLACEBO_COMPARATOR|Placebo Control group (Pseudo HRV-BFB training)|Participants assigned to the placebo group will undergo a pseudo HRV Biofeedback training using the same Inner Balance Coherence Plus® software and ear sensor. The software will similarly display the participant's HRV-BFB curve on their smartphone. The installation of the program and necessary instructions for its use will be provided at the first visit (V1). To manage placebo effects, the same fractional training sessions of 8 minutes will be recommended, twice daily for 30 days (during the period V1-V2 or the period V2-V3). Respiratory instructions will differ between the two interventions. During the placebo pseudo BFB training, participants will be instructed to no have specific effect on HRV.
62828060|NCT04276896|EXPERIMENTAL|pathogen-specific DC and CTLs|Patients will receive approximately 5x10\^6 LV-DC vaccine and 1x10\^8 CTLs via sub-cutaneous injections and iv infusions, respectively.
62828061|NCT01712035||Treatment-active NVAMD|Patients with NVAMD who have received treatment with an anti-VEGF agent (Avastin, Lucentis, Macugen, or Eylea) 6 weeks prior enrollment visit
62828062|NCT01712035||Treatment-naive NVAMD|Individuals who have not received any treatment for neovascular AMD in the study eye
62828063|NCT03100149|EXPERIMENTAL|Part 1: RO7046015 High Dose|Participants will receive RO7046015 at high dose level as intravenous infusion every 4 weeks (Q4W) up to 52 weeks in Part 1.
62438200|NCT00770991|EXPERIMENTAL|Black Raspberry (BRB) Slurry plus BRB suppositories|20 grams BRB Slurry BID plus two, 730 mg BRB suppositories HS
62438201|NCT00770991|EXPERIMENTAL|Black Raspberry (BRB) Placebo Slurry plus BRB suppositories|20 grams BRB Placebo Slurry BID plus two, 730 mg BRB suppositories HS
62438202|NCT04033939|EXPERIMENTAL|HSK3486-01|Randomized to receive HSK3486 (0.016mg/kg,0.064mg/kg )as a single IV injection. HSK3486-01 was blinded.(2 HSK3486-01: 1 Placebo-01)
62438203|NCT04033939|PLACEBO_COMPARATOR|Placebo-01|Randomized to receive placebo (0.016mg/kg,0.064mg/kg )as a single IV injection. placebo-01 was blinded.(2 HSK3486-01: 1 Placebo-01)
62438204|NCT04033939|EXPERIMENTAL|HSK3486-02|Randomized to receive either HSK3486（0.128mg/kg,0.192mg/kg,0.288mg/kg,0.432mg/kg,0.540mg/kg,0.648mg/kg,0.810mg/kg) as a single IV injection. HSK3486-02 was open-label.(5 HSK3486-02: 1 propofol-02)
62438205|NCT04033939|ACTIVE_COMPARATOR|Propofol-02|Randomized to receive propofol (2.5mg/kg) as a single IV injection. Propofol-02 was open-label.(5 HSK3486-02: 1 propofol-02)
62438206|NCT02659202|EXPERIMENTAL|Precision Spinal Cord Stimulator System|Intervention:the precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads lead extensions, each packaged as a separate kit.
62438207|NCT04467333||All lung cancer patients|There will not be an intervention.
62438208|NCT00748007|EXPERIMENTAL|A|
62438209|NCT00748007|PLACEBO_COMPARATOR|Placebo|Placebo
62438210|NCT05852782|EXPERIMENTAL|Light exposure broadband|Participants will be exposed to indoor levels of light that appear colorless for one hour
62438211|NCT05852782|EXPERIMENTAL|Light exposure long wavelength|Participants will be exposed to indoor levels of light that appear red for one hour
62438212|NCT05852782|EXPERIMENTAL|Light exposure short wavelength|Participants will be exposed to indoor levels of light that appear blue for one hour
62438213|NCT05852782|EXPERIMENTAL|Light exposure darkness|Participants will be exposed to darkness for one hour
62605356|NCT04586634|NO_INTERVENTION|Standard of care|subjects continue with their standard of care treatment
62605357|NCT05615805|EXPERIMENTAL|3-mL washout with saline based ocular rinse post injection|
62605358|NCT05615805|EXPERIMENTAL|10-mL washout with saline based ocular rinse post injection|
62828064|NCT03100149|EXPERIMENTAL|Part 1: RO7046015 Low Dose|Participants will receive RO7046015 at low dose level as intravenous infusion Q4W up to 52 weeks in Part 1.
62828065|NCT03100149|PLACEBO_COMPARATOR|Part 1: Placebo|Participants will receive placebo as intravenous infusion Q4W up to 52 weeks in Part 1.
62828066|NCT03100149|EXPERIMENTAL|Part 2: RO7046015 High Dose|Part 1 RO7046015 high dose group participants and placebo group participants randomized to high dose level will receive RO7046015 at high dose level as intravenous infusion Q4W for additional 52 weeks in Part 2.
62828067|NCT03100149|EXPERIMENTAL|Part 2: RO7046015 Low Dose|Part 1 RO7046015 low dose group participants and placebo group participants randomized to low dose level will receive RO7046015 at low dose level as intravenous infusion Q4W for additional 52 weeks in Part 2.
62045853|NCT03191487|EXPERIMENTAL|ChimioPal|Systematic collection of clinical and laboratory toxicities.
62438214|NCT03404206|EXPERIMENTAL|Naproxen Sodium (Aleve, BAY117031)|Participants received one single dose of 440 mg naproxen sodium tablets (200 mg x 2 tablets, oral) after randomization
62438215|NCT03404206|ACTIVE_COMPARATOR|Ibuprofen (Advil)|Participants received one single dose of 400 mg ibuprofen tablets (200 mg x 2 tablets, oral) after randomization
62438216|NCT03404206|PLACEBO_COMPARATOR|Placebo|Participants received one single dose of matching placebo tablets (2 tablets, oral) after randomization
62438217|NCT02657993|EXPERIMENTAL|Hypnosis|The hypnosis intervention involves three, face-to-face, hypnosis sessions delivered by doctoral-level psychology professionals
62438218|NCT02657993|ACTIVE_COMPARATOR|Attention Control (Non-Hypnosis)|The attention control intervention is matched to the hypnosis intervention in terms of the amount of professional time received by patients.
62438219|NCT01038583||Aspirin|100 mg enteric-coated aspirin
62605359|NCT05615805|EXPERIMENTAL|15-mL washout with saline based ocular rinse post injection|
62605360|NCT00880386|EXPERIMENTAL|Losartan Group|50 mg Losartan tablet taken daily for 24 weeks
62605361|NCT01890226|NO_INTERVENTION|Control|
62605362|NCT01890226|EXPERIMENTAL|Experimental: Intervention|Participants randomized to the intervention arm will receive the mobile personal health record.
62828068|NCT03100149|EXPERIMENTAL|Part 3: RO7046015 Low Dose|Part 2 RO7046015 low dose group participants and high dose group participants will receive RO7046015 at low dose level as intravenous infusion Q4W for additional 5 years in Part 3.
62045854|NCT03191487|ACTIVE_COMPARATOR|Standard|The usual management and logistic pathways will be respected.
62045855|NCT01652144|EXPERIMENTAL|AT7519M|AT7519M: 27 mg/m2 IV injection, 1 hour infusion, 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
62045856|NCT00428090|EXPERIMENTAL|Rosiglitazone|XR (extended release) oral tablets
62045857|NCT00428090|OTHER|Placebo|Placebo (Double-Dummy to Match)
62045858|NCT02858050||MEMs Cap Real-Time Monitoring|Group 1 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and will transmit data in real-time
62045859|NCT02858050||MEMs Cap Without Real-Time Monitoring|Group 2 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and data will be downloaded at each study visit while taking hepatitis C medications
62045860|NCT01123668||ADHD and non-ADHD Smokers|Those that are defined as regular smokers (10 cigarettes/day or Carbon Monoxide reading of 10 ppm). The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
62045861|NCT02686580|EXPERIMENTAL|Collagen paste|Injection of Permacol Collagen paste into the fistula tract.
62045862|NCT01213602||Femoral block preoperative|In one group (T1) with performance of femoral block before general anesthesia and administration of bolus of local anesthetic through stimulating catheter (combined anesthesia)
62605363|NCT05876793|EXPERIMENTAL|remimazolam tosylate|The fixed dose of propofol in this study was 0.5mg/kg, with an injection time of 30 seconds. Subsequently, remimazolam was administered at an initial dose of 0.1mg/kg. After 1 minute of administration, sedation was evaluated using MOAA/S. When the MOAA/S score was ≤ 1, endoscopic examination could begin. If the patient did not show physical activity or coughing, sedation was considered successful, and the next patient's medication dose was reduced by 0.02mg/kg; On the contrary, if sedation fails, the next patient will receive an additional 0.02mg/kg of medication.
62605364|NCT03138694||Methotrexate injection|Patients with Ectopic pregnancy treated with Methotrexate injection.
62045863|NCT01213602||Femoral block postoperative|In second group (T2) with a administration of local anesthetic through stimulating femoral catheter until awareness of patient (balanced anesthesia).
62045864|NCT04969484|EXPERIMENTAL|ImPAcTT intervention|Within 48-72 hours of enrollment in the study, the primary participant and family will receive an ImPAcTT Telehealth visit with the PC provider. The provider will conduct a comprehensive PC assessment aligned with the National Consensus Project for Quality Palliative Care guidelines. Visits, which may include remote physical assessment using a digital stethoscope, dermatoscope, etc., will be documented and transmitted to the NH. Advanced Care Planning (ACP) and goals of care discussions will be facilitated by the ability to virtually share and edit documents, such as the Physician Orders for Life Sustaining Treatment (POLST), in real time with primary participants and/or family. The PC provider will conduct follow-up visits 1 week following the initial visit, then on a case-by-case basis.
62248143|NCT03530917|EXPERIMENTAL|MAD: Cohort 1|Eight participants will be administered 100mg RO7020531 orally on Day 1 and every other day (QOD) for 14 days.
62248144|NCT03530917|EXPERIMENTAL|MAD: Cohorts 2 and 3|Sixteen participants will be administered 150mg RO7020531 orally on Day 1 and every other day (QOD) for 14 days.
62248145|NCT02351479|OTHER|Hula|Hula is an ancient, Native Hawaiian dance form of cultural expression and physical activity. Participants will attend one-hour hula classes twice a week for six months.
62248146|NCT01148706|EXPERIMENTAL|ActiSight Needle Guidance System|
62248147|NCT01135862|EXPERIMENTAL|platelet administered|patients will receive 6 packs of platelets
62045865|NCT04969484|NO_INTERVENTION|Usual care|Participants will receive the standard of care established at the NH.
62045866|NCT02130310|EXPERIMENTAL|CureXcell®|CureXcell® injection will be administered about every 4 weeks for up to 3 treatments, or until ulcer closure, whichever occurs first.
62045867|NCT02130310|PLACEBO_COMPARATOR|Placebo injection|The placebo will be administered by injecting normal saline at each centimeter of the ulcer bed.
62248148|NCT01135862|NO_INTERVENTION|no platelets administered|patients will not receive platelets
62248149|NCT05261035|EXPERIMENTAL|stretching exercises group|Pregnant women with RLS were instructed to perform stretching exercises daily for one week
62248150|NCT05261035|ACTIVE_COMPARATOR|Thermotherapy group|Pregnant women with RLS were instructed to apply warm water immersion of their legs daily for one week.
62248151|NCT03341741|EXPERIMENTAL|Tobramycin powder / Colistin|TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off); and Colistin solution 2 x daily 1 Mega continuously for 112 days
62248152|NCT03341741|ACTIVE_COMPARATOR|Colistin|Colistin solution 2 x daily 1 Mega continuously for at least 30 days
62248153|NCT05361109|EXPERIMENTAL|Barcitinib|All subjects will initially receive baricitinib 2mg daily for 8 weeks. If no unexpected serious adverse events related to baricitinib have occurred during the first 8 weeks of treatment in the opinion of the investigator, the dose will be increased to 4 mg daily for 16 weeks.
62438220|NCT01038583||Placebo|Placebo
62438221|NCT04809779|EXPERIMENTAL|Sintilimab|
62438222|NCT05994456|EXPERIMENTAL|PD-1 inhibitor|Neoadjuvant therapy with PD-1 inhibitor (Toripalimab)
62605365|NCT03138694||Self resolution|"Patients with Ectopic pregnancy that had signs of self resolution with our Watchful waiting protocol."
62828069|NCT03067077|ACTIVE_COMPARATOR|SMILE|SMILE surgery
62828070|NCT03067077|ACTIVE_COMPARATOR|Wavefront-guided LASIK|Wavefront-guided LASIK
62828071|NCT06603480|ACTIVE_COMPARATOR|Aerobic Exercise|12 week aerobic exercise
62828072|NCT06603480|EXPERIMENTAL|Metformin|Metformin 2\*1 given
62828073|NCT06603480|NO_INTERVENTION|Control|Only routine
62045868|NCT01489579|ACTIVE_COMPARATOR|BST counseling group|The patients in the Brief, structured, telephone tobacco cessation, BST, counseling group, will receive tobacco cessation counseling, intervention, by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources.
62045869|NCT01489579|PLACEBO_COMPARATOR|Usual care group|Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
62045870|NCT06578988||Symptomatic breast clinic.|Patients 18 years or older attending symptomatic breast clinic from January 2015 to December 2019.
62045871|NCT06146491|ACTIVE_COMPARATOR|Drugs|oral combination of paracetamol (500mg) - ibuprofen (400mg) will be given to group A. they are provided in tablet and prescribed at 8 hourly for three days
62045872|NCT06146491|ACTIVE_COMPARATOR|Drug|Transdermal diclofenac patch - 200mg for group B. Patch is applied on right hand in deltoid region , and ask the patient to change patch every 24 hourly.
62045873|NCT02697851|EXPERIMENTAL|Group 1|Microgynon 30® for 21 days, Followed by Microgynon 30® for 21 days plus Evotaz® for 14 days, Followed by Evotaz® for 14 days
62045874|NCT02697851|EXPERIMENTAL|Group 2|Evotaz® for 14 days followed by 7 days wash-out, Followed by Microgynon 30® for 21 days plus Evotaz® for 14 days, Followed by Microgynon 30® for 14 days (participants may chose to complete a 21 day pack). The total duration of the study is 57 days (+screening and follow up visits) and patients will have 3 intensive pharmacokinetic days on days 14, 35 and 56
62045875|NCT01951638|EXPERIMENTAL|Vericiguat (BAY1021189)(10 mg)|2.5 mg orally once daily for 2 weeks, up-titration to 5 mg orally once daily for 2 weeks, up-titration to 10 mg orally once daily for 8 weeks
62045876|NCT01951638|EXPERIMENTAL|Vericiguat (BAY1021189) (5 mg)|2.5 mg orally once daily for 2 weeks, then 5 mg orally once daily for 10 weeks (with sham titration)
62045877|NCT01951638|EXPERIMENTAL|Vericiguat (BAY1021189) (2.5 mg)|2.5 mg orally once daily for 12 weeks (with sham titrations)
62605366|NCT06250634|EXPERIMENTAL|Double group ( Esomeprazole )|
62605367|NCT06250634|ACTIVE_COMPARATOR|Quadruple group ( Esomeprazole )|
62828074|NCT06599593|EXPERIMENTAL|Nutrition-Intervention-SMC Integration|"In conjunction with SMC administration, CHWs screen children for MUAC. CHW refers children with MUAC \<12.5 to the CSPS for MAM/SAM care and to receive all standard nutritional program.~CHW provides all children ages 6-24 months who do not have acute malnutrition with SQ-LNS (Enov'nutributter; Nutriset; 20 g/day, approximately 100-120 calories)."
62828075|NCT06599593|ACTIVE_COMPARATOR|Standard of Care Plus SQ-LNS Provision|"Separately from SMC administration, CHWs screen children ages 6-59 months for MUAC as part of their routine program. CHW refers children with MUAC \<12.5 to the CSPS for MAM/SAM care and to receive all standard nutritional program.~CHW provides all children ages 6-24 months who do not have acute malnutrition with SQ-LNS (Enov'nutributter; Nutriset; 20 g/day, approximately 100-120 calories)."
62045878|NCT01951638|EXPERIMENTAL|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg orally once daily for 12 weeks (with sham titrations)
62045879|NCT01951638|PLACEBO_COMPARATOR|Placebo|Orally once daily for 12 weeks (with sham titrations)
62045880|NCT05450315|EXPERIMENTAL|TARG|Group will receive physical activity information targeted to young adult cancer survivors
62045881|NCT05450315|ACTIVE_COMPARATOR|CPAG|Group will receive the Canadian Public Health Guidelines
62045882|NCT00770107|ACTIVE_COMPARATOR|Thiamine|
62045883|NCT00770107|PLACEBO_COMPARATOR|Placebo|
62045884|NCT06274255||Controlle group|healthy children presenting to the pediatric neurology clinic at the same times were enrolled as the control group. The demographic characteristics (age, sex, and body mass index) of the patient group and their clinical (attack durations and frequencies, symptoms during attacks, and treatments) and laboratory (hemoglobin (Hb), hematocrit (Hct), platelet, glucose, calcium (Ca), magnesium (Mg), vitamin D, folate and ferritin levels) characteristics were recorded.
62248154|NCT01145495|EXPERIMENTAL|Treatment (lenalidomide, rituximab)|Patients receive lenalidomide PO QD on days 1-21. Treatment with lenalidomide repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, 15, and 22 and in weeks 13, 21, 29, and 37 in the absence of disease progression or unacceptable toxicity.
62248155|NCT04215666||Mild ARDS|Oxygenation standards were calculated based on the Berlin diagnostic high element correction formula combined with local atmospheric pressure
62248156|NCT04215666||Moderate ARDS|Oxygenation standards were calculated based on the Berlin diagnostic high element correction formula combined with local atmospheric pressure
62605368|NCT06250634|EXPERIMENTAL|Double group ( Vonoprazan )|
62605369|NCT06250634|ACTIVE_COMPARATOR|Triple group (Vonoprazan )|
62605370|NCT05236101|EXPERIMENTAL|CD:H Scale|Pictures drawn using the CD:H Scale were evaluated.
62605371|NCT03112733||Patients with ovarian carcinoma|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of patients with a presumed diagnosis of ovarian carcinoma will be determined prior to surgery.
62605372|NCT03112733||Control group|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women without any adnexal mass nor malignancy will be determined to compare with other groups.
62828076|NCT05800080|EXPERIMENTAL|Single immunotherapy group；|one group receives peri operative treatment of Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy；
62045885|NCT06274255||Patients diagnosed with migraine were included as the study group|"Patients diagnosed with migraine were included as the study group The demographic characteristics (age, sex, and body mass index) of the patient group and their clinical (attack durations and frequencies, symptoms during attacks, and treatments) and laboratory (hemoglobin (Hb), hematocrit (Hct), platelet, glucose, calcium (Ca), magnesium (Mg), vitamin D, folate and ferritin levels) characteristics were recorded.~Patients and controls in whom Mg therapy was contraindicated (renal failure or nephrolithiasis), with non-migraine headaches, with substance/drug addiction (abuse), with psychiatric and/or chronic systemic diseases, and cases with histories of drug use (antidepressants, neuroleptics, tranquilizer group, antiepileptic medications (lithium and carbamazepine), using headache prophylaxis (beta blockers and calcium antagonists), and patients with deficient file data were excluded from the study."
62045886|NCT03326505|ACTIVE_COMPARATOR|Injection of Umbilical cord derived UC- MSCs|Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients
62045887|NCT03326505|ACTIVE_COMPARATOR|injection of UC- MSCs and SPT|Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients along with a supervised physical therapy program
62045888|NCT03326505|ACTIVE_COMPARATOR|Supervised Physical Therapy (SPT)|Supervised physical therapy program without stem cells
62045889|NCT02324218||Diabetes mellitus Group|All the subjects with diabetes mellitus diagnosed with hepatitis B, reported in the CPRD database of UK, from the Year 2000 to 2012.
62045890|NCT02324218||Non-Diabetes mellitus Group|All the subjects with hepatitis B who are diagnosed negative diabetes mellitus, reported in the CPRD database of UK, from the Year 2000 to 2012.
62828077|NCT05800080|EXPERIMENTAL|Double immune treatment group|one group receives peri operative treatment of Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy
62605373|NCT03112733||Benign adnexal mass|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women with an adnexal mass will be determined to compare with other groups.
62045891|NCT06166693|EXPERIMENTAL|Treatment group|Adults between the ages of 18 and 60 were recruited and randomly assigned to the treatment group and waitlist group in the ratio of 2:1. Based on the screening results, 75 participants were assigned to each of the four intervention programs within MINDLiNG (Riggy, Pleaser, Shelly, and Jumpy).
62045892|NCT06166693|NO_INTERVENTION|Waitlist group|Adults between the ages of 18 and 60 were recruited and randomly assigned to the treatment group and waitlist group in the ratio of 2:1. Based on the screening results, 25 participants were assigned to each of the four intervention programs waitlist.
62045893|NCT02474550||CISL 14-03|"* Patients who were newly diagnosed with Diffuse Large B cell Lymphoma (DLBCL).~* Aged 19 or more~* Treated with R-CHOP therapy"
62045894|NCT03789682||FUSCC cystectomy cohort|patients underwent cystectomy in Fudan University Shanghai Cancer Center
62045895|NCT06346379|EXPERIMENTAL|Baduanjin exercise|Before starting dialysis, Patients perform Baduanjin exercises. All Baduanjin training is provided by a professional doctor who has received training on BaduanJin and obtained certificate. Each session is approximately 30 minutes in duration, consisting of 5 minutes of warm-up exercises, 20 minutes of Baduanjin practice, and 5 minutes of cool-down exercises.
62045896|NCT06346379|NO_INTERVENTION|Control group|Patients in this group maintain their conventional therapy and daily life activities, and there is no intervention given.
62605374|NCT02209805|EXPERIMENTAL|BIRB 796 BS, low dose|
62605375|NCT02209805|EXPERIMENTAL|BIRB 796 BS, high dose|
62605376|NCT02209805|PLACEBO_COMPARATOR|Placebo|
62605377|NCT02209805|EXPERIMENTAL|BIRB 796 BS, medium dose|
62828078|NCT01052727|OTHER|overnight stay group|Group of patients who rests at least one night in Hospital
62828079|NCT01052727|OTHER|day-care Group|Group of patients who is discharged tha same day of operation
62828080|NCT05899426|EXPERIMENTAL|Motor learning based clinical pilates|Participants in this group will receive training for 60 minutes 2 times a week for 12 weeks and will be followed up with the same assessments at the 3rd months after the treatment.
62828081|NCT05899426|ACTIVE_COMPARATOR|Conventional Physiotherapy|Participants in this group will receive training for 60 minutes 2 times a week for 12 weeks and will be followed up with the same assessments at the 3rd months after the treatment.
62045897|NCT03315143|EXPERIMENTAL|Sotagliflozin|Sotagliflozin 200 mg tablet once daily, with possible up-titration in the first 6 months to 400 mg, for up to 28.9 months.
62045898|NCT03315143|PLACEBO_COMPARATOR|Placebo|Matching placebo to sotagliflozin 200 mg once daily, with possible up-titration in the first 6 months to matching placebo to sotagliflozin 400 mg, for up to 29.6 months.
62045899|NCT01921296|EXPERIMENTAL|Cyclobenzaprine|Cyclobenzaprine (Flexeril) 5 milligrams orally 2 hours before bed, for a total of 24 weeks.
62045900|NCT01248273|EXPERIMENTAL|immunization|This trial will investigate the safety and immune responses following immunization with the unimolecular pentavalent Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21. This is a phase I study to assess toxicity and immunogenicity.
62045901|NCT04883307|EXPERIMENTAL|Coaching Intervention|Paired with a coach outside of their specific area of interest; encouraged to meet 3 times over 9 months for a 1:1 coaching meeting
62045902|NCT04883307|ACTIVE_COMPARATOR|Wellness Resources|Emailed wellness resources
62045903|NCT04553341|EXPERIMENTAL|Therepeutic|rTMS
62605378|NCT06228872|EXPERIMENTAL|Experimental Group|Participants will receive Computerized Cognitive Training and anodal tDCS daily for one month. Stimulation will consist of 20 min of anodal 2mA tDCS stimulation over the DLPFC, followed by 15 min of computerized cognitive training.
62828082|NCT01456039|EXPERIMENTAL|Romidepsin|Patients will receive romidepsin intravenously for 4 hours on Days 1, 8, and 15 of each 28-day cycle until when/if a discontinuation criterion, e.g., disease progression, severe adverse events, or consent withdrawal.
62828083|NCT02087280||Anorexia Nervosa|
62828084|NCT02087280||Healthy controls|
62828085|NCT05809557|PLACEBO_COMPARATOR|Usual Care|
62828086|NCT05809557|EXPERIMENTAL|Chemotherapy Toxicity Tool|
62828087|NCT03806361|EXPERIMENTAL|With ADRC|Supplementation of fat grafts with ADRC
62828088|NCT03806361|ACTIVE_COMPARATOR|Structural|Structural fat grafting
62828089|NCT01217229|EXPERIMENTAL|PLX3397|
62045904|NCT06378892|EXPERIMENTAL|Lorlatinib|Lorlatinib 100mg once daily. Carboplatin AUC 5 or Cisplatin 75 mg/m\^2 for an induction phase of four cycles. Pemetrexed 500 mg/m\^2 during the maintenance phase.
62045905|NCT06225167||Protocol Group|Patients will be analyzed during the time frame of February 2020 to February 2023 for the protocol group
62045906|NCT06225167||Non Protocol Group|Patients will be analyzed during the time frame of February 2017 to February 2020 for the non-protocol group.
62045907|NCT06185933|ACTIVE_COMPARATOR|lidocaine spray alone|patient in this arm will receive lidocaine spray five puffs of 10 % lidocaine spray (Xylocaine 10 % Spray, Astra Zeneca) (1 puff = 10 mg of lidocaine) 5 minutes before the start of the procedure
62045908|NCT06185933|ACTIVE_COMPARATOR|receive lidocaine spray + lidocaine viscous solution|patient in this arm will receive lidocaine spray + lidocaine viscous solution five puffs of 10 % lidocaine spray (Xylocaine 10 % Spray, Astra Zeneca) (1 puff = 10 mg of lidocaine) Plus 5 mL of 2 % viscous lidocaine solution (20 mg/mL) (Xylocaine 2 %, Astra Zeneca, London, UK)
62045909|NCT03221621|ACTIVE_COMPARATOR|Adalimumab Monotherapy|Adalimumab injections will be administered through subcutaneously in a weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2, continued for 2 years in total.
62045910|NCT03221621|EXPERIMENTAL|Adalimumab + Surgery|Patients will be treated with a combination of adalimumab and wide excision, with a maximum of three surgical interventions within the first year. Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2, continued until the last surgery.
62045911|NCT05563103|EXPERIMENTAL|AIH + Walking Training with transcutaneous spinal stimulation (WALKtSTIM)|Acute Intermittent Hypoxia will be used as a pretreatment before walking training paired with transcutaneous spinal cord stimulation.
62045912|NCT05563103|SHAM_COMPARATOR|Sham + WALKtSTIM|Sham acute intermittent hypoxia will be used as a pretreatment before walking training paired with transcutaneous spinal cord stimulation.
62045913|NCT05563103|SHAM_COMPARATOR|AIH + Walking Training with sham transcutaneous spinal stimulation (WALKtSHAM)|Acute Intermittent Hypoxia will be used as a pretreatment before walking training paired with sham transcutaneous spinal cord stimulation.
62045914|NCT00774579||1|Patients with growth hormone (GH) deficiency starting GH replacement.
62045915|NCT00774579||2|Patients with growth hormone (GH) deficiency not starting GH replacement.
62045916|NCT06567678|EXPERIMENTAL|Colchicine 0.5mg po bd|Patients with coronary disease taking Colchicine 0.5mg twice-daily orally for two weeks
62045917|NCT04360525||Elderly patients|Elderly patients (60≤ age) with sigmoid volvulus
62045918|NCT04360525||Young patients|Young patients (\<60 age) with sigmoid volvulus
62045919|NCT05349825||Patients with Hypertensive episode|50 individuals presenting with a hypertensive episode (patients under 60, \>140/90 mmHg, patients over 60, \>150/90 mmHg, according to the JNC8 guidelines) while under losartan treatment
62045920|NCT05349825||Patients with controlled hypertension|50 patients whose blood pressure was regulated while receiving losartan treatment and who were admitted to the ED for reasons other than hypertensive episode. The eligible patients matching the inclusion and exclusion criteria were recruited for the study.
62045921|NCT01356355|EXPERIMENTAL|Herbmed plus|One capsule twice a day daily till ureteral stent in situ
62248157|NCT04215666||Severe ARDS|Oxygenation standards were calculated based on the Berlin diagnostic high element correction formula combined with local atmospheric pressure
62045922|NCT01356355|PLACEBO_COMPARATOR|Placebo|One capsule twice a day daily till ureteral stent in situ
62045923|NCT01356355|ACTIVE_COMPARATOR|Tolterodine|One capsule twice a day daily till ureteral stent in situ
62045924|NCT04311606|EXPERIMENTAL|Saline and aflibercept|Group 1: Sub-tenon's injection of saline followed by sub-tenon injection of aflibercept
62045925|NCT04311606|EXPERIMENTAL|Hyaluronidase and aflibercept|Group 2: Sub-tenon's injection of hyaluronidase (HA) followed by sub-tenon injection of aflibercept
62045926|NCT04311606|PLACEBO_COMPARATOR|Hyaluronidase alone|Group 3: Sub-tenon injection of HA injection alone
62045927|NCT03495011||Cohort A|Patient with recently identified calcifications on mammography requiring biopsy. Patients will undergo a quantitative, multiparametric breast MRI as part of their clinical care. MRI will not change need for biopsy, but could identify additional suspicious sites. Only patients diagnosed with pure DCIS at biopsy and eventual surgical excision will receive Oncotype DX DCIS score testing.
62828090|NCT06507111|ACTIVE_COMPARATOR|Active|Lab4P Multi-strain Probiotic (comprising Lactobacilli and bifidobacteria species) with Vitamin C, Vitamin D and Zinc
62045928|NCT03495011||Cohort B|Patient with recent diagnosis of biopsy-proven DCIS would complete a research quantitative, multiparametric breast MRI as part of their clinical care. Only patients diagnosed with pure DCIS at surgical resection will receive Oncotype DX DCIS score testing.
62045929|NCT06113601||Patients admitted to the ICU.|
62045930|NCT06113601||Patients who are not admitted to the ICU.|
62045931|NCT05632510|OTHER|EPDS Group|
62045932|NCT05632510|NO_INTERVENTION|Courent practice Group|
62248158|NCT02483624|EXPERIMENTAL|Low Dose|10 patients 225 mg of BR-DIM. 2 capsules AM and 1 PM. 52 weeks duration.
62248159|NCT02483624|EXPERIMENTAL|High Dose|10 patients 375 mg of BR-DIM. 3 capsules AM and 2 PM. 52 weeks duration.
62248160|NCT02483624|PLACEBO_COMPARATOR|Placebo|10 patients receiving weight matched placebo. 5 for high dose and 5 for low dose. 52 weeks of weight matched pills.
62828091|NCT06507111|PLACEBO_COMPARATOR|Placebo|Matching placebo
62045933|NCT05339048||General group|18-80 years old adults from the Colombian Caribbean Coast.
62045934|NCT02240095|EXPERIMENTAL|Interventions: A + B + C|"See Interventions Description. In this arm, students will be offered all 3 online interventions combined:~* Intervention A - Online Clinical Questions Recorder~* Intervention B - Online Evidence Retrieval Coach~* Intervention C - Online Audit and Feedback"
62248161|NCT01668407|EXPERIMENTAL|Robot-Assisted Gait Training (RAGT)|Robot-Assisted Gait Training (RAGT): Subjects (at least 40) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.
62248162|NCT01668407|ACTIVE_COMPARATOR|Treadmill Gait Training (TT)|Treadmill Gait Training (TT): Subjects (at least 40) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.
62248163|NCT00478933|EXPERIMENTAL|ICD Therapy, blood sampling|Blood sampling Defibrillator, Dual Chamber ; Implantable
62248164|NCT04682704|EXPERIMENTAL|Frequency 20Hz; amplitude 1mA below discomfort threshold|Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 20Hz; amplitude 1mA below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
62605379|NCT06228872|SHAM_COMPARATOR|Control Group|Participants will receive Computerized Cognitive Training and sham tDCS daily for one month. Sham stimulation will consist of 60 seconds of anodal 2mA tDCS stimulation over the DLPFC, followed by 19 mins of no current delivery. The same 15 min of computerized cognitive training will be provided after the end of the Sham Stimulation.
62045935|NCT02240095|EXPERIMENTAL|Interventions A + B|"See Interventions Description. In this arm, students will be offered the 2 following interventions combined:~* Intervention A - Online Clinical Questions Recorder~* Intervention B - Online Evidence Retrieval Coach"
62248165|NCT04682704|ACTIVE_COMPARATOR|Frequency 5Hz; amplitude 1mA below discomfort threshold|Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 5Hz; amplitude 1mA below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
62248166|NCT04682704|ACTIVE_COMPARATOR|Frequency 20Hz; amplitude 50% below discomfort threshold|Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 20Hz; amplitude 50% below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
62248167|NCT04682704|ACTIVE_COMPARATOR|Frequency 5Hz; amplitude 50% below discomfort threshold|Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 5Hz; amplitude 50% below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
62248168|NCT02176187|EXPERIMENTAL|natural technique, without instructions|randomised sequence of Berodual® Respimat® and Berodual® MDI
62605380|NCT03461016|EXPERIMENTAL|Smartphone-Based Exposure Therapy|Participants assigned to the Smartphone-Based Exposure Therapy group will receive two weeks of exposure therapy via their smartphone. Participants will have the opportunity to receive up to 50 minutes of exposure video intervention daily for the two weeks.
62605381|NCT03461016|NO_INTERVENTION|Waitlist Control|Participants who have been randomly assigned to participate in the Waitlist Control group will not receive treatment; however, after the two weeks of no intervention, participants in this condition will be offered the same treatment as the treatment condition.
62605382|NCT01844505|EXPERIMENTAL|Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Ipilimumab 0 mg/kg solution intravenously on weeks 1, 4 and Placebo matching with Nivolumab on weeks 4 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
62605383|NCT01844505|EXPERIMENTAL|Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab|Nivolumab 1 mg/kg solution intravenously combined with Ipilimumab 3 mg/kg solution intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Nivolumab on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
62605384|NCT01844505|EXPERIMENTAL|Arm C: Ipilimumab+Placebo for Nivolumab|Ipilimumab 3 mg/kg solution intravenously every 3 weeks for a total of 4 doses plus Placebo matching with Nivolumab 0 mg/kg solution intravenously on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends (Placebo matching with Nivolumab is no longer required)
62605385|NCT00574223|EXPERIMENTAL|Arm 1|
62605386|NCT00574223|PLACEBO_COMPARATOR|Arm 2|
62045936|NCT02240095|EXPERIMENTAL|Interventions A + C|"In this arm, students will be offered the 2 following online interventions combined:~* Intervention A - Online Clinical Questions Recorder~* Intervention C - Online Audit and Feedback"
62248169|NCT02176187|EXPERIMENTAL|optimal technique, with instructions|randomised sequence of Berodual® Respimat® and Berodual® MDI
62248170|NCT01611753|ACTIVE_COMPARATOR|liberal group|Patients in the liberal group received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL.
62605387|NCT04498416||Group 1 Post-Traumatic Stress Disorder (PTSD)|children with an identified traumatic history
62605388|NCT04498416||Group 2 Pathology|children with psychological follow-up treatment for a psychiatric disorder, without traumatic history;
62605389|NCT04498416||Group 3 Control|children without traumatic experience and without psychiatric or psychological follow-up treatment.
62045937|NCT02240095|EXPERIMENTAL|Interventions B + C|"See Interventions Description. In this arm, students will be offered the 2 following online interventions combined:~* Intervention B - Online Evidence Retrieval Coach~* Intervention C - Online Audit and Feedback"
62045938|NCT02240095|EXPERIMENTAL|Intervention A alone|"See Interventions Description. In this arm, students will be offered only the following intervention:~\* Intervention A - Online Clinical Questions Recorder"
62248171|NCT01611753|ACTIVE_COMPARATOR|restrictive group|Patients in the liberal group received transfusions immediately, as the objective was to maintain hemoglobin levels above 7.0 g/dL.
62248172|NCT00514163|EXPERIMENTAL|1|gemcitabine + S-1
62045939|NCT02240095|EXPERIMENTAL|Intervention B alone|"See Interventions Description. In this arm, students will be offered only the following intervention:~\* Intervention B - Online Evidence Retrieval Coach"
62045940|NCT02240095|EXPERIMENTAL|Intervention C alone|"See Interventions Description. In this arm, students will be offered only the following intervention:~\* Intervention C - Online Audit and Feedback"
62045941|NCT02240095|NO_INTERVENTION|No intervention|In this arm, students will be offered none of the 3 online interventions, but will just be using the usual features of the search engine available to all users.
62248173|NCT00514163|ACTIVE_COMPARATOR|2|S-1
62045942|NCT06199258||Normal lung function|Normal lung function: After using a bronchodilator, FEV1/FVC ≥70%, FEV1 and FVC ≥80% of reference values.
62248174|NCT02615821|EXPERIMENTAL|Affective Mental Contrasting|"Before the goal formation or mental contrasting activities, participants will receive information about the affective benefits of exercising (e.g. regular physical activity has been shown to reduce stress, physical activity is enjoyable), and related research support including appropriate references. During the mental contrasting component of the activity the prompts will remain the same as the standard condition, with minor variations in questions in order to elicit affective judgements. Specifically, the affective condition will include the additional prompts Why might you find exercise to be enjoyable, pleasant, exciting, or fun? for eliciting outcomes, and Why might you find exercise to be unenjoyable, unpleasant, boring, or miserable? for eliciting obstacles."
62248175|NCT02615821|ACTIVE_COMPARATOR|Instrumental Mental Contrasting|"Before the goal formation or mental contrasting activities,participants will receive information about the instrumental benefits of exercising (e.g., regular physical activity reduces the risk of developing cancer) and related research support, again including appropriate references. During the mental contrasting component of the activity the prompts will remain the same as the standard condition, with minor variations in questions in order to elicit either instrumental judgements. Specifically, the instrumental conditions will include the prompts Why might you find exercise to be useful, advantageous, beneficial, or important? for eliciting outcomes, and Why might you find exercise to be unimportant, useless, inconvenient, or detrimental? for eliciting obstacles."
62248176|NCT02615821|ACTIVE_COMPARATOR|Standard Mental Contrasting|In the standard condition, the space where the affective and instrumental benefits of physical activity were listed in the instrumental and affective conditions, will be left blank in the standard condition, and no additional prompting questions will be given, allowing for the idiosyncratic identification of obstacles and outcome.
62248177|NCT02933632|ACTIVE_COMPARATOR|Standard Assistance Protocol-SAP|Patients underwent physical therapy once a day. Patients receive intervention by Physical Therapy-SAP.
62248178|NCT02933632|ACTIVE_COMPARATOR|Accelerated Rehabilitation Protocol-ARP|Patients underwent physical therapy three times a day. Patients receive intervention by Physical Therapy-ARP.
62248179|NCT03720899|EXPERIMENTAL|NicoBloc|NicoBloc participants will be provided with NicoBloc to use during counseling sessions and will test smoking their conventional cigarette with NicoBloc.
62248180|NCT03720899|ACTIVE_COMPARATOR|Nicotine Lozenge|Participants who receive nicotine lozenge will use the lozenge in session and will discuss the effects of using the lozenge in session.
62248181|NCT03298425|ACTIVE_COMPARATOR|Treatment NMES|Patients allocated to the NMES group will be given an information booklet on NMES machines. The Cefar Compex three electrical stimulator will be used. Participants are expected to use the NMES machine for half an hour and complete bed exercises twice daily. Patients should relax during the NMES as completing both does not demonstrate better results, due to unsynchronised activation of the NMES (Gregory \& Bickel, 2005). Using the machine once daily will allow for the recovery of the muscle. A voluntary contraction would normally be 20-30Hz but due to the high intensities of the NMES (35-75Hz) it can cause muscle fatigue (Maffiuletti, 2011).
62248182|NCT03298425|PLACEBO_COMPARATOR|Placebo NMES|The placebo group will act as the control group. They will be expected to complete the same regime as previously described above, however these machines will be on TENS setting (80-100Hz) as even low Hz can trigger motor stimulation (Paillard 2008). This setting is designed as a sensory stimulus therefore will have no effects on muscle strength however the patient will feel a small twitch sensation. This setting is not painful and will have no effect on muscle fatigue. The patient will not be expected to complete the bed exercises and the TENS session together.
62248183|NCT05744570||Male anesthesiologist|The anesthesiologist gender defined by first name
62605390|NCT05914675|EXPERIMENTAL|treatment arm|
62045943|NCT06199258||Preserved ratio impaired spirometry|After using a bronchodilator, FEV1/FVC≥70%, FEV1 and/or FVC\<80% of reference values.
62045944|NCT06199258||Chronic obstructive pulmonary disease|After using a bronchodilator, FEV1/FVC \<70%.
62045945|NCT06052241|ACTIVE_COMPARATOR|Post-treatment|After treatment using shampoo and scalp serum personalized according to their Scalp Photographic Index Artificial Intelligence (SPI-AI)-defined scalp types
62045946|NCT06052241|NO_INTERVENTION|Pre-treatment|
62248184|NCT05744570||Female anesthesiologist|The anesthesiologist gender defined by first name
62248185|NCT03476564|EXPERIMENTAL|intervention group|intervention group will receive pentoxifylline (Trental S.R.) 400 mg/BD plus vit E (PHARCO) 400 mg/BD 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled.
62605391|NCT00866333|EXPERIMENTAL|Entinostat|"Regimen determined by protocol version.~Regimen 1: entinostat 10 mg (two 5 mg tablets) orally, once every two weeks (Days 1 and 15) in a 28-day cycle until disease progression or unacceptable toxicity.~Regimen 2: entinostat 10 mg (two 5 mg tablets) orally on Day 1, increased to 15 mg (three 5 mg tablets) beginning on Day 15 of Cycle 1 for participants who had not experienced treatment-related adverse events with severity grade ≥2 (moderate), then continue 15 mg every two weeks (Days 1 and 15) in a 28-day cycle until disease progression or unacceptable toxicity.~Regimen 3: entinostat 15 mg (three 5 mg tablets), orally, once weekly for 3 weeks followed by a 1-week break in a 4-week (28-day) cycle until disease progression or unacceptable toxicity."
62605392|NCT03294291|ACTIVE_COMPARATOR|Quadratus Lumborum block group|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.7 ml/kg bupivacaine 0.25 % injected unilaterally at the posterior border of the quadratus lumborum muscle.
62605393|NCT03294291|ACTIVE_COMPARATOR|Caudal block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory caudal block wil performe with bupivacaine 0.7 ml/kg as 0.25%.
62605394|NCT03138746||HBO|On day 2, the participant will undergo a 2-hour hyperbaric exposure breathing 100% oxygen
62605395|NCT03138746||Hyperbaric air|On day 2, the participant will undergo a 2-hour hyperbaric exposure breathing air
62605396|NCT03564080|NO_INTERVENTION|Control - PAD|This group of patients will complete the 'standard care' of supervised exercise as recommended by NICE.
62605397|NCT03564080|EXPERIMENTAL|Combined - PAD and CAD|This group of PAD patients will exercise alongside CAD patients in an established supervised exercise programme (Cardiac Rehabilitation).
62605398|NCT01643733|EXPERIMENTAL|Transonics Arm|Intervention will be guided by flow through the fistula as guided by Transonics flow measurements
62605399|NCT01643733|NO_INTERVENTION|Control arm|Patient will undergo normal fistula intervention guided only by angiographic assessment
62828092|NCT02961894|EXPERIMENTAL|Revolution Treatment Arm|This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.
62045947|NCT01936857|EXPERIMENTAL|Buprenorphine/naloxone|Office based treatment of opioid dependence with buprenorphine/naloxone
62045948|NCT01936857|ACTIVE_COMPARATOR|Methadone Maintenance Therapy|Referral to methadone maintenance therapy for treatment of opioid dependence.
62045949|NCT01944631|PLACEBO_COMPARATOR|Placebo|Nasal spray 4 times a day over 4 to 10 days
62045950|NCT01944631|EXPERIMENTAL|Iota-Carrageenan nasal spray|Nasal spray 4 times a day over 4 to 10 days
62045951|NCT02203474|EXPERIMENTAL|Tiotropium HFA BAI 5 mcg|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
62045952|NCT02203474|EXPERIMENTAL|Tiotropium HFA BAI 10 mcg|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
62045953|NCT02203474|EXPERIMENTAL|Tiotropium HFA BAI 15 mcg|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
62045954|NCT02203474|ACTIVE_COMPARATOR|SPIRIVA HandiHaler|2 inhalations from one 18 mcg capsule daily
62045955|NCT02203474|PLACEBO_COMPARATOR|Placebo|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
62248186|NCT03476564|NO_INTERVENTION|comparison group|. The comparison group will not receive the above drugs. The main outcome measure will be clinical pregnancy rate.
62248187|NCT02925572|EXPERIMENTAL|Concentric cycling exercise (CON)|40 obese adolescents will be randomized into 2 groups: CON or EXC
62248188|NCT02925572|EXPERIMENTAL|eccentric cycling exercise (EXC)|40 obese adolescents will be randomized into 2 groups: CON or EXC
62045956|NCT02652741|EXPERIMENTAL|Drug administration|Enalapril Orodispersible Minitablet (ODMT), 0.25 mg or 1 mg, administered 1x/day or 2x/day for up to 8 weeks
62045957|NCT03764332|OTHER|Stabilometry|The Podoprint pressure platform was used as a measuring device. The Podoprint platform is a low profile floor platform consisting of 1.4 sensors / cm2 with a sampling frequency of 40Hz.
62045958|NCT04303949|EXPERIMENTAL|Experimental|e-book for termination
62045959|NCT04303949|OTHER|Control|routine care Written form health education
62045960|NCT01578148|EXPERIMENTAL|Noxipoint Therapy|
62045961|NCT01578148|ACTIVE_COMPARATOR|Physical Therapy|
62045962|NCT03797521|EXPERIMENTAL|SXC-2023 50mg QD|SXC-2023 50mg dosed once daily for 6 weeks
62045963|NCT03797521|EXPERIMENTAL|SXC-2023 200mg QD|SXC-2023 200mg dosed once daily for 6 weeks
62045964|NCT03797521|EXPERIMENTAL|SXC-2023 800mg QD|SXC-2023 800mg dosed once daily for 6 weeks
62045965|NCT03797521|PLACEBO_COMPARATOR|Matching Placebo QD|Matching Placebo dosed once daily for 6 weeks
62045966|NCT01299948|ACTIVE_COMPARATOR|prednisolone|5 mg prednisolone per os daily administration
62045967|NCT01299948|PLACEBO_COMPARATOR|placebo|The placebo is designed to the equal look like the study medication.
62045968|NCT03494166|NO_INTERVENTION|Low Need Benchmark or Follow-up|In the low need benchmark or follow-up group, survivors completed detailed baseline and 13-week assessments (about 30-40 minutes) over the telephone. A brief assessment (about 5 minutes) at week 4 over the telephone was used to assess symptoms.
62045969|NCT03494166|EXPERIMENTAL|High Need A: Start with SMSH alone for 4 weeks|Participants were mailed the printed Symptom Management and Survivorship Handbook (SMH). The Group A participant was called every week for 4 weeks to ask about symptoms and suggest strategies from the SMH to relieve symptoms. After 4 weeks, participants were re-randomized to continue in SMH for 8 more weeks or to add Telephone Interpersonal Counseling (TIPC) Intervention for the subsequent 8 weeks. If the TIPC was added, the counselor called the participant once per week for about 35-40 minutes to assess and discuss interpersonal relationships, communication, social support, managing symptoms and survivorship. At week 13, the participant completed the second assessment.
62045970|NCT03494166|EXPERIMENTAL|High Need B: Start with SMSH+TIPC|Participants were called every week for the first 8 weeks using a combination of TIP-C and SMH. The counselor called to assess and discuss interpersonal relationships, communication, social support, managing symptoms and survivorship. At the end of 8 weeks, the final 4 calls followed the SMSH alone protocol. At week 13, the second assessment was conducted.
62045971|NCT02055131|PLACEBO_COMPARATOR|aspirn fixed dose|patients of this arm will receive 100 mg of aspirin daily.over the period of follow up we will detect all thromboembolic events.
62045972|NCT02055131|PLACEBO_COMPARATOR|aspirin dose titrated with PFA-100|patients of this arm will receive 100 mg of aspirin daily.this dose will be multiplied whenever the PFA-100 is not suitable.once the time of occlusion is correct ,we will keep the same dose of aspirin and continue monitoring the PFA-100 durin the follow up period.
62045973|NCT02055131|NO_INTERVENTION|placebo arm|in this group of patients we will just supervise thromboembolic events of the vascular access.
62045974|NCT06270654|ACTIVE_COMPARATOR|Control group|Pre incision of 0.375% ropivacaine 10ml local infiltration will be given.
62045975|NCT06270654|EXPERIMENTAL|Ropivacaine group|Bilateral erector spinae plane block (0.375% 20ml ropivacaine on each side + adrenaline 1:200,000) pre incision.
62045976|NCT02047500|EXPERIMENTAL|TH-302 plus Nab-paclitaxel plus Gemcitabine|
62045977|NCT06492824|EXPERIMENTAL|Enjoyable Activities Condition|Watched an introduction video that discussed the rationale for the enjoyable activities intervention. During the initial visit, enjoyable activities participants were asked to choose five enjoyable activities from a large list that they wanted to do more frequently over the next four weeks. Over the next four weeks, daily text message reminders were sent each morning. These text messages reminded participants of the five enjoyable activities that they wanted to do and encouraged them to complete at least two of the of the enjoyable activities that day. Additionally, participants received a link to complete a daily checklist where they reported if they had completed any of their five activities on the previous day. At the end of the four-week period, enjoyable activities participants completed a post-intervention online survey consisting of the same measures from the initial survey.
62045978|NCT06492824|ACTIVE_COMPARATOR|Healthy Activities Condition|Participants in the healthy activities condition were promoted to complete the following five activities each day: drinking more water, going to bed early, brushing their teeth, showering or bathing that day, and eating well-balanced meals. Healthy activities condition participants also watched an introduction video that discussed the rationale for the healthy activities intervention. Daily text reminders were sent regarding these five healthy living activities each morning. Consistent with the enjoyable activities condition, healthy activities participants were asked to try to complete at least two of the five healthy activities each day but could do more if they desired. At the end of the month, they completed an online post-intervention survey consisting of the same measures from the pre-intervention assessment.
62045979|NCT06492824|NO_INTERVENTION|Passive Control|Control participants completed an initial online survey which also included an introduction video (approximately one and half minutes long) explaining the rationale for this specific condition and that researchers wanted to understand the naturalistic course of mood and behavior over the course of one month. However, passive control participants were not explicitly asked to complete any enjoyable activities or healthy living activities during the subsequent four weeks. Passive control participants were not sent daily text reminders or checklists to complete over the four-week period. They were asked to complete the same short weekly questionnaire asking about their mood for the preceding week. At the end of the month, they also completed a post online survey consisting of the same measures from the initial survey. Participants in this condition also had the option to complete the enjoyable activities digital intervention after completing the passive control condition if they desired.
62045980|NCT00754338|ACTIVE_COMPARATOR|Phase1 - Arm 1|
62045981|NCT00754338|ACTIVE_COMPARATOR|Phase1 - Arm 2|
62438223|NCT02387814|EXPERIMENTAL|Abemaciclib: Normal Hepatic Function|Single dose of Abemaciclib administered orally on Day 1 to participants with normal hepatic function.
62438224|NCT02387814|EXPERIMENTAL|Abemaciclib: Mild Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with mild hepatic impairment.
62828093|NCT03217604|PLACEBO_COMPARATOR|Placebo|Placebo
62828094|NCT03217604|EXPERIMENTAL|PF-06852231|Single ascending doses of PF-06852231
62045982|NCT00754338|ACTIVE_COMPARATOR|Phase 2 - Arm 1|
62045983|NCT00754338|ACTIVE_COMPARATOR|Phase 2 - Arm 2|
62045984|NCT04717726|EXPERIMENTAL|MT|Participants in the MT group will be supplemented with Milk Thistle extract for 12 weeks
62045985|NCT04717726|EXPERIMENTAL|LAC|Participants in the LAC group will be supplemented with Lactobacillus Gassri for 12 weeks
62045986|NCT04717726|EXPERIMENTAL|EX|Participants in the EX group will perform aerobic exercise, 5 days per week for 12 weeks
62045987|NCT04717726|EXPERIMENTAL|MT + EX|Participants in the MT + EX group will be supplemented with Milk Thistle extract and exercise for 12 weeks
62045988|NCT04717726|EXPERIMENTAL|LAC + EX|Participants in the LAC + EX group will be supplemented with Lactobacillus Gassri and exercise for 12 weeks
62045989|NCT04717726|PLACEBO_COMPARATOR|CON|Participants in the CON group will be supplemented with maltodextrin pills made to look like the pills received by the MT and LAC groups for 12 weeks
62438225|NCT02387814|EXPERIMENTAL|Abemaciclib: Moderate Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with moderate hepatic impairment.
62045990|NCT00335218|EXPERIMENTAL|Arm 1|
62045991|NCT00335218|PLACEBO_COMPARATOR|Arm 2|
62045992|NCT03364322||Dry eye syndrome|
62248189|NCT05511493|EXPERIMENTAL|fractional(Er: YAG) laser with platelet-rich plasma|"Subjected to fractional erbium: yttrium-aluminum-garnet (Er: YAG) laser (FotonaXs~* Dynamis, Slovenia) with the energy of 1400 mJ in short pulse mode (SP) with spot size of 7 mm diameter, frequency of 3 Hz, and pixel 1. PRP is applied over the treated areas.This procedure will be repeated every two weeks for six months"
62045993|NCT04823429|EXPERIMENTAL|High intensity-interval training (HIIT)|Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
62045994|NCT04823429|EXPERIMENTAL|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
62045995|NCT04823429|NO_INTERVENTION|Control group|Without any exercise training
62248190|NCT05511493|EXPERIMENTAL|Microneedling with platelet-rich plasma|"Subjected to microneedling using electronic dermapen device (Dr Pen Derma Pen Ultima A6®) which has a disposable head that personalized for each patient and sterilized after each session. The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern from the perilesional areas toward the depigmented center until pinpoint bleeding appears then the PRP is applied over the treated areas.~- This procedure will be repeated every two weeks for six months."
62248191|NCT02261779|EXPERIMENTAL|Tretinoin & Tranylcypromine|Tretinoin started with 45mg/m2 on day 7 for one year, administered orally as soft capsules, Tranylcypromine started with 10mg/d up to a maximum dose of 60mg/d for on year, administered orally as tablets
62438226|NCT02387814|EXPERIMENTAL|Abemaciclib: Severe Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with severe hepatic impairment.
62438227|NCT01993394|EXPERIMENTAL|ventilation|hypergravity gas mixture
62045996|NCT01276925|ACTIVE_COMPARATOR|B3: Blockade of three nerves|Peripheral nerve blockade of the femoral nerve, the anterior division of the obturator nerve, and the lateral femoral cutaneous nerve with ropivacaine.
62045997|NCT01276925|ACTIVE_COMPARATOR|B2: Blockade of 2 nerves|"Peripheral nerve blockade of the anterior division of the obturator nerve and the lateral femoral cutaneous nerve with ropivacaine.~Sham blockade of the femoral nerve with saline."
62045998|NCT01276925|SHAM_COMPARATOR|K: Control group|Sham blockade of the femoral nerve, the anterior division of the obturator nerve, and the lateral femoral cutaneous nerve with saline.
62045999|NCT05590780||Control|Evaluation of plasma cfDNA levels
62046000|NCT05590780||Periodontitis|Evaluation of plasma cfDNA levels
62046001|NCT05590780||Cardiovascular disease|Evaluation of plasma cfDNA levels
62046002|NCT05590780||Periodontitis + cardiovascular disease|Evaluation of plasma cfDNA levels
62438228|NCT04292574||Participants with Spinal Muscular Atrophy|
62449273|NCT05796609|EXPERIMENTAL|Treatment Group|"Driving under the influence of alcohol~Aware of the possible induction of alcohol (purpose of the study), but blinded to the actual amount and target blood alcohol concentration"
62449274|NCT05796609|NO_INTERVENTION|Reference Group|"Driving without the influence of alcohol or placebo~Fully informed"
62046003|NCT05741684|EXPERIMENTAL|iCBT and ABM|A combined internet-delivered Cognitive Behavioral Therapy (iCBT) and Attention Bias Modification (ABM) intervention to reduce depressive symptoms in firefighters.
62046004|NCT05741684|NO_INTERVENTION|Control|No intervention
62046005|NCT04021810|ACTIVE_COMPARATOR|CPAP only|Obstructive sleep apnea patients with CPAP treatment only
62248192|NCT02334124|EXPERIMENTAL|Home|Patients will be treated at home through the Hospital-In-The-Home program with intravenous once daily ceftriaxone (50mg/kg once daily), administered by a nurse/doctor visiting once daily.
62605400|NCT01934075|EXPERIMENTAL|Mental health treatment|Participants will receive twice-weekly exposure to 6 sessions of individual mental health treatment in a private room. Sessions will follow the intervention manual and be delivered by a full-time nurse facilitator who has a counseling background and receives supervision by a trained therapist.
62046006|NCT04021810|ACTIVE_COMPARATOR|Mandibular Advancement Device only|Obstructive sleep apnea patients with Mandibular Advancement Device only
62046007|NCT04021810|EXPERIMENTAL|CPAP + Mandibular Advancement Device|Obstructive sleep apnea patients with combined CPAP and Mandibular Advancement Device
62046008|NCT00441701|EXPERIMENTAL|Part 1: Navarixin 3 mg|Cohort 1: Participants receive navarixin 3 mg (three 1 mg capsules) once daily (QD) for up to 12 weeks
62046009|NCT00441701|PLACEBO_COMPARATOR|Part 1: Placebo to navarixin 3 mg|Cohort 1: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
62046010|NCT00441701|EXPERIMENTAL|Part 1: Navarixin 10 mg|Cohort 2: Participants receive navarixin 10 mg (one 10 mg capsule and two placebo capsules) QD for up to 12 weeks
62046011|NCT00441701|PLACEBO_COMPARATOR|Part 1: Placebo to navarixin 10 mg|Cohort 2: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
62046012|NCT00441701|EXPERIMENTAL|Part 1: Navarixin 30 mg|Cohort 3: Participants receive navarixin 30 mg (three 10 mg capsules) QD for up to 12 weeks
62248193|NCT02334124|ACTIVE_COMPARATOR|Ward|Patients will be admitted to hospital ward and treated with six hourly flucloxacillin (50mg/kg), administered by a ward nurse as per routine practice.
62248194|NCT05723354|ACTIVE_COMPARATOR|5ml axillary block group|interfascial plane axillary block group using 5 ml local anesthetics
62605401|NCT01934075|NO_INTERVENTION|Standard of Care|Participants in the control condition will receive counseling that is the current standard of care for fistula patients at KCMC.
62248195|NCT05723354|ACTIVE_COMPARATOR|10ml axillary block group|interfascial plane axillary block group using 10 ml local anesthetics
62046013|NCT00441701|PLACEBO_COMPARATOR|Part 1: Placebo to navarixin 30 mg|Cohort 3: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
62046014|NCT00441701|EXPERIMENTAL|Part 2: Navarixin 3 mg|Cohort 4: Participants receive navarixin 3 mg (three 1 mg capsules) QD for up to 12 weeks
62046015|NCT00441701|EXPERIMENTAL|Part 2: Navarixin 10 mg|Cohort 4: Participants receive navarixin 10 mg (one 10 mg capsule and two placebo capsules) QD for up to 12 weeks
62046016|NCT00441701|EXPERIMENTAL|Part 2: Navarixin 30 mg|Cohort 4: Participants receive navarixin 30 mg (three 10 mg capsules) QD for up to 12 weeks
62046017|NCT00441701|PLACEBO_COMPARATOR|Part 2: Placebo to navarixin|Cohort 4: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
62046018|NCT05242328|ACTIVE_COMPARATOR|post-operative VAS score of Ultrasound-guided erector spinae plane block|
62248196|NCT06491082||Baseline and after 4th cycle|Histopathologically diagnosed Solid Cancer Patients Planned for Platinum and Taxane based chemotherapy will be going for Neuropathy test- Nerve conduction test(NCV), vitamin D, B12 and Nox4 expression at Baseline and after 4th cycle of chemo
62248197|NCT02080247|ACTIVE_COMPARATOR|Intervention: Skin care regimen with Calmoseptine ointment|In this arm the patients with IAD will receive treatment with Calmoseptine Ointment for 6 days as a part of a structured skin regimen
62046019|NCT05242328|ACTIVE_COMPARATOR|post-operative VAS score of surgical thoracoscopic intercostal nerve block|
62046020|NCT03540654||Patients with CML discontinuing TKI treatment|
62046021|NCT03244072|ACTIVE_COMPARATOR|Treatment group|Intracameral injection of moxifloxacin solution after cataract surgery
62046022|NCT03244072|PLACEBO_COMPARATOR|Placebo group|Intracameral injection of placebo after cataract surgery
62046023|NCT05201573||Subjects historically treated with DIAM|Subjects randomized to the DIAM arm and treated with the DIAM™ Spinal Stabilization System in the IDE study OR randomized to the Control arm and crossed over to receive treatment with the DIAM™ Spinal Stabilization System in the IDE study
62046024|NCT00753792|ACTIVE_COMPARATOR|1|methylprednisolone 1.000 mg/day intravenous administration during three days + placebo of methylprednisolone orally administered
62046025|NCT00753792|EXPERIMENTAL|2|methylprednisolone 1.250 mg/day orally administered during three days + placebo of methylprednisolone intravenous administered
62248198|NCT02080247|ACTIVE_COMPARATOR|Control: Skin care regimen with Destin ointment|In this arm , patient will receive treatment with Destin Maximum Strength 40% Zinc Oxide. Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
62046026|NCT03501433|EXPERIMENTAL|Nicotinamide Riboside Chloride (Niagen)|7 days of nicotinamide riboside supplementation (250 mg/d x 2/day).
62046027|NCT03501433|PLACEBO_COMPARATOR|Placebo|7 days of placebo supplementation (2/day)
62046028|NCT05241704|EXPERIMENTAL|Endovenous ablation of superficial venous reflux + Fat grafting|Endovenous ablation of the main truncal venous reflux to the lowest point of incompetence, where possible (routine practice) + Fat grafting
62046029|NCT05241704|ACTIVE_COMPARATOR|Endovenous ablation of superficial venous reflux only|Endovenous ablation of the main truncal venous reflux to the lowest point of incompetence, where possible (routine practice)
62046030|NCT00286845||II|
62046031|NCT00286845||1|
62449275|NCT05796609|PLACEBO_COMPARATOR|Placebo Group|"Driving under the influence of a placebo~Not informed (blinded)"
62449276|NCT04207281|ACTIVE_COMPARATOR|Honey|Raw honey (1.5 tablespoons)
62449277|NCT04207281|PLACEBO_COMPARATOR|Comparator|Honey comparator(1.5 tablespoons)
62449278|NCT04645095|ACTIVE_COMPARATOR|Conventional TENS|Frequency:80 Hz, duration:100 μs
62449279|NCT04645095|ACTIVE_COMPARATOR|Burst TENS|Frequency:100 Hz, fr mod: 0, 200 µs, 2 Bps Hz
62449280|NCT04645095|ACTIVE_COMPARATOR|Modulated TENS|Frequency:80 Hz, fr mod: 50%, Amplitude mode: 40%, duration: 200 µs
62046032|NCT01696981|ACTIVE_COMPARATOR|Colorectal Screening|Participants undergo a colorectal examination with a flexible sigmoidoscope at baseline and year 5. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident colorectal cancers as all deaths that occur among both screened and control subjects during the trial.
62046033|NCT01696981|NO_INTERVENTION|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
62046034|NCT00419822|ACTIVE_COMPARATOR|Acupuncture|
62046035|NCT00419822|SHAM_COMPARATOR|Sham Acupuncture|
62046036|NCT00419822|PLACEBO_COMPARATOR|Standard of Care|
62046037|NCT05276466|OTHER|Single arm|All subject's samples will undergo the same diagnostic test utilizing Polymerase Chain Reaction and Next-Generation DNA Sequencing
62046038|NCT01864239|EXPERIMENTAL|Patient-centred tailored intervention|Medicines Advice Service
62046039|NCT01864239|NO_INTERVENTION|Control|Usual care
62046040|NCT03980444|EXPERIMENTAL|control group, no basket of wire|"The dividing person and the patients themselves were not aware of which group they were in. They were double-blind Was.~In each group, ureteroscopy was performed using a standard F9.5 ureteroscope. After reaching the rock in group A (control), the probe of the pneumatic crusher was passed through the working channel of the ureteroscope and began crushing the rock.~During the crushing process, the minimum flow of water, flattening and the single-shot impact was used to minimize the stone's retropulsion."
62046041|NCT03980444|SHAM_COMPARATOR|using a basket of wires|In group B (using a basket of wires3F) the helical type was passed through the four wires of the working channel of the orthoscope and routed to the proximal part of the rock, and the stone was routed to the bowl, then the stone was ducted The gasket was kept, and the probe of the pneumatic crusher also passed through the working channel and proceeded to break it down. Conditions were observed during the stomach as control group. Urethroscopic crushing was performed by a urologist in both groups under similar technical conditions. Findings during and after the completion of crushing include the success, stone retropulsion or parts larger than 3 mm, which requires secondary measures (SWL - ureter stenting, resection ureteroscopy), the duration of stone breakdown and traumatic ureteric complications in both groups it is registered
62046042|NCT02034708|EXPERIMENTAL|Dotarem®/Gadovist®|Dotarem®-enhanced MRI, then Gadovist®/Gadavist®-enhanced MRI
62046043|NCT02034708|EXPERIMENTAL|Gadovist®/Dotarem®|Gadovist®/Gadavist®-enhanced MRI then Dotarem® enhanced MRI
62046044|NCT05190250||Study group - women with idiopathic infertility|Endometrial biopsy during implantation window Blood analysis
62046045|NCT05190250||Control group - women with naturally conceived offspring|Endometrial biopsy during implantation window Blood analysis
62248199|NCT05691049|EXPERIMENTAL|HCC_45 treatment group|"Treatment of acne scars of the face by using a subcision+injection technique: the needle (25 G) or cannula (25 G) (wider areas are treated with the cannula) is inserted into the skin and made to move with a back-and-forth motion in order to detach scar collagen bundles. Then 1 syringe (2 ml) of HCC_45 is injected.~Day 0: Information and consent form provided, Clinical assessment, Digital clinical pictures, Instrumental assessment, Profilometry measurement.~First treatment of HCC_45 (refer to study protocol).~Day 30 (1 month after day 0): Clinical assessment, Digital clinical pictures, Instrumental assessment, Profilometry measurement.~Second treatment of HCC_45 (refer to study protocol).~Day 120 (4 months after day 0): Clinical assessment, Digital clinical pictures, Instrumental assessment, Profilometry measurement.~NO treatment, Self-evaluation questionnaire."
62605402|NCT01642485|ACTIVE_COMPARATOR|Moxifloxacin 400 mg fasted|Moxifloxacin 400 mg fasted was administered on Day 3. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo. Additionally, Caucasian vs Japanese subjects were analysed.
62046046|NCT03530930|EXPERIMENTAL|Comarum Palustre|Patients taking Comarum Palustre together with conventional treatment for osteoarthritis
62046047|NCT01708330|PLACEBO_COMPARATOR|Placebo gel|Placebo gel applied topically to the cervix
62046048|NCT01708330|EXPERIMENTAL|Lidocaine gel|2% lidocaine gel applied topically to the cervix
62605403|NCT01642485|EXPERIMENTAL|Moxifloxacin 400 mg fed|"Moxifloxacin 400 mg fed was administered on Day 3 after Continental breakfast. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo.~Additionally, Caucasian vs Japanese subjects were analysed."
62605404|NCT01143064|ACTIVE_COMPARATOR|Progesterone|
62605405|NCT01143064|PLACEBO_COMPARATOR|Lipid emulsion without progestrone|
62605406|NCT05150782|EXPERIMENTAL|Curcumin/Boswellia Serrata/Ascorbic acid mixture|The daily intake of 2x10 drops of a mixture of micellized curcumin(2%), boswellia serrata (1,5%) and ascorbic acid (6%).
62046049|NCT05308732|EXPERIMENTAL|Copaiba arm|It will consist of the group of patients who will use copaiba mouthwash. It will be subdivided into 6 consecutive cohorts.
62046050|NCT03672994||Asthma|Patients with prior confirmed diagnosis of bronchial asthma
62046051|NCT03672994||Chronic Obstructive Pulmonary Disease|Patients with prior confirmed COPD
62046052|NCT03672994||Pneumonia|Patients with X-ray confirmed community acquired pneumonia
62046053|NCT03672994||Heart failure|Patients with confirmed heart failure
62046054|NCT03672994||Healthy volunteers|Healthy participants with no otherwise known cardiorespiratory condition
62046055|NCT06029101|EXPERIMENTAL|chiari I malformation patients undergoing craniectomy|modalities and outcomes of surgical treatment of chiari I malformation patients
62046056|NCT02815462|EXPERIMENTAL|Intervention|FAM-FACE-SG risk score + decision making algorithm
62046057|NCT02815462|ACTIVE_COMPARATOR|Control|Usual Care
62046058|NCT01792479|EXPERIMENTAL|Arm A: BIND-014 every 3 weeks|
62046059|NCT01792479|EXPERIMENTAL|Arm B: BIND-014 weekly|
62046060|NCT01379872||Study Protocol A - IMRT Post Prostatectomy|"* Prospective TROG 08.03 (RAVES) Participants~* Prospective Participants (NOT participating in TROG 08.03 (RAVES))~* Retrospective TROG 08.03 (RAVES) Participants~* Participating in dosimetric evaluation and toxicity/QoL study~* Participating in dosimetric evaluation only"
62046061|NCT01379872||Study Protocol B - IMRT Anal Cancer|"* Retrospective Patient Datasets~* Prospective Participants (dosimetric evaluation and toxicity/QoL study)"
62046062|NCT01379872||Study Protocol C - IMRT Nasopharynx|"* Retrospective Patient Datasets~* Prospective Participants (dosimetric evaluation and toxicity/QoL study)~* Post-Treatment Prospective Participants (toxicity/QoL and cost study)"
62046063|NCT01379872||Study Protocol D - IGRT Intact Prostate|"Patients with prostate cancer~- A sample of 30 patients from at least 10 centres that are to be treated for intermediate risk prostate cancer will be enrolled. The sample will be selected to comprise at least 10 patients that will undergo non-IGRT, 10 that will undergo IGRT with fiducials and planar imaging, and 10 that will undergo IGRT with volumetric imaging."
62046064|NCT00689026|EXPERIMENTAL|Experimental|The lubiprostone group will receive an additional two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).
62046065|NCT00689026|ACTIVE_COMPARATOR|Control|All patients in the study will receive a standard oral dosing of 4L Polyethylene glycol with electrolytes colonoscopy preparation the day prior to their scheduled colonoscopy.
62046066|NCT02635451||study group|Study group included 20 pregnant women with PPROM and fulfilled the inclusion and exclusion criteria.
62046067|NCT02635451||control group|Control group also included 20 pregnant women without PPROM following every recorded case of PPROM and matched for gestational age.
62046068|NCT03089437|EXPERIMENTAL|Prolonged Standing|Subject stand for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
62046069|NCT03089437|EXPERIMENTAL|Prolonged Sitting|Subject sit for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
62046070|NCT03811964|OTHER|primary sleep-wake disorder|Subjects with primary sleep-wake disorder
62605407|NCT04744259|EXPERIMENTAL|Behavioural activation|The treatment is designed to be delivered to individuals alongside a carer who provides regular support to them. It is a structured, time limited, manualised psychological therapy, developed to treat those with an intellectual disability and depressive symptoms.
62046071|NCT03811964|OTHER|neurological pathology|subjects presenting a neurological pathology with disorder of the controls of the wake and the sleep
62605408|NCT04744259|NO_INTERVENTION|Treatment as usual|This will include the existing treatments available in NHS and social care for adults with intellectual disability with depression, including anti-depressants, mood stabilizers, and any available psychological interventions. Additionally, for all those in the study, we will provide their General Practitioner with a summary of the NICE guidelines on treatment of depression for adults with intellectual disabilities.
62046072|NCT03811964|OTHER|psychiatric pathology|subject presenting a psychiatric pathology with disorder of the controls of the wake and the sleep
62046073|NCT03811964|OTHER|ophthalmological pathology|subject presenting an ophthalmological pathology with possible alteration of the photoreception and / or phototransduction
62046074|NCT03811964|OTHER|photosensitivity|subjects with photosensitivity with regulation disorder of sleep and wake
62046075|NCT03811964|OTHER|group control|healthy subject
62046076|NCT05276830|EXPERIMENTAL|40 micrograms|Sublingual film containing 40 micrograms Dexmedetomidine
62046077|NCT05276830|EXPERIMENTAL|60 micrograms|Sublingual film containing 60 micrograms Dexmedetomidine
62046078|NCT05276830|EXPERIMENTAL|Placebo|Sublingual Placebo film
62046079|NCT04987762|EXPERIMENTAL|Adhansia XR|Adhansia XR capsules taken orally once daily in the morning
62046080|NCT03531047|EXPERIMENTAL|Refractive CXL|Tomography-customised CXL
62449281|NCT02748226||Retrospective cohort|This cohort retrospectively enrolls patients with lower extremity artery disease who underwent endovascular treatment from January 2006 to the date of approval by IRB in the participating hospitals.
62046081|NCT06016452|EXPERIMENTAL|Stratum A (Symptomatic)|Response rates at 1 month with a combination of steroids and CHL in this study is expected to be 65% as compared to the standard 50% response with the use of dexamethasone alone. For the study with an α of 0.1 and power of 80%,50 pts will be needed to achieve the desired output. In the first stage, 22 patients will be needed for assessment and continued to stage 2 if \>10 responses are seen.The stage 2 of the study will be considered successful if \>29 responses are achieved using the pre-specified response assessment criteria.Considering an attrition rate of 10% from lack of follow-up and another 10% for disease progression, an estimated 60 patients will be accrued in stratum A with the purpose of achieving 50 patients with endpoints available for analysis.
62046082|NCT06016452|EXPERIMENTAL|Stratum B (Asymptomatic)|"This stratum includes pts without neurological worsening during imaging diagnosis of RN (asymptomatic RN).Approx 30% of patients continue to be neurologically/ radiologically stable or regression of imaging findings without need for further interventions (including corticosteroids).In the proposed study with the use of CHL, 45% patients are assumed to remain clinically and neurologically stable. With an α of 0.1 and power of 80%, 48 patients will be needed to achieve the desired outcome. In the first stage, 23 patients will be needed for assessment and continue to stage 2 if \>6 responses are seen.~The phase 2 study will be considered successful if \>18 responses are achieved using the pre-specified response assessment criteria. Further considering an attrition rate of 10% from lack of follow-up and another 10% for disease progression, an estimated 58 patients will be accrued in stratum B with the purpose of achieving 48 patients with endpoints available for analysis."
62046083|NCT00511875|EXPERIMENTAL|Doxycycline Monohydrate|stratified equally to doxycycline monohydrate 50mg taken once daily for 24 months
62046084|NCT00511875|PLACEBO_COMPARATOR|Placebo|stratified equally to placebo taken once daily for 24 months
62046085|NCT00487617|EXPERIMENTAL|fruit juice|300 mL of fruit juice
62046086|NCT00487617|PLACEBO_COMPARATOR|placebo|300 mL of fruit juice without polyphenols
62046087|NCT04814082|ACTIVE_COMPARATOR|Medial-Pivot Knee System|Total Knee Arthroplasty will be done by implanting the MicroPort Medial Pivot Knee System into subjects.
62046088|NCT04814082|ACTIVE_COMPARATOR|Single Radius Design Total Knee System|Total Knee Arthroplasty will be done by implanting the Stryker Triathlon Tritanium Knee System into subjects.
62046089|NCT04886882|PLACEBO_COMPARATOR|Group placebo|Isotonic solution will be administered daily to 6 female rats.
62449282|NCT02748226||Prospective cohort|This cohort prospectively enrolls patients with lower extremity artery disease who undergo endovascular treatment from the date of approval by IRB to July, 2018 in the participating hospitals.
62046090|NCT04886882|SHAM_COMPARATOR|Group sham|Base cream to be applied twice a day to 6 female rats.
62046091|NCT04886882|EXPERIMENTAL|Group %1 mgso4|Cream containing 1% MgSO4 will be applied twice a day to 6 female rats.
62046092|NCT04886882|EXPERIMENTAL|Group %10 MgSO4|Cream containing 10% MgSO4 will be applied twice a day to 6 female rats.
62438229|NCT01138150|ACTIVE_COMPARATOR|Treximet|"Fourteen participants randomized to receive Treximet (sumatriptan \& naproxen) during an acute migraine attack. Blood drawn for immune \& inflammatory markers (adipocytokines,cytokines, sex hormones) at different time points - on presentation with moderate to severe migraine pain; then 30 minutes, 1 hour and 2 hours after administration of study drug (Treximet).~Participants will be offered a traditional headache rescue medicine at 2 hours after administration of Treximet if participant still reports moderate to severe pain and desires further treatment. Rescue medicine may include the following: prochlorperazine 10 mg IV preceded by diphenhydramine 25 mg IV/PO or metoclopramide 10 mg IV preceded by diphenhydramine 25 mg IV/PO or Toradol 30 mg IV to be determined by the physician."
62046093|NCT04886882|ACTIVE_COMPARATOR|Group positive control|Cream containing centella asiatica will be applied twice a day to 6 female rats.
62046094|NCT00799643|ACTIVE_COMPARATOR|1|Salsalate, 3.5 g/d orally, divided dosing
62605409|NCT05109871|EXPERIMENTAL|Kforce Link|
62046095|NCT00799643|PLACEBO_COMPARATOR|2|Salsalate Placebo, orally, divided dosing
62046096|NCT04011774|EXPERIMENTAL|PLANI-REV|Persons with schizophrenia who will benefit from the fifteen weekly sessions of PLANI-REV group program
62046097|NCT04011774|ACTIVE_COMPARATOR|RELAXATION|Persons with schizophrenia who will benefit from a non cognitive stimulation, namely RELAXATION, in a day-care clinic or day-care therapeutic activities center during fifteen weekly sessions. This activity will be 15 groups sessions of relaxation.
62046098|NCT00578084||surgery|those subjects who went to surgery to treat their lung cancer
62046099|NCT00578084||no surgery|those subjects who did not go to surgery for their lung cancer
62046100|NCT00578084||NSCLC|subjects with NSCLC
62046101|NCT00578084||Small cell lung cancer|those with small cell lung cancer
62605410|NCT01232621|EXPERIMENTAL|Physician introduction|Physicians will introduce Research Coordinators (RCs) by name to SDMs and acknowledge patient eligibility to participate in a study using a standardized script.
62046102|NCT04893655|EXPERIMENTAL|Dobutamine|dobutamine infusion will be started at 2mcg/kg/min after min 10 minutes dobutamine infusion will be raised to 5mcg/kg/min
62605411|NCT01232621|ACTIVE_COMPARATOR|Non-physician introduction (usual approach)|RCs will either introduce themselves or be introduced by a non-physician member of the health care team.
62605412|NCT02330757|ACTIVE_COMPARATOR|HRT group|Women will be subjected to HRT using Estradiol valerate before FET
62046103|NCT05242640|EXPERIMENTAL|Mindful attention|16 sessions over 8 weeks (2x/week) of mindful attention audio recordings delivered via headphones
62046104|NCT05242640|EXPERIMENTAL|Exercise|16 sessions over 8 weeks (2x/week) of moderate-intensity treadmill walking
62046105|NCT05242640|EXPERIMENTAL|Exercise with mindful attention|16 sessions over 8 weeks (2x/week) of moderate-intensity treadmill walking utilizing mindful attention audio recordings delivered via headphones
62046106|NCT05242640|NO_INTERVENTION|No intervention|No intervention sessions
62046107|NCT01459861|EXPERIMENTAL|Canal Block and Capsular Injection|Adductor canal block with a continuous catheter and ultrasound guided posterior capsular injection with local anesthetic solution.
62046108|NCT01459861|ACTIVE_COMPARATOR|Femoral with Tibial Nerve Block|Continuous femoral nerve block with catheter and selective tibial nerve block in the popliteal fossa.
62046109|NCT05458648||Persistent AF Arm|Patients undergoing cardiac ablation for the treatment of persistent atrial fibrillation
62046110|NCT01774513|EXPERIMENTAL|Procore Needle|
62046111|NCT02119910|EXPERIMENTAL|Technology Supported Manual|Participants in this arm will receive behavioral intervention for a period of 5 consecutive days. A total of 3, 45-minute meals will be held at regularly scheduled times (e.g., 9:00 a.m., 10:30 a.m., and 12:00 p.m.) each day for a total of 15 meals throughout treatment.
62046112|NCT02119910|NO_INTERVENTION|Waitlist|Participants will serve as the control condition.
62046113|NCT03985891|EXPERIMENTAL|JS001 in combination with Folfox|Patients who meet the enrollment criteria will receive Folfox(Oxaliplatin 85mg/m2 iv Day1; Leucovorin 400mg/m2 iv Day1; 5-FU 400mg/m2 iv bolus on Day1, then1200mg/m2/d x 2days(total 2400mg/m2 over 46-48 hours) iv continuous infusion repeat every 2 weeks) in combination with JS001 (3mg/kg, Q2W). Patients will receive 6 cycles treatment in pre-operation and same cycles after operation.
62046114|NCT03985891|ACTIVE_COMPARATOR|Folfox|Patients who meet the enrollment criteria will receive Folfox(Oxaliplatin 85mg/m2 iv Day1; Leucovorin 400mg/m2 iv Day1; 5-FU 400mg/m2 iv bolus on Day1, then1200mg/m2/d x 2days(total 2400mg/m2 over 46-48 hours) iv continuous infusion repeat every 2 weeks). Patients need to receive 6 cycles treatment in pre-operation and same cycles after operation.
62046115|NCT00703690|EXPERIMENTAL|1|MK0767; 2.5 mg/day
62046116|NCT00703690|EXPERIMENTAL|2|MK0767; 5mg/day
62046117|NCT00703690|EXPERIMENTAL|3|MK0767; 10 mg/day
62046118|NCT00703690|ACTIVE_COMPARATOR|4|fenofibrate 200 mg
62046119|NCT00703690|PLACEBO_COMPARATOR|5|Matching Placebo
62046120|NCT06149793|ACTIVE_COMPARATOR|empagliflozin|randomized to study medication (empagliflozin) 10 mg taken by mouth daily for 4 weeks
62046121|NCT06149793|PLACEBO_COMPARATOR|placebo control|randomized to placebo control taken by mouth daily for 4 weeks
62046122|NCT00349479|ACTIVE_COMPARATOR|Intervention|
62046123|NCT00349479|NO_INTERVENTION|Control|
62046124|NCT02495480|EXPERIMENTAL|sheathed group|The sterilized disposable sheath covered the outer surface of the colonoscope, then colonoscope will be performed in conventional way;a new sheath will be placed on the endoscope in sheathed group as a intervention
62046125|NCT02495480|NO_INTERVENTION|conventional group|Colonoscopy will be performed with air insufflation during insertion
62248200|NCT01106495|EXPERIMENTAL|Enhanced External Counterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. Patients with subclinical atherosclerosis whose serum LDL high than 160mg/ml receive EECP 1- hour session every working day over a 7 week period. Simvastatin is used to decrease cholesterol level for 7 weeks.
62605413|NCT02330757|ACTIVE_COMPARATOR|MOS group|Women will be subjected to MOS using sequential clomiphene citrate and gonadotropin before FET
62605414|NCT01920867|ACTIVE_COMPARATOR|RB, ST, IV|Injections of BMSC retrobulbar (RB), subtenon (ST) and intravenous (IV)
62605415|NCT01920867|ACTIVE_COMPARATOR|RB, ST, IV, IVIT|Injections of BMSC retrobulbar, subtenon, intravenous and intravitreal ( IVIT )
62605416|NCT01920867|ACTIVE_COMPARATOR|RB, ST, IV, IO|Injection of BMSC retrobulbar, subtenon, intravenous and intraocular (IO) with vitrectomy
62605417|NCT04240275||Children with Cerebral Palsy|Children diagnosed with Spastic Cerebral Palsy (Unilateral or Bilateral) among the age range of 5-15 who can walk independently
62605418|NCT01432964||1|Adult patients (\>18 years) presenting a unilateral orbital blow-out or blow-in fracture of ≥ 2.0cm2, causing an actual or expected functional or aesthetical deficit.
62605419|NCT00431873|EXPERIMENTAL|1|MGCD0103 administered orally three times per week.
62046126|NCT01033357|ACTIVE_COMPARATOR|Graft, Vascular Wrap|Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
62046127|NCT01033357|PLACEBO_COMPARATOR|Graft|Lifespan® ePTFE Vascular Graft Only
62046128|NCT05904665|EXPERIMENTAL|ctDNA dynamic monitoring + routine postoperative follow-up|"Dynamic monitoring of ctDNA + routine postoperative follow-up: ctDNA detection is performed within one month before surgery, within one month after surgery, and every three months after surgery, for a period of 2 years. At the same time, routine postoperative follow-up is given.~Follow-up intervention\*: After completion of adjuvant chemotherapy in the patient, if ctDNA detection suggests positive, immediate chest, abdomen, and pelvis CT and other imaging examinations are performed to determine whether there is recurrence or metastasis. If it is not confirmed, repeat imaging examinations are carried out every two months in the follow-up process, and ctDNA detection is continued every three months according to the schedule. If two consecutive ctDNA retests are negative, the above imaging follow-up will resume at the frequency of routine follow-up."
62605420|NCT03094676|NO_INTERVENTION|Control|Only the HRV will be followed for two hours without intervention.
62046129|NCT05904665|NO_INTERVENTION|Routine postoperative follow-up|Routine postoperative follow-up: Only routine postoperative follow-up is given as follows: Physical examination and CEA were performed every 3-6 months for the first 2 years, every 6 months within the third to fifth year, and then annually. Chest/abdominal/pelvis computed tomography was performed annually for up to 5 years, and colonoscopy was performed for proper patients the first year after treatment and repeated in the third year if no advanced adenoma was found and then every 5 years.
62046130|NCT05052086|EXPERIMENTAL|Magnetomotoric ultrasound|Magnetomotoric ultrasound in addition to MRI.
62046131|NCT02905201||mCRPC participants|Participants will not receive any intervention as a part of this study. Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) who have adequate response to treatment (abiraterone Acetate + prednisone) will be observed to collect data for ECOG performance status, safety assessments (as described above), the collection of PROs (BPI-short form, Pain VAS, HCU questionnaire), the assessment of disease status and parameters, and the assessment of participant compliance to treatment.
62046132|NCT04763057|EXPERIMENTAL|indirect pulp treatment with NeoPUTTY MTA|
62046133|NCT04763057|ACTIVE_COMPARATOR|indirect pulp treatment with calcium hydroxide|
62046134|NCT02610738|EXPERIMENTAL|Junior KICk-OFF education programme|Participants will attend an age appropriate self management programme (Junior KICk-OFF) designed to improve their knowledge and understanding of type 1 diabetes
62046135|NCT01961336|EXPERIMENTAL|Testosterone|"Long depot follicular GnRH agonist protocol. On day 21 initiation of ovarian stimulation with recombinant FSH for ICSI. If necessary downregulation will be achieved with additional daily agonist s.c.~10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI."
62046136|NCT01961336|NO_INTERVENTION|Control|Long depot follicular GnRH agonist protocol. On day 21 initiation of ovarian stimulation with recombinant FSH for ICSI. If necessary downregulation will be achieved with additional daily agonist s.c.
62046137|NCT04779138|EXPERIMENTAL|Increasing Uptake of COVID-19 Vaccination|"This is a pre-experimental one group pretest-posttest design to increase COVID-19 vaccine uptake and completion among African American and Latinx public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by our ACTIVATE triad leaders and our researchers. We will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention."
62046138|NCT06118268|ACTIVE_COMPARATOR|Active iTBS|
62046139|NCT06118268|SHAM_COMPARATOR|Sham iTBS|
62046140|NCT00569582|EXPERIMENTAL|1|
62046141|NCT02311205|EXPERIMENTAL|TACE+sorafenib|Concurrent Conventional Transarterial Chemoembolization (TACE) and Sorafenib
62438230|NCT01138150|PLACEBO_COMPARATOR|Sugar Pill|"Fourteen participants randomized to receive placebo during an acute migraine attack. Blood is drawn for immune \& inflammatory markers (adipocytokines,cytokines), sex hormones at different time points - on presentation with moderate to severe migraine pain, then 30 minutes, 1 hour and 2 hours after administration of placebo.~Participants will be offered a traditional headache rescue medicine at 2 hours after administration of placebo if participant still reports moderate to severe pain and desires further treatment. Rescue medicine may include the following: prochlorperazine 10 mg IV preceded by diphenhydramine 25 mg IV/PO or metoclopramide 10 mg IV preceded by diphenhydramine 25 mg IV/PO or Toradol 30 mg IV to be determined by the physician."
62438231|NCT00996554|EXPERIMENTAL|Double-Layer-Suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
62046142|NCT00885092|OTHER|FID 114675A / RepleniSH|FID 114675A in Period 1; RepleniSH in Period 2. Each solution was used for 7 days for cleaning, rinsing, conditioning, disinfecting, and storing silicone hydrogel contact lenses, per protocol-specified instructions. A new pair of silicone hydrogel contact lenses was dispensed at the start of each period and worn bilaterally on a daily wear basis.
62248201|NCT01106495|ACTIVE_COMPARATOR|Control|Subjects whose LDL higher than 160 mg/dl with subclinical atherosclerosis. Simvastatin is used to decrease cholesterol level for 7 weeks.
62438232|NCT00996554|ACTIVE_COMPARATOR|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread).
62046143|NCT00885092|OTHER|RepleniSH / FID 114675A|RepleniSH in Period 1; FID 114675A in Period 2. Each solution was used for 7 days for cleaning, rinsing, conditioning, disinfecting, and storing silicone hydrogel contact lenses, per protocol-specified instructions. A new pair of silicone hydrogel contact lenses was dispensed at the start of each period and worn bilaterally on a daily wear basis.
62046144|NCT03284034|ACTIVE_COMPARATOR|Cyrolipolysis|
62046145|NCT03284034|EXPERIMENTAL|Deoxycholic Acid|
62248202|NCT03122275|EXPERIMENTAL|Stepwise intervention|"Stepwise approach, with increasing complexity and cost, to improve adherence to organized cervical cancer screening, implemented through three steps:~step 1a - customized text message invitation; step 1b - customized automatic phone call invitation; step 2 - secretary phone call; step 3 - health professional phone call and face-to-face appointment.~Intervention stops whenever the participant adheres to organized screening or after undergoing the complete stepwise intervention."
62438233|NCT02531022|ACTIVE_COMPARATOR|Control|Participants will be given standard exercise recommendations that are given to all patients based on the federal guidelines. They will monitor their step counts using a wearable device and receive daily feedback.
62438234|NCT02531022|EXPERIMENTAL|Intervention|Participants will be given a wearable device to monitor daily step counts with automated daily feedback on goal attainment via text message or email. A baseline step count will be calculated for each participant (weeks 1-2) and then they will be given a daily step goal with an increase of 15 percentage point each week during the 8-week ramp-up period (weeks 3-10) with a maximum goal of 10,000 steps. Then they'll be asked to maintain that step count (maintenance period). During the ramp-up and maintenance period they'll have a financial incentive of $14 allocated each week and $2 taken away each day the goal is not achieved. They'll be followed up for 8 weeks without incentives
62449283|NCT01911975|PLACEBO_COMPARATOR|Placebo|Patients with gain-of-function Nav 1.7 related small fiber neuropathy in this arm will receive placebo.
62605421|NCT03094676|EXPERIMENTAL|Only Massage|Only the massage, and will have the monitoring of the HRV on the techniques and accompanied for two hours.
62605422|NCT03094676|EXPERIMENTAL|Only Exercise|Only the exercise, and will have the monitoring of the HRV on the techniques and accompanied for two hours.
62605423|NCT03094676|EXPERIMENTAL|Exercise and Massage immediately|Performing the exercise and massage immediately after, will be accompanied by the HRV during the techniques and two hours after.
62605424|NCT03094676|EXPERIMENTAL|Exercise and Massage after recovery|Performing the exercise and massage will be applicated after recovery of HRV, will be accompanied by the HRV during the techniques and two hours afte
62605425|NCT04439305|EXPERIMENTAL|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62046146|NCT05449964|EXPERIMENTAL|TEST GROUP|INTERVENTION: Scaling and root planning (SRP) of two contra-lateral quadrants (randomly allocated) in single sitting with ultrasonic scaler, hand scalers and curettes under local anaesthesia.
62605426|NCT05267990|ACTIVE_COMPARATOR|coronary artery calcium-guide|"1500 asymptomatic T2DM patients who will receive Coronary artery calcium (CAC) imaging using 256 sliced multi-detector computerized tomography (MDCT) scanner If CAC score \>0, Treadmill ECG or Thallium201 Scan would be arranged. If Treadmill ECG or Thallium201 show significant ischemia, further study such as CT angiography or coronary angiography will be arranged.~If CAC score \> 100， Aspirin 100mg QD will be suggested to decrease the cardiovascular risk in patients with low risk of bleeding. Previous studies revealed aspirin for patients with CAC score\>100 at low bleeding risk indicated net benefit If CAC score \> 400，statin therapy will be suggested to control lipidemia aggressively and target LDL level\<70 mg/dL"
62605427|NCT05267990|NO_INTERVENTION|usual care|The investigators will enroll 500 age, gender, risk factor matched T2DM patient from our hospital. The doctor in charge will give usual care according to the Diabetes associate of Taiwan clinical practice guidelines for diabetes care.
62046147|NCT05449964|ACTIVE_COMPARATOR|CONTROL GROUP|INTERVENTION: Supra-gingival scaling followed by sub-gingival scaling and root planing of two contra-lateral quadrants (randomly allocated) in two sittings with ultrasonic scaler, hand scalers and curettes under local anaesthesia.
62046148|NCT02396745|EXPERIMENTAL|TECR & ECM|Subjects undergoing TECR with ECM placement Intervention is Trans-oral Endoscopic circumferential resection (TECR) with placement of extra-cellular matrix (ECM)
62046149|NCT00602056|EXPERIMENTAL|1|Redesigned immunization card
62046150|NCT00602056|EXPERIMENTAL|2|Center based education to mothers/caregivers
62046151|NCT00602056|EXPERIMENTAL|3|Redesigned immunization card with center based education to mothers/caregivers
62046152|NCT00602056|NO_INTERVENTION|4|Standard care only
62248203|NCT03122275|ACTIVE_COMPARATOR|Written Letter|Comparator will be the standard of care of invitation to cervical cancer screening: written letter
62248204|NCT01782365|EXPERIMENTAL|0,75 Hz stimulation|transcranial slow oscilliating stimulation (tSOS)during periods of SWS
62828095|NCT06655051|ACTIVE_COMPARATOR|Fully covered self-expanding metal stent|A single biliary fcSEMS will be placed under ERCP. During stenting period , if symptoms of biliary obstruction occur due to stent occlusion or migration, ERCP replacement or implantation of a new stent should be performed according to the condition. After 6 months of stenting, imaging evaluation will be performed. ERCP is not needed if the stent undergoes spontaneous complete distal migration and the patient is asymptomatic and has normal liver function. If the stent is visible, ERCP will be performed to remove the stent and the stricture will be evaluated. If stricture persists after 6 months of stenting, a follow-up treatment plan should be developed through multidisciplinary discussion. One month after ERCP, complications will be followed up by telephone. Follow-up after biliary stent removal will be conducted to inquire about symptoms, signs and liver function test results, and to evaluate the recurrence of biliary stricture.
62046153|NCT01615874|EXPERIMENTAL|MF/F MDI 50/10 mcg BID|
62605428|NCT06363526|EXPERIMENTAL|Patients with Duchenne muscular dystrophy and Becker muscular dystrophy|A group of 12 patients with Duchenne muscular dystrophy and Becker muscular dystrophy that will be following a digital respiratory physiotherapy program.
62605429|NCT01904903|OTHER|HER2 therapies, cardiac medications|"Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses~Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:~* Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.~* Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.~* Ado trastuzumab emtansine (TDM1): 3.6mg/kg IV every three weeks."
62046154|NCT01615874|EXPERIMENTAL|MF/F MDI 100/10 mcg BID|
62046155|NCT01615874|EXPERIMENTAL|MF/F MDI 200/10 mcg BID|
62248205|NCT01782365|SHAM_COMPARATOR|SHAM stimulation|SHAM stimulation during periods of SWS
62248206|NCT01942148|EXPERIMENTAL|Aripiprazole|Aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over 52 weeks to subjects who complete the 031-09-003 study
62449284|NCT01911975|EXPERIMENTAL|Lacosamide|Patients with gain-of-function Nav 1.7 related small fiber neuropathy in this arm will receive lacosamide.
62605430|NCT03286933|EXPERIMENTAL|Yoga therapy intervention|Participants will participate in weekly yoga therapy sessions and have the opportunity to use the home video online.
62605431|NCT06482177|OTHER|Dry Eye Disease|Patient with dry eye disease
62605432|NCT01195844||Brazilian Children With Rotavirus Gastroenteritis|Brazilian children under 5 years of age who have diarrhea attributed to rotavirus located in 4 hospitals from 4 different Brazilian regions
62605433|NCT01005888|EXPERIMENTAL|C1INH-nf First, then Placebo|1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by matching placebo (saline) administered IV every 3 to 4 days for 12 weeks.
62605434|NCT01005888|EXPERIMENTAL|Placebo First, then C1INH-nf|Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by 1,000 U of C1INH-nf administered IV every 3 to 4 days for 12 weeks.
62605435|NCT02243046|PLACEBO_COMPARATOR|Control toothpaste|1450 ppm Fluoride toothpaste
62605436|NCT02243046|EXPERIMENTAL|Experimental toothpaste|1450 ppm sodium fluoride toothpaste with a zinc base
62605437|NCT02243046|ACTIVE_COMPARATOR|Active comparator|1450 ppm sodium fluoride/triclosan toothpaste
62605438|NCT04554992|EXPERIMENTAL|Treatment|All subjects recruited will be transfused with COVID 19 convalescent plasma. A prospective comparison with matched historical controls receiving standard care will be employed.
62605439|NCT05963828|OTHER|Standard group|Patients are managed according to the routine methods after enrollment.
62605440|NCT05963828|EXPERIMENTAL|Experimental group|Patients are managed by the social network platform.
62605441|NCT02733198|EXPERIMENTAL|Prognosis-guided|Duration of bed rest and duration of length of stay will be guided according to a predefined prognostic algorithm.
62605442|NCT02733198|NO_INTERVENTION|Standard medical therapy|Duration of bed rest and duration of length of stay will be decided by the attending physician.
62605443|NCT00948415|EXPERIMENTAL|SURI Enhanced|
62605444|NCT00948415|ACTIVE_COMPARATOR|SURI Standard|
62605445|NCT03558841|EXPERIMENTAL|Intervention Group|Gait training with the THERA-Trainer Lyra (3x/week) in addition to conventional geriatric rehabilitation physical therapy (6x/week) during inpatient period. After discharge home, continuation of Lyra gait training (3x/week), discontinuation of physical therapy.
62605446|NCT03558841|ACTIVE_COMPARATOR|Control Group|Conventional geriatric rehabilitation physical therapy (6x/week) during inpatient period. After discharge home, discontinuation of physical therapy.
62605447|NCT03101852|EXPERIMENTAL|Nutritional therapy|Children included in the study with severe acute malnutrition receive Plumpy Nut: WHO recommends a Plumpy Nut® prescription of 75 to 100 kcal/kg/d in children aged 5 to 10 years and 60 to 90 kcal/kg/d above that age. The lowest value was used and maximum energy intake provided by RUF was limited to 2,000 kcal/d i.e. 4 sachets in order to preserve habitual diet and prevent appetite saturation
62046156|NCT01615874|ACTIVE_COMPARATOR|BDP HFA 160 mcg BID|
62046157|NCT01615874|ACTIVE_COMPARATOR|Montelukast 5 mg QD (4 mg QD for 5-year-olds)|
62046158|NCT05872373|EXPERIMENTAL|Intervention Group|Cases are the community people in the study area where interventions will be provided to measure the outcome of the study.
62046159|NCT01102244|EXPERIMENTAL|Tobradex ST|tobramycin 0.3%, dexamethasone 0.05%
62046160|NCT01102244|ACTIVE_COMPARATOR|Azasite|azithromycin 1%
62248207|NCT04077450|NO_INTERVENTION|Modified Waitlist Control Arm|Participants will complete the following components of baseline (T1) data collection: demographics, questionnaire, heart rate variability assessment. Two weeks later, participants will be asked to complete post-intervention data collection (T2), which consists of a questionnaire and heart rate variability assessment. After the completion of data collection, participants will be offered the online heart-focused breathing intervention.
62248208|NCT04077450|EXPERIMENTAL|Intervention Arm|Participants will complete the following components of baseline (T1) data collection: demographics, questionnaire, heart rate variability assessment. These participants will receive an online heart-focused breathing intervention. Participants will be asked to practice their breathing skills while monitoring their heart rate variability using the Welltory app on their smart device for the following two weeks. Participants will be instructed to maintain a log to record the date and time of each practice session. Research staff will make biweekly reminder calls to participants. After the two-week period, participants will complete post-intervention data collection (T2), which includes a questionnaire and HRV assessment.
62248209|NCT00343616|EXPERIMENTAL|Tamoxifen for 5 years|Patients treated with tamoxifen for 5 years after randomization.
62248210|NCT00343616|EXPERIMENTAL|Letrozole for 5 years|Patients treated with letrozole for 5 years after randomization.
62605448|NCT03101852|EXPERIMENTAL|Nutritional supplementation|Children included in the study with moderate acute malnutrition receive Plumpy Sup: 60kcal/kg/day, limited to 4 doses/day.
62046161|NCT04266379|EXPERIMENTAL|Closed-Loop Control (CLC)|Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm
62046162|NCT04266379|ACTIVE_COMPARATOR|Sensor Augmented Pump (SAP)|Closed-loop subcutaneous insulin infusion and continuous glucose monitoring manage by patient
62046163|NCT04767607||Breast cancer plus chemotherapy|Patients of the group will receive chemotherapy treatment.
62046164|NCT04767607||Breast cancer without chemotherapy|Patients of the group will not receive chemotherapy treatment.
62828096|NCT06655051|EXPERIMENTAL|single plastic stent|A single biliary plastic stent will be placed under ERCP. During stenting period , if symptoms of biliary obstruction occur due to stent occlusion or migration, ERCP replacement or implantation of a new stent should be performed according to the condition. After 6 months of stenting, imaging evaluation will be performed. ERCP is not needed if the stent undergoes spontaneous complete distal migration and the patient is asymptomatic and has normal liver function. If the stent is visible, ERCP will be performed to remove the stent and the stricture will be evaluated. If stricture persists after 6 months of stenting, a follow-up treatment plan should be developed through multidisciplinary discussion. One month after ERCP, complications will be followed up by telephone. Follow-up after biliary stent removal will be conducted to inquire about symptoms, signs and liver function test results, and to evaluate the recurrence of biliary stricture.
62046165|NCT01010594|ACTIVE_COMPARATOR|Fruit restricted|Type 2 diabetics are advised to restrict their fruit intake to two pieces or less daily.
62046166|NCT01010594|ACTIVE_COMPARATOR|Fruit ad libitum|Type 2 diabetics are advised to eat at least two pieces of fruits daily
62046167|NCT01179204||Patiens operated with TKA|
62046168|NCT02275065|EXPERIMENTAL|Bictegravir 5 mg|Bictegravir 5 mg (1 × 5 mg tablet) for 10 days
62046169|NCT02275065|EXPERIMENTAL|Bictegravir 25 mg|Bictegravir 25 mg (1 × 25 mg tablet) for 10 days
62046170|NCT02275065|EXPERIMENTAL|Bictegravir 50 mg|Bictegravir 50 mg (2 × 25 mg tablets) for 10 days
62046171|NCT02275065|EXPERIMENTAL|Bictegravir 100 mg|Bictegravir 100 mg (1 × 100 mg tablet) for 10 days
62828097|NCT04530617|ACTIVE_COMPARATOR|Camostat mesilate|100 mg tablet, 600 mg/day. Oral, 2 tablets three times a day, after a meal (600 mg total daily dose) Days 1-14.
62828098|NCT04530617|PLACEBO_COMPARATOR|Camostat Placebo|Matched placebo
62828099|NCT04530617|ACTIVE_COMPARATOR|Artemisia annua|Tea 225mg per bag,1350 mg/day. Oral, one 8 oz brewed tea (two bags) three times a day, Days 1-14.
62046172|NCT02275065|PLACEBO_COMPARATOR|Placebo|Placebo matched to bictegravir tablet for 10 days
62046173|NCT00833560|EXPERIMENTAL|Cyclophosphamide + Bortezomib + Dexamethasone|Part 1 will be the dose titration part for cyclophosphamide. Participants will receive cyclophosphamide, bortezomib, and dexamethasone for 3 cycles. In Part 2, participants will receive cyclophosphamide (dose determined in Part 1) with pre-defined dose of bortezomib and dexamethasone for 3 cycles.
62046174|NCT02865720|EXPERIMENTAL|Subjects 2 to 5 years of age|500 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks
62046175|NCT02865720|EXPERIMENTAL|Subjects 6 years of age and older|1000 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks.
62046176|NCT01499082|EXPERIMENTAL|HOE901-U300|
62046177|NCT01499082|ACTIVE_COMPARATOR|Lantus|
62046178|NCT03192605|EXPERIMENTAL|Blueberry|150 grams wild blueberries
62046179|NCT03192605|PLACEBO_COMPARATOR|Placebo|Placebo control
62046180|NCT04781738||patients with history of vascular ring who didn't have corrective surgery|patients with history of vascular ring who didn't have corrective surgery
62046181|NCT04781738||patients with history of vascular ring who underwent corrective surgery|patients with history of vascular ring who underwent corrective surgery
62046182|NCT01032733|EXPERIMENTAL|Lifestyle Counseling|In the experimental condition, participants attended a group-based weight management session plus three supervised exercise sessions each week.
62046183|NCT01032733|PLACEBO_COMPARATOR|Educational Control|Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss.
62046184|NCT01186445|EXPERIMENTAL|Morphine chlorhydrate|Intracoronary injection of morphine chlorhydrate during reperfusion
62046185|NCT01186445|PLACEBO_COMPARATOR|Saline solution|Intracoronary injection of saline solution during reperfusion
62046186|NCT00566579|EXPERIMENTAL|A|Double-freezing cryotherapy was done within one month after the primary hpv testing was positive. Pap smear and colposcopy were done at 6 months and 12 months. HPV testing was repeated again at 12 months.
62046187|NCT00566579|NO_INTERVENTION|B|Pap smear and colposcopy were done at 6 months and 12 months. HPV testing was repeated again at 12 months.
62046188|NCT03386201|EXPERIMENTAL|Intravenous methylene blue|
62248211|NCT00343616|EXPERIMENTAL|Tamoxifen 2 years plus letrozole 3 years|Patients treated with tamoxifen for 2 years and afterwards with letrozole for 3 years.
62248212|NCT00343616|EXPERIMENTAL|Letrozole for 2 years plus tamoxifen for 3 years|Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.
62248213|NCT01968395|OTHER|Caspofungin 70 mg|Infusion of one dose of Caspofungin 70 mg
62828100|NCT04530617|PLACEBO_COMPARATOR|Artemisia annua Placebo|Matched placebo
62828101|NCT05423210|EXPERIMENTAL|Treatment|
62828102|NCT04558619|OTHER|Kōmmour Prenatal|
62828103|NCT01748292|ACTIVE_COMPARATOR|Monthly IVT ranibizumab|Monthly intravitreal injections (IVT) ranibizumab for 24 months, not less than 21 days apart to not more than 35 days apart
62248214|NCT00916539|EXPERIMENTAL|Cast that immobilizes the thumb|Cast that immobilizes the thumb
62828104|NCT01748292|EXPERIMENTAL|Treat and Extend IVT ranibizumab|0.5 mg intravitreal injections (IVT) ranibizumab for 3 consecutive months followed by a treat and extend protocol in which follow-up intervals are increased when there is no clinical and SD-OCT evidence of disease activity by 2-week intervals and patients are treated at every visit. (Comparator arm)
62828105|NCT01632696|EXPERIMENTAL|I-124 PGN650 for PET/CT|
62828106|NCT06654128|NO_INTERVENTION|high-definition white-light endoscopy|patients undergoing first and second colonoscopy with high-definition white-light endoscopy
62828107|NCT06654128|ACTIVE_COMPARATOR|artificial intelligence|patients undergoing first colonoscopy with high-definition white-light endoscopy and second colonoscopy with artificial intelligence
62828108|NCT03609073|EXPERIMENTAL|Intervention|
62828109|NCT04502095|EXPERIMENTAL|Group I (trimethoprim-sulfamethoxazole, nitrofurantoin)|Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care. At the time of full diet, patients receive trimethoprim-sulfamethoxazole PO daily or nitrofurantoin PO daily on days 1-30. Patients complete a drug diary for each day they receive the antibiotic.
62248215|NCT00916539|ACTIVE_COMPARATOR|Cast that does not immobilize the thumb|Cast that does not immobilize the thumb
62248216|NCT04056065|ACTIVE_COMPARATOR|Normal Saline|Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
62248217|NCT04056065|EXPERIMENTAL|PMZ-2010 (centhaquine)|Hypovolemic shock patients will be provided the standard of care. Following randomization PMZ-2010 (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.
62248218|NCT03332914|ACTIVE_COMPARATOR|First group|control group fisrt and after washing out Microcurrent therapy: Channel A: 100µA; 200 Hz Duration of each treatment session: 30 minutes Number of sessions: 10
62248219|NCT03332914|ACTIVE_COMPARATOR|Second group|"Microcurrent therapy: Channel A: 100µA; 200 Hz Duration of each treatment session: 30 minutes Number of sessions: 10~after washing out control group"
62828110|NCT04502095|ACTIVE_COMPARATOR|Group II (standard of care)|Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care.
62828111|NCT04013997|EXPERIMENTAL|Exoskeletal-assisted walking training group|Prospective subjects were recruited following admission to the SCI inpatient unit at Mount Sinai Hospital. Attending physicians and rehabilitation clinicians identified patients admitted to the unit who may be eligible for the study.
62438235|NCT02443428||Eribulin Mesilate|Participants will be treated in accordance with normal clinical practice. The recommend dose of eribulin is 1.23 mg/m2 administered intravenously on days 1 and 8 of every 21-day cycle. Treatment with eribulin is continued until disease progression, onset of unacceptable drug toxicities, or participant/physician's request to discontinue.
62449285|NCT02137083|EXPERIMENTAL|Docetaxel Plus Fulvestrant|"Docetaxel:75mg/m2 D2 every 21 days~Fulvestrant:500mg D1, D15, D29, D57, every 28 days later"
62449286|NCT02137083|ACTIVE_COMPARATOR|Docetaxel|Docetaxel:75mg/m2 D2 every 21 days
62449287|NCT03958890|EXPERIMENTAL|HLX10|
62449288|NCT03958890|PLACEBO_COMPARATOR|placebo|
62248220|NCT05662475|EXPERIMENTAL|group 1: Systemically Healthy, Periodontally Healthy (n:11)|Plaque index, gingival index, bleeding on probing index, probing pocket depth and clinical attachment level were measured at 6 sites (buccomesial, midbuccal, buccodistal, lingual/palatal mesial, midlingual/palatal, lingual/palatal distal) of each tooth to evaluate the periodontal status of the patients. On the day of examination, panoramic radiographs were taken from all patients to determine alveolar bone loss. Gingival crevicular fluid is collected from the patients. Gingival crevicular fluid samples were collected from 5 randomly selected teeth with GI=0, PI=0 and PPD ≤3. Then, each paper strip from each tooth was individually placed in sterile 0.5 ml eppendorf tubes. Eppendorf tubes were stored at -80°C. Oral hygiene education was given to each patient. Modified Bass technique was explained as a brushing technique. Interdental brush or dental floss was recommended for interdental cleaning according to the condition of the patient's interdental areas and its use was demonstrated.
62248221|NCT05662475|EXPERIMENTAL|group 2: Systemically Healthy, Periodontitis (n:11)|Plaque index, gingival index, bleeding on probing index, probing pocket depth and clinical attachment levels were measured from 6 sites of each tooth to evaluate the periodontal status of the patients. Panoramic radiographs were taken from all patients. Vertical/horizontal bone loss on the radiographs was evaluated to determine the stage and grade of periodontitis. Gingival crevicular fluid samples were collected from the 5 periodontal pockets with the deepest PPD before and 3 months after treatment. Eppendorf tubes were stored at -80°C. Non-surgical periodontal treatments were started under local anesthesia. Oral hygiene education was given to each patient after treatment. Modified Bass technique was explained as a brushing technique. Interdental cleaning was explained. The patient was told not to use any chemical agent for plaque removal. 3 months after the treatment gingival crevicular fluid samples are collected and clinical examination parameters were measured again.
62438236|NCT03360201|EXPERIMENTAL|Intervention: Tuko Pamoja|The intervention, Tuko Pamoja, is delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. The content and structure has been adapted in both content and implementation model based on formative research in this context. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection.
62438237|NCT02517359|EXPERIMENTAL|Single dose, healthy volunteers|
62438238|NCT02517359|EXPERIMENTAL|14 day repeat dose, healthy volunteers|
62438239|NCT02517359|EXPERIMENTAL|28 day repeat dose, healthy volunteers|
62438240|NCT02517359|EXPERIMENTAL|14 day repeat dose, asthma patients|
62438241|NCT02517359|EXPERIMENTAL|14 day repeat dose, smokers|
62438242|NCT02330679|OTHER|Desvenlafaxine|2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine
62828112|NCT04013997|NO_INTERVENTION|Matched control group|"Twenty inpatients with SCI were identified as the matched control group through reviewing an acute inpatient rehabilitation database of Uniform Data System for Medical Rehabilitation by a person blinded to the study.~The control group received a minimum of 15 hours of standard of care, including physical and occupational therapy, for acute inpatient rehabilitation per week. The control groups received the same amount of acute rehabilitation time per week as the intervention group."
62828113|NCT06601595||(TNF) inhibitors|1- Patients taking biologic (infliximab) treatment
62438243|NCT00497367|EXPERIMENTAL|TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent|This arm received the TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent.
62828114|NCT06601595||conventional IBD medical Treatment|patients taking conventional IBD medical Treatment
62828115|NCT05855707|EXPERIMENTAL|maximum tolerated dose|"1. x10e6 WJ-MSC/kg/infusion for 3 weekly infusions 1.5x10e6 WJ-MSC/kg/infusion for 3 weekly infusions~2. x10e6 WJ-MSC/kg/infusion for 3 weekly infusions"
62605449|NCT06528795|EXPERIMENTAL|İntervention group (n:40)|"Intervention group students will be practiced with the Lactation Simulator, a high-reality simulator, in the simulation laboratory, accompanied by a scenario.~Lactation Simulation Model (LSM) is a high fidelity simulator and is an applied and wearable breastfeeding model that educators can use for interactive training. LSM can be worn like a t-shirt and is placed over the shoulders and placed on the chest, then secured with a seat belt from the back. Thus, the seat belt can be adjusted for every size and weight. LSM is a simulator with the ability to respond to hand manipulation.~Thanks to this feature, simulated milk release occurs when pressure is applied to the breast tissue, which is approximately 3 cm behind both nipples. It is also a suitable model for expressing milk by hand or with a pump. LSM has four different skin tones. The fact that LSM can be applied on clothing contributes significantly to the protection of privacy."
62248222|NCT05662475|EXPERIMENTAL|grup 3: Controlled Type 2 Diabetes, Periodontally Healthy (n:11)|Plaque index, gingival index, bleeding on probing index, probing pocket depth and clinical attachment level were measured at 6 sites (buccomesial, midbuccal, buccodistal, lingual/palatal mesial, midlingual/palatal, lingual/palatal distal) of each tooth to evaluate the periodontal status of the patients. On the day of examination, panoramic radiographs were taken from all patients to determine alveolar bone loss. HbA1c values were measured. Gingival crevicular fluid is collected from the patients. Gingival crevicular fluid samples were collected from 5 randomly selected teeth with GI=0, PI=0 and PPD ≤3. Then, each paper strip from each tooth was individually placed in sterile 0.5 ml eppendorf tubes. Eppendorf tubes were stored at -80°C. Oral hygiene education was given to each patient. Modified Bass technique was explained as a brushing technique. Interdental cleaning was explained.
62248223|NCT05662475|EXPERIMENTAL|group 4: Controlled Type 2 Diabetes, Periodontitis (n:11)|Plaque index, gingival index, bleeding on probing index, probing pocket depth and clinical attachment levels were measured from 6 sites of each tooth to evaluate the periodontal status of the patients. Panoramic radiographs were taken from all patients. Vertical/horizontal bone loss on the radiographs was evaluated to determine the stage and grade of periodontitis. HbA1c levels are determined. Gingival crevicular fluid samples were collected from the 5 periodontal pockets with the deepest PPD before and 3 months after treatment. Samples were stored at -80°C. Non-surgical periodontal treatments were started under local anesthesia. Oral hygiene education was given after treatment. Modified Bass technique was explained as a brushing technique. Interdental cleaning was explained. The patient was told not to use any chemical agent for plaque removal. 3 months after the treatment gingival crevicular fluid samples are collected and clinical examination parameters were measured again.
62438244|NCT04158830|OTHER|Group 1 - ACOG recommended dose|oral dose: 81 mg aspirin daily; designated by odd number assignment \[1-001, 1-003, 1-005, etc. to 899\]
62605450|NCT06528795|NO_INTERVENTION|Control group (n:40)|"Control group students will practice on a simple breast model within the scope of classical education.~Simple Breast Model: Can be used to teach and practice breast palpation techniques. The breast has real female breast size, skin color and elastic softness. Institutional permission will be requested for the Simple breast model in the basic skills laboratory of the Midwifery Department of Hamidiye Faculty of Health Sciences."
62605451|NCT02553707|EXPERIMENTAL|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
62605452|NCT01671150|PLACEBO_COMPARATOR|Placebo control|half of the participants will receive a placebo control
62605453|NCT01671150|ACTIVE_COMPARATOR|Endotoxin (Inflammatory challenge)|
62605454|NCT04318639|EXPERIMENTAL|Donepazil+CRT|Donepazil+CRT
62605455|NCT03218319|EXPERIMENTAL|All patients|
62828116|NCT04080505|ACTIVE_COMPARATOR|SSKI (Potassium Iodide)|Participants randomized to receive 7 days of pre-operative SSKI
62828117|NCT04080505|NO_INTERVENTION|NO SSKI|Participants randomized to not receive any drug pre-operative
62828118|NCT02360254||Patients shifting to insulin degludec|Patients shifting from twice daily glargine or detemir to once daily degludec. This change in therapy will have to be decided by the diabetologist and the patient, not done for the purpose of the study.
62828119|NCT02360254||Patients remaining on twice daily glargine/detemir|Patients continuing on twice daily glargine or detemir
62828120|NCT04475146||Standard information and video visualization|Standard information and video visualization
62828121|NCT04475146||Standard information, no video|Standard information, no video
62828122|NCT06586645|EXPERIMENTAL|"Safety Planning and Give to Others Module"|"A standard suicide risk assessment and management protocol followed by the Give to Others Module which is a brief cognitive behavioral intervention."
62828123|NCT06586645|ACTIVE_COMPARATOR|Safety Planning|A standard suicide risk assessment and management protocol.
62828124|NCT06603766|ACTIVE_COMPARATOR|Nebulized magnesium (NebMag) group 1|NebMag group (n=20) was administered nebulized isotonic magnesium (64 mg/mL). For nebulization, an isotonic MgSO₄ solution (64 mg/mL) was formulated by diluting a 10% intravenous preparation of MgSO₄ heptahydrate with sterile distilled water. 4 mL aliquots of the isotonic MgSO₄ solution (containing 256 mg of MgSO₄) were administered every 15 minutes through the jet nebulizer connected to the ventilator during the 24 hour study period.
62828125|NCT06603766|ACTIVE_COMPARATOR|Intravenous magnesium (IVMag) group 2|IVMag group (n=20) received intravenous magnesium. For intravenous administration, a 10% MgSO₄ solution was prepared by diluting a 50% intravenous formulation of MgSO₄ heptahydrate with 5% glucose and administrated in a loading dose of 2 mL/kg over 30 minutes (equivalent to 200 mg/kg of MgSO₄), followed by a continuous infusion at a rate of 0.5 mL/kg/h (equivalent to 50 mg/kg/h of MgSO₄) over the 24 hour study period.
62828126|NCT03730753|ACTIVE_COMPARATOR|Control group|Continuous infusion + patient controlled epidural analgesia
62828127|NCT03730753|EXPERIMENTAL|Study group|Programmed intermittent epidural bolus + patient controlled analgesia
62828128|NCT02515370|EXPERIMENTAL|Friends for Life Circles (FLC)|The intervention will include formation of peer support groups of eight to ten women in the community with incorporation of income generating activities to improve maternal adherence to clinic appointments and life long antiretroviral therapy
62828129|NCT02515370|NO_INTERVENTION|Standard of Care (SOC)|Normal standard of care and follow up. The standard care provided in the clinic will be provided for the control arem
62828130|NCT01473888|OTHER|T89|
62605456|NCT02739308|EXPERIMENTAL|Intervention: Proprioceptive Training|"The intervention will be the implementation of a proprioceptive training program for the fencing athletes in the intervention group.~In this study the training program will be developed for 12 weeks and will be applied during the heating of the athletes, three times a week and the duration of each session is 30 minutes. Each week will be chosen three of the 14 exercises adapted for fencing athletes, and preferably one of each category. The categories have exercises with different levels of difficulty and can change the exercises occur by different proposed levels or the complexity of the exercise by changing category. The training program will be implemented by the same evaluator over the 12 weeks."
62046189|NCT06121154||PEX-positive patients|The criteria to diagnose Pseudoexfoliation syndrome (PEX) were, after pupillary dilatation, the presence of white fluffy dandruff-like material on one or more anterior segment structures, including the pupillary margin, the anterior lens capsule, or the angle in biomicroscopic examination. The patients were divided into two groups: solely based on PEX-positive (n=48) and PEX-negative (n=48) status
62248224|NCT05662475|EXPERIMENTAL|grup 5: Uncontrolled Type 2 Diabetes, Periodontally Healthy (n:11)|Plaque index, gingival index, bleeding on probing index, probing pocket depth and clinical attachment level were measured at 6 sites (buccomesial, midbuccal, buccodistal, lingual/palatal mesial, midlingual/palatal, lingual/palatal distal) of each tooth to evaluate the periodontal status of the patients. On the day of examination, panoramic radiographs were taken from all patients to determine alveolar bone loss. HbA1c values were measured. Gingival crevicular fluid is collected from the patients. Gingival crevicular fluid samples were collected from 5 randomly selected teeth with GI=0, PI=0 and PPD ≤3. Then, each paper strip from each tooth was individually placed in sterile 0.5 ml eppendorf tubes. Eppendorf tubes were stored at -80°C. Oral hygiene education was given to each patient. Modified Bass technique was explained as a brushing technique. Interdental cleaning was explained.
62438245|NCT04158830|ACTIVE_COMPARATOR|Group 2 - Comparison Dose|oral dose: 162 mg aspirin daily; designated by even number assignment \[2-002, 2-004, 2-006, etc. to 900\]
62605457|NCT02739308|PLACEBO_COMPARATOR|Control|The control group will not make the intervention and will continue with the usual training fencing.
62605458|NCT03240224|ACTIVE_COMPARATOR|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (\> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62605459|NCT03240224|ACTIVE_COMPARATOR|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
62828131|NCT06414369|EXPERIMENTAL|Experimental group|This group will receive eight sessions of 20 minutes, for four weeks, twice a week.
62828132|NCT06414369|PLACEBO_COMPARATOR|Control group|The treatment will be simulated during eight sessions of 20 minutes (machine will be off), for four weeks, twice a week.
62828133|NCT06595797|EXPERIMENTAL|Treatment group 1|
62438246|NCT05554510||Hospitalized Patients with Arterial Catheters|
62438247|NCT02546284|EXPERIMENTAL|Single Agent lenzilumab|Dose levels: lenzilumab IV infusion once monthly for a 28 day dosing cycle (with extra dose on Day 15 during cycle). Three (3) to Six (6) subjects will be enrolled into planned escalating cohorts of 200 mg, 400 mg or 600 mg lenzilumab.
62438248|NCT02071381|EXPERIMENTAL|A|only DW330SR 45mg
62438249|NCT02071381|EXPERIMENTAL|B|only DW1030 75mg
62828134|NCT06595797|EXPERIMENTAL|Treatment group 2|
62828135|NCT06595797|EXPERIMENTAL|Treatment group 3|
62828136|NCT04611646|EXPERIMENTAL|Heat-suit training|Low-intensity endurance training with heat suit
62828137|NCT04611646|OTHER|Non-heat-suit training|Low-intensity endurance training without heat suit
62828138|NCT06587841|EXPERIMENTAL|Group 1 Treatment|TSCS at or between cervical spinal segment 5 (C5) and thoracic spinal segment 10 (T10) at Intervention Phases 1 and 2, 8 weeks each.
62828139|NCT06587841|SHAM_COMPARATOR|Group 2 Sham|TSCS at or between C5 and T10 at Intervention Phase 2; 8 weeks.
62828140|NCT04857476|OTHER|skin psoriasis participants|Single arm study
62248225|NCT05662475|EXPERIMENTAL|group 6: Uncontrolled Type 2 Diabetes, Periodontitis (n:11)|Plaque index, gingival index, bleeding on probing index, probing pocket depth and clinical attachment levels were measured from 6 sites of each tooth to evaluate the periodontal status of the patients. Panoramic radiographs were taken from all patients. Vertical/horizontal bone loss on the radiographs was evaluated to determine the stage and grade of periodontitis. HbA1c levels are determined. Gingival crevicular fluid samples were collected from the 5 periodontal pockets with the deepest PPD before and 3 months after treatment. Samples were stored at -80°C. Non-surgical periodontal treatments were started under local anesthesia. Oral hygiene education was given after treatment. Modified Bass technique was explained as a brushing technique. Interdental cleaning was explained. The patient was told not to use any chemical agent for plaque removal. 3 months after the treatment gingival crevicular fluid samples are collected and clinical examination parameters were measured again.
62248226|NCT00843648||preterms|mother and preterm babies
62248227|NCT00843648||term-bfing|term breastfed babies and mothers
62248228|NCT00843648||term-PIF|term non breastfed babies and mothers
62248229|NCT00843648||c-section|c-section babies and their mothers
62248230|NCT05638815||Parkinson's Disease (PD)|
62248231|NCT05638815||Multiple System Atrophy (MSA)|
62248232|NCT05638815||Health volunteers|
62248233|NCT05141162|EXPERIMENTAL|case group|In the first stage, an information form including socio-demographic characteristics prepared within the framework of the literature and State-Trait Anxiety Inventory will be applied to mothers before surgery. Later, the experimental group will be knitted by the researcher during the surgical operation. The necessary materials (knitting needle and thread) for the knitting attempt will be given to the participants in the experimental group by the researcher. A neutral color, white, will be used as the knitting yarn color. Knitting will start 15 minutes after the child enters the operation and will be knitted for 30-40 minutes on average. At the end of the surgery, the State-Trait Anxiety Inventory scale will be applied again to evaluate the anxiety levels of the participants in the experimental and control groups. The vital signs of the mothers will be measured at the beginning of the operation and close to the end of the operation.
62248234|NCT05141162|NO_INTERVENTION|control group|An information form including socio-demographic characteristics prepared within the framework of the preoperative literature and State-Trait Anxiety Inventory will be applied to mothers. No attempt will be made to this group. At the end of the surgery, the State Trait Anxiety Inventory scale will be applied again to evaluate the anxiety levels of the participants in the experimental and control groups. The vital signs of the mothers will be measured at the beginning of the operation and near the end of the operation.
62828141|NCT04029636||Established LONIPC|The first cohort will comprise of patients with established LONIPCs and the investigative procedures in this study will provide data on the scope of abnormalities and pathology across the spectrum of these conditions.
62828142|NCT04029636||Trajectory of LONIPC|The second, prospectively followed, cohort will provide data on the sequence and temporal development of these abnormalities, and therefore provide information on the trajectory of LONIPCs
62828143|NCT03889808||Non immunosuppressed patients|without treatment or treated with Salicylates and that have not received immunosuppressive therapy, steroids, or biologics in the last 6 months.
62605460|NCT03240224|EXPERIMENTAL|Combination therapy|"In this group, the patients will receive combination therapy, including ablation and life information rehabilitation therapy. They will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (\> 2 cm), then drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
62248235|NCT03123250|EXPERIMENTAL|Aquablation procedure|
62248236|NCT05112627||Observational (biospecimen collection)|Patients undergo blood sample collection at baseline prior to SBRT or PCA, then at 14 days, 3 and 6 months after SBRT or PCA.
62248237|NCT02671045||A - Genomic profile by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and an actionable target has been identified and the patient/physician agree to receive the targeted therapy
62248238|NCT02671045||B - Genomic profiling by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and an actionable target has been identified. However, the patient does not receive the targeted therapy.
62248239|NCT02671045||C - Genomic profiling by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and no actionable target has been identified.
62248240|NCT02671045||D - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target has been identified and the patient/physician agrees to receive the targeted therapy.
62438250|NCT02071381|EXPERIMENTAL|C|DW330SR 45mg and DW1030 75mg
62828144|NCT03889808||Patients with immunosuppressive therapy|Azathioprine, 6-Mercaptopurine, Methotrexate in standard dosage at least the past 6 months and that have not received steroids or biologics in the last 6 months.
62828145|NCT03889808||Patients with biologic agents|in standard dosage at least the past 6 months and that have not received steroids in the previous 6 months.
62828146|NCT03889808||Patients with steroid treatment|Must have received daily steroid treatment ≥ 20 mg for ≥ 2 weeks.
62828147|NCT03889808||Healthy subjects|A healthy subject is defined as not having and immunosuppressive underlying condition, not receiving immunosuppressive therapy, has not received antibiotic treatment in the last 6 months, has no past C. difficile infections and has not been in contact with the health care system or hospitalized in the previous 6 months.
62046190|NCT06121154||PEX-negative patients|The criteria to diagnose Pseudoexfoliation syndrome (PEX) were, after pupillary dilatation, the presence of white fluffy dandruff-like material on one or more anterior segment structures, including the pupillary margin, the anterior lens capsule, or the angle in biomicroscopic examination. The patients were divided into two groups: solely based on PEX-positive (n=48) and PEX-negative (n=48) status
62046191|NCT02872987||B-ALL/NHL|
62046192|NCT02872987||ALL/ Lymphoblastic Lymphoma (LBL)|
62046193|NCT03371940|EXPERIMENTAL|Talk therapy (CBT)|"Participants randomized the talk therapy arm received 10 weeks of CBT or talk therapy. The goal of CBT was to provide individuals with skills and concepts that they may use to: 1) manage and reduce depressive symptoms; 2) prevent the onset and severity of future depressive episodes; and 3) generalize these skills to diabetes management.~CBT interventionists facilitated patient management of depressive symptoms by providing participants with:~* Education about depression and the cognitive-behavioral therapy model;~* A safe relationship for participants to explore their symptom patterns and try to new tools to address them;~* Coaching as participants fully engage emotional and behavioral strategies."
62046194|NCT03371940|EXPERIMENTAL|Exercise (EXER)|Participants randomized to the exercise arm were enrolled in a 12-week physical activity intervention designed to increase aerobic physical activity. Participants were asked to complete 100 minutes of aerobic activity in Week 1, 125 minutes in Week 2, and 150 minutes per week of physical activity in Weeks 3-12. In addition, participants received 6 exercise training classes in which safe exercise practices were introduced and practiced, free access to a local exercise facility, use of a pedometer, completion of activity logs each week, and received an exercise workbook that addressed social and motivational aspects of physical activity.
62046195|NCT03371940|EXPERIMENTAL|Talk therapy + exercise (CBT+EXER)|Participants randomized to the combination therapy received both talk therapy and exercise concurrently over a 12-week period as detailed above.
62046196|NCT03371940|PLACEBO_COMPARATOR|Usual care (UC)|Participants randomized to usual care received no study intervention.
62046197|NCT01693068|EXPERIMENTAL|Pimasertib|
62046198|NCT01693068|ACTIVE_COMPARATOR|Dacarbazine|
62046199|NCT05938257|EXPERIMENTAL|TMJ dysfunction|TMJ discopexy
62248241|NCT02671045||E - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target has been identified. However, the patient does not receive targeted therapy.
62828148|NCT05005234|EXPERIMENTAL|GFH925|"Phase Ia Dose Escalation Subjects with advanced NSCLC and gastrointestinal tumors will be enrolled in dose escalation cohorts based on Bayesian optimal interval (BOIN) design.~Phase Ia Dose Expansion Upon completing the dose exploration part of the study and depending on data obtained, dose expansion may proceed with responsive groups consisting of subjects with KRAS G12C mutant advanced NSCLC. Dose expansion may be done concurrently.~Phase Ib Subjects with KRAS G12C mutant advanced colorectal cancer or other tumors will be enrolled and treated at the monotherapy RP2D to evaluate the efficacy.~Phase 2 Subjects with KRAS G12C mutant advanced NSCLC will be enrolled and treated at the monotherapy RP2D to evaluate the safety and efficacy."
62828149|NCT05196152|ACTIVE_COMPARATOR|MomMoodBooster Online|
62828150|NCT05196152|EXPERIMENTAL|MomMoodBooster + Coach|
62046200|NCT04747730|EXPERIMENTAL|Transcendental Meditation training|The intervention of the project is the teaching and learning of Transcendental Meditation technique. The technique involves the use of a sound (mantra) to effortlessly allow the mind to settle down to a state of inner calm. It is a simple, natural and effortless practise, and unlike other meditation strategies, it does not involve concentration or control of the mind. The practice does not require any religion, philosophy, or change in lifestyle. Once learned the technique, participants will practice it twice a day, 20 minutes every morning and 20 minutes in the afternoon.
62046201|NCT04747730|NO_INTERVENTION|control|no intervention
62046202|NCT04928105|EXPERIMENTAL|CD7 CAR-T|
62248242|NCT02671045||F - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target NOT has been identified.
62248243|NCT02671045||G - No genomic profiling|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has not been sent for genomic profiling.
62248244|NCT02079090|ACTIVE_COMPARATOR|Ketofol|Patient will receive 0.5 mg/kg Ketamine, and 2 minutes later receive 1 mg/kg Propofol.
62046203|NCT01257841|PLACEBO_COMPARATOR|Fasting alone|
62046204|NCT01257841|ACTIVE_COMPARATOR|Fasting plus leptin|
62046205|NCT01231529|EXPERIMENTAL|Part 1 Cohort 1|8 subjects with moderate hepatic impairment defined by a Child-Pugh score of 7 to 9 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug.
62248245|NCT02079090|EXPERIMENTAL|Fentofol|Patient will receive 1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol.
62248246|NCT03759483||AI group|The visual field reports in this group will be evaluated by the convolutional neural network.
62248247|NCT03759483||Human group|The visual field reports in this group will be evaluated by 3 ophthalmologists independently.
62248248|NCT05018260|EXPERIMENTAL|GCMRT|Attention bias modification: participants will receive gaze-contingent feedback according to their viewing patterns on disgusted and neutral faces
62828151|NCT02476877||Prescribed-drug treatment group|Eight hundred (800) subjects of which 200 subjects in each of the four mental illnesses will continue to receive prescription drug therapy (as prescribed by their physician/psychiatrist) and counseling to treat their mental illness.
62828152|NCT02476877||Naïve drug group|Two hundred (200) subjects of which about 50 subjects in each of the four mental illnesses will be initially drug naïve (i.e. currently not taking psychotropic drugs) at the beginning of the study and continue to be drug naïve until the end of the study (6 months) as they receive counseling for their mental illness.
62828153|NCT06011850||Kidney Donor QLB Group|Quadratus lumborum block (QLB) will be applied to the kidney donor in kidney transplant surgery immediately after induction of general anesthesia before the surgical incision is started.
62046206|NCT01231529|EXPERIMENTAL|Part 1 Cohort 2|8 healthy subjects matched by gender, age and BMI to the subjects in Cohort 1 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug.
62046207|NCT01231529|EXPERIMENTAL|Part 2 Cohort 3|8 subjects with mild hepatic impairment defined by a Child-Pugh score of 5 to 6 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug. This cohort will only be done if the AUC from Cohort 1 is greater than or equal to 2 times the AUC from Cohort 2.
62046208|NCT01231529|EXPERIMENTAL|Part 2 Cohort 4|8 healthy subjects matched by gender, age and BMI to the subjects in Cohort 3 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug. This cohort will only be done if the AUC from Cohort 1 is greater than or equal to 2 times the AUC from Cohort 2.
62828154|NCT06011850||Kidney Donor Paracetamol Group|In kidney transplantation surgery, 1000 milligrams of Paracetamol will be administered intravenously to the kidney donor before the surgical incision is started, immediately after induction of general anesthesia.
62046209|NCT04445480|EXPERIMENTAL|Popliteal block group|
62046210|NCT04445480|ACTIVE_COMPARATOR|Control group|
62046211|NCT01407081|EXPERIMENTAL|Training|telerehabilitation cognitive strategy training
62046212|NCT00149305||Patients with gouthy diathesis|
62046213|NCT00149305||Healthy subjects|
62046214|NCT05935917|ACTIVE_COMPARATOR|Treatment AB - Form H (test tablet) first|"Treatment AB:~Participants assigned to Treatment AB in Period 1, will be given a single 100 mg tablet of Form H (test tablet). In Period 2, participants will be given a single 100 mg tablet of Form II (reference tablet) after a 14 day washout period."
62046215|NCT05935917|ACTIVE_COMPARATOR|Treatment BA - Form II (reference tablet) first|"Treatment BA:~Participants assigned to Treatment BA in Period 1, will be given a single 100 mg tablet of Form II (reference tablet). In Period 2, participants will be given a single 100 mg tablet of Form H (test tablet) after a 14 day washout period."
62046216|NCT02029079|EXPERIMENTAL|E+ drink, enriched with energy and nutrients.|The intervention consists of 300 ml E+ per day for 35 days in addition to a normal food intake. This means 525 kcal, and 22.5 gram protein extra per day for five weeks.
62046217|NCT02029079|NO_INTERVENTION|Control|Subjects in the control group will be assessed in the same way and same time as the intervention group.
62046218|NCT03475082|PLACEBO_COMPARATOR|Placebo TENS|30 minute TENS treatment where the stimulation ramps slowly to zero after 45 seconds. The lights/display on the unit are identical to the Active unit.
62046219|NCT03475082|ACTIVE_COMPARATOR|High Frequency TENS|30 minute TENS treatment at 100 Hertz (HZ). Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
62046220|NCT03475082|ACTIVE_COMPARATOR|Alternating frequency TENS|30 minute TENS treatment with a pre programed mode alternating from 4 Hz and 100 HZ. Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
62248249|NCT05018260|EXPERIMENTAL|attention control|Attention control modification: participants will receive gaze-contingent feedback according to their viewing patterns on rounded and sharp geometric shapes
62248250|NCT02232126|NO_INTERVENTION|Usual Care|
62828155|NCT06011850||Kidney Recipient QLB Group|Quadratus lumborum block (QLB) will be applied to the kidney recipient in kidney transplant surgery immediately after induction of general anesthesia before the surgical incision is started.
62828156|NCT06011850||Kidney Recipient Paracetamol Group|In kidney transplantation surgery, 1000 milligrams of Paracetamol will be administered intravenously to the kidney recipient before the surgical incision is started, immediately after induction of general anesthesia.
62828157|NCT04257357|EXPERIMENTAL|Exercise group|Eight-week supervised exercise program: Patients in the intervention group receive the same usual care as the patients in the control group. In addition, the patients participate in an eight-week supervised interval training program. Briefly put, the patients are required to participate in at least 16 out of 20 possible training passes over the period of eight weeks. The training consists of a brief warm up followed by 35-50 minutes of interval training on a bicycle. The intensity and duration will increase over time
62828158|NCT04257357|ACTIVE_COMPARATOR|Control group|"Patients in the control group receive usual care as a minimum. This includes three-five days of hospitalization where the anticoagulant treatment is initiated. The patient and the relatives receive general information about the disease and the course of treatment, the medication and future prevention of embolism. In the year following discharge the patient is booked for a check-up of their anticoagulant treatment with a physician or a nurse as required.~It is considered an active comparator as all patients in the control group perform a watt-max cycle ergometer test with VO2 measurement 3 times, and this in it-self can influence patients' activity level."
62828159|NCT06594198|EXPERIMENTAL|One center and 40 patients|Monitor the values of 3 brain parameters: SctO2, bcSEF and ANI measured by the ARGOS sensor.
62046221|NCT03475082|ACTIVE_COMPARATOR|Modulated frequency TENS|30 minute TENS treatment at a pre programmed mode that ramps between 4 and 125 HZ over 12 seconds. Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
62046222|NCT03475082|ACTIVE_COMPARATOR|High frequency TENS - increasing intensity|30 minute TENS treatment at 100 HZ. Intensity set at initial strong but comfortable setting on day one as above, then subjects asked for possible increases in intensity every 5 minutes on all five days.
62046223|NCT02054767|EXPERIMENTAL|lidocaine|injections of 3.6 mL of 2% lidocaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
62046224|NCT02054767|EXPERIMENTAL|mepivacaine|injections of 3.6 mL of 2% mepivacaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
62046225|NCT02054767|EXPERIMENTAL|articaine|injections of 3.6 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
62046226|NCT03323333|EXPERIMENTAL|Intervention|
62438251|NCT03964454|EXPERIMENTAL|SC + BFI|Participants randomized into SC+BFI will receive the same services as the Standard Care Control (SC) group (standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving) plus financial incentives contingent on observed breastfeeding.
62438252|NCT03964454|ACTIVE_COMPARATOR|SC|Participants randomized into Standard Care (SC) will receive standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving.
62046227|NCT02433743|NO_INTERVENTION|Control|Control group (n=33) didn't received intervention. The received the standard hospital diet
62248251|NCT02232126|EXPERIMENTAL|Intervention|
62046228|NCT02433743|EXPERIMENTAL|Ready-to-use therapeutic food (RUTF)|RUTF group (n=32) received the standard hospital diet combined with 100 g/day of RUTF
62248252|NCT03182985|EXPERIMENTAL|Time Restricted Feeding|Patients will reduce daily oral intake to 10 hours per day
62438253|NCT06358313|ACTIVE_COMPARATOR|atorvastatin|The Atorvastatin arm consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, an open-label aspirin at a loading dose of 75 to 300 mg and then 75 mg daily till the end of the 3 months, and an open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months
62605461|NCT03240224|NO_INTERVENTION|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62605462|NCT01902212|EXPERIMENTAL|Oral Nutritional Supplement|2 servings a day
62046229|NCT04843033|EXPERIMENTAL|Daily oral administration of SH3809 tablet|
62828160|NCT06590259|EXPERIMENTAL|Multi-mode thermal ablation combined with systemic therapy including PD-1 inhibitor|Multi-mode ablation therapy +systemic therapy including PD-1 inhibitor (sintilimab 200 mg IV D1+ mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab（determined according to the subject's first-line chemotherapy regimen), Q3W, chemotherapy for 4-6 cycles. Sintilimab continues until disease progression, not exceeding a maximum of 2 years.)
62828161|NCT01670344|OTHER|A|Treatment with investigational method (virtual implant positioning system)
62828162|NCT01670344|OTHER|B|Treatment with surgical standard of care
62248253|NCT03207113|EXPERIMENTAL|Ned Group|"Participants in the Ned case study (patients, caregivers, clinicians) will receive access to the Ned application.~Ned (No Evident Disease) is the first application to provide patients with access to individual-level prostate-specific antigen values streamed directly from the Ontario Laboratory Information System to their own smartphone. The application aims to promote self-care by informing patients directly of their PSA results and providing them with a personalised view of their own symptoms. It supports real-time clinical decision-making by providing clinicians with patient-reported outcomes collected in-app, and includes a curated educational feed and support group links."
62248254|NCT00647153|EXPERIMENTAL|Radiation: iodine I 123 anti-CEA recombinant diabody T84.66|
62605463|NCT00842998|EXPERIMENTAL|1 - Trastuzumab|Day1 Week1: 8 mg/kg iv in 90 min. Following 1st week: 2 mg/kg once/weekly for 8 weeks
62438254|NCT06358313|ACTIVE_COMPARATOR|rosuvastatin|The rosuvastatin arm consisted of 300 patients who received 20 mg daily rosuvastatin for 3 months, an open-label aspirin at a loading dose of 75 to 300 mg and then 75 mg daily till the end of the 3 months, and an open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months
62828163|NCT03371667|EXPERIMENTAL|Methotrexate|"* 5mg/Kg/day methotrexate for 4 weeks then 3 mg/m2 every two weeks for 12 weeks~* 2mg/kg/day PO prednisone prednisone (or 1.6 mg/kg/day IV methylprednisolone) once daily.~* 10 mg po or iv lederfolin after each MTX administration"
62438255|NCT03666182||Whole Sample|Female, Caucasian participants aged 18-65 years.
62438256|NCT00207714|EXPERIMENTAL|Golimumab (CNTO 148) with Methotrexate (MTX)|
62828164|NCT03371667|PLACEBO_COMPARATOR|Placebo|"* Once a week placebo for 4 weeks then every two weeks for 12 weeks~* 2 mg/kg/day PO prednisone (or 1.6 mg/kg/day IV methylprednisolone) once daily.~* 10 mg po or iv lederfolin after each placebo administration"
62828165|NCT00406250|EXPERIMENTAL|Bevacizumab|
62828166|NCT06591559|NO_INTERVENTION|No Device|Children will play for 30 minutes using no mobility device.
62828167|NCT06591559|ACTIVE_COMPARATOR|Explorer Mini in a Seated Posture|Children will play for 30 minutes using the Explorer Mini a seated posture.
62828168|NCT06591559|ACTIVE_COMPARATOR|Explorer Mini in a Standing Posture|Children will play for 30 minutes using the Explorer Mini a standing posture.
62605464|NCT00842998|EXPERIMENTAL|2 - Lapatinib|1500 mg/die orally
62605465|NCT03456999|ACTIVE_COMPARATOR|MAU868|BKV-specific, pan-serotype neutralizing antibody
62605466|NCT03456999|PLACEBO_COMPARATOR|Placebo|Matching placebo
62438257|NCT00207714|EXPERIMENTAL|Infliximab with MTX|
62438258|NCT00207714|PLACEBO_COMPARATOR|Placebo with MTX|
62605467|NCT05735990||640PM implanted|Patients implanted binocularly with Medicontur's intraocular lens model 640PM.
62605468|NCT02933905||Non-PVD subjects|Patients with no PVD on SD-OCT at basal visit
62605469|NCT02933905||PVD subjects|Patients with PVD on SD-OCT at basal visit
62605470|NCT01885494||15µg AFFITOPE® PD01A|Patients With Parkinson's Disease vaccinated with 4 injections of 15µg AFFITOPE® PD01A adsorbed to adjuvant during AFF008
62605471|NCT01885494||75µg AFFITOPE® PD01A|Patients With Parkinson's Disease vaccinated with 4 injections of 75µg AFFITOPE® PD01A adsorbed to adjuvant during AFF008
62605472|NCT01885494||Control group|Untreated control group
62605473|NCT01079754|EXPERIMENTAL|Spinal morphine 0.05 mg|Patient received spinal morphine 0.05 mg
62605474|NCT01079754|ACTIVE_COMPARATOR|Spinal morphine 0.1 mg|Patient received spinal morphine 0.1 mg
62605475|NCT03180515|EXPERIMENTAL|Activa PC+S Neurostimulator|All patients will complete motor testing on both continuous DBS and adaptive DBS during a study visit. The UPDRS rater and the patient will be blind to which type of stimulation they are on.
62828169|NCT06591559|ACTIVE_COMPARATOR|Portable Mobility Aid Partial Body Weight Support Harness (PUMA)|Children will play for 30 minutes with partial bodyweight support provided by the PUMA.
62828170|NCT06428968|EXPERIMENTAL|Individual with type 2 diabetes|Individual with type 2 diabetes
62828171|NCT06428968|EXPERIMENTAL|Healthy volunteers|
62828172|NCT05408741|EXPERIMENTAL|Group 1 (The Intervention Group)|Participants will receive guided imagery and deep breathing technique exercises.
62828173|NCT05408741|EXPERIMENTAL|Group 2 ( The Control Group)|Participants will not receive any relaxation techniques. Participants will receive the current standard of care.
62828174|NCT03928184|EXPERIMENTAL|0.07 mg lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle
62828175|NCT03928184|PLACEBO_COMPARATOR|Vehicle|One intra-articular injection of 0 mg lorecivivint in 2 ml vehicle
62828176|NCT05419895|EXPERIMENTAL|Families with children enrolled in BCW with suspected diagnosis of autism|Post-consent, families with children between 16-33 months will receive a link to complete the EAC Developmental History Survey on REDCap and a link to complete parent/caregiver questionnaires about developmental and/or adaptive information. Then, the family will be assigned to a clinician for the autism assessment and scheduled their assessment and feedback session (one week later).
62046230|NCT02075879|EXPERIMENTAL|Nurse-led interviewing|Participants in experimental arm received the in-center exercise training (20 minutes) before hemodialysis sessions weekly for 6 weeks and were instructed to perform exercise at home. They were additionally instructed to start walking or brisk walking at low duration and gradually progress to a maximum of 30 minutes daily per week. To facilitate exercise progression, the nurse case managers discussed exercise benefits, explored exercise barriers and developed mutual goals with patients. The nurse motivated them and checked the exercise behaviors to ensure adherence to the recommended exercise regime. The nurse case managers interviewed the patients weekly for six weeks and biweekly for another six weeks.
62828177|NCT06477120|EXPERIMENTAL|Time-restricted eating|Participants randomized to the time-restricted eating arm will be instructed to eat ad libitum during an 8-hr window daily 11am - 7pm in the 2nd trimester and 10-hr eating window from 10am - 8pm in the 3rd trimester and abstain from caloric foods and beverages for the remaining 14-16 hours. During the eating window there will be no restrictions on types or quantities of foods consumed. Moreover, participants will not be required to monitor calorie intake during the ad libitum eating period. During the fasting period, participants will be encouraged to drink plenty of water and will be allowed to consume calorie-free beverages.
62046231|NCT02075879|ACTIVE_COMPARATOR|Brief group exercise|Participants received the in-center exercise training (20 minutes) before hemodialysis sessions weekly for 6 weeks and were instructed to perform exercise at home. The in-center training was conducted by the researcher with a group of four-to six participants focusing on flexibility and strengthening exercise only.
62438259|NCT03120585|EXPERIMENTAL|Fluid Management Intervention|Restricting IV fluids to infants with respiratory distress to mimic fluid intake of normal healthy breast fed infants (less fluid that current standard of care)
62438260|NCT03120585|NO_INTERVENTION|Control Group|Infants with respiratory distress will receive standard of care fluid management.
62828178|NCT06477120|NO_INTERVENTION|Standard Care|The standard care arm will not receive diet-related counseling. Participants will meet with study staff weekly to record health changes and to transmit weight through the text messaging platform. The remote videoconferencing visits will occur at the same day and time each week. Standard care participants will attend the in-person research data collection visits. Participants will be asked to maintain current (baseline) level of physical activity throughout the intervention.
62828179|NCT06587451|EXPERIMENTAL|JPB898|Participants will receive JPB898 combined with Yervoy-EU during the induction phase. Participants will receive JPB898 during maintenance phase.
62438261|NCT04275947||Training|
62438262|NCT04275947||Validation|
62438263|NCT03406689|ACTIVE_COMPARATOR|Nepafenac 0.1% Oph Susp|One drop of Nepafenac 0.1% will be administered 45' prior to the injection
62046232|NCT03581812|ACTIVE_COMPARATOR|Intervention snack 1|Snack food believed to selectively promote the growth of beneficial bacterial strains in the human colon.
62828180|NCT06587451|ACTIVE_COMPARATOR|Opdivo-EU|Participants will receive Opdivo-EU combined with Yervoy-EU during the induction phase. Participants will receive Opdivo-EU during the maintenance phase.
62828181|NCT06587451|ACTIVE_COMPARATOR|Opdivo-US|Participants will receive Opdivo-US combined with Yervoy-EU during the induction phase. Participants will receive Opdivo-EU during the maintenance phase.
62046233|NCT03581812|ACTIVE_COMPARATOR|Intervention snack 2|Snack food believed to selectively promote the growth of beneficial bacterial strains in the human colon.
62046234|NCT03581812|PLACEBO_COMPARATOR|Control snack|Control snack food reflecting the macro-nutrient profile of a typical UK snack.
62438264|NCT03406689|ACTIVE_COMPARATOR|Nepafenac 0.3% Oph Susp|One drop of Nepafenac 0.3% will be administered 45' prior to the injection
62046235|NCT04028284|ACTIVE_COMPARATOR|Group 1|In Group 1 (control), the staff anesthesiologist will follow the traditional technique for US-guided thoracic epidural insertion. Briefly, the anesthesiologist will use the US to identify and mark the appropriate spot for placement of the thoracic epidural catheter. The US probe is then placed at rest and the anesthesiologist will proceed with thoracic epidural needle insertion following standard techniques.
62046236|NCT04028284|ACTIVE_COMPARATOR|Group 2|In Group 2 (intervention), the staff anesthesiologist will use the HoloLens tool to assist with the traditional technique as described above for Group 1. In combination with the US, a hologram image of the trajectory towards the epidural space will be generated, thereby mitigating the need to walk off the lamina. The holographic system will mark the appropriate spot for placement of the thoracic epidural catheter. Then, the needle will be inserted following the holographic trajectory overlaid on the patient's back.
62046237|NCT06057376|OTHER|Low FODMAP group|Participants randomized to this group will be instructed based on published low-FODMAP diet guidelines and provided with sample meal plans to aid in compliance. Each participant will be randomized to low-FODMAP diet group (LFD) for 3 weeks.
62046238|NCT06057376|OTHER|Low Added Sugar group|Each participant will be randomized to either the low-FODMAP diet group (LFD) or the low added sugar diet group (LAS) for 3 weeks. Each participant will be randomized to the low added sugar diet group (LAS) for 3 weeks.
62046239|NCT04342351|EXPERIMENTAL|Experimental: sacubitril/valsartan|sacubitril/valsartan will be applied from 25mg b.i.d to 100mg b.i.d. for 3 months
62046240|NCT04342351|ACTIVE_COMPARATOR|Active Comparator: perindopril|perindopril will be applied from 2mg q.d, to 8mg q.d for 3 months
62438265|NCT03406689|PLACEBO_COMPARATOR|Artificial tears|One drop of Artificial Tears will be administered 45' prior to the injection
62438266|NCT01094366|SHAM_COMPARATOR|No Paracervical Block for Pain Control|Subject will not receive a paracervical block during the procedure
62046241|NCT04777864|NO_INTERVENTION|Usual Care|
62046242|NCT04777864|EXPERIMENTAL|Decision Aid|Usual care, plus introduction of a decision aid
62046243|NCT04354987|EXPERIMENTAL|Group A|R+R+T+T Period 1 : R Period 2 : R Period 3 : T Period 4 : T
62438267|NCT01094366|ACTIVE_COMPARATOR|Paracervical Block for Pain Control|Subject will receive a paracervical block during the procedure.
62828182|NCT02731586|EXPERIMENTAL|osseointegration using Allogenic MSC's|Evaluation of Osseointegration of Dental Implants to be done using Allogenic Mesenchymal Stem Cells.Primary and Secondary stability are measured using RFA.
62046244|NCT04354987|EXPERIMENTAL|Group B|R+T+R+T Period 1 : R Period 2 : T Period 3 : R Period 4 : T
62046245|NCT04354987|EXPERIMENTAL|Group C|T+R+T+R Period 1 : T Period 2 : R Period 3 : T Period 4 : R
62046246|NCT04354987|EXPERIMENTAL|Group D|T+T+R+R Period 1 : T Period 2 : T Period 3 : R Period 4 : R
62046247|NCT06140108|EXPERIMENTAL|Empagliflozin 10mg|Each participant will receive empagliflozin 10mg daily for 3 months
62046248|NCT06140108|ACTIVE_COMPARATOR|Metformin 500mg|Each participant will receive metformin 1000mg daily for 3 months
62046249|NCT02883062|ACTIVE_COMPARATOR|Arm A (carboplatin, paclitaxel, mastectomy, lumpectomy)|Patients receive carboplatin IV over 30 minutes Q3W and paclitaxel IV over 1 hour QW. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo the collection of blood samples throughout the trial.
62605476|NCT04590677||Group 1|Pregnant women at 36 weeks gestational age, who are not expected to have risk factors for preterm birth, n=150.
62828183|NCT03296605||Obesity|Patients with obesity already received bariatric surgery
62828184|NCT03296605||Healthy control|Volunteers with normal body weight and already received abdominal surgery
62046250|NCT02883062|EXPERIMENTAL|Arm B (atezolizumab, carboplatin, paclitaxel, breast surgery)|Patients receive atezolizumab IV over 30-60 minutes and carboplatin IV over 30 minutes Q3W, and paclitaxel IV over 1 hour QW. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo the collection of blood samples throughout the trial.
62828185|NCT03104127|EXPERIMENTAL|Alter G Bionic Leg|Participants randomised to a group including normal therapy (physiotherapy) and the use of a Alter G robotic bionic leg. All participants have previously completed normal NHS therapy.
62828186|NCT03104127|ACTIVE_COMPARATOR|Normal therapy|Participants randomised to a group including normal therapy (physiotherapy) only. All participants have previously completed normal NHS therapy.
62828187|NCT03104127|NO_INTERVENTION|Usual care|Have completed normal NHS therapy and no longer (\> 6 months) receive active physiotherapy.
62438268|NCT02542306|EXPERIMENTAL|fibrinogen concentrate-treated group|The initial fibrinogen concentrate dose was 25 - 50 mg/kg, but additional fibrinogen concentrate was administered repeatedly if the first infusion of fibrinogen concentrate did not increase the fibrinogen level over 2.0 g/L.
62438269|NCT02542306|NO_INTERVENTION|non-fibrinogen concentrate-treated group|The participants who did not received fibrinogen concentrate treatment were enrolled as the non-fibrinogen concentrate-treated group
62438270|NCT00936975|EXPERIMENTAL|18F-Fluoride PET|Patients undergo fluorine F 18 sodium fluoride PET scan at baseline and then at 12 weeks after initiation of treatment with dasatinib. Dasatinib was administered under a concurrent protocol and was not considered part of the intervention on this protocol
62438271|NCT03300193||Tremor patients|Essential Tremor and Parkinson's Disease patients with Tremor refractory to pharmacological therapy who underwent Magnetic Resonance guided Focused Ultrasound Surgery (MRgFUS)
62046251|NCT00700921|EXPERIMENTAL|Active Drug (Lovastatin)|
62046252|NCT00700921|PLACEBO_COMPARATOR|Placebo (inactive comparator)|
62438272|NCT05012137|EXPERIMENTAL|SASIS-FICB|All subjects will be enrolled in the experimental group and receive an Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB)
62605477|NCT04590677||Group 2|Pregnant women who have presented with signs and symptoms of threatened preterm labour (e.g. ruptured membranes, contractions, bleeding), at or after 24 weeks gestation, n=50.
62605478|NCT03973333|EXPERIMENTAL|IMC-C103C - Monotherapy IV dose escalation|n= approximately 50 patients to establish the MTD/expansion dose
62605479|NCT03973333|EXPERIMENTAL|IMC-C103C and atezolizumab dose escalation|n=approximately 12 patients to establish the MTD/expansion dose
62828188|NCT05955716|EXPERIMENTAL|Virtual reality glasses|During the episiotomy incision and repair, women in this group watched a relaxation video with virtual reality glasses.
62828189|NCT05955716|NO_INTERVENTION|Control Group|Women in this group received routine care in the hospital.
62828190|NCT02851277|EXPERIMENTAL|Low dose ASP0892 Intradermal|Participants will receive study drug once every 2 weeks for a total of 4 doses. After participants complete the Low dose arms, the Dose Escalation Committee (DEC) will determine if the study can progress to the parallel higher dose arms.
62828191|NCT02851277|EXPERIMENTAL|High dose ASP0892 Intradermal|Participants will receive study drug once every 2 weeks for a total of 4 doses.
62046253|NCT01435811|EXPERIMENTAL|Norovirus challenge pool (GII.4, CIN-1)|
62046254|NCT01435811|PLACEBO_COMPARATOR|Sterile water|
62046255|NCT03736603|EXPERIMENTAL|Pathway Intervention 1|Hospitals randomized to group 1 receive PIPA Intervention Bundle 1.
62046256|NCT03736603|EXPERIMENTAL|Pathway Intervention 2|Hospitals randomized to group 2 receive PIPA Intervention Bundle 2, which adds a mobile app.
62046257|NCT03736603|NO_INTERVENTION|Control|Hospitals are in the control arm (usual care) after January 2017 until active implementation begins, which includes 3-6 months of implementation preparation (identifying local multidisciplinary champions, educational sessions/webinars for local champions, one teleconference with an external practice facilitator).
62605480|NCT03973333|EXPERIMENTAL|IMC-C103C - expansion|Patients will be enrolled n=9-24 per expansion cohort (up to 4 total): metastatic/unresectable tumors of interest patients treated at the expansion dose of IMC-C103C to assess preliminary anti-tumor efficacy
62046258|NCT02240433|EXPERIMENTAL|LY2157299 + Sorafenib|LY2157299 will be administered orally twice daily for 14 days, followed by 14 days with no study drug per 28-day cycle. Sorafenib will be administered orally twice daily for 28 days, in each cycle.
62046259|NCT02151266|EXPERIMENTAL|Exercise and Cognitive retraining|Aerobic exercise; Computerized cognitive retraining program; Heart failure education; Home visits; telephone follow-up.
62605481|NCT03973333|EXPERIMENTAL|IMC-C103C monotherapy SC dose escalation|Patients will be enrolled n=9-12 to establish the MTD/expansion dose
62828192|NCT02851277|PLACEBO_COMPARATOR|Placebo Intradermal|Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.
62046260|NCT02151266|EXPERIMENTAL|Exercise only|Each participant will be provided with an individualized target heart rate (THR)zone based on treadmill results. Under the supervision of a research nurse, participants will begin the walking sessions at 60% of THR and increase to 70% by week 5. Participants will walk a minimum of 5 times per week for a duration of 30 minutes.
62046261|NCT02151266|SHAM_COMPARATOR|Stretching and Flexibility|Stretching and flexibility movements; heart failure education; home visits; telephone follow-up.
62046262|NCT04731454|EXPERIMENTAL|Healthy Nordic Diet (ND)|A healthy diet meeting and exceeding the Nordic Nutrition Recommendations and with more than 80% foods from the Nordic region.
62046263|NCT04731454|EXPERIMENTAL|Control Diet (CD)|A control diet approximating the average depressed person's diet, i.e. of somewhat lower quality than the average Swedish diet.
62248255|NCT04858984|EXPERIMENTAL|Virtual reality group|"All participants experienced an immersive guided meditation virtual reality (VR1) and an interactive game virtual reality (VR2) experience during labour. Both VR interventions were offered for 10 minutes. Before and immediately after an intervention, the patient was asked to fill out a Numeric Rating Scale (NRS) score for pain.~During the 30-minute intermission after the VR intervention the patient completed the post-intervention questionnaire.~VR1 consisted of a video of an exotic location guided by the sound of the waves and a calm English-speaking voice. VR2 required women to use the controller to throw snowballs in order to catch presents and reach the next level. Patients were allowed to stop using the VR at any moment during the intervention.~Five days post-partum all participants who completed both VR interventions were contacted by telephone for an interview."
62248256|NCT00910195|EXPERIMENTAL|CPAP before Bi-Level-APAP|receiving CPAP treatment during the first night and then Bi-level-APAP treatment during second night
62248257|NCT00910195|EXPERIMENTAL|Bi-Level-APAP before CPAP|receiving Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
62248258|NCT03805750|EXPERIMENTAL|CBD/THC|Treatment arm consisting of Tetrahydrocannabinol (5mg/capsule) and Cannabidiol (100mg/capsule).
62605482|NCT05215912|EXPERIMENTAL|Single Ascending Dose (SAD -Arm A)|Up to 5 cohorts of subjects receiving sequentially ascending dose of TNB-738 or placebo are planned until maximum tolerated dose is reached or recommended phase 2 dose is identified
62605483|NCT05215912|EXPERIMENTAL|Multiple Ascending Dose (MAD- Arm B)|An expansion cohort (upto 4 cohorts) will be enrolled after maximum tolerated dose or recommended phase 2 dose is established.
62828193|NCT02851277|EXPERIMENTAL|High dose ASP0892 Intramuscular|Participants will receive study drug once every 2 weeks for a total of 4 doses.
62828194|NCT02851277|PLACEBO_COMPARATOR|Placebo Intramuscular|Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.
62828195|NCT05189717|EXPERIMENTAL|Single Group|Firstly Dose Escalation and Dose Expansion of HRS-8080 monotherapy should be conducted. After RP2D and MTD of the HRS-8080 monotherapy were confirmed, Dose Escalation and Dose Extension of HRS-8080 in combination with other anti-cancer treatment would be completed, including SHR 6390, or Abemaciclib, or Everolimus.
62828196|NCT06603896|SHAM_COMPARATOR|Placebo group|a sham unscented aromatherapy patch will be applied to subjects clothing, 4-6 inches below the neck on the thorax
62828197|NCT06603896|ACTIVE_COMPARATOR|Combined Aromatherapy Group|A combined scents Citrus Lavendar infused aromatherapy patch will be applied to subjects clothing, 4-6 inches below the neck on the thorax
62828198|NCT06603896|ACTIVE_COMPARATOR|Single Aromatherapy Lavendar Group|A single scent Lavander aromatherapy patch will be applied 4-6 inches below nose on front of thorax on subjects clothing
62046264|NCT01278134|EXPERIMENTAL|Arm B Extension|All patients in treatment arm B were offered to receive Pegasys/Cogepus therapy for an additional 24 weeks.
62046265|NCT01278134|EXPERIMENTAL|RO5024048 & ritonavir-boosted danoprevir without Ribavirin (B)|
62046266|NCT01278134|EXPERIMENTAL|RO5024048 and ritonavir-boosted danoprevir with Ribavirin (A)|
62605484|NCT01876979|ACTIVE_COMPARATOR|IMF Screws|Use of IMF screws as a means to wire the jaws.
62605485|NCT01876979|ACTIVE_COMPARATOR|Erich Arch Bars|Use of Erich Arch bars in the wiring of the jaws.
62605486|NCT04761406|EXPERIMENTAL|Phaeosol group|Daily supplementation of Phaeosol softgel capsule (218mg/d), active ingredients of Microphyt. Each randomized subject will consume 1 softgel capsule (before breakfast) per day during 12 weeks
62605487|NCT04761406|PLACEBO_COMPARATOR|Placebo group|Daily supplementation of placebo softgel capsule (218mg/d of 100% sunflower oil) with the same appearance and packaging than experimental product. Each randomized subject will consume 1 softgel capsule (before breakfast) per day during 12 weeks
62605488|NCT02566603|EXPERIMENTAL|PRTX-100|Patients will be assigned to consecutive PRTX-100 interventions as they are enrolled into the study. Between three and six patients will be enrolled per intervention level. Intervention levels range from 3 to 24 micrograms of PRTX-100 per kilogram of patient weight. Patients may receive up to four weekly infusions of PRTX-100 over the study treatment period. PRTX-100 doses ≤ 500 μg will be infused intravenously over 30 minutes. PRTX-100 doses \> 500 μg will be infused over 60 minutes. Patients will remain under observation for 4 hours after initiation of PRTX-100 dosing for safety management.
62605489|NCT04272827|ACTIVE_COMPARATOR|Intervention group|In the intervention group, patients will receive liposuction treatment (number of surgeries at the discretion of the attending study physician: a maximum of 4 surgical procedures, with a minimum of 5 and a maximum of 7 weeks between each surgery) with concomitant complex decongestive therapy (CDT), if necessary, to maintain surgical outcomes as required by the patient.
62605490|NCT04272827|OTHER|Control group|"After randomisation, the control group will be treated for 12 months with complex decongestive therapy (CDT) alone.~After these 12 months, patients can opt for liposuction treatment if they continue to meet the inclusion and exclusion criteria."
62605491|NCT04308980|EXPERIMENTAL|Active treatment|Patients with verified non-alcoholic fatty liver disease, who signed informed consent to participate in the study and are randomly selected to use specialized medical nutrition product together with diet based on the measured individual requirements in energy and protein intake.
62605492|NCT04308980|PLACEBO_COMPARATOR|Control group|Patients with verified non-alcoholic fatty liver disease, who signed informed consent to participate in the study and are randomly selected to use masked placebo together with diet based on the measured individual requirements in energy and protein intake.
62605493|NCT05302024|EXPERIMENTAL|Iguratimod treatment|Iguratimod is given at a dose of 25 mg bid for 12 weeks.
62605494|NCT03066219|ACTIVE_COMPARATOR|BRM421 Ophthalmic Solution|The active control with BRM421 solution
62605495|NCT03066219|PLACEBO_COMPARATOR|Placebo|The vehicle solution
62605496|NCT01685853|ACTIVE_COMPARATOR|PEG 4 litres split|Polyethylene glycol with electrolytes (PEG)
62605497|NCT01685853|EXPERIMENTAL|Bisacodyl plus PEG-CS|Bisacodyl plus PEG-CS: Bisacodyl plus Polyethylene glycol with citrate and simethicone (PEG-CS)
62605498|NCT00432315|EXPERIMENTAL|1|Resectable NSCLC
62828199|NCT05087706||Locally advanced patients with molecular-guided therapy|Locally advanced patient will be assigned to molecularly-guided therapy based on genomic profile.
62828200|NCT05087706||Advanced patients with molecular-guided therapy|Advanced patient will be assigned to molecularly-guided therapy based on genomic profile.
62828201|NCT02269969|EXPERIMENTAL|Once daily aminoglycoside|Once daily dosing of Tobramycin
62828202|NCT01479296|EXPERIMENTAL|Group 1: rAd5 Plus Placebo|Participants will receive the VRC rAd5 gag-pol/env A/B/C vaccine injection in their right arm (1×10\^10 PU), and placebo vaccine injections in their left arm, right thigh, and left thigh.
62828203|NCT01479296|EXPERIMENTAL|Group 2: Separated Vaccine Components|Participants will receive the rAd5 gag-pol vaccine injection in their right arm (0.5×10\^10 PU), the rAd5 env A vaccine injection in their left arm (0.17×10\^10 PU), the rAd5 env B vaccine injection in their right thigh (0.17×10\^10 PU), and the rAd5 env C vaccine injection in their left thigh (0.17×10\^10 PU).
62828204|NCT01479296|EXPERIMENTAL|Group 3: Divided Dose rAd5|Participants will receive the VRC rAd5 gag-pol/env A/B/C vaccine injection divided into fourths, with one fourth of the total dose given in each of 4 sites: right arm, left arm, right thigh, and left thigh (each at 0.25×10\^10 PU).
62828205|NCT03422900|EXPERIMENTAL|Specific Diabetes Formula|"Diabetes-Specific Enteral Formula:~* Caloric density: 1,0 kcal/ml~* Energy: 100 kcal~* Carbohydrates: 10,1 g/100 ml;~* Fat: 4,5 g/100 ml~* Prot: 3,8 g/100 ml~* Osmolarity: 345 mOsm/l~* Fiber: 1,78 g/100 ml (80% soluble; 20% insoluble)."
62605499|NCT00432315|EXPERIMENTAL|2|Unresectable NSCSC
62828206|NCT03422900|ACTIVE_COMPARATOR|Standard Formula|"Standard Enteral Formula:~* Caloric density: 1,0 kcal/ml~* Energy: 100 kcal~* Carbohydrates: 13,8 g/100 ml;~* Fat: 3,4 g/100 ml~* Prot: 3,8 g/100 ml~* Osmolarity: 220 mOsm/l~* Fiber: 0 g/100 ml"
62828207|NCT05784480|OTHER|Evaluation of reversible causes using digital checklist and diagnostic support|
62605500|NCT03994744|EXPERIMENTAL|Sintilimab and Metformin|"Participants will be given intravenous administration of Sintilimab (1200mg/3w) Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab a a dose of 2000 mg daily (1000mg BID).~The duration of treatment will be up to one year, or till the disease progression, death, or unacceptable toxicity show up."
62605501|NCT03990935|ACTIVE_COMPARATOR|sodium fluoride varnish|"The fluoride varnish will be bifluorid 10 single use by voco (Germany). It Contains 5 % sodium fluoride (equal to 22,600 ppm fluoride).~A thin coat will be applied on the tooth surface by using a brush. 10-20 s are sufficient for the varnish to be absorbed and then dry with air. Participants will be informed that they should not brush their teeth for 12-24 hours after the application and not to eat, or drink for at least 30 minutes after use to get the best results."
62828208|NCT05705934|EXPERIMENTAL|Group 1|Participants in this group will receive holistic-based group exercise program. All evaluations in this group will be done in the form of before and after. The exercise program will be applied for 12 weeks, 3 days a week.
62828209|NCT05705934|NO_INTERVENTION|Group 2|Participants in this group will continue their routine habits and nutrition programs. All assessments in this group will be done in the form of before and after.
62828210|NCT04403334|EXPERIMENTAL|Intracameral levofloxacin|0.5% unpreserved solution
62828211|NCT04403334|EXPERIMENTAL|Intracameral moxifloxacin|0.5% unpreserved solution
62828212|NCT06654154|OTHER|study the variation in serum vitamin B12 level|Each patient is his own witness to express the variation in the serum level of vitamin B12
62828213|NCT05135767|ACTIVE_COMPARATOR|Alcohol Use Disorder Only|Individuals in the Alcohol Use Disorder Only arm will meet criteria for alcohol use disorder but will not show evidence of advanced alcohol-associated liver disease. Both arms receive the same brief motivational intervention with personalized feedback.
62046267|NCT02961023|ACTIVE_COMPARATOR|Training|15 patients are randomised to receive 15 weeks exercise therapy as per study protocol at point of study entry.
62605502|NCT03990935|EXPERIMENTAL|Ginger and rosemary gel|First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.
62605503|NCT02086825|EXPERIMENTAL|Rifaximin|
62605504|NCT02086825|EXPERIMENTAL|Lactulose|
62605505|NCT06137534|EXPERIMENTAL|Exercise Group|Proprioceptive neuromuscular facilitation upper extremity pattern exercises will be actively applied to 20 individuals in groups of 5 in a standing position for 30 minutes in each session 3 days a week for 4 weeks.
62828214|NCT05135767|ACTIVE_COMPARATOR|Alcohol Associated Liver Disease + Alcohol Use Disorder|Individuals in the Alcohol Associated Liver Disease + Alcohol Use Disorder arm will meet criteria for alcohol use disorder and also show evidence of advanced alcohol-associated liver disease. Both arms receive the same brief motivational intervention with personalized feedback.
62828215|NCT02032459||Minority Women|Study data pulled from already collected data (N=1141 from the Camden Study of low income gravidae and minority gravidae (White, African-American and Hispanic) living in the northeastern United States (New Jersey).
62828216|NCT06654349||Trapeziectomy|This cohort consist of patients receiving a trapeziectomy for arthrosis of the first carpometacarpal joint. The cohort will include 100 patients
62828217|NCT06654349||TMC-arthroplasty|This cohort consist of patients receiving TMC-arthroplasty for arthrosis of the first carpometacarpal joint. The cohort will include 100 patients
62828218|NCT03715114|EXPERIMENTAL|GV-971 900 mg|900 mg oral
62828219|NCT03715114|EXPERIMENTAL|GV-971 1200 mg|1200 mg oral
62046268|NCT02961023|OTHER|Control|15 patients are randomised to receive 15 weeks of standard care, acting as a control arm, followed by 15 weeks of exercise therapy.
62046269|NCT01610310|EXPERIMENTAL|peginterferon beta-1a PFS/autoinjector|A single dose of peginterferon beta-1a 125 mcg administered by prefilled syringe (PFS) on Day 1, then by a single dose of peginterferon beta-1a 125 mcg by autoinjector on Day 22.
62046270|NCT01610310|EXPERIMENTAL|peginterferon beta-1a autoinjector / PFS|A single dose of peginterferon beta-1a 125 mcg administered by autoinjector on Day 1, then by a single dose of peginterferon beta-1a 125 mcg by prefilled syringe (PFS) on Day 22.
62046271|NCT02382068|EXPERIMENTAL|Supportive care (intratympanic dexamethasone)|Patients receive dexamethasone via intratympanic injection in one ear and placebo via intratympanic injection in the other ear. Cisplatin standard of care treatment.
62046272|NCT00339612||HIV-infected children who acquired HIV infection through mothe|HIV-infected children in who acquired HIV infection through mother-to-child transmission (MTCT).
62046273|NCT02063152||Entire Taiwan women|
62046274|NCT06221579|EXPERIMENTAL|Interview|Conducting interviews with MCI patients to identify their needs and preferences related to the intervention to be developed
62248259|NCT03805750|PLACEBO_COMPARATOR|Placebo|Matched placebo capsule with no active ingredients.
62605506|NCT05011890|OTHER|Single-arm|Participants will be assigned to the single-arm involving weekly monitoring of their patient-reported outcomes using Moovcare®.
62605507|NCT06107907|OTHER|Group A|follow the sequence of oxygen mask, HFOT 40L, HFOT 50L, HFOT 60L, oxygen mask, CPAP 4cmH2O, CPAP 5cmH2O, and CPAP 6cmH2O.
62605508|NCT06107907|OTHER|Group B|follow the sequence of oxygen mask, CPAP 4cmH2O, CPAP 5cmH2O, CPAP 6cmH2O, oxygen mask, HFOT 40L, HFOT 50L, and HFOT 60L.
62605509|NCT01236950|EXPERIMENTAL|Delmopinol mouthrinse|Subjects use the delmopinol mouthrinse
62605510|NCT01236950|NO_INTERVENTION|Control|Subjects with no use of mouthrinse
62605511|NCT01236950|EXPERIMENTAL|Essential oils mouthrinse|Subjects using the essential oils mouthrinse
62828220|NCT03715114|EXPERIMENTAL|GV-971 1500 mg|1500 mg oral
62828221|NCT03715114|PLACEBO_COMPARATOR|Placebo|Oral placebo
62828222|NCT06654934|ACTIVE_COMPARATOR|Short duration|6-month prednisolone (shorter treatment)
62828223|NCT06654934|ACTIVE_COMPARATOR|Long duration|12-month prednisolone (longer treatment)
62828224|NCT03697148|EXPERIMENTAL|Diagnostic (mpMRI)|Patients undergo mpMRI within 3 months prior to schedule surgery.
62828225|NCT02631408|NO_INTERVENTION|Control Group|No additional treatment. Routine iv. antibiotic prophylaxis only.
62828226|NCT02631408|EXPERIMENTAL|Vancomycin Group|Vancomycin powder is applied before wound closure. Routine iv. prophylaxis stays unchanged
62828227|NCT04317287|EXPERIMENTAL|Cardio formulation|Tomato-based formulation with dietary supplement
62828228|NCT04317287|PLACEBO_COMPARATOR|Placebo|Placebo softgels
62828229|NCT04119115||Interstitial Lung Disease (ILD)|CT-V and metabolite analysis of breath and serum at baseline
62828230|NCT04119115||COPD/Emphysema: Age-matched control|CT-V and metabolite analysis of breath and serum at baseline
62828231|NCT04119115||Healthy Volunteers: Age-matched + /- 10 yrs controls|Metabolite analysis of breath and serum at baseline
62828232|NCT04944992|EXPERIMENTAL|Efinopegdutide|Efinopegdutide 20 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 2.4 mg from day 1 to week 3, 5.0 mg from week 4 to 7, and 10.0 mg from week 8 to 24.
62828233|NCT04944992|ACTIVE_COMPARATOR|Semaglutide|Semaglutide 1.34 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 0.25 mg from day 1 to week 3, 0.5 mg from week 4 to 7, and 1.0 mg from week 8 to 24.
62828234|NCT01706133|NO_INTERVENTION|Basal phase|Integrated measurement of all variables involved impact and frequency of prior use of health services and specifically to the emergency room, service access, patient characteristics, features for the classification of frailty, cognitive impairment and depression, why consultation, triage scale level on admission to the service and to the service variables in terms of length of stay, diagnosis and medical management, and related services with internal consultants percentage of inpatients discharged or deceased, in further analysis the researchers undertake group estimating frequency of use and the identification of factors associated with the use of emergency departments and adverse events
62828235|NCT01883258|EXPERIMENTAL|High intensity aerobic interval training|Type 2 diabetes subjects will complete 8 weeks of high intensity aerobic interval exercise training.
62046275|NCT01472705||everolimus-eluting stents (EES)|Second-generation everolimus-eluting stents (EES) have been shown to be superior to the first-generation paclitaxel eluting stents (PES) in terms of safety and efficacy.
62046276|NCT01472705||biolimus-eluting stents (BES)|Third generation biolimus-eluting stents (BES) have been shown to be superior to the PES and non inferior to first-generation sirolimus eluting stents in terms of safety and efficacy.
62046277|NCT05719441|EXPERIMENTAL|Arm 1: VRC07-523LS + PGT121.414.LS + ART|
62046278|NCT05719441|PLACEBO_COMPARATOR|Arm 2: Placebo + ART|
62046279|NCT06580847|EXPERIMENTAL|Group Singing|12 week group singing program consisting of 1.5 hours of in-person choir instruction per week.
62828236|NCT01883258|EXPERIMENTAL|Continuous moderate intensity exercise|Type 2 diabetes subjects will complete 8 weeks of continuous moderate intensity exercise training.
62828237|NCT01883258|NO_INTERVENTION|Non-exercise control group|Type 2 diabetes subjects assigned to the non-exercise control group will maintain their normal lifestyle for 8 weeks.
62828238|NCT01883258|NO_INTERVENTION|Healthy control group|Healthy subjects will be assigned to the healthy control group and will undergo baseline measures only.
62046280|NCT06580847|ACTIVE_COMPARATOR|Audiobook Club|12 week group program consisting of 1.5 hours of in-person audiobook club discussion per week.
62046281|NCT00523159|OTHER|1|Pre-treatment with a single low dose of Cyclophosphamide followed by IMA901 vaccination plus GM-CSF as adjuvant
62046282|NCT00523159|OTHER|2|No pre-treatment with Cyclophosphamide before vaccination with IMA901 and GM-CSF as adjuvant
62046283|NCT03434938|EXPERIMENTAL|MI Intervention|Standard geriatric rehabilitation combined with 4 MI sessions (within 72 hours from admission, within 6 days, at 1 week from the second session and pre-discharge, respectively). MI will be delivered by nurses trained through a certified MI course and additional group coaching sessions will be offered them throughout the study. Quality control of the MI sessions will be carried out using Motivational Interviewing Treatment Integrity (MITI) Code 3.1.1 through random video recording.
62046284|NCT03434938|NO_INTERVENTION|Standard rehabilitation|Routine geriatric rehabilitation will include a multidisciplinary and individualized treatment plan based on comprehensive geriatric and specific rehabilitation assessments. As a specific control intervention, within 72 hours from admission a nurse without training in MI will handle the patient written information about generic benefits of exercising.
62046285|NCT01989026|ACTIVE_COMPARATOR|BCG at admission to NICU|These children will receive the BCG (and OPV) vaccines at admission to the Neonatal Intensive Care Unit (NICU).
62438273|NCT03774979|EXPERIMENTAL|SHR-1701|intravenous infusion
62438274|NCT01324245|EXPERIMENTAL|Enalapril|2.5 mg every 12 hours for two doses
62438275|NCT03109873|EXPERIMENTAL|Arm I (EBRT, metformin hydrochloride)|Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
62438276|NCT03109873|PLACEBO_COMPARATOR|Arm II (EBRT, placebo)|Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
62438277|NCT02271815||Oral Hygiene|Oral Hygiene
62438278|NCT04352842||Non-survivors|Patients deceased during the study period
62438279|NCT04352842||Survivors|Patients survived during the study period
62438280|NCT04195984|EXPERIMENTAL|Treatment|Transcatheter mitral valve replacement with the Mi-thos® valve and transcatheter delivery system
62438281|NCT03139565|EXPERIMENTAL|Fluzone High-dose Influenza Vaccine|This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
62438282|NCT03139565|ACTIVE_COMPARATOR|Standard 2016-2017 Flu vaccine|This will be the Standard 2016-2017 influenza vaccine made available by public health. It will contain 15 microgram of each strain and will be delivered in the deltoid muscle of non-dominant arm.
62438283|NCT02373384|EXPERIMENTAL|Study group|"Eligible patients, who fulfilled the study criteria, will be instructed For;~1. Oral alkalinization~   * Potassium citrate 20 mEq three times daily~  * Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females), will receive Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily.~2. Life style modification Adequate fluid intake in order to maintain urine volume between 2-3 L per day.~3. Dietary recommendations~In hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) ;~- Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables."
62438284|NCT05676333|EXPERIMENTAL|Secukinumab|
62438285|NCT04025970||Cancer of Unknown Primary (CUP)|"Subjects referred, based on standardised criteria, for investigation and diagnosis for possible cancer of unknown primary (CUP).~Blood samples to be investigated for presence of circulating tumor cells and circulating tumor DNA."
62438286|NCT04025970||Suspected CANcer (SCAN)|"Subjects referred, based on standardised criteria, for investigation and diagnosis for suspected cancer (SCAN) based on serious non-specific symptoms and signs of cancer.~Blood samples to be investigated for presence of circulating tumor cells and circulating tumor DNA."
62828239|NCT06604156||Gastroscopy group|This study used an EEG bispectral index monitor (Apolo 9000A) to monitor quantitative consciousness (qCON) index and quantitative nociceptive (qNOX) index during gastroscopy. Anesthesia induction was performed using 1.5-2.5mg/kg propofol and 3-5 μ g sufentanil; The injection speed of propofol is between 120s and 180s. When the patient's consciousness disappears (the patient's eyelash reflex disappears, and there is no response to calls and external stimuli), and the Modified Alertness/Sedation (MOAAS) score is ≤ 1, gastroscopy examination will begin. During the examination, propofol 4-12mg/kg. h will be pumped to make MOAA/S ≤ 1, and there will be no body movement reaction.
62828240|NCT06604156||Colonoscopy group|This study used an EEG bispectral index monitor (Apolo 9000A) to monitor quantitative consciousness (qCON) index and quantitative nociceptive (qNOX) index during Colonoscopy. Anesthesia induction was performed using 1.5-2.5mg/kg propofol and 3-5 μ g sufentanil; The injection speed of propofol is between 120s and 180s. When the patient's consciousness disappears (the patient's eyelash reflex disappears, and there is no response to calls and external stimuli), and the Modified Alertness/Sedation (MOAAS) score is ≤ 1, Colonoscopy examination will begin. During the examination, propofol 4-12mg/kg. h will be pumped to make MOAA/S ≤ 1, and there will be no body movement reaction.
62605512|NCT02034812||Radiation Oncologists|"Radiation oncologists targeted for recruitment into the study must meet the following criteria:~* Practicing, board-certified radiation oncologists~* Perform consultations on at least 80 patients with prostate cancer annually~Each participant is asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant's opinion is collected based on a random selection of cases."
62046286|NCT01989026|NO_INTERVENTION|BCG at discharge (as usual)|These children will only receive the BCG (and OPV) vaccines at discharge, as per current standard of care.
62046287|NCT05159622|EXPERIMENTAL|Intervention|Description of behavioral intervention Water Up! at Home: The intervention is theory-based and was designed to be sensitive to the context, perceptions and needs of this high risk population. It was collaboratively developed with key stakeholders in the predominantly Latino immigrant community. The curriculum consists of 12 infographics and lessons (bilingual Spanish/English) designed to increase knowledge of drinking water health benefits, safety/cleanliness, cost/convenience, prior experience. The 12-week intervention will be delivered in participants' home by the home visitor. Participants will receive a water filter for use in their home in addition to educational information about water and sugary beverages. Throughout the lessons, they will be asked to complete various activities such as taking pictures and engaging in discussions about their water drinking habits.
62248260|NCT03436381||Overweight and obese patients|Patient undergoing elective upper endoscopy or colonoscopy, body mass index equal or greater than 25 kg/m2.
62605513|NCT03515629|ACTIVE_COMPARATOR|Pembrolizumab|Pembrolizumab
62605514|NCT03515629|EXPERIMENTAL|REGN2810/ipi|REGN2810/ipi
62605515|NCT03515629|EXPERIMENTAL|REGN2810/chemo/ipi|REGN2810/chemo/ipi
62605516|NCT02553785|EXPERIMENTAL|Revivent TC|Surgical treatment of left ventricle using the Revivent TC System
62605517|NCT05767242||MEDEA BabyLab Cohort|
62605518|NCT04234269||Assessment Group|Individuals with spinal cord injury. There is one group.
62605519|NCT02222441|EXPERIMENTAL|Fixed sequence modafinil DDI arm (Cohort 1)|Fixed sequence study with treatment A of palbociclib alone, followed by treatment B of palbociclib with modafinil in Cohort 1.
62605520|NCT02222441|EXPERIMENTAL|Fixed sequence pioglitazone DDI arm (Cohort 2)|For Cohort 2, fixed sequence study with treatment A of palbociclib alone, followed by treatment C of palbociclib with pioglitazone.
62605521|NCT00669552||Medtronic defibrillator|Patients undergoing a percutaneous coronary intervention (PCI) with an implanted Medtronic defibrillator with the capability of telemetry of the intracardiac signal.
62605522|NCT05814705|ACTIVE_COMPARATOR|Protein supplement|
62605523|NCT05814705|EXPERIMENTAL|Protein supplement with Urolithin A|
62605524|NCT00650416|EXPERIMENTAL|1|Carvedilol Tablets 12.5 mg
62605525|NCT00650416|ACTIVE_COMPARATOR|2|Coreg® Tablets 12.5 mg
62605526|NCT01186913||Stratum A: Typical SCID +HCT|"Stratum A: Typical Severe Combined Immunodeficiency (SCID) treated with HCT therapy.~Participants with typical (formerly referred to as classic) SCID + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol."
62605527|NCT01186913||Stratum B: Atypical SCID +HCT|"Stratum B: Atypical Severe Combined Immunodeficiency (SCID) treated with HCT therapy.~Participants with leaky SCID, Omenn syndrome, or Reticular Dysgenesis (RS) + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol."
62605528|NCT01186913||Stratum C:SCID +Non-HCT|"Stratum C: Severe Combined Immunodeficiency (SCID) who receive alternative therapy per standard of care, non-standard care and/or investigational. This stratum includes:~* Adenosine Deaminase-Deficient SCID (ADA Deficient SCID) with intention to treat with Polyethylene Glycol -Adenosine Deaminase Enzyme Replacement Therapy (PEG-ADA ERT)~* ADA Deficient SCID with intention to treat with gene therapy~* X-linked SCID (XSCID) with intention to treat with gene therapy~* Any individual with SCID previously treated with a thymus transplant (includes intention to treat with HCT, as well as PEG-ADA ERT or gene therapy)"
62605529|NCT02119975|PLACEBO_COMPARATOR|Placebo working memory training|
62248261|NCT05085951|EXPERIMENTAL|Prophylactic pyloric balloon dilatation|OGD and dilatation
62248262|NCT05085951|PLACEBO_COMPARATOR|No endoscopic intervention|OGD but no dilatation
62248263|NCT00618436|ACTIVE_COMPARATOR|Levetiracetam|Group 1 - The levetiracetam (Keppra®) group will receive a loading dose of 20 mg/kg IV over 15 minutes (rounded to the nearest 250mg) up to a maximum of 2000 mg, then started on maintenance dose (1000 mg, IV BID)as prophylaxis for 7 days.
62438287|NCT00580359|ACTIVE_COMPARATOR|A|S-1 40mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
62438288|NCT00580359|ACTIVE_COMPARATOR|B|Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
62605530|NCT02119975|EXPERIMENTAL|Working memory training|
62605531|NCT01055405|EXPERIMENTAL|Sildenafil plus pulmonary rehabilitation|
62605532|NCT01055405|PLACEBO_COMPARATOR|Placebo plus pulmonary rehabilitation|
62605533|NCT01162148|EXPERIMENTAL|1|conventional
62605534|NCT01162148|EXPERIMENTAL|2|sham IMT
62605535|NCT01162148|EXPERIMENTAL|3|Conventional plus threshold IMT
62605536|NCT01162148|EXPERIMENTAL|4|threshold IMT alone
62605537|NCT04615806|EXPERIMENTAL|NIR-ICG|After positioning,Indocyanine green（ICG） dye (Yichuang Pharmaceutical, Liaoning, China) stored at a dose of 25 mg in a small bottle was diluted with 5 ml sterile water. Then, 2 ml of this solution was added to 8 ml sterile water in a dis-posable dressing bowl, resulting in a final concentration of 1.25 mg/ml.
62605538|NCT04615806|NO_INTERVENTION|Control|This group of patients received only conventional radical resection of esophageal cancer without Indocyanine green injection.
62605539|NCT06088251|EXPERIMENTAL|Nutri Training|Nutri Training will begin with 1) a presentation of diet counseling evidence and best practices for advising patients, along with information about nutrition recommendations for patients with chronic illness and 2) tools supporting the patient for follow-up. This content will be delivered via a live demonstration of the Nutri interactive software and case demonstration, a novel approach to delivering the learning objectives of standard nutrition education for residents.
62828241|NCT02309346|EXPERIMENTAL|clindamycin once a day|Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day until clinical improvement
62828242|NCT02309346|ACTIVE_COMPARATOR|clindamycin thrice a day|Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
62828243|NCT06313307|ACTIVE_COMPARATOR|Thulium 1927nm fractional laser|1927nm fractional laser (South Korea, WONTECH, Lavieen) was performed with 4-week interval (Week 0, 4, 8, 12 and 16) for a total of 4 treatments. The parameter of 1927nm fractional laser was as follows: duration 600-800um, 10w, density 0.8mm, 1 pass.
62828244|NCT06313307|EXPERIMENTAL|Thulium 1927nm fractional laser and topical H2R antagonist|Topical H2RA (2% famotidine solution solved in double-distilled water (containing poloxamer 407, glycerol, lauryl alcohol polyether-4, polyethylene glycol-8, and propylene glycol)) was applied immediately after the laser therapy and then topically twice per day in the morning and the evening for 16 weeks.
62828245|NCT02850653|OTHER|Endophthalmitis sufferers|Patients hospitalized for diagnostic and therapeutic evaluation of a post-operative acute endophthalmitis.
62828246|NCT02850653|OTHER|Healthy control patient|Patients hospitalized in the context of a scheduled surgery with sampling of aqueous humour.
62828247|NCT06595329|ACTIVE_COMPARATOR|Epidural analgesia|An epidural catheter will be placed before induction to the anesthesia. A local anesthetic Levobupivacaine 0.25% (Levobupivakain Kabi ®, Fresenius Kabi Norge AS, Svinesundsveien, Norway, 5 mg/ml) will be administered as a bolus dose during the surgery and continuously (0.125% levobupivacaine) during the first 24 hours postoperatively. After the intervention, patients will undergo general anesthesia.
62605540|NCT06088251|ACTIVE_COMPARATOR|Standard Nutrition Education|Standard Nutrition Training will present an overview of 1) nutrition recommendations for patients with chronic disease and 2) cover the role of a registered dietitian and referrals.
62605541|NCT06287710||study of diagnostic accuracy|Patients included in this study would have received fluid expansion in all cases, as the prescription of 10 to 20ml/kg fluid expansion by the physician in charge is the main inclusion criterion.
62605542|NCT06095635|PLACEBO_COMPARATOR|Placebo Protocol|exercise and placebo capsules 500 mg (starch)
62605543|NCT06095635|EXPERIMENTAL|Protocol Beet|exercise and beet extract 500 mg
62828248|NCT06595329|OTHER|Intrathecal opioid analgesia|Patients in the Intervention group will receive a single dose of 300 mcg of morphine (Morphine Kalceks ®, Kalceks, AS, Riga, Latvija, 10mg/ml) intrathecally before induction to general anesthesia.
62828249|NCT05121272|EXPERIMENTAL|young men|Individuals will participate in 1 familiarization and 3 test sessions
62828250|NCT05121272|EXPERIMENTAL|young women|Individuals will participate in 1 familiarization and 3 test sessions
62828251|NCT05121272|EXPERIMENTAL|older men|Individuals will participate in 1 familiarization and 3 test sessions
62248264|NCT00618436|ACTIVE_COMPARATOR|Phenytoin|Group 2-The phenytoin group will receive a loading dose of 20 mg/kg IV to a maximum of 2000mg, then started on maintenance dose at 5 mg/kg/day (rounded to nearest 100mg dose, IV, divided into three doses a day) as prophylaxis for 7 days. Phenytoin levels are to be checked daily and dose adjusted as needed to maintain therapeutic levels of 10-20 µg/dL.
62046288|NCT05159622|NO_INTERVENTION|Control|Participants will receive the standard educational curriculum from the home visiting program (and also a water filter as a token of appreciation).
62046289|NCT01835392|EXPERIMENTAL|Remote Ischemic Preconditioning|Four 5-minute cycles of leg ischemia interspersed with 5-minute cycles of reperfusion using a blood pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure.
62046290|NCT01835392|SHAM_COMPARATOR|Control|Placement of blood pressure cuff around leg without inflation for 40 minutes
62046291|NCT00736645|EXPERIMENTAL|Arm I|Patients receive oral selenomethionine and oral finasteride once daily for 4-5 weeks.
62046292|NCT00736645|EXPERIMENTAL|Arm II|Patients receive oral placebo and oral finasteride once daily for 4-5 weeks.
62248265|NCT00356889|EXPERIMENTAL|Bevacizumab and Erlotinib Hydrochloride|"Patients receive 5 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15 and 150 mg oral erlotinib hydrochloride daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.~Tumor tissue and blood specimens are collected periodically for correlative studies. Specimens are examined by immunohistochemistry for epidermal growth factor receptor (EGFR) and P-EGFR protein levels; AKT p-AKT, mitogen-activated protein kinase (MAPK) and P-MAPK protein levels; and vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR-2 protein levels. EGFR mutations are detected by laser capture microdissection. Enzyme-linked immunosorbent assay is used to measure total and free serum VEGF levels."
62248266|NCT03426787|EXPERIMENTAL|Decision Aid|A decision supports tool that guides patients with Hepatitis C and Chronic Kidney Disease through choices about whether, when, and how to treat each illness.
62828252|NCT05121272|EXPERIMENTAL|older women|Individuals will participate in 1 familiarization and 3 test sessions
62248267|NCT05008536|EXPERIMENTAL|Anti-BCMA CAR-NK Cells|After preconditioning with chemotherapy, the Anti-BCMA CAR-NK Cells will be evaluated
62248268|NCT01995578|EXPERIMENTAL|low dose 5'-azacitidine|This is a single arm phase II trial to assess the efficacy and confirm the safety of maintenance therapy with 5'-azacitadine compared to historical control after TCD allogeneic hematopoietic stem cell transplant for patients with MDS and AML who are at high risk of relapse.
62828253|NCT05972655|EXPERIMENTAL|Treatment Arm|Participants will receive 5\*5Gy modified short-course radiation (radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes) concurrently with CAPOX and tislelizumab regimens: Oxaliplatin, 130mg/m2, intravenous infusion,d1 of each cycle; Capecitabine, 1000mg/m2, PO, BID, d1-14 and tislelizumab, 200mg intravenous infusion d1 of each cycle. CAPOX and tislelizumab repeat every 3 weeks for 4 cycles, followed by total mesorectal excision surgery.
62605544|NCT06095635|EXPERIMENTAL|Protocol Resveratrol|exercise and resveratrol capsules 500 mg
62828254|NCT06078501|EXPERIMENTAL|Misoprostol 400mcg buccal|Participants will take 400mcg buccal misoprostol 2-3 hours prior to their procedure
62046293|NCT00736645|EXPERIMENTAL|Arm III|Patients receive oral selenomethionine and oral placebo once daily for 4-5 weeks.
62046294|NCT00736645|PLACEBO_COMPARATOR|Arm IV|Patients receive two oral placebos once daily for 4-5 weeks.
62046295|NCT05264025|ACTIVE_COMPARATOR|Fexo group|
62046296|NCT05264025|PLACEBO_COMPARATOR|Placepo|
62046297|NCT01552954|EXPERIMENTAL|Intensive education of low salt diet|"For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks. (\*Intervention in this trial is the intensity of education)"
62605545|NCT06095635|EXPERIMENTAL|Protocol Beet and Resveratrol|exercise and beet extract 500mg and resveratrol capsules 500 mg
62046298|NCT01552954|NO_INTERVENTION|Conventional diet group|Education for low salt diet will be conducted as in office with brief communication with a patient and a physician.
62605546|NCT04734275|EXPERIMENTAL|Treatment A (Test Formulation): AZD5718 Dose A, fasted|Subjects will receive single dose of AZD5718 (Dose A), in fasted condition.
62248269|NCT00525044|PLACEBO_COMPARATOR|Control|
62605547|NCT04734275|EXPERIMENTAL|Treatment B (Test Formulation): AZD5718 Dose A, fed|Subjects will receive single dose of AZD5718 (Dose A) in fed condition
62828255|NCT06078501|PLACEBO_COMPARATOR|Placebo|Participants will take a placebo buccally 2-3 hours prior to their procedure
62248270|NCT00525044|EXPERIMENTAL|Ambroxol|
62248271|NCT00064519||Families with MI|"In conjunction with collaborators in Germany, we have established one of the largest collections of families with MI, comprising 1,406 individuals in 513 Western-European families. Based on this collection, our total genome scan and linkage analysis has identified a region on chromosome 14 with a significant linkage signal for myocardial infarction (LOD = 3.9, pointwise P = 0.00015, genome-wide P \< 0.05)5. Preliminary results from an association study in a subset of these families has identified a small set of single nucleotide polymorphisms (SNPs) within candidate genes in this region as being suggestively associated with MI.~No drugs are to be administre"
62248272|NCT02693522|EXPERIMENTAL|somatropin|Subcutaneous injection
62248273|NCT02693522|ACTIVE_COMPARATOR|Eutropin|Subcutaneous injection
62248274|NCT06378671|EXPERIMENTAL|Cryotherapy Treatment|The plan is to enroll 20 patients, who will be randomly assigned in a 1:1 ratio to the experimental group and the control group according to the protocol criteria. The experimental group will undergo routine bronchoscopy examination, lavage, and mucosal biopsy, followed by cryotherapy treatment locally (around the left and right main bronchi, upper trachea, and carina).
62828256|NCT04739761|EXPERIMENTAL|Trastuzumab Deruxtecan|Participants with or without BM at baseline will receive intravenous (IV) T-DXd, 5.4 mg/kg, every 3 weeks (21-day cycle) until Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) defined radiological progression outside central nervous system, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.
62828257|NCT05866458||Single Arm Cohort|The study population consists of women with newly diagnosed T1-3 node negative breast cancer with no clinical evidence of distant metastatic disease, that have been treated with NAC, BCS and axillary staging surgery with final pathology demonstrating a pCR (defined as absence of residual invasive and in situ breast cancer within the breast or lymph nodes).
62828258|NCT00361296|EXPERIMENTAL|K562/GM-CSF cell vaccine|Vaccinations of 1x10\^8 cells are given to participants at weeks 0, 3, 6, 9, and 17.
62828259|NCT01184092|EXPERIMENTAL|Sequence 1|
62828260|NCT01184092|EXPERIMENTAL|Sequence 2|
62828261|NCT01184092|EXPERIMENTAL|Sequence 3|
62828262|NCT01184092|EXPERIMENTAL|Sequence 4|
62828263|NCT01184092|EXPERIMENTAL|Sequence 5|
62828264|NCT01184092|EXPERIMENTAL|Sequence 6|
62828265|NCT05271240|EXPERIMENTAL|SIACI of Bevacizumab (Avastin) with Temozolomide and Radiation|Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation
62828266|NCT05271240|ACTIVE_COMPARATOR|Standard of care Temozolomide and Radiation|Standard of care Temozolomide and Radiation
62828267|NCT03902444||Credo® Stent and NeuroSpeed® PTA balloon catheter|Patients treated with Credo® Stent and NeuroSpeed® PTA balloon catheter in the clinical routine
62828268|NCT04719078|OTHER|All patients|There are no study arms. All patients obtain all imaging modalities.
62828269|NCT01393821|EXPERIMENTAL|Arm I (lotion)|Patients apply menadione topical lotion BID for 28 days.
62828270|NCT01393821|PLACEBO_COMPARATOR|Arm II (placebo)|Patients apply topical placebo lotion BID for 28 days.
62605548|NCT04734275|ACTIVE_COMPARATOR|Treatment C (Reference Formulation): AZD5718 Dose A, fasted|Subjects will receive single dose of AZD5718 (Dose A) in fasted condition
62605549|NCT02568618|OTHER|Immediate|Subjects will receive the results of the Pain Medication DNA Insight (TM) test at Visit 1.
62605550|NCT02568618|OTHER|Delayed|Subjects will receive the results of the Pain Medication DNA Insight (TM) test at Visit 4. After 3 months of standard treatment.
62605551|NCT03879057|EXPERIMENTAL|Surufatinib 200mg/JS001 240mg|Surufatinib at a dose of 200mg Qd, with humanized anti-PD-1 monoclonal antibody（JS001） injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
62605552|NCT03879057|EXPERIMENTAL|Surufatinib 300mg/JS001 240mg|Surufatinib at a dose of 300mg Qd, with humanized anti-PD-1 monoclonal antibody（JS001) injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
62828271|NCT06601023|EXPERIMENTAL|Problem Management plus Mindfulness-informed LegalEducation (PM+MiLE)|The PM+MiLE is a six sessions intervention lasting approximately 90 minutes. A session will be delivered weekly for six week.
62828272|NCT06601023|NO_INTERVENTION|Control - Waitlist Group|The control group will receive no intervention until after the assessment periods at baseline, end of intervention and 3 months follow up before they will be administered the PM+MiLE.
62828273|NCT03708432||Fulvestrant|Fulvestrant 500mg per month (D1, D28, q28d), with a loading dose 500mg of first dose at D15
62828274|NCT03574584|EXPERIMENTAL|NNC0165-1562 + Semaglutide|Participants will receive NNC0165-1562 and semaglutide once weekly for 20 weeks.
62828275|NCT03574584|EXPERIMENTAL|Placebo (NNC0165-1562) + Semaglutide|Participants will receive placebo (NNC0165-1562) and semaglutide once weekly for 20 weeks.
62828276|NCT06603922|EXPERIMENTAL|Personalized MCT (P-MCT)|Personalized Metacognitive training
62828277|NCT06603922|ACTIVE_COMPARATOR|Metacognitive training (MCT)|Metacognitive training
62828278|NCT06587503|PLACEBO_COMPARATOR|Placebo|Receive an intramuscular injection of a placebo concurrently with a dose of rVSV∆G-ZEBOV-GP vaccine
62828279|NCT06587503|EXPERIMENTAL|Concurrent vaccination|Receive an intramuscular dose of BioNTech - Pfizer COVID-19 concurrently with a dose of rVSV∆G-ZEBOV-GP vaccine
62828280|NCT02113982|EXPERIMENTAL|First-Line Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Intervention: Tagraxofusp
62828281|NCT02113982|EXPERIMENTAL|Relapse/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Intervention: Tagraxofusp
62828282|NCT02113982|EXPERIMENTAL|Acute Myeloid Leukemia|Intervention: Tagraxofusp
62828283|NCT04051424|ACTIVE_COMPARATOR|ConMed bite block|Standard bite block (Conmed Bite Block; Conmed Corp., Utica NY, USA)
62828284|NCT04051424|ACTIVE_COMPARATOR|Williams Airway|Williams Airway Intubator (Williams Airway Intubator Ltd, Calgary, Canada)
62828285|NCT04051424|EXPERIMENTAL|McKay airway|A new device that enables maintenance of jaw thrust. (US patent application 16/098,530)
62046299|NCT05435781|ACTIVE_COMPARATOR|RCT group - hydrocortisone|Patients with polymyalgia rheumatica/giant cell arteritis with glucocorticoid-induced adrenal insufficiency (Synacthen test response \<420 nmol/l) that are randomised to receive hydrocortisone
62828286|NCT01069003|PLACEBO_COMPARATOR|Placebo Arm|Subjects are randomized to receive 18 months of placebo thienopyridine and aspirin (ASA). Eligible subjects are without death, myocardial ischemia, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.
62828287|NCT01069003|ACTIVE_COMPARATOR|Thienopyridine Therapy|Subjects are randomized to receive 18 months of active thienopyridine and aspirin (ASA). Eligible subjects are without death, myocardial ischemia, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.
62046300|NCT05435781|PLACEBO_COMPARATOR|RCT group - placebo|Patients with polymyalgia rheumatica/giant cell arteritis with glucocorticoid-induced adrenal insufficiency (Synacthen test response \<420 nmol/l) that are randomised to receive placebo
62248275|NCT06378671|SHAM_COMPARATOR|Not receiving cryotherapy treatment|The plan is to enroll 20 patients, who will be randomly assigned in a 1:1 ratio to the experimental group and the control group according to the protocol criteria. The control group will undergo routine bronchoscopy examination, lavage, and mucosal biopsy.
62248276|NCT04422990|EXPERIMENTAL|LID018869|Lehfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses will be worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
62605553|NCT04939675|EXPERIMENTAL|Anti-seizure medication|The intervention group will receive anti-epileptic drug treatment according to the guideline of American Epilepsy Society 15 for 12 weeks. The recommended regimens include zonisamide, lamotrigine, or levetiracetam at the minimal therapeutic doses (zonisamide 100mg twice daily, levetiracetam 500mg twice daily, lamotrigine 50mg twice daily), and the choices depend on tolerability of the participants and contraindications (allergy to any drugs, or allergy to sulphonamides in zonisamide users). The participants will be followed every 4 weeks.
62248277|NCT04422990|ACTIVE_COMPARATOR|Biofinity|Comfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses will be worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
62248278|NCT02293447|NO_INTERVENTION|Control|The control group will undergo uterine artery embolization according to regular protocol, without the administration of lidocaine.
62248279|NCT02293447|EXPERIMENTAL|Lidocaine per-embolization|This group will receive 10mL of 1% lidocaine in both uterine artery during the embolization; the lidocaine will be mixed with the embolization particles.
62248280|NCT02293447|EXPERIMENTAL|Lidocaine post-embolization|10mL of 1% lidocaine will be injected in both uterine arteries after embolization endpoint is achieved.
62248281|NCT04558463|EXPERIMENTAL|Favipiravir|The favipiravir group received loading dose and maintenance dose of Favipiravir for 2 up to 7 days in addition to standard therapy
62248282|NCT04558463|ACTIVE_COMPARATOR|Oseltamivir|The oseltamivir group was given oseltamivir for 7 days.
62248283|NCT00286481|EXPERIMENTAL|Lapaquistat Acetate 50 mg QD + Simvastatin|
62248284|NCT00286481|EXPERIMENTAL|Lapaquistat Acetate 100 mg QD + Simvastatin|
62248285|NCT00286481|ACTIVE_COMPARATOR|Simvastatin|
62248286|NCT01555151|EXPERIMENTAL|Mometasone furoate 80 μg|Description: Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 80 ug delivered via the Concept1 device for 4 weeks.
62605554|NCT04939675|NO_INTERVENTION|Observation|The participants will be followed every 4 weeks without anti-seizure medication.
62605555|NCT01848236|EXPERIMENTAL|Vitamin D2|Total of 500,000 IU vitamin D2 (50,000 IU twice weekly for 5 weeks)
62828288|NCT01069003|OTHER|Surveillance Arm|Non randomized subjects followed through 24 months
62046301|NCT05435781|NO_INTERVENTION|Control group|Patients with polymyalgia rheumatica/giant cell arteritis with normal adrenal function (Synacthen test response ≥420 nmol/l)
62248287|NCT01555151|EXPERIMENTAL|Mometasone furoate 200 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 200 ug delivered via the Twisthaler® device for 4 weeks.
62248288|NCT01555151|EXPERIMENTAL|Mometasone furoate 320 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 320 ug delivered via the Concept1 device for 4 weeks.
62248289|NCT01555151|EXPERIMENTAL|Mometasone furoate 800 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 800 ug delivered via the Twisthaler® device for 4 weeks.
62248290|NCT01378104|EXPERIMENTAL|80% dosage group of peginterferon alfa 2a|This group patients will treated the same full dose (180ug/week) of peginterferon alfa 2a during the first 12 weeks and then reduce the 75% dose (135ug/week) of peginterferon alfa 2a during remnant 36 weeks. At a result, these patients treated with 80% dosage of originally prescribed peginterferon alfa-2a for standard 48 weeks of treatment.
62248291|NCT01378104|ACTIVE_COMPARATOR|100% dosage group of peginterferon alfa 2a|These group patients would be treated with standard dose 180 ug/week for 48 weeks.
62449289|NCT03915938|EXPERIMENTAL|Group S-Ketamine|S-Ketamine will be diluted in normal saline and administrated in a target controlled infusion using an infusion pump to obtain a plasma target of 60 ng/ml according to Domino's model. Infusion will start during the interval between the 3rd and 4th blocks of the task.
62449290|NCT03915938|PLACEBO_COMPARATOR|Group Placebo|A previously prepared identical solution containing only normal saline will be infused at the same infusion rates of group ketamine.
62449291|NCT00249821|EXPERIMENTAL|Saizen® 0.057 mg/kg/day|Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.057 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the Height-Standard Deviation Score (H-SDS) at this time (less than \[\<\] -2 SDS or greater than \[\>\] -2 SDS)
62605556|NCT01848236|EXPERIMENTAL|Vitamin D3|Total of 500,000 IU vitamin D3 (50,000 IU twice weekly for 5 weeks)
62605557|NCT05717764|EXPERIMENTAL|Experimental group|Patients will receive mitoxantrone hydrochloride liposome injection combined with capecitabine therapy
62605558|NCT05717764|ACTIVE_COMPARATOR|Control group|Patients will receive capecitabine monotherapy.
62605559|NCT06219330||Group I (control group)|15 Healthy participants without any oral lesions
62605560|NCT06219330||Group II:|15 Patients having atrophic/erosive oral lichen planus (OLP). Group III: 15 Patients having oral leukoplakia
62605561|NCT06219330||Group III:|15 Patients having oral leukoplakia
62605562|NCT00615979||Miniature echo machine|Diagnostic capabilities Wireless transfer
62605563|NCT01022775|EXPERIMENTAL|1: Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
62605564|NCT01022775|ACTIVE_COMPARATOR|2: Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
62828289|NCT06245954|EXPERIMENTAL|Standardized training group|The bronchoscopists in this group will accept simulation training by means of simulators and extracorporeal lungs
62828290|NCT06245954|OTHER|Traditional teaching model group|The bronchoscopists in this group will accept traditional lectures, hands-on demonstrations and so on to learn TBLC
62828291|NCT01452698|EXPERIMENTAL|TAK-438 20 mg QD|
62828292|NCT01452698|ACTIVE_COMPARATOR|AG-1749 30 mg QD|
62828293|NCT02326155||Remsima™|Patients were not treated with infliximab before enrollment. Patients were administered CT-P13 5mg/kg by intravenous infusion at weeks 0, 2, and 6, and every 8 weeks thereafter.
62828294|NCT02326155||Switched to Remsima|Patients were treated with infliximab prior to enrollment of the study. Patients were administered CT-P13 5mg/kg by intravenous infusion at weeks 0, 2, and 6, and every 8 weeks thereafter.
62828295|NCT04533503||HF-OCT imaging|Enrolled subjects who meet lesion-specific eligibility criteria and undergo HF-OCT imaging
62828296|NCT06542835|EXPERIMENTAL|Video text message, mailed FIT, and social needs navigation|Tailored video text message, mailed FIT, and navigation to address patients' social needs.
62828297|NCT06542835|ACTIVE_COMPARATOR|Usual care|Colorectal cancer (CRC) screening offers during in-person clinic visits.
62828298|NCT02083900|EXPERIMENTAL|Banana Leaf Dressing Group|The Banana Leaf Dressing site will receive a single layer of banana leaf dressing
62828299|NCT02083900|ACTIVE_COMPARATOR|Hydrocolloid Dressing Arm|The donor under Hydrocolloid dressing was covered with hydrocolloid (DuoDERM CGF).
62828300|NCT05174416|EXPERIMENTAL|Mavacamten|Mavacamten Capsules
62828301|NCT05174416|PLACEBO_COMPARATOR|placebo|Matching Placebo Capsules
62605565|NCT01546597|EXPERIMENTAL|Metformin, Ranolazine|"Single cohort, 4-period study:~* Period 1, metformin 500 mg bid on Days 1-5~* Period 2, metformin 850 mg bid on Days 6-10~* Period 3, metformin 500 mg bid + ranolazine 1000 mg bid on Days 11-15~* Period 4, metformin 850 mg bid + ranolazine 1000 mg bid on Days 16-20"
62828302|NCT06604559|EXPERIMENTAL|Application discharge|"The discharge is conditional on the approval of a senior physician or the attending physician in charge. The participant will sign on a Form for discharge and consent to receive a discharge letter, using the Apollo application in which the discharge process, recommendations and contact information of the department are described. Thereafter, the patient will be discharge home and the discharge letter will be available in the app once it is written. The participant is guided to contact the department, in case the discharge letter is not received in the application up to 24 hours after discharge."
62828303|NCT06604559|OTHER|Regular discharge|The discharge is conditional on the approval of a senior physician or the attending physician in charge. The patient will go home only after the discharge letter is written.
62828304|NCT06597071|ACTIVE_COMPARATOR|Parkinson patients|Patients diagnosed with Parkinson's disease, ages 50-80, Hoehn \& Yahr scale 1-3
62828305|NCT06597071|ACTIVE_COMPARATOR|PSP patients|Patients diagnosed with PSP, according to actual diagnostic criteria from Höglinger GU et al, 2017.
62828306|NCT06597071|ACTIVE_COMPARATOR|MSA patients|Patients diagnosed with MSA, according to actual diagnostic criteria from Wenning et al, 2022.
62828307|NCT06597071|ACTIVE_COMPARATOR|Healthy|Healthy subjects with no neurological diseases or cognition deficits
62438289|NCT05343949|EXPERIMENTAL|HIIT protocol ABC|"HIIT protocol A, then HIIT protocol B, then HiIT protocol C. Patients first received HIIT A -High-intensity duration and intensity: 5 seconds, Rest duration: 40 seconds, Number of Repetitions: 54, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds).~After a rest of at least 2 days they received HIIT B: High-intensity duration and intensity: 10 seconds, Rest duration: 80 seconds, Number of Repetitions: 27, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds).~After a further rest of at least 2 days they received HIIT C-High-intensity duration and intensity: 30 seconds, Rest duration: 240 seconds, Number of Repetitions: 9 Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds)."
62828308|NCT02584686|EXPERIMENTAL|(BTX) A Group|The treatment group will be injected intracavernously with a trimix solution for colour Doppler assessment, followed, on a separate day by 50 units of Botulinum toxin (BTX) A.
62605566|NCT02294175|ACTIVE_COMPARATOR|Larval Debridement Therapy|Larval debridement therapy intervention (Biobags) filled with sterile green bottle fly maggots (larvae) placed in open, chronic lower extremity or diabetic foot ulcer once every 4 days for total of 2 applications over the 8 day study period.
62828309|NCT02584686|PLACEBO_COMPARATOR|Saline Group|The control group, 12 patients, will be injected with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) during penile colour Doppler assessment followed on a separate day with a normal saline injection.
62828310|NCT04263285|EXPERIMENTAL|rTMS (Repetitive Transcranial Magnetic Stimulation)|
62828311|NCT05045586|EXPERIMENTAL|Modified Coronally Advanced Tunnel With Connective Tissue Graft|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
62449292|NCT00249821|EXPERIMENTAL|Saizen® 0.035 mg/kg/day|Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.035 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the H-SDS at this time (\< -2 SDS or \> -2 SDS)
62438290|NCT05343949|EXPERIMENTAL|HIIT protocol CAB|"HIIT protocol C, then HIIT protocol A, and lastly HIIT protocol B. Patients first received HIIT C:-High-intensity duration and intensity: 10 seconds, Rest duration: 80 seconds, Number of Repetitions: 27, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds). After a rest of at least 2 days they received HIIT A:-High-intensity duration and intensity: 5 seconds, Rest duration: 40 seconds, Number of Repetitions: 54, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds).~After a further rest of at least 2 day they performed HIIT protocol B:-High-intensity duration and intensity: 10 seconds, Rest duration: 80 seconds, Number of Repetitions: 27 Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds)."
62828312|NCT05045586|ACTIVE_COMPARATOR|MCAT With Cross-linked Hyaluronic Acid in Addition to CTG|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The root surfaces are applied with cross-linked hyaluronic acid. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
62828313|NCT03742557|ACTIVE_COMPARATOR|Ketamine|"Ketamine 50 MG/ML - at a dose of 0.5 mg/kg IV diluted in 100cc of saline solution 0.9% over 40 minutes.~The intervention will be done twice weekly for 8 weeks."
62605567|NCT02294175|ACTIVE_COMPARATOR|Sharp Debridement Therapy|Bedside sharp debridement therapy as a comparator performed by wound care clinician once every 7 days in a chronic lower extremity or diabetic foot ulcer for a total of 2 sharp debridements over the 8 day study period.
62828314|NCT03742557|PLACEBO_COMPARATOR|Placebo|Saline solution 0.9% over 40 minutes. The intervention will be done twice weekly for 2 weeks, and then patients will receive intervention with ketamine as described above in the Active Comparator.
62828315|NCT05104112|NO_INTERVENTION|control group|Pregnant women followed by the center in the period before the intervention is implemented (the start of which is determined by randomization)
62828316|NCT05104112|EXPERIMENTAL|experimental group|Pregnant women followed by the center during the period after the intervention is implemented (the start of which is determined by randomization)
62828317|NCT06604403|EXPERIMENTAL|Massage Group|Patients in the intervention group will receive post-hemodialysis massage twice a week for four weeks.
62828318|NCT06604403|NO_INTERVENTION|Control Group|Routine nursing care was given to the patients in this group without any message.
62828319|NCT03545555|EXPERIMENTAL|Kale Powder|"5 capsules with kale preparation kale powder per day for 8 weeks"
62828320|NCT03545555|EXPERIMENTAL|Kale Extract|"5 capsules with kale preparation kale extract per day for 8 weeks"
62828321|NCT03545555|EXPERIMENTAL|Flavonoid Extract|"5 capsules with kale preparation flavonoid extract (from kale) per day for 8 weeks"
62828322|NCT03545555|PLACEBO_COMPARATOR|Placebo|"5 capsules with placebo per day for 8 weeks"
62828323|NCT06592989||experimental group|This study is a single arm design, with only one experimental group set up. Medication plan and cycle: oral administration. Sorafenib: once a day, 250mg each time. Gefitinib: once a day, 250mg each time. Every 4 weeks is a treatment cycle.
62605568|NCT05619406|ACTIVE_COMPARATOR|Control|The Control Group will be screened at baseline and be informed of their risk factors. They will be counselled to consult their provider following baseline risk factor assessment but this advice will not be reinforced by exposure to the app, stroke video, or module content. At the end of the study (EOS), they will complete a questionnaire to assess possible contamination with the intervention.
62828324|NCT04537624||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
62828325|NCT05613140||Cohort 1 - Adult HFrEF patients|adult HFrEF patients who newly initiated sacubitril/valsartan
62828326|NCT05613140||Cohort 2 - Adult CHF patients|adult CHF patients who newly initiated sacubitril/valsartan
62828327|NCT06592131|EXPERIMENTAL|Cohort-1 First dose of SAD cohort (6 treatment + 2 placebo)|Drug: BF844
62449293|NCT03308448|ACTIVE_COMPARATOR|Group 1|Intervention is Intra-Venous injection of Eprex or EPO \[recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe\], 300 units/kg/day for three consecutive days (total:900/kg in 3 days)
62605569|NCT05619406|EXPERIMENTAL|Intervention|The riskometer app will be administered one-on-one to the participants using a smartphone and eventually score and assess them using the global risk score
62605570|NCT04912388|EXPERIMENTAL|The stabilization group|The stabilization group will perform lumbal stabilization exercises in lying, sitting, standing and on a swisball 3 times a week during 6 weeks.
62605571|NCT04912388|EXPERIMENTAL|The general exercise group|The general exercise group will perform conventional exercises 3 times a week during 6 weeks.
62828328|NCT06592131|EXPERIMENTAL|Cohort-2 Second dose of SAD cohort (6 treatment + 2 placebo)|Drug: BF844
62828329|NCT06592131|EXPERIMENTAL|Cohort-3 Third dose of SAD cohort (6 treatment + 2 placebo)|Drug: BF844
62828330|NCT06592131|EXPERIMENTAL|Cohort-4 Fourth dose of SAD cohort (6 treatment + 2 placebo)|Drug: BF844
62828331|NCT06592131|EXPERIMENTAL|Cohort-5 Fifth dose of SAD cohort (6 treatment + 2 placebo)|Drug: BF844
62828332|NCT06592131|EXPERIMENTAL|Cohort-6 Using one of the BF844 doses(with/without food) that were tested in SAD|Drug: BF844
62828333|NCT06592131|EXPERIMENTAL|Cohort-7 First dose of MAD cohort (6 treatment + 2 placebo)|Drug: BF844
62828334|NCT06592131|EXPERIMENTAL|Cohort 8 Second dose of MAD cohort (6 treatment + 2 placebo)|Drug: BF844
62828335|NCT06592131|EXPERIMENTAL|Cohort 9 Third dose of MAD cohort (6 treatment + 2 placebo)|Drug: BF844
62828336|NCT06521398|EXPERIMENTAL|Doula Intervention|Participants randomized to the intervention will be offered doula support including care coordination to mental and medical health services in the neonatal intensive care unit (NICU), with a warm handoff to a community doula to continue the support once infants leave the Hospital of the University of Pennsylvania (HUP) NICU.
62828337|NCT06521398|NO_INTERVENTION|Control|Participants randomized to usual care will get the same care they normally would with their own provider, outside of research enrollment, and receive a resource guide with information about the importance of postpartum follow-up care.
62828338|NCT01222689|EXPERIMENTAL|Treatment (erlotinib hydrochloride, selumetinib)|Patients receive selumetinib PO QD and erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62828339|NCT04269668|ACTIVE_COMPARATOR|Medtronic Minimed 670G 3.0 HCL|Hybrid closed loop system
62828340|NCT04269668|EXPERIMENTAL|Medtronic Minimed 670G 4.0 AHCL|Advanced hybrid closed loop system
62828341|NCT05701189|EXPERIMENTAL|Efgartigimod Alfa-Fcab|20mg/kg of Intravenous efgartigimod on days 1 and 5, with normal saline administered as placebo on days 2-4
62828342|NCT05701189|ACTIVE_COMPARATOR|Intravenous Immunoglobulin (IVIg)|0.4g/kg of IVIg daily for 5 days
62449294|NCT03308448|ACTIVE_COMPARATOR|Group 2|Intervention is Intra-Venous injection of Eprex or EPO \[recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe\], 600 units/kg/day for three consecutive days (total:1800/kg in 3 days)
62605572|NCT04912388|NO_INTERVENTION|The control group|Individuals in the control group will not be treated.
62605573|NCT06072404|EXPERIMENTAL|Group A (OZONE_EXO)|intra-tissutal perialveolar injections of a 15-mL mixture of OxigenOzone (O2O3) with a 26Gx1⁄2 - 0.45x13 mm needle and insufflation of the same mixture in the post-extraction site in patients at risk of medication-induced osteonecrosis of the jaw (ONJ).
62605574|NCT06072404|NO_INTERVENTION|Group B (NO_OZONE_EXO)|Tooth extraction in patients at risk of medication-induced osteonecrosis of the jaw (ONJ) without the use of ozone application.
62828343|NCT02889952||NIR-|All consecutive patients (n=174) who underwent conventional total thyroidectomy (TT)+/- lymph node dissection (LND) without the use of NIR - parathyroid identification was done by naked eye only- by surgeon 1, from January 2015 to January 2016 (period 1)
62828344|NCT02889952||NIR|All consecutive patients (n=63) who underwent conventional total thyroidectomy (TT)+/- lymph node dissection (LND) with intraoperative use of NIR - surgical field was examined with NIR before any thyroid dissection- by surgeon 1, from February 2016 to May 2016 (period 2)
62828345|NCT02889952||Control1|Patients (n=30) patients randomly selected among the patients who underwent TT+/- LND without the use of NIR, by another surgeon in the unit (surgeon 2), during period 1.
62605575|NCT02097797|EXPERIMENTAL|Fecal Transplantation|patients receiving the fecal transplant (fecal microbiota from a healthy donor)
62828346|NCT02889952||Control2|Patients (n=30) patients randomly selected among the patients who underwent TT+/- LND without the use of NIR, by surgeon 2, during period 2.
62828347|NCT01256788|EXPERIMENTAL|Viscosupplementation|Hyaluronic acid injection
62438291|NCT05343949|ACTIVE_COMPARATOR|HIIT protocol BCA|"HIIT protocol B, then HIIT protocol C, and lastly HIIT protocol A. Patients firstly received HIIT protocol B:-High-intensity duration and intensity: 10 seconds, Rest duration: 80 seconds, Number of Repetitions: 27, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds).~Following at least 2 days rest the patient will receive HIIT protocol C:-High-intensity duration and intensity: 10 seconds, Rest duration: 80 seconds, Number of Repetitions: 27, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds). After at least another 2 days rest they will lastly receive Protocol A:-High-intensity duration and intensity: 5 seconds, Rest duration: 40 seconds, Number of Repetitions: 54, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds)."
62438292|NCT02281630|EXPERIMENTAL|KWA-0711 High dose|
62438293|NCT02281630|EXPERIMENTAL|KWA-0711 Low dose|
62438294|NCT02281630|PLACEBO_COMPARATOR|Placebo|
62438295|NCT03945344|EXPERIMENTAL|Treatment A|Tiotropium with concomitant charcoal
62438296|NCT03945344|EXPERIMENTAL|Treatment B|Tiotropium without concomitant charcoal.
62828348|NCT01256788|PLACEBO_COMPARATOR|Saline injection|
62828349|NCT02757235|ACTIVE_COMPARATOR|Irrigation fluid of body temperature|During burr hole evacuation of the chronic subdural hematoma the irrigation fluid used will be of body temperature (approximately 37 degrees Celsius)
62828350|NCT02757235|ACTIVE_COMPARATOR|Irrigation fluid of room temperature|During burr hole evacuation of the chronic subdural hematoma the irrigation fluid used will be of room temperature (approximately 22 degrees Celsius)
62828351|NCT01806441|EXPERIMENTAL|3-days high fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
62828352|NCT01806441|ACTIVE_COMPARATOR|3-days low fat diet|During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
62828353|NCT03729739|EXPERIMENTAL|QFR-based diagnostic strategy|"Intermediate stenosis with indication for evaluation are diagnosed by Quantitative flow ratio (QFR).~Revascularization is indicated if QFR≤0.80. Treatment is performed according to standard clinical practice."
62828354|NCT03729739|ACTIVE_COMPARATOR|FFR-based diagnostic strategy|"Intermediate stenosis with indication for evaluation are diagnosed by fractional flow reserve (FFR).~Revascularization is indicated if FFR≤0.80. Treatment is performed according to standard clinical practice."
62438297|NCT06527313|EXPERIMENTAL|Movement Mobilization Concept Group|MWM and appropriate taping will be applied to the cases included in the Mulligan group, according to the Mulligan Concept, and home exercises will be given to the patient as recommended by the concept.
62438298|NCT06527313|SHAM_COMPARATOR|Sham Movement Mobilization Concept Group|The technique will be applied to cases in the sham group with only hand contact, without any slippage or rotation in any direction. Then, rigid taping will be applied without any tension or direction, and home exercises will be given.
62828355|NCT06598566||Geriatric patients above 60 years undergoing hip fracture surgery|Efficacy of NHFS and APACHE-II in predicting 30-day mortality in geriatric patients above 60 years undergoing hip fracture surgery.
62828356|NCT03227913|ACTIVE_COMPARATOR|Good chewing ability|
62828357|NCT03227913|EXPERIMENTAL|Impaired chewing ability|
62828358|NCT03656159|ACTIVE_COMPARATOR|Non-directive support group|This intervention will provide time and space to discuss the impact of AD. The objective will be to help participants feel less alone and better understood and to address the implications of AD in their daily life.
62828359|NCT03656159|EXPERIMENTAL|Cognitive-Behavioral group therapy|The intervention will include behavioral activation, cognitive restructuring, and stress/anger management strategies (e.g. abdominal breathing, progressive muscle relaxation). In addition, knowledge about memory management and sleep disorders will be provided.
62828360|NCT01263080|ACTIVE_COMPARATOR|mirtazapine+folic acid|mirtazapine 30mg QD, folic acid 0.4mg QD
62828361|NCT01263080|ACTIVE_COMPARATOR|mirtazapine+folic acid placebo|mirtazapine 30mg QD, folic acid placebo 1 tablet QD
62828362|NCT01263080|ACTIVE_COMPARATOR|mirtazapine placebo+folic acid|mirtazapine placebo 1 tablet QD, folic acid 0.4mg QD
62828363|NCT01263080|PLACEBO_COMPARATOR|mirtazapine placebo+folic acid placebo|mirtazapine placebo 1 tablet QD, folic acid placebo 1 tablet QD
62828364|NCT02201953|EXPERIMENTAL|SOF/VEL 12 Weeks|SOF/VEL FDC for 12 weeks
62828365|NCT02201953|EXPERIMENTAL|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
62046302|NCT06338657|EXPERIMENTAL|Treatment (FID-007)|Patients receive FID-007 IV over 30 minutes once a week for 3 weeks on days 1, 8, and 15 of a single 28 day cycle in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery. Patients undergo CT or MRI during screening and blood sample collection throughout the study.
62046303|NCT04983381|EXPERIMENTAL|Education Group|Participants were grouped as; those who were given information about vaginal examination in the training group (n=40) and those who were not given information about vaginal examination in the control group (n=40).
62046304|NCT04983381|NO_INTERVENTION|Control Group|Women were not given information about vaginal examination in the control group
62046305|NCT03919136||Primary Objective|Evaluation of the devices accuracy referenced to interventional (A-line) measurement.
62438299|NCT06527313|ACTIVE_COMPARATOR|Control Group|Subjects in the control group will be shown home exercises customized for knee osteoarthritis and asked to continue them.
62438300|NCT06410937|ACTIVE_COMPARATOR|Drain used in the thyroid surgery|
62438301|NCT06410937|ACTIVE_COMPARATOR|No Drain used in the thyroid surgery|
62828366|NCT04369404|NO_INTERVENTION|Usual care|In the usual care group, the providers do not have access to the decision aids.
62438302|NCT02134574||hematologic malignancy|hematologic malignancy with a sampling of blood
62438303|NCT03874806|EXPERIMENTAL|single|local anesthetic is delivered as a single bolus
62438304|NCT03874806|ACTIVE_COMPARATOR|continuous|local anesthetic is delivered as a continuous infusion
62828367|NCT04369404|EXPERIMENTAL|Patient Decision Aid|Providers have access to patient decision aids to review and discuss during the visit.
62828368|NCT03659045|EXPERIMENTAL|Mifegyne® 600MG|Patients assigned to this group will receive three 200 mg tablets of Mifegyne® taken during the consultation Patients will answer to a scale of pain
62828369|NCT03659045|PLACEBO_COMPARATOR|Mifegyne® 200MG|"Patients assigned to this group will receive one 200 mg Mifegyne® tablet and two placebo tablets that will be taken during the consultation.~Patients will answer to a scale of pain"
62828370|NCT00854750|EXPERIMENTAL|ACTHAR- placebo first|Placebo, 20 mg, 40 mg, 80 mg
62828371|NCT00854750|EXPERIMENTAL|ACTHAR- placebo second|20mg, Placebo, 40 mg, 80mg
62828372|NCT00854750|EXPERIMENTAL|ACTHAR- placebo third|20 mg, 40 mg, Placebo, 80 mg
62438305|NCT03847883|ACTIVE_COMPARATOR|0.6 mg/kg Ateplase|Low dose 0.6 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke (n = 26 in cohort A)
62438306|NCT03847883|ACTIVE_COMPARATOR|0.75 mg/kg Ateplase|Low dose 0.75 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke(n = 26 in cohort A)
62438307|NCT03847883|ACTIVE_COMPARATOR|0.9 mg/kg Ateplase|Low dose 0.9 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke(n = 26 in cohort A and n= 330 in Cohort B)
62828373|NCT00854750|EXPERIMENTAL|ACTHAR- placebo fourth|20 mg, 40 mg, 80 mg, Placebo
62828374|NCT04234477|EXPERIMENTAL|Beta-blocker strategy|MICU patients assigned to Team Blue will receive an intravenous (IV) beta-blocker strategy to manage AF with RVR
62828375|NCT04234477|EXPERIMENTAL|Calcium channel blocker strategy|MICU patients assigned to Team Red will receive an intravenous (IV) calcium channel blocker strategy to manage AF with RVR
62828376|NCT04234477|ACTIVE_COMPARATOR|Physician preference strategy|MICU patients assigned to Team Green will receive a physician preference strategy with usual/standard of care interventions to manage AF with RVR
62828377|NCT01245556|EXPERIMENTAL|BMS-908662 or Ipilimumab (A)|
62828378|NCT01245556|EXPERIMENTAL|BMS-908662 or Ipilimumab (B)|
62828379|NCT04804241|EXPERIMENTAL|10 mg daily Senicapoc|10 mg daily Senicapoc for 52 weeks
62828380|NCT04804241|PLACEBO_COMPARATOR|Placebo Group|Placebo daily for 52 weeks
62828381|NCT00423579|EXPERIMENTAL|Ezetimibe/Simvastatin 10/20 mg + Simvastatin placebo|Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin 10/20 mg. The second tablet is simvastatin placebo. Subjects will receive a maximum of 6 weeks of treatment
62828382|NCT00423579|ACTIVE_COMPARATOR|Ezetimibe/Simvastatin placebo + Simvastatin 40 mg|Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin placebo. The second tablet is simvastatin 40 mg. Subjects will receive a maximum of 6 weeks of treatment.
62046306|NCT05788757||Enrolled Subjects|Patients recruited from the population undergoing knee arthroplasty as part of standard of care. Patients who meet all the inclusion criteria and none of the exclusion criteria should be presented with an opportunity to undergo the informed consent process.
62605576|NCT02097797|SHAM_COMPARATOR|Sham Transplantation|patients receiving the vehicle (Physiological serum)
62605577|NCT02631278|OTHER|single arm|Intraoperative radiofrequency ablation
62605578|NCT02274064|EXPERIMENTAL|Intervention|Donors randomly assigned to this group will receive a motivational interview and implementation intention intervention telephone call.
62046307|NCT06157242|EXPERIMENTAL|Open Label, Single Dose Combination of Ceftibuten & Xeruborbactam oral prodrug|"32 participants will be enrolled with varying degrees of renal impairment as well as participants with normal renal function (NRF). 8 participants will be enrolled in each group based on estimated glomerular filtration rate at screening:~* Group 1: Mild renal impairment (eGFR 60 to 89 mL/min/1.73m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration equation)~* Group 2: Moderate renal impairment (eGFR 30 to \< 60 mL/min/1.73m2 calculated using the CKD-EPI equation)~* Group 3: Severe renal impairment (eGFR \< 30 mL/min/1.73m2 calculated using the CKD-EPI equation) not receiving HD therapy~* Group 4: Healthy participants with NRF matched to patients in Groups 1, 2 and 3 based on age, gender and BMI~All subjects will receive a single dose of ceftibuten \& QPX7831 on Day 1.~Participants will remain in the clinic until completion of the post-dose procedures on Day 6. Participants will be contacted by phone between Days 8-10 for follow-up."
62046308|NCT02276222|EXPERIMENTAL|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
62046309|NCT02276222|ACTIVE_COMPARATOR|Spiriva 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
62605579|NCT02274064|NO_INTERVENTION|Control|Donors randomly assigned to this group will receive a standard donor recruitment telephone call.
62605580|NCT02939716|ACTIVE_COMPARATOR|Rhubarb|300g frozen rhubarb, microwaved; served with 65g lactose free cream and saccharine sweetener
62046310|NCT03141957||Young patients|Patients with non-small cell lung carcinoma younger than 75y
62605581|NCT02939716|ACTIVE_COMPARATOR|Bread|2 slices of white bread, 40g each; served with 10g butter
62046311|NCT03141957||Elderly patients|Patients with non-small cell lung carcinoma aged 75 or more
62046312|NCT04529668|EXPERIMENTAL|group I|twenty-five patients with the clinical diagnosis of chronic rhinosinusitis with nasal Polyposis will receive vitamin D supplementation
62046313|NCT04529668|ACTIVE_COMPARATOR|group II|twenty-five patients with the clinical diagnosis of chronic rhinosinusitis with nasal Polyposis will NOT receive vitamin D supplementation
62605582|NCT02939716|EXPERIMENTAL|Lettuce|300g lettuce; served with 30g mayonnaise
62605583|NCT01779167|EXPERIMENTAL|All Patients|Daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in patients with previously treated WM
62605584|NCT04094831|ACTIVE_COMPARATOR|Intervention arm|Intervention group (Health education through CKD campaign and mHealth) technology
62605585|NCT04094831|ACTIVE_COMPARATOR|Control|No intervention
62046314|NCT06579027|EXPERIMENTAL|SPEED (Strength and Power in upper Extremities through Exploratory Driving)|Children will receive training focused on improving affected arm function using modified, joystick-operated ride-on toys. The commercial ride-on toys will be modified to allow operation in a single joystick control mode provided on the child's affected side. The manualized SPEED sessions will involve 2 components: (a) Multidirectional navigational games where children will use their affected UE to drive and maneuver the toy and (b) Object-based UE tasks completed at intermediate stops/stations during navigation. Navigational opportunities will encourage children to navigate through paths of different shapes, sizes, and complexity levels (e.g., straight, circle, diamond, slalom, obstacle courses etc.) Object-based tasks will encourage functional UE movement patterns during object interactions such as reaching, throwing, catching, pulling, pushing, lifting, knocking, holding, grasping, opening, closing, release, and manipulation.
62248292|NCT04818424|EXPERIMENTAL|REAL training|Robotic Exosuit Augmented Locomotion (REAL) refers to gait training with soft robotic exosuits, performed under a speed-based approach where participants are asked to walk at faster speeds in treadmill and overground environments. Cues and summary feedback emphasizing walking speed and forward propulsion are provided by the physical therapist to facilitate goal-directed walking practice. Training is progressively challenging based on environmental complexity and practice variability. REAL includes 12 training sessions, administered 2-3x/week. Each session includes 30 minutes of total walking time.
62828383|NCT06599892||Patients from the 47 CF French center|National registry indicator study = 7513 patients in total, including 5000 eligible for highly effective CFTRm, for the study of pathways at national level, for which clinical and healthcare consumption data are available in the national registry linked to the SNDS
62828384|NCT06599892||Healthcare professionels|Case study: 8 to 10 CRCMs, 7 to 8 professionals and 7 to 8 patients per CRCM, i.e. 56 to 80 professionals, 200 to 400 patients DELPHI: panel of 80 professionals and patients/parents
62828385|NCT01781546|EXPERIMENTAL|drug-eluting balloon (DEB)|Patients treated with drug-eluting balloon (DEB). Provisional stenting with BMS is permitted in case of a flow-limiting dissection or significant recoil (\>30% in main branch and \>50% side-branch), Includes both stable CAD and ACS patients.
62828386|NCT01781546|ACTIVE_COMPARATOR|bare-metal stent (BMS)|Patients treated with bare-metal stent (BMS). Includes both stable CAD and ACS patients.
62828387|NCT06588621||Residents at Cochin Port Royal Hospital|Residents at Cochin Port Royal Hospital assessed by the occupational health department during the analysis period (November 2023- October 2025).
62248293|NCT04818424|ACTIVE_COMPARATOR|Control training|Control training refers to similarly structured gait training as with REAL, with the only exception of using soft robotic exosuits. Control training is performed under a speed-based approach where participants are asked to walk at faster speeds in treadmill and overground environments. Cues and summary feedback emphasizing walking speed and forward propulsion are provided by physical therapist to facilitate goal-directed walking practice. Training is progressively challenging based on environmental complexity and practice variability. Control training includes 12 training sessions, administered 2-3x/week. Each session includes 30 minutes of total walking time.
62248294|NCT05269342|EXPERIMENTAL|the nurse-led counseling and after intervention exercise|"The NUCAI aims to help patients manage themselves physically and psychologically by giving support, education, and exercise tracking.~The participants in the control group were care as usual.Intervention group were the nurse-led counseling and after intervention exercise (NUCAI), in patients with HNC."
62248295|NCT05189613|EXPERIMENTAL|Severe Asthma+BE|Patients with severe eosinophilic asthma with co-presence of Bronchiectasis (BE) in treatment with Mepolizumab
62248296|NCT05189613|ACTIVE_COMPARATOR|Severe Asthma without BE|Patients with severe eosinophilic asthma without Bronchiectasis (BE) in treatment with Mepolizumab
62248297|NCT05016206|EXPERIMENTAL|Treatment Arm (ABC)|"Treatment Sequence ABC - Participants received all 3 doses of danicopan in ascending fashion over 3 periods:~Treatment A (Period 1): Danicopan 400 milligrams (mg) and moxifloxacin-matching placebo.~Treatment B (Period 2): Danicopan 800 mg and moxifloxacin-matching placebo.~Treatment C (Period 3): Danicopan 1200 mg and moxifloxacin-matching placebo."
62438308|NCT06279897|EXPERIMENTAL|Skin Temperature Control During Simulated Blood Loss After Exercise Cold Stress|After exercise in the cold and participants skin will remain cold (\~82°F), be returned to normal (\~90°F), be slightly warmed (\~93°F) or heated (\~95°F) sixty seconds after the onset of LBNP.
62438309|NCT01381900|EXPERIMENTAL|Canagliflozin 100mg|Each participant will receive 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
62828388|NCT00656448|EXPERIMENTAL|Procrit Arm|Participants receive Procrit along with blood transfusions. Procrit 40,000 units subcutaneously every week starting within two weeks (before or after) from the start of induction chemotherapy.
62828389|NCT00656448|NO_INTERVENTION|No Procrit: Standard Arm|Participants do not receive Procrit before receiving blood transfusions.
62828390|NCT01128634|OTHER|GSK573719|GSK573719
62828391|NCT01128634|OTHER|GSK573719/GW642444|GSK573719/GW642444
62828392|NCT04565132|EXPERIMENTAL|HD-tDCS|Each patient received a total of six sessions of anodal HD-tDCS of right DLPFC.
62828393|NCT06603792|EXPERIMENTAL|Real EEG-neurofeedback|the NF intervention group will receive feedback based on the genuine real-time EEG activity
62046315|NCT06579027|ACTIVE_COMPARATOR|CRAFT (Creative Rehabilitation for Arm Functional Training)|Children will engage in seated creative motor games focused on promoting gross and fine motor UE function. Training sessions will encourage use of the affected UE during unimanual and bimanual activities. Each training session will involve the following components: (a) Stretching exercises and (b) Task-oriented strengthening activities. Stretching exercises will involve range of motion exercises to encourage active warmup of proximal (shoulder, elbow) and distal (wrist, hand) UE muscles and movement dissociation. Task-oriented strengthening will involve use of the affected UE as a mobilizer and a stabilizer during building (e.g., Play-Doh, blocks, puzzles) and art-craft activities (e.g., folding, cutting, pasting, coloring). Task-oriented practice will emphasize skills such as reaching, grasping, release, and manipulation of training supplies.
62605586|NCT00365209|EXPERIMENTAL|2g (curcumin)|Patients receive 2 grams of oral curcumin once daily. Treatment continues for up to 30 days in the absence of unacceptable toxicity or disease progression.
62605587|NCT00365209|EXPERIMENTAL|4g (curcumin)|Patients receive 4 grams of oral curcumin once daily. Treatment continues for up to 30 days in the absence of unacceptable toxicity or disease progression.
62605588|NCT02073565|EXPERIMENTAL|Combo|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
62046316|NCT04451122|OTHER|Treatment of ocular demodicosis|
62046317|NCT05085119|EXPERIMENTAL|FiO2 stepwise modifications|Intubation ICU patients will be challenged with stepwise modifications of FiO2. The following steps will be done: 30, 40, 60, 80, 100, 80, 60, 40 and 30%.
62248298|NCT05016206|PLACEBO_COMPARATOR|Control Arm (EFG and IJK)|"Participants received 1 of 2 treatment sequences (Treatment Sequence EFG or Treatment Sequence IJK) over 3 periods:~Treatment E (Period 1): Danicopan-matching placebo (400 mg) and moxifloxacin-matching placebo.~Treatment F (Period 2): Danicopan-matching placebo (800 mg) and moxifloxacin 400 mg.~Treatment G (Period 3): Danicopan-matching placebo (1200 mg) and moxifloxacin-matching placebo.~Treatment I (Period 1): Danicopan-matching placebo (400 mg) and moxifloxacin 400 mg.~Treatment J (Period 2): Danicopan-matching placebo (800 mg) and moxifloxacin-matching placebo.~Treatment K (Period 3): Danicopan-matching placebo (1200 mg) and moxifloxacin 400 mg."
62605589|NCT02073565|ACTIVE_COMPARATOR|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
62605590|NCT00367484|EXPERIMENTAL|Rebif® (clone 484-39)|Rebif® 44 mcg, three times per week (tiw), subcutaneously (s.c.) During the first 4 weeks of the study, subjects underwent a dose titration regimen of 40% of Rebif® 22 mcg or 20% of Rebif® 44 mcg tiw (8.8 mcg per injection) in the first and second week followed by 100% of Rebif® 22 mcg or 50% of Rebif® 44 mcg (22 mcg per injection) in the third and fourth week. After 4 weeks, subjects received 44 mcg injected s.c. tiw.
62605591|NCT03374670|EXPERIMENTAL|Cohort 1|Zimura dosage 1 + Eylea 2 mg
62828394|NCT06603792|SHAM_COMPARATOR|Sham EEG-neurofeedback|The sham-group will receive another participant's EEG-training protocol as a prerecorded signal. The feedback signal will consist of 15-25 rewards per minute. Meanwhile, the threshold for the sham group remains fixed, ensuring a consistent 70% positive feedback rate.
62828395|NCT06587672||Patients received Micra AV implantation|Patients received Micra AV implantation
62828396|NCT02202421|ACTIVE_COMPARATOR|T-ABA Parent Training Only|Participants in the T-ABA Parent Training Only group will be given Targeted Applied Behavior Analysis (T-ABA) Intervention with five weeks of parent group training and five weeks of parent-therapists one-on-one sessions. They will also be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
62248299|NCT05972382||Cervicogenic Headache|Individuals with chronic cervicogenic headache (\>3 months duration)
62248300|NCT02783131|EXPERIMENTAL|MedNav|Team getting taught to use mednav, and using mednav in simulation managing Post partum Haemorrhage.
62248301|NCT02783131|NO_INTERVENTION|non MedNav|Team undergoing routine simulation training in Post Partum Haemorrhage.
62605592|NCT03374670|EXPERIMENTAL|Cohort 2|Zimura dosage 2 + Eylea 2 mg
62828397|NCT02202421|EXPERIMENTAL|T-ABA Parent Group + Individual Therapy|Participants in the T-ABA Parent Group plus Individual Therapy group will be given Targeted Applied Behavior Analysis (T-ABA) Intervention with five weeks of parent group training and five weeks of parent-therapists one-on-one sessions. They will also be offered eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions.
62828398|NCT05994196|EXPERIMENTAL|Optimum|the secondary prioritization software of patients
62605593|NCT01206413|EXPERIMENTAL|LGI|Low glycemic index
62605594|NCT01206413|ACTIVE_COMPARATOR|HGI|High glycemic index
62605595|NCT01206413|EXPERIMENTAL|HB|Home-based exercise
62605596|NCT01206413|ACTIVE_COMPARATOR|CONTROL|Non-exercisers
62605597|NCT03161626||Moderate to Severe Factor X Deficiency|
62828399|NCT05994196|NO_INTERVENTION|Control|the standard dashboard of patients
62828400|NCT03604783|EXPERIMENTAL|Single Arm TP-1287|TP-1287 by oral administration
62605598|NCT03070405|ACTIVE_COMPARATOR|Tenofovir|Tenofovir disoproxil fumarate 300mg single dose administration
62605599|NCT03070405|EXPERIMENTAL|Tenofovir + PAS|Tenofovir disoproxil fumarate 300mg single dose, Para-aminosalicylic acid Ca Granule 5.28 g BID seven dose administration
62828401|NCT03521284||Mothers with education program during their mat|
62605600|NCT03005431|EXPERIMENTAL|Parent training and support|Parents will be given access to participate in an on-line support forum and a set of on-line parent training modules.
62828402|NCT03521284||Mothers without education program during their mat|
62828403|NCT06594692|EXPERIMENTAL|Node-Sparing Short-Course Radiotherapy Combined with CAPOX and Sintilimab|"Intervention Procedure:~1. Radiotherapy: Short-course radiotherapy is administered, with a total dose of 25Gy (5Gy per session for 5 sessions) targeting the primary tumor.~2. Chemotherapy and Immunotherapy: On the 8th day after the start of radiotherapy, CAPOX chemotherapy combined with Sintilimab is initiated for 4 cycles.~3. Surgery: One week after the completion of chemotherapy and immunotherapy, patients will undergo radical total mesorectal excision surgery.~4. Postoperative Adjuvant Chemotherapy: Starting 3-4 weeks after surgery, patients will resume CAPOX chemotherapy for an additional 4 cycles as adjuvant treatment."
62828404|NCT06594692|ACTIVE_COMPARATOR|Preoperative CAPOX Regimen as Neoadjuvant Therapy|"Intervention Procedure:~1. Chemotherapy: Administer CAPOX chemotherapy for 4 cycles.~2. Surgery: One week after the completion of chemotherapy, patients will undergo radical total mesorectal excision surgery.~3. Postoperative Adjuvant Chemotherapy: Starting 3-4 weeks after surgery, patients will resume CAPOX chemotherapy for an additional 4 cycles as adjuvant treatment."
62828405|NCT02703597|EXPERIMENTAL|ASPIRE Group|Participants engage in up to five 70-minute sessions of ASPIRE spread over a period of 5 weeks. Each session completion has a window of 2 weeks, taking into account site availability, presence of students, holidays, and site resources. During ASPIRE use, participants face a screen and individually watch videos and engage in computer-based activities related to the negative effects of tobacco. At baseline, after 3 sessions, following the last session of the intervention, and about one month after the intervention has ended, participants complete psychosocial surveys and social network surveys. Baseline survey again completed. About one month after assessment 4, this group receives a 5th assessment followed by a hybrid version of the GSA-ASPIRE-Network program (moderated by Kahoot!). The group receives additional assessments after 3 sessions, following the last session of the program, and about one month after the program has ended (assessment 8).
62828406|NCT02703597|EXPERIMENTAL|GSA-ASPIRE-Network Group|Participants engage in five 70-minute sessions of ASPIRE conducted over a period of 5 weeks, with 2 booster sessions. Each session completion has a window of 2 weeks, taking into account site availability, presence of students, holidays, and site resources. ASPIRE use is coupled with game-based social activities (GSAs). ASPIRE use, participants watch videos and engage in activities on the same computer. Each session, participants will alternate between 10 minutes of ASPIRE use and 5-minute GSAs. Participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSAs contain games about the effects of tobacco. Groups are allocated based on adolescents' network of friendships. At baseline, after 3 sessions, following the last session of the intervention, and about one month after the intervention has ended (assessment 4), participants complete psychosocial surveys and social network surveys.
62828407|NCT00594490||Silicone|patients undergoing placement of silicone breast prosthetics
62828408|NCT01314586|PLACEBO_COMPARATOR|placebo|placebo pill, diet counseling to comply with NCEP Step I diet
62828409|NCT01314586|EXPERIMENTAL|150 mg/day Beneflax|2 pills taken at breakfast and dinner containing a total of 150 mg secoisolariciresinol (SDG) per day for 12 weeks
62828410|NCT01314586|EXPERIMENTAL|300 mg/day Beneflax|2 pills taken at breakfast and dinner containing a total of 300 mg secoisolariciresinol (SDG) per day for 12 weeks
62828411|NCT01553890|OTHER|Patients diagnosed with scleroderma|patients diagnosed with scleroderma, clinical and lab support
62828412|NCT01553890|OTHER|No disease|Blood sample, venous blood, about 10 ml will be drawn from participants
62248302|NCT02483377||Observational (treatment summaries and plan report)|"Patients receive treatment summaries and plan report that captures patient data through the use of an intake checklist completed during the initial consultation with the breast oncology team and used to guide referrals to existing services and programmed with generic information related to disease and treatment management plan. Additional elements, such as psycho-social services, exercise, and/or nutrition, identified by the patient self-report, will be incorporated. Patients also complete 3 questionnaires at each clinic visit."
62248303|NCT00268307|EXPERIMENTAL|Cell therapy|Intracoronary, one time infusion of autologous, unfractionated bone marrow mononuclear cells.
62248304|NCT00199914|EXPERIMENTAL|Shortwave diathermy|continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
62248305|NCT00199914|SHAM_COMPARATOR|control|continuous sham shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
62248306|NCT02777229|EXPERIMENTAL|Dolutegravir|Dolutegravir 50 mg Quaque die (QD) + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg Fixed Dose Combination (FDC) QD
62248307|NCT02777229|ACTIVE_COMPARATOR|Efavirenz|Efavirenz 400 mg QD + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg FDC QD
62248308|NCT05151120||Group A: Hyperthyroid|30 patients will be included and divided into three categories: A1: 10 patients with suppressed TSH, around 0.01 milli-international unit/liter (mIU/L) A2: 10 patients with TSH values between 0.01 - 0.1 mIU/L A3: 10 patients with TSH values between 0.1 - 0.4 mIU/L
62248309|NCT05151120||Group B: Euthyroid|30 Patients (under treatment) with TSH values between 0.4 - 4 mIU/L will be included
62248310|NCT05151120||GROUP C: Hypothyroid|40 patients will be included and divided into two categories: C1: 20 patients with TSH values between 4 - 50 mIU/L C2: 20 patients with TSH values \> 50 mIU/L up to 100 mIU/L. Even distribution (if possible).
62248311|NCT00865904|PLACEBO_COMPARATOR|Placebo|Placebo matched to VX-809 capsule orally once daily for 28 days.
62248312|NCT00865904|EXPERIMENTAL|VX-809, 25 mg|VX-809, 25 milligram (mg) capsule orally once daily for 28 days.
62605601|NCT03005431|NO_INTERVENTION|Waitlist control group|These parents will receive regular or typical services
62605602|NCT02900417|EXPERIMENTAL|sitagliptin|All the patients will receive sitagliptin 100mg daily.
62248313|NCT00865904|EXPERIMENTAL|VX-809, 50 mg|VX-809, 50 mg capsule orally once daily for 28 days.
62248314|NCT00865904|EXPERIMENTAL|VX-809, 100 mg|VX-809, 100 mg capsule orally once daily for 28 days.
62605603|NCT06509971|EXPERIMENTAL|Experimental Arm|"QL1706: 5 mg/kg Q3W, IV , up to 34 courses.~Albumin-binding paclitaxel: 260 mg/m2 Q3W, IV, 6 courses.~Bevacizumab: 15 mg/kg Q3W, IV, up to 22 courses."
62605604|NCT04363918|ACTIVE_COMPARATOR|intervention (IG1)|
62605605|NCT04363918|ACTIVE_COMPARATOR|intervention (MyoStim group)|
62605606|NCT04363918|SHAM_COMPARATOR|control (CG)|
62828413|NCT06319690|EXPERIMENTAL|Experimental Group (Lion breath)|Lion's Breath Technique + Chest Percussion Therapy
62828414|NCT06319690|ACTIVE_COMPARATOR|Control Group (Routine treatment)|Chest Percussion Therapy only
62828415|NCT04420234|EXPERIMENTAL|Pharmacokinetics study of single and multiple administration|During the study session, 30 healthy subjects will be administered a single and multiple dose of narfurine hydrochloride orally disintegrating tablets 5 µg (2.5 µg/table) to evaluate the pharmacokinetic parameters and the safety profile.
62828416|NCT06474832|EXPERIMENTAL|High-intensity interval training group|The intervention is a 42-minute session and 3-sessions/week, totaling 8 weeks.
62828417|NCT06474832|ACTIVE_COMPARATOR|Moderate intensity continuous training group|The intervention is a 45-minute session and 3-sessions/week, totaling 8 weeks.
62828418|NCT05333263|EXPERIMENTAL|Balance assessment on specialized treadmill|Subjects will undergo a balance assessment on a microprocessor-controlled treadmill
62828419|NCT00573508|ACTIVE_COMPARATOR|Placebo|Matching placebo tablet taken once daily
62605607|NCT04861194|EXPERIMENTAL|Neurovascular-sparing 5x7.25 Gy MRgRT|MRgRT to the prostate in 5 fractions of 7.25 Gy, additionally sparing the neurovascular bundles, internal pudendal arteries, corpora cavernosa, and penile bulb
62605608|NCT02057913|EXPERIMENTAL|Vinflunine|All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
62605609|NCT02690519|EXPERIMENTAL|GLPG1837 dose 1 and GLPG1837 dose 2|GLPG1837 twice daily oral dosing - morning and evening, for 4 weeks
62605610|NCT04685668|EXPERIMENTAL|Women in labour|"All women in labour during the study period will be included for this pre- vs. post-study of the PartoMa intervention.~The following subgroups will be studied in-depth:~1. All stillbirths~2. All children born with low Apgar score"
62605611|NCT02849392|EXPERIMENTAL|Pistachio|Pistachio added 20% of kcals to diet
62605612|NCT02849392|NO_INTERVENTION|No Pistachio|No pistachios in diet (control)
62605613|NCT05270915|EXPERIMENTAL|Family supportive EOLC|The intervention 'family supportive EOLC' was developed based on the international guidelines of family-centered care (25) with additional aspects of care and support. The investigators designed a separated single-bedded EOLC room for the infant and parents. Other family members, such as grandparents or siblings, were allowed to visit the infant and parents. The design of the room included the option for parents to stay comfortably on a sofa to relax and to play soothing music. Parents were encouraged to stay as long as they want and participate in basic care including physical contact with their infant. The nurses supported the parents in creating commemorative items such as a 'Yuan man' box with photos, baby handprint cards, footprint cards, a lock of hair and other precious memory items. A psychologist, in collaboration with our NICU, and a neonatologist supported the parents by individual interviews.
62605614|NCT05270915|ACTIVE_COMPARATOR|The standard EOLC|The standard EOLC included the international guidance of palliative care and EOLC in neonatology (21-23). In China, parents are often the decision-makers of their infant's treatment and the NICU clinicians usually respect the parent's decision (24). After parents have decided to withdraw treatment, standard EOLC is initiated and includes monitoring of vital signs and withholding or withdrawing rescue procedures such as intubation and intravenous infusion. Unnecessary lines are removed and pain management is provided by analgesia. Comfort care is provided by nurses including basic care such as skin care and oral care. After the infant died, the NICU physician informs the parents by phone.
62605615|NCT04936698||Hyperthyroidism|Elevated fT4, low TSH
62605616|NCT04936698||Hypothyroidism|Elevated TSH, low fT4
62605617|NCT04936698||Euthyroid|Normal TSH/fT4 level
62605618|NCT02433067|EXPERIMENTAL|Physical activity intervention|"- Arm A standard oncologic care coupled with physical activity intervention (3 times / week)  during 3 months"
62605619|NCT02433067|ACTIVE_COMPARATOR|Control group|"- Arm B (control group) standard oncologic care"
62605620|NCT00766467|EXPERIMENTAL|Group 1|Armodafinil
62828420|NCT00573508|EXPERIMENTAL|Solifenacin Succinate|5mg or 10mg tablet taken once daily
62828421|NCT05695521|EXPERIMENTAL|CK0803|"CK0803 (cryopreserved, allogeneic, cord blood derived T regulatory cells that express neurotropic homing markers) will be administered intravenously Dose: 100 million Treg cells (fixed dose)~Dose regimen:~* Induction: one infusion every 7 days (+/-3) x 4 doses~* Consolidation: one infusion every 28 days (+/-3) x 5 doses"
62828422|NCT05695521|PLACEBO_COMPARATOR|Placebo|Excipient
62248315|NCT00865904|EXPERIMENTAL|VX-809, 200 mg|VX-809, 200 mg capsule orally once daily for 28 days.
62248316|NCT01908972|ACTIVE_COMPARATOR|Prednisolone|Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
62828423|NCT06331819||Patients|Patients referred for sleep study by in-lab polysomnography to enrolled hospitals and those provided with an at-home sleep study kit.
62248317|NCT01908972|EXPERIMENTAL|Propranolol|Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
62828424|NCT01907854|EXPERIMENTAL|Liraglutide + metformin + sitagliptin placebo|
62605621|NCT00766467|PLACEBO_COMPARATOR|Group 2|Placebo
62605622|NCT06729892|EXPERIMENTAL|Adjusted-group|After administering esketamine at low dose , this group adjusted drug dosage under closed-loop control based on the new BIS baseline(50＋N).
62605623|NCT06729892|EXPERIMENTAL|Non-adjusted group|After administering esketamine at low dose, this group adjusted drug dosage under closed-loop control based on the original BIS baseline(50).
62828425|NCT01907854|EXPERIMENTAL|Sitagliptin + metformin + liraglutide placebo|
62828426|NCT00783783||Poor metabolizers|Patients with CYP2D6 genotypes predictive of poor metabolizer phenotype
62828427|NCT00783783||Non poor metabolizers|Patients with CYP2D6 genotypes predictive of intermediate, extensive, or ultra-rapid metabolizer phenotypes
62828428|NCT01151189|PLACEBO_COMPARATOR|Placebo|The placebo is a licensed product manufactured by Allermed, Inc. and is used for evaluation of delayed-type of hypersensitivity reactions in adults.
62046318|NCT03570684|EXPERIMENTAL|tie group|During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was much easier as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum.
62605624|NCT06729892|PLACEBO_COMPARATOR|control group|This group adjusted drug dosage under closed-loop control based on the original BIS baseline(50) with an equivalent volume of saline.
62605625|NCT04493151|EXPERIMENTAL|Imipenem-Cilastatin-Relebactam|Participants will receive a four to six doses of intravenous imipenem-cilastatin-relebactam as per current prescribing information based on estimated creatinine clearance.
62605626|NCT04511195|EXPERIMENTAL|Sphaeralcea angustifolia standardized extract|Patients with diagnosis of knee osteoarthritis will be included in the experimental group and assigned the treatment consisting of a topical administration of a gel elaborated with the pharmaceutical formulation prepared with a standardized extract from S. angustifolia, which will be administered three times a day for four weeks.
62605627|NCT04511195|ACTIVE_COMPARATOR|Diclofenac 2 %|Patients with diagnosis of knee osteoarthritis will be included in the control group and assigned the treatment consisting of a topical administration of a gel elaborated with 2% diclofenac, which be administered three times a day for four weeks
62605628|NCT02927106||Acute Myeloid Leukemia (AML)|AML samples will be collected from individuals with newly diagnosed or relapsed/refractory Acute Myeloid Leukemia (AML) as defined by World Health Organization 2016.
62605629|NCT01398189|EXPERIMENTAL|clozapine|patients with refractory schizophrenia or schizoaffective disorder
62828429|NCT01151189|EXPERIMENTAL|MVA85A/AERAS-485|MVA85A/AERAS-485 is a recombinant modified vaccinia virus Ankara expressing the M. tuberculosis antigen, Ag85A. Dosage of the study vaccine to be administered will be 1x10\^8 pfu.
62828430|NCT06591910||Induction chemoimmunotherapy followed by surgery or radiotherapy for unresectable stage III NSCLC|
62438310|NCT01381900|EXPERIMENTAL|Canagliflozin 300mg|Each participant will receive 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
62438311|NCT01381900|PLACEBO_COMPARATOR|Placebo|Each participant will receive matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
62605630|NCT06511323|EXPERIMENTAL|Observational|This is a prospective, single-arm, pilot diagnostic study to evaluate the diagnostic accuracy of using dynamic \[18F\]FDG PET in 70 patients with brain metastases managed with stereotactic radiosurgery(SRS)/fractionated stereotactic radiotherapy (FSRT). The study will include imaging assessments at baseline, at 10 weeks after treatment, and at first concern for progression or 12 months post-treatment, whichever comes earlier.
62605631|NCT03646305|EXPERIMENTAL|Verbally repeat body-related thoughts|A cognitive defusion strategy in which participants repeat a target unwanted thought out loud and as quickly as possible for 60 seconds.
62605632|NCT03646305|EXPERIMENTAL|Sing negative body-related thoughts|A cognitive defusion strategy in which participants sing a target unwanted thought to the tune of 'twinkle, twinkle' for 60 seconds
62605633|NCT03646305|NO_INTERVENTION|Verbally repeat body-unrelated thoughts|"A control condition in which participants repeat the phrase I am talking out loud and as quickly as possible for 60 seconds."
62605634|NCT03646305|NO_INTERVENTION|Sing body-unrelated thoughts|"A control condition in which participants sing the phrase I am singing to the tune of 'twinkle, twinkle' for 60 seconds"
62605635|NCT05313282|EXPERIMENTAL|treatment group|combination of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX7) , targeted drugs (Apatinib 250mg), and anti-PD-1 immunotherapy (Camrelizumab 200mg)
62046319|NCT03570684|NO_INTERVENTION|non-tie group|
62046320|NCT06489561|EXPERIMENTAL|Behavioral Testing|Behavioral and Neuronal Recordings
62046321|NCT02230202||Healthy control|Healthy control that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
62046322|NCT02230202||Stage III or IV CKD patients|Stage III or IV CKD patients that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
62438312|NCT04645290|EXPERIMENTAL|"Intervention group: Educational Intervention KARER"|General objective of the intervention: Implement self-care strategies and care actions aimed at people facing chronic diseases with disabilities, applying knowledge, ability and attitudes that allow them to act in a timely manner, reducing the risk of complications, improving well-being and the quality of life of the person cared for and of himself. Through face-to-face, virtual interdisciplinary educational actions (B-learning) and with simulation support.
62605636|NCT05313282|ACTIVE_COMPARATOR|control group|combination of targeted drugs (Apatinib 250mg), and anti-PD-1 immunotherapy (Camrelizumab 200mg)
62605637|NCT05422209|ACTIVE_COMPARATOR|Mesh-augmented sacrospinal fixation with posterior colporrhaphy and perineoplasty.|
62828431|NCT02878031|EXPERIMENTAL|Oral amoxicillin for CI pneumonia|Community management of chest indrawing pneumonia using oral amoxicillin by CHWs
62828432|NCT02386813||Training cohort|"1. Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31, 2013;~2. Patients treated with non-anthracycline based therapy as an initial treatment."
62828433|NCT02386813||Validation cohort|"1. Patients diagnosed with ENKTL, nasal type between January 1, 1998 and December 31, 2014;~2. Patients treated with non-anthracycline based therapy as an initial treatment."
62828434|NCT01961037|EXPERIMENTAL|Physical activity intervention|Tai Chi: Moving for Better Balance exercise program
62046323|NCT02230202||Post-transplant patients|Stage III or IV CKD Post-transplant patients that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
62828435|NCT05895188|EXPERIMENTAL|Virtual Reality Group|Before starting the process, participants will be informed about the study and their verbal and written consent will be obtained. Participants in the virtual reality group will be shown and introduced to virtual reality glasses before the procedure. After the woman goes to the examination table and takes the appropriate position for the pap smear procedure, virtual reality glasses will be put on the woman by the researcher. The selected video will be played until the Pap smear process is completed. (https://www.youtube.com/watch?v=6ud18oSuCiY\&t=30s). When the Pap smear is finished, the glasses will be removed and the woman will be helped to get up from the examination table. In this process, no form will be filled until the participant woman gets dressed and takes the ready position. Thus, the privacy of women will be protected and there will be no violation of ethical rights.
62828436|NCT05895188|NO_INTERVENTION|Control Group|Verbal and written consent will be obtained from the participants before starting the procedure. No intervention will be applied to the participants in the control group. The forms that need to be filled before the procedure will be filled. With the help and guidance of the researcher, the woman will prepare, move to the examination table and take a position. After the Pap smear process is over, the participant woman will get off the examination table with the help of the researcher and get dressed. After the woman is ready after the procedure, she will go to the waiting room and fill out the forms.
62605638|NCT05422209|ACTIVE_COMPARATOR|Mesh-augmented sacrospinal fixation with posterior colporrhaphy.|
62605639|NCT04687748|EXPERIMENTAL|EMG BF Group|Pelvic floor muscle contraction will be performed via an S-EMGBF device; patients in the s-EMGBF group will receive visual and auditory feedback.
62605640|NCT04687748|ACTIVE_COMPARATOR|Control Group|Patients would be advised to maximally contract the pelvic floor muscles as forcefully a possible for about 5 seconds.
62828437|NCT04415372||Cognitive Impairment|Adults diagnosed with MS that have evidence of cognitive decline.
62828438|NCT04415372||No Cognitive Impairment|Adults diagnosed with MS that have no evidence of cognitive decline.
62828439|NCT04415372||Healthy Controls|Healthy adult volunteers will form a control group matched for age, gender, education, handedness
62828440|NCT01895413|EXPERIMENTAL|Mesenchymal stem cells|Bone marrow aspiration, Autologous bone marrow-derived mesenchymal stem cells
62828441|NCT06591416|ACTIVE_COMPARATOR|Minimally invasive surgical technique with total removal of granulation tissue|Minimally invasive surgical technique with total removal of granulation tissue
62828442|NCT06591416|EXPERIMENTAL|Minimally invasive surgical technique with partial removal of granulation tissue|Minimally invasive surgical technique with partial removal of granulation tissue
62828443|NCT06117618|NO_INTERVENTION|No alert|Participants will receive no physician alert or registered nurse (RN) alert.
62828444|NCT06117618|EXPERIMENTAL|Nurse alert|Participants will receive RN alert.
62828445|NCT06117618|EXPERIMENTAL|Prescribing clinician alert|Participants will receive physician alert.
62046324|NCT03521596||Patient enrolled|Part of the patients will be retrospectively enrolled (learning sample) and part prospectively (validation sample)
62046325|NCT02736695|EXPERIMENTAL|Tau PET Scan, F-18 AV 1451|All subjects will receive a Tau PET scan.
62248318|NCT05806775|EXPERIMENTAL|Low-load resistance training with blood flow restriction|Exercises will target bilateral 1) knee extensor, 2) ankle plantarflexor, and 3) elbow extensor muscles. Exercises will be dosed based on 1RM and individualized for each participant from a standardized exercise set. Progression will be based on 1) body position (supine, seated, standing), and 2) degree of resistance. Dosing will be re-assessed every 2 weeks and progressed as tolerated. Resistance will be provided by the Shuttle Mini-Press (Shuttle Systems), a portable resistance trainer that allows for precise dosing but is also adaptable to people with mobility limitations.
62248319|NCT04608760|ACTIVE_COMPARATOR|Meksibel|Intravenous 0.1 30 minutes before the procedure and 0.1 once a day for 3 days after the procedure
62605641|NCT06731218|EXPERIMENTAL|RGB-5088|Transplantation under the anterior rectus sheath
62605642|NCT02917824|EXPERIMENTAL|High-intensity IMT|Participants enrolled in this arm received high-intensity IMT
62605643|NCT02917824|ACTIVE_COMPARATOR|Low-intensity IMT|Participants enrolled in this arm received low-intensity IMT
62605644|NCT03860714||study group|400 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University \[Jiangsu China\].We do the neuropsychological tests,MMSE,CCI，CDR,QoR-40,GDS,CAGE Alcoholism Questionnaire，Pure Tone Audiometry，blood albumin、hemoglobin content、ALT、AST、BUN、Cr、serum folic acid、vitamin B12、homocysteine and branched chain amino acid content 1 day before the surgery（baseline）； 1 day before the surgery（baseline）； Confusion Assessment Method（CAM)，NRS once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery； Neuropsychological tests and MMSE 6±1 days and one month after surgery.
62605645|NCT04823793||Healthy group : Stool specimens from participants with healthy colon|"Stool specimens will be collected from participants before having a colonoscopy.~If the participant's colon has a healthy colon without any cancerous lesion, the stool specimen will be included in the healthy group."
62605646|NCT04823793||Disease group : Stool specimens from participants with adenoma/colorectal cancer|"Stool specimens will be collected from participants before having a colonoscopy.~If the participant's colon has precancerous lesion, such as adenoma, the stool specimen will be included in the disease group.~Also, specimens from confirmed colorectal cancer patients are included in the disease group."
62605647|NCT03767556|NO_INTERVENTION|Control|This group will not receive intervention
62828446|NCT06117618|EXPERIMENTAL|Nurse alert and prescribing clinician alert|Participants will receive physician alert and RN alert.
62828447|NCT06589570|ACTIVE_COMPARATOR|Conventional impression-based fabrication of cobalt-chromium framework|The conventional impression-based fabrication of a cobalt-chromium framework for partial dentures follows a well-established process that involves multiple steps to ensure an accurate and functional prosthesis. This method, which has been widely used for decades, relies on manual techniques and skilled craftsmanship to create the metal framework that supports the artificial teeth and secures the denture in place.
62605648|NCT03767556|EXPERIMENTAL|Inspiratory Muscle Training|This group, for inspiratory muscle training, will use the Powerbreathe® K5 device. This device will be adjusted with a load of 55% of previously assessed MIP. The volunteer will be instructed to inhale with sufficient force to overcome the resistance of the equipment and subsequently perform a normal expiration. During the 4-week period of respiratory muscle training volunteers will be instructed to perform 2 sets with 30 inspiratory efforts, 5 days a week. The training load will be readjusted on the first day of training each week, after a new reassessment of the PIMax in order to guarantee the overload during inspiratory muscle training.
62605649|NCT03672461|EXPERIMENTAL|Yoga Practice Program|The 3-month yoga intervention will provide instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population. The study will feature a therapeutic program based primarily on Iyengar yoga, a form of Hatha yoga that is known for its potential therapeutic applications.
62828448|NCT06589570|EXPERIMENTAL|CAD design, and CAM milling of titanium framework|The CAD (Computer-Aided Design) and CAM (Computer-Aided Manufacturing) process for creating a titanium framework for partial dentures represents a modern, highly precise approach to dental prosthesis fabrication. This digital process offers several advantages over traditional methods, such as improved accuracy, a more comfortable fit, and a reduction in the number of manual steps involved.
62828449|NCT06001918|EXPERIMENTAL|Treatment Arm|"Participants assigned to the treatment arm will undergo an endovascular procedure using the Nectero EAST System to deliver the Stabilizer Infusion Solution directly inside the aneurysm. This is a one-time local delivery of the product. Following treatment, surveillance of their AAA will be conducted using CT scans at 6 months, 12 months, 18 months, 24 months, and annually for 5 years.~Intervention: Drug: Stabilizer"
62828450|NCT06001918|NO_INTERVENTION|Control Arm|Participants assigned to the control arm will undergo surveillance of their AAA using CT scans at 6 months, 12 months, 18 months, 24 months, and annually for 5 years.
62438313|NCT04645290|NO_INTERVENTION|Usual Care|The people assigned to this group will receive their own responses from the institution providing care services to which they belong. These instructions consist of: information on the disease process and treatment received from the medical group, information on assistance by the nursing group and finally, the administrative procedures carried out by social work.
62248320|NCT04608760|ACTIVE_COMPARATOR|Indometacin|Into the rectum 1 hour before the procedure and 1 candle 1 time a day for 3 days after the procedure
62248321|NCT04608760|ACTIVE_COMPARATOR|Meloksicam|Intravenous 15 mg 30 minutes before the procedure and 15 mg once a day for 3 days after the procedure
62248322|NCT04608760|ACTIVE_COMPARATOR|Oktride|Intravenous 3 ml 30 minutes before the procedure and 3 ml once a day for 3 days after the procedure
62248323|NCT03842163||Patients with LVH of unknown etiology|
62248324|NCT04159766|ACTIVE_COMPARATOR|NLY01 (2.5 mg)|
62248325|NCT04159766|ACTIVE_COMPARATOR|NLY01 (5.0 mg)|
62248326|NCT04159766|ACTIVE_COMPARATOR|NLY01 (10 mg)|
62248327|NCT04159766|PLACEBO_COMPARATOR|Placebo|
62248328|NCT05844371|EXPERIMENTAL|study group|chemotherapy with oxaliplatin + heroda regimen (oxaliplatin 130mg / m2 D1, heroda tablets 1000mg / m2 bid d1-14, 21d repeated), during which tirelizumab (200mg, q3w) was used. After 6 cycles of chemotherapy, monotherapy with tirelizumab (200 mg, q3w) was maintained until 1 year.
62248329|NCT05844371|ACTIVE_COMPARATOR|Control group|6 cycles of oxaliplatin + heroda regimen chemotherapy.
62438314|NCT03712969|EXPERIMENTAL|Intervention group|Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
62438315|NCT03712969|NO_INTERVENTION|Control group|Patients receive conventional adjuvant chemotherapy.
62248330|NCT01582542|EXPERIMENTAL|Desmopressin|
62248331|NCT02695433|EXPERIMENTAL|Active treatment (AT) diet plan|1 Avocado 7 days/week (5-7 days is acceptable) over a 12 week period
62248332|NCT02695433|PLACEBO_COMPARATOR|Control (CT) diet plan|at least 1 serving of a low fat, low fiber, high glycemic carbohydrate and eliminate avocado 7 days / week (5-7 days is acceptable) over a 12 week period
62248333|NCT01526096|ACTIVE_COMPARATOR|Standard ASCT (Grp 1)|Standard autologous stem cell transplantation (ASCT)
62248334|NCT01526096|EXPERIMENTAL|Depletion of T-cells after ASCT (Grp 2)|Standard ASCT followed by treatment with basiliximab to remove certain immune cells (called regulatory T-cells or Tregs) from the blood
62248335|NCT01526096|EXPERIMENTAL|Depletion of T-cells before ASCT(Grp 3)|Blood collected for an ASCT will be processed using a special cell sorting machine (CliniMACS device) to remove Treg cells before the stem cells are infused back into the body during stem cell transplant.
62248336|NCT03420079|EXPERIMENTAL|Dose escalation cohort of FCN-411|"* FCN-411 will be orally administrated at five sequential dose levels, which are 4 mg, 8 mg, 16 mg, 24 mg, and 32 mg.~* Patients must be diagnosed with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).~* Participants will receive FCN-411 monotherapy once daily (QD) for sequential 21-day cycles."
62248337|NCT03420079|EXPERIMENTAL|Dose expansion cohort of FCN-411|"* FCN-411 will be orally administrated at MTD.~* Patients must be diagnosed with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).~* Participants will receive FCN-411 monotherapy once daily (QD) for sequential 21-day cycles."
62438316|NCT05344066|ACTIVE_COMPARATOR|Best NHS Care|Best National Health Service (NHS) Care
62438317|NCT05344066|EXPERIMENTAL|Intermittent Low Energy Diet|Intermittent Low Energy Diet
62438318|NCT02148666||experimental : intracoronary stem cells|intracoronary stem cells will be injected in infarct related artery.
62438319|NCT01478503|EXPERIMENTAL|Treatment Arm A|mirabegron
62828451|NCT06184022|EXPERIMENTAL|Augmented reality serious game|"Before the test started, the experimenter gave the basic information of the experiment to the participants. The participants were requested to complete a cognitive exam on the notion of light, and were asked to perform a POE test for each question. The experimental group utilized the three game lesson modules of the AR science education app designed for this study, including Animals vision,  Light transmission, and Color-Light mixing. On their initial encounter with the game, respondents were given around 10 minutes to comprehend its mechanics. The experimental group's total learning time was limited to 20 minutes, the testing process was completed under the supervision of the instructor and the experimenter. During the experiment, the participants were not disturbed in any way; researchers only intervened when they faced difficulties or requested assistance. The participants were given a 15-minute respite at the conclusion of the trial to take another POE test."
62438320|NCT01478503|PLACEBO_COMPARATOR|Treatment Arm B|matching placebo
62438321|NCT03549130|EXPERIMENTAL|Active nasal strip group|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
62438322|NCT03549130|PLACEBO_COMPARATOR|Placebo nasal strip group|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
62438323|NCT01974271||Cohort|
62438324|NCT04131361|ACTIVE_COMPARATOR|Crystalloid -control group:|
62438325|NCT04131361|EXPERIMENTAL|Colloid- study group:|
62046326|NCT01185626|NO_INTERVENTION|Usual care|The gynaecological oncologist (GO) provides care as usual. Currently, hospitals provide follow-up following the Dutch guidelines, meaning that they see their patients on given time points based on the number of years after diagnosis. Most hospitals give their patients leaflets regarding the diagnosis and treatment they receive, however none of them provide personalized information. All information is given during the initial treatment phase, but none of the GOs give additional information during follow-up. None of the GOs is actively screening on psychosocial needs. As this might change in time, we will ask the providers and patients about the type of information they provide, respectively, receive.
62605650|NCT03672461|ACTIVE_COMPARATOR|Physical Conditioning Program|"The 3-month muscle stretching/strengthening intervention program (also referred to as the physical conditioning program) has been designed by the study physical therapist consultants. Similar to postures in the yoga intervention program, the exercises in the stretching/strengthening program have been selected for their potential to be performed safely by women across a range of ages and flexibility levels."
62605651|NCT06730009|EXPERIMENTAL|SLOG + Allogeneic NK cells|Ph I SLOG + Allogeneic NK cell dose escalation (Cohort 1:10 × 10\^8 cells ; Cohort 2:20 × 10\^8 cells) Ph II Arm 1 SLOG + Allogeneic NK cell
62605652|NCT06730009|ACTIVE_COMPARATOR|SLOG chemotherapy|Ph II Arm 2
62605653|NCT05541094||Fortified Arm|Individuals from families who are consume fortified milk + oil
62046327|NCT01185626|EXPERIMENTAL|SCP care|After initial treatment, the GO provides the patient with a paper SCP and takes time to discuss all items in the SCP. Each time during follow-up meetings between patient and GO, the patient will receive an updated SCP if applicable. The paper SCP is extracted from the online registration system 'ROGY' (Registrationsystem Oncological GYnaecology) and combines personal patient and disease data with tailored information that is related to the specific situation of this patient. Recurrences, toxicities or additionally involved specialists will be registered in ROGY and automatically updated in the personal SCP.
62828452|NCT06184022|ACTIVE_COMPARATOR|non-ar serious game|"The control group completed the same three game courses for a maximum of 20 minutes using the non-AR app Light and Color after completing the pre-test.For the non-AR game we used Light and Color designed by Tinybop available in Appstore Tools for young artists and scientists. Both games have the same scientific educational content on optics (in fact, to experiment with control variables, we adopted the same scientific knowledge as in this non-AR app at the stage of designing the content), so it is possible to perform a POE test. The participants took a 15-minute break at the conclusion of the trial to complete another POE test and the IMI scale."
62828453|NCT06287580|ACTIVE_COMPARATOR|Antihypertensive drug treatment Arm|Participants will take a fixed dose of chlorthalidone (a diuretic, 25 mg orally once daily) for two week, with study visits for laboratory assessment at before and after intervention.
62828454|NCT06287580|PLACEBO_COMPARATOR|Placebo treatment Arm|Participants will receive placebo treatment for two weeks, with study visits for laboratory assessment at before and after intervention.
62046328|NCT01394354|EXPERIMENTAL|1|"Vorinostat. To determine the MTD, dose escalation for Vorinostat will be conducted following the 3 + 3 design The first cohort of 3 patients will be given 100mg/d on days 1-4, 8-11, 15-18. The second cohort of 3 new patients will be treated with Vorinostat 200mg/d. The third cohort will be given Vorinostat 300mg/d. Cycles will be repeated every 28 days. Maximum treatment cycles: 6. Bortezomib will be administered intravenously (i.v.) 1.3mg/m2 BSA an days 1, 8, 15.~Doxorubicin will be administered i.v. with a total dose of 18mg/m2 BSA per cycle (9mg/m2 BSA, d1 and 8).~Dexamethasone will be administered per os (p.o.) with 40mg (first cycle) or 20mg (all other cycles) on d1, 8, 15, and 22."
62046329|NCT00633464|EXPERIMENTAL|Arm A (ixabepilone 40 mg^2)|ixabepilone 40 mg/m\^2 every 3 weeks
62605654|NCT05541094||Unfortified Arm|families habitually consuming unfortified milk and oil
62605655|NCT06016439|EXPERIMENTAL|Arthroscopic rotator cuff partial repair with superior capsule augmentation with LHBBT|"If a tear is intra-operatively determined irreparable, randomization takes place.~Irreparable tears that are randomly selected to receive arthroscopic rotator cuff partial repair including superior capsular augmentation with proximal part of the long head of the biceps tendon. The long head of the biceps tendon will be released from bicipital groove and proximal part of the tendon will be used to cover the rotator cuff gap and anchored to the greater tuberosity."
62605656|NCT06016439|ACTIVE_COMPARATOR|Arthroscopic partial rotator cuff repair|"If a tear is intra-operatively determined irreparable, randomization takes place.~Irreparable tears that are randomly selected to receive arthroscopic partial repair."
62605657|NCT06016439|OTHER|Arthroscopic rotator cuff repair|Arthroscopic complete repair.
62605658|NCT06016439|NO_INTERVENTION|Rotator cuff tear conservative treatment|Conservative treatment following physiotherapy protocol.
62605659|NCT01028248|ACTIVE_COMPARATOR|2.0 mg Ranibizumab|
62605660|NCT01028248|ACTIVE_COMPARATOR|0.5 mg Ranibizumab|
62828455|NCT00648440|EXPERIMENTAL|1|Midodrine HCl Tablets 5 mg
62046330|NCT00633464|EXPERIMENTAL|Arm B (cetuximab 250 mg/m^2 + ixabepilone 40 mg/m^2)|cetuximab 400 mg/m\^2 loading dose then 250 mg/m\^2 weekly + ixabepilone 40 mg/m\^2 every 3 weeks
62046331|NCT05542043||Women with normal blood loss (BV < 500 mL)|
62605661|NCT02865590|EXPERIMENTAL|Lyophilized Equine Bone Allograft|Sinus Lift with Lyophilized Equine Bone Allograft
62605662|NCT02865590|ACTIVE_COMPARATOR|deproteinized bovine bone allograft|Sinus lift with deproteinized bovine bone allograft
62828456|NCT00648440|ACTIVE_COMPARATOR|2|ProAmatine® Tablets 5 mg
62828457|NCT05038098|EXPERIMENTAL|Cohort I (preoperative injection)|Patients receive FerroTrace peritumorally within days 1-21. Patients then undergo gastrectomy and receive ICG peritumorally.
62828458|NCT05038098|EXPERIMENTAL|Cohort II (intraoperative)|Patients undergo gastrectomy and receive FerroTrace and ICG peritumorally during surgery.
62046332|NCT05542043||Women with increased blood loss (BV ≥ 500 mL)|
62605663|NCT02357667||Exposed cases|African American women with concern for severe preterm (37 weeks gestation) preeclampsia who are admitted to the inpatient obstetrical unit at HUP.
62605664|NCT02357667||Unexposed controls|African American women without preeclampsia or medical comorbidity who are matched by gestational age, maternal age, and BMI in the outpatient setting.
62605665|NCT00844480|EXPERIMENTAL|zoledronic acid|
62605666|NCT00844480|PLACEBO_COMPARATOR|placebo|
62605667|NCT00725101||Fibromyalgia (FM) Participants|FM participants starting any new pharmacologic FM agent.
62605668|NCT03325894|EXPERIMENTAL|SHP465|Group A participants who have been rolled-over from antecedent SHP465 studies and Group B participants who will be newly enrolled into the study will receive SHP465 capsule 6.25 mg orally once daily for 360 days.
62605669|NCT04687020|OTHER|Non-interventional (United States) / Low-interventional (Canada) : Viltolarsen|Patients will receive viltolarsen (recommended dose 80mg/kg/week) during a treatment period up to 120 months.
62828459|NCT05258721|EXPERIMENTAL|Treatment Group|Participants with gingivitis or periodontitis (Stage I or II) brush with ClōSYS® Sensitive Fluoride Toothpaste twice daily and rinse with ClōSYS® Sensitive Rinse twice daily after brushing.
62828460|NCT06600399||Correlation between PSMA PET and ASL|The relationship between multimodal images
62828461|NCT06377540|EXPERIMENTAL|Pembrolizumab+BEAM followed by ASCT followed by Pembrolizumab maintenance for 1 year.|Patients will receive Pembrolizumab before BEAM ASCT followed by Pembrolizumab maintenance for 1 year. Patients will receive 200 mg Pembrolizumab starting at day - 28 before stem cell transplant until 1 year after autologous stem cell transplant.
62828462|NCT06589765|EXPERIMENTAL|Treatment group A|subjects will receive HRS-7535 tablet orally at dose 1.
62605670|NCT02174003||Open Treatment Group|The Open Treatment Group (all participants in this study) will receive the active / WBH treatment in an open fashion.
62605671|NCT03625310|ACTIVE_COMPARATOR|Sodium Fluoride|Varnish containing 5% Sodium Fluoride, was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
62605672|NCT03625310|EXPERIMENTAL|Sodium Fluoride with TCP|Varnish containing 5% Sodium Fluoride with tricalcium phosphate (TCP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
62828463|NCT06589765|EXPERIMENTAL|Treatment group B|subjects will receive HRS-7535 tablet orally at dose 2.
62046333|NCT01621126|EXPERIMENTAL|Intra-op neuromonitoring|
62046334|NCT02558582|EXPERIMENTAL|Immediate Rehabilitation|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
62046335|NCT02558582|EXPERIMENTAL|Immediate Rehabilitation with oxygen|"The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
62046336|NCT02558582|EXPERIMENTAL|Delayed Rehabilitation|Waiting group that participates in the rehabilitation program after 3 months. The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
62605673|NCT03625310|EXPERIMENTAL|Sodium Fluoride with CXP|Varnish containing 5% Sodium Fluoride with Xylitol-coated Calcium and Phosphate (CXP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
62438326|NCT01857791|EXPERIMENTAL|multidisciplinary, behavior modification|
62605674|NCT03625310|EXPERIMENTAL|Sodium Fluoride with CPP-ACP|Varnish containing 5% Sodium Fluoride with casein phosphopeptide amorphous calcium phosphate (CPP-ACP), varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
62605675|NCT06109376|EXPERIMENTAL|Hypothermia|Patients in Hypothermia group received hypothermia combined with endovascular thrombectomy.
62605676|NCT06109376|ACTIVE_COMPARATOR|Control|Patients in Control group received endovascular thrombectomy alone.
62605677|NCT05489640||HAE Participants|Adult participants with a diagnosis of HAE who are receiving treatment according to routine clinical practice and prescribed all treatments in accordance with the approved marketing authorization will be enrolled in this study. Data will be directly collected from participants via patient reported diaries and paper- based and/or electronic homecare records as appropriate for UK participants using homecare services for icatibant. No study specific intervention will be administered in this study.
62605678|NCT06708949|EXPERIMENTAL|Treatment with Nivolumab + Ipilimumab|Participants will randonmized to study and treatment will be administered on an outpatient basis.
62605679|NCT06708949|EXPERIMENTAL|Treatment with Nivolumab + Relatlimab + Ipilimumab|Participants will randonmized to study and treatment will be administered on an outpatient basis.
62046337|NCT02558582|EXPERIMENTAL|Delayed Rehabilitation with oxygen|"Waiting group that participates in the rehabilitation program after 3 months. The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
62046338|NCT05582564|OTHER|concrete text|Italian and French unvaccinated cohorts (n= 164; n=163)
62438327|NCT02247570|EXPERIMENTAL|Vestibular Rehabilitation|Vestibular Rehabilitation
62605680|NCT02984267|EXPERIMENTAL|Ultrasound Group|The interventional group that will have their spine evaluated by ultrasound prior to epidural placement
62605681|NCT02984267|OTHER|Palpation Group|The control group that will have their epidural placed in the usual fashion based on palpation
62605682|NCT02510313|NO_INTERVENTION|Classic VUP (Control)|Families receive benefits (cash) in exchange for state-sanctioned labour intensive work.
62605683|NCT02510313|NO_INTERVENTION|Expanded VUP|Families receive benefits (cash) in exchange for state-sanctioned flexible labour within close proximity (2 km) to household. Eligible for variation of minimum graduation package benefits, such as asset transfer, financial literacy, skills training, sensitizations.
62605684|NCT02510313|EXPERIMENTAL|Sugira Muryango & Classic VUP|Families receive combination of Sugira Muryango and benefits (cash) in exchange for state-sanctioned labour intensive work.
62605685|NCT02510313|EXPERIMENTAL|Sugira Muryango & Expanded VUP|Families receive combination of Sugira Muryango and benefits (cash) in exchange for state-sanctioned flexible labour within close proximity (2 km) to household. Eligible for variation of minimum graduation package benefits, such as asset transfer, financial literacy, skills training, sensitizations.
62605686|NCT02991716||Recorded patients|Patients requiring Intracradiac Defibrillator (ICD) implantation, Electrophysiology (EP) study or a holter monitor recording, mainly due to suspected ventricular tachy - arrhythmias
62605687|NCT04529304|EXPERIMENTAL|Visual EEG|Individual dosing of anesthetic medications based on EEG AND other standardized clinical observations (BP, HR)
62828464|NCT06589765|EXPERIMENTAL|Treatment group C|subjects will receive HRS-7535 tablet orally at dose 3.
62828465|NCT06589765|ACTIVE_COMPARATOR|Treatment group D|subjects will receive dapagliflozin tablet orally.
62046339|NCT05582564|OTHER|abstract text|Italian and French unvaccinated cohorts (n=155; n=153)
62046340|NCT05582564|OTHER|abstract task|Italian and French unvaccinated cohorts (n=54; n=55)
62046341|NCT05582564|OTHER|concrete task|Italian and French unvaccinated cohorts (n=55; n=56)
62046342|NCT05582564|OTHER|control|Italian and French unvaccinated cohorts (n=103; n=110)
62046343|NCT02525965|EXPERIMENTAL|Wide resection margin >1cm|Surgical removal of lesions choosing the method of wide resection margin \>1cm
62046344|NCT02525965|ACTIVE_COMPARATOR|Narrow resection margin <1cm|Surgical removal of lesions choosing the method of narrow resection margin \<1cm
62046345|NCT04741308|EXPERIMENTAL|CBT group|Patients randomly assigned to CBT group will receive 8 times of CBT treatment during chemotherapy.
62438328|NCT05678920||Pregnant and postpartum patients|Pregnant patients older than 28th gestational week and patients up to postpartum 6th week who were hospitalized in the obstetrics department
62438329|NCT01818570|PLACEBO_COMPARATOR|Placebo solution|A 100 ml placebo solution will be administered through an esophageal probe. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with placebo in one out of three visit days.
62438330|NCT01818570|ACTIVE_COMPARATOR|PPC-5650|"PPC-5650 is a asic-sensing ion channel-1a antagonist that can block the acid-sensing ion channels, leading to a reduction in the pain signal under up-regulated conditions. A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered through an esophageal probe to assess local effects. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with PPC-5650 in one out of three visit days."
62438331|NCT01372787||Arm I|
62438332|NCT02524106|EXPERIMENTAL|Bococizumab|150 mg bococizumab injected subcutaneously every 2 weeks for a duration of 52 weeks
62438333|NCT02524106|PLACEBO_COMPARATOR|Placebo|150 mg placebo injected subcutaneously every 2 weeks for a duration of 52 weeks
62605688|NCT04529304|EXPERIMENTAL|Blinded EEG|Individual dosing of anesthetic medications based on standardized clinical observations (BP, HR).
62605689|NCT01327313|EXPERIMENTAL|EMD525797 250 milligram (mg)|
62828466|NCT05944302|EXPERIMENTAL|Intervention group (EMDR)|"Since the aim of the study was to examine the effect of EMDR on pain, the pain levels of 32 the patients in the intervention group were examined before the first session and after the last session EMDR application. The control measurement was made 1 month after the last session of EMDR. To the initiative group; The first EMDR session was applied after the Personal Information Form and VAS were applied.~The Personal Information Form was applied only once before the first session. Each EMDR session lasts between 45 and 90 minutes. EMDR was applied to the patients between 3-12 sessions. After the last EMDR session, VAS and Individual In-depth Interview Question Form . were applied."
62046346|NCT04741308|NO_INTERVENTION|non-CBT group|"Patients randomly assigned to non-CBT group will receive four sessions of health education in a month after surgery.~Each session will last 1 hour, including lectures and Q\&A . The content of each session is different, including: diagnosis and treatment of colorectal cancer, adverse reactions and management of chemotherapy, nutritional support during chemotherapy and physical exercise during chemotherapy."
62046347|NCT03838926|EXPERIMENTAL|Trichostatin A|
62046348|NCT02414048|OTHER|Pimonidazole|All patients will receive Pimonidazole to demarcate hypoxia regions in the tumour
62046349|NCT06164925||Inpatients of the Tartu University Hospital|"Inclusion Criteria:~Age of 18+ years, able and willing to sign the consent form, inpatients of the Tartu University Hospital, admitted within 72 hours before enrolment.~Exclusion Criteria:~Age of \<18 years, inability or refusal to sign the consent form, pregnant or lactating women, more than 72 hours passed since admission, patients isolating with an infection."
62046350|NCT05777330|OTHER|Autoantibody-positive first-degree relatives of type 1 diabetes patients|
62438334|NCT05871879||All adult patients who underwent urologic procedures|The included procedures included all urologic oncology surgeries, suburethral sling placement, laparoscopic pyeloplasty, transurethral resection of the prostate, transurethral resection of the bladder tumor, ureteroscopy, hydrocelectomy, orchiectomy, spermatocelectomy, epididymectomy, and varicocelectomy.
62438335|NCT06433349||Patients with breast-, prostate- colorectal cancer or lymphoma|"Patients will complete the following questionnaires at baseline, 3, 6, 12, and 18 months:~Family Health Scale (Long-form), the ICE Family Perceived Support Questionnaires, EQ-5D-5L, The general self-efficacy scale (GSE), the Patient Health Questionnaire-9 (PHQ-9), the National Comprehensive Cancer Network Distress thermometer (NCCN DT) and resilience was assessed with the Danish version of the 2-item Connor-Davidson-Resilience Scale (CD-RISC2).~A subset of the patients will also participate in family interviews (n=12-15)."
62449295|NCT03308448|ACTIVE_COMPARATOR|Group 3|Intervention is Intra-Venous injection of Eprex or EPO \[recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe\], 600 units/kg/day for three consecutive days then repetition of the same treatment in month 1 (Total: 3600/kg in 2 set of 3-day treatment, 1 month apart)
62449296|NCT02396381|EXPERIMENTAL|THS 2.2|Ad libitum use of THS 2.2
62605690|NCT01327313|EXPERIMENTAL|EMD525797 500 mg|
62605691|NCT01327313|EXPERIMENTAL|EMD525797 1000 mg|
62605692|NCT01327313|EXPERIMENTAL|EMD525797 1500 mg|
62046351|NCT03948191|ACTIVE_COMPARATOR|Methylprednisolone(ivMP)|Methylprednisolone(ivMP) 500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.
62605693|NCT06022354|EXPERIMENTAL|Part 1 : cohort 1: SIM0278 or placebo|
62046352|NCT03948191|EXPERIMENTAL|99Tc-MDP|99Tc-MDP 15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions.
62605694|NCT06022354|EXPERIMENTAL|Part 1 : cohort 2: SIM0278 or placebo|
62046353|NCT04025151|EXPERIMENTAL|Intervention group|Alcohol brief intervention, leaflets, regular personalized messages on ABI through IM Apps, real-time chat-based support through IM Apps
62046354|NCT04025151|ACTIVE_COMPARATOR|control group|Alcohol brief intervention, leaflets, regular messages on general health through SMS
62046355|NCT03640702||Prolonged second stage of labor|Women with prolonged second stage of labor as specified before.
62046356|NCT05920980|EXPERIMENTAL|Lidocaine group|Patients in the lidocaine groups, lidocaine 1.5mg/kg/h was continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg), diluted to 200ml with saline until 72h after surgery. Blood samples will be collected from some patients in the lidocaine group for the measurement of lidocaine plasma concentration.
62046357|NCT05920980|PLACEBO_COMPARATOR|Placebo group|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.
62046358|NCT04576468|EXPERIMENTAL|open flap debridement|envelope full thickness flap reflection, removal of granulation tissue then suturing with simple loop sutures.
62046359|NCT04576468|EXPERIMENTAL|perforated membrane (PM)|envelope full thickness flap reflection, removal of granulation tissue placing resorbable membrane after perforating it over the vertical defect then suturing with simple loop sutures.
62046360|NCT04576468|EXPERIMENTAL|leucocyte platelet rich fibrin (L-PRF)|envelope full thickness flap reflection, removal of granulation tissue after withdrawal of blood and placing it in intraspin centrifuge , placing the resulting L-PRF in the defect then suturing with simple loop sutures.
62046361|NCT04576468|EXPERIMENTAL|L-PRF + PM|envelope full thickness flap reflection, removal of granulation tissue after withdrawal of blood and placing it in intraspin centrifuge , placing the resulting L-PRF covered by resorbable membrane after perforating it in the defect then suturing with simple loop sutures.
62046362|NCT05724979|NO_INTERVENTION|control|Oocytes of the control group were injected with conventionally selected spermatozoa based on sperm morphology and motility after being processed density gradient centrifugation
62046363|NCT05724979|EXPERIMENTAL|treatment|ZP-bound sperm were selected from the surface of the immature oocytes through the use of a microneedle (Sunlight Medical, Jacksonville, FL, USA) and transferred in a 10 % polyvinylpyrrolidone (PVP) solution (SAGE, USA), immobilized, and then used to inject sibling MII oocytes
62046364|NCT01993225|PLACEBO_COMPARATOR|Placebo|Placebo Gel and Placebo capsules
62046365|NCT01993225|EXPERIMENTAL|Androxal Treatment|Androxal 12.5mg/25 mg and Placebo gel
62046366|NCT01993225|ACTIVE_COMPARATOR|AndroGel Treatment|AndroGel 1.62% and Placebo Capsules
62828467|NCT05944302|NO_INTERVENTION|Control group|Pre-test (VAS) and post-test (VAS), and 1 month later, control measurement (VAS) data collection forms were applied simultaneously with the admitted 32 the patients. No application was made to the patients except for routine follow-up, anamnesis and medical treatment.
62828468|NCT04718077|EXPERIMENTAL|IO dexamethasone injection|
62828469|NCT04718077|ACTIVE_COMPARATOR|SM dexamethasone injection.|
62828470|NCT05286749|ACTIVE_COMPARATOR|Control|Participants take a workshop where they are provided education on standard-of-care for cervical cancer screening such as pap smear and HPV testing through clinician-collection methods using speculum and cervical swabs.
62046367|NCT04896268|EXPERIMENTAL|Radiofrequency|Rafaelo's technique consists of delivering a low temperature 4 MHz radiofrequency wave current into the haemorrhoidal vascular tissue using a large single-use needle with microfibre electrodes at the end. The intracellular water in the tissue and the injection of a locally injectable Xylocaine cushion serve as resistance to the vaporisation waves without releasing water vapour, thus avoiding the damage usually encountered in electrosurgery. The delayed phenomenon is cell volatilisation. Vaporisation of the tissue allows significant haemostasis without burns. Tissue changes will depend directly on the temperature emitted and the duration of exposure to the radiofrequence current. The fibrosis process starts during the session and continues for several days to weeks, allowing the reduction of the haemorrhoidal cushions.
62449297|NCT02396381|ACTIVE_COMPARATOR|CC|Ad libitum use of CC
62828471|NCT05286749|EXPERIMENTAL|Intervention|Participants take a workshop where they are provided all the same education as control as well as additional education on self-collection for HPV-only testing using vaginal swab as an additional method.
62046368|NCT04896268|ACTIVE_COMPARATOR|Arterial ligation then recto-anal repair with Doppler|"Arterial ligation aims to de-arterialise the haemorrhoids by selectively decreasing the arterial flow of the haemorrhoidal plexuses while avoiding obstructing the venous return. It is distinguished from mucopexy or recto anal repair (RAR®) which fixes the prolapsed hemorrhoidal plexus. Instead of excising the haemorrhoids, the principle is to reduce their size and to restore the anatomical relationships of the haemorrhoidal plexuses in the anal canal."
62046369|NCT03697109|EXPERIMENTAL|Relacorilant (open-label phase)|The dose of relacorilant will be increased sequentially from 100 mg orally once daily to a target dose of 400 mg once daily.
62449298|NCT00902083|EXPERIMENTAL|surgery plus p53 gene|using p53 gene therapy before surgery
62449299|NCT00902083|ACTIVE_COMPARATOR|surgery alone|Surgery without pre-p53 gene therapy
62449300|NCT00902083|EXPERIMENTAL|p53 plus chemotherapy|p53 gene therapy with concurrent chemotherapy
62449301|NCT00902083|EXPERIMENTAL|p53 gene therapy alone|Intra-tumor injectio of rAd-p53 gene with no concurrent treatment
62449302|NCT04620109|PLACEBO_COMPARATOR|SDE Placebo|Subjects will receive placebo (drops without drug).
62449303|NCT04620109|ACTIVE_COMPARATOR|SDE 0.03 mg/eye|Actual dose is 0.03 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 0.5 mg/mL for 1 time.
62449304|NCT04620109|ACTIVE_COMPARATOR|SDE 0.06 mg/eye|Actual dose is 0.06 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 1.0 mg/mL for 1 time.
62449305|NCT04620109|ACTIVE_COMPARATOR|SDE 0.12 mg/eye|Actual dose is 0.12 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 2.0 mg/mL for 1 time.
62828472|NCT06604065|EXPERIMENTAL|AMS2434 (amino acids)|"Product AMS2434. A single dose providing 10g of essential amino acids (EAAs).~Study products will be in powder form and packaged in individual serving sizes and will be dissolved in 8 oz water for consumption."
62828473|NCT06604065|PLACEBO_COMPARATOR|Placebo|"Matched non-caloric placebo.~Study products will be in powder form and packaged in individual serving sizes and will be dissolved in 8 oz water for consumption."
62828474|NCT03111823|EXPERIMENTAL|Supportive Care (aerobic exercise)|Patients undergo aerobic exercise sessions consisting of cycling or walking at a low-moderate intensity and progressing to moderate intensity for 30 minutes 2 times a week for up to 8 weeks.
62828475|NCT04345120|EXPERIMENTAL|SY-008-6mg/d|2mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. The researchers will decide whether to move on to the next stage，12mg/d.
62828476|NCT04345120|EXPERIMENTAL|SY-008-12mg/d|4mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. The researchers will decide whether to move on to the next stage，18mg/d.
62438336|NCT06433349||Caregivers to patients with breast-, prostate- colorectal cancer or lymphoma.|"Caregivers will complete the following questionnaires at baseline, 3, 6, 12, and 18 months:~Family Health Scale (Long-form), the ICE Family Perceived Support Questionnaires, EQ-5D-5L, The general self-efficacy scale (GSE), the Patient Health Questionnaire-9 (PHQ-9), the National Comprehensive Cancer Network Distress thermometer (NCCN DT) and resilience was assessed with the Danish version of the 2-item Connor-Davidson-Resilience Scale (CD-RISC2).~A subset of the caregivers will also participate in family interviews (n=12-15)."
62828477|NCT04345120|EXPERIMENTAL|SY-008-18mg/d|6mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8, and then the test will be terminated.
62828478|NCT04345120|PLACEBO_COMPARATOR|SY-008 matching placebo|Oral administration of the same number of tablets in the corresponding test group.
62828479|NCT02994121||People with Multiple Sclerosis or Related Disorders|Individuals must be 7 years or older, diagnosed with multiple sclerosis or related disorders, including a first central nervous system demyelinating episode with a positive MRI scan or abnormal MRI scans characteristic of MS but no clinical symptoms of the disease
62605695|NCT06022354|EXPERIMENTAL|Part 1 : cohort 3: SIM0278 or placebo|
62828480|NCT02994121||People without Multiple Sclerosis or Related Disorders|Control participants must be 7 years or older, have no known personal history of multiple sclerosis or related disorders, no other chronic disease, and can be a family member, unrelated household control, or control from the general population.
62605696|NCT06022354|EXPERIMENTAL|Part 1 : cohort 4: SIM0278 or placebo|
62828481|NCT06553937|EXPERIMENTAL|Macitentan and Tadalafil|Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
62605697|NCT06022354|EXPERIMENTAL|Part 1 : cohort 5: SIM0278 or placebo|
62605698|NCT06022354|EXPERIMENTAL|Part 1 : cohort 6: SIM0278 or placebo|
62605699|NCT06022354|EXPERIMENTAL|Part 1 : cohort 7: SIM0278 or placebo|
62828482|NCT06553937|ACTIVE_COMPARATOR|PrOpsynvi® film-coated tablets|PrOpsynvi® film-coated tablets10 mg/40 mg
62828483|NCT06655519|EXPERIMENTAL|RD140 injection|subjects will receive a single infusion of Fully Human Anti-BCMA/GPRC5D Chimeric Antigen Receptor T Cells with does of 1-6×10\^5 CAR T cells/kg.
62605700|NCT06022354|EXPERIMENTAL|Part 2 : cohort 1: SIM0278 or placebo|
62605701|NCT06022354|EXPERIMENTAL|Part 2 : cohort 2: SIM0278 or placebo|
62605702|NCT06022354|EXPERIMENTAL|Part 2 : cohort 3: SIM0278 or placebo|
62828484|NCT05847192||Alzheimer's disease|"* Age 65-85 years old.~* Diagnosis of probable AD dementia according to NIA-AA criteria.~* Mini-Mental State Examination (MMSE) score ≥ 10 and ≤ 26 at the screening visit.~* Clinical Dementia Rating (CDR) score ≥ 0.5.~* Logical Memory delay score of ≤8 for 16+ years of education, ≤4 for 8-15 years of education, and ≤2 for 0-7 years of education~Participants will undergo neuropsychological examination, blood collection, sensorimotor gating/ERP testing, MRI and \[18F\]-PI2620 PET scan."
62828485|NCT05847192||Alzheimer's disease with psychosis|"- All the criteria for AD are met.~Presence of one (or more) of the following symptoms:~* Visual or auditory hallucinations (e.g., seeing silent individuals standing in the room, seeing children in the yard, or seeing animals in the house).~* Delusions (fixed false beliefs that the patient believes to be true, e.g., that the spouse is unfaithful, that possessions are being stolen, or that one is not who one claims to be).~Participants will undergo neuropsychological examination, blood collection, sensorimotor gating/ERP testing, MRI and \[18F\]-PI2620 PET scan."
62828486|NCT05847192||Cognitively Unimpaired Healthy|"Age 65-85 years old.~* No known genetic risk factors for dementia.~* No cognitive complaint~* Mini-Mental State Examination (MMSE) score ≥ 26 at the screening visit.~* Logical Memory delay score of ≥9 for 16+ years of education, ≥5 for 8-15 years of education, and ≥3 for 0-7 years of education~Participants will undergo neuropsychological examination, blood collection, sensorimotor gating/ERP testing, MRI and \[18F\]-PI2620 PET scan."
62046370|NCT03697109|EXPERIMENTAL|Relacorilant (randomized-withdrawal phase)|Patients who meet any of the response criteria will advance to the randomized-withdrawal phase of the study and receive the same highest dose as in the open-label phase.
62046371|NCT03697109|PLACEBO_COMPARATOR|Placebo (randomized-withdrawal phase)|Placebo matched to study drug
62828487|NCT01105481|EXPERIMENTAL|amisulpride add-on|
62046372|NCT01501708|EXPERIMENTAL|Caspofugin based combination therapy|"Caspofugin based combination therapy:~Patients will recieve caspofungin with voriconazole or amphotericin B"
62438337|NCT04303845|EXPERIMENTAL|Treatment with Erenumab|Subjects diagnosed with hemicrania continua will receive single dose of Erenumab
62046373|NCT05088070|EXPERIMENTAL|SPH 3348 tablets|6 different dosage group of SPH 3348 will be assigned with 16mg, 40mg, 80mg, 160mg, 240mg and 320mg respectively.
62046374|NCT03839264||Graft stenosis and thrombosis|Diagnostic performance for stenosis at angiography of non invasive screening tools (duplex ultrasound, access blood flow (Qa), dynamic and static dialysis machine venous pressures, dynamic dialysis machine arterial pressure, and monitoring) and incipient thrombosis (within 4-month period) of the presence and degree of stenosis at angiography, non invasive screening techniques and acute hypotensive episode/s during the follow-up
62438338|NCT03639428||6 - 23 months|8 infants between 6 and 23 months received a single 0.3mg/kg midazolam dose of ADV6209
62438339|NCT03639428||2-11 years|17 children between 2 and 11 years received a single 0.3mg/kg midazolam dose of ADV6209
62828488|NCT01105481|PLACEBO_COMPARATOR|placebo add-on|
62438340|NCT03639428||12-17 years|12 adolescents between 12 and 17 years received a single 0.3mg/kg midazolam dose of ADV6209
62828489|NCT04560400|SHAM_COMPARATOR|No Concussion Conventional KD|Participants without concussion history perform conventional King-Devick Test.
62828490|NCT04560400|ACTIVE_COMPARATOR|No Concussion Reverse KD|Participants without concussion history perform reverse King-Devick Test.
62828491|NCT04560400|SHAM_COMPARATOR|Single Concussion Conventional KD|Participants with 1 concussion history perform conventional King-Devick Test.
62046375|NCT00906841|EXPERIMENTAL|90Y-DOTA-hLL2|Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)
62046376|NCT06102265||group 1|"In one arm of the study group, the surgeon changed the gown and the glove between each case with hand sterilization with alcohol before and after wearing the next glove.~Each keratome and MVR were used for multiple patients until they became blunt. We used the same IOL cartridge for every three cases and the same OVD in multiple patients. We immersed keratome, MVR, IOL cartridge, and cannulas of OVD in alcohol between cases.~As regard the phaco machine, we used Alcon Infiniti and Alcon Centurion and the same tip for all cases. The tip was immersed in a test chamber filled with alcohol between cases and not changed until we noticed a morphological change or they became blunt. Also, the same cassette was used in multiple surgeries and changed after collecting the plastic bag full of fluid."
62438341|NCT01166971|EXPERIMENTAL|ReSTOR +3|Bilateral Implantation of ReSTOR +3 Intraocular lenses after cataract extraction
62438342|NCT01166971|ACTIVE_COMPARATOR|Tecnis MF|Bilateral Implantation of Tecnis Multifocal Intraocular lenses after cataract extraction
62438343|NCT01567215|EXPERIMENTAL|Granuloma|
62438344|NCT01590433|EXPERIMENTAL|Exenatide|Subjects will be randomly assigned to the exenatide study treatment group or to the placebo study treatment group. Subjects will have a 33 percent chance of being assigned to the placebo study treatment group and a 66 percent chance of being assigned to exenatide study treatment. Subjects will not be able to choose the study group to which they will be assigned. All study participants will receive individualized dietary counseling based on food logs. Subjects who receive exenatide will not be assigned to follow a reduced-calorie diet in addition to study treatment. Subjects will not know whether they are receiving exenatide or placebo, but the unblinded members of study team will know which they are receiving.
62605703|NCT06022354|EXPERIMENTAL|Part 2 : cohort 4: SIM0278 or placebo|
62438345|NCT01590433|PLACEBO_COMPARATOR|Placebo|Subjects will be randomly assigned to the exenatide study treatment group or to the placebo study treatment group. Subjects will have a 33 percent chance of being assigned to the placebo study treatment group and a 66 percent chance of being assigned to exenatide study treatment. Subjects will not be able to choose the study group to which they will be assigned. All study participants will receive individualized dietary counseling based on food logs. Subjects who receive placebo will be assigned to follow a reduced-calorie diet in addition to study treatment. Subjects will not know whether they are receiving exenatide or placebo, but the unblinded members of the study team will know which they are receiving.
62438346|NCT04028583|EXPERIMENTAL|PIM-Check group|
62438347|NCT04028583|ACTIVE_COMPARATOR|STOPP/START group|
62438348|NCT00873210||Patients treated with Sutent|125 consecutive patients in outpatient care with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
62438349|NCT04506528||Patients with COVID-19|Analyses of the cohort data will include (1) all patients, or (2) hospitalized patients meeting specific inclusion criteria.
62248338|NCT04575142|EXPERIMENTAL|CO2 laser device group|Participants who will be undergoing laser treatment for their vocal nodes with a specific laser device. AcuPulse Duo, a CO2 laser is absorbed by water found in soft tissues and is independent of tissue color. It is very precise and causes less damage of the deep tissues, which results in less swelling and faster recovery. The absence of a long healing process means that most patients can resume their normal activities even on the same day The CO2 laser is the preferred laser for use in the operating room.
62605704|NCT01371877|EXPERIMENTAL|Vitamin D3 4000 IU|"Subjects will be randomized 1:1 to high dose vitamin D defined as 4000 IU per day for 3 months.~Subjects will be given Vitamin D3 supplementation at 4000 IU daily."
62828492|NCT04560400|ACTIVE_COMPARATOR|Single Concussion Reverse KD|Participants with 1 concussion history perform reverse King-Devick Test.
62828493|NCT04560400|SHAM_COMPARATOR|Multiple Concussion Conventional KD|Participants with 2 or more concussion history perform conventional King-Devick Test.
62828494|NCT04560400|ACTIVE_COMPARATOR|Multiple Concussion Reverse KD|Participants with 2 or more concussion history perform reverse King-Devick Test.
62828495|NCT02190695|ACTIVE_COMPARATOR|Decitabine|Decitabine 20mg/m2 IV over 1hour daily times 5 days every 28 days
62248339|NCT01033435||chronic Hemodialysis patients, treated in our unit.|
62248340|NCT01033435||chronic Hemodialysis patients , No intervention|chronic Hemodialysis patients, treated in our unit.
62248341|NCT00566917|ACTIVE_COMPARATOR|1|Anterior colporrhaphy (standardised)
62248342|NCT00566917|EXPERIMENTAL|2|Anterior PROLIFT
62248343|NCT00773136|ACTIVE_COMPARATOR|Bimatoprost Suspension|Intervention to be administered: Each subject was given two suspensions, one mixed with Bimatoprost and one mixed with normal saline. They were instructed to use each suspension to a pre-determined eyelash (prepared prior to study enrollment in double blind fashion and marked after randomization with right and left). The intervention was the one eye with the Bimatoprost.
62248344|NCT04341168||Children and Adolescents with COVID-19|age range: newborn - 18 years old, subgroups will be established
62248345|NCT04341168||Adults with COVID-19|age range: from 18 years old, subgroups will be established
62248346|NCT04341168||Control group|all ages, any respiratory tract infection, subgroups will be established
62248347|NCT02752750||AD_GROUP|Patients with Alzheimer's disease
62248348|NCT02752750||HC_GROUP|Healthy controls
62248349|NCT02094963|EXPERIMENTAL|Ticagrelor|
62248350|NCT02094963|ACTIVE_COMPARATOR|Clopidogrel|
62248351|NCT00947362|EXPERIMENTAL|ETC + DAC N-055|
62248352|NCT00947362|ACTIVE_COMPARATOR|ETC + physiological saline|
62828496|NCT02190695|EXPERIMENTAL|Decitabine and Carboplatin|Decitabine 20mg/m2 IV over 1hour daily times 5 days, plus Carboplatin AUC 5 IV over 1hour on day 8. repeat every 28 days.
62248353|NCT00686296|ACTIVE_COMPARATOR|Group II|Taliderm™ dressing applied until the next scheduled dressing change (up to eight hours), then replaced by a gauze dressing. Gauze dressing changes will continue per standard of care until the scheduled follow-up visits (first or second visit). At the scheduled follow-up visits, the subject will have a Taliderm™ dressing applied and left in place until the next scheduled dressing change (up to eight hours), then will continue standard of care wet to dry gauze dressing changes until next scheduled follow-up visit.
62828497|NCT02190695|EXPERIMENTAL|Decitabine and Arsenic|Decitabine 20mg/m2 IV over 1 hour daily for 5 days plus Arsenic Trioxide 0.15mg/kg IV daily for 5 days. repeat every 28 days
62828498|NCT03591406|EXPERIMENTAL|Ferric carboxymaltose (FCM)|Subjects treated with FCM given by IV injection or drip infusion
62828499|NCT03591406|ACTIVE_COMPARATOR|Iron sucrose (IS)|Subjects treated with IS given by IV injection or drip infusion
62248354|NCT00686296|OTHER|III|standard wet to dry dressing with gauze
62248355|NCT00686296|ACTIVE_COMPARATOR|group I|Taliderm™ dressing applied until the next scheduled dressing change (up to eight hours), then replaced by a gauze dressing
62248356|NCT04535180||Hemophilia|
62248357|NCT04966793||Bronchiectasis patients group|Bronchiectasis patients group: Sputum specimens from bronchiectasis patients aged 18 to 79 years old .
62248358|NCT04966793||Healthy control group|Healthy control group: Sputum specimens from healthy people.
62248359|NCT02991508|PLACEBO_COMPARATOR|Placebo|Vehicle (20 mM His/HCl pH 6.0)
62248360|NCT02991508|ACTIVE_COMPARATOR|Adrecizumab 0.5 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
62449306|NCT04620109|ACTIVE_COMPARATOR|SDE 0.24 mg/eye|Actual dose is 0.24 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 4 mg/mL for 1 time.
62449307|NCT04620109|ACTIVE_COMPARATOR|RDE 0.06 mg/eye|The actual dosage is 0.06 mg/eye given 4 times a day for a maximum daily dosage of 0.24mg (60μL KDR2-2 eyedrops concentration of 1.0 mg/mL), which will continues for 6 days plus 1 administration of 0.06 mg/eye in the morning of Day 7. That cohort only started after safety proof from SDE 0.24 mg/eye cohort.
62449308|NCT04620109|ACTIVE_COMPARATOR|RDE 0.12 mg/eye|The actual dosage is 0.12 mg/eye given 4 times a day for a maximum daily dosage of 0.48mg (60μL KDR2-2 eyedrops concentration of 2.0 mg/mL), which will continues for 6 days plus 1 administration of 0.12 mg/eye in the morning of Day 7. That cohort might be optional based on emerging data from this study.
62449309|NCT04620109|ACTIVE_COMPARATOR|RDE 0.24 mg/eye|The actual dosage is 0.24 mg/eye given 4 times a day for a maximum daily dosage of 0.96mg (60μL KDR2-2 eyedrops concentration of 4.0 mg/mL), which will continues for 6 days plus 1 administration of 0.24 mg/eye in the morning of Day 7. That cohort might be optional based on emerging data from this study.
62449310|NCT04620109|PLACEBO_COMPARATOR|RDE Placebo|Subjects will receive placebo (drops without drug).
62449311|NCT01235052|EXPERIMENTAL|TEP with 18F-FMISO|TEP with 18F-FMISO
62449312|NCT04867395|NO_INTERVENTION|Usual Care|75 participants will receive standard care, consisting of verbal discharge counseling given by doctors and nurses supplemented by written instructions (all unstandardized).
62438350|NCT04980521|PLACEBO_COMPARATOR|Print brochures|Participants assigned to the print brochure group will receive three educational print brochures about radon published by EPA via postal mails for three months (one per each month).
62046377|NCT06102265||group 2|In another arm, we used the same steps except that the surgeon changed the glove only and used alcohol for hand sterilization before and after wearing the next glove. One gown was used for all the cases. As regard the intracameral antibiotic prophylaxis, a bottle of Vigamox, 5ml, was withdrawn, and each 1 ml was diluted with 5 ml saline. Using this dilution, 0.1 ml was injected intracamerally at the end of the operation. Finally, we did corneal hydration of the main wound and the side ports.
62605705|NCT01371877|ACTIVE_COMPARATOR|Vitamin D3 600 IU|"Subjects will be randomized 1:1 to low dose vitamin D as defined as 600 IU per day for 3 months.~Subjects will be given Vitamin D3 supplementation at 600 IU daily"
62605706|NCT05391581|PLACEBO_COMPARATOR|SAL-WAT|Saline infusion, saline injection, water ingestion
62605707|NCT05391581|ACTIVE_COMPARATOR|SAL-GLU|Saline infusion, saline injection, glucose ingestion
62605708|NCT05391581|ACTIVE_COMPARATOR|SAL-GIP|Saline infusion, GIP injection, water ingestion
62605709|NCT05391581|ACTIVE_COMPARATOR|SAL-GLP-2|Saline infusion, GLP-2 injection, water ingestion
62605710|NCT05391581|EXPERIMENTAL|GIA-WAT|GIPR antagonist infusion, saline injection, water ingestion
62605711|NCT05391581|EXPERIMENTAL|GIA-GLU|GIPR antagonist infusion, saline injection, glucose ingestion
62605712|NCT05391581|EXPERIMENTAL|GLA-WAT|GLP-2R antagonist infusion, saline injection, water ingestion
62248361|NCT02991508|ACTIVE_COMPARATOR|Adrecizumab 2.0 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
62248362|NCT02991508|ACTIVE_COMPARATOR|Adrecizumab 8.0 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
62248363|NCT04221854|EXPERIMENTAL|Stool-based SDC2 DNA methylation test group|Subjects will received the stool-based SDC2 DNA methylation test for the screening of colorectal advanced adenomatous polyps and cancer.
62438351|NCT04980521|EXPERIMENTAL|The radon app|Participants assigned to the radon app group will be asked to use the radon app for three months where they will be exposed to mobile friendly educational content that is created from educational print brochures about radon published by EPA.
62438352|NCT04363411|EXPERIMENTAL|drug use|
62438353|NCT05773690|EXPERIMENTAL|Movement Quality group|movement quality training based on mobility, stability and motor control exercises
62605713|NCT05391581|EXPERIMENTAL|GLA-GLU|GLP-2R antagonist infusion, saline injection, glucose ingestion
62046378|NCT02468401|EXPERIMENTAL|Coronary angiography|Patients undergoing coronary angio with or without percutaneous coronary intervention using a new protocol designed to minimize the exposure to contrast medium
62248364|NCT04221854|ACTIVE_COMPARATOR|Fecal immunochemical test group|Subjects will received the fecal immunochemical test for the screening of colorectal advanced adenomatous polyps and cancer.
62248365|NCT00611338|ACTIVE_COMPARATOR|Standard of Care, Wait-List Control|Participants received standard medical care, which in most clinics included informational brochures provided by physicians and clinic staff. Participants were given HIV prevention information and materials in English and Spanish and were provided referrals for services. Each individual completed assessments at immediate post intervention, 3-, 6-, and 12- months. At the end of the 12-month assessment, the wait-list control participants participated in the Trauma + HIV group arm.
62438354|NCT05773690|EXPERIMENTAL|Conventional resistance training group|traditional strength training exercises
62438355|NCT01598649|EXPERIMENTAL|Lupin protein|Lupin protein isolate (cultivar: Lupinus angustifolius Boregine; incorporated in study products) and placebo capsules with mannitol
62438356|NCT01598649|ACTIVE_COMPARATOR|Milk protein|Milk Protein Isolate (75% sodium caseinate (EM7; DMV international) and 25% whey protein (Megglosat HP; Meggle), incorporated in study products) and Placebo capsules
62438357|NCT01598649|ACTIVE_COMPARATOR|Milk protein and arginine|Milk Protein Isoalte (75% sodium caseinate (EM7; DMV international) and 25% whey protein (Megglosat HP; Meggle), incorporated in study products) and 1,6 g Arginin in four caspules per day
62605714|NCT03725501|EXPERIMENTAL|Ranibizumab + ALS-L1023 600mg|"* ALS-L1023 600 mg - Take 2 tablets orally twice a day.~* Ranibizumab (Lucentis®)~  * Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.~ * PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
62605715|NCT03725501|EXPERIMENTAL|Ranibizumab + ALS-L1023 1200mg|"* ALS-L1023 1200 mg - Take 2 tablets orally twice a day.~* Ranibizumab (Lucentis®)~  * Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.~ * PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
62605716|NCT03725501|PLACEBO_COMPARATOR|Ranibizumab + Placebo|"* Placebo - Take 2 tablets orally twice a day.~* Ranibizumab (Lucentis®)~  * Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.~ * PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
62438358|NCT01735058|ACTIVE_COMPARATOR|Sodium hyaluronate|Ultrasound guided injection of sodium hyaluronate
62438359|NCT01735058|PLACEBO_COMPARATOR|Normal saline|Ultrasound guided injection of normal saline
62438360|NCT05221606|EXPERIMENTAL|Nurse AMIE Supportive Care Intervention|Participants in the intervention arm will receive the computer tablet with the Nurse AMIE program. Nurse AMIE will assess their symptoms daily and provide an intervention to help manage their symptoms.
62438361|NCT05221606|ACTIVE_COMPARATOR|Usual Care|Participants in the usual care arm will receive a book with some supportive care educational materials and recommendations.
62248366|NCT00611338|ACTIVE_COMPARATOR|HIV Prevention|Eight, 90 minute group sessions. Three of the sessions focused on health education (e.g., medication adherence, nutrition, exercise) and five focused on HIV prevention skills (e.g., condom skills, communication, social support). Each individual completed assessments at immediate post intervention, 3-, 6-, and 12- months. At the end of the 12-month assessment, the participants in this arm were given the option to receive the 3 trauma-focused sessions from the Trauma + HIV group arm.
62828500|NCT05270434|EXPERIMENTAL|Endoscopic group <12h|The patients received intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). After the last ESWL session, the patients are treated with following ERCP within 12h. ERCP was performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy was performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent for drainage and nasopancreatic catheters will be inserted for temporary drainage if necessary.
62828501|NCT05270434|ACTIVE_COMPARATOR|Endoscopic group ≥12 h|The patients received intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). The time scale between the last ESWL session and following ERCP is greater than 12h. ERCP was performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy was performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent for drainage and nasopancreatic catheters will be inserted for temporary drainage if necessary.
62828502|NCT01817153|PLACEBO_COMPARATOR|placebo|10 mL normal saline iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H8, H14 and H20
62828503|NCT01817153|ACTIVE_COMPARATOR|hydrocortison|50 mg hydrocortison iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H12, H18 and H24
62248367|NCT00611338|ACTIVE_COMPARATOR|HIV Prevention plus Trauma|The same format as the HIV Prevention arm with eight, 90 minute group sessions. The participants received the same five HIV prevention skills sessions along with three sessions that focused on reducing trauma-related stress (e.g., breathing training, relaxation exercises, grounding exercises, coping, trauma-related triggers). Each individual completed assessments at immediate post intervention, 3-, 6-, and 12- months.
62248368|NCT02193048||Patients newly diagnosed with Crohn's disease|This study will evaluate a new clinical scoring system in patients receiving routine treatment
62248369|NCT02510781|EXPERIMENTAL|A group|docetaxel+carboplatin+trastuzumab
62248370|NCT02510781|ACTIVE_COMPARATOR|B group|Epirubicin+docetaxel+trastuzumab-docetaxel+trastuzumab
62438362|NCT01624831||Individuals with Longstanding Psychosis|Individuals with symptoms of psychosis that have been present for 5 or more years
62438363|NCT03266549|EXPERIMENTAL|Botulinum toxin augmented surgery group|unilateral recess-resect procedure, or bilateral rectus muscle recession plus intraoperative injection of 2.5 to 5 units of botulinum toxin A into the recessed muscle.
62438364|NCT03266549|ACTIVE_COMPARATOR|conventional surgery group|unilateral recess-resect procedure, bilateral rectus muscle recession, or 3 horizontal rectus muscle surgery according to the type of strabismus and the presence or absence of deep amblyopia.The standard correction tables will be used as a guide for the amount of muscle recession and, or resection
62623459|NCT01440985|ACTIVE_COMPARATOR|Nicotine Microtab|After being randomized to the gum or tablet, subjects will receive instructions according to their baseline level of nicotine dependence. Highly dependent smokers will be instructed to use a 4 mg dosage of the Microtab (2 x 2 mg tablets), while low nicotine-dependent smokers will be instructed to use a 2 mg dosage of the Microtab to help them quit. Subjects will be advised to use the treatment frequently, according to the product labeling, in order to minimize or avoid symptoms of tobacco withdrawal. Study medication will be used for 12 weeks.
62623460|NCT02117609|EXPERIMENTAL|New DELICAL formula|New high-protein oral nutrient supplement
62248371|NCT00392353|EXPERIMENTAL|Treatment (azacitidine, vorinostat)|Patients receive azacitidine SC QD on days 1-7 and vorinostat PO 2-3 times daily on days 3-5, 3-9, or 3-16. Treatment repeats every 28 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
62248372|NCT05726539|ACTIVE_COMPARATOR|Intervention|participants receive group-based peer support
62248373|NCT05726539|NO_INTERVENTION|Waitlist|participants wait to receive peer support until pre and post assessments are complete with their matched intervention group
62438365|NCT04382157|EXPERIMENTAL|Mablet|Mablet 360 mg. Twice daily for 4 weeks. If tolerated trice daily for following 20 weeks. Treatment for 24 weeks in total.
62438366|NCT04382157|PLACEBO_COMPARATOR|Placebo|Placebo. Twice daily for 4 weeks. If tolerated trice daily for following 20 weeks. Treatment for 24 weeks in total.
62438367|NCT04665479|EXPERIMENTAL|Intervention group|A total of 30 children with any progressively declining (acute or chronic) life-threatening diagnosis per parent report (aged 8 to 17) and their primary parent caregivers will be recruited as a dyad. Dyads will participate in a nurse-delivered intervention that will guide children to create electronic digital storyboards about themselves during 6 sessions over 6 weeks.
62438368|NCT00910858|EXPERIMENTAL|10 mg Lenalidomide|"Participants in the Pharmacokinetic Phase received a single 10 mg oral dose of lenalidomide on Day -7. During the Monotherapy Phase participants received 10 mg oral lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or erythroid failure.~During the Combined Treatment Phase participants who were erythroid nonresponders and erythroid responders who had developed an erythroid relapse continued treatment with 10 mg lenalidomide in conjunction with recombinant human erythropoietin (rhu EPO) 40,000 units administered weekly by subcutaneous injection for 8 weeks. Responding patients could continue combined treatment."
62438369|NCT00910858|EXPERIMENTAL|15 mg Lenalidomide Non-del 5q|Following the enrollment of the first 25 patients into the Monotherapy Phase, a second group of 15 patients with low- or intermediate-1-risk MDS not associated with a del 5q (non-del 5q) cytogenetic abnormality were enrolled to receive 15 mg of lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or erythroid failure. During the Combined Treatment Phase participants who were erythroid nonresponders and erythroid responders who had developed an erythroid relapse continued treatment with 15 mg lenalidomide in conjunction with recombinant human erythropoietin (rhu EPO) 40,000 units administered weekly by subcutaneous injection for 8 weeks. Responding patients could continue combined treatment.
62438370|NCT00939705|EXPERIMENTAL|Torrent Topiramate|
62438371|NCT00939705|ACTIVE_COMPARATOR|Topamax|
62605717|NCT01801241|ACTIVE_COMPARATOR|Anatomic TSA using SOC Instrumentation|During Anatomic Total Shoulder Arthroplasty, the surgeon will use the pre operative CT scan at least two weeks prior to surgery to define the glenoid pathology, select the implant of choice and plan the placement of that implant in the desired position. This information will be available to the surgeon at the time of surgery but the SmartBone models and the IRI will not be available. The surgeon will have pre operative x-rays and the pre operative CT scan provided by the radiology department for intra - use. The surgeon will perform the surgery using any of the instruments provided for guide pin placement operative the. These include a wide variety of free hand and adjustable guides that assist the surgeon for placement of the guide pin for location and trajectory.
62605718|NCT01801241|EXPERIMENTAL|Anatomic TSA Using IRI Instrumentation|During Anatomic Total Shoulder Arthroplasty, the surgeon will have use of the SmartBone model of the patient's anatomy and glenoid guide-pin location, and the Intelligent Reuseable Instrument for placement of the glenoid implant.
62605719|NCT03679169|EXPERIMENTAL|Group RAMPS|Radical antegrade modular pancreatosplenectomy
62605720|NCT03679169|ACTIVE_COMPARATOR|Group SPS|standard pancreatosplenectomy
62605721|NCT00112021|EXPERIMENTAL|Pramlintide Acetate|
62605722|NCT00112021|PLACEBO_COMPARATOR|Placebo|
62605723|NCT04655040|EXPERIMENTAL|Caffeine and Ritlecitinib|"In Period 1 Day 1, participants will be dosed with a single oral administration of caffeine 100 milligram (mg) tablet.~In Period 2 Day 1 to Day 7, participants will be dosed with a single oral administration of ritlecitinib 200 milligram (mg) tablet. On Day 8, participants will be dosed with caffeine 100 milligram (mg) tablet within 5 minutes after administration of a 200 milligram (mg) dose of ritlecitinib on the morning of Day 8. Dosing with oral 200 milligram (mg) ritlecitinib QD will continue until Day 9."
62605724|NCT03673501|EXPERIMENTAL|Ripretinib|Ripretinib (150 mg) once a day continuous dosing for 6-week (42 days) cycles
62605725|NCT03673501|ACTIVE_COMPARATOR|Sunitinib|Sunitinib (50 mg) once a day in 6-week (42 days) cycles with 4 weeks continuous dosing followed by 2 week break.
62605726|NCT00759057|EXPERIMENTAL|1 - Investigational|Dynesys Non-Fusion Spinal System
62605727|NCT00759057|ACTIVE_COMPARATOR|2 - Control|Silhouette Posterior Pedicle Screw System as an adjunct to Posterior Lateral Fusion with Autograft.
62605728|NCT03408444|EXPERIMENTAL|EMO-114|Test Lens 1
62605729|NCT03408444|EXPERIMENTAL|EMO-116|Test Lens 2
62605730|NCT03408444|EXPERIMENTAL|EMO-118|Test Lens 3
62605731|NCT03408444|ACTIVE_COMPARATOR|EMO-117|Test Lens 4
62605732|NCT04536870|EXPERIMENTAL|STAREE Statin group|Participants in STAREE trial randomised to statin
62605733|NCT04536870|EXPERIMENTAL|STAREE Placebo group|Participants in STAREE trial randomised to placebo
62605734|NCT02826265||pulmonary disease|patients with known or suspected pulmonary disease
62605735|NCT02887222|ACTIVE_COMPARATOR|PIEB volume of 7 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 7mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
62605736|NCT02887222|ACTIVE_COMPARATOR|PIEB volume of 8 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 8mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
62605737|NCT02887222|ACTIVE_COMPARATOR|PIEB volume of 9 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 9mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
62605738|NCT02887222|ACTIVE_COMPARATOR|PIEB volume of 10 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
62605739|NCT02887222|ACTIVE_COMPARATOR|PIEB volume of 11 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 11mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
62605740|NCT02887222|ACTIVE_COMPARATOR|PIEB volume of 12 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 12mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
62605741|NCT01507402|EXPERIMENTAL|Cohort 1|Dose regimen 1 (Participants 18 to ≤ 65 yrs old)
62605742|NCT01507402|EXPERIMENTAL|Cohort 2|Dose regimen 2 (Participants 18 to ≤ 65 yrs old)
62248374|NCT06318351||Transcutaneous Electrical Acupoint Stimulation|The effect of Transcutaneous Electrical Acupoint Stimulation on postoperative vision was observed according to anesthesiologist's habit of using or not using it.
62828504|NCT00089297|EXPERIMENTAL|Cetuximab/Paclitaxel/Carboplatin|"Induction: Cetuximab (C225) 400 mg/m2 at wk 1 then 250 mg/m2 for 5 weeks. Paclitaxel (P) 90 mg/m2 IV and carboplatin (C) AUC = 2 IV were given weekly.~Restaging biopsy of primary site scheduled at wk 7. Concurrent chemoradiation: Radiation therapy at 200cGy/d/5 wks for a total of 50Gy and C225 at 250 mg/m2/wk. P following C225 at 30 mg/m2/wk and C following P at AUC = 1/week. Patients with a negative biopsy continued concurrent therapy to complete radiation (68-72Gy).~Restaging biopsy of primary site: Patients with positive biopsy at wk 7 or patients without a clinical complete response at the primary site after induction therapy had re-biopsy at wk 14. If the biopsy was negative, the patients continued concurrent therapy to complete radiation (68-72 Gy). If positive, resection of the primary site was done.~Additional concurrent chemoradiation: C225 at 250mg/m2/wk IV followed by P 30mg/m2/wk IV followed by C AUC = 1/wk and RT for 3 wks."
62438372|NCT03920436|EXPERIMENTAL|Infrared water group|This group takes drinking water using a tumbler that emits far infrared rays at room temperature for 8 weeks.
62828505|NCT01980563|ACTIVE_COMPARATOR|ultrasound|
62828506|NCT01980563|ACTIVE_COMPARATOR|combined monitoring|
62438373|NCT03920436|SHAM_COMPARATOR|sham group|This group takes drinking water using a tumbler at room temperature for 8 weeks.
62828507|NCT03846336|EXPERIMENTAL|Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS and physician-administered EDSS range of 1-3.5.
62828508|NCT03846336|OTHER|Healthy individuals|20 healthy volunteers with matching ages and genders.
62248375|NCT04358510||COViage|Machine learning intervention
62248376|NCT02514408||Ancillary-Correlative (collection of blood samples)|Patients undergo placement of a central line via the right femoral vein and undergo ORC. Blood samples are collected and analyzed for CTCs pre-surgery, at 30 minutes and 1 hour once ORC begins, post-surgery, and 7 days after surgery.
62248377|NCT04677699||Birth Cohort|Newborns less than 8 months old and born in the state of Washington.
62438374|NCT04403100|ACTIVE_COMPARATOR|Hydroxychloroquine Sulfate|Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days
62828509|NCT01409707|EXPERIMENTAL|Healthy lifestyles sessions|Healthy lifestyles sessions is a structured 9-12 session intervention that provides education about a variety of health-related topics. Each therapy session was 50-60 minutes long. Sessions included the provision of information, discussing participants' understanding of information, and answering questions about the information provided.
62828510|NCT01409707|EXPERIMENTAL|Trauma-focused exposure therapy|Trauma focused exposure therapy is a well-described cognitive-behavioral therapy that utilizes imaginal and in vivo exposure techniques to reduce the symptoms of posttraumatic stress disorder. In addition to imaginal and iv vivo exposure techniques, in the current study patients were provided psychoeducation about posttraumatic stress disorder, a rationale for trauma focused exposure therapy, and were taught breathing retraining as a method to manage arousal associated with posttraumatic stress disorder. Nine to 12 50-60 minutes sessions were provided.
62248378|NCT04677699||Kids Cohort|Children ages 4-7 years and born in the state of Washington.
62605743|NCT01507402|EXPERIMENTAL|Cohort 3|Dose regimen 3 (Participants 18 to ≤ 65 yrs old)
62248379|NCT00181584|ACTIVE_COMPARATOR|Group 1|
62248380|NCT00181584|PLACEBO_COMPARATOR|Group 2|
62248381|NCT01509079|EXPERIMENTAL|Vitamin D3 4000 IU|
62248382|NCT01509079|ACTIVE_COMPARATOR|Vitamin D3 600 IU|
62438375|NCT04403100|ACTIVE_COMPARATOR|Lopinavir/ Ritonavir|Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days
62248383|NCT05597709||Patients who diagnosed as T2DM|Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes
62248384|NCT05054595|ACTIVE_COMPARATOR|Standard Pain Psychoeducation|
62605744|NCT01507402|EXPERIMENTAL|Cohort 4|Dose regimen 4 (Participants 18 to ≤ 65 yrs old)
62605745|NCT01507402|EXPERIMENTAL|Cohort 5|Dose regimen 5 (Participants 18 to ≤ 65 yrs old)
62605746|NCT01507402|EXPERIMENTAL|Cohort 6|Dose regimen 6 (Participants 18 to ≤ 65 yrs old)
62605747|NCT01507402|EXPERIMENTAL|Cohort 7|Dose regimen 7 (Participants 18 to ≤ 65 yrs old)
62605748|NCT01507402|EXPERIMENTAL|Cohort 8|Dose regimen 3 (Participants \> 65 to ≤ 85 yrs old)
62248385|NCT05054595|ACTIVE_COMPARATOR|Audio-Recorded Mindfulness-Based Intervention|
62449313|NCT04867395|EXPERIMENTAL|Intervention group|75 participants will be randomized to receive behavioral intervention, consisting of discharge counseling using the health literacy-informed discharge instructions
62605749|NCT01507402|EXPERIMENTAL|Cohort 9|Dose regimen 9 (Participants 18 to ≤ 65 yrs old)
62623461|NCT02117609|ACTIVE_COMPARATOR|Standard DELICAL formula|Standard isoenergetic isoprotein formula
62623462|NCT01340742|ACTIVE_COMPARATOR|1|Arm remote preconditioning
62623463|NCT01340742|PLACEBO_COMPARATOR|2|Control group.
62046379|NCT04475549|EXPERIMENTAL|IW-6463|Open-label IW-6463 15 mg once daily (QD), with possibility to dose reduce to 10 mg.
62046380|NCT00988403|EXPERIMENTAL|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
62046381|NCT00988403|EXPERIMENTAL|Fructan - 10 grams|Subjects will consume 10 grams of fructan
62046382|NCT00988403|EXPERIMENTAL|Fructan - 12.5 grams|Subjects will consume 12.5 grams of fructan
62046383|NCT00988403|EXPERIMENTAL|5 grams Fructan|"Experimental - 5 grams Fructan~Subjects will consume 5 grams of Fructan."
62046384|NCT02036203|EXPERIMENTAL|SCu300A IUB|
62046385|NCT02036203|ACTIVE_COMPARATOR|TCu380A|
62046386|NCT05639790|SHAM_COMPARATOR|Counselling|Health counselling from a licensed mental health counselor
62046387|NCT05639790|EXPERIMENTAL|Eletronic cigarette|Ad libitum use of electronic cigarettes for 1 month and health counselling from a licensed mental health counselor
62046388|NCT02462707|EXPERIMENTAL|PF-03084014|
62438376|NCT04403100|ACTIVE_COMPARATOR|Hydroxychloroquine plus Lopinavir/ Ritonavir|"Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days~Plus~Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days"
62828511|NCT01409707|EXPERIMENTAL|Motivational enhancement + trauma-focused exposure therapy|A one session, 90 min. trauma-focused motivational enhancement therapy session was provided prior to starting the trauma-focused exposure therapy. Trauma focused exposure therapy is a well-described cognitive-behavioral therapy that utilizes imaginal and in vivo exposure techniques to reduce the symptoms of posttraumatic stress disorder. In addition to imaginal and iv vivo exposure techniques, in the current study patients were provided psychoeducation about posttraumatic stress disorder, a rationale for trauma focused exposure therapy, and were taught breathing retraining as a method to manage arousal associated with posttraumatic stress disorder. Nine to 12 50-60 minutes sessions were provided.
62828512|NCT00535496|EXPERIMENTAL|1|sugammadex 1.0 mg/kg, TOF-Watch® SX (dominant forearm) and PNS (non-dominant forearm)
62046389|NCT05860127|ACTIVE_COMPARATOR|Referral for Cognitive Stimulation Therapy|This group will receive a referral from their physician for CST treatment
62046390|NCT05860127|PLACEBO_COMPARATOR|Standard of Care|This group will receive standard of care and no CST referral.
62046391|NCT01858467|EXPERIMENTAL|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway (Airway Device) with gastric tube. Preoxygenation, rapid sequence induction and cricoid pressure. Propofol 2 to 3mg/kg with 100mg succinylcholine. General anaesthesia with sevoflurane.
62046392|NCT01858467|ACTIVE_COMPARATOR|Endotracheal Intubation|Endotracheal intubation (Airway Device) using Macintosh Laryngoscope with tracheal tube with gastric tube insertion after placement. Preoxygenation, rapid sequence induction and cricoid pressure. Propofol 2 to 3mg/kg with 100mg succinylcholine. General anaesthesia with sevoflurane.
62046393|NCT03661138|EXPERIMENTAL|Arm A|Upadacitinib Dose A is administered once daily along with Topical Corticosteroids (TCS).
62046394|NCT03661138|EXPERIMENTAL|Arm B|Upadacitinib Dose B is administered once daily along with Topical Corticosteroids (TCS).
62046395|NCT03661138|EXPERIMENTAL|Arm C|Placebo administered once daily and TCS followed by Upadacitinib Dose A once daily along with TCS.
62046396|NCT03661138|EXPERIMENTAL|Arm D|Placebo administered once daily and TCS followed by Upadacitinib Dose B once daily along with TCS.
62046397|NCT03977090|EXPERIMENTAL|GB226+Fruquintinib|Geptanolimab combined with Fruquintinib
62046398|NCT05525273|EXPERIMENTAL|Dabrafenib and trametinib|Dabrafenib 75 mg twice daily and trametinib 2 mg once daily
62248386|NCT05054595|EXPERIMENTAL|Nurse-Led Mindfulness-Based Intervention|
62438377|NCT04403100|PLACEBO_COMPARATOR|Placebo|"Placebo~Twice a day from day 1 through day 10."
62828513|NCT00535496|EXPERIMENTAL|2|sugammadex 1.0 mg/kg, TOF-Watch® SX (non-dominant forearm) and PNS (dominant forearm)
62828514|NCT00535496|EXPERIMENTAL|3|sugammadex 4.0 mg/kg, TOF-Watch® SX (dominant forearm) and PNS (non-dominant forearm)
62828515|NCT00535496|EXPERIMENTAL|4|sugammadex 4.0 mg/kg, TOF-Watch® SX (non-dominant forearm) and PNS (dominant forearm)
62046399|NCT03731689|NO_INTERVENTION|Control group|Control group( Intrauterine patients) do not apply intrauterine lavage therapy or intrauterine gel-injection therapy after surgery.
62046400|NCT03731689|EXPERIMENTAL|Intrauterine lavage therapy group|Intrauterine lavage therapy group apply intrauterine lavage therapy after surgery.
62248387|NCT02560064||laparotomy and small bowel length|measurement of small bowel length in laparotomies
62248388|NCT01345396|EXPERIMENTAL|Education|
62438378|NCT02266706|EXPERIMENTAL|Cohort 1: ≥12 to <18 years TOL/TAZ 1000/500 mg FDC|Participants ≥12 to \<18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.
62438379|NCT02266706|EXPERIMENTAL|Cohort 2: ≥7 to <12 years TOL/TAZ 18/9 mg/kg|Participants ≥7 to \<12 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1.
62438380|NCT02266706|EXPERIMENTAL|Cohort 3: ≥2 to <7 years TOL/TAZ 18/9 or 30/15 mg/kg|Participants ≥2 to \<7 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
62248389|NCT01345396|NO_INTERVENTION|No education|
62046401|NCT03731689|EXPERIMENTAL|Intrauterine gel-injection therapy group|Intrauterine gel-injection therapy group apply intrauterine gel-injection therapy after surgery.
62046402|NCT03731689|NO_INTERVENTION|Healthy control group|Healthy control group 1)have regular menstrual cycles,diagnostic hysteroscopy with endometrial biopsy and laparoscopy as part of their infertility diagnostic work-up prior to IVF, hysteroscopy and subsequent pathological results having shown no abnormality in the uterine cavities and abdominal cavity.2) had male partners who were infertile and diagnosed with defective sperm function,such as asthenozoospermia, oligoasthenozoospermia, severe oligoasthenozoospermia and azoospermia, defined according to guidelines published by the World Health Organization.
62046403|NCT01637779|EXPERIMENTAL|fact sheet review|mothers will review a fact sheet containing information about pain management during immunization then complete a knowledge test afterward
62623464|NCT02250456||Turner syndrome patients and vascular abnormalities|
62828516|NCT06384196|EXPERIMENTAL|Identity-Based Transdiagnostic Therapy (IBTT)|IBTT is based on Personal Construct Therapy enhanced with Virtual Reality. In this version, psychotherapy focuses on identity conflicts and processes using an immersive exploration of self and others. After some observational evidence, this is the first study to test the efficacy of this innovative approach rigorously.
62248390|NCT00072358|EXPERIMENTAL|patients have refractory bone marrow disease|This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.
62248391|NCT00072358|EXPERIMENTAL|patients have no evidence of disease|This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.
62828517|NCT06384196|ACTIVE_COMPARATOR|Unified Protocol (UP)|The UP is a transdiagnostic psychotherapy for anxiety and/or depression based on Cognitive-Behavioral Therapy (CBT). Several previous studies provide substantive evidence for the efficacy of the UP for these disorders.
62828518|NCT04032301|EXPERIMENTAL|Intravenous ketamine infusions|Six infusions of 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.
62828519|NCT04032301|PLACEBO_COMPARATOR|Intravenous saline infusions|Six infusions of normal saline solution over 3 weeks.
62828520|NCT04306276||Patients undergoing direct IVF|Patients directly undergo IVF without receiving previous hormonal treatment
62046404|NCT01637779|PLACEBO_COMPARATOR|control unrelated material|mothers will review material unrelated to pain management during immunization then complete a knowledge test
62046405|NCT01637779|EXPERIMENTAL|pre-test, review of fact sheet|mothers do a pre-test, then read a fact sheet about how to manage immunization pain, then repeat the test
62248392|NCT04635566|ACTIVE_COMPARATOR|Mebeverine|Mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
62248393|NCT04635566|PLACEBO_COMPARATOR|Placebo|Placebo one time/day at the evening.
62248394|NCT04156217|EXPERIMENTAL|EBV-TCR-T cells|Patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
62248395|NCT05990751|EXPERIMENTAL|GD2 CAR T cells|Treatment with GD2 CAR T cells
62248396|NCT01726244|NO_INTERVENTION|Control group|Habitual Clinical Practice
62449314|NCT05289765|EXPERIMENTAL|Group 1|Ecological Extra Virgin Olive Oil
62449315|NCT05289765|ACTIVE_COMPARATOR|Group 2|Conventional
62449316|NCT02860481|OTHER|first cohort : first 100 patients|first cohort : first 100 patients 10 patients with ovarian and/or endometrial cancer 10 patients with colorectal cancer 10 patients with head and neck cancer 10 patients with uveal melanoma 40 patients with invasive breast cancer 10 patients with breast ductal carcinoma in situ 10 patients with other tumor type
62449317|NCT02860481|OTHER|second cohort : 100 patients|Patients with breast cancer of with ovarian and/or endometrial cancer
62623465|NCT02051088|EXPERIMENTAL|Revascularization with drug eluting technology|Revascularization with drug eluting technology
62828521|NCT04306276||Patients pretreated with DNG|Patients having received a three-month treatment with DNG before undergoing IVF
62449318|NCT00358384|EXPERIMENTAL|Subjects receiving treatment A|Eligible subjects will receive 0.1 percent pazopanib ointment.
62828522|NCT04271878|OTHER|All participants|All participants will receive the same interventions
62828523|NCT04073173|EXPERIMENTAL|LISA-analgesic|Less Invasive Surfactant Administration (LISA) with remifentanil (0.5-2 micrograms/kg/dose) as the analgesic drug.
62828524|NCT04073173|EXPERIMENTAL|LISA-no analgesic|Less Invasive Surfactant Administration (LISA) without an analgesic drug.
62828525|NCT04073173|EXPERIMENTAL|INSURE-analgesic|INtubation-SURfactant-Extubation (INSURE) with remifentanil (0.5-2 micrograms/kg/dose) as the analgesic drug.
62828526|NCT04073173|EXPERIMENTAL|INSURE-no analgesic|INSURE without an analgesic drug.
62828527|NCT02582775|EXPERIMENTAL|RDEB: HCT plus MSC Arm B|Recessive dominant epidermolysis bullosa (RDEB) patients treated per study regimen on a post-transplant cyclophosphamide allogeneic hematopoietic cell transplant (HCT) platform conditioned with reduced intensity chemotherapy and low dose total body irradiation (300 cGy), followed post-HCT by serial infusions of donor-derived mesenchymal stromal cells (MSC).
62828528|NCT02582775|EXPERIMENTAL|JEB: HCT plus MSC Arm B|Junctional epidermolysis bullosa (JEB) patient treated per study regimen on a post-transplant cyclophosphamide allogeneic hematopoietic cell transplant (HCT) platform conditioned with reduced intensity chemotherapy and low dose total body irradiation (300 cGy), followed post-HCT by serial infusions of donor-derived mesenchymal stromal cells (MSC).
62046406|NCT01637779|PLACEBO_COMPARATOR|pre-test, control unrelated information|mothers do a pre-test, then read unrelated material, then repeat the test
62046407|NCT01082094|EXPERIMENTAL|ACRX-100|"Cohort 1 = Low dose~Cohort 2 = Middle dose~Cohort 3 = High Dose"
62046408|NCT02502201|ACTIVE_COMPARATOR|six-minute walk study indoors first|Participants randomized to indoor six-minute walk test first
62046409|NCT02502201|EXPERIMENTAL|six-minute walk study outdoors first|Participants randomized to outdoor six-minute walk test first
62046410|NCT02502201|ACTIVE_COMPARATOR|six-minute walk study indoors second|Participants randomized to indoor six-minute walk test second
62046411|NCT02502201|EXPERIMENTAL|six-minute walk study outdoors second|Participants randomized to outdoor six-minute walk test second
62046412|NCT00644397||Blade Plate Group|95-degree Angled Blade Plate
62046413|NCT00644397||Locking Plate Group|4.5mm Condylar Locking Plate
62046414|NCT02084459|NO_INTERVENTION|Control|Standard of care
62046415|NCT02084459|EXPERIMENTAL|Autonomy-supportive counselling (GSD)|GSD, an educational method, comprising 32 semi-structured reflection sheets inviting the patients in groups of 4 through 8 sessions of 150 minutes' duration to reflect on the patient's own situation and to be active in co-operation with the nurses.
62046416|NCT03235505|EXPERIMENTAL|Nicotine containing e-cigarettes|Nicotine containing e-cigarettes + placebo-varenicline + Motivational Interview (MI)
62248397|NCT01726244|EXPERIMENTAL|Intervention Group|Multidisciplinary intervention consisting in controlling disease and stress associated to it, and modifying eating habits. A Nurse, nutritionist and a psychologist will be the responsible of these educational sessions. it will be three educational sessions. Patients with a BMI lower than 20 or bigger than 30 will be receive a closer follow up by nutritionist. In addition, patients with a score of 9 or more in the Patients Health Questionnaire-9 questionnaire will be also a closer follow up with the psychologist.
62248398|NCT02763228|EXPERIMENTAL|Group 1: Exercise Program|"The exercise in this study will consist of two types of exercise training: resistance training and aerobic exercise. Resistance training is like weight lifting to improve strength and function. Participants will complete resistance training by using resistance machines and free weights. Aerobic exercise is exercise that intends to improve the cardiopulmonary or oxygen/lung and heart systems. It is often referred to as cardio exercise. Treadmill walking, stationary cycling sessions, and/or other exercises will be used for aerobic exercise.~Participants will be instructed in the exercise routine by physical fitness experts and trainers."
62046417|NCT03235505|ACTIVE_COMPARATOR|Nicotine-free e-cigarettes|Nicotine-free e-cigarettes + varenicline tartrate+ MI
62046418|NCT03235505|PLACEBO_COMPARATOR|Motivational Interview (MI)|Placebo-varenicline + nicotine -free e-cigarettes + MI
62046419|NCT02622165|EXPERIMENTAL|The REWARD serious game intervention|A mobile 4-week serious game intervention will be administered.
62046420|NCT02622165|NO_INTERVENTION|Control group|School curriculum as usual
62046421|NCT01610427|EXPERIMENTAL|HIV-1 Group|Antiretroviral Therapy-naïve HIV1-infected subjects, aged 18 to 55 years, from whom samples for cell-mediated immunity (CMI) were collected. No investigational vaccine was administered.
62046422|NCT00510094|EXPERIMENTAL|1|Participants will receive the Friend to Friend program
62046423|NCT00510094|ACTIVE_COMPARATOR|2|Participants will receive the psychoeducational attention control intervention
62248399|NCT02763228|ACTIVE_COMPARATOR|Group 2: Support Group|"First 20 Weeks: Participants will take part in a structured Health Education and Support Group sessions once a week.~Last 32 weeks: Participants will be encouraged to take part in any of the Support Group sessions offered regularly on their own schedule."
62449319|NCT00358384|EXPERIMENTAL|Subjects receiving treatment B|Eligible subjects will receive 0.5 percent pazopanib ointment.
62046424|NCT01477853|EXPERIMENTAL|Sitagliptin/Sitagliptin + Atorvastatin|In Phase A, participants received sitagliptin 100 mg plus matching placebo to atorvastatin daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
62046425|NCT01477853|ACTIVE_COMPARATOR|Atorvastatin/Atorvastatin + Glimepiride|In Phase A, participants received atorvastatin 80 mg plus matching placebo to sitagliptin daily for 16 weeks. Participants continuing to Phase B received atorvastatin 80 mg plus matching placebo to sitagliptin plus glimepiride daily for an additional 38 weeks.
62046426|NCT01477853|EXPERIMENTAL|Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin|In Phase A, participants sitagliptin 100 mg plus atorvastatin 80 mg daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
62046427|NCT05431075|EXPERIMENTAL|Tid group|Tid group: Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 20mg bid
62046428|NCT05431075|ACTIVE_COMPARATOR|Qid group|Qid group: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 20mg bid
62046429|NCT03377023|EXPERIMENTAL|Phase 1 - Dose Escalation|"Nivolumab + Ipilimumab + Nintedanib dose escalation.~Nivolumab: 3 mg/kg IV Q2 weeks.~Ipilimumab: 1 mg/kg Q6 weeks.~Nintedanib Level -1: 100 mg by mouth (PO) once a day (QD) Days 1-14 (Daily dose =100 mg).~Nintedanib Level 0:150 mg by mouth (PO) once a day (QD) Days 1-14 (Daily dose =150 mg)~Nintedanib Level 1: 100 mg PO twice daily (BID) Days 2-28 (Daily dose = 200 mg).~Nintedanib Level 2: 150 mg PO BID Days 1-14 (Daily dose = 300 mg).~Nintedanib Level 3: 200 mg PO BID Days 1-14 (Daily dose = 400 mg)."
62248400|NCT03718065|EXPERIMENTAL|Lofexidine Men|Men will receive lofexidine (Lucemyra) for 5 weeks. Titration schedule is as follows: 0.36 mg on the first two evenings, 0.36 mg in the morning and evening on days 3 and 4; 0.36 mg in the morning, afternoon, and at bedtime on days 5 and 6; 0.36 mg in the morning and afternoon and 0.72 mg at bedtime on days 7 and 8; 0.36 mg in the morning and 0.72 mg in the afternoon and at bedtime on days 9 and 10, and 0.72 mg in the morning, afternoon and at bedtime on Day 11 and throughout the rest of the study.
62248401|NCT03718065|EXPERIMENTAL|Lofexidine Women|Women will receive lofexidine (Lucemyra) for 5 weeks. Titration schedule is as follows: 0.36 mg on the first two evenings, 0.36 mg in the morning and evening on days 3 and 4; 0.36 mg in the morning, afternoon, and at bedtime on days 5 and 6; 0.36 mg in the morning and afternoon and 0.72 mg at bedtime on days 7 and 8; 0.36 mg in the morning and 0.72 mg in the afternoon and at bedtime on days 9 and 10, and 0.72 mg in the morning, afternoon and at bedtime on Day 11 and throughout the rest of the study.
62828529|NCT02582775|EXPERIMENTAL|RDEB: HCT Plus MSC Arm E|Recessive dominant epidermolysis bullosa (RDEB) patients treated per study regimen on a post-transplant cyclophosphamide allogeneic hematopoietic cell transplant (HCT) platform conditioned with reduced intensity chemotherapy and low dose total body irradiation (400 cGy), followed post-HCT by serial infusions of donor-derived mesenchymal stromal cells (MSC).
62248402|NCT03718065|PLACEBO_COMPARATOR|Placebo Men|Men will receive matching placebo for five weeks.
62248403|NCT03718065|PLACEBO_COMPARATOR|Placebo Women|Women will receive matching placebo for five weeks.
62438381|NCT02266706|EXPERIMENTAL|Cohort 4: ≥3 months to <2 years TOL/TAZ 18/9 or 30/15 mg/kg|Participants ≥3 months to \<2 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
62248404|NCT00930722||quinapril|quinapril
62248405|NCT05518903|EXPERIMENTAL|Diagnostic (gallium GA 68 FAPi-46, PET/CT)|Patients receive 68Ga-FAP-46 IV, then allow 60 minutes for 68Ga-FAPI-46 uptake. Patients then undergo PET/CT scans over 30 minutes at baseline (before SOC therapy), up to 2 scans approximately 8 weeks apart (at SOC re-staging visits), and a then a scan within 4 weeks of SOC surgical resection, if applicable.
62248406|NCT02360930||Tanner Stage </=2|Patients will be stratified by phase of treatment, and they will be classified into Tanner stage ≤ 2 or ≥ 4, based on physical examination. We plan to have 15 patients in Tanner staging ≤ 2 and 15 patients in Tanner staging ≥ 4.
62248407|NCT02360930||Tanner Stage >/= 4|Patients will be stratified by phase of treatment, and they will be classified into Tanner stage ≤ 2 or ≥ 4, based on physical examination. We plan to have 15 patients in Tanner staging ≤ 2 and 15 patients in Tanner staging ≥ 4.
62248408|NCT05909930|EXPERIMENTAL|Therapeutic exercise and education|The treatment will consist of a progressive resistance exercise program along with education.
62248409|NCT01956734|EXPERIMENTAL|DNX2401 and Temozolomide|"DNX2401: Virus injection in the brain parenchyma. Total dose will be 3x1010 vp suspended in 1 ml for all cases.~Temozolomide: 14 (window 14-28 days) days after the virus injection, patients will begin therapy with temozolomide in a dose of 150mg/m2 in days 1-7 and 15 -21 of a 28 days cycle, (dose dense scheme 7 days on, 7 days off), until a maximum of 2 x 28 days cycles in absence of toxicity."
62248410|NCT01028950|EXPERIMENTAL|YM150 group|
62438382|NCT02266706|EXPERIMENTAL|Cohort 5: birth to <3 months TOL/TAZ 20/10 mg/kg|Participants from birth (\>32 weeks gestation, 7 days postnatal) to \<3 months of age received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 mg/kg was changed to TOL/TAZ 20/10.
62438383|NCT02266706|EXPERIMENTAL|Cohort 6: birth to <3 months TOL/TAZ 12/6 or 20/10 mg/kg|Participants from birth (≤32 weeks gestation, 7 days postnatal) to \<3 months of age with creatinine clearance =20 - 49 mL/min/1.73 m\^2 received a single dose of TOL/TAZ 12/6 mg/kg as a 60-minute infusion on Day 1; participants with creatinine clearance ≥50 mL/min/1.73 m\^2 received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 was changed to TOL/TAZ 20/10 mg/kg for participants with creatinine clearance ≥50 mL/min/1.73 m\^2.
62438384|NCT01140178|EXPERIMENTAL|HPPH|a fixed HPPH dose of 4 mg/m2 infused over 1 hour, and 24 hours later light doses escalating from 100 J/cm2 to 125 and 140 J/cm2, respectively.
62438385|NCT01880710|ACTIVE_COMPARATOR|Total hysterectomy|removal of the entire uterus including the cervix. open abdominal surgery. No specific procedures were asked of the surgeon. They were free to do the procedure the way they were used to doing it.
62828530|NCT02582775|EXPERIMENTAL|HCT with 300 cGy of TBI Arm A|Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant without mesenchymal stem cell infusions.
62248411|NCT04593667|OTHER|Full Inflation|100% TR Band inflation relative to recommended inflation with 15-18 cc air injected in TR band bladder
62248412|NCT04593667|OTHER|Mid Inflation|75% TR Band inflation relative to recommended inflation with 11-14 cc air injected in TR band bladder
62248413|NCT04593667|OTHER|Low Inflation|50% TR Band inflation relative to recommended inflation with 8-9 cc air injected in TR band bladder
62248414|NCT02112136|OTHER|GeneQuest|"* No drug will be administrated in this study~* Blood collection"
62248415|NCT02114775|ACTIVE_COMPARATOR|Recombinant Growth Hormone|Double blind placebo/Genotropin cross over design for 6 months with cross over at 3 months. Then open label Genotropin from month 6 - 12.
62828531|NCT02582775|EXPERIMENTAL|Re-Transplant Arm C|Epidermolysis bullosa patients treated regardless of original transplant arm with re-transplant using 300 cGy of TBI.
62438386|NCT01880710|EXPERIMENTAL|Subtotal Hysterectomy|removal of the uterine body only leaving the cervix in situ. The surgeon was free to do the procedure as he was used to. The only direction was that the cervical canal should be electrocoagulated.
62438387|NCT04897100|EXPERIMENTAL|Needle tenotomy|Patient will receive an Achilles tendon tenotomy using a 22G needle when randomized into the needle group. Follow-up to measure dorsiflexion and register complications will be assured at 3 weeks and 3 months.
62438388|NCT04897100|ACTIVE_COMPARATOR|Blade tenotomy|Patient will receive an Achilles tendon tenotomy using a 11 blade when randomized into the needle group. Follow-up to measure dorsiflexion and register complications will be assured at 3 weeks and 3 months.
62438389|NCT01851590|EXPERIMENTAL|Resin Lacquer|Topical 30% Resin Lacquer applied once daily for 9 months (Abicin® 30% Nail Lacquer).
62248416|NCT02114775|ACTIVE_COMPARATOR|Sildenafil|Double blinded placebo/Sildenafil crossover design for 6 months with crossover at month 3. Then open label Sildenafil from months 6-12.
62248417|NCT02472379|EXPERIMENTAL|Writing: Group 1|Subjects will be asked to write about experiences with familiar individuals in their lives.
62248418|NCT02472379|PLACEBO_COMPARATOR|Writing: Group 2|Subjects will be asked to write about experiences with familiar places in their lives.
62248419|NCT01063829|EXPERIMENTAL|Dose regimen 1|60 mg AIC246, one tablet per day
62248420|NCT01063829|EXPERIMENTAL|Dose regimen 2|120 mg AIC246, one tablet per day
62248421|NCT01063829|EXPERIMENTAL|Dose regimen 3|240 mg AIC246, one tablet per day
62248422|NCT01063829|OTHER|Placebo|Placebo arm
62438390|NCT01851590|ACTIVE_COMPARATOR|Amorolfine|Topical 5% Amorolfine Lacquer applied once weekly for 9 months (Loceryl® 5% Nail Lacquer).
62438391|NCT01851590|ACTIVE_COMPARATOR|Terbinafine|250 mg of Terbinafine taken orally once daily for 3 months (Generics).
62438392|NCT06528756|ACTIVE_COMPARATOR|Type I calcifications|Type I calcifications according to the Bianchi Martinoli classification
62438393|NCT06528756|ACTIVE_COMPARATOR|Type II/III calcifications|Type II/III calcifications according to the Bianchi Martinoli classification
62438394|NCT02615327|EXPERIMENTAL|Active Treatment 1|8g Polydextrose
62438395|NCT02615327|EXPERIMENTAL|Active Treatment 2|12 g Polydextrose
62438396|NCT02615327|EXPERIMENTAL|Active Treatment 3|16 g Polydextrose
62438397|NCT02615327|PLACEBO_COMPARATOR|Placebo|0 g Polydextrose
62438398|NCT02642627|EXPERIMENTAL|Bellafill Injections|Correctable acne scars will be individually identified and only scars that the Investigator determines to be correctable will receive study treatment. All eligible scars within the treatment area will be treated. Bellafill will be injected using a standard tunneling technique whereby the filler is injected in a retrograde manner utilizing several passes until the scar reaches a desired level of correction. A touch-up treatment is allowed if additional treatment is required to achieve optimal correction.
62438399|NCT06543784||Experts of experience|Health care professionals involved in preconception carrier screening at Amsterdam UMC, UMC Groningen and Australia
62438400|NCT06543784||Gynaecologists (in training)|
62438401|NCT06543784||Midwives|
62438402|NCT06543784||General practitioners|
62438403|NCT06543784||Nurse practitioners and/or clinical geneticists|
62438404|NCT06543784||Potential prospective patients who might want to undergo preconception carrier screening|
62438405|NCT05747365||Case group|Patients with thyroid cancer diagnosis within 5 years before study enrollment
62438406|NCT05747365||Control group|Patients without clinical diagnosis of thyroid disease
62438407|NCT01360957|PLACEBO_COMPARATOR|Water flavored placebo|to be given orally in a dosage of 30 ml trice daily for 60 days
62438408|NCT01360957|EXPERIMENTAL|Black cumin water extract as a traditional medicine|Black cumin water extract as a traditional medicine to be given orally in a dosage of 30 ml trice daily for 60 days
62438409|NCT04146220|EXPERIMENTAL|Low dose group|Prednisolone 0.5 mg/kg/day
62438410|NCT04146220|ACTIVE_COMPARATOR|High dose group|Prednisolone 1 mg/kg/day
62438411|NCT04503798|EXPERIMENTAL|Online Goal Management Training (GMT)|The online version of GMT with a therapist on the back-end monitoring progress and giving feedback throughout the program. Online GMT takes 5-9 weeks (self-paced) to complete 9 modules involving instructional video with interactive content, practice of cognitive strategies through games, and between-module exercises.
62438412|NCT04503798|NO_INTERVENTION|Treatment-as-usual control group|Participants randomized to this arm will receive no additional information or access to the intervention program. They will continue to receive treatment-as-usual from their care providers.
62438413|NCT03103659|EXPERIMENTAL|Elderly patient with cancer living in a nursing home|
62605750|NCT02982044|EXPERIMENTAL|Experimental-Control|"Participants will undergo all interventions, while simultaneously serving as their own within-subject control. The left side of the body will be designated experimental, and all interventions will be applied to the left arm. The right side of the body will be designated as control, and will not receive any interventions."
62046430|NCT03377023|ACTIVE_COMPARATOR|Phase 2 - Arm A|"Arm A: Newly diagnosed or treatment-naïve patients, with a target overall response rate (ORR) of 50%.~Nivolumab + Ipilimumab + Nintedanib at RP2D."
62248423|NCT02049268|EXPERIMENTAL|Nicotine + Alcohol|A nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (nicotine only) measurements will be made, then participants will drink an alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
62438414|NCT04841239|EXPERIMENTAL|Herbal topical formulation|
62605751|NCT04578093|EXPERIMENTAL|Intervention|Will receive adjusts curriculum
62438415|NCT04841239|NO_INTERVENTION|Control|
62438416|NCT02500017|EXPERIMENTAL|Melatonin|A commercially available rapid-release formulation of melatonin (5 mg) capsules to be administered once a day for a total of 8 weeks
62438417|NCT02500017|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules to be administered once a day for a total of 8 weeks
62438418|NCT00063960|EXPERIMENTAL|floxuridine + irinotecan|"Within 4-8 weeks after prior resection or ablation, patients receive hepatic arterial infusion of floxuridine continuously on days 1-14 and irinotecan IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of unacceptable toxicity.~Patients are followed every 3 months for 2 years."
62438419|NCT00408876|EXPERIMENTAL|Duloxetine 20 mg|duloxetine 20 mg once a day (QD), by mouth (PO) for 13 weeks
62438420|NCT00408876|EXPERIMENTAL|Duloxetine 60 mg|duloxetine 30 mg once a day (QD), by mouth (PO) for 1 week then duloxetine 60 mg QD, PO for 12 weeks
62438421|NCT00408876|EXPERIMENTAL|Duloxetine 120 mg|duloxetine 30 mg once a day (QD), by mouth (PO) for 1 week followed by duloxetine 60 mg QD, PO for 1 week, then duloxetine 120 mg QD, PO for 11 weeks
62605752|NCT04578093|NO_INTERVENTION|Control|Will receive unadjusted curriculum
62605753|NCT05007041|ACTIVE_COMPARATOR|Zoster Vaccine Recombinant (RZV) and Quadrivalent Adjuvanted Influenza Vaccine (FLUAD®)|In this study arm, subjects will receive Dose 1 of RZV (SHINGRIX®) and Dose 1 of the adjuvanted influenza vaccine (FLUAD® Quadrivalent) simultaneously during Visit 1 and Dose 2 of RZV (SHINGRIX®) during Visit 6.
62828532|NCT02582775|EXPERIMENTAL|HCT Arm D|HLA-matched epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGY BID of TBI (400 cGy total).
62828533|NCT02582775|EXPERIMENTAL|HCT Alone Arm F|HLA-mismatched epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGy BID of TBI (400 cGy total) + addition of low dose busulfan for recipients of HLA-mismatched bone marrow
62248424|NCT02049268|EXPERIMENTAL|Placebo Nicotine + Alcohol|A placebo nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (placebo nicotine) measurements will be made, then participants will drink an alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
62248425|NCT02049268|EXPERIMENTAL|Nicotine + Placebo Alcohol|A nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (nicotine only) measurements will be made, then participants will drink a placebo alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
62248426|NCT04229953||US scan with 3D/4D VRU software|
62828534|NCT02582775|EXPERIMENTAL|HCT plus MSC Arm G|HLA-mismatched epidermolysis bullosa patients treated with hematopoietic cell transplant plus serial MSC infusions using 200 cGy BID of TBI (400 cGy total) + addition of low dose busulfan for recipients of HLA-mismatched bone marrow
62828535|NCT06654466|NO_INTERVENTION|Control Arm|Patients in the control arm will complete a standard genetic counseling or follow-up visit and a post-visit survey.
62828536|NCT06654466|EXPERIMENTAL|Intervention Arm|Patients in the intervention arm will complete a genetic counseling or follow-up visit with a clinician using Nest Clinical Decision Support and a post visit-survey. Intervention arm patients will be given access to the Nest Patient Navigator.
62828537|NCT00129246|ACTIVE_COMPARATOR|Bupropion only|The placebo comparator was a group of matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen in a similar 7-week study investigation compared to naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day).
62046431|NCT03377023|ACTIVE_COMPARATOR|Phase 2 - Arm B|"Arm B: Patients who have been previously exposed to immunotherapy, such as anti-PD-1, anti-PD-L1 or anti-CTLA-4, with a target ORR of 20%.~Nivolumab + Ipilimumab + Nintedanib at RP2D."
62438422|NCT00408876|PLACEBO_COMPARATOR|Placebo|placebo once a day (QD), by mouth (PO) for 13 weeks
62438423|NCT03381885|EXPERIMENTAL|Intervention Group|"A nudge grounded in behavioral economic theory (nudge=gentle incentive, preserving freedom of choice)"
62438424|NCT03381885|PLACEBO_COMPARATOR|Control|"No nudge"
62438425|NCT04782115|EXPERIMENTAL|1.0mg RC28-E injection Q8|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 1.0 mg RC28-E every 4 weeks, for 3 consecutive times; From then on to the 48th week, the patients were visited every 4 weeks and given medicine every 8 weeks.
62438426|NCT04782115|EXPERIMENTAL|1.0mg RC28-E injection as needed|In the loading phase (from week 0 to week 16), the study eye will receive intravitreal injection of 1.0mg RC28-E every 4 weeks, for 5 consecutive times;In the as needed (pro re nata,PRN)phase (from then on to week 48), the study eye will receive the same dose on an PRN schedule based upon the physician assessment in accordance with pre-specified criteria.
62438427|NCT04782115|EXPERIMENTAL|2.0mg RC28-E injection Q8|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 2.0mg RC28-E every 4 weeks, for 3 consecutive times; From then on to the 48th week, the patients were visited every 4 weeks and given medicine every 8 weeks.
62605754|NCT05007041|ACTIVE_COMPARATOR|Zoster Vaccine Recombinant (RZV) and High-Dose Quadrivalent Influenza Vaccine (Fluzone®)|In this study arm, subjects will receive Dose 1 of RZV (SHINGRIX®) and Dose 1 of the (Fluzone® HD Quadrivalent) influenza vaccine simultaneously during Visit 1 and Dose 2 of RZV (SHINGRIX®) during Visit 6.
62605755|NCT05616429|EXPERIMENTAL|Alcat based personal diet|
62605756|NCT05616429|SHAM_COMPARATOR|Standard balanced diet|
62605757|NCT04102865|OTHER|Abdominal|Abdominal surgery type with investigational single use NPWT dressing
62828538|NCT00129246|EXPERIMENTAL|Naltrexone +Bupropion|The active comparator in this 7-week open label study investigation was naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day) compared to matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen (bupropion only).
62438428|NCT04782115|EXPERIMENTAL|2.0mg RC28-E injection as needed|In the loading phase (from week 0 to week 16), the study eye will receive intravitreal injection of 2.0mg RC28-E every 4 weeks, for 5 consecutive times;In the as needed (pro re nata,PRN)phase (from then on to week 48), the study eye will receive the same dose on an PRN schedule based upon the physician assessment in accordance with pre-specified criteria.
62438429|NCT04782115|EXPERIMENTAL|control group|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of Conbercept every 4 weeks, for 3 consecutive times;In the as needed (pro re nata,PRN)phase (from then on to week 48), the study eye will receive the same dose on an PRN schedule based upon the physician assessment in accordance with pre-specified criteria.
62605758|NCT04102865|OTHER|Knee|Knee surgery type with investigational single use NPWT dressing
62046432|NCT02934152|EXPERIMENTAL|Early eradication|Group A (H pylori eradication timing: early eradication, n=100): Initial H pylori eradication with triple therapy (rabeprazole 20 mg qd, amoxicillin 1gm bid, clarithromycin 500 mg bid) for two weeks.
62248427|NCT01846624|EXPERIMENTAL|Decitabine, then midostaurin|"INDUCTION THERAPY Subjects receive decitabine intravenously (IV) over 1 hour on days 1 to 10 and midostaurin orally (PO) twice daily (BID) on days 11 to 28. Treatment repeats every 28 days until documented bone marrow response is achieved or for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving documented bone marrow response by course 6 continue treatment with induction therapy; patients achieving response after course 6 proceed to post-remission therapy.~POST-REMISSION THERAPY Subjects receive decitabine IV over 1 hour on days 1 to 5 and midostaurin PO BID on days 6 to 28. Treatment repeats every 28 days for up to 12 courses (including induction therapy) in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed up for up to 1 year."
62248428|NCT03492554|OTHER|Atrial fibrillation (AF)|Patient with a known history of AF who are in AF at the time of study screening.
62248429|NCT03492554|OTHER|Normal Sinus Rhythm (SR)|Patient with no known diagnosis of AF or other arrhythmia
62248430|NCT02632565|ACTIVE_COMPARATOR|intra-articular 0.5% lidocaine|intra-articular 7 mL 0.5% lidocaine injection for 3 times with one week intervals
62248431|NCT02632565|ACTIVE_COMPARATOR|intra-articular saline|intra-articular 7 mL saline injection for 3 times with one week intervals
62438430|NCT01239147|OTHER|Whole grain diet|
62438431|NCT01239147|OTHER|Refined grain diet|
62438432|NCT05036915|EXPERIMENTAL|Control group (Pacifier randomly 30 min)|Pacifier is randomly given to the infant for 30 min independent from feeding during the day
62438433|NCT05036915|EXPERIMENTAL|Experimental Group (Pacifier randomly 30 min+ routine 5 min before each feeding)|Pacifier is randomly given to the infant for 30 min independent from feeding during the day. In addition, pacifier is given to the infant for 5 min before each feeding.
62438434|NCT04728113|EXPERIMENTAL|Early together group|Oncological standard of care at M0, M3, M6, M9 and M12 with early introduction of supportive care every 6 weeks.
62438435|NCT04728113|ACTIVE_COMPARATOR|Control group|Oncological standard of care at M0, M3, M6, M9 and M12.
62438436|NCT01901315|EXPERIMENTAL|Online consultation|Monthly video consultations with psychiatrist
62438437|NCT01901315|EXPERIMENTAL|Face-to-face consultation|Monthly face-to-face consultations with psychiatrist
62248432|NCT00445705|PLACEBO_COMPARATOR|Placebo|Part A: Placebo every 12 hours for 4 weeks
62248433|NCT00445705|EXPERIMENTAL|AGN 203818 3 mg|Part A: 3 mg AGN 203818 every 12 hours for 4 weeks
62248434|NCT00445705|EXPERIMENTAL|AGN 203818 20 mg|Part A: 20 mg AGN 203818 every 12 hours for 4 weeks
62438438|NCT05122585|EXPERIMENTAL|Prospective MagTrace patients|All prospective patients will receive a MagSeed in the diagnosed breast cancer tumor. In addition, they will receive MagTrace to detect the sentinel lymph node during surgery. Since this is an experimental study, the patients will also be injected with the golden standard of Technetium tracer.
62605759|NCT05510076||Group A|in which full-thickness vertical compression suture combined with inflated intrauterine balloon are used to control bleeding
62248435|NCT00445705|EXPERIMENTAL|AGN 203818 60 mg|Part A: 60 mg AGN 203818 every 12 hours for 4 weeks
62248436|NCT04199962||pneumonia without sepsis|adult patients with community acquired pneumonia change in SOFA score \<2 (other than respiratory component)
62248437|NCT04199962||pneumonia with sepsis|adult patients with community acquired pneumonia change in SOFA score greater or equal to 2 (other than respiratory component)
62248438|NCT04338373|EXPERIMENTAL|experimental|"0.01% Atropine Sulfate solution in Comfort Drops, nightly instillations to both eyes"
62248439|NCT00888381|EXPERIMENTAL|Adults|Healthy volunteers aged 18 to 59 years
62248440|NCT00888381|EXPERIMENTAL|Older Adults|Healthy volunteers aged 60 years or older
62248441|NCT00990054|EXPERIMENTAL|plerixafor|
62605760|NCT05510076||Group B|in this group, a resective-reconstructive technique is used, which involves resecting the invasive accreta area followed by immediate uterine reconstruction and bladder reinforcement
62605761|NCT05510076||Group C|In this group, bilateral uterine artery ligations combined with cervical tamponade which is performed by elevating the cervix into the uterine cavity with Allis forceps, then suturing the anterior and/ or posterior cervical lip(s) into the anterior and/ or posterior uterine segment(s) depending on the site of bleeding with two or three simple interrupted stitches, with the patency of the cervical canal confirmed, followed by closure of the uterine incision
62438439|NCT04524481||Patients with mild haemophilia A or B|(FVIII or IX \>5 %, ≥ 18 years' old)
62438440|NCT04524481||Patients with moderate haemophilia A or B|(FVIII or IX 1-5 %, ≥ 18 years' old)
62438441|NCT04524481||Patients with severe haemophilia A or B|(FVIII or IX \<1 %, ≥ 18 years' old)
62605762|NCT04820231|OTHER|PRP injection group|"Intra-articular PRP injection with ultrasound guidance~Three times PRP injections with an interval of one week"
62248442|NCT02982239|OTHER|Sleep Intervention|N=20 Participants received fitness tracker, information session, a link to complete a daily sleep diary, intermittent text messages that included adherence reminders, encouraging statements, and tips for improving sleep. Daily monitoring with sleep diaries, daily monitoring of sleep tracker sync activity and regret lottery for 10 weeks
62605763|NCT01592292||Rituximab|Participants who have inadequate response or were intolerant to the first anti-tumor necrosis factor (anti-TNF) agent in rheumatoid arthritis (RA), receiving rituximab as per physician's discretion for RA treatment were observed for 12 months.
62605764|NCT01592292||Other anti-TNF agent|Participants who have inadequate response or were intolerant to the first anti-TNF agent in RA, receiving other anti-TNF agent, including adalimumab, etanercept and infliximab, as per physician's discretion for RA treatment were observed for 12 months.
62438442|NCT01743677|EXPERIMENTAL|CP-690,550 100 mg|
62438443|NCT01743677|PLACEBO_COMPARATOR|Placebo|
62438444|NCT01743677|ACTIVE_COMPARATOR|Moxifloxacin hydrochloride|
62438445|NCT01403350|NO_INTERVENTION|Current Practice|Study Phase I: No RDT or other parasite based diagnosis; Study Phase II: RDT used under the standard programme of training and support
62438446|NCT01403350|ACTIVE_COMPARATOR|Intervention Arm|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
62438447|NCT03548376|EXPERIMENTAL|One-group intervention|Hippotherapy sessions were delivered once a week for 30 minutes, during 6 months.
62438448|NCT01317732|EXPERIMENTAL|MOTIONPOD (TM)|
62438449|NCT05211050|ACTIVE_COMPARATOR|Levcromakalim-Sumatriptan|20 participants with migraine without aura will receive a 20 min infusion of levcromakalim followed by a 10 min infusion of sumatriptan.
62438450|NCT05211050|PLACEBO_COMPARATOR|Levcromakalim-Placebo|20 participants with migraine without aura will receive a 20 min infusion of levcromakalim followed by a 10 min infusion of saline.
62438451|NCT01513057|EXPERIMENTAL|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
62438452|NCT01513057|ACTIVE_COMPARATOR|Cellcept|Cellcept 250 mg capsules of Roche Laboratories Inc.
62605765|NCT01299415|EXPERIMENTAL|ASA404 + Fluvoxamine|ASA404 + Fluvoxamine (Core Phase), ASA404 + either paclitaxel or docetaxel or paclitaxel plus carboplain chemotherapy combination (Extension Phase)
62605766|NCT00911209|EXPERIMENTAL|Intervention|The Intervention group at each session will receive information on Heart healthy diet, lifestyle recommendations and diet and exercise counseling with a dietitian in order to achieve at least 7% weight loss (for example a person weighing 200 pounds will be encourage to lose at least 14 pounds).
62438453|NCT02541695|ACTIVE_COMPARATOR|1E10 CFU Escherichia coli (E. coli)|"1E10 Colony Forming Units (CFU) Diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food research). Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain.~At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
62605767|NCT00911209|NO_INTERVENTION|No Intervention|The standard of care group will receive information on Heart healthy diet at baseline visit and will return to a final visit about 28 weeks later.
62605768|NCT06525636|EXPERIMENTAL|Part I: Cohort 1|Low Dose, single dose of KK8123
62449320|NCT00358384|EXPERIMENTAL|Subjects receiving treatment C|Eligible subjects will receive 1 percent pazopanib ointment.
62449321|NCT00358384|PLACEBO_COMPARATOR|Subjects receiving treatment D|Eligible subjects will receive pazopanib vehicle as negative control.
62605769|NCT06525636|EXPERIMENTAL|Part I: Cohort 2|Mild dose, multiple doses of KK8123
62605770|NCT06525636|EXPERIMENTAL|Part I: Cohort 3|High dose, multiple doses of KK8123
62605771|NCT06525636|EXPERIMENTAL|Part I: Cohort 4|Optional, multiple doses of KK8123
62605772|NCT06525636|EXPERIMENTAL|Part 2: Extension Period|High dose, multiple doses as confirmed for Cohort 3 of KK8123.
62605773|NCT06504667|EXPERIMENTAL|Prosthesis|Patient is temporarily fit with Point Mini finger prosthetic system
62605774|NCT05052216||NORM|healthy children
62605775|NCT05052216||OSA|children with obstructive sleep apnea
62605776|NCT06514378|EXPERIMENTAL|Treatment group|
62605777|NCT06514378|NO_INTERVENTION|Control|
62623466|NCT02051088|ACTIVE_COMPARATOR|Revascularization without drug elution|Revascularization without drug elution technology
62623467|NCT04953741|ACTIVE_COMPARATOR|Stop Fluticasone propionate Inhaled Aerosol Firstly|Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day
62828539|NCT06472609|EXPERIMENTAL|interactive group|diabetes, enhanced interactive education program through weekly phone call for 12 weeks
62828540|NCT00303069|EXPERIMENTAL|V710 5 μg|V710 S. aureus vaccine
62248443|NCT02982239|OTHER|Sleep Intervention plus Tech|N=20 Participants received fitness tracker, LED light, Blue-blocking glasses along with information session, a link to complete a daily sleep diary, intermittent text messages that included adherence reminders, encouraging statements, and tips for improving sleep. Daily monitoring with sleep diaries, daily monitoring of sleep tracker sync activity and regret lottery for 10 weeks.
62248444|NCT06321926|EXPERIMENTAL|Intervention group|Participants in the intervention group use the ActiveWaiting App for one week.
62248445|NCT06321926|OTHER|Waitlist control group|Participants in the waitlist control group go through a one-week control period without any intervention first, before they are using the app for one week.
62248446|NCT00303979||Cohort A (longitudinal)|Longitudinal Cohort: Approximately 15,000 patients followed at baseline, 12 months and 24 months
62248447|NCT00303979||Cohort B (6 Month)|6 Month Cohort: Approximately 10,000 patients reviewed at single time point
62248448|NCT00303979||Cohort C (18 Month)|18 Month Cohort: Approximately 10,000 patients reviewed at single time point
62248449|NCT03472924|EXPERIMENTAL|Kinesio Tape|Kinesiotaping of the peroneus longus according to the guidelines provided by the Kinesio Taping Association (Kase, K. 2016) followed by standardized set of therapeutic exercises that are commonly implemented in ankle rehabilitation programs.
62438454|NCT02541695|EXPERIMENTAL|5E10 CFU Escherichia coli (E. coli)|"5E10 Colony Forming Units (CFU) Diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food research). Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain.~At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 5E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
62438455|NCT04835298||Myotonic dystrophy type 1|adult patients with myotonic dystrophy type 1
62438456|NCT02334956|EXPERIMENTAL|Patient|Patient with addiction
62438457|NCT02334956|EXPERIMENTAL|Control|healthy subject
62438458|NCT01696474|EXPERIMENTAL|Bortezomib therapy|A single course of Bortezomib will be given at the dose of 1,3 mg/sqm iv on days 1, 4, 8, 11. Prophylaxis of HZ reactivation will be given with oral acyclovir at the dosage of 400 mg twice daily for one month after the end of Bortezomib.
62438459|NCT01997528|EXPERIMENTAL|Extracorporeal CO2 elimination by ILA Activve(R)|
62438460|NCT00833781|ACTIVE_COMPARATOR|mRNA-transfected dendritic cells|Participants in this arm/group received mRNA-transfected autologous dendritic cells
62438461|NCT00833781|PLACEBO_COMPARATOR|Dendritic cells without mRNA|Participants in this arm/group received autologous dendritic cells with no mRNA transfection
62438462|NCT00231296|ACTIVE_COMPARATOR|Treatment with CryoCor Cryoablation System|Intervention includes ablation therapy with the CryoCor catheter for the treatment of symptomatic PAF.
62828541|NCT00303069|EXPERIMENTAL|V710 30 μg|V710 S. aureus vaccine
62248450|NCT03472924|NO_INTERVENTION|Control|Baseline measures followed by standardized set of therapeutic exercises that are commonly implemented in ankle rehabilitation programs, but no use of kinesiotape.
62248451|NCT02433171||Melanoma Brain Metastases|Stage 4 cancer patient population with melanoma with brain metastases previously treated with SRS
62248452|NCT02433171||Lung Cancer Brain Metastases|Stage 4 cancer patient population with non-small cell lung cancer with brain metastases previously treated with SRS
62248453|NCT05735808|ACTIVE_COMPARATOR|Standart physicain based education|In this arm, patient education will be conducted by the physician as the gold standard.
62248454|NCT05735808|EXPERIMENTAL|VR based education|In this arm, patient education will be performed using 3D educational material presented in VR glasses.
62248455|NCT01169220|EXPERIMENTAL|Split prep|
62248456|NCT01169220|ACTIVE_COMPARATOR|Whole prep|
62248457|NCT00646594|EXPERIMENTAL|1|budesonide/formoterol
62248458|NCT00646594|ACTIVE_COMPARATOR|2|fluticasone/salmeterol
62248459|NCT05785572|EXPERIMENTAL|Radiofrequency group|Patient group that undergoes Radiofrequency of supraescapular nerve before shoulder arthroplasty surgery
62248460|NCT05785572|ACTIVE_COMPARATOR|Interscalenic braquial plexus block group|Interscalenic braquial plexus block done at the moment of the surgery.
62248461|NCT02281929|ACTIVE_COMPARATOR|amoxicillin+ prednisolone|Oral antibiotherapy during 30 days using amoxicillin+clavulanic acid at a daily dose of 3 gram (amoxicillin) and 375 mg (clavulanic acid) in three daily doses of 1g/125mg. Oral corticotherapy during 30 days with prednisolone at 40 mg/j in a single daily dose in the morning.
62828542|NCT00303069|EXPERIMENTAL|V710 90 μg|V710 S. aureus vaccine
62828543|NCT00303069|PLACEBO_COMPARATOR|Placebo|Placebo
62828544|NCT03212274|EXPERIMENTAL|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan and/or MRI, as well as a tumor biopsy and blood sample collection on study.
62828545|NCT05724329|EXPERIMENTAL|Tislelizumab + Dasatinib + Quercetin|"Neoadjuvant treatment with Tislelizumab, dasatinib and quercetin for up to 3 cycles (cycle length: 21 days):~Tislelizumab (IV), dose= 200mg, day=1. Dasatinib (PO), dose=100mg/day, day= 1,2,3. Quercetin (PO), dose=1250mg/day, day= 1,2,3.~Following surgical resection, participants will receive adjuvant therapy:~Tislelizumab (200 mg, day=1) Cycle=1-15cycle Dasatinib (100mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10 Quercetin (1250mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10"
62248462|NCT02281929|PLACEBO_COMPARATOR|Placebo + prednisolone|Oral placebo of amoxicillin- clavulanic acid in three daily doses during 30 days Oral corticotherapy during 30 days with prednisolone at 40 mg/j in a single daily dose in the morning.
62248463|NCT01576172|ACTIVE_COMPARATOR|Arm I (abiraterone acetate and prednisone)|Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62248464|NCT01576172|EXPERIMENTAL|Arm II (abiraterone acetate, prednisone, and veliparib)|Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62248465|NCT01434550|ACTIVE_COMPARATOR|TBRI Subgroup: TBRI and SBRT|"Six patients will be asked to be part of a subgroup called TBRI (Tissue, Blood, Research Imaging). In this subgroup, we want to study if there is early death of tumor cells from the treatment by looking at the tumor using PET/CT scans and biopsies, and by testing the participant's body's white blood cells taken by a procedure called leukapheresis.~Participants do not have to take part in the TBRI subgroup to get treatment on this study with SBRT.~SBRT:~1. 30 Gy in 5 fractions to pancreatic tumor~2. 50 Gy in 5 daily consecutive fractions unresectable portion and avoiding bowel, stomach, and duodenum"
62248466|NCT01434550|ACTIVE_COMPARATOR|SBRT Alone|"1. 30 Gy in 5 fractions to pancreatic tumor~2. 50 Gy in 5 daily consecutive fractions unresectable portion and avoiding bowel, stomach, and duodenum"
62248467|NCT03130179|EXPERIMENTAL|Nicorette Strongmint lozenge 4mg|A single dose of one nicotine 4 mg lozenge will be administrated orally to slowly dissolve in the mouth for nicotine absorption via the buccal mucosa.
62438463|NCT00231296|ACTIVE_COMPARATOR|Treatment with standard medical therapy|Intervention includes treatment with ant-arrhythmic medications alone.
62438464|NCT00514995|EXPERIMENTAL|1|
62248468|NCT03130179|ACTIVE_COMPARATOR|Niquitin Minimint lozenge 4mg|A single dose of one nicotine 4mg lozenge will be administrated orally to slowly dissolve in the mouth for nicotine absorption via the buccal mucosa.
62438465|NCT02112903|EXPERIMENTAL|Encapsulated vortioxetine IR tablet, 20 mg|Single oral dose
62438466|NCT02112903|EXPERIMENTAL|Vortioxetine MR capsule 20 mg (pH 5.5)|Single oral dose
62438467|NCT02112903|EXPERIMENTAL|Vortioxetine MR capsule 20 mg (pH 6.0)|Single oral dose
62438468|NCT02112903|EXPERIMENTAL|Vortioxetine MR capsule 20 mg (pH 7.0)|Single oral dose
62438469|NCT00618969|EXPERIMENTAL|Haploidentical allogeneic PBSC transp|Non-myeloablative preparative regimen (reduced-intensity) of busulfan, melphalan and alemtuzumab followed by a haploidentical-related peripheral blood stem cell transplant.
62438470|NCT03902756|EXPERIMENTAL|Flow-Volume loop guided endotracheal cuff inflation|Endotracheal cuff will be inflated by Flow-Volume loop guided until getting proper sealing.
62438471|NCT03902756|ACTIVE_COMPARATOR|Stethoscope-guided endotracheal cuff infration|Endotracheal cuff will be inflated by Stethoscope-guided until getting proper sealing.
62438472|NCT02327520||Colitis with CDI|Patients who diagnosed with CDI will be analysed
62248469|NCT03100669||Pectus surgery|Single arm study: patient undergoing pectus repair surgery
62248470|NCT02080351|EXPERIMENTAL|Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
62248471|NCT02080351|NO_INTERVENTION|Usual care|Usual care in the emergency department
62438473|NCT02131896|EXPERIMENTAL|Mediterranean Diet|Mediterranean Diet
62438474|NCT02131896|ACTIVE_COMPARATOR|Regular nutritional instructions|Regular nutritional instructions
62438475|NCT06038188|NO_INTERVENTION|Control group|The control group will receive usual care alone
62828546|NCT06596239|EXPERIMENTAL|Lower-clear-plate-based intermaxillary traction (LCP-IMT)|Patients in this group will be treated using the LCP-IMT technique.
62438476|NCT06038188|EXPERIMENTAL|SIT LESS Booster|The intervention group will receive usual care in combination with the remote 3-week SIT LESS Booster program.
62438477|NCT06338020|EXPERIMENTAL|Adaptive-VRT|Participants in this group received the adaptive variable-resistance training program in besides the standard physical therapy care.
62438478|NCT06338020|ACTIVE_COMPARATOR|Standard Physical Therapy|Participants in this group received the standard exercise program.
62438479|NCT02922803|ACTIVE_COMPARATOR|Vitamin D insufficient|Subjects with Vitamin D level in blood \> 25 nmool/L \< 50 nmol/L will be treated with 1 combination tablet of Vitamin D3/calcium per day
62438480|NCT02922803|ACTIVE_COMPARATOR|Vitamin D deficient|Subjects with Vitamin D level in blood \< 25 nmol/L (25-OHD) will be treated with 2 combination tablets of Vitamin D3/calcium per day
62438481|NCT02531828|EXPERIMENTAL|Biopolymer Film|Application of dressings for surgical correction.
62438482|NCT02531828|ACTIVE_COMPARATOR|Polyurethane Film, or the like|Application of dressings for surgical correction
62438483|NCT05935774|EXPERIMENTAL|Treatment (atezolizumab, trabedersen)|Patients recieve atezolizumab IV on day 1 and trabedersen continuous IV on days 1-4 and days 15-19 of each cycle. Cycles repeat every 28 days for 104 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI during screening and every 8 weeks for the first 24 weeks and then every 12 weeks thereafter. Patients undergo blood sample collection prior to initiation of therapy, on day 4 of cycles 1-4, prior to weeks 4 and 8 of therapy, and at time of progression. Patients may also undergo biopsy during screening and/or 6-8 weeks after initiation of therapy.
62438484|NCT03654534|EXPERIMENTAL|oral nutritional supplements|NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
62438485|NCT03654534|NO_INTERVENTION|standard diet|The control group was given no additional postoperative nutritional supplementation (standard diet).
62623468|NCT04953741|ACTIVE_COMPARATOR|Stop Montelukast Secondly|Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day
62828547|NCT06596239|ACTIVE_COMPARATOR|Removable mandibular retractor (RMR)|Patients in this group will be treated using the RMR appliance.
62828548|NCT04246684|ACTIVE_COMPARATOR|Control arm|In the control arm patients receive 5x5 Gy followed by 9 cycles of consolidation chemotherapy mFOLFOX6 or alternatively 6 cycles of CAPOX, followed by re-staging at week 22-24 as established as new preferred neoadjuvant regimen by the RAPIDO trial.
62828549|NCT04246684|EXPERIMENTAL|Experimental arm|The experimental arm starts with Fluoropyrimidin/Oxaliplatin-based CRT (1.8 Gy to 45 Gy to the primary tumor and pelvic lymph nodes; followed by sequential boost of 9 Gy to the gross tumor volume) followed by consolidation chemotherapy with 6 cycles mFOLFOX6 or alternatively 4 cycles CAPOX, followed by re-staging at week 22-24. In both arms, for patients achieving a clinical complete response (cCR), as strictly assessed by clinical investigation, endoscopy and MRI, a W\&W option with close follow-up is scheduled. In case of non-complete response, immediate TME surgery is performed.
62828550|NCT05382845|OTHER|Pregnant women without symptoms of pregnancy related pelvic girdle pain|There is only one arm in this study. The intervention consists of tests to rule out ongoing pelvic pain, manual pain provocation tests, and questionnaire.
62046433|NCT02934152|EXPERIMENTAL|Late eradication|Group B (H pylori eradication timing: late eradication, n=100): PPI with rabeprazole 20 mg qd for 4 weeks, followed by H pylori eradication with triple therapy for two weeks
62046434|NCT02934152|ACTIVE_COMPARATOR|Negative Hp|For patients with negative H. p infection documented by UBT (Group C, n=200), No H pylori eradication treatment will be given but PPI with rabeprazole 20 mg qd will be given for 8 weeks.
62438486|NCT05126381||Smoker with taking levamlodipine besylate tablets|The subjects are allowed to smoke during the time taking levamlodipine besylate tablets.
62438487|NCT05126381||Non-smoker with taking levamlodipine besylate tablets|The subjects are not allowed to smoke during the time taking levamlodipine besylate tablets.
62438488|NCT05126381||Smoker with taking metformin sustained-release tablets|The subjects are allowed to smoke during the time taking metformin sustained-release tablets。
62438489|NCT05126381||Non-smoker with taking metformin sustained-release tablets|The subjects are not allowed to smoke during the time taking metformin sustained-release tablets.
62438490|NCT04597606||Cohort|"All patients will be performed a basal test that consist on continuous cyclergometer exercise, under constant load, with spontaneous breathing, after that the same exercise protocol performed will be carried out under non-invasive ventilation (NIV test). Parameters will be titrated previosuly.~Finally the patient will perform the same exercise at a constant load under high flow oxygen therapy ( HFNC test)."
62438491|NCT02006147|EXPERIMENTAL|TLC399 (Group 1)|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
62046435|NCT03021824||Moderate-Severe ARDS|All adults admitted to participating ICUs with study-defined moderate-to-severe ARDS.
62605778|NCT02865811|EXPERIMENTAL|Pembrolizumab in Combination With PLD|"A safety lead in with 6 patients will be studied prior the start of the treatment.~* If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced.~* If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD)~* Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV~* Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosage"
62623469|NCT04953741|ACTIVE_COMPARATOR|Stop Montelukast Firstly|stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day
62623470|NCT02065401|EXPERIMENTAL|Deferitazole (disodium salt, granule)|
62828551|NCT03304626|EXPERIMENTAL|Study Group|"Budesonide EC 3 mg capsule. The dose will be as follows~Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Budesonide 9 mg Days 31-45 SIS + Budesonide 6 mg Days 46-90 SIS + Budesonide 3 mg Days 90 onwards SIS1"
62046436|NCT04414449|EXPERIMENTAL|Intervention group|During the tutoring time, the intervention program is carried out in the experimental group, through emoTIC. EmoTIC is an emotional education program focused on the development of social-emotional competences through an application that can be used in mobile devices and tablets.
62248472|NCT02527525|EXPERIMENTAL|Stepped Care|150 subjects will be randomized to the stepped care intervention. All 150 participants will be assigned a parent coach after randomization to stepped care condition. At the child's next follow up clinic visit participants who have elevated depression scores OR who's child has not met A1c target will move on to Step 2 of the intervention- 5 sessions with a study interventionist. At the following child's clinic visit, participants can either remain in Step 1, move to Step 2, or if needed, move on to Step 3- using a continuous glucose monitor for 1 week followed by a meeting with a certified diabetes educator and a diabetes team clinical psychologist.
62438492|NCT02006147|EXPERIMENTAL|TLC399 (Group R1)|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
62623471|NCT02065401|EXPERIMENTAL|Deferitazole (disodium salt, tablet)|
62623472|NCT02065401|EXPERIMENTAL|Deferitazole (magnesium hydroxide salt)|
62623473|NCT00813878||Normal participants|
62623474|NCT00813878||Breast Cancer Patients|
62828552|NCT03304626|ACTIVE_COMPARATOR|Control Group|"Standard of Care~Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Prednisone 15-60 mg Days 31-45 SIS + Prednisone 10 mg Days 46-90 SIS + Prednisone 2.5 to 7.5 mg Days 90 onwards SIS"
62828553|NCT00810563|PLACEBO_COMPARATOR|1|Saline solution 0.9% 5mL in each portal
62828554|NCT00810563|ACTIVE_COMPARATOR|2|Bupivacaine 0.5% 5mL in each portal
62438493|NCT02006147|EXPERIMENTAL|TLC399 (Group 2)|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
62438494|NCT02006147|EXPERIMENTAL|TLC399 (Group 3)|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
62438495|NCT05454423|EXPERIMENTAL|aquatic exercise + Traditional physical therapy + anti-hyperuricemia medication|consisted of 50 Patients received aquatic exercise and Traditional physical therapy in addition to anti-hyperuricemia medication (a potent purine xanthine oxidase (XO) inhibitor) in therapeutic dose.
62438496|NCT05454423|PLACEBO_COMPARATOR|traditional physical therapy + anti-hyperuricemia medication|consisted of 50 Patients received traditional physical therapy in addition to anti-hyperuricemia medication (a potent purine xanthine oxidase (XO) inhibitor) in therapeutic dose.
62438497|NCT01238822|PLACEBO_COMPARATOR|Placebo|
62438498|NCT01238822|ACTIVE_COMPARATOR|Low Dose Methylphenidate|Low dose: 18 mg methylphenidate
62438499|NCT01238822|ACTIVE_COMPARATOR|Medium Dose Methylphenidate|Medium Dosage: 36 mg if more than 50 kg and 27 mg if less than 50 kg
62438500|NCT01238822|ACTIVE_COMPARATOR|High Dose Methylphenidate|54 mg if more than 50 kg and 36 mg if less than 50 kg
62438501|NCT02558426||CVD patients|Patients with CVD at various stages (C2-C6 of CEAP classification of CVD) with varicose veins and eligible to receive Open Venous Surgery.
62438502|NCT00439764|ACTIVE_COMPARATOR|1|Routine clinical practice and talk on general health
62046437|NCT04414449|NO_INTERVENTION|Control group|During the period in which the intervention program is conducted in the experimental group, the control group will remain in the waitlist (will not participate in the intervention), and will carry out the program once the study is finished.
62046438|NCT01549431|EXPERIMENTAL|Combo of Panobinostat and Carfilzomib|A cycle of therapy is 4 weeks (28 days in duration). Carfilzomib (with dexamethasone during cycle 1) will be administered intravenously infusion on days 1, 2 and 8, 9 and 15, 16 of every 28 day cycle. Panobinostat is administered orally three times per week.
62046439|NCT00491803|ACTIVE_COMPARATOR|1|Sildenafil 20mg
62046440|NCT00491803|ACTIVE_COMPARATOR|2|Sildenafil 40mg
62046441|NCT06078605|EXPERIMENTAL|Nicotinamide(Mitovita)|Group2 Baseline-6week: (Mitovita: 1.0 g/day, QD) 6-12week: (Mitovita: 2.0 g/day, BID) Crossover 12-18week: (Placebo: 1.0 g/day, QD) 18-24week: (Placebo: 2.0 g/day, BID)
62046442|NCT06078605|PLACEBO_COMPARATOR|Placebo|Group1 Baseline-6week: (Placebo: 1.0 g/day, QD) 6-12week: (Placebo: 2.0 g/day, BID) Crossover 12-18week: (Mitovita: 1.0 g/day, QD) 18-24week: (Mitovita: 2.0 g/day, BID)
62046443|NCT05698238|EXPERIMENTAL|Treatment arm|
62046444|NCT05071690||Arm 1|on breast milk 50 baby full-term and infant follow up for covid-19 symptoms and measurement of plasma DHA
62046445|NCT05071690||arm 2|50 baby depend on DHA source like infant formula milk or supplement with DHA
62046446|NCT04275700|EXPERIMENTAL|A-PRP|The cortex of each ovary will be injected with autologous platelet rich plasma.
62046447|NCT02414269|EXPERIMENTAL|modified T cells alone (without chemotherapy)|Following enrollment, leukapheresis product will be obtained in the blood donor facility at MSKCC and cryopreserved in the Cell Therapy and Cell Engineering Facility (CTCEF). Before protocol treatment, the leukapheresis product will be thawed, and T cell isolation, transduction, and expansion of iCasp928z T cells will be performed in the MSKCC CTCEF Facility. It is estimated that it will take approximately 3 to 6 weeks to generate T cells for treatment.
62046448|NCT02414269|EXPERIMENTAL|modified T cells with cyclophosphamide|Patients will receive cyclophosphamide intravenously (at 1.5 g/m\^2) , 2 - 7 (Day (-7) -(-2) days before T cell infusion. On Day 1 , patients will be admitted to the MSKCC Inpatient Service (if not already inpatients) for intravenous hydration, clinical monitoring, and blood work for immune monitoring. Standard MSKCC antiemetic therapy will be administered prior to chemotherapy to prevent nausea/vomiting. Administration of corticosteroids will be avoided as steroids may impede the efficacy of CAR T cells.
62046449|NCT02414269|EXPERIMENTAL|CAR T cell and pembrolizumab|Pembrolizumab 4 weeks (+3/-1 week window) after completing CAR T cell administration. Patients will receive 3 doses of pembrolizumab given on a recurring schedule followed by reassessment. Those responding or deriving clinical benefit, without unacceptable toxicity, will continue pembrolizumab. Patients will be followed weekly for the first four weeks. Patients in cohorts 9 and in Phase II will receive pembrolizumab 4 weeks(+3/- 1 week window) following CAR T cell administration.
62046450|NCT06313801|ACTIVE_COMPARATOR|Control group|FLOT: Docetaxel 50 mg/m2 intravenously on day 1 + Oxaliplatin 85 mg/m2 intravenously on day 1 + Calcium folinate 200 mg/m2 2-hour intravenous infusion on day 1 + fluorouracil 2600 mg/m2 x intravenous infusion 24-hours (infusion of the same of the total dose of fluorouracil for 48 hours) on day 1. Repeat every 2 weeks. 6 courses.
62046451|NCT06313801|EXPERIMENTAL|Study group|"mFLOT: Oxaliplatin 85 mg/m2 intravenously on day 1 + Calcium folinate 200 mg/m2 2-hour intravenous infusion on day 1 + fluorouracil 2600 mg/m2 x intravenous infusion 24-hours (infusion of the same of the total dose of fluorouracil for 48 hours) on day 1. Repeat every 2 weeks. 6 courses.~+ The drugs for PIPAC - Docetaxel 50 mg/ m2 diluted with saline sodium chloride to a total volume of 200 ml (intraperitoneal pressurized infusion)."
62046452|NCT05448300|ACTIVE_COMPARATOR|Water exchange|This group of participants receives water exchange colonoscopy with the computer-aided polyp detection system.
62046453|NCT05448300|ACTIVE_COMPARATOR|Air insufflation|This group of participants receives air insufflation colonoscopy the computer-aided polyp detection system.
62046454|NCT06296836|ACTIVE_COMPARATOR|Metformin continuation|Continuation of home metformin regimen during hospitalization to an internal medicine service
62046455|NCT06296836|NO_INTERVENTION|Metformin discontinuation|Holding home metformin regimen during hospitalization to an internal medicine service
62046456|NCT01290406|EXPERIMENTAL|BEZ235|
62046457|NCT01274182|EXPERIMENTAL|GP2013|
62046458|NCT01274182|ACTIVE_COMPARATOR|MabThera|
62046459|NCT01274182|ACTIVE_COMPARATOR|Rituxan|
62046460|NCT01391520|EXPERIMENTAL|CRMD001-Deferiprone|CRMD001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days
62046461|NCT01391520|PLACEBO_COMPARATOR|Placebo|3 placebo tablets matching the appearance of the experimental treatment arm (CRMD001) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
62046462|NCT00796250|EXPERIMENTAL|Group A|
62046463|NCT00796250|ACTIVE_COMPARATOR|Group B|
62046464|NCT01764087|EXPERIMENTAL|KX2-391 and Paclitaxel|"The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. 3 or 6 subjects with solid tumor per dose group will likely be necessary to determine the MTD of KX2-391 in combination with weekly paclitaxel. With paclitaxel dose fixed at 80 mg/m2/weekly, KX2-391 treatment will be started at 20 mg dose once daily (QD)~The phase II portion of this trial has a design to determine the efficacy of KX2-391 when administered in combination with paclitaxel in 20 subjects with stomach cancer and 20 subjects with breast cancer"
62248473|NCT02527525|NO_INTERVENTION|Usual Care|Participants randomized to usual care will participate in regular diabetes clinic visits and diabetes education, as they would have done without participation in this study.
62248474|NCT01682122||Newborns|Healthy newborns in Regular and Observation nurseries who are between 0-72 hrs of age. Infants with gestational age \> or = 35weeks and birth weight \> 2500g, who are hemodynamically stable, have no cardiorespiratory abnormalities and have no evidence of sepsis. If a blood culture was drawn due to the presence of maternal risk factors (e.g. maternal fever, prolonged rupture of membranes), patients will be included only if the blood culture result is negative and in case of intrapartum antibiotic treatment, ancillary blood tests (CBC with differential, CRP) are also within the normal range
62046465|NCT02269566|ACTIVE_COMPARATOR|Allergen extract|0.1 ml of allergen extracts
62046466|NCT02269566|PLACEBO_COMPARATOR|Placebo|Normal saline, 0.1 ml
62438503|NCT00439764|ACTIVE_COMPARATOR|2|Talk on back health and handout of The Back Book
62605779|NCT06135025|ACTIVE_COMPARATOR|TLM_group|the patients included receive a weekly phone call from the participating physician to to support self-management improvement, use of inhalation devices, rehabilitation, monitoring of signs/symptoms by treatment management, counseling, motivation, and prevention of exacerbations, early recognition of exacerbation signs and planify access to health care facility. at 1 month a Face to Face visit is planned at the pneumology clinic which also unifies the criteria for monitoring and treatment of respiratory disease. Whenever patients came to the emergency room (ER), they were evaluated by the Pneumologist in charge, ergo maintaining a similar approach in the assessment of ERs and deciding whether the patient should be admitted or discharged, independently of their group assignment.
62605780|NCT06135025|NO_INTERVENTION|STD_group|Patients in this group receive usual monitoring and treatment regimen is left to the discretion of the treating physicians. At inclusion, patients receive a phone call to collect data.at 1 month a Face to Face visit is planned at the pneumology clinic which also unifies the criteria for monitoring and treatment of respiratory disease. Whenever patients came to the emergency room (ER), they were evaluated by the Pneumologist in charge, ergo maintaining a similar approach in the assessment of ERs and deciding whether the patient should be admitted or discharged, independently of their group assignment.
62046467|NCT04040751|EXPERIMENTAL|CARE-CITE Carepartner|This study arm consists of carepartners receiving the CARE-CITE intervention. The CARE-CITE intervention will occur over 4 weeks in the dyad's home. The research interventionist will conduct two in-home visits (at orientation and during week 4), two phone call visits (at weeks 2 and 3), and one telephone follow up at week 8.
62046468|NCT04040751|ACTIVE_COMPARATOR|Control Carepartners|"Carepartners in this study arm receive customary care outpatient rehabilitation therapy but no CARE-CITE intervention. The carepartner will receive the same number of structured weekly phone calls and the booster call to answer any questions, assess helpfulness of the information and ascertain if there was any use of the web resources or social support groups."
62438504|NCT00439764|ACTIVE_COMPARATOR|3|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
62605781|NCT00013000|OTHER|Arm 1|
62605782|NCT06731634||One group will be assigned|The group will include people with smartphone addiction, who will receive a Finkelstein test for both dominant and non dominant hand, then the both hands grip and bench strength will be tested.
62605783|NCT05245734|EXPERIMENTAL|Main group|"Patients receive two prophylactic doses of the Human Anti-D (rh) immunoglobulin at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery. Patients receive the second dose only in the case of the birth of an Rh-positive child.~Before and after each injection of the drug, blood will be taken to control the level of anti-Rh0 (D) antibodies. after the last injection of the drug, blood samples are taken after 3 and 6 months to assess sensitization to the Rh antigen.~15 participants from the Main group are formed the Pharmacokinetics subgroup for additional blood samples taking, to determine the pharmacokinetic parameters"
62605784|NCT04446351|EXPERIMENTAL|Participants receiving GSK6097608 monotherapy (Arm A)|Participants will be administered an intravenous (IV) infusion of GSK6097608 every 3 weeks as monotherapy in escalating doses.
62605785|NCT04446351|EXPERIMENTAL|Participants receiving GSK6097608 plus dostarlimab (Arm B)|Participants will be administered IV infusion of GSK6097608 every 3 weeks in escalating doses followed by dostarlimab.
62828555|NCT03208829|EXPERIMENTAL|Group 1|Rehabilitation Exercises Group 1 will be submitted to an exercise protocol based on muscle strength training, with duration of 6 weeks and frequency of two weekly sessions, lasting 45 minutes.
62828556|NCT03208829|ACTIVE_COMPARATOR|Group 2|Postoperative guidance Group 2 will receive an orientation booklet and weekly links from researchers to address possible questions.
62828557|NCT06596707|EXPERIMENTAL|Zirconomer in Class II cavities|Zirconia modified glass ionomer restorative material
62248475|NCT04967781||"Group Severe"|"Each enrolled patient was allocated into control group Non-severe or case group Severe as per the disease severity which was defined according to the Chinese novel coronavirus pneumonia prevention and control guideline (version 6.0), severe and critical types were grouped into case group as Severe."
62605786|NCT04446351|EXPERIMENTAL|Participants receiving dostarlimab monotherapy (Arm D)|Participants will be administered an IV infusion of dostarlimab monotherapy (1 cohort will receive dostarlimab every 3 weeks and 1 cohort will receive dostarlimab every 6 weeks).
62605787|NCT04446351|EXPERIMENTAL|Participants receiving dostarlimab plus belrestotug (Arm E)|Participants will be administered IV infusions of dostarlimab followed by belrestotug, every 3 weeks.
62828558|NCT06596707|ACTIVE_COMPARATOR|Nanohybrid composite in Class II cavities|Conventionally used aesthetic restorations in class II
62828559|NCT02158546|EXPERIMENTAL|ALKS 5461|
62828560|NCT02158546|PLACEBO_COMPARATOR|Placebo|
62828561|NCT03469557|EXPERIMENTAL|Esophageal Squamous Cell Carcinoma (ESCC)|
62248476|NCT04967781||"Group Non-severe"|"Each enrolled patient was allocated into control group Non-severe or case group Severe as per the disease severity which was defined according to the Chinese novel coronavirus pneumonia prevention and control guideline (version 6.0), mild and moderate types were grouped into control group as Non-severe."
62248477|NCT00445484|EXPERIMENTAL|Group 1|Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
62438505|NCT04496089|EXPERIMENTAL|89Zr-girentuximab|A single administration of 37 Megabecquerel (MBq) (±10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab
62438506|NCT04035837|EXPERIMENTAL|short-course combination group|Nucleoside analogue is used during the first 3 months.
62605788|NCT04446351|EXPERIMENTAL|Participants receiving dostarlimab plus belrestotug plus GSK6097608 (Arm F)|Participants will be administered an IV infusion of dostarlimab followed by belrestotug followed by GSK6097608 every 3 weeks.
62605789|NCT04446351|EXPERIMENTAL|Participants receiving dostarlimab plus cobolimab (Arm G)|Participants will be administered an IV infusion of cobolimab followed by dostarlimab
62605790|NCT01237093|EXPERIMENTAL|1. Meat, no fish or soda|weight maintaining diet with meat but no fish or soda for 12 weeks
62828562|NCT03469557|EXPERIMENTAL|Gastric (GC) and Gastroesophageal Junction (GEJ) Carcinoma|
62438507|NCT04035837|EXPERIMENTAL|full-course combination group|Nucleoside analogue is used during all the course of study.
62438508|NCT04035837|EXPERIMENTAL|Monotherapy group|Only Peg-IFN is used during all the course of study.
62438509|NCT01853007|NO_INTERVENTION|Usual care|Patients in this arm will receive only the education offered by the transplant center, as required by Medicaid. Upon completion of all data collection activities, patients in this arm will be offered the program.
62605791|NCT01237093|EXPERIMENTAL|2. Meat and soda, no fish|weight maintaining diet with meat and soda but no fish for 12 weeks
62605792|NCT01237093|EXPERIMENTAL|4. Meat and fish and soda|weight maintaining diet with meat, fish, and soda for 12 weeks
62438510|NCT01853007|EXPERIMENTAL|COACH Program|Participants randomized to the intervention condition will attend a COACH session held in a small group format. The session provides information on living and deceased donor transplantation (i.e., the processes, risks and benefits) and on the key communication skills needed to effectively initiate and maintain conversations about transplantation.
62438511|NCT03673384|EXPERIMENTAL|experimental group|"Received infrared-C ray irradiation by hot compress with a powered heating compress and an eye mask for 40 minutes/time/day Treated regions: eyes and nose region, back region of head, shoulder neck and low back.~Received medical treatment, e.g., Xyzal Oral Product and Fluticasone Furoate."
62438512|NCT03673384|PLACEBO_COMPARATOR|Control group|received only medical treatment, e.g., Xyzal Oral Product and Fluticasone Furoate.
62438513|NCT00996528|EXPERIMENTAL|Philani Intervention Program|
62438514|NCT00996528|NO_INTERVENTION|Standard Care|No intervention during study. Referral to clinic-based health care that is delivered by the province. Offered intervention at end of study, i.e. after 18 months.
62605793|NCT01237093|EXPERIMENTAL|5. Fish, no meat or soda|weight maintaining diet with meat, fish, and soda for 12 weeks
62605794|NCT01237093|EXPERIMENTAL|6. Fish and soda, no meat|weight maintaining diet with fish and soda but no meat for 12 weeks
62605795|NCT01237093|EXPERIMENTAL|7. No meat, fish, or soda|no fish, and no soda (vegetarian) for 12 weeks
62605796|NCT01237093|EXPERIMENTAL|8. Soda, no meart or fish|weight maintaining diet with soda but no meat or fish (vegetarian + soda) for 12 weeks
62605797|NCT01237093|EXPERIMENTAL|Meat and fish, no soda|weight maintaining diet with meat and fish but no soda for 12 weeks
62438515|NCT00721682||Case|The CASE group will be composed of children for whom the medical team will have chosen to carry out a sign of alert of ill-treatment during his hospitalization and with no plausible cause of traumatism
62438516|NCT00721682||control|The Control group will be composed of children, consulting with the emergency care for traumatism, not having a sign of alarm and having a plausible cause of traumatism.
62438517|NCT01337154|EXPERIMENTAL|Tamibarotene|Subjects will receive tamibarotene, 6 mg/m2, divided as twice daily orally starting 1 week before chemotherapy and continuing through all 6 cycles and through the duration of the study. Chemotherapy will include paclitaxel (IV; 200 mg/m2) and carboplatin (IV; AUC=6)administered once every 3 weeks for up to 6 cycles.
62605798|NCT05940025|EXPERIMENTAL|MORT-LBP|Participants randomly assigned to this arm will use the app, MORT-LBP.
62438518|NCT01337154|PLACEBO_COMPARATOR|Placebo|Subjects will take an equal number of placebo tablets as the group receiving tamibarotene divided as twice daily orally, starting 1 week before chemotherapy and continuing through all 6 cycles and through the duration of the study. Paclitaxel (IV; 200 mg/m2) and carboplatin (IV; AUC=6) will be administered once every 3 weeks for up to 6 cycles.
62438519|NCT02241681|OTHER|Peptamen 1.5|500 mL of Peptamen 1.5
62438520|NCT03799978|EXPERIMENTAL|Treatment A: ACT-541468 50 mg under fasted conditions|Single oral dose administered on Day 1 under fasted conditions.
62438521|NCT03799978|EXPERIMENTAL|Treatment B: ACT-541468 50 mg under fed conditions|Single oral dose administered on Day 1 administered after food intake.
62605799|NCT05940025|ACTIVE_COMPARATOR|treatment as usual (TAU)|Participants randomly assigned to this arm will receive their TAU only (no use of the app, MORT-LBP).
62605800|NCT02672358|EXPERIMENTAL|Dabrafenib +Trametinib|Oral Dabrafenib plus Oral Trametinib
62828563|NCT03891407|EXPERIMENTAL|HIV Self-testing Group|Camp members will receive information about HIV self-testing from peer educators who will be nominated by you and other camp members in your camp. Camp members in the STEP project will receive pretest counseling and a 10 minute demonstration. They will receive 1 oral fluid HIV self-test kit to conduct the self-test at home or in a private location during the next 1 month and a phone number to call in case you need assistance when performing the self-test at home. They will also receive information about the nearest HIV Care and Treatment Center where they can seek a confirmatory HIV test and start HIV treatment in the event of a positive self-test result.
62828564|NCT03891407|NO_INTERVENTION|Non-intervention Group|Camp members will be encouraged to seek HIV testing at the clinics.
62828565|NCT03923166|EXPERIMENTAL|pyrotinib+ capecitabine|
62828566|NCT04271852|EXPERIMENTAL|UUI patients|50 UUI patients will have biofeedback treatment once a week.
62828567|NCT04271852|NO_INTERVENTION|Control|
62438522|NCT02987595|EXPERIMENTAL|Whole-grain rye then wheat|Whole-grain rye, high lignan Whole-grain rye products for 8 weeks, then a wash-out period of 8 weeks, and then whole-grain wheat products for 8 weeks
62438523|NCT02987595|EXPERIMENTAL|Whole-grain wheat then rye|Whole-grain wheat, low lignan Whole-grain wheat products for 8 weeks, then a wash-out period of 8 weeks, and then whole-grain rye products for 8 weeks
62438524|NCT00682383|OTHER|ARM 1|"Cisplatin 75 mg/m2 day 1 and 22~Etoposide 80mg/m2 days 1-3, 22-24~Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)~Filgrastim 5µg/kg\* SQ injection days 4-13 and days 25-34~Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles~Pegfilgrastim 6 mg SQ injection day 2 of each cycle"
62605801|NCT02311556|EXPERIMENTAL|DSC-PMR|DSC-PMR (dynamic susceptibility-weighted contrast- enhanced perfusion magnetic resonance imaging) at baseline (screening or time of radiosurgery) and after radiosurgery
62623475|NCT02190721|EXPERIMENTAL|tbo-filgrastim|Patients will receive subcutaneous doses of tbo-filgrastim 5 μg/kg body weight daily; each daily dose, to be administered at the investigative site
62438525|NCT02785172|EXPERIMENTAL|IDP-118 Lotion|Lotion
62438526|NCT02785172|ACTIVE_COMPARATOR|Ultravate Cream|Cream
62438527|NCT02785172|ACTIVE_COMPARATOR|IDP-118 Vehicle Lotion|Lotion
62438528|NCT02785172|ACTIVE_COMPARATOR|IDP-118 Vehicle Cream|Cream
62605802|NCT03851146|EXPERIMENTAL|LeY CAR T cells|"One arm study consisting of 3 + 3 dose escalation study design (see below) followed by dose expansion phase at determined MTD.~Dose level : Target Number LeY CART cells infused \*~-1 (if needed): 1 x 10e8~1. 2 x 10e8~2. 5 x 10e8~3. 1 x 10e9~4. 5 x 10e9~   * Targeted number of LeY CAR T cells (minus 40% acceptance range) for manufacture according toTGA-approved standard protocols~Treatment follows a lymphodepleting, chemotherapy regimen that consists of Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 consecutive days prior to cell infusion, with chemotherapy completed at least 48 hours before the re-infusion of the LeY CAR T cells."
62605803|NCT05564650|EXPERIMENTAL|Treatment (navitoclax, decitabine, venetoclax)|
62605804|NCT04629924|EXPERIMENTAL|sleeper one|"Topical anesthesia: to be applied during 1 to 2 minutes on a previously dried mucous membrane (Lidocaine Gingival Gel, Septodont).~Osteocentral anesthesia performed with the SleeperOne® 5 system (Dental Hi Tec) loaded with Articaine 1/200000 carpule."
62605805|NCT04629924|ACTIVE_COMPARATOR|conventional technique|"Topical anesthesia: to be applied during 1 to 2 minutes on a previously dried mucous membrane (Lidocaine Gingival Gel, Septodont).~Anaesthesia using a conventional technique, i.e. a metal syringe loaded with Articaine 1/200000 carpule."
62605806|NCT05910060||before protocol|patients between 5 and 18 years of age consulting the paediatric emergency department for ankle trauma, before protocol implementation.
62605807|NCT05910060||after protocol|patients between 5 and 18 years of age consulting the paediatric emergency department for ankle trauma, after the implementation of the protocol
62605808|NCT00629876|EXPERIMENTAL|Peginesatide|
62605809|NCT00248833|EXPERIMENTAL|1) 25ug Group B Meningococcal 44/76 MOS NOMV 5D w/o adjuvant|Subjects received 25ug Group B Meningococcal 44/76 MOS NOMV 5D without AI (OH)3 adjuvant intramuscularly at 0, 6, and 24 weeks.
62605810|NCT00248833|EXPERIMENTAL|2) 25ug Group B Meningococcal 44/76 MOS NOMV 5D with adjuvant|Subjects received 25ug Group B Meningococcal 44/76 MOS NOMV 5D with AI (OH)3 adjuvant intramuscularly at 0, 6, and 24 weeks.
62605811|NCT00248833|EXPERIMENTAL|3) 50ug Group B Meningococcal 44/76 MOS NOMV 5D w/o adjuvant|Subjects received 50ug Group B Meningococcal 44/76 MOS NOMV 5D without AI (OH)3 adjuvant intramuscularly at 0, 6, and 24 weeks.
62438529|NCT04076306|OTHER|iSTEP Feasibility Study Protocol|All participants will be asked to undergo the entire protocol: iSTEP exercise test, 10 metre incremental shuttle walk test, myometry, accelerometry and Haemophilia Joint Health Score.
62605812|NCT02460523|ACTIVE_COMPARATOR|conservative|"1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen ) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones.~1. Improvement: If the stone spontaneously passes to the duodenum and CBD is clear completely from the stones proved by US, the patient will undergo laparoscopic cholecystectomy (LC) within 3 days.~2. No improvement: the patient will undergo ERCP and then LC."
62605813|NCT02460523|ACTIVE_COMPARATOR|ERCP (endoscopic)|"2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.cholecystectomy (LC) within 3 days.~b- No improvement: the patient will undergo ERCP and then LC."
62605814|NCT05735912|EXPERIMENTAL|Endoscopic ultrasound-guided radiofrequency ablation|"Endoscopic ultrasound-guided radiofrequency ablation will be performed using the EUSRA system (Taewoong, Seoul, Korea). The system consists of a 19-gauge needle electrode (140-cm long), a radiofrequency current generator (VIVA RF generator; Taewoong), and an inner cooling system that circulates chilled saline solution during the radiofrequency ablation procedure. The inner metal part is insulated over its entire length, with the exception of the terminal 5 to 20mm for energy delivery. The needle electrode is attached to the radiofrequency current generator and to a cooling pump. The generator, in addition to providing radiofrequency current, allows the control of physical power and impedance parameters."
62605815|NCT05735912|ACTIVE_COMPARATOR|Surgery|Surgical resection will be performed in an inpatient setting. The type and extension of surgical resection, as well as need for lymphadenectomy, will be decided by the treating surgeons according to the tumor position, distance from the main pancreatic duct, and local expertise.
62605816|NCT05307796|EXPERIMENTAL|Semantic Feature Analysis plus metacognitive strategy training|Participants attend three treatment sessions per week for eight weeks. Treatment sessions include: strategy education (participants learn about anomia, circumlocution, and circumlocution's purpose), Semantic Feature Analysis plus strategy application (participants build self-awareness and practice circumlocution), and strategy debriefing (participants reflect and receive feedback on their performance, and generate scenarios in which they could use the strategy in everyday life).
62828568|NCT06380621|EXPERIMENTAL|Bilateral TEP group|Bilateral TEP repair
62828569|NCT06380621|ACTIVE_COMPARATOR|Unilateral TEP group|Unilateral TEP repair
62046469|NCT04040751|EXPERIMENTAL|CARE-CITE Stroke Survivor|This study arm consists of stroke survivors of carepartners receiving the CARE-CITE intervention. The CARE-CITE intervention will occur over 4 weeks in the dyad's home. The research interventionist will conduct two in-home visits (at orientation and during week 4), two phone call visits (at weeks 2 and 3), and one telephone follow up at week 8.
62046470|NCT04040751|ACTIVE_COMPARATOR|Control Stroke Survivors|"Stroke survivors in this study arm receive customary care outpatient rehabilitation therapy but no CARE-CITE intervention. Carepartners of the stroke survivors will receive the same number of structured weekly phone calls and the booster call to answer any questions, assess helpfulness of the information and ascertain if there was any use of the web resources or social support groups."
62046471|NCT00508430|EXPERIMENTAL|1|Low dose group
62438530|NCT06544213|EXPERIMENTAL|Control Group|Control group does not receive any countermeasure program during the head down tilt phase.
62438531|NCT06544213|EXPERIMENTAL|Artificial Gravity and Supine Bike|"The volunteers in this group receive countermeasure exercises during the head down tilt phase.~6 days over 7, they will perform a 30 minutes exercises on a supine bike (incremental steps) combined with artificial gravity generated with a short arm centrifuge."
62046472|NCT00508430|EXPERIMENTAL|2|Middle dose group
62046473|NCT00508430|EXPERIMENTAL|3|High dose group
62046474|NCT00508430|PLACEBO_COMPARATOR|4|
62046475|NCT05046054|ACTIVE_COMPARATOR|transcutaneous electrical nerve stimulation group|Transcutaneous electrical nerve stimulation was givent via two electrodes on the venous cannulation site 20 min before propofol injection
62438532|NCT06544213|EXPERIMENTAL|Supine Bike|"The volunteers in this group receive countermeasure exercises during the head down tilt phase.~6 days over 7, they will perform a 30 minutes exercises on a supine bike (incremental steps)."
62438533|NCT03535883||patients taking NOAC's|Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement and are taking Novel Oral Anti-Coagulants (NOAC).
62605817|NCT03180424|ACTIVE_COMPARATOR|L Carnitine + Exercise at home|Patients who will receive L Carnitine, in liquid form, at a dosage of 2g per day, in a single intake, in addition to physical exercise advice at home for which a manual will be delivered in the consultation, for 12 weeks.
62605818|NCT03180424|EXPERIMENTAL|L Carnitine + supervised exercise|Patients receiving L Carnitine, in liquid form, at doses of 2g per day, in a single intake, in addition to a supervised physical exercise plan, for 12 weeks.
62605819|NCT03180424|PLACEBO_COMPARATOR|Placebos + supervised exercise|Patients receiving placebo and supervised exercise plan.
62605820|NCT02707315|EXPERIMENTAL|A|"Chemotherapy:~Gemcitabine 1000 mg/m2 weekly x 3 on 28 day cycle~Radiation:~25 Gy over 5 fractions~Surgery:~surgical resection of pancreas~treatment plan:~1 cycle of chemotherapy, followed by stereotactic radiosurgery, followed by an additional 6 cycles of chemotherapy or surgical resection"
62605821|NCT00568139||Mitotane|Patients with adrenocortical carcinoma treated with mitotane monotherapy
62605822|NCT03678896|EXPERIMENTAL|CrewD Program approach|"The aim was to increase education about the disease by using narrative skills through the CrewD Program. The sessions were conducted by two group leaders: a health professional and a literature professor manager of creative writing groups.~Each session had a title, which parallels the classical structured educational approach (active comparator condition), which was known in advance by the subjects: a) Who I am in Diabetes?; b) Nutrition; c) The body where I live; d) Fears; e) Can attention change things?; and f) Roots.~Team leaders directed a discussion of different texts used in the sessions with the participants focusing on their feelings and on how the texts relate to themselves and to their diabetes. Patients were encouraged to participate and freely express their opinion."
62605823|NCT03678896|ACTIVE_COMPARATOR|Classical structured education|"Each session was 90 minutes long, with a similar internal structure in all of them. Each session included the following topics: a) Chronic Disease; b) Nutrition; c) Exercise; d) Complications; e) Self-management; and f) Diabetic foot. The sessions were held in a large room, in which the seats were arranged in circle. Every session was chaired by two healthcare providers, who worked as group leaders.~There was a different visual presentation in each session, with relevant theoretical information. A board with sheets of paper was available for use in the discussion along with brochures about the disease.~Patients were encouraged to actively participate and take part in group-problem solving. Group leaders guided the discussion by asking questions and encouraging the discussion."
62046476|NCT05046054|PLACEBO_COMPARATOR|control group|No transcutaneous electrical nerve stimulation was not given via two electrodes on the venous cannulation site 20 min before propofol injection
62046477|NCT05167266|EXPERIMENTAL|Cognitive psychoeducation|"1) The cognitive intervention is a 4-session, psycho-educative, integrative and multidimensional intervention designed to prevent post-acute cognitive symptoms. Each individual session will last 90' and will concern a specific cognitive domain:~* Cognition in covid, fatigue and sleep~* Working memory and attentional functioning~* Executive functioning~* Memory functioning~The structure of the sessions will be similar: (1) explanation about (dys)functioning of processes associated to the domain of interest: (2) identification of problems in daily life translated into functional objectives (e.g. keeping papers organized; scheduling activities to avoid fatigue); (3) discovery and application of (meta)cognitive strategies.~Material (videos, tips,...) will be provided that the patients can consult when needed. The patients will have a diary to complete to explain when they applied the content of the intervention in daily life, and how successful it was."
62248478|NCT00445484|EXPERIMENTAL|Group 2|Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
62248479|NCT00730964|OTHER|Phase 4|Open Label
62248480|NCT01919554|PLACEBO_COMPARATOR|Placebo Sub Lingual Immunotherapy Tablets (SLIT)|Placebo tablets Matching the HDM allergen extract Sub Lingual Immunotherapy Tablets
62438534|NCT03535883||patients not taking NOAC's|Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement who are not taking Novel Oral Anti-Coagulants (NOAC).
62248481|NCT01919554|EXPERIMENTAL|SLIT of HDM allergen extracts|Sublingual Immunotherapy Tablets of House Dust Mite allergen extracts
62248482|NCT02710136|EXPERIMENTAL|Glycerinated CR Allergenic Extract|"Complete Arm Title: Glycerinated German Cockroach Allergenic Extract.~Cockroach sensitive subjects are exposed to cockroach nasal allergen (NAC) intranasally at at increasing doses per protocol. The NAC aim is pursuit of optimal dose range as determined by tolerability and eliciting a threshold of nasal symptoms."
62248483|NCT03518138|EXPERIMENTAL|Group 1, study drug|65 patients treated with Q-122, 100 mg BID
62248484|NCT03518138|PLACEBO_COMPARATOR|Group 2, placebo|65 patients treated with placebo
62438535|NCT01263899|EXPERIMENTAL|SB1518|
62438536|NCT03428659||Sub-acute stroke|More than 1 week post-stroke Ischemic or hemorrhagic stroke
62438537|NCT04555525|EXPERIMENTAL|sarecycline|weight-based dose per label by mouth once daily for 12 weeks
62438538|NCT04555525|OTHER|Centrum Adult Multivitamin|one tablet by mouth daily for 12 weeks
62438539|NCT02815904|EXPERIMENTAL|Yakson touch and Kinesthetic stimulation|"Yakson touch (YT) The therapist will relax arms and shoulder muscles for 1 minute and will do deep breathing to accumulate Ki energy on the palms. The Therapist will apply Yakson on the neonate.~Kinesthetic stimulation (KS) For giving kinesthetic stimulation the neonate will be placed in supine position. There will be six passive flexion and extension movements. Each of the movement will each last for approximately 10 seconds. The movements will be performed in the following order -right arm, left arm, right leg, left leg, both legs simultaneously"
62449322|NCT00358384|PLACEBO_COMPARATOR|Subjects receiving treatment E|Eligible subjects will receive 0.1 percent betamethasone valerate ointment as steroid positive control.
62046478|NCT05167266|ACTIVE_COMPARATOR|Affective psychoeducation|"2) The affective intervention is also a psychoeducation program based on four sessions, in which different strategies and resources will be proposed to increase self-efficacy for emotion management:~* Recognizing emotions and affective states~* Accepting and communicating emotions and difficulties~* Accepting the uncertainty associated with difficulties~* Behavioural activation~Material (videos, tips,...) will be provided that the patients can consult when needed. The patients will have a diary to complete to explain when they applied the content of the intervention in daily life, and how successful it was."
62438540|NCT02815904|ACTIVE_COMPARATOR|Conventional Handling and KMC|"Conventional Handling (CH) The neonates in control group will receive developmental positioning(positioning of preterm infants for optimal physiological development) for 20 minutes per hour for 5 days.~Kangaroo mother care (KMC) Holding the neonate skin to skin by mother for one hour a day"
62438541|NCT01023269|OTHER|ON / OFF|Stimulation ON for 4 weeks, followed by stimulation OFF for 4 weeks.
62605824|NCT05941741|EXPERIMENTAL|Low-dose RT plus ICI|Patients will receive induction chemotherapy plus low-dose radiotherapy and immuce checkpoint inhibitor then followed by concurrent chemoradiotehrapy.
62438542|NCT01023269|OTHER|OFF / ON|Stimulation OFF for 4 weeks, followed by stimulation ON for 4 weeks.
62438543|NCT01332110|EXPERIMENTAL|Knee abduction moment-reducing footwear|Footwear that is known to decrease knee abduction moments of force in healthy subjects. May include orthotics, or footwear that allows relative movement between the heel section of the outsole and rest of the shoe.
62438544|NCT01332110|PLACEBO_COMPARATOR|Control footwear|Standard, off-the-shelf running shoes with no mechanical modifications.
62438545|NCT05778149|EXPERIMENTAL|Treatment|single arm,Treatment plan: Aumolertinib 110mg p.o QD; Anlotinib 12mg, oral for 2 weeks, three weeks a cycle, until disease progression.
62438546|NCT01109459|EXPERIMENTAL|Pediatric vision screening|intervention
62438547|NCT01109459|ACTIVE_COMPARATOR|Pediatric blood pressure screening|control
62438548|NCT01109459|NO_INTERVENTION|Primary care providers observation only|Observational
62438549|NCT05571761|EXPERIMENTAL|Study group|Refers to the experimental group that will receive the cognitive stimulation program intervention.
62438550|NCT05571761|OTHER|Waiting list control group|Will be the control group that remains without intervention until the study group completes the cognitive stimulation program and the subsequent neuropsychological assessment has been done. Once the intervention is completed with the study group, the same program will be applied to the control group.
62438551|NCT00979628|EXPERIMENTAL|Basal Plus Regimen|glargine subcutaneously once daily plus corrective doses of glulisine subcutaneously before meals and bedtime as needed
62438552|NCT00979628|EXPERIMENTAL|Basal Bolus|glargine subcutaneously once daily plus glulisine subcutaneously before meals (plus corrective doses of glulisine as needed)
62438553|NCT00979628|ACTIVE_COMPARATOR|sliding scale regular insulin (SSRI)|sliding scale regular insulin subcutaneously four-times daily in patients with T2DM admitted to general medicine and surgery wards.
62438554|NCT00857025|EXPERIMENTAL|Treatment (beta-glucan MM-10-001)|Patients receive oral beta-glucan MM-10-001 once or twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62438555|NCT03786289|EXPERIMENTAL|Recombinant human serum albumin/erythropoietin fusion protein|Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection
62438556|NCT03786289|ACTIVE_COMPARATOR|Recombinant human erythropoietin injection (CHO cells)|Recombinant erythropoietin injection (CHO cells) 10000IU single subcutaneous injection
62438557|NCT04611659|ACTIVE_COMPARATOR|Information Only|Women in both the control and treatment conditions will complete a baseline survey that includes the Mini-International Neuropsychiatric Interview (MINI),34 a contraceptive use survey,35 and the WHO Quality of Life-Brief (WHO-QOL-B).36 Women in the control group will be provided a color brochure with easy-to-read information about the advantages of LARC. Via this brochure, control group women will be provided no-cost options and corresponding referral information for receiving LARC.
62438558|NCT04611659|EXPERIMENTAL|Motivational Interviewing and Educational Training (MIET)|Women randomized to the treatment group will complete the baseline survey and receive the same brochure; however, they also will receive structured education regarding unintended pregnancies among women using opioids, potential complications associated with opioid, alcohol, and other drug use, and education on contraceptive use (with an emphasis on LARC). This structured education will be coupled with a brief, initial MI conversation. The interventionist will receive respective patients' MINI for opioids,37 contraceptive survey, and WHO-QOL-B from the research coordinator, and the answers to the survey forms will expedite the conversation around each woman's contraceptive desires.
62438559|NCT00549198|EXPERIMENTAL|ABC/3TC + EFV|
62438560|NCT00549198|ACTIVE_COMPARATOR|TDF/FTC + EFV|
62438561|NCT00929903|EXPERIMENTAL|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62438562|NCT05555082|EXPERIMENTAL|Massage|30 minutes of classical swedish massage given by a certified masseur 10 times monthly during 12 months
62438563|NCT05063019|EXPERIMENTAL|Magnetic resonance imaging and enterography following computed tomography|Magnetic resonance imaging and enterography will be performed after computed tomography but before surgery.
62605825|NCT05941741|ACTIVE_COMPARATOR|IC+CCRT|Patients will receive induction chemotherapy plus concurrent chemoradiotehrapy.
62605826|NCT04604405|EXPERIMENTAL|photobiomodulation|Eyes are irradiated with 650nm low energy red light
62605827|NCT04604405|NO_INTERVENTION|blank|no intervention except for wear glasses
62605828|NCT06133946||Combined screening|All newborns underwent combined hearing and genetic screening.
62438564|NCT03686800|EXPERIMENTAL|Rivelin® plain patches|This is an open label study with the objectives to establish information on adhesion time, tolerability and usability of Rivelin® plain patches when applied to VLS lesions. Furthermore, the design of the Rivelin® plain patch will also be evaluated.
62438565|NCT01066481|EXPERIMENTAL|PF-01913539 5 mg three times daily|PF-01913539 5 mg three times daily for 6 months
62046479|NCT06405503||English as primary language|
62046480|NCT06405503||Non-English as primary language|
62046481|NCT03851796|ACTIVE_COMPARATOR|TEENS+Parents as Coaches|"Parents are taught strategies to support and facilitate child weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on strategies to facilitate healthy weight management in their child(ren). Topics include role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen. They receive personalized feedback throughout the program.~All adolescents participate in a group-based empirically supported behavioral weight management treatment, that includes dietary and physical activity goals, and instructions to self-monitor key information. Adolescents will receive training in core behavioral weight loss strategies (e.g. goal setting, stimulus control) and techniques to help them achieve these goals. They also receive personalized feedback throughout the program."
62046482|NCT03851796|ACTIVE_COMPARATOR|TEENS+Parent Weight Loss|"Parents are given a weight loss goal of 1-2 lbs/week, and specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents receive training in core behavioral weight loss strategies (e.g. goal setting, stimulus control) and techniques to help them achieve these goals. They also receive personalized feedback throughout the program.~All adolescents participate in a group-based empirically supported behavioral weight management treatment, that includes dietary and physical activity goals, and instructions to self-monitor key information. Adolescents receive training in core behavioral weight loss strategies (e.g. goal setting, stimulus control) and techniques to help them achieve these goals. They also receive personalized feedback throughout the program."
62046483|NCT02219984||patients anticoagulated|
62046484|NCT01457911|EXPERIMENTAL|AMARYL M (Glimepiride and Metformin hydrochloride combination)|AMARYL M at a dosage regimen from 1 tablet to 6 tablets, once during a meal or twice during a meal
62046485|NCT01457911|ACTIVE_COMPARATOR|AMARYL (Glimepiride)|AMARYL at a dosage regimen from 1 mg to 6 mg, once during a meal or twice during a meal
62438566|NCT01066481|EXPERIMENTAL|PF-01913539 20 mg three times daily|PF-01913539 20 mg three times daily for 6 months
62605829|NCT03897114|EXPERIMENTAL|Cocoa group|The cocoa will be provided in sachets. The intervention will be carried out for 10 weeks. Cocoa is provided in a single daily dose of 5 g, which contains 83 mg of flavonoids per gram of cocoa (dose at which a prebiotic effect has been shown).
62438567|NCT01066481|PLACEBO_COMPARATOR|Placebo|Placebo three times daily for 6 months
62828570|NCT05127733|EXPERIMENTAL|Online Cogntivie Behavioural Therapy|"Breaking Free Online (BFO) is an online intervention, supporting adults struggling with substance use. It provides psychoeducation and skills building exercises in CBT and compatible approaches. The intervention strategies contained within BFO are provided via a six-domain biopsychosocial model used in CBT. Each domain of the model corresponds to a module in the BFO program which contains psychoeducation and an 'action' strategy to facilitate behaviour change. Data captured at the baseline assessment is used by the program to provide feedback to the individual on their levels of functioning across the six domains. The program then guides the user to concentrate on intervention strategies for domains with the greatest level of impairment.~All groups will receive 'clinical monitoring,' including biweekly study assessments during the acute treatment period and monthly assessments during the six month follow-up period."
62828571|NCT05127733|EXPERIMENTAL|Online Cognitive Behavioural Therapy Plus Individual Peer Support|"BFO delivered with peer support will comprise BFO with at least weekly contact with a peer with lived experience. Peer support workers will receive training on how to facilitate participant engagement with and progress through the BFO program, as well as a weekly session plan. As part of this training, peer support workers will be given their own access code to use BFO and be encouraged to use the program. Session One constitutes an initial orienting to the program. Subsequent sessions review each information and action strategy in the BFO program, with a series of prompts to guide peer support of this content.~All groups will receive 'clinical monitoring,' including biweekly study assessments during the acute treatment period and monthly assessments during the six month follow-up period."
62828572|NCT05127733|ACTIVE_COMPARATOR|Group Peer Support|"The control condition will consist of group peer support facilitated by trained peers and offered through the Community Addictions Peer Support Association (CAPSA). The group meets weekly and will offer participants a space to share their experiences and receive support.~All groups will receive 'clinical monitoring,' including biweekly study assessments during the acute treatment period and monthly assessments during the six month follow-up period."
62828573|NCT00999102|EXPERIMENTAL|Nebivolol, followed by Metoprolol|Participants first received Nebivolol at a dose of 5 mg daily for 4 weeks, followed by 10 mg daily for another 4 weeks (i.e., weeks 1-8 in total). The participants then received Metoprolol at a dose of 50 mg daily for 4 weeks, followed by 100 mg daily for another 4 weeks (i.e., weeks 9-16 in total).
62438568|NCT01637311|EXPERIMENTAL|Failed HM|Patients were eligible for enrollment in the study if they were age greater than 18 years and had recurrence/persistence of symptoms after primary HM with an Eckardt symptom score ≥ 4.
62438569|NCT02972411|EXPERIMENTAL|Intervention|Voluntary increase in respiration
62438570|NCT02972411|ACTIVE_COMPARATOR|Acetazolamide|Administration of Acetazolamide 125mg. since 24 hours before ascent and until 48 hours post altitude exposure, and absence of altitude sickness symptoms
62828574|NCT00999102|EXPERIMENTAL|Metoprolol, followed by Nebivolol|Participants first received Metoprolol at a dose of 50 mg daily for 4 weeks, followed by 100 mg daily for another 4 weeks (i.e., weeks 1-8 in total). The participants then received Nebivolol at a dose of 5 mg daily for 4 weeks, followed by 10 mg daily for another 4 weeks (i.e., weeks 9-16 in total)
62828575|NCT03193957|EXPERIMENTAL|SB4|SB4 (etanercept) 50 mg/mL
62828576|NCT06070883|OTHER|Amniotic membrane|Amniotic membrane (AM) is the innermost layer of the placenta, which consists of a single layer of meta-bolically active epithelium, a thick basement membrane, and an avascular stromal matrix.It has been shown to exhibit a wide array of biological properties, including wound healing, anti-inflammatory, antimicrobial, and anti-angiogenic properties, amongst others
62828577|NCT06331936|EXPERIMENTAL|Intervention arm|The intervention arm aims at improving children's emotional regulation skills.
62605830|NCT03897114|PLACEBO_COMPARATOR|Placebo group|Maltodextrin will be supplied as a placebo, which will be provided in sachets. Athletes will take 5g of product per day.
62046486|NCT05895136|EXPERIMENTAL|Enoxaparin plus human albumin|Cohort 1 will receive standard medical treatment plus a combinatorial therapy of enoxaparin and human Albumin.
62046487|NCT05895136|ACTIVE_COMPARATOR|Standard medical treatment|Cohort 2 (control) will receive only standard medical treatment.
62605831|NCT00564044|ACTIVE_COMPARATOR|2|
62828578|NCT06331936|NO_INTERVENTION|Control Arm|The control arm participants will not receive any interventions.
62438571|NCT02880072|EXPERIMENTAL|refeeding syndrome|6 patients with head and neck cancer and refeeding syndrome, 4 different of preparations of phosphate orally
62828579|NCT06003972|ACTIVE_COMPARATOR|Control|This arm serves as the control arm, patients allocated receive guideline directed medical therapy only
62438572|NCT02880072|EXPERIMENTAL|no refeeding syndrome|6 patients with head and neck cancer without refeeding syndrome, 4 different of preparations of phosphate orally
62828580|NCT06003972|EXPERIMENTAL|Copaxone arm|Patients receive guideline directed medical therapy with an add-on GA therapy for 14 days
62828581|NCT04624126|EXPERIMENTAL|3D-Erect arm|Participants will be asked to use the 3D-printed penile device during their intercourse with partners.
62828582|NCT04400643|EXPERIMENTAL|INTELLiVENT-ASV|INTELLiVENT-ASV is a software accessory that automatically adjusts ventilation and oxygenation variables to keep the patient within clinician-set target ranges, from intubation until extubation.
62828583|NCT04400643|ACTIVE_COMPARATOR|Non-Automated ventilation|In conventional ventilation modes, clinicians adjust and modify the oxygenation and ventilation parameters manually.
62828584|NCT06592157||Patients using New Epi epidermal growth factor|Patients using New Epi epidermal growth factor who are over 18 years old, confirmed to require fistula surgery, without significant surgical contraindications, able to understand and willing to participate in the study, and willing to sign the informed consent form.
62828585|NCT06592157||Patients receiving standard wound care|Patients receiving standard wound care who are over 18 years old, confirmed to require fistula surgery, without significant surgical contraindications, able to understand and willing to participate in the study, and willing to sign the informed consent form.
62046488|NCT03953235|EXPERIMENTAL|Phase 1|"* GRT-C903~* GRT-R904~* nivolumab~* ipilimumab"
62248485|NCT06417918|EXPERIMENTAL|Intervention: Tuko Pamoja|The intervention, Tuko Pamoja, is in-home family counseling delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices including family systems and solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. The content and structure has been adapted based on formative research in this context. Tuko Pamoja is manualized and includes a tablet-based manual material and video content to support psychoeducation components and data collection.
62438573|NCT04532541||Patients with childhood onset SLE|Participants in this group were derived from patients diagnosed with SLE at an age of less than 18 years old, and these patients were hospitalized in our center. Peripheral blood was collected from the patient and their biological parents for gene analysis to obtain the overall incidence of monogenic lupus in the cohort.
62605832|NCT01821209|NO_INTERVENTION|Control|Standard robot assisted radical prostatectomy
62605833|NCT01821209|EXPERIMENTAL|Sling|Placement of sling at time of robot assisted radical prostatectomy
62828586|NCT00907335|EXPERIMENTAL|Retin-A Micro|Retin-A Micro 0.04% facial acne treatment used once daily
62828587|NCT00907335|PLACEBO_COMPARATOR|Vehicle Control|Color matched facial gel vehicle control used once daily
62828588|NCT04789070|ACTIVE_COMPARATOR|Sirolimus|2mg capsules once daily
62828589|NCT04789070|PLACEBO_COMPARATOR|Placebo|2mg capsules once daily
62438574|NCT05334654|ACTIVE_COMPARATOR|Enoxaparin sodium|Enoxaparin sodium twice daily, according to the renal function and clinical indication
62605834|NCT04850573|EXPERIMENTAL|EAA|Participants in this arm will take part in eight weekly thirty minute sessions of equine facilitated learning where they interact with a horse and learn basic horsemanship skills.
62605835|NCT04850573|NO_INTERVENTION|Control|
62605836|NCT00432796|ACTIVE_COMPARATOR|1|"patients are randomized post-operative to receive either active treatment or placebo.~Active treatment is Dalteparin injectable. Patients randomized to active treatment will receive Dalteparin 5,000 iu or 200 iu/kg once daily depending on the type of surgery they have had."
62605837|NCT00432796|EXPERIMENTAL|2|patients will be randomized post-operative to receive either active treatment or placebo
62605838|NCT05526222|EXPERIMENTAL|Jaktinib low dose|Low dose
62605839|NCT05526222|EXPERIMENTAL|Jaktinib high dose|High dose
62605840|NCT05526222|PLACEBO_COMPARATOR|Placebo|Placebo
62605841|NCT03662113|EXPERIMENTAL|Experimental: Domperidone|5ml domperidone prior to VCE
62605842|NCT03662113|OTHER|Control: water|5ml warm water prior to VCE
62605843|NCT04934176||Group 1|Group 1 will have had a muscle transfer driven by the trigeminal nerve (nV).
62605844|NCT04934176||Group 2|Group 2 will have had a muscle transfer driven by a cross-face nerve graft (nVII).
62605845|NCT04934176||Group 3|Group 3 will have had a muscle transfer driven by dual innervation using both the trigeminal and cross-face nerve graft.
62828590|NCT06514950|EXPERIMENTAL|Ujjayi yogic breathing training|This study will be a small (N = 20) prospective cohort study with a single unblinded intervention of Ujjayi resistance breathing.
62828591|NCT05311709|EXPERIMENTAL|Sotorasib|Single arm trial. All patients will be included in this interventional arm.
62828592|NCT06016309||Phase 1|"In Phase 1 of the study, we aim to include a minimum of 300 patients to identify how often which CEBA symptoms occur among pwMS and which symptoms cluster together, forming CEBA profiles. In addition, in Phase 1, an on age and education level matched group of 100 Healthy controls will be included to allow comparison of performance-based measures.~In Phase 2 of the study, we aim to include a minimum of 100 patients, after approximately two years, to investigate whether we can replicate the results of Phase 1, validating the different CEBA profiles."
62605846|NCT04934176||Group 4|Group 4 will have had manipulations that involve performing direct coaptation between the trigeminal nerve and a branch to the native zygomaticus major muscle (5-7 transfer) and selective neurolysis in which several facial nerve branches that innervate muscles antagonistic to the smile animation.
62605847|NCT04673656|PLACEBO_COMPARATOR|Test Group 1|Group 1 will receive 84 days of placebo BID
62828593|NCT06016309||Retest Phase 1|After a year, a retest of around 50 patients will take place in order to determine whether CEBA symptoms are stable over time which is important information in deciding whether CEBA profiles can be used as a guide for further care.
62828594|NCT04764071|ACTIVE_COMPARATOR|percutaneous nephrolithotomy|Patients are positioned in the lithotomy position and a 6F ureteral catheter is placed and the bladder is drained with a 16F urethral Foley catheter. After ureteral catheterization, patients are placed in the prone position, and percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 30F. Pneumatic lithotripter is used for fragmentation and stone removal is accomplished with retrieval graspers through a rigid 22F nephroscope. An 18-24 F nephrostomy tube is placed at the end of the operation.
62828595|NCT04764071|EXPERIMENTAL|ultra-mini percutaneous nephrolithotomy|Patients are positioned in the lithotomy position and a 6 F ureteral catheter is placed and the bladder is drained with a 16F urethral Foley catheter. After ureteral catheterization, patients are placed in the prone position, and percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 12-14 F fascial dilator was used to dilate the nephrostomy tract to pass the 13 F semi-rigid plastic sheath. Then, a 9.5-F, rigid ureteroscope (KARL STORZ Medical Instruments) was introduced to the sheath. The renal stones were broken into pieces using holmium laser lithotripsy. Finally, the ureteroscope and sheath were removed and the tract site was packed for 2-3 min. then placement of double J stent will be done according to the decision of the operating surgeon for 3 to 4 weeks.
62828596|NCT06544824||Healthy subjects|This group includes healthy subjects over 4 years of age; with the ability to walk independently without walking aids and/or orthoses.
62828597|NCT06544824||Subjects with a diagnosis of cerebral palsy and right hemiplegia|This group includes subjects with a diagnosis of cerebral palsy and right hemiplegia over 4 years of age; with the ability to walk independently without walking aids and/or orthoses.
62828598|NCT06544824||Subjects with a diagnosis of cerebral palsy and left hemiplegia|This group includes subjects with a diagnosis of cerebral palsy and left hemiplegia over 4 years of age; with the ability to walk independently without walking aids and/or orthoses.
62046489|NCT03953235|EXPERIMENTAL|Phase 2|"* GRT-C903~* GRT-R904~* nivolumab~* ipilimumab~Phase 2 for some patients includes a monthly or every two month treatment schedule"
62046490|NCT00111670|EXPERIMENTAL|1|
62046491|NCT00111670|EXPERIMENTAL|2|
62438575|NCT05334654|EXPERIMENTAL|Bivalirudin|Bivalirudin will be administered by continuous infusion, until day 7. Bivalirudin will be administered at dosage of 0,25 mg/kg in first 30 minutes, followed by continuous infusion of 0,2 mg/kg/h until 7 days. The infusion rate will be adjusted targeting a prothrombin time ratio of about 1.5.
62438576|NCT00819650|EXPERIMENTAL|Licartin|patients who receive Licartin therapy after liver resection
62438577|NCT00819650|NO_INTERVENTION|placebo|control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive Licartin therapy after liver resection
62438578|NCT02139306|EXPERIMENTAL|Ataluren (PTC124®)|Participants received ataluren as oral powder for suspension at the dosages of 10, 10, and 20-mg/kg at morning, midday and evening, respectively for 48 weeks of treatment duration or until treatment discontinuation.
62438579|NCT02139306|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo orally at morning, midday and evening for 48 weeks of treatment duration or until treatment discontinuation.
62438580|NCT03124485|EXPERIMENTAL|Endoscopic Sleeve Gastroplasty|A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava\[29\] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
62449323|NCT00358384|PLACEBO_COMPARATOR|Subjects receiving treatment F|Eligible subjects will receive 0.005 percent calcipotriol ointment as vitamin D agonist positive control.
62449324|NCT01412541|EXPERIMENTAL|Moxy Drug Coated Balloon|Paclitaxel coated balloon catheter
62449325|NCT01412541|ACTIVE_COMPARATOR|Standard Uncoated Angioplasty Balloon|PTA Catheter
62605848|NCT04673656|ACTIVE_COMPARATOR|Test Group 2|Group 2 will receive 84 days of 0.5 g of BKR-017 BID
62046492|NCT00111670|EXPERIMENTAL|3|
62046493|NCT00111670|EXPERIMENTAL|4|
62046494|NCT00111670|PLACEBO_COMPARATOR|5|
62046495|NCT06525194|EXPERIMENTAL|Educational Intervention Group|Participants in this group included undergraduate healthcare students from the faculties of dentistry, medicine, and health sciences at a higher education institution in Turkey. The group underwent an interprofessional education (IPE) program designed based on the ARCS-V motivational design model. The program consisted of three sessions and was delivered in a hybrid format, incorporating both online and face-to-face elements. Various tactics and strategies from the motivational model were used throughout the training process. The Readiness for Interprofessional Learning Scale (RIPLS) and the ARCS-V Motivation Scale were administered to assess the students' readiness for interprofessional education and the program's effectiveness. The educational content included scenarios, multimedia elements, messages, emails, reflection assignments, and group tasks, which aimed to enhance students' motivation, interest, and overall learning experience.
62046496|NCT00466882||Inamed Lap-Band System|The LAPBAND is positioned laparoscopically around the stomach and requires an overnight hospitalization and an upper GI swallow the next morning. The device can be gradually adjusted to increase stomach constriction by the physician in an office setting so that the patient loses approximately 1-2 pounds per week over two years.
62046497|NCT02200796|EXPERIMENTAL|Low Protein Meal|Low Protein Test Meal (15 g)
62438581|NCT03124485|ACTIVE_COMPARATOR|Laparoscopic Sleeve Gastrectomy|Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
62046498|NCT02200796|EXPERIMENTAL|Moderate Protein Meal|Moderate Protein Meal (30 g)
62046499|NCT02200796|EXPERIMENTAL|High Protein Meal|High Protein Meal (45g)
62248486|NCT06417918|NO_INTERVENTION|Control|Waitlist control (will receive the in-home counseling after the final data collection point)
62248487|NCT05109286|EXPERIMENTAL|CrossFit training|CrossFit training twice a week.
62248488|NCT05109286|NO_INTERVENTION|Control arm|Exercise according to their ideas.
62248489|NCT02237781|EXPERIMENTAL|AMH levels|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists. Levels of AMH will be measured prior and during the ovarian stimulation.
62438582|NCT01548469|ACTIVE_COMPARATOR|Perio Total Care toothpaste|A Group which use Perio Total Care toothpaste during participation.
62438583|NCT01548469|EXPERIMENTAL|Bio Mineral toothpaste|A Group which use Bio Mineral toothpaste during participation.
62438584|NCT06066385|EXPERIMENTAL|Small bites suturing technique of the abdominal wall during midline laparotomy|In the experimental group of 288 patients the small bites technique was applied with bite widths of 0,5 cm and inter suture spacing of 0,5 cm with the use of PDS plus ll 2-0 single suture material with a 31 mm needle placed in the linea alba. In the small bites technique, twice as many stitches will be placed per sutured cm, with a smaller needle and thinner suture material.
62438585|NCT06066385|ACTIVE_COMPARATOR|Large bites suturing technique of the abdominal wall during midline laparotomy|As control the conventional large bites technique (mass closure) was applied with bites widths of 1 cm and inter-suture spacing of 1 cm with the use of PDS plus ll 1-0 double loop suture material with a 48 mm needle.
62438586|NCT01832090|EXPERIMENTAL|Radiesse® Injectable Dermal Filler|Device: Radiesse Dermal Filler mixed with 2% lidocaine-HCl (final concentration: 0.3% lidocaine-HCl)
62438587|NCT01832090|ACTIVE_COMPARATOR|Delayed Treatment|Untreated controls crossed over to treatment with Radiesse Dermal Filler mixed with 2% lidocaine-HCl (final concentration: 0.3% lidocaine) at 3 months
62449326|NCT04480203|ACTIVE_COMPARATOR|Cognitive based stress management (CBSM)|Cognitive based digital intervention.
62828599|NCT06544824||Subjects with a diagnosis of spastic paraparesis|TThis group includes subjects with a diagnosis of spastic paraparesis over 4 years of age; with the ability to walk independently without walking aids and/or orthoses.
62828600|NCT04902976|ACTIVE_COMPARATOR|CPC+Zn|patients submitted to mouth rinse with 0.075% Cetylpyridinium Chloride associated with 0.28% zinc lactate solution.
62046500|NCT02200796|EXPERIMENTAL|Control Meal|High Carbohydrate Control Meal (7 g of protein)
62046501|NCT05303779|EXPERIMENTAL|experimental group|experimental group will receive eye exercises in addition to medication and eye glasses post strabismus surgery
62046502|NCT05303779|ACTIVE_COMPARATOR|control group|control group will receive medication and eye glasses post strabismus surgery
62046503|NCT04963127||Prospective Cohort|400 patients who are scheduled to undergo a clinically requested CT scan of parts of the skeleton using a Dual-Energy/Multi-Energy/Spectral acquisition mode to exclude or further define bone fractures.
62046504|NCT04963127||Retrospective Cohort|400 patients who had undergone a clinically requested CT scan of the skeleton in standard acquisition mode in the past to exclude or further define bone fractures.
62248490|NCT02087072||Recently discharged homebound patients|
62248491|NCT06047847|EXPERIMENTAL|TOTUM-448|"10 healthy men will consume an acute intake of 4.284g of TOTUM-448 on three separate occasions.~Phase 1: once per galenic form (capsule and powder). Phase 2: once (capsule only)."
62046505|NCT01741519|EXPERIMENTAL|LDLL600|Landiolol hydrochloride, intravenous infusion of 10, 20 and 40 µg/kg/min for 2 h each followed by 18 h long-term infusion of best tolerated dose.
62046506|NCT01741519|ACTIVE_COMPARATOR|Brevibloc|Esmolol, intravenous infusion of 50, 100 and 200 µg/kg/min for 2 h each followed by 18 h long-term infusion of best tolerated dose.
62046507|NCT06393621|EXPERIMENTAL|KEFPEP®|"1. Dosage form: Powder (directly take the powder with appropriate amount of warm water)~2. Dose(s): Total 2.8 g kefir-fermented milk powder with increased peptide content 1.2 g."
62046508|NCT06393621|PLACEBO_COMPARATOR|Placebo|"1. Dosage form: Powder (directly take the powder with appropriate amount of warm water).~2. Dose(s): Total 2.8 g starch power."
62046509|NCT00705133|EXPERIMENTAL|Treprostinil-treated|Patients with pulmonary fibrosis with an advanced pulmonary hypertension phenotype will be treated with parenteral treprostinil in an open-label fashion
62046510|NCT06400550||13C-glucose infusion|Tumor samples of patients who receive the optional 13C-glucose infusion will be studied using flux analysis and metabolomic profiling.
62046511|NCT06400550||No 13C-glucose infusion|Tumor samples of patients who do not receive the optional 13C-glucose infusion will be studied using metabolomic profiling alone.
62248492|NCT02825004|EXPERIMENTAL|Psychological Intervention|All the professionals workers involved in the experimental group will attend three intensive psychological meetings about emotional exhaustion, depersonalisation, low personal accomplishment and how to improve coping skills.
62046512|NCT03105674|ACTIVE_COMPARATOR|Standard Therapy|Patients will receive a combination of Marcaine and Lidocaine injection (standard local anesthetics) as a part of their peri-anal block prior to the surgery.
62248493|NCT02825004|NO_INTERVENTION|Control Group|There is not any intervention.
62248494|NCT05031754||Infants with atopic dermatitis|Infants with atopic dermatitis
62248495|NCT05031754||Infants without atopic dermatitis|Infants without atopic dermatitis
62248496|NCT04179747|EXPERIMENTAL|Group A|The cognitive behavior psychotherapy was administered to participants in this treatment arm.
62248497|NCT04179747|ACTIVE_COMPARATOR|Control Group|This group received the administration of pharmacotherapy (PDE5i) for treatment of Erectile Dysfunction.
62248498|NCT06301672|EXPERIMENTAL|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition. The observation group receives Intermittent Oro-esophageal Tube Feeding for enteral nutrition support
62248499|NCT06301672|ACTIVE_COMPARATOR|Nasogastric Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition.The control group receives nasogastric tube for enteral nutrition support
62438588|NCT05777265|EXPERIMENTAL|Training Group|CT will be applied to the participants, taking into account the recommendations of the American College of Sports Medicine (ACSM), 3 days a week, an average of 40 minutes a day, for a total of 16 weeks
62438589|NCT04632420||Women with child birth|Women attending chronic pain clinic who have previously experienced childbirth
62438590|NCT04632420||Women without childbirth|Women attending chronic pain clinic who have not previously experienced childbirth
62438591|NCT00248339|ACTIVE_COMPARATOR|1|PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin \~13.3 mg/kg QD
62438592|NCT00248339|ACTIVE_COMPARATOR|2|PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
62438593|NCT00248339|ACTIVE_COMPARATOR|3|PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
62438594|NCT06365827||AMI vs. non-AMI|AMI, those with a acute mesenteric ischemia vs. non-AMI, those without a condition
62438595|NCT01873768|ACTIVE_COMPARATOR|Tranexamic acid (TXA)|1g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 50ml of saline will be infused over 30 minutes beginning at the time of wound closure.
62438596|NCT01873768|ACTIVE_COMPARATOR|ε-Aminocaproic Acid (EACA)|7g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 50ml saline will be infused over 30 minutes beginning at the time of wound closure.
62046513|NCT03105674|EXPERIMENTAL|Multi-drug local anaesthetics|"Patients will receive a combination \[Multi-drug local anesthetics (Combination)\] of following drugs as a part of their peri-anal block prior to the surgery (multi-drug local anesthetics)~1. Ropivacaine 0.5% - 30 ml~2. Ketorolac 30mg/ml - 1 ml~3. Kenalog 10 mg/ml - 5 ml~4. Lidocaine 1% with Epinephrine 1:100,000 - 20ml"
62046514|NCT02964416|EXPERIMENTAL|Tramadol|Injection Tramadol 100mg diluted in 10 cc syringe (10mg/ml) to be given as 1mg/kg or (1ml/10kg) via intravenous route, once, at the time of dura closure
62046515|NCT02964416|PLACEBO_COMPARATOR|Placebo|0.9% Normal saline in 10 cc syringe,1ml/10kg via intravenous route, once at the time of dura closure
62046516|NCT01552590|ACTIVE_COMPARATOR|Tolvaptan|Tablet, QD, 2 weeks
62046517|NCT01552590|PLACEBO_COMPARATOR|Placebo|Tablet, QD, 2 weeks
62248500|NCT00298025|EXPERIMENTAL|Cetrotide®|
62248501|NCT00298025|ACTIVE_COMPARATOR|Antagon ™|
62438597|NCT05232578|EXPERIMENTAL|Arm A- early salvage radiotherapy (eSRT)|Early salvage radiotherapy (eSRT) will be administered immediately after the confirmation of the biochemical relapse (prostate-specific antigen PSA level increase to ≈ 0,2 ng/ml) after radical prostatectomy with defined risk factors and no clinical recurrence signs on prostate specific membrane antigen positron emission tomography and computed tomography (PSMA PET/CT).
62449327|NCT04480203|ACTIVE_COMPARATOR|Mindfulness based intervention (MBI)|Mindfulness based digital intervention.
62605849|NCT04673656|ACTIVE_COMPARATOR|Test Group 3|Group 3 will receive 84 days of 1.0 g of BKR-017 BID
62605850|NCT04673656|ACTIVE_COMPARATOR|Test Group 4|Group 4 will receive 84 days of 1.5 g of BKR-017 BID
62046518|NCT00243880|EXPERIMENTAL|lovastatin|lovastatin at escalating dosages: 1 mg/kg/day, 3 mg/kg/day, 6 mg/kg/day, 8 mg/kg/day, 10 mg/kg/day
62046519|NCT06150651|EXPERIMENTAL|CAR T-cell therapy|Subjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide, followed by the infusion of 1x10\^6 cells/kg CD-19 CAR-T cells.
62046520|NCT01340469|ACTIVE_COMPARATOR|study|Probiotics supplementation .
62046521|NCT01340469|PLACEBO_COMPARATOR|control|The control group received daily placebo liquid .
62046522|NCT01551732|ACTIVE_COMPARATOR|Anger Control Therapy|10 session manualized cognitive behavioral anger control therapy
62046523|NCT01551732|EXPERIMENTAL|ACT with RAGE-Control|10 session manualized cognitive behavioral anger control therapy augmented with an interactive biofeedback videogame.
62046524|NCT01738984|EXPERIMENTAL|MomZing Web Program|Features include selection one to three 10-minute videos demonstrating yoga, aerobics, and strengthening, specifically designed for mothers with infants 2 to 8 months of age. Women will sequence together videos personalized to their fitness level, preference for exercise type, and a choice to actively exercise with her baby or alone. Exercises with a baby will be tailored to the infant's weight and include interactions that promote cognitive development and mother-child bonding.
62605851|NCT00970099|ACTIVE_COMPARATOR|Exercise|12 week exercise regimen
62605852|NCT00970099|PLACEBO_COMPARATOR|non-exercise|Normal lifestyle routine with no exercise for 12 weeks.
62605853|NCT03729414|ACTIVE_COMPARATOR|mucopexy with Doppler artery ligation|Doppler guided hemorrhoidal artery ligation and mucopexy: Group of patients with III degree hemorrhoids treated by THD or AMI device is introduced into the anal canal. The terminal branches of the rectal artery are detected by the Doppler 2-3 cm above the dentate line. The tip of the instrument is tilted and arteries ligated with a figure-of-eight suture inserted using a special needle-holder. After the haemorrhoid artery ligation, the suture is continued with 3/5 sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all artery ligations (6 ligations
62605854|NCT03729414|EXPERIMENTAL|mucopexy without Doppler artery ligation|Non Doppler guided hemorrhoidal artery ligation and mucopexy: A lubricating gel is applied to the tip of the THD or the AMI device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. the mucopexy will start at two o'clock and repeated at 4, 6 8, 10, 12, in clockwise direction
62828601|NCT04902976|ACTIVE_COMPARATOR|CPC|patients submitted to mouth rinse with 0.075% Cetylpyridinium Chloride solution.
62828602|NCT04902976|PLACEBO_COMPARATOR|Negative Control|patients submitted to mouth rinse with distilled water.
62046525|NCT01738984|EXPERIMENTAL|Standard exercise DVD|Exercise DVD that demonstrates yoga or strengthening exercises a mother can perform with her infant.
62046526|NCT04051268|EXPERIMENTAL|Vi-DT TCV Batch 1|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 1
62046527|NCT04051268|EXPERIMENTAL|Vi-DT TCV Batch 2|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 2
62046528|NCT04051268|EXPERIMENTAL|Vi-DT TCV Batch 3|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 3
62046529|NCT04051268|ACTIVE_COMPARATOR|PQed Typhoid Conjugate Vaccine (subjects 6 mo-45 yo)|1 dose of 0.5 ml of PQed TCV Vaccine
62046530|NCT04051268|ACTIVE_COMPARATOR|Vi Polysaccharide Vaccine (subjects 46-60 years old)|1 dose of 0.5 ml of Vi Polysaccharide Vaccine
62046531|NCT01990846|EXPERIMENTAL|Flufirvitide-3 dose level 1|Single dose administration for dose level 1
62046532|NCT01990846|EXPERIMENTAL|Flufirvitide 3-Dose level 2|Single dose administration for Dose Level 2
62046533|NCT01990846|PLACEBO_COMPARATOR|Placebo|Single Dose administration Placebo for Flufirvitide-3
62046534|NCT01990846|EXPERIMENTAL|Flufirvitide-3 Dose level 1- Repeat dose|Repeat dose administration for five days
62248502|NCT00401739|EXPERIMENTAL|I|Treatment with CSL360
62438598|NCT05232578|EXPERIMENTAL|Arm B- delayed salvage radiotherapy (dSRT)|The patient is by the biochemical relapse analysis (PSA level 0,2 ng/ml) referred for further follow-up of PSA values. dSRT is initiated, if PSA further increase to values of ≥ 0.4 ng/ml is confirmed and the presence of a potential clinical relapse is excluded with repeated PSMA-PET-CT in line with standard procedures
62605855|NCT06254508|ACTIVE_COMPARATOR|FITT to CON|Online program that includes exercise guided by the FITT-VP principle and dietary advice for 16 weeks, followed by conventional in-clinic nutrition and exercise advice and self-control for 16 weeks.
62046535|NCT01990846|EXPERIMENTAL|Flufirvitide-3-Dose level 2 Repeat dose|Repeat dose administration for 5 days
62605856|NCT06254508|ACTIVE_COMPARATOR|CON to FITT|Conventional in-clinic nutrition and exercise advice and self-control for 16 weeks, followed by online program that includes exercise guided by the FITT-VP principle and dietary advice for 16 weeks.
62605857|NCT00866567||1|Premature infants of less than 28 weeks of gestational age
62605858|NCT00866567||2|Premature infants of more than 28 weeks and less than 32 weeks of gestational age
62046536|NCT01990846|PLACEBO_COMPARATOR|Placebo for Flufirvitide-3 Repeat dose|Repeat dose administration for 5 days
62046537|NCT02709005|EXPERIMENTAL|5% Monolaurin Vaginal Gel|80 subjects will receive 5% Monolaurin Gel twice daily for three successive days for a total of 6 doses
62046538|NCT02709005|PLACEBO_COMPARATOR|Vehicle Placebo|40 subjects will receive placebo Gel twice daily for three successive days for a total of 6 doses
62046539|NCT06169514||Policy and stakeholder analysis across 6 countries|Policy and stakeholder analysis across 6 countries
62046540|NCT04855032|EXPERIMENTAL|Reactive Perturbations|
62449328|NCT04480203|PLACEBO_COMPARATOR|Control|Control arm. No intervention.
62605859|NCT00866567||3|Term newborns
62605860|NCT00866567||4|Adults
62046541|NCT04855032|EXPERIMENTAL|Proactive Perturbations|
62046542|NCT06578975|EXPERIMENTAL|Multi-Omics diagnosis|Participants in this arm will be diagnosed with the mutli-omics based biomarker
62605861|NCT01786538|EXPERIMENTAL|Regorafenib/FOLFOX|
62828603|NCT03137381|EXPERIMENTAL|Cohort 1: CTP-543 4 mg BID|Participants will receive CTP-543 4 mg tablets, twice daily for up to 24 weeks.
62828604|NCT03137381|EXPERIMENTAL|Cohort 2: CTP-543 8 mg BID|Participants will receive CTP-543 8 mg tablets, twice daily for up to 24 weeks.
62438599|NCT03440281||Preterm group|included pregnant females delivered prior to completed 37 weeks of gestation. All participants underwent assessment of uterine artery Doppler indices and maternal serum homocysteine estimation
62828605|NCT03137381|EXPERIMENTAL|Cohort 3: CTP-543 12 mg BID|Participants will receive CTP-543 12 mg tablets, twice daily for up to 24 weeks.
62828606|NCT03137381|PLACEBO_COMPARATOR|Combined Placebo|Participants will receive CTP-543 matched placebo tablets, twice daily for up to 24 weeks in Cohorts 1, 2, and 3.
62438600|NCT03440281||Term group|Included pregnant females delivered after completed 37 weeks of gestation. All participants underwent assessment of uterine artery Doppler indices and maternal serum homocysteine estimation
62828607|NCT06654986|EXPERIMENTAL|Salmeterol + amino acid availability|The participants will be administered salmeterol from an inhaler device and amino acid availability (protein powder in a shaker) daily during a 6-week intervention.
62828608|NCT06654986|EXPERIMENTAL|Salmeterol + placebo|The participants will be administered salmeterol from an inhaler device. Furthermore they will be administered placebo (carbo fuel in a shaker) daily during a 6-week intervention.
62828609|NCT06654986|PLACEBO_COMPARATOR|Placebo + placebo|The participants will be administered placebo from an inhaler device. Furthermore they will be administered placebo (carbo fuel in a shaker) daily during a 6-week intervention.
62248503|NCT03019250|EXPERIMENTAL|Colostrum|Intervention patients will be received enteral formula and colostrum powder 20 g/kg/day given via nasogastric tube as boluses q 4hrs.
62248504|NCT03019250|PLACEBO_COMPARATOR|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
62248505|NCT01845454|ACTIVE_COMPARATOR|Dose 1|The first 15 patients enrolled will receive a dose of 1 application of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
62248506|NCT01845454|ACTIVE_COMPARATOR|Dose 2|If a second cohort of 15 participants is necessary, the next dose will include 1 application of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
62248507|NCT01845454|ACTIVE_COMPARATOR|Dose 3|If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
62248508|NCT01845454|ACTIVE_COMPARATOR|Dose 4|If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
62248509|NCT00979706|ACTIVE_COMPARATOR|HAART|Patients assigned to this arm will receive standard HAART
62248510|NCT00979706|EXPERIMENTAL|HAART + Immunotherapy|Patients assigned to this arm will receive HAART plus cyclosporin A during the first two months and after that will receive IFN, GM-CSF and IL-2.
62248511|NCT01552655|OTHER|Dual-time PET/CT|
62248512|NCT06027736|EXPERIMENTAL|Intervention group|
62248513|NCT06027736|NO_INTERVENTION|Control group|
62828610|NCT02677441|EXPERIMENTAL|Conservative management|Conservative management includes a sling for 10 days, followed by specific standardized validated rehabilitation that includes range of motion recovery and progressive reinforcement.
62828611|NCT02677441|ACTIVE_COMPARATOR|Surgery|Surgical fixation of ACJD with coracoclavicular and acromioclavicular fixation, followed by specific standardized validated rehabilitation that includes range of motion recovery and progressive reinforcement.
62828612|NCT06489951|EXPERIMENTAL|Standard Behavioral Therapy Combined with Solifenacin Drug Treatment|Solinasine succinate 5mg once daily with a maximum dose of 10mg/day. Standard Behavioral Therapy
62828613|NCT06489951|EXPERIMENTAL|Standard behavioral therapy combined with short-term high dose exogenous vitamin D supplementation|Oral vitamin D drops, 2400iu/d, continued for 6 weeks after follow-up. Standard Behavioral Therapy
62828614|NCT01708356|EXPERIMENTAL|Normal cycling|Cycling on a residential and downtown route (crossover design)
62046543|NCT06578975|OTHER|Normal diagnosis|
62046544|NCT04124926|EXPERIMENTAL|Healing Phase: Vonoprazan 20 mg|Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 8 weeks.
62248514|NCT03840694|OTHER|Smoking Abstinence|Participants will abstain from smoking for 24 hours before one MRI scan. Smoking abstinence will be confirmed using exhaled carbon monoxide breath testing
62248515|NCT03840694|OTHER|Ad Lib Smoking|"Participants will continue smoking as usual (i.e. ad lib) before one MRI scan and smoke one additional cigarette immediately prior to scanning. Continued smoking will be confirmed using exhaled carbon monoxide breath testing."
62248516|NCT03392792|ACTIVE_COMPARATOR|tissue plasmnogen activator|
62248517|NCT03392792|ACTIVE_COMPARATOR|thrombectoy|
62248518|NCT01638078|ACTIVE_COMPARATOR|Thalidomide|Thalidomide
62248519|NCT01638078|PLACEBO_COMPARATOR|Placebo|Placebo
62248520|NCT03428074||Patients with the surgery of Ivor-Lewis|Pathologically diagnosed IA-IIIB patients with esophageal cancer who received minimally invasive surgery of Ivor-Lewis
62438601|NCT05544383|EXPERIMENTAL|Intervention group|Interdisciplinary Pain Education Program and conventional physical therapy treatment
62605862|NCT01786538|ACTIVE_COMPARATOR|Placebo/FOLFOX|
62605863|NCT06730477||Untreated EGFR mutated lung adenocarcinoma patients|Patients diagnosed with lung adenocarcinoma with EGFR mutations for the first time.
62605864|NCT06730477||Patients with EGFR-mutated lung adenocarcinoma who are responding to targeted therapy|Patients with EGFR-mutated lung adenocarcinoma treated with targeted therapy combined with or without chemotherapy as first-line therapy, and the therapeutic effect was in the response stage.
62828615|NCT04806685|EXPERIMENTAL|Intervention|Diet therapy plus sleep education
62828616|NCT04806685|OTHER|Control|Diet therapy
62046545|NCT04124926|ACTIVE_COMPARATOR|Healing Phase: Lansoprazole 30 mg|Participants will receive oral lansoprazole 30 mg once per day (QD) for a maximum of 8 weeks.
62046546|NCT04124926|EXPERIMENTAL|Maintenance Phase: Vonoprazan 10 mg|Participants will receive oral vonoprazan 10 mg once per day (QD) for a maximum of 24 weeks.
62248521|NCT03428074||Patients with the surgery of Mckeown|Pathologically diagnosed IA-IIIB patients with esophageal cancer who received minimally invasive surgery of Mckeown
62438602|NCT05544383|ACTIVE_COMPARATOR|Comparison group|Conventional physical therapy treatment
62828617|NCT06182254|EXPERIMENTAL|Experimental group: OPTIMISTIC follow-up|follow-up by nurses specialized in collecting the patient's point of view concerning his or her state of health, in addition to the usual conventional follow-up according to routine care directive interviews carried out preoperatively and at Days 1, 3, 14 and 28 postoperatively (modified QoR-15f score, PROMS...)
62046547|NCT04124926|EXPERIMENTAL|Maintenance Phase: Vonoprazan 20 mg|Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 24 weeks.
62248522|NCT04948242||Consecutive critically ill patients admitted to ICU with severe SARS-CoV-2 infection|Consecutive adult patients (\> 16 years) with laboratory confirmed SARS-CoV-2 infection, detected by RT-PCR positive test of nasopharyngeal, oropharyngeal , swab or invasive respiratory samples according to the WHO recommendations. The follow-up of patients was to ICU discharge or death whichever occurred first. No interventions will be made. Only anonymized demographic data, clinical data, laboratory data and ventilatory support data will be collected. There is no standardized pharmacological treatment protocol. Only basic data are collected about the different treatments administered by the attending physician.
62248523|NCT01733342|ACTIVE_COMPARATOR|Celsite|patients received celsite chemoport implantation under local anesthesia
62248524|NCT01733342|EXPERIMENTAL|Humanport|patients received Humanport chemoport implantation under local anesthesia
62248525|NCT06495528|EXPERIMENTAL|BLISS Arm|Port-A-Cath setting under local anesthesia combined with Bliss DTx use
62248526|NCT06495528|OTHER|GOLD STANDARD Arm|Port-A-Cath setting under local anesthesia combined with site standard of care sedation protocol
62248527|NCT04559945|EXPERIMENTAL|Aveir VR Leadless Pacemaker|VVIR pacing
62248528|NCT02897232||Community Group Survey|Community members coming into the University Health Shreveport Ambulatory Care Facility.
62248529|NCT02897232||Physician Group Survey|Physicians affiliated with LSU Health Shreveport School of Medicine
62248530|NCT02464228|EXPERIMENTAL|Tipifarnib|tipifarnib, oral
62248531|NCT04474457||COVID-19/Favipiravir|"Turkish patient cohort diagnosed with COVID-19 and previously initiated treatment with Favipiravir."
62248532|NCT03599037|EXPERIMENTAL|ICOUGH Recovery App|The ICOUGH Recovery app v2.0 will be downloaded to participants who have a smartphone and want to use the app after their surgery. These participants will be instructed to use the app daily after their surgery until discharge and to select a care coach. Prior to discharge subjects will complete a questionnaire to assess usability and will participate in a brief recorded interview of their experience using the app. Inpatient post operative complications will be abstracted from medical records.
62248533|NCT03599037|NO_INTERVENTION|Standard of care|Participants who either do not have a smartphone or have a smartphone but don't want to use the app will receive the standard of care after surgery which includes an ICOUGH protocol checklist. Inpatient post operative complications will be abstracted from medical records.
62248534|NCT05636189|ACTIVE_COMPARATOR|warming group|warming of the patient with whole body warming blanket in the OR during induction of anesthesia, prewarmed intravenous fluid during the operation.
62438603|NCT05206032||healthy participants|healthy participants
62438604|NCT05206032||acute aortic dissection (AAD)|acute aortic dissection (AAD)
62438605|NCT05206032||acute myocardial infarction (AMI)|acute myocardial infarction (AMI)
62605865|NCT06730477||Patients with EGFR-mutated lung adenocarcinoma who are resistant to targeted therapy|Patients with EGFR-mutated lung adenocarcinoma treated with targeted therapy combined with or without chemotherapy as first-line therapy, and the therapeutic effect was in drug resistance stage, or disease progression.
62605866|NCT05900336|EXPERIMENTAL|Sodium Naproxen first|Participants take the dose of sodium naproxen during the first menstrual cycle and take the placebo during the second menstrual cycle.
62828618|NCT06182254|ACTIVE_COMPARATOR|Control group: Usual conventional follow-up|usual conventional follow-up according to routine care (modified QoR-15f score will be administered to all patients at visit 0 and Day 35).
62248535|NCT05636189|NO_INTERVENTION|no warming group|There will be no whole body warming during induction.
62248536|NCT04561596|EXPERIMENTAL|Autohypnosis|Use of virtual reality with head mounted display
62248537|NCT04561596|OTHER|Control|Treatment as usual
62248538|NCT03027375|EXPERIMENTAL|Qishen granules|The QSG treatment group will receive Qishen granules (13.6 g/pouch, twice per day-30 minutes after breakfast and dinner-for 12 weeks; dosage based on the requirements of Pharmacopoeia of the People's Republic of China).
62438606|NCT05206032||pulmonary embolism (PE)|pulmonary embolism (PE)
62438607|NCT05206032||angina|angina
62438608|NCT01401920||patients undergoing open heart surgery|small infant or children patients undergoing open heart surgery
62438609|NCT00721461|EXPERIMENTAL|1|V930
62438610|NCT02831530|EXPERIMENTAL|Abemaciclib|Patients randomized to the treatment arm will start treatment from 15 days before the surgery (day 1 of the study) to receive the last dose of treatment the day before the surgical procedure (day 14 of the study). Abemaciclib will be taken orally at a dose of 150 mg/ twice a day (Every 12h +/- 2h) on day 1 to day 14. The treatment should be taken in the morning and evening with a big glass of water (250ml) at approximately the same time.
62438611|NCT02831530|NO_INTERVENTION|No treatment|
62449329|NCT00586521|EXPERIMENTAL|rFVIII-FS (octocog-alfa), (Kogenate FS)|On-demand treatment was to follow the same treatment pattern the subject was using before entering the study. While on prophylactic treatment, all subjects were to be treated at a dose of 20-40 IU/kg, 3 times per week at a stable dose.
62605867|NCT05900336|EXPERIMENTAL|Placebo first|Participants take the dose of placebo during the first menstrual cycle and take the sodium naproxen during the second menstrual cycle.
62605868|NCT06173804|EXPERIMENTAL|Lifestyle intervention group|The study team will assess improvements in physical function assessed by the short physical performance battery and other health-related measures (diabetes knowledge, self-efficacy, social support, physical activity, diet consumption, HbA1c, and quality of life).
62605869|NCT00505661|EXPERIMENTAL|Letrozole|2.5 mg by mouth (PO) daily
62605870|NCT03724851|EXPERIMENTAL|Dose Expansion (300mg BID)|TEW-7197 300mg BID, 5D/W + Pembrolizumab 200mg Q3W (n= 30)
62605871|NCT03724851|EXPERIMENTAL|Dose Expansion (200mg BID)|TEW-7197 200mg BID, 5D/W + Pembrolizumab 200mg Q3W (n= 30)
62438612|NCT06294171|OTHER|measurement of alveolar ridge width|the surgical procedure started with envelop flap reflection. A mucoperiosteal elevator was used to reflect the buccal and palatal flaps that were enough to expose the crestal part of alveolar ridge with clear visibility and accessibility. Measuring the width of the alveolar ridge 1 mm below the crest using bone caliber. Using piezoelectric surgery unit (Piezosurgery Ultrasonic® mectron, Italy), a horizontal crestal cut was produced along the crest of the bone. The cut depth extended into the same depth of the final dental implant to be inserted and then Versah Drills will be used in a successive manner and under copious irrigation with chilled sterile normal saline.We will measure the rate of ridge expansion by bone caliber to determine the efficacy of combining Versah drills with piezo surgery in expanding narrow alveolar bone.
62248539|NCT03027375|PLACEBO_COMPARATOR|placebo granules|The placebo group will receive placebo granules (13.6 g/pouch, twice per day-30 minutes after breakfast and dinner-for 12 weeks).
62248540|NCT05340725|ACTIVE_COMPARATOR|DEX-IV|Patients will receive iv DEX 1µ/kg diluted in 100 ml saline and given slowly iv infusion over 10 min. and rectal placebo 30 min. before induction of anesthesia.
62438613|NCT01538316|ACTIVE_COMPARATOR|Quercetin supplement|
62605872|NCT03724851|EXPERIMENTAL|Dose Expansion (200mg QD)|TEW-7197 200mg QD, 5D/W + Pembrolizumab 200mg Q3W (n= 30)
62605873|NCT06057714||All Participants|All subjects to receive inhaled perfluoropropane via standard Douglas bag at every visit (3-5 visits). They will breathe the gas for 5 breath hold cycles (variable volumes as lung capacity/size varies per participant). Not to exceed 30 liters inhaled at each visit as this is the max capacity of our Douglas bag.
62605874|NCT04093791|EXPERIMENTAL|"Collective Intervention G"|"HAPPY MAMA intervention will follow the following steps: listening and establishing relationship phases; analysis of the problems; definition of the problem and the goal of intervention.~The duration will be of 3.5 hours in one day and the intervention will happen in Sapienza University of Rome, in a group of 15 women.~This group fill in an on line questtionarie for four times, the first before the intervention."
62605875|NCT04093791|EXPERIMENTAL|"Individual Intervention I"|"The same intervention of G group (HAPPY MAMA), but at individual level and the intervention will happen at the participants' house.~This group fill in an on line questtionarie for four times, the first before the intervention."
62605876|NCT04093791|NO_INTERVENTION|"Control group C"|The women from this group will not receive any intervention. This group fill in an on-line questtionarie for four times.
62605877|NCT05240469|NO_INTERVENTION|Standard sperm selection|In the control group the oocytes will be injected with sperm that is selected by embryologists using conventional methods in the IVF lab.
62605878|NCT05240469|EXPERIMENTAL|Automated sperm selection|The only intervention is the additional sperm selection step using software immediately prior to ICSI.
62605879|NCT05267223||Individuals with Paraplegia|After screening the participants according to the inclusion/exclusion criteria, informed consent will be obtained from all the selected participants. Their demographic details will be obtained and asked for their comfortable time for the interview. Data will be collected by in-depth face to face, semi- structured interviews. Audio/video recording of the interview will be taken \& it will be written in English and will be transcribed verbatim also manual notes will be prepared for their analysis after the interview is conducted
62438614|NCT01538316|ACTIVE_COMPARATOR|Genistein supplement|
62438615|NCT01538316|PLACEBO_COMPARATOR|Placebo|
62438616|NCT02415166|EXPERIMENTAL|VACCINE MDD|SEASONAL INFLUENZA VACCINE (0.5ML) DELIVERED I.M.
62438617|NCT02415166|PLACEBO_COMPARATOR|PLACEBO MDD|SALINE (0.5ML) DELIVERED I.M.
62438618|NCT02415166|EXPERIMENTAL|VACCINE HC|SEASONAL INFLUENZA VACCINE (0.5ML) DELIVERED I.M.
62828619|NCT04854187|ACTIVE_COMPARATOR|Intervention Arm - Indoor air purifier and N95 mask|Intervention arm will be for 4 weeks. Blood pressure and/or blood glucose will be recorded on day 0; end of week 2 and end of the intervention. Participants in the intervention group will be asked to use an indoor air purifier (Atlanta Healthcare 7-Stage 43-Watt Air Purifier) daily for 4 weeks between the hours of ¬8 PM and 8 AM. The purifier will be placed in their bedroom or in the room where participants sleep at night. When the participants are outdoors (commuting, working outdoors, running errands, etc.), they will be asked to use a N95 mask (PureMe Reusable N95 Anti-Pollution Mask). It is a reusable mask which can be washed by the participants. Every 2 weeks, the filter of the mask will be replaced, and the filter of the indoor purifier will be washed.
62248541|NCT05340725|ACTIVE_COMPARATOR|DEX-Rectal|Patients will receive rectal DEX suppository formulation at approximately 1µ/kg an iv. saline placebo. at 30 min. before induction of anesthesia.
62438619|NCT02415166|PLACEBO_COMPARATOR|PLACEBO HC|SALINE (0.5ML) DELIVERED I.M.
62438620|NCT04393805||MED-Cohort|Patients hospitalized for SARS-COVID-2 infection in a medical ward
62438621|NCT04393805||ICU-Cohort|Patients hospitalized for SARS-COVID-2 infection in a sub-intensive or intensive care unit
62605880|NCT06620185|EXPERIMENTAL|LAIV|
62605881|NCT06620185|EXPERIMENTAL|IAV Challenge|
62605882|NCT00061373|EXPERIMENTAL|MRI Selected Patients|"Patients are eligible for the MRI arm if all clinical and all MRI inclusion and exclusion criteria are met.~A single dose of aspirin 81 mg orally (or rectal dose equivalent), a single weight-based dose of subcutaneous tinzaparin sodium. Possible dose escalated iv eptifibatide."
62605883|NCT00061373|EXPERIMENTAL|non-MRI Selected Patients|"Patients are eligible for the non-MRI arm if all clinical inclusion-exclusion criteria are met, if MRI is contraindicated or if MRI compromises iv tPA delivery within 3-hours of symptom onset.~A single dose of aspirin 81 mg orally (or rectal dose equivalent) and a single weight-based dose of subcutaneous tinzaparin sodium. Possible dose escalated iv eptifibatide.~--------------------------------------------------------------------------------"
62605884|NCT03667417||subjects carrying a BRCA gene mutation|subjects carrying a BRCA gene mutation
62605885|NCT01663194||N/L ratio tertile 2|patients were divided in to the tertiles
62605886|NCT01663194||N/L ratio tertile 3|patients were divided in to the tertiles
62605887|NCT01663194||N/L ratio tertile 1|patients were divided in to the tertiles
62605888|NCT05415332||Cardiogenic shock patients|"We will collect patient's demographic information, medical history, vital signs, cardiac arrest, the maximum dose of the drug at shock treatment and whether mechanical circulatory support devices are inserted, indicators of deterioration and improvement of shock.~For follow-up observations, only prospective subjects are examined for results and administrative information conducted by visiting an outpatient at the time of one, six, one, two, three, four, and five or more years after the shock."
62605889|NCT05415332||Patients hospitalized in cardiovascular intensive care unit|we will collect patient's demographic information, medical history related to cardiovascular disease, and vital signs on the admission date to the cardiovascular critical care unit.
62605890|NCT04973241||OPG|
62046548|NCT04124926|ACTIVE_COMPARATOR|Maintenance Phase: Lansoprazole 15 mg|Participants will receive oral lansoprazole 15 mg once per day (QD) for a maximum of 24 weeks.
62828620|NCT04854187|NO_INTERVENTION|Washout period - No intervention|At the end of either control or intervention arm, participants will have a washout period of 2 weeks, after which participants will be crossed over to the other group for the subsequent 4 weeks. For example, after Participant AB is in intervention arm for 4 weeks, he/she will then have a wash out period of 2 weeks in which they will return to their usual state of living. At the end of the washout period, the participant AB will be put in the control arm for 4 weeks.
62438622|NCT01088152|ACTIVE_COMPARATOR|Usual care of celiac disease women|Written information corresponding to that offered when seeking medical advice for celiac disease in primary care
62438623|NCT01088152|EXPERIMENTAL|Celiac School|Structured education using problem-based learning at 10 sessions
62605891|NCT04973241||CBCT|
62828621|NCT04854187|SHAM_COMPARATOR|Controlled Arm - Indoor air purifier and N95 mask with sham filter|Control arm will be for 4 weeks. Blood pressure, blood glucose and indoor air pollution level will be recorded similarly as in the intervention group on day 0, end of week 2 and week 4. The participant will be provided an air purifier and a N-95 mask (of the same manufacturer), with the filter removed. At the end of two weeks, the health worker will make dummy adjustments to the mask and indoor air purifier, to maintain blinding of the participant.
62438624|NCT02056730|EXPERIMENTAL|Regpara|calcium sensing receptor agonist
62605892|NCT04779606|EXPERIMENTAL|Chloroprocaine|Chloroprocaine 3% ocular gel (30 mg/mL), 3 drops instilled at a 1 min ± 15 sec interval.
62828622|NCT04003246|EXPERIMENTAL|Single Arm: Therapeutic Intervention|
62046549|NCT01666951|EXPERIMENTAL|LCP-Tacro|LCP-Tacro Tablets, once daily (Veloxis Pharmaceuticals A/S, Horsholm, DK)
62046550|NCT01666951|ACTIVE_COMPARATOR|Prograf|Prograf Capsules, twice daily (Astellas Pharma US, Deerfield, IL)
62046551|NCT05001724|EXPERIMENTAL|Cohort 1: KN046 plus Lenvatinib RP3D.|Experimental arm: Cohort 1: KN046 5mg/kg every 3 weeks + lenvatinib RP3D every day until progressive disease or unacceptable toxicity.
62438625|NCT01026610|EXPERIMENTAL|LB80380 90 mg|LB80380 90 mg (90 mg + placebo), once daily oral dose
62605893|NCT04779606|PLACEBO_COMPARATOR|Placebo|Vehicle for chloroprocaine 3% ocular gel, 3 drops instilled at a 1 min ± 15 sec interval.
62438626|NCT01026610|EXPERIMENTAL|LB80380 150 mg|LB80380 150 mg (60 mg + 90 mg), once daily oral dose
62438627|NCT01026610|ACTIVE_COMPARATOR|entecavir 0.5 mg|entecavir 0.5 mg, once daily oral dose
62438628|NCT03947047||Placenta Accreta|Women found to have abnormal placentation (any degree of placenta accreta) during the cesarean section.
62438629|NCT03947047||No Placenta Accreta|Women found to have normal placenta separation during the cesarean section.
62605894|NCT01474031||20 DAA subjects|20 DAA subjects: THA with a Deltamotion articulating surface utilizing the Direct Anterior Approach
62605895|NCT01474031||Control group|healthy volunteers
62605896|NCT05110521|EXPERIMENTAL|Intervention (PROMPTS and MENTORS offered)|Health facilities randomized into the Intervention Arm will be offered the MENTORS program, which trains in-facility nurse-mentors to provide health workers with training and mentorship on aspects of basic and emergency obstetric and newborn care. At health facilities in the intervention arm, patients attending antenatal care clinics will be offered the PROMPTS program, which is a digital health platform that connects mothers with information, advice and referrals to care.
62605897|NCT05110521|NO_INTERVENTION|Control (Routine Care/No PROMPTS or MENTORS OFFERED)|In the control arm, neither the PROMPTS program nor the MENTORS program will be offered during the study period.
62605898|NCT01071239|EXPERIMENTAL|Bone marrow processing|Bone Marrow processing using the CliniMACs device
62605899|NCT02893904|EXPERIMENTAL|Propofol|General anesthesia by TCI Propofol and Remifentanil guided by BIS EEG monitoring intervention
62605900|NCT02893904|EXPERIMENTAL|Sevoflurane|General anesthesia by Sevoflurane and Remifentanil guided by BIS EEG monitoring intervention
62605901|NCT03013764|PLACEBO_COMPARATOR|normal protein intake|subjects will undergo 10 days of low physical activity while consuming a normal protein diet
62828623|NCT05673967||Cohort 1|Real-world (RW) patients with RRMM who have either at least three prior lines of therapy (LOT) and are triple-class exposed (3L+/TCE), or are triple-class refractory (TCR), meet similar inclusion/exclusion criteria used to establish phase 2 cohort 2 of the R5458-ONC-1826 trial, and are initiating currently available therapies.
62046552|NCT05001724|ACTIVE_COMPARATOR|Docetaxel|Active Comparator: docetaxel 75 mg/m² every 3 weeks until progressive disease or unacceptable toxicity.
62046553|NCT02744833|EXPERIMENTAL|GMI-1271|
62046554|NCT02744833|ACTIVE_COMPARATOR|Enoxaparin Sodium (Lovenox®)|
62046555|NCT05939154||mental disorders|Patients in Shanghai Mental Health Center; meet ICD-11 or DSM-5 diagnosis of depressive disorders, bipolar disorders, schizophrenia, obsessive-compulsive disorder, anxiety disorders, addictive disorders and sleep-wake disorders (do not limit subtypes and current disease state); age ≥15 years and \< 60 years.
62046556|NCT05939154||healthy controls|Age ≥15 years and \< 60 years; gender match with patient group; understand the research content and sign the informed consent; no family history of mental disorders.
62046557|NCT04238364|EXPERIMENTAL|EI-1071 Tablet|EI-1071 tablet(s) administered orally as single ascending dose(SAD), multiple ascending daily dose(MAD)
62046558|NCT04238364|PLACEBO_COMPARATOR|Placebo|EI-1071 tablet(s) administered orally as single ascending dose(SAD), multiple ascending daily dose(MAD)
62438630|NCT02630745|ACTIVE_COMPARATOR|Immediate periodontal surgery (Group 1)|periodontal surgical procedure in the form of open flap debridement will be performed immediately( in which after debridement mucoperiosteal flaps will be repositioned and secured by using 3-0 non-absorbable black silk surgical suture) after obturation of the root canal system( using calcium hydroxide intracanal medicament placed with the help of 27 gauge endodontic syringe for 10 days and access cavity will be sealed with suitable sealer).
62438631|NCT02630745|ACTIVE_COMPARATOR|Delayed periodontal surgery (Group 2)|periodontal surgical procedure in the form of open flap debridement( in which after debridement mucoperiosteal flaps will be repositioned and secured by using 3-0 non-absorbable black silk surgical suture) will be performed 3 months after obturation of the root canal system ( using calcium hydroxide intracanal medicament placed with the help of 27 gauge endodontic syringe for 10 days and access cavity will be sealed with suitable sealer).
62605902|NCT03013764|EXPERIMENTAL|high protein intake|subjects will undergo 10 days of low physical activity while consuming a high protein diet
62828624|NCT05640193|EXPERIMENTAL|Participants with Melanoma Brain Metastases|Participants have melanoma brain metastases who will undergo surgical excision to generate LN-144.
62828625|NCT00656513|ACTIVE_COMPARATOR|Pilocarpine: Phase III|
62828626|NCT00656513|EXPERIMENTAL|ALTENS: Phase III|
62828627|NCT00656513|EXPERIMENTAL|ALTENS: Phase II|
62828628|NCT06306807|EXPERIMENTAL|Experimental Group|Participants in the experimental group underwent the exercise program including active cervical range of motion, strengthening, and posture correction exercises for 6 weeks, 3 days a week, once a day for 10 repetitions. Active cervical range of motion exercise program consists of the general range of movement for flexors, extensors, both sides flexors, and rotator neck muscles. Strengthening exercises were planned for weak, lengthened, inhibited muscles. Ergonomic modifications while using a smartphone were taught. Additionally, participants in the experimental group were included in a PNF exercise program to be applied by a physiotherapist 3 days a week for 6 weeks. The contract-relax technique for the neck extension pattern and the replication technique for the scapular posterior elevation pattern were used.
62046559|NCT04232514|EXPERIMENTAL|Part A|Subjects will receive HEC74647 on Day 1\~7 and Day13\~19, co-administration with HEC110114 on Day13\~19.
62046560|NCT04232514|EXPERIMENTAL|Part B|Subjects will receive HEC110114 on Day 1\~7 and Day13\~19, co-administration with HEC74647 on Day13\~19.
62046561|NCT02618616|EXPERIMENTAL|ZPL-389|Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally once daily (OD) for 12 weeks.
62046562|NCT02618616|PLACEBO_COMPARATOR|Placebo|Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.
62046563|NCT04648540|EXPERIMENTAL|Opioid-Free Anesthesia (OFA)|"The following drugs will be administered 10 minutes before induction of anesthesia in group I (OFA):~* Pregabalin 150 mg orally with a small sip of water~* Acetaminophen 1 gm and Ketorolac 30 mg in 100 mL i.v. over 10 minutes~* Dexmedetomidine loading dose of 0.5 mic/kg i.v. over 10 minutes~* Lidocaine loading dose of 1.5 mg/kg i.v. over 10 minutes~For simplicity, the weight-based doses of dexmedetomidine and lidocaine will be prepared in a 20 mL syringe~the following drugs will be administered as a continuous infusion:~* Dexmedetomidine 0.5 mic/kg/h~* Lidocaine 0.5 mg/kg/h~Patients in both groups will be extubated when they meet our institutional criteria for extubation. Postoperative analgesia will be started as follows:~Group I (OFA):~* Acetaminophen 1 gm/6h~* ketorolac 30 mg/8h~* Pregabalin 150 mg once at night~* Celecoxib 200 mg/24 hours"
62046564|NCT04648540|ACTIVE_COMPARATOR|Opioid Anesthesia (OA)|"Before induction In Group II (OA) patients will receive placebo pills and normal saline in equivalent volumes .~Maintenance~In Group II (OA) patients will receive a continuous infusion of Fentanyl (1 mic/kg/h)~Patients in both groups will be extubated when they meet our institutional criteria for extubation. Postoperative analgesia will be started as follows:~• Morphine 0.1 mg /kg PRN every 8 hours"
62046565|NCT03515928|ACTIVE_COMPARATOR|Noise Exposed Group|
62248542|NCT05340725|ACTIVE_COMPARATOR|DEX Nano-Rectal|Patients will receive rectal DEX suppository in the Niosomes formulation at approximately 1µ/kg an iv. saline placebo at 30 min. before induction of anesthesia
62248543|NCT04085341|EXPERIMENTAL|GB-102 Dose 1 (1 mg)|Participants will receive intravitreal (IVT) GB-102 (1 mg) in the study eye at Baseline.
62438632|NCT05214807|ACTIVE_COMPARATOR|Control group receiving Synvisc-One®|
62438633|NCT05214807|EXPERIMENTAL|IMD group receiving KiOmedine® CM-Chitosan|
62605903|NCT03849963||Hyperpolarized [13C]pyruvate|Hyperpolarized stable isotope injection (\[13C\]pyruvate) during magnetic resonance spectroscopic imaging
62605904|NCT00631085|OTHER|1|
62623476|NCT06349707||18 ICU-patients group|18 ICU (Intensive Care Unit)-patients group, from the whole population of patients (1,614) who were hospitalized for respiratory infections from early 2021 to mid-2022 in Nancy University hospital, France.
62046566|NCT03515928|PLACEBO_COMPARATOR|Control Group|
62046567|NCT05365321|EXPERIMENTAL|WP1122|Experimental drug with Concentration 100mg/mL - administered q12h PO for 10 days
62046568|NCT05365321|PLACEBO_COMPARATOR|placebo|Placebo Administered q12h PO for 10 days
62605905|NCT01298141|EXPERIMENTAL|Replagal®|All eligible patients may receive Replagal produced by the bioreactor process (AF Replagal) on this treatment plan until AF Replagal is commercially available for the patient, the patient's participation is discontinued, or the study is discontinued, whichever comes first.
62605906|NCT02961062|EXPERIMENTAL|Treatment Sequence 1|
62605907|NCT02961062|PLACEBO_COMPARATOR|Treatment Sequence 2|
62605908|NCT06354907|EXPERIMENTAL|The KEP Group|Children in the KEP group will be interviewed before and after participation in the 12 weeks Kids' Empowerment Program in their classroom. Their parent will complete an online assessment via survey software before their child begins the program and again after 12 weeks.
62605909|NCT06354907|NO_INTERVENTION|The Comparison Group|Children in the comparison group will be interviewed once and again 12 weeks later. Their parent will complete an online assessment once and again 12 weeks later. Children in the Comparison group will then participate in the Kids' Empowerment Program in their classroom.
62605910|NCT04605432|EXPERIMENTAL|PEG-FFI prep|"On the day before colonoscopy, an experienced researcher would go to the ward to have a face-to-face conversation with the patient to know if patients have the risk factors for bowel preparation failure.~The bowel preparation regimens for patients with risk factors would be optimized. In addition to drink single dose of 120g Polyethylene Glycol (PEG-4000) with 3L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min, the patient also drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at 20:00- 21:00 hours on the day before the colonoscopy. Patients without risk factors drink single dose of 120g Polyethylene Glycol (PEG-4000) with 3L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min.~Patients would received a booklet to explain the details of diet restriction, preparation method and the pictures of bowel preparation of results.The researcher would give a detailed oral explanation of the booklet."
62605911|NCT04605432|ACTIVE_COMPARATOR|PEG-nonFFI prep|Patients in the PEG-nonFFI group would only receive routine patient education on bowel preparation of colonoscopy, which was completed by ward nurse. all the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 3L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min.
62605912|NCT05024981|ACTIVE_COMPARATOR|Classic reeducation|
62605913|NCT05024981|EXPERIMENTAL|Classic reeducation + videographic feedback|
62605914|NCT02290600||type 1 diabetes|type 1 diabetes with continuous glucose monitor (CGM)
62605915|NCT00299559|OTHER|1|cross over application of both specimen
62605916|NCT02824536|EXPERIMENTAL|Group 1|Participants will be randomized in a 3:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.
62605917|NCT02824536|EXPERIMENTAL|Group 2|Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 3 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.
62605918|NCT02824536|EXPERIMENTAL|Group 3|Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.
62828629|NCT06306807|ACTIVE_COMPARATOR|Control Group|Participants in the experimental group underwent the exercise program including active cervical range of motion, strengthening, and posture correction exercises for 6 weeks, 3 days a week, once a day for 10 repetitions. Active cervical range of motion exercise program consists of the general range of movement for flexors, extensors, both sides flexors, and rotator neck muscles. Strengthening exercises were planned for weak, lengthened, inhibited muscles. Ergonomic modifications while using a smartphone were taught.
62605919|NCT02406300|ACTIVE_COMPARATOR|Subarachnoid anesthesia|"Patients submitted to subarachnoid anesthesia for proximal femur fracture surgical repair.~Up to 12.5 mg of bupivacaine or levobupivacaine will be used"
62605920|NCT02406300|ACTIVE_COMPARATOR|PNB/GA|Patients are submitted to a femoral, a lateral cutaneous nerve of the thigh and an anterior obturator nerve blocks with ropivacaine and an inhalational general anesthesia with sevoflurane or desflurane
62605921|NCT00426777|ACTIVE_COMPARATOR|risedronate|
62605922|NCT00426777|PLACEBO_COMPARATOR|placebo|
62605923|NCT02223325||Elderly, acute pancreatitis|No intervention
62605924|NCT02223325||Adults <65 y, acute pancreatitis|No intervention
62828630|NCT01795677|EXPERIMENTAL|RUXOLOTINIB|Ruxolotinib : patient with donor HSCT 4 months later patients without donor: ruxolotinib alone
62828631|NCT00952510||Whiplash patients|The cohort is based on 100 whiplash patients which underwent the measure procedure to obtain cervical range of motion.
62046569|NCT02469948|EXPERIMENTAL|Ultrasonography direct-guidance|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
62605925|NCT02096068|EXPERIMENTAL|Study group|"Application of Dexmedetomidine (Dexdor®) perioperatively for a maximum of 48 hours~Dosing Scheme:~during operation and mechanical ventilation: 0,7μg/kgABW/h; recovery time until extubation: 0,4μg/kgABW/h; after extubation: 0,2-1,4μg/kgABW/h"
62605926|NCT02096068|PLACEBO_COMPARATOR|Control group|Application of placebo for a maximum of 48 hours
62605927|NCT02096068|NO_INTERVENTION|POCD control group|A non-surgical control group of 15 ASA II/III- patients is collected for measuring the learning experience during the cognitive testings. The participants are matched on age, education, and gender to the study patients.
62605928|NCT06730867|EXPERIMENTAL|People Living With HIV (PLHIV)|
62605929|NCT03152825||Viable myocardium Group|"At least ONE of the following:~1. Late gadolinium enhancement \<75%.~2. Improvement in segmental function ≥1 grade during low dose dobutamine"
62605930|NCT03152825||Non-viable myocardium group|"At least ONE of the following:~1. Late gadolinium enhancement ≥75%.~2. No improvement in segmental function during low dose dobutamine"
62605931|NCT03152825||Inducible ischaemia group|"At least ONE of the following:~* perfusion defect (≥ 1,5 segments) assessed during peak infusion of adenosine or dobutamine~* new wall motion abnormalities or worsening ≥1 grade during peak infusion of dobutamine"
62046570|NCT02469948|ACTIVE_COMPARATOR|Surface anatomy landmark|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.
62046571|NCT00683826|EXPERIMENTAL|L-Leucine 4grams|This will be a triple arm design where subjects will be randomized into three groups. Arm #1 will be 4g of Leucine.
62046572|NCT00683826|EXPERIMENTAL|L-Leucine 8 grams|Arm number two of the study will be a dose of Leucine of 8g.
62046573|NCT00683826|PLACEBO_COMPARATOR|L-Leucine 0 grams|The third arm of the study will be composed of a control drink with no leucine in it.
62046574|NCT02659761|EXPERIMENTAL|dolutegravir/abacavir/lamivudine|All study subjects will receive triumeq (600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine) single tablet that will be taken orally, once daily, during 96 weeks
62046575|NCT03442712|ACTIVE_COMPARATOR|Treatment arm 1|"Auricular acupressure (AA) plus smartphone App:~Semen Vaccaria laccaria will be applied on one ear only, and seed plasters will be changed every 3 days to 4 days to the opposite ear. Subjects will be requested to apply pressure on the acupoints thrice per day. The subjects will install the smartphone App specifically designed for this study. The App will send out regular AA reminders to the subjects. The total treatment period will be 8 weeks."
62046576|NCT03442712|ACTIVE_COMPARATOR|Treatment arm 2|The participants will only receive AA treatment and are required to perform daily self-administered seeds pressing.
62046577|NCT03442712|NO_INTERVENTION|Treatment arm 3|The participants in the waitlist control group will maintain their usual dietary and exercising patterns.
62605932|NCT03152825||Non-inducible ischaemia group|"None of conditions qualifying for the Inducible ischemia group"
62605933|NCT06121882|EXPERIMENTAL|Micro Fragmented Adipose Tissue (MFat)|"Injection of Microfragmented Adipose Tissue derived using Lipogems® Kit~The cases assigned to this group will be injected intra-articularly with Lipogems®. The patients will undergo lipoaspiration of their own adipose tissue for MFat then this MFat will be injected intra-articularly in the knee. It will be administered once at the baseline visit of the study."
62605934|NCT06121882|ACTIVE_COMPARATOR|Saline Injection|The cases assigned to this group will be injected intra-articularly in the knee with saline. It will be administered once at the baseline visit of the study.
62828632|NCT02856568|EXPERIMENTAL|Treatment (cisplatin, gemcitabine hydrochloride, ricolinostat)|Patients receive cisplatin IV followed by gemcitabine hydrochloride IV on days 1 and 8, and ricolinostat PO on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62828633|NCT03878563||ascites with/without SBP|Cirrhosis with ascites and existing SBP or prior SBP
62828634|NCT03878563||ascites and decreased protein concentrati|Cirrhosis with ascites and decreased protein concentration \<1,5 g/d
62828635|NCT03878563||ascites and normal protein concentration|Liver cirrhosis witha scites and protein concentration \>1,5 g/d
62828636|NCT03878563||Liver cirrhosis without ascites|Patients with liver corrhosis without ascites
62828637|NCT03878563||Healthy controls without liver cirrhosis or other pathology|Healthy pacients (without chronic disease) undergoing screening coloscopy or gastroscopy
62828638|NCT02638194|ACTIVE_COMPARATOR|Hookah Smoking Group|10 participants will smoke tobacco hookah for 2 hours
62828639|NCT02638194|ACTIVE_COMPARATOR|Hookah Secondhand Smoke Group|10 individuals will be exposed to secondhand hookah tobacco smoke for 2 hours
62046578|NCT05563194|EXPERIMENTAL|Children and young people with a diagnosis of Juvenile Idiopathic arthritis|Single arm study where all participants will receive the three prototype interventions.
62046579|NCT06048510|EXPERIMENTAL|Pregnant women|"Pregnant women, with gestational age at inclusion \<28 weeks of amenorrhea, with or without risk factors for GDM will be included in the first consultation at the Maternity Hospital (Bordeaux University Hospital).~Determination of glycation markers (HbA1c, glycated albumin, and skin autofluorescence)."
62046580|NCT02303353||Cancer patients|Patients suffering from a carcinoma (either breast, ovarian, lung, colon, stomach, pancreas, rectum or plasmacytoma)
62046581|NCT03897257|EXPERIMENTAL|UHE-103A1 cream|Topical cream applied twice daily for 2 weeks.
62046582|NCT03897257|EXPERIMENTAL|UHE-103A2 cream|Topical cream applied twice daily for 2 weeks.
62046583|NCT03897257|EXPERIMENTAL|UHE-103B cream|Topical cream applied twice daily for 2 weeks.
62046584|NCT03897257|EXPERIMENTAL|UHE-103A1B cream|Topical cream applied twice daily for 2 weeks.
62605935|NCT00067769|ACTIVE_COMPARATOR|TAU|Patients received treatment as usual (TAU) as defined as continued clinical care.
62605936|NCT00067769|EXPERIMENTAL|TAU+UCanPoopToo|Patients received treatment as usual (TAU) plus the Internet intervention (UCanPoopToo.)
62828640|NCT03513159|EXPERIMENTAL|Pathfinder support|Pathfinder support with development of an individual care plan for the intervention patients and their informal caregivers, with the hospital physicians already inside the hospital setting. This will then be developed and improved further during up to twelve months after hospital release with the primary physician. The pathfinders will coordinate the ambulatory care team services and closely involve the primary physicians. The patients and their informal caregivers will be empowered and educated to achieve a stabilization or improvement in functionality, independence, quality of life, coping with disease, nutritional status and wound healing process. In the regular assessments they will be tested for functionality and nutritional parameters, quality of life and stress scores.
62828641|NCT03513159|NO_INTERVENTION|Control without pathfinder support|Control patients will not be supported by pathfinders. In regular assessments they will be tested for functionality and nutritional parameters, quality of life and stress scores.
62828642|NCT03350594|ACTIVE_COMPARATOR|Systemic Family Therapy|"SyFT involves the patient, the parents, and siblings over the age of 6 living at home. Therapists do not manage the issues relating to AN, which are taken on by referent psychiatrist who can be called on in case of any concern. Without denying personal suffering and its intra-psychic and meta-psychological impact, or the somatic and biological aspect of the pathology, the emphasis is on interactions around the symptom.~There will be free exchanges along the lines between therapist and family, within the family and between therapists.~Session is possible with sibling alone or the parents alone or in inter-generational mode (other family relatives)"
62828643|NCT03350594|EXPERIMENTAL|Multiple Family Therapy|"Each session will involve 5 families of patients suffering from AN including the parents and non-systematically the siblings. There will be exchanges in groups and mediation via different exercises involving different sub-groups according to the theme: complete families, patients on their own for problems specific to them, or  cross-parenting  exercises whereby parents adopt another patient for the duration of the exercise. This organization enables mutual support and social propping, favoring the emergence of family resources. Direct exchanges between families (between parents, siblings, or mixes) with and between therapists are also sought."
62828644|NCT01816217|EXPERIMENTAL|Intubated patient|Adult intubated in Intensive Care Unit (ICU) with The McGrath Mac videolaryngoscope (intervention described)
62828645|NCT06332599||BQT|
62828646|NCT06332599||PBM4M4|
62828647|NCT06332599||PBM3M3|
62828648|NCT06332599||PBM2M4|
62828649|NCT06332599||PBM2M3|
62828650|NCT05396547|EXPERIMENTAL|Treated|Treatment with Ledinbio device
62828651|NCT02116036|EXPERIMENTAL|Rivaroxaban|Rivaroxaban 20mg po daily
62828652|NCT01202786||miRview mets Disclosed|Patients of group 1 will be submitted to the standard conventional work-up (see below) as well as miRview™ mets assay. Their physician will treat the patient based upon both results
62828653|NCT01202786||Control|Patients of group 2 will be submitted to the standard conventional work-up. miRview™ mets assay will be performed but will remain blinded for both the patient and referring physician. Treatment will be decided based on standard work-up results
62828654|NCT01253837|EXPERIMENTAL|L19TNFa|"Phase I: Prospective, open-label, dose escalation study.~Phase II: Prospective, single-arm, open-label study, equivalent to the stage 1 of the Simon two-stage phase II design."
62046585|NCT03897257|EXPERIMENTAL|UHE-103A2B cream|Topical cream applied twice daily for 2 weeks.
62248544|NCT04085341|EXPERIMENTAL|GB-102 Dose 2 (2 mg)|Participants will receive intravitreal (IVT) GB-102 (2 mg) in the study eye at Baseline.
62248545|NCT00418665|ACTIVE_COMPARATOR|750 mcg AMG 531|750 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
62248546|NCT00418665|PLACEBO_COMPARATOR|Placebo Part B|Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
62248547|NCT00418665|PLACEBO_COMPARATOR|Placebo Part A|Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
62248548|NCT00418665|ACTIVE_COMPARATOR|500 mcg AMG 531|500 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
62248549|NCT00418665|ACTIVE_COMPARATOR|750 mcg AMG531 Part B|750 μg AMG 531 biweekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
62248550|NCT02012296|ACTIVE_COMPARATOR|Treatment (enzalutamide)|Patients receive enzalutamide PO per standard of care.
62248551|NCT02012296|EXPERIMENTAL|Treatment (enzalutamide, mifepristone)|Patients receive enzalutamide PO and mifepristone PO.
62248552|NCT03801954||RC Patients|Patients at the University of Kansas Medical Center who have not yet had their radical cystectomy, after their radical cystectomy, or between the completion of chemotherapy and the radical cystectomy.
62605937|NCT00481767|ACTIVE_COMPARATOR|Cervarix Group|Healthy female subjects who received 3 doses of Cervarix at Months 0, 1 and 6, administered intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.
62605938|NCT00481767|PLACEBO_COMPARATOR|Placebo Group|Healthy female subjects who received 3 doses of placebo at Months 0, 1 and 6, administered intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.
62605939|NCT04375813|ACTIVE_COMPARATOR|Active Study Drug Group|Patients will be given 0.5mg eRapa (encapuslated rapamycin) orally each weekday (Monday-Friday) for one year.
62605940|NCT04375813|PLACEBO_COMPARATOR|Placebo Group|Patients will be given a placebo (visually identical to the eRapa (encapsulated rapamycin)) orally each weekday (Monday-Friday) for one year.
62046586|NCT03833297||Hepatological toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of hepatological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity
62046587|NCT00388310|ACTIVE_COMPARATOR|Cephalexin|Cephalexin 250 mg PO q6h x5 days
62438634|NCT04674176|EXPERIMENTAL|Rifaxamin (R)|Patients in the experimental group will receive additional instructions to take 550 mg of Rifaximin 3 times a day for 12 days at the start of the diet. The experimental group will be provided the required doses of Rifaximin at the initial weigh-in and office visit.
62046588|NCT00388310|ACTIVE_COMPARATOR|Clindamycin|Clindamycin 300 mg PO q6h x5 days
62046589|NCT00388310|ACTIVE_COMPARATOR|trimethoprim/sulfamethoxazole|trimethoprim/sulfamethoxazole 160 mg/800 mg PO q12h x 5 days
62605941|NCT03242187|EXPERIMENTAL|Trans-anal TME (TaTME)|Trans-anal total mesorectal excision(TaTME) will be offered to patients in this group (assisted by minilaparoscopy to control the IMA and splenic flexure mobilisation)
62605942|NCT03242187|ACTIVE_COMPARATOR|Lap. TME|Laparoscopic total mesorectal excision(Lap.TME) starting by IMA ligation then splenic flexure mobilisation and pelvic dissection
62605943|NCT01589107|NO_INTERVENTION|control group|usual care
62828655|NCT03000608|EXPERIMENTAL|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
62828656|NCT03000608|PLACEBO_COMPARATOR|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
62248553|NCT01893229|EXPERIMENTAL|Valproate|Name: Valproate; dosage form: tablet, 250mg; dosage and frequency: 800mg-- 1200mg/d; duration: 6 weeks.
62828657|NCT03933202||Cladribine Tablets|No intervention will be administered as a part of this study. Participants who had decided prior to enrollment to transition from any oral or infusion DMD to treatment with cladribine tablets under routine clinical care and who meet all eligibility criteria will receive an initial treatment course with cladribine tablets in Year 1 and are planned to receive a second course in Year 2, as per the approved United States Prescribing Information (USPI). Data sources for this study will include data extracts from participants' medical records performed by site personnel as well as questionnaires directly filled out by participants.
62828658|NCT02254070|EXPERIMENTAL|BIBT 986 BS|
62046590|NCT00388310|PLACEBO_COMPARATOR|Placebo|
62046591|NCT02510430|EXPERIMENTAL|Reducing Sitting Time Group|This group will be asked to reduce overall accumulated sitting time by 2 hours per day.
62248554|NCT01893229|EXPERIMENTAL|Oxcarbazepine|Name: Oxcarbazepine, dosage form: 300mg, tablet; dosage and frequency: 600-1200mg/d; duration: 6 weeks
62248555|NCT01893229|EXPERIMENTAL|Quetiapine|name: Quetiapine, dosage form: 200mg,tablet; dosage and frequency: 600mg-- 800mg/d; duration: 6 weeks
62248556|NCT01893229|EXPERIMENTAL|Olanzapine|Name: Olanzapine, dosage form: 5mg tablet; dosage and frequency: 10mg--20mg/d; duration: 6 weeks
62248557|NCT01893229|EXPERIMENTAL|Ziprasidone|Name: Ziprasidone, dosage form: 10mg tablet; dosage and frequency: 80mg-160mmg/d; duration: 6 weeks
62438635|NCT04674176|NO_INTERVENTION|Control|Participants in the control group will undergo no intervention and will only be asked to follow an Intermittent fasting diet.
62438636|NCT00528437|OTHER|Myeloablative Chemo-Temozolomide, Thiotepa, and Carboplatin.|
62438637|NCT01391182|ACTIVE_COMPARATOR|EACA arm|In order to obtain sufficient power, a total of 120 patients will be studied, 60 in each group. The surgeon performing the case, their staff, the anesthesiologist, nurse anesthetist and the patient will be blinded to whether the patient received EACA or placebo. Pharmacy will prepare the EACA dose or the saline. Serum hemoglobin levels with be drawn preoperatively and on post operative days one, two, and three. The first dose will be given in the operating room prior to incision (within 30 minutes of the incision). The second dose will be given four hours after the first dose. Two doses are given due to the short half-life of EACA. The timing of administration of EACA will be recorded.
62449330|NCT04812587|EXPERIMENTAL|Experimental group|The healthy elderly will be were recruited to participate in this study. All the subjects were independent in basic daily living activities, but at least one or more given assistance in the instrumental IADL assessment (ability to use telephone, shopping, food preparing, housekeeping, laundry, mode of transportation, responsibility for own medications, ability to handle finances). Their age should be ranged between 65 - 81 years.
62605944|NCT01589107|EXPERIMENTAL|Video Arm|
62605945|NCT05576441|EXPERIMENTAL|test group: VCMX|Volume stable collagen matrix will be placed at recipient site and suturing will be done with a 5-0 vicryl suture.
62046592|NCT02510430|EXPERIMENTAL|Re-Patterning Sitting Time Group|This group will be asked to use standing breaks to interrupt long bouts of sitting time.
62046593|NCT02510430|PLACEBO_COMPARATOR|Usual Care|This is an attention control group and is not asked to make changes to sitting time.
62046594|NCT02526654|EXPERIMENTAL|Glaucoma Subjects|Subjects with glaucoma were recruited based on characteristic glaucomatous disc damage and visual field changes. They will perform visual field with Heidelberg Edge Perimeter and Octopus visual field. Optical Coherence Tomography will image the retinal nerve fiber layer.
62046595|NCT02526654|EXPERIMENTAL|Healthy Controls|Subjects that do not have glaucoma and are recruited for testing will perform visual field with Heidelberg Edge Perimeter and Octopus visual field. Optical Coherence Tomography will image the retinal nerve fiber layer.
62046596|NCT00677833|EXPERIMENTAL|1|
62046597|NCT00677833|EXPERIMENTAL|2|
62046598|NCT04492527|EXPERIMENTAL|Telehealth coaching sessions|Receives the Telehealth-delivered coaching sessions.
62248558|NCT01893229|EXPERIMENTAL|Lithium|name: lithium; dosage form: 250mg Tablet; dosage and frequency: 750mg-2000mg/d;serum Li level: 0.6mmol-1.2mmol/L; duration: 6 weeks
62248559|NCT00558155|EXPERIMENTAL|SEN|standard enteral nutrition
62248560|NCT00558155|EXPERIMENTAL|IMEN|immunostimulating enteral nutrition
62248561|NCT00558155|EXPERIMENTAL|SPN|standard parenteral nutrition
62248562|NCT00558155|EXPERIMENTAL|IMPN|immunostimulating parenteral nutrition
62248563|NCT00161486|PLACEBO_COMPARATOR|1|Placebo acyline injections every two weeks (2 doses) + placebo testosterone gel daily for 4 weeks
62248564|NCT00161486|ACTIVE_COMPARATOR|2|Acyline 300 μg/kg every two weeks (2 doses) + placebo Testosterone gel daily for 4 weeks
62605946|NCT05576441|EXPERIMENTAL|Control group:SCTG|SCTG will be harvested from donor site as per the requirement and will be placed at the recipient and suturing will be done with 5-0 vicryl suture.
62046599|NCT03827057|EXPERIMENTAL|Reconsolidation of Traumatic Memories (RTM)|"Participants in each arm of the study will receive up to 10 90-minute manualized treatment sessions. RTM will follow a manual developed by the Research and Recognition Project, who will also train and supervise the therapists. It is anticipated that these treatments will most often be administered once per week for 10 weeks. To best meet participant needs, we will allow therapy in either arm to be massed in the pattern recently reported by Foa et al. for PE, with sessions separated by at least 24 hours over two weeks. This schedule has been used with both RTM and PE without hurting response rates, and may reduce drop-out rates. Participants who achieve remission of their PTSD before 10 sessions, measured by a PCL5 \<34, can decide with their therapist whether early cessation of therapy is appropriate."
62046600|NCT03827057|ACTIVE_COMPARATOR|Prolonged Exposure (PE)|"Participants in each arm of the study will receive up to 10 90-minute manualized treatment sessions. PE will follow a manual written by the Foa and colleagues, and the therapists will be trained by expert trainers from the Center for Deployment Psychology. It is anticipated that these treatments will most often be administered once per week for 10 weeks. To best meet participant needs, we will allow therapy in either arm to be massed in the pattern recently reported by Foa et al. for PE, with sessions separated by at least 24 hours over two weeks. This schedule has been used with both RTM and PE without hurting response rates, and may reduce drop-out rates. Participants who achieve remission of their PTSD before 10 sessions, measured by a PCL5 \<34, can decide with their therapist whether early cessation of therapy is appropriate."
62046601|NCT01117272||PCOS group|Who met the 2003 Rotterdam criteria.
62046602|NCT01117272||Mild hyperprolactinaemia group|Who were diagnosed with prolactin levels above the upper limit of normal (24.29 ng/ml) and under 100 ng/ml.
62046603|NCT01117272||Control group|Without PCOS and with normal prolactin levels.
62046604|NCT00378352|PLACEBO_COMPARATOR|Dose Escalation Safety|The objective of the first phase is to evaluate the safety of escalating doses of Epoetin alfa in patients with STEMIs.
62046605|NCT00378352|PLACEBO_COMPARATOR|Single Dose Efficacy|Single parenteral administration of 60000 U of epoetin alfa. The objectives of the second phase are to investigate the effects of the highest safe dose on infarct size, left ventricular remodeling and endothelial progenitor cells.
62046606|NCT02904876|EXPERIMENTAL|Magnetic Resonance Imaging at 6 months|2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
62046607|NCT03918863|EXPERIMENTAL|Neuromuscular electrical stimulation|8-week exercise program, twice a week, with neuromuscular eletrical stimulation on vastus medialis and gluteus medius.
62046608|NCT03918863|ACTIVE_COMPARATOR|Exercise|8-week exercise program, twice a week.
62605947|NCT04438499|EXPERIMENTAL|Subjects Indicated for a UDS study|The investigational device, i.e. the eSense catheter will be used in all the subjects to assess primary and exploratory objectives. It is a single arm study with no comparative, placebo, sham or control arm.
62828659|NCT02631239|ACTIVE_COMPARATOR|MESA|Methotrexate, etoposide, dexamethasone, Peg-asparaginase and sandwiched radiotherapy
62828660|NCT02631239|EXPERIMENTAL|ESA|Etoposide, dexamethasone, Peg-asparaginase and sandwiched radiotherapy
62828661|NCT04885998|EXPERIMENTAL|Phase 1: Dose Exploration|The recommended phase 2 target dose (RP2D) of tarlatamab in combination with AMG 404 will be estimated using a modified toxicity probability interval (mTPI-2) design. A combination RP2D may be identified based on emerging safety, efficacy, and pharmacodynamic data prior to reaching an maximum tolerated dose (MTD).
62828662|NCT04885998|EXPERIMENTAL|Phase 2: Dose Expansion|Participants will receive the RP2D of tarlatamab in combination with AMG 404 identified in Phase 1 (dose exploration) of the study.
62828663|NCT03873116|EXPERIMENTAL|BCX7353 110mg once daily|BCX7353 capsules administered orally once daily
62828664|NCT03873116|EXPERIMENTAL|BCX7353 150mg once daily|BCX7353 capsules administered orally once daily
62046609|NCT03977675|EXPERIMENTAL|Ketamine 0.3 mg/kg|Subjects are assigned to receive a dose of 0.3 mg/kg of Ketamine.
62046610|NCT03977675|EXPERIMENTAL|Ketamine 0.5 mg/kg|Subjects are assigned to receive a dose of 0.5 mg/kg of Ketamine.
62046611|NCT03977675|EXPERIMENTAL|Ketamine 0.7 mg/kg|Subjects are assigned to receive a dose of 0.7 mg/kg of Ketamine.
62248565|NCT00161486|ACTIVE_COMPARATOR|3|Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks + Testosterone gel 100 mg daily for 4 weeks
62605948|NCT06531772||Tuberculosis without HIV|
62605949|NCT06531772||Tuberculosis with HIV Coinfection|
62605950|NCT01890616||Motility|This arm will ingest the SmartPill.
62828665|NCT03873116|PLACEBO_COMPARATOR|Placebo|Matching placebo oral capsules administered orally once daily
62828666|NCT02166346|EXPERIMENTAL|Dalfampridine then Placebo|All subjects were randomized for the first double-blinded 8-week part of the study to the dalfampridine group. Then subjects were crossed over to the placebo arm for another 8 weeks.
62828667|NCT02166346|EXPERIMENTAL|Placebo the Dalfampridine|All subjects were randomized for the first double-blinded 8-week part of the study to the placebo arm. Then subjects were crossed over to the dalfampridine arm for another 8 weeks.
62828668|NCT04730102||Patients undergoing rectal washout in transanal mesorectal excision|Patients undergoing rectal washout in transanal mesorectal excision for rectal cancer.
62828669|NCT02798627|EXPERIMENTAL|NS2359|The initial dose of the NS2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
62828670|NCT02798627|PLACEBO_COMPARATOR|placebo|Placebo pills matched to NS2359 pills will be given once daily. Patients with difficult adverse events at the 2 mg placebo will be allowed to reduce to 1 mg placebo once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
62438638|NCT01391182|PLACEBO_COMPARATOR|Placebo arm|In order to obtain sufficient power, a total of 120 patients will be studied, 60 in each group. The surgeon performing the case, their staff, the anesthesiologist, nurse anesthetist and the patient will be blinded to whether the patient received EACA or placebo. Pharmacy will prepare the EACA dose or the saline. Serum hemoglobin levels with be drawn preoperatively and on post operative days one, two, and three. The first dose will be given in the operating room prior to incision (within 30 minutes of the incision). The second dose will be given four hours after the first dose. Two doses are given due to the short half-life of EACA. The timing of administration of EACA will be recorded.
62828671|NCT01148368|EXPERIMENTAL|renal impairment patients|renal impairment patients who eGFR is lower than 30 ml/min/1.73m\^2 without hemodialysis
62828672|NCT01148368|ACTIVE_COMPARATOR|healthy volunteers|healthy volunteers group
62828673|NCT05706298|NO_INTERVENTION|Habitual lifestyle|Participants in the control group will be asked to maintain their habitual lifestyle.
62046612|NCT05194904|ACTIVE_COMPARATOR|group 1|ketorolac group: number = 30 patients , time : after intubation, dose 0.9 mg/kg
62046613|NCT05194904|ACTIVE_COMPARATOR|group 2|Dexmedetomidine group: number : 30 patients, time : after intubation, dose 1 μg/kg
62046614|NCT02096328|EXPERIMENTAL|POL7080, Anti-pseudomonal antibiotics|POL7080 daily co-administered with standard of care treatment
62248566|NCT04907747|EXPERIMENTAL|Group A: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 10 days|Vonoprazan 20mg qd, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 10days
62438639|NCT02172716|EXPERIMENTAL|Nonsurgical periodontal treatment|Nonsurgical periodontal treatment will be conducted following a full-mouth approach; no antibiotics or chemical plaque control will be provided.
62438640|NCT03501550|EXPERIMENTAL|CDI-31244 + SOF/VEL|CDI-31244 in combination with SOF/VEL
62438641|NCT03491878|EXPERIMENTAL|3D approach|Three dimensional laparoscopic cholecystectomy including segments IVB and V
62438642|NCT03491878|ACTIVE_COMPARATOR|open approach|Open cholecystectomy including segments IVB and V
62828674|NCT05706298|EXPERIMENTAL|Active breaks|Participants will be asked to interrupt sitting with 3 min bouts of walking every 30 min (16 bouts per day, equalling 48 min of walking) from 9am-5pm every day throughout the 4 week period. To improve adherence should participants miss a bout of walking they will be asked to do 6 min during the next bout.
62828675|NCT01222052|EXPERIMENTAL|Arm A Taxane-containing|3 courses FEC q3weeks followed by 3 courses Docetaxel q3weeks
62828676|NCT01222052|ACTIVE_COMPARATOR|Arm B standard anthracyclin|6 courses of FEC q3weeks
62828677|NCT01222052|NO_INTERVENTION|Observation|
62828678|NCT04230889|OTHER|Usual Diet Group|Instructed to continue to maintain a diet pattern of three main meals (breakfast, lunch and dinner) with two daily snacks including a usual snack (of their own choosing) mid-morning and a usual snack (of their own choosing) mid-afternoon.
62828679|NCT04230889|EXPERIMENTAL|Group 1 Nutritional Shake|Instructed to consume one nutrition shake instead of their usual breakfast and consume the second nutrition shake for their mid-afternoon snack.
62046615|NCT03493243||Adolescents exposed|Only clinical questionnaires
62046616|NCT03466086|EXPERIMENTAL|Test/Control|Subjects between the ages of 18-69 years of age will sequentially try the Test and Control eye drops in a random order
62046617|NCT03466086|EXPERIMENTAL|Control/Test|Subjects between the ages of 18-69 years of age will sequentially try the Control and Test eye drops in a random order.
62828680|NCT04230889|EXPERIMENTAL|Group 2 Nutritional Shake|Instructed to consume one Study Shake instead of their usual breakfast and the second Study Shake for the second snack before bed-time.
62828681|NCT04231578|EXPERIMENTAL|Immediate Couple HOPES|Immediately assigned to receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
62828682|NCT04231578|NO_INTERVENTION|Delayed Intervention|Participants will not receive Couple HOPES for the first 8 weeks, and complete assessments at the beginning, middle, and end of this period. After this 8-week delay, participants will then receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
62248567|NCT04907747|EXPERIMENTAL|Group B: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 14 days|Vonoprazan 20mg qd, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 14days
62438643|NCT01131728|EXPERIMENTAL|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.
62605951|NCT06726837|ACTIVE_COMPARATOR|Group 1: AH Plus Root Canal Sealer|"Patients will be informed and have an informed consent form signed. Infiltrative anesthesia (4% articaine hydrochloride containing 1:100,000 adrenaline) will be applied. The relevant tooth will be isolated, and the access cavity will be prepared.~The canal length will be determined, and canals will be prepared with Reciproc R25 files. 15 ml of 2.5% sodium hypochlorite (NaOCl) will be used. In the final irrigation, 5 ml of 17% EDTA, 5 ml of 2.5% NaOCl, and 2 ml of distilled water will be used and activated with a sonic activation device.~All canals will be filled using the warm vertical condensation technique and AH Plus root canal sealer (n=24). All treatments will be completed in a single session.~Patients will be given a visual analog scale (VAS) form and asked to mark their pain levels between 0 and 10 at 6, 24, 48, 72 hours, and 7 days after treatment. At the end of the 7th day, patients will be called for a check-up, and VAS questionnaires will be collected."
62605952|NCT06726837|ACTIVE_COMPARATOR|Group 2: TotalFill BC Sealer|All anesthesia, isolation, root canal preparation procedure, and filling technique are the same as in group 1. However, TotalFill BC root canal sealer will be used in this group instead of Ah Plus, which was used in group 1.
62828683|NCT06474247|EXPERIMENTAL|Postbiotic|Postbiotic at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks
62605953|NCT06726837|ACTIVE_COMPARATOR|Group 3: Bio-C Root Canal Sealer|All anesthesia, isolation, root canal preparation procedure, and filling technique are the same as in group 1. However, Bio-C root canal sealer will be used in this group instead of Ah Plus, which was used in group 1.
62605954|NCT06619886|EXPERIMENTAL|TP53 R248Q specific TCR transduction T cell therapy|Dose Escalation of TCR T cell product
62605955|NCT06730256|EXPERIMENTAL|CAR-T cells Infusion chimeric antigen receptor T cells|Drug: CAR-T cells Infusion chimeric antigen receptor T cells
62605956|NCT05873335|EXPERIMENTAL|Healthy Adults|Healthy adults
62438644|NCT01131728|ACTIVE_COMPARATOR|Aleve Cold and Sinus|Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).
62605957|NCT06451549|EXPERIMENTAL|Syndi recommender system for mental health apps|Syndi is a recommender system for mental health apps, delivered via a website. It guides users through a clinically-validated self-assessment and uses a machine learning system to provide personalised recommendations of independently-rated mental health tools.
62605958|NCT00558051|ACTIVE_COMPARATOR|Intradermal administration|Intradermal administration
62605959|NCT00558051|ACTIVE_COMPARATOR|Intranodal administration|Intranodal administration
62248568|NCT04907747|ACTIVE_COMPARATOR|Group C: Esomeprazole taken with bismuth, amoxicillin, furazolidone for 14 days|Esomeprazole 20 mg bid, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 14days
62438645|NCT03085082||skeletal class II subjects|patients with wits appraisal more than 3 mm measured on a cephalometric x ray obtained during diagnosis
62438646|NCT03085082||skeletal class III subjects|patients with wits appraisal less than -3 mm measured on a cephalometric x ray obtained during diagnosis
62438647|NCT03085082||skeletal class I patients|patients with Wits appraisal between -3 and +3 that is measured from a cephalometric x ray obtained during diagnosis of arch length discrepancy. this group will serve as control and obtained after recruitment of the other 2 groups in 1 to 1 fashion
62438648|NCT01909583|ACTIVE_COMPARATOR|STAGES PRE-GROUP|"INTERVENTION: this group will receive our STAGES booklet PRE-operatively"
62438649|NCT01909583|PLACEBO_COMPARATOR|STAGES POST-GROUP|INTERVENTION: This arm will only receive the STAGES-booklet POST-operatively
62605960|NCT00558051|ACTIVE_COMPARATOR|Intralymphatic infusion|Intralymphatic infusion
62605961|NCT06022042|EXPERIMENTAL|On1 Abutment + Nobel PMC implant Set|Subjects who takes implant therapy using On1 Abutment + Nobel PMC implant
62605962|NCT06022042|EXPERIMENTAL|On1 Abutment + Nobel PCC Implant Set|Subjects who takes implant therapy using On1 Abutment + Nobel PCC Implant
62605963|NCT06022042|EXPERIMENTAL|On1 Abutment + Nobel CC Implant Set|Subjects who takes implant therapy using On1 Abutment + Nobel CC Implant
62605964|NCT06022042|ACTIVE_COMPARATOR|One-Stage Abutment + Nobel PMC Implant Set|Subjects who takes implant therapy using One-Stage Abutment + Nobel PMC Implant
62605965|NCT06022042|ACTIVE_COMPARATOR|One-Stage Abutment + Nobel PCC Implant Set|Subjects who takes implant therapy using One-Stage Abutment + Nobel PCC Implant
62605966|NCT06022042|ACTIVE_COMPARATOR|One-Stage Abutment + Nobel CC Implant Set|Subjects who takes implant therapy using One-Stage Abutment + Nobel CC Implant
62828684|NCT06474247|PLACEBO_COMPARATOR|Placebo|Placebo at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks
62828685|NCT05285371|PLACEBO_COMPARATOR|CONT Group|CONT group will receive standard traditional intravenous fluid of D50.45% NaCl + 20 mEq/L KCl at 2/3 maintenance rate.
62828686|NCT05285371|EXPERIMENTAL|BOL Group|BOL group will receive intravenous boluses of Lactated Ringer's three times daily at 2/3 maintenance rate.
62828687|NCT05159440|EXPERIMENTAL|Monotherapy Dose Dose Finding - Part 1|TORL-2-307-MAB
62828688|NCT05159440|EXPERIMENTAL|Expansion as Monotherapy - Part 2|TORL-2-307-MAB
62828689|NCT02680249|EXPERIMENTAL|CTP-656 Fed, low fat|Single dose of CTP-656 150 mg administered after a low-fat breakfast
62828690|NCT02680249|EXPERIMENTAL|CTP-656 Fasted|Single dose of CTP-656 150 mg administered fasted
62828691|NCT02680249|EXPERIMENTAL|CTP-656 Fed, high fat|Single dose of CTP-656 150 mg administered after a moderate-fat breakfast
62828692|NCT03642587||Study Population|People between the ages of 2 and 85 years old with out of hospital cardiac arrest of no obvious cause who are attended to by paramedics who survive or die
62828693|NCT06586099|EXPERIMENTAL|treatment arm|azacytidine 75mg/m2/d, IH,day1-7, every 28 days for three cycles tislelizumab 200mg,day 8,every three weeks, for 4 doses
62828694|NCT02987426|EXPERIMENTAL|Mindfulness-oriented intervention|Patients will get a mindfulness-oriented intervention daily for 10 minutes.
62605967|NCT02180802|EXPERIMENTAL|motivational intervieing group|The behavioral intervention targets were improved eating and physical activity behavior in order to reduce obesity levels. Each adolescent was encouraged to eat a variety of foods from each of the four major food groups and low-fat alternatives . Moreover, each adolescent was encouraged to achieve at least 60 minutes of moderate-to-vigorous intensity physical activity daily as recommended by the World Health Organization
62438650|NCT05004818|SHAM_COMPARATOR|sham procedure|Participants with severe motion sickness were sited in the the rotatory chair with the videonystagmography recorder masking their eyes, while two galvanic vestibular stimulation electrodes were connected to the mastoid processes. No active stimulus was given.
62046618|NCT00995072|EXPERIMENTAL|Arm A|Nebivolol 5 mg daily for 12 weeks followed by Metoprolol succinate 100 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to metoprolol.
62605968|NCT02180802|EXPERIMENTAL|motivational interviewi group with parental involvement|an additional single session with parents or guardians over 60 minutes in the clinic
62438651|NCT05004818|EXPERIMENTAL|GVS stimulation coupled with inverse phase rotatory chair stimulation|Participants with severe motion sickness were sited in the the rotatory chair with the videonystagmography recorder masking their eyes, while two galvanic vestibular stimulation electrodes were connected to the mastoid processes. The rotatory chair was activated in sinusoidal harmonic acceleration protocol in inverse phase to galvanic vestibular stimulation.
62605969|NCT02180802|ACTIVE_COMPARATOR|Control|The patients received routine care
62828695|NCT02987426|NO_INTERVENTION|Treatment as Usual|This group will continue receiving their normal inpatient psychiatric care and receive information (paper brochures) about health promotion.
62828696|NCT05794958|ACTIVE_COMPARATOR|Safety Run-in phase|First three patients (maximum of 6) will receive 0.5 x 106/kg CART cells (25% standard dose) as reinfusion product between days 7 through 14 if CRS/ICANS has resolved to a grade 1 or less.
62828697|NCT05794958|EXPERIMENTAL|Phase 1b|Up to 20 evaluable subjects will receive the target dose of AxiCel infusion to evaluate efficacy of Axi-Cel-2 in adults with high risk relapsed/refractory LBCL
62828698|NCT06594458|EXPERIMENTAL|Neonatal Respiratory Distress Arm|Newborn manifesting tachypnea or respiratory distress in the delivery room (that responds to supplementary oxygen with FiO2 \<30% and without the need for mechanical ventilation) are placed in a preheated incubator with the required oxygen concentration (if necessary) and carefully monitored by medical and nursing clinicians.
62438652|NCT01892995|EXPERIMENTAL|Ketamine|active arm
62438653|NCT01892995|SHAM_COMPARATOR|Diphenhydramine|sham arm
62438654|NCT01892995|PLACEBO_COMPARATOR|Saline|placebo
62828699|NCT06202482|EXPERIMENTAL|Experimental group|Participants in the intervention group will participate in a 6-week Connect Active Program (CAP). Young participants will be the pioneers and take the initiative to change their inactive and sedentary lifestyles by including exercise into their daily routines about once a week, at least 45 minutes each time. For instance, they could organize family field trips to waterfront parks or involve their older family members in their favorite sports. All walking activities included in the study should be done with the Nike Run Club App for record and outcome measures. For other activities in CAP, participants will use other apps following that week's topic. For instance, they will use Google Maps to search for the best routes to their destinations; transportation apps such as Kowloon Motor Bus, Long Win Bus, and Mass Transit Railway apps to search for stops and exits.
62828700|NCT06202482|NO_INTERVENTION|Control group|Participants in the control group will be provided with a leaflet as usual care. The pamphlet contains information about the benefits and some instructions for walking exercises for older adults.
62828701|NCT04829201||Obstructive sleep apnea (OSA)|OSA patients who are eligible for either functional septorhinoplasty or oropharyngeal/orthognathic surgery
62828702|NCT02435953|EXPERIMENTAL|TACE-RFA|1-2 times of TACE treatment, then followed by RFA treatment.
62828703|NCT02435953|ACTIVE_COMPARATOR|TACE alone|TACE treatment several times till tumor progress to advance stage
62828704|NCT03977961||DDD Patients|All patients presenting to the neurosurgical department of the Kantonsspital St. Gallen (KSSG) with a diagnosed DDD fulfilling the inclusion criteria and scheduled for surgery will be considered for this study.
62828705|NCT04268004|NO_INTERVENTION|Standard of Care (Control)|Participants will receive a standard of care fertility consult.
62828706|NCT04268004|EXPERIMENTAL|FP Decision Tool and Discussion (Treatment)|Participants will receive a standard of care fertility consult and will participate in a family-centered psychoeducational intervention consisting of completing a FP Decision Tool and participating in a guided discussion about responses and discrepancies identified in the FP Decision Tool.
62046619|NCT00995072|EXPERIMENTAL|Arm B|Metoprolol succinate 100 mg daily for 12 weeks followed by nebivolol 5 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to nebivolol.
62046620|NCT03865602|EXPERIMENTAL|Sepsis Transition And Recovery (STAR)|Virtual sepsis navigation delivered across the peri-hospital discharge interval
62438655|NCT06528678||EMV monovision|Cataract surgery with EMV IOL
62438656|NCT05687045|EXPERIMENTAL|High Flow Nasal Cannula|High Flow Nasal cannula is a system to deliver heated and humidified oxygen with an inspired oxygen fraction between 21 and 100% through large bore nasal cannula. The system delivers a flow up to 60 liters/min.
62438657|NCT05687045|ACTIVE_COMPARATOR|Standard Treatment|If peripheral oxygen saturation will be \< 95%, conventional oxygen therapy will be administered through common nasal cannula with a flow up to 6 Liters per minute
62438658|NCT01563471|EXPERIMENTAL|Treatment sequence 1|
62438659|NCT01563471|EXPERIMENTAL|Treatment sequence 2|
62605970|NCT01432275|EXPERIMENTAL|ADC, Then Comparator, Then ADC With Calculator|Subject used the ADC blood glucose meter for 7 days with the insulin calculator not activated, followed by a comparator blood glucose meter for 7 days. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.
62605971|NCT01432275|EXPERIMENTAL|Comparator, Then ADC, Then ADC With Calculator|Subject used a comparator blood glucose meter for 7 days, followed by the ADC blood glucose meter for 7 days, with the insulin calculator not activated. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.
62605972|NCT05795205|EXPERIMENTAL|Normal dinner consumption|Participants will have their dinner between 1800-1830pm
62605973|NCT05795205|EXPERIMENTAL|Delayed dinner consumption|Participants will have their dinner between 2200-2230pm
62046621|NCT03865602|ACTIVE_COMPARATOR|Usual Care|Patients and their providers will have no access to the STAR program. Aspects of usual care will be determined by treating clinicians independent of trial assignment.
62046622|NCT05207514|EXPERIMENTAL|Nanoxel M|AC(Doxorubicin, Cyclophosphamide) followed by Nanoxel M
62046623|NCT05207514|ACTIVE_COMPARATOR|Taxotere|AC(Doxorubicin, Cyclophosphamide) followed by Taxotere
62248569|NCT00851123|EXPERIMENTAL|1. Modified Constraint-Induced Movement therapy|Modified Constraint-Induced Movement Therapy at the rehabilitation unit or in an outpatient clinic.
62248570|NCT00851123|EXPERIMENTAL|2.Task-specific bimanual training|Task-specific bimanual training at the rehabilitation unit or in an outpatient clinic.
62248571|NCT06373471|EXPERIMENTAL|Intervention arm|Comprehensive Geriatric Assessment and treatment
62248572|NCT06373471|NO_INTERVENTION|Control|Standard hematological evaluation of comorbidity and needs during hematological cancer treatment.
62438660|NCT01563471|EXPERIMENTAL|Treatment sequence 3|
62438661|NCT01563471|PLACEBO_COMPARATOR|Treatment sequence 4|
62438662|NCT01907659|NO_INTERVENTION|Standard of care|Standard of care for respiratory infections
62438663|NCT01907659|EXPERIMENTAL|Release of test results|Health care providers will receive viral PCR and PCT test results along with an algorithm recommending antibiotic treatment based on PCT level.
62438664|NCT02184494|EXPERIMENTAL|Blood Lactate Response in PD|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in a PD population. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
62438665|NCT02184494|EXPERIMENTAL|Blood Lactate Response in MS|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in an MS population. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
62438666|NCT02184494|EXPERIMENTAL|Blood Lactate Responses in Controls|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in healthy, older adults. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
62605974|NCT05795205|EXPERIMENTAL|Exercise with delayed dinner consumption|Participants will exercise on a treadmill for 45 min followed by delayed dinner between 2200-2230pm
62046624|NCT04206189|ACTIVE_COMPARATOR|Carbohydrate group|
62046625|NCT04206189|NO_INTERVENTION|Control group|
62046626|NCT00780858||Ganirelix|Patients with premature lutenization (progesterone \>1,2 ng/ml) who did not get pregnant during the first IUI underwent a second IUI.
62248573|NCT00509067|EXPERIMENTAL|A|Participants assigned to receive galantamine and CDP-choline
62248574|NCT00509067|PLACEBO_COMPARATOR|B|Participants assigned to receive placebo
62248575|NCT00915772|EXPERIMENTAL|Linagliptin + metformin bid|Linagliptin low dose + metformin 500 mg, bid
62248576|NCT00915772|EXPERIMENTAL|Linagliptin+ metformin bid|Linagliptin low dose + metformin 1000 mg bid
62605975|NCT02818621|ACTIVE_COMPARATOR|Group Dex|"The Dex group received 1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure.~Interventions:~◦Drug: Dexmedetomidine"
62605976|NCT02818621|PLACEBO_COMPARATOR|Group Placebo|"The Placebo group received equal amount of normal saline.~Interventions:~◦Drug: Normal saline"
62605977|NCT02535234|ACTIVE_COMPARATOR|Arm 1|Participants randomised to Arm 1 will receive an intervention of 7 nights with the Novel system followed by 7 nights with theTraditional system
62828707|NCT01310777|EXPERIMENTAL|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months
62046627|NCT00780858||Control|Patients without premature lutenization (progesterone \>1,2 ng/ml) underwent a only one IUI.
62248577|NCT00915772|ACTIVE_COMPARATOR|Metformin bid|Metformin 1000 mg bid
62248578|NCT01095367|ACTIVE_COMPARATOR|Seprafilm™|Subject will have 3 sheets of Seprafilm™ placed in her abdominal cavity (in the pelvis, upper abdomen and below the incision) at the end of debulking surgery. At 7-21 days after surgery the subject will receive a contrast dye, Iohexol (Omnipaque™), into her intraperitoneal port. The subject will then undergo 3 abdominal X-rays, to assess the extent of abdominal adhesions.
62248579|NCT01095367|NO_INTERVENTION|No Seprafilm™|Subject will undergo debulking surgery without Seprafilm™ placement (standard care). At 7-21 days after surgery the subject will receive a contrast dye, Iohexol (Omnipaque™), into her intraperitoneal port. The subject will then undergo 3 abdominal X-rays, to assess the extent of abdominal adhesions.
62248580|NCT06461767|ACTIVE_COMPARATOR|group (1) will rTMS over left motor cortex|"Repetitive transcranial magnetic stimulation parameters:~stimulation site: left motor cortex intensity: 70% of resting motor threshold frequency: 15 Hz number of pulses: 30 number of trains: 40"
62605978|NCT02535234|ACTIVE_COMPARATOR|Arm 2|Participants randomised to Arm 1 will receive an intervention of 7 nights with the Traditional system followed by 7 nights with the Novel system
62605979|NCT00561470|PLACEBO_COMPARATOR|Placebo/FOLFIRI|Participants with Metastatic Colorectal Cancer administered Placebo followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
62605980|NCT00561470|EXPERIMENTAL|Aflibercept/FOLFIRI|Participants with Metastatic Colorectal Cancer administered Aflibercept followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
62605981|NCT00322127|EXPERIMENTAL|1|AMD3100 given as a single 240 g/kg dose followed 14-90 days later by a single 320 g/kg dose
62046628|NCT02712034|PLACEBO_COMPARATOR|Medication-assisted treatment (MAT)|Patients will receive standard medication-assisted treatment (MAT) as prescribed by their health care provider.
62046629|NCT02712034|EXPERIMENTAL|MAT + A-CHESS|Patients in the MAT + A-CHESS arm will receive MAT as described plus the A-CHESS recovery support system via a smartphone.
62046630|NCT03959462|EXPERIMENTAL|Real tDCS|20 min of 1 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the decision task.
62046631|NCT03959462|SHAM_COMPARATOR|Sham tDCS|30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the decision task.
62046632|NCT04548063|EXPERIMENTAL|6,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 6,000 words.
62046633|NCT04548063|EXPERIMENTAL|4,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 4,000 words.
62046634|NCT04548063|EXPERIMENTAL|2,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 2,000 words.
62046635|NCT00406133|NO_INTERVENTION|Standard intensive glucose monitoring|Patients in the control group were given blood glucose meters and test strips and asked to perform home blood glucose monitoring at least four times daily.
62046636|NCT00406133|ACTIVE_COMPARATOR|Continuous Glucose Monitoring (CGM)|Patients in the CGM group were instructed to use the CGM device on a daily basis and to verify the accuracy of the glucose measurement with a home blood glucose meter (provided by the study) before making management decisions (as per the regulatory labeling of the devices).
62046637|NCT05638633|ACTIVE_COMPARATOR|1st arm (prednisolone and placebo)|Day 1-5: prednisolone 20mg 1x1 and placebo 1x1 Day 6-28: prednisolone 5mg 1x1 and placebo 1x1
62046638|NCT05638633|ACTIVE_COMPARATOR|2nd arm (placebo and Vitamin B compound)|Day 1-5: Placebo 1x1 and Vitamin B compound (100 mg B1, 50 mg B6, 500µ B12) 1x1 Day 6-28: placebo 1x1 and Vitamin B compound (100 mg B1, 50 mg B6, 500 µg B12) 1x1
62046639|NCT05638633|ACTIVE_COMPARATOR|3rd arm (prednisolone and Vitamin B compound)|Day 1-5: prednisolone 20mg 1x1 and Vitamin B compound (100 mg B1, 50 mg B6, 500µg B12) 1x1 Day 6-28: prednisolone 5mg 1x1 and Vitamin B compound (100 mg B1, 50mg B6, 500µg B12) 1x1
62046640|NCT05638633|PLACEBO_COMPARATOR|4rd arm (placebo and placebo)|Day 1-5: Placebo 1x1 and placebo 1x1 Day 6-28: placebo 1x1 and placebo 1x1
62248581|NCT06461767|ACTIVE_COMPARATOR|group (2) will receive rTMS over left dorsolateral prefrontal cortex|"Repetitive transcranial magnetic stimulation parameters:~stimulation site: left dorsolateral prefrontal cortex intensity: 70% of resting motor threshold frequency: 15 Hz number of pulses: 30 number of trains: 40"
62046641|NCT03232983|EXPERIMENTAL|LY900014 (SC Abdomen)|Single dose of 15-U of LY900014 administered subcutaneously (SC) into the abdomen in one period
62046642|NCT03232983|EXPERIMENTAL|LY900014 (SC Thigh)|Single dose of 15-U of LY900014 administered SC into the thigh in one period
62046643|NCT03232983|EXPERIMENTAL|LY900014 (SC Arm)|Single dose of 15-U of LY900014 administered SC into the arm (deltoid) in one period
62046644|NCT03232983|ACTIVE_COMPARATOR|LY900014 (IV)|Single dose of 15-U of LY900014 administered intravenously (IV) in one period
62248582|NCT06461767|ACTIVE_COMPARATOR|group (3) will receive rTMS over left dorsolateral prefrontal cortex and left motor cortex|"Repetitive transcranial magnetic stimulation parameters:~stimulation site: left dorsolateral prefrontal cortex and left motor cortex intensity: 70% of resting motor threshold frequency: 15 Hz number of pulses: 30 number of trains: 40"
62605982|NCT00322127|EXPERIMENTAL|2|AMD3100 given as a single 320 g/kg dose followed 14-90 days later by a single 400 g/kg dose
62605983|NCT00322127|EXPERIMENTAL|3|AMD3100 given as a single 400 g/kg dose followed 14-90 days later by a single 480 g/kg dose.
62605984|NCT00322127|EXPERIMENTAL|4|randomized to either receive 240 g/kg first followed by 480 g/kg after a washout period or 480 g/kg first followed by 240 g/kg after a washout period.
62605985|NCT04012281||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with 2nd generation drug-eluting stent (DES) and measured fractional flow reserve after PCI
62605986|NCT02671734|NO_INTERVENTION|control|Subjects in this arm received the standard consent form to read and underwent standard discussions with the procedurist prior to the procedure.
62605987|NCT02671734|ACTIVE_COMPARATOR|intervention|Subjects in this arm viewed a video detailing key elements of informed consent. Subjects in this arm also received the standard consent form to read and underwent standard discussions with the procedurist prior to the procedure.
62438667|NCT04289220|EXPERIMENTAL|Anti-CD19 CAR-T Cells Injection|Anti-CD19 CAR-T Cells Injection, Dosage form：injection Dosage:1-2.5x10\^6/kg, 100ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes, Frequency: total one time
62438668|NCT03435432|ACTIVE_COMPARATOR|Glucose|50 grams of glucose in 50 ml water
62438669|NCT03435432|PLACEBO_COMPARATOR|Water|50 ml water
62438670|NCT00950183|OTHER|Foot and Ankle Surgery|Please note that the study was terminated prior to randomization of patients.
62438671|NCT00249457|EXPERIMENTAL|Therapeutic Workplace|Contingency management. Invited to work in the Therapeutic Workplace. Completed monthly assessments.
62438672|NCT00249457|NO_INTERVENTION|Usual Care Control Group|No intervention. Not invited to work int the Therapeutic Workplace. Completed monthly assessments.
62438673|NCT02632656||Patients with congestive heart failure|Patients with congestive heart failure (CHF) who are followed in the hospital or clinic setting, with optimization of medical therapy
62438674|NCT01907087|EXPERIMENTAL|BMN190|recombinant human tripeptidyl peptidase-1 (rhTPP1/cerliponase alfa)
62438675|NCT02600806|OTHER|Azithromycin/levofloxacin|Azithromycin or levofloxacin are given according to serum procalcitonin levels
62438676|NCT01527825|ACTIVE_COMPARATOR|Single dose|Trivalent Influenza Vaccine (seasonal)
62438677|NCT01527825|EXPERIMENTAL|Double dose TIV|Trivalent Influenza vaccine (seasonal) Two doses will be administered at enrolment
62828708|NCT01310777|ACTIVE_COMPARATOR|Brinz|Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months
62248583|NCT06461767|SHAM_COMPARATOR|group (4) will receive sham stimulation|"Repetitive transcranial magnetic stimulation parameters:~stimulation site: the coil will be perpendicular over vertex of skull intensity: 70% of resting motor threshold frequency: 15 Hz number of pulses: 30 number of trains: 40"
62438678|NCT01527825|EXPERIMENTAL|Two dose TIV|Trivalent Influenza vaccine (seasonal) Participants will receive two doses of TIV, one month apart
62438679|NCT01859390|EXPERIMENTAL|AquADEKs-2|Two control multivitamin softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 4 weeks for the screening run in period. For those subjects randomized to the AquADEKs-2 arm, two AquADEKs-2 softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 16 weeks.
62438680|NCT01859390|ACTIVE_COMPARATOR|Control multivitamin|Two control multivitamin softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 4 weeks for the screening run in period for all participants and for 16 weeks for those randomized to this comparative therapy.
62438681|NCT05278377||Apprenti en Action (intervention group)|"Apprenti en Action consists of six, one-hour culinary workshops offered once a week during school hours."
62438682|NCT05278377||Control group|"Students in the control group do not receive the Apprenti en Action program."
62605988|NCT03182634|EXPERIMENTAL|Cohort A - Extended-dose fulvestrant|Fulvestrant 500mg IM on Cycle 1 Days 1, 8 and 15 and Cycle 2 onwards Days 1 and 15
62605989|NCT03182634|EXPERIMENTAL|Cohort B - Neratinib|Neratinib 240mg PO on a continuous schedule starting on Cycle 1 Day 1 AND in ER positive breast cancer, fulvestrant 500mg IM on Cycle 1 Days 1 and 15 and Cycle 2 onwards Day 1
62828709|NCT01310777|ACTIVE_COMPARATOR|Brim|Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye 2 times a day for 6 months
62248584|NCT02790255|EXPERIMENTAL|Cold air|Subjects to be seated in an airtight chamber at an ambient temperature between 16 to 20 degrees Celsius for 1 hour.
62248585|NCT02790255|EXPERIMENTAL|Cold water|Subjects to be seated in an airtight chamber at an ambient temperature of 24 degrees Celsius, with their hands and feet fully immersed in cold water for 5 minutes.
62248586|NCT02485457|EXPERIMENTAL|Low volume|"The protocol will follow the following steps :~* basal measurements (heart rate, arterial pressure, stroke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~* followed by passive leg rising and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~* second basal measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~* followed by low volume loading (250 ml of Ringer solution) and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)"
62248587|NCT02485457|EXPERIMENTAL|High volume|"The protocol will follow the following steps :~* basal measurements (heart rate, arterial pressure, stroke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~* followed by passive leg rising and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~* second basal measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~* followed by low volume loading (500 ml of Ringer solution) and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)"
62438683|NCT05953428|EXPERIMENTAL|Opioid Sparing Anesthesia Protocol|The OSA protocol will include boluses of dexmedetomidine and ketamine at anesthesia induction, followed by a ketamine infusion that will continue until PACU discharge. Another bolus of ketamine will be administered upon surgical incision and another dexmedetomidine bolus will be given at surgical closure to reduce the use of opioids.
62438684|NCT05953428|OTHER|Opioid Based Anesthesia Protocol|The OBA group will be administered a saline infusion at the same rate of the ketamine infusion (only while in the PACU) up until PACU discharge so that surgeons, patients, and PACU nurses will be blinded. The OBA group will be administered fentanyl 100 mcg IV for anesthesia induction followed by 50 mcg IV boluses when heart rate or systolic blood pressure is 20% above baseline throughout the case.
62605990|NCT03182634|EXPERIMENTAL|Cohort C - AZD5363 and fulvestrant|AZD5363 400mg PO BID on a 7 day schedule of 4 days on treatment followed by 3 days off treatment AND fulvestrant 500mg IM Cycle 1 Days 1 and 15 and Cycle 2 onwards Day 1
62605991|NCT03182634|EXPERIMENTAL|Cohort D - AZD5363|AZD5363 480mg PO BID on a 7 day schedule of 4 days on treatment followed by 3 days off treatment
62605992|NCT03182634|EXPERIMENTAL|Cohort E - olaparib and AZD6738|AZD6738 160mg to be administered once daily on Days 1-7 of each cycle and olaparib 300mg to be administered twice daily on a continuous schedule starting on Cycle 1 Day 1.
62438685|NCT04928833|EXPERIMENTAL|Pilates Group|Pilates training was carried out as group exercises for about 1 hour, 3 days a week for 8 weeks.
62438686|NCT04928833|ACTIVE_COMPARATOR|Control Group|Breathing exercises, active range of motion exercises and relaxation exercises were given to the control group as a home program. They were asked to do the exercises 3 days a week for 8 weeks.
62605993|NCT00877149|EXPERIMENTAL|A|
62828710|NCT05030129|EXPERIMENTAL|Ergoloid mesylates (EM)|During treatment period 1, subjects will receive EM 1 mg (Medisca) and matching placebo for 5-HTP 100mg (ascorbic acid powder). One of each capsule (both size 00) will be taken three times per day for four weeks.
62828711|NCT05030129|EXPERIMENTAL|Ergoloid mesylates (EM) and 5-hydroxytryptophan (5-HTP)|During treatment period 2, subjects will receive EM 1 mg (Medisca) and 5-HTP 100 mg (5-HTP, Basic Vitamins). One of each capsule (both size 00) will be taken three times per day for four weeks.
62828712|NCT05030129|EXPERIMENTAL|5-hydroxytryptophan (5-HTP)|During treatment period 3, subjects will receive 5-HTP 100 mg (5-HTP, Basic Vitamins) and matching placebo for EM 1 mg (ascorbic acid powder). One of each capsule (both size 00) will be taken three times per day for four weeks.
62828713|NCT05030129|PLACEBO_COMPARATOR|Placebo|During treatment period 4, subjects will receive matching placebo for EM 1mg (ascorbic acid powder) and matching placebo for 5-Hydroxytryptophan 100mg (ascorbic acid powder). One of each capsule (both size 00) will be taken three times per day for four weeks.
62046645|NCT01649232||active tDCS|The patients with ADHD received electro-stimulation at 20 sessions with 2 mAmp 1 session per day alternative days. The investigators used an ERP analysis derived of 20 channel EEG recordings during resting state and visual CPT to define the tDCS site and polarity at refractory ADHD patients to conventional treatments. Time courses, topography and amplitude of ERPs, correlated with clinical scores, were compared with the controls average (data base)to guide the selection of personal tDCS parameters. The following relation shown how many patients were submitted to intervention in each electrode, according to their polarity: Anodal tDCS: T5, T6, etc. Cathodal tDCS: T5, T6, etc.
62046646|NCT01649232||controls|Healthy people that not receive tDCS
62046647|NCT01409148|OTHER|I-124 Mu 11-1F4 sterile injection|Single arm study
62046648|NCT00534131|ACTIVE_COMPARATOR|Arm 1|Patients for whom a standard abdominal approach is adequate to excise the distal third of the rectum (without jeopardising oncological clearance if appropriate).
62046649|NCT00534131|EXPERIMENTAL|Arm 2|Combined abdominal and trans-perineal approach to excise the distal third of the rectum, while preserving the anal canal
62248588|NCT02163460|EXPERIMENTAL|Drain|In group 1(Drain), a 4.8 mm diameter continuous closed-suction tubular drain : was placed between the aponeurosis and the subcutaneous tissue caudally to the incision.
62248589|NCT02163460|EXPERIMENTAL|Progressive Tension Sutures|Drains were not used in group 2, but separate absorbable polyglactin 920 2/0 sutures were placed from the subcutaneous mesh to the aponeurosis every 2 cm by means of the progressive tension suture (or Quilting Sutures) technique, as described by Pollock et al
62248590|NCT00870766|ACTIVE_COMPARATOR|CT|All patients in the CT arm undergo abdominal CT scanning within 24 hours of admission to the ER.
62248591|NCT00870766|NO_INTERVENTION|Current practice|The patients in the current practice arm are referred to radiological examinations, such as US, plain radiography or CT, based on the clinical need only.
62248592|NCT00733304|EXPERIMENTAL|5 mg/ml TID|eligible participants received 5 mg/ml Pazopanib eye drops three times daily (TID)
62605994|NCT01764724||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is a online consumer monitor panel which answers surveys every 8-10 weeks about diet and health.
62605995|NCT03525782|EXPERIMENTAL|CAR-T|Anti-MUC1 CAR-T cells will be prepared ex vivo and infused back to the patients.
62046650|NCT00534131|ACTIVE_COMPARATOR|Arm 3|Standard proctectomy to excise the distal third of the rectum and the anal canal
62248593|NCT00733304|EXPERIMENTAL|2 mg/ml TID|eligible participants received 2 mg/ml Pazopanib eye drops three times daily
62046651|NCT01429480|ACTIVE_COMPARATOR|TAP Block|
62046652|NCT01429480|ACTIVE_COMPARATOR|II/IH Block|
62046653|NCT01429480|ACTIVE_COMPARATOR|Control Group|
62046654|NCT01869842|ACTIVE_COMPARATOR|DM, angio group|
62046655|NCT01869842|EXPERIMENTAL|DM, OCT group|
62046656|NCT01869842|ACTIVE_COMPARATOR|non DM, angio group|
62248594|NCT00733304|EXPERIMENTAL|5 mg/ml QD|eligible participants received 5 mg/ml Pazopanib eye drops once daily (QD)
62248595|NCT06425484|EXPERIMENTAL|Group T|Group epidural with bilateral US TAP block
62248596|NCT06425484|ACTIVE_COMPARATOR|Group E|Group epidural alone
62248597|NCT01301456|PLACEBO_COMPARATOR|Treatment Arm 1 (Stage 1A)|
62248598|NCT01301456|EXPERIMENTAL|Treatment Arm 2 (Stage 1A)|
62248599|NCT01301456|EXPERIMENTAL|Treatment Arm 3 (Stage 1A)|
62248600|NCT01301456|EXPERIMENTAL|Treatment Arm 4 (Stage 1A)|
62248601|NCT01301456|PLACEBO_COMPARATOR|Treatment Arm 5 (Stage 1B)|
62248602|NCT01301456|EXPERIMENTAL|Treatment Arm 6 (Stage 1B)|
62248603|NCT01301456|EXPERIMENTAL|Treatment Arm 7 (Stage 1B)|
62248604|NCT01301456|EXPERIMENTAL|Treatment Arm 8 (Stage 1B)|
62248605|NCT01301456|PLACEBO_COMPARATOR|Treatment Arm 9 (Stage 2)|
62438687|NCT04928833|NO_INTERVENTION|Evaluation of 'Core' Stability|"Core stability was evaluated with two important dimensions, core strength and endurance tests."
62605996|NCT03525782|EXPERIMENTAL|CAR-T combining PD-1 knockout|Anti-MUC1 CAR-T cells and PD-1 knockout Engineered T cells will be prepared ex vivo and infused back to the patients.
62605997|NCT03525782|EXPERIMENTAL|PD-1 knockout|PD-1 knockout Engineered T cells will be prepared ex vivo and infused back to the patients.
62605998|NCT03525782|ACTIVE_COMPARATOR|PD-1 mAb|Patients will be treated with a FDA approved monoclonal antibody for an identical course of treatment. This group will serve as PD-1 antibody treated group.
62248606|NCT01301456|EXPERIMENTAL|Treatment Arm 10 (Stage 2)|
62248607|NCT01301456|EXPERIMENTAL|Treatment Arm 11 (Stage 2)|
62248608|NCT01301456|EXPERIMENTAL|Treatment Arm 12 (Stage 2)|
62248609|NCT01301456|EXPERIMENTAL|Treatment Arm 13 (Stage 2)|
62248610|NCT00585429||1|ESLD subjects on active liver transplant waiting list
62605999|NCT03525782|PLACEBO_COMPARATOR|Sham Control|Patient's T cells will be separate without genetic or engineered modification ex vivo and infused back to the patients.
62606000|NCT05069311|EXPERIMENTAL|Hysterectomy|Patients who undergo surgical hysterectomy that fits inclusion and exclusion criteria
62606001|NCT04098445||Pediatric and young adult HSCT recipients|Prospective multi-institutional cohort study in pediatric patients undergoing allogeneic (alloHSCT) or autologous hematopoietic stem cell transplantation (autoHSCT).
62606002|NCT02882880|OTHER|Started|Intervention: Treatment with the Luco Hybrid OSA Appliance (LHOA) Group 1, fitted with LHOA Group 2: LHOA removed for 48 hours
62606003|NCT02882880|ACTIVE_COMPARATOR|Completed|Intervention: The LUco Hybrid OSA APpliance The subjects that actually completed the study in both groups. Group 1 n = 32, in Group 2 n=19
62606004|NCT06509893|ACTIVE_COMPARATOR|Clopidogrel and aspirin|Patients post PCI randomized to Aspirin 80 mg and clopidogrel 75 mg daily
62606005|NCT06509893|EXPERIMENTAL|ticagrelor|Patients post PCI randomized to Ticagrelor 90 mg PO two times daily
62606006|NCT00070213|ACTIVE_COMPARATOR|MdG (modified de Gramont)|2 weekly 5FU/FA schedule
62248611|NCT00585429||2|Subjects post-liver transplant with good liver function
62248612|NCT00585429||3|Subjects without liver disease undergoing kidney biopsy for diagnostic purposes
62248613|NCT01486641|ACTIVE_COMPARATOR|Anterolateral approach|"Patients with a displaced femoral neck fracture operated through the anterolateral approach to the hip arthroplasty.~Lubinus total hip arthroplasty or varikopf hemiarthroplasty."
62248614|NCT01486641|NO_INTERVENTION|Posterolateral approach|"Patients with a displaced femoral neck fracture operated through the posterolateral approach to the hip arthroplasty.~Lubinus total hip arthroplasty or varikopf hemiarthroplasty."
62606007|NCT00070213|EXPERIMENTAL|OxMdG (80%) for 12 weeks|MdG + oxaliplatin
62606008|NCT00070213|EXPERIMENTAL|Capcitabine|
62606009|NCT00070213|EXPERIMENTAL|OxCap|
62606010|NCT05207904|EXPERIMENTAL|tislelizumab plus chemotherapy|
62828714|NCT05649215||Patients group|Patients with low back pain
62828715|NCT06603805||MAST group|patients 1) aged between 18-40 years; 2) with a primary pathological diagnosis of invasive breast cancer; 3) receiving MAST; 4) having detailed information on T stage, N stage, clinical stage, hormone receptor status, endocrine therapy, and targeted therapy.
62828716|NCT06603805||BCS+RT group|Patients 1) aged between 18-40 years; 2) with a primary pathological diagnosis of invasive breast cancer; 3) receiving BCS+ RT; 4) having detailed information on T stage, N stage, clinical stage, hormone receptor status, endocrine therapy, and targeted therapy.
62046657|NCT01869842|EXPERIMENTAL|non DM, OCT group|
62248615|NCT04611854|ACTIVE_COMPARATOR|ICBT for alcohol misuse: Guidance|In this arm, participants will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse with guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
62248616|NCT04611854|EXPERIMENTAL|ICBT for alcohol misuse: Self-Guidance|Participants who select this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no guidance from a health educator will be provided. Clients will be monitored by providing brief measures on alcohol each week and measures of depression and anxiety administered at the beginning of week 5. However, clients will only be contacted if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms of depression and suicidal ideation).
62248617|NCT02871973|EXPERIMENTAL|SDP|Families randomized to intervention group will receive Sit Down and Play while they wait in the waiting room to be seen by their primary care provider at current and subsequent well-child visit.
62248618|NCT02871973|ACTIVE_COMPARATOR|CDC Handout|Families in the control group will receive the Center for Disease Control and Prevention (CDC) Handout at enrollment.
62606011|NCT02470819|EXPERIMENTAL|Targeted Therapy|Those who will receive targeted therapy based on their genetic profiling
62606012|NCT02747849|PLACEBO_COMPARATOR|Hand neuromodulation|The stimulation characteristics for this arm include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for finger twitching - or the intensity that the subject feels comfortable with. Subjects will be asked to use the stimulator for a minimum of 60 minutes prior to bedtime for two weeks, or longer if they can tolerate it, have the time, and accurately record the total duration. Stimulation will be performed during the first, second, and third weeks of the study.
62606013|NCT02747849|ACTIVE_COMPARATOR|Foot Neuromodulation|The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will be asked to wear socks on their foot to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a minimum of 60 minutes prior to bedtime for two weeks, or longer if they can tolerate it, have the time, and accurately record the total duration. Stimulation will be performed during the first, second, and third weeks of the study.
62623477|NCT01737879|EXPERIMENTAL|Peginesatide / Epoetin Alfa|Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks.
62623478|NCT05223816|EXPERIMENTAL|Safety Run-in Cohort|10 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days.
62828717|NCT06397170|EXPERIMENTAL|Graded repetitive arm supplementary program group|Patients in Group A will receive Graded repetitive arm supplementary program.
62828718|NCT06397170|ACTIVE_COMPARATOR|Task based training group|Patients in Group B will receive Task based training.
62606014|NCT06006013|EXPERIMENTAL|Treatment (cabozantinib, Atezolizumab)|Patients receive cabozantinib orally (PO) once daily (QD) on days 1-21 of each cycle and Atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) and/or magnetic resonance imaging (MRI) at screening and then every 12 weeks on study and undergo collection of blood samples at screening, on study, and at end of treatment. Patients without archival tissue also undergo biopsy at screening.
62606015|NCT04587401|EXPERIMENTAL|normotensive patients|Cerebral perfusion of normotensive patients who will have lumbar surgery at the prone position will be measured by transcranial doppler ultrasonography
62606016|NCT04587401|EXPERIMENTAL|patients with high blood pressure diagnosis|Cerebral perfusion of patients with high blood pressure diagnosis who will have lumbar surgery at the prone position will be measured by transcranial doppler ultrasonography
62606017|NCT04587401|EXPERIMENTAL|patients who do not know they are hypertensive but actual blood pressure is high|cerebral perfusion of patients who do not have high blood pressure diagnosis but actual preoperative blood pressure is higher than normal levels will be measured by transcranial doppler ultrasonography during lumbar surgery
62606018|NCT01004601|ACTIVE_COMPARATOR|low dose docetaxel|Low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)
62606019|NCT01004601|ACTIVE_COMPARATOR|Pemetrexed|Pemetrexed (500 mg/m2 every 3 weeks)
62606020|NCT01473394|PLACEBO_COMPARATOR|Dose-matched placebo|Participants received dose-matched placebo orally once daily for 9 weeks.
62606021|NCT01473394|EXPERIMENTAL|Vilazodone|Participants received vilazodone orally once daily for 9 weeks, as follows: Week 1, 10 mg once a day; Week 2, 20 mg once a day; Weeks 3 to 8, 40 mg once a day; and Week 9 (down-taper period), 20 mg once a day for 4 days, then 10 mg once a day for 3 days.
62606022|NCT06730750|EXPERIMENTAL|Part 1A|
62828719|NCT06590285|NO_INTERVENTION|Standard of Care Monitoring|Usual care will be undergoing alloHSCT without any additional sleep-related educational interventions.
62828720|NCT06590285|EXPERIMENTAL|App-based Educational Intervention|The intervention is a pioneering, evidence-based educational program designed to optimize sleep and physical activity outcomes in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT).
62046658|NCT04141527||Primiparous women|82 primiparous obstetrical patients given intrathecal sufentanil for labor pain.
62046659|NCT04141527||Multiparous women|82 multiparous obstetrical patients given intrathecal sufentanil for labor pain.
62046660|NCT04716348|EXPERIMENTAL|group A|suboccipital muscle energy technique
62046661|NCT04716348|SHAM_COMPARATOR|group B|sham muscle energy technique
62606023|NCT06730750|EXPERIMENTAL|Part 2A - Colorectal Cancer (CRC)|
62606024|NCT06730750|EXPERIMENTAL|Part 2A - Non-Small Cell Lung Cancer/Gastric Cancer (NSCLC/GC)|
62438688|NCT04928833|NO_INTERVENTION|Ultrasound Examination of M. Transversus Abdominus and M. Multifidus|M. transversus abdominus (TrA) and m. multifidus (MF) muscles were visualized by ultrasonography and the evaluations were performed by an experienced radiologist who was blind to the case groups.
62606025|NCT06730750|EXPERIMENTAL|Part 1B|
62606026|NCT06730750|EXPERIMENTAL|Part 2B|
62606027|NCT00787917|EXPERIMENTAL|Omalizumab|"Eligible participants received a maximum dose of 600 mg omalizumab via subcutaneous injection for 6 months in the double-blind phase of the study. The study medication was to be administered at the same time of day. Study medication was injected subcutaneously into the upper arm in the area of the deltoid or to the thigh. A maximum 600 mg dose required 4 injections. All participants who entered the study received itraconazole twice daily, while receiving oral corticosteroids, with a maximum daily dose of 400 mg.~Participants who completed double-blinded phase, entered open-label treatment period of 6 months and continued the same regimen of omalizumab of double-blinded phase."
62606028|NCT00787917|PLACEBO_COMPARATOR|Placebo|Eligible participants received placebo comparator via subcutaneous injection for 6 months in the double-blind phase of the study. The study medication was to be administered at the same time of day. Study medication was injected subcutaneously into the upper arm in the area of the deltoid or to the thigh. All participants who entered the study received itraconazole twice daily, while on oral corticosteroids, with a maximum daily dose of 400 mg.
62828721|NCT06599853|EXPERIMENTAL|Group to be trained|Parents in the experimental group were randomly assigned. Parents in the experimental group will be trained with parent fever management training material via home visits. Repeated measurements will be made one month after the training and at 3 months. Parent fever management training material was created by the researcher according to the literature. Opinions of experts in the field were obtained for the suitability of the training booklet.
62828722|NCT06599853|NO_INTERVENTION|Control group|No intervention will be made to the control group. Only measurements will be made on parallel dates with the experimental group.
62828723|NCT04467593|EXPERIMENTAL|Cohort A1|Three patients with advanced solid cancer will be subjected to repetitive hyperthermia starting with 2 hours (day 1), 4 hours (day 8) and 6 hours (day 15)
62828724|NCT04467593|EXPERIMENTAL|Cohort A2|One patient with advanced solid cancer will receive 3 hyperthermia treatments of 4 hours per treatment. The next patient with advanced solid cancer will receive 3 hyperthermia treatments of 6 hours per treatment.
62046662|NCT00082173|EXPERIMENTAL|1|INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks
62046663|NCT00082173|PLACEBO_COMPARATOR|2|INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks
62438689|NCT04928833|NO_INTERVENTION|Evaluation of Lower Extremity Functional Strength|Lower extremity functional strength was evaluated with the 5-Times Sit-and-Stand Test.
62438690|NCT04928833|NO_INTERVENTION|Evaluation of Balance|Balance was evaluated using the Berg Balance Scale (BBS).
62438691|NCT04928833|NO_INTERVENTION|Evaluation of Functional Mobility|Functional mobility was evaluated using the Timed Up and Go Test (TUG).
62248619|NCT05148182||low risk|According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as low-risk population.
62248620|NCT05148182||medium risk|According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as medium-risk population.
62248621|NCT05148182||high risk|According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as high-risk population.
62606029|NCT03502018|PLACEBO_COMPARATOR|Saline|This arm will receive Saline along with Bupivacaine
62606030|NCT03502018|EXPERIMENTAL|Bupivacaine liposome|This arm will receive Exparel along with Bupivacaine
62606031|NCT04940715|EXPERIMENTAL|Passive joint mobilization|Patients lay down on a prone position, with their hands around the body and neck placed comfortable. The therapist performed a postero-anterior joint mobilization using Maitland's technique, applying pressure to spinous process of targeted vertebra (the one who reproduces patient's symptoms).
62606032|NCT04940715|EXPERIMENTAL|Mobilization with movement|Patients perform their painful movement (flexion, extension...). If pain wasn't reproduced, a combination of movements will be performed (flexion + rotation...). The most painful vertebral level was assessed too with passive accessory vertebral movements. Afterwards, with the patient on a seated position on a stretcher with feet supported and a belt around the waist, the therapist performed a sustained glide on the targeted vertebra (spinous process) with the force and direction that relieved pain to the lowest level.
62606033|NCT04940715|NO_INTERVENTION|Control group|"Patients were measured at baseline and then were placed on wait list until the end of the study. At this time, they were measured again."
62046664|NCT01406626|EXPERIMENTAL|Peer Navigation Intervention Arm|"Subjects will receive the following peer navigation services:~1) 10 Navigator meetings: Navigators will meet with participants in person to teach linkage/retention skills and knowledge~2a) 2 Navigator accompaniment sessions: the peer navigator will accompany participants to HIV care appointment. Before and after the appointment, participants and navigators will review linkage and retention skills/knowledge and things that make it hard or easy for him/her to get regular HIV care~2b) Optional peer navigator accompaniment sessions: If the participant requests, the peer navigator will provide accompaniment to supportive HIV care appointments (one per month max)~3) 14 peer navigator care calls: During these calls, navigators and participants will talk about any problems that could make it difficult to get regular HIV care."
62046665|NCT01406626|NO_INTERVENTION|Usual Care|Participants assigned to the control arm will receive the transitional case management (TCM) services that are currently offered at the jail
62046666|NCT05804045|EXPERIMENTAL|Part 1/Part 2/Part 3- Pimicotinib(ABSK021)/ Pimicotinib(ABSK021)|Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 and continue on the open-label Pimicotinib(ABSK021) in Part 2 and Part 3.
62606034|NCT06126094|EXPERIMENTAL|Probiotic|"Participants will consume 800 mg of probiotic Myrkl before consuming alcohol in the form of one capsule. (Myrkl, De Fair Medical, Stockholm, Sweden). This formulation contains AB001™, and one capsule (800mg) consists of:~* 560 mg of naturally fermented rice bran~* Bacillus subtilis~* B. coagulans~* L-cysteine~* dextrin~* 36 mg of excipients: magnesium stearate salts, calcium phosphate, potassium phosphate"
62606035|NCT06126094|EXPERIMENTAL|Placebo|The subject who consumed 800 mg of placebo- dextrin (maltodextrin) in the form of two capsules before consuming alcohol.
62606036|NCT04472026|EXPERIMENTAL|Intervention group|Counseling using the electronic conversation aid
62606037|NCT01477294|EXPERIMENTAL|Caffeine|Intervention with Caffeine in a random order
62606038|NCT01477294|PLACEBO_COMPARATOR|Placebo|Placebo (malt dextrin) administered in a random order
62046667|NCT05804045|PLACEBO_COMPARATOR|Part 1- Placebo/ Pimicotinib(ABSK021)|Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 and have option to receive the open-label Pimicotinib(ABSK021) in Part 2.
62046668|NCT02384759|EXPERIMENTAL|A|Aflibercept + LV5FU2
62046669|NCT02384759|ACTIVE_COMPARATOR|B|LV5FU2
62248622|NCT00709111|EXPERIMENTAL|Maraviroc|Maraviroc (MVC) was taken for 24 weeks, in addition to the subject's current antiretroviral therapy (ART) drug regimen. At week 24, subjects discontinued MVC and were followed for an additional 24 weeks off MVC, but still on current ART drug regimen.
62248623|NCT06383156|ACTIVE_COMPARATOR|Auscultation|correct position of LDLT during single lung ventilation will be confirmed by clinical methods.
62606039|NCT05425680|EXPERIMENTAL|Core muscle training|specific rehabilitation exercise for improving functional movements
62606040|NCT05608278|EXPERIMENTAL|Bergen 4-Day Treatment (B4DT)|"Patients in this arm will receive an intensive treatment delivered mostly in group format. The group sizes will be 3-6 participants with a 1:1 patient to therapist ratio. In the week before the intensive part of the treatment, participants will have two scheduled phone/video calls with a therapist. Day 1 (half-day) of the intensive treatment includes psychoeducation and deciding on exposure tasks. Days 2 and 3 (whole days) focus on individually tailored and therapist-assisted ERP in as many most relevant settings as possible. In the evenings, patients are encouraged to continue with self-guided ERP and may receive therapist support via text messages or phone calls on demand. On day 3, patients can invite relatives to a psychoeducation session. Day 4 (half-day) of the intensive treatment focuses on treatment summary and relapse prevention, as well as planning self-guided ERP for the upcoming 3 weeks.~After 16 weeks, participants have individual follow-up sessions without ERP."
62623479|NCT05223816|EXPERIMENTAL|Cohort 2 (HCC)|21 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days.
62623480|NCT05223816|EXPERIMENTAL|Cohort 3 (ICC)|20 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days.
62623481|NCT05223816|EXPERIMENTAL|Cohort 4 (HCC and ICC)|Up to 12 patients will be treated with IT injection of VG161 ar dose level of 1.0x10E8 PFU x 3 days. and Nivolumab per approved label.
62438692|NCT04928833|NO_INTERVENTION|Evaluation of Functional Exercise Capacity|Functional exercise capacity was evaluated using the 6 Minute Walking Test (6-MWT).
62438693|NCT04928833|NO_INTERVENTION|Activities of Daily Living and Evaluation of Motor Impairment|Activities of daily living and motor impairment were evaluated with activities of daily living (II) and motor impairment (III) sub-dimensions of the Unified Parkinson's Disease Rating Scale (UPDRS).
62438694|NCT04928833|NO_INTERVENTION|Evaluation of Freezing|The Freezing of Gait Questionnaire (FOGQ) was used to identify and evaluate the subjective perception of Parkinson's patients regarding the severity and effect of freezing on gait performance.
62438695|NCT04928833|NO_INTERVENTION|Evaluation of Fatigue|Fatigue, one of the non-motor findings associated with Parkinson's, was evaluated with the Parkinson's Fatigue Scale-16 (PFS-16).
62438696|NCT04928833|NO_INTERVENTION|Evaluation of Quality of Life|Quality of Life was evaluated with Parkinson's Disease Questionnaire-39 (PDQ-39).
62438697|NCT00272337|ACTIVE_COMPARATOR|1|81 mg Aspirin
62438698|NCT00272337|ACTIVE_COMPARATOR|2|162 mg Aspirin
62438699|NCT00272337|ACTIVE_COMPARATOR|3|325 mg Aspirin
62438700|NCT00272337|ACTIVE_COMPARATOR|4|650 mg Aspirin
62438701|NCT00272337|ACTIVE_COMPARATOR|5|1300 mg Aspirin
62438702|NCT03846921||Viral infection|Patients with proven viral infections will have laboratory blood test taken
62046670|NCT01040260|EXPERIMENTAL|Contingency management|Use of tangible rewards for verified abstinence
62248624|NCT06383156|ACTIVE_COMPARATOR|Ultrasound|correct position of LDLT during single lung ventilation will be confirmed when lung USG revealed correct lung isolation
62438703|NCT03846921||Bacterial Infection|Patients with proven bacterial infections will have laboratory blood test taken
62438704|NCT02856074|EXPERIMENTAL|Ischemic stroke patients|
62438705|NCT05874869|ACTIVE_COMPARATOR|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine will be administered to the intervention arm
62438706|NCT05874869|NO_INTERVENTION|Control|Individuals that will get malaria infection and present at the health facility with clinical signs and symptoms will be treated according to the Tanzania National Malaria Treatment guidelines using artemether-lumefantrine.
62438707|NCT02833857|EXPERIMENTAL|Etelcalcetide|Participants received a single, intravenous (IV) bolus administration of 0.035 mg/kg etelcalcetide at the end of hemodialysis on study day 1.
62438708|NCT01093859|EXPERIMENTAL|PRX-105 Infusion|
62438709|NCT01234259|EXPERIMENTAL|Study group|Device: Venus Freeze (MP)2 V2 system
62606041|NCT05608278|ACTIVE_COMPARATOR|Gold standard cognitive behavioral therapy (gold standard CBT)|Patients will receive 16 sessions of individual CBT for OCD with an emphasis on ERP, delivered over a time period of 14 weeks according to a validated protocol. Sessions will be held twice weekly at a specialist clinic during the first 2 weeks and once a week for the remaining 12 weeks. Sessions 1-2 contain psychoeducation about OCD and CBT, goal setting, and planning of ERP exercises. Sessions 3-14 include therapist-guided ERP (at the clinic, in the patients' homes or elsewhere as needed) with planned self-practice ERP between sessions. Sessions 15-16 contain a summary of the treatment and lessons learned, as well as relapse prevention and planning of continued self-practice ERP.
62606042|NCT05556564||No group|
62606043|NCT02432391|NO_INTERVENTION|Routine Care|Participants continue their routine medical care for type 2 diabetes
62606044|NCT02432391|EXPERIMENTAL|GEM|Participants receive the GEM (Glycemic load, Exercise, and Monitoring blood glucose) lifestyle modification program and continue their routine medical care for type 2 diabetes.
62606045|NCT04305106|EXPERIMENTAL|Bevacizumab|Bevacizumab 7.5mg/kg body weight, intravenous drip, single-dose administration, and standard of care, including prophylactic doses of low molecular weight heparin or unfractionated heparin without contraindications, and therapeutic doses of anticoagulants with the evidence of thrombosis risk or occurrence.
62046671|NCT01040260|ACTIVE_COMPARATOR|Counseling plus nicotine patches|Counseling plus nicotine patches
62248625|NCT06383156|ACTIVE_COMPARATOR|Fluoroscopy|correct position of LDLT during single lung ventilation will be confirmed when fluoroscopy visualizes the left bronchial cuff and lumen in left main bronchus.
62248626|NCT02700568|EXPERIMENTAL|axitinib|Patients will receive axitinib.
62248627|NCT03957395|EXPERIMENTAL|scs high-frequency|high-frequency stimulation
62248628|NCT03957395|EXPERIMENTAL|scs tonic|tonic stimulation
62248629|NCT03957395|EXPERIMENTAL|scs burst|burst stimulation
62248630|NCT03957395|PLACEBO_COMPARATOR|scs off|off stimulation
62248631|NCT00003653|ACTIVE_COMPARATOR|Intermittent Androgen Suppression|
62248632|NCT00003653|ACTIVE_COMPARATOR|Continuous Androgen Suppression|
62248633|NCT01549483||Asthma|asthmatic subjects
62248634|NCT01549483||Asymptomatic AHR|Asymptomatic subjects with airway hyperresponsiveness
62248635|NCT01549483||Control|Healthy controls, without airway hyperresponsiveness
62248636|NCT00880555||Arm 1: Non-Dementia Memory Disorder|Elderly patients with non-dementia memory disorder (mild cognitive impairment)
62248637|NCT00880555||Arm 2: Control|Elderly controls without memory impairment
62248638|NCT00880555||Arm 3: Mild Alzheimer Disease|Patients with mild Alzheimer disease (but preserved routine activities of daily living)
62248639|NCT04652154|OTHER|Control|Control group is recieving treatment as ususal
62248640|NCT04652154|EXPERIMENTAL|Intervention group|The intervention group getting the new assessment by a complementary professional team
62248641|NCT04521036|EXPERIMENTAL|Convalescent plasma|Standard of care plus 500 mL of convalescent plasma from COVID-19 recovered donors
62248642|NCT04521036|NO_INTERVENTION|Standard of care|Standard of care (Supportive care, oxygen, antibiotics, no convalescent plasma)
62248643|NCT01992133|EXPERIMENTAL|Vitamin D3|Vitamin D3 at 4000 iu per day for 6 months
62606046|NCT04305106|PLACEBO_COMPARATOR|Placebo|Placebo (inactive excipient) 7.5mg/kg body weight, intravenous drip, single-dose administration, and standard of care, including prophylactic doses of low molecular weight heparin or unfractionated heparin without contraindications, and therapeutic doses of anticoagulants with the evidence of thrombosis risk or occurrence.
62606047|NCT04326439|EXPERIMENTAL|Aflac-AML Regimen for Low Risk AML Patients|"Participants in this arm will receive the standard Aflac-AML Regimen with the following chemotherapy:~* Induction-1: patients on Induction-I will receive gemtuzumab + ADE therapy based on genotyping. Lasts a total of 28 days.~* Induction II - MA~* Intensification I - AE~* Intensification II - HD ARAC/LASP~Patients with low risk status who had low risk markers and were MRD positive at the end of Induction I and continue to be MRD positive after Induction II will come off protocol."
62606048|NCT04326439|EXPERIMENTAL|Aflac-AML Regimen for High Risk AML Patients|"Participants in this arm will receive standard Aflac-AML Regimen with the following chemotherapy:~* Induction-1: patients will receive gemtuzumab in addition to ADE therapy based on genotyping. Induction I lasts a total of 28 days.~* Induction 1 for FLT3-ITD patients - ADE (10+3+5) with GO with Sorafenib~* Induction II - MA~* Induction II for FLT3-ITD patients - MA with Sorafenib~* Intensification I - AE~* Intensification I for FLT3-ITD patients - AE with sorafenib~* Intensification II - HD ARAC/LASP~* Intensification II for FLT3-ITD patients - HD ARAC/LASP with sorafenib~* Hematopoietic stem cell transplantation (HSCT)~If a patient is classified as High risk after Induction I, they may proceed to best allogenic donor SCT following Induction II. These patients may receive a third course of chemotherapy prior to HSCT. In cases where HSCT is not an option, patients can receive 4 cycles of chemotherapy. Only patients with FLT3-ITD mutation will receive sorafenib."
62606049|NCT05714475||Pancreas resection for colorectal metastasis|"Patient underwent a pancreas resection (whipple, distal pancreasectomy ...) with inclusion criteria. Criteria~Inclusion Criteria:~* Isolated pancreatic metastases from Colorectal cancer~* Previous surgery for colorectal cancer~* Surgically manageable lesions: duodenal-pancreatectomy surgical removal of metastatic repetitions in pancreas~* Other procedures:~total-pancreatectomy distal-pancreatectomy other metastases resection~* R0 resection~* no signs of peritoneal metastasis or tumor manifestations outside of the pancreas.~* CT Scan before surgery~Exclusion Criteria:~* metastases from different malignancies~* other malignancies~* surgically unmanageable lesions~* Multiple synchronous colorectal metastasis"
62606050|NCT00987402|ACTIVE_COMPARATOR|Plain soap and water|Surgical hand preparation with plain soap and water
62606051|NCT00987402|ACTIVE_COMPARATOR|Alcohol based hand rubs|Surgical hand preparation with alcohol based alcohol hand rub
62606052|NCT02484638|EXPERIMENTAL|CSL689 low-dose|"* Part 1: single injection of low-dose CSL689 for PK evaluation~* Part 2: up to 2 injections of low-dose CSL689 per bleeding event (bleeding events 1 to 3\*)~* Part 3: up to 3 injections of low-dose CSL689 per bleeding event \* Note: All subjects in the low-dose arm will be treated with high-dose CSL689 for bleeding events 4-6 in Part 2"
62606053|NCT02484638|EXPERIMENTAL|CSL689 high-dose|"* Part 1: single injection of high-dose CSL689 for PK evaluation~* Part 2: up to 2 injections of high-dose CSL689 per bleeding event (bleeding events 4 to 6\*)~* Part 3: up to 3 injections of high-dose CSL689 per bleeding event~  * Note: All subjects in the high-dose arm will be treated with low-dose CSL689 for bleeding events 1-3 in Part 2"
62606054|NCT02484638|ACTIVE_COMPARATOR|Eptacog alfa low-dose|Single injection of low-dose Eptacog alfa in Part 1 for PK evaluation
62606055|NCT02484638|ACTIVE_COMPARATOR|Eptacog alfa high-dose|Single injection of high-dose Eptacog alfa in Part 1 for PK evaluation
62606056|NCT03669718|EXPERIMENTAL|Active ISA101b and cemiplimab.|ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months
62606057|NCT03669718|PLACEBO_COMPARATOR|Placebo and cemiplimab|Placebo 3 times plus cemiplimab every 3 weeks for up to 24 months
62606058|NCT06013202|EXPERIMENTAL|Group 1 (TEST GROUP) Nigella Sativa oil mouth rinse|Ten patients will receive Nigella Sativa oil mouth rinse. Patients will be asked to use the NS oil mouth rinse (10 ml each 6 hrs.) four times daily . Subjects will be provided with 72 hours supply of the study product. Patients will be instructed to use it for 72 hours with a minimum frequency of four times per day, swished for one minute at each use, in which the first dose was used upon awakening and the last dose just before evening sleep. Patients will be instructed not to use over the counter (OTC) or pharmacy formulated oral rinses or gels during the active treatment phase.
62606059|NCT06013202|ACTIVE_COMPARATOR|Group 2 (CONTROL GROUP)|Ten patients will receive the placebo isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl). Patients will be asked to use it as mouth rinse (10 ml each 6 hrs.) four times daily . Subjects will be provided with 72 hours supply of the study product. Patients will be instructed to use it for 72 hours with a minimum frequency of four times per day, swished for one minute at each use, in which the first dose was used upon awakening and the last dose just before evening sleep. Patients will be instructed not to use over the counter (OTC) or pharmacy formulated oral rinses or gels during the active treatment phase.
62828725|NCT04467593|EXPERIMENTAL|Cohort B|Three pancreatic cancer patients will be subjected to three hyperthermia treatments (2 hours duration per treatment) alone (1st treatment) or in combination with (2nd and 3rd treatment) Standard of Care (SOC) chemotherapy according to the NCCN guidelines.
62828726|NCT04467593|EXPERIMENTAL|Cohort C|Three pancreatic cancer patients will be subjected to three hyperthermia treatments (4 hours duration per treatment) alone (1st treatment) or in combination with (2nd and 3rd treatment) Standard of Care (SOC) chemotherapy according to the NCCN guidelines.
62248644|NCT01992133|PLACEBO_COMPARATOR|Placebo|matching placebo- capsules containing soya oil at 4 capsules a day for 6 months
62438710|NCT01234259|SHAM_COMPARATOR|control group:|Sham comparator
62828727|NCT04467593|EXPERIMENTAL|Cohort D|Three pancreatic cancer patients will be subjected to three hyperthermia treatments (6 hours duration per treatment) alone (1st treatment) or in combination with (2nd and 3rd treatment) Standard of Care (SOC) chemotherapy according to the NCCN guidelines.
62828728|NCT00897832||pancreatic cancer|Patients with pancreatic cancer
62046672|NCT02778100|EXPERIMENTAL|Nasal Glucagon (NG) - Common Cold|Cohort 1 - Nasal Glucagon (NG) administered once in participants with a common cold.
62046673|NCT02778100|EXPERIMENTAL|Nasal Glucagon (NG) - Symptom-Free|Cohort 1 - NG administered once in participants who have recovered from a common cold.
62248645|NCT00564824|EXPERIMENTAL|CAD patients|Patients with prior history of coronary artery disease (CAD) (myocardial infarction, cerebrovascular accident, coronary angioplasty, S/p CABG operation) who will be given on the first day either caffeine of placebo tablet and 1-2 hours thereafter a brachial artery endothelial function testing (BRT) will be assessed for measuring the FMD. After 1 week the patients will come for a second BRT on placebo/caffeine tablets. If the patient received caffeine tablet the first BRT, he will be receiving placebo tablet the second week, however, if the patient received placebo the first BRT, a caffeine tablet will be given prior to the second BRT.
62438711|NCT02478593|EXPERIMENTAL|Experimental group|Group to receive educational booklet regarding risk/benefits of Benzodiazepine.
62046674|NCT02778100|EXPERIMENTAL|NG - Common Cold+Oxymetazoline|Cohort 2 - NG administered once in participants with a common cold who are taking oxymetazoline.
62046675|NCT02690974|OTHER|LCZ696 (sacubitril / valsartan)|All patients were initiated on either LCZ696 at 24 mg sacubitril / 26 mg valsartan or LCZ696 at 49 mg sacubitril / 51 mg valsartan bid for 2-4 weeks and were up-titrated to the next higher dose for another 2 - 4 weeks as applicable.
62046676|NCT05394025||Veterans who tested positive for COVID-19 (case)|"The investigators will organize the sampling of cases (and later of comparators) around the waves of the epidemic, as defined by their nadirs between national death rates-each approximately 3-4 months long. The investigators will initiate surveys of Veterans who have survived their initial SARS-CoV-2 infection. The viral infection index date will be defined as date of each patient's first positive test."
62438712|NCT02478593|NO_INTERVENTION|Control group|Group to receive educational booklet regarding risk/benefits of exercise.
62438713|NCT01708928|ACTIVE_COMPARATOR|Group A|Subjects who have previous history of submentoplasty and or rhytidectomy
62438714|NCT01708928|ACTIVE_COMPARATOR|Group B|Subjects naïve to submentoplasty and or rhytidectomy
62438715|NCT00813371|ACTIVE_COMPARATOR|1|Airway Pressure Release Ventilation Arm
62046677|NCT05394025||Veterans who did not test positive for COVID-19 (comparator)|To support causal inference, the investigators will also sample Veterans without COVID who are matched to participants with COVID-19. In general, cases will be compared to comparators matched on risk of developing COVID infection during a given wave.
62046678|NCT03534973|ACTIVE_COMPARATOR|Caffeine intake|Caffeine is given orally prior to cataract surgery
62046679|NCT03534973|SHAM_COMPARATOR|No caffeine intake|Caffeine is not given orally prior to cataract surgery
62046680|NCT01971723|ACTIVE_COMPARATOR|T+ Supplement|This arm requires the participants to take a prescribed dose of the T+ supplement for 4 weeks while completing an exercise regiment.
62046681|NCT01971723|PLACEBO_COMPARATOR|Placebo|This arm requires the participants to take a prescribed dose of a calorie matched placebo for 4 weeks while completing an exercise regiment.
62046682|NCT00671931|ACTIVE_COMPARATOR|I|Dexmedetomidine low infusion, Propofol low infusion
62046683|NCT00671931|ACTIVE_COMPARATOR|II|Dexmedetomidine high infusion, Propofol low infusion
62438716|NCT00813371|ACTIVE_COMPARATOR|2|ARDSnet protocol
62828729|NCT03010215|OTHER|Minimally Invasive Surgery (MIS)|Patients with plantar chronic diabetic foot ulcers will be treated by Distal Metatarsal Minimally invasive Osteotomy (DMMO).
62046684|NCT00671931|ACTIVE_COMPARATOR|IV|Dexmedetomidine high infusion, Propofol high infusion
62046685|NCT00671931|ACTIVE_COMPARATOR|V|Dexmedetomidine intermediate infusion, Propofol intermediate infusion
62046686|NCT00671931|ACTIVE_COMPARATOR|III|Dexmedetomidine low infusion, Propofol high infusion
62438717|NCT05360433|ACTIVE_COMPARATOR|10 tablet prescription group|These participants receive 10 tablets of oxycodone 5 mg at discharge for postoperative pain.
62438718|NCT05360433|ACTIVE_COMPARATOR|20 tablet prescription group|These participants receive 20 tablets of oxycodone 5 mg at discharge for postoperative pain.
62438719|NCT01232257|EXPERIMENTAL|Healthy volunteers|
62438720|NCT01232257|EXPERIMENTAL|CKD patients|Patients with CKD stage 3-4 (GFR 15-60 ml/min)
62438721|NCT01232257|EXPERIMENTAL|Hemodialysis patients|
62438722|NCT01232257|EXPERIMENTAL|Peritoneal dialysis patients|
62438723|NCT02277821|EXPERIMENTAL|Stendo pulsating suit System|One 20 minutes Stendo pulsating suit session will be applied to the patient.
62438724|NCT03591978||Healthy non smokers|Healthy subjects with no respiratory disease and never smokers
62828730|NCT06591611|ACTIVE_COMPARATOR|Co-Cr reinforced fixed all-on-four prosthesis|
62828731|NCT06591611|EXPERIMENTAL|PEEK reinforced fixed all-on-four prosthesis|
62828732|NCT03524508|EXPERIMENTAL|5-FU/LV/Onivyde|Onivyde 70 mg/m2 (90 minutes), dl-LV 400mg/m2 or l-LV 200mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.
62248646|NCT00564824|EXPERIMENTAL|Placebo|Patients with prior history of coronary artery disease (CAD) (myocardial infarction, cerebrovascular accident, coronary angioplasty, S/p CABG operation) who will be given on the first day either caffeine of placebo tablet and 1-2 hours thereafter a brachial artery endothelial function testing (BRT) will be assessed for measuring the FMD. After 1 week the patients will come for a second BRT on placebo/caffeine tablets. If the patient received caffeine tablet the first BRT, he will be receiving placebo tablet the second week, however, if the patient received placebo the first BRT, a caffeine tablet will be given prior to the second BRT.
62606060|NCT01869569|ACTIVE_COMPARATOR|Pregabalin|Arm I:At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
62606061|NCT01869569|PLACEBO_COMPARATOR|Placebo|Arm II:At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
62828733|NCT03524508|ACTIVE_COMPARATOR|5FU/LV|dl-LV 400mg/m2 or l-LV 200mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.
62828734|NCT01709721|EXPERIMENTAL|Hydromorphone Hydrochloride (Randomized/Double-Blind)|Subjects on hydromorphone hydrochloride for the duration of therapy.
62828735|NCT01709721|ACTIVE_COMPARATOR|Hydromorphone Hydrochloride Titrated Downward/Control (Randomized/Double-Blind)|Subjects on hydromorphone hydrochloride titrated downward
62046687|NCT06309108|EXPERIMENTAL|Education Group|Education group was given training with a training booklet.
62248647|NCT04720404|EXPERIMENTAL|Mindfulness Based Stress Reduction program|Healthcare workers in the MBSR arm will be invited to participate in an adapted online MBSR program added to support as usual
62248648|NCT04720404|ACTIVE_COMPARATOR|Daily self-help mindfulness exercises via YouTube-channel|Healthcare workers in the self-help arm will be invited to follow a self-help program with mindfulness/compassion exercises of 30 minutes per day via YouTube channel
62438725|NCT03591978||Healthy smokers|Healthy subjects without respiratory disease and at least a cumulative tobacco consumption history of \<10 pack-years
62438726|NCT03591978||COPD|COPD patients (diagnosed as recommended by GOLD 2017 strategy) former or current smokers with at least \>10 pack-years
62438727|NCT02533999|EXPERIMENTAL|Surgical Instrument|"PEAK® Plasma Surgery System \[PEAK PlasmaBlade® TnA Tonsil and Adenoid Tissue Dissection Device\] (Medtronic, Inc) is a marketed device. The PEAK® system generates plasma, an electrically conductive cloud produced when radiofrequency energy contacting tissue and the tissue breaks down. The system was designed to have the precision of a scalpel, minimal bleeding as with electrosurgery, but reduced collateral thermal tissue damage. The PEAK® Plasma System setting will be standardized for tonsils, to 2 for coagulation and 1 for cutting; and for adenoids, to 7 for coagulation, and 7 for cutting."
62606062|NCT01313494|EXPERIMENTAL|Roflumilast|Roflumilast 500 μg, tablet, oral, once daily for up to 24 weeks.
62606063|NCT01313494|PLACEBO_COMPARATOR|Placebo|Placebo to roflumilast, tablet, oral, once daily for up to 24 weeks.
62606064|NCT00894244|EXPERIMENTAL|Treatment|Treatment using a non-invasive skin tightening radiofrequency device to observe skin shrinkage in the arms
62623482|NCT03883776|EXPERIMENTAL|healthy volunteers and NET patients|"In the first part of the study, 6 healthy volunteers will receive a single intravenous single injection of Al18F-NOTA-octreotide, followed by whole-body PET/CT scans at various time points for an initial safety assessment and dosimetry study.~In the second part of the study, a single dose of Al18F-NOTA-octreotide will be intravenously injected in 6 patients with neuroendocrine tumors. Patients will first undergo a dynamic PET scan, followed by whole-body PET/CT scans at various time points for a pharmacokinetics study and initial efficacy assessment."
62828736|NCT04384484|EXPERIMENTAL|Part 1: Loncastuximab Tesirine + Rituximab (Lonca-R)|"Part 1 consists of a non-randomized safety run-in period evaluating the study drug for the first 20 participants.~Participants will receive Lonca-R on Day 1 of each cycle for up to 8 cycles, where 1 cycle is 3 weeks. Lonca-R will be administered via an intravenous infusion of loncastuximab tesirine 150 µg/kg + rituximab 375 mg/m\^2 Q3W for 2 cycles, then loncastuximab tesirine 75 µg/kg + rituximab 375 mg/m\^2 Q3W for up to 6 additional cycles."
62828737|NCT04384484|EXPERIMENTAL|Part 2: Loncastuximab Tesirine + Rituximab (Lonca-R)|Randomized participants will receive Lonca-R on Day 1 of each cycle for up to 8 cycles, where 1 cycle is 3 weeks. Lonca-R will be administered via an intravenous infusion of loncastuximab tesirine 150 µg/kg + rituximab 375 mg/m\^2 every Q3W for 2 cycles, then loncastuximab tesirine 75 µg/kg + rituximab 375 mg/m\^2 Q3W for up to 6 additional cycles.
62828738|NCT04384484|ACTIVE_COMPARATOR|Part 2: Standard Immunochemotherapy (R-GemOx)|Randomized participants will receive R-GemOx consisting of rituximab, gemcitabine and oxaliplatin as a standard immunochemotherapy treatment on Day 1 or Day 2 of each cycle for up to 8 cycles, where 1 Cycle is 2 weeks. R-GemOx will be administered via an intravenous infusion of rituximab 375 mg/m\^2 + gemcitabine 1000 mg/m\^2 + oxaliplatin 100 mg/m\^2 every 2 weeks (Q2W) for up to 8 cycles.
62046688|NCT06309108|EXPERIMENTAL|Augmented Reality Group|Augmented reality group was given training with a augmented reality with 3DQR application.
62046689|NCT06309108|NO_INTERVENTION|Control Group|Control group was given training with a hospital routine.
62248649|NCT00853398|EXPERIMENTAL|Minimal Invasive Surgery,|
62248650|NCT00853398|ACTIVE_COMPARATOR|Standard Surgical Technique|
62606065|NCT01683422|EXPERIMENTAL|Proton Radiation|"Pre-Proton-chemotherapy (PCT) Patients will receive a combination of the agents (Gemcitabine plus Erlotinib) for 8 weeks prior to PCT Gemcitabine 1000 mg/m2 IV, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43~PCT to be started in 4 to 8 weeks after completion of Pre-PCT Proton therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day for 5 ½ weeks.~Chemotherapy: Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed~Post-PCT to be started in 4 to 6 weeks after completion of PCT Oxaliplatin 130 mg/m2, day 1 Capecitabine 1000 mg/m2 po bid on days 2 to 15 for 14 days The CapOx regimen (Capecitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles"
62828739|NCT06603376|EXPERIMENTAL|FOLFIRI + Vemurafenib + Cetuximab|Experimental Group: Liposomal Irinotecan Hydrochloride Injection (II): 60 mg/m², intravenous infusion over at least 90 minutes, on day 1; Leucovorin: 400 mg/m², intravenous infusion over 2 hours, on day 1; 5-FU: 400 mg/m², intravenous bolus; 5-FU: 2400 mg/m², continuous infusion over 46-48 hours, on day 1; Cetuximab: 500 mg/m², intravenous infusion over at least 2 hours, on day 1; Vemurafenib: 720 mg, orally twice daily. Repeat every 2 weeks.
62828740|NCT06603376|ACTIVE_COMPARATOR|FOLFIRI ± Bevacizumab|Control Group: Liposomal Irinotecan Hydrochloride Injection (II): 60 mg/m², intravenous infusion over at least 90 minutes, on day 1; Leucovorin: 400 mg/m², intravenous infusion over 2 hours, on day 1; 5-FU: 400 mg/m², intravenous bolus; 5-FU: 2400 mg/m², continuous infusion over 46-48 hours, on day 1; Bevacizumab: 5 mg/kg, intravenous infusion, on day 1. Repeat every 2 weeks.
62046690|NCT05165342|EXPERIMENTAL|Treatment|This treatment is delivered by contact electrodes built in a mask, which is worn by the patient over closed eyes. The device setup is really easy and intuitive.
62046691|NCT05165342|SHAM_COMPARATOR|Sham-intervention|The same device as treatment but the power of device will be set to ZERO power.
62046692|NCT05514912|EXPERIMENTAL|Arm A (nab-paclitaxel, cisplatin, gemcitabine, infigratinib)|"While awaiting NGS molecular profile results, all patients receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 8 of one 21-day cycle in the absence of disease progression or unacceptable toxicity.~Patients who are FGFR2 fusion/translocation positive receive infigratinib PO QD for days 1-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients whose cancer is stable or improved undergo surgery to remove the tumor within 8 weeks of completing preoperative therapy per standard of care."
62248651|NCT04701385||NSTEMI|Patients presenting with a myocardial infarction will have blood samples taken for analysis. At the time of their angiography/angioplasty procedure they will have an OCT assessment of the culprit coronary artery to distinguish if the heart attack was caused by a plaque rupture or plaque erosion event
62248652|NCT04701385||Control|Patients undergoing planned angioplasty will have blood samples taken pre and post angioplasty to help as a control for the flow cytometry and for biomarker analysis
62438728|NCT02533999|ACTIVE_COMPARATOR|Electrosurgery|Electrosurgery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to achieve hemostasis or varying degrees of tissue destruction. It is commonly used for tonsillectomy and adenoidectomy in pediatric patients. The electrocautery setting will be standardized to 12 for tonsils and 30 for adenoids.
62438729|NCT05481580||Restored|Molars with a 2nd class restoration or a crown
62438730|NCT05481580||Non-restored|Molars with no restorations
62438731|NCT03947788|EXPERIMENTAL|Interventional Practices|These clinics, including physicians, clinical and administrative staff, will receive the One Key Question training program, delivered by Power to Decide, via an in-person group training session.
62438732|NCT03947788|NO_INTERVENTION|Control Practices|These clinics will not receive the OKQ training program during the study period. They will have the opportunity to receive the training after the study period is over.
62438733|NCT01657487|EXPERIMENTAL|Fluticasone/salmeterol high dose|COPD patients treating with high dose of ICS (Fluticasone 1000ug/day) combined with Salmeterol (25ug/day)
62606066|NCT04028622|EXPERIMENTAL|TCAD (telemedicine anesthesia consultation)|Patients having a telemedicine anesthesia consultation
62606067|NCT01348113|EXPERIMENTAL|Brief Alcohol Intervention|
62606068|NCT01348113|NO_INTERVENTION|No intervention|
62606069|NCT03978247|EXPERIMENTAL|NASHMIR group|Validation of the NASHMIR Test
62828741|NCT06595771||225 patients with obstructive sleep apnea syndrome|Patients with obstructive sleep apnea syndrome recieved CPAP therapy
62828742|NCT06543199|EXPERIMENTAL|CONTROL|Group in which no agent was used in the area left for secondary healing at the donor site.
62248653|NCT00788762||Villagers in Taxiarchis|
62248654|NCT00127920|EXPERIMENTAL|Single Arm|Paclitaxel, Carboplatin and Avastin on day1 every 21 days
62248655|NCT04686578||Fibromyalgia group|Diagnosed as Fibromyalgia according to American College of Rheumatology Fibromyalgia 2018 classification criteria over 1 year, and disease activity was stabil with the same drug at least 3 months.
62248656|NCT04686578||Control Group|The participants who have no physicological or severe musculoskeletal, rheumatologic diseases.
62623483|NCT03123003|EXPERIMENTAL|SonicBone Ultrasound|Assessment of bone age by SonicBone Ultrasound will compared to wrist X-ray assessment
62623484|NCT01385540||Task-based fMRI|
62248657|NCT01364623|EXPERIMENTAL|Low dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.24% testosterone gel to deliver a single dose of 300 μg of testosterone per nostril, for a total dose of 600 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 1 (Low dose testosterone nasal gel, single dose)
62248658|NCT01364623|EXPERIMENTAL|Medium dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.48% testosterone gel to deliver a single dose of 600 μg of testosterone per nostril, for a total dose of 1200 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 2 (Medium dose testosterone nasal gel, single dose)
62606070|NCT04888715|EXPERIMENTAL|DWN12088 and Pirfenidone|T1 - Pirfenidone A mg, Tablet, oral, once daily, T2 - 1) DWN12088 X mg, Tablet, oral, once daily, 2) DWN12088 X mg, Tablet, oral, twice daily, T3 - DWN12088 X mg, Tablet, oral, once daily+ Pirfenidone A mg, Tablet, oral, once daily
62606071|NCT04888715|EXPERIMENTAL|DWN12088 and Nintedanib|T1 - Nintedanib B mg, Tablet, oral, once daily, T2 - DWN12088 X mg, Tablet, oral, twice daily, T3 - DWN12088 X mg, Tablet, oral, once daily+ Nintedanib B mg, Tablet, oral, once daily
62606072|NCT06292793|ACTIVE_COMPARATOR|Pain Coping Information|
62606073|NCT06292793|EXPERIMENTAL|Cyclical Sighing|
62248659|NCT01364623|EXPERIMENTAL|High dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.72% testosterone gel to deliver a single dose of 900 μg of testosterone per nostril, for a total dose of 1800 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 3 (High dose testosterone nasal gel, single dose)
62248660|NCT01364623|EXPERIMENTAL|Medium dose TBS-2 multiple doses|TBS-2 dispensers prefilled with 0.48% testosterone gel to deliver a single dose of 600 μg of testosterone per nostril, for a total dose of 1200 μg given t.i.d. daily at 0800 hours (± 30 minutes), 1600 hours (± 30 minutes), and 2400 hours (± 30 minutes) on Days 1 and 2 of Period 2, and once in the morning at 0800 hours (± 30 minutes) on Day 3 of Period 2 (Multi-dose group) (Medium dose testosterone nasal gel, multiple dose)
62248661|NCT05425914|ACTIVE_COMPARATOR|Conventional Treatment|Receiving conventional dry eye treatment in the form of artificial tears four times per days for 90 days.
62248662|NCT05425914|EXPERIMENTAL|Vitamin D3 Supplementation|Receiving vitamin d3 supplementation 6000IU per day along with artificial tears for 90 days.
62248663|NCT05058287|EXPERIMENTAL|Group 1: Topical Steroid|
62248664|NCT05058287|PLACEBO_COMPARATOR|Group 2: Topical Normal Saline|
62248665|NCT02530983||Esophagectomy/Esophageal Reconstruction/Treatment|Patients who have undergone esophagectomy, esophageal reconstruction, or treatment
62828743|NCT06543199|EXPERIMENTAL|HYPERICUM PERFORATUM L|Group using hypericum perforatum L agent in the area left for secondary healing at the donor site.
62828744|NCT06543199|EXPERIMENTAL|HYALURONIC ASID|Group using hyaluronıc acid agent in the area left for secondary healing at the donor site.
62828745|NCT02425293|EXPERIMENTAL|Intervention|Patients participating in a patient education seminar
62828746|NCT02425293|NO_INTERVENTION|Control|Patients not participating in a patient education seminar
62248666|NCT02530983||Upper Digestive Disease|Patients who have an upper digestive disease.
62248667|NCT03980834|ACTIVE_COMPARATOR|Professional Learning, Program Training and Coaching|
62248668|NCT03980834|ACTIVE_COMPARATOR|Program for Parents of Pre-K Students|
62248669|NCT03980834|ACTIVE_COMPARATOR|Program for Pre-K Students|
62248670|NCT03465631|EXPERIMENTAL|SMART Glove system with dual-tDCS|VR-based SMART Glove system with dual-tDCS
62248671|NCT03465631|SHAM_COMPARATOR|SMART Glove system with sham-tDCS|VR-based SMART Glove system with sham-tDCS
62248672|NCT01671423|ACTIVE_COMPARATOR|Prednisone|In addition to standard care for cellulitis, subject will receive a single 60 mg dose of Prednisone orally during their initial visit.
62248673|NCT01671423|PLACEBO_COMPARATOR|Placebo|In addition to standard care for cellulitis, subjects will receive a single placebo pill to take during their initial visit.
62248674|NCT05944042||Intra-Operative Data:|Intra-Operative Data: Operative time, donor type, transfusions, intraoperative adverse events, mechanical ventilation, portal vein thrombosis, etc.
62248675|NCT05944042||Post-Operative Data and Follow-Up:|Post-Operative Data and Follow-Up: Post-operative laboratories (MELD score, ctDNA, etc.), adverse events, discharge status, hospital length of stay, readmissions, recurrence of primary disease, graft survival, renal disease, post-transplant metabolic syndrome and major cardiovascular events, etc.
62248676|NCT01447368|EXPERIMENTAL|Cinacalcet treatment|Oral Cinacalcet treatment arm, 25mg daily to be administered and gradually step up as required to control iPTH between 2 - 9 times lab reference range, Maximum dose to be given is 100mg daily
62606074|NCT01085136|ACTIVE_COMPARATOR|Investigator's choice of chemotherapy|Patients will be treated with investigator's choice of chemotherapy
62606075|NCT01085136|EXPERIMENTAL|BIBW 2992 and Paclitaxel|Patients will be treated with BIBW 2992daily with a medium dose and weekly administration of Paclitaxel at a dose of 80 mg/m2
62606076|NCT00328094|EXPERIMENTAL|CII, Continuous Insulin Infusion|Continuous intravenous insulin infusion to control glucose to \<150 mg/dL in patients undergoing open peripheral vascular bypass surgery
62828747|NCT02345070|PLACEBO_COMPARATOR|Placebo qw|Participants received one injection of placebo (matched to SAR156597) subcutaneously once every week (qw) for 52 weeks.
62828748|NCT02345070|EXPERIMENTAL|SAR156597 200 mg q2w|Participants received one injection of SAR156597 200 mg subcutaneously once every 2 weeks (q2w) alternating with placebo (matched to SAR156597) for 52 weeks.
62828749|NCT02345070|EXPERIMENTAL|SAR156597 200 mg qw|Participants received one injection of SAR156597 200 mg subcutaneously qw for 52 weeks.
62248677|NCT01447368|ACTIVE_COMPARATOR|Surgical total parathyroidectomy|Surgical total parathyroidectomy with forearm autografting will be performed for patients randomized to this arm.
62248678|NCT03627897|EXPERIMENTAL|Regional analgesia group|ESP block at bilateral side will be performed in the lateral decubitis position and at T5 transverse process level by using 10-MHz liner ultrasound probe. The probe will be located 1 cm lateral to T5 spinous process in longitudinal parasagittal orientation. Simplex A 50mm (B.Braun, Germany) will be inserted by using out of plane technique. The ESP blocks proceed with 0,5 ml/kg of 0,25% bupivacaine
62248679|NCT03627897|OTHER|Control group|
62248680|NCT03517787|EXPERIMENTAL|FES+TE|Participants receiving Functional electrical stimulation (FES) combined with therapeutic exercise (TE)
62248681|NCT03517787|ACTIVE_COMPARATOR|TE|Participants receiving only therapeutic exercise
62623485|NCT00235248|EXPERIMENTAL|Clopidogrel-aspirin|Clopidogrel-aspirin
62623486|NCT00235248|ACTIVE_COMPARATOR|Warfarin|Warfarin
62828750|NCT04953494||Amyotrophic lateral sclerosis patients group|
62828751|NCT04102098|EXPERIMENTAL|Arm A (atezolizumab plus bevacizumab)|Participants will receive Atezolizumab + Bevacizumab until disease recurrence or unacceptable toxicity.
62828752|NCT04102098|NO_INTERVENTION|Arm B (active surveillance)|Active surveillance of participants.
62828753|NCT03439228|EXPERIMENTAL|Brace|Lumbar brace wear prescribed for 3 months post-operation
62828754|NCT03439228|NO_INTERVENTION|No brace|No lumbar brace prescribed
62606077|NCT00328094|ACTIVE_COMPARATOR|IIB, Intermittent insulin boluses|Intermittent intravenous insulin insulin boluses to a blood glucose target of \<150mg/dL in patients undergoing peripheral vascular bypass surgery
62606078|NCT00674856|EXPERIMENTAL|naproxcinod|naproxcinod 750mg(375mg caps x2), administered twice a day.
62606079|NCT02921750|EXPERIMENTAL|Dressing Exufiber®Gelling Fibre Dressing|will receive dressing Exufiber®
62606080|NCT02921750|ACTIVE_COMPARATOR|Dressing Aquacel®ExtraHydrofiber®Dressing with Strengthenin|Will receive Aquacel®Extra™
62606081|NCT05212415||Children with CP|Children and adolescents with spastic CP are the group of the observational study.
62606082|NCT01920256|EXPERIMENTAL|Personalized type 2 diabetes care.|Remote, personalized type 2 diabetes clinic provided by an endocrinologist using frequent remote contacts for medication adjustments.
62606083|NCT01920256|ACTIVE_COMPARATOR|Usual Endocrine Care|Usual Endocrine care will be provided by an endocrinologist.
62606084|NCT05247892|ACTIVE_COMPARATOR|Fluoroscopic-guided S1 Radiofrequency stimulation|
62046693|NCT05514912|ACTIVE_COMPARATOR|Arm B (nab-paclitaxel, cisplatin, gemcitabine)|"While awaiting NGS molecular profile results, all patients receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 8 of one 21-day cycle in the absence of disease progression or unacceptable toxicity.~Patients who are FGFR2 fusion/translocation negative continue receiving nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients whose cancer is stable or improved undergo surgery to remove the tumor within 8 weeks of completing preoperative therapy per standard of care."
62248682|NCT03517787|OTHER|REF-FES+TE|Healthy adults (reference group REF) that participate only in 1 session and receive FES and therapeutic exercise
62438734|NCT01657487|ACTIVE_COMPARATOR|Fluticasone/Salmeterol medium dose|COPD patients treating with medium dose of ICS (Fluticasone 500ug/day) combined with Salmeterol (25ug/day)
62248683|NCT03517787|OTHER|REF-TE|Healthy adults that participate only in 1 session and receive only therapeutic exercise
62248684|NCT03753009||iontophoretic transepithelial corneal cross-linking (I-ON CXL)|Twenty eyes of 15 patients with keratoconus (mean age 13±3.5 \[SD\] years, range 9 to 18) underwent Iontophoresis epi-on CXL
62438735|NCT01261533|EXPERIMENTAL|FCVB team|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB)
62606085|NCT05247892|EXPERIMENTAL|Ultrasound-guided S1 Radiofrequency stimulation|
62248685|NCT03753009||epithelium-off collagen cross-linking (epi-off CXL)|Twenty eyes of 13 patients with keratoconus (14±4 \[SD\] years, range 10 to 18) underwent standard epi-off CXL
62606086|NCT06308757|EXPERIMENTAL|VLCKD arm|"The VLCKD dietary intervention consists of five phases:~Ketogenic Low-Calorie Period (2 months):~* Phase 1 (30 days - Visits 1-3): Ketogenic diet with low-fat content, 600 kcal/day.~* Phase 2 (15 days - Visit 5): 660 kcal/day.~* Phase 3 (15 days - Visit 5): 730 kcal/day~Low-Calorie Period (2 months):~Phase 4 (30 days - Visits 6-7): Hypocaloric diet with the reintroduction of different foods, 1,050 kcal/day.~- Phase 5 (30 days - Visits 7-8): 1,400 kcal/day.~During these phases, the patient will receive nutritional supplementation with vitamins, trace elements, and omega-3 fatty acids. Throughout the very low-calorie ketogenic period, the patient will have three interim dietetic consultations (Visits 2-4) and a medical visit (Visit 5). During the low-calorie period, the patient will receive alternating two dietetic consultations (Visits 6 and 7) and one medical visit every 30 days (Visit 8)."
62606087|NCT06308757|ACTIVE_COMPARATOR|Control LCD arm|"The control LCD arm consists of a diet with natural low-calorie foods (1200-1500 kcal/day or a reduction of 500-1000 kcal/day compared to baseline) and a low glycemic index based on the Mediterranean Diet model, following the most recent guidelines on MAFLD/NAFLD. Similar to the VLCKD arm, for the entire duration of the dietetic treatment, the patient will alternately receive dietetic consultations and medical visits.~At the end of the dietary intervention, patients from both study arms will continue with a controlled, low glycemic index diet tailored to the patient's basal metabolic rate (BMR) (estimated with bioimpedance assessment) for an additional six months.~Both study arms will follow a physical activity schedule and will have psychological-motivational support."
62438736|NCT06449079||Pacing induced cardiomyopathy|Patients who received a pacing device and developed pacing induced cardiomyopathy
62438737|NCT06449079||Non-pacing induced cardiomyopathy|Patients who received a pacing device and did not develop pacing induced cardiomyopathy
62438738|NCT01799733|ACTIVE_COMPARATOR|LWT+AM BWL|Late-wake therapy in combination with morning bright white light
62438739|NCT01799733|PLACEBO_COMPARATOR|EWT+PM BWL|Early-wake therapy in combination with evening bright white light
62438740|NCT04950283||Magnetic resonance examination and anthropometric, metabolic characterization|
62606088|NCT04045080|EXPERIMENTAL|AMADEO Training|Twenty PD patients with hand bradykinesia will be treated with the AMADEO® system. They will undergo 15 training sessions, 5 a week for 3 weeks, each session lasting about 60 minutes. During each session, both the hands will be treated using the endeffector in its active and active-assisted modality.
62606089|NCT04045080|ACTIVE_COMPARATOR|OT training|"Twenty control subjects (PD patients) will be treated with traditional rehabilitation focused on fine hand-finger movement skills. The patients in this group will undergo the same amount of treatment.~Both the groups will be trained with conventional physiotherapy concerning postural, balance and gait."
62046694|NCT03356379|EXPERIMENTAL|Patients|Patients suspected of PES will have a transcutaneous oximetry test during tiptoeing
62248686|NCT01495858|EXPERIMENTAL|Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|
62438741|NCT04951388|EXPERIMENTAL|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
62248687|NCT01495858|ACTIVE_COMPARATOR|Naproxen Sodium 440 mg (BAYH6689)|
62606090|NCT04217005|EXPERIMENTAL|experimental group|amputees or diabetics receiving intervention
62606091|NCT01319240|EXPERIMENTAL|IDegLira|
62606092|NCT01319240|ACTIVE_COMPARATOR|IDeg|
62046695|NCT03356379|SHAM_COMPARATOR|Controls|Healthy asymptomatic athletes will have a transcutaneous oximetry test during tiptoeing
62046696|NCT02089256|EXPERIMENTAL|Liraglutide|Liraglutide 0.6 mg/day subcutaneously.
62046697|NCT04620291|EXPERIMENTAL|Cohort A|250 mg UB-421 SC: ART-treated subjects
62248688|NCT01495858|ACTIVE_COMPARATOR|DPH 50 mg|
62248689|NCT03100799|OTHER|Patients with osteoarthritis of the knee|This is an exploratory non-drug, interventional biomarker study, however, there are study related procedures which are interventional such as arthroscopy, arthrocentesis and MRI assessment with infusion of a gadolinium-contrast agent.
62248690|NCT01537536|EXPERIMENTAL|EndoTAG-1|Weekly treatment with EndoTAG-1 (22 mg/m2) plus paclitaxel (70 mg/m2) for 12 weeks (ET+P) followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
62248691|NCT01141400||depression & initial prescription for an antidepressant|A sample of adults with a diagnosis of depression and an initial prescription fill for an antidepressant
62606093|NCT01319240|ACTIVE_COMPARATOR|Lira|
62606094|NCT03578146|EXPERIMENTAL|Module 2 (210 mg)|210 mg andexanet IV bolus administered over 7 minutes (\~30 mg/min)
62046698|NCT04620291|EXPERIMENTAL|Cohort B|500 mg UB-421 SC: ART-treated subjects
62046699|NCT04620291|EXPERIMENTAL|Cohort C|700 mg UB-421 SC: ART-treated subjects
62046700|NCT04620291|EXPERIMENTAL|Cohort D|500 mg UB-421 SC: Treatment naive subjects
62046701|NCT04620291|EXPERIMENTAL|Cohort E|700 mg UB-421 SC: Treatment naive subjects
62248692|NCT02838095|NO_INTERVENTION|No nap|After each night with a 5-hour sleep opportunity, participants did not have a daytime nap opportunity, but instead watched documentaries.
62248693|NCT02838095|EXPERIMENTAL|Nap|After each night with a 5-hour sleep opportunity, participants had the chance to take a daytime nap from 14:00 to 15:00.
62248694|NCT03621527|ACTIVE_COMPARATOR|Standard group|"For each vertebra treated: 10 ml of lidocaine hydrochloride 1% are applied to the skin and the lower structures including the periosteum.~An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure"
62248695|NCT03621527|EXPERIMENTAL|Epidural group|"Fluoroscopy-guided epidural anesthesiaI is the identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air.~According to patient's height, 10-15 ml of lidocaine hydrochloride 1% are injected by the radiologist into the epidural space.~An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure"
62046702|NCT01569438|EXPERIMENTAL|Gefapixant|Female participants receive gefapixant, a total dose titrated from 50 mg to highest tolerated dose (maximum of 300 mg) twice daily (BID), orally over a period of 6 days with food depending on safety and tolerability, and then maintain that dose for the course of a 4-week treatment period. Participants were allowed to decrease the dose if tolerability issues occurred.
62248696|NCT03380351||SCDIC interventions|Careful detail the intervention components and the implementation strategies (i.e., the mechanisms by which the interventions are being delivered in usual care) being developed by the consortium.
62438742|NCT04951388|PLACEBO_COMPARATOR|MVC-COV1901(Saline)|Saline/0.5 mL
62438743|NCT04882683|EXPERIMENTAL|control group|Prednisone+Azathioprine/Adalimumab
62438744|NCT04882683|EXPERIMENTAL|UCB-MNCs group|Prednisone+Azathioprine/Adalimumab+UCB-MNCs
62449331|NCT04812587|NO_INTERVENTION|Comparison group|The healthy elderly will be were recruited to participate in this study. All the subjects were independent in basic daily living activities, but at least one or more given assistance in the instrumental IADL assessment (ability to use telephone, shopping, food preparing, housekeeping, laundry, mode of transportation, responsibility for own medications, ability to handle finances). Their age should be ranged between 65 - 81 years.
62606095|NCT03578146|EXPERIMENTAL|Module 2 (420 mg)|420 mg andexanet IV bolus administered over 14 minutes (\~30 mg/min)
62606096|NCT03578146|EXPERIMENTAL|Module 2 (600 mg)|600 mg andexanet IV bolus administered over 20 minutes (\~30 mg/min)
62046703|NCT01569438|PLACEBO_COMPARATOR|Placebo|Female participants receive dose matched placebo tablets, BID, orally, with food for 4 weeks.
62046704|NCT04483310|EXPERIMENTAL|MR therapy|MR therapy is a psychological treatment for SP, comprised of the following steps applied directly during the attack: Step I: Reappraisal of the meaning of the attack; Step II: psychological and emotional distancing; Step III: inward focused-attention meditation; Step IV: Muscle relaxation.
62046705|NCT04483310|ACTIVE_COMPARATOR|Control intervention|The control intervention was identical, except participants engaged in deep breathing; entailing slow deep breaths, while repeatedly counting from 1-10. This is an active control (breathing-distraction exercise) rather than a placebo.
62046706|NCT06579287|EXPERIMENTAL|SHJ002|The assigned eyedrops will be instilled in both eyes once per day, one drop per application, 7 days a week, for 52 weeks.
62046707|NCT06579287|ACTIVE_COMPARATOR|Atropine|The assigned eyedrops will be instilled in both eyes once per day, one drop per application, 7 days a week, for 52 weeks.
62248697|NCT02014740|EXPERIMENTAL|Liraglutide|• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued.
62248698|NCT02014740|ACTIVE_COMPARATOR|Metformin|M-group will be treated with Metformin for the duration of the study. Metformin (from 500 mg twice daily to a maximum of 1000 mg twice daily) regimen will be continued to achieve fasting glucose between 80 and 140 mg/dl
62248699|NCT05766709|EXPERIMENTAL|Group 1|Participants will receive separate injections of NNC0194-0499 B and Semaglutide B for 24 weeks. Dose escalation manner every 4 weeks for 20 weeks (30 mg NNC0194-0499 B and 0.24 mg Semaglutide B for Weeks 1-4, 30 mg NNC0194-0499 B and 0.5 mg Semaglutide B for Weeks 5-8, 30 mg NNC0194-0499 B and 1.0 mg Semaglutide B for Weeks 9-12, 30 mg NNC0194-0499 B and 1.7 mg Semaglutide B for Weeks 13-16 and 30 mg NNC0194-0499 B and 2.4 mg Semaglutide B for Weeks 17-20). Participants will receive NNC0194-0499/Semaglutide A 40/3.20 mg/mL co-formulation at the target dose of 30/2.4 mg during the weeks 21-24 (maintenance dosing period).
62248700|NCT05766709|EXPERIMENTAL|Group 2|Participants will receive NNC0194-0499/Semaglutide A 40/3.20 mg/mL co-formulation for 24 weeks. Dose escalation manner every 4 weeks for 20 weeks (3.1mg/0.25mg for Weeks 1-4, 6.3mg/0.5mg for Weeks 5-8, 12.5mg/1.0mg for Weeks 9-12, 21.3mg/1.7mg for Weeks 13-16 and 30mg/2.4mg for weeks 17-20). Participants will receive NNC0194-0499/Semaglutide 40/3.20 mg/mL co-formulation at the target dose of 30mg/2.4mg during the weeks 21-24 (maintenance dosing period).
62248701|NCT05766709|EXPERIMENTAL|Group 3|Participants will receive 4 weekly injections of NNC0194-0499/Semaglutide A 40/0.33 mg/mL co-formulation at the dose level of 30mg/0.25 mg.
62248702|NCT03306355|EXPERIMENTAL|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
62248703|NCT03306355|ACTIVE_COMPARATOR|IOL implantation active comparator|hydrophilic, trifocal intraocular lens POD F
62248704|NCT05291442|NO_INTERVENTION|control group|The control group received no intervention, except for the regular care followed by the nurses in general in the rehabilitation ward.
62438745|NCT06476444||1. Women with Overweight and Obesity (25.0-34.9 BMI)|"Healthy women with overweight and women without any chronic conditions other than obesity~In this cross-sectional study, indirect calorimetry will be used to determine resting fat oxidation in these participants. Subsequently, the relationship between the resting fat oxidation data obtained with the habitual diet and physical activity status of these participants will be evaluated. Dietary patterns and physical activity will be assessed with 4 consecutive daily food consumption records and Actigraph GT3X+ devices, respectively."
62438746|NCT06476444||2. Women with normal weight (18.5-24.9 BMI)|"Healthy women with normal weight.~In this cross-sectional study, indirect calorimetry will be used to determine resting fat oxidation in these participants. Thus, resting fat oxidation data of healthy women with normal weight and women with obesity/overweight will be compared. Subsequently, the relationship between the resting fat oxidation data obtained with the habitual diet and physical activity status of these participants will be evaluated. Dietary patterns and physical activity will be assessed with 4 consecutive daily food consumption records and Actigraph GT3X+ devices, respectively."
62438747|NCT01084005|EXPERIMENTAL|linagliptin|patients receive linagliptin 5 mg tablets once daily
62438748|NCT01084005|PLACEBO_COMPARATOR|placebo|patients receive placebo tablets matching linagliptin 5 mg once daily
62438749|NCT00005615|EXPERIMENTAL|Interferon Alfa Plus Radiation|"Combined Therapy: interferon alfa plus radiation therapy.~Patients receive interferon alfa IV over 20 minutes daily for 5 consecutive days a week for 4 weeks. Patients then receive radiotherapy on days 2 and 4 and interferon alfa subcutaneously (SQ) on days 1, 3, and 5 for 2.5 weeks. Interferon alfa SQ continues 3 times a week for 10 months in the absence of disease progression or unacceptable toxicity. Patients are followed every month for 3 months, then every 3 months for 2 years, then every six months until year 5, and then annually thereafter."
62438750|NCT06527183||Patients with fibromyalgia|Patients with fibromyalgia based on ACR criteria
62606097|NCT03578146|EXPERIMENTAL|Module 2 (720 mg bolus + 240 mg infusion)|720 mg IV bolus administered over 24 minutes \[\~30 mg/min\] followed by 240 mg continuous IV infusion \[4 mg/min over 60 min)
62606098|NCT03578146|EXPERIMENTAL|Module 2 (800 mg bolus + 960 mg infusion)|800 mg IV bolus administered over 26.7 minutes \[\~30 mg/min\] followed by 960 mg continuous IV infusion \[8 mg/min over 120 min\]
62606099|NCT03578146|EXPERIMENTAL|Module 2 Placebo|Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous fusion.
62828755|NCT04018755|EXPERIMENTAL|treatment|anakinra 100 mg subcutaneous once daily
62828756|NCT04882202|EXPERIMENTAL|Acetaminophen group|patients receiving acetaminophen
62828757|NCT04882202|PLACEBO_COMPARATOR|Placebo group|patients receiving equal amount of normal saline
62046708|NCT05590455|EXPERIMENTAL|Adalimumab arm|"* Standard TBM treatment~* Adalimumab 40 mg: one sub-cutaneous injection, every 2 weeks for 10 weeks (total 6 injections), started as soon as possible during the first 3 days of antituberculosis treatment and high-dose steroids"
62046709|NCT05590455|NO_INTERVENTION|Control arm|- Standard TBM
62046710|NCT04563221|EXPERIMENTAL|Balloon occlusion microcatheter|Participants will undergo the PAE procedure using LC Bead LUMI delivered through a balloon occlusion microcatheter.
62438751|NCT06527183||Patients with other chronic pain (paired for the other groups)|Patients with chronic pain other than fibromyalgia and neuropathic pain, eg nociplastic pains or nociceptive pains
62438752|NCT06527183||Paired healthy subjects|Healthy subjects paired for gender and age
62828758|NCT02506088|EXPERIMENTAL|Your Voice Your View|Participants in schools assigned to the treatment group will engage in a four session intervention aimed at prevention of sexual violence. Your Voice Your View is grounded in social norms theory and bystander intervention training. The intervention also includes a social norms marketing campaign.
62248705|NCT05291442|EXPERIMENTAL|Intervention group|"To integrate Family System Care and Theme Care Action Module to improve resilience, family function, self-efficacy, and quality of life for stroke patients and their caregivers.~First, understand the care needs of patients and caregivers, and apply The Specific Thematic Nursing Care Action Modules (STNC-AM) platform for education and training.~The Specific Thematic Nursing Care Action Modules (STNC-AM) platform that we present here is an educational program that integrates education and coaching. STNC-AM has six key aspects: stroke prevention, management of emotions, management of fatigue, physical activity, caregiver training, and integrative resources. Each scope contains detailed care guidance."
62248706|NCT04901481|EXPERIMENTAL|Active treatment|Participants will self-administer treatment with the Empower device at the active treatment anatomic location twice daily for six weeks. Treatment adherence will be assessed and participants will complete surveys to evaluate the feasibility and acceptability Empower active treatment.
62828759|NCT02506088|NO_INTERVENTION|Wait List Control Group|Participants in schools assigned to the wait list control group will complete survey assessments at the same schedule as schools assigned to the treatment group. Schools will have the option to implement Your Voice Your View following completion of the 6-month survey.
62248707|NCT04901481|SHAM_COMPARATOR|Sham treatment|Participants will self-administer treatment with the Empower device at the sham treatment anatomic location twice daily for six weeks. Treatment adherence will be assessed and participants will complete surveys to evaluate the feasibility and acceptability Empower sham treatment.
62248708|NCT00393796|ACTIVE_COMPARATOR|SUTENT|Study participants randomized to received SUTENT will receive a dose of 50 mg PO (capsules) as a single agent to be taken once daily for four consecutive weeks followed by a two week rest period to form a complete cycle of six weeks.
62248709|NCT00393796|PLACEBO_COMPARATOR|Placebo|Study participants randomized to receive placebo will receive 50 mg/day PO (capsules) of an inactive substance to be taken once daily for four consecutive weeks followed by a two week rest period to form a complete cycle of six weeks.
62248710|NCT02281357|EXPERIMENTAL|Tralokinumab|Tralokinumab subcutaneous injection
62248711|NCT02281357|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection
62248712|NCT05923021|EXPERIMENTAL|Cheek acupuncture treatment group|"Needle selection: Select disposable trocars（φ0.18 × 25mm） (Wujiang Jiachen acupuncture and moxibustion Instrument Co., Ltd.) .~Acupoints selection: bilateral Sanjiao points, bilateral head points, bilateral neck points, Needling depth: about 5mm-7.5mm, Needle retaining time: 30 minutes, course of treatment: 3 times a week, with a total of 36 cheek acupuncture treatments for 12 weeks."
62438753|NCT02988752|EXPERIMENTAL|Electronic Mobile Device|Use an Electronic Low Cost Mobile Device To Determine C/D Ratio And Compare Results With Gold Standard Optical Coherence Tomography Results. The equipment needs mydriatic conditions and does not touch the patient's eye. The equipment uses a panoptik and a camera to access eye fundus.
62438754|NCT02988752|ACTIVE_COMPARATOR|Optical Coherence Tomography|Device considered as gold standard to determine c/d ratio. Needs mydriatic conditions.
62438755|NCT02462070|EXPERIMENTAL|IDP-118 Lotion|Lotion
62438756|NCT02462070|ACTIVE_COMPARATOR|IDP-118 Vehicle Lotion|Vehicle Lotion
62046711|NCT04563221|EXPERIMENTAL|Standard microcatheter|Participants will undergo the PAE procedure using LC Bead LUMI delivered through a standard microcatheter.
62046712|NCT00140504|EXPERIMENTAL|MedCheck|Electronic medication safety queries via PatientSite portal
62046713|NCT00140504|NO_INTERVENTION|Usual care|No electronic medication safety messages via PatientSite portal
62438757|NCT01271699||Observation|Patients at age 18-50 with a confirmed or probably diagnosis of Multiple Sclerosis according to the McDonald diagnostic criteria for MS
62438758|NCT05142436|EXPERIMENTAL|Cohort 1: Non-combusted cigarette variant 42001402 and product use mode B|Subjects randomized to use of a non-combusted cigarette variant and product use mode B
62606100|NCT02621658|ACTIVE_COMPARATOR|Clear Liquid Diet|Clear Liquid Diet the day before colonoscopy.
62046714|NCT00053989|EXPERIMENTAL|All patients|All patients enrolled on study
62828760|NCT06592066|ACTIVE_COMPARATOR|Splinted Conventional Impression Technique|Splinted open tray conventional impression technique will be used for the mandibular full-arch implants, utilizing medium body impression material.
62046715|NCT02316964|EXPERIMENTAL|Treatment (decitabine, allogeneic NK cells, aldesleukin)|Patients receive decitabine IV over 60 minutes on days -4 to 0 and undergo infusion of allogeneic NK cells on day 0. Beginning 1 hour after infusion allogeneic NK cells, patients also receive aldesleukin SC every other day for 6 doses.
62046716|NCT01256411|EXPERIMENTAL|LCZ696|
62046717|NCT06579313||HBV cohort|2000 HBsAg positive patients during 2016.7-2019.12
62046718|NCT06579313||HCV cohort|500 HCV Ab positive and HCV RNA positive patients during 2020.7-2023.12
62046719|NCT05117138|EXPERIMENTAL|NSCLC/HNSCC：AMT-116 CAR-T cells|Patients with moderate or far advanced non-small cell lung carcinomav or head and neck Squamous Cell Carcinoma.
62438759|NCT05142436|EXPERIMENTAL|Cohort 2: Non-combusted cigarette variant 42001399 and product use mode B|Subjects randomized to use of a non-combusted cigarette variant and product use mode B
62828761|NCT06592066|EXPERIMENTAL|Digital impression technique with scan bodies|Digital impression technique will be employed for mandibular full-arch implants, using intraoral scanning with scan bodies to capture the implant positions.
62828762|NCT06592066|EXPERIMENTAL|Digital impression technique with scan bodies with Prefabricated Landmarks|Digital impression technique will be employed for mandibular full-arch implants, using intraoral scanning with scan bodies with prefabricated landmarks to capture the implant positions.
62828763|NCT02080715|EXPERIMENTAL|Tolcapone|Tasmar
62828764|NCT04020809|EXPERIMENTAL|Atezolizumab|Atezolizumab will be administered as 1200 mg intravenously on Day 1 every 3 weeks for 2 cycles.
62046720|NCT05117138|EXPERIMENTAL|MEL：AMT-253 CAR-T cells|Patients with moderate or far advanced melanoma.
62046721|NCT00373399|PLACEBO_COMPARATOR|Inactive Marijuana (0, 1.8, or 3.9% THC)|In this randomized, placebo-controlled study, every participant received all 3 treatment interventions in randomized order. Inactive marijuana (0% THC) served as a placebo comparator. Participants received an inactive marijuana cigarette (0% THC; provided by NIDA) in 1 of the 3 outpatient sessions in randomized order.
62046722|NCT00373399|EXPERIMENTAL|Active Marijuana|In this randomized, placebo-controlled study, every participant received all 3 treatment interventions in randomized order. Participants received active marijuana cigarettes (1.8, or 3.9% THC; provided by NIDA) over 2 of 3 outpatient sessions in randomized order.
62046723|NCT00568048|EXPERIMENTAL|Combination Therapy Temozolomide & Bevacizumab|"Combination therapy~* Temozolomide 150 mg/m2 p.o., days 1-7, repeated every 14 days~* Bevacizumab 10 mg/kg i.v., day 1, repeated every 14 days"
62438760|NCT05142436|EXPERIMENTAL|Cohort 3: Non-combusted cigarette variant 42001401 and product use mode B|Subjects randomized to use of a non-combusted cigarette variant and product use mode B
62438761|NCT05142436|EXPERIMENTAL|Cohort 4: Non-combusted cigarette variant 40007386 and product use mode B|Subjects randomized to use of a non-combusted cigarette variant and product use mode B
62438762|NCT05142436|EXPERIMENTAL|Cohort 5: Non-combusted cigarette variant 42001402 and product use mode A|Subjects randomized to use of a non-combusted cigarette variant and product use mode A
62248713|NCT05923021|SHAM_COMPARATOR|Sham cheek acupuncture treatment group|"Needle selection: Select disposable flat head trocars（φ0.18 × 25mm） (Wujiang Jiachen acupuncture and moxibustion Instrument Co., Ltd.) .~Acupoints selection: Translate the bilateral Sanjiao points forward by 1cm（towards the front midline of the body）, translate the bilateral head points forward by 1cm, bilateral back points, Needling depth: Retained on the surface of the skin with the help of a cannula， Needle retaining time: 30 minutes, course of treatment: 3 times a week, with a total of 36 times of cheek acupuncture treatments for 12 weeks."
62248714|NCT05923021|ACTIVE_COMPARATOR|Drug group|"Drug name: Sertraline Hydrochloride Tablets (trade name: Levofloxacin Sertraline, produced by Pfizer Pharmaceutical Co., Ltd., batch number: H10980141),~Dosage form: tablets~Usage: Take orally. 50 mg/d, taken after breakfast.~Depending on the patient's condition, the dosage can be increased to 200mg/d, taken after breakfast, or divided twice a day after meals~Treatment cycle: a total of 12 weeks."
62248715|NCT04095780|EXPERIMENTAL|Advanced oral hygiene care programme|Patients with stroke will receive the advanced oral hygiene care programme (AOHCP) comprising powered tooth brushing and mouth rinsing with chlorhexidine (with a supply of standardized power tooth brushes, mouth rinse, tooth paste and oral hygiene instruction).
62248716|NCT04095780|EXPERIMENTAL|Oral hygiene instruction|Patients with stroke will only receive the oral hygiene instruction.
62248717|NCT01931748|EXPERIMENTAL|UNCNT|6 times/ 12 days
62248718|NCT01931748|ACTIVE_COMPARATOR|MELSMON|6 times/ 12 days
62248719|NCT02890758|EXPERIMENTAL|Cytokine Arm|Two infusions of Natural Killer (NK) cells and ALT803
62248720|NCT02890758|ACTIVE_COMPARATOR|No Cytokine Arm|Two infusions of Natural Killer (NK) Cells
62606101|NCT02621658|EXPERIMENTAL|Full Liquid Diet|Full Liquid Diet the day before colonoscopy.
62248721|NCT01108965||Extraventricular Drainage|Includes hydrocephalus patients that are in recovery from shunt explanation.
62248722|NCT04778345|EXPERIMENTAL|18F-FDG PET/CT and 68Ga-FAPI PET/CT scan after abdominal enhanced CT|After the patient received abdominal enhanced CT, 18F-FDG PET/CT and 68Ga-FAPI PET/CT were further performed. The interval between 18F-FDG PET/CT and 68Ga-FAPI PET/CT was 2 days to 1 week.
62606102|NCT04885894||MS Zeposia|Individuals with MS who will begin taking Zeposia as part of standard care.
62606103|NCT04885894||MS High dose efficacy medication|Individuals with MS who will begin taking high dose efficacy oral medication as part of standard of care.
62438763|NCT05142436|NO_INTERVENTION|Cohort 6: Usual Brand Cigarettes|Subjects randomized to continue to smoke usual brand cigarettes
62606104|NCT04885894||Healthy Control|Healthy controls, all of whom will be matched on age, education and gender to the MS groups.
62606105|NCT00394771|EXPERIMENTAL|Low Dose DR-1031|42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
62828765|NCT01011894|EXPERIMENTAL|pts getting lenalidomide|Patients with intermediate or high-risk chronic lymphocytic leukemia (≥ 65 years old) will receive lenalidomide until disease progression at the 20mg dose level (recognizing that progression at this dose requires non-protocol alternate therapy) or unacceptable toxicity.
62438764|NCT05142436|NO_INTERVENTION|Cohort 7: Assisted Smoking Cessation|Subjects assigned to assisted smoking cessation
62438765|NCT05142436|NO_INTERVENTION|Cohort 8: Never-Smokers|Never-smokers
62438766|NCT00736528|EXPERIMENTAL|PF-04447943 05 mg dose|
62438767|NCT00736528|EXPERIMENTAL|PF-04447943 15 mg dose|
62438768|NCT00736528|EXPERIMENTAL|PF-04447943 45 mg dose|
62438769|NCT00736528|PLACEBO_COMPARATOR|Placebo|
62438770|NCT02798068|ACTIVE_COMPARATOR|Solu - Medrol|Solu - Medrol (methylprednisolone sodium succinate) 500mg IV once single administration
62606106|NCT00394771|EXPERIMENTAL|Midrange Dose DR-1031|21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
62606107|NCT00394771|EXPERIMENTAL|High Dose DR-1031|21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
62606108|NCT00394771|ACTIVE_COMPARATOR|Seasonale|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.
62606109|NCT00919906|NO_INTERVENTION|Handwriting without Tears|Standard practice
62606110|NCT00919906|EXPERIMENTAL|Haptic guidance|
62248723|NCT03961971|EXPERIMENTAL|Treatment (MBG453, spartalizumab, stereotactic radiosurgery)|Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62438771|NCT02798068|PLACEBO_COMPARATOR|Placebo|NaCl 0,9% 100ml IV once single administration
62438772|NCT05426122|EXPERIMENTAL|Barley rice protein|Barley rice protein powder presented as a shake
62606111|NCT03215719|EXPERIMENTAL|HPV-Positive Oropharyngeal Carcinoma (OPSCC)|Standard radiation therapy + cisplatinum
62606112|NCT00316862|EXPERIMENTAL|Treatment (chemotherapy, chemoradiotherapy, surgery)|"INDUCTION CHEMOTHERAPY (COURSES 1-2): Patients receive cisplatin intravenously (IV) over 30 minutes and irinotecan hydrochloride IV over 30-90 minutes on days 1 and 8 of courses 1 and 2. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CHEMORADIOTHERAPY (COURSES 3-4): Beginning 2 weeks after completion of induction chemotherapy, patients receive cisplatin and irinotecan hydrochloride as in induction chemotherapy on days 1 and 8 of courses 3 and 4 and undergo radiotherapy daily 5 days a week in course 3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Approximately 4-8 weeks after completion of chemoradiotherapy, patients undergo surgery to remove the tumor."
62606113|NCT04486469|EXPERIMENTAL|Subjects with Irritable bowel syndrome|Experimental group is formed with 24 patients diagnosed with IBS treated in the digestive system service of the Virgen de la Arrixaca and Reina Sofía General University Hospitals.
62606114|NCT01291134||Cervical Degenerative Disc Disease|Subjects suffering from symptoms of cervical degenerative disc disease in one to four contiguous levels between C3 and T1.
62828766|NCT05016531|EXPERIMENTAL|Low Intensity Focused Ultrasonic Stimulation|There are different combinations of intensity and frequency with LIFUS
62248724|NCT00518427|EXPERIMENTAL|1|insulin glargine
62438773|NCT05426122|EXPERIMENTAL|Pea protein|Pea protein powder presented as a shake
62438774|NCT05426122|EXPERIMENTAL|Whey protein|Whey protein powder presented as a shake
62828767|NCT02294708|EXPERIMENTAL|supine|postoperative postures: patients in this arm are assigned to adopt supine position for 24 hours after the surgery
62248725|NCT03228069|EXPERIMENTAL|single visit 4-site ID vaccination|Blood would be drawn from those who received a single visit 4-site ID rabies booster vaccination in the previous trial.
62248726|NCT03228069|ACTIVE_COMPARATOR|Conventional IM vaccination|Blood would be drawn from those who received a conventional intramuscular rabies booster vaccination in the previous trial.
62248727|NCT05223114||HIV+COPD+|40 male and female adults \> 35 years with COPD and HIV
62438775|NCT02257359|EXPERIMENTAL|Epelsiban Cohort 1|Subjects will receive 300 mg of epelsiban administered orally twice (every 12 hr) on Day 1 (total daily dose of 600 mg)
62438776|NCT02257359|EXPERIMENTAL|Epelsiban Cohort 2|Epelsiban dose for Cohort 2 will be determined based on data from Cohort 1, but will not exceed a total daily dose of 900 mg, administered orally in divided doses (450 mg every 12 hrs or 300 mg every 8 hrs).
62606115|NCT05883059|EXPERIMENTAL|robot group|The participants in the robot group received lower limb robot assisted walking training combined with routine rehabilitation therapy. Routine rehabilitation therapy includes lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, and functional electrical stimulation.
62248728|NCT05223114||HIV+COPD-|40 male and female adults \> 35 years with HIV but no COPD
62623487|NCT02776540|ACTIVE_COMPARATOR|900 mg Clopidogrel|67 patients will receive 12 tablets clopidogrel ( each 75 mg) as total 900 mg each patient
62828768|NCT02294708|EXPERIMENTAL|temporal lateral|postoperative postures: patients in this arm are assigned to adopt temporal lateral position for 24 hours after the surgery
62606116|NCT05883059|ACTIVE_COMPARATOR|control group|Routine rehabilitation therapy includes lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, and functional electrical stimulation.
62046724|NCT05956288|EXPERIMENTAL|Blood flow restriction (BFR) with low load resistance training|A single BFR exercise (Biceps curl with dumbell) will be perform. The initial resistance load for performing the above exercise will correspond to 5% of the body weight of each participant (±0.250 kg). Participants will be asked to perform 4 sets of bicep curls. The first set will consist of repetitions until failure (inability to follow the rhythm or inability to perform an additional contraction) followed by 3 sets of 15 repetitions with 30 seconds rest between sets. In case that for any of the participants will not be able to complete all the repetitions, or they are unable to follow the pace of the metronome, the resistance load will be reduced by 0.5 kg. Vascular Occlusion Pressure will be set at 50-60% of the complete occlusion pressure for the intervention group .Five minutes after the execution of the biceps curl exercise, each participant will receive a specific training which will consist of six therapeutic exercises targeting in loading the rotator cuff and scapula muscles
62606117|NCT06730386|EXPERIMENTAL|AK138D1|AK138D1 will be administered in pre-specified dose levels.
62606118|NCT00637806|ACTIVE_COMPARATOR|1|Megestrol acetate concentrated suspension 110 mg/mL
62046725|NCT05956288|PLACEBO_COMPARATOR|Sham-Blood flow restriction (sham-BFR) with low load resistance training|Same procedure as experimental . The only difference between the two groups regarding the intervention will be the percentage of blood flow restriction cuff pressure. In the sham BFR group, as much pressure as 2 fingers can penetrate the cuff will be automatically applied via MADUP®, where based on the literature seems not to promote adaptations related to the use of the method.
62248729|NCT05223114||HIV-COPD+|40 male and female adults \> 35 years with COPD not HIV
62248730|NCT05223114||HIV-COPD-|40 male and female adults \> 35 years with no COPD and no HIV
62248731|NCT03734549||technical success group|Technical success was defined as crossing the CTO and placement of a guidewire in the distal true lumen confirmed by angiography.
62248732|NCT03734549||technical failure group|Technical failure was defined that guidewire could not crossing through the CTO nor reture to the true lumen by angiography.
62248733|NCT03734549||had adverse events group|Patients had one of the adverse events such as all-cause death, nonfatal myocardial infarction, repeat revascularization or amputation.at 12 months after procedures.
62248734|NCT03734549||had no adverse events group|Patients had none adverse events such as all-cause death, nonfatal myocardial infarction, repeat revascularization and amputation at 12 months after procedures
62248735|NCT06256809||Oral Lesion Risk Assessment Group|This group comprises individuals undergoing evaluation for dermatoglyphic patterns indicative of a predisposition to oral premalignant and malignant lesions. The group includes two sub-cohorts: one consisting of patients with diagnosed oral conditions like Oral Leukoplakia (OL), Oral Submucous Fibrosis (OSF), and Oral Squamous Cell Carcinoma (OSCC), and a control sub-cohort of individuals without these conditions. Dermatoglyphic analysis, including qualitative (whorls, loops, arches) and quantitative (Total Finger Ridge Count (TFRC), atd angles) parameters, will be conducted to assess potential predictive patterns and their correlation with oral lesion risks. No direct interventions are involved; the study focuses on observation and pattern analysis for potential early diagnosis and risk assessment.
62248736|NCT06256809||Healthy Control Group|"This group consists of individuals with no history or diagnosis of oral premalignant or malignant lesions. They serve as a baseline comparison to the Oral Lesion Risk Assessment Group. The dermatoglyphic patterns (whorls, loops, arches) and quantitative parameters (Total Finger Ridge Count (TFRC), atd angles) of this group are analyzed and compared with those of the patient group to identify distinctive patterns or traits associated with oral health conditions. This comparison aims to enhance the understanding of dermatoglyphic variations and their potential role in predicting oral health risks. No interventions are involved; the group is purely observational for comparative analysis"
62248737|NCT06079944|ACTIVE_COMPARATOR|Group A- Control group|"Group (A)/ control group Involves participants receiving~1. TENS+ hot pack (10mins)~2. Pendulum exercises and stretching exercises This group will not receive resistance training from 5 repetitions to 20 repetitions of door way stretch (maintained for 30seconds), pendulum exercises and foam roll strtech will be provided over the 6 weeks protocol"
62248738|NCT06079944|EXPERIMENTAL|Group B- Study Group|"Group (B)/ Experimental group involves participants receiving Traditional l physical therapy for shoulder impingement syndrome for 6 weeks.~1. TENS+ hot pack (10mins)~2. Pendulum exercises and stretching exercises 3-6RM Load will be determined after which multipulley system will be used for treatment and treatment will be divided in to two series of 8 repetition: 25%, 30%,35%,40%, 50% of 6RM over the period of 6 weeks Speed of movement will be 2 seconds for both the eccentric and concentric phases.~To strengthen the shoulder muscles patients will perform flexion, extension, medial and lateral rotation It is a combined treatment so study group will receive both study group and control group intervention"
62248739|NCT04796922|EXPERIMENTAL|Treatment Group A|Participants will be administered with parsaclisib in combination with investigator choice of rituximab or obinutuzumab.
62248740|NCT04796922|PLACEBO_COMPARATOR|Treatment Group B|Participants will be administered with placebo in combination with investigator choice of rituximab or obinutuzumab
62248741|NCT02906787|EXPERIMENTAL|BAS+|Participants will attend 8 counseling sessions and receive a behavioral activation intervention to smoking cessation and to post-cessation weight gain (BAS+).
62248742|NCT02906787|PLACEBO_COMPARATOR|SC|Participants will attend 8 counseling sessions and receive standard smoking cessation counseling (SC).
62248743|NCT05444842|EXPERIMENTAL|insulin iontophoresis|the patients will receive insulin iontophoresis for thirty weeks
62606119|NCT00637806|ACTIVE_COMPARATOR|2|Megestrol acetate concentrated suspension 60 mg/mL
62606120|NCT00637806|PLACEBO_COMPARATOR|3|
62606121|NCT01416155|EXPERIMENTAL|natalizumab|300 mg intravenous (IV) infusions of natalizumab every 4 weeks until product is approved in Japan or development is discontinued in Japan, whichever comes first.
62606122|NCT01329588|PLACEBO_COMPARATOR|Sugar pill|
62606123|NCT01329588|EXPERIMENTAL|Treatment arm|
62828769|NCT01164514|ACTIVE_COMPARATOR|Group 1 - vaccine alone|8 subjects to receive vaccine (10 mcg) alone on Days 0, 29 and 59.
62828770|NCT01164514|EXPERIMENTAL|Group 3 - vaccine + CPG 7909 (250 mcg)|8 subjects to receive vaccine (10 mcg) with 250 mcg of adjuvant on Days 0, 29 and 59.
62248744|NCT05444842|EXPERIMENTAL|topical insulin|the patients will receive topical insulin for thirty weeks
62248745|NCT05444842|ACTIVE_COMPARATOR|conventional treatment|the patients will receive standard dressing and normal saline twice daily for thirty weeks
62248746|NCT05510765|EXPERIMENTAL|Study arm|Low resource, high risk individuals with limited transportation options as a social determinant of health.
62248747|NCT00890253|EXPERIMENTAL|CNI-free Immunosuppression|Immunosuppression after OLT including basiliximab, enteric-coated mycophenolate sodium (EC-MPS), and everolimus.
62248748|NCT02901496|EXPERIMENTAL|Endurance exercise + infusion of Tocilizumab|Endurance exercise training + monthly infusion of Tocilizumab
62606124|NCT06108739|EXPERIMENTAL|ATG-PTCy cohort|The conditioning regimen is ATG/G-CSF based protocol (the so-called Beijing protocol). The rabbit ATG (Sangstat-Genzyme) 2.5mg/kg/day i.v., on days from - 5 to - 2 were administered.Two doses of 14.5 mg/kg Cy were given on days 3 and 4 post-HCT in ATG-PTCy cohort.
62828771|NCT01164514|EXPERIMENTAL|Group 2 - vaccine + CPG 7909 (500 mcg)|8 subjects to receive vaccine (10 mcg) with 500 mcg of adjuvant on Days 0, 29 and 59.
62828772|NCT01164514|PLACEBO_COMPARATOR|Group 4 - Placebo|4 subjects to receive normal saline (placebo) on Days 0, 29 and 59.
62828773|NCT06441201||Gastrointestinal Bleeding Peripheral Pulse Volume|Subject undergoing an emergency endoscopic evaluation for active gastrointestinal bleeding will have their peripheral pulse volumes monitored using a pulse flowmeter throughout the procedure and 2 hours after the procedure.
62828774|NCT01236209|ACTIVE_COMPARATOR|web page|"Control group:~Information web page with some mindfulness exercises"
62828775|NCT01236209|EXPERIMENTAL|Webpage and situational feedback|"Intervention group:~have access to the same web-page with information about coping with pain and relaxation and are completing 3 diaries and receiving personalized feedback for 4 weeks at home through a smartphone."
62828776|NCT05838846|EXPERIMENTAL|Group A (iMil)|"Patients will receive 2 doses of inhaled milrinone at the following time points (after sternotomy and after aortic cross clamp off) at dosage of 50 mcg/kg by nebulization, inhaled milrinone will be administered through Aerogen solo with Pro-X controller - continuous mode- attached to ventilator circuit distal to viral/ bacterial heat and moisture exchange filter.~Then pulmonary vascular resistance and systemic vascular resistance will be calculated after first dose ended by 2 minutes and after second dose ended by 15 minutes till stabilization of post CPB other variables like temperature and acid-base status, both measurements will be done while using inspired oxygen of 0.80."
62828777|NCT05838846|ACTIVE_COMPARATOR|Group B (IvMil)|Patients will receive intravenous milrinone - started after induction of anesthesia - infusion at dosage of 0.5 mcg/kg/min without loading dose (24), Pulmonary vascular resistance and systemic vascular resistance will be calculated at the same corresponding time points to group A.
62248749|NCT02901496|EXPERIMENTAL|Endurance exercise + infusion of placebo|Endurance exercise training + monthly infusion of placebo
62606125|NCT06108739|ACTIVE_COMPARATOR|ATG cohort|The conditioning regimen is ATG/G-CSF based protocol (the so-called Beijing protocol). The rabbit ATG (Sangstat-Genzyme) 2.5mg/kg/day i.v., on days from - 5 to - 2 were administered.
62248750|NCT02901496|EXPERIMENTAL|No exercise + infusion of Tocilizumab|No exercise + monthly infusion of Tocilizumab
62248751|NCT02901496|PLACEBO_COMPARATOR|No exercise + infusion of placebo|No exercise training + monthly infusion of placebo
62248752|NCT02901496|EXPERIMENTAL|Resistance exercise + infusion of placebo|Resistance exercise training + monthly infusion of placebo
62248753|NCT04876755|EXPERIMENTAL|Cohort 1|Cohort 1 patients will administered 600 mg/day of MBM-02 for 20 weeks.
62248754|NCT04876755|EXPERIMENTAL|Cohort 2|Cohort 2 patients will administered 1000 mg/day of MBM-02 for 20 weeks.
62248755|NCT04876755|EXPERIMENTAL|Cohort 3|Cohort 3 patients will administered 1200 mg/day of MBM-02 for 20 weeks.
62248756|NCT04876755|EXPERIMENTAL|Cohort 4|Cohort 4 patients will administered 600 mg/day of MBM-02 for 20 weeks.
62606126|NCT03098017|ACTIVE_COMPARATOR|Couscous (dry)|Cooked couscous (50g available carbohydrate, 70g uncooked) eaten with 500 mL of water
62606127|NCT03098017|EXPERIMENTAL|Short pasta (dry)|Cooked penne (50g available carbohydrate, 71g uncooked) eaten with 500 mL of water
62046726|NCT02545777|ACTIVE_COMPARATOR|treatment group|Take oral medicine of tonifying spleen and descending turbid, one bag each time, two times a day, continuous treatment for 10 days.The onset of the joints afford steeping washing and wet wrapping medicine of descending turbid and clearing heat, once per day, continuous treatment for 10 days.
62438777|NCT02257359|EXPERIMENTAL|Additional Cohorts TBD (to be decided)|Subjects will be enrolled if determined necessary, based on data collected in Epelsiban Cohort 1 and Cohort 2
62438778|NCT03619161|NO_INTERVENTION|No cleaning (control)|Patients will have a bacterial culture taken from their bathtub and then continue regular care. We will offer to clean their bathrooms after the 4 week intervention period ends.
62606128|NCT03098017|EXPERIMENTAL|Long pasta (dry)|Cooked spaghetti (50g available carbohydrate, 71g uncooked) eaten with 500 mL of water
62606129|NCT03098017|ACTIVE_COMPARATOR|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
62606130|NCT04336813|EXPERIMENTAL|Group A|Receive ARS in lecture 1 and act as controller in lecture 2
62828778|NCT06595667|EXPERIMENTAL|Pulse pressure variation guidance fluid administration|In the PPV group, fluids will be administered to maintain the PPV below 13%. If hypotension coincided with a PPV exceeding 13%, an initial bolus of 200 ml crystalloid fluid solution will be given in10 minutes. PPV reassessment occurred within the subsequent 10 minutes. Alternatively, if hypotension occurs with a PPV measuring less than 13%, vasopressors such as ephedrine at a dose of 3-6 mg or norepinephrine at a dosage of 5-10 mcg intravenously as a bolus, or norepinephrine infusion at a rate of 0.03-0.3 mcg/kg/min, will be given to sustain mean arterial pressure above 65 mmHg.
62046727|NCT02545777|ACTIVE_COMPARATOR|Control group|Take diclofenac sodium enteric-coated, 50 mg, three times a day, continuous treatment for 10 days.
62248757|NCT04876755|EXPERIMENTAL|Cohort5|Cohort 5 patients will administered 600 mg/day of MBM-02 for 20 weeks.
62248758|NCT04876755|EXPERIMENTAL|Cohort 6|Cohort 6 patients will administered 600 mg/day of MBM-02 for 20 weeks.
62248759|NCT03846349|EXPERIMENTAL|Study Group|Participants from the study group will follow an upper airway reinforcement regimen using the IOPI device over 6 weeks. The reinforcement protocol will be adapted each week to improve Percentage of initial strength Exercises will be adapted each week
62248760|NCT03846349|SHAM_COMPARATOR|Control group|"Participants from the control group will perform a sham reeducation protocol using an EMT threshold at minimal resistance. The expiratory pressure will remain unchanged over the weeks."
62248761|NCT02637479|EXPERIMENTAL|Pituitary radiosurgery group|Subjects will receive a pituitary radiosurgery by GammaKnife® during a brief hospitalization associated with standards of care for pain according to recommendations (Standards, Options and Recommendations about drug analgesic treatments for nociceptive cancer pain in adults)
62248762|NCT02637479|ACTIVE_COMPARATOR|Control group|Subject will receive standards of care for pain according to recommendations (Standards, Options and Recommendations about drug analgesic treatments for nociceptive cancer pain in adults)
62248763|NCT00941668|ACTIVE_COMPARATOR|Total Toothpaste|Triclosan/Copolymer/fluoride toothpaste
62248764|NCT00941668|PLACEBO_COMPARATOR|Fluoride toothpaste|sodium monofluorophosphate toothpaste
62438779|NCT03619161|EXPERIMENTAL|Bubbles|Patients will have a bacterial culture taken from their bathtub and have their bathrooms cleaned by the investigators
62438780|NCT03619161|ACTIVE_COMPARATOR|Bleach and Bubbles|Patients will have a bacterial culture taken from their bathtub, have their bathrooms cleaned by the investigators, and be given instructions to perform bleach baths twice weekly.
62248765|NCT05378841|EXPERIMENTAL|Surgical denervation|It consists of a section of the nerve branches destined for the PIPJ, coming from the digital collateral nerves as well as the dorsal sensory branches of the radial and ulnar nerves respectively for the index and fifth fingers.
62606131|NCT04336813|ACTIVE_COMPARATOR|Group b|Receive ARS in lecture 2 and act as controller in lecture 1
62606132|NCT06731478|EXPERIMENTAL|Main Cohort: Arm M1|Participants will receive T-DXd plus fluoropyrimidine (5-FU or capecitabine) plus pembrolizumab
62248766|NCT02677948|EXPERIMENTAL|Pacritinib and Ibrutinib|"Phase I: Patients will receive Pacritinib 100-200 mg twice daily along with Ibrutinib 420mg/day.~Phase II Lead-In: Pacritinib at MTD daily continuous x 2 months followed by Pacritinib at MTD twice daily along with Ibrutinib 420mg/day."
62248767|NCT06490302|EXPERIMENTAL|Lens A (ocufilcon D)|All participants will wear lens A for 15 minutes (Period 1).
62248768|NCT06490302|EXPERIMENTAL|Lens B (fanfilcon A)|All participants will wear lens B for 15 minutes (Period 2).
62438781|NCT04900506|ACTIVE_COMPARATOR|cemented hemiarthroplasty , posterior SPAIRE approach|Posterior SPAIRE approach: lateral decubitus position, preservation of the piriformis tendon and obturator internus, detatchment of obturator externus , capsular T-incision, femoral neck resection, femoral canal reaming according to preoperative templating, third generation cementation technique, capsular repair, repair of obturator externus.
62606133|NCT06731478|EXPERIMENTAL|Main Cohort: Arm M2|Participants will receive Trastuzumab plus platinum-based chemotherapy (cisplatin plus 5-FU or oxaliplatin plus capecitabine) plus pembrolizumab
62606134|NCT06731478|EXPERIMENTAL|Exploratory Cohort: Arm E1|Participants will receive T-DXd plus fluoropyrimidine (5-FU or capecitabine)
62606135|NCT06731478|EXPERIMENTAL|Exploratory Cohort: Arm E2|Participants will receive Trastuzumab plus platinum-based chemotherapy (cisplatin plus 5-FU or oxaliplatin plus capecitabine)
62606136|NCT02636556|EXPERIMENTAL|chemoradiation|concurrent chemoradiation.
62606137|NCT04650906|EXPERIMENTAL|Intervention group|The intervention group gets information about the Mindhelper website and the control group does not get information about the Mindhelper website.
62606138|NCT04650906|NO_INTERVENTION|Control group|The intervention group gets information about the Mindhelper website and the control group does not get information about the Mindhelper website.
62606139|NCT04564924||MRI & DXA patients|No intervention
62606140|NCT04564924||MRI & DXA volunteers|No intervention
62606141|NCT06731426|EXPERIMENTAL|Cognitive Bias Modification for Thought-Action-Fusion (CBM-TAF)|CBM-TAF will employ an ambiguous sentence-completion task, where participants have to fill in a missing letter in a fragmented word and resolve emotional ambiguity of a given scenario. At the beginning of each training session, participants will watch a brief animated video about TAF, OCD, and modifying TAF. Each training session will consist of 40 scenarios, which will take about 20 minutes to complete. There will be a total of 6 sessions (2x/week for 3 weeks).
62606142|NCT06731426|ACTIVE_COMPARATOR|Cognitive Bias Modification for Stress Management Psychoeducation (CBM-SMP)|Similar to CBM-TAF, CBM-SMP will employ an ambiguous sentence-completion task, where participants have to fill in a missing letter in a fragmented word. However, the content of scenarios in CBM-SMP will focus on general stress management techniques. At the beginning of each training session, participants will watch a brief animated video about OCD and stress management techniques. Each training session will consist of 40 scenarios, which will take about 20 minutes to complete. There will be a total of 6 sessions (2x/week for 3 weeks).
62828779|NCT06595667|EXPERIMENTAL|Central venous pressure guidance fluid administration|In the CVP group, intraoperative fluid administration aimed to maintain CVP between 8-12 cmH2O while on mechanical ventilation, ensuring mean arterial pressure remains above 65 mmHg and heart rate within 20% of baseline.
62248769|NCT04860375|EXPERIMENTAL|Multidisciplinary, holistic and patient-centered care|Based on the outcome from the assessment and disease phenotype, personalized care plans will be prepared and given to the patients, including dietary program, adjusted exercise program, psychological counselling, treatment of comorbidities etc. Patients will come for planned follow-up visits, according to the protocol (total 5 visits).
62248770|NCT04860375|ACTIVE_COMPARATOR|Standard care|The control group will be recruited from the Swedish Airway Register at the end of the study. Selection will be based on propensity score matching to the intervention group.
62248771|NCT01298583|EXPERIMENTAL|ankle tracking|subjects track a target with ankle movement
62248772|NCT01298583|NO_INTERVENTION|ankle movement|
62248773|NCT02810847|EXPERIMENTAL|I-BiT Plus|6 weeks of I-Bit treatment plus (at least 30 mins/day, 6 days/week)
62248774|NCT02810847|NO_INTERVENTION|Control|Refractive adaption or observation
62248775|NCT04431336||younger aortic dissection or aneurysm patients|this is an observation cohort study about younger aortic dissection or aneurysm patients without intervention.
62438782|NCT04900506|ACTIVE_COMPARATOR|cemented hemiarthroplasty, anterior approach|Anterior approach: supine position, both legs washed and draped, intermuscular plane between m. tensor fascia lata and m. sartorius, capsular T-incision, femoral neck resection, femoral canal reaming according to preoperative templating, third generation cementation technique, capsular repair
62438783|NCT05472610|EXPERIMENTAL|BZ019|The subjects are enrolled into single-dose(1～5x10\^6/kg) of BZ019 ( non viral vector CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Injection).
62438784|NCT03005470|EXPERIMENTAL|TELEM group|Participants in the telemonitoring home blood pressure group will receive an oscillometric monitor to measure blood pressure at home for six months. Measurements will be made for at least five days a week (including one day during the weekend). Each blood pressure measure will be sent to the center of the study coordination center through software downloaded on the participant's smartphone.
62606143|NCT06731426|NO_INTERVENTION|Waitlist (WL)|Participants in WL group will only complete weekly assessment measures without engaging in any training sessions.
62606144|NCT06018506|EXPERIMENTAL|BR108|
62606145|NCT01664832|EXPERIMENTAL|S-nIMV|nIMV synchronized using abdominal pressure capsule sensor device
62606146|NCT01664832|PLACEBO_COMPARATOR|nIMV|non-synchronized nasal intermittent mandatory ventilation group
62606147|NCT06012955||TCI group|patients receiving general anesthesia using target-controlled infusion delivery system
62606148|NCT06012955||MCI group|patients receiving general anesthesia using conventional manual controlled infusion delivery
62828780|NCT05180227|PLACEBO_COMPARATOR|Without Stimulation|Participant will complete an orthostatic challenge without transcutaneous stimulation.
62828781|NCT05180227|ACTIVE_COMPARATOR|With Stimulation|Participant will complete an orthostatic challenge with transcutaneous stimulation.
62248776|NCT05837520|EXPERIMENTAL|i-BiSSkApp Group|This group will complete daily swallowing behavioral exercises with simultaneous at-home sEMG biofeedback using a tablet application. Participants will participate in weekly clinic visits and at-home therapy for 12 weeks.
62248777|NCT05837520|ACTIVE_COMPARATOR|Traditional Treatment|This group will receive traditional swallowing therapy once a week for 12 weeks using standard therapy practices. They will also complete at-home daily practice of these exercises.
62248778|NCT04060563|SHAM_COMPARATOR|Sham (fake) microcurrent therapy|Sham (fake) microcurrent therapy (placing the microcurrent pads on the patient and turning the microcurrent box on placebo mode )
62606149|NCT06061172|NO_INTERVENTION|Control group|Care as usual
62623488|NCT02776540|ACTIVE_COMPARATOR|600 mg Clopidogrel|67 patient will receive 8 tablets clopidogrel (each 75 mg) as total 600 mg each patient and 4 tablets placebo to receive 12 tablets as total
62606150|NCT06061172|EXPERIMENTAL|Intervention group|GPs in the intervention arm have to use the web application for every patient at least twice (i.e., at least once a quarter), and have to use at least four specific questionnaires at least once, i.e. 1a is required, and either 2a or 2b, and either 3a or 3b, and either 4a or 4b or 4c. Results from the questionnaires need to be discussed between GPs and patients. Additionally, at least one medication review is obligatory.
62248779|NCT04060563|EXPERIMENTAL|Frequency specific microcurrent therapy|Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8),
62606151|NCT01023841|ACTIVE_COMPARATOR|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
62248780|NCT02078635|EXPERIMENTAL|Portfolio Plus Diet|Participants will be advised to follow a low glycemic index dietary portfolio. Specifically, the advice will be to limit saturated fat (to \<7% of total calories and cholesterol to \<200 mg/d) plus inclusion of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat and selection of low glycemic index foods; emphasizing current recommendations for fruit and vegetable intakes (5-10 servings/d)
62606152|NCT01023841|PLACEBO_COMPARATOR|Vehicle Sterile Solution|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
62248781|NCT02078635|ACTIVE_COMPARATOR|DASH-like (high fibre) diet|The DASH-like dietary advice will emphasize a diet of whole grains, low-fat dairy and current recommendations for fruit and vegetables (5-10 servings/day)
62248782|NCT02417155|EXPERIMENTAL|HTR|The 'Hoftraining' group (HTR): a group of subjects (n=10) that will be trained extensively by mr. Hof and his team in both hyper/hypoventilation and strength ventilation breathing techniques. Total time training is 8 days.
62248783|NCT02417155|ACTIVE_COMPARATOR|EIN|The 'extensive instruction' group (EIN): a group of subjects (n=10) that will receive an extensive instruction course supervised by the research team (in absence of Mr. Hof) in both hyper/hypoventilation and strength ventilation breathing techniques.
62438785|NCT03005470|EXPERIMENTAL|TELEMEV group|In the telemonitoring of lifestyle group, participants will receive customized standardized text messages to stimulate lifestyle changes and adherence to blood pressure lowering medication. The messages will be focused on the adoption of DASH diet, sodium restriction, increase of physical activity, weight control and adherence to drug treatment. They will be sent to the smarphones on four of the five days of the week at random times using a software developed for this study.
62606153|NCT05159102|EXPERIMENTAL|Workshop group|Participants in the workshop group will be offered four one-day workshops (3-hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) Sports (during intervention)-\[Parents and Children-Workshop Group\]. These workshops will be offered in person. In addition to the workshops, this group and the home-based group will receive information (activity booklets via the Fit Families App) and physical education (physical activity)-related equipment.
62606154|NCT05159102|EXPERIMENTAL|Home-based group|Participants in the home-based group will not participate in the four half-day workshops (face to face), but they will receive the same information remotely (workshop content) and will have access to the activity booklets (via the App) and physical activity equipment as the workshop group (during intervention)-\[Parents and Children-Home Group\].
62606155|NCT05159102|OTHER|wait-listed home-based group|Wait-list home-based group will serve as the control group (during intervention)-\[Parents and Children-Control Group\]. This group will be instructed to continue their typical routines and activities for the duration of the intervention. They will be asked to attend the pre and posttest, as well as a follow up three weeks after the completion of the 12-week period. Immediately following the follow-up test, participants in the wait-list home-based group will be offered the home-based program (e.g., receiving the same intervention protocol and materials (physical education equipment and lesson plans/workbook) following all procedures as described for that group previously.
62606156|NCT02670382|EXPERIMENTAL|EPA intervention|Subjects randomized to receive 3000 mg EPA/day, provided as EPA 750 mg/capsule will be instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
62606157|NCT02670382|EXPERIMENTAL|DHA intervention|Subjects randomized to 3000 mg DHA/day provided as DHA 750 mg/capsule will instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
62623489|NCT02776540|PLACEBO_COMPARATOR|400 mg Aspirin|67 patients will receive 4 tablets Aspirin ( each 75 mg) as total 300 mg for each patient and 8 tablets placebo to receive 12 tablets as total
62828782|NCT06451406|ACTIVE_COMPARATOR|Selective serotonin re-uptake inhibitor|Patients received selective serotonin re-uptake inhibitor (SSRI) as medical treatment for treatment of premature ejaculate.
62828783|NCT06451406|EXPERIMENTAL|Hyaluronic acid|Patients received hyaluronic acid gel injection in the glans penis.
62828784|NCT05559749|EXPERIMENTAL|collaborative care|The collaborative care team roles include the care manager/social worker and psychiatrist who interact with the patient participant and the patient's neurologist/neurology provider.
62248784|NCT02417155|ACTIVE_COMPARATOR|STR|The 'short training' group (STR): a group of subjects (n=10) that will receive only a short training of 1 hour (immediately prior to the study) by Mr. Hof and his team in both hyper/hypoventilation and strength ventilation breathing techniques.
62248785|NCT02417155|ACTIVE_COMPARATOR|SIN|The 'short instruction' group (SIN): a group of subjects (n=10) that will receive no training, but only an short instruction course of 1 hour (immediately prior to the study) supervised by the research team (in absence of Mr. Hof) in both hyper/hypoventilation and strength ventilation breathing techniques.
62248786|NCT02088788|EXPERIMENTAL|"Board (Rad Board)"|Radial artery catheterization is performed using radio-opaque armboard
62248787|NCT02088788|ACTIVE_COMPARATOR|No Board|Regular radio-penetrating armboard is used (the one normally used during non-study procedures) with a radio-opaque pelvic shield
62438786|NCT03005470|EXPERIMENTAL|TELEM-TELEMEV group|Participants in the telemonitoring home blood pressure plus telemonitoring of lifestyle group (TELEM-TELEMEV) will receive both interventions as previously described.
62606158|NCT02670382|PLACEBO_COMPARATOR|Placebo|3000 mg high oleic acid sunflower oil/day; 750 mg high oleic acid sunflower oil/capsule; subjects instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals during 4 week long lead-in phase.
62046728|NCT03044964|ACTIVE_COMPARATOR|Ranolazine|At randomization, patients will be started on 500mg of Ranolazine, twice daily for 1 week. After 1 week, the dosage may be increased to 1000mg of Ranolazine, twice daily for 5 weeks.
62046729|NCT03044964|PLACEBO_COMPARATOR|Placebo|At Randomization, patients will be started on 500mg of a placebo, twice daily for 1 week. After 1 week, the dosage of the placebo may be increased to 1000mg, twice daily for 5 weeks.
62606159|NCT03005457|EXPERIMENTAL|Stroke|
62606160|NCT03005457|EXPERIMENTAL|Hemiparesis other|
62046730|NCT03369275|EXPERIMENTAL|Mesenchymal Stromal Cells (MSCs)|Intravenous infusion of 300 million Allogeneic, Bone Marrow-Derived Human Mesenchymal Stromal Cells
62248788|NCT02150499|EXPERIMENTAL|levalbuterol tartrate HFA inhalation aerosol plus placebo HFA|Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol
62248789|NCT02150499|EXPERIMENTAL|levalbuterol tartrate HFA inhalation aerosol plus levalbuterol|Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.
62248790|NCT05039333||RUS (Surgical navigation, anatomy 3D-reconstruction)|single-arm study : prospective observational 1-arm (RUS group)
62046731|NCT03369275|PLACEBO_COMPARATOR|Placebo|Intravenous infusion of Placebo, with excipients
62046732|NCT01034267|EXPERIMENTAL|1|(Open-label) F2695 SR capsules, oral administration, once daily, flexible dosing
62046733|NCT02541890|EXPERIMENTAL|Work place intervention|Work place intervention in addition to rehabilitation program.
62046734|NCT02541890|NO_INTERVENTION|Rehabilitation program only|Rehabilitation program without intervention at the work place.
62248791|NCT03329196|EXPERIMENTAL|MT-6548|
62248792|NCT03329196|ACTIVE_COMPARATOR|Darbepoetin alfa|
62438787|NCT03005470|ACTIVE_COMPARATOR|Usual clinical treatment (UCT)|Participants in the control group will be under antihypertensive treatment, chosen at the discretion of the assistant physician. Participants will not receive any technological tool to stimulate blood pressure control or lifestyle modification.
62606161|NCT02787018|PLACEBO_COMPARATOR|Block with Ropivacaine and Normal saline|Patients will receive brachial plexus block with 20 ml 0.5% ropivacaine with 1ml normal saline: Total volume 21 ml
62606162|NCT02787018|ACTIVE_COMPARATOR|Block with Ropivacaine and Dexamethasone|Patients will receive brachial plexus block with 20ml 0.5% ropivacaine with 4mg (1ml) dexamethasone: Total volume 21 ml
62828785|NCT05559749|ACTIVE_COMPARATOR|usual neurology care|Ongoing usual neurology care, without the addition of the collaborative care program - current standard care and is thus an ethically appropriate control condition for effectiveness and implementation trials.
62828786|NCT02323789|EXPERIMENTAL|Intervention arm|10 patients with RDEB will be selected to receive the intervention - mesenchymal stromal cells.
62828787|NCT04351581|EXPERIMENTAL|A: COVID+ Continuation|The enrolled patients will continue their prescribed ACEi/ARB in the same dose. The clinicians will be encouraged to continue the medication throughout the hospital admission but it will be permissable for the clinician to stop treatment if necessary e.g. due to hypotension.
62046735|NCT03424434||Medical staff of an UHC, practitioners and residents|The target population is practitioners and residents who works at hospital in an UHC, they are also specialists, surgeons, dental surgeons.
62046736|NCT01362439|EXPERIMENTAL|Paliperidone ER|
62438788|NCT03077633|ACTIVE_COMPARATOR|Cervical Cerclage + Progesterone|Placement of a Cervical Cerclage plus the daily administration of vaginal progesterone (200mg tab)
62438789|NCT03077633|PLACEBO_COMPARATOR|Progesterone|Daily administration of vaginal progesterone (200mg tab)
62438790|NCT04140006|ACTIVE_COMPARATOR|Alendronate Gel (ALN)|After preparation, 0.05 ml of the gel containing 100 µg of ALN will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
62438791|NCT04140006|ACTIVE_COMPARATOR|Bone Morphogenic Protein Gel (BMP)|After preparation, 0.05 ml of the gel containing 100 µg of BMP will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
62606163|NCT02787018|EXPERIMENTAL|Block with Ropivacaine and Dexmedetomidine|Patients will receive brachial plexus block with 20ml 0.5% ropivacaine with 50mcg (1ml) dexmedetomidine: Total volume 21 ml
62606164|NCT00476892|OTHER|1|"It consists of five outpatient appointments (weeks 0, 2, 6, 11 and 16) with a local trial physiotherapist at a trial centre. At the first appointment a standardised history is taken from the woman, anatomy and function of the pelvic floor muscles are taught, and types of prolapse described, using diagrams and a model pelvis. Women are taught how to contract the muscles, and also how to contract and hold prior to an event that increases intra-abdominal pressure (the Knack). Pelvic floor muscles are assessed by vaginal examination and recorded on a dedicated form at each appointment thus determining the content of a single set of exercises for each woman. At least three sets of exercises daily is recommended. Women use an exercise diary to record compliance. Tailored advice is given on ways of reducing intra-abdominal pressure, e.g. advice on weight loss, chronic cough, heavy lifting and general exercise."
62623490|NCT03282591|EXPERIMENTAL|5 mg Serlopitant Tablets|Serlopitant Tablets
62623491|NCT03282591|PLACEBO_COMPARATOR|Matching Placebo Tablets|Placebo Tablets
62828788|NCT04351581|EXPERIMENTAL|B: Covid+ Discontinuation|The enrolled patients will discontinue their prescribed ACEi/ARB. If hypertensive treatment is necessary during hospital admission the clinicians will first be encouraged to start non-ACEi/non-ARB treatment; however, if needed it will be possible to start ACEi/ARB again during hospital admission. After study completion (30 days from randomization) the patients will be reminded to seek their generel practitioner to reinitiate ACEi/ARB treatment.
62828789|NCT04351581|EXPERIMENTAL|C: COVID% Continuation|The enrolled patients will continue their prescribed ACEi/ARB in the same dose.
62828790|NCT04351581|EXPERIMENTAL|D: COVID% DIscontinuation|The enrolled patients will discontinue their prescribed ACEi/ARB. If hypertensive treatment is necessary during the study period clinicians will first be encouraged to start non-ACEi/non-ARB treatment; however, if needed it will be possible to start ACEi/ARB again during the study period. After study completion (30 days from randomization) the patients will be reminded to seek their generel practitioner to reinitiate ACEi/ARB treatment.
62046737|NCT03536546|EXPERIMENTAL|Alcohol Peer-Mentor Intervention|A Veteran Peer research assistant will have contact with a study participant once in person in the emergency department at enrollment, and up to 6 times after enrollment over the course of 2 months. Participants will receive brief advice from a peer. Brief advice content will be based on strengths-based discussions with participants regarding their drinking and personal goals and preferences. Participants will also receive a resource pamphlet on alcohol and other health issues. Follow-up contact will be made by phone. The content of the follow-up peer intervention will be based on the manual developed by the study team to address strengths-based intervention topics.
62438792|NCT04140006|ACTIVE_COMPARATOR|Mixture Gel of ALN and BMP|After preparation, 0.05 ml of mixture gel containing 50 µg of ALN and 50 µg of BMP will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
62438793|NCT04140006|SHAM_COMPARATOR|Control|After preparation, the fixture will be inserted without topical application of any medication (20 fixtures)
62438794|NCT04371783|OTHER|Immediate FET group|FET will be performed in the first menstrual cycle following the stimulated IVF cycle
62438795|NCT04371783|OTHER|Delayed FET group|FET will be performed in the second menstrual cycle following the stimulated IVF cycle
62438796|NCT01410383|PLACEBO_COMPARATOR|Placebo|
62438797|NCT01410383|EXPERIMENTAL|Eprotirome I|
62828791|NCT05880134|ACTIVE_COMPARATOR|conventional posterior nerve neurectomy|"A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results."
62828792|NCT05880134|ACTIVE_COMPARATOR|cartilage reinforcement after posterior nerve neurectomy|"A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results."
62828793|NCT00508794|EXPERIMENTAL|Group 1 Yoga Program|3 sessions of yoga each week for 6 weeks. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
62438798|NCT01410383|EXPERIMENTAL|Eprotirome II|
62438799|NCT02060461|EXPERIMENTAL|FS200 femtosecond laser LASIK|LASIK flap created with an FS200 femtosecond laser system
62438800|NCT02060461|EXPERIMENTAL|IntraLase femtosecond laser LASIK|LASIK flap created with an IntraLase femtosecond laser system
62438801|NCT06528353|OTHER|Control group|For the first 500 participants enrolled, one additional blood sample will be drawn in DNA-free tubes for HPV ctDNA analysis. As we expect to have around 1% seropositive cases, most of these 500 samples will be seronegative and will constitute our control group. These controls will be tested for HPV ctDNA to confirm that seronegative participants are also HPV ctDNA-negative
62438802|NCT06528353|EXPERIMENTAL|Experimental Group|Individuals who are seropositive for HPV16-E6 will be contacted to propose the participation in the second part of the study and benefit from specific assessment and monitoring for 5 years (HPV ctDNA testing, regular clinical examinations of the head \& neck and anal-genital regions, imaging if needed).
62438803|NCT01620489|EXPERIMENTAL|Lira 1.8 mg|
62438804|NCT01620489|PLACEBO_COMPARATOR|Placebo|
62438805|NCT01976390|ACTIVE_COMPARATOR|Zortress (Everolimus)|Zortress will be started on day of transplant and initially dosed at 0.75 mg twice a day (12 hours apart) dosed simultaneously with Neoral.
62438806|NCT01976390|ACTIVE_COMPARATOR|Rapamune (Sirolimus)|Rapamune will be dosed on day of transplant at 5 mg/d, decreasing to 3 mg/d.
62438807|NCT02878291|EXPERIMENTAL|High dose Group|Received Vaccine: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine,40μg/dose
62438808|NCT02878291|EXPERIMENTAL|low dose Group|Received Vaccine: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine,20μg/dose
62438809|NCT02039479|PLACEBO_COMPARATOR|TAU + Placebo|Treatment as Usual + Placebo
62438810|NCT02039479|ACTIVE_COMPARATOR|TAU + Lithium|Treatment as Usual + Lithium
62606165|NCT00476892|NO_INTERVENTION|2|Women allocated to the control group will be sent a lifestyle advice leaflet only, and will have no planned contact with the centre until their consultant review appointment at six months. The leaflet gives instructions on seeking advice where appropriate about weight loss, constipation, and avoidance of heavy lifting, coughing and high impact exercise, with a view to minimising increases in intra-abdominal pressure which may cause prolapse to worsen.
62248793|NCT04020939|EXPERIMENTAL|Patients undergoing intestinal resections|"* Interventions to be administered: indocyanine green intravenous injection and subsequent visualisation of intestinal viability under fluorescence~* Drug:~Indocyanine green dye (ICG) Dosage: 0.5 mg/kg (diluted with aqueous solution) Maximum: 2 mg/kg Frequency: maximum of 3 boluses Duration: intraoperative use only"
62438811|NCT03552120|EXPERIMENTAL|Mindfulness|MORE is a manualized integrative treatment strategy that targets transdiagnostic mechanisms in stress-related conditions. MORE is made up of three primary components: mindfulness training, cognitive restructuring, and savoring. Mindfulness training aims to increase attentional control to reduce cognitive bias toward negative information. Cognitive reappraisal promotes restructuring of maladaptive cognitions, which would otherwise intensify negative emotion and addictive behavior. Finally, MORE promotes savoring - mindful attention to and appreciation of pleasant events in life as a means of increasing positive emotion regulation.
62606166|NCT03877757||Family Planning Elevated Contraceptive Access Clinics Program|This group consists of community clinics who apply and are accepted for FPE CAP membership during the Family Planning Elevated initiative. These clinics will receive the intervention and will provide monthly service delivery data to the FPE evaluation team.
62606167|NCT03877757||Control Clinics|This group consists of non-participating community clinics matched on clinic size, geography, and client populations who are not interested in participating in the initiative but are willing to provide monthly service delivery data to the FPE evaluation team.
62606168|NCT01681316|EXPERIMENTAL|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
62606169|NCT01681316|PLACEBO_COMPARATOR|Placebo|Based on the standard medical care, placebo was 40ml of 0.9% saline, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
62046738|NCT03536546|ACTIVE_COMPARATOR|Brief Advice|Participants will receive brief substance use advice from a non-peer research staff member in the emergency department. Brief advice content will mirror standard care practices currently provided in VHA when a patient endorses hazardous drinking behaviors. Participants will also receive a resource pamphlet on alcohol and other health issues.
62438812|NCT03552120|ACTIVE_COMPARATOR|Supportive Psychotherapy|Supportive psychotherapy is a form of non-directive talk therapy, which follows a Rogerian person-centered approach. The therapist's primary objectives during a session will be (1) to communicate unconditional positive regard for the participant, (2) to communicate engagement and empathic understanding, and (3) to mirror a participant's affect.
62248794|NCT01248286|EXPERIMENTAL|Whole grain rice|
62248795|NCT01248286|ACTIVE_COMPARATOR|Refined grain rice|
62438813|NCT05101499|EXPERIMENTAL|AKIN osteotomy with screw fixation|
62438814|NCT05101499|ACTIVE_COMPARATOR|AKIN osteotomy without screw fixation|
62438815|NCT06324214|PLACEBO_COMPARATOR|Placebo Group|Participants will participate in a standard PR program and will receive placebo.
62248796|NCT02265861|EXPERIMENTAL|Group 1|typical PCOS
62248797|NCT02265861|EXPERIMENTAL|Group 2|PCOS without PCO
62248798|NCT02265861|EXPERIMENTAL|Group 3|PCOS without HA
62248799|NCT02265861|EXPERIMENTAL|Group 4|Control
62438816|NCT06324214|ACTIVE_COMPARATOR|Intervention (Urolithin A: Mitopure) Group|Participants will participate in a standard PR program and will receive the oral supplement.
62438817|NCT03094806|EXPERIMENTAL|Acapella Vibratory PEP Therapy Device|Subject will use the device 3 times a day throughout hospital stay
62438818|NCT03094806|PLACEBO_COMPARATOR|Sham Acapella Vibratory PEP Device|Subject will use the sham device 3 times a day throughout hospital stay
62438819|NCT03334565|SHAM_COMPARATOR|Sham|Participants were exposed to unfiltered ambient air (sham) filtered air using air filtration systems in the bedroom and main living space of each residence.
62438820|NCT03334565|ACTIVE_COMPARATOR|Low efficiency|"Participants were exposed to low-efficiency (LE) HEPA-type filtered air using air filtration systems in the bedroom and main living space of each residence."
62438821|NCT03334565|ACTIVE_COMPARATOR|High efficiency|"Participants were exposed to high-efficiency (HE) true-HEPA filtered air using air filtration systems in the bedroom and main living space of each residence."
62438822|NCT03655210|EXPERIMENTAL|Experimental|HL151(1Tab,Bepostatine salicylate) once a day, 4 weeks of treatment
62248800|NCT02556996|EXPERIMENTAL|Killed ETEC/rCTB vaccine|Three doses administered orally at 2-week intervals
62438823|NCT03655210|PLACEBO_COMPARATOR|Placebo Comparator|HL151 Placebo (1Tab,Placebo of Bepostatine salicylate) once a day, 4 weeks of treatment
62606170|NCT00898599|PLACEBO_COMPARATOR|Maltodextrin|
62248801|NCT02556996|PLACEBO_COMPARATOR|Placebo|Three doses administered orally at 2-week intervals
62248802|NCT05973097|ACTIVE_COMPARATOR|total glucosides of paeony treatment|Total glucosides of paeony capsules were given 0.6 g once, 3 times a day.
62248803|NCT05973097|ACTIVE_COMPARATOR|photodynamic therapy treatment|Cover the lesion with photosensitizer and fix it. Remove the photosensitizer and treat with laser diode.
62606171|NCT00898599|EXPERIMENTAL|Prebiotic|Inulin type fructooligosaccharides
62606172|NCT02940093||Stem cell transplant recipient|
62606173|NCT02940093||Stem cell donor|
62623492|NCT06136260|EXPERIMENTAL|CommunityRx-Bereavement (CRx-B)|
62623493|NCT06136260|ACTIVE_COMPARATOR|General Bereavement Support Information (GBSI)|
62606174|NCT00456508|EXPERIMENTAL|DX-88 (ecallantide)|DX-88 (ecallantide) Patients were treated with DX-88 (ecallantide) when they experienced an HAE attack. 30 mg dose of ecallantide given via 3 SC injections; a second 30 mg dose can be administered if needed. Patients were to be assessed until 4 hrs post-dose. Patients were asked to return for 3 follow-up visits: 7 days, 28 days and 90 days post-dose.
62438824|NCT02416583|ACTIVE_COMPARATOR|Oxytocin & Membrane sweeping|"Women assigned to Concurrent oxytocin with membrane sweeping had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, followed by oxytocin infusion the next day"
62606175|NCT01625689|EXPERIMENTAL|SIIL LAIV|SII LAIV is a live, trivalent seasonal influenza vaccine. The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
62606176|NCT01625689|PLACEBO_COMPARATOR|Placebo|Placebo identical in appearance to experimental vaccine.
62606177|NCT00757185|EXPERIMENTAL|1|GNRH antagonist alone
62606178|NCT00757185|EXPERIMENTAL|2|GnRH with Testosterone
62606179|NCT02344797|ACTIVE_COMPARATOR|Intervention|Remote ischemic preconditioning, 4 cycles of 5 minutes ischemia and 5 minutes reperfusion of the forearm before surgery.
62606180|NCT02344797|NO_INTERVENTION|Control|
62438825|NCT02416583|ACTIVE_COMPARATOR|Oxytocin & Dinoprostone|"For women assigned to Concurrent oxytocin with dinoprostone vaginal insert: The 10mg dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening, followed by oxytocin infusion the next day"
62438826|NCT02874963|ACTIVE_COMPARATOR|Surgical periodontal treatment|"Type 2 Diabetes Patients with periodontitis (without initial non-surgical periodontal therapy) at least one tooth extraction will be performed.~Non-Diabetes Patients with periodontitis (without initial non-surgical periodontal therapy) at least one tooth extraction will be performed.~Intervention:~Procedure: Surgery (Tooth Extraction)"
62449332|NCT03887195||students|The clinical sample is made up of 501 students (male and female) in the 4th year of medicine at Paris Descartes University, participating at the obligatory training module during the 2018-2019 academic year : this constitutes the entire population concerned by the intervention.
62449333|NCT00721409|EXPERIMENTAL|Arm A|letrozole + PD 0332991
62606181|NCT00533052|EXPERIMENTAL|Affective and Cognitive Skills Training|Standard Behavioral Weight Loss Treatment Plus Affective and Cognitive Skills Training
62606182|NCT02958358|EXPERIMENTAL|Pulmonary Hypertension|Patients with Group I pulmonary arterial hypertension to undergo CT imaging, functional PET imaging before and after 3 months of treatment with ambrisentan
62606183|NCT02973113|EXPERIMENTAL|EBVST Cells + Nivolumab|"PD1 inhibitor - nivolumab 3 mg/kg (max dose: 240 mg) Q 2 weeks for total 4 doses and repeat a day prior to each EBVST infusion.~EBVST- 1 x 10\^8/m2 at days +1 and +15. PD1 inhibitor - nivolumab 3 mg/kg (max dose: 240 mg) Q 2 weeks for total 4 doses and repeat a day prior to each EBVST infusion.~Can receive up to 3 additional infusions of EBVSTs with a single dose of nivolumab at 6-12 week intervals starting at least 6 weeks after the second infusion if stable disease or a partial response at Week 8 evaluation"
62606184|NCT04703361|EXPERIMENTAL|Niacin|12 patients with Heart failure with reduced ejection fraction (HFrEF) investigated with echocardiography and right heart catheterization.
62606185|NCT04703361|EXPERIMENTAL|Na-3-OHB|"12 patients with Heart failure with reduced ejection fraction (HFrEF) investigated with echocardiography and right heart catheterization.~All patients will receive Aspirin before intervention and randomization."
62606186|NCT02908074|EXPERIMENTAL|BGS649 0.1 mg|Drug: BGS649 Dose 1 weekly
62606187|NCT02908074|EXPERIMENTAL|BGS649 0.3 mg|Drug: BGS649 Dose 2 weekly
62606188|NCT02908074|EXPERIMENTAL|BGS649 1.0 mg|Drug: BGS649 Dose 3 weekly
62606189|NCT04258540|EXPERIMENTAL|Intervention group|The intervention group received a yoga course for 12 weeks, two times a week. Each yoga class was 1.25 hr in duration.
62606190|NCT04258540|ACTIVE_COMPARATOR|Control group waitlist|The control group were on a waitlist during the period of measurements, and received the same yoga course after all measurements had been completed.
62606191|NCT03760328|ACTIVE_COMPARATOR|therapeutic stimulation|Therapeutic Stimulation: optimal therapy setting for home use
62248804|NCT05973097|EXPERIMENTAL|glucosides of paeony and photodynamic therapy combined treatment|Glucosides of paeony and photodynamic therapy are combined for the treatment
62606192|NCT03760328|SHAM_COMPARATOR|sham stimulation|Sham Stimulation (Control Group): stimulation voltage programmed at 0.1 volts
62606193|NCT00771264|ACTIVE_COMPARATOR|Urgent PC|
62606194|NCT00771264|NO_INTERVENTION|Sham / Placebo|
62248805|NCT05942430|EXPERIMENTAL|The costa group|Autologous costal osteochondral transplantation
62248806|NCT05942430|ACTIVE_COMPARATOR|The ilium group|Autologous iliac osteoperiosteal transplantation
62248807|NCT02678338|EXPERIMENTAL|Hu5F9-G4|Dose Escalation: CD47 blocking antibody Hu5F9-G4
62248808|NCT01958723||Hospitalists|Introduction of Problem Specific Templates
62248809|NCT06035796||tNGS(targeted second generation sequencing)|tNGS detection of lower respiratory tract samples (BALF) from VAP patients.By means of super-multiple PCR amplification or probe hybridization capture, tNGS can enrich dozens to hundreds of known pathogenic microorganisms and their virulence and drug resistance genes in the samples to be tested, and then conduct high-throughput sequencing.
62248810|NCT06035796||non-tNGS(non-targeted second generation sequencing)|Perform routine clinical testing on lower respiratory tract samples (BALF) from VAP patients and collect patient clinical information. Clinical routine testing includes culture (necessary), microscopy, serology, PCR, etc., and drug sensitivity tests are conducted on positive culture samples as needed.
62248811|NCT02765087|EXPERIMENTAL|Pleural TB|"This group consist of patients with TB pleural effusion.~Intervention:~1. Inform Consent~2. Medical History~3. E-Nose Device~4. Chest CT~5. Cytomorphologic \& Cytochemistry of pleural Fluid.~6. Adenosine Deaminase value of pleural Fluid."
62248812|NCT02765087|ACTIVE_COMPARATOR|Control|"Patients with pleural effusion with different aetiologies than Tuberculosis.~Intervention:~1. Inform Consent~2. Medical History~3. E-Nose Device~4. Chest CT~5. Cytomorphologic \& Cytochemistry of pleural Fluid.~6. Adenosine Deaminase value of pleural Fluid."
62248813|NCT00698204|EXPERIMENTAL|I- Celecoxib|
62248814|NCT00698204|PLACEBO_COMPARATOR|II|
62248815|NCT06328998|EXPERIMENTAL|Routine rehabilitation treatment+Intra-articular Injection|The patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients in the experimental group are given routine rehabilitation treatment and intra-articular injections. Lidocaine is used as the injected medication at a dose of 2ml, administered once every 5 days for a total of three injections.
62248816|NCT06328998|ACTIVE_COMPARATOR|Routine rehabilitation treatment|The patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients are given routine rehabilitation treatment.
62248817|NCT03085979|EXPERIMENTAL|Burch|Burch Colposuspension
62248818|NCT03085979|EXPERIMENTAL|Trans Obturator Tape|Trans Obturator Tape sling
62248819|NCT03085979|EXPERIMENTAL|Tension free vaginal tape|Tension free vaginal tape sling
62248820|NCT05614687|EXPERIMENTAL|Community-informed art-based programme (CiAbP)|The CiAbP sessions will cover relevant aspects of art, such as poetry, spoken words, painting, drawing, literature, and music, in tackling trauma and negative attitudes towards ex-offenders reintegration.
62248821|NCT05614687|ACTIVE_COMPARATOR|Government intervention involving media messages|It will involve media messages from the National Orientation Agency devoid of CiAbP and other media sources on materials such as health and public awareness.
62248822|NCT02438891|EXPERIMENTAL|CBT course|8-week internet-based cognitive behavioral therapy and sound therapy course
62248823|NCT06271642|EXPERIMENTAL|Bluetooth Haptic Device (Experimental Frequency) + Needle Sham|Bluetooth Haptic Device with experimental vibrating frequency will be placed on the arm of the participant, with weighted pinpricks with fixed stimulus intensities will be applied.
62248824|NCT06271642|SHAM_COMPARATOR|Bluetooth Haptic Device (Control Frequency) + Needle Sham|Bluetooth Haptic Device with control vibrating frequency will be placed on the arm of the participant, with weighted pinpricks with fixed stimulus intensities will be applied.
62449334|NCT00721409|ACTIVE_COMPARATOR|Arm B|letrozole
62449335|NCT02047266|EXPERIMENTAL|MICS CABG|"Minimally invasive cardiac surgery coronary artery bypass grafting (complete multivessel minimally invasive off-pump revascularization via left minithoracotomy), which is performed with a help of Octopus® Nuvo, Starfish® Non-Sternotomy, ThoraTrak®, Starfish®, Octopus®, Clearview® blower, ClearView® Shunt.~(MICS CABG group, n=50)"
62449336|NCT02047266|ACTIVE_COMPARATOR|OPCABG|"Off-pump coronary artery bypass grafting treatment which is performed with a help of Starfish®, Octopus®, Clearview® blower, ClearView® Shunt.~(OPCABG group, n=50)"
62449337|NCT02047266|ACTIVE_COMPARATOR|ONCABG|On-pump coronary artery bypass grafting treatment (ONCABG group, n=50)
62449338|NCT04226911|EXPERIMENTAL|Sweeteners and sweetness enhancers (S&SEs)|Healthy diet \< 10 energy % (E%) sugar, foods and drinks with S\&SEs allowed.
62449339|NCT04226911|ACTIVE_COMPARATOR|Sugar group|Healthy diet, \< 10 E% sugar, foods and drinks with S\&SEs not allowed.
62449340|NCT06441552||Ofakim|Non-interventional group, recruited at Adi-Negev Rehabilitation Center, Israel.
62449341|NCT06441552||Haifa|Non-interventional group, recruited at Rambam Health Care Campus, Israel.
62449342|NCT06441552||Hebron|Non-interventional group, recruited through Green Land Society for Health Development, Palestine.
62449343|NCT00125359|EXPERIMENTAL|1|All eligible patients will receive continuous daily oral erlotinib 150mg with daily bexarotene oral capsules 400mg.
62449344|NCT05004428||Type 2 Diabetes Mellitus patients with Chronic Kidney Disease|Canadian patients with type 2 diabetes mellitus data will be collected retrospectively.
62449345|NCT05899790|NO_INTERVENTION|Control Group|Forty patients who received standard care in the pre-abdominal surgery clinic and preoperative waiting area will form the control group.
62449346|NCT05899790|EXPERIMENTAL|intervention group|In addition to standard care, 40 patients who were informed about the SG application and the operating room environment will form the intervention group.
62449347|NCT05042635|EXPERIMENTAL|Ixekizumab (4 weeks) + Jueyin Granules (12 weeks)|Subjects received Ixekizumab in the first 4 weeks (biologic treatment period); After the cessation of biologic treatment, only Jueyin Granules was used in the 12-week traditional Chinese medicine treatment period.
62449348|NCT05042635|PLACEBO_COMPARATOR|Ixekizumab (4 weeks) + Jueyin placebo Granules(12 weeks)|Subjects received Ixekizumab in the first 4 weeks (biologic treatment period); After the cessation of biologic treatment, only Jueyin placebo Granules was used in the 12-week traditional Chinese medicine treatment period.
62449349|NCT06382116|EXPERIMENTAL|BL-B01D1|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62449350|NCT06382116|EXPERIMENTAL|Pemetrexed+Cisplatin or Carboplatin|Participants receive Pemetrexed +Cisplatin or Carboplatin in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62449351|NCT03177603|EXPERIMENTAL|GSK2586881 - 0.1 mg/kg|Eligible subjects will receive a single dose of 0.1 mg/kg GSK2586881. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
62449352|NCT03177603|EXPERIMENTAL|GSK2586881 - 0.2 mg/kg|Eligible subjects will receive a single dose 0.2 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
62449353|NCT03177603|EXPERIMENTAL|GSK2586881 - 0.4 mg/kg|Eligible subjects will receive a single dose of 0.4 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
62449354|NCT03177603|EXPERIMENTAL|GSK2586881 - 0.8 mg/kg|Eligible subjects will receive single dose of 0.8 mg/kg of GSK2586881 IV infusion. Dose escalation will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
62606195|NCT06267521|EXPERIMENTAL|Group 1: Mediation Only|"* Baseline measures including imaging~* Meditation plus Sham Stimulation 2 nights per week for 4 weeks~* Post Intervention (week 5) measures including imaging~* Follow up measures (week 20)"
62606196|NCT06267521|EXPERIMENTAL|Group 2: Stimulation Only|"* Baseline measures including imaging~* Sham Meditation plus Stimulation in Lab 2 nights per week for 4 weeks~* Post Intervention (week 5) measures including imaging~* Follow up measures (week 20)"
62606197|NCT06267521|EXPERIMENTAL|Group 3: Combined, Low Frequency|"* Baseline measures including imaging~* Meditation plus Stimulation in Lab 1 night per week for 4 weeks~* Post Intervention (week 5) measures including imaging~* Follow up measures (week 20)"
62606198|NCT06267521|EXPERIMENTAL|Group 4: Combined, High Frequency|"* Baseline measures including imaging~* Meditation plus Stimulation in Lab 2 nights per week for 4 weeks~* Post Intervention (week 5) measures including imaging~* Follow up measures (week 20)"
62606199|NCT05125913||COVID-19 group|Patients with CKD stage 3-5, on dialysis or kidney transplanted patients with confirmed SARS-CoV-2 infection by reverse transcriptase polymerase chain reaction (RT-PCR), at minimum 2 weeks after the confirmed test.
62606200|NCT05125913||non-COVID-19 group|CKD stage 3-5, dialysis or kidney transplantation matched patients without confirmed SARS-CoV-2 infection
62606201|NCT06428721|EXPERIMENTAL|Fractionated Laser Resurfacing - Right Arm|Right forearm treatment of fractionated laser resurfacing.
62606202|NCT06428721|EXPERIMENTAL|Fractionated Laser Resurfacing - Left Arm|Left forearm treatment of fractionated laser resurfacing.
62606203|NCT03589963|NO_INTERVENTION|Pre-intervention|regular CPNP programming
62606204|NCT03589963|EXPERIMENTAL|Post-intervention|regular CPNP programming plus access to postnatal lactation support
62606205|NCT04960852|EXPERIMENTAL|a single shade structurally colored universal resin composite|Cavities will be prepared. one shade universal composite (Omnichroma) a will be applied according to the manufacturer.
62606206|NCT04377464||COVID-19 Survivors|Patients following-up at the PWH outpatient clinics will be enrolled for further evaluation via telephone follow-up at one, three, and six months after hospital discharge. SF12, EQ-5D-5L and work status standardized quantitative assessments of quality of life will be implemented via telephone follow-up at these time-points.
62606207|NCT04895813|EXPERIMENTAL|Group 1:|The patient will be given training on the day the appointment is made for colonoscopy, educational material will be given as a reminder, information will be given on the phone and the training will be reminded on the day he should start diet for colonoscopy. No different application will be made on the day and after the colonoscopy.
62606208|NCT04895813|NO_INTERVENTION|Group 2|Routine information in the service will be made
62606209|NCT05604794|EXPERIMENTAL|Clients|Adult patients coping with symptoms of depression, anxiety, and post traumatic stress
62606210|NCT00741091|EXPERIMENTAL|Registry|Registry to gather data on early clinical outcomes for the Carotid WALLSTENT Endoprosthesis and FilterWire EZ System in routine clinical practice.
62606211|NCT04981093|EXPERIMENTAL|Group Dexamethasone|"Group dexamethasone patients received intravenous injection after anesthesia induction~Injection 0.15mg/kg dexamethasone (2ml）"
62828794|NCT00508794|EXPERIMENTAL|Group 2 Stretching Program|3 sessions of stretching each week for 6 weeks. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
62248825|NCT02389751|EXPERIMENTAL|Treatment (ganetespib, paclitaxel, carboplatin, radiation)|Patients receive ganetespib IV over 1 hour, paclitaxel IV over 1 hour, and carboplatin IV over 30 minutes once a week on day 1. Patients also undergo radiation therapy 5 days a week for 5.5 weeks or for a total of 28 treatments. Treatment continues for 28 treatment days (5.5 weeks) in the absence of disease progression or unacceptable toxicity
62828795|NCT00508794|OTHER|Group 3 Waitlist Control Group|Option of participating in the yoga or stretching program after the study has ended. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
62248826|NCT00375557|ACTIVE_COMPARATOR|1|Quetiapine
62606212|NCT04981093|PLACEBO_COMPARATOR|Group Saline|Group Control patients were also given 2ml of normal saline intravenously after induction of anesthesia
62606213|NCT06394466||Women undergoing ovarian stimulation in our ART clinic|Inclusion criteria were: women attended in the outpatient clinic with baseline exams before ART and during ovarian stimulation between July 2021 and July 2023. Exclusion criteria were: patients with known clinical hypothyroidism, patients using medications that may influence the hypothalamic-pituitary-thyroid axis, such as glucocorticoids in supraphysiological doses; or that could interfere with thyroid hormone metabolism (lithium, amiodarone and aspirin in anti-inflammatory dosages).
62248827|NCT00375557|ACTIVE_COMPARATOR|2|Divalproex ER
62248828|NCT00236925|ACTIVE_COMPARATOR|Low dose Hydrocortisone|Low Dose Hydrocortisone
62828796|NCT03501498|EXPERIMENTAL|loperamide|Slows intestinal transit time
62828797|NCT03501498|EXPERIMENTAL|senna|Speeds up intestinal transit time
62248829|NCT00236925|PLACEBO_COMPARATOR|Placebo|Placebo
62606214|NCT02506127|EXPERIMENTAL|Open-label|"Theta burst stimulation (TBS) is a form of repetitive transcranial magnetic stimulation (TMS). Standard TBS parameters consisting of 3-pulse, 50Hz bursts every 200 ms (5 Hz) at an intensity of 80% motor threshold (MT) will be utilized. Intermittent TBS will be delivered in 2-second trains of bursts repeated every 10 seconds for a total of 570 seconds (1800 pulses) in each session.~Each treatment session thus involves \< 10 minutes of stimulation. The subject and researchers know what treatment is being administered."
62606215|NCT02506127|ACTIVE_COMPARATOR|Blinded Active|"Standard TBS parameters consisting of 3-pulse, 50Hz bursts every 200 ms (5 Hz) at an intensity of 80% motor threshold (MT) will be utilized. Intermittent TBS will be delivered in 2-second trains of bursts repeated every 10 seconds for a total of 570 seconds (1800 pulses) in each session.~Each treatment session thus involves \< 10 minutes of stimulation. The subject and researcher will not know what type of treatment will be administered."
62828798|NCT05647408|ACTIVE_COMPARATOR|Intravenously DMX|Male and female volunteers received one dose of DXM. Drugs formulations employed were DXM phosphate injectable solution 8 mg/2 mL (Alin, Productos Farmaceuticos, Mexico). The drug was administered to 4 subjects intravenously (treatment A) according to a randomization list generated prior to the start of the clinical phase.
62606216|NCT02506127|SHAM_COMPARATOR|Blinded Sham|"This is a sham treatment which will mimic the open-label and blinded active to enable the effects of the supposedly active treatment to be assessed objectively. The subject and researcher will not know what type of treatment will be administered.~Each treatment session will be \< 10 minutes in duration."
62606217|NCT01069419||Cimzia|All patients will be treated with Cimzia according to normal clinical practice for the prescribing physician and as defined by the SmPC
62248830|NCT04458103|EXPERIMENTAL|prospective interventional cohort|The prospective interventional cohort will consist of patients undergoing LVAD implantation at Massachusetts General Hospital. These patients will receive an RVAD (either the ProtekDuo or Impella RP) prior to or during LVAD implantation.
62248831|NCT04458103|NO_INTERVENTION|retrospective control cohort|The historical control cohort will consist of retrospective data collection on patients who have undergone LVAD implantation in the past. This group will be age and sex matched with the enrolled prospective interventional patients.
62248832|NCT03128476|ACTIVE_COMPARATOR|1 bottle|
62248833|NCT03128476|ACTIVE_COMPARATOR|2 bottles|
62248834|NCT03128476|PLACEBO_COMPARATOR|Placebo|
62606218|NCT02436031|ACTIVE_COMPARATOR|Desipramine First, Placebo Second|Desipramine 200 mg administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching desipramine administered 2 hours before normal sleep time on second study night.
62606219|NCT02436031|EXPERIMENTAL|Placebo First, Desipramine Second|Placebo-matching desipramine administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then desipramine administered 2 hours before normal sleep time on second study night.
62248835|NCT01820936|EXPERIMENTAL|Treatment A: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water 30 minutes after completing a high-fat breakfast
62248836|NCT01820936|EXPERIMENTAL|Treatment B: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water after fasting for at least 10 hours and 30 minutes before starting a high-fat breakfast
62248837|NCT01820936|EXPERIMENTAL|Treatment C: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water 2 hours after completing a high-fat breakfast
62248838|NCT01820936|EXPERIMENTAL|Treatment D: PCI-32765|420 mg capsules administered with 240 mL noncarbonated water after fasting at least 10 hours
62248839|NCT01820936|EXPERIMENTAL|Treatment E: PCI-32765|840 mg capsules administered with 240mL noncarbonated water 30 minutes after completing a high-fat breakfast
62248840|NCT03966781|ACTIVE_COMPARATOR|ESWL followed by ERCP|Patients enrolled in the active treatment group will be subjected to ESWL followed by ERCP and pancreatic duct stenting.
62248841|NCT03966781|SHAM_COMPARATOR|Sham ESWL followed by sham ERCP|Patients enrolled in the sham treatment group will be subjected to sham ESWL followed by sham ERCP with no pancreatic duct intervention.
62248842|NCT02274181|EXPERIMENTAL|25 mg (approximately equivalent to [(~]) 500 nanocurie|A single 25 mg (approximately equivalent to \[(\~\]) 500 nanocurie \[nCi\]) dose of \[14C\]Androxal
62248843|NCT02650336||CIN proup|The occurrence of CIN was defined as an increase in serum creatinine of 0.5 mg/dL above the baseline value within 48-72 h after PCI. Follow-up SCr and BUN levels were measured 1, 2, and 3 days after the procedure.
62248844|NCT02650336||control group|The occurrence of CIN was defined as an increase in serum creatinine of 0.5 mg/dL above the baseline value within 48-72 h after PCI. Follow-up SCr and BUN levels were measured 1, 2, and 3 days after the procedure.
62248845|NCT05495139|EXPERIMENTAL|A single arm study, only investigational product|To evaluate the preliminary effectiveness and safety of the Gastric Bypass Stent System in treating nonalcoholic fatty liver disease.
62248846|NCT03189862|EXPERIMENTAL|CHAMP|CHAMP, is a mastery climate motor skills interventions, that provides children the opportunity to establish behaviors that reinforces decision-making while participating in a variety of challenging movement \& physical activity tasks. Duration of CHAMP is 30 min/day 4 days/week for 30 weeks. CHAMP consist of a) a 2-3 min of motor skill introductory activity that includes a group motor activity, the teaches the lesson, includes a demonstration, and understanding of developmentally appropriate learning clues b) 25 min of motor skill instruction \& practice where preschoolers engage in 3-4 motor activity stations that align with the TARGET structures c) \& 2-3 min motor skill closure activity that involves a review of the lesson \& critical elements.
62248847|NCT03189862|NO_INTERVENTION|Control - Free Play|The control/free play condition will be the preschools typical activity programs (i.e., outdoor/indoor recess) and will be implemented according to the existing procedures within the preschool centers. The centers outdoor program consist of outdoor free-play activity on a large playground area with a variety of play structures (swings, slides, ladders) that promote gross movement and activity in preschoolers. For the control condition, there will be no planned instruction nor activities provided by the classroom teachers.
62449355|NCT03758365|EXPERIMENTAL|MC2-01 Cream|Single application of MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
62449356|NCT03758365|ACTIVE_COMPARATOR|Clobetasol propionate 0.05% lotion|Single application of Clobetasol propionate 0.05%,
62606220|NCT06293105||People who are homeless|People who are currently homeless, as per UK Government definition, or have experience of homelessness.
62606221|NCT06293105||Stakeholders|People with work or other experience relating to homelessness in London
62606222|NCT03383575|EXPERIMENTAL|Arm I (enasidenib, azacitidine)|Patients who are HMA-naive receive enasidenib PO QD on days 1-28 and azacitidine IV over 30-60 minutes or SC on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62046739|NCT05569746|EXPERIMENTAL|INM004|2 doses of 4 mg/kg separated by 24 h
62046740|NCT04498130|EXPERIMENTAL|12-Week Home Exercise Group|The 12-week theory-based physical activity intervention will involve mailing participants an exercise manual with health and exercise information (i.e. information about exercising safely, modules related to the social cognitive theory, weekly goal setting worksheets, exercise-tracking logs, etc.), a resistance band, and a standard Omron pedometer. Participants will receive a weekly 30-minute Zoom--based group meetings to discuss different strategies to begin and maintain a consistent exercise routine and access to a social media page to facilitate social support and interaction among the group participants. Participants will be able to join the group if they would like, but it will not be required. Participants will be encouraged to connect with each other to promote social support and social modeling. Lastly participants will receive a weekly exercise video to follow along with on their own time and tailored weekly step goals.
62438827|NCT02874963|ACTIVE_COMPARATOR|Surgical and non-surgical periodontal treatment|"Type 2 Diabetes Patients with periodontitis (with initial non-surgical periodontal therapy) at least one tooth extraction will be performed.~Non-Diabetes Patients with periodontitis (with initial non-surgical periodontal therapy) at least one tooth extraction will be performed.~Interventions:~Procedure: Surgery (Tooth Extraction)~Procedure: Non-surgical periodontal therapy-full mouth scaling and root planing (FM-SRP) with ultrasonic device and periodontal curets for mechanical debridement of the supra- and sub-gingival plaque and calculus, post operative rinsing thrice a day for 3 weeks."
62438828|NCT03994445|EXPERIMENTAL|Intervention group|Intervention group will be enrolled to the intervention program proposed to be (pharmacotherapy + counseling+ motivator phone messages).
62438829|NCT03994445|NO_INTERVENTION|Control group|Control group will receive the standard treatment of the Ministry of the Health program (pharmacotherapy + counseling) only.
62438830|NCT04193631|EXPERIMENTAL|Pure Green Tablet|A water-soluble sublingual tablet that contains 5 mg of cannabidiol (CBD).
62438831|NCT03910803|OTHER|Brodalumab - Open Label|"Randomized subjects will be receiving Brodalumab (210 mg) administered by subcutaneous injection at the following visits: Baseline, week 1, week 2 and every two weeks thereafter, until Week 24.~Investigational Product not to be administer into areas where the skin is tender, bruised, red, hard, thick, scaly, or affected by Hidradenitis Suppurativa."
62438832|NCT00337805|ACTIVE_COMPARATOR|1 colloid|Boluses of fluids are a pentastarch (up to 1000 ml)
62438833|NCT00337805|ACTIVE_COMPARATOR|2. Crytalloid|Boluses are given as normal saline
62438834|NCT02847533|OTHER|resistant depression|patients suffering from resistant unipolar depression (at least 2 failed antidepressant treatments for the current episode)
62438835|NCT02847533|OTHER|non resistant depression|patients in remission from unipolar depressive disorder
62438836|NCT03295799|EXPERIMENTAL|Patient Self-Management|Patients will go through a preparatory phase (creation of warfarin dosing chart, process for documentation and retrieval of labs), a practical training phase (formulate warfarin management plan with support) and then perform patient-self management of their own warfarin.
62438837|NCT03295799|NO_INTERVENTION|Anticoagulation Clinic Care|Patients will not have their care altered, and will continue to be managed by our Anticoagulation Clinic.
62438838|NCT01732965|PLACEBO_COMPARATOR|NB-UVB phototherapy|NB-UVB alone
62438839|NCT01732965|EXPERIMENTAL|phototherapy and photochemotherapy|NB-UVB and PUVA
62438840|NCT02002013||Adult ICU patient receiving Fluid resus|Adult patients present in the ICU at the start of the study day or admitted during the 24-hour study period will be included in the study sample.
62438841|NCT02143947|EXPERIMENTAL|Full Contact Orthosis|Full Contact Orthosis
62438842|NCT02143947|EXPERIMENTAL|Maximal Arch Subtalar Stabilization|Maximal Arch Subtalar Stabilization Orthoses
62438843|NCT05524987|EXPERIMENTAL|INTERVENTION|"Participants in the ANDES intervention group will receive the ANDES implementation package consisting of health agent home visits for 12 consecutive months. Implementation package delivery will end after month 12, at which time intervention participants will be advised to obtain standard care from their local healthcare facility. ANDES is an adaptation of the World Health Organization (WHO) HEARTS package and consists of the following components:~A. Health agent-managed home care~* BP monitoring~* Health coaching~* Health system navigation~* Medication adherence support B. Text message-based health coaching Specifically, the ANDES strategy is aligned with four WHO HEARTS technical package components."
62449357|NCT03758365|ACTIVE_COMPARATOR|Betamethasone dipropionate 0.05% cream|Single application of Betamethasone dipropionate 0.05%,
62606223|NCT03383575|EXPERIMENTAL|Arm II (enasidenib)|Patients relapsed and/or refractory to HMA therapy receive enasidenib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62606224|NCT01622725|EXPERIMENTAL|Resorbable mesh|Long-term resorbable mesh implanted to treat primary and secondary ventral hernia.
62606225|NCT01622725|ACTIVE_COMPARATOR|Non-resorbable mesh|Non-resorbable synthetic mesh implanted to treat primary and secondary ventral hernia.
62606226|NCT05521841|EXPERIMENTAL|Erector Spinae Plane Block|Bilateral Ultrasound Guided Erector Spinae Plane Block
62046741|NCT04498130|ACTIVE_COMPARATOR|Educational Comparison Group|The education group participants will receive the same exercise manual, fitness items, exercise videos, and same weekly tailored step goal as the 12-week intervention group. This group will not have weekly zoom discussions, or be a part of the same social media page as the 12-week intervention group. Instead, the education group will be contacted by research staff once a week via telephone to discuss their manuals and activity for the week, and to ensure they have been safely engaging in exercise. A separate social media page will be created for this group, where pre-existing materials related to physical activity recommendations, benefits, other resources, and more will be shared.
62606227|NCT05521841|ACTIVE_COMPARATOR|Transversus abdominis plane block|Bilateral Ultrasound-guided bilateral Transversus abdominis plane block
62606228|NCT02647879||Hepatitis C infected|All patients diagnosed with hepatitis C in Iceland
62606229|NCT04512313|ACTIVE_COMPARATOR|Group receiving rocuronium 0,3 mg/kg|Rocuronium 0,3 mg/kg at induction
62606230|NCT04512313|ACTIVE_COMPARATOR|Group receiving rocuronium 0,9 mg/kg|Rocuronium 0,9 mg/kg at induction
62606231|NCT00430352|EXPERIMENTAL|1|
62606232|NCT06343376|EXPERIMENTAL|Cohort A (EGFRt/19- 28z/IL-12 CAR T cells)|Patients undergo leukapheresis prior to treatment. Patients receive EGFRt/19- 28z/IL-12 CAR T cells IV over 5 to 30 minutes on day 0. Patients also undergo ECHO or MUGA during screening. Patients also undergo CT or PET as well as bone marrow biopsy and aspiration and blood sample collection throughout the trial. Additionally, patients undergo a tissue biopsy during screening and on the trial.
62606233|NCT06343376|EXPERIMENTAL|Cohort B (EGFRt/19- 28z/IL-12 CAR T cells, conditioning)|Patients undergo leukapheresis prior to treatment and receive lymphodepletion chemotherapy with cyclophosphamide IV over 2 hours and fludarabine IV over 30 minutes on days -5, -4, and -3. Patients then receive EGFRt/19- 28z/IL-12 CAR T cells IV over 5 to 30 minutes on day 0. Patients also undergo ECHO or MUGA during screening. Patients also undergo CT or PET as well as bone marrow biopsy and aspiration and blood sample collection throughout the trial. Additionally, patients undergo a tissue biopsy during screening and on the trial.
62606234|NCT03790449|EXPERIMENTAL|PreLiFe-programme|A Mobile Preconception Lifestyle programme
62606235|NCT03790449|OTHER|Attention Control|Attention Control Programme
62606236|NCT05297929|EXPERIMENTAL|Experimental: Reference formulation|Irbesartan tablet (0.15g/tablet) , Manufacturer: Sanofi Winthrop Industries
62438844|NCT05524987|NO_INTERVENTION|CONTROL|Participants in the usual care group will be referred to their local healthcare facility for evaluation and/or to receive medical therapy per typical standard of care and at the discretion of the treating physician for the entirety of the ANDES study.
62449358|NCT03758365|ACTIVE_COMPARATOR|Triamcinolone acetonide 0.1% cream|Single application of Triamcinolone acetonide 0.1%,
62606237|NCT05297929|EXPERIMENTAL|Experimental: Test formulation|Irbesartan tablet (0.15g/tablet) , Manufacturer: Zhejiang Hua Hai Pharmaceutical Co. LTD
62606238|NCT01197170|EXPERIMENTAL|Anastrozole|1 mg PO (by mouth) daily for 28 days.
62606239|NCT01197170|EXPERIMENTAL|Anastrozole + Bevacizumab|Anastrozole 1 mg PO daily and Bevacizumab starting dose 10 mg IV Day 1 of 21 day cycle. Expansion group added when MTD dose of Anastrozole + Bevacizumab found.
62046742|NCT04549363|EXPERIMENTAL|Participants undergoing IC|IC will be performed on some participants who received or are receiving treatment with belantamab mafodotin for RRMM and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination and who do not agree to undergo SK.
62449359|NCT03758365|ACTIVE_COMPARATOR|Hydrocortisone Butyrate 0.1% cream|Single application of Hydrocortisone Butyrate 0.1% Cream
62449360|NCT03758365|ACTIVE_COMPARATOR|Desonide 0.05% cream|Single application of Desonide 0.05%
62449361|NCT03758365|PLACEBO_COMPARATOR|Vehicle cream|Single application of Vehicle
62449362|NCT01547195|EXPERIMENTAL|Group-swimming|
62606240|NCT01197170|EXPERIMENTAL|Anastrozole + Everolimus|Anastrozole 1 mg PO daily and Everolimus starting dose 5 mg PO daily for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Everolimus found.
62606241|NCT01197170|EXPERIMENTAL|Anastrozole + Sorafenib|Anastrozole 1 mg PO daily and Sorafenib starting dose 200 mg PO twice a day for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Sorafenib found.
62606242|NCT01197170|EXPERIMENTAL|Anastrozole + Erlotinib|Anastrozole 1 mg PO daily and Erlotinib starting dose 75 mg PO daily for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Erlotinib found.
62606243|NCT03403946|EXPERIMENTAL|Intervention|"All patients received the same treatment.~1. Laryngscopy with C-MAC PM + Macintosh blade~2. Laryngscopy with C-MAC PM + D-Blade~3. Intubation with C-MAC PM + D-Blade"
62606244|NCT06094101|EXPERIMENTAL|Peptide vaccination|"Peptides will be administered subcutaneously (s.c.) together with the novel toll like receptor (TLR) 1/2 ligand XS15 emulsified in Montanide ISA 51 VG as adjuvant.~Three vaccinations will be applied every 28 days."
62606245|NCT00223964|EXPERIMENTAL|dose level 1|1.5 mg/kg
62606246|NCT00223964|EXPERIMENTAL|dose level 2|3 mg/kg
62606247|NCT01046032|ACTIVE_COMPARATOR|Metformin|Drug (including placebo)
62606248|NCT01046032|PLACEBO_COMPARATOR|Sugar pill|Drug (including placebo)
62606249|NCT01124292|EXPERIMENTAL|Able-bodied subject with piercing|Able-bodied subjects who already have tongue piercing.
62606250|NCT01124292|EXPERIMENTAL|Able-bodied subject without piercing|Able-bodied subjects who willing to receive a tongue piercing for this study.
62606251|NCT01124292|EXPERIMENTAL|Subjects with spinal cord injury|Persons with mobility limitations requiring power wheel chair, able to move tongue, able to follow simple commands, and have some experience with computers. All participants willingly received a mid-line tongue piercing.
62606252|NCT01510535|EXPERIMENTAL|Placebo and then LBSA0103|The experimental group receive once weekly for 2 weeks intraarticular injections of Placebo(saline). And then, they receive once intraarticular injections of LBSA0103 into the target knee.
62606253|NCT01510535|ACTIVE_COMPARATOR|Hyruan Plus|The control group received once weekly for 3 weeks intraarticular injections of Hyruan Plus Inj. into the target knee.
62606254|NCT06463418|EXPERIMENTAL|Exoskeleton (Intervention)|Exoskeleton walking delivered three times per week for twelve weeks. Each session will be one hour duration.
62606255|NCT06463418|ACTIVE_COMPARATOR|Relaxation (Comparator)|An equally dosed blended relaxation program delivered online for two sessions per week and in-person one session per week.
62046743|NCT04549363|EXPERIMENTAL|Participants undergoing SK|SK will be performed on some participants who received or are receiving treatment with belantamab mafodotin for RRMM and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination.
62046744|NCT06385743|EXPERIMENTAL|Neuromuscular Training-based Exercise Program Group|"Patient Education: Both groups will be given patient education on pain mechanism, posture/posture, exercise training, the role of the shoulder joint in shooting mechanics, situations, and positions to be avoided.~Neuromuscular Training-based Exercise Program: This group will be given a neuromuscular training-based exercise program in a total of 24 physiotherapy sessions, 3 days a week, for eight weeks. In addition to shoulder strength, stabilization and kinetic chain exercises, this program includes internal and external focus (sound, touch, light, dual task, etc.), sport-specific exercises and plyometric exercises (speed, agility)."
62449363|NCT01547195|ACTIVE_COMPARATOR|Control-walk|
62606256|NCT02951572|OTHER|Patients with RLD initiating NIV|Patients with RLD initiating NIV according to Belgian Health guidelines are followed-up before and after NIV initiation
62606257|NCT02594774|EXPERIMENTAL|Osteopathic treatment|Manipulative osteopathy (and standard medical treatment)
62606258|NCT02594774|NO_INTERVENTION|Standard medical treatment|Standard medical treatment
62606259|NCT06730503||Anti-PD-1/PD-L1 monoclonal antibody|
62606260|NCT00920179||Dry eye group|Dry eye patients with Primary Sjogren's syndrome
62606261|NCT00920179||Controls|Healthy subjects without dry eyes
62606262|NCT00055861|EXPERIMENTAL|Treatment (bevacizumab, docetaxel)|Patients receive bevacizumab IV over 30-90 minutes on weeks 1 and 3 and docetaxel IV over 60 minutes on weeks 1, 2, and 3. Treatment repeats every 4 weeks for up to 12 courses in the absence of unacceptable toxicity or disease progression.
62449364|NCT02703610|ACTIVE_COMPARATOR|Oxycodone/acetaminophen|Oxycodone/acetaminophen (5 mg/325 mg)
62606263|NCT00955981|EXPERIMENTAL|RDEA594 200 mg qd for 28 days|
62606264|NCT00955981|EXPERIMENTAL|RDEA594 200 mg, 400 mg|RDEA594 200 mg qd for 7 days followed by 400 mg qd for 21 days
62606265|NCT00955981|EXPERIMENTAL|RDEA594 200 mg, 400 mg and 600 mg|RDEA594 200 mg qd for 7 days followed by 400 mg qd for 7 days followed by 600 mg qd for 14 days
62606266|NCT00955981|PLACEBO_COMPARATOR|Matching placebo|RDEA594 matching placebo qd for 28 days
62449365|NCT02703610|ACTIVE_COMPARATOR|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen (400 mg/500 mg)
62606267|NCT05171244|EXPERIMENTAL|Experimental group|
62828799|NCT05647408|ACTIVE_COMPARATOR|Intranasally DMX|Male and female volunteers received one dose of either DXM Drugs formulations employed were DXM phosphate injectable solution 8 mg/2 mL (Alin, Productos Farmaceuticos, Mexico). The drug was administered to 4 healthy subjects intranasally (treatment B). According to a randomization list generated prior to the start of the clinical phase.
62449366|NCT01523964|OTHER|DMD subject ages 3-7 inclusive|Young DMD Testing with EIM
62449367|NCT01523964|OTHER|DMD subject ages 8-12 inclusive|Older DMD Testing with EIM
62606268|NCT05171244|SHAM_COMPARATOR|Control group|
62606269|NCT01677481||Femoral|Coronary angiography procedures performed using transfemoral access
62606270|NCT01677481||Left radial access|Coronary angiography procedures performed using left radial access site.
62606271|NCT01677481||Right radial Access|Coronary angiography procedures performed using Right radial access site.
62606272|NCT05532176|OTHER|postural group|one healthy group of different age
62606273|NCT01935700|EXPERIMENTAL|colchicine treated patients|2 tablets (0.5 mg/tablet) of colchicine three times per day (after breakfast, lunch and dinner); continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial
62606274|NCT06320041|EXPERIMENTAL|low dose oxelidine group|Oxelidine fumarate (10ml, 20mg) + normal saline 190ml diluted to 200ml. PCIA parameters were set as follows: background infusion rate was 0, self-controlled dosage was 0.35mg (3.5ml), locking time was 6min, and load was 1.5mg
62606275|NCT06320041|EXPERIMENTAL|high dose oxelidine group|Oxelidine fumarate (10ml, 20mg) + normal saline 190ml diluted to 200ml. PCIA parameters were set as follows: background infusion rate was 0, self-controlled dosage was 0.5mg (5ml), locking time was 6min, and load was 1.5mg
62606276|NCT06320041|ACTIVE_COMPARATOR|hydromorphone group|Hydromorphone (6ml, 12mg) + normal saline (194ml) diluted to 200ml. PCIA parameters were set as follows: background infusion rate was 0, self-controlled dosage was 0.3mg (5ml), locking time was 6min, and load was 1mg
62606277|NCT03334318||Allopurinol-treated|Participants in the PERL Clinical Trial (NCT02017171) randomized to allopurinol
62606278|NCT03334318||Placebo-treated|Participants in the PERL Clinical Trial (NCT02017171) randomized to placebo
62623494|NCT06513832|EXPERIMENTAL|The Asthma Navigator|The Children's electronic medical record (EMR) of each child will be screened weekly for up to 52 weeks. When an asthma exacerbation prompting unscheduled healthcare utilization is noted (primary outcome), or at the end of 52 weeks, participant involvement in the study will end.
62606279|NCT04475354||Cervical cancer patients and their partners|520 cervical cancer patients will complete questionnaires, online food diary and wear a fitbit after diagnosis, after 6 months, and after 1, 2, 5 and 10 years. In addition, a subsample (n=116) will donate blood samples and a scalp hair sample after diagnosis and 6, 12 and 24 months. We expect 312 partners of cervical cancer patients to included in the study and complete questionnaires after diagnosis, after 6 months, and after 1, 2, 5 and 10 years
62606280|NCT06069921||maligant|female patients with US-visible solid maligant breast masses who underwent biopsy and/or surgical resection.
62046745|NCT06385743|ACTIVE_COMPARATOR|Thrower's Ten Exercise Program Group|"Patient Education: Both groups will be given patient education on pain mechanism, posture/posture, exercise training, the role of the shoulder joint in shooting mechanics, situations, and positions to be avoided.~Thrower's Ten Exercise Program: This group will be given include Thrower's Ten Exercise Program in a total of 24 physiotherapy sessions, 3 days a week, for eight weeks. This program includes 10 different shoulder strengthening and shoulder stabilization exercises in a diagonal pattern. Advanced Thrower's Ten exercises that include kinetic chain exercises (covering more than one joint) in addition to shoulder exercises planned to be used in the late stages of rehabilitation into the program, progression is considered after the 3rd week will be added."
62438845|NCT02970669|ACTIVE_COMPARATOR|Enalapril|"Double blind treatment epoch: Patients randomized to this arm received 1 tablet of enalapril and 1 tablet of matching placebo sacubitril/valsartan twice daily for 8 weeks. All Patients began the study on Dose Level 1 (i.e. 2.5 mg enalapril BID). Patients may have been sequentially up-titrated to achieve desired dose of Dose Level 3 (i.e. 10 mg enalapril BID). Patients not tolerating dose escalation could have been titrated down to next lower dose level.~Open-label treatment epoch: All patients entering this epoch (8 weeks) were given sacubitril/valsartan 49/51 mg BID (Dose Level 2) unless they completed the double-blind treatment epoch on enalapril Dose Level 1. Instead, these patients entered open-label epoch on Dose Level 1 of sacubitril/valsartan. Patients may have been sequentially up-titrated to achieve desired dose of Dose Level 3 of sacubitril/valsartan. Patients not tolerating dose escalation could have been titrated down to next lower dose level."
62606281|NCT06069921||benign|female patients with US-visible solid benign breast masses who underwent biopsy and/or surgical resection.
62828800|NCT05411029||Healthy Somali Americans|Somali Americans with no known history of hypertension, diabetes, or sleep disorders will have a 24 hour blood pressure monitoring and polysomnography.
62828801|NCT06470711||Observational|Participants complete a survey and undergo MRI on study.
62046746|NCT01503632|EXPERIMENTAL|Arm I (intervention program and mercaptopurine)|See detailed description.
62046747|NCT01503632|ACTIVE_COMPARATOR|Arm II (standard of care and mercaptopurine)|Patients receive the usual standard of care and the mercaptopurine from the MEMS® medication bottle with TrackCap™ as patients in arm I. Patients and caregivers also view an interactive multimedia educational program on day 29.
62248848|NCT04249323|EXPERIMENTAL|Part 1: SAD Cohorts A through H CORT113176|Cohorts will receive a single dose of CORT113176 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. Cohort A will receive a 50-mg dose in a fasted state. Cohort B will receive a ≤3-fold increase in dose from Cohort A in a fasted state; the dose will be determined after evaluation of safety and PK data for Cohort A. Subsequent cohorts will receive a ≤3-fold increase in CORT113176 dose from the previous cohort in a fasted or fed state; the dose and prandial state will be determined after evaluation of safety and PK data from previous cohorts. Following interim review of PK data, an alternative lipidic formulation may be administered beginning with Cohort B.
62248849|NCT04249323|PLACEBO_COMPARATOR|Part 1: SAD Cohorts A through H Placebo|Cohorts will receive a single dose of placebo matching CORT113176 lipid capsule formulation by mouth on Day 1. The dose of placebo, prandial state, and choice of formulation will match that used for the corresponding SAD cohorts receiving CORT113176.
62248850|NCT04249323|EXPERIMENTAL|Part 2: MAD Cohorts A through D CORT113176|Cohorts will receive once- or twice-daily doses of CORT113176 lipid capsule formulation by mouth for 14 days. The anticipated exposure will not exceed the highest exposure considered safe and well-tolerated during Part 1. The dose schedule and prandial state will be determined after evaluation of safety and PK data from Part 1. The choice of formulation of CORT113176 to be used in Part 2 will depend on data review for Part 1.
62449368|NCT01523964|OTHER|Healthy Control ages 3-7 inclusive|Young Healthy Testing with EIM
62449369|NCT01523964|OTHER|Healthy Control ages 8-12 inclusive|Older Healthy Testing with EIM
62606282|NCT05029193|EXPERIMENTAL|Stroke survivors - Mindfulness intervention|Participants who have had a stroke who are receiving the mindfulness intervention immediately after enrollment (no wait period).
62606283|NCT05029193|NO_INTERVENTION|Stroke survivors - Waitlist control|Participants who have had a stroke who are assigned to the waitlist.
62606284|NCT05029193|EXPERIMENTAL|Caregivers - Mindfulness intervention|Participants caring for someone who have had a stroke and receiving the mindfulness intervention immediately after enrollment (no wait period).
62606285|NCT05029193|NO_INTERVENTION|Caregivers - Waitlist control|Participants caring for someone who have had a stroke assigned to the waitlist.
62828802|NCT01499836|EXPERIMENTAL|general anesthesia and PVB|general anesthetics consisting of propofol, cisatracurium and fentanyl for endotracheal intubation and deaflurane for maintenance will be given. After intubation, paravertebral injections will be performed under ultrasound guidance.
62828803|NCT01499836|EXPERIMENTAL|sedation and PVB|After sedation with midazolam and fentanyl, the patients in sedation and PVB group will receive PVB. paravertebral injections will be performed under ultrasound guidance.Intraoperative sedation will be provided with propofol titrated to moderate sedation.
62606286|NCT03039491|EXPERIMENTAL|HIV+ 50-65, CD4>200 PCV/PPV|"HIV+ individuals , 50-65 years of age with a nadir cluster of differentiation (CD) 4 count \>200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
62606287|NCT03039491|EXPERIMENTAL|HIV+ 50-65, CD4<200 PCV/PPV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count \<200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
62828804|NCT01499836|ACTIVE_COMPARATOR|general anesthesia|general anesthetics consisting of propofol, cisatracurium and fentanyl for endotracheal intubation and deaflurane for maintenance will be given.
62606288|NCT03039491|EXPERIMENTAL|HIV+ 50-65, CD4>200 PPV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count \>200 to receive PPV23 only~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
62606289|NCT03039491|EXPERIMENTAL|HIV+ 50-65, CD4<200 PCV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count \<200 to receive PPV23 only~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
62449370|NCT03567109||Shoulder rotator cuff tendinopathy|unilateral rotator cuff tendinopathy, 3 months or more duration, confirmed by imagery,
62828805|NCT04383210|EXPERIMENTAL|Cohort 1|"A minimum of 55 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, excluding prior ERBB-directed therapy.~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
62828806|NCT04383210|EXPERIMENTAL|Cohort 2|"Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, including prior ERBB-directed therapy.~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
62828807|NCT04383210|EXPERIMENTAL|Cohort 3|"Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions lacking an EGF-like domain, who have received prior standard treatment, which may have included prior ERBB-directed therapy.~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
62248851|NCT04249323|PLACEBO_COMPARATOR|Part 2: MAD Cohorts A through D Placebo|Cohorts will receive once- or twice-daily doses of placebo matching CORT113176 lipid capsule formulation by mouth for 14 days. The dose of placebo, prandial state, and choice of formulation will match that used for the corresponding MAD cohorts receiving CORT113176.
62248852|NCT04249323|EXPERIMENTAL|Part 3: Single Dose Pharmacodynamic Effect|In Period 1, participants will receive a single dose of prednisone 25 mg tablet by mouth on Day 1 in a fasted or fed state. After a 7-day washout, in Period 2, participants will receive a single dose of prednisone as in Period 1 plus a single dose of CORT113176 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. The dose of CORT113176 and the prandial state will be determined after evaluation of safety and PK data from Part 1. The choice of formulation of CORT113176 to be used in Part 3 will depend on data review for Part 1. Part 3 will proceed only if sufficiently high plasma CORT113176 exposure is achieved in Part 1.
62248853|NCT05107804|EXPERIMENTAL|Exercise with caloric-restriction|"Exercise: Participants engaged in supervised exercise training sessions (to expend \~20% of baseline energy needs) in Noll Laboratory; 4 times per week.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that reduced dietary intake 20-35% of baseline energy needs. Diet composition was 55% carbohydrates, 30% fat, and 15% protein."
62606290|NCT03039491|ACTIVE_COMPARATOR|HIV- 50-65, PCV/PPV|"HIV- individuals , 50-65 years of age immunized with PCV13 followed by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
62606291|NCT03039491|ACTIVE_COMPARATOR|HIV- 50-65, PPV|"HIV- individuals, 50-65 years of age immunized with PPV23 only.~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
62606292|NCT03039491|ACTIVE_COMPARATOR|HIV+ 21-40, CD4>200 PCV/PPV|"HIV+ individuals , 21-40 years of age with a nadir CD4 count \>200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
62606293|NCT03039491|ACTIVE_COMPARATOR|HIV+ 21-40, CD4<200 PCV/PPV|"HIV+ individuals , 21-40 years of age with a nadir CD4 count \<200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
62606294|NCT01700738|EXPERIMENTAL|gastric ring surgery|in this group a gastric ring will be put by surgery.
62606295|NCT01700738|ACTIVE_COMPARATOR|nutritional help|the usual treatment of obesity in France with nutritional care will be dispensed for this arm
62606296|NCT02293759|ACTIVE_COMPARATOR|HoLEP|Holmium laser enucleation of the prostate
62606297|NCT02293759|ACTIVE_COMPARATOR|Greenlight laser PVP|Phtoselective vaporization of the prostate
62606298|NCT01084395|EXPERIMENTAL|Adolescent Safer Sex Intervention|
62606299|NCT01084395|EXPERIMENTAL|Parent Safer Sex Intervention|
62828808|NCT05409625|EXPERIMENTAL|Young adults|Participants aged between 18 and 30 years old without chronic diseases but with two caries lesions or more
62828809|NCT02528994|EXPERIMENTAL|Serine 6g daily|Randomized participants will take 6g daily of dietary serine supplement
62606300|NCT01084395|OTHER|Adolescent Health Promotion Control|
62606301|NCT01084395|OTHER|Parent Health Promotion Control|
62828810|NCT02528994|EXPERIMENTAL|Serine 12g daily|Randomized participants will take 12g daily of dietary serine supplement
62828811|NCT02528994|EXPERIMENTAL|Serine 24g daily|Randomized participants will take 24g daily of dietary serine supplement
62828812|NCT02528994|EXPERIMENTAL|Serine 48g daily|Randomized participants will take 48g daily of dietary serine supplement
62828813|NCT02351817|EXPERIMENTAL|Baseline - Test A - Test B|"Three period investigation. First each subject tests baseline product, then Test A and finally Test B.~Baseline product: the subject's usual product~Test A: A newly developed 1-piece, open ostomy appliance for collecting feces~Test B: A newly developed 1-piece, open ostomy appliance for collecting feces"
62828814|NCT02351817|EXPERIMENTAL|Baseline - Test B - Test A|"First each subject tests baseline product, then Test B and finally Test A.~Baseline product: the subject's usual product~Test A: A newly developed 1-piece, open ostomy appliance for collecting feces~Test B: A newly developed 1-piece, open ostomy appliance for collecting feces"
62828815|NCT03964831|OTHER|Ultra widefield image capture|
62828816|NCT03375788|EXPERIMENTAL|Tesamorelin|tesamorelin (brand name Egrifta) 2mg daily given subcutaneously
62828817|NCT03375788|PLACEBO_COMPARATOR|Placebo|identical placebo given subcutaneously daily
62248854|NCT05107804|ACTIVE_COMPARATOR|Light Conditioning (reference group)|"Exercise: Participants engaged in supervised exercise training sessions (to expend \~10% of baseline energy needs) in Noll Laboratory; 1-2 times per week.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight and additional calories to remain in energy balance. Diet composition was 55% carbohydrates, 30% fat, and 15% protein."
62606302|NCT01863498|ACTIVE_COMPARATOR|PCA pain control|Patients will have PCA for pain control
62606303|NCT01863498|ACTIVE_COMPARATOR|Epidural pain control|Patients will have an epidural for pain control
62606304|NCT06505551|EXPERIMENTAL|SCG142 T cells|This is a single arm study.
62046748|NCT05351255|EXPERIMENTAL|rTMS Intervention|In aim 2 of the study, participants receive a repetitive transcranial magnetic stimulation intervention called theta burst stimulation (TBS) to study its effect on motor learning behavior. All participants will complete 3 sessions in which they will receive continuous TBS, intermittent TBS, or sham TBS before completing a behavioral motor learning task. The order of TBS sessions will be counter-balanced across participants.
62606305|NCT05363163|EXPERIMENTAL|Gana X|Participants will receive Gana X in both buttocks
62046749|NCT03389542|EXPERIMENTAL|Early mitral valve repair|Surgery will be performed within 3 months after randomization. Clinical interview will be performed at discharge, at 6 months and afterwards yearly until the end of follow-up. Echocardiography will be performed at discharge, at 6 months and at the end of follow-up.
62046750|NCT03389542|ACTIVE_COMPARATOR|Conservative management|Patients will be followed up by clinical interview and echocardiography every 6 months.
62046751|NCT03066050||SMR MV Repair|This group of patients had been randomized in the SMR study to mitral valve repair with annuloplasty ring.
62046752|NCT03066050||MV Replacement|This group of patients had been randomized in the SMR study to mitral valve replacement.
62248855|NCT05365555||Fascia Iliaca Compartment Block (FICB)|Participants with a radiologically verified hip fracture receiving a FICB using a blind technique guided by anatomical landmarks.
62248856|NCT05365555||Femoral Nerve Block (FNB)|Participants with a radiologically verified hip fracture receiving a FNB using ultrasound guidance for direct nerve visualisation.
62248857|NCT01924013|PLACEBO_COMPARATOR|Group A|"Prenatal Period 0 IU; Postpartum Period 0 IU (placebo)~Overall:The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery. The Postpartum Period will last from delivery until 6 months postpartum."
62248858|NCT01924013|EXPERIMENTAL|Group B|Prenatal Period 4,200 IU/week of vitamin D3 (=600 IU/d); Postpartum Period 0 IU/week (placebo)
62248859|NCT01924013|EXPERIMENTAL|Group C|Prenatal Period 16,800 IU/week of vitamin D3 (=2,400 IU/d); Postpartum Period 0 IU/week (placebo)
62248860|NCT01924013|EXPERIMENTAL|Group D|Prenatal Period 28,000 IU/week of vitamin D3 (=4,000 IU/d); Postpartum Period 0 IU/week (placebo)
62449371|NCT03567109||chronic low back pain|non specific chronic (3 months) low back pain
62606306|NCT04872556|EXPERIMENTAL|Laser acupuncture group|The experiment group would arrange laser acupuncture on day1 and day3 after Taxanes treatment, besides the control group arrange pseudo-laser acupuncture. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
62606307|NCT04872556|SHAM_COMPARATOR|Pseudo-laser acupuncture group|The experiment group would arrange laser acupuncture on day1 and day 3 after Taxanes treatment, besides the control group arrange pseudo-laser acupuncture. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
62606308|NCT05646758|EXPERIMENTAL|TQB2934 injection|"intravenous injection. 0.09mg, 0.36 mg, 1mg, 2mg, 3mg, 5mg, 6mg, 10mg, 12mg, 16mg, 20mg each time.~once a week in Cycle 1-3. once every 2 weeks in Cycle 4-6. if reach PR and above remission after 6 cycles of administration, once every 4 weeks,28 days as a treatment cycle."
62449372|NCT03567109||carpal tunnel syndrome|unilateral carpal tunnel syndrome, confirmed by electromyogram, 3 months or more duration
62606309|NCT02716493|EXPERIMENTAL|Telerehabilitation group|Patients with unresectable thoracic neoplasia receiving chemotherapy treatment
62606310|NCT05008809|EXPERIMENTAL|Treatment|Active treatment with mFOLFOXIRI or mFOLFOX6 or FOLFIRI q2w or CAPOX q3w up to six months followed by structured Follow-up for up to five years after randomization
62606311|NCT05008809|NO_INTERVENTION|Control|Structured Follow-up for up to five years after randomization
62606312|NCT01859052|OTHER|Obese migraineurs|Low carbohydrate diet
62606313|NCT01859052|OTHER|low-fat diet|Obese Migraineurs
62046753|NCT03066050||MMR MV Repair|This group of patients had been randomized in the MMR study to mitral valve repair with annuloplasty ring.
62046754|NCT03066050||CABG|This group of patients had been randomized in the MMR study to receive CABG
62046755|NCT00895986|EXPERIMENTAL|1|Conversation Maps Diabetes Education
62046756|NCT00895986|EXPERIMENTAL|2|Heart Healthy Living Diabetes Education
62046757|NCT02525848|ACTIVE_COMPARATOR|dexamethasone|intravenous dexamethasone 8 mg 2 minutes before induction of anesthesia;
62248861|NCT01924013|EXPERIMENTAL|Group E|Prenatal Period 28,000 IU/week of vitamin D3 (=4,000 IU/d); Postpartum Period 28,000 IU/week(=4,000 IU/d)
62248862|NCT06316245||Group DASI ≤ 34|Patients with Duke Activity Status Index (DASI) scores are ≤ 34 before the surgery.
62248863|NCT06316245||Group DASI > 34|Patients with Duke Activity Status Index (DASI) scores are \> 34 before the surgery.
62449373|NCT03567109||control|healthy subjects
62449374|NCT05402449|PLACEBO_COMPARATOR|Placebo group|Subjects received two placebo sachets per day
62449375|NCT05402449|EXPERIMENTAL|Probiotic group|Subjects received two probiotic sachets per day
62606314|NCT01859052|OTHER|Controls|Controls receiving AHA diet recommendations
62606315|NCT04170907|OTHER|Nicotine salt 20 mg/mL|Vaping of nicotine salt e-liquids with a nicotine concentration of 20 mg/mL.
62606316|NCT04170907|OTHER|Nicotine salt 40 mg/mL|Vaping of nicotine salt e-liquids with a nicotine concentration of 40 mg/mL.
62046758|NCT02525848|ACTIVE_COMPARATOR|gapabentin|oral gabapentin 600 mg 1 hour before induction of anesthesia
62046759|NCT02525848|ACTIVE_COMPARATOR|Aprepitant|aprepitan 80mg 1 hour before induction of anesthesia.
62046760|NCT02884297|EXPERIMENTAL|surgical termination of pregnancy|Contrast agent: SonoVue®: Hexafluoride (SonoVue®, injectable solution to solubilisate, 8µg/mL) is injected in all patients for ultrasound angiography during the termination of pregnancy. 2,4 mL are administrated per patient, divided into two injections of 1,2 mL.
62046761|NCT03856710|ACTIVE_COMPARATOR|Group 1 (Self-gripping Mesh),|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh , which would be decided by randomization by sealed envelope. This group will receive self-gripping mesh
62046762|NCT03856710|ACTIVE_COMPARATOR|Group 2 (Stapled Mesh)|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh , which would be decided by randomization by sealed envelope. This group will receive stapled mesh
62606317|NCT04170907|OTHER|Free-base nicotine 20 mg/mL|Vaping of free-base nicotine e-liquids with a nicotine concentration of 20 mg/mL.
62046763|NCT01046539|ACTIVE_COMPARATOR|RDC-0313 + Buprenorphine|Cohort 1 (1 and 4 mg) + 8 mg Cohort 2 (dependent on Cohort 1 results)
62046764|NCT01046539|PLACEBO_COMPARATOR|Placebo|
62046765|NCT02281669||Research group|The study group includes all CL cases for whom the treating physician decides to treat by IL Pentostam. The patients will return to follow up and additional treatment every 3 weeks until full recovery \[as our current policy\].
62046766|NCT01816750|EXPERIMENTAL|Anatomical accuracy Cardiac GSI vs ICA|The identification and quantification of coronary artery stenoses using Cardiac in comparison to ICA.
62046767|NCT01816750|EXPERIMENTAL|Stress perfusion Cardiac GSI vs MPI-SPECT|Assessment of the functional impact of coronary stenoses using Cardiac GSI in comparison to MPI-SPECT
62046768|NCT01816750|EXPERIMENTAL|Delayed enhancement Cardiac GSI vs CMR|Assessment of abnormal myocardial tissue characteristics representing ischaemic or scarred tissue using Cardiac GSI in comparison to CMR.
62606318|NCT02147405||ARV naive|Patients that have not started or have ever been on ARV therapy.
62606319|NCT02147405||IRIS|Patients that are on medication but are possibly experiencing an IRIS event.
62606320|NCT01523288||Prader-Willi patients|
62606321|NCT01523288||Control group|Control group for ultrasound scan
62046769|NCT02142933|OTHER|rectal swab and vagino-perineal swab|single-arm
62046770|NCT02107209|EXPERIMENTAL|Bronchoscopic Lung volume reduction using Autologous blood.|Injection of 30 ml autologous blood plus 3ml calcium chloride plus 3 ml tranexamic acid per segment via fiber-optic bronchoscope
62438846|NCT02970669|EXPERIMENTAL|Sacubitril/Valsartan|"Double blind treatment epoch: Patients randomized to this arm received 1 tablet of sacubitril/valsartan and 1 tablet of matching placebo enalapril twice daily for 8 weeks. All Patients began the study on Dose Level 1 (i.e. 24/26 mg sacubitril/valsartan BID). Patients may have sequentially been up-titrated to achieve desired dose of Dose Level 3 (i.e. 97/103 mg sacubitril/valsartan BID). Patients not tolerating dose escalation could have been titrated down to next lower dose level.~Open-label treatment epoch: All patients entering this epoch (8 weeks) were given sacubitril/valsartan 49/51 mg BID (Dose Level 2) unless they completed the double-blind treatment epoch on Dose Level 1. Instead, these patients entered open-label epoch on Dose Level 1. Patients may sequentially have been up-titrated to achieve desired dose of Dose Level 3. Patients not tolerating dose escalation could have been titrated down to next lower dose level."
62046771|NCT02107209|ACTIVE_COMPARATOR|Bronchoscopic Lung volume reduction using Fibrin glue|injection of 30 ml locally prepared fibrin glue per segment via triple lumen balloon catheter passing through fiberoptic bronchoscopy
62046772|NCT03943784||Endoscopic Variceal Ligation|From January 2014 to April 2017, all paediatric patients with a known chronic liver disease with suspicion of portal hypertension who presented grade 2 or 3 esophageal varices or red spots in the upper endoscopy received primary prophylaxis with endoscopic variceal ligation.
62248864|NCT04749966||Emergency services staff|Emergency Services staff recruited from the Ambulance, Police, and Fire and Rescue Services.
62248865|NCT03623451|EXPERIMENTAL|Chinese Medicine Formula|All 100 patients were treated with Chinese Medicine Formula(CMF) for three menstrual cycles.
62248866|NCT04184492|EXPERIMENTAL|GP-40081|Single subcutaneous administration of GP-40081 in dose 0.4 IU / kg
62248867|NCT04184492|ACTIVE_COMPARATOR|NovoMix® 30 Penfill®|Single subcutaneous administration of NovoMix® 30 Penfill® in dose 0.4 IU / kg
62438847|NCT03999281||Diabetic Foot Ulcers (DFU)|Study began with 214 consecutive patient; After excluding patients who did not meet the study criteria, the final eligible cohort consisted of 188 subjects, with 54 with diabetic foot ulcers
62438848|NCT03999281||Venous Leg Ulcer (VLU)|Study began with 214 consecutive patient; After excluding patients who did not meet the study criteria, the final eligible cohort consisted of 188 subjects, with 134 venous leg ulcers.
62606322|NCT05481918|ACTIVE_COMPARATOR|Standardized therapy|"The standardized outpatient rehabilitation program after ACL reconstruction contains 16 physiotherapeutic visits (groups+ individual), exclusively a stationary supervision.~Therapies: stationary: 1x individual (30 min); from 2nd to 6th week: 2x individual (30 min), 5x group (30 min), 4x group (30min); From 6th week: 5x group (30 min)"
62606323|NCT05481918|EXPERIMENTAL|Home-based therapy|The home-based program consists of five outpatient physiotherapeutic units (each 60 minutes) at the department of physical medicine and rehabilitation of the UHK. The timing of the physiotherapeutic supervisions was defined based on pre-existing studies, concerning home based therapy after ACL reconstruction. The five physiotherapeutic sessions will be executed by a physiotherapist in first, third, seventh, ninth and eleventh postsurgical week. In addition to a general information sheet, the patients of this group will receive phase-adapted training documents (with photographs) at each physiotherapeutic appointment.
62606324|NCT04858594||Arm A: with Periodontitis|Patients with periodontitis
62606325|NCT04858594||Arm B: without Periodontitis|Patients without periodontitis
62606326|NCT00937248|EXPERIMENTAL|Interventional|Patient randomized to be immobilized using a prone pillow and simple ankle fixation device with a CVID.
62046773|NCT03943784||Propranolol Group|Patients in the Endoscopic Variceal Ligation group were compared with an historical cohort of 30 consecutive patients with portal hypertension and grade 2 or 3 esophageal varices or red spots who received propranolol as primary prophylaxis from January 2009 to December 2013. All patients were treatment-naïve in regards of their upper gastrointestinal bleeding prophylaxis at the time of the first upper endoscopy.
62046774|NCT02804568|EXPERIMENTAL|Group 1|Olanzapine/samidorphan 10 mg/10 mg
62046775|NCT02804568|EXPERIMENTAL|Group 2|Olanzapine/samidorphan 20 mg/10 mg
62606327|NCT00937248|ACTIVE_COMPARATOR|Standard Arm|Patient randomized to be immobilized using a prone pillow and simple ankle fixation device without a CVID
62606328|NCT06430775||ACLR-patients|The participants to be studied will have an anterior cruciate ligament injury for which surgical treatment is scheduled.
62046776|NCT02807636|EXPERIMENTAL|Atezolizumab+Gemcitabine+Carboplatin/Cisplatin|Participants will receive blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
62046777|NCT02807636|PLACEBO_COMPARATOR|Placebo+Gemcitabine+Carboplatin/Cisplatin|Participants will receive blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
62046778|NCT02807636|EXPERIMENTAL|Atezolizumab Monotherapy|Eligible participants will receive open-label atezolizumab as monotherapy.
62046779|NCT03157609|EXPERIMENTAL|Thermometry with SpotOn|Application of SpotOn sensor on forehead.
62046780|NCT03157609|ACTIVE_COMPARATOR|Thermometry with oesophageal probe|Nasal insertion of oesophageal temperature probe in the lower fourth of the oesophagus.
62606329|NCT06726902|EXPERIMENTAL|Test Group I (GBT and SI + erythritol powder)|will receive GBT and SI with adjunctive air-polishing using Standard/ Subgingival nozzle + erythritol powder
62606330|NCT06726902|EXPERIMENTAL|Test Group II (GBT and SI + glycine powder)|will receive GBT and SI with adjunctive air-polishing using Standard/ Subgingival nozzle + glycine powder
62046781|NCT06182306||Trial Cohort|Patients with advanced or metastatic triple negative breast cancer, due to start a new line of systemic therapy (targeted drug or immunotherapy)
62046782|NCT03129854|EXPERIMENTAL|experimental group|Prostate cryotherapy plus ADT
62046783|NCT03129854|NO_INTERVENTION|control group|standard of care ADT continually
62046784|NCT05534022|EXPERIMENTAL|Test myopia control lenses (BSL)|Myopia control spectacle lenses (test lenses) will be given to subjects throughout the 24 months trial.
62046785|NCT03223974|EXPERIMENTAL|Paclitaxel DCB for MB and/or SB|Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM(atmosphere), lasting for \>30 seconds
62046786|NCT03223974|ACTIVE_COMPARATOR|DES in MB|with regular techniques
62046787|NCT00553696|EXPERIMENTAL|A|
62046788|NCT02718703|EXPERIMENTAL|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
62438849|NCT05153356||Parkinson Disease patients|To examine the relationship between in-home continuous measures of tremor, bradykinesia, mobility, and dyskinesia acquired over a 7-day period, from 2 mobile health technologies (Personal Kinetigraph, Kinesia 360) with one-time in-clinic measures of motor functional ability pertaining to the same 7-day period as assessed by Part 2 of the MDS-UPDRS, Part 4 of the MDS-UPDRS, Neuro-QOL, and PDQ-39. This will be examined in n=20 patients (10 patients assigned to each technology with a crossover at 3 months for a total of 20 patients over 6 months, 6 timepoints with data collected every 2 weeks). Patients will then be following for an observational period of an additional 6 months.
62449376|NCT04861883||76 healthy the Middle and Third Trimester pregnant women in the trial group|The pulse sound waves of three parts and five layers of each of the two hands of 76 pregnant women will be collected by Pulse Detection System of Sound Waves.
62606331|NCT06726902|EXPERIMENTAL|Test Group III (GBT and SI + Trehalose powder)|will receive GBT and SI with adjunctive air-polishing using Standard/ Subgingival nozzle + Trehalose powder
62606332|NCT06726902|EXPERIMENTAL|Control Group VI (SRP and SI)|will receive conventional Scaling and Root planning (SRP) and (SI) without adjunctive air polishing powder
62046789|NCT00877643|EXPERIMENTAL|Upstream rhythm control|
62046790|NCT00877643|ACTIVE_COMPARATOR|Conventional rhythm control|
62606333|NCT05068492||Training cohort|Training cohort was set to develop the novel non-invasive model for virtual HVPG
62606334|NCT05068492||Validation cohort|Validation cohort was set to validate the novel non-invasive model for virtual HVPG in different people in same environments
62606335|NCT05068492||Test cohort|Test cohort was set to test the novel non-invasive model for virtual HVPG in different environments
62606336|NCT03457805|OTHER|Prostatic Artery Embolization (PAE)|PAE performed under local anesthesia using officially approved microspheres.
62828818|NCT04220307|EXPERIMENTAL|AK104 6 mg/kg|AK104 IV every 2 weeks (q2w)
62046791|NCT05039372|EXPERIMENTAL|training and consultancy|"Patient Description Form, Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire, McGill Pain Scale Short Form, Stanford Health Assessment Questionnaire will be administered to the patients in this group at the first interview. Individual training will be given to the patient in line with the training guide prepared for the rheumatoid arthritis patient, and the guide will be shared after the training. In line with the theory of planned behavior in patients with rheumatoid arthritis, counseling service will be provided by the researcher to the extent of the training plan prepared for symptom management. At the end of the 3rd month, the patients will be interviewed face to face and the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire, McGill Pain Scale Short Form, Stanford Health Assessment Questionnaire will be administered again."
62046792|NCT05039372|NO_INTERVENTION|control|"After obtaining written consent from the patients who agreed to participate in the study, the patients included in the control group were asked to continue their rheumatologist follow-up and their normal lives (hospital routine, daily life). Patients in this group will fill out the Patient Description Form, Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire, McGill Pain Scale Short Form, Stanford Health Evaluation Questionnaire at the first interview. After 3 months, data collection tools other than the Patient Identification Form will be applied to the patients and the training guide to be prepared for rheumatoid arthritis patients will be given."
62046793|NCT03449810|EXPERIMENTAL|DSE plus MET (group A)|"The DSE will consist of seven exercise activities that will be administered at random viz; 1. Bridging 2. Supine twist stretch 3. Double leg knee to chest stretch 4. Plank heel raise 5. Ball squat 6. Leg press on ball 7. Hip Lifts.~The MET procedure will involve a total of 5-10 contralateral isometric voluntary contractions that will be resisted by force equal to the participant's for 30 seconds with 5 seconds rest between contractions (corresponding to 20-30%)."
62046794|NCT03449810|ACTIVE_COMPARATOR|DSE only (group B)|The DSE will consist of seven exercise activities that will be administered at random viz; 1. Bridging 2. Supine twist stretch 3. Double leg knee to chest stretch 4. Plank heel raise 5. Ball squat 6. Leg press on ball 7. Hip Lifts.
62046795|NCT03449810|ACTIVE_COMPARATOR|Standard Physiotherapy Treatment (group C)|This group will involve classical massage, therapeutic exercises (strengthening spinal and abdominal muscles) and a combination of interferential therapy and therapeutic ultrasound (INF/UTS) applied to the lumbosacral region. The participants will be asked to perform the therapeutic exercises once a day at home.
62046796|NCT05047367||single-group studies|A total of 149 patients diagnosed with CTS, 126 female and 23 male, were included in the study
62449377|NCT04861883||76 relatively healthy non-pregnant women in the control group|The pulse sound waves of three parts and five layers of each of the two hands of 76 relatively healthy non-pregnant women will be collected by Pulse Detection System of Sound Waves.
62449378|NCT04744740||PTSD+Suicidal Ideation|US Military Veterans diagnosed with PTSD and identified via the REACH VET or local high-risk list as requiring intensified surveillance by their VA's Suicide Prevention Coordinators in collaboration with their Primary Care Providers
62449379|NCT04744740||PTSD-Suicidal Ideation|US Military Veterans diagnosed with PTSD not identified as requiring intensified surveillance by their VA's Suicide Prevention Coordinators in collaboration with their Primary Care Providers
62606337|NCT00011180||Incident Cohort with VTE|Olmsted County, Minnesota residents with with a first-lifetime deep vein thrombosis (DVT) or pulmonary embolism (PE) during the five year period, 1996-2000.
62606338|NCT00011180||Controls without VTE|Two Olmsted County, Minnesota residents without venous thromboembolism (VTE) were matched by age and gender to each definite or probable case of VTE within the 1996-2000 cohort.
62606339|NCT06625593|EXPERIMENTAL|Phase 1a: Dose Escalation and Safety Expansion|Sequential cohorts of increasing dose levels of BG-C137 will be evaluated as monotherapy
62046797|NCT04028986||Surgery group|patients treated by surgery before starting the IVF/ICSI treatment
62046798|NCT04028986||Ulipristalacetate group|patients treated by ulipristalacetate before starting IVF/ICSI treatment
62606340|NCT06625593|EXPERIMENTAL|Phase 1b: Dose Expansion|Recommended Dose(s) of BG-C137 as determined from Ph1a will be evaluated in select indications
62046799|NCT03934736|EXPERIMENTAL|HEPLISAV-B®|A single dose of 0.5 mL HEPLISAV-B® administered intramuscularly in the deltoid muscle at Week 0 (Visit 1), Week 4 (Visit 2), Week 8 (Visit 3), and Week 16 (Visit 4).
62046800|NCT06248918|EXPERIMENTAL|Intervention Group|Participants will receive an exercise plan, activity tracker, and physical activity coaching program based Social Cognitive Theory.
62046801|NCT06248918|NO_INTERVENTION|Control Group|The control group will not take any intervention but take a standard care, the post-tests will be collected at the end of 12 weeks.
62828819|NCT04220307|EXPERIMENTAL|AK104 15 mg/kg|AK104 IV every 3 weeks (q3w)
62046802|NCT04162769|EXPERIMENTAL|12-Week Double-Blind Treatment Period: Etrasimod 1 milligrams (mg)|
62046803|NCT04162769|EXPERIMENTAL|12-Week Double-Blind Treatment Period: Etrasimod 2 mg|
62046804|NCT04162769|PLACEBO_COMPARATOR|12-Week Double-Blind Treatment Period: Placebo|
62046805|NCT04162769|EXPERIMENTAL|52-Week Open-Label Extension Period: Etrasimod 2 mg|
62046806|NCT03590756|EXPERIMENTAL|High mango group|250g (1.5 cup) of mango intake per day, 4 days a week for 16 weeks
62046807|NCT03590756|OTHER|Low mango group|85g (0.5 cup) of mango intake per day, 4 days a week for 16 weeks
62606341|NCT04268654|EXPERIMENTAL|Ischemic Conditioning|"Preoperative artery embolization prior to esophagectomy~Tissue pressure of oxygen measurement in both arms by Licox system. The probe is inserted directly through the skin as a cervical drainage and it is fixed by Witzel technique in the gastric conduit. It is removed after the three measurements (intraoperatively, 24h and 48h after surgery) of the PtiO2 as a normal drainage."
62046808|NCT00338884|EXPERIMENTAL|SUNITINIB MALATE.|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
62046809|NCT05772780|EXPERIMENTAL|Group A|Training will be performed for two days a week
62046810|NCT05772780|EXPERIMENTAL|Group B|Training will be performed three days a week
62046811|NCT01686789|ACTIVE_COMPARATOR|Pegylated interferon alpha-2a plus standard dose ribavirin|Pegylated interferon alpha-2a 180 mcg weekly plus standard dose ribavirin 100-1200 mg/day for 48 weeks
62046812|NCT01686789|EXPERIMENTAL|Pegylated interferon alpha-2a 180 mcgs adjusted dose ribavirin|Pegylated interferon alpha-2a 180 mcg weekly plus adjusted dose ribavirin for 48 weeks
62828820|NCT05967507|EXPERIMENTAL|Intervention group|0.2 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with conventional nasal cannula during tracheal intubation performed with the C-MAC videolaryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
62828821|NCT05967507|ACTIVE_COMPARATOR|Control group|2 L/kg/min FiO2 1.0 high-flow nasal supplemental oxygen with the Optiflow (Fisher \& Paykel Healthcare, Auckland, New Zealand) during tracheal intubation performed with the C-MAC videolaryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
62828822|NCT06597799|EXPERIMENTAL|Single Ascending Dose|"Single Ascending Dose of either:~MRT-6160 or matching placebo"
62828823|NCT06597799|EXPERIMENTAL|Multiple Ascending Dose|"Multiple Ascending Dose of either:~MRT-6160 or matching placebo"
62046813|NCT04086420|EXPERIMENTAL|Mindfulness|Delivered through an audio-recording consisting of a single meditation exercise that lasted for 30 minutes
62046814|NCT04086420|ACTIVE_COMPARATOR|Heart-Rate|Given a heart rate monitor and instructed to use it to determine the intensity of their exercise
62046815|NCT00340015||AARP|Members of the AARP, aged 50-71 years, and who resided in one of six states
62046816|NCT02784483|EXPERIMENTAL|Atezolizumab (1200mg via IV infusion)|
62046817|NCT02565290|ACTIVE_COMPARATOR|Omega-3|2 capsules of omega 3 - 2 times a day
62046818|NCT02565290|PLACEBO_COMPARATOR|Soy oil|2 capsules of soy oil - 2 times a day
62046819|NCT06111222|OTHER|Bilateral implantation of investigational device|Bilateral implantation of investigational device
62046820|NCT04064879|EXPERIMENTAL|Deployment of AD-SVF|Administration of autologous adipose derived SVF
62046821|NCT05760001|EXPERIMENTAL|Intervention Arm|"At the individual level, participants in the intervention arm will receive place-based and financial well-being interventions.~These will include, at the individual level:~* Tax preparation~* Access to public benefits~* Financial counseling and microgrants~At the neighborhood level:~* Abandoned house remediation~* Trash cleanup~* Vacant lot greening~* Tree planting"
62046822|NCT05760001|NO_INTERVENTION|Control Arm|Participants in the control arm will not receive any of the listed interventions
62046823|NCT03455374|EXPERIMENTAL|Treatment with CSI atherectomy device|removal of the plaque from vessel wall by optical coherence tomography
62046824|NCT04688424|EXPERIMENTAL|FES + Cycling|Functional electrical stimulation cycling group
62046825|NCT04688424|ACTIVE_COMPARATOR|Cycling only|Volitional cycling group (no electrical stimulation)
62046826|NCT04688424|NO_INTERVENTION|Control|control group
62046827|NCT05586152|EXPERIMENTAL|INV-102 0.1% Twice daily (BID)|Part 1, Cohort 1: INV-102 ophthalmic solution 0.1% administered twice daily for 2 weeks
62046828|NCT05586152|EXPERIMENTAL|INV-102 0.25% BID|Part 1, Cohort 2: INV-102 ophthalmic solution 0.25% administered twice daily for 2 weeks
62046829|NCT05586152|EXPERIMENTAL|INV-102 0.7% BID|Part 1, Cohort 3: INV-102 ophthalmic solution 0.7% administered twice daily for 2 weeks
62046830|NCT05586152|EXPERIMENTAL|INV-102 0.7% Three times daily (TID)|Part 1, Cohort 4: INV-102 ophthalmic solution 0.7% administered three times daily for 2 weeks
62046831|NCT05586152|EXPERIMENTAL|INV-102 TBD% BID|Part 2, Cohort 5: INV-102 ophthalmic solution administered for 2 weeks using a dose based on the results from Part 1, Cohorts 1 to 4
62046832|NCT05586152|PLACEBO_COMPARATOR|Vehicle|Part 1 (Cohorts 1-4) and Part 2 (Cohort 5): Vehicle ophthalmic solution administered two or three times daily (dependent on the cohort and the frequency of dosing of INV-102) for 2 weeks
62606342|NCT04268654|NO_INTERVENTION|Control|"Surgery without previous ischemic conditioning of the gastric conduit~Tissue pressure of oxygen measurement in both arms by Licox system. The probe is inserted directly through the skin as a cervical drainage and it is fixed by Witzel technique in the gastric conduit. It is removed after the three measurements (intraoperatively, 24h and 48h after surgery) of the PtiO2 as a normal drainage."
62248868|NCT05740033|ACTIVE_COMPARATOR|STSG arm|"Patient demographics will be recorded during the enrollment visit. During the participant's surgery in which the radial forearm free flap (RFFF) has been used, surgeons will perform a split-thickness thigh graft to close the forearm donor site. A photograph will be taken of the participants' forearm upon the removal of the dressing and splint.~On each of the two follow-up clinic visits, another photo will be taken of the forearm scar and patient-reported outcome questionnaires will be provided for completion."
62828824|NCT02931877|EXPERIMENTAL|Sevoflurane|Maintenance of anesthesia with sevoflurane during the cardiac valvular surgery.
62828825|NCT02931877|ACTIVE_COMPARATOR|Propofol|Maintenance of anesthesia propofol during the cardiac valvular surgery.
62606343|NCT04962828|EXPERIMENTAL|Collaboration group|This group of children will have targets and vocabulary that has been designed collaboratively and then the therapist and teacher both reinforce the vocabulary during the week
62606344|NCT04962828|ACTIVE_COMPARATOR|Non-collaborative group|This group of children will have targets and vocabulary that has been designed collaboratively but they will only be practiced with the therapist during the week
62046833|NCT03249051|EXPERIMENTAL|Indirect Calorimetry|The energy need is being determined by using indirect calorimetry and if necessary, optimized by parenteral, enteral and additive parenteral nutrition.
62046834|NCT03249051|NO_INTERVENTION|Standard Care|"This group receives nutrition supply according to the hospital routine (standard care)"
62046835|NCT05674760|ACTIVE_COMPARATOR|Arterial Blood Gas (ABG) arm - Control arm|Patients in this arm will undergo arterial blood gas sampling to monitor CO2 as per the British Thoracic Society guidance which is standard practice.
62046836|NCT05674760|EXPERIMENTAL|transcutaneous CO2 arm|Patients in this arm will undergo transcutaneous monitoring to monitor CO2. This will be the experimental arm.
62046837|NCT05858697||Declining group|Children with obesity 5-7 years of age who were invited to the intervention but declined participation.
62046838|NCT05858697||Interventions group|Children with obesity 5-7 years of age who accepted and subsequently received treatment.
62046839|NCT05858697||'Non intervention' group|Children with obesity at age 5-7 years living in Aarhus, who were never invited to participate in the lifestyle interventions.
62248869|NCT05740033|ACTIVE_COMPARATOR|Hatchet flap arm|"Patient demographics will be recorded during the enrollment visit. The hatchet flap closure of the forearm donor site will be performed following the RFFF's usage. A photograph will be taken of the participants' forearm upon the removal of the dressing and splint.~On each of the two follow-up clinic visits, another photo will be taken of the forearm scar and patient-reported outcome questionnaires will be provided for completion."
62828826|NCT02787902|EXPERIMENTAL|Communication|Behavioral weight loss program with communication skills training
62046840|NCT00981084|EXPERIMENTAL|armodafinil and placebo|All participants will receive one dose of armodafinil and one dose of placebo in a cross-over design
62046841|NCT01104610|ACTIVE_COMPARATOR|NIV-PSV without Target Volume|Pressure Support Non Invasive Ventilation without Target Volume
62046842|NCT01104610|ACTIVE_COMPARATOR|NIV-PSV with Target Volume|Non Invasive Pressure Support Ventilation with Target Volume set
62046843|NCT01104610|ACTIVE_COMPARATOR|NIV-CPAP|Pressure Support Ventilation in CPAP mode
62046844|NCT02386995||BIS and Entropy monitoring|Depth of anesthesia monitoring (BIS and entropy) are compared with standard clinical monitoring in patients with deep brain stimulators inserted at internalization whilst they are having a general anesthesia.
62046845|NCT04285450|EXPERIMENTAL|Vitamin K 1mg|
62046846|NCT04285450|PLACEBO_COMPARATOR|Control|
62248870|NCT03694613|OTHER|Placental/Umbilical Cord Blood sample|Placental/Umbilical Cord Blood sample will be collected after delivery from every participant.
62449380|NCT05127993|EXPERIMENTAL|Novel prosthesis|A unilateral transtibial amputee will conduct experiments with the novel prosthesis followed by experiments with the current prosthesis.
62449381|NCT05127993|ACTIVE_COMPARATOR|Current prosthesis|A unilateral transtibial amputee will conduct experiments with the current prosthesis followed by experiments with the novel prosthesis.
62828827|NCT02787902|ACTIVE_COMPARATOR|Standard|Standard behavioral weight loss program
62828828|NCT06587178|EXPERIMENTAL|SED patient|SED patients who received semi-elemental exclusive enteral nutrition.
62046847|NCT01694732|EXPERIMENTAL|varenicline with counselling|Active varenicline associated with intensive smoking cessation counselling
62248871|NCT05458050|OTHER|PU Sensor examination|Device:PU Sensor will assess the microcirculation in sacrum with and without pressure (subject will lay on side and after that on back) the total measurement time is 5-10 minutes
62828829|NCT06587178|PLACEBO_COMPARATOR|PD patient|PD patients who received polymeric exclusive enteral nutrition.
62046848|NCT01694732|PLACEBO_COMPARATOR|Placebo with counselling|Placebo of varenicline associated with intensive smoking cessation counselling
62046849|NCT05794438|EXPERIMENTAL|Adaptive Approach Bias Modification|
62046850|NCT05794438|EXPERIMENTAL|Static Approach Bias Modification|
62046851|NCT05794438|NO_INTERVENTION|Control|
62046852|NCT01685138|EXPERIMENTAL|LDK378 (Ceritinib)|Participants on this arm took oral LDK378 750 mg once daily.
62046853|NCT02908373||Case group|Nursing homes benefiting first the implementation of the coaching model (methodological help for professionals on the patient safety culture): just after the first measure (overview of the situation)
62248872|NCT05867082|EXPERIMENTAL|Neural Mobilization Group|Each participant underwent 15 treatment sessions (5 days per week for 3 weeks). Further, in the NM group, in addition to conventional treatment, 10 sessions of neural mobilization were performed.
62248873|NCT05867082|EXPERIMENTAL|Control Group|Each participant underwent 15 treatment sessions (5 days per week for 3 weeks).
62248874|NCT01851278|ACTIVE_COMPARATOR|high dose|intraarticular wrist injection of 40mg, 2ml
62248875|NCT01851278|ACTIVE_COMPARATOR|low dose|intraarticular wrist injection of 20mg, 1ml.
62449382|NCT05049044||Cohort 1: cRT-CT+IO|Concomitant radio-chemotherapy and consolidation immunotherapy (cRT-CT+IO)
62449383|NCT05049044||Cohort 2: sRT-CT+IO|Sequential radio-chemotherapy and consolidation immunotherapy (sRT-CT+IO)
62046854|NCT02908373||Control group|Nursing homes benefiting the implementation of the coaching model (methodological help for professionals on the patient safety culture): after the second measure (impact of the device on case group)
62046855|NCT04766268|EXPERIMENTAL|PAE group|Patients with BPH with moderate lower urinary tract symptoms fulfilling the inclusion criteria and exclusion criteria will be enrolled in the trial to determine safety and effectiveness of prostate artery embolization and determine factors associated with improved procedure outcome.
62046856|NCT02138630|PLACEBO_COMPARATOR|Placebo|
62046857|NCT02138630|EXPERIMENTAL|Capsaicin|"Single Capsule, Capsimax 100 mg, ingested 60 min prior to exercise"
62046858|NCT05877300|EXPERIMENTAL|Short Segment Esophageal Replacement|
62046859|NCT04995185|EXPERIMENTAL|PET/CT imaging|Intravenous injection of 370MBq ± 10% (18)F-fluoromisonidazole
62046860|NCT03371875|EXPERIMENTAL|Transition Clinics|Clinics in this arm will assess the adolescent's readiness for youth-to-adult transition using the TRAQ questionnaire. Physicians will then be given reminders based on the subject's deficiencies in transition management, and given the opportunity to intervene.
62449384|NCT05049044||Cohort 3: cRT-CT|Concomitant radio-chemotherapy (cRT-CT)
62828830|NCT04692259|EXPERIMENTAL|experimental arm|Single arm study. All patient who had an MRI performed before liver resection is included
62828831|NCT03942796|ACTIVE_COMPARATOR|lyrica, vronogabic (pregabalin)|Patients would receive oral pregabalin
62828832|NCT03942796|ACTIVE_COMPARATOR|pulsed radiofrequency ablation of the dorsal root ganglion und|Patients would receive pulsed radiofrequency ablation of dorsal root ganglion
62828833|NCT03104907|EXPERIMENTAL|Prostatic Artery Embolization|Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
62828834|NCT01808586|EXPERIMENTAL|Dexamethasone|Intra-articular corticosteroid number 2.
62828835|NCT01808586|EXPERIMENTAL|Betamethasone|Subjects will receive either betamethasone or dexamethasone injected into the cervical facet joints (levels determined by experienced physician).
62046861|NCT03371875|NO_INTERVENTION|Control Clinics|Clinics in this arm will assess the adolescent's readiness for youth-to-adult transition using the TRAQ questionnaire. No reminders will be provided to providers for care transition.
62438850|NCT01155583|EXPERIMENTAL|Arm A - Azacitidine/Lenalidomide/Dexamethasone|"Dose Level (DL) 1 - Azacitidine 30mg/m2 1x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 2 - Azacitidine 40mg/m2 1x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 3 - Azacitidine 30mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 4 - Azacitidine 40mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 5 - Azacitidine 50mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~Patients (with GFR \> 60 ml/min) receive azacitidine subcutaneously 1 or 2x per weekly and oral Dexamethasone 1x weekly starting on day 1. Patients receive oral lenalidomide 1x daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
62449385|NCT05049044||Cohort 4: sRT-CT|Sequential radio-chemotherapy (sRT-CT)
62606345|NCT03603977||Lpv/r+3TC|These cases were given simplified therapy regimen including lopinavir(200mg) and ritonavir(50mg)500 mg,oral,bid) combined with lamivudine (300 mg,oral,qd).
62606346|NCT02457832|EXPERIMENTAL|Internal guidance training (IG)|Adapted tango dancing is a sophisticated, yet accessible system of tactile communication that conveys motor intentions and goals between a leader and follower. Those in IG training will choose direction, timing and amplitude of each successive step, and will communicate this information to their partner through moving their frame and center of mass.
62606347|NCT02457832|EXPERIMENTAL|Externally guided training (EG)|Those in EG will learn to attend to sensory cues for movement direction, timing and amplitude of steps, communicated from their partner to them via the frame and center of mass. The 'follower' will wait to receive the movement cue before moving.
62606348|NCT02457832|ACTIVE_COMPARATOR|Behavioral Control (BC)|BC participants will attend group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety. Participants in this training will be instructed not to change their habitual exercise routines. After completing health education, participants will be assigned to an IG or EG training class but will not undergo evaluations.
62606349|NCT02457832|NO_INTERVENTION|Normal Control (NC)|Age-matched controls without Parkinson's disease will come in for a single assessment including MRI.
62606350|NCT01071863||Rheumatoid Arthritis (RA) Patient Group|Patients with RA who have been refered for biological drug treatment
62828836|NCT01808586|ACTIVE_COMPARATOR|Intramuscular injection|Subjects in this group will receive lidocaine injection directly into tender myofascial trigger points.
62046862|NCT05556720|EXPERIMENTAL|People living with Human Immunodeficiency Virus (HIV)|"Eligible participants living with HIV will be randomised 1:1:1 to receive a one or two doses of bivalent COVID-19 vaccine:~1. Moderna bivalent COVID-19 vaccine, SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran); 25 micrograms of imelasomeran that targets the Omicron variant BA.4-5, and 25 micrograms of elasomeran that targets the ancestral strain of SARSCoV-2.~2. Pfizer bivalent COVID-19 vaccine, COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran); 15 µg of tozinameran and 15 µg of famtozinameran.~3. TBC"
62046863|NCT05556720|EXPERIMENTAL|Solid Organ Transplant recipients|"Eligible participants who have previously received at least one solid organ transplant, including kidney, pancreas, liver, heart, lung, or any combination of these organs at least 6 weeks prior and without episodes of severe rejection requiring T- or B-cell depleting agents in the prior 3 months, will be randomised 1:1:1 to receive a one or two doses of bivalent COVID-19 vaccine:~1. Moderna bivalent COVID-19 vaccine, SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran); 25 micrograms of imelasomeran that targets the Omicron variant BA.4-5, and 25 micrograms of elasomeran that targets the ancestral strain of SARSCoV-2.~2. Pfizer bivalent COVID-19 vaccine, COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran); 15 µg of tozinameran and 15 µg of famtozinameran.~3. TBC"
62046864|NCT05556720|EXPERIMENTAL|People with Haematological Neoplasms (CLL, NHL, MM)|"Undergoing chemotherapy, immunotherapy and/or targeted therapy, or completed in the last 2 years for chronic lymphocytic leukemia, multiple myeloma or non-Hodgkin lymphoma will be randomised 1:1:1 to receive a one or two doses of bivalent COVID-19 vaccine:~1. Moderna bivalent COVID-19 vaccine, SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran); 25 micrograms of imelasomeran that targets the Omicron variant BA.4-5, and 25 micrograms of elasomeran that targets the ancestral strain of SARSCoV-2.~2. Pfizer bivalent COVID-19 vaccine, COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran); 15 µg of tozinameran and 15 µg of famtozinameran.~3. TBC"
62046865|NCT03220243|EXPERIMENTAL|MSC-AFP Single Treatment Group|Eligible patients will be treated, single treatment group, no placebo arm.
62046866|NCT01389830||Older Latinos With Cancer|Monthly Telephone Survey of Cohort with stage III or greater of breast, colorectal, or prostate cancer up until 12 months.
62046867|NCT01389830||Older Latinos Without Cancer|Single Telephone Survey of Cohort without a history of cancer.
62606351|NCT01071863||Control Group|20 people of same age and sex as the RA patient cohort
62606352|NCT02352987|EXPERIMENTAL|Patients treated with 3 drugs|Neem plus propylene glycol plus salicylic acid: Neem extract, propylene glycol (40%) and salicylic acid (10%) once daily on palm for 12 weeks
62606353|NCT02352987|ACTIVE_COMPARATOR|Patients treated with 1 drug|Salicylic acid once daily on palm for 12 weeks
62828837|NCT01808586|ACTIVE_COMPARATOR|Home exercise|Subjects in this group will receive education and a pamphlet on a set of standardized home exercises for neck pain
62828838|NCT06064279|EXPERIMENTAL|Poly-ICLC + IVIG|Patients with stage IV NSCLC will be treated with poly-ICLC + IVIG
62828839|NCT04106492|EXPERIMENTAL|Dose Escalation Cohort (10 mL SQL70)|Participants will receive 10 mL of SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion and then receive escalating doses of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.
62828840|NCT04106492|EXPERIMENTAL|Dose Escalation Cohort (20 mL SQL70)|Participants will receive 20 mL of SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion and then receive escalating doses of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.
62046868|NCT04102579|EXPERIMENTAL|Valbenazine|Capsule, administered orally once daily for 12 weeks.
62606354|NCT03570554|EXPERIMENTAL|Treatment A-D-C-B|Participants received naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by placebo for 4 days; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.
62606355|NCT03570554|EXPERIMENTAL|Treatment B-C-D-A|Participants received acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by placebo for 4 days; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.
62248876|NCT03742635|EXPERIMENTAL|GMA Assessment|"Conduct General Movements Assessment (GMA) in-person/via-telemedicne (real-time) and recorded (standard of care)"
62606356|NCT03570554|EXPERIMENTAL|Treatment C-A-B-D|Participants received celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by placebo for 4 days. Treatment periods were separated by a washout period of 3 to 7 days.
62606357|NCT03570554|EXPERIMENTAL|Treatment D-B-A-C|Participants received placebo for 4 days; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days
62606358|NCT06342583|EXPERIMENTAL|Experimental group|15 children from the experimental group will see social stories on a technological device (PC, tablet) and then see slides on a technological device concerning the correct use of social media.
62606359|NCT06342583|OTHER|Traditional group|15 children in the control group will see social stories in paper form (flashcards) and then be exposed to the explanation of risks and correct use of social media in a traditional way (flashcards).
62606360|NCT05021458|EXPERIMENTAL|Group A|Ten patients will be treated with Gong's mobilization.
62606361|NCT05021458|ACTIVE_COMPARATOR|Group B|Ten patients will be treated with SNAGs
62606362|NCT00525902|EXPERIMENTAL|Adalimumab|
62248877|NCT01165372|EXPERIMENTAL|Artesunate 2mg|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with artesunate 2mg/kg/day for 3 days and followed by DHA-PPQ treatment at doses according to National guidelines for 3 days.
62606363|NCT01040936|ACTIVE_COMPARATOR|conventional group|patients will be treated by atorvastation 20mg/d after randomization, and continued for one year.
62606364|NCT01040936|EXPERIMENTAL|intensive group|patient will be loaded with 80mg atorvastatin, continued by atorvastatin 40mg/d for 30d, then receive atorvastatin 20mg/d for the following 11 months.
62606365|NCT04585620|ACTIVE_COMPARATOR|BTX-A|"Onabotulinum toxin A is reconstructed with 4 ml of normal saline in a vial containing 100 U (Allergen Units).~At a single treatment session, test subjects receive a series of subcutaneous injections with 2,5 U Onabotulinum toxin A equivalent to 0,1 ml of solution after reconstruction. One injection is given per 1 square centimeter in the painful area in relation to the scar on the chest wall. The maximum number of subcutaneous injections is 40, equivalent to a maximum dose of 100 U of Onabotulinum toxin in a total volume of 4 ml solution. The subcutaneous injections are administered using 26G 0.45 x 15 mm cannulae and 1 ml syringes."
62606366|NCT04585620|PLACEBO_COMPARATOR|Placebo|At a single treatment session, test subjects receive a series of subcutaneous injections with one injection per 1 square centimeter in the painful area in relation to the scar on the chest wall with an inert solution, i.e. 0.1 ml injections of normal saline up to a total volume of 4 ml, depending on the area of the painful area. The subcutaneous injections are administered using 26G 0.45 x 15 mm cannulae and 1 ml syringes.
62248878|NCT01165372|EXPERIMENTAL|Artesunate 4mg|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with artesunate 4mg/kg/day for 3 days and followed by DHA-PPQ treatment at doses according to National guidelines for 3 days.
62248879|NCT01165372|EXPERIMENTAL|DHA-piperaquine|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with dihydroartemisinin-piperaquine once daily according to weight for 3 days.
62248880|NCT03564951|ACTIVE_COMPARATOR|Control|ablation of Atrial fibrillation using spatio-temporal dispersion
62046869|NCT04102579|PLACEBO_COMPARATOR|Placebo|Capsule, administered orally once daily for 12 weeks.
62248881|NCT03564951|EXPERIMENTAL|Isochrone|ablation of concordance zones using isochrone and voltage maps
62248882|NCT03540082|ACTIVE_COMPARATOR|Fall Exposure|An instructor will implicitly be exposed to the falling technique. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
62248883|NCT03540082|NO_INTERVENTION|Control|Written instructions will be provided on the correct way to fall without physical practice.
62248884|NCT03540082|OTHER|Tuck and Roll Group|An instructor will explicitly verbally and visually demonstrate the falling technique and provide feedback on participant performance. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
62606367|NCT02271399|ACTIVE_COMPARATOR|acetylsalicylic acid|aspirin 300mg tablet by mouth, every 24 hours for postoperatively 10 days
62606368|NCT02271399|EXPERIMENTAL|rivaroxaban|xarelto 10mg tablet by mouth, every 24 hours for postoperatively 10 days
62606369|NCT04748172||Study Group: Women who are planning to be vaccinated|Women that are planning to be vaccinated, before receiving the first shot of the vaccine
62046870|NCT02514018|OTHER|Immediate Group|Live-attenuated varicella-zoster virus vaccine (≥ 19,400 Plaque-forming unit - PFU) administered as a single-dose at day 0
62606370|NCT00782600|EXPERIMENTAL|50 mg oral suspension|once daily for one day
62606371|NCT00782600|EXPERIMENTAL|50 mg CR Type 1|once daily for one day
62606372|NCT00782600|EXPERIMENTAL|50 mg CR Type 2|once daily for one day
62606373|NCT00782600|EXPERIMENTAL|50 mg SR Type 3|once daily for one day
62606374|NCT05718323|EXPERIMENTAL|Treatment Arm|
62606375|NCT01214252||Permacol Patients|Patients who have undergone surgical repair of their abdominal wall defect with Permacol Surgical Implants with at least 12 months follow up.
62606376|NCT03150394|EXPERIMENTAL|Treatment of quadruple eradication therapy with GASTRUS|
62606377|NCT03150394|PLACEBO_COMPARATOR|Treatment of quadruple eradication therapy with PLACEBO|
62046871|NCT02514018|OTHER|Delayed Group|Live-attenuated varicella-zoster virus vaccine (≥ 19,400 PFU) administered as a single-dose at day 84 (+/- 3 days)
62828841|NCT04106492|EXPERIMENTAL|Cohort A|Participants will receive SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion as determined in Dose Escalation. Then will receive a lower dose than RP2D of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.
62828842|NCT04106492|EXPERIMENTAL|Phase 2a Expansion Group 1 (Extremity STS)|Participants with soft tissue sarcomas of the extremity AJCC Stage III OR IV (\>5 cm injectable tumors locally advanced and or metastatic, not amendable to primary surgical intervention and who are anthracycline naïve.
62828843|NCT04106492|EXPERIMENTAL|Phase 2a Expansion Group 2 (Unresectable STS)|Locally advanced, unresectable or metastatic, soft tissue sarcomas who are anthracycline naïve.
62828844|NCT04106492|EXPERIMENTAL|Phase 2a Expansion Group 3a (Head and Neck)|Participants with histologically or cytologically confirmed relapsed or metastatic squamous-cell carcinoma of the head and neck, who have exhausted curative intent therapies or patients with distant metastases who may have received one or less chemotherapy regimen.
62828845|NCT00702221|EXPERIMENTAL|ATV with CoVaccine HT™|Angiotensin Therapeutic Vaccine with CoVaccine HT™ adjuvant (an ingredient that may improve the immune response of the vaccine)
62828846|NCT00702221|PLACEBO_COMPARATOR|CoVaccine HT™ adjuvant alone|CoVaccine HT™ adjuvant alone
62828847|NCT05380180|EXPERIMENTAL|OneClick Social Engagement Intervention Group|Intervention group participants will receive the social engagement OneClick intervention for 8 weeks, and will complete a mid-assessment at week 4, and a post-assessment at week 8.
62828848|NCT05380180|OTHER|OneClick Social Engagement Waitlist Control Group|Waitlist control group participants will receive no intervention for the first 8 weeks and will complete assessments at week 4 and week 8. Following the completion of the 8-week controlled portion, waitlist participants will be provided with the opportunity to participate in the OneClick social engagement intervention through the intervention extension.
62828849|NCT02144610|EXPERIMENTAL|Gene Therapy HGF Plasmid (AMG0001)|Randomized subjects will receive 4 sets of intramuscular (IM) injections of HGF plasmid two weeks apart starting at Day 0 and again at Month 3 (first cycle) and at Month 9 and again at Month 12 (second cycle) in muscles of the affected lower limb.
62828850|NCT02144610|PLACEBO_COMPARATOR|Placebo|Randomized subjects will receive 4 sets of intramuscular (IM) injections of matching placebo two weeks apart starting at Day 0 and again at Month 3 (first cycle) and at Month 9 and again at Month 12 (second cycle) in muscles of the affected lower limb.
62828851|NCT06655831||IgG4-ROD|IgG4-ROD patients from the Department of Ophthalmology at Peking University Third Hospital.
62828852|NCT06655831||Lacrimal gland ptosis|Patients with lacrimal gland ptosis undergoing surgical repositioning fromthe Department of Ophthalmology at Peking University Third Hospital.
62828853|NCT06396273||participants with cognitive impairment aged 65|
62828854|NCT06396273||older adults without cognitive impairment|
62828855|NCT02819011|EXPERIMENTAL|MBB AFO Group|This group will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO for the duration of the study.
62828856|NCT02819011|ACTIVE_COMPARATOR|No MBB AFO Group|This group will be provided with a pair of New Balance 813 shoes for the duration of the study.
62828857|NCT01213888|EXPERIMENTAL|Arm II|
62828858|NCT01213888|PLACEBO_COMPARATOR|Arm I. Placebo + Pan-Retinal Photocoagulation|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
62828859|NCT05903898|EXPERIMENTAL|Patients enrolled to a primary stroke center with access to AI-software image processing tool|Patients enrolled to a primary stroke center with access to AI-software image processing tool to aid the radiologist in LVO and MeVO detection.
62828860|NCT05903898|NO_INTERVENTION|Patients enrolled to a primary stroke center without access to AI-software image processing tool|Patients enrolled to a primary stroke center without access to AI-software image processing tool to aid the radiologist in LVO and MeVO detection (standard care).
62828861|NCT02741739|EXPERIMENTAL|Reference Drug|REGN1033 Reference Formulation
62046872|NCT04166253|NO_INTERVENTION|Control group|Control group of breast cancer patients will receive adjuvant AC chemotherapy
62046873|NCT04166253|EXPERIMENTAL|Vitamin D group|Intervention group of breast cancer patients will receive adjuvant AC chemotherapy in addition to vitamin D (alfacalcidol 0.5 mcg orally once daily
62606378|NCT02720900|PLACEBO_COMPARATOR|Maltodextrin|powder, 1.8g/day
62828862|NCT02741739|EXPERIMENTAL|Test Drug|REGN1033 Test Formulation
62828863|NCT02059278|EXPERIMENTAL|T-2345|T-2345 Ophthalmic Solution dosed 1 drop QD in the eye(s) in the evening (8 pm +/- 30 minutes)
62828864|NCT02059278|EXPERIMENTAL|Xalatan|Xalatan (Latanoprost 0.005% Ophthalmic Solution) dosed 1 drop QD in the eye(s) in the evening (8 pm +/- 30 minutes)
62828865|NCT03149679|EXPERIMENTAL|Cyclophosphamide arm|Dose dense cyclophosphamide (1800 Mg/m2) administered intravenously every second week.
62828866|NCT02642185||Ablation|Patients that are primarily treated with microwave ablation of colorectal liver metastases
62828867|NCT02642185||Resection|Patients identified in the Swedish liver registry during the same time frame subjected to liver resection, propensity score matched to the ablation group
62828868|NCT04094558|ACTIVE_COMPARATOR|IBS-D|Participant diagnosed with Irritable Bowel Syndrome, diarrhea predominant, confirmed by study doctors using Rome IV criteria.
62606379|NCT02720900|ACTIVE_COMPARATOR|B-GOS|powder, 1.8g/day
62606380|NCT05442606|NO_INTERVENTION|Conservative medical therapy|Patients in this group received only medication prescribed by an Ear, Nose and Throat specialist.
62828869|NCT04094558|ACTIVE_COMPARATOR|IBS-C|Participant diagnosed with Irritable Bowel Syndrome, constipation predominant, confirmed by study doctors using Rome IV criteria.
62828870|NCT04094558|ACTIVE_COMPARATOR|Healthy Control|Participant with no ongoing medical conditions affecting GI health.
62828871|NCT00183755||1|Control participants
62828872|NCT00183755||2|Participants with MDD
62828873|NCT03135327|EXPERIMENTAL|Interventional Phase - Ocufolin Group|Participants in this group will receive the Ocufolin medical food for 6 months.
62828874|NCT03135327|NO_INTERVENTION|Observational Phase Group|Participants in this group will be studied and followed up for 1-2 years.
62606381|NCT05442606|EXPERIMENTAL|Medication and Physiotherapy program|Patients in this group received medication prescribed by an Ear, Nose and Throat specialist, in addition to integrated Physiotherapy program
62606382|NCT05481268|EXPERIMENTAL|Kinesiotaping Group|In the Kinesiotaping Group patients had muscle technique-inhibition method. An 'I' shaped tape was used for both SCM and upper trapezius.
62606383|NCT05481268|EXPERIMENTAL|Stretching Group|The patient was stretched in a relaxed and supported position and physiotherapist positioned the patient passively for stretching.
62606384|NCT05481268|OTHER|Control Group|Control Group patients, after the assessment by the dentist, the treatment method approved by the dentist was performed.
62046874|NCT05620212||RC Group|Recovery College partakers in any way (see description of intervention).
62046875|NCT05620212||Control Group|Participants with similar mental health profile as RC group, but do not participate in an RC. These participants are sampled from the Panel Psychisch Gezien (PPG), monitored by the Trimbos-institute.
62046876|NCT03103243|OTHER|Intervention|This is a single arm trial. All participants will be administered two baseline fMRIs and blood analysis prior to participation in a mindfulness group and individual mindfulness intervention sessions. A post intervention fMRI and blood analysis will complete the trial participation.
62248885|NCT04429906||test group|"Wear the pulse-oxygen monitoring finger set of the medical monitor while wearing the Huami Smart Wearable device on the ipsilateral wrist according to the instructions for use. The medical monitor displays a steady pulse oximetry level for at least 30 seconds, starts the first measurement, slides the main dial page of the wearable device to the Oxygen Saturation measurement interface, clicks the measurement button to start the single measurement of blood oxygen saturation. Record the pulse oximetry and pulse rate values measured at the same time by the medical monitor and the Huami Smart Wearable Pulse Oximetry Device, respectively. After an interval of 30 seconds, repeat the above steps to start the second measurement and record the measured value. After an interval of 30 seconds, repeat the above steps to start the third measurement and record the measured value. The average of three measurements was taken as data for the test group."
62438851|NCT01155583|EXPERIMENTAL|Arm B - Chronic Kidney Disease (CDK) Cohort|"DL (-1) - Azacitidine 30mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 1 - Azacitidine 40mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 2 - Azacitidine 50mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week~Patients (with GFR 30-59 ml/min Chronic Kidney Disease (CKD)) receive azacitidine subcutaneously 1 or 2x per weekly and oral dexamethasone 1x weekly starting on day 1. Patients receive oral lenalidomide 1x daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
62606385|NCT06529172|ACTIVE_COMPARATOR|Control|The CG group maintained their original lifestyle without engaging in regular exercise.
62606386|NCT06529172|EXPERIMENTAL|Resistance training|RT group (RG, n = 21), YJJ group (YG, n = 22), BDJ group (BG, n = 21). These groups performed the assigned exercises for 24 weeks (3 times/week, 60 min/time).
62449386|NCT05049044||Cohort 5: CT|Chemotherapy only (CT)
62606387|NCT06529172|EXPERIMENTAL|Yijinjing|RT group (RG, n = 21), YJJ group (YG, n = 22), BDJ group (BG, n = 21). These groups performed the assigned exercises for 24 weeks (3 times/week, 60 min/time).
62606388|NCT06529172|EXPERIMENTAL|Baduanjing|RT group (RG, n = 21), YJJ group (YG, n = 22), BDJ group (BG, n = 21). These groups performed the assigned exercises for 24 weeks (3 times/week, 60 min/time).
62606389|NCT05547061|EXPERIMENTAL|Phase 1 Part A(Healthy/Disease group)|Subjects are administered intravenously a single dose of 2MBq/kg of Ga-68-NGUL.
62606390|NCT05547061|EXPERIMENTAL|Phase 1 : Part B(Low dose)|Subjects with positive lesions for Ga-68-NGUL are administered intravenously with low dose(150mCi) of Lu-177-DGUL.
62606391|NCT05547061|EXPERIMENTAL|Phase 1 : Part B(High dose)|Subjects with positive lesions for Ga-68-NGUL are administered intravenously with high dose(200mCi) of Lu-177-DGUL.
62606392|NCT05547061|EXPERIMENTAL|Phase 2|Subjects with positive lesions for Ga-68-NGUL are administered intravenously with Lu-177-DGUL with the determined RP2D.
62606393|NCT05344690||cases|diabetic patients suffering from clinically confirmed diabetic retinopathy
62606394|NCT05344690||controls|matched (based on gender and duration of diabetes) diabetic patients free from diabetic retinopathy will be recruited.
62606395|NCT03906292|EXPERIMENTAL|Asciminib 60mg QD|Standard therapy of Imatinib 400 mg QD and asciminib 60 mg QD
62606396|NCT03906292|EXPERIMENTAL|Asciminb 20 mg BID|Standard therapy of Nilotinib 300 mg BID and asciminib 20 mg BID
62046877|NCT04263597|EXPERIMENTAL|2'-fucosyllactose for ages 0-5 years|Dose for ages 0-5 years: 2.5 g/day;
62046878|NCT04263597|EXPERIMENTAL|2'-fucosyllactose for ages 5.1-10 years|Dose for ages 5.1-10 years: 5 g/day;
62046879|NCT04263597|EXPERIMENTAL|2'-fucosyllactose for ages >10 years|Dose for ages \>10 years: 10 g/day;
62046880|NCT00908167|OTHER|Research Participants|Participants treated with sorafenib, cytarabine and clofarabine.
62046881|NCT02853890||pregnant woman|
62046882|NCT06324266|EXPERIMENTAL|arm CTX|Cyclophosphamide monotherapy: CTX, 0.1g×7days，1/every other week, 28 days per course of treatment,total two years
62046883|NCT06324266|PLACEBO_COMPARATOR|arm Len|Lenalidomide monotherapy:Len,10mg/day×21days， 28 days per course of treatment,total two years
62046884|NCT01050816|EXPERIMENTAL|Chondron implantation|ankle cartilage defect patients who had CHONDRON transplantation
62046885|NCT02674893|EXPERIMENTAL|type 2 diabetics treated with GLP1 analogue|
62606397|NCT03906292|EXPERIMENTAL|Asciminib 40 mg QD|Standard therapy of Nilotinib 300 mg BID and asciminib 40 mg QD
62606398|NCT03906292|EXPERIMENTAL|Asciminib 80 mg QD|Standard therapy of Dasatinib 100 mg QD and asciminib 80 mg QD
62606399|NCT03906292|EXPERIMENTAL|Asciminib 80 mg QD monotherapy|Asciminib 80 mg QD as a single agent
62606400|NCT06517173|EXPERIMENTAL|Y-3 for injection test group|The special solvent Y-3 for injection was extracted with a sterile syringe and injected into a Y-3 lyophilized powder vial for injection. The vial was artificially vibrated until the powder was completely dissolved, and then injected into 250mL 0.9% sodium chloride injection with a sterile syringe for dilution, gently shaken and mixed, and intravenous infusion was performed for 60min±10min. The treatment was performed 10 times for 10 days. The first dose should be completed as soon as possible after randomization; The time from the second dose to the first dose shall not be less than 12h, but not more than 24h+1h. The time interval of each subsequent administration is 24h±1h
62606401|NCT06517173|PLACEBO_COMPARATOR|Placebo control group|The special solvent Y-3 for injection was extracted with a sterile syringe and injected into the lyophilized powder vial of Y-3 simulant for injection. The vial was artificially vibrated until the powder was completely dissolved, and then injected into 250mL 0.9% sodium chloride injection with a sterile syringe for dilution, gently shaken and mixed, and intravenous infusion was performed for 60min±10min. The treatment was performed 10 times for 10 days. The first dose should be completed as soon as possible after randomization; The time from the second dose to the first dose shall not be less than 12h, but not more than 24h+1h. The time interval of each subsequent administration is 24h±1h
62606402|NCT02713854|EXPERIMENTAL|Endometrial biopsy group|Women who have an endometrial biopsy 2-3 months prior to IVF
62606403|NCT01668953|EXPERIMENTAL|Platelet Rich Plasma (PRP) Injection|Patients in this arm will receive a platelet rich plasma injection at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises.
62606404|NCT01668953|ACTIVE_COMPARATOR|Whole Blood Injection|Patients in this arm will receive a whole blood injection at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises.
62046886|NCT02674893|ACTIVE_COMPARATOR|Type 2 diabetics not treated with incretins|
62046887|NCT02674893|OTHER|Healthy subjects|
62046888|NCT03780348|EXPERIMENTAL|New Method|'New' weight-for-height method will be used to assess children assigned to this arm
62046889|NCT03780348|ACTIVE_COMPARATOR|Existing Method|'Existing' weight-for-height method will be used to assess children assigned to this arm
62438852|NCT04147715|PLACEBO_COMPARATOR|Part 1: Placebo|Participants received a single oral dose of matching placebo in a fasted state on Day 1.
62449387|NCT05049044||Cohort 6: CT+IO|Chemotherapy plus immunotherapy (CT+IO)
62606405|NCT01668953|ACTIVE_COMPARATOR|Dry Needle Fenestration|Patients in this arm will receive 15-25 gentle strokes of dry needling (piercing of the tendon) at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.
62606406|NCT01668953|PLACEBO_COMPARATOR|Sham Injection|Patients in this arm will receive a sham injection, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.
62606407|NCT02935582||Enstilar®|Patients for whom a new treatment strategy has been decided which involves start of topical treatment with Enstilar® according to the current local labelling
62828875|NCT00780312|NO_INTERVENTION|2|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse before onset of radiotherapy treatment.
62828876|NCT00780312|EXPERIMENTAL|1|physiotherapy
62828877|NCT02944149|ACTIVE_COMPARATOR|assistant medical officer (AMO)|Assistant medical officers (AMO) are currently allowed to provide tubal ligation by minilaparotomy, however government regulations do not allow clinical officers (COs) to provide this service.
62828878|NCT02944149|EXPERIMENTAL|clinical officer (CO)|Experimental: clinical officer (CO) In Tanzania, COs are mid-level providers who offer diagnosis, treatment, and minor surgeries. They are more common in rural areas than medical officers (MOs) and assistant medical officers (AMOs) and are generally considered capable of performing minor surgery. Almost all facilities in Tanzania are understaffed, but COs vastly outnumber MOs and AMOs. COs are more prevalent in poorer and/or rural areas than other higher level cadres; thus, task-shifting to COs would increase access to tubal ligation by minilaparotomy for many women who are most in need.
62828879|NCT06061796|EXPERIMENTAL|prone position extended|prone position extended all patients included
62828880|NCT02191111|EXPERIMENTAL|Task-focused facilitation|An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
62828881|NCT02191111|NO_INTERVENTION|Control|These sites will continue practice as usual, with no contact from study staff.
62828882|NCT02055885||Positive responders|Positive responders (R+): patients exhibiting an increase in the 6WT distance ≥ 10% and/or a decrease in dyspnea ≥ 10% (i.e., ≥ 1 point on the visual analogue scale).
62606408|NCT02935582||Other topical|Patients for whom a new treatment strategy has been decided which involves start of topical treatment not including Enstilar®
62828883|NCT02055885||negative responders|Negative responders(R-): patients exhibiting a decrease in the distance ≥ 10% and/or an increase in dyspnea ≥ 10%.
62828884|NCT06600256||pre-Viz|The number of HCM diagnosed patients (based on hospital records over the 6 months prior to site activation with the Viz HCM software) \[pre-Viz\]
62828885|NCT06600256||post-Viz|The number of HCM patients (flagged by Viz HCM and confirmed by follow-up transthoracic ECHO and/or CMR diagnostic imaging) after site activation with the Viz HCM software \[post-Viz\]
62828886|NCT05338684|EXPERIMENTAL|diagnostic catheter intervention then therapeutic if indicated|
62438853|NCT04147715|EXPERIMENTAL|Part 1: 10 mg S-648414|Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.
62438854|NCT04147715|EXPERIMENTAL|Part 1: 30 mg S-648414|Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.
62828887|NCT04636125|OTHER|Revision Total Shoulder Arthroplasty|Routine cultures are taken at the time of surgery. All patients are seen by an Infectious Disease Specialist and placed on 2 weeks oral doxycycline 100 mg (or alternative based on allergy or sensitivity) pending culture results.
62046890|NCT03780348|EXPERIMENTAL|Health Extension Workers|Health Extension workers will do weight-for-height assessment using the new method
62248886|NCT04429906||control group A|Pulse oximetry monitor/desktop ECG monitor with a medical device registration certificate was selected as reference device A. The mean value of qualified pulse oximetry measured by pulse oximetry monitor/desktop ECG monitor within 2 minutes of each successive measurement of the Huami Smart Wearable Device was used as control group A measurement.
62248887|NCT04429906||control group B|A carbon monoxide blood gas analyzer (CO-oximeter) was selected as reference device B. Arterial blood was sampled and arterial oxygen saturation (SaO2) was obtained from the blood gas analyzer as a control group B measurement.
62248888|NCT01347775|SHAM_COMPARATOR|Sham inspiratory muscle training|Patients in the sham group used the threshold trainer (Threshold at IMT device URES HS730, Respironics, New Jersey, Inc, Cedar Grove, NJ, USA), with the diaphragm removed.
62248889|NCT01347775|EXPERIMENTAL|Inspiratory muscle training|Inspiratory muscle training will be by a threshold trainer (Threshold at IMT device URES HS730, Respironics, New Jersey, Inc, Cedar Grove, NJ, USA), a commercially available spring-loaded inspiratory muscle training device. It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
62248890|NCT00902187|OTHER|Reference|fesoterodine (Toviaz™ 4 mg) tablet manufactured at Zwickau (Reference)
62248891|NCT00902187|OTHER|Test|fesoterodine (Toviaz™ 4 mg) tablet manufactured at Vega Baja (Test)
62248892|NCT04374409|EXPERIMENTAL|High-flavanol Cocoa powder|Dietary supplement: single serving of a high-flavanol cocoa powder containing 150 mg of (-)-epicatechin and 35.5 mg of (+)-catechin
62248893|NCT04374409|ACTIVE_COMPARATOR|Low-flavanol Cocoa powder|Dietary supplement: single serving of a low-flavanol cocoa powder intervention containing \< 4 mg of (-)-epicatechin and (+)-catechin and matched as best as possible for macronutrients and micronutrients, such as caffeine and theobromine.
62248894|NCT06241807|EXPERIMENTAL|Camrelizumab Plus Chemotherapy Arm|Patients were assigned to receive 3 cycles of camrelizumab (200 mg) plus chemotherapy (nab-paclitaxel, 130 mg/m2 or pemetrexed (for adenocarcinoma), 500mg/m2 plus platinum \[cisplatin, 75 mg/m2; carboplatin, area under the curve, 5\])
62248895|NCT01627002|EXPERIMENTAL|PA401|PA401 is a potent inhibitor of neutrophil activation and transmigration under development as a novel parenteral anti-inflammatory therapy for respiratory indications such as chronic obstructive pulmonary disease (COPD) and Cystic Fibrosis (CF). PA401 is a genetically engineered and recombinantly expressed mutant of the bioactive form of human interleukin-8.
62248896|NCT01627002|PLACEBO_COMPARATOR|Placebo|Placebo
62248897|NCT02525250|EXPERIMENTAL|Acute myeloïd leukemia|Realization of 3 blood samples at day 0, day 15 and day 28.
62248898|NCT00789880|EXPERIMENTAL|Vitamin D3|Subjects received a 21-day course of oral vitamin D3 (cholecalciferol, 4,000 international units \[IU\]
62248899|NCT00789880|PLACEBO_COMPARATOR|Placebo|Subjects received a 21-day course of oral vitamin D3-placebo
62248900|NCT02048618|EXPERIMENTAL|GLPG0634 200 mg QD|2 tablets of 100 mg GLPG0634 in the morning
62248901|NCT02048618|EXPERIMENTAL|GLPG0634 100 mg QD|1 tablet of 100 mg GLPG0634 and 1 placebo tablet in the morning
62248902|NCT02048618|PLACEBO_COMPARATOR|Placebo QD|2 placebo tablets in the morning
62248903|NCT01274936|EXPERIMENTAL|Qishe|
62248904|NCT01274936|PLACEBO_COMPARATOR|Control|Qishe Placebo
62606409|NCT03782974|EXPERIMENTAL|Proglucamune treatment|Participants were treated with 2 tablets of Proglucamune per day (containing 200mg of beta glucan) for a total duration of 8 weeks.
62046891|NCT03982602|EXPERIMENTAL|Subjects on Ketogenic diet|Treatment with KD will consist of 4:1 \[fat\]: \[protein + carbohydrate\] weight ratio. KD will be started as soon as the patient is ready for alimentation (while they are in neurocritical care unit). The rate of feeds will be calculated by trained dietician on service. Ketogenic diet will be continued during the entire length of ICU stay. Supplementation with vitamins, calcium and phosphorus will be done.
62046892|NCT01914835|EXPERIMENTAL|Motivational Chess & Active Control|Ten meetings of 90 minutes each.
62248905|NCT05793138|PLACEBO_COMPARATOR|Usual Care|Participants will receive usual dialysis care for 12 months, then they will receive the geriatric care model.
62248906|NCT05793138|ACTIVE_COMPARATOR|Geriatric Care Model|While specifics of the intervention will be finalized after aim 2, the investigators anticipate participants will complete the GOLD and telehealth prioritization visit. Information gathered will guide the research geriatric team's recommendation report to the participants' dialysis care team. The dialysis teams will receive training on how to use the recommendation report and local resources to initiate geriatric problem management.
62248907|NCT02231463||ultrasound measurement|"measuring subclavian vein Diameter in six Groups:~neutral positioning, PEEP 0 cm H2O, neutral positioning, PEEP 5cm H2O, neutral positioning, PEEP 10cm H2O, Trendelenburg positioning -20°, PEEP 0 cmH2O, Trendelenburg positioning -20°, PEEP 5 cmH2O, Trendelenburg positioning -20°, PEEP 10 cmH2O After these measurements a central venous catheter is used to measure the central venous pressure."
62248908|NCT01191372|PLACEBO_COMPARATOR|saline for injection|
62248909|NCT01191372|EXPERIMENTAL|ARC19499 Low Dose|
62248910|NCT01191372|EXPERIMENTAL|ARC19499 Mid Dose|
62438855|NCT04147715|EXPERIMENTAL|Part 1: 100 mg S-648414|Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1 followed by a single dose of S-648414 in a fed state (after a high-fat meal) on Day 14.
62828888|NCT06588075|EXPERIMENTAL|study group|all cases that will be allocated in this group will undergo treatment using a full digital protocol depending on planning software and the planning will be carried out into the operating room using 3D printed predictive holes surgical guides to determine accurately the optimum position of customized plates
62438856|NCT04147715|EXPERIMENTAL|Part 1: 250 mg S-648414|Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.
62438857|NCT04147715|EXPERIMENTAL|Part 1: 500 mg S-648414|Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.
62438858|NCT04147715|EXPERIMENTAL|Part 1: 1000 mg S-648414|Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.
62438859|NCT04147715|PLACEBO_COMPARATOR|Part 2: Placebo + Midazolam|Participants received matching placebo once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the placebo dose on Day 14.
62248911|NCT01191372|EXPERIMENTAL|ARC19499 High Dose|
62248912|NCT00791258|EXPERIMENTAL|1|Azor tablets and hydrochlorothiazide tablets (if necessary) will be administered for up to 20 weeks
62248913|NCT02762279|EXPERIMENTAL|Patients|"1. Patient baseline characteristics will be collected.~2. Specific nasogastric tube installation: a specific nasogastric tube equipped with pressure transducers (Gaeltec® probe) will be installed.~3. Connection of a pressure transducer to the existing chest-tube.~4. Simultaneous recordings of PES (Gaeltec®), PPL, PAW, respiratory volume and flow (5 minutes).~5. Removal of the Gaeltec® probe, and repositioning of the pre-existing nasogastric tube in the esophagus for PES measurement.~6. Simultaneous recordings of PES (feeding tube), PPL, PAW, respiratory volume and flow (5 minutes).~7. Repositioning of the nasogastric tube in the stomach, and disconnection of the different recording equipment."
62248914|NCT04924712||Patient with nephrotic syndrome idiopathic|20 nephrotic INS patients in primary visit: harvesting of 27.5 ml supplementary blood, 40 mlurine and feces at inclusion visit and at 3 months. No intervention, no treatment administration other than usual/routine INS treatment.
62248915|NCT04924712||Patient with nephrotic syndrome no idiopathic, IgA or GEM type|10 NS no idipathic patients: harvesting of 27.5 ml supplementary blood, 40 ml urine and feces at inclusion visit and at 3 months. No intervention, no treatment administration other than usual/routine care treatment.
62248916|NCT03911973|EXPERIMENTAL|Talazoparib + Gedatolisib|"Talazoparib + Gedatolisib~Phase 1:~Dose Level -1: Gedatolisib 150mg IV, Days 1,8,15,22; Talazoparib 0.75 mg/orally qd, Days 1-28 Dose Level 1: Gedatolisib 180mg IV, Days 1,8,15,22; Talazoparib 0.75 mg/orally qd, Days 1-28 Dose Level 2: Gedatolisib 180mg IV, Days 1,8,15,22; Talazoparib 1.00 mg/orally qd, Days 1-28~Phase 2:~Gedatolisib 180 mg IV on days 1, 8, 15 and 22; Talazoparib 1.00 mg once daily, Days 1-28. Subjects receiving weekly gedatolisib may continue current regimen or may switch to gedatolisib 180 mg IV on days 1, 8, and 15; Talazoparib 1.00 mg once daily, Days 1-28 (3 weeks on/ 1 week off). All changes will be permanent."
62248917|NCT01212653|ACTIVE_COMPARATOR|Golimumab|"In this 52-week, randomized, placebo-controlled study, patients will be randomized to receive either golimumab 50 mg monthly or matching placebo for 12 months using a 1:1 randomization procedure.~The doctors and patients and the nurse who administer the study medication (Golimumab) will be blinded. There will be one unblinded nurse to prepare the study medication."
62248918|NCT01212653|PLACEBO_COMPARATOR|Pacebo-controlled|"In this 52-week, randomized, placebo-controlled study, patients will be randomized to receive either Golimumab 50 mg monthly or matching placebo for 12 months using a 1:1 randomization procedure.~The doctors and patients and the nurse who administer the study medication (Golimumab) will be blinded. There will be one unblinded nurse to prepare the study medication."
62248919|NCT03932734||survey|
62248920|NCT03601936|OTHER|Infants less than 6 months of age|The Evivo Infant Gut Bifidobacterium Screening Test study is a single-group interventional study of 600 female and male infants who are less than 6 months of age and generally healthy.
62248921|NCT05525728|OTHER|patient|One cohort of patients
62248922|NCT06424951|EXPERIMENTAL|LKCMs|
62248923|NCT01805960|EXPERIMENTAL|Canakinumab|1 s.c. injection of canakinumab 150mg directly after cardioversion
62248924|NCT01805960|PLACEBO_COMPARATOR|Placebo|1 s.c. injection directly after cardioversion
62248925|NCT00380770|EXPERIMENTAL|HAART alone|Arm 1. HAART These patients will be given one tablet twice daily of Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
62248926|NCT00380770|ACTIVE_COMPARATOR|Combination HAART and chemotherapy|Arm 2. CTX PLUS HAART. HAART will be given as above. In addition, CTX will be administered at 2 weekly intervals in the Oncology Dept at KEH VIII Hospital and will consist of:- Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
62248927|NCT01648894|EXPERIMENTAL|11 weeks|The cancer surgery is practice 11 weeks after neoadjuvant radio-chemotherapy
62248928|NCT01648894|OTHER|7 weeks|The cancer surgery is practice 7 weeks after neoadjuvant radio-chemotherapy
62248929|NCT02638350|EXPERIMENTAL|Intervention lung ultrasound|All patients will have strategy with lung ultrasoundlung ultrasound
62248930|NCT02742753||Study cohort|The Total population will include all subjects included in the study. Only aggregated information will be collected for these subjects.
62248931|NCT00348920|NO_INTERVENTION|1- General Anesthesia|General Anesthesia includes administration of a routine cardiac anesthetic as per institutional norms.
62248932|NCT00348920|EXPERIMENTAL|2- High Spinal and General Anesthesia|High Spinal and General Anesthesia includes a high dose intrathecal anesthetic administered prior to the induction of a standardized cardiac general anesthetic.
62438860|NCT04147715|EXPERIMENTAL|Part 2: 50 mg S-648414 + Midazolam|Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.
62438861|NCT04147715|EXPERIMENTAL|Part 2: 30 mg S-648414 + Midazolam|Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.
62438862|NCT04147715|EXPERIMENTAL|Part 3: 100 mg S-648414 + Dolutegravir|Participants received 50 mg dolutegravir orally once a day on Days 1 to 7, 100 mg S-648414 orally once a day on Days 15 to 21, and 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.
62438863|NCT04147715|EXPERIMENTAL|Part 3: 200 mg S-648414 + Dolutegravir|Participants received 50 mg dolutegravir orally once a day on Days 1 to 7, 200 mg S-648414 orally once a day on Days 15 to 21, and 50 mg dolutegravir co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.
62438864|NCT00756964|ACTIVE_COMPARATOR|Rasburicase|patients receiving rasburicase to lower serum uric acid
62438865|NCT00756964|PLACEBO_COMPARATOR|Placebo|patients will receive a placebo
62438866|NCT01486706|EXPERIMENTAL|Gabapentin|Two to three months of behavioral therapy prior to start of Gabapentin 100mg/capsule, initially 1 capsule once a day for 1 week then titrate dosage according to symptoms until maximum dose of 1500mg/day Placebo tablet of Solifenacin Succinate will titrate dose same as Solifenacin arm according to symptoms of patient
62046893|NCT04474743||Liver Cirrhosis|Patients diagnosed with liver cirrhosis.
62248933|NCT03497806|EXPERIMENTAL|High Dose CP101|The active ingredient of CP101, Full-Spectrum Microbiota™, is derived from the stools of normal healthy donors who are highly screened, tested, and monitored in a clinically structured donation program.
62248934|NCT00300768|EXPERIMENTAL|2 mg moxidectin|2 mg moxidectin (Dose-escalation 1st step)
62248935|NCT00300768|ACTIVE_COMPARATOR|Ivermectin 150 mcg/kg|Active comparator arm (ivermectin 150 mcg/kg).
62248936|NCT00300768|EXPERIMENTAL|4 mg moxidectin|4 mg moxidectin (dose escalation second step)
62248937|NCT00300768|EXPERIMENTAL|8 mg moxidectin|8 mg moxidectin (dose escalation third step)
62438867|NCT01486706|ACTIVE_COMPARATOR|Solifenacin Succinate|Two to three months of behavioral therapy prior to Solifenacin Succinate 5mg/tablet initially 1 tablet once a day then titrate dosage according to symptoms upto maximum dose of 10mg/day Placebo form of Gabapentin will titrate dosage same as Gabapentin group according to symptoms of patient
62438868|NCT01486706|PLACEBO_COMPARATOR|Placebo|Two to three months of behavioral therapy prior to Placebo form of Gabapentin and Solifenacin and titrate accordingly same as the treatment arms
62438869|NCT06254209|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62438870|NCT06254209|EXPERIMENTAL|Verum1|Combination of clove (Syzygium aromaticum) and immortelle (Helichrysum italicum) extracts
62438871|NCT06254209|EXPERIMENTAL|Verum2|Olive fruit extract (Olea europaea)
62438872|NCT06254209|EXPERIMENTAL|Verum3|Hibiscus flower extract (Hibiscus sabdariffa)
62438873|NCT05008237|EXPERIMENTAL|Cisplatin plus docetaxel|"D1, D8 Docetaxel 35 mg/m2 + D5W 100mL MIV over 1hr D1 Cisplatin 70mg/m2 + NS 150mL MIV over 1hr every 3 weeks~Treatment will be continued until disease progression or unacceptable toxic effects."
62438874|NCT04377178|EXPERIMENTAL|Dentin chips group from automated mill|Dentin particles prepared from dentin grinder will be placed in extraction socket immediately after extraction
62438875|NCT04377178|ACTIVE_COMPARATOR|Manually milled Dentin chips|Dentin particles prepared from bone mill will be placed in extraction socket immediately after extraction.
62438876|NCT02917200|ACTIVE_COMPARATOR|MOX + CTRL|Moxifloxacin, 400 mg/day oad, 5 days + Negative control, tid, 7 days
62438877|NCT02917200|EXPERIMENTAL|MOX + DAV132 7.5 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g tid, 7 days
62438878|NCT02917200|EXPERIMENTAL|MOX + DAV132 7.5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g bid, 7 days
62438879|NCT02917200|EXPERIMENTAL|MOX + DAV132 5 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g tid, 7 days
62438880|NCT02917200|EXPERIMENTAL|MOX + DAV132 5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g bid, 7 days
62438881|NCT02917200|EXPERIMENTAL|MOX + DAV132 3.3 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3.3 g tid, 7 days
62438882|NCT02917200|EXPERIMENTAL|MOX + DAV132 3 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3 g bid, 7 days
62438883|NCT02917200|EXPERIMENTAL|MOX + DAV132 2 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 2 g tid, 7 days
62438884|NCT02917200|EXPERIMENTAL|MOX + DAV132 1.5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1.5 g bid, 7 days
62438885|NCT02917200|EXPERIMENTAL|MOX + DAV132 1 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g tid, 7 days
62438886|NCT02917200|EXPERIMENTAL|MOX + DAV132 1 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g bid, 7 days
62438887|NCT02917200|OTHER|CTRL|Negative control, tid, 7 days
62438888|NCT06312332|EXPERIMENTAL|MEDIC site|
62438889|NCT03246568|ACTIVE_COMPARATOR|Pulmonary vein isolation alone|PVI by cryo-balloon ablation without linear ablation
62046894|NCT04474743||Chronic Pancreatitis|Patients diagnosed with chronic pancreatitis.
62046895|NCT04474743||Short Bowel Syndrome|Patients diagnosed with short bowel Syndrome.
62438890|NCT03246568|EXPERIMENTAL|Renal nerve denervation|PVI by cryo-balloon ablation without linear ablation plus bilateral RND using a multi-electrode renal denervation catheter.
62438891|NCT03502421|EXPERIMENTAL|Ketamine|Continuous infusion of Ketamine 0.3 to 0.5 mg/kg per hour PCA Dilaudid 2.0-2.5 mg
62046896|NCT04474743||Control Patients|Otherwise healthy patients visiting hospital with other non-severe diseases.
62046897|NCT04474743||Healthy Controls|Healthy subjects recruited from the general population.
62046898|NCT01169675|EXPERIMENTAL|BIBW 2992 low dose|patient receives low dose tablet BIBW 2992 po daily plus pemetrexed 500mg/m\^2 on day 1 of 21 day cycle
62046899|NCT01169675|EXPERIMENTAL|BIBW 2992 medium dose|patient receives medium dose BIBW 2992 po daily plus pemetrexed 500mg/m\^2 on day 1 of 21 day cycle
62046900|NCT01169675|EXPERIMENTAL|BIBW 2992 high dose|patient receives high dose BIBW 2992 po daily plus pemetrexed 500mg/m\^2 on day 1 of 21 day cycle
62046901|NCT01169675|EXPERIMENTAL|BIBW 2992 low dose 6 day|patient receives low dose BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m\^2 on day 1 of 21 day cycle
62438892|NCT03502421|NO_INTERVENTION|Opioid Only|Patient-controlled analgesia Dilaudid 2.0-2.5 mg
62438893|NCT01140984|EXPERIMENTAL|treatment|
62438894|NCT00318266||patients with suerficial transitional cell carcinoma|
62438895|NCT06118359|EXPERIMENTAL|SITe training for accepting providers|UW Health (accepting) providers will participate in a training to learn how to utilize SITe intervention tools during EGS transfer calls.
62438896|NCT01339195|EXPERIMENTAL|Behavioral|Behavioral: French adaptation of NINDS-Canadian Stroke Network battery
62438897|NCT03137082|EXPERIMENTAL|Guanfacine XR 3mgs/daily|"* Guanfacine XR tablet by mouth every 24 hours for 12 weeks~* 21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)~* Full dose: 3mgs/d (day 21- day 70)~* 2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)"
62438898|NCT03137082|PLACEBO_COMPARATOR|Placebo (for guanfacine)|"* Guanfacine XR tablet by mouth every 24 hours for 12 weeks~* 21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)~* Full dose: 3mgs/d (day 21- day 70)~* 2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)"
62438899|NCT01844934|NO_INTERVENTION|Standard treatment|The no intervention group will receive standard treatment that includes a four hour class pre-surgery consisting of a description of the surgery, what to expect in the hospital and during recovery and some exercises to be done in preparation for surgery.
62606410|NCT03782974|PLACEBO_COMPARATOR|Placebo|Participants were treated with 2 tablets of placebo per day (contain no beta glucan) for a total duration of 8 weeks.
62606411|NCT06011304|EXPERIMENTAL|18F-Florastamin Injection|
62828889|NCT06588075|ACTIVE_COMPARATOR|control group|patients in this group will be treated using a conventional protocol of reduction depending on visualization intraoperative and tactile sensation and will be fixed using a stock miniplates and screws.
62248938|NCT01773642|EXPERIMENTAL|Cognitive-behavioral intervention|A cognitive-behavioural intervention aimed at supporting caregivers through paediatric HIV diagnosis disclosure to the child in their care.
62248939|NCT01773642|NO_INTERVENTION|Standard of Care|
62828890|NCT03324269|OTHER|NOL|"After tracheal intubation and before surgical incision, a calibration Tetanus test of 100Hz, 60 mAmp during 30 sec at remifentanil level (Ce) of 4 ng/ml will be done (starting NOL below 10).~According to the NOL response, there will be an increment of 1 ng/ml of RemiCe if NOL gradient ≥ 20 or decrement of 1 ng/ml if NOL gradient \< 10. Ideal remifentanil Ce is the remifentanil Ce at which the variation of NOL index will be less than 10 units at a NOL starting value below 10. Thus this individual remifentanil Ce will be the remifentanil level programmed before surgical incision. NOL and hemodynamic responses will be recorded during the entire duration of surgery."
62248940|NCT04215614|ACTIVE_COMPARATOR|Group Lateral Sagittal|Ultrasound-Guided lateral sagittal brachial plexus block with 1:1 ratio 2% lidocaine, and 0.5% bupivacaine
62046902|NCT01169675|EXPERIMENTAL|BIBW 2992 medium dose 6 day|patient receives medium BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m\^2 on day 1 of 21 day cycle
62248941|NCT04215614|ACTIVE_COMPARATOR|Group Costoclavicular|Ultrasound-Guided costoclavicular brachial plexus block with 1:1 ratio 2% lidocaine, and 0.5% bupivacaine
62449388|NCT05049044||Cohort 7: RT|Radiation therapy only (RT)
62046903|NCT01169675|EXPERIMENTAL|BIBW 2992 high dose 6 day|patient receives high dose BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m\^2 on day 1 of 21 day cycle
62046904|NCT02713802|EXPERIMENTAL|Test product|Propofol solution (1% \[10 mg/mL\]), via intravenous injection
62046905|NCT02713802|ACTIVE_COMPARATOR|Reference product|Propofol emulsion (1% \[10 mg/mL\]), via intravenous injection
62046906|NCT04730050|EXPERIMENTAL|Drug: TT-01025-CL|TT-01025-CL
62248942|NCT03217942|EXPERIMENTAL|Low dose|All participants will receive 5 i.m injections of NGF (1 ug/0.5ml) into the tibialis anterior muscle (either left or right leg)
62248943|NCT03217942|EXPERIMENTAL|High dose|All participants will receive 1 high dose i.m bolus injection of NGF (5 ug/0.5ml) and 4 injections of saline (control/same volume) into the tibialis anterior muscle (either left or right leg)
62248944|NCT05989698|EXPERIMENTAL|C-mo System|
62248945|NCT05178550|EXPERIMENTAL|Group 1 (low dose-high dose)|Participants receive 25 IU/kg heparin on days 1 and 2, and 50 IU/kg Heparin on days 4 and 5
62248946|NCT05178550|EXPERIMENTAL|Group 2 (high dose-low dose)|Participants receive 50 IU/kg heparin on days 1 and 2, and 25 IU/kg Heparin on days 4 and 5
62449389|NCT05049044||Cohort 8: IO|Immunotherapy only (IO)
62606412|NCT02470403|EXPERIMENTAL|Part 1: LIK066 150 mg once daily (qd)|LIK066 150 mg qd within 15 minutes before starting lunch
62606413|NCT02470403|PLACEBO_COMPARATOR|Part 1: Placebo once daily|Matching placebo tablets of LCZ696 150 mg within 15 minutes before starting lunch.
62606414|NCT02470403|EXPERIMENTAL|Part 2: LIK066 75 mg twice daily (bid)|LIK066 75 mg bid before breakfast and dinner
62606415|NCT02470403|EXPERIMENTAL|Part 2: LIK066 50 mg three times daily (tid)|LIK066 50 mg tid before all 3 meals;
62606416|NCT02470403|PLACEBO_COMPARATOR|Part 2: Placebo three times daily|Matching placebo tablets tid before meals.
62438900|NCT01844934|EXPERIMENTAL|Prehabilitation|Prehabilitation:The experimental group will receive a three week prehabilitation program prior to surgery in addition to standard treatment.
62438901|NCT03555721||Oral examination followed by biopsy, CytID, and hpvID|Identification of oral lesions with oral examination with both incandescent light and fluorescent light (OralID), and subsequent testing of suspicious oral lesions with biopsy, CytID, and hpvID
62828891|NCT01615939|ACTIVE_COMPARATOR|Single Shot Sciatic Nerve Block|Single shot sciatic nerve blocks will be performed by resident trainees supervised by faculty. Bupivacaine 0.625% with epinephrine 1:300,000 will be injected incrementally in 3-ml aliquots to a total volume of 0.4 ml/kg (minimum, 20 ml; maximum, 35 ml).
62438902|NCT02010580||Osphena|Subjects will be randomized in a ratio of 1:1 to receive either 60 mg of ospemifene (Osphena, Shionogi, Florham, NJ) or placebo tablet.
62046907|NCT04730050|PLACEBO_COMPARATOR|Drug: Placebo|Placebo of TT-01025-CL
62248947|NCT04654481|ACTIVE_COMPARATOR|Standard Care Plus Monitoring|All subjects will be monitored via home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments.
62248948|NCT04654481|EXPERIMENTAL|Standard Care Plus Monitoring and HCFWO|In addition to home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments, subject will receive an Afflovest device for home use.
62248949|NCT06363279|OTHER|Questionnaires on predisposition to the use of technology|"The questionnaire is divided into 4 main sections:~* General information: Questions on age, gender, postal code, country, socio-professional status and level of education.~* ATI questionnaire in French: Questionnaire consisting of 9 items to assess affinity for interaction with technological systems (such as mobile phones, computers, television, etc.).~* Face validity and perceived usefulness: Five statements designed to assess the face validity and perceived usefulness of the questionnaire to respondents. The response options for each statement are in the form of a Likert scale ranging from 'strongly disagree' to 'strongly agree'.~* Predisposition to use technology: Questionnaire to assess predisposition to use new technologies in general and specifically in telerehabilitation."
62248950|NCT06252259|EXPERIMENTAL|Ethnicity and Culture in Focus|"CTM (Phase 5) is a 3-month, flexible, choice-based health-promoting program for low active older adults that can be delivered in-person or online. The program includes:~* 1-on-1 Consultation: Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop a physical activity action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~* Group Meetings: Participants will attend eight, 1-hour group-based meetings (max of 15 participants) led by their activity coach. Meetings cover a health-related discussion topic and provide time and space for social connection among participants. Meetings can be held online or in-person.~The CTM program will be adapted for South Asian older adults, and may include additional intervention components customized for this population."
62438903|NCT01416376|ACTIVE_COMPARATOR|50mg SRT2379|Single oral administration of 50mg SRT2379
62438904|NCT01416376|ACTIVE_COMPARATOR|250mg SRT2379|Single oral administration of 250mg SRT2379
62438905|NCT01416376|ACTIVE_COMPARATOR|1000mg SRT2379|Single oral administration of 1000mg SRT2379
62438906|NCT01416376|PLACEBO_COMPARATOR|Placebo|Single oral administration of placebo
62438907|NCT00490061|EXPERIMENTAL|Radiotherapy and Lapatinib with DCE-MRI|DCE-MRI will precede radiotherpy before and after Lapatinib loading. 1500mg/d once daily oral Lapatinib will be administration for seven days prior to and throughout radiotherapy. Radiotherapy will be delivered as Intensity Modulated Radio Therapy (IMRT) using a G.E. Healthcare 1.5T MR, systems revision 12.0 M5 for a total dose of 70Gy delivered in 2-2.12 Gy/ fraction over the course of 6.5-7 weeks.
62438908|NCT05425966|EXPERIMENTAL|CLS-R-FUERTE|Active program participation in: a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). via school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
62438909|NCT01005550|EXPERIMENTAL|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
62438910|NCT01005550|EXPERIMENTAL|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
62438911|NCT01005550|EXPERIMENTAL|10 mg of ropivacaine|10 mg of ropivacaine are used for the spinal anaesthesia
62606417|NCT04840459|EXPERIMENTAL|BAMLANIVIMAB|The dosage of bamlanivimab in adults and pediatric patients 12 years of age and older weighing at least 40 kg is a single IV infusion of 700 mg bamlanivimab administered over at least 60 minutes
62046908|NCT02645981|EXPERIMENTAL|Donafenib|Drug:Donafenib; Dose:200mg,bid,po.
62046909|NCT02645981|ACTIVE_COMPARATOR|Sorafenib(Nexavar)|Drug:Sorafenib; Dose:400mg,bid,po.
62438912|NCT01005550|EXPERIMENTAL|12 mg of ropivacaine|12 mg of ropivacaine are used for the spinal anaesthesia
62606418|NCT04840459|EXPERIMENTAL|CASIRIVIMAB + IMDEVIMAB|10 mL of casirivimab and 10 mL of imdevimab from each respective vial using two separate syringes and dilute together in the infusion bag containing 0.9% Sodium Chloride Injection
62606419|NCT04655144|EXPERIMENTAL|Dexamethasone Arm|A total of 5mg dexamethasone will be administered into each uterine artery (10mg total) prior to uterine artery embolization.
62606420|NCT04655144|PLACEBO_COMPARATOR|Saline Arm|A volume of normal saline, equal to the total volume delivered in the Dexamethasone Arm, will be administered into each uterine artery prior to uterine artery embolization.
62046910|NCT06031532||cases group|Non-alcoholic fatty liver patients
62046911|NCT06031532||control group|healthy persons
62046912|NCT04879914|EXPERIMENTAL|Butyrate|Patients taking butyrate
62046913|NCT04879914|EXPERIMENTAL|Placebo|Patients taking placebo
62046914|NCT02108379|EXPERIMENTAL|Rhinix Nasal Filters|All included will receive rhinix nasal filters
62046915|NCT03094780|OTHER|Quality of Life Counseling|
62046916|NCT02966756|EXPERIMENTAL|Cohort 1: Venetoclax|Participants with 17p deletion status will receive various doses of venetoclax once daily (QD).
62606421|NCT03042754|OTHER|suspected TB|Patients suspected with TB will be sent for XpertMTB/RIF and urine LAM test
62606422|NCT04508114|NO_INTERVENTION|control group|Participants in the control group will not receive the ATP testing result (pretest) immediately until finished the research.
62606423|NCT04508114|EXPERIMENTAL|experimental group|Participants in the experimental group will be informed the ATP testing result (pretest) and receive the explanation by research assistant.
62438913|NCT06225583||Bertolotti's Syndrome|Subjects with Bertolotti's Syndrome.
62438914|NCT06225583||Non-Bertolotti's Lower Back Pain|Subjects without Bertolotti's Syndrome with lower back pain.
62606424|NCT02962323|EXPERIMENTAL|Test|Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets 40 mg
62438915|NCT01331785|EXPERIMENTAL|Midodrine|
62438916|NCT05583890||Healthy participants|Continuous glucose monitors will be fitted for 7 days, along with activity trackers and a food diary to monitor the impact of these factors on blood glucose concentrations. Participants will also complete questionnaires related to health inequalities and quality of life.
62606425|NCT02962323|ACTIVE_COMPARATOR|Reference|Crestor 40 mg of AstraZeneca Pharmaceuticals LP, USA
62606426|NCT03589118|EXPERIMENTAL|Qi Gong|Qi gong sessions added to usual well defined medical and psychological support
62606427|NCT03589118|NO_INTERVENTION|Control|Usual well defined medical and psychological support
62606428|NCT05099107|ACTIVE_COMPARATOR|Treatment|congenital myopathy patients in this group will receive daily oral salbutamol, three times daily.
62438917|NCT05583890||Pancreatic cancer patients undergoing chemotherapy|Continuous glucose monitors will be fitted for 7 days, along with activity trackers and a food diary to monitor the impact of these factors on blood glucose concentrations whilst they are undergoing chemotherapy. Participants will also complete questionnaires related to health inequalities and quality of life.
62606429|NCT05099107|NO_INTERVENTION|Non treatment|Congenital myopathy patients in this group will not receive any salbutamol nor placebo.
62606430|NCT01078506||Hong Kong Chinese|Without a history of known intracranial pathologies.
62606431|NCT04568291|ACTIVE_COMPARATOR|routine treatment|routine treatment
62606432|NCT04568291|EXPERIMENTAL|model treatment|model treatment
62606433|NCT02368743||mesalazine|Treatment according to standard clinical practice.
62606434|NCT01072513|OTHER|Semen analysis|Analysis of semen before and after proton radiation therapy.
62606435|NCT03437876|EXPERIMENTAL|patients with HBV induced cirrhosis|patients with HBV induced cirrhosis will be recruited for study, which involved a 4 times intestinal microbiota transplant and the time interval is generally 2 weeks.
62248951|NCT06252259|EXPERIMENTAL|Men on the Move|"CTM (Phase 5) is a 3-month, flexible, choice-based health-promoting program for low active older adults that can be delivered in-person or online. The program includes:~* 1-on-1 Consultation: Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop a physical activity action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~* Group Meetings: Participants will attend eight, 1-hour group-based meetings (max of 15 participants) led by their activity coach. Meetings cover a health-related discussion topic and provide time and space for social connection among participants. Meetings can be held online or in-person.~The CTM program will be adapted for older men, and may include additional intervention components customized for this population."
62828892|NCT01615939|ACTIVE_COMPARATOR|Continuous Sciatic Nerve Block|Continuous sciatic nerve block catheters will be performed using an insulated needle connected to the negative lead of a constant current nerve stimulator. The catheter will be advanced under ultrasound guidance. A test dose of 1.5% lidocaine with epinephrine will be injected to confirm catheter placement. All subjects will receive a portable pump that will infuse 0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr. The subjects will follow standard protocol discharge instructions in regards to removing the catheter themselves.
62828893|NCT04514861|OTHER|Tissue Oxygen Dynamics with Lumee Oxygen and TcPO2|Monitoring local subcutaneous tissue oxygen dynamics using the Wireless Lumee Oxygen Platform in correlation to TcPO2 measurements in the arm and foot
62828894|NCT02396576|NO_INTERVENTION|Usual Care|NEVHC has two main Department of Mental Health (DMH) contracted clinical partners where the majority of the patients are referred to -these are Child and Family Guidance Center (CFGC) in the San Fernando Valley and Child and Family Center (CFC) in the Santa Clarita Valley.
62828895|NCT02396576|EXPERIMENTAL|Telehealth Intervention|The telehealth model will enhance patient coordination as well as clinician communication via live videoconferencing. Developmental behavioral services will be provided by a Developmental Behavioral Pediatrician (DBP) housed at UCLA from Children's Hospital Los Angeles (CHLA). Mental Health services will be provided by Child Family Center (CFC) and Child Family Guidance Center (CFGC). The location of the telehealth visit will be at the same clinic location as the index PCP visit with a telehealth coordinator facilitating the encounter between patient and clinicians.The clinician communication will be enhanced through monthly telehealth topic-based educational sessions as well as case-based educational sessions for the transfer cases.
62248952|NCT06252259|EXPERIMENTAL|The Forgotten North|"CTM (Phase 5) is a 3-month, flexible, choice-based health-promoting program for low active older adults that can be delivered in-person or online. The program includes:~* 1-on-1 Consultation: Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop a physical activity action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~* Group Meetings: Participants will attend eight, 1-hour group-based meetings (max of 15 participants) led by their activity coach. Meetings cover a health-related discussion topic and provide time and space for social connection among participants. Meetings can be held online or in-person.~The CTM program will be adapted for older adults living in Northern BC, and may include additional intervention components customized for this population."
62248953|NCT02822950|OTHER|Ceftazadime/avibactam|Ceftazadime/avibactam 2500 mg (1250 mg for CrCl 31-50 mL/min) IV over 120 minutes, every 8 hours \[other antibiotics can also be administered as needed\]. Patients will receive at least 3 doses (steady-state) of Avycaz prior to obtaining serum samples.
62438918|NCT05583890||Pancreatic cancer patients not undergoing chemotherapy|Continuous glucose monitors will be fitted for 7 days, along with activity trackers and a food diary to monitor the impact of these factors on blood glucose concentrations. Participants will also complete questionnaires related to health inequalities and quality of life.
62438919|NCT03546582|EXPERIMENTAL|Arm I|Patients receive Stereotactic Body Radiation Therapy (SBRT) over 2 weeks and then receive pembrolizumab every 3 weeks for up to 2 years.
62438920|NCT03546582|OTHER|Arm II|Patients receive Stereotactic Body Radiation Therapy (SBRT) over 2 weeks. Arm II patients who experience progressive disease within 2 years after the start of SBRT will be allowed to cross over to receive pembrolizumab for up to 2 years.
62438921|NCT01907724|EXPERIMENTAL|IDX719 + RTV|Participants take IDX719 150 mg once daily (QD) + ritonavir 30 mg QD on Days 1-7, and then take IDX719 150 mg QD + simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 8-14.
62438922|NCT01907724|EXPERIMENTAL|Simeprevir/TMC647055 + RTV|Participants take simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 1-7, and then take IDX719 150 mg QD + simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 8-14.
62438923|NCT05798403|EXPERIMENTAL|Electroacupuncture group|"Participants will receive electroacupuncture treatment at Shenshu (BL23), Ciliao (BL32), Zhonglvshu (BL29), Huiyang (BL35), Weizhong (BL40), Zhongji (CV3), Dahe (KI12), Shuidao (ST28), Sanyinjiao (SP6). It should be noted that CV3, KI12, ST28, SP6 are used as the group A acupoints and BL23, BL32, BL29, BL35, BL40 as the group B acupoints. Patients will be treated with alternating group A and B acupoints. The frequency of treatment is 3 times a week and each treatment will last for 30 minutes for a total of 12 sessions over the course of four weeks. The follow-up observation will be recorded on week 8 and 16.~At the same time, participants will also receive placebo medication. Oral Solifenacin Succinate placebo will be used and taken once a day for 4 weeks."
62449390|NCT05049044||Cohort 9: TT|Targeted therapy only (TT)
62828896|NCT04043299|EXPERIMENTAL|Intervention|This arm will receive 100% oxygen at a rate of 10L/min for 15 minutes
62828897|NCT04043299|ACTIVE_COMPARATOR|Control|This arm will receive medical air (21% oxygen) at a rate of 10 L/min for 15 minutes
62828898|NCT05277415|ACTIVE_COMPARATOR|Ghrelin infusion|Ghrelin infusion 30 pmol/kg/min, 0.50 ml/min during 120 minutes
62606436|NCT02147522|EXPERIMENTAL|A Helping Hand (AHH)|Participants receive DHS-PCMH usual care from their respective county health clinic providers plus the AHH intervention provided by study promotoras. AHH intervention includes 6 weekly in-person or via-telephone intervention sessions followed by 3 monthly telephone booster sessions aimed at reducing the burden and strain on patients, families, and care providers by assessing, enhancing, and facilitating patient depression and co-morbid illness self-care management, and activating patient communication with clinic medical providers.
62606437|NCT02147522|NO_INTERVENTION|Usual Care (UC)|"Participants receive DHS Patient Centered Medical Home (PCMH) clinic team usual care from their respective county health clinic providers.~PCMH model has available DHS medical providers and social workers for depression care and refer patients when indicated to community mental health clinics. Problem-Solving Therapy (PST) is available in some of participating clinics."
62606438|NCT03534115|PLACEBO_COMPARATOR|Placebo|Placebo was prepared by using the same solution containing buffers that were used in the preparation of NAC solution, except it did not contain NAC
62606439|NCT03534115|EXPERIMENTAL|Experimental Arm|solution containing NAC with buffers
62606440|NCT04936659|EXPERIMENTAL|Treatment group|
62606441|NCT02201095|NO_INTERVENTION|Normal care|Normal care - no active warming
62606442|NCT02201095|ACTIVE_COMPARATOR|Forced air warming|Underbody forced air warming blanket
62828899|NCT05277415|PLACEBO_COMPARATOR|Placebo|Saline 0.50 ml/min during 120 minutes
62046917|NCT02966756|EXPERIMENTAL|Cohort 2: Venetoclax|Participants who have failed a B-Cell Receptor Signaling Pathway Inhibitor (BCRI) therapy and who have also failed, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status will receive various doses of venetoclax once daily (QD).
62248954|NCT01657097|EXPERIMENTAL|INCS|Fluticasone propionate 400 microgram daily
62248955|NCT01657097|PLACEBO_COMPARATOR|Placebo|Placebo
62248956|NCT02491567||Hashimoto Thyroiditis (HT)|Children and adolescents with Hashimoto thyroiditis either hypothyroidic or euthyroidic.
62248957|NCT02491567||Graves Disease (GD)|Children and adolescents with Graves Disease both those on remission and under antihyroid medication.
62248958|NCT02491567||Controls (C)|Healthy individuals matched for gender and age without 1) any autoimmune disease 2) family history of autoimmune disease in the first degree relatives
62248959|NCT03752775|EXPERIMENTAL|subacute device assisted group|
62828900|NCT01910298|ACTIVE_COMPARATOR|Breast Reconstruction, Direct to Implant (DTI) with Strattice™|Participants underwent immediate post-mastectomy breast reconstruction with a breast implant and Strattice™ reconstructive tissue matrix (surgical mesh).
62248960|NCT03752775|ACTIVE_COMPARATOR|subacute conventional group|
62248961|NCT03752775|OTHER|chronic device assisted group|
62606443|NCT02201095|ACTIVE_COMPARATOR|Conduction warming mattress|Underbody conduction warming mattress
62828901|NCT01910298|ACTIVE_COMPARATOR|Two Stage Breast Reconstruction|Participants underwent immediate, two-stage post-mastectomy breast reconstruction without reinforcement. Initial placement of a tissue expander that was inflated for approximately one to six months, and then replaced with an implant.
62828902|NCT04790617|EXPERIMENTAL|Intervention|Community health navigator program for six months.
62606444|NCT02698644|EXPERIMENTAL|isoamyl2cyanoacrylate|Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
62606445|NCT05100498|EXPERIMENTAL|Web-based oncofertility support tool|"User-centered design practices were used to develop an oncofertility support website for women with breast cancer before treatment. The steps of the Ottawa Decision Support Framework were used throughout the development process. A multidisciplinary steering group was assembled, and the input was provided. Guidelines from the International Patient Decision Aid Standards were applied to test the quality of the oncofertility support website.~Three steps included:~1. Identify the supportive needs of a patient;~2. Guide the development of support interventions;~3. Evaluate the quality of web-based oncofertility support."
62828903|NCT04790617|NO_INTERVENTION|Control|Usual health care.
62828904|NCT02383576||Bevacizumab|Participants who received bevacizumab in IMELDA (MO22223) P-trial and were in maintenance phase were observed.
62828905|NCT02383576||Bevacizumab and Capecitabine|Participants who received bevacizumab and capecitabine in IMELDA (MO22223) P-trial and were in maintenance phase were observed.
62828906|NCT04647188||Urology group|Includes patients undergoing prostatectomy (n=100)
62046918|NCT00796692|EXPERIMENTAL|Group 2|Low molecular weight heparin
62046919|NCT00796692|ACTIVE_COMPARATOR|Group 1|Unfractionated heparin(UFH)
62248962|NCT04221698|EXPERIMENTAL|Gait Retraining Group|Athletes from the Triathlon Plan in High Performance of the Valencian Community in Spain performing individual gait retraining sessions
62248963|NCT06428487|EXPERIMENTAL|Prolgolimab monotherapy|The patients will be treated with prolgolimab 1 mg/kg every 2 weeks during 6 months (12 cycles) until surgery
62248964|NCT03391206||presence of BCRL|presence of breast cancer related lymphedema after surgical treatment using Inbody 720 and arm circumference measurement
62248965|NCT03391206||absence of BCRL|absence of breast cancer related lymphedema after surgical treatment using Inbody 720 and arm circumference measurement
62248966|NCT06417112||Normal sinus rhythm and normotensive|"All participants are in normal sinus rhythm at the time of the transthoracic echocardiogram and no previous history of atrial fibrillation.~All participants have blood pressure measurements within normal limits and are not prescribed anti-hypertensive medication."
62248967|NCT06417112||Normal sinus rhythm and hypertensive|"All participants are in normal sinus rhythm at the time of the transthoracic echocardiogram and no previous history of atrial fibrillation.~All participants are known to have raised blood pressure measurements previously and are receiving anti-hypertensive medication."
62248968|NCT06417112||Known atrial fibrillation|All participants are known to have a history of atrial fibrillation (paroxysmal, persistent or permanent).
62248969|NCT00757536|ACTIVE_COMPARATOR|Group 1|
62248970|NCT00757536|ACTIVE_COMPARATOR|Group 2|
62606446|NCT04205461||Programmed ventricular stimulation before PVR|
62828907|NCT04647188||Colorectal group|Includes patients undergoing anterior rectal resection (n=100)
62828908|NCT04647188||Thoracic group|Includes patients undergoing lobectomy or segmentectomy (n=100)
62828909|NCT04647188||Gynaecological group|Includes patients undergoing hysterectomy (n=100)
62606447|NCT05051800|EXPERIMENTAL|Early Intervention|Families will receive the online program to support coping and communication near the time of a child's cancer diagnosis
62606448|NCT05051800|ACTIVE_COMPARATOR|Delayed Intervention|Families will receive the online program to support coping and communication approximately 6 months after a child's cancer diagnosis
62606449|NCT03764228|EXPERIMENTAL|hAECs|Infusion of hAECs at the day before HSCT and 7th days after HSCT. The dose is 1×10\^6, 2×10\^6, 5×10\^6 cell/kg, successively.
62606450|NCT05117398|EXPERIMENTAL|Dalbavancin|Dalbavancin (Xydalba®) 1500 mg - One unique dose
62606451|NCT05117398|ACTIVE_COMPARATOR|Standard documented antibiotic therapy for 14 days according to national guidelines.|"As currently recommended, investigators will be encouraged to use the intravenous route for the entire duration of treatment. However, in order to interfere as little as possible with usual practice in each center, the antimicrobial therapy will be let to the choice of the physician in charge of the patient after a minimum of 7 days of intravenous treatment.~During all the duration of the study, in case of worsening of the clinical condition requiring the prescription of antistaphylococcal, the clinician will prescribe additional antibiotherapy according to standard good practice."
62606452|NCT00718796|EXPERIMENTAL|1|Individualized naturopathic treatment consisting of dietary and lifestyle advice and individualized supplementation
62606453|NCT00718796|ACTIVE_COMPARATOR|2|Current care control provided by participants' medical doctor
62248971|NCT05913310|ACTIVE_COMPARATOR|Kui-Yuan Chewable Tablets|
62248972|NCT05913310|PLACEBO_COMPARATOR|Placebo of Kui-Yuan Chewable Tablets|
62248973|NCT01132612|EXPERIMENTAL|Fixed-time interval regimen|Secukinumab 150 mg subcutaneous (sc) administered at Week 1 (baseline) of the extension study and every 12 weeks thereafter
62248974|NCT01132612|EXPERIMENTAL|Treatment at start of relapse regimen|Placebo administered at Week 1 (baseline) of the extension study and every 12 weeks thereafter. If relapse, then switch to secukinumab 150 mg sc administered every 4 weeks
62248975|NCT01132612|EXPERIMENTAL|Open-label|Secukinumab 150 mg sc administered every 4 weeks
62248976|NCT02801955||tumor marker|serum CEA and CA 19-9 levels in patients with curative gastrectomy preoperatively and peritoneal CEA and CA 19-9 levels in patients taken at the beginning of curative gastrectomy via sampling of peritoneal washing aspirate
62248977|NCT01091584|ACTIVE_COMPARATOR|intervention group|The intervention is to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse.
62248978|NCT01091584|NO_INTERVENTION|control group|usual care
62248979|NCT05149027|EXPERIMENTAL|HBM4003+Toripalimap|HBM4003 combined with toripalimab in patients with advanced HCC and other solid tumors
62248980|NCT03873766|ACTIVE_COMPARATOR|Intrapleural fibrinolytic therapy (IPFT)|"* Procedure/Surgery: Pleural Sampling~* Procedure/Surgery: Pleural fluid drainage~* Protocol Image #1: After chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage.~* Other: Surgical Consultation~* Intrapleural Medications (IPFT): The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day.~* Protocol Image #2: Chest X-ray PA/Lateral: The morning after intervention completion, a chest X-ray PA/lateral will be obtained~* Quality of Life: Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires"
62248981|NCT03873766|ACTIVE_COMPARATOR|Surgery|"* Procedure/Surgery: Pleural Sampling~* Procedure/Surgery: Pleural fluid drainage: Chest tube placement~* Protocol Image #1: Once the chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage.~* Other: Surgical Consultation~* Surgery: The surgical arm will have either open surgery or a VATS approach at the discretion of the surgeon~* Protocol Image #2: Chest X-ray PA/Lateral: The morning after intervention completion (surgery or last dose of IPFT), a chest X-ray PA/lateral will be obtained~* Quality of Life: Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires"
62248982|NCT05010850|EXPERIMENTAL|Colovac|Patients receive Colovac during colorectal surgery
62248983|NCT05010850|ACTIVE_COMPARATOR|Standard of Care|Patients receive the standard of care, a protective stoma, during colorectal surgery
62623495|NCT06513832|NO_INTERVENTION|Standard of Care|"This arm will not have access to the Asthma Navigator.~The Children's EMR of each child will be screened weekly for up to 52 weeks. When an asthma exacerbation prompting unscheduled healthcare utilization is noted (primary outcome), or at the end of 52 weeks, participant involvement in the study will end."
62623496|NCT01187277|EXPERIMENTAL|Group A|Group A = conventional therapy means: 50 min individual physiotherapy and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
62828910|NCT04647188||HpB group|Includes pancreatic tumour resection patients (n=50)
62828911|NCT04647188||Ear, Nose & Throat group|Includes patients undergoing lateral oropharyngectomy (n=50)
62438924|NCT05798403|ACTIVE_COMPARATOR|Solifenacin Succinate group|"Participants will take Solifenacin Succinate (Wuhan Human well Puracap (Likang) Pharmaceuticals Co., Ltd.) orally before breakfast for 4 consecutive weeks at 5 mg (1 tablet) per day.~At the same time, the participants will receive sham electroacupuncture with a pragmatic placebo needle on sham acupoints. Participants will have the same needle retention time, treatment time, and follow-up time as the electroacupuncture group."
62438925|NCT01288833|EXPERIMENTAL|Close focus HD NBI Colonoscopy System|Use of close focus to make optical diagnosis
62438926|NCT01288833|NO_INTERVENTION|Current HD NBI Colonoscopy System|Use of standard focus for optical diagnosis
62438927|NCT01987804|EXPERIMENTAL|Oxytocin 100 i.u.|N=24 patients are administrated Oxytocin 100 i.u. vaginally
62438928|NCT01987804|EXPERIMENTAL|Oxytocin 400 i.u.|N=24 patients are administrated Oxytocin 400 i.u. vaginally
62438929|NCT01987804|PLACEBO_COMPARATOR|Placebo|N=16 patients are administrated placebo vaginally
62438930|NCT00058357|ACTIVE_COMPARATOR|Lidocaine patch|Participants will be instructed to apply a patch or patches (up to 3 maximum simultaneously) directly to the affected area. The patch(es) should be applied during awake hours and then left on continuously for approximately 18 hours or until usual bedtime sleep.
62449391|NCT05049044||Cohort 10: BSC|Best supportive care only (BSC)
62606454|NCT06327685|EXPERIMENTAL|Dose Escalation|"Participants will be enrolled in cohorts of size 1-3. Participants will take a combination of Avapritinib and Decitabine. Decitabine will be administered in one of the following forms: I) Decitabine: starting IV dose of 20 mg/m2 on days 1-5 of a 28-day treatment cycle. II) Decitabine/Cedazuridine: starting dose of 35mg/100 mg oral tablet on days 1-5 of a 28-day treatment cycle. The starting dose of Avapritinib for the first cohort of patients will begin at dose level 1 with dose modifications to be made according to a Bayesian design.~Avapritnib Dose levels Level -1: 50mg Level 1: 100mg Level 2: 150mg Level 3: 200mg"
62606455|NCT06327685|EXPERIMENTAL|Dose Expansion|Participants with baseline platelet count (cycle 1, day 1) ≥ 75 x 10\^9/L will begin the combination of Avapritinib at the dose determined by the dose-finding portion of the study and decitabine or Decitabine/Cedazuridine will be initiated during the first cycle. Participants with a baseline platelet count between 25 x 10\^9/L and 74 x 10\^9/L will receive decitabine or Decitabine/Cedazuridine (choice of investigator) as a single-agent for at least the first two cycles. Starting with cycle 3 and continuing with each subsequent cycle, patients will be eligible to receive Avapritinib in combination with decitabine or Decitabine/Cedazuridine if the platelet count on day 1 of the cycle is ≥ 75 x 10\^9. If the platelet count is \< 75 x 10\^9/L on day 1 of the cycle, patient will receive single-agent Decitabine or Decitabine/Cedazuridine. In the absence of clear disease progression, patients will be treated for at least 6 cycles before being judged to have not responded.
62606456|NCT03356119|EXPERIMENTAL|RemovAid arm|New IMD Subjects with contraceptive implants to be removed, are subjected to the novel device by personnel skilled in traditional removal.
62606457|NCT01706575|EXPERIMENTAL|Pegylated Interferon (Peginterferon) Alfa-2a|Participants receiving nucleos(t)ide analogues (NA) therapy with Hepatitis B surface Antigen (HBsAg) decline less than \<0.5 log 10 international unit/milliliter (IU/ml) at baseline received peginterferon alfa-2a 180 microgram (mcg), subcutaneously (SC) once weekly for 48 weeks along with their NA therapy.
62606458|NCT04982016|NO_INTERVENTION|Control group|There is no treatment before anesthesia induction.
62606459|NCT04982016|EXPERIMENTAL|Crystal group|The fluid reactivity was determined by PLR test before anesthesia induction. The basic value was measured when maintain the head height at 45° for 2 min. and the liquid reactivity value was measured when both legs were raised 45° for 2 min. If △SV \>16%, restore the head height to 45°, and 250ml carbonated Ringer's solution was infused (infusion time \>10min).
62606460|NCT04982016|EXPERIMENTAL|Colloidal group|The fluid reactivity was determined by PLR test before anesthesia induction. The basic value was measured when maintain the head height at 45° for 2 min. and the liquid reactivity value was measured when both legs were raised 45° for 2 min. If △SV \>16%, restore the head height to 45°, and 250ml colloidal fluid was infused (infusion time \>10min).
62606461|NCT01619020|ACTIVE_COMPARATOR|Flaxseed Lignans|Capsules
62606462|NCT01619020|PLACEBO_COMPARATOR|Placebo|Capsules
62606463|NCT00073892|EXPERIMENTAL|PI-88|Patients receive four consecutive days treatment each week in a 4-week cycle.
62606464|NCT02645552|EXPERIMENTAL|Tranexamic acid|Focused intervention
62606465|NCT02645552|PLACEBO_COMPARATOR|Sodium chloride|Placebo control
62606466|NCT05405660|EXPERIMENTAL|barzolvolimab 150 mg in patients with Symptomatic Dermographism|barzolvolimab 150 mg injection subcutaneous every 4 weeks for 20 weeks
62606467|NCT05405660|EXPERIMENTAL|barzolvolimab 300 mg in patients with Symptomatic Dermographism|barzolvolimab 300 mg injection subcutaneous every 8 weeks for 20 weeks
62248984|NCT01473342|OTHER|Control & Intervention Phases|The control phase will run for 8 weeks, including survey completion and accelerometer wear during Week 1 and Week 8. The intervention phase will run for the 9 weeks following the control phase; where participants are assigned a smartphone to interact with the Mila Blooms gaming app and integrated social network \& receive weekly supportive coaching phone calls from study staff for 8 weeks (Week 9 - Week 16) followed by accelerometer wear \& survey completion during the 9th and final week (Week 17).
62248985|NCT04224844|ACTIVE_COMPARATOR|Erector spinae plane block group (Group 1)|Patients will receive erector spinae plane block in addition to intravenous patient-controlled analgesia device containing tramadol.
62248986|NCT04224844|ACTIVE_COMPARATOR|Control group (Group 2)|Control group will receive only intravenous patient-controlled analgesia device containing tramadol.
62248987|NCT05805943|EXPERIMENTAL|IMM0306 Monotherapy|"Phase I dose escalation part, participants with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma (B-NHL) will be enrolled to receive IMM0306. The dose of IMM0306 will depend on when you join this study. About 1-6 participants will be enrolled at each dose level.~Phase II dose expansion part, participants will receive IMM0306 at the recommended dose that was found in dose escalation part."
62606468|NCT05405660|PLACEBO_COMPARATOR|Placebo Comparator in patients with Symptomatic Dermographism|Placebo injection subcutaneous every 4 weeks for 20 weeks
62606469|NCT05405660|EXPERIMENTAL|barzolvolimab 150 mg in patients with Chronic Inducible Cold Urticaria|barzolvolimab 150 mg injection subcutaneous every 4 weeks for 20 weeks
62606470|NCT05405660|EXPERIMENTAL|barzolvolimab 300 mg in patients with Chronic Inducible Cold Urticaria|barzolvolimab 300 mg injection subcutaneous every 8 weeks for 20 weeks
62606471|NCT05405660|PLACEBO_COMPARATOR|Placebo Comparator in patients with Chronic Inducible Cold Urticaria|Placebo injection subcutaneous every 4 weeks for 20 weeks
62606472|NCT06408311|EXPERIMENTAL|ENC-201-CED hPI|
62606473|NCT00088959|EXPERIMENTAL|Treatment (erlotinib hydrochloride, celecoxib)|Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
62606474|NCT01582763||GBS|Guillain-Barré syndrome \>1000, follow-up 1-3 years
62606475|NCT01582763||NC|Normal controls (NC)
62606476|NCT01582763||IC|Infectious controls (IC)
62606477|NCT01582763||OND|Other neurological diseases (OND)
62623497|NCT01187277|ACTIVE_COMPARATOR|Group B|Group B = conventional therapy plus robot-assisted means: 30 min individual physiotherapy plus 20 min robot-assisted gait training and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
62449392|NCT00119613|EXPERIMENTAL|Group 1 - darbepoetin alfa|Darbepoetin alfa 300 mcg QW for the first 4 weeks, followed by Q3W dosing commencing on week 5 for the remainder of the treatment period.
62606478|NCT03477994|ACTIVE_COMPARATOR|dexmedetomidine group|"Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4~+4 Combative ,+3 Very agitated ,+2 Agitated,+1 Restless, 0 Alert and calm, -1 Drowsy , -2 Light sedation, -3 Moderate sedation, -4 Deep sedation, -5 Unarrousable Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h. Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur."
62606479|NCT03477994|SHAM_COMPARATOR|clonidine group|In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4 Five ampoules of clonidine(750 μg) will be drawn up and diluted in 45ml of normal saline.
62606480|NCT03650725||Mandatory Split bowel preparation|Patients will be advised to take 4 liters of polyethylene glycol (PEG), split into two 2 liter doses. The first 2 liters are to be taken starting at 1800 hours the day before the colonoscopy, and the second dose is to be taken starting 4-5 hours prior to the scheduled time for the colonoscopy. Each dose will be taken within a 2-hour time span.
62606481|NCT03650725||Optional Split bowel preparation|Patients will be advised on split-dose bowel preparation (as per option 1), but will also receive instructions on day before bowel preparation. The instructions will indicate that split-dose bowel preparation is the optimal preparation for cleansing the bowel and for visualizing polyps, but they may choose day before bowel preparation if the split dose preparation is too difficult for them.
62606482|NCT01712334|EXPERIMENTAL|eRapid Nebulizer|Dornase alfa (Pulmozyme®) inhaled once daily by the Pari eRapid nebulizer for 2 weeks.
62606483|NCT01712334|ACTIVE_COMPARATOR|Jet Nebulizer|Dornase alfa (Pulmozyme®) inhaled once daily by the Pari LC Plus jet nebulizer for 2 weeks.
62606484|NCT00924391|ACTIVE_COMPARATOR|dairy milk|Control phase with 1% milk.
62606485|NCT00924391|EXPERIMENTAL|phytosterol enhanced soy based beverage|Treatment phase where control-phase diets are provided with phytosterol enhanced soy based beverage.
62606486|NCT01886781|EXPERIMENTAL|Lactobacillus plantarum 299v|Lactobacillus plantarum 299v capsules
62606487|NCT01886781|PLACEBO_COMPARATOR|Crytalline cellulose powder|Placebo capsule, filled with micro-crystalline cellulose powder
62606488|NCT01886781|NO_INTERVENTION|Run in period|Run in period of one to two weeks, no treatment. At baseline randomization and treatment commenced.
62606489|NCT01886781|NO_INTERVENTION|Wash out period|Wash out period of two weeks, no treatment.
62248988|NCT02934997||Community-Acquired Sepsis|The Adult ED at UF JAX is a high volume, high acuity ED which treats approximately 90,000 patients per year. All CA-sepsis patients will be recruited from the UF JAX ED. Patients meeting the recently updated definition of sepsis (suspected or confirmed infection plus ≥ 2 SOFA points) OR septic shock (hypotension not responsive to 30 mL/kg IV fluids, vasopressor requirement, and lactate ≥ 2) and being treated with an institutional, evidence-based guideline (EBG) management bundle for sepsis within 24 hours presenting to the UF Health Jacksonville Emergency Department (ED) will be approached for enrollment.
62248989|NCT02934997||Hospital-Acquired Sepsis|UFH (Gainesville) is a Level 1 Trauma Center and surgical tertiary care center with 24 trauma intensive care unit (ICU) and 24 surgery ICU beds and are the primary ICUs for almost every surgical patient in the hospital and the location for recruitment for Project #1 of the Sepsis P50. Patients meeting the recently updated definition of sepsis (suspected or confirmed infection plus ≥ 2 SOFA points) OR septic shock (hypotension not responsive to 30 mL/kg IV fluids, vasopressor requirement, and lactate ≥ 2) and being treated with an institutional, evidence-based guideline (EBG) management bundle for sepsis within 24 hours in the UFH Surgical ICU will be approached for enrollment.
62248990|NCT04636424|EXPERIMENTAL|spastic diplegic group|assessment of the speed and weight distribution during gait
62248991|NCT04636424|EXPERIMENTAL|hemiplegic group|assessment of the speed and weight distribution during gait
62438931|NCT00058357|PLACEBO_COMPARATOR|Placebo patch|Participants will be instructed to apply a patch or patches (up to 3 maximum simultaneously) directly to the affected area. The patch(es) should be applied during awake hours and then left on continuously for approximately 18 hours or until usual bedtime sleep.
62438932|NCT06378983|EXPERIMENTAL|oral isotretinoin combined with microneedle radiofrequency therapy group|Oral isotretinoin was administered using the same method as the isotretinoin group, while microneedle radiofrequency therapy was also administered.Using the Peninsula radiofrequency therapy device (Peninsula Company, China). A total of 3 treatments were conducted, with a treatment interval of 1 month, and the total course of treatment was 8 weeks.
62606490|NCT01591551|OTHER|Natalizumab (Tysabri) naive|Patients who are newly prescribed Natalizumab (TYSABRI®), but have not received their first infusion, will be invited to participate.
62606491|NCT03442166|ACTIVE_COMPARATOR|LED group|The patients (n=17) will receive daily intra and extra oral LED applications from the immediate postoperative period up to 7 days after the surgical procedure. The LED irradiation will be performed in two areas, one intra and one extra oral. The LED to be used in the intraoral site will be red, 660+/-20nm wavelength, 5 mW power, 2.7J/cm2 energy density for 7 min, 2J energy per point, knowing that the 6 irradiated spots will have 12J in total. In the extra oral site the infra-red LED will be used, 850+/-20nm wavelength, power of 5mW, 3.8J/cm2 of energy density for 10 min, 3J of energy per point, knowing that 36 will be irradiated, so we will have 108J in total.
62606492|NCT03442166|SHAM_COMPARATOR|Sham group|Patients (n=17) will be treated in the same way as the LED group. The person in charge of the application will simulate the intraoral and extraoral irradiation by positioning the LED in the same locations described for the LED group, but the equipment will be kept off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of application.
62606493|NCT02223819|EXPERIMENTAL|Crizotinib|Subjects will receive 48 weeks (12 four-week cycles) of crizotinib 250 mg PO twice a day (BID). Subjects will be evaluated by routine bloodwork and physical exam every 4 weeks while they are receiving crizotinib and during follow up period.
62438933|NCT06378983|OTHER|oral isotretinoin alone group|Oral isotretinoin capsules at a dose of 10mg/time, once per day, orally, for a total course of 8 weeks.
62828912|NCT05716802|ACTIVE_COMPARATOR|dance/movement therapy (DMT), twice a week, 12 weeks,|The multiple-session DMT intervention was applied to participants twice a week as a total of 24 sessions of 60 minutes over three months. The DMT intervention protocol was developed based on the therapist's experience, the theoretical frameworks, and the DMT approach described in a previous study (Bryl and Goodill 2019).
62828913|NCT05716802|PLACEBO_COMPARATOR|Treatment as usual (TAU), twice a week, 12 weeks,|The TAU group sessions were conducted by the licensed professional employed at the hospital. The patients received regular daily antipsychotic medication and supportive psychotherapy once a week. They also participated in daily activities from Monday to Friday for at least two hours each day, including indoor activities (watching TV, playing games, playing poker) and outside activities (walking and doing radio gymnastics).
62828914|NCT06338098|EXPERIMENTAL|Heartfulness Group|Participants in the meditation program will be provided with guided meditation and relaxation audio clips to spend approximately 20 minutes per day on the meditation and relaxation activities and participate each week in a 20-30 minutes online meditation webinar with a certified meditation trainer. All meditation and relaxation exercises can be performed in the comfort of your own home or other place of your choosing. The intervention will be entirely online.
62828915|NCT06338098|NO_INTERVENTION|Control Group|The control group had no change in their daily routines.
62828916|NCT02887677|ACTIVE_COMPARATOR|Dapagliflozin|Dapagliflozin for oral administration. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group.
62828917|NCT02887677|PLACEBO_COMPARATOR|Placebo|Placebo for oral administration. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group.
62248992|NCT01188720|NO_INTERVENTION|Baseline|Assessment only baseline
62248993|NCT01188720|EXPERIMENTAL|Acute exercise|Exercise immediately before sexual activity, three times per week.
62248994|NCT01188720|ACTIVE_COMPARATOR|General exercise|Exercise not immediately before sexual activity, three times per week.
62248995|NCT05571748|EXPERIMENTAL|G6PD deficiency (only) - Intervention|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 10 G6PD deficient individuals.
62248996|NCT05571748|PLACEBO_COMPARATOR|G6PD deficiency (only) - Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 120 G6PD deficient individuals.
62828918|NCT02283853|EXPERIMENTAL|BG00012|Participants will receive the recommended dose of 240 mg orally, twice a day
62828919|NCT02283853|ACTIVE_COMPARATOR|IFN β-1a (Avonex)|Participants will receive the recommended dose of 30 μg (weekly)
62828920|NCT06507774||3D reconstruction|Patients in this group underwent surgical planning with the aid of 3D reconstruction technology, which included preoperative imaging and 3D modeling to assist in the planning of thoracic surgery.
62248997|NCT05571748|EXPERIMENTAL|G6PD deficiency and CHO metabolism disorder - Intervention|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 10 individuals with G6PD deficiency and a CHO metabolism disorder.
62248998|NCT05571748|PLACEBO_COMPARATOR|G6PD deficiency and CHO metabolism disorder - Placebo|Placebo for 4 weeks in a counterbalanced manner to 10 individuals with G6PD deficiency and a CHO metabolism disorder.
62248999|NCT05571748|EXPERIMENTAL|CHO metabolism disorder (only) - Intervention|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 10 individuals with a CHO metabolism disorder.
62249000|NCT05571748|PLACEBO_COMPARATOR|CHO metabolism disorder (only) - Placebo|Placebo for 4 weeks in a counterbalanced manner to 10 individuals with a CHO metabolism disorder.
62249001|NCT05571748|EXPERIMENTAL|Controls - Intervention|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 10 individuals without G6PD deficiency and/or any CHO metabolism disorder.
62828921|NCT06507774||Non-3D reconstruction|Patients in this group underwent traditional surgical planning without the use of 3D reconstruction technology, relying on standard preoperative imaging and planning techniques.
62828922|NCT05943600||Osteoporosis patients|Participants will fill out the self-report scales.
62249002|NCT05571748|PLACEBO_COMPARATOR|Controls - Placebo|Placebo for 4 weeks in a counterbalanced manner to 10 individuals without G6PD deficiency and/or any CHO metabolism disorder.
62249003|NCT05619302|EXPERIMENTAL|[68Ga]CBP8 PET/MRI Amyloid Subjects|Individuals with documented cardiac amyloidosis will undergo \[68Ga\]CBP8 PET/MRI.
62249004|NCT05619302|ACTIVE_COMPARATOR|[68Ga]CBP8 PET/MRI Recent Myocardial Infarction Subjects|Individuals with recent myocardial infarction will undergo \[68Ga\]CBP8 PET/MRI.
62249005|NCT05619302|PLACEBO_COMPARATOR|[68Ga]CBP8 PET/MRI Healthy Controls|Individuals without documented cardiovascular disease will undergo \[68Ga\]CBP8 PET/MRI.
62249006|NCT05619302|ACTIVE_COMPARATOR|[68Ga]CBP8 PET/MRI Hypertrophic Cardiomyopathy Subjects|Individuals with hypertrophic cardiomyopathy will undergo \[68Ga\]CBP8 PET/MRI.
62249007|NCT02663050|EXPERIMENTAL|Kinesio taping group|only Kinesio taping treatment group
62249008|NCT02663050|ACTIVE_COMPARATOR|NSAID treatment group|only NSAIDs taking group
62249009|NCT02663050|ACTIVE_COMPARATOR|Combination treatment group|NSAIDs plus Kinesio taping group
62249010|NCT01145716|OTHER|Surgical exploration|Descriptive
62249011|NCT00437502|EXPERIMENTAL|tumor peptide vaccine|2 cohorts: High and low dose tumor peptide vaccine
62249012|NCT00909233||Group 1|
62249013|NCT02361827||A1, Vitamin D deficient|Vitamin D level before cycle \< 20 ng/mL.
62438934|NCT05307263|ACTIVE_COMPARATOR|Atherectomy plus DCB|
62249014|NCT02361827||B1, Vitamin D insufficient|Vitamin D level before cycle 20-29.9 ng/mL
62606494|NCT03482791|EXPERIMENTAL|Arm 1: Resectable (proton beam therapy)|"* Proton beam therapy: total dose of 50 or 50.4 Gy~* Standard of care chemotherapy - the clinical trial doesn't dictate anything about the chemotherapy given, it is the treating physician's decision~* Surgery should ideally be performed no later than 8 to 10 weeks after completing chemoradiation~* Patient-reported outcome measures (PROs) performed at several time points"
62606495|NCT03482791|EXPERIMENTAL|Arm 2: Unresectable (proton beam therapy)|"* Proton beam therapy: total dose of 59.4 or 60 Gy~* Standard of care chemotherapy - the clinical trial doesn't dictate anything about the chemotherapy given, it is the treating physician's decision~* Patient-reported outcome measures (PROs) performed at several time points"
62606496|NCT06047132||Periodontal health status|Categorized according to 2018 classification of periodontal diseases (Papapanou et al. 2018), including healthy, gingivitis, treated periodontitis (stable/unstable), periodontitis Stages I \& II, and periodontitis Stages III and IV.
62606497|NCT06598371|EXPERIMENTAL|Backfill IL-2: Treatment with Lymphodepletion and KSQ-004EX + IL-2|Participants will receive KSQ-004EX and pre-medicated with cyclophosphamide and fludarabine to prevent the lymphodepletion of the chemotherapy.
62249015|NCT02361827||C1, Vitamin D replete|Vitamin D level before cycle \> 30 ng/mL
62249016|NCT02361827||A2, Vitamin D deficient|Vitamin D level before ET \< 20 ng/mL (FET with Euploid embryos)
62249017|NCT02361827||B2, Vitamin D insufficient|Vitamin D level before ET 20-29.9 ng/mL (FET with Euploid embryos)
62249018|NCT02361827||C2, Vitamin D replete|Vitamin D level before ET \> 30 ng/mL (FET with Euploid embryos)
62249019|NCT01377064|EXPERIMENTAL|Physical activity group|Subjects will participant in physical activity program
62249020|NCT01377064|ACTIVE_COMPARATOR|Standard care group|This group will not receive a physical activity intervention
62249021|NCT06393582|EXPERIMENTAL|Accuracy of full-arch implant impressions|Conventional and digital impressions will be made for each patient to compare the accuracy.
62249022|NCT04299191|EXPERIMENTAL|Dose Escalation|"The dose level corresponds to 80% of the maximum tolerated dose of LAM561 in adult patients when adjusted for body surface area. The escalation will be to the 100%, and 120% of the maximum tolerated dose of LAM561 in adult patients when adjusted for body surface area. Dose escalation decisions will be made by all active Investigators in collaboration with the Medical Monitor when at least three patients have completed the DLT observation period (Cycle 1) at each dose level. When the third patient at any given dose level has received 14 days of therapy, an escalation teleconference will be scheduled after that patient has completed the DLT observation period (Cycle 1). The decision to progress to the next dose level will be made on the basis of review of all significant LAM561-related toxicities."
62606498|NCT06598371|EXPERIMENTAL|Phase 1 mLDC: Treatment with Modified Lymphodepletion and KSQ-004EX|Participants will receive KSQ-004EX and pre-medicated with cyclophosphamide and fludarabine to prevent the lymphodepletion of the chemotherapy.
62606499|NCT06598371|EXPERIMENTAL|Phase 1/Phase 2: Treatment with Lymphodepletion and KSQ-004EX|Participants will receive KSQ-004EX and pre-medicated with cyclophosphamide and fludarabine to prevent the lymphodepletion of the chemotherapy.
62249023|NCT00393952|EXPERIMENTAL|1|FlutiForm 250/10
62438935|NCT05307263|ACTIVE_COMPARATOR|DCB|
62438936|NCT03207659|EXPERIMENTAL|Dusting|small stones will be left to pass spontaneously.
62438937|NCT03207659|EXPERIMENTAL|Basketing|stones will be actively extracted.
62438938|NCT02058433|EXPERIMENTAL|pharmacokinetics group|Based on pharmacokinetics. Observe safety and efficacy. In first cycle a fixed Paclitaxel dose depends on BSA. In subsequent cycles the dosage of Paclitaxel will be adjusted depending on pharmacokinetics follow up .
62438939|NCT02058433|ACTIVE_COMPARATOR|Body surface area(BSA) group|Based on body surface area. The dosage of Paclitaxel is based on the BSA of the patient. Paclitaxel/carboplatin up to 4 cycles or disease progression or intolerable toxicity.
62249024|NCT00393952|ACTIVE_COMPARATOR|2|FlutiForm 100/10
62249025|NCT00393952|ACTIVE_COMPARATOR|3|Fluticasone 250
62249026|NCT00393952|ACTIVE_COMPARATOR|4|Formoterol 10
62249027|NCT00393952|PLACEBO_COMPARATOR|5|Placebo
62438940|NCT05114226|EXPERIMENTAL|experimental group (BH4 solvent 50 ug/ml)|A sterile gauze was soaked with BH4 solvent (50 ug/ml), wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
62438941|NCT05114226|EXPERIMENTAL|experimental group (BH4 solvent 100 ug/ml)|A sterile gauze was soaked with BH4 solvent (100 ug/ml), wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
62449393|NCT00119613|PLACEBO_COMPARATOR|Group 2 - Placebo|Placebo QW for the first 4 weeks, followed by Q3W dosing commencing on week 5 for the remainder of the treatment period.
62438942|NCT05114226|EXPERIMENTAL|experimental group（BH4 solvent 200 ug/ml)|A sterile gauze was soaked with BH4 solvent (200 ug/ml), wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
62606500|NCT03896672|EXPERIMENTAL|Treatment with Continuous Positive Airway Pressure|All patients will undergo to physiotherapeutic treatment based on the previous training of the physiotherapist
62606501|NCT03458923|ACTIVE_COMPARATOR|Group A|15 eyes will receive 0.1 ml containing 500µg of diclofenac intravitreally, repeated monthly for 3 months.
62606502|NCT03458923|ACTIVE_COMPARATOR|Group B|15 eyes will receive 0.5 mg Ranibizumab intravitreally, repeated monthly for 3 months.
62606503|NCT06027502|EXPERIMENTAL|Passive Heating|Passive heating will be achieved by approximately 45 min of immersion in a Hot Tub at 40 degrees celsius
62606504|NCT06181630|EXPERIMENTAL|Lactating women receiving treatment with Ozanimod and their infants|
62606505|NCT03860116|EXPERIMENTAL|Intervention group|participants in this arm receive the APP-based case management service and standard-of-care followup service.
62606506|NCT03860116|ACTIVE_COMPARATOR|control group|participants in the control arm receive standard-of-care followup service
62046920|NCT03149068||75 patient|Seventy five (75) CKD patients in different stages will be included in our study from Nephrology unit, Internal Medicine department, Assuit University Hospital
62249028|NCT02308631|EXPERIMENTAL|Colostomy with colopexy by endoscopy|Colostomy with colopexy by endoscopy. 5 porks underwent endoscopic assisted colostomy with percutaneous colopexy. Animals were evaluated in post-operative days 1, 2, 5 and 7 Procedure/Surgery: ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY
62249029|NCT06392295|EXPERIMENTAL|PSMA-Guided PA-RT Group|"Participants in this group will undergo up to six months of systemic androgen deprivation therapy (ADT) and Androgen receptor signaling inhibitor (ARSI). During system therapy, participants will undergo five weeks of para-aortic radiation therapy.~Total participation duration is up to five years."
62249030|NCT06018818|OTHER|Amvia pacemaker or CRT-P implantation|
62249031|NCT06116227|EXPERIMENTAL|Group A: Whole Body Vibration Training plus conventional physical therapy exercise program|30 patients received whole body vibration training on a vibration platform for 12-15 minutes, 3 times per week, plus a traditional physical therapy exercise program in the form of a 60-minute supervised exercise program for 8 weeks.
62249032|NCT06116227|EXPERIMENTAL|Group B: Conventional Physical Therapy Exercise Program.|30 patients will receive a traditional physical therapy program. The program consists of 60 minutes of supervised exercise stretching exercise to all involved joints followed by strengthening for affected muscles for 8 weeks.
62249033|NCT03385720|EXPERIMENTAL|Experimental group|
62249034|NCT03385720|ACTIVE_COMPARATOR|Control group|
62249035|NCT03056560|EXPERIMENTAL|Video Bystander Program|TakeCARE video
62249036|NCT03056560|NO_INTERVENTION|Control Video|Study Skills Video
62438943|NCT05114226|EXPERIMENTAL|experimental group（BH4 solvent 400 ug/ml)|A sterile gauze was soaked with BH4 solvent (400 ug/ml), wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
62046921|NCT03149068||25 healthy control|twenty five (25) age and sex matched apparently healthy individuals will be enrolled as controls
62438944|NCT05114226|EXPERIMENTAL|experimental group（BH4 solvent 600 ug/ml)|A sterile gauze was soaked with BH4 solvent (600 ug/ml), wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
62438945|NCT05114226|EXPERIMENTAL|experimental group（BH4 solvent 800 ug/ml)|A sterile gauze was soaked with BH4 solvent (800 ug/ml), wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
62449394|NCT03361423|ACTIVE_COMPARATOR|treatment of migraine with active device|Treatment of acute migraine with an active form of Nerivio migra-1 device
62606507|NCT03025568|ACTIVE_COMPARATOR|group 1|Patient will receive partial denture constructed from Bre_flex
62606508|NCT03025568|EXPERIMENTAL|group 2|Patients will receive removable partial denture constructed from PEEK
62606509|NCT03824821||IBS|
62606510|NCT02938624|EXPERIMENTAL|cohort1|Pembrolizumab 200 mg I.V single dose
62606511|NCT02938624|EXPERIMENTAL|Cohort II|Pembrolizumab 200 mg I.V Twice interval 21 days
62046922|NCT00404365|EXPERIMENTAL|Arm I (control)|Arm I (control): Patients complete screening questionnaires about their mood and experience with lung cancer once before and once after a visit with their physician. Neither the patient nor physician receives the screening results before the visit.
62046923|NCT00404365|EXPERIMENTAL|Arm II|Arm II: Patients complete screening questionnaires as in arm I. Only the patient receives the screening results before their visit with the physician; the physician remains blinded to the results.
62249037|NCT01145014|EXPERIMENTAL|BI 660848 2 mg|oral drinking solution
62249038|NCT01145014|EXPERIMENTAL|BI 660848 10 mg|oral drinking solution
62249039|NCT01145014|EXPERIMENTAL|BI 660848 20 mg|oral drinking solution
62249040|NCT01145014|EXPERIMENTAL|BI 660848 50 mg|oral drinking solution
62249041|NCT01145014|EXPERIMENTAL|BI 660848 100 mg|oral drinking solution
62606512|NCT02938624|EXPERIMENTAL|Cohort III|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
62606513|NCT02938624|EXPERIMENTAL|COHORT -1|Pembrolizumab 100 mg I.V single dose
62606514|NCT01007292|EXPERIMENTAL|YM155 plus rituximab|
62606515|NCT05072275||Subjects receiving care from Scripps Health physicians in Cardiology and Primary Care|A confidential data request will be submitted to screen the Scripps Health EHR system for individuals meeting study inclusion criteria and having seen a participating study physician in the past two years.
62623498|NCT04999449|EXPERIMENTAL|Pharmacokinetic|Participants receive 1 dose of Scopolamine 0.4 mg delivered via a intranasal nebulizer developed by Creare LLC.
62438946|NCT05114226|EXPERIMENTAL|experimental group（BH4 solvent 1000 ug/ml)|A sterile gauze was soaked with BH4 solvent (1000 ug/ml), wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
62438947|NCT01952574|PLACEBO_COMPARATOR|Placebo|"Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
62438948|NCT01952574|EXPERIMENTAL|Erenumab 7 mg QM|"Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
62438949|NCT01952574|EXPERIMENTAL|Erenumab 21 mg QM|"Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
62606516|NCT05846217|EXPERIMENTAL|PBMT Group|"In PBMT group, we choose 9 points on the affected face, include Mastoid, Preauricular, Temple, Frontalis muscle, Zygomatic muscle, Buccinator muscle, Masseter, Orbicularis oris and Depressor angulli oris. Based on clinical experience, we choose 7 acupoints, including LI4 (HeGu), LI11(QuChi), ST25 (TianShu), ST36 (ZuSanLi), SP6 (SanYinJiao), KI3 (TaiXi), LR3 (TaiChong). All the acupoint were applied bilaterally.~Laser divice directly contacts the points. All those points near the superficial roots of facial nerve. At each point, we treated for 1min, 1500 Hz, 50% laser intensity. And patients in PBMT group wore safety glasses to prevent eye damage during the laser sessions. All treatments were performed in the outpatient clinic by the same physician."
62606517|NCT05846217|SHAM_COMPARATOR|Control Group|Patients in the control group received no intervention but were free to pursue therapies if desired.
62606518|NCT03870529|EXPERIMENTAL|Vitamin A compound|Participants receive vitamin A compound PO for 7 consecutive days in the absence of disease progression or unacceptable toxicity. Within 21 days of completing treatment, participants then undergo surgical resection.
62606519|NCT03870529|ACTIVE_COMPARATOR|Therapeutic Conventional Surgery|Description Participants undergo surgical resection.
62828923|NCT06587971|EXPERIMENTAL|Comprehensive Periodontal Intervention Group|"Administering the current guideline-recommended comprehensive periodontal treatment protocol to participants, which includes:~Oral hygiene education: Providing guidance on proper brushing techniques, smoking cessation, dietary control, and blood sugar management.~Standard periodontal treatment protocol: Administering standard treatments for chronic periodontitis according to the current guidelines, including supragingival scaling, subgingival scaling, root planing, and periodontal flap surgery."
62828924|NCT06587971|PLACEBO_COMPARATOR|Oral hygiene education group|Administering Oral Hygiene Education to Participants. Providing guidance on proper brushing techniques, smoking cessation, dietary control, and blood sugar management.
62828925|NCT03525236|EXPERIMENTAL|Taste of 5 flavors|"* Each patient will taste 5 products, in sequential-monadic test, randomized, one by one.~* Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients)~* For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product.~* Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes"
62828926|NCT01235312||Healthy subjects|
62828927|NCT01235312||Patients suffering from Diabetes mellitus|
62249042|NCT01145014|EXPERIMENTAL|BI 660848 150 mg|oral drinking solution
62249043|NCT01145014|EXPERIMENTAL|BI 660848 200 mg|oral drinking solution
62249044|NCT01145014|EXPERIMENTAL|BI 660848 400 mg|oral drinking solution
62249045|NCT01145014|EXPERIMENTAL|BI 660848 600 mg|oral drinking solution
62606520|NCT02453854|ACTIVE_COMPARATOR|Treatment as Usual|A Treatment as Usual (TAU) group received a psycho-educational programme for weight management over one year
62606521|NCT02453854|EXPERIMENTAL|Group Motivational Intervieiwng|A Motivational interviewing group received one year of programme using motivational interviewing as the approach for treatment.
62606522|NCT00693602|EXPERIMENTAL|1|
62828928|NCT01235312||Patients suffering from peripheral arterial occlusive disease|
62828929|NCT03405246|ACTIVE_COMPARATOR|KIDFIT SAFE|The Control Group will be provided 12 web-based monthly Homestyles Safe Guides about safe home environments for raising children and related material emailed monthly to the moms. KIDFIT Safe web site targets environmentally safe childcare related topics such as use of sun screen, avoidance of choking hazards, pet safety, protection from electrical appliances, etc. KIDFIT Safe participants will attend both baseline and 12 month clinical visits.
62046924|NCT00404365|EXPERIMENTAL|Arm III|Arm III: Patients complete screening questionnaires as in arm I. Only the physician receives the screening results before their visit with the patient; the patient remains blinded to the results.
62249046|NCT01145014|EXPERIMENTAL|BI 660848 10,0 mg|immediate release tablet
62249047|NCT01145014|EXPERIMENTAL|BI 660848 50,0 mg|immediate release tablet
62249048|NCT01145014|EXPERIMENTAL|Placebo|matching placebo (oral drinking solution and IR tablets)
62249049|NCT03812484|EXPERIMENTAL|SCF Parole|Parolee supervised under the SCF Supervision model
62249050|NCT03812484|ACTIVE_COMPARATOR|Parole-As-Usual|Parolees are supervised under standard parole supervision practice in New Jersey.
62249051|NCT01321359|PLACEBO_COMPARATOR|Vehicle|Vehicle
62249052|NCT01321359|ACTIVE_COMPARATOR|Active|Active NB-001(0.3%)
62249053|NCT06190236|EXPERIMENTAL|Experimental|This arm with utilize a stand-alone web-based cognitive behavioral therapy (CBT4CBT) for alcohol use disorder
62249054|NCT06190236|NO_INTERVENTION|Control|No intervention
62249055|NCT03970850|ACTIVE_COMPARATOR|Multi-arm - Symptomatic and Asymptomatic Males|Arm 1 - Urine from males subjects
62249056|NCT03970850|ACTIVE_COMPARATOR|Multi-arm - Symptomatic and Asymptomatic Females|Arm 2 - Endocervical, self-collected (in the clinical setting) and physician-collected vaginal swabs and urine from female subjects
62606523|NCT00975858|ACTIVE_COMPARATOR|Percutaneous Coronary Intervention|
62828930|NCT03405246|EXPERIMENTAL|KIDFIT HEALTHY|The KIDFIT intervention group combines traditional in-person and electronic participant contacts, including two scheduled individual visits with a nutrition coach, coaching calls throughout the year, and monthly group videoconferencing-type sessions. KIDFIT Healthy participants will attend both baseline and 12 month clinical visits.
62828931|NCT04135274||Sepsis group|
62828932|NCT04135274||Non Sepsis group|
62046925|NCT00404365|EXPERIMENTAL|Arm IV|"Arm IV: Patients complete screening questionnaires as in arm I. Both physician and patient receive the screening results before the visit.~All patients and physicians are notified of the screening results before the patient leaves the clinic. All patients are offered supportive counseling."
62046926|NCT06578936|EXPERIMENTAL|abdominal massage and warm application group|The experimental group will receive abdominal massage and warm application 2 times a day, morning and evening, until defecation, starting from the evening of the first day after the surgical intervention.
62046927|NCT06578936|NO_INTERVENTION|control group|In the control group, bowel sounds will be listened during hot application and abdominal massage hours, daily laxative use will be determined and recorded in the Excretory Activity Form.
62046928|NCT01717781|EXPERIMENTAL|Thunderbeat|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with Thunderbeat technology: using Thunderbeat technique, surgeons can avoid changing instruments during surgery since Thunderbeat combines bipolar energy for haemostasis and ultrasound for dissection and cut.~Thunderbeat is used to divide the round ligaments, to seal ovarian pedicles, to open the anterior and posteriors leaves of the broad ligaments peritoneum, to incise the bladder peritoneum, to develop the paravesical and pararectal spaces, to seal uterine arteries and uterine pedicles, to dissect the bladder and develop rectovaginal septum, to unroof the ureter, to cut parametria, and to divide the uterosacral ligaments. Monopolar hook is used in the culdotomy. Thunderbeat is also used to perform pelvic lymphadenectomy."
62249057|NCT03970850|ACTIVE_COMPARATOR|Multi-arm - FDA cleared NAATs (Comparator)|Arm 3 - Comparator (for females - vaginal and urine NAATs and for males - 3 urine NAATs)
62828933|NCT05625308|EXPERIMENTAL|Co-treatment with EGCG, FA, B12, and HA|One tablet per day containing 200 mg of EGCG, 400 mcg of Folic Acid, 1 mg of Vitamin B12 and 50 mg of Hyaluronic Acid for twelve weeks.
62828934|NCT05625308|NO_INTERVENTION|Control|Untreated women.
62828935|NCT00812708|EXPERIMENTAL|Morcher iris diaphragm implantation|This is a non-randomized, non-comparative interventional surgical series. Patients will undergo Morcher iris diaphragm implantation in their affected eye(s). After surgery, patients will complete 5 postoperative examinations. At each examination, they will be evaluated for changes in light and glare sensitivity and visual acuity. They will also be monitored for adverse reactions.
62828936|NCT00338845|EXPERIMENTAL|1|Participants will receive the Share Safer Sex counseling program
62828937|NCT00338845|ACTIVE_COMPARATOR|2|Participants will receive a standard didactic safer-sex counseling session
62828938|NCT05007054||Percutaneous coronary intervention|The PCI performed following current standard guidelines. All patients were pre-treated with aspirin and clopidogrel before catheterization. Thereafter, heparin (70-100 IU/kg) was administered before PCI, however, the use of glycoprotein IIb/IIIa inhibitors was at the physician's discretion. Dual-antiplatelet medication was administered to the patients after PCI for at least 12 months.
62249058|NCT03819036|EXPERIMENTAL|Patients|Questionnaires for patients requiring dental emergencies care
62249059|NCT00844207|EXPERIMENTAL|Treatment A|Two of the fixed combination tablets each containing 250 mg of azithromycin and 155 mg of chloroquine base.
62249060|NCT00844207|ACTIVE_COMPARATOR|Treatment B|A single tablet containing 500 mg of azithromycin and a single tablet containing 300 mg of chloroquine base.
62438950|NCT01952574|EXPERIMENTAL|Erenumab 70 mg QM|"Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
62606524|NCT00975858|EXPERIMENTAL|Off Pump Coronary Artery Bypass Surgery|
62828939|NCT05007054||Coronary artery bypass grafting|The left internal mammary artery was routinely used to graft to the left anterior descending artery and completed by venous grafts to other coronary branches with standard bypass techniques. Te procedure was performed by surgeons experienced in onpump or of-pump surgery at the operator's discretion.
62828940|NCT05007054||Medical therapy|Patients with neither PCI nor CABG treatment were allocated to the MT alone group. For medical therapy, antiplatelet medication, statins, renin-angiotensin system blockade, β-blockers, and nitrate were used.
62828941|NCT01826019|EXPERIMENTAL|Intervention|Intensive CV risk detection, counselling and follow-up program by NPHW; recommended CV medications will include combinations of anti-hypertensive medications (both low and high doses) and a lipid lowering agent (e.g. statin) in accordance with treatment algorithm \[precise formulations used may differ in each country\]; use of treatment supporters to reinforce adherence.
62828942|NCT01826019|OTHER|Control - Usual Care|Participants in control communities will be referred to usual care.
62249061|NCT05747508|ACTIVE_COMPARATOR|Inhaled Nitric Oxide (iNO)|Pulsed inhaled iNO30, 45 and 75 mcg/kg Ideal Body Weight (IBW)/hour (hr)
62606525|NCT05409430|EXPERIMENTAL|Patients with Acute Ischemic Stroke (AIS)|Patients with Acute Ischemic Stroke (AIS), indicated for treatment with ANA 5F device in combination with Solitaire stent retriever, whose stroke is attributable to an occlusion of a large artery in the neurovasculature.
62606526|NCT00583375|ACTIVE_COMPARATOR|Group 1|"Standard Rigid Fixation plus autograft~Standard of Care: Autologous Bone Graft"
62606527|NCT00583375|EXPERIMENTAL|Group 2|Standard Rigid Fixation plus Augment® Bone Graft
62828943|NCT01184157|EXPERIMENTAL|Home|Home-based STI screening using self-obtained vaginal swabs and postal return of samples.
62828944|NCT01184157|ACTIVE_COMPARATOR|Clinic|Receive STI screening in a clinical setting such as a private physician or clinic.
62606528|NCT05365269|EXPERIMENTAL|Computer-generated feedback on health risk behaviors|Proactive Automatized Lifestyle intervention Frequency: 3 times (month 0, 1, 3) Dosage: Individually tailored feedback corresponding to about 1-6 pages Duration: 3 months
62606529|NCT04064541|OTHER|Virtual Visit|"At the baseline visit patients will complete an in-clinic baseline visit consisting of Medical Hx review, NYHA assessment, Questionnaires (EQ-5D-5L, KCCQ, Frailty Index for Elders \& Mini Cog) and Functional Assessments (Timed Up \& Go and 6MWT). Patients will also receive virtual visit training and complete an in-clinic virtual visit consisting of the previously stated functional assessments.~All follow-up visits will occur via virtual distance health visits. These f/u visits will occur at Day 7and Day 14 At the initiation of each distance health f/u visit the patient's current state of health will be assessed as well as NYHA. Patient Questionnaires(EQ-5D-5L, KCCQ \& Frailty Index) and Functional Assessments(Timed Up \& Go and 6MWT) will be completed."
62438951|NCT01952574|EXPERIMENTAL|CHU Substudy: Erenumab 140 mg PFS|Participants in the open-label treatment phase in the United States randomized to self-administer 140 mg erenumab via two 70 mg injections using a prefilled syringe (PFS) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).
62438952|NCT01952574|EXPERIMENTAL|CHU Substudy: Erenumab 140 mg AI/Pen|Participants in the open-label treatment phase in the United States randomized to self-administer 140 mg erenumab via two 70 mg injections using an autoinjector/pen (AI)/pen) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).
62606530|NCT03121924|EXPERIMENTAL|Immediately oocyte denudation|"After the retrieval , sybling oocytes were assigned to one o more recipient and then ,the oocytes were randomized in two arms .~The first arm is the immediately denudation and immediately ICSI of the oocytes, and in the second arm the oocyte are denuded and injected after 4 hours from the pick up ."
62606531|NCT03121924|EXPERIMENTAL|Delayed oocyte denudation|"After the retrieval , sybling oocytes were assigned to one o more recipient and then ,the oocytes were randomized in two arms .~In this arm, the oocyte are denuded and injected after 4 hours from the pick up ."
62606532|NCT01538992|EXPERIMENTAL|renal denervation|in this group percutaneous renal denervation with Standard steerable Mariner Radiofreqency ablation Catheter (5F or 7F)
62606533|NCT01538992|NO_INTERVENTION|medical thrapy|medical treatment
62606534|NCT00776802|EXPERIMENTAL|GCS-10|
62606535|NCT02036671|EXPERIMENTAL|EndoAVF|The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access
62606536|NCT01552148|ACTIVE_COMPARATOR|Group TAP (US guided)|23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
62606537|NCT01552148|OTHER|Group Control|
62438953|NCT04765033|ACTIVE_COMPARATOR|5% Hypertonic saline|5% hypertonic saline nebuliser 4 mls twice in a day for 3 months
62606538|NCT02753387|EXPERIMENTAL|CHLORHEXIDINE|Patients will receive 1 preoperative oral preparation and 1 peroperative oral preparation of chlorhexidine
62606539|NCT02753387|PLACEBO_COMPARATOR|NaCl 0.9 %|Patients will receive 1 preoperative oral preparation and 1 peroperative oral preparation of NaCl 0.9%
62606540|NCT05805085|EXPERIMENTAL|Lens A|Participants wore Lens A for 15 minutes (Period 1)
62606541|NCT05805085|EXPERIMENTAL|Lens B|Participants wore Lens B for 15 minutes (Period 2)
62606542|NCT00805077|EXPERIMENTAL|1|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
62606543|NCT00805077|OTHER|2|tidal volume of 10 ml/kg of ideal body weight without PEEP
62606544|NCT04826133|ACTIVE_COMPARATOR|Acute Pretreatment with Calcitriol|To explore the effects of acute pre-treatment with Calcitriol on attempts to self-administer and ultimate number of infusions/boluses of cocaine, in experienced, non treatment-seeking users of the drug
62438954|NCT04765033|PLACEBO_COMPARATOR|Placebo|0.9% saline nebuliser 4 mls twice in a day for 3 months
62438955|NCT04023630|EXPERIMENTAL|rivaroxaban plus ticagrelor|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus ticagrelor 90 mg tablet twice daily for 12 months
62438956|NCT04023630|ACTIVE_COMPARATOR|rivaroxaban plus clopidogrel|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily for 12 months
62249062|NCT05747508|PLACEBO_COMPARATOR|Placebo|Pulsed inhaled N2, 99.999% gas
62606545|NCT04826133|PLACEBO_COMPARATOR|Acute Pretreatment with Placebo|To explore the effects of acute pre-treatment with placebo on attempts to self-administer and ultimate number of infusions/boluses of cocaine, in experienced, non treatment-seeking users of the drug
62606546|NCT05674877|PLACEBO_COMPARATOR|Opioid-based group (OB)|".Patients in the opioid-based group will receive placebo boluses and infusions of saline.~The intra-operative hemodynamics target will be to maintain the mean arterial blood pressure and heart rate within 20% of baseline value. Significant hemodynamic alterations will be managed as follows:~Hypertension and/or tachycardia defined as more than 20% increase of the baseline readings will be managed by top-up doses of fentanyl 1µg/kg"
62623499|NCT04999449|EXPERIMENTAL|Chair|Participants receive 1 dose of Scopolamine 0.2 mg, 1 dose of Scopolamine 0.4 mg, and 1 dose of placebo saline delivered via the Creare LLC intranasal nebulizer. These dosages are all 1 week apart and the order is randomized.
62249063|NCT05747508|ACTIVE_COMPARATOR|Long Term Follow Up|Pulsed inhaled iNO30, 45 or 75 mcg/kg IBW/hr
62249064|NCT00763230|EXPERIMENTAL|active|Full active tDCS treatment
62249065|NCT00763230|SHAM_COMPARATOR|sham|Placebo tDCS will be give
62249066|NCT03341572|EXPERIMENTAL|high response group|patients undergo 5,10 and 15cmH2O positive end expiratory pressure ,the change of central venous pressure is more than 2.5cmH2O
62438957|NCT05975021|EXPERIMENTAL|Istaroxime|Istaroxime delivered as an IV infusion via a syringe pump. Dosage regime is 1.0 µg/kg/min for 6 hours, 1.0 or 0.5 µg/kg/min for 18 hours, 0.5 µg/kg/min for 24 hours. Total duration 48 hours.
62438958|NCT05975021|PLACEBO_COMPARATOR|Placebo|Placebo (lactose) delivered as an IV infusion via a syringe pump. Total duration 48 hours.
62606547|NCT05674877|ACTIVE_COMPARATOR|Opioid sparing group (OS)|"Patients in the Opioid Sparing group will receive a loading dose of dexmedetomidine (1µg/kg over 10 minutes). This will be followed by a fixed continuous maintenance infusion of 0.5µg/kg/hour. Furthermore, a single induction analgesic dose of 0.5 mg/kg ketamine will be given to all patients in the OS group. This will be followed by 0.25 mg/kg/h continuous maintenance infusion. Dexmedetomidine and ketamine infusions will be stopped 30 minutes prior to the conclusion of surgery.~The intra-operative hemodynamics target will be to maintain the mean arterial blood pressure and heart rate within 20% of baseline value. Significant hemodynamic alterations will be managed as follows:~Hypertension and/or tachycardia defined as more than 20% increase of the baseline readings will be managed by top-up doses of fentanyl 1µg/kg in the two study groups."
62249067|NCT03341572|PLACEBO_COMPARATOR|low response group|the change of CVP is less than 2.5cmH2O
62438959|NCT06399419|EXPERIMENTAL|Treatment (CBM588 capsules, nivolumab, ipilimumab)|Patients receive CBM588 PO BID on days 1-21, nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 4 cycles. Patients then receive CBM588 PO BID on days 1-28 and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT, bone scan and blood sample collection throughout the study. Patients may optionally undergo MRI on study.
62438960|NCT06142656|ACTIVE_COMPARATOR|Metformin|
62606548|NCT05531448|EXPERIMENTAL|2wT (2-way texting)|2wT participants will receive weekly motivational messages without any HIV-related information. They will receive visit reminders with an option to respond they will attend, they transfered, or they need scheduling help. If they do not attend their visit, they will be traced at 14 days.
62606549|NCT05531448|NO_INTERVENTION|Routine retention|Control participants will have routine Back to Care retention support services and tracing at 14 days after a visit it missed.
62249068|NCT04114188|EXPERIMENTAL|Antithymocyte Immunoglobulin (Rabbit)|rATG induction on day 0 \& 1 post op
62249069|NCT02256605||Insufficient Group|D-3 Chewable Wafer - 14,000 IU/wafer weekly Vitamin D-3 Caps - 2,000 IU/Cap daily Vitamin D-3 Liquid - 5,000 IU/ml (0.4) ml daily
62249070|NCT02256605||Deficient Group|D-3 Chewable Wafer - 50,000 IU/wafer weekly Vitamin D-3 Liquid - 5,000 IU/ml daily
62249071|NCT01760928||Asthma patients|all
62249072|NCT06272786|EXPERIMENTAL|Experimental Group|In addition to the conventional physiotherapy program, patients in the intervention group will receive a suprascapular nerve block with musculoskeletal USG guidance available in our clinic at the beginning of rehabilitation. Bupivacaine hydrochloride will be used in this injection. 5 ml of bupivacaine hydrochloride 5% and 5 ml of saline will be drawn into a 10 ml syringe and ejection will be performed from the superior of the suprascapular noch under USG guidance.
62249073|NCT06272786|ACTIVE_COMPARATOR|Control Group|Patients in the control group will only receive a conventional physiotherapy program.
62249074|NCT01085552|OTHER|1|Group A consists of 11 Caucasian male subjects Group B consists of 12 Japanese male subjects
62249075|NCT00521924|EXPERIMENTAL|Infliximab + basic treatment|3 mg/kg infliximab plus basic treatment
62249076|NCT00521924|ACTIVE_COMPARATOR|Basic treatment (DMARDs)|Rheumatoid Arthritis basic therapy (disease modifying anti-rheumatic drugs \[DMARDs\])
62438961|NCT06142656|ACTIVE_COMPARATOR|Vildagliptin|
62438962|NCT00863369|EXPERIMENTAL|Treatment (bortezomib, gemcitabine hydrochloride, rituximab)|Patients receive bortezomib IV, gemcitabine hydrochloride IV over 3-4 hours, and rituximab IV on days 1 and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
62249077|NCT00522054|OTHER|A|Single group study
62249078|NCT05037864||Ballet Dancer Group (Adolescent Ballet Dancers)|Adolescent ballet dancer student aged 7-17 years who have been actively attending a ballet dance school for at least 1 year will be form ballet dancer group. The age, body weight (kg) and height (centimeter) of each individual included in the study will record. The assessment form, which includes demographic data such as, ballet duration(min/day), frequency (times/week) and continuity (year) will record by asking the parents. All measurements will be take before lesson and without warm-up. All measurements will be evaluate by an experienced physiotherapist. Postural alignment will assess with New York Posture Rating Scale (NYPR). Static and dynamic balance will determine with Romberg's Test, Flamingo Balance Test (FBT) and Star Excursion Balance Test (SEBT). Participants will be evaluate for flexibility outcomes by applying following test: sit up and reach test, Thomas test and straight leg raise test. Quality of life will be assess with SF36.
62438963|NCT04537247|EXPERIMENTAL|Open partial nephrectomy (Group A)|patients in this group will have open partial nephrectomy for their renal tumors.
62438964|NCT04537247|EXPERIMENTAL|Robotic partial nephrectomy (group B)|patients in this group will have robotic partial nephrectomy for their renal tumors.
62438965|NCT03104205|EXPERIMENTAL|Evaluate home-based MOWI|Conduct and assess the feasibility, acceptability, and potential effectiveness of home-based MOWI in improving physical function.
62438966|NCT02382471|PLACEBO_COMPARATOR|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
62438967|NCT02382471|ACTIVE_COMPARATOR|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
62046929|NCT01717781|ACTIVE_COMPARATOR|Standard|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with standard bipolar electrosurgery.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope.~Two additional 5 mm ports are placed under direct visualization. One more 5-mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
62438968|NCT01035320|EXPERIMENTAL|simvastatin + ezetimibe|Cross-over study with placebo only run-in period. All patients participate in this arm with simvastatin + ezetimibe either as first treatment period (8-10 weeks)or second treatment period (8-10 weeks). The primary comparison is ezetimibe vs. placebo on top of simvastatin. A secondary comparison will be simvastatin vs. placebo run-in.
62438969|NCT00603343|ACTIVE_COMPARATOR|1|
62438970|NCT00603343|PLACEBO_COMPARATOR|2|
62438971|NCT04923529|EXPERIMENTAL|TAS-102|Single group assignment of TAS-102 in Patients with Advanced, Refractory Pancreatic Adenocarcinoma
62438972|NCT05765110|EXPERIMENTAL|Parkinson's disease patients with DBS|All Parkinson's disease patients with bilateral deep brain stimulation (DBS) in the subthalamic nucleus
62438973|NCT05765110|EXPERIMENTAL|Parkinson's disease patients without DBS|All Parkinson's disease patients without bilateral deep brain stimulation (DBS) in the subthalamic nucleus
62438974|NCT05765110|NO_INTERVENTION|Healthy Controls|All healthy volunteers
62438975|NCT04607603|EXPERIMENTAL|Cannabidiol|In the Cannabidiol (CBD) arm CBD will be titrated up to 600 mg per die (titration 1 week) in capsules (3 daily doses) and maintained at 600mg per die (3 daily doses) for 7 weeks
62438976|NCT04607603|PLACEBO_COMPARATOR|Placebo|In the placebo arm the placebo comparator will be administered in capsules in 3 daily doses
62438977|NCT06111456||Population 1Q|Parents or co-parents of a newborn child.
62438978|NCT06111456||Population 2|Parents or co-parents whose youngest child is 1 week to 3 years old.
62438979|NCT06111456||Population 3|Parents or co-parents whose child had a suspicious newborn screening result that was confirmed at the diagnosis phase (except hearing).
62438980|NCT06111456||Population 4|Parents or co-parents whose child was diagnosed later based on clinical signs for diseases not included in the list of diseases screening in French newborn screening, but included in the list of diseases screened in newborn screening in other countries.
62438981|NCT04780737||Prophylactic cholecystectomy|Patient who undergo resection of primary ileal neuroendocrine tumor and contemporarly cholecystectomy
62438982|NCT04780737||On-demand cholecystectomy|Patient resected for primary ileal neuroendocrine tumor, treated with cholecystectomy in a different operation and only if needed, for the development of biliary stone disease
62438983|NCT00494806|EXPERIMENTAL|Rocking Group|Patients rocked in a rocking chair in 10-20 minute increments for at least one hour per day beginning on the first day after surgery. Activity was increased each day and continued until passage of first postoperative flatus.
62046930|NCT02328885|EXPERIMENTAL|Experimental|DLI of the 20 fraction of the UCBT
62438984|NCT00494806|NO_INTERVENTION|Standard Care|Standard care group got out of bed and sat in a non-rocking chair and ambulated beginning the first day after surgery. Activity was increased each day and continued until passage of first postoperative flatus.
62606550|NCT00290381|EXPERIMENTAL|Placebo followed by Drug (OC000459)|Placebo and Drug are followed by Nasal Allergen Challenge
62606551|NCT00290381|EXPERIMENTAL|Drug (OC000459) followed by Placebo|Drug and Placebo are followed by Nasal Allergen Challenge
62046931|NCT03602417|EXPERIMENTAL|Flare type stent|Flare type stent (Taewoong medical) has a wide diameter at proximal end to prevent stent migration.
62438985|NCT05730777|EXPERIMENTAL|Bifidobacterium Bifidum Oral Capsule in addition to conventional treatment|Bifidobacterium Bifidum Oral Capsule for 6 months in addition to conventional treatment
62438986|NCT05730777|ACTIVE_COMPARATOR|conventional antitumor treatment|Patients in the control group will receive conventional antitumor treatment only.
62438987|NCT06546280|EXPERIMENTAL|Experimental group|
62438988|NCT01439841|EXPERIMENTAL|Probiotics|A multi-strain Probiotic consisting of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk (Biola®, TINE SA, Oslo), 250 mL/day for 8 weeks.
62438989|NCT01439841|PLACEBO_COMPARATOR|Placebo|Fermented and subsequently heat-treated, sterile skimmed milk (TINE SA) as active placebo.
62438990|NCT01439841|NO_INTERVENTION|Control|No intervention
62438991|NCT03283865|EXPERIMENTAL|Ultrasound|"The attending anesthesiologist will perform or instruct the placement of a caudal block according to their standard of practice. At the time of administration of local anesthetic into the caudal space, the study collaborator (SC) will ultrasound the caudal space keeping the provider placing the block blinded to the imaging. The provider placing the block will inject 0.5mL of saline. The provider will then be asked to state if they are correctly in the caudal space or not. If the provider feels they are not in the caudal space, they will re-do the procedure. If the provider fails to identify incorrect location and this is noted by ultrasound, the SC will inform the provider to re-do the procedure.~All study participants will have ultrasound used for caudal block."
62438992|NCT05170425||Cohort 1|1) Cohort 1: Previously enrolled AND randomized in LAMBDA 001 Participants enrolled to Cohort 1 will be enrolled at least 12 and up to 18 months post-transplant.
62438993|NCT05170425||Cohort 2|2) Cohort 2: Not previously randomized in LAMBDA 001 Participants who were enrolled in LAMBDA 001 but who were not randomized in LAMBDA 001 may be enrolled to Cohort 2.
62438994|NCT01286142||Influenza treatment with oseltamivir|Patients 24 months of age and younger initially presenting with confirmed or presumed influenza A or B infection treated with oseltamivir.
62606552|NCT06496204||SPAF|"At the beginning of the study, in 1974, a group of 429 (224 males, and 205 females) of pupils at secondary high school in Sweden was systematically selected: The country was stratified into six regions with a similar population size and climate. In each region, one or more secondary high schools were randomly selected. At each school, the number of pupils was selected in proportion to the distribution of girls and boys in secondary high school, the number of pupils in the region, and the proportion of pupils in each school program (theoretical three-year program to prepare for higher studies or practical two-year program to prepare for working life). Individual subjects were then randomly selected at each school based on these criteria and are representative of 16-year-old girls and boys attending secondary high school in Sweden.~All participants have been invited to followups at age 34, 52 and 63 years"
62606553|NCT05837728||Older adults ≥75 living at home|Older adults ≥75 years living at home applying for a municipal health and care service for an estimated period of more than two weeks.
62606554|NCT02098616|EXPERIMENTAL|Arm 1|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 8 weeks
62828945|NCT01782378|ACTIVE_COMPARATOR|Real LED Treatment Series|Participants in this group receive a series of 15 real LED treatments with the helmet and intranasal devices: Transcranial NIR, 830nm LED Helmet and two intranasal nose clips (633 nm, and 810 nm, Vielight, Inc., Toronto), 28-minute treatment, 2 days/ week, 7.5 weeks, at least 48 hours between treatments. Additionally, two NIR 870nm LED cluster heads (MedX Health, Toronto) were placed over the L and R ears during the last 4 minutes of the treatment session. LEDs are FDA-cleared, non-significant risk. Both the participant and the person performing the treatment wore goggles that block red wavelength (from the red intranasal). Real or Sham LED devices look and feel identical.
62606555|NCT02098616|EXPERIMENTAL|Arm 2|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 6, 8 or 12 weeks
62606556|NCT02098616|EXPERIMENTAL|Arm 3|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 4 weeks
62606557|NCT02098616|EXPERIMENTAL|Arm A|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 8 weeks
62606558|NCT02098616|EXPERIMENTAL|Arm B|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 6, 8 or 12 weeks
62606559|NCT02098616|EXPERIMENTAL|Arm C|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 4 weeks
62606560|NCT05850897|EXPERIMENTAL|Massage Group|Appropriate position is given to the patients. Thumb and finger movements, patting, rubbing and squeezing techniques are used in foot massage. During training, the active hand applies pressure, while the passive hand uses both hands to support the foot. The intervention begins with rubbing and warming the feet. The duration of the foot warming process is approximately 5 minutes, and after the foot warming maneuvers, the methods of moving the thumbs of both hands towards the soles of the feet and spinning the laundry are used. The inner and outer parts of the foot are patted in a balanced way. This caressing movement on both feet is done with these movements in a light and rhythmic way and the massage is completed. Data will be obtained with Patient Descriptive Information Form, Vital Signs Follow-up Form, Surgical Anxiety Scale for Adult Patients, Perianesthesia Comfort Scale, Numerical Pain Scale.
62606561|NCT05850897|NO_INTERVENTION|Control Group|Massage will not be applied to the control group; intervention scales will be applied by taking vital signs after waiting until the massage application in the group (20 minutes in total) and the rest period (30 minutes).
62606562|NCT01821950|NO_INTERVENTION|Physical education as usual|Physical education curriculum established by the school, including competitive sports, aerobic and anaerobic activities, balance and coordination skills. Yoga is not a component of the curriculum.
62606563|NCT01821950|EXPERIMENTAL|Yoga during physical education|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
62606564|NCT01416714||Gastric Cancer|
62606565|NCT01416714||Gastrointestinal Stromal Tumors (GIST)|
62606566|NCT01416714||Esophageal Cancer|
62606567|NCT01416714||Pancreas Cancer|
62606568|NCT01416714||Hepatocellular Cancer|
62606569|NCT01416714||Biliary Cancer|
62606570|NCT01416714||Neuroendocrine Cancer|
62046932|NCT03602417|ACTIVE_COMPARATOR|Conventional D-type stent|Conventional D-type (Taewoong medical) stent has a same diameter at both ends.
62606571|NCT01416714||Peritoneal Mesothelioma|
62606572|NCT01416714||Anal Cancer|
62606573|NCT01416714||Colorectal Cancer|
62438995|NCT01286142||Influenza prophylaxis with oseltamivir|Patients 24 months of age and younger prescribed oseltamivir for influenza prophylaxis
62606574|NCT00033657|EXPERIMENTAL|Cisplatin / Irinotecan / Radiation therapy (Arm A)|"Days 1 - 35 : Concurrent radiation therapy (RT) and Cisplatin / Irinotecan Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Cisplatin 30 mg/m² days 1, 8, 22, 29. Irinotecan 65 mg/m² days 1, 8, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy~Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
62046933|NCT03894852||AML|cases with denovo AML and t-AML
62249079|NCT05037864||Control Group (Sedentary Adolescents)|The control group (Sedentary Adolescent) of the study, are not ballet dance students who aged 7-17 years and have not experience in competitive sport or activity. The age, body weight (kg) and height (centimeter) of each individual included in the study will record. All measurements will be take before lesson and without warm-up. All measurements will be evaluate by an experienced physiotherapist. Postural alignment will assess with New York Posture Rating Scale (NYPR). Static and dynamic balance will determine with Romberg's Test, Flamingo Balance Test (FBT) and Star Excursion Balance Test (SEBT). Participants will be evaluate for flexibility outcomes by applying following test: sit up and reach test, Thomas test and straight leg raise test. Quality of life will be assess with SF36.
62249080|NCT06348550|ACTIVE_COMPARATOR|Active treatment|
62438996|NCT01286142||Influenza patients with no antiviral treatment|A comparator group of patients 24 months of age and younger presenting with confirmed or presumed influenza A or B and not treated with any influenza antiviral.
62438997|NCT01589003|ACTIVE_COMPARATOR|Low GI group|Low Glycaemic index growing up milk
62438998|NCT01589003|OTHER|High GI group|Hi Glycaemic index growing up milk
62438999|NCT03080181|EXPERIMENTAL|pasireotide|Pasireotide was administered in a 12 months period
62606575|NCT00033657|EXPERIMENTAL|Paclitaxel / Cisplatin / Radiation therapy (Arm B)|"Days 1 - 35 : Concurrent radiation therapy (RT) and Paclitaxel/Cisplatin Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29. Cisplatin 30 mg/m² days 1, 8, 15, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy.~Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles."
62046934|NCT03894852||MDS|cases with denovo MDS and t-MDS
62249081|NCT06348550|PLACEBO_COMPARATOR|Placebo treatment|
62249082|NCT03045783|EXPERIMENTAL|Prophylactic use of antibiotics group|Prophylactic use of antibiotics during endoscopic treatment, cefotiam 2.0g intravenous
62249083|NCT03045783|NO_INTERVENTION|On-demand group|Routine endoscopic examination and treatment. Antibiotics are not used during endoscopic treatment
62249084|NCT01440868|EXPERIMENTAL|SLI group|In this group the preterm infants will receive sustained lung inflation (SLI) with mask in the delivery room
62249085|NCT01440868|NO_INTERVENTION|Control|Preterm infants will be assisted in the delivery room without sustained lung inflation.
62249086|NCT04234165|ACTIVE_COMPARATOR|Monopolar arm|monopolar cautery was used for TURBT
62249087|NCT04234165|EXPERIMENTAL|Bipolar Arm|bipolar cautery was used for TURBT
62249088|NCT01905163|EXPERIMENTAL|laparoscopic management|Tumor Debulking Surgery by laparoscopy
62249089|NCT04311216||Shoulder instability participants|Participants with previous a previous episode(s) of shoulder instability
62249090|NCT04311216||Age matched controls (no instability)|Participants with no previous a previous episode(s) of shoulder instability
62249091|NCT06359366|EXPERIMENTAL|intervention arm|perineal massage combined hip joint training
62249092|NCT06359366|NO_INTERVENTION|comparison arm|Routine antenatal examination combined self-exercise
62249093|NCT00544648|EXPERIMENTAL|Treatment|nab-paclitaxel+ carboplatin + radiation
62249094|NCT05728515|EXPERIMENTAL|PET scan|Patients will receive an intravenous injection of 68Ga-NY104
62439000|NCT01303991|EXPERIMENTAL|Hexvix PDT|
62439001|NCT03108105|EXPERIMENTAL|AOS-C2001-B|A new 2-piece appliance composed with 2 parts: a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
62439002|NCT06277791|EXPERIMENTAL|Treatment group|"TP: docetaxel 75 mg/m2, cisplatin 75 mg/m2 Adebrelimab: 20mg/kg, intravenous infusion, D1 Every three weeks, a total of two cycles. Surgery will be performed 1-3 weeks after the completion of neoadjuvant therapy.~After surgery, radiotherapy and chemotherapy combined with immunotherapy were chosen based on the patient\&#39;s condition, and a total of two years of follow-up were conducted."
62439003|NCT04669899|EXPERIMENTAL|Stage 1, Dose Escalation: JTX-8064 monotherapy dose escalation|Dose Escalation, Stage 1: JTX-8064 Monotherapy. Cohorts will enroll subjects with histologically or cytologically confirmed advanced/metastatic extracranial solid tumor malignancies.
62828946|NCT01782378|SHAM_COMPARATOR|Sham LED Treatment Series|Participants in this group first receive a series of 15 sham LED treatments with the helmet and intranasal devices containing sham LEDs (no photons were emitted): Transcranial LED Helmet and two intranasal nose clips (sham LEDs, Vielight, Inc., Toronto), 28-minute treatment, 2 days/ week, 7.5 weeks, at least 48 hours between treatments. Additionally, two sham LED cluster heads (MedX Health, Toronto) were placed over the L and R ears during the last 4 minutes of the treatment session. These participants were offered an optional Second Real Series of identical 15 real LED treatments. Both the participant and the person performing the treatment wore goggles that block red wavelength (from the red intranasal). Real or Sham LED devices look and feel identical.
62046935|NCT03854968|EXPERIMENTAL|Quality control|The participants home mechanical ventilator will be tested in order to performe a quality control
62046936|NCT03633942||Observational: LMA Supreme|"An appropriately sized LMA Supreme will be prepared by removing all air from the cuff while applying manual pressure. A water soluble non-local anesthetic containing lubricant gel will be applied to the fully deflated airway before insertion. A 1 cm column of the gel will be preloaded into the gastric port of the LMA Supreme for the Gel Test.~The cuff will be inflated with a manometer to a pressure of approximately 30cm H2O. If a significant leak is detected, the cuff will be inflated in increments of 5cm H2O until a satisfactory seal is obtained. The final cuff pressure will be recorded. The lungs will then be gently inflated by applying manual pressure to the anesthesia circuit bag while observing the gel column in the LMA Supreme gastric port for movement."
62046937|NCT04285008|NO_INTERVENTION|standard Colonoscopy|"Control arm~Colonoscopy procedure using standard flushing and suctioning - standard of care"
62046938|NCT04285008|OTHER|Pure-Vu System|Intervention - Colonoscopy procedure using Pure-Vu System
62249095|NCT00964145||Nulliparous female patients|Nulliparous female patients ages 21-70 years old.
62249096|NCT04553848|EXPERIMENTAL|Augmented Reality+ Treadmill training|Participants allocated to this group will receive treadmill training with body weight support (BWS) incorporating augmented feedback games chosen to address clinically perceived deficits using the C-Mill training system.
62439004|NCT04669899|EXPERIMENTAL|Stage 2, Dose Escalation: JTX-8064 in combination with pimivalimab|Dose Escalation, Stage 2: JTX-8064 in combination with pimivalimab. Cohorts will enroll subjects with histologically or cytologically confirmed advanced/metastatic extracranial solid tumor malignancies.
62606576|NCT06583447|ACTIVE_COMPARATOR|CRD group|Based on the standardized lifestyle intervention, the study subjects in the control group will be treated with CRD. Total daily energy intake will be restricted to 80% of the energy requirement for each age group in the Dietary Reference Intakes of Nutrients for Chinese Residents DRIs 2013. A daily food diary will be kept at least one weekday and one weekend per week.
62606577|NCT06583447|EXPERIMENTAL|TRE group|Based on the standardized lifestyle intervention, TRE is administered to the study subjects in the intervention group. The eating window is limited to 12 hours per day, with the last meal no later than 7:00 p.m., and the study subjects are free to choose their eating window. Energy intake is not restricted during the eating period, and calorie-free, sugar-free beverages (water, tea, coffee) are allowed during the fasting period. A daily food diary will be kept for at least one weekday and one weekend per week.
62606578|NCT02109016|EXPERIMENTAL|Lucitanib|Lucitanib given orally once daily on a continuous schedule. Starting dose is 10 mg/day.
62623500|NCT04962087|EXPERIMENTAL|Health enSuite Insomnia|Health enSuite: Insomnia has been designed based on established cognitive behavioural treatments for insomnia and adapted to fit an automated interactive platform available via an internet enabled device. The program is divided into a series of treatment modules or levels that will be delivered over the course of 6-8 weeks. The content of these 6 levels includes the following components, a sleep diary, sleep restriction clock, sleep hygiene, relaxation techniques, sleep related thoughts and beliefs, and involving a support person.
62828947|NCT04323969|EXPERIMENTAL|Specific Modification Target|A 15 degree relative increase to foot progression angle
62828948|NCT04323969|EXPERIMENTAL|Self-directed Modification|"A self-directed increase to foot progression angle that is as much as is comfortable."
62046939|NCT04932876||ESKD - HD|End Stage Kidney Disease on Long Term Dialysis
62046940|NCT04932876||KTR|Kidney Transplant Recipient
62046941|NCT02976441|EXPERIMENTAL|Focal RT, Temozolomide, Stem Cell Collection/Reinfusion|"* Autologous stem cell collection will be performed 1-4 days prior to initiating radiation therapy and temozolomide~* Focal radiation therapy: standard of care dose daily for approximately 6 weeks~* Temozolomide: standard of care dose by mouth daily for 6 weeks with radiation~* 2-7 days after the end of the radiation therapy and temozolomide the stem cells will be reinfused into the patient~* Temozolomide: standard of care dose by mouth on days 1-5 every 28 days for 6 months following a 4-6 week rest period after the initial radiation and temozolomide"
62046942|NCT03880838|NO_INTERVENTION|No contact control|Participants are not contacted.
62046943|NCT03880838|EXPERIMENTAL|Letter|Participants are only contacted through a letter with a personal testimonial.
62046944|NCT03880838|EXPERIMENTAL|Link and no nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and no nudges.
62046945|NCT03880838|EXPERIMENTAL|Link and commitment nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and a commitment nudge.
62046946|NCT03880838|EXPERIMENTAL|Link and prevention nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and a prevention nudge.
62046947|NCT03880838|EXPERIMENTAL|Link and both nudges|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and both commitment and prevention nudges.
62046948|NCT03880838|EXPERIMENTAL|DVD and no nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and no behavioral nudges.
62439005|NCT04669899|EXPERIMENTAL|Stage 3 Expansion: JTX-8064 monotherapy (Ovarian)|Cohort will enroll subjects with advanced/metastatic PD-1/PD-L1 (PD-(L)1)-naïve, platinum-resistant ovarian cancer.
62439006|NCT04669899|EXPERIMENTAL|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (ccRCC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1i-experienced clear cell renal cell carcinoma (ccRCC).
62449395|NCT03361423|SHAM_COMPARATOR|treatment of migraine with sham device|Treatment of acute migraine with a sham form of the Nerivio Migra-1 device
62249097|NCT04553848|ACTIVE_COMPARATOR|Treadmill training|Participants allocated to this group will receive treadmill training with body weight support (BWS) using the C-Mill training system.
62249098|NCT04553848|ACTIVE_COMPARATOR|Over ground training/standard of care|Participants allocated to this group will receive over ground balance and mobility training that would be considered standard of care in outpatient rehabilitation.
62249099|NCT06062745|EXPERIMENTAL|18F-fluciclovine|"Participants with low prostate-specific membrane antigen (PSMA) expression or neuroendocrine prostate cancer will receive:~* 18F-fluciclovine PET/CT within 6 weeks of standard of care exam and 68Ga-PSMA PET/CT~* 2x Blood test at time of 18F-fluciclovine PET/CT and prior to treatment as determined by participants primary oncologist"
62249100|NCT00515736|EXPERIMENTAL|AOX group|Treatment group - double dose (loading) for 48 hours then single dose (Se 270 mcg, Zn 30 mg, vit C 1.2 g, B1 100 mg, vit E 300 mg enteral)
62249101|NCT00515736|PLACEBO_COMPARATOR|0|Group receiving vehicle solution for 5 days (double dose for 48 hours)
62249102|NCT01007032|EXPERIMENTAL|Cixutumumab|Participants receive IV cixutumumab every 2 or 3 weeks. A cycle equals 6 weeks, with radiological evaluation of tumor response after each cycle. After 1st cycle, pts with a complete response (CR), PR, or SD continue to receive cixutumumab cohort dose and schedule disease progression. 3 pts enroll in each cohort. Starting dose in Cohort 1 is 6 mg/kg every 2 weeks. Dose escalation from Cohort 1 to Cohort 2 (10 mg/kg every 2 weeks) occurs at least 3 pts in Cohort 1 completes 1 cycle of therapy. Enrollment into Cohort 3 (starting dose: 15 mg/kg administered every 3 weeks) will not proceed until at least 3 pts have completed one cycle of therapy in Cohort 2. Pts enroll in Cohort 4 once at least 3 pts have completed once cycle of therapy in Cohort 3; pts in Cohort 4 receive 20 mg/kg every 3 weeks.
62439007|NCT04669899|EXPERIMENTAL|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (TNBC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1i-experienced triple negative breast cancer (TNBC).
62439008|NCT04669899|EXPERIMENTAL|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (HNSCC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve, PD-L1+ head and neck squamous cell carcinoma (HNSCC).
62249103|NCT05554796|EXPERIMENTAL|Endoscopic classic stapedotomy|This groups contains 30 patients and will undergo classic stapedotomy
62249104|NCT05554796|EXPERIMENTAL|Endoscopic reversal stapedotomy|This groups contains 30 patients and will undergo reversal stapedotomy
62249105|NCT02705521|NO_INTERVENTION|Treatment as usual group|Patients will attend physiotherapy on a weekly basis for assessment (standard physiotherapy). They will be assessed for progression and be provided with a home exercise program. Range of motion in their shoulder will be collected on a weekly basis using the MIRA technology. Patients will be required to complete an exercise diary documenting the exercises performed as well as duration and frequency.
62249106|NCT02705521|EXPERIMENTAL|Treatment as usual plus Exergames group|Patients will attend physiotherapy on a weekly basis for assessment (standard physiotherapy). Rather than use a home exercise program patients will be provided with a laptop computer and kinect sensor. they will use the new technology to play 'Exergames' each program will be tailored to the patients progress and patients can play the system as often as they wish. Patients will be required to complete an exercise diary documenting the exercises performed as well as duration and frequency.
62249107|NCT03244410||immune thrombocytopenic purpura|immune thrombocytopenic purpura an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number we used complete blood picture
62249108|NCT01031550|ACTIVE_COMPARATOR|standard anesthetic management|standard anesthetic management with propofol 100-150mcg/kg/min
62249109|NCT01031550|EXPERIMENTAL|preconditioning with 2 MAC isoflurane group|After induction, anesthesia will be maintained with 1MAC (minimum alveolar concentration) of Isoflurane according to age and end-expiratory concentration. Thirty minutes before the anticipated inflow occlusion and commencement of liver transaction, Isoflurane concentration will be gradually increased to 2 MAC over a period of 5 minutes (induction) and maintained at 2 MAC for 10 minutes (preconditioning). Then the concentration of Isoflurane will be decreased to 1 MAC during next 15 minutes (washout).
62249110|NCT05175313||normal people|people who don't complain of respiratory diseases will be examined by chest ultrasound and pulmonary function test.
62249111|NCT05175313||obstructive respiratory diseases|the patients who are diagnosed with either COPD or asthma.
62249112|NCT05175313||restrictive respiratory diseases|patient with either ILD
62249113|NCT03138187|NO_INTERVENTION|control|without physical exercise sessions
62439009|NCT04669899|EXPERIMENTAL|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (Ovarian)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve, platinum-resistant ovarian cancer.
62439010|NCT04669899|EXPERIMENTAL|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (NSCLC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-experienced non-small cell lung cancer (NSCLC).
62439011|NCT04669899|EXPERIMENTAL|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (cSCC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-experienced cutaneous squamous cell carcinoma (cSCC).
62439012|NCT04669899|EXPERIMENTAL|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (UPS & LPS)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve undifferentiated pleomorphic sarcoma (UPS) and liposarcoma (LPS).
62449396|NCT03543956||Systemic Sclerosis patient|patients affected by SSc according to EULAR 2013 criteria
62449397|NCT00675649|EXPERIMENTAL|001|
62828949|NCT04682366|EXPERIMENTAL|Tamsulosin|Patients in this arm will receive 10 days of 0.4 mg of oral tamsulosin once daily starting 5 days pre-operatively and continuing until all pills are completed.
62606579|NCT02418585|EXPERIMENTAL|Intranasal Esketamine plus oral antidepressant|Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase. All participants will start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg per investigator's discretion. On Days 8 and 11 the dose may be increased to 84 mg (from 56 mg), remain same, or be reduced to 56 mg (from 84 mg) per investigator's discretion. On Day 15, a dose reduction from 84 mg to 56 mg is permitted, if required for tolerability; no dose increase permitted. After Day 15, dose must remain stable (unchanged). In addition participants will simultaneously initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release \[XR\]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
62606580|NCT02418585|ACTIVE_COMPARATOR|Placebo plus oral antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (ie, duloxetine, escitalopram, sertraline, or venlafaxine extended release \[XR\]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
62606581|NCT04286477||15 conventional hemodialysis patients|15 patients undergoing hemodialysis with high-flux dialyzer
62046949|NCT03880838|EXPERIMENTAL|DVD and commitment nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and a commitment nudge.
62249114|NCT03138187|EXPERIMENTAL|Moderate exercise group|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
62249115|NCT03138187|EXPERIMENTAL|Vigorous exercise group|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
62439013|NCT04669899|EXPERIMENTAL|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (PD-(L)1i-experienced HNSCC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with PD-(L)1i-experienced HNSCC.
62439014|NCT04669899|EXPERIMENTAL|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (BTC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with biliary tract cancer (BTC), including intra-and extra-hepatic biliary duct cancer and cancer of the gallbladder. All subjects must have progressed on or after gemcitabine/cisplatin (Gem/Cis) in the metastatic setting, must have PD-(L)1i resistance.
62439015|NCT05743283|EXPERIMENTAL|SynEx|The experimental arm will receive SynEx Wound Cleanser to cleanse the wound as directed by their healthcare provider.
62439016|NCT05743283|ACTIVE_COMPARATOR|Saline|The comparator arm will receive Saline Solution to cleanse the wound as directed by their healthcare provider.
62439017|NCT02393196|ACTIVE_COMPARATOR|Group Preloading (Group P)|Group Preloading (Group P): 500 mL hydroxyethyl starch (6% HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible before spinal anesthesia.
62439018|NCT02393196|ACTIVE_COMPARATOR|Group Coloading (Group C)|Group Coloading (Group C): After the patients have been monitored, spinal anesthesia will be performed. Recognizing the cerebrospinal fluid, 500 mL hydroxyethyl starch (%6 HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible.
62439019|NCT01173159|EXPERIMENTAL|Omegaven|Subjects will receive Omegaven at a dose of up to 1 g/kg body weight/day until they no longer require Total Parenteral Nutrition or until their conjugated/direct bilirubin has normalized and their enteral lipid intake is sufficient to discontinue intravenous lipids.
62439020|NCT01506583||General population|This group of participants is primarily an out-patient population.
62439021|NCT01506583||In-patient population|This group of participants is primarily an in-patient population.
62046950|NCT03880838|EXPERIMENTAL|DVD and prevention nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and a prevention nudge.
62046951|NCT03880838|EXPERIMENTAL|DVD and both nudges|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and both commitment and prevention nudges.
62046952|NCT03880838|EXPERIMENTAL|Link and DVD and no nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and no behavioral nudges.
62439022|NCT01506583||Pediatric Group|Participants in this group are children 18 years or younger.
62439023|NCT05950724|EXPERIMENTAL|Etanercept|Participants receive one dose (25mg) Etanercept via subcutaneous injection just prior to lung transplant. Following transplant, participants receive standard lung transplant care.
62439024|NCT05950724|NO_INTERVENTION|Control|Participants receive standard lung transplant care.
62449398|NCT00675649|PLACEBO_COMPARATOR|002|
62046953|NCT03880838|EXPERIMENTAL|Link and DVD and commitment nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and a commitment nudge.
62046954|NCT03880838|EXPERIMENTAL|Link and DVD and prevention nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and a prevention nudge.
62046955|NCT03880838|EXPERIMENTAL|Link and DVD and both nudges|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and both commitment and prevention nudges.
62046956|NCT04573465|EXPERIMENTAL|Phone Coaching Condition|Participants will receive weekly, 10-15 minute phone coaching from a trained peer-support coach throughout the 10 weeks that they use ACT Guide, an online program for general mental health. Coaches will adhere to an ACT-based protocol that includes reinforcing adherence, identifying and problem solving non-adherence, strengthening and generalizing ACT skills, and using ACT skills to increase commitment to ongoing program adherence.
62046957|NCT04573465|EXPERIMENTAL|Text Message Coaching Condition|Participants assigned to the text messaging condition will receive weekly text messages from their peer-support coach throughout the 10 weeks that they use ACT Guide, an online program for general mental health. These text messages will reflect content delivered in the phone coaching group, but through a briefer protocol that accounts for the abbreviated, asynchronous nature of texting. Text messages will similarly focus on reinforcing adherence, problem solving non-adherence, strengthening ACT skills, and using ACT to increase program adherence. However, these areas will be covered in short messages and with limited exchanges between participants and coaches due to the asynchronous nature of texting.
62046958|NCT04573465|ACTIVE_COMPARATOR|No Coaching Condition|Participants will be asked to use ACT Guide, an online program for general mental health, over the course of 10 weeks while receiving no coaching.
62046959|NCT06414551||CTO patients who underwent attempted PCI|Patients with coronary CTO who underwent attempt at PCI and also underwent a CTCA
62046960|NCT02154984|EXPERIMENTAL|Behavioral (time restricted diet)|Participants follow a time restricted diet, which restricts daily eating to an 8 hour time window between 12:00-8:00 pm. Participants are allowed to consume non-caloric beverages (water, black tea, black coffee, diet soda, etc.) during the fasting hours and required to record daily food consumption in the smartphone app for 6 months. Participants are also coached by telephone over approximately 10-15 minutes weekly for 1 month and then biweekly for 5 months.
62046961|NCT06013254|EXPERIMENTAL|Intervention group|4 ml of freshly squeezed lemon juice with a pH of 2.8 at room temperature was administered under the supervision of the physician before breakfast, lunch, and dinner for patients with ischemic stroke. For patients with severe swallowing disorders according to the GUSS, lemon juice was administered using a syringe, drop by drop, at a volume of 4 ml over approximately 15-20 minutes, as tolerated by the patient, under the supervision of the physician. Patients with severe swallowing disorders were unable to swallow and consequently drooled the lemon juice out of their mouths. This procedure was continued for seven days.
62046962|NCT06013254|NO_INTERVENTION|Control group|4 ml of room temperature water was administered under the supervision of the physician before breakfast, lunch, and dinner. For patients with severe swallowing disorders according to the GUSS, water was administered using a syringe, drop by drop, at a volume of 4 ml over approximately 15-20 minutes, as tolerated by the patient, under the supervision of the physician. Patients with severe swallowing disorders were unable to swallow and consequently drooled the water out of their mouths. This procedure was continued for seven days.
62046963|NCT04996615||high risk population|women at high risk of breast cancer undergoing enhanced MRI
62046964|NCT00587964|EXPERIMENTAL|Treatment|
62046965|NCT04385368|EXPERIMENTAL|Durvalumab + SoC chemotherapy|Intravenous administration of Experimental and Standard of Care Therapy
62046966|NCT04385368|PLACEBO_COMPARATOR|Placebo + SoC chemotherapy|Intravenous administration of Placebo and Standard of Care Therapy
62046967|NCT05790538||Observational (survey, assessment, SmartSocks, monitor)|Patients complete surveys and clinic assessments at baseline, every 4-6 weeks during chemotherapy, and then every 3 months for 1 year after completion of chemotherapy. Clinic assessments include tests of neuropathy, upper and lower body strength, balance, and mobility. Patients complete weekly symptom surveys and wear instrumented socks and an activity monitor at regular intervals at home during chemotherapy treatment and for 1 year after completion of chemotherapy. Patients' medical records are also reviewed. After main study, patients may optionally complete surveys every 6 months for up to 5 years on study.
62439025|NCT01483872|EXPERIMENTAL|NAC/Tigecycline/Heparin combination lock solution|A combination of the above three drugs will form the catheter lock solution that will be instilled into the catheter
62046968|NCT04525495|EXPERIMENTAL|Dopamine treatment|
62046969|NCT04135157|EXPERIMENTAL|PECS II or ESP|PECS II or ESP block are performed 30 minutes before general anesthesia. PCA is used for all the patients in the first 24 hours postoperatively.
62046970|NCT04135157|ACTIVE_COMPARATOR|Control|In the control group, patients will have only general anesthesia. PCA is used for all the patients in the first 24 hours postoperatively.
62046971|NCT04216030|EXPERIMENTAL|High iron Irish potato|Meal sequence B, IP High Fe
62046972|NCT04216030|ACTIVE_COMPARATOR|Regular Irish potato|Meal sequence A, OFSP control
62046973|NCT04499807|OTHER|Smart Watch|The patients will wear the Smart Watch to generate data to assess their rhythm as confirmed by the ILR done during the same time.
62046974|NCT04274400||Patients referred for polysomnography|Patients referred for polysomnography will be classified according to the presence of OSA, insomnia or both.
62439026|NCT01483872|PLACEBO_COMPARATOR|Standard anticoagulant (heparin or citrate)|Standard anticoagulant (heparin or citrate)
62439027|NCT00003833||Normal and tumor tissue pairs|Matched normal and tumor DNA is analyzed for 8p allelic imbalance with at least 8 markers: D8S262 and D8S1825 localized to 8p23, D8S254 and D8S261 at 8p22, D8S560 and D8S136 at 8p21, and D8S1820 and D8S283 at 8p12. Normal/tumor tissue pairs are used for fine mapping studies.
62439028|NCT00526890|EXPERIMENTAL|CPSR|Concurrent Carboplatin, Paclitaxel and Selenomethionine in Combination with Radiation
62439029|NCT05893212|EXPERIMENTAL|Nature-group|Primary care patients identified to be in the target group for health promoting activity by health or social service professionals. Participants chose to take part in the 8 week nature-group, meeting weekly in outdoor areas.
62449399|NCT02081521|EXPERIMENTAL|Community behaviour change campaign|Participants will be exposed to the community behaviour change intervention.
62046975|NCT04496726|EXPERIMENTAL|Cranberry and Quillaja|one 450mg cranberry capsule and one 50mg quillaja capsule in the morning and evening for 14 days.
62046976|NCT02182973||DHM|Infants identified with neonatal abstinence syndrome requiring pharmacologic management and who will not be fed own mother's milk
62046977|NCT02120508|EXPERIMENTAL|1 Hz rTMS, real|1 Hz rTMS over unaffected hemisphere for 15 minutes
62046978|NCT02120508|SHAM_COMPARATOR|1Hz rTMS, sham|1Hz sham rTMS, over unaffected hemisphere for 15 minutes
62046979|NCT04032665||Stable coronary and peripheral artery disease (CAD/PAD)|Stable CAD/PAD patients with previous percutaneous coronary intervention and drug eluting stent-implantation treated with dual antiplatelet therapy (ASA+clopidogrel)
62249116|NCT05467215|EXPERIMENTAL|Hyperoxia followed by room air|Group 1 will receive oxygen (99%) in Phase 1, and room air (placebo) in Phase 2. Each phase will consist of 2 experiments. In Phase 1, the first experiment will test skin sensation using von Frey Hairs, while the second experiment will test a cutaneous reflex. In Phase 2, the first experiment will test the cutaneous reflex, while the second experiment will test skin sensation with von Frey Hairs. Both high oxygen and room air will be delivered through a face mask. The flow rate will be 10 litres/min for a 2-min period. Participants and experimenters will be blinded to the intervention. Measures will be taken before and after each exposure. In this way, each participant will be involved in four experimental sessions with a minimum of 2-week intervals between every testing session. Each experimental session will take approximately 1.5 to 2 hours. A total duration of involvement in the study is a minimum of 7 weeks.
62439030|NCT05893212|ACTIVE_COMPARATOR|Sports-group|Primary care patients identified to be in the target group for health promoting activity by health or social service professionals. Participants chose to take part in the 8 week sports-group, meeting weekly in community sports facilities.
62439031|NCT02942251|EXPERIMENTAL|Clinical features and medication|A group patients with significant high risk of clinical features and medications.
62828950|NCT04682366|PLACEBO_COMPARATOR|Placebo|Patients in this arm will receive 10 days of identical-appearing placebo once daily starting 5 days pre-operatively and continuing until all pills are completed.
62828951|NCT02023463|EXPERIMENTAL|Treatment (enzalutamide, radiation therapy, hormone therapy)|Patients receive enzalutamide PO QD for 6 months. Beginning 2 weeks after start of enzalutamide, patients receive LHRH agonist therapy with goserelin acetate SC or leuprolide acetate IM or SC for 6 months (intermediate risk patients) or 24 months (high risk patients) post-radiation therapy. Beginning 8 weeks after the start of LHRH therapy, patients undergo either IMRT or VMAT daily five days a week for 8 weeks.
62828952|NCT06582927|EXPERIMENTAL|Mindfulness Training Group A|Participants in this group will receive mindfulness training in up to 4 weeks. After the 4-week period, participants will have access to the materials provided.
62828953|NCT06582927|ACTIVE_COMPARATOR|Wait-list condition Group B|Participants in this group will be on a waiting list to receive the identical intervention as the experimental group after 4 weeks. Total participation in the mindfulness training will be 4 weeks
62828954|NCT05511233|NO_INTERVENTION|CONTROL GROUP|Control Group: Electronic health records of the newborns who do not receive breast milk in the first 48 hours of the postoperative period will be in the control group.
62828955|NCT05511233|EXPERIMENTAL|ERAS GROUP|ERAS Group: Electronic health records of the newborns who had breastmilk within the first 48 hours in the postoperative period will be in the ERAS group.
62828956|NCT05806580|EXPERIMENTAL|Relma-cel secondary infusion|
62828957|NCT00199381|EXPERIMENTAL|Single Arm|Treatment with oral istradefylline (KW-6002) 20 or 40 mg once daily.
62828958|NCT00231569|EXPERIMENTAL|Cohort A|Loading doses followed by weekly maintenance doses
62828959|NCT00231569|EXPERIMENTAL|Cohort B|Loading doses followed by weekly maintenance doses
62828960|NCT00231569|EXPERIMENTAL|Cohort C|Loading doses followed by weekly maintenance doses
62828961|NCT00231569|EXPERIMENTAL|Cohort D|Loading doses followed by weekly maintenance doses
62046980|NCT04032665||Acute coronary artery disease (ACS)|Patients with troponin-positive ACS (NSTEMI/STEMI) with planned percutaneous coronary intervention and drug eluting stent-implantation treated with P2Y12 inhibitor (ticagrelor) and ASA
62046981|NCT02922348|EXPERIMENTAL|Hormone Replacement Therapy|Patient will be given hormones in the form of: transdermal estradiol patch (Climara) 100 mcg/24 hours weekly, progesterone (Prometrium) 200 mg per day for first 12 calendar days of each month (If patients insurance plan does not cover transdermal estradiol, they will be prescribed oral estradiol 2 mg daily. If patients insurance plan does not cover Prometrium, they will be prescribed medroxyprogesterone (Provera) 10 mg per day for first 12 calendar days of each month).
62046982|NCT02922348|EXPERIMENTAL|Combined Oral Contraceptives|Patients will be given hormones in the form of: monophasic combined oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.25 mg, 1 tablet daily (21 days of active pills and 7 days of inactive pills)
62046983|NCT06239155|EXPERIMENTAL|Phase I: dose escalation phase|AST-3424 (1.0 mg/m\^2 to 10.0 mg/m\^2 or higher doses) will be administered by IV infusion on Day1 and Day8 of each 21-day cycle. 1mg/m\^2 and 2mg/m\^2 cohort will enroll 1 participant respectively . 4mg/m\^2 or higher dose cohorts will use 3+3 dose escalation design to determine the MTD and RP2D.
62828962|NCT00231569|EXPERIMENTAL|Cohort E|Loading doses followed by weekly maintenance doses
62828963|NCT00231569|EXPERIMENTAL|Cohort F|Loading doses followed by extended weekly maintenance doses
62828964|NCT00231569|EXPERIMENTAL|Cohort G|Loading doses followed by extended weekly maintenance doses
62828965|NCT02008799|EXPERIMENTAL|Bone marrow stem cell injection|through special butterfly inject stem cell in testicular artery and inside tubules
62828966|NCT05270720|EXPERIMENTAL|experimental group|This arm will evaluate the safety of administering a total dendritic cell dose of 5x106. A total of 3 to 6 patients will be enrolled. If this dose is associated with unacceptable side effects, as detailed in the study protocol, no further patients will be enrolled at this dose.
62828967|NCT02491632|EXPERIMENTAL|Arm I (high-dose dexamethasone, physical activity)|Patients receive high-dose dexamethasone PO BID for 7 days. Patients also follow a graded resistance exercise program 3 days a week and a walking regimen at least 5 days a week for 4 weeks. The frequency, duration, and intensity of the exercises will be evaluated and adjusted as necessary.
62606582|NCT04286477||15 patients undergoing online-hemodiafiltration|15 patients undergoing conventional hemodialysis with high-flux dialyzer will be allocated to online-hemodiafiltration with the same dialyzer
62249117|NCT05467215|PLACEBO_COMPARATOR|Room air followed by hyperoxia|Group 2 will receive room air (placebo) in Phase 1, and oxygen (99%) in Phase 2. Each phase will consist of 2 experiments. In Phase 1, the first experiment will test the cutaneous reflex, while the second experiment will test skin sensation with von Frey Hairs. In Phase 2, the first experiment will test skin sensation using von Frey Hairs, while the second experiment will test a cutaneous reflex. Both high oxygen and room air will be delivered through a face mask approved by Health Canada. The flow rate will be 10 litres/min for a 2-min period. Participants and experimenters will be blinded to the intervention. Measures will be taken before and after each exposure.In this way, each participant will be involved in four experimental sessions with a minimum of 2-week intervals between every testing session. Each experimental session will take approximately 1.5 to 2 hours. A total duration of involvement in the study is a minimum of 7 weeks.
62046984|NCT06239155|EXPERIMENTAL|Phase II: cohort expansion phase|6mg/m\^2, administrated on Day1 and Day 8 of each 21-day cycle
62249118|NCT05035576|ACTIVE_COMPARATOR|400 mg OPN-019|
62249119|NCT05035576|NO_INTERVENTION|Standard of Care (SOC)|
62249120|NCT02748330|EXPERIMENTAL|Ticagrelor|Oral ticagrelor 90 mg tablet, twice daily for 15±2 days. Oral aspirin 100 mg tablet, once daily for 15±2 days
62046985|NCT02417818|EXPERIMENTAL|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Plasma Therapy (PlasmaDerm)"
62046986|NCT02417818|EXPERIMENTAL|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.~Intervention: Plasma Therapy (PlasmaDerm)"
62046987|NCT02417818|EXPERIMENTAL|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Plasma Therapy (PlasmaDerm)"
62046988|NCT02417818|ACTIVE_COMPARATOR|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Plasma Therapy (PlasmaDerm)"
62249121|NCT02748330|ACTIVE_COMPARATOR|Clopidogrel|Oral clopidogrel 75 mg tablet, once daily for 15±2 days. Oral aspirin 100 mg tablet, once daily for 15±2 days
62439032|NCT02942251|EXPERIMENTAL|Psycho-social|A group patients with significant high risk of psycho-social problems.
62439033|NCT02942251|EXPERIMENTAL|immunology|A group patients with significant high risk of immune disturbance.
62606583|NCT04286477||15 patients undergoing expanded hemodialysis with MCO dialyzer|15 hemodialysis patients undergoing hemodialysis with a high-flux dialyzer will be allocated to HDx with an MCO dialyzers (THERANOVA dialyzer, Baxter International Inc. (NYSE: BAX))
62828968|NCT02491632|EXPERIMENTAL|Arm II (low dose dexamethasone, physical activity)|Patients receive low-dose dexamethasone PO BID for 7 days. Patients also follow a graded resistance exercise program 3 days a week and a walking regimen at least 5 days a week for 4 weeks. The frequency, duration, and intensity of the exercises will be evaluated and adjusted as necessary.
62249122|NCT05023564||Early onset dementia|Dementia patients with onset age lower than 65y/o
62249123|NCT05023564||Late onset dementia|Dementia patients with onset age between 65y/o and 85y/o
62439034|NCT02942251|EXPERIMENTAL|Laboratory abnormality|A group patients with significant high risk of Laboratory abnormalities.
62828969|NCT03536208|EXPERIMENTAL|Warfarin|Patients will be assigned to warfarin by mouth daily on an outpatient basis. Dose level will increase after 5 patients enrolled. Dose 1 = 1 mg warfarin; Dose 2 = 2 mg warfarin; Dose 3 = 2.5 mg warfarin; Dose 4 = 4 mg warfarin and Dose 5 = 5 mg warfarin
62828970|NCT06430970|OTHER|patients with iron deficiency anemia|
62046989|NCT02417818|EXPERIMENTAL|Second-Degree Burn (repetitive)|"Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
62249124|NCT05023564||Oldest old dementia|Dementia patients with onset age older than 85y/o
62249125|NCT05023564||Cognitive normal control|Normal Aging with normal cognitive function
62249126|NCT03713749|EXPERIMENTAL|Robot Esophagectomy (RE)|Patients in the RE group will receive robotic-assisted esophagectomy with standard total two-field lymphadenectomy.
62828971|NCT06600009||Secukinumab|Patients had received secukinumab treatment.
62828972|NCT06600009||Adalimumab|Patients had received adalimumab treatment.
62046990|NCT02417818|EXPERIMENTAL|Skin Excision (for Skin Graft) (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
62439035|NCT02942251|EXPERIMENTAL|Comorbidity|A group patients with physical or mental disorders comorbidities.
62439036|NCT02942251|EXPERIMENTAL|Treatment as usual|Control group.
62439037|NCT04052399|ACTIVE_COMPARATOR|Anodal tDCS|Anodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network (2 conditions)
62439038|NCT04052399|ACTIVE_COMPARATOR|Cathodal tDCS|Cathodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network (2 conditions)
62606584|NCT04286477||15 patients undergoing peritoneal dialysis|15 patients undergoing peritoneal dialysis
62606585|NCT01010958|EXPERIMENTAL|Valproate|Valproic Acid taken orally, daily to reach serum levels between 50 to 100 µg/mL.
62606586|NCT05642624||sepsis group|invasive fungal infection patients who were diagnosed sepsis accoreding to the sepsis 3.0 guidlines.
62828973|NCT04849247|EXPERIMENTAL|177Lu-DOTA-FAPI dose escalation therapy study|Patients will be undergo 68Ga-DOTA-FAPI PET/CT scans to confirm eligibility for the 177Lu-DOTA-FAPI therapy. Patients with sufficient lesion uptake of 68Ga DOTA-FAPI PET/CT will be offered therapy. Escalating doses of 30-150 mCi of 177Lu-DOTA-FAPI will be administered in a traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort.
62606587|NCT05642624||septic shock group|invasive fungal infection patients who were diagnosed septic shock accoreding to the sepsis 3.0 guidlines.
62606588|NCT04281316|ACTIVE_COMPARATOR|Non Invasive Ventilation device group|The patients in the NIV arm will receive treatment as in their usual care with an additional educational session of one hour for improving compliance.
62606589|NCT04281316|EXPERIMENTAL|Nasal High Flow (MyAirvo) device group|The patients in the NHF arm will receive NHF treatment and two hours training adaptation session will be conducted in the hospital.
62606590|NCT06173739|ACTIVE_COMPARATOR|Peri-implant mucositis|"It is defined as widespread inflammatory disease of the soft tissue surrounding endosseous implants without loss of crestal bone or marginal bone. Peri-implant mucositis is diagnosed by pain, swelling, redness and bleeding on probing in the soft tissue around the dental implant.~Diagnosis will be completed based on radiographic and clinical findings at the first encounter with the patient.~In the second session, PICF (peri-implant crevicular fluid) will be collected from both groups of implants and phenotype evaluations will be made.~Following the recording of clinical parameters (PD, GI, PI, CAL, BOP), non-surgical mechanical treatment will be applied to both groups."
62828974|NCT04849247|EXPERIMENTAL|Recommended Phase 2 dose 177Lu-DOTA-FAPI therapy study|Patients will be undergo 68Ga-DOTA-FAPI PET/CT scans to confirm eligibility for the 177Lu-DOTA-FAPI therapy. 10 patients will be enrolled in the dose expansion cohort and received the highest dose achieved in the 177Lu-DOTA-FAPI dose escalation therapy study
62828975|NCT05707728||totally resection of glioma using intraoperative ultrasound|totally resection of glioma using intraoperative ultrasound
62046991|NCT02417818|EXPERIMENTAL|Chronic Wound (repetitive)|"Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
62046992|NCT02417818|ACTIVE_COMPARATOR|Intact Skin (repetitive)|"Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
62046993|NCT02417818|EXPERIMENTAL|Hypertrophic burn scar|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
62046994|NCT02417818|EXPERIMENTAL|Hypertrophic burn scar (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
62249127|NCT03713749|NO_INTERVENTION|Video-assisted thoracoscopic esophagectomy (VATE)|Patients in the VATE group will receive thoracoscopic esophagectomy with standard total two-field lymphadenectomy.
62249128|NCT05589779||With cardiovascular disease|Asthma patients with cardiovascular disease
62249129|NCT05589779||Without cardiovascular disease|Asthma patients without cardiovascular disease
62249130|NCT00000387|EXPERIMENTAL|A,1,III|Behavioral intervention - Self management therapy
62249131|NCT00000387|ACTIVE_COMPARATOR|A,2,III|Regular treatment
62249132|NCT02380950|OTHER|250 ml alcohol consumption|"Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510."
62249133|NCT06474910|EXPERIMENTAL|Connective tissue massage group|In addition to the exercise program for hand rehabilitation, 15 patients in this group will receive connective tissue massage of the hand and forearm area. The exercise program will include stretching exercises for the hand, strengthening exercises, normal joint movement exercises, functional exercises and tendon sliding exercises.
62606591|NCT06173739|ACTIVE_COMPARATOR|Peri-implantitis|"Peri-implantitis is a pathology that occurs in the tissues around dental implants, characterized by inflammation of the peri-implant mucosa and destruction of marginal and crestal bone. Clinical diagnosis is defined by the presence of bleeding on probing, the presence of pathological pockets, exudate, swelling, edema, and hyperemia, while findings of bone loss are supported by radiography.~Diagnosis will be completed based on radiographic and clinical findings at the first encounter with the patient.~In the second session, PICF (peri-implant crevicular fluid) will be collected from both groups of implants and phenotype evaluations will be made.~Following the recording of clinical parameters (PD, GI, PI, CAL, BOP), non-surgical mechanical treatment will be applied to both groups."
62606592|NCT02107287|EXPERIMENTAL|IMRT Hypofractionated|Neo-adjuvant hormone therapy for three months followed by IMRT combined with a 24-month hormonal therapy.
62046995|NCT02417818|EXPERIMENTAL|Flap|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
62249134|NCT06474910|EXPERIMENTAL|Exercise group|Only exercise program will be applied to 15 patients in this group. The exercise program will include stretching exercises for the hand, strengthening exercises, normal joint movement exercises, functional exercises and tendon sliding exercises.
62249135|NCT01704040|EXPERIMENTAL|Part 1: Healthy participants (CNTO 3157 + HRV-16)|
62249136|NCT01704040|PLACEBO_COMPARATOR|Part 1: Healthy participants (placebo + HRV-16)|
62828976|NCT04964180|ACTIVE_COMPARATOR|indomethacin group|group indomethacin (40 patients) recived two 100 mg indomethacin rectal suppositories 2 hours prior to surgery
62828977|NCT04964180|ACTIVE_COMPARATOR|intraperitoneal lidocaine|200 ml saline containing 200 mg 2%lidocaine immediately after abdominal cO2 insufflation( pneumoperitoneum) the surgeon sprayed the total solution on the upper surface of the liver under the right subdiaphragmatic space, left subdiaphragmatic space and around the cholecystectomy site , all patients were maintained in trendelenberg position
62249137|NCT01704040|EXPERIMENTAL|Part 2: Asthmatic patients (CNTO 3157 + HRV-16)|
62249138|NCT01704040|PLACEBO_COMPARATOR|Part 2: Asthmatic patients (placebo + HRV-16)|
62828978|NCT01323114|ACTIVE_COMPARATOR|Medical Control Group|Control group of patients who will receive conventional medical treatment for type 2 diabetes, along with regular dietary and diabetic education, under the monitoring of the study endocrinologist.
62606593|NCT03196375|EXPERIMENTAL|Experimental|
62606594|NCT03196375|PLACEBO_COMPARATOR|Placebo Comparator|
62606595|NCT06278727||Regression group|Regression group contains the patients whose FMR regresses after taking GDMT for at least 3 months.
62249139|NCT02163187|EXPERIMENTAL|InterStimTM the device on|The device will be set to stimulate for 4 weeks, then off for two weeks, and then the device will be on but will not stimulate for 4 weeks.
62249140|NCT02163187|EXPERIMENTAL|InterStimTM the device off|The device will be on but will not stimulate for 4 weeks, then off for two weeks, and then the device will be set to stimulate for 4 weeks.
62249141|NCT01540825|EXPERIMENTAL|BI 113608 high dose 1|Powder for oral solution
62249142|NCT01540825|EXPERIMENTAL|BI 113608 low dose 1|Powder for oral solution
62249143|NCT01540825|EXPERIMENTAL|BI 113608 low dose 2|Powder for oral solution
62249144|NCT01540825|EXPERIMENTAL|BI 113608 low dose 4|Powder for oral solution
62249145|NCT01540825|EXPERIMENTAL|BI 113608 low dose 5|Powder for oral solution
62249146|NCT01540825|EXPERIMENTAL|BI 113608 medium dose 1|Powder for oral solution
62249147|NCT01540825|EXPERIMENTAL|BI 113608 medium dose 2|Powder for oral solution
62249148|NCT01540825|EXPERIMENTAL|BI 113608 medium dose 3|Powder for oral solution
62249149|NCT01540825|EXPERIMENTAL|BI 113608 high dose 2|Powder for oral solution
62249150|NCT01540825|EXPERIMENTAL|BI 113608 high dose 3|Powder for oral solution
62249151|NCT01540825|PLACEBO_COMPARATOR|Placebo|Powder for oral solution
62249152|NCT04475640|EXPERIMENTAL|Screening (biospecimen collection)|Patients undergo collection of blood or saliva sample for genetic testing.
62249153|NCT04754282|ACTIVE_COMPARATOR|Traditional sitting position|Expecting women are positioned in a traditional sitting position for epidural analgesia catheter placement during labour.
62606596|NCT06278727||No-reaction group|No-reaction group contains the patients whose FMR has no regression by every clinical visit.
62606597|NCT03933722||Caretaker|Comparing blood pressure obtained using routine blood pressure sphygmomanometer to a non-invasive device that continuously monitors central blood pressure (CareTaker).
62606598|NCT04747444|OTHER|100% body weight walking|Individuals with knee osteoarthritis will walk 45 minutes on a treadmill at 100% full body weight loading
62606599|NCT04747444|OTHER|50% body weight walking|Individuals with knee osteoarthritis will walk 45 minutes on a treadmill at 50% full body weight loading
62606600|NCT02889250|EXPERIMENTAL|Open Label DBS|6 months of DBS
62606601|NCT04706806|EXPERIMENTAL|liquid vinegar|2 tablespoons (diluted in water) taken twice daily with meals
62606602|NCT04706806|PLACEBO_COMPARATOR|vinegar pill|1 vinegar pill taken daily
62606603|NCT04276610|NO_INTERVENTION|Healthy Control Participants|Older adults (65+) without impairments in vision or hearing. This groups will simply be followed for the study period (1 year), measured at 6 months intervals, to provide control comparison data for all outcome measures
62606604|NCT04276610|EXPERIMENTAL|Low Vision Participants|Older adults (65+) with impairments in vision but without hearing impairment. This groups will receive regular standard of low vision rehabilitation care and will be followed for the study period (1 year), measured at 6 months intervals.
62606605|NCT04276610|EXPERIMENTAL|Dual Sensory Impairment Participants|Older adults (65+) with impairments in both vision hearing hearing. This groups will receive regular standard of low vision rehabilitation care and will be followed for the study period (1 year), measured at 6 months intervals.
62606606|NCT02484300|EXPERIMENTAL|Melatonin 4hrs before bed|Time of dosage comparison on blood serum melatonin phase and subjective sleepiness
62606607|NCT02484300|EXPERIMENTAL|Melatonin 2hrs before bed|Time of dosage comparison on blood serum melatonin phase and subjective sleepiness
62606608|NCT02484300|EXPERIMENTAL|Melatonin|To determine effects of 10mg daily melatonin on chemoreflex control, oxidation status, loop gain and apnea hypopnea index in obstructive sleep apnea
62249154|NCT04754282|EXPERIMENTAL|Cross-legged sitting position|Expecting women are positioned in a crosse-legged sitting position for epidural analgesia catheter placement during labour.
62249155|NCT03254654|EXPERIMENTAL|Vinorelbine Plus Apatinib|"Vinorelbine: 20 mg/m2, D6, D13, D20~Apatinib: 250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2."
62249156|NCT03254654|ACTIVE_COMPARATOR|Vinorelbine|Vinorelbine: 25 mg/m2, D1, D8, D15
62249157|NCT05782270|OTHER|DAPT|Comparison group: dual antiplatelet only
62249158|NCT05782270|EXPERIMENTAL|DAPT+warfarin|Intervention group: dual antiplatelet combined with warfarin
62249159|NCT01166503||Early Surgery|This group will be made up of subjects whose parents choose to have them undergo corrective surgery at or before age 11 months.
62249160|NCT01166503||Standard Surgery|This group will be made up of subjects who present after age 11 months or whose parents choose to have them undergo corrective surgery between 11-18 months.
62249161|NCT06257771||Women 1-5 years post-SG|"* Alcohol orally administered (0.5 grams per kg of Fat-free mass) after overnight fast or after a standard meal~* Alcohol administered IV using an alcohol clamp (target concentration of 0.6g/L after an overnight fast or one hour after consuming a standard mixed meal)"
62249162|NCT06257771||Men 1-5 years post-SG|"* Alcohol orally administered (0.5 grams per kg of Fat-free mass) after overnight fast or after a standard meal~* Alcohol administered IV using an alcohol clamp (target concentration of 0.6g/L after an overnight fast or one hour after consuming a standard mixed meal)"
62249163|NCT06257771||Women, non-operated control|"* Alcohol orally administered (0.5 grams per kg of Fat-free mass) after overnight fast or after a standard meal~* Alcohol administered IV using an alcohol clamp (target concentration of 0.6g/L after an overnight fast or one hour after consuming a standard mixed meal)"
62249164|NCT06257771||Men, non-operated control|"* Alcohol orally administered (0.5 grams per kg of Fat-free mass) after overnight fast or after a standard meal~* Alcohol administered IV using an alcohol clamp (target concentration of 0.6g/L after an overnight fast or one hour after consuming a standard mixed meal)"
62249165|NCT03764371||sMPLC|Lung cancer related genes in tumor tissues and patients with at least 2 tumors that were confirmed as invasive adenocarcinoma by pathology after sMPLC resection (residual non-resectable or non-qualitative pulmonary nodules).
62249166|NCT04532736|EXPERIMENTAL|Methotrexate|10 mg Emthexate, PO, once a week during 8 weeks
62249167|NCT04532736|ACTIVE_COMPARATOR|Methylprednisolone|8 mg/day Prednol, PO, for 8 weeks
62606609|NCT02484300|PLACEBO_COMPARATOR|Placebo|Placebo outcomes versus melatonin
62606610|NCT03768700||Cohort|Hospitalization in a Post-Resuscitation Rehabilitation Care Units (SRPR)
62606611|NCT04733716|ACTIVE_COMPARATOR|Total Knee Arthroplasty with using Tourniquet|A pneumatic tourniquet was used before surgery at the proximal thigh and inflated before the skin incision until skin closure in this group. The tourniquet was inflated to either 275 or 325 mmHg, depending on the patient's systolic blood pressure.
62828979|NCT01323114|EXPERIMENTAL|Surgical Treatment Group|Experimental group in which patients will undergo the laparoscopic duodenal bypass procedure along with regular dietary and diabetic education, under the monitoring of the study endocrinologist.
62828980|NCT06593730|EXPERIMENTAL|NRL001 cream 0.5%w/w|0.5%w/w NRL001 (1R,2S-methoxamine) 1 mL, twice daily administration (morning and afternoon) for 14 days (study Days D1 to D14).
62828981|NCT06593730|EXPERIMENTAL|NRL001 cream 0.75% w/w|0.75%w/w NRL001 (1R,2S-methoxamine) 1 mL, twice daily administration (morning and afternoon) for 14 days (study Days D1 to D14).
62828982|NCT06593730|EXPERIMENTAL|NRL001 cream 1.0% w/w|1.0%w/w NRL001 (1R,2S-methoxamine) 1 mL, twice daily administration (morning and afternoon) for 14 days (study Days D1 to D14).
62249168|NCT04532736|ACTIVE_COMPARATOR|Control|200 mcg/day, intranasal mometasone furoate, for 8 weeks
62249169|NCT04728022|EXPERIMENTAL|Students|Education program
62828983|NCT06593730|EXPERIMENTAL|NRL001 cream 1.5% w/w|1.5%w/w NRL001 (1R,2S-methoxamine) 1 mL, twice daily administration (morning and afternoon) for 14 days (study Days D1 to D14).
62828984|NCT06593730|EXPERIMENTAL|NRL001 cream 2.0% w/w|2.0%w/w NRL001 (1R,2S-methoxamine) 1 mL, twice daily administration (morning and afternoon) for 14 days (study Days D1 to D14).
62828985|NCT06593730|EXPERIMENTAL|NRL001 cream 2.5% w/w|2.5%w/w NRL001 (1R,2S-methoxamine) 1 mL, twice daily administration (morning and afternoon) for 14 days (study Days D1 to D14).
62046996|NCT02417818|EXPERIMENTAL|Flap (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
62046997|NCT04899882|NO_INTERVENTION|Control group|
62046998|NCT04899882|EXPERIMENTAL|KinHémo group|
62046999|NCT04853680|EXPERIMENTAL|Treatment|Use of Anti-adhesion barrier on the thyroidectomy space. After the thyroidectomy, anti-adhesion barrier will be applied on the thyroidectomy space, around the trachea, cricothyroid muscle and platysma muscle before the closure of surgical wound.
62249170|NCT02170779|EXPERIMENTAL|A Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
62249171|NCT02170779|OTHER|B Usual care|2 visits: baseline and given usual treatment of brochure for stretching, outcome measures
62249172|NCT00972426|EXPERIMENTAL|Treatment A Group|Mikelan LA + Xalatan
62249173|NCT00972426|ACTIVE_COMPARATOR|Treatment B Group|Timoptol XE + Xalatan
62249174|NCT04823611|PLACEBO_COMPARATOR|Part A:Placebo|Placebo solution for subcutaneous injection.
62249175|NCT04823611|EXPERIMENTAL|Part A:AZD8233|AZD8233 for subcutaneous injection.
62249176|NCT04823611|PLACEBO_COMPARATOR|Part B:Placebo|Placebo solution for subcutaneous injection.
62249177|NCT04823611|EXPERIMENTAL|Part B:AZD8233 medium dose|AZD8233 medium dose for subcutaneous injection.
62249178|NCT04823611|EXPERIMENTAL|Part B:AZD8233 low dose|AZD8233 low dose for subcutaneous injection.
62249179|NCT04823611|PLACEBO_COMPARATOR|Part C: Placebo|Placebo solution for subcutaneous injection.
62249180|NCT04823611|EXPERIMENTAL|Part C: AZD8233 medium dose|AZD8233 medium dose for subcutaneous injection.
62249181|NCT04993794|ACTIVE_COMPARATOR|XueBiJing|XBJ (Composed of Carthamus tinctorius L., Paeonia Lactifora Pall, Ligusticum wallichii, Salvia miltiorrhiza, Angelica sinensis, etc. Tianjin Chase Sun Pharmaceutical Group, Tianjin, China, batch No. 1603231) 100ml Xuebijing injection every 12 h (q12h) for 60 min
62249182|NCT04993794|PLACEBO_COMPARATOR|Normal saline|0.9% saline every 12 h (q12h) for 60 min
62249183|NCT00017121|EXPERIMENTAL|sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) twice a day on days 1-7 and 15-21. Treatment repeats every 28 days for 2 courses. Patients with no disease progression after completion of course 2 may continue on treatment until disease progression. Patients are grouped to 1 of 2 dose-escalation regimens (part A vs B).~After completion of study therapy, patients are followed at 3 months, every 2 months for 1 year, and then every 3-4 months for 5 years."
62249184|NCT04280445|EXPERIMENTAL|Psychological therapy|All participants will receive psychological therapy. There will be no placebos or waiting list controlled participants to compare findings to.
62249185|NCT05148039|ACTIVE_COMPARATOR|Community cohort|Participants from the Ehlers Danlos UK society community who low diet quality
62249186|NCT05148039|ACTIVE_COMPARATOR|Clinic cohort|Participants from a Tertiary Neurogastroenterology clinic who have low die quality
62249187|NCT04048590|NO_INTERVENTION|Control|Control subjects will receive care at a skilled nursing facility.
62439039|NCT04052399|PLACEBO_COMPARATOR|Sham stimulation|Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds in order to simulate the active condition without any further continuous administration of current)
62606612|NCT04733716|ACTIVE_COMPARATOR|Total Knee Arthroplasty without using Tourniquet|A pneumatic tourniquet was not used in this group during the total knee arthroplasty.
62606613|NCT02358980||Study group|Participants will receive FLC removal HD undertaken using an extended dialysis schedule on KIDNEY therapy system. Treatments (4 hours each) were carried out for 8 consecutive days and then every other day.
62606614|NCT05489991|EXPERIMENTAL|TmPSMA-02|
62606615|NCT00616603|OTHER|Group A|This is the control arm and subjects in Group A will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 2ml IV of normal saline.
62606616|NCT00616603|EXPERIMENTAL|Group B|Subjects in Group B will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 8mg Dexamethasone + 2ml IV of normal saline.
62606617|NCT00616603|ACTIVE_COMPARATOR|Group C|Subjects in Group C will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 2ml IV (8mg)of Dexamethasone.
62606618|NCT05530200|EXPERIMENTAL|Radiotherapy, PD-L1 inhibitors Sequential GM-CSF and IL-2|
62606619|NCT05426824|EXPERIMENTAL|P-GOD|P-GOD (peasparaginase + gemcitabine + oxaliplatin + dexamethasone) ;
62249188|NCT04048590|ACTIVE_COMPARATOR|Intervention|Intervention subjects will go home from the hospital and receive care from a specialized care team.
62606620|NCT05426824|EXPERIMENTAL|PEMD|PEMD (peaspargase + etocytidine + methotrexate + dexamethasone)
62606621|NCT02672332|EXPERIMENTAL|SB204 4%|SB204 4% topically once daily
62249189|NCT03617250||Active patients|50 rheumatoid patients with active disease according to Disease Activity Score-28
62249190|NCT03617250||patients with remission|50 patients with remission according to Disease Activity Score-28
62249191|NCT02412020|EXPERIMENTAL|PA101|PA101, 40 mg administered via inhalation three times daily for 14 days
62249192|NCT02412020|PLACEBO_COMPARATOR|Placebo|Placebo PA101, administered via inhalation three times daily for 14 days
62249193|NCT01043679|ACTIVE_COMPARATOR|Seroquel|Efficacy and Safety of Seroquel
62249194|NCT01043679|ACTIVE_COMPARATOR|Utapine|Efficacy and Safety of Utapine
62439040|NCT03567057|EXPERIMENTAL|ADS-5102, 274 mg|274 mg ADS-5102, administered once daily at bedtime for up to 52 weeks
62439041|NCT03397563|EXPERIMENTAL|CPAP treatment|Continuous Positive Airway Pressure (CPAP)
62606622|NCT02672332|PLACEBO_COMPARATOR|Vehicle Gel|Vehicle Gel topically once daily
62606623|NCT05848882|EXPERIMENTAL|Elastodontic removable device|Patients in this group will be treat with an elastodontic device adapted to the patient according to the shape of the dental arches. This device is similar to a mouthguard and embraces both dental arches. This appliance is worn overnight and the patient will be checked every month. The distance between the palatal cusps of the first upper premolars will be taken at T0( before the start of the therapy), at T1 (after six months)and at T2 (after one month). All the dental recors will be taken by the same operator with an intraoral scanner 3D.
62828986|NCT02241616|EXPERIMENTAL|Entecavir+Fuzheng Huayu+TCM Granule|Tablet with Entecavir+ Tablet with Fuzheng Huayu+ Granule with TCM
62249195|NCT04340557|EXPERIMENTAL|Group A (Study drug+SOC)|Standard of Care plus an ARB to be taken orally twice daily for up to 10 days or until discharged from the hospital, whichever occurs first. Investigator may increase dose on days 2 - 10 if confident the subject will tolerate.
62439042|NCT03397563|SHAM_COMPARATOR|Sham-CPAP treatment|sham Continuous Positive Airway Pressure (sham-CPAP)
62606624|NCT05848882|EXPERIMENTAL|Schwarz removable device|Patients in this group will be treat with a Schwarz removable device constructed individually by the dental technician.This device has a resin baseplate with an activation screw in the center and Adams hooks on the upper first molars and it works by turning the expansion screw in the center of the palate one-quarter turn, once or twice a month by the ortodontist. This appliance is worn overnight and some hours during the day (totally 16 hours).The distance between the palatal cusps of the first upper premolars will be taken at T0( before the start of the therapy), at T1 (after six months)and at T2 (after one month). All the dental recors will be taken by the same operator with an intraoral scanner 3D.
62606625|NCT01420679|EXPERIMENTAL|Pralatrexate|Patients randomized to the Pralatrexate Arm will receive pralatrexate injection and Vitamins B12 and Folic Acid until a criterion for pralatrexate injection treatment discontinuation is met.
62047000|NCT04853680|NO_INTERVENTION|Control|No use of anti-adhesion barrier. After the thyroidectomy, don't use the anti-adhesion barrier before the wound closure.
62249196|NCT04340557|NO_INTERVENTION|Group B (SOC)|Standard of Care
62249197|NCT04710953|EXPERIMENTAL|CPAP arm|In addition to standard of care, CPAP will be provided at high altitude posts where Gamow bag is not available and all patients of HAPE will be given CPAP when evacuation/descent is either not possible or delayed due to weather conditions.
62439043|NCT05724433|EXPERIMENTAL|Virtual HF care|Patients will receive virtual HF care to optimize medical therapies
62439044|NCT05724433|OTHER|Routine HF care|Participants will receive routine HF care
62439045|NCT02370966|PLACEBO_COMPARATOR|Potato starch|Potato powder will be incorporated in the placebo product.
62439046|NCT02370966|ACTIVE_COMPARATOR|Berry powder|Several different berry powders including rose hip, bilberry, blackcurrant, sea buckthorn, and lingonberry will be prepared and studied.
62439047|NCT00762671|PLACEBO_COMPARATOR|2|Placebo
62439048|NCT00762671|ACTIVE_COMPARATOR|1|Ebselen
62606626|NCT01420679|NO_INTERVENTION|Observation|Patients randomized to the Observation Arm will receive Vitamins B12 and Folic Acid and remain under observation until a criterion for observation discontinuation is met.
62606627|NCT04018040|EXPERIMENTAL|Intervention Group|Patients will follow a lacto-ovo vegetarian diet for an 8 week period. patients will be provided with a lacto-ovo vegetarian food box delivery service with fresh ingredients and recipes to cover four dinners per week.
62828987|NCT02172274|EXPERIMENTAL|[14C]-BI 10773 - oral solution|
62828988|NCT05900596||pH < 3|Patients one or two fetal blood sampling
62828989|NCT05900596||pH > 3|Patients with three or more fetal blood sampling
62828990|NCT01780974|PLACEBO_COMPARATOR|Placebo|Three placebo oil capsules per day (2 caps morning, 1 cap evening) + 2 placebo LA capsules per day. Capsules will be taken with food or a meal.
62606628|NCT06420375|ACTIVE_COMPARATOR|Active Comparator: BRS201 Arm|"In Group 1 of the study, subjects will take oral study drug at 1.2g twice daily, PO (2.4g daily) with 120mg oral butyrate twice daily (240mg daily) for 4 weeks.~In Group 2 of the study, subjects will take oral study drug at 2g twice daily, PO (4g daily) with 120mg oral butyrate twice daily (240mg daily) for 4 weeks.~In Group 3 of the study, subjects will take oral study drug at 2g twice daily, PO (4g daily) with 120mg oral butyrate twice daily (240mg daily) for 4 weeks. Subjects will also receive a one time 2.5g dose of study drug at initiation.~In Group 4 of the study, subjects will repeat the previous conditions of the group that proves to be the most effective."
62828991|NCT01780974|EXPERIMENTAL|Lipoic acid plus omega-3 fatty acids|Three 1-gram fish oil concentrate capsules per day (2 caps morning, 1 cap evening) containing a daily dose of 675 mg docosahexaenoic acid (DHA) and 975 mg eicosapentaenoic acid (EPA) plus 2 LA capsules per day with a daily dose of 600 mg. Capsules will be taken with food or a meal.
62047001|NCT02112981|EXPERIMENTAL|Sirolimus Eluting Coronary Stent|BioMime Sirolimus Eluting Stent of Meril Life Sciences
62047002|NCT02112981|ACTIVE_COMPARATOR|Everolimus-eluting Coronary stent|XIENCE family (V, Xpedition or Prime) of Everolimus-eluting stent system of Abbott Vascular Inc.
62828992|NCT00512889|EXPERIMENTAL|Cohort 1|Different dose of CTL
62828993|NCT00512889|EXPERIMENTAL|Cohort 2|Different dose of CTL
62249198|NCT04710953|NO_INTERVENTION|Gamow bag arm/hyperbaric chamber|Posts where Gamow bag would be available, the patients of HAPE will be given standard of care and will be asked to lie inside Gamow bag inflated at 2 Psi for several hours to simulate a descent of 1500 meters when evacuation/descent is either not possible or delayed due to weather conditions.
62828994|NCT00512889|EXPERIMENTAL|Cohort 3|Combination of CTL with GMCSF +/- radiation
62828995|NCT06271577|EXPERIMENTAL|AliveCor 12-lead ECG|A single research-related procedure will be required (i.e., an AliveCor 12-lead ECG). Effort will be made to ensure that the performance of this procedure will not delay any treatment and/or diagnostic procedures that are part of usual or specialized care that the patient requires.
62828996|NCT06146920|OTHER|Active Surveillance|Patients with 12 month history of immune checkpoint inhibitors (ICI) with stable or partial or complete responses and negative ctDNA at pre-screening, will stop ICI therapy and begin active surveillance with blood draws and standard of care imaging for 12 months.
62828997|NCT01770418|EXPERIMENTAL|Proton Radiotherapy with Chemotherapy|
62828998|NCT06654778|EXPERIMENTAL|Group I: PEEP|Patients will be ventilated with PEEP of 8 cm H2O and fluid management: 500 ml of Ringer's lactate in the recovery room before surgery and Ringer's lactate at a rate of 4 mL/kg/hour from the beginning to the end of the surgery.
62828999|NCT06654778|EXPERIMENTAL|Group II: PEEP/RM|Patients will be ventilated with PEEP of 8 cm H2O, and then RM (30 cm H2O for 30 s) will be applied immediately after the second LUS examination and repeated every 30 minutes till emergence and fluid management: 500 ml of Ringer's lactate in recovery room before surgery and Ringer's lactate at a rate of 4 mL/kg/hour from the beginning to the end of the surgery
62829000|NCT06654778|EXPERIMENTAL|Group III: PEEP/RM/RF|Patients will be ventilated with PEEP of 8 cm H2O, and then RM (30 cm H2O for 30 s) will be applied immediately after the second LUS examination and repeated every 30 minutes till emergence and restrictive fluid management (RF). Ringer's lactate at a rate of 3 mL/kg/hour from the beginning to the end of the surgery
62829001|NCT06651944|EXPERIMENTAL|Invisalign® System with Mandibular Advancement|all participants will receive the study device
62047003|NCT01753921||DKA Group|Subjects who presented in diabetic ketoacidosis.
62047004|NCT01753921||Healthy control|Control subjects without diabetes.
62249199|NCT00695851|EXPERIMENTAL|1|15 mg/m2 weekly of PCK3145
62249200|NCT00695851|EXPERIMENTAL|2|7.5 mg/m2 twice per week of PCK3145
62249201|NCT01293968|EXPERIMENTAL|5cc Ibuprofen100mg,10 cc Diphenhydramine25mg,10 cc AlMgS550mg|
62249202|NCT01293968|ACTIVE_COMPARATOR|100 cc Diphenhydramine, 25 mg and 100 cc AlMgS 550 mg|
62249203|NCT03274050||patient group|Surgery with robot - all patients operated in surgery department with indication of robot in the routine care (all specialities).
62249204|NCT03274050||control group|Retroperitoneal coelioscopy - patient operated for pyeloplasty - only for pediatry
62249205|NCT03443128|EXPERIMENTAL|Vinorelbine monotherapy treatment|Patients will be treated with Vinorelbine. Four weeks as a course. There are 20 courses in total.
62249206|NCT01131416|EXPERIMENTAL|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
62249207|NCT01131416|NO_INTERVENTION|Conventional|Conventional postoperative feeding schedule
62249208|NCT05524922||Neurodegenerative disorders associated with sleep disorders|
62249209|NCT01091597|ACTIVE_COMPARATOR|usual ablation|Wide-area circumferential ablation of the pulmonary veins
62439049|NCT04482010|NO_INTERVENTION|Classic HIV care|Participants diangosed HIV positive at the time of the community-based activities conducted by ARCAD Santé PLUS. They will be referred to the referral centers (CSRéf) for the classic HIV care in the Malian public health system.
62439050|NCT04482010|OTHER|Community-based HIV care|Participants diagnosed HIV positive at the time of the community-based activities by ARCAD Santé PLUS. They will receive community-based HIV care by the NGO at the gold-mining site.
62829002|NCT06072053||BHC group|Patients with CSDH recruited from the neurosurgery departments of 6 medical centers in China who had clinically significant symptoms confirmed by computed tomography or magnetic resonance imaging and ultimately treated with Bulr-hole Craniotomy.
62829003|NCT06072053||YL-1 Needle Puncture group|Patients with CSDH recruited from the neurosurgery departments of 6 medical centers in China who had clinically significant symptoms confirmed by computed tomography or magnetic resonance imaging and ultimately treated with YL-1 needle puncture.
62829004|NCT02307825|ACTIVE_COMPARATOR|Azithromycin|Patients will receive the active study drug, azithromycin, as well as sinus irrigations with budesonide.
62829005|NCT02307825|PLACEBO_COMPARATOR|Placebo|Patients will receive a placebo as well as sinus irrigations with budesonide.
62829006|NCT02739906|EXPERIMENTAL|HinsBet®|
62829007|NCT02739906|ACTIVE_COMPARATOR|Humalog®|
62829008|NCT02739906|ACTIVE_COMPARATOR|Huminsulin® Normal|
62829009|NCT06513091||OCS Lung Transplant Recipients|The US National TOP Registry will enroll all liver transplant recipients who are transplanted with OCS-perfused donor lung(s) in the Registry.
62439051|NCT03129737|EXPERIMENTAL|Tricuspid valve annuloplasty|Concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (\>21mm /m2) with or without TR≤ moderate in pts undergoing mitral valve surgery
62439052|NCT03129737|ACTIVE_COMPARATOR|Mitral valve repair|No concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (\>21mm/m2) with or without TR ≤ moderate in pts undergoing mitral valve surgery
62249210|NCT01091597|EXPERIMENTAL|Box isolation of the pulmonary veins|Single Box lesion set encompassing all four pulmonary veins and the posterior wall of the left atrium.
62249211|NCT04139044|EXPERIMENTAL|Stable Ankle Training Group (SG)|Balance Exercise Training for Only The Stable Ankle
62439053|NCT02878850|EXPERIMENTAL|Augmented Blood Pressure|Subjects will have their blood pressure kept in a higher range.
62439054|NCT02878850|NO_INTERVENTION|Conventional Blood Pressure|Subjects will have their blood pressure kept in a normal range.
62439055|NCT05222815|EXPERIMENTAL|CGM (continuous glucose monitoring)|"Use CGM, with availability of Ambulatory Glucose Profile (AGP) data, to monitor and manage glucose over 12 months, in individuals with type 2 diabetes on insulin with or without other glycemic therapies. Glucose management over the 12 months study period will be in primary care, using usual care resources."
62249212|NCT04139044|EXPERIMENTAL|Unstable Ankle Training Group (UG)|Balance Exercise Training for Only The Unstable Ankle
62829010|NCT06513091||Non-OCS Lung Transplant Recipients|Patients transplanted using other preservation modalities for benchmarking clinical outcomes.
62249213|NCT04139044|NO_INTERVENTION|Control Group (CG)|No balance exercise training
62249214|NCT04107883|EXPERIMENTAL|control group|perform artificial colloidal solution transfusion during anhapetic phase.
62249215|NCT04107883|EXPERIMENTAL|anhapetic group|Perform plasma transfusion during anhapetic phase.
62249216|NCT04280536|EXPERIMENTAL|Cohort A|Patients with prior exposure to fluoropyrimidines
62249217|NCT04280536|EXPERIMENTAL|Cohort B|Patients without prior exposure to fluoropyrimidines
62249218|NCT01899625|ACTIVE_COMPARATOR|Motivation Enhanced BWL|12 week treatment program consisting of 2, 90-minute individual sessions with a focus on motivation, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Participants will pick from one of three dietary goals and one of three physical activity goals.
62249219|NCT01899625|ACTIVE_COMPARATOR|Brief Behavioral Weight Loss (BWL)|12 Week treatment program consisting of 2, 90-minute individual sessions, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Treatment consistent with behavioral weight loss, low calorie, low fat diet. Increased physical activity of up to 250 minutes/week.
62249220|NCT02636933||59 prematurely born children|Lung function assessment of 59 prematurely born children (of both sex and 3-5 years old) attending as outpatient clinic of Pediatric Allergology \& Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR)
62249221|NCT02636933||93 full-term born children|Lung function assessment of a Control group of full-term born children (N=93), recruited by a collaborative Pediatricians network within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy.
62439056|NCT05222815|ACTIVE_COMPARATOR|SMBG (Self-monitoring of blood glucose)|"Use SMBG, as currently used in primary care, to monitor and manage glucose over 12 months, in individuals with type 2 diabetes on insulin with or without other glycemic therapies. Glucose management over the 12 months study period will be in primary care, using usual care resources."
62439057|NCT00437151|ACTIVE_COMPARATOR|1|More frequent than normal office visits
62439058|NCT00437151|ACTIVE_COMPARATOR|2|Electronic reminders (voice, e-mail, text messages)
62439059|NCT00437151|ACTIVE_COMPARATOR|3|Parental involvement / intervention reminders
62439060|NCT00437151|ACTIVE_COMPARATOR|4|No intervention or reminders
62249222|NCT05303870|EXPERIMENTAL|IAPT|
62249223|NCT02611804|EXPERIMENTAL|Diclofenac Sodium Gel, 3%|Diclofenac Sodium Gel, 3%, applied twice daily for 60 days
62249224|NCT02611804|ACTIVE_COMPARATOR|Solaraze®|Solaraze® (diclofenac sodium) Gel, 3%, applied twice daily for 60 days
62249225|NCT02611804|PLACEBO_COMPARATOR|Vehicle of Test Product|Vehicle of Test Product, Gel, applied twice daily for 60 days
62439061|NCT05447611||high score CARE group|"Patient-perceived empathy was assessed using the Consultation and Relational Empathy (CARE) questionnaire that has been validated in cancer care. This is a self-reported ten-point questionnaire with a five-point Likert-type scale ranging from poor to excellent Likert-type scale. It has excellent psychometric properties with α = 0.92. High scores indicate a higher perception of the health care personnel empathy.~The three distinct empathic processes were also assessed with the CARE measure. 'Relationship' was assessed with items 1-3, 'emotional process' with items 4-6, and 'cognitive process' with items 7-10."
62439062|NCT05447611||lower score CARE group|In line with the recent literature, we considered differentiating the study population into two groups: those with a high perceived empathy (maximum CARE score) and those without.
62829011|NCT02512705|OTHER|Seclusion Room|The current practice is followed as a control group A.
62249226|NCT03388918|EXPERIMENTAL|Intervention group|"The intervention group has three steps:~Step I: Titration of medicine ( 0-3 months)~Step II: Telerehabilitation program at healthcare center or by call center ( 3 months)~Step III: Rehabilitation in everyday life ( 6 months)~The patients is monitoring vital signs such as blood pressure, pulse, weight, steps, respiration, and sleep. Have access to a Heart Portal that is an information cite on heart failure. Via the portal patients can see measured values \& communicate with staff. Every other week the patients fill in an online questionnaires on symptoms, sleep and well being."
62249227|NCT03388918|NO_INTERVENTION|Traditional rehabilitation group|"This group follows the International Cardiac Guidelines. There are three steps in this arm:~Step I: Titration of medicine (3 months).~Step II: Traditional rehabilitation at the healthcare center ( 3 months).~Step III: Everyday life with HF ( 6 months)~The participants do not have access to the Heart Portal and is not monitoring any vital signs."
62249228|NCT01280448||Case Group|
62439063|NCT01374399|EXPERIMENTAL|resistance and endurance exercise|
62439064|NCT01374399|ACTIVE_COMPARATOR|relaxation|
62439065|NCT02956720|EXPERIMENTAL|single arm|
62249229|NCT01280448||Control Group|
62249230|NCT05891184||1|the 1st group will be patients with current or past history of variceal bleeding,
62249231|NCT05891184||2|the 2nd group will be patients having gastroesophageal varices without variceal bleeding,
62439066|NCT01983956|EXPERIMENTAL|Experimental arm|The structured approach intervention with the SENS model is based on the bio-psycho-social-spiritual model of care and the WHO definitions of palliative care as well as the NCCN Practice Guidelines for Palliative Care. It supports the assessment of areas and complexity of concerns from the patient perspective, determines the priority and structures the support needed. The intervention is performed by palliative care physicians and nurses collaboratively. It is utilized as baseline assessment and afterwards integrated in each routine oncology care out-patient and in-patient visit. Depending on the goals it may be applied between routine visits. In addition, patients will receive usual oncology care throughout the study period.
62439067|NCT01983956|NO_INTERVENTION|Control arm|Patients in the usual care group will receive routine oncology care throughout the study. This incorporates a routine assessment according to the standard SAKK - protocol which assesses overall symptoms. Patients are not seen by nurses during a routine visit to the outpatient clinic unless they need a blood withdrawal or any intravenous or subcutaneous treatment. Only nursing staff of the palliative care unit is familiar with using the SENS-assessment instrument. Participants assigned to usual care may meet with the palliative care service on request according to established practice.
62439068|NCT05445115|EXPERIMENTAL|Treatment|Actual treatment device
62439069|NCT05445115|SHAM_COMPARATOR|Sham|Sham/placebo device
62439070|NCT03588156|EXPERIMENTAL|Benapenem|Investigatial Product: Benapenem: 11 group : 62.5mg one dose; 125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
62439071|NCT03588156|PLACEBO_COMPARATOR|Placebo|Placebo control 11 group : 62.5mg one dose;125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
62439072|NCT03104153|NO_INTERVENTION|Output-based|
62439073|NCT03104153|ACTIVE_COMPARATOR|Early-removal|
62449400|NCT02081521|NO_INTERVENTION|No community behaviour change campaign|No community intervention will take place in the control arm, although exposure to some intervention messaging (radio adverts) may take place.
62829012|NCT02512705|EXPERIMENTAL|Physical Restraint|Patient is placed in physical restraints to enable delivery of chemical restraints and medical monitoring and is monitored 1:1.
62829013|NCT01655459||Ultrasound exam of upper airway|Following Internal Review Board approval(4-2011-0800) and written informed consent, total 100 patients(ASA I and II children aged 1 month to 6years) undergoing infra-umblicular urologic surgeries were included in the study. Children with upper respiratory tract infection, restricted mouth opening, congenital heart disease and those at risk for aspiration were excluded.
62829014|NCT02446964|EXPERIMENTAL|Treatment (TMLI, chemotherapy, transplant, GVHD prophylaxis)|"CONDITIONING: Patients undergo TMLI BID on days -7 to -4 or -3 (depending on the dose level). Patients also receive fludarabine phosphate IV on days -7 to -3 and cyclophosphamide IV on days -7, -6, 3, and 4.~TRANSPLANT: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0.~GHVD PROPHYLAXIS: Patients receive tacrolimus\* IV QD or PO BID on days 5-180. Patients also receive mycophenolate mofetil PO TID or IV on days 5-35. Treatment with tacrolimus and mycophenolate mofetil may continue in the presence of active GVHD.~\*NOTE: Patients intolerant of tacrolimus may receive cyclosporine."
62829015|NCT04730700|ACTIVE_COMPARATOR|Radiofrequency ablation (RFA) with MEE|Radiofrequency ablation involves a minimally invasive procedural technique. It uses radiofrequency waves to burn the nerve causing pain. This nerve will no longer be able to send pain signals to your brain. For this study, the multi-tined expandable electrode needle will be used. This needle will result in a larger treatment area. This may result in better pain relief and longer lasting pain relief. If you undergo the radiofrequency ablation procedure you will have pain medication injected where the ablation will be done. The procedure will take about 20 mins to complete. You will be allowed to go home afterward.
62829016|NCT04730700|ACTIVE_COMPARATOR|Conventional Medical Management (CMM) Treatment Only|Your current standard of care treatment may already consist of some CMM therapies. Standard of care includes a variety of intervention types such as medication, physical therapy, home exercise programs, back brace, walking aid, and chiropractic care.
62829017|NCT01605708|EXPERIMENTAL|Cohort 1|
62829018|NCT00403377|EXPERIMENTAL|Intervention|Phase II include two arms. In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
62249232|NCT05891184||3|3ed group will be patients without gastroesophageal varices or variceal bleeding.
62449401|NCT05559268|EXPERIMENTAL|Denosumab|
62449402|NCT05559268|PLACEBO_COMPARATOR|Placebo|
62449403|NCT00198029|EXPERIMENTAL|Pilot Study of Hylan G-F 20|32 Subjects have received Synvisc Injections and followed for 6 months.
62249233|NCT01186900|EXPERIMENTAL|Ultrasound-guided needle aspiration|One arm is ultrasound-guided needle aspiration, the other active comparison is traditional open incision and drainage of skin abscess
62249234|NCT01186900|ACTIVE_COMPARATOR|open incision and drainage|
62249235|NCT02618005|EXPERIMENTAL|LcS group|Consuming probiotic capsule
62249236|NCT02618005|NO_INTERVENTION|Control group|
62829019|NCT00403377|NO_INTERVENTION|Control|Phase II include two arms. In the control arm, a souvenir photograph is taken of the participants and they then receive product samples that are irrelevant to skin cancer risk reduction (e.g., skin moisturizer, hair gel, chewing gum). Participants also receive educational materials at the completion of the study.
62829020|NCT05303012||Overweight and obese patient cohort|"* Age: 18 years and older~* BMI ≥ 25kg/m²"
62829021|NCT05303012||Overweight and obese patient cohort with bariatric surgery|"* Age: 18 years and older~* BMI ≥ 25kg/m²~* Status post sleeve or gastric bypass surgery"
62829022|NCT02187419|ACTIVE_COMPARATOR|5 Therapist-Delivered Hypnosis Session|Participants will complete five therapist-delivered hypnosis relaxation sessions with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
62829023|NCT02187419|ACTIVE_COMPARATOR|3 Therapist-Delivered Hypnosis Session|Participants will complete three therapist-delivered hypnosis relaxation sessions with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
62829024|NCT02187419|ACTIVE_COMPARATOR|5 Phone Calls; Hypnosis Recordings Only|Participants will complete five phone calls with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
62829025|NCT02187419|ACTIVE_COMPARATOR|3 Phone Calls; Hypnosis Recordings Only|Participants will complete three phone calls with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
62249237|NCT04538872|EXPERIMENTAL|MS group implicit|
62829026|NCT04538521|EXPERIMENTAL|Niacin in early-stage mitochondrial myopathy patients|The arm includes mitochondrial myopathy patients supplemented with niacin.
62829027|NCT06259916|EXPERIMENTAL|Cannabis Group|Participants in this group will self-administer their own flower cannabis product (that they purchased for use in the study from a legal-market dispensary) ad libitum inside their homes. Researchers will not handle the product or instruct participants on how much to use during the session.
62439074|NCT03500939|EXPERIMENTAL|Normobaric hyperoxygenation + standard of care|Normobaric hyperoxygenation (NBHO), i.e. inhalation of 100% oxygen at high flow (≥ 40 L/min) via a sealed non-rebreather face-mask with reservoir, or in case of intubation/ventilation for (study-independent) TBY, ventilation with an inspiratory oxygen fraction (FiO2) of 1.0. NBHO is started within 3 hours of stroke symptom onset (witnessed or last seen well) and within 20 minutes after end of baseline brain imaging and applied until the end of TBY procedure (defined by removal of guide catheter from sheath) or, in case TBY is not attempted, 4 hours after start of study treatment.
62439075|NCT03500939|ACTIVE_COMPARATOR|standard of care alone|standard of care alone; oxygen supplementation if SpO2 ≤ 94% at 2 to 4 L/min via nasal cannula according to guidelines of the European Stroke Organisation (ESO), or in case of TBY-related intubation/ventilation, ventilation with an initial FiO2 of 0.3 to be gradually increased if SpO2 ≤ 94%.
62829028|NCT06259916|EXPERIMENTAL|Alcohol Group|Participants in this group will be administered a dose of alcohol by researchers in our mobile lab. The dose is designed (based on participant sex and body weight) to bring blood alcohol concentration to .06 g/dL.
62829029|NCT06259916|EXPERIMENTAL|Alcohol + Cannabis Group|Participants in this group will first self-administer their own flower cannabis product (that they purchased for use in the study from a legal-market dispensary) ad libitum inside their homes. Researchers will not handle the product or instruct participants on how much to use during the session. They will then return to the mobile lab which will be parked outside their residence and will be administered a dose of alcohol by researchers. The dose is designed (based on participant sex and body weight) to bring blood alcohol concentration to .06 g/dL.
62829030|NCT04054986|EXPERIMENTAL|Breast Cancer|Breast cancer
62829031|NCT04670588||Locally advanced rectal cancer patients|Patients with LARC undergoing TNT.
62249238|NCT04538872|EXPERIMENTAL|MS group explicit|
62439076|NCT05342090|ACTIVE_COMPARATOR|Standardized Counselling Tool|If randomized to the treatment group, patients will be counselled using the structured counselling tool, and given a bulleted list of the counseling instrument to take home with them.
62829032|NCT05796583|ACTIVE_COMPARATOR|Active Pulsed Shortwave Treatment with SofPulse|Application of 8 days of nonthermal, pulsed shortwave (radiofrequency) therapy with Endonovo Therapeutics SofPulse
62829033|NCT05796583|SHAM_COMPARATOR|Sham Treatment|Application of 8 days of sham device
62829034|NCT06654245|EXPERIMENTAL|SHAREDCare Supportive care arm|Patients receive a SHAREDCare call with a navigator to discuss identified distress and social needs and develop/deploy a shared response plan to address identified needs on study. Patients also receive standard of care automated referrals on study. Two weeks following the initial call, patients receive a second SHAREDCare call with a navigator to follow-up on the shared response plan.
62829035|NCT04814277||MRI Data Collection|A group of 34 subjects will be scanned on a 3Tesla (3T) and on a 7T MRI scanner. The images will be compared.
62829036|NCT06601803|ACTIVE_COMPARATOR|Total Shoulder Arthroplasty washed with Saline|This arm will consist of sterile normal saline to be used before and after placement of shoulder arthroplasty components
62249239|NCT04538872|ACTIVE_COMPARATOR|HC group implicit (Healthy Controls)|
62249240|NCT04538872|ACTIVE_COMPARATOR|HC group explicit (Healthy controls)|
62249241|NCT06472583|EXPERIMENTAL|Experimental (Immunotherapy with pembrolizumab)|"Pembrolizumab (Keytruda) + Preoperative Stereotactic Radiotherapy.~IP will administered at a dose of 200 mg by intravenous infusion every 21 days - 4 administrations planned."
62249242|NCT06472583|PLACEBO_COMPARATOR|Control (placebo)|"Placebo+ Preoperative Stereotactic Radiotherapy~The solvent is 0.9% NaCl in a volume of 100 ml, with an adequate cover of the drug bag will be used as a placebo."
62249243|NCT03662139||Cerebral Palsy Group|16 patients will be included. Dynamic Gait Index and other assessments will be performed twice with a 7 - 10 day interval by two evaluators
62249244|NCT03662139||Healthy Control Group|16 healthy children will be included. Dynamic Gait Index and other assessments will be performed twice with a 7 - 10 day interval by two evaluators
62829037|NCT06601803|ACTIVE_COMPARATOR|Total Shoulder Arthroplasty washed with Surgiphor (Povidone Iodine)|This arm will consist of Surgiphor to be used before and after placement of shoulder arthroplasty components
62249245|NCT01283230||chronic liver disease|Any cause of liver disease that involves a process of progressive destruction and regeneration of the liver parenchyma leading to fibrosis and cirrhosis such as hepatitis B, hepatitis C, alcoholic liver disease.
62606629|NCT06420375|PLACEBO_COMPARATOR|Placebo Comparator: Placebo Arm|"In Group 1 of the study, subjects will take oral placebo at 1.2g twice daily, PO (2.4g daily) with 120mg oral butyrate twice daily (240mg daily) for 4 weeks.~In Group 2 of the study, subjects will take oral placebo at 2g twice daily, PO (4g daily) with 120mg oral butyrate twice daily (240mg daily) for 4 weeks.~In Group 3 of the study, subjects will take oral placebo at 2g twice daily, PO (4g daily) with 120mg oral butyrate twice daily (240mg daily) for 4 weeks. Subjects will also receive a one time 100mg dose of cyanocobalamin at initiation.~In Group 4 of the study, subjects will repeat the previous conditions of the group that proves to be the most effective."
62606630|NCT01236326|ACTIVE_COMPARATOR|LESS-DN|
62829038|NCT03713736|OTHER|Female patients with spondyloarthritis or rheumatoid arthritis|Female patients (18 to 65 years old) with spondyloarthritis or rheumatoid arthritis will undergo HPV screening and a have a close gynecologic follow-up.
62829039|NCT06184217|EXPERIMENTAL|Experimental group (MSPE programme group).|Experimental (MSPE group). The experimental group received the Mindful Sport Performance Enhancement programme (MSPE), with some changes and adaptations taking into account the characteristics and needs of the Para-athletes and the overall aim of the study. Such as reducing the session time (2h), including staff and support material, extending the pre-session time (35-40 min), and incorporating the dynamics of emotions and Mindful Yoga into the floor of the MBSR programme \[2\].
62829040|NCT06184217|ACTIVE_COMPARATOR|Control group (relaxation group).|Control group. Control group. Athletes with physical disabilities participating in the home were provided with a guide to body awareness-based relaxation training guidelines \[3\].
62439077|NCT05342090|NO_INTERVENTION|Control|Routine postoperative counselling and care will be administered with no specific standardized counselling for return to sexual activity after surgery.
62439078|NCT02058628|EXPERIMENTAL|Arm 1|A total of 110 subjects will receive clindamycin + BPO once daily in the evening for 12 weeks as per the randomization schedule.
62439079|NCT02058628|EXPERIMENTAL|Arm 2|A total of 110 subjects will receive azelaic acid twice daily (1 in the morning and 1 in the evening) for 12 weeks as per the randomization schedule.
62439080|NCT03170505||Acellular Dermal Matrix|
62439081|NCT03170505||Conchal Cartilage|
62439082|NCT02621515|EXPERIMENTAL|Nivolumab|All patients in this trial will receive treatment with nivolumab for 24 months. Treatment will be discontinued if confirmed disease progression has been demonstrated, if unacceptable toxicity or intercurrent illness prevents further treatment, and when informed consent is withdrawn. After discontinuation of treatment, follow-up will start. Duration of follow-up depends on survival of patients, with a maximum of 24 months. Therefore the end of this study is determined as 24 months after the last patient in this trial has started follow-up, has died, withdraws consent or is lost to follow-up for a different reason
62606631|NCT01236326|ACTIVE_COMPARATOR|Conventional LDN|
62606632|NCT06019403||People without musculoskeletal pain|People who do not suffer from musculoskeletal pain (neck pain, low back pain and/or temporomandibular pain), with or without a healthy lifestyle behavior.
62606633|NCT06019403||People with musculoskeletal pain|People suffering from musculoskeletal pain (neck pain, low back pain and/or temporomandibular pain), with or without a healthy lifestyle behavior.
62606634|NCT02745691||A. Surgery|A.1 Surgery alone and/or before any adjuvant therapy A.2 Surgery (late effects)
62606635|NCT02745691||B. Radiochemotherapy|B.1 Chemotherapy alone B.2 Radiotherapy alone B.3 Sequential radiochemotherapy B.4 Concurrent radiochemotherapy
62606636|NCT02745691||C. Targeted therapy|C.1 Targeted therapy alone C.2 Targeted therapy in combination with any other therapy
62606637|NCT02745691||D. Immunotherapy|Any new immunotherapy for lung cancer
62249246|NCT01283230||Healthy liver and kidney donor|Healthy liver and kidney donor who have normal liver condition
62249247|NCT04263350|EXPERIMENTAL|Treatment A:Fixed- dose combination mini-tablet|
62249248|NCT04263350|EXPERIMENTAL|Treatment B: Separate products taken at the same time|
62606638|NCT04621838|EXPERIMENTAL|Assigned intervention.|"Silicone Foam Dressing. Silicone Foam Lite.~Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with Silicone Foam dressing and Silicone Foam Lite Dressing."
62606639|NCT00691639||1|Patients who are or were participants in any Alcon AL-3789 study.
62606640|NCT02491801|EXPERIMENTAL|3.25% M.F. Milk|3.25% M.F. Milk
62249249|NCT00579683||1|This is a protocol to study tissue specimens to identify changes in tumor DNA in NSCLC patients who have previously responded to therapy and who have subsequently experienced disease progression.
62606641|NCT02491801|EXPERIMENTAL|Greek Yogurt|Greek Yogurt (2% M.F.)
62047005|NCT04020848||Patients with Alternating Hemiplegia of Childhood (AHC)|"Patients who fit the Aicardi Alternating Hemiplegia of Childhood clinical criteria of any age. The Aicardi Criteria are six (Heinzen et al 2015). (1) Paroxysmal hemiplegia episodes. (2) Bilateral hemiplegia or quadriplegia episodes. (3) Other paroxysmal manifestations, such as abnormal eye movements, nystagmus, strabismus, ataxia, dystonia, choreoathetosis, tonic spells, or autonomic disturbances. (4) Evidence of permanent neurological dysfunction, which can manifest as cognitive impairment, developmental delay, and/or persistent motor deficits such as spastic diplegia/quadriplegia, hypotonia, ataxia, choreoathetosis, or dystonia. (5) Sleep relieves symptoms, although attacks may resume soon after awakening. (6) First signs of dysfunction occur prior to the age of 18 months.~Patients having some but not all the above criteria and have the mutation in ATP1A3 gene can be included."
62047006|NCT05177458|EXPERIMENTAL|Moderate Intensity Exercise|"Visit 1: Participants will complete study screening, PTSD assessments, and provide written narrative for a traumatic event and a neutral control event.~Visit 2: Participants will complete eight trials of imaginal exposure (blocks of four neutral and four trauma narrative trials presented as text and sound) with heart rate monitoring and skin conductance. Anxiety will be measured at baseline and after each imagery trial. Participants will then complete 30 minutes of moderate intensity (70-75% maximum heart rate) exercise on a treadmill.~Visit 3: Participants will complete eight more imaginal trials with heart rate and anxiety ratings as per visit 2."
62606642|NCT02491801|EXPERIMENTAL|Cheddar Cheese|Regular Fat Cheddar Cheese
62249250|NCT00805025|EXPERIMENTAL|AZLI|Participants were evaluated beginning 14 days prior to starting a 28-day course of AZLI (Day 0 to Day 28), followed by post-treatment assessments every 14 days through Day 56, for a total of 70 days of participation in the study.
62249251|NCT02790138|PLACEBO_COMPARATOR|Placebo IV|Vedolizumab placebo-matching intravenous (IV) infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.
62829041|NCT02614001|EXPERIMENTAL|inspiratory muscle training, stroke rehabilitation|Inspiratory muscle training with a pressure threshold device (Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA) will be start at a resistance equal to 30% of their MIP or at a load which patient can tolerate, and then the loading will be gradually increased 2cm H2O per week or as symptom tolerated and according to the RPE scale. Each patient will receive regular post-stroke rehabilitation program.
62829042|NCT02614001|OTHER|control group|stroke rehabilitation.
62829043|NCT00802308|EXPERIMENTAL|Treatment A|Single dose administration of Egalet® morphine with alcohol
62829044|NCT00802308|EXPERIMENTAL|Treatment B|Single dose administration of Egalet® morphine with alcohol
62829045|NCT00802308|EXPERIMENTAL|Treatment C|Single dose administration of Egalet® morphine with alcohol
62829046|NCT00802308|PLACEBO_COMPARATOR|Treatment D|Single dose administration of Egalet® morphine with water
62829047|NCT04461275|EXPERIMENTAL|ERAS 2.0 group|Patients included in the ERAS 2.0 group will follow the ERAS 2.0 accelerated care protocol.
62249252|NCT02790138|EXPERIMENTAL|Vedolizumab IV 300 mg|Vedolizumab 300 mg, IV infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.
62249253|NCT01956149|EXPERIMENTAL|Cabazitaxel|Cabazitaxel 20 mg/m2 over 1 hour i.v., repeated on day 22
62249254|NCT01406288||HUS epidemy in Bordeaux, E. coli of the O104H4 serotype|
62249255|NCT05869292|EXPERIMENTAL|Test: Immediate implant loading|Implants will be immediately following surgical procedure loaded with temporary restorations.
62249256|NCT05869292|EXPERIMENTAL|Control: Early implant loading|Implants will not be received prosthetic restoration, and will left with healing abutments (HA) for 6 weeks.
62249257|NCT03553914|EXPERIMENTAL|12 mg/m^2 dose group|Subjects will receive PLM60 at 12 mg/m\^2 dose.
62249258|NCT03553914|EXPERIMENTAL|16 mg/m^2 dose group|Subjects will receive PLM60 at 16 mg/m\^2 dose.
62606643|NCT02491801|EXPERIMENTAL|Control 1|Skim milk
62606644|NCT02491801|EXPERIMENTAL|Control 2|Filtered water, calorie-free control
62606645|NCT02041650|OTHER|Patients with ACS treated medically|
62606646|NCT03153267|ACTIVE_COMPARATOR|EM-7 days doxycycline|
62606647|NCT03153267|ACTIVE_COMPARATOR|EM-14 days doxycycline|
62829048|NCT06565949|EXPERIMENTAL|Education group|Caregivers in the experimental group will be given a detailed and planned training programme on pressure sores.
62829049|NCT06565949|NO_INTERVENTION|Control group|
62606648|NCT03153267|PLACEBO_COMPARATOR|Controls|
62249259|NCT03553914|EXPERIMENTAL|20 mg/m^2 dose group|Subjects will receive PLM60 at 20 mg/m\^2 dose.
62439083|NCT02711150|EXPERIMENTAL|EPD Measurements|"Intervention:~PLL Length Measured through US will be done with the subject placed on the Epidural Positioning Device."
62606649|NCT06618144|EXPERIMENTAL|CIRCA Texting|Participants will be invited to text with a secure, closed artificial intelligence system with clinician oversight to triage patients along predetermined algorithms related to early pregnancy care.
62249260|NCT05968599||Enzalutamide cohort|Patients with mCRPC initiating enzalutamide
62439084|NCT02711150|ACTIVE_COMPARATOR|Flexed Position Measurements|"Intervention:~PLL Length Measured through US will be done with the subject placed in a flexed lumbar spine position."
62606650|NCT06579404|EXPERIMENTAL|Fully closed-loop insulin delivery (CamAPS HX)|"The automated closed loop system (CamAPS FX) will consist of:~* YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland)~* FreeStyle Libre 3 glucose sensor (Abbott Diabetes Care, CA, USA)~* Smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm~* Cloud upload system to review CGM/insulin data.~Participants will use the fully closed-loop system for 26 weeks at home"
62606651|NCT06579404|ACTIVE_COMPARATOR|Standard insulin therapy with glucose sensor|Usual insulin therapy and FreeStyle Libre 3 glucose sensor (Abbott Diabetes Care, CA, USA) for 26 weeks at home.
62249261|NCT05968599||Abiraterone cohort|Patients with mCRPC initiating abiraterone acetate
62249262|NCT00718549|EXPERIMENTAL|Induction: Rituximab, Cladribine, Cyclophosphamide|Participants will receive rituximab at a dose of 375 milligrams per meter squared (mg/m\^2) as intravenous (IV) infusion on Day 1, cladribine at a dose of 0.12 milligrams per kilogram per day (mg/kg/day) as IV infusion on Days 2-4, and cyclophosphamide at a dose of 250 mg/m\^2/day as IV infusion over 15-30 minutes on Days 2-4 in Cycle 1. Then, rituximab at a dose of 500 mg/m\^2 as IV infusion on Day 1, cladribine at a dose of 0.12 mg/kg/day as IV infusion on Days 2-4, and cyclophosphamide at a dose of 250 mg/m\^2/day as IV infusion over 15-30 minutes on Days 2-4 will be administered in Cycles 2-6. Each cycle will be of 28 days in duration.
62439085|NCT01006668|EXPERIMENTAL|Sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
62439086|NCT01006668|ACTIVE_COMPARATOR|Propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary
62439087|NCT01070966||VYTORIN® 10/10 (ezetimibe 10 mg/simvastatin 10 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/10 (ezetimibe 10 mg/simvastatin 10 mg tablets)
62439088|NCT01070966||VYTORIN® 10/20 (ezetimibe 10 mg/simvastatin 20 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/20 (ezetimibe 10 mg/simvastatin 20 mg tablets)
62439089|NCT01070966||VYTORIN® 10/40 (ezetimibe 10 mg/simvastatin 40 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/40 (ezetimibe 10 mg/simvastatin 40 mg tablets)
62439090|NCT01070966||VYTORIN® 10/80 (ezetimibe 10 mg/simvastatin 80 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/80 (ezetimibe 10 mg/simvastatin 80 mg tablets)
62439091|NCT05960851|EXPERIMENTAL|LY3871801 (Part A)|LY3871801 administered orally in Japanese and Non-Asian Participants.
62439092|NCT05960851|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered orally in Japanese and Non-Asian Participants.
62606652|NCT04731025|PLACEBO_COMPARATOR|Irrigation of implants with sterile isotonic saline|The placebo solution will consist of 500 mL of sterile isotonic (9%) saline contained in a infusion bag.
62606653|NCT04731025|EXPERIMENTAL|Irrigation of implants with a triple antibiotic solution|The antibiotic solution will contain 1000 mg vancomycin, 80 mg gentamicin and 1000 mg cefazolin in 500 mL sterile isotonic (9%) saline
62606654|NCT00109876|EXPERIMENTAL|Treatment (RFA therapy)|A radiofrequency electrode is placed by CT guidance into the target tumor. Patients undergo RFA directly to the tumor for up to 12 minutes to obtain an intratumoral temperature \> 60° C. Patients may receive 3 RFA treatments (a total of 36 minutes) to obtain the target temperature.
62249263|NCT00718549|EXPERIMENTAL|Maintenance Arm: Rituximab|Participants with PR or CR after induction phase who will be randomized to maintenance arm will receive rituximab treatment for 8 cycles. Twelve weeks after the last induction cycle, participants will receive rituximab at a dose of 375 mg/m\^2 as IV infusion on Day 1 of each 12-week cycle until disease progression (up to approximately 96 weeks).
62439093|NCT05960851|EXPERIMENTAL|LY3871801 (Part B)|LY3871801 administered orally in Chinese Participants.
62439094|NCT05960851|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered orally in Chinese Participants.
62439095|NCT04813822|EXPERIMENTAL|Miconazole Nitrate 2% + Domiphen Bromide Low Dose Vaginal Cream|The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.
62047007|NCT05177458|ACTIVE_COMPARATOR|Control - Low Intensity Exercise|"Visit 1: Participants will complete study screening, PTSD assessments, and provide written narrative for a traumatic event and a neutral control event.~Visit 2: Participants will complete eight trials of imaginal exposure (blocks of four neutral and four trauma narrative trials presented as text and sound) with heart rate monitoring and skin conductance. Anxiety will be measured at baseline and after each imagery trial. Participants will then complete 30 minutes of light intensity (40-50% maximum heart rate) exercise on a treadmill.~Visit 3: Participants will complete eight more imaginal trials with heart rate and anxiety ratings as per visit 2."
62047008|NCT00816881|EXPERIMENTAL|1|flutter mucus clearance device
62439096|NCT04813822|EXPERIMENTAL|Miconazole Nitrate 2% + Domiphen Bromide High Dose Vaginal Cream|The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.
62606655|NCT05949541|EXPERIMENTAL|Arm-A|"Everolimus + CDK4/6 inhibitor+ Endocrine therapy group:~Everolimus, 10mg po. qd; Dalpiciclib 125mg po. qd. for 3 weeks, followed by 1 week off, 4 weeks as a cycle.~Aromatase inhibitors (Letrozole/Anastrozole/Exemestane), po. qd. at specific doses (Letrozole 2.5mg/day; Anastrozole 1mg/day, Exemestane 25mg/day); Or Fluvestrant, 500mg im. q28d, (Extra 500mg given after 2 weeks of first dose); Premenopause participants: Goserelin 3.6mg, subcutaneously, once every 4 weeks."
62829050|NCT03568214|EXPERIMENTAL|Individualized moderate + high-intensity|"* 12 weeks of moderate-intensity continuous training (MICT) combined with high-intensity interval training (HIIT)~* 4 days per week of MICT for 50 minutes per session~* 1 day per week of HIIT for 35 minutes per session~* Exercise intensity for MICT will be established according to ventilatory thresholds one and two (VT1 and VT2)~* The HIIT protocol will consist of eight, 60 second intervals at 100% maximal oxygen uptake (VO2max), separated by 150 seconds active recovery"
62047009|NCT00816881|NO_INTERVENTION|2|Observation
62249264|NCT00718549|NO_INTERVENTION|Observation Arm: No Intervention|Participants with PR or CR after induction phase who will be randomized to observation arm will not receive any intervention. Participants will be assessed every 4-weeks for the first 12 weeks and every 12-weeks afterwards up to 96 weeks.
62249265|NCT06182150|EXPERIMENTAL|PAUSE-Cardio Moderate-Intensity Exercise Arm|Arm receiving moderate-intensity indoor cycling exercise once weekly for 4 weeks.
62249266|NCT02785965|EXPERIMENTAL|acupuncture & lifestyle modification|Electro-acupuncture is given three times a week with diet restriction to 1400 calories a day and moderate aerobic exercise 3h a week for 12 weeks.
62249267|NCT02785965|ACTIVE_COMPARATOR|lifestyle modification|diet restriction to 1400 calories a day and moderate aerobic exercise 3h a week for 12 weeks
62249268|NCT05529056|EXPERIMENTAL|Test Arm 1|LPTAT01
62249269|NCT05529056|EXPERIMENTAL|Test Arm 2|LPTAT02
62249270|NCT05529056|EXPERIMENTAL|Test Arm 3|LPTAT03
62439097|NCT04813822|ACTIVE_COMPARATOR|Gyno-Daktarin® Vaginal Cream|The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.
62439098|NCT03773094|EXPERIMENTAL|Guava leaves extract|A natural product that is prepared as a mouthwash
62047010|NCT03153579|OTHER|Placebo, LSD|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo or lysergic acid diethylamide (LSD)
62249271|NCT05529056|PLACEBO_COMPARATOR|Reference Arm|LPTAT04
62249272|NCT02248259|EXPERIMENTAL|Extensive Metabolisers: Ref / Test|"Participants who were extensive metabolisers received two treatments in a randomised order, the treatments were:~* Reference (ref) treatment (1 single tablet of 25 mg BI 409306 taken orally on day 1).~* Test treatment (2 capsules of 100 mg itraconazole taken orally twice daily on day -3 (loading dose) and once daily on day -2 to day 2, plus 1 tablet of 25 mg BI 409306 taken orally as a single dose 1 hour after the itraconazole administration on day 1."
62249273|NCT02248259|EXPERIMENTAL|Poor Metabolisers: Ref / Test|"Participants who were poor metabolisers received two treatments in a randomised order, the treatments were:~* Reference (ref) treatment (1 single tablet of 25 mg BI 409306 taken orally on day 1).~* Test treatment (2 capsules of 100 mg itraconazole taken orally twice daily on day -3 (loading dose) and once daily on day -2 to day 2, plus 1 tablet of 25 mg BI 409306 taken orally as a single dose 1 hour after the itraconazole administration on day 1."
62439099|NCT03773094|ACTIVE_COMPARATOR|Chlorhexidine|chemical agent Chlorhexidine as a mouthwash
62439100|NCT06190847||Experimental|cancer
62439101|NCT04654728|ACTIVE_COMPARATOR|ePTFE graft|In this group, anterior sector of the right lobe graft will be reconstructed using ePTFE vascular grafts
62439102|NCT04654728|OTHER|Dacron graft|In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
62449404|NCT02315898|EXPERIMENTAL|Treatment-inhaled tPA|All patients with plastic bronchitis enrolled into the study will receive inhaled tPA.
62606656|NCT05949541|ACTIVE_COMPARATOR|Arm-B|"CDK4/6 inhibitor+ Endocrine therapy group:~Dalpiciclib 125mg po. qd. for 3 weeks, followed by 1 week off, 4 weeks as a cycle.~Aromatase inhibitors (Letrozole/Anastrozole/Exemestane), po. qd. at specific doses (Letrozole 2.5mg/day; Anastrozole 1mg/day, Exemestane 25mg/day); Or Fluvestrant, 500mg im. q28d, (Extra 500mg given after 2 weeks of first dose); Premenopause participants: Goserelin 3.6mg, subcutaneously, once every 4 weeks."
62047011|NCT03153579|OTHER|LSD, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo or lysergic acid diethylamide (LSD)
62047012|NCT03238300|EXPERIMENTAL|N-Acetylcysteine, then Placebo|Participants first received N-Acetylcysteine 600mg capsules by mouth, two pills twice daily will be taken for 10 days. After washout for 11 days, they then received placebo capsules mimicking N-Acetylcysteine (two pills, twice daily) will be taken for 10 days.
62439103|NCT05687305|ACTIVE_COMPARATOR|Intervention Group|On the 0th and 1st postoperative days, patients in the intervention group will listen to white noise with a bluetooth headset for 30 minutes before going to sleep, and they will be kept under observation during this time.Patients in the control group will be monitored according to their routine clinical procedures. Since there are no procedures or interventions in clinical procedures, only patient monitoring will be performed. Patients in the control group will also be followed up at the same times and with the same forms.
62439104|NCT05687305|NO_INTERVENTION|No Intervention Group|Patients in the control group will not receive any intervention other than their routine. Data collection forms will be applied to the participants in the control group at the same time as the intervention group.
62439105|NCT01992289||No treatment|This is a long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002.
62439106|NCT00350857|ACTIVE_COMPARATOR|Equetro active|
62439107|NCT01337050|EXPERIMENTAL|A|PF-03446962
62829051|NCT03568214|EXPERIMENTAL|Standardized moderate-intensity|"* 12 weeks of MICT~* 5 days per week of MICT for 50 minutes per session~* Exercise intensity for MICT will be established according to 40-65% heart rate reserve (HRR)"
62829052|NCT03568214|NO_INTERVENTION|Control|non-exercise control group testing at baseline and post-program (12 weeks)
62829053|NCT03802006||fasted patient with previous gastrectomy|The fasted patient with previous subtotal gastrectomy except exclusion criteria are included
62829054|NCT05826938|EXPERIMENTAL|Virtual reality|The intervention group receives stimuli in the form of Virtual Reality technology before and during oocyte retrieval. In addition, patients receive standard treatment
62047013|NCT03238300|EXPERIMENTAL|Placebo, then N-Acetylcysteine|Participants first received placebo capsules mimicking N-Acetylcysteine (two pills, twice daily) will be taken for 10 days. After washout for 11 days, they then received N-Acetylcysteine 600mg capsules by mouth, two pills twice daily will be taken for 10 days.
62249274|NCT02248259|EXPERIMENTAL|Extensive Metabolisers: Test / Ref|"Participants who were extensive metabolisers received two treatments in a randomised order, the treatments were:~* Test treatment (2 capsules of 100 mg itraconazole taken orally twice daily on day -3 (loading dose) and once daily on day -2 to day 2, plus 1 tablet of 25 mg BI 409306 taken orally as a single dose 1 hour after the itraconazole administration on day 1.~* Reference (ref) treatment (1 single tablet of 25 mg BI 409306 taken orally on day 1)."
62249275|NCT02248259|EXPERIMENTAL|Poor Metabolisers: Test / Ref|"Participants who were poor metabolisers received two treatments in a randomised order, the treatments were:~* Test treatment (2 capsules of 100 mg itraconazole taken orally twice daily on day -3 (loading dose) and once daily on day -2 to day 2, plus 1 tablet of 25 mg BI 409306 taken orally as a single dose 1 hour after the itraconazole administration on day 1.~* Reference (ref) treatment (1 single tablet of 25 mg BI 409306 taken orally on day 1)."
62249276|NCT01195753|EXPERIMENTAL|Liver Cell Infusion|
62249277|NCT04653168|EXPERIMENTAL|LY3041658 Low Dose|LY3041658 administered by subcutaneous (SC) injection.
62249278|NCT04653168|EXPERIMENTAL|LY3041658 High Dose|LY3041658 administered by SC injection.
62249279|NCT03595319|EXPERIMENTAL|Young patients|Patients between 19 and 40 years-old
62249280|NCT03595319|EXPERIMENTAL|Elder patients|Older than 65
62249281|NCT00687440|EXPERIMENTAL|Caelyx, Docetaxel, Trastuzumab|"Stage 1: subjects will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles. At the end of this stage, based on the number of cardiac events, subjects will proceed to a second stage or restart with a lower dose of Caelyx.~Stage 2: subjects will be treated with the recommended dose of Caelyx (defined in the first stage) in combination with docetaxel and trastuzumab."
62249282|NCT00745693|EXPERIMENTAL|1|1 hour exposure to filtered air, followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin-1 (5pmol/min)
62249283|NCT00745693|EXPERIMENTAL|2|1 hour exposure to filtered air, followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin receptor antagonists BQ-123 and BQ-788
62439108|NCT04605419|EXPERIMENTAL|Calcium electroporation|Calcium chloride
62439109|NCT01709097||With Med-O-Wheel™|Kidney Transplant Recipient with Med-O-Wheel™
62829055|NCT05826938|NO_INTERVENTION|Control|The control group, does not receive stimuli in the form of Virtual Reality technology, but only the standard treatment
62439110|NCT01709097||With out Med-O-Wheel™|Kidney Transplant Recipient with out Med-O-Wheel™
62439111|NCT01299038|ACTIVE_COMPARATOR|Group 1|Rosuvastatin 20mg taken orally once a day for 4 weeks
62439112|NCT01299038|ACTIVE_COMPARATOR|Group 2|Rosuvastatin 40mg taken orally once a day for 4 weeks
62449405|NCT05531266|EXPERIMENTAL|hUC-MSCs combined with glucocorticoids group.|91 patients will be involved in this group
62606657|NCT03393429|ACTIVE_COMPARATOR|DAVID assisted training|Group I: Training assisted by DAVID devices
62829056|NCT02784756|OTHER|Quantiferon-CMV assay|All patients will receive a CMV-immunity test at specific time points during the study. This is a single arm design
62829057|NCT04645758|ACTIVE_COMPARATOR|Dry Needling Group or (DN)|Dry needling for 5 mins on the flexor group of muscles of dominant forearm.
62047014|NCT05843916|EXPERIMENTAL|AGA BETA BS|The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks
62249284|NCT00745693|EXPERIMENTAL|3|1 hour exposure to dilute diesel exhaust (300mcg/m3), followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin-1 (5pmol/min)
62249285|NCT00745693|EXPERIMENTAL|4|1 hour exposure to dilute diesel exhaust (300mcg/m3), followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin receptor antagonists BQ-123 and BQ-788
62249286|NCT00832520|EXPERIMENTAL|Remeron (Mirtazapine)|Mirtazapine 15 mg orally at bed time for 8 weeks
62249287|NCT04110548|EXPERIMENTAL|HCs on Emotion Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on. They are instructed to complete the emotion regulation task on the computer.
62249288|NCT04110548|EXPERIMENTAL|IGDs on Emotion Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on.They are instructed to complete the emotion regulation task on the computer.
62249289|NCT04110548|EXPERIMENTAL|IGDs on Craving Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on. They are instructed to complete the craving regulation task on the computer.
62439113|NCT03753854|ACTIVE_COMPARATOR|SS patients|"Homozygous sickle cell patients~Each patient will undergo the following:~1. polysomnography and oxygen saturation exam~2. calculation of VOC rate within the two previous years~3. Blood samples~4. Physiological measurements"
62439114|NCT03753854|EXPERIMENTAL|SS patients apneic|"Homozygous sickle cell patients after one year of continuous positive airway pressure treatment~Each patient will undergo the following:~1. polysomnography and oxygen saturation exam~2. calculation of VOC rate within the two previous years~3. Blood samples~4. Physiological measurements"
62439115|NCT05021627|EXPERIMENTAL|Cardiac autonomic nerve modification|
62439116|NCT05021627|ACTIVE_COMPARATOR|Pacemaker|
62439117|NCT00767325|EXPERIMENTAL|Abatacept, 10 mg/kg|
62439118|NCT05686733|OTHER|Single arm (The SEAL™ Saccular Endovascular Aneurysm Lattice System)|First In Human (FIH), prospective, single-arm, multicenter, interventional study.
62829058|NCT04645758|ACTIVE_COMPARATOR|Extra corporeal Shockwave therapy Group or (ESWT)|Delivering of Shock wave pulses of 1250 at the energy intensity of 0.58 mj/mm2 on the flexor group of muscles of dominant forearm
62829059|NCT00707083|ACTIVE_COMPARATOR|Standard- or Intermediate-Risk Maintenance Arm I|Patients receive oral mercaptopurine and oral methotrexate on days 1-56, dexamethasone IV on days 1-5 and 29-33, vincristine IV on days 1 and 29, and methotrexate IT on day 50. Treatment repeats every 8 weeks for up to 8 (girls)-11 (boys) courses.
62249290|NCT06270342||MS|patients with multiple sclerosis
62249291|NCT06270342||Control|healthy volunteers
62439119|NCT03164590|ACTIVE_COMPARATOR|ketamine|
62439120|NCT03164590|ACTIVE_COMPARATOR|dexmedetomidine|
62439121|NCT03164590|PLACEBO_COMPARATOR|bupivacaine|
62439122|NCT03717766||Patients|Intraaxial brain tumors that are tributary to surgical treatment. Prospective observational study of the use and effectiveness of intraoperative neuronavigation ultrasound, intraoperative tractography, intraoperative fluorescence, advanced neuronavigation and intraoperative neurophysiology in the resection of intracranial supratentorial tumors.
62439123|NCT00864942|EXPERIMENTAL|BL-NHL|Bendamustine and lenalidomide for NHL
62439124|NCT00864942|EXPERIMENTAL|BLR-CLL|Bendamustine, lenalidomide, rituximab for CLL
62439125|NCT00864942|EXPERIMENTAL|BLR-NHL|Bendamustine, lenalidomide, and rituximab for NHL
62439126|NCT00864942|EXPERIMENTAL|BL-CLL|bendamustine and lenalidomide in patients with CLL
62439127|NCT00511563|EXPERIMENTAL|GW876008 and GSK561679|GW876008 and GSK561679
62439128|NCT02070848||Concentric vs eccentric|One arm study in which each subject will act as his own control.
62606658|NCT03393429|PLACEBO_COMPARATOR|training recommendation|"Group II: Training based on stay active recommendations"
62606659|NCT05014581|EXPERIMENTAL|Pre-emptive vasopressor|Pre-emptive continuous infusion of norepinephrine during intubation
62606660|NCT05014581|NO_INTERVENTION|No vasopressor|No pre-emptive administration of vasopressors
62047015|NCT04701151|EXPERIMENTAL|Intervention|"Study Subjects randomized to the interventional arm will be assigned to BCG induction therapy once-weekly for 6 weeks and subsequent 1 year of maintenance (6+3x3) of which dwell-time during the first of the 6 induction instillations is 2 hours.~If side effects are registered before the second and all further instillations, Study Subject in the intervention arm will be reduced in dwell-time according to the grading of side effects as given by the study algorithm."
62047016|NCT04701151|ACTIVE_COMPARATOR|Control|The Study Subjects will be treated according to guidelines with BCG instillation therapy once weekly for 6 weeks and subsequent 1 year of maintenance therapy (6+3x3) with 2 hours of dwelltime.
62439129|NCT01078090||Rheumatoid arthritis|Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 5 years.
62047017|NCT05597657|OTHER|Fluid administration (substudy 2)|
62047018|NCT02163733|OTHER|Fasted|AZD9291 tablets following a period of fasting
62047019|NCT02163733|OTHER|High-fat meal|AZD9291 tablets following a high-fat meal.
62249292|NCT05658016|EXPERIMENTAL|TK112690|TK112690 treatment
62047020|NCT01973660|EXPERIMENTAL|Dual HER2 blockade|For a total of 18 weeks, HR-negative patients will be given dual blockade consisting of daily lapatinib at 1000 mg and trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks.
62249293|NCT05658016|PLACEBO_COMPARATOR|Placebo|TK112690 formulation
62047021|NCT01973660|EXPERIMENTAL|Dual HER2 blockade plus endocrine therapy|For a total of 18 weeks, HR-positive patients will be given letrozole (2.5 mg daily) or tamoxifen (20 mg daily) with concurrent dual blockade consisting of daily lapatinib at 1000 mg and trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks.
62047022|NCT02203240|EXPERIMENTAL|Cocoa|3 servings of polyphenol-rich cocoa beverage consumed per day.
62047023|NCT02203240|PLACEBO_COMPARATOR|Placebo|3 servings of non-cocoa beverage consumed per day.
62047024|NCT03289234|EXPERIMENTAL|mild hepatic impairment|
62249294|NCT04485273|ACTIVE_COMPARATOR|Dexmedetomedine Group|Laryngeal mask airway is inserted and anesthesia is maintained with sevoflurane. Subtenon's block is performed and local anesthetic solution is injected, in addition to dexmedetomedine.
62249295|NCT04485273|PLACEBO_COMPARATOR|Control Group|Laryngeal mask airway is inserted and anesthesia is maintained with sevoflurane. Subtenon's block is performed and local anesthetic solution is injected.
62249296|NCT01951079|EXPERIMENTAL|second trimester abortion , feticide|all patients admitting to second trimester abortion above 22 weeks will be injected intra-amniotic DIGOXIN for feticide .
62249297|NCT06235450|EXPERIMENTAL|Therapeutic iLIDS arm|Subjects apply iTEAR100 device with iLIDS100 accessory
62249298|NCT04248309|EXPERIMENTAL|A1|The included patient should test serum progesterone level on D3 no matter which day perform the embryo transfer. According to the progesterone level, there are two groups, Group A: serum progesterone \<7.24ug/L, followed by randomized A1: plus additional treatment（intramuscular progesterone 20-40mg from D3 ）
62449406|NCT05531266|ACTIVE_COMPARATOR|glucocorticoids group|91 patients will be involved in this group
62606661|NCT03057223|EXPERIMENTAL|3D Jaw Plate|3D Jaw Plate will be used in internal fixation.
62047025|NCT03289234|EXPERIMENTAL|moderate hepatic impairment|
62047026|NCT03289234|EXPERIMENTAL|normal hepatic function|
62047027|NCT01472198|EXPERIMENTAL|Simtuzumab (open-label)|Participants will receive simtuzumab 700 mg plus gemcitabine in cycles of 28 days for up to 3 years.
62047028|NCT01472198|EXPERIMENTAL|Simtuzumab 200 mg (randomized)|Participants will receive simtuzumab 200 mg plus gemcitabine in cycles of 28 days for up to 3 years.
62047029|NCT01472198|EXPERIMENTAL|Simtuzumab 700 mg (randomized)|Participants will receive simtuzumab 700 mg plus gemcitabine in cycles of 28 days for up to 3 years.
62047030|NCT01472198|PLACEBO_COMPARATOR|Placebo (randomized)|Participants will receive placebo to match simtuzumab plus gemcitabine in cycles of 28 days for up to 3 years.
62047031|NCT04233476|EXPERIMENTAL|99mTc-3PRGD2 injection for SPECT/CT imaging, with 18F-FDG PET/CT for head-to-head comparison.|"Participants will receive a single-dose intravenous injection of 99mTc-3PRGD2 at a dosage of approximate 11.10 MBq (0.30 mCi) per kilogram body weight. Whole-body planar scan and chest SPECT/CT imaging will be performed 40-50 min later. Chest low-dose spiral CT (120 kV, 50 mAs) will be used for attenuation correction and anatomical localization.~The conventional metabolic imaging by 18F-FDG PET/CT of the same patients within one week will be used for a self-controlled head-to-head comparison."
62249299|NCT04248309|NO_INTERVENTION|A2|The included patient should test serum progesterone level on D3 no matter which day perform the embryo transfer. According to the progesterone level, there are two groups, Group A: serum progesterone \<7.24ug/L, followed by randomized A2：without additional treatment
62249300|NCT04248309|NO_INTERVENTION|B|Group B：serum progesterone ≥7.24ug/L， without additional treatment
62249301|NCT06374472||80 cases of thoracolumbar spine fractures|
62249302|NCT04645043|EXPERIMENTAL|US_Eso|US application on the participant
62249303|NCT03031379|NO_INTERVENTION|A - control|standard fast, at least 6 hours prior to tracheotomy
62249304|NCT03031379|EXPERIMENTAL|B - shortened fast|fast of only 45 minutes prior to incision
62249305|NCT02371122|ACTIVE_COMPARATOR|RestoreSensor or RestoreUltra Setting 1|Therapy Setting 1
62249306|NCT02371122|ACTIVE_COMPARATOR|RestoreSensor or RestoreUltra Setting 2|Therapy Setting 2
62249307|NCT02371122|ACTIVE_COMPARATOR|RestoreSensor or RestoreUltra Setting 3|Therapy Setting 3
62249308|NCT02371122|SHAM_COMPARATOR|RestoreSensor or RestoreUltra Setting 4|Therapy Setting 4
62606662|NCT03473613|ACTIVE_COMPARATOR|Calcium infusion|10ml 10%calcium gluconate in 200ml normal saline solution given intravenously over thirty minutes, on ovum pick up day and continued for 4days
62606663|NCT03473613|ACTIVE_COMPARATOR|Oral Cabergoline|Receiving oral Cabergoline (cabergamon 0.5 milligram tablet ) from ovum pick up day and continued for 7days,once daily
62606664|NCT03493750|NO_INTERVENTION|Healthplan guide alone|"Nurse applies the daily-practice questionnaire called Healthplan guide to screen and identify people with dental diseases, among those in vulnerable situation, and to sensitize them about the importance of oral hygiene and how to improve it.~After that, the nurse has to state if, from her/his point of view the patient needs dental care or not. Whatever the answer, the nurse makes an appointment to a dental practice, in the 30 following days, and gives it to the patient with a free bus ticket. Randomization is done at that time.~The dentist, blinded of the patient's group, makes a dental exam and says if the patient needs dental care or not.~If care are indicated, they will be organized but outside this trial."
62606665|NCT03493750|EXPERIMENTAL|Oral and dental evaluation|"After application of the Healthplan guide, nurse statement of the need of dental care or not, making of an appointment to the dental practice and gift of a free bus ticket, if the patient is randomized in the experimental group, the nurse completes the evaluation with a mouth inspection in order to count missing, coloured, injured teeth, and evaluate dental plaque, halitosis, inflammatory gums, mucosal injuries, low masticatory surface. At the end of this exam, the nurse has to state again if, from her/his point of view the patient needs dental care or not.~The dentist, blinded of the patient's group, makes a dental exam and says if the patient needs dental care or not.~If care are indicated, they will be organised but outside this trial."
62606666|NCT05201040|EXPERIMENTAL|Mannitol-combined Hyaluronic acid|2.0mL/syringe for one treatment
62606667|NCT05201040|PLACEBO_COMPARATOR|Normal saline|2.0mL for one treatment
62606668|NCT04392167|EXPERIMENTAL|a/LCI-OCT Imaging of the Esophagus|
62606669|NCT01866267|OTHER|Maraviroc|Patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen \[Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)\] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
62829060|NCT00707083|EXPERIMENTAL|Standard- or Intermediate-Risk Maintenance Arm II|Patients receive oral mercaptopurine once daily on days 8-28 and 36-56; oral methotrexate once on days 8,15, 22, 36, 43, and 50; dexamethasone IV on days 1-5 and 29-33; and vincristine IV on days 1 and 29. Patients also receive methotrexate IT on day 1, every 8 weeks, for 8 courses.
62606670|NCT02596217|EXPERIMENTAL|Stage 1 (low dose SC)|Low dose administered by subcutaneous (SC) injection
62606671|NCT02596217|EXPERIMENTAL|Stage 1 (medium dose SC)|Medium dose administered by subcutaneous (SC) injection
62606672|NCT02596217|EXPERIMENTAL|Stage 1 (high dose SC)|High dose administered by subcutaneous (SC) injection
62606673|NCT02596217|EXPERIMENTAL|Stage 2 (low dose IV)|Low dose administered by intraveneous (IV) infusion
62829061|NCT03925012|EXPERIMENTAL|Intervention|Child participants will attend the healthy lifestyle summer program for 4 weeks, five days per week. The summer intervention will include daily one-hour nutrition education, one-hour behavioral counseling, and 3 one-hour exercise sessions. These physical activities include flexibility, games, traditional fitness, and dancing. Counseling and school psychology students, registered dietitian/nutrition educators, and fitness specialists will lead the respective sessions. Parental guardians will participate in a two-hour weekly parental sessions that involve: 1)nutrition education with cooking demonstrations of healthy recipes; 2)behavioral counseling to learn effective parenting strategies on how to support their child's healthy nutrition and exercise habits and goals; and 3)exercise sessions where parents will engage in different physical activities and will receive fitness tips on how to promote an active lifestyle for the entire family.
62829062|NCT01499940|EXPERIMENTAL|Vitamin D3 2000 IU/day|Vitamin D3 2000 IU/day on day of 1st cycle of oxaliplatin; continue as long as patient treated with oxaliplatin and remains on study
62606674|NCT02596217|EXPERIMENTAL|Stage 2 (medium dose IV)|Medium dose administered by intraveneous (IV) infusion
62606675|NCT02596217|EXPERIMENTAL|Stage 2 (high dose IV)|High dose administered by intraveneous (IV) infusion
62606676|NCT02596217|PLACEBO_COMPARATOR|Placebo SC (Stage1)|Placebo administered by subcutaneous (SC) injection
62047032|NCT04202380|OTHER|Azithromycin 1 day group|Patients will receive Azithromycin 1000mg once orally
62249309|NCT04928690||Arm 1: MCI amyloid positive|"* Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's~* Positive amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)"
62047033|NCT04202380|OTHER|Azithromycin 5 days group|Patients will receive Azithromycin 500mg once orally, followed by Azithromycin 250mg orally daily for 4 days
62249310|NCT04928690||Arm 2: MCI amyloid negative|"* Non-AD Mild Cognitive Impairment (MCI)~* Negative amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)"
62249311|NCT04928690||Arm 3: CN amyloid positive|"* Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Positive amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)"
62249312|NCT04928690||Arm 4: CN amyloid negative|"* Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Negative amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)"
62439130|NCT04570410|EXPERIMENTAL|Subgroup1:Patients who can tolerate cisplatin chemotherapy|"GC plus Tislelizumab Participants receive GC (Gemcitabine plus cisplatin), in combination with Tislelizumab administered intravenously (IV) every 3 weeks (Q3W) before surgery.Immunotherapy was continued for 6 months after excision of the primary lesion.~Intervention/treatment： Biological: Tislelizumab Tislelizumab IV infusion of 200 mg Q3W~Biological: GC GC (Gemcitabine plus cisplatin): Gemcitabine 1000mg/m2 D1,D8 iv every 3 weeks Cisplatin70mg/m2,D2,3,4 iv every 3 weeks"
62606677|NCT02596217|PLACEBO_COMPARATOR|Placebo IV (Stage2)|Placebo administered by intraveneous (IV) infusion
62606678|NCT01270386|EXPERIMENTAL|Apatinib|Apatinib 750 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62249313|NCT06033781|EXPERIMENTAL|Treatment Right-Away|Child will start the CBT-NC treatment right away.
62606679|NCT01270386|PLACEBO_COMPARATOR|Placebo|Placebo qd p.o., and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62606680|NCT02580864||IBD patients|120 adult patients (Caucasian, male/female,18-65 years old) with moderate-severe active Crohns disease (220≤ CDAI ≤450; blood CRP ≥5 mg/L and/or fecal calprotectin ≥250mg/L) and with indication for anti-TNF therapy according to the normal clinical practice
62606681|NCT02580864||No-IBD patients|30 no-IBD controls with no GI disorders, as defined by medical history and standard clinical chemistry values, afferent to the out-patient clinic
62249314|NCT06033781|NO_INTERVENTION|Waitlist Control|Waitlist control group will complete the assessments at the same time as the treatment group, without receiving any treatment. They will be offered treatment after finishing the waitlist.
62606682|NCT01539395||Inactive Disease|Inactive disease; RRMS patients who have been treated with monthly infusions of Tysabri for 12 months and have had stable disease for the last 6 months or more and show stable or improving neurological deficits over 3 months on Tysabri.
62606683|NCT01539395||Active Disease|Active disease; RRMS patients in acute clinical relapse or with active MRI. Blood sample obtained within 30 days of event AND before steroid treatment (or) patients in early disease on or off first line agents with relapse in prior 3 months AND not treated with steroids for at least 2 months.
62439131|NCT04570410|EXPERIMENTAL|Subgroup2:Patients who cannot tolerate cisplatin chemotherapy|"Tislelizumab Participants receive Tislelizumab administered intravenously (IV) every 3 weeks (Q3W) before surgery.Immunotherapy was continued for 6 months after excision of the primary lesion.~Intervention/treatment： Biological: Tislelizumab Tislelizumab IV infusion of 200 mg Q3W"
62606684|NCT01539395||Active Disease - Steroid Therapy|Patient with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin steroid therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
62606685|NCT03698968|OTHER|Single prospective intervention|
62829063|NCT06370806|NO_INTERVENTION|Usual Care|Participants from the usual care group will not receive any type of intervention apart from the usual care (CPAP).
62829064|NCT06370806|EXPERIMENTAL|Lifestyle Intervention|Participants from this group will receive a interdisciplinary intervention addressing weight loss and lifestyle change including nutritional behavior change, aerobic exercise, sleep hygiene, and alcohol and tobacco cessation combined with usual care (i.e., CPAP)
62047034|NCT01466985|EXPERIMENTAL|Panel A: Doravirine 25 mg or Placebo|Participants will receive oral doses of doravirine 25 mg or placebo once daily for 7 days.
62249315|NCT06470399|ACTIVE_COMPARATOR|Control Group|
62249316|NCT06470399|EXPERIMENTAL|AI-Guided Group|
62249317|NCT01131351|EXPERIMENTAL|Delamanid 250 mg BID+ OBR|Participants received delamanid five 50 milligrams (mg) (250 mg) tablets, twice a day (BID), along with at least 2 additional anti-TB medications per optimized background regimen (OBR) for up to 28 weeks.
62439132|NCT00200005|EXPERIMENTAL|InterStim therapy|Patients being treated with sacral neuromodulation with InterStim therapy.
62439133|NCT05574426|EXPERIMENTAL|Cardiovascular Movement Breaks|Participants will perform 3-4 exercise snacks (30-60s bursts of exercise) on at least 3 days of the week. The exercises prescribed in this arm will be designed to increase heart rate.
62439134|NCT05574426|ACTIVE_COMPARATOR|Mobility Movement Breaks|Participants will perform 3-4 mobility snacks (30-60s of mobility exercises or stretching) on at least 3 days of the week. The exercises prescribed in this arm are not designed to increase heart rate.
62439135|NCT01193517|EXPERIMENTAL|Phase I|Dose Escalation of Azacitidine + CAPOX (Capecitabine, Oxaliplatin)
62439136|NCT01193517|EXPERIMENTAL|Phase II|MTD of Azacitidine + CAPOX
62606686|NCT00908076|ACTIVE_COMPARATOR|amitiza|Amitiza
62606687|NCT00908076|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62606688|NCT02537834|EXPERIMENTAL|Tofogliflozin ＋GLP-1 analogue|Tofogliflozin administered once daily for 52 weeks. GLP-1 analogue administered as base treatment.
62606689|NCT02235441|EXPERIMENTAL|Cardiopulmonary Fitness|All eligible subjects will participate in treadmill exercise to measure cardiopulmonary fitness during chemoradiation therapy.
62249318|NCT01131351|EXPERIMENTAL|Delamanid 300 mg BID+ OBR|Participants received delamanid six 50 mg (300 mg) tablets, BID, along with at least 2 additional anti-TB medications per OBR for up to 28 weeks.
62606690|NCT04919876|EXPERIMENTAL|fruit/vegetable supplement (FVS)|The experimental product will be prepared by combing Juice Plus+ Garden Blend, Juice Plus+ Orchard Blend, and Juice Plus+ Berry Blend in an equal proportion.
62606691|NCT04919876|PLACEBO_COMPARATOR|placebo|The placebo comprises microcrystalline cellulose and 0.5% magnesium stearate.
62606692|NCT05650346|ACTIVE_COMPARATOR|Control Group ( Deep Cervical Training )|
62249319|NCT03779971|PLACEBO_COMPARATOR|Control|The placebo comparator will be a fully controlled diet made from typical American foods and containing no beans or pulses.
62606693|NCT05650346|EXPERIMENTAL|Experimental group I (Deep cervical training + Upper cervical mobilization group)|
62829065|NCT01352715|EXPERIMENTAL|Arm A: LPV/r plus RAL|Participants were administered LPV/r plus RAL orally twice daily throughout follow-up.
62249320|NCT03779971|EXPERIMENTAL|Lentil|The lentil arm will consist of a fully controlled diet made from the same foods as the placebo arm and will also contain lentils.
62249321|NCT03779971|EXPERIMENTAL|Chickpeas|The chickpea arm will consist of a fully controlled diet made from the same foods as the placebo arm and will also contain chickpeas.
62249322|NCT01958788|EXPERIMENTAL|Cognitive-Behavioural Treatment|12 sessions of cognitive-behavioral treatment targeting negative beliefs about uncertainty
62439137|NCT06306495||University students|Study data will be collected with the International Physical Activity Survey, Demographic Data Form, Sleep Hygiene Index, Distress Tolerance Scale and Pittsburgh Sleep Quality Index administered to all participants.
62439138|NCT04771819|EXPERIMENTAL|SoftOx Wound Irrigation Solution (SWIS)|Blister wounds will be irrigated and soaked for 15 minutes.
62439139|NCT04771819|ACTIVE_COMPARATOR|Normal Saline|Blister wounds will be irrigated and soaked for 15 minutes.
62439140|NCT04945720|EXPERIMENTAL|Hepatic artery infusion chemotherapy（HAIC） plus Durvalumab|The therapeutic scheme was modified FOLFOX6 regimens including oxaliplatin (130 mg/m2 infusion for 3 hours on day 1), leucovorin (200 mg/m2 from hour 3 to 5 on day 1) and Fluorouracil (400 mg/m2 in bolus, and then 2,400 mg/m2 continuous infusion 46 hours). All chemo-drugs were given by HAI.Patients received anti-PD-L1 agents will begin no earlier than 7 days following the first HAIC procedure. Anti-PD-L1 agents were used intravenously at the standard dose: Durvalumab was given every 3 weeks during HAIC treatment (Q3W) and every 4 weeks after HAIC treatment (Q4W).
62829066|NCT01352715|EXPERIMENTAL|Arm B: LPV/r plus best available NRTIs|"Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs (listed below) throughout follow-up-~* FTC/TDF orally twice daily~* ABC/3TC/ZDV orally twice daily~* ABC/3TC orally once daily~* 3TC/ZDV orally twice daily~* ABC 300mg orally twice daily or 600 mg once daily~* 3TC orally twice daily~* ZDV orally twice daily"
62439141|NCT00000372|EXPERIMENTAL|Glycine|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with 30 grams of glycine in 7 ounces of lemonade twice a day in addition to clozapine treatment.
62439142|NCT00000372|PLACEBO_COMPARATOR|Placebo|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with 30 grams of placebo powder in 7 ounces of lemonade twice a day in addition to clozapine treatment.
62439143|NCT00000372|EXPERIMENTAL|D-Cycloserine|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with D-cycloserine in addition to clozapine treatment.
62439144|NCT04641481|EXPERIMENTAL|Study vaccine|BBV152B (6µg-Algel-IMDG)
62829067|NCT05074290|EXPERIMENTAL|Epidiferphane + taxane chemotherapy|
62439145|NCT04641481|PLACEBO_COMPARATOR|Placebo|Phosphate buffered saline with Alum (without antigen)
62439146|NCT00840983|NO_INTERVENTION|1-Immediate Cord Clamping|infants received the routine care of immediate clamping of the umbilical cord
62439147|NCT00840983|EXPERIMENTAL|2-Delayed Cord Clamping|after birth, cord clamping was delayed 30 to 45 seconds while infant was held lower than the level of the placenta.
62439148|NCT06379399|EXPERIMENTAL|Cetuximab Combined With Trifluridine/Tipiracil|
62439149|NCT06189755||Cases|Moderate-severe OSA (defined as AHI ≥15 events/hour)
62439150|NCT06189755||Controls|No OSA (defined as AHI \<5 events/hour)
62439151|NCT05702359|EXPERIMENTAL|Glucose as reference food|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food, along with 300mL water. Fingertip capillary blood glucose samples were collected at baseline and 15, 30, 45, 60, 90, 120, 150, and 180 min after test drink consumption. Salivary insulin samples were collected at baseline, 15, 30, 45, 60, 90, 120, and 180 min after test drink consumption.
62606694|NCT05650346|EXPERIMENTAL|Experimental group II (Deep cervical training + Upper thoracic mobilization group)|
62606695|NCT03901053|EXPERIMENTAL|AB|Participants in this arm will receive the Reaktiv AFO made by FabTech Systems LLC first, then the PhatBrace AFO by Bio-Mechanical Composites Inc. second.
62047035|NCT01466985|EXPERIMENTAL|Panel B: Doravirine 200 mg or Placebo|Panel B (doravirine 200 mg or placebo once daily for 7 days) will initiate upon satisfactory review of safety and tolerability from Panel A, and all safety, tolerability and pharmacokinetic data from the study MK-1439-001.
62606696|NCT03901053|EXPERIMENTAL|BA|Participants in this arm will receive the PhatBrace AFO by Bio-Mechanical Composites Inc. first, then the Reaktiv AFO made by FabTech Systems LLC second.
62439152|NCT05702359|EXPERIMENTAL|Control juice|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from control mixed fruit juice (pomegranate, grape, apple and orange), tested once, in random order, along with 300mL water. Fingertip capillary blood glucose samples were collected at baseline and 15, 30, 45, 60, 90, 120, 150, and 180 min after test drink consumption. Salivary insulin samples were collected at baseline, 15, 30, 45, 60, 90, 120, and 180 min after test drink consumption.
62439153|NCT05702359|EXPERIMENTAL|Juice containing vitamin D3|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from mixed fruit juice enriched with vitamin D3, tested once, in random order, along with 300mL water. Fingertip capillary blood glucose samples were collected at baseline and 15, 30, 45, 60, 90, 120, 150, and 180 min after test drink consumption. Salivary insulin samples were collected at baseline, 15, 30, 45, 60, 90, 120, and 180 min after test drink consumption.
62606697|NCT02335749|EXPERIMENTAL|Treatment with Small Area Applicator|Each enrolled subject was treated on a single thigh, in the distal region.
62606698|NCT06625398|EXPERIMENTAL|VRDN-003 every 4 weeks|6 subcutaneous administrations of VRDN-003
62606699|NCT06625398|EXPERIMENTAL|VRDN-003 every 8 weeks|3 subcutaneous administrations of VRDN-003 and 3 subcutaneous administrations of placebo
62439154|NCT05702359|EXPERIMENTAL|Juice containing n-3 polyunsaturated fatty acids (PUFA)|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from mixed fruit juice enriched with n-3 PUFA, tested once, in random order, along with 300mL water. Fingertip capillary blood glucose samples were collected at baseline and 15, 30, 45, 60, 90, 120, 150, and 180 min after test drink consumption. Salivary insulin samples were collected at baseline, 15, 30, 45, 60, 90, 120, and 180 min after test drink consumption.
62439155|NCT05702359|EXPERIMENTAL|Juice containing probiotics|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from mixed fruit juice enriched with probiotics, tested once, in random order, along with 300mL water. Fingertip capillary blood glucose samples were collected at baseline and 15, 30, 45, 60, 90, 120, 150, and 180 min after test drink consumption. Salivary insulin samples were collected at baseline, 15, 30, 45, 60, 90, 120, and 180 min after test drink consumption.
62606700|NCT06625398|PLACEBO_COMPARATOR|Placebo every 4 weeks|6 subcutaneous administrations of placebo
62606701|NCT03643367|EXPERIMENTAL|Sevoflurane Sedation|Patients randomized into experimental group will be treated with sevoflurane during 4 hours
62606702|NCT03643367|ACTIVE_COMPARATOR|Propofol Sedation|Patients randomized into Control Group will get continued intravenous sedation with propofol
62606703|NCT03536949|EXPERIMENTAL|RVL-1201 Ophthalmic Solution, 0.1%|RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
62606704|NCT03536949|PLACEBO_COMPARATOR|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
62606705|NCT04813913|EXPERIMENTAL|bevacizumab|bevacizumab in combination with IV fluoropyrimidine chemotherapy.
62606706|NCT01306435|EXPERIMENTAL|Laser Group|
62606707|NCT01306435|PLACEBO_COMPARATOR|Placebo Group|
62829068|NCT06592378|ACTIVE_COMPARATOR|Control Adult|Patients in this arm will be adults who undergo standard at-home acute pain management with opioids after treatment for isolated bone fracture (n=25)
62829069|NCT06592378|ACTIVE_COMPARATOR|Control Child|Patients in this arm will be children who undergo standard at-home acute pain management with opioids after treatment for isolated bone fracture (n=25)
62249323|NCT02000427|EXPERIMENTAL|Blinatumomab|"Participants will receive blinatumomab by continuous intravenous (CIVI) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieve a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.~The initial dose will be 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 for all subsequent cycles of treatment."
62249324|NCT05924737|EXPERIMENTAL|Sleep|Sleep deprivation
62249325|NCT01069172|EXPERIMENTAL|FS Laser Surgery|For femtosecond laser-assisted cataract surgery group (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the femtosecond laser device. If necessary, ultrasound (U/S) phacoemulsification will also be applied to facilitate removal of the crystalline lens during cataract surgery.
62249326|NCT01069172|ACTIVE_COMPARATOR|CCC Surgery|For the continuous curvilinear capsulorhexis (CCC) group (CCC Surgery), subjects will receive the standard of care for CCC and U/S phacoemulsification surgery to facilitate removal of the crystalline lens during cataract surgery.
62249327|NCT00797290||Photon/Proton Radiation Therapy|Photon/Proton Radiation Therapy
62439156|NCT05702359|EXPERIMENTAL|Juice containing probiotics, vitamin D3, and n-3 PUFA|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from a mixed juice enriched with probiotics, vitamin D3, and n-3 PUFA, tested once, in random order, along with 300mL water. Fingertip capillary blood glucose samples were collected at baseline and 15, 30, 45, 60, 90, 120, 150, and 180 min after test drink consumption. Salivary insulin samples were collected at baseline, 15, 30, 45, 60, 90, 120, and 180 min after test drink consumption.
62829070|NCT06592378|EXPERIMENTAL|Device Adult|Patients in this arm will be adults who undergo at-home acute pain management using the Addinex system after treatment for isolated bone fracture (n=25)
62829071|NCT06592378|EXPERIMENTAL|Device Child|Patients in this arm will be children who undergo at-home acute pain management using the Addinex system after treatment for isolated bone fracture (n=25)
62249328|NCT01794520|EXPERIMENTAL|Phase 1: Venetoclax 300 mg|Participants in the dose-escalation cohort received 300 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.
62249329|NCT01794520|EXPERIMENTAL|Phase 1: Venetoclax 600 mg|Participants in the dose-escalation cohort received 600 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.
62249330|NCT01794520|EXPERIMENTAL|Phase 1: Venetoclax 900 mg|Participants in the dose-escalation cohort received 900 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.
62249331|NCT01794520|EXPERIMENTAL|Phase 1: Venetoclax 1200 mg|Participants in the dose-escalation cohort received 1200 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.
62249332|NCT01794520|EXPERIMENTAL|Phase 1 Safety Expansion: Venetoclax 1200 mg|Participants in the safety expansion cohort received 1200 mg of venetoclax daily on Days 1 - 21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.
62249333|NCT01794520|EXPERIMENTAL|Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg|Participants with t(11;14) translocation multiple myeloma received daily venetoclax at a dose of 800 mg (no lead-in period) on Days 1- 21 of each cycle concomitant with weekly dexamethasone at a dose of 40 mg (20 mg for those aged ≥ 75 years).
62249334|NCT01794520|EXPERIMENTAL|Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg|The Phase 2 cohort further explored the efficacy of venetoclax in combination with dexamethasone in relapsed or refractory participants with t(11;14) translocation multiple myeloma. Participants received daily venetoclax at a dose of 800 mg (no lead-in period) on Days 1- 21 of each cycle concomitant with weekly dexamethasone at a dose of 40 mg (20 mg for those aged ≥ 75 years).
62439157|NCT00630669|ACTIVE_COMPARATOR|1|Rubber band ligation
62439158|NCT00630669|ACTIVE_COMPARATOR|2|Bipolar coagulation
62439159|NCT02452060|PLACEBO_COMPARATOR|treatment/placebo|saline infusion
62439160|NCT02452060|EXPERIMENTAL|treatment|ketamine (0.4mg/kg)
62439161|NCT03306056|EXPERIMENTAL|Control|Nutritional therapy / no exercise
62439162|NCT03306056|EXPERIMENTAL|Standard Strength Training|Nutritional therapy combined with a Standard Strength Training program
62829072|NCT04869826||Outpatients Complicated Hypertension Clinic|This study population consists of approximately 200 adult male and female participants (≥ 19 years of age; minimum 30% male/female). Participants will be recruited from eligible patients who are referred to the Complicated Hypertension Clinic at the Saint John Regional Hospital (SJRH) as well as non-patient participants who are willing to volunteer to consent to participate in the study.
62439163|NCT03306056|EXPERIMENTAL|Low-volume Strength Training|Nutritional therapy combined with a low-volume Strength Training program
62439164|NCT03306056|EXPERIMENTAL|Whole-body Electromyostimulation|Nutritional therapy combined with Whole-Body Electromyostimulation
62606708|NCT00705185||1|Adults with Major Depressive Disorder- as defined by the criteria in the DSM-IV
62606709|NCT00705185||2|Healthy Controls- research subjects who have not met criteria for any lifetime Axis-I disorder (DSM-IV)
62829073|NCT05996237||Registry participants|Participants in the University of Pittsburgh Claude D. Pepper Center community research registry. Potential participants will have stable regimens of 5+ prescribed medications and recent physician contact but no hospitalization in the prior 6 months.
62829074|NCT03431259|EXPERIMENTAL|Enrollment group|
62829075|NCT03431259|NO_INTERVENTION|Information group|
62249335|NCT03137186|ACTIVE_COMPARATOR|Investigational arm|Metformin will be added to standard of care
62249336|NCT03137186|NO_INTERVENTION|Control arm|Patients will treated according to Standard of care only
62249337|NCT05584254|EXPERIMENTAL|Elderly with gastrointestinal symptoms|The target group for the intervention and cohort of interest used for comparison of baseline characteristics between control groups. Went into a cross-over design with 2 yeast-derived beta-glucan supplements and a placebo.
62439165|NCT05138198|EXPERIMENTAL|Mediterranean Diet & Physical Activity|Nutrition with a Physical Activity component. 10-week intervention implementing the Mediterranean Diet.
62439166|NCT05138198|ACTIVE_COMPARATOR|Usual Care|Usual care involves one-on-one monthly nutrition counseling
62439167|NCT04175327||CardioCel group|Patients who require repair of cardiac and vascular defects including intracardiac defects; septal defects, valve and annulus repair; great vessel reconstruction, peripheral vascular reconstruction and suture line buttressing
62439168|NCT04570020||Clinically-Selected Scleral Lens|The clinically-selected lens is based on slit lamp assessment. This lens will be compared against an OCT-selected lens.
62439169|NCT04570020||OCT-Selected Scleral Lens|The OCT-selected lens is based on OCT measurements. This lens will be compared against a clinically-selected lens.
62439170|NCT04933578||Children|"1. The Faces Version of Modified Child Dental Anxiety Scale (MCDASf), which is a psychometric dental anxiety scale for children with eight questions, was used to determine the dental anxiety levels of the children.~2. The children's preferences for the appearance of dentists were determined in the second part.~3. Routine dental examinations of children with a dental mirror and artificial light were completed by an experienced pediatric dentist according to the World Health Organization (WHO) guidelines and criteria."
62606710|NCT06051331|EXPERIMENTAL|Experimental group|Simulation-based breast health education
62829076|NCT05637710|EXPERIMENTAL|Group 1|Investigational group: FDC levocetirizine 5mg / pseudoephedrine 240mg from Eurofarma Laboratórios S.A.
62249338|NCT05584254|NO_INTERVENTION|Senior orienteers|A model of healthy aged elderly used as a control group for the baseline characteristics.
62249339|NCT05584254|NO_INTERVENTION|Young healthy adults|A cohort of young healthy adults used as a control group for the baseline characteristics.
62606711|NCT06051331|NO_INTERVENTION|Control group|The control group will not take part the simulation-based breast health education
62829077|NCT05637710|ACTIVE_COMPARATOR|Group 2|Comparator group: Levocetirizine 5mg (Zina® - comparator drug)
62249340|NCT01713270|EXPERIMENTAL|renal sympathetic denervation|Contrast renal angiography was performed to localize and assess the renal arteries. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter was introduced into each renal artery. This was then maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 60 seconds each were performed in both renal arteries. After renal sympathetic denervation, patients with persistent AF accepted direct-current cardioversion immediately.
62829078|NCT04464486|EXPERIMENTAL|COVID-19 Symptom Augmented SCH Intervention|The SCH intervention group will report COVID-19 and cancer-related symptom presence and severity daily into the automated SCH system. Participants receive automated self-management support messages for symptoms reported and a Nurse Practitioner monitors and responds to alerts for COVID-19 symptoms and poorly controlled or worsening cancer symptoms. Participants in this group complete baseline and monthly measures.
62829079|NCT04464486|NO_INTERVENTION|Enhanced Usual Care|Participants in the control group are given information by research staff reviewing COVID-19 symptoms, home precautions, and instructions on what to do to address concerns that arise. Participants in this group complete baseline and monthly measures.
62829080|NCT05361668|EXPERIMENTAL|40 mg Paltusotine|
62829081|NCT05361668|EXPERIMENTAL|80 mg Paltusotine|
62249341|NCT01713270|ACTIVE_COMPARATOR|drug therapy|Patients in the drug treatment group will be followed-up at 3, 6, 9 and 12 months after randomization. All the patients in this group will take their baseline antihypertensive medication at the original doses, without any changes except when medically required. Antiarrhythmic drugs treatment is consistent in both arms.
62249342|NCT02383290|EXPERIMENTAL|Decision support|This is a feasibility trial so all patients will give a saliva sample and the pharmacist/ Family Physician will use the decision support for generating prescription recommendations
62249343|NCT04517734||Pregnant Adolescents|
62249344|NCT04517734||Pregnant Women Carrying Multiple Fetuses|
62249345|NCT00744133|EXPERIMENTAL|Group 1: 1, 3, or 5 bites|Part A: 18 subjects receive 1, 3, or 5 bites of Anopheles stephensi mosquitoes infected with the NF54 strain of Plasmodium falciparum.
62249346|NCT00744133|EXPERIMENTAL|Group 2: N bites|Part B: 20 subjects receive N bites of Anopheles stephensi mosquitoes infected with the NF54 strain of Plasmodium falciparum.
62249347|NCT02463721|OTHER|SBP patients|ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
62249348|NCT05617183|EXPERIMENTAL|CT-P47 Auto-injector|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via auto-injector (AI)
62249349|NCT05617183|ACTIVE_COMPARATOR|CT-P47 Pre-filled Syringe|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
62249350|NCT02529007|ACTIVE_COMPARATOR|Standard|These patients have standard colonoscopy performed
62249351|NCT02529007|EXPERIMENTAL|Endocuff|These patients have colonoscopy performed with the endo-cuff attached to the end of the colonoscope
62606712|NCT01187667||Haloperidol prevention group|ICU patients with a high risk for delirium who are treated with haloperidol for preventive reason.
62829082|NCT06592339|EXPERIMENTAL|Sequence 1: MK-0616 Reference capsule→MK-0616 Formulation 1 (F1)→MK-0616 Formulation 2 (F2)|Period 1: Participants receive MK-0616 reference capsule single dose on Day 1 orally (Period 1 = 15 days). Period 2: Participants receive MK-0616 F1 single dose on Day 1 orally (Period 2 = 15 days). Period 3: Participants receive MK-0616 F2 single dose on Day 1 orally (Period 3 = 15 days). A washout period of 14 days will separate Period 1, Period 2 and Period 3.
62829083|NCT06592339|EXPERIMENTAL|Sequence 2: MK-0616 Reference capsule→MK-0616 F2→MK-0616 F1|Period 1: Participants receive MK-0616 reference capsule single dose on Day 1 orally (Period 1 = 15 days). Period 2: Participants receive MK-0616 F2 single dose on Day 1 orally (Period 2 = 15 days). Period 3: Participants receive MK-0616 F1 single dose on Day 1 orally (Period 3 = 15 days). A washout period of 14 days will separate Period 1, Period 2 and Period 3.
62606713|NCT01187667||Control group|Historical cohort group of patients (2008-2009)with a determined risk of 50% or more for delirium who were not treated with haloperidol for preventive reason.
62606714|NCT04679051|EXPERIMENTAL|8 hours time in bed|Participants will be asked to spend 8 hours time in bed with the aim of achieving one week of normal sleep duration (7 to 8 hours).
62606715|NCT04679051|EXPERIMENTAL|11 hours time in bed|Participants will be asked to spend 11 hours time in bed with the aim of achieving one week of long duration sleep as defined as 9+ hours of sleep.
62606716|NCT02359799|EXPERIMENTAL|Lab group|Lab-based intervention includes 18 training sessions using the IntelliStretch in the lab .
62439171|NCT04933578||Parents|"1. The questionnaire including demographic information (age, sex, and medical and dental history) was applied to the parents.~2. In the second section, the MDAS was administered to parents, differently from children.~3. The parents' preferences for the appearance of dentists were determined in the second part."
62439172|NCT05873777|EXPERIMENTAL|68Ga-FAPI-LM3|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAPI-LM3, and undergo PET/CT imaging within the specified time.
62829084|NCT06592339|EXPERIMENTAL|Sequence 3: MK-0616 F1→MK-0616 Reference capsule→MK-0616 F2|Period 1: Participants receive MK-0616 F1 single dose on Day 1 orally (Period 1 = 15 days). Period 2: Participants receive MK-0616 reference capsule single dose on Day 1 orally (Period 2 = 15 days). Period 3: Participants receive MK-0616 F2 single dose on Day 1 orally (Period 3 = 15 days). A washout period of 14 days will separate Period 1, Period 2 and Period 3.
62829085|NCT06592339|EXPERIMENTAL|Sequence 4: MK-0616 F1→MK-0616 F2→MK-0616 Reference capsule|Period 1: Participants receive MK-0616 F1 single dose on Day 1 orally (Period 1 = 15 days). Period 2: Participants receive MK-0616 F2 single dose on Day 1 orally (Period 2 = 15 days). Period 3: Participants receive MK-0616 reference capsule single dose on Day 1 orally (Period 3 = 15 days). A washout period of 14 days will separate Period 1, Period 2 and Period 3.
62829086|NCT06592339|EXPERIMENTAL|Sequence 5: MK-0616 F2→MK-0616 Reference capsule →MK-0616 F1|Period 1: Participants receive MK-0616 F2 single dose on Day 1 orally (Period 1 = 15 days). Period 2: Participants receive MK-0616 reference capsule single dose on Day 1 orally (Period 2 = 15 days). Period 3: Participants receive MK-0616 F1 single dose on Day 1 orally (Period 3 = 15 days). A washout period of 14 days will separate Period 1, Period 2 and Period 3.
62829087|NCT06592339|EXPERIMENTAL|Sequence 6: MK-0616 F2→MK-0616 F1→MK-0616 Reference capsule|Period 1: Participants receive MK-0616 F2 single dose on Day 1 orally (Period 1 = 15 days). Period 2: Participants receive MK-0616 F1 single dose on Day 1 orally (Period 2 = 15 days). Period 3: Participants receive MK-0616 reference capsule single dose on Day 1 orally (Period 3 = 15 days). A washout period of 14 days will separate Period 1, Period 2 and Period 3.
62829088|NCT06588595|EXPERIMENTAL|ABCD-GENE-guided de-escalation|ABCD-GENE ≥10: prasugrel 10 mg qd or ticagrelor 90 mg od monotherapy. ABCD-GENE \<10: Aspirin 81 mg qd and clopidogrel 75 mg qd.
62829089|NCT06588595|ACTIVE_COMPARATOR|Unguided de-escalation|Aspirin 81 mg qd and clopidogrel 75 mg qd.
62829090|NCT02667119|EXPERIMENTAL|Prolonged Exposure + Contingency Management|Standard services plus Prolonged Exposure and Contingency Management
62829091|NCT02667119|ACTIVE_COMPARATOR|Standard Care|Standard substance abuse treatment services
62829092|NCT02252666|EXPERIMENTAL|Neuromodulation Rehabilitation|Balance, posture and gait activities; therapeutic exercise for isolated muscle control; transfer training; and relaxation training using neurostimulation modulation. 2-week in lab intervention training, training at home and periodic return for follow-up testing and instruction on the next phase of the intervention.
62829093|NCT01750151|EXPERIMENTAL|Glucose beverage|Glucose beverage
62829094|NCT01750151|EXPERIMENTAL|Control beverage and video game playing|Control beverage and video game playing
62439173|NCT00717210|ACTIVE_COMPARATOR|A|Conventional Radiotherapy
62606717|NCT02359799|EXPERIMENTAL|Home group|Home-based intervention includes 18 training sessions using the IntelliStretch at home.
62606718|NCT04785040||1|
62606719|NCT00756197|EXPERIMENTAL|Cryo Spray Ablation Group 1|4 cycles of 10 seconds each
62606720|NCT00756197|EXPERIMENTAL|Cryo Spray Ablation Group 2|2 cycles of 20 seconds each
62606721|NCT05583643|OTHER|Phase 1 therapy|
62829095|NCT01750151|EXPERIMENTAL|Glucose beverage and video game playing|Glucose beverage and video game playing
62829096|NCT01750151|EXPERIMENTAL|Control beverage|Control beverage
62829097|NCT06200662|OTHER|premature newborns|"premature newborns . 2 groups composed of the same children but benefiting from 2 different analgesic strategies, each applied at one of two different times. The groups compared were the order S then M group and the order M then S group."
62829098|NCT06200662|OTHER|premature|"premature newborns . 2 groups composed of the same children but benefiting from 2 different analgesic strategies, each applied at one of two different times. The groups compared were the order S then M group and the order M then S group."
62606722|NCT05583643|ACTIVE_COMPARATOR|Phase 1 therapy with atorvastatin loaded into cubosomal in-situ gel|
62439174|NCT00717210|EXPERIMENTAL|B1/2|1:1 randomization between temozolomide and procarbazine/lomustine/vincristine (PCV)
62606723|NCT05583643|ACTIVE_COMPARATOR|Phase 1 therapy with atorvastatin loaded into in-situ gel|
62606724|NCT00365001|EXPERIMENTAL|1|
62606725|NCT00365001|ACTIVE_COMPARATOR|2|
62606726|NCT05111392|PLACEBO_COMPARATOR|Placebo|Water
62606727|NCT05111392|EXPERIMENTAL|Oral rehydration solution 1|Beverage with 2.5% glucose with 45 mmol sodium/L.
62606728|NCT05111392|EXPERIMENTAL|Oral rehydration solution 2|Beverage with 1.7% glucose with 60 mmol sodium/L.
62606729|NCT01464801|EXPERIMENTAL|Resveratrol|Subjects are given resveratrol 500 mg 3 times daily for 6 months.
62606730|NCT01464801|PLACEBO_COMPARATOR|Placebo|Subjects are given Placebo tablets 3 times daily for 6 months.
62047036|NCT01466985|EXPERIMENTAL|Panel C: Doravirine or Placebo|Panel C is optional. If conducted, the dose will be confirmed after review of data from prior panels.
62249352|NCT05538520|EXPERIMENTAL|Traditional Pilates|"5 stretching exercises will be performed, followed by 15 strengthening exercises (5 for core, 5 for lower limbs and 5 for upper limbs), all in a series of 10 repetitions, 3x-week, for 8 weeks, maintaining an effort level 7-8 on the Omni-Scale. Below are the exercises and equipment used.~1) Stretching the Chain Posterior (Reformer); 2) Front Splits Modified (Reformer); 3) Stomach Massage (Reformer); 4) Stretches Front (Barrel); 5) Back Stretches: Quadriceps Stretch (Barrel); 6) Bridge (Mat with Magic Circle); 7) The Hundred (Mat with Swiss ball); 8) Teaser (Mini Barrel); 9) Swan (Mini Barrel); 10) Swimming (Mini Barrel); 11) Footwork Double Leg Pumps (Chair); 12) Pump One Leg Front (Chair); 13) Forward Lunge (Chair); 14) Wall Side (Wall with Swiss ball and dumbbells); 15) Tower (Cadillac); 16) Arms Pulling Up (Cadillac); 17) Rowing Front: Hug a Tree (Cadillac); 18) Arm Pulling Down (Wall Unit); 19) Horizontal Arm Pulling (Wall Unit); 20) Extension Arm Up (Wall Unit)."
62606731|NCT02946814|ACTIVE_COMPARATOR|essential oils|a single mouthwash with 20 ml of essential oils for 30 seconds.
62606732|NCT02946814|EXPERIMENTAL|essential oils without mouthwash|a single mouthwash with 20 ml of essential oils without alcohol for 30 seconds.
62606733|NCT02946814|SHAM_COMPARATOR|sterile water|a single mouthwash with 20 ml of sterile water for 30 seconds.
62829099|NCT02450370|ACTIVE_COMPARATOR|Conventional IBS diet group|Subjects in this group will follow a conventional diet for up to 10 weeks. They will receive 3 dietetic consultations at week 0,6 and 10. This diet will focus on small frequent meals, no skipping meals and dietary adjustments for bloatedness, diarrhea and constipation. Advice on intake of caffeine and alcohol will also be given. Dietary leaflets will be provided.
62439175|NCT01892423|EXPERIMENTAL|Cetaphil Moisturizing Lotion Daily Advance|Each subject had Cetaphil Moisturizing Lotion Daily Advance applied
62439176|NCT00417027|ACTIVE_COMPARATOR|2.5 mL bolused every 15 minutes|
62829100|NCT02450370|EXPERIMENTAL|Low FODMAP diet group|Subjects in this group will follow a low FODMAP diet for up to 10 weeks. Foods that are high in oligosaccharides, disaccharides, monosaccharides and polyols will be avoided. They will receive 3 dietetic consultations at week 0,6 and 10. Dietary leaflets, including meal samples and Yes/No food lists will be provided.
62829101|NCT05459181|NO_INTERVENTION|Control arm|465 participants undergoing standard of care post-transplant surveillance
62829102|NCT05459181|EXPERIMENTAL|Intervention arm|465 participants undergoing HeartCare protocol surveillance
62829103|NCT05156385|EXPERIMENTAL|Hypertensive women|
62439177|NCT00417027|ACTIVE_COMPARATOR|5ml bolused every 30 minutes|
62829104|NCT06597890|EXPERIMENTAL|RCT 1 - group 1|Sleep Hygiene Ecological Momentary Intervention (EMI)
62829105|NCT06597890|EXPERIMENTAL|RCT 1 - group 2|Personalised Sleep Guideline EMI
62829106|NCT06597890|NO_INTERVENTION|RCT 1 - group 3|Control
62829107|NCT06597890|EXPERIMENTAL|RCT 2 - group 1|Stair Climbing EMI
62829108|NCT06597890|EXPERIMENTAL|RCT 2 - group 2|Vigorous Intermittent Lifestyle Physical Activity (VILPA) EMI
62829109|NCT06597890|NO_INTERVENTION|RCT 2 - group 3|Control
62829110|NCT06597890|EXPERIMENTAL|RCT 3 - group 1|Screentime Breaktime EMI
62829111|NCT06597890|EXPERIMENTAL|RCT 3 - group 2|Screentime Goal EMI
62829112|NCT06597890|NO_INTERVENTION|RCT 3 - group 3|Control
62829113|NCT04614363|EXPERIMENTAL|68 Ga PSMA|Comparison between the results of 68 Ga-PSMA PET/CT to conventional imaging (bone scan, CT) in men with high risk prostate cancer.
62439178|NCT00417027|ACTIVE_COMPARATOR|10ml bolused every 60 minutes|
62439179|NCT01904383||Trazenta|
62439180|NCT03604926||chemo-naive patients|
62439181|NCT03604926||pre-treated patients with systemic chemotherapy +/- a targeted|
62439182|NCT01271764|NO_INTERVENTION|endometrial cancer|
62829114|NCT02943434|OTHER|Processed Food|Changes in resting energy expenditure will be measured via indirect calorimetry after consumption of a processed foods meal to determine changes in diet-induced thermogenesis.
62047037|NCT04602533|EXPERIMENTAL|Durvalumab|"Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy)~Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities."
62606734|NCT05531305|EXPERIMENTAL|Study intervention|
62606735|NCT04805359|EXPERIMENTAL|Normoxic exercise (NE)|The subjects were trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax) under 21%O2 in air (NE) for 30 minutes per day, 5 days per week for 6 weeks
62606736|NCT04805359|EXPERIMENTAL|Hypoxic exercise (HE)|The subjects were trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax) under 15%O2 in air (HE) for 30 minutes per day, 5 days per week for 6 weeks
62606737|NCT04805359|NO_INTERVENTION|Normoxic control|Without any exercise training
62606738|NCT00772824|NO_INTERVENTION|1|10 patients (30 cycles) of chemotherapy will receive placebo
62606739|NCT00772824|ACTIVE_COMPARATOR|2|Intravenous glutamine
62829115|NCT02943434|OTHER|Whole Food|Changes in resting energy expenditure will be measured via indirect calorimetry after consumption of a whole foods meal to determine changes in diet-induced thermogenesis.
62829116|NCT06604091||Mild adenomyosis group|disease extent :\< 25% of uterine volume affected by adenomyosis
62829117|NCT06604091||Moderate adenomyosis group|disease extent: 25-50% of uterine volume affected by adenomyosis
62829118|NCT06604091||Severe adenomyosis group|disease extent: \> 50% of uterine volume affected by adenomyosis
62829119|NCT06604091||Control group|infertile patients caused by simple male factor
62606740|NCT00772824|EXPERIMENTAL|3|Oral Glutamine
62249353|NCT05538520|EXPERIMENTAL|Pilates without stretching|"15 strengthening exercises will be performed (the same performed by the TP group), all in a series of 10 repetitions, 3x-week, for 8 weeks, maintaining an effort level 7-8 on the Omni-Scale. Below are the exercises and equipment used.~1) Bridge (Mat with Magic Circle); 2) The Hundred (Mat with Swiss ball); 3) Teaser (Mini Barrel); 4) Swan (Mini Barrel); 5) Swimming (Mini Barrel); 6) Footwork Double Leg Pumps (Chair); 7) Pump One Leg Front (Chair); 8) Forward Lunge (Chair); 9) Wall Side (Wall with Swiss ball and dumbbells); 10) Tower (Cadillac); 11) Arms Pulling Up (Cadillac); 12) Rowing Front: Hug a Tree (Cadillac); 13) Arm Pulling Down (Wall Unit); 14) Horizontal Arm Pulling (Wall Unit); 15) Extension Arm Up (Wall Unit)."
62249354|NCT04509141|ACTIVE_COMPARATOR|acupuncture|acupuncture three times a week
62249355|NCT04509141|ACTIVE_COMPARATOR|standard treatment for migraine by neurologist|standard treatment for migraine that was given by a neurologist
62249356|NCT04278300||case|patient with age-related exudative macular degeneration
62249357|NCT04278300||control|Patient with no macular disorder and in need of cataract surgery
62249358|NCT00495820|EXPERIMENTAL|Arm 1|Methylphenidate
62249359|NCT00495820|PLACEBO_COMPARATOR|Arm 2|Placebo
62249360|NCT03126526|EXPERIMENTAL|Food specific inhibitory control training|The stimuli in this task will involve pictures of food.
62249361|NCT03126526|ACTIVE_COMPARATOR|General inhibitory control training|The stimuli in this task will not involve pictures of food, but pictures of stationary and household items.
62249362|NCT03126526|NO_INTERVENTION|Baseline brain activation assessment (healthy controls)|This arm is included to assess brain activation using EEG among healthy controls at baseline in order to compare responses to participants with eating disorders.
62249363|NCT02053324|EXPERIMENTAL|AvidinOX/ST2210|AvidinOX/ST2210 - vial containing 22.5 mg AvidinOX + vials containing 10 ml of water for injection (WFI) for the reconstitution in a clear solution with an AvidinOX concentration of 3 mg/ml. One Intralesion administration of a volume of reconstituted AvidinOX equal to 15 % of the lesion volume followed by intravenous infusion of 177Lu-ST2210 Diagnostic dose : 10 ml, 250 MBq±10%177Lu, approximately 1 mg ST2210, 100 mg/mL ascorbic acid, followed by intravenous infusion of a therapeutic dose: 25 ml, escalating 177Lu dose starting at 5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210, 100 mg/ml ascorbic acid
62249364|NCT02859376|ACTIVE_COMPARATOR|sucrose24% 2 minutes before|sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if \> 1000 g two minutes BEFORE the skin breaking procedure
62249365|NCT02859376|EXPERIMENTAL|sucrose24% 2minutes before and during|sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if \> 1000 g two minutes BEFORE and DURING the skin breaking procedure
62249366|NCT04175106|EXPERIMENTAL|a phytochemical-rich blueberry variety|Single-time consumption of 150 g phytochemical-rich blueberry per participant.
62249367|NCT04175106|EXPERIMENTAL|a phytochemical-poor blueberry variety|Single-time consumption of 150 g phytochemical-poor blueberry per participant.
62249368|NCT04175106|EXPERIMENTAL|"a minimally processed blueberry-rich protein bar"|Single-time consumption of blueberry-rich protein bar matched for 150 g blueberry phytochemicals.
62249369|NCT04175106|PLACEBO_COMPARATOR|a blueberry control beverage of matched-nutritive content|Single-time consumption of control beverage matched for the macronutrient content of the blueberry-rich protein bar.
62249370|NCT02753660|ACTIVE_COMPARATOR|Traditional sitting position|Patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion before spinal anesthesia begun.
62249371|NCT02753660|EXPERIMENTAL|Pendant position|Patients sit with both their underarms propped up on a metal prop, thus both arms hanging from the prop before spinal anesthesia begun.
62249372|NCT04377711|ACTIVE_COMPARATOR|Group 1|Participants receive Alvesco 320mcg, twice daily for 30 days via pMDI
62249373|NCT04377711|PLACEBO_COMPARATOR|Group 2|Participants receive Placebo matching Alvesco , twice daily for 30 days via pMDI
62249374|NCT00601705|EXPERIMENTAL|Epirubicin, Oxaliplatin and Fluorouracil|
62249375|NCT00861913|EXPERIMENTAL|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62249376|NCT04946396|EXPERIMENTAL|dexmedetomidine intravenous infusion|Patients who will receive continuous intraoperative infusion of dexmedetomidine hydrochloride (0.5 µg/kg/h).
62249377|NCT04946396|SHAM_COMPARATOR|0.9% saline solution intravenous infusion|Patients who will receive continuous infusion of 0.9% saline solution (sham group).
62249378|NCT01458366|EXPERIMENTAL|Bendamustine 70mg/m^2|Level 1: Bendamustine 70mg/m\^2 Ofatumumab, Carboplatin, and Etoposide
62249379|NCT01458366|EXPERIMENTAL|Bendamustine 50mg/m^2|Level -1: Bendamustine 50mg/m\^2 Ofatumumab, Carboplatin, and Etoposide
62249380|NCT01458366|EXPERIMENTAL|Bendamustine 90mg/m^2|Level 2: Bendamustine 90mg/m\^2 Ofatumumab, Carboplatin, and Etoposide
62249381|NCT01458366|EXPERIMENTAL|Bendamustine 120mg/m^2|Level 3: Bendamustine 120mg/m\^2 Ofatumumab, Carboplatin, and Etoposide
62606741|NCT04192058|SHAM_COMPARATOR|sham tDCS|For sham treatment we will use the same assembly as the active ETCC. However, we will apply the current for 30s at the start of the stimulation session and 30s at the end of the session.
62606742|NCT04192058|EXPERIMENTAL|active tDCS|The anode will be positioned over the left hemisphere at C3 while the cathode will be positioned over the contralateral hemisphere F3. During active stimulation a 2.0mA current released by a 35 cm2 electrode will be used for 20 min. The position of the electrodes will be performed based on a 10-20 system according to the international EEG unit system, with the location of the electrodes at C3 and F3, respectively.
62606743|NCT02314754|EXPERIMENTAL|71-77 days gestational age|Women whose pregnancies are estimated to have a gestational age of 71-77 days.
62249382|NCT01458366|EXPERIMENTAL|Phase II MTD|Phase II: Bendamustine at MTD from Phase I, Ofatumumab, Carboplatin, and Etoposide
62606744|NCT02314754|NO_INTERVENTION|64-70 days gestational age|Women whose pregnancies are estimated to have a gestational age of 64-70 days.( Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range).
62606745|NCT04969380|EXPERIMENTAL|face and/or neck and/or submental zones|the full face and/or neck and/or submental zones including 1. -The forehead and temples (left and right including the peri orbital zone) to lift the eyebrows 2. The cheeks (left and right including perioral zone and nasolabial folds) 3. Submental and sides of the neck
62439183|NCT04120220|EXPERIMENTAL|Heavy Cream|Participants will receive a meal containing 30 g of fat prepared with heavy cream.
62439184|NCT04120220|EXPERIMENTAL|Soybean Oil|Participants will receive a meal containing 30 g of fat prepared with soybean oil.
62606746|NCT04026412|EXPERIMENTAL|Arm A: nivolumab + CCRT + ipilimumab|Concurrent chemoradiotherapy (CCRT)
62606747|NCT04026412|EXPERIMENTAL|Arm B: nivolumab + CCRT|Concurrent chemoradiotherapy (CCRT)
62829120|NCT02435186|EXPERIMENTAL|p53 gene plus chemotherapy|Intraperitoneal p53 gene plus cisplatin, and paclitaxel iv
62829121|NCT02435186|ACTIVE_COMPARATOR|chemotherapy|Intraperitoneal cisplatin, and paclitaxel iv
62829122|NCT05375032|EXPERIMENTAL|Cycling combined with cognitive tasks|
62439185|NCT02061085|EXPERIMENTAL|monotherapy treatment with Eribulin|Eribulin Dosage: 1.4 mg/m2 Route of administration: IV bolus Schedule of cycle: D1 and D8 every 21 days
62439186|NCT04627220||group 1|Group 1: Pressure of arterial oxygen\> 200 mmHg during the coronary surgery
62249383|NCT04098042||Scaffold|"Patients receiving during PCI the implantation of at least one Magnesium Made Bioresorbable Scaffold Magmaris"
62439187|NCT04627220||group 2|Group 2: Pressure of arterial oxygen\<200 mmHg and \>80 mmHg during the coronary surgery
62439188|NCT04427709|OTHER|Oxytocin First, then Placebo|Subjects in this arm will receive Intramuscular injection of Oxytocin (Pitocin®) first then placebo injection.
62439189|NCT04427709|OTHER|Placebo, Then Oxytocin|Subjects in this arm will receive Intramuscular placebo injection first then oxytocin injection
62439190|NCT02754323|OTHER|apparatus CODESNA|correlation between job stress measurement by the Maslach Burnout INVENTORY and KARASEK questionnaires and measurement of chronic stress by CODESNA tool
62439191|NCT04523142|EXPERIMENTAL|CyclASol Ophthalmic Solution|Cyclosporine A solution in vehicle
62249384|NCT02675816|OTHER|Inspire® (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System.
62249385|NCT00706550|OTHER|Immediate|"Arm 1 will receive PV (23-valent pneumococcal polysaccharide vaccine) prior to starting antiretroviral treatment and will receive PLACEBO after at least 6 months of starting antiretroviral treatment.~PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine"
62439192|NCT02760550||never smokers|who have never smoked at all
62439193|NCT02760550||ex-smokers|formerly smokers but currently do not smoke at all
62606748|NCT04026412|EXPERIMENTAL|Arm C: CCRT + durvalumab|Concurrent chemoradiotherapy (CCRT)
62606749|NCT02727426|EXPERIMENTAL|low salt diet|All subjects will be instructed to maintain a low-sodium (LS) diet, with an intake of less than 2.3 g of salt per day (DASH eating plan; US Department of Health and Human Services, 2006) for 7 days (washout period).
62606750|NCT02727426|EXPERIMENTAL|high salt diet|After washout period, all subjects will be instructed to maintain a high-sodium (HS) diet, with an intake of 11.2 g of salt per day for 7 days.
62606751|NCT05821075|ACTIVE_COMPARATOR|Prednisolone|
62606752|NCT05821075|ACTIVE_COMPARATOR|Cerebrolysin|
62606753|NCT05821075|ACTIVE_COMPARATOR|Prednisolone and Cerebrolysin|
62606754|NCT03744845|NO_INTERVENTION|Control group|Usual anesthetic care.
62606755|NCT03744845|EXPERIMENTAL|Virtual Reality Intervention Group|Virtual Reality Distraction
62606756|NCT03974022|EXPERIMENTAL|Part A Dose escalation|
62606757|NCT03974022|EXPERIMENTAL|Part A Dose expansion cohort 1|
62606758|NCT03974022|EXPERIMENTAL|Part A Dose expansion cohort 2|
62606759|NCT03974022|EXPERIMENTAL|Part A Dose expansion cohort 3|Patients with EGFR Exon20ins, previously treated with at least one line of systemic therapy
62606760|NCT03974022|EXPERIMENTAL|Part A Dose expansion cohort 4|Patients with EGFR Exon20ins, previously treated with at least one line of systemic therapy
62606761|NCT03974022|EXPERIMENTAL|Part A Dose expansion cohort 5|Patients with EGFR Exon20ins, treatment naïve
62829123|NCT05375032|ACTIVE_COMPARATOR|Cycling|
62439194|NCT02760550||current smokers|current smokers who, at the time of the survey, smoke any tobacco product either daily or occasionally. Social smokers fall into this category and are defined as those who smoke less than one cigarette per week or smoke only in some occasions
62439195|NCT01913730|NO_INTERVENTION|No prolonged therapy is scheduled|
62439196|NCT01913730|EXPERIMENTAL|Bortezomib Dexamethasone (Biochemical relapse)|Patients randomized in this group will be observed. At the occurrence of biochemical relapse, 4 VD cycles will be administered: Bortezomib (SC) and Dexamethasone (PO) weekly.
62439197|NCT03903640|EXPERIMENTAL|Optune + Ipilimumab + Nivolumab|"* Ipilimumab at 3 mg/kg IV over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.~* Nivolumab at 1 mg/kg IV over 30 minutes on Day 1 of each 21-day cycle for 4 cycles, then at 240 mg IV over 30 minutes on Days 1 and 15 of each 28-day cycle for up to 20 doses~* Within 2 weeks of the start of ipilimumab (before or after), treatment with Optune will begin. All patients will be required to shave their heads to initiate array placement and Optune therapy.~* Treatment may continue for up to 1 year"
62606762|NCT03974022|EXPERIMENTAL|Part A Dose expansion cohort 6|
62606763|NCT03974022|EXPERIMENTAL|Part B Dose extension cohort 1|Patients with EGFR Exon20ins
62606764|NCT03974022|EXPERIMENTAL|Part B Dose extension cohort 2|Patients with EGFR Exon20ins
62606765|NCT05368415|ACTIVE_COMPARATOR|3 mcg grup|this group will receive Norepinephrine bolus of 3 mcg for management of hypotension.
62606766|NCT05368415|ACTIVE_COMPARATOR|4 mcg group|this group will receive Norepinephrine bolus of 4 mcg for management of hypotension
62829124|NCT03888443||uCP children|15 Children aged from 6 to 17 with unilateral spastic Cerebral Palsy and a sufficient level of manipulation will realize the bimanual protocol twice separated from 2 to 4 weeks
62249386|NCT00706550|OTHER|Delayed|"Arm 2 will receive PLACEBO prior to starting antiretroviral treatment and will receive PV (23-valent pneumococcal polysaccharide vaccine) after at least 6 months of starting antiretroviral treatment.~PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine"
62439198|NCT01787370||Patients undergoing coronary angiography|Consecutive patients referred for coronary angiography for the suspect of coronary artery disease
62829125|NCT03888443||uCP children with botulinum toxin injections|5 children aged from 6 to 17 with unilateral spastic Cerebral Palsy and a sufficient level of manipulation will realize the bimanual protocol three times
62829126|NCT03888443||healthy volunteers (TDC children)|20 children aged from 6 to 17 (healthy volunteers) will realize the bimanual protocol once
62829127|NCT04862468|EXPERIMENTAL|Treatment|
62829128|NCT04862468|SHAM_COMPARATOR|Control|
62606767|NCT05368415|ACTIVE_COMPARATOR|5 mcg group|this group will receive Norepinephrine bolus of 5 mcg for management of hypotension
62249387|NCT01715753|ACTIVE_COMPARATOR|Weight Loss Control|Diet counseling and group education lessons. Subjects follow a calorie-reduction diet for a weight loss of ≥10%.
62439199|NCT02444533|ACTIVE_COMPARATOR|Liposomal Bupivacaine|Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy
62606768|NCT01752894|ACTIVE_COMPARATOR|Angio guided PCI|
62606769|NCT01752894|EXPERIMENTAL|OCT-guided PCI|
62829129|NCT01995838|EXPERIMENTAL|E2006|E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
62829130|NCT01995838|PLACEBO_COMPARATOR|Placebo|E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
62829131|NCT06600139|EXPERIMENTAL|The Collaboration-Screening-Referral model|The Collaboration-Screening-Referral model (in Swedish: Samverkan-Screening-Hänvisning - SSH) - an approach to screen parents involved with child welfare services for symptoms of mental illness, establish intra-agency collaboration, and facilitate referrals to mental health services. Social workers are trained to employ the SSH.
62249388|NCT01715753|EXPERIMENTAL|Weight Loss-High Protein|Protein supplementation. Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of protein, including substantial amounts of supplemental protein provided as lean beef. Intakes of \> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
62249389|NCT03526887|EXPERIMENTAL|Cohort 1|Patients who experienced progression disease while on treatment progression disease \< 12 weeks after stopping treatment. After that the patients took chemotherapy ≥ 4 cycles and progressed again. After the last progression the patient is included in the study to be retreated with Pembrolizumab 200mg
62439200|NCT02444533|NO_INTERVENTION|No treatment|Patient will not be given any medications in the tonsillar fossae after tonsillectomy
62449407|NCT02992171|EXPERIMENTAL|care management by oncology nurses|The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
62449408|NCT02864758||Group 1|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with rivaroxaban
62606770|NCT01752894|ACTIVE_COMPARATOR|BES|
62606771|NCT01752894|EXPERIMENTAL|EES|
62606772|NCT01752894|ACTIVE_COMPARATOR|Keep dual antiplatelet therapy (DAPT)|Study subjects will be allocated into this arm with non-randomization method
62606773|NCT01752894|ACTIVE_COMPARATOR|Discontinue Dual antiplatelet therapy (DAPT)|Study subjects will be allocated into this arm with non-randomization method
62606774|NCT05461456|EXPERIMENTAL|OP2101|Treatment with Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)
62606775|NCT02144636|EXPERIMENTAL|treament|herbalife protein shake along with exercise
62606776|NCT02144636|NO_INTERVENTION|control|diet and exercise only
62606777|NCT05233384||Patients with hereditary dysfibrinogenemia|Patient, male or female, aged over 18, with confirmed hereditary dysfibrinogenemia
62606778|NCT03861871|EXPERIMENTAL|Fenfluramine Hydrochloride|"Study medication will be administered as equal doses twice a day in the morning and in the evening approximately 12 hours apart.~Patients will first be titrated over 14 days to a dose of ZX008 0.8 mg/kg/day (maximum dose 30 mg/d).~After completion of the Titration Period, patients will continue to receive the ZX008 0.8 mg/kg/day dose and be treated for an additional 12 weeks (Maintenance Period). Study medication will continue to be administered twice a day in the morning and in the evening, approximately 12 hours apart.~After completion of the Maintenance Period, patients will enter the Taper Period, where they will decrease from 0.8 mg/kg twice a day to a dose of 0.4 mg/kg twice a day (maximum 30 mg/day). After 4 days at this dose level, patients will decrease their dose to 0.2 mg/kg/day. On day 9 of the Taper Period, all participants will stop taking study medication."
62829132|NCT03519035||Borderline personality disorder Patient|"Patients will be recruited in the different services. They have to respect inclusion criteria which are : patient with BPD (clinical diagnosis), patients 18 years of age or older, patients who can give their consent.~In this study, patients will have to pass different questionnaires (DIB-R, DES II, THQ, PCL-S, PSAS, qualitative questionnaire) in order to compare the characteristics between BDL patients with and without hallucinations."
62439201|NCT02780661|EXPERIMENTAL|Denture Cleanser Daily Use Period|Participants will be instructed to soak upper arch dentures in the evening in cup of very warm water (150 millilitre \[ml\]) with 1 denture cleansing tablet from Day 0 to Day 7 for 15 minutes (mins). Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds. Cleaning of upper arch dentures in the morning is not permitted. Lower arch dentures will be cleaned using the participant's normal oral hygiene procedures in the morning and evening. If the participants will have lower removable partial or complete dentures, the soaking of these dentures will be done in a separate cup from the cup provided for soaking the upper denture.
62439202|NCT02780661|EXPERIMENTAL|Denture Cleanser Weekly Use Period|Participants will be instructed to soak upper arch dentures in the evening in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds. Cleaning of upper arch dentures in the morning is not permitted. Lower arch dentures will be cleaned using the participant's normal oral hygiene procedures in the morning and evening. If the participants will have lower removable partial or complete dentures, the soaking of these dentures will be done in a separate cup from the cup provided for soaking the upper denture.
62439203|NCT01643369|EXPERIMENTAL|Compassion Meditation Group|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
62439204|NCT01643369|ACTIVE_COMPARATOR|Health Education and Wellness Group|Eight week training in health and wellness, using a curriculum developed specifically for this study.
62439205|NCT01643369|EXPERIMENTAL|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
62439206|NCT03650933|EXPERIMENTAL|G-CHOP|GB241 plus CHOP, six cycles. GB241: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
62439207|NCT03650933|ACTIVE_COMPARATOR|R-CHOP|Rituximab plus CHOP, six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
62439208|NCT02579330|EXPERIMENTAL|Coloshield Group|In the Intervention group the Coloshield Device (double balloon system) will be introduced at the beginning of surgery followed by a washout of the rectum with 500ml of saline solution. The grade of macroscopic contamination will be assessed.
62439209|NCT02579330|SHAM_COMPARATOR|Control Group|In the control Group the grade of macroscopic contamination will be assessed after rectal washout with 500ml of saline solution.
62439210|NCT03367026|ACTIVE_COMPARATOR|Ivabradine oral product|Patients in the ivabradine treatment arm receive interventions:an additional enteral preparation (orally, via nasogastric tube or Jejunum tube) of ivabradine for 4 days.
62439211|NCT03367026|NO_INTERVENTION|control group|All patients receive established medical therapy according to current guidelines and therapeutic standards.
62439212|NCT06484192|ACTIVE_COMPARATOR|Group 1: NSAID Group|Participants in the NSAID group will receive NSAIDs in addition to our standard postoperative regimen after their Lumbar spine fusion surgery
62439213|NCT06484192|ACTIVE_COMPARATOR|Group 2: Control Group|Participants in the control group will only receive our standard postoperative regimen after their Lumbar spine fusion surgery
62439214|NCT02057952|NO_INTERVENTION|Usual Care Control|No intervention.
62439215|NCT02057952|ACTIVE_COMPARATOR|In Person Weight Management|Education and exercise in a community health center environment.
62439216|NCT02057952|EXPERIMENTAL|Video Conference Weight Management|Education and exercise delivered through video conference.
62439217|NCT02947113|EXPERIMENTAL|chemotherapy combined with radiotherapy|Patients will be treated with two 3-weekly courses of cisplatin (Day 1: 75mg/m2) and pemetrexed (Day 1: 500mg/m2 for non-squamous) or etoposide (Day1-3 100mg/m2 for squamous), together with hypofractionated radiotherapy (24 daily fractions of 2.42 Gy to the involved mediastinal lymph nodes with an integrated boost of 2.75 Gy to the primary tumor).
62829133|NCT06595628|ACTIVE_COMPARATOR|Lichtenstein Mesh-Based Repair|Participants in this arm will undergo the Lichtenstein tension-free hernioplasty, which involves reinforcing the inguinal canal floor using a synthetic mesh. The mesh is fixed to the inguinal ligament and internal oblique aponeurosis, minimizing tension in the repair and reducing the risk of recurrence.
62439218|NCT04823871|OTHER|High risk patients for breast and/or ovarian cancer|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
62439219|NCT04823871|OTHER|Suspected Ovarian Epithelial Cancer|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
62439220|NCT01044147|EXPERIMENTAL|VLM-S|"Participants in this arm receive standard lifestyle coaching, which is delivered on a specified schedule. They will also receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle."
62439221|NCT01044147|EXPERIMENTAL|VLM-M|"Participants in this arm receive modulated lifestyle coaching, where coaching frequency may be adjusted according to whether the participant is meeting program goals for program use and targeted behaviors. They will also receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle."
62449409|NCT02864758||Group 2|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with vitamin k anatognists
62606779|NCT05597579||Study Group|Patients diagnosed with psychotic disorder.
62606780|NCT05597579||Control Group|Healthy Controls
62829134|NCT06595628|EXPERIMENTAL|Combined Modified Guarnieri-Desarda Tissue-Based Repair|Participants in this arm will receive the combined modified Guarnieri-Desarda tissue-based repair. This approach involves reconstructing the inguinal canal without the use of synthetic mesh, using the patient's own tissues to reinforce the canal and reduce tension. The technique combines aspects of both the Guarnieri and Desarda methods, aiming to preserve the natural physiology of the inguinal canal while providing tension-free repair.
62439222|NCT01044147|ACTIVE_COMPARATOR|OGR|Participants in this arm will receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle, but not personalized lifestyle coaching.
62439223|NCT05321810||Warfarin cohort (Reference)|Patients with NVAF treated with warfarin
62439224|NCT05321810||Apixaban cohort|Patients with NVAF treated with apixaban
62439225|NCT00440154|EXPERIMENTAL|1|oral administration 5 mg breakfast timing
62439226|NCT00440154|EXPERIMENTAL|2|oral administration 25 mg breakfast timing
62439227|NCT00440154|EXPERIMENTAL|3|oral administration 50 mg breakfast timing
62439228|NCT00440154|EXPERIMENTAL|4|oral administration 100 mg breakfast timing
62439229|NCT00440154|EXPERIMENTAL|5|oral administration 25 mg dinner timing
62439230|NCT00440154|PLACEBO_COMPARATOR|6|oral administration
62439231|NCT00440154|ACTIVE_COMPARATOR|7|oral administration 10mg breakfast timing
62439232|NCT03806894||Jewish communities|Ashkenazi, Sephardi, Ethiopian
62439233|NCT03806894||Arab populations|Muslim, Christian, Druze
62439234|NCT01725477|EXPERIMENTAL|Dye& normal saline/ 20ml methylene blue +50 ml normal saline|first arm:20 ml methylene blue washing with50 ml normal saline
62439235|NCT01725477|ACTIVE_COMPARATOR|injection of 20ml metheylen blue|20 ml methylene blue injected without washing
62439236|NCT06334523|EXPERIMENTAL|Continuous Tracheal Gas Insufflation|the preterm infant intubated and ventilated with Continuous Tracheal Gas Insufflation
62439237|NCT06334523|NO_INTERVENTION|standar ventilation|the preterm infant intubated and ventilated by standard ventilation
62439238|NCT01740856|EXPERIMENTAL|Rest three hours|Rest three hours
62439239|NCT01740856|EXPERIMENTAL|Rest five hours|Rest five hours
62439240|NCT03944486|OTHER|On-Track|Stroke survivors receiving the OnTrack intervention for 12 weeks consisting of arm activity tracking and self-management coaching. Assessments are done before and after the intervention.
62439241|NCT02919137|EXPERIMENTAL|Visible light exposure Red 30 lux|The participants will be exposed to red LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
62439242|NCT02919137|EXPERIMENTAL|Visible light exposure Red 120 lux|The participants will be exposed to red LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
62439243|NCT02919137|EXPERIMENTAL|Visible light exposure Blue 30 lux|The participants will be exposed to blue LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
62439244|NCT02919137|EXPERIMENTAL|Visible light exposure Blue 120 lux|The participants will be exposed to blue LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
62439245|NCT02919137|EXPERIMENTAL|Visible light exposure Green 30 lux|The participants will be exposed to green LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
62439246|NCT02919137|EXPERIMENTAL|Visible light exposure Green 120 lux|The participants will be exposed to green LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
62439247|NCT02919137|EXPERIMENTAL|Visible light exposure White 30 lux|The participants will be exposed to white LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
62606781|NCT01899807|OTHER|Single Arm|
62606782|NCT03324828|ACTIVE_COMPARATOR|Hydroxyzine+no clowns|Patients will receive hydroxyzine solution and no additional intervention
62606783|NCT03324828|EXPERIMENTAL|Hydroxyzine+clowns|Patients will receive hydroxyzine solution and clowns intervention
62606784|NCT03324828|ACTIVE_COMPARATOR|Placebo+clowns|Patients will receive placebo solution and clowns intervention
62047038|NCT04602533|OTHER|standard of care|"Induction phase: Radiochemotherapy according to guideline~Maintenance: Standard of care"
62047039|NCT00733603|SHAM_COMPARATOR|Global Therapeutic Massage (GTM)|Non-specific somatic treatment with full-body Western massage.
62606785|NCT03324828|NO_INTERVENTION|Placebo+no clowns|Patients will receive placebo solution and no additional intervention
62606786|NCT01538004||BpTRU readings in private office area|Consenting patients will be randomly allocated using a random number table to BpTRU in an exam room. The first reading will be done with the research assistant present to ensure proper placement and recording and will then be left alone for the subsequent five measurements at one minute intervals. This will be immediately followed by a second set of readings in the alternate location. During both sets of readings the patient will be seated comfortably in a chair with arms and will be instructed not to talk or cross their legs. The same arm will be used for both sets of measurements with the blood pressure cuff at heart level. The average of the last five out of six blood pressure readings for each office location will be recorded. The decibel levels in each location will be recorded during BP readings using a Reed Sound Level Meter C-322. The patient's weight in kg, height in cm, gender and self reported history of hypertension will also be recorded.
62606787|NCT01538004||BpTRU readings in open office area|Consenting patients will be randomly allocated using a random number table to BpTRU in an open office area The first reading will be done with the research assistant present to ensure proper placement and recording and will then be left alone for the subsequent five measurements at one minute intervals. This will be immediately followed by a second set of readings in the alternate location. During both sets of readings the patient will be seated comfortably in a chair with arms and will be instructed not to talk or cross their legs. The same arm will be used for both sets of measurements with the blood pressure cuff at heart level. The average of the last five out of six blood pressure readings for each office location will be recorded. The decibel levels in each location will be recorded during BP readings using a Reed Sound Level Meter C-322. The patient's weight in kg, height in cm, gender and self reported history of hypertension will also be recorded.
62606788|NCT02408224||one arm|patients on Ticagrelor
62606789|NCT04611230||Adult Volunteers (Low Risk Group)|Volunteers with jobs that do not require close contact with (i.e., within 6 feet of) the general public or co-workers.
62606790|NCT04611230||Adult Volunteers (Medium - Low Risk Group)|Volunteers with jobs that require in-frequent contact with (i.e., within 6 feet of) the general public or co-workers.
62606791|NCT04611230||Adult Volunteers (Medium - High Risk Group)|Volunteers with jobs that require frequent contact with (i.e., within 6 feet of) the general public or co-workers.
62606792|NCT04611230||Adult Volunteers (High Risk Group)|Volunteers with jobs that require frequent and/or close contact with (i.e., within 6 feet of) individuals with high potential for exposure to known or suspected sources of COVID-19.
62606793|NCT01467154||Control group|
62606794|NCT01467154||NAC group|
62606795|NCT02616315|PLACEBO_COMPARATOR|Group A: Placebo|Naltrexone hydrochloride (HCl)/bupropion hydrochloride (HCl) placebo-matching tablet, orally, 1 tablet in the AM, daily, during Week 1, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 1 tablet in the AM and 1 in the PM, during Week 2, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 2 tablets in the AM and 1 in the PM, during Week 3, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 2 tablets in the AM and 2 in the PM, in Week 4 through Week 49. Participants must be re-titrated if off treatment for ≥1 week (≥7 days).
62829135|NCT06446661|ACTIVE_COMPARATOR|High Intensity|Receives high-intensity text messaging for 2 cycles of treatment
62829136|NCT06446661|ACTIVE_COMPARATOR|Low Intensity|Receives no texts for 1st cycle and low-intensity texts for 2nd cycle
62047040|NCT00733603|ACTIVE_COMPARATOR|Myofascial Tissue Manipulation (MTM)|Targeted internal and external Connective Tissue Manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen.
62249390|NCT03526887|EXPERIMENTAL|Cohort 2|Stop treatment and progression \> 12 weeks after stopping treatment. After the last progression the patient is included in the study to be retreated with Pembrolizumab 200mg
62829137|NCT05007769|EXPERIMENTAL|Ramucirumab + Atezolizumab + N-803|-Ramucirumab intravenously (IV) on Day 1, atezolizumab IV on Day 1, and N-803 subcutaneous (SC) on Day 1 of each cycle. Cycles are 21 days.
62829138|NCT02922244|NO_INTERVENTION|Standard skin care|standard skin care
62829139|NCT02922244|PLACEBO_COMPARATOR|Control|Moisture Cream
62829140|NCT02922244|ACTIVE_COMPARATOR|Cucumber cream|Apply Cucumber cream everyday after radiation therapy on the treatment aria skin.
62829141|NCT02922244|ACTIVE_COMPARATOR|Centella cream|Apply Centella asiatica cream everyday after radiation therapy on the treatment aria skin.
62829142|NCT02922244|ACTIVE_COMPARATOR|Thunbergia cream|Apply Thunbergia cream everyday after radiation therapy on the treatment aria skin.
62829143|NCT04631419|EXPERIMENTAL|Maxillary flapless laser corticotomy group|Flapless laser corticotomy will randomly be assigned to one side of the 14 maxillary arches (experimental side) before canine retraction.
62829144|NCT04631419|ACTIVE_COMPARATOR|Maxillary control group|Canine retraction will be done on the other side without Laser corticotomy .
62047041|NCT05919693|EXPERIMENTAL|Dose 1|Part 1 MAD Portion Dose 1 - Low Dose
62047042|NCT05919693|EXPERIMENTAL|Dose 2|Part 1 MAD Portion Dose 2 - Low-Mid Dose
62047043|NCT05919693|EXPERIMENTAL|Dose 3|Part 1 MAD Portion Dose 3 - Mid-High Dose
62047044|NCT05919693|EXPERIMENTAL|Dose 4|Part 1 MAD Portion Dose 4 - High Dose
62047045|NCT05919693|EXPERIMENTAL|DME Medium Dose|Part 2 Naïve DME monotherapy Medium Dose
62249391|NCT03520478|EXPERIMENTAL|SHR3680|Participants will receive SHR3680 orally
62249392|NCT03520478|ACTIVE_COMPARATOR|bicalutamide|Participants will receive bicalutamide orally
62249393|NCT03712436|EXPERIMENTAL|patients receiving palliative care|Patients receiving standard oncologic care plus palliative care.
62606796|NCT02616315|EXPERIMENTAL|Group B: Naltrexone HCl/Bupropion HCl|Naltrexone HCl 8 mg/bupropion HCl 90 mg, tablet, orally, 1 tablet in the AM, daily, during Week 1, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 1 tablet in the AM and 1 in the PM, during Week 2, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 2 tablets in the AM and 1 in the PM, during Week 3, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 2 tablets in the AM and 2 in the PM, in Week 4 through Week 49. Participants must be re-titrated if off treatment for ≥1 week (≥7 days).
62606797|NCT03644056|EXPERIMENTAL|IMC-001|Multiple Dose Level (IMC-001 2 mg/kg etc. every 2 weeks)
62439248|NCT02919137|EXPERIMENTAL|Visible light exposure White 120 lux|The participants will be exposed to white LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
62606798|NCT05571202||Anorectal surgery patient under general anesthesia plus local infiltration|Anorectal surgery patient under general anesthesia plus local infiltration
62606799|NCT05571202||Anorectal surgery patient under spinal anesthesia|Anorectal surgery patient under spinal anesthesia alone
62606800|NCT04506398||Retrospective cohort|20 HCC patients experienced post-transplant HCC
62606801|NCT04506398||Perspective cohort|20 HCC patients who underwent liver transplant, the patients would be recruited if recurrence would be diagnosed \>6 months after liver transplant
62606802|NCT03274258|EXPERIMENTAL|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62606803|NCT01122940|ACTIVE_COMPARATOR|Epamin: McNeil LA LLC|
62249394|NCT03712436|ACTIVE_COMPARATOR|patients receiving standard oncological care|Patients receiving standard oncologic care.
62606804|NCT01122940|EXPERIMENTAL|Phenytoin: Laboratorios Pfizer SA DE CV|
62249395|NCT04820283|EXPERIMENTAL|Care manager intervention (nurse)|
62249396|NCT04820283|ACTIVE_COMPARATOR|Internet-based CBT|
62249397|NCT05590936|ACTIVE_COMPARATOR|Dimenydrinate|Preoperative per os administration of 50 mg dimenydrinate
62249398|NCT05590936|OTHER|Ondasentron|Intraoperative intravenous administration of 4 mg ondansetron
62249399|NCT00395889|EXPERIMENTAL|Rehabilitation + Lifestyle Counseling|Multicomponent Pulmonary Rehabilitation Program including structured exercise training
62606805|NCT01240928|EXPERIMENTAL|MK-2206 + exemestane +/- goserelin|Oral MK-2206 and oral exemestane and subcutaneous goserelin (for pre-menopausal participants only)
62606806|NCT06461416|EXPERIMENTAL|Intervention|Group A will receive telehealth occupational therapy services for 12 weeks
62606807|NCT06461416|NO_INTERVENTION|Control|Group B will meet three times via zoom but not receive an intervention
62606808|NCT02320227|EXPERIMENTAL|Miami w/o frag Personal lubricant|Healthy subjects use Miami w/o frag Personal lubricant at least 4 times per week for 2 weeks
62249400|NCT00395889|ACTIVE_COMPARATOR|Lifestyle Counseling|
62249401|NCT01028326|EXPERIMENTAL|Group A|Group A of children will receive 2 doses of PCV10 vaccine, one at the time of enrolment and one 2 months later, followed by a dose of DTaP vaccine 4 months later
62249402|NCT01028326|EXPERIMENTAL|Group B|Group B of children will receive PCV10 vaccine, followed by a dose of DTaP vaccine after 2 months, and another dose of PCV10 4 months later.
62606809|NCT04600362|EXPERIMENTAL|Dupilumab|Patients randomized to this arm will receive two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by single 300 mg injection of Dupilumab every 2 weeks (q2w) from week 2 to week 16.
62606810|NCT04600362|PLACEBO_COMPARATOR|Placebo|Patients randomized to this arm will receive identically matching doses of placebo. Two subcutaneous injections of placebo as a loading dose (to mimic the experimental Dupilumab arm) on Day 1 followed by a single injection q2w from Week 2 to Week 16.
62606811|NCT06066541|ACTIVE_COMPARATOR|Scorecard|"Participants randomized to this arm will receive a scorecard from Humana reporting patients' medication adherence using a refill score. Two messages will be sent during the intervention: The first message will contain the baseline refill score. The second message will note any changes in the refill score."
62249403|NCT01028326|ACTIVE_COMPARATOR|Group C|Group C of children will receive a dose of hepatitis A vaccine, followed by a dose of DTaP vaccine after 2 months, and another dose of hepatitis A 4 months later, along with a dose of PCV10.
62439249|NCT03679754|EXPERIMENTAL|Ad-RTS-hIL-12 + veledimex|Intratumoral Ad-RTS-hIL-12 and oral veledimex
62449410|NCT02864758||Group 3|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with dabigatran
62606812|NCT06066541|EXPERIMENTAL|Scorecard + Social norms|Participants randomized to this arm will receive the Arm 1 scorecard plus dynamic social norms messaging (noting the proportion of Humana members improving their medication refill scores). Two messages will be sent during the intervention: The first message will contain the baseline refill score. The second message will note any changes in the refill score.
62606813|NCT06066541|EXPERIMENTAL|Scorecard + Messenger effects|Participants randomized to this arm will receive the Arm 1 scorecard, coming from the trusted messenger of a Humana-identified pharmacist taking the same medication. Two messages will be sent during the intervention: The first message will contain the baseline refill score. The second message will note any changes in the refill score.
62249404|NCT01251263|OTHER|Group 1|Cyclic OC users prior to initiating study OC. Estradiol or placebo given in a certain sequence depending on the randomization.
62439250|NCT05085964|OTHER|QR421a RNA antisense oligonucleotide for intravitreal injection|There is only one treatment arm in the PQ-421a-002 study; All participants that are eligible to be dosed will receive QR-421a in an open label fashion.
62606814|NCT06066541|EXPERIMENTAL|Processing fluency|"Participants randomized to this arm will receive a modified scorecard increasing processing fluency through a visual metaphor of closing the ring. Two messages will be sent during the intervention: The first message will contain the baseline refill score. The second message will note any changes in the refill score."
62249405|NCT01251263|OTHER|Group 2|Spontaneous ovulation group prior to initiating study OC. Estradiol or placebo given in a certain sequence depending on the randomization.
62249406|NCT05552625|ACTIVE_COMPARATOR|TADIOS + Standard of care treatment|4 tablets of 300 mg each will be administered to the subjects twice daily (1200 mg in the morning and 1200mg in the evening making it 2400 mg/day) for a maximum of 10 days. The subject can consume standard of care treatment as per prescribed by the physician.
62249407|NCT05552625|PLACEBO_COMPARATOR|Placebo + Standard of care treatment|4 tablets of 300 mg each will be administered to the subjects twice daily (1200 mg in the morning and 1200mg in the evening making it 2400 mg/day) for a maximum of 10 days. The subject can consume standard of care treatment as per prescribed by the physician.
62606815|NCT06066541|EXPERIMENTAL|Processing fluency + Social norms|Participants randomized to this arm will receive the Arm 4 processing fluency scorecard plus dynamic social norms messaging. Two messages will be sent during the intervention: The first message will contain the baseline refill score. The second message will note any changes in the refill score.
62829145|NCT04631419|EXPERIMENTAL|Mandibular flapless laser corticotomy group|Flapless laser corticotomy will randomly be assigned to one side of the 14 mandibular arches (experimental side) before canine retraction.
62829146|NCT04631419|ACTIVE_COMPARATOR|Mandibular control group|Canine retraction will be done on the other side without Laser corticotomy .
62829147|NCT05626621|ACTIVE_COMPARATOR|Azelastine and Mometasone Nasal Spray|The study intervention will be saline irrigation (240 mL) followed by azelastine spray (137 mcg/spray) and mometasone spray (50 mcg/spray). Participants will have to dissolve the salt packet in a 240 mL sinus rinse bottle to create the saline solution. All participants will be instructed to perform the following twice a day: irrigation of right and left nasal cavity with half of the saline solution for each side followed by 2 sprays per nostril of both of the nasal sprays.
62249408|NCT02224599|EXPERIMENTAL|CYP, TAPA-pulsed DC vaccine, Imiquimod|TAPA-Pulsed DC Vaccine Cyclophosphamide Pill Imiquimod Topical Cream
62249409|NCT06235814|ACTIVE_COMPARATOR|Thyroid Lobectomy|"Randomization Protocol~Patients with intermediate molecular-risk thyroid nodules will be randomized to thyroid lobectomy or total thyroidectomy. We will perform a 1:1 randomization in a consecutive manner. Patients will be informed of what operation they will receive and providers will also be aware what operation was performed as it dictates care moving forward. Details of operative management will be discussed further.~Peri-operative Protocol~Thyroid Lobectomy Patients undergoing thyroid lobectomy will have the thyroid lobe containing the cancer removed in the standard surgical technique. These operations will be performed at either the UCLA Health Westwood Ambulatory Surgery Center, UCLA Ronald Reagan Medical Center, or UCLA Santa Monica Medical Center. Patients will undergo our usual postoperative care."
62249410|NCT06235814|ACTIVE_COMPARATOR|Total Thyroidectomy|"Randomization Protocol~Patients with intermediate molecular-risk thyroid nodules will be randomized to thyroid lobectomy or total thyroidectomy. We will perform a 1:1 randomization in a consecutive manner. Patients will be informed of what operation they will receive and providers will also be aware what operation was performed as it dictates care moving forward. Details of operative management will be discussed further.~Total Thyroidectomy and Completion Thyroidectomy~Patients undergoing total thyroidectomy will have their whole thyroid gland removed in the standard surgical technique. Patients undergoing a completion thyroidectomy will have their remaining thyroid lobe removed. These operations will be performed at UCLA Ronald Reagan Medical Center or UCLA Santa Monica Medical Center. Patients will undergo our usual postoperative care."
62249411|NCT01721057|PLACEBO_COMPARATOR|Placebo|"Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.~Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study."
62249412|NCT01721057|EXPERIMENTAL|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
62249413|NCT01721057|EXPERIMENTAL|Baricitinib 4 mg|"Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
62249414|NCT05995015|EXPERIMENTAL|Universal 4SCAR19U cells to treat CD19-positive hematological malignancies|
62249415|NCT06400342|ACTIVE_COMPARATOR|TAVR-explant|TAVR surgical explantation
62249416|NCT06400342|ACTIVE_COMPARATOR|Redo-TAVR|TAV-in-TAV
62249417|NCT00786565|EXPERIMENTAL|Advanced Akreos Adapt|Advanced Akreos Adapt Aspheric Intraocular Lens (IOL).
62249418|NCT00786565|EXPERIMENTAL|Akreos Adapt|Akreos Adapt Spherical Intraocular Lens (IOL).
62249419|NCT05868551||Persons with onchocerciasis nodules with OAE and without epilepsy|nodulectomy to extract adult worms
62439251|NCT00192127|ACTIVE_COMPARATOR|1|FluMist
62439252|NCT00192127|PLACEBO_COMPARATOR|2|Placebo
62439253|NCT05774509|EXPERIMENTAL|Treated group|"A maximum of 12 patients will be included in the study following a dose-escalating design:~* Cohort 1 (4 patients) will receive 20x10E9 particles/kg for each infusion, with a total of 3 infusions, for a cumulative dose of 60x10E9 particles/kg;~* Cohort 2: in the absence of safety issues in Cohort 1, 8 patients will receive 40x10E9 particles/kg for each infusion, with a total of 3 infusions, for a cumulative dose of 120x10E9 particles/kg."
62449411|NCT03953170|ACTIVE_COMPARATOR|Teduglutide|Teduglutide 0.05 g/kg/day
62606816|NCT06066541|EXPERIMENTAL|Processing fluency + Messenger effects|Participants randomized to this arm will receive the Arm 4 processing fluency scorecard coming from the trusted messenger of a Humana-identified pharmacist taking the same medication. Two messages will be sent during the intervention: The first message will contain the baseline refill score. The second message will note any changes in the refill score.
62606817|NCT06066541|NO_INTERVENTION|Usual care|Participants randomized to this arm will not receive any mailed message.
62606818|NCT04327661|EXPERIMENTAL|Tradipitant High Dose|
62249420|NCT06343935|EXPERIMENTAL|Treatment group(linperlisib 80mg qd)|After enrollment, the patients in treatment group were orally administered with a starting dose of 80mg qd for 21 days. On the 21st day of the 4th cycle, if the patient has no tumor progression and no intolerable toxicity, after the researcher determines that the drug therapy can be continued, the patient should take linperlisib 80mg qd for two consecutive weeks per cycle and stop taking it for one week, and conduct regular safety and tumor efficacy evaluation until the disease progresses, toxicity becomes intolerable or the researcher determines that it is not suitable to continue treatment. The maximum duration of treatment is two years.
62439254|NCT02089542|EXPERIMENTAL|MB and fluorescent imaging|Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
62606819|NCT04327661|EXPERIMENTAL|Tradipitant Low Dose|
62606820|NCT04327661|PLACEBO_COMPARATOR|Placebo|
62606821|NCT03479944|EXPERIMENTAL|FLACS|Femtosecond laser assisted cataract surgery (FLACS) in 1 eye, with manual conventional surgery in the fellow eye, as randomized
62606822|NCT03479944|ACTIVE_COMPARATOR|Conventional|Manual conventional surgery in 1 eye, with FLACS in the fellow eye, as randomized
62606823|NCT03921359|EXPERIMENTAL|Conventional physical training|Participants assigned to this arm will receive the conventional physical training.
62606824|NCT03921359|EXPERIMENTAL|SMARTfit training|Participants assigned to this arm will receive the SMARTfit training.
62606825|NCT05896683|EXPERIMENTAL|Part 1: Sequence AB|Participants will receive intervention A (lazertinib reference formulation) on Day 1 of intervention period 1. After washout period of 14 to 21 days, participants will receive intervention B (lazertinib test formulation) on Day 1 of intervention period 2.
62606826|NCT05896683|EXPERIMENTAL|Part 1: Sequence BA|Participants will receive intervention B (lazertinib test formulation) on Day 1 of intervention period 1. After washout period of 14 to 21 days, participants will receive intervention A (lazertinib reference formulation) on Day 1 of intervention period 2.
62606827|NCT05896683|EXPERIMENTAL|Part 2: Sequence CD|Participants will receive Intervention C (lazertinib reference formulation) on Day 1 of intervention period 1. After washout period of 14 to 21 days, participants will receive intervention D (lazertinib test formulation) on Day 1 of intervention period 2.
62606828|NCT05896683|EXPERIMENTAL|Part 2: Sequence DC|Participants will receive intervention D (lazertinib test formulation) on Day 1 of intervention period 1. After washout period of 14 to 21 days, participants will receive intervention C (lazertinib reference formulation) on Day 1 of intervention period 2.
62606829|NCT01590732|EXPERIMENTAL|Treatment (romidepsin, ifosfamide, carboplatin, etoposide)|Participants receive romidepsin IV over 4 hours on days 1 and 4, ifosfamide IV over 24 hours on day 1, carboplatin IV over 1 hour on day 1, and etoposide IV over 2 hours on day 1-3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62606830|NCT06730854||Main cohort of patient|"In the included patients the occurrence of acute kidney injury (AKI) will be investigated. So patient will be grouped as 'no AKI' and 'AKI' For the subanalysis, patient will be grouped according to their admission central venous pressure.~There are no interventions."
62606831|NCT05347134|ACTIVE_COMPARATOR|SKB264|5 mg/kg, IV (in the vein) on day 1 and Day 15 of each 28 day cycle.
62606832|NCT05347134|ACTIVE_COMPARATOR|Eribulin or Capecitabine or Gemcitabine or Vinorelbine|"Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle.~Capecitabine:1000-1250mg/m2, po,bid, from day 1 to Day 15 of each 21 day cycle.~Gemcitabine:800-1000 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21day cycle.~Vinorelbine:25 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle."
62439255|NCT03685019|EXPERIMENTAL|Valgus stress - lateral compartment|Valgus stress radiograph. Joint space width measured in lateral compartment.
62439256|NCT03685019|EXPERIMENTAL|Varus stress - medial compartment|Varus stress radiograph. Joint space width measured in medial compartment.
62606833|NCT02614131|EXPERIMENTAL|LY2599666 (Part A)|LY2599666 given subcutaneously (SC) once.
62439257|NCT03685019|EXPERIMENTAL|0 degree flexion - medial compartment|0 degree flexion radiograph. Joint space width measured in medial compartment.
62439258|NCT03685019|EXPERIMENTAL|0 degree flexion - lateral compartment|0 degree flexion radiograph. Joint space width measured in medial compartment.
62439259|NCT03685019|EXPERIMENTAL|20 degree flexion - medial compartment|20 degree flexion radiograph. Joint space width measured in medial compartment.
62439260|NCT03685019|EXPERIMENTAL|20 degree flexion - lateral compartment|20 degree flexion radiograph. Joint space width measured in lateral compartment.
62449412|NCT03953170|PLACEBO_COMPARATOR|Placebo|Placebo
62606834|NCT02614131|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo matching LY2599666 given SC once.
62606835|NCT02614131|EXPERIMENTAL|LY2599666 (Part B)|LY2599666 given SC once weekly for 12 weeks (13 doses).
62606836|NCT02614131|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo given SC once weekly for 12 weeks (13 doses).
62606837|NCT02614131|EXPERIMENTAL|Solanezumab (Part C)|Solanezumab given intravenously (IV) once weekly or once every 4 weeks for 12 weeks.
62606838|NCT02614131|PLACEBO_COMPARATOR|Placebo (Part C)|Placebo given IV once weekly or once every 4 weeks for 12 weeks.
62829148|NCT05626621|EXPERIMENTAL|Mometasone Nasal Irrigation|The study intervention will be mometasone (1 mg/capsule). Participants will be required to dissolve the contents of the capsule into a 240 mL sinus rinse bottle along with the salt packet to create the rinse solution. All participants will be instructed to perform the following twice a day: irrigation of right and left nasal cavity with half of the rinse solution for each side.
62606839|NCT04527913|EXPERIMENTAL|Control group|15 patients receiving oral hygiene instructions as determined by their group allocation (use of manual toothbrush alone)
62047046|NCT05919693|EXPERIMENTAL|DME High Dose|Part 2 Naïve DME monotherapy High Dose
62047047|NCT05919693|EXPERIMENTAL|Naïve NVAMD Medium Dose|Part 2 Naïve NVAMD combination therapy Medium Dose
62439261|NCT03685019|EXPERIMENTAL|45 degree flexion - medial compartment|45 degree flexion radiograph. Joint space width measured in medial compartment.
62439262|NCT03685019|EXPERIMENTAL|45 degree flexion - lateral compartment|45 degree flexion radiograph. Joint space width measured in lateral compartment.
62439263|NCT05030857|EXPERIMENTAL|GLPG4716 and Midazolam|
62439264|NCT04883398||Breast cancer survivors|Breast cancer survivors ages 50-70 with AJCC stages 0-3 breast cancer who are at least 1 year post-treatment (including surgery, radiation, and chemotherapy, with or without current endocrine therapy)
62829149|NCT05626621|EXPERIMENTAL|Azelastine and Mometasone Nasal Irrigation|The study intervention will be azelastine (1mg) and mometasone (1 mg). The azelastine and mometasone will be provided in one capsule identical to the mometasone capsule. Participants will be required to dissolve the contents of the capsule into a 240 mL sinus rinse bottle along with the salt packet to create the rinse solution. All participants will be instructed to perform the following twice a day: irrigation of right and left nasal cavity with half of the rinse solution for each side.
62829150|NCT04716231|EXPERIMENTAL|Atacicept Dose 150mg|Atacicept 150mg once weekly subcutaneous (SC) injections
62829151|NCT04716231|PLACEBO_COMPARATOR|Placebo to match Atacicept (Part C/D)|Placebo to match Atacicept once weekly subcutaneous (SC) injection
62829152|NCT02328924|OTHER|LH value in fixed group|LH value predictive of IVF in 104 patients entered in fixed protocol
62829153|NCT02328924|OTHER|LH value in flexible group|LH value predictive of IVF in 109 patients entered in flexible protocols
62829154|NCT04369573|ACTIVE_COMPARATOR|Early intra-aortic balloon pump (IABP) implantation|IABP implantation within 6 hours since cardiogenic shock symptoms onset
62829155|NCT04369573|OTHER|Standard of care as vasoactive agent|Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20
62829156|NCT04041635|EXPERIMENTAL|Stimuli Reduction|This group will receive reduced visual and auditory stimuli in addition to usual care during venipuncture. Phototherapy goggles and earmuffs will be placed 3 minutes before the venipuncture (leaving the patient in resting state after the manipulation) and will be maintained during the procedure. Monitor alarms and devices will be silenced and will remain silenced and noise in the unit will be minimized during the procedure.
62829157|NCT04041635|ACTIVE_COMPARATOR|Usual Care|Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
62829158|NCT00935584|OTHER|PACE Study|"The study utilized a quasi-experimental pre-post intervention design. The intervention provided was physician education to improve EMR use and communication.~Physician training in patient-centered EMR use was developed. The conceptual model of patient-centered communication will provide the underlying framework for the training aimed at improving physicians interviewing and communication skills."
62439265|NCT04883398||Healthy controls|Healthy controls ages 50-70 with no history of cancer.
62439266|NCT01080105|EXPERIMENTAL|AIM + surveillance|Participants will receive access to the AIM website and calls from a motivational coach for 12 weeks plus an additional year of surveillance and optional coach support.
62439267|NCT01080105|EXPERIMENTAL|AIM intervention|Participants will receive access to the AIM web based intervention and calls from a motivational coach for 12 weeks
62829159|NCT01296880||LCM group|Patients who are having lacosamide (LCM) added to their anti-epileptic drug regimen
62829160|NCT01296880||control group|Patients who are NOT having lacosamide (LCM) added to their anti-epileptic drug regimen
62829161|NCT05024968|EXPERIMENTAL|Treatment (sintilimab)|The study drug is sintilimab. The first dose of study treatment should start on Day 1 of Cycle 1. For the rest of the treatment cycles, the study treatment can be administered 3 day before or 3 days after the scheduled day of administration. Treatment can be delayed for up to 1 week if the administration day is on a holiday or if the subject is otherwise unavailable.
62829162|NCT03133793|PLACEBO_COMPARATOR|Placebo Only|Participants in this group will receive placebo pills and placebo powder.
62829163|NCT03133793|ACTIVE_COMPARATOR|CoQ10 Only|Participants in this group will receive CoQ10 pills and placebo powder
62829164|NCT03133793|ACTIVE_COMPARATOR|D-ribose Only|Participants in this group will receive placebo pills and D-ribose oral powder.
62829165|NCT03133793|EXPERIMENTAL|CoQ10 + D-ribose|Participants in this group will receive CoQ10 pills and D-ribose oral powder.
62829166|NCT05610345|EXPERIMENTAL|Placenta Blood Drained|Immediately after delayed cord clamping and cutting of the umbilical cord, the cord will be unclamped and blood with be drained until cessation of flow.
62829167|NCT05610345|ACTIVE_COMPARATOR|Placenta Blood Not Drained|This is the control group. The cord will not be unclamped.
62829168|NCT01850667|EXPERIMENTAL|Stereotactic body radiotherapy|Stereotactic body radiotherapy for unresectable hepatocellular carcinoma after incomplete trans-arterial chemo-embolization
62439268|NCT01080105|ACTIVE_COMPARATOR|Educational website|Participants will be given access to a static website with depression prevention related materials and handouts.
62439269|NCT06093828|OTHER|Single-arm|Single-arm: subjects with Tricuspid valve regurgitation who meet the study eligibility criteria
62606840|NCT04527913|EXPERIMENTAL|Test group 1|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus dental floss)
62606841|NCT04527913|EXPERIMENTAL|Test group 2|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus interdental brushes)
62606842|NCT04527913|EXPERIMENTAL|Test group 3|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus rubber interdental picks)
62606843|NCT00692107|ACTIVE_COMPARATOR|1|68 Gy
62606844|NCT00692107|EXPERIMENTAL|2|78 Gy
62829169|NCT05533606||AKI Group|
62249421|NCT06343935|EXPERIMENTAL|control group(linperlisib 80mg 14d-on 7d-off)|In the control group, patients were orally administered at the starting dose of 80mg qd for 21 days after enrollment. On the 21st day of the 4th cycle, if the patient has no tumor progression and no intolerable toxicity, the patient will continue to receive Linperlisib 80mg qd after the investigator determines that the drug therapy can be continued, and the safety and tumor efficacy evaluation will be conducted regularly until the disease progresses, toxicity becomes intolerable, or the investigator determines that the treatment is not suitable for further treatment. The maximum duration of treatment is two years.
62829170|NCT05533606||Non-AKI Group|
62249422|NCT03366675|EXPERIMENTAL|AZD2811|AZD2811 200mg IV QD CnD1 \& D4 every 4weeks
62439270|NCT01815411|EXPERIMENTAL|Mushroom extract|The patients are given the mushroom extract (Andosan) in doses 30 mlx2 per day for 1 days. The experimental group is selected by randomisation.
62439271|NCT01815411|NO_INTERVENTION|Control group|The control group is selected by randomisation.
62439272|NCT03506009|EXPERIMENTAL|Argatroban combined with rt-PA|
62606845|NCT00779532|ACTIVE_COMPARATOR|Group A|"Once daily intake (orally) of 5 NOMAC-E2 placebo tablets from Day -1 to Day 14.~Once daily intake (orally) of one moxifloxacin placebo capsule at Day -1.~Once daily intake (orally) of one moxifloxacin capsule of 400 mg at Day 14."
62606846|NCT00779532|EXPERIMENTAL|Group B|"Once daily intake (orally) of 4 NOMAC-E2 placebo tablets and 1 NOMAC-E2 (2.5/1.5 mg) tablet from Day 1 to Day 14.~Once daily intake (orally) of 5 NOMAC-E2 placebo tablets and 1 moxifloxacin placebo capsule at Day -1.~Once daily intake (orally) of 1 moxifloxacin placebo capsule at Day 14."
62606847|NCT00779532|EXPERIMENTAL|Group C|"Once daily intake (orally) of 5 NOMAC-E2 (2.5/1.5 mg) tablets from Day 1 to Day 14.~Once daily intake (orally) of 5 NOMAC-E2 placebo tablets and 1 moxifloxacin placebo capsule at Day -1.~Once daily intake (orally) of 1 moxifloxacin placebo capsule at Day 14"
62829171|NCT00960999|EXPERIMENTAL|Single-fraction SBRT (34 Gy)|Single-fraction stereotactic body radiation therapy (SBRT) of 34 Gy
62829172|NCT00960999|EXPERIMENTAL|Multiple-fraction SBRT (48 Gy)|Multiple-fraction stereotactic body radiation therapy (SBRT) given in four daily 12 Gy fractions for a total dose of 48 Gy
62606848|NCT00779532|PLACEBO_COMPARATOR|Group D|"Once daily intake (orally) of 5 NOMAC-E2 placebo tablets from Day -1 to Day 14.~Once daily intake (orally) of 1 moxifloxacin placebo capsule at Days -1 and 14."
62606849|NCT04865939|ACTIVE_COMPARATOR|gemcitabine|intravesical instillation of gemcitabine (1 g in 50 mL saline) with dwell time of 1 - 3 hours
62606850|NCT04865939|EXPERIMENTAL|sterile water irrigation|intravesical continuous bladder irrigation with sterile water for 1 - 3 hours and a total instilled volume of approximately 4 - 16 liters
62606851|NCT05553470|EXPERIMENTAL|No Hepatic Impairment|Participants will receive a single oral dose of miricorilant (6 X100 mg) tablets.
62606852|NCT05553470|EXPERIMENTAL|Moderate Hepatic Impairment|Participants will receive a single oral dose of miricorilant (6 X100 mg) tablets.
62606853|NCT05553470|EXPERIMENTAL|Mild Hepatic Impairment|Participants will receive a single oral dose of miricorilant (6 X100 mg) tablets.
62829173|NCT06155292|PLACEBO_COMPARATOR|Arm 1: Standard Communication Arm|"Quarterly email communication:~Quarterly standard communication via email providing a link to physicians to check their PCCE program performance over the prior quarter, and a link to access the PCCE dashboard. The email will also include a link to resources. Starting with the email communication in February 2024, there will be a reminder email sent two weeks after the first email with the same content.~Quarterly survey:~Quarterly standard communication via survey with questions about physician attitudes and beliefs."
62829174|NCT06155292|EXPERIMENTAL|Arm 2: Personalized Report Card|"Quarterly email communication:~Quarterly personalized communication via email providing individualized performance metrics to physicians for the PCCE program from the prior quarter. All the links in the Arm 1 emails will be included in Arm 2 emails. Starting with the email communication in February 2024, there will be a reminder email sent two weeks after the first email with the same content.~Quarterly survey:~Quarterly standard communication via survey with the same questions about physician attitudes and beliefs as in Arm 1."
62439273|NCT03506009|ACTIVE_COMPARATOR|rt-PA|
62439274|NCT02277223|EXPERIMENTAL|Interventional|In addition to induction therapy, patients will receive oral capsules of curcumin (Bara Herbs Inc): Weight\<20kg: 1 gram, twice daily, 20-30 kg: 1.5 grams twice daily, weight\>30kg: 2 grams twice daily. For Maintenance, in addition to oral 5-ASA maintenance treatment, responding patients will receive oral capsules of curcumin (Bara Herbs Inc): Weight\<30kg: 500 milligram, twice daily, weight\>30kg: 1 gram twice daily
62439275|NCT02277223|PLACEBO_COMPARATOR|Control|In addition to induction and maintenance therapy, patients will receive matched oral placebo capsules for induction and maintenance (Bara Herbs Inc), twice daily.
62606854|NCT06525662|EXPERIMENTAL|30-degree straight to cuff|The endotracheal tube to be used for endotracheal intubation will have a stylet inserted into it and manipulated into a shape that is straight from its proximal end to the cuff. At the cuff, there will be a 30 degree anterior bend.
62606855|NCT06525662|ACTIVE_COMPARATOR|Arcuate|The endotracheal tube to be used for endotracheal intubation will have a stylet inserted into it and manipulated into an arcuate shape, and thus curved throughout the length of the tube.
62606856|NCT01925157|EXPERIMENTAL|LY3090106 (Healthy)|Healthy participants will receive a single dose of LY3090106 in dose escalation cohorts subcutaneously (SQ).
62606857|NCT01925157|PLACEBO_COMPARATOR|Placebo (Healthy)|Healthy participants will receive a single dose of placebo matching LY3090106 SQ.
62606858|NCT01925157|EXPERIMENTAL|LY3090106 (RA)|Participants with RA will receive a single dose of LY3090106 in dose escalation cohorts SQ or intravenously (IV).
62606859|NCT01925157|PLACEBO_COMPARATOR|Placebo (RA)|Participants with RA will receive a single dose of placebo matching LY3090106 SQ.
62606860|NCT04511949|OTHER|No arm|No arm
62606861|NCT03557268||On a GnRHa|Half of subjects will be on a puberty blocker or gonadotropin-releasing hormone analogue
62606862|NCT03557268||Not on GnRHa|Half of subjects will NOT be on a puberty blocker or gonadotropin-releasing hormone analogue
62606863|NCT00800605|EXPERIMENTAL|1|Vero cell-derived, trivalent, seasonal influenza vaccine
62606864|NCT00800605|PLACEBO_COMPARATOR|2|Phosphate-buffered saline
62606865|NCT04469959|EXPERIMENTAL|L-Dopa First / Placebo Second|"STEP 1(3 weeks): Participants initially assigned to L-DOPA will begin with a Week 1 L-DOPA daily dosage of 150mg, (1.5 25mg carbidopa/100mg levodopa capsules) at 9am. Week 2 will increase to a L-DOPA daily dose of 300mg (1.5 25mg carbidopa/100mg levodopa capsules) at 9am and 5pm, followed by a Week 3 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa capsules) three times daily. After completing post-trial assessments, participants then enter a 1 week taper period before proceeding to Step 2.~Step 2 (3 Weeks): Participants will receive matching placebo capsules daily. Participants take placebo capusles once daily during week 1 (9am), twice daily during week 2 (9am, 5pm), and three times daily during week 3 (9am, 1pm, 5pm) over three weeks. Following post-trial assessments, participants then enter a 1-week taper period and study drug is withdrawn."
62249423|NCT00591214|EXPERIMENTAL|MP-424|
62249424|NCT02128451|ACTIVE_COMPARATOR|Meperdine group|15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
62606866|NCT04469959|PLACEBO_COMPARATOR|Placebo First / L-Dopa Second|"Step 1 (3 Weeks): Participants will receive matching placebo capsules daily. Participants take placebo capsules once daily during week 1 (9am), twice daily during week 2 (9am, 5pm), and three times daily during week 3 (9am, 1pm, 5pm) over three weeks. Following post-trial assessments, participants then enter a 1-week taper period before proceeding to Step 2.~Step 2 (3 Weeks): Participants will begin with a Week 1 L-DOPA daily dosage of 150mg, (1.5 25mg carbidopa/100mg levodopa capsules) at 9am. Week 2 will increase to a L-DOPA daily dose of 300mg (1.5 25mg carbidopa/100mg levodopa capsules) at 9am and 5pm, followed by a Week 3 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa capsules) three times daily. After completing post-trial assessments, participants then enter a 1 week taper period and study drug will be discontinued."
62829175|NCT06155292|EXPERIMENTAL|Arm 3: Personalized Report Card + Bottom-Up Framing|"Quarterly email communication as in Arm 2. Bottom-up intervention: The quarterly email communication will also describe the ways in which the PCCE program and its features were informed by physician feedback and recommendations.~Quarterly survey: The quarterly survey will include information about the ways in which the PCCE program and its features were informed by physician feedback and recommendations. Physicians will respond to the same questions about physician attitudes and beliefs as in Arms 1 and 2."
62249425|NCT02128451|ACTIVE_COMPARATOR|Fentanyl group|15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
62606867|NCT00909714|EXPERIMENTAL|Anodal tDCS|Direct Current (DC)-Stimulator to apply tDCS + Training
62606868|NCT00909714|SHAM_COMPARATOR|Sham tDCS|Direct Current (DC)-Stimulator to apply Sham tDCS (Placebo) + Training
62249426|NCT00719550|PLACEBO_COMPARATOR|Phase 2 Arm C|AMG 102 placebo plus ECX
62249427|NCT00719550|OTHER|Phase 1b|Phase 1b dose study with open-labe AMG 102 at 15mg/kg de-escalating to 7.5mg/kg and 5mg/kg if needed.
62249428|NCT00719550|ACTIVE_COMPARATOR|Phase 2 Arm B|AMG 102 at 7.5mg/kg plus ECX
62249429|NCT00719550|ACTIVE_COMPARATOR|Phase 2 Arm A|AMG 102 at 15mg/kg plus ECX
62249430|NCT05830799|EXPERIMENTAL|Experimental: C21|C21, single dose, oral administration twice daily, for 15 days
62249431|NCT03294525||Escitalopram-for MDD|Eligible patients were assigned to escitalopram treatment based on investigators' clinical practice.
62047048|NCT05919693|EXPERIMENTAL|Naïve NVAMD High Dose|Part 2 Naïve NVAMD combination therapy High Dose
62606869|NCT03070041|EXPERIMENTAL|Mothers and staff members|The mothers who will give birth at the study hospital and all the staff members taking care about mothers and/or infants
62606870|NCT05262868|ACTIVE_COMPARATOR|Active|Magnetic stimulus intensity of 80% of the motor threshold applied at the frequency of 20 Hz over the left DLPFC with a total number of pulses of 1200 / treatment session for a total of 5 sessions /week for 3 consecutive weeks
62829176|NCT02809235|EXPERIMENTAL|coconut oil|Subjects will be instructed to supplement their diet with 3 tablespoons of coconut oil daily for three weeks.
62829177|NCT02654444||GenASIs HiPath IHC #1|Expression of HER2 antibody. Semi-Quantitative value
62829178|NCT02654444||GenASIs HiPath IHC #2|Expression of HER2 antibody. Semi-Quantitative value
62829179|NCT02654444||GenASIs HiPath IHC #3|Expression of HER2 antibody. Semi-Quantitative value
62829180|NCT03672578|EXPERIMENTAL|Loss-frame, text-only, no attribution|Label participants will see is loss-frame, text-only, and with no attribution
62829181|NCT03672578|EXPERIMENTAL|Gain-frame, text-only, no attribution|Label participants will see is gain-frame, text-only, and with no attribution
62829182|NCT03672578|EXPERIMENTAL|Loss-frame, icon, no attribution|Label participants will see is loss-frame, icon, and with no attribution
62249432|NCT03294525||Duloxetine-for MDD|Eligible patients were assigned to duloxetine treatment based on investigators' clinical practice.
62047049|NCT05919693|EXPERIMENTAL|Experienced NVAMD Medium Dose|Part 2 Experienced NVAMD combination therapy Medium Dose
62047050|NCT05919693|EXPERIMENTAL|Experienced NVAMD High Dose|Part 2 Experienced NVAMD combination therapy High Dose
62047051|NCT05684406||Group I|patients with type 2 diabetes mellitus
62047052|NCT05684406||Group II|apparently healthy controls with no chronic illness of matched age and sex
62249433|NCT03294525||Mirtazepine-for MDD|Eligible patients were assigned to mirtazepine treatment based on investigators' clinical practice.
62249434|NCT03294525||other antidepressant-for MDD|Eligible patients were assigned to other antidepressant treatment (including sertraline, paroxetine, fluoxetine, venlafaxine, etc) based on investigators' clinical practice.
62047053|NCT05019248||vaccination prior to first cladribine exposition|
62047054|NCT05019248||vaccination shortly after first cladribine exposition|
62047055|NCT05019248||vaccination prior to second cladribine exposition|
62249435|NCT01419782|EXPERIMENTAL|Whole-body vibration|whole body vibration will be applied the right lower limb.
62249436|NCT06466785|EXPERIMENTAL|Efepoetin Alfa (GX-E4)|"Dose: 0.3 mg/0.3 mL, 0.6 mg/0.6 mL and 1 mg/1 mL pre-filled syringe (PFS) solution. The dose of study drug can be varied depending on the level of Hb.~Frequency: Efepoetin alfa should be administered at 1-week intervals from Day 1 (Visit 2) to Week 28 (Visit 30), but the administration interval may be changed to 1 or 2 weeks from Week 29 (Visit 31) to Week 52 (Visit 54) according to the investigator's judgement.~Mode of administration: intravenous injection. When the dose of investigational product (IP) is planned on the same day as hemodialysis (HD), the IP should be injected at the end of HD."
62449413|NCT04480463|EXPERIMENTAL|SCD411|
62449414|NCT04480463|ACTIVE_COMPARATOR|Aflibercept|
62449415|NCT02579096|ACTIVE_COMPARATOR|Allopurinol / Sham Comparator (Febuxostat)|Patients will be titrated up to the dose that will lower to target uric acid levels. A placebo resembling Febuxostat will be given with allopurinol
62449416|NCT02579096|ACTIVE_COMPARATOR|Febuxostat / Sham Comparator (Allopurinol)|Febuxostat will be titrated up to the dose that will lower to target uric acid levels. A placebo resembling Allopurinol will be given with Febuxostat
62449417|NCT03147196|EXPERIMENTAL|Arm A (raloxifene hydrochloride)|Patients receive low dose raloxifene hydrochloride PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62449418|NCT03147196|EXPERIMENTAL|Arm B (bicalutamide)|Patients receive low dose bicalutamide PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62449419|NCT03147196|EXPERIMENTAL|Arm C (raloxifene hydrochloride, bicalutamide)|Patients receive low dose raloxifene hydrochloride PO daily and low dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62449420|NCT03147196|EXPERIMENTAL|Arm D (raloxifene hydrochloride, bicalutamide)|Patients receive high dose raloxifene hydrochloride PO daily and high dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62449421|NCT02651636|EXPERIMENTAL|Open label|Therapy with alpha-lipoic acid (800 mg), myoinositol (2000 mg) and folic acid (400 mcg) daily for six months
62449422|NCT06000423|EXPERIMENTAL|Treatment|After three consecutive days of bleeding, five days of 1300mg TXA three times per day (TID).
62449423|NCT06000423|PLACEBO_COMPARATOR|Placebo|After three consecutive days of bleeding, five days of placebo three times per day.
62449424|NCT01491620|EXPERIMENTAL|532 nm KTP laser treatment|
62449425|NCT04306900|EXPERIMENTAL|Combo 1|TTX-030 plus budigalimab plus mFOLFOX6
62449426|NCT04306900|EXPERIMENTAL|Combo 2|TTX-030 plus budigalimab plus docetaxel
62449427|NCT04306900|EXPERIMENTAL|Combo 3|TTX-030 plus mFOLFOX6
62449428|NCT04306900|EXPERIMENTAL|Combo 4|TTX-030 plus pembrolizumab
62449429|NCT04306900|EXPERIMENTAL|Combo 5|TTX-030 plus budigalimab (selected tumors evaluated in expansion)
62449430|NCT04306900|EXPERIMENTAL|Combo 6|TTX-030 plus budigalimab plus nab-paclitaxel + gemcitabine
62449431|NCT04306900|EXPERIMENTAL|Combo 7|TTX-030 plus nab-paclitaxel + gemcitabine
62449432|NCT04306900|EXPERIMENTAL|Combo 8|Budigalimab plus mFOLFOX6
62606871|NCT05262868|PLACEBO_COMPARATOR|Sham|"Sham procedure implies the use of a sham coil of exactly the same dimension and appearance as the one used for the effective treatment. This sham coil is made for research purposes by the producing company and used in accordance with the instructions for use, which explicitly mention it (cf. instruction manual page 34: Stimulation Coil DuoMAG 70BFP (70BFP1, 70BFP2), typical use for blinded studies)."
62439276|NCT01275313|EXPERIMENTAL|Custom-Fitted Lightweight Wheelchair & Cushion|Receive a new custom-fitted lightweight wheelchair, skin protection cushion and wheelchair skills training
62439277|NCT01275313|OTHER|Cushion Only|Receive a skin protection cushion and wheelchair training, but remain in facility-issued wheelchair
62606872|NCT00101036|EXPERIMENTAL|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62829183|NCT03672578|EXPERIMENTAL|Grain-frame, icon, no attribution|Label participants will see is gain-frame, with an icon, and with no attribution
62829184|NCT03672578|EXPERIMENTAL|Loss-frame, icon, attribution|Label participants will see is loss-frame, icon, and with attribution
62439278|NCT02541656|EXPERIMENTAL|preloaddependence indice after volume expansion in laparoscopy|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
62439279|NCT05849428|OTHER|Measuring Arm|Participants will wear 2 Freestyle Libre 3 sensors on each arm, 1 on the left and 1 on the right for 2 consecutive weeks (total of 14 days).
62439280|NCT00909077|ACTIVE_COMPARATOR|1|Combination therapy with Dexamethasone and Rituximab
62606873|NCT02783456|ACTIVE_COMPARATOR|Noise and silence|Exposition of 80dB flight noise for 30 minutes and 30 minutes silence.
62829185|NCT03672578|EXPERIMENTAL|Gain-frame, icon, attribution|Label participants will see is grain-frame, icon, and with attribution
62249437|NCT06466785|ACTIVE_COMPARATOR|Darbepoetin Alfa (Aranesp®)|"Dose: 20 µg/0.5 mL, 30 µg/0.3 mL, 60 µg/0.3 mL, 100 μg/0.5 mL PFS. The dose of comparator drug can be varied depending on the level of Hb.~Frequency: Darbepoetin alfa should be administered at 1-week intervals from Day 1 (Visit 2) to Week 28 (Visit 30), but the administration interval may be changed to 1 or 2 weeks from Week 29 (Visit 31) to Week 52 (Visit 54) according to the investigator's judgement.~Mode of administration: intravenous injection."
62249438|NCT01294488|EXPERIMENTAL|Phone Consultation|Therapists receive phone consultation for 6 months during the course of the project.
62829186|NCT03672578|EXPERIMENTAL|Loss-frame, text-only, attribution|Label participants will see is loss-frame, text-only, and with attribution
62249439|NCT01294488|EXPERIMENTAL|Remote Real-Time Consultation|Therapists receive consultation for 6 months via polycommunication technology.
62249440|NCT03825055||Young patients with MS|young adults (i.e., 18-45 years) newly diagnosed with MS (Case-Only)
62249441|NCT04302584|ACTIVE_COMPARATOR|NE|patients received IV Norepinephrine infusion starting with (0.1mcg/kg/min)
62829187|NCT03672578|EXPERIMENTAL|Gain-frame, text-only, attribution|Label participants will see is gain-frame, text-only, and with attribution
62829188|NCT03672578|PLACEBO_COMPARATOR|No label|Participant will not see a label
62829189|NCT05672758||Sprint-Trained Athletes|Highly trained track sprinters at the national or international level aged 18-35 years with sport experience 5-10 years; structured periodized training
62439281|NCT00909077|ACTIVE_COMPARATOR|2|Dexamethasone as monotherapy
62439282|NCT03564925|ACTIVE_COMPARATOR|Wide area circumferential ablation|Device:Smart Touch® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
62439283|NCT03564925|EXPERIMENTAL|Cryoballoon ablation|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
62439284|NCT06114433|ACTIVE_COMPARATOR|Traditional model group|Received a regular learning
62439285|NCT06114433|EXPERIMENTAL|3D-printed presention group|Received a regular learning plus 3D printing model
62606874|NCT02783456|ACTIVE_COMPARATOR|silence and noise|Exposition of 30 minutes silence.and 80dB flight noise for 30 minutes
62606875|NCT00774007|PLACEBO_COMPARATOR|Placebo|Placebo
62606876|NCT00774007|ACTIVE_COMPARATOR|Mesalazine|mesalazine 800 mg t.i.d.
62829190|NCT05672758||Endurance-Trained Athletes|Highly trained long-distance runners and triathletes at the national or international level aged 18-35 years with sport experience 5-10 years; structured periodized training
62829191|NCT05672758||Amateur/Recreational Athletes (Controls)|Individuals participating in amateur non-professional sport aged 18-35 years with activity experience 5-10 years; unstructured non-periodized training
62829192|NCT01396304|EXPERIMENTAL|Restore Calcium Alginate Dressing Silver|Restore Calcium Alginate Dressing Silver under compression wrap
62829193|NCT01396304|ACTIVE_COMPARATOR|Aquacel Ag Wound Dressing|Aquacel Ag Wound Dressing under compression wrap
62047056|NCT05019248||vaccination following completion of cladribine treatment|
62047057|NCT05019248||vaccination in patients with RRMS not subjected to cladribine|
62047058|NCT05738187|EXPERIMENTAL|local cryotherapy treatment|
62047059|NCT02362048|EXPERIMENTAL|Experimental: Arm 1|ACP-196 alone
62047060|NCT02362048|EXPERIMENTAL|Experimental: Arm 2|ACP-196 in combination with pembrolizumab
62249442|NCT04302584|ACTIVE_COMPARATOR|NE/VP|patients received IV Norepinephrine infusion (Starting with (0.1 mcg/kg/min). +Vasopressin infusion at the rate of (0.03 unit/min)
62439286|NCT04165278|EXPERIMENTAL|Hyperthermic baths|On the first, third and fifth day of the first week, each subject will take the Hyperthermic Baths (HTB) at the same time. They will receive subjective measures before and after HTB. In the second week, no subjects accepted any intervention. On the fifteenth, seventeenth and nineteenth days of the third week, these subjects will receive two subjective measures without HTB in the same environment and scoring time as the experimental group.
62439287|NCT02519426||Cumulative complexity score <9|Mandibular third molar surgery patients with Juodzbalys and Daugela impacted mandibular third molars surgical extraction complexity index cumulative score lower than 9.
62439288|NCT02519426||Cumulative complexity score y≥9|Mandibular third molar surgery patients with Juodzbalys and Daugela impacted mandibular third molars surgical extraction complexity index cumulative score higher than 9.
62439289|NCT02519426||Pell Gregory index <Class 2B|Mandibular third molar surgery patients with Pell Gregory index Class 1A, Class 1B, Class 1C, or Class 2A
62439290|NCT02519426||Pell Gregory index ≥Class 2B|Mandibular third molar surgery patients with Pell Gregory index Class 2B, Class 2C, Class 3A, Class 3B, or Class 3C
62439291|NCT02519426||Winter index <Horizontal impaction|Mandibular third molar surgery patients with Winter predicted index of Mesio-Angular, Disto-Angular or Vertical impaction
62439292|NCT02519426||Winter index ≥Horizontal impaction|Mandibular third molar surgery patients with Winter predicted index of Horizontal, Buccal / Lingual Obliquity, Transverse, Inverse impaction
62439293|NCT06016855|EXPERIMENTAL|Treatment (surgical debulking, 177Lu dotatate)|Patients undergo surgical debulking on day 0 and receive 177Lu dotatate IV over 30 to 40 minutes on day 1 of each cycle. Treatment repeats every 56 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI throughout the trial, and undergo dotatate PET/CT during screening and on study.
62439294|NCT03350022|EXPERIMENTAL|Sham Feeding|
62606877|NCT02479971|ACTIVE_COMPARATOR|Normal saline irrigation|An irrigation of the entire abdominal cavity with 500 ml normal saline will be performed.
62047061|NCT02471651|ACTIVE_COMPARATOR|Implant|Subjects randomized to dexamethasone intravitreal implant (0.7mg) will receive the initial treatment at Month 3 (visit 4) and Month 6 (visit 7) and are eligible to receive one additional dose at Month 9 (visit 10), Month 10 (visit 11) or Month 11 (visit 12) for persistent or recurrent macular edema documented on SDOCT. If dexamethasone intravitreal implant (0.7mg) is administered at Month 10 (visit 11) or Month 11 (visit 12) an additional safety study visit will be required at one to two months following Month 12 (visit 13). The investigator can withhold treatment with dexamethasone intravitreal implant (0.7mg) beginning at Month 9 if there is complete resolution of diabetic macular edema document on SDOCT.
62047062|NCT02471651|ACTIVE_COMPARATOR|Intravitreal anti-VEGF injection|Subjects randomized to continue on anti-vegf therapy will receive intravitreal anti-vegf injections at Month 3 (visit 4) Month 4 (visit 5) and Month 5 (visit 6). Beginning at Month 6 (visit 7), subjects who have received 6 intravitreal anti-vegf injections and continue to present with persistent diabetic macular edema defined as less than 10% reduction or any increase in CST compared to baseline values and CST is greater than 300 microns, will receive dexamethasone intravitreal implant (0.7mg) at Month 6 (visit 7) and Month 9 (visit 10). The follow-up period for all subjects will continue through 12 months from the baseline study visit.
62047063|NCT01064206||Buerger's disease patients|200 thromboangiitis obliterans patients (Buerger's disease or TAO)
62047064|NCT01064206||Control group|200 atheromatous arteritis patients
62047065|NCT05204225|EXPERIMENTAL|Tablet Application|An exercise program based on the current evidence will be provided through a tablet application (ReHand) along with the face-to-face conventional approach of each recruitment centres. A follow-up of the use of the application will be carried out. The treatment protocol will last 4 weeks, including daily exercise sessions of 30-60 minutes of duration at home though the application tablet.
62249443|NCT00619255|EXPERIMENTAL|Intervention|Adolescent Trauma Support Program
62249444|NCT00619255|NO_INTERVENTION|Control|Usual Care Control Condition
62249445|NCT01531322|EXPERIMENTAL|Group 1|Adults aged 18 through 55 years (before the fifty sixth birthday)
62249446|NCT01531322|EXPERIMENTAL|Group 2|Children aged 3 through 5 years (before the sixth birthday)
62249447|NCT01531322|EXPERIMENTAL|Group 3|Infants aged approximately 2 months (42 to 98 days)
62439295|NCT02132299|EXPERIMENTAL|Group 1|Three volunteers will receive 3 ascending doses of PfSPZ Vaccine by IV administration four weeks apart. The three doses are 3x10\^4, 1.35x10\^5, and 2.7x10\^5 PfSPZ. This is the safety group that will be inoculated first before all others for demonstration of safety and will be followed up for assessment of safety after the completion of the three doses. The follow up will be at weeks 1, 2, 4, 8 and 24 after completion of vaccination. Volunteers in Group 1 will not undergo CHMI. Group 1 is unblinded.
62606878|NCT02479971|EXPERIMENTAL|Clindamycin-gentamicin irrigation|An irrigation of the entire abdominal cavity with 500 ml gentamicin and clyndamycin solution will be performed.
62606879|NCT06027632|OTHER|Remotely-supervised online cognitive stimulation intervention|
62606880|NCT06027632|OTHER|Open access to online home-based cognitive exercises without supervision|
62606881|NCT05324280|EXPERIMENTAL|Acupuncture Group|"Acupuncture treatment will be performed according to a defined protocol, and includes body and ear acupuncture. The needles will be stimulated manually and will remain for 20 minutes.~Body acupuncture needles (diameter 0.3mm, length 30 mm) will be placed on the following positions:~On the lower abdomen and back within Th11 and L1~* Kidney 13 and 14; alternately unilaterally~* Ren2 and 3 (midline) On classical acupuncture points on the extremities and the head~* Stomach 36, Spleen 6; bilaterally~* Large intestine 4, Liver 3; Bladder 60 bilaterally~* Du 20 (midline)~Ear acupuncture:~Ear acupuncture needles (diameter 0,2 mm, length 20mm) will be used:~Veg. I (Sympathetic), lower pelvis, hypogastric plexus, Heart,Thalamus, genital system (combining Chinese and French ear acupuncture)~For point detection an electric potentiometer will be used. Ear points are punctured according to their generally accepted positions."
62249448|NCT05295004|NO_INTERVENTION|No Treatment|Patient will receive no mindfulness meditation training.
62249449|NCT05295004|EXPERIMENTAL|Mindfulness at Pre-Op|Patient will receive a one time training at their pre-operative appointment.
62606882|NCT05324280|NO_INTERVENTION|Waiting list Group|Participants allocated to the waiting list control group may continue previously initiated standard therapy, but must not initiate any new treatment. They will be asked not to undergo acupuncture treatment for any condition within the next 3 months. After this period they are offered 10 acupuncture treatments over a period of 3 months.
62606883|NCT04989634|ACTIVE_COMPARATOR|standard care|In the early pregnancy ( 8-12 weeks of pregnancy ) , a group education on dietary weight management will be carried out according to the current medical system and the regulations of our hospital , followed by routine prenatal examination . According to the corresponding diagnosis and treatment guidelines, examinations and follow-up interventions will be carried out if the metabolic diseases are occurred during pregnancy.
62606884|NCT04989634|EXPERIMENTAL|dietary and weight management|A randomized controlled trial in pregnant women will be initiated at 8-12 weeks of gestation util delivery. The intervention contents included health education , nutritional analysis and individualized dietary guidance combined with mobile medical treatment and face-to-face teaching during the early , middle and late pregnancy stages.
62606885|NCT01718145|EXPERIMENTAL|Arm 1: Daclatasvir + Asunaprevir|"Daclatasvir 60 mg tablets by mouth once daily and Asunaprevir 200 mg capsules by mouth twice daily for 24 weeks~- Naive cohort"
62249450|NCT05295004|EXPERIMENTAL|Multiple Mindfulness Meditation|Mindfulness Video Training at Pre-Op, 1 Day Prior to surgery, 3 day's Post OP and 2 Weeks Post OP.
62249451|NCT01763151|ACTIVE_COMPARATOR|toric IOL|aspherical, toric acrylic IOL (Lentis L-312T, Oculentis, Germany)
62439296|NCT02132299|EXPERIMENTAL|Group 2(A)|Group 2: Two sub groups: 2A and 2B. Grp 2A (n=20) receives 5 vaccinations IV of 1.35x10\^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 2 will undergo the first CHMI by IV injection of 3.2x10\^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 2 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10\^3 PfSPZ Challenge (NF54).
62606886|NCT01718145|ACTIVE_COMPARATOR|Arm 2: Telaprevir + pegIFNα-2b + Ribavirin|"Telaprevir 750 mg tablets by mouth three times daily, pegIFNα-2b 1.5 μg/kg solution by Subcutaneous weekly \& Ribavirin 600- 1000 mg Capsules by mouth twice daily for 24 Weeks~- Naive cohort"
62606887|NCT01718145|EXPERIMENTAL|Arm 3: Daclatasvir + Asunaprevir|"Daclatasvir 60 mg tablets by mouth once daily and Asunaprevir 200 mg capsules by mouth twice daily for 24 weeks~- Relapser cohort"
62249452|NCT01763151|ACTIVE_COMPARATOR|IOL combined with opposite clear corneal incision (OCCI)|aspherical, acrylic IOL with OCCI
62249453|NCT02098642||Patients with passive joint mobilization|Patients diagnosed with PD according to the Gelb et al in Hoen\&Yahr stage 3, with Freezing of Gait and treated with a Multidisciplinary intensive rehabilitation treatment (MIRT), including the mobilization of the metatarsophalangeal joint of the hallux
62606888|NCT00769535|EXPERIMENTAL|HSP70 and TNF polymorphisms|
62606889|NCT02013570|ACTIVE_COMPARATOR|Dexmedetomidine|Group S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration.
62606890|NCT02013570|PLACEBO_COMPARATOR|Normal saline, postoperative pain|Group S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration.
62606891|NCT06304558|EXPERIMENTAL|Intervention|"T The total number of sessions to be conducted for each patient will be 10 sessions, spread over 5 weeks, which means a frequency of twice a week.~Each NESA microcurrent session will last 60 minutes. A maximum time of 15 minutes will be allowed for connecting the patient at the beginning and for removing the device at the end.~During the 10 sessions of the treatment, the programming will evolve to optimize the response.~The directing electrode will be located throughout the treatment between the spinous processes of C6 and C7 to act generally on the individual, and in later sessions, the electrode will be placed in the abdominal area to cover the hypogastric plexus and at S2-S3 to influence the sacral plexus.~The intensity will be set to Low (3 volts) in all sessions, following the Arndt-Schulz law. The other device parameters range between 100-900 microamperes and between 1.14 and 14.29 hertz, and are preset by each program"
62606892|NCT06304558|PLACEBO_COMPARATOR|Placebo|Non-active Non-invasive Neuromodulation (NESA)
62829194|NCT06599398||Intervention group|The intervention group comprise patients and families who had an intermediate stay between hospital and home in the Jeroen Pit Huis (JPH)
62249454|NCT02098642||No passive joint mobilization|Patients diagnosed with PD according to the Gelb et al in Hoen\&Yahr stage 3, with Freezing of Gait and treated with a Multidisciplinary intensive rehabilitation treatment (MIRT)
62249455|NCT03135171|EXPERIMENTAL|Trastuzumab, Pertuzumab and Tocilizumab|
62249456|NCT01118416|EXPERIMENTAL|intervention condition|Participants randomized to the intervention condition will undergo 4 one-hour sessions of motivational interviewing (MI), during which their sexual risk taking and substance use patterns will be discussed with a trained counselor with the goal of reducing instances of unprotected anal sex and substance use.
62606893|NCT02253121|EXPERIMENTAL|Dapagliflozin + sliding scale insulin.|Treatment with dapagliflozin 10mg once daily orally. Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days). In case of persistent glucose levels \> 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.
62606894|NCT02253121|PLACEBO_COMPARATOR|Placebo + sliding scale insulin|Treatment with placebo once daily orally. Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days). In case of persistent glucose levels \> 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.
62606895|NCT00834730|ACTIVE_COMPARATOR|Ketamine|Ketamine 2mg/kg IV
62606896|NCT00834730|EXPERIMENTAL|N2O gas|50%-70% N2O gas inhalation
62606897|NCT05581433|ACTIVE_COMPARATOR|vapocoolan spray applied group before injection|Vapocoolant spray will be applied to patients in this group before intra-articular knee injection.
62606898|NCT05581433|PLACEBO_COMPARATOR|placebospray applied group before injection|Placebo spray will be applied to patients in this group before intra-articular knee injection.
62606899|NCT05581433|NO_INTERVENTION|No administration group before injection|In this group, no pain reliever application will be made before the application.
62606900|NCT03203460|EXPERIMENTAL|Exercise Group|Supervised high-intensity aerobic interval training (HIIT) during active surveillance
62606901|NCT03203460|NO_INTERVENTION|Usual Care Group|The usual care group will be provided with standard active surveillance medical care.
62606902|NCT02061449|EXPERIMENTAL|Initiating therapy with Romidepsin (Arm A)|Patients who are starting therapy with Romidepsin (intravenously on days 1, 8, and 15 of every 21-day cycle or alternate schedule per treating physician) also receive focal lesional radiation on days 1,3, and 5 without (level 1) or with (level 2) Poly ICLC (subcutaneously on days 1, 3, and 5) on the first cycle.
62606903|NCT02061449|EXPERIMENTAL|treatment with Romidepsin with SD or PR (Arm B)|Patients with stable disease on the treatment with Romidepsin (intravenously on days 1, 8, and 15 of every 21-day cycle or alternate schedule per treating physician) also receive focal lesional radiation on days 1,3, and 5 without (level 1) or with (level 2) Poly ICLC (subcutaneously on days 1, 3, and 5) on the first cycle.
62606904|NCT06431685|EXPERIMENTAL|whole brain LDRT + ICI + intrathecal chemotherapy|The treatment regimen consisted of intrathecal chemotherapy (via lumbar puncture, pemetrexed 30 mg, once per three weeks, 4 cycles in total), PD-1 inhibitor (Sintilimab, via intravenous infusion, once per three weeks, 4 cycles in total)), pemetrexed chemotherapy (via intravenous infusion, once per three weeks, 4 cycles in total) and radiotherapy. Whole brain LDRT will be administered at 3 cohorts with increasing dose fractions: 4 Gy/2f of 2 fraction (administered a daily dose of 2 Gy for two days) in group 1; 4 Gy/2f of 4 fractions (administered a daily dose of 2 Gy for two days, once per three weeks, 2 cycles in total) in group 2; 4 Gy/2f of 8 fractions (administered a daily dose of 2 Gy for two days, once per three weeks, 4 cycles in total) in group 3.
62606905|NCT03794934|PLACEBO_COMPARATOR|Control|Without structured education when applying CGM for 3months, and as a sequential extension clinical trial, after 3 months, structured education is provided, followed by CGM apply
62606906|NCT03794934|ACTIVE_COMPARATOR|Intervention|provide structured education when applying CGM for 3 months
62606907|NCT02827435|EXPERIMENTAL|Rocuronium bolus|rocuronium bromide 1st bolus 0.1mg/kg, rocuronium bromide 2nd bolus 0.4mg/kg
62249457|NCT01118416|ACTIVE_COMPARATOR|Education condition|Participants randomized to the education condition will undergo 4 one-hour sessions during which they will view video segments and discuss sexual risk taking and substance use with a health educator, with the goal of reducing instances of unprotected anal sex and substance use by making informed decisions.
62249458|NCT00290186|EXPERIMENTAL|Hyperbaric Oxygen Treatment (HBO)|100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
62249459|NCT00290186|ACTIVE_COMPARATOR|Hyperbaric Air Treatment (HBA)|14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
62249460|NCT01490853||CML and interpheron alpha|Adult Ph+CML pts in CCgR after IFN alpha.
62249461|NCT02294084|EXPERIMENTAL|Sitagliptin|Subjects will receive Sitagliptin in a dosage of 100 mg/day p.o. for 12 weeks. The dosage corresponds to 1 gift/day.
62249462|NCT02294084|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo for 12 weeks. Placebo will be given in 1 gift/day
62249463|NCT04822610|EXPERIMENTAL|Study group: interscalene block + IV PCA|preop usg guided interscalene block and IV PCA
62606908|NCT03058367|EXPERIMENTAL|High dose IQP-AE-103 (1980mg)|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
62606909|NCT03058367|EXPERIMENTAL|Low dose IQP-AE-103 (990mg)|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
62606910|NCT03058367|PLACEBO_COMPARATOR|Placebo|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
62606911|NCT04766255|ACTIVE_COMPARATOR|Control Group|Implant placement and prosthetic rehabilitation of the missing tooth
62606912|NCT04766255|EXPERIMENTAL|SCTG group|Implant placement, soft tissue augumentation of Connective Tissue Graft (from the palate) (SCTG) at the implant site and prosthetic rehabilitation of the missing tooth.
62606913|NCT04766255|EXPERIMENTAL|CM group|Implant placement, soft tissue augumentation of porcine collagen matrix (CM) at the implant site and prosthetic rehabilitation of the missing tooth.
62606914|NCT04766255|EXPERIMENTAL|PADM group|Implant placement, soft tissue augumentation of Porcine acellular dermal matrix (PADM) at the implant site and prosthetic rehabilitation of the missing tooth.
62606915|NCT02710344|NO_INTERVENTION|Usual Care|Usual care at community mental health care provider
62606916|NCT02710344|EXPERIMENTAL|Telehealth|Usual care at community mental health care provider PLUS psychiatric telehealth program with remote monitoring.
62606917|NCT03704948|EXPERIMENTAL|Trial #1: (RCT) Treatment Group: Listening Visits delivered by NICU nurse in person|Listening Visits delivered by a NICU nurse in person in the RCT
62606918|NCT03704948|ACTIVE_COMPARATOR|Trial #1: (RCT): Control Group -Mental health care delivered by NICU social work|Mental health care provided by NICU social workers.
62606919|NCT03704948|EXPERIMENTAL|Trial #2Open Trial: Listening Visits delivered by NICU nurse over zoom|Open Trial: Listening Visits delivered by NICU nurse over zoom
62606920|NCT02258269|EXPERIMENTAL|SQ|Patients with rheumatoid arthritis exercise square dance
62439297|NCT02132299|PLACEBO_COMPARATOR|Group 2(B)|Group 2: Two sub groups: 2A and 2B. Grp 2B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 2 will undergo the first CHMI by IV injection of 3.2x10\^3 PfSPZ Challenge (NF54).
62606921|NCT02258269|SHAM_COMPARATOR|Control|Patients with rheumatoid arthritis listen to accompany music of square dance at home
62249464|NCT04822610|EXPERIMENTAL|Study group: suprascapular block + axillary block + IV PCA|preop usg guided suprascapular block + axillary block and IV PCA
62249465|NCT04822610|NO_INTERVENTION|Control group: IV PCA|no block + IV PCA
62249466|NCT02761395|EXPERIMENTAL|Group 1: ALhijama|20 patients under went Al-hijamah procedure for iron chelation
62829195|NCT06599398||Control groups|The control groups comprise patients and families who undergo the hospital to home transition directly from the hospital. This includes patients from the EMC, RUMC, and UMCG. Patients from the AUMC who transition directly from hospital to home without an intermediate stay in the JPH will also be included in the control group.
62829196|NCT05197972|EXPERIMENTAL|Experimental group|Classic management of the preoperative period with a cardiac coherence program coupled with hypnosis.
62829197|NCT05197972|NO_INTERVENTION|Control group|Classic management of the preoperative period
62047066|NCT05204225|ACTIVE_COMPARATOR|Conventional Treatment|Participants included in this group will receive the conventional treatment protocol usually prescribed on each recruitment centres. Participants will be asked to perform an exercise program on paper during 4 weeks at home, along with face-to-face sessions.
62249467|NCT02761395|EXPERIMENTAL|Group 2: AL-hijama with deferasirox|20 patients receive deferasirox and Al-hijamah.
62249468|NCT02761395|ACTIVE_COMPARATOR|Group 3:deferasirox|20 patients already receiving deferasirox
62249469|NCT02257996|EXPERIMENTAL|Interventional Group|Online Systematic Brief Psychodynamic Psychotherapy
62249470|NCT02257996|NO_INTERVENTION|Control Group|Waiting list
62249471|NCT00701090|EXPERIMENTAL|1|sitagliptin
62249472|NCT00701090|ACTIVE_COMPARATOR|2|glimepiride
62249473|NCT01372722|EXPERIMENTAL|Sham then Stimulation|
62249474|NCT01372722|EXPERIMENTAL|Stimulation then Sham|
62249475|NCT01022502|ACTIVE_COMPARATOR|refined indigo naturalis ointment|Refined indigo naturalis ointment was applied topically to one of 2 bilaterally symmetrical psoriatic plaque lesions of the same patient for 8 weeks, starting on the date of enrollment in the study
62249476|NCT01022502|ACTIVE_COMPARATOR|crude indigo naturalis ointment|Crude indigo naturalis ointment was applied topically to one of 2 bilaterally symmetrical psoriatic plaque lesions of the same patient for 8 weeks, starting on the date of enrollment in the study
62249477|NCT02575404|EXPERIMENTAL|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
62249478|NCT02575404|EXPERIMENTAL|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
62249479|NCT02575404|EXPERIMENTAL|8 mg/kg GR-MD-02|8 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
62249480|NCT02575404|EXPERIMENTAL|4 mg/kg GR-MD-02 17 Cycles Maximum|4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment up to a maximum of 17 cycles.
62249481|NCT04809311||Other oral antidiabetic drugs (OADs) ± metformin|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
62606922|NCT02258542|EXPERIMENTAL|Benralizumab Arm A|Benralizumab administered subcutaneously
62606923|NCT02258542|EXPERIMENTAL|Benralizumab Arm B|Benralizumab administered subcutaneously
62606924|NCT00634595|EXPERIMENTAL|A|E10A combined with Cisplatin and Paclitaxel
62606925|NCT00634595|ACTIVE_COMPARATOR|B|Cisplatin and Paclitaxel
62249482|NCT04809311||Basal insulin ± OADs|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
62249483|NCT04809311||Glucagon-like peptide-1 (GLP-1) ± Basal insulin (loose and fixed combination) ± OADs|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
62249484|NCT03881384||ctDNA level|ctDNA level during neoadjuant chemotherapy
62249485|NCT03614312||BMI 18-25 Pregnant Women|BMI 18-25 less than 36 weeks pregnant
62249486|NCT06489756|ACTIVE_COMPARATOR|Ambient air|Highlanders with HAPH will perform the echocardiography on ambient air at 3200m
62606926|NCT06237816|EXPERIMENTAL|Patient Education Intervention|"A multimedia educational series is designed to provide patient education on cancer clinical trials.~The following topics are addressed:~* What is a clinical trial?~* Types of clinical trials.~* Phases of clinical trials.~* Benefits and drawbacks.~* Costs.~* FAQs. This section covers common myths and clarifies these myths using a Q\&A format.~* How to join a clinical trial. Information about eligibility and informed consent.~* Clinical trial stories. Testimonies from oncology providers and patients. Each module is approximately 2-5 minutes, and they can be reviewed in the order/schedule preferred by the patient.~The overall program is 30 minutes to view including the videos. The tablet provided to patients provides additional benefits for participation."
62829198|NCT03077334||K-type|FDG uptake in pancreatic cancer is similar to that of kidney
62249487|NCT06489756|EXPERIMENTAL|10 L/min SOT through face mask|Supplemental oxygen therapy (SOT) at 10 L/min will be provided via face mask from oxygen concentrators
62829199|NCT03077334||non K-type|FDG uptake in pancreatic cancer is lower than that of kidney
62829200|NCT06388993|EXPERIMENTAL|Bilateral Hip Bone Marrow Collection|Collection of bone marrow aspirate from both hips. One collected using the Zimmer Biomet Biocue system and the other using the Marrow Cellution system.
62829201|NCT05176288|EXPERIMENTAL|Axitinib, Avelumab and Palbociclib|"During each 28 day (+/- 3 days) study cycle, all participants will receive:~* Axitinib: 2x Daily until it is determined participant must stop the drug~* Palbociclib: Taken 1x time per day on days 8-28 of each cycle until it is determined participant must stop the drug.~* Avelumab: Once every 2 weeks continued for up to 2 years or earlier if it is determined participant must stop the study drug"
62249488|NCT06320288||Children with cerebral palsy|"All children will undergo :~* A neuro-articular assessment~* A gait analysis on a walking track and with three inertial units to analyze the behavior of their trunk and center of mass during walking.~* Assessment of gross motor function~* Static posturography~* Functional assessment of the trunk~* Functional assessment of balance"
62249489|NCT06320288||Children with typical development|"All children will undergo :~* A neuro-articular assessment~* A gait analysis on a walking track and with three inertial units to analyze the behavior of their trunk and center of mass during walking.~* Static posturography~* Functional assessment of the trunk~* Functional assessment of balance"
62249490|NCT02716675|EXPERIMENTAL|Group 1: Low-Dose VRC01|Participants will receive an intravenous (IV) infusion of 10 mg/kg of VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
62249491|NCT02716675|EXPERIMENTAL|Group 2: High-Dose VRC01|Participants will receive an IV infusion of 30 mg/kg of VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
62249492|NCT02716675|PLACEBO_COMPARATOR|Group 3: VRC01 Placebo|Participants will receive an IV infusion of placebo for VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
62249493|NCT05483036||Persons with Parkinson's disease (PwPD)|
62249494|NCT04375787|ACTIVE_COMPARATOR|Statin group|100 patients were randomly assigned to receive atorvastatin (80 mg) just before coronary intervention
62249495|NCT04375787|PLACEBO_COMPARATOR|Placebo group|100 patients received placebo
62249496|NCT02901574|ACTIVE_COMPARATOR|tDCS plus computerized naming therapy|Anodal or cathodal tDCS, 2 milliamps (mA) plus computerized naming treatment for 15 sessions (20 minutes per each 45 minute treatment session) over the course of 3-5 weeks.The electrical current will be administered to the right cerebellum. The stimulation will be delivered at an intensity of 2 mA for a maximum of 20 minutes. Language therapy will be a computer delivered naming +picture matching task.
62249497|NCT02901574|SHAM_COMPARATOR|Sham plus computerized naming therapy|Sham tDCS plus computerized naming treatment for 15 sessions (20 minutes per each 45 minute treatment session) over the course of 3-5 weeks. Current will be administered in the in a ramp like fashion for 15-30 seconds but then the current is gradually decreased and drop to 0 mA. Language therapy will be a computer delivered naming +picture matching task.
62249498|NCT00813332|EXPERIMENTAL|1|Endostar combined with Docetaxel for Advanced NSCLC: All eligible patients will receive Endostar in combination with Docetaxel chemotherapy for 2 cycles (21 days for each cycle) and cases of good response(CR+PR+SD) will continue treatment for 2 cycles. Endostar treatment will continue after completion of first 4 cycles until disease progression.
62439298|NCT02132299|EXPERIMENTAL|Group 3(A)|Group 3: Two sub groups: 3A and 3B. Grp 3A (n=20) receives 5 vaccinations IV of 2.7x10\^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 3 will undergo the first CHMI by IV injection of 3.2x10\^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 3 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10\^3 PfSPZ Challenge (NF54).
62439299|NCT02132299|PLACEBO_COMPARATOR|Group 3(B)|Group 3: Two sub groups: 3A and 3B. Grp 3B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 3 will undergo the first CHMI by IV injection of 3.2x10\^3 PfSPZ Challenge (NF54).
62439300|NCT02132299|EXPERIMENTAL|Group 4|The fourth group will include 6 volunteers who will be unblinded and will receive 5 vaccinations of 2.7 x 10\^5 PfSPZ Vaccine by IV administration. Four vaccinations at 4 weeks intervals of 2.7x10\^5 PfSPZ will be given and the fifth dose will be administered 8 weeks after the 4th. Volunteers from Group 4 will start their vaccinations 48 hours after the four safety volunteers from Group 3 have received their first dose, at each dosing time point. This group will participate in only one CHMI assessment at 24 weeks to assess duration of protection at 24 weeks.
62439301|NCT02132299|PLACEBO_COMPARATOR|Group 5|The 5th group will be divided into 3 sub groups 5A, 5B, 5C, who will be screened and recruited to serve as unblinded controls for the 1st and 2nd CHMI at 3 and 24 weeks. They will participate only in the screening and 4 weeks follow up of the 1st and 2nd CHMI assessments. Group 5A (n=2) will be challenged at the time of the 3-week CHMI of Group 2. Group 5B (n=2) will be challenged at the time of the 3-week CHMI of Group 3. Groups 5A and 5B will supplement the 4 NS- injected volunteers as infectivity controls, totaling 6 altogether. Group 5C (n=6) will be challenged at the time of the 24-week CHMI for Groups 3 and 4.
62439302|NCT04551482|EXPERIMENTAL|Oxytocin|Oxytocin nasal spray (24 IU nasal spray, 4 times per day for 12 weeks)
62439303|NCT04551482|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray (24 IU nasal spray, 4 times per day for 12 weeks)
62249499|NCT00813332|PLACEBO_COMPARATOR|2|Docetaxel combined with placebo for Advanced NSCLC: All eligible patients will receive placebo in combination with Docetaxel chemotherapy for 2 cycles (21 days for each cycle) and cases of good response(CR+PR+SD) will continue treatment for 2 cycles. Placebo will continue after completion of first 4 cycles until disease progression.
62606927|NCT06237816|EXPERIMENTAL|Provider Education Intervention|"The provider education intervention will consist of 3 provider informational sessions conducted individually. These individual provider sessions will be conducted by teleconference by the research team and scheduled according to provider's availability.~Provider workshops are designed to provide both a background on clinical trial infrastructure in Hawaii and resources for additional information. The content of these sessions includes:~* An overview of clinical trials infrastructure in Hawaii.~* Available trials in Hawaii. At each informational session, the research team will review available trials and any new/upcoming trials with the provider.~* An overview of how to get involved in clinical trials. As experience and background re: clinical trials may vary across providers, the content of these informational sessions will be tailored to each provider. Following the initial session, 2 additional meetings will be scheduled in 4-6 months as follow-up sessions."
62606928|NCT00000774|EXPERIMENTAL|1|Patients who will receive rgp120/HIV-1MN
62606929|NCT00000774|EXPERIMENTAL|2|Patients who will receive rgp120/HIV-1SF2
62606930|NCT00000774|PLACEBO_COMPARATOR|3|Patients who will receive the placebo counterpart of 120/HIV-1MN
62606931|NCT00000774|PLACEBO_COMPARATOR|4|Patients who will receive the placebo counterpart of rgp120/HIV-1SF2
62829202|NCT03416985|ACTIVE_COMPARATOR|Manual Toothbrush|Patients will be asked to use a manual toothbrush for 30 days
62829203|NCT03416985|ACTIVE_COMPARATOR|Sonic Toothbrush|Patients will be asked to use a sonic toothbrush for 30 days
62249500|NCT03700151|EXPERIMENTAL|Children with SSD|Participants will receive a piloted treatment programme for children with severe speech sound disorders, especially childhood apraxia of speech.
62249501|NCT06232512|EXPERIMENTAL|Exploratory Arm|Individuals will complete standardized balance and walking tasks with and without sensory substitution from the haptic device system.
62249502|NCT02912299||Septic patients|Patients admitted to the ICU that fulfill the criteria for the systemic inflammatory response syndrome in the presence of a(n expected) new infection. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
62249503|NCT02912299||CABG patients|Patients admitted to the ICU after coronary artery bypass grafting. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
62249504|NCT02912299||Patients before hip replacement|Patients that will undergo a hip replacement because of arthrosis. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
62249505|NCT05406843||Preoperative cognitive status of participants undergoing open heart surgery|"Detection of postoperative cognitive impairment is difficult and it starts with testing in the preoperative period.~In this study, it was aimed to determine postoperative cognitive impairment by comparing cognitive functions by using Minimental status test in the preoperative period in participants scheduled for open heart surgery for one year. It was planned to compare the obtained data in terms of participants undergoing valve and coronary bypass surgery, age, gender, diabetes, kidney disease, chronic obstructive pulmonary disease (COPD), surgical characteristics, bypass time, and crossclamping time."
62249506|NCT05406843||Postoperative cognitive status of participants undergoing open heart surgery|Detection of postoperative cognitive impairment is difficult and it starts with testing in the preoperative period. In this study, it was aimed to determine the postoperative cognitive impairment by comparing it with the cognitive functions in the preoperative period using the Minimental status test in the postoperative period in participants scheduled for open heart surgery for a year. It was planned to compare the obtained data in terms of participants undergoing valve and coronary bypass surgery, age, gender, diabetes, kidney disease, chronic obstructive pulmonary disease (COPD), surgical characteristics, bypass time, and crossclamping time.
62439304|NCT05208411|EXPERIMENTAL|ImPACT group|Group of children at elevated likelihood of ASD who will receive the ImPACT intervention
62439305|NCT05208411|NO_INTERVENTION|No intervention group|Group of children at elevated likelihood of ASD who won't receive any intervention
62439306|NCT01774006||Group culture|Embryos cultured in groups of 2-10
62439307|NCT01774006||Individual culture|Embryos cultured individually
62439308|NCT02579083|EXPERIMENTAL|Segment A: Single MB66 Administration|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
62439309|NCT02579083|PLACEBO_COMPARATOR|Segment B: Repeated Administrations Placebo Film|The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
62439310|NCT02579083|EXPERIMENTAL|Segment B: Repeated Administrations MB66|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
62439311|NCT01573247|EXPERIMENTAL|AKN-028|
62439312|NCT00720642||PSAP|This is the population of patients in whom surgical intervention could possibly be avoided. These patients will be those in whom all imaging evidence (mammographic or sonographic) was removed during the Intact BLES procedure, and in whom a definitive diagnosis of ADH could be made using the pathology assessment criteria outlined in the protocol.
62439313|NCT00720642||NPSAP|Patients with a pathology diagnosis of ADH in whom all imaging evidence (mammographic or sonographic) of the target lesion was NOT removed OR in whom a definitive diagnosis of ADH COULD NOT be made by implementing the pathology criteria for evaluation outlined in the protocol AND patients with a diagnosis of DCIS will undergo open surgical excision and will be analyzed separately from the PSAP group.
62439314|NCT04526678|EXPERIMENTAL|Iron supplements|The intervention group will ingest 27 mg iron supplement per day for three months while the control group will not ingest iron supplements.
62439315|NCT04526678|NO_INTERVENTION|Control group|The control group will not ingest iron supplements.
62439316|NCT00633152|EXPERIMENTAL|Ceftaroline|Intramuscular every 12 hours
62439317|NCT00633152|ACTIVE_COMPARATOR|linezolid plus optional aztreonam|Intravenous every 12 hours
62439318|NCT01745328|ACTIVE_COMPARATOR|LVX-AMX|subject is treated with LAV-AMX, then followed by placebo.
62439319|NCT01745328|ACTIVE_COMPARATOR|TCM treatment|subject is treated with TCM
62829204|NCT03416985|ACTIVE_COMPARATOR|Pulsating Toothbrush|Patients will be asked to use a pulsating toothbrush for 30 days
62829205|NCT04859907|EXPERIMENTAL|Clamp-like system|
62249507|NCT03274583||Study Group|Patients being treated in the wards of Heart Center and Acute Internal Medicine of Turku University Hospital, Turku Finland between April and September 2017 with atrial fibrillation as the prevalent rhythm.
62439320|NCT05566379|EXPERIMENTAL|Mindfulness Intervention|All participants will attend a virtual 6-week course entitled Mindful Awareness Practices (MAPs) created, hosted and led by expert facilitators from the Mindful Awareness Research Center at UCLA. Participants will learn Mindful concepts and a variety of Mindfulness practices. This intervention will consist of a mix of lecture, practice, group feedback, and discussion regarding mindfulness. Mindfulness is the mental state achieved by focusing one's awareness on the present while acknowledging and accepting any feelings, thoughts, or bodily sensations. MAPs classes meets weekly for two hours per week for six weeks. Participants are encouraged to complete some daily meditation practice starting at five minutes a day and working up to 20 minutes daily by the end of the course.
62439321|NCT00860106|OTHER|Follow up|"ED score and DDimer level of patients who have stopped their VKA treatment (after the first or the second previous proximal VTE).~Phone follow up for 2 years."
62439322|NCT03764059|EXPERIMENTAL|Investigational device/experimental group: Filtek™ Bulk Fill Posterior Restorative|"The investigational device, Filtek™ Bulk Fill Posterior Restorative, was used for class 1 or 2 restorative in experimental group. The clinical assessments were performed immediately after restoration and included restoration retention/fracture, marginal fracture, anatomic form/marginal integrity, proximal contact, color match, surface texture/roughness, staining, marginal discoloration/secondary caries and pulp vitality.~Subjects returned to the site for follow up visits at 1 week and 1 year postoperative for the same clinical assessments."
62439323|NCT03764059|ACTIVE_COMPARATOR|Control device/control group: Filtek™ Z350XT Universal Restorative|"The control device, Filtek™ Z350XT Universal Restorative, which was approved by CFDA in 2010 and has been in the market for 5 years with some validated clinical data, was used for class 1 or 2 restorative in control group. The clinical assessments were performed immediately after restoration and included restoration retention/fracture, marginal fracture, anatomic form/marginal integrity, proximal contact, color match, surface texture/roughness, staining, marginal discoloration/secondary caries and pulp vitality.~Subjects returned to the site for follow up visits at 1 week and 1 year postoperative for the same clinical assessments."
62439324|NCT01889862|ACTIVE_COMPARATOR|BMN165 20mg/day|BMN165 20mg/day self-administered daily
62439325|NCT01889862|PLACEBO_COMPARATOR|20 mg/day Placebo|20 mg/day Placebo self-administered daily
62439326|NCT01889862|ACTIVE_COMPARATOR|BMN165 40mg/day|BMN165 40mg/day self-administered daily
62439327|NCT01889862|PLACEBO_COMPARATOR|40 mg/day Placebo|40 mg/day Placebo self-administered daily
62606932|NCT03989934|EXPERIMENTAL|The Mind in Action|The Mind in Action is a mindfulness intervention developed by the Holistic Life Foundation (HLF), a Baltimore-based non-profit organization. The curriculum will be delivered over approximately 40 sessions and will follow HLF's typical program modifications for high school students (i.e., sustained focus on breath work and meditation). Each program session will include an initial exercise of focusing on the breath to center oneself, followed by the introduction and practice of different breathing techniques (e.g., rhythmic breathing) that enhance calmness and reduce physiological arousal, and concluding with a brief guided meditation. Instructors will describe benefits of the practices for health and stress management. Participants are given assignments between sessions to reinforce lessons (e.g., breathing exercises or periods of meditation).
62623501|NCT04962087|NO_INTERVENTION|Psychoeducation Control|Participants allocated to the Control group will receive a version of the Health enSuite Insomnia app that contains a static psychoeducation module. It will contain information related to insomnia and its treatment. Topics covered will include a brief description of cognitive behavioural therapy for insomnia.
62829206|NCT04859907|ACTIVE_COMPARATOR|Plates and screws|
62829207|NCT05419050|EXPERIMENTAL|treatment|treatment arm
62249508|NCT03274583||Control group|Patients being treated in the wards of Heart Center and Acute Internal Medicine of Turku University Hospital, Turku Finland between April and September 2017 with sinus rhythm as the prevalent rhythm.
62439328|NCT03562299|EXPERIMENTAL|Experimental|Reconstruction of the Anterior Cruciate Ligament (ACL) using OrthoPure™ XT in patients with a partial or complete tear of the Anterior Cruciate Ligament (ACL)
62829208|NCT05465317||Empagliflozin initiators|Patient with type 2 diabetes, with or without Chronic Kidney Disease (CKD), who initiated Empagliflozin between January 1, 2016 and December 31, 2020.
62829209|NCT05465317||Dipeptidyl peptidate-4 inhibitor (DPP4i) initiators|Patient with type 2 diabetes, with or without Chronic Kidney Disease (CKD), who initiated dipeptidyl peptidate-4 inhibitor (DPP4i) between January 1, 2016 and December 31, 2020.
62829210|NCT06594432|OTHER|MCD, BN2, and N1 subtypes|
62829211|NCT06594432|OTHER|EZB, A53, and other gene subtypes|
62249509|NCT01931787|EXPERIMENTAL|Treatment (CPI-613)|Patients receive CPI-613 IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62439329|NCT01249339|ACTIVE_COMPARATOR|General 1 g pouch|Oral pouch 0.3-1g, single dose. One pouch administered over 30 minutes.
62606933|NCT03989934|ACTIVE_COMPARATOR|Healthy Topics|Adapted from the Glencoe Health Curriculum (McGraw Hill), Healthy Topics is designed to control for the effects of a positive adult, time and attention, a small group learning environment, engaged instruction, and interesting material. The Healthy Topics curriculum has been successfully implemented as an effective active control condition, with student engagement and participation comparable to the intervention arm. The curriculum includes information about nutrition, exercise, sleep, drug use, and other topics related to physical health.
62606934|NCT01047332|ACTIVE_COMPARATOR|Uncovered Wallstent|Endoscopically-placed biliary self-expanding metal stent (SEMS) (uncovered type).
62606935|NCT01047332|EXPERIMENTAL|Partially Covered Wallstent|Endoscopically-placed biliary self-expanding metal stent (SEMS) (partially covered type).
62606936|NCT04336462|EXPERIMENTAL|oxyhydrogen|conventional treatment + hydrogen/ oxygen inhaled
62606937|NCT04336462|EXPERIMENTAL|oxygen|conventional treatment + oxygen inhaled
62606938|NCT05899075|EXPERIMENTAL|group A|
62606939|NCT05899075|PLACEBO_COMPARATOR|group B|
62606940|NCT03309696|EXPERIMENTAL|tDCS and 1 Hz rTMS delivered over TC|Participants receive sham and active 2mA tDCS over the temporal cortex (TC) prior to receiving sham and active 1 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC. .
62606941|NCT03309696|EXPERIMENTAL|tDCS and 10Hz rTMS delivered over TC|Participants receive sham and active 2mA tDCS over the temporal cortex (TC) prior to receiving sham and active 10 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
62249510|NCT04712396|EXPERIMENTAL|Capivasertib + Itraconazole|Subjects will receive a single oral dose of capivasertib on Day 1 during treatment period 1, itraconazole on Days 3, 4, and 5 during treatment period 2, and single oral dose of capivasertib plus a dose of itraconazole on Day 6, followed by itraconazole alone on Day 7 during treatment period 3.
62439330|NCT01249339|ACTIVE_COMPARATOR|Catch Licoice 1 g pouch|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
62439331|NCT01249339|ACTIVE_COMPARATOR|Catch Licorice Mini 0.5 g pouch|Oral pouch 0.5g, single dose. One pouch administered over 30 minutes.
62606942|NCT03309696|EXPERIMENTAL|tDCS over DLFC and 1 Hz rTMS over TC|Participants receive sham and active 2mA tDCS over the dorsolateral frontal cortex (DLFC) prior to receiving sham and active 1 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
62606943|NCT03309696|EXPERIMENTAL|tDCS over DLFC and 10 Hz rTMS over TC|Participants receive sham and active 2mA tDCS over the dorsolateral frontal cortex (DLFC) prior to receiving sham and active 10 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
62606944|NCT02283736|EXPERIMENTAL|Periodontal treatment, Probitic|Periodontal treatment (scaling and root planning) and one tablet containing Lactobacillus rhamnosus SP1 per day during 3 months.
62606945|NCT02283736|PLACEBO_COMPARATOR|Periodontal treatment, talc powder tab|Periodontal treatment (scaling and root planning) and one tablet containing talc powder per day during 3 months
62606946|NCT00737893|EXPERIMENTAL|Erythropoietin (EPO)|20,000 units of EPO given on the day before surgery, the day of surgery, and the day after surgery.
62606947|NCT00737893|PLACEBO_COMPARATOR|Placebo|Placebo doses given the day before surgery, the day of surgery, and the day after surgery.
62606948|NCT04926922||HONOR TB participants with positive IGRA and/or TST during initial phase|Adult participants who who tested positive on IGRA and or TST during initial phase and meet the study-specific eligibility criteria.
62606949|NCT00671827||Robotic Gynecologic Surgery|Patients who have undergone or will undergo a robotic-assisted gynecologic procedure.
62606950|NCT04560621|EXPERIMENTAL|MAPS+|
62606951|NCT04560621|NO_INTERVENTION|Standard of Care|
62606952|NCT03186859|ACTIVE_COMPARATOR|Roux-en-Y Gastric Bypass (RYGB) surgery|
62606953|NCT03186859|ACTIVE_COMPARATOR|Sleeve Gastrectomy (SG) surgery|
62606954|NCT03259672|ACTIVE_COMPARATOR|Sevoflurane|
62606955|NCT03259672|EXPERIMENTAL|Desflurane|
62606956|NCT06355648||Emergency Care Advanced Clinical Practitioners|These are nurses, paramedics, or allied health professionals who have undertaken an MSc and work in an Emergency Department.
62606957|NCT06355648||Clinical Colleagues of ACPs|These are staff who work directly with ACPs in the ED; they may be doctors, nurses, or allied health professionals.
62606958|NCT06355648||Non-Clinical Colleagues|These staff work with Advanced Clinical Practitioners but not in the clinical environment. Examples may be local managers or directors of the organisation.
62606959|NCT06730802|EXPERIMENTAL|PCSK9 inhibitor|the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later
62249511|NCT00510991|EXPERIMENTAL|A|NIPPV
62249512|NCT02029820|ACTIVE_COMPARATOR|RenalGuard|Hydration with the device renalguard
62249513|NCT02029820|NO_INTERVENTION|Saline|Hydration with saline 1ml/Kg/h for 12h
62249514|NCT01358760|PLACEBO_COMPARATOR|Placebo|
62249515|NCT01358760|EXPERIMENTAL|0.25% DHEA|
62249516|NCT01358760|EXPERIMENTAL|0.5% DHEA|
62249517|NCT00594516|EXPERIMENTAL|001|tapentadol (CG5503) Immediate Release (IR) Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100 150 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second,tapentadol (CG5503) Immediate Release IR 21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period
62249518|NCT00594516|EXPERIMENTAL|002|tapentadol (CG5503) Extended Release (ER) During 2 double blind periods: Tapentadol ER 100 150 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second
62249519|NCT01524133|ACTIVE_COMPARATOR|Sertraline + enhanced medication management (SERT/EMM)|24 weeks of sertraline + enhanced medication management
62249520|NCT01524133|ACTIVE_COMPARATOR|Prolonged Exposure + sertraline (PE/SERT)|Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline
62249521|NCT01524133|ACTIVE_COMPARATOR|Prolonged Exposure + placebo (PE/PLB)|Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo
62249522|NCT04167748|EXPERIMENTAL|PGT-A transfer|Transfer of single chromosomally normal (euploid) blastocyst after PGT-A
62606960|NCT06730802|SHAM_COMPARATOR|Statin|the control group will receive standard statin therapy.
62606961|NCT01746238|EXPERIMENTAL|Treatment Arm|Bevacizumab, metronomic doxorubicin and radiation therapy
62606962|NCT01094652|EXPERIMENTAL|Whole grain diet|Participants in this group will be given whole grain snacks on school days and food packages consisting of whole grain breads, breakfast cereals, rice, snack foods, and pasta to replace their typical grains consumed at home.
62606963|NCT01094652|ACTIVE_COMPARATOR|Refined grain diet|Participants in this group will be given refined grain snacks on school days and food packages consisting of refined grain breads, breakfast cereals, rice, snack foods, and pasta to replace their typical grains consumed at home.
62606964|NCT05865275|EXPERIMENTAL|Test group|it is the group for testing the effectiveness of low power of a diode laser on the onset of dental sensitivity
62249523|NCT04167748|NO_INTERVENTION|Untested blastocyst transfer|Transfer of single untested blastocyst based on embryo morphology criteria.
62249524|NCT02194062|ACTIVE_COMPARATOR|fluticasone nasal spray|Group one will be prescribed fluticasone nasal spray ( to use 2-50 mcg sprays to each nostril two times per day)
62249525|NCT02194062|ACTIVE_COMPARATOR|budesonide respule in head upright|Group two will be prescribed budesonide respules (0.5 mg/2mL) to instill into each nostril in the upright position two times per day
62249526|NCT02194062|ACTIVE_COMPARATOR|budesonide head forward|Group three will be prescribed budesonide respules (0.5 mg/2mL) to use instill into each nostril in the head forward position two times per day with their head angled downwards by having their head lean forward off the side of a bed.
62249527|NCT01761045|ACTIVE_COMPARATOR|Soup 1|Consommé soup with Monosodium L-Glutamate (MSG)
62249528|NCT01761045|ACTIVE_COMPARATOR|Soup 2|Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
62249529|NCT01761045|PLACEBO_COMPARATOR|Soup 3|Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
62249530|NCT02170675|EXPERIMENTAL|Dabigatran etexilate + Ketoconazole|"Period 1 - Dabigatran etexilate~Period 2 - Dabigatran etexilate and single dose of 400 mg Ketoconazole on Day 8 and 9~Period 3 - Dabigatran etexilate and multiple doses of 400 mg Ketoconazole on Day 10 to 16"
62249531|NCT02745366|EXPERIMENTAL|BFPSC+|The combination of BFPSC+FDBA+PRF is utilized in cortical tenting technique with block graft obtained from lateral ramus for posterior mandible augmentation procedure.
62249532|NCT02745366|ACTIVE_COMPARATOR|BFPSC-|The combination of FDBA+PRF is utilized in cortical tenting technique with block graft obtained from lateral ramus for posterior mandible augmentation procedure
62249533|NCT01817751|EXPERIMENTAL|Treatment (sorafenib tosylate, valproic acid, sildenafil)|"* Sorafenib 400 mg orally twice a day;~* Valproic acid (to levels ≥ Lower Level of Normal (LLN) orally twice a day;~* Sildenafil 50 mg orally twice a day~A cycle consists of 4 weeks.~\*The first 6 patients evaluable for qualifying toxicity assessment will be treated as a safety lead-in; enrollment will be gated (the first 3 evaluable patients must complete 4 weeks of the combination therapy before the next 3 patients start combination treatment on protocol)"
62249534|NCT04360499|EXPERIMENTAL|Low-weight-high-repetitions training|Low-weight-high-repetitions (LWHR) refer to a specific form of resistance exercise which utilizes low weights and very high repetitions. Participants will be exercised 3 times per week for 3 months in small groups.
62249535|NCT04360499|ACTIVE_COMPARATOR|Pilates Training|Pilates exercises focused on breathing, concentration, control and precision. Participants will be exercised 3 times per week for 3 months in small groups
62606965|NCT05865275|PLACEBO_COMPARATOR|Placebo group|this represents the control group with tooth bleaching without preliminary laser treatment
62249536|NCT04678596|ACTIVE_COMPARATOR|EonAligner|Patients in the EonAligner group were given a single thickness and hardness aligner and were asked to use the same it for 3 weeks.
62249537|NCT04678596|ACTIVE_COMPARATOR|Clearfix|In the Clearfix group, the patients were given three different thickness and hardness aligner and they were asked to use each aligner for one week from soft to hard.
62249538|NCT03076931|EXPERIMENTAL|Study: Airway Reconstruction Patients|These participants have significant airway abnormalities that require invasive surgery, such as Laryngotracheoplasty, to rectify, and whose voice quality may suffer as a result of the surgery. The goal of this study is to improve voice outcomes of these patients, and their clinical data will be collected.
62249539|NCT03076931|EXPERIMENTAL|Control: Normal Airway Patients|These participants have normal airways and voice who will undergo a microlaryngoscopy and voice evaluation, the data from which will be compared to study patients.
62249540|NCT01279850||Pregabalin (Lyrica) capsule|"Patients administered Pregabalin capsule."
62249541|NCT03725514|ACTIVE_COMPARATOR|conventional|Conventional blood clot technique
62249542|NCT03725514|EXPERIMENTAL|PRF|Platelet Rich Fibrin Technique
62249543|NCT03890991|EXPERIMENTAL|SCOPE-DM only|Participation in SCOPE-DM programme without supply of glucometers and accessories
62249544|NCT03890991|ACTIVE_COMPARATOR|SCOPE-DM with 3 months' supply of glucometer|Participation in SCOPE-DM programme with 3 months' supply of glucometers and accessories
62249545|NCT03890991|ACTIVE_COMPARATOR|SCOPE-DM with 6 months' supply of glucometer|Participation in SCOPE-DM programme with 6 months' supply of glucometers and accessories.
62606966|NCT01585610|EXPERIMENTAL|DVD Program|
62606967|NCT01585610|ACTIVE_COMPARATOR|Standard Care Printed Materials|
62606968|NCT01569256|ACTIVE_COMPARATOR|Cabergoline administered group|"The patients in this group will have cabergoline (Dostinex tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days) for prevention of OHSS.~All patients were administered long luteal protocol for ovulation induction."
62606969|NCT01569256|NO_INTERVENTION|Control arm|"The patients in the control group had no manipulation for prevention of OHSS and age-, BMI-matched with the active comparator group.~All patients were administered long luteal protocol for ovulation induction."
62606970|NCT03572400|EXPERIMENTAL|Gemcitbine/Durvalumab|"Neoadjuvant CCRT with Gemcitbine/Durvalumab~+Adjuvant Gemcitabine/Durvalumab Total 6 cycles, after that, Durvalumab q4wks up to total 1 year"
62249546|NCT03890991|NO_INTERVENTION|Control|Usual care by healthcare provider/ clinics of Tsao Foundation without participation in SCOPE-DM programme
62249547|NCT06007365||Z5m Dental Implants|
62249548|NCT00381563|OTHER|Intervention to placebo|Participants will wear the patellofemoral realigning knee brace for 6 weeks, followed by the non-aligning knee brace for 6 weeks.
62249549|NCT00381563|OTHER|Placebo to intervetion|Participants will wear the non-aligning knee brace for 6 weeks, followed by the patellofemoral realigning knee brace for 6 weeks.
62249550|NCT05861687|EXPERIMENTAL|Esomeprazole in combination with Amoxicillin and Clarithromycin|Esomeprazole : once a day per oral; 0.4 mg/kg Amoxicillin: thrice a day per oral; 25 mg/kg Clarithromycin: twice a day per-oral; 7.5 mg/kg
62249551|NCT05861687|ACTIVE_COMPARATOR|Lansoprazole in combination with Amoxicillin and Clarithromycin|Lansoprazole: once a day per oral; 15 mg if body weight \< 30 kg and 30 mg if body weight \> 30 kg Amoxicillin: thrice a day per oral; 25 mg/kg Clarithromycin: twice a day per-oral; 7.5 mg/kg
62606971|NCT04151485|EXPERIMENTAL|Mind/Body Group|All persons allocated to the intervention group will take part in a 10-week Mind/Body skills development fertility program parallel with fertility workup and treatment.
62606972|NCT04151485|ACTIVE_COMPARATOR|Support Group|All persons allocated to the comparison intervention group will take part in a 10-week fertility support program parallel with fertility workup and treatment.
62606973|NCT01600274|EXPERIMENTAL|Diena|Dienogest-Ethinyl Estradiol (test product) tablet
62606974|NCT01600274|ACTIVE_COMPARATOR|Valette®|Dienogest-Ethinyl Estradiol (reference product) tablet
62249552|NCT06465719|EXPERIMENTAL|Tract-based AI Robot Guiding System Group|Patients will be operated on minimally invasive puncture and aspiration using Tract-based AI Robot guidance System
62249553|NCT06465719|SHAM_COMPARATOR|Conservative Group|Patients will be managed with guideline-based medications without surgery
62606975|NCT02919267|OTHER|Intra-pulmonary pressure determination|A pressure tubing catheter will be connected to the luerlock adaptor of the bronchial blocker (BB) or to the adaptor located on the side of the occluding system mounted at the extremity of the double lumen tube (DLT). The catheter will then be connected to a differential pressure transducer (AD Instruments, Colorado Springs, CO, USA), allowing direct visualisation of the bronchial pressures. Along with intra-bronchial pressure, esophageal pressure will also be measured to eliminate the pressure generated by the positive pressure of the ventilated lung (Adult esophageal balloon catheter, Cooper Surgical, Trumbull, CT, USA). Intra-bronchial pressures will be measured at end-inspiration and end-expiration.
62606976|NCT02919267|OTHER|Volume determination|A one-liter bag (Roxon, Etobicoke, ON, Canada) will be filled precisely with 300 mL of air with the use of a calibrated syringe of 3 liters (Hans Rudolph inc, Shawnee, Kansas, United States), through a three-way valve (Hans Rudolph inc, Shawnee, Kansas, United States). Following the filling of the bag, it will be connected to the non-ventilated lumen of the double lumen tube (DLT) or to the bronchial blocker (BB) through the three-way connector. At the end of the observation period, the collector bag will be connected to the calibrated syringe and will emptied from its residual volume.
62606977|NCT06613360|EXPERIMENTAL|Part A Dose Escalation|Patients with SLE treated with CLN-978 in dose escalation cohorts
62606978|NCT06613360|EXPERIMENTAL|Part B Further Dose Evaluation|Further evaluation of CLN-978 treatment of patients with SLE
62249554|NCT02495220|EXPERIMENTAL|subtenon block Group (SB)|received SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
62249555|NCT02495220|EXPERIMENTAL|intravenous dexmedetomidine Group(IV)|received 1µ/kg IV dexmedetomidine after induction of anesthesia
62606979|NCT01870804|ACTIVE_COMPARATOR|Rosuvastatin|Rosuvastatin (40 mg on-admission followed by 20 mg/day) until discharge; then 20 mg/day (10 mg/day if creatinine clearance \< 30 ml/min)
62249556|NCT04030039||chronic hepatitis B patients during the immune control period|Patients with chronic HBV infection during the immune control period do not have any clinical treatment intervention cohort
62249557|NCT04030039||Therapy group A|After chronic hepatitis B patients were treated with interferon, HBsAg level of these patients \< 100 IU / ml, and they continued to be treated with interferon
62249558|NCT04030039||Therapy group B|After chronic hepatitis B patients were treated with interferon, HBsAg level of these patients \< 100 IU / ml, and they stopped to be treated with interferon
62249559|NCT04030039||Therapy group C|After chronic hepatitis B patients were treated with interferon, HBsAg level of these patients \< 100 IU / ml, and they continued to be treated with sequential nucleoside analogues
62249560|NCT04030039||Therapy group D|After chronic hepatitis B patients were treated with nucleoside analogues, HBsAg level of these patients \< 100 IU / ml, and they continued to be treated with sequential interferon
62249561|NCT04030039||Therapy group E|After chronic hepatitis B patients were treated with nucleoside analogues, HBsAg level of these patients \< 100 IU / ml, and they continued to be treated with the nucleoside analogues
62249562|NCT06134050|EXPERIMENTAL|55% correction|HTO using PSI targeted at 55% correction axis
62606980|NCT01870804|ACTIVE_COMPARATOR|Atorvastatin|atorvastatin (80 mg on-admission followed by 40 mg/day before and after discharge)
62249563|NCT06134050|ACTIVE_COMPARATOR|62% correction|HTO using PSI targeted at 62% correction axis
62249564|NCT04029181|EXPERIMENTAL|Dose finding cohort|In part A of this imaging trial, a dose finding study will be performed to establish safety, to assess the appropriate protein dose for PET-scanning and to assess the appropriate PET scanning interval.
62249565|NCT04029181|EXPERIMENTAL|Feasibility cohort|The purpose of part B of the study is to analyze the PK of the anti-CD8 imaging agent in patients before and during treatment with checkpoint inhibitors.
62829212|NCT06654921|EXPERIMENTAL|RIC group|Subjects in the intervention group will receive remote ischemic conditioning and standard background medical treatment.
62829213|NCT06654921|SHAM_COMPARATOR|Sham group|Subjects in the placebo group will receive sham remote ischemic conditioning and standard background medical treatment.
62829214|NCT01798043|EXPERIMENTAL|Septal RV lead with >50% pacing (B1)|Cardiac MRI with pacemaker stimulation
62829215|NCT01798043|EXPERIMENTAL|Septal RV lead with <50% pacing (B2)|Cardiac MRI with and without pacemaker stimulation
62829216|NCT01798043|EXPERIMENTAL|Apical RV lead with >50% pacing (A1)|Cardiac MRI with pacemaker stimulation
62249566|NCT00201669|EXPERIMENTAL|Arm I|
62249567|NCT01164566|EXPERIMENTAL|Arm I|Patients undergo transnasal esophagoscopy at baseline and 3 months following completion of radiation therapy and/or chemotherapy.
62606981|NCT05588245|ACTIVE_COMPARATOR|Comparison Group (Standard of Care)|Participants will receive the standard of care.
62829217|NCT01798043|EXPERIMENTAL|Apical RV lead with <50% pacing (A2)|Cardiac MRI with and without pacemaker stimulation
62047067|NCT01723722|ACTIVE_COMPARATOR|1 (Phenobarbital and Methadone)|"The following is a dosing guide for methadone:~1. The neonatal concentration is 1 mg/ml of methadone. It is administered orally every 12 hours.~2. For the first 24 hours, doses will be prescribed every 6 hours using a sliding scale in response to the last NAS score:~   NAS Score Methadone dose 8-11 0.05 mg/kg/dose 12-15 0.1 mg/kg/dose~   ≥16 0.15 mg/kg/dose~3. Maximum dose of methadone will be 0.15 mg/kg/dose.~4. After the first 24 hours of treatment, the total methadone dose will be summed and that dose divided into two doses, given 12 hours apart. For the following 24 hours, additional doses may be given every 6 hours as needed and added to the next 24 hour's doses divided every 12 hours, until NAS scores are consistently \<8 for 48 hours.~5. If at any pointthe maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the dDTO arm."
62047068|NCT01723722|ACTIVE_COMPARATOR|2 (Phenobarbital and Diluted Deodorized Tincture of Opium)|"The following is a dosing guide for dDTO:~1. The neonatal concentration is 1:24 dilution for a concentration of 0.4%, equivalent to 0.4 mg/ml of morphine. It is administered orally every 4 hours.~2. The starting dose will be determined using a sliding scale in response to the last NAS score before starting.~   NAS Score Starting dDTO dose 8-11 0.4 mg/kg/day 12-15 0.6 mg/kg/day~   ≥16 0.8 mg/kg/day~3. The maximum dose of DTO will be 0.8 mg/kg/day.~4. After the first 24 hours of treatment, if the NAS scores are still ≥8, the dose will be increased to the next level.~5. If at any point the maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the methadone arm."
62047069|NCT00522301|EXPERIMENTAL|Oral Sorafenib (BAY43-9006)|Sorafenib is supplied as 200-mg tablets. Sorafenib will be administered as 400 mg orally daily x 28 days (continuous). One cycle = 28 days. There is no planned treatment interruption between cycles. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating). In the absence of intolerable toxicity, a patient may continue to receive treatment with sorafenib until disease progression, or until 24 months have elapsed.
62047070|NCT02096523|EXPERIMENTAL|platelet disease|patients with inherited platelet disorders
62047071|NCT02096523|EXPERIMENTAL|Healthy|Healthy family members of patients with inherited platelet disorders
62047072|NCT01096992|EXPERIMENTAL|Phase 1 20 mg/m^2|Bendamustine, Fludarabine + Rituximab
62047073|NCT01096992|EXPERIMENTAL|Phase 2|Bendamustine 30 mg/m\^2 by vein (fixed), Days 1,2,3 + Fludarabine + Rituximab
62606982|NCT05588245|EXPERIMENTAL|Intervention Group|Participants will receive a community-based patient navigator with 3 prenatal contacts and 5 postpartum contacts; during each contact, the community-based patient navigator will offer health assessment and education, along with group education and social support.
62829218|NCT01720108|ACTIVE_COMPARATOR|rivaroxaban|rivaroxaban 10mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients
62829219|NCT01720108|EXPERIMENTAL|ASA|ASA 81mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients
62249568|NCT01454245|EXPERIMENTAL|001|"JNJ-39439335 Part 1:Type=1 unit=mg number=25 form=capsule route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.~or Part 1:Type=2 unit=mg number=12.5 form=capsule route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods.,JNJ-39439335 Part 2:Type=2 unit=mg number=12.5 form=capsule route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods."
62249569|NCT03923751||Polish Hospitals|Hospitals with anesthesia or intensive care practices
62249570|NCT02674698|OTHER|VA Integrated Service Networks Group 1|Access to the CNH Dashboard Step 1
62606983|NCT00979420||HIV treatment|
62829220|NCT06600646||Refractory or Unexplained Chronic Cough|
62829221|NCT06600646||Healthy Controls|
62829222|NCT05985499|EXPERIMENTAL|"Dumpling suture for ileostomy"|The stoma is fixed with sutures in a skin fold method, and the incision is progressively reduced in a process similar to the process of folding and pinching the Chinese small dumplings. This procedure may reduce stoma complications by progressively reducing the incision and realizing the effect of hiding the skin incision.
62829223|NCT05985499|OTHER|Traditional suture for ileostomy|The stoma was fixed at the skin using traditional sutures. The incision is narrowed by 2-3 interrupted sutures at the distal and proximal ends of the skin incision on the abdominal wall. The stoma is then fixed at the right lower abdominal incision with sutures.
62829224|NCT04683484|EXPERIMENTAL|Low dose of Nanocovax|Intramuscular injection, two doses given 28 days apart
62829225|NCT04683484|EXPERIMENTAL|Middle dose of Nanocovax|Intramuscular injection, two doses given 28 days apart
62829226|NCT04683484|EXPERIMENTAL|High dose of Nanocovax|Intramuscular injection, two doses given 28 days apart
62829227|NCT04683484|PLACEBO_COMPARATOR|Placebo|Intramuscular injection, two doses given 28 days apart
62829228|NCT05376150|EXPERIMENTAL|XEN1101 10 mg|During the double blind treatment period (42 days), subjects will take 1 capsule of XEN1101 10 mg, orally with food, per day
62829229|NCT05376150|EXPERIMENTAL|XEN1101 20 mg|During the double blind treatment period (42 days), subjects will take 1 capsule of XEN1101 20 mg, orally with food, per day
62829230|NCT05376150|PLACEBO_COMPARATOR|placebo|During the double blind treatment period (42 days), subjects will take 1 capsule of placebo, orally with food, per day
62829231|NCT04197245|EXPERIMENTAL|group on treatment|saline injection has been given intradermal in atrophic scars of acne on face.
62829232|NCT05992922|EXPERIMENTAL|IC265 Ophthalmic Solution 1%|1 drop will be instilled in each eye twice daily.
62829233|NCT05992922|PLACEBO_COMPARATOR|Placebo Ophthalmic Solution (Vehicle)|1 drop will be instilled in each eye twice daily.
62829234|NCT04032964|EXPERIMENTAL|Arm L19TNF + DOXO|"Patients will be treated with:~* doxorubicin 75 mg/m2 i.v. on day 1 of each 21-day cycle;~* L19TNF 13 µg/kg i.v. on day 1, 3 and 5 of each 21-day cycle"
62829235|NCT03322696||Cirr-PVT|Cirrhotic patients developing over 1 yr period thrombosis of portal vein or collaterals
62829236|NCT01183806|EXPERIMENTAL|Rivastigmine and exercise program|Experimental group: Rivastigmine and exercise program: All patients will monthly receive Rivastigmine (Exelon patch). The exercise training program consists of two 40-minute sessions per week for six months and includes aerobic, strength, flexibility and balance training
62829237|NCT01183806|ACTIVE_COMPARATOR|Rivastigmine|Control group : Rivastigmine All patients will monthly receive Rivastigmine (Exelon patch)
62829238|NCT06601114|ACTIVE_COMPARATOR|Group A: Paracetamol Group|Group A: Paracetamol Group will receive Oral form of paracetamol with dosage of 15mg/kg every 6 hours for 3 days
62439332|NCT01249339|ACTIVE_COMPARATOR|Catch Licorice dry mini 0.3 g pouch|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
62606984|NCT01201174|NO_INTERVENTION|Patients with Hereditary Spherocytosis|All patients should have clinical and laboratory findings, consistent with mild to severe HS, diagnosed on the basis of spherocyte morphology, elevated MCHC (33-38 g/dl), with a mean value of (35.47 g/dl), increased osmotic fragility , splenomegaly and non-immune mediated hemolysis.
62829239|NCT06601114|EXPERIMENTAL|Group B: Ibuprofen Group|Group B: Ibuprofen Group will receive oral form of ibuprofen at initial dosage of 10mg/kg followed by 5mg/kg after 24 hours and 48 hours.
62249571|NCT02674698|OTHER|VA Integrated Service Networks Group 2|Access to the CNH Dashboard Step 2
62249572|NCT02674698|OTHER|VA Integrated Service Networks Group 3|Access to the CNH Dashboard Step 3
62249573|NCT02674698|OTHER|VA Integrated Service Networks Group 4|Access to the CNH Dashboard Step 4
62249574|NCT04731038|EXPERIMENTAL|Experimental|Anlotinib 12mg qd. po. d1-d14 q3w Toripalimab 240mg ivgtt. d1 q3w Paclitaxel 135mg/m2 ivgtt. d1 q3w Cisplatin 50mg/m2 ivgtt. d1 q3w Carboplatin AUC=5 ivgtt. d1 q3w
62249575|NCT02568475|EXPERIMENTAL|Decision aid|"Provision of Go to the Hospital or Stay Here?"
62249576|NCT02568475|NO_INTERVENTION|No decision aid|Does not receive the decision aid.
62439333|NCT04676932|EXPERIMENTAL|Nursing Care Based on Kolcaba's Comfort Theory|"In this study, nursing care based on Kolcaba's Comfort Theory will be applied to the intervention groups.~Care will given when women after receiving the HSG attendance appointment. Care will terminated on the 15 minutes after the end of HSG undergoing.~The time of the study 1-3 days for each women. Intervention Nursing Care Based on Kolcaba's Comfort Theory"
62439334|NCT04676932|NO_INTERVENTION|Routine hospital schedule|The researcher sincerely answered all questions asked by the control group during the HSG period.
62439335|NCT02328599||Surgical|Prior Bariatric surgery
62439336|NCT02328599||Non-surgical|Medical / Lifestyle management
62439337|NCT04689958|EXPERIMENTAL|Experimental Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline and vitamin D 5000 IU once daily (experimental group).
62439338|NCT04689958|ACTIVE_COMPARATOR|Control Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline
62439339|NCT06422611||Digital|Impression was taken with intraoral scanners
62249577|NCT02109562|EXPERIMENTAL|RBP-7000 90 mg|Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 90 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
62249578|NCT02109562|EXPERIMENTAL|RBP-7000 120 mg|Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 120 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
62249579|NCT02109562|PLACEBO_COMPARATOR|Placebo|Risperidone tablets given during the screening period to check for sensitivity. Placebo administered by subcutaneous injection on Days 1 and 29 for a total of two injections.
62249580|NCT06401564|EXPERIMENTAL|Virtual Reality Therapy|
62439340|NCT06422611||Conventional|Impression was taken with silicone impression material
62439341|NCT00626483|EXPERIMENTAL|CMV pp65-LAMP mRNA-loaded DC vaccination|Basiliximab will be safe in combination with CMV pp65-LAMP mRNA-loaded DC vaccination and GM-CSF
62439342|NCT00735683|PLACEBO_COMPARATOR|1|
62439343|NCT00735683|EXPERIMENTAL|2|
62439344|NCT00735683|EXPERIMENTAL|3|
62439345|NCT00735683|EXPERIMENTAL|4|
62439346|NCT00735683|EXPERIMENTAL|5|
62439347|NCT00735683|EXPERIMENTAL|6|
62439348|NCT01371578|EXPERIMENTAL|Arm 2|"AM Dosing: One GS-5885 30 mg tablet, two GS-9451 100 mg tablets, orally with RBV and with food.~PM Dosing: RBV with food.~PEG, 180 µg, will be administered weekly by subcutaneous injection for the specified period of time (see Study Design). Pegasys® prefilled syringes (Hoffman-La Roche) will be supplied by Gilead Sciences."
62439349|NCT05585359|EXPERIMENTAL|injectable platelet rich fibrin with Vitamin C|Injectable platelet rich fibrin: 10-mL sample of whole venous blood will be drawn from the patient's forearm and transferred into two plain plastic test tubes without an anticoagulant and will centrifuge immediately at 700 rpm for 3 minutes (60×g) . After centrifugation, the upper yellow fluid liquid (i-PRF) will be collected as close as possible to the layer of red cells the will be mixed with 250 micromole of Vitamin C.
62829240|NCT04062630|ACTIVE_COMPARATOR|Standard care|Multilevel Lumbar Fusion Surgery
62829241|NCT04062630|EXPERIMENTAL|Standard Care + iFuse 3-D|Multilevel Lumbar Fusion Surgery with additional placement of iFuse 3-D in a trajectory parallel to the S2AI screws
62829242|NCT06591325|EXPERIMENTAL|exercise group = participants performed 12 weeks of strength training|
62829243|NCT06591325|NO_INTERVENTION|control group = participants maintained their usual activities normally|
62829244|NCT05659953|EXPERIMENTAL|LMT503|Subjects receiving LMT503 orally
62829245|NCT05659953|PLACEBO_COMPARATOR|Placebo|Subjects receiving Matched Placebo orally
62829246|NCT04799834||CASES|Subjects who have had a severe form of COVID-19 and developed respiratory failure requiring oxygen supplementation or CPAP mechanical ventilation or intubation
62439350|NCT05585359|ACTIVE_COMPARATOR|Injectable platelet rich fibrin alone|injectable platelet rich fibrin: 10-mL sample of whole venous blood will be drawn from the patient's forearm and transferred into two plain plastic test tubes without an anticoagulant and will centrifuge immediately at 700 rpm for 3 minutes (60×g) . After centrifugation, the upper yellow fluid liquid (i-PRF) will be collected as close as possible to the layer of red cells
62439351|NCT04132232|EXPERIMENTAL|Treatment Group|"1. The patient will exhaled into the Smokerlyzer® device will at each visit~2. Exhaled carbon monoxide and fetal carboxyhemoglobin levels will be disclosed to the patient~3. Risks of adverse perinatal outcomes related to maternal carboxyhemoglobin and fetal carboxyhemoglobin level will be provided."
62606985|NCT01267201|EXPERIMENTAL|POS formulation #1|
62606986|NCT01267201|EXPERIMENTAL|POS formulation #2|
62606987|NCT01267201|ACTIVE_COMPARATOR|commercial tablet|
62829247|NCT04799834||CONTROLS 1|Subjects, comparable in age, sex and risk factors (such as concomitant diseases) with the CASES, who contracted the virus but either did not fall ill or had mild symptoms
62829248|NCT04799834||CONTROLS 2|Subjects, comparable in age, sex and risk factors (such as concomitant pathologies) with the CASES, who did not contract the virus
62829249|NCT04181333||TRASTUZUMAB BS|Unresectable Advanced/Recurrent HER2-Overexpressing Gastric Cancer patients injected TRASTUZUMAB BS
62829250|NCT00686413|EXPERIMENTAL|1|
62829251|NCT00686413|EXPERIMENTAL|2|
62829252|NCT03782246|NO_INTERVENTION|Usual Care|No intervention, participant will continue their usual care for pain and MS. We will collect information about what treatments are used by the usual care participants. They will be offered the opportunity to participate in one of the two active study treatments (MBCT or CBT) after completion of the 6-month followup.
62249581|NCT01460095|EXPERIMENTAL|HbA1c measurement and education|3-monthly Hba1c determination with immediate feedback and targeted education delivered to all participants
62249582|NCT02024568|ACTIVE_COMPARATOR|Pregabalin|"Includes 19 out of 38 subjects reporting athralgia-myalgia in the wake of paclitaxel infusion in the course of breast cancer treatment.~Pregabalin started on the evening before receiving infusion of paclitaxel and 5 day thereafter. Initial dosing of 75mg twice daily (morning + evening). Option for dose increase with additional 75mg in case of inadequate pain control. A minimal interval of 2 hours is required between doses.~In case of poorly tolerated side effects a reduction to 50mg doses is available.~Access to additional analgesic interventions is open as required for patient wellbeing."
62439352|NCT04132232|NO_INTERVENTION|Control Group|"1. The patient will exhale into the Smokerlyzer® device at each visit.~2. Exhaled carbon monoxide and fetal carboxyhemoglobin level will NOT be disclosed to the patient~3. No risks of adverse perinatal outcomes related to maternal carbon monoxide and fetal carboxyhemoglobin levels will be provided"
62439353|NCT02307474|EXPERIMENTAL|Treatment (Stereotactic Radiosurgery, pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO daily for up to 60 days. Patients then continue to receive pazopanib hydrochloride PO daily and undergo stereotactic radiosurgery (SBRT) every other day over days 60-65.
62439354|NCT03314129|EXPERIMENTAL|Contrast sensitivity|UltimEyes
62439355|NCT03314129|EXPERIMENTAL|Perceptual organization|Contour Integration Training
62439356|NCT03314129|EXPERIMENTAL|Contrast sensitivity + Perceptual org.|UltimEyes + Contour Integration Training
62439357|NCT03314129|ACTIVE_COMPARATOR|Cognitive remediation|MyBrainSolutions
62829253|NCT03782246|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy (MBCT)|Participants will attend eight, 2-hour group treatment MBCT sessions delivered using free video-conferencing technology. Groups will consist of 6-8 people who also have MS and chronic pain. Participants will be asked to practice skills learned in session between sessions. MBCT integrates mindfulness meditation practices within a CBT-oriented framework to address not only unhelpful pain cognitions and behaviors but also attentional control, decoupling of attention from emotion, mindful cognitions, and meditative behavior.
62829254|NCT03782246|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT)|Participants will attend eight, 2-hour group treatment CBT sessions delivered using free video-conferencing technology. Groups will consist of 6-8 people who also have MS and chronic pain. Participants will be asked to practice skills learned in session between sessions. CBT focuses on increasing adaptive pain coping strategies and reducing unhelpful thoughts and behaviors related to pain. Strategies include relaxation techniques, goal-setting, activity pacing, and changing unhelpful thinking patterns.
62439358|NCT00692926|OTHER|20% primed UCB|20% of UCB is ALDHbr sorted and primed and give on transplant day after conventional graft
62439359|NCT00692926|OTHER|20% un-primed|20% of UCB is ALDHbr freshly sorted and give on transplant day 4-8 hrs after conventional graft
62439360|NCT00692926|OTHER|Double- 1 unit primed|patient receives 1 conventional UCB unit and 1 unit that has been ALDHbr sorted and primed
62439361|NCT00692926|OTHER|Double- 1 unit unprimed|Patient receives 1 UCB unit and a second UCB unit that has been freshly ALDHbr sorted
62439362|NCT01081028||Cohort 1: Patients enrolled between Sep 2009 and Nov 2011|Newly diagnosed multiple myeloma patients enrolled between Sep 2009 and Nov 2011.
62439363|NCT01081028||Cohort 2: Patients enrolled between December 2012 and mid-2016|Newly diagnosed multiple myeloma patients enrolled between Dec 2012 and mid-2016
62829255|NCT06243536|PLACEBO_COMPARATOR|Type 2 diabetic patients without disordered eating behaviour|Treated with standard of care.
62829256|NCT06243536|PLACEBO_COMPARATOR|Type 2 diabetic patients with disordered eating behaviour A|Treated with standard of care.
62829257|NCT06243536|EXPERIMENTAL|Type 2 diabetic patients with disordered eating behaviour B|Receiving semaglutide for 12 weeks
62439364|NCT01081028||Cohort 3: Patients enrolled from 2023|Relapsed/Refractory multiple myeloma patients receiving second-line therapy
62829258|NCT06601231||all patients who are eligible for HCC surveillance|"All patients with cirrhosis~* Non-cirrhotic chronic hepatitis B patients meeting any of the following criteria: positive family history for HCC, intermediate-high aMAP and/or (m)PAGE-B score (if non-Caucasian)~* Non-cirrhotic chronic hepatitis C patients (with or without SVR) with a history of F3 fibrosis (based on histology or liver stiffness assessment)~* Non-cirrhotic NASH patients with a history of F3 fibrosis (based on histology or liver stiffness assessment)"
62439365|NCT03417349||Aspiration thrombectomy|Patients with acute ischemic stroke of the anterior circulation whom the treating physician deemed eligible to be treated with SOFIA™/ SOFIA™ as a first line treatment technique
62829259|NCT01966016|EXPERIMENTAL|biventricular pacing|The first configuration will be biventricular pacing (RV and postero-lateral branch of CS for LV pacing), as accepted
62829260|NCT01966016|EXPERIMENTAL|triventricular pacing|The second configuration will be triventricular pacing (RV+ postero-lateral branch of CS for LV pacing+ antero-lateral branch of CS for LV pacing) i.e. multisite LV pacing
62829261|NCT01669837||Patient group|Administration of surgical tissue glue.
62829262|NCT00751582|EXPERIMENTAL|2|Food supplementation and nutrition education
62829263|NCT00751582|EXPERIMENTAL|1|Nutrition Education only
62829264|NCT03576586|EXPERIMENTAL|Intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department"
62829265|NCT03576586|PLACEBO_COMPARATOR|Control|Attention placebo control (cognitive task for same amount of time) plus usual care in the maternity department
62439366|NCT02152020||Cancer survivors|
62439367|NCT03154879||Comatose cardiac arrest survivors|
62829266|NCT05353270|EXPERIMENTAL|Yoga|Yoga sessions (35 minutes each) will be performed 5 times weekly for 4 weeks.
62829267|NCT05353270|OTHER|Waitlist control|Waitlisted participants will maintain their normal diet and exercise patterns for 4 weeks prior to rerandomization to the yoga group.
62829268|NCT02995746|EXPERIMENTAL|0.7mg dexamethasone intravitreal implant|Single intravitreal implantation of 0.7mg dexamethasone with a six month follow up period
62829269|NCT02558088|EXPERIMENTAL|salmeterol|
62829270|NCT02886819|EXPERIMENTAL|WBV group|whole-body vibration (WBV) group
62249583|NCT02024568|PLACEBO_COMPARATOR|Placebo|"Includes 19 out of 38 subjects reporting athralgia-myalgia in the wake of paclitaxel infusion in the course of breast cancer treatment.~Placebo externally identical to the pregabalin 75mg capsules will be started on the evening before receiving infusion of paclitaxel and 5 day thereafter. Initial dosing of 1 capsule twice daily (morning + evening). Option for dose increase with additional capsule in case of inadequate pain control. A minimal interval of 2 hours is required between doses.~In case of poorly tolerated side effects a reduction to capsules with the appearance of 50mg pregabalin capsules is available.~Access to additional analgesic interventions is open as required for patient wellbeing."
62606988|NCT00571571|EXPERIMENTAL|TFP-A|Specific aspects of TFP-A involve the setting up of a treatment contract/collaboration between patient and therapist to deal with the likely threats both to the treatment and to the patient's well being that may occur in the course of the treatment. After the behavioral symptoms of identity pathology are contained through structure and limit setting, the psychological structure that is believed to be the core of identity pathology are analyzed. In particular, treatment would involve the family in setting up the contract parameters, provide a psychoeducational component to the family and patient, inclusion of school personnel as appropriate to reinforce contract parameters, place an emphasis on the technique of clarification to understand specific emotional states.
62606989|NCT00571571|ACTIVE_COMPARATOR|Control|The Control Group is treatment as usual in the outpatient clinic. Treatment in this arm will be carried out by therapists in the Outpatient Department. Treatment will be determined by the therapist(s) and carried out according to their particular orientation and their assessment of patient's needs. It is expected based on clinic data that the majority of patients will be seen at least one time per week.
62606990|NCT01420562||Posaconazole oral suspension|"One group of patients will receive posaconazole oral suspension as prophylactic agent.~Blood sampling: At day of transplantation, day 7 and 14, 9 blood samples will be collected to calculate AUC. Moreover, citrulline will be determined to objectively evaluate the severity of mucositis."
62606991|NCT01420562||Posaconazole oral tablet|"Once the oral tablet is available for adminstration to patients, a second group of patients will receive these tablets as prophylactic agent.~Blood sampling: At day of transplantation, day 7 and 14, 9 blood samples will be collected to calculate AUC. Moreover, citrulline will be determined to objectively evaluate the severity of mucositis."
62606992|NCT05284734|EXPERIMENTAL|Caudal block group|A 22 gauge 50 mm echogenic block needle placed through the sacrococcygeal membrane into the sacral canal in the longitudinal position, using the in-plane technique Negative aspiration was then performed 0.125% bupivacaine at a dose of 1 ml/kg was administered
62606993|NCT05284734|EXPERIMENTAL|Erector spinae block group|The erector spinae muscle and the transverse process were identified, and a 22 G, 80 mm echogenic block needle was advanced towards the transverse process until contact. Following hydrodissection, 1 ml/kg of 0.125% bupivacaine was injected deep into the erector spinae muscle
62829271|NCT04529902||Tumor necrosis factor inhibitors|Reference group
62249584|NCT06345521||End-Stage Heart Failure Group|Children with end-stage heart failure
62249585|NCT06059924||leak|Patients with diagnosed anastomotic leakage after low rectal resection for rectal cancer UICC stage I to III
62829272|NCT04529902||Abatacept|Exposure group
62829273|NCT00905164|EXPERIMENTAL|Test First|Topiramate Capsules, 25 mg
62829274|NCT00905164|ACTIVE_COMPARATOR|Reference First|Topamax® Capsules, 25 mg
62829275|NCT06300463|EXPERIMENTAL|Botensilimab and Balstilimab|Two balstilimab infusions will be given prior to surgery and two infusions will be given after surgery, for a total of four doses. Each infusion will be scheduled approximately 3 weeks apart. On the same day as the first and third balstilimab infusions, botensilimab will also be given, for a total of two doses, one before and one after surgery.
62249586|NCT06059924||noleak|Patients without anastomotic leakage after low rectal resection for rectal cancer UICC stage I to III
62829276|NCT06300463|EXPERIMENTAL|Botensilimab, Balstilimab, and AGEN1423|Two balstilimab infusions will be given prior to surgery and two infusions will be given after surgery, for a total of four doses. On the same day as each balstilimab infusion, participants will also receive AGEN1423 infusions, for a total of four doses. Each infusion will be scheduled approximately 3 weeks apart. On the same day as the first and third balstilimab + AGEN1423 infusions, botensilimab will also be given, for a total of two doses, one before and one after surgery.
62249587|NCT06335810|EXPERIMENTAL|Social Network Intervention|Participants will complete 3 communication skills sessions with their social network members during weeks 3, 5, and 15.
62439368|NCT00924066|EXPERIMENTAL|Squamous and Nonsquamous participants|"Squamous cell carcinoma is a histologic subtype of cervical cancer. Squamous cell carcinoma of the cervix (80%) is much more common than adenocarcinoma of the cervix.~Non squamous carcinoma is a histologic subtype of cervical cancer. It is the second most common form of cervical cancer; consists of adenocarcinoma, adenosquamous and non squamous (not otherwise specified) subtypes.~All participants in both arms received ixabepilone 6 mg/m\^2 x 5 days, each cycle."
62439369|NCT02564991||Healthy Controls|125 non-substance abusing controls (NSAC)
62439370|NCT02564991||Individuals with Alcohol Use Disorder|This group includes individuals who enrolled NIAAA alcohol treatment.
62047074|NCT01096992|EXPERIMENTAL|Phase 1 30 mg/m^2|Bendamustine, Fludarabine + Rituximab
62439371|NCT02116686||Heart failure patients with sleep apnea syndrom|For heart failure patients, a standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the America Academy of Sleep Medicine (AASM) recommendations (RemLogic® software, Broomfield, USA).
62439372|NCT00638157|ACTIVE_COMPARATOR|Daptomycin Alone|daptomycin 6 mg/kg q24h for treatment of right-sided infective endocarditis
62047075|NCT01096992|EXPERIMENTAL|Phase 1 40 mg/m^2|Bendamustine, Fludarabine + Rituximab
62047076|NCT01096992|EXPERIMENTAL|Phase 1 50 mg/m^2|Bendamustine, Fludarabine + Rituximab
62439373|NCT00638157|EXPERIMENTAL|Daptomycin plus gentamicin|daptomycin 6 mg/kg q24h with concomitant initial gentamicin dosed for the first 2 days of therapy for the treatment of right-sided infective endocarditis
62047077|NCT03918746|EXPERIMENTAL|internet Attachment-Based Compassion Therapy (iABCT)|"The intervention will consist of an internet version of Attachment-Based Compassion Therapy (iABCT).~The length of the intervention will depend on the pace of each participant that will be advised to carry out one module per week, taking days between sessions to complete homework assignments. It is estimated that the online intervention can be completed in eight weeks, with a maximum period of ten weeks. However, each participant will be free to advance at his/her own pace. Formal telephone support will be not systematically provided, but participants will contact for technical assistance (i.e., web accessibility problems or forgotten password) if necessary."
62047078|NCT04043923|EXPERIMENTAL|Norketotifen|Norketotifen oral capsules, once daily for 5 days
62047079|NCT04043923|PLACEBO_COMPARATOR|Placebo|Placebo oral capsules, once daily for 5 days
62047080|NCT06184828|EXPERIMENTAL|Whole Blood Transfusion|Transfusion of whole blood units
62606994|NCT02437032|ACTIVE_COMPARATOR|Group 1: recombinant FSH|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of rFSH (Gonal-F®, Merck-Serono, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously
62606995|NCT02437032|ACTIVE_COMPARATOR|Group 2:urinary FSH|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of urinary FSH (uFSH) (Fostipur®, Angelini, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously.
62606996|NCT02437032|ACTIVE_COMPARATOR|Group 3: with hMG|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of hMG (HMG-Lepori®, Angelini, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously, and transvaginal oocyte retrieval was performed 36 h later.
62606997|NCT05123391|EXPERIMENTAL|Low-Intermediate favorable risk 5 Fraction SBRT arm|36.25 Gy in 5 fractions to the prostate weekly or every other day
62606998|NCT05123391|EXPERIMENTAL|Low-Intermediate favorable risk 2 Fraction SBRT arm|26 Gy in 2 fractions to the prostate
62606999|NCT05123391|EXPERIMENTAL|Intermediate unfavorable-high risk prostate only SBRT arm|36.25 Gy in 5 fractions to the prostate and seminal vesicles base, weekly or every other day
62607000|NCT05123391|EXPERIMENTAL|Intermediate unfavorable-high risk prostate and pelvis SBRT arm|25 Gy in 5 fractions to the elective pelvic nodes and simultaneous integrated boost to 36.25 Gy in 5 fractions to the prostate and seminal vesicles base, weekly
62607001|NCT05123391|EXPERIMENTAL|Pelvic node positive moderate hypofractionated radiotherapy|44 Gy in 20 daily fractions to the elective pelvic nodes and simultaneous integrated boost to 60 Gy to the prostate and seminal vesicles base and 54 Gy to positive lymph nodes
62607002|NCT05123391|EXPERIMENTAL|Pelvic node positive moderate ultra-hypofractionated radiotherapy|25 Gy in 5 fractions to the elective pelvic nodes and simultaneous integrated boost to 36.25 Gy in 5 fractions to the prostate and seminal vesicles base and to 30 Gy to positive lymph nodes.
62607003|NCT03631719||Early-release|Resident in areas that receive early Wolbachia deployments.
62607004|NCT03631719||Late-release|Resident in areas that receive late Wolbachia deployments.
62607005|NCT06034925|ACTIVE_COMPARATOR|Control|valganciclovir 900mg once daily
62607006|NCT06034925|EXPERIMENTAL|Intervention|maribavir 400mg twice daily
62607007|NCT02491125|PLACEBO_COMPARATOR|Placebo|12 weeks placebo maltodextrin 15g/day ( 5 g in beverage, to be consumed three times a day)
62607008|NCT02491125|EXPERIMENTAL|soluble wheat bran fibre|12 weeks soluble wheat bran fibre 15g/day (5 g in beverage, to be consumed three times a day)
62829277|NCT06300463|EXPERIMENTAL|Botensilimab, Balstilimab, and Radiation|Participants will receive 3 doses of radiation prior to surgery. Additionally, two balstilimab infusions will be given prior to surgery and two infusions will be given after surgery, for a total of four doses. Each infusion will be scheduled approximately 3 weeks apart. On the same day as the first and third balstilimab infusions, botensilimab will also be given, for a total of two doses, one before and one after surgery.
62829278|NCT06654973|EXPERIMENTAL|SARS-CoV-2 Delta human infection challenge|GMP-produced Delta SARS-CoV-2 virus will be given to participants via intranasal drops.
62829279|NCT02546388|EXPERIMENTAL|Indium-111 Pentreotide (OctreoScan)|Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Indium-111 Pentreotide (OctreoScan). The imaging protocol will consist of imaging at 4 and 24 hours after OctreoScan injection.
62829280|NCT02546388|EXPERIMENTAL|Gallium-68 DOTATATE|Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Gallium-68 DOTATATE. The imaging protocol will consist of imaging 1 hour after injection for DOTATATE.
62047081|NCT06184828|ACTIVE_COMPARATOR|Blood Component Transfusion|Transfusion of blood components units
62249588|NCT06335810|PLACEBO_COMPARATOR|Individual Lifestyle Intervention|Participants will complete standard diabetes prevention program (DPP) based health coaching sessions during weeks 3, 5, and 15.
62249589|NCT06335810|OTHER|Social Network Member|Social Network Members will complete 3 communication skills sessions with the social network intervention participant during weeks 3, 5, and 15.
62607009|NCT03218267|EXPERIMENTAL|Individuals after total hip replacement|Individuals after total hip replacement. Patients treated at the Out-Patient Ward of W. Dega Orthopaedic-Rehabilitation Clinical Hospital of Karol Marcinkowski University of Medical Sciences in Poznań. The examination of participants included the static posturography and one-leg standing test.
62607010|NCT03218267|ACTIVE_COMPARATOR|control group|The group with healthy individuals; without total hip replacement. The examination of participants included the static posturography and one-leg standing test.
62439374|NCT03846271|EXPERIMENTAL|Oxytocin then placebo|Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo.
62439375|NCT03846271|EXPERIMENTAL|Placebo then oxytocin|Participants first receive placebo. After a washout period of 2 weeks, they receive oxytocin (24 IU).
62439376|NCT02884206|EXPERIMENTAL|LCZ696 200 mg bid|Patients who were able to tolerate the treatment during the single-blind treatment run-in epoch. Following the run-in period, patients randomized in this arm were given LCZ696 at 200 mg twice daily for three years
62607011|NCT02240069|EXPERIMENTAL|Education (Tx1)|Education on best burn practices
62439377|NCT02884206|ACTIVE_COMPARATOR|Valsartan 160 mg bid|Patients who were able to tolerate the treatment during the single-blind treatment run-in epoch. Following the run-in period, patients randomized in this arm were given valsartan at 160 mg twice daily for three years.
62439378|NCT01075139|EXPERIMENTAL|Brief Motivational Intervention|Subjects in this condition met one-on-one with a counselor for 30 minutes. Subjects received personalized feedback regarding their current physical activity levels and fruit/vegetable intake. Counselors used a motivational interviewing style to try to help resolve ambivalence about changing their current behaviors.
62439379|NCT01075139|ACTIVE_COMPARATOR|Educational information|Subjects in this condition received general educational information about the benefits associated with physical activity and fruit/vegetable intake.
62439380|NCT02963753||hyperemesis gravidarum group|The study group consisted of women hospitalized for hyperemesis during first trimester of their pregnancy
62439381|NCT02963753||the control group|whereas the control group included all other women who delivered in the same period.
62607012|NCT02240069|ACTIVE_COMPARATOR|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove."
62829281|NCT06446089|EXPERIMENTAL|Adapted THP group|"Participants will be invited to complete three modules relevant to the health and well-being of mothers and fetus/infants during the perinatal period, through an Android based app on their mobile device.~In addition, each section incorporates the three healthy thinking steps to help the mother negotiate each of the three areas.~After the introductory session, each session involves four tasks that mothers are required to complete. The tasks include 1) a review of the key message from the previous section, 2) a review of the mood chart, 3) engaging in the three steps to thinking healthy on the designated area for the section, and 4) practicing suggested activities between sessions."
62829282|NCT04608552|ACTIVE_COMPARATOR|Active Myofunctional Therapy|Active Myofunctional Therapy is comprised of five 30-minute weekly sessions for 4 weeks.
62829283|NCT04608552|SHAM_COMPARATOR|Inactive Myofunctional Therapy|Sham MT will be comprised of recommendations for five 30-minute nasal breathing exercises each week, use of nasal lavage with application of 10ml of saline in each nostril two times per day.
62829284|NCT06593899|EXPERIMENTAL|Hypofractionated Radiotherapy|The patients in the study underwent a 1-week course of hypofractionated radiotherapy. Following the completion of radiotherapy, chemotherapy with the AI regimen (doxorubicin + ifosfamide) was initiated one week later. The AI regimen chemotherapy was administered for a duration of 9 weeks. Subsequently, surgery was scheduled to commence 1-2 weeks after the completion of chemotherapy.
62829285|NCT06471972||Adult out-of-hospital cardiac arrest patients in participating sites of the STEPCARE trial|Patients will not be randomized within the biomarker substudy, but are already randomised as participants within the STEPCARE trial to either of 3 interventions
62829286|NCT06588309||Addiction and PTSD|
62829287|NCT06588309||Addiction and CPTSD|
62829288|NCT03776968|EXPERIMENTAL|HC1119|Fasting state:40 mg, 80 mg, 160 mg; After meal: 160mg;
62829289|NCT04765683||Patients|Attending surgical outpatients
62829290|NCT04765683||Surgeons|Running surgical outpatients
62829291|NCT04179136|ACTIVE_COMPARATOR|High enterolactone producer's (intervention)|lignan capsules contain 300 mg flaxseed (SDG) extract
62829292|NCT04179136|PLACEBO_COMPARATOR|High enterolactone producer's (Control)|Placebo treatment matching intervention
62829293|NCT04179136|ACTIVE_COMPARATOR|Low enterolactone producer's (intervention)|lignan capsules contain 300 mg flaxseed (SDG) extract
62829294|NCT04179136|PLACEBO_COMPARATOR|Low enterolactone producer's (Control)|Placebo treatment matching intervention
62439382|NCT00686920|EXPERIMENTAL|Rifaximin|Participants from a previous rifaximin HE study and new participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for at least 24 months, until regulatory approval of rifaximin for reduction in risk of overt HE recurrence, or until the sponsor closed the study.
62829295|NCT05092100|EXPERIMENTAL|Behavioral|This arm will use behavioral procedures to test memory for different visual stimulus conditions.
62829296|NCT05092100|EXPERIMENTAL|fMRI pattern similarity|This arm will use fMRI and behavioral methods to test memory for different visual stimulus conditions.
62829297|NCT05092100|EXPERIMENTAL|eye tracking|This arm will use eye tracking and behavioral methods to test memory for different visual stimulus conditions.
62607013|NCT02240069|SHAM_COMPARATOR|Placebo Intervention (Tx3)|"A 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
62607014|NCT06021366||12-month follow-up cohort|
62607015|NCT06021366||Treatment-naïve 12-month sub-cohort|
62607016|NCT06021366||Treatment-experienced 12-month sub-cohort|
62607017|NCT06021366||Treatment-experienced, persistent 12-month sub-cohort|
62607018|NCT06021366||18-month follow-up cohort|
62047082|NCT02159131|EXPERIMENTAL|OC containing levonorgestrel and ethinyl estradiol + GSK126574|Eligible subjects will enter a run-in-period of 21 days (may extend to 49 days) to stabilize on OC containing levonorgestrel and ethinyl estradiol in order to synchronize the menstrual cycles of multiple subjects. Subjects completing run-in-period will enter Treatment period 1 and will be dosed OC once daily on Days 1 to 10. At day 11 subjects will enter Treatment period 2 and will be dosed with OC containing levonorgestrel and ethinyl estradiol + 744 once daily on Day 12 to 19. Subjects completing Treatment period 2 will have 7 OC free days (Day 22 to 28) during which withdrawal menses should occur. Subjects will then be followed up for 7 to 14 days (Day 28 to 35/49).
62047083|NCT05279625|EXPERIMENTAL|Interval exercise training|Interval exercise training using either elastic band, dumbbells, treadmill, cycling for 6 months
62047084|NCT05279625|EXPERIMENTAL|continuous exercise training|continuous exercise training using either elastic band, dumbbells, treadmill, cycling for 6 months
62249590|NCT02661698|PLACEBO_COMPARATOR|Placebo 1|"Placebo~All participants will be given a placebo for the first visit. The other 3 arms will be randomised in a counterbalanced order."
62439383|NCT01536756|EXPERIMENTAL|Exercise Intervention -- Physical Rehabilitation Program|
62607019|NCT06021366||Treatment-naïve 18-month sub-cohort|
62607020|NCT06021366||Treatment-experienced 18-month sub-cohort|
62607021|NCT06021366||Treatment-experienced, persistent 18-month sub-cohort|
62607022|NCT02380495||Allergic rhinitis with/without asthma, from 14 to 17 years age|600 adolescents with allergic rhinitis with/without asthma, from 14 to 17 years age, recruited from Pediatricians of the Italian territory.
62607023|NCT02380495||Without respiratory pathology|600 subject (5 for each participant Pediatrician) of the same age range, without respiratory pathology (patient family)
62047085|NCT05279625|EXPERIMENTAL|machine-assisted exercise training|machine-assisted exercise training for 6 months
62047086|NCT05279625|ACTIVE_COMPARATOR|traditional rehabilitation|traditional rehabilitation for 6 months
62249591|NCT02661698|PLACEBO_COMPARATOR|Placebo 2|Placebo
62249592|NCT02661698|ACTIVE_COMPARATOR|DHA rich oil|Omega-3 oil: DHA enriched
62249593|NCT02661698|ACTIVE_COMPARATOR|EPA rich oil|Omega-3 oil: EPA enriched
62249594|NCT05482074|EXPERIMENTAL|OLAPARIB|"The research study procedures include screening for eligibility, study treatment including evaluations, surveys, optional biopsies, and follow up visits~Olaparib- Each study treatment cycle lasts 28 days . This will continue for as long as the study treatment is providing clinical benefit"
62249595|NCT05563675|NO_INTERVENTION|Morning administration of LAMA|Participants randomized to this group (with or without the combination of ICS and/or LABA) will be instructed to take their LAMA as usual in the morning between 6 and 12am.
62439384|NCT01536756|OTHER|Wait List Control Group|
62439385|NCT00645775|PLACEBO_COMPARATOR|1|Compare active to placebo
62439386|NCT06479759|EXPERIMENTAL|Cohort 1|Cohort 1 patients receive LM-108 monoclonal antibody combined with sintilimab.
62439387|NCT06479759|EXPERIMENTAL|Cohort 2|Cohort 2 patients receive LM-108 monoclonal antibody combined with sintilimab and chemotherapy for 4-6 cycles. LM-108 monoclonal antibody combined with sintilimab will be maintained.
62607024|NCT00376272|EXPERIMENTAL|1|
62607025|NCT00376272|PLACEBO_COMPARATOR|2|
62607026|NCT01895348|ACTIVE_COMPARATOR|propofol only|
62607027|NCT01895348|ACTIVE_COMPARATOR|propofol-remifentanil|
62607028|NCT01895348|ACTIVE_COMPARATOR|dexmedetomidine-remifentanil|
62607029|NCT03838237||Fabry Disease patients|Patients with genetic diagnosis of Fabry Disease, clinical indication to Migalastat and signs of cardiac involvement (early or advanced) will undergo cardiological evaluation before and 18 months after therapy with Migalastat (123 mg every other day)
62607030|NCT02947906||Study group|Participants with multiple sclerosis who able to walk at least 30 meters independently.
62607031|NCT02947906||Control Group|Healthy participants
62607032|NCT06540417|ACTIVE_COMPARATOR|eTNS treatment|Bilateral supraorbital regions were selected as the stimulation sites for external trigeminal nerve stimulation (eTNS).
62607033|NCT06540417|NO_INTERVENTION|Control treatment|The standard treatment group received physician-directed treatment for acute ischemic stroke, which included medication and rehabilitation therapy.
62047087|NCT03132428||P Neonates|Premature (P) neonates \[at least 27 weeks but less than 34 weeks of gestational age\]
62047088|NCT03132428||TNT Neonates|Term-Near-Term (TNT) neonates at least 34 weeks of gestational age
62047089|NCT03840590|EXPERIMENTAL|AI-assisted Colonoscopy|Participants in this arm undergo AI-assisted colonoscopy using CSK AI system.
62047090|NCT03840590|ACTIVE_COMPARATOR|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy.
62047091|NCT04432701|ACTIVE_COMPARATOR|group A|children were extubated in a light plane of anesthesia, when they are still asleep or have swallowing reflex.
62047092|NCT04432701|NO_INTERVENTION|group B|Tracheal extubation was performed when the patient regained consciousness, facial grimace, spontaneous eye opening, and purposeful arm movement.
62047093|NCT01123382|EXPERIMENTAL|IM Electrical Stimulation (IM ES)|The IM ES Group will receive electrical stimulation treatment for three weeks (6 hrs daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
62607034|NCT00676572||Severe asthma|
62439388|NCT03532256||Treated Patients|This prospective, observational study includes adult patients (age ≥18) undergoing elective surgical procedures within the departments of orthopedics, sports medicine, and neurosurgery, as well as patients treated for an acute injury and prescribed an opioid from the ED who own a mobile phone and can receive SMS text messaging at the University of Pennsylvania or Penn Presbyterian Medical Center.
62047094|NCT01123382|ACTIVE_COMPARATOR|Usual Care (UC)|The Usual Care Group will receive outpatient therapy for four weeks, coupled with prescribed daily home exercises.
62047095|NCT04225988|EXPERIMENTAL|Extended-release tacrolimus|Kidney transplant recipients will receive extended-release tacrolimus in addition to standard-dose mycophenolate and prednisone for maintenance immunosuppression.
62047096|NCT04225988|ACTIVE_COMPARATOR|Immediate-release tacrolimus|Kidney transplant recipients will receive immediate-release tacrolimus in addition to standard-dose mycophenolate and prednisone for maintenance immunosuppression.
62047097|NCT02529501||SA|Patients undergoing spinal anesthesia
62439389|NCT03532256||Treated patients randomized to receive survey|A subset of patients (described above) will receive an automated SMS text message with a link to an online survey. This survey contains the script questions about pain management and opioid use.
62047098|NCT02529501||GA|Patients undergoing short general anesthesia
62047099|NCT02984657||2012 patients|Surgical patients in 2012 with anesthesia and nursing staff less attuned to intraoperative RTP.
62047100|NCT02984657||2015 patients|Surgical patients in 2015 with enhanced anesthesia and nursing staff awareness and use of intraoperative RTP.
62439390|NCT03532256||Treated patients randomized to receive text script|A subset of patients (described above) will receive an automated questionnaire conducted via text message. Questions will be about pain management and opioid use.
62439391|NCT03803722|EXPERIMENTAL|Arm A Eyestil Protection®|"No inferiority of Eyestil Protection® unidose versus Vismed® unidose The intervention consists of Eyestil Protection® : sterile preservative free, medical device, class IIa and CE marked. It contains 0.2% xanthan gum, presented in 0.3 ml unidose containers. It is not available yet on the French Market.~dosage: 6 drops a day for three months period."
62439392|NCT03803722|NO_INTERVENTION|Arm B Vismed®|"Vismed®: sterile preservative free, medical device class IIb and CE marked. It contains 0.18% sodium hyaluronate, presented in 0.3 ml unidose containers. It is already on the French market.~dosage: 6 drops a day for three months period."
62439393|NCT03096613|EXPERIMENTAL|Levothyroxine group|The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.
62439394|NCT03096613|NO_INTERVENTION|Standard therapy group|The patients in this group receive standard therapy in consistent with the local clinical practice.
62439395|NCT01854788|ACTIVE_COMPARATOR|Autogenic drainage|All patients performed all interventions in a randomized order. Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
62439396|NCT01854788|ACTIVE_COMPARATOR|Slow expiration with glottis opened in lateral posture|All patients performed all interventions in a randomized order.Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
62439397|NCT01854788|ACTIVE_COMPARATOR|Temporary-Positive Expiratory Pressure|All patients performed all interventions in a randomized order. Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
62607035|NCT00676572||Non-severe asthma|
62607036|NCT05901584|EXPERIMENTAL|Cadonilimab (AK104) combined with chemotherapy|Cadonilimab(10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy or Cadonilimab(10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit), Q3W, 4cycles), every 3 weeks (21 days) is a treatment cycle
62607037|NCT01366794|EXPERIMENTAL|Type 2 diabetes|Administration of macronutrients in type 2 diabetes
62607038|NCT01366794|EXPERIMENTAL|Healthy volunteers|Administration of macronutrients in healthy volunteers
62047101|NCT02671032|EXPERIMENTAL|Implantation with Nucleus CI532 cochlear implant|All participants will receive the same treatment - Implantation with Nucleus CI532 cochlear implant.
62047102|NCT01252823|EXPERIMENTAL|Implantable loop recorder (ILR) in hemodialysis patients|implantation of loop recorder in hemodialysis patients
62607039|NCT01541839|EXPERIMENTAL|Septal Stapler|This group will have closure of their nasal septal flaps via septal stapler.
62607040|NCT01541839|NO_INTERVENTION|Control (Suture)|This arm will have closure of their nasal septal flaps as routinely performed with suture passed in a quilting fashion.
62607041|NCT06431113|EXPERIMENTAL|Citicoline 500 mg+Homotaurine 50 mg+Pyrroloquinoline quinone (Neuprozin Mito®-NPM)|Citicoline 500 mg plus Homotaurine 50 mg plus Pyrroloquinoline quinone (Neuprozin Mito® - NPM) fixed combination for 4 months followed by Cebrolux -CIT for 4 months, besides standard topical treatment
62829298|NCT00124943|EXPERIMENTAL|10 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 10 mg/m\^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesion) or balloon angioplasty (in-stent restenosis lesions).
62047103|NCT03327766||RPL group|history of unexplained recurrent pregnancy loss (defined as two or more consecutive missed miscarriage before 14 weeks of gestation).
62829299|NCT00124943|EXPERIMENTAL|22 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 22 mg/m\^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
62047104|NCT03327766||Control group|womens coming for contraception after normal pregnancy outcome.
62249596|NCT05563675|EXPERIMENTAL|Bedtime administration of LAMA|Participants randomized to this group (with or without the combination of inhaled corticosteroids (ICS) and/or long-acting beta2-agonists (LABA)) will be instructed to take their LAMA-containing inhalation between 8pm. and 2am.
62439398|NCT03624270|EXPERIMENTAL|Frontline oral arsenic trioxide, ATRA and ascorbic acid (AAA)|"Induction:~* Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses) and Ascorbic acid 1g daily for 42 days~* Daunorubicin at 50mg/m2 daily for 3 days (omitted if WBC at diagnosis \< 10 x 10\^9/L; or age ≥ 65 years; or cardiac function impairment)~* Hydroxyurea 2-4g per day if WBC \> 5 x 10\^9/L during the first 7 days of induction.~Consolidation (for all patients):~- Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses) and ascorbic acid 1g daily for 14 days every 28 days for 2 cycles~Maintenance (for all patients):~- Oral Arsenic trioxide 10mg daily, ATRA (45mg/m2 per day in divided doses) and ascorbic acid 1g daily for 2 weeks every 2 months for 24 months."
62439399|NCT00541281|ACTIVE_COMPARATOR|A|weekly docetaxel and prednisone
62439400|NCT00541281|ACTIVE_COMPARATOR|B|weekly docetaxel (35mg/m\&) plus prednisone 10mg a day associated with estramustine form day 1to 5 and 8 to 12
62439401|NCT04859855|EXPERIMENTAL|Restrictive strategy (arm A)|Transfusion of RBC if Hb ≤7,0g/dL with the aim of maintaining Hb levels between 7,0-9,0g/dL.
62439402|NCT04859855|EXPERIMENTAL|Liberal strategy (arm B)|Transfusion of RBC if Hb ≤9,0g/dL, with the aim of maintaining Hb levels between 9,0-10,0g/dL.
62607042|NCT06431113|ACTIVE_COMPARATOR|Cebrolux -CIT for 4 months|Citicoline 800 (Cebrolux-CIT) for 4 months followed by Citicoline 500 mg plus Homotaurine 50 mg plus Pyrroloquinoline quinone (Neuprozin Mito® - NPM) for 4 months, besides standard topical treatment
62607043|NCT04220086|EXPERIMENTAL|Pediatric massage|Children with ASD will receive pediatric massage for 12 weeks.
62607044|NCT04220086|SHAM_COMPARATOR|Waitlist control|Waitlist control
62829300|NCT00124943|EXPERIMENTAL|35 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 35 mg/m\^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
62829301|NCT00124943|EXPERIMENTAL|45 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 45 mg/m\^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
62829302|NCT03953352|OTHER|Radiotherapy treatment|
62047105|NCT03202706||Patients|
62047106|NCT05089838|EXPERIMENTAL|CMV-TCR-T cells|Patients who enrolled will receive one dose of CMV-TCR-T cells. The dosage ranges from 0.3×10\^6 to 1×10\^7 TCR+T/Kg.
62047107|NCT05973448|OTHER|Lighting Sequence 1: CCLL|"In this arm, the participant will receive the control lighting condition (C) for the first two quarters (180 days) and then crossover to the novel lighting condition (L) for the last two quarters (180 days).~Q1 - Control lighting Q2 - Control lighting Q3 - Novel lighting Q4 - Novel lighting"
62249597|NCT01363388|PLACEBO_COMPARATOR|Placebo|Placebo plus a full dose of oral glucocorticoids for steps 1 and 2 of the study
62249598|NCT01363388|EXPERIMENTAL|CCX168|30 mg Active study medication, plus either two-thirds reduced dose of oral glucocorticoids for step 1 of the study, or no oral glucocorticoids for step 2 of the study
62249599|NCT01053442|EXPERIMENTAL|NaFeEDTA|The maize porridge is fortified with 2.5mg iron as NaFeEDTA
62439403|NCT00647608|EXPERIMENTAL|1|Propranolol Hydrochloride Extended-Release Capsules 160 mg
62607045|NCT04220086|OTHER|Healthy Control|15 healthy controls (age- and sex- matched with ASD patients) will be recruited. All of them will receive clinical evaluations, EEG and fNIRS detection.
62607046|NCT00005005|EXPERIMENTAL|1|Participants will receive PTH for 1 year followed by alendronate for 1 year.
62607047|NCT00005005|EXPERIMENTAL|2|Participants will receive PTH and alendronate for 1 year followed by alendronate for 1 year.
62607048|NCT00005005|EXPERIMENTAL|3|Participants will receive alendronate for 2 years.
62607049|NCT00005005|ACTIVE_COMPARATOR|4|Participants will receive PTH for 1 year followed by placebo for 1 year.
62607050|NCT00874562|ACTIVE_COMPARATOR|Steroid Only|Corticosteroid Alone
62047108|NCT05973448|OTHER|Lighting Sequence 2: CLLC|"In this arm, the participant will receive the control lighting condition (C) for the first quarter (90 days) and then crossover to the novel lighting condition (L) for the next two quarters (180 days) and finally crossover again to the control condition (C) for the last quarter (90 days).~Q1 - Control lighting Q2 - Novel lighting Q3 - Novel lighting Q4 - Control lighting"
62047109|NCT05973448|OTHER|Lighting Sequence 3: LCCL|"In this arm, the participant will receive the novel lighting condition (L) for the first quarter (90 days) and then crossover to the control lighting condition (C) for the next two quarters (180 days) and finally crossover again to the novel condition (L) for the last quarter (90 days).~Q1 - Novel lighting Q2 - Control lighting Q3 - Control lighting Q4 - Novel lighting"
62047110|NCT05973448|OTHER|Lighting Sequence 4: LLCC|"In this arm, the participant will receive the novel lighting condition (L) for the first two quarters (180 days) and then crossover to the control lighting condition (C) for the last two quarters (180 days).~Q1 - Novel lighting Q2 - Novel lighting Q3 - Control lighting Q4 - Control lighting"
62047111|NCT00504426|PLACEBO_COMPARATOR|1|
62047112|NCT00504426|ACTIVE_COMPARATOR|2|
62047113|NCT00504426|ACTIVE_COMPARATOR|3|
62047114|NCT00504426|ACTIVE_COMPARATOR|4|
62047115|NCT02077348|NO_INTERVENTION|Insulin|"good glycemic control: 50 % of the subject's basal insulin dosage will be given as a continuous IV administration of insuman rapid overnight (hospitalized and fasting from 10 p.m.) and on the study-day. Basal period from 7.00 am to 12.00pm. The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
62047116|NCT02077348|EXPERIMENTAL|Insulin withdrawal|"10 % of the individual subject's regular insulin dosage will be given as a continuous IV administration of insuman rapid overnight (hospitalized and fasting from 10 p.m.) Basal period from 7.00 am to 12.00 pm (without insulin). The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
62047117|NCT02077348|EXPERIMENTAL|Norditropin (Growth Hormone)|"Same amount of insulin administered on the control day (good glycemic control) overnight and on the study day (hospitalized and fasting from 10 p.m.). On the study day, a bolus injection of 0,4 mg of growth hormone (Norditropin) will be administered at 7.05 am. Basal period from 7.00 am to 12.00 pm (good glycemic control).The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
62047118|NCT05055102||Patient with WOVEX bifurcated prosthesis|"* Patients who have undergone open abdominal aortic surgery between January 1st, 2013 and December 31, 2017 in Burgundy Dijon Hospital.~* Patients who have been treated with a WOVEX bifurcated prosthesis (Wovex® Polyester Vascular Protheses)"
62047119|NCT00538590|ACTIVE_COMPARATOR|MITOMYCIN-C|Following ethics committee approval, 20 patients with uncontrolled glaucoma will be will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with Mitomycin-C.
62047120|NCT00538590|EXPERIMENTAL|ologen (Oculusgen)|20 patients will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with ologen implant. The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
62047121|NCT05288426||participant post first BNT162b2 vaccination|Patients which developed myocarditis after the first dose of BNT162b2 vaccination
62047122|NCT05288426||participant post second BNT162b2 vaccination|Patients which developed myocarditis after the second dose of BNT162b2 vaccination
62047123|NCT05288426||participant post third BNT162b2 vaccination|Patients which developed myocarditis after the third dose of BNT162b2 vaccination diagnosed with MIS
62249600|NCT01053442|ACTIVE_COMPARATOR|FeSO4|The maize porridge is fortified with 2.5 mg iron as ferrous sulphate plus ascorbic acid.
62047124|NCT05288426||participant post COVID-19|Patients which developed myocarditis after COVID-19 infection
62047125|NCT01421251||Matched cohorts - population based|Two cohorts: vaccinated individuals are matched to unvaccinated individuals on the basis of age, sex, and postal code of residence.
62249601|NCT00003042|EXPERIMENTAL|1 cycle of neoadjuvant chemotherapy|Patients receive chemotherapy, surgical removal of the cancer followed by additional chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.
62249602|NCT00003042|EXPERIMENTAL|More than 1 cycle of neoadjuvant chemotherapy|Patients receive chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.
62439404|NCT00647608|ACTIVE_COMPARATOR|2|Inderal® LA Capsules 160 mg
62439405|NCT05660057|EXPERIMENTAL|Newly designed computer monitor|Participants will read a short story and then watch moving images for 30 minutes or until any of their persisting concussion symptoms arise. The number and severity of symptoms will be assessed by completing SCAT -III pre- and post-study tasks.
62607051|NCT00874562|ACTIVE_COMPARATOR|Steroid plus Rapamycin|Corticosteroid plus Rapamycin
62607052|NCT06016985|EXPERIMENTAL|caffeine gum|Chewed caffeine gum containing 3 mg/kg for 10 minutes
62607053|NCT06016985|PLACEBO_COMPARATOR|placebo|Chewed placobo gum for 10 minutes
62607054|NCT02165475|EXPERIMENTAL|Biofeedback|
62607055|NCT02165475|EXPERIMENTAL|medical treatment|
62607056|NCT02165475|EXPERIMENTAL|combination of the two treatments|
62607057|NCT01291576|ACTIVE_COMPARATOR|Rectal/colorectal segmental resection|
62607058|NCT01291576|ACTIVE_COMPARATOR|Rectal nodule excision|
62607059|NCT06558188|ACTIVE_COMPARATOR|Romosozumab|romosozumab
62607060|NCT06558188|ACTIVE_COMPARATOR|Romosozumab and Teriparatide|romosozumab and teriparatide
62607061|NCT00709007|EXPERIMENTAL|DAART|Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
62047126|NCT04444167|EXPERIMENTAL|AK104 and Lenvatinib|AK104 6 mg/kg IV every 2 weeks (Q2W) Lenvatinib 12mg weight≥60kg or 8mg weight\<60kg,PO QD
62607062|NCT00709007|ACTIVE_COMPARATOR|SAT|Participants take their HIV medications on their own but visit the clinic for opioid agonist substitution therapy.
62047127|NCT03656705|EXPERIMENTAL|CCCR-NK92 cells immunotherapy|Preparation of CCCR-NK92 cells suspended in a saline and plasma solution.
62047128|NCT06397131|EXPERIMENTAL|NT-501 CNTF Implant with Medica Hollow Fiber Membrane (MHFM)|Participants to receive CNTF implant in one eye using MHFM.
62047129|NCT06020222|EXPERIMENTAL|Cryotherapy group|Both hands and feet received cryotherapy gloves and boots
62047130|NCT06020222|PLACEBO_COMPARATOR|Usual care group|health education leaflets
62047131|NCT02555540|ACTIVE_COMPARATOR|Boostrix, Male, >/= 5 years, D2 visit|"25 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
62439406|NCT05660057|SHAM_COMPARATOR|Standard computer monitor|Same participants will read a short story and watch moving images for 30 minutes or until any of their persisting concussion symptoms arise on the standard computer screen.The number and severity of symptoms will be assessed by completing SCAT -III pre- and post-study tasks.
62439407|NCT03967132|ACTIVE_COMPARATOR|Control Infant Formula|Milk-based infant formula
62439408|NCT03967132|EXPERIMENTAL|Experimental Infant Formula|Milk-based Infant Formula with oligosaccharides
62439409|NCT03967132|OTHER|Reference Group|Human-milk fed
62439410|NCT02818283|EXPERIMENTAL|Soy Pretzel-Short Feasibility|6 week intervention involving daily consumption of soy pretzel (two packets, 5 oz./packet) for 28 days. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. This arm will precede the longer 28 week study
62439411|NCT02818283|ACTIVE_COMPARATOR|Soy Pretzel|28 week intervention involving daily consumption of soy pretzel (two packets, 5 oz./packet) for 12 weeks. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. Participants will be randomized to start with soy pretzel or wheat pretzel arm and crossover to the other pretzel at week 14.
62439412|NCT02818283|PLACEBO_COMPARATOR|Wheat Pretzel|28 week intervention involving daily consumption of wheat pretzel (two packets, 5 oz./packet) for 12 weeks. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. Participants will be randomized to start with soy pretzel or wheat pretzel arm and crossover to the other pretzel at week 14.
62607063|NCT00077441|EXPERIMENTAL|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62607064|NCT05248724|EXPERIMENTAL|Intervention,|Patients allocated to the intervention group received a periarticular infiltration with a solution containing 200 mg of ropivacaine hydrochloride (10mg/ml Kabi Fresenius Kabi Norway AS),150 mg if the patient weight was below 65kg, 5 mg of morphine hydrochloride (10mg/ml Braun Medical SA Spain), 30 mg of ketorolac tromethamine (Normon Spain), 300 micrograms of adrenaline (epinephrine Braun Medical SA Spain), and saline 0.9% till reaching 50 ml of volume
62829303|NCT04994509|EXPERIMENTAL|Blinded Phase: LEN + Placebo-to-match (PTM) F/TAF|"Participants will receive the following for at least 52 weeks:~* Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks~* Oral PTM Emtricitabine/Tenofovir Alafenamide (F/TAF) once daily~* Oral LEN 600 mg on Days 1 and 2"
62047132|NCT02555540|ACTIVE_COMPARATOR|Boostrix, Male, >/= 5 years, D3 visit|"25 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
62047133|NCT02555540|ACTIVE_COMPARATOR|Boostrix, Female, >/= 5 years, D2 visit|"25 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
62439413|NCT04480099|ACTIVE_COMPARATOR|CHOP|Patients in this arm will receive conventional CHOP regimen for 6 cycles
62439414|NCT04480099|EXPERIMENTAL|CHOP+X|Patients in this arm will receive targeted drug in combination with conventional CHOP regimen for 6 cycles, based on NGS results
62439415|NCT02019979|EXPERIMENTAL|metformin /carbohydrate restricted diet|metformin and carbohydrate restricted diet added to platinum based chemotherapy regimen
62607065|NCT05248724|PLACEBO_COMPARATOR|placebo|Participants in the placebo group received a periarticular infiltration of 50 ml of saline 0.9%.
62439416|NCT06539364|ACTIVE_COMPARATOR|NON-SURGICAL PERIODONTAL TREATMENT|Patients included in this group underwent full-mouth scaling followed by root planning in the necessary areas. At the 3-week follow-up session, periodontal surgery was not planned. Periodontal records were maintained, and surveys were administered at follow-up visits.
62439417|NCT06539364|EXPERIMENTAL|SURGICAL PERIODONTAL TREATMENT|Patients included in this group received full-mouth scaling followed by root planning in the necessary areas. After a 3-week follow-up period, periodontal records were taken and surgical periodontal treatment was administered to the required areas. Periodontal records were maintained and surveys were conducted at follow-up visits.
62439418|NCT03214757||group with dilated cardiomyopathy without anemia|
62047134|NCT02555540|ACTIVE_COMPARATOR|Boostrix, Female, >/= 5 years, D3 visit|"25 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
62249603|NCT03353974|EXPERIMENTAL|Video game therapy|Subjects belonging to the experimental group will receive a Video Game Therapy (VGT) protocol using the Xbox console. They will receive 12 sessions of treatment within 4 weeks (3 sessions per week); each session will last 1 hour. To manage possible absence lasting one or more treatment sessions, a potential window of 5 weeks will be set to ensure the achievement of all 12 sessions. Will be required to concentrate in games whose major purposes are increasing balance, selective attention and attention shifting. During sessions the patient will be carefully controlled by a researcher who will prevent the risk of falling
62249604|NCT03353974|ACTIVE_COMPARATOR|Balance platform therapy|"Subjects belonging to the control group will receive the same amount of therapy (12 sessions) using a balance platform (Biodex Medical Systems, Inc., Shirley, NY). Balance/rebalancing, postural stability and weight-shifting exercises ill be administered with and without visual feedback. During the first session, the tasks will be performed at an entry level, and the exercise progression will be adjusted over time according to the patients' functional level (intermediate and difficult level). Balance platform therapy offered visual feedback and knowledge of performance (augmented feedback). The physiotherapist, as during VGT, provided additional external feedback."
62249605|NCT02830672|ACTIVE_COMPARATOR|Open surgical release A1 Pulley|
62249606|NCT02830672|ACTIVE_COMPARATOR|Ultrasound guided close release A1 pulley|
62249607|NCT02895503|EXPERIMENTAL|Arm I (yoga)|Patients undergo traditional medical treatment, participate in yoga comprising basic postures and breathing exercises 3-4 times per week, and attend yoga class once weekly over 30-60 minutes for 12 weeks.
62249608|NCT02895503|ACTIVE_COMPARATOR|Arm II (emotional support group therapy)|Patients undergo traditional medical treatment and participate in emotional support group therapy with a chaplain to work on mind-body therapies comprising guided imagery and spirituality once weekly for 12 weeks.
62439419|NCT03214757||group with dilated cardiomyopathy with anemia|
62439420|NCT00719654||EOS-Preeclampsia|Women with symptoms of early-onset preeclampsia
62439421|NCT00719654||Normal|Women who do not have symptoms of early-onset preeclampsia
62439422|NCT03339635|EXPERIMENTAL|Testosterone gel|Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
62439423|NCT03339635|PLACEBO_COMPARATOR|Placebo gel|Patients will be randomized to treatment with placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
62439424|NCT02008110|EXPERIMENTAL|CA125 guided strategy|In this group, physician will be encouraged to maximize all treatment measures aimed to keep CA125≤35 U/ml (normal values).
62439425|NCT02008110|ACTIVE_COMPARATOR|Standard treatment strategy|Therapy is based on established european current guidelines
62439426|NCT02627014|EXPERIMENTAL|INTERVENTION|Manual Therapy in temporomandibular joint and cervical region. Home physical therapy in temporomandibular joint and cervical region.
62439427|NCT02627014|ACTIVE_COMPARATOR|CONTROL|Manual therapy in cervical region Home physical therapy in cervical region
62607066|NCT05212324||widening|widening of first web space by flaps, tendon transfer to extensor policis longus tendon, fractional lengthening of flexor policis longus tendon
62439428|NCT01075620|EXPERIMENTAL|PFC sigma RP|Posterior stabilized rotating platform knee (press Fit Condylar Sigma rotating-platform, Depuy, Warsaw, Indiana)
62439429|NCT01075620|ACTIVE_COMPARATOR|LCS RP|non posterior stabilized Low Contact Stress Rotating-Platform; Depuy, Warsaw, Indiana
62439430|NCT04718220|PLACEBO_COMPARATOR|Unexposed (SARS-CoV-2 negative) cohort|Women who do not experience laboratory-confirmed SARS-CoV-2 infection during pregnancy.
62047135|NCT02555540|PLACEBO_COMPARATOR|Placebo, Male, >/= 5 years, D2 visit|"5 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
62439431|NCT04718220|ACTIVE_COMPARATOR|Exposed (SARS-CoV-2 positive) cohort|Women who experience laboratory-confirmed SARS-CoV-2 infection during pregnancy.
62439432|NCT04179071|EXPERIMENTAL|Savolitinib|Subjects will receive single dose of 600mg savolitinib after a high-fat, high-calorie meal.
62439433|NCT04179071|EXPERIMENTAL|Savolitinib + Famotidine|Subjects will receive savolitinib 600mg single dose after high-fat, high-calorie meal and after 1.5 hours (Part A) or 5.5 hours (Part B) of famotidine 40mg dose. Famotidine will be administered after an overnight fast of at least 8 hours with approximately 240 mL of water.
62439434|NCT02990832|EXPERIMENTAL|Exciton|Treatment of diabetic foot ulcer with Exciton Exsalt wound dressing
62439435|NCT00289458|EXPERIMENTAL|Aquatic Education|Exercise combined with education
62439436|NCT00289458|EXPERIMENTAL|Aquatic|
62439437|NCT00289458|PLACEBO_COMPARATOR|Control|
62607067|NCT03123796||Only PPI|Kidney transplant recipients who used only proton pump inhibitors and did not use histamine H2 receptor antagonists.
62607068|NCT03123796||Only H2RA|Kidney transplant recipients who used only histamine H2 receptor antagonists and did not use proton pump inhibitors.
62607069|NCT03123796||PPI and H2RA|Kidney transplant recipients who used both proton pump inhibitors and histamine H2 receptor antagonists.
62439438|NCT00374543|EXPERIMENTAL|Ziprasidone|Ziprasidone will be dosed on a twice daily (BID) basis, with flexible dosing based on tolerability, with a total daily dose in the range of 40 to 160 mg/day, for 8 weeks. This time period reflects the rapid onset of effect seen in studies of atypical antipsychotics, but allows time for a potentially longer response for some anxiety symptoms.
62439439|NCT00374543|PLACEBO_COMPARATOR|Placebo Capsules|Identical placebo capsules will be dosed on a BID basis, with flexible dosing based on tolerability, with a total daily dose in the range of 40 to 160 mg/day.
62439440|NCT00470444|ACTIVE_COMPARATOR|1|Liberal transfusion strategy
62439441|NCT00470444|ACTIVE_COMPARATOR|2|Restrictive transfusion strategy
62439442|NCT03961776||non-metastatic rectal adenocarcinoma nRCT indicated|Patients with histologically confirmed non-metastatic rectal adenocarcinoma and for whom treatment with nRCT has been indicated.
62439443|NCT01127854||Cases|
62047136|NCT02555540|PLACEBO_COMPARATOR|Placebo, Male, >/= 5 years, D3 visit|"5 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
62047137|NCT02555540|PLACEBO_COMPARATOR|Placebo, Female, >/= 5 years, D2 visit|"5 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
62439444|NCT01127854||Controls|
62607070|NCT03123796||No Acid Suppressive Treatment|Kidney transplant recipients who used neither proton pump inhibitors nor histamine H2 receptor antagonists.
62607071|NCT01651338|EXPERIMENTAL|accupuncture,|The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
62607072|NCT00778102|EXPERIMENTAL|1|
62829304|NCT04994509|EXPERIMENTAL|Blinded Phase: LEN + PTM F/TDF|"Participants will receive the following for at least 52 weeks:~* SC LEN 927 mg every 26 weeks~* Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily~* Oral LEN 600 mg on Days 1 and 2"
62829305|NCT04994509|EXPERIMENTAL|Blinded Phase: Placebo LEN + F/TAF|"Participants will receive the following for at least 52 weeks:~* SC placebo LEN every 26 weeks~* Oral F/TAF 200/25 mg once daily~* Oral PTM LEN on Days 1 and 2"
62829306|NCT04994509|EXPERIMENTAL|Blinded Phase: Placebo LEN + F/TDF|"Participants will receive the following for at least 52 weeks:~* SC placebo LEN every 26 weeks~* Oral F/TDF 200/300 mg once daily~* Oral PTM LEN on Days 1 and 2"
62829307|NCT04994509|EXPERIMENTAL|LEN Open-Label Extension (OLE) Phase|"After completion of the Blinded phase, participants will be offered entry into the LEN OLE Phase.~Participants randomized to LEN will continue to receive SC LEN 927 mg every 26 weeks for a total of 2 doses.~Participants randomized to F/TAF or F/TDF will receive SC LEN 927 mg on OLE Day 1 and OLE Week 26, and will also receive oral LEN 600 mg on OLE Days 1 and 2."
62829308|NCT04994509|EXPERIMENTAL|Pharmacokinetic (PK) Tail Coverage Phase|"At the completion of the LEN OLE phase, participants will transition into the PK Tail Coverage phase.~Additionally, participants that either prematurely discontinue the study drug during the blinded phase or choose not to continue in the LEN OLE phase (if randomized to LEN in the blinded phase) or who discontinue the study drug in the LEN OLE phase are also eligible to transition to the PK Tail Coverage phase.~Participants will receive oral F/TDF once daily for 78 weeks beginning 26 weeks after the last LEN injection."
62829309|NCT02636595|EXPERIMENTAL|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
62047138|NCT02555540|PLACEBO_COMPARATOR|Placebo, Female, >/= 5 years, D3 visit|"5 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
62047139|NCT02555540|ACTIVE_COMPARATOR|Boostrix, Male, <5 years, D2 visit|"25 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
62439445|NCT02049359|NO_INTERVENTION|Control group|Care as usual; no bidirectional texting
62439446|NCT02049359|EXPERIMENTAL|Texting|Bidirectional texting weekly for 12 weeks
62439447|NCT04345471|EXPERIMENTAL|MD-120 100 mg|
62439448|NCT04345471|EXPERIMENTAL|MD-120 50 mg|
62439449|NCT04345471|PLACEBO_COMPARATOR|Placebo|
62439450|NCT06329596|EXPERIMENTAL|Xylitol gum|Participants will receive 6.36grams of daily xylitol; Epic dental gum, 1.06 grams Xylitol per piece of gum; to chew two pieces for 5 minutes after meals, thrice a day.
62439451|NCT06329596|PLACEBO_COMPARATOR|Sorbitol gum|Participants will receive Epic sorbitol-containing gum (0 grams xylitol/day); to chew two pieces for 5 minutes after meals, thrice a day.
62607073|NCT00778102|ACTIVE_COMPARATOR|2|
62607074|NCT05329051|EXPERIMENTAL|SCTV01E Group|Participants will receive one dose of SCTV01E on Day 0
62607075|NCT05329051|ACTIVE_COMPARATOR|Comirnaty Group|Participants will receive one dose of Comirnaty on Day 0
62607076|NCT05679817|EXPERIMENTAL|D-GAE group|This group received a 12-week aerobic training in addition to the traditional physical rehabilitation.
62607077|NCT05679817|ACTIVE_COMPARATOR|Control group|This group received the traditional physical rehabilitation only
62607078|NCT00551161|EXPERIMENTAL|single-arm|24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 20 mg per day, in addition to their ongoing stable cholinesterase inhibitor treatment
62249609|NCT00545402|EXPERIMENTAL|MMF, Adjusted Dose; Tacrolimus; Corticosteroids|Participants received mycophenolate mofetil (MMF) 3 grams per day (g/d), orally (PO), twice per day (BID) with meals from Day 0 to Day 4; the dose was adjusted based on total exposure (AUC) using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12. Participants also received tacrolimus adjusted to a target trough level of 8 to (-) 12 nanograms per milliliter (ng/mL) from Day 0 to Month 1; the dose was adjusted to reach a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12. Participants also received corticosteroids 10-15 milligrams per kilogram (mg/kg), intravenously (IV), pre-operation on Day 0.
62607079|NCT04898972|EXPERIMENTAL|Mindfulness-based stress reduction intervention|Patient-family caregiver dyads will take part in 8-week Mindfulness-based stress reduction intervention (MBSR).
62607080|NCT04898972|ACTIVE_COMPARATOR|information booklet|Patient-informal caregiver dyads will receive an informative booklet on stress reduction strategies
62607081|NCT02033200|EXPERIMENTAL|Active|Stendra 200 mg
62607082|NCT02033200|PLACEBO_COMPARATOR|Placebo|placebo
62439452|NCT03918551|OTHER|Sequence AB|25 subjects assigned to the sequence AB will receive a single 120 mg dose of the test product Febuxostat (1 x 120 mg film-coated tablet), marked as A in the sequence, in Period 1 and a single 120 mg dose of the reference product Adenuric (1 x 120 mg film-coated tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62439453|NCT03918551|OTHER|Sequence BA|25 subjects assigned to the sequence BA will receive a single 120 mg dose of the reference product Adenuric (1 x 120 mg film-coated tablet), marked as B in the sequence, in Period 1 and a single 120 mg dose of the test product Febuxostat (1 x 120 mg film-coated tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62439454|NCT04046042|ACTIVE_COMPARATOR|Conventional exercise time|During 12 months subjects will exercise during the first two hours of the hemodialysis session. A virtual reality exercise program will be implemented
62439455|NCT04046042|EXPERIMENTAL|Experimental group|During 12 months subjects will exercise during the last two hours of the hemodialysis session. A virtual reality exercise program will be implemented
62439456|NCT05442983|EXPERIMENTAL|PanCytoVir™ 500 mg twice daily|
62439457|NCT05442983|EXPERIMENTAL|PanCytoVir™ 1000 mg twice daily|
62607083|NCT01108419|ACTIVE_COMPARATOR|1 = Test Product normal dose|Fermented dairy product containing probiotics - normal dose
62607084|NCT01108419|ACTIVE_COMPARATOR|2 = Test Product high dose|Fermented dairy product containing probiotics - high dose
62607085|NCT01108419|SHAM_COMPARATOR|3 = Control Product normal dose|Non-fermented dairy product - normal dose
62047140|NCT02555540|ACTIVE_COMPARATOR|Boostrix, Male, <5 years, D3 visit|"25 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
62607086|NCT01108419|SHAM_COMPARATOR|4 = Control Product high dose|Non-fermented dairy product - high dose
62607087|NCT03197870|EXPERIMENTAL|AKB-9778 15mg Daily|AKB-9778 15 mg (QD); To maintain masking, subjects will receive BID dosing with masked study medication administered as one dose of active and one dose of matching placebo
62607088|NCT03197870|EXPERIMENTAL|AKB-9778 15mg Twice Daily|AKB-9778 15 mg (BID)
62607089|NCT03197870|PLACEBO_COMPARATOR|Placebo Twice Daily|Placebo Group: SC Phosphate-Buffered-Saline (PBS) (BID)
62607090|NCT03345888||resuscitation time line group|The ETCO2 will be arrange in resuscitation time line.
62607091|NCT03345888||ETCO2 time line group|The ETCO2 will be arrange in time line which the beginning time is the time of starting to show stable ETCO2 wave.
62607092|NCT05510219|EXPERIMENTAL|Intravenous rapid infusion of obinutuzumab|Patients with B-cell non-Hodgkin's lymphoma were treated with the standard infusion regimen of obinutuzumab in cycle 1, and for patients who did not develop severe infusion-related reactions in cycle 1, a rapid 90-min obinutuzumab infusion regimen was used from cycle 2 onward while recording any occurrence of infusion reactions in different treatment cycles.
62607093|NCT04796883|EXPERIMENTAL|single arm|Hanita Glaucoma shunt Ver.3.2
62047141|NCT02555540|ACTIVE_COMPARATOR|Boostrix, Female, <5 years, D2 visit|"25 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
62047142|NCT02555540|ACTIVE_COMPARATOR|Boostrix, Female, <5 years, D3 visit|"25 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
62047143|NCT02555540|PLACEBO_COMPARATOR|Placebo, Male, <5 years, D2 visit|"5 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
62047144|NCT02555540|PLACEBO_COMPARATOR|Placebo, Male, <5 years, D3 visit|"5 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
62047145|NCT02555540|PLACEBO_COMPARATOR|Placebo, Female, <5 years, D2 visit|"5 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
62047146|NCT02555540|PLACEBO_COMPARATOR|Placebo, Female, <5 years, D3 visit|"5 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
62047147|NCT06489873|ACTIVE_COMPARATOR|LZF Supplement|Participants will take one LZF supplement daily for six months.
62249610|NCT00545402|ACTIVE_COMPARATOR|MMF, Standard Dose; Tacrolimus; Corticosteroids|Participants received MMF 2 g/d, PO, BID with meals from Day 0 to Month 12. Participants also received tacrolimus adjusted to a target trough level of 8-12 ng/mL from Day 0 to Month 1; the dose was reduced to reach a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12. Participants also received corticosteroids 10-15 mg/kg, IV, pre-operation on Day 0; followed by 20 mg/d, PO, 4 times per day (QDS) from Day 0 through Month 1; 15 mg/d, PO, 3 times per day (TID) from the end of Month 1 through Month 2; 10 mg/d, PO, BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
62439458|NCT05442983|PLACEBO_COMPARATOR|Placebo twice daily|
62047148|NCT06489873|PLACEBO_COMPARATOR|Placebo|Participants will take on placebo supplement daily for six months.
62249611|NCT01848886|OTHER|Grp 1: ERAH, Mammarioradial (Y-graft)|Endoscopic radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an composite graft (Y-graft).
62249612|NCT01848886|OTHER|Grp 2: ERAH, Aortoradial (Free RA)|Endoscopic radial artery harvest Aortooradial (free RA) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an free RA graft.
62439459|NCT02002117||DNA mass spectrometry|DNA mass spectrometry
62439460|NCT03277183|PLACEBO_COMPARATOR|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
62439461|NCT03277183|EXPERIMENTAL|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
62439462|NCT00626925|ACTIVE_COMPARATOR|Total Topiramate Group|topiramate capsules beginning at 25 mg/day with gradual increase to a maximum of 200 mg orally)
62607094|NCT01678885|EXPERIMENTAL|Sub-study 1, Dig Photo, Actical & IDEEA|During one week of the doubly labeled water (DLW), participants will use digital photography of foods. During the other week of the DLW phase, participants will wear the Intelligent Device for Energy Expenditure and Activity (IDEEA) monitor and Actical monitor. Whether the participants wear the monitors first or complete digital photography first will be randomozed. Participants who complete the first two weeks and have a BMI over 25kg/m2 will receive a partial supplement low-calorie diet (LCD) for 8 weeks. This diet plan is a 1000-1150 kcal/day diet that participants will complete in a free-living environment. All participants will return to follow-up at six and twelve months after they completed the LCD. Anthropometric and questionnaire data will be collected.
62607095|NCT01678885|EXPERIMENTAL|Sub-study 2 - Dig Photo & Sensewear|During one week of the doubly labeled water (DLW) period, participants will use digital photography of foods. During the other week of the DLW phase, participants will wear the Sensewear armband. Whether the participants wear the monitor first or complete digital photography first will be randomozed. Participants who complete the first two weeks and have a BMI over 25kg/m2 will receive a partial supplement low-calorie diet (LCD) for 8 weeks. This diet plan is a 1000-1150 kcal/day diet that participants will complete in a free-living environment. All participants will return to follow-up at six and twelve months after they completed the LCD. Anthropometric and questionnaire data will be collected.
62607096|NCT03530813|ACTIVE_COMPARATOR|Face-To-Face Group|Asthma First Aid Management in Schools 3 Hour Face to Face Training Group, selected a training session to attend in their local area.
62607097|NCT03530813|EXPERIMENTAL|Ebook Group|Asthma Management in Schools eBook training group were sent a cloudStor link to download and complete training
62249613|NCT01848886|OTHER|Grp 3: ORAH, Mammarioradial (Y-graft)|Open radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an open procedure and positioned on the heart as an composite graft (Y-graft).
62249614|NCT01848886|OTHER|Grp 4: ORAH, Aortoradial graft (Free RA)|Aortooradial graft (free RA) Open radial artery harvest In this group the radial artery is harvested as an open procedure and positioned on the heart as an free RA graft.
62829310|NCT01722617|NO_INTERVENTION|DAS 28|Patients in this group will be asked to fill basic questionnaires, but without the FLARE questionnaires.
62249615|NCT00580372|EXPERIMENTAL|Study Treatment|Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.
62249616|NCT01580865|ACTIVE_COMPARATOR|Mycophenolate Mofetil (MMF)|MMF was initiated at a dose of 500 mg twice daily (for patients \> 50 Kg and Estimated Glomerular Filtration rate (eGFR) \> 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. .
62249617|NCT01580865|EXPERIMENTAL|Tacrolimus (TAC)|TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter
62249618|NCT01482585||early stage lung adenocarcinoma|
62249619|NCT02046096|EXPERIMENTAL|Günther Tulip® Vena Cava Filter|Günther Tulip® Vena Cava Filter
62249620|NCT02046096|EXPERIMENTAL|Cook Celect® Vena Cava Filters|Cook Celect® Vena Cava Filters
62439463|NCT00626925|PLACEBO_COMPARATOR|Total Placebo Group|inactive placebo matched in appearance with topiramate capsules
62439464|NCT03822962|OTHER|Standard Tylenol Regimen|"Patient will be given a standard regimen:~Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed."
62439465|NCT03822962|ACTIVE_COMPARATOR|Ibuprofen 600mg|Tylenol 1000 mg by mouth every 6 hours scheduled and ibuprofen 600 mg tablet by mouth every 8 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
62439466|NCT03270137|ACTIVE_COMPARATOR|Condition A: rTMS on L-DLPFC|"Repetitive transcranial magnetic stimulation- IDLPFC. The intervention will be rTMS delivered on left dorsolateral prefrontal cortex (L-DLPFC).~Every patient will receive 15 rTMS sessions (in weekdays) along three weeks at 5 Hz of frequency and at its 100% of motor threshold. Each session will consist of 30 trains separated by 10 seconds inter-train interval and 1500 total pulses per session.~Equipment to rTMS includes a Magpro R30 stimulator (Magventure, Denmark) with an 8-shape coil model MCF-B70."
62829311|NCT01722617|ACTIVE_COMPARATOR|DAS 28 + FLARE questionnaires|Patients in this group will be asked to fill basic questionnaires and FLARE questionnaires.
62249621|NCT02248948|PLACEBO_COMPARATOR|Medium Chain Triglycerides Supplement|Medium Chain Triglycerides Oil with 5 micrograms of Vitamin D and 6 mg of Vitamin E in 4 ml.
62829312|NCT01722617|ACTIVE_COMPARATOR|DAS 28+FLARE + information to doctor|Patients in this group will fill basic and FLARE questionnaires which then will be transmitted to physician.
62249622|NCT02248948|EXPERIMENTAL|Omega-3 Fatty Acids Supplement|The Omega-3 Fatty Acid supplement provides 540 mg of eicosapentaenoic acid (EPA), 340 mg of docosahexaenoic acid (DHA), 60 mg of gamma linolenic acid (GLA/Omega-6), 5 micrograms of Vitamin D and 6 mg of Vitamin E in 4 ml.
62249623|NCT05147467|EXPERIMENTAL|APG-2575 single agent in Relapse/Refractory CLL/SLL|APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.
62249624|NCT04766476|EXPERIMENTAL|Active Treatment (BMS-963272) Dosing Regimen 1|
62249625|NCT04766476|EXPERIMENTAL|Active Treatment (BMS-963272) Dosing Regimen 2|
62249626|NCT04766476|PLACEBO_COMPARATOR|Placebo|
62249627|NCT04513886|ACTIVE_COMPARATOR|Suture Group|After harvesting a subepithelial connective tissue graft using the single incision technique collagen haemostatic sponge placement and subsequent compression with gauze soaked in saline for 5 minutes, a cross- mattress suture and interrupted single sutures were performed using nylon 5-0 when appropriate.
62047149|NCT02421484|EXPERIMENTAL|allogeneic mesenchymal stromal cells|This is a Phase 1 dose escalation clinical trial that constitutes 3 dose cohorts with 3 participants per cohort who will receive intravenous doses of allogeneic bone marrow derived allogeneic mesenchymal stromal cells--0.3 million cells/kg, 1.0 million cells/kg, and 3.0 million cells/kg. We will proceed from the lower dose to the next higher dose if there are no safety concerns for each cohort.
62047150|NCT01118533|EXPERIMENTAL|metallic blades|laryngoscope blade material
62249628|NCT04513886|EXPERIMENTAL|no Suture Group|After harvesting a subepithelial connective tissue graft using the single incision technique, collagen haemostatic sponge placement and subsequent compression with gauze soaked in saline for 5 minutes no suture was performed.
62249629|NCT04795726|EXPERIMENTAL|Treatment group|Patients received treatment in phase 3 clinical trials FIDELIO-DKD (16244) and FIGARO-DKD (17530).
62607098|NCT05919095|EXPERIMENTAL|Carrilizumab plus GEMOX|Carrilizumab combinated With gemcitabine and oxaliplatin (GEMOX)
62047151|NCT01118533|ACTIVE_COMPARATOR|plastic laryngoscope blades|Laryngoscope Blade Material
62607099|NCT01043705||CIED replacement with CRT and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with a CRT and the TYRX Anti-bacterial envelope, with or without lead revision.
62829313|NCT01748734|EXPERIMENTAL|Supportive care (cognitive behavioral therapy)|Cognitive behavioral therapy comprising progressive muscle relaxation training, behavioral activation, seeking information as a coping strategy, enhancing social support, cognitive reappraisal, assertive communication, changing depressive core beliefs, goal setting and planning for maintenance, and maintenance over 1 hour once weekly sessions for 12-20 weeks, biweekly sessions for 4-6 weeks, and monthly sessions for 2-3 months for a total of 16-26 sessions.
62249630|NCT04795726|PLACEBO_COMPARATOR|Placebo group|Patients received placebo in phase 3 clinical trials FIDELIO-DKD (16244) and FIGARO-DKD (17530).
62249631|NCT04262050|EXPERIMENTAL|TMS + tDCS group|
62249632|NCT04262050|EXPERIMENTAL|sham TMS + tDCS group|
62047152|NCT04669730|PLACEBO_COMPARATOR|Arm A: usual care|Routine usual care
62047153|NCT04669730|ACTIVE_COMPARATOR|Arm B: walk|Walk 30mins per day, 5 days per week.
62047154|NCT04669730|ACTIVE_COMPARATOR|Arm C: Baduanjin|Baduanjin 12 mins per day, 5 days per week.
62047155|NCT04669730|EXPERIMENTAL|Arm D: Baduanjin plus walk|Walk 30mins then Baduanjin 12 mins per day, 5 days per week.
62047156|NCT04900129|EXPERIMENTAL|Study Group|This group inhaled vapor containing Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm% twice daily in addition to conventional treatment. That is, 100 gram of emulsion contain diclofenac sodium 1 gram, N-acetyl cysteine 1.2 gm, menthol 20 mg, and methyl salicylic acid 50 mg. These drugs have no systemic and local side effects in these small doses, though it may cause slight eye irritation.
62047157|NCT04900129|NO_INTERVENTION|Control Group|This group inhaled plain aquatic vapor in addition to conventional treatment.
62047158|NCT05394662|EXPERIMENTAL|Transcervical Gynecological Procedure + Juveena Hydrogel|Transcervical Gynecological Procedure + Juveena Hydrogel
62047159|NCT05394662|NO_INTERVENTION|Transcervical Gynecological Procedure alone (standard of care)|Transcervical Gynecological Procedure alone (standard of care)
62047160|NCT01861184||LRTI group|Non-pneumonic LRTI (no radiological consolidation but the presence of clinical signs) or community acquired pneumonia (radiological consolidation) Able to give fully informed consent (mental capacity assessed using trust guidelines) Age\>18yrs old Fluent English speaker
62047161|NCT01861184||Control group|Able to give fully informed consent (mental capacity assessed using trust guidelines) Age\>18yrs old Fluent English speaker
62047162|NCT05225623|EXPERIMENTAL|Intervention|16-week behavioural weight loss classes
62249633|NCT04262050|EXPERIMENTAL|tDCS group|
62249634|NCT04262050|EXPERIMENTAL|TMS group|
62249635|NCT05013645|EXPERIMENTAL|Sterilized probiotic (LfQi601)|Sterilized probiotic topically administered.
62249636|NCT05013645|PLACEBO_COMPARATOR|Gel control product|Inactive placebo.
62249637|NCT02726971|EXPERIMENTAL|Low dose of oestrogen|"Patients in this group will build artificial cycle by Femoston.(oral one red tablet daily for 11 days and oral one yellow tablet in the next 10 days). This process will last for 3 months after the surgery.~P.S.1.A red tablet contains 2mg estradiol. 2.A yellow tablet contains 2mg estradiol and 10mg dydrogesterone."
62249638|NCT02726971|ACTIVE_COMPARATOR|High dose of oestrogen|"Patients in this group will build artificial cycle by Femoston.(oral three red tablets daily for 11 days and oral two yellow tablets in the next 10 days). This process will last for 3 months after the surgery.~P.S.1.A red tablet contains 2mg estradiol. 2.A yellow tablet contains 2mg estradiol and 10mg dydrogesterone."
62607100|NCT01043705||CIED replacement with ICD and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with an ICD and the TYRX Anti-bacterial envelope, with or without lead revision.
62607101|NCT01043705||CIED replacement with ICD or CRT and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with an ICD or CRT and the TYRX Anti-bacterial envelope, with or without lead revision.
62607102|NCT01043705||CIED replacement w/ CRT & no TYRX|(Retrospective Case-Control Arm) Patients who have undergone CIED replacement with a CRT and no TYRX Anti-bacterial envelope, with or without lead revision/addition.
62607103|NCT01043705||CIED replacement w/ CRT & TYRX vs. Case Match Arm|Patients who have undergone CIED replacement with a CRT and TYRX Anti-bacterial envelope, with or without lead revision/addition. Cohort is TYRX Case, Matched to Retrospective Case-Control Arm)
62607104|NCT01264848|EXPERIMENTAL|Balloon angioplasty and/or stenting|Balloon angioplasty and/or stenting of stenosed internal jugular vein and/or azygous vein and/or brachiocephalic vein
62607105|NCT02315872|EXPERIMENTAL|ACTH|The study drug (ACTH 40 units) will be given subcutaneously twice weekly for 2 weeks. If the patient tolerates this dosage regimen, the dose will be increased to 80 units twice weekly. If the 80 unit dosage is not tolerated, the dosage will be reduced to 40 units twice weekly for the remainder of the 24 week participation. The weekly doses will be given 3 days apart, for example, on every Monday and Thursday or every Tuesday and Friday.
62047163|NCT05225623|OTHER|Waitlist Control|Participants in this arm will receive their treatment as usual for Psoriatic Arthritis and receive BWLT after the intervention group.
62439467|NCT03270137|ACTIVE_COMPARATOR|Condition B: rTMS on six regions|"Repetitive transcranial magnetic stimulation - Six regions. Two sub-conditions will alternate each session, starting with day 1: rTMS on Broca and Wernicke area and lDLPFC and then day 2: rTMS on left and right parietal association cortex (lPAC; rPAC) and right dorsolateral prefrontal cortex (rDLPFC).~Patients will receive 15 intervention sessions (in weekdays) along three weeks at 5 Hz frequency and 100% of motor threshold. Each area will receive 10 trains (500 pulses) separated by 10 seconds of inter-train interval that correspond to 1500 total pulses per session.~Equipment to rTMS includes a Magpro stimulator (Dantec, Denmark) with an 8-shape coil model MC-B70."
62439468|NCT05353374|EXPERIMENTAL|Sodium fusidate ointment|Electrosurgery was carried out using Ellman® Surgitron. The tissue was cleaned using sterile gauze or a cotton swab that had been moistened with 0.9% NaCl. Following electrosurgery, sodium fusidate ointment was applied to the wound according to the allocation sequence. The patient also received a wound care instruction sheet. Each subject was given two or four pots of ointment that should be applied twice daily on the wound.
62607106|NCT02315872|PLACEBO_COMPARATOR|Placebo|Placebo will be given subcutaneously twice weekly for 28 weeks.
62607107|NCT00618709|EXPERIMENTAL|Cohort 1|ATX-101 (1 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid
62607108|NCT00618709|EXPERIMENTAL|Cohort 2|ATX-101 (2 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid
62607109|NCT00618709|EXPERIMENTAL|Cohort 3|3 subgroups in Cohort 3: 3a: ATX-101 (4 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid 3b: ATX-101 (2 mg/cm2) at a volume of 0.2 ml on a 0.7 cm grid 3c: ATX-101 (2 mg/cm2) at a volume of 0.4 ml on a 1.0 cm grid
62607110|NCT00618709|EXPERIMENTAL|Cohort 4|3 subgroups in Cohort 4: 4a: ATX-101 (8 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid 4b: ATX-101 (4 mg/cm2) at a volume of 0.2 ml on a 0.7 cm grid 4c: ATX-101 (4 mg/cm2) at a volume of 0.4 ml on a 1.0 cm grid
62607111|NCT02107573|ACTIVE_COMPARATOR|Rotator cuff repair without Suprascapular Nerve decompression|approximately 17 subjects in the study will receive traditional rotator cuff repair surgical intervention with no suprascapular nerve decompression surgical intervention
62607112|NCT02107573|ACTIVE_COMPARATOR|Rotator Cuff Repair with Suprascapular Nerve decompression|approximately 17 subjects in the study will undergo rotator cuff repair with arthroscopic suprascapular nerve decompression surgical intervention
62829314|NCT01695226|PLACEBO_COMPARATOR|placebo|pre-operative placebo twice daily for two to three weeks
62829315|NCT01695226|EXPERIMENTAL|celecoxib|pre-operative celecoxib (400 mg) twice daily for two to three weeks
62829316|NCT05148468|EXPERIMENTAL|Active stimulation|During active stimulation phase, patients will receive through the spinal cord stimulator active tonic stimulation with amplitude set to 90% of paresthesia inducing threshold, therefore allowing blinding. Patients will be evaluated after a three week wash out period with no stimulation and after three weeks of continuous active stimulation.
62829317|NCT05148468|SHAM_COMPARATOR|Sham stimulation|"During sham stimulation phase, patients will receive through the spinal cord stimulator a zero amplitude stimulation, therefore having no electrical current passing through epidural leads but with the program status still displayed as on if checked with patient's personal controller. Patients will be evaluated after a three week wash out period with no stimulation and after three weeks of continuous sham stimulation."
62829318|NCT02123901|EXPERIMENTAL|Walking meditation & Walking|
62829319|NCT02123901|ACTIVE_COMPARATOR|Walking meditation & No exercise|
62829320|NCT04177823|EXPERIMENTAL|Chinese participants with relapsed/refractory multiple myeloma|Participants will be administered belantamab mafodotin 2.5 mg/kg or 3.4 mg/kg as an intravenous infusion on Day 1 of each 21-day cycle over 30 minutes. Participants will be treated until disease progression, intolerable toxicity, end of study or informed consent withdrawal.
62829321|NCT03922386|OTHER|JX model|Subjects implanted with an RA XFINE lead (JX model)
62829322|NCT03922386|OTHER|TX model|Subjects implanted with an RV XFINE lead (TX model)
62829323|NCT04133818||Multidisciplinary program.|Patients with subacute or chronic LBP for whom first-line treatments had failed but for whom an intensive multidisciplinary rehabilitation program was not indicated.
62829324|NCT01809600||Patients with Burkitt's Lymphoma|should be diagnosed pathologically by WHO 2008 criteria
62047164|NCT05550116|ACTIVE_COMPARATOR|Icon resin infiltration material|Smooth surface resin infiltration comprises three steps for resin infiltration; Icon etch, Icon dry, and Icon infiltrant
62829325|NCT00836693|EXPERIMENTAL|Tadalafil|
62829326|NCT00836693|PLACEBO_COMPARATOR|Placebo|
62829327|NCT01763697|ACTIVE_COMPARATOR|Morhpine/Taste acuity|Taste acuity assessment after 1mg subcutaneous morphine injection
62829328|NCT01763697|PLACEBO_COMPARATOR|Placebo/Taste acuity|Taste acuity assessment after subcutaneous placebo injection
62829329|NCT01763697|ACTIVE_COMPARATOR|Morphine4/Taste acuity|Taste acuity assessment after 4mg subcutaneous morphine injection
62829330|NCT05386420|EXPERIMENTAL|Experimental group|Conventional treatment combined with Hymecromone tablets, 0.4g , tid ac, 7 days.
62829331|NCT05386420|PLACEBO_COMPARATOR|Control group|Conventional treatment combined with placebo.
62829332|NCT06655389||Sepsis cardiac insufficiency group|"Cardiac dysfunction or hemodynamic abnormalities in patients with sepsis, combined with abnormal cardiac ultrasound findings, markers of myocardial injury, and/or markers of cardiac function~1. From April 2024 to December 2026, in the first ICU area of Dongzhimen Hospital, Beijing University of Chinese Medicine,Hospitalized patients in Zone II;~2. consistent with the diagnosis of sepsis cardiac insufficiency;~3. Age ≥ 50 and ≤ 90 years old;~4. SOFA score≥ 2 points;~5. Within 24 hours of the diagnosis of cardiac insufficiency in sepsis;~6. The patient or his/her family members sign the informed consent form."
62829333|NCT06655389||Healthy subjects|"1. Aged ≥ 50 and ≤ 90 years old, permanent residents of Beijing community;~2. Good health (blood routine, liver and kidney function, blood lipids, blood coagulation, no obvious abnormalities, no diagnosis cardiac insufficiency, acute coronary syndrome, old myocardial infarction, or cardiomyopathy);~3. There is no history of long-term use of drugs that affect platelet function and coagulation function, and those who are willing to cooperate with the test Crowd;~4. The subject himself signed the informed consent form."
62829334|NCT01873872|ACTIVE_COMPARATOR|Theralac probiotic|
62047165|NCT05550116|EXPERIMENTAL|PRG Barrier Coat|fluoride-releasing coating material containing surface reaction-type pre-reacted glass-ionomer (S-PRG) fillers
62047166|NCT05550116|EXPERIMENTAL|Permaseal composite resin sealant|Permaseal unfilled composite resin sealants
62047167|NCT05550116|EXPERIMENTAL|Optiguard|Optiguard unfilled composite resin sealant
62047168|NCT01825681|EXPERIMENTAL|positive affect intervention|positive affect intervention
62047169|NCT01825681|NO_INTERVENTION|wait list control|wait list control
62047170|NCT01757626|EXPERIMENTAL|Hu3F8 with GM-CSF|The phase I single arm trial assesses escalating doses of iv hu3F8 (days 1, 3, 5) in the presence of sc GM-CSF (day -4 through 5). These 3 doses of hu3F8 and 10 days of GM-CSF constitute a treatment cycle. The expansion phase II single arm trial assesses the anti-NB activity of hu3F8+GM-CSF.in 3 groups of patients: Group 1 patients have primary refractory disease (no prior relapse but incomplete response to treatment) in BM as documented by histology and/or 123I-MIBG scan. Group 2 patients are in ≥2nd CR and at high risk for another relapse. Group 3 patients have secondary refractory disease (prior relapse and incomplete response to retrieval therapy) in BM as documented by histology and/or 123I-MIBG scan. Ph II: Groups 1 \& 3 pts can continue to get cycles every 1-2 months for up to 24 months from study enrollment or until they receive 5 cycles after a major response (CR or PR) is achieved.
62047171|NCT01757626|EXPERIMENTAL|expansion phase II single arm trial|Group 1 patients have primary refractory disease (no prior relapse but incomplete response to treatment) in BM as documented by histology and/or 123\^I-MIBG scan. Group 2 patients are in \>2nd CR/VGPR and at high risk for another relapse. Group 3 patients have secondary refractory disease (prior relapse and incomplete response to retrieval therapy) in BM as documented by histology and/or 123\^I-MIBG scan. GM-CSF can be omitted if patients have a history of an allergy to GM-CSF or develop an allergic reaction to GM-CSF after initiating therapy while on the protocol.
62829335|NCT01873872|ACTIVE_COMPARATOR|Culturelle probiotic|
62047172|NCT00255931|EXPERIMENTAL|1|
62249639|NCT00660270|EXPERIMENTAL|Arm 1|"Surgery (pancreaticoduodenectomy, either standard or pylorus-preserving, with either standard or extended lymph node dissection, with or without portal vein resection) should occur at 8 weeks (plus or minus 2, not to exceed 10)~Radiation therapy will occur 8 weeks (plus or minus 2, not to exceed 10) postoperatively. Daily dose of 1.8 Gy five days per week. The first 45 Gy will be given to planning target volume 1. After 45 Gy, portals will be reduced to encompass planning target volume 2. The boost dose will be 5.4 Gy.~Cisplatin IV 25 mg/m2 on days 1, 8, 15, 22, 29, and 36 during radiation.~5-FU CIVI at 175 mg/m2/d on days 1-38 without interruption during radiation.~Alpha-interferon SQ 3,000,000 units on Mondays, Wednesdays, and Fridays during radiation therapy.~Gemcitabine IV 1000 mg/m2 4 weeks after conclusion of radiation (on a 3 weeks on/1 week off schedule) on days 71, 78, 85, 99, 106, and 113."
62249640|NCT04142528||Parkinson's Disease|Smartwatch-based sensor assessment of PD symptoms during standard care
62829336|NCT01873872|PLACEBO_COMPARATOR|Placebo|
62829337|NCT06208969|EXPERIMENTAL|intensive nutrition counseling|Five-stage nutrition counseling vith educational materials was carried out during hospitalization in the intensive nutrition counseling. Telephone interviews were conducted at the 2nd week and 2nd month after discharge.
62829338|NCT06208969|ACTIVE_COMPARATOR|standard nutrition counseling|Routine nutritional counseling was applied. Interviewed only at admission and at discharge if patient is consulted.
62047173|NCT00255931|PLACEBO_COMPARATOR|2|
62047174|NCT00255931|NO_INTERVENTION|3|Usual Care
62047175|NCT06162650|EXPERIMENTAL|Experimental arm|The total neoadjuvant therapy with the short-course radiotherapy (5×5 Gy over a maximum of 8 days) followed by chemotherapy with mFOLFOX6 for 9 cycles will be administered.
62439469|NCT05353374|PLACEBO_COMPARATOR|Petrolatum|Electrosurgery was carried out using Ellman® Surgitron. The tissue was cleaned using sterile gauze or a cotton swab that had been moistened with 0.9% NaCl. Following electrosurgery, petrolatum was applied to the wound according to the allocation sequence. The patient also received a wound care instruction sheet. Each subject was given two or four pots of ointment that should be applied twice daily on the wound.
62439470|NCT02558933|EXPERIMENTAL|Epigallocatechin gallate (EGCG) treated|Intervention: Epigallocatechin gallate (EGCG) administered FAS children: An oral dose of 9 mg/Kg/day of EGCG will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment
62439471|NCT02319681|EXPERIMENTAL|Simple Reminiscence (SR) caregiver|Subjects are caregivers for a persons with EAD and will be administered SR intervention and an attention control treatment four times
62439472|NCT02319681|EXPERIMENTAL|Simple Reminiscence (SR) EAD|Subjects are persons with EAD and will be administered SR intervention and an attention control treatment four times
62439473|NCT01891591||obese female subjects|16 obese female subjects with BMI \> 40 kg/m2 on a waiting list for bariatric surgery
62439474|NCT01079676|EXPERIMENTAL|Filgrastim|
62439475|NCT01079676|ACTIVE_COMPARATOR|Granulokine|
62439476|NCT04676191|EXPERIMENTAL|Patients with sleep disorders, cardiorespiratory or neuromuscular disorders|
62439477|NCT00673790|ACTIVE_COMPARATOR|Nebivolol|Nebivolol with concomitant losartan or lisinopril
62439478|NCT00673790|ACTIVE_COMPARATOR|Hydrochlorothiazide (HCTZ)|HCTZ with concomitant losartan or lisinopril
62439479|NCT00673790|PLACEBO_COMPARATOR|Placebo|Placebo with concomitant losartan or lisinopril
62439480|NCT03618979|EXPERIMENTAL|PPP treatment|Platelet Poor Plasma (PPP) into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
62249641|NCT02368067|ACTIVE_COMPARATOR|Standard of Care Sentinal Node Dye|Surgery route, as determined by the patient and clinician, will determine which standard clinical dye will be used.
62249642|NCT02368067|EXPERIMENTAL|Installation of Study Sentinal Node Dye|Surgery route, as determined by the patient and clinician, will determine which study dye will be used for delivery by the experimental route.
62047176|NCT03640351|ACTIVE_COMPARATOR|Preservative free diquafosol group|The subjects use preservative free diquafosol ophthalmic solution after cataract surgery
62607113|NCT02956057|ACTIVE_COMPARATOR|PEG1D|Polyethylene glycols single dose a day before colonoscopy
62607114|NCT02956057|ACTIVE_COMPARATOR|PEG2D|Polyethylene glycols split dose
62607115|NCT02956057|ACTIVE_COMPARATOR|SPMC1D|Natrium picosulfate/ Magnesium citrate single dose day before colonoscopy
62607116|NCT02956057|ACTIVE_COMPARATOR|SPMC2D|Natrium picosulfate/ Magnesium citrate split dose
62607117|NCT02956057|ACTIVE_COMPARATOR|PEGA1D|Polyethylene glycol / Ascorbic acid single dose day before colonoscopy
62607118|NCT02956057|ACTIVE_COMPARATOR|PEGA2D|Polyethylene glycol / Ascorbic acid split dose
62607119|NCT05160194|OTHER|GROW Intervention|Every participant received the GROW Intervention, chose not to participate in the GROW intervention, or dropped out before completing the GROW Intervention.
62607120|NCT04800874|EXPERIMENTAL|Cohort 1|Subjects will receive 6 grams of BBP-418 once daily x 90 days, then 12 grams twice daily (BID, a least 8 hours apart) of BBP-418 daily until study completion.
62607121|NCT04800874|EXPERIMENTAL|Cohort 2|Subjects will receive 6 grams of BBP-418 twice daily (BID, at least 8 hours apart) x 90 days, then 12 grams BID of BBP-418 daily until study completion.
62607122|NCT04800874|EXPERIMENTAL|Cohort 3|Subjects will receive 12 grams of BBP-418 twice daily (BID, at least 8 hours apart) x 90 days, then 12 grams BID of BBP-418 daily until study completion.
62607123|NCT04614103|EXPERIMENTAL|Cohort 1|Patients whose tumors did not express programmed cell death-ligand 1 (PD-L1), i.e., tumor proportion score (TPS) \< 1% prior to ICI treatment and Patients with no available historical TPS for PD-L1 expression
62047177|NCT03640351|ACTIVE_COMPARATOR|Preservative containing diquafosol group|The subjects use preservative containing diquafosol ophthalmic solution after cataract surgery
62047178|NCT03640351|ACTIVE_COMPARATOR|Preservative free sodium hyaluronate group|The subjects use preservative free sodium hyaluronate ophthalmic solution after cataract surgery
62249643|NCT03494751|EXPERIMENTAL|Heart Monitor|We used the device (heart monitor) in the patients with myocardial infarction.
62249644|NCT03494751|ACTIVE_COMPARATOR|No Heart Monitor|No heart monitor device in the patients with myocardial infarction (control).
62249645|NCT01656421||COPD|Patients with Chronic Obstructive Pulmonary Disease, including mild, moderate, severe and very severe airflow obstruction
62047179|NCT03297515|EXPERIMENTAL|Omega 3 fatty acids|Omega 3 fatty acids
62047180|NCT03297515|PLACEBO_COMPARATOR|Placebo|Placebo (sunflower oil)
62047181|NCT05841979|EXPERIMENTAL|group-based therapy|Group therapy delivered via moodlifters
62047182|NCT05841979|EXPERIMENTAL|physical activity|Physical Activity and Exercise
62047183|NCT05841979|EXPERIMENTAL|nature experience|Nature Experiences
62249646|NCT01656421||Comparators|Current or ex-smokers free from from Respiratory Disease
62249647|NCT05893602||Primary tumor prosthesis of the knee containing the PEEK HD coupling mechanism|This group consists of patients with a primary MUTARS knee endoprosthesis containing the PEEK-HD coupling mechanism.
62439481|NCT03618979|EXPERIMENTAL|PRP treatment|5x concentration Platelet Rich Plasma (PRP) injected into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
62439482|NCT03618979|EXPERIMENTAL|PRP and PL Combo treatment|5x concentration PRP injected into the multifidus, along with a facet joint injection with 14x PRP into each joint and capsule, and transforaminal epidural injection with of 3x concentrated platelet lysate (PL) and 0.5% ropivacaine on each side and at each level 1 time every 2 weeks for 6 weeks total (series of 3 injections)
62439483|NCT05832606|EXPERIMENTAL|High Fiber diet|During the first 12 weeks of immune checkpoint inhibitor therapy, patients will receive weekly boxes containing 30 different plants (vegetables, fruits, nuts, grains) according to seasonal availability following the Flemish Superior Health Council guidelines. Recipes will be added to inspire processing of the box. Boxes will be ordered at an online supermarket, who will deliver the boxes at patients' homes. Weekly follow-up will ensure a minimum daily intake of 20 g of fiber, progressively increasing over the first 4 weeks.
62439484|NCT04648579|EXPERIMENTAL|Hillrom|The intervention involves an automated vital signs document system consisting of a mobile medical device for measuring vital signs (CSM / Hillrom) that collects and analyzes data acquired at the bedside to be sent to a remote data processing point (Digital Control Station), using Hillrom Connecta software.
62439485|NCT04648579|ACTIVE_COMPARATOR|Control|Hospital usual care.
62607124|NCT04614103|EXPERIMENTAL|Cohort 2|Patients whose tumors expressed PD-L1 TPS ≥1% prior to ICI treatment
62607125|NCT04614103|EXPERIMENTAL|Cohort 3|Patients, regardless of tumor PD-L1 TPS prior to ICI treatment, who are unable to safely undergo a surgical tumor resection for TIL generation
62607126|NCT04614103|EXPERIMENTAL|Cohort 4|Patients, regardless of tumor PD-L1 expression status prior to ICI treatment, who have meet all inclusion/exclusion criteria except the requirement to have documented disease progression may elect to have the tumor harvest procedure and TIL production prior to disease progression on their current anticancer treatment. Documentation of progressive disease and identification of a target lesion for RECIST v1.1 assessment is required at Baseline for these patients.
62607127|NCT04614103|EXPERIMENTAL|Retreatment Cohort|Patients who were previously treated with LN-145 in Cohort 1, 2, 3, or 4.
62607128|NCT04580537|EXPERIMENTAL|Laser-assisted Enstilar delivery|Ablative fractional laser (AFL) pre-treatment + daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)
62607129|NCT04580537|ACTIVE_COMPARATOR|Enstilar|Daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)
62607130|NCT06386692|EXPERIMENTAL|PA promotion intervention|"Behavioral: FCHV visit~- FCHVs will provide family based physical activity educational intervention through household visit in selected households monthly for 3 months."
62607131|NCT06386692|NO_INTERVENTION|Wait-list control|No intervention
62047184|NCT05841979|NO_INTERVENTION|self-monitoring|Placebo control
62047185|NCT05168891|EXPERIMENTAL|Test group (TG)|Patients will receive professional supragingival teeth/implant prophylaxis, oral hygiene instructions, and implant-supported prosthesis corrections if needed. After 1 week, peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed. Finally, the patients will be enrolled in a peri-implant maintenance therapy (PIMT) program every 3 months.
62047186|NCT05168891|EXPERIMENTAL|Control group (CG)|Patients will receive professional supragingival teeth/implant prophylaxis, oral hygiene instructions, and implant-supported prosthesis corrections if needed. After 1 week, peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed. After one month, the regenerative surgical therapy will be performed as it follows: the intrabony component of the defect will be filled with a xenograft and covered with a collagen membrane allowing a non-submerged healing. Finally, the patients will be enrolled in a PIMT program every 3 months.
62047187|NCT00875004|EXPERIMENTAL|Erythropoietin beta|
62047188|NCT02110901|ACTIVE_COMPARATOR|PRT-201|PRT-201 administered at the time of radiocephalic fistula creation
62047189|NCT02110901|PLACEBO_COMPARATOR|Placebo|Placebo administered at the time of radiocephalic fistula creation. The placebo is identical in appearance and composition to PRT-201 but lacks the active ingredient.
62047190|NCT04016948|EXPERIMENTAL|Probe-based confocal laser endomicroscopy(pCLE)|Confocal laser endomicroscopy optical biopsy will be performed in surgery for patients assigned to this group
62047191|NCT04016948|ACTIVE_COMPARATOR|Intra-operative frozen section(IFS)|Intra-operative frozen section will be performed for patients assigned to this group
62249648|NCT05893602||Revision tumor prosthesis of the knee containing the PEEK-HD coupling mechanism|This group consists of patients requiring revision surgery of their MUTARS knee endoprosthesis containing the MoM coupling mechanism (for any reason), which is exchanged/revised for the PEEK-HD coupling mechanism.
62249649|NCT04442191|EXPERIMENTAL|Convalescent plasma|This study will utilize convalescent plasma from donors recovered from infection with SARS-CoV-2 (which causes COVID-19) with neutralizing antibody titers \>1:64.
62249650|NCT04442191|PLACEBO_COMPARATOR|Placebo|Placebo utilized in this study will include Fresh Frozen Plasma collected before the COVID-19 pandemic began. As an extra control, some of this plasma will be saved and tested for COVID-19 antibodies to ensure they are not present.
62249651|NCT04171518||Catalys Precision Laser System|Cataract Surgery with use of Catalys Precision Laser System
62249652|NCT00896779|OTHER|ranibizumab Group 1|Group 1: 3 monthly injections of 0.5mg then prn
62439486|NCT01302314|EXPERIMENTAL|cognitive rehabilitation|
62607132|NCT01542034|EXPERIMENTAL|Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
62607133|NCT01542034|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
62249653|NCT00896779|OTHER|ranibizumab Group 2|Group 2: 6 monthly injections of 0.5 mg then prn
62249654|NCT03702751|EXPERIMENTAL|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
62249655|NCT03702751|ACTIVE_COMPARATOR|Continuous subcuticular skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
62249656|NCT05436769|EXPERIMENTAL|Test Drug|Klaribact (Clarithromycin 500 mg) Film Coated Tablet (Merck Pvt. Ltd, Pakistan)
62249657|NCT05436769|ACTIVE_COMPARATOR|Reference Drug|Klaricid 500 mg (Clarithromycin 500 mg) Film Coated Tablet (Abbot Laboratories (Pakistan) Limited)
62249658|NCT03093753|PLACEBO_COMPARATOR|Control (study 1)|Control will be 50g glucose dissolved in 200 mL water
62249659|NCT03093753|EXPERIMENTAL|Test (study 1)|The test meals will comprise 50 g glucose plus 50 mg oleuropein from olives dissolved in 200 mL water
62439487|NCT05539183|EXPERIMENTAL|Solid cancer patients with malignant pleural effusion|Solid cancer patients that have to undergo pleural evacuation because of diagnosed malignant pleural effusion mediated discomfort.
62439488|NCT00460473|EXPERIMENTAL|Dexmedetomidine|
62439489|NCT00460473|PLACEBO_COMPARATOR|Placebo (PBO)|
62439490|NCT04504864|EXPERIMENTAL|low-dose aspirin|Management policy is to use 50 mg aspirin per day as a secondary prevention strategy for patients with non-cardioembolic ischemic stroke and microbleeds. 50mg aspirin is recommended by the guideline of ASA/AHA in prevention of stroke. But this dose is rarely used clinically, especially in East Asia area.
62607134|NCT01851187|EXPERIMENTAL|emotional management (EM) group|emotional management (EM) group received antenatal psychological intervention
62047192|NCT02178748|EXPERIMENTAL|Group 1|Group 1 (Schistosoma mansoni uninfected): 12-24 BCG-vaccinated volunteers with no helminth infection. Single dose of 1x10\^8pfu MVA85A intramuscular vaccination at D0.
62047193|NCT02178748|EXPERIMENTAL|Group 2|Group 2 (Schistosoma mansoni infected): 12-24 BCG-vaccinated volunteers with helminth infection. Single dose of 1x10\^8pfu MVA85A intramuscular vaccination at D0.
62047194|NCT06580613|ACTIVE_COMPARATOR|Control|At the Control Primary Health Care Centers care continues as usual
62047195|NCT06580613|EXPERIMENTAL|Intervention|Hypertension management based on cardiovascular risk assessment. Low/medium risk: Digital contact with nurse, contact with GP only if needed High risk: Planned contacts with GP Group education on Hypertension for staff and participants
62047196|NCT05821738|EXPERIMENTAL|Treatment Group|The treatment group will receive avapritinib orally. The dosage is 100mg to 300mg qd, allowed to combine with other chemotheray drugs.
62249660|NCT03093753|PLACEBO_COMPARATOR|Control (study 2)|Control will be white bread (109 g) to give 50 g available carbohydrates with 200 mL water
62249661|NCT03093753|EXPERIMENTAL|Test (study 2)|The test meals will comprise 109 g white bread plus 50 mg oleuropein from olives
62249662|NCT03093753|PLACEBO_COMPARATOR|Control (study 3)|Control will be whole-meal bread (132 g) to give 50 g available carbohydrates with 200 mL water
62607135|NCT01851187|ACTIVE_COMPARATOR|the usual care (UC) group|the usual care (UC) group was given routine prenatal care only
62607136|NCT04523870|EXPERIMENTAL|Botanical extract|
62047197|NCT02671448|EXPERIMENTAL|Homebound After Stem Cell Transplantation|The primary research outputs and measurements are the instruments/surveys, assessments, and video diaries to be completed by the patients, their caregivers and the healthcare providers during the time of the home transplantation care. Protocol-specific interventions during homebound care will continue until patient has achieved neutrophil engraftment. Post engraftment, standard of care practice will resume. Once discharged from homebound care, the patient will complete routine post-HSCT follow-up visits in the clinic setting.
62047198|NCT02802800|EXPERIMENTAL|Water|Plyometric Training in water, twice per week for 6 weeks.
62607137|NCT04523870|EXPERIMENTAL|Major compound of the extract|
62607138|NCT04523870|PLACEBO_COMPARATOR|Placebo|
62607139|NCT03452241|EXPERIMENTAL|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver it and other materials about the harm of substance use.
62607140|NCT03452241|OTHER|Control Group|The participants only receive the materials about the harm of substance use
62607141|NCT03452241|EXPERIMENTAL|Intervention Group 1|The medical staffs who received the training will use the manual of brief intervention twice to deliver it and other materials about the harm of substance use.
62249663|NCT03093753|EXPERIMENTAL|Test (study 3)|The test meals will comprise whole-meal bread (132 g) with 50 mg oleuropein dissolved in 200 mL water
62607142|NCT01884012|EXPERIMENTAL|Supplemental oxygen|Supplemental oxygen 3 liters/minute given via a nasal cannula for 16 hours a day
62829339|NCT03405792|EXPERIMENTAL|Optune System combined with Temozolomide (TMZ) + Pembrolizumab|Patients with newly-diagnosed GBM who undergo maximal safe resection (biopsy alone is eligible) followed by chemoradiation consisting of concomitant TMZ daily and radiation therapy (RT) with minimal RT will be eligible for this trial. Four to six weeks after finishing chemoradiation, patients will start monthly cycles of adjuvant TMZ. Treatment with Optune will start at approximately the same time as the first cycle of adjuvant TMZ and continue until second disease progression or a maximum of 2 years. Within one week after starting Cycle 2 of adjuvant TMZ and Optune therapy, patients will begin open-label treatment with pembrolizumab every 3 weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.
62829340|NCT03405792|OTHER|Historical Control|Historical control of patients treated with Optune System combined with Temozolomide alone from the EF-14 study will be compared with the Optune System combined with Temozolomide (TMZ) + pembrolizumab
62607143|NCT01884012|SHAM_COMPARATOR|Sham room air|Room air given at a flow rate of 3 liters per minute for 16 hours a day
62607144|NCT05479838||ST Elevation MI|ST-segment in adjacent ≥2 leads Elevation ( ≥2 mm in precordial leads, ≥1 mm in extremity leads) or left bundle branch block, ischemic type chest pain lasting longer than 30 minutes, and two or more elevations of serum creatine kinase myocardial band and troponin levels will be used as diagnostic criteria for STEMI. Patients with ST-elevation on the ECG will be referred to as STEMI, non -STEMI with twice the troponin level despite the absence of ST elevation. Patients who do not have ST elevation on ECG and whose troponin values do not exceed the reference range, but who are diagnosed as USAP presenting with typical chest pain and undergoing coronary angiography will be included in the study.
62829341|NCT00698763|EXPERIMENTAL|A|Levosimendan
62829342|NCT00698763|PLACEBO_COMPARATOR|B|Placebo
62829343|NCT00782990|ACTIVE_COMPARATOR|tvt group|Surgical treatment for incontinence: TVT
62829344|NCT00782990|ACTIVE_COMPARATOR|Burch group|Surgical treatment for incontinence: Colposuspension
62829345|NCT06169969|EXPERIMENTAL|Magnetic therapy group|receive magnetic therapy plus pelvic floor exercises.
62829346|NCT06169969|NO_INTERVENTION|Pelvic floor exercises group|pelvic floor exercises only
62829347|NCT05467059||Nap-modulated participants|Patients with rises of tinnitus intensity after taking a nap or after a short period of sleep. If possible with a characteristic ON/OFF tinnitus (sometimes they have a tinnitus for several days and then stop for several days also). This condition is determined by previous questionnaire.
62607145|NCT01286194||Experimental 1|
62829348|NCT00330434|OTHER|Trial Withdrawn 2|Trial Withdrawn 2
62829349|NCT00330434|OTHER|Trial Withdrawn 1|Trial Withdrawn 1
62829350|NCT06600945||Group c control group|Group C (Control group): Will undergo peribulbar block using 6ml of local anesthetic: 2ml of 0.5%bupivacaine and 1ml of 2% lidocaine mixed with hyaluronidase (150 U) + 2ml lidocaine 2 %+ 1ml 0.9% saline without atracurium and magnesium sulphate
62047199|NCT02802800|EXPERIMENTAL|Land|Plyometric training on land, twice per week for 6 weeks.
62047200|NCT04991467|EXPERIMENTAL|Parents of children receiving mental health treatment at Montefiore|Participants will either CARE program alone; b) Valera Health app; c) CARE program and Valera Health app .
62047201|NCT04991467|EXPERIMENTAL|Parents of children being treated for autoimmune disorders at Montefiore|Participants will either CARE program alone; b) Valera Health app; c) CARE program and Valera Health app.
62047202|NCT04991467|EXPERIMENTAL|Healthcare workers at Montefiore|Participants will either CARE program alone; b) Valera Health app; c) CARE program and Valera Health app.
62047203|NCT03468556|EXPERIMENTAL|test drug|2 tabs of SNP-610
62249664|NCT03093753|PLACEBO_COMPARATOR|Control (study 4)|Control will be 50 g sucrose dissolved in 200 mL water
62249665|NCT03093753|EXPERIMENTAL|Test (study 4)|The test meals will comprise 50 mg oleuropein and 50 g sucrose dissolved in 200 ml water
62607146|NCT03340233|EXPERIMENTAL|Group 1|Group 1 includes 25 healthy subjects recruited in Year 1 to undergo cardiac MRI without contrast.
62607147|NCT03340233|EXPERIMENTAL|Group 2|Group 2 includes 25 healthy subjects recruited in Year 2 to undergo cardiac MRI without contrast.
62607148|NCT03340233|EXPERIMENTAL|Group 3|Group 3 includes 33 patients with Heart Failure with Preserved Ejection Fraction (HFpEF) who will undergo cardiac MRI at baseline and at six months to assess diagnostic sensitivity of MRI measurement.
62607149|NCT03532815|ACTIVE_COMPARATOR|Lifestyle Modification group|
62829351|NCT06600945||Group A atracurium group|Group A (Atracurium group): Will undergo peribulbar block using 6ml of local anesthetic: 2ml of 0.5% bupivacaine and 1ml of 2% lidocaine mixed with hyaluronidase (150 U) + 2ml lidocaine 2%+ 0.05 mg/kg atracurium (maximum 5 mg) in 1 ml of 0.9% saline .
62047204|NCT03468556|PLACEBO_COMPARATOR|placebo|2 tabs of placebo
62607150|NCT03532815|NO_INTERVENTION|Control group|
62607151|NCT00607100||1|Patients with Band atrophy of the optic nerve
62607152|NCT00607100||2|Normal Controls
62607153|NCT01570569|ACTIVE_COMPARATOR|Omeprazole|
62607154|NCT01570569|ACTIVE_COMPARATOR|Losartan|
62607155|NCT01570569|ACTIVE_COMPARATOR|Dextromethorphan|
62607156|NCT01570569|ACTIVE_COMPARATOR|Caffeine|
62607157|NCT01570569|ACTIVE_COMPARATOR|Midazolam|
62607158|NCT03619824|EXPERIMENTAL|Intervention arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 \& 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 66-70Gy will be given in six to seven weeks. Concurrent cisplatin 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Sintilimab 200mg will be given every 3 weeks for 6 cycles, started on day 1 of induction chemotherapy.
62607159|NCT00574249|ACTIVE_COMPARATOR|adalimumab + placebo|adalimumab + placebo (vehicle ointment)
62607160|NCT00574249|ACTIVE_COMPARATOR|adalimumab + calcipotriol/betamethasone|adalimumab + calcipotriol/betamethasone ointment
62607161|NCT02846870|ACTIVE_COMPARATOR|Standard Education|Patients receive standard-of-care prostate cancer radiation oncology consultation.
62047205|NCT05502705|EXPERIMENTAL|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the first hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
62439491|NCT04504864|ACTIVE_COMPARATOR|conventional-does aspirin|Management policy is to use 100 mg aspirin per day as a secondary prevention strategy for patients with non-cardioembolic ischemic stroke and microbleeds. 100mg aspirin is recommended by the guideline of ASA/AHA in prevention of stroke, and this dose is widely used clinically.
62439492|NCT00851032||Molecular Profiling Analyses|Participants seen in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center in Houston, Texas
62439493|NCT01564758||Group 1|Subjects that are diagnosed with gram positive infection
62439494|NCT03411590|OTHER|200ml|Toddlers will be allocated to the 200 ml group
62829352|NCT06600945||Group M magnesium sulphate group|Group M (Atracurium+ Magnesium sulfate): Will undergo peribulbar block using 6ml of local anesthetic: 2 ml of 0.5%bupivacaine and 1 ml of 2% lidocaine mixed with hyaluronidase (150 U) +2ml lidocaine2%+ (0.05 mg/kg atracurium (maximum 5 mg) + 50 mg magnesium sulfate) in 1 ml of 0.9% saline
62047206|NCT05502705|PLACEBO_COMPARATOR|Normal saline|Normal saline administered as a bolus and an infusion with identical volume and rate changes as the treatment group.
62439495|NCT03411590|OTHER|400ml|Toddlers will be allocated to the 400 ml group
62439496|NCT03411590|OTHER|600ml|Toddlers will be allocated to the 600 ml
62439497|NCT03218735|EXPERIMENTAL|Labor induction at 37.0 weeks to 37.6 weeks of gestation|Diagnosis of LGA with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
62439498|NCT03218735|ACTIVE_COMPARATOR|Expectant monitoring and delivery|Diagnosis of LGA with expectant monitoring and delivery as indicated by standard obstetric practices
62439499|NCT05480878|PLACEBO_COMPARATOR|Control|"Participants in this arm will receive Placebo with the current DMARDs treatments for rheumatoid arthritis for 12 weeks.~."
62439500|NCT05480878|EXPERIMENTAL|Nitazoxanide|Participants in this arm will receive Nitazoxanide 1 gm/day + DMARDs for 12 weeks.
62439501|NCT05480878|EXPERIMENTAL|Escitalopram|Participants in this arm will receive Escitalopram 10 mg/day + DMARDs for 12 weeks.
62607162|NCT02846870|EXPERIMENTAL|Visually Enhanced Education|Patients receive a visually enhanced prostate cancer educational Powerpoint presentation including prostate anatomy, pathologic results, surgical options, radiation therapy, and prognosis with pictographs during radiation oncology consultation.
62607163|NCT01451242||brain injury|
62607164|NCT04182438|EXPERIMENTAL|Low potassium then normal potassium|After giving the vegetables with low potassium content vegetables for 2 weeks, the serum potassium level was recorded; after 2 weeks of washing time, the normal potassium content vegetables was given for 2 weeks, and the serum potassium concentration was recorded and the test was terminated.
62047207|NCT02548767|EXPERIMENTAL|HFCS-EB|Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided energy-balanced diet. The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain 75% of energy requirement. All and only the provided beverage and diet will be consumed for eight weeks.
62249666|NCT03093753|PLACEBO_COMPARATOR|Control (study 5)|Control will be 25 g sucrose dissolved in 200 mL water
62607165|NCT04182438|EXPERIMENTAL|Normal potassium then low potassium|After giving the normal potassium content vegetables for 2 weeks, the serum potassium concentration was recorded; after 2 weeks of washing time, the low potassium content vegetables use for 2 weeks, then the serum potassium level was recorded at the time. The test was terminated.
62607166|NCT01470014||IVNC|
62607167|NCT01470014||differential diagnosis to IVNC|
62607168|NCT05571176|EXPERIMENTAL|S-ketamine infusion|12 healthy volunteers, S-ketamine infusion 0.29 mg/kg/h for 4 hours
62607169|NCT05571176|PLACEBO_COMPARATOR|Placebo (NaCl 0.9%) infusion|12 healthy volunteers, placebo (NaCl 0.9%) infusion for 4 hours
62607170|NCT04068740||Mitral valve disease|
62607171|NCT04068740||Aortic valve disease|
62607172|NCT05814822|EXPERIMENTAL|Cognitive Behavioral Therapy for insomnia (CBTi-CB-TM)|Delivered via telemedicine
62607173|NCT05814822|ACTIVE_COMPARATOR|Sleep Hygiene Education|Delivered via telemedicine
62607174|NCT05280899|ACTIVE_COMPARATOR|Partial Weight-bearing (PWB)|Patients will PWB for 3 weeks following surgery, followed by a gradual return to FWB.
62607175|NCT05280899|EXPERIMENTAL|Weight-bearing As Tolerated (WBAT)|Patients will WBAT immediately following surgery.
62607176|NCT00110916|EXPERIMENTAL|Anakinra|anakinra
62607177|NCT00110916|PLACEBO_COMPARATOR|placebo|placebo
62607178|NCT03077659|EXPERIMENTAL|NanoPac® 6 mg/mL|NanoPac® 6 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
62607179|NCT03077659|EXPERIMENTAL|NanoPac® 10 mg/mL|NanoPac® 10 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
62439502|NCT02181257|OTHER|Newly Diagnosed Bronchiolitis Obliterans (NEW BOS)|"Participants with NEW BOS will be randomized to Early Photopheresis Intervention (EPI) or Control (Standard of Care). EPI patients will receive 24 treatments in a 6-month period and may continue maintenance treatments. Twenty-two (22) NEW BOS participants were enrolled nationwide.~The Control group will receive local Standard of Care for the management of BOS. Therapy will involve changes in immunosuppressive agents."
62607180|NCT03077659|EXPERIMENTAL|NanoPac® 15 mg/mL|NanoPac® 15 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
62607181|NCT05745467|EXPERIMENTAL|Povidone Iodine|5% povidone iodine will be swabbed in patients' nares (experimental group), one in each nostril, twice before incision.
62607182|NCT05745467|NO_INTERVENTION|Usual Care|Half of the patients will not receive 5% povidone iodine and will proceed with usual care.
62607183|NCT01436864|EXPERIMENTAL|0.5 mg KH902|Patients will receive intravitreal injection of KH902 0.5mg/eye once per month for three times in the study eye, and then patients will receive 2 sham injections monthly, respectively, at the end of month 3 (visit 5), and following these injections you will receive intravitreal injection of KH902 once every three months, till month 12 (respectively at month 5, month 8 and month 11)
62249667|NCT03093753|EXPERIMENTAL|Test (study 5)|The test meals will comprise 160 mg oleuropein and 25 g sucrose dissolved in 200 ml water
62607184|NCT01436864|SHAM_COMPARATOR|Sham-injection|Patients will receive sham injection once per month for three times, and then you will receive intravitreal injection of KH902 0.5mg/eye once per month for three times in the study eye, after three months' treatment they will receive intravitreal injection of KH902 once every three months, till month 12 (respectively at month 8 and month 11.
62607185|NCT03579628|EXPERIMENTAL|AsiDNA|"Part A: AsiDNA as a single agent:~The study will follow a dose escalation 3 + 3 cohort design (with 6 dose levels).~All patients will receive a loading dose of AsiDNA for 3 consecutive days as iv infusion at Day 1 (D1), Day 2 (D2) and Day 3 (D3), followed by iv infusion once a week (at D8 and D15 of a 21 days treatment period (1 cycle = 21 days). Each subsequent cycle will be administered on a weekly basis (D1, D8, D15) of a 21 days treatment period.~Part B: AsiDNA combination with Carboplatin with or without Paclitaxel (Background treatments):~* Part B1: Combination cohort of AsiDNA at DL3 (600mg) with Carboplatin AUC 5.~* Part B2: Combination cohort of AsiDNA at DL3 (600mg) with Carboplatin AUC 5 and weekly Paclitaxel: 80 mg/m2 (full dose)."
62607186|NCT02860117|ACTIVE_COMPARATOR|Ketatamine|Ketamine continuous infusion 0,2mg/kg/h
62607187|NCT02860117|PLACEBO_COMPARATOR|Placebo|Placebo in continuous infusion
62607188|NCT06731465|ACTIVE_COMPARATOR|Fixed labial braces group|Participants in this group will be treated with pre-adjusted fixed orthodontic appliances.
62607189|NCT06731465|ACTIVE_COMPARATOR|Clear aligner group|Participants in this group will receive clear aligners customized based on a digital model of each patient's dentition.
62607190|NCT05057572|EXPERIMENTAL|Carvedilol with Standard Medical Treatment|Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP \>90, HR \>55.
62607191|NCT05057572|ACTIVE_COMPARATOR|Standard Medical Treatment|- Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.
62607192|NCT03724266|EXPERIMENTAL|chitosan|chitosan as intracanal medication 0.2% in form of gel
62829353|NCT03146923|ACTIVE_COMPARATOR|Standard Care Arm|Patients randomised to the standard care arm will be re educated using the current low phosphorus diet prescription.
62829354|NCT03146923|EXPERIMENTAL|Modified Intervention Arm|Patients randomised to the intervention arm will be educated using a modified low phosphorus diet prescription.
62249668|NCT03093753|PLACEBO_COMPARATOR|Control (study 6)|Normal diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
62829355|NCT04322526|EXPERIMENTAL|Naltrexone, then placebo|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate neural responses during the Contextual Framing and the Antidepressant fMRI Task.
62829356|NCT04322526|PLACEBO_COMPARATOR|Placebo, then naltrexone|In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride.
62829357|NCT02821234|EXPERIMENTAL|Insomnia group|Patients with insomnia: sleep complaints, of at least 3 nights a week, for at least 3 months, affected daytime functioning, objectified low sleep quality (SE \<85%) with 10 days actigraphy occurred in the last 2 months
62829358|NCT02821234|EXPERIMENTAL|Control group|Volunteer without sleep problems either self-reported or objectified through actigraphy (SE ≥85%)
62829359|NCT04356898||Diabetes fasting|Diabetes patients who decided to fast during the month of Ramadan
62249669|NCT03093753|EXPERIMENTAL|Test (study 6)|High carbohydrate diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
62249670|NCT03093753|PLACEBO_COMPARATOR|Control (study 7)|Normal diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
62249671|NCT03093753|EXPERIMENTAL|Test (study 7)|High fat diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
62249672|NCT01500850|ACTIVE_COMPARATOR|NPH insulin + insulin glulisine|Patients will be randomized to be treated with NPH insulin + Insulin Glulisine for 24 weeks.
62249673|NCT01500850|ACTIVE_COMPARATOR|NPH insulin + human insulin|Patients will be randomized to be treated with NPH insulin + human insulin for 24 weeks.
62607193|NCT03724266|ACTIVE_COMPARATOR|calcium hydroxide|intracanal medication
62607194|NCT03677934|EXPERIMENTAL|PDS Implant Arm|Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals
62607195|NCT03677934|ACTIVE_COMPARATOR|Intravitreal Arm|Participants will receive ranibizumab 0.5 mg monthly intravitreal injections of 10 mg/mL formulation at Day 1 and every month thereafter.
62607196|NCT04460534|EXPERIMENTAL|COHORT|Cohort
62607197|NCT04459598|EXPERIMENTAL|Efavirenz 600 mg + Quizartinib 60 mg|Participants who received efavirenz 600 mg once daily (QD) for 34 days and a single, oral dose of quizartinib 60 mg on Day 15 concurrently with efavirenz.
62047208|NCT02548767|PLACEBO_COMPARATOR|Asp-EB|Consume 3 servings/day of aspartame-sweetened beverage along with the provided energy-balanced diet. The 3 aspartame-sweetened beverages will contain 0% of energy requirement and the remainder of the provided diet will contain 100% of energy requirement. All and only the provided beverage and diet will be consumed for eight weeks.
62607198|NCT04459598|ACTIVE_COMPARATOR|Quizartinib 60 mg|Participants who received a single, oral dose of quizartinib 60 mg on Day 1.
62047209|NCT02548767|EXPERIMENTAL|HFCS-AL|Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided ad libitum diet. The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain approximately 125% of energy requirement. All the provided beverage will be consumed for eight weeks. Only the provided beverage and diet will be consumed for eight weeks. The provided diet will be consumed ad libitum and the uneaten portions will be returned to study staff.
62607199|NCT01987232|EXPERIMENTAL|Carfilzomib Combination|Participants received carfilzomib on days 2, 3, 9, and 10 of each 21-day cycle as per the dose escalation schema, carboplatin at a target area under the curve (AUC) of 5 on day 1 of each cycle, and etoposide 100 mg/m² on days 1, 2, 3 of each 21-day cycle for up to 6 cycles. Participants with stable disease or better continued to receive carfilzomib alone until progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death, whichever occurred earliest.
62607200|NCT06611397|EXPERIMENTAL|Treatment Group|Study subjects in the treatment group (Arm 1) will receive 3 daily Discogen treatments unilaterally within a one week (M-M) period, each lasting 25 minutes.
62607201|NCT06611397|SHAM_COMPARATOR|Sham Control Group|Subjects in the sham control arm (Arm 2) will receive 3 daily non-powered treatments unilaterally within a one week (M-M) period, each lasting 25 minutes
62047210|NCT02548767|PLACEBO_COMPARATOR|Asp-AL|Consume 3 servings/day of aspartame-sweetened beverage along with the provided ad libitum diet. The 3 aspartame-sweetened beverages will contain 0% of energy requirement and the remainder of the provided diet will contain approximately 125% of energy requirement. All the provided beverage will be consumed for eight weeks. Only the provided beverage and diet will be consumed for eight weeks. The provided diet will be consumed ad libitum and the uneaten portions will be returned to study staff.
62047211|NCT02008604||Stroke patients|
62047212|NCT02008604||TIA patients|patients with a transient ischemic attack (control group)
62249674|NCT01500850|EXPERIMENTAL|Insulin glargine + insulin glulisine|Patients will be randomized to be treated with insulin glargine + insulin glulisine for 24 weeks.
62249675|NCT01500850|EXPERIMENTAL|Insulin Glargine + Human insulin|Patients will be randomized to be treated with insulin glargine + human insulin for 24 weeks.
62249676|NCT03710486||Cohort 1: Vedolizumab|Participants diagnosed with UC or CD, who have initiated vedolizumab treatment between January 2017 until date of site initiation from the 25 participating sites will be observed from the date of UC or CD diagnosis until one day prior to the date of index vedolizumab treatment initiation during the eligibility period, and then from date of index vedolizumab treatment initiation until the earliest of 6 months (post-index treatment discontinuation, death of participant, lost-to-follow up, or date of chart abstraction). Index date is defined as the date when vedolizumab treatment was initiated.
62249677|NCT03710486||Cohort 2: Other Biologic|Participants diagnosed with UC or CD, who have initiated other biologic treatment (infliximab, adalimumab, or golimumab \[UC only\]) between January 2017 until date of site initiation from the 25 participating sites will be observed from the date of UC or CD diagnosis until one day prior to the date of index other biologic treatment initiation during the eligibility period, and then from date of index other biologic treatment initiation until the earliest of 6 months (post-index treatment discontinuation, death of participant, lost-to-follow up, or date of chart abstraction). Index date is defined as the date when other biologic treatment was initiated.
62249678|NCT03974334|EXPERIMENTAL|OWL-Hypertension 8 Wk Trial|Two groups of thirteen participants will use the Our Whole Lives - Hypertension eHealth online tool for 8 weeks each, with baseline, midline, and follow-up data collected to determine any change due to the intervention.
62607202|NCT05005689|ACTIVE_COMPARATOR|Mouthwash|Fluoride mouthwash (0.05%; 225ppm) 10ml for 1 minute daily
62607203|NCT05005689|EXPERIMENTAL|Tooth Mousse|"Tooth Mousse Plus (Recaldent™ CPP-ACP \[casein phosphopeptide (CPP)-amorphous calcium phosphate (ACP)\] and Sodium Fluoride 0.2% w/w; 900 ppm).~Tooth creme; 2ml smear daily"
62607204|NCT02363985|OTHER|Multiple vitamin A exposer|"55 children who are using~* Mega-dose vitamin A supplementation~* Food diversification (promotion and education on vitamin A rich food consumption)~* Promotion of orange flash sweet potato production and consumption in collaboration with international potato center (CIP) in one of the study area"
62607205|NCT02363985|OTHER|Only vitamin A supplementation|"55 children who are using~* Mega-dose vitamin A supplementation~* Food diversification (promotion and education on vitamin A rich food consumption)"
62607206|NCT04911335|EXPERIMENTAL|phase 2 open intervention|All patients assisted by the palliative care center (hospice and home) will receive the oral hygiene protocol and the propolis-based product. The oral hygiene protocol will be applied starting from the day of taking care of the patient in the service and until discharge / death. Administration of the study product will be continued for 2 weeks or stopped sooner if the patient loses the ability to swallow.
62829360|NCT04356898||Diabetes non-fasting|Diabetes patients who decided to not fast during the month of Ramadan
62829361|NCT04356898||Healthy|Healthy volunteers that decided to fast during the month of Ramadan
62829362|NCT06595810||Older adult participants|The data collection procedure for the study outlined in the document involves a cross-sectional exploratory approach. The researchers will recruit 20 participants from Neighborhood Elderly Centers and support groups. These participants, who are community-dwelling older adults with chronic pain, will be interviewed individually or in groups. During the 20-minute interviews, they will be asked about their pain situations, including pain intensity and sites of pain, as well as their exercise habits and preferences.
62829363|NCT04020549|EXPERIMENTAL|Intervention|
62829364|NCT04020549|SHAM_COMPARATOR|Study Skills Control|
62829365|NCT03414502|ACTIVE_COMPARATOR|Methotrexate Therapy|Subjects will receive methotrexate therapy for RA treatment.
62829366|NCT03414502|ACTIVE_COMPARATOR|Abatacept Therapy|Subjects will receive abatacept therapy for RA treatment.
62829367|NCT03414502|ACTIVE_COMPARATOR|Adalimumab Therapy|Subjects will receive adalimumab therapy for RA treatment.
62829368|NCT03414502|ACTIVE_COMPARATOR|Azathioprine Therapy|Subjects will receive azathioprine therapy for RA treatment.
62829369|NCT03414502|ACTIVE_COMPARATOR|Barcitinib Therapy|Subjects will receive barcitinib therapy for RA treatment.
62607207|NCT06083844|EXPERIMENTAL|Pembrolizumab in Combination with Bevacizumab and Oral Cyclophosphamide|"Participants will begin receiving the study drug Pembrolizumab in Combination with Bevacizumab and Oral Cyclophosphamide.~Each study cycle is 21 days."
62829370|NCT03414502|ACTIVE_COMPARATOR|Certolizumab Therapy|Subjects will receive certolizumab therapy for RA treatment.
62829371|NCT03414502|ACTIVE_COMPARATOR|Etanercept Therapy|Subjects will receive etanercept therapy for RA treatment.
62829372|NCT03414502|ACTIVE_COMPARATOR|Golimumab Therapy|Subjects will receive golimumab therapy for RA treatment.
62047213|NCT05686005|NO_INTERVENTION|Control|No intervention
62047214|NCT05686005|ACTIVE_COMPARATOR|Oral tranexamic|The participants will receive 4 tablets of tranexamic acid 500mg (equal 2gm) 2 hours before surgery in the ward.
62047215|NCT05686005|ACTIVE_COMPARATOR|Intravenous tranexamic|The participants will receive 15 mg/kg in a 20ml syringe slowly tranexamic acid during induction.
62047216|NCT01348061||Elderly Healthy Control (EHV)|No clinically significant deviation from healthy in medical history, physical examination, ECGs, MRI and clinical laboratory determinations for their respective age group.
62607208|NCT05030675|EXPERIMENTAL|Treatment (fostamatinib)|Patients receive fostamatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles (week 24) in the absence of disease progression or unacceptable toxicity.
62607209|NCT06355089|PLACEBO_COMPARATOR|Placebo milk product|Use of low protein milk product
62607210|NCT06355089|ACTIVE_COMPARATOR|Whey protein hydrolysate milk product|Use of milk product with whey protein hydrolysate
62607211|NCT06355089|ACTIVE_COMPARATOR|Postbiotic and whey protein hydrolysate milk product|Use of milk product with whey protein hydrolysate and Lacticaseibacillus rhamnosus GG
62607212|NCT05165199|EXPERIMENTAL|Elobixibat|10mg Elobixibat administration for 4 weeks
62607213|NCT01448603||Placebo|Subjects previously randomised to placebo in TR002
62439503|NCT02181257|OTHER|Refractory Bronchiolitis Obliterans Syndrome (REFRACTORY BOS)|"Participants with REFRACTORY BOS will be electronically assigned to either ECP treatment or Observation based on the participant's pre-enrollment Forced Expiratory Volume in 1 second (FEV1). Values from pulmonary function tests from the preceding 12 months will be entered into a web-based treatment allocation which will perform an automated calculation. Patients who have a statistically significant rate of decline within the preceding 6 months, and a derived protocol defined slope, will be assigned to the ECP Treatment arm. If a patient does not meet these criteria, the participant will be assigned to the Observation arm.~Two hundred and fifty-eight (258) participants were enrolled with Refractory BOS nationwide."
62607214|NCT01448603||ToleroMune Ragweed Regimen 1|Subjects previously randomised to receive ToleroMune Ragweed regimen 1 in study TR002
62607215|NCT01448603||ToleroMune Ragweed Regimen 2|Subject previously randomised to receive ToleroMune Ragweed regimen 2 in study TR002
62607216|NCT01448603||ToleroMune Ragweed regimen 3|Subject previously randomised to receive ToleroMune Ragweed regimen 3 in study TR002
62607217|NCT01448603||ToleroMune Ragweed regimen 4|Subjects previously randomised to receive ToleroMune Ragweed regimen 4 in study TR002
62607218|NCT05639010|ACTIVE_COMPARATOR|regular hemodialysis|Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week
62607219|NCT05639010|EXPERIMENTAL|hemoperfusion combined with hemodialysis|Routine blood purification therapy 3 times a week + Combination of hemodialysis and hemoperfusion treatment once a week
62607220|NCT01559376||Endoscopic radial artery harvest|
62607221|NCT01559376||Conventional open radial artery harvest|
62607222|NCT06011954||PADCEV|Patients who receive PADCEV Injection 20 mg and 30 mg (enfortumab vedotin) in routine clinical practice according to the drug label approved at the time of marketing authorization.
62607223|NCT04992013|EXPERIMENTAL|Niraparib|Participants will receive niraparib 1x daily for each 28 day study treatment cycle up to 2 years or until disease worsens or unacceptable side effects occur.
62607224|NCT04684589|ACTIVE_COMPARATOR|Tadalafil|Subjects will be randomized to one of two arms. 50 obese adult subjects will be randomized to the Tadalafil arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of Tadalafil (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the active comparator subjects will undergo the following visit protocol: screening visit, baseline visit, an interim visit (10 weeks post-baseline), and a 12-week visit.
62047217|NCT01348061||Progressive Supranuclear Palsy (PSP)|A diagnosis of possible or probable PSP according to clinical criteria of National Institute of Neurologic Diseases and Stroke - the Society for PSP plus a MRI at screening to exclude other potential causes of parkinsonism as well as a mild-to-moderate stage of disease severity according to a score of 1 to 3 in Golbe Staging System.
62607225|NCT04684589|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to one of two arms. 50 obese adult subjects will be randomized to the placebo arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of a placebo pill (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the placebo comparator subjects will undergo the following visit protocol: screening visit, baseline, an interim visit (10 weeks post-baseline), and a 12-week visit.
62607226|NCT03422159|EXPERIMENTAL|Treatment Arm|Based on published clinical data, vitamin C pharmacokinetic modeling, the package insert as well as the preliminary study by Marik et al, Vitamin C will be administered as an intravenous dose of 6gm per day divided in 4 equal doses. This dosage is reported to be devoid of any complications or side effects. Hydrocortisone will be dosed according to the consensus guidelines of the American College of Critical Care Medicine. Thiamine will be administered according to current recommendations in a dose of 200mg q 12 hourly. This will be continued for 4 days, or less if discharged from the ICU prior.
62607227|NCT03422159|PLACEBO_COMPARATOR|Placebo Arm|"Vitamin C placebo will consist of an identical bag of 100mL normal saline (but with no vitamin C) and will be labeled Vitamin C or Placebo. Placebo will be infused over 30 minutes as per the infusion instructions of the active vitamin and protected from light with a brown bag. Hydrocortisone placebo will be provided as an identical 3mL syringe as 1mL of normal saline.The thiamine placebo will be placed in a 50mL bag of Normal Saline labeled Thiamine 200mg or Placebo and run over 30 minutes (100mL/hr) Placebo patients will receive a matching 50mL bag of Normal Saline. All of these will be given for up to 4 days, or less if discharged from the ICU prior."
62607228|NCT05980143|EXPERIMENTAL|Metacognitive Therapy|MCT will be delivered in accordance with the MCT-PATHWAY treatment manual.
62607229|NCT05854615|EXPERIMENTAL|Stempeucel®|Stempeucel® (Ex-vivo cultured MSCs) supplied in 15 ml cryo bags consisting of 200 million or 150 million MSCs, 85% PlasmaLyte-A, 5% HSA and 10% DMSO in a total volume of 15 ml. Following thawing, 35 ml of PlasmaLyte A will be added to the Stempeucel® to make a total volume of 50 ml. The final concentration of components will be 1.5% HSA and 3% DMSO.
62607230|NCT03380104|EXPERIMENTAL|Single Arm|Intradural Spinal Cord Stimulation; Administration of Questionnaires
62607231|NCT03003000|EXPERIMENTAL|ibuprofen + caffeine|Fixed Dose Combination
62607232|NCT03003000|ACTIVE_COMPARATOR|ibuprofen|
62607233|NCT03003000|PLACEBO_COMPARATOR|placebo|
62829373|NCT03414502|ACTIVE_COMPARATOR|Hydroxycholoroquine Therapy|Subjects will receive hydroxychloroquine therapy for RA treatment.
62829374|NCT03414502|ACTIVE_COMPARATOR|Infliximab Therapy|Subjects will receive infliximab therapy for RA treatment.
62249679|NCT04349878|PLACEBO_COMPARATOR|Control|scaling and root planing alone
62439504|NCT02181257|OTHER|Standard of Care Comparator Retrospective Chart review|Data for the SOC comparator will be obtained via a retrospective data capture mechanism either medical chart review or electronic medical record query that meet all of the inclusion criteria and through an IRB approved waiver of consent. The SOC comparator data will be identical to the data collected for the Refractory BOS patients with the exception of inclusion of all spirometry values after transplant.
62439505|NCT06074120|EXPERIMENTAL|Women with genitourinary symptoms of menopause|Receive low-level laser therapy
62439506|NCT01216111|EXPERIMENTAL|6 cycles of PC adjuvant chemotherapy|paclitaxel 80 mg/m2 and carboplatin (area under the curve \[AUC\]= 2) on day 1, 8, 15 every 28 days for six cycles
62439507|NCT01216111|ACTIVE_COMPARATOR|3 cycles of FEC followed by 3 cycles of Docetaxel|fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously
62439508|NCT00845585|ACTIVE_COMPARATOR|Owniflow II|
62439509|NCT00845585|ACTIVE_COMPARATOR|PTFE|
62439510|NCT03750474|EXPERIMENTAL|patient with chronic low back pain|magnetic resonance elastography and shear wave elastography of the back muscles
62829375|NCT03414502|ACTIVE_COMPARATOR|Leflunomide Therapy|Subjects will receive leflunomide therapy for RA treatment.
62829376|NCT03414502|ACTIVE_COMPARATOR|Minocycline Therapy|Subjects will receive minocycline therapy for RA treatment.
62249680|NCT04349878|ACTIVE_COMPARATOR|phytotherapeutic|scaling and root planing plus phytotherapeutic agent
62249681|NCT01587378|EXPERIMENTAL|metformin|
62249682|NCT01587378|PLACEBO_COMPARATOR|placebo|
62249683|NCT00053703|ACTIVE_COMPARATOR|olanzapine|oral olanzapine 5-20mg per day for up to 52 weeks
62249684|NCT00053703|ACTIVE_COMPARATOR|risperidone|oral risperidone 0.5mg to 6mg daily for up to 52 weeks
62249685|NCT00053703|ACTIVE_COMPARATOR|molindone|oral molindone from 10-140mg/daily for up to 52 weeks
62249686|NCT01903070|EXPERIMENTAL|Linagliptin in TD2 subjects|Linagliptin in TD2 subjects with normal renal function
62249687|NCT01903070|EXPERIMENTAL|Linagliptin in TD2 subjects with impaired renal function|Linagliptin in TD2 subjects with impaired renal function
62249688|NCT04713202|EXPERIMENTAL|Telotristat Ethyl + PRRT|"Telotristat ethyl, 250 mg, PO, three times daily, continuous.~+ Peptide Receptor Radionuclide Therapy(PRRT) every 8 weeks"
62249689|NCT04713202|PLACEBO_COMPARATOR|Placebo + PRRT|"Placebo, PO, three times daily, continuous.~+ Peptide Receptor Radionuclide Therapy(PRRT) every 8 weeks"
62249690|NCT05740020|EXPERIMENTAL|Group (A)|Group (A) will receive virtual reality in addition to the traditional exercise program.
62249691|NCT05740020|ACTIVE_COMPARATOR|Group (B)|Group (B) will receive traditional exercise program.
62439511|NCT03750474|OTHER|healthy controls|magnetic resonance elastography and shear wave elastography of the back muscles
62829377|NCT03414502|ACTIVE_COMPARATOR|Rituximab Therapy|Subjects will receive rituximab therapy for RA treatment.
62249692|NCT00077051|EXPERIMENTAL|Single Arm|
62249693|NCT01643525||Subjects with Stroke Symptoms|Suspected stroke subjects that present to hospital with stroke symptoms and are evaluated for stroke
62249694|NCT01643525||Normal Cohort|Subjects that are not being evaluated for stroke and are confirmed to have no cerebrovascular disease
62249695|NCT00623974|EXPERIMENTAL|Calcium + Calcitriol|1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
62249696|NCT00623974|EXPERIMENTAL|Teriparatide 20 mcg|Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
62249697|NCT00623974|EXPERIMENTAL|Teriparatide 40 mcg|Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
62249698|NCT00623974|EXPERIMENTAL|Teriparatide 60 mcg|Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
62249699|NCT05831826||healthy controls|Healthy controls are ≥18 years old, no previous history of SARS-CoV-2 infection, and no previous history of autoimmune diseases. All the HC group were injected with 2 or 3 doses of inactivated SARS-CoV-2 vaccines.
62249700|NCT05831826||the vaccinated patients with ADs|The vaccinated patients with ADs are ≥18 years old, no previous history of SARS-CoV-2 infection, and diagnosed with autoimmune diseases. All the group were injected with the inactivated SARS-CoV-2 vaccines.
62249701|NCT05831826||the unvaccinated patients with ADs|The vaccinated patients with ADs are ≥18 years old, no previous history of SARS-CoV-2 infection, and diagnosed with autoimmune diseases. All the group were not injected with the inactivated SARS-CoV-2 vaccines.
62249702|NCT05697263|EXPERIMENTAL|Follicle phase based training|Follicular phase-based training five times a week during the follicular phase (the first two weeks of the menstrual cycle) and thereafter once a week for the rest of the cycle.
62249703|NCT05697263|EXPERIMENTAL|Luteal phase based training|Luteal phase-based training five times a week during the luteal phase (from ovulation to next menstruation) and once a week in the follicular phase.
62439512|NCT05535712|EXPERIMENTAL|Da Vinci SP intervnetion group|for patients who received Da Vinci SP robotic surgery
62439513|NCT04436328|EXPERIMENTAL|Surgical treatment|Surgical treatment of native vertebral osteomyelitis followed by antimicrobial therapy
62439514|NCT04436328|ACTIVE_COMPARATOR|Antimicrobial treatment|No surgical intervention, antimicrobial therapy only
62439515|NCT04780659|EXPERIMENTAL|Vaccination with Comirnaty according to standard of care treatment|All study participants will receive Comirnaty according to current approval.
62439516|NCT01713153|EXPERIMENTAL|Misoprostol|600 mcg oral misoprostol administered during the third stage of labor
62439517|NCT01713153|EXPERIMENTAL|UnijectTM|10 IU oxytocin delivered IM with UnijectTM during he third stage of labor
62439518|NCT06182683|ACTIVE_COMPARATOR|Angiography-guided PCI group|This group of patients are intended to undergo PCI with conventional angiography-guidance. Procedural optimization determined by angiographic assessment.
62829378|NCT03414502|ACTIVE_COMPARATOR|Sarilumab Therapy|Subjects will receive sarilumab therapy for RA treatment.
62829379|NCT03414502|ACTIVE_COMPARATOR|Sulfasalazine Therapy|Subjects will receive sulfasalazine therapy for RA treatment.
62829380|NCT03414502|ACTIVE_COMPARATOR|Tofacitinib Therapy|Subjects will receive tofacitinib therapy for RA treatment.
62829381|NCT05907863|EXPERIMENTAL|Intracardiac echo guided ablation|
62249704|NCT05697263|EXPERIMENTAL|Regular training|Regular training three times a week throughout the menstrual cycle (control group).
62829382|NCT05907863|NO_INTERVENTION|Standard, electroanatomical mapping system guided ablation|
62047218|NCT01348061||Alzheimer's Disease (AD)|A diagnosis of probable AD Based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association and The Diagnostic and Statistical Manual of Mental Disorders as determined by a mini-mental state examination (MMSE) score of 16 to 26, inclusive.
62829383|NCT06494449|EXPERIMENTAL|Higher protein|
62829384|NCT06494449|ACTIVE_COMPARATOR|Lower protein|
62249705|NCT05668039|EXPERIMENTAL|Enhanced external counterpulsation|Enhanced external counterpulsation (EECP/ECPT) is a non-invasive technique used to improve cardiac and cerebral perfusion. It aims to achieve 'diastolic augmentation' by increasing arterial blood pressure and retrograde aortic blood flow during diastole. This technique is currently used to treat refractory angina and heart failure, and was demonstrated to be well tolerated without limiting side effect. Practially, blood pressure cuffs are put along the lower limbs and are inflated to 300 mmHg pressure intermittently during one hour session. 15 sessions will be performed over 15 weeks.
62249706|NCT05668039|SHAM_COMPARATOR|Sham procedure|The procedure will be identical to the experimental procedure, excluding the pressure that will reach only 80 mmHg.
62249707|NCT02409290|ACTIVE_COMPARATOR|Regimen A|Regimen A locally-used WHO-approved MDR-TB regimen in accordance with 2011 WHO MDR-TB treatment guidelines.
62249708|NCT02409290|ACTIVE_COMPARATOR|Regimen B|"Regimen B is based on the regimen described by Van Deun 2010. With Version 8.0 of the protocol Regimen B (Regimen Bmox) is modified by replacement of moxifloxacin with levofloxacin (Regimen Blev). Regimen B without specification of which fluoroquinolone is in the regimen refers to either (Bmox or Blev).~Product and dose for \[\<33 kg, 33-50kg, \>50 kg\] respectively:~Moxifloxacin \[400mg, 600mg, 800mg\] OR Levofloxacin \[750mg, 750mg,1000mg\]; Clofazimine \[50mg,100mg,100mg\]; Ethambutol \[800mg,800mg,1200mg\]; Pyrazinamide \[1000mg,1500mg, 2000mg\]; Isoniazid 300mg, 400mg, 600mg\]; Prothionamide \[250mg,500mg,750mg\]; Kanamycin \[15mg per kilogram body weight (maximum 1g)\]."
62249709|NCT02409290|EXPERIMENTAL|Regimen C|"Regimen C is a 40-week all-oral regimen consisting of bedaquiline, clofazimine, ethambutol, levofloxacin, and pyrazinamide given for 40 weeks supplemented by isoniazid and prothionamide for the first 16 weeks (intensive phase).~Product and dose for \[\<33kg, 33-50kg, \>50 kg\] respectively:~Bedaquiline 400mg once daily for first 14 days/200 mg thrice weekly thereafter; Levofloxacin \[750mg, 750mg,1000mg\]; Clofazimine \[50mg, 100mg, 100mg\]; Ethambutol \[800mg, 800mg, 1200mg\]; Pyrazinamide \[1000mg,1500mg, 2000mg\]; Isoniazid \[300mg, 400mg, 600mg\]; Prothionamide \[250mg, 500mg,750mg\]."
62249710|NCT02409290|EXPERIMENTAL|Regimen D|"Regimen D is a 28-week regimen consisting of bedaquiline, clofazimine, levofloxacin, and pyrazinamide given for 28 weeks supplemented by isoniazid and kanamycin for the first 8 weeks (intensive phase).~Product and dose for \[\<33kg, 33 to\<40kg, 40-50kg, \>50-60 kg, \>60 kg\] respectively:~Bedaquiline 400mg once daily for first 14 days/200mg thrice weekly thereafter; Levofloxacin \[750mg, 750mg, 750mg, 1000mg, 1000mg\]; Clofazimine \[50mg, 100mg, 100mg, 100mg, 100mg\]; Pyrazinamide \[1000mg,1500mg, 1500mg, 2000mg, 2000mg\]; Isoniazid \[400mg, 500mg, 600mg, 800mg, 900mg\]; Kanamycin \[15 mg per kilogram body weight (maximum 1g)\]."
62249711|NCT06070844|EXPERIMENTAL|yoga nidra|yoga nidra
62249712|NCT06070844|NO_INTERVENTION|control|control group
62829385|NCT00394095|EXPERIMENTAL|Topiramate Group|Patients' initial dose of topiramate 25mg bid, which was titrated over 18 days to 150 mg bid (with flexibility to titrate to 200mg bid) as tolerated.
62829386|NCT00394095|PLACEBO_COMPARATOR|Placebo Group|Sugar pill
62829387|NCT06655259|EXPERIMENTAL|TURP Combined with Standard Systemic Therapy|Participants in this arm will undergo Transurethral Resection of the Prostate (TURP) to alleviate urinary obstruction and reduce tumor burden, followed by Standard Systemic Therapy. This includes Androgen Deprivation Therapy (ADT) with either an LHRH agonist or antagonist, combined with a second-generation anti-androgen, such as abiraterone or enzalutamide, depending on the patient's condition. The goal is to assess the efficacy and safety of this combined approach in treating patients with metastatic prostate cancer (mPCa).
62047219|NCT01129388|EXPERIMENTAL|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~* Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions~* Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily~Period 2:~* Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily~* Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~* Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily"
62249713|NCT01020591|ACTIVE_COMPARATOR|Osteopathic evaluation|osteopathic evaluation of motion and tissue mobility
62249714|NCT01020591|EXPERIMENTAL|Osteopathic evaluation with treatment|osteopathic evaluation of motion and tissue mobility followed by osteopathic manual therapy release of the tight or restricted tissues
62439519|NCT06182683|EXPERIMENTAL|Concurrent OCT/FFR-guided PCI group|This group of patients are intended to undergo PCI with concurrent OCT/FFR-guidance. Procedural optimization determined by OCT and FFR assessment.
62439520|NCT03958981|EXPERIMENTAL|castor oil group|60 mL of castor oil in 140 mL of orange juice
62439521|NCT03958981|PLACEBO_COMPARATOR|placebo group|Patients will receive sunflower oil as a placebo
62829388|NCT06080334|EXPERIMENTAL|Dry needling+eccentric exercises|Application of dry needling on the hyperalgesic trigger points of the gastrocnemius muscle and subsequent inclusion of eccentric exercises.
62829389|NCT06080334|EXPERIMENTAL|Electrolysis+eccentric exercises|Application of electrolysis to the Achilles tendon and subsequent inclusion of eccentric exercises.
62829390|NCT03410277|EXPERIMENTAL|All Subjects|Experimental hypoglycemia
62439522|NCT02843074|EXPERIMENTAL|ERd Therapy|"INDUCTION:~Cycles 1-2: elotuzumab 10mg/kg IV days 1, 8, 15, 22; lenalidomide (len) 25mg orally (PO), once daily (QD) on days 1-21; dexamethasone (dex) 28 mg PO (3-24 hrs before elotuzumab IV) and 8mg IV (45-90 minutes before elotuzumab) days 1, 8, 15, 22.~Cycles 3-4: elotuzumab 10mg/kg IV days 1 and 15; len 25mg PO QD days 1-21; dex 8mg PO (3-24 hrs before elotuzumab IV) and 8mg IV (45-90 minutes before elotuzumab) days 1 and 15; dex 40mg PO days 8 and 22.~CONSOLIDATION:~Four 28-day cycles: elotuzumab 10mg/kg IV days 1 and 15; len 15mg PO QD days 1-21; dex 28mg PO (3-24 hrs before elotuzumab) and 8mg IV (45-90 minutes before elotuzumab) days 1 and 15; dex 40mg PO days 8 and 22.~MAINTENANCE:~After completing consolidation therapy patients without progressive disease will receive, for up to 24 months, 28-day cycles of elotuzumab 20mg/kg IV day 1; len 10mg +/- 5mg PO QD days 1-21; dex 28mg PO (3-24 hrs before elotuzumab) and 8mg IV (45-90 minutes prior to elotuzumab) day 1."
62439523|NCT01561183|EXPERIMENTAL|Indirect pulp capping (IPC)|Indirect pulp capping
62439524|NCT01561183|EXPERIMENTAL|Direct pulp capping (DPC)|Direct pulp capping
62607234|NCT02735707|OTHER|Antibiotic Domain|"Patients with community-acquired pneumonia admitted to participating intensive care units and requiring empiric antibiotic therapy will be randomised one of five antibiotic interventions.~Note: the ceftaroline + macrolide intervention has been closed to recruitment."
62047220|NCT01129388|PLACEBO_COMPARATOR|Group placebo - placebo + omeprazole|"Period 1:~* Day 1: placebo loading dose in the morning under fasted conditions~* Day 2 to Day 5: placebo in the morning under fasted conditions, once daily~Period 2:~* Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily~* Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~* Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily"
62829391|NCT06597773|EXPERIMENTAL|Online patient navigation and supportive care referrals|"The intervention group will participate in an online patient navigation program designed to identify patients' nutrition, psychology, and sexology counseling needs, and to facilitate referrals and web-based systematic interventions to address these supportive care needs.~Participants in this group will complete the study surveys at baseline (T1) and 4 weeks (T2) of follow-up."
62829392|NCT06597773|ACTIVE_COMPARATOR|In-person patient navigation and supportive care referrals|"The control group will participate in an in-person patient navigation program designed to identify patients' nutrition, psychology, and sexology counseling needs, and to facilitate referrals to in-person supportive care services.~Participants in this group will complete the study surveys at baseline (T1) and 4 weeks (T2) of follow-up."
62439525|NCT01561183|EXPERIMENTAL|Miniature pulpotomy (MP)|Miniature pulpotomy
62439526|NCT01561183|EXPERIMENTAL|Full pulpotomy (FP)|Full pulpotomy
62439527|NCT06543368|EXPERIMENTAL|PRP Injection|"45mL of blood is drawn from the subject in a standard-of-care manner into 3 x 20mL syringes, each containing 2mL of sodium citrate (anticoagulant). Each syringe is prepared and capped, then placed into a centrifuge. The resulting separated blood is then drawn off into a single new sterile syringe, which can be used for the injection. Blood and PRP analysis: We will perform a full analysis (a complete blood count \[CBC\] with differential) on subjects' whole blood and their prepared LC-PRP. Importantly, we will include all data required in the PRP minimum reporting standards, including platelet, differential leukocyte, and red cell analysis of all samples."
62829393|NCT02342808|EXPERIMENTAL|Structured center-based lifestyle intervention|The Structured center-based Lifestyle Intervention (C-LIFE) will include individualized plans for the DASH diet, weight management, and aerobic exercise.
62047221|NCT01129388|EXPERIMENTAL|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~* Day -5 to Day -1: omeprazole 80 mgin the evening 2 hours after dinner, once daily~* Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~* Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily~Period 2:~* Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions~* Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily"
62047222|NCT01129388|PLACEBO_COMPARATOR|Group placebo + omeprazole placebo|"Period 1:~* Day -5 to Day -1: omeprazole 80 mg, once daily in the evening 2 hours after dinner~* Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~* Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily~Period 2:~* Day 1: placebo loading dose in the morning under fasted conditions~* Day 2 to Day 5: placebo in the morning under fasted conditions, once daily"
62047223|NCT01533493|PLACEBO_COMPARATOR|Placebo|Subjects randomized to receive memantine-matched placebo in addition to open-label OROS-Methylphenidate
62439528|NCT00418873|EXPERIMENTAL|1. Zotepine|
62439529|NCT00418873|ACTIVE_COMPARATOR|2. Risperidone|
62439530|NCT05539573||Treatment|Patients with planned transcatheter treatment of severe aortic stenosis with the ACURATE neo2™ aortic bioprosthesis and ACURATE neo2™ transfemoral delivery system.
62439531|NCT04502758|ACTIVE_COMPARATOR|Sequential bilateral accelerated theta burst stimulation|Three sessions of Sequential bilateral accelerated theta burst stimulation (aTBS) are administered daily for 10 days (5 days per week).
62439532|NCT04502758|SHAM_COMPARATOR|Sham seqential billateral accelerated theta burst stimulation|Three sessions of Sequential bilateral sham accelerated theta burst stimulation (aTBS) are administered daily for 10 days (5 days per week).
62607235|NCT02735707|OTHER|Macrolide Duration Domain|Patients with community-acquired pneumonia admitted to participating intensive care units who have been allocated to a beta-lactam antibiotic intervention in the Antibiotic Domain will be randomised to either a standard course or extended course of macrolide therapy
62829394|NCT02342808|EXPERIMENTAL|Standard education and physician advice|The Medical Management with Standardized Education and Physician Advice (SEPA) will consist of encouragement to achieve an ideal body weight and engage in exercise as part of routine counseling in primary care, but no special program will be delivered to enhance the participants' ability to comply with these recommendations.
62829395|NCT06263582|EXPERIMENTAL|Artesunate vaginal inserts/ pessaries|Artesunate vaginal inserts/pessaries are used as a treatment for cervical precancerous lesions.
62829396|NCT00985764||placental previa|
62829397|NCT03401346|EXPERIMENTAL|INP104|Single dose 1.45 mg Dihydroergotamine Mesylate (DHE), administered by I123 Precision Olfactory Delivery (POD) device nasal spray (INP104)
62047224|NCT01533493|ACTIVE_COMPARATOR|Memantine|Subjects randomized to receive memantine in addition to open-label OROS-Methylphenidate
62047225|NCT06049875||Home Hospitalization|Patients who arrived at the emergency department and were discharged to home hospitalization or were hospitalized for a day and discharged to comprehensive home hospitalization under the management of a remote internist and a nurse who will make home visits on a daily basis.
62047226|NCT06049875||Internal Ward Hospitalization|Patients who arrived at the emergency department and received a regular treatment.
62047227|NCT06486532|EXPERIMENTAL|HeartBeet Clinic|16 week group based lifestyle intervention
62047228|NCT06486532|ACTIVE_COMPARATOR|Self-paced education|Online learning of lifestyle medicine
62047229|NCT02820220||Patient/patient attendants|"1. Study subjects will be females.~2. Age at enrolment should be more than 18 years.~3. Attending Department of Paediatrics OPD/emergency/well-baby clinics/immunisation clinics OR Department of Gynaecology and Obstetrics OPD/emergency/Ante-natal clinics/Post-natal clinics of Lady Hardinge Medical College and associated hospitals.~4. Written informed consent to participate in the study."
62047230|NCT02820220||Students,nursing|"1. Pursuing Bsc Nursing(in their final year) or intern of college of nursing LHMC~2. Written informed consent to participate in the study"
62047231|NCT02820220||In-service nurses|"1. Posted in Department of Paediatrics indoor/OPD/well-baby clinics/immunisation clinics or Department of Gynaecology and Obstetrics indoor/OPD/emergency/Ante-natal clinics/Post-natal clinics of Lady Hardinge Medical College and associated hospitals.~2. Written informed consent to participate in the study."
62047232|NCT03676179|ACTIVE_COMPARATOR|unicompartment knee arthroplasty and patella denervation|UKA and patella denervation
62047233|NCT03676179|EXPERIMENTAL|unicompartment knee arthroplasty and patella non-denervation|UKA and patella non-denervation
62047234|NCT05101629|EXPERIMENTAL|Pembrolizumab Lenvatinib|Single arm with Pembrolizumab 200 mg over 30 minutes IV infusion on Day 1 every 3 weeks until disease progression or inacceptable toxicity or end of study treatment. Lenvatinib 8 mg for a body weight \< 60 kg and 12 mg for a body weight ≥ 60 kg orally continuously once daily, starting on Day 1 of every 3 week cycle until disease progression or inacceptable toxicity or end of study treatment.
62047235|NCT01778348|EXPERIMENTAL|Overnight closed-loop combined with CGM|Glucose level is controlled by the automated closed loop glucose control system. After initial training with the closed-loop system devices, subjects will use the closed-loop system overnight at home for a total duration of 12 weeks.
62047236|NCT01778348|ACTIVE_COMPARATOR|Real-time CGM alone|The subjects will use the study CGM alone at home for the period of 12 weeks. Glucose level will be controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
62047237|NCT02139722|NO_INTERVENTION|Provider Panel Notification (PPN) Alone|The comparison procedures consist of a panel notification given to providers and an audio-visual presentation on diet and exercise given to patients.
62439533|NCT05235594|EXPERIMENTAL|Experimental: Smart shirt|The research intervention is, for all twenty patients, to wear a smart t-shirt connected to a smart phone throughout the day (preferably 8 hours pr day) for 2 weeks.
62439534|NCT00197756||Vitamin A|Participants in the in the parent study who had been randomized to receive either Vitamin A alone or multivitamins including vitamin A.
62439535|NCT00197756||No Vitamin A|Participants in the parent study who were randomized to receive either multivitamins excluding vitamin A, or placebo.
62829398|NCT03401346|ACTIVE_COMPARATOR|D.H.E. 45 Injection (IV)|Single dose 1 mg Dihydroergotamine Mesylate (DHE) for intravenous injection
62829399|NCT03401346|ACTIVE_COMPARATOR|Migranal Nasal Spray|Single dose 2 mg Migranal Nasal Spray Dihydroergotamine Mesylate (DHE)
62047238|NCT02139722|EXPERIMENTAL|Video Doctor, PA + PPN|Video Doctor (VD) and Provider Alert (PA) intervention combined with Provider Panel Notification (PPN)
62047239|NCT00975845||BioCleanse Tibialis Tendon Allograft|Tibialis Tendon allograft from donor 18-65 years old
62047240|NCT03401684|EXPERIMENTAL|Resilient Minds|Four comprehensive, skill-building learning modules in the areas of psychological trauma, mental health problems, resiliency and workplace stress.
62439536|NCT00197756||Multivitamins|Participants in the parent study who were randomized to receive multivitamins including vitamin A or multivitamins excluding vitamin A
62439537|NCT00197756||No Multivitamins|Participants from the parent study who had been randomized to vitamin A alone or placebo
62439538|NCT02410512|EXPERIMENTAL|Dose Escalation: MOXR0916 + Atezolizumab|Cohorts of at least 3 participants each will be treated at escalating doses of MOXR0916 in combination with a fixed dose of atezolizumab to determine the MTD or maximum administered dose (MAD).
62439539|NCT02410512|EXPERIMENTAL|Expansion: MOXR0916 + Atezolizumab|Approximately 250-580 participants will be enrolled in the expansion stage to better characterize the safety, tolerability, pharmacokinetic variability, biomarkers of anti-tumor activity, and preliminary efficacy of MOXR0916 + atezolizumab in different cancer types.
62439540|NCT05896059|EXPERIMENTAL|Tislelizumab combined with Anlotinib|
62439541|NCT06543602||control group: monitoring by manual way|
62439542|NCT06543602||multiple-model monitoring group: agitation monitoring by remote video-radar wave|
62439543|NCT01156571|EXPERIMENTAL|cangrelor|"Cangrelor was administered as a 30 µg/kg bolus followed by a 4.0 µg/kg/min cangrelor IV infusion for a minimum of 2 hours or until conclusion of the index procedure, whichever is longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours.~Following the discontinuation of the cangrelor infusion, 600mg of clopidogrel was administered."
62439544|NCT01156571|ACTIVE_COMPARATOR|clopidogrel|"Clopidogrel 300 mg or 600 mg administered pre or post PCI. Selection of dose and timing of dose were per investigator discretion.~During the PCI a placebo infusion was given to maintain the blinding of the trial. In addition, placebo capsules were administered at the end of the infusion mimic the 600mg post infusion dose provided in the cangrelor arm."
62439545|NCT00342264||1|The study cohort will be comprised of underground, and surface workers (excluding administrative workers) who have been employed in the candidate non-metal mines for at least one year during the period between the date of dieselization of each mine and December 31, 1996.
62829400|NCT01954498|EXPERIMENTAL|Walnuts|2 ounces whole-shelled walnuts per day for 12 weeks
62829401|NCT01954498|ACTIVE_COMPARATOR|OTC (over-the-counter) multivitamin|OTC multivitamin tablet 2 per day for 12 weeks
62829402|NCT01328886|EXPERIMENTAL|Omalizumab|
62249715|NCT00074022|EXPERIMENTAL|Treatment (GTI-2040, docetaxel)|"Phase I (closed to accrual as of 8/5/2004): Patients receive GTI-2040 IV continuously on days 1-14. Patients also receive docetaxel IV over 1 hour on day 3 during course 1 and on day 1 for all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of GTI-2040 and docetaxel until the MTD is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The RP2D is defined as the dose preceding the MTD.~Phase II: Patients receive GTI-2040 and docetaxel at the RP2D as in phase I."
62249716|NCT06155747||People infected with related NTM isolates identified as having membership in a related cluster|Characterize the source(s) of acquisition and/or direct or indirect patient-to-patient transmission of NTM within a healthcare setting among participants with highly related isolates.
62249717|NCT04879641|NO_INTERVENTION|1_Waiting List control|Randomized participants will only get the full intervention after study completion period (6 months since the randomization)
62249718|NCT04879641|EXPERIMENTAL|2_Exposure only|Randomized participants will only get the Exposure component
62249719|NCT04879641|EXPERIMENTAL|3_Attention Training only|Randomized participants will only get the Attention Training component
62439546|NCT06251128|EXPERIMENTAL|Self-management|This group of participants will be given education and will be taught about overcoming the barriers to a healthy lifestyle and medication adherence. No drugs or devices will be administered to the participants/
62439547|NCT04156074|EXPERIMENTAL|Vitamin D enriched (20 mcg/day) olive oil emulsion drink|30 mL vitamin D enriched drink consumed daily for 4 weeks
62439548|NCT04156074|ACTIVE_COMPARATOR|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink|30 mL vitamin D enriched drink consumed daily for 4 weeks
62439549|NCT04156074|PLACEBO_COMPARATOR|Placebo coconut oil emulsion drink|30 mL placebo drink consumed daily for 4 weeks
62439550|NCT04156074|ACTIVE_COMPARATOR|Vitamin D supplement (20 mcg/day)|Vitamin D supplement consumed daily for 4 weeks
62439551|NCT02189616|OTHER|regular care group|receive regular care which contains filling a paper asthma diary daily.
62439552|NCT02189616|EXPERIMENTAL|SMS reminder group|receive weekly mobile phone short message reminders for 3 months
62439553|NCT02189616|EXPERIMENTAL|SMS reminder and SMS consultation group|receive weekly mobile phone short message reminders and can consult asthma nurse by mobile phone short message when needed for 3 months
62439554|NCT05058742|EXPERIMENTAL|Nervus vagus stimulation|Non-invasive Nervus vagus stimulation called AuriStim Intermittent stimluation cycle of three hours of activity and three hours of rest, equating to four cycles of three hours of Stimulation in 24 hours) is performed. The stimulation is performed until the patient's condition is better and he or she isdischarged from OCU or transferred to normal ward or dies.
62439555|NCT05058742|NO_INTERVENTION|Control|There is no Nervus vagus stimulation.
62439556|NCT03467412|EXPERIMENTAL|0.00625 μg FOL-005|50 μl solution (a total dose of 0.00625 μg FOL-005) injected intradermally three times per week for 12 weeks.
62439557|NCT03467412|EXPERIMENTAL|0.025 μg FOL-005|50 μl solution (a total dose of 0.025 μg FOL-005) injected intradermally three times per week for 12 weeks.
62439558|NCT03467412|EXPERIMENTAL|0.050 μg FOL-005|50 μl solution (a total dose of 0.050 μg FOL-005) injected intradermally three times per week for 12 weeks.
62439559|NCT03467412|EXPERIMENTAL|0.100 μg FOL-005|50 μl solution (a total dose of 0.100 μg FOL-005) injected intradermally three times per week for 12 weeks.
62439560|NCT03467412|PLACEBO_COMPARATOR|Placebo|50 μl solution (placebo) injected intradermally three times per week for 12 weeks.
62439561|NCT06346236||THOP treated|Level of circulating T4 \< 12 pmol/L at any time of life associated, on the same date, with a level of circulatingon thyro-stimulating hormone \< 15 mUI/L if the sample was realiszed before or on the fifteenth day of life OR \< 58 mUI/L if the sample was realiszed after the fifteenth day of life, and L-thyroxine treatment is recorded in the medical record (at any dose and with any duration)
62439562|NCT06346236||THOP un-treated|Level of circulating T4 \< 12 pmol/L at any time of life associated, on the same date, with a level of circulation thyro-stimulating hormone \< 15 mUI/L if sample was realiszed before or on the fifteenth day of life OR \< 5 mUI/L if sample was realiszed after the fifteenth day of life, and no L-thyroxine treatment recorded in the medical record.
62439563|NCT06346236||No-THOP|all level of circulating T4 \> 12 pmol/L at any time in life
62439564|NCT02343887|ACTIVE_COMPARATOR|control group|"patients without taking into cognitive or psychological treatment for 6 months (period 1) and~* if the situation improves in the neuropsychological assessment of M6 further with simple monitoring neuropsychological evaluation M12~* or persistence or worsening of the disorder, the beginning of a cognitive remediation program for 6 months (period 2)."
62829403|NCT00832299|EXPERIMENTAL|6 cycles of FOLFOX pre and post TME|
62249720|NCT04879641|EXPERIMENTAL|4_Exposure + Attention Training|Randomized participants will get Exposure + Attention Training components
62249721|NCT04879641|EXPERIMENTAL|5_Cognitive Restructuring only|Randomized participants will only get the Cognitive Restructuring component
62249722|NCT04879641|EXPERIMENTAL|6_Cognitive Restructuring + Exposure|Randomized participants will get Cognitive Restructuring + Exposure components
62249723|NCT04879641|EXPERIMENTAL|7_Cognitive Restructuring + Attention Training|Randomized participants will get Cognitive Restructuring + Attention Training components
62249724|NCT04879641|EXPERIMENTAL|8_Cognitive Restructuring + Attention Training + Exposure|Randomized participants will get Cognitive Restructuring + Attention Training + Exposure components
62249725|NCT04879641|EXPERIMENTAL|9_Psychoeducation only|Randomized participants will only get the Psychoeducation component
62439565|NCT02343887|EXPERIMENTAL|group with cognitive rehabilitation,|"patients treated for 6 months Cognitive remediation (period 1), then~* Stop if the situation improves in the evaluation and monitoring of M6 to M12 with neuropsychological assessment,~* or persistence or worsening of the disorder, further cognitive remediation for 6 months (period 2)."
62829404|NCT02894346||Teachers|Public school teachers in Denmark - across age, gender, subject, class and experience.
62829405|NCT06586632|ACTIVE_COMPARATOR|AID group|AID technology combined with on-demand consultations
62829406|NCT06586632|PLACEBO_COMPARATOR|CGM group|Standard care with insulin pen based therapy combined with CGM
62047241|NCT04997954|EXPERIMENTAL|MediCabilis CBD Oil|MediCabilis CBD Oil to be taken no more than 7ml/day orally based from participants' individual 14 day titration period completed at the beginning of the trial. The frequency of the drug intake can range between once and three times a day depending on the outcome of the 14 day titration period. Titration period allows participants to gradually increase study drug intake in order to find appropriate dose for participants without or with minimal undesired side effects. The treatment will last no more than 6 months.
62047242|NCT05586594|OTHER|patients labelled as Type 1 or Type 2 Diabetes|"paediatric or adult patients already diagnosed with either type 1 or type 2 diabetes mellitus, following up with Tawam Hospital Diabetes clinics for at least 1 year, (who have negative autoimmunity, lack of significant ketosis and either family history of diabetes in one parent or BMI\<40).~Patient with age \> 11; both male or female, Emirati patients only, who attended Diabetes clinic Tawam hospital during the last 1 year AND Diagnosed to have Type 1 or Type 2 Diabetes Mellitus diagnosed before the age of 40 and after the age of 6 months (to exclude neonatal diabetes).~• ."
62047243|NCT06174311|EXPERIMENTAL|Active Cognitive Bias Modification|Based on the outcomes of pre-intervention measurements, 50 participants who score high on intolerance to uncertainty measurement will be chosen randomly to be included in this condition. This group of participants will receive three interventions targeting interpretation biases related to uncertainty, with each intervention administered at three-day intervals. Each session is scheduled to have an estimated duration of around 30 minutes.
62829407|NCT06651684|NO_INTERVENTION|Care-as-usual|Participants assigned to this group will receive care as usually delivered in participating clinics and list of smoking cessation resources, including instructions to access Nicotine Replacement Therapy (NRT).
62829408|NCT06651684|EXPERIMENTAL|CanCEASE with Health Navigator|Participants assigned to this arm will receive smoking cessation resources, including instructions to access Nicotine Replacement Therapy (NRT) at Baseline, 6 and 12 months. They will also have the choice to schedule support sessions with a Health Navigator, which will be an individual with lived experience related to tobacco and trained to provide support for unmet social needs.
62829409|NCT04976621|EXPERIMENTAL|Behavioral Activation (BA) intervention group|Participants in the BA group will receive BA treatment and treatment as usual. BA is a brief behavioral treatment that helps people define goals, create and execute plans to attain them, and engage in meaningful activities. The BA intervention will be delivered in 6 sessions over 3 months by Occupational Therapists trained in BA for post-TBI depression. BA sessions will be conducted in an office at the VA rehabilitation clinic or the home, depending on the veteran's preference.
62047244|NCT06174311|NO_INTERVENTION|Control (Waitlist) Cognitive Bias Modification|The waitlist control group will not receive any interventions during the process. They will only undergo pre-test, post-test, and follow-up measurements. If they still wish to receive the intervention, it will be provided to them after the follow-up assessment.
62047245|NCT00696410|EXPERIMENTAL|CHF patients Given Zinc Acetate|Patients with CHF received zinc acetate 50 mg po TID. This is a pre-post study
62047246|NCT00696410|NO_INTERVENTION|Healthy controls|Health controls; no zinc acetate administered.
62249726|NCT04879641|EXPERIMENTAL|10_Psychoeducation + Exposure|Randomized participants will get the Psychoeducation + Exposure components
62249727|NCT04879641|EXPERIMENTAL|11_Psychoeducation + Attention Training|Randomized participants will get the Psychoeducation + Attention Training components
62829410|NCT04976621|OTHER|Treatment as Usual Control Group|Participants in the Control group receive treatment as usual (TAU), which is usual care provided by the VA medical center.
62047247|NCT06136975||genitourinary symptoms of menopause|Women with genitourinary symptoms of menopause (GSM). Menopause was defined as no spontaneous menstruation for at least one year. GSM defined as vulvovaginal dryness and related symptoms, such as irritation, dyspareunia, or lower urinary tract symptom (LUTS) including urinary urgency, dysuria and recurrent urinary tract infection after menopause .
62047248|NCT06136975||stress urinary incontinence|Women with stress urinary incontinence (SUI). SUI was defined as involuntary loss of urine on effort or physical exertion including sporting activities, or on sneezing or coughing.
62047249|NCT02489955|EXPERIMENTAL|AUC group|
62047250|NCT02489955|ACTIVE_COMPARATOR|Trough dose monitoring|
62249728|NCT04879641|EXPERIMENTAL|12_Psychoeducation + Attention Training + Exposure|Randomized participants will get the Psychoeducation + Attention Training + Exposure components
62439566|NCT02343887|EXPERIMENTAL|group with psychological support.|"patients treated with counseling for six months (period 1) and~* Stop if the situation improves with neuropsychological assessment and monitoring to M12,~* or if persistent or worsening unrest in the neuropsychological assessment of M6, the beginning of a cognitive remediation program for 6 months (period 2)."
62439567|NCT03483285|ACTIVE_COMPARATOR|heart rate|Effects of İntubation with Airtraq or Storz to heart rate
62439568|NCT03483285|ACTIVE_COMPARATOR|mean arterial pressure|Effect of intubation with Airtraq or Storz to mean arterial pressure
62607236|NCT02735707|OTHER|Corticosteroid Domain|"Patients with community acquired pneumonia (CAP) admitted to participating hospitals will be randomised to a steroid use strategy.~Note: this domain is now closed to patients with suspected or proven COVID-19. It remains open to patients with CAP without COVID-19.~Note: the fixed-course hydrocortisone has been closed to recruitment"
62249729|NCT04879641|EXPERIMENTAL|13_Psychoeducation + Cognitive Restructuring|Randomized participants will get the Psychoeducation + Cognitive Restructuring components
62249730|NCT04879641|EXPERIMENTAL|14_Psychoeducation + Cognitive Restructuring + Exposure|Randomized participants will get the Psychoeducation + Cognitive Restructuring + Exposure components
62439569|NCT00624871|ACTIVE_COMPARATOR|A|Infants will receive intravenous ascorbic acid and oral ibuprofen for 3 days
62439570|NCT00624871|PLACEBO_COMPARATOR|B|Infants will receive equivalent amount of placebo
62439571|NCT01284595|EXPERIMENTAL|AZD8931|\[14C\] AZD8931
62439572|NCT01283633|EXPERIMENTAL|programming with non-experienced nurse|Programming done by an experienced neuromodulation clinician will be compared to the patient satisfaction of a programming session with an inexperienced nurse via remote presence robotics, which will be directed by the experienced clinician
62607237|NCT02735707|OTHER|Influenza Antiviral Domain|Patients with community-acquired pneumonia admitted to participating hospitals with microbiological testing confirmed influenza infection will be randomised to one of six interventions.
62829411|NCT06594250||Experimental group|Experimental group comprising patients with S. aureus bacteremia with or without IE
62047251|NCT05195073|ACTIVE_COMPARATOR|3 D laparoscopy group|salpingectomy will be performed by using Storz image 1 S 3D laparoscopy system (Karl Storz, Tuttlingen, Germany) which is comprised of a 10 mm scope with 2 full HD sensors at the tip of the scope and a 3 D control unit plus a 3 D display
62047252|NCT05195073|ACTIVE_COMPARATOR|2 D laparoscopy group|salpingectomy will be performed by using a conventional 2 D laparoscopy system.
62607238|NCT02735707|OTHER|COVID-19 Antiviral Domain|"Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to no ivermectin or ivermectin.~Note: an earlier version of this domain evaluated lopinavir-ritonavir, hydroxychloroquine, and combination lopinavir-ritonavir and hydroxychloroquine against a 'no antiviral' control.~This domain is now closed."
62047253|NCT05350241|EXPERIMENTAL|Split-belt treadmill walking group|Participants in this group performed repeated split-belt treadmill training with an error-augmentation strategy.
62047254|NCT05350241|ACTIVE_COMPARATOR|Control group|Participants in this group received the standard physical rehabilitation program
62047255|NCT00035529|OTHER|1|
62249731|NCT04879641|EXPERIMENTAL|15_Psychoeducation + Cognitive Restructuring + Attention Training|Randomized participants will get the Psychoeducation + Cognitive Restructuring + Attention Training components
62249732|NCT04879641|EXPERIMENTAL|16_full version (Psychoeducation + Cognitive Restructuring + Attention Training + Exposure)|Randomized participants will get the Psychoeducation + Cognitive Restructuring + Attention Training + Exposure components
62249733|NCT03120806|ACTIVE_COMPARATOR|continous subcuticular|skin closed with continous subcuticular mattress suture using non-absorbable polypropylene
62829412|NCT06594250||Control group|Control group comprising patients with bacteremia with a pathogenic bacterial species other than S. aureus with or without IE.
62829413|NCT00425269|EXPERIMENTAL|Intervention|The intervention group was divided into nine subgroups of ten to twelve women who were offered six educational sessions, each lasting 2 h, during a 7 +- 1-month period. The main focus was on the physiological importance of blood glucose and its regulation by diet and physical activity, and on knowledge about the Pakistani lifestyle in Pakistan and Norway
62829414|NCT00425269|NO_INTERVENTION|Control|One lesson recieved after post-test
62829415|NCT02067078|EXPERIMENTAL|Combined saphenous nerve and obturator nerve block|
62829416|NCT02067078|EXPERIMENTAL|Saphenous nerve block|
62829417|NCT02067078|ACTIVE_COMPARATOR|Local infiltration analgesia|
62829418|NCT06368635||CCMD|The correlation between coronary microcirculation disease and cerebral microcirculation
62047256|NCT00035529|ACTIVE_COMPARATOR|2|
62249734|NCT03120806|ACTIVE_COMPARATOR|Interrupted subcuticular|skin closed with interrupted subcuticular mattress suture using non-absorbable polypropylene
62249735|NCT01161602|EXPERIMENTAL|0.2mg Pumosetrag|
62829419|NCT00093041|EXPERIMENTAL|Zalutumumab 0.15 mg/kg|
62829420|NCT00093041|EXPERIMENTAL|Zalutumumab 0.5 mg/kg|
62829421|NCT00093041|EXPERIMENTAL|Zalutumumab 1 mg/kg|
62047257|NCT00035529|ACTIVE_COMPARATOR|3|
62047258|NCT03086330|EXPERIMENTAL|Semaglutide|
62047259|NCT03086330|PLACEBO_COMPARATOR|Placebo|
62047260|NCT04614233|EXPERIMENTAL|RiduZone (90% Oleoylethanolamide (OEA))|Participants will be randomly assigned to take 2 capsules of RiduZone (each capsule contains 90% OEA) daily for 16 months.
62439573|NCT00622141|ACTIVE_COMPARATOR|A|Day 1: receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg 7-day washout period will follow. Day 8: take generic GPO squinavir/Norvir
62829422|NCT00093041|EXPERIMENTAL|Zalutumumab 2 mg/kg|
62047261|NCT04614233|PLACEBO_COMPARATOR|Placebo|Participants will be randomly assigned to take 2 capsules of placebo daily for 16 months.
62047262|NCT04462861|EXPERIMENTAL|CVAD securement device|Patients with a pre-existing CVAD who will trial the new securement dressing
62047263|NCT04639674|EXPERIMENTAL|AST-120|"sachet Three times a day. (2g/pack\*3pack/box)~1 month"
62047264|NCT04639674|NO_INTERVENTION|Control|No intervention
62047265|NCT03233243|EXPERIMENTAL|Patients with positive 18F-NaF plaques|Patients with 18F-NaF-positive plaques (coronary, aortic or carotid) with TBR \> 1.5
62047266|NCT03233243|NO_INTERVENTION|Patients without 18F-NaF-positive plaques|Subjects without 18F-NaF- positive plaques will be excluded from the pharmacological intervention study
62047267|NCT05166044||Safety group|All of the participants(N=12500) received one dose of EV71 vaccine and one of other vaccines(such as MMR vaccine,encephalitis vaccine,mumps vaccine,inactivated poliomyelitis vaccine,influenza vaccine and so on ) at the same time.
62047268|NCT01523054|EXPERIMENTAL|Metoprolol- Toprol XL|Metoprolol extended release (CR/XL) tablet 200 mg once daily
62047269|NCT01523054|ACTIVE_COMPARATOR|Metoprolol- Lopressor|Metoprolol immediate release (IR) tablet
62047270|NCT04746573||Natrox Topical Oxygen Therapy managed by telehealth|Pilot study using topical oxygen managed by telehealth in the home setting.
62249736|NCT01161602|EXPERIMENTAL|0.5mg Pumosetrag|
62249737|NCT01161602|EXPERIMENTAL|0.8mg Pumosetrag|
62249738|NCT01161602|PLACEBO_COMPARATOR|Placebo|
62249739|NCT03933384|ACTIVE_COMPARATOR|Tenofovir alafenamide group|Study subjects will receive tenofovir alafenamide 25 mg/tab once daily for 3 years (144 weeks).
62249740|NCT03933384|ACTIVE_COMPARATOR|Entecavir group|Study subjects will receive entecavir 0.5 mg/tab once daily for 3 years (144 weeks).
62249741|NCT02486848|PLACEBO_COMPARATOR|5% Topical Minoxidil Solution|5% Topical Minoxidil Solution
62249742|NCT02486848|ACTIVE_COMPARATOR|15% Topical Minoxidil Solution|15% Topical Minoxidil Solution
62249743|NCT02202291|EXPERIMENTAL|Patient with Raynaud's phenomenon|
62249744|NCT02204384|EXPERIMENTAL|HFD Meal: high fiber from food|HFD Meal: high amount of fiber from diet food sources (total fiber 9.7g; soluble fiber 5.4g)
62829423|NCT00093041|EXPERIMENTAL|Zalutumumab 4 mg/kg|
62829424|NCT00093041|EXPERIMENTAL|Zalutumumab 8 mg/kg|
62829425|NCT01611844|EXPERIMENTAL|Medical device : micro-needle BD 1.5 mm 30G|
62829426|NCT01611844|ACTIVE_COMPARATOR|Manthoux method: lance 26G X 16mm|
62829427|NCT00807911|ACTIVE_COMPARATOR|Adjuvant FL|FL (5-FU 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles)
62829428|NCT00807911|EXPERIMENTAL|Adjuvant FOLFOX|FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-FU bolus 400 mg/m2 on D1, 5-FU infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles)
62607239|NCT02735707|OTHER|COVID-19 Immune Modulation Domain|"Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five interventions.~Note: this domain is now closed."
62047271|NCT02434094||T1DM Clinicians|Clinicals currently teaching T1DM patients how to use insulin pumps and continuous glucose monitors will be asked to complete the eDAPT on-line training program.
62249745|NCT02204384|EXPERIMENTAL|HFS Meal: High fiber from supplement|HFS Meal: high amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - Fiber Mais, Nestlé
62249746|NCT02204384|EXPERIMENTAL|UF Meal: usual amount of fiber|UF Meal: usual amount of fiber (total fiber 2.4g; soluble fiber 0.8g)
62607240|NCT02735707|OTHER|Anticoagulation Domain|"Patients admitted to participating intensive care units with suspected or microbiological testing confirmed COVID-19 will be randomised to an anticoagulation strategy.~Note: A previous version of this domain evaluated local standard venous thromboprophylaxis against therapeutic dose anticoagulation. This domain is now closed."
62249747|NCT05449197||Community pharmacists chosen by the patient with haemophilia A for dispensing Emicizumab|
62249748|NCT01704287|EXPERIMENTAL|Pembrolizumab 2 mg/kg|Participants were initially randomized to receive pembrolizumab 2 mg/kg intravenously (IV) once every 3 weeks (Q3W). With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to \~66 months)
62829429|NCT01875809||Renal denervation (RDN)|Change of catecholamine spill-over during RDN
62829430|NCT01875809||Electrophysiology (EP) Ablation|Change of catecholamine spill-over during EP ablation
62829431|NCT05686902|EXPERIMENTAL|PH 5.5 BABY SHAMPOO GROUP|Distilled water+Ph 5.5 baby shampoo for stoma care of patients in the first group
62829432|NCT05686902|ACTIVE_COMPARATOR|SERUM PHYSIOLOGIC GROUP|0.9% saline solution for stoma care of patients in the second group
62829433|NCT06654414|EXPERIMENTAL|PRIDE QUIT|"Participants in this adapted intervention arm (n=30) will receive empirically-based, Cognitive-Behavioral therapy-based strategies, tailored for transgender and gender diverse (TGD) individuals, which aims to help participants quit smoking and address gender minority stressors, anxiety, depression, and improve distress tolerance.~This intervention group will likely receive 6-10 active weekly sessions, with the quit day set around session 4-6. They will also receive transdermal nicotine patches (TNP) for a period of 8 weeks prior to the quit session."
62439574|NCT00622141|ACTIVE_COMPARATOR|B|Day 1: take generic GPO squinavir/Norvir 7-day washout period will follow. Day 8: receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg
62607241|NCT02735707|OTHER|Immunoglobulin Domain|"Immunosuppressed patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive no immunoglobulin for COVID-19, or to receive high-titre convalescent plasma.~Note: an earlier version of this domain was not restricted to immunosuppressed patients."
62829434|NCT06654414|ACTIVE_COMPARATOR|Enhanced Treatment As Usual (ETAU)|Participants in this arm (n=30) will receive enhanced treatment as usual at Fenway Health. These participants will attend one session (brief counseling), will come to the clinic for weekly assessments only, and receive the option of transdermal nicotine patch (TNP) and referral to the Quit Line.
62829435|NCT00921375|EXPERIMENTAL|Tuly, uric acid lowering drug|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
62829436|NCT06653959|ACTIVE_COMPARATOR|active Transcranial Magnetic Stimulation|The most relevant site of functional connectivity between vlPFC-VTA will be targeted for continuous theta burst stimulation
62829437|NCT06653959|PLACEBO_COMPARATOR|sham Transcranial Magnetic Stimulation|The most relevant site of functional connectivity between vlPFC-VTA will be targeted for sham continuous theta burst stimulation
62829438|NCT06163443|EXPERIMENTAL|Vitamin B group|Patients with polymorphisms in the MTHFR, MTR, and MTRR will take methylfolate, P5P, and methylcobalamin genes 2 capsules/day.
62829439|NCT06163443|PLACEBO_COMPARATOR|Placebo group|Patients with polymorphisms in the MTHFR, MTR, and MTRR will take placebo capsules will be identical in appearance, matched for color coating, shape, and size - 2 capsules/day..
62047272|NCT02434094||T1DM Subjects with DiAs experience|T1DM subjects will prior DiAs experience will be asked to complete the eDAPT on-line training program.
62047273|NCT02434094||T1DM Subjects with no prior DiAs experience|T1DM subjects will no prior DiAs experience will be asked to complete the eDAPT on-line training program.
62607242|NCT02735707|OTHER|Vitamin C Domain|"Patients admitted to participating hospitals with community-acquired pneumonia will be randomised to receive no vitamin C, or vitamin C.~Note: this domain is now closed."
62607243|NCT02735707|OTHER|Simvastatin Domain|"Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no simvastatin, or simvastatin.~Note: this domain is now closed."
62607244|NCT02735707|OTHER|Antiplatelet Domain|"Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no antiplatelet, aspirin, or site-preferred P2Y12 inhibitor.~Note: this domain is now closed."
62047274|NCT04138589||CF patients aged 6-18 years homozygeous for delta F508|CF patients aged 6-18 years homozygeous for delta F508 starting with lumacaftor/ ivacaftor or tezacaftor/ ivacaftor
62047275|NCT03343197|EXPERIMENTAL|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 .
62607245|NCT02735707|OTHER|Mechanical Ventilation Domain|Patients with community-acquired pneumonia admitted to participating intensive care units who are intubated and receiving invasive mechanical ventilation will be randomised to protocolised mechanical ventilation strategy, or clinician-preferred mechanical ventilation strategy
62047276|NCT03343197|EXPERIMENTAL|AG-881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-881.
62249749|NCT01704287|EXPERIMENTAL|Pembrolizumab 10 mg/kg|Participants were initially randomized to receive pembrolizumab 10 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to \~66 months)
62607246|NCT02735707|OTHER|COVID-19 Immune Modulation (2) Domain|"Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive one of three interventions.~Note: this domain is now closed."
62607247|NCT02735707|OTHER|ACE2 RAS Domain|"Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five renin-angiotensin system blockade strategies.~Note: this domain is now closed."
62607248|NCT02735707|OTHER|Cysteamine Domain|"Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no cysteamine, or cysteamine.~Note: this domain is now closed."
62607249|NCT02735707|OTHER|Endothelial Domain|Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no endothelial modulator or enteral imatinib.
62607250|NCT02735707|OTHER|Influenza Immune Modulation|Patients with community-acquired pneumonia admitted to participating intensive care units with microbiological testing confirmed influenza infection will be randomised to one of three interventions.
62607251|NCT02735707|OTHER|COVID-19 Antiviral (II) Domain|Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to one of up to four interventions.
62607252|NCT04089345|EXPERIMENTAL|Open label ustekinumab|All patients will receive intravenously (IV) ustekinumab \~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48. All subjects will receive concomitant antibiotic treatment with ciprofloxacin or metronidazole from baseline through Week 4. Intravenous induction doses will be 260mg for patients \<55kg, 390mg for patients between 55 and 85kg, and 520mg for patients with a body weight \>85 kg.
62249750|NCT01704287|ACTIVE_COMPARATOR|Investigator-Choice Chemotherapy (ICC)|Participants were initially randomized to receive 1 of 4 possible chemotherapy regimens decided at the treating institution (carboplatin+paclitaxel, paclitaxel alone, dacarbazine, or temozolomide). Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to \~66 months)
62439575|NCT06150378|ACTIVE_COMPARATOR|Corticoid|Patients that recieve corticosterone injection instead of plathet rich plasma.
62439576|NCT06150378|EXPERIMENTAL|Plathet rich plasma|Patients that recieve plathet rich plasma instead of corticoesterone
62439577|NCT06388291|EXPERIMENTAL|ON/OFF-stimulation|This group will have the stimulator switched on for two weeks followed by off for two weeks
62607253|NCT00881907|EXPERIMENTAL|Group A|Group A subjects will be asked to attend a recall visit 2 months following completion of the treatment visits.
62829440|NCT06653972|EXPERIMENTAL|PLD+NVB|Pegylated Liposomal Doxorubicin 25mg/m2 ivgtt d1 + vinorelbine25mg/m2 ivgtt d1/q14d.
62607254|NCT00881907|EXPERIMENTAL|Group B|Group B subjects will be asked to attend a recall visit at 4 months following completion of the treatment visits.
62047277|NCT03343197|NO_INTERVENTION|No Treatment Pre-Surgery|Subjects will not receive treatment prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 or AG-881.
62047278|NCT04143841|ACTIVE_COMPARATOR|Single treatment|A single treatment will be administered for both eyes for each subject. The treatment will be administered for 11 minutes per treated eye.
62047279|NCT04143841|SHAM_COMPARATOR|Single sham treatment|A single treatment will be administered for both eyes for each subject. The treatment will be administered for 11 minutes per treated eye.
62047280|NCT05050201|EXPERIMENTAL|Sleepio Intervention|Participants using the Sleepio application - access for 6 sessions, over 10 weeks
62607255|NCT00881907|EXPERIMENTAL|Group C|Group C subjects will be asked to attend a recall visit at 6 months following completion of the treatment visits.
62249751|NCT01704287|EXPERIMENTAL|ICC→Pembrolizumab 2 mg/kg|Participants who were initially randomized to ICC, subsequently experienced confirmed progressive disease (PD) and met all switching criteria at study treatment Week 12, had the opportunity to switch to receive pembrolizumab 2 mg/kg or 10 mg/kg. Participants received pembrolizumab 2 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to PD, toxicity, or choice. (Up to \~66 months)
62607256|NCT05537623|EXPERIMENTAL|Safe Alternatives for Teens and Youths (SAFETY)|SAFETY is a transdiagnostic cognitive-behavioral family treatment informed by Dialectical Behavior Therapy (DBT) and Multisystemic Therapy (MST). The twelve week long treatment is principle based, structured in phases, and individually tailored based on a cognitive-behavioral fit analysis that specifies key risk and protective processes. Each session contains one individual component for youth and parents respectively, and one family component where youth and parents work together with therapists to practice skills identified as critical for preventing future suicidal behavior. Treatment targets are arranged in a SAFETY Pyramid, consisting of (a) safe settings; (b) safe people; (c) safe activities and actions; (d) safe thought; and (e) safe stress reactions, emphasizing strengthening protective support and validation within the family and/or social environment surrounding the youth.
62607257|NCT05537623|ACTIVE_COMPARATOR|Supportive Therapy|Supportive Therapy is a manualized client-centered therapy. The Supportive Therapy will be adapted to match SAFETY to control for nonspecific treatment factors such as therapist characteristics, time, and treatment exposure. The Supportive Therapy program consists of twelve weekly individual sessions with the youth, focusing on the therapeutic supporting relationship between the therapist and the youth, and follow-ups with parents. Therapeutic strategies include acceptance and validation, to increase feelings of connectedness and belonging and counteract thwarted belongingness, helplessness, and hopelessness. Cognitive-behavioral techniques (e.g., active modeling, problem-solving training, cognitive restructuring) are not allowed.
62607258|NCT05180370||Outpatient or inpatient diagnosed with Heart Failure at least 6 months ago|ADAPTATION HF is a prospective, observational, cross-sectional, multicenter, survey-based study. Patients who applied to the cardiology outpatient clinic with a preliminary diagnosis of HF or were hospitalized for HF and had a diagnosis of HF for at least 6 months will be included in the study.
62607259|NCT02110030|EXPERIMENTAL|Transcutaneous nerve stimulation|"The group with transcutaneous nerve stimulation (TENS) received electrical stimulation for 15 sessions at a frequency of 80 Hz and with a pulse width of 150 ns.~The group with TENS received electrical stimulation by using an approved electrotherapy device (Endomed 182, Enraf-nonius, Germany). The TENS was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: supraspinatus fossa and the insertion of the rotator cuff (channel 1) and V deltoid  (channel 2)."
62607260|NCT02110030|ACTIVE_COMPARATOR|Interferential Currents|The group with Interferential Currents (IC) received a base frequency of 4000 Hz by using the same approved electrotherapy device than the TENS group (Endomed 182, Enraf-nonius, Germany).
62607261|NCT01996657||Standard intensity of anticoagulation|After mechanical valve replacement，patients should be gave oral anticoagulants，such as warfarin.and The intensity of anticoagulation for this group was standard intensity (INR:2.5-3.5).
62607262|NCT01996657||Low intensity and adjusted by elevated D-dimer|The intensity of anticoagulation maintained at low level initiatively, D-dimer testing were analyzed at 3 month later. In case of D-dimer level elevated, adjusted the intensity to standard level.
62607263|NCT01996657||Low intensity without adjustment|The intensity of anticoagulation for this group was kept at low intensity without adjustment (INR:1.8-2.6),
62607264|NCT03837119||Heterozygous Hemoglobinopathy|pregnancy outcome in women with heterozygous hemoglobinopathy
62607265|NCT03837119||No Heterozygous Hemoglobinopathy|pregnancy outcome in women without heterozygous hemoglobinopathy
62607266|NCT00980018|EXPERIMENTAL|nilotinib|Participants received two 150 \[a total of 300 mg at each dosing\] mg nilotinib capsules twice daily (bid) orally every morning and every evening approximately 12 hours apart and two 200 mg capsules \[a total of 400 mg at each dosing\] for patients enrolled prior to Protocol Amendment 1).
62249752|NCT01704287|EXPERIMENTAL|ICC→Pembrolizumab 10 mg/kg|Participants who were initially randomized to ICC, subsequently experienced confirmed progressive disease (PD) and met all switching criteria at study treatment Week 12, had the opportunity to switch to receive pembrolizumab 2 mg/kg or 10 mg/kg. Participants received pembrolizumab 10 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to PD, toxicity, or choice. (Up to \~66 months)
62439578|NCT06388291|EXPERIMENTAL|OFF/ ON -stimulation|This group will have the stimulator switched off for two weeks followed by on for two weeks
62607267|NCT02980354||Lacunar stroke|Blood samples will be taken from 50 patients who have been diagnosed to have lacunar stroke and are 65 years of age or above.
62607268|NCT02980354||Cortical stroke|Blood samples will be taken from 50 patients who have been diagnosed to have cortical stroke and are 65 years of age or above.
62607269|NCT02980354||Elderly healthy volunteers|Blood samples will be taken from 50 healthy individuals who are 65 years of age or above.
62607270|NCT02980354||Young healthy volunteers|Blood samples will be taken from 50 healthy individuals who are between 18 and 64 years of age.
62607271|NCT05026047|EXPERIMENTAL|patients consulting in an infectious disease department|no comparator
62829441|NCT04632680|EXPERIMENTAL|PVI followed by targeting of drivers|Patients will undergo intra-procedural mapping using the ECG-I. The pulmonary veins will be isolated. Drivers will then be targeted as guided by the ECG-I system aiming for termination of AF.
62829442|NCT04402086||Biorepository|Participants with rheumatic diseases who contributed biospecimen samples (blood, saliva, urine, stool, tissue).
62047281|NCT02683564|EXPERIMENTAL|BOW015|Infliximab-EPIRUS, 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks thereafter up to Week 46.
62607272|NCT06300476|EXPERIMENTAL|Low dose group|Subretinal injection low dose of JWK006 in one eye
62829443|NCT05228587|EXPERIMENTAL|Liver Transplants|"Indocyanine Green will be injected in liver donors for measuring plasma disappearance rate with a non invasive measurement device.~Liver recipients will receive indocyanine green injection for measuring plasma disappearance rate at different time-points."
62249753|NCT04157816|EXPERIMENTAL|Digital Training (DGT)|Participants allocated to this arm receive a low-intensity digital program accessible by smart phone app for training non-specialist health workers to deliver an evidence-based brief psychological treatment for depression, called the Healthy Activity Program (HAP), in primary care settings in India.
62249754|NCT04157816|EXPERIMENTAL|Digital Training with Coaching Support (DGT+)|Participants allocated to this arm receive a high-intensity digital program accessible by smart phone app augmented with weekly telephone coaching support for training non-specialist health workers to deliver an evidence-based brief psychological treatment for depression, called the Healthy Activity Program (HAP), in primary care settings in India.
62249755|NCT04157816|ACTIVE_COMPARATOR|Face-to-Face Training|Participants allocated to this arm receive a traditional classroom-based (face-to-face) program hosted in community settings for training non-specialist health workers to deliver an evidence-based brief psychological treatment for depression, called the Healthy Activity Program (HAP), in primary care settings in India.
62439579|NCT02625545|EXPERIMENTAL|UroLift System procedure|All eligible,enrolled subjects will undergo a UroLift procedure
62439580|NCT04061564|ACTIVE_COMPARATOR|Active transcutaneous vagal nerve stimulation|The participant will be administered vagal nerve stimulation to each ear (20 minutes in total)
62607273|NCT06300476|EXPERIMENTAL|Medium dose group|Subretinal injection medium dose of JWK006 in one eye
62249756|NCT05485584|EXPERIMENTAL|Healthy subjects(A1)|Each nostril: 2 sprays/time; Pharynx: 4 sprays/time; Once daily
62249757|NCT05485584|PLACEBO_COMPARATOR|Healthy subjects(A2)|Each nostril: 2 sprays/time; Pharynx: 4 sprays/time; Once daily
62249758|NCT05485584|EXPERIMENTAL|COVID-19 subjects(B1)|Each nostril: 2 sprays/time; Pharynx: 4 sprays/time; Twice daily
62249759|NCT05485584|PLACEBO_COMPARATOR|COVID-19 subjects(B2)|Each nostril: 2 sprays/time; Pharynx: 4 sprays/time; Twice daily
62249760|NCT04672265|EXPERIMENTAL|Mother tongue and Norwegian|Written material related to screening sent to the invitee in two languages.
62439581|NCT04061564|SHAM_COMPARATOR|Sham transcutaneous vagal nerve stimulation|The participant will be administered sham stimulation to each ear (20 minutes in total)
62607274|NCT06300476|EXPERIMENTAL|High dose group|Subretinal injection high dose of JWK006 in one eye
62829444|NCT06521125||Patients with FPF and sporadic IPF|
62829445|NCT06521125||First-degree relatives of patients with FPF and sporadic IPF|
62829446|NCT06655246|EXPERIMENTAL|Dose Escalation|
62829447|NCT06655246|EXPERIMENTAL|Recommended Phase 2 Dose Determination|
62249761|NCT04672265|NO_INTERVENTION|Norwegian|Written material related to screening sent to the invitee in Norwegian only.
62249762|NCT04533087||Candida blood stream infection|
62249763|NCT04533087||Aspergillosis|
62249764|NCT04533087||Rare mold infections|
62249765|NCT02954146|ACTIVE_COMPARATOR|CBT only|Veterans will receive 12 weekly individual cognitive behavioral therapy (CBT only) sessions for anger management.
62439582|NCT01819766||IBD or PSC|Subjects will be men and women, 18 to 84 years of age, inclusive, who are at increased risk of developing colorectal cancer.
62439583|NCT02408406|EXPERIMENTAL|Arm I (PatientCareAnywhere program system)|Patients are encouraged to use the PatientCareAnywhere program at least once weekly either in the clinic or at home. Patients receive reminder emails after 1 week of inactivity. If patients indicate they are experiencing moderate to severe symptoms, an alert message is sent to at least 1 member of the patient's support team along with a list of expected response times.
62607275|NCT03557476|EXPERIMENTAL|Octacosanol|Two capsules (20-mg x 2) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed daily by the octacosanol group for six days, one capsule 30 minutes after morning and afternoon meals.
62607276|NCT03557476|PLACEBO_COMPARATOR|Placebo|A placebo pill was taken twice daily in replacement of the octacosanol supplement
62607277|NCT01273714|ACTIVE_COMPARATOR|BST|bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each)
62607278|NCT01273714|EXPERIMENTAL|TT|extracapsular total thyroidectomy
62607279|NCT05032742|EXPERIMENTAL|mHealth parenting stress app|mHealth parenting stress app intervention to reduce parenting stress and improving youth community-based treatment engagement.
62829448|NCT06655246|EXPERIMENTAL|Dose Expansion|
62249766|NCT02954146|EXPERIMENTAL|CBT + Connectd mobile health app|Veterans will receive 12 weekly individual cognitive behavioral therapy (CBT) sessions for anger management. In addition, veterans in this group will also receive instructions for using Connectd mobile health app with a family member or friend that will provide data for the CBT clinician.
62249767|NCT00804570|EXPERIMENTAL|LY2196044|
62607280|NCT05032742|NO_INTERVENTION|Standard of care|Caregiver participants will receive an informational brochure describing ways to support one's adolescent during detention and community reentry and any other usual care.
62829449|NCT03542877|EXPERIMENTAL|Oral Cabozantinib|Patients will be enrolled to take 60mg of cabozantinib, by mouth, once a day, every day, for 12 weeks. If less than three patients have Progression Free Survival (PFS) lasting at least 12 weeks, the study will be terminated.
62829450|NCT00625170|ACTIVE_COMPARATOR|1|Healthy men
62829451|NCT00625170|ACTIVE_COMPARATOR|2|Healthy men with a positive family anamneses of schizophrenia
62829452|NCT06070064|EXPERIMENTAL|Music|"The music group will carry out an initial familiarisation session of the main study variables. Subsequently, through an incremental test, MR will be evaluated through the control of execution speed.~The heaviest load at which each participant could correctly lift with full knee extension shall be considered as their 1RM.~For lighter loads (average speed\> 1.0 m-s-1), there will be 3 attempts per load.There shall be two attempts with medium loads(0.50 m-s-1 ≥ average speed ≤ 1.0 m-s-1); and only one for close to maximum loads (average speed \< 0.50 m-s-1).~After the first 1RM visit described above, participants will complete two additional random counterbalanced visits, each with a different condition.~The music group started the whole evaluation process with the music conditioning factor present. After completion of the measurements and the necessary rest time, the measurement was repeated in the non-music condition."
62829453|NCT06070064|EXPERIMENTAL|Non-music|"The non-music group developed the same protocol but started the measurements without the presence of music."
62829454|NCT01287962|EXPERIMENTAL|Apatinib|750 mg，po，QD； 28 days every cycle
62829455|NCT01287962|PLACEBO_COMPARATOR|Placebo|
62829456|NCT05310019|EXPERIMENTAL|Physiotherapy plus Electroacupuncture Group|The physiotherapy treatment (50min): warm compress with facial thermal blanket, respiratory muscle mobility training and cervical muscle relaxation, facial lymphatic drainage, start of myolymphokinetic exercises for the orbicularis, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma, release of intraoral adhesions, vacuum therapy at 60 mmHg, active exercises free of mandibular movements, maintenance of mandibular opening with wooden tongue depressors. The electroacupuncture treatment lasting another 30 min. Electroacupuncture treatment lasting another 30min. The repetition time of 1 sec; (F1-10 Hz, F2= 45 Hz; 10 mA). Facial acupuncture needles are disposable with 0.20 mm gauge and 10 mm length. Each needle will be inserted at the indicated points, totaling 10 needles and electrodes will be connected to each one. Electrical stimulation will be performed on the face points: E4, Jiachengjiang (extra point), E5, E6, bilaterally and point CV-24.
62829457|NCT05310019|ACTIVE_COMPARATOR|Physiotherapy Group|The physiotherapy protocol will be the same as the active group. Protocol: warm compress with facial thermal blanket (5 min), respiratory muscle mobility training and cervical muscle relaxation (5 min) facial lymphatic drainage (10 min), start of myolyphokinetic exercises for the orbicularis oris, zygomatic major and minor, levator labii superioris and nasal ala, buccinator and platysma (5 min), release of intraoral adhesions (5 min) vacuum therapy at 60 mmHg (5 min), active exercises free of mandibular movements of right and left laterality, protrusion and mandibular opening (5 min), maintenance of mandibular opening with wooden tongue depressors (10 min).
62829458|NCT01122238|EXPERIMENTAL|1, Nicotine Patch, Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
62829459|NCT01122238|EXPERIMENTAL|2, Nicotine Patch, Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
62829460|NCT01122238|EXPERIMENTAL|3, Nicotine Patch, Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
62829461|NCT01122238|EXPERIMENTAL|4, Nicotine Patch, Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
62829462|NCT01122238|EXPERIMENTAL|5, Nicotine Patch, No Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
62829463|NCT01122238|EXPERIMENTAL|6, Nicotine Patch, No Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
62829464|NCT01122238|EXPERIMENTAL|7, Nicotine Patch, No Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
62829465|NCT01122238|EXPERIMENTAL|8, Nicotine Patch, No Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
62249768|NCT00804570|PLACEBO_COMPARATOR|Placebo|
62607281|NCT00310076|EXPERIMENTAL|Chemo therapy followed by thalidomide|After cytoreductive surgery with intraperitoneal hyperthermic chemotherapy, patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
62607282|NCT06187961|EXPERIMENTAL|HAIC-len-cado|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus lenvatinib (Len) and cadonilimab as conversion therapy for downstaging.
62249769|NCT01117454|OTHER|Flecainide then placebo|In this crossover study, half of the subjects will be randomized to flecainide plus standard therapy with beta-blockers first, then crossover to placebo plus standard therapy with beta-blockers.
62607283|NCT06596317|EXPERIMENTAL|Chromoendoscopy with indigo carmine solution spray|Patients in this group will be carefully observed with spraying indigo carmine solution during the colonoscopy withdraw.
62607284|NCT06596317|ACTIVE_COMPARATOR|Conventional colonoscopy without indigo carmine solution spray|Patients in this group will be carefully observed without spraying anything during the colonoscopy withdraw.
62047282|NCT02683564|ACTIVE_COMPARATOR|Remicade|Remicade (infliximab) , 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks thereafter up to Week 46.
62047283|NCT06380218|EXPERIMENTAL|Nutrional and physical activity program|10 collective combined workshops of nutrition and physical activity = 1 per week during 10 weeks associated to margarine consumption
62607285|NCT04364113|ACTIVE_COMPARATOR|Study A Usual Protein Usual Pressure|Study A Usual Protein and Usual Pressure
62607286|NCT04364113|EXPERIMENTAL|Study A Usual Protein Low Pressure|Study A Usual Protein and Low Pressure
62607287|NCT04364113|EXPERIMENTAL|Study A Low Protein Usual Pressure|Study A Low Protein and Usual Pressure
62047284|NCT04631263|EXPERIMENTAL|Treatment Group|
62047285|NCT04631263|NO_INTERVENTION|Control Group|
62047286|NCT05724355|EXPERIMENTAL|Dalpiciclib plus Camrelizumab|
62047287|NCT05548101|NO_INTERVENTION|Conventional Insemination|Oocytes will be fertilized via conventional insemination: Oocytes will be washed with multipurpose handling medium (MHM) plus 0.5% human serum albumin (HSA). Excess cumulus cells and blood will be trimmed. Oocytes will be transferred to a dish containing Irvine Scientific Continuous Cell Culture Complete Medium with two oocytes per dish. The dish will then be transferred to the incubator. Insemination will occur 4-6 hours post-retrieval. Sperm will be collected as a fresh specimen and washed with Irvine Scientific Continuous Single Culture-NX. Sperm concentration and motility will be assessed before and after washing according to WHO 6th edition criteria. Sperm will be prepared to achieve a concentration of 200,000 sperm per 100 microliter drop. 6 drops of prepared sperm will be added to each dish.
62047288|NCT05548101|ACTIVE_COMPARATOR|Intracytoplasmic Sperm Injection (ICSI)|Oocytes will be fertilized via ICSI: Oocytes will be washed with multipurpose handling medium (MHM) plus 0.5% human serum albumin (HSA). Excess cumulus cells and blood will be trimmed. Oocytes will be transferred to a dish containing Irvine Scientific Continuous Cell Culture Complete Medium with two oocytes per dish. The dish will then be transferred to the incubator. Oocytes will be immediately exposed to hyaluronidase to strip the cumulus and coronal cells. Embryologists will assess the maturation status under inverted microscopy. ICSI will be performed on all mature metaphase II oocytes 4 hours after retrieval. Injected oocytes will then be placed in a fresh culture dish and returned to the incubator.
62047289|NCT00895401|ACTIVE_COMPARATOR|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
62249770|NCT01117454|OTHER|Placebo then flecainide|In this crossover study, half of the subjects will be randomized to placebo plus standard therapy with beta-blockers first, then crossover to flecainide plus standard therapy with beta-blockers.
62249771|NCT00492323|PLACEBO_COMPARATOR|002|placebo twice daily for 4 weeks
62249772|NCT00492323|EXPERIMENTAL|001|carisbamate 200 mg tablet twice daily for 4 weeks
62439584|NCT02408406|ACTIVE_COMPARATOR|Arm II (usual care)|Patients receive usual care, including a one-time use of SupportScreen, a touchscreen questionnaire system that identifies patient issues before appointments, at the clinic during the first treatment consultation after diagnosis. Consultation, printed education materials, and specialist referrals may be generated based on SupportScreen responses.
62439585|NCT01186978|OTHER|Single arm|This phase II study will evaluate whether a reduction in the RT dose, concomitant with a decrease in the RT field size, in patients that achieve CR and have a negative post-chemotherapy PET scan following 4 to 6 cycles of rituximab containing chemotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity.
62607288|NCT04364113|EXPERIMENTAL|Study A Low Protein Low Pressure|Study A Low Protein and Low Pressure
62607289|NCT04364113|ACTIVE_COMPARATOR|Study B Low Protein Usual Pressure|Study B Low Protein and Usual Pressure
62607290|NCT04364113|EXPERIMENTAL|Study B Low Protein Low Pressure|Study B Low Protein and Low Pressure
62607291|NCT04364113|EXPERIMENTAL|Study B Very Low Protein Usual Pressure|Study B Very Low Protein and Usual Pressure
62607292|NCT04364113|EXPERIMENTAL|Study B Very Low Protein Low Pressure|Study B Very Low Protein and Low Pressure
62607293|NCT03235115|ACTIVE_COMPARATOR|Methafilcon A IV|Subjects are randomized to wear Methafilcon A IV for 1 hour during the cross over study.
62249773|NCT03216811|EXPERIMENTAL|nutraceutical|after 4 weeks of lifestyle advice and changes, all subjects will receive for 8 weeks the administration of CARDIOVIS COLESTEROLO 3 mg, a nutraceutical compound containing containing red rice fermented with Monascus purpureus titrated with 3% monacolin K, hydrol mixture of olive fruit titrated with vitamin E, Coenzyme Q10 and polymethoxyflavones
62249774|NCT04198454|ACTIVE_COMPARATOR|Compression bandages|Class I (20-30 mmHg) compression bandages or stocking. This is considered a standard measure in the recovery of lower extremity wounds and often recommended.
62607294|NCT03235115|ACTIVE_COMPARATOR|Ocufilcon B|Subjects are randomized to wear Ocufilcon B for 1 hour during the cross over study.
62607295|NCT03235115|ACTIVE_COMPARATOR|Omafilcon A|Subjects are randomized to wear Omafilcon A for 1 hour during the cross over study.
62607296|NCT01122784|ACTIVE_COMPARATOR|Group 1|160 Volunteers will be vaccinated with 80 mcg rF1V vaccine with adjuvant at Study Days 0, 56 and 182
62249775|NCT04198454|OTHER|Standard wound dressings|Wound dressings alone consisting of gauze and skin tape to cover the wound.
62249776|NCT04198454|EXPERIMENTAL|Compression bandages with FACL|Class I compression (20-30 mmHg) bandage or stocking with FACL.
62439586|NCT00655421|EXPERIMENTAL|Unaided|Unaided Visual Inspection of the Oral Cavity
62439587|NCT00655421|EXPERIMENTAL|VelScope|VelScope assisted examination of the oral cavity
62439588|NCT00655421|EXPERIMENTAL|Toluidine|Examination of oral cavity after the local application of Toluidine Blue dye
62607297|NCT01122784|ACTIVE_COMPARATOR|Group 2|40 Volunteers will be vaccinated with 80 mcg rF1V vaccine without adjuvant at Study Days 0, 56 and 182
62607298|NCT01122784|ACTIVE_COMPARATOR|Group 3|160 Volunteers will be vaccinated with 80 mcg rF1V vaccine with adjuvant at Study Days 0, 56 and 121
62607299|NCT01122784|ACTIVE_COMPARATOR|Group 4|40 Volunteers will be vaccinated with 80 mcg rF1V vaccine without adjuvant at Study Days 0, 56 and 121
62607300|NCT06385197|EXPERIMENTAL|patients using the app for dosing regimen|All of the enrolled patients will receive their dimethyl fumarate prescribed by their GP. During the 12 weeks' study period, patients in the intervention arm will receive the medication timed by the app- dose and time of administration will be determined using a designated app. The app will implement random changes in time of administration limited by a pre-defined range assigned by the therapeutic windows
62607301|NCT04757233|OTHER|Single arm|Intervention: GlucoType Single arm study; all participants assigned to use the intervention
62607302|NCT03059121||HIV-infected ART-naïve|HIV-infected subjects ≥ 16 years who are ART-naïve starting their first antiretroviral regimen
62607303|NCT01036659|ACTIVE_COMPARATOR|Ecallantide in conjunction with Conventional Therapy|
62607304|NCT01036659|PLACEBO_COMPARATOR|Conventional therapy and placebo|
62607305|NCT01036659|NO_INTERVENTION|Historical Evaluation|
62249777|NCT01992120|EXPERIMENTAL|Debriefing of high-fidelity sepsis simulation scenarios|"First visit:~* Subjects will fill out a self-assessment focusing on perceptions of their knowledge and ability in the recognition and management of sepsis in hospitalized patient~* Subjects will be specifically exposed to high-fidelity simulated sepsis scenarios and be debriefed on their performance in these scenarios (intervention)~* Subjects will take a written test focusing on early recognition and management of sepsis~* Subjects will receive a didactic teaching session focusing on recognition and management of early sepsis in the hospitalized patient~In the second visit:~* Subjects will be exposed to a number of high-fidelity simulated sepsis scenarios and be scored on their performance in management of these scenarios~* Subjects will take a written test of knowledge focusing on early recognition and management of sepsis~* Subjects will then be debriefed specifically on their performance in the simulation scenarios"
62607306|NCT02771600|EXPERIMENTAL|Buzzy|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
62607307|NCT02771600|ACTIVE_COMPARATOR|Standard Care (Maxilene)|Maxilene topical anaesthetic cream will be applied 30 minutes before the needle-related procedure on the insertion site
62607308|NCT06182046|EXPERIMENTAL|Intervention group: Balance exercise with BOSU Ball added to complete decongestive treatment|Complete decongestive treatment program consists of manual lymph drainage, multi-layer bandaging, skin/nail care and exercise treatments. The treatment will last 45 minutes/session, 5 sessions/week and 3 weeks. Patients in the intervention group will also receive balance exercises with a BOSU ball. These exercises will be performed in 2 sets, 5 days a week for 3 weeks. Each set will last 15 minutes. It will take 15 sessions in total. These exercises include 10 balance exercise movements performed on a bosu ball.
62607309|NCT06182046|ACTIVE_COMPARATOR|Active Control group: Complete decongestive treatment|Patients in this group will receive only a complete decongestive treatment program consisting manual lymph drainage, multilayer bandaging, skin/nail care, and exercise treatments. The treatment will last 45 minutes/session, 5 sessions/week and 3 weeks.
62607310|NCT04958902|EXPERIMENTAL|RESTORE intervention|Participants who screen eligible and consent will receive RESTORE with guidance.
62607311|NCT04306250|EXPERIMENTAL|anterior approach for apical fixation to the SSL|In this group the apical fixation will be done using the anterior access, ie dissection through the anterior vaginal wall.
62047290|NCT00895401|EXPERIMENTAL|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available nutritional supplement designed to meet the nutritional needs of malnourished hemodialysis patients. The serving size is 8 oz which provides 425 kcal and 19 g protein
62439589|NCT05494775|ACTIVE_COMPARATOR|Diabetic macular edema|Cases with diabetic macular edema that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
62439590|NCT05494775|ACTIVE_COMPARATOR|Wet age related macular edema|Cases with wet age related macular degenerations that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
62607312|NCT04306250|ACTIVE_COMPARATOR|posterior approach for apical fixation to the SSL|In this group the apical fixation will be done using the posterior access, ie fixation through the vaginal posterior wall.
62607313|NCT03684824|OTHER|obese group|100 obese patients with BMI between 30 and 35 who are undergoing IVF/ICSI treatment for infertility
62607314|NCT05794009|EXPERIMENTAL|Immersive Virtual Reality Exercise (IVRE)|VR exercise training for at least three times a week for 12 consecutive weeks (a total of 36 sessions) guided by the e-therapist: The tailored VR-based exercise program involves aerobic and resistance exercises, and VR games.
62607315|NCT05794009|ACTIVE_COMPARATOR|Home Exercise|Individuals randomized to the control group will attend a briefing session prior to the start of the program to complete demographic data collection and physical assessment. They will be given an exercise booklet and guided through a set of home-based exercises (identical training to the intervention group except for VR games) in the briefing session. Stepping exercises will be implemented as a substitution of cycling as an aerobic exercise training at home.
62047291|NCT00446381|EXPERIMENTAL|1|Patients with Proliferative Diabetic Retinopathy
62439591|NCT05494775|ACTIVE_COMPARATOR|Retinal vein occlusion|Cases with macular edema secondary to retinal vein occlusion that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
62439592|NCT05494775|ACTIVE_COMPARATOR|Myopic choroidal new vascularization|Cases with myopic choroidal new vascularization that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
62439593|NCT03165890|ACTIVE_COMPARATOR|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
62607316|NCT04705519|EXPERIMENTAL|Nab-paclitaxel Combined With Bevacizumab|Nab-paclitaxel, Bevacizumab
62607317|NCT04068688|EXPERIMENTAL|Caregiver-Child Dyads with ASD (Autism Spectrum Disorder)|Participants in this arm will be caregivers of and children with ASD.
62047292|NCT00446381|EXPERIMENTAL|2|Patients with Clinically Significant Macular Edema
62439594|NCT03165890|PLACEBO_COMPARATOR|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
62607318|NCT04068688|NO_INTERVENTION|Children with typical development|Participants in this arm will be children with typical development.
62607319|NCT04068688|NO_INTERVENTION|Children with developmental delay|Participants in this arm will be children with developmental delay.
62607320|NCT04068688|EXPERIMENTAL|Caregiver-Child Dyads with ASD (Autism Spectrum Disorder) Telehealth Adaptation|Participants in this arm will be caregivers of and children with ASD receiving telehealth intervention (adaptation due to COVID-19 restrictions).
62607321|NCT04068688|NO_INTERVENTION|Early Childhood Development (ECD) Practitioners and ECD Practitioner School Supervisors|The ECD worker and/or school supervisor are 1) employed by our participating recruitment partners (Western Cape Education Department Schools) and 2) involved in delivery of the caregiver coaching sessions, either in person or remotely.
62047293|NCT00892112|ACTIVE_COMPARATOR|intravenous immunoglobulins|IV, 40 ml/kg over 4 days
62047294|NCT00892112|PLACEBO_COMPARATOR|plasma volume expander Albuman|IV, 40 ml/kg over 4 days
62047295|NCT03703466|EXPERIMENTAL|200 mg Abemaciclib With a Meal|200 mg abemaciclib given twice a day (BID) orally with a meal.
62047296|NCT03703466|EXPERIMENTAL|200 mg Abemaciclib Without a Meal|200 mg abemaciclib given twice a day (BID) orally without a meal, taken in the modified fasted condition.
62047297|NCT03703466|EXPERIMENTAL|200 mg Abemaciclib Without Regard to Food|200 mg abemaciclib given twice a day (BID) orally without regard for food.
62047298|NCT05061316|EXPERIMENTAL|Nutrition intervention group|Participants will receive Nestlé Impact Advanced Recovery Immunonutrition two times daily for 5 days leading up to the date of surgery. Nestlé Impact Advanced Recovery will be administered either orally or through a feeding tube.
62047299|NCT00696384|EXPERIMENTAL|Azilsartan Medoxomil QD-Open Label Phase (Baseline - Week 26)|
62047300|NCT00696384|EXPERIMENTAL|Azilsartan Medoxomil QD - Double-Blind Phase (Week 26-32)|
62047301|NCT00696384|PLACEBO_COMPARATOR|Placebo QD - Double-Blind Phase (Week 26- 32)|
62047302|NCT03030222|ACTIVE_COMPARATOR|Empagliflozin|Empagliflozin 10 mg tab, once daily, for 12 weeks
62047303|NCT03030222|PLACEBO_COMPARATOR|Placebo|Empagliflozin matching placebo oral tablet, once daily for 12 weeks
62047304|NCT01530230|OTHER|Oxytocin 5 units|
62047305|NCT01530230|OTHER|Oxytocin 10 units|
62047306|NCT04918784|EXPERIMENTAL|Treatment with Synthetic Hybrid-Scale Fiber Matrix|Diabetic foot ulcers will be treated by application of the Synthetic Hybrid-Scale Fiber Matrix. The synthetic matrix will be applied weekly or as needed based on the clinician discretion and ongoing wound assessment.
62047307|NCT04918784|ACTIVE_COMPARATOR|Treatment with Standard of Care|Diabetic foot ulcers will be treated by application of an appropriate dressing (foam or alginate dressing) to maintain wound moisture balance in the wound and changed daily.
62047308|NCT05307848||Female patients with bipolar disorder without medication|
62047309|NCT05307848||Female patients with bipolar disorder after stable prescription for ≥6 months|
62047310|NCT05307848||Age and BMI-matched healthy controls|
62047311|NCT02026323|EXPERIMENTAL|acupuncture|"Normal weight group,the PCOS women with insulin resistance who are normal weight( BMI=18.5-23Kg/m2).The acupuncture treatment will last for six months, 3 times per week, 30 minutes per treatment."
62047312|NCT02026323|EXPERIMENTAL|acupuncture 2|"Over weight or obese group ,the PCOS women with insulin resistance who are overweight or obese: BMI \>23 Kg/m2.The acupuncture treatment will last for six months, 3 times per week, 30 minutes per treatment."
62607322|NCT04068688|NO_INTERVENTION|Early Start Denver Model (ESDM) Supervisors|The local supervisors are 1) trained ESDM therapist, 2) supervise weekly coaching sessions in the schools, and/or 3) supervise remote intervention delivery sessions.
62607323|NCT05191667|EXPERIMENTAL|Patients with unresectable locally advanced/locally recurrent esophageal cancer|Patients will receive AN0025 orally once daily (QD) and chemoradiotherapy followed by the maintenance of AN0025
62607324|NCT04505449||Left heart catheterization|Symptomatic patients who underwent left heart catheterization and coronary angiography.
62047313|NCT01132326|EXPERIMENTAL|Droxidopa|Open-Label Droxidopa
62047314|NCT05854225|OTHER|single-arm|a prospective single-arm clinical study
62047315|NCT06150365|EXPERIMENTAL|TCR-T cells|KSX01-TCRT cell therapy
62047316|NCT05148325|EXPERIMENTAL|Single group|First Phase: dose escalation study. It was divided into six dose groups: 0.1mg/kg, 0.3mg/kg, 0.5mg/kg ,1.0mg/kg, 3.0mg/kg and 10.0mg/kg. The safety, tolerability and pharmacokinetics of bat4706 injection were explored according to the 3 + 3 dose increasing mode. It is expected that 18-36 cases will be included in the group Second Phase: dose expansion study. After the completion of dose increment, 1-2 tolerated doses were selected for extended research on melanoma (20-40 cases), so as to provide recommended doses for subsequent clinical trials
62047317|NCT01621698|ACTIVE_COMPARATOR|Early paravertebral block|The early group will have Local anaesthetic placed at the start of surgery and have normal saline placed at the close.
62047318|NCT01621698|ACTIVE_COMPARATOR|Late paravertebral block|The late group will have normal saline placed at the start of surgery and local anaesthetic placed at the close.
62047319|NCT01176487|EXPERIMENTAL|A|A clinical trial using 3-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer
62047320|NCT05361655||Palbociclib + an aromatase inhibitor|Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy between Feb 3, 2015 to March 31, 2020 in the Flatiron Health Analytic Database.
62047321|NCT05361655||Aromatase inhibitor|Adult metastatic breast cancer patients who initiated an aromatase inhibitor as first line therapy between Feb 3, 2015 to March 31, 2020 in the Flatiron Health Analytic Database.
62439595|NCT04784481|EXPERIMENTAL|Experimental Group|"The EG received Ivermectin orally 4 tablets of 6 mg = 24 mg every 7 days for 4 weeks.~All participants were evaluated by physical examination COVID-19 diagnosed with positive RT-PCR at the beginning, and final of the protocol"
62439596|NCT04784481|NO_INTERVENTION|Control Group|Conventional treatment. All participants were evaluated by physical examination COVID-19 diagnosed with positive RT-PCR at the beginning, and final of the protocol
62439597|NCT06185712|EXPERIMENTAL|Nurse-led disease management education|Individual patient education was provided, and patients were followed up by telephone at two-week intervals beginning the week after their clinic visit.
62439598|NCT06185712|NO_INTERVENTION|Control Group|No interventions were performed other than routine clinical procedures.
62439599|NCT01736553||Infants with Spinal Muscular Atrophy|Infants diagnosed Spinal Muscular Atrophy
62439600|NCT01736553||Healthy controls|Healthy control infants
62047322|NCT05806749|EXPERIMENTAL|Immune tolerance in mismatched kidney transplant recipient|"Our goal is to establish this regimen as a novel, safe and effective approach for induction of transplant tolerance in HLA single haplotype-matched related and HLA mismatched unrelated recipients of combined Hematopoietic Stem Cell Transplant(HSCT)/ Kidney Transplant (KT). Patients will undergo conditioning with rATG and TLI, followed by infusion of hematopoeitic stem cells from the same donor, a triple immunosuppressive regimen, and receive belumosudil following the kidney transplant. Immunosuppression taper will be stopped and/or immunosuppression will be resumed for any of the following conditions:~(1) loss of chimerism 2) clinical or pathological evidence of acute rejection and (3) clinical or pathological evidence of graft vs host disease."
62607325|NCT04063657|ACTIVE_COMPARATOR|External fixation|Adults diagnosed with an acute (\<2 days from injury) calcaneal fracture recommended for operative treatment will be placed in external fixator until the patient is deemed clinically appropriate for definitive surgical fixation.
62607326|NCT04063657|ACTIVE_COMPARATOR|Splinting|Adults diagnosed with an acute (\<2 days from injury) calcaneal fracture recommended for operative treatment will be placed in a short leg splint until the patient is deemed clinically appropriate for definitive surgical fixation.
62439601|NCT00740727|EXPERIMENTAL|EASI|Subjects will undergo placement of EASI catheters. All subjects in whom EASI catheters are placed, will receive Human Recombinant Hyaluronidase (HRH) as part of the EASI placement. (No subject will receive HRH, other than as part of EASI catheter placement.)
62439602|NCT03410381|EXPERIMENTAL|Group using the application EMMA|Patients with personal history of suicide attempt or with suicidal ideation, will use the application during 6 months. Assessment of the predictive value of the algorithm for suicidal risk, acceptbability and satisfaction
62607327|NCT01751581|ACTIVE_COMPARATOR|Habitual Sleep|Women sleep 8 h/night throughout the study phase
62829466|NCT01122238|EXPERIMENTAL|9, No Nicotine Patch, Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
62829467|NCT01122238|EXPERIMENTAL|10, No Nicotine Patch, Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
62047323|NCT03116048|OTHER|Pecs group (study group)|Chronic pain assessment with study questionnaire
62249778|NCT01992120|PLACEBO_COMPARATOR|Debriefing of high-fidelity non-sepsis simulation scenarios|"First visit:~* Subjects will fill out a self-assessment survey of their perceptions of their knowledge and ability in the recognition and management of sepsis in the hospitalized patient~* Subjects will be exposed to high-fidelity simulation scenarios (non-sepsis) and be debriefed in terms of their performance in these scenarios~* Subjects will take a written test of knowledge focusing on early recognition and management of sepsis~* Subjects will receive a didactic teaching session focusing on recognition and management of early sepsis in the hospitalized patient~In the second visit:~* Subjects will be exposed to a number of high-fidelity simulated sepsis scenarios and be scored on their performance in management of the scenarios~* Subjects will take a written test of knowledge focusing on early recognition and management of sepsis~* Subjects will then be debriefed specifically on their performance in the simulation scenarios"
62439603|NCT05661877|EXPERIMENTAL|DengueAid intervention group|The participants in this arm would be given the DengueAid mobile app which can be downloaded through Google Play
62439604|NCT05661877|ACTIVE_COMPARATOR|MyHealth website control group|The participants in this arm would be required to use the MyHealth dengue website
62439605|NCT01785784|EXPERIMENTAL|burn patients|
62439606|NCT00576199|EXPERIMENTAL|Bevacizumab 5 mg/kg|Participants received bevacizumab 5 mg/kg intravenously every 2 weeks and within 24-48 hours prior to each transarterial chemoembolization (TACE) until disease progression or unmanageable toxicity. TACE was conducted for 4 sessions at 8-10 week intervals.
62439607|NCT02268045|EXPERIMENTAL|RTXM83|Active Ingredient: Rituximab (Biosimilar)
62439608|NCT02268045|ACTIVE_COMPARATOR|MabThera|Active Ingredient: Rituximab
62607328|NCT01751581|EXPERIMENTAL|Short Sleep|Women sleep 4 h/night throughout the study phase
62607329|NCT01800019|ACTIVE_COMPARATOR|NRT arm|"Drug: Nicotine Replacement Therapy (Nico-Derm® and Nicorette®)~Dose: 7mg - 42mg depending on # of cigarettes smoked per day at study baseline, and withdrawal symptoms.~Mode of Administration: Transdermal Patch~Duration of Treatment: up to 24 Weeks~Additionally, participants will be provided with a supply of short-acting nicotine gum in order to supplement their long acting NRT patch regimen.~Individuals who smoke their first cigarette more than 30 minutes after waking are advised to use the 2 mg NRT gum. Participants who smoke their first cigarette within 30 minutes of waking will be advised to use the 4 mg NRT gum. Both NRT gum dosages will be recommended for use on an ad lib basis to address cravings and/or withdrawal symptoms, up to a maximum of 12 pieces of NRT gum per day."
62829468|NCT01122238|EXPERIMENTAL|11, No Nicotine Patch, Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
62829469|NCT01122238|EXPERIMENTAL|12, No Nicotine Patch, Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
62829470|NCT01122238|EXPERIMENTAL|13, No Nicotine Patch, No Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
62829471|NCT01122238|EXPERIMENTAL|14, No Nicotine Patch, No Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
62047324|NCT03116048|OTHER|Control group (placebo group)|Chronic pain assessment with study questionnaire
62047325|NCT02428322|EXPERIMENTAL|Intervention|2,000iu vitamin D3 per day for 15 weeks
62047326|NCT02428322|PLACEBO_COMPARATOR|Placebo|An identical placebo capsule daily for 15 weeks.
62047327|NCT04415450|EXPERIMENTAL|Nutrition Education Group|The experimental group is the group who received the intervention which is the nutrition education and counseling. Phase I of the data collection from the experimental group which is the pregnant women (baseline assessment) using a questionnaire immediately before receiving nutrition counseling from their ANC providers first took place. Health professionals then started providing nutrition education to pregnant women preselected and assessed before the intervention. Immediate post education evaluation of the pregnant women was done by the same questionnaire used to assess in the pretest. Phase II or post intervention data collection of pregnant women was done after the client was appointed for 6 weeks after the counseling session.
62607330|NCT01800019|ACTIVE_COMPARATOR|NRT and HIV Tailored Quit Smoking Counseling|"Drug: Nicotine Replacement Therapy (Nico-Derm®)~Dose: 7mg - 42mg depending on # of cigarettes smoked per day at study randomization and withdrawal symptoms.~Mode of Administration: Transdermal Patch~Duration of Treatment: up to 24 Weeks~HIV tailored Smoking Cessation Counseling: The counseling consists of face-to-face sessions with a trained smoking cessation counselor at the start of the study, on your chosen quit date, and then at weeks 4, 8, 12 and 24; supportive telephone calls if needed."
62047328|NCT06524674|ACTIVE_COMPARATOR|Sleep|Participants self-administered one serving of an oral rehydration solution followed by subsequent blood draws
62047329|NCT06524674|ACTIVE_COMPARATOR|Energy|Participants self-administered one serving of an oral rehydration solution followed by subsequent blood draws
62047330|NCT06524674|PLACEBO_COMPARATOR|Sleep Comp|Participants self-administered one serving of an oral rehydration solution followed by subsequent blood draws
62047331|NCT06524674|PLACEBO_COMPARATOR|Energy Comp|Participants self-administered one serving of an oral rehydration solution followed by subsequent blood draws
62249779|NCT03837704|ACTIVE_COMPARATOR|IQOS Arm|Patients diagnosed with AAA, switching from cigarette smoking to IQOS use
62249780|NCT03837704|ACTIVE_COMPARATOR|CC Arm|Patients diagnosed with AAA, continuing to smoke cigarettes
62249781|NCT03837704|ACTIVE_COMPARATOR|Smoking Cessation Arm|Patients diagnosed with AAA, who have completely stopped smoking and are not using any other tobacco or nicotine-containing product(s)
62249782|NCT05902078|EXPERIMENTAL|Eldecalcitol|Participants receive oral eldecalcitol 0.75μg daily for 12 months
62249783|NCT05902078|ACTIVE_COMPARATOR|Calcitriol|Participants receive oral calcitriol 0.5μg daily for 12 months
62249784|NCT05106504||Parkinson's disease patients|Parkinson's disease patients receiving medical cannabis for pain related to the disease
62249785|NCT04054089|EXPERIMENTAL|A|B/F/TAF
62249786|NCT04054089|ACTIVE_COMPARATOR|B|DTG+3TC
62439609|NCT02427373|ACTIVE_COMPARATOR|fish oil ethyl ester|1.3g/d dose of DHA+EPA in fish oil EE (6 capsules) administered for 4 weeks
62439610|NCT02427373|ACTIVE_COMPARATOR|fish oil triglyceride|1.3g/d dose of DHA+EPA in fish oil TG (6 capsules) administered for 4 weeks
62439611|NCT02427373|ACTIVE_COMPARATOR|krill oil|1.3g/d dose of DHA+EPA in krill oil (6 capsules) administered for 4 weeks
62607331|NCT01800019|ACTIVE_COMPARATOR|Varenicline (VR) Arm|"Drug: Varenicline (Champix®)~Doses: 0.5 mg once daily for 3 days(i.e.day 1-3 of the week prior to quit date) 0.5 mg twice daily for 4 days i.e. day 4-7) and 1 mg twice daily for the remainder of the treatment period~Mode of Administration: Oral~Duration of Treatment: 24 Weeks (+ 1 Week of Dose Escalation, total of 25 weeks)"
62047332|NCT02678130|ACTIVE_COMPARATOR|InterFuse Group|Patients are randomized based on last digit (odd) of social security number to be treated with an InterFuse T device
62047333|NCT02678130|ACTIVE_COMPARATOR|Control Group: Standard of care TLIF|treated with a standard of care TLIF (Transforaminal Lumbar Interbody Fusion) device (e.g. Stryker's AVS Unilif)
62047334|NCT06579729|EXPERIMENTAL|Intervention group|
62047335|NCT06579729|NO_INTERVENTION|Control group|
62249787|NCT04062526|EXPERIMENTAL|Patient with Parkinson Disease|"Subject should have a history of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria per neurologist review.~Subject must have been diagnosed with Parkinson's Disease at least 3 year prior to enrollment."
62249788|NCT04062526|EXPERIMENTAL|Healthy Control|Subject must be a Healthy.
62047336|NCT03676426|EXPERIMENTAL|Web-based AD|Patients will be encouraged to use the web platform for advance care planning/advance directive to document their care preferences..
62047337|NCT03676426|ACTIVE_COMPARATOR|Paper AD|Patients will be given the standard advance directive and encouraged to complete on their own.
62047338|NCT00787657||Arm 1|
62047339|NCT01494428|EXPERIMENTAL|rhBMP-2/ACS|
62047340|NCT01494428|ACTIVE_COMPARATOR|Autogenous Bone|
62047341|NCT04183270||Patients|Non-valvular atrial fibrillation (NVAF) patients who will start treatment with a non-VKA oral anticoagulants (NOAC).
62047342|NCT04183270||Physicians|Treating physicians for NVAF patients.
62047343|NCT00976352|EXPERIMENTAL|rAAV1-CMV-GAA administration-cohort 1|rAAV1-CMV-GAA (study agent) Administration: 1.0 x 10e12 vector genomes. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.
62047344|NCT00976352|EXPERIMENTAL|rAAV1-CMV-GAA administration-cohort 2|rAAV1-CMV-GAA (study agent) Administration: 5.0 x 10e12 vector genomes Cohort 2 = 6 subjects. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.
62249789|NCT06098898|EXPERIMENTAL|Group A (low-dose NK510 monotherapy)|NK510 9×10\^9 NK cells/dose.
62249790|NCT06098898|EXPERIMENTAL|Group B (low-dose NK510 combined mAbs)|NK510 9×10\^9 NK cells/dose. PD-1 blockade or anti-HER2 mAbs.
62249791|NCT06098898|EXPERIMENTAL|Group C (high-dose NK510 combined mAbs)|NK510 12×10\^9 NK cells/dose. PD-1 blockade or anti-HER2 mAbs.
62439612|NCT01373892|ACTIVE_COMPARATOR|Surgery|Slevve vs. Roux-Y
62439613|NCT01373892|NO_INTERVENTION|Healthy lean volunteers|
62439614|NCT00218686|EXPERIMENTAL|1|behavioral social network risk reduction intervention
62439615|NCT00218686|ACTIVE_COMPARATOR|2|voluntary counseling and testing (VCT
62439616|NCT03857685||Proliferation in an in-vitro model|An in-vitro model is used to study lens epithelial cell proliferation
62607332|NCT01800019|ACTIVE_COMPARATOR|Varenicline (VR) and HIV Tailored Quit Smoking Counseling|"Drug: Varenicline (Champix®)~0.5 mg once daily for 3 days(i.e.day 1-3 of the week prior to quit date) 0.5 mg twice daily for 4 days i.e. day 4-7) and 1 mg twice daily for the remainder of the treatment period~Mode of Administration: Oral~Duration of Treatment: 24 Weeks (+ 1 Week of Dose Escalation, total of 25 weeks)~Intervention: HIV tailored Smoking Cessation Counseling: The counseling consists of face-to-face sessions with a trained smoking cessation counselor at the start of the study, on your chosen quit date, and then at weeks 4, 8, 12 and 24; supportive telephone calls if needed."
62607333|NCT05923411|EXPERIMENTAL|Cohort 1|Participants will receive PF-07220060 tablet by mouth
62607334|NCT05923411|EXPERIMENTAL|Cohort 2|Participants will receive PF-07220060 tablet by mouth
62607335|NCT05923411|EXPERIMENTAL|Cohort 3|Participants will receive PF-07220060 tablet by mouth
62047345|NCT06109792|ACTIVE_COMPARATOR|• Group I|Ten overdentures with locator retentive caps and blue inserts were picked up by the indirect method.
62249792|NCT05956145|EXPERIMENTAL|Intervention group|Colchicine 0.5 mg QD
62249793|NCT05956145|PLACEBO_COMPARATOR|Placebo group|Placebo
62249794|NCT02576444|EXPERIMENTAL|Group 1|Patients with cholangiocarcinoma harboring IDH 1/2 tumors will be treated with olaparib. Patients with tumors harboring mutation in HDR genes will be treated with olaparib.
62249795|NCT02576444|EXPERIMENTAL|Group 2|Patients with tumors harboring PTEN, PIK3CA, AKT, or ARID1A mutations or other molecular aberrations leading to dysregulation of the PI3K/AKT pathway will be treated with AZD5363 plus olaparib.
62249796|NCT02576444|EXPERIMENTAL|Group 3|Patients with tumors harboring either TP53 or KRAS mutations or mutations in KRAS and TP53 will be treated with AZD1775 plus olaparib. TP53 mutations must be found on the TP53 mutation eligibility list.
62249797|NCT02576444|EXPERIMENTAL|Group 4|Patients with tumors harboring mutations in HDR genes, including ATM, CHK2, APOBEC, MRE11 complex, will be treated with AZD6738 and olaparib.
62439617|NCT01996878||Case (Parkinson's disease patients)|Clinical diagnosis of Parkinson's disease (cases are diagnosed by the presence of at least three of the five following primary signs: rest tremor, bradykinesia, rigidity, impaired postural refluxes, and the presence of a sustained L-dopa response.)
62439618|NCT01996878||Control (Healthy volunteers)|Healthy volunteers without Parkinson's disease
62439619|NCT02304575||Testicular cancer survivors|Patients treated for testicular cancer, will receive questionnaires and hormonal function measurement.
62607336|NCT05923411|EXPERIMENTAL|Cohort 4|Participants will receive PF-07220060 tablet by mouth
62607337|NCT05923411|EXPERIMENTAL|Cohort 5|Participants will receive PF-07220060 tablet by mouth
62607338|NCT05923411|EXPERIMENTAL|Cohort 6|Participants will receive PF-07220060 and Rabeprazole tablets by mouth
62249798|NCT02357134|EXPERIMENTAL|Arm I (high-flow oxygen)|Patients receive high-flow oxygen via nasal prongs during a structured stationary bicycle exercise session.
62249799|NCT02357134|EXPERIMENTAL|Arm II (high-flow air)|Patients receive high-flow air via nasal prongs during a structured stationary bicycle exercise session
62249800|NCT02357134|ACTIVE_COMPARATOR|Arm III (low-flow oxygen)|Patients receive low-flow oxygen via a nasal cannula during a structured stationary bicycle exercise session.
62249801|NCT02357134|ACTIVE_COMPARATOR|Arm IV (low-flow air)|Patients receive low-flow air via a nasal cannula during a structured stationary bicycle exercise session.
62439620|NCT02304575||Surgery for benign testicular problems|Patients treated for benign testicular conditions, will receive questionnaires and hormonal function measurement.
62439621|NCT02304575||Healthy males|Healthy volunteers, will receive questionnaires and hormonal function measurement.
62439622|NCT03387059|EXPERIMENTAL|Forielle Endometrial Washing|
62439623|NCT03387059|NO_INTERVENTION|No Endometrial Washing|
62439624|NCT05168956||Sexual offender|Patients followed up in the sexual offender's department of University Hospital of Saint Etienne will be included.
62607339|NCT05923411|EXPERIMENTAL|Cohort 7|Participants will receive PF-07220060 and Rabeprazole tablet by mouth
62607340|NCT05923411|EXPERIMENTAL|Cohort 8|Participants will receive PF-07220060 tablet by mouth
62607341|NCT03802565|EXPERIMENTAL|Tolperisone 50 mg|TID (150 mg/day)
62047346|NCT06109792|ACTIVE_COMPARATOR|• Group II|Ten overdentures with locator retentive caps and pink inserts were picked up by the indirect method.
62047347|NCT06109792|ACTIVE_COMPARATOR|Group III|Ten overdentures with locator retentive caps and blue inserts were picked up by the direct method.
62047348|NCT06109792|ACTIVE_COMPARATOR|Group IV|Ten overdentures with locator retentive caps and pink inserts were picked up by the direct method.
62249802|NCT05137249||patients with COVID 19 disease|Patients diagnosed with and hospitalized due to COVID-19. Subgroups: ICU admitted COVID-19 + patients vs COVID 19 pts. at normal ward-
62249803|NCT05137249||Healthy volunteers|healthy volnuteers
62249804|NCT03392272|EXPERIMENTAL|Tisseel|Müller's Muscle-Conjunctival Resection (MMCR) using glue instead of sutures
62249805|NCT03392272|ACTIVE_COMPARATOR|Sutures|Müller's Muscle-Conjunctival Resection (MMCR) using the usual procedure
62249806|NCT00951301|ACTIVE_COMPARATOR|mangosteen juice|subjects randomized 1:1 to this arm will receive juice containing the mangosteen ingredient
62439625|NCT05796622|EXPERIMENTAL|HIVST-Chatbot (HIV self-testing services with counseling provided by a Chatbot)|Promote and implement HIV self-testing (HIVST) services with real-time counselling provided by a fully-automated artificial intelligence Chatbot (HIVST-Chatbot)
62047349|NCT02201914|EXPERIMENTAL|Clomiphene citrate|
62047350|NCT02201914|EXPERIMENTAL|Daily FSH and LH plus Cetrorelix|
62047351|NCT02201914|EXPERIMENTAL|Triptorelin plus daily FSH and LH|
62047352|NCT01514214|ACTIVE_COMPARATOR|Winged perimeter stent|Patients who receive the Viaduct stent during ERCP
62047353|NCT01514214|ACTIVE_COMPARATOR|polyethylene stent arm|Patient who receive the traditional polyethylene stent during ERCP
62607342|NCT03802565|EXPERIMENTAL|Tolperisone 100 mg|TID (300 mg/day)
62607343|NCT03802565|EXPERIMENTAL|Tolperisone 150 mg|TID (450 mg/day)
62607344|NCT03802565|EXPERIMENTAL|Tolperisone 200 mg|TID (600 mg/day)
62607345|NCT03802565|PLACEBO_COMPARATOR|Placebo|TID
62047354|NCT06240585||patients with ICU-acquired bacteremia|
62047355|NCT06240585||patients without ICU-acquired bacteremia|
62047356|NCT03638895|ACTIVE_COMPARATOR|ECAL group|Intervention group (ECAL) - practitioners and participants receive measured energy information from ECAL indirect calorimeter including resting energy expenditure and respiratory quotient to diagnose, manage and advise on modification of caloric restriction and physical activity level. Energy information also allows participant and practitioner to monitor and compare changes to their metabolic health throughout the duration of intervention.
62047357|NCT03638895|PLACEBO_COMPARATOR|SC group|Standard care (SC) - participants receive standard care (diet, exercise \& behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
62047358|NCT02551081||Birth Defects|Neonates were diagnosed as birth defects who were recieving genomic sequencing and personalized treatment in NICU.
62047359|NCT06466850|EXPERIMENTAL|Treatment|Patients with moderate to severe osteoarthritis, Kellgren-Lawrence grade 2,3 in both knees; accompanied by mild to moderate pain and swelling are included.
62047360|NCT01161979|EXPERIMENTAL|Zonisamide|Zonisamide Capsules 100 mg of Dr.Reddy's laboratories Limited
62047361|NCT01161979|ACTIVE_COMPARATOR|Zonegran|Zonegran Capsules 100 mg of EISAI INC
62047362|NCT01269996|ACTIVE_COMPARATOR|Metformin followed by gliclazide and protaphane|
62047363|NCT01269996|ACTIVE_COMPARATOR|Janumet followed by Lantus insulin injection|
62047364|NCT02001766|EXPERIMENTAL|High intensity exercise|3 times per week in a total of 12 weeks
62047365|NCT02001766|EXPERIMENTAL|Low intensity exercise|3 times per week in a total of 12 weeks
62047366|NCT02001766|EXPERIMENTAL|Control|Normal lifestyle for 12 weeks
62047367|NCT02241122|EXPERIMENTAL|MRI guided prostate biopsy|prostate biopsy after MR-imaging
62439626|NCT05796622|ACTIVE_COMPARATOR|HIVST-OIC (HIV self-testing services with counseling provided by administrators)|Promote and implement HIV self-testing (HIVST) services with real-time counselling provided by trained administrators)
62047368|NCT04839965|EXPERIMENTAL|IV Ampion|Ampion administered via intravenous infusion
62047369|NCT04839965|PLACEBO_COMPARATOR|IV placebo|Placebo administered via intravenous infusion
62047370|NCT00238433|EXPERIMENTAL|Filgrastim/Melphalan/Thiotepa|"Biological/Vaccine: filgrastim~5mcg/kg intravenous piggyback (IVPB) will be administered beginning on day +5 and continued until absolute neutrophil count (ANC) \> 1500 for 2 consecutive days.~Drug: busulfan~3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.~Drug: melphalan~50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.~Drug: thiotepa~250 mg/m2/day/iv on days -3 and -2 Procedure/Surgery: bone marrow ablation with stem cell support~The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.~Procedure/Surgery: peripheral blood stem cell transplantation~Performed 36-48 hours following last chemotherapy dose."
62047371|NCT05305287|EXPERIMENTAL|NAFL TZD|T2D with non-alcoholic fatty liver (NAFL), treated with pioglitazone
62047372|NCT05305287|PLACEBO_COMPARATOR|NAFL Placebo|T2D with non-alcoholic fatty liver (NAFL), treated with placebo
62047373|NCT05305287|EXPERIMENTAL|NASH TZD|T2D with non-alcoholic steatohepatitis (NASH), treated with pioglitazone
62047374|NCT05305287|PLACEBO_COMPARATOR|NASH Placebo|T2D with non-alcoholic steatohepatitis (NASH), treated with placebo
62047375|NCT05853679|EXPERIMENTAL|Lumoral Treatment (Study group)|"A complete clinical intraoral examination shall be performed for all subjects. Same demographic and clinical data will be obtained from subjects in both arms. The study group shall receive the Lumoral treatment -device, Lumorinse -tablets and instructions for their use.~All subjects shall receive new electric toothbrushes, standard oral hygiene instructions for the use of an electric toothbrush, interdental brush, and dental floss."
62047376|NCT05853679|OTHER|Control group|A complete clinical intraoral examination shall be performed for all subjects. Same demographic and clinical data will be obtained from subjects in both arms. All subjects shall receive new electric toothbrushes, standard oral hygiene instructions for the use of an electric toothbrush, interdental brush, and dental floss.
62047377|NCT02332720|EXPERIMENTAL|A1: GT3 NC TN Grazoprevir+Uprifosbuvir+Elbasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (300 mg) + elbasvir (50 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
62047378|NCT02332720|EXPERIMENTAL|A2: GT3 NC TN Grazoprevir+Uprifosbuvir+Ruzasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (300 mg) + ruzasvir (60 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
62439627|NCT01199432|EXPERIMENTAL|Group B(CEF)|
62439628|NCT01199432|EXPERIMENTAL|Group A(CEFci)|
62439629|NCT01199432|ACTIVE_COMPARATOR|Group C(EC)|
62607346|NCT03542591||Participants of the VegMed congress (Berlin, April 2018)|
62607347|NCT06190756|EXPERIMENTAL|T1 Diabetic group|Group with diabetic patients
62607348|NCT06190756|OTHER|Healthy Control Group|Control group with healthy participants
62607349|NCT04505202|EXPERIMENTAL|Experimental group|0.12% chlorhexidine gluconate
62607350|NCT04505202|PLACEBO_COMPARATOR|Placebo group|sodium bicarbonate
62607351|NCT00696202|EXPERIMENTAL|Arm 1|
62607352|NCT01649310|EXPERIMENTAL|WVB Training|
62607353|NCT05040334|ACTIVE_COMPARATOR|group(1)|69 patients receiving a single dose of oral doxycycline (200 mg) and metronidazole (500 mg)tablets
62607354|NCT05040334|PLACEBO_COMPARATOR|Group (2)|69 patients receiving placebo
62607355|NCT03653091|ACTIVE_COMPARATOR|Duodenal Mucosal Resurfacing (DMR)|Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal mucosa in an upper endoscopic procedure in patients with type 2 diabetes.
62607356|NCT03653091|SHAM_COMPARATOR|Duodenal Mucosal Resurfacing Sham (Sham)|Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with type 2 diabetes.
62607357|NCT06731140|EXPERIMENTAL|retinoic acid with anti-PD-1 immunotherapy|retinoic acid with anti-PD-1 immunotherapy
62607358|NCT00478114|EXPERIMENTAL|1|Sorafenib
62047379|NCT02332720|EXPERIMENTAL|A3: GT3 NC TN Grazoprevir+Uprifosbuvir+Elbasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (450 mg) + elbasvir (50 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
62249807|NCT00951301|PLACEBO_COMPARATOR|placebo juice|subjects randomized 1:1 to this arm will receive specially prepared juice not containing mangosteen ingredient
62249808|NCT03882203|EXPERIMENTAL|treatment|Patients receive the study protocol: CLAGE sequential with Flu-Bu as conditioning regimen followed by low-dose decitabine maintenance
62249809|NCT04795856|ACTIVE_COMPARATOR|chronic compensated moderate-severe primary mitral regurgitation (PMR)|
62249810|NCT04795856|ACTIVE_COMPARATOR|Healthy Volunteers|
62249811|NCT00490633|EXPERIMENTAL|Facemask and hand hygiene|Facemask and hand hygiene provided for participants.
62607359|NCT02646384|EXPERIMENTAL|Ovarian tissue cryopreservation|Children faced with a fertility threatening diagnosis or treatment plan will be offered ovarian tissue cryopreservation, particularly if pre menarchal and without other options to preserve fertility. Although considered experimental, there are over 120 live births worldwide using this technique
62607360|NCT02841566||Problem glambers|The group of problem gamblers will consist of patients already included in the cohort EVALADD \[favorable opinion of GNEDS 06/09/2012; CNIL authorization No. 912631 of 10.09.2013\], and the data will be extracted directly from the database EVALADD
62607361|NCT02841566||Non-problem gamblers|The subjects of this group will be matched on sex, age and education level with the group problem gamblers. They will be recruited over the Internet and using the volunteer base \[normal declaration with the CNIL: No. 1761543 of 21/05/2014\].
62607362|NCT04668170||hospitalized patients|"very well-defined population of COVID-19 patients with the following outcomes:~Patients with severe disease requiring on admission ICU management for SARS, Non-severe hospitalized patients with secondary clinical worsening requiring ICU management, Non-severe hospitalized patients without clinical worsening requiring ICU management."
62607363|NCT04668170||healthcare workers|mildly symptomatic patients among healthcare workers attending outpatient dedicated clinics will be recruited
62607364|NCT01186380||TEE Procedure|patients requiring TEE procedure by their physician
62607365|NCT02686658|EXPERIMENTAL|Zimura 1 mg [Part 1]|Participants received 1 mg of Zimura in the study eye administered via IVT injection (50 µL) on Day 1 and monthly up to 18 months.
62249812|NCT00490633|EXPERIMENTAL|Facemask only|Facemask only provided for participants.
62607366|NCT02686658|EXPERIMENTAL|Zimura 2 mg [Part 1]|Participants received 2 mg of Zimura in the study eye administered via IVT injection (100 µL) on Day 1 and monthly up to 18 months.
62607367|NCT02686658|SHAM_COMPARATOR|Sham [Part 1]|Participants received a Sham injection of an empty, needleless syringe administered in the study eye on Day 1 and monthly up to 18 months.
62607368|NCT02686658|EXPERIMENTAL|Zimura 2 mg (Zimura 2mg+Sham) [Part 2]|Participants received 2 mg of Zimura in the study eye administered via IVT injection (100 µL) and a subsequent Sham administration on Day 1 and monthly up to 18 months.
62607369|NCT02686658|EXPERIMENTAL|Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2]|Participants received 4 mg of Zimura in the study eye administered via two consecutive IVT injections (2 x 100 µL) on Day 1 and monthly up to 18 months.
62607370|NCT02686658|SHAM_COMPARATOR|Sham (Sham+Sham) [Part 2]|Participants received two consecutive Sham injections of empty, needleless syringes administered in the study eye on Day 1 and monthly up to 18 months.
62607371|NCT06045442|EXPERIMENTAL|Intervention|3 months intradialytic exercise intervention: 30 minutes of endurance training at the dialysis unit with a dialysis training device, twice a week.
62249813|NCT00490633|NO_INTERVENTION|Control|Control, no intervention.
62249814|NCT01553188|EXPERIMENTAL|Abiraterone, Prednisone and AMG|Abiraterone and prednisone will be given with maximum tolerated dose (MTD) of Trebananib (AMG)
62249815|NCT01553188|ACTIVE_COMPARATOR|Abiraterone and Prednisone only|Abiraterone and prednisone only
62249816|NCT01553188|OTHER|Run in|Dose escalation phase to determine MTD of AMG
62249817|NCT06161662|EXPERIMENTAL|Transcutaneous electrical stimulation|At the beginning of anesthesia induction, the electrodes are attached to the skin at the Neiguan point and Shenmen point and connected to the percutaneous acupoint electrical stimulation device (Hwato , Suzhou Medical Equipment Factory). Electrical stimulation is given.
62249818|NCT06161662|OTHER|Control|At the beginning of anesthesia induction, the electrodes are attached to the skin at the Neiguan point and the Shenmen point without stimulation
62607372|NCT06045442|ACTIVE_COMPARATOR|Control|Usual Care
62607373|NCT03219151|EXPERIMENTAL|eMAR game|Participants provided access to eMAR simulator game in advance of simulated return-demonstration; also receive normal education pre-work related to eMAR administration
62607374|NCT03219151|ACTIVE_COMPARATOR|Normal pre-work|Participants receive normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
62607375|NCT06019962||Group A|20 postpartum women who delivered by cesarean section
62047380|NCT02332720|EXPERIMENTAL|A4/B4: GT3 NC TN Grazoprevir+Uprifosbuvir+Ruzasvir (8 weeks)|Participants will be randomized to either Part A or Part B. In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (450 mg) + ruzasvir (60 mg) q.d. by mouth for 8 weeks. In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
62047381|NCT02332720|EXPERIMENTAL|B5: GT3 NC TN MK-3682B + RBV (8 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 8 weeks.
62439630|NCT02340156|EXPERIMENTAL|SGT-53 with Temozolomide|SGT-53, at 3.6 mg DNA/infusion, will be administered twice weekly in a 28 day cycle starting on Day 1 (cycle 1), Day 29 (cycle 2) and Day 57 (cycle 3). Temozolomide (TMZ) will be administered by mouth daily on days 9-13 of each cycle. Patients who are responding to treatment may receive three additional cycles of SGT-53/TMZ therapy or continue on TMZ alone at investigator's discretion. Surgical resection of recurrent or progressive tumor for tumor analysis is an optional procedure. In these individuals SGT-53, at 3.6 mg DNA/infusion, will be administered twice (on days -1 and -3) in the week prior to surgery. Surgical resection is Day 0. 14-21 days post operatively and having recovered from the effects of surgery, the patients will then start cyclical TMZ with SGT-53 as described above.
62047382|NCT02332720|EXPERIMENTAL|B6: GT3 NC TN MK-3682B (12 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
62047383|NCT02332720|EXPERIMENTAL|B7: GT3 NC TN MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
62047384|NCT02332720|EXPERIMENTAL|B8: GT3 NC TE MK-3682B (8 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks.
62047385|NCT02332720|EXPERIMENTAL|B9: GT3 NC TE MK-3682B + RBV (8 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 8 weeks.
62047386|NCT02332720|EXPERIMENTAL|B10: GT3 NC TE MK-3682B (12 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
62047387|NCT02332720|EXPERIMENTAL|B11: GT3 NC TE MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682 FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
62047388|NCT02332720|EXPERIMENTAL|B12: GT3 NC TE MK-3682B (16 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
62047389|NCT02332720|EXPERIMENTAL|B13: GT3 C TN MK-3682B (12 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
62047390|NCT02332720|EXPERIMENTAL|B14: GT3 C TN MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
62047391|NCT02332720|EXPERIMENTAL|B15: GT3 C TN MK-3682B (16 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
62047392|NCT02332720|EXPERIMENTAL|B16: GT3 C TE MK-3682B (12 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
62249819|NCT03589495|ACTIVE_COMPARATOR|N acetylcysteine group|N Acetyl L Cysteine IV bolus (100 mg/kg dissolved in dextrose5%) infused over 15 minutes, followed by continuous infusion of 50mg/kg/day dissolved in dextrose 5% starting 1hr before induction of anesthesia, and continued for 48 hours after operation
62249820|NCT03589495|PLACEBO_COMPARATOR|placebo group|received equal volume of dextrose 5% administrated at the same rate and duration as in the study group as a placebo
62249821|NCT03165435|EXPERIMENTAL|CV-MG01|The active targeted immunotherapy candidate, CV-MG01 comprises two short synthetic peptides separately conjugated to a carrier protein for the potential treatment of myasthenia gravis
62439631|NCT04598672|EXPERIMENTAL|Cognitive behavioral therapy for insomnia (CBTi)|
62607376|NCT06019962||Group B|20 females who did not experience pregnancy
62607377|NCT01542905|EXPERIMENTAL|Korean Red Ginseng|
62047393|NCT02332720|EXPERIMENTAL|B17: GT3 C TE MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
62249822|NCT03165435|PLACEBO_COMPARATOR|Placebo|Aluminium hydroxide adjuvant alone
62249823|NCT01262937||Biliary Confocal Imaging|
62249824|NCT01262937||Esophageal Confocal Imaging|
62249825|NCT03483909|EXPERIMENTAL|left IFG iTBS|intermittent theta burst stimulation over the left inferior frontal gyrus
62249826|NCT03483909|ACTIVE_COMPARATOR|right IPL cTBS|continuous theta burst stimulation over the right inferior parietal cortex
62249827|NCT03483909|PLACEBO_COMPARATOR|placebo|Placebo TMS stimulation over the left inferior parietal cortex
62249828|NCT01091688|EXPERIMENTAL|Just-in-Time intervention|"The infants and physicians in the experimental group will receive the Just-in-Time intervention sheets at the time of discharge."
62249829|NCT01091688|NO_INTERVENTION|Routine discharge care|The infants and physicians in the routine discharge care arm will receive the same information and details as is per normal routine in the nursery.
62249830|NCT03561792|NO_INTERVENTION|traditional RSBI|the decision to continue SBT depends on the traditional RSBI (RSBI \< 105 predicts successful weaning)
62047394|NCT02332720|EXPERIMENTAL|B18: GT3 C TE MK-3682B (16 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
62047395|NCT02332720|EXPERIMENTAL|B19: GT3 C TE MK-3682B + RBV (16 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 16 weeks.
62047396|NCT02332720|EXPERIMENTAL|B20: GT4 NC TN MK-3682B (8 weeks)|In Part B, HCV GT4-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks.
62047397|NCT02332720|EXPERIMENTAL|B21: GT5 NC TN MK-3682B (12 weeks)|In Part B, HCV GT5-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
62047398|NCT02332720|EXPERIMENTAL|B22: GT6 NC TN MK-3682B (12 weeks)|In Part B, HCV GT6-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
62047399|NCT03124979|OTHER|Test Subject|All subjects are enrolled into the test group and all subjects received the LNCS DBI Sensor.
62047400|NCT06412627|NO_INTERVENTION|control group|The control group received only usual care, while the Oral moisture checker (Mucus, Life Co., Ltd.), the Oral Health Assessment Tool, and the Bedside Oral Exam were used to assess oral mucosal moisture and oral health status before (day 0) and after 7 days.
62047401|NCT06412627|EXPERIMENTAL|experimental group|The experimental group had 4°C saline-soaked gauze applied to the oral cavity for 15 minutes at 06:00 AM and 06:00 PM daily for one week, while the Oral moisture checker (Mucus, Life Co., Ltd.), the Oral Health Assessment Tool, and the Bedside Oral Exam were used to assess oral mucosal moisture and oral health status before (day 0) and after 7 days.
62047402|NCT00439205||MDM + FastEEM4|Multispectral digital microscope (MDM) + FastEEM4 Systems
62047403|NCT01171326|EXPERIMENTAL|Topical Minocycline Foam FXFM244 - 4%|Minocycline Foam FXFM244 - 4%
62047404|NCT01171326|EXPERIMENTAL|Topical Minocycline Foam FXFM244 - 1%|Minocycline Foam FXFM244 - 1%
62047405|NCT00269035|EXPERIMENTAL|Treatment Group 1|Subjects in group 1 will receive SB-773812 tablet once daily till still steady Cp
62439632|NCT01759537|EXPERIMENTAL|Implants placed at sub-crestal position.|Ankylos dental endosseous implants-Sub-crestal
62439633|NCT01759537|ACTIVE_COMPARATOR|Epi-crestal implants.|Ankylos dental endosseous implants-Epi-crestal
62047406|NCT00269035|EXPERIMENTAL|Treatment Group 2|Subjects in group 2 will receive SB-773812 tablets once daily over 6 weeks. Risperidone tablets 6 mg once daily from Days 1-7 two tablets of 3 mg and days 8 until stable Cp 6 mg tablets
62249831|NCT03561792|EXPERIMENTAL|Diaphragmatic RSBI|diaphragm ultrasound was done to measure diaphragmatic displacement which is used to calculate DRSBI and The investigator takes the decision about SBT continuation based on the result of DRSBI (DRSBI \< 1.3 predicts successful weaning)
62249832|NCT02818166|EXPERIMENTAL|Endoaortic Clamp|Right mini-thoracotomy mitral valve surgery with retrograde perfusion and endoaortic balloon clamp
62439634|NCT01780727|NO_INTERVENTION|Standard Hemodynamic Management (SHEM)|use of standard hemodynamic management
62439635|NCT01780727|EXPERIMENTAL|EGHEM|use of echocardiography guided hemodynamic management to control fluid and drug therapy.
62607378|NCT01542905|PLACEBO_COMPARATOR|Placebo|
62047407|NCT02126501|NO_INTERVENTION|Sudden wean|When ready Nasal Continuous Positive Airway Pressure (NCPAP) will be removed from the neonate
62047408|NCT02126501|ACTIVE_COMPARATOR|Gradual pressure wean|NCPAP will be removed by gradually decreasing pressure over 24 hours once the weaning is decided
62047409|NCT03338894|OTHER|Yoga group|Each subject will serve as their own control
62047410|NCT05676580|OTHER|Abstention|After keratoconus diagnosis the patient won't be assigned to intervention
62047411|NCT05676580|OTHER|Intervention (cross-linking surgery or intra corneal ring)|After keratoconus diagnosis the patient was assigned to cross linking surgery or intra corneal ring surgery
62047412|NCT06073730|EXPERIMENTAL|Venetoclax in combination with Decitabine (+-sorafenib)|Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time \>2h) Sorafenib 600mg/d, d8-14 (FLT3/ITD mutation positive patients)
62047413|NCT06073730|ACTIVE_COMPARATOR|Standard dose of Venetoclax + Azacitidine|Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-28 Azacitidine (AZA) 75mg/m2/d, d3-9
62047414|NCT03119324|EXPERIMENTAL|B-Cure® diode laser|"Thirty patients receiving LLLT by the B-Cure® diode laser (Good Energies, Haifa, Israel) 808nm low power device at 5 Joules/min, 250 milliWatts 15 KiloHertz for 8', (40 Joules each) in contact mode directly over the painful area, twice a day for 7 consecutive days.~The laser must be placed directly over the painful area, after having cleaned it with a soft cotton socket to remove skin impurities that could interfere with therapeutic light absorption.~The first application is performed at the Department of Oral Sciences of Sapienza University of Rome by a laser expert investigator and serves as instruction. The remnants must be performed by the patients themselves at home, once on the first day and twice a day in the following 6 days.~Patients were instructed to perform the applications always at the same time."
62249833|NCT02818166|ACTIVE_COMPARATOR|Transthoracic Clamp|Right mini-thoracotomy mitral valve surgery with retrograde perfusion and transthoracic clamp.
62249834|NCT06227364||MCI patients|patients with mild cognitive impairment submitted to Magnetic Resonance, neuropsychological evaluation, neurological assessment
62249835|NCT06227364||Metabolic patients|patietns with obesity and metabollic dysfunction submitted to haematological tests, psychological and neuropsychological evaluations and endocrinology assessment
62249836|NCT06426485|EXPERIMENTAL|Toludesvenlafaxine Hydrochloride Sustained-release Tablets 80 mg or 160 mg group|orally once a day
62249837|NCT06426485|PLACEBO_COMPARATOR|Placebo|orally once a day
62249838|NCT02448225|EXPERIMENTAL|Diagnostic (18F-FDG PET/CT, 18F-FSPG PET/CT)|Patients undergo 18F-FDG PET/CT scan per standard of care. Within 15 working days, patients also undergo 18F-FSPG PET scan over 60 minutes followed by an 18F-FSPG PET/CT scan over 30 minutes.
62249839|NCT03901573|EXPERIMENTAL|Checkpoint Inhibitor-Naive cSCC, MCC Pts|Anti-PD-1/PD-L1 naïve patients with cSCC and MCC
62249840|NCT03901573|EXPERIMENTAL|Checkpoint Inhibitor-Relapsed/Refractory cSCC MCC Melanoma Pts|Anti-PD-1/PD-L1 relapsed/refractory patients with cSCC, MCC and melanoma
62607379|NCT06242418|EXPERIMENTAL|FOLFOXIRI|Eight cycles of FOLFOXIRI: Oxaliplatin 85mg/m2 ivgtt over 2 hours on day 1, Irinotecan 165mg/m2 ivgtt over 90 minutes on day 1, Calcium folinate 400mg/m2 ivgtt over 2 hours on day 1, 5-Fluorouracil 2400mg/m2 civ48h; Each cycle lasts for 2 weeks.
62607380|NCT06242418|ACTIVE_COMPARATOR|XELOX|Five cycles of XELOX: Oxaliplatin 130mg/m2 on day 1, Capecitabine 1000mg/m2 bid from day 1 to day 14; Each cycle lasts for 3 weeks.
62607381|NCT00722566|EXPERIMENTAL|1|VELCADE administered by subcutaneous injection
62829472|NCT01122238|EXPERIMENTAL|15, No Nicotine Patch, No Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
62047415|NCT03119324|PLACEBO_COMPARATOR|B-Cure® diode laser sham device|"Thirty patients that follows the same protocol of the SG but receive a B-Cure laser® sham device, seemingly identical to the effective one but devoid of main diode source.~The laser must be placed directly over the painful area, after having cleaned it with a soft cotton socket to remove skin impurities that could interfere with therapeutic light absorption.~The first application is performed at the Department of Oral Sciences of Sapienza University of Rome by a laser expert investigator and serves as instruction. The remnants must be performed by the patients themselves at home, once on the first day and twice a day in the following 6 days.~Patients were instructed to perform the applications always at the same time."
62047416|NCT03119324|ACTIVE_COMPARATOR|Nimesulide Ratiopharm® and Flexiban®|"Thirty patients follows the conventional drug therapy protocol, of two non-consecutive cycles of 5 days of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® (100 mg a day), interspersed with one 5 days cycle of Myorelaxant, Flexiban® (10 mg a day).~From day 1 to 5, patients assumed 50mg of Nimesulide Ratiopharm®, twice a day; from 6th to 10th day they assumed 10mg of Flexiban® in single dose, from day 11 to 15 they assumed 50mg of Nimesulide Ratiopharm® twice a day.~Patients were instructed to assume the therapy always at the same time"
62047417|NCT01829438|NO_INTERVENTION|Without music|6MWT without music
62047418|NCT01829438|EXPERIMENTAL|With fast music|6MWT with a fast music
62047419|NCT01829438|EXPERIMENTAL|With slow music|6MWT with a slow music
62829473|NCT01122238|EXPERIMENTAL|16, No Nicotine Patch, No Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
62607382|NCT00722566|ACTIVE_COMPARATOR|2|VELCADE administered by intravenous infusion
62607383|NCT04800614|EXPERIMENTAL|Fasted dosing followed by fed dosing (high-fat meal) followed by fed dosing (low-fat meal)|Dosing in the fasted state followed by fed dosing after high and low fat meals
62607384|NCT04800614|EXPERIMENTAL|Fasted dosing followed by fed dosing (low-fat meal) followed by fed dosing (high-fat meal)|Dosing in the fasted state followed by fed dosing after low and high fat meals
62607385|NCT04800614|EXPERIMENTAL|Fed dosing (high-fat meal) followed by fasted dosing followed by fed dosing (low-fat meal)|Dosing after a high-fat meal followed by doing in the fasted sate followed by dosing after a low-fat meal
62829474|NCT04774094|EXPERIMENTAL|CAZ-AVI|
62829475|NCT05279755|EXPERIMENTAL|Prosetin|Part A: single-ascending dose; Part B: multiple doses (7 days)
62047420|NCT01829438|EXPERIMENTAL|With preferred music|6MWT with the preferred music of the child
62047421|NCT03037450|OTHER|Miniinvasive corneal neurotization|
62047422|NCT03905330|EXPERIMENTAL|Maralixibat|Participants will receive Maralixibat oral solution (up to 600 microgram per kilogram \[mcg/kg\]) orally twice daily for 26 weeks.
62047423|NCT03905330|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.
62047424|NCT04584229||question not suitable for study|question not suitable for study
62607386|NCT04800614|EXPERIMENTAL|Fed dosing (high-fat) followed by fed dosing (low-fat) followed by dosing in the fasted state|Fed dosing (high-fate meal) followed by fed dosing (low-fate meal) followed by dosing in the fasted state
62607387|NCT04800614|EXPERIMENTAL|Fed dosing (low-fat) followed dosing in the fasted state followed by fed dosing (high fat)|Fed dosing (low-fat) meal followed dosing in the fasted state followed by fed dosing (high-fat meal)
62829476|NCT05279755|PLACEBO_COMPARATOR|Placebo|Part A: single-ascending dose; Part B: multiple doses (7 days)
62829477|NCT02088008|EXPERIMENTAL|cilnidipine/valsartan|cilnidipine/valsartan tablet
62829478|NCT02088008|ACTIVE_COMPARATOR|cilnidipine+valsartan|coadministration of cilnidipine and valsartan
62829479|NCT06055140||Idiopathic scoliosis without pain|In this group, there will be individuals diagnosed with idiopathic scoliosis whose Cobb angle is above 15 degrees and whose pain level, as assessed by the Visual Analog Scale, is below 3.
62829480|NCT06055140||Idiopathic scoliosis with pain|In this group, there will be individuals diagnosed with idiopathic scoliosis whose Cobb angle is above 15 degrees, and their pain level, as assessed by the Visual Analog Scale, is above 3.
62439636|NCT05743790|EXPERIMENTAL|Group A: RS2 first|Crackers were provided during each of 3 treatment periods in a crossover design. The 3 types of crackers were matched for total carbohydrate content. Treatment period 1 (10 days): After a 3-day ramp up, participants received 120g of crackers/day containing resistant starch type 2 (30g/day) for 7 days; Treatment period 2 (10 days): Participants received control crackers with 100% digestible starch; Treatment period 3 (10 days): After a 3-day ramp up, participants received 120g of crackers/day containing resistant starch type 4 (30g/day) for 7 days. There were 5-day washout periods between the treatment periods.
62439637|NCT05743790|EXPERIMENTAL|Group B: RS4 first|Crackers were provided during each of 3 treatment periods in a crossover design. The 3 types of crackers were matched for total carbohydrate content. Treatment period 1 (10 days): After a 3-day ramp up, participants received 120g of crackers/day containing resistant starch type 4 (30g/day) for 7 days; Treatment period 2 (10 days): Participants received control crackers with 100% digestible starch; Treatment period 3 (10 days): After a 3-day ramp up, participants received 120g of crackers/day containing resistant starch type 2 (30g/day) for 7 days. There were 5-day washout periods between the treatment periods.
62249841|NCT01086410|ACTIVE_COMPARATOR|FF/444 Dose B|Fluticasone furoate/GW642444 Dose B inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
62439638|NCT04052100|ACTIVE_COMPARATOR|Usual care|Patients following the standard preoperative policies of opur institution
62607388|NCT04800614|EXPERIMENTAL|Fed dosing (low-fat) followed by fed dosing (high-fat) followed by dosing in the fasted state|Fed dosing after a low-fat and high-fate meals followed by dosing in the fasted state
62829481|NCT06055140||Control|In this group, there will be healthy individuals whose pain level, as assessed by the Visual Analog Scale, is below 3.
62829482|NCT06651606|EXPERIMENTAL|Progressive Ratio Training|"Participants in the progressive ratio training Arm will experience the novel reinstatement-mitigation tactic: Progressive Ratio Training (PRT).~Progressive ratio training (PRT) is used to prevent recurrence of the proxy response when extinction errors occur. PRT involves providing a reinforcer for the proxy response on a geometric progressive ratio (PR) scale. The schedule requirement will increase for the target response each time a reinforcer is delivered. For example, once a reinforcer is delivered on the PR-2 schedule, the requirement will increase to a PR-4, then to a PR-8, -16,~-32, etc."
62249842|NCT01086410|ACTIVE_COMPARATOR|FF/444 Dose A|Fluticasone furoate/GW642444 Dose A inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
62249843|NCT01086410|PLACEBO_COMPARATOR|Placebo|Placebo inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
62249844|NCT01086410|ACTIVE_COMPARATOR|Prednisolone|Placebo inhalation powder once daily for 6 weeks' treatment + 1 oral prednisolone 10mg capsule each day on the last 7 days of the study
62249845|NCT03914404|EXPERIMENTAL|Test group|"* γ-linoleic acid (Evoprim soft capsule) twice a day and 4 capsules at a time.~* Thioctic Acid(LipoA HR Tab. 600mg) placebo once a day and 1 tablet at a time."
62249846|NCT03914404|EXPERIMENTAL|Control Group|"* Thioctic Acid(LipoA HR Tab. 600mg) once a day and 1 tablet at a time.~* γ-linoleic acid (Evoprim soft capsule) placebo twice a day and 4 capsules at a time."
62249847|NCT01585948||Diabetes Mellitus|All patients undergoing coronary angiography who are diabetics.
62249848|NCT01585948||No diabetes mellitus|All patients undergoing coronary angiography that are non-diabetics.
62249849|NCT01585948||Coronary angiography patients|Diabetics and non-diabetics with or without known CV disease who are admitted in the Department of Cardiology in the University Hospital of Ioannina and the Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. The study will include subjects who 1) have suspected CAD and undergo a scheduled diagnostic angiogram for clinical reasons, and 2) are hospitalized because of an acute coronary syndrome and thus undergo diagnostic angiography (with or without previous history of CAD).
62439639|NCT04052100|EXPERIMENTAL|Prehabilitation|Patients following the standard preoperative policies of opur institution and the multimodal prehabilitation program
62439640|NCT05499364|ACTIVE_COMPARATOR|Quit.gov program|Generic intervention based on quit.gov sessions.
62439641|NCT05499364|EXPERIMENTAL|TinCat|Individualized asynchronous telehealth including LGBTQ+ affirming components.
62439642|NCT01532882|EXPERIMENTAL|Diosmin|
62829483|NCT06651606|EXPERIMENTAL|Standard of Care|"Participants in the standard of care Arm will receive an analogue to the standard of care approach for problem behavior: differential reinforcement of alternative behavior (DRA) with extinction.~In DRA with extinction, the proxy for problem behavior will cease to produce reinforcement while the proxy for communication behavior will produce reinforcement on a fixed-ratio 1 schedule of reinforcement."
62249850|NCT06170905|EXPERIMENTAL|Oral glucose tolerance test with whey protein pre-load|30 minutes prior to the 75 g OGTT, a whey protein solution is given.
62607389|NCT06133413|NO_INTERVENTION|Standard of care group|Standard follow-up
62829484|NCT03925090|EXPERIMENTAL|Neoadjuvant and Adjuvant Toripalimab+CCRT|Drug: Cisplatin cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy Other Names: DDP Drug: Toripalimab Toripalimab 240mg every 2 weeks with a total of 2 cycles as neoadjuvant anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 8 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT Other Names:anti-PD-1 antibody, JS001
62829485|NCT03925090|PLACEBO_COMPARATOR|Neoadjuvant and Adjuvant Placebo+CCRT|Drug: Cisplatin cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy Other Names: DDP Drug: placebo placebo 240mg every 2 weeks with a total of 2 cycles as neoadjuvant treatment; placebo 240mg every 3 weeks with a total of 8 cycles as adjuvant treatment 2 weeks after CCRT.
62249851|NCT06170905|NO_INTERVENTION|Control oral glucose tolerance|75 g OGTT without whey protein pre-load.
62249852|NCT05198336|EXPERIMENTAL|Experimental Group of children aged 3-5 years old|200 subjects aged 3-5 years old who have received two doses of inactivated COVID-19 vaccine(CoronaVac) manufactured by Sinovac Research \& Development Co., Ltd and is currently 28-42 days after the second dose
62607390|NCT06133413|EXPERIMENTAL|Connected scale group|Standard follow up + Use weekly of Body Comp Pro connected scale, associated with a remote monitoring by medical team allowing alert generation and early intervention
62607391|NCT06536088||Patient with Femoroacetabular Impingement|Symptomatic femoroacetabular impingement patients scheduled for hip arthroscopy
62047425|NCT01514448|EXPERIMENTAL|Everolimus|Everolimus 10 mg orally once daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawn consent.
62047426|NCT00945464||No treatment|Women over the age of 30 undergoing breast imaging at the Scripps Polster Breast Care Center.
62047427|NCT02239393|EXPERIMENTAL|Autologous Mesenchymal Stem Cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0.
62047428|NCT02239393|EXPERIMENTAL|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0.
62047429|NCT00365391|EXPERIMENTAL|Treatment (monoclonal antibody, enzyme inhibitor)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory studies to determine EGFR and phosphorylated-EGFR protein levels using initial diagnostic biopsy specimens by IHC for correlation with clinical outcome. Levels of proteins through which EGFR signals, including Akt, phosphorylated-Akt, MAPK, and phosphorylated-MAPK, are also determined using initial diagnostic biopsy specimens by IHC and correlated with clinical outcome. Total and free serum vascular endothelial growth factor levels are determined at the start of study and prior to course 3 by ELISA.
62047430|NCT06059105|EXPERIMENTAL|Test Group|Inverted Co-Axis 12º Southern Implants (15 patients): The implant is placed in the center of the socket due to that has an angled neck of 12º, which allows the implant to be placed in the center of the alveolus, optimizing the alveolar bone and improving the prosthetic emergence. This is due to the access of the screw being located palatally, simplifying the restoration of the crown, avoiding cemented crowns, lowering the laboratory cost and of prosthetic accessories.
62047431|NCT06059105|ACTIVE_COMPARATOR|Control Group|Internal Conical (Deep Tapered Conical) South Implants (15 patients): conventional conical implant with internal connection. The implant is placed palatally in order to have a good emergence profile.
62047432|NCT00814294|PLACEBO_COMPARATOR|1; Placebo|Patients receive a sugar pill.
62047433|NCT00814294|EXPERIMENTAL|2; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)|Patients receive Oral HDV-Insulin (U-5).
62047434|NCT00814294|EXPERIMENTAL|3; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)|Patients receive Oral HDV-Insulin (U-15).
62047435|NCT05388500|ACTIVE_COMPARATOR|Group A (Paclitaxel + Trastuzumab)|
62047436|NCT05388500|EXPERIMENTAL|Group B (Trastuzumab)|
62047437|NCT01024608|EXPERIMENTAL|BDP HFA 320 µg/day|During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning.
62047438|NCT01024608|PLACEBO_COMPARATOR|Placebo|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily each morning.
62047439|NCT04489043|EXPERIMENTAL|Exercise and healthy life style recommendations|A planned exercise programme to test the impact of this treatment. An Oral Glucose Tolerant Test (OGTT) at intermediate time points in order to increase the frequency and duration of aerobic exercise and eventually to add anaerobic/resistance training.
62047440|NCT01002872|ACTIVE_COMPARATOR|Lanthanum Carbonate (Fosrenol)|Subjects will receive the study drug Lanthanum Carbonate ( Fosrenol)
62047441|NCT01002872|PLACEBO_COMPARATOR|Placebo|Subject will receive placebo
62047442|NCT01876316|ACTIVE_COMPARATOR|Moxifloxacin|single oral administration of 400mg of moxifloxacin
62439643|NCT01532882|PLACEBO_COMPARATOR|Placebo|
62439644|NCT00624481|ACTIVE_COMPARATOR|1|
62439645|NCT00624481|EXPERIMENTAL|2|
62439646|NCT00624481|EXPERIMENTAL|3|
62047443|NCT01876316|PLACEBO_COMPARATOR|Placebo|single oral administration of 400mg of placebo
62047444|NCT00718003||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
62047445|NCT02329548|EXPERIMENTAL|Alizarin Red|All participating patients will undergo the Alizarin Red intervention.
62047446|NCT03404310|EXPERIMENTAL|Treatment|Zinc Sulfate 220mg twice daily for three months.
62047447|NCT03404310|PLACEBO_COMPARATOR|Placebo|Gelatin Placebo tablet twice daily for three months.
62047448|NCT04721925|NO_INTERVENTION|Control group|Link to an educational website about alcohol; link to resources.
62047449|NCT04721925|EXPERIMENTAL|Social media messaging|Health coaching via social media for 8 weeks
62047450|NCT01304030|EXPERIMENTAL|Experimental Group|The experimental group receives Empathy Training. The control Group receives residency training as usual
62047451|NCT01304030|ACTIVE_COMPARATOR|Control Group|The control group receives residency training as usual
62439647|NCT00624481|EXPERIMENTAL|4|
62439648|NCT00624481|EXPERIMENTAL|5|
62439649|NCT02363751|EXPERIMENTAL|1|Patients will be treated for a maximum of 6 (21 days) chemotherapy cycles (Gemcitabine+platinum salt+bevacizumab)
62439650|NCT00416403|EXPERIMENTAL|Arm I|Patients receive oral fluvastatin sodium once daily for 3-6 weeks in the absence of disease progression or unacceptable toxicity.
62439651|NCT00416403|EXPERIMENTAL|Arm II|Patients receive oral fluvastatin sodium as in arm I at a higher dose.
62439652|NCT00416403|EXPERIMENTAL|Arm III|Patients do not receive fluvastatin sodium. breast Cancer surgery only
62607392|NCT06536088||Control group|Healthy indivicuals without Femoroacetabular Impingement
62047452|NCT00826306|EXPERIMENTAL|Video-based education arm|Subjects receiving the video-based educational material
62047453|NCT00826306|ACTIVE_COMPARATOR|Written education arm|Subjects receiving the written educational material
62047454|NCT05773118|EXPERIMENTAL|orthokeratology lens|The subjects will wear an orthokeratology lens with 3-zone reverse geometry design. The subjects are instructed to wear the lenses for at least eight hours every night and are removed during daytime hours.
62607393|NCT01463267|ACTIVE_COMPARATOR|Device 2 passive|Device 2 will NOT remind patients to take medications
62607394|NCT01463267|ACTIVE_COMPARATOR|Device 2 active|Device 2 will remind patients to take medications
62829486|NCT06319014|EXPERIMENTAL|AE Group|"The AE group will exercise on aerobic machines (i.e. treadmill, elliptical, bicycle)~All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data."
62047455|NCT05773118|EXPERIMENTAL|multifocal soft contact lens|The subjects will wear a multifocal soft contact lens during daytime hours and remove the lens at night
62047456|NCT05773118|ACTIVE_COMPARATOR|single vision spectacle|The subjects will wear single vision spectacle lens as control.
62439653|NCT06186440|EXPERIMENTAL|Experimental|Cisplatin 20mg/m2 Cisplatin days 1-5 plus Temozolomide 150-200mg/m2 days 1-5
62439654|NCT06186440|ACTIVE_COMPARATOR|Temozolomide|Temozolomide 150-200mg/m2 days 1-5
62249853|NCT05198336|EXPERIMENTAL|Experimental Group of children aged 6-11 years old|200 subjects aged 6-11 years old who have received two doses of inactivated COVID-19 vaccine(CoronaVac) manufactured by Sinovac Research \& Development Co., Ltd and is currently 28-42 days after the second dose
62607395|NCT01463267|ACTIVE_COMPARATOR|Device 1 active|Device 1 will remind patients to take their medications
62607396|NCT01463267|PLACEBO_COMPARATOR|Device 1 Passive|Device 1 will NOT remind patients to take medications.
62607397|NCT05106920|EXPERIMENTAL|NMP 3 Hz|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
62829487|NCT06319014|EXPERIMENTAL|RE Group|"The RE group will perform 12-15 repetitions of 10-12 resistance exercises in a circuit, for 3 sets, with a rest period of 30-60 seconds between sets as needed.\[172\] Seated isokinetic exercise using resistance machines will target all major muscle groups. Light dumbbells and resistance bands will be used if the participant is unable to lift the minimal load on machines. Core exercises will be performed at the end of the session (i.e. seated side bends)~All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data."
62829488|NCT06319014|EXPERIMENTAL|AERE Group|"AERE group will alternate between AE exercise and RE; for this group, RE exercises will consist of 1 set of 12-15 repetitions of 4 resistance exercises, then 5 minutes of AE, then repeat this cycle with different exercises.~All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data."
62829489|NCT06319014|NO_INTERVENTION|Control|The Control group will participate in weekly sessions that focus on stretching, breathing, and healthy lifestyle.
62829490|NCT03760094|EXPERIMENTAL|Study group|patients with lymphadenopathy
62829491|NCT05798767||PCI group|Patients with a Mini-Cog score of 3 or less were in the PCI group
62829492|NCT05798767||Normal group|Patients with a Mini-Cog score of 3 or 4 were in the normal group
62829493|NCT04927195|EXPERIMENTAL|Cohort 1|12 healthy volunteers; 8 on EDP1867, 4 on placebo. Dose = upto 7.5 x 10\^11 cells, capsules, once daily, 14 days total
62829494|NCT04927195|EXPERIMENTAL|Cohort 2|12 healthy volunteers; 8 on EDP1867, 4 on placebo. Dose = upto 1.5 x 10\^12 cells, capsules, once daily, 14 days total
62047457|NCT01313702|EXPERIMENTAL|polipillV1|poli pill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
62047458|NCT01313702|EXPERIMENTAL|polipillV2|Polipill versão2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
62047459|NCT01313702|ACTIVE_COMPARATOR|usual care|
62047460|NCT04710082|ACTIVE_COMPARATOR|Patients planned to undergo conventional 2 step trans-epithelial PTK-PRK|"Patients planned to undergo:~1. Epithelial removal using Phototherapeutic Keratectomy PTK as a separate step.~2. Laser Vision Correction using Excimer laser wavefront optimized technology."
62047461|NCT04710082|ACTIVE_COMPARATOR|Patients planned to undergo the new single step trans-epithelial (StreamLight) PRK.|"Patients planned to undergo:~Epithelial removal and Excimer wavefront optimized Laser Vision Correction in a single step using the new StreamLight Technology."
62439655|NCT04758871|EXPERIMENTAL|Dydrogesterone|Luteal phase support for hormone replacement therapy frozen embryo transfer cycles using dydrogesterone 10 mg 3 times daily
62439656|NCT04758871|ACTIVE_COMPARATOR|Micronized progesterone|Luteal phase support for hormone replacement therapy frozen embryo transfer cycles using micronized progesterone 2x200 mg twice daily vaginally
62607398|NCT05106920|EXPERIMENTAL|NMP 10 Hz|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 10 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
62607399|NCT03914027|NO_INTERVENTION|Control|Patients allocated to the control group will follow the same procedure except for not using tele-rehabilitation.
62439657|NCT01388647|EXPERIMENTAL|Eribulin, carboplatin, and trastuzumab|During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle. Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle. Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
62047462|NCT02885987|NO_INTERVENTION|Standard Colonoscopy|AmplifEYE will not be used.
62607400|NCT03914027|EXPERIMENTAL|Intervention|The intervention is the use of a tele-rehabilitation program during 12 weeks. The patient's training time will be registered automatically. The control group will receive standard treatment only.
62607401|NCT02418741|EXPERIMENTAL|Degree of neck flextion|Two degrees of neck flexion were achieved using a 4 cm or 8 cm height of pillow
62607402|NCT03702712|ACTIVE_COMPARATOR|Aerobic Exercise Only|Participants in the Aerobic Exercise Only arm will engage in three separate 20-minute sessions comprised of a 5-minute, resistance-free warm-up, and 15 minutes of moderate stationary aerobic cycling on a Cybex bike #525C (50-70% age-predicted heart rate max). Each session will be followed by 20 minutes of uninterrupted quiet rest. The bike will provide feedback including speed, rotations per minute, and time.
62607403|NCT03702712|ACTIVE_COMPARATOR|Relaxation Only|Participants in the Relaxation Only arm will complete three separate 20-minute sessions of relaxation using a commercial wearable neurofeedback (headband) device. The device's accompanying software (connected to the headband through Bluetooth) encourages breathing strategies in response to recorded brain wave activity. Real time auditory feedback includes sounds of calm (soft) or loud winds in response to detected brain activity. A visual report of affective states and the user's brain activity is given (alpha and beta waves). Participants will also be asked to take part in 20 minutes of uninterrupted quiet rest in order to match the time of the aerobic only condition.
62607404|NCT03702712|EXPERIMENTAL|Aerobic Exercise and Relaxation|Participants in the Aerobic Exercise and Relaxation arm will complete the three separate 20-minute aerobic exercise sessions (identical to the aerobic exercise only condition) followed by the same 20-minute neurofeedback-guided mindfulness training (identical to the relaxation only condition).
62047463|NCT02885987|EXPERIMENTAL|Colonoscopy with AmplifEYE|AmplifEYE accessory device will be attached to the colonoscope prior to starting the procedure
62607405|NCT03919500|EXPERIMENTAL|Erythropoietin|Infants in the EPO group are given EPO 500IU/kg dissolved in 2 ml saline intravenously every other day for 2 weeks starting within 72 hours after birth.
62607406|NCT03919500|PLACEBO_COMPARATOR|Normal saline|Infants in the control group are given normal saline intravenously with the same volume as EPO every other day for 2 weeks.
62607407|NCT01561599|PLACEBO_COMPARATOR|Normal saline|Placebo
62829495|NCT04927195|EXPERIMENTAL|Cohort 3|24 subjects with moderate atopic dermatitis; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10\^11 cells, capsules, once daily, 56 days
62607408|NCT01561599|ACTIVE_COMPARATOR|BB3|Small molecule mimetic of hepatocyte growth factor/scatter factor
62829496|NCT04927195|EXPERIMENTAL|Cohort 4|24 subjects with moderate psoriasis; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10\^11 cells, capsules, once daily, 56 days
62829497|NCT04927195|EXPERIMENTAL|Cohort 5|24 subjects with mild asthma; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10\^11 cells, capsules, once daily, 56 days
62829498|NCT02458313|EXPERIMENTAL|DMXB-A|150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
62829499|NCT02458313|PLACEBO_COMPARATOR|Placebo|Placebo capsules b.i.d. for 12 weeks.
62829500|NCT06436092||JDEPTH-LM Registry Participants|Subjects ≥ 18 years of age with de novo LMD with LCx ostium stenosis presenting with stable angina, non-ST-elevation myocardial infarction, or unstable angina that are suitable for percutaneous coronary intervention including W-KBT processes. Approximately 280 subjects at 17 sites in Japan will be enrolled. Subjects will be followed through discharge and 12 months in routine clinical practice.
62829501|NCT06492902|EXPERIMENTAL|XFS + AA|Auricular acupuncture in addition to Xiao-Feng-San.
62829502|NCT06492902|PLACEBO_COMPARATOR|XFS + Sham AA|Sham auricular acupuncture in addition to Xiao-Feng-San.
62829503|NCT03159429|EXPERIMENTAL|Experimental arm|"Patients randomized to this arm will participate in the new rehabilitation programme.~Intervention: Nasal breathing rehabilitation"
62829504|NCT03159429|ACTIVE_COMPARATOR|Comparator arm|"Patients randomized to this arm will participate in the usual rehabilitation programme.~Intervention: Standard rehabilitation"
62829505|NCT04232722|EXPERIMENTAL|Sorafenib + arsenical|After enrollment, the patients received oral treatment at sorafenib 200mg bid continuous and realgar-indigo naturalis formula preparation at 60mg/kg tid p.o, d1-14, q4w
62249854|NCT03311451|OTHER|C2 CryoBalloon 180 Ablation System|C2 CryoBalloon 180 Ablation System will be used to ablate visible Barrett's esophagus
62249855|NCT02756351|EXPERIMENTAL|CytaCoat Nasal Prong|The CytaCoat Nasal Prong is composed of the reference device coated with CytaCoat technology.
62249856|NCT02756351|ACTIVE_COMPARATOR|Reference Nasal Prong|Inspiration Healthcare Inspire nCPAP Nasal Prong consists of silicone. Is a Conformité Européenne marked (CE-marked) commercially available medical device.
62249857|NCT04727203|EXPERIMENTAL|Intervention|Partcipants in this group will receive the 8 week healthy lifestyle program
62829506|NCT02480387|EXPERIMENTAL|Treatment Arm|8 weeks treatment with Ledipasvir/Sofosbuvir FDC
62047464|NCT04502576|ACTIVE_COMPARATOR|High-flow nasal cannula|"High-flow nasal cannula will be delivered with the Optiflow system. Initial set flow will be ≥ 50 /min and flows will be decreased in case of intolerance and/or according to patients' requirements: flows≥30 L/min will be mandatory in all enrolled patients. Humidification chamber (MR860, Fisher and Paykel healthcare, New Zealand) will be set at 37 °C or 34 °C according to patient's comfort. FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.~The treatment according to the assigned protocol will be continued until the patient requires endotracheal intubation or (in case of no intubation) up to ICU discharge. Weaning from high-flow will be considered as standardized criteria are met."
62249858|NCT04727203|NO_INTERVENTION|Control|Participants in this group will not receive any intervention
62439658|NCT01063179|EXPERIMENTAL|Arm A: VMPT|Induction therapy with nine 5-week courses of VELCADE/Melphalan/Prednisone/Thalidomide (V-MPT) followed by maintenance therapy with Thalidomide and VELCADE
62439659|NCT01063179|ACTIVE_COMPARATOR|VMP|"Induction therapy with nine 5-week courses of either VELCADE/Melphalan/Prednisone (V-MP).~No maintenance is scheduled."
62439660|NCT05494554||Pressure control mode group|On the 2nd day of intensive care hospitalization, while under deep sedation and in the controlled mode (VCV or PRVC) and in the supine position, the ventilator in the VCV mode was switched to PRVC mode for 60 minutes without changing any of the set ventilator settings (RR, PEEP, TV, I:E ratio).
62607409|NCT04600063|OTHER|Conventional procedure|In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.
62829507|NCT03910244|EXPERIMENTAL|Pomalidomide|Oral Pomalidomide will be provided as a capsule at 4 mg/day dose. There will be 6 treatment cycles of 28 days (4 weeks) each. Total treatment phase duration will be 24 weeks.
62829508|NCT03910244|PLACEBO_COMPARATOR|Placebo|A placebo matching the study drug will be provided as a capsule. There will be 6 treatment cycles of 28 days (4 weeks) each. Total treatment phase duration will be 24 weeks.
62829509|NCT03722238|EXPERIMENTAL|Ibuprofen 600 mg Immediate Release/Extended Release Tablets|Ibuprofen 600 mg Immediate Release/Extended Release Tablets
62249859|NCT06061679|EXPERIMENTAL|Omron C28P cohort|Patients diagnosed with COPD using the study device (OMRONC28P) for 24 weeks.
62249860|NCT05876091|EXPERIMENTAL|Vaping -|"Description The order of directed and ad libitum bouts are randomized within participants at each session.~SESSION 1: Participants puff their own brand liquid on study.~SESSIONS 2-5: Participants puff 1 of 4 randomly assigned tobacco flavor formulations at each visit on study.~SESSIONS 6-7: Participants puff 1 of 2 randomly assigned nicotine formulations at each visit on study.~Participants also undergo collection of saliva samples and optionally undergo collection of oral cell and oral rinse samples throughout study."
62439661|NCT05494554||Volume control mode group|Likewise, if it is in PRVC mode, it is also switched to VCV mode for 60 minutes. In this way, two dependent groups were formed.
62439662|NCT06302855|ACTIVE_COMPARATOR|dental visit invited|Patients will only be invited or asked to schedule a complimentary periodontal check-up visit without any previous assessment.
62439663|NCT06302855|EXPERIMENTAL|dental visit recommended based on dental expertise|Patients' oral cavities will be photographed. Based on the remote assessment of periodontitis risk conducted by the same periodontist from the Division of Regenerative Dental Medicine and Periodontology at the University Clinic of Dental Medicine, patients will be invited or asked to schedule a complimentary periodontal check-up visit at the CUMD. The appointment will be arranged directly at the diabetologist's office.
62439664|NCT04155983|ACTIVE_COMPARATOR|High ACB|In the pre-operative cohort, the adductor canal block is administered by anesthesia staff immediately prior to patient transport to the operating room. The thigh is prepped with cholorhexidine at the midpoint between the anterior superior iliac spine and the patella and sterile drapes are applied. An ultrasound probe is then used to localize the adductor canal and confirm that the femoral artery, femoral vein and saphenous nerve can be visualized deep to the sartorious. The probe is moved proximally or distally until the neurovascular bundle is centered under the sartorius. A 20cc syringe with a blunt tip 1.5in 18ga needle is then used to inject 15cc of 0.5% ropivocaine. Following this, the wound is prepped and draped in usual sterile fashion for the arthroplasty procedure.
62607410|NCT04600063|EXPERIMENTAL|Isolation procedure (RAMPS procedure)|In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).
62249861|NCT01925898|EXPERIMENTAL|Ketamine|Oral ketamine
62249862|NCT01925898|ACTIVE_COMPARATOR|Midazolam|Oral Midazolam
62249863|NCT02290626|EXPERIMENTAL|Elemental diet|"Study 1: Elemental diet (300 kcal/300 ml) containing a contrast medium (5 ml) is administered within 15 min using the PEG.~Study 2: Elemental diet (200 kcal/200 mL) labeled with 100 mg \[13C\]sodium acetate is administered within 15 min using the PEG."
62249864|NCT02290626|ACTIVE_COMPARATOR|Semi-solid diet|"Study 1: Semi-solid diet (300 kcal/300 ml) containing a contrast medium (5 ml) is administered within 15 min using the PEG.~Study 2: Semi-solid diet (200 kcal/200 mL) labeled with 100 mg \[13C\]sodium acetate is administered within 15 min using the PEG."
62439665|NCT04155983|ACTIVE_COMPARATOR|Low ACB|Surgeon Administered Group In the intra-operative cohort, the block will be administered after the final components are in place and cement debris is removed. The knee joint is irrigated with dilute hibiclens or betadine followed by pulsatile lavage per institutional protocol. A blunt tip 1.5in 18ga needle was then used to administer 15cc of 0.5% ropivocaine.. The location of the saphenous nerve as it exits the adductor canal will be estimated to be 1.5x the TEA proximal to the medial epicondyle in men and 1.3x the TEA proximal in women as described by Kavolus et al. The 60cc of the anesthetic will then injected through the vastus medialis musculature in a field extending from 1cm proximal to one cm distal to the assumed location of the nerve with the needle directed in from 20° to 45° medial. The wound is then irrigated pulsatile lavage one final time and closed in layered fashion.
62249865|NCT05622825|EXPERIMENTAL|cryoablation combined DC-CIK|To explore the therapeutic effect and safety of cryoablation combined with autologous DC-CIK (through hepatic artery infusion, HIA) for patients with advanced liver cancers
62439666|NCT00988234|EXPERIMENTAL|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
62439667|NCT00988234|EXPERIMENTAL|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
62439668|NCT00988234|EXPERIMENTAL|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
62439669|NCT00988234|EXPERIMENTAL|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
62439670|NCT03599310|EXPERIMENTAL|Advance care planning|The intervention is a facilitator-based ACP process with a structured guide as a communication tool to aid the interventionists in broaching end-of-life care issues and eliciting patients' values and preferences in a consistent manner.
62607411|NCT05106751|EXPERIMENTAL|YVOIRE Classic plus|
62607412|NCT05106751|ACTIVE_COMPARATOR|Restylane Lidocaine|
62047465|NCT04502576|EXPERIMENTAL|Helmet noninvasive ventilation|"Patients will receive continuous helmet pressure support ventilation for at least 16 hours/day the first 2 calendar days. Continuous noninvasive ventilation without interruptions will be strongly encouraged in the first 24 hours of treatment. The ventilator will be set in pressure support mode. Use of continuous positive airway pressure by flow generators and Venturi systems instead of pressure support ventilation will be allowed in case of shortage of ventilators. Maintenance of positive end-expiratory pressure ≥ 8-10 during the treatment is mandatory.~After weaning and during any interruption from noninvasive ventilation, patients will undergo low-flow or high-flow oxygen, according to the decision of the attending physician.~The treatment according to the assigned protocol will be continued until the patient requires endotracheal intubation or (in case of no intubation) up to ICU discharge."
62829510|NCT06655441|EXPERIMENTAL|OS eye receives 3% trehalose drops and OD eye receives control drops|
62047466|NCT05079074||Patients with late-stage metastatic breast cancers.|This cohort included patients with late-stage metastatic breast cancers and their disease progressed after at least two-line treatment.
62829511|NCT06655441|OTHER|OD eyes receives 3% trehalose drops and OS eye receives control drops|
62829512|NCT00474487|EXPERIMENTAL|Novartis MenACWY Vaccine (19 to 55 Years)|Novartis meningococcal ACWY conjugate vaccine administered to subjects 19 years to 55 years
62829513|NCT00474487|ACTIVE_COMPARATOR|Licensed polysaccharide vaccine|Licensed meningococcal ACWY polysaccharide vaccine
62047467|NCT05559502|EXPERIMENTAL|HFNO group|Patients will receive HFNO therapy during laryngomicrosurgery.
62047468|NCT05559502|ACTIVE_COMPARATOR|ET group|Endotracheal intubation was performed for general anesthesia
62047469|NCT06579898|EXPERIMENTAL|PRET|All participants participate in a progressive resistance exercise training programme for 24 weeks.
62047470|NCT04169308|EXPERIMENTAL|Experimental: Restylane-L® Filler injection|
62047471|NCT05488132|EXPERIMENTAL|anti-siglec-6 CAR-T cell therapy|anti-siglec-6 CAR-T cell therapy
62439671|NCT03599310|PLACEBO_COMPARATOR|Usual care|A leaflet covering the concept of ACP and advance directives (AD), purposes and potential benefits will be distributed to all participants as part of usual information support to standardize the information provided. The health care team will encourage patients to discuss the matters with their family carers and/or significant others.
62439672|NCT03409679|EXPERIMENTAL|Murepavadin|Murepavadin IV + one anti-pseudomonal antibiotic
62439673|NCT03409679|ACTIVE_COMPARATOR|Two anti-pseudomonal antibiotics|Association of 2 anti-pseudomonal antibiotics
62439674|NCT05464732|EXPERIMENTAL|Monovision|"The target refraction is plano (0.00 D) for the dominant eye and between -0.50 D and -0.75 D for the non-dominant eye. The Vivity IOL will be implanted bilaterally.~Corrected vision will involve correcting the dominant eye for emmetropia and the non-dominant eye for -0.50 D."
62439675|NCT05464732|ACTIVE_COMPARATOR|Emmetropia|Subject's vision will be tested with both eyes corrected for emmetropia.
62439676|NCT01438554|EXPERIMENTAL|Pazopanib and GSK1120212|Treatment will be administered on an outpatient basis. Both drugs are taken orally. Each cycle lasts 28 days. The doses of each drug will depend on when patient enters study.
62439677|NCT06091410|EXPERIMENTAL|C group|concomitant administration of COVID-19 booster and quadrivalent influenza vaccination
62439678|NCT06091410|PLACEBO_COMPARATOR|S group (COVID-19 vaccine only)|separate administration of influenza vaccination followed by COVID-19 booster 4 weeks later
62439679|NCT06091410|PLACEBO_COMPARATOR|S group (influenza vaccine only)|separate administration of influenza vaccination followed by COVID-19 booster 4 weeks later
62439680|NCT01944228|EXPERIMENTAL|Vagal Nerve Stimulation|30 minutes of vagal nerve stimulation using a catheter in the IJV
62439681|NCT01944228|SHAM_COMPARATOR|Sham stimulation|Catheter placed in the IJV without stimulation
62439682|NCT04207086|EXPERIMENTAL|6 wk pembrolizumab & lenvatinib, surgery, 46 wk pembrolizumab|Neoadjuvant pembrolizumab \& lenvatinib for 6 weeks followed by definitive surgery then adjuvant pembrolizumab alone for 46 weeks.
62829514|NCT00474487|ACTIVE_COMPARATOR|Licensed Conjugate Vaccine|Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
62047472|NCT04749732|EXPERIMENTAL|WalkingPad plus Psychological Intervention - PsyWPad Group|The participants in Experimental Group 1 will receive a prescription of an HBET consisting of a walking plan with a duration greater than 30 min per session, frequency of at least three sessions per week, use of near-maximal pain during training as claudication pain endpoint, with the support of a behavioral motivational intervention delivered by a health psychologist.
62047473|NCT04749732|EXPERIMENTAL|WalkingPad plus Virtual Assistant - CyberWPad Group|The participants in Experimental Group 2 will receive a prescription of an HbET consisting of a walking plan with a duration greater than 30 min per session, frequency of at least three sessions per week, use of near-maximal pain during training as claudication pain endpoint, with the support of a virtual assistant that will give motivational support.
62439683|NCT04576806|ACTIVE_COMPARATOR|Body temperature fluid bolus of crystalloid|Fluid bolus at 38 degrees celsius of 500ml crystalloid over 15 minutes
62439684|NCT04576806|EXPERIMENTAL|Room temperature fluid bolus of crystalloid|Fluid bolus at 22 degrees celsius of 500ml crystalloid over 15 minutes
62439685|NCT04402749||Nephrectomy|Patients underwent nephrectomy
62439686|NCT03670979|EXPERIMENTAL|bone swaging alone|xenograft alone
62829515|NCT00474487|EXPERIMENTAL|Novartis MenACWY Vaccine (56 to 65 Years)|Novartis meningococcal ACWY conjugate vaccine administered to subjects 56 years to 65 years
62829516|NCT03228550|EXPERIMENTAL|Efamol Active 50+ and exercise|Efamol Active 50+ Multinutrient supplement and aerobic exercise
62829517|NCT03228550|EXPERIMENTAL|Efamol Active 50+ and non-exercise|Efamol Active 50+ Multinutrient supplement and non-aerobic exercise
62439687|NCT03670979|EXPERIMENTAL|bone swaging plus EDTA|bone swaging with EDTA
62439688|NCT00669578|EXPERIMENTAL|CC-4047|
62439689|NCT05794399|EXPERIMENTAL|Rivaroxaban|In this arm, the patients with post-myocardial infarction and left ventricular thrombus will be treated with Rivaroxaban 20mg or 15mg as indicated.
62439690|NCT05794399|ACTIVE_COMPARATOR|Warfarin|In this arm, the patients with post-myocardial infarction and left ventricular thrombus will be treated with warfarin with a dose adjusted with the International Normalised ratio range of 2.0 to 3.0.
62607413|NCT04517045|SHAM_COMPARATOR|Conventional treatment group|Control the primary disease, prevent infection, reduce gastrointestinal decompression, and actively maintain organ function.
62607414|NCT04517045|EXPERIMENTAL|Conventional treatment plus L92 group|Conventional treatment combined with L92
62607415|NCT04517045|EXPERIMENTAL|Conventional treatment plus Dachengqi decoction group|Conventional treatment combined with Dachengqi Decoction
62047474|NCT04749732|ACTIVE_COMPARATOR|Paper WalkingPad group - PaperWPad Group|The participants in the Active Control Group will receive a prescription of an HbET consisting of a walking plan with a duration greater than 30 min per session, frequency of at least three sessions per week, use of near-maximal pain during training as claudication pain endpoint, with the support of a behavioral motivational intervention delivered by a health psychologist.
62439691|NCT06045585|EXPERIMENTAL|infusion of JY231 injection|Infusion of JY231 Injection by dose of 1-10 x10\^6 TU/kg、 1-5 x10\^7 TU/kg、 5-10 x10\^7 TU/kg Administration method: intravenous infusion、intraperitoneally infusion、Lymph node infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion（PI evaluation is required）.
62607416|NCT04517045|EXPERIMENTAL|Conventional treatment plus Dachengqi decoction plus L92 group|Conventional treatment combined with L92 and Dachengqi Decoction
62607417|NCT03725033|EXPERIMENTAL|Subetta|Tablet for oral use. 2 tablets twice daily. The tablets should be held in mouth until completely dissolved 15 min prior to meal.
62607418|NCT03725033|PLACEBO_COMPARATOR|Placebo|Tablet for oral use. 2 tablets twice daily. The tablets should be held in mouth until completely dissolved 15 min prior to meal.
62607419|NCT02163642||Non-CF Bronchiectasis|Cyranose® 320
62607420|NCT05244434|EXPERIMENTAL|Prospective cohort (SOC treatment, biopsy, blood collection)|Patients receive SOC treatment consisting of ribociclib or palbociclib plus AI. Patients undergo biopsy of tumor tissue at baseline and post-treatment. Patients also undergo collection of blood samples at baseline, on day 1 of SOC treatment cycles 2, 4, and 6, every 6 cycles thereafter, and at post-treatment.
62607421|NCT05244434|EXPERIMENTAL|Retrospective cohort|Patients' tumor tissue collected during previous SOC treatment (ribociclib or palbociclib plus AI) is used for analysis.
62607422|NCT01679912|EXPERIMENTAL|1: phone to call center|recommendations to phone to the call center for all the patients who have an acute attack
62607423|NCT01679912|NO_INTERVENTION|2: usual strategy|usual strategy. No intervention (patients does not change their practice)
62829518|NCT03228550|EXPERIMENTAL|Placebo and exercise|Placebo supplement and aerobic exercise
62829519|NCT03228550|EXPERIMENTAL|Placebo and non-exercise|Placebo supplement and non- exercise
62829520|NCT04788329|EXPERIMENTAL|Relaxation Group|This program teaches patients how to feel calmer before surgery. Patients are taught relaxation techniques by phone or in person by trained NYU personnel.
62829521|NCT04788329|EXPERIMENTAL|Meditation Group|"This treatment group will be enrolled in Wim Hof Method, a meditation program. Patients in this group will take the online The Fundamentals Course provided by the Wim Hof Method. The patients will be introduced to the online course preoperatively"
62829522|NCT04788329|NO_INTERVENTION|Standard Care Group|The control group will get the standard of care therapy after surgery.
62829523|NCT02706977|EXPERIMENTAL|Diabetes Group - Low Dose Sinemet CR|Participants with diabetes mellitus type-2 and electroretinogram (ERG) delays will receive low dose Sinemet CR twice daily for two weeks.
62829524|NCT02706977|EXPERIMENTAL|Diabetes Group - High Dose Sinemet CR|Participants with diabetes mellitus type-2 and electroretinogram (ERG) delays will receive high dose Sinemet CR twice daily for two weeks.
62829525|NCT02706977|OTHER|Diabetes Group - No Electroretinogram (ERG) Delays|Participants with diabetes mellitus type-2 who do not have electroretinogram (ERG) delays. Participants in this group will have one baseline visit only.
62607424|NCT01680653|EXPERIMENTAL|Mini-Glucagon and Remote Monitoring|"Subjects glucose data are remotely monitored at night using the University of Virginia (UVA) Diabetes Assistant (DiAs) Android Platform. Study staff intervenes with a fingerstick blood glucose measurement when sensor value falls below 70mg/dL. If fingerstick value is less than 70 mg/dL, hypoglycemic treatment is administered as below.~Administer mini-glucagon as treatment for nocturnal hypoglycemia. Administer 0.01 cc per number of years in age via insulin syringe, subcutaneously. This amounts to 1 unit per age, for example: an 8 year old gets 8 units glucagon."
62607425|NCT01680653|OTHER|Carbohydrates and Remote Monitoring|"Subjects glucose data are remotely monitored at night using the University of Virginia (UVA) Diabetes Assistant (DiAs) Android Platform. Study staff intervenes with a fingerstick blood glucose measurement when sensor value falls below 70mg/dL. If fingerstick value is less than 70 mg/dL, hypoglycemic treatment is administered as below.~Administration of carbohydrate per camp protocol to treat nocturnal hypoglycemia. Expected treatment is 15-45g."
62607426|NCT01680653|OTHER|Carbohydrates No Remote Monitoring|"Subjects wear a continuous glucose monitor for their own use, but they are not remotely monitored.~If hypoglycemia occurs and is acknowledged through standard camp protocol it will be treated with standard camp protocol administration of carbohydrates. Expected treatment is 15g-45g."
62607427|NCT01680653|OTHER|Mini-Glucagon and No Remote Monitoring|"Subjects wear a continuous glucose monitor for their own use, but they are not remotely monitored.~If hypoglycemia occurs and is acknowledged through standard camp protocol it will be treated with mini-glucagon.~Administer mini-glucagon as treatment for nocturnal hypoglycemia. Administer 0.01 cc per number of years in age via insulin syringe, subcutaneously. This amounts to 1 unit per age, for example: an 8 year old gets 8 units glucagon."
62607428|NCT04663425||Sleeve gastrectomy operation|Outcome of patients that underwent sleeve gastrectomy with BMI greater than 60.
62607429|NCT04663425||Gastric bypass operation|Outcome of patients that underwent gastric bypass with BMI greater than 60.
62607430|NCT04663425||Gastric Band operation|Outcome of patients that underwent gastric banding with BMI greater than 60.
62829526|NCT02706977|OTHER|Age-Matched Controls|Participants will serve as age-matched controls for participants with diabetes. This group will participate in the baseline, week 2, and week 4 visits only.
62829527|NCT01697670|EXPERIMENTAL|Photodynamic therapy with Gliolan|Intervention: Laser light illumination with a cylindrical light diffuser (Model RD, Medlight SA) is performed 3 hours after administration of 15 mg/kg 5-aminolevulinic acid (5-ALA, Gliolan)
62047475|NCT03645759|EXPERIMENTAL|I'm Whole|This arm will receive 6 behavioral health treatment sessions that focus on stroke self-management, psychological distress and social re-integration. Treatments will occur weekly. They will also receive 3 assessments at 0, 6, and 12 weeks.
62047476|NCT03645759|ACTIVE_COMPARATOR|Education + usual care|This arm will only receive the standard usual care for stroke self-management provided by the Michael E. Debakey VA Medical facility and will receive 6 brief health education calls unrelated to stroke or psychological distress.
62047477|NCT04128644|OTHER|Standard of care+Thoughts & health|12 sessions of Thoughts \& Health. Baseline questionnaires and follow up assessments
62047478|NCT04128644|OTHER|Standard of care|Baseline questionnaires and follow up assessments, intervention as usual Student Health
62047479|NCT00558311|EXPERIMENTAL|Clazosentan|A continuous intravenous infusion of clazosentan was started within 56 hours post-aSAH and was scheduled to continue during the hospitalization until Day 14 post-aSAH, or at least until Day 10.
62249866|NCT06494215|OTHER|Pressure Support Variation|Patients shall be submitted to pressure support variation in a randomly assigned manner. First 30 minutes after plethysmogram stabilization shall be recorded at clinical pressure support. Next, a blood gas sample shall be collected by a nurse or a physician, and three inspiratory pauses of at least 2 seconds shall be performed in between eight respiratory cycles. Next three expiratory pauses shall be performed in between eight respiratory cycles. All data shall be recorded and analysed offline. Subsequently the same sequence of events shall be performed at a 50% higher pressure support and at a 50% lower pressure support. The sequence in which this will happen shall be randomly assigned (first lower PS vs higher PS or first higher PS vs lower PS).
62439692|NCT04511364|EXPERIMENTAL|AGN1 treated patients|Patients have been treated with the AGN1 LOEP kit in AgNovos study PST-EU-101.1. An X-ray and DXA scan are performed at 24 and 60 months post AGN1 LOEP treatment.
62439693|NCT03715595|EXPERIMENTAL|SSDM group|The patients in will use the SSDM at home every month for one year.
62607431|NCT04128891|EXPERIMENTAL|Sacubitril/Valsartan|30 participants to be administered Sacubitril/Valsartan (Entresto) tablets, minimum dose of 49/51mg or maximum dose of 97/103 mg twice daily for the duration of the study (two years).
62607432|NCT04128891|ACTIVE_COMPARATOR|Valsartan|30 participants to be administered Valsartan tablets, minimum dose 80 mg or maximum dose of 160 mg twice daily for the duration of the study (two years).
62439694|NCT03715595|NO_INTERVENTION|Control group|The patients will receive the conventional therapy for half a year. After half a year, all the patients will use the SSDM at home monthly for half a year.
62439695|NCT04551079|EXPERIMENTAL|TAK-994 Dose A+ Placebo + TAK-994 Dose B|TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 Dose B tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
62047480|NCT00558311|PLACEBO_COMPARATOR|Placebo|A continuous intravenous infusion of placebo-matching clazosentan was started within 56 hours post-aSAH and was scheduled to continue during the hospitalization until Day 14 post-aSAH, or at least until Day 10.
62047481|NCT00136955|EXPERIMENTAL|irinitecan/cisplatin|experimental arm consists of patients who receive irinotecan/cisplatin
62047482|NCT05374226|EXPERIMENTAL|JS019 0.3 mg/kg|repeat dose every 21 days up
62047483|NCT05374226|EXPERIMENTAL|JS019 1 mg/kg|repeat dose every 21 days up
62047484|NCT05374226|EXPERIMENTAL|JS019 3 mg/kg|repeat dose every 21 days up
62047485|NCT05374226|EXPERIMENTAL|JS019 10 mg/kg|repeat dose every 21 days up
62047486|NCT06145243|ACTIVE_COMPARATOR|Visual brochure based resistive home exercise group,|In the 8-week exercise training, the exercise resistance of the patients will start with 60-70% according to1 Repetition Maximum in the first 4 weeks and will be increased to 70-80% according to 1 Repetition Maximum in the last 4 weeks according to the American College of Sports Medicine safe exercise intensity guideline for elderly individuals.
62249867|NCT02774616|OTHER|Ilivia ICD Family|Implant of the new Ilivia ICD Family. Device measurements, pre-defined programming and Adverse Event Reporting
62439696|NCT04551079|EXPERIMENTAL|TAK-994 Dose B + TAK-994 Dose A + Placebo|TAK-994 Dose B tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
62249868|NCT02774616|OTHER|Plexa ICD lead|Implant of the new Plexa ICD lead. Device measurements and Adverse Event Reporting
62249869|NCT02774616|OTHER|Ilivia ICD and Plexa lead|Implant of the new Ilivia ICD Family and the new Plexa lead. Device measurements, pre-defined programming and Adverse Event Reporting
62249870|NCT00731055|EXPERIMENTAL|Intervention 1|"Each participant participates in 4 consecutive interventions in random order.~1. Placebo, 1 capsule before the session~2. 0.5 mg varenicline, 1 capsule before the session 3.1 mg varenicline, 1 capsule before the session~4. 2 mg varenicline, 1 capsule before the session"
62439697|NCT04551079|EXPERIMENTAL|Placebo + TAK-994 Dose B+ TAK-994 Dose A|TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 Dose B tablets orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
62439698|NCT03119532|EXPERIMENTAL|Receive feedback email|Anesthesia care providers who receive monthly feedback emails on the participants specific quality measures
62439699|NCT03119532|NO_INTERVENTION|Did not receive feedback email|Anesthesia care providers who did NOT receive monthly feedback emails on the participants specific quality measures
62439700|NCT06438783|EXPERIMENTAL|1200mg of TQB2928 injection +Anlotinib|21 days as a treatment cycle.
62439701|NCT06438783|EXPERIMENTAL|1800mg of TQB2928 injection+Anlotinib|21 days as a treatment cycle.
62439702|NCT02400905|EXPERIMENTAL|BioMimics 3D Vascular Stent|Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Vascular Stent System
62439703|NCT01277328||Cohort|Cohort
62047487|NCT06145243|ACTIVE_COMPARATOR|Video-based resistive home exercise group|In the 8-week exercise training, the exercise resistance of the patients will start with 60-70% according to 1 Repetition Maximum in the first 4 weeks and will be increased to 70-80% according to 1 1 Repetition Maximum in the last 4 weeks according to the American College of Sports Medicine safe exercise intensity guideline for elderly individuals.
62047488|NCT06145243|EXPERIMENTAL|Supervised resistance exercise group|In the 8-week exercise training, the exercise resistance of the patients will start with 60-70% according to 1 Repetition Maximum in the first 4 weeks and will be increased to 70-80% according to 1 Repetition Maximum in the last 4 weeks according to the American College of Sports Medicine safe exercise intensity guideline for elderly individuals.
62439704|NCT05781477|EXPERIMENTAL|Bmum GROUP|Mothers in this group were given supportive breastfeeding support with web based
62439705|NCT05781477|NO_INTERVENTION|control group|Mothers in the control and intervention groups were given standard care based on the Baby-Friendly Hospital Intervention Standard.
62439706|NCT02468661|EXPERIMENTAL|INC280 200mg BID + ERL 150mg QD|Subjects who took INC280 200mg twice a day (BID) in combination with erlotinib (ERL) 150mg one a day (QD)
62439707|NCT02468661|EXPERIMENTAL|INC280 400mg BID + ERL 150mg QD|Subjects who took INC280 400mg twice a day (BID) in combination with erlotinib (ERL) 150mg one a day (QD)
62047489|NCT03949166|NO_INTERVENTION|Fasting|After completion of an epidural block patients that agreed to participate in the study and were randomised to the fasting arm will be allowed to drink water and clear fluids during labor and delivery as accepted by the institute protocol.
62047490|NCT03949166|EXPERIMENTAL|Eating|After completion of an epidural block patients that agreed to participate in the study and were randomized to the eating arm will be allowed to eat during their labor and delivery. They will be provided with the list of food that was approved and accepted by the anesthesia team. They will be asked to try eating every 2 hours but if they feel lack of need to eat or any side effects preventing them to eat they can choose not to eat. When reaching full dilatation of 10cm they will ber asked to stop eating.
62249871|NCT00731055|EXPERIMENTAL|Intervention 2|Each participant participates in 4 consecutive interventions in random order. 1.0.5 mg varenicline, 1 capsule before the session 2. 1 mg varenicline, 1 capsule before the session 3.2 mg varenicline, 1 capsule before the session 4. Placebo, 1 capsule before the session
62249872|NCT00731055|EXPERIMENTAL|Intervention 3|Each participant participates in 4 consecutive interventions in random order. 1.1 mg varenicline, 1 capsule before the session 2. 2 mg varenicline, 1 capsule before the session 3.Placebo, 1 capsule before the session 4. 0.5 mg varenicline, 1 capsule before the session
62249873|NCT00731055|EXPERIMENTAL|Intervention 4|Each participant participates in 4 consecutive interventions in random order. 1.2 mg varenicline, 1 capsule before the session 2. Placebo, 1 capsule before the session 3. 0.5 mg varenicline, 1 capsule before the session 4. 1 mg varenicline, 1 capsule before the session
62249874|NCT05320562|NO_INTERVENTION|Control group|Participants underwent 3 exercise sessions for 60 minutes each. Exercise program was created to improve range of motion and muscle strength. Participants executed active exercise in lying, sitting, and standing positions, isometric exercise, exercise with resistance band. All exercises were repeated 12 times in 3 sets and depending on the capacity of the subject. Breaks between sets 10 sec.
62249875|NCT05320562|SHAM_COMPARATOR|Sham taping|Participants underwent 3 exercise sessions for 60 minutes each. Exercise program was created to improve range of motion and muscle strength. Participants executed active exercise in lying, sitting, and standing positions, isometric exercise, exercise with resistance band. All exercises were repeated 12 times in 3 sets and depending on the capacity of the subject. Breaks between sets 10 sec.
62249876|NCT05320562|EXPERIMENTAL|Kinesio taping|Participants underwent 3 exercise sessions for 60 minutes each. Exercise program was created to improve range of motion and muscle strength. Participants executed active exercise in lying, sitting, and standing positions, isometric exercise, exercise with resistance band. All exercises were repeated 12 times in 3 sets, 10 s breaks between sets.
62249877|NCT04444960||Intracoronary physiology and imaging-guided group|
62439708|NCT06442683|EXPERIMENTAL|Simulation group|Theorical training, simulation-based training and bedside training
62439709|NCT06442683|NO_INTERVENTION|Control group|Theorical and bedside training
62249878|NCT04444960||Angiography-guided group|
62249879|NCT05199675|EXPERIMENTAL|Digital Peer Support Training Program|The intervention arm will undergo bite size modules on the four active ingredients of youth mental well-being-specifically, Mattering, selfhood, compassion and mindfulness, which will be delivered through training workshops, simulation activities, and homework assignments. The pre-post with control evaluation design will be utilized to evaluate program outcomes. Fidelity will be the primary outcome assessed to demonstrate the effectiveness of the digital peer support training program. It will be measured by the extent to which adolescents' responses to real-cases of peer disclosure indicate Mattering, selfhood, compassion and mindfulness. Reach, acceptability, cost-effectiveness, and adolescent self-reported psychological well-being will be assessed as secondary outcomes. Cost-effectiveness analysis will inform the development of a scalability and sustainability plan.
62249880|NCT05199675|ACTIVE_COMPARATOR|Waitlist control for Digital Peer Support Training Program|Students in the wait-list control arm will receive the training program after the conclusion of the trial with the intervention arm. The pre-post with control evaluation design will be utilized to evaluate program outcomes. The intervention arm will undergo bite size modules on the four active ingredients of youth mental well-being-specifically, Mattering, selfhood, compassion and mindfulness, which will be delivered through training workshops, simulation activities, and homework assignments.The same set of primary and secondary outcomes assessed in the experimenter arm will be included. Specifically, fidelity will be the primary outcome assessed. Reach, acceptability, cost-effectiveness, and adolescent self-reported psychological well-being will be assessed as secondary outcomes.
62607433|NCT02930525|ACTIVE_COMPARATOR|Standard care|Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
62047491|NCT04472286||Pediatric Cancer Survivors|Children and adolescents who have completed treatment of for acute lymphoblastic leukemia (ALL) and lymphoma.
62047492|NCT00746122|OTHER|Open repair|Immediate Open Surgery
62047493|NCT00746122|EXPERIMENTAL|Endovascular strategy|Endovascular strategy involves immediate computed tomography (CT) and emergency Endovascular aneurysm repair (EVAR), with open repair for patients anatomically unsuitable for EVAR
62047494|NCT01811212|EXPERIMENTAL|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62607434|NCT02930525|EXPERIMENTAL|High Flow nasal cannula|Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
62607435|NCT04787328|EXPERIMENTAL|HA121-28 tablets|Patients will receive HA121-28 tablets at 450 mg once daily (QD) for 21 days on a 28-day treatment cycle.
62607436|NCT00162149|NO_INTERVENTION|A1|
62607437|NCT00162149|EXPERIMENTAL|A2|
62607438|NCT00162149|EXPERIMENTAL|A3|
62607439|NCT00162149|NO_INTERVENTION|B1|
62607440|NCT05708183||Intervention|Districts that have substituted MMS for IFA as part of routine antenatal care
62607441|NCT05708183||Comparison|Districts that continue to deliver IFA as part of routine antenatal care
62607442|NCT00005601|EXPERIMENTAL|rituximab+dexamethasone+cisplatin+cytarabine+sargramostim|"Patients receive rituximab IV on days 1, 8, 15, and 22 for the first course only. Patients receive dexamethasone orally or IV on days 1-4, cisplatin IV continuously for 24 hours on day 1, cytarabine IV over 3 hours every 12 hours for 2 doses on day 2, and sargramostim (GM-CSF) subcutaneously on days 3-12 or until blood counts recover. Chemotherapy repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
62607443|NCT03104218|EXPERIMENTAL|tDCS group|tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training). The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles), contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
62607444|NCT03104218|SHAM_COMPARATOR|Placebo group|"The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition. The parameters on the tDCS will be set-up by a research assistant before each session. The treating physiotherapist will not have access to the control board of the tDCS."
62607445|NCT04302480|EXPERIMENTAL|Alternative smoking products (ASP)|
62607446|NCT04302480|ACTIVE_COMPARATOR|Sugar-sweetened beverages (SSB)|
62607447|NCT02633566|ACTIVE_COMPARATOR|Functional plantar orthoses|Functional plantar orthoses in polypropylene with Medial Heel Skive technique
62607448|NCT02633566|PLACEBO_COMPARATOR|Placebo plantar orthoses|Plantar orthoses made in Ethil Vinyl Acetate (22º Shore) without correction of the pronation
62607449|NCT06301009|EXPERIMENTAL|AI-CAC arm|All patients included in the study and undergoing AI-CAC calculation on a chest x-ray
62607450|NCT01500967|ACTIVE_COMPARATOR|Traction|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
62607451|NCT01500967|EXPERIMENTAL|Manipulations|Shi-style manipulations is a cervical manipulation for cervical radiculopathy.This manipulation is a kind of traditional Chinese massage and it can dredge the meridians. Patients are treated every day for 30 minutes. Seven times as one course and totally there are two courses. 3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
62607452|NCT02673268|EXPERIMENTAL|Patients with breast cancer|
62607453|NCT00630084|ACTIVE_COMPARATOR|A|40 naïve CHC patients concomitant with malignancy other than hepatocellular carcinoma
62607454|NCT00630084|ACTIVE_COMPARATOR|B|80 naïve CHC patients without malignancy
62607455|NCT01982838|ACTIVE_COMPARATOR|Group E|Epidural de novo technique
62607456|NCT01982838|ACTIVE_COMPARATOR|Group BF|Combined spinal epidural (CSE) technique with intrathecal 0.5% Bupivicaine 2.5mg + Fentanyl 15mcg
62249881|NCT04983368|EXPERIMENTAL|Xanamem® 5 mg|Oral Xanamem® capsules 5 mg, to be administered once daily
62607457|NCT01982838|ACTIVE_COMPARATOR|Group F|Combined spinal epidural (CSE) technique with intrathecal fentanyl 25mcg
62607458|NCT04202315|NO_INTERVENTION|Control|Standard of care, no Virtual Reality
62607459|NCT04202315|EXPERIMENTAL|Virtual Reality|Standard of care plus Virtual Reality
62607460|NCT03955965||Emergency patients with medication reconciliation|All patients who beneficiated from medication reconciliation in the emergency department between November 2017 and April 2018
62607461|NCT06429137|EXPERIMENTAL|BI 3731579 dose group 1|
62607462|NCT06429137|EXPERIMENTAL|BI 3731579 dose group 2|
62607463|NCT06429137|EXPERIMENTAL|BI 3731579 dose group 3|
62607464|NCT06429137|EXPERIMENTAL|BI 3731579 dose group 4|
62607465|NCT06429137|EXPERIMENTAL|BI 3731579 dose group 5|
62607466|NCT06429137|EXPERIMENTAL|BI 3731579 dose group 6|
62607467|NCT06429137|EXPERIMENTAL|BI 3731579 dose group 7|
62607468|NCT06429137|EXPERIMENTAL|BI 3731579 dose group 8|
62607469|NCT06429137|PLACEBO_COMPARATOR|Placebo|
62607470|NCT06326684|PLACEBO_COMPARATOR|Placebo|Subjects will be treated daily with an oral placebo.
62607471|NCT06326684|EXPERIMENTAL|Suvorexant Dose 1|Subjects will be treated daily with oral suvorexant (10 mg).
62607472|NCT06326684|EXPERIMENTAL|Suvorexant Dose 2|Subjects will be treated daily with oral suvorexant (20 mg).
62607473|NCT02507843|ACTIVE_COMPARATOR|Vitamin D group|Cholecalciferol will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
62249882|NCT04983368|EXPERIMENTAL|Xanamem® 10 mg|Oral Xanamem® capsules 10 mg, to be administered once daily
62607474|NCT02507843|PLACEBO_COMPARATOR|Placebo group|Placebo will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
62607475|NCT02394236|EXPERIMENTAL|Continuous exercise training|The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
62047495|NCT01919203|EXPERIMENTAL|group R|The starting dose of remifentanil is 0.5μg/kg and a step size was 0.05μg/kg.
62047496|NCT02448251|EXPERIMENTAL|single dose per day (QD)|Phase I Arm 1: AC0010MA orally taking once daily, starting from 100 mg per day.
62439710|NCT01821027|EXPERIMENTAL|Canagliflozin + simvastatin|Each volunteer will receive a single dose of simvastatin on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 2 through 6. On Day 7 volunteers will receive a single dose of simvastatin in combination with a single dose of canagliflozin.
62439711|NCT04653870|EXPERIMENTAL|cyriax manipulation|cyriax manipulation have three types of classes, rotation, extension and anti-deviation, which is further divided into subclasses. On the inferior level of lumber spine L4-L5 and L5-S1rotation intervention of manipulation are capable of having striking effects of decreasing herniation. First of all we have to perform the simple 'stretch' on lumber spine, which is being the little rotation pressure applied on the body. The patient position of the body is in side lying with the effected side upward so that the outside part of the joint are separated easily on the involved side. After that, whenever it is essential by making use of femur as a rigid bar or support, this maneuver is go along with powerful rotation technique.
62439712|NCT04653870|EXPERIMENTAL|lumber decompresion|Spinal decompression therapy has been developed a treatment without surgery for the prolapsed disc and deteriorative spinal disc disease one of the considerable reason for low back pain. This noninvasive interventional treatment for herniated disc and deteriorative disc diseases operated on the principle of remarkably decreasing the pressure on the disc between vertebras.
62047497|NCT02448251|EXPERIMENTAL|two doses per day (BID)|Phase I Arm 2: AC0010MA orally taking twice daily, starting from 200 mg per day (100 mg BID). Arm 2 will be initiated once the drug plasma t1/2 is 10 hours or below in the first dose cohort (100 mg QD).
62607476|NCT02394236|EXPERIMENTAL|interval exercise training|The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
62607477|NCT02671019|EXPERIMENTAL|Internet-based treatment|A five-module Internet-based treatment program for harmful alcohol use (including therapist support) based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
62607478|NCT02671019|ACTIVE_COMPARATOR|Face-to-face treatment|Same treatment content as in the Internet-based treatment delivered via face-to-face treatment sessions in specialized addiction treatment.
62047498|NCT04158011||CNS ALL at lymphodepletion|Patients with active CNS leukemia at the time of lymphodepletion
62047499|NCT04158011||CNS ALL at inclusion|Patients who were referred to CAR T-cells with CNS disease, which was cleared by the time of lymphodepletion
62047500|NCT02120027|EXPERIMENTAL|Ibodutant 10 mg|Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will continue on ibodutant 10 mg for additional 28 weeks of treatment via mock-re-randomisation at week 25 .
62047501|NCT02120027|PLACEBO_COMPARATOR|Placebo|Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the placebo arm will be re-randomised at week 25 in a 1:1 ratio to ibodutant or placebo for additional 28 weeks of treatment.
62047502|NCT06472401|EXPERIMENTAL|Integrated Learning Support System (ILSS)|For the Experimental Group, in addition to the Standard Learning Model (MPA), an Integrated Learning Support System (ILSS) will be added, consisting of strategies to achieve different learning styles
62047503|NCT06472401|ACTIVE_COMPARATOR|Standard Learning Model (SLM)|In the Control Group, students will be submitted to the Standard Learning Model (SLM) during the preparation stage for the immersive simulated training, consisting of: use of expository video lessons, participation in doubt forums, reading and critical analysis of scientific articles.
62249883|NCT04983368|PLACEBO_COMPARATOR|Placebo|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily.
62249884|NCT02937025|EXPERIMENTAL|Left Atrial Appendage Closure Device Group|Device:LAmbre Left Atrial Appendage Occluder（Shanghai Push Medical Device Technology CO.td） to close the left atrial appendage
62439713|NCT04008342|EXPERIMENTAL|Intervention group|The intervention group (IG) was submitted to 16 multisensory sessions that followed the protocol.
62607479|NCT02334176|ACTIVE_COMPARATOR|single injection|Axillary plexus block performed with single injection dorsally to the artery
62607480|NCT02334176|ACTIVE_COMPARATOR|Double injection|Axillary plexus block performed with 2 injections: one over musculocutaneous nerve the second one dorsally to the artery
62607481|NCT00971061|EXPERIMENTAL|MSPI|Molteno single-plate implant
62607482|NCT00971061|ACTIVE_COMPARATOR|AVI|Ahmed valve implant
62607483|NCT03514706|EXPERIMENTAL|Volume controlled ventilation|Group V: Patients will receive volume controlled mechanical ventilation. (Vt 7ml/kg ideal body weight).
62047504|NCT06268158|EXPERIMENTAL|Intervention group|Patients in the experimental group will wear an eye patch after 22:00, when clinical interventions are less frequent, and will be listened to calming music once a day for 1 hour for 3 days.
62047505|NCT06268158|NO_INTERVENTION|Control group|No treatment will be performed on patients in the control group outside of their clinical routine.
62249885|NCT03975270|EXPERIMENTAL|Sintilimab in Combination With Nab-paclitaxe|Sintilimab 200 mg intravenous drip, first day Nab-paclitaxe120 mg/m2, intravenous drip, first day and eighth day
62249886|NCT02749032|ACTIVE_COMPARATOR|Vildagliptin - stratum diet/exercise|"Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.~Mixed meal test were performed in the morning after an overnight fast."
62607484|NCT03514706|EXPERIMENTAL|Pressure controlled ventilation|Group P: Patients will receive pressure controlled mechanical ventilation. (to achieve Vt 7 ml/kg ideal body weight, Pmax 30 cmH2O)
62607485|NCT06029153|EXPERIMENTAL|Middle meningeal artery embolization|Middle meningeal artery embolization with coil.
62607486|NCT00565669|EXPERIMENTAL|Blink Tears|
62607487|NCT00565669|EXPERIMENTAL|Systane|
62607488|NCT02707042|OTHER|Group A|Control
62607489|NCT02707042|OTHER|Group B|Amoxicillin
62607490|NCT02707042|OTHER|Group C|Azithromycin
62607491|NCT06289686|EXPERIMENTAL|BioEnthesis|Allogenic, acellular, biphasic allograft (BioEnthesis)
62607492|NCT06289686|ACTIVE_COMPARATOR|Standard of Care|Standard rotator cuff repair (suture and anchor based technique)
62607493|NCT03632226||1|Healthy Volunteers
62607494|NCT03528057|ACTIVE_COMPARATOR|Group 1|Patients undergoing RALPN with the use of HAs by a surgeon.
62607495|NCT03528057|NO_INTERVENTION|Group 2|Patients undergoing RALPN without the use of HAs by a surgeon
62607496|NCT00546455|EXPERIMENTAL|A|Subjects in this cohort will be given Fenretinide
62607497|NCT00546455|PLACEBO_COMPARATOR|B|Subjects in this cohort will be given placebo.
62607498|NCT02842229||Patients with Haematologic Neoplasms|"Patients with Myelodysplastic Syndromes (MDS), any IPSS (International Prognostic Scoring System) risk, or Acute Myeloid Leukemia (AML) who participated in the Geriatric Assessment in Haematology (GAH) study(CEL-GAH-2011-01).~Patients with Multiple Myeloma (MM), symptomatic or asymptomatic who participated in the Geriatric Assessment in Haematology (GAH) study (CEL-GAH-2011-01).~Patients with Chronic Lymphocytic Leukemia who participated in the Geriatric Assessment in Haematology (GAH) study (CEL-GAH-2011-01)."
62607499|NCT01848509|NO_INTERVENTION|Without telemonitoring|Without teletransmission of alerts
62607500|NCT01848509|EXPERIMENTAL|With telemonitoring|With teletransmission of alerts
62607501|NCT00114738|EXPERIMENTAL|EPOCH-R + Bortezomib|Combo chemo etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH)-Rituxan (R) + Bortezomib (B)
62607502|NCT00114738|EXPERIMENTAL|"Bortezomib window"|Bortezomib alone
62607503|NCT00114738|ACTIVE_COMPARATOR|Bortezomib maintenance|Bortezomib maintenance
62607504|NCT00114738|OTHER|Observation|At the beginning of part C patients are randomized to receive bortezomib maintenance or observation without bortezomib.
62607505|NCT05127824|EXPERIMENTAL|HLA-A2 postive|The study will include 21 participants over the 18 years of age with newly diagnosed, clinically localized clear cell renal cell carcinoma, planned for surgical resection with curative intent. Participants receiving vaccine much be HLA-A2 positive.
62607506|NCT05127824|NO_INTERVENTION|HLA-A2 negative|Up to 21 additional participants who screen as HLA-A2 negative will be enrolled as non-treatment controls. These participants will not be required to undergo blood collection or study procedures
62607507|NCT04775576|ACTIVE_COMPARATOR|Group 1|This group will have fluid theraphy due to conventional methods. The participants in this group will have 8-10 ml/kg/hour cristalloid infusion. If the mean arterial pressure (MAP) is \<65 mmHg or the decrease in MAP is more than 20%, 250 ml iv colloid will be applied. If the decrease in MAP continues despite the colloid bolus or if the MAP is below 65 mmHg, noradrenaline infusion will be started.
62607508|NCT04775576|ACTIVE_COMPARATOR|Group 2|Patients in the PVI group will be started on maintenance fluid therapy at 2-3 ml / kg / hour. In addition to standard monitoring, if PVI is \<13% and OAB≥65mmHg in measurements made with PVI, current fluid therapy will continue. If PVI is \<13% and MAP \<65 mmHg, noradrenaline infusion will be started. If PVI is\> 13% and OAB≥65 mmHg, 250 ml iv colloid bolus will be administered, and iv colloid bolus will be continued until the PVI is \<13% in the 5-minute follow-ups. If PVI\> 13% and MAP \<65 mmHg, patients should receive 250 ml i.v. colloid infusion will be given, if MAP \<65mmHg continues in 5 minutes follow-up, 250 ml i.v. Colloid and noradrenaline infusion will be started and repeated until the OAB≥65 mmHg and PVI \<13%.
62607509|NCT05878665|EXPERIMENTAL|Double low-dose CT|Weight-adjusted low-dose contrast media paired with low-radiation dose abdomen CT
62607510|NCT02086448|NO_INTERVENTION|Obese, SDB negative|No intervention, observational comparison group
62607511|NCT02086448|ACTIVE_COMPARATOR|Obese, SDB postive, CPAP|Therapeutic CPAP
62047506|NCT01977300|PLACEBO_COMPARATOR|Mood stabilizer & Placebo|Patients will receive lithium or valproate plus placebo for 52 weeks (risperidone or olanzapine tapering will begin on the day of randomization with discontinuation of the drug within 2 weeks).
62607512|NCT02086448|SHAM_COMPARATOR|Obese, SDB postive, sham-CPAP|Sham (non-therapeutic) CPAP
62607513|NCT02086448|OTHER|Obese, SDB postive, sleep hygiene|Sleep hygiene information and local sleep resources
62607514|NCT05083676|EXPERIMENTAL|Acceset Intervention|The qualified participants (seekers) will be randomly allocated into two arms. Arm 1 (n = 50) seekers will engage with the Acceset platform for a period of 3 weeks, together with befrienders (n = 30) and moderators (n = 30). Both seekers and befrienders will be monitored using a questionnaire battery listed (including help seeking behaviors beyond the Acceset platform) at 4 time points: baseline (before the intervention), 3 weeks (the end of the intervention), 6 weeks and 9 weeks (to measure carry over effects).
62607515|NCT05083676|ACTIVE_COMPARATOR|waitlist for Acceset intervention|Arm 2 (n = 50) a control group will be placed on a waitlist for Acceset intervention. These individuals will be age and gender matched with the intervention group (i.e., arm 1). Their mental well-being, as well as their help seeking behavior, at the same time points and via the same questionnaire battery will be compared with those in arm 1.
62607516|NCT04888845|ACTIVE_COMPARATOR|Structured interview and Safety Plan|In the structured interview approach, clinicians ask a series of predetermined questions and/or assess a specified set of risk and protective factors, typically using a checklist-based approach. The safety plan is a written, prioritized list of coping strategies and resources for reducing suicide risk.
62607517|NCT04888845|ACTIVE_COMPARATOR|Structured interview and Crisis Response Plan|In the structured interview approach, clinicians ask a series of predetermined questions and/or assess a specified set of risk and protective factors, typically using a checklist-based approach. Crisis response planning intervention teaches a range of coping strategies and provides support that can reduce suicide attempts and ideation.
62047507|NCT01977300|EXPERIMENTAL|"'24 week  arm"|Continuation of the lithium or valproate plus risperidone or olanzapine for 24 weeks followed by mood stabilizer plus placebo for another 28 weeks. Dosages: 1 to 6 mg of risperidone, 5 to 20 mg olanzapine.
62047508|NCT01977300|ACTIVE_COMPARATOR|"52 week arm"|Continuation of the atypical antipsychotic, risperidone or olanzapine, plus lithium or valproate for 52 weeks.
62607518|NCT04888845|ACTIVE_COMPARATOR|Narrative assessment and Safety Plan|"In the narrative assessment approach, clinicians ask patients to tell the story of their suicidal crisis. The safety plan is a written, prioritized list of coping strategies and resources for reducing suicide risk."
62829528|NCT05767749|EXPERIMENTAL|Lidocaine + epinephrine vs Ropivacaine|Each site of the nasal ala will be tested for normal sensation using sterile 30-gauge needles. Other eligibility criteria will be confirmed. Participants in this arm will receive an injection of 0.5ml of . Xylocaine + epinephrine 1:100,000 (lidocaine + epinephrine 1:100,000), buffered 1/10 with sodium bicarb into one side of the nose (nasal ala) and 0.5ml of Naropin (ropivacaine) 0.5% into the opposite nasal ala. Laterality of each anesthetic administration will be randomly assigned for each patient. Subjects will be evaluated for duration of effect of anesthesia every 15 minutes on both sides of the face, until the patient reports return of a sharp sensation upon the pinprick test.
62829529|NCT05767749|EXPERIMENTAL|Lidocaine + epinephrine vs Bupivacaine|Each site of the nasal ala will be tested for normal sensation using sterile 30-gauge needles. Other eligibility criteria will be confirmed. Participants in this arm will receive an injection of 0.5ml of lidocaine + epinephrine into one side of the nose (nasal ala) and 0.5ml of Marcaine (bupivacaine) 0.5% into the opposite nasal ala. Laterality of each anesthetic administration will be randomly assigned for each patient. Subjects will be evaluated for duration of effect of anesthesia every 15 minutes on both sides of the face, until the patient reports return of a sharp sensation upon the pinprick test.
62047509|NCT05307380||patients with pain|patients with acute postoperative or post-traumatic pain or chronic pain
62047510|NCT04573621|ACTIVE_COMPARATOR|Pelvic drain|Placement of a pelvic drain
62047511|NCT04573621|EXPERIMENTAL|No pelvic drain|No pelvic drain placed
62047512|NCT02038894|ACTIVE_COMPARATOR|Intubated with Sevoflurane (IS)|Anesthetic technique during (EGD)
62249887|NCT02749032|ACTIVE_COMPARATOR|Vildagliptin - stratum metformin|"Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.~Mixed meal test were performed in the morning after an overnight fast."
62249888|NCT02749032|ACTIVE_COMPARATOR|Sitagliptin - stratum diet/exercise|"The dosage of sitagliptin depended on the stratum defined by the background diabetes medication. In patients treated with diet and exercise (no other glucose-.lowering medication), sitagliptin was given as one 100 mg in the morning (15 minutes prior to breakfast or the test meal, on the last day of the treatment period), and a corresponding placebo tablet was administered in the evening (no temporal relation to dinner required).~Mixed meal test were performed in the morning after an overnight fast."
62249889|NCT02749032|ACTIVE_COMPARATOR|Sitagliptin - stratum metformin|"In patients treated with metformin, sitagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening.~Mixed meal test were performed in the morning after an overnight fast."
62249890|NCT02749032|PLACEBO_COMPARATOR|Placebo - stratum diet/exercise|"Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).~Mixed meal test were performed in the morning after an overnight fast."
62249891|NCT02749032|PLACEBO_COMPARATOR|Placebo - stratum metformin|"Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).~Mixed meal test were performed in the morning after an overnight fast."
62249892|NCT03342313|EXPERIMENTAL|healthy weight|BMI (kg/m2) ≥ 18.5 and \< 23
62439714|NCT04008342|NO_INTERVENTION|Control group|The control group (CG) received usual care with routine interventions and services in the LTC, such as bath, hygiene care, watching TV and so on.
62439715|NCT03429296|EXPERIMENTAL|Autohypnosis learning|In this arm, patients are taught autohypnosis during sessions in groups of 3 to 6 with a qualified hypnotherapist. Sessions are set every two weeks, for a total of 6 sessions. Individual sessions are possible for patients who missed a session.
62439716|NCT03429296|NO_INTERVENTION|Standard of care|In this arm, patients are not taught autohypnosis and are treated according to standard of care.
62439717|NCT03515785||Ph+ ALL Patients|Patients with Ph+ ALL being treated with Iclusig®.
62607519|NCT04888845|ACTIVE_COMPARATOR|Narrative assessment and Crisis Response Plan|"In the narrative assessment approach, clinicians ask patients to tell the story of their suicidal crisis. Crisis response planning intervention teaches a range of coping strategies and provides support that can reduce suicide attempts and ideation."
62829530|NCT05767749|EXPERIMENTAL|Ropivacaine vs Bupivacaine|Each site of the nasal ala will be tested for normal sensation using sterile 30-gauge needles. Other eligibility criteria will be confirmed. Participants in this arm will receive an injection of 0.5ml of Naropin (ropivacaine) 0.5% into one side of the nose (nasal ala) and 0.5ml of Marcaine (bupivacaine) 0.5% into the opposite nasal ala. Laterality of each anesthetic administration will be randomly assigned for each patient. Subjects will be evaluated for duration of effect of anesthesia every 15 minutes on both sides of the face, until the patient reports return of a sharp sensation upon the pinprick test.
62829531|NCT04524780|EXPERIMENTAL|left atrial appendage radiography|
62047513|NCT02038894|ACTIVE_COMPARATOR|Intubated with Propofol (IP)|Anesthetic technique during (EGD)
62439718|NCT00737321||2- Diabetics without wound (s)|These group of subject will be control arm, included who have good glycemic control diabetic with HbA1c 8.4 or lower and also without any open wounds. Samples will be collected.
62439719|NCT00737321||1-Subjects with diabetes with wound|This group of subjects will have wound and come for couple of follow up visits for saliva collection, biopsy collection and blood draw.
62439720|NCT05906264|NO_INTERVENTION|Pulmonary rehabilitation, Control|"for COPD patients, who have been trained with the pulmonary rehabilitation program~* Compliance will be checked by monitoring wearable device at one month~* Pulmonary function and symptom improvement effect will be checked at 3 months"
62439721|NCT05906264|ACTIVE_COMPARATOR|Pulmonary rehabilitation, Intervention|Compared to Control group, Intervention group will be provided with additional tele-intervention every week to check the compliance and encourage of the rehabilitation
62607520|NCT03084068|EXPERIMENTAL|Human umbilical cord allograft|Open Rotator Cuff Repair patched with human dehydrated umbilical cord allograft
62607521|NCT03084068|PLACEBO_COMPARATOR|Placebo Control|Open Rotator Cuff Repair with standard suture repair
62607522|NCT00792506|EXPERIMENTAL|ITF2357|Eligible patients had to be treated with weekly single doses of ITF2357 according to the above mentioned treatment plan.
62607523|NCT03285659|EXPERIMENTAL|Intervention: INDI Implementation|Primary care centres which will implement the collaborative (INDI) care model for depression
62829532|NCT04524780|EXPERIMENTAL|intracardiac echocardiography guidance|
62047514|NCT02038894|ACTIVE_COMPARATOR|Native Airway - no intubation|Anesthetic technique during (EGD)
62047515|NCT01143688|ACTIVE_COMPARATOR|albuterol inhaler|albuterol
62047516|NCT01143688|PLACEBO_COMPARATOR|placebo inhaler|placebo
62047517|NCT01143688|PLACEBO_COMPARATOR|placebo acupuncture|placebo
62047518|NCT03715205|EXPERIMENTAL|Cohort A: Melanoma|Participants with unresectable or metastatic melanoma receive 200 mg of pembrolizumab as an intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 cycles.
62047519|NCT03715205|EXPERIMENTAL|Cohort B: NSCLC|Participants with NSCLC who are either treatment naïve or have progressed after prior treatment receive 200 mg of pembrolizumab as an IV infusion every Q3W for up to 35 cycles.
62607524|NCT03285659|NO_INTERVENTION|Control: no INDI implementation|Primary care centres in which the collaborative care strategy INDI will not be implemented, but will be compared in terms of their clinical practice towards depression
62607525|NCT01315041|ACTIVE_COMPARATOR|"Pi medicine"|
62607526|NCT01315041|PLACEBO_COMPARATOR|Placebo|
62607527|NCT01007760|PLACEBO_COMPARATOR|Room air|
62047520|NCT01722942|ACTIVE_COMPARATOR|ICD group|ICD implantation will be performed according to the Institution protocol of each participating center; single-chamber devices are preferred and programming should prioritize the patient's own pace, avoiding ventricular stimulation.
62047521|NCT01722942|ACTIVE_COMPARATOR|Amiodarone Group|"Patients randomized for this group will receive amiodarone hydrochloride (once a day) according to the following regimen:~* Initial oral loading dose of 600 mg/day for 10 days on an outpatient basis;~* After the loading period, an oral dose between 200 and 400 mg/day should be maintained until study termination. The determination of the optimal maintenance dose will be left at the discretion of each investigator; this dose may be based on the therapeutic response on 24-hour Holter monitoring, resting heart rate (HR), side effects, prolonged corrected QT interval (QTc), etc. Dose adjustments will be allowed throughout the study period provided the maintenance dose is kept between 200 and 400 mg/day. If the patient cannot tolerate the minimum 200 mg/day dose, amiodarone should be discontinued permanently and treatment should be considered interrupted."
62249893|NCT03342313|EXPERIMENTAL|Overweight|BMI (kg/m2) ≥23 chewing 15 times and 50 times per bite
62607528|NCT01007760|ACTIVE_COMPARATOR|Low dose exposure second-hand smoke|
62047522|NCT00735995|EXPERIMENTAL|A|Individual CBT
62047523|NCT00735995|EXPERIMENTAL|B|Group CBT
62249894|NCT02739620|EXPERIMENTAL|NMES|Neuromuscular electrical stimulation (NMES) group
62249895|NCT02739620|NO_INTERVENTION|Control|Control group
62249896|NCT01727765|EXPERIMENTAL|Experimental|6 weeks of inspiratory muscle training, 6 days per week. The intensity of training will be equivalent to up to 50% of pre-training maximal inspiratory mouth pressure and will be adapted weekly to reflect the improvement in inspiratory muscle strength
62249897|NCT01727765|SHAM_COMPARATOR|Sham Comparator|6 weeks of sham inspiratory muscle training, 6 days per week. The intensity of training will be equivalent to 5% of pre-training inspiratory mouth pressure throughout the 6 week period.
62249898|NCT04869163|ACTIVE_COMPARATOR|red meat consumers|Consumes red meat 3 times a week
62607529|NCT01007760|ACTIVE_COMPARATOR|High dose exposure second-hand smoke|
62607530|NCT04384770||Group I (CT-SBRT)|Patients undergo 5 fractions of CT-guided SBRT over 14 days in the absence of disease progression or unacceptable toxicity.
62607531|NCT04384770||Group II (MRI-SBRT)|Patients undergo 5 fractions of MRI-guided SBRT over 14 days in the absence of disease progression or unacceptable toxicity.
62607532|NCT05559424|ACTIVE_COMPARATOR|POT/KISSING/POT (PKP)|"* SB rewiring is performed with the objective to cross distal stent struts (distal rewiring) through pullback technique.~* KBI is performed using short non-compliant balloons (balloon of MV sized in a 1:1 ratio with distal MV reference diameter and SB balloon sized in a 1:1 ratio with SB reference diameter), with sequential followed by simultaneous inflation.~* Final POT is performed at the same way as initial POT"
62607533|NCT05559424|ACTIVE_COMPARATOR|POT/SIDE/POT (PSP)|"* SB rewiring is performed with the objective to cross distal stent struts (distal rewiring) through pullback technique.~* SB dilatation is performed with a balloon sized 1:1 according to SB reference diameter.~* Final POT is performed at the same way as initial POT."
62607534|NCT06731595|NO_INTERVENTION|Standard of care|Usual standard of care post atrial fibrillation ablation.
62607535|NCT06731595|EXPERIMENTAL|Colchicine|0.6mg colchicine oral twice daily for 7 days.
62607536|NCT02259634|EXPERIMENTAL|Patient Navigation|Intensive Patient Navigation with Motivational Interviewing and Health Education for 8 months 18 month follow-up
62607537|NCT02259634|NO_INTERVENTION|Treatment as Usual|Case Management and Medical Care as provided by the Coming Home Program at Mount Sinai St. Luke's Institute of Advanced Medicine, Morningside Clinic
62607538|NCT02093390|EXPERIMENTAL|TAK-385 + fluconazole|TAK-385 40 mg, tablet, orally once on Day 1 and fluconazole 400 mg, tablet, orally on Day 6 then 200 mg, tablet, orally once daily on Days 7 to 9 followed by a single dose of TAK-385 in combination with fluconazole 200 mg on Day 10 then fluconazole 200 mg, tablet, orally once daily alone on Days 11 to 14.
62047524|NCT00735995|NO_INTERVENTION|C|Waiting-list control
62249899|NCT04869163|EXPERIMENTAL|non-red meat consumers|Consumes a non-red meat comparison product 3 times a week
62607539|NCT02093390|EXPERIMENTAL|TAK-385 + atorvastatin|TAK-385 40 mg, tablet, orally once on Day 1 and atorvastatin 80 mg, tablet, orally once daily on Days 6 to 9 followed by a single dose of TAK-385 in combination with atorvastatin 80 mg on Day 10 then atorvastatin 80 mg, tablet, orally once daily alone on Days 11 to 14.
62047525|NCT04841941|EXPERIMENTAL|single arm|G4 Multifocal soft contact lens with a 54% water content for presbyopia
62249900|NCT04673591|EXPERIMENTAL|Tregalizumab|
62249901|NCT04673591|PLACEBO_COMPARATOR|Matched placebo|
62607540|NCT05061017|EXPERIMENTAL|Pixatimod (PG545) + Nivolumab|"Pixatimod : 25 mg IV, weekly~Nivolumab: 480 mg IV, Q4 weeks~Cohort 1 (MSS CRC)"
62607541|NCT05061017|EXPERIMENTAL|Pixatimod (PG545) + Nivolumab + cyclophosphamide|"Pixatimod : 25 mg IV, weekly~Nivolumab: 480 mg IV, Q4 weeks~cyclophosphamide: 50 mg PO twice daily (Day 1-Day 7; Day 15-Day 21) with a 7-day drug free interval (Day 8-Day 14 and Day 22-Day 28)~Cohort 2 (PD-1 R/R melanoma) and Cohort 3 (PD-1 R/R NSCLC)"
62607542|NCT02467894|EXPERIMENTAL|Group-based Care|Participants who are randomized to group-based care will attend monthly outpatient clinic visits as part of a group of 8-10 patients with CKD and hypertension.
62607543|NCT02467894|NO_INTERVENTION|Usual Care|Participants who are randomized to usual care will see their provider on clinic days when there is no group meeting.
62607544|NCT05196906||Modified Broström operation group|Patients who accept a modified Broström operation
62607545|NCT05196906||Anatomic reconstruction operation group|Patients who accept an anatomic reconstruction
62607546|NCT01549262|ACTIVE_COMPARATOR|Standard Incubator|
62607547|NCT01549262|EXPERIMENTAL|ESD Time-lapse Monitoring system|
62607548|NCT06424587|EXPERIMENTAL|Music intervention group|In addition to the routine practice of the clinic, the pediatric patients in this group listened to music through headphones for 20 minutes just before the procedure to reduce the child's anxiety and fear. The therapeutic effect of music was used. Before the study, children between the ages of 6 and 12 who were inpatients at the clinic were asked what music they most liked to listen to, what kind of music they liked, and what their favorite artists and songs were. The music was selected based on the children's answers. In addition, the researcher added children's songs by a musician named Banu Kanıbelli.
62607549|NCT06424587|NO_INTERVENTION|Control Group|Children were verbally informed about the treatment process and invasive procedures from the day they were diagnosed with the disease. The children in this group were verbally informed by the nurse in charge of the clinic about the intrathecal chemotherapy treatment and why it was performed
62439722|NCT03357432|EXPERIMENTAL|effects of gelatin, collagen on PINP levels|The study is aimed at determining if the same dose of gelatin, hydrolyzed collagen (administered in a beverage form) or a mixture gelatin/hydrolyzed collagen (administered in a gummy form) with a standard dose of vitamin C (50 mg) has a similar effect a marker of collagen synthesis (PINP). In a randomized, crossover design subjects consume 3 different nutritional supplements: (a) 15 of gelatin, (b) 15 hydrolyzed collagen (administered in a beverage form) or (c) 15 g of gelatin/hydrolyzed collagen mixture all with a standard dose of vitamin C (50 mg) 1 hour prior to exercise stimulus (6 minutes of jump rope). A baseline assessment with only the jump rope and no intervention will also be conducted prior to the interventions. Each intervention will be separated by a \>24 hr washout. Following completion of exercise, subjects will remain in the lab in a rested state for the subs
62439723|NCT00548353|EXPERIMENTAL|1|MK3207 Orally administered to patients with water. During each period (with and without acute migraine).
62439724|NCT00548353|PLACEBO_COMPARATOR|2|MK3207 placebo as tablets will be Orally administered to patients with water. During each period (with and without acute migraine).
62439725|NCT02472977|ACTIVE_COMPARATOR|BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (SCLC)|Small cell lung cancer (SCLC)
62439726|NCT02472977|ACTIVE_COMPARATOR|BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (PAC)|Pancreatic cancer (PAC)
62439727|NCT03534297|EXPERIMENTAL|dapansutrile capsules|"A total of 8 patients in each cohort will receive dapansutrile capsules:~* Cohort 1 will receive 5x 100 mg dapansutrile capsules QD for 14 days~* Cohort 2 will receive 5x 100 mg dapansutrile capsules BID for 14 days~* Cohort 3 will receive 5x 100 mg dapansutrile capsules QID for 14 days"
62607550|NCT03161886|EXPERIMENTAL|Pan-enteric capsule endoscopy (PCE)|Evidence of active disease by PCE prompted a change in therapy at the discretion of the treating clinician and according to current available pediatric guidelines. The definition of medical treatment adjustment after evidence of inflammation was: the introduction of steroids or enteral nutrition, the introduction or optimization of immunosuppressives; the introduction, optimization of biologics; or the introduction of both immunosuppressive agents and biologics. In case of a negative PCE and presence of symptoms, the magnetic resonance enterography (MRE) could help in guiding therapeutic decisions.
62607551|NCT00901472||Stable type 2 Diabetes (ST2D)|Adults with Type 2 diabetes who receive medical care at the University of Chicago
62607552|NCT03598582|OTHER|epoetin zeta|Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.
62607553|NCT06730139||Head and Neck Cancer (HNC) Survivors|"Target Population:~Age: 18 years and older Diagnosis: Head and Neck Cancer (HNC) Treatment Status: Within the first year post-treatment completion"
62607554|NCT02674802||Retrospective study|People who has successfully eradicated helicobacter pylori more than six months detected helicobacter pylori by the C-urea breath test in order to evaluate the reinfection.
62607555|NCT02674802||Prospective study|People who has infected helicobacter pylori received regular eradication therapy after the 4 weeks, 8 weeks and 6 months detected helicobacter pylori by the C-urea breath test in order to prospect the reinfection .
62829533|NCT03109496||OME Patients|Suffer from chronic Otitis Media with Effusion (OME) for at least 3 months and undergo ventilation tube placement.
62829534|NCT03109496||Healthy Control|Undergo surgery that gives access to the middle ear space (e.g. cochlear implant surgery) or adenoids, in absence of upper respiratory tract infections.
62249902|NCT03122496|EXPERIMENTAL|durvalumab (MEDI4736) & tremelimumab with SBRT|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks. SBRT delivered to one metastatic site per standard of care using a standard 9Gy x 3 fractions will be given within 2 weeks after the completion of the first cycle of durvalumab (MEDI4736) and tremelimumab. After 4 cycles of durvalumab (MEDI4736) and tremelimumab, patients will then continue with single agent durvalumab (MEDI4736) every 4 weeks until disease progression or unacceptable toxicity or a total of 12 months from date of initial treatment.
62249903|NCT02879604|EXPERIMENTAL|Compensatory cognitive training|Compensatory cognitive training
62249904|NCT02879604|PLACEBO_COMPARATOR|usual treatment|usual treatment for shizophrenai
62249905|NCT01821833|EXPERIMENTAL|Arm I (Omega-3 fatty acid)|"Four Omega-3 fatty acid capsules (at 1 gram/capsule) are administered orally daily.~The capsules may be administered either once daily or as 2 capsules two times daily."
62249906|NCT01821833|PLACEBO_COMPARATOR|Arm II (placebo)|"Four placebo capsules (at 1 gram microcrystalline cellulose/capsule) are administered orally daily.~The capsules may be administered either once daily or as 2 capsules two times daily."
62249907|NCT04495855||Visanne treatment|Patients from post-menarche to menopause with clinically or surgically diagnosed endometriosis, who have been prescribed Visanne
62607556|NCT02920814|EXPERIMENTAL|Time Intensive CBT for SPOV|Time intensive CBT for SPOV involving 6 weekly sessions and 2 intensive days of 4 hours each (over 8 weeks in total).
62607557|NCT02182466||Colonic endoscopy indicated|
62607558|NCT02974205|ACTIVE_COMPARATOR|Rehabilitation with orthosis (Jack brace)|
62829535|NCT05916235|EXPERIMENTAL|Experimental: Active PBM|PBM has been used clinically in the treatment of musculoskeletal and other pain conditions for over 30 years. Despite the low quality of the existing evidence, PBM has been increasingly used in other countries for the treatment of TMD. However, in the US PBM is not widely used for the treatment of TMD pain. Due to the multifactorial nature of chronic TMD pain, we propose that a multimodal PBM protocol targeting multiple pathophysiological mechanisms will be the optimal approach for PBM implementation in patients with TMD.
62249908|NCT03685864|EXPERIMENTAL|Suture Embedding Acupuncture|Suture Embedding Acupuncture 1 time for two weeks, total 3 times.
62249909|NCT03685864|SHAM_COMPARATOR|Sham acupuncture|Sham Acupuncture 1 time for two weeks, total 3 times.
62249910|NCT01440842|EXPERIMENTAL|Closed-loop (Model Predictive Control Algorithm)|
62439728|NCT03534297|PLACEBO_COMPARATOR|Placebo Capsules|"A total of 2 patients in each cohort will receive placebo capsules:~* Cohort 1 will receive 5 placebo capsules QD for 14 days~* Cohort 2 will receive 5 placebo capsules BID for 14 days~* Cohort 3 will receive 5 placebo capsules QID for 14 days"
62249911|NCT01440842|ACTIVE_COMPARATOR|Open loop (Standard treatment)|
62249912|NCT03109158|EXPERIMENTAL|NC-6004 and 5-FU|"Phase I, continual reassessment method, dose-escalation study to determine the maximum tolerated dose (MTD) and an RPII dose of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.~In Part 1, patients will be assigned to receive cetuximab followed by NC-6004 and 5-FU.~Phase II, adaptive, open-label expansion study evaluating the activity, safety, and tolerability of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck at the RPII dose identified in Part 1.~In Part 2, all patients will receive NC-6004 at the RPII dose established in Part 1, in combination with cetuximab and 5-FU according to the same schedule as used in Part 1."
62249913|NCT05803304|EXPERIMENTAL|PATH Intervention|Insufficiently active adults with obesity assigned to the PATH intervention.
62249914|NCT05803304|ACTIVE_COMPARATOR|Attention Control Group|Insufficiently active adults with obesity assigned to the attention control group. At the end of the 6-month study period, participants will receive access to the PATH program, with out the coaching component.
62439729|NCT05124756|EXPERIMENTAL|Bioelectric stimulation|Bioelectric stimulation on quadriceps muscle and kidneys: 45 minutes, 3 times/week, 8 weeks, 24 sessions.
62439730|NCT05124756|NO_INTERVENTION|Control|No intervention.
62439731|NCT01148290|ACTIVE_COMPARATOR|Tension free vaginal tape|
62439732|NCT01148290|EXPERIMENTAL|Bulking agent injection|
62439733|NCT03216733|EXPERIMENTAL|COMBO|PCI with COMBO stent
62439734|NCT03216733|ACTIVE_COMPARATOR|ORSIRO|PCI with ORSIRO stent
62439735|NCT04788589|EXPERIMENTAL|Sedation and Ventilator Weaning Protocol|"Sedation: start midazolam 5-10 mins (max 3x). If MV 12 hrs-2d: Pain: morphine @2 hrs if needed (max 10mg/x). Sedation: midazolam @ 1-2 hrs if needed (max 10mg/x). If MV \>2 d: morphine \& midazolam drip (max 10mg/hr). MV weaning checklist @morning. Pass if no incr of sedation dose due to agitation, NMBAs, incr in ICP. Fail: reassessed tomorrow. Pain and SBS scores assessed @morning until extubation. Stop all sedation and analgetic for sedation. Continue analgetics for pain. Subjects monitored for 4 hrs. Assess pain and WAT-1 score. Pass (GCS of E3, tolerate sedation interruption for \> 4 hrs): MV weaning protocol. Fail (Persistent anxiety/agitation, incr pain score, incr RR \> 5 mins, SpO2 \<88% \>5 mins, acute heart dysrhythmia, \>=2 signs of ARDS): sedation resumed ½ dose, up titrated.~MV weaning: CPAP 5/PS \< 7. Pass: No failure criteria for 2 hrs. Fail (Incr RR \> 5 mins, SpO2 \<88% \> 5 mins, acute decr in GCS/acute heart dysrhythmia, \>=2 signs of ARDS): previous MV setting."
62439736|NCT04788589|NO_INTERVENTION|Control|"1. Informed consent~2. Randomization into groups~3. Sedation and ventilator weaning according to attending physicians~4. Pain scores and SBS score is noted every 6 hours for the first 24 hours, and every day for the next 24 hours until extubation.~5. Attending physicians assessed that subject could be weaned: pain scores, SBS score, WAT-1 score~6. Extubation. Researcher did not take part in the judgement of extubation."
62439737|NCT01694511|ACTIVE_COMPARATOR|Introductory conventional endoscopy|Conventional endoscopy followed by HRME+CVC after 30 days.
62439738|NCT01694511|ACTIVE_COMPARATOR|Introductory HRME+CVC|HRME+CVC followed by conventional endoscopy after 30 days.
62439739|NCT01434459|EXPERIMENTAL|Gemcitabine with TheraSphere|
62439740|NCT03799887|ACTIVE_COMPARATOR|0% unweighed BWSTT|0% unweighed Body Weight Supported Treadmill Training
62439741|NCT03799887|EXPERIMENTAL|10% unweighed BWSTT|0% unweighed Body Weight Supported Treadmill Training
62607559|NCT02974205|ACTIVE_COMPARATOR|Rehabilitation without orthosis|
62249915|NCT06127927|EXPERIMENTAL|Interventional Left Ventricular Assist System Pre-trial|The design of the first phase pre-trial clinical study will involve a total of 6 subjects. The survival rate of subjects before discharge or 30 days after weaning was the main effectiveness evaluation indicator, and the safety and effectiveness of the test device were preliminarily evaluated. All SAE events during the study will be reviewed by CEC experts. According to the expert review opinions, if no unexpected serious complications and product defects are found, the Formal Research phase will be started.
62439742|NCT03799887|EXPERIMENTAL|20% unweighed BWSTT|20% unweighed Body Weight Supported Treadmill Training
62439743|NCT02245191|EXPERIMENTAL|Ephedrine Group|Patients who will receive ephedrine after spinal anesthesia
62439744|NCT02245191|EXPERIMENTAL|Phenylephrine Group|Patients who will receive Phenylephrine after spinal anesthesia
62439745|NCT02245191|EXPERIMENTAL|Metaraminol|Patients who will receive Metaraminol after spinal anesthesia
62439746|NCT02415959|EXPERIMENTAL|Creon IR low dose|Creon IR 300 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
62439747|NCT02415959|EXPERIMENTAL|Creon IR medium dose|Creon IR 1,200 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
62439748|NCT02415959|EXPERIMENTAL|Creon IR high dose|Creon IR 2,400 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
62439749|NCT02415959|EXPERIMENTAL|Creon IR maximum dose|Creon IR 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
62439750|NCT02415959|ACTIVE_COMPARATOR|Creon® (DR/GR)|Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
62607560|NCT02974205|ACTIVE_COMPARATOR|Rehabilitation with orthosis (össur brace)|
62607561|NCT03623542||Dementia or alzheimer dementia|All patients presenting with dementia syndrome and whose admission was unplanned between May 2010 and November 2011 were consecutively included in the study.
62047526|NCT01975896|EXPERIMENTAL|Meditation|The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
62047527|NCT01975896|NO_INTERVENTION|Health Education|The health education curriculum will be informed by: 1) the dietary and PA didactic units and materials developed as part of our school based trial, adapted for adolescents from the Diabetes Prevention Program (DPP) and 2) the standard curricula for school-based health education programs with particular attention to the unique needs of adolescents:increasing fruits and vegetables, reducing sugar sweetened drinks, and decreasing foods high in fat, unhealthy carbohydrates, and calories. The PA component will be based on current recommendations of engaging in at least 1 hour of moderate-to-vigorous physical activity (MVPA) most days of the week, building PA into the teen's lifestyle,and reducing sedentary behavior.
62249916|NCT06127927|EXPERIMENTAL|Interventional Left Ventricular Assist System Formal Research|A formal clinical trial to evaluate the effectiveness and safety of interventional left ventricular assist system for hemodynamic support in patients with cardiogenic shock through a prospective, multicenter, single-group target value study.The total number of patients enrolled in this study is planned to be 54. This sample size is calculated according to statistical principles, combining the research hypothesis and the estimate of the expected level of efficacy. The sample size calculation is based on the main efficacy index and the main safety index. Since it is set according to the common evaluation index, the sample size is calculated for the two main evaluation indicators separately, and the largest one is used as the final sample size of this trial.
62607562|NCT04066777|OTHER|Hypertrophic obstructive cardiomyopathy|injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction
62607563|NCT01926938||adults at risk|Latino adults with family history of type 2 diabetes
62829536|NCT05916235|SHAM_COMPARATOR|Sham PBM|When applying PBM therapy, there are some heating elements in the treatment device, and most of the sham treatment devices available do not offer this feature, which increases the likelihood of unblinding both the patient and the interventionist. The THOR® LX2.3 PBM machine includes this new feature, such that the sham condition mimics the heating activity of the active treatment.
62829537|NCT01152957|EXPERIMENTAL|Community Health Worker Model|Care, Attention, Resources, Information, Nutrition and Optimism Project (CARIÑO Project) will provide outreach support services to patients with poorly controlled diabetes, such as health education, lifestyle changes, home visits, follow-up phone calls, support groups, one on one counseling and coaching, and assistance with resource referrals.
62249917|NCT00715195|EXPERIMENTAL|1|Cognitive-behavioral therapy : 50 patients planned
62249918|NCT00715195|NO_INTERVENTION|2|50 patients planned
62249919|NCT02018406|EXPERIMENTAL|Intervention|Intervention Group
62249920|NCT02018406|PLACEBO_COMPARATOR|Control|Control Group
62249921|NCT01974089||Pneumonia and dysphagia|Patients with community aquired pneumonia and oropharyngea dysphagia
62249922|NCT01974089||Pneumonia|Patients with community aquired pneumonia
62249923|NCT01518283|EXPERIMENTAL|Cabazitaxel|Drug: Cabazitaxel 10 mg/m2
62249924|NCT06490393||A:paper vs digitally|Arm A: patients in Arm A will receive first an invitation to complete the QoL questionnaires on paper under supervision of an HCP in the hospital before their cycle of systemic antineoplastic therapy starts. Prior to their subsequent cycle of systemic antineoplastic therapy (regardless of duration of cycle), patients in Arm A will be asked to complete the same QoL questionnaires digitally at home.
62249925|NCT06490393||B: digitally vs paper|Arm B: patients in Arm B will receive first an invitation to complete the QoL questionnaires digitally at home before their cycle of systemic antineoplastic therapy starts. Prior to their subsequent cycle of systemic antineoplastic therapy (regardless of duration of cycle), patients in Arm B will be asked to complete the same QoL questionnaires on paper under supervision in the hospital.
62439751|NCT00905489|EXPERIMENTAL|Nevirapine IR / Nevirapine XR|In this pharmaco-kinetic (PK) cross-over design trial, all patients initially receive nevirapine immediate release and then all patients are switched to nevirapine extended release 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).
62607564|NCT01926938||controls|Latino adults without family history of type 2 diabetes and normal glucose tolerance
62607565|NCT05655468|EXPERIMENTAL|dronedarone|dronedarone 400mg twice a day for 9 months
62829538|NCT01152957|ACTIVE_COMPARATOR|Enhanced Usual Care|Usual Care and mailing of 4 health education brochures over the year.
62829539|NCT02948127|EXPERIMENTAL|RSV LID cp ΔM2-2 Vaccine|Participants will receive a single dose of the RSV LID cp ΔM2-2 vaccine at study entry (Day 0).
62829540|NCT02948127|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
62829541|NCT02781714|EXPERIMENTAL|Two-way SMS|Pre-programmed SMS messages by partner track will be delivered twice weekly to participants in participants' preferred languages from enrollment to 6 months postpartum. They will include a question soliciting a response from the participant(s). Interactive SMS communication will be responded to and managed by the study nurse at each site. Content themes will include: general support/encouragement, postpartum visit reminders, postpartum pregnancy risk and benefits of birth spacing, postpartum contraceptive options and side effects, family planning misconceptions, and couple communication.
62607566|NCT05655468|PLACEBO_COMPARATOR|placebo|Placebo(for dronedarone ) a day for 9 months
62829542|NCT02781714|NO_INTERVENTION|Control|The control arm will receive standard education and counseling provided in antenatal care and in postnatal care.
62829543|NCT05535725|EXPERIMENTAL|expose|A group of patients receiving 1g of powdered vancomycin in the operative wound before its closure, and another group not receiving it
62829544|NCT05535725|NO_INTERVENTION|non expose|A group of patients not receiving 1g of powdered vancomycin in the operative wound before its closure
62829545|NCT03790202||single cohort of up to 30 patients|patients with acute or chronic lower limb wounds to be treated with the VistaCare® device
62829546|NCT00944853|EXPERIMENTAL|Zinc syrup|Liquid Zinc Syrup (ZnSO4) solution provided daily
62829547|NCT00944853|EXPERIMENTAL|Zinc tablet|Dispersible zinc tablets provided daily
62829548|NCT00944853|PLACEBO_COMPARATOR|Placebo|Liquid placebo supplement provided daily
62829549|NCT06599424||subjects with PCI|
62829550|NCT06599424||subjectis with Impella-protected PCI|
62047528|NCT04697277|ACTIVE_COMPARATOR|Group 1|Group 1 (Prophylactic antibiotic 30 minutes before skin incision): Antibiotic diluted in 10 ml syringe 30 minutes before skin incision and after cord clamping, 0.9% NaCl in 10 ml syringe will be administered intravenously within 15 seconds.
62047529|NCT04697277|ACTIVE_COMPARATOR|Group 2|Group 2 (prophylactic antibiotic after cord clamping): 30 minutes before the skin incision, 0.9% NaCl in a 10 ml injector and after the cord is clamped, the antibiotic diluted in a 10 ml syringe will be administered intravenously within 15 seconds.
62047530|NCT01315834||Couples coping with CHD|The target group will be 127 male patients and their partners. The couples will be recruited during the patients' first hospitalization for ACS. The participants will complete questionnaires during the hospitalization and again six months later. The patients will also be asked to be weighed and have their blood drawn and at the six-month follow-up for measurement of blood Cholesterol level. Relevant data will be obtained from their medical files.
62047531|NCT01315834||control group|The control group will be 100 couples who are not coping with a life threatening illness. The couples will complete self report questionnaires at one point of time.
62047532|NCT04512066|EXPERIMENTAL|150 mg Once Daily (QD) RO6889450|Participants will receive 150 mg of RO6889450 QD for 4 weeks or 12 weeks or 48 weeks.
62047533|NCT04512066|EXPERIMENTAL|45 mg QD RO6889450|Participants will receive 45 mg of RO6889450 QD for 4 weeks or 12 weeks or 48 weeks.
62249926|NCT02218242|EXPERIMENTAL|Ultrasound|Participants in this study have elected to have surgical resection of non-small cell lung cancer tumors as part of their standard of care. During that surgical procedure, participants will also receive laparoscopic intraoperative ultrasound to assess the thoracic wall lymph nodes as part of the experimental procedure. The ultrasound procedure will add about 15 minutes to the total surgical time. Because it is laparoscopic and utilizes non-ionizing radiation, the risk to the participant is minimal.
62249927|NCT04353596|EXPERIMENTAL|Stopping/replacing ACEI/ARB|Chronic treatment with ACEI or ARB will be stopped or replaced.
62829551|NCT01761968|EXPERIMENTAL|givinostat|"Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.~If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination."
62829552|NCT06590311||PSV|
62829553|NCT06590311||PAV+|
62829554|NCT01135550|ACTIVE_COMPARATOR|Standard Arm|"Subjects scheduled to undergo radiation therapy are enrolled before the therapy is started. Once radiation therapy begins they will complete a daily diary about any headaches or nausea/vomiting they experience.~If they experience increased headache or vomiting they will be randomized to receive either a high or a low dose of dexamethasone, to control these symptoms."
62047534|NCT04512066|PLACEBO_COMPARATOR|Placebo|Participants will receive oral placebo QD for 4 weeks. Participants from this arm that continue to the extension period will be randomized to either 45 mg or 150 mg QD of RO6889450 for up to an additional 8 weeks or additional 44 weeks (optional 36-Week Safety Extension Phase).
62249928|NCT04353596|NO_INTERVENTION|Control|No intervention, which means further treatment with ACEI or ARB.
62249929|NCT02217436|EXPERIMENTAL|iPad|iPad with age-appropriate applications, videos, and music
62249930|NCT02217436|ACTIVE_COMPARATOR|Standard Care|All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
62249931|NCT03008954|PLACEBO_COMPARATOR|Placebo|Microcyrstalline cellulose (Avicel): provided in 5 capsules (350 mg each), twice daily (BID) prior to lunch and dinner.
62249932|NCT03008954|EXPERIMENTAL|GSP3 (2.25g)|GSP3: provided in 3 capsules (750 mg each), plus 2 placebo capsules (350 mg each), twice daily (BID) prior to lunch and dinner
62249933|NCT03008954|EXPERIMENTAL|GSP3 (3.75g)|GSP3: provided in 5 capsules (750 mg each), twice daily (BID) prior to lunch and dinner
62249934|NCT01191866||Diabetes mellitus|All children and adolescents with type 1 diabetes mellitus attending Assaf Harofeh Pediatric Diabetes Clinic
62829555|NCT01135550|ACTIVE_COMPARATOR|Control Arm|"Subjects scheduled to undergo radiation therapy are enrolled before the therapy is started. Once radiation therapy begins they will complete a daily diary about any headaches or nausea/vomiting they experience.~If they experience increased headache or vomiting they will be randomized to receive either a high or a low dose of dexamethasone, to control these symptoms."
62829556|NCT00347022|EXPERIMENTAL|Xenetix|The patient receive one injection of Xenetix 300 (300 mg of iodine/ml)
62829557|NCT00347022|ACTIVE_COMPARATOR|Visipaque|The patient receive one injection of Visipaque 270 (270 mg of iodine/ml)
62829558|NCT03248908|EXPERIMENTAL|Intervention 1|Pupillary dilation reflex based perioperative intravenous remifentanil administration. Starting dose 5 ng/ml by continous infusion, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, the dosage is decreased with 0.2 ng/ml. When PPI score is greater than 1, the dosage is increased with 0.2 ng/ml.
62607567|NCT02764567|EXPERIMENTAL|Aromatherapy|"The participants randomized to aromatherapy will be offered one of three essential oils, 'applied' to their smell zone via cotton ball that are known to have anti-anxiety effect. These are:~* ginger~* calming~* lavender The participant's choice will be documented in a database. The participant can chose an oil each time (i.e., they are not bound to use only the first choice oil). Pain and anxiety will be measured prior to receiving the essential oils and again after the phlebotomy procedure. Blood pressure and pulse will also be measured post-phlebotomy."
62607568|NCT02764567|NO_INTERVENTION|Standard of Care|The participants randomized to standard of care will proceed to the outpatient phlebotomy room in the Heart Care Clinic as per usual care. Pain, anxiety, blood pressure and pulse will be assessed pre and post-procedure.
62607569|NCT05904080|ACTIVE_COMPARATOR|Arm A (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and collection of blood samples throughout the trial.
62249935|NCT00670501|EXPERIMENTAL|1|LY333334 40 micrograms/day plus calcium and vitamin D
62249936|NCT00670501|EXPERIMENTAL|2|LY333334 20 micrograms/day plus calcium and vitamin D
62249937|NCT00670501|PLACEBO_COMPARATOR|3|Placebo plus calcium and vitamin D
62249938|NCT00636467|EXPERIMENTAL|No label|Injection of Nanocis® or Nanocoll® (Tc-colloid) on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)
62047535|NCT04512066|ACTIVE_COMPARATOR|4 mg QD Risperidone|Participants will receive 4 mg of risperidone QD for 4 weeks or 12 weeks or 48 weeks.
62249939|NCT00833144||1|Congestive Heart Failure
62249940|NCT00833144||2|Patients without congestive heart failure
62249941|NCT01865526|ACTIVE_COMPARATOR|Low protein diet|The patients of this group received a classical low protein diet (LPD),according to their desired body weight (DBW), obtained by multiplying the squared value of the height times a reference body mass index (BMI) value of 23. LPD were individually prepared and explained to the patients by a dedicated dietician and contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
62249942|NCT01865526|EXPERIMENTAL|Six point diet|These patients were assigned to receive the 6-points-diet, and were given by the Nephrologist the list of six items indicating how to modify their dietary habits; all the items were thoroughly explained and discussed with the patients
62249943|NCT04680728||patient|Patient admitted to intensive care for less than 24 hours.
62439752|NCT06441565|ACTIVE_COMPARATOR|Fruquintinib monotherapy group (control group)|Participants in the fruquintinib monotherapy group will undergo a treatment cycle every 4 weeks, taking 4 mg orally once daily for 3 weeks, followed by a 1-week break.
62249944|NCT04714736|ACTIVE_COMPARATOR|DyeVert group|Patients will receive intravenous 0.9% sodium chloride as soon as in the catheterization laboratory. The hydration regimen will be defined according to the hemodynamic conditions and modulated according to the left ventricular end diastolic pressure (LVEDP). During the PCI the CM injection will be handled by the DyeVert TM system.
62439753|NCT06441565|EXPERIMENTAL|Fruquintinib plus HAI-FOLFOX treatment group (experimental group)|The experimental group will receive fruquintinib plus HAI-FOLFOX, with HAI-FOLFOX given every 2 weeks
62439754|NCT04648761|EXPERIMENTAL|OPTIMAL group|This group will have their anti IL 5 biologics titrated by OPTIMAL algorithm
62439755|NCT04648761|NO_INTERVENTION|Control group|This group will continue their treatment with anti IL 5 biologics unchanged
62439756|NCT04188925|EXPERIMENTAL|Group A|True LA with EA
62439757|NCT04188925|SHAM_COMPARATOR|Group B|Sham LA with EA
62439758|NCT05353556|EXPERIMENTAL|Study Group|Patients who perform inspiratory muscle training (IMT) with %50 loading
62439759|NCT05353556|SHAM_COMPARATOR|Sham Group|Patients who perform Sham IMT
62439760|NCT04184375|EXPERIMENTAL|TONIC|"The cognitive stimulation sessions are carried out using Liliane Israël's TRAIN YOUR MEMORY software, and are divided into two parts: the first part is essentially cognitive and the second relates to the daily life of the Bipolar patient.~This training method consists of combining two means of intervention, pedagogical action and psychotherapeutic effect. It aims to stimulate, develop and strengthen the basic mechanisms underlying memory phenomena (sensory acuity, attention, associations, structuring, executive functions, spatial and temporal landmarks, associative recruitment). It is presented in the form of exercises divided into eight modules."
62439761|NCT04184375|NO_INTERVENTION|Control|The usual practice consists of interviews with the psychiatrist with the possibility of home visits by the nurse.
62439762|NCT05588206|EXPERIMENTAL|Hypofractionated Stereotactic Radiotherapy for Brain Metastases|
62439763|NCT02011594|EXPERIMENTAL|Arm A|Nimotuzumab
62829559|NCT03248908|ACTIVE_COMPARATOR|Intervention 2|Anesthesiologist based perioperative intravenous remifentanil administration (daily practice, standard of care). Starting dose 5 ng/ml, dosage adjustments are made when deemed necessary by attending anesthesiologist.
62047536|NCT01059630|ACTIVE_COMPARATOR|Bendamustine Alone|Participants will receive bendamustine 120 milligrams per meter square (mg/m\^2) Intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.
62249945|NCT04714736|SHAM_COMPARATOR|Control group|"Patients will receive intravenous 0.9% sodium chloride as soon as in the catheterization laboratory. The hydration regimen will be defined according to the hemodynamic conditions and modulated according to the left ventricular end diastolic pressure (LVEDP). During the PCI the CM injection will be carried out by a conventional manual injection syringe. Strategies for limiting CM volume are:~1. angiograms will be performed with injection of contrast using a 3-cm 3 syringe; this provides strict control of CM delivery by limiting the volume of contrast that can be administered in a single injection;~2. catheters with sideholes will be strictly avoided during percutaneous intervention;~3. when exchanging catheters, unused contrast is withdrawn from the catheter lumen (e.g., by back-bleeding through an opened ''Y''-connector or by aspirating residual contrast from the catheter using a syringe)~4. ''tests'' with ''puffs'' of CM are discouraged."
62439764|NCT02011594|PLACEBO_COMPARATOR|Arm B|Placebo (normal saline)
62439765|NCT04524533|EXPERIMENTAL|Intervention group|Participants randomized into the intervention arm will watch smoking cessation videos (ready to quit or not ready to quit) during a dental cleaning clinic visit, receive a brochure about EBTs, and participate in a 4-week text message program which consists of automated and tailored text messages to motivate EBT utilization. After the 4-week program, the intervention group will receive monthly assessment text messages.
62249946|NCT01486797|EXPERIMENTAL|NOX-A12|
62249947|NCT01338623|EXPERIMENTAL|Tansulosine|
62249948|NCT04248582|EXPERIMENTAL|Cryotherapy before chemoradiation|Patients receive 2 sessions of liquid nitrogen spray cryotherapy prior to chemoradiation
62607570|NCT05904080|EXPERIMENTAL|Arm B (nivolumab, ipilimumab, cabozantinib)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 and cabozantinib S-malate PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may continue with cabozantinib S-malate after 2 years per treating investigator. Patients undergo CT or MRI and collection of blood samples throughout the trial.
62607571|NCT06066528|EXPERIMENTAL|Survodutide 3.6 mg|
62249949|NCT04248582|EXPERIMENTAL|Cryotherapy before chemoradiation and during|Patients receive 2 sessions of liquid nitrogen spray cryotherapy prior to chemoradiation and one session during chemoradiation
62439766|NCT04524533|ACTIVE_COMPARATOR|Control group|Participants randomized into the control arm will watch a control video during a dental hygiene visit and receive a brochure about EBTs, and a 4-week assessment-only text message program.
62439767|NCT00544583|ACTIVE_COMPARATOR|A|Interrupted closure with Vicryl equivalent sutures (USP 2, 45 cm)
62439768|NCT00544583|EXPERIMENTAL|B|Continuous closure with PDS II equivalent sutures (USP 1, 150 cm loops)
62439769|NCT02141178|ACTIVE_COMPARATOR|Bupivacaine|Patients will received 0.5% Bupivacaine subcutaneously for local anesthesia during surgery
62439770|NCT02141178|EXPERIMENTAL|Exparel|Patients will received Exparel subcutaneously for local anesthesia during surgery
62439771|NCT00697112||A|
62607572|NCT06066528|EXPERIMENTAL|Survodutide 6.0 mg|
62829560|NCT03248908|EXPERIMENTAL|Intervention 3|Pupillary dilation reflex based perioperative intravenous sufentanil administration. Starting dose 0.1 mcg/kg bolus, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, no supplementary administration is executed. When PPI score is greater than 1, a supplementary bolus of 0.1 mcg/kg is given.
62607573|NCT06066528|PLACEBO_COMPARATOR|Placebo|
62047537|NCT01059630|EXPERIMENTAL|Obinutuzumab + Bendamustine|"Induction phase: Participants will receive bendamustine 90 mg/m\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants will also receive obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6.~Maintenance phase: Participants with complete response (CR), partial response (PR) or stable response (SD) then will receive obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurs first)."
62047538|NCT05780489|EXPERIMENTAL|DONORS UNDER CONTROLLED OVARIAN STIMULATION|Saliva samples will be analyzed using oestradiol and progesterone ELISA kits.
62047539|NCT06276270|EXPERIMENTAL|Device is administered directly onto the area affected by mucositis.|
62249950|NCT04977102|EXPERIMENTAL|Intraocular caliper-assisted capsulotomy group|In intraocular caliper-assisted capsulotomy group, a modified intraocular caliper with standard calibration on the rinse needle was used to measure and locate the position of capsulorhexis with 5.3 mm diameter and the principle of pupillary margin in concentric circles. The surgeon could gently use the blunt needle in the front of the intraocular caliper to further make corresponding markers on the lens anterior capsule, and then carry out capsulotomy according to the marks.
62249951|NCT04977102|ACTIVE_COMPARATOR|Verion navigation system-assisted capsulotomy group|In the Verion-assisted capsulotomy group, Verion navigation system was applied to project a 5.3 mm capsulorhexis centered on the corneal vertex. According to the projected capsulorhexis, capsulotomy was performed.
62249952|NCT03332329|EXPERIMENTAL|Sequential combination arm|Drug: Entecavir for 60 weeks Drug: HBV vaccine (60ug/month, every four weeks) for 24 weeks Drug: Granulocyte Macrophage Colony Stimulating Factor (75 μg/day, first 5 days each month, subcutaneous) from baseline to week 16 and from week 60 to week 84 Drug: Y peginterferon alfa-2b (180 μg/week, subcutaneous) from week 16 to week 108
62249953|NCT06401122||diabetic dialysis patients|fifty diabetic patients on regular haemodialysis more than 6 months
62249954|NCT06401122||Non-diabetic dialysis patients|fifty Non-diabetic patients on regular haemodialysis more than 6 months
62249955|NCT01881893|NO_INTERVENTION|Usual Care|Patients in this arm of the study will continue to receive their regular level of care.
62607574|NCT04309565|ACTIVE_COMPARATOR|Standard Primary Care|Those randomized to the standard primary care arm will be referred to primary care and community Opioid Treatment Program (OTP). Participants may receive buprenorphine or Extended-release naltrexone (XR-NTX) through primary care or with a community addiction treatment provider.
62607575|NCT04309565|EXPERIMENTAL|Transitions Clinic Network Primary Care|Transitions Clinic Network (TCN)- participants in this arm will be referred to a TCN program for primary care and community Opioid Treatment Program (OTP). All TCN programs have the ability to prescribe buprenorphine and Extended-release naltrexone (XR-NTX) and assist with referrals to methadone. The primary features of the TCN include (1) primary care and onsite MOUD or referral to community treatment when indicated, (2) addressing social determinants of OUD and care coordination through a Community Health Worker (CHW), and (3) addressing the discrimination and stigma that exist based on incarceration.
62829561|NCT03248908|ACTIVE_COMPARATOR|Intervention 4|Anesthesiologist based perioperative intravenous sufentanil administration (daily practice, standard of care). Starting dose 0.1 mcg/kg bolus, dosage adjustments are made when deemed necessary by attending anesthesiologist.
62829562|NCT05248815||Study group|Patients scheduled for total knee replacement.
62829563|NCT05248815||Control|Healthy age-matched controls.
62047540|NCT01367509|EXPERIMENTAL|Arm 1|SC Methylnaltrexone (MNTX)
62047541|NCT04870710|EXPERIMENTAL|cathodal transcranial direct current stimulation (tDCS)|Two, twenty minute sessions of cathodal tDCS to the bilateral extrastriate visual cortex for 5 days (10 total sessions).
62047542|NCT04870710|EXPERIMENTAL|Anodal transcranial alternating current stimulation (tACS)|Two, twenty minute sessions of anodal tACS delta phase aligned for 5 days (10 total sessions).
62047543|NCT04663022||Child with cochlear implant|15 childs with coclear implant but without autism spectrum disorder
62047544|NCT04663022||Child with cochlear implant and autism spectrum disorder|15 childs with coclear implant and with autism spectrum disorder
62047545|NCT01755442|ACTIVE_COMPARATOR|AMG 151|
62249956|NCT01881893|EXPERIMENTAL|ACHD-CARE Program|"Group based psychosocial intervention.~* Educational: congenital heart disease information~* Behavioral: cognitive behavioral therapy~* Behavioral: social interactions and communication skills"
62249957|NCT01034592|EXPERIMENTAL|Lenalidomide|Subjects will initially receive lenalidomide 2.5 mg, and may escalate up to 2.5 mg/wk up to 5 mg 3x/wk, depending toxicity and response.
62249958|NCT02423304||test|"50 periodontitis patients~• Patients will be categorized by Periodontal Disease Index (PDI) by P. Ramfjord(1959) blood samples collected from all patients serum separated and evaluated for77A/G AND 11A/12A associated gene polymorphism of Matrix Metallo Proteinase( MMP)-13 in all the patients. studies showing that there is co relation of these genes with increase inflammation."
62607576|NCT02999724|EXPERIMENTAL|gabapentin|gabapentin 300-600 mg 1 hour preop
62607577|NCT02999724|PLACEBO_COMPARATOR|placebo|placebo capsule(s) 1 hour preop
62607578|NCT03654131|ACTIVE_COMPARATOR|MWA|Percutaneous ultrasound-guided MWA or open surgery MWA. The patient is fully anesthetized during the treatment.
62047546|NCT01755442|PLACEBO_COMPARATOR|Placebo|
62047547|NCT01463722|OTHER|Amniotic fluid Lamellar Body Counting|
62047548|NCT03825783|EXPERIMENTAL|RP-L201|RP-L201 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic stem cells transduced with Chim-CD18-WPRE lentiviral vector administered as a single infusion in subjects with severe LAD-I
62047549|NCT00724152|EXPERIMENTAL|Arm 1/Cognitive Behavioral Therapy|Participants randomly assigned to this experimental group received six weeks of tinnitus education plus cognitive behavioral therapy. Cognitive behavioral therapy for tinnitus participants addressed cognitive and behavioral skills targeting the management of tinnitus and the negative impacts of tinnitus. Long-term self-efficacy and self-sufficiency were emphasized. The major components of CBT for tinnitus included identification of individual responses and beliefs about tinnitus and hearing loss, re-conceptualization of the tinnitus experience as one in which the patient has personal control, presentation of skills to modify cognitions and change behaviors, and reinforcement of skills via goals setting, homework and activities. Skills related to attention control, sleep hygiene, relaxation training are provided. Tinnitus education also included causes, treatments, current research, etc.
62249959|NCT02423304||control|50 periodontally healthy individuals blood samples collected from all patients serum separated and evaluated for77A/G AND 11A/12A associated gene polymorphism of Matrix Metallo Proteinase (MMP)-13 in all the patients
62607579|NCT03654131|ACTIVE_COMPARATOR|SBRT|3 fractions of 15 Gy (in total 45 Gy), 3 fractions per week. The dose is prescribed to the PTV encompassing 67% isodose. The SBRT plan is normalized such that the mean dose to the GTV is 100% = 67.5 Gy.
62829564|NCT05900167||enteral nutrition group|
62829565|NCT03207971|ACTIVE_COMPARATOR|SCTG from palatal area with predominance of lamina propria|
62829566|NCT03207971|ACTIVE_COMPARATOR|SCTG from palatal area with predominance of submucosa|
62829567|NCT05479695|EXPERIMENTAL|Patient who use spinal orthoses and insoles|Spinal Orthoses: Devices that used in spinal deformities. Insoles: Devices that used in foot deformities.
62829568|NCT05479695|OTHER|Patient who use only spinal orthoses|Spinal Orthoses: Devices that used in spinal deformities.
62829569|NCT02939287|ACTIVE_COMPARATOR|Aprepitant|aprepitant plus standard anti-emetic regimen
62829570|NCT02939287|EXPERIMENTAL|Olanzapine|olanzapine plus standard anti-emetic regimen
62829571|NCT02939287|EXPERIMENTAL|Aprepitant plus olanzapine|aprepitant and olanzapine plus standard anti-emetic regimen
62829572|NCT01815918|PLACEBO_COMPARATOR|Placebo|Patients receive a saline placebo before surgery, 8 hours after the first dose and 16 hours after the first dose.
62829573|NCT01815918|ACTIVE_COMPARATOR|Treatment|Patients receive 3 100 mg of hydrocortisone: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
62829574|NCT04402138|EXPERIMENTAL|Acalabrutinib|Acalabrutinib will be self-administered orally for up to approximately 2 years post-BMT.
62047550|NCT00724152|ACTIVE_COMPARATOR|Arm 2/Tinnitus Education|Participants randomly assigned to this group received six weeks of tinnitus education. Tinnitus education and skills related to attention control, sleep hygiene and relaxation training such as imagery techniques were provided. Tinnitus education included causes, treatments, current research, epidemiological information, basic anatomy of the ear and brain, and support resources.
62047551|NCT00724152|NO_INTERVENTION|Arm 3/Standard Care|Participants randomly assigned to this control group received only standard care. Standard care involves audiological measurement and brief education during the standard care appointment.
62249960|NCT03042182|EXPERIMENTAL|Single pill of V3-X vaccine administered once daily|One pill of oral therapeutic vaccine V3-X administered to patients with cholangiocarcinoma for two months and changes in CA19.9 tumor marker from baseline levels versus post-treatment levels will be assessed as correlates of changes in tumor burden
62829575|NCT02786849|EXPERIMENTAL|Group of high frequency and intensity|Group realized high frequency and intensity neuromuscular electrical stimulation
62829576|NCT02786849|EXPERIMENTAL|Group of low frequency and intensity|Group realized neuromuscular electrical stimulation of low frequency and intensity
62829577|NCT01187602||Women at average risk for ovarian cancer|Women at average risk for ovarian cancer (no first degree relatives with breast or ovarian cancer) undergoing gynecologic evaluation at UVA for non-malignant or routine indications.
62829578|NCT01187602||Women with ovarian cancer|Women with known or suspected ovarian cancer who are undergoing evaluation and/or treatment at UVA Cancer Center
62829579|NCT01187602||Increased risk for ovarian cancer|Women at increased risk of ovarian cancer based on family history, personal history, or genetic factors defined as either BRCA1 or BRCA2 mutations who still retain both fallopian tubes and both ovaries.
62829580|NCT06296069|EXPERIMENTAL|Intervention group|"The intervention group will conduct an exergame-based cognitive-motor intervention on a unstable surface (on top of their standard inpatient treatment).~Intervention duration will be tailored to the stay in the inpatient rehabilitation clinic (3-4 weeks). Training sessions will last 20-28 minutes (progressive increase)."
62829581|NCT06296069|ACTIVE_COMPARATOR|Control group|"The intervention group will conduct an exergame-based cognitive-motor intervention on a stable surface (on top of their standard inpatient treatment).~Intervention duration will be tailored to the stay in the inpatient rehabilitation clinic (3-4 weeks). Training sessions will last 20-28 minutes (progressive increase)."
62829582|NCT04469907|EXPERIMENTAL|Treatment - AZD9977|There are 4 cohorts in this arm based on renal function (mild, moderate, severe, and normal). Each cohort will have 8 participants.
62829583|NCT01951963|EXPERIMENTAL|Ketamine|Ketamine, single dose, 0.3 mg/kg, IV
62829584|NCT01951963|ACTIVE_COMPARATOR|Morphine|Morphine, single dose, 0.05 mg/kg, IV
62829585|NCT00828776|EXPERIMENTAL|1|Heparin Cristália
62829586|NCT00828776|ACTIVE_COMPARATOR|2|Heparin - Roche
62829587|NCT05202886|EXPERIMENTAL|Liver from deceased donors|This study included all consecutive subjects with chronic liver disease who underwent LT for the first time with a deceased donor liver
62829588|NCT03785015|EXPERIMENTAL|Withold aspirin till after endoscopic haemostasis|Withhold the standard treatment of aspirin within 12 hours after endoscopic haemostasis.
62829589|NCT03785015|ACTIVE_COMPARATOR|Withold aspirin till 72 hours|Withhold the standard treatment of aspirin till 72 after endoscopic haemostasis.
62829590|NCT02288741|EXPERIMENTAL|A1: Induction chemotherapy|Anthracycline/dexamethasone-based induction chemotherapy Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
62047552|NCT03630822|EXPERIMENTAL|beneficiary of the advance directive program|
62047553|NCT03630822|ACTIVE_COMPARATOR|beneficiary of standard Support|
62047554|NCT02891057|EXPERIMENTAL|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62249961|NCT05183113|EXPERIMENTAL|Acute Intermittent Hypoxia|Both healthy participants and those with spinal cord injury will receive the acute intermittent hypoxia (AIH) intervention. All participants are imaged pre- and post-AIH intervention, and thus serve as a self-comparison to observe the hypothesized improvement in bilateral hand strength.
62829591|NCT02288741|ACTIVE_COMPARATOR|A2: No induction chemotherapy|Dexamethasone for control of symptoms Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
62829592|NCT02288741|OTHER|B: Observation|Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
62829593|NCT04852172|ACTIVE_COMPARATOR|Arm 1 (L-citrulline)|25 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
62829594|NCT04852172|ACTIVE_COMPARATOR|Arm 2 (L-citrulline)|50 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
62829595|NCT04852172|ACTIVE_COMPARATOR|Arm 3 (L-citrulline)|100 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
62829596|NCT04852172|ACTIVE_COMPARATOR|Arm 4 (L-citrulline)|100 mg/kg bolus + 11 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
62829597|NCT04852172|ACTIVE_COMPARATOR|Part 2 Arm 1 (L-citrulline)|Subjects will be randomized to 2 of the doses selected from Part 1 and placebo in a 1:1:1 ratio. L-citrulline will be administered to the active arm.
62047555|NCT03391609|PLACEBO_COMPARATOR|control group|Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
62047556|NCT03391609|ACTIVE_COMPARATOR|Dex. group|Caesarian section will be performed under standard general anesthesia plus pre and intra operative Dexmedetomidine infusion in a dose of 0.5mic/kg/hour starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
62047557|NCT01763879|ACTIVE_COMPARATOR|The PCV-VCV group|The dependent lung will be ventilated with pressure controlled (PCV) followed by the volume-controlled ventilation (VCV)
62047558|NCT01763879|ACTIVE_COMPARATOR|The VCV-PCV group|The dependent lung will be ventilated with volume-controlled ventilation (VCV) followed by the pressure controlled (PCV)
62047559|NCT06033248||patients diagnosed with NSCLC|In phase I, the researchers will assess the ability of a rat-based ABP to detect the presence or absence of NSCLC-specific VOCs in urine samples from subjects with and without NSCLC. In phase II, the researchers will assess the ability of the ABP to detect the presence of NSCLC-specific VOCs in urine samples from subjects with suspected but undiagnosed NSCLC (clinical stage I to IIIA). Urine samples will be collected from 50 patients diagnosed with NSCLC and from 50 subjects without NSCLC for phase I and from 110 patients with suspected but undiagnosed NSCLC for phase II (total number of subjects = 210).
62047560|NCT03546517|EXPERIMENTAL|Intervention with DNHS technique|Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
62249962|NCT00605592|EXPERIMENTAL|1|Islet cell transplant
62439772|NCT05092334|EXPERIMENTAL|Proprioceptive exercises|"Group A treated with proprioceptive exercises. proprioception exercises included.~1. Head relocation it involve the practice of relocating head back to natural head posture and to predetermined positions in range first with eyes open using feedback from a laser attached to their head and then with closed all active movement of cervical flexion extension lateral flexion and rotations were used.~2. Gaze stability oculomotor exercises commencing with eyes movement with the head stationary, progressing to movement of head with visual fixation on a target.~3. Eye head coordination exercises, commenced with rotation of eyes and head to the same side in both right and left directions. Then progressed with both eyes and head move in opposite direction"
62829598|NCT04852172|PLACEBO_COMPARATOR|Part 2 Arm 2 D5 1/2NS|Subjects will be randomized to 2 of the doses selected from Part 1 and placebo in a 1:1:1 ratio.
62829599|NCT01065727|EXPERIMENTAL|mitoxantrone followed by immunomodulator|
62829600|NCT01065727|ACTIVE_COMPARATOR|natalizumab|
62047561|NCT03546517|SHAM_COMPARATOR|Sham Dry Needling|Sham Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
62047562|NCT03349801||no AMD|No interventions
62047563|NCT03349801||early AMD|No interventions.
62047564|NCT03349801||intermediate AMD|No interventions.
62047565|NCT03349801||late AMD|No interventions.
62047566|NCT03295890|SHAM_COMPARATOR|Sham Needling|Intervention = Sham Needling
62249963|NCT01739569|EXPERIMENTAL|Dietary treatment|Dietary treatment with healthy lunch and snack meal during working hours
62249964|NCT01739569|NO_INTERVENTION|Habitual meals|Dietary treatment with habitual diet
62829601|NCT00941213|ACTIVE_COMPARATOR|Monopolar Electrosurgery|Preparation during the operation with Monopolar Electrosurgery
62249965|NCT01519765|EXPERIMENTAL|Buccal misoprostol+placebo vaginal pill|
62249966|NCT01519765|ACTIVE_COMPARATOR|Vaginal Misoprostol+placebo buccal pill|
62829602|NCT00941213|EXPERIMENTAL|Ultrasound scissors|Preparation during the operation with ultrasound scissors
62829603|NCT01187355|EXPERIMENTAL|Alcon MPDS|MPDS used for 30 days as specified in protocol for contact lens care.
62829604|NCT01187355|ACTIVE_COMPARATOR|renu fresh MPS|MPS used for 30 days as indicated for contact lens care.
62607580|NCT02923245|EXPERIMENTAL|POCUS|Patients will be given consecutive IV fluid boluses until a full bladder is visualized by the ED physician on POCUS or the patient endorses maximal bladder fullness on a 0-4 Likert Scale. The patient will then have a transabdominal pelvic ultrasound performed by a radiologist or ultrasound technician.
62829605|NCT05270395|EXPERIMENTAL|mPal intervention|Participants in this group will receive the mPal intervention. mPal's patient content includes a multi-component web-based tool with the following: (1) a brief educational video that seeks to educate patients about palliative care; (2) and assessment of palliative care knowledge; (3) assessment of palliative care needs; and (4) an assessment of whether patients would like to meet with palliative care or discuss palliative care and their palliative care needs with their oncology provider. mPal's provider content (not randomized) will include education. System-level modifications will also be made to the electronic health record to facilitate palliative care discussions and referrals.
62829606|NCT05270395|NO_INTERVENTION|Standard of care|Participants in this group will receive standard of care (applies to patients only).
62829607|NCT04506411|EXPERIMENTAL|TPG|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive Turmipure GOLD® product during 12 weeks
62829608|NCT04506411|ACTIVE_COMPARATOR|STE|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive standard turmeric extract 95% curcuminoids (STE) product during 12 weeks
62047567|NCT03295890|ACTIVE_COMPARATOR|Active Needling|Intervention = Active Needling
62047568|NCT01907191|EXPERIMENTAL|Liposomal bupivacaine|Ultrasound guided injection of liposomal bupivacaine for patients undergoing hip arthroscopy
62047569|NCT01907191|ACTIVE_COMPARATOR|Bupivacaine|Bupivacaine (around the anterior, lateral and medial aspect of hip joint) for patients undergoing hip arthroscopy
62047570|NCT04794231|ACTIVE_COMPARATOR|Standard dressing group|Patients were randomly assigned to one of two dressings, both of which were being actively used as part of standard care.
62047571|NCT04794231|ACTIVE_COMPARATOR|Chlorhexidine gluconate -impregnated dressing group|Patients were randomly assigned to one of two dressings, both of which were being actively used as part of standard care.
62047572|NCT05925933|EXPERIMENTAL|High Protein Diet|High protein diet (carbohydrates 45%, protein 29%, and fat 26%) over 8-week periods. All assessments as done on day 1 will be repeated on day 60.
62047573|NCT05925933|OTHER|Control Group|Equicaloric normal diet (carbohydrates 60%, protein 15%, and fat 25%)
62249967|NCT01085786|ACTIVE_COMPARATOR|14-day sequential treatment|One in which the first component consists of a proton pump inhibitor and amoxicillin given for 7 days followed by the PPI, clarithromycin and metronidazole for 7 days.
62829609|NCT04506411|PLACEBO_COMPARATOR|Control|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive placebo (maltodextrin) product during 12 weeks
62829610|NCT06653998||Intensive care unit patients|Patients aged ≥ 18 years admitted to intensive care units and receiving the institutional early mobilisation protocol.
62829611|NCT05417620|OTHER|Standard of Care|"Full-time peer educators employed by the TB HIV Care programme to engage women, layer PrEP promotion across prevention programs, and implement refer a friend strategies, information, education and communication (IEC) materials, service user testimonials, risk reduction posters to increase young women's perception of risk, working after hours/weekends to reach young women, working with school governing bodies, and door-to-door outreach."
62829612|NCT05417620|EXPERIMENTAL|Enhanced social media campaign|Social media campaign which will be disseminated on Facebook, Instagram, and WhatsApp with targeted ads/promotion of materials in intervention districts.
62047574|NCT06364657||Sjogren's related dry-eye|Patients over the age of 18 years with known dry eye with underlying Sjogren's syndrome. Includes a previous diagnosis of dry eye made by an eye care specialist and a previous diagnosis of Sjogren's made according to the 2016 revised Sjogren's classification criteria.
62249968|NCT01085786|EXPERIMENTAL|14-day hybrid treatment|esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
62439773|NCT05092334|EXPERIMENTAL|Strengthening exercises|Group B treated with strengthening exercises which are performed with prone and supine position by placing a towel under head, press towel for 5 seconds with 10-12 repetitions ,one set in a week for six weeks for cervical muscles
62439774|NCT05720481|PLACEBO_COMPARATOR|Periodontitis quadrant Scaling root planing (SRP)|Each selected subject underwent to quadrant SRP
62439775|NCT05720481|ACTIVE_COMPARATOR|Periodontitis full mouth scaling root planing (SRP)|Each selected subject underwent to full mouth SRP
62439776|NCT05740670|EXPERIMENTAL|Dr. Kellyann's Bone Broth|During the bone broth phases, each week will be separated into 'fasting days' and 'feeding days'. There will be 2 non-consecutive fasting days and 5 feeding days per week. On fasting days, participants will be instructed to consume 1 packet of bone broth every 2 hours, for a total of 7 packets/day. On feeding days, participants will consume 3 meals/day, made up of 'Yes' foods portioned according to instructions provided in the Bone Broth Diet Quick Reference Guide and 1 packet of bone broth, twice a day, as snacks between meals. If a bone broth serving is missed participants are instructed to consume the serving as soon as they remember. Participants will be advised not to exceed 7servings of bone broth on fasting days and 2 servings on feeding days. During the maintenance phase, participants will not consume any bone broth.
62829613|NCT05417620|EXPERIMENTAL|Enhanced social media campaign + PrEP champions|Venue-based peers who will provide PrEP information, share personal experiences with PrEP, and refer young women to TB HIV Care to receive PrEP if interested in addition to the enhanced social media campaign.
62249969|NCT04582942|PLACEBO_COMPARATOR|PEG (low-risk patients and high-risk patients)|The dosing regimen of low-risk patients and high-risk patients will only be PEG.
62249970|NCT04582942|EXPERIMENTAL|PEG+lactulose (low-risk patients and high-risk patients)|The dosing regimen of low-risk patients and high-risk patients will be PEG combined with lactulose.
62829614|NCT05417620|EXPERIMENTAL|Enhanced social media campaign + Community mobilization|Peers will work within wards to organize and attend community meetings to share PrEP information and facilitate discussions with young women, male partners, family members, and other community members in addition to the enhanced social media campaign.
62047575|NCT06364657||non-Sjogren's related dry-eye|Patients over the age of 18 years with known dry eye without underlying Sjogren's syndrome. Includes a previous diagnosis of dry eye made by an eye care specialist and a previous diagnosis of Sjogren's according to the 2016 revised Sjogren's classification criteria was definitively excluded
62047576|NCT06364657||Control|Age-matched healthy controls with no known history of ocular surface diseases or dry eye or any underlying autoimmune disease
62047577|NCT05021510|EXPERIMENTAL|Simultaneous Cervical Traction & Neural Mobilization|Traction is a maneuver of distracting force to the cervical spine to cervical segments/grants decompression of nerve roots. For traction, 10% of the total body weight would be taken. Previous researches that investigated cervical traction found adequate effectiveness on pain reduction in neck and arm as well as improvement in nerve function parameters, and enhancement in neck mobility. The patient would be placed in a supine lying position with the cervical spine placed at 15º of flexion. The head strap will be fitted under the patient's occiput and chin. A safety switch will be given to the patient and ask him to press it if he would feel any kind of discomfort.
62249971|NCT01936909|EXPERIMENTAL|Anakinra (short)|Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks
62249972|NCT01936909|EXPERIMENTAL|Anakinra (long)|Anakinra 100 mg daily for 12 weeks
62249973|NCT01936909|PLACEBO_COMPARATOR|Placebo|Placebo injections daily for 12 weeks
62249974|NCT00572962|EXPERIMENTAL|1|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
62439777|NCT02873481|EXPERIMENTAL|Yoga (CPC+Y)|Women in Centering Pregnancy Care (CPC) will receive the intervention which is a 30 minute yoga sessions during each of the 2-hour CPC meetings (CPC+Y)
62439778|NCT02873481|NO_INTERVENTION|Comparison (CPC alone)|To strengthen our ability to examine causal relationships between the intervention and outcomes, we will use longitudinal comparison group data contributed from deidentified archival data from an existing IRB-approved study (PI: Masho) which includes pregnant women who participated in the CPC model of care alone (without the yoga component) and were followed throughout their pregnancies using numerous measures identical to those in the proposed study, including weight/BMI, depressive symptoms, anxiety, and stress.
62439779|NCT03511859||Control Group|Mammography/ultrasonography confirmed no findings.
62439780|NCT03511859||Cancer Group|The biopsy result is breast cancer.
62439781|NCT03094208|EXPERIMENTAL|study group|muscle strengthening, weight transfer, dual task balance exercises, dual task gait exercises.
62607581|NCT02923245|NO_INTERVENTION|Usual Care|Patients will be given consecutive IV fluid boluses until the patient endorses sensation of maximum bladder fullness on a 0-4 Likert Scale. The patient will then have a transabdominal pelvic ultrasound performed by a radiologist or ultrasound technician
62607582|NCT01472939|ACTIVE_COMPARATOR|SSP-002358 (0.1 mg) + Proton Pump Inhibitor (PPI)|
62607583|NCT01472939|ACTIVE_COMPARATOR|SSP-002358 (0.5 mg) + PPI|
62607584|NCT01472939|ACTIVE_COMPARATOR|SSP-002358 (2.0 mg) + PPI|
62249975|NCT03773198|EXPERIMENTAL|ERCS Group|
62249976|NCT03773198|PLACEBO_COMPARATOR|Control Group|
62249977|NCT00283049|EXPERIMENTAL|Insulins + Sulfonylurea (SU) + Thiazolidinedione (TZD)|Arm 1: Insulin glargine administered subcutaneously once daily plus a sulfonylurea and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c \>6.5%)
62249978|NCT00283049|EXPERIMENTAL|Insulins + Metformin (MET) + Thiazolidinedione (TZD)|Arm 2: Insulin glargine administered subcutaneously once daily plus metformin and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c \>6.5%)
62249979|NCT00283049|EXPERIMENTAL|Insulins + Metformin (MET) + Sulfonylurea (SU)|Arm 3: Insulin glargine administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added arms after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c \>6.5%)
62439782|NCT03094208|ACTIVE_COMPARATOR|control group|muscle strengthening, weight transfer, balance exercises, gait exercises.
62439783|NCT03238027|EXPERIMENTAL|Ph1a D1: 1 mg/kg Axatilimab|Three (3) patients receive starting dose of 1 mg/kg of axatilimab and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
62607585|NCT01472939|PLACEBO_COMPARATOR|Placebo + PPI|
62607586|NCT05958745|EXPERIMENTAL|Aerobic Exercise|12 week aerobic exercise
62607587|NCT05958745|ACTIVE_COMPARATOR|Aerobic + Resistance Exercise|12 week aerobic + resistance exercise
62607588|NCT05958745|NO_INTERVENTION|Control|control
62607589|NCT00603382|PLACEBO_COMPARATOR|Placebo|
62607590|NCT00603382|EXPERIMENTAL|GW685698X|
62829615|NCT05417620|EXPERIMENTAL|Enhanced social media campaign + PrEP champions + Community mobilization|Clusters in this arm will receive both the PrEP champion and community mobilization interventions in addition to the enhanced social media campaign.
62607591|NCT05769634|EXPERIMENTAL|Interoceptive Challenge Battery|During simultaneous stereoelectroencephalography recording (n=30) patients will complete a series of three computer-based tasks designed to evoke changes in interoceptive attention, arousal and anticipation.
62439784|NCT03238027|EXPERIMENTAL|Ph1a D2: 3 mg/kg Axatilimab|Three (3) patients receive next higher dose of 3 mg/kg of axatilimab and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
62439785|NCT03238027|EXPERIMENTAL|Ph1a D3: 6 mg/kg Axatilimab|Three (3) patients receive next higher dose of 6 mg/kg of axatilimab and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
62607592|NCT03080480|EXPERIMENTAL|Pioglitazone|Treatment for chronic granulomatous disease patients with severe infection.
62607593|NCT02060864|PLACEBO_COMPARATOR|Placebo|2 Placebo pills
62607594|NCT02060864|EXPERIMENTAL|AN-PEP 80.000 PPI|1 pill AN-PEP 80.000 PPI and 1 pill Placebo.
62607595|NCT02060864|EXPERIMENTAL|AN-PEP 160.000 PPI|2 pills AN-PEP 80.000 PPI
62607596|NCT06459869|EXPERIMENTAL|NG-350A plus CRT during a 12-week active study treatment period|
62607597|NCT06731361|NO_INTERVENTION|Control|Control group, care as usual
62829616|NCT02110069|ACTIVE_COMPARATOR|Vincristine|"Induction phase: participants assigned to vincristine will receive vincristine weekly at a dose of 0.05mg/kg/dose IV (for participants less than 10kg) or a dose of 1.5 mg/m2/dose (for participants greater than 10kg) for 2 months.~Maintenance: if participants continue to receive vincristine weekly for 2 months, every 2 weeks for 5 months and every 3 weeks for 5 months."
62439786|NCT03238027|EXPERIMENTAL|Ph1a D4: 10 mg/kg Axatilimab|Three (3) patients receive next higher dose of 10 mg/kg of axatilimab and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
62439787|NCT03238027|EXPERIMENTAL|Ph1b D1: 1 mg/kg Axatilimab+1500 mg durvalumab|Three (3) patients receive starting dose of 1 mg/kg of axatilimab every two weeks and 1500 mg durvalumab every four weeks and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee. If 1 DLT is observed in 1 of 3 patients, then 3 additional patients will be treated at the 1 mg/kg axatilimab dose level; if none of the 3 additional patients experience a DLT (i.e. 1 of 6), the dose will be escalated to an intermediate dose of 2 mg/kg. Escalation from 2 mg/kg to 3 mg/kg will follow the general dose escalation rules described above for both study phases.
62439788|NCT03238027|EXPERIMENTAL|Ph1b D2: 3 mg/kg Axatilimab+1500 mg durvalumab|Three (3) patients receive next higher dose of 3 mg/kg of axatilimab every two weeks and 1500 mg durvalumab every four weeks and are followed for possible DLTs. For cohorts with doses ≥3 mg/kg, a sentinel recruitment approach will be utilized. Initially 1 patient in each cohort will be treated with the combination therapy and safety will be evaluated by SRC at Cycle 1, Day 8; if no safety concerns are identified, the next 2 patients can be treated in that cohort. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
62607598|NCT06731361|EXPERIMENTAL|Educational intervention|The clusters that fall into the experimental arm receive the educational intervention: they receive an in-house training in combination with supporting tools, educational materials and intervision moments.
62607599|NCT06229405||Nonfunctioning adrenal adenoma|Incidentally detected adrenal mass without hormone production
62607600|NCT06229405||Mild autonomous cortisol secretion|Adrenal tumors that do not meet the criteria for adrenal Cushing's syndrome but are not suppressed to below 1.8 µg/dL after the dexamethasone suppression test
62607601|NCT06229405||Adrenal Cushing syndrome|Adrenal diseases characterized by biochemical hypercortisolism accompanying with overt Cushingoid features.
62607602|NCT06229405||Primary aldosteronism|"Adrenal diseases characterized by the excessive production of the hormone aldosterone and suppressed renin.~Diagnostic criteria are as the following:~1. Plasma aldosterone level of ≥6 ng/dL after a seated saline infusion test~2. Plasma aldosterone level of ≥13 ng/dL after a captopril challenge test."
62607603|NCT06229405||Pheochromocytoma and paraganglioma|Chromaffin-originated tumors in the adrenal gland and others, characterized by catecholamine excess
62607604|NCT06229405||Adrenal cortical carcinoma|Malignant tumors originated from the adrenal cortex, which was confirmed by biopsy or pathology results
62607605|NCT01861873|OTHER|liver metastases|measuring liver function by PET/CT at patients where SBRT is planned for liver metastases
62607606|NCT03724240|PLACEBO_COMPARATOR|Placebo solution|Placebo Comparator: Placebo The product will be supplied as ready-to-use vials containing 1.5 mL of aqueous buffered solutions at pH 7.4 containing sodium phosphate, NaCl, mannitol and trehalose. the dosage is100 µg/ml. The treatment schedule will consist in a subcutaneous injection over four visits during 3 consecutive weeks. The patient will receive two injections (1 per arm)with an interval of 30 minutes between both.
62607607|NCT03724240|EXPERIMENTAL|gpASIT+™ (Grass Pollen-ASIT+™)|Experimental: gpASIT+™ The product will be supplied as ready-to-use vials containing 1.5 mL of aqueous buffered solutions at pH 7.4 with a grass pollen peptide concentration of 100 µg/mL. Excipients are sodium phosphate, NaCl, mannitol and trehalose. the dosage is100 µg/ml.The treatment schedule will consist in a subcutaneous injection over four visits during 3 consecutive weeks.The patient will receive two injections (1 per arm)with an interval of 30 minutes between both.
62607608|NCT06730945|EXPERIMENTAL|Isosorbide Mononitrate + Amlodipine|Oral isosorbide mononitrate 40mg (if unable to tolerate, use 20mg) once daily + amlodipine 5mg (if unable to tolerate, use 2.5mg) once daily for 24 weeks after CABG
62249980|NCT01329887|OTHER|administration of ketanserin|
62829617|NCT02110069|EXPERIMENTAL|Sirolimus|"Sirolimus will be administered at a dose of 0.8mg/m2/dose twice a day on a continuous dosing schedule throughout the trial for participants randomized to Sirolimus or for participants who fail vincristine may cross-over to the sirolimus arm.~Sirolimus trough levels will be maintained between 10-15 ng/ml."
62047578|NCT05021510|ACTIVE_COMPARATOR|consecutive Cervical Traction & Neural Mobilization|the same description is for active comparator except for treatment mode to consecutive.
62047579|NCT01185067|ACTIVE_COMPARATOR|grape seed extract capsule|Grape seed extract (MegaNatural BP, Polyphenolics, Inc.) 300 milligram capsules twice daily for six weeks
62047580|NCT01185067|PLACEBO_COMPARATOR|maltodextrin capsule|Maltodextrin capsules (matched for appearance and taste to grape seed extract capsules) twice daily for six weeks
62047581|NCT04182100|EXPERIMENTAL|P1101|Conventional treatment based on phlebotomies, low-dose aspirin (acetylsalicylic acid, 75-150 mg/day) plus the subcutaneous administration of pegylated proline-interferon alpha-2b (P1101, ropeginterferon alfa-2b) once every 2 weeks.
62047582|NCT03941275||Subjects undergoing bi-plane fluoroscopy|
62607609|NCT06730945|NO_INTERVENTION|Blank control|no use of any nitrates or CCBs for 24 weeks after CABG. if there are indications of hypertension, use RAASi rather than CCB.
62607610|NCT04246645|NO_INTERVENTION|CONTROL GROUP|received the selective physiotherapy exercises
62829618|NCT05947357|EXPERIMENTAL|Nutrition Assistance Program|A total of 30 Latinx cancer patients on active cancer treatment who have screened positive for food insecurity will receive a $40.00 voucher for use each month for 6 months for nutrition assistance in the produce section of local grocery stores after enrollment in the program.
62829619|NCT05947357|NO_INTERVENTION|Usual Care|A total of 30 patients who have screened positive for food insecurity will receive usual care consisting of referral to the local food bank as part of the nutrition assistance program.
62829620|NCT06082362||Infertile men|Men with infertility
62829621|NCT06082362||Fertile men|Fertile men
62829622|NCT06082362||Oncologic patients|Patients with kidney, bladder, chest, or pancreas tumors
62829623|NCT05483777|EXPERIMENTAL|PRF|If the patient is in the experimental group, platelet rich fibrin will be applied to the diabetic foot wound.
62829624|NCT05483777|NO_INTERVENTION|CWD|If the patient is in the control group, classic wound dressing will be applied to the diabetic foot wound.
62829625|NCT02923726|ACTIVE_COMPARATOR|ATP and Shock|Once tachycardia has been detected and duration met, this group would receive antitachycardia pacing prior to shock therapy.
62047583|NCT03065270|EXPERIMENTAL|A group|
62047584|NCT03065270|EXPERIMENTAL|B group|
62829626|NCT02923726|EXPERIMENTAL|Shock only|Once tachycardia has been detected and duration met, this group would receive shock therapy only.
62829627|NCT04568616|EXPERIMENTAL|Treatment|Letrozole 2.5mg tablet administered once daily for 4 to \~12 weeks (window of + 4 weeks for surgical scheduling flexibility) final dose taken the day of surgery.
62829628|NCT02870595|ACTIVE_COMPARATOR|Parallel lidocaine injection|Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
62607611|NCT04246645|EXPERIMENTAL|STUDY GROUP|received the same selective physiotherapy exercises program in addition to core stability exercises three times/week for 60 min for 12 weeks
62829629|NCT02870595|SHAM_COMPARATOR|Parallel|In the sham comparator, the device will be placed on the skin, but not turned on. Digit block anesthesia will progress in usual fashion as with active comparator, except without the vibratory device engaged.
62829630|NCT03157817||Chronic Obstructive Pulmonary Disease|Patients with a diagnosis of Chronic Obstructive Pulmonary Disease
62829631|NCT03157817||Healthy Volunteers|Volunteers without any respiratory condition or symptoms
62047585|NCT02456402|EXPERIMENTAL|Drug Coated Balloon|PCB (SeQuent Please®, paclitaxel-coated balloon catheter, B. Braun, Melsungen, Germany)
62047586|NCT02456402|ACTIVE_COMPARATOR|Bare Metal Stent|BMS (Vision®)
62047587|NCT01180348|EXPERIMENTAL|Botulift|Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
62607612|NCT01239836|EXPERIMENTAL|Self-management|
62607613|NCT01239836|SHAM_COMPARATOR|General Health Lecture|
62607614|NCT01239836|EXPERIMENTAL|Combined workshop and self-management|
62607615|NCT01239836|EXPERIMENTAL|Workshop|
62047588|NCT01180348|ACTIVE_COMPARATOR|Botox|Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
62047589|NCT02080468|EXPERIMENTAL|Arm 1: Lomitapide & EE/Norgestimate - Taken Together|Lomitapide \& EE/Norgestimate - Taken Together 2 single oral doses of lomitapide (20 mg) (Day 1 \& Day 22) 21 single oral doses of EE/Norgestimate(Day 8 through day 28)
62047590|NCT02080468|EXPERIMENTAL|Arm 2: Lomitapide & EE/Norgestimate - Taken 12 Hours Apart|Lomitapide \& EE/Norgestimate - Taken 12 hours apart 2 single oral doses of lomitapide (20 mg) (Day 1 \& Day 22) 21 single oral doses of EE/Norgestimate(Day 9 through day 29)
62249981|NCT00698451|EXPERIMENTAL|001|doxorubicin HCL liposome; bevacizumab; carboplatin30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
62249982|NCT00698997|EXPERIMENTAL|1 Early Start Denver Model|"Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching \& coaching parents to use the ESDM in all natural caretaking routines \& play periods with their child. Parents are taught \& coached on 1 aspect of the ESDM each week in the clinic session, \& then practice it at home daily in natural family routines \& play.~Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines \& play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week."
62249983|NCT00698997|OTHER|2 Standard Care available in the Community|Any intervention that were available and that families accessed in their communities
62249984|NCT03662217|EXPERIMENTAL|Algorithm-based diet|Subjects randomized to this arm will receive personally tailored dietary recommendations based on their predicted glycemic responses according to the study algorithm.
62249985|NCT03662217|OTHER|ADA- based diet|Subjects randomized to this arm will receive nutritional recommendations according to the standard American dietary approach for treating diabetes
62249986|NCT02232282|SHAM_COMPARATOR|Minimal Acupuncture|"Fifteen (15) will be allocated in the control sham/minimal acupuncture + standard medical treatments of IC. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture."
62249987|NCT02232282|ACTIVE_COMPARATOR|Standard acupuncture treatment|Fifteen (15) will be allocated in the standard acupuncture treatment + medical management of IC. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
62249988|NCT01087957|ACTIVE_COMPARATOR|Ankle-Foot Orthosis (AFO)|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
62249989|NCT01087957|ACTIVE_COMPARATOR|WalkAide|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
62249990|NCT02443649|EXPERIMENTAL|Sleep hypnosis plus sleep hygiene|Those randomized into this group will receive the sleep hygiene program plus hypnosis.
62249991|NCT02443649|ACTIVE_COMPARATOR|Sleep hygiene only|Those randomized into this group will receive the Optimizing Sleep Hygiene program during the intervention visit and hypnosis recording after the follow-up visit.
62249992|NCT01903642|OTHER|Patients with inflammatory syndrome|
62249993|NCT04170790|EXPERIMENTAL|Healthy volunteer|Day 1: Sildenafil 50 mg single dose Day 2-Day 8: Washout period Day 9-12: Saxagliptin 5 mg Once/day Day 13: Sildenafil 50 mg+ Saxagliptin 5 mg
62439789|NCT03238027|EXPERIMENTAL|Ph1b D3: 6 mg/kg Axatilimab+1500 mg durvalumab|Three (3) patients receive next higher dose of 6 mg/kg of axatilimab every two weeks and 1500 mg durvalumab every four weeks and are followed for possible DLTs. For cohorts with doses ≥3 mg/kg, a sentinel recruitment approach will be utilized. Initially 1 patient in each cohort will be treated with the combination therapy and safety will be evaluated by SRC at Cycle 1, Day 8; if no safety concerns are identified, the next 2 patients can be treated in that cohort. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
62439790|NCT02532010|ACTIVE_COMPARATOR|Arm A: Pacritinib and Decitabine|Arm A: Each cycle: Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
62439791|NCT02532010|ACTIVE_COMPARATOR|Arm B: Pacritinib and Cytarabine|Arm B: Each cycle: Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
62829632|NCT00631072|OTHER|GM-CSF +INKT|"INKT will be administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.~GM-CSF will be given subcutaneously once daily for 10 days beginning the second day of the second and third infusion"
62047591|NCT02150018||non invasive ventilation (NIV)|
62249994|NCT02910960|ACTIVE_COMPARATOR|Acquire EUS Biopsy Device|All patients will undergo sampling of pancreatic masses using the Acquire EUS Biopsy Device. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
62829633|NCT06595199|EXPERIMENTAL|Intervention: online group|Online peer support group
62829634|NCT06595199|NO_INTERVENTION|Control: standard care|Standard care
62829635|NCT04145661|EXPERIMENTAL|DR group|Participants who have cochlear dead regions, identified by the thresholds equalising noise test will be placed in this group.
62047592|NCT02115555|EXPERIMENTAL|HIT-aided approach|Adolescents and their parents randomized to this arm will be oriented on a HIT system. The system transmits self monitoring blood glucose self monitoring blood glucose data to a secure web portal. The subject will receive messages from the HIT system on the meter based upon the Self Monitored Blood glucose tests.
62047593|NCT02115555|EXPERIMENTAL|Contracted conflict management system|Adolescent-parent pairs will meet with a health educator to establish a behavioral contract that will set patient-centered self-management goals for the adolescent.
62047594|NCT02115555|EXPERIMENTAL|HIT plus contracted conflict management|Adolescents and their parents randomized to this arm will be oriented on a HIT system. The system transmits self monitoring blood glucose data to a secure web portal. The subject will receive messages from the HIT system on the meter based upon the tests. In addition, adolescent-parent pairs will meet with a health educator to establish a behavioral contract that will set patient-centered self-management goals for the adolescent. This arm combines arms 1 and 2.
62047595|NCT03996850||Health service research (MIBI SPECT/CT, questionnaire)|Patients receive technetium Tc-99m sestamibi IV then undergo SPECT/CT.
62047596|NCT03428425|EXPERIMENTAL|apatinib paclitaxel S-1|
62249995|NCT02910960|ACTIVE_COMPARATOR|SharkCore Biopsy System|All patients will undergo sampling of pancreatic masses using the SharkCore Biopsy System. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
62249996|NCT02126033|EXPERIMENTAL|celiac disease|
62439792|NCT00410722|EXPERIMENTAL|Full-Dose Nut|Subjects will be given tree nuts (almonds, hazelnuts, pistachios, macadamia nuts, pecans, walnuts, and cashews) and peanuts (at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
62439793|NCT00410722|EXPERIMENTAL|Half-Dose Nut|Subjects will be given tree nuts (almonds, hazelnuts, pistachios, macadamia nuts, pecans, walnuts, and cashews) and peanuts as well as the control supplement (wheat bran muffin)(at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
62829636|NCT04145661|EXPERIMENTAL|No DR group|Participants who have no cochlear dead regions, identified by the thresholds equalising noise test will be placed in this group.
62829637|NCT04790916|EXPERIMENTAL|RO7049665 3.5 mg|Participants will receive RO7049665 3.5 mg, administered as subcutaneous (SC) injection, every 2 weeks (Q2W) until participants experience relapse or the study is closed.
62829638|NCT04790916|EXPERIMENTAL|RO7049665 7.5 mg|Participants will receive RO7049665 7.5 mg, administered as SC injection, Q2W until participants experience relapse or the study is closed.
62047597|NCT04196426|EXPERIMENTAL|nutrition education group|The nutrition education group receive the intervention first, which include 2 nutrition lessons about osteoporosis and calcium and calcium rich foods. The 2 lessons are delivered in one week for 2 hours each lesson. After this week, participants in the intervention group receive handouts about osteoporosis and calcium once a week for a period of 4 weeks.
62047598|NCT04196426|ACTIVE_COMPARATOR|delayed nutrition education group|After the intervention group finish their intervention (5 weeks period), post data collection will be administered in both nutrition education and delayed nutrition education group. After this post data collection, the delayed nutrition education group receive the same intervention.
62047599|NCT03610295|EXPERIMENTAL|PPI group|cataract extraction surgery with prophylactic peripheral iridectomy
62047600|NCT03610295|ACTIVE_COMPARATOR|historical control group|cataract extraction surgery
62047601|NCT01037855||Group 1: 6-23 months|
62249997|NCT01507779|EXPERIMENTAL|Influenza vaccine|Received 0.50 mL of inactivated monovalent influenza vaccine (IVACFLU), administered intramuscularly, on days 0 and 21
62249998|NCT01507779|PLACEBO_COMPARATOR|Placebo|Received placebo, administered intramuscularly, on days 0 and 21
62829639|NCT04790916|PLACEBO_COMPARATOR|Placebo|Participants will receive RO7049665-matching placebo, administered as SC injection, Q2W until participants experience relapse or the study is closed.
62047602|NCT01037855||Group 2: 2-8 years|
62047603|NCT01037855||Group 3: 9-17 years|
62047604|NCT01037855||Group 4: 18-44 years|
62047605|NCT01037855||Group 5: 45-60 years|
62249999|NCT03143010|PLACEBO_COMPARATOR|control group|intrathecal Dexmedetomidine received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline .
62250000|NCT03143010|EXPERIMENTAL|1.5 DEX|Dexmedetomidine 1.5 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (1.5μg) dexmedetomidine
62250001|NCT03143010|EXPERIMENTAL|3 DEX|Dexmedetomidine 3 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (3μg) dexmedetomidine
62250002|NCT03143010|EXPERIMENTAL|5 DEX|Dexmedetomidine 5 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (5μg) dexmedetomidine
62250003|NCT00744211|PLACEBO_COMPARATOR|Vehicle|Vehicle Group
62047606|NCT01037855||Group: >60 years|
62250004|NCT00744211|EXPERIMENTAL|ET-ARA 1mg/kg|ET-ARA 1 mg/kg
62250005|NCT00744211|EXPERIMENTAL|ET-ARA 2mg/kg|ET-ARA 2 mg/kg
62250006|NCT01587339||Drug-resistant (or refractory) partial epilepsy of all types|Drug-resistant (or refractory) partial epilepsy of all types
62250007|NCT01069120|ACTIVE_COMPARATOR|50 mg Proellex®|2, 25 mg capsules
62047607|NCT02297022|EXPERIMENTAL|Deep Brain Stimulation|Patients with Prader-Willi syndrome to receive DBS.
62047608|NCT06256133||ANS-Surg-ERAS group|fully implementing ERAS pathway including anesthesiology-related components
62250008|NCT01069120|ACTIVE_COMPARATOR|25 mg Proellex®|1, 25 mg capsule
62250009|NCT05843682|OTHER|Avatr|"In the inclusion visit, it will be install the Avatr App in the mobile device of the patients. The patients will give an evaluation to perform by the medical and nursing staff, where clinical data (office blood pressure, weight, height, abdominal circumference) will be collected and will answer questionnaires on quality of life, anxiety, sleep quality, food intake and therapeutic adherence. They will receive an automatic blood pressure measurement device to make household blood pressure measurement according to nursing guidance. Also, the patients will collected blood samples to further analysis for biochemical profile and 24-hour urine collection sample for urinary sodium dosage.~The patients will take four in person visits after the initial visit, with the final visit after 12 months."
62250010|NCT05843682|NO_INTERVENTION|Control|"The patients will perform the same initial evaluation and answer the same questionnaires as described above for the Intervention Group. In this evaluation they will receive guidance regarding the adoption of life habits by the multidisciplinary team. The Control Group will receive reinforcement of guidance only in face-to-face visits.~The patients will take four in person visits after the initial visit, with the final visit after 12 months."
62250011|NCT03771586|EXPERIMENTAL|SAGE-718|
62250012|NCT03771586|PLACEBO_COMPARATOR|Placebo|
62829640|NCT01940952|ACTIVE_COMPARATOR|Zydena 50mg|Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg
62047609|NCT06256133||Surg-ERAS group|preoperative and postoperative ERAS protocol without anesthesiology-related components
62047610|NCT06256133||Conventional group|non-ERAS group
62047611|NCT05795101|EXPERIMENTAL|HER2 Positive|"Participants will be enrolled into one of two cohorts: HER2 positive IBC (cohort 1) and HER2 low IBC (cohort 2).~* HER2-positive determined locally by the current ASCO/CAP guidelines~* Participants will receive trastuzumab deruxtecan plus durvalumab for eight cycles prior to surgery. (Cycle Length is 21 days)~* After surgery, Participants will receive therapy per physician's choice and to reflect current standard of care."
62439794|NCT00410722|ACTIVE_COMPARATOR|Control|Subjects will be given a control supplement (wheat bran muffin)(at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
62829641|NCT01940952|PLACEBO_COMPARATOR|Placebo|Placebo + Donepezil 5mg or 10mg
62829642|NCT01940952|ACTIVE_COMPARATOR|Zydena 100mg|Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg
62829643|NCT04381364|EXPERIMENTAL|Medical treatment|Treatment with ciclesonide
62829644|NCT04381364|NO_INTERVENTION|Standard of Care|Standard Medical Care
62829645|NCT06508190|ACTIVE_COMPARATOR|continuous positive airway pressure therapy|The continuous positive airway pressure therapy equipment is used for 12 weeks, all patients in this group groups must utilize the CPAP machine for 4 hours each night.
62829646|NCT06508190|EXPERIMENTAL|Free walking & continuous positive airway pressure therapy|"Each patient is required to walk 30 minutes, seven days a week for 12 weeks.~\& The continuous positive airway pressure therapy equipment is used for 12 weeks, all patients in both groups must utilize the CPAP machine for 4 hours each night."
62829647|NCT03755713|EXPERIMENTAL|ASP0892 Low Dose (Cohort A)|Each cohort will consist of 10 participants (ASP0892 n = 8 and placebo n = 2). The data will be assessed by the Data Monitoring Committee (DMC) after all enrolled cohort A participants complete visits through day 43. Assessments for safety, tolerability, and dose escalation will occur prior to beginning cohort B.
62829648|NCT03755713|EXPERIMENTAL|ASP0892 High Dose (Cohort B)|After all participants in cohort A complete study procedures, the DMC will review the safety and tolerability data and provide recommendations depending on the nature, frequency and severity of the safety profile reviewed. Recommendations will be to proceed with escalation to the next higher dose or stop dose escalation (i.e., no further dosing with study drug).
62047612|NCT05795101|EXPERIMENTAL|HER2-Low|"Participants will be enrolled into one of two cohorts: HER2 positive IBC (cohort 1) and HER2 low IBC (cohort 2)~* HER2-low tumor expression (IHC 2+/ISH-, IHC 1+/ISH-, or IHC 1+/ISH untested)~* Participants will receive trastuzumab deruxtecan plus durvalumab for eight cycles prior to surgery (Cycle Length is 21 days)~* After surgery, Participants will receive therapy per physician's choice and to reflect current standard of care."
62607616|NCT01811836|EXPERIMENTAL|Resistant Starch|"Oral and intravenous zinc stable isotopes. Zinc: 67Zn (\>97% enrichment),68Zn (\>99% enrichment) and 70Zn (\>95% enrichment) Days 1 and 38: children will be administered 40-75 μg of 67Zn through consumed food. At the end of these days, children will be given an intravenous injection of an accurately measured quantity of \~800 μg of 68Zn.~Days 3-35: resistant starch feeding -- which will be given to mothers and integrated into the food."
62047613|NCT05539092|EXPERIMENTAL|intervention group|the researcher will change angle of bed from 15° to 45°. The severity of pain will be assessed for five times starting immediately after sheath removal. Vascular complications monitoring scales will be assessed I for five times starting immediately after sheath removal.
62607617|NCT03348098|EXPERIMENTAL|single arm|Apatinib Combined With Paclitaxel in Neoadjuvant Therapy of Locally Advanced Exploratory Research on Single-arm of TNBC
62829649|NCT03755713|PLACEBO_COMPARATOR|Placebo|Each cohort will consist of 10 participants (ASP0892 n = 8 and placebo n = 2). The data will be assessed by the Data Monitoring Committee (DMC) after all enrolled cohort A participants complete visits through day 43. Assessments for safety, tolerability, and dose escalation will occur prior to beginning cohort B.
62829650|NCT04117555||Control|Diagnostic Test: Pupillometry
62829651|NCT04117555||Parkinson patients|Diagnostic Test: Pupillometry
62829652|NCT06116838|EXPERIMENTAL|Carrier frequency + Waveform|Spinally Evoked Motor Potentials (sEMP) will be obtained while stimulating the spinal cord at a single site with single pulses. sEMP are the electromyograph responses of the peripheral muscles to electrical stimulation of the spinal cord. We will test various waveform combinations of biphasic and monophasic waveforms with modulation frequencies of 0-10 kHz. Participants will also ambulate while receiving continuous stimulation of the various waveform combinations to determine what stimulation intensity is comfortable for each combination. The order we complete this testing will be randomized. All participants will perform testing in a different order.
62829653|NCT06116838|EXPERIMENTAL|Stimulation Location|Spinally Evoked Motor Potentials (sEMP) will be obtained while stimulating the spinal cord at various stimulation locations with single pulses. sEMP are the electromyograph responses of the peripheral muscles to electrical stimulation of the spinal cord. Participants will also ambulate while receiving continuous stimulation to various stimulation locations to determine what stimulation intensity is comfortable for each location. The order we complete this testing will be randomized. All participants will perform testing in a different order.
62829654|NCT04409925|EXPERIMENTAL|rhDNase1 (Pulmozyme, Roche/Genentech)|Single Arm: rhDNase1 (Pulmozyme, Roche/Genentech) 2.5 mg inhaled nebulisations BID, for a maximum of 14 consecutive days.
62829655|NCT01434615|EXPERIMENTAL|No-CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
62829656|NCT01434615|EXPERIMENTAL|CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
62829657|NCT05684822|EXPERIMENTAL|The experimental group received acupuncture treatment|The experimental group received acupuncture treatment (Taichong, Shenmen, Neiguan points) twice a week, total three weeks, plus sleep hygiene guidance
62829658|NCT05684822|SHAM_COMPARATOR|The control group received subcutaneous sham acupuncture|The control group received subcutaneous acupuncture (non-therapeutic acupuncture points) twice a week, total three weeks and given sleep Health guidance.
62829659|NCT00574197|OTHER|Enteric-coated Mycophenolate Sodium (Myfortic)|1440mg/day (720mg by mouth, twice a day) of enteric-coated Mycophenolate Sodium (Myfortic) for 6 months
62829660|NCT02578069|EXPERIMENTAL|Experimental|NOVA Intracranial sirolimus eluting stent system
62829661|NCT02578069|ACTIVE_COMPARATOR|Control|Apollo Intracranial stent system
62829662|NCT06541548|EXPERIMENTAL|Patient group|Describe bone quality and quantity with HR-pQCT, pQCT and DEXA in the group of patients at risk of osteoporosis.
62829663|NCT06541548|EXPERIMENTAL|Control group|Describe the quality and quantity of bones with HR-pQCT, pQCT and DEXA in the group of patients not at risk of osteoporosis.
62829664|NCT03938259||Control group; patients without obstructive sleep apnea|Children without OSA having procedures requiring endotracheal intubation and an who will receive opioids for evaluation of respiratory changes
62829665|NCT03938259||Patients with known obstructive sleep apnea|Children with OSA having adenotonsillectomy for obstructive apnea will receive opioids with evaluation of respiratory changes
62829666|NCT03898544||Group primary TKA|Patients operated of primary TKA Stryker for knee osteoarthritis.
62829667|NCT03898544||Group TKA revision|Patients operated of a first revision of TKA for a mechanical failure, with the revision Stryker TKA
62829668|NCT01716377|PLACEBO_COMPARATOR|Placebo|37.5mg QD 1 week 75mg QD 1 week 150mg QD 8 weeks 75mg QD 1 week 37.5mg QD 1 week
62829669|NCT01716377|ACTIVE_COMPARATOR|Venlafaxine|37.5mg QD 1 week 75mg QD 1 week 150mg QD 8 weeks 75mg QD 1 week 37.5mg QD 1 week
62607618|NCT00989859||Plethysmographic monitoring|Plethysmographic monitoring
62607619|NCT00236275|EXPERIMENTAL|1|Fluoro-L-thymidine-(18F)
62829670|NCT02706106|EXPERIMENTAL|Knee brace with a hole|Patients will be prepared to receive the device of knee brace with a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
62607620|NCT01311934||HBV-infected|
62607621|NCT01311934||HCV-infected|
62047614|NCT05539092|NO_INTERVENTION|control group|positioning the patients in supine for 6 hours and the affected leg was straight and immobilized. The severity of pain will be assessed for five times starting immediately after sheath removal. Vascular complications monitoring scales will be assessed I for five times starting immediately after sheath removal.
62607622|NCT05530980|EXPERIMENTAL|GameDay Ready Program|The GameDay Ready Program is a 12-week, football-themed, behavioral weight management intervention that promotes gradual increases in physical activity, reductions in sedentary time, and improvements in dietary habits through education, self-monitoring of physical activity and diet, personalized goal setting, group-based competition, social support, identifying and overcoming barriers, and including physical activity as a substantial component of meeting sessions. The program is sensitive to unique cultural influences surrounding gender, race, and rurality; and issues related to motivation are threaded throughout the program.
62047615|NCT06579066|EXPERIMENTAL|probiotics|"Patients will administer Linex ® capsule orally along with the standard care of therapy for duration of 4 weeks.~Dose: Capsule once daily"
62047616|NCT06579066|EXPERIMENTAL|activated charcoal|"Patients will administer Charclone® 1000mg tab orally along with the standard care of therapy for duration of 4 weeks.~Dose: Tablet three times daily."
62250013|NCT06374875|ACTIVE_COMPARATOR|Metabolic Surgery|FLAMES will examine the class effect (not the specific procedure effect) of metabolic surgery. The study is not intended to compare Roux-en-Y Gastric Bypass (RYGB) vs Sleeve Gastrectomy (SG) head-to-head. RYGB and SG constitute one group as a metabolic surgery group. Assignment of RYGB or SG is not based on a randomized design. Each patient and surgical team will make a shared decision about the most appropriate surgical procedure.
62250014|NCT06374875|ACTIVE_COMPARATOR|Incretin-Based Therapy|Three incretin-based medications that have been approved for treatment of obesity including liraglutide, semaglutide, or tirzepatide will be used in the nonsurgical group. The FLAMES will examine the class effect (not the specific drug effect) of incretin-based therapies. The study is not intended to compare semaglutide vs tirzepatide vs liraglutide head-to-head.
62250015|NCT00827684|ACTIVE_COMPARATOR|Response or stable disease|will receive Temsirolimus
62250016|NCT00827684|EXPERIMENTAL|Progression|Will receive a combination of Temsirolimus and Irinotecan
62439795|NCT04854720|EXPERIMENTAL|Group 1 (Fuji II LC-Fuji Triage)|In Group 1, newly erupted mandibular permanent first molars were sealed with resin-modified glass ionomers containing fissure sealant material (Fuji® II LC, GC Corporation, Tokyo, Japan) (test 1). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).
62439796|NCT04854720|EXPERIMENTAL|Group 2 (Clinpro XT Varnish-Fuji Triage)|In Group 2, newly erupted mandibular permanent first molars were sealed with resin-modified glass ionomers containing fissure sealant material (Clinpro™ XT Varnish, 3M ESPE, St. Pauls, Miniapolis, MN, USA) (test 2). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).
62607623|NCT00314132|PLACEBO_COMPARATOR|Placebo|All subjects received a single injection of placebo on Day 0.
62047617|NCT06579066|NO_INTERVENTION|Control|Patients will administer standard care of therapy alone Telfast®120mg tablet for duration of 4 weeks.. Dose: Tablet once daily
62047618|NCT01866943|PLACEBO_COMPARATOR|Group 1|Patients undergo primary total hip arthroplasty and have a wash of 100cc of normal saline applied to the tissues under the skin prior to skin closure. The wash sits in the wound for 5 minutes then is suctioned out and the skin is closed.
62250017|NCT05030103|ACTIVE_COMPARATOR|Glasses|The participants are asked to wear reading glasses during near-work. The reading glasses have a lenspower of +2.0 diopters.
62250018|NCT05030103|NO_INTERVENTION|Control|Age matched children and adolescents, no intervention.
62250019|NCT02941887||Down's Syndrome|Behavior analysis in Down's Syndrome patients
62250020|NCT06034535|EXPERIMENTAL|Treatment|CD62L depleted donor lymphocyte infusion
62250021|NCT00117507|EXPERIMENTAL|Deferasirox|Participants received deferasirox 20mg/kg/day OD for 12 months. Deferasirox was taken every morning 30 minutes before breakfast, if possible consistently around the same time between 7:00 and 9:00 AM. The tablets was dropped into water or orange juice and gently stirred for 1 to 3 minutes until completely dispersed.
62439797|NCT04854720|EXPERIMENTAL|Group 3 (Beautiful Flow- Fuji Triage)|In Group 3, newly erupted mandibular permanent first molars were sealed with Giomer containing fissure sealant material (Beautifil Flow, Shofu, Kyoto, Japan) (test 3). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).
62439798|NCT01191255|ACTIVE_COMPARATOR|Active Control|PhosLo (calcium acetate) Renvela (sevelamer carbonate)
62829671|NCT02706106|PLACEBO_COMPARATOR|Knee brace without a hole|Patients will be prepared to receive the device of knee brace without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
62047619|NCT01866943|EXPERIMENTAL|Group 2|Patients undergo primary total hip arthroplasty and have a wash of 100cc of normal saline plus 1.5 g (100 mg/mL)Tranexamic Acid is applied to the tissues under the skin prior to skin closure. The wash sits in the wound for 5 minutes then is suctioned out and the skin is closed.
62047620|NCT04496102|ACTIVE_COMPARATOR|Cemented TKA|Cemented TKA (Triathlon, Stryker) include patellar resurfacing
62047621|NCT04496102|EXPERIMENTAL|Cementless TKA|Cementless TKA (Triathlon Tritanium, Stryker) include patellar resurfacing
62047622|NCT03451734||treatment cohort|in sub-project 1, participants are randomized into olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups, we give them evaluation, and adjust dose of medication and deal with side effect if necessary.
62829672|NCT03207295|EXPERIMENTAL|Intervention-Nesiritide|A standard dose of Nesiritide(0.001ug/kg/min) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
62829673|NCT03207295|PLACEBO_COMPARATOR|Control-Normal saline|Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
62829674|NCT06591793|EXPERIMENTAL|Cohort 1|AAVB-081 dose level 1
62047623|NCT03451734||adjunctive group|Patients who do not have an ideal response to antipsychotics treatment (reduction rate of Positive and Negative Symptom Scale (PANSS) score less than 25%) in sub-project 2 are recruited in this trial. They are randomly assigned to antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups, and the antipsychotic drugs used at this stage are still consistent with the first trial of sub-project 2. At baseline, 4 weeks and 8 weeks after treatment, all participants receive evaluations.
62047624|NCT03451734||metformin and lifestyle intervention for MetS|Participants who develop MetS at the last visit in sub-project 1 and sub-project 2 are recruited in this trial. Patients are randomized into low-dose metformin (1000 mg/d), high-dose metformin (1500 mg/d), low dose metformin plus lifestyle intervention group (1000 mg/d), high dose metformin plus lifestyle intervention (1500 mg/d), lifestyle intervention, and placebo groups. The timepoints of the visits are at baseline, the 4th week, the 8th week, and the 12th week.
62250022|NCT02934308|EXPERIMENTAL|ICU patients|
62250023|NCT03800888|EXPERIMENTAL|Arm A|Participants in Arm A will receive a Wisepill device for Real- time monitoring plus Daily SMS reminders plus Social Supporter notifications (for 3 months) sent according to participant's preferred time and then shall receive Linked SMS for missed dose (Right after missed dose) plus Social Support notifications (3 months).
62250024|NCT03800888|EXPERIMENTAL|Arm B|Participants in Arm B will receive a wisepill device for Real-time monitoring plus Weekly SMS reminders plus Social support notifications (for 3 months) sent according to participant's preferred time and date and then shall receive Linked SMS for missed dose (Right after missed dose) plus Social Support notifications (3 months).
62250025|NCT03800888|NO_INTERVENTION|Arm C|Participants in Arm C will receive only the Wise pill device (No SMS)
62439799|NCT01191255|PLACEBO_COMPARATOR|Placebo|Placebo
62439800|NCT01191255|EXPERIMENTAL|KRX-0502 (Ferric Citrate)|ferric citrate
62439801|NCT06531096|EXPERIMENTAL|Intervention group- v-DOT|"The intervention group will have the v-DOT (video directly observed therapy) App downloaded to their Phone or Tablet and will be instructed on how to take and upload audio-videos of themselves or their child taking their inhaler and/or nasal spray.~The audio videos will be time/date stamped and forwarded to the secure repository. Depending on the prescribed frequency of the preventer asthma and allergic rhinitis inhalers or sprays these audio videos will be uploaded once or twice-daily. These videos will be reviewed every morning by the lead researcher (trained in inhaler and nasal spray technique assessment and training) who will provide feedback via email or an instant messenger service. Videos will be evaluated using an inhaler/ nasal spray checklist.~The use of v-DOT to upload audio videos with feedback will continue until the patient has uploaded 3 consecutive days of correct technique (up to a maximum of 21 days)."
62829675|NCT06591793|EXPERIMENTAL|Cohort 2|AAVB-081 dose level 2
62829676|NCT06591793|EXPERIMENTAL|Cohort 3|AAVB-081 dose level 3
62829677|NCT04139798|EXPERIMENTAL|NOV03 4 times daily (QID)|100% Perfluorohexyloctance solution 4 times daily (QID)
62829678|NCT04139798|PLACEBO_COMPARATOR|Placebo 4 times daily (QID)|Saline solution (0.6% sodium chloride solution) 4 times daily (QID)
62047625|NCT03451734||metformin and lifestyle prevention for high risk of MetS|Participants who are at a high risk of MetS are recruited in this trial. Participants are randomized into low dose metformin (750 mg/d), high dose metformin (1000 mg/d), lifestyle intervention, and placebo groups. The timepoints of the visits are at baseline, the 4th week, the 8th week, and the 12th week.
62047626|NCT03451734||validation cohort|in sub-project 2, there are1,800 first-episode schizophrenia patients recruited from 19 hospitals, and six groups as with sub-project 1. The assessments (timepoint and content) are conducted as in sub-project 1.
62047627|NCT02529826|EXPERIMENTAL|Testicular biopsy|Cancer affected prepubertal boys will undergo testicular biopsy for testicular fragments cryopreservation. The biopsy will be performed by an attending urologist, before any gonadotoxic therapy is initiated. Testicular biopsy specimens will be divided immediately on the operating table. Two thirds of the specimen will be cryopreserved for potential use by the patient at a later date and will have the patient's details and will stay at the sperm bank of Hadassah Medical Center. The other third of specimen will be used for research purposes in an effort to advance the science of isolating and culturing human SSC's for fertility research.
62047628|NCT06311279|ACTIVE_COMPARATOR|Group A|the first group included patients who will have anterior resection with end-to-end anastomosis
62047629|NCT06311279|ACTIVE_COMPARATOR|Group B|the second group included patients will have anterior resection with side to end anastomosis.
62047630|NCT01654432|PLACEBO_COMPARATOR|General anaesthesia and sham nerve block|Breast cancer surgery under general anaesthesia
62047631|NCT01654432|ACTIVE_COMPARATOR|Paravertebral Blocks (PVB)|Breast cancer surgery under ultrasound-guided paravertebral blocks plus general anesthesia
62047632|NCT05333406|EXPERIMENTAL|Dose group A (Low dose)|Participants will receive EN001 intravenously (IV) once on Day 0.
62047633|NCT05333406|EXPERIMENTAL|Dose group B (High dose)|Participants will receive EN001 intravenously (IV) once on Day 0.
62047634|NCT00384904|NO_INTERVENTION|A1|
62047635|NCT00384904|EXPERIMENTAL|A2|
62047636|NCT00384904|EXPERIMENTAL|A3|
62047637|NCT00384904|NO_INTERVENTION|B1|
62047638|NCT00384904|EXPERIMENTAL|B2|
62047639|NCT00384904|EXPERIMENTAL|B3|
62047640|NCT02879812|EXPERIMENTAL|Multi-Component Intervention|End Stage Renal Disease (ESRD) facilities will receive feedback reports containing facility specific data, an educational webinar for dialysis facility medical directors and staff, and an educational video for patients and staff.
62047641|NCT02879812|ACTIVE_COMPARATOR|Standard Care + Pamphlet|End Stage Renal Disease (ESRD) facilities will conduct usual care and receive United Network for Organ Sharing (UNOS) educational pamphlets for staff.
62047642|NCT03940820|EXPERIMENTAL|anti-tumor response of ROBO1 CAR-NK cells|Patients will receive a single dose of ROBO1 CAR-NK cells without any conditioning chemotherapeutic regimen.
62047643|NCT00232830|EXPERIMENTAL|1|Cypher Sirolimus-eluting Coronary Stent
62047644|NCT00232830|ACTIVE_COMPARATOR|2|Bare-metal stent
62439802|NCT06531096|NO_INTERVENTION|Control group- standard care|"All enrolled patients will have an educational session with an asthma nurse using teach back methodology to teach inhaler and/or nasal spray technique and personalised asthma action plan (PAAP). During this session education is given on what asthma is, identifying and avoiding triggers, asthma treatments, and side effects of treatment.~The control participants will have further assessment and educational sessions using teach back methodology to ensure correct inhaler technique is mastered and understanding of how to action the three zones of the PAAP until they have achieved 'mastery' of the technique and understanding of their PAAP."
62047645|NCT02314624|EXPERIMENTAL|WILLOW|Clinicians have access to WILLOW's dynamic progress monitoring, clinical decision support, rich visual displays of client outcomes, online training modules in ESTs, just-in-time training for guided real-time assistance in delivering ESTs, educational videos, and a client portal
62047646|NCT02314624|ACTIVE_COMPARATOR|Treatment-as-Usual|Usual care without access to WILLOW.
62047647|NCT03230773|EXPERIMENTAL|Defibrillator - Model 1|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
62047648|NCT03230773|EXPERIMENTAL|Defibrillator - Model 2|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
62047649|NCT03230773|EXPERIMENTAL|Defibrillator - Model 3|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
62047650|NCT03230773|EXPERIMENTAL|Defibrillator - Model 4|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
62047651|NCT03230773|EXPERIMENTAL|Defibrillator - Model 5|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
62047652|NCT03230773|EXPERIMENTAL|Defibrillator - Model 6|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
62047653|NCT01224301|EXPERIMENTAL|School based flu vaccine: High intensity|Interventions: Parents in high intensity schools have access to school-based flu vaccine clinics and 3 or more communications from schools about influenza illness, influenza vaccine, and school based clinics.
62439803|NCT01968616|OTHER|Intravitreal Lucentis 0.5mg|One arm
62607624|NCT00314132|EXPERIMENTAL|ChimeriVax™ JE 4 log10 PFU Vaccine|All participants received a single injection of ChimeriVax™ JE 4 log10 Plaque-forming unit (PFU) Vaccine on Day 0.
62047654|NCT01224301|EXPERIMENTAL|School based flu vaccine: Low intensity|Interventions: Parents in low intensity schools have access to school-based flu vaccine clinics and less than 3 communications from schools about influenza illness, influenza vaccine, and school based clinics.
62047655|NCT01224301|NO_INTERVENTION|Standard of Care|Control Schools did not have any in school seasonal influenza vaccine clinics. Parents of children in control schools got no notification from the schools and sought seasonal influenza vaccines for their children as they normally would.
62047656|NCT06580873|EXPERIMENTAL|Treatment Arm|"Switch to Dolutegravir/Lamivudine (DOVATO) from current suppressive antiretroviral therapy in people living with HIV-1 receiving opioid agonist therapy."
62047657|NCT02185625|EXPERIMENTAL|Safe Delivery smartphone application|
62047658|NCT02185625|NO_INTERVENTION|Control|
62047659|NCT05189951|EXPERIMENTAL|circular motion|The phlebotomy site was wiped in a circular motion from the center outwards, approximately 5x5 cm wide.
62607625|NCT05885633|ACTIVE_COMPARATOR|PCOS|Infertile PCOS patients (n=44)
62047660|NCT05189951|EXPERIMENTAL|vertical motion|The phlebotomy site was wiped vertically from top to bottom with a single maneuver.
62047661|NCT05189951|EXPERIMENTAL|first vertical then circular motion|The phlebotomy site was first vertically wiped from top to bottom with a single maneuver, and then it was wiped in a circular motion from the center to the outside. Different swabs were used in both wipes.
62439804|NCT05581186|ACTIVE_COMPARATOR|PEMT + exercise|A total of 15 sessions of pulse electromagnetic field therapy using an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057, Italia),five times a week and once a day for three weeks, were applied to the patients. The patients were then given a daily exercise program once a day by a physiotherapist.
62607626|NCT05885633|ACTIVE_COMPARATOR|Non-PCOS control|Non-PCOS control with male factor infertility
62607627|NCT05885633|ACTIVE_COMPARATOR|Phenotype A|Phenotype A: HA+OD+PCOM (classical/complete, n=17)
62607628|NCT05885633|ACTIVE_COMPARATOR|Phenotype B|phenotype B: HA+OD (classical/non-PCOM, n=10)
62829679|NCT03626103|EXPERIMENTAL|+ Brief ED Intervention (BI), + Text|Participants receive both the Brief ED Intervention component (a 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant) and the Text Message Intervention component (8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills).
62439805|NCT05581186|SHAM_COMPARATOR|Sham PEMT + exercise|Sham therapy was applied in five sessions a week for three weeks, with a total of 15 sessions, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist.
62439806|NCT05581186|OTHER|Exercise only|Exercise program was applied in five sessions a week for three weeks, with a total of 15 sessions a day with the physiotherapist.
62047662|NCT06291610|OTHER|Decision intervention group|The decision intervention will be tested in one arm (group)
62047663|NCT01261702|PLACEBO_COMPARATOR|Placebo|Normal saline IV
62047664|NCT01261702|EXPERIMENTAL|Magnesium sulphate|Magnesium sulphate 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
62439807|NCT03209830|EXPERIMENTAL|Arm A|OSU6162, drug given to half of the patients after randomization
62439808|NCT03209830|PLACEBO_COMPARATOR|Arm B|Placebo oral tablet, drug given to halv of the patients after randomization
62439809|NCT01261481|EXPERIMENTAL|Tolvaptan Intact Tablet Orally|
62439810|NCT01261481|EXPERIMENTAL|Tolvaptan via Nasogastric Tube|
62439811|NCT05517512||Gestational Hypertension|
62439812|NCT05517512||Pre Eclampsia|
62607629|NCT05885633|ACTIVE_COMPARATOR|Phenotype C|phenotype C: HA+PCOM (ovulatory, n=9)
62607630|NCT05885633|ACTIVE_COMPARATOR|Phenotype D|phenotype D: OD+PCOM (non-hyperandrogenic, n=8).
62607631|NCT01878734|NO_INTERVENTION|Control|This arm will act as a control and will not receive Micronutrient Powders
62607632|NCT01878734|EXPERIMENTAL|Micronutrient Powders|This is the treatment arm, which will be receiving Micronutrient Powders (MNP)
62607633|NCT05076747|EXPERIMENTAL|Cardiovascular training|Cardiovascular training will comprise 4 weeks of moderate-to-vigorous continuous training followed by 4 weeks of progressive high-intensity interval training (HIIT) performed on recumbent steppers. This intervention will be performed in addition to the conventional standard therapy sessions. We will start with very moderate intensities and prepare participants for higher intensities. Introducing HIIT will allow us to use higher intensities over short bursts of exercise interspersed with periods of active rest. HIIT is more effective than continuous training to increase BDNF and we have shown that even a single bout of HIIT reduces interhemispheric imbalances in excitability and improves motor learning in chronic stroke.
62607634|NCT05076747|ACTIVE_COMPARATOR|Standard Therapy|Will comprise 8 weeks of the control protocol that includes regular sessions of physiotherapy, occupational therapy, and speech therapy.
62607635|NCT04577534|EXPERIMENTAL|Tocilizumab (TCZ)|Participants will receive one infusion of iv TCZ (according to weight of patient)
62607636|NCT04577534|NO_INTERVENTION|standard of care (no TCZ)|Participants will receive standard of care
62829680|NCT03626103|EXPERIMENTAL|+ Brief ED Intervention (BI), no Text|Participants receive the Brief ED Intervention component only (which is a 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant).
62439813|NCT05517512||Control|
62439814|NCT03932487||AITD group|Thyroid antibody positive and hypothyroidism
62439815|NCT03932487||normal group|Thyroid antibody negative and hypothyroidism
62439816|NCT02702206|EXPERIMENTAL|corticosteroids SASD injection|under US guidance 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
62439817|NCT02702206|EXPERIMENTAL|hyaluronic acid (ARTZ) SASD injection|under US guidance 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
62439818|NCT02702206|PLACEBO_COMPARATOR|normal saline SASD injection|under US guidance 2.5ml normal saline and 0.5ml distilled water and 1ml 1% lidocaine
62439819|NCT02098356|EXPERIMENTAL|Low bicarbonate|Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
62047665|NCT05049759|EXPERIMENTAL|Feasibility testing|The feasibility trial, aims to assess the feasibility of the intervention, including assessment of acceptability and outcome measures. Twenty youths with anxiety and/or depressive symptoms will be recruited to the intervention. Physical activity will be measured using the Actigraph GT3X+ monitor at baseline and post-intervention. Outcome measures concerning symptom change will be assessed (anxiety and depression). Semi-structured qualitative interview with participants, caregivers and referring specialists will help identify possible contextual and practical factors associated with delivery of the intervention and explore acceptability of assessment procedures, the intervention, and perceived benefits and barriers to participation.
62047666|NCT05323539|ACTIVE_COMPARATOR|Patients with endometrioma|Patients having a prediagnosis of surgically planned endometrioma occured this group.
62047667|NCT05323539|ACTIVE_COMPARATOR|Control group|Patients who had planned gynecological surgery for a reason (ovarian cycts) other than endometrioma
62047668|NCT02036957|EXPERIMENTAL|BALM ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. Will be applied twice a day (after showering and at night), massaging the area until completely absorption.
62047669|NCT02036957|PLACEBO_COMPARATOR|PLACEBO ARM|It be applicated in like manner that balm arm
62439820|NCT02419638||Randomized Treatment Arm: Rebif|120 patients treated with Rebif (IFN β-1a subcutaneous three times per week)
62439821|NCT02419638||Randomized Treatment Arm: Tecfidera|120 patients treated with Tecfidera (dimethyl fumarate)
62829681|NCT03626103|EXPERIMENTAL|No Brief ED Intervention (BI), + Text|Participants receive the Text Message Intervention component only (8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills). Participants receive a brochure containing online and community resources for violence and depression prevention instead of the Brief ED Intervention component.
62439822|NCT05941091|EXPERIMENTAL|Intervention Group or HafifMod Group|The HafifMod Programme; It consists of modular education practice and a mobile application offered to HD patients.
62439823|NCT05941091|ACTIVE_COMPARATOR|Control group|"Prepared by a dietitian; As a result of the distribution of a printed material called Nutrition Guide for Dialysis Patients to the active control group, individuals will be informed about nutrition."
62439824|NCT02742181|EXPERIMENTAL|Alvimopan group|In addition to standard postoperative care, patients randomized to the study group will be given 12mg of alvimopan orally twice a day, from the time of diagnosis of postoperative ileus to the time of return of bowel function or for 5 days.
62439825|NCT02742181|OTHER|Control Group|Patients randomized to the control group receive standard postoperative care which includes but is not limited to NPO status, IV fluid rehydration, and nasogastric decompression.
62439826|NCT05512325||Gene evolution of glioma in vivo|Group A: gene evolution with relapsed. From the first day after the operation, the ctDNA was extracted from TISF before concurrent chemoradiotherapy as the baseline, and then the ctDNA was detected again after concurrent chemoradiotherapy. For the third time, ctDNA was detected in intensive chemotherapy with temozolomide. The image showed that the tumor progress was detected for the fourth time, and the ctDNA was detected for the fifth time when the tumor recurred. Patients with glioma were routinely treated with temozolomide chemotherapy from the 4th week after operation, for 5 days continuously, once every 4 weeks, with a single dose as follows: Single dose = BSA (body surface area) \* 150mg/m2/day BSA(Body Surface Area)=\[weight (kg)\* height (cm)/3600\]2,
62439827|NCT05512325||Gene evolution and molecular response under Bevacizumab treatment|After the recurrence, temozolomide combined with bevacizumab was used for chemotherapy, After bevacizumab was applied after six week , ctDNA is tested every six weeks. temozolomide combined with bevacizumab (600mg) in the course of tumor progression once a month.
62439828|NCT05485181|EXPERIMENTAL|Cohort 1|8 subjects get psychological assessments and fMRI brain scan followed by 9 week psychotherapeutic intervention. With intervention completion, psychological assessments and fMRI scan are repeated.
62439829|NCT05485181|ACTIVE_COMPARATOR|Cohort 2|"8 subjects get psychological assessments at same time as Cohort 1, but do not receive the intervention at that time - serving as control group.~When Cohort 1 is completed, Cohort 2 will repeat psychological assessments, receive fMRI scan, then receive same 9 week intervention as Cohort 1, followed by repeat psychological assessments and fMRI scan."
62439830|NCT00570856|EXPERIMENTAL|1|Folic acid supplementation
62439831|NCT00570856|PLACEBO_COMPARATOR|2|
62439832|NCT05426252|EXPERIMENTAL|PTIS followed by abatacept and sirolimus|Administration of reduced-toxicity conditioning regimen combined with pre-transplant immunosuppression, followed by abatacept and sirolimus as graft-versus-host disease (GVHD) prophylaxis for allogeneic transplant with either Human Leukocyte Antigen (HLA)-matched sibling donors or haploidentical donors
62439833|NCT01881399|EXPERIMENTAL|Fluorescence/Virtual cholangiography/IOC|"Prior to cholecystectomy, patients will undergo:~* Fluorescence cholangiography (visualization following up to a maximum of 0.5 mg/kg ICG - usually 10 ml of 0,5 mg/ml solution)~* Virtual cholangiography (enhanced-reality) superimposed on fluorescence images~* Conventional IOC (intraoperative cholangiography)"
62439834|NCT02449291|EXPERIMENTAL|APD421 standard|Single (standard) dose IV APD421
62250026|NCT01473563|EXPERIMENTAL|Pemetrexed|500 milligrams per square meter (mg/m\^2) pemetrexed administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle. Maintenance therapy administered until disease progression or the participant is discontinued for any other reason. The first dose of maintenance therapy will be administered at the hospital; thereafter, therapy will be administered in the home setting by qualified oncology homecare nurses.
62250027|NCT04747093|EXPERIMENTAL|ITNK group|
62439835|NCT02449291|EXPERIMENTAL|APD421 high|Single (high) dose IV APD421
62250028|NCT05606250|NO_INTERVENTION|Physical therapy protocol|The physiotherapy protocol is based on manual therapy (passive joint mobilization), myofascial work, active exercise, high intensity neuromuscular electrical stimulation and cryotherapy.
62439836|NCT02449291|PLACEBO_COMPARATOR|Placebo|Single IV placebo
62439837|NCT01789281|EXPERIMENTAL|Everolimus|Participants who were receiving everolimus in a Novartis-sponsored study, were not progressing on the current study treatment and were unable to access everolimus treatment outside of a clinical trial. Participants receiving everolimus treatment in combination with Sandostatin LAR Depot on the parent protocol were allowed to continue Sandostatin LAR Depot treatment.
62829682|NCT03626103|NO_INTERVENTION|No Brief ED Intervention (BI), no Text|Participants receive neither the Brief ED Intervention component, nor the Text Message Intervention component. Participants receive a brochure containing online and community resources for violence and depression prevention, instead of the Brief ED Intervention component.
62829683|NCT05650697|EXPERIMENTAL|CBD oil + Silicone|These participants will treat the one half of their forehead scar with a combination of silicone ointment and cannabidiol (CBD) oil + silicone ointment . They will attend clinic visits over the course of 7 months, have pictures taken of the scar's healing progress and complete a questionnaire at each visit.
62829684|NCT05650697|EXPERIMENTAL|Silicone Only|These participants will treat the one half of their forehead scar with silicone ointment only. They will attend clinic visits over the course of 7 months, have pictures taken of the scar's healing progress and complete a questionnaire at each visit.
62047670|NCT03383770|ACTIVE_COMPARATOR|Tuohy|"After a careful disinfection of the puncture site, under sterile conditions and under ultrasonographic control with the application of nerve stimulation (settings: stimulation current primary 2.0 mA with stepwise reduction over 1.0 mA to 0.5 mA, pulse width 0.1 ms, pulse frequency 2 Hz) of the N. ischiadicus blocked by 20 ml ropivacaine 0.75 %. (electrical nerve stimulation and ultrasound) If no motor response can be triggered by stimulation, the closest possible needle-nerve distance is generated at a pulse strength of 1mA and regional anesthesia is performed. (protective nerve stimulation) Subsequently, the transplantation into the supine position and the further procedure specific to the operation (use of other regional procedures in combination or general anaesthesia).~A tuohy needle is used."
62047671|NCT03383770|ACTIVE_COMPARATOR|Facet|"After a careful disinfection of the puncture site, under sterile conditions and under ultrasonographic control with the application of nerve stimulation (settings: stimulation current primary 2.0 mA with stepwise reduction over 1.0 mA to 0.5 mA, pulse width 0.1 ms, pulse frequency 2 Hz) of the N. ischiadicus blocked by 20 ml ropivacaine 0.75 %. (electrical nerve stimulation and ultrasound) If no motor response can be triggered by stimulation, the closest possible needle-nerve distance is generated at a pulse strength of 1mA and regional anesthesia is performed. (protective nerve stimulation) Subsequently, the transplantation into the supine position and the further procedure specific to the operation (use of other regional procedures in combination or general anaesthesia).~A facet needle is used."
62047672|NCT02265302|EXPERIMENTAL|BIIL 284 BS oral solution|
62047673|NCT02265302|EXPERIMENTAL|BIIL 284 BS WIF tablets|
62047674|NCT02265302|PLACEBO_COMPARATOR|Placebo|
62250029|NCT05606250|EXPERIMENTAL|Ultrasound-Guided Percutaneous Neuromodulation|"Ultrasound-guided percutaneous neuromodulation (e-NMP) is the electrical stimulation by means of a needle with ultrasound guidance of a peripheral nerve at some point in its course or of a muscle at a motor point, with a therapeutic purpose.~The application of the stimulation is carried out with a puncture needle accompanied by a low or medium frequency electrical current.~In e-MPN, a sensory and/or motor response is sought when the peripheral nerve is stimulated, and a motor response is achieved by stimulating the motor point (uncontrolled exaggerated response that normalizes after the application of the technique)."
62250030|NCT01401842|EXPERIMENTAL|Strengthening Exercise|Lumbar ext. high intensity progressive resistance exercise
62607637|NCT02861417|EXPERIMENTAL|Group I (haploidentical donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -13, -12, and -6 to -3, thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
62047675|NCT01836705|EXPERIMENTAL|Single-sequence|SAR302503 Placebo (1 day)-SAR302503 (500 mg, oral, qd, 14 days)
62250031|NCT01401842|ACTIVE_COMPARATOR|Stabilization Exercise|Low intensity core stabilization exercise
62250032|NCT03772470|NO_INTERVENTION|Control|No airtime incentive was given for completing the survey
62250033|NCT03772470|EXPERIMENTAL|1X Incentive|1X airtime incentive
62250034|NCT03772470|EXPERIMENTAL|2X incentive|2X airtime incentive
62250035|NCT03772470|EXPERIMENTAL|Lottery Incentive|Lottery airtime incentive given to one in 20 participants
62439838|NCT06153524|EXPERIMENTAL|Physical Activity|The PA group will be guided by sports scientists to progressively build up to 60-minutes of daily moderate-vigorous exercise. The goals will be tailored to existing activity levels so as not to increase physical activity too quickly and will be set out in an action plan to be handed out at the beginning of the intervention. For the autonomous PA plan, participants from the PA group will be given Fitbits and a comprehensive manual of instructions to help them build their own weekly plan, and they will participate in weekly online meetings. The manual is structured with four main sections: 1. General information on training, 2. Moderate activity, 3. Vigorous activity, 4. Training agenda. The latter is for the participants to fill in after every training session. This information is then cross-checked by the PA specialists with the comments gathered during the weekly meetings.
62439839|NCT06153524|EXPERIMENTAL|Smartphone|The ST group will be guided by psychologists/psychotherapists to reduce their average daily phone use by 50% over the first two months of the intervention and to maintain this for the final month, and this will be measured using a screen time recording application. This intervention group will receive a list of nudge strategies (adapted from Olson et al., 2022) to add small barriers which guide them into reducing their phone use (e.g. disabling notifications, not using phone in bed). Participants will select three strategies (minimum) to try in the first month, then an additional two (minimum) for the second month. They will also receive a list of potential replacement activities to do instead of using their phone and are asked to choose which activities they want to try and/or list their own ideas. How easy/difficult each strategy is, how enjoyable the replacement activities are, and whether they want to change will be discussed in the meetings.
62607638|NCT02861417|EXPERIMENTAL|Group II (matched donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -13, -12, and -6 to -3, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months.
62250036|NCT03059927|ACTIVE_COMPARATOR|Knee arthroplasty, Cruciate retaining|Total knee replacement with preserved posterior cruciate ligament and a cruciate retaining insert.
62250037|NCT03059927|ACTIVE_COMPARATOR|Knee arthroplasty, Anterior stabilized|Total knee replacement with sacrificed posterior cruciate ligament and an anterior stabilized insert.
62250038|NCT03059927|ACTIVE_COMPARATOR|Knee arthroplasty, Posterior stabilized|Total knee replacement with sacrificed posterior cruciate ligament and a posterior stabilized design.
62250039|NCT02794467|EXPERIMENTAL|Epelsiban 75 mg|Approximately 24 subjects will receive 75 mg of epelsiban three times a day (TID) via oral administration
62250040|NCT02794467|EXPERIMENTAL|Epelsiban 200 mg|Approximately 24 subjects will receive 200 mg of epelsiban TID via oral administration
62250041|NCT02794467|PLACEBO_COMPARATOR|Placebo|Approximately 24 subjects will receive a matching placebo TID via oral administration
62250042|NCT00227565|EXPERIMENTAL|pemetrexed + carboplatin + radiation|"Patients receive pemetrexed disodium IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease in the CNS only may receive whole-brain radiotherapy and then continue chemotherapy after completion of whole-brain radiotherapy for up to 6 courses.~After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 4 years."
62250043|NCT02454335|ACTIVE_COMPARATOR|Anterior Approach|For the anterior approach, an incision will be made in the 1 to 2 o'clock position of the esophageal wall.
62250044|NCT02454335|ACTIVE_COMPARATOR|Posterior Approach|For the posterior approach, a mucosal incision will be made at the 5 to 6 o'clock position
62250045|NCT01101438|EXPERIMENTAL|Arm I|Patients receive oral metformin hydrochloride twice daily (once daily in weeks 1-4). Treatment continues for up to 5 years in receptor positive (ER and/or PgR positive) subjects in the absence of disease progression or unacceptable toxicity.
62250046|NCT01101438|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo twice daily (once daily in weeks 1-4). Treatment continues for up to 5 years in receptor positive (ER and/or PgR positive) subjects in the absence of disease progression or unacceptable toxicity.
62829685|NCT02741063|EXPERIMENTAL|high autistic and oxytocin group|subject with high ASQ scores will receive oxytocin treatment
62250047|NCT02596243|EXPERIMENTAL|GX-188E|GX-188E + EP
62250048|NCT02596243|PLACEBO_COMPARATOR|placebo|Placebo + EP
62250049|NCT02478905||surveillance cohort|Flocked mid-turbinate nasal swabs for influenza PCR will be collected from study participants daily
62607639|NCT02861417|EXPERIMENTAL|Group III (haploidentical donor transplant, chemotherapy)|Patients receiving haploidentical related donor transplant, diagnosis of myelofibrosis, \> 60 years old, or patients with comorbidity scores \> 3 will go in Group 3 or 4. If patients with comorbidity score \> 3, then the principal investigator is the final arbiter of eligibility for comorbidity score \> 3. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.
62829686|NCT02741063|EXPERIMENTAL|low autistic and oxytocin group|subject with low ASQ scores will receive oxytocin treatment
62829687|NCT02741063|PLACEBO_COMPARATOR|high autistic and placebo group|subject with high ASQ scores will receive placebo treatment
62829688|NCT02741063|PLACEBO_COMPARATOR|low autistic and placebo group|subject with low ASQ scores will receive placebo treatment
62829689|NCT03430297|EXPERIMENTAL|JS001 240mg Q2W|
62829690|NCT03430297|ACTIVE_COMPARATOR|Dacarbazine 1000mg/m2 Q3W|
62829691|NCT04201262|EXPERIMENTAL|Ravulizumab|"During the Primary Treatment Period, all participants will receive open-label ravulizumab via intravenous (IV) infusion starting on Day 1. The end of the Primary Treatment Period will be triggered when the last enrolled participant completes between 26 and 50 weeks in the study (depending on the number of adjudicated On-Trial Relapse observed).~After completion of the Primary Treatment Period, all participants will have the opportunity to continue receiving ravulizumab in the Long-Term Extension Period of the study. For each participant, the Long-Term Extension Period continues for up to 2 years, or until ravulizumab is approved and/or available (in accordance with country-specific regulations), whichever occurs first."
62829692|NCT04027517|EXPERIMENTAL|JTZ-951|Oral doses once daily
62829693|NCT04027517|ACTIVE_COMPARATOR|Darbepoetin Alfa|Intravenous doses of Darbepoetin Alfa administered once weekly
62829694|NCT00911170|PLACEBO_COMPARATOR|Placebo|Participants received standard chemotherapy (FOLFOX or FOLFIRI) on Days 1-2, and bevacizumab 5 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle plus placebo subcutaneous injection once per cycle, for a maximum of 4 cycles, 24 hours after chemotherapy (Day 4).
62829695|NCT00911170|PLACEBO_COMPARATOR|Pegfilgrastim|Participants received standard chemotherapy (FOLFOX or FOLFIRI) on Days 1-2 and bevacizumab 5 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle plus pegfilgrastim 6 mg administered as a single subcutaneous injection once per cycle, for a maximum of 4 cycles, 24 hours after chemotherapy (Day 4).
62829696|NCT00648609||Home-based palliative care services|Patients who are 60 or more years of age and have a diagnosis of COPD.Patients who have received two or more unscheduled acute care visits during the 12 months prior to the start of the study.
62829697|NCT00648609||Standard of care|Patients who are 60 or more years of age and have a diagnosis of COPD.Patients who have received two or more unscheduled acute care visits during the 12 months prior to the start of the study.
62829698|NCT02770014|EXPERIMENTAL|EGFR mutation Positive, Treatment With Erlotinib|Eligible EGFR mutations include exon 19 deletion or exon 21 L858R mutation. Erlotinib will be initially dosed at a pre-determine dosage daily, and it will be given on a 6-week cycle with treatment administered on an outpatient basis
62607640|NCT02861417|EXPERIMENTAL|Group IV (matched donor transplant, chemotherapy)|Patients receiving haploidentical related donor transplant, diagnosis of myelofibrosis, \> 60 years old, or patients with comorbidity scores \> 3 will go in Group 3 or 4. If patients with comorbidity score \>3, then the principal investigator is the final arbiter of eligibility for comorbidity score \> 3. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.
62607641|NCT02861417|EXPERIMENTAL|Group V (haploidentical donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
62047676|NCT04450602|ACTIVE_COMPARATOR|ALRV5XR|The ALRV5XR (active) group will receive ALRV5XR (Patent Pending) active treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the placebo products.
62047677|NCT04450602|PLACEBO_COMPARATOR|Placebo|The Placebo group will receive a placebo (vehicle) treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the active products. The placebo shampoo, conditioner and serum will have the same base materials (vehicle) as their counterparts but will not contain active ingredients, and will therefore be similar in viscosity and color.
62250050|NCT05014334|EXPERIMENTAL|Berberine-containing triple therapy|vonoprazan 20 mg , amoxicillin 1000 mg , and berberine 500 mg by mouth,twice daily for 14 days.
62250051|NCT05014334|ACTIVE_COMPARATOR|Bismuth-containing quadruple therapy|Bismuth potassium citrate 220 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
62607642|NCT02861417|EXPERIMENTAL|Group VI (matched or haploidentical transplant, chemotherapy)|Patients receiving fully matched or haploidentical donor transplant receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
62607643|NCT02631070|EXPERIMENTAL|Experimental Arm - Luspatercept (ACE-536)|Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks
62047678|NCT01137474|EXPERIMENTAL|Dapagliflozin, 10 mg|Oral tablets administered as 10 mg once daily for up to 12 weeks
62047679|NCT01137474|PLACEBO_COMPARATOR|Placebo-matching dapagliflozin|Oral tablets administered once daily in the morning
62047680|NCT01137474|EXPERIMENTAL|Dapagliflozin, 2. 5 mg|Oral tablets administered as 2.5 mg once daily for up to 12 weeks (Arm discontinued as of Protocol Amendment 8)
62047681|NCT01137474|EXPERIMENTAL|Dapagliflozin, 5 mg|Oral tablets administered as 5 mg once daily for up to 12 weeks (Arm discontinued as of Protocol Amendment 8)
62250052|NCT05014334|ACTIVE_COMPARATOR|vonoprazan-containing quadruple therapy|Bismuth potassium citrate 220 mg, vonoprazan 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
62250053|NCT02320136||epilepsy|epilepsy patients
62250054|NCT02320136||tumor with epilepsy|tumor patients with epileptic seizures
62250055|NCT02320136||tumor without epilepsy|tumor patients without epileptic seizures
62250056|NCT01848353|ACTIVE_COMPARATOR|Standard payment, phase 1|All participants will perform exercise training. Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes during weeks 1-16 (phase 1). All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
62439840|NCT06153524|NO_INTERVENTION|Control|The control group will receive basic written explanatory information on the study and will then simply record all their physical activity and screen time, without being set specific goals. This group will receive a list of mental health resources, all materials for increasing physical activity and reducing screen time and will be invited to a psychoeducation talk at the end of the study.
62439841|NCT01405976|ACTIVE_COMPARATOR|1|NIV for severe OSA group
62607644|NCT02631070|PLACEBO_COMPARATOR|Control Arm: Placebo|Subcutaneous injection every 3 weeks
62829699|NCT01023763|NO_INTERVENTION|Usual care|"Nursing home residents who require intravenous fluids and intravenous antibiotics was treated as usual (hospital admissions for intravenous treatment).~In control nursing homes that had not completed the training program (intervention period), nursing home residents who require intravenous fluids and intravenous antibiotics was treated as usual. The majority of these patients were admitted to hospital for intravenous treatment. A few nursing homes or nursing home departments had sufficient expertise and capacity to provide treatment locally."
62250057|NCT01848353|ACTIVE_COMPARATOR|Standard payment, phase 2|All participants will perform exercise training. Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes during weeks 17-32 (phase 2). All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
62439842|NCT01405976|ACTIVE_COMPARATOR|2|CPAP for severe OSA group
62439843|NCT01405976|ACTIVE_COMPARATOR|3|Life stile modification for severe OSA group
62439844|NCT01405976|ACTIVE_COMPARATOR|4|NIV for non-severe OSA group
62439845|NCT01405976|ACTIVE_COMPARATOR|5|Life stile modification for non-severe OSA group
62829700|NCT01023763|OTHER|A training program in iv treatment|"A structured training program in intravenous treatment in nursing homes:~Each of 30 participating nursing homes sequentially received theory and practical training in intravenous treatment. In nursing homes that had completed the training program (intervention period), and had sufficient expertise and capacity, nursing home residents in need of intravenous fluids or antibiotics were treated locally; otherwise they were hospitalized."
62829701|NCT04049786|ACTIVE_COMPARATOR|Simvastatin - Healthy volunteers|Adult patients (18-65 years old) with body mass index \< 25 kg/mˆ2 treated with a single oral dose of 40 mg simvastatin for Pk analysis. Blood samples collected for blood tests, genomics and transcriptomic analysis
62047682|NCT06412653|EXPERIMENTAL|Interventional Arm|Zinc acetate dihydrate in age-adapted dosage ranging from 50mg to 150mg Zn2+ per day according to the recommended dosage in Wilsons Disease.
62250058|NCT01848353|ACTIVE_COMPARATOR|Ramp-down payment, phase 3|All participants will perform exercise training. This phase will last from weeks 33-48 (phase 3). Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes, but the value of the payments will decrease weekly (ramp-down) until reaching zero in week 41. All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
62250059|NCT01848353|EXPERIMENTAL|Incentivized payment, phase 1|All participants will perform exercise training. Participants in this arm will receive an increasing amount of money when they increase exercise frequency (number of days) during weeks 1-16 (phase 1). All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior
62250060|NCT01848353|EXPERIMENTAL|Incentivized payment, phase 2|All participants will perform exercise training. Participants in this arm will receive an increasing amount of money when they exercise for longer than 20 minutes per session during weeks 17-32 (phase 2). All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior
62250061|NCT01848353|EXPERIMENTAL|Raffle payment, phase 3|All participants will perform exercise training. In weeks 33-48 (phase 3)participants in this arm will receive fewer financial incentives than in the prior 32 weeks but they will be delivered through a raffle system to utilize a variable reinforcement approach. All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior.
62250062|NCT01848353|NO_INTERVENTION|Normal weight, low activity group|This group of participants will complete only the baseline tests and assessments and will serve as a reference group. They will be selected to have low physical activity and fitness like the intervention group. Therefore differences in their results with the intervention group will reflect the effects of overweight/obesity on the variables of interest.
62250063|NCT01848353|NO_INTERVENTION|Normal weight, high activity group|This group of participants will complete only the baseline tests and assessments and will serve as a reference group. They will be selected to have higher physical activity and fitness than the intervention group. They will therefore serve as a healthy reference group and differences in their results with the intervention group will reflect the effects of both overweight/obesity and physical activity on the variables of interest.
62250064|NCT05322928|EXPERIMENTAL|Engagement in daily occupations|The experimental contents will include 1-hour video appointments with an occupational therapist a week in four weeks and a maintenance phase of similar session format every second week in two months.
62607645|NCT06553768|EXPERIMENTAL|Maralixibat|Participants will receive maralixibat oral solution 300 μg/kg orally once daily for 1 week and then twice daily for 39 weeks.
62607646|NCT06553768|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to maralixibat oral solution orally once daily for 1 week and then twice daily for 19 weeks. After 20 weeks, participants will receive maralixibat oral solution 300 μg/kg orally once daily for 1 week and then twice daily for 19 weeks.
62607647|NCT03628248|EXPERIMENTAL|embolization|
62047683|NCT06579664|ACTIVE_COMPARATOR|iTBS group|
62250065|NCT02448693|EXPERIMENTAL|WLE-NBI|Participants will be evaluated by same endoscopist, tandem colonoscopy. It consists of two revisions of the polypectomy scar using firstly High Definition White Light Endoscopy (WLE) and secondly Narrow Band Imaging. All suspected neoplasia will be classified macroscopically and resected and differentiated from both techniques. The rest of the gut will be inspected following conventional standards.
62607648|NCT03628248|OTHER|No embolization|
62607649|NCT00672399|EXPERIMENTAL|Sequence 1|Period 1 = placebo exenatide/placebo moxifloxacin; Period II = exenatide/placebo moxifloxacin; Period III = placebo exenatide/moxifloxacin
62607650|NCT00672399|EXPERIMENTAL|Sequence 2|Period I = exenatide/placebo moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = placebo exenatide/placebo moxifloxacin
62607651|NCT00672399|EXPERIMENTAL|Sequence 3|Period 1 = placebo exenatide/moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = exenatide/placebo moxifloxacin
62607652|NCT00672399|EXPERIMENTAL|Sequence 4|Period I = placebo exenatide/moxifloxacin; Period II = exenatide/placebo moxifloxacin; Period III = placebo exenatide/placebo moxifloxacin
62607653|NCT00672399|EXPERIMENTAL|Sequence 5|Period I = placebo exenatide/placebo moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = exenatide/moxifloxacin
62607654|NCT00672399|EXPERIMENTAL|Sequence 6|Period I = exenatide/placebo moxifloxacin; Period II = placebo exenatide/placebo moxifloxacin; Period III = placebo exenatide/moxifloxacin
62607655|NCT04515641|EXPERIMENTAL|Moderate Hepatic Impairment|Participants receive a single dose of ISL 60 mg.
62607656|NCT04515641|EXPERIMENTAL|Healthy Controls|Participants receive a single dose of ISL 60 mg.
62829702|NCT04049786|ACTIVE_COMPARATOR|Carvedilol Study - Healthy volunteers|Adult patients (18-65 years old) with body mass index \< 25 kg/mˆ2 treated with a single oral dose of 25 mg carvedilol for Pk analysis. Blood samples collected for blood tests, genomics and transcriptomic analysis
62829703|NCT04049786|ACTIVE_COMPARATOR|Simvastatin - Obese|Adult patients (18-65 years old) with body mass index \> 30 kg/mˆ2 treated with a single oral dose of 40 mg simvastatin for Pk analysis. Blood samples collected for blood tests, genomics and transcriptomic analysis.
62829704|NCT04049786|ACTIVE_COMPARATOR|Carvedilol study - Obese|Adult patients (18-65 years old) with body mass index \> 30 kg/mˆ2 treated with a single oral dose of 25 mg carvedilol for Pk analysis. Blood samples collected for blood tests, genomics and transcriptomic analysis.
62047684|NCT06579664|SHAM_COMPARATOR|sham iTBS group|
62047685|NCT01175525|PLACEBO_COMPARATOR|sugar pill|sugar pill dissolved in water to be given 4 times a day 30 minutes prior to meals
62047686|NCT01175525|ACTIVE_COMPARATOR|Cromolyn|Cromolyn dose of 200mg(dissolved in water) will be given 4 times a day(30 minutes before a meal)
62047687|NCT01168193|OTHER|Patients that underwent surgery|Single arm
62439846|NCT06527092|EXPERIMENTAL|Virtual reality|The child was given a comfortable position. A nurse independent from the study assessed the child with the Child Anxiety Scale-Condition (CAS-D), Child Fear Scale, and Visual Analogue Scale (VAS) before the procedure. The child was fitted with virtual reality goggles and a video of the child's choice was shown. One of the videos was a video of visiting animals in the zoo, while the other video was an aquarium video containing colorful fish and creatures under the sea. The zoo visit video is 3 minutes 51 seconds and the aquarium visit video is 11 minutes 55 seconds. Two minutes after the child started watching the video, peripheral catheter insertion was started. During the procedure, the same nurse, who was independent of the study, assessed the child with the Child Anxiety Scale-Condition(CAS-D), Child Fear Scale, and Visual Analogue Scale (VAS) and recorded the duration of the procedure and the child's crying (how many seconds it lasted).
62607657|NCT02532114|EXPERIMENTAL|Treatment (niclosamide, enzalutamide)|Patients receive niclosamide PO TID and enzalutamide PO daily. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
62607658|NCT06730620|EXPERIMENTAL|Test preparation：Methylcholine chloroacetate for inhalation|Inhale methacholine solution for 1 minute
62047688|NCT04759690|EXPERIMENTAL|Action observation and exercise group|Action observation group consist of 30 randomly selected participants.Action observation + conventional balance exercise group
62047689|NCT04759690|OTHER|Exercise group|Exercise group is the control group.Consist of 30 randomly selected participants. The participants will only do the conventional balance exercise.
62607659|NCT06730620|ACTIVE_COMPARATOR|Reference preparation：Methylcholine chloroacetate for inhalation（(Provocholin）|Inhale methacholine solution for 1 minute
62250066|NCT02448693|EXPERIMENTAL|NBI-WLE|Participants will be evaluated by same endoscopist, tandem colonoscopy. It consists of two revisions of the polypectomy scar using firstly Narrow Band Imaging and secondly High Definition White Light Endoscopy (WLE). All suspected neoplasia will be classified macroscopically and resected and differentiated from both techniques. The rest of the gut will be inspected following conventional standards.
62250067|NCT04919291|ACTIVE_COMPARATOR|Topoguided LASIK|Topoguided ablation profile on dominant eye
62250068|NCT04919291|ACTIVE_COMPARATOR|Wavefront optimized LASIK|Wavefront optimized ablation profile on non-dominant eye
62250069|NCT01841190||PROCALCITONIN|
62250070|NCT01841190||DELTA SOFA|
62250071|NCT01982721|EXPERIMENTAL|Transfemoral amputees|Locking mechanism for prosthetic knee (no trade mark provided)
62250072|NCT01982721|NO_INTERVENTION|Healthy volunteers|
62250073|NCT04062019|EXPERIMENTAL|interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU/m2 once every other day, for 3 months.
62250074|NCT02558387|EXPERIMENTAL|Nintedanib arm|Nintedanib has never been applied to salivary gland cancer. Nintedanib was given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
62047690|NCT01984684|EXPERIMENTAL|Delafloxacin|Delafloxacin 300 mg IV Q12H for 6 doses, then Delafloxacin 450 mg oral tablet Q12H for a minimum of 10 up to a maximum of 28 doses total
62047691|NCT01984684|ACTIVE_COMPARATOR|Vancomycin plus Aztreonam|Vancomycin 15 mg/kg IV plus two grams Aztreonam every 12 hours for a minimum of 10 up to a maximum of 28 doses total (Aztreonam was discontinued as soon as possible if a gram-negative organism was not identified in baseline cultures)
62047692|NCT01954355|EXPERIMENTAL|LDE225 & Paclitaxel|"Phase I, Part A: LDE225: dose escalation in cohorts of 3-6 patients (days 1-28) and Paclitaxel 80 mg/m2 (days 1, 8, 15)~Phase I, Part B and C: LDE225: RP2D established in Part A (days 1-28) and Paclitaxel 80 mg/m2 (days 1, 8, 15)"
62047693|NCT06535841|EXPERIMENTAL|MTX-474|Biological: MTX-474
62047694|NCT06535841|PLACEBO_COMPARATOR|Placebo|Placebo
62250075|NCT01655329||Standard chest radiographs|The radiologists will be viewing two groups of chest images. The first group are standard chest radiographs.
62250076|NCT01655329||Modified chest radiographs|This group of chest radiographs will be presented with the modified image. The modified image is intended to increase the visibility of tubes, lines and wires on chest radiographs
62250077|NCT03708120|EXPERIMENTAL|Consumer Dose and Tick Repellency|Consumer dose: Dosimetry test of insect repellent application to forearms. Tick repellency: Treatment of forearm with insect repellent and exposure to ticks every 15 minutes for 10 hours.
62250078|NCT02700152|EXPERIMENTAL|all subjects|"Eligible subjects will receive 3 treatments, 2 weeks interval, with the UltraShape device according to the study protocol and user manual.~The subject will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment, for total expected study duration of 16 weeks"
62250079|NCT01701076|EXPERIMENTAL|Bendamustine|All patients are treated with bendamustine in combination with lenalidomide and dexamethasone for a maximum of 6 cycles.
62250080|NCT06493539|ACTIVE_COMPARATOR|Control group: Standard of Care|Following amputation, at POD 1, application of standard care (short stretch compression bandages and standard post-operative wound care) daily.
62607660|NCT00423189|ACTIVE_COMPARATOR|Ranibizumab only|drug - intravitreal ranibizumab
62607661|NCT00423189|EXPERIMENTAL|40% fluence PDT/procedure|40% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab
62607662|NCT00423189|EXPERIMENTAL|20% fluence photodynamic therapy|20% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab
62607663|NCT02185287||Lower urinary tract dysfunction, female, age: 18-40 years|
62607664|NCT02185287||Healthy female subjects, age: 18-40 years|
62607665|NCT05581992|EXPERIMENTAL|AMG 510 + Omeprazole|Participants will receive AMG 510 on Day 1, daily doses of omeprazole on Days 4 to 8, and a single dose of both omeprazole and AMG 510 on Day 9.
62607666|NCT05451615|EXPERIMENTAL|Abatacept|D2T RA patients receive Abatacept
62607667|NCT05451615|EXPERIMENTAL|JAK inhibitor|D2T RA patients receive JAKi
62607668|NCT05768191|ACTIVE_COMPARATOR|Humulin N plus Humulin R|10 subjects will receive insulin human isophane suspension (Humulin N) twice daily plus regular human insulin (Humulin R) before meals
62607669|NCT05768191|EXPERIMENTAL|Premix human isophane suspension plus insulin human injection|10 subjects will receive premix insulin human isophane suspension and insulin human injection twice daily
62607670|NCT05648240||Patients with polyps|
62607671|NCT05648240||Patients without polyps|
62607672|NCT01430624|EXPERIMENTAL|PPRS video|Prevention of post sexual assault stress
62047695|NCT06495671|EXPERIMENTAL|Magnetically enhanced diffusion|Intra-arterial iron nanoparticles (4 x 1mg doses delivered every 3 minutes) delivered via microcatheter proximal to site of arterial occlusion(s) with external rotating magnet, total procedure 30min.
62047696|NCT03017079|EXPERIMENTAL|semi-solidification with nutrient|"semi-solidification with nutrient:after infusion of semi-solid agent, enteral nutrition is applied less than 60 mins.~Intervention: Other: bolus Intermittent enteral feeding"
62250081|NCT06493539|EXPERIMENTAL|CiNPWT treatment group|"Following amputation, at POD 1, CiNPWT will be applied in an envelope-like fashion, incorporating the incison line as well as \~10 cm of intact proximal residual limb tissue. The underlying skin will be protected with a contact layer and the negative pressure foam is applied for maximal surface area coverage. Negative pressure parameters are set to dynamic pressure control therapy (DPC) from -25 mmHg to -125 mmHg with a 2 minute on/2 minute off cycle and the dressing is left in place for three to five days.~A patient may always be removed from treatment intervention whenever they wish."
62250082|NCT06150573|EXPERIMENTAL|Test Dentifrice|Participants will dose the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 parts per million \[ppm\] fluoride as sodium fluoride) and will brush for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice will be used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants will perform the first application of peroxide tooth bleaching as per the instructions provided and continue the application daily for up to 7 days.
62250083|NCT06150573|ACTIVE_COMPARATOR|Reference Dentifrice|Participants will dose the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and will brush for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice will be used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants will perform the first application of peroxide tooth bleaching as per the instructions provided and continue the application daily for up to 7 days.
62250084|NCT06474975|EXPERIMENTAL|Identification of positive margins with PET/CT specimen imager|Identification of all positive margins of the invasive component during BCS using PET/CT specimen imager
62250085|NCT00761852|ACTIVE_COMPARATOR|1|Ruboxistaurin
62250086|NCT00761852|PLACEBO_COMPARATOR|2|Placebo
62250087|NCT01812889|ACTIVE_COMPARATOR|Part 2|10 women diagnosed with BV, 10 diagnosed with VVC will be randomized to receive either TOL-463 gel or TOL-463 ovules administered intravaginally once daily for 7 consecutive days
62250088|NCT01812889|ACTIVE_COMPARATOR|Part 1|20 Healthy women randomized, two-way crossover design will receive a single dose of TOL-463 gel and ovule intravaginally, separated by a minimum of 7 day washout period between administrations
62250089|NCT01591967|NO_INTERVENTION|Control|Control -- no intervention
62250090|NCT01591967|NO_INTERVENTION|Placebo w/ sham|"Sham intervention with the adjusting tool turned off"
62250091|NCT01591967|EXPERIMENTAL|Activator treatment|Treatment with Activator
62250092|NCT01017367|EXPERIMENTAL|MDX-1100|MDX-1100 10 mg/kg administered i.v. over 60 minutes on days 1, 15, 29, 43, 57, and 71
62250093|NCT01017367|PLACEBO_COMPARATOR|Placebo|Placebo (saline) administered i.v. over 60 minutes on days 1, 15, 29, 43, 57, and 71
62250094|NCT01864187|EXPERIMENTAL|Dexmedetomidine|Each team will be administered for 1μg/kg of dexmedetomidine eace one.
62250095|NCT03654976|EXPERIMENTAL|Active treatment|Subject's ICS or ICS/LABA background medication plus HDM SLIT-tablet
62250096|NCT03654976|PLACEBO_COMPARATOR|Placebo|Subject's ICS or ICS/LABA background medication plus placebo oral tablet
62250097|NCT00295633|EXPERIMENTAL|Saxagliptin plus open-label TZD (A)|"Saxagliptin PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)"
62607673|NCT01430624|ACTIVE_COMPARATOR|PIRI video|Pleasant imagery and relaxation instruction
62607674|NCT01430624|NO_INTERVENTION|Standard care|Treatment as usual
62607675|NCT03526198|EXPERIMENTAL|Group 1 (adult)|Each volunteer stood on the platform. The duration of the tests was standardized at 10 seconds for each angulation variant of the test. The tilt variables occurred every 5 degrees oscillating in the two-dimensional movement of the ankle joint. The test was discontinued when the volunteer failed to remain balanced at the tested angulation for more than 10 seconds (thus shifting the foot (s) from the initial position or supporting with one and / or both arms at the therapist or at the support bars ) or when it reached maximum angulation
62607676|NCT03526198|EXPERIMENTAL|Group 2 (elderly)|Each volunteer stood on the platform. The duration of the tests was standardized at 10 seconds for each angulation variant of the test. The tilt variables occurred every 5 degrees oscillating in the two-dimensional movement of the ankle joint. The test was discontinued when the volunteer failed to remain balanced at the tested angulation for more than 10 seconds (thus shifting the foot (s) from the initial position or supporting with one and / or both arms at the therapist or at the support bars ) or when it reached maximum angulation
62607677|NCT05828212|EXPERIMENTAL|Treatment Group|Recurrent/Refractory Neuromyelitis Optica
62607678|NCT06125067||Control Group (no peripheral block applied)|No peripheral block was applied to this group and it was accepted as the control group. Standard multimodal analgesia and rescue analgesia according to NRS score were applied to each group
62607679|NCT06125067||Fascia Iliaca Compartment Block Group|Fascia Iliaca Compartment block was applied to this group under ultrasound guidance. Standard multimodal analgesia and rescue analgesia according to NRS score were applied to each group.
62829705|NCT04049786|ACTIVE_COMPARATOR|Simvastatin - Post-RYGB|Adult patients (18-65 years old) previously submitted to RYGB surgery treated with a single oral dose of 40 mg simvastatin for Pk analysis. Blood samples collected for blood tests, genomics and transcriptomic analysis.
62829706|NCT04049786|ACTIVE_COMPARATOR|Carvedilol - Post-RYGB|Adult patients (18-65 years old) previously submitted to RYGB surgery treated with a single oral dose of 25 mg carvedilol for Pk analysis. Blood samples collected for blood tests, genomics and transcriptomic analysis.
62250098|NCT00295633|EXPERIMENTAL|Saxagliptin plus open-label TZD (B)|"Saxagliptin PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)"
62439847|NCT06527092|EXPERIMENTAL|Bubbles|The child was given a comfortable position. A nurse independent from the study assessed the child with the Child Anxiety Scale-Condition(CAS-D), Child Fear Scale and Visual Analogue Scale (VAS) before the procedure. The child was given a colourful, lighted bubble gun. Two minutes after the child used the coloured-light bubble gun, peripheral catheter insertion was started. During the procedure, the same nurse, who was independent from the study, assessed the child with the Child Anxiety Scale-Condition (CAS-D), Child Fear Scale and Visual Analogue Scale (VAS) and recorded the duration of the procedure and the child's crying (how many seconds it lasted).
62439848|NCT06527092|NO_INTERVENTION|Control|The child was given a comfortable position. A nurse independent from the study assessed the child with the Child Anxiety Scale- Condition (CAS-D), Child Fear Scale and Visual Analogue Scale (VAS) before the procedure. Peripheral catheter insertion was started. Distraction techniques such as asking questions and talking were used during the procedure. During the procedure, the same nurse, who was independent from the study, evaluated with the Child Anxiety Scale- Condition (CAS-D), Child Fear Scale and Visual Analogue Scale (VAS) and recorded the duration of the procedure and the crying status of the child (how many seconds it lasted).
62607680|NCT06125067||iPACK Block Group|iPACK block was applied to this group under ultrasound guidance. Standard multimodal analgesia and rescue analgesia according to NRS score were applied to each group.
62607681|NCT04240457|EXPERIMENTAL|Pulsed, accelerated|18mW, 5 seconds on, 5 seconds off, 10 minutes of illumination.
62829707|NCT06079814|EXPERIMENTAL|experiment group|Patients will wear virtual reality glasses 10 minutes before cystoscopy. The content chosen by the patient (there will be three options) will be watched throughout the procedure.
62250099|NCT00295633|PLACEBO_COMPARATOR|Placebo plus open-label TZD (C)|"Placebo PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)"
62250100|NCT03809455|EXPERIMENTAL|FAR Arm|
62250101|NCT03809455|PLACEBO_COMPARATOR|Placebo Arm|
62250102|NCT04275141|OTHER|Mauriac syndrome|An oral dose of glucose (labelled with 1% U-13C6-glucose) will be given at time 0 min followed by a 30-min cycling exercise at time 300 min.
62250103|NCT04275141|OTHER|Type 1 diabetes mellitus|An oral dose of glucose (labelled with 1% U-13C6-glucose) will be given at time 0 min followed by a 30-min cycling exercise at time 300 min.
62250104|NCT05169684|EXPERIMENTAL|Arm 1A: Docetaxel + BMS-986218|
62829708|NCT06079814|NO_INTERVENTION|control group|Standard procedure.
62829709|NCT01367106|EXPERIMENTAL|exposed offspring|
62829710|NCT01367106|OTHER|controls|
62829711|NCT02976038|EXPERIMENTAL|elamipretide|Open-label once daily subcutaneous injection of 40mg elamipretide
62829712|NCT03788512||AICVD patients with CoCCA|acute ischemic cerebrovascular disease patients with coexistence of cerebral and coronary atherosclerosis.
62829713|NCT03753802|EXPERIMENTAL|Treated|The treated group will receive chest physiotherapy treatment using slow extended and passive expiratory maneuvers.
62829714|NCT03753802|PLACEBO_COMPARATOR|Control|The control group will not receive physiotherapy treatment.
62250105|NCT05169684|EXPERIMENTAL|Arm 1B: Docetaxel + BMS-986218 + Nivolumab|
62250106|NCT05169684|EXPERIMENTAL|Arm 2A: Docetaxel|
62250107|NCT05169684|EXPERIMENTAL|Arm 2B: Docetaxel + BMS-986218|
62250108|NCT05169684|EXPERIMENTAL|Arm 2C: Docetaxel + BMS-986218 + Nivolumab|
62250109|NCT05169684|EXPERIMENTAL|Arm 2D (Optional Crossover): BMS-986218 + Nivolumab|
62250110|NCT02146599||Pseudophakic|
62250111|NCT01010633|EXPERIMENTAL|Loteprednol Etabonate|Loteprednol etabonate
62250112|NCT01010633|PLACEBO_COMPARATOR|Vehicle|Vehicle of loteprednol etabonate
62250113|NCT00141895|ACTIVE_COMPARATOR|A|Vaginal Cytotec at doses of 400 microgram every 4 hours until delivery
62250114|NCT00141895|ACTIVE_COMPARATOR|B|Sublingual Cytotec at doses of 400 microgram every 4 hours until delivery
62250115|NCT04422548|ACTIVE_COMPARATOR|AI-assisted Group|
62250116|NCT04422548|ACTIVE_COMPARATOR|Standard|
62250117|NCT02794077|EXPERIMENTAL|Cyclophosphamide|Patients receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progression or unacceptable toxicity.
62439849|NCT02109133|EXPERIMENTAL|Deep neuromuscular blockade|Deep neuromuscular blockade
62439850|NCT02109133|ACTIVE_COMPARATOR|moderate neuromuscular blockade|moderate neuromuscular blockade
62607682|NCT04240457|ACTIVE_COMPARATOR|Conventional|9mW continuous, 10 minutes of illumination.
62607683|NCT00588081|OTHER|1|Participants will receive a cover letter, questionnaire and invitation to participate in a post-operative interview.
62607684|NCT05215379|OTHER|neoadjuvant chemoradiation therapy|neoadjuvant chemoradiation therapy
62829715|NCT01355952|EXPERIMENTAL|Alpha Lipoic Acid|taking 1800mg daily (600mg 3 times per day) Alpha Lipoic Acid (ALA) open-label for 10 weeks.
62829716|NCT05695378|EXPERIMENTAL|Main Study: KM-819|Subjects will receive 400 mg of KM-819 orally from Week 0 to Week 36.
62829717|NCT05695378|PLACEBO_COMPARATOR|Main Study: Placebo|Subjects will receive visually identical placebo pills of KM-819 orally.
62607685|NCT05215379|EXPERIMENTAL|neoadjuvant chemoradiation therapy +immunotherapy|neoadjuvant chemoradiation therapy +immunotherapy
62829718|NCT05695378|EXPERIMENTAL|Ancillary Study: KM-819|Subjects will receive 400 mg of KM-819 orally from Week 40 to Week 76.
62047697|NCT03017079|PLACEBO_COMPARATOR|Standard enteral nutrition|"After infusion of Sterile Water for Injection,bolus Intermittent enteral feeding via the nasogastric tube is applied less than 60 mins.~Intervention: Other: Standard enteral feeding"
62047698|NCT01030861|ACTIVE_COMPARATOR|teplizumab|Intravenous infusions of teplizumab given for 14 consecutive days. Each infusion takes about 30 minutes and is followed by a 2 hour observation period.
62047699|NCT01030861|PLACEBO_COMPARATOR|Placebo infusion|Intravenous infusion of placebo (saline) will be given for 14 consecutive days. Infusions will take approximately 30 minutes and will be followed by a two hour observation period.
62829719|NCT01094236|EXPERIMENTAL|Supervisor Treatment Group|Supervisors watched the CD intervention
62829720|NCT01094236|EXPERIMENTAL|Administrators - Treatment|School administrators got access to the intervention binder with CD's, workbook and worksheets
62829721|NCT01094236|EXPERIMENTAL|Students|3rd grade students at participating study schools
62829722|NCT01094236|EXPERIMENTAL|Supervisor Control Group|Supervisors watched a video on playground equipment safety
62829723|NCT01094236|EXPERIMENTAL|Administrators - Control|Administrators did not have access to any treatment materials.
62047700|NCT04465357|EXPERIMENTAL|Erenumab-Aooe 140 MG/ML [Aimovig]|Participants received 140 mg/mL administered subcutaneously once every 4 weeks in the abdomen, thigh, or upper arm for three months (12 weeks).
62047701|NCT01440426|ACTIVE_COMPARATOR|Autologous connective tissue graft|Soft tissue harvested from patient palate
62047702|NCT01440426|EXPERIMENTAL|Collagen Matrix Construct|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland
62250118|NCT02091154|EXPERIMENTAL|USDA Regulations Only|Implement USDA Regulations in assigned school cafeterias during the intervention period.
62250119|NCT02091154|EXPERIMENTAL|USDA Regulations and Marketing Kit|Implement new USDA regulations in assigned schools along with the Marketing Kit during the intervention period.
62250120|NCT02091154|EXPERIMENTAL|USDA Regulations and SLM|Implement USDA Regulations and Smarter Lunchrooms Makeover in assigned schools during intervention period.
62250121|NCT02091154|NO_INTERVENTION|Control|Schools assigned to this intervention made no changes to their lunchroom or menus.
62250122|NCT00578136|ACTIVE_COMPARATOR|1|1) One group will receive the rectus sheath block prior to Umbilical hernia repair.
62250123|NCT00578136|ACTIVE_COMPARATOR|2|2) The second group will receive local anesthetic infiltration of the surgical site at the end the umbilical hernia repair.
62250124|NCT03808389|EXPERIMENTAL|Treatment group: Donor FMT|Fecal microbiota transplantation using fecal matter from a healthy donor selected through strict inclusion criteria assessing the presence of any infectious diseases.
62250125|NCT03808389|SHAM_COMPARATOR|Control group: Autologous FMT|Fecal microbiota transplantation using the patient's own fecal matter.
62250126|NCT04967222|EXPERIMENTAL|Cognitive Reappraisal-by-Distancing (CRD)|Subjects will be coached to use cognitive reappraisal-by-distancing to downregulate their negative reactions to aversive emotional pictures usng practice pictures.
62829724|NCT01094236|EXPERIMENTAL|School Staff|School staff surveyed at staff meetings
62250127|NCT04967222|ACTIVE_COMPARATOR|Control Downregulate Condition (CD)|Subjects will be coached to practice their customary emotion regulatory techniques in a treatment occurring twice a week for 6 weeks.
62250128|NCT00714467|ACTIVE_COMPARATOR|1|Expert system (stage-based manual and 3 individualized tailored feedback reports) only for smokers, paired-supporters (family or friend participant) do not receive any study intervention
62607686|NCT01836991|OTHER|D2 surgery|D2 surgery(No.1、No.3、No.4sb、No.4d、No.5、No.6、No.7 and No.8a、No.9、No.11p、No.12a lymph node)
62607687|NCT01836991|EXPERIMENTAL|D2+ surgery|D2+ surgery(D2+8p、12b、13、14v lymph node)
62829725|NCT00061087|ACTIVE_COMPARATOR|METHYLPHENIDATE|Methylphenidate
62829726|NCT00061087|ACTIVE_COMPARATOR|BUPROPION|Bupropion
62829727|NCT00061087|PLACEBO_COMPARATOR|PLACEBO|Placebo
62829728|NCT04764708|ACTIVE_COMPARATOR|Control Group|Cognitive behavioral therapy plus standard psychopharmacological treatment.
62829729|NCT04764708|EXPERIMENTAL|Experimental Group|A Third Wave Cognitive Therapy that integrates Compassion Focused Therapy and Metacognitively Oriented Psychotherapy.
62829730|NCT03614650|EXPERIMENTAL|EIE cells to treat cancer|EIE cells to treat cancer
62829731|NCT02553226|ACTIVE_COMPARATOR|Continued group|Recieve routine treatment with oxytocin according to the danish national guidelines.
62829732|NCT02553226|PLACEBO_COMPARATOR|discontinued group (placebo)|The routine treatment with oxytocin will be discontinued and replaced with isotonic saline, when the active phase of labour is established.
62047703|NCT04928820|EXPERIMENTAL|Diagnostic (68Ga-PSMA-11 PET/CT)|Patients receive gallium Ga 68 gozetotide IV. After 50-100 minutes, patients undergo whole body PET/CT.
62047704|NCT03371810|EXPERIMENTAL|Bright light therapy|"Mobile therapeutic light (10.000 LUX), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total.~Additional treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise) is allowed."
62047705|NCT03371810|EXPERIMENTAL|Physical exercise|"Aerobic exercise of moderate-to-vigorous intensity three days a week plus muscle-strengthening exercises two days a week during 10 weeks in total.~Additional treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise) is allowed."
62439851|NCT05073900|EXPERIMENTAL|Rhomboid intercostal block|Ultrasound guided rhomboid intercostal block
62829733|NCT00710411||A, 2|Polytraumatized patients with ISS \> 18 and healthy controls
62829734|NCT06054490|ACTIVE_COMPARATOR|Self-management group (SM group)|Subjects in this group received a scheme of self-management protocol consisting of verbal and written information on the etiology and prognosis of TMD.
62829735|NCT06054490|EXPERIMENTAL|Self-management plus home exercises group (SM+EX group)|Subjects in this group received self-management protocol in combination with a home self-exercise routine. Basic exercise therapy includes mobilization, stretching, and muscle strengthening exercises.
62047706|NCT03371810|NO_INTERVENTION|Treatment as usual|Stable treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise).
62047707|NCT03508843|EXPERIMENTAL|interactive virtual presence|install a car seat using advice from a remotely-located certified car seat technician communicating via interactive virtual presence
62047708|NCT04127838|EXPERIMENTAL|Low Vision Occupational Therapy|The anticipated low vision occupational therapy intervention strategy includes training participants to compensate for their vision more effectively for increased participation in ADLs and IADLs.
62047709|NCT05400343|ACTIVE_COMPARATOR|Standard care (control group)|fluid therapy will be guided by conventional ICU policies to maintain an adequate intravascular volume and good urine output
62047710|NCT05400343|EXPERIMENTAL|US-guided ﬂuid management (active group)|Fluid therapy will be guided by measurements of lung and IVC sonography
62047711|NCT02586025|EXPERIMENTAL|Trastuzumab, Pertuzumab, and Chemotherapy|Prior to surgery: trastuzumab, pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC): trastuzumab and pertuzumab up to 1 year total.
62047712|NCT02586025|EXPERIMENTAL|Trastuzumab, Placebo, and Chemotherapy|Prior to surgery: trastuzumab, placebo, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/FEC chemotherapy: trastuzumab and placebo up to 1 year total.
62047713|NCT03642925|EXPERIMENTAL|Meal replacement diet|Obese subjects (BMI\>27; n=50, male 23, female 27) were requested to replace (intervention) two meals/day (breakfast and lunch or dinner) by balanced nutritional meal replacement diet (equal to 240 kcal) for 8 weeks
62047714|NCT00566683|ACTIVE_COMPARATOR|1|Diazemuls-Pethidine
62829736|NCT03882606|OTHER|SML implantation|prospective study of a cohort of patients with age-related macular degeneration or myopic maculopathy treated with SML implantation
62047715|NCT00566683|ACTIVE_COMPARATOR|2|Propofol- Alfentanil
62047716|NCT04335045|ACTIVE_COMPARATOR|100mg Dose|1 x 100 mg PH100 capsule (n=6)
62047717|NCT04335045|PLACEBO_COMPARATOR|Control for 100mg Dose|1 placebo capsule (n=2)
62047718|NCT04335045|ACTIVE_COMPARATOR|200mg Dose|1 x 200 mg PH100 capsule (n=6)
62829737|NCT01930968||Ultrasound measurement|There is only 1 arm in this study. The ocular tumors will be imaged using ultrasound and the contrast agent. The patient's history will be noted, lung and heart auscultation will be performed, and blood pressure readings will be obtained to ensure the patient has no contraindications to using Definity®. If there are no contraindications, routine ocular ultrasonography, both A and B scans, will be performed using an Ellex Eye Cubed ultrasound machine. Definity® (the microbubble contrast agent) will be prepared per package instruction and the dose calculated according to the following formula: Patient weight (kg) X 10 microliters = Definity® dose. If necessary, a second 10 microliter/kg dose may be given 30 minutes after the first IV injection.
62829738|NCT00733018|ACTIVE_COMPARATOR|A|Diet A - Western diet
62047719|NCT04335045|PLACEBO_COMPARATOR|Control for 200mg Dose|1 placebo capsule (n=2)
62250129|NCT00714467|EXPERIMENTAL|2|Expert system (stage-based manual and 3 individualized tailored feedback report) to all the smoker participants; a family assisted intervention in a form of a self-help booklet that discusses specific strategies to work with smokers at each stage of change to the paired-supporters
62607688|NCT05995457|EXPERIMENTAL|"Intramuscular injection of Haloperidol decanoate using the Z-track and Airlock techniques"|"Intramuscular injection involves administering the drug treatment Haloperidol decanoate into muscle tissue using the Z-track and Airlock techniques."
62829739|NCT00733018|ACTIVE_COMPARATOR|B|Diet B - Balanced diet
62829740|NCT03230461|EXPERIMENTAL|Target compression depth 4.0-5.0 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
62829741|NCT03230461|EXPERIMENTAL|Target compression depth 4.5-5.5 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
62047720|NCT04335045|ACTIVE_COMPARATOR|400mg Dose|2 x 200 mg PH100 capsules (n=6)
62047721|NCT04335045|PLACEBO_COMPARATOR|Control for 400mg Dose|2 placebo capsules (n=2)
62047722|NCT04335045|ACTIVE_COMPARATOR|800mg Dose|4 x 200 mg PH100 capsules (n=6)
62047723|NCT04335045|PLACEBO_COMPARATOR|Control for 800mg Dose|4 placebo capsules (n=2)
62047724|NCT04335045|ACTIVE_COMPARATOR|1200mg Dose|6 x 200 mg PH100 capsules (n=6)
62047725|NCT04335045|PLACEBO_COMPARATOR|Control for 1200mg Dose|6 placebo capsules (n=2)
62047726|NCT04335045|ACTIVE_COMPARATOR|1600mg Dose|8 x 200 mg PH100 capsules (n=6)
62047727|NCT04335045|PLACEBO_COMPARATOR|Control for 1600mg Dose|8 placebo capsules (n=2)
62047728|NCT03940599|EXPERIMENTAL|Fitbit with visible screen|The first group will receive a FitBit with the screen visible, displaying their daily step count (the Step-Counter group).
62829742|NCT03230461|EXPERIMENTAL|Target compression depth 5.0-6.0 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
62250130|NCT05546450|NO_INTERVENTION|Control Group|Among those who applied to the clinic, those who do not want to follow their diet will be randomized into this group.
62439852|NCT05073900|ACTIVE_COMPARATOR|Erector spinae plane block|Ultrasound guided erector spinae plane block
62439853|NCT04872426|EXPERIMENTAL|Low intensity exercise|70% of maximal leg work load capacity
62250131|NCT05546450|EXPERIMENTAL|Cornus mas L. and Diet Group|Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet and will receive 30 g/day lyophilized Cornus mas L. fruit powder for their one portion of fruit a day.
62250132|NCT05546450|EXPERIMENTAL|Diet Group|Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet.
62250133|NCT05546450|EXPERIMENTAL|Cornus mas L. Group|Among those who applied to the clinic, those who do not want to follow their diet will be randomized into this group. Patients in this group will receive 30 g/day lyophilized Cornus mas L. fruit powder
62250134|NCT05546450|NO_INTERVENTION|Healthy Control Group|This group included healthy individuals who were not diagnosed with Metabolic Associated Fatty Liver.
62607689|NCT05995457|OTHER|Control arm, Intramuscular injection as usual|Intramuscular injection involves administering the drug Haloperidol decanoate into muscle tissue using the usual technique
62829743|NCT00610896||Observation|30 Patients with dualchamber pacemakers or implantable cardioverter-defibrillators (ICDs)
62829744|NCT01529970||parkinson's disease, young onset|
62829745|NCT01529970||Normal|
62829746|NCT03889496|OTHER|Scheduled for (partial) pancreatectomy or Whipple procedure|I.v. injection with In-111-DTPA-exendin-4 and SPECT/CT scan
62829747|NCT04197596|EXPERIMENTAL|BK CTL|Eligible patients with refractory BK infection will receive up to 5 infusions of BK CTLs that are donor derived.
62829748|NCT06599944||Students who applied Diseases and Nursing Care 3 at the Migrant Health Centre|Students who carry out the application for the Diseases and Nursing Care 3 course at the Migrant Health Centre will be included in this group and the relevant measurement tools will be applied.
62250135|NCT05075837|EXPERIMENTAL|Virus-specific T cells for the treatment of active viral infections following allogeneic HSCT.|Virus specific T lymphocytes selected in vitro from a family donor to treat some refractory viral infections as Adenovirus (ADV), Ebstein Barr virus (EBV), Cytomegalovirus (CMV) that developed in young patients (age between 0 and 21 years) after allogeneic hematopoietic cell transplantation (allo-HSCT)
62250136|NCT00938717|PLACEBO_COMPARATOR|Placebo|
62250137|NCT00938717|EXPERIMENTAL|290 μg Linaclotide|
62250138|NCT05188820|ACTIVE_COMPARATOR|Corticosteroid group|Patients will receive intra-articular z-joint injection of cortisone
62250139|NCT05188820|EXPERIMENTAL|PRP group|Patients will receive intra-articular z-joint injection of PRP
62439854|NCT04872426|EXPERIMENTAL|High intensity exercise|70% and 95% of maximal work load capacity (alternately every 5 min)
62439855|NCT04872426|EXPERIMENTAL|Low intensity exercise + intermittent ischemia-reperfusion|70% of maximal leg work load capacity with intermittent ischemia (25 seconds every 2 min)
62439856|NCT03043274|EXPERIMENTAL|Cangrelor|Approximately 30 patients in this arm will receive standard STEMI care but will also receive standard dosing of cangrelor at the time of their PCI.
62439857|NCT03043274|NO_INTERVENTION|No cangrelor|Approximately 30 patients in this arm will receive standard STEMI but will not receive cangrelor at the time of their PCI.
62439858|NCT04572620||group 1(rituximab)|
62439859|NCT04572620||group 2 (abatacept)|
62439860|NCT00593996|PLACEBO_COMPARATOR|1|oral placebo 3 times weekly
62607690|NCT03484221|EXPERIMENTAL|FOLFOXIRI+short-course radiation+XELOX|Firstly, 4 cycles of neoadjuvant FOLFOXIRI chemotherapy were administered. Subsequently, a short-course radiation therapy (5Gy\*5) will be performed. After that, 4 cycles of XELOX chemotherapy will be administered followed by surgery.
62047729|NCT03940599|EXPERIMENTAL|Scale group|The second will receive a BodyTrace scale that will display and record their weight in kilograms and a FitBit with the screen covered as it was for the run-in period so their physical activity can be measured, but the only feedback they will receive is from the scale (the Scale group).
62250140|NCT02596620|EXPERIMENTAL|Sequential therapy|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily, amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 5 days followed by esomeprazole (Nexium) (40 mg) twice daily, levofloxacin(Cravit)(500 mg), 1 tablet once daily and metronidazole (Flagyl)(250 mg) 2 tablets three times daily for 5 days
62047730|NCT03940599|EXPERIMENTAL|Step counter and scale|The third group will receive a BodyTrace scale and a FitBit with the screen visible (the Step-Counter and Scale group).
62047731|NCT03940599|SHAM_COMPARATOR|Fitbit with screen covered|The remaining 5 participants will serve as normal controls and continue wearing the FitBit with the screen covered as it was during the run in period for the duration of follow up.
62047732|NCT01353222|EXPERIMENTAL|DN24-02|Subjects received infusion of DN24-02, at 2-week intervals, for a total of 3 infusions.
62047733|NCT01353222|OTHER|Standard of Care|Subjects randomized to the control arm were treated per standard of care, which in this patient population is generally observation, as there is currently no evidence that treatment with non-cisplatin containing chemotherapy is beneficial in the adjuvant setting for this patient population.
62047734|NCT02621580|NO_INTERVENTION|Control|Patients with type 1 or type 2 diabetes mellitus (according to ADA or WHO guidelines) that have severe preproliferative or proliferative diabetic retinopathy and do not require laser or anti-VEGF treatment in at least one eye.
62047735|NCT02621580|EXPERIMENTAL|Treatment: Pan-Retinal Photocoagulation|Patients with type 1 or type 2 diabetes mellitus (according to ADA or WHO guidelines) that have severe preproliferative or proliferative diabetic retinopathy and require PRP laser in at least one eye.
62047736|NCT03613311||Evident urodynamic stress incontinence(USI)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. USI is noted during filling cystometry and is defined as the involuntary leakage of urine during increased abdominal pressure, in the absence of a detrusor contraction.
62047737|NCT03613311||Occult USI|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. USI is noted during filling cystometry and is defined as the involuntary leakage of urine during increased abdominal pressure, in the absence of a detrusor contraction after prolapse reduction by vaginal gauze.
62439861|NCT03158259|EXPERIMENTAL|Intervention group MSU|Patient will be diagnosed (NIHSS, CT and conventional blood-measures) and given thrombolytic treatment (when indicated) prehospitally by anesthesiologist in Mobile Stroke Unit (MSU)
62439862|NCT03158259|ACTIVE_COMPARATOR|Conventional ambulance|Patient will be brought to hospital by normal ambulance according to existing procedures. Diagnosis (NIHSS, CT and conventional blood-measures) and thrombolytic treatment (when indicated) will be given in hospital.
62829749|NCT06599944||Students who practiced Diseases and Nursing Care 3 in a unit other than the Migrant Health Centre|Related measurement tools will be applied to students who perform the practice for the Diseases and Nursing Care 3 course in a different unit other than the migrant health centre.
62829750|NCT03643848|EXPERIMENTAL|Sleep with Sound Cues|Sounds played at time of memory encoding will be replayed during sleep to cue memory processing.
62047738|NCT03613311||ND USI|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. No USI was noted in this group.
62047739|NCT05941130|EXPERIMENTAL|Group A|Patients assigned into group A (NSAID) will receive only Ibuprofen 600mg (Mylan)
62047740|NCT05941130|EXPERIMENTAL|Group B|Patients assigned into group B (CORT + NSAID) will receive Ibuprofen 600mg (Mylan) with methylprednisolone (Medrol, 16mg Pfizer Laboratories)
62047741|NCT02440633|EXPERIMENTAL|14C-OPS-2071|Suspension containing 50 mg of 14C-OPS-2071
62047742|NCT01118364|EXPERIMENTAL|cigarette with cannabis|"a cigarette tobacco trade mark Drum with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)"
62047743|NCT01118364|OTHER|cigarette without cannabis|"a cigarette tobacco trade mark Drum"
62047744|NCT02827006|ACTIVE_COMPARATOR|Bone graft|Bone graft from iliac crest as gapfiller
62047745|NCT02827006|EXPERIMENTAL|Calcium phosphate bone cement|CaP bone cement as gapfiller
62047746|NCT05087082|OTHER|App and Case Management system with algorithms|Feasibility study of hospital at home model including telemedicine and specifically developed app and case management system
62047747|NCT01269879|ACTIVE_COMPARATOR|Active control (Flexi-Bar only)|Flexi-Bar vibration training only over 12 weeks with three distinct exercises and 10min training twice daily
62047748|NCT01269879|EXPERIMENTAL|Intervention Flexi-Bar + XCO-Trainer|Combination intervention using vibration device Flexi-Bar and XCO-Trainer (oscillating mass witin a tube moved during running 40-60min/week suggested)
62047749|NCT01844752|EXPERIMENTAL|NVN1000 1% Gel|NVN1000 1% Gel twice daily
62047750|NCT01844752|EXPERIMENTAL|NVN1000 4% Gel|NVN1000 4% Gel twice daily
62607691|NCT05259384|EXPERIMENTAL|MIPD-ROB|Patients with PCN locates HEAD and NECK of pancreas who were randomized to ROBOTIC pancreaticoduodenectomy.
62047751|NCT01844752|PLACEBO_COMPARATOR|Vehicle Gel|Vehicle Gel twice daily
62829751|NCT03643848|SHAM_COMPARATOR|Sleep with Sham Cues|Sounds that were not played at time of memory encoding will be played during sleep as a sham comparison
62829752|NCT01003717||Endeavor|Patients treated with at least 1 Endeavor, zotarolimus-eluting, Stent as the primary treatment for acute coronary syndrome
62047752|NCT03458884|EXPERIMENTAL|Cardiorespiratory interval training|Cardiorespiratory interval training program on ergometer cycle, 30-40 minutes, 3 days a week for 8 weeks.
62829753|NCT03780244|EXPERIMENTAL|Investigational Study Product|Injection with Sculptra Aesthetic reconstituted with 8ml Sterile Water for Injection (SWFI)
62047753|NCT03458884|NO_INTERVENTION|Usual care|Usual ESD care including information about post-stroke fatigue, support and practical advice about how to identify and manage fatigue symptoms in daily tasks, such as the adaptation and prioritization of activities, physical activity and rest.
62047754|NCT00236301|ACTIVE_COMPARATOR|1|17 Beta-estradiol (2mg/day)and (1mg/day)
62047755|NCT00236301|ACTIVE_COMPARATOR|2|CLIMASTON
62047756|NCT00236301|PLACEBO_COMPARATOR|3|placebo
62047757|NCT02879266|EXPERIMENTAL|TetraVax-DV TV005|Participants will receive a subcutaneous injection of TetraVax-DV TV005 at study entry (Day 0).
62047758|NCT02879266|PLACEBO_COMPARATOR|Placebo|Participants will receive a subcutaneous injection of placebo at study entry (Day 0).
62047759|NCT06451120|EXPERIMENTAL|Platelet-rich plasma (PRP)|A vacutainer vial containing 50 mL of peripheral blood will be processed immediately to create PRP using a previously optimized two-step centrifugation protocol viii. First, the whole blood will be centrifuged at 500 x g for 8 minutes at 4°C. The plasma will be collected above the buffy coat using a sterile pipette, placed into a separate sterile tube, and centrifuged a second time at 700 x g for 17 minutes at 12° C. The top 70% will be collected as the PPP and the bottom 30% will be resuspended as the PRP. PPP will be aliquoted into cryovials for storage at -80 °C. Approximately 6 mL of PRP will be produced from each 50 mL vial of whole blood. Five mL will be allocated for administration to patients and the remaining one mL will be aliquoted into cryovials for storage at -80 °C. The syringe containing PRP will be covered with Aluminum foil, such that the investigator cannot tell what fluid is to be injected.
62047760|NCT06451120|EXPERIMENTAL|Control saline injection (wait-list control)|A placebo injection of 6 mL of 0.9% saline will be prepared by the unblinded research assistant in an adjacent room. The syringed will be prepared in a 10 mL syringe and covered with Aluminum foil, such that the investigator performing the injection cannot tell if there is PRP or saline to be injected.
62047761|NCT03977558|EXPERIMENTAL|Intervention group|Isocaloric diet, based on individual energy requirements calculated from indirect calorimetry and physical activity adjustment Participants will be asked to eat daily \~50g canola oil
62607692|NCT05259384|ACTIVE_COMPARATOR|MIPD-LAP|Patients with PCN locates HEAD and NECK of pancreas who were randomized to LAPAROSCOPIC pancreaticoduodenectomy.
62829754|NCT03780244|ACTIVE_COMPARATOR|Reference Product|Injection with Sculptra Aesthetic reconstituted with 5ml SWFI
62829755|NCT05482971|EXPERIMENTAL|Ropeginterferon alfa-2b (P1101)|Pre-filled Syringe, Q2W, SC injection
62607693|NCT05259384|EXPERIMENTAL|MIDP-ROB|Patients with PCN locates BODY and TAIL of pancreas who were randomized to ROBOTIC distal pancreatectomy.
62047762|NCT03977558|ACTIVE_COMPARATOR|Control group|Standard dietary advice that is used as current best practice in the treatment of lipid disturbances of European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) Guidelines for the management of dyslipidemias)
62607694|NCT05259384|ACTIVE_COMPARATOR|MIDP-LAP|Patients with PCN locates BODY and TAIL of pancreas who were randomized to LAPAROSCOPIC distal pancreatectomy.
62607695|NCT00624650|ACTIVE_COMPARATOR|Modified FACTT (control)|The investigators control arm consists of a simplified algorithm for conservative management of fluids in patients with ALI, as to be published by the ARDSnet group, based on the protocol used in the FACTT trial. The protocol calls for strict adherence to ARDSnet ventilation, our weaning protocol and use of only select vasoactive, beta-adrenergic drugs as it is felt that variation in these treatments could seriously confound our results. Albuterol administration will not be permitted in the either arm except for life threatening bronchospasm not responsive to ipratropium. Ipratropium may be administered at the treating physician's discretion for bronchospasm. PiCCO's will be placed in each control patient and data recorded twice daily. The treating physician's will be blinded to this data.
62607696|NCT00624650|EXPERIMENTAL|EVLW|"When EVLW exceeds 9 ml/kg PBW the algorithmic treatment is begun and continued until EVLW ≤9 ml/kg PBW or extubation whichever comes first as tolerated (see figure 6). Furosemide and volume contraction are initiated when sufficient volumetric preload (GEDI) is available to enact volume contraction as a means to decrease measured EVLW without causing concomitant hypoperfusion. Fluid administration is also guided by changes in EVLW. An increase in EVLW \> 2ml/kg PBW as a result of fluid administration curtails any further fluid administration until the next scheduled measurement.~Our ultimate treatment goal is to maximally lower EVLW towards the normal range - thus improving lung mechanics and gas exchange - without causing concomitant hemodynamic compromise and end-organ injury. By doing so we feel this algorithmic, goal directed, therapeutic approach should improve outcome."
62607697|NCT02583867|EXPERIMENTAL|Exercise|Participants will complete an exercise dose of 15 kilocalories per kilogram of bodyweight per week (KKW). This is equivalent to approximately 150 minutes/week of aerobic exercise. This dose will be completed in at least 3 sessions per week for 12 weeks.
62829756|NCT02142699|ACTIVE_COMPARATOR|Heme arginate 1mg/kg|"This is the lower of the 2 doses of Heme arginate (HA). This will be given as a single dose of 1mg/kg on the first study visit.~This is given over 1 hour intravenously."
62829757|NCT02142699|ACTIVE_COMPARATOR|Heme arginate 3mg/kg|"This is the larger dose, Heme arginate 3mg/kg (up to a maximum dose of 250mg)~This will be given intravenously, as a single dose on the first study visit, over one hour."
62829758|NCT03857854|EXPERIMENTAL|treatment group|pirfenidone group
62829759|NCT03857854|PLACEBO_COMPARATOR|placebo group|control group
62250141|NCT02596620|ACTIVE_COMPARATOR|Triple therapy|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily; amoxicillin (Amolin)(500 mg) 2 tablets twice daily and levofloxacin(Cravit)(500 mg), 1 tablet once daily for 10 days
62250142|NCT02463071|EXPERIMENTAL|AZD0585 2g group|AZD0585 1g × 2 capsules and AZD0585 placebo 1g × 2 capsules once daily
62250143|NCT02463071|EXPERIMENTAL|AZD0585 4g group|AZD0585 1g × 4 capsules once daily
62250144|NCT02463071|PLACEBO_COMPARATOR|Placebo control group|AZD0585 placebo 1g × 4 capsules once daily
62439863|NCT04867161||Patients with COVID-19 pneumonia without superinfection|Patients with confirmed COVID-19 pneumonia not fulfilling criteria for diagnosis HAP/VAP (International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia )
62439864|NCT04867161||Patients with COVID-19 pneumonia with superinfection|Patients with confirmed COVID-19 pneumonia fulfilling criteria for diagnosis HAP/VAP (International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia )
62439865|NCT05340556|EXPERIMENTAL|sRPL patient|sRPL with an older brother and at least one child prior to diagnosis
62250145|NCT06388304|EXPERIMENTAL|Online Program|Online program
62439866|NCT05340556|EXPERIMENTAL|Brother or child to the sRPL patient|An older brother (with at least same biological mother) og child to the sRPL patient
62439867|NCT05778370||Group 1|will include 15 patients (30 eyes) of age matched non-diabetic candidates (control group)
62439868|NCT05778370||Group 2|will include 15 patients (30 eyes) of diabetic patients with good glycemic control (HbA1c ≤7%),
62439869|NCT05778370||Group 3|will include 15 patients (30 eyes) of diabetic patients with poor glycemic control (HbA1c \<7% (
62829760|NCT03301311|EXPERIMENTAL|Specific Carbohydrate Diet (First)|Participants will be following the Specific Carbohydrate Diet (SCD). Allowed foods include meat/fish/poultry, eggs, some legumes (e.g., lentils and split peas are permitted, chickpeas and soybeans are not), fully fermented yogurt, non-starchy vegetables, ripe fruit, nuts/seeds, honey and nut flours (e.g. almond flour or coconut flour). Restricted foods include all grains, milk products aside from 24-hour fermented SCD yogurt and cheeses aged greater than 30 days, starchy vegetables, processed foods with food additives and sweeteners other than honey.
62829761|NCT03301311|EXPERIMENTAL|Modified Specific Carbohydrate Diet (First)|Participants will be following a modified Specific Carbohydrate Diet (MSCD). In addition to the foods in the SCD, allowed foods will expand to include organic rice, oats, sweet potatoes, grade A maple syrup and cocoa. Gluten, corn products, milk products (except yogurt and hard cheeses), sweeteners (except honey), and process foods are still restricted.
62829762|NCT01745939|ACTIVE_COMPARATOR|Lumbar manipulation|Patients will receive thrust joint manipulation to their lumbar spine in side lying
62829763|NCT01745939|SHAM_COMPARATOR|Sham manipulation|Patients will receive oscillations into slight rotation, without cavitation, in side lying
62829764|NCT04772001|EXPERIMENTAL|CCRT+Anlotinib|Classical chemoradiotherapy will be conducted by clinical routine method. Radiation will be given by external beam of 45Gy total dose and 3D-brachytherapy of 30Gy/5F or 28Gy/4F. Duration of radiotherapy will be no more than 8 weeks. Concurrent chemotherapy will be administrated weekly during radiation for a total of 5-6 doses. Cisplatin of 40mg/m2 will be the most preferred regime and for patients with intolerable toxicity of cisplatin, carboplatin of AUC 2 will be the alternative drug. Hydrochloride anlotinib will be orally taken daily at a dose level of 12mg for 14 days. Then rest for 7 days and start a new cycles for a total of 3 cycles. First capsule of anlotinib will be taken 7 days before the first radiation.
62047763|NCT06323733|EXPERIMENTAL|Exercise intervention|"The exercise intervention will consist of a personalized and supervised program lasting 12 weeks with two sessions per week, held on Tuesdays and Thursdays at the Sports and Medicine Center SPORMED in Rennes, France.~Each session will combine endurance and resistance training, commencing with a 6-minute cardiovascular warm-up on ergometers (cycling ergometer or treadmill). This will be followed by 20 minutes at moderate intensity (60-70% of Heart Rate Reserve (HRR)), concluding with a 2-minute recovery period at light intensity. Heart rate will be monitored using a pulse oximeter. Participants will report their rate of perceived exertion during endurance training using a 5-point scale (very easy, easy, moderate, difficult, very difficult)."
62047764|NCT05917639|EXPERIMENTAL|Vitruvian plot|
62829765|NCT01517399|OTHER|Test drug administration|All drugs except vitamin K will be administered as a single dose once by itself as a reference treatment and once with tivantinib
62047765|NCT05917639|EXPERIMENTAL|Kilim plot|
62047766|NCT05917639|ACTIVE_COMPARATOR|Summary of findings table|
62047767|NCT05909514|EXPERIMENTAL|3 month PelvicSense(R) program|PelvicSense® is a home-based physiotherapy program integrating multiple techniques, including relaxation, breathing, stretching, strengthening and at-home manual therapy. This program also educates participants about the anatomy and physiology of the pelvis and teaches strategies to strengthen the mind-muscle connection to the pelvis.
62047768|NCT01615328|EXPERIMENTAL|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs(TM), which is the PEEK cage filled with b-TCP.
62439870|NCT02193984|EXPERIMENTAL|Peer support|Study participants are assigned a volunteer peer supporter who has been trained to offer support on diabetes management.
62439871|NCT02193984|NO_INTERVENTION|Control|No intervention
62829766|NCT01016249|ACTIVE_COMPARATOR|Treatment 1. 5% Saline + Epinephrine|Nebulization with 4ml of 5% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
62829767|NCT01016249|OTHER|Treatment 3. 3% Saline + Epinephrine|Nebulization with 4ml of 3% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
62047769|NCT01615328|EXPERIMENTAL|Bonion|The ACDF surgery will be carried out with Bonion(TM), which is the PEEK cage with HA/DBM.
62047770|NCT04010071|EXPERIMENTAL|axitinib plus toripalimab|"Axitinib (Inlyta, Pfizer Inc.) is a novel oral angiogenesis inhibitor that selectively targets vascular endothelial growth factor (VEGFR) 1, 2 and 3.~Toripalimab (Shanghai Junshi Biosciences Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody."
62047771|NCT02348450|EXPERIMENTAL|Irinotecan plus Cisplatin|first line: irinotecan 65mg/m2 d1,8. Cisplatin 30mg/m2，d1,8, 21days/cycle×6 cycles Second-line: etoposide alone OR etoposide plus cisplatin, dosage will be same as first line or on investigator's discretion.
62439872|NCT02561390|EXPERIMENTAL|Skin prick test with aeroallergens|Mean wheal diameters of SPT with commercial and local American coakroach, house dust mite, cat, dog and mold
62439873|NCT02561390|EXPERIMENTAL|specific IgE measurement|specific IgE levels of commercial and local American coakroach, house dust mite, cat, dog and mold
62439874|NCT01023906||18-49 years|Younger
62439875|NCT01023906||50-85 years|Older
62439876|NCT01506089|EXPERIMENTAL|36 degree group|36 degrees Celsius for the incubators is the experimental condition in this study.
62250146|NCT00332839|ACTIVE_COMPARATOR|Calcineurin Inhibitor (CNI) group|Participants received Cyclosporine A (CsA) plus Enteric Coated Mycophenolate Sodium (EC-MPS) plus corticosteroids, or Tacrolimus A (CsA) plus Enteric Coated Mycophenolate Sodium (EC-MPS) plus corticosteroids.
62250147|NCT00332839|EXPERIMENTAL|Certican group|Participants were switched in a step-wise fashion from the CNI based regimen to Everolimus (RAD001).
62250148|NCT02980120||Anorexia Nervosa Group|n=50 female patients with Anorexia Nervosa (AN) who fulfill the criteria for DSM-IV, BMI z-scores will be used for age and sex specific cut-off points that are extrapolated from the adult BMI cut-off \<17.5 Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
62250149|NCT02980120||Bulimia Nervosa Group|n=30 female patients with Bulimia Nervosa (BN) who have BMI z-scores from the adult range \<17.5-25.0 (this reflects the lower prevalence rates of BN compared to AN) Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
62250150|NCT02980120||Healthy Control Group|n=30 healthy females who have BMI z-scores from the adult range from 19.0-25.0 and who do not fulfill diagnostic criteria for any psychiatric disorder.Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
62607698|NCT01744002|EXPERIMENTAL|Shoulder Treatment with Neck Mobilization|The experiment group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and Unlateral Posterior Anterior Mobilization to the cervical spine; applied as 3 X 30 seconds, to each comparable (stiff or painful) segment.
62607699|NCT01744002|ACTIVE_COMPARATOR|Control Group|The control group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
62607700|NCT06385522|EXPERIMENTAL|BITR2101|
62607701|NCT06730542|EXPERIMENTAL|Zanubrutinib in combination with Pola-R-CHP and in combination with Methotrexate Group|Participants will be in this group for up to 2 years
62829768|NCT01016249|OTHER|Treatment 2 . 0.9% Saline + Epinephrine|Nebulization with 4ml of 0.9% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
62829769|NCT05304754|ACTIVE_COMPARATOR|KIR mismatch aloreactive NK donor cells|Three patients from each cohort will receive NK aloreactive cells from a KIR mismatch donor
62829770|NCT05304754|EXPERIMENTAL|NK cells stimulated ex vivo with IL-15 from KIR match donor|Three patients in each cohort will receive ex vivo stimulated NK cells with IL-15 from a KIR match donor.
62829771|NCT02756286||ADHD: Adults with ADHD|NAT electroencephalography (EEG) test
62829772|NCT02756286||Controls: Healthy adults without ADHD|NAT electroencephalography (EEG) test
62829773|NCT01752335|OTHER|tocilizumab|"All the patients are treated with tocilizumab before inclusion. The doses, frequency and duration are in acordance with the Summary of Characteristics of the Product authorised by EMA.~Usually 8mg/kg (not minor than 480 mg), once each 4 weeks."
62829774|NCT06591650|EXPERIMENTAL|Gemcitabine + Cisplatin + Nab-Paclitaxel + Durvalumab|Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes, cisplatin IV over 60 minutes and nab-paclitaxel over 30 minutes on days 1 and 8. Durvalumab intravenously (IV) on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62047772|NCT02348450|EXPERIMENTAL|Etoposide plus Cisplatin|first line: etoposide 60mg/m2 d1-5 Cisplatin 75mg/m2，d1(recommended), or administer three times with same total daily dose , 21days/cycle×6 cycles Second-line: irinotecan alone or irinotecan plus cisplatin, dosage is same as first line or on investigator's discretion.
62250151|NCT04042870|EXPERIMENTAL|Joint Loosening Yoga|Yoga Intervention. Dose: 15 minutes, M-F for 4-weeks.
62607702|NCT03881891|EXPERIMENTAL|Follow-app intervention arm|This arm will comprise of patients who are prompted to complete the PROMIS pain intensity scale through text/Short Message Service(SMS) or email mobile device notifications at pre-defined time intervals on Days 1, 3, 5 and 7 post-operatively.
62829775|NCT03431207||healthy group|"For the healthy group, the visual acuity of both eyes was in the 95% referenced range with no structural abnormalities.~The referenced range could be found in the following publication:~Mayer, DL., et al. Monocular acuity norms for the Teller Acuity Cards between ages one month and four years. Investigative Ophthalmology \& Visual Science. 36(3):671 (1995)"
62829776|NCT03431207||mildly impaired group|"The mildly impaired group was defined as a VA out of the 95% reference range in at least 1 eye, but the VA of both eyes was in the 99% referenced range with structural abnormalities."
62829777|NCT03431207||severely impaired group|"For the severely impaired group, the VA of both eyes was out of the 99% referenced range or worse than light perception with structural abnormalities."
62250152|NCT02626481|EXPERIMENTAL|Daratumumab + Dexamethasone|patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
62250153|NCT02851420|PLACEBO_COMPARATOR|control|
62607703|NCT03881891|NO_INTERVENTION|Standard care arm|This arm will comprise of patients who receive the usual care.
62607704|NCT06712186|EXPERIMENTAL|Intervention group/Group D|Intervention group: Group D patients will be administer 0.5 mcg/kg dexmedetomidine intravenously over 10 min preoperatively.
62607705|NCT06712186|PLACEBO_COMPARATOR|Control group/Group C|Control group: Group C patients will be administer the same volume of normal saline (also intravenously for 10 min)
62250154|NCT02851420|EXPERIMENTAL|patient|
62250155|NCT04354220||no shunt, no lung injury|ventilated newborns / infants / children with healthy lungs and without or corrected congenital heart disease and no intra-/extra-cardiac shunt
62250156|NCT04354220||mild lung injury|ventilated newborns / infants / children with mild lung injury (OI between 4 and 8)
62250157|NCT04354220||moderate-severe lung injury|ventilated newborns / infants / children with moderate or severe lung injury (OI above 8)
62250158|NCT04354220||shunt lesion|ventilated newborns / infants / children with cyanotic heart diseases and therefore existing intra-cardiac or extra- cardiac right-left shunt lesions
62439877|NCT01506089|NO_INTERVENTION|37 degree group|37 degrees Celsius is the standard incubator temperature for the culture of embryos.
62607706|NCT06283641||Saxenda®|Patients with obesity treated with Saxenda® for weight management in routine clinical practice in Taiwan
62047773|NCT01806987|EXPERIMENTAL|KITS Program|The KITS Program consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
62829778|NCT02612779|EXPERIMENTAL|Elotuzumab + Pomalidamide + Low Dose Dexamethasone (EPd)|patients will receive treatment with elotuzumab in combination with pomalidomide and low-dose dexamethasone. Patients are eligible to receive Nivolumab at progression.
62829779|NCT02612779|EXPERIMENTAL|Elotuzumab + Nivolumab (EN)|Patients will receive treatment with a combination of elotuzumab and nivolumab
62829780|NCT05902689|NO_INTERVENTION|blank group|After non-traumatic tooth extraction, the control group will undergo natural healing.
62829781|NCT05902689|ACTIVE_COMPARATOR|control group|After non-traumatic tooth extraction, the control group will use alveolar ridge preservation with bio-oss collagen
62829782|NCT05902689|EXPERIMENTAL|experimental group|After non-traumatic tooth extraction, the experimental group will use Sticky Bone for alveolar ridge preservation
62829783|NCT02651207||local anaesthetic spray group|women will either chose the above, ethyl chloride spray prior to having their contraceptive implant fitted or the below injection. This comes in a canister and a maximum of 5 spray for 5 seconds will be applied topically to the skin at the site of the contraceptive implant insertion
62829784|NCT02651207||local anaesthetic injection group|women will either chose ethyl chloride spray prior to having their contraceptive implant fitted or the injection, subcutaneous 1% lidocaine, usually a dose of about 1-2 mls to the area skin where the contraceptive implant is to be inserted.
62829785|NCT05777499|EXPERIMENTAL|Music Therapy|See Intervention section
62829786|NCT05777499|ACTIVE_COMPARATOR|Control Therapy|See Intervention section
62829787|NCT02420821|EXPERIMENTAL|Atezolizumab + Bevacizumab|Participants will receive both atezolizumab and bevacizumab until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression, withdrawal of consent, or death, whichever occurs first.
62829788|NCT02420821|ACTIVE_COMPARATOR|Sunitinib|Participants will receive sunitinib until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression, withdrawal of consent, or death, whichever occurs first.
62047774|NCT01806987|NO_INTERVENTION|Services as usual|These include any services that the child and family might already be receiving in the community.
62250159|NCT05080699|EXPERIMENTAL|Peptamen Intense in obese home enteral nutrition patients after stroke|Subjects currently enrolled in Mayo Clinic Home Enteral Nutrition (HEN) program and anticipated to require tube feedings to provide 90% or more of feeding needs will be placed on a Peptamen Intense VHP for up to 12 weeks.
62439878|NCT04468971|PLACEBO_COMPARATOR|Arm 1|Excipient
62829789|NCT03913520|OTHER|Congenital Heart Disease|Undergoing evaluation at 30 days
62829790|NCT00515372|ACTIVE_COMPARATOR|Intervention Group|Weekly phone calls lasting about 30 minutes. Lists of professional resources and referral recommendations will be provided.
62829791|NCT00515372|OTHER|Usual Care Group|Lists of professional resources and referral recommendations will be provided.
62829792|NCT06293599|EXPERIMENTAL|scapular stabilization exercise|thirty patients with scapular dyskinesia will receive scapular stabilization exercise and regular routine three times a week for eight weeks
62829793|NCT06293599|EXPERIMENTAL|virtual reality exercise|thirty patients with scapular dyskinesia will receive virtual reality exercise and regular routine three times a week for eight weeks
62829794|NCT06293599|ACTIVE_COMPARATOR|Regular routine exercise|thirty patients with scapular dyskinesia will receive regular routine exercises three times a week for eight weeks
62047775|NCT00330174|EXPERIMENTAL|1|Acamprosate tablets
62047776|NCT00330174|PLACEBO_COMPARATOR|2|Matching placebo tablets
62047777|NCT05802368|EXPERIMENTAL|study group|a 30-minute VR-based training session utilizing Kinect Xbox after the session of traditional physical therapy.
62047778|NCT05802368|EXPERIMENTAL|control group|Traditional physical therapy, 30-minutes physical therapy exercise program each week with 48-hour intervals at least
62047779|NCT04679181|EXPERIMENTAL|Active arm|use of telemedicine
62250160|NCT05197517|EXPERIMENTAL|Rosuvastatin 10 mg film coated tablets|Single oral dose of 1 tablet (10 mg)
62250161|NCT05197517|ACTIVE_COMPARATOR|Crestor® 10 mg film coated tablets|Single oral dose of 1 tablet (10 mg)
62439879|NCT04468971|EXPERIMENTAL|Arm 2|CK0802: 1x10\^8 cells
62439880|NCT04468971|EXPERIMENTAL|Arm 3|CK0802: 3x10\^8 cells
62439881|NCT02459613|EXPERIMENTAL|Imaging|99mTc Annexin V-128 SPECT
62829795|NCT02194660||M- main hospital|Patient enrolled in the main hospital
62829796|NCT02194660||B- Beihu branch|Patients enrolled in the Beihu branch
62829797|NCT00887809|EXPERIMENTAL|gemcitabine and docetaxel with bevacizumab|Patients will receive bevacizumab at 15 mg/kg on day 1 of each 21-day cycle intravenously over 30 minutes followed by a one hour (+30/-15 min) break. For cycles 1 through 6, gemcitabine will be administered at 900 mg/m2 over 90 minutes on day 1 and 8 of a 21-day cycle. Docetaxel will be administered at 75 mg/m2, over 60 minutes, on day 8. This will be followed by either 5 days of filgrastim or a single injection of pegfilgrastim. For cycles 7 and beyond, gemcitabine will be given at 800 mg/m2 over 30 minutes on day 1 and 8; docetaxel will be given at 35 mg/m2 over 30 minutes, also on days 1 and 8.
62829798|NCT05397951|EXPERIMENTAL|Wearing Biosensor Before & After Exercise|Each study participant will wear the bioelectronic sensors during a slow deep breath. Participants will wear the sensors and devices for 15 minutes before and after a brisk 6-minute walk.
62829799|NCT05397951|EXPERIMENTAL|Wearing Biosensor for an Extended Period|Each study participant will wear the bioelectronic sensors during a slow deep breath. Participants will wear the sensors and devices continuously for 2 hours.
62047780|NCT04151225|PLACEBO_COMPARATOR|Participants receiving placebo|Participants will receive placebo loading dose followed by placebo for 12 weeks during Induction phase. Participants with clinical response at Week 12 will continue to receive placebo into a 40-weeks blinded maintenance period. Participants without a clinical response at Week 12 will receive a 450mg GSK2330811 SC loading dose at Week 12, followed by 150 mg SC every week from Week 13 until Week 23, followed by 150 mg SC every 2 weeks until Week 50.
62829800|NCT00538902|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously every other week
62829801|NCT00538902|EXPERIMENTAL|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously every other week
62829802|NCT00538902|EXPERIMENTAL|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week
62829803|NCT05069948|EXPERIMENTAL|HeadOn intervention|Participants are given access to HeadOn - a web application that delivers a CBT programme to patients following concussion.
62829804|NCT03649646||Patients|Patients with hypertension uncontrolled by antihypertensive drug
62829805|NCT06600308|EXPERIMENTAL|Patient|
62829806|NCT04495244||Investigational Population|"Suspected Invasive Breast Cancer (any size) or DCIS (pre-invasive) are of particular interest. Women with abnormal screening mammograms (R3-5) recalled for further investigation.~Inclusion criteria~* Women with suspected Invasive Breast Cancer (tumours of any size and/or DCIS).~* Individuals with an abnormal or suspicious screening mammogram recalled for further evaluation.~* Suspected Invasive Breast Cancer (tumours of any size and/or DCIS).~* Willing to give written Informed Consent and provide whole blood samples~* Age 30-75 years~Exclusion criteria~* Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)~* Inoperable (T4 category) or inflammatory breast cancer~* Previous history of cancer previously at any site~* Previous history of breast cancer~* Concomitant or other concurrent anti-cancer therapy~* Male~* No histopathological diagnosis"
62829807|NCT04495244||Borderline (Atypica and LCIS) Population|"Women with borderline pathological B3 lesions (suspected atypia Ductal or Lobular and benign proliferative disease without DCIS or invasion) Inclusion criteria~* Abnormal screening mammogram with suspected benign breast disease or proliferative changes~* Willing to give Written Informed Consent and provide whole blood samples~* Aged 30-75 years~Exclusion criteria~* Existing cancer diagnosis~* Male~* Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)~* Previous history of any cancer~* Previous history of breast cancer~* Concomitant or other concurrent anti-cancer therapy"
62829808|NCT04495244||Control Population|"Healthy Controls Inclusion criteria~* Normal breast examination - No cancer detected/suspected by physical exam, diagnostic radiology or screening mammography~* Willing to give Written Informed Consent and provide whole blood samples~* Aged 30-75 years~Exclusion criteria~* Cancer diagnosis~* Male~* Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)~* Previous history of any cancer~* Concomitant or other concurrent anti-cancer therapy"
62829809|NCT04862546|EXPERIMENTAL|Laser Acupoint|Laser will be performed 3 times per week for 2-week measurement. The duration of each cession will be 10 minutes treatment.
62047781|NCT04151225|EXPERIMENTAL|Participants receiving GSK2330811 450mg loading dose/150mg Q1W|Participants will receive 450mg GSK2330811 SC as loading dose followed by 150 mg GSK2330811 Q1W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150 mg GSK2330811 SC Q2W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
62439882|NCT06479694|EXPERIMENTAL|Real-life Dual-Task Training|Ten real-life dual-task training sessions with explicit focus on motor and cognitive components of instrumental activities of daily living. Training occurs with a licensed occupational therapist.
62829810|NCT04862546|ACTIVE_COMPARATOR|Tap water iontophoresis|Tap water iontophoresis will be performed 3 times per week for 2-weeks. The duration of each cession will be 20 minutes treatment session.
62829811|NCT06554184|EXPERIMENTAL|HR20013 + dexamethasone + palonosetron placebo|
62829812|NCT06554184|ACTIVE_COMPARATOR|Palonosetron + dexamethasone + HR20013 placebo|
62607707|NCT03404349|EXPERIMENTAL|Mindfulness for Adolescence Course|Participants will attend mindfulness classes to include deep breathing, yoga, listening to music and meditation.
62607708|NCT06631326||HAIC plus Lenvatinib and PD-1 inhibitors|Each patient should receive at least 2 cycles of HAIC, 2 cycles of PD-1inhibitors and take at least 2 months of Lenvatinib. The interval between HAIC and Lenvatinib plus PD-1 inhibitors should be within 2 months.
62250162|NCT02795533||Clinical follow-up|As part of the regular follow-up of aSAH patients at Oslo University Hospital patients with as aSAH in 2011-2012 will be invited to a clinical interview, medical examination and neuropsychological test. Patients will also be asked to answer Quality of Life Questionnaires.
62607709|NCT06631326||Lenvatinib plus PD-1 inhibitors|Each patient should receive at least 2 cycles of PD-1 inhibitors and 2 months of Lenvatinib.
62607710|NCT02100137||Women with endometrial hyperplasia|
62607711|NCT01303640|ACTIVE_COMPARATOR|Biolimus-eluting stent|Biolimus-eluting stent
62829813|NCT02614300|ACTIVE_COMPARATOR|Pulmonary Rehabilitation|These sessions will be individually designed and they will be a combination of global aerobic interval training using a cycloergometer. The aim is to achieve a training intensity of 80% HR or greater of the obtained during the ISWT. This intensity will be progressively increased during the firsts four weeks until achieving the target. The duration will be of about 45 minutes per session. Oxygen Saturation, HR and Borg scale for dyspnoea and fatigue will be measured before, during and at the end of the session in order to monitories the effort.
62829814|NCT02614300|ACTIVE_COMPARATOR|Chest Physiotherapy|"The ELTGOL technique (total slow expiration with glottis open in lateral decubitus) for airways clearance will be used in order to move respiratory secretions from the distal bronchial tree. It will be applied during 15 minutes each side (right and left lungs) assuming an approximate session length of 30 minutes. The patient could perform the cough technique when it's necessary."
62829815|NCT02614300|ACTIVE_COMPARATOR|Pulmonary Rehabilitation and Chest Physiotherapy|"This group will perform a combination of the two programs in the same session with a total duration of 1h and 15 minutes. The session will be divided in different parts: First, we will execute 15min of chest physiotherapy (7.5min for each side); second, the pulmonary rehabilitation session (45min) and finally, another 15min of chest physiotherapy (7.5min for each side). The patient will have a rest when it's necessary and we will continue with the session when there is a decrease of 2 points in the Borg scale.~Intensity of physiotherapy exercises and drainage techniques will be maintained similar to the PR and CP programs."
62250163|NCT04540770|PLACEBO_COMPARATOR|Part A 1 (1 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
62250164|NCT04540770|PLACEBO_COMPARATOR|Part A 2 (3 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
62439883|NCT02323906|EXPERIMENTAL|CC-122 + Fixed-dose Sorafenib|"A dose escalation and expansion clinical study of CC-122 in combination with sorafenib in subjects with unresectable HCC who have received no prior systemic therapy for HCC.~The dose escalation part of the study will explore several dose levels of CC-122 in combination with sorafenib, followed by an expansion part."
62607712|NCT01303640|ACTIVE_COMPARATOR|Everolimus-eluting stent|Everolimus-eluting stent
62607713|NCT04427137|EXPERIMENTAL|Accelerated LFR|In the acute treatment phase, treatment will occur 8 times daily (50 min pause between treatments) on weekdays, until symptom remission is achieved (HRSD-24 score \< to 10) or a maximum of 10 working days of daily treatment. In the tapering phase, treatments will be reduced to 2 treatment days per week for 2 weeks and then 1 treatment day per week for 2 weeks (4 weeks total). Patients that have responded to treatment will then enter the symptom-based relapse prevention phase including virtual check-in with study staff and a treatment schedule based on symptom level according to a modified relapse prevention algorithm that has been developed to prevent relapse after a successful course of ECT (known as the STABLE algorithm). The relapse prevention phase will last a maximum of 6 months.
62607714|NCT05473689|EXPERIMENTAL|Early-CPAP therapy group|Individuals diagnosed with moderate-to-severe sleep-related breathing disorders (SRBDs) who will start CPAP therapy within the first 6 weeks after SCI.
62439884|NCT01087879|ACTIVE_COMPARATOR|Oral contraceptive pill|9 weeks treatment with contraceptive pill.
62607715|NCT05473689|ACTIVE_COMPARATOR|Delayed-CPAP therapy group|Individuals diagnosed with moderate-to-severe SRBDs who will start on CPAP therapy at the 5th month after SCI.
62607716|NCT05473689|NO_INTERVENTION|Non-CPAP therapy group|Individuals who are diagnosed with no or mild SRBD.
62607717|NCT05191368||Normal group|Healthy people who received two doses of COVID-19 vaccine
62829816|NCT02614300|NO_INTERVENTION|Control Group|"For the control group, participants will attend educational sessions to improve patients' understanding and awareness of the respiratory diseases. These sessions will be performed at beginning and at 12 weeks by the physiotherapist and the pulmonologist.~The physiotherapist will also do monthly telephone calls for patient's monitoring."
62829817|NCT04294043|EXPERIMENTAL|Infusion of IV Gallium|Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device using an ambulatory infusion pump infused over 24 hours for 5 sequential days for each cycle. There is a maximum of 2 cycles.
62250165|NCT04540770|PLACEBO_COMPARATOR|Part A 3 (5 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
62829818|NCT00520182|ACTIVE_COMPARATOR|1|ADA 2003 diet
62829819|NCT00520182|ACTIVE_COMPARATOR|2|Low Glycemic index (LGI) diet
62047782|NCT04151225|EXPERIMENTAL|Participants receiving GSK2330811 300mg loading dose/150mg Q2W|Participants will receive 300mg GSK2330811 SC as loading dose followed by 150mg GSK2330811 SC Q2W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150mg GSK2330811 SC Q2W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
62829820|NCT00520182|ACTIVE_COMPARATOR|3|MUFA diet
62829821|NCT02704325|EXPERIMENTAL|GALGT2 Viral Vector|Dose: 1E12 vg (total dose) (n=3) of rAAVrh74.MCK.GALGT2 vs Placebo (Saline). All participants will receive rAAVrh74.MCK.GALGT2 in the right or the left EDB muscle and receive Saline in the opposite EDB muscles. The investigator will not know which side will receive rAAVrh74.MCK.GALGT2 vs Saline until after the trial is over. At the end of the trial the investigator will be unblinded.
62829822|NCT02704325|EXPERIMENTAL|Saline|Dose: 1E12 vg (total dose) (n=3) of rAAVrh74.MCK.GALGT2 vs Placebo (Saline). All participants will receive rAAVrh74.MCK.GALGT2 in the right or the left EDB muscle and receive Saline in the opposite EDB muscles. The investigator will not know which side will receive rAAVrh74.MCK.GALGT2 vs Saline until after the trial is over. At the end of the trial the investigator will be unblinded.
62250166|NCT04540770|EXPERIMENTAL|Part B 1 (Selected Dose)|"At the end of Part A, the SRC will review the accumulated unblinded data of safety, tolerability, PK (any available data), and immunogenicity (any available data) to select a dose to initiate Part B in IPF subjects. Part B will be conducted in multiple-dose, uncontrolled, and open-label manner to explore the safety, tolerability, PK, and immunogenicity in IPF subjects. Only one cohort will be enrolled to receive 3 repeated doses of the selected HuL001 dose, which will be administered bi-weekly.~A total of 6 IPF subjects will be enrolled in this multiple-dose cohort."
62439885|NCT01087879|ACTIVE_COMPARATOR|Contraception vaginal ring|9 weeks treatment with vaginal ring.
62439886|NCT01087879|ACTIVE_COMPARATOR|Transdermal contraceptive patch|9 weeks treatment with a transdermal contraceptive patch.
62439887|NCT00401856|EXPERIMENTAL|1|This arm will receive eplerenone
62250167|NCT04353479|EXPERIMENTAL|Camrelizumab(SHR-1210) Combined With Decitabine|Patients will be administered Camrelizumab(SHR-1210) at D1 and D15 and decitabine at D1-5. Treatment repeats every 28 days until disease progression or unacceptable toxicity.
62250168|NCT03001960|EXPERIMENTAL|Group 1- PREloading BEFORE TAVI|"* Aspirin 100 mg loading orally 6-12 hours before TAVI and~* Clopidogrel 600mg loading 6-12 before TAVI followed by maintenance dose of 100mg aspirin and 75mg clopidogrel per day"
62250169|NCT03001960|EXPERIMENTAL|Group 2 - POSTLoading AFTER TAVI|"* Aspirin 100 mg loading orally 6-12 hours after TAVI and~* Clopidogrel 600mg loading 6-12 hours after TAVI followed by maintenance dose of 100mg aspirin and 75mg clopidogrel per day"
62250170|NCT05916105||Ciprofloxacin|151 record of Ciprofloxacin
62250171|NCT06037603|EXPERIMENTAL|Intervention|The intervention group will be asked to visit the UNLV study site three times to evaluate baseline (T1), post-intervention (T2), and at 1-month post-intervention (T3) for functional assessments and saliva collection. Each participant will complete the BraW-Day program between baseline (T1) and post-intervention (T2). The program consists of 15-minute-long daily cognitive-walking tasks for 14 consecutive days. The program will be delivered on the Uplode mobile app. Each participant will be asked to perform three different 5-minute-long cognitive tasks (e.g., subtracting numbers or remembering long phrases) and one physical task (tandem walking or 8-shape walking) either indoors or outdoors at the same time for 15 minutes every day, which they will repeat daily for the next 13 days (2 weeks in total).
62439888|NCT00401856|PLACEBO_COMPARATOR|2|This group will receive the placebo
62439889|NCT01249105|EXPERIMENTAL|Part 1|Patients with recurrent glioblastoma multiforme (GBM) who require reoperation.
62607718|NCT05191368||RA Patients injected with 2 doses of vaccine|RA Patients who received two doses of COVID-19 vaccine
62829823|NCT06594562|EXPERIMENTAL|Telementored eFAST|Ultrasound examination guided in real-time by a remote expert for detecting free fluid, compared to standard ultrasound performed by on-site radiologist.
62829824|NCT04663204|EXPERIMENTAL|Sparsentan|Sparsentan will be administered once daily, starting at a dose of 200 mg (two 100 mg oral capsules) for the first 2 weeks of the study. Patients who tolerate the initial dose of 200 mg after 2 weeks will increase their dose to 400 mg (one 400 mg tablet). Patients who do not tolerate the target dose will have their dose reduced back to 200 or 100 mg/day; throughout the study, patients will be maintained on the maximum allowed dose of sparsentan they can tolerate. All patients will be treated with sparsentan for a total of 110 weeks.
62439890|NCT01249105|EXPERIMENTAL|Part 2|Participants with GBM and with anaplastic glioma
62607719|NCT05191368||Unvaccinated RA patients|RA Patients who received zero doses of COVID-19 vaccine
62047783|NCT04151225|EXPERIMENTAL|Participants receiving GSK2330811 300mg loading dose/150mg Q4W|Participants will receive 300mg GSK2330811 SC as loading dose followed by 150mg GSK2330811 SC Q4W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150 mg GSK2330811 SC Q4W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
62829825|NCT03529695|ACTIVE_COMPARATOR|Standard HVP Curriculum|"Participants will receive the standard Healthy Families America (HFA) home visitation curriculum delivered by trained home visitors. The HFA model meets the Department of Health and Human Services criteria for an evidence-based early childhood home visiting service delivery model. HFA services begin prenatally and continue until children are 2-5yo. The curriculum focuses on strengthening parent-child relationships and family functioning, promoting positive child development, and linkage to community resources. Accredited home visitors are matched to families on cultural background and language, to provide culturally sensitive services. Home visitors receive weekly supervision, ongoing developmental training, and have limited caseloads (10-15 families) to meet their families' needs."
62829826|NCT03529695|EXPERIMENTAL|Obesity Prevention|Participants will receive the standard Healthy Families America home visitation curriculum with the obesity prevention enhancement module, delivered by trained home visitors. Families are matched to home visitors based on their ethnicity/race and language preferences. The obesity prevention program targets 4 key behaviors (physical activity, fruit and vegetable consumption, sugary beverages, fried foods) aimed at reducing obesity risks in mothers and their children. Participants will also be provided opportunities to meet in groups with other participating mothers/infants to enhance social networks that support healthy eating and physical activity.
62829827|NCT06654219|EXPERIMENTAL|Prolonged fasting|
62829828|NCT06654219|ACTIVE_COMPARATOR|Standard nil per os (NPO)|
62829829|NCT04139057|EXPERIMENTAL|EBV TCR-T|EBV-specific TCR-T cell with anti-PD1 auto-secreted element
62829830|NCT05674786|EXPERIMENTAL|vestibular implant|Up to 8 participants will undergo implantation, activation and deactivation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System
62829831|NCT03239392|EXPERIMENTAL|BNZ-1|IV PEGylated BNZ132-1-40
62829832|NCT03725397|EXPERIMENTAL|Outpatients with a transcervical Foley catheter|Women with a transcervical Foley catheter in place that will spend the night at home.
62829833|NCT03725397|ACTIVE_COMPARATOR|Inpatients with a transcervical Foley catheter|"Women to be admitted to the hospital overnight which has been a standard of care."
62829834|NCT05455879||Impact of antenatal corticosteroid therapy on surfactants use postnatal|Intervention Description: Retrospective study on preterm infants to evaluate the impact of antenatal corticosteroid therapy on surfactants use postnatal
62829835|NCT03733015|ACTIVE_COMPARATOR|cTBS group|"Transcranial magnetic stimulation (TMS) is used to stimulate small regions of the brain. During a TMS procedure, a magnetic field generator, or coil, is placed near the head of the person receiving the treatment. TBS refers to a rTMS protocol where pulses are applied in bursts of three, delivered at a frequency of 50 Hz and an inter-burst interval of 200 ms (5 Hz)."
62047784|NCT04151225|EXPERIMENTAL|Participants receiving GSK2330811 150mg Q8W|Participants will receive GSK2330811 SC 150 mg Q8W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150 mg GSK2330811 SC Q8W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
62047785|NCT05346003|EXPERIMENTAL|Intervention Group|In the pre-test, all students will be given a BLS information form, followed by blended e-learning with theory and video in a virtual environment. he BLS knowledge post-test will be administered immediately after class.T-shirts and standard pillows (550 g silicon fiber pillow 50x70 cm size) with a simulation of an adult human size (approximately) sternum, rib and heart drawing (printed as picture) will be given to the intervention group only after the pretest. In the study, the BLS will be simulated for adult patients only. To simulate a half-body human CPR mock-up, a pre-made simulation t-shirt will be fitted on a standard pillow to create a CPR mock-up in a home environment, and after blended e-learning, they will be able to perform CPR iteratively on a T-shirt-clad simulation pillow (TCSP) model. In this way, autonomous learning will be supported. All students will practice CPR in a real simulation model two weeks after the blended e-learning.
62607720|NCT04022239|EXPERIMENTAL|Schedule I (non-lymphoma)|Patients receive fludarabine IV over 1 hour on days -5 to -2, melphalan IV over 30 minutes on days -5 and -4, and undergo TBI on day -1 and stem cell transplantation IV over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal.
62829836|NCT03733015|ACTIVE_COMPARATOR|High frequenct rTMS group|High frequency refers to a rTMS protocol where pulses are applied in at 10Hz frequency
62829837|NCT04499326|EXPERIMENTAL|Intervention|Patients undergoing catheter ablation of VT
62829838|NCT04499326|ACTIVE_COMPARATOR|Comparator|Patients undergoing AAD therapy for VT
62829839|NCT06357689||Breast cancer Cases|Histopathologically confirmed primary female breast cancer patients with age group (20-70 years)
62829840|NCT06357689||Controls|Healthy female volunteers not suffering from any disease
62829841|NCT01959503|EXPERIMENTAL|Progel Vascular Sealant|Progel Vascular Sealant after confirmation of anastomotic leakage during intra-procedure leak test.
62829842|NCT01959503|ACTIVE_COMPARATOR|Gelfoam Plus|Gelfoam Plus Sealant after confirmation of anastomotic leakage during intra-procedure leak test.
62829843|NCT05417646|ACTIVE_COMPARATOR|HNF1A-MODY - SGLT2 inhibition|3-hour hyperglycemic clamp with inhibition of SGLT2 (single-dose empagliflozin 25 mg two hours before clamp)
62829844|NCT05417646|PLACEBO_COMPARATOR|HNF1A-MODY - Placebo|3-hour hyperglycemic clamp without inhibition of SGLT2 (placebo comparator to empagliflozin)
62829845|NCT05417646|ACTIVE_COMPARATOR|Type 2 Diabetes - SGLT2 inhibition|3-hour hyperglycemic clamp with inhibition of SGLT2 (single-dose empagliflozin 25 mg two hours before clamp)
62047786|NCT05346003|NO_INTERVENTION|Control Group|In the pretest, all students will be given a BLS knowledge test, followed by e-learning blended with theory and video in a virtual environment. The BLS knowledge post-test will be administered immediately after class. Two weeks after the blended e-learning, all students will practice CPR in a real simulation model. Psychomotor skills will be recorded in the evaluation form.
62047787|NCT01410474|EXPERIMENTAL|2-18 years|
62250172|NCT06037603|ACTIVE_COMPARATOR|Wait-list Control|The wait-list control group will be will be asked to visit the UNLV study site four times to evaluate pre-baseline (T0), baseline (T1), post-intervention (T2), and at 1-month post-intervention (T3) for functional assessments and saliva collection. Each participant will complete the BraW-Day program between baseline (T1) and post-intervention (T2). The program consists of 15-minute-long daily cognitive-walking tasks for 14 consecutive days. The program will be delivered on the Uplode mobile app. Each participant will be asked to perform three different 5-minute-long cognitive tasks (e.g., subtracting numbers or remembering long phrases) and one physical task (tandem walking or 8-shape walking) either indoors or outdoors at the same time for 15 minutes every day, which they will repeat daily for the next 13 days (2 weeks in total).
62607721|NCT04022239|EXPERIMENTAL|Schedule II (lymphoid malignancies)|Patients receive fludarabine IV over 1 hour, bendamustine IV over 30-60 minutes on days -5 to -3 and undergo TBI on day -1 and stem cell transplantation over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal. CD20+ patients receive rituximab IV over 4-6 hours on days -13, -6, 1, and 8.
62607722|NCT04742309|EXPERIMENTAL|Pecs-2|For Pecs-2 blocks, the needle will be advanced to the tissue plane between the pectoralis major and minor muscles at the vicinity of the pectoral branch of the acromiothoracic artery where 10 mL of local anesthetic will be deposited. In a similar manner, 20 mL will be deposited at the level of the third rib above the serratus anterior muscle with the intent of spreading injectate to the axilla. The study fluid will be ropivacaine 0.3% with epinephrine.
62829846|NCT05417646|PLACEBO_COMPARATOR|Type 2 Diabetes - Placebo|3-hour hyperglycemic clamp without inhibition of SGLT2 (placebo comparator to empagliflozin)
62829847|NCT03554525|EXPERIMENTAL|Experimental product : FAT-BINDER DAMM|3 sticks of the dietary supplement (1.4 grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner.
62829848|NCT03554525|PLACEBO_COMPARATOR|Control product : PLACEBO|3 sticks of the dietary supplement (1.4grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner.
62829849|NCT02368587|PLACEBO_COMPARATOR|Intracoronary infusion WJMSCs|Intracoronary infusion WJMSCs or placebo in patients with ischemic heart failure
62829850|NCT02368587|PLACEBO_COMPARATOR|Intravenous infusion WJMSCs|Intravenous infusion WJMSCs or placebo in patients with ischemic heart failure.
62829851|NCT01264796|EXPERIMENTAL|behavioral intervention, counseling|2hr group education for 6 weeks
62250173|NCT05922657||Treated patients|This is a registry study with no active intervention outside standard of care. Women will be treated with Cerene per standard of care.
62607723|NCT04742309|ACTIVE_COMPARATOR|Paravertebral|For paravertebral blocks, ropivacaine 0.5% (with epinephrine) 9 mL will be administered at each of two levels per side: the T3 and T5 levels for sides without axillary involvement; and at the T2 and T4 level for sides with axillary involvement.
62607724|NCT02065414|PLACEBO_COMPARATOR|Neg Control Mouth Rinse W002194-0221-P|"Mouth rinse containing 5% Hydroalcohol~Twice each day, brush in usual manner with a fluoride-containing dentifrice, rinse mouth with water, and then rinse with 20 ml of mouth rinse W002194-0221-P for 30 seconds and spit it out."
62250174|NCT00449670|EXPERIMENTAL|H5N1 Adjuvanted Group|Subjects received 2 doses of H5N1 adjuvanted split virus vaccine (lot 1, 2, 3 or 4) containing A/Vietnam/1194/2004 strain at Day 0 and Day 21 during Primary Phase. A subset of these subjects (Boosted sub-cohort) received a single dose of heterologous H5N1 adjuvanted vaccine containing A/Indonesia/05/2005 strain at Month 6 during Booster Phase. The remaining subjects (Non-Boosted sub-cohort) received a single booster dose at Month 12 or 36 after initial priming in study 111443 (NCT00652743).
62607725|NCT02065414|EXPERIMENTAL|Experimental: Mouth Rinse 19668-012|Listerine Advance Gum Defense Twice each day, brush in usual manner with a fluoride-containing dentifrice, rinse mouth with water, and then rinse with 20 ml of mouth rinse 19668-012 for 30 seconds and spit it out - do not swallow.
62829852|NCT01264796|NO_INTERVENTION|delyed intervention|control group
62829853|NCT04798196|PLACEBO_COMPARATOR|Control group|Participants will receive treatment as usual (TAU).
62829854|NCT04798196|EXPERIMENTAL|ElderTree on laptop (ET- LT)|Participants will receive ElderTree on a laptop.
62829855|NCT04798196|EXPERIMENTAL|ElderTree on smart system (ET- SS)|Participants will receive ElderTree on a smart system.
62829856|NCT05908825|OTHER|20 day application of study product A and B|Subjects will be given study drug and instructed to topically apply to the treatment area, Study Product A or Study Product B, placebo serum or novel exfoliative serum, to the respectively randomized half of the face, once daily for 20 consecutive days.
62047788|NCT03016767|EXPERIMENTAL|oral stimulation|"All the subjects of the study will receive the usual medical and nursing care for premature babies. They also will receive the physiotherapeutic treatment prescribed by the rehabilitation physician, focused mainly on respiratory and musculoskeletal care.~Infants of the experimental group, in addition, will be applied a manual oral stimulation protocol designed ad hoc for this study, which consists of 12 maneuvers performed by a physiotherapist."
62047789|NCT03016767|NO_INTERVENTION|non oral stimulation|All the subjects of the study will receive the usual medical and nursing care for premature babies. They also will receive the physiotherapeutic treatment prescribed by the rehabilitation physician, focused mainly on respiratory and musculoskeletal care. But this group will not be applied the oral stimulation protocol.
62439891|NCT03232528|EXPERIMENTAL|Herb-partitioned moxibustion|Drug: Herbal cake, Device: Moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Herbal cakes with moxa cones will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
62047790|NCT02657616||No anticoagulation with VKA/NOAC|No prescriptions of vitamin-k-antagonists/novel anticoagulants in all observational period; No prescriptions of low molecular weight heparins/Clopidogrel during observation period to the extent of more than 30 days.
62047791|NCT02657616||Anticoagulation with vitamin-k-antagonists|The patient should be treated stable during the observation period with vitamin-k-antagonists (at least one prescription per half-year). The patient should be not been around on other anticoagulants during the observation period. This means that no prescriptions of novel anticoagulants and not more than 30 days should be observable prescriptions of low molecular weight heparins/Clopidogrel per year.
62439892|NCT03232528|SHAM_COMPARATOR|Sham herb-partitioned moxibustion|Drug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
62439893|NCT00877175|EXPERIMENTAL|1|Lower conjunctival fornix packing arm. For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix.
62439894|NCT00877175|ACTIVE_COMPARATOR|2|Conventional instillation arm. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
62439895|NCT01983059||Patients with Liver Venous Thrombosis|
62439896|NCT05580926|EXPERIMENTAL|Watch your Weight During Holidays Program|
62439897|NCT05580926|PLACEBO_COMPARATOR|Control group (minimal intervention)|
62439898|NCT05188040|EXPERIMENTAL|Virtual Reality Intervention Group|Hand Therapy Exercises utilizing Oculus Quest 2 VR system with augmented feedback for patient to perform active hand therapy. Specific interventions / games will be selected by the participants individual therapist.
62439899|NCT02047942|ACTIVE_COMPARATOR|Center-based cardiac rehabilitation|Patients randomized to the center-based training group will continue their training sessions at the outpatient clinics of UZ Leuven under direct supervision of physical therapists
62439900|NCT02047942|EXPERIMENTAL|Home-based training with telemonitoring guidance|Patients will receive an patient-tailored exercise prescription and will be asked to perform the exercise sessions in their home environment wearing heart rate monitors. Training data will be accessed by the research group on weekly basis in order to keep a record of frequency; duration and intensity of the sessions. Feedback will be given weekly to every patient.
62439901|NCT02047942|NO_INTERVENTION|Control|
62439902|NCT04091542|EXPERIMENTAL|FiO2 group 1|FiO2 changes over the four days in 60 with ventilator, 80 with ventilator, 60 with optiflow and 80 with optiflow.
62607726|NCT02065414|ACTIVE_COMPARATOR|Active Comparator Mouth Rinse 5000347078873|"Mouth rinse containing Chlorhexidine Corsodyl ®Mouthwash~Twice each day, brush in usual manner with a fluoride-containing dentifrice, in the usual manner, rinse mouth with water, wait 5 minutes after brushing and then rinse with 10 ml of mouth rinse 5000347078873for 60 seconds and spit it out - do not swallow."
62439903|NCT04091542|EXPERIMENTAL|FiO2 group 2|FiO2 changes over the four days in 80 with ventilator, 60 with ventilator, 80 with optiflow and 60 with optiflow.
62439904|NCT04091542|EXPERIMENTAL|Duration 1|In duration goup changes the preparation over the four days in 2 min. with ventilator, 6 min. with ventilator, 2 min. with optiflow and 8 min. with optiflow.
62829857|NCT05908825|OTHER|42 day application of study product A and B|Subjects who the investigator decides to continue treatment at Day 21, will be given study drug and instructed to topically apply to the treatment area, Study Product A or Study Product B, placebo serum or novel exfoliative serum, to the respectively randomized half of the face, once daily for an additional 21 consecutive days.
62047792|NCT02657616||Anticoagulation with novel oral anticoagulants|The patient should be treated stable during the observation period with a novel anticoagulant (at least one prescription per half-year). This means that no vitamin-k-antagonists prescriptions and not more than 30 days should be observable prescriptions of low molecular weight heparins/Clopidogrel per year from the start of the observation period.
62829858|NCT05791708||cold agglutinin disease (CAD)|Patient with a diagnosis of CAD as per investigator judgment based on the diagnosis criteria listed in study protocol. In addition, this group includes a cohort of CAD patients treated with sutimlimab
62047793|NCT00760149|PLACEBO_COMPARATOR|1|50 patients, treated with the standard anti-TB regimen, including rifampicin (600 mg), isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 2 placebo tablets resembling rifampicin 300 mg.
62439905|NCT04091542|EXPERIMENTAL|Duration 2|In duration goup changes the preparation over the four days in 6 min. with ventilator, 2 min. with ventilator, 6 min. with optiflow and 2 min. with optiflow.
62439906|NCT04091542|EXPERIMENTAL|respiratory rate 1|In the RR group changes the respiratory rate in the four days: 16 times with ventilator, 20 times with ventilator, 16 times with optiflow and 20 times with optiflow.
62829859|NCT05791708||cold agglutinin syndrome (CAS)|Patient with a diagnosis of CAS as per investigator judgment based on the diagnosis criteria listed in study protocol
62047794|NCT00760149|ACTIVE_COMPARATOR|2|50 patients, treated with rifampicin (900 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 1 placebo tablet resembling rifampicin 300 mg.
62047795|NCT00760149|ACTIVE_COMPARATOR|3|50 patients, treated with rifampicin (1200 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment.
62439907|NCT04091542|EXPERIMENTAL|respiratory rate 2|In the RR group changes the respiratory rate in the four days: 20 times with ventilator, 16 times with ventilator, 20 times with optiflow and 16 times with optiflow.
62439908|NCT04091542|EXPERIMENTAL|Position 1|The position changes over the four days in supine with ventilator, prone with ventilator, supine with optiflow and prone with optiflow.
62439909|NCT04091542|EXPERIMENTAL|Position 2|The position changes over the four days in prone with ventilator, supine with ventilator, prone with optiflow and supine with optiflow.
62829860|NCT04756856|EXPERIMENTAL|Muscle-target oral nutritional supplementation|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, and 800 IU vitamin D
62829861|NCT04280250|ACTIVE_COMPARATOR|Group 1|Active control arm: Volitional help-sheet with instruction: We want you to plan to increase your level of physical activity. Research shows that if people can identify situations in which they are likely to be tempted not to be physically active and ways to overcome temptation they are much more likely to be successful in their intention to increase their level of physical activity. On the left hand side of the page are a series of common situations in which people feel tempted not to be physically active; please tick all those that apply to you personally. On the right hand side of the page are a series of possible solutions; please tick all those that apply to you personally. Tick as many or as few situations and solutions as you like.
62047796|NCT03523468|EXPERIMENTAL|uniportal sleeve lobectomy|locally advanced central lung cancer resection by uniportal VATS sleeve lobectomy
62047797|NCT03523468|ACTIVE_COMPARATOR|open sleeve lobectomy|locally advanced central lung cancer resection by open chest sleeve lobectomy
62047798|NCT04888091|ACTIVE_COMPARATOR|Cervical mucus removal with cotton swab|Cervical mucus will be removed with cotton swab before embryo transfer
62439910|NCT02600728|EXPERIMENTAL|experimental group (EG)|The experimental training (ET) consisted of eight gait training sessions, twice a week, using the declarative memory cues strategy (DMCS).
62047799|NCT04888091|ACTIVE_COMPARATOR|Cervical mucus removal with cannula|Cervical mucus will be removed with cannula before embryo transfer
62047800|NCT04888091|NO_INTERVENTION|No cervical mucus removal|Cervical mucus will not be removed prior to embryo transfer
62047801|NCT01094925|PLACEBO_COMPARATOR|Placebo|
62047802|NCT01094925|ACTIVE_COMPARATOR|Gabapentin 300mg|
62047803|NCT01094925|ACTIVE_COMPARATOR|Gabapentin 600mg|
62439911|NCT02600728|ACTIVE_COMPARATOR|control group (CG)|The control training (CT) consisted of a similar gait training without DMCS.
62439912|NCT03673189|EXPERIMENTAL|Healthy volunteers|Sensors assigned for 3 weeks
62439913|NCT03673189|EXPERIMENTAL|Patients with arythmic disease or peripheral vascular disease|Sensors assigned for 3 weeks
62439914|NCT02588625|EXPERIMENTAL|Part A - BMS-986020|BMS-986020 or Placebo tablets specified dose on specified days
62607727|NCT03976414||eMOM website users|"Any woman who visits the research tab on the eMOM website will see an invitation to participate in a research study about the impact of the website on her bladder and bowel symptoms. Women may use the intervention (the website) regardless of whether they opt to participate in the research study.~The intervention is the use of the website (eMOM), which is the electronic adaption of the program, Mind Over Matter: Healthy Bowels, Healthy Bladder (MOM), a small-group, community-based health promotion program that builds skills and self-efficacy to make behavior changes that improve urinary and bowel symptoms among older women with incontinence."
62047804|NCT05009342|EXPERIMENTAL|Below-knee soft resin cast|"Below-knee soft resin cast is administered to participants in emergency department. Investigator puts three layers of jersey supplemented by strips of soft resins to be unrolled along the leg after immersion in warm water~Duration to ankle immobilization with soft resin boot : 21 days."
62439915|NCT02588625|EXPERIMENTAL|Part B - BMS-986020|BMS-986020 or Placebo tablets specified dose on specified days
62439916|NCT01257854||Busulfan, pharmacogenetic, pharmacokinetic, children|Children who receive Busulfan IV and have a pharmacokinetic of Busulfan
62047805|NCT05009342|OTHER|Below-knee rigid resin cast|"Below-knee soft resin cast is administered to participants in emergency department. Investigator puts one layer of jersey and then one layer of foam composed by strips of cotton wool to be unrolled supplemented by strips of rigid resins to be unrolled along the leg after immersion in warm water.~Duration to ankle immobilization with soft resin boot : 21 days."
62047806|NCT05154383|EXPERIMENTAL|High-Dose Quadrivalent Influenza Vaccine|One injection of the high-dose Efluelda vaccine will be given to the patient
62047807|NCT05154383|ACTIVE_COMPARATOR|Standard-Dose Quadrivalent Influenza Vaccine|One injection of the standard-dose Influvactetra vaccine will be given to the patient
62439917|NCT00896285|ACTIVE_COMPARATOR|1|
62439918|NCT00896285|ACTIVE_COMPARATOR|2|
62439919|NCT00896285|ACTIVE_COMPARATOR|3|
62439920|NCT00896285|ACTIVE_COMPARATOR|4|
62439921|NCT00521898|EXPERIMENTAL|DMEK|DMEK as intervention
62439922|NCT03201783|OTHER|immediate group|the intervention: immediate frozen-thawed embryo transfer (FET) which means FET will be performed in the first cycle following the stimulated IVF cycle
62439923|NCT03201783|OTHER|delayed group|the intervention: delayed frozen-thawed embryo transfer (FET) which means FET will be performed at least in the second cycle following the stimulated IVF cycle
62607728|NCT00388297|EXPERIMENTAL|Levothyroxine for Subclinical Hypothyroidism|100 µg of Levothryoxine for participants with subclinical hypothyroidism
62829862|NCT04280250|EXPERIMENTAL|Group 2|"Experimental arm: Volitional help-sheet with instruction:~We want you to plan to increase your level of physical activity. Research shows that if people link being tempted not to be physically active with a way to overcome that temptation, they are much more likely to be successful in their intention to increase their level of physical activity. On the left hand side of the page below is the temptation not to be physically active; on the right hand side of the page are a series of possible solutions. Please draw lines linking being tempted not to be physically active (left hand side) to solutions (right hand side) that you think might work for you personally. Please make as many situation-solution links as you like."
62250175|NCT00449670|ACTIVE_COMPARATOR|H5N1 Un-adjuvanted Group|Subjects received 2 doses of a H5N1 non-adjuvanted split virus vaccine containing A/Vietnam/1194/2004 strain at Day 0 and Day 21 and two booster doses of heterologous H5N1 adjuvanted vaccine containing A/Indonesia/05/2005 strain at Month 6 and Month 6 + 21 days.
62607729|NCT00388297|PLACEBO_COMPARATOR|Placebo for Levothyroxine - Subclinincal Hypothyroidism|Placebo for Levothyroxine for participants with subclinical hypothyroidism
62607730|NCT00388297|EXPERIMENTAL|Levothyroxine for Hypothyroxinemia - Hypothyroxinemia|50 µg of Levothyroxine for participants with hypothyroxinemia
62829863|NCT00002485||Stratum 1|Not Enrolled / No IRB Applied
62829864|NCT00002485||Stratum 2|Not Enrolled / IRB Approved
62829865|NCT06653985|EXPERIMENTAL|Hyaluronic and corticosteroid injection with physical therapy|Patients will receive an ultrasound-guided injection consisting of 3 ml hyaluronic acid (Durolane™) mixed with 40 mg triamcinolone (Kenalog™) into their hip joint. Patients will also receive an 8-week physiotherapy protocol, consisting of 8 visits. The protocol will consist of 1 visit per week.
62829866|NCT06653985|ACTIVE_COMPARATOR|Hyaluronic and corticosteroid injection|Patients will receive an ultrasound-guided injection consisting of 3 ml hyaluronic acid (Durolane™) mixed with 40 mg triamcinolone (Kenalog™) into their hip joint.
62829867|NCT03220035|EXPERIMENTAL|Treatment (vemurafenib)|Patients receive vemurafenib PO BID on day 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62829868|NCT02633150|EXPERIMENTAL|Polyphenol|red grapes polyphenol supplementation on metabolic parameters in obese insulinoresistant subjects
62829869|NCT02633150|PLACEBO_COMPARATOR|Placebo|Placebo supplementation on metabolic parameters in obese insulinoresistant subjects
62829870|NCT02267551|OTHER|Mimic dV-Trainer|
62829871|NCT02267551|OTHER|daVinci Skills Simulator|
62829872|NCT04680468|EXPERIMENTAL|Belantamab mafodotin|Patients receive Belantamab mafodotin 2.5 mg/kg by intravenous infusion on day -42 relative to autologous stem cell infusion (day 0), on day +60, and every 90 days thereafter, for up to 2 years following ASCT.
62829873|NCT05572073||Retrospective|
62829874|NCT05572073||Prospective|
62829875|NCT06515197|EXPERIMENTAL|Motivational Music|Participants in this group will listen to pre-selected motivational music tracks for 30 minutes before each basketball training and performance test. This intervention will be conducted three times a week for 12 weeks. The aim is to assess the impact of motivational music on mental energy, mental toughness, psychological skills, mindfulness, athletic identity, and sports performance.
62829876|NCT06515197|EXPERIMENTAL|Self-Selected Music|Participants in this group will choose their own music to listen to for 30 minutes before each basketball training and performance test. This intervention will be conducted three times a week for 12 weeks. The goal is to determine the effect of self-selected music on mental energy, mental toughness, psychological skills, mindfulness, athletic identity, and sports performance.
62047808|NCT00686140|EXPERIMENTAL|Celecoxib, immune adjustor|Celecoxib
62250176|NCT02803528|EXPERIMENTAL|Biodentine|The exposed area of the pulp is going to be covered with Biodentine.
62250177|NCT02803528|ACTIVE_COMPARATOR|MTA|The exposed area of the pulp is going to be covered with MTA
62250178|NCT00382018|ACTIVE_COMPARATOR|Group 1|Patients continue to receive regular treatment without change at the discretion of the physician. Patients are eligible for other first-line chemotherapy trials. No further blood is collected.
62250179|NCT00382018|EXPERIMENTAL|Group 2|Patients continue to receive their current chemotherapy regimen without change.
62250180|NCT00382018|ACTIVE_COMPARATOR|Group 3, Arm I|Patients continue with their current chemotherapy regimen without change.
62607731|NCT00388297|PLACEBO_COMPARATOR|Placebo for Levothyroxine|Placebo for Levothyroxine for participants with hypothyroxinemia
62607732|NCT04815499|EXPERIMENTAL|Food supplement|One tablet a day, during 12 months
62607733|NCT04815499|PLACEBO_COMPARATOR|Placebo|One tablet a day, during 12 months
62607734|NCT04294433|ACTIVE_COMPARATOR|Infanrix-hexa+Infanrix-hexa+Infanrix-hexa|Children vaccinated at the age of 2, 4 and 18 months with a standard dose of Infanrix-hexa
62607735|NCT04294433|EXPERIMENTAL|Infanrix-hexa+Infanrix-hexa|Children vaccinated at the age of 2 and 18 months with a standard dose of Infanrix-hexa
62607736|NCT04294433|EXPERIMENTAL|Infanrix-hexa+Twinrix|Children vaccinated at the age of 2 and 18 months with a standard dose of Infanrix-hexa and a standard dose of Infanrix-Junior, respectively
62607737|NCT00798018|PLACEBO_COMPARATOR|Air|air was used to inflate the cuff.
62607738|NCT00798018|PLACEBO_COMPARATOR|Normal Saline|Normal saline was used to inflate the cuff.
62607739|NCT00798018|ACTIVE_COMPARATOR|lidocaine|2% lidocaine was used to inflate the cuff.
62607740|NCT00798018|EXPERIMENTAL|tetracaine|1% tetracaine was used to inflate the cuff.
62607741|NCT01174810|NO_INTERVENTION|Control|
62607742|NCT01174810|EXPERIMENTAL|Exenatide|
62607743|NCT06272006|EXPERIMENTAL|Coronally Positioned Flap (CPF) with Connective Tissue Graft (CTG)|Participants in this arm will receive a Coronally Positioned Flap (CPF) surgery combined with a Connective Tissue Graft (CTG). The CPF technique involves surgically repositioning the gum tissue to cover exposed root surfaces, while the CTG procedure involves transplanting connective tissue to the area of gingival recession to encourage regeneration and coverage of exposed roots. This arm aims to evaluate the effectiveness of CPF with CTG in improving gingival recession and periodontal health.
62607744|NCT06272006|EXPERIMENTAL|Modified Coronally Advanced Tunnel (MCAT) with Connective Tissue Graft (CTG)|This arm involves participants receiving the Modified Coronally Advanced Tunnel (MCAT) procedure along with a Connective Tissue Graft (CTG). The MCAT technique is a less invasive approach that creates a tunnel under the gum through which the connective tissue graft is placed without making significant incisions. This method aims to treat gingival recession by encouraging gum regeneration over the exposed roots, with the goal of improving periodontal outcomes and reducing recession.
62607745|NCT01720329|ACTIVE_COMPARATOR|Probiotics|Participants randomized to probiotics will receive 2 capsules supplemented with 10 billion cfu of Lactobacillus rhamnosus GG on a daily basis for six months
62607746|NCT01720329|PLACEBO_COMPARATOR|Probiotic placebo|Participants randomized to placebo will receive 2 capsules of matching placebo on a daily basis for six months
62607747|NCT01361113|OTHER|Single Arm Neoadjuvant Pazopanib|Pazopanib 800 mg PO once daily for 8 weeks
62607748|NCT06515210|EXPERIMENTAL|Acacia Gum|"Acacia gum is a dietary fibre with low-viscosity and is fermentable.~Female participants consume 12.5 grams each day for the first two days of the intervention, then consume 25 grams each day for the rest of the six-week intervention.~Male participants consume 17.5 grams each day for the first two days of the intervention, then consume 35 grams each day for the rest of the six-week intervention.~Those participants who voluntarily extend their treatment for an additional six weeks will continue with consuming the full dose daily."
62439924|NCT02614703|EXPERIMENTAL|Chromoendoscopy using Acetic Acid 2.5%|Patient will have endoscopic examination of esophagus. Esophageal mucosa sprayed with 5cc solution of Acetic Acid 2.5% one time only. Esophageal mucosa examined again. Biopsies are obtained. Abnormal areas identified by Acetic Acid 2.5% will be submitted on separate containers for pathology review. If no abnormalities seen, random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
62607749|NCT06515210|EXPERIMENTAL|Microcrystalline Cellulose|"Microcrystalline cellulose is a dietary fibre that is non-viscous and and non-fermentable.~Female participants consume 12.5 grams each day for the first two days of the intervention, then consume 25 grams each day for the rest of the six-week intervention.~Male participants consume 17.5 grams each day for the first two days of the intervention, then consume 35 grams each day for the rest of the six-week intervention.~Those participants who voluntarily extend their treatment for an additional six weeks will continue with consuming the full dose daily."
62607750|NCT06515210|PLACEBO_COMPARATOR|Maltodextrin|"Maltodextrin is a digestible carbohydrate. It is provided in isocaloric doses to the dietary fibres.~Female participants consume 6.3 grams each day for the first two days of the intervention, then consume 12.5 grams each day for the rest of the six-week intervention.~Male participants consume 8.8 grams each day for the first two days of the intervention, then consume 17.5 grams each day for the rest of the six-week intervention."
62607751|NCT02991014|ACTIVE_COMPARATOR|researcher-selected frequency-modulated music|
62607752|NCT02991014|PLACEBO_COMPARATOR|researcher-selected non-modulated music|
62607753|NCT02991014|EXPERIMENTAL|participant-selected non-modulated music|
62439925|NCT02614703|ACTIVE_COMPARATOR|Standard random esophageal biopsies|Patient will have endoscopic examination of the esophagus. Esophageal mucosa will not be sprayed with Acetic Acid 2.5%. Random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
62607754|NCT05690165|EXPERIMENTAL|Exercise Group|Participants will exert a heart rate controlled aerobic walking training 3-5 times per week for 30-45 minutes per training. This exercise as well as the daily amount of steps will be assessed via smartwatch.
62607755|NCT05690165|NO_INTERVENTION|No Exercise Group|Participants receive no demands regarding the daily exercise. Their daily amount of steps will be assessed via smartwach.
62607756|NCT03328494|EXPERIMENTAL|Part A: Monotherapy (BOS172722)|BOS172722 will be administered on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycles in participants with histopathologically confirmed advanced nonhaematologic malignancies.
62607757|NCT03328494|EXPERIMENTAL|Part A: Combination therapy (BOS172722 + Paclitaxel)|BOS172722 will be administered on Cycle 0 Day 1 and on Days 1, 2, 8, 9, 15, and 16 in Cycle 1 and subsequent 28-day cycles in participants with histopathologically confirmed advanced nonhaematologic malignancies. The participants will also receive 80 milligrams per meters squared (mg/m\^2) paclitaxel as an intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. During dose escalation, further exploration of the treatment schedule for the BOS172722-paclitaxel combination will be initiated. In such combination cohorts, BOS172722 will be administered with paclitaxel on Days 1, 8, and 15 only of each treatment cycle (except for Cycle 2 Day1), and will not be administered on Day 2, 9, and 16. These alternative schedules will be explored to further characterize the pharmacokinetics and tolerability of such a dosing regimen.
62607758|NCT03328494|EXPERIMENTAL|Part B: Combination therapy (BOS172722 + Paclitaxel)|Participants with triple-negative breast cancer will be treated with oral BOS172722 at the recommended Phase 2 dose (RP2D) established in Part A on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle and IV paclitaxel at 80 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle.
62607759|NCT00401960|EXPERIMENTAL|Daptomycin adjunctive group|Patients with enterococcal endocarditis who elect to receive daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving
62607760|NCT00401960|NO_INTERVENTION|standard of care|Patients with enterococcal endocarditis who elect to receive standard of care therapy as prescribed by their primary physician
62607761|NCT01945294|EXPERIMENTAL|Arm 1: 16-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 4 weeks of BOC + PR, for a total of 16 weeks of treatment. At Week 16, participants underwent 12 weeks of follow-up (participation complete at Week 28).
62607762|NCT01945294|EXPERIMENTAL|Arm 2: 28-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 16 weeks of BOC + PR, for a total of 28 weeks of treatment. At Week 28, participants underwent 12 weeks of follow-up (participation complete at Week 40).
62607763|NCT01945294|EXPERIMENTAL|Arm 3: 48-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with detectable HCV RNA were allocated to receive an additional 24 weeks of BOC + PR and an additional 12 weeks of PR, for a total of 48 weeks of treatment. At Week 48, participants underwent 12 weeks of follow-up (participation complete at Week 60).
62607764|NCT04533243|EXPERIMENTAL|2.5ug/h transdermal fentanyl|
62607765|NCT04533243|ACTIVE_COMPARATOR|Oral immediate-released morphine|
62607766|NCT03927027|ACTIVE_COMPARATOR|Group I (ALND)|Patients receive isosulfan blue SC and undergo ALND.
62607767|NCT03927027|EXPERIMENTAL|Group II (ARM, ALND)|Patients undergo ARM. Patients then receive isosulfan blue and undergo ALND as in Group I.
62607768|NCT02623842|EXPERIMENTAL|Radiofrequency|
62607769|NCT03690973|ACTIVE_COMPARATOR|Alveolar socket preservation with graft and flap surgery|
62047809|NCT00686140|PLACEBO_COMPARATOR|Placebo|Placebo looks like the active drug celecoxib, with the same dose
62607770|NCT03690973|EXPERIMENTAL|Immediate implant placement with bone using flapless surgery|
62607771|NCT03690973|EXPERIMENTAL|Immediate implant placement with bone and flap surgery|
62607772|NCT03690973|EXPERIMENTAL|Alveolar socket preservation with graft and flapless surgery|
62607773|NCT03349905|ACTIVE_COMPARATOR|Fresh transfer|"Women randomized in the non experimental group will have:~* Antagonist stimulation protocol~* Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France)~* All of their embryo kept in prolonged culture~* A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage)~* Supernumerary blastocysts cryopreserved"
62829877|NCT06515197|NO_INTERVENTION|No Music Control|Participants in this group will not listen to any music before basketball training and performance tests. This control group will help compare the effects of no music intervention against the motivational and self-selected music interventions. The sessions will be conducted three times a week for 12 weeks.
62829878|NCT04636684|EXPERIMENTAL|patients undergoing surgical valve replacement for degenerative aortic stenosis|
62829879|NCT00804076|EXPERIMENTAL|NP2|Intradermal injection
62829880|NCT05864859|EXPERIMENTAL|Normal birth group|It consisted of preliminary information (10 minutes), practice (10 minutes) and analysis (20 minutes) sessions with groups of 2 people (1 midwife, 1 pregnant) accompanied by a scenario where there was no complication during labor.
62829881|NCT05864859|EXPERIMENTAL|Breech birth group|It consisted of preliminary information (10 minutes), practice (10 minutes) and analysis (20 minutes) sessions with groups of 2 people (1 midwife, 1 pregnant) accompanied by a scenario that experienced complications during labor.
62829882|NCT05864859|NO_INTERVENTION|Control group|She continued her education in accordance with the (1+32) hour curriculum within the scope of the midwifery undergraduate program Integrated Practice I and EBE402 Integrated Practice II courses.
62829883|NCT06651619|NO_INTERVENTION|Control|No hydration education or fluid prescription. Pre-practice urine specific gravity (USG), pre- and post-practice body mass, thirst scale measures. Fluid intake during practice (whatever the team is drinking) .
62829884|NCT06651619|EXPERIMENTAL|Hydration Education between Week 1 and Week 2|In-depth education session regarding the effects of dehydration, the performance benefits of proper hydration, and how to properly hydrate before, during, and after activity. Pre-practice urine specific gravity (USG), pre- and post-practice body mass, thirst scale measures. Fluid intake during practice (whatever the team is drinking).
62047810|NCT05471648|EXPERIMENTAL|420 mg EirGenix Pertuzumab|EirGenix Pertuzumab given intravenous with an infusion bag as a single dose of 420 mg over 60min.
62047811|NCT05471648|ACTIVE_COMPARATOR|420 mg Pertuzumab Perjeta EU Origin|EU Pertuzumab given intravenous with an infusion bag as a single dose of 420 mg over 60min.
62047812|NCT05471648|ACTIVE_COMPARATOR|420 mg Pertuzumab Perjeta US Origin|US Pertuzumab given intravenous with an infusion bag as a single dose of 420 mg over 60min.
62829885|NCT06651619|EXPERIMENTAL|Hydration Education between Week 1 and Week 2 plus Prescribed Hydration Week 2|In-depth education session regarding the effects of dehydration, the performance benefits of proper hydration, and how to properly hydrate before, during, and after activity. Pre-practice urine specific gravity (USG), pre- and post-practice body mass, thirst scale measures. Provided a standard amount of bottled water to drink the evening prior (1 liter) and in the two hours before practice (20 oz). Fluid intake will be recorded in an intake log. Subjects will be permitted to eat or drink whatever they like in addition to the prescribed fluid. Fluid intake during practice (whatever the team is drinking).
62829886|NCT03469453|EXPERIMENTAL|Internet-delivered CBT|Internet-delivered Cognitive Behavioral Therapy (ICBT) for GAD, 10 weeks. Patients and their parents work with separate programs via the Internet. Both have contact with a therapist. Participants practice awareness of worry through daily worry monitoring. They identify their own behaviors that reinforce worry, i.e. control and avoidance behaviors. The program gives a rationale for behavior change, which is then implemented. Participants practice problem solving and exposure to uncertainty inducing situations and thoughts. Parents receive support and psycho education about worry. They practice alternative parental behaviors, which decrease focus on worry while validating the child's feelings. Treatment contains planning for maintenance of treatment gains for both patients and parents.
62829887|NCT06300112|EXPERIMENTAL|Experimental group|Yoga
62829888|NCT06300112|NO_INTERVENTION|Control group|No Intervention
62829889|NCT06598150|EXPERIMENTAL|Shoulder Abduction|
62829890|NCT04312178|OTHER|return vaginal self-swab by mail|Socially disadvantaged women who have received a vaginal self-swab and have to return it by mail
62829891|NCT04312178|OTHER|financial incentive mail-back vaginal self-swab|Socially disadvantaged women who have received a vaginal self-swab and have to return it by mail to obtain a cash incentive
62829892|NCT04312178|OTHER|handing over the vaginal swab to a professional|Socially disadvantaged women who have received a vaginal self-swab and need to report it to a health professional
62829893|NCT04312178|OTHER|financial incentive the vaginal self-swab to a pro|Socially disadvantaged women who have received a vaginal self-swab and have to report it to a health professional to obtain a cash incentive
62047813|NCT02204995|ACTIVE_COMPARATOR|Trapeziectomy with LRTI|Trapeziectomy with Ligament Reconstruction and Tendon Interposition
62047814|NCT02204995|ACTIVE_COMPARATOR|Trapeziectomy|Trapeziectomy
62829894|NCT05987930|EXPERIMENTAL|bone lid technique|ten patients with mandibular benign lesions which were treated with bone lid technique to enucleate the lesion using piezo-electric device to allow removal of buccal bone cortex with preservation of it to have access to lesion then reposition of bone lid in its place
62829895|NCT05987930|EXPERIMENTAL|standard technique|ten patients with mandibular benign lesions in which the buccal cortex was removed by gridding using surgical rotary bur to allow enucleation of lesion
62829896|NCT06596681|EXPERIMENTAL|GA intracranial injection combined with oral clozapine|Patients were first given intracranial injections of GA , followed by the oral clozapine.
62829897|NCT01622166|EXPERIMENTAL|art therapy|12 sessions of art therapy / 6 weeks
62829898|NCT01622166|NO_INTERVENTION|TAU|treatment as usual / 6 weeks
62047815|NCT01011621|EXPERIMENTAL|0.5% prednisolone acetate cream|
62047816|NCT01011621|ACTIVE_COMPARATOR|0.1% betamethasone valerate cream|
62047817|NCT01314040|OTHER|Run in|
62047818|NCT01314040|EXPERIMENTAL|High meat protein diet|
62047819|NCT01314040|EXPERIMENTAL|High dairy protein diet|
62047820|NCT01314040|EXPERIMENTAL|High grain protein diet|
62047821|NCT03917667||Geriatric patients|Patients aged 70 years and older who are admitted to the acute care geriatric units.
62047822|NCT03956472|EXPERIMENTAL|Osteopathic group|LCS Drainage before altitude exposure
62047823|NCT03956472|EXPERIMENTAL|PEEP 10 cmH2O|10 min at rest
62047824|NCT03956472|SHAM_COMPARATOR|Control group|Sham PEEP and fake osteopathic protocol
62829899|NCT01138449|EXPERIMENTAL|Vitamin A|Vitamin A capsules have retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil
62829900|NCT01138449|PLACEBO_COMPARATOR|Placebo|Placebo capsules contain minute amounts of vitamin E in soybean oil
62607774|NCT03349905|EXPERIMENTAL|Deferred-frozen embryo transfer|"Women randomized in the experimental group will have:~* Antagonist stimulation protocol~* Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France)~* All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture.~* A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation"
62607775|NCT03969264|ACTIVE_COMPARATOR|Carb Snacks|Will follow study diet based on the Dietary Guidelines and consume study carbohydrate snacks between meals.
62607776|NCT03969264|EXPERIMENTAL|Tree Nut Snacks|Will follow study diet based on the Dietary Guidelines and consume study tree nut snacks between meals.
62607777|NCT04115410||PD-1 inhibitor|Patients over 18 years of age with a diagnosis of non-small cell lung cancer and being received PD-1 inhibitors as a second line treatment from cytotoxic chemotherapy or as a third line for those received tyrosine kinase inhibitors as a first line, from August 2017 (the first month PD-1 inhibitors were reimbursed in South Korea) to September 2018.
62250181|NCT00382018|EXPERIMENTAL|Group 3, Arm II|Patients switch to a different chemotherapy regimen. Selection of a new chemotherapy regimen is made by the patient's doctor.
62250182|NCT01114282|EXPERIMENTAL|VELCADE with pralatrexate|Pralatrexate,10 mg/m2, IV bolus on days 1, 8, and 15 VELCADE,1.3 mg/m2, IV bolus on days 1, 8, and 15
62607778|NCT04115410||Chemotherapy Drugs, Cancer|Patients over 18 years of age with a diagnosis of non-small cell lung cancer and being received cytotoxic chemotherapy or tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors) from August 2017 to September 2018. Each patient switching to PD-1 inhibitor will be matched to three reference standard chemotherapy users.
62607779|NCT02570334|EXPERIMENTAL|HIV-infected children diagnosed before 7 months of life|HIV-infected children diagnosed before 7 months of life
62607780|NCT02570334|EXPERIMENTAL|HIV-exposed uninfected children|HIV-uninfected children born to HIV-infected mothers
62607781|NCT02570334|EXPERIMENTAL|HIV-unexposed uninfected children|Children born to HIV-uninfected mothers
62607782|NCT05153668|EXPERIMENTAL|Adjuvant Everolimus After Surgical Dilation|Individuals will take low dose everolimus for 6 weeks after dilation.
62607783|NCT05921149|ACTIVE_COMPARATOR|Carboplatin and paclitaxel with standard diet|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6-10 cycles in the absence of disease progression or unacceptable toxicity. A standard diet is consumed throughout each cycle of therapy.
62607784|NCT05921149|EXPERIMENTAL|Carboplatin and paclitaxel with fasting mimicking diet (FMD)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6-10 cycles in the absence of disease progression or unacceptable toxicity. A fasting mimicking diet (FMD) is consumed beginning 3 days prior to chemotherapy and on the day of chemotherapy (days -2, -1, 0 and 1 of each cycle).
62829901|NCT05991635|EXPERIMENTAL|Intervention group|Participants in this group (all participants) are asked to complete a questionnaire and then receive access to the online gatekeeper training (e-learning) during three days, after which they were asked to complete another questionnaire. After three months, a third questionnaire is sent.
62607785|NCT05615233|EXPERIMENTAL|Intervention Group|Patient will use TACAD and the Alzheimer's Association Website
62250183|NCT00450242|EXPERIMENTAL|5% Lidocaine cream|5% topical lidocaine cream.
62607786|NCT05615233|ACTIVE_COMPARATOR|Active Control Group|Patient will use only the Alzheimer's Association Website
62607787|NCT06426160|ACTIVE_COMPARATOR|Tocilizumab|8 mg / kg Tocilizumab will be diluted to a final volume of 100 mL with sterile, non-pyrogenic sodium chloride 9 mg/mL (0.9 %)
62607788|NCT06426160|PLACEBO_COMPARATOR|Placebo|100 ml sodium chloride 9 mg/mL (0.9 %).
62607789|NCT03257241|ACTIVE_COMPARATOR|A arm (DA-90)|"Induction I:~* DNR 90 mg/m2 D 1-3 in 30-60 min i.v. infusion~* Ara-C 100 mg/m2 D 1-7 in 24 h i.v. infusion"
62250184|NCT00450242|PLACEBO_COMPARATOR|Placebo cream|
62250185|NCT06025669|EXPERIMENTAL|Nap rested and nap restriction|There are two conditions in the single-arm, that is, the nap rested condition and the nap restriction condition. The sequence of two conditions is randomized.
62250186|NCT00610545|ACTIVE_COMPARATOR|1|Use Atorvastatin 80mg for 60 days , and the vascular surgery will be made between day-7 and day-60
62607790|NCT03257241|ACTIVE_COMPARATOR|B arm (DAC)|"Induction I:~* DNR 60 mg/m2 D 1-3 in 30-60 min i.v. infusion~* cladribine 5 mg/m2 D 1-5 in 2 h i.v. infusion prior to Ara-C~* Ara-C 200 mg/m2 D 1-7 in 22 h i.v. infusion."
62829902|NCT01580163|EXPERIMENTAL|JITAI combined therapy group|The investigator will adopt JITAI combined psychological intervention and social support in Shanghai-related community.
62829903|NCT01580163|EXPERIMENTAL|Methadone combined herapy group|The investigator will adopt JITAI combined psychological intervention and social support in Shanghai-related community.
62829904|NCT01580163|EXPERIMENTAL|JITAI therapy group|The investigator will adopt JITAI combined social support in Shanghai-related community and outside of Shanghai.
62250187|NCT00610545|ACTIVE_COMPARATOR|2|Use Atorvastatin 20 mg for 60 days , and the vascular surgery will be made between day-7 and day-60
62250188|NCT00780013|EXPERIMENTAL|1|metformin hydrochloride (HCI) liquid 500 mg/5 mL of Ranbaxy
62829905|NCT05809375|ACTIVE_COMPARATOR|Coping Skills Training Group|Coping skills training (CST) will be given to the intervention group in line with the goals of the International Headache Society. Of the participants included in this study, the ones in the intervention group will be evaluated before and after the intervention.
62829906|NCT05809375|NO_INTERVENTION|Control Grup|The participants in the control group will be evaluated at the beginning and after four weeks. CST will be given to the control group participants, if they want to, after the final evaluation.
62829907|NCT03545958|EXPERIMENTAL|High-intensity Interval Training (HIT)|Participants in this groups will receive 15 minutes in the mind-motor training (i.e., Square-Stepping Exercise) followed by a 45-minute HIT intervention.
62829908|NCT03545958|ACTIVE_COMPARATOR|Moderate-intensity Continuous Training (MCT)|Participants in this groups will receive 15 minutes in the mind-motor training (i.e., Square-Stepping Exercise) followed by a 45-min MCT intervention.
62829909|NCT01673542|EXPERIMENTAL|Lidocaine-Prilocaine 5%|
62829910|NCT01673542|PLACEBO_COMPARATOR|Dexeryl|
62829911|NCT02746653|EXPERIMENTAL|Use of TroClose1200(TM) for access port and closure device|TroClose in 1 port
62829912|NCT02952820|EXPERIMENTAL|lemborexant 5 milligrams (mg)|Lemborexant 5 mg will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
62829913|NCT02952820|EXPERIMENTAL|lemborexant 10 mg|Lemborexant 10 mg will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
62829914|NCT02952820|PLACEBO_COMPARATOR|Placebo matched to lemborexant|Lemborexant-matched placebo will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
62047825|NCT01572779|EXPERIMENTAL|Intervention|BSM device with bio-feedback
62829915|NCT05992831|SHAM_COMPARATOR|Dose Step 1 - 0 Active Accelerated iTBS Sessions|Participant will receive 10 sessions of accelerated iTBS on each of 6 treatment days, including 0/10 active sessions and 10/10 sham sessions per day for a total of 0 active sessions
62829916|NCT05992831|EXPERIMENTAL|Dose Step 2 - 12 Active Accelerated iTBS Sessions|Participant will receive 10 sessions of accelerated iTBS on each of 6 treatment days, including 2/10 active sessions and 8/10 sham sessions per day for a total of 12 active sessions (7,200 active pulses).
62047826|NCT01572779|PLACEBO_COMPARATOR|Control|The BSM device without feed-back
62047827|NCT01963325|EXPERIMENTAL|S-1 plus Abraxane|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, \<1.25 m2: 80mg/day, 1.25\~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
62047828|NCT06048770|EXPERIMENTAL|Multiple Ascending Dose (MAD) Cohorts, Cohort 1: RBI-4000 0.1 mcg|Participants will receive RBI-4000 0.1 micrograms (mcg) via intramuscular injection, once on Day 1 and Day 57.
62047829|NCT06048770|EXPERIMENTAL|MAD Cohorts, Cohort 2: RBI-4000 1 mcg|Participants will receive RBI-4000 1 mcg via intramuscular injection, once on Day 1 and Day 57.
62829917|NCT05992831|EXPERIMENTAL|Dose Step 3 - 24 Active Accelerated iTBS Sessions|Participant will receive 4/10 active sessions and 6/10 sham sessions per day for a total of 24 active sessions (14,400 active pulses).
62829918|NCT05992831|EXPERIMENTAL|Dose Step 4 - 36 Active Accelerated iTBS Sessions|Participant will receive 6/10 active sessions and 4/10 sham sessions per day for a total of 36 active sessions (21,600 active pulses).
62829919|NCT05992831|EXPERIMENTAL|Dose Step 5 - 48 Active Accelerated iTBS Sessions|Participant will receive 8/10 active sessions and 2/10 sham sessions per day for a total of 48 active sessions (28,800 active pulses).
62829920|NCT05992831|EXPERIMENTAL|Dose Step 6 - 60 Active Accelerated iTBS Sessions|Participant will receive 10/10 active sessions and 0/10 sham sessions per day for a total of 60 active sessions (36,000 active pulses).
62829921|NCT06142682|EXPERIMENTAL|CIDEXEL|MED-EL Cochlear Implant Mi1250 +FLEX28 DEX (CIDEXEL)
62047830|NCT06048770|EXPERIMENTAL|MAD Cohorts, Cohort 3: RBI-4000 10 mcg|Participants will receive RBI-4000 10 mcg via intramuscular injection, single dose on Day 1.
62047831|NCT06048770|EXPERIMENTAL|MAD Cohorts, Cohort 4: RBI-4000 10 mcg|Participants will receive RBI-4000 ,10 mcg via intramuscular injection, once on Day 1 and Day 57.
62250189|NCT00780013|ACTIVE_COMPARATOR|2|Glucophage® 1000 mg tablets
62250190|NCT03459599|ACTIVE_COMPARATOR|Prophylaxis|Current protocol of administering antibiotics maintained
62829922|NCT03441321|EXPERIMENTAL|Group I (focusing on tanning and healthy body image)|Participants periodically read the content on the study-specific private and hidden Facebook group related to living a healthy lifestyle including avoiding tanning and excessive ultraviolet exposure, managing stress, healthy eating, promoting physically active lifestyles, and promoting a healthy body image, and participate in the group by providing reactions, commenting on the posts, or by sharing study relevant information within the group for 8 weeks.
62829923|NCT03441321|ACTIVE_COMPARATOR|Group II (focusing on other health topics)|Participants participate in private and hidden Facebook groups that utilize content from the intervention content library related to other health topics of interest (e.g., physical activity, healthy eating, alcohol misuse prevention, stress reduction, sleep) for 8 weeks.
62829924|NCT01884467|EXPERIMENTAL|Gentamicin|Intervention: Gentamicin; Dosage form: 120mg reconstituted in 250cc of normal saline; Dosage: 30mL; Frequency: nightly instillation into bladder (to remain overnight until draining it out in morning); Duration: 1 year
62829925|NCT01884467|PLACEBO_COMPARATOR|Placebo|Drug: Normal saline; Dosage form: N/A; Dosage: 30 mL; Frequency: nightly bladder instillation; Duration: 1 year
62829926|NCT00800670|EXPERIMENTAL|Lower dose|Lower dose of Ad5Ag85A: 10\^8pfu
62829927|NCT00800670|EXPERIMENTAL|Higher dose|Higher dose of vaccine Ad5Ag85A: 10\^9pfu
62829928|NCT04379856|EXPERIMENTAL|Dose 1|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
62829929|NCT04379856|EXPERIMENTAL|Dose 2|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
62829930|NCT04379856|EXPERIMENTAL|Dose 3|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
62829931|NCT05593367||VD-， VD deficiency group|The IBS-D patients whose serum 25(OH)D level was\<20ng/ml
62250191|NCT03459599|ACTIVE_COMPARATOR|No prophylaxis|Antibiotics withheld, with appropriate observation and follow up
62250192|NCT02310776|OTHER|Automated & Handheld breast US exams|"1. Automated breast ultrasound exam: 3D supine automated breast ultrasound scanner.~2. Handheld breast ultrasound exam: High-resolution handheld breast ultrasound."
62607791|NCT03257241|ACTIVE_COMPARATOR|A arm (CLAG-M)|Cladribine 5mg/m2 in 2 h i.v. infusion on days (1-5) Ara-C 2 g/m2 in 4 h i.v. infusion, 2 h after cladribine infusion on days (1-5) Mitoxantrone 10 mg/m2 i.v. 1xd on days (1-3) G-CSF 30MU s.c. 1xd from day 0 to 5 of the treatment (6 doses).
62607792|NCT03257241|ACTIVE_COMPARATOR|B arm (FLAG-IDA)|Fludarabine 30 mg/m2 in 30-min i.v. infusion on days (1-5) Ara-C 2 g/m2 in 4 h i.v. infusion, 2 h after fludarabine infusion on days (1-5). Idarubicin 8 mg/m2 i.v. 1xd on days (1-3) G-CSF 30MU s.c. 1xd from day 0 to 5 of the treatment (6 doses).
62829932|NCT05593367||VD+， VD normal group|The IBS-D patients whose serum 25(OH)D level was ≥20ng/ml
62829933|NCT05251558|EXPERIMENTAL|Telerehabilitation (TR)|Self PNF exercises determined for facial muscles (M. Frontalis, M. Orbicularis Oculi, M. Orbicularis Oris, M. Risorius etc.) will be applied.
62829934|NCT05251558|ACTIVE_COMPARATOR|Conventional Education Program (CEP)|Education will be given to cases with Bell's Palsy. Some exercises will be suggested in front of the mirror. Patients will be advised to gently massage upwards with their fingertips after applying a warm towel with a towel on the facial muscles.
62829935|NCT02964689|EXPERIMENTAL|Combination of binimetinib, pemetrexed and cisplatin|"The trial consists of two parts:~* Part 1: dose escalation based on the 3+3 design with 2 doses of binimetinib~* Part 2: expansion cohort at the recommended maximum tolerated dose (MTD) level of binimetinib"
62829936|NCT01703143|EXPERIMENTAL|Laser Ablation|Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
62829937|NCT03854175|ACTIVE_COMPARATOR|Sildenafil group|40 women are give sildenafil citrate 25mg vaginally every 6 hours (a half of 50 mg tablet is crushed and dissolved in 2cc of distilled water and injected in to vagina) starting from day 2-14 of the cycle, in addition to oral 2mg of estradiol valerat 6-8 hourly from the day 2-14 of the menstrual cycle
62829938|NCT03854175|ACTIVE_COMPARATOR|estradiol group|40 women are given oral estradiol valerate tablets 2mg 6-8 hourly from the day 2-14 of the cycle to prepare the endometrium in addition to placebo in the same way as sildenafil
62829939|NCT00765206|EXPERIMENTAL|Zegerid|Omeprazole 20 mg /sodium bicarbonate 1100 mg over-the-counter (OTC) Capsule
62829940|NCT00765206|ACTIVE_COMPARATOR|Prilosec|Omeprazole magnesium 20 mg OTC tablet
62829941|NCT00371150|EXPERIMENTAL|Arm1|
62829942|NCT06591754|EXPERIMENTAL|ISTDP|ISTDP combined group- and individual therapy
62829943|NCT01553968|OTHER|Endurance Trained Subjects|
62829944|NCT01553968|OTHER|Untrained Subjects|
62829945|NCT04353648||Duke ICU/Trauma Center Patients|Any patient admitted to the Duke Trauma Center or Duke ICU will be approached to participate in this study.
62829946|NCT06595680|EXPERIMENTAL|Medialipide 20% - NaCl 0,9%|Group 1 will receive during the first interventional hemodialysis session a perfusion of Medialipide 20% perfused at a rate of 0,11 gram/kilogram/hour (g/kg/h) during 4 hours. One week late, they will receive during the second interventional hemodialysis session a perfusion of NaCl 0,9% with a volume corresponding to the one of Medialipide also during 4 hours.
62829947|NCT06595680|EXPERIMENTAL|NaCl 0,9% - Medialipide 20%|Group 2 will receive during the first interventional hemodialysis session a perfusion of NaCl 0,9% with a volume corresponding to the one of Medialipide during 4 hours. One week late, they will receive during the second interventional hemodialysis session a perfusion of Medialipide 20% perfused at a rate of 0,11 gram/kilogram/hour (g/kg/h) also during 4 hours.
62829948|NCT04257110|OTHER|Part 1: Dose-escalation|Eight doses levels have been selected for evaluation in the Part 1 of the study. Dose escalation decisions will be determined based on toxicities observed during the first cycle ( 21 days or 28 days).
62829949|NCT04257110|EXPERIMENTAL|Part 2: Cohort 1|Breast Cancer with HER2 overexpressing or positive
62829950|NCT04257110|EXPERIMENTAL|Part 2: Cohort 2|Breast Cancer with HER2 low expressing
62250193|NCT04841824||Critically ill patients with sepsis|
62250194|NCT04841824||Critically ill patients without sepsis|
62250195|NCT06231576|EXPERIMENTAL|Hospital|Prehabilitation at the hospital, with guidance by a dedicated physiotherapist physically present.
62250196|NCT06231576|EXPERIMENTAL|Digital|Prehabilitation at home, with guidance from a dedicated physiotherapist through a digital platform, realtime.
62829951|NCT04257110|EXPERIMENTAL|Part 2 Cohort 3|Gastric Cancer or gastroesophageal junction cancer with HER2 overexpressing or positive
62607793|NCT01342172|EXPERIMENTAL|Lenalidomide|capsules for oral administration
62607794|NCT00607633||1|Patient with essential hypertension and LVH under treatment with candesartan or candesartan HCT
62607795|NCT02046772|EXPERIMENTAL|Bupivacaine + Morphine Chloride|People in this arm will receive treatment with morphine chloride in addition to a low dose solution of the local intradural anaesthetic bupivacaine.
62607796|NCT02046772|ACTIVE_COMPARATOR|Bupivacaine standard dose|People in this arm will receive treatment with the standard dose of the local intradural anaesthetic bupivacaine
62829952|NCT04257110|EXPERIMENTAL|Part 2 Cohort 4|Solid Tumors other than Breast Cancer and Gastric Cancer with HER2 overexpressing or positive
62047832|NCT06048770|ACTIVE_COMPARATOR|Cohort 5: RabAvert 1 mL|Participants will receive RabAvert 1 milliliter (mL), intramuscular injection, once on Day 1 and Day 8.
62047833|NCT03121157|EXPERIMENTAL|Intervention|The intervention group will receive two sessions of computer-delivered motivational interviewing via CIAS software programmed to target adherence to medications. The intervention group will also receive text messaged adherence reminders between sessions. Both the computer-delivered sessions and text messages will be tailored to the participant using ecological momentary assessment.
62047834|NCT03121157|NO_INTERVENTION|Control|Control participants complete CIAS-delivered asthma education modules matched for length, location, and method of delivery of the intervention session. Control participants complete each module at their own pace and then complete a short quiz to assess their knowledge. Control participants also receive text messages between intervention sessions. Message content is the same for all control participants and contains general facts about asthma (not tailored). Message timing is not tailored and is sent at the same time every day (4:00 PM--time chosen to avoid AM and PM medication times but to not interfere with sleep and school activities).
62047835|NCT02954354|EXPERIMENTAL|Adults: Baloxavir Marboxil|Participants aged 20 to 64 years will receive two or four 20 mg baloxavir marboxil tablets orally on Day 1 and one oseltamivir placebo capsule orally twice a day (BID) on Days 1 to 5.
62047836|NCT02954354|ACTIVE_COMPARATOR|Adults: Oseltamivir|Participants aged 20 to 64 years will receive 75 mg oseltamivir twice a day on Days 1 to 5 and two or four baloxavir marboxil placebo tablets on Day 1.
62047837|NCT02954354|PLACEBO_COMPARATOR|Adults: Placebo|Participants aged 20 to 64 years will receive two or four baloxavir marboxil placebo tablets on Day 1 and one oseltamivir placebo capsule orally twice a day on Days 1 to 5.
62047838|NCT02954354|EXPERIMENTAL|Adolescents: Baloxavir Marboxil|Participants aged 12 to 19 years will receive two or four baloxavir marboxil 20 mg tablets on Day 1.
62047839|NCT02954354|PLACEBO_COMPARATOR|Adolescents: Placebo|Participants aged 12 to 19 years will receive two or four baloxavir marboxil placebo tablets on Day 1.
62047840|NCT06418555|EXPERIMENTAL|Home Rehabilitation Team|Adding an immediate information-based intervention to the routine home care intervention with a home cardiac rehabilitation program intervention for TAVR patients.
62047841|NCT06418555|EXPERIMENTAL|Routine care group|Routine care
62439926|NCT04914793|NO_INTERVENTION|Reference phase|"At the start (month 0), a point prevalence surveys (PPS) on hospital antimicrobial use are performed (more details on conduct of PPS are given in following section) to collect baseline data before introducing paper-based guidelines.~All medical doctors of each participating hospital are asked to complete an AMS knowledge survey and pre-prescribing guidelines survey after PPS is conducted. Then, paper-based prescribing guidelines in both adult and paediatric versions (one adult guideline and one paediatric guideline) are distributed to all doctors at participating hospitals, followed by guideline introductory session of the guidelines. After introduction of the paper-based guidelines, all six hospitals are formally included in the reference period."
62439927|NCT04914793|EXPERIMENTAL|Intervention phase|"1. Antimicrobial Prescribing guidelines mobile phone application (MicroGuide) Both paediatric and adult antimicrobial prescribing guidelines are transferred to MicroGuide; which is a medical guideline application. MicroGuide is an offline application, free-of-charge for the individual users. The app can monitor the number of users and which guidelines are being accessed. The app is installed to the personal smart phones of local physicians by the PI. Both mobile app and paper guidelines will be available in Lao languages.~2. Antimicrobial stewardship (AMS) training AMS training sessions are given to prescribers in participating hospitals when they firstly enter to the intervention phase. This session is given alongside an introduction of mobile phone app prescribing guideline. The training focus on good practices of antimicrobial prescription. Providing training after introducing treatment guidelines is not routine practice in many hospitals in Laos."
62607797|NCT01606748|EXPERIMENTAL|Necitumumab, Gemcitabine and Cisplatin|The study will be conducted in two sequential periods: a 3-week PK run-in participants will be treated sequentially with single doses of cisplatin, gemcitabine, and necitumumab. Cycle 1 will begin immediately following the PK run-in period.
62607798|NCT02117713|EXPERIMENTAL|LUM001 (Maralixibat)|Participant will receive LUM001 also known as Maralixibat (MRX) administered orally once per day.
62607799|NCT02388412||Vulnerable plaque in optical coherence tomogrpahy|OCT-derived vulnerable plaque is defined as composite of thin-cap fibrous atheroma (cap thickness in optical coherence tomography \< 60um), prominent macrophage, or prominent microvessels.
62607800|NCT02388412||Non-vulnerable plaque in Optical coherence tomogrpahy|OCT-derived vulnerable plaque is defined as composite of thin-cap fibrous atheroma (cap thickness in optical coherence tomography \< 60um), prominent macrophage, or prominent microvessels. OCT-derived non-vulnerable plaque is defined as a plaque without any of the findings
62607801|NCT00851773|EXPERIMENTAL|A|
62607802|NCT00851773|EXPERIMENTAL|B|
62607803|NCT00851773|EXPERIMENTAL|C|
62607804|NCT00851773|EXPERIMENTAL|D|
62607805|NCT00851773|EXPERIMENTAL|E|
62607806|NCT00851773|PLACEBO_COMPARATOR|F1|
62607807|NCT00851773|PLACEBO_COMPARATOR|F2|
62607808|NCT00851773|PLACEBO_COMPARATOR|F3|
62607809|NCT00851773|PLACEBO_COMPARATOR|F4|
62829953|NCT02705742|OTHER|stem cells group|mesenchymal stem cells only
62829954|NCT04424134|EXPERIMENTAL|Bromhexine And Spironolactone|
62829955|NCT04424134|ACTIVE_COMPARATOR|Base therapy|
62829956|NCT06652932|EXPERIMENTAL|Low temperature (16℃) group|Subjects in the exposure group will be exposed to low temperature (16℃) for about 2 hours in a chamber.
62829957|NCT06652932|EXPERIMENTAL|Moderate temperature (22℃) group|Subjects in the exposure group will be exposed to moderate temperature (22℃) for about 2 hours in a chamber.
62829958|NCT03747562|EXPERIMENTAL|Experimental group|"Patients randomised to the experimental group will receive a prescription for a gabapentin starting dose of 100 mg three times a day (ter in die, t.i.d) /day per orally, additional to the analgesics according to standard local practices.~Gabapentin dosage may be gradually increased based on individual patient response and tolerability, and as per standard practice in accordance with the drug label. The dose can be further increased in 300 mg/day increments (dose increments of 50% - 100%) every two to three days, up to a maximum dose of 3600 mg/day. The minimum time to reach a dose of 1800 mg/day is one week, to reach 2400 mg/day is a total of two weeks, and to reach 3600 mg/day is a total of three weeks."
62829959|NCT03747562|PLACEBO_COMPARATOR|Control group|Patients randomised to the control group will receive a prescription for a matching placebo. The starting dose will be the same as in the experimental group (100 mg three times a day per orally), additional to the analgesics according to standard local practices. Placebo can optionally follow the same dose scheme as described in the experimental arm.
62829960|NCT05670301|EXPERIMENTAL|Intervention|Cytokine assessment
62829961|NCT00514839|NO_INTERVENTION|C|Control group receiving a booklet on health behavior
62829962|NCT00514839|EXPERIMENTAL|MI|Counselling based on Motivational Interviewing plus individualized feedback
62829963|NCT06587074||Group 1|
62829964|NCT06587074||Group 2|
62250197|NCT06231576|NO_INTERVENTION|Control|Information about the general benefit of a healthy lifestyle at inclusion, thereafter no further follow-up prior to surgery.
62047842|NCT05282797|EXPERIMENTAL|Part A - ANEB-001|Subjects receive THC and varying amounts of ANEB-001
62829965|NCT03399019|EXPERIMENTAL|Dexmedetomidine|"Dexmedetomidine~: initial loading 0.5- 1 mng/kg for 10 minutes and maintenance 0.2-0.7mng/kg/hr~Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
62829966|NCT03399019|ACTIVE_COMPARATOR|Propofol|"Propofol~: 0.75-3 mg/kr/hr continous infusion Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
62047843|NCT05282797|PLACEBO_COMPARATOR|Part A - Placebo|Subjects receive THC and placebo
62047844|NCT05282797|EXPERIMENTAL|Part B - Cohort 1 - ANEB-001|Subjects receive 21 mg of THC and 30 mg of ANEB-001
62047845|NCT05282797|PLACEBO_COMPARATOR|Part B - Cohort 1 - Placebo|Subjects receive 21 mg of THC and placebo
62250198|NCT02667873|EXPERIMENTAL|SL-801|The starting dose regimen of SL-801 (i.e., the dose regimen in Cohort 1) is 5 mg/day on Days 1-4 and 8-11 every 21 days. In the 2nd portion of the dose escalation stage, patients receive SL-801 PO once daily on days 1-2, 8-9, 15-16 and 22-23 of a 28-day cycle. The starting dose will be 70 mg/day (the next planned dose level).The SL-801 dose regimen for a particular patient is dependent on the cohort in which the patient is enrolled
62829967|NCT03399019|ACTIVE_COMPARATOR|Midazolam|"Midazolam~: initial loading 0.5- 1 mng/kg for 10 minutes and maintenance 0.2-0.7mng/kg/hr~Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
62829968|NCT02300961|EXPERIMENTAL|Cognitive rehabilitation arm|Cognitive rehabilitation program
62829969|NCT06604117||Conventional Lipid-Lowering Therapy Group|Participants who choose this group will receive conventional lipid-lowering therapy following current clinical guidelines, which may include statins, ezetimibe, or PCSK9 inhibitors. The treatment regimen will be tailored to the participants' individual needs but will not include Probucol.
62829970|NCT06604117||Combined Lipid-Lowering Therapy with Probucol Group|Participants who choose this group will receive a combination of conventional lipid-lowering therapy following current clinical guidelines (statins, ezetimibe, or PCSK9 inhibitors) and additional treatment with Probucol 0.5g twice daily. This regimen aims to further reduce atherosclerotic plaque burden and improve cardiovascular outcomes.
62829971|NCT05162963|ACTIVE_COMPARATOR|Patients treated with fixed implant denture|Patients quality of life will be compared when using a removable implant denture and a fixed implant denture, in a cross-over design. Fixed denture is considered the standard protocol.
62829972|NCT05162963|EXPERIMENTAL|Patients treated with removable implant denture|Patients quality of life will be compared when using a removable implant denture and a fixed implant denture, in a cross-over design. Removable denture is considered the experimental protocol.
62829973|NCT05692375|EXPERIMENTAL|Experimental|The experimental group will be inveted to use the game. Two weeks were defined as the time to use the game. The use of the game can be seen by the coded digital record on its digital platform .
62829974|NCT05692375|NO_INTERVENTION|Control|The control group neither used nor had access to the game.
62829975|NCT04592302||Smoking Cessation Group|participants are required to cease smoking for 4 weeks prior to and 2 weeks after TJA without any nicotine replacement (any other smoking cessation aids the patient chooses will be allowed)
62829976|NCT04592302||Smoker Group 2|participants who are allowed to continue smoking and using nicotine in any form at their own discretion during the perioperative period
62829977|NCT06521320|EXPERIMENTAL|Upper airway patency|Upper airway patency confirmed by speaking valve combined with airway pressure measurement or bronchoscopy
62829978|NCT06521320|EXPERIMENTAL|Upper airway obstruction|Upper airway obstruction confirmed by speaking valve combined with airway pressure measurement or bronchoscopy
62607810|NCT00851773|PLACEBO_COMPARATOR|F5|
62829979|NCT06590792|EXPERIMENTAL|football player|14-18 years old male football players who play in the infrastructure of a football club
62829980|NCT06590792|ACTIVE_COMPARATOR|healthy control group|14-18 years old male healthy participants who don't involve any regular sports training
62829981|NCT00758667|NO_INTERVENTION|Standard treatment|Standard treatment
62829982|NCT00758667|EXPERIMENTAL|Use of Mesna|Standard surgical procedure with Mesna
62829983|NCT03501849|EXPERIMENTAL|Polypectomy using a cold snare|Polypectomy by cold-snare technique
62829984|NCT04912258|EXPERIMENTAL|Arm A|DEB-TACE before liver surgery
62829985|NCT04912258|NO_INTERVENTION|Arm B|direct liver surgery
62829986|NCT03122509|EXPERIMENTAL|durvalumab and tremelimumab plus Radiotherapy (RT)|Patients will receive 1500 mg durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 1500 mg durvalumab q4w starting on Week 16. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice. RT will be initiated within 7 days after the first of durvalumab and tremelimumab.
62829987|NCT03122509|EXPERIMENTAL|durvalumab and tremelimumab plus ablation|Patients will receive 1500 mg durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 1500 mg durvalumab q4w starting on Week 16. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. The ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice. Ablation will be performed within 7 days after the first of durvalumab and tremelimumab.
62829988|NCT04784247|EXPERIMENTAL|Leiomyosarcoma|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
62829989|NCT04784247|EXPERIMENTAL|High grade undifferentiated pleomorphic sarcoma|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal . Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
62829990|NCT04784247|EXPERIMENTAL|Vascular sarcomas (including angiosarcoma and epithelioid hemangioendothelioma)|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal. Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
62047846|NCT05282797|EXPERIMENTAL|Part B - Cohort 2 - ANEB-001|Subjects receive 21 mg of THC and 10 mg of ANEB-001
62047847|NCT05282797|PLACEBO_COMPARATOR|Part B - Cohort 2 - Placebo|Subjects receive 21 mg of THC and placebo
62047848|NCT05282797|EXPERIMENTAL|Part B - Cohort 3 - ANEB-001|Subjects receive 21 mg of THC and 1 hour later, 30 mg ANEB-001
62047849|NCT05282797|PLACEBO_COMPARATOR|Part B - Cohort 3 - Placebo|Subjects receive 21 mg THC and 1 hour later, placebo
62047850|NCT05282797|EXPERIMENTAL|Part B - Cohort 4 - ANEB-001|Subjects receive 40 mg of THC and 1 hour later, 10 mg of ANEB-001
62047851|NCT05282797|PLACEBO_COMPARATOR|Part B - Cohort 4 - Placebo|Subjects receive 40 mg of THC and 1 hour later, placebo
62047852|NCT05282797|EXPERIMENTAL|Part B - Cohort 5 - ANEB-001|Subjects receive 30 mg of THC and 1 hour later, 10 mg of ANEB-001
62047853|NCT05282797|PLACEBO_COMPARATOR|Part B - Cohort 5 - Placebo|Subjects receive 30 mg of THC and 1 hour later, 10 mg of ANEB-001
62047854|NCT05282797|EXPERIMENTAL|Part B - Cohort 6 - ANEB-001|Subjects will consume a high fat meal prior to receiving 30 mg of THC and 1 hour later, 10 mg of ANEB-001
62047855|NCT05282797|PLACEBO_COMPARATOR|Part B - Cohort 6 - Placebo|Subjects will consume a high fat meal prior to receiving 30 mg of THC and 1 hour later, placebo
62047856|NCT05282797|EXPERIMENTAL|Part C - Cohort 7 - ANEB-001|Subjects receive a 40 mg dose of THC and a 10 mg dose of ANEB-001
62047857|NCT05282797|EXPERIMENTAL|Part C - Cohort 8 - ANEB-001|Subjects receive a 60 mg dose of THC and a 20 mg dose of ANEB-001
62047858|NCT01285622||Gynecology patients|female subjects scheduled for elective robotic gynecological surgery under general anesthesia.
62047859|NCT05596305|EXPERIMENTAL|undergraduate medical students|an educational anti-stigma intervention delivered to undergraduate medical students comparing the outcomes of the study before and after the intervention at two time intervals
62607811|NCT00732680|EXPERIMENTAL|Botulinum Toxin Type A|Treatment will be in the form of 10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
62607812|NCT03040505||Patients with schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
62047860|NCT05576584|PLACEBO_COMPARATOR|Single Ascending Dose|Five dose groups: 5mg (group I), 15mg (Group II), 30mg (Group III), 60mg (Group IV) and 100mg (Group V). According to the safety, tolerance and PK parameters of group V, higher dose group studies (150mg and 200mg alternatively) are not excluded. There were 10 subjects in each group, of which 8 received GST-HG121 tablets and 2 received placebo.
62607813|NCT03040505||Control participants|- Control participants without psychiatric nor neurological history
62829991|NCT04784247|EXPERIMENTAL|Other soft tissue sarcomas (including synovial sarcoma and malignant peripheral nerve sheath tumor|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal. Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
62829992|NCT04784247|EXPERIMENTAL|Bone sarcomas (including osteosarcoma and chondrosarcoma)|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal. Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
62829993|NCT06590246|EXPERIMENTAL|C-CAR031|"* Dose escalation section (Part A1) utilizes a '3+3' design to explore the recommended dose for expansion (RDE). Initially, two dose levels (DLs) will be assessed. Patients in the dose escalation section will receive autologous C-CAR031 via intravenous (IV) infusion at DL1 and DL2.~* Dose expansion (Part A2) will evaluate the safety and tolerability of C-CAR031 to determine RP2D to be used in Part B (Phase II). Patients in the dose expansion section will receive autologous C-CAR031 via IV infusion at the RDE.~* The patients in the Phase II section (Part B) will receive autologous C-CAR031 via IV infusion at the RP2D, which will be determined after Part A by SRC."
62829994|NCT02263599||Conservatively treated ventral hernias|
62829995|NCT02263599||Surgically treated ventral hernias|
62607814|NCT03387345|EXPERIMENTAL|bread-50/50-steelcut-80/20-flake-rice|25 g of available carbohydrate was delivered to participants via (1) white bread, followed by (2) 50/50 rice-barley mix, followed by (3) 100% steel cut barley, followed by (4) 80/20 rice-barley mix, followed by (5) 100% barley flakes, followed by (6) 100% rice
62250199|NCT03843281|EXPERIMENTAL|Paracetamol|Paracetamol 1 g (100 mL) IV + Morphine 0.1 mg/kg IV (repeatable in Doses of 0.05 mg/kg), 100 patients over 4 hours
62250200|NCT03843281|PLACEBO_COMPARATOR|Placebo|Placebo (NaCl 0.9% 100 mL IV) + Morphine 0.1 mg/kg IV (repeatable in Doses of 0.05 mg/kg), 100 patients over 4 hours
62607815|NCT03387345|EXPERIMENTAL|50/50-steelcut-80/20-flake-rice-bread|25 g of available carbohydrate was delivered to participants via (1) 50/50 rice-barley mix, followed by (2) 100% steel cut barley, followed by (3) 80/20 rice-barley mix, followed by (4) 100% barley flakes, followed by (5) 100% rice, followed by (6) white bread
62607816|NCT03387345|EXPERIMENTAL|steelcut-80/20-flake-rice-bread-50/50|25 g of available carbohydrate was delivered to participants via (1) 100% steel cut barley, followed by (2) 80/20 rice-barley mix, followed by (3) 100% barley flakes, followed by (4) 100% rice, followed by (5) white bread, followed by (6) 50/50 rice-barley mix
62250201|NCT01504165|EXPERIMENTAL|Group 1|Healthy volunteers: matched subjects with normal renal function
62047861|NCT05576584|PLACEBO_COMPARATOR|Multiple Ascending Dose|According to the results of single dose study, it is planned to select 1-3 dose groups within the range of single dose for oral administration for 7 consecutive days. There were 12 subjects in each group, of which 10 received GST-HG121 tablets and 2 received placebo. From D 1 to d 7, take GST-HG121 tablets or placebo orally on an empty stomach every day, tentatively once a day (the specific administration frequency may be adjusted based on the results of the single dose increase test)
62047862|NCT05576584|PLACEBO_COMPARATOR|food affects（A）|10 subjects (8 received GST-HG121 tablets and 2 received placebo)
62829996|NCT01857492|SHAM_COMPARATOR|SHAM|We will apply sham tDCS on the primary motor cortex. We will use the same montage and parameters of active tDCS. However the current will be applied for 30 seconds in the beginning of the procedure and after that the current is turned off. This parameter for sham stimulation was chosen based on previous studies that have shown that perceived sensations on the scalp such as tingling usually fade out in the first 30 seconds of tDCS. It should be noted that less than 3 minutes of tDCS induces no effects on cortical excitability \[29\] and also using 30 seconds of sham is a reliable method of blinding as shown by a randomized controlled study \[30\]. Subjects will also meditate while receiving stimulation
62829997|NCT01857492|ACTIVE_COMPARATOR|ACTIVE|"A 1x1 Low-intensity DC Stimulator such as the Soterix Medical Inc. (Model 1224-B New York, NY, USA) or an equivalent device will be used to deliver direct current through 35cm² saline-soaked electrodes. The anodal electrode will be placed over the left primary motor cortex (M1) while the cathodal electrode will be placed over the contralateral supra-orbital area. Primary motor cortex will be localized using the 10/20 EEG system (C3 or C4) and this is a reliable method for the technique of tDCS \[5\]. During active tDCS, a 2mA constant current will be delivered for 20 minutes while the subject meditates. The primary motor cortex is a reliable entry port to modulate dysfunctional activity in pain-related neural networks."
62829998|NCT06590818|EXPERIMENTAL|varus knee osteoarthritis Group|About 50 patients had varus knee osteoarthritis underwent high tibial osteotomy (HTO)
62829999|NCT00744497|PLACEBO_COMPARATOR|Placebo|Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m\^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
62830000|NCT00744497|ACTIVE_COMPARATOR|Dasatinib|Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m\^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
62830001|NCT00948376||Patients|All ages
62047863|NCT05576584|ACTIVE_COMPARATOR|food affects（B）|8 subjects (all received GST-HG121 tablets)
62047864|NCT02426788|EXPERIMENTAL|CBT+SMC|"Cognitive behavioural therapy + Standard Medical Care (cognitive-behavioural therapy+SMC):~8 hour-long manual-based CBT sessions with a therapist, weekly or fortnightly."
62047865|NCT02426788|NO_INTERVENTION|Standard Medical Care (SMC)|Participants assigned to the SMC group (i.e., control group) will receive all the treatment and support they would otherwise receive outside of a research trial.
62047866|NCT03742024||Children and adolescents|Children and adolescents between the ages of 4 and 17 years old (inclusive)
62250202|NCT01504165|EXPERIMENTAL|Group 2|Mild renal impaired subjects
62250203|NCT01504165|EXPERIMENTAL|Group 3|Moderate renal impaired subjects
62830002|NCT00948376||Fetuses|
62830003|NCT02065037|EXPERIMENTAL|Warmed Carbon Dioxide Insufflation|warmed carbon dioxide insufflation used in colonoscopy
62830004|NCT02065037|ACTIVE_COMPARATOR|Room Temperature Air Insufflation|room temperature air insufflation used in colonoscopy
62830005|NCT06599281|OTHER|Pygopagus conjoined twins receiving physiotherapy after separation surgery|Physiotherapy was applied to all cases after surgery. The physiotherapy program included neurodevelopmental exercises, balance and proprioception exercises, and stretching exercises.
62830006|NCT03216512|EXPERIMENTAL|Noise cancelling headphone first, then sham control headphone|This group will use the noise cancelling headphone during the first experimental session as they complete study assessments. They will then return within a week, for experimental session day 2, to complete the same assessments this time using a sham control headphone.
62830007|NCT03216512|EXPERIMENTAL|Sham control headphone first, then noise cancelling headphone|This group will use the sham control headphone during the first experimental session as they complete study assessments. They will then return within a week for experimental session day 2, to redo the same assessments this time using a noise cancelling headphone.
62830008|NCT05602246|EXPERIMENTAL|Transobturator cystocele repair (TOCR)|"The technique of TOCR was published previously including a video \[Kalis et al. Trans-obturator cystocele repair (TOCR) of level 2 paravaginal defect. Int Urogynecol J. 2020, 31(11):2435-38. doi:10.1007/s00192-020-04337-x\].~The anterior vaginal wall is incised in the midline and the pubocervical fascia is dissected to open the paravaginal space towards the ATFP and the fascia of the obturator internus muscle. 3-4 continuous non-locking stitches of non-absorbable suture 1-0 Ti-Cron™ braided polyester are taken into the pubocervical fascia and threaded using Shirodkar needles through skin incisions in genitofemoral sulci passing through the full thickness of the obturator membrane, obturator internus muscle. After closure of the vaginal skin incision, both ends of the Ti-Cron™ sutures are tied ensuring the obliteration of the paravaginal defect.~Indometacin rectal suppository 100 mg is inserted transrectally for early postoperative pain management."
62830009|NCT05602246|ACTIVE_COMPARATOR|standard anterior colporrhaphy (anterior repair - AR)|The anterior vaginal wall is incised in the midline from the level of the bladder neck up to vaginal apex or anterior vaginal fornix. The bladder is sharply dissected from the vaginal wall with pubocervical fascia attached to the bladder wall. The fascia is approximated in the midline with several simple interrupted 0 polyglactin 910 sutures or equivalent. The surplus of distended vaginal epithelium is trimmed. The vaginal incision is closed using a continuous non-locking polyglactin 910 2-0 suture or equivalent. Indometacin rectal suppository 100 mg is inserted transrectally for early postoperative pain management.
62830010|NCT04593862|EXPERIMENTAL|Exercise Group|The exercise intervention will consist of 36 high-volume high-intensity interval sessions over a 12-week period. The exercise frequency will be three times per week during the 6 weeks of intravesical therapy and the 6 weeks of recovery (total 12 weeks) prior to a surveillance cystoscopy.
62047867|NCT03294330|EXPERIMENTAL|Patients with Melanoma or Breast Cancer|The SPY machine used in conjunction with the IC-green kit will be used exclusively to identify sentinel nodes in patients diagnosed with Melanoma or Breast Cancer who are undergoing sentinel lymph node biopsy.
62047868|NCT00817180|ACTIVE_COMPARATOR|A|Positive Expiratory Pressure (PEP) - an airway clearance technique
62047869|NCT00817180|ACTIVE_COMPARATOR|B|High Frequency Chest Wall Oscillation (HFCWO) also known as the 'Vest technique' - an airway clearance technique.
62250204|NCT01504165|EXPERIMENTAL|Group 4a|First group of Severe renal impaired subjects
62607817|NCT03387345|EXPERIMENTAL|80/20-flake-rice-bread-50/50-steelcut|25 g of available carbohydrate was delivered to participants via (1) 80/20 rice-barley mix, followed by (2) 100% barley flakes, followed by (3) 100% rice, followed by (4) white bread, followed by (5) 50/50 rice-barley mix, followed by (6) 100% steel cut barley
62250205|NCT01504165|EXPERIMENTAL|Group 4b|Second group of severe renal impaired subjects
62830011|NCT04593862|NO_INTERVENTION|Usual Care:|Patients randomized to the control group will be asked not to initiate any exercise program or to increase their exercise level from baseline during the 12-week study. After the post-intervention assessments and 3-month cystoscopy, patients in the control group will be offered a 4-week supervised exercise program at the Behavioural Medicine Fitness Centre, University of Alberta.
62830012|NCT04467905|PLACEBO_COMPARATOR|Placebo|Administration of placebo at the emergency department for an episode of atrial fibrillation
62830013|NCT04467905|EXPERIMENTAL|Etripamil|Administration of 70 mg etripamil at the emergency department for an episode of atrial fibrillation
62830014|NCT01560663||Docetaxel Carboplatino|Doses of AUC 5-6 of carboplatin in combination with 75 mg/m2 of docetaxel are easily combined, being myelosuppression the most important toxicity. This combination has been studied in metastatic breast cancer as well as in the neoadjuvant setting. The combination of taxanes and platinum salts is increasingly used as neoadjuvant chemotherapy for TNBC. The docetaxel-carboplatin (TCb) regimen is an active and tolerable regimen in metastatic and locally advanced breast cancer, and the efficacy and toxicity characterization in the clinical setting are regaining interest in the era where the role of anthracyclines is controversial in the adjuvant setting. The avoidance of potentially serious long-term toxicities in specific breast cancer subtypes is a real challenge in an attempt to individualize therapies.
62830015|NCT04965701||Untreated EGFR-mutant advanced non-small-cell lung cancer patients|
62047870|NCT00627380|PLACEBO_COMPARATOR|STOC|Standard of care arm continues to receive standard of care treatment for HIV, but does not receive any new treatment/intervention or change in anti-HIV medications. Runs parallel to experimental group. At the end of this 16-wk control period, participants are invited to crossover into the experimental group
62047871|NCT00627380|EXPERIMENTAL|YOGA|Yoga lifestyle intervention administered by certified yoga instructor.
62250206|NCT01555047|ACTIVE_COMPARATOR|males who were not infected by mycoplasma|100 male patients whose spouse was going to conduct IUI, was not infected by mycoplasma.
62250207|NCT01555047|EXPERIMENTAL|infected by mycoplasma males|100 male patients whose spouse was going to conduct IUI, was infected by mycoplasma.
62607818|NCT03387345|EXPERIMENTAL|flake-rice-bread-50/50-steelcut-80/20|25 g of available carbohydrate was delivered to participants via (1) 100% barley flakes, followed by (2) 100% rice, followed by (3) white bread, followed by (4) 50/50 rice-barley mix, followed by (5) 100% steel cut barley, followed by (6) 80/20 rice-barley mix
62607819|NCT03387345|EXPERIMENTAL|rice-bread-50/50-steelcut-80/20-flake|25 g of available carbohydrate was delivered to participants via (1) 100% rice, followed by (2) white bread, followed by (3) 50/50 rice-barley mix, followed by (4) 100% steel cut barley, followed by (5) 80/20 rice-barley mix, followed by (6) 100% barley flakes
62830016|NCT03829228|EXPERIMENTAL|Proglucamune treatment|Participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks.
62047872|NCT02255357|PLACEBO_COMPARATOR|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
62047873|NCT02255357|ACTIVE_COMPARATOR|Intranasal Syntocinon|Intranasal Oxytocin 24 IU per day.
62250208|NCT01555047|NO_INTERVENTION|fertile males|50 fertile males were chose as control samples
62250209|NCT05410613|EXPERIMENTAL|combined electromagnetic field and a plantar resistance|
62250210|NCT05410613|EXPERIMENTAL|electromagnetic field|
62250211|NCT05410613|ACTIVE_COMPARATOR|conservative treatment for the ulcer|
62250212|NCT00768326|EXPERIMENTAL|Zicronapine. Study Part A|
62250213|NCT00768326|EXPERIMENTAL|Zicronapine. Study Part B|
62250214|NCT00768326|EXPERIMENTAL|Zicronapine. Study Part C|
62250215|NCT00768326|EXPERIMENTAL|Zicronapine. Study Part D|
62250216|NCT00768326|EXPERIMENTAL|Zicronapine. Study Part E|
62250217|NCT00768326|PLACEBO_COMPARATOR|2A, 2B, 2C, 2D, 2E|
62250218|NCT06464757||Children with laryngomalacia|
62250219|NCT06464757||Healthy children|
62250220|NCT05845658|ACTIVE_COMPARATOR|Active VeNS|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
62047874|NCT04417998|ACTIVE_COMPARATOR|Motion Correction|Aim 1 involves the prospective data collection of subjects who are already enrolled in Mayo Clinic Rochester research study 08-005553 (PI: Dr Val Lowe) and are scheduled to be scanned on the Siemens Biograph Vision 600 PET/CT system (hereafter referred to as the V600-R1) in the PET/CT Molecular Imaging Research Center on Charlton 6 of Mayo Clinic Rochester. The purpose of this arm is to evaluate the effectiveness of motion correction software.
62250221|NCT05845658|SHAM_COMPARATOR|Sham VeNS|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
62250222|NCT06429267|ACTIVE_COMPARATOR|Control Group (Receiving Metal Screws)|Patients that are randomly assigned to receive traditional, metal screws
62830017|NCT02386397|EXPERIMENTAL|Treatment|"Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment mGEMOX: infusion on days 1 and 8~* Gemcitabine 900 mg/m² IV in 30 minutes~* Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine"
62250223|NCT06429267|EXPERIMENTAL|Experimental Group (Receiving Bioabsorbable Screws)|Patients that are randomly assigned to receive Bioabsorbable screws
62250224|NCT02042651|EXPERIMENTAL|Low intensity extracorporeal shockwave therapy|Active treatment with low intensity extracorporeal shockwave therapy applied to the perineum.
62607820|NCT04312841|EXPERIMENTAL|Treatment (letermovir)|Beginning within 7 days of the first administration of standard alemtuzumab, patients receive letermovir PO (or IV over 1 hour if patient is unable to take PO for an extended period of time) daily on days 1-28. Cycles repeat every 28 days for up to 3 months after the last dose of alemtuzumab in the absence of unacceptable toxicity.
62830018|NCT02386397|OTHER|Standard treatment|"mGEMOX: infusion on days 1 and 8~* Gemcitabine 900 mg/m² IV in 30 minutes~* Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine"
62830019|NCT03580811|ACTIVE_COMPARATOR|Dental Implant & ADMG|Dental implant placed with simultaneous grafting using one layer of ADMG
62830020|NCT03580811|EXPERIMENTAL|Dental implant & ADMG & BDX|Dental implant placed plus simultaneous grafting using ADMG with BDX
62830021|NCT06654869|NO_INTERVENTION|Arm 2|
62250225|NCT02042651|SHAM_COMPARATOR|Sham low intensity extracorporeal shockwave therapy|Sham treatment with low intensity extracorporeal shockwave therapy applied to the perineum.
62250226|NCT02284620|EXPERIMENTAL|CFNB group|Particiants in this group will receive a single injection for femoral nerve block intra-operatively combined continuous femoral nerve block post-operatively. This technique will be guided by ultrasound and nerve stimulator.The regimen is a loading dose of 0.8% ropivacaine 30 ml intra-operatively and 0.15% ropivacaine 300ml in the form of continuous femoral nerve block post-operatively.
62250227|NCT02284620|ACTIVE_COMPARATOR|LWI group|Particiants in this group will receive a peri-articular injection of suspension (48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone) combined with intravenous patient controlled analgesia post-operatively (tramadol 800 mg and flurbiprofenaxetil 100 mg with saline added up to a volume of 80 ml )
62250228|NCT01806857|OTHER|Nuedexta then Matching Placebo|Subjects in this arm will receive treatment with Nuedexta first for 28 days (±3 days) and then crossed over to receive treatment with matching placebo for 28 days (±3 days).
62250229|NCT01806857|OTHER|Matching Placebo then Nuedexta|Subjects in this arm will receive treatment with matching placebo first for 28 days (±3 days) and then crossed over to receive treatment with Nuedexta for 28 days (±3 days).
62607821|NCT06731153|EXPERIMENTAL|Safety run-in|Ivarmacitinib + Camrelizumab + Eribulin
62607822|NCT06731153|EXPERIMENTAL|Treatment group|Ivarmacitinib + Camrelizumab + Eribulin, RP2D
62607823|NCT06731153|ACTIVE_COMPARATOR|Control group|Ivarmacitinib + Eribulin, RP2D
62607824|NCT03647605|EXPERIMENTAL|VR Mind|Two VR Mind sessions using experimental virtual reality scenarios. During these two sessions, participants will be exposed to virtual reality environment, for 2 x 10 min each session.
62830022|NCT06654869|EXPERIMENTAL|Arm 1|laughter yoga
62830023|NCT02775786|NO_INTERVENTION|Healthy Volunteers|Normal volunteers with no pancreas mass or risk factors for pancreas cancer will be recruited for MRI protocol optimization and nothing more. No intravenous contrast will be given. They will be asked to lie in the scanner for up to 1 hour and non-contrast imaging will be performed.
62830024|NCT02775786|EXPERIMENTAL|Pancreatic Mass or Risk Factors Group|Participants with pancreatic adenocarcinoma who are planning to undergo surgical resection. Participants will undergo up to two MRIs with and without intravenous contrast. The first MRI will be performed using an extracellular contrast agent and the second 1-14 days later, with a macromolecular contrast agent. If patient cannot undergo the second MRI for any reason eg. not enough time before surgery, one MRI with either contrast agent will still be used for analysis .
62830025|NCT06257433|EXPERIMENTAL|Motivation|Trials in which participants are motivated by hypothesis testing or not.
62830026|NCT05842616|EXPERIMENTAL|Transcranial doppler pulsatility index guided protocol|Norepinephrine titration that will be guided by Transcranial doppler (TCD) pulsatility index.
62830027|NCT05842616|ACTIVE_COMPARATOR|Mean arterial blood pressure guided protocol|Norepinephrine titration that will be guided by Mean arterial blood pressure (MAP).
62830028|NCT03171363|EXPERIMENTAL|Gaze-contingent feedback|Participants will receive gaze-contingent feedback according to their viewing patterns
62830029|NCT02392637|EXPERIMENTAL|Treatment (nab-paclitaxel, cisplatin, gemcitabine)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62830030|NCT03129568|EXPERIMENTAL|CDC infusion|CDCs infusion by coronary intervention.
62830031|NCT00091949|ACTIVE_COMPARATOR|Pioglitazone|pioglitazone
62830032|NCT00091949|PLACEBO_COMPARATOR|Placebo|inactive substance
62830033|NCT01437657|PLACEBO_COMPARATOR|Placebo|Matching RO4917523 placebo orally daily, 6 weeks
62830034|NCT01437657|EXPERIMENTAL|RO4917523 0.5 mg|0.5 mg orally daily, 6 weeks
62830035|NCT01437657|EXPERIMENTAL|RO4917523 1.5 mg|1.5 mg orally daily, 6 weeks
62830036|NCT05482997|NO_INTERVENTION|Control Group: Subjects with no protien intake|20 subjects will receive no intervention for 10 weeks but complete performance tests and assessments during weeks 0, 4, 6, and 10.
62607825|NCT00179205|ACTIVE_COMPARATOR|1|
62607826|NCT00179205|PLACEBO_COMPARATOR|2|
62607827|NCT06215755|EXPERIMENTAL|VRG50635|The study drug is VRG50635 200 mg oral capsules. VRG50635 will be administered as oral capsules once daily in the morning after a low-fat meal, approximately 30 minutes prior to VRG50635 administration. Following administration there is a 5 to 6-hour restriction period where participants should consume only low-fat food.
62250230|NCT01488279|ACTIVE_COMPARATOR|Dexamethasone 2.5mg and Sitagliptin100mg|Participants received Dexamethasone 2.5 mg plus Sitagliptin 100 mg daily for 8 days
62607828|NCT05414266|EXPERIMENTAL|4 months Placebo, then 8 months SADBE 5%|
62607829|NCT05414266|EXPERIMENTAL|12 months SADBE 5%|
62607830|NCT02539654|EXPERIMENTAL|EXE844|EXE844 Sterile Otic Suspension, 0.3%, single ototopical dose (4 drops) in each ear following tympanostomy tube insertion
62607831|NCT02949908||Rebif in Relapsing-Remitting Multiple Sclerosis (RRMS)|
62607832|NCT02241265||Past Bronchial Thermoplasty data|Data will be collected from records of patients who, in the past, have undergone bronchial thermoplasty.
62250231|NCT01488279|PLACEBO_COMPARATOR|Dexamethasone 2.5mg and placebo tablet|Participants received Dexamethasone 2.5 mg plus Sitagliptin-matched placebo tablet daily for 8 days.
62250232|NCT03811457|EXPERIMENTAL|Welgenaleucel (UWC19)|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage: 100mL in total Frequency:the first day, the second day, the third day Duration:total three times
62607833|NCT04076371|EXPERIMENTAL|olanzapine-sertraline combination|the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)
62607834|NCT04076371|PLACEBO_COMPARATOR|only olanzapine|the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)
62607835|NCT04076371|EXPERIMENTAL|risperidone-sertraline combination|the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)
62830037|NCT05482997|EXPERIMENTAL|Whey Protein, Then Plant-based Protein|"Performance tests/assessments will be conducted as baseline testing without whey protein, followed by four weeks of whey protein intervention consisting of one 70cc (32g) scoop of supplement provided within an hour after athletic practice, five days a week. For athletes with more than one practice a day, the supplement will be provided after the strength training session. The powder will be shaken with 8-12oz water. Performance measured at the end of 4 weeks.~After a two-week washout period, they will undergo another performance evaluation and begin the same protein supplement regimen, but with a 70cc (32g) scoop of the plant-based protein supplement."
62250233|NCT02767323|EXPERIMENTAL|Active or Sham rTMS over the DLPFC (Aim1a)|excitatory rTMS applied over the DLPFC (fMRI-guided). Active and Sham rTMS will be tested in a within subject design
62250234|NCT02767323|EXPERIMENTAL|Active or Sham rTMS over the Parietal cortex (Aim1b)|excitatory rTMS applied over the parietal cortex (fMRI-guided). Active and Sham rTMS will be tested in a within subject design
62250235|NCT02767323|EXPERIMENTAL|Active or Sham rTMS over the DLPFC and the Parietal cortex (Aim1c)|excitatory rTMS applied over the DLPFC and the parietal cortex (fMRI-guided). Active and Sham rTMS will be tested in a within subject design
62250236|NCT00962442|ACTIVE_COMPARATOR|nutritional support + N-Acétylcysteine|N-Acétylcysteine 300 mg/kg intravenously for 14 days Beside usual meals, patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days
62250237|NCT00962442|PLACEBO_COMPARATOR|nutritional support + placebo|placebo perfusion for 14 days Beside usual meals patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days
62250238|NCT02602912|EXPERIMENTAL|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is a spinal needle that has bioimpedance measurement capability.
62250239|NCT05024799|EXPERIMENTAL|F-P group|the combination of fentanyl and propofol
62607836|NCT04076371|PLACEBO_COMPARATOR|only risperidone|the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)
62607837|NCT04076371|EXPERIMENTAL|paliperidone-sertraline combination|the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)
62607838|NCT04076371|PLACEBO_COMPARATOR|only paliperidone|the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)
62607839|NCT04076371|EXPERIMENTAL|ziprasidone-sertraline combination|the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)
62607840|NCT04076371|PLACEBO_COMPARATOR|only ziprasidone|the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)
62607841|NCT06047600|NO_INTERVENTION|Control Group|The control group is based on the pre-existing organization, with no digital patient follow-up tools.
62250240|NCT05024799|EXPERIMENTAL|F-D group|the combination of fentanyl and dexmedetomidine
62250241|NCT05024799|EXPERIMENTAL|B-P group|the combination of butorphanol and propofol
62607842|NCT06047600|EXPERIMENTAL|Uroconnect Follow Up Group|"The UroConnect device has a patient interface for presenting self-questionnaires and access to a library of educational content and a caregiver interface to rationalize and optimize the nurse's activity of perioperative coordination in his task"
62607843|NCT05104879|EXPERIMENTAL|Biosketch Card|Patients within the experimental group received a biosketch card during rooming, pre-clinician encounter, and were not informed about their involvement. To blind the outcome measure, the research assistant did not explain the reason for the card upon rooming the patient nor did they inform the midlevel provider.
62607844|NCT05104879|NO_INTERVENTION|No Card|No bio sketch card was provided to these participants.
62607845|NCT02376296||hormone naïve|Subjects with hormone naïve metastatic prostate cancer that have high-volume disease and have been on androgen deprivation therapy for less than 120 days prior to starting docetaxel therapy.
62607846|NCT02376296||castrate resistant|Subjects with castrate resistant prostate cancer (CRPC) \[defined as having evidence of prostate specific antigen (PSA) progression despite androgen deprivation therapy\] that have had at least four weeks elapse between the withdrawal of anti-androgens (Bicalutamide, Flutamide or Nilutamide) and the initiation of docetaxel therapy.
62607847|NCT06373159||Sepsis patient cohort|Patients diagnosed with sepsis in patient inclusion period, regardless of etiology, including subgroups: sepsis with thrombocytopenia patient cohort and septic shock patient cohort
62607848|NCT06373159||Sepsis-associated DIC patient cohort|Sepsis patients with onset of DIC in the patient record in patient inclusion period
62607849|NCT06373159||Non-sepsis-associated DIC patient cohort|DIC patients without sepsis in patient inclusion period
62830038|NCT05482997|EXPERIMENTAL|Plant-based Protein, Then Whey Protein|"Performance tests/assessments will be conducted as baseline testing without plant-based protein, followed by four weeks of plant-based protein intervention consisting of one 70cc (32g) scoop of supplement provided within an hour after athletic practice, five days a week, for four weeks. For athletes with more than one practice a day, the supplement will be provided after the strength training session. The powder will be shaken with 8-12oz water. Performance measured at the end of 4 weeks.~After a two-week washout period, they will undergo another performance evaluation and begin the same protein supplement regimen, but with a 70cc (32g) scoop of the whey protein supplement."
62047875|NCT04417998|ACTIVE_COMPARATOR|Parametric Imaging|Aim 2 involves the prospective data collection of subjects undergoing brain or whole body oncologic PET/CT scans on the V600-R1. The purpose of this arm is to evaluate the data acquisition and image processing workflow.
62250242|NCT05024799|EXPERIMENTAL|B-D group|the combination of butorphanol and dexmedetomidine
62047876|NCT00077064|NO_INTERVENTION|Observation|Clinical observation
62047877|NCT00077064|EXPERIMENTAL|Captopril|Captopril
62047878|NCT00708240|EXPERIMENTAL|Escitalopram|
62250243|NCT02675842|ACTIVE_COMPARATOR|Smoked Cannabis High CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
62250244|NCT02675842|PLACEBO_COMPARATOR|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
62607850|NCT04609241|EXPERIMENTAL|Administration of CD79b CAR-T Cell|
62607851|NCT05470075|EXPERIMENTAL|Experimental A: HR18042 175mg|
62607852|NCT05470075|EXPERIMENTAL|Experimental B: HR18042 225mg|
62607853|NCT05470075|EXPERIMENTAL|Experimental C: HR18042 275mg|
62607854|NCT05470075|ACTIVE_COMPARATOR|Active Drug Comparator：Tramadol hydrochloride SR Tablets 100mg|
62830039|NCT04493008|OTHER|MIU students and patents|Educational session
62047879|NCT04826601|EXPERIMENTAL|Experimental|
62250245|NCT03600064|OTHER|Misoprostol group|
62250246|NCT03600064|NO_INTERVENTION|NO intervention|
62250247|NCT03926754|ACTIVE_COMPARATOR|Mirabegron|Active treatment arm (mirabegron)
62250248|NCT03926754|PLACEBO_COMPARATOR|Placebo|Placebo
62250249|NCT06209008|EXPERIMENTAL|Intravesical PRP injection|Patients will receive 20 submucosal injections of PRP solution, each injection site receives 0.5 mL PRP. The injection needle will be inserted about 1 mm into the at the posterior and lateral walls of the bladder, using a 23 gauge needle and 22 F rigid cystoscope.
62607855|NCT05470075|PLACEBO_COMPARATOR|Placebo Comparator: Placebos match to HR18042 and Tramadol hydrochloride SR Tablets|
62607856|NCT00849134|PLACEBO_COMPARATOR|Cohort 1,2 & 3|This part of the study will start with a very low dose of study drug, which will then be gradually increased in subsequent doses. This is known as dose-rising and is the way to assess safety and tolerability (i.e. possible presence of any side effects that make taking the drug unpleasant) of increasing the study drug. Effects will be compared to those seen when a placebo is taken. Up to 3 groups of 8 healthy male and female volunteers may be enrolled.
62607857|NCT00849134|ACTIVE_COMPARATOR|Cohort 4|If an investigation of food effect is not possible in Cohorts 2 or 3, this Cohort will be used to check if there is a difference in the blood levels of the study drug when taken with or without a high fat meal.
62607858|NCT02683148|EXPERIMENTAL|Arm 1: DHEA Dose Level 1|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
62047880|NCT05064852||Surufatinib|Patients with BTC visited the site from 2021 to 2023 and received Surufatinib therapy.
62047881|NCT02520167|EXPERIMENTAL|Dietary and Lifestyle Counseling|Women randomized to the intervention group will meet with a dietary counselor for 15 minutes at every prenatal appointment. They will receive a dietary and lifestyle curriculum based on the Diabetes Prevention Program curriculum (11 lessons) with one additional lesson providing prenatal breastfeeding education. They will also have access to a private online Facebook page for additional education and peer group support.
62607859|NCT02683148|EXPERIMENTAL|Arm 2: DHEA Dose Level 2|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
62047882|NCT02520167|NO_INTERVENTION|Standard of Care|Usual prenatal care consists of regular clinical appointments, pregnancy ultrasounds, and recommendations to use prenatal multivitamins, eat a balanced diet, and remain physically active. Women with a pre-pregnant body mass index \> 30 complete early glucose screening (as early as possible after presentation at the clinic) to detect pre-existing diabetes, and all women undergo routine gestational diabetes screening at 24-28 weeks. Women who test positive for pre-existing diabetes or gestational diabetes are referred to a registered dietitian.
62047883|NCT03286374|OTHER|Occupational rehabilitation|The participants will receive the current occupational rehabilitation program at Muritunet.
62047884|NCT06282679|EXPERIMENTAL|left cheek and right cheek|"First, apply an appropriate amount of lidocaine cream to your face and wait (30-45 minutes) for the anesthetic to take effect;~Second step, after cleaning, mark the injection site on your face, about 25-30 points on one cheek, 1 cm apart, using a randomized half face control trial, Use of botulinum toxin type A for injection (Botox) (Allergan Pharmaceticals Ireland Limited, Import Drug Registration No. : S20171003), 0.5U botulinum toxin type A (Botox) was injected per point on one cheek and 1U on the other. The total amount of botulinum toxin type A was between 15 and 30U on each side."
62047885|NCT01187979|ACTIVE_COMPARATOR|Control|All eligibly enrolled learners in the intervention schools will receive a prevention program delivered by MIET Africa and the KwaZulu-Natal Department of Education. No cash incentives will be paid for meeting milestones
62047886|NCT01187979|EXPERIMENTAL|Cash incentive|All eligibly enrolled learners in the intervention schools will receive a cash incentivised prevention program delivered by MIET Africa and the KwaZulu-Natal Department of Education
62607860|NCT02683148|EXPERIMENTAL|Arm 3: DHEA Dose Level 3|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
62607861|NCT02683148|EXPERIMENTAL|Arm 4: DHEA Phase II|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
62047887|NCT01430260|EXPERIMENTAL|ciclesonide nasal spray|ciclesonide nasal spray, alone
62047888|NCT01430260|ACTIVE_COMPARATOR|Levocetirizine|Levocetirizine, alone
62047889|NCT01430260|ACTIVE_COMPARATOR|Ciclesonide nasal spray & Levocetirizine|Ciclesonide nasal spray \& Levocetirizine in combination
62047890|NCT04419090|EXPERIMENTAL|Monogenic positive FH, direct contact|
62047891|NCT04419090|NO_INTERVENTION|Monogenic positive FH, usual care|
62250250|NCT02421068||Preterm neonates|All neonates that receive at least one of the 9 drugs (phenobarbital, paracetamol, levetiracetam, midazolam, sildenafil, fentanyl, doxapram, ibuprofen, fluconazole) are included in the studied cohort
62250251|NCT02419326|EXPERIMENTAL|Couples|The patient and their significant other receive psychotherapy treatment for the patient's BED.
62250252|NCT04541290|EXPERIMENTAL|Treatment|Women with stage 1-2 lymphedema due to breast cancer treatment
62250253|NCT01671813|EXPERIMENTAL|Brentuximab vedotin Treatment|Participants will have screening tests up to 4 weeks before study treatment and dosing for up to 48 weeks. Brentuximab vedotin will be given with a dose of 1.8 mg (per kilogram of participant's body weight) intravenously (an IV through their vein) every 21 days, over 30 minutes for 16 cycles. Follow-up assessments will be performed up to 104 weeks (2 years).
62607862|NCT03956342||Pediatric Clinicians - Group 1|"Pediatric clinical care clinicians who work with patients who are sedated for diagnostic or therapeutic procedures. May included, MDs, DOs, PharmDs, Nurse Practitioners, or nurses with a BSN or higher level nursing degree.~This cohort will complete a first round of interviews to assess measure content."
62607863|NCT03956342||Pediatric Clinicians - Group 2|"Pediatric clinical care clinicians who work with patients who are sedated for diagnostic or therapeutic procedures. May included, MDs, DOs, PharmDs, Nurse Practitioners, or nurses with a BSN or higher level nursing degree.~This smaller cohort will be a randomized subset of the original cohort and will complete interviews to assess changes made based on the feedback from the first cohort."
62607864|NCT04724577|EXPERIMENTAL|Carbon ion treatment|dose escalation study with five dose levels \[54GGyE(Gray equivalent)/12Fx,55.2GyE/12Fx,56.4GyE/12Fx,57.6GyE/12Fx and 58.8GyE/12Fx \].
62607865|NCT01523015|EXPERIMENTAL|Combined therapy|The combined modality therapy will be consisted of preoperative chemoradiotherapy (Docetaxel, Oxaliplatin, 5-Fluorouracil, 45Gy) for type I i II cancer or preoperative chemotherapy (Docetaxel, Oxaliplatin, 5-Fluorouracil) for type III cancer and followed by surgery.
62830040|NCT01502826||Group A|less insulin-resistant
62830041|NCT01502826||Group B|severely insulin-resistant
62047892|NCT04419090|EXPERIMENTAL|Monogenic negative FH, direct contact|
62047893|NCT04419090|NO_INTERVENTION|Monogenic negative FH, usual care|
62047894|NCT04621110|EXPERIMENTAL|intranasal dexmedetomidine and fentanyl|Dexmedetomidine (precedex®) and fentanyl will be administered by intranasal routes, seeing if both sedative (dexmedetomidine) and analgesic (fentanyl) can give enough sedation for procedure
62047895|NCT04621110|ACTIVE_COMPARATOR|intravenous ketamine and midazolam|ketamine (ketalar®) and midazolam intravenous will be using to compare the efficiency of intranasal drugs
62047896|NCT04861857|EXPERIMENTAL|Parmigiano Reggiano|participants will consume 50 g/die of the dietary supplement and undergo to eccentric exercise training 3 times/week
62047897|NCT04861857|ACTIVE_COMPARATOR|Whey Protein|participants will consume 20 g/die of the dietary supplement and undergo to eccentric exercise training 3 times/week
62047898|NCT03450902|EXPERIMENTAL|Chinese herb & acupuncture|Participants will take Yiqi Suoquan granule and receive acupuncture.
62047899|NCT03450902|ACTIVE_COMPARATOR|Chinese herb & sham acupuncture|Participants will take Yiqi Suoquan granule and receive sham acupuncture.
62439928|NCT03239275|EXPERIMENTAL|Labial biocreative therapy group|"Upper six anterior teeth will be bonded (0.018-inch slot brackets), leveled and aligned until reaching 0.017\*0.025 stainless steel archwire.~Right and left bracket head mini-screw (1.6\*8 mm) will be inserted under local anaesthetic into the inter-radicular space between upper second premolar and first molar at the level of mucogingival junction. Crimpable hooks (10 mm) will be crimped onto the archwire between the upper lateral incisor and canine. 200 grams retraction force will be applied using NiTi coil springs from the hooks to the minscrew on both sides. Overlay reverse curve 0.016\*0.022 NiTi will be inserted posteriorly into the mini-screw and ligated anteriorly to the archwire in the midline."
62439929|NCT03239275|ACTIVE_COMPARATOR|Lingual biocreative therapy group|En masse retraction of the six anterior teeth was accomplished using a lingual retractor bonded on to the lingual surface of the 6 anterior teeth, C-palatal plate fixed near the median palatal suture with 3 micro-screws, and Nickel Titanium (Ni-Ti) closing coil springs to apply a force of 200 g per side (total 400 g) directly from the C-plate to the lingual retractor.
62439930|NCT05127382||untreated patients with advanced EGFR positive non-small cell lung cancer|
62439931|NCT03830047|ACTIVE_COMPARATOR|nd yag laser|Applying nd yag laser to vulva
62439932|NCT03830047|SHAM_COMPARATOR|Co2 laser|Applying CO2 laser to vulva
62439933|NCT00359229|EXPERIMENTAL|1|For 3 weeks
62439934|NCT05433337|OTHER|Digital Acceptance and Commitment Therapy (ACT) Arm|
62439935|NCT04652921|EXPERIMENTAL|Creatine-guanidinoacetic acid|2 grams of creatine and 2 grams of GAA Administered one dose two times per day on an empty stomach in the morning and at the evening
62439936|NCT04652921|PLACEBO_COMPARATOR|Inulin|4 grams of inulin Administered one dose two times per day on an empty stomach in the morning and at the evening
62439937|NCT03091530|EXPERIMENTAL|Sleeper Stretch THEN Balloon Blow|Sleeper Stretch CROSSOVER TO 90/90 Hip Lift with Balloon Blow Exercise
62439938|NCT03091530|EXPERIMENTAL|Balloon Blow THEN Sleeper Stretch|90/90 Hip Lift with Balloon Blow Exercise CROSSOVER TO Sleeper Stretch
62439939|NCT03607630|NO_INTERVENTION|Waiting Pre-Intervention Control|Participant completes measures for 1-3 weeks (randomly chosen) before they complete the intervention. Participants act as their own controls
62439940|NCT03607630|EXPERIMENTAL|Imagery Rescripting|3 Sessions of Imagery Rescripting
62439941|NCT05085054|EXPERIMENTAL|targeted therapy+salvage surgery|"Participants treated with targeted therapy without progression and radiological confirmation of tumor downstaging (≤stage IIIA) by PET-CT followed by salvage surgery were enrolled into the group of targeted therapy plus salvage surgery.~The molecular targeted agents used in our study included osimertinib (80 mg, once a day) . Salvage surgery was defined as surgical intervention based on standard operation (lobectomy plus lymphadenectomy) of NSCLC for advanced patients who initially had no surgical indications, but achieved significant downstaging (≤stage IIIA) without progression after targeted therapy.~Targeted therapy was continued after salvage surgery until progression."
62439942|NCT03136783|OTHER|Patient with stage IV melanoma|
62439943|NCT01247896|EXPERIMENTAL|Active|
62439944|NCT01247896|PLACEBO_COMPARATOR|Placebo|
62439945|NCT05330845|OTHER|Patients with COVID-19 acute respiratory distress syndrome|Patients with acute respiratory distress syndrome due to COVID-19 and requiring mechanical ventilation
62439946|NCT01166854||Muscle weakness|Diffuse Optical Spectroscopy
62439947|NCT04221555|EXPERIMENTAL|the main treatment group|pMMR tumor
62439948|NCT04221555|ACTIVE_COMPARATOR|the exploratory group|dMMR tumor
62439949|NCT00947856|EXPERIMENTAL|BV Retreatment|Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (retreatment after relapse)
62439950|NCT00947856|EXPERIMENTAL|BV Extension|Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (continued treatment)
62439951|NCT05994781|NO_INTERVENTION|No treatment|The control group is a non-treatment group, and for 3 months after the procedure, general moisturizers that have been used or will be used are available.
62439952|NCT05994781|EXPERIMENTAL|Treatment|In the case of the study group among the subjects of the clinical study, The experimental group apply an appropriate amount of EasyDew MD Regen Cream twice a day (morning and evening) and can be absorbed well.
62439953|NCT03745625|EXPERIMENTAL|HSK3486|First-stage: 1mg/kg/h, 0.4mg/kg/h; Second-stage:Single loading dose: 0.2mg/kg, maintenance dose: 0.35mg/kg/h,
62439954|NCT03745625|ACTIVE_COMPARATOR|Propofol|First-stage: 5mg/kg/h, 2mg/kg/h; Second-stage:Single load ing dose: 1mg/kg, maintenance dose: 1.75mg/kg/h
62439955|NCT01898910|ACTIVE_COMPARATOR|PVI+renal denervation+OMT|
62439956|NCT01898910|ACTIVE_COMPARATOR|PVI+GP ablation+OMT|
62439957|NCT00006031|ACTIVE_COMPARATOR|I: Radioactive Seed Localized Breast Biopsy|Arm I: Patients undergo radiographic placement of a radioactive seed (either iodine I 125 or palladium Pd 103) into the suspicious lesion. Patients then undergo surgery to remove the lesion along with the seed and a small margin of surrounding breast tissue followed 3 months later by a postoperative mammogram.
62439958|NCT00006031|ACTIVE_COMPARATOR|Arm II: Needle Localized Breast Biopsy|Arm II: Patients undergo a needle localized breast biopsy with a specimen x-ray.
62439959|NCT05660083|EXPERIMENTAL|iNOS inhibitor and nab-paclitaxel in combination with alpelisib.|iNOS inhibitor and nab-paclitaxel in combination with alpelisib in patients with HER2 negative, metastatic or locally advanced MpBC.
62830042|NCT01820338|EXPERIMENTAL|Behavioral Family Intervention|Child and Parent attend intervention including nutrition and physical activity education, plus behavioral strategies to facilitate behavior and weight status change
62830043|NCT01820338|EXPERIMENTAL|Behavioral Parent-Only Intervention|Only parents attend intervention including nutrition and physical activity education, plus behavioral strategies to facilitate behavior and weight status change
62047900|NCT03450902|ACTIVE_COMPARATOR|Placebo & acupuncture|Participants will take placebo granule and receive acupuncture.
62047901|NCT03450902|PLACEBO_COMPARATOR|Placebo & sham acupuncture|Participants will take placebo granule and receive sham acupuncture.
62047902|NCT03298451|EXPERIMENTAL|Arm 1|Durvalumab
62047903|NCT03298451|EXPERIMENTAL|Arm 2|Durvalumab in combination with tremelimumab (Regimen 1)
62439960|NCT02826603|EXPERIMENTAL|Secukinumab|Secukinumab
62830044|NCT01820338|ACTIVE_COMPARATOR|Education Control|Child and parent attend intervention that includes only nutrition and physical activity education; no instruction or assistance in the use of behavioral strategies are included in this condition
62830045|NCT03632850||Doctors|This is a group of oncologists who have experience in treatment deliberations with patients of advanced cancer.
62047904|NCT03298451|EXPERIMENTAL|Arm 3|Durvalumab in combination with tremelimumab (Regimen 2)
62047905|NCT03298451|ACTIVE_COMPARATOR|Arm 4|Sorafenib
62047906|NCT00765349||All patients undergoing major surgery|
62439961|NCT02826603|ACTIVE_COMPARATOR|Ustekinumab|Ustekinumab
62047907|NCT03182335||Mechanical Ventilation (MV) with vasoactive infusions|adult ICU patients who are mechanically ventilated with sedative infusion and/or analgesic infusion and also requiring vasoactive drug infusions for the treatment of shock. Patients will be excluded if receiving dexmedetomidine as sedative.
62047908|NCT05437081|EXPERIMENTAL|EMERGE program|Participants were randomly assigned to one of two conditions: intervention or control. Intervention participants engaged in a 4 session program named the EMERGE program focused on identity development (emerging adults) or support for emerging adults (parents). Control participants received referrals to community agencies for behavioral and mental health support as needed.
62047909|NCT05437081|NO_INTERVENTION|Referral services as needed|Participants were randomly assigned to one of two conditions: intervention or control. Control participants received services as usual.
62047910|NCT05608850|OTHER|Exercise Then Stretch|Participants in AB will perform the experimental (exercise) intervention first and the control (stretch) intervention second
62830046|NCT03632850||Nurses|This is a group of clinical nurse specialists who have experience in treatment deliberations with patients of advanced cancer
62830047|NCT03632850||Patients|this is a group of adult patients who have been diagnosed with advanced pancreatic cancer
62047911|NCT05608850|OTHER|Stretch Then Exercise|Participants in BA will perform the experimental (exercise) intervention second and the control (stretch) intervention first
62047912|NCT00541450|EXPERIMENTAL|Sita/Met FDC|"In Phase A (Treatment Day 1 to Week 12), participants were administered 100 mg once daily (q.d.) of sitagliptin and matching placebo to 15 mg pioglitazone q.d. for 6 weeks followed by matching placebo to 30 mg pioglitazone for the next 6 weeks.~In Phase B (Treatment Week 12-Week 40), participants were switched to the Sita/Met Fixed-Dose Combination (FDC) at a dose of 50/500 mg twice a day (b.i.d.), which was increased to 50/1000 mg b.i.d. over a period of 4 weeks; as well as matching placebo to 45 mg pioglitazone."
62047913|NCT00541450|ACTIVE_COMPARATOR|Pioglitazone|"In Phase A (Treatment Day 1 up to Week 12), randomized participants in the pioglitazone group were administered 15 mg q.d. of pioglitazone and matching placebo to sitagliptin. At Week 6, participants were up-titrated to 30 mg pioglitazone q.d.~In Phase B (Treatment Week 12 to Week 40), participants were administered 45 mg pioglitazone q.d.; as well as matching placebo to Sita/Met FDC (50/500 increased to 50/1000 b.i.d. after 4 weeks)."
62250254|NCT01740960|ACTIVE_COMPARATOR|delta-9-tetrahydrocannabinol|Subjects will be randomized to receive 3 doses Namisol® (3 mg, 5 mg, 6,5 mg)
62439962|NCT03421652|EXPERIMENTAL|Treatment (nivolumab, radiation therapy)|Given IV
62047914|NCT05263466|EXPERIMENTAL|Brain tumour patients|Patients will be those undergoing routine care of primary brain tumours. Study group patients will undergo additional PET-MRI examination and biopsies in addition to the standard of care.
62047915|NCT04355351|OTHER|hospital staff exposed to SARS-Cov-2|
62047916|NCT04355351|OTHER|SARS-Cov-2 infected patient|
62439963|NCT01977326|EXPERIMENTAL|counseling intervention|Each woman recruited into the intervention arm will undergo 6 sessions of basic counselling by lay-health workers
62439964|NCT01977326|ACTIVE_COMPARATOR|Enhanced usual care|usual antenatal care with additional 3 - 4 monthly phone calls.
62830048|NCT03632850||Relatives|this is a group of adults who are involved in providing support for their loved ones who are diagnosed with advanced pancreatic cancer
62830049|NCT03525678|EXPERIMENTAL|Participants receiving frozen 2.5 mg/kg belantamab mafodotin|Participants will receive 2.5 mg/kg frozen liquid belantamab mafodotin. Participants will be administered with frozen liquid belantamab mafodotin via infusion pump every 3 weeks.
62830050|NCT03525678|EXPERIMENTAL|Participants receiving frozen 3.4 mg/kg belantamab mafodotin|Participants will receive 3.4 mg/kg frozen liquid belantamab mafodotin. Participants will be administered with frozen liquid belantamab mafodotin via infusion pump every 3 weeks.
62830051|NCT03525678|EXPERIMENTAL|Participants receiving lyophilized belantamab mafodotin|Participants in lyophilized arm will receive lyophilized belantamab mafodotin once lyophilized configuration becomes available and enrollment has been completed for frozen liquid arms.
62830052|NCT01224145|EXPERIMENTAL|Drug: Bupivacaine Collagen Sponge|bupivacaine collagen sponges
62830053|NCT05519982|EXPERIMENTAL|Sleep Treatment Education Program (STEP-1)|"Prior to being randomized, all participants will complete health questionnaires.~Participants assigned to the Sleep Treatment Education Program (STEP-1) group will receive online instruction on making changes to sleep habits and health behaviors.~Participants will be contacted at 1 month and 2 months after the education session to complete follow up online questionnaires."
62830054|NCT05519982|ACTIVE_COMPARATOR|Enhanced Usual Care: Relaxation Education|"Prior to being randomized, all participants will complete health questionnaires.~Participants assigned to the Enhanced Usual Care group will receive information on relaxation techniques to improve sleep~Participants will be contacted at 1 month and 2 months after the education session to complete follow up online questionnaires."
62830055|NCT06591195|EXPERIMENTAL|Distraction|The intervention group will undergo a dressing change procedure with distraction by use of a kaleidoscope as additional method for pain alleviation. In both groups, patients will receive paracetamol or non-steroidal anti-inflammatory drugs when required according to hospital protocol.
62250255|NCT01740960|PLACEBO_COMPARATOR|Placebo|The control product is placebo, consisting of a tablet with similar appearance and taste of the test product.
62439965|NCT02684695||Group A|Patients with enthesitis-related arthritis
62439966|NCT02684695||Group B|Patients with other forms of juvenile idiopathic arthritis (extended oligoarticular JIA and polyarticular JIA)
62439967|NCT05102799||Anoctaminopathies|Anoctaminopathies including Limb Girdle Muscular Dystrophy R12, Miyoshi distal Muscular Dystrophy type 3 and asymptomatic hyperCKemia
62439968|NCT05092711||in patients with coronary heart disease and COVID 19|
62439969|NCT03602898|EXPERIMENTAL|Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive anti-thymocyte globulin IV over 4-6 hours on days -3 to -1. Beginning day -1, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease progression or unacceptable toxicity.
62830056|NCT06591195|NO_INTERVENTION|Control|The control group will undergo the standard dressing change procedure without additional distraction methods. In both groups, patients will receive paracetamol or non-steroidal anti-inflammatory drugs when required according to hospital protocol.
62830057|NCT03208946|EXPERIMENTAL|High-CML diet|An isocaloric, high-CML content diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat.
62830058|NCT03208946|SHAM_COMPARATOR|Low-CML diet|An isocaloric, low-CML content diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat.
62830059|NCT04833582|EXPERIMENTAL|Combination ZN-c3 with Gemcitabine|
62830060|NCT03980080|EXPERIMENTAL|OSE-127: Part 1 (SAD), Cohort A & Cohort B|
62830061|NCT03980080|PLACEBO_COMPARATOR|Placebo: Part 1 (SAD), Cohort A & Cohort B|
62830062|NCT03980080|EXPERIMENTAL|OSE-127: Part 2 (MAD)|
62830063|NCT03980080|PLACEBO_COMPARATOR|Placebo: Part 2 (MAD)|
62830064|NCT03737929|EXPERIMENTAL|Hybrid ablation procedure|In the hybrid ablation procedure, the epicardial surgical ablation procedure will be combined with percutaneous endocardial catheter ablation procedure in a single step procedure.
62830065|NCT03737929|ACTIVE_COMPARATOR|Percutaneous endocardial catheter ablation procedure|In the percutaneous catheter ablation arm, the procedure will be performed according to the current guidelines (pulmonary vein isolation, linear ablation and fragmented potentials ablation if needed, with the achievement of sinus rhythm during the procedure being the optimal endpoint).
62830066|NCT00174187|EXPERIMENTAL|Somatropin|
62830067|NCT00860093|EXPERIMENTAL|1|MPC-5971
62830068|NCT00860093|PLACEBO_COMPARATOR|2|placebo identical in appearance to study drug
62830069|NCT03833505||Group 1,|E. vermicularis-positive
62830070|NCT03833505||Group 2|E. vermicularis-negative
62250256|NCT00029913||1|Observation of participants includes a physical exam and collection of fluids. Study visits occur at Days 0, 7, 14, 28 and at Months 2, 3, 6 and every 6 months thereafter.
62439970|NCT03602898|EXPERIMENTAL|Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning day 5, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50 in the absence of disease progression or unacceptable toxicity.
62439971|NCT03602898|EXPERIMENTAL|Arm 3 (tacrolimus or cyclosporine, methotrexate)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Beginning day -1, participants receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11.
62439972|NCT02269202|EXPERIMENTAL|Midazolam and crobenetine|
62439973|NCT02269202|PLACEBO_COMPARATOR|Midazolam and placebo|
62439974|NCT03032497|EXPERIMENTAL|EEG-based BCI analysis of fear avoidance|"All participants complete two experiments one after another-EEG patterns, skin conductance and pulse rate are recorded. The EEG cap is mounted on the participant's head, the GSR sensor secured on the fingers and the PPG sensor secured on the wrist using a Velcro strap. Exp 1-participants watch a series of 15, 1 min videos of people doing daily activities. Exp 2-participants do 15 movements (15 reps each in 1 min) as guided by a physiotherapist. 2 identical buzzers (labelled lesser pain and more pain) are available to press accordingly should participants experience 'lesser' or 'more' pain any time during the experiment. If 'more' pain experienced, participants' condition will be assessed and they can choose to continue the experiment at a lower intensity or stop."
62439975|NCT02911389|ACTIVE_COMPARATOR|Home PT via web-based platform|unsupervised, home rehabilitation delivered by a web-based platform
62830071|NCT05247671||Case|All eligible patients will be recruited to the study and will be assessed for SNPs in both ERCC1 and OCT2 and their association with cisplatin-induced nephrotoxicity through the measurement of cystatin C before taking cisplatin and after receiving the second cycle of cisplatin.
62830072|NCT06654609|EXPERIMENTAL|Insoles for Foot|
62830073|NCT00671736|EXPERIMENTAL|1|daily inhalation
62047917|NCT04073602|EXPERIMENTAL|RC48-ADC|Participants will be treated with RC48-ADC 2.0 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
62439976|NCT02911389|ACTIVE_COMPARATOR|Home PT via paper manual|unsupervised, home rehabilitation delivered by a paper manual
62439977|NCT02911389|ACTIVE_COMPARATOR|outpatient PT|outpatient physical therapy
62439978|NCT05448703||Group 1|Lung cancer patients treated with thoracic radiotherapy
62439979|NCT06324253|ACTIVE_COMPARATOR|Erector Spinae Block|after induction of anesthesia bilateral US ESP block will be performed in the left lateral decubitus position under strict aseptic precautions. linear ultrasound transducer will be placed in a sterile cover, and positioned on the midline to identify the T10 spinous process. From this position, the ultrasound transducer will be moved 2-3 cm laterally to visualise the hyperechoic line of the T10 transverse process with its associated acoustic shadow inferiorly, and the overlying erector spinae muscle superiorly. Using in-plane approach a needle will be inserted in caudal-cephalad direction, until the tip is contact with the T10 transverse process and will be in the interfacial plane deep to the erector spinae muscle group and A dose of 30 ml 0.125% Bupivacaine will be injected bilateral in this plane . All patients will receive 1g intravenous paracetamol and 4 grams ondansetron 8mg dexamethasone
62830074|NCT00671736|EXPERIMENTAL|2|inhalation every other day
62830075|NCT00671736|EXPERIMENTAL|3|inhalation twice a week
62047918|NCT00464815|EXPERIMENTAL|Group A|Subjects of 11-17 years of age who will receive GSK134612
62047919|NCT00464815|ACTIVE_COMPARATOR|Group B|Subjects of 11-17 years of age who will receive MencevaxTM ACWY
62607866|NCT01523015|ACTIVE_COMPARATOR|Surgery|The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
62607867|NCT00908427|ACTIVE_COMPARATOR|1|PVP group
62607868|NCT00908427|ACTIVE_COMPARATOR|2|TURP group
62047920|NCT03081390|EXPERIMENTAL|No migraine, normal weight|"* Mixed meal tolerance testing~* Skin conductance \& cold pressor test~* Flow-mediated dilation testing"
62047921|NCT03081390|EXPERIMENTAL|No migraine, obese|"* Mixed meal tolerance testing~* Skin conductance \& cold pressor test~* Flow-mediated dilation testing"
62047922|NCT03081390|EXPERIMENTAL|Migraine, normal weight|"* Mixed meal tolerance testing~* Skin conductance \& cold pressor test~* Flow-mediated dilation testing"
62830076|NCT00671736|PLACEBO_COMPARATOR|4|daily inhalation
62830077|NCT05910996||Conversion from vv-ECMO to va-ECMO Positive|
62830078|NCT05910996||Conversion from vv-ECMO to va-ECMO Negative|
62830079|NCT05410210|EXPERIMENTAL|Pharmaceutical care|The intervention group will receive the pharmaceutical care from a pharmacist and the existing standard care available in the Parkinson's disease and movement disorders clinic.
62830080|NCT05410210|NO_INTERVENTION|Usual care|The usual care includes the current existing care provided to patients in the Parkinson's disease and movement disorders clinic except the pharmaceutical care provided by pharmacists.
62830081|NCT01625299|EXPERIMENTAL|Gluten and Milk group|Subject on a gluten and dairy free diet will receive supplement of gluten and dry milk daily
62830082|NCT01625299|PLACEBO_COMPARATOR|Rice flour|Subjects will be on a gluten and dairy free diet and receive daily supplement of rice flour (placebo)
62439980|NCT06324253|ACTIVE_COMPARATOR|Thoracic Epidural Block|"before induction of anesthesia under strict aseptic precautions, 18Gauge Tuohy's needle with Huber's tip will be inserted via median approach after local infiltration with 5 ml of 2% lignocaine at the level of T9-T10 or T10-T11 intervertebral space in the sitting position. After identifying epidural space using loss of resistance technique, 5 ml of saline will be administered after negative aspiration for blood or cerebrospinal fluid and 20Gauge epidural catheter will be threaded 5 cm cranially.~the patients in group B will be administered with a bolus dose of 10 ml of 0.125% bupivacaine through epidural catheter followed by continuous infusion of 0.125% bupivacaine at the rate of 0.1 ml/kg/hour All patients will receive 1g intravenous paracetamol and 4 grams ondansetron 8mg dexamethasone"
62439981|NCT04110275|EXPERIMENTAL|low dose group|"Recombinant human tissue-type plasminogen activator derivative(rPA) for injection: 18 mg, Intravenous injection for 2 minutes or more.~A separate venous access should be used for bolus injection,a common venous access shared with other drugs is not allowed for injection. And no other drugs mixed with test drug during the injection."
62439982|NCT04110275|EXPERIMENTAL|high dose group|"Recombinant human tissue-type plasminogen activator derivative (rPA) for injection: the first injection of 18 mg rPA is pushed slowly for 2 minutes or more,the second injection of 9mg rtPA is pushed for 1 minute or more.The interval between the two injections should be controlled accurately about 30 minutes.~A separate venous access should be used for bolus injection,a common venous access shared with other drugs is not allowed for injection. And no other drugs mixed with test drug during the injection."
62607869|NCT05610800|ACTIVE_COMPARATOR|Exenatide, NRT, and Smoking Cessation Counseling|Participants will receive once weekly exenatide injections, daily nicotine patches (NRT), and once weekly individual smoking cessation counseling sessions.
62607870|NCT05610800|PLACEBO_COMPARATOR|Placebo, NRT, and Smoking Cessation Counseling|Participants will receive once weekly saline injections, daily nicotine patches (NRT), and once weekly individual smoking cessation counseling sessions.
62607871|NCT01021488|EXPERIMENTAL|Experimental: Rosuvastatin + enoxaparin arm|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
62607872|NCT01021488|ACTIVE_COMPARATOR|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
62830083|NCT06417424|EXPERIMENTAL|experimental group 1|Received both gastrointestinal external stimulation and transcutaneouselectrical acupoint stimulation for 3 days, and then oral administration of polyethylene glycol for intestinal cleansing.
62439983|NCT04110275|ACTIVE_COMPARATOR|comparative group|Recombinant tissue plasminogen activator for injection: continuous intravenous injection for 2 hours.
62439984|NCT00669955|ACTIVE_COMPARATOR|OAC 7 days|Triple therapy, given for 7 days at a dose of omeprazole 20 mg twice daily, amoxicillin 500 mg 2 capsules twice daily, and clarithromycin 500 mg 1 tablet twice daily
62439985|NCT00669955|EXPERIMENTAL|OBMT 10 days|OBMT (Pylera), consisting of a 3 in 1 capsule, made of bismuth subcitrate potassium 120 mg, metronidazole 125 mg, and tetracycline 125 mg, administered as 3 capsules 4 times daily. Omeprazole 20 mg is administered twice daily.
62439986|NCT02100956|EXPERIMENTAL|Oxytocin, then Placebo|The subject first received oxytocin 100 micrograms administered intrathecally (IT). After at least one week, they received normal saline placebo IT.
62439987|NCT02100956|EXPERIMENTAL|Placebo, then Oxytocin|The subject first received normal saline placebo intrathecally (IT). After at least one week, they then received oxytocin 100 micrograms administered IT.
62439988|NCT04194905|EXPERIMENTAL|Levonorgestrel Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg. The tablets will be taken with water and in a fasting condition.
62607873|NCT04308915|EXPERIMENTAL|Game-based training|Participants play games for cognitive training
62830084|NCT06417424|EXPERIMENTAL|experimental group 2|Received gastrointestinal external stimulation singly, and then oral administration of polyethylene glycol for intestinal cleansing.
62250257|NCT00267033|EXPERIMENTAL|1|injection of orthopaedic cement into vertebral bodies
62607874|NCT00259285|EXPERIMENTAL|A|
62830085|NCT06417424|EXPERIMENTAL|experimental group 3|Received transcutaneouselectrical acupoint stimulation singly, and then oral administration of polyethylene glycol for intestinal cleansing.
62830086|NCT06417424|NO_INTERVENTION|Control|No stimulation was given. Oral administration of polyethylene glycol for intestinal cleansing.
62047923|NCT03081390|EXPERIMENTAL|Migraine, obese|"* Mixed meal tolerance testing~* Skin conductance \& cold pressor test~* Flow-mediated dilation testing"
62047924|NCT01181726|EXPERIMENTAL|Investigational Test Product|Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg
62047925|NCT01181726|ACTIVE_COMPARATOR|Reference Listed Drug|Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets
62047926|NCT00994838|ACTIVE_COMPARATOR|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
62250258|NCT05260905||Intervention|All participants will perform 2 experimental sessions, each involving a REHIT exercise session.
62250259|NCT02000596|EXPERIMENTAL|Cohort 1: T+P|Trastuzumab plus Pertuzumab as first line treatment for HER2 overexpressed Metastatic Breast Cancer (without hormonal therapy or chemotherapy)
62250260|NCT02000596|EXPERIMENTAL|Cohort 2 - Arm A|Hormonal Therapy with Anastrozole and Fulvestrant in addition Trastuzumab plus Pertuzumab for women who progressed on T+P alone, and who are ER/PR +
62250261|NCT02000596|EXPERIMENTAL|Cohort 2 - Arm B|Chemotherapy with Eribulin in addition to Trastuzumab plus Pertuzumab for women who progressed on T+P alone and who are ER/PR -
62439989|NCT04194905|ACTIVE_COMPARATOR|Levonorgestrel Ethinyl estradiol Reference Product|Participants will receive two tablets of the marketed reference formulation containing Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg. The tablets will be taken with water and in a fasting condition.
62439990|NCT01953159||Patients with severe neuropathy|Patients with severe neuropathy after treatment with paclitaxel. Blood samples and patient questionnaires will be collected.
62439991|NCT01953159||Patients without neuropathy|Patients will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age (within 10 years), tumor type, chemotherapy regimen or total paclitaxel dosage, race, and ethnicity
62250262|NCT00152282|EXPERIMENTAL|1|
62250263|NCT00152282|EXPERIMENTAL|2|
62250264|NCT00152282|EXPERIMENTAL|3|
62047927|NCT00994838|NO_INTERVENTION|standard diet|
62047928|NCT05035472|ACTIVE_COMPARATOR|Phenylephrine group|Prophylactic phenylephrine bolus simultaneous with spinal anesthesia
62047929|NCT05035472|EXPERIMENTAL|Norepinephrine group|Prophylactic norepinephrine bolus simultaneous with spinal anesthesia
62047930|NCT01479387||Group 1|
62047931|NCT00993655|ACTIVE_COMPARATOR|IV carboplatin + IV paclitaxel|ARM 1: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intravenous day 1; Paclitaxel 60 mg/m2 intravenous day 8. Cycles given Q 21 days x 3 cycles
62047932|NCT00993655|ACTIVE_COMPARATOR|IP cisplatin + IV/IP paclitaxel|ARM 2: Paclitaxel 135 mg/m2 intravenous day 1 plus Cisplatin 75 mg/m2 intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles (Phase II cisplatin arm closed to accrual on 2014-FEB-03)
62047933|NCT00993655|ACTIVE_COMPARATOR|IP carboplatin + IV/IP paclitaxel|ARM 3: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles
62047934|NCT02470130|ACTIVE_COMPARATOR|relax actor|actor during simulation and relaxation before debriefing
62047935|NCT02470130|NO_INTERVENTION|no relax actor|actor during simulation and no relaxation before debriefing
62439992|NCT01207128|ACTIVE_COMPARATOR|Voriconazole, Micafungin|Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV) Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
62607875|NCT06002776||preoperative and perioperative anaesthetic management|We have planned to retrospectively review data for patients aged 18 and above who underwent major abdominal surgery at our center between October 2017 and February 2022. The study aims to record data regarding the administration of thromboprophylaxis, preoperative hemoglobin values, and Revised Cardiac Risk Index scores and their impact on one-year postoperative mortality. Additionally, we intend to examine the effects of the amount of fluid administered during the perioperative period, the application of epidural analgesia, and the use of blood products on hospital stay duration and one-year postoperative mortality.
62607876|NCT01343992|ACTIVE_COMPARATOR|Bedrest|Patients will rest in bed ten minutes after the embryo transfer.
62607877|NCT01343992|EXPERIMENTAL|No bed rest|Patients will not rest after the embryo transfer.
62607878|NCT04424511|PLACEBO_COMPARATOR|Control|"Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age:~1. Single-dose of 0.5 ml / kg child weight~2. Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of placebo mixture."
62047936|NCT02470130|ACTIVE_COMPARATOR|relax observer|observer during simulation and relaxation before debriefing
62830087|NCT02875353|OTHER|Standard endoscopy (not experimental)|For Standard treatment group, the Doppler probe will not be used, nor will hemoclip closure of post-polypectomy ulcers be attempted. Standard published guidelines will be followed for management of blood thinners (anti-coagulants) and/or aspirin like drugs (anti-platelet drugs) before and after the colonoscopic polypectomies. This is the standard of care at the investigators' medical centers and part of written instructions that are given to the participants and their referring physicians during the scheduling process and prior to their preparation for screening or surveillance outpatient colonoscopies.
62047937|NCT02470130|NO_INTERVENTION|no relax observer|observer during simulation and no relaxation before debriefing
62047938|NCT03731754|ACTIVE_COMPARATOR|Traditional Closure|Patients receive primary closure discontinuously for reconstruction of APR perineal wound
62047939|NCT03731754|EXPERIMENTAL|"Cross Closure"|"Patients receive cross closure for reconstruction of APR perineal wound"
62250265|NCT00152282|PLACEBO_COMPARATOR|4|
62250266|NCT03090087|EXPERIMENTAL|Healthy person|The purpose is to investigate the effect of A2A adrenoceptor stimulation using the drug regadenoson (Rapiscan) on the diameter of retinal arterioles during hypoxia in vivo.
62439993|NCT01207128|NO_INTERVENTION|Voriconazole+Micafungin or Voriconazole+Placebo|Voriconazole+Micafungin or Voriconazole+Placebo
62439994|NCT06024863||Sportsmen|Sportsmen (at least 1 hour of physical activity per week) over 35 years of age, referred by their doctor for a screening stress test on a bicycle ergometer in the sports medicine unit from September 2011 to August 2014
62439995|NCT02629952|EXPERIMENTAL|Blueberry Tea|3 cups of blueberry tea per day x 4 weeks
62439996|NCT02629952|NO_INTERVENTION|No Treatment|No Treatment
62607879|NCT04424511|ACTIVE_COMPARATOR|Azithromycin-biannually (Azi-biannual)|"Azithromycin or placebo will be administered as a single dose in oral suspension form for children 1-11 months of age:~1. Single-dose of 0.5 ml / kg child weight~2. Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of study drug.~3. Azithromycin will be given at quarterly visits between January and June, and Placebo mixture will be given at quarterly visits between July and December. Azithromycin dose will be 20 mg / kg."
62830088|NCT02875353|EXPERIMENTAL|Doppler treatment (experimental)|A colon length catheter (probe) will be used to check the non-bleeding post-polypectomy ulcer with shallow and medium depth Doppler probe settings (\< 4 mm deep) for arterial blood flow. If arterial flow is found, treatment through the colonoscope (either hemoclipping or multipolar electrocoagulation probe) will be used to stop the arterial flow. This will be confirmed by rechecking with Doppler probe after endoscopic treatment. Tatoos (Spot method) will be placed on two sides of the ulcer so treated.
62047940|NCT01063101|EXPERIMENTAL|BAX 513|Capsule - one of 5 dose levels (per randomization) - BID (= twice a day)
62047941|NCT01063101|PLACEBO_COMPARATOR|Capsule (cellulose)|Capsule - one of 5 dose levels (per randomization) - BID
62047942|NCT04430751|ACTIVE_COMPARATOR|Immediate start|
62047943|NCT04430751|ACTIVE_COMPARATOR|wait time control|
62250267|NCT03366051|ACTIVE_COMPARATOR|Sentinel Node Mapping plus Lymphadenectomy|Patients with high risk endometrial cancer will undergo Sentinel Node Mapping followed by Systematic Pelvic and Para-Aortic Lymphadenectomy
62250268|NCT03366051|EXPERIMENTAL|Sentinel Node Mapping|Patients with high risk endometrial cancer will undergo Sentinel Node Mapping per NCCN algorithm
62439997|NCT04922398|ACTIVE_COMPARATOR|Group A: PRP group|Preparation of PRP sample fro the patient own blood then the volume immediately above the erythrocyte layer was collected. Calcium gluconate in conc. 1:9 will be used as an activator. After activation, in a period less than 2 min, approximately 4 ml of the PRP will be injected into each ovary by TVUS.
62439998|NCT04922398|PLACEBO_COMPARATOR|Group B: saline group|consists of 30 patients, who will receive 4 ml of a normal saline inj. 0.9% Nacl. then injected into each ovary by TVUS.
62439999|NCT04380571|EXPERIMENTAL|Biofeedback|Biofeedback therapy in addition to the conventional measures done in the control Group. It was performed in the same position used for baseline manometry. The used protocol included strength and sensory training, twice weekly for 3 months. Strength training was performed by a double-lumen rectal PVC balloon clothed catheter (MMS U-72210).
62047944|NCT03664505|ACTIVE_COMPARATOR|Garment based on manual measurement|Garment based on manual measurement is used on burn scar
62047945|NCT03664505|EXPERIMENTAL|Garment based on scan measurement|Garment based on scan measurement is used on burn scar
62607880|NCT04424511|ACTIVE_COMPARATOR|Azithromycin-quarterly|"Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age:~1. Single-dose of 0.5 ml (20 mg) / kg child weight.~2. Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of azithromycin."
62607881|NCT04764786|EXPERIMENTAL|EVOO+POLY|Acute test meal
62607882|NCT04764786|ACTIVE_COMPARATOR|OO-POLY|Acute test meal
62607883|NCT03759366|EXPERIMENTAL|Eculizumab Intravenous (IV) Infusion|"In the Primary Evaluation Treatment Period (26 weeks), eculizumab will be administered weekly during the initial induction phase and every 2 weeks during the maintenance phase.~In the Extension Period (up to 208 weeks), participants will continue to receive eculizumab every 2 weeks.~Eculizumab will be administered at doses of 300, 600, 900, or 1200 milligrams (mg), based on the participant's current body weight."
62607884|NCT00807391|OTHER|TBCA/TBNA|Under fluoroscopy first transbronchial forceps biopsy is performed, afterwards in random order transbronchial catheter aspiration(TBCA) and transbronchial needle aspiration (TBNA).
62607885|NCT04990401|EXPERIMENTAL|Behavioral Activation Teletherapy|All eligible participants will be assigned to receive the behavioral activation teletherapy intervention.
62607886|NCT00568256|EXPERIMENTAL|Experimental|Mind/Body Course
62607887|NCT00568256|OTHER|Other|Mind/Body Course
62830089|NCT02604394|ACTIVE_COMPARATOR|Rheolytic Thrombectomy with PCI|"Rheolytic Thrombectomy (RT) will be performed with the The AngioJet rheolytic thrombectomy system (Medrad Interventional/Possis, Minneapolis, Minnesota).~The single-pass antrograde thrombectomy technique will be used."
62830090|NCT02604394|SHAM_COMPARATOR|Conventional PCI|In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
62830091|NCT06587165|EXPERIMENTAL|N15-thymidine|Study participants will receive thymidine preparations for pre-defined blocks of time prior to the scheduled routine resection of myocardium.
62830092|NCT03841396|ACTIVE_COMPARATOR|Fraxiparine|Nadroparine, Pre-filled syringe, 3800IU, single dose
62830093|NCT03841396|ACTIVE_COMPARATOR|Clexane|Enoxaparin, Pre-filled syringe, 40 mg, single dose
62830094|NCT05535296|EXPERIMENTAL|Intervention group|Standard health examination and related feedback. Functional examination. Risk profile and related advice.
62440000|NCT04380571|EXPERIMENTAL|Electrical Stimulation|Bilateral (TPTNS); was applied with an electrode above the medial malleolus A second electrode) was applied just below the same malleolus. Electrical stimulation with a low-frequency current (10 Hz), and adjustable intensity. The procedure was done for 20-30 minutes, three times per week for 3 months together with the conventional maneuvers applied in the control group.
62440001|NCT04380571|ACTIVE_COMPARATOR|Control group|were managed by conventional methods through Kegal exercises and dietetic regulation where they had received bulky food including vegetables, fruits bran and cereals. Fast foods, spicy drinks and caffeine should be limited in child's diet. Local hygiene and zinc oxide application to the perianal skin were advised to prevent skin excoriation.
62440002|NCT05578573|EXPERIMENTAL|KARAHOC group|A group of patients in which paracentesis will be performed using a KARAHOC device.
62440003|NCT05578573|ACTIVE_COMPARATOR|conventional group|A group of patients in which paracentesis will be performed using an angiocatheter.
62607888|NCT02284763|EXPERIMENTAL|Change of EtCO2|Changes of rSO2 after adjustment of EtCO2 between 27-45 mmHg
62607889|NCT00770133|EXPERIMENTAL|Ketotifen/naphazoline|Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
62607890|NCT00770133|PLACEBO_COMPARATOR|Vehicle|Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
62607891|NCT00770133|ACTIVE_COMPARATOR|Naphazoline|Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
62607892|NCT00770133|ACTIVE_COMPARATOR|Ketotifen|Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
62607893|NCT04324866||Group 1|Patients with chronic plaque psoriasis on immunosuppressant therapy
62607894|NCT04324866||Group 2|Psoriatic patients' partners
62607895|NCT04324866||Group 3|Patients with atopic dermatitis treated with dupilumab
62047946|NCT02425332|EXPERIMENTAL|Lokomat assessment|
62607896|NCT05209841|EXPERIMENTAL|Catheter sealing with low dose heparin|Catheters will be sealed with 3mL of Fibrillin Ⓡ (heparin 20UI/mL)
62607897|NCT05209841|ACTIVE_COMPARATOR|Catheter sealing with normal saline|Catheters will be sealed with 3mL of 0.9% sodium chloride
62607898|NCT00553982|EXPERIMENTAL|1|Patellar resurfacing
62607899|NCT00553982|ACTIVE_COMPARATOR|2|Patellar retention
62607900|NCT03013608|EXPERIMENTAL|relocation of nail plate|the simple relocation of the nail plate in nailbed injuries in paediatric population
62607901|NCT02176460|EXPERIMENTAL|colchicine|0.5mg twice daily for 16 weeks
62607902|NCT02176460|PLACEBO_COMPARATOR|placebo tablet|1 tablet twice daily for 16 weeks
62607903|NCT06441617|EXPERIMENTAL|Fatigue Program A added to Treatment as Usual|An MS-specific fatigue management program, delivered as a stand-alone, fully automated intervention via an internet-browser.
62607904|NCT06441617|ACTIVE_COMPARATOR|Fatigue Program B added to Treatment as Usual|Fatigue Program B will use a web-based interface with similar design and functionality as Fatigue Program A.
62607905|NCT06441617|NO_INTERVENTION|Treatment as Usual|
62607906|NCT04027075|EXPERIMENTAL|Intervention|This group will be asked to use the Qlarity app daily in the month following the baseline assessment. This group will also receive services as usual from the Department of Youth Services.
62830095|NCT05535296|NO_INTERVENTION|Control group|Standard health examination and related feedback. Functional examination.
62830096|NCT02550639|ACTIVE_COMPARATOR|A1-prophylaxis group,positive elispot test|POSITIVE ELISPOT TEST, PROPHYLAXIS GROUP (CMV PROPHYLAXIS)
62830097|NCT02550639|EXPERIMENTAL|A2- preemptive group,positive elispot test|POSITIVE ELISPOT TEST, PREEMPTIVE GROUP (NO CMV PROPHYLAXIS)
62607907|NCT04027075|NO_INTERVENTION|Services as usual|This group will receive services as usual from the Department of Youth Services.
62440004|NCT01269983|EXPERIMENTAL|fascial manipolation|8 treatment sessions: 4 of fascial manipulation treatment, and 4 of standard physiotherapy (rexing exercise, stretching, abdominal and paravertebral isometric muscular recruiting)
62607908|NCT04846816|EXPERIMENTAL|SQIN-01|The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.
62607909|NCT06730425||Pediatric patients seen at the pediatric or orthodontic department|New pediatric patients seen for the first time at either the pediatric or the orthodontic department at the dental clinic of Midwestern University to start either a dental procedure or an orthodontic treatment
62607910|NCT00504959|EXPERIMENTAL|1|ranibizumab
62830098|NCT02550639|ACTIVE_COMPARATOR|B1- prophylaxis group,negative elispot test|NEGATIVE ELISPOT TEST, PROPHYLAXIS GROUP (CMV PROPHYLAXIS)
62830099|NCT02550639|EXPERIMENTAL|B2- preemptive group,negative elispot test|NEGATIVE ELISPOT TEST, PREEMPTIVE GROUP (NO CMV PROPHYLAXIS)
62440005|NCT01269983|ACTIVE_COMPARATOR|physiotherapy|8 treatment sessions of standard physiotherapy (rexing exercise, stretching, abdominal and paravertebral isometric muscular recruiting)
62440006|NCT02917447|EXPERIMENTAL|DESTRESS-WV|Tailored online intervention for PTSD for women Veterans with coach support.
62440007|NCT02917447|PLACEBO_COMPARATOR|Phone Monitoring|Weekly check-in calls from a study coach.
62607911|NCT00552032|EXPERIMENTAL|Mometasone Furoate nasal spray|
62607912|NCT00552032|PLACEBO_COMPARATOR|Placebo|
62607913|NCT06223555|ACTIVE_COMPARATOR|1|Fixed Mixed Meal Test
62607914|NCT06223555|ACTIVE_COMPARATOR|2|Adjusted Mixed Meal Test
62607915|NCT03785899|NO_INTERVENTION|RMC only|routine manual control (RMC) of the fraction of inspired oxygen (FIO2)
62830100|NCT04281862|EXPERIMENTAL|Group A|Dextenza
62830101|NCT04281862|ACTIVE_COMPARATOR|Group B|Topical Prednisolone
62830102|NCT05481151|EXPERIMENTAL|P1101 250-350-500mcg|Pre-filled Syringe, Q2W starting at 250-350-500, SC injection
62830103|NCT05481151|ACTIVE_COMPARATOR|Ropeginterferon alfa-2b-njft|Pre-filled Syringe, Q2W starting at 100 up to 500 (50mcg increases), SC injection
62607916|NCT03785899|EXPERIMENTAL|SPOCnew and 2s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with new algorithm of the fraction of inspired oxygen (FIO2).~The SpO2 signal averaging time is 2s."
62607917|NCT03785899|EXPERIMENTAL|SPOCnew and 8s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with new algorithm of the fraction of inspired oxygen (FIO2).~The SpO2 signal averaging time is 8s."
62607918|NCT03785899|ACTIVE_COMPARATOR|SPOCold and 2s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with old algorithm of the fraction of inspired oxygen (FIO2).~The SpO2 signal averaging time is 2s."
62607919|NCT03785899|ACTIVE_COMPARATOR|SPOCold and 8s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with old algorithm of the fraction of inspired oxygen (FIO2).~The SpO2 signal averaging time is 8s."
62607920|NCT05705115|NO_INTERVENTION|LBNP 0 + no intravenous fluid|
62830104|NCT00773006||A|Stable/elective PCI patients
62830105|NCT00773006||B|NSTEMI PCI patients
62830106|NCT00773006||C|STEMI PCI patients
62830107|NCT06175806|EXPERIMENTAL|arm I (group A) who will receive dispersible film ondansetron|arm I (group A) who will receive dispersible film ondansetron in a dose of 4 mg for those who will weigh more than 15 Kg up to 30 kg, and 8 mg for those who will weigh more than 30 Kg. The dose will be repeated if the patient had another vomiting episode within 15 minutes of taking the medicine.
62830108|NCT06175806|EXPERIMENTAL|Arm II (group B) who will receive oral Granisetron|Arm II (group B) who will receive oral Granisetron in a dose of 40 microgram/kg/dose; the dose could be repeated if needed after 12 hours.
62607921|NCT05705115|EXPERIMENTAL|LBNP 0 + Ringer's acetate|
62830109|NCT06188910|EXPERIMENTAL|Neurofeedback|3 weekly 30-minute neurofeedback sessions per week for 12 weeks
62830110|NCT06188910|ACTIVE_COMPARATOR|Control|Health education, a 25-minute session, on mobile phone addiction and promotion of healthy lifestyles
62830111|NCT06655571|OTHER|ultrasound|Caudal bloc guided by Ultrasound
62830112|NCT06655571|OTHER|Conventionel|Caudal Block based on anatomical landmarks
62830113|NCT04404491|ACTIVE_COMPARATOR|PD-1 and Concurrent chemoradiotherapy|Camrelizumab: 200mg,d1,15,29,43,57,I.V oxaliplatin：65mg/m2，d1，8，22, 29 capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total. radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
62830114|NCT04404491|PLACEBO_COMPARATOR|placebo and Concurrent chemoradiotherapy|placebo: 200mg,d1,15,29,43,57,I.V oxaliplatin：65mg/m2，d1，8，22, 29 capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total. radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
62830115|NCT04971434|EXPERIMENTAL|laser|In fatty liver patients (30 patients), a daily application of 4-minute laser (for one month, except Fridays) on acupoint number 25,40,36 of stomach meridian, acupoint number 3 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
62830116|NCT04971434|EXPERIMENTAL|cupping with scarification|In fatty liver patients (30 patients),every-two-week applied cupping (with scarification) session within one month on back of upper thorax
62607922|NCT05705115|ACTIVE_COMPARATOR|LBNP 40 + no intravenous fluid|
62607923|NCT05705115|EXPERIMENTAL|LBNP 40 + Ringer's acetate|
62607924|NCT06710899|EXPERIMENTAL|Treatment phase A|Methenamine Hippurate 1g BD for 6 months
62607925|NCT06710899|EXPERIMENTAL|Treatment phase B|Methenamine Hippurate 1g BD + Vitamin C 1g BD for 6 months
62830117|NCT00598338|ACTIVE_COMPARATOR|1|Prucalopride
62830118|NCT00598338|PLACEBO_COMPARATOR|2|Placebo
62830119|NCT06524843||Patients|Male and female patients affected by bone metastases derived from carcinoma, treated at Rizzoli Orthopaedic Institute from 01/01/2010 to 31/12/2022
62830120|NCT06655012|EXPERIMENTAL|Salmeterol|Participants are administered salmeterol from an inhaler device
62830121|NCT06655012|PLACEBO_COMPARATOR|Placebo|Participants are administered placebo from an inhaler device
62830122|NCT00571493|EXPERIMENTAL|Bortezomib Dose Escalation|"The phase I section of the study will follow a standard 3 + 3 design to determine the maximum tolerated dose (MTD) of bortezomib when added to a standard BEAM (BCNU (carmustine), etoposide, cytarabine, melphalan) conditioning regimen followed by autologous hematopoietic stem cell transplantation (ASCT).~After the MTD is defined, additional patients will enroll in Phase II to obtain preliminary estimates of survival using the Phase I regimen."
62440008|NCT04566783||Women and men fulfilling PGAD-criteria|"Inclusion criteria:~- Female and male patients or subjects between 18-65 years of age fulfilling the diagnostic criteria of persistent genital arousal disorder (PGAD) according to Leiblum \& Nathan (2001).~Exclusion criteria:~- Any exclusion criteria for magnetic resonance imaging (MRI), mental retardation, severe and acute somatic or mental disease such as acute psychosis, brain damage, Alzheimer's disease, severe bacterial infection requiring immediate medical treatment.~Age:~- 18 - 65 years of age~Gender:~- Female and male subjects"
62440009|NCT04566783||Controls|"Inclusion criteria:~- Age and education matched healthy controls."
62440010|NCT04902339|EXPERIMENTAL|MORE+NF|
62440011|NCT04902339|ACTIVE_COMPARATOR|MORE|
62440012|NCT04902339|ACTIVE_COMPARATOR|Supportive Psychotherapy|
62440013|NCT01060774|EXPERIMENTAL|Bupivacaine|0.5% bupivacaine/1:200,000 epinephrine
62440014|NCT01060774|EXPERIMENTAL|Lidocaine|2% lidocaine/1:200,000 epinephrine
62440015|NCT00799006|PLACEBO_COMPARATOR|Placebo|
62440016|NCT00799006|EXPERIMENTAL|PF-04620110|
62440017|NCT04108169|ACTIVE_COMPARATOR|Active Comparator|
62440018|NCT04108169|NO_INTERVENTION|Sham Comparator|
62440019|NCT05442333|ACTIVE_COMPARATOR|preoperative radiotherapy|The patients which will receive preoperative radiotherapy
62440020|NCT05442333|ACTIVE_COMPARATOR|postoperative radiotherapy|The patients which will receive postoperative radiotherapy
62440021|NCT02517710|PLACEBO_COMPARATOR|Control|Group of patients receiving standard hysterotomy closure with synthetic braided suture
62440022|NCT02517710|EXPERIMENTAL|Stratfix|group of patients having the hysterotomy incision closed with barbed synthetic suture. Time to closure, blood loss, and postoperative pain
62440023|NCT03263195||Women with HIV only|Pregnant women with HIV infection only
62830123|NCT05784038||Human cases of monkeypox confirmed by PCR|Laboratory-confirmed mpox infection is defined as determined by polymerase chain reaction assay (PCR), culture, or antigen test obtained from a sample collected from blood, oropharynx, anal or skin lesion within 5 days of inclusion.
62440024|NCT03263195||Women with ZIKV only|Pregnant women with ZIKV infection only
62440025|NCT03263195||Women with HIV and ZIKV|Pregnant women with HIV and ZIKV infection
62440026|NCT03263195||Women without HIV or ZIKV|Pregnant women without HIV or ZIKV infection
62440027|NCT03263195||Infants of women with HIV only|Infants of women with HIV infection during pregnancy
62440028|NCT03263195||Infants of women with ZIKV only|Infants of women with ZIKV infection during pregnancy
62440029|NCT03263195||Infants of women with HIV and ZIKV|Infants of women with HIV and ZIKV infection during pregnancy
62440030|NCT03263195||Infants of women without HIV or ZIKV|Infants of women without HIV or ZIKV infection during pregnancy
62440031|NCT06222463|ACTIVE_COMPARATOR|low tidal volume ventilation|Flow-controlled ventilation will be established with a PEEP of 5 cmH2O, peak pressure set to achieve a tidal volume of 7 ml/kg predicted body weight and the flow set to achieve normocapnia at an I:E ration of 1:1. Three consecutive measurements of power dissipation with 15 minutes in between will be obtained. Additionally secondary outcome parameters such as respiratory parameters and results of arterial blood gas analysis will be recorded at each measurement timepoint.
62830124|NCT00106704|EXPERIMENTAL|Sitagliptin|Sitagliptin 10 mg tablet daily for 54 weeks
62440032|NCT06222463|EXPERIMENTAL|individualized FCV|Flow-controlled ventilation will be individualized with compliance guided PEEP and peak pressure titration. The flow will be set to achieve normocapnia at an I:E ration of 1:1. Three consecutive measurements of power dissipation with 15 minutes in between will be obtained. Additionally secondary outcome parameters such as respiratory parameters and results of arterial blood gas analysis will be recorded at each measurement timepoint.
62440033|NCT01412671||Group 1|
62440034|NCT05091814||Radiotherapy (Yes or no) - Exercise (YES or NO)|with or without radiotherapy
62440035|NCT05091814||MMO (in mm)|with or without radiotherapy
62440036|NCT03979677|EXPERIMENTAL|Intervention Group|All participants will be provided written and verbal instructions regarding the lifestyle modification intervention.
62440037|NCT00101972|EXPERIMENTAL|RAV12|
62440038|NCT04119661|EXPERIMENTAL|Max-i-Probe|
62440039|NCT04119661|ACTIVE_COMPARATOR|NaviTip|
62440040|NCT03321747|EXPERIMENTAL|Phase 1/Dose Level 1|11 Gy will be given in 5 fractions for a total dose of 55 Gy
62440041|NCT03321747|EXPERIMENTAL|Phase 1/Dose Level 2|12 Gy will be given in 5 fractions for a total dose of 60 Gy
62440042|NCT03321747|EXPERIMENTAL|Phase 1/Dose Level 3|13 Gy will be given in 5 fractions for a total dose of 65 Gy
62440043|NCT03321747|EXPERIMENTAL|Phase 1/Dose Level 4|14 Gy will be given in 5 fractions for a total dose of 70 Gy
62440044|NCT03321747|EXPERIMENTAL|Phase 2|The maximum tolerated radiation dose determined during Phase 1 (i.e. 11, 12, 13, or 14 Gy) will be given in 5 fractions for a total dose of 55, 60, 65, or 70 Gy.
62607926|NCT06710899|EXPERIMENTAL|Treatment phase C|Methenamine 1g BD for 6 months
62607927|NCT06336148|EXPERIMENTAL|ACTM-838 Monotherapy|Escalating doses of ACTM-838 in Part 1a followed by expansion in Part 1b at the recommended dose determined in Part 1a
62607928|NCT01733485|ACTIVE_COMPARATOR|Aspirin|
62607929|NCT01733485|ACTIVE_COMPARATOR|Indomethacin|
62607930|NCT01733485|NO_INTERVENTION|Control|
62830125|NCT00106704|PLACEBO_COMPARATOR|Placebo/ Pioglitazone|Placebo tablet daily for 24 weeks followed by Pioglitazone tablet daily for 30 weeks
62830126|NCT01942694|PLACEBO_COMPARATOR|Placebo|One pill daily
62830127|NCT01942694|ACTIVE_COMPARATOR|Vitamin D (Cholecalciferol)|One vitamin D pill daily
62830128|NCT05274815|EXPERIMENTAL|Tezepelumab|Tezepelumab subcutaneous injection
62250269|NCT02019823|ACTIVE_COMPARATOR|Enhanced usual care|"In addition to usual care participants will receive the pre-randomisation Welcome to the \*StAR Study SMS-text, post-randomisation they will received a Happy Birthday SMS-text on their date of birth and up to six additional SMS-text messages containing study specific information and thanking the participant for taking part in the study. Participants in the Enhanced Usual Care group will receive no more than one study specific SMS-text every two months."
62440045|NCT05216614|EXPERIMENTAL|Fluvoxamine|"This arm will be given the active treatment, oral fluvoxamine capsules of 25 mg each.~The first six weeks will be gradual titration (weeks 1 \& 2 25mg BID, weeks 3 \& 4 75mg BID, weeks 5 \& 6 100mg BID).~The following six weeks will be fixed dose of 100mg TID.~The last two weeks will be a taper down (first week 50mg BID and second week 25mg BID)~There will be 14 weeks of active treatment and assessments will be conducted after completion of week 12, prior to beginning taper down period."
62440046|NCT05216614|PLACEBO_COMPARATOR|Placebo|"Placebo capsules that look, smell, and taste like fluvoxamine capsules will be given to the placebo arm.~To preserve double-blinding of the study, subjects will receive one capsule BID during the first six weeks following the titration schedule and one capsule TID during the next six weeks for the fixed-dose period.~Subjects will then taper-down placebo to imitate the fluvoxamine arm for two weeks.~Assessments will be conducted at 12 weeks following completion of fixed-dose period, prior to starting taper down period."
62440047|NCT01424982|EXPERIMENTAL|Treatment (combination chemotherapy, ponatinib hydrochloride)|See Detailed Description.
62440048|NCT04032678|EXPERIMENTAL|1 (DGT7)|"Cardioversion with a pulsed biphasic waveform Cardioversion is performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard Touch 7 - DGT7, Schiller Medical, France) with recommended by the manufacturer adult pads (FRED-PA1, Schiller) following an energy protocol of 3 consecutive shocks with constant selected energy: 200J, 200J, 200J. The protocol is stopped at successful cardioversion (sinus rhythm at 1 minute post-shock), otherwise after the 3rd shock. Primary endpoint: The cumulative energy delivered by the consecutive defibrillation shocks during cardioversion.~Other Name: DGT7"
62440049|NCT04032678|ACTIVE_COMPARATOR|2 (LP15)|"Cardioversion with a biphasic truncated exponential waveform Cardioversion is performed by a biphasic truncated exponential waveform (LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA) with recommended by the manufacturer adult pads (Redipak QUICK COMBO, Physio-Control) following an energy protocol of 3 consecutive shocks with constant selected energy: 200J, 200J, 200J. The protocol is stopped at successful cardioversion (sinus rhythm at 1 minute post-shock), otherwise after the 3rd shock. Primary endpoint: The cumulative energy delivered by the consecutive defibrillation shocks during cardioversion.~Other Name: LP15"
62440050|NCT00229541|EXPERIMENTAL|IG|intervention group, receives counselling on medical inpatient rehabilitation by statutory health insurance, is intended to apply for a 3-wek medical inpatient rehabilitation at the co-operating clinic (Bad Bramstedt)
62440051|NCT00229541|NO_INTERVENTION|KG|control group, receives usual care
62607931|NCT04753268|EXPERIMENTAL|Treatment group: Noom Healthy Weight Program|The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging.
62607932|NCT06425445|EXPERIMENTAL|Affected participants|
62607933|NCT06425445|EXPERIMENTAL|Healthy participants|
62830129|NCT01463501|EXPERIMENTAL|Neoadjuvant Treatment|Preoperative chemotherapy/radiotherapy
62830130|NCT01463501|EXPERIMENTAL|Adjuvant Treatment|Postoperative chemotherapy/radiotherapy
62830131|NCT03957928|ACTIVE_COMPARATOR|Low fat cookies|Subjects consume 100 kcal of low fat cookies daily for 12 weeks.
62830132|NCT03957928|EXPERIMENTAL|Mango fruit|Subjects consume 100 kcal of mango fruit daily for 12 weeks.
62047947|NCT00385580|EXPERIMENTAL|1|
62607934|NCT05009407||HOSTS|patients ongoing corneal transplantation procedure which a full-thickness cornea from the host is replaced by a graft from a donor
62607935|NCT05009407||DONORS|grafts from donors that would be analyzed
62607936|NCT06318819|EXPERIMENTAL|Dental Floss Holders|Dental Floss Holders was constructed.
62250270|NCT02019823|EXPERIMENTAL|Informational SMS-text|"In addition to enhanced usual care, participants allocated to the informational SMS-text support group will receive a series of text-messages covering the following areas:~I. Medication pick-up reminders send 48 hours before scheduled medication pick-up date a) Participants who fail to pick-up medication within 3 days of scheduled pick-up date will be sent one further reminder SMS-text~II. III. Clinic appointment reminder 48 hours before scheduled follow-up appointment~a) Participants who fail to attend clinic appointment will be sent an additional SMS-text checking they are alright and inviting them to rebook their appointment via the clinic IV. Messages which support medication adherence (focused on organisation, memory, and habit) or provide hypertension related health information"
62250271|NCT02019823|EXPERIMENTAL|Interactive SMS-text|"In addition to enhanced usual care and informational SMS-text messages, SMS-text messages sent to participants in the interactive SMS-text group will contain a prompt to respond which will guide participants to additional SMS-text based resources."
62250272|NCT04543058|EXPERIMENTAL|BeatPark Experimental Group|Group of participants who will make its self-rehabilitation in walking program using BeatPark application, delivering synchronized music adapted to the patient walking progression.
62250273|NCT04543058|ACTIVE_COMPARATOR|Control Group with Music at Random Tempo|Group of participants who will make its self-rehabilitation in walking program using an application delivering music at random tempo.
62607937|NCT06318819|ACTIVE_COMPARATOR|conventional flossing|conventional flossing to the opposite arch.
62607938|NCT04291677|EXPERIMENTAL|Intervention group in which musical intervention|Group A: Experimental group in which musical intervention will be applied between the first and the third day of mechanical ventilation.
62607939|NCT04291677|OTHER|Control group|Group B: Control group with standard treatment without musical intervention.
62607940|NCT06644222|ACTIVE_COMPARATOR|Groupe A|Experimental groupe A will receive AIRROSTI exercises for 45 minutes / one session daily for five days per week.
62607941|NCT06644222|ACTIVE_COMPARATOR|Groupe B|Group B will receive Thera band exercises for 45 minutes/one session per day for five days per week.
62607942|NCT05503875|EXPERIMENTAL|treatment|Patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.
62830133|NCT02606643|ACTIVE_COMPARATOR|Group 1 Catheter to slight traction|"For the Tension arm (research related), slight tension will be placed on the catheter, which will then be taped to the patient's inner thigh. The tension will be assessed and retaped as needed every 30 minutes by the research and/or the nursing staff.~Only slight tension will be applied to those catheters assign to the tension group. The catheter will be taped to the inner thigh so there is no sag in the catheter from the urethra to the tape. There is no method or device to measure the tension placed on these catheters, if the patient moves her leg it can lessen or increase the tension, these are known factors."
62830134|NCT02606643|ACTIVE_COMPARATOR|Group 2 Catheter to no traction|"Foley catheter to no traction placed as SOC No traction applied"
62250274|NCT04543058|ACTIVE_COMPARATOR|Control Group without Music|Group of participants who will make its self-rehabilitation in walking program using an application without music.
62250275|NCT02866799|EXPERIMENTAL|Multi-PAP intervention|Complex intervention with general practitioners and patients
62250276|NCT02866799|ACTIVE_COMPARATOR|Usual care|Patients will receive the usual clinical care
62250277|NCT04373954|EXPERIMENTAL|Forgiveness Therapy|6-month Forgiveness Therapy; Participants meet once per week, in group setting.
62250278|NCT04373954|ACTIVE_COMPARATOR|Carey Guides|6-month Carey Guides; Participants meet once per week, in group setting.
62607943|NCT03196037|EXPERIMENTAL|Tai Chi|The Tai Chi intervention will be lead by an expert Tai Chi instructor with 15 years of teaching experience, and will take place at a local Yoga studio. The 8-week intervention entails two 75-minute sessions per week for a total of 16 sessions. Each session will begin with a 15- minute warm-up followed by 25 minutes of performing basic stances, footwork, upper-body/arm/hand movement, proper body alignment, mental/visual focus, and balance; 30 minutes of instruction in a choreographed form (first section of the Yang style long-form); and ending with a 5-minute cool-down.
62607944|NCT01382316|EXPERIMENTAL|Making Alcoholics Anonymous Easier|Six session, group format intervention, consisting of introductory session, four core sessions (sponsorship, principles not personalities, spirituality, living sober), and return to introductory session as MAAEZ graduate
62607945|NCT01382316|ACTIVE_COMPARATOR|Usual care|Usual group sessions on education about alcohol and drug problems
62440052|NCT03182920|EXPERIMENTAL|200 mg Lasmiditan (Group 1 Elderly)|200 milligrams (mg) lasmiditan on Day 1 of 1 of 2 dosing periods.
62607946|NCT04272606|ACTIVE_COMPARATOR|Treatment|1:1 randomization, given tranexamic acid during surgery, visual acuity exam
62440053|NCT03182920|PLACEBO_COMPARATOR|Placebo (Group 1 Elderly)|Placebo on Day 1 of 1 of 2 dosing periods.
62250279|NCT04323085|ACTIVE_COMPARATOR|Speech-in-Noise Treatment Program|A behavioural speech therapy program involving 12, one-hour treatment sessions over a 4-week period
62250280|NCT04323085|ACTIVE_COMPARATOR|Speech-to-Noise Feedback Device Program|A speech treatment program involving the use of a speech-to-noise feedback device during 12, one-hour treatment sessions over a 4-week period
62440054|NCT03182920|EXPERIMENTAL|200 mg Lasmiditan (Group 2 Young)|200 mg lasmiditan on Day 1.
62830135|NCT05599893|EXPERIMENTAL|Tele - physical therapy group|Participants in the tele-physical therapy group underwent tele-physical therapy sessions which includes an internet-based video conference under the supervision of physical therapists. Before commencing training, warm-up exercises involving upper and lower extremity joint movements were performed for 10 times. During the first and second weeks, the third and fourth weeks, the fifth and sixth weeks and the seventh and eighth weeks, the exercises were performed 10-15, 15-20, 20-25 and 25-30 times per session, respectively. Each session lasted for 10 minutes of warm-up, 60 minutes of training and 10 minutes of a cool-down phase. The participants in the tele physical therapy group received training four times a week, for 8 weeks, each session lasted for 60 minutes.
62440055|NCT05242419|EXPERIMENTAL|Treatment group|Huperzine A Injection
62607947|NCT04272606|PLACEBO_COMPARATOR|Placebo|1:1 randomization, given standard of care treatment during surgery, visual acuity exam
62607948|NCT00345878|EXPERIMENTAL|Cervarix Group|Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.
62607949|NCT00345878|PLACEBO_COMPARATOR|Placebo Group|Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.
62607950|NCT03755518|EXPERIMENTAL|Administration of Fedratinib 400mg/day|Self-administered Investigational Product (IP) (400 mg/day) on an outpatient basis, once daily preferably with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles.
62830136|NCT05599893|ACTIVE_COMPARATOR|Control intervention group|During the first visit, participants in the control intervention group (CIG) received patient education for 10 minutes from physical therapists and also received a pamphlet containing these instructions in written form. They were informed to do their normal daily activities, avoid sedentary lifestyle, perform regular physical activities such as household activities, maintain balance diet and have 6-8 hours of sleep per day.
62830137|NCT04321057||Group questionnaire|Patient's height and weight are asked by questionnaire in this group. It includes patients at the cardiological department of Saarland University.
62830138|NCT04321057||Group male doctor|Patient's height and weight are asked by a male doctor in this group. It includes patients at the cardiological department of Saarland University.
62830139|NCT04321057||Group female doctor|Patient's height and weight are asked by a female doctor in this group. It includes patients at the cardiological department of Saarland University.
62830140|NCT04321057||Group male nurse|Patient's height and weight are asked by a male nurse in this group. It includes patients at the cardiological department of Saarland University.
62440056|NCT05242419|PLACEBO_COMPARATOR|Control group|0.9% Sodium Chloride Injection
62440057|NCT02139345|EXPERIMENTAL|TC-A PS|Subject will be implanted with the TC-A PS Total Knee Replacement System
62440058|NCT02139345|ACTIVE_COMPARATOR|TC-PLUS Solution PS|Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System.
62607951|NCT02983916||Group 1: adhesiolysis|Group 1 (the operative group) consisted of all patients who underwent laparoscopy and/or laparotomy. Typically patients had positive cine-MRI. A few patients with inconclusive cine-MRI who underwent diagnostic laparoscopy are also included in this group. Patients with no adhesions found during operation remain in group 1, because analysis is performed on intention-to-treat basis.
62607952|NCT02983916||Group 2: Adhesions, conservative|Patients with evidence of adhesions based on cine-MRI who did not undergo laparoscopy or laparotomy.
62830141|NCT04321057||Group female nurse|Patient's height and weight are asked by a female nurse in this group. It includes patients at the cardiological department of Saarland University.
62047948|NCT00385580|EXPERIMENTAL|2|
62250281|NCT04323085|NO_INTERVENTION|Delayed Treatment|Assessments but no intervention for a period of 13 weeks.
62250282|NCT01937598|EXPERIMENTAL|Sitagliptin, then Placebo|
62250283|NCT01937598|EXPERIMENTAL|Placebo, then Sitagliptin|
62440059|NCT03282435|EXPERIMENTAL|CIK cells with PD-1 blocking|CIK cellular therapy with PD-1 blocking combined with standard lung cancer treatment
62440060|NCT03282435|ACTIVE_COMPARATOR|CIK cells without PD-1 blocking|CIK cellular therapy without PD-1 blocking combined with the same standard lung cancer treatment as the experimental group patients receive
62440061|NCT02099266|EXPERIMENTAL|Hyperbaric Oxygen Treatment|Administration of hyperbaric oxygen the morning of UCB transplant.
62440062|NCT02261571|EXPERIMENTAL|Moxibustion|A series of moxibustion sessions within six weeks from baseline with adjuvant chemotherapy.
62440063|NCT02261571|NO_INTERVENTION|Waiting|Participants who will be allocated to waitlist will receive no moxibustion treatments throughout the 6 weeks while receiving adjuvant chemotherapy
62440064|NCT05062109|EXPERIMENTAL|Multimodal geriatric prehabilitation|
62440065|NCT02222142||Isoflurane group|Isoflurane inhalational anesthesia during OPCAB
62440066|NCT02222142||Propofol group|Total intravenous anesthesia with propofol during OPCAB
62440067|NCT04093180|EXPERIMENTAL|Experimental group|Experimental group undergoing treatment course according to INRS
62607953|NCT02983916||Group 3: No adhesions|Patients in whom no evidence of adhesions was found on cine-MRI, and who did not undergo laparoscopy or laparotomy .
62830142|NCT04321057||Group family doctor|Patient's height and weight are asked by questionnaire in this group. This is the control group,including patients at a family doctor.
62607954|NCT04351126|OTHER|Control group|patients at high risk for OHSS who are receiving conventional treatment either as a prophylaxis (in the form of bromocriptine) or as a management in case of developing OHSS (as continual bromocriptine and fluid monitoring and or paracentesis and or tube thoracostomy)
62607955|NCT04351126|EXPERIMENTAL|treatment group|patient who has developed OHSS while on conventional lines of management (as continual bromocriptine and fluid monitoring and or paracentesis and or tube thoracostomy) patients in this group, fludrocortisone was added to conventional lines of management.
62607956|NCT04351126|EXPERIMENTAL|prevention group|patients at high risk for OHSS who are receiving fludrocortisone as a prophylaxis
62607957|NCT06731348|ACTIVE_COMPARATOR|Standard Opioid Prescribing - Oxycodone HCl 5mg|Participants will receive standard opioid prescribing - Oxycodone 5mg x10 tablets for major cases, 5 tablets for minor cases.
62607958|NCT06731348|EXPERIMENTAL|Restricted Opioid Prescribing - Oxycodone HCl 5mg|Participants in the restricted opioid prescribing group will receive restricted opioid prescribing after surgery. They will receive 1 tablet of Oxycodone HCl 5mg
62607959|NCT02077413|ACTIVE_COMPARATOR|Healthy Muscle Group|Six subjects will be enrolled in this group. MRI measures will be performed at baseline and 48 hours post-exercise, when the largest amount of muscle damage is typically observed. They will be tested for maximum strength of the dorsiflexors and then undergo an eccentric exercise protocol for both lower legs on the Biodex with varying loads. Approximately two days after the exercise protocol, the participants will have another MRI of the lower legs to assess any change in T2 relaxation time as a construct of muscle edema/damage.
62607960|NCT02077413|EXPERIMENTAL|Stretch-Contract Pre-rehabilitation Group|"All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors. They will also receive the stretch-contract protocol on one leg consisting of the following: a 5 second passive stretch of the dorsiflexors, followed immediately by a 5 second active isometric contraction of the dorsiflexors, and a 5 second rest/relaxation period. This cycle will continue for a duration of \~5 minutes."
62607961|NCT02077413|ACTIVE_COMPARATOR|Stretch-Contract Control Group|All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors.
62607962|NCT02077413|EXPERIMENTAL|Muscle Atrophy|These subjects will undergo MRI and strength testing at baseline and will also be assessed for CK levels, pain report, and ROM. They will then receive an eccentric loading paradigm for the dorsiflexor muscles of the involved leg using an isokinetic dynamometer with varying loads. Approximately two days after the exercise protocol, follow-up assessment of MRI, CK levels, pain report, ROM, and strength will be done.
62830143|NCT06655818|EXPERIMENTAL|Belantamab mafodotin + Dostarlimab|
62830144|NCT06506812|EXPERIMENTAL|High-Dose Influenza Vaccine|Single injection of high-dose influenza vaccine at Day 0
62830145|NCT06506812|ACTIVE_COMPARATOR|Standard-Dose Influenza Vaccine|Single injection of standard-dose influenza vaccine at Day 0
62440068|NCT04093180|OTHER|Control group|Wait-list delayed intervention. Control group continues usual activity and care while staying in the waiting list.
62440069|NCT02376985|PLACEBO_COMPARATOR|Brushing instruction group|"Drug: Everolimus and Exemestane Everolimus, 10 mg/day Exemestane, 25 mg/day Administration on consecutive days once daily after breakfast until tumor progression or for a minimum 8 weeks.~Oral treatment:~Brushing and gargling with saline after every meal (initially instructed by a dental/oral surgeon)."
62607963|NCT00436098|EXPERIMENTAL|1|physical training
62607964|NCT00436098|NO_INTERVENTION|2|
62607965|NCT06731543||Patients who have atrial fibrillation|
62607966|NCT04524585|EXPERIMENTAL|Partial NMB|
62830146|NCT05913765|ACTIVE_COMPARATOR|Intervention|an air cleaner with HEPA and carbon filter installed
62830147|NCT05913765|PLACEBO_COMPARATOR|Placebo|an air cleaner with the primary filter removed
62830148|NCT00587522|EXPERIMENTAL|A|NDO Full-thickness Plicator Procedure
62830149|NCT03012503|PLACEBO_COMPARATOR|Control|Five minutes before cervical manipulation, controls received a placebo gel applied to their neck.
62830150|NCT03012503|EXPERIMENTAL|Treatment|Five minutes before cervical manipulation the treatment group received a menthol containing gel (Biofreeze®) applied to their neck.
62250284|NCT01095406|ACTIVE_COMPARATOR|S1 ventilation|Mechanical ventilation with S1 the thrid hour of ventilation
62250285|NCT01095406|NO_INTERVENTION|Servo i ventilation|1 hour ventilation in pressure support mode with Servo i
62250286|NCT04233164|EXPERIMENTAL|Group A: Glucocorticoids 1 mg/kg dose|Participants with Systemic Lupus Erythematosus (SLE) received a single intravenous dose of methylprednisolone 1 mg/kg and blood was collected two hours and four hours after the start of the infusion.
62250287|NCT04233164|EXPERIMENTAL|Group B: Glucocorticoids 250 mg dose|Participants with Systemic Lupus Erythematosus (SLE) received a single intravenous dose of 250 mg of methylprednisolone and blood was collected two hours and four hours after the start of the infusion.
62250288|NCT00848133|ACTIVE_COMPARATOR|mini-midvastus|
62250289|NCT00848133|ACTIVE_COMPARATOR|mini-subvastus|
62250290|NCT01421927|EXPERIMENTAL|lenalidomide|
62607967|NCT06422936|EXPERIMENTAL|Cohort I|patients with low risk nodular BCC
62607968|NCT06422936|EXPERIMENTAL|Cohort II|patients with high risk BCC
62607969|NCT05710679|EXPERIMENTAL|Interventional|
62250291|NCT03734250||Group Sugammadex HD|Sugammadex used as neuromuscular blocker reverse agent with Vitamin D status equal or above 30ng/ml
62830151|NCT06591871|EXPERIMENTAL|Forty women with post-mastectomy lymphedema participated in this study.|"Forty women with post-mastectomy lymphedema participated in this study. All were free from other disabling conditions impeding self-care practices, hadn't previously received any educational programs about post-mastectomy lymphedema. The educational program was implemented through (5) sessions; (2 theoretical \& 3 practical). Theoretical part included the following: a brief overview of anatomy and physiology of the lymphatic system, definition, causes, signs and symptoms, risk factors, stages, diagnosis and complications of post mastectomy lymphedema, also instructions about general practices for preventing and managing infection, hand and arm care, a healthy nutrition and when you call your physician. While, the practical part included the use of compression bandages, garments and their care, upper extremity lymphedema exercises and Manual Lymphatic Drainage (MLD) massage.~Each session lasted 45 to 60 minutes and was conducted individually or in small groups of 2-3 women."
62830152|NCT04959877||1|Patients diagnosed with oropharyngeal dysphagia who require speech therapy treatment for this reason and who have voluntarily opted for the blended treatment modality.
62607970|NCT02689882|EXPERIMENTAL|pharmacokinetic study|Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
62607971|NCT01712308|EXPERIMENTAL|Treatment Monotherapy (sotatercept)|Patients receive sotatercept SC once every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients unable to achieve anemia-response after 8 cycles will be taken off study.
62607972|NCT01712308|EXPERIMENTAL|Treatment combination (Ruxolitinib + sotatercept)|patients that are already on therapy with ruxolitinib (for at least for 6 months, and on stable dose for last 2 months) will continue ruxolitinib in addition to sotatercept SC once every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients unable to achieve anemia-response after 8 cycles will be taken off study.
62607973|NCT05292976|PLACEBO_COMPARATOR|Zero dose:|
62607974|NCT05292976|ACTIVE_COMPARATOR|Reference 0.09 mg|
62830153|NCT03631251|EXPERIMENTAL|Open Placebo|Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
62830154|NCT06655025|ACTIVE_COMPARATOR|Group B (Dexmedetomidine)|Dexmedetomidine infusion
62830155|NCT06655025|PLACEBO_COMPARATOR|Group A (control)|normal saline infusion
62830156|NCT03102437|EXPERIMENTAL|Optimizer Smart System|All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
62830157|NCT06522646|EXPERIMENTAL|SPCM|Patients will be fitted with the SPCM prothesis
62830158|NCT06522646|ACTIVE_COMPARATOR|Usual Prosthesis|Patients will be fitted with their usual microprocessor prosthesis
62830159|NCT06341257|EXPERIMENTAL|SCART|The patient will receive a dose of 21 Gy in 3 fractions, with the dose maintained at 5 Gy per fraction for the entire tumor GTV boundary.
62830160|NCT04496713|NO_INTERVENTION|Telemedicine - Phone|Patients will continue with their telephone-based telemedicine visit as scheduled. There will be no change to their care. Patients will receive a survey by mail about the visit.
62830161|NCT04496713|EXPERIMENTAL|Telemedicine - Audio/Video|Patients will be given an internet-connected tablet to have their upcoming visit with their physician by audio/video. A survey can be completed on the tablet. The devices will be sent back to the research time after their single use.
62830162|NCT04930471||Metformin (all participants)|Patients with a new indication for Metformin (standard dosage as assigned by the treating physician) therapy. Samples will be collected before and after 12 weeks of Metformin treatment.
62250292|NCT03734250||Group neostigmine HD|Neostigmine used as neuromuscular blocker reverse agent with Vitamin D status equal or above 30 ng/ml
62607975|NCT05292976|ACTIVE_COMPARATOR|Reference 0.18 mg|
62607976|NCT05292976|EXPERIMENTAL|Test 0.09 mg|
62250293|NCT03734250||Group Sugammadex LD|Sugammadex used as neuromuscular reverse agent with Vitamin D status under 30 ng/ml
62607977|NCT05292976|EXPERIMENTAL|Test 0.18 mg|
62607978|NCT00693342|EXPERIMENTAL|Arm I|Patients receive polyvalent antigen-KLH conjugate vaccine in combination with OPT-821 subcutaneously (SC) once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.
62607979|NCT00693342|EXPERIMENTAL|Arm II|Patients receive OPT-821 SC once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.
62607980|NCT05996536||Non-lipodystrophic controls|Non-lipodystrophic controls
62607981|NCT05996536||Partial Lipodystrophy|Partial Lipodystrophy
62830163|NCT04163016|EXPERIMENTAL|Pharmacokinetics Sampling|"This study will include pregnant women who have decided to continue treatment with commercial certolizumab pegol (CZP) in accordance with their treating physician prior to participating in the study. Study participants will be responsible for obtaining and administering commercially available CZP under the care of their physician and according to the locally approved product label.~From all study participants blood samples will be drawn for pharmacokinetics during the study."
62830164|NCT04457882|EXPERIMENTAL|Without Drainage Tube|No place the drainage tube after the intraperitoneal laparoscopic radical prostatectomy
62830165|NCT04457882|ACTIVE_COMPARATOR|With Drainage Tube|Place the drainage tube after the intraperitoneal laparoscopic radical prostatectomy
62250294|NCT03734250||Group Neostigmine LD|Neostigmine used as neuromuscular reverse agent with Vitamin D status under 30ng/ml
62250295|NCT01971983|EXPERIMENTAL|HVLA|The subjects allocated to this group will receive a 'High-velocity, low-amplitude (HVLA) technique over the lumbar spine.
62250296|NCT01971983|EXPERIMENTAL|ME|Subjects allocated to this group will receive a muscle energy (ME) technique.
62250297|NCT01971983|SHAM_COMPARATOR|Sham group|"The individuals allocated to this group received an intervention of the sham. The sample of this group will consist of subjects with history of dysfunctions of the lumbar spine."
62607982|NCT03017027|EXPERIMENTAL|Therapy dog visitation (TDV)|The TDV intervention consists of a one-time 10 minute TDV with the dog handler and his/her dog interacting with the patient. The therapy dog visitation program is a currently established program and each therapy dog meets obedience, temperament, and health standards required by the organization and are deemed appropriate to therapy dog visitation. For hygienic reasons, dogs are bathed before visitation and the patient is required to wash hands before and after the visit. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. The therapy dog will be leashed and controlled by the dog handler. If the participant wants the dog to be placed on the bed, a clean sheet will be placed on the bed in between the dog and patient. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Tactile and visual contact with the dog will be promoted.
62830166|NCT00495313|ACTIVE_COMPARATOR|Cohort 1: doxycycline|Vibramycin plus metronidazole
62830167|NCT00495313|ACTIVE_COMPARATOR|Cohort 2|Oracea® delayed release plus metronidazole
62830168|NCT03171649|EXPERIMENTAL|RETRAINER-S1 & Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the RETRAINER-S1 system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
62250298|NCT05796726||Capmatinib Patients|Patients who received first- or second-line treatment with capmatinib in Study GEOMETRY mono-1
62250299|NCT05796726||Standard of Care Patients|Patients who received appropriate comparative therapy (ACT) defined by the German HTA agency G-BA or standard of care (SoC) practiced in German routine care
62047949|NCT03133026|ACTIVE_COMPARATOR|Sludge group|If Single operator cholangioscopy reveals only sludge then sludge will be cleared using conventional technique during ERCP.
62047950|NCT03133026|ACTIVE_COMPARATOR|Ingrowth / Overgrowth|If Single operator cholangioscopy reveals tumour ingrowth or overgrowth then to evaluate the role of biliary RFA for occluded stent due to tumour ingrowth or overgrowth
62047951|NCT00941993|EXPERIMENTAL|local anesthesia|tympanic membrane local anesthesia delivery system
62047952|NCT02507648|EXPERIMENTAL|A Test|Test drug (Oseltamivir) 1 tablet contains 75 mg Oseltamivir
62047953|NCT02507648|ACTIVE_COMPARATOR|B Reference|Reference drug (Tamiflu®) 1 tablet contains 75 mg Oseltamivir
62047954|NCT03281148|EXPERIMENTAL|Computer guided implant insertion group|According to the allocation, the experimental group will receive implants immediately placed in extraction sockets using CAD/CAM surgical guides.
62047955|NCT03281148|ACTIVE_COMPARATOR|Free hand implant insertion group|According to the allocation, the control group will receive implants immediately placed in extraction sockets using traditional free hand technique.
62250300|NCT03088475|EXPERIMENTAL|Experimental Group|A six-month nurse-led smartphone-based self-management programme (i.e. NSSMP) will be provided to the participants in the experimental group.
62250301|NCT03088475|ACTIVE_COMPARATOR|Control Group|the patients in the control group will receive the exiting nurse-led diabetes service (i.e. NDS) provided by the hospital
62047956|NCT06319417|EXPERIMENTAL|HT treatment|Every caramel contained 15 mg of HT, cyclodextrins and xylitol. Patients consumed 4 caramels/day, totalling 60 mg of HT/day.
62250302|NCT05824286|EXPERIMENTAL|HbA1c prediction model group|HbA1c was predicted every month based on self-monitoring blood glucose for patients in HbA1c prediction model group. Study physicians adjusted patients' hypoglycemic therapy based on self-monitoring blood glucose records/glycated albumin and predicted HbA1c every month.
62440070|NCT02376985|EXPERIMENTAL|Dental oral management group|"Drug: Everolimus and Exemestane Everolimus, 10 mg/day Exemestane, 25 mg/day Administration on consecutive days once daily after breakfast until tumor progression or for a minimum 8 weeks.~Oral treatment:~Scaling and enamel polishing will be performed by a dental and oral surgeon or dental hygienist before everolimus treatment, and once weekly after everolimus treatment.~Brushing and gargling with Neostelin Green 0.2% mouthwash solution after every meal (initially instructed by a dental/oral surgeon)."
62440071|NCT06528574|ACTIVE_COMPARATOR|Conventional root canal treatment|Irrigation will be performed with side vented needles only
62250303|NCT05824286|NO_INTERVENTION|Conventional treatment group|Study physicians adjusted patients' hypoglycemic therapy based on self-monitoring blood glucose records/glycated albumin, without predicted HbA1c.
62250304|NCT02584322|EXPERIMENTAL|ERAS patients|Enhanced recovery pathway
62440072|NCT06528574|EXPERIMENTAL|Irrigant activation with Ultrasonic|Final irrigant activation will be done by ultrasonic
62250305|NCT03476941|EXPERIMENTAL|Antibiotic Irrigation|The drain will be irrigated twice/day with the above antibiotic solution for 7 days maximum
62250306|NCT03476941|PLACEBO_COMPARATOR|Normal Saline Irrigation|The drain will be irrigated twice/day with normal saline
62440073|NCT06528574|EXPERIMENTAL|Irrigant activation with negative pressure|Final irrigant activation will be performed with apical negative pressure
62440074|NCT06528574|EXPERIMENTAL|Irrigant activation with both Ultrasonic and negative pressure|Final irrigation with a combination of ultrasonic and apical negative pressure using the IVAC device.
62047957|NCT06319417|PLACEBO_COMPARATOR|Placebo treatment|Every caramel contained cyclodextrins and xylitol. Patients consumed 4 caramels/day.
62047958|NCT05443165|EXPERIMENTAL|Symptom self-management with an online decision support system|Symptom frequency and severity level of NHL patients will be evaluated with an online web-based application. NHL patients, who will be applying symptom self-management with an online decision support system, will be expected to additionally manage their symptom self-management using with this system. Participants in the intervention group will be asked to evaluate the frequency and severity of symptoms through the online symptom evaluation system on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy courses, and to use the decision support system for symptom self-management according to symptom severity. During the follow-up period, a short SMS message will be sent to the patients on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy cycles. In the third month, after the follow-up phase of the study is completed, the patients in the intervention group who come to the hospital for follow-up or treatment will receive post-tests.
62250307|NCT05529459|EXPERIMENTAL|quantitative coronary angiography-guided percutaneous coronary intervention|Successful revascularization of all coronary artery lesions or segments ≥2.25 mm\* in diameter with ≥50% diameter stenosis by QCA regardless of their functional significance
62440075|NCT04098874|EXPERIMENTAL|Bupropion|Participants randomized to extended-release bupropion. Once-daily
62607983|NCT03017027|OTHER|non-TDV control|Participants randomized to the control condition will receive a new plush stuffed animal for the same 10-min timeframe without any structured activities. At the end of the session, a stuffed animal will be offered to the participant to keep.
62830169|NCT03171649|ACTIVE_COMPARATOR|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
62830170|NCT02611297|OTHER|Transbronchial lung biopsy with cryoprobe|
62830171|NCT04103619|ACTIVE_COMPARATOR|AccuTite|15 patients will receive AccuTite treatment only
62830172|NCT04103619|ACTIVE_COMPARATOR|AccuTite & Morpheus 8 Arm|15 patients will receive AccuTite and Morpheus8 treatment and additional 2 monthly Morpheus8 treatments
62047959|NCT05443165|ACTIVE_COMPARATOR|Symptom self-management with an education booklet|Symptom frequency and severity level of NHL patients will be evaluated with an online web-based application. NHL patients, who will be treated with the symptom self-management with education booklet. Participants will be asked to evaluate the frequency and severity of symptoms through the online symptom evaluation system on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy courses for three months. They will be able to do symptom self-management within the scope of the patient education booklet sent to them via SMS. During the follow-up period, a short SMS message will be sent to the patients on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy cycles. In the third month, after the follow-up phase of the study is completed, the patients in the intervention group who come to the hospital for follow-up or treatment will receive post-tests.
62047960|NCT02306759|EXPERIMENTAL|Treatment|Ketamine 0.3mg/kg intravenous piggyback (IVPB) in 50ml NS over 15 minutes Morphine 0.1mg/kg intravenous push (IVP) PRN at designated intervals
62250308|NCT05529459|ACTIVE_COMPARATOR|fractional flow reserve-guided PCI|Successful revascularization of all coronary artery lesions or segments ≥2.25 mm in diameter with evidence of ischemia or hemodynamic significance by FFR ≤ 0.80 regardless of their anatomic severity†
62250309|NCT01092143|EXPERIMENTAL|BI 671800 (low dose)|Patients receive BI 671800 (low dose) capsules twice daily
62440076|NCT04098874|PLACEBO_COMPARATOR|Placebo|Participants randomized to placebo. Once-daily
62440077|NCT04660942||Control|Healthy child
62440078|NCT04660942||Experimental|Patients with developmental delay
62440079|NCT04763837|EXPERIMENTAL|Intraureteral stent group|Patients assigned to this group will undergo placement of an intraureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in only in the kidney and NOT in the bladder. This group will be the experimental group.
62607984|NCT03489941|EXPERIMENTAL|EM-100|One drop of EM-100 in either the right or left eye once on Day 1.
62607985|NCT03489941|EXPERIMENTAL|Zaditor®|One drop of Zaditor® in either the right or left eye once on Day 1.
62607986|NCT03489941|EXPERIMENTAL|Vehicle|One drop of Vehicle in either the right or left eye once on Day 1.
62830173|NCT06492239|EXPERIMENTAL|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (symptoms onset ≤4.5 h) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
62830174|NCT06492239|PLACEBO_COMPARATOR|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (symptoms onset ≤4.5 h) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
62830175|NCT03171961|EXPERIMENTAL|online visit group|in online visit group , subjects has online visit with dietitian every 2 weeks
62830176|NCT03171961|EXPERIMENTAL|clinic visit group|clinic visit group ,subject has every 2 weeks in person visit at clinic
62830177|NCT03171961|EXPERIMENTAL|self-directed group|self-directed group ,subjects receive nutritional information via web and their energy needs for weight loss
62830178|NCT01780506|EXPERIMENTAL|E/C/F/TAF (Double-Blind Phase)|E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks
62830179|NCT01780506|ACTIVE_COMPARATOR|E/C/F/TDF (Double-Blind Phase)|E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks
62830180|NCT01780506|EXPERIMENTAL|Open-Label Extension Phase|After study unblinding, participants who complete 144 weeks of the study had the option to receive open-label E/C/F/TAF until commercially available, or until Gilead Sciences terminated the study in that country.
62440080|NCT04763837|ACTIVE_COMPARATOR|Conventional Double-J stent|Patients assigned to this group will undergo placement of a double-J ureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in both the kidney and the bladder. This group will serve as the control.
62607987|NCT06381154|EXPERIMENTAL|Treatment (verteportin, photoradiation, pembrolizumab)|Patients receive verteporfin IV and undergo a biopsy and intratumoral photoradiation over 60-90 minutes using EUS or CT guidance on day 0. Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care oxaliplatin IV over 2-6 hours, leucovorin IV over 15 minutes - 2 hours, irinotecan IV over 90 minutes, and fluorouracil IV on days 3, 15 and 29 of cycle 1 only, then on days 1, 15, and 29 of remaining cycles. Cycles repeat every 42 days for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients may optionally undergo lymph node biopsy on day 2 or 3 of cycle 1. Additionally, patients undergo blood sample collection, CT, PET/CT and optional PET/MRI on study.
62830181|NCT05369741|EXPERIMENTAL|TIME™ at Home|TIME™ at Home is a licensed, pre-recorded video-based, group, community exercise program. One program will have a maximum of 10 participants registered. March of Dimes Canada will run two programs. A 1.5-hour session will be hosted by two facilitators using Zoom twice a week for 8 weeks, starting with the Level 1 video (beginner level). All participants will switch to the Level 2 video (advanced level) mid-program.
62830182|NCT04249245||Parkinson Patients|"These patients are Hospitalized or consult in the participating hospitals of the Pointe à Pitre (Guadeloupe), or at the Pitié-Salpêtrière hospital (Paris).~They were diagnosed Idiopathic PD (Parkinson Disease). The diagnosis is made according to the MDS criteria described in Postuma and al. 2015."
62830183|NCT04249245||Control Subjects|"They are Spouse of Parkinson Patients group , with an age difference \<5 years compared to the patient concerned.~If the Spouse can't be included, a corresponding control subject could be recruited in the consultation with an age difference \<5 years compared to the patient concerned, in respecting the final gender ratio of the PD group."
62830184|NCT04053660|NO_INTERVENTION|Control|Periodontally healthy group
62830185|NCT04053660|EXPERIMENTAL|Chronic Periodontitis|Patients with chronic periodontitis
62830186|NCT02691507|ACTIVE_COMPARATOR|Positive Control|Marketed - EpiCeram(R) Skin Barrier Emulsion: Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin.
62830187|NCT02691507|EXPERIMENTAL|Experimental|Not Yet Marketed - 1% Colloidal Oatmeal Balm: Apply at least once per night or more if needed.
62830188|NCT02000206|ACTIVE_COMPARATOR|propofol + alfentanil|"Patients from the Propofol / Alfentanil group will receive in addition:~1. A loading dose of 10-15 mcg/kg Alfentanil + 0.4 mg/kg Propofol, 2 minutes prior to the beginning of the procedure.~2. Additional boluses of Propofol (aliquots of 10-50 mg) throughout the procedure if required"
62830189|NCT02000206|ACTIVE_COMPARATOR|propofol + ketamine|"Patients from the Propofol / Ketamine group will receive in addition:~1. A loading dose of 0.2-0.3 mg/kg Ketamine + 0.4 mg/kg Propofol, 2 minutes prior to the beginning of the procedure.~2. Additional boluses of Propofol (aliquots of 10-50 mg) and/or Ketamine (aliquots of 5-25 mg) throughout the procedure if required."
62830190|NCT03371498|EXPERIMENTAL|Methylprednisolone Group|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L will receive methylprednisolone
62047961|NCT02306759|PLACEBO_COMPARATOR|Placebo|Normal saline 50ml intravenous piggyback (IVPB) over 15 minutes Morphine 0.1mg/kg intravenous push (IVP) PRN at designated intervals
62047962|NCT01843192||VATS for suspected or confirmed NSCLC|Single arm study
62047963|NCT01271348|ACTIVE_COMPARATOR|Etoricoxib|
62047964|NCT01271348|PLACEBO_COMPARATOR|Placebo tablet|
62047965|NCT01865786||FTC/TDF for PrEP|The study has one target prospective cohort defined as HIV-1 negative women who had been prescribed FTC/TDF for pre-exposure prophylaxis (PrEP); with two strata: a) those who continue to take FTC/TDF for PrEP during their pregnancy, and b) those who decide to stop FTC/TDF for PrEP during pregnancy.
62047966|NCT01865786||ARV population|The study has one comparison cohort defined as HIV-positive women who were on any antiretroviral (ARV) medication at the time the pregnancy was detected. This is a propensity score matched retrospective cohort selected from the prospective arm of the APR. This cohort is assembled retrospectively in order to appropriately match the subjects by calendar time and the correlates of exposure, with exposure being defined as being on FTC/TDF for PrEP vs being exposed to other ARVs.
62047967|NCT01665664|OTHER|Hypocaloric feeding group|intervention - Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
62830191|NCT03371498|PLACEBO_COMPARATOR|Control Group|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L will receive placebo
62830192|NCT01815346|EXPERIMENTAL|Acupuncture Group - Twice a Week|Acupuncture 2 times a week for 6 weeks. Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.
62830193|NCT01815346|EXPERIMENTAL|Acupuncture Group - Three Times a Week|Acupuncture 3 times a week for 4 weeks. Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.
62250310|NCT01092143|ACTIVE_COMPARATOR|Fluticasone propionate|Patients inhale from Fluticasone propionate metered dose inhaler (MDI) twice daily
62250311|NCT01092143|PLACEBO_COMPARATOR|Placebo|Patients receive placebo capsules twice daily
62250312|NCT01092143|EXPERIMENTAL|BI 671800 (medium dose)|Patients receive BI 671800 (medium dose) capsules twice daily
62440081|NCT01157728||Relapsing Multiple Sclerosis patients|
62607988|NCT00943176|PLACEBO_COMPARATOR|Sugar Pill|
62047968|NCT01665664|NO_INTERVENTION|Full energy feeding group|Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 100% of REE will be provided.
62047969|NCT04072094|EXPERIMENTAL|Minimally Invasive Locking Plate Fixation|Patients randomized to the Minimally Invasive Locking Plate Fixation arm will be treated with plate fixation. The plate may be applied in a percutaneous fashion. Any combination of locked and/or non-locked screws may be used.
62440082|NCT01157728||healthy volunteer|
62607989|NCT00943176|EXPERIMENTAL|Modafinil|
62607990|NCT04202289|ACTIVE_COMPARATOR|Silver Sulfadiazine Cream 1%|In the control group, after cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of Silver Sulfadiazine Cream 1% was applied and covered with gauze and bandage. The dressing changes occurred every 48 hours. The patients were evaluated every 48 hours for the study parameters.
62607991|NCT04202289|EXPERIMENTAL|Nile Tilapia Fish Skin|In the test group, the treatment was Nile Tilapia Fish Skin, which have a patent registered at the National Institute of Industrial Property (INPI) under number BR 10 2015 021435 9. Nile Tilapia Fish Skin was subjected to a rigorous process of chemical sterilization, glycerolization and irradiation, followed by microbiological tests for bacteria and fungi, before storage in sterile refrigerated packaging. Prior to its use in the patient, the skin was washed thrice in sterile 0.9% saline for 5 minutes, in order to remove glycerol. Regarding application in the study patients, after cleaning the lesion with tap water and 2% chlorhexidine gluconate, Nile Tilapia Fish Skin was applied and covered with gauze and bandage. Throughout the treatment, dressings with Nile Tilapia Fish Skin were only changed if the biomaterial was not properly adhered to the wound bed. The patients were evaluated every 48 hours for the study parameters.
62047970|NCT04072094|ACTIVE_COMPARATOR|Intramedullary Nail Fixation|Patients randomized to the Intramedullary Nail Fixation arm will be receive a standard locked intramedullary nail fixation. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with a reamed technique.
62047971|NCT00654901|EXPERIMENTAL|DTaP-IPV-Hep B-PRP~T Batch 1|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component \[aP\]), Hepatitis B (Hep B, \[recombinant DNA\]) and poliomyelitis (Inactivated \[IPV\]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP\~T) in Study A3L11 (NCT00404651); and will receive a booster dose of (DTaP-IPV-Hep B-PRP\~T) at Day 0 in the present study.
62047972|NCT00654901|EXPERIMENTAL|DTaP-IPV-Hep B-PRP~T Batch 2|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component \[aP\]), Hepatitis B (Hep B, \[recombinant DNA\]) and poliomyelitis (Inactivated \[IPV\]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP\~T) in Study A3L11 (NCT00404651) and will receive a booster dose of (DTaP-IPV-Hep B-PRP\~T) at Day 0 in the present study.
62047973|NCT00654901|EXPERIMENTAL|DTaP-IPV-Hep B-PRP~T Batch 3|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component \[aP\]), Hepatitis B (Hep B, \[recombinant DNA\]) and poliomyelitis (Inactivated \[IPV\]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP\~T) in Study A3L11 (NCT00404651) and will receive a booster dose of (DTaP-IPV-Hep B-PRP\~T) at Day 0 in the present study.
62047974|NCT00654901|ACTIVE_COMPARATOR|Infanrix Hexa™|Participants had received 3 primary doses of Diphtheria (D), Tetanus (T), Pertussis (acellular, component \[aP\]), Hepatitis B (Hep B, \[recombinant DNA\]) and poliomyelitis (Inactivated \[IPV\]), (Infanrix Hexa™) plus Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed in Study A3L11 (NCT00404651) and received a booster dose of (DTaP-IPV-Hep B-PRP\~T) at Day 0 in the present study.
62250313|NCT01092143|EXPERIMENTAL|BI 671800 (high dose)|Patients receive BI 671800 (high dose) capsules twice daily
62250314|NCT03554551||Patients with Parkinsons disease|Disease duration \> 4 years, Hoehn \& Yahr stage 2-3, 50-85 years old
62250315|NCT03554551||Healthy controls|50-85 years
62250316|NCT03517891|EXPERIMENTAL|WIC +|"The intervention consist in the implementation of an enhanced nutritional education and services model through the use of a combination of modalities to disseminate messages and educational materials framed in the health empowerment model. Each component of the intervention has been developed to provide the information consistent with the theoretical framework of the modality being used.~The intervention targets the following behaviors: Infant activation, Healthy sleep patterns, Screen time, Healthy feeding practices."
62607992|NCT06730633|EXPERIMENTAL|Intervention Group|This group will receive the Heart Matters intervention, delivered by community-based facilitators. All participants consenting to the present study will be assigned to this arm.
62607993|NCT06730633|ACTIVE_COMPARATOR|Propensity-matched Control Group|This group received the Heart Matters intervention, delivered by researchers, under NCT02707432.
62607994|NCT04965103|ACTIVE_COMPARATOR|Bridging|Tendon repair with graft interposition
62607995|NCT04965103|EXPERIMENTAL|SCR|Superior Capsule reconstruction
62607996|NCT02844907|EXPERIMENTAL|Hyperglycemic clamp + Exendin (9-39)|During the 2-hour procedure, a variable infusion of 20% dextrose and blood glucose will be clamped at basal + 3mM. Participants will receive an infusion of the GLP-1 receptor antagonist Exendin (9-39) between the 60-120 minute time-points of the clamp. The amount of Ex-9 infused will be 750 pmol/kg/min for 60 minutes.
62607997|NCT02844907|EXPERIMENTAL|Dexamethasone|Subjects will be asked to take 4 mg once daily between Visit-2 and Visit-3.
62830194|NCT02833233|EXPERIMENTAL|Cryoablation and Immune Therapy|Patients will undergo breast biopsy with cryoablation 7-10 days prior to the planned surgery, and ipilimumab with nivolumab administration 1-5 days before cryoablation. All patients will undergo surgery at the pre-determined day defined at the initial surgical consultation. Women will receive ipilimumab and nivolumab 1-5 days prior to US or MRI-guided core biopsy and cryoablation date. Intravenous ipilimumab will be administered as a single 1 mg/kg dose to be infused intravenously over 90 minutes. Intravenous nivolumab will be administered as a single 3 mg/kg dose to be infused intravenously over 60 minutes.
62830195|NCT04402034|EXPERIMENTAL|Application of tele-rehabilitation|Individuals that will perform the protocol of virtual reality intervention.
62830196|NCT02769117|ACTIVE_COMPARATOR|Ultrasound on fractured bone|An ultrasound technique will be used to record the acoustic response of the fractured bone at each clinical visit until the fracture is healed. The ultrasound probe and a small hydrophone are placed on the exposed portion of the forearm on either sides of the fracture. The ultrasound intensity will be at the safe level according to the FDA regulation. Investigators will conduct the tests on the fracture and on the unaffected (contralateral) bone as the control. Typically this is at 1-, 2-, 4-, and 6- weeks following the fracture.
62830197|NCT02769117|ACTIVE_COMPARATOR|Ultrasound on contralateral intact bone|An ultrasound technique will be used to record the acoustic response of the intact bone as control at each clinical visit. The ultrasound probe and a small hydrophone are placed on the exposed portion of the forearm or clavicle. The ultrasound intensity will be at the safe level according to the FDA regulation. Investigators will conduct the tests on the fractured forearm/clavicle and on the unaffected (contralateral) forearm/clavicle as the control. Typically this is at 1-, 2-, 4-, and 6- weeks following the fracture.
62250317|NCT03517891|NO_INTERVENTION|WIC Standard of care (Control)|Participants recruited in randomly assigned control clinics will receive the WIC program standard of care. This includes the projected implementation of a web page for the nutritional education contacts. We will update our definition of the PR WIC program standard of care upon recruitment initiation and throughout the study implementation phase. We will also document the utilization rate of the web base platform provided by WIC among the control participants to determine baseline use of distance learning platforms.
62607998|NCT06234111||Patients with severe obesity and multimorbidity|Patients with morbid obesity (mainly class II and III) with multiple chronic conditions. Most patients are initially referred for bariatric surgery, but are deemed ineligible for various reasons (typically inability to independently induce weight loss, severe mental disease, eating disorder, and serious comorbidity).
62607999|NCT00982852||Acute|Patients in acute need for angioplasty or left heart catheterization.
62608000|NCT00982852||Chronic or non-acute|Patients will planned angioplasty or left heart catheterization.
62830198|NCT03110523|EXPERIMENTAL|Group A|High Dose: X0002 or placebo, BID (in the morning and before going to bed), n=376
62830199|NCT03110523|EXPERIMENTAL|Group B|Low Dose: X0002 or placebo, BID (in the morning and before going to bed), n=376
62830200|NCT00674817|EXPERIMENTAL|400 microgrammes GSK961081 and salbutamol|400 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3x 200 microgrammes at 20 min intervals, administered via spacer) of salbutamol at 1h, 12h and 24h of dosing.
62830201|NCT00674817|EXPERIMENTAL|1200 microgrammes GSK961081 and salbutamol|1200 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (3x 200 microgrammes at 20 min intervals, administered via spacer) of salbutamol at 1h, 12h and 24h of dosing.
62830202|NCT00674817|EXPERIMENTAL|400 microgrammes GSK961081 and ipratropium bromide|400 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (20 microgrammes, 20 microgrammes and 40 microgrammes at 20 min intervals, administered via spacer) of ipratropium bromide at 1h, 12h and 24h of dosing.
62830203|NCT00674817|EXPERIMENTAL|1200 microgrammes of GSK961081 and ipratropium bromide|1200 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (20 microgrammes, 20 microgrammes and 40 microgrammes at 20 min intervals, administered via spacer) of ipratropium bromide at 1h, 12h and 24h of dosing.
62830204|NCT00674817|PLACEBO_COMPARATOR|400 microgrammes of GSK961081 and placebo|400 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3 doses at 20 min intervals, administered via spacer) of placebo at 1h, 12h and 24h of dosing.
62830205|NCT00674817|PLACEBO_COMPARATOR|1200 microgrammes of GSK961081 and placebo|1200 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3 doses at 20 min intervals, administered via spacer) of placebo at 1h, 12h and 24h of dosing.
62830206|NCT01512927||ESRD with regular hemodialysis|
62830207|NCT04254003|OTHER|Test, then Control|DT1 Toric contact lenses worn first, followed by AO1DfA contact lenses, as randomized. Each product will be worn in both eyes for approximately 1 hour.
62830208|NCT04254003|OTHER|Control, then Test|AO1DfA contact lenses worn first, followed by DT1 Toric contact lenses, as randomized. Each product will be worn in both eyes for approximately 1 hour.
62830209|NCT04417517|EXPERIMENTAL|evorpacept (ALX148) + azacitidine|"Phase 1: Participants will receive escalating doses of evorpacept (ALX148) in combination with azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28 day cycle~Phase 2: Participants will receive evorpacept (ALX148) at the recommended Phase 2 dose in combination with azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28-day cycle"
62830210|NCT04417517|ACTIVE_COMPARATOR|azacitidine|Phase 2 only: Participants will receive azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28-day cycle
62250318|NCT00971763|EXPERIMENTAL|R-GCVP|"Up to 6 x 21 day cycles of R-GCVP:~* Gemcitabine 750mg/m\^2 days 1 \& 8 (increasing to 875mg/m\^2 for cycle 2 \& 1g/m\^2 for subsequent cycles if tolerated satisfactorily)~* Cyclophosphamide 750mg/m\^2 day 1~* Vincristine 1.4mg/m\^2 day 1 (capped at 2mg)~* Prednisolone 100mg/day days 1-5~* Rituximab 375mg/m\^2 day 1~* Neulasta 6mg day 9"
62440083|NCT05625711|EXPERIMENTAL|Robot assisted surgery|The robot will assist doctors to complete lower limb artery surgery, including but not limited to the transfer and withdrawal of guide wire, catheter and stent
62830211|NCT01481753|ACTIVE_COMPARATOR|Braun arm|patients received Braun enteroenterostomy
62830212|NCT01481753|ACTIVE_COMPARATOR|Non Braun Arm|Patients do not receive a Braun enteroenterostomy
62830213|NCT06655272|EXPERIMENTAL|Intervention|Bacterial lysate p.o. administered for two three-months cycles.
62830214|NCT06655272|PLACEBO_COMPARATOR|Control|Matching placebo.
62830215|NCT02201394|EXPERIMENTAL|Loading dose|Patients with stable CVD given a single ticagrelor loading dose and aspirin loading dose
62830216|NCT02201394|EXPERIMENTAL|Maintenance dose|Patients with stable CVD given ticagrelor maintenance dose and aspirin maintenance dose for one week.
62830217|NCT02115048|ACTIVE_COMPARATOR|Arm A|Continuous regimen of oral Letrozole 2.5 mg daily
62047975|NCT04238026|EXPERIMENTAL|Distal radial artery approach|Puncture in the snuff box area of the arm with through and through technique, advancement of a wire and placement of an hydrophilic sheath introducer.
62250319|NCT03926845|ACTIVE_COMPARATOR|Isobutylamido-thiazolyl-resorcinol Cream 0.2%|The cream contains 0.2% Isobutylamido-thiazolyl-resorcinol.
62250320|NCT03926845|PLACEBO_COMPARATOR|Vehicle|The cream contains no active ingredients.
62830218|NCT02115048|EXPERIMENTAL|Arm B|Continuous regimen of oral Letrozole 2.5 mg daily plus oral Afatinib 30 mg daily
62440084|NCT03099395||No re-MI, one re-MI, > one re-MI|From a population with MI surviving one year (78 468 pts) the number of pts with no re-MI, one re-MI or \> re-MI will be described.
62830219|NCT04617678|ACTIVE_COMPARATOR|Prospective Prehabilitation|Prospectively enrolling patients into a prehabilitation program for head and neck cancer.
62830220|NCT04617678|NO_INTERVENTION|Prospective Control|Prospectively enrolling patients to a control arm with no intervention.
62830221|NCT04155762|EXPERIMENTAL|Intervention|Both suspension systems were applied consecutively to the participants. Initially, participants used the Pin Suspension System (PSS) for three months following fabrication and adjustment of the prosthesis, and a prosthetic training period. They then employed the Vacuum-Assisted Suspension System (VASS) for three months after a similar training period.
62830222|NCT06314802||Learning curve of Surgeon I|
62830223|NCT06314802||Learning curve of Surgeon II|
62830224|NCT06314802||Learning curve of Surgeon III|
62830225|NCT06314802||Learning curve of Surgeon IV|
62047976|NCT04238026|ACTIVE_COMPARATOR|Proximal radial artery approach|Puncture in the ventral side of the arm (2 cm proximal to the styloid apophysis) with through and through technique, advancement of a wire and placement of an hydrophilic sheath introducer.
62250321|NCT01855763|EXPERIMENTAL|metformin|group A1:Consists of patients with GDM who were given drug metformin as treatment group B1:Consists of patients with type 2 diabetes in pregnancy were given the drug metformin as treatment intervention with drug metformin is given for control of diabetes in esclation dose of 500mg /day upto 2.5 grams per day in two to three divided doses till delivery
62440085|NCT03316079|ACTIVE_COMPARATOR|Chest physiotherapy techniques|Manual chest physiotherapy techniques applied
62440086|NCT03316079|EXPERIMENTAL|Chest physiotherapy techniques + Mechanical in-exsufflation|Mechanical insufflation-exsufflation in addition to manual chest physiotherapy techniques
62047977|NCT03177668|EXPERIMENTAL|YS110|"Phase 1 part: Administration of 3 different dose cohort~Phase 2 part: Administration of recommended dose determined from result of Phase 1 part"
62047978|NCT04575168||Positive for COVID-19|Subjects positive for COVID-19 as indicated by the Standard of Care test.
62047979|NCT04575168||Negative for COVID-19|Subjects negative for COVID-19 as indicated by the Standard of Care test.
62047980|NCT05521854|SHAM_COMPARATOR|Control|Participants in this group will have access to the DynamiCare app; however, no behavioral incentives will be provided to this group.
62047981|NCT05521854|EXPERIMENTAL|Escalating Low|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and reset to the lowest amount when a test is positive or missed. The Low group will receive lower incentive amounts than the High group."
62047982|NCT05521854|EXPERIMENTAL|Escalating High|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and reset to the lowest amount when a test is positive or missed. The High group will receive higher incentive amounts than the Low group."
62047983|NCT05521854|EXPERIMENTAL|De-Escalating Low|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The Low group will receive lower incentive amounts than the High group."
62250322|NCT01855763|ACTIVE_COMPARATOR|insulin|GroupA2:gestational diabetes on insulin treatment Group B2:type 2 diabetes on insulin treatment intervention:insulin treatment till delivery
62440087|NCT02965820|OTHER|OFPM, then HMPS|OPTI-FREE® PureMoist® multi-purpose contact lens solution in Period 1, followed by subject's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
62440088|NCT02965820|OTHER|HMPS, then OFPM|Subject's habitual multi-purpose contact lens solution in Period1, followed by OPTI-FREE® PureMoist® contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
62047984|NCT05521854|EXPERIMENTAL|De-Escalating High|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The High group will receive higher incentive amounts than the Low group."
62250323|NCT02772640|ACTIVE_COMPARATOR|Arm I: R+E morning->evening|Rosuvastatin and Ezetimibe morning or evening administration: Rosuvastatin (R) plus Ezetimibe (E) administration in the morning (8:00) for 6 weeks. After 6 weeks - intervention - change of the timing of study drug administration to the evening hours (20:00).
62250324|NCT02772640|ACTIVE_COMPARATOR|ARM II: R+E evening->morning|Rosuvastatin and Ezetimibe evening or morning administration: Rosuvastatin (R) plus Ezetimibe (E) administration in the evening (20:00) for 6 weeks. After 6 weeks - intervention - change of the timing of study drug administration to the morning hours (8:00).
62250325|NCT02145533||Group I|patient with ruptured aneurysms
62250326|NCT02145533||Group II|patients with non-ruptured aneurysms
62250327|NCT02145533||Group III|Healthy volunteers
62250328|NCT02931942||A: Acute leukemia|Patients that will receive intensive clinical chemotherapy for acute leukemia or high risk myelodysplasia (RAEB2) Blood withdrawn 5-7 x
62250329|NCT02931942||B: Autologous transplantation|Patients that will receive high dose chemotherapy and autologous stem cell rescue for varies hematological malignancies Blood withdrawn 5-7 x
62250330|NCT02931942||C: controls|Healthy controls, found amongst family members of patients of group A and B Blood withdrawn 5-7 x
62250331|NCT02931942||D: lung cancer|Patients that will receive relatively mild immunosuppressive chemotherapy for lung cancer, that will mostly be in the outpatient setting Blood withdrawn 5-7 x
62250332|NCT02931942||E: colon cancer|Patients that will receive relatively mild immunosuppressive chemotherapy for colon cancer, that will mostly be in the outpatient setting and mostly adjuvant Blood withdrawn 5-7 x
62250333|NCT02931942||F: controls|Healthy controls, found amongst family members of patients of group D and E Blood withdrawn 5-7 x
62608001|NCT06325670|EXPERIMENTAL|BED treatment|The BED group therapy program consists of 11 sessions, followed by a 3-month follow-up session. Each 3-hour session accommodates eight patients and two psychologists. Treatment follows a manualized cognitive behavioral therapy approach, with patients receiving a complimentary manual at the start. Sessions are conducted both in-person and online using a blended care model, with about one-third delivered virtually.
62047985|NCT05521854|EXPERIMENTAL|Constant High|"In the Constant groups, incentive amounts will remain unchanged across time. The High group will receive higher incentive amounts than the Low group."
62250334|NCT06281067|EXPERIMENTAL|"full-physiology approach arm"|"In the full-physiology approach arm, patients will be, during CA, simultaneously subjected to a full interventional diagnostic procedure, including:~* resting distal coronary pressure to aortic pressure ratio (Pd/Pa);~* fractional flow reserve (FFR) after intravenous adenosine administration;~* Resting Ful-Cycle Ratio (RFR);~* coronary flow reserve (CFR) and index of microvascular resistance (IMR);~* assessment of FFR, CFR and IMR after inotropic stimulation with dobutamine (respectively FFR-d, CFR-d and IMR-d);~* acetylcholine (ACH) provocative test."
62608002|NCT06325670|OTHER|Waitlist|The waitlist control group consists of participants who are placed on a waiting list to receive treatment. While participants in the treatment group immediately receive BED treatment (Arm 1), those in the waitlist control group do not receive active treatment initially. They remain on the waiting list for 6 months until the treatment group completes their intervention. At that point, participants in the waitlist control group also receive the same BED treatment, serving as a comparison group to evaluate the intervention's effectiveness.
62608003|NCT03813134|ACTIVE_COMPARATOR|Immediate PCI with medical therapy|"Group 1 will receive immediate revascularisation with Percutaneous Coronary Intervention (PCI) to the culpirit lesion only) + standard care (pharmacological support titrated to attain SBP \>90mmHg).~No mechanical support device allowed."
62250335|NCT06281067|OTHER|"standard approach arm"|"In the standard approach arm, patients will undergo only an angiographic evaluation, without any invasive intracoronary assessment."
62608004|NCT03813134|EXPERIMENTAL|Immediate PCI with early VA-ECMO|Group 2 will receive immediate PCI plus standard pharmacological support with early peripheral veno-arterial ECMO.
62608005|NCT01934127|EXPERIMENTAL|Formulation 1 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 1 at a 21 day interval
62830226|NCT02037971|EXPERIMENTAL|Aerobic Exercise|Subjects will follow one defined exercise process, according their cardiopulmonary exercise test, during 16 weeks, two times per a week.
62830227|NCT02037971|EXPERIMENTAL|Control Group|A non-exercise group will receive regular educational information relating to their condition.
62047986|NCT05521854|EXPERIMENTAL|Constant Low|"In the Constant groups, incentive amounts will remain unchanged across time. The Low group will receive lower incentive amounts than the High group."
62830228|NCT03865901||Non-diabetic pregnant women|Non-diabetic women with singleton pregnancy undergoing screening for gestational diabetes who provide plasma samples for testing with the Mellitus GCD59 Test
62830229|NCT04986904|EXPERIMENTAL|SHUTi (Sleep Healthy Using the Internet)|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention. They will spend 1-2 hours each week for 6-9 weeks completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention. As users progress through the intervention, they will receive automated, tailored instructions for how to improve their sleep.
62250336|NCT02553122|OTHER|Control Group|This group of patients will receive standard protocol to control intra-operative blood loss.
62250337|NCT02553122|ACTIVE_COMPARATOR|Treatment Group|This group of patients will receive TXA, Evicel and standard protocol to control intra-operative blood loss.
62830230|NCT06390436|ACTIVE_COMPARATOR|Control arm : conventional strategy|At W0, ADA administration will be continued every 14 days. At W24, the control arm will continue to receive ADA every 14 days regardless of serum ADA concentration.
62830231|NCT06390436|EXPERIMENTAL|Arm 2: Interventional arm : adalimumab dose spacing strategy|At W0, if the serum ADA concentration is ≥ 8 μg/mL, ADA administration will be spaced every 21 days. At W24, if the ADA concentration is \< 3.3 μg/mL (having a serum ADA concentration above this threshold was associated with a complete therapeutic response according to one study), administrations will be repeated every 14 days. If the ADA concentration is ≥ 3.3 and \< 8μg/mL, administrations will be left every 21 days. If ADA concentration is still ≥8μg/mL, ADA administrations will be spaced every 28 days.
62830232|NCT01804400|EXPERIMENTAL|QAW039 + Montelukast|
62047987|NCT06156423|EXPERIMENTAL|Motor Control Rehabilitation|
62047988|NCT06156423|ACTIVE_COMPARATOR|Standard Rehabilitation|
62250338|NCT00078325|EXPERIMENTAL|1|Armodafinil 250 mg/day
62440089|NCT04473352||Single Group|Patients with suspected acute viral status for COVID 19 will be invited to participate in the identification of the first symptoms. The diagnosis of COVID-19 will be confirmed according to the determinations of the MS through the reaction of qRT-PCR in the nasopharynx swab. Patients will undergo multiple collections of biological material including blood, saliva, semen, and urine. Each patient will be subjected to serial sample collections. The samples will be processed and analyzed for the presence of viral RNA. Patients with 2 consecutive negative samples did not need to perform subsequent collections.
62440090|NCT05821179||Group I|12 patients diagnosed with OSCC.
62440091|NCT05821179||Group II|12 patients diagnosed with OLP.
62440092|NCT05821179||Group III|12 systemically free individuals with no oral mucosal lesions.
62440093|NCT03779191|EXPERIMENTAL|Intervention|Patients in this intervention arm will receive the therapeutic combination of Alectinib dosed PO 600 mg bis in die (BID) with meals and Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol
62440094|NCT03501784|EXPERIMENTAL|Novidia Dental bonding and flow|Nobio particles incorporated within Novidia Dental Bonding and Flow.
62440095|NCT03501784|ACTIVE_COMPARATOR|Filtek bond and flow composite|standard of care class V composite restoration performed with Filtek and 3M
62440096|NCT05074589|EXPERIMENTAL|Treatment group A|Irinotecan liposome plus 5-fluorouracil, Leucovorin
62440097|NCT05074589|ACTIVE_COMPARATOR|Treatment group B|Placebo plus 5-fluorouracil, Leucovorin
62440098|NCT00534625|PLACEBO_COMPARATOR|1|
62440099|NCT00534625|EXPERIMENTAL|2|150 mg zileuton by intravenous injection
62440100|NCT00534625|EXPERIMENTAL|3|300 mg zileuton by intravenous injection
62440101|NCT03294083|EXPERIMENTAL|Part 1, Dose escalation|"Pexa-Vec will be administered via IV infusion at a dose of 3 x 10\^8 pfu once per week for 4 treatments. Based on the occurrence of dose-limiting toxicities, patients may subsequently be enrolled to receive Pexa-Vec on the same schedule at a dose of 1 x 10\^9 pfu.~Cemiplimab will be administered via IV infusion every 3 weeks."
62440102|NCT03294083|EXPERIMENTAL|Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab|"Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments.~Cemiplimab will be administered via IV infusion every 3 weeks."
62440103|NCT03294083|EXPERIMENTAL|Part 2-Arm B, Cemiplimab|"Cemiplimab will be administered via IV infusion every 3 weeks.~At disease progression, Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments. Cemiplimab will continue every 3 weeks."
62250339|NCT00078325|EXPERIMENTAL|2|Armodafinil 150 mg/day
62250340|NCT00078325|PLACEBO_COMPARATOR|3|Placebo
62250341|NCT02289651|EXPERIMENTAL|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
62440104|NCT03294083|EXPERIMENTAL|Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab|"Pexa-Vec will be administered via IV infusion once per week for 4 treatments.~Cemiplimab will be administered via IV infusion every 3 weeks."
62440105|NCT03294083|EXPERIMENTAL|Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab|"Pexa-Vec will be administered via IV infusion once per week for 4 treatments.~Cemiplimab will be administered via IV infusion every 3 weeks."
62440106|NCT06162403|EXPERIMENTAL|Peripheral Nerve Stimulation|Participants will be asked to have PNS leads inserted via a needle, which will provide a mild, stimulating electrical current to the effected nerves 24 hours a day for up to 60 days. Participants will have study visits during and after this time.
62440107|NCT04488471||high-risk group|IBD patients who were high risk of infection and were shielding
62440108|NCT04488471||low-risk group|IBD patients who were low risk of infection and were following standard quarantine guidance
62608006|NCT01934127|EXPERIMENTAL|Formulation 2 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 2 at a 21 day interval
62830233|NCT01804400|EXPERIMENTAL|QAW039 Once a day (q.d.)|
62830234|NCT01804400|EXPERIMENTAL|QAW039 Twice a day (b.i.d.)|
62830235|NCT01804400|ACTIVE_COMPARATOR|Montelukast|
62250342|NCT02289651|EXPERIMENTAL|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
62250343|NCT03738878|ACTIVE_COMPARATOR|valsartan then LCZ696|"After four-week treatment with valsartan, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.~Then, after three-week washout and four week therapy with LCZ696, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin."
62250344|NCT03738878|ACTIVE_COMPARATOR|LCZ696 then valsartan|"After four-week treatment with LCZ696, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.~Then, after three-week washout and four week therapy with valsartan, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin."
62250345|NCT05998083|ACTIVE_COMPARATOR|control group|continued their normal education and physiotherapy
62250346|NCT05998083|EXPERIMENTAL|experimental group|they continued their normal training and physiotherapy, in addition, purposeful balance and coordination exercises were given for 40 minutes a day, 2 days a week for 8 weeks.
62250347|NCT02179879||Video validation group|This will include video taping of experts (defined as one who has performed more than 500 labor epidurals in preceding 5 year period) and novices (defined as one who has done less than 50 epidurals in preceeding 2 years) perfoming labor epidural
62250348|NCT01033526|PLACEBO_COMPARATOR|Arm 2|
62250349|NCT01033526|EXPERIMENTAL|Arm 1|
62830236|NCT01804400|PLACEBO_COMPARATOR|Placebo|
62830237|NCT06403397|EXPERIMENTAL|Experimental group|"* Working in the intensive care unit,~* Willing to participate in the study voluntarily,~* Nurses willing to use the monitor alarm control tool."
62830238|NCT06403397|NO_INTERVENTION|Control group|"* Working in the intensive care unit,~* Willing to participate in the study voluntarily,"
62830239|NCT04513223|EXPERIMENTAL|SHR-A1811|
62250350|NCT05829642||ECM intervention arm|The Enhanced Care Management (ECM) intervention consists of training and coaching family physicians and their teams to develop holistic care and pro-active outreach plans for chronically ill patients or those vulnerable to developing chronically illnesses, as identified and agreed between the enrolled providers and the Estonian Health Insurance Fund (EHIF). The core goal of ECM is to improve the quality of care provided to complex patients, including by increasing the use of preventive care, improving coordination of care across health system levels, and increasing patient involvement in care. These elements can improve patient health and quality of life, and may reduce the need for curative medical services.
62250351|NCT05829642||Control|The control group will not receive any intervention.
62250352|NCT03889665|EXPERIMENTAL|Suspension training group|
62250353|NCT04494230||Attention deficit hyperactivity disorder (ADHD) only|the diagnosis of ADHD
62440109|NCT04488471||young people from affiliated study|32 IBD patients from an affiliated study
62440110|NCT05699707|EXPERIMENTAL|Ketone monoester|0.75 g/kg body mass of ketone monoester to be consumed within 5 minutes with venous blood samples obtained pre-ingestion, and 30-, 60- and 90-minutes post-ingestion.
62608007|NCT01934127|EXPERIMENTAL|Formulation 3 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 3 at a 21 day interval
62608008|NCT01934127|EXPERIMENTAL|Formulation 4 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 4 at a 21 day interval
62830240|NCT04907136|EXPERIMENTAL|Preferred ENDS|All participants will complete a lab visit where they will use their preferred ENDS ad libitum for up to 60 minutes
62250354|NCT04494230||Attention deficit hyperactivity disorder (ADHD) andSpecificand|the diagnosis of ADHD and SLD
62250355|NCT04494230||ADHD and oppositional defiant disorder (ODD)|the diagnosis of ADHD and ODD
62440111|NCT01297647|EXPERIMENTAL|Spinal cord injured|Patients with neurogenic lower urinary tract infection (Spinal Cord Injury,MS,M. Parkinson)
62830241|NCT04907136|EXPERIMENTAL|Preferred ENDS with HWL|All participants will complete a lab visit where they will use their preferred ENDS with a HWL on the device ad libitum for up to 60 minutes
62250356|NCT04494230||ADHD and Anxiety Disorder|the diagnosis of ADHD and Ank. Dis.
62250357|NCT04494230||Typical Development Children|no mental symptoms described by their teachers or parents and showing healthy development
62440112|NCT04495777||students|students were assessed in order to have a risk for TMD in order to their status of having parafunctional habits and neck pain
62608009|NCT01934127|EXPERIMENTAL|Formulation 5 Group|Subjects in this group will receive two doses of GSK2789868A H7N1 vaccine formulation 5 at a 21 day interval
62608010|NCT01934127|PLACEBO_COMPARATOR|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
62830242|NCT00566319|EXPERIMENTAL|1|
62830243|NCT00566319|ACTIVE_COMPARATOR|2|
62830244|NCT00949702|EXPERIMENTAL|Single arm|
62830245|NCT04978168|EXPERIMENTAL|Implementation Core|During baseline Exploration, staff organizational surveys are collected. During Preparation, staff focus groups conduct needs assessment with system mapping of linkage points for screening, assessment, and referral, and the agencies/staff involved in these activities. During Implementation, sites use facilitated local change teams (LCT) provided with a core set implementation strategies to facilitate linkages between probation agencies and local community treatment providers. The LCTs identify barriers to change, approaches to overcome barriers, do goal selection using SMART (specific, measurable, achievable, relevant, timely) goals and evidence for medications, address stigma, and clarify needs/expectations/roles of probation officers and treatment providers, then choose and implement goals and strategies. Sustainability Phase: Facilitators work with LCTs for 12 months using a written action plan based on goal selection.
62608011|NCT00998348|NO_INTERVENTION|Comparison Group|The comparison group will receive children's picture books (1 per month for the duration of the 8-month program).
62830246|NCT04978168|EXPERIMENTAL|Randomized Trial of Peer Support Specialist Model|After Core implementation is complete, half of adult participants in probation who consent will be randomly assigned to a Peer Support Specialist (PSS) condition. PSS are assigned to adults diagnosed with OUD within 6 months of entry into probation, in addition to treatment as usual. PSS establish linkages to community providers (medical, mental health, substance use treatment); educate about recovery support services, transportation assistance, MOUD; provide experiential, non-clinical support to individuals with SUD; share skills, offer support for setting goals and navigating the recovery process); and provide referrals and support for treatment, housing, employment, drug court, and probation.
62830247|NCT04978168|ACTIVE_COMPARATOR|Randomized to Treatment as Usual|After Core Implementation is complete, half of adult participants in probation who consent will be randomly assigned to continue with usual care.
62047989|NCT05933759|EXPERIMENTAL|Intervention group|Lifestyle intervention with education via the Low-Insulin-App, low-carb diet, self-monitoring of weight and steps, and telemedical coaching.
62830248|NCT01958164|EXPERIMENTAL|Actilyse 2 mg/2 ml|First dose of Actilyse 2mg/2ml will be given at time 0. Second dose will be given at 120 if CVAD function has not been restored.
62250358|NCT04616391|NO_INTERVENTION|MDI group:|The patient continues MDI treatment as per routine procedures
62440113|NCT02577081|EXPERIMENTAL|CAT scan|A CAT scan will be done for all participants. The scan will include the pelvis and 2 femurs.
62608012|NCT00998348|EXPERIMENTAL|Parenting Program|The parenting program is an 8-month obesity prevention intervention for parents with preschool-age children.
62830249|NCT01958164|SHAM_COMPARATOR|Saline solution (NaCl 0.9%)|Saline solution will be given at time 0. First dose of Actilyse 2mg/2ml will be given to patients if CVAD function has not been restored.
62830250|NCT02120898|EXPERIMENTAL|Generic Imiquimod Cream 2.5%|Generic imiquimod cream 2.5% will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face \[excluding the ears\] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
62250359|NCT04616391|EXPERIMENTAL|AHCL group|The patient will use MiniMed 780G AHCL system
62250360|NCT02116257|EXPERIMENTAL|Propacetamol|
62250361|NCT02116257|PLACEBO_COMPARATOR|PCA regimen|routine PCA drug
62250362|NCT03988231|ACTIVE_COMPARATOR|Enoxaparin 40mg once daily|All patients will have enoxaparin prophylaxis or placebo initiated at 8 hours after surgery. Prophylaxis or placebo will be provided every 24 hours and will be continued for the duration of inpatient stay.
62250363|NCT03988231|PLACEBO_COMPARATOR|Placebo|All patients will have enoxaparin prophylaxis or placebo initiated at 8 hours after surgery. Prophylaxis or placebo will be provided every 24 hours and will be continued for the duration of inpatient stay.
62250364|NCT04828187||Study group|8 patients aged between 18 to 75 years with Uncorrected Distance Visual Acuity ≥ 5/10
62250365|NCT06306079|EXPERIMENTAL|Feasibility intervention|The intervention will be foot insole (lateral wedge) insole, which has already been delivered in routine UK NHS and SA environments by at least one physiotherapist. Clinical testing will be done with 15-25 knee osteoarthritis subjects. These individuals will be assigned to a single intervention group for 4-6 weeks of re-gait training intervention. It involves a personalised gait retraining programme (sizable insole) for the KOA subjects to evaluate the impact on knee pain and improve function. It is set within 4-6 weeks of VAS and the WOMAC tools for knee pain \& function outcome.
62830251|NCT02120898|ACTIVE_COMPARATOR|Zyclara® (Imiquimod) Cream 2.5%|Zyclara® (imiquimod) cream 2.5% will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face \[excluding the ears\] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
62830252|NCT02120898|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle cream will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face \[excluding the ears\] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
62830253|NCT04633278|EXPERIMENTAL|CMP-001 and Pembrolizumab|All subjects will receive CMP-001 IT and pembrolizumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
62250366|NCT01788657|EXPERIMENTAL|Standard internet-based cognitive behavior therapy|Standard internet-based cognitive behavior therapy for depression with a written treatment material consisting of 60000 words (textmaterial only).
62250367|NCT01788657|EXPERIMENTAL|Condensed internet-based cognitive behavior therapy|Condensed internet-based cognitive behavior therapy for depression with a written treatment material consisting of 30000 words (available as text or audio).
62250368|NCT02964299||Standard|Standard bite block
62250369|NCT02964299||Mandibular advancement bite block|Mandibular advancement by 3 mm, 6 mm or 9 mm from neutral position
62440114|NCT05694988|NO_INTERVENTION|Baseline therapy|Basic therapy - the routine practice of an institution for the treatment of patients with uninfected acute pancreatitis
62440115|NCT05694988|EXPERIMENTAL|Basic therapy + Efferon CT + HVHF|Basic therapy, which is the routine practice of an institution for the treatment of patients with acute nonseptic pancreatitis in combination with extracorporeal hemoperfusion therapy (Efferon CT) and high-volume hemofiltration (HVHF).
62440116|NCT02175849||Drug resistant TB patients|Patients with rifampicin resistant TB or MDR-TB newly confirmed by drug susceptibility tests (DST)
62440117|NCT02175849||Contacts|Contacts of patients with newly detected rifampicin resistant TB or MDR-TB in households, schools, workplaces and other locations.
62608013|NCT03035734|ACTIVE_COMPARATOR|A|Single oral dose BMS-986141 Form A tablet under fasting conditions
62608014|NCT03035734|EXPERIMENTAL|B|Single oral dose BMS-986141 Form B tablet (low-dose) under fasting conditions
62608015|NCT03035734|EXPERIMENTAL|C|Single oral dose BMS-986141 Form B tablet (high-dose) under fasting conditions
62608016|NCT03035734|EXPERIMENTAL|D|Single oral dose BMS-986141 Form B tablet (high-dose) under fed conditions
62608017|NCT05171634|EXPERIMENTAL|Colonoscopy assisted by DiscoveryTM|
62608018|NCT05171634|ACTIVE_COMPARATOR|Virtual Colonoscopy with iSCAN|
62440118|NCT03343106|EXPERIMENTAL|ACT plus ERP|Sessions 1 and 2 involved information-gathering, discussion of the ACT model of OCD and ERP, and introduction to self-monitoring of rituals. Session 3 involved the development of an exposure hierarchy and response prevention plan, and further explanation of the ACT-based approach to ERP which focuses on learning flexible responding in the presence of obsessions, anxiety, and urges to ritualize. Exposure practices (sessions 4-16) were procedurally similar to the ERP condition, but focused on the facilitation of ACT processes rather than on fear extinction. Homework exposure practice was linked to the participant's goals and values. Session 16 included an ACT model of relapse prevention focusing on following one's values in the presence of obsessive thoughts and compulsive urges.
62440119|NCT03343106|EXPERIMENTAL|ERP alone|ERP followed Kozak and Foa's treatment manual. Sessions 1 and 2 included information-gathering, psychoeducation about the cognitive-behavioral model of OCD and rationale for ERP, and introduction to self-monitoring of rituals. Session 3 was dedicated to developing the treatment plan (exposure hierarchy, response prevention plan). Sessions 4-16 included in-session prolonged and repeated gradual exposure therapy (in vivo and imaginal as needed), the assignment of daily exposure practices for between-sessions, and instructions to refrain from rituals (response prevention in session and between sessions), along with self monitoring of any rituals that were performed. Session 16 also addressed discontinuation and relapse prevention.
62440120|NCT06503744|ACTIVE_COMPARATOR|Transthoracic ablation|Transthoracic ablation
62440121|NCT06503744|EXPERIMENTAL|Transbronchial ablation|Transbronchial ablation
62440122|NCT02514590|EXPERIMENTAL|Freedom SCS System - 1500 HZ|Epidural Space covering vertebrae level T8-T11 determined by paresthesia mapping for painful area.
62440123|NCT01093742|EXPERIMENTAL|cohort 1|HM10560A 0.089 mg/kg or Placebo
62440124|NCT01093742|EXPERIMENTAL|cohort 2|HM10560A 0.179 mg/kg or Placebo
62440125|NCT01093742|EXPERIMENTAL|cohort 3|HM10560A 0.357 mg/kg or Placebo
62440126|NCT01093742|EXPERIMENTAL|cohort 4|HM10560A 0.714 mg/kg or Placebo
62440127|NCT02592694|EXPERIMENTAL|Cocktail with thrombus aspiration|Intracoronary cocktail (tirofiban, bivalirudin, tenecteplase) injection combined with thrombus aspiration
62440128|NCT02592694|ACTIVE_COMPARATOR|Thrombus aspiration|Thrombus aspiration alone
62830254|NCT05830396|EXPERIMENTAL|Ambroxol|Ambroxol 1800mg/day
62830255|NCT05830396|PLACEBO_COMPARATOR|Placebo|Placebo
62440129|NCT04931628|ACTIVE_COMPARATOR|salvianolic acid group|salvianolic acid group 100mg+0.9%NaCl 250ml, injection, 14 days
62830256|NCT05589857|EXPERIMENTAL|Group 1 (Spellbound)|Participants will play SpellBound using the iPad's standard camera, which will show you your hospital room and the decal/stickers s as they appear in the real world.
62830257|NCT05589857|EXPERIMENTAL|Group 2 (Spellbound)|Participants will play the game using augmented reality.
62830258|NCT03530982|EXPERIMENTAL|Intervention group|Intensive goal training of relevant activities reported by adolescents in the beginning of the study. Therapists will grade the level of complexity of the proposed activities, considering the relevant movements, task demands and contextual factors involved in the performance of each task. Adolescents will be asked to practice these activities at home (1 hour/daily) and to discuss their difficulties and improvements with the therapists. The intervention will be provided in a day-camp model.
62830259|NCT06589908|EXPERIMENTAL|Group with RELAX glasses|Behavioral : RELAX glasses Glasses which are a solution of audiovisual sedation by positive distraction for hospital medical use
62830260|NCT06589908|NO_INTERVENTION|Group without RELAX glasses|
62830261|NCT04500899|EXPERIMENTAL|Mydfrin|Phenylephrine is available as phenylephrine hydrochloride injection, 10 mg/mL in 1 mL vial. For intravascular bolus administration, the investigators will prepare a solution containing 100 mcg/mL of phenylephrine hydrochloride, by withdrawing 10 mg (1ml of 10mg/mL) of phenylephrine injection and diluting with 99 mL of 5% dextrose injection or 0.9% sodium chloride injection.
62440130|NCT04931628|PLACEBO_COMPARATOR|0.9% NaCl|0.9%NaCl 250ml, injection, 14 days
62440131|NCT04011969||Colorectal cancer suspects|Patients suspected with colorectal cancer who come to our hospital to conduct colonoscopy procedure will be recruited for this study and will undergo a series of examinations.
62440132|NCT02242513|ACTIVE_COMPARATOR|pulsed mode radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury. One dose of PRF was given in tibial nerve behine the medial ankle in intervention group.
62440133|NCT02242513|PLACEBO_COMPARATOR|Xylocaine|2 c.c xylocaine was given in tibial nerve behind the medial ankle in control group.
62047990|NCT05933759|ACTIVE_COMPARATOR|Control group|Lifestyle intervention with education via the Low-Insulin-App, low-carb diet, self-monitoring of weight and steps.
62440134|NCT04966897|EXPERIMENTAL|GBNS + PERT placebo|GBNS + PERT placebo (drink volume sufficient to supply 0.5 g of MAG per kg of body weight plus PERT placebo capsules according to patient body weight.
62440135|NCT04966897|ACTIVE_COMPARATOR|Standard Nutritional Supplement + PERT|Standard nutritional supplement + PERT (drink volume sufficient to supply 0.5 g of TAG per kg of body weight plus PERT capsules according to body weight).
62608019|NCT00002644|EXPERIMENTAL|Tamoxifen citrate|Tamoxifen citrate 20 mg/day for 5 years
62608020|NCT00002644|PLACEBO_COMPARATOR|Placebo|Placebo 20 mg/day for 5 years
62608021|NCT02696954|EXPERIMENTAL|Group A|
62608022|NCT02696954|EXPERIMENTAL|Group B|
62608023|NCT01167634|NO_INTERVENTION|1|
62608024|NCT01167634|EXPERIMENTAL|2|Deposit contract with a 1:1 match
62608025|NCT01167634|EXPERIMENTAL|3|Deposit contract with a 2:1 match
62608026|NCT01167634|EXPERIMENTAL|Experimental 4|Deposit contract with no match
62047991|NCT05902962|EXPERIMENTAL|Single arm dose escalation study of VP-001|
62608027|NCT01205074|EXPERIMENTAL|Repeatability|
62608028|NCT01205074|EXPERIMENTAL|COPD|
62608029|NCT01205074|EXPERIMENTAL|Smokers|
62608030|NCT01205074|EXPERIMENTAL|CYP450 1A2 Inhibitors|
62608031|NCT01205074|EXPERIMENTAL|Cirrhosis Beta Blockers|
62608032|NCT01205074|EXPERIMENTAL|Alcohol|
62608033|NCT03536052|EXPERIMENTAL|Virtual Heart Guided Ablation|
62608034|NCT01192035|ACTIVE_COMPARATOR|NNRTI|
62608035|NCT01192035|ACTIVE_COMPARATOR|Protease inhibitor|
62608036|NCT05289687|EXPERIMENTAL|Course 1|Daratumumab-hyaluronidase
62608037|NCT01224652|EXPERIMENTAL|paclitaxel|Paclitaxel 70 mg/m2 on Days 1, 8 and 15 of a 28-day cycle
62608038|NCT01224652|EXPERIMENTAL|irinotecan|irinotecan 150 mg/m2 on Days 1 and 15 of a 28-day cycle
62608039|NCT03906721|EXPERIMENTAL|Conditioning & Open-Label Placebo (COLP)|Days 1 to 3 will include the acquisition phase where oxycodone will be prescribed on a schedule of 3-4 times per day and paired with open-placebo and smelling the essential oil. Days 4 to 6 will be the evoked phase, and patients will receive full oxycodone dosage on alternating days with open placebo and smelling the essential oil.
62250370|NCT01898936|EXPERIMENTAL|Pretreatment CO2 laser|"The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.~The laser settings will be as follows:~The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluato"
62250371|NCT01898936|SHAM_COMPARATOR|Only photodynamic therapy|This group will not get pretreatment with CO2 laser
62440136|NCT06157281|EXPERIMENTAL|Connect Intervention|"HIV providers withing each clinic will participate in the Intervention. The intervention, called Connect, consists of several strategies within three domains, as follows:~Domain 1: Engage, Encourage, Support Staff~Strategy 1a: Monthly staff huddle with staff recognition activities and compassion-focused rounds~Strategy 1b: Compassion training~Domain 2: Create a welcome physical environment~Strategy 2a: Aesthetic improvements toward a warm, welcoming environment~Domain 3: Expedite and workflow practices~Strategy 3a: Pre-pull patient folders; hold folders for immediate tracking; map patients to identify locations~Strategy 3b: Integrate welcome-back services for those who miss follow-up appointments"
62250372|NCT00711425|EXPERIMENTAL|A|
62608040|NCT03906721|OTHER|Treatment-as-usual|For the duration of the study, days 1 to 6, oxycodone will be prescribed on a schedule of 3-4 times per day.
62608041|NCT06081959|EXPERIMENTAL|SKB264 for injection|
62608042|NCT06081959|ACTIVE_COMPARATOR|Treatment of Physician's Choice|Eribulin, capecitabine, gemcitabine or vinorelbine will be administered and managed according to the investigator's clinical judgment, guided by clinical practice.
62608043|NCT04876976|EXPERIMENTAL|Cases of group (I) cyanoacrylate glue|Cases of group (I) underwent multilayered closure using dartos facial flap and cyanoacrylate glue as an interposition layer.
62608044|NCT04876976|ACTIVE_COMPARATOR|Cases of the control group (II) , classic repair|Cases of the control group (II) underwent the same procedure without using cyanoacrylate.
62250373|NCT03329222|EXPERIMENTAL|Intervention group|An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose
62250374|NCT03329222|ACTIVE_COMPARATOR|Control group|Standard cow's milk with prebiotics mixture
62608045|NCT06731673||Venous thromboembolism|Patients with acute deep vein thrombosis diagnosed on UL or pulmonary embolism diagnosed on CTA. \>18 years of age. 120 patients in total.
62608046|NCT06731673||Acute myocardial infarction|With ST segment elevation on ECG and confirmed culprit lesion on coronary angiography. \>18 years of age. 50 patients in total.
62608047|NCT06731673||Stroke in relation to atrial fibrillation|Stroke confirmed on MRI and diagnosis of atrial fibrillation. \>18 years of age. 50 patients in total.
62047992|NCT03462732|ACTIVE_COMPARATOR|Group I|Endotracheal tube plus Nelaton catheter
62250375|NCT03521830|ACTIVE_COMPARATOR|Previous Systemic Therapy Patients|Cohort A: Nivolumab 480mg IV q4weeks for up to 48 weeks (six 8-week cycles)
62250376|NCT03521830|EXPERIMENTAL|Progression after anti-PD-1 therapy (Cohort A) and Cohort C|Cohort B: Nivolumab 240mg IV + ipilimumab 1mg/kg IV q3 weeks x 4 doses, then nivolumab 480mg IV q4 weeks x 7 doses for up to 48 total weeks of therapy.
62608048|NCT06731673||Healthy participants|No known or prior diseases, no medication. \>18 years of age. 120 in total.
62608049|NCT03907020|EXPERIMENTAL|Meabolic Availabiliy of Barley|Healthy adult men
62608050|NCT04786093|ACTIVE_COMPARATOR|Stereotactic Ablative Radiotherapy (SAbR) Arm plus Durvalumab arm|SAbR with each radiation treatment fraction delivered every other day
62608051|NCT04786093|EXPERIMENTAL|Personalized Ultra-fractionated Stereotactic Radiotherapy (PULSAR) plus Durvalumab arm|PULSAR with each radiation treatment fraction delivered every 4 weeks
62047993|NCT03462732|ACTIVE_COMPARATOR|Group II|Endotracheal tube
62608052|NCT02655419|EXPERIMENTAL|ATM-AVI + Metronidazole|Aztreonam-avibactam + metronidazole
62608053|NCT01323816||Traditional|ICU staffed by a resident, pulmonary fellow and attending
62608054|NCT01323816||Non-Traditional|ICU staffed by Nurse Practitioners as the direct care deliverer, a pulmonary fellow, and an attending
62608055|NCT03490396|EXPERIMENTAL|Arm 1 (Gelclair at time of conditioning)|All subjects in study Arm 1 will receive GEL starting on the first day of conditioning.
62608056|NCT03490396|ACTIVE_COMPARATOR|Arm 2 (Gelclair when OM diagnosed)|Subjects in Arm 2 will be observed from initiation of conditioning to Day +14. If subjects develop G1 or G2 OM via WHO OM scale during this period, they will at that time be randomized to immediately receive GEL.
62608057|NCT03490396|ACTIVE_COMPARATOR|Arm 3 (MMW when OM diagnosed)|Subjects in Arm 2 will be observed from initiation of conditioning to Day +14. If subjects develop G1 or G2 OM via WHO OM scale during this period, they will at that time be randomized to immediately receive MMW.
62608058|NCT05590117|PLACEBO_COMPARATOR|Group 1 placebo|n=24 which will receive 12 cycles of FOLFOX-6 regimen plus placebo tablets twice daily.
62047994|NCT04272580|SHAM_COMPARATOR|Control group|No preload was given before spinal anesthesia
62608059|NCT05590117|ACTIVE_COMPARATOR|Group 2 pentoxifylline|n=24 which will receive FOLFOX-6 regimen in addition to pentoxifylline 400 mg twice daily.
62608060|NCT02954185|EXPERIMENTAL|WellClub Device|Hand held device that patients use for home therapy
62608061|NCT02954185|ACTIVE_COMPARATOR|Standard Therapy|Standard care therapy for should pain
62608062|NCT00941694|EXPERIMENTAL|Self-Management Intervention|Will receive 6 asthma self-management group or individual session over a 7 week period
62608063|NCT00941694|PLACEBO_COMPARATOR|Control|Group will receive 3 phone calls not related to asthma self management over a 7 week period
62608064|NCT01894659|NO_INTERVENTION|Control|Neonates randomized to this arm will receive the standard of practice at Loma Linda University NICU.
62608065|NCT01894659|EXPERIMENTAL|24% oral sucrose with pacifier|Neonates randomized to this arm will receive 24% sucrose before every painful procedure on days of life 3-7 in the NICU.
62608066|NCT01894659|EXPERIMENTAL|30% oral glucose with pacifier|Neonates randomized to this arm will receive 30% oral glucose before every painful procedure on days of life 3-7.
62608067|NCT05524480|EXPERIMENTAL|Salud en Mis Manos - Dissemination and Implementation Assistance|The multi-component and multi-faceted implementation strategy SEMM-DIA
62047995|NCT04272580|EXPERIMENTAL|4 ml/kg group|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia
62608068|NCT05524480|ACTIVE_COMPARATOR|Salud en Mis Manos - Usual Implementation Practice|The SEMM-Usual Implementation Practice arm includes all existing SEMM program materials.
62608069|NCT03652649|EXPERIMENTAL|3:1 Ketogenic Complete Meal Replacement|Evaluating glycemic control and weight loss in obese participants with type 2 diabetes treated for 6 months with 3:1 \[fat\]:\[protein+carbohydrate\] ratio, 1600 kcal/day complete meal replacement ketogenic diet
62047996|NCT04272580|EXPERIMENTAL|8 ml/kg group|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
62608070|NCT00860041||Group I|Patients complete pain questionnaires at baseline, 2-8 days after each weekly paclitaxel treatment given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
62440137|NCT06157281|NO_INTERVENTION|Control|Staff in control clinics will not receive an intervention.
62608071|NCT00860041||Group II|Patients complete pain questionnaires at baseline, 2-8 days after each weekly paclitaxel treatment not given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
62830262|NCT05828147|EXPERIMENTAL|Rituximab group|Rituximab will be administered as two IV infusions of 1000 mg each, given two weeks apart at Day 0 and Week 2. All subjects will receive 40 mg of prednisone orally the night before and morning of each infusion with diphenhydramine and acetaminophen orally thirty to sixty minutes prior to each infusion of rituximab. Subjects will remain on their baseline standard medical regimen.
62830263|NCT05786651|EXPERIMENTAL|Within-Subjects Attentional Information|Within-Subjects, all participants receive all interventions
62830264|NCT03039218|ACTIVE_COMPARATOR|Active|Subjects assigned to this group will receive Active treatments using the Dornier Aries 2.
62830265|NCT03039218|PLACEBO_COMPARATOR|Placebo / Sham|Subjects assigned to this group will receive placebo / sham (no active treatment).
62830266|NCT06231589|NO_INTERVENTION|Control|111 Males have normal Teratozoospermia index (TZI) less than 1.6. Semen processing is done by double layer density gradient method only.
62047997|NCT04272580|EXPERIMENTAL|12 ml/kg group|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
62047998|NCT06525948|EXPERIMENTAL|two-drug combination group|rhTPO combined with cyclosporine
62047999|NCT06525948|ACTIVE_COMPARATOR|drug-free group|cyclosporine alone
62048000|NCT02428465|EXPERIMENTAL|Purposeful Parenting|Families randomized to the intervention group will receive their pediatric provider's usual anticipatory guidance plus Purposeful Parenting.
62048001|NCT02428465|NO_INTERVENTION|Control Group|Families randomized to the control group will receive usual anticipatory guidance, delivered at the discretion of their pediatric provider, at each well-child visit in the first 12 months of life.
62250377|NCT03521830|EXPERIMENTAL|Progression after anti-PD-1 therapy (Cohort A)|Cohort C: Nivolumab 480 mg IV q4 weeks plus relatlimab 480 mg IV q4 weeks for up to 48 weeks.
62440138|NCT05896293|EXPERIMENTAL|kisspeptin pump|SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)
62440139|NCT05971121||ciprofol group|Hypotensive ICU patient sedated with ciprofol
62440140|NCT05971121||propofol group|Hypotensive ICU patient sedated with propofol
62440141|NCT03480711|EXPERIMENTAL|Group (A)|20 eyes of 20 patients of uncontrolled POAG administrated intervention will be subscleral trabeculectomy (SST) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml
62440142|NCT03480711|EXPERIMENTAL|group (B)|20 eyes of 20 patients of uncontrolled POAG d Administrated intervention will be ESST another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)
62440143|NCT00415532|EXPERIMENTAL|Romiplostim|Romiplostim administered by subcutaneous injection once weekly at a starting dose of 3 μg/kg, adjusted to a maximum dose of 10 μg/kg to maintain a platelet count between 50 and 200 x 10\^9/L for up to 52 weeks.
62440144|NCT00415532|OTHER|Standard of Care|Medical standard of care treatments were selected and prescribed by the investigator according to standard institutional practices or therapeutic guidelines and administered for up to 52 weeks.
62608072|NCT00860041||Group III|Patients complete pain questionnaires at baseline, 2-8 days after each 2-4 week paclitaxel treatment given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
62608073|NCT00860041||Group IV|Patients complete pain questionnaires at baseline, 2-8 days after each 2-4 week paclitaxel treatment not given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
62608074|NCT02191436||Patients with haemophilia|Hemophilia patients (children, youth and adults) and parents of children with hemophilia under 18
62608075|NCT05764746|EXPERIMENTAL|Artemether-lumefantrine followed by artesunate amodiaquine|a standard 3-days dosage, twice a day course of Artemether-Lumefantrine (20/120mg) immediately followed by a standard 3-days, once a day course of Artesunate-Amodiaquine (40base)
62608076|NCT05764746|EXPERIMENTAL|Artemether-lumefantrine with Amodiaquine|a standard 3-days dosage of Artemether-Lumefantrine (20/120mg) given together with Amodiaquine hydrocloride(40 base) followed by placebo for another 3 days;
62608077|NCT05764746|ACTIVE_COMPARATOR|Artemether-Lumefantrine alone|a standard 3-days dosage of Artemether-Lumefantrine (20/120mg) followed by placebo for another 3 days
62608078|NCT03310294|PLACEBO_COMPARATOR|placebo|one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)
62608079|NCT03310294|ACTIVE_COMPARATOR|Prebiotics and Probiotics|one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS), 90 grams)
62608080|NCT04602572||Non-surgical group.|Patients will be offered a standardized program comprised of individual consultations by a trained nurse every 3 months over 2 years, participation in a lifestyle course with 13 group sessions focusing on healthy diet and physical activity, and pharmacotherapy.
62608081|NCT04602572||Surgical group|After completing the systematic work-up and the lifestyle course, eligible subjects will be offered bariatric surgery. The surgical procedure will be chosen at the surgeon's discretion taking into consideration the target weight, comorbidities, risk of complications, the patient's ability to cope with side effects and complications, and the patient's motivation.
62608082|NCT03872258|ACTIVE_COMPARATOR|Control|Counseling on physical activity
62608083|NCT03872258|EXPERIMENTAL|Intervention|Add an intensive program of combined exercise for 6 months and use during this period a Smartband, in order to encourage and increase physical activity and decrease sedentary lifestyle
62608084|NCT01433744|EXPERIMENTAL|Chronic periodontal disease|C-reactive protein levels assesments and periodontal treatment
62608085|NCT01433744|NO_INTERVENTION|Periodontally healthy|
62608086|NCT04295343||Patients with suspicious of rectosigmoid endometriosis|
62608087|NCT06730763|EXPERIMENTAL|Group 1|will receive selected traditional physical therapy program for improve balance and decrease risk of falling only.
62608088|NCT06730763|ACTIVE_COMPARATOR|Group 2|will receive transcranial direct current stimulation plus selected traditional physical therapy program.
62608089|NCT00766285|ACTIVE_COMPARATOR|TIV|50 subjects to receive 45 mcg of TIV administered on Day 0 and Day 28.
62608090|NCT00766285|EXPERIMENTAL|rHAO|50 subjects to receive 405 mcg of rHAO administered on Day 0 and Day 28.
62608091|NCT05158686||Paclitaxel-coated balloon angioplasty|Patients with previous failed recanalization of a CTO treated with paclitaxel coated balloon immediately proximal to the CTO during the index procedure
62608092|NCT05158686||Non-coated balloon angioplasty|Patients with previous failed recanalization of a CTO treated with non-coated balloon immediately proximal to the CTO during the index procedure
62608093|NCT03217019|EXPERIMENTAL|Guidewire|"1. Radial artery puncture with direct radial pulse palpation.~2. 24G angiocatheter insertion with guidewire-assist. (Catheter over guidewire)"
62608094|NCT03217019|ACTIVE_COMPARATOR|Direct|"1. Radial artery puncture with direct radial pulse palpation.~2. 24G angiocatheter insertion without guidewire-assist. (Catheter over needle)"
62608095|NCT05724485|ACTIVE_COMPARATOR|BCAA group|12.45 grams of branched-chain amino acids orally per day before bedtime for 12 weeks.
62608096|NCT05724485|PLACEBO_COMPARATOR|Placebo group|12.45 grams of placebo (Maltodextrin) orally per day before bedtime for 12 weeks.
62608097|NCT00394433|EXPERIMENTAL|Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA)|Patients received bevacizumab 10 mg/kg IV on day 1 every 3 weeks while on study. Additionally, they received docetaxel 30 mg/m2 IV over 30 minutes, followed by cisplatin 25 mg/m2 IV over 30 minutes, followed by irinotecan 50 mg/m2 IV over 30 minutes on days 1 and 8 of each 3-week cycle until disease progression or unacceptable toxicity. Dose reductions were not permitted for bevacizumab although treatment could be held up to 2 months. If bevacizumab was discontinued, treatment with other agents could continue. When docetaxel, cisplatin, or irinotecan was held on day 1 of a cycle, all agents were held.
62608098|NCT06032520||Forensic Outpatient Systemic Therapy (FAST)|FAST is a promising treatment for juveniles showing severe antisocial behavior, including aggression, (domestic) violence, and delinquent behavior. FAST has a flexible intensity and length, addresses individual and systemic risk and protective factors, and is responsive to the abilities of the client (system), intervention characteristics all considered crucial for effective treatment.
62608099|NCT01428115||Patients with severe active Crohn's disease|Patients with severe active Crohn's disease for whom adalimumab was prescribed in the usual manner in accordance with the terms of the local marketing authorization.
62608100|NCT06354205|OTHER|Patients selection|Children under 1 year of age will be recruited for saliva and blood sample collection in the study
62608101|NCT05489419|EXPERIMENTAL|Prehabilitation|Patients undergo prehabilitation during 3-4 weeks before undergoing pancreatic surgery.
62608102|NCT01110668|EXPERIMENTAL|Nilotinib|
62608103|NCT03597022|EXPERIMENTAL|BAY1093884 100mg|Subjects received BAY1093884 100 mg once a week until premature termination of the study
62608104|NCT03597022|EXPERIMENTAL|BAY1093884 225mg|Subjects received BAY1093884 225 mg once a week until premature termination of the study
62608105|NCT03597022|EXPERIMENTAL|BAY1093884 400mg|Subjects received BAY1093884 400mg once a week until premature termination of the study
62608106|NCT00796744|PLACEBO_COMPARATOR|Placebo Vehicle Control|control placebo vehicle gel
62440145|NCT01767441||Roux-en-Y-gastric bypass|morbidly obese subjects undergoing gastric bypass surgery
62608107|NCT00796744|ACTIVE_COMPARATOR|0.03% DSC127|0.03 % DSC127 in Vehicle Control
62608108|NCT00796744|ACTIVE_COMPARATOR|0.01% DSC127|0.01% DSC127 in Vehicle Control
62608109|NCT05156710|EXPERIMENTAL|BIVV020 with Standard of Care (SOC) Cohort A|Eligible participants will receive BIVV020 and SOC immunosuppression including induction therapy, tacrolimus, and mycophenolate.
62608110|NCT05156710|EXPERIMENTAL|BIVV020 with Standard of Care (SOC) Cohort B|Eligible participants will receive BIVV020 and SOC which includes plasmapheresis, IVIg, corticosteroids, rituximab.
62608111|NCT05156710|OTHER|Standard of Care (SOC) Cohort B|SOC includes plasmapheresis, IVIg, corticosteroids, rituximab.
62440146|NCT01767441||gastric banding|morbidly obese subjects undergoing laparoscopic adjustable gastric banding
62250378|NCT06432088|EXPERIMENTAL|Extended Magnetic Grasper Device|Evaluation of the safety and effectiveness of the Extended Magnetic Grasper Device in patients undergoing bariatric and/or hiatal hernia procedures, as a liver retractor grasping the liver and/or the tissue surrounding the crus of the diaphragm.
62608112|NCT03781583|EXPERIMENTAL|Outdoor and ODG|Participants used the first version of the SmartHMD device, which used custom software running on commercially available ODG R7 smart glasses and accompanying earbuds. Participants used the device to navigate across an outdoor crosswalk.
62608113|NCT03781583|EXPERIMENTAL|Indoor and Laptop|Participants use the second version of the SmartHMD device, which uses RGB-D smart glasses, custom software running on a laptop, and bone-conducting earphones. Participants use the device to locate the door within an indoor course.
62608114|NCT03781583|EXPERIMENTAL|RGBD & Jetson - Indoor Course|Participants use a new iteration of the SmartHMD device, which uses RGB-D smart glasses, bone-conducting earphones, a Jetson mobile computer, and custom software. Participants use the device to navigate their way through an indoor course.
62250379|NCT05512793|ACTIVE_COMPARATOR|Standard Technique followed by Combination|Back-to-back tandem colonoscopies by the same endoscopist. The first colonoscopy will be performed without PolyDeep (standard technique) followed immediately by another colonoscopy with PolyDeep (combination technique).
62440147|NCT01767441||sleeve gastrectomy|morbidly obese subjects undergoing laparoscopic sleeve gastrectomy
62608115|NCT03781583|EXPERIMENTAL|RGBD & Jetson - Outdoor Crosswalk|Participants use the SmartHMD device, which uses RGB-D smart glasses, bone-conducting earphones, a Jetson mobile computer, and a specific version of custom software. Participants use the device to navigate their way through an outdoor crosswalk.
62608116|NCT05937607|EXPERIMENTAL|Hand massage|hand massage was applied to the patients to receive intracavitary brachytherapy using lavender baby oil for three sessions of 10 minutes each, starting 5 minutes before the procedure.
62608117|NCT05937607|NO_INTERVENTION|Control Group|The control group did not receive any intervention during the study period
62608118|NCT05738837|EXPERIMENTAL|A-EAAA (Adolescent Enhanced Assess, Acknowledge, Act) immediately|Adolescent adaptation of EAAA sexual assault resistance education (4, 3-hr sessions) begun immediately after baseline randomization
62608119|NCT05738837|ACTIVE_COMPARATOR|Waitlist Control|Usual care 30-min session (brief presentation on consent/sexual assault; access to local resource pamphlets) immediately after baseline randomization; A-EAAA (4, 3-hr sessions) at 6-months post-randomization
62608120|NCT03761173||FlowTriever|Mechanical thrombectomy for pulmonary embolism
62608121|NCT03761173||Conservative Therapy Sub-Study|Anticoagulation medication for pulmonary embolism (as directed by treating physician)
62608122|NCT06354790||All patients|
62608123|NCT04312594|EXPERIMENTAL|Jaktinib 50mg BID|Patients receive the dose of Jaktinib Hydrochloride Tablets orally 50mg twice daily (BID) for 24 weeks.
62608124|NCT04312594|EXPERIMENTAL|Jaktinib 75mg BID|Patients receive the dose of Jaktinib Hydrochloride Tablets orally 75mg twice daily (BID) for 24 weeks.
62608125|NCT04312594|PLACEBO_COMPARATOR|Placebo|Patients receive the dose of placebo orally twice daily (BID) for 24 weeks.
62608126|NCT05031637|EXPERIMENTAL|treatment by night-time BP|titrate drug treatment in the evening against night home blood pressure monitoring (HBPM) SBP (aiming SBP of \<120 mmHg; intervention group)
62250380|NCT05512793|ACTIVE_COMPARATOR|Combination followed by Standard Technique|Back-to-back tandem colonoscopies by the same endoscopist. In this arm, the first colonoscopy with be performed with PolyDeep (combination technique) followed immediately by another colonoscopy without PolyDeep (standard technique)
62440148|NCT01767441||control group|morbidly obese subjects not undergoing bariatric surgery, on diet treatment
62608127|NCT05031637|OTHER|treatment by daytime BP|Usual care - titrate drug treatment in the morning against HBPM SBP (aiming SBP of \<135 mmHg; control group)
62608128|NCT06490172|NO_INTERVENTION|Delphi Study|The survey will be re-circulated a minimum of three, and maximum of four rounds, with an aim for a minimum of 30 participants and response rate of greater than 70 percent per round. The results will be collected and collated at each round to determine a consensus amongst shoulder specialists for further review. This information will be used to guide the treatment protocol in phase two.
62608129|NCT06490172|EXPERIMENTAL|Shock wave therapy quantitative data collection and analysis|"This phase will involve the piloting of the shock wave therapy protocol determined by the results collected in phase one Delphi study~Following participant consent, the research healthcare practitioner will provide patient reported outcome measure questionnaires for the participant to complete independently to measure baseline data. This will occur at baseline, 6 and 12 weeks following shock wave therapy treatment."
62608130|NCT06490172|NO_INTERVENTION|Qualitative semi-structured interviews|All participants in phase 2 and those who declined participation in the quantitative study at the recruitment stage will be invited to take part in semi-structured qualitative interviews of a duration of 30 - 45 minutes. The interview protocol and questions will be developed based on the findings of the quantitative data analysis. Interviews will take place approximately 12 weeks from last ESWT treatment.
62608131|NCT03728998|OTHER|PLR & Clearsight measurements|All patients 16years or older presenting to the ED with uncomplicated sepsis (see inclusion and exclusion criteria) will undergo a Passive Leg Raise (PLR, non-invasive) and multiple measurements by the Clearsight non-invasive hemodynamic monitoring system. Followed by a fluid challenge (common practice; non interventional)
62048002|NCT03802864|EXPERIMENTAL|Liposomal Bupivacaine|Participants in this arm will have a single injection of liposomal bupivacaine admixed with standard bupivacaine (266mg liposomal bupivacaine mixed with 50mg bupivacaine hydrochloride) at the conclusion of their surgical sperm retrieval procedure.
62608132|NCT03304795||Vitamin D deficiency|Serum 25-hydroxyvitamin D level is less than 50 nmol/L.
62608133|NCT03304795||Normal|Serum 25-hydroxyvitamin D level is 50 nmol/L or greater.
62608134|NCT00939471|OTHER|Relieva™ Balloon Sinuplasty™ System|Balloon Dilation of sinus ostium
62608135|NCT02014051|EXPERIMENTAL|SyB C-1101|
62608136|NCT06236724|EXPERIMENTAL|Treatment with Asciminib|Participants will take tablets of asciminib by mouth every day on this study. Participants should take it at least 1 hour before and 2 hours after eating. The tablets should be swallowed whole, not crushed.
62608137|NCT06730893|EXPERIMENTAL|Shared decision making|provide share decision aids before deciding on a treatment(surgery or active surveillance)
62608138|NCT06730893|NO_INTERVENTION|Standard care|do not provide share decision aids before deciding on a treatment(surgery or active surveillance)
62608139|NCT03081143|EXPERIMENTAL|FOLFIRI plus Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus FOLFIRI (Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle)
62608140|NCT03081143|ACTIVE_COMPARATOR|Paclitaxel plus Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus Paclitaxel 80 mg/m2 on day 1, 8, 15
62608141|NCT04343053|OTHER|SARS-Cov-2 infection|Single study group of patients with respiratory failure due to SARS-Cov-2 infection. Three blood samples will be collected at different stages of disease: early, defined as first 96 hours, mid, defined as time from 96 hours and 14 days, late. defined as \>14 days
62608142|NCT03696485|EXPERIMENTAL|group 1: low dose|One intrathecal (IT) administration of SCM-010 at baseline visit
62608143|NCT03696485|EXPERIMENTAL|group 2: high dose|One intrathecal (IT) administration of SCM-010 at baseline visit
62608144|NCT04832750||Major Depressive Episode|At least one failed pharmaco trial in current episode
62608145|NCT04832750||Major Depressive Episode with comorbid Borderline Personality Disorder|At least one failed pharmaco trial in current episode
62608146|NCT04832750||Healthy Controls|No psychiatric disorders
62608147|NCT01484860|EXPERIMENTAL|AUY922|AUY922 will be administered as a weekly infusion at a dose of 70 mg/m2 based on the recommended phase II dose from the phase I study or alternate dose based on the phase I study final results.The drug will be continued until disease progression or unacceptable toxicity. One cycle will be defined as 4 weeks of treatment.
62608148|NCT06036784|EXPERIMENTAL|MBX 1416 (Part A)|Single ascending subcutaneous (SC) doses
62048003|NCT03802864|ACTIVE_COMPARATOR|Standard Bupivacaine|Participants in this arm will have a single injection of standard bupivacaine (100mg bupivacaine hydrochloride) at the conclusion of their surgical sperm retrieval procedure.
62048004|NCT03610425||Post-op evidence based bundle w/ Pre-op education|25 patients undergoing hysterectomy from October 1, 2017 to December 31, 2017 will receive the post-operative evidence based bundle/standard pre-operative education.
62250381|NCT03021395|EXPERIMENTAL|MRD-positive|MRD-positive patients receive Decitabine regimen.
62250382|NCT03021395|NO_INTERVENTION|MRD-negative|MRD-negative patients receive no intervention.
62250383|NCT02575248|EXPERIMENTAL|Group A|patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2
62608149|NCT06036784|EXPERIMENTAL|MBX 1416 (Part B)|Repeated ascending subcutaneous (SC) doses
62608150|NCT06036784|PLACEBO_COMPARATOR|Placebo|
62608151|NCT06036784|EXPERIMENTAL|MBX 1416 (Part C)|Single subcutaneous (SC) dose of MBX 1416, single dose of rosuvastatin and acetaminophen.
62048005|NCT03610425||Standard pre-operative education alone|25 patients undergoing hysterectomy from October 1, 2017 to December 31, 2017 will receive the standard pre-operative education alone.
62250384|NCT02575248|ACTIVE_COMPARATOR|group B|patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2
62250385|NCT02689284|EXPERIMENTAL|Cohort 1: Margetuximab 10 mg/kg plus pembrolizumab 200 mg|margetuximab administered in combination with pembrolizumab
62250386|NCT02689284|EXPERIMENTAL|Cohort 2: Margetuximab 15 mg/kg plus pembrolizumab 200 mg|margetuximab administered in combination with pembrolizumab
62250387|NCT05794165|EXPERIMENTAL|Thrombate infusion|
62608152|NCT03600155|EXPERIMENTAL|Arm A (nivolumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive nivolumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62048006|NCT00811382|EXPERIMENTAL|1: Access to HMSC (Home Monitoring Service Center)|Full functionality of the Home Monitoring System for an early optimization of CRT and management of AF with a full access for the treating physician to the HMSC
62250388|NCT05794165|PLACEBO_COMPARATOR|Placebo|
62608153|NCT03600155|EXPERIMENTAL|Arm B (ipilimumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62608154|NCT03600155|EXPERIMENTAL|Arm C (nivolumab and ipilimumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive nivolumab IV over 60 minutes on days 1, 14, and 28, and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62608155|NCT05949424|ACTIVE_COMPARATOR|Control group|Standard SmPC dosing with dose adjustments for toxicity as per SmPC
62608156|NCT05949424|EXPERIMENTAL|Intervention group|Lower starting dose with dose-escalation inversely following the dosing steps from the SmPC every 2 weeks in case of good tolerability
62608157|NCT02452840||NVAMD Patients with PDA|NVAMD Patients with PDA
62608158|NCT04633603||All patients|There is no pre-specified group or subgroup of participant(s) assigned to receive the specific intervention(s) (or no intervention) according to the protocol. All patients get the same possibility to register their data and follow management advice.
62608159|NCT03114657|PLACEBO_COMPARATOR|Placebo|Participants received intravenous (IV) infusion of Placebo every 4 weeks (Q4W) for 100 weeks.
62608160|NCT03114657|EXPERIMENTAL|Crenezumab|Participants received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W) for 100 weeks.
62608161|NCT00630747|EXPERIMENTAL|Idursulfase|
62608162|NCT06718387|NO_INTERVENTION|Without group intervention|Patient refusing group care and/or assessment ended after the inclusion end dates
62440149|NCT05895084|EXPERIMENTAL|Group Yoga|Yoga includes breath work (pranayama), gentle stretching and holding of postures (asanas), and meditation (dhyana). Modifications/adaptations are incorporated so all participants can successfully complete the yoga intervention. Yoga is delivered in a standardized progression, including: focused, slow breath with movement and breathwork throughout every session; mantras, progressively challenging yoga postures (sitting, standing, and floor); and meditation
62608163|NCT06718387|EXPERIMENTAL|With group intervention|Patient in agreement with group management and available for participation
62608164|NCT06717854|NO_INTERVENTION|standard of care|The standard of care (SOC) was implemented following low anterior resection, which included the distribution of pamphlets and instructional videos to patients and their caregivers.
62608165|NCT06717854|EXPERIMENTAL|antegrade enema|Participants assigned to this group received the standardized of care as the basis for the intervention. The enema is administered through the distal end of the ileocecal stoma, directed towards the anus.
62608166|NCT06717854|EXPERIMENTAL|retrograde enema|Participants assigned to this group received the standardized of care as the basis for the intervention. The enema is administered retrogradely via the anus.
62440150|NCT00423800|EXPERIMENTAL|Pegetron® - 24 Weeks|Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 16 weeks of treatment
62608167|NCT01325259|EXPERIMENTAL|Alzheimer's disease|30 patients suffering from Alzheimer's disease
62608168|NCT01325259|EXPERIMENTAL|Mild Cognitive Impairment|20 patients suffering from Mild Cognitive Impairment
62608169|NCT01325259|EXPERIMENTAL|Control|15 subjects with no cognitive impairment
62608170|NCT05801900|ACTIVE_COMPARATOR|Ketorolac group|ketorolac 30 mg (diluted in 200 mL normal saline) intravenously over 5 minutes
62608171|NCT05801900|ACTIVE_COMPARATOR|Ibuprofen group|ibuprofen 800 mg intravenously (Diluted in 200 mL of normal saline) over 5 minutes
62608172|NCT05555316|EXPERIMENTAL|TACE combined with Lenvatinib|Three days after the first TACE treatment, when the liver function was evaluated as grade A / B, Lenvatinib was taken orally, 8mg / day (body weight less than 60kg) or 12mg / day (body weight equal to or more than 60kg).
62608173|NCT06104280|EXPERIMENTAL|MOUD therapy methadone|50 methadone participants
62608174|NCT06104280|EXPERIMENTAL|MOUD therapy buprenorphine|50 buprenorphine participants
62608175|NCT06104280|EXPERIMENTAL|MOUD therapy extended-release naltrexone|50 extended-release naltrexone (XR-NTX) participants
62608176|NCT06104280|OTHER|Non-opioid using controls|non-opioid using controls
62608177|NCT05691491|EXPERIMENTAL|Treatment (tuvusertib, temozolomide)|Patients receive tuvusertib PO QD) on days 1-7 and temozolomide PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and MRI as well as collection of blood samples throughout the trial. Patients also undergo a biopsy at baseline and may undergo one on study and/or at time of progression.
62608178|NCT02508571|SHAM_COMPARATOR|Control|Two 15-minute sessions of sham intervention/day, five days a week
62608179|NCT02508571|EXPERIMENTAL|DST group|One session of DST and the other of sham intervention/day, five days a week
62608180|NCT02508571|EXPERIMENTAL|DST+OSMS group|One session of DST and the other of OSMS/day, five days a week
62608181|NCT02129634|ACTIVE_COMPARATOR|CB-PTA arm|After successful crossing of the trial lesion, a conventional angioplasty balloon with a diameter matching the trial vessel is advanced over the guidewire and is inflated at the trial lesion site, according to the normal practice of the operator. Comparisons of pre- and post-angioplasty percentage stenosis will be made in the same angiographic projection(s).
62608182|NCT02129634|EXPERIMENTAL|DEB-PTA arm|After successful crossing of the trial lesion, angioplasty with a conventional angioplasty balloon is performed before DEB-PTA. This is because the paclitaxel coating may be scrapped off the balloon if the DEB is used to cross the trial lesion. A conventional angioplasty balloon with a diameter matching the trial vessel is advanced over the guidewire and is inflated at the trial lesion site, according to the normal practice of the operator. A DEB with a diameter matching the trial vessel and lesion length is then advanced over the 0.018 inch guidewire and inflated at the trial lesion site for 60 seconds. If the lesion length is longer than the length of the balloon, a second inflation with another DEB will be required. The maximal total lesion length of the treated lesions will not exceed 20cm. Comparisons of pre- and post-angioplasty percentage stenosis will be made in the same angiographic projection(s).
62608183|NCT06210373|EXPERIMENTAL|Myrialen Gel Group|Myrialen® gel: sterile ophthalmic gel containing 5% dexpanthenol
62608184|NCT06210373|ACTIVE_COMPARATOR|Recugel Group|Recugel®: sterile ophthalmic gel containing 5% dexpanthenol
62048007|NCT00811382|ACTIVE_COMPARATOR|2: No access to HMSC|Limited access of the treating physician to the HMSC where only events regarding implant and lead status will be generated and sent to the physician.
62608185|NCT06436755||Serratus anterior plane block (SAP) group|Patients who underwent serratus anterior plane block
62608186|NCT06436755||Serratus anterior plane block (SAP) and Transversus thoracic plane block (TTP) group|Patients who underwent Serratus anterior plane block (SAP) and Transversus thoracic plane block (TTP) group
62608187|NCT02951039||Edoxaban|Patients with established NVAF treated with edoxaban according to package information. Physician's prescribing behaviour will not be influenced; patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
62608188|NCT00622596|EXPERIMENTAL|Mobile Access to Buprenorphine|High risk populations accessing a mobile health care system can obtain Buprenorphine for treatment.
62250389|NCT04942652|EXPERIMENTAL|Itraconazole 200 mg under fasted condition|A single oral administration of itraconazole 200 mg under fasted condition
62440151|NCT00423800|ACTIVE_COMPARATOR|Pegetron®- 48 Weeks|Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 40 weeks of treatment.
62440152|NCT05885360|EXPERIMENTAL|Istradefylline 20 and 40 mg|The study intervention will be to add 20 mg Istradefylline for 2 weeks, following which the dose will be increased to 40 mg daily for the remainder of the 24 weeks.
62440153|NCT04721457|PLACEBO_COMPARATOR|Distilled Water|Vigorously rinse with 15 ml of the distilled water for 30 s (Water for Injections BP; Pharmaceutical Solutions Industry, Jeddah, SA)
62440154|NCT04721457|ACTIVE_COMPARATOR|Povidone Iodine (PVP-I)|Vigorously rinse with 15 ml of the 1% povidone-iodine (PVP-I) (Betadine Mouthwash/Gargle; Avrio Health LP, Stamford, CT, USA) for 30 s
62440155|NCT04721457|ACTIVE_COMPARATOR|Hydrogen Peroxide (H2O2)|Vigorously rinse with 15 ml of the 1.5% hydrogen peroxide (H2O2) (Peroxyl; Colgate-Palmolive, Guildford, UK) for 30 s
62440156|NCT04721457|ACTIVE_COMPARATOR|Cetylpyridinium Chloride (CPC)|Vigorously rinse with 15 ml of the 0.075% cetylpyridinium chloride (CPC) (Colgate Total; Colgate-Palmolive, Guildford, UK) for 30 s
62440157|NCT04721457|ACTIVE_COMPARATOR|Sodium Hypochlorite|Vigorously rinse with 15 ml of the 80 ppm sodium hypochlorite (NaOCl) (Clinisept Dental Mouthwash; Clinical Health Technologies, Hinckley, Leicestershire, UK) for 30 s
62440158|NCT04721457|PLACEBO_COMPARATOR|No rinse group|There is no mouth rinse in this group. Patients will collect the saliva at all 4-time points without gargling with the mouth rinse.
62440159|NCT02886975|EXPERIMENTAL|low protein diet plus α-keto acid|A comparison of normal diet and low protein diet plus α-keto acid after intervention in the same individual
62440160|NCT02042911|EXPERIMENTAL|SyB L-0501|
62440161|NCT04186390||Medical doctors|Medical doctors with no prior experience in the evaluation of small bowel capsule endoscopy.
62440162|NCT03720483|EXPERIMENTAL|N-acetyl cysteine then placebo|This arm will receive NAC followed by placebo
62440163|NCT03720483|EXPERIMENTAL|Placebo then N-acetyl cysteine|This arm will receive placebo followed by NAC
62440164|NCT01164033|ACTIVE_COMPARATOR|A|
62440165|NCT01164033|EXPERIMENTAL|B|
62608189|NCT04106362|ACTIVE_COMPARATOR|Arm I (radiation therapy, cisplatin)|Beginning on day 0, patients undergo radiation therapy over 6 weeks for a total of 35 fractions. Patients also receive cisplatin IV over 1-2 hours on days 0 and 21.
62250390|NCT04942652|EXPERIMENTAL|Itraconazole 200 mg under fed condition|A single oral administration of itraconazole 200 mg under fed condition
62250391|NCT04942652|EXPERIMENTAL|Esomeprazole 40 mg + Itraconazole 200 mg under fasted condition|Oral administration of esomeprazole 40 mg once daily for 6 days and then a single oral administration of itraconazole 200 mg under fasted condition
62440166|NCT01164033|EXPERIMENTAL|C|
62440167|NCT01164033|EXPERIMENTAL|D|
62440168|NCT04251182|PLACEBO_COMPARATOR|Placebo|Placebo, matching T3D-959 active capsules, is pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects randomized to placebo will ingest three size 0 placebo capsules once per day in the morning.
62440169|NCT04251182|EXPERIMENTAL|15mg T3D-959|T3D-959 15 mg dose: T3D-959 is a small molecule dual nuclear receptor agonist that regulates transcription of genes, in particular those involved in glucose energy and lipid metabolism. T3D-959 is 15-times more potent for PPAR delta than for the secondary target of the drug, PPAR gamma. The 15 mg strength contains 15mg T3D-959, pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects will ingest one size 0, 15mg capsule and two placebo capsules once per day in the morning.
62440170|NCT04251182|EXPERIMENTAL|30mg T3D-959|T3D-959 30 mg dose: Subjects will ingest two size 0, 15mg capsules and one placebo capsule once per day in the morning.
62440171|NCT04251182|EXPERIMENTAL|45mg T3D-959|T3D-959 45 mg dose: Subjects will ingest three size 0, 15mg capsules once per day in the morning.
62440172|NCT00095290|EXPERIMENTAL|A1|
62440173|NCT00095290|PLACEBO_COMPARATOR|A2|
62440174|NCT04109157|OTHER|Study population|Women who had fulfilled the standardization of terminology of lower urinary function from ICS were diagnosed as urodynamic stress incontinence (USI) after urodynamic study (UDS) and enrolled for analysis in this study.
62440175|NCT05332561|EXPERIMENTAL|Arm 1 Atezolizumab (Immune Evasion)|Atezolizumab Dosage: 1200 mg, intravenous, on d1, q21d
62440176|NCT05332561|EXPERIMENTAL|Arm 2 Inavolisib (PI3K)|Inavolisib Dosage: 9 mg, oral, on d1-d28, q28d
62440177|NCT05332561|EXPERIMENTAL|Arm 3 Ipatasertib (AKT)|Ipatasertib Dosage: 400 mg, oral, on d1-d21, q28d
62440178|NCT05332561|EXPERIMENTAL|Arm 4 Olaparib (PARP, DNA-Repair)|Olaparib Dosage: 300 mg, oral, bid d1-d28, q28d
62440179|NCT05332561|EXPERIMENTAL|Arm 5 Sacituzumab Govitecan (TROP-2)|Sacituzumab Govitecan Dosage: 10 mg/kg BW, intravenous, on d1 and d8, q21d
62440180|NCT05332561|EXPERIMENTAL|Arm 6 Trastuzumab/Pertuzumab (ERBBB)|Trastuzumab/Pertuzumab Administration: subcutaneous; Initial dose: Trastuzumab 600 mg, Pertuzumab 1200 mg, 30 000 units hyaluronidase; Maintainance dose: Trastuzumab 600 mg, Pertuzumab 600 mg, 20 000 units hyaluronidase; Frequency: on d1, q21d
62440181|NCT05332561|NO_INTERVENTION|Arm 7 Observation|Observation
62440182|NCT06529315|EXPERIMENTAL|Group PoCUS|Participants assigned to Group PoCUS will undergo point-of-care ultrasound evaluations by nurse practitioners/physicians within their first 24 hours of admission to the general ward.
62440183|NCT06529315|NO_INTERVENTION|Group Usual Care|Participants assigned to Group Usual Care will receive usual standard care.
62440184|NCT02765828||Late-Onset Pompe Disease|
62440185|NCT02765828||Acquired/Hereditary Myopathy|
62440186|NCT02765828||Neuropathy|
62440187|NCT00306384|EXPERIMENTAL|Alogliptin 12.5 mg|Alogliptin 12.5 tablet, orally, once daily for up to 4 years.
62048008|NCT03634124|EXPERIMENTAL|interventional group|
62830267|NCT06231589|EXPERIMENTAL|Sperm selection group PICSI or MACS (SS-Group)|"90 Males with high TZI and sperm selection techniques such as PICSI or MACS are performed. Semen processing is done by double layer density gradient method followed by:~(1) In case of PICSI: adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Individual bound sperm selection is done followed by ICSI.~or (2) In case of MACS: Semen processing is done by double layer density gradient method. The resulted pellet is labeled with annexin V microbeads followed by separation on MACS Column, the eluted fraction contains non apoptotic sperm suitable for ICSI."
62830268|NCT06231589|NO_INTERVENTION|No sperm selection group (NO SS-Group)|63 Males with high TZI more than 1.8 and no sperm selection techniques are performed. Semen processing is done by double layer density gradient method only.
62830269|NCT05311488||Symptomatic TTRv|Patients with known TTR mutations and neuropathy
62048009|NCT04367857||Prior Positive polymerase chain reaction (PCR) and Recovered|Prior Positive PCR result, fully recovered, back at work and symptom free for greater than or equal than 14 days.
62048010|NCT04367857||Never tested, history of COVID-19 Symptoms and Recovered|Never tested and history of COVID-19 symptoms and symptom-free for more than 14 days
62048011|NCT04367857||Never tested and current COVID-19 Symptoms|Never tested and current COVID-19 Symptoms (e.g. referred by a provider or clinic)
62048012|NCT04367857||Never tested and asymptomatic|Never tested and asymptomatic for COVID-19 symptoms, including asymptomatic health care worker
62048013|NCT03758963|EXPERIMENTAL|Active Laser|"1. Once the energy to be applied for the treatment is determined through the laser irradiation testing, conduct laser therapy after selecting T corresponding to treatment laser on GUI.~2. At irradiation, excluding the circle area with a 100 μm radius (200 μm diameter) from the center of the fovea, irradiate laser in the form of surrounding the leakage site with an interval of 0.5-1 spot diameter (fovea = 1 spot size). As for the test spots, the serial number needs to be given for each treatment spot with the order of irradiation, as described above.~3. If pigment epithelial detachment (PED) occurs at the leakage site, irradiate laser around the PED (excluding the circle area with a 100 μm radius (200 μm diameter) from the center), not to the leakage site.~4. Within 2 hours after therapy, perform tests for efficacy evaluation (color fundus photography and fluorescein angiography)."
62048014|NCT03758963|SHAM_COMPARATOR|Sham Laser procedure|"1. Select C corresponding to Sham Therapy on GUI of the laser device, and then perform Sham therapy.~   * During Sham therapy, for patient's blinding, both light from the slit lamp and sound from laser oscillation are same as laser irradiation, and no laser oscillation will occur for treatment.~2. Perform subsequent procedures in the same manner as the procedure of study group."
62048015|NCT06243705|EXPERIMENTAL|Robot-Pet Group|The robot-pet sits on the child's lap while the fissure sealant is applied. Preoperative (T1) baseline levels of dental anxiety will be measured using the Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) and the Facial Image Scale (FIS), and behavior rating will be measured using the Frankl Behavior Rating Scale (FBRS). Intraoperative (T2) cooperation level will be recorded using the Modified Houpt Scale (MHS) during the surface cleaning (T2A), isolation (T2B) and washing (T2C) phases of fissure sealant application. Postoperative(T3) anxiety level and behavior rating measurements (CFSS-DS, FIS, FBRS) will be repeated. Physiological markers for dental anxiety, such as heart rate and oxygen saturation, will be measured at all time points (T1, T2A-B-C, T3). Children and parents in this group will received a questionnaire for their perception about the use of their distraction technique(T3).
62440188|NCT00306384|EXPERIMENTAL|Alogliptin 25 mg|Alogliptin 25 mg tablet, orally, once daily for up to 4 years.
62440189|NCT04316052|EXPERIMENTAL|aerobic training group|At the visit, participants will be first instructed in the use of the treadmill, which included heart rate assessment capability. Walking intensity and duration prescriptions will be accordance with recommendations of the American College of Sports Medicine.
62440190|NCT04316052|EXPERIMENTAL|strength training group|Strength training prescriptions will be in accordance with recommendations of the American College of Sports Medicine.
62440191|NCT03237585|EXPERIMENTAL|i) Intervention arm- Receive Gender Centre's RRS package|
62608190|NCT04106362|EXPERIMENTAL|Arm II (cetuximab, radiation therapy, cisplatin)|Patients receive cetuximab IV over 120 minutes 5-7 days prior to start of radiation therapy and then IV over 60 minutes weekly on Monday or Tuesday for 7 weeks. Patients also undergo radiation therapy and receive cisplatin as in Arm I.
62608191|NCT00848978|EXPERIMENTAL|2|The experimental group will participate in the aerobic and strength training program.
62440192|NCT03237585|NO_INTERVENTION|No intervention|
62830270|NCT05311488||Asymptomatic TTRv|Patients with TTR mutation and no symptoms within less than 10 years of typical onset of disease
62830271|NCT05311488||Healthy controls|Age and sex matched healthy controls without neuropathy or other neurological disorder.
62830272|NCT05758194|ACTIVE_COMPARATOR|Standardized RV Management|Physicians will follow prespecified parameters for RV management (consistent with SOC)
62440193|NCT00594633|EXPERIMENTAL|1|donepezil and questionaires
62440194|NCT04378010|EXPERIMENTAL|EDP-305 1.5 mg|Once a day orally for 72 weeks
62440195|NCT04378010|EXPERIMENTAL|EDP-305 2 mg|Once a day orally for 72 weeks
62440196|NCT04378010|PLACEBO_COMPARATOR|Placebo|Once a day orally for 72 weeks
62608192|NCT00848978|NO_INTERVENTION|1|The usual care group will receive general physical activity guidelines.
62608193|NCT00662558|EXPERIMENTAL|celecoxib|
62608194|NCT00662558|ACTIVE_COMPARATOR|tramadol|
62830273|NCT05758194|ACTIVE_COMPARATOR|Usual Care RV Management|Physicians will use their own clinical judgement with no prespecified goals for RV management parameters (consistent with SOC)
62830274|NCT06603857|ACTIVE_COMPARATOR|Group A|Subjects who will receive two treatments with 1927nm (Clear and Brilliant Perméa®) non-ablative fractional diode laser for rejuvenation of photodamaged skin of the face in pairing with Skinceuticals CE Ferulic
62830275|NCT06603857|SHAM_COMPARATOR|Group B|Subjects who will receive two treatments with 1927nm (Clear and Brilliant Perméa®) non-ablative fractional diode laser for rejuvenation of photodamaged skin of the face in pairing with vehicle serum
62608195|NCT06719219|EXPERIMENTAL|LTB-SA7 low dose, 1 vaccination|The candidate toxoid vaccine (LTB-SA7) is administered once, 1 month later participant receives a placebo.
62048016|NCT06243705|ACTIVE_COMPARATOR|Virtual Reality Glasses Group|During the application of fissure sealant, the child watches a cartoon through virtual reality glasses. Preoperative (T1) baseline levels of dental anxiety will be measured using the Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) and the Facial Image Scale (FIS), and behavior rating will be measured using the Frankl Behavior Rating Scale (FBRS). Intraoperative (T2) cooperation level will be recorded using the Modified Houpt Scale (MHS) during the surface cleaning (T2A), isolation (T2B) and washing (T2C) phases of fissure sealant application. Postoperative(T3) anxiety level and behavior rating measurements (CFSS-DS, FIS, FBRS) will be repeated. Physiological markers for dental anxiety, such as heart rate and oxygen saturation, will be measured at all time points (T1, T2A-B-C, T3). Children and parents in this group will received a questionnaire for their perception about the use of their distraction technique(T3).
62048017|NCT06243705|NO_INTERVENTION|Control Group|Tell-Show-Do technique will be used to apply the fissure sealant. No additional distraction will be applied. Preoperative (T1) baseline levels of dental anxiety will be measured using the Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) and the Facial Image Scale (FIS), and behavior rating will be measured using the Frankl Behavior Rating Scale (FBRS). Intraoperative (T2) cooperation level will be recorded using the Modified Houpt Scale (MHS) during the surface cleaning (T2A), isolation (T2B) and washing (T2C) phases of fissure sealant application. Postoperative(T3) anxiety level and behavior rating measurements (CFSS-DS, FIS, FBRS) will be repeated. Physiological markers for dental anxiety, such as heart rate and oxygen saturation, will be measured at all time points (T1, T2A-B-C, T3).
62048018|NCT04557930|NO_INTERVENTION|Usual Care Control|The control arm occurred prior to receipt of the video game intervention. Each hospital group 'crossed over' from control to intervention at a randomized time point based on their assignment to the 'step' of the trial.
62048019|NCT04557930|EXPERIMENTAL|Video Game Intervention|Each hospital group 'crossed over' from control to intervention at a randomized time point. Physicians working at these hospitals, who agreed to participate in the trial, received a study iPad and were asked to play the video game loaded on the iPad for a minimum of 2 hours.
62250392|NCT03275181||Prostate cancer patient/survivor with ADT history|Prostate cancer patients or survivors who have a treatment history that includes androgen deprivation therapy. This includes 1) orchiectomy (surgical castration), 2) luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or Gonadotrophin-releasing hormone (GnRH) agonists), 3) LHRH antagonist, 4) CYP17 inhibitor, or 5) anti-androgen.
62250393|NCT03275181||Prostate cancer patient/survivor without ADT history|Prostate cancer patients or survivors who have never been treated with androgen deprivation therapy.
62250394|NCT03275181||Control|Individuals with no history of prostate caner androgen deprivation therapy. Free of known clinical cardiovascular disease
62608196|NCT06719219|EXPERIMENTAL|LTB-SA7 low dose, 2 vaccinations|The candidate toxoid vaccine (LTB-SA7) is administered twice, 1 month apart.
62608197|NCT06719219|EXPERIMENTAL|LTB-SA7 medium dose, 1 vaccination|The candidate toxoid vaccine (LTB-SA7) is administered once, 1 month later participant receives a placebo.
62608198|NCT06719219|EXPERIMENTAL|LTB-SA7 medium dose, 2 vaccinations|The candidate toxoid vaccine (LTB-SA7) is administered twice, 1 month apart.
62250395|NCT03051282|ACTIVE_COMPARATOR|non-carrier control group|Subjects who do not carry the CES1 variant G143E (rs71647871) will receive 10 mg Enalapril orally once daily for 7 consecutive days.
62250396|NCT03051282|ACTIVE_COMPARATOR|G143E carriers group|Subjects who carry the CES1 variant G143E (rs71647871) will receive 10 mg Enalapril orally once daily for 7 consecutive days.
62250397|NCT02985099|ACTIVE_COMPARATOR|Rosuvastatin group|Oral prophylaxis followed by 1.2% Rosuvastatin drug in gel form placed in intrabony defects
62250398|NCT02985099|PLACEBO_COMPARATOR|Placebo group|Oral prophylaxis followed by placebo gel placement in intrabony defects
62250399|NCT02339064|EXPERIMENTAL|Apomorphine infusion|Continuous subcutaneous apomorphine infusion
62250400|NCT04196803|ACTIVE_COMPARATOR|magnesium treatment|Participants were assigned to magnesium glycinate
62250401|NCT04196803|PLACEBO_COMPARATOR|placebo|Participants were assigned to placebo group
62250402|NCT05515861|EXPERIMENTAL|EUS group|The EUS group uses endoscopic ultrasound to observe the diameter and blood flow of residual variceal veins after endoscopic cyanoacrylate injection for gastric varices to evaluate the embolization effect.
62608199|NCT06719219|EXPERIMENTAL|LTB-SA7 high dose, 1 vaccination|The candidate toxoid vaccine (LTB-SA7) is administered once, 1 month later participant receives a placebo.
62608200|NCT06719219|EXPERIMENTAL|LTB-SA7 high dose, 2 vaccinations|The candidate toxoid vaccine (LTB-SA7) is administered twice, 1 month apart.
62608201|NCT06719219|PLACEBO_COMPARATOR|Placebo|Participant receives placebo twice, 1 month apart.
62608202|NCT04397471||Healthy Volunteer|A one time only 30-80 mL sample of bone marrow will be collected from both posterior superior iliac crests.
62608203|NCT03299894|EXPERIMENTAL|systematic calculation of qSOFA|Usual procedure for patient triage AND systematic calculation of qSOFA at Emergency Department triage in patients admitted with a suspected or proven bacterial infection.
62608204|NCT03299894|NO_INTERVENTION|no systematic calculation of qSOFA|Usual procedures for patient triage at Emergency Department admission and management of suspected or proven bacterial infection. No systematic calculation of qSOFA.
62608205|NCT04967365||Case patients|500 patients who experience greater than or equal to 3 nights in a pediatric ICU with intensive care instrumentation.
62608206|NCT04967365||Control patients|250 patients who experience an overnight stay in a pediatric ICU without intensive care instrumentation.
62608207|NCT00100841|EXPERIMENTAL|Treatment (combination chemotherapy)|Patients receive cetuximab IV over 60-120 minutes on day 1 in weeks 1-8. Patients also receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 48 hours on days 1 and 2 of weeks 1, 3, 5, and 7. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
62048020|NCT02006082||COPD patients followed after TVC|All COPD patients living in the southern part of Rogaland county in Western Norway, with a habitual value of FEV1 \< 50%, who were monitored at home by TVC following discharge after emergency hospitalization for COPD exacerbation at Stavanger University Hospital, or who had tele-monitoring at home under outpatient treatment for acute COPD deterioration during the pilot project period (16th April 2010 - 31st December 2011). The telemedicine equipment consisted of a computer with a web camera with a microphone, through which the patient at home and the specially trained nurse in hospital were able to communicate, and also comprised requisites to measure the patient's oxygen saturation and heart rate, and to perform a spirometry.
62048021|NCT06545981||Idiopathic intracranial hypertension (Group 1)|24 subjects with idiopathic intracranial hypertension
62608208|NCT06071221|EXPERIMENTAL|Living Healthy educational program + Peer Coaching|Home Health Aides (HHAs) will receive educational content via the CareConnect application, an eLearning mobile platform that provides educational courses for HHA certification and keeps track of their service hours to maintain NYS compliance. HHAs in this intervention arm will receive the 8-session adapted Living Healthy program via CareConnect over 3 months. Each HHA will be paired with a trained Peer Coach participant who will work through the structured program with the HHA.
62048022|NCT06545981||Healthy control subjects (Group 2)|24 age- and sex-matched control subjects
62048023|NCT03210155|ACTIVE_COMPARATOR|Active Comparator|About the size of a smart phone, the Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The active intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
62048024|NCT03210155|SHAM_COMPARATOR|Sham Comparator|The Alpha-Stim® AID CES sham device is identical in appearance to the active device but is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
62048025|NCT02840357|EXPERIMENTAL|Treatment Group|Purple Wheat Convenience Bars The treatment group will consume 4 servings /day of bran-enriched purple wheat convenience bars (40g/ serving)
62048026|NCT02840357|PLACEBO_COMPARATOR|Control Group|Control Wheat Convenience Bars The control group will consume 4 servings /day of bran-enriched ordinary wheat convenience basr (40g/ serving)
62048027|NCT04523987|EXPERIMENTAL|gemcitabine and nab-paclitaxel chemotherapy|Patients who are recommended gemcitabine and nab-paclitaxel chemotherapy as a standard-of-care by their treating physician will be offered to participate in this study.
62048028|NCT01194570|EXPERIMENTAL|Placebo|Participants with primary progressive multiple sclerosis (PPMS) received placebo matched to ocrelizumab at a schedule interval of 24 weeks up to at least 120 weeks.
62048029|NCT01194570|PLACEBO_COMPARATOR|Ocrelizumab 600 mg|Participants with PPMS received ocrelizumab as two IV infusions of 300 mg separated by 14 days at a scheduled interval of every 24 weeks up to at least 120 weeks.
62048030|NCT05338099|EXPERIMENTAL|Dose group A (Low dose)|Participants will receive EN001 intravenously (IV) once on Day 1. Before 30 minutes EN001 dosing, there will be premedication (solu-cortef 1-2 mg/kg + Lorazepam 0.1 mg/kg (max 2 mg) + Ondansetron (5 mg/m\^2) + Chlorpheniramine (1 mg for 2\~6 years old; 2 mg for 6\~12 years old; 4 mg for over 12 years old)+ Acetaminophen) administered to assure safety of participants from issues such as immune rejection, due to the process of thawing in a frozen state of EN001.
62048031|NCT05338099|EXPERIMENTAL|Dose group B (High dose)|Participants will receive EN001 intravenously (IV) once on Day 1. Before 30 minutes EN001 dosing, there will be premedication (solu-cortef 1-2 mg/kg + Lorazepam 0.1 mg/kg (max 2 mg) + Ondansetron (5 mg/m\^2) + Chlorpheniramine (1 mg for 2\~6 years old; 2 mg for 6\~12 years old; 4 mg for over 12 years old)+ Acetaminophen) administered to assure safety of participants from issues such as immune rejection, due to the process of thawing in a frozen state of EN001.
62048032|NCT05120089|EXPERIMENTAL|muscle energy technique|Muscle energy technique is an associate degree of osteopathic manipulation methodology. The muscles of patients were used, on request, to type a singular controlled position, in a very specific direction, and against a distinctly executed therapist-applied counterforce. Muscle energy technique could be a post-isometric relaxation, because it reduces the tone of a muscle or cluster of muscle after a brief period following an isometric contraction. The result of post-isometric relaxation is mediated by receptive input from Golgi connective tissue organ (GTO) that has associate degree repressive result on the antagonist muscles mediated by the muscle spindle receptive. The technique will be applied for three month (3 session/week)
62250403|NCT05515861|NO_INTERVENTION|Control group|The control group doesn't perform endoscopic ultrasound after endoscopic cyanoacrylate injection for gastric varices.
62250404|NCT01120548|EXPERIMENTAL|Rehabilitation + Ventilation Group|Patient Heart Failure with sleep disordered breathing who follows ventilation therapy and physical training.
62608209|NCT06071221|ACTIVE_COMPARATOR|Living Healthy educational program|Home Health Aides (HHAs) in the attention control arm will receive an 8-session CareConnect delivered general health program (covering topics distinct from the Living Healthy intervention) that is strictly informational without any elements of CBT.
62048033|NCT05120089|EXPERIMENTAL|myofacial release|The technique will be applied for three month (3 session/week). All participants underwent ipsilateral side bending in a side-lying position, with the goals being de-rotation and scoliosis reduction.
62250405|NCT01120548|NO_INTERVENTION|Rehabilitation Only Group|
62250406|NCT05214417|EXPERIMENTAL|KAP (Ketamine-assisted Psychotherapy) Recipients|Two separate IM ketamine injection sessions, with possible multiple doses administered at each session not to exceed 100 mg IM ketamine total for the session.
62250407|NCT05214417|OTHER|Naturalistic Comparator|Pre-existing conventional treatment will continue for this group during the study period.
62250408|NCT01512602|ACTIVE_COMPARATOR|Dialectical Behavior Therapy DBT|16 weeks DBT-treatment
62250409|NCT01512602|ACTIVE_COMPARATOR|CAMS|Collaborative Assessment and Management of Suicidality, CAMS-informed supportive psychotherapy
62048034|NCT01236079|EXPERIMENTAL|Assisted Referral & IVR|
62048035|NCT01236079|NO_INTERVENTION|Usual Care|
62048036|NCT01345630|EXPERIMENTAL|Maraviroc|Maraviroc 150 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for emtricitabine/tenofovir once daily.
62048037|NCT01345630|ACTIVE_COMPARATOR|Emtricitabine/tenofovir|Emtricitabine/tenofovir 200/300 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for maraviroc once daily.
62048038|NCT04499573|EXPERIMENTAL|intervention/treatment|"Intervention:~1. Patient (cohort 1 and 2) or donor (cohort 3) leukapheresis~2. Drug therapy:~   * Fludarabine 120 mg/m2~  * Cyclophosphamide 750 mg/m2~  * Etoposide 450 mg/m2~  * Cytarabine 900 mg/m2~  * Dexamethasone 30 mg/m2~  * Tocilizumab 8 mg/kg BW~3. Biological:~Cohort 1 and 2: autologous CD19/CD22 CAR-T lymphocytes, dose 0.15 - 1.5х106/kg~Cohort 3: allogeneic CD19/CD22 CAR-T lymphocytes, dose 0.1х106/kg + allogeneic HSCT from a haploidentical or matched related donor"
62048039|NCT05543850|ACTIVE_COMPARATOR|Open loop control|In this arm, the patients will use their usual diabetes therapy. Additionally, patients will wear a blinded DexcomG6 for data collection during the open loop period.
62048040|NCT05543850|EXPERIMENTAL|Bi-hormonal closed-loop control|In this arm, treatment consists of the bi-hormonal closed-loop system. A short acting insulin analogue (Humalog, 3 ml pre-filled cartridge, Eli Lilly) and glucagon (Glucagen, Novo Nordisk; 3.15 ml cartridge Accu-Chek Spirit, Roche) will be administered according to the closed-loop algorithm. Additionally, patients will wear a blinded DexcomG6 for data collection during the closed loop period.
62048041|NCT01067248||COPD, osteoporosis|The subjects are divided into 6 groups of 20 subjects each, I: COPD patients with osteoporosis based on T-score and without vertebral fractures, II: COPD patients with osteoporosis based on T-score and vertebral fractures, III: COPD patients with vertebral fractures and without osteoporosis based on T-score, IV: COPD patients without osteoporosis based on T-score and without vertebral fractures, V: healthy controls with osteoporosis based on T-score and without vertebral fractures, VI: healthy controls without osteoporosis based on T-score and without vertebral fractures.
62048042|NCT05673226|EXPERIMENTAL|Surface disinfection with organosilane|Organosilane will be sprayed on the surfaces, using an atomizer. When the environment has been completely covered (i.e., when all surfaces and equipment have a slightly damp film), we will proceed with the second phase of the disinfection of all heavily touched surfaces. surfaces of the bed, with a microfiber cloth with organosilane.
62048043|NCT05673226|NO_INTERVENTION|Usual surface disinfection|The control group will perform standard cleaning and disinfection of the beds and the environment according to their previous protocols, using the usual products.
62048044|NCT06082245|ACTIVE_COMPARATOR|TLIP Group|Patients were anesthetized before surgery using TLIP lumbar block (L3) under ultrasound with 20ml of ropivacaine 0.25% anesthetic on each side. After that, the patient was given general anesthesia for surgery
62048045|NCT06082245|ACTIVE_COMPARATOR|ESP Group|Patients were anesthetized before surgery with lumbar (L3) ESP block method under ultrasound with 20ml of Ropivacaine 0.25% anesthetic on each side. After that, the patient was given general anesthesia for surgery.
62048046|NCT06082245|EXPERIMENTAL|Control Group|Patients received general anesthesia, then the incision was anesthetized with 15ml of 1% lidocaine mixed with 1/200,000 adrenaline on each side before surgery
62250410|NCT03146767|EXPERIMENTAL|Tetanic Group|A Tetanic stimulation (Tetanus stabilization of baseline) is administered to the monitorized arm before calibrating the neuromuscular block monitor. Then Train-of-four (TOF) stimuli are administered every 20 seconds for 20 minutes.
62250411|NCT03146767|NO_INTERVENTION|Control Group|Conventional monitor baseline stabilization: Train-of-four stimuli are administered every 20 seconds for 20 minutes
62250412|NCT06287814||Stage III colorectal cancer patients|MRD assessment by ctDNA analysis Patients will be managed according to current standard-of-care
62250413|NCT01678482|EXPERIMENTAL|lession count reduction post treatment|"* A total of 50 subjects were included.~* The majority are female (62 %)~* At baseline the average number of lesions was 20.5±7.1, ranging from 6 to 36 lesions.~* All subjects demonstrated a reduction in lesion count.~* The average improvement after one month was 56.7%±8.9%, and remained similar also after 3 months 57.7%±9.4%.~* The percent of responders (with at least 40% of reduction) was 94% after 1 month and 96% after 3 months~* The Percent of responders is similar for males \& females and similar for cheeks \& front."
62830276|NCT01213316||Overall Participants|HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks (Initial Cohort), 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.
62830277|NCT01213316||Aging Participants|"HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.~Includes newly enrolled participants ≥ 50 years of age (Amendment Cohort), plus participants from the Initial Cohort who were ≥ 50 years of age at time of recruitment and who completed 48 weeks of treatment (Prolonged Cohort)."
62048047|NCT05210855|EXPERIMENTAL|Patients with head trauma|
62250414|NCT05513625|EXPERIMENTAL|100 mg pritelivir|Single dose 100 mg pritelivir (PTV) administered day 1
62250415|NCT05513625|EXPERIMENTAL|40 mg qd ESO and 100 mg pritelivir|40 mg qd ESO Day -3 to Day1. Single dose of 100 mg PTV on Day 1
62250416|NCT00943527||1|Premenopausal Women who are not taking hormones or birth control. Ages 35-45 who have had a negative mammograph performed at the Mayo Clinic in Rochester within the last year.
62250417|NCT00943527||2|Women Initiating Hormone Therapy and have had a negative mammogram preformed at the Mayo Clinic Rochester within the last year.
62250418|NCT00943527||3|Women Initiating Tamoxifen who have had a negative mammogram preformed at the Mayo Clinic Rochester.
62250419|NCT03126396|EXPERIMENTAL|Urgo 310 3166 dressing|Urgo 310 3166 dressing
62250420|NCT06471426|EXPERIMENTAL|Osteopathic Manipulative Treatment Group|
62048048|NCT02256215|EXPERIMENTAL|Vitamin D|• All patients will have their serum vitamin D levels measured at the baseline visit. Those assigned to the treatment arm (group A) will receive either 50,000 international units of vitamin D3 by mouth once or more per week for six to eight weeks, then 800 to 1000 (or more) international units of vitamin D3 daily thereafter, this is according to the recommendations of the Endocrine Society clinical practice guideline 2011. Group B patients will receive placebo supplements identical in appearance to the vitamin D supplements.
62048049|NCT02256215|PLACEBO_COMPARATOR|Placebo|
62048050|NCT00903526||candidemia|
62048051|NCT05004987|ACTIVE_COMPARATOR|Escitalopram (ESC)|
62048052|NCT05004987|PLACEBO_COMPARATOR|Placebo (PBO)|
62048053|NCT05182567|EXPERIMENTAL|GLS-5310 ID + GeneDerm 65 kPa, 30 seconds|GLS-5310 ID + GeneDerm administered at Visit 1
62048054|NCT05182567|EXPERIMENTAL|GLS-5310 ID + GeneDerm 65 kPa, 30 seconds + GLS-5310 IN|GLS-5310 ID + GeneDerm + GLS-5310 IN administered at Visit 1
62048055|NCT05182567|EXPERIMENTAL|GLS-5310 ID + GeneDerm 65 kPa, 15 seconds|GLS-5310 ID + GeneDerm administered at Visit 1
62048056|NCT05182567|EXPERIMENTAL|GLS-5310 ID + GeneDerm 80 kPa, 30 seconds|GLS-5310 ID + GeneDerm administered at Visit 1
62608210|NCT06189313|EXPERIMENTAL|Mechanical Thrombectomy via Cleaner Pro|Participants will receive catheter-directed therapy via mechanical aspiration thrombectomy for the treatment of pulmonary embolism (PE) using the Cleaner Pro Thrombectomy System.
62830278|NCT02135796||Sepsis/Septic Shock|Individuals who are admitted to the Intensive Care Unit (ICU) with an infection called Sepsis or Septic Shock. This group will receive transthoracic echocardiography as part of the study.
62608211|NCT05849584||Pregnant women|
62048057|NCT02044185||high dose chemotherapy|group of using myeloablation regimen, autologous stell cell transplantation
62048058|NCT02044185||control group|normal population with health screening
62048059|NCT00800839|EXPERIMENTAL|Busulfan + Fludarabine + Cyclophosphamide|Busulfan starting dose of 32 mg/m\^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3. Fludarabine dose of 40 mg/m\^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan. Cyclophosphamide dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
62048060|NCT03362450||Pregnant patients seen for second or third trimester|Foetus with diagnosis of prenatal volvulus based on post-natal findings and prenatal imaging findings
62048061|NCT05280418|ACTIVE_COMPARATOR|Tezepelumab|"Tezepelumab 210 mg subcutaneous injections every 4 weeks as an investigational drug.~Sterile tezepelumab will be provided 110 mg/mL pre-filled vial, with a dose of 210 mg delivered by pre-filled syringe."
62048062|NCT05280418|PLACEBO_COMPARATOR|Matched placebo|Sterile placebo for tezepelumab will be provided in identically matched pre-filled syringes.
62048063|NCT05408806||Virtual Reality Games Group with Nintendo Wii Balance Platform|In addition to neurodevelopmental treatment, the cases are treated with virtual reality (VR) games on nintendo wii balance board for 8 weeks, 2 sessions a week. The VR games are performed twice in the first four weeks at the beginner level. During the following four weeks, advanced levels of the same games are selected and virtual reality therapy is performed with 2 repetitions.
62048064|NCT05408806||Hippotherapy Simulator Group|In addition to neurodevelopmental treatment, the cases are treated on a hippotherapy simulator for 8 weeks, 2 sessions a week. In the first 4 weeks, the warm-up and 1 speed intensities of the hippotherapy simulator are applied. During the next 4 weeks, cases are treated warm-up, 1, 2, 3, speed intensities, respectively.
62048065|NCT01484639|ACTIVE_COMPARATOR|Restrictive transfusion triggers|"Patients allocated to a restrictive transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively."
62048066|NCT01484639|ACTIVE_COMPARATOR|Liberal transfusion triggers|"Patients allocated to a liberal transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward."
62048067|NCT05925374|EXPERIMENTAL|Training group|Professionals working at a primary care site who has direct interaction with patients. They receive a one-time 2-hour interactive in-person training focused on improving care for patients who use drugs and reducing provider-based stigma. Their baseline attitudes and intended actions are compared to their post-intervention answers to questions in the same domains. Thus, the participants act as their own comparison group, where baseline answers are compared to post-intervention answers.
62048068|NCT00698594|ACTIVE_COMPARATOR|1|Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
62608212|NCT05230615||Patients with type 2 diabetes|once-daily oral semaglutide in a real-world adult population with type 2 diabetes
62608213|NCT06631846|EXPERIMENTAL|Music therapy|
62608214|NCT06631846|EXPERIMENTAL|Mindfulness meditation|
62608215|NCT06631846|EXPERIMENTAL|Combination of music therapy and mindfulness meditation|
62608216|NCT06631846|ACTIVE_COMPARATOR|Conventional phase-1 cardaic rehabilitation|
62830279|NCT06650579|EXPERIMENTAL|Arm I (leuprolide plus abiraterone acetate/prednisone)|Patients receive leuprolide IM or SC injections every 3 to 6 months plus oral abiraterone acetate (AA) with prednisone daily for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo standard of care radiation therapy.
62830280|NCT06650579|EXPERIMENTAL|Arm II (relugolix + abiraterone acetate/prednisone)|Patients receive oral relugolix daily plus oral abiraterone acetate (AA) with prednisone daily for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo standard of care radiation therapy.
62048069|NCT00698594|ACTIVE_COMPARATOR|2|Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group
62048070|NCT00698594|PLACEBO_COMPARATOR|3|Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
62048071|NCT00765843|ACTIVE_COMPARATOR|custom foot orthoses|Subjects will receive custom fabricated orthoses created from casts of the feet and according to individualized prescriptions. These orthoses are to be used in the standardized shoes provided to all subjects in the study.
62048072|NCT00765843|ACTIVE_COMPARATOR|pre-fabricated orthoses|Subjects will be provided pre-fabricated (non-customized) orthoses. These orthoses are to be used in the standardized shoes provided to all subjects in the study. for use in their shoes.
62048073|NCT00765843|SHAM_COMPARATOR|sham insoles|Subjects will receive sham orthoses that are soft and pliable, but not designed to relieve pain. These orthoses are to be used in the standardized shoes provided to all subjects in the study.
62048074|NCT06020092|EXPERIMENTAL|Injectable biphasic calcium phosphate (maxresorb inject, botiss GmbH)|This biomaterial is an alloplastic bone substitute material in the form of a paste that is placed into the defect with a plastic syringe. The material consists of an aqueous gel containing granules of biphasic calcium phosphate in the composition of 60% HA and 40% β-TCP (particle size between 15-50 nm).
62048075|NCT06020092|ACTIVE_COMPARATOR|Bovine xenograft (cerabone, botiss GmbH)|The material is completely anorganic and consists of 100% HA. For this study, the material will be used in granular form (the size of the granules is between 0.5 and 1 mm), mixed with physiological solution prior to placement into the defect.
62048076|NCT00762450|ACTIVE_COMPARATOR|A- Positive Control|fluoride/triclosan/copolymer toothpaste
62048077|NCT00762450|PLACEBO_COMPARATOR|B - Silica control|fluoride only toothpaste
62048078|NCT00762450|EXPERIMENTAL|C- Experimental product|fluoride/triclosan/amino acid toothpaste
62048079|NCT04060875||Feasibility group|First phase group will involve piloting a novel virtual reality treatment for chronic pain to investigate feasibility and safety with a smaller number of patients
62048080|NCT03706118|EXPERIMENTAL|MRI and Neuropsychologic testing|"102 healthy controls will be examined by magnetic resonance imaging (MRI) of brain, spinal and thoracic cord at month 0, 12, 24 and 36.~102 healthy controls will be examined by neuropsychological and walking testing designed for patients with multiple sclerosis at month 0, 12, 24 and 36."
62048081|NCT00981890|EXPERIMENTAL|Sunitinib|
62048082|NCT03587246||Pregnant women|
62250421|NCT06115941|EXPERIMENTAL|Incentive spirometer group|"incentive spirometry group patients were directed to start incentive spirometry, 48 hours prior to surgery. They were given an incentive spirometer and were briefed that they should inhale into the mouth piece of spirometer to lift the balls to the roof of tube and hold for five seconds and then exhale. 13 They were asked to perform 10 such breaths for 6 times in a day till surgery under direct supervision of researcher and this was charted in patient file."
62250422|NCT06115941|NO_INTERVENTION|No Incentive spirometer group|"In group B or no incentive spirometry group patients were not asked to perform incentive spirometry."
62250423|NCT01909648|OTHER|HbA2 Leuven|Presence of HbA2 Leuven mutation, demonstrated by molecular diagnosis on blood sample.
62440197|NCT01942798|ACTIVE_COMPARATOR|Cognitive Games|"The Cognitive Games group will receive 40 minute supervised group training three times per week for a period of four weeks. The group for the first week will be held at the clinic, while the remaining three weeks be conducted at the subject's home and supervised by the Trainer remotely using a tablet with video conferencing capability. At the end of the four-week Supervised Phase, subjects will retain the Wii units and they will be encouraged to use the program on their own for an additional period of four weeks (Unsupervised Phase).~Subjects in the control group will play cognitive oriented video games using Wii Big Brain Academy Degree program. BigBrain™ is a video gaming system which has games and exercises to improve cognitive function(identify, memorize, analyze, compute, and visualize). Subjects use the Wii handheld remote to participate in the games by pointing and clicking the remote to select on-screen answers in response to on-screen questions."
62608217|NCT03337594||Control|Pediatric patients who have not been exposed to gadolinium-based contrast agent administration and who require cardiac surgery as part of their standard clinical treatment.
62830281|NCT03622489|EXPERIMENTAL|Tab ibuprofen + IV acetaminophen|"All women will receive immediately after surgery, in the recovery room:~1. IV morphin 5 mg, repeat doses every 10 minutes for VNS\>3~2. IV Tramal 100 mg, once~After Admitted to Maternity ward:~- Scheduled doses: 08:00 hr, Tab. Ibuprofen 400 mg, and IV Acetaminophen 1 gr 14:00 hr, IV Acetaminophen 1 gr 19:00 hr, Tab. Ibuprofen 400 mg 00:00 hr, IV Acetaminophen 1 gr~-Additional analgesia if needed according to VNS scale: PO drops Dipyrone 1 gr, for VNS\>4, up to 4 times a day, at least 6 hours between doses.~Tab Tramadex 100 mg, for VNS\>6, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 4 hours between doses."
62830282|NCT03622489|EXPERIMENTAL|Tab Ibuprofen + Tab acetaminophen|"All women will receive immediately after surgery, in the recovery room:~1. IV morphin 5 mg, repeat doses every 10 minutes for VNS\>3~2. IV Tramal 100 mg, once~After Admitted to Maternity ward:~- Scheduled doses: 08:00 hr, Tab. Ibuprofen 400 mg, and PO Acetaminophen 1 gr 14:00 hr, PO Acetaminophen 1 gr 19:00 hr, Tab. Ibuprofen 400 mg 00:00 hr, PO Acetaminophen 1 gr~- Additional analgesia if needed according to VNS scale: PO drops Dipyrone 1 gr, for VNS\>4, up to 4 times a day, at least 6 hours between doses.~Tab Tramadex 100 mg, for VNS\>6, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 4 hours between doses."
62048083|NCT03587246||non-pregnant women|
62048084|NCT00389883|ACTIVE_COMPARATOR|1|propofol et remifentanil
62048085|NCT00389883|EXPERIMENTAL|2|sevoflurane et sufentanil
62048086|NCT06222515||Women with storage lower urinary tract symptom|The women with lower urinary tract symptoms, including urinary urgency (UU), stress urinary incontinence(SUI), urgency urinary incontinence (UUI), nocturia (N) and frequency (F).
62048087|NCT03470779|EXPERIMENTAL|Treatment group|Participants randomly assigned to the treatment group will participate in an interdisciplinary treatment program in which local Kurdish psychotherapists and physiotherapists provide a 10-week intervention program. Treatment will consist of group physiotherapy and group psychotherapy
62048088|NCT03470779|NO_INTERVENTION|Wait-list group|Participants randomly assigned to the wait-list group will not receive treatment but will participate in outcome data collection for comparison purposes.
62048089|NCT01032655|EXPERIMENTAL|sequential, susceptibility guided|single arm
62449433|NCT06081751|EXPERIMENTAL|İntervention Group|"Children in the intervention group will play traditional games for 60 minutes, 3 days a week for 8 weeks. The program to be implemented is as follows;~Week 1 (Day 1 - I Sell Oil, I Sell Honey game, Day 2 - Snatch game, Day 3 - Corner Snatch Game) Week 2 (Day 1 - Handkerchief game, Day 2 - My Fire game, 3 Day 2 - Kurt Baba Game) Week 3 (Day 1 - Chubby game, Day 2 - Jump rope game, Day 3 - Mouse game in the middle) Week 4 (Day 1 - Rook dodgeball game, Day 2 - Stop game, Day 3 - Old cushion mouse game) Week 5 (Day 1 - I Sell Oil, I Sell Honey game, Day 2 - Snatch game, Day 3 - Corner Catch Game) Week 6 (Day 1 - Handkerchief grabbing game, Day 2 - My Fire game, Day 3 - Daddy Wolf Game) Week 7 (Day 1 - Chubby game, Day 2 - Jumping rope game, Day 3 - Mouse game in the middle) Week 8 ( Day 1 - Dodgeball game, Day 2 - Stopping game, Day 3 - Old matte mouse game)"
62449434|NCT06081751|ACTIVE_COMPARATOR|Control Group|no intervention will be made
62048090|NCT05340959||Adult patient with single or multiple missing tooth or teeth requiring dental implants|"Adult patient with single or multiple missing tooth or teeth requiring dental implants, 40 dental implants will be placed in osteotomy sites based on radiographic findings (CBCT), the primary stability will be measured immediately after implant installation and secondary stability will be measured after 12 weeks .~Both primary and secondary stability will be measured by three devices:~1. Osstell®: based on Resonance Frequency Analysis (RFA).~2. Periotest®: based on damping effect.~3. AnyCheck®: based on tapping-motion."
62048091|NCT05805995|EXPERIMENTAL|intervention group|The exercise group received vertebral derotation with posterior correction in addition to routine chest physiotherapy (group A).
62048092|NCT05805995|EXPERIMENTAL|control|The Control group received only posterior correction with routine chest physiotherapy (group B).
62048093|NCT04475432|EXPERIMENTAL|Active|TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days
62250424|NCT02460705|EXPERIMENTAL|IBD patients receiving FMT|IBD patients receiving biologically active human fecal material sourced from OpenBiome. The physician will administer 250 mL of the fecal suspension in aliquots of 50-60 mL, through the endoscope. The material will be delivered to the most proximal point of insertion.
62250425|NCT05793294||Birth cohort|All infants age 0 - 28 days will be recruited and followed until 24 months of age
62250426|NCT03429439|EXPERIMENTAL|IMT Combined with Antiviral Therapy|"60 chronic hepatitis B patients ongoing antiviral therapy will be recruited for the study, which involved a 6 times intestinal microbiota transplant and the time interval is generally 2 weeks.~Interventions:~Procedure: Intestinal Microbiota Transplantation Procedure: antiviral therapy"
62449435|NCT04326777|OTHER|Ballon pulmonary angioplasty|Ballon pulmonary angioplasty(BPA) is a stepwise procedure requiring several separate sessions. The interval of a series of BPA is one month. In a series of BPA, there are 2 sessions, which are repeated at a 2-week interval. BPA is performed primarily on one side of the lung in the first session, then after 2 weeks, performed on the other side of the lung. In each session, the fluoroscopy time or the amount contrast are less than 60min and 200ml, respectively.
62449436|NCT06433453|EXPERIMENTAL|Indomethacin|Oral indomethacin 50 mg three times daily for 1-7 days. The administration is terminated when signs of anovulation are observed.
62608218|NCT03337594||Dotarem|Pediatric patients who have undergone routine contrast-enhanced MRI using only Dotarem contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.
62048094|NCT04475432|PLACEBO_COMPARATOR|Control|Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days
62048095|NCT00447148|NO_INTERVENTION|1|Paired comparison of 2 angiographic techniques
62048096|NCT01939704|NO_INTERVENTION|Pediatric Primary Care Control|Baseline survey with a social needs assessment, health care status, health care satisfaction and health care utilization assessment and two telephone-based follow up surveys at 3 and 6 months.
62048097|NCT01939704|NO_INTERVENTION|Pediatric Urgent Care Control|Baseline survey with a social needs assessment, health care status, health care satisfaction and health care utilization assessment and two telephone-based follow up surveys at 3 and 6 months.
62250427|NCT03429439|OTHER|Antiviral Agents|"60 chronic hepatitis B patients ongoing antiviral therapy will be recruited for the study, which involved 12 months antiviral therapy.~Interventions:~Procedure: antiviral therapy"
62250428|NCT04347070||Patients accepted in ICU diagnosed with COVID-19|Patients accepted in ICU diagnosed with COVID-19
62048098|NCT01939704|EXPERIMENTAL|Pediatric Primary Care Intervention|Baseline survey that includes social needs assessment, health care status, health care satisfaction and health care utilization assessment; 30 minute on-site intervention, twice monthly follow-up phone calls for up to 3 months to help address social needs
62608219|NCT03337594||MultiHance|Pediatric patients who have undergone routine contrast-enhanced MRI using only MultiHance contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.
62608220|NCT06027307|EXPERIMENTAL|Enavogliflozin|Enavogliflozin 0.3 mg qd for 18 months
62608221|NCT06027307|PLACEBO_COMPARATOR|Placebo|Placebo qd for 18 months
62830283|NCT03622489|EXPERIMENTAL|"On demand analgesia"|"All women will receive immediately after surgery, in the recovery room:~1. IV morphin 5 mg, repeat doses every 10 minutes for VNS\>3~2. IV Tramal 100 mg, once~After Admitted to Mternity ward:~Will not receive scheduled pain medication, but offered some only upon patients' request according to VNS score:~* Tab. Acetaminophen 1 gr, for VNS 1-3, up to 4 times a day, at east 6 hours between doses.~* PO drops Dipyrone 1 gr, for VNS 4-7, or if pain persists for 1 hour after receiving Acetaminophen, up to 4 times a day, at least 6 hours between doses.~* Tab Ibuprofen 400 mg, for VNS 8-10, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 8 hours between doses."
62830284|NCT01584375|OTHER|Flat midline head position|
62830285|NCT01584375|OTHER|Right flat lateral head position|
62048099|NCT01939704|EXPERIMENTAL|Pediatric Urgent Care Intervention|Baseline survey that includes social needs assessment, health care status, health care satisfaction and health care utilization assessment; 30 minute on-site intervention, twice monthly follow-up phone calls for up to 3 months to help address social needs
62250429|NCT06071767|EXPERIMENTAL|Arm A: Active ChAdV and MVA vaccines, vesatolimod and bnAbs|
62250430|NCT06071767|PLACEBO_COMPARATOR|Arm B: Placebos for vaccines, vesatolimod and bnAbs|
62250431|NCT01765842|ACTIVE_COMPARATOR|Rituximab (1 cycle)|"1 cycle of Rituximab (4 i.v. infusions):~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2"
62250432|NCT01765842|EXPERIMENTAL|Rituximab (2 cycles)|"A second cycle of Rituximab~First cycle of Rituximab (4 i.v. infusions):~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2~Second cycle of Rituximab (4 i.v. infusions, 6 months later)"
62250433|NCT02871804|ACTIVE_COMPARATOR|separated resection of the splenic vein|separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
62440198|NCT01942798|EXPERIMENTAL|WiiNWALK Intervention|"The intervention group will also receive 40 minute supervised group training three times per week for a period of four weeks. Interventions conducted over the first week will be held at the clinic, while the remaining three weeks be conducted at the subject's home and supervised by the Trainer remotely. At the end of the four-week Supervised Phase, subjects will retain the Wii units and they will be encouraged to use the program on their own for an additional period of four weeks (Unsupervised Phase).~The WiiNWALK protocol consists of performing Nintendo WiiFit activities. Subjects stand on the WiiFit balance board and interact with the WiiFit games through weight shifting or by using the Wii handheld remote control. The intervention protocol will include selected exercises consisting of: 1) Yoga 2) Balance Tasks 3) Strength training and 4) Aerobics.~At the in-clinic sessions in Vancouver, a motion-sensing device will also record video and skeleton data of the participant."
62608222|NCT02153229|EXPERIMENTAL|patients who undergo RP plus photofrin-based PDT|
62608223|NCT02153229|EXPERIMENTAL|patients who undergo RP alone|
62608224|NCT05241600|EXPERIMENTAL|Mindfulness-Based Childbirth and Parenting (MBCP)|Child-bearers randomized to MBCP participate in the 9-week course with a partner (co-parenting partner or other support person who will be involved in the birth). During the training, mothers receive instruction in formal and informal mindfulness practices, and how these apply to the experience of childbirth and parenting an infant. Each weekly 3-hour class includes demonstration and discussion of a practice to be carried out at home over the coming week.
62608225|NCT05241600|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Child-bearers randomized to the treatment as usual comparison group participate (also with a partner) in a non-mindfulness-based childbirth class of their choice from a list provided. To maintain ecological validity of this treatment as usual condition, using an established comparative-effectiveness/pragmatic trial approach, no attempt is made to control the length or contact hours of the class.
62608226|NCT01744171|EXPERIMENTAL|Treatment (recombinant hsp110-gp100 chaperone complex vaccine)|Patients receive recombinant hsp110-gp100 chaperone complex vaccine ID on days 1, 15, and 43 in the absence of unacceptable toxicity.
62608227|NCT06338215|EXPERIMENTAL|Moderation|Advice about alcohol intake following a Mediterranean Alcohol Drinking Pattern: Moderation (7 or less drinks/wk in women and 14 or less drinks/wk in men), avoidance of binge drinking, consumption of alcohol with meals and preference for red wine.
62830286|NCT06053671|EXPERIMENTAL|Patients with histologically confirmed FCDIIA/B undergoing or post Epilepsy Surgery|Genetic screening of DNA samples (blood, mucosal swab, brain tissue)
62830287|NCT03902977|EXPERIMENTAL|Arm A|quilting
62830288|NCT03902977|ACTIVE_COMPARATOR|Arm B|conventional suture
62830289|NCT05056233|EXPERIMENTAL|Systane Hydration|Systane Hydration lubricant eye drops dosed 4 times a day for 6 weeks (2 weeks prior to surgery and 4 weeks post surgery), with investigator defined post-operative standard of care
62830290|NCT05056233|NO_INTERVENTION|No Treatment|Investigator defined post-operative standard of care
62830291|NCT05999357|EXPERIMENTAL|adult patients with KRAS G12C+ NSCLC and brain metastases|"Cohort A: adult patients with KRAS G12C+ NSCLC and untreated asymptomatic BM Cohort B: Adult patients with KRAS G12C+ NSCLC and treated asymptomatic BM~JDQ443 200 mg BID until unacceptable toxicity or disease progression"
62830292|NCT01812863|EXPERIMENTAL|Supraclavicular Nerve Block|Maximum dose of 5 mL of 0.25% bupivacaine, and we base the dose on a ml/ kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. Bupivacaine is given with 1:200,000 epinephrine
62048100|NCT01256853|EXPERIMENTAL|MVA Vaccine|
62048101|NCT04905615|NO_INTERVENTION|Baseline Measures|The first two-weeks within each school children's baseline physical activity data will be collected. Children will be blinded to the data, receiving no feedback. Teachers will be instructed not to change normal school practices or encourage children's physical activity.
62048102|NCT04905615|EXPERIMENTAL|Data-Driven Strategy Based Intervention|During the following 2-weeks teachers will be implementing strategies to improve their class' physical activity. These are individualised strategies which will be co-developed during semi-structured interviews where teachers will discuss data visualisations with the researcher which depicts their class' physical activity over the 2-week baseline period. Teachers will then implement these strategies over the subsequent 2-weeks. During this time teachers are able to share the physical activity data with their pupils if they wish.
62048103|NCT05899842|EXPERIMENTAL|Systematic protein pump inhibitor therapy|
62048104|NCT05899842|NO_INTERVENTION|Protein pump inhibitor therapy as necessary|
62048105|NCT00542880|EXPERIMENTAL|Symbicort Turbuhaler First, then Seretide Diskus|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg First, then Seretide Diskus (salmeterol/fluticasone) 50/500 μg
62048106|NCT00542880|EXPERIMENTAL|Seretide Diskus First, then Symbicort Turbuhaler|Seretide Diskus (salmeterol/fluticasone) 50/500 μg First, then Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg
62048107|NCT03078088|PLACEBO_COMPARATOR|saline|normal saline
62048108|NCT03078088|EXPERIMENTAL|treatment|tham
62048109|NCT01945151|EXPERIMENTAL|Group 1 (G1) NMES is applied in the spastic antagonist muscle|The parameters considered for the application of NMES are: frequency of 50Hz, the wavelength of 350m / s, 10 seconds of contraction of 20 seconds of rest to total 15 minutes. During the application of NMES patients will be positioned supine on the bed with knees flexed semi supported on roller positioning. The G1 apply NMES on the motor point of the tibialis anterior and triceps surae lengthening held along with the contraction (reciprocal inhibition).
62048110|NCT05947929|EXPERIMENTAL|treadmill exercise Group|30 women will perform treadmill exercise following low food map diet three times \\weak for 3 months
62048111|NCT05947929|EXPERIMENTAL|acupuncture Group|30 women will receive acupuncture session following low food map diet three times \\ weak for 3 months.
62048112|NCT03458455||A|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions
62048113|NCT03458455||B|Patients with brain metastases from malignant melanoma receiving stereotactic radiosurgery to selected lesions
62048114|NCT03458455||C|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions + nivolumab or pembrolizumab
62048115|NCT03458455||D|Patients with brain metastases from malignant melanoma receiving stereotactic radiosurgery to selected lesions + ipilimumab, nivolumab or pembrolizumab
62048116|NCT03458455||E|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions + epidermal growth factor receptor (EGFR) inhibitors
62048117|NCT00762944||Biomet TMJ Replacement System|All patients required total reconstruction of the temporomandibular joint (unilateral or billateral)
62048118|NCT00643058|EXPERIMENTAL|1|Sterile Saline, LPS endotoxin
62048119|NCT03260868|EXPERIMENTAL|Virtual|Participants included in this virtual trial approach group did not visit the study sites during the study course. All study assessments, including vital signs, weight, laboratory variables, etc., were completed via the Bluetooth devices that instantly transfer the digital data.
62048120|NCT03260868|ACTIVE_COMPARATOR|Traditional|Participants included in this traditional trial approach group visited the study site, followed the study visit schedules for all study assessments that was performed either in-person or phone visits.
62048121|NCT01996579|EXPERIMENTAL|Lactoferrin|Patients randomized to the Lactoferrin arm will receive Lactoferrin delivered to the oral cavity as a mouth swab and Lactoferrin down a nasogastric tube; a total of 2 grams administered in 4 divided doses per day.
62048122|NCT01996579|PLACEBO_COMPARATOR|Placebo (sterile water)|Placebo (sterile water) will also be delivered down the nasogastric tube; administered in 4 divided doses per day.
62048123|NCT01531452|EXPERIMENTAL|treatment|oxaliplatin+s1
62048124|NCT01633879|EXPERIMENTAL|parent education|audio-CD parent EDC supporting positive parenting practices
62048125|NCT01633879|EXPERIMENTAL|parent and school intervention|health and success parent and school intervention
62048126|NCT01633879|NO_INTERVENTION|print materials|brochures to parents
62048127|NCT04511455|EXPERIMENTAL|Experimental|"Cabozantinib peroral 60 mg/day~A stepwise dose de-escalation schedule on individual level is available for patients with lower tolerability against cabozantinib.~The study treatment will be limited to a maximum of 12 months (including interruptions)."
62048128|NCT01867931||Erosive Esophagitis|
62048129|NCT01867931||Non-erosive Reflux Disease|
62048130|NCT01867931||Heatlhy volunteers|
62048131|NCT02270151|ACTIVE_COMPARATOR|MyDiagnostick|Everyone aged 65 years or over, who visits the GP practice will be screened for AF with the MyDiagnostick. When the device indicates a positive result, the single lead ECG will be assessed to confirm/reject the diagnosis. Every new case of diagnosed AF will be evaluated for further treatment by the general practitioner.
62440199|NCT00796237|EXPERIMENTAL|WBV|In their regular physiotherapy sessions, the subjects in the experimental group will receive whole body vibration therapy for a duration of 4 weeks during their stay in the Tung Wah Hospital.
62440200|NCT00796237|ACTIVE_COMPARATOR|CON|The subjects in this group will not receive whole body vibration therapy.
62048132|NCT02270151|NO_INTERVENTION|Control|Control arm will perform care as usual with selective screening by feeling the pulse.
62048133|NCT03063294|ACTIVE_COMPARATOR|Toolkit only|Clinics in this arm are given access to an online care coordination toolkit.
62048134|NCT03063294|EXPERIMENTAL|Toolkit plus coaching|Clinics in this arm are given access to an online care coordination toolkit plus quality improvement support from a distance-based coach.
62048135|NCT04099043|EXPERIMENTAL|Continuous Monitoring|Single Arm, Randomized
62440201|NCT03210675|OTHER|Study group|Will have a PSG at home every 6 months (± 1 month) from the age of 6 months until the age of 3 years.
62048136|NCT03114826||Renal cell carcinoma in renal transplant patients|
62048137|NCT03399032||Caspofungin|Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day
62048138|NCT01825668|EXPERIMENTAL|High cholesterol|600 mg cholesterol/day in 240 ml milk shake
62048139|NCT01825668|EXPERIMENTAL|Plant sterols|2.0 g of plant sterols/day in 240 ml milk shake containing 50 mg cholesterol
62048140|NCT01825668|PLACEBO_COMPARATOR|Placebo|50 mg cholesterol/day in 240 ml of milk shake
62048141|NCT00822133|ACTIVE_COMPARATOR|lodocaine|lidocaine 5% cream will be put on the skin
62048142|NCT00822133|EXPERIMENTAL|ketamine|ketamine 5% will be put on the skin
62048143|NCT00822133|PLACEBO_COMPARATOR|placebo|non-active cream will be put on the skin
62048144|NCT05085626|EXPERIMENTAL|fluzoparib+chidamide|"Fluzoparib: 150 mg twice daily (morning and evening) for 21 consecutive days as a cycle until disease progression or intolerance.~Chidamide: It is recommended to take 20 mg (4 tablets) twice a week, with an interval of no less than 3 days between doses (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), for 30 minutes. Until disease progression or intolerable to patient."
62250434|NCT02871804|EXPERIMENTAL|combined resection of the splenic vein|combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
62250435|NCT00745199|EXPERIMENTAL|1|Patients on hemodialysis with pruritus, receiving cromolyn sodium
62608228|NCT06338215|ACTIVE_COMPARATOR|Abstention|Advice on alcohol abstention.
62608229|NCT06469385|EXPERIMENTAL|ENS-002|"ENS-002 lotion to be applied topically either once or twice per day depending on assigned study cohort.~Cohort 1 - once daily dose (QD) of low dose ENS-002. This dose will be applied topically to a single target site once daily for 7 days.~Cohort 2 - QD dose of high dose ENS-002 in subjects with moderate to severe Atopic Dermatitis. This dose will be applied topically to all affected skin (excluding scalp, face, groin, genitalia) once daily for 14 days.~Cohort 3 - twice daily (BID) dose of high dose ENS-002 in subjects with moderate to severe Atopic Dermatitis applied topically to all affected skin (excluding scalp, face, groin, genitalia) twice daily for 14 days"
62608230|NCT04038619|EXPERIMENTAL|Treatment (loperamide, colonoscopy, FMT)|Patients receive loperamide PO. After 4 hours, patients undergo FMT via colonoscopy over 15-30 minutes.
62608231|NCT03700203||Early cardiac arrest patients|Cases will be consecutive adult patients with EMS-treated OHCA and transport to the 14 emergency departments of participating hospitals. A prospective OHCA patient cohort will be developed and all survived OHCA cases will be followed at 1-month and 6-month after ED discharge by telephone. During the study period, the investigators aim to recruit a total 1,780 cases (200 cases between September 2017 and August 2018, 600 cases between September 2018 and August 2020, 80 cases between September 2020 and December 2020, and 900 cases between January 2021 and December 2023).
62608232|NCT03700203||Matched community-based controls|Matched community-based controls (2:1 matching) will be selected from two health screening centers. Controls are those who visit the participating health screening centers for their annual routine physical examinations. During the study period, the investigators aim to recruit a total 3,560 controls (400 controls between September 2017 and August 2018, 1200 controls between September 2018 and August 2020, 160 controls between September 2020 and December 2020, and 1800 controls between January 2021 and December 2023).
62608233|NCT04399603||COVID critically unwell patients|
62830293|NCT01812863|PLACEBO_COMPARATOR|No Nerve Block|A band-aid will be placed on all patients where a supraclavicular nerve block would have been inserted, and parents will be asked to leave the band-aid on for 3 days to maintain the blindness to the treatment type by the patient.
62830294|NCT06653413||COPD group|any patient who complains of dyspnea, chronic cough or sputum, a history of recurrent lower respiratory infection and/or a history of exposure to disease risk factors, Pulmonary function examination indicated that FEV1/FVC \<0.7 after bronchodilator was used to confirm COPD.
62830295|NCT06653413||normal group|No acute or chronic cardiopulmonary disease in the past, no abnormal lung physical examination and lung imaging examination in the past month, no history of infectious diseases.
62830296|NCT01310452|ACTIVE_COMPARATOR|neutral protamine insulin, metformin|NPH insulin once daily plus oral metformin twice or thrice daily during 26 weeks
62830297|NCT01310452|EXPERIMENTAL|insulin detemir, metformin|Insulin detemir once daily plus oral metformin twice or thrice daily during 26 weeks
62830298|NCT04728633|EXPERIMENTAL|Treatment (carmustine, ethiodized oil, gelatin sponge)|Patients undergo TACE by receiving an infusion of carmustine dissolved in ethiodized oil and an injection of gelatin sponge. Treatment repeats Q4W for bilobar disease or Q7W for unilobar disease in the absence of disease progression or unacceptable toxicity or until maximum clinical benefit is obtained.
62830299|NCT06474715|NO_INTERVENTION|Control Arm: Fitness classes only|"There will be 3 Shape Up NYC classes offered weekly for one hour free of charge to consenting participants in all three arms with a total of 12 classes offered per participant.~Weekly reminders for each class will be sent via automated text messages to individuals."
62830300|NCT06474715|ACTIVE_COMPARATOR|Comparator Arm: Fitness classes + childcare|"There will be 3 Shape Up NYC classes offered weekly for one hour free of charge to consenting participants in all three arms with a total of 12 classes offered per participant.~In addition, they will receive childcare in an adjacent space to the fitness class.~Weekly reminders for each class will be sent via automated text messages to individuals."
62048145|NCT05085626|EXPERIMENTAL|fluzoparib+camrelizumab|"Fluzoparib: 150 mg twice daily (morning and evening) for 21 consecutive days as a cycle until disease progression or intolerance.~Camrelizumab: 200 mg IV drip over approximately 30 minutes (no less than 20 minutes and no more than 60 minutes) on Day 1 of each 3-week treatment cycle until disease progression or intolerance."
62048146|NCT04110002|EXPERIMENTAL|Injury Prevention Program|Those allocated to the injury prevention program will be instructed on the program, the added exercises, and the additional time commitment.
62250436|NCT00745199|EXPERIMENTAL|2|patients on hemodialysis with pruritus, receiving placebo
62250437|NCT00745199|NO_INTERVENTION|3|Patients on hemodialysis but without pruritus who do not receive any treatment.
62250438|NCT01045798|EXPERIMENTAL|Caspofungin|caspofungin acetate
62250439|NCT01045798|PLACEBO_COMPARATOR|Placebo|normal saline
62250440|NCT02126449|EXPERIMENTAL|Fasting mimicking diet|Short term fasting using Fasting mimicking diet around neoadjuvant chemotherapy (AC\>T)
62250441|NCT02126449|NO_INTERVENTION|regular diet|Standard neoadjuvant chemotherapy (AC\>T)
62250442|NCT01817907|PLACEBO_COMPARATOR|Placebo|Subjects will receive a sugar pill during their placebo night sleep study.
62250443|NCT01817907|ACTIVE_COMPARATOR|Trazodone|Subjects will receive trazodone during their treatment night sleep study
62608234|NCT04399603||Non-Covid critically unwell Patietns|
62608235|NCT06155513|EXPERIMENTAL|Group A: Serum and Cream of formulation A (light)|Daily application of glyceryl Eicosapentaenoate serum and glyceryl Eicosapentaenoate cream of formulation A on the targeted skin area. The skin area must be clean and dry. Subjects must proceed with at least one application of products each day for 42 consecutive days. Subjects may proceed with additional daily product applications if needed.
62048147|NCT04110002|NO_INTERVENTION|Control|The control group will practice and perform with no change to pre-existing years' standard operating practice.
62048148|NCT01487317|EXPERIMENTAL|Rivastigmine transdermal patch|
62048149|NCT01487317|PLACEBO_COMPARATOR|placebo|
62048150|NCT02030782|ACTIVE_COMPARATOR|Usual Care|Patients received usual care through primary care, enhanced by provider education regarding depression evaluation and management (1-2 hour training, plus study manual)
62048151|NCT02030782|EXPERIMENTAL|Quality Improvement for Depression|Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.
62048152|NCT03051971|ACTIVE_COMPARATOR|Jet nebulizer|short-acting bronchodilator (albuterol and/or ipratropium bromide) according to standard of care practices and physician discretion will be administered with a jet nebulizer
62048153|NCT03051971|ACTIVE_COMPARATOR|Vibrating Mesh Nebulizer|short-acting bronchodilator (albuterol and/or ipratropium bromide) according to standard of care practices and physician discretion will be administered with a vibrating mesh nebulizer
62048154|NCT00637208|EXPERIMENTAL|1|
62048155|NCT00637208|NO_INTERVENTION|2|Watch-full follow-up
62608236|NCT06155513|EXPERIMENTAL|Group B: Serum and Cream of formulation B (rich)|Daily application of glyceryl Eicosapentaenoate serum and glyceryl Eicosapentaenoate cream of formulation B on the targeted skin area. The skin area must be clean and dry. Subjects must proceed with at least one application of products each day for 42 consecutive days. Subjects may proceed with additional daily product applications if needed.
62608237|NCT05198154||Advanced NSCLC patients with long-term benefit after first-line immunotherapy|For patients with advanced NSCLC who have long-term benefit (PFS 12 months) after first-line immunotherapy
62608238|NCT04662294|EXPERIMENTAL|T-ALL|
62608239|NCT04662294|EXPERIMENTAL|T-NHL|
62608240|NCT04662294|EXPERIMENTAL|AML|
62608241|NCT05320068|EXPERIMENTAL|Intervention group|A group of patients will be treated with a blinded capsule that contains 125mg of vancomycin every 6 hours for 10 days.
62250444|NCT04719494|EXPERIMENTAL|Training Group|During the 12-training day sessions, subjects will walk on the treadmill for a total of 30 minutes. Participants will walk at a comfortable pace while we perform controlled movements to the treadmill system. Subjects will be fitted with a fall-arrest harness and assisted onto the treadmill system. In the dynamic balance training group, we will move the motion base as participants walk in order to challenge their balance.
62250445|NCT04719494|NO_INTERVENTION|Control Group|Subjects who are in the control group will also walk on the treadmill, but the motion base will remain stationary. They will complete 12-training day sessions.
62608242|NCT05320068|PLACEBO_COMPARATOR|Placebo group|A group of patients will be treated with a blinded capsule that contains a placebo every 6 hours for 10 days.
62608243|NCT06730204|EXPERIMENTAL|Standardized nutrition management（+ short peptide ONS) Group|"The children in this group will be given standardized nutrition management after admission. They will follow the five-step treatment principle of malnutrition. Diet + nutrition education is the basic way, which is successively promoted to diet + oral nutrition supplement, enteral nutrition, partial enteral nutrition + supplementary parenteral nutrition, and total parenteral nutrition. When a nutritional treatment does not meet 60% of the target energy requirements for 3 to 5 days, the upper step of the treatment can be selected. For infants or newborns, when 75-80% of the target amount cannot be reached for 3-5 days, the upper step of the treatment can be selected.~During the study period, an additional 3 months of short peptide oral nutritional supplements (ONS) is expected to be performed in children enrolled from December 1, 2024 to February 28, 2025 to explore the improvement of the nutritional status of the children."
62048156|NCT00526630|ACTIVE_COMPARATOR|1. MPD|Randomized to receive active Methylphenidate first. At cross-over, participants will receive placebo.
62250446|NCT02140333|EXPERIMENTAL|Erlotinib 100mg|Erlotinib 100mg
62250447|NCT02140333|ACTIVE_COMPARATOR|Erlotinib 150mg|Erlotinib 150mg
62048157|NCT00526630|PLACEBO_COMPARATOR|2. Placebo|Randomized to receive placebo first. At cross-over, participants will receive the active Methylphenidate.
62048158|NCT00003796|EXPERIMENTAL|Arm I|Patients receive irofulven IV over 30 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
62048159|NCT05554068|EXPERIMENTAL|Shingrix|Patients 1-3 years post transplant will receive the Shingrix vaccine in standard dosing and schedule.
62048160|NCT00919074|ACTIVE_COMPARATOR|Pancreatic duct stent|Placement of a pancreatic duct stent to facilitate bile duct cannulation
62048161|NCT00919074|ACTIVE_COMPARATOR|Pancreatic wire|Placement of a guidewire into the pancreatic duct to facilitate bile duct cannulation.
62048162|NCT05011994|EXPERIMENTAL|Maintenance intervention|Participants will receive a 12-week mobile health (mHealth) intervention that consists of action planning, text messages, and coordinator support.
62048163|NCT03384173||NIRS monitoring|These infants will be monitored with NIRS
62048164|NCT05311800|EXPERIMENTAL|High intensity interval training - BIKE (HIIE BIKE)|10 cycles of speeding up for 45 s at 80-thPHR followed by pedaling slowly (40% thPHR) for 1m30s (37min30s)
62250448|NCT03660709|EXPERIMENTAL|Intervention|enhanced version of HIV testing and counseling
62608244|NCT06730204|NO_INTERVENTION|Control group|Clinical variables, biochemical markers, dietary data, and physical activity data will be collected at baseline and at each visit (admission to hospital, 1, 2, 3, 6, 12, 18, and 24 months after diagnosis).
62608245|NCT05600062|PLACEBO_COMPARATOR|Placebo|Placebo tablet to be taken three times a day for three days
62608246|NCT05600062|EXPERIMENTAL|Racecadotril|Racecadotril 100 milligrams (mg) three times a day for three days
62608247|NCT01259375|EXPERIMENTAL|All patients|All participants who received Amrubicin.
62048165|NCT05311800|EXPERIMENTAL|High intensity interval training - RUN (HIIE RUN)|9 cycles of speeding up for 45 s at 80-thPHR followed by pedaling slowly (40% thPHR) for 1m30s (35min15s)
62048166|NCT01342705|EXPERIMENTAL|phlebotomy|
62250449|NCT03660709|ACTIVE_COMPARATOR|Control|standard-of-care HIV testing and counseling
62250450|NCT03039166|EXPERIMENTAL|parkinson|
62608248|NCT01969084|EXPERIMENTAL|Linagliptin|Subjects given Linagliptin
62608249|NCT01969084|PLACEBO_COMPARATOR|Sugar pill|Subjects given sugar pill/placebo
62048167|NCT01342705|NO_INTERVENTION|control|
62048168|NCT02450266|ACTIVE_COMPARATOR|A: Transrectal ultrasound-guided biopsy|Patients of arm A receive a systematic transrectal ultrasound-guided prostate biopsy (12-18 biopsy cores depending on individual prostate volume)
62048169|NCT02450266|EXPERIMENTAL|B: MRI/ultrasound fusion-guided biopsy|Patients of arm B receive a targeted MRI/ultrasound fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
62048170|NCT03313518|ACTIVE_COMPARATOR|Anodal tDCS|Transcranial Direct Current Stimulation using anodal electrode, 15 patients received real anodal tDCS 2mA for 20 minutes for 10 consecutive days.
62250451|NCT03039166|EXPERIMENTAL|partial epilepsy|
62440202|NCT03210675|OTHER|Standard Care Group|Will have a single PSG at home which will give a reference in the Down Syndrome population of 3 years old and will be used as reference to the study group
62608250|NCT00737334|ACTIVE_COMPARATOR|1|All patients will have continuous EEGo, BIS and FORE-SIGHT monitoring, which will be correlated with arterial to jugular venous lactate differences.
62608251|NCT05210153||Standard dose|Patients are allocated to this group at visit V1 if 100 mg/day sertraline dose resulted in optimal sertraline exposure (20-40 ng/ml) as measured at VK. These patients continue to be treated with 100 mg/day during the V1-V2 period.
62608252|NCT05210153||Adjusted dose|Patients are allocated to this group at visit V1 if 100 mg/day sertraline dose resulted in high (\>40 ng/ml) or low (\<20 ng/ml) sertraline exposure, as measured at VK. These patients continue to be treated with the adjusted sertraline dose, different from 100 mg/day, during the V1-V2 period.
62048171|NCT03313518|SHAM_COMPARATOR|sham group|Fifteen patients received sham anodal tDCS 2mA for 20 minutes for 10 consecutive days.
62440203|NCT03293927|EXPERIMENTAL|Fentanyl + Dexmedetomidine|
62440204|NCT03293927|EXPERIMENTAL|Dexmedetomidine + Fentanyl|
62440205|NCT03293927|EXPERIMENTAL|Fentanyl only|
62608253|NCT05605639|EXPERIMENTAL|Phrenic nerve anesthetics infiltration|The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
62608254|NCT05605639|PLACEBO_COMPARATOR|Physiological serum infiltration|The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
62048172|NCT01547897|ACTIVE_COMPARATOR|NOX-E36|
62048173|NCT01547897|PLACEBO_COMPARATOR|Placebo|
62048174|NCT00868465|ACTIVE_COMPARATOR|1|Artemether-lumefantrine; currently the first line treatment in Tanzania
62048175|NCT00868465|EXPERIMENTAL|2|Dihydroartemisinin-piperaquine, alternative ACT
62250452|NCT03039166|EXPERIMENTAL|alzheimer disease|
62250453|NCT03039166|EXPERIMENTAL|multiple sclerosis|
62048176|NCT06347094|EXPERIMENTAL|Metabotype X, Treatment|Subjects belonging to a specific aggregate phenolic metabotype (X) to which a diet with an increase of 50% in the actual (poly)phenol intake will be given, through personalized dietary plans.
62048177|NCT06347094|EXPERIMENTAL|Metabotype X, Control|Subjects belonging to a specific aggregate phenolic metabotype (X) to which general dietary recommendations for a healthy diet will be given.
62048178|NCT06347094|EXPERIMENTAL|Metabotype Y, Treatment|Subjects belonging to a specific aggregate phenolic metabotype (Y) to which a diet with an increase of 50% in the actual (poly)phenol intake will be given, through personalized dietary plans.
62048179|NCT06347094|EXPERIMENTAL|Metabotype Y, Control|Subjects belonging to a specific aggregate phenolic metabotype (X) to which general dietary recommendations for a healthy diet will be given.
62048180|NCT01435863|EXPERIMENTAL|SP-02L|
62048181|NCT02508467|EXPERIMENTAL|Fisogatinib (BLU-554)|Fisogatinib (BLU-554) capsules for oral administration.
62048182|NCT01223157|EXPERIMENTAL|Obese patients|
62048183|NCT01223157|EXPERIMENTAL|Normal weight subjects|
62048184|NCT03143725|EXPERIMENTAL|Treatment A|GLPG1972 oral solution after overnight fast
62048185|NCT03143725|EXPERIMENTAL|Treatment B|GLPG1972 oral DC tablet after breakfast
62048186|NCT03143725|EXPERIMENTAL|Treatment C|GLPG1972 oral WG tablet after overnight fast
62048187|NCT03143725|EXPERIMENTAL|Treatment D|GLPG1972 oral WG tablet after breakfast
62250454|NCT03039166|EXPERIMENTAL|amyotrophic lateral sclerosis|
62250455|NCT03039166|ACTIVE_COMPARATOR|healthy control patients|
62250456|NCT04169022|EXPERIMENTAL|AML patients at diagnosis|AML patients at diagnosis (except AML3)
62250457|NCT04169022|EXPERIMENTAL|AML patients at relapse|AML patients at relapse after chemotherapy, targeted therapy or allograft
62250458|NCT04416347||Workstream 1|Adult patients admitted to SGHFT (St. Georges Hospital Foundation Trust) with or without laboratory confirmed SARS- CoV-2.
62440206|NCT03293927|EXPERIMENTAL|Dexmedetomidine only|
62440207|NCT00585091|OTHER|A|All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
62440208|NCT00539539|ACTIVE_COMPARATOR|Feedback On|Automated real-time feedback on CPR Process activated
62048188|NCT01417429|ACTIVE_COMPARATOR|Galantamine|galantamine will be given with intravenous nicotine
62048189|NCT01417429|EXPERIMENTAL|Nicotine|Subject will be given IV Nicotine
62048190|NCT02001194|NO_INTERVENTION|Control|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Control Arm will receive no financial incentive.
62048191|NCT02001194|EXPERIMENTAL|Individual|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $50 if that participant met the step goal during the prior day.
62048192|NCT02001194|EXPERIMENTAL|Team|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $50 only if all four team members met the step goal during the prior day.
62048193|NCT02001194|EXPERIMENTAL|Individual Plus Team|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $20 if the participant met the step goal during the prior day the participants met their own goal. Each participant will also receive an additional $10 for every one of the other three team members that also met the goal.
62250459|NCT04416347||Workstream 2|Adult patients admitted to to SGHFT (St. Georges Hospital Foundation Trust) ITU with respiratory failure.
62250460|NCT00128284||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
62608255|NCT05988710|EXPERIMENTAL|Buccal Buprenorphine 300mcg and oral Placebo|In randomized order (crossover) across 5 laboratory sessions approximately 5 days apart, participants will receive: 1) Buccal buprenorphine 300 mcg and oral placebo, 2) Buccal buprenorphine 450 mcg and oral placebo 3) Buccal buprenorphine 600 mcg and oral placebo, 4) Buccal buprenorphine 900 mg and oral placebo, 5) oral immediate-release oxycodone 10mg and oral placebo, or 6) buccal placebo and oral placebo.
62830301|NCT06474715|EXPERIMENTAL|Enhanced intervention arm: Fitness classes + childcare + peer support|"There will be 3 Shape Up NYC classes offered weekly for one hour free of charge to consenting participants in all three arms with a total of 12 classes offered per participant.~In addition, they will receive childcare in an adjacent space to the fitness class.~In addition to childcare, Arm C will also receive peer support activities. Peer support activities will consist of group volunteer activities at food pantries, free deliveries of food pantry groceries, and group play dates at local playgrounds. A Community Champion will also facilitate group text messages."
62830302|NCT03150953|NO_INTERVENTION|Standard of Care|Patients will receive standard of care which is 1-2 warm blankets.
62830303|NCT03150953|EXPERIMENTAL|MRI-safe warming device|The MRI-safe bore covering consists of a clear covering sheet positioned over the openings of the MRI scanner.
62048194|NCT03685591|EXPERIMENTAL|Dose Level 1 (Part 1A)|PF-06952229 at 20mg twice daily (BID)
62048195|NCT03685591|EXPERIMENTAL|Dose Level 2 (Part 1A)|PF-06952229 at 40 mg BID
62048196|NCT03685591|EXPERIMENTAL|Dose Level 3 (Part 1A)|PF-06952229 at 80 mg BID
62048197|NCT03685591|EXPERIMENTAL|Dose Level 4 (Part 1A)|PF-06952229 at 150 mg BID
62048198|NCT03685591|EXPERIMENTAL|Dose Level 5 (Part 1A)|PF-06952229 at 250 mg BID
62048199|NCT03685591|EXPERIMENTAL|Dose Level 6 (Part 1A)|PF-06952229 at 375 mg BID
62048200|NCT03685591|EXPERIMENTAL|Dose Level 7 (Part 1A)|PF-06952229 at 500 mg BID
62048201|NCT03685591|EXPERIMENTAL|Dose Level 8 (Part 1A)|PF-06952229 at 625 mg BID
62048202|NCT03685591|EXPERIMENTAL|Dose Level 9 (Part 1A)|PF-06952229 at 750 mg BID
62250461|NCT00128284||Gastroparesis|Subjects with documented gastroparesis
62830304|NCT03150953|EXPERIMENTAL|MRI-safe warming device and Bair hugger|IN addition to positioning the MRI-safe bore covering over the opening of the MRI scanner, the opening of the covering sheet will be connected to a device which blows warm air called a Bair Hugger. The Bair Hugger is an approved device, and MRI safe.
62830305|NCT01469169|EXPERIMENTAL|Arm 1|
62830306|NCT02246790|ACTIVE_COMPARATOR|Biatrial radiofrequency ablation and CABG|Biatrial radiofrequency ablation during CABG
62830307|NCT02246790|ACTIVE_COMPARATOR|Left atrial radiofrequency ablation and CABG|Left atrial radiofrequency ablation during CABG
62830308|NCT06593756|EXPERIMENTAL|Entire Study Population|The entire study population will undergo serial hemodynamic assessments throughout the course of ECMO therapy. Hemodynamic variables are obtained using transthoracic echocardiography, uncalibrated pulse contour analysis, and optionally - depending on device availability - transpulmonary thermodilution, bioreactance and esophageal doppler. Maneuvers for assessing volume responsiveness include passive leg raising (PLR), respiratory pulse pressure variation (PPV), stroke volume variation (SVV), inferior vena cava ultrasound (IVC), and end-inspiratory or end-expiratory occlusion tests.
62830309|NCT03987269|ACTIVE_COMPARATOR|Intervention, Virtual Reality Group|The intervention group to experience the virtual reality embodied narrative experience.
62830310|NCT03987269|PLACEBO_COMPARATOR|Control, Narrative Video Group|The control group to watch the same narrative video content that has been formatted for standard television
62830311|NCT01529892|EXPERIMENTAL|methamphetamine EM|Extensive metabolizer will be give a single oral 5 mg of duterium labeled methamphetamine
62830312|NCT01529892|EXPERIMENTAL|methamphetamine PM|Poor Metabolizers will be give a single oral 5 mg of duterium labeled methamphetamine
62830313|NCT06086717|ACTIVE_COMPARATOR|Group A|Kinesio Taping Group
62830314|NCT06086717|ACTIVE_COMPARATOR|Group B|Dry Needling Group
62830315|NCT03516188|EXPERIMENTAL|Alginate-antacid group|Participants will take normal meals with late night supper (i.e.two chicken burgers and one cup or 250 ml of teh-tarik) plus alginate-antacid.
62250462|NCT00941161|EXPERIMENTAL|combination|long acting Metformin/Glimepiride
62250463|NCT00941161|ACTIVE_COMPARATOR|metformin|metformin hydrocloride
62250464|NCT00941161|ACTIVE_COMPARATOR|glimepiride|glimepiride
62250465|NCT02465983|EXPERIMENTAL|CART-meso-19 T cells|A single dose of CART-meso-19 T cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting.
62608256|NCT05988710|EXPERIMENTAL|Buccal Buprenorphine 600mcg and oral Placebo|In randomized order (crossover) across 5 laboratory sessions approximately 5 days apart, participants will receive: 1) Buccal buprenorphine 300 mcg and oral placebo, 2) Buccal buprenorphine 450 mcg and oral placebo 3) Buccal buprenorphine 600 mcg and oral placebo, 4) Buccal buprenorphine 900 mg and oral placebo, 5) oral immediate-release oxycodone 10mg and oral placebo, or 6) buccal placebo and oral placebo.
62608257|NCT05988710|EXPERIMENTAL|Buccal Buprenorphine 900mcg and oral Placebo|In randomized order (crossover) across 5 laboratory sessions approximately 5 days apart, participants will receive: 1) Buccal buprenorphine 300 mcg and oral placebo, 2) Buccal buprenorphine 450 mcg and oral placebo 3) Buccal buprenorphine 600 mcg and oral placebo, 4) Buccal buprenorphine 900 mg and oral placebo, 5) oral immediate-release oxycodone 10mg and oral placebo, or 6) buccal placebo and oral placebo.
62830316|NCT03516188|EXPERIMENTAL|Non antacid alginate group|Participants will take normal meals with late night supper (i.e.two chicken burgers and one cup or 250 ml of teh-tarik) plus antacid alone.
62830317|NCT06593860|EXPERIMENTAL|Intervention: Behavioral, remote speech rehabilitation and counseling|Speech therapy will replicate the dose prescribed by many treatment programs including LSVT LOUD, LSVT ARTIC and Be Clear, consisting of 16 sessions of 50-60 minutes duration delivered over four weeks. Participants will also be set 15 to 20 minutes of daily home practice. Family education/training will take place once a week over 4 weeks, including two components: family counseling (30 min) and family conversation training (30 min). Family counseling aims to increase the PD families' knowledge about PD in general and to identify goals and potential solutions to problems which cause emotional turmoil. Family conversation training which aims to increase the PD families' knowledge about PD-related communication problems and to raise awareness of their communication patterns, and to support the development of functional strategies. All activities will remotely occur (using Zoom).
62830318|NCT06593860|NO_INTERVENTION|No Intervention:Waitlist control|No intervention programs (speech therapy, counseling) will be provided.
62830319|NCT02580539|EXPERIMENTAL|Autologous or allogenic (stem cell donor) T cells|Subjects receive an autologous anti-EBV T-cell line or a T-cell line derived from the patient's allogeneic (stem cell transplant) donor.
62830320|NCT02580539|EXPERIMENTAL|"Allogeneic third party T cells"|Subjects receive a T-cell line from a matched or partially matched related donor.
62830321|NCT01850121||Infliximab|Patients with active AS defined as BASDAI score above 4 and no exclusion criteria were consecutively included in this single-armed unblinded trial.
62830322|NCT01477398|ACTIVE_COMPARATOR|inspired CO2|Inspired CO2
62830323|NCT01477398|NO_INTERVENTION|No intervention: Standard of Care|tidal volume and respiratory rate are not changed during recovery from anesthesia
62440209|NCT00539539|NO_INTERVENTION|Feedback Off|For the first three to six months, participating EMS agencies will have defibrillators with automated, real-time feedback inactivated. During this period, the baseline rate of ROSC (and secondary outcomes) will be collected. At the end of this baseline period, EMS agencies will be randomized to one of two interventions, with randomization stratified within site by agency, station, or device. All clusters will cross-over to the opposite feedback strategy at least once during the intervention phase.
62440210|NCT01696864|EXPERIMENTAL|stroke patients - hand|stroke patients with the ability to move their hand
62830324|NCT03071588|ACTIVE_COMPARATOR|Control|the conventional protocol in indirect pulp capping include the use of mechanical rotary burs for caries removal in teeth with reversible pulpitis.
62830325|NCT03071588|EXPERIMENTAL|Conservative|the conservative protocol of indirect pulp capping include the use of Carisolv gel for caries removal in teeth with reversible pulpitis.
62440211|NCT01696864|EXPERIMENTAL|stroke patient - arm|stroke patients with the ability to move their arms
62440212|NCT05673187|EXPERIMENTAL|Treatment Arm|Adagrasib to be administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.
62830326|NCT04931563|PLACEBO_COMPARATOR|placebo|Placebo will be administered via controlled IV infusion pump into a peripheral vein over a minimum of 30 minutes Q4W from Week 0 to Week 48. Each dose must be at least 14 days apart.
62830327|NCT04931563|ACTIVE_COMPARATOR|anifrolumab|Anifrolumab will be administered via controlled IV infusion pump into a peripheral vein over a minimum of 30 minutes Q4W from Week 0 to Week 48. Each dose must be at least 14 days apart.
62830328|NCT01598532|EXPERIMENTAL|Transcranial LED Treatment|All study subjects received treatment during 6-Week period (3x per week) for a total of 18 Transcranial LED Treatments using the MedX Health Phototherapy (light). Each session was 30 minutes in duration.
62830329|NCT03448796|ACTIVE_COMPARATOR|HTO-group|Group receives opening wedge high tibial osteotomy with Tomofix -plate. Operative intervention is followed by supervised physiotherapeutic rehabilitation.
62830330|NCT03448796|ACTIVE_COMPARATOR|FT -group|Group receives only supervised physiotherapeutic rehabilitation.
62830331|NCT05488665|EXPERIMENTAL|Crush technique group|Two stenting with the Crush technique
62830332|NCT05488665|ACTIVE_COMPARATOR|Culotte technique group|Two stenting with the Culotte technique
62830333|NCT03384134|EXPERIMENTAL|Pain Buddy|Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily diaries using Pain Buddy and will also be taught cognitive and behavioral coping skills, like deep breathing, imagery, and relaxation, to deal with pain and symptoms. The skills will be taught through the electronic tablet. Pain and symptom information, collected daily by Pain Buddy, will be sent to a health care provider on the oncology treatment team, who will contact patients when certain thresholds are reached and will instruct the patients on best ways to control pain and symptoms.
62830334|NCT03384134|NO_INTERVENTION|Control|Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily pain diaries using Pain Buddy, but will not receive skills training or remote monitoring of data.
62830335|NCT06389955|EXPERIMENTAL|Part A - Sequence 1|Following a screening period of up to 28 days, eligible participants will be admitted to the clinical research unit on Day -1. Participants will fast overnight from Day -1 to Day 1. On Day 1, participants randomly assigned to Sequence 1 will take TP 3654 with or without food as follows: Day 1 - 480mg (4 x 120mg capsules) once daily with low fat meal, Day 4 - 480mg (4 x 120mg capsules) once daily fasted, Day 7 - 480mg (4 x 120mg capsules) once daily with high fat meal, and Day 10 - 480mg (2 x 240mg tablets) once daily fasted.
62048203|NCT03685591|EXPERIMENTAL|Prostate Cancer Dose Level 1 (Part 1B)|PF-06952229 at 375 mg BID in combination with enzalutamide
62048204|NCT03685591|EXPERIMENTAL|Prostate Cancer Dose Level 2 (Part 1B)|PF-06952229 at 500 mg BID in combination with enzalutamide
62830336|NCT06389955|EXPERIMENTAL|Part A - Sequence 2|Following a screening period of up to 28 days, eligible participants will be admitted to the clinical research unit on Day -1. Participants will fast overnight from Day -1 to Day 1. On Day 1, participants randomly assigned to Sequence 2 will take TP 3654 with or without food as follows: Day 1 - 480mg (4 x 120mg capsules) once daily fasted, Day 4 - 480mg (2 x 240mg tablets) once daily fasted, Day 7 - 480mg (4 x 120mg capsules) once daily with low fat meal, and Day 10 - 480mg (4 x 120mg capsules) once daily with high fat meal.
62830337|NCT06389955|EXPERIMENTAL|Part A - Sequence 3|Following a screening period of up to 28 days, eligible participants will be admitted to the clinical research unit on Day -1. Participants will fast overnight from Day -1 to Day 1. On Day 1, participants randomly assigned to Sequence 3 will take TP 3654 with or without food as follows: Day 1 - 480mg (2 x 240mg tablets) once daily fasted, Day 4 - 480mg (4 x 120mg capsules) once daily with high fat meal, Day 7 - 480mg (4 x 120mg capsules) once daily fasted, and Day 10 - 480mg (4 x 120mg capsules) once daily with low fat meal.
62830338|NCT06389955|EXPERIMENTAL|Part A - Sequence 4|Following a screening period of up to 28 days, eligible participants will be admitted to the clinical research unit on Day -1. Participants will fast overnight from Day -1 to Day 1. On Day 1, participants randomly assigned to Sequence 4 will take TP 3654 with or without food as follows: Day 1 - 480mg (4 x 120mg capsules) once daily with high fat meal, Day 4 - 480mg (4 x 120mg capsules) once daily with low fat meal, Day 7 - 480mg (2 x 240mg tablets) once daily fasted, and Day 10 - 480mg (4 x 120mg capsules) once daily fasted.
62608258|NCT05988710|ACTIVE_COMPARATOR|Oral immediate release oxycodone 10mg and buccal placebo|In randomized order (crossover) across 5 laboratory sessions approximately 5 days apart, participants will receive: 1) Buccal buprenorphine 300 mcg and oral placebo, 2) Buccal buprenorphine 450 mcg and oral placebo 3) Buccal buprenorphine 600 mcg and oral placebo, 4) Buccal buprenorphine 900 mg and oral placebo, 5) oral immediate-release oxycodone 10mg and oral placebo, or 6) buccal placebo and oral placebo.
62048205|NCT03685591|EXPERIMENTAL|Prostate Cancer Dose Level 3 (Part 1B)|PF-06952229 at 625 mg BID in combination with enzalutamide
62048206|NCT03685591|EXPERIMENTAL|Prostate Cancer Dose Level 4 (Part 1B)|PF-06952229 at 750 mg BID in combination with enzalutamide
62048207|NCT03685591|EXPERIMENTAL|Prostate Cancer (Part 2A)|PF-06952229 at recommended Phase 2 Dose BID
62608259|NCT05988710|PLACEBO_COMPARATOR|Oral placebo and buccal placebo|In randomized order (crossover) across 5 laboratory sessions approximately 5 days apart, participants will receive: 1) Buccal buprenorphine 300 mcg and oral placebo, 2) Buccal buprenorphine 450 mcg and oral placebo 3) Buccal buprenorphine 600 mcg and oral placebo, 4) Buccal buprenorphine 900 mg and oral placebo, 5) oral immediate-release oxycodone 10mg and oral placebo, or 6) buccal placebo and oral placebo.
62608260|NCT05988710|EXPERIMENTAL|Buccal Buprenorphine 450mcg and oral Placebo|In randomized order (crossover) across 5 laboratory sessions approximately 5 days apart, participants will receive: 1) Buccal buprenorphine 300 mcg and oral placebo, 2) Buccal buprenorphine 450 mcg and oral placebo 3) Buccal buprenorphine 600 mcg and oral placebo, 4) Buccal buprenorphine 900 mg and oral placebo, 5) oral immediate-release oxycodone 10mg and oral placebo, or 6) buccal placebo and oral placebo.
62608261|NCT01131039|EXPERIMENTAL|Single|
62608262|NCT02897388|NO_INTERVENTION|Pre-intervention|all very low birth weight infants admitted to the NICU at Fudan University Children's Hospital from January 2015 through March 2015 (which is the period before any intervention started)who meet the enroll criteria
62608263|NCT02897388|EXPERIMENTAL|intervention|all very low birth weight infants admitted to the NICU at Fudan University Children's Hospital from April 2015 through June 2016 who meet the enroll criteria. A series of breast milk consume promotion interventions would implemented during this intervention period, which including build local lactation team, set breast milk feeding room, train NICU staff etc.
62608264|NCT05122533||Study group|"18-30 year-old, healthy volunteers~* Age: 18-30 years~* BMI: \<30~* No previous surgery on lower limb or spine~* No known developmental disorder~* Without any orthopaedic complaint"
62608265|NCT01420016|ACTIVE_COMPARATOR|Prioritized Clinical Decision Support|The Prioritized Clinical Decision Support (CDS) intervention is a protocol driven CDS system linked within the EMR that identifies patients with high cardiovascular risk and provides tailored, prioritized decision support to the provider and patient at the point of care. The CDS was printed at intervention sites. It i) compiled most recent lab data (A1c, SBP, and LDL), BMI, smoking status, and aspirin use, (ii) calculated a 10-year risk for stroke or heart attack, (iii) prioritized clinical domains based on the absolute risk reduction for each component, (iv) compiled information related to renal and liver function, creatine kinase level, and previous diagnoses (CHF, CVD, DM), and (v) provided recommendations for intensification of therapy for A1c, SBP and/or LDL if not at goal.
62608266|NCT01420016|NO_INTERVENTION|Usual Care|Providers in the usual care arm did not have access to the prioritized clinical decision support tool.
62608267|NCT04030260|EXPERIMENTAL|Regorafenib and PD-1 antibody in Combination with Radiotherapy|
62048208|NCT03685591|EXPERIMENTAL|Prostate Cancer (Part 2B)|PF-06952229 at recommended phase 2 dose BID in combination with enzalutamide
62048209|NCT04334226||Patient and Caregiver Dyad|Individuals who participated in the Stoma Boot Camp study and their caregiver will form a dyad
62250466|NCT02263521||physicians|Nationally-representative sample of physicians in all specialties who have direct or indirect patient care responsibilities
62048210|NCT03527394||Families|"We plan to recruit a sample of 100 families (dyads) for this study, which will include 100 youth and 100 parents.~Note: For the sake of transparency, this sample size differs from the original estimate (n=250 families; see Ball et al., BMC Health Serv Res, 2017;17:261). A recent systematic review (Park et al., Int J Nurs Stud, 2018;79:58-69) suggested that sample size estimates for studies that evaluate test-retest reliability (a key psychometric property we will examine) should include \~5 participants for every survey item. Given the design of the interview, and in light of current patient volumes at the clinical recruitment sites, we are confident that a sample of 100 families will be both achievable and satisfactory for psychometric analyses."
62048211|NCT05980182|EXPERIMENTAL|Tailored Screen to Save (S2S) content|Content to be delivered using a combination of short video and text-based information optimized for delivery via Quick Response (QR) codes for smartphones.
62048212|NCT06258018|EXPERIMENTAL|Niraparib + Temodal Level 0|Niraparib 100 mg/die + TMZ 75 mg/m2 both given for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days (starting dose).
62608268|NCT03032601|ACTIVE_COMPARATOR|N-acetyl Cysteine Cohort|Intravenous N-acetyl Cysteine - 50mg in 200ml of D5W over one hour 1 x per week Oral N-acetyl Cysteine - 1 500mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
62608269|NCT03032601|NO_INTERVENTION|Control Cohort|Standard of Care Treatment
62608270|NCT03005613|ACTIVE_COMPARATOR|sacrospinous ligament fixation group|The patients will receive sacrospinous ligament fixation operation.
62608271|NCT03005613|EXPERIMENTAL|ischial spine fascia fixation group|The patients will receive ischial spine fascia fixation operation.
62608272|NCT01537978|EXPERIMENTAL|Video game play|Changes in upper limb; strength, active range of motion, electromyographic activity as well as heart rate response.
62608273|NCT04427488|EXPERIMENTAL|Morning Chronotype (MC) Group|In the MC group, exercises were applied in the morning hours for the first 6 weeks and in the evening hours for the next 6 weeks.
62250467|NCT02263521||resident physicians|Nationally-representative of resident physicians in all specialties
62250468|NCT02263521||medical students|Nationally-representative sample of 4th year medical students in all US allopathic medical schools.
62608274|NCT04427488|EXPERIMENTAL|Evening Chronotype (EC) Group|The EC exercises were applied in the evening hours for the first 6 weeks and in the morning hours for the next 6 weeks
62608275|NCT06436391|EXPERIMENTAL|Kinesio tape group|To the infants in the experimental group; Kinesio tape application will be performed by an experienced physiotherapist whom has a M.Sc. degree and kinesio tape certificate.
62250469|NCT03645265|EXPERIMENTAL|Gestures|Use of hand gestures to improve speech rhythm and speech production
62250470|NCT03645265|EXPERIMENTAL|Auditory|Use of auditory cues to improve speech rhythm and speech production
62250471|NCT03535714|ACTIVE_COMPARATOR|MANTR-a group|"Patients who are in the MANTR-a group attend the MANTR-a treatment program, which consists of 20 once-weekly therapy sessions. Caregivers can be invited to 2 sessions. After 20 weeks, therapy continues with four monthly booster-sessions. In sum, each patient (whose bodyweight is above the 3rd BMI percentile) can attend 24 therapy sessions. In patients whose bodyweight is below the 3rd BMI percentile treatment will be extended to 30 once-weekly and 4 monthly booster sessions. Besides therapy the patients are in nutritional consultation by a dietician and under regular medical care to monitor the physical health and weight gain.~Patients who who have already an existing psychotherapy are attached to the control group."
62830339|NCT06389955|EXPERIMENTAL|Part B - Sequence 1|Following a screening period of up to 28 days, eligible participants will be admitted to the clinical research unit on Day -1. Participants will fast overnight from Day -1 to Day 1. On Day 1, participants randomly assigned to Sequence 1 will take TP 3654 tablets with or without food as follows: Day 1 - 480mg once daily with low fat meal, Day 4 - 480mg once daily fasted, and Day 7 - 480mg once daily with high fat meal.
62830340|NCT06389955|EXPERIMENTAL|Part B - Sequence 2|Following a screening period of up to 28 days, eligible participants will be admitted to the clinical research unit on Day -1. Participants will fast overnight from Day -1 to Day 1. On Day 1, participants randomly assigned to Sequence 2 will take TP 3654 tablets with or without food as follows: Day 1 - 480mg once daily fasted, Day 4 - 480mg once daily with high fat meal, and Day 7 - 480mg once daily with low fat meal.
62048213|NCT06258018|EXPERIMENTAL|Niraparib + Temodal Level 1|Niraparib 100 mg/die + TMZ 100 mg/m2 both given for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days.
62830341|NCT06389955|EXPERIMENTAL|Part B - Sequence 3|Following a screening period of up to 28 days, eligible participants will be admitted to the clinical research unit on Day -1. Participants will fast overnight from Day -1 to Day 1. On Day 1, participants randomly assigned to Sequence 3 will take TP 3654 tablets with or without food as follows: Day 1 - 480mg once daily with high fat meal, Day 4 - 480mg once daily with low fat meal, and Day 7 - 480mg once daily fasted.
62250472|NCT03535714|NO_INTERVENTION|control group|Patients of the control group receive treatment as usual (TAU). It consists of medical care and monitoring, psychotherapy in a single or family setting, parents counselling and dietetics.
62250473|NCT02616744|EXPERIMENTAL|Arm A: Ibandronic acid|Ibandronic acid 150 mg per os per month for two years
62608276|NCT06436391|EXPERIMENTAL|ShotBlocker group|To the infants in the second experimental group; Shotblocker application will be performed by another researcher.
62608277|NCT06436391|NO_INTERVENTION|Control group|These infants will not receive any intervention in the heel prick procedure. Routine heel blood collection will be performed.
62608278|NCT01534364|NO_INTERVENTION|control|Ad libitum alimentation
62608279|NCT01534364|OTHER|calorie restriction|Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery day 0 corresponds to day of surgery)
62608280|NCT06406387||ATRX/DAXX loss|"The positive group including patients with loss of DAXX or ATRX expression evaluated on immunohistochemistry on endoscopic ultrasound biopsy specimens"
62608281|NCT06406387||ATRX/DAXX preserved|"The negative group including those with preserved DAXX and ATRX expression evaluated on immunohistochemistry on endoscopic ultrasound biopsy specimens"
62608282|NCT06518278||Musculoskeletal Pain|Adults aged 18 years or older self-reporting one or more of the following: Osteoarthritis, Fibromyalgia, Chronic Low Back Pain, Inflammatory Arthritis and pain of \>3/10 for most days in the past 3 months before baseline.
62830342|NCT02969746|EXPERIMENTAL|Charcoal|Patients will receive a single dose (20 gram) of oral activated charcoal
62830343|NCT02969746|NO_INTERVENTION|control|Standard practice
62048214|NCT06258018|EXPERIMENTAL|Niraparib + Temodal Level 2|Niraparib 200 mg/die + TMZ 75 mg/m2 both given for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days
62048215|NCT06258018|EXPERIMENTAL|Niraparib + Temodal Level 3|Level 3: Niraparib 200 mg/die + TMZ 100 mg/m2 both given for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days.
62250474|NCT02616744|PLACEBO_COMPARATOR|Arm B: Placebo|Placebo per os per month for two years
62608283|NCT06720077|EXPERIMENTAL|acupressure + diaphragmatic breathing exercises + general bowel care advise|"It consisted of 30 postmenopausal women. Each of them received acupressure on the (san jio 6/ stomach 25/ spleen 15/ joining vally  large intestine 4 ) acupoints, 1 minute for each point with 3 repetitions on both sides (about 30 minutes as total time), 3 times per week in addition to diaphragmatic breathing exercises for 15 minutes and general bowel care advise, for 6 weeks."
62048216|NCT06258018|EXPERIMENTAL|Niraparib + Temodal Level -1|Niraparib 100 mg given on alternate days for 7 days, followed by 7 days of OFF + TMZ given 75 mg/m2 for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days.
62250475|NCT01202279|ACTIVE_COMPARATOR|Mucinex D|Mucinex D (1200 mg guaifenesin and 120 mg pseudoephedrine HCl) extended release bilayer tablet twice a day (bid) with a full glass of water for 7 days
62608284|NCT06720077|ACTIVE_COMPARATOR|diaphragmatic breathing exercises + general bowel care advise|It consisted of 30 postmenopausal women who performed diaphragmatic breathing exercises for 15 minutes 3 times per week in addition to general bowel care advice only, for 6 weeks.
62608285|NCT00822575|ACTIVE_COMPARATOR|A|
62608286|NCT00822575|SHAM_COMPARATOR|B|
62608287|NCT02732327|EXPERIMENTAL|CAZ-AVI + Vancomycin or Linezolid|Ceftazidime-Avibactam (CAZ-AVI) 2.5 mg intravenous (IV) infusion every 8 hours for 5 to 14 days, duration determined by the investigator, plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local standard of care \[SOC\]) may be allowed after at least 72 hours (ie, minimum of 9 doses for CAZ-AVI) of inpatient IV study drug.
62250476|NCT01202279|PLACEBO_COMPARATOR|Placebo|Placebo given bid with a full glass of water for 7 days
62608288|NCT02732327|ACTIVE_COMPARATOR|Standard of Care+Vancomycin or Linezolid|Standard of Care (cefepime 2 g IV infusion every 8 hours or meropenem 1 g IV infusion every 8 hours or piperacillin/tazobactam 4.5 g IV infusion every 6 hours for 5 to 14 days, duration determined by the investigator) plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local SOC) may be allowed after at least 72 hours (ie, minimum of 9 doses for SOC therapies, except piperacillin/tazobactam, which is a minimum of 12 doses) of inpatient IV study drug.
62250477|NCT05349526||stenotic carotid|patients with a stenotic carotid
62608289|NCT04296786|EXPERIMENTAL|Chidamide plus Sintilimab|Patients in experimental group will receive fixed does of Sintilimab and Chidamide. This regimen is repeated every 21 days. The response will be evaluated every 2 cycles in the first 36 weeks and every 4 cycles from week 36 till the end of treatment.
62608290|NCT06028334|EXPERIMENTAL|Immediate Treatment|"The 10-week GetUp\&Go intervention will be delivered entirely remotely, with 2 weekly sessions with a therapist delivered over videoconference (Zoom for Healthcare) followed by 3 sessions in weeks 3, 5, and 8, over Zoom or phone according to participant preference.~The overall goal of the intervention is to develop and support a personalized plan to increase physical activity and decrease sedentary behavior, in concert with the unique capabilities, opportunities, and motivational factors of each participant. In session 2 and thereafter, RehaBot will be supplied to participants to deliver therapeutic ingredients to supplement those provided by the therapist."
62250478|NCT05349526||non stenotic carotid|patients with non stenotic carotid
62250479|NCT01835925||Tissue specmien|
62608291|NCT06028334|PLACEBO_COMPARATOR|Waitlist|A 10-week waitlist with baseline and outcome assessment, followed by receipt of the full GetUp\&Go program.
62608292|NCT01534806|EXPERIMENTAL|ketorolac|
62830344|NCT04536558|EXPERIMENTAL|olanzapine plus fosaprepitant-based triple regimen|Olanzapine（5mg p.o. d1-d5）plus fosaprepitant（150mg i.v. d1-d3） plus ondansetron（8mg i.v. d1-d3）and dexamethasone（6mg p.o. d1-d5） before undergoing chemotherapy.
62830345|NCT04536558|PLACEBO_COMPARATOR|Placebo plus fosaprepitant-based triple regimen|Placebo plus fosaprepitant（150mg i.v. d1-d3） plus ondansetron（8mg i.v. d1-d3）and dexamethasone（6mg p.o. d1-d5） before undergoing chemotherapy.
62250480|NCT02293850|EXPERIMENTAL|single intra-tumoral injection|OBP-301 ; Cohort 1: 1x10 10 viral particle (VP)/ tumor Cohort 2: 1x10 11 viral particle (VP)/ tumor Cohort 3: 1x10 12 viral particle (VP)/ tumor
62250481|NCT03129451||Tremor-dominant|Tremor-dominant Parkinson's disease
62048217|NCT06258018|EXPERIMENTAL|Niraparib + Temodal Expansion Phase|Niraparib RP2D dose given on alternate days for 7 days, followed by 7 days of OFF + TMZ given RP2D for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days.
62250482|NCT03129451||Akinetic-Rigid|Akinetic-Rigid type Parkinson's disease
62250483|NCT03129451||Multiple systems atrophy|Multiple systems atrophy PD
62250484|NCT03129451||Levodopa-naïve|Levodopa-naïve Parkinson's disease
62250485|NCT03129451||Tremor-dominant / app|Tremor-dominant Parkinson's disease with an appendectomy
62250486|NCT03129451||Akinetic-Rigid / app|Akinetic-Rigid Parkinson's disease with an appendectomy
62250487|NCT03129451||Levodopa-naïve w/app|Levodopa-naïve Parkinson's disease with an appendectomy
62250488|NCT04022187||Bulbocavernosus reflex assessment|Patients over 18 years old, consulting in neuro-urology department for urinary, anorectal or genito-sexual disorders.
62608293|NCT01534806|PLACEBO_COMPARATOR|Placebo|Placebo IV push
62608294|NCT02232152|EXPERIMENTAL|Treatment (6,8-bis(benzylthio)octanoic acid, fluorouracil)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-4 and fluorouracil IV over 46 hours on days 2-4. Courses repeat every 2 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
62608295|NCT01859962|ACTIVE_COMPARATOR|PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin|PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin dosed in combination
62048218|NCT01446666||HCC high-risk group|"Patients with liver cirrhosis with the 1-year risk of HCC of 5% or higher~; High Risk Index (\>=2.33)~Risk Index = 1.65 (if the prothrombin activity is \<=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is \<=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus \[HCV\] or hepatitis B surface antigen \[HBsAg\] is positive)."
62830346|NCT06038539|EXPERIMENTAL|Treatment Arm A: PERT-IJS plus trastuzumab, carboplatin and docetaxel|"Part 1 (Cycle 1 to 6):~Initial loading dose of PERT-IJS is 840 mg administered as an approximately 60-minute IV infusion followed every 3 weeks by a maintenance dose of 420 mg administered as an IV infusion over a period of approximately 30 to 60 minutes.~Trastuzumab: Initial dose of trastuzumab is 8 mg/kg administered as approximately 90-minute IV infusion followed every 3 weeks by 6 mg/kg IV infusion over 30 to 90 minutes Carboplatin: Area Under the Curve (AUC) 6 for Cycles 1 to 6 Docetaxel: 75 mg/m2 by IV infusion every 3 weeks for Cycles 1 to 6~Part 2 (Cycle 7 - till end of 1 year from Cycle 1 day 1):~Initial loading dose of PERT-IJS is 840 mg administered as approximately 60-minute IV infusion followed every 3 weeks by a maintenance dose of 420 mg administered as an IV infusion over a period of approximately 30 to 60 minutes.~Trastuzumab: As mentioned in part 1"
62830347|NCT06038539|ACTIVE_COMPARATOR|Treatment Arm B: EU-Perjeta plus trastuzumab, carboplatin and docetaxel|"Part 1 (Cycle 1 to 6):~Initial loading dose of EU- Perjeta is 840 mg administered as approximately 60-minute IV infusion followed every 3 weeks by a maintenance dose of 420 mg administered as an IV infusion over a period of approximately 30 to 60 minutes.~Trastuzumab: Initial dose of trastuzumab is 8 mg/kg administered as approximately 90-minute IV infusion followed every 3 weeks by 6 mg/kg IV infusion over 30 to 90 minutes Carboplatin: Area under the curve 6 for Cycles 1 to 6 Docetaxel: 75 mg/m2 by IV infusion every 3 weeks for Cycles 1 to 6~Part 2 (Cycle 7 onwards till end of 01 year from Cycle 1 day 1):~The patients will be re-randomized (1:1) to receive EU- Perjeta + trastuzumab or PERT-IJS + trastuzumab.~Initial loading dose of PERT-IJS is 840 mg administered as approximately 60-minute IV infusion followed every 3 weeks by a maintenance dose of 420 mg administered as an IV infusion over a period of approximately 30 to 60 minutes.~Trastuzumab: As mentioned in part 1"
62830348|NCT00653510|EXPERIMENTAL|Euglycemic|The patients will be examined with a blood glucose at around 5-7 mmol/L.
62830349|NCT00653510|EXPERIMENTAL|Hyperglycemic|The patients will be examined with a blood glucose at around 18-20 mmol/L
62830350|NCT03886896|EXPERIMENTAL|Group A - lidocaine group|Group A: children receiving standard general anesthesia with intravenous lidocaine infusion 1,5 mg/kg for 5 minutes before induction of anesthesia. After 5 minutes, lidocaine infusion continued at rate of 1.5 mg/kg/h during operation, and discontinued before move the patients to PACU.
62830351|NCT03886896|NO_INTERVENTION|Group B - control group|Group B: children receiving standard general anesthesia (involving fentanyl and sevoflurane) without lidocaine infusion
62830352|NCT03075072|ACTIVE_COMPARATOR|Whole Brain Radiation|"* MRI will be performed prior to radiation is administered~* A hippocampal sparing approach will be used when possible~* Dose will be 30 Gy in 10 fractions"
62830353|NCT03075072|EXPERIMENTAL|Stereotactic Radiation (SRS)|"* MRI will be performed prior to radiation is administered~* Radiation will be given in 1-5 fractions (dose depends on the size of the tumor that will be treated)"
62830354|NCT04618536|EXPERIMENTAL|Inorganic sunscreen|
62830355|NCT04618536|EXPERIMENTAL|Organic sunscreen|
62830356|NCT06566989|EXPERIMENTAL|[¹⁴C]Opevesostat|On Day 1, participants receive a single dose of \[¹⁴C\]opevesostat as an oral solution. Participants then receive single doses of 5.0 mg prednisone and 0.05 mg fludrocortisone tablets 4 hours later as hormone replacement therapy.
62830357|NCT00759213||1|Any infant with a length of stay in the NICU of at least 7 days.
62830358|NCT01318915|EXPERIMENTAL|Induction (Rituximab and ATG)|Study participants will undergo induction with rituximab and ATG and an initial maintenance therapy with tacrolimus, mycophenolate mofetil (MMF) and sirolimus. MMF will be discontinued on day 12. Participants will be evaluated for eligibility for tacrolimus withdrawal which must be initiated between weeks 26 and 38. Tacrolimus withdrawal must be completed in no fewer than 4 weeks and no more than 8 weeks. Then after at least 26 weeks on sirolimus monotherapy, participants will be evaluated for eligibility for sirolimus withdrawal which must be initiated between weeks 56 and 88. Sirolimus withdrawal must be completed in no fewer than 12 weeks and no more than 26 weeks.
62048219|NCT00707265|EXPERIMENTAL|Investigational|Open bilateral posterolateral implantation of the rhBMP-2/CRM/CD HORIZON® Spinal System.
62830359|NCT03429699|EXPERIMENTAL|Intervention group|
62830360|NCT03429699|OTHER|Control group|
62830361|NCT06025773|EXPERIMENTAL|Arm-A|Period 1 : Reference Drug (AD-2121), Period 2 : Test Drug (AD-212-A)
62830362|NCT06025773|EXPERIMENTAL|Arm-B|Period 1 : Test Drug (AD-212-A), Period 2 : Reference Drug (AD-2121)
62830363|NCT06653361|EXPERIMENTAL|TRP|Targeted Retinal Photocoagulation
62048220|NCT00707265|ACTIVE_COMPARATOR|Control|The bilateral posterolateral implantation of the autogenous bone harvested from the iliac crest with the CD HORIZON® Spinal System.
62048221|NCT01797679|OTHER|Strength Training|"The strength group include progressive strength training and neuromuscular exercises. The inclusion will be performed 2-3 times a week for 12 weeks.~Intervention: Other: Strength training"
62048222|NCT01797679|EXPERIMENTAL|Aerobic exercise|The aerobic exercise group will cycle on an ergometer bicycle 2-3 times a week for 12 weeks on moderate loading. The loading will be controlled by a heart rate monitor and is defined as 85% of maximal heart rate.
62830364|NCT06653361|ACTIVE_COMPARATOR|PRP|Panretinal Photocoagulation
62830365|NCT03939689|ACTIVE_COMPARATOR|Enzalutamide|
62830366|NCT03939689|EXPERIMENTAL|I-131-1095 in combination with enzalutamide|
62830367|NCT06327269|ACTIVE_COMPARATOR|A new generation of targeted therapies and adjuvant therapy after LDLT.|The proton therapy or yttrium 90 as a more aggressive down-staging therapy may contribute to change tumor behavior. Lenvatinib is applied to adjuvant therapy after LDLT.
62830368|NCT06327269|ACTIVE_COMPARATOR|prolong the recurrence-free survival to high risk of HCC after LDLT|Lenvatinib which is applied to adjuvant therapy after LDLT may prolong the recurrence-free survival
62048223|NCT01797679|NO_INTERVENTION|Control Group|The control group will do as usual.
62048224|NCT03026790|ACTIVE_COMPARATOR|Telecare collaborative management (TCM)|Uses medication management approach delivered by a clinical pharmacist care manager with a collaborating physician to address common barriers to effective pain medication management in primary care.
62608296|NCT01859962|ACTIVE_COMPARATOR|PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin|PPI-668, BI 207127 Dose 2, BI 207127 Placebo, Faldaprevir, and Ribavirin dosed in combination
62250489|NCT04843215|EXPERIMENTAL|Experimental group/D2 radical gastrectomy with partial omentectomy|Partial omentectomy with preservation of the greater omentum at \>3 cm from the gastroepiploic arcade.
62250490|NCT04843215|NO_INTERVENTION|Control group/D2 radical gastrectomy with total omentectom|Control group with total omentectomy
62608297|NCT01859962|ACTIVE_COMPARATOR|PPI-668, BI 207127 Dose 1, and Faldaprevir|PPI-668, BI 207127 Dose 1, and Faldaprevir dosed in combination
62608298|NCT05027048|EXPERIMENTAL|Calcium chloride|"1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.~This intervention occurs IN ADDITION TO standard care with oxytocin 2 unit bolus and infusion at 7.5 units per hour which begins immediately after fetal delivery."
62608299|NCT05027048|PLACEBO_COMPARATOR|Saline placebo|"60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.~This intervention occurs IN ADDITION TO standard care with oxytocin 2 unit bolus and infusion at 7.5 units per hour which begins immediately after fetal delivery."
62608300|NCT06181786|EXPERIMENTAL|Phase 1a, Single Ascending Doses (SAD) Cohorts: IMB-101 or Placebo|Healthy participants will receive either planned dose levels of IMB-101 or placebo through a single intravenous administration.
62608301|NCT06181786|EXPERIMENTAL|Phase 1b, Multiple Ascending Dose (MAD) Cohorts: IMB-101 or Placebo|Participants with RA will either receive multiple doses of IMB-101 or placebo through multiple intravenous administration once every 2 weeks for up to 10 weeks.
62608302|NCT02929966|PLACEBO_COMPARATOR|standard respiratory care|"The patients will receive the usual respiratory care that included both the classical treatments with antifibrotic drugs and oxygen therapy"
62830369|NCT03762057||Surgical patients|All postoperative patients admitted to surgical ICU with foley catheter in place
62830370|NCT05848557|NO_INTERVENTION|Usual care|Counseling will be provided using standard Ministry of Health (MoH) items and screening data and specimen tracking will be done using MoH registers.
62830371|NCT05848557|EXPERIMENTAL|mSaada platform|Counseling, specimen tracking and case management will be facilitated using mSaada.
62830372|NCT06023238||Chronic TKA PJI Group|Patients presenting for surgical management of a chronic total knee arthroplasty (TKA) prosthetic joint infection (PJI). Patients will be excluded if they are less than 18 years of age, have a prior history of ipsilateral or contralateral PJI warranting operative management, or are unable to provide informed consent.
62830373|NCT01213563|EXPERIMENTAL|Actrapid insulin|Intensive glycaemic control Intervention: Actrapid insulin
62830374|NCT01213563|ACTIVE_COMPARATOR|Actrapid insulin+Gloucose|conventional glycaemic control Intervention: Actrapid insulin+Glucose
62608303|NCT02929966|EXPERIMENTAL|standard respiratory care PLUS a palliative care program|"The patients will receive the usual respiratory care that included both the classical treatments with antifibrotic drugs and oxygen therapy PLUS a palliative care program that includes paid to assessing physical and psychosocial symptoms"
62048225|NCT03026790|ACTIVE_COMPARATOR|Integrated pain team (IPT)|Uses a biopsychosocial management approach delivered by a multidisciplinary team that emphasizes non-pharmacological pain management options.
62048226|NCT03026790|ACTIVE_COMPARATOR|Standard taper options|The standard taper options arm uses patient education and shared decision-making to guide opioid medication management.
62048227|NCT03026790|ACTIVE_COMPARATOR|Expanded taper options|The expanded taper options arm uses patient education and shared decision-making to guide opioid medication management and includes the additional option of rotation to buprenorphine-naloxone.
62250491|NCT03511534|ACTIVE_COMPARATOR|Psychotherapy|Participants will receive evidenced based psychotherapy by a trained psychologist
62250492|NCT03511534|ACTIVE_COMPARATOR|Pharmacotherapy|Participants will receive pharmacotherapy by a psychiatrist
62608304|NCT04944303|ACTIVE_COMPARATOR|Sugammadex|In the early group, the injection of muscle relaxant was stopped 2min the operation finish, and 4mg kg-1 of sugammadex was injected .
62250493|NCT04427683|EXPERIMENTAL|Brief mindful parenting program|The program will consist of a four-session and last for eight hours integrating mindfulness skills and psychoeducation in managing stress under social unrest and promoting strategies for emotion regulation, conflict management, and self-care.
62830375|NCT03887923|EXPERIMENTAL|Vestibular Physical Therapy|Balance, Gaze Stabilization, Habituation, and Walking exercises
62830376|NCT01694914|EXPERIMENTAL|Animal Compound Free Medium|Patients in this arm receive a corneal graft stored in organ culture in a animal compound free medium
62830377|NCT01694914|ACTIVE_COMPARATOR|organ culture medium containing 2% of fœtal calf serum|Patients in this arm receive a corneal graft stored in organ culture in a commercial organ culture medium containing 2% of fœtal calf serum
62830378|NCT03303963||Rifampicin resistant and susceptible patients|Study 1: Patients detected positive by the GeneXpert Mycobacterium tuberculosis/Rifampicin (susceptible and resistant to rifampicin)
62830379|NCT03303963||Rifampicin resistant patients|Study 2: Follow up of the rifampicin resistant patients included in the study 1 during their treatment
62830380|NCT01040910|ACTIVE_COMPARATOR|cannabis smoking for IBD|patients with active disease receiving active cannabis for smoking
62830381|NCT01040910|PLACEBO_COMPARATOR|patients smoking non active cannabis|patients with active disease receiving cannabis from which active ingredients have been chemically removed
62830382|NCT06094478|NO_INTERVENTION|Control Phase|Pre-implementation of HI-SPEED Protocol
62608305|NCT04944303|PLACEBO_COMPARATOR|Normal Saline|the injection of muscle relaxant was stopped 2min the operation finish, and equal normal saline was injected .
62830383|NCT06094478|ACTIVE_COMPARATOR|Implementation Phase|Post-Implementation of HI-SPEED Protocol
62830384|NCT02667795|EXPERIMENTAL|Monitored walking based exercise|Participants will be given a personalised daily exercise target. Participants will be given an activity tracker (a Fitbit ZipTM). The participants will be asked to wear the device all day to monitor their activity. Once a day the participants will be asked to complete the walking target they have been given at completion of their baseline assessment. This target should be completed in one go. The walking programme will last a minimum of 2 weeks and a maximum duration of 4 weeks. The length of time will depend on the length of time between recruitment and when the participant is scheduled to have their surgery.
62830385|NCT02667795|NO_INTERVENTION|Control|No intervention
62830386|NCT04646473|EXPERIMENTAL|App only|Sweetgoals app only
62830387|NCT04646473|EXPERIMENTAL|App plus Incentives|SweetGoals app + incentives=yes + coaching=no
62830388|NCT04646473|EXPERIMENTAL|App plus Coaching|Sweetgoals app + incentives=no + coaching=yes
62830389|NCT04646473|EXPERIMENTAL|App plus Coaching plus Incentives|Sweetgoals app + incentives=yes + coaching=yes
62830390|NCT03140241|EXPERIMENTAL|PDR measurement|Two measurements of PDR perioperatively before and after opioid administration
62830391|NCT02628288|ACTIVE_COMPARATOR|PCI with Axxess device + AbsorB BVS|Bifurcation lesion will be treated percutaneously by performing coronary stenting with AXXESS device and additional Absorb BVS.
62830392|NCT02628288|ACTIVE_COMPARATOR|PCI with Modified T with Absorb BVS|Bifurcation lesion will be treated percutaneously by performing coronary stenting with a modified T stenting technique using Absorb BVS.
62830393|NCT03510650||Patients|50 patients with sepsis versus 50 patients with HLH \[anticipated\]
62830394|NCT01294553||rosiglitazone/metformin group|Korean subjects who are administered rosiglitazone/metformin according to the prescription information
62830395|NCT01457703|ACTIVE_COMPARATOR|BMI ≥30 kg/m2|"Group 2:~* BMI ≥30 kg/m2~* History of regular menstrual cycles every 25-40 days~Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2."
62830396|NCT01457703|EXPERIMENTAL|BMI 18-25 kg/m2|"* BMI 18-25 kg/m2~* History of regular menstrual cycles every 25-35 days~Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2."
62830397|NCT00577889|EXPERIMENTAL|Arm I (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 154 mg/m2 tanespimycin IV over 1 hour on day 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
62830398|NCT00577889|EXPERIMENTAL|Arm II (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 154 mg/m2 tanespimycin IV over 1 hour on days 2 and 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
62608306|NCT06254235|EXPERIMENTAL|Test|
62608307|NCT06254235|ACTIVE_COMPARATOR|Reference|
62608308|NCT03219905|EXPERIMENTAL|Kinesio-taping Group|Therapeutic Kinesio-taping
62608309|NCT03219905|SHAM_COMPARATOR|Control Group|Sham Kinesio-taping
62608310|NCT06433505|EXPERIMENTAL|Part A|
62608311|NCT06433505|EXPERIMENTAL|Part B - Arm 1|
62608312|NCT06433505|EXPERIMENTAL|Part B - Arm 2|
62608313|NCT06264674|EXPERIMENTAL|Inhaler CHF5993 200/6/12.5 μg pMDI HFA-152a|Active ingredients: BDP/FF/GB 200/6/12.5 μg per actuation; Excipients: HFA-152a propellant.
62048228|NCT06208748|EXPERIMENTAL|bezuclastinib in combination with sunitinib|"Bezuclastinib 600 mg (tablet) administered orally daily Sunitinib 37.5 mg administered orally daily~Patients will begin bezuclastinib and add sunitinib 2 weeks later. Each cycle is 28 days."
62250494|NCT04427683|OTHER|Wait-list control group|A four-minute educational video will be distributed to the participants who accept the randomisation. It includes brief information on mental health. After the participants from experimental group complete the intervention, those in wait-list control group will receive the same intervention.
62440213|NCT01199601|EXPERIMENTAL|Concentrated postpartum counseling|Women randomized to receiving concentrated postpartum counseling from the retrained provider.
62830399|NCT00577889|EXPERIMENTAL|Arm III (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on day 8 and 154 mg/m2 tanespimycin IV over 1 hour on days 1 and 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
62830400|NCT02323217|EXPERIMENTAL|Healthy Volunteers|
62830401|NCT02963506|PLACEBO_COMPARATOR|Placebo|Subjects will receive for 12 Weeks Placebo and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
62830402|NCT02963506|EXPERIMENTAL|Bimekizumab Dose 1|Subjects will receive for 12 Weeks Bimekizumab Dose 1 and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
62830403|NCT02963506|EXPERIMENTAL|Bimekizumab Dose 2|Subjects will receive for 12 Weeks Bimekizumab Dose 2 and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
62830404|NCT02963506|EXPERIMENTAL|Bimekizumab Dose 3|Subjects will receive for 48 Weeks Bimekizumab Dose 3.
62830405|NCT02963506|EXPERIMENTAL|Bimekizumab Dose 4|Subjects will receive for 48 Weeks Bimekizumab Dose 4.
62830406|NCT00945958|EXPERIMENTAL|SPARC0913|
62830407|NCT02386475|PLACEBO_COMPARATOR|Placebo|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
62830408|NCT02386475|ACTIVE_COMPARATOR|citalopram 20 mg|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
62830409|NCT02386475|ACTIVE_COMPARATOR|sinemet plus 100 mg|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
62830410|NCT02386475|ACTIVE_COMPARATOR|Sinemet Plus + citalopram group|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
62830411|NCT00963859|EXPERIMENTAL|Robotic-assisted laparoscopic surgery|Robotic-assisted laparoscopic extended pelvic lymph node dissection
62830412|NCT04817163|EXPERIMENTAL|Stepped care CBT-I|
62250495|NCT01148849|EXPERIMENTAL|Cohort 1: 0.1 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
62440214|NCT01199601|NO_INTERVENTION|Routine postpartum counseling|Women receiving intra-partum testing and post-partum counseling from existing cadres of hospital providers at standard of care.
62830413|NCT04684888|ACTIVE_COMPARATOR|Visumax Femto-flap|Fifty eyes of fifty patients with age range 20-38 years, with myopic astigmatism refractive errors, ranged from -2 to- 6 DS and from -1 to -3.00DC, with stable refraction for at least one year before the surgery, normal corneal topography, anterior and posterior segments examinations. Refractive surgery was planned for both eyes and they chose the Visumax Femto-LASIK after a complete explanation of all the possible complications, costs, and differences. The right eye of each patient was taken for analysis, LASIK flap thickness was measured six months after the procedures using the anterior segment OCT, at seven points (one central and 3 points at each side of the horizontal meridian). The three nasal points were located (1mm, 2mm, 3mm respectively) from the center, and the remaining three temporal points located again ( 1mm, 2mm, 3mm) from the center.
62048229|NCT02365519|EXPERIMENTAL|LME636|LME636 ophthalmic solution, 1 drop (approx. 40 µL; 2.4 mg) administered topically in each eye 3 times a day (TID) for 6 weeks
62048230|NCT02365519|PLACEBO_COMPARATOR|Vehicle|LME636 Vehicle, 1 drop administered topically in each eye TID for 6 weeks
62250496|NCT01148849|EXPERIMENTAL|Cohort 2: 0.3 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
62440215|NCT01162499|EXPERIMENTAL|Exendin-(9-39) first, then Vehicle|"After an overnight fast, an intravenous (IV) infusion of Exendin-(9-39) will be started 1 hour prior to the meal challenge and continued for 5 hours. After the first hour of the infusion, subjects will undergo a mixed meal tolerance test in which Pediasure (10cc/kg) will be consumed by mouth or gastrostomy/nasogastric tube over a period of 15 minutes (for infants under 12 months, Pediasure will be replaced by the infant's formula). Blood samples will be drawn at different time points during the infusion to measure blood glucose, plasma insulin, glucagon and plasma glucagon-like-peptide-1 (GLP-1). The Exendin-(9-39) dose for the first 3 subjects will be 300pmol/kg/min and, if tolerated, the dose will be increased to 500pmol/kg/min for subsequent subjects.~The next day, all procedures will be repeated except subjects will receive an IV infusion of normal saline (vehicle) over 6 hours."
62608314|NCT06264674|ACTIVE_COMPARATOR|Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a|Active ingredients: BDP/FF/GB 200/6/12.5 μg per actuation; Excipients: HFA-134a propellant.
62830414|NCT04684888|ACTIVE_COMPARATOR|Sub Bowman's keratomileusis (SBK )-Flap group|Fifty eyes of fifty patients with age range 20-38 years, with myopic astigmatism refractive errors, ranged from -2 to- 6 DS and from -1 to -3.00DC, with stable refraction for at least one year before the surgery, normal corneal topography, anterior and posterior segments examinations. They chose LASIK with mechanical SBK microkeratome surgical approach to be their refractive surgery for both eyes after all the possible complications, costs and differences had been explained clearly. The right eye of each patient was taken for analysis, LASIK flap thickness was measured six months after the procedures using the anterior segment OCT, at seven points (one central and 3 points at each side of the horizontal meridian). The three nasal points were located (1mm, 2mm, 3mm respectively) from the center, and the remaining three temporal points located again ( 1mm, 2mm, 3mm) from the center.
62250497|NCT01148849|EXPERIMENTAL|Cohort 3: 1.0 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
62830415|NCT02665390|EXPERIMENTAL|treatment|Patients who are medically inoperable peripheral lung cancer will enroll in this study.They will receive percutaneous cryoablation and follow-up according to schedule.
62830416|NCT05370638|EXPERIMENTAL|rounding on discharging patients first|Rounding on discharging patients meant that the attending physician and accompanying team (i.e. if they were working with advanced practice providers or learners) would prioritize seeing any patients that were going to discharge that day.
62830417|NCT05370638|NO_INTERVENTION|usual practice|Usual practice was categorized as: seeing discharging patients first, sickest patients, decompensating patients, new patients (i.e. patients admitted to their team overnight), or based on geography.
62830418|NCT06655506||Fulfilled ERAS criteria group|This group will include patients that achieved a compliance rate that exceeded 80% of the required predetermined criteria of ERAS protocols.
62830419|NCT06655506||Control group|This group will include patients that achieved a compliance rate that did not reach at least 80% of the required predetermined criteria of ERAS protocols.
62440216|NCT01162499|ACTIVE_COMPARATOR|Vehicle first, then Exendin-(9-39)|"After an overnight fast, an intravenous (IV) infusion of normal saline (vehicle) will be started 1 hour prior to the meal challenge and continued for 5 hours. After the first hour of the infusion, subjects will undergo a mixed meal tolerance test in which Pediasure (10cc/kg) will be consumed by mouth or gastrostomy/nasogastric tube over a period of 15 minutes (for infants under 12 months, Pediasure will be replaced by the infant's formula). Blood samples will be drawn at different time points during the infusion to measure blood glucose, plasma insulin, glucagon and plasma glucagon-like-peptide-1 (GLP-1).~The next day, all procedures will be repeated except subjects will receive an IV infusion of Exendin-(9-39) which will be started 1 hour prior to the meal challenge and continue for 5 hours. The dose for the first 3 subjects will be 300pmol/kg/min and, if tolerated, the dose will be increased to 500pmol/kg/min for subsequent subjects."
62440217|NCT05989360|EXPERIMENTAL|observational|
62830420|NCT03723642|ACTIVE_COMPARATOR|OAE group|All patients will undergo measurements of oxydative stress (initial serum malondialdehyde level and final serum malondialdehyde level), White blood cell count (initial differential white blood cell count and final differential white blood cell count), c-reactive protein measurements (initial c-reactive protein serum level and final c-reactive protein serum level) as well as volatile organic compound (VOC) sampling (initial VOC, VOC 5min, VOC 15min, VOC 30min, VOC 45min and final VOC).
62830421|NCT03723642|ACTIVE_COMPARATOR|LAE group|All patients will undergo measurements of oxydative stress (initial serum malondialdehyde level and final serum malondialdehyde level), White blood cell count (initial differential white blood cell count and final differential white blood cell count), c-reactive protein measurements (initial c-reactive protein serum level and final c-reactive protein serum level) as well as volatile organic compound (VOC) sampling (initial VOC, VOC 5min, VOC 15min, VOC 30min, VOC 45min and final VOC).
62830422|NCT02279914|EXPERIMENTAL|400 mcg|receives 400 mcg of misoprostol 3 hours prior to the procedure
62440218|NCT02797964|EXPERIMENTAL|Open label|
62440219|NCT03305432|EXPERIMENTAL|PPI group|take preoperative PPI for 10 days
62440220|NCT03305432|ACTIVE_COMPARATOR|Control group|take placebo for for 10 days preoperative
62608315|NCT05264103|EXPERIMENTAL|Experimental group.|Healthy subjects and brain damaged patients with gait disorder.
62830423|NCT02279914|EXPERIMENTAL|600 mcg|receives 600 mcg of misoprostol 90 minutes prior to the procedure
62830424|NCT06586450|EXPERIMENTAL|Low level laser group|The participants will receive low level laser therapy and core stability exercises
62830425|NCT06586450|EXPERIMENTAL|Interferential current group|The participants will receive interferential current and core stability exercises
62830426|NCT06586450|ACTIVE_COMPARATOR|Core stability exercise group|The participants will perform core stability exercises only
62830427|NCT05259189|EXPERIMENTAL|NBL-012 Injection|Two subjects will be enrolled in the initial dose. 8 out of 10 healthy subjects will be randomized to receive a single dose of NBL-012 Injection for subsequent dose cohorts
62830428|NCT05259189|PLACEBO_COMPARATOR|Placebo|2 out of 10 healthy subjects will be randomized to receive a single dose of placebo.
62048231|NCT03655795|EXPERIMENTAL|Bronchial basal cells|Autologous transplantation of bronchial basal cells
62250498|NCT01148849|EXPERIMENTAL|Cohort 4: 3.0 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
62250499|NCT01148849|EXPERIMENTAL|Cohort 5: 6.0 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
62608316|NCT05570370||ADAD family members, mutation carriers|asymptomatic and presymptomatic individuals
62048232|NCT05696210||High transfusion rate group|patients requiring Veno-arterial extracorporeal membrane oxygenation for medical or post cardiotomy cardiogenic shock and with a blood transfusion rate greater than or equal to 7 red blood cells.
62250500|NCT01148849|EXPERIMENTAL|Cohort 6: 10 mg/kg weekly every 3 weeks|Anti-HER2 monoclonal antibody (margetuximab)
62250501|NCT01148849|EXPERIMENTAL|Cohort 7: 15 mg/kg weekly every 3 weeks|Anti-HER2 monoclonal antibody (margetuximab)
62608317|NCT05570370||ADAD family members, non-mutation carriers|age-matched family members (non-mutation carriers) relative to the asymptomatic/presymptomatic group
62608318|NCT05315154|EXPERIMENTAL|No axillary surgery|
62608319|NCT05315154|ACTIVE_COMPARATOR|Sentinel lymph node biopsy|
62048233|NCT05696210||Low transfusion rate group|patients who required Veno-arterial extracorporeal membrane oxygenation for medical or post cardiotomy cardiogenic shock and with a blood transfusion rate strictly below 7 red blood cells.
62048234|NCT03319537|EXPERIMENTAL|Pevonedistat|
62048235|NCT03319537|EXPERIMENTAL|pevonedistat in combination with pemetrexed and cisplatin|
62048236|NCT03248375|OTHER|Radiation Segmentectomy|Radiation Segmentectomy on Resectable HCC
62048237|NCT01418274|EXPERIMENTAL|Single arm|
62048238|NCT04241094|EXPERIMENTAL|Loved one assisted treatment|The investigators propose to bring a loved one into PE, one of the most researched and efficacious treatments for PTSD, to increase support for PE adherence. The intervention is a 13-session cognitive-behavioral, intimate partner-assisted treatment for PTSD that draws from PE, ICBT, and PE2.
62048239|NCT04023864|EXPERIMENTAL|Platycodon Grandiflorus Extract(GCWB107) group|Once-daily, once a tablet, after meals (900 mg/day, 571 mg/day as a Platycodon Grandiflorus Extract(GCWB107))
62048240|NCT04023864|PLACEBO_COMPARATOR|Placebo group|Once-daily, once a tablet, after meals (900 mg/day, 0 mg/day as a Platycodon Grandiflorus Extract(GCWB107))
62048241|NCT01782443|EXPERIMENTAL|Experimental Treatment Arm|Ziv-aflibercept IV every 2 weeks, 4 mg/kg
62048242|NCT01201057|EXPERIMENTAL|0.5% SPL7013 Gel|
62048243|NCT01201057|EXPERIMENTAL|1.0% SPL7013 Gel|
62048244|NCT01201057|EXPERIMENTAL|3.0% SPL7013 Gel|
62048245|NCT01201057|PLACEBO_COMPARATOR|Placebo Gel|
62048246|NCT02244255|EXPERIMENTAL|FLOMAX®|
62048247|NCT02244255|ACTIVE_COMPARATOR|HYTRIN®|
62048248|NCT05183022|EXPERIMENTAL|Total30 Sphere Contact Lenses|All qualified participants will be refit into Total30 Sphere contact lenses.
62048249|NCT01550198||Newborns|"Critically ill newborns admitted to level III neonatal intensive care unit of a university hospital, who will be monitored using transpulmonary ultrasound dilution (advanced hemodynamic monitoring)"
62048250|NCT06132555||Drug abusers|"Drug abusers who registered in any of the 80 streets and 40 towns selected according to the economic level and population distribution of each city and other reference standards have been included in the study. A total of 6906 valid questionnaires have been collected.~The interviewees were selected from 5000 participants in the quantitative questionnaire. Priority is given to drug users who have abstained for more than three years, and all age groups under 30 years old, between 30 and 50 years old and over 50 years old are covered."
62048251|NCT06132555||Drug rehabilitation institutions|The drug rehabilitation institutions included social work organization, compulsory detoxification center and rehabilitation center, which were selected according to the specific conditions of the selected cities, and the final number of participants was determined according to the personnel Settings of these institutions.
62048252|NCT03033654|EXPERIMENTAL|Intervention|Two Consecutive Sunscreen Applications
62048253|NCT06380335||Group 1|Patients with liver cirrhosis who have been hospitalised following a recent hepatic decompensation which is at least 6 months after any hospitalisation for a prior decompensation event.
62048254|NCT06380335||Group 2|Out-patients with medically refractory ascites that recurs (i.e., second LVP) within a 6-month period.
62048255|NCT04791501||Hypoxemic Respiratory Failure|Consecutive intubated patients receiving invasive mechanical ventilation with a PaO2/FiO2 ≤300 mmHg under a PEEP of 5 cmH2O or more and FiO2 of 0.3 or more.
62830429|NCT00313014|ACTIVE_COMPARATOR|BTDS 5|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
62830430|NCT00313014|EXPERIMENTAL|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
62048256|NCT06246786|EXPERIMENTAL|Cyclosporin A|Patients with newly diagnosed triple negative breast cancer with low or negative RAD51 (A protein coding gene that provides instructions for making a protein that is essential for repairing damaged DNA)
62048257|NCT01385345|ACTIVE_COMPARATOR|Vitamin D3 high dose|200,000 units (time 0) followed by (100,000 units) at months 1.5, 3 and 5. Participants will also have daily 1,000 units per day to mirror the control arm and maintain double blinding.
62048258|NCT01385345|PLACEBO_COMPARATOR|Vitamin D3|Participants will have a placebo liquid (to mirror the active arm high dose Vitamin D3) and also have daily 1,000 units Vitamin D3.
62048259|NCT01357616|EXPERIMENTAL|AZARGA|Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension, 1 drop in the affected eye(s) dosed twice daily (9AM and 9PM) for 8 weeks. Both eyes were dosed unless there was a potential safety issue to the patient in the opinion of the Investigator.
62048260|NCT01357616|ACTIVE_COMPARATOR|AZOPT + Timolol|Brinzolamide 1% ophthalmic suspension, 1 drop instilled in the affected eye(s), followed by Timolol 0.5% ophthalmic solution, 1 drop instilled in the affected eye(s). Approximately 10 minutes separated the 2 instillations. The study drugs were instilled twice daily (9AM and 9PM) for 8 weeks. Both eyes were dosed unless there was a potential safety issue to the patient in the opinion of the Investigator.
62830431|NCT00313014|EXPERIMENTAL|Oxycodone Immediate-Release|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
62830432|NCT01765283|EXPERIMENTAL|Hepastem Low dose|12.5x106cells/kg
62830433|NCT01765283|EXPERIMENTAL|Hepastem Intermediate dose|50x106cells/kg
62830434|NCT01765283|EXPERIMENTAL|Hepastem High dose|200x106cells/kg
62830435|NCT03271658|EXPERIMENTAL|Intervention|Patient/family are randomized to either the active intervention (web based life support patient decision aid - eLSDA and decision coaching) or usual care comparison.
62440221|NCT02974413|EXPERIMENTAL|Intervention|The intervention to be performed will be based on the principles and steps of supported self-care, guided by Behavior Change Protocol (Behavior Change Protocol - BCP) and consists of an educational program with quarterly meetings, and individual at home, through home visits, and group in the Basic Health Unit (BHU), in addition to telephone monitoring in the interval between two meetings. This intervention will be applied together adult men with type 2 diabetes who are randomized in the intervention group (IG) for six months. Thus, these men will take part in three meetings, individual or group, and will receive four telephone calls in between the face meetings. Our objective is to draw with this intervention by the participant, an individual plan of self-care, based on concretras goals and supports you in the implementation of this plan, in order to improve their self-efficacy in self-care and therefore glycemic control.
62250502|NCT01148849|EXPERIMENTAL|Cohort 8: 18 mg/kg weekly every 3 weeks|Anti-HER2 monoclonal antibody (margetuximab)
62440222|NCT02974413|NO_INTERVENTION|Control|The study will also include a Control Group (CG), and the participants of this group will participate in conversation circles at the beginning and the end of the six month follow-up.
62440223|NCT06073795||FL group|Patients will receive FL-guided LSGB with 10 mL of 0.25% bupivacaine.
62608320|NCT04364464|EXPERIMENTAL|Riociguat, healthy participants|Participants with creatinine clearance (CLCR) \>80 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
62608321|NCT04364464|EXPERIMENTAL|Riociguat, mild renal impairment|Participants with CLCR 50-80 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
62830436|NCT03271658|NO_INTERVENTION|Usual Care Comparison|Patients may also randomized to review current web based resources provided by the health region for seriously ill patients.
62830437|NCT01658033|EXPERIMENTAL|Avastin + mFOLFOX6|Avastin plus FOLFOX6 regimen in the management of her-2 negative breast cancer patients.
62830438|NCT04170608|EXPERIMENTAL|FARAPULSE Endocardial Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
62830439|NCT04994288|EXPERIMENTAL|Supaglutide RP3D high dose|during the IIb phase 140 subjects were randomly assigned to supaglutide 1mg, 2mg ,3mg and placebo ; when these subjects meets the 12wks HbA1C result, an interim analysis will be made andRP3D high dose is confirmed by IDMC accoding to interim analysis. So during the phase 3 , subjets will be assigned to RP3D hign dose, RP3D low dose and placebo
62830440|NCT04994288|EXPERIMENTAL|supaglutide RD3D Low dose|during the IIb phase 140 subjects were randomly assigned to supaglutide 1mg, 2mg ,3mg and placebo ; when these subjects meets the 12wks HbA1C result, an interim analysis will be made and RP3D high dose is confirmed by IDMC accoding to interim analysis. So during the phase 3, subjets will be assigned to RP3D hign dose, RP3D low dose and placebo
62830441|NCT04994288|PLACEBO_COMPARATOR|placebo|placebo injection
62250503|NCT02748850|ACTIVE_COMPARATOR|leukemia patients|Patients with acute leukemia and / or refractory anemia with excess blasts and comprising a number of blasts in the blood greater than 5% device.
62250504|NCT02748850|PLACEBO_COMPARATOR|apheresis patients|patients with non-myeloid hematological malignancy
62608322|NCT04364464|EXPERIMENTAL|Riociguat, moderate renal impairment|Participants with CLCR 30-\<50 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
62608323|NCT04364464|EXPERIMENTAL|Riociguat, severe renal impairment|Participants with CLCR \<30 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
62830442|NCT02644655|EXPERIMENTAL|CD19-specific chimeric antigen receptor|After pretreatment, cluster of differentiation antigen 19 (CD19)-specific chimeric antigen receptor will be transfused.
62830443|NCT02261935|ACTIVE_COMPARATOR|Existing Home Care Nursing Practice|Home care nurses provide care based on existing home care practice
62830444|NCT02261935|EXPERIMENTAL|Practice Support Tool Intervention|"The practice support tool intervention will be the routine use of the Carer Support Needs Assessment Tool (CSNAT) in the practice of home care nurses (once every 4 weeks with each family caregiver) to document, monitor and address family caregiver support needs.~Update - December 22, 2016 - In some home care offices only, a study nurse will meet with family caregivers who are in the intervention group to deliver the CSNAT intervention. Information arising from the CSNAT about family caregivers' support needs will be communicated by the study nurse to the home care nurse, and incorporated by the home care nurse into the home care plan for the patient and patient's family."
62250505|NCT05049980|EXPERIMENTAL|Medical treatment|Patients choosing medical treatment with Mifégyne® and MisoOne®
62250506|NCT05049980|ACTIVE_COMPARATOR|Surgical treatment|Patients choosing surgical treatment by endo-uterine aspiration.
62608324|NCT03383900|EXPERIMENTAL|G-IMT|The experimental group will first carry out a diaphragmatic reeducation program, followed a posteriori by an inspiratory muscle training program use progressive resistance loads up to 80% of the PImax during the 8 weeks
62608325|NCT03383900|PLACEBO_COMPARATOR|Gn-IMT|The Gn-IMT will use by an inspiratory muscle training program use resistance loads up to 20% PImax during the 8 weeks.
62608326|NCT06061055|EXPERIMENTAL|Anchor|Patient group who are intubated with triple-cuffed double-lumen endobronchial tube (VentiBronc Anchor)
62608327|NCT06061055|ACTIVE_COMPARATOR|Shiley|Patient group who are intubated with conventional double-lumen endobronchial tube (Shiley)
62830445|NCT01002339|EXPERIMENTAL|Tacrolimus with rapid steroid withdrawal|Basiliximab induction. Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
62830446|NCT01002339|ACTIVE_COMPARATOR|Tacrolimus with steroids minimization|Basiliximab induction.Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
62250507|NCT01536951|PLACEBO_COMPARATOR|Placebo|Placebo matching LY3009104 tablets in size and appearance will be administered orally in 1 out of 3 study periods in Part A and Part B.
62830447|NCT01002339|EXPERIMENTAL|CsA with steroid minimization|Basiliximab induction. Ciclosporin A (CsA) plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
62830448|NCT05759702||normal weight|normal weight students will be enrolled in this group their BMI range from 5th percentile to less than the 85th percentile on CDC growth chart
62250508|NCT01536951|EXPERIMENTAL|LY3009104|"Part A. Single escalating dose of up to 40 milligrams (mg) of LY3009104 administered orally in 2 out of 3 study periods separated by at least a 3 day wash-out period between each dose.~Part B. Single dose of LY3009104 determined in Part A administered orally in 1 out of 3 study periods separated by at least a 3 day wash-out period between each period."
62830449|NCT05759702||overweight|overweight students will be enrolled in this group their BMI range from 85th to less than the 95th percentile on CDC growth chart
62440224|NCT06073795||US group|Patients will receive US-assisted LSGB with 10 mL of 0.25% bupivacaine.
62440225|NCT05822700|EXPERIMENTAL|K-wire|k wire transfixing hip
62440226|NCT01536678|ACTIVE_COMPARATOR|Test formulation of levothyroxine|Single dose of 600 mcg of levothyroxine administered in dosing period 1 or 2..
62608328|NCT02978885|OTHER|Normal preoperative lung function|Patients with normal lung function undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
62608329|NCT02978885|OTHER|Preoperative COPD|Patients with moderate COPD undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
62608330|NCT01523704|EXPERIMENTAL|Home Monitoring(HM)|Patients assigned to HM Group(HM follow-up ONLY) will have Home Monitoring programmed ON. They will be seen in the office for device interrogations at the 3-month follow-up, and at 27 month follow-up. In the meanwhile the device status will be evaluated using HM only for the 9, 15 and 21 month scheduled follow-up. Patients will visit the hospital for device interrogation on 27 month final follow-up.
62830450|NCT05759702||obese|obese students will be enrolled in this group their BMI range from Equal to or greater than the 95th percentile on CDC growth chart
62830451|NCT02621450|PLACEBO_COMPARATOR|standart dialysate|dialysate sodium 140 mEq/L
62250509|NCT01536951|ACTIVE_COMPARATOR|400 mg moxifloxacin|Part B. 400 mg moxifloxacin will be administered orally in 1 out of 3 study periods separated by at least a 3 day wash-out period between each period.
62830452|NCT02621450|OTHER|low sodium dialysate|dialysate sodium will be reduced from 140 mEq/L to 137 mEq/L
62830453|NCT02633124|EXPERIMENTAL|Edelvaiss Multiline NEO|The Edelvaiss Multiline NEO design allows to position the access to the infusion line outside of the incubator, without increasing the residual volume and this device has been validated by the manufacturer as part of CE marking for a period of 21 days.
62830454|NCT02633124|OTHER|Standard Infusion Set|The infusion set used for the standard group is the infusion set usually used.
62830455|NCT06326320|OTHER|Combined serratus anterior plane block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area. Then, with the same needle, will be returned 1-2 cm from the deep serratus anterior area to superficial serratus anterior area above the serratus anterior muscle and will be injected 2 ml normal saline for hydrodissection. Finally 20ml of 0.25% bupivacaine will be injected for superficial serratus anterior block into the interfacial area.
62250510|NCT02630732|ACTIVE_COMPARATOR|Brain School|Pain Neuroscience Education Program
62250511|NCT02630732|ACTIVE_COMPARATOR|Back School|Classical Back School
62250512|NCT02608060|EXPERIMENTAL|Epoetin Beta - 30000 IU|Dosage at Initiation: Subcutaneous injection of 30000 IU epoetin beta administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
62250513|NCT01504490|EXPERIMENTAL|CS-7017 and Bexarotene|Combination of CS-7017 and Bexarotene
62250514|NCT03195751||Manual Goniometer measurements|Measurements of shoulder range of motion using manual goniometer
62250515|NCT03195751||Software development kit measurements|Measurements of shoulder range of motion using a proprietary SDK
62440227|NCT01536678|ACTIVE_COMPARATOR|Reference formulation of levothyroxine|Single dose of 600 mcg of levothyroxine administered in dosing period 1 or 2.
62440228|NCT06107361|ACTIVE_COMPARATOR|Arm 1 (6.35cm 20 gauge ultralong intravenous catheter)|Arm 1 Device: B. Braun 6.35cm 20 gauge ultralong intravenous catheter
62440229|NCT06107361|EXPERIMENTAL|Arm 2 (5.71 cm 20 gauge Accucath)|Arm 2 Device: BD 5.71 cm 20 gauge Accucath, ultralong intravenous catheter with guide wire
62440230|NCT02429700|EXPERIMENTAL|PT (Arm 1)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
62440231|NCT02429700|ACTIVE_COMPARATOR|BEP (Arm 2)|"Patients receive bleomycin IM daily for days 1-3, etoposide IV daily for days 1-5, cisplatin IV for days 1-5. Treatment repeats every 21 days for 3 or 4\* courses in the absence of disease progression or unacceptable toxicity.~NOTE: \*Patients who have good risk will have 3 courses and those who have poor risks will have 4 courses."
62608331|NCT01523704|ACTIVE_COMPARATOR|Control|Patients assigned to Control Group (HM + Conventional In-office follow-up - Control group) will have HM programmed ON. In addition to HM, these patients will visit the hospital for device interrogation at 3, 9, 15, 21 and 27 month follow-ups.
62608332|NCT01101659|EXPERIMENTAL|001|JNJ-40411813 500 mg as 20 mL of oral suspension single dose
62250516|NCT00136409|EXPERIMENTAL|Mono-Therapy Gleevec|Gleevec administered orally at a pre-determined dose once daily.
62608333|NCT01101659|PLACEBO_COMPARATOR|002|Placebo 20 mL of oral suspension single dose
62608334|NCT01101659|OTHER|003|ketamine Ketanest S. vials of 20 ml with 5 mg/ml diluted with saline to 0.02 mg Ketamine per mL and per kg bodyweight of the volunteer
62608335|NCT01101659|OTHER|004|normal saline infusion 0.5 mL /min over 90 minutes
62608336|NCT01279174|OTHER|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
62608337|NCT01279174|EXPERIMENTAL|Whole-body-vibration exercises|Patients in this study group will attend whole body vibration exercise sessions of one hour three times a week for six weeks, using the Galileo® Fitness device. Initial training sessions will focus on patient acclimatization, and afterwards improved on muscular capacity and body coordination. During exercise sessions, patients will do 6 training cycles of 3 minutes each. The goals of this treatment are improved proprioception of the ankle and knee joints, as well as optimization of neuronal reactivation of the muscles and thereby improved joint stability. This should also increase endogenous analgesia
62608338|NCT05763368|ACTIVE_COMPARATOR|Minimally Invasive Lateral Approach|
62608339|NCT05763368|ACTIVE_COMPARATOR|Anterior Approach|
62608340|NCT02847338|EXPERIMENTAL|Mono-therapy group|"The monotherapy group will be treated with the following treatments:~A) 1 to 2 weeks of Amlodipine 5mg followed by 6 to 7 weeks of Amlodipine 10mg B) 1 to 2 weeks of Lisinopril 10mg followed by 6 to 7 weeks of Lisinopril 20mg C) Approximately 8 weeks of 25mg Chlortalidone~Participants will be randomly allocated to one of six possible sequences of treatments of the three-treatment-three period Williams design: ABC, ACB, BAC, BCA, CAB, and CBA."
62608341|NCT02847338|EXPERIMENTAL|Dual-therapy arm|"The dual-therapy group will be treated with the following treatments:~A) Approximately 8 weeks of Amlodipine 5mg and Lisinopril 20mg B) Approximately 8 weeks of Amlodipine 5mg and Chlortalidone 25mg C) Approximately 8 weeks of Lisinopril 20mg and Chlortalidone 25mg D) Approximately 8 weeks of Amiloride 10mg and Chlortalidone 25mg~Participants will be randomly allocated to one of four possible sequences of treatments of the four-treatment four-period Williams design: ABDC, BCAD, CDBA, and DACB."
62608342|NCT03878875||High Noise Exposure|One group (16, 8f:8m) with previous exposure i.e. nightclubs ++
62608343|NCT03878875||Low Noise Exposure|Group (16, 8f:8m) with less exposure measured through NESI
62830456|NCT02379728|EXPERIMENTAL|PrenaBelt|"Participants will be instructed to use the PrenaBelt nightly for the remainder of their pregnancy in addition to receiving the local standard of care.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
62830457|NCT02379728|EXPERIMENTAL|PrenaBelt with Body Position Sensor|"Participants will be instructed to use the PrenaBelt (with integrated body position sensor (BPS)) nightly for the remainder of their pregnancy in addition to receiving the local standard of care. The BPS will be securely integrated into a small pocket on the PrenaBelt. The BPS is not expected to affect body position or sleep.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
62830458|NCT02379728|SHAM_COMPARATOR|Control|"Participants will be instructed to use the sham-PrenaBelt nightly for the remainder of their pregnancy in addition to receiving the local standard of care.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
62830459|NCT02379728|SHAM_COMPARATOR|Control with Body Position Sensor (BPS)|"Participants will be instructed to use the sham-PrenaBelt (with integrated BPS) nightly for the remainder of their pregnancy in addition to receiving the local standard of care. The BPS will be securely integrated into a small pocket on the sham-PrenaBelt. The BPS is not expected to affect body position or sleep.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
62608344|NCT01973335|EXPERIMENTAL|Acetazolamide/low-dose loop diuretics, upfront spironolactone|"2x2 factorial design: This group is the experimental group for both study interventions (acetazolamide and upfront spironolactone).~See interventions for more details."
62608345|NCT01973335|EXPERIMENTAL|High-dose loop diuretics, upfront spironolactone|"2x2 factorial design: This group is the experimental group for the study intervention with upfront spironolactone. This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide.~See interventions for more details."
62830460|NCT01679314|ACTIVE_COMPARATOR|Active AlphaCore device|AlphaCore active stimulation treatment
62830461|NCT01679314|SHAM_COMPARATOR|Sham AlphaCore device|AlphaCore sham device
62830462|NCT06276829||Behçet's Disease|
62830463|NCT06276829||healthy individuals|
62830464|NCT04184700|EXPERIMENTAL|EHCF + LGG|Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG
62830465|NCT04184700|ACTIVE_COMPARATOR|RHF|Extensively hydrolyzed rice formula
62608346|NCT01973335|EXPERIMENTAL|Acetazolamide/low-dose loop diuretics, no spironolactone|"2x2 factorial design: This group is the experimental group for the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.~See interventions for more details."
62608347|NCT01973335|ACTIVE_COMPARATOR|High-dose loop diuretics, no spironolactone|"2x2 factorial design: This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.~See interventions for more details."
62250517|NCT05718479|EXPERIMENTAL|Trauma Informed Prenatal Intervention (TPI)|The experimental arm consists of four weekly, individual (30-60 minute) sessions via Zoom with a trained behavioral health scientist and therapist facilitating motivational interviewing focused on behavior change and mental wellness skills.
62250518|NCT05718479|ACTIVE_COMPARATOR|Prenatal Education Topics|The active comparator arm consists of four weekly, individual (30-45 minute) sessions via Zoom with a research staff member delivering prenatal education topics consisting of lecture (power point slides) and video.
62608348|NCT00003045|EXPERIMENTAL|Hyperthermia|XRT and Hyperthermia Post-therapy evaluation PSA, Clinical Exam, and Prostate Biopsy ( @ 12 Months)
62608349|NCT00990067|OTHER|duloxetine, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
62608350|NCT06545344|ACTIVE_COMPARATOR|Arm I (Usual care)|Patients receive usual care and undergo evaluation by a tumor board within 14 days of baseline.
62608351|NCT06545344|EXPERIMENTAL|Arm II (Palliative care visit)|Patients attend a palliative care visit over 60 minutes to discuss their illness, quality of life, fears and concerns and communication preferences within 7 days of baseline. Patients also undergo evaluation by a tumor board within 14 days of baseline.
62830466|NCT04184700|ACTIVE_COMPARATOR|EHWF|Extensively hydrolyzed protein formula
62830467|NCT04184700|ACTIVE_COMPARATOR|AAF|Amino acid based formula
62830468|NCT04184700|ACTIVE_COMPARATOR|SF|Soy formula
62608352|NCT05078749|ACTIVE_COMPARATOR|Exercise training group|Continuous progressive exercise training will be applied to the treatment group. The exercises will be performed every day, twice a day, for an average of 10 minutes/session, for eight weeks. Exercise training will be updated regularly at two-week intervals. A different and progressive new exercise will be sent to the patients as a Youtube link. The patients will be interviewed by video every week.
62830469|NCT00071890|ACTIVE_COMPARATOR|Interleukin 2 group|HAART (standard of care) and three cycles of IL-2
62830470|NCT00071890|ACTIVE_COMPARATOR|Control group|HAART alone
62830471|NCT06215170|NO_INTERVENTION|Control|General Instructions on Opioid Disposal
62830472|NCT06215170|ACTIVE_COMPARATOR|Treatment|General Instructions on opioid disposal Device: SafeMedWaste Opioid Disposal Kit
62250519|NCT06473883|EXPERIMENTAL|Training recommendation|The intervention group will receive training recommendations to prevent concussions and other injuries and improve their performance.
62250520|NCT06473883|NO_INTERVENTION|Normal training|The control group will continue with their regular training without any recommendations for the prevention of head injuries.
62250521|NCT03433495|ACTIVE_COMPARATOR|Melodic Intonation Therapy|The duration of therapy was 12 sessions performed over a 6-week period. Each session lasted 30 minutes. They were performed individually by a speech-experienced therapist previously trained in Melodic Intonation Therapy.
62608353|NCT05078749|SHAM_COMPARATOR|Control training group|The control group will be followed up as a home program by explaining the exercises and giving a brochure. They will be asked to do the exercises regularly for 7 days/week, 2 sessions/day, for eight weeks. Patients in the control group will be followed up by phone once a week.
62608354|NCT03434249|EXPERIMENTAL|Group I|patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
62830473|NCT03938090|PLACEBO_COMPARATOR|Standard biventricular pacing|Cardiac resynchronization therapy (CRT) devices will be programmed as per standard biventricular pacing settings
62830474|NCT03938090|ACTIVE_COMPARATOR|Optimised MultiSite Pacing (MSP)|Cardiac resynchronization therapy (CRT) devices will be programmed as per optimal MSP programming settings; determined by greatest change in dP/dtmax and narrowest QRS duration.
62830475|NCT06205277||Patients with pT1 NMIBC who underwent second TURBt|Patients with pT1 NMIBC who underwent second TURBt after a macroscopically completede first TURBt within 6-8 weeks
62830476|NCT00305188|EXPERIMENTAL|Xaliproden (SR57746A)|
62830477|NCT00305188|PLACEBO_COMPARATOR|Placebo|
62250522|NCT03433495|NO_INTERVENTION|Waiting list|No intervention
62250523|NCT00943709|EXPERIMENTAL|Arm I|Patients with goal blood glucose 80-14 mg/dL receive the Robert Wood Johnson Hospital IV insulin infusion protocol followed by insulin glargine and insulin glulisine (Apidra™) subcutaneously for 4 weeks.
62250524|NCT00943709|ACTIVE_COMPARATOR|Arm II|Patients with goal blood glucose \< 250 mg/dL are started on subcutaneous insulin sliding scale at the discretion of the treating physician with blood glucose monitoring and adjustment according to the insulin sliding scale.
62250525|NCT03573609|NO_INTERVENTION|Control|Usual respiratory care
62250526|NCT03573609|ACTIVE_COMPARATOR|Supranav|"Respiratory care with supranav which is a continuous supraglottic suction device"
62830478|NCT06593808|NO_INTERVENTION|Preterm infants in incubator|Preterm infant in stable conditions transferred from the incubator to the open crib at a weight greater than or equal to 1600 grams
62830479|NCT06593808|EXPERIMENTAL|Preterm infants in open coat|Preterm infant in stable conditions transferred from the incubator to the open crib at a weight greater than or equal to 1400 grams
62830480|NCT03762811|OTHER|NanoFUSE® PMCF|NanoFUSE® Bioactive Matrix will be implanted according to labeling and the intended surgical treatment plan of the surgeon.
62608355|NCT03434249|PLACEBO_COMPARATOR|Group II|patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
62608356|NCT05524844||Control|Non-BE controls undergoing endoscopy for any indication who are on stable dose Proton Pump Inhibitors for the past month.
62608357|NCT05524844||Barrett's Esophagus|Patients scheduled for upper endoscopy for clinical purposes, with a history of histologically confirmed Barrett's esophagus (2 cm length); 40 with no history of dysplasia, and 40 with high grade dysplasia or esophageal adenocarcinoma.
62608358|NCT04701918|EXPERIMENTAL|Pembrolizumab/Avelumab + Cryoablation|"If patient is receiving pembrolizumab: Participants will be given 200 mg pembrolizumab intravenously once every 3 weeks. This will continue for up to 2 years as per standard of care. Participants will receive cryoablation between the 1st and 2nd doses of pembrolizumab. Cryoablation consists of using a CT scan to guide one or more thin needles to the tumor through your skin, where extreme cold is applied.~If patient is receiving avelumab: Participants will be given 800 mg avelumab intravenously once every 2 weeks. This will continue for up to 2 years as per standard of care. Participants will receive cryoablation between the 1st and 2nd doses of avelumab. Cryoablation consists of using a CT scan to guide one or more thin needles to the tumor through your skin, where extreme cold is applied."
62250527|NCT01772901|NO_INTERVENTION|Control|Usual outpatient antenatal care consists of routine checking of the maternal and foetal health by either clinic midwives or obstetricians along with health education to promote a healthy pregnancy.
62250528|NCT01772901|EXPERIMENTAL|Influenza Vaccine Intervention|The intervention group will receive a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions.
62608359|NCT01389336||Add-on Ayurveda - Group|In the Āyurveda add-on-group 20 patients will receive individualized treatment according to the Āyurveda diagnosis which may include manual treatments, massages, dietary advice, specific consideration of selected food items, āyurvedic lifestyle \& yoga posture advice and daily self-applied massage on top of standard care.
62608360|NCT01389336||Standard Care|20 Patients will receive the individually adjusted complex conventional standard care according to the current AWMF-guidelines including physiotherapy, occupational therapy, specific pain therapy and psychotherapy.
62608361|NCT06368804|EXPERIMENTAL|Oral fluoroquinolone + nebulized colistimethate sodium|
62608362|NCT06368804|ACTIVE_COMPARATOR|IV beta-lactam antibiotic (ceftazidime) + oral fluoroquinolone + nebulized colistimethate sodium|
62608363|NCT03053427|PLACEBO_COMPARATOR|Placebo|Placebo was administered orally once daily after the evening meal.
62608364|NCT03053427|EXPERIMENTAL|Gabapentin enacarbil|Gabapentin enacarbil was administered orally once daily after the evening meal. Participants with an estimated creatinine clearance of ≥ 60 mL/min to \< 90 mL/min at the start of the run-in period were administrated gabapentin enacarbil 300 mg for 1 week followed by gabapentin enacarbil 600 mg for 11 weeks.
62608365|NCT04565899|EXPERIMENTAL|Practice facilitation implementation intervention|6 months during which practice facilitation is implemented to support the primary care clinic in improving routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs.
62608366|NCT04306887|EXPERIMENTAL|TQ-B3101|TQ-B3101 capsule administered orally.
62608367|NCT04097197|EXPERIMENTAL|Patients receiving information|Patients in the experimental arm will receive a brief educational intervention if they initially refuse flu vaccination. The intervention was designed towards the most common barriers to flu vaccination that were found after a brief review of the literature. After the intervention, patients will be asked again whether or not they wish to receive the flu vaccine.
62608368|NCT02073656|EXPERIMENTAL|LDV/SOF 12 Weeks|LDV/SOF for 12 weeks
62830481|NCT06655350||Harvested ankle|
62608369|NCT02073656|EXPERIMENTAL|Retreatment Substudy|LDV/SOF plus RBV for 24 weeks
62250529|NCT02809014|PLACEBO_COMPARATOR|Placebo|Dentifrice without fluoride and tara gum.
62250530|NCT02809014|ACTIVE_COMPARATOR|Dentifrice standard|Dentifrice 1100 ppm sodium fluoride (NaF) without tara gum. Positive control
62250531|NCT02809014|PLACEBO_COMPARATOR|Dentifrice with tara gum|Dentifrice without fluoride but with hydrocolloid tara gum.
62440232|NCT01772368|EXPERIMENTAL|FS MDPI 100/6.25 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 6.25 mcg salmeterol xinafoate.
62440233|NCT01772368|EXPERIMENTAL|FS MDPI 100/12.5mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 12.5 mcg salmeterol xinafoate.
62440234|NCT01772368|EXPERIMENTAL|FS MDPI 100/25|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 25 mcg salmeterol xinafoate.
62440235|NCT01772368|EXPERIMENTAL|FS MDPI 100/50|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate.
62830482|NCT06655350||Native ankle|
62830483|NCT04819607||BMFS patients|Patients with BMFS attending Peter MacCallum Cancer Centre haematology clinic.
62830484|NCT02946658|EXPERIMENTAL|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
62830485|NCT02946658|EXPERIMENTAL|AD-cSVF Arm 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
62830486|NCT02946658|EXPERIMENTAL|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
62830487|NCT06440434|ACTIVE_COMPARATOR|Early night shift (midnight-4am)|
62830488|NCT06440434|ACTIVE_COMPARATOR|Late night shift (4am - 8am)|
62830489|NCT01123798||Stable controls|Uninjured soldiers to provide normative data for stable physiological status
62830490|NCT01123798||Critical controls|"Critically injured soldiers with no lower extremity traumatic injuries (excepting skin abrasions and small/superficial fragmentation wounds) to provide normative data for the shock physiological status."
62440236|NCT01772368|ACTIVE_COMPARATOR|Fp MDPI 100 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate.
62830491|NCT01123798||Lower extremity trauma|Soldiers with severe traumatic lower extremity injuries in stable and shock physiologic status. This is the investigational cohort.
62830492|NCT03755310|EXPERIMENTAL|Suvorexant|10mg tabs during the first week, 10-20 mg tabs on the second week.
62440237|NCT01772368|ACTIVE_COMPARATOR|Advair Diskus 100/50 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate. This arm is the only arm which is open-label because the inhaler device was different than the MDPI used in the other treatment arms.
62440238|NCT03619499|EXPERIMENTAL|non invasive|infants who fulfill criteria of severe bronchiolitis will be connected to non invasive ventilation
62440239|NCT03619499|NO_INTERVENTION|invasive|infants who were connected to invasive mechanical ventilation
62830493|NCT03755310|PLACEBO_COMPARATOR|Placebo|Equivalent dosage, route of administration and dose regimen.
62440240|NCT06479044||LC- Scientific Expert|
62440241|NCT06479044||LL- Organizer-Introvert|
62830494|NCT00815659|EXPERIMENTAL|Rosuvastatin|medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
62830495|NCT06655805||One cohort of consecutive patients|One cohort of consecutive patients admitted to the intensive care unit while on IMV or in need of HFNO, NIV lung support due to acute respiratory failure.
62830496|NCT00469599|ACTIVE_COMPARATOR|1|alfacalcidol 16 weeks, 6 weeks wash out, paricalcitol 16 weeks
62830497|NCT00469599|ACTIVE_COMPARATOR|2|paricalcitol ´16 weeks, 6 weeks wash out, alfacalcidol 16 weeks
62830498|NCT06362044||Chronic Lymphocytic Leukemia (CLL) Participants|Participants will receive treatments for CLL in accordance with approved local label.
62830499|NCT06305728||High Risk Pancreatic Cystic Neoplasm|Participants will be diagnosed with a pancreatic cystic neoplasm deemed to be high risk and requiring surgical resection
62830500|NCT04949490|EXPERIMENTAL|Group A, BNT162b2s01 30 μg (1 dose)|Trial participants from BNT162-01 (excluding transplant participants from Cohort 13) who received two injections of 30 μg BNT162b2 (Comirnaty) in the parent trial received one booster injection of BNT162b2s01 on Day 1. Day 1 (baseline in this trial) must have occurred ≥24 weeks after the last BNT162b2 (Comirnaty) injection in the parent BNT162-01 trial.
62830501|NCT04949490|EXPERIMENTAL|Group A, BNT162b2 30 μg (1 dose)|Trial participants from BNT162-01 (excluding transplant participants from Cohort 13) who received two injections of 30 μg BNT162b2 (Comirnaty) in the parent trial received one booster injection of BNT162b2 (Comirnaty) on Day 1. Day 1 (baseline in this trial) must have occurred ≥24 weeks after the last BNT162b2 (Comirnaty) injection in the parent BNT162-01 trial.
62830502|NCT04949490|EXPERIMENTAL|Group B, BNT162b2 30 μg (2 doses)|Trial participants in either the trial BNT162-01 (excluding transplant participants from Cohort 13) or BNT162-04 who did not receive the full two vaccinations of 30 μg BNT162b2 (Comirnaty) in the respective parent trial were offered two injections of 30 μg BNT162b2 (Comirnaty) as per the conditional marketing authorization on Day 1 and Day 21. Day 1 (baseline in this trial) must have occurred ≥12 weeks after receiving the last BNT162 candidate vaccine in the respective parent BNT162-01 or BNT162-04 trial.
62830503|NCT04949490|EXPERIMENTAL|Group B transplant subjects, BNT162b2 30 μg (2 doses)|Transplant trial participants from Cohort 13 of the trial BNT162-01 received one injection of 30 μg BNT162b2 (Comirnaty) on Day 1 which was followed 3 to 7 months afterward by a second injection of BNT162b2 (Comirnaty). Day 1 (baseline in this trial) must have occurred ≥12 weeks after receiving the last BNT162 candidate vaccine in the parent BNT162-01 trial.
62830504|NCT01101867|EXPERIMENTAL|Aspart flexible dose|aspart dose determined based upon carbohydrate intake.
62830505|NCT01101867|ACTIVE_COMPARATOR|Aspart fixed dose|fixed meal dose of aspart (based upon weight or total daily insulin dose)
62830506|NCT05751187|EXPERIMENTAL|Pembrolizumab + Bevacizumab + Chemotherapy|Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m\^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m\^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4-6 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m\^2 IV Q3W until progression.
62440242|NCT06479044||RC- Interpersonal Strategist|
62440243|NCT06479044||RL- Imaginative Communicator|
62440244|NCT01798485|EXPERIMENTAL|Ganetespib and Docetaxel|Ganetespib (150 mg/m\^2) and docetaxel (75 mg/m\^2) were administered as separate 1-hour IV infusions on Day 1 of each 3-week treatment cycle. Administration of ganetespib preceded the administration of docetaxel. Ganetespib was administered again on Day 15 of each cycle.
62440245|NCT01798485|ACTIVE_COMPARATOR|Docetaxel|Docetaxel (75 mg/m\^2) was administered on Day 1 of a 3-week treatment cycle by 1-hour IV infusion.
62830507|NCT04030507|EXPERIMENTAL|Inflammatory Breast Cancer Managed with Curative Intent|"* Patients will receive an initial screening magnetic resonance imaging (MRI) of the brain~* If no evidence of intracranial involvement is identified, additional screening MRIs of the brain every six months for two years and at initial systemic progression."
62830508|NCT04030507|EXPERIMENTAL|HR+ or HER2+ Metastatic Breast Cancer - Screening Arm|"* An initial MRI screening will be conducted~* If negative, patients will receive a second MRI of the brain at first systemic progression after study entry"
62830509|NCT04030507|NO_INTERVENTION|HR+ or HER2+ Metastatic Breast Cancer - No Screening Arm|No initial MRI screening will be conducted
62830510|NCT04030507|EXPERIMENTAL|Triple Negative Breast Cancer|"* An initial MRI screening will be conducted~* If negative, patients will receive a second MRI of the brain at first systemic progression after study entry"
62830511|NCT06218797|ACTIVE_COMPARATOR|Group C|Control group
62440246|NCT06419348|EXPERIMENTAL|99mTc-QULIC-5-P1|Patients will receive a single administration of 99mTc-QULIC-5-P1
62440247|NCT06528041|EXPERIMENTAL|Pure Inulin|12 g/day prebiotic supplement
62830512|NCT06218797|ACTIVE_COMPARATOR|Group ND|Nebulisation with dexmedetomidine
62440248|NCT06528041|PLACEBO_COMPARATOR|Placebo|6 g/day maltodextrin
62440249|NCT01231061|EXPERIMENTAL|Arm A: SBRT|
62440250|NCT01231061|EXPERIMENTAL|Arm B: Radiosurgery|
62440251|NCT05606692|ACTIVE_COMPARATOR|Sevoflurane group|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
62440252|NCT05606692|EXPERIMENTAL|Propofol group|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
62440253|NCT05139966|PLACEBO_COMPARATOR|G0 - placebo|All placebo mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, NO FLUORIDE WAS INCORPORATED.
62608370|NCT03634683|EXPERIMENTAL|LioCyx|"This is a single-arm study.~Patients will receive escalating doses of LioCyx on Day 1, Day 8, Day 15 and Day 22 of the first 28-day treatment cycle, followed by every 2-week dosing on Day 1, Day 15, Day 29 and Day 43 of repeated cycle. A 21-day treatment break will be given between each cycle."
62608371|NCT05496608|PLACEBO_COMPARATOR|Open Flap Debridement|Subjects with infrabony defects had full thickness flap reflection and debridement of periodontal lesion
62830513|NCT01253278|EXPERIMENTAL|20 mg LY2393910|
62830514|NCT01253278|EXPERIMENTAL|60 mg LY2393910|
62830515|NCT01253278|EXPERIMENTAL|150 mg LY2393910|
62830516|NCT01253278|EXPERIMENTAL|450 mg LY2393910|
62830517|NCT01253278|PLACEBO_COMPARATOR|Placebo|
62830518|NCT05743335|EXPERIMENTAL|Investigational product|Patients randomized to this arm will be given the investigational product (JCXH-221).
62830519|NCT05743335|PLACEBO_COMPARATOR|Placebo|Patients randomized to this arm will be given a placebo vaccine.
62830520|NCT01704716|EXPERIMENTAL|R0: COJEC plus G-CSF|Patients randomised to G-CSF during induction treatment (Rapid COJEC) received a single daily subcutaneous injection of 5 microgram/kg/day G-CSF (filgrastim) beginning 24 hours after the last chemotherapy dose.
62440254|NCT05139966|EXPERIMENTAL|G1: 100% - sodium fluoride (100% free NaF)|These mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm NaF (SODIUM FLUORIDE) WAS INCORPORATED.
62440255|NCT05139966|EXPERIMENTAL|G2: 50% nano fluoride (225 ppm, 50% free NaF + 50% nanoF)|These mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm (50% free NaF + 50% nanoF) WAS INCORPORATED.
62440256|NCT05139966|EXPERIMENTAL|G3: 100% nano fluoride (225 ppm)|These mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm (100% nanoF) WAS INCORPORATED.
62440257|NCT04091269|PLACEBO_COMPARATOR|PSV-10%|PSV mode using E5 ventilator with fixed flow trigger and Esense 10%
62250532|NCT02809014|EXPERIMENTAL|Dentifrice F-Complex + NaF|Dentifrice experimental with fluoride (1100 ppm) being half of fluoride incorporated in tara gum and other half freeform of NaF
62250533|NCT02809014|EXPERIMENTAL|Dentifrice F-Complex|Dentifrice experimental with fluoride (1100 ppm) all incorporated in tara gum.
62250534|NCT04615468|EXPERIMENTAL|TQ-B3525 tablets|TQ-B3525 tablet administered orally.
62440258|NCT04091269|PLACEBO_COMPARATOR|PVS-30%|PSV mode using E5 ventilator with fixed flow trigger and Esense 30%
62440259|NCT04091269|PLACEBO_COMPARATOR|PSV-50%|PSV mode using E5 ventilator with fixed flow trigger and Esense 50%
62440260|NCT04091269|EXPERIMENTAL|PSV-auto|PSV mode using automatic adjustmen of inspiratory triger and cycling-off based on waveform
62440261|NCT04091269|ACTIVE_COMPARATOR|PSV-neuro|NAVA mode using NAVA level of 15 cmH2O/uV and pressure limit function to simulated EAdi triggered PSV.
62440262|NCT03843177||Ingrown toenails|
62440263|NCT03843177||Control|
62440264|NCT02911883||Normal|Not having glaucoma or retinal pathology
62440265|NCT02911883||Glaucoma|Having glaucoma.
62440266|NCT02911883||Retina|Having retinal pathology
62608372|NCT05496608|ACTIVE_COMPARATOR|L-PRF|Subjects with infrabony defects had full thickness flap reflection and debridement of periodontal lesion followed by application of the L-PRF within the bony defect
62608373|NCT05496608|ACTIVE_COMPARATOR|L-PRF + CM|Subjects with infrabony defects had full thickness flap reflection and debridement of periodontal lesion followed by application of the L-PRF within the bony defect and coverage with collagen xenogeneic membrane
62608374|NCT05048589|ACTIVE_COMPARATOR|Standard-Dose Quadrivalent Influenza Vaccine|QIV-SD single injection at Day 0
62830521|NCT01704716|ACTIVE_COMPARATOR|R0: COJEC|Induction treatment (COJEC) without filgrastim Patients randomised to Rapid COJEC alone will receive induction Treatment without G-CSF
62830522|NCT01704716|ACTIVE_COMPARATOR|R1: BuMel MAT|"The BuMel MAT regimen consists of oral administration of busulphan and the short i.v. infusion of melphalan.~In July 2007 (amendment 3) oral busulfan was changed to i.v. Busulfan (Busilvex)"
62830523|NCT01704716|EXPERIMENTAL|R1: CEM MAT|The CEM MAT regimen uses three drugs: the dose of Carboplatin must be based on renal function with a target area under the concentration versus time curve (AUC) of 16.4 mg/ml.min, etoposide 350 mg/m2/course and melphalan 210 mg/m2/course
62830524|NCT01704716|ACTIVE_COMPARATOR|R2: ch14.18/CHO|ch14.18/CHO is given at a dose of 20 mg/m2/day over five days every four weeks for five courses
62830525|NCT01704716|EXPERIMENTAL|R2: ch14.18/CHO plus Aldesleukin|Patients randomised to receive ch14.18/CHO plus Aldesleukin
62048261|NCT00611858|EXPERIMENTAL|Cetuximab, 5-FU and Radiation|"Cetuximab: Participants first receive cetuximab at the initial dose of 400 mg/m2 intravenously (IV) administered over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes. Cetuximab is given as single agent during the first 3 weeks on study and then in combination with 5-FU and radiation.~Radiation: Radiation therapy given as standard of care is initiated after the 3rd dose of cetuximab with a total dose of 50.4 Gray (Gy) in 28 fractions over approximately 5.5 weeks.~5-FU: Participants receive 5-Fluorouracil (5-FU) continuous infusion through central venous access at 225 mg/m2/day given 7 days a week starting day 1 of radiation (no later than 3 days) and lasting the duration of radiation therapy.~Duration of neoadjuvant therapy is estimated to be 9 weeks. Surgery follows at week 13-17. Sigmoidoscopy is performed for biopsy prior to the 1st dose and after 3rd dose of cetuximab before the initiation of radiation and/or 5-FU."
62048262|NCT02375295|EXPERIMENTAL|Arm A: 2 weeks Abx post PCNL|Oral antibiotics: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin are administered for 2 weeks at full dose.
62048263|NCT02375295|ACTIVE_COMPARATOR|Arm B: 12 weeks/3 months Abx post PCNL|Oral antibiotics: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin are administered for 2 weeks at full dose followed by a suppressive dose for another 10 weeks (total = 12 weeks or 3 months).
62048264|NCT02978755|EXPERIMENTAL|GM102 escalating doses|8 successive cohorts
62440267|NCT02611752|EXPERIMENTAL|CAM2038 q1w, 24 mg|CAM2038 q1w 24 mg will be administered on Day 0 and Day 7. Hydromorphone 0 mg (placebo), 6 mg and 18 mg will be subsequently administered during 4 challenge sessions on Days 1-3, 4-6, 8-10 and 11-13
62440268|NCT02611752|EXPERIMENTAL|CAM2038 q1w, 32 mg|CAM2038 q1w 32 mg will be administered on Day 0 and Day 7. Hydromorphone 0 mg (placebo), 6 mg and 18 mg will be subsequently administered during 4 challenge sessions on Days 1-3, 4-6, 8-10 and 11-13
62830526|NCT01704716|ACTIVE_COMPARATOR|R3: COJEC Induction|"Rapid COJEC induction treatment is applied over ten weeks; three different courses are given every ten days:~Course A (given on days 0 and 40): vincristine, carboplatin, and etoposide Course B (given on days 10, 30, 50, and 70): vincristine and cisplatin Course C (given on days 20 and 60): vincristine, etoposide, and cyclophosphamide"
62830527|NCT01704716|EXPERIMENTAL|R3: Modified N7|The modified N7 induction is a dose intense induction chemotherapy regimen including two putatively non cross-resistent drug combinations: high-dose cyclophosphamide plus doxorubicin/vincristine (CAV) and high-dose cisplatin/etoposide (P/E).
62830528|NCT01704716|ACTIVE_COMPARATOR|R4: cnt inf ch14.18/CHO|ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO
62608375|NCT05048589|EXPERIMENTAL|High-Dose Quadrivalent Influenza Vaccine|QIV-HD single injection at Day 0
62608376|NCT06730776|ACTIVE_COMPARATOR|Control group (group A)|It will include 19 women with dyspareunia. They will receive only topical medication (lidocaine ointment applied as required for symptoms and 30 minutes before sexual activity)
62830529|NCT01704716|EXPERIMENTAL|R4: cnt inf ch14.18/CHO plus Aldesleukin|"ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO.~In addition, Aldesleukin is given at a dose of 3 x 10e6 on days 1 to 5 and on days 9, 11, 13, 15, and 17 during ch14.18/CHO infusion"
62830530|NCT03397069|PLACEBO_COMPARATOR|Group C(control)|Peribulbar block without midazolam (peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml)
62830531|NCT03397069|EXPERIMENTAL|Group M1|Peribulbar block with midazolam 50 µg (peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 50 µg/ml)
62830532|NCT03397069|EXPERIMENTAL|Group M2|Peribulbar block with midazolam 100 µg(peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 100 µg/ml
62830533|NCT05438862|EXPERIMENTAL|Early surgery|Early surgical treatment, state of art aortic valve surgery.
62830534|NCT05438862|NO_INTERVENTION|Watchful waiting|Watchful waiting strategy, regular follow-up of patients with severe valve disease. Guideline-based indication for surgery only during the follow-up.
62830535|NCT03523988|ACTIVE_COMPARATOR|Acetaminophen|Acetaminophen 650mg powder in gel capsule taken by mouth before entering appointment
62830536|NCT03523988|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
62830537|NCT03523988|EXPERIMENTAL|Acetaminophen and Ibuprofen|Acetaminophen 650mg and Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
62830538|NCT02271269|NO_INTERVENTION|Usual Care (UC)|"Patients receiving Usual Care for Glaucoma comprising:~* Education on effective glaucoma treatment~* Routine check-ups with an ophthalmologist and prescription of glaucoma eye drops~* Glaucoma counselling \[Can be recommended by ophthalmologist for non-adherent patients\] covering:~  * Glaucoma risk factors and symptoms~ * Management and treatment~ * Medications and optimal dosage windows~ * Risks of medication non-adherence~ * Formulation of a dosing schedule that compliments each patient's lifestyle"
62250535|NCT06034171|EXPERIMENTAL|Group A|Implant with phosphate surface device in the right side of the lower jawbone, and the hydroxylapatite surface treatment implant is placed in the left side of the lower jaw.
62440269|NCT04866797|ACTIVE_COMPARATOR|cyclic merocyanine long-UVA absorber|
62440270|NCT04866797|PLACEBO_COMPARATOR|placebo|
62608377|NCT06730776|EXPERIMENTAL|Study group (group B)|It will include 19 women with dyspareunia. They will receive Acu-TENS (30 minutes per session, once per week for 10 weeks), topical medication(lidocaine ointment applied as required for symptoms and 30 minutes before sexual activity)
62608378|NCT05866549|EXPERIMENTAL|Intervention Group|
62608379|NCT05866549|NO_INTERVENTION|Control Group|
62250536|NCT06034171|EXPERIMENTAL|Group B|Implant with phosphate surface device for the lower jaw on the left side, and the implant with hydroxylapatite surface treatment is inserted into the right side of the jawbone.
62440271|NCT01007916|OTHER|Lotrafilcon B / Habitual|Lotrafilcon B contact lenses worn first, with habitual contact lenses worn second. Both products worn bilaterally as often as is typical for habitual lenses, and in the same modality as is typical for habitual lenses, as prescribed by regular eye care practitioner, with extended wear not to exceed 6 nights.
62440272|NCT01007916|OTHER|Habitual / Lotrafilcon B|Habitual contact lenses worn first, with lotrafilcon B lenses worn second. Both products worn bilaterally as often as is typical for habitual lenses, and in the same modality as is typical for habitual lenses, as prescribed by regular eye care practitioner, with extended wear not to exceed 6 nights.
62250537|NCT04596020|EXPERIMENTAL|Blood Flow Restriction Group|This group will perform 2 lower extremity exercises (sitting unilateral knee extension, standing unilateral knee curl) under occlusion (i.e., BFR) for 4 sets (30/15/15/15 reps) each followed by 2 shoulder exercises (scaption and sidelying external rotation) 3 sets x 15 reps each. Exercises will be performed at 30% of 1RM.
62250538|NCT04596020|ACTIVE_COMPARATOR|Non-Blood Flow Restriction Group|This group will perform the same exercises for the same volume without the use of BFR.
62250539|NCT01747967|EXPERIMENTAL|Meal test|Both new-onset T1D children and adults will be recruited and followed up through 4 meal tests at 0, 6, 12 , 18, 24 and 30 months.
62440273|NCT05364099|EXPERIMENTAL|Suprascapular Nerve Block in Participants with Spinal Cord Injuries (SCI) Group|Participants in this group will receive standard of care (SOC) suprascapular nerve block using a mixture of Lidocaine and Triamcinolone.
62440274|NCT03355378|EXPERIMENTAL|study group|gum chewing during spinal anesthesia and early ambulation
62440275|NCT03355378|NO_INTERVENTION|Control group|no gum chewing
62608380|NCT03499288||Children and youth with cerebral palsy|Subjects between 1 month and 18 years of age with Cerebral Palsy who visited the coordinating HCP within the past 12 months.
62608381|NCT04352218|ACTIVE_COMPARATOR|PTA Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty of internal jugular vein non-thrombotic stenosis in patients with chronic headache
62440276|NCT05025423|EXPERIMENTAL|venetoclax and rituximab in patients over 60 yrs old with previously untreated mantle cell lymphoma|Venetoclax dose escalation for Cycles 1-4. If Complete response (CR) at Cycle 4, continue with cycles 5-12 at fixed venetoclax 400mg dose. If partial response (PR) at Cycle 4, continue with cycles 5-8 at fixed venetoclax 800mg dose. If CR at Cycle 8 after PR, continue with cycles 9-12 at fixed venetoclax 800mg dose. If continued PR at Cycle 8, reduce venetoclax to 400mg and add bendamustine 90 mg/m2.
62440277|NCT03035838|OTHER|Treatment|There is only one arm in this study. Intracranial pressure and brain swelling will be monitored before and after administration of fosaprepitant
62608382|NCT04352218|EXPERIMENTAL|"PTA + Stenting using Petalo stent"|Percutaneous Transluminal Angioplasty + Stenting of internal jugular vein non-thrombotic stenosis in patients with chronic headache
62608383|NCT04722952|EXPERIMENTAL|Anti-PD-1 mAb Combined With Azacytidine and HAG regimen|Anti-PD-1 mAb combined with DNA methyltransferase inhibitor Azacytidine and HAG regimen
62830539|NCT02271269|EXPERIMENTAL|Value Pricing (VP)|Patient receiving Usual Care for Glaucoma and given the opportunity to receive Value Pricing Subsidies.
62608384|NCT02957045|EXPERIMENTAL|Cough|
62830540|NCT04617626|OTHER|Azithromycin|All children ages 1 to 5 months in the targeted health district will be offered a single dose of azithromycin suspension dosed at 20 mg per kg of weight in place of the standard tetracycline ointment, during a mass drug administration targeting trachoma prevention and treatment. All children ages 6 months and older, and all adults already receive the single dose of azithromycin during the MDA event. For this pilot study, single dose of azithromycin is being extended to include the 1 to 5 month old population as well.
62830541|NCT03234322|EXPERIMENTAL|Intervention group|In the intervention group the routine health check is expanded by usage of a non-invasive diabetes risk score.
62830542|NCT03234322|NO_INTERVENTION|Control group|In the control group the routine health check is conducted.
62830543|NCT04004741|EXPERIMENTAL|Osteopathic Manipulative Treatment|Group A will receive osteopathic treatment by NMM/OMM board certified attending physicians. The protocol for the OMT intervention group is based on the guidelines set forth previously in textbooks. The protocol will last 25 minutes total, with 10 minutes for the evaluation and 15 minutes for treatment. The protocol will start in ribs so as to not exacerbate any tachyarrhythmias with rib raising, thoracic myofascial release, and a pectoralis lift. The investigator will then proceed with opening the thoracic inlet, cervical myofascial release, suboccipital release, and then end by checking for and treating Chapman's points. The physician will submit their osteopathic evaluation and fill out a form in order to determine if certain arrhythmias have an associated trigger point.
62440278|NCT03878355|EXPERIMENTAL|radical endoscopic sinus surgery plus Draf 3 surgery|
62830544|NCT04004741|SHAM_COMPARATOR|Light Touch Treatment|Group B will receive a light touch treatment, based on previous research done studying heart rate variability and OMM, where sham treatment was utilized. The protocol consisted of contacting the right ankle, left knee, right hip, diaphragm, right shoulder, neck, and cranium for precisely two minutes each, with the goal of preventing placebo autonomic nervous system stimulation. The protocol is 25 minutes long, with 10 minutes for the evaluation and 15 minutes for treatment.
62830545|NCT01008020|NO_INTERVENTION|Dietary supplement: placebo|
62830546|NCT01008020|ACTIVE_COMPARATOR|Tea catechin extracts|
62440279|NCT03878355|EXPERIMENTAL|radical endoscopic sinus surgery|
62440280|NCT03878355|EXPERIMENTAL|functional endoscopic sinus surgery|
62440281|NCT00564369|EXPERIMENTAL|1|2006 CDC recommendations
62440282|NCT00564369|ACTIVE_COMPARATOR|2|Prior CDC recommendations
62440283|NCT02561312||RMPET|For rapid manual partial exchange transfusion, participants with a weight \>50kg, 500 ml of whole blood is removed from the participant via a single lumen central venous line, followed by infusion of 500 ml of saline. A 30 second wait time is utilized for equilibration to occur. A second 500 ml aliquot is removed, and then two units of packed red blood cells (PRBC) are infused. (This is customized for a patient with large red blood cell mass). For participants \<50 kg, the individual exchange aliquots are adjusted to 10 ml/kg or normal saline and PRBC.
62048265|NCT02978755|EXPERIMENTAL|GM102 escalating doses + carboplatin+paclitaxel|2 successive cohorts
62048266|NCT02978755|EXPERIMENTAL|GM102 recommended dose|3 parallel cohorts in sex cord stromal, epithelial ovarian and cervix cancers
62608385|NCT00265525|EXPERIMENTAL|Cardio fit|
62608386|NCT00265525|NO_INTERVENTION|Usual Care|
62608387|NCT04742166|EXPERIMENTAL|Side to side gastrojejunal reconstruction|"The post-operative care: usual practise Follow-up: 90 days postoperatively~At Day 90:~* a blood test for albumin and prealbumin~* a GIQLI questionnaire (quality of life score) to be completed by the patient"
62608388|NCT04742166|ACTIVE_COMPARATOR|Terminolateral gastrojejunal reconstruction|"The post-operative care: usual practise Follow-up: 90 days postoperatively~At Day 90:~* a blood test for albumin and prealbumin~* a GIQLI questionnaire (quality of life score) to be completed by the patient"
62608389|NCT01554176|EXPERIMENTAL|Filorexant 10 mg (Treatment Phase)|Treatment Phase: Participants in this group were administered filorexant 10 mg once daily at bedtime for 6 weeks.
62608390|NCT01554176|PLACEBO_COMPARATOR|Placebo (Treatment Phase)|Treatment Phase: Participants in this group were administered placebo once daily at bedtime for 6 weeks.
62440284|NCT02561312||Simple Transfusion|For simple transfusion, the volume of packed red blood cells (PRBC) to be transfused in the participant is 10-15 cc/kg. No normal saline exchange is required. All blood is transfused through a single lumen central venous line.
62440285|NCT03801096|EXPERIMENTAL|Narrative Based Therapuetic Assessment|
62440286|NCT03801096|ACTIVE_COMPARATOR|Health Education (HE)|
62440287|NCT05816733|EXPERIMENTAL|Dapagliflozin group|Patients who will be randomized to receive dapagliflozin following the Cox-Maze IV Procedure.
62440288|NCT05816733|PLACEBO_COMPARATOR|Placebo group|Patients who will be randomized to receive placebo following the Cox-Maze IV Procedure.
62440289|NCT06316271||Normotensive Group|BP less than or equal to 129/84 mmHg
62440290|NCT06316271||Prehypertensive Group|BP 130-139/85-89 mmHg
62440291|NCT06316271||Hypertensive Group|BP 140-150/90-100 mmHg
62608391|NCT01554176|EXPERIMENTAL|Filorexant 10 mg/Filorexant 10 mg (Run-out Phase)|Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered filorexant 10 mg once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
62608392|NCT01554176|PLACEBO_COMPARATOR|Filorexant 10 mg/Placebo (Run-out Phase)|Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
62608393|NCT01554176|PLACEBO_COMPARATOR|Placebo/Placebo (Run-out Phase)|Run-out Phase: Following completion of the 6-week Treatment Phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received placebo once daily during the Treatment Phase.
62608394|NCT02960555|EXPERIMENTAL|Treatment (isatuximab)|Patients receive isatuximab IV over 5 hours on day 1 of cycle 1, and over 3 hours thereafter on days 8, 15, and 22 of cycle 1, on days 1 and 15 of cycles 2-6, and on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity.
62830547|NCT05678881|EXPERIMENTAL|High dose RLS103|8 mg CBD inhaled dry powder
62830548|NCT05678881|PLACEBO_COMPARATOR|Placebo|placebo inhaled dry powder
62440292|NCT03815357||Children with IPD|Children with IPD will be referred for immunological evaluation. The protocol for immune work up will be the same but between centres there is variation in the age criteria for referral i.e. \>2 years in some, \>6 months in others.
62440293|NCT04921683|EXPERIMENTAL|Treatment LIFUP|LIFUP will be performed at the bedside using frameless stereotaxy. Specifically, the LIFUP transducer will be fit to the patient's head employing adjustable straps, and will be positioned over the patient's left temporal bone to minimize bone absorption and refraction. Accurate aiming will be ensured using the Brain Sight neuronavigation device, customized for tracking our LIFUP transducer. Following LIFUP, the patient will undergo a second EEG session, except for the EEG cap being fit to the patient's head prior to the LIFUP session so that, as soon as LIFUP administration is complete, the EEG paradigm can be promptly administered. The patient will then be allowed to rest (\~1h).The patient will then be administered a second dose of tracer in order to undergo a second PET measurement. Finally, at the end-of-day, the clinical coordinator will collect an Adverse Event Questionnaire and will fit the PSG device for night monitoring.
62608395|NCT05191459||Heart failure and preserved ejection fraction|42 patients 50-90 years with preserved ejection fraction (EF ≥50%)
62608396|NCT05191459||Heart failure and reduced ejection fraction|42 patients 50-90 years with reduced ejection fraction ((EF≤40%)
62608397|NCT01185262|EXPERIMENTAL|Lenalidomida, Rituximab|Phase I: Lenalidomide will be administered from day 1 to 21 of 28 days cycles, escalating doses (from 2,5mg to 25 mg).Rituximab dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).
62830549|NCT05678881|EXPERIMENTAL|Low dose RLS103|4 mg CBD inhaled dry powder (open label)
62830550|NCT05607381|EXPERIMENTAL|Mindfulness|A well-validated mindfulness meditation-based therapy \[8 sessions\] is used to teach patients to independently practice meditation to cope with pain.
62830551|NCT05607381|EXPERIMENTAL|Meditation|A validated meditation-based therapy \[8 sessions\] is used to teach patients to independently practice meditation to cope with pain.
62830552|NCT05607381|ACTIVE_COMPARATOR|Usual Care|Patients will receive usual medical care for chronic low back pain.
62830553|NCT06228170|EXPERIMENTAL|The observation group|"The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Based on the invention above, the patients in the observation group were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)"
62830554|NCT06228170|ACTIVE_COMPARATOR|The control group|The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
62440294|NCT02268513||MASALA study|"Mediators of Atherosclerosis in South Asians Living in America (MASALA) study participants will be invited to participate in this ancillary study.~Objective of MASALA study:~The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study is investigating the prevalence, correlates, and outcomes associated with subclinical CVD in a population-based sample of South Asian men and women age 40-79 years at 2 US clinical field centers."
62830555|NCT00993577|EXPERIMENTAL|Exercises|Global Postural Reeducation Static Stretching Exercises
62830556|NCT01486407||Intravenous (IV) drug delivery|patients on whom intravenous vascular access has been established for the purpose of rapid sequence intubation drug delivery.
62830557|NCT01486407||Intraosseous (IO) drug delivery|Patients on whom intraosseous vascular access has been established for rapid sequence intubation drug delivery.
62830558|NCT02046577|EXPERIMENTAL|5600 IU Vitamin D3|Oral 5600 IU Vitamin D3 in liquid weekly during 6 months
62830559|NCT02046577|EXPERIMENTAL|Oral 11200 IU Vitamin D3 weekly|Oral 11200 IU Vitamin D3 in liquid weekly during 6 months
62830560|NCT02046577|PLACEBO_COMPARATOR|Placebo|Oral placebo in liquid weekly during 6 months
62440295|NCT02684500||aneurysmal subarachnoid hemorrhage|Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) using abdominal ultrasound in order to evaluate the potential additional risk of non-occlusive mesenteric ischemia (NOMI) and non occlusive bowel necrosis (NOBN) for a aneurysmal subarachnoid hemorrhage in subjects undergoing hypertensive therapy for cerebral vasospasm in SAH, to justify the withholding of enteral nutrition.
62440296|NCT01787214|ACTIVE_COMPARATOR|Full dose|full dose of walnuts (20% energy needs)
62440297|NCT01787214|ACTIVE_COMPARATOR|Half-dose|Half dose of walnuts (10% of energy needs)
62440298|NCT01787214|OTHER|Control|Walnut free meals
62440299|NCT00977964|EXPERIMENTAL|Milk Based Protein Formula Process A|
62440300|NCT00977964|EXPERIMENTAL|Milk Based Protein Formula Process B|
62440301|NCT00977964|EXPERIMENTAL|Milk Based Protein Formula Process C|
62440302|NCT00977964|EXPERIMENTAL|Milk Based Protein Formula Process D|
62830561|NCT06595134||Arm 1|Standard Care plus Fitnesstracker and Citizen App
62048267|NCT01445652|EXPERIMENTAL|nelfilcon A|Nelfilcon A contact lenses worn in both eyes on a daily disposable basis a minimum of five days per week, eight hours per day, for six months
62250540|NCT04533282||Acute IHD with STEMI and PCI|"Acute ischemia in IHD is represented by the recruitment of patients presenting with ST-elevation myocardial infarction (STEMI patients) to the Meilahti Cardiac Care Unit (CCU) and admitted for Percutaneous Coronary Intervention (PCI) revascularization. The informed consent and blood samples from these patients will be collected during the first 72 hours after PCI, during their stay either in CCU or medical ward.~Inclusion of this cohort to the IHD-EPITRAN opens the possibility to identify novel circulative epitranscriptomic biomarkers representing acute ischemic myocardial damage as well as particularly insightful comparison of acute and chronic states of IHD when compared against the second study cohort."
62830562|NCT06595134||Arm 2|Standard Care
62440303|NCT00977964|EXPERIMENTAL|Milk Based Protein Formula Process E|
62830563|NCT02946138|EXPERIMENTAL|carbon-ion radiotherapy with GM-CSF|Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gray(Gy) \[relative biological effectiveness (RBE)\] in 5 fractions for intrahepatic cases away from gastro-intestinal (GI) tract (\>1cm) with concurrent GM-CSF 125ug/m2/d, subcutaneous injection d1-28;
62440304|NCT00977964|EXPERIMENTAL|Milk Based Protein Formula Process F|
62048268|NCT01445652|ACTIVE_COMPARATOR|Spectacles|Spectacles per current prescription worn a minimum of five days per week, eight hours per day, for six months
62048269|NCT04365595||SARS-CoV-2 associated respiratory failure|Participants will receive a daily HrQoL questionnaire on their personal smartphone using the docdok health application during 3 months. A selection of participants will furthermore receive a custom-built home disease monitoring device during 1 month. Both procedures start at least 4 weeks after hospital discharge.
62440305|NCT05544851|EXPERIMENTAL|Educated Reproductive Women|"Inclusion Criteria / Patient~Women of reproductive age (range 18-49 years) No history of STD, literate, Ability to understand and answer questions Those who have not received training on STDs before,~Exclusion Criteria from Research~Getting training on STDs before Absence from education for at least two sessions, Women with a history of STD (HIV, HPV, etc.) disease will be excluded from the study."
62440306|NCT05544851|EXPERIMENTAL|Non-Educated Reproductive Women|"Inclusion Criteria / Patient~Women of reproductive age (range 18-49 years) No history of STD, literate, Ability to understand and answer questions Those who have not received training on STDs before,~Exclusion Criteria from Research~Getting training on STDs before Absence from education for at least two sessions, Women with a history of STD (HIV, HPV, etc.) disease will be excluded from the study."
62048270|NCT00979979||HCV patients|HCV patients with detectable viremia; all sera are tested both by Abbott RealTime HCV genotype II test and by direct HCV sequencing both at 5'UTR and NS5B
62048271|NCT00979979||Non-HCV patients|Patient without evidence of HCV infection (negative both for anti-HCV and HCV RNA); all sera are both tested by Abbott RealTime HCV genotype II test and by direct HCV sequencing at 5'UTR and NS5B
62440307|NCT01534975|ACTIVE_COMPARATOR|Iodixanol 320|"group 1 will receive iodixanol 320 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
62830564|NCT04252144|EXPERIMENTAL|GERD|Patients with verified gastroesophageal reflux disease
62048272|NCT02145221|EXPERIMENTAL|Music therapy|Music therapy post surgery
62440308|NCT01534975|ACTIVE_COMPARATOR|iohexol 350|"group 2 will receive iohexol 350 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
62830565|NCT04252144|OTHER|Contol|Mostly healthy subjects who have no symptoms and other manifestations of gastroesophageal reflux disease by complex examination
62830566|NCT00389259|EXPERIMENTAL|A|IV Scopolamine 0.25mg in adults and 0.006mg/kg in children Q4h
62830567|NCT00389259|PLACEBO_COMPARATOR|B|IV Look alike drug Q 4h
62830568|NCT01352793|EXPERIMENTAL|rLP2086 vaccine|rLP2086 vaccine
62830569|NCT01352793|OTHER|control|The control treatment will be HAVRIX vaccine at month 0 and 6 and a normal saline injection at month 2.
62830570|NCT04894266|OTHER|Standard of Care|All subjects will receive SOC during their hospital admission. This will include daily vital signs, WHO Ordinal Scale assessment and adverse events. On Days 3, 5, 7 and 11, hematology, chemistry, oropharyngeal or nasopharyngeal swabs for Covid-19 viral levels and biomarkers samples the same as at the screening visit will be taken if the patient remains in hospital.
62830571|NCT04894266|EXPERIMENTAL|Standard of Care plus apabetalone|All subjects will receive SOC during their hospital admission. This will include daily vital signs, WHO Ordinal Scale assessment and adverse events. On Days 3, 5, 7 and 11, hematology, chemistry, oropharyngeal or nasopharyngeal swabs for Covid-19 viral levels and biomarkers samples the same as at the screening visit will be taken if the patient remains in hospital. For the apabetalone cohort, treatment will be administered BID with meals.
62830572|NCT03223896|ACTIVE_COMPARATOR|Group A|max 8 mg/per day naloxone nasal spray
62830573|NCT03223896|ACTIVE_COMPARATOR|Group B|max 16 mg/per day naloxone nasal spray
62830574|NCT01345617||cystic fibrosis patients|cystic fibrosis patients
62048273|NCT02145221|NO_INTERVENTION|No intervention|
62048274|NCT03084666|EXPERIMENTAL|Treatment Group|The treatment will receive 200 mmHg of pressure from a Zimmer automatic tourniquet system (ATS) for three 5 minute intervals.
62440309|NCT01534975|ACTIVE_COMPARATOR|iopamidol 370|"group 3 will receive iopamidol 370 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
62440310|NCT01534975|ACTIVE_COMPARATOR|iodixanol 270|"group 4 will receive iodixanol 270 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
62830575|NCT01345617||non-cystic fibrosis patients|non-cystic fibrosis patients
62830576|NCT01440894||Body Analysis|
62830577|NCT02826070|OTHER|Off-treatment|Patients who had stopped treatment during EFFORT extension study could receive 2-year off-treatment follow-up. All the patients in Part I will be followed up at the interval of 12 weeks. For these patients, if they have hepatitis flare during follow-up, they will be re-treated with telbivudine combined with adefovir for the left study period ( the total study period is 2 years) and followed up at the interval of 12 weeks. Hepatitis flare is defined as HBV DNA\>4 Log10 copies/mL with either ALT≥5 times upper limit of normal (ULN) or TBIL≥2×ULN，or 2 ≤ALT ≤5 ×ULN (at two consecutive visits at least 2 weeks apart) and total bilirubin (TBIL) \<2×ULN.
62830578|NCT02826070|OTHER|On-treatment|Patients with continuous treatment during EFFORT extension study will continue treatment, without off-treatment rule in the further extension study. The treatment strategy is depended on the HBV DNA level of each individual, that is, for patients with negative HBV DNA level (defined as HBV DNA \<20 IU/mL) will continue their previous treatment strategy; and for patients with positive HBV DNA level (defined as HBV DNA\>=20 IU/mL) will receive the combination therapy of telbivudine and adefovir, irrespective of their previous treatment strategy. All the patients in Part II will be followed up at the interval of 24 weeks until they complete the 2-year on-treatment follow-up. Patients will be conducted liver biopsy at the sixth year of treatment. All the patients with telbivudine monotherapy will be switched to telbivudine plus adefovir once confirmed HBV DNA breakthrough developed.
62830579|NCT06303388|EXPERIMENTAL|Egoscue Exercise|"• The Egoscue exercise comprise of 10 exercises which Included~1. Static back alone and with breathing.~2. Abdominal contraction while in the static back position.~3. abductor press~4. overhead extension~5. elbow curls on a wall~6. static wall~7. upper spinal twist 8 pelvic tilts~9.supine groin progressive 10.air bench exercises."
62830580|NCT06303388|ACTIVE_COMPARATOR|Bruegger's Exercise|"steps include in Breugger's Exercise~1. Sit with your buttocks at the edge of a chair.~2. Spread your legs apart slightly.~3. Turn your toes out slightly.~4. Rest your weight on your legs/feet \& relax your abdominal muscles.~5. Tilt your pelvis forward (i.e. arch your lower back) while lifting your chest up~6. Rotate your arms outward while turning your palms up.~7. Hold your head high in the air, with a slight arch in the neck. The patient is to slowly exhale by breathing out through their lips while actively externally rotating their arms and spreading their fingers. The patient is to perform this exercise once or twice every 20-30 minutes of prolonged sitting and held in this position for 30-60 seconds"
62830581|NCT00424710|OTHER|Single Arm study|"Single arm study:~Drug: ranibizumab intravitreal injection liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year"
62830582|NCT02293694|ACTIVE_COMPARATOR|self-injection|Women randomized to this arm will be trained to self-inject Sayana Press at home every three months
62830583|NCT02293694|ACTIVE_COMPARATOR|provider injection|Women randomized to this arm will received Sayana press from a family planning provider every three months.
62048275|NCT03084666|EXPERIMENTAL|Control Group|Our control group will receive 20 mmHg of pressure from a Zimmer automatic tourniquet system (ATS) for three 5 minute intervals.
62048276|NCT05128643|EXPERIMENTAL|Population Ⅰ|At 0,1,6 months, 3 doses of experimental vaccine were injected into the deltoid muscle of the upper arm.
62048277|NCT05128643|EXPERIMENTAL|Population II|At 0,1,4 months, 3 doses of experimental vaccine were injected into the deltoid muscle of the upper arm.
62048278|NCT02009670|EXPERIMENTAL|13C inulin|13C inulin combined with an inulin load are administered orally
62048279|NCT02009670|PLACEBO_COMPARATOR|Placebo|A placebo is administered orally
62048280|NCT06517667|EXPERIMENTAL|Cross-linked hyaluronic acid|Tear substitute based on 0.20% Cross-linked hyaluronic acid
62440311|NCT00772577|EXPERIMENTAL|1|Aliskiren Hydrochlorothiazide(HCTZ)
62440312|NCT00772577|ACTIVE_COMPARATOR|2|Ramipril
62830584|NCT05510388|EXPERIMENTAL|High-flow nasal cannula oxygenation group|
62830585|NCT05510388|ACTIVE_COMPARATOR|Regular nasal cannula oxygenation group|
62048281|NCT06517667|ACTIVE_COMPARATOR|Hyaluronic acid|Tear substitute based on 0.15% Cross-linked hyaluronic acid
62048282|NCT03824379|EXPERIMENTAL|Magnesium arm|30 patients will receive the standard therapy (anti-diabetic ) + magnesium supplement
62048283|NCT03824379|ACTIVE_COMPARATOR|Control|30 patients will receive the standard therapy (anti-diabetic)
62440313|NCT04822662|EXPERIMENTAL|Experimental Group: Epilepsy education program|The training prepared for epilepsy will be held in 3 main modules and 5 sessions with two weeks intervals. Each session will last 25 minutes. Trainings will be given to adolescents and their parents online.
62250541|NCT04533282||Chronic IHD and elective CABG|"The second study cohort composes of patients with stable IHD phenotype with angina pectoris or exertional dyspnea provoked by either moderate or severe physical exertion, corresponding either NYHA or CCS classes II to IV, respectively, destined to undergo an elective coronary artery bypass grafting (CABG) operation as method for revascularization. The duration of stable symptoms must exceed a month in order to exclude acute events.~The obtained blood samples from this main cohort of the IHD-EPITRAN project provides insightful overview into the circulation-borne RNAs' epitranscriptomic landscape for identification of novel biomarkers for stable IHD. Furthermore, availability of right atrial appendage tissue pieces following CABG surgery from this patient cohort gives invaluable organ-specific information in its own right as well as a crucial reference point, against of which the alterations observed in circulation can be compared."
62250542|NCT04533282||Elective aortic valve stenosis (AVS) replacement therapy|"The third study cohort consists of patients admitted for surgical (open heart surgery) valve replacement due to aortic valve calcification and critical stenosis with no IHD as a comorbidity. As to elective CABG patients, here patients are also required to be either moderately or severely symptomatic equaling NYHA or CCS II to IV classes, respectively.~This cohort will provide insights into how the pathological pressure overloaded left ventricular remodelling is reflected to the epitranscriptomes of the supposedly relatively spared right atrial appendage tissue and blood RNA. Comparison of this data to the data of the first two IHD study cohorts opens the window to assess the possible differences for these differing pathologies, thus functioning as an active control cohort."
62440314|NCT04822662|NO_INTERVENTION|Control Group|The control group will receive standard epilepsy treatment without any training intervention. The group did not receive any other intervention.
62830586|NCT05972980||Non-COVID-19 cohort|"Patients with Ventilator Acquired Pneumonia without COVID-19.~The patients belonging to the NON-COVID cohort were admitted to three intensive care units at Molinette Hospital (Turin, Italy):~* General Intensive Care Unit - admitting primarily medically critical patients and a smaller proportion of surgical patients, originating from the Hospital's Emergency Department or other Intensive Care Units in Piedmont. It serves as the regional referral center for Extracorporeal Membrane Oxygenation (ECMO).~* Emergency Department - Intensive Care Unit (PSAR) - admitting both medical and surgical patients in urgent conditions.~* Cardiac - Intensive Care Unit- admitting patients undergoing elective or emergency cardio-surgical interventions, and serving as a referral center for heart and lung transplants and the implantation of external ventricular assists."
62440315|NCT04579328|EXPERIMENTAL|Lessons with Growth Mats|Participants, clustered by neighbor groups, will be given lessons on stunting. During the lessons the trainers will use the growth mats to demonstrate their points. In these villages, village-wide events will expose the full community to the messages in combination to the mats.
62440316|NCT04579328|NO_INTERVENTION|Lessons without Mats|Participants, clustered by neighbor groups, will be given lessons on stunting without the aid of the growth mats. In these villages, village-wide events will expose the full community to the messages without the aid of the mats.
62440317|NCT01945099|ACTIVE_COMPARATOR|ePID closed loop system without hyaluronidase|Hyaluronidase will not be given while subject uses ePID closed loop system
62830587|NCT05972980||COVID-19 cohort|"Patients with Ventilator Acquired Pneumonia with COVID-19. Confirmation of pneumonia was achieved by using the Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) technique on a sample collected from the lower respiratory tract.~The COVID-19 cohort consists of patients admitted at the Città della Salute e della Scienza University Hospital (Turin, Italy) in two intensive care units at Molinette Hospital, dedicated to treating critically ill patients with COVID-19."
62830588|NCT01540552||Budesonide Arm|Retrospective Medical Chart Review of low dose CT scans for participants who received Budesonide.
62830589|NCT01540552||Placebo Arm|Retrospective Medical Chart Review of low dose CT scans for participants who received Placebo.
62830590|NCT02135432|EXPERIMENTAL|Ivacaftor (VX-770)|twice a day administration of Ivacaftor: 150mg
62440318|NCT01945099|EXPERIMENTAL|ePID closed loop system with hyaluronidase at infusion site|Hyaluronidase will be injected at insulin pump infusion site prior to the time that subject uses ePID closed loop system
62440319|NCT01945099|EXPERIMENTAL|ePID closed loop system with hyaluronidase co-formulation|Hyaluronidase-insulin co-formulation will be used in study pump while subject uses ePID closed loop system
62830591|NCT02135432|PLACEBO_COMPARATOR|Placebo|matching placebo
62440320|NCT04749524||Newborns|Newborns from NICU or well-baby nursery.
62440321|NCT04749524||Newborn Hearing Screening Results|Newborns identified as having difficulty passing newborn hearing screening.
62440322|NCT04749524||Adults with Normal Hearing|Adults with normal hearing thresholds.
62440323|NCT04749524||Participants with Neural Hearing Loss|Participants, children and adults, with neural hearing loss.
62440324|NCT03035227|ACTIVE_COMPARATOR|Catheter Ablation|Catheter ablation procedure of atrial and/or ventricular arrhythmias.
62440325|NCT03035227|ACTIVE_COMPARATOR|Medical Therapy|Medical management using antiarrhythmic drugs per standard of care of treating physician.
62830592|NCT05254535|OTHER|Intervention|Up to 10 rural health systems will be participating in I-SITE implementation with cluster-randomization of the order of initiation for the intervention. All sites will receive usual care teleophthalmology prior to I-SITE implementation.
62830593|NCT00783068|ACTIVE_COMPARATOR|GTS-21|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0).
62830594|NCT00783068|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
62830595|NCT06653114|EXPERIMENTAL|Chronic Musculoskeletal Pain + Communication skills|Participants will complete both parts of the educational program (assessment and management of chronic musculoskeletal pain and development of communication skills).
62830596|NCT06653114|EXPERIMENTAL|Chronic Musculoskeletal Pain|Participants will complete only the management of chronic musculoskeletal pain portion of the educational program.
62830597|NCT04906564||Moyamoya disease patients|"Moyamoya disease patients' inclusion Criteria:~1. Written informed consent is obtained; 2. Patients with age between 4-60 years; 3. Cerebral digital subtraction contrast angiography (DSA) reveal severe stenosis or occlusion of the distal internal carotid or proximal middle and anterior cerebral arteries with prominent lenticulostriate 'moyamoya collaterals'.~Exclusion Criteria:~1. There are other vascular diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy; 2. Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement; 3. Physical or subjective failure to cooperate with the examination or serious comorbid diseases."
62830598|NCT06566456|EXPERIMENTAL|The puncture site is within 2-4 cm above the second wrist transverse crease|The ultrasound-guided radial artery puncture site is within 2-4 cm above the second wrist transverse crease, where the clearest radial artery image can be obtained.
62830599|NCT06566456|ACTIVE_COMPARATOR|The puncture site is within 0-1.9 cm above the second wrist transverse crease|The ultrasound-guided radial artery puncture site is within 0-1.9 cm above the second wrist transverse crease, where the clearest radial artery image can be obtained.
62830600|NCT01213680|ACTIVE_COMPARATOR|1000 mg iron isomaltoside as intravenous infusion|
62830601|NCT01213680|ACTIVE_COMPARATOR|500 mg iron isomaltoside 1000 as bolus injection|
62830602|NCT05760040|EXPERIMENTAL|Virtual Reality (VR)|During the intrauterine device application, 40 women who were included in the virtual reality group will be put on virtual reality glasses and watched the video.
62250543|NCT04533282||IHD-negative healthy controls verified by coronary CT|The fourth study cohort shall consist of patients referred to Meilahti Heart Unit's Coronary Artery Computerised Tomography (CT) Angiogram imaging in order to investigate the possibility of atherosclerotic coronary artery disease (i.e. IHD) behind symptoms such as pressing chest pain (i.e. angina pectoris) or abnormal dyspnea provoked by exertion. Based on the results from CT angiogram, only those patients' blood samples are selected for further study that show negative results for IHD (no visualisation of either atherosclerotic strands or plaques in coronary arteries). This patient cohort functions as a critical IHD-healthy control group in the IHD-EPITRAN project (i.e. negative control).
62250544|NCT03453073||chocolate consumption level referent|women who ate 1 oz. (28.35 g) of chocolate \<1 time/month
62830603|NCT05760040|EXPERIMENTAL|Control group|Routine hospital protocol will be applied to 40 women included in the control group while intrauterine device application is being made.
62830604|NCT01049022|EXPERIMENTAL|Moxifloxacin (Avelox, BAY12-8039), Cohort 1|
62830605|NCT01049022|EXPERIMENTAL|Moxifloxacin (Avelox, BAY12-8039), Cohort 2|
62830606|NCT01049022|EXPERIMENTAL|Moxifloxacin (Avelox, BAY12-8039), Cohort 3|
62830607|NCT04438265||quadratus lumborum|analgesic technique. The evaluation of the patient will consist of 2 stages. The first of these will consist of the evaluation consultation (clinical history, EVN evaluation, WOMAC) and initial treatment (QL2 block). In the second stage, the patient will be followed up with interviews at 3 weeks, 3 and 6 months.
62830608|NCT04438265||Control|Current analgesia , no QL block apply
62830609|NCT02772458|EXPERIMENTAL|Crohn's Disease|Active Crohn's Disease
62830610|NCT02772458|EXPERIMENTAL|Healthy|Healthy volunteers
62250545|NCT03453073||chocolate consumption level 2|women who ate 1 oz. (28.35 g) of chocolate between 1 and \<1.5 times/month
62830611|NCT03763084|EXPERIMENTAL|acetaminophen|For patients randomized to OVA group, OVA 500mg was given every 8 hours for the first 48 hours postoperatively. Numeric Pain Rating Scale pain score is assessed every 15 minutes during the 1 hour of ICU stay and when needed.
62250546|NCT03453073||chocolate consumption level 3|women who ate 1 oz. (28.35 g) of chocolate between 1.5 and \<3.5 times/month,
62250547|NCT03453073||chocolate consumption level 4|women who ate 1 oz. (28.35 g) of chocolate between 3.5 times/month and \<3 times/week
62830612|NCT03763084|ACTIVE_COMPARATOR|Sufentanil|Sufentanil injection 500μg /10ml in normal saline, total volume 50 ml.Constant infusion dosage is 0.05μg/kg/h. Numeric Pain Rating Scale pain score is assessed every 15 minutes during the 1 hour of ICU stay and when needed.
62830613|NCT00646048|EXPERIMENTAL|Arm 1|This arm is for patient that receive the TriVascular Stent-Graft System.
62830614|NCT02578147|EXPERIMENTAL|Mighty Girls|Girls in this group complete 3 different activities after school: 6 classroom sessions, 4 DRAMA-RAMA game play sessions, and 4 short game experience surveys. Classroom sessions are 1 hour long, 3 days a week for 2 weeks. Topics include: goal setting, choices and their effects; defining what makes a behavior risky; learning how to not get talked into doing risky things by friends (e.g., going to a party at a house where parents are not home); and learning to be critical of TV shows and other media that make it seem like lots of teens are having sex. These sessions teach girls skills and strategies that help them score game points in DRAMA-RAMA. These are important skills and strategies that they can use in everyday life to make wise choices. Classroom sessions are designed to be fun.
62250548|NCT03453073||chocolate consumption level 5|women who ate 1 oz. (28.35 g) of chocolate \>3 times/week
62250549|NCT03453073||No physician diagnosis|No incidence of serious chronic disease prior to visit 3
62048284|NCT01342224|EXPERIMENTAL|tadalafil and vaccination|Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV). This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine.
62608398|NCT05143008|EXPERIMENTAL|SMART Intervention|Counseling sessions will be completed with a toolbox approach so that clinicians can work on topics that are of interest and relevant to each participant. SMART will focus on weight, physical activity, eating and psychosocial issues. Intervention goals will emphasize adherence to healthy behaviors rather than absolute weight goals. Specifically, women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.
62608399|NCT04939753||Sevoflurane group|Patients that received sevoflurane while in ICU care.
62830615|NCT02578147|ACTIVE_COMPARATOR|Game Girls|Girls in this group take part in activities that can be done from home or anywhere they have Wi-Fi access: 4 Science Valley game play sessions and 4 short game experience surveys. Science Valley is a web based game in which girls explore a virtual world and experiment with objects in this world using a computer, tablet or cell phone. Girls will play this game for about 20-30 minutes. There are no classroom sessions required to be able to play Science Valley. Science Valley is designed to be fun and to give girls a chance to build skills important to doing well in school: her problem solving and critical thinking skills. Girls will be given a link to use to access Science Valley on the internet. At the end of the game, they do a short game experience survey that asks questions about how easy, how hard, how fun etc. it was to play Science Valley. This survey will appear on the screen at the end of the Science Valley game play session.
62830616|NCT02987712|NO_INTERVENTION|Survey 1|Common practice
62830617|NCT02987712|EXPERIMENTAL|Survey 2|Thromboelastography based protocol
62250550|NCT03453073||Physician diagnosis|Incidence of serious chronic disease prior to visit 3
62250551|NCT03453073||Younger|Age\<65 years at follow-up baseline
62250552|NCT03453073||Older|Age\>=65 years at follow-up baseline
62440326|NCT05383274|EXPERIMENTAL|Optilume Urethral DCB|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
62608400|NCT06658886||Paraffin treatment group|Patients with carpal tunnel syndrome who have received paraffin therapy
62830618|NCT05836506|EXPERIMENTAL|Part 1: Sequence A|In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 1 after a high fat meal. Participants will be followed up for 30 days.
62830619|NCT05836506|EXPERIMENTAL|Part 1: Sequence B|In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Participants will be followed up for 30 days.
62830620|NCT05836506|EXPERIMENTAL|Part 2: Sequence A|In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 2 after a high fat meal. Participants will be followed up for 30 days.
62048285|NCT02889133|ACTIVE_COMPARATOR|Iron repletion|Subjects will donate blood donation and undergo 24-hour PTR and receive IV iron-dextran. After 5 months, subjects will donate blood again, receive IV saline and undergo 24-hour PTR.
62250553|NCT00307333|EXPERIMENTAL|1|Very low birth weight infants with their HRC index continuously displayed. Clinicians can utilize the HRC score to develop treatment plan.
62250554|NCT00307333|NO_INTERVENTION|2|Very low birth weight infants for whom the HRC index is not displayed. Infants receive standard of care treatment.
62250555|NCT00454857||Patients with ITP|Participants with ITP and currently treated for ITP were followed prospectively for a period of 12 months.
62250556|NCT03364361|OTHER|Acupuncture|Feasibility Study
62250557|NCT00224094|EXPERIMENTAL|Sequence A|Oral ERT then transdermal ERT
62250558|NCT00224094|EXPERIMENTAL|Sequence B|Transdermal ERT then oral ERT
62440327|NCT00919958|EXPERIMENTAL|PLX-PAD low dose|
62440328|NCT00919958|EXPERIMENTAL|PLX-PAD intermediate dose|
62608401|NCT06658886||Injection group|Patients with carpal tunnel syndrome who have applied ultrasound-guided steroid injection
62608402|NCT02959515|ACTIVE_COMPARATOR|Capnothorax|Capnothorax is obtained by the insufflation of CO2in the right pleural cavity and maintained at a preset pressure of 10 mmHg .Arterial and central venous blood gasanalyses, hemodynamic and respiratory variables will be recorded.
62608403|NCT02959515|ACTIVE_COMPARATOR|Capnothorax and CPAP|Capnothorax is obtained by the insufflation of CO2in the right pleural cavity and maintained at a preset pressure of 10 mmHg. CPAP on the non ventilated lung is set at 10 cm H2O and FiO2=1. Arterial and central venous blood gasanalyses, hemodynamic and respiratory variables will be recorded.
62048286|NCT02889133|PLACEBO_COMPARATOR|Placebo|Subjects will donate blood donation and undergo 24-hour PTR and receive IV saline. After 5 months, subjects will donate blood again, receive IV iron-dextran and undergo 24-hour PTR.
62250559|NCT03306082|EXPERIMENTAL|Image-guided Cochlear Implant Programming (IGCIP)|Cochlear implant programming using IGCIP.
62250560|NCT04195048||Cancer patients with acute ischemic stroke|Eighty patients previously or currently suffering from manifest cancer on or not on cancer treatment who developed stroke
62250561|NCT04195048||Control patients with acute ischemic stroke without cancer|Eighty patients with acute ischemic stroke without cancer
62250562|NCT03821818||Control|Food Allergen Elimination only
62440329|NCT00919958|EXPERIMENTAL|PLX-PAD high dose|
62440330|NCT01692158|EXPERIMENTAL|Teste|Enoxalow (Heparin, Low-Molecular-Weight) - Blau Farmacêutica S/A.
62608404|NCT06671587|EXPERIMENTAL|iGlarLixi (insulin glargine/lixisenatide)|Participants will receive iGlarLixi once daily for 20 weeks. iGlarLixi is to be initiated with the starting daily dose of 5-10 dose steps on Visit 4 (Day 1) and will be titrated according to fasting SMBG to achieve glycemic target of ≥80 and ≤110 mg/dL.
62608405|NCT06671587|ACTIVE_COMPARATOR|Gla-100 (insulin glargine)|Participants will receive Gla-100 once daily for 20 weeks. Gla-100 is to be initiated with the starting daily dose of 5-10 U on Visit 4 (Day 1) and will be titrated according to fasting SMBG to achieve and maintain same glycemic target of ≥80 and ≤110 mg/dL.
62830621|NCT05836506|EXPERIMENTAL|Part 2: Sequence B|In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Participants will be followed up for 30 days.
62830622|NCT00986765|EXPERIMENTAL|Lovenox® , 4000 UI/day (+ Aspegic®)|Lovenox® (enoxaparin), 4000 UI/day (+ Aspegic® (Aspirin), 100 mg)
62440331|NCT01692158|ACTIVE_COMPARATOR|Comparador|Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis
62608406|NCT04662255|EXPERIMENTAL|Arm A (Pirtobrutinib)|Orally
62608407|NCT04662255|ACTIVE_COMPARATOR|Arm B (Ibrutinib, Acalabrutinib, or Zanubrutinib)|Investigator's choice (based on local availability) of ibrutinib, acalabrutinib or zanubrutinib orally. Options are limited to those that are available/approved in the specific country.
62608408|NCT00775554|OTHER|traditional hematoma block|people will receive traditional hematoma block for closed forearm fractures
62830623|NCT00986765|ACTIVE_COMPARATOR|Aspegic ®, 100 mg/day|Aspegic® (Aspirin),100 mg/day
62830624|NCT01094119|ACTIVE_COMPARATOR|Bair Hugger heated blanket|Patients will be warmed during surgery with the Bair Hugger heated blanket.
62830625|NCT01094119|ACTIVE_COMPARATOR|LMA PerfecTemp system|Patients will be warmed during surgery with the PerfecTemp heated pad .
62608409|NCT00775554|OTHER|ultrasound guided hematoma block|pts. will receive a hematoma block using bedside ultrasound to guide the placement
62608410|NCT01890213|EXPERIMENTAL|Vaccine|AVX701 Vaccine:4 x 10EE8 IU intramuscularly every 3 weeks for 4 total immunizations
62608411|NCT01941836|EXPERIMENTAL|ETC-1002 120 mg/day|Orally, once daily in morning as capsules
62830626|NCT02177032|EXPERIMENTAL|4-sites, 1-week without HRIG|"PCEC rabies vaccine, administered ID according to the 4-sites, 1-week regimen"
62830627|NCT02177032|EXPERIMENTAL|4-sites, 1-week with HRIG|"PCEC rabies vaccine, administered ID to adults, according to the 4-sites, 1-week regimen plus HRIG"
62830628|NCT02177032|ACTIVE_COMPARATOR|2-sites, TRC without HRIG|"PCEC rabies vaccine, administered ID according to the 2-sites, TRC regimen"
62830629|NCT02177032|ACTIVE_COMPARATOR|2-sites, TRC with HRIG|"PCEC rabies vaccine, administered ID to adults , according to the 2-sites, TRC regimen plus HRIG"
62830630|NCT04199806|OTHER|Questionnaire Review|
62830631|NCT05100550|EXPERIMENTAL|Intervention|"This group will receive~1. Health education regarding nutrition in pregnancy (including the importance of micronutrients, recognizing malnutrition, practicing breastfeeding)~2. Screening of Low birth weight risk~3. Zinc Supplementation 20 mg/daily from gestation week for 12 weeks, followed by 12 weeks of supplementation on the third day postpartum."
62830632|NCT05100550|ACTIVE_COMPARATOR|Control|Standard antenatal care for third trimester will be applied without supplementation of zinc
62830633|NCT03469037|EXPERIMENTAL|Oxygen first|Optiflow with an inspired fraction of oxygen of 100% in the first seance Optiflow with an inspired fraction of oxygen of 21 % in the second seance
62608412|NCT01941836|EXPERIMENTAL|ETC-1002 180 mg/day|Orally, once daily in morning as capsules
62830634|NCT03469037|EXPERIMENTAL|Air first|Optiflow with an inspired fraction of oxygen of 21 % in the first seance Optiflow with an inspired fraction of oxygen of 100 % in the second seance
62440332|NCT03054025|EXPERIMENTAL|Supportive care (smart phone application)|Participants download the physical activity readiness smart phone application onto their personal smartphone and receive training on how to use the app which includes animated video clips, tailored email reminders, and feedback on progress for 3 weeks.
62440333|NCT02243020|EXPERIMENTAL|Vagus Nerve Stimulation (VNS) + Rehabilitation (1)|This group receives vagus nerve stimulation during rehabilitation. VNS and rehabilitation are the interventions.
62440334|NCT02243020|ACTIVE_COMPARATOR|Vagus Nerve Stim (VNS) + Rehabilitation (2) - Comparator|This group receives rehabilitation and VNS, but the VNS is different than given in the other group (rehabilitation is the only true intervention in this group). It may not be as effective as the other group's settings. Both groups receive the same amount of rehabilitation.
62440335|NCT00773877||1|Primary open angle glaucoma
62440336|NCT00773877||2|Normal Controls
62608413|NCT01941836|ACTIVE_COMPARATOR|ezetimibe 10mg/day|Orally, once daily in morning as capsules
62830635|NCT06589076||Case Group (AP+):|This group consists of participants who have apical periodontitis (AP), an oral inflammatory condition. These participants are diagnosed with AP based on radiographic evidence. They may exhibit symptoms of AP, but AP is often asymptomatic, so radiographic confirmation is key.
62440337|NCT03414164|EXPERIMENTAL|procyanidine group|
62830636|NCT06589076||Control Group (AP-):|This group consists of participants who do not have apical periodontitis (AP). These participants are healthy individuals with no clinical or radiographic signs of apical periodontitis. They will be matched with the case group based on age, gender, and other relevant characteristics, but they will not have any dental lesions related to apical periodontitis.
62830637|NCT04552652|EXPERIMENTAL|High-intensity interval training - telerehabilitation|12 weeks of high-intensity interval training. Three sessions per week will be performed (36 total sessions).
62830638|NCT04552652|ACTIVE_COMPARATOR|Moderate-intensity continuous training - telerehabilitation|12 weeks of moderate-intensity continuous training. Three sessions per week will be performed (36 total sessions).
62440338|NCT03414164|NO_INTERVENTION|control group|
62830639|NCT04111380|EXPERIMENTAL|Nab-paclitaxel and Cisplatin|cisplatin and nab-paclitaxel: Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.
62830640|NCT06029348|EXPERIMENTAL|Paced Auditory Serial Addition Task|For the Paced Auditory Serial Addition Task, volunteers are presented with single digit numbers (1-9), and are instructed to add any given number to the previously presented number, and call out the answer. Volunteers are told that their performance is being monitored by research assistants. Volunteers are provided with a signaling device that they can use to discontinue testing. Lastly, participants will be asked to complete brief questionnaires to assess their levels of experienced threat, challenge, valence, arousal, and sense of control.
62830641|NCT02353208|ACTIVE_COMPARATOR|Sham Feeding of Bacon Bits|"In addition to the standard procedure, subjects will be asked to perform sham feeding on two occasions: 1) Immediately after having swallowed the capsule and 2) One hour after having swallowed the capsule.~Sham feeding will be performed as follows: The patients will be asked to chew 10 times on a piece of bacon over a period of 30 seconds, prior to spitting saliva and bacon into a container. This will be repeated 10 times at one minute intervals.~The patient will then complete the capsule study as per the standard procedure.~Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada."
62830642|NCT02353208|PLACEBO_COMPARATOR|Placebo|The control group will not chew bacon bits while undergoing capsule endoscopy.
62830643|NCT02466893|OTHER|ADAPT Technique/Standard SR Group|
62830644|NCT02559284|EXPERIMENTAL|A - Experimental|Treatment Arm: 100 patients using Respimer® NetiFlow® solution as standard treatment for healing of nasal surgery wounds following an endoscopic ethmoidectomy as a postoperative care after ethmoid sinus surgery
62830645|NCT02559284|ACTIVE_COMPARATOR|B - Comparator|Control Arm: 100 patients using saline solution (0.9% NaCl) as standard treatment for healing of nasal surgery wounds following an endoscopic ethmoidectomy as a postoperative care after ethmoid sinus surgery
62830646|NCT03525795|EXPERIMENTAL|CPI-1205 Combination with ipilimumab|
62830647|NCT01582477|EXPERIMENTAL|EXPAREL 20 mL (undiluted)|20 mL (266 mg) undiluted EXPAREL with 133 mg infiltrated on each the right and left side of the abdomen.
62830648|NCT01582477|ACTIVE_COMPARATOR|EXPAREL 40 mL (diluted)|20 mL (266 mg) EXPAREL diluted with an equal volume of preservative-free 0.9% normal saline to a total of 40 mL and infiltrated equally to the right and left side of the abdomen.
62830649|NCT03740451|EXPERIMENTAL|Experimental group 1|Active mobilization of soft tissues
62830650|NCT03740451|EXPERIMENTAL|Experimental group 2|Passive mobilization
62830651|NCT03740451|NO_INTERVENTION|Control group|No intervention
62830652|NCT03817359|EXPERIMENTAL|Mix infusion using single TCI pump|participants receive total intravenous anesthesia with remifentanil-propofol mixture by single TCI pump infusion
62830653|NCT03817359|NO_INTERVENTION|Separate infusion using two TCI pumps|participants receive total intravenous anesthesia with remifentanil and propofol separately by two TCI pumps infusion
62830654|NCT04349267|EXPERIMENTAL|BMS-986315|
62830655|NCT04349267|EXPERIMENTAL|BMS-986315 + nivolumab|
62830656|NCT04349267|EXPERIMENTAL|BMS-986315 + cetuximab|
62830657|NCT02930863|ACTIVE_COMPARATOR|Control Non-Automated Group|Participants assigned to this group will receive the standard of care procedures for the monitoring and treatment of hypoxemia. Complete brief post-PACU stay survey.
62830658|NCT02930863|EXPERIMENTAL|Automated Prompt Group|Participants assigned to this group will utilize the automated verbal prompts to enable their ability to improve their current condition by following generated commands. Complete a questionnaire focused around their experience with the pulse oximetry software and its effects on the patient's satisfaction and experience.
62830659|NCT02930512||patients with idiopathic Parkinson's disease|
62830660|NCT06558643|EXPERIMENTAL|Cohort 1 Single Ascending Dose Regime A|MMV371 Long-acting injection (LAI) 112mg (0.5 ml) or Placebo for MMV371 Long-acting injection(0.5 ml)
62830661|NCT06558643|EXPERIMENTAL|Cohort 2 Single Ascending Dose Regime B|MMV371 Long-acting injection (LAI) 223mg (1.0 ml) or Placebo for MMV371 Long-acting injection (1.0 ml)
62440339|NCT04342403||Sarcoidosis|Patients with sarcoidosis willing to participate
62440340|NCT03720756|EXPERIMENTAL|Subjects WITH nickel-sensitivity|Subjects on nickel-free diet who have a positive patch-test result, indicating nickel-sensitivity.
62440341|NCT03720756|ACTIVE_COMPARATOR|Subjects WITHOUT nickel-sensitivity|Subjects on nickel-free diet who have a negative patch-test result, indicating they do NOT have nickel-sensitivity.
62440342|NCT02967198|EXPERIMENTAL|CT/US fusion|patients undergo routine conventional feasibility planning ultrasound, and clinical decision of percutaneous liver biopsy or RFA feasibility is made based on conventional planning ultrasound. Then additional planning ultrasound using CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging.
62440343|NCT03989960|EXPERIMENTAL|LISA+SNIPPV group|receives PS by the way of invasive surfactant administration technique and selects nasal synchronized intermittent positive pressure ventilation
62440344|NCT03989960|ACTIVE_COMPARATOR|InSurE group|receives intubation-surfactant- extubation technique and selects CPAP ventilation
62440345|NCT06544317|EXPERIMENTAL|training group|
62830662|NCT06558643|EXPERIMENTAL|Cohort 3 Single Ascending Dose Regime C|MMV371 Long-acting injection (LAI) 446mg (2.0 ml) or Placebo for MMV371 Long-acting injection (2.0 ml)
62830663|NCT02724891||Arm 1 paper form first|paper questionnaires first then web/smart phone questionnaires after a 2-week washout period
62830664|NCT02724891||Arm 2 web/smartphone form first|web/smart phone questionnaires first then paper questionnaires after a 2-week washout period
62830665|NCT04077099|EXPERIMENTAL|REGN5093|Monotherapy in dose escalation cohorts (phase 1) followed by an expansion phase (phase 2)
62830666|NCT04071717|EXPERIMENTAL|NIRS group|Participants with obesity, 12 sessions of NIRS feedback
62830667|NCT04071717|SHAM_COMPARATOR|Sham NIRS group|Participants with obesity, 12 sessions of sham NIRS feedback
62830668|NCT04071717|OTHER|Healthy control group|Healthy participants, 12 sessions of NIRS feedback
62830669|NCT06007950|NO_INTERVENTION|Ad-libitum eating duration|24 patients will be randomly assigned to the control group. Participants will be asked to continue usual eating duration. Participants will receive the standard care and heart-healthy nutrition education.
62830670|NCT06007950|EXPERIMENTAL|Time-restricted eating (TRE) duration|24 patients will be randomly assigned to the intervention group. Participants in this arm will be asked to limit the number of hours they eat in a day to 10 hours in addition to receiving the standard of care health and heart-healthy nutrition education.
62830671|NCT06474611|NO_INTERVENTION|Birth year = odd|No intervention, care as usual
62250563|NCT03821818||Allergen Elimination + Willis Exercise|Subjects will have food allergens eliminated and also perform Aerobic-surge, brief high intensity exercise \> 75% max HR), five times/day.
62250564|NCT04494139|ACTIVE_COMPARATOR|Canteen Only|Train canteen staff and implement canteen intervention in the canteen space: interventions targeting food quality and quantity, intervention targeting food choice at point of sale, interventions target improved supply, interventions targeting price and promotional material.
62250565|NCT04494139|EXPERIMENTAL|Behavioral and Canteen intervention|The behavioral intervention will be comprised of a combination of intensive education sessions and goal setting and monitoring based on a validated worksite curriculum tailored to local needs. The curriculum includes 24 sessions: 16 core weekly sessions during the first four months of the intervention followed by 8 weekly maintenance sessions (text messages). Each session will be facilitated by a nutritionist/dietitian and a peer educator; and will last one hour. Broadly, the curriculum covers the subject matters of importance of healthy weight, eating a healthy diet, increasing physical activity, stress management, and challenges of lifestyle changes. Participants will be encouraged to keep food and activity diaries throughout the course of the study. During the maintenance period, the focus will be on overcoming declines in motivation and on maintaining long-term healthy behaviors.
62250566|NCT04714528|ACTIVE_COMPARATOR|Physical Exercise Group|45 minutes of aerobic, high intensity group training, three times per week during a 12-week period.
62250567|NCT04714528|OTHER|Relaxation Group|45 minutes of relaxation therapy once per week for 12 weeks.
62250568|NCT00750971|EXPERIMENTAL|1|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation
62250569|NCT00750971|ACTIVE_COMPARATOR|2|Best currently available immunosuppressive/immunomodulatory therapy
62250570|NCT03496012|EXPERIMENTAL|BIIB111 High Dose|Participants will receive a single administration of high dose BIIB111 in one eye through sub-retinal injection after vitrectomy.
62440346|NCT06544317|NO_INTERVENTION|control group|
62830672|NCT06474611|EXPERIMENTAL|Birth year = even AND active on KP.org|Has an upcoming primary care visit, qualifies for lung cancer screening based on USPSTF criteria, receives an electronic letter via KP.org informing that they qualify for LCS and reminding to talk to PCP about LCS at next visit.
62830673|NCT06474611|EXPERIMENTAL|Birth year = even AND not active on KP.org|Has an upcoming primary care visit, qualifies for LCS based on USPSTF criteria, receives a mailed letter informing that they qualify for LCS and reminding to talk to provider about LCS at next visit.
62830674|NCT05163522|EXPERIMENTAL|Part 1 (SAD): Participants receiving VH4004280|
62830675|NCT05163522|PLACEBO_COMPARATOR|Part 1 (SAD): Participants receiving placebo|
62830676|NCT05163522|EXPERIMENTAL|Part 2 (MAD) Non Drug-Drug Interaction (DDI) cohort: Participants receiving VH4004280|
62830677|NCT05163522|PLACEBO_COMPARATOR|Part 2 (MAD) Non DDI cohort: Participants receiving placebo|
62250571|NCT03496012|EXPERIMENTAL|BIIB111 Low Dose|Participants will receive a single administration of low dose BIIB111 in one eye through sub-retinal injection after vitrectomy.
62608414|NCT01941836|EXPERIMENTAL|ETC-1002 120 mg/day + ezetimibe 10mg/day|Orally, once daily in morning
62608415|NCT01941836|EXPERIMENTAL|ETC-1002 180 mg/day + ezetimibe 10mg/day|Orally, once daily in morning
62608416|NCT05385224|EXPERIMENTAL|PillSense (Active)|This is a single-arm, non-randomized study.
62608417|NCT06073743|ACTIVE_COMPARATOR|Conventional Physiotherapy Group|30 minutes of upper and lower extremity strengthening exercises, upper and lower extremity stretching exercises, functional exercises to increase joint range of motion, tone regulation exercises, 30 minutes of weight transfer exercises to the upper and lower extremities, exercises to improve elective motor control (including isolated joint movements). exercises), balance and coordination exercises (weight transfer to the right-left, front-back on the balance board, cross-arm-leg exercises, exercises for balance and protective reactions), walking training will be applied.
62608418|NCT06073743|EXPERIMENTAL|Video Game Based Exercise Training Group|30 minutes of upper and lower extremity strengthening exercises, upper and lower extremity stretching exercises, functional exercises to increase joint range of motion, tone regulation exercises, 30 minutes of XBox Video Games (10 minutes of Reflex Ridge, 10 minutes of Rallyball, 10 minutes of River rush games) will be applied.
62608419|NCT00087126|EXPERIMENTAL|Topotecan|Topotecan weekly
62608420|NCT03903367|ACTIVE_COMPARATOR|control|standard GA and receive fentanyl infusion 2 mcg/kg/h after tracheal intubation and stopped at the end of the operation ,When HR or MBP increased ≥20% from base line readings, incremental dose of fentanyl will be given (2mcg /kg).
62608421|NCT03903367|ACTIVE_COMPARATOR|paravertebral block|Bilateral thoracic paraverteberal catheters will be inserted preoperative at level of T4 in order to block thoracic dermatomal levels from T3-T7 and 0.3ml/kg 0.25% bupivacaine bouls dose in each catheter maximum 20 ml in each catheter before induction and testing sensation bilaterally by pinprick and ice after 15-20min from injection then standard GA and after tracheal intubation continuous infusion of 0.1 ml /kg/h 0.25% bupivacaine in each catheter and stopped at the end of the operation , When HR or MBP increased ≥20% from base line readings, increamental dose of fentanyl will be given (2mcg /kg), the catheters will be removed after 24 h.
62608422|NCT04963959|OTHER|Healthy donor|
62608423|NCT01827215|EXPERIMENTAL|Intervention (Virtual Patient Advocate)|The Intervention Virtual Patient Advocate (VPA) Group participants will be given a username and secure password to log on to the Gabby site for the 12 months of the intervention. They will be encouraged to log on every two weeks or twice a month, but using the system is voluntary. They will be given the contact information of the Program Manager in the event that they have any issues or questions about the system. The research team will call each intervention participant after 6 and 12 months to conduct a follow-up phone call to collect outcome data. At the end of the intervention period, intervention participants will be invited to participate a focus group session.
62608424|NCT01827215|NO_INTERVENTION|Control (Letter)|The control group will receive a letter listing the preconception risks identified in the risk assessment and they will be encouraged to see their clinician to discuss them.
62830678|NCT05163522|EXPERIMENTAL|Part 2 (MAD) DDI cohort: Participants receiving VH4004280 and Midazolam|
62830679|NCT05163522|PLACEBO_COMPARATOR|Part 2 (MAD) DDI cohort: Participants receiving Placebo and Midazolam|
62830680|NCT05163522|EXPERIMENTAL|Part 3 (Single dose): Participants receiving VH4004280 (new formulation)|
62830681|NCT01108185||Acute Respiratory Infections|Slovak patients with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP).
62830682|NCT06037902|EXPERIMENTAL|CPAP|patients will undergo simulation twice, with and without CPAP
62250572|NCT03496012|NO_INTERVENTION|Untreated Control Group|Participants will receive no sham surgery or study medication.
62250573|NCT05707832|EXPERIMENTAL|Amphotericin B cholesteryl Sulfate Complex for Injection|Subjects will receive ABCD intravenous injection.
62250574|NCT05638451|EXPERIMENTAL|Sintilimab and Bevacizumab and Temozolomide|single arm study
62440347|NCT06544317|ACTIVE_COMPARATOR|typically developing|
62440348|NCT00827827|EXPERIMENTAL|Arm 1|Participants in this group undergo lower-extremity strength training on three pneumatic resistance machines (Keiser Leg Press, Keiser Leg Extension, and Keiser Leg Curl). Training sessions happen 3 times per week (M,W,F) and last approximately 45 minutes to 1 hour. Participants in this group exercise each limb individually to account for the large discrepancies in strength between legs in stroke survivors.
62440349|NCT00827827|ACTIVE_COMPARATOR|Arm 2|Participants in this group receive equal exposure to study staff compared with the experimental ST group (approximately 45 minutes to 1 hour 3 times per week). Exercise sessions for this group involve a full battery of active and passive...upper and lower body...stretching and range of motion exercises performed on raised padded tables.
62440350|NCT04889183|EXPERIMENTAL|Semaglutide|Patients will be treated with semaglutide 3 mg/ml s.c. once weekly for 24 weeks. The starting dose of semaglutide will be 0.24 mg subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg once weekly.
62440351|NCT04889183|PLACEBO_COMPARATOR|Placebo|Patients will receive a matching placebo s.c. once weekly.
62250575|NCT03677050|NO_INTERVENTION|Control|patients receiving standard care (verbal and written instructions) before colonoscopy
62250576|NCT03677050|EXPERIMENTAL|Intervention|Patients instructed to use a smart phone patient education app in addition standard care
62440352|NCT02961920|EXPERIMENTAL|IE ratio 1:1|Set an I(inspiration):E(expiration) ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
62440353|NCT02961920|ACTIVE_COMPARATOR|IE ratio 1:2|Set an I(inspiration):E(expiration) ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
62440354|NCT05269719||Digital nerve injury, surgical treatment, isolated injury|Patient over the age of 18 with an isolated injury to a digital nerve.
62440355|NCT05269719||Digital nerve injury, surgical treatment, concomittant flexor tendon injury|Patient over the age of 18 with an injury to a digital nerve and a concomittant flexor tendon injury.
62440356|NCT02509728|ACTIVE_COMPARATOR|standard nutrition|standard nutrition
62830683|NCT04642092|EXPERIMENTAL|PsicAP protocol|The treatment of the experimental group will be according to the PsicAP protocol: seven sessions of a psychological treatment based on transdiagnostic approaches, collaborative interventions, group-sessions, and evidence-based psychological techniques derived from cognitive behavioral therapy.
62830684|NCT04642092|ACTIVE_COMPARATOR|Conventional treatment|The control group will have seven sessions based on the typical psychological services that currently are offered in the Dominican Primary Care Units.
62250577|NCT04162184|OTHER|Health Educator Intervention|As the population of focus in this study is diverse, including men and women regardless of pregnancy desire, the primary focus for the intervention for this study will be education, particularly for men. All participants that enroll in the study will be offered the intervention. The study health educator will use the PATH (Parenthood/Pregnancy Attitude, Timing, and How) framework questions to initially guide the conversation. Depending on the participant's desires, the educator will provide education on other topics such as sexually transmitted infections (STIs) and we will also navigate to clinical services as needed. The health educator will use a study manual to guide all intervention activities including engagement. Additionally, the health educator will collect data on intervention outreach, engagement, topics discussed, participant needs and outcomes.
62250578|NCT03086057|EXPERIMENTAL|Strength Based Case Management|Stage 1: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
62250579|NCT03086057|EXPERIMENTAL|PrEP adherence training and counseling|Stage 2: Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
62250580|NCT03086057|NO_INTERVENTION|Standard of Care:Stage 1|Stage 1: Referral to The Miriam Hospital PrEP Clinic.
62250581|NCT03086057|NO_INTERVENTION|Standard of Care: Stage 2|Stage 2: Doctor visit every three months to assess for side effects and receive a HIV test.
62250582|NCT04973020|EXPERIMENTAL|Treatment group|
62250583|NCT03084406|EXPERIMENTAL|Enhanced Implementation (EI)|Providers in the Free Talk EI condition will receive access to CV-ATOD. They will participate in an online training course that mirrors the training in the IAU condition. EI providers will also receive access to interactive online exercises and practice activities within the training module. They will have online access to the Free Talk: Group MI for Teens searchable manual and materials via CV-ATOD. Providers may complete an optional CE course following the completion of the training module. EI providers will have access to all EBP implementation tools provided by CV-ATOD. Student providers in the CHOICE EI condition will receive access to CV-ATOD. They will participate in an online training course that mirrors the training in the IAU condition. However, EI providers will also receive access to interactive online exercises and practice activities within the training module. They will have online access to the CHOICE: Group MI for Teens searchable manual and materials via CV-ATOD.
62250584|NCT03084406|NO_INTERVENTION|Implementation As Usual (IAU)|CMH providers in the Free Talk IAU condition will receive access to the Group MI for Teens website that provides asynchronous, self-paced training videos as well as downloadable intervention materials and resources. CMH providers in this condition are only required to watch the first two training videos before receiving access to download the Free Talk training manual and materials. Providers may also complete an optional CE course following the completion of all training videos. Student providers in the CHOICE IAU condition will receive access to the Group MI for Teens website that provides online training videos as well as downloadable intervention materials and resources. IAU providers are only required to watch the first two training videos before receiving access to download the CHOICE training manual and materials. Providers may also complete an optional EBP knowledge test following the completion of all training videos.
62250585|NCT05048953||MRC GROUP|All newly admitted patients (shifted to ICU within 48 h of hospital admission), aged ≥ 16 years and expected to stay in ICU or critical care areas for 7 days will be included in the study after excluding those who fulfill excluding criterial. In all the participants, muscle strength will be assessed at day 1, day 4 and day 7, if the patients are awake as assessed by Richmond Agitation Sedation Scale (RASS) (19) between -1 and 1, and cooperative (20) assessed by being able to follow at least 3 out of 5 verbal commands with facial muscles (scored by the Score of 5 Questions). Assessment will be done by an ICU physician blinded to the result of ultrasound. The MRC score will be used for assessment of strength in the following six muscle groups bilaterally: wrist dorsiflexors, elbow flexors, shoulder abductors, hip flexors, knee extensors and ankle dorsiflexors. ICU-AW will be defined as MRC sum score \< 48, in accordance with the international consensus statement.(1)
62250586|NCT05048953||Muscle ultrasound measurements (the index test)|"Muscle ultrasound will be performed by an ICU faculty or a DM resident of Critical care medicine (who has an experience of at least 25 muscle ultrasonography with at least 10 muscle ultrasonography performed under supervision) (21) and will be blinded to the result of MRC score of the patient. Muscle ultrasound images on day 1, day 4 and day 7 will be obtained in the participants.~The following parameters will be measured by muscle ultrasound~1. Muscle thickness~2. Muscle echogenicity~3. Muscle fasciculations Muscle thick"
62440357|NCT02509728|EXPERIMENTAL|choline supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
62250587|NCT00570973|ACTIVE_COMPARATOR|1|Endoscopic Band ligation combined with medical therapy (orally, daily administered propranolol and mononitrate)
62440358|NCT02509728|EXPERIMENTAL|DHA supplementation|in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
62440359|NCT02509728|EXPERIMENTAL|choline and DHA supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride and 60mg/kg of DHA for 10 days
62440360|NCT01427920|EXPERIMENTAL|Subject-driven titration BIAsp 30 (BID) + metformin|The subjects performed the titration of BIAsp 30 dose.
62440361|NCT01427920|ACTIVE_COMPARATOR|Investigator-driven titration BIAsp 30 (BID) + metformin|The investigator performed the titration of BIAsp 30 dose.
62440362|NCT05977270|EXPERIMENTAL|Lifebloom One intervention|
62440363|NCT01091376|EXPERIMENTAL|Concomitant Erlotinib and radiotherapy|Patients received Erlotinib and radiation therapy.
62440364|NCT03430700|EXPERIMENTAL|Treatment|All patient will receive Pembrolizumab (100 mg/ 4mL) every 3 weeks for a maximum of 2 years. Pembrolizumab 200mg will be administered as a 30 minute IV infusion every 3 weeks.
62608425|NCT03078127|ACTIVE_COMPARATOR|Sequence A|"In this arm, the interventions were performed in the following order:~Baseline (prior to randomization), Whole body vibration, High Frequency Chest Wall Oscillation (HFCWO, aka Vest or TheVest®), Oscillatory Positive Expiratory Pressure (OPEP) (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
62608426|NCT03078127|ACTIVE_COMPARATOR|Sequence B|"In this arm, the interventions were performed in the following order:~Baseline (prior to randomization), HFCWO, OPEP, Whole body vibration (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
62608427|NCT03078127|ACTIVE_COMPARATOR|Sequence C|"In this arm, the interventions were performed in the following order:~Baseline (prior to randomization), OPEP, Whole body vibration, HFCWO (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
62608428|NCT02555124|EXPERIMENTAL|Cohort A|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 or Placebo on Day 1, fasted condition.
62608429|NCT02555124|EXPERIMENTAL|Cohort B|Participants will receive single oral dose of 20 mg of JNJ-42847922 or Placebo on Day 1, fasted condition.
62608430|NCT02555124|EXPERIMENTAL|Cohort C|Participants will receive single oral dose of 40 mg of JNJ-42847922 or Placebo on Day 1, fasted condition.
62048287|NCT02178605||Cervical arthrodesis candidates|Patients scheduled to undergo cervical arthrodesis to treat their spinal pathology will undergo cervical arthrodesis with rhBMP-2
62250588|NCT00570973|ACTIVE_COMPARATOR|2|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent
62608431|NCT02721303|ACTIVE_COMPARATOR|obese older aged, aged 65-85, BMI 30-40|Older aged patients who are obese and between the ages of 65-85 with a BMI between 30-40.
62250589|NCT06466538|ACTIVE_COMPARATOR|Calcium Hydroxide|intracanal medicament
62250590|NCT06466538|ACTIVE_COMPARATOR|Leddermix|intracanal medicament
62250591|NCT06466538|ACTIVE_COMPARATOR|Boswellia|intracanal medicament
62250592|NCT01408433|OTHER|Single Embryo Transfer|Patients will have a single, chromosomally normal embryo transferred.
62250593|NCT01408433|OTHER|Double Embryo Transfer|Patients will have two (2) untested embryos transferred.
62440365|NCT02883829|EXPERIMENTAL|Peer-Based Delivery|The Peer-Based Delivery Arm will receive a brief health information intervention (delivered as video content) about diabetes self-management and alcohol use risks, measuring effects on health knowledge. For this arm, a peer will be the spokesperson delivering the intervention content.
62440366|NCT02883829|EXPERIMENTAL|Provider-Based Delivery|The Provider-Based Delivery Arm will receive a brief health information intervention (delivered as video content) about diabetes self-management and alcohol use risks, measuring effects on health knowledge. For this arm, a healthcare provider will be the spokesperson delivering the intervention content.
62830685|NCT06185725|ACTIVE_COMPARATOR|Group M-TAPA (Modified Perichondral Approach Thoracoabdominal Nerve block group)|Patients will be performed to block at the end of the surgery. Patients will be administered paracetamol 1 gr (PERFALGAN® ) IV every 8 hours in the postoperative period.. If the patient's NRS score is ≥ 4 0,5 mg/kg IV meperidine (Aldolan ampul 100 mg/2 ml) will be administered.
62048288|NCT05522725|EXPERIMENTAL|Intervention phase|Single-use wipes installed at the bedside
62048289|NCT05522725|NO_INTERVENTION|Non-intervention phase|Standard practice according to Israeli ministry of health (MOH)
62440367|NCT00441584|EXPERIMENTAL|PegIntron plus Rebetol|PegIntron 1.5 μg/kg/week plus Rebetol 800-1400 mg/day administered for 48 weeks
62440368|NCT06259942|EXPERIMENTAL|Intervention 1 group|only the group heated throughout surgery with carbon fiber underbody heaters
62440369|NCT06259942|ACTIVE_COMPARATOR|Intervention 2 group|the group that was both warmed throughout the operation with carbon fiber underbody heaters and given warmed intravenous fluids
62440370|NCT06259942|NO_INTERVENTION|Control group|routine practice of the hospital where the surgery was performed (no heater applied group)
62440371|NCT00084539|EXPERIMENTAL|Radiation therapy|"Radiation Therapy~Daily 5 days per week for 4 weeks~45 Gy in 20 fractions whole breast~56 Gy in 20 fractions to boost volume"
62048290|NCT01930357|EXPERIMENTAL|VRVg Group|Participants will receive receive 3 vaccinations of Purified Vero Rabies Vaccine Serum Free (VRVg)
62048291|NCT01930357|ACTIVE_COMPARATOR|Imovax® Rabies Group|Participants will receive receive 3 vaccinations of Human Diploid Cell Vaccine (HDCV), Imovax® Rabies
62048292|NCT04202939||nursing homes residents|all residents present in a nursing home unit on nutritionDay
62250594|NCT00589498|EXPERIMENTAL|1|Subjects who are randomized to overfeed will visit with the General Clinical Research Center dieticians as often as necessary to gain 2 kg of fat (about 4 kg overall) over a period of 8 weeks.
62250595|NCT00589498|NO_INTERVENTION|2|Subjects who are randomized to non-overfeeding will continue with their normal diet and activity levels for a period of 8 weeks.
62440372|NCT01786720||Prior Triple Therapy|Patients prescribed triple therapy prior to initial date of COPD diagnosis
62440373|NCT01786720||Triple therapy at COPD diagnosis|Patients prescribed triple therapy on date of initial COPD diagnosis
62440374|NCT01786720||Triple therapy after COPD diagnosis|Patients prescribed triple therapy after initial date of COPD diagnosis
62440375|NCT02144584|PLACEBO_COMPARATOR|Placebo plus standard of care|Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will titrate up on the dose of placebo until taking twice daily. Participants will continue for 90 days with placebo. Continue with standard of care for other treatment of stroke.
62440376|NCT02144584|ACTIVE_COMPARATOR|Memantine plus standard of care|Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will use a titration schedule starting at 7mg daily for 1 week, increasing by 7mg (1 capsule) per week until at a goal dose of 28mg daily (goal dose) as recommend by the manufacturer. Participants will continue memantine for 90 days. Continue with standard care for stroke.
62608432|NCT02721303|ACTIVE_COMPARATOR|normal weight older aged, aged 65-85, BMI 18-25|Older aged patients who are of normal weight and between the ages of 65-85 with a BMI between 18-25.
62440377|NCT02423174||Total Mesorectal Excision|Patients with an indication for surgical intervention for a total mesorectal excision
62440378|NCT01040221|EXPERIMENTAL|Trichuris Suis Ova (TSO)|the eggs of intestinal helminthes (trichuris suis ova) administered as 2500 ova doses every two weeks.
62440379|NCT01040221|PLACEBO_COMPARATOR|Placebo|placebo dosage received every two weeks.
62440380|NCT04849026|EXPERIMENTAL|Group A|"1. Period 1: WID-CLZ18~2. Period 2: Clozaril 100 mg (Clozapine)"
62440381|NCT04849026|EXPERIMENTAL|Group B|"1. Period 1: Clozaril 100 mg (Clozapine)~2. Period 2: WID-CLZ18"
62440382|NCT04574310||Frozen embryo transfer (FET)|Collect retrospectively data on embryo implantation rate
62440383|NCT04574310||Intracytoplasmic sperm injection (ICSI)|Collect retrospectively data on embryo implantation rate
62440384|NCT04574310||oocyte donation|Collect retrospectively data on embryo implantation rate
62440385|NCT05926908||Geriatric ward|Interventions are: Patients' self-reported level of mealtime mobilisation, observations of the patients' mobilisation level and environment at mealtimes, focus group interviews with health care professionals at the wards, survey on mobilisation awareness among the nursing staff, a Mobilisation Initiative, and formal education for all nursing staff
62440386|NCT05926908||Medical ward|Interventions are: Patients' self-reported level of mealtime mobilisation, observations of the patients' mobilisation level and environment at mealtimes, focus group interviews with health care professionals at the wards, survey on mobilisation awareness among the nursing staff, a Mobilisation Initiative, and formal education for all nursing staff
62440387|NCT01860391|EXPERIMENTAL|Application of Diammine SIlver Fluoride|"GROUP A (6 TEETH): 18 mcL will be expressed from a Hamilton syringe into a dappen dish, and then a single preweighed microbrush will be used to apply the material to the tooth surface after drying with cotton gauze. The 6 teeth will be treated consecutively until all the material in the dappen dish will be used. Then the brush will be reweighed to establish the non-applied amount.~GROUP B (28 TEETH) Measure out 3 mcL X number of teeth present into dappen dish. Procedure is the same."
62440388|NCT05465915|ACTIVE_COMPARATOR|Blue|"1. Session - Titration with 0.30ms pulse width~2. Session - Titration with 0.15ms pulse width~3. Session and further - continue with 0.15ms pulse width"
62608433|NCT02721303|ACTIVE_COMPARATOR|obese younger aged, aged 21-45, BMI 30-40|Younger aged patients who are obese and between the ages of 21-45 with a BMI between 30-40 .
62608434|NCT05765253|ACTIVE_COMPARATOR|TIPS with Scorpion Portal Vein Access Kit|Scorpion or Scorpion X access set
62048293|NCT02080780|EXPERIMENTAL|2% Diltiazem & Clarithromycin XL|"3 parts:~1. - Single Dose, Diltiazem (Day 1)~2. - Multiple Dose, Clarithromycin XL (Days 4-9)~3. - Single Dose, Diltiazem (Day 8)"
62440389|NCT05465915|ACTIVE_COMPARATOR|Red|"1. Session - Titration with 0.15ms pulse width~2. Session - Titration with 0.3ms pulse width~3. Session and further - continue with 0.3ms pulse width"
62608435|NCT05765253|ACTIVE_COMPARATOR|TIPS with Cook Transjugular Liver Access Set|Ring or Rosch-Uchida access set
62608436|NCT01546038|EXPERIMENTAL|Arm A (Phase 1B)|PF-04449913 in combination with low dose ARA-C (LDAC)
62608437|NCT01546038|EXPERIMENTAL|Arm B (Phase 1B)|PF-04449913 in combination with Decitabine
62830686|NCT06185725|ACTIVE_COMPARATOR|Group TAP (Transversus Abdominal Plane block group)|Patients will be performed to block at the end of the surgery. Patients will be administered paracetamol 1 gr (PERFALGAN® ) IV every 8 hours in the postoperative period.. If the patient's NRS score is ≥ 4 0,5 mg/kg IV meperidine (Aldolan ampul 100 mg/2 ml) will be administered.
62830687|NCT04123197|OTHER|Young Participants with Prior MI|Participants aged 60 or less who experienced a MI within the last 8 months will undergo a stress challenge to assess MSI and will then be followed for 3 years.
62830688|NCT03774576|EXPERIMENTAL|RO7017773|Single dose of RO7017773
62830689|NCT03774576|EXPERIMENTAL|RO7017773 and Itraconazole|Single dose of RO7017773 and multiple doses of itraconazole
62830690|NCT01114698|EXPERIMENTAL|JNJ26489112|
62250596|NCT00102960|EXPERIMENTAL|Deferred therapy Arm|"Zidovudine: First Line Regimen: Given twice daily at a dose of 240 mg/m\^2 of body surface area. Dose was adjusted by age as the children grew older.~Lamivudine: First Line Regimen: 4 mg/kg taken orally twice daily Lopinavir/Ritonavir: First Line Regimen: taken orally twice daily. Dosage depends on age and weight.~Ritonavir: First Line Regimen taken orally twice a day. Started at 250 mg/m\^2 Abacavir sulfate: Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.~Didanosine: Second Line Regimen: Either 100 mg/m\^2 or 120 mg/m\^2 taken orally twice daily. Dosage depends on age.~Efavirenz: Second Line, once daily Nevirapine: Second Line, once daily"
62440390|NCT03770000|EXPERIMENTAL|Tenalisib+Romidepsin|Participants receive Tenalisib in escalating doses daily Orally BID and Romidepsin in escalating doses intravenously on day 1, 8 and 15
62440391|NCT02066584||Universal IVF Medium|An oocyte culture medium containing 5.55 Mm glucose (Origio, Medi-Cult)
62440392|NCT02066584||ISM1 Medium|An oocyte culture medium containing 1mM glucose ((Origio, MediCult)
62440393|NCT02066584||P1 Medium|An oocyte culture medium containing no glucose (Irvine)
62830691|NCT01114698|ACTIVE_COMPARATOR|Venlafaxine XR|
62440394|NCT02066584||ECM Medium|An oocyte culture medium containing 0.5mM glucose (Irvine)
62440395|NCT03381066|EXPERIMENTAL|Intercalating arm|gefitinib, pemetrexed,cisplatin
62440396|NCT03381066|ACTIVE_COMPARATOR|chemotherapy alone arm|Vinorelbine, cisplatin
62440397|NCT04437069|NO_INTERVENTION|Standard Care (Control)|Participants will receive standard care and will not view either the Decision Aid or the Values Clarification Exercise
62440398|NCT04437069|EXPERIMENTAL|Decision Aid|Participants view the Decision Aid only
62440399|NCT04437069|EXPERIMENTAL|Decision Aid & Values Clarification Exercise|Participants view both the Decision Aid and the Values Clarification Exercise
62440400|NCT04927754|EXPERIMENTAL|Group 1 (cartoon movie, then tell-show-do technique)|Group 1: Dental treatment was carried out with showing cartoon movie as a visual/auditory distraction during the treatment in the second visit. The third visit did not consist any visual/auditory distractions, tell-show-do technique was used as a behavioural guidance technique.
62440401|NCT04927754|EXPERIMENTAL|Group 2 (tell-show-do technique, then cartoon movie)|Group 2: Dental treatment was carried out using tell-show-do technique without any visual/auditory distraction in the second visit. The third visit consisted cartoon movie as a visual/auditory distraction.
62440402|NCT03594877|EXPERIMENTAL|Psoriasis patients|Patients with verified diagnosis of psoriasis would be given standard treatment for the first 3 months, and then followed with the standard therapy accompanied with the sublimated mare milk supplement for additional 3 months.
62440403|NCT03594877|NO_INTERVENTION|Healthy volunteers|Healthy patients will be enrolled in this study, and their gut microbiota composition as well as immune system indicators will be used for comparison with the psoriasis group.
62608438|NCT01546038|EXPERIMENTAL|Arm C (Phase 1B)|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
62830692|NCT01114698|PLACEBO_COMPARATOR|Placebo|
62830693|NCT06323434||cSDH|"1. Chronic subdural hematoma on imaging (CT/MRI)~2. Age: 18 years or older~3. Informed consent"
62830694|NCT05939882|EXPERIMENTAL|0.01% atropine|0.01% atropine eye drop
62830695|NCT05939882|EXPERIMENTAL|0.02% atropine|0.02% atropine eye drop
62830696|NCT05939882|EXPERIMENTAL|0.04% atropine|0.04% atropine eye drop
62830697|NCT05939882|PLACEBO_COMPARATOR|placebo|placebo eye drop
62830698|NCT02080598|NO_INTERVENTION|Controle|The volunteer do not smoke any cigarette during the study period
62830699|NCT02080598|EXPERIMENTAL|smoking|the volunteer smokes 2 cigarettes in 15 minutes
62830700|NCT06325813|ACTIVE_COMPARATOR|Active repetitive TMS|
62830701|NCT06325813|SHAM_COMPARATOR|Sham repetitive TMS|
62830702|NCT02540629|NO_INTERVENTION|Before intervention|The before intervention group will include patients from January, 2013 through December, 2014, as to refer to the historic control population who did not receive any of study interventions.
62048294|NCT02098980|ACTIVE_COMPARATOR|Dietary Supplement: Vitamin D|Vitamin D supplement 4000 IU/day for 6 months
62440404|NCT04561310|EXPERIMENTAL|Post facilitation stretch|Post facilitation stretch with Maitland mobilization
62440405|NCT04561310|ACTIVE_COMPARATOR|Active release technique|Active release technique with Maitland mobilization
62608439|NCT01546038|EXPERIMENTAL|P2 Fit (Phase 2 Single Arm)|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
62608440|NCT01546038|OTHER|P2 Unfit (Phase 2 Randomized)|Patients will be randomized 2:1 (low dose ARA-C in combination with PF-04449913: low dose ARA-C alone).
62048295|NCT02098980|PLACEBO_COMPARATOR|Placebo|Placebo for 6 months
62440406|NCT03623256|ACTIVE_COMPARATOR|Spinal Fentanyl|Spinal dose of preservative-free fentanyl 25 mcg (Volume 0.5 mL)
62608441|NCT06588634|ACTIVE_COMPARATOR|FlowTriever|
62608442|NCT06588634|ACTIVE_COMPARATOR|Standard of Care|
62830703|NCT02540629|EXPERIMENTAL|After intervention|The main study phase was planned to begin in January, 2016 through December, 2017, for a total of two years. Patients during the main study phase will have received one or more study interventions as applicable. However, because we could not continue our project in 2017, we changed after period. We included implementation period (2015) in after period. Therefore, final after period begins in January 2015 to December 2016.
62830704|NCT01149291||End stage renal disease patients|
62830705|NCT06160843|EXPERIMENTAL|Study Treatment|Pembrolizumab with Daily Olaparib.
62830706|NCT00622050|EXPERIMENTAL|1|This arm will be experiencing the same protocol as the control group, only their TV viewing time will be reduced. The TV viewing time reduction is the experimental intervention.
62048296|NCT06275152|EXPERIMENTAL|RIC group|RIC interventions will be applied to the upper extremity for a total of 20 cumulative minutes of limb ischemia, at a pressure of 200 mmHg.
62048297|NCT06275152|SHAM_COMPARATOR|Sham Remote Ischemic Conditioning|The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
62440407|NCT03623256|ACTIVE_COMPARATOR|Spinal Bupivacaine|Spinal dose of preservative-free 0.25% bupivacaine (Volume 0.5 mL)
62440408|NCT03623256|ACTIVE_COMPARATOR|Spinal Fentanyl and Bupivacaine|Spinal combination of preservative-free 0.25% bupivacaine (0.5 mL) and fentanyl 25 mcg (0.5 mL). (Total Volume 1 mL).
62440409|NCT03623256|EXPERIMENTAL|Epidural fentanyl /spinal bupivacaine|Spinal preservative-free 0.25% bupivacaine (Volume 0.5 mL) and epidural fentanyl 100 mcg (Volume 2 mL).
62440410|NCT06461923|EXPERIMENTAL|Insole wearing|
62608443|NCT04736173|ACTIVE_COMPARATOR|Arm A - Study Part 1 (Platinum-based Chemotherapy)|Participants will receive carboplatin, pemetrexed, and paclitaxel by intravenous (IV) infusion.
62608444|NCT04736173|EXPERIMENTAL|Arm B - Study Part 1 (Zimberelimab Monotherapy)|Participants will receive zimberelimab monotherapy by IV infusion.
62608445|NCT04736173|ACTIVE_COMPARATOR|Arm C - Study Part 1 (Domvanalimab + Zimberelimab Combination Therapy)|Participants will receive zimberelimab in combination with AB154 by IV infusion.
62608446|NCT04736173|EXPERIMENTAL|Arm D - Study Part 2 (Domvanalimab + Zimberelimab Combination Therapy)|Participants will receive domvanalimab in combination with zimberelimab by IV infusion.
62608447|NCT04736173|EXPERIMENTAL|Arm E - Study Part 2 (Pembrolizumab)|Participants will receive pembrolizumab by IV infusion.
62608448|NCT06033833|EXPERIMENTAL|Treatment group 1|Subcutaneous Injection as per protocol
62608449|NCT06033833|EXPERIMENTAL|Treatment group 2|Subcutaneous injection as per protocol
62608450|NCT03051516|EXPERIMENTAL|Arm I (recombinant human papillomavirus nonavalent vaccine)|Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline, 2 months, and 6 months.
62830707|NCT00622050|ACTIVE_COMPARATOR|Control|The control group will be experiencing the exact protocol; only their TV viewing time will not be reduced.
62608451|NCT03051516|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo IM at baseline, 2 months, and 6 months.
62830708|NCT02660151|EXPERIMENTAL|Treatment A-B|Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.
62830709|NCT02660151|EXPERIMENTAL|Treatment B-A|Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.
62830710|NCT05132907|EXPERIMENTAL|Cohort 1 (previously vaccinated, two dose recipients)|Cohort 1 will include individuals with vaccination against COVID-19 who will receive a two-dose schedule of HDT-301 56 days apart. Dose will be escalated from low to mid to high according to predefined safety parameters.
62830711|NCT05132907|EXPERIMENTAL|Cohort 2 (previously vaccinated, single dose recipients)|Cohort 2 will include individuals with vaccination against COVID-19 who will receive a one-dose schedule of HDT-301. Dose will be escalated from low to mid to high according to predefined safety parameters.
62830712|NCT05132907|EXPERIMENTAL|Cohort 3 (previously unvaccinated)|Cohort 3 will include 21 individuals with no history of vaccination against COVID-19 who will receive a two-dose schedule of HDT-301 56 days apart. Dose will be escalated from low to mid to high according to predefined safety parameters.
62830713|NCT02817646||Intensive care patients|Patients admitted to the intensive care unit for 4 days or more with a computed tomography scan made for clinical reasons early during intensive care stay and who receive enteral and/or parenteral nutrition as per hospital protocol
62830714|NCT03607890|EXPERIMENTAL|Cohort 1: Nivolumab and Relatlimab|480mg/160mg (co-administered)
62830715|NCT03607890|EXPERIMENTAL|Cohort 2: Nivolumab and Relatlimab|480mg/960mg or 480mg/160mg (sequential administration)
62830716|NCT03607890|EXPERIMENTAL|Cohort 3: Nivolumab and Relatlimab|480mg/480mg (sequential administration)
62830717|NCT03543644|ACTIVE_COMPARATOR|Sugar-sweetened beverage (SSB)|"The SSB intervention will consist the participants' consuming their usual serving of cans SSBs (each 355 ml, 42 grams sugar) per day. The calories of the SSB group will not be matched to allow for real-world substitutions using products available on the market."
62608452|NCT06176313|EXPERIMENTAL|mandala|
62608453|NCT06176313|EXPERIMENTAL|Coping with Premenstrual Symptoms Education Group|
62608454|NCT06176313|EXPERIMENTAL|Control Group|
62830718|NCT03543644|EXPERIMENTAL|Non-nutritive sweetened beverage (NSB)|"The NSB intervention consists of substituting the participants' usual serving of cans SSBs with NSBs (each 355 ml, 0 grams sugar) per day. The calories of the NSB group will not be matched to allow for real-world substitutions using products available on the market."
62830719|NCT03543644|EXPERIMENTAL|Water|"The water intervention consists of substituting the participants' usual serving of cans SSBs with bottles or cans of still or sparkling water (each 355 ml bottle or can, 0 grams sugar) per day. The calories of the water group will not be matched to allow for real-world substitutions using products available on the market."
62830720|NCT03544684|EXPERIMENTAL|Control day with no exercise|glycaemic profile will be assessed using continuous glucose monitors following a single 24-hour period in which participants performed no exercise
62830721|NCT03544684|EXPERIMENTAL|High intensity interval training (HIT)|glycaemic profile will be assessed using continuous glucose monitors following a 24-hour period whereby participants performed a single bout of high-intensity interval training (HIT) in the morning under fasted conditions
62830722|NCT03544684|EXPERIMENTAL|moderate intensity continuous training (MICT)|glycaemic profile will be assessed using continuous glucose monitors following a 24-hour period whereby participants performed a single bout of moderate-intensity continuous training (MICT) in the morning under fasted conditions
62830723|NCT04960202|EXPERIMENTAL|PF-07321332/ritonavir|Orally administered PF-07321332+ritonavir
62830724|NCT04960202|PLACEBO_COMPARATOR|Placebo|Orally administered placebo
62830725|NCT01334177|EXPERIMENTAL|Treatment (immunotherapy and monoclonal antibody therapy)|Patients receive cetuximab IV over 60-120 minutes on days -28, -21, -14, -7 of weeks -4 to -1. Patients then receive cetuximab IV on days 1, 8, 15, and 22 and TLR8 agonist VTX-2337 SC on days 1, 8, 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62830726|NCT01619280|EXPERIMENTAL|Nebulized sodium nitroprusside|
62830727|NCT00414596|EXPERIMENTAL|DRX Group|Patients using the device DRX9000™.
62830728|NCT03561480|EXPERIMENTAL|Ferric carboxymaltose group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with postoperative anemia after total knee arthroplasty.
62830729|NCT03561480|ACTIVE_COMPARATOR|Placebo group|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with postoperative anemia after total knee arthroplasty.
62830730|NCT03054246|OTHER|Healthy volunteers|Seventy-five healthy volunteers with no oral/dental problems with Angle I occlusion relationship and without any missing teeth will be included in the study. Evaluation of chewing side preference and laterality will be performed.
62830731|NCT00904605|EXPERIMENTAL|1- Lidoderm®|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
62830732|NCT00904605|ACTIVE_COMPARATOR|2-Celecoxib 200mg|Celecoxib (Celebrex®, G.D. Searle \& Co., Chicago, IL), one 200 mg oral capsule QD
62830733|NCT03645720|NO_INTERVENTION|Metal needle gruop|puncture using metal needle
62830734|NCT03645720|EXPERIMENTAL|plastic cannula|puncture using plastic cannula
62830735|NCT02902458|EXPERIMENTAL|Psychological follow-up|Patients undergoing implantation of an ICD for primary prevention will have an individual interview with a qualified psychologist in addition to standard medical follow-up.
62830736|NCT02902458|NO_INTERVENTION|Control|Patients undergoing implantation of an ICD for primary prevention will have standard medical follow-up.
62830737|NCT02277938||Amantadine|Lung cancer patients being prescribed chemotherapy
62440411|NCT02702752|OTHER|DYNASDY|The study considers changes in SDF-1α levels in response to treatment of cardiac disease (myocardial infarction, heart failure or atrial fibrillation). SDF-1α levels will be measured at the acute stages of the disease, after stabilization and at longer term as detailed below. Levels of SDF-1α will be correlated to the outcome of disease.
62440412|NCT02702752|ACTIVE_COMPARATOR|Control group|A control group of 20 subjects without cardiac disease (including hypertension), diabetes, hypercholesterolemia, and malignant disease.
62440413|NCT06546683|EXPERIMENTAL|Short-Chain Fatty Acids|SCFAs will be delivered directly to the colon using pH-dependent colon delivery capsules
62440414|NCT06546683|PLACEBO_COMPARATOR|Placebo|Colon-delivery capsules of microcrystalline cellulose
62440415|NCT03778047|EXPERIMENTAL|enzalutamide|160mg
62440416|NCT03778047|EXPERIMENTAL|HC-1119|To be determined
62440417|NCT03873779|EXPERIMENTAL|Fat Reduction|The treatments are designed to see if the fat can be reduced in the submental/submandibular area.
62440418|NCT02827903|EXPERIMENTAL|Group I|Metformin + Rosuvastatin, Dosing to Type II DM with Dyslipidemia
62440419|NCT02827903|ACTIVE_COMPARATOR|Group II|Metformin + placebo, Dosing to Type II DM with Dyslipidemia
62440420|NCT02827903|ACTIVE_COMPARATOR|Group III|Placebo + Rosuvastatin, Dosing to Type II DM with Dyslipidemia
62440421|NCT04888650||angiodema hereditary patients|Patient with HAE with or without C1 inhibitor deficiency will respond to an electronic questionnaire
62440422|NCT04699981|EXPERIMENTAL|Control: Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure|Known patients colonized rectally with ESBL-producing enterobacteria and not subjected to antibiotic pressure
62440423|NCT04699981|EXPERIMENTAL|Case: Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure|Known patients colonized rectally with ESBL-producing enterobacteriaceae and subjected to antibiotic pressure (antibiotic therapy predicted greater than 24 hours) with beta-lactams or dual therapy comprising a beta-lactam. The prescription of antibiotic therapy, a decision independent of the study procedures, will be carried out as part of routine care in the context of microbiologically documented infection. The choice of molecules will be left to the discretion of clinicians.
62830738|NCT04291469|PLACEBO_COMPARATOR|Control group|Identical-appearing Placebo (maltodextrin tables) ,oral, daily for 14 weeks
62830739|NCT04291469|EXPERIMENTAL|Probiotics group|Combined Bifidobacteria+lactobacillus+maltodextrin tables, each table contain more than 1.0\*10\^9 colony forming units, oral, daily for 14 weeks
62830740|NCT04291469|EXPERIMENTAL|Prebiotics group|Combined inulin+maltodextrin tables, oral, daily for 14 weeks
62830741|NCT04313244|EXPERIMENTAL|9vHPV+TDV|Participants will receive 0.5 mL 9vHPV intramuscularly (IM) with 0.5 mL TDV subcutaneously (SC) once on Day 1 (Month 0) followed by 0.5 mL TDV SC once on Day 90 (Month 3) and 0.5 mL 9vHPV IM once on Day 180 (Month 6).
62830742|NCT04313244|EXPERIMENTAL|9vHPV|Participants will receive 0.5 mL 9vHPV vaccine IM once on Day 1 (Month 0) followed by 0.5 mL 9vHPV vaccine IM once on Day 180 (Month 6).
62830743|NCT04190641|OTHER|Flexible cystoscopy|Visualization of the urethra and bladder with the Ambu® aScope™ 4 Cysto and aView™ Urologia
62440424|NCT00757666|ACTIVE_COMPARATOR|Accelerometer|Patients implanted with a Boston Scientific ALTRUA 60 pacemaker with accelerometer (motion-based) sensor.
62608455|NCT04267185|EXPERIMENTAL|Immediate Intervention|PwMS-CG dyads will receive six group telerehabilitation sessions (\~60 min each) every other week for a period of 12 weeks. This will be interspersed with brief one-on-one support telephone calls in the weeks that group sessions do not occur. All participants will be taught techniques for monitoring PA behaviour, setting personalized goals to increase PA and reduce sedentary time, and strategies for overcoming challenges to PA participation. Make-up sessions will be offered to those who miss group sessions. The one-on-one support telephone calls will serve to reinforce the information provided during the group sessions, monitor safety and troubleshoot any issues with intervention content.
62608456|NCT04267185|NO_INTERVENTION|Delayed Control|The delayed control group will not receive the intervention during the study period. Participants assigned to the control group will be offered the intervention once the study is completed.
62608457|NCT05760222|EXPERIMENTAL|Acupuncture arm|Intervention with 10 acupuncture sessions twice per week for 4 weeks followed by 2 more sessions once per week
62608458|NCT05760222|NO_INTERVENTION|Usual care arm|Lifestyle recommendations
62608459|NCT05758272|EXPERIMENTAL|mobile phone-based simple physical exercise intervention|Regular messages supporting participants in practicing simple physical exercises and assist in managing cravings will be sent to participants via IM apps and scheduled in a tapering manner for 3 months (twice per week in the first month to once per week in the third month). Images and videos explaining and demonstrating the simple physical exercises will be sent to the participants via IM apps, which serves as a reminder and supporting materials for participants. The benefits of exercise in SC will be explained. The investigators will also encourage the practice of moderate/ vigorous exercises to further improve the physical activity and well-being of the participants. Various delivery formats of messages will be considered to attract participants' interest such as text, emojis, voice, image, animation, and video. The simple exercises consist of a) Zero-time exercises (ZTEx), b) handgrip exercises and c) resistance exercises.
62608460|NCT05758272|PLACEBO_COMPARATOR|regular text-based intervention|The control group will receive 6 regular messages via IM at twice per month within 3 months. These messages cover simple cessation advice and reminders for telephone follow-ups.
62608461|NCT04432116|EXPERIMENTAL|virtual reality 1|the subject is in a virtual room and is asked to emit a retrospective time duration judgement at the end of the session
62608462|NCT04432116|EXPERIMENTAL|virtual reality 2|the subject is in a virtual environment mimicking a space ship. The subject is asked to detect targets as fast as possible while the background of the virtual environment is a starfield with standard speed vs. self-determined speed vs. static stars
62608463|NCT04432116|EXPERIMENTAL|virtual reality 3|the subject is in a virtual environment mimicking a space ship. The subject is asked to detect targets as fast as possible.Asynchronous distracters vs. synchronous distracters, vs no distracters are displayed while the subjects wait for the target
62830744|NCT03772158|EXPERIMENTAL|Treatment A|Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast and followed with 240 mL ambient water. Subjects will be instructed to chew the tablet completely before swallowing.
62830745|NCT03772158|EXPERIMENTAL|Treatment B|Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast without water. Subjects will be instructed to chew the tablet completely before swallowing.
62830746|NCT03772158|EXPERIMENTAL|Treatment C|Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast and 30 minutes after the start of the standard high-fat breakfast and followed with 240 mL ambient water. Subjects will be instructed to chew the tablet completely before swallowing.
62608464|NCT06002438|EXPERIMENTAL|Egg powder|15g egg powder per day for 24 weeks
62830747|NCT03772158|ACTIVE_COMPARATOR|Treatment D|Single dose of currently marketed US 10 mg cetirizine as immediate release tablet (ZYRTEC®), administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.
62830748|NCT03772158|ACTIVE_COMPARATOR|Treatment E|Single dose of currently marketed EU/Australian 10 mg cetirizine film coated tablet (REACTINE®) administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.
62830749|NCT06592586|NO_INTERVENTION|Non-Pregnant Participants: No GBS-NN/NN2 Booster Dose|Participants who received at least one dose of GBS-NN/NN2 during the parent studies but do not become pregnant during this study will not receive the GBS-NN/NN2 booster dose.
62608465|NCT06002438|ACTIVE_COMPARATOR|Corn powder|15g corn powder per day for 24 weeks
62608466|NCT02009059||Non-invasive temperature in hypothermia|Adult patients undergoing elective thoracic surgery in deep hypothermia
62830750|NCT06592586|EXPERIMENTAL|Pregnant Participants: GBS-NN/NN2 Booster Dose|Participants who received at least one dose of GBS-NN/NN2 during the parent studies and, become pregnant during this study, and qualify, will receive become pregnant during this study will receive the GBS-NN/NN2 booster dose.
62830751|NCT06592586|NO_INTERVENTION|Pregnant Participants: No GBS-NN/NN2 Booster Dose|Participants who received at least one dose of GBS-NN/NN2 during the parent studies and, become pregnant during this study but do not qualify for receiving the GBS-NN/NN2 booster dose.
62830752|NCT05310240||Hip arthroscopy|Patients that underwent hip arthroscopy at this department between 2013 and 2021.
62830753|NCT05855811|EXPERIMENTAL|Dostarlimab|4 intravenous injections maximum of dostarlimab, 500mg, every 3 weeks
62830754|NCT05855811|NO_INTERVENTION|No treatment|
62440425|NCT00757666|ACTIVE_COMPARATOR|Minute Ventilation|Patients implanted with a Boston Scientific ALTRUA 60 pacemaker with minute ventilation sensor.
62440426|NCT05562336||Patients with age related macular degeneration with CNV|
62440427|NCT05562336||Patients with pathological myopia with CNV|
62830755|NCT04935710|EXPERIMENTAL|R34#1 Aim 2 COPE2Thrive Intervention|Randomly clustered youth who have completed the screening will be randomized to receive a resilience based digital intervention, COPE2Thrive.
62830756|NCT04935710|ACTIVE_COMPARATOR|Control arm|The comparator arm is treatment as usual. For each monthly crossover, 12 students in a cluster are eligible to receive C2T in a stepped wedge study design. Student outcomes prior to receiving C2T will be compared to outcomes after receiving C2T.
62830757|NCT02937116|EXPERIMENTAL|Phase 1a|"Participants will receive IBI308 1mg/kg, 3mg/kg or 10mg/kg intravenous every 2 weeks, or 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity.~Drug: IBI308"
62830758|NCT02937116|EXPERIMENTAL|Phase 1b Cohort A|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308"
62830759|NCT02937116|EXPERIMENTAL|Phase 1b Cohort B|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308"
62830760|NCT02937116|EXPERIMENTAL|Phase 1b Cohort C|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308"
62830761|NCT02937116|EXPERIMENTAL|Phase 1b Cohort D|"Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308/Cisplatinum/Pemetrexed"
62830762|NCT02937116|EXPERIMENTAL|Phase 1b Cohort E|"Participants will receive IBI308 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308\\gemcitabine\\cisplatin"
62830763|NCT02937116|EXPERIMENTAL|Phase 1b Cohort F|"Participants will receive IBI308 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308\\oxaliplatin\\capecitabine"
62830764|NCT02937116|EXPERIMENTAL|Phase 1b Cohort G|"Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 intravenously and etoposide 100mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles. Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308\\etoposide\\cisplatin"
62830765|NCT02937116|EXPERIMENTAL|Phase 1b Cohort H|"Participants will receive IBI308 200mg in combination with irinotecan 125mg/m2 intravenously day 1and 8 and 5-FU 1000mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles.Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308\\irinotecan\\5-FU"
62830766|NCT05132023|EXPERIMENTAL|Empagliform|Test drug
62830767|NCT05132023|ACTIVE_COMPARATOR|Synjardy|Reference drug
62830768|NCT02734875|EXPERIMENTAL|Intervention|Primary care providers in the intervention arm will receive lists of their patients with AF who are identified as being at high risk of stroke but not currently on anticoagulation therapy. Along with this list, which includes information on risks and benefits of anticoagulation, primary care providers will receive an offer of assistance from a respected Anticoagulation Management Service within the hospital network to help manage anticoagulation for referred patients.
62830769|NCT02734875|NO_INTERVENTION|Usual Care|Primary care providers will provide usual care.
62608467|NCT06448195|EXPERIMENTAL|Growth hormone treatment group|A total of 20 patients with liver fat content greater than 11% determined by proton magnetic resonance spectroscopy (1H MRS) method were recruited six months to two years after operation of pituitary adenoma, and underwent growth hormone replacement therapy, the total course of treatment was 6 months, and finally the liver fat content was determined
62608468|NCT06448195|NO_INTERVENTION|Lifestyle intervention control group|A total of 20 patients with liver fat content greater than 11% determined by proton magnetic resonance spectroscopy (1H MRS) method were recruited six months to two years after operation of pituitary adenoma. The patients were treated as the control group and underwent lifestyle intervention. Finally, the liver fat content was determined
62608469|NCT03738449|EXPERIMENTAL|Group 1|"* Period 1: D484~* Period 2: CKD-387"
62440428|NCT02273674|EXPERIMENTAL|Left rTMS 5 Hz|This group receive transcranial magnetic stimulation at 5 Hz of frequency over left dorsolateral prefrontal cortex. Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
62440429|NCT02273674|EXPERIMENTAL|Right r TMS 1 Hz|This group receive transcranial magnetic stimulation at 1 Hz of frequency over right dorsolateral prefrontal cortex. Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
62608470|NCT03738449|EXPERIMENTAL|Group 2|"* Period 1: CKD-387~* Period 2: D484"
62608471|NCT03938649|EXPERIMENTAL|Conventional IMRT|"* RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).~* 38 fractions of daily treatment, Monday to Friday"
62608472|NCT03938649|EXPERIMENTAL|SBRT|"* RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes)~* 5 fractions of weekly treatment. Once fraction per week."
62608473|NCT05801419|EXPERIMENTAL|Baseline, post e-cigarette without nicotine and post e-cigarette with nicotine|Pattern visual event-related potential (ERP) and pattern electroretinogram (pERG) on right eye (non-dilated pupil), followed by eye fundus tissue oximetry on left eye (dilated pupil), followed by optical coherence tomography angiography (OCT-A) on left eye (dilated pupil).
62608474|NCT00930631|OTHER|Single Arm|Single arm PK study
62608475|NCT01229033|ACTIVE_COMPARATOR|Ablation|Ablation of atrial tachycardia
62608476|NCT01229033|ACTIVE_COMPARATOR|Cardioversion|Cardioversion of atrial tachycardia
62608477|NCT06425666|EXPERIMENTAL|Experimental intervention /arm 1|"After randomisation the investigational therapy (arm 1), patients undergo a cataract surgery with preservation of the diseased endothelial cells. The cataract surgery will take approximately 10-20 minutes.~The follow-up period after surgery will be 22 weeks ± 14 days."
62608478|NCT06425666|OTHER|Control intervention /arm2|"After randomisation, patients in the comparator therapy (arm 2) undergo triple-DMEK which is a cataract surgery combined with DMEK (removal of the diseased endothelial cells followed by transplantation of a healthy endothelial cell layer).~Triple-DMEK takes approximately 5-10 minutes longer than cataract surgery. The follow-up period after surgery will be 22 weeks ± 14 days."
62608479|NCT06247553|EXPERIMENTAL|Gait Training|The gait training in the experimental group will use a treadmill with a partial body-weight support system and our gait training device. A gait training session will include 2-minute warming up at the beginning and 2-minute cooling down at the end, at a treadmill speed of 0.6 mph. After the warming up, the treadmill speed will increase at every two minutes by an increment of 0.2 mph. Participant's heart rate will be monitored throughout the training session by using a Polar OH1 optical HR sensor placed in the participant's left forearm. Reseachers will stop the increase and maintain the same treadmill speed after the HR reaching the target heart rate zone of 50% - 60% of age-predicted heart rate reserve.
62608480|NCT06247553|ACTIVE_COMPARATOR|Leg Cycling Exercise|The leg cycling exercise will use a stationary bicycle and the similar protocol as in the experimental group. The cycling exercise will include 2-minute warming up in the beginning and 2-minute cooling down at the end with a speed of 10 rpm and resistance of level 1 of 4. After warming up, the speed will increase at every two minutes by an increment of 5 rpm until reaching the target heart rate zone of 50% - 60% of age-predicted maximum heart rate. If the participant cannot tolerate any more increase in cycling speed before reaching the target heart rate, the resistance will be increased. The training duration will be individualized at the beginning and increase weekly by 5 minutes, depending on the tolerance of the participant, up to the maximum of 30 minutes. Both heart rate and blood pressure will be monitored before, during, and after each session to ensure safety. Each session including setting up will be about one hour.
62608481|NCT01362517|EXPERIMENTAL|Quinvaxem|
62830770|NCT03829540|EXPERIMENTAL|Treatment|"Redirected autologous T cells transduced with the anti-CD4 lentiviral vector (referred to as CD4CAR cells)"
62830771|NCT01062958||Arm #1 (Test group)|50 subjects administered Neevo® or Neevo®DHA daily
62830772|NCT01062958||Arm #2 (Control group)|50 subjects administered a prenatal vitamin daily
62830773|NCT05266989||Fibromyalgia|All participants will randomly participate through three tDCS conditions (1mA, 2mA and sham)
62830774|NCT05266989||Healthy Controls|All participants will randomly participate through three tDCS conditions (1mA, 2mA and sham)
62830775|NCT03613441|EXPERIMENTAL|Mindful Awareness Practices (MAPs)|Mindful Awareness Practices is a mindfulness-based intervention developed at UCLA's Mindful Awareness Research Center. It is a weekly 2-hour, 6-session, group-based course in mindfulness meditation that is available in-person or online.
62440430|NCT05494905|EXPERIMENTAL|Virtual Reality (VR)|
62440431|NCT05494905|ACTIVE_COMPARATOR|Functional Strength Training (FST)|
62440432|NCT04523493|EXPERIMENTAL|Experimental group|Toripalimab combined with Lenvatinib
62830776|NCT03613441|NO_INTERVENTION|Control|Waitlist control (intervention will be available to this group at the end of the study period)
62830777|NCT03915197|EXPERIMENTAL|group 1|cohorts of infants with acute bronchiolitis
62440433|NCT04523493|PLACEBO_COMPARATOR|Control group|Placebo combined with Lenvatinib
62440434|NCT06288165||Coronary Sinus Reducer implantation|Subject after Coronary Sinus Reducer implantation due to chronic disabling refractory angina pectoris (Canadian Cardiovascular Society \[CCS\] classes 2-4) despite maximally tolerated anti-angina medical therapy. All patients were evaluated by the local Heart Team and considered not amenable to percutaneous or surgical revascularization procedures. After the Heart Team evaluation patients were qualified for the procedure or Coronary Sinus Reducer implantation unless they meet one of the exclusion criteria. Initial patient evaluation (prior to device implantation) consists of past medical history, actual clinical assessment with an evaluation of CCS class, Seattle Angina Questionnaire - 7 items (SAQ-7) scores, 6-min walk distance (6-MWT) test, and echocardiography. First, a follow-up visit is scheduled 1 month after the implantation procedure than the follow-up is planned twice a year.
62608482|NCT06408142||Emergency Department Patients|Universal Test and Connect: universal screening with HIV testing followed by demographic/clinical information to determine number of patients who would be eligible for HIV PrEP
62830778|NCT00000817|EXPERIMENTAL|1|Participants will receive standardized or alternate point acupuncture treatment twice weekly for the first 6 weeks, then once weekly for the next 8 weeks, plus either oral amitriptyline or placebo daily for the entire 14 weeks.
62250597|NCT00102960|EXPERIMENTAL|Early therapy for 40 weeks|"Zidovudine: First Line Regimen: 10 mg/mL taken orally twice per day. Dose was adjusted by age as the children grew older.~Lamivudine: First Line Regimen: 4 mg/kg taken orally twice daily Lopinavir/Ritonavir: First Line Regimen: taken orally twice daily. Dosage depends on age and weight.~Ritonavir: First Line Regimen taken orally twice a day. Started at 250 mg/m\^2~Abacavir sulfate: Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.~Didanosine: Second Line Regimen: Either 100 mg/m\^2 or 120 mg/m\^2 taken orally twice daily. Dosage depends on age.~Efavirenz: Second Line, once daily Nevirapine: Second Line, once daily"
62250598|NCT00102960|EXPERIMENTAL|Early therapy for 96 weeks|"Zidovudine: First Line Regimen: 10 mg/mL taken orally twice per day. Dose was adjusted by age as the children grew older.~Lamivudine: First Line Regimen: 4 mg/kg taken orally twice daily Lopinavir/Ritonavir: First Line Regimen: taken orally twice daily. Dosage depends on age and weight.~Ritonavir: First Line Regimen taken orally twice a day. Started at 250 mg/m\^2 Abacavir sulfate: Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.~Didanosine: Second Line Regimen: Either 100 mg/m\^2 or 120 mg/m\^2 taken orally twice daily. Dosage depends on age.~Efavirenz: Second Line, once daily Nevirapine: Second Line, once daily"
62250599|NCT06456528|EXPERIMENTAL|QL0911|
62250600|NCT06456528|EXPERIMENTAL|QL0911 plus Placebo|
62250601|NCT06456528|PLACEBO_COMPARATOR|Placebo|
62250602|NCT00854698|EXPERIMENTAL|Group with MVA|
62250603|NCT00854698|OTHER|group without MVA|
62830779|NCT06655857|OTHER|Community Health Worker and Intervention Providers-Assisted Kidney Transplant Support|Participants will receive assignment to a community health worker who will educate them on the kidney transplant process, assist them through the kidney transplant process and connect them with any necessary social services.
62830780|NCT06655857|OTHER|Usual Care|Participants will receive usual care and at the end of the study will receive education, and work with CHWs in a more limited capacity. Control clinicians will receive the education intervention.
62830781|NCT03585881|EXPERIMENTAL|window bracket positioning tray|
62830782|NCT03585881|NO_INTERVENTION|conventional indirect boning tray|
62830783|NCT06651905|EXPERIMENTAL|Dexmedetomidine group|Patients were given 0.5 mcg/kg of dexmedetomidine over 10 minutes via a syringe pump, followed by a maintenance dose of 0.2-0.7 mcg/kg/hour until the end of intubation based on Hemodynamics.
62830784|NCT06651905|ACTIVE_COMPARATOR|Superior laryngeal nerve block group|Patients received an airway nerve block through bilateral superior laryngeal nerve block and trans-tracheal injection for recurrent laryngeal nerve.
62830785|NCT02464540|ACTIVE_COMPARATOR|Light-cured resin cement|Laminate veneers luted using light-cured resin cement
62250604|NCT01699542|ACTIVE_COMPARATOR|Metal Stent|The WallFlex Biliary Fully Covered Esophageal Stent System is being evaluated for treatment of refractory anastomotic esophageal strictures.
62250605|NCT01699542|ACTIVE_COMPARATOR|Bougie Dilation|Esophageal Bougie Dilator commercially available devices used per Investigator preference are being evaluated for treatment of refractory anastomotic esophageal strictures.
62440435|NCT01110980|EXPERIMENTAL|Swallowing therapy|Swallowing therapy in combination with individual dietary counselling
62440436|NCT01110980|ACTIVE_COMPARATOR|Individual dietary counselling|Swallowing therapy only on indication. (usual care)
62830786|NCT02464540|ACTIVE_COMPARATOR|Light-cured flowable composite|Laminate veneers luted using light-cured flowable composite
62830787|NCT06602622|ACTIVE_COMPARATOR|Integrase inhibitors|Second generation integrase inhibitor: 1) Bictegravir 50 mg/ alafenamide tenofovir 25 mg/ emtricitabine 200 mg (BIC/TAF/FTC) 2) Dolutegravir 50 mg/ abacavir 600 mg/ lamivudine 300 mg (DTG/ABC/3TC) or ) dolutegravir 50 mg+ disoproxil fumarate tenofovir/ emtricitabine 300mg/ 200 mg (DTG+TDF/FTC) Each will be prescribed one tablet every day during 48 weeks
62830788|NCT06602622|EXPERIMENTAL|DOR/TDF/3TC|Individuals who meet the selection criteria will be randomized to maintain their same regimen with second-generation integrase inhibitors or switch to Doravirine/Tenofovir Disoproxil Fumarate/Emtricitabine 100/300/300 mg (DOR/TDF/3TC) It will be prescribed one tablet every day during 48 weeks
62830789|NCT02322632|EXPERIMENTAL|Paricalcitol Capsules, 4 mcg|Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
62830790|NCT02322632|EXPERIMENTAL|Zemplar Capsules, 4 mcg|Zemplar Capsules, 4 mcg of Abott Laboratories USA
62250606|NCT05627544||First 6 year group|Patients who underwent hip replacement between 2010 and 2016 by the same experienced surgeon in our hospital
62440437|NCT03198702|EXPERIMENTAL|Toxin group|The babies receive a botulinum toxin type A injection at the age of 12 months
62048298|NCT04686786|EXPERIMENTAL|CVL-865 25 mg|Participants will receive CVL-865 tablets orally twice daily (BID) up to the maximum dose of 25 milligrams (mg) until Week 57 during the treatment period.
62048299|NCT04334473|OTHER|cataract patients|Patients having cataract candidates for phacoemulsification with or without glaucoma are prepared to do cataract surgery with preoperative and postoperative assessment of intraocular pressure and ocular bio-metrics using UBM.
62048300|NCT01619202|EXPERIMENTAL|Risk Anticipation-Perception Training|Complete the Risk Anticipation-Perception Training (RAPT) program
62250607|NCT05627544||Second 6 year group|Patients who underwent hip replacement between 2017 and 2022 by the same experienced surgeon in our hospital
62440438|NCT03198702|SHAM_COMPARATOR|Sham group|The babies receive a simulated injection procedure at the age of 12 months
62440439|NCT06546397|EXPERIMENTAL|medication group|Starting from the day of the induced abortion surgery, take 17β-estradiol/dydrogesterone tablets orally for 28 days (take 2mg of 17β-estradiol orally once a day for the first 14 days, and then take 2mg of 17β-estradiol + 10mg of dydrogesterone tablets orally once a day for the next 14 days).
62608483|NCT03630913|EXPERIMENTAL|Tagged axillary metastatic node|"Patients undergo axillary sonography assessment routinely performed to seek suspicious nodes. A cytological examination (biopsy is optional) of the suspicious node is performed.~The involved node is then tagged with a metal clip under sonography. Then, patients receive NAC before surgery. Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC."
62250608|NCT03078712|ACTIVE_COMPARATOR|Peripheral Perfusion guided resuscitation|Resuscitation will be aimed at normalization of capillary refill time.
62830791|NCT05094362|EXPERIMENTAL|Validation of the new training system|The researchers will measure changes in H-reflex size achieved with the use of the new system and compare these measures with the existing results in 25 spastic individuals with chronic incomplete SCI. Each participant completes 6 baseline sessions and 30 conditioning sessions. In the 30 conditioning sessions, the soleus H-reflex will be down-conditioned to decrease the activity of the hyperactive spinal stretch reflex pathway in people with spasticity that is characterized by exaggerated reflex activity. It is anticipated that the magnitude of reflex change obtained with the use of the new system would be greater or at least the same as the bench-marked values from the previous studies that used the old prototype reflex conditioning system.
62830792|NCT02426021|EXPERIMENTAL|Cohort J1: MLN1202 (75 mg)|Single subcutaneous administration of MLN1202 (75 mg) in 6 healthy Japanese male adults
62250609|NCT03078712|ACTIVE_COMPARATOR|Lactate guided resuscitation|Resuscitation will be aimed at normalization or significant decrease in lactate levels.
62250610|NCT03161288|EXPERIMENTAL|Cohorts 1-3|Healthy volunteers will receive single rising doses of KY1005 or placebo
62830793|NCT02426021|EXPERIMENTAL|Cohort J1: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
62830794|NCT02426021|EXPERIMENTAL|Cohort J2:MLN1202 (105 mg)|Single subcutaneous administration of MLN1202 (105 mg) in 6 healthy Japanese male adults
62048301|NCT01619202|NO_INTERVENTION|No training program|Does not complete the Risk Anticipation-Perception Training (RAPT) program
62048302|NCT03616184|EXPERIMENTAL|Ruxolitinib|Patients will receive oral ruxolitinib at a dose of 10 mg twice daily.
62048303|NCT00777374|EXPERIMENTAL|1|Allergen containing patch
62048304|NCT00777374|PLACEBO_COMPARATOR|2|Placebo patch
62250611|NCT03161288|EXPERIMENTAL|Cohorts 4-8|Healthy volunteers will receive multiple rising doses of KY1005 or placebo
62250612|NCT02841202|ACTIVE_COMPARATOR|oral contraceptive pills group|healthy women using oral contraceptive pills for only contraception for more than one year was called OCP group
62250613|NCT02841202|NO_INTERVENTION|control group|The second group was called control group consisting 20 healthy women and using no drug
62440440|NCT06546397|NO_INTERVENTION|Blank group|The blank control group did not receive 17β-estradiol/dydrogesterone tablets after induced abortion surgery.
62608484|NCT02561741|EXPERIMENTAL|COV155|
62830795|NCT02426021|EXPERIMENTAL|Cohort J2: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
62048305|NCT04218448|NO_INTERVENTION|Somatosensory evoked potentials without hypnorelaxation|"As part of this research, the patient must complete a pain scale and a Spielberger Stay-A anxiety self-assessment questionnaire before the PES examination.~Somatosensory evoked potentials are carried out according to the usual management."
62250614|NCT04434950|EXPERIMENTAL|Intervention|Intervention group
62250615|NCT06214247|EXPERIMENTAL|Test Group|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Wedge NC Scoring Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure.
62250616|NCT06214247|EXPERIMENTAL|Control Group|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using a similar product(Scoring Balloon Dilatation Catheter) on the market in the control group, subsequently completing the remaining procedure.
62250617|NCT01809132|EXPERIMENTAL|Anakinra & Pentoxifylline & Zinc Sulfate|anakinra 100mg subcutaneous injection daily for 14 days pentoxifylline 400 mg orally three times daily for 28 day zinc sulfate 220 mg orally for 180 days
62250618|NCT01809132|ACTIVE_COMPARATOR|Methylprednisolone|methylprednisolone 32 mg orally daily for 28 days
62250619|NCT01809132|NO_INTERVENTION|Observational|Individuals who choose not to participate in the interventional arm of the trial will be receive standard care and be observed for 6 months. They will be enrolled to have baseline and interval health information and laboratory results collected.
62250620|NCT04354909||Biological samples|levels of s-CD95-L (ELISA test)
62250621|NCT03101774|EXPERIMENTAL|threshold-IMT group|Using inspiratory muscle training using threshold load device for 8 weeks
62250622|NCT03101774|EXPERIMENTAL|resisive-IMT group|Using inspiratory muscle training using resistive device for 8 weeks
62250623|NCT03101774|SHAM_COMPARATOR|control group|not conduct inspiratory muscle training for 8 weeks
62250624|NCT01161043|EXPERIMENTAL|Sensor|All subjects that wear sensors (all subjects)
62250625|NCT05563519|ACTIVE_COMPARATOR|I-PRF + collagen|I-PRF will be applied with type 1 collagen to the extraction socket after the wisdom tooth operation.
62440441|NCT03308110|OTHER|Relative Bioavailability Cohort|Relative Bioavailability cohort
62608485|NCT00006994|ACTIVE_COMPARATOR|L-glutamine in suspension + radiation|20 cc three times daily for 60 days plus radiation therapy.
62608486|NCT00006994|PLACEBO_COMPARATOR|Placebo in suspension + radiation|20 cc three times daily for 60 days plus radiation therapy.
62250626|NCT05563519|ACTIVE_COMPARATOR|L-PRF|Only L-PRF will be applied to the extraction socket after the wisdom tooth operation
62830796|NCT02426021|EXPERIMENTAL|Cohort J3: MLN1202 (150 mg)|Single subcutaneous administration of MLN1202 (150 mg) in 6 healthy Japanese male adults
62830797|NCT02426021|EXPERIMENTAL|Cohort J3: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
62830798|NCT02426021|EXPERIMENTAL|Cohort J4: MLN1202 (450 mg)|Single subcutaneous administration of MLN1202 (450 mg) in 6 healthy Japanese male adults
62830799|NCT02426021|EXPERIMENTAL|Cohort J4: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
62830800|NCT02426021|EXPERIMENTAL|Cohort C1: MLN1202 (75 mg)|Single subcutaneous administration of MLN1202 (75 mg) in healthy Causacian male adults
62830801|NCT02426021|EXPERIMENTAL|Cohort C2: MLN1202 (150 mg)|Single subcutaneous administration of MLN1202 (150 mg) in healthy Causacian male adults
62830802|NCT06519604|EXPERIMENTAL|Human insulin enteric coated capsules in dose 16mg|Single oral administration of human insulin enteric coated capsules in dose 16mg.
62250627|NCT02002351||Pulmonary disease|
62830803|NCT06519604|EXPERIMENTAL|Human insulin enteric coated capsules in dose 8mg|Single oral administration of human insulin enteric coated capsules in dose 8mg
62830804|NCT06519604|ACTIVE_COMPARATOR|Human Insulin Injection in dose 5IU|Single subcutaneous administration of Human Insulin Injection in dose 5IU
62250628|NCT02154542|ACTIVE_COMPARATOR|Experimental A|NAVA then standard mode
62830805|NCT02481674|EXPERIMENTAL|VX15/2503|The study drug VX15/2503 will be administered via monthly intravenous infusions
62830806|NCT02481674|PLACEBO_COMPARATOR|Placebo|A placebo control will be administered via monthly intravenous infusions
62830807|NCT01487798|EXPERIMENTAL|Treatment period 1|
62830808|NCT01487798|ACTIVE_COMPARATOR|Treatment period 2|
62830809|NCT03898739|ACTIVE_COMPARATOR|traction therapy from neutral position|Patients in this group will receive traction decompression from neutral neck position with rope angle (0°)
62830810|NCT03898739|ACTIVE_COMPARATOR|traction therapy from lateral bending|patients will undergo traction decompression from (30°) lateral bending of the neck toward the non-affected side
62830811|NCT03898739|ACTIVE_COMPARATOR|traction from flexion with lateral bending and rotation|patients will be treated with traction decompression from (15°) neck flexion, (30°) lateral bending toward non- affected side and (15°) rotation to the affected side.
62830812|NCT04042064||Inhalation|Patient anesthetised with Inhalation anesthetic agents.
62830813|NCT04042064||TIVA (total intravenous anesthesia)|Patient anesthetised with total total intravenous anesthesia.
62830814|NCT06590415|EXPERIMENTAL|T2D/DGE patients|Diagnostic age of diabètes mellitus less than or equal to 40 years and epicardial fat volume greater than 72 mL.
62830815|NCT06590415|ACTIVE_COMPARATOR|Control patients|Age at diagnosis of diabetes greater than 40 and/or epicardial fat volume less than 72 mL.
62830816|NCT03063177|EXPERIMENTAL|1840Newtons/s(N/s);125ms;250 Newtons(N)|Participants will receive a spinal manipulative therapy of 20 Newtons (N) preload leading to a peak force of 250N over 125ms (rate of force application of 1840N/s).
62830817|NCT03063177|EXPERIMENTAL|920N/s;125ms;135N|Participants will receive a spinal manipulative therapy of 20N preload leading to a peak force of 135N over 125ms (rate of force application of 920N/s).
62830818|NCT03063177|EXPERIMENTAL|920N/s;250ms;250N|Participants will receive a spinal manipulative therapy of 20N preload leading to a peak force of 250N over 250ms (rate of force application of 920N/s).
62250629|NCT02154542|ACTIVE_COMPARATOR|Experimental B|Standard mode then NAVA
62250630|NCT02616757|ACTIVE_COMPARATOR|Simple Bone Cyst Patients|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline and once annually for 2 years.~There will also be optional blood samples taken o measure bone alkaline phosphatase."
62440442|NCT01810796|EXPERIMENTAL|Ranolazine treatment|Ranolazine 500-1000mg bid
62440443|NCT01810796|PLACEBO_COMPARATOR|Placebo|Placebo
62440444|NCT03366285||Fullterm infants|Quality of bonding is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from the local elementary school.
62440445|NCT03366285||Moderate to late preterm infants|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the trauma and depression in late preterm parents study (TraDelPP) conducted 2010 to 2011."
62608487|NCT06729970|EXPERIMENTAL|Part A|
62830819|NCT03063177|NO_INTERVENTION|control|Spinal stiffness will be assessed at each sesssion, however, participants won't receive any spinal manipulative therapy.
62830820|NCT01723878||Cohort|
62830821|NCT00966134||probands|
62830822|NCT03123731|ACTIVE_COMPARATOR|Control Arm|Participants will wear a Fitbit but will not receive any additional elements of the iSTEP intervention.
62830823|NCT03123731|EXPERIMENTAL|iSTEP PA intervention|Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA) and reduce sedentary behavior, including setting weekly goals to increase average daily step counts.
62608488|NCT06729970|EXPERIMENTAL|Part B|
62608489|NCT06729970|EXPERIMENTAL|Part C|
62608490|NCT06729970|EXPERIMENTAL|Part D|
62608491|NCT06665971|EXPERIMENTAL|EoE participants treated with Dupilumab|All the participants will be treated with once a week subcutaneous injection of Dupilumab 300 mg through for 12 weeks. There is no placebo arm in the study.
62830824|NCT03123731|EXPERIMENTAL|iSTEP PA and diet intervention|Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA), reduce sedentary behavior, and promote adherence to a Mediterranean-style diet. Participants will also be administered diet counseling from a registered dietitian and receive weekly feedback on both physical activity and diet behaviors.
62830825|NCT02888600|ACTIVE_COMPARATOR|Mindfulness Training|The Mindfulness Meditation Program consists of eight weekly 2- 2.5 hour group sessions, a day-long retreat in the sixth week, and daily mindfulness meditation homework.
62830826|NCT02888600|ACTIVE_COMPARATOR|Health Education|The Health Education Program also consists of eight weekly 2- 2.5 hour group sessions, a day-long retreat in the sixth week, and daily health practice homework
62830827|NCT01546610|EXPERIMENTAL|intervention foot orthoses|Ethyl vinyl acetate (EVA) insole with medial arch support and bar retrocapital
62608492|NCT02151435||Patients with IPF|Observation of longitudinal biomarkers in IPF patients
62830828|NCT01546610|PLACEBO_COMPARATOR|placebo insole|Foot orthose with support retrocapital and support of medial arch insole intervention
62250631|NCT02616757|ACTIVE_COMPARATOR|Fracture patients|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline, after 3 months and at future follow-up visits as clinically indicated or at a one year follow-up visit.~There will also be optional blood samples taken to measure bone alkaline phosphatase."
62250632|NCT02616757|PLACEBO_COMPARATOR|Health volunteers|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline, after 3 months and at a one year follow-up visit.~There will also be optional blood samples taken to measure bone alkaline phosphatase."
62608493|NCT01255462|EXPERIMENTAL|LFG316 0.15mg|
62608494|NCT01255462|EXPERIMENTAL|LFG316 0.5mg|
62608495|NCT01255462|EXPERIMENTAL|LFG316 1.5mg|
62830829|NCT02906748|EXPERIMENTAL|new site for parathyroid auto-graft|choose the site fairly close to the antecubital vein for parathyroid auto-transplantation
62830830|NCT02906748|ACTIVE_COMPARATOR|traditional parathyroid autograft|choose not intensely close to antecubital vein for parathyroid auto-transplantation
62830831|NCT00458263|EXPERIMENTAL|single arm|
62830832|NCT01407432|EXPERIMENTAL|Folic acid|tablets of 5 mg of folic acid
62830833|NCT01407432|PLACEBO_COMPARATOR|Placebo|Tablets of placebo of folic acid
62608496|NCT01255462|EXPERIMENTAL|LFG316 5mg|
62830834|NCT02842619|EXPERIMENTAL|Intervention Arm|1 Arm - IMP treatment arm
62830835|NCT01698333|EXPERIMENTAL|122-0551|
62830836|NCT01107054|EXPERIMENTAL|PF-00610355 450 µg|An orally inhaled dose of PF-00610355 450 µg
62830837|NCT01107054|EXPERIMENTAL|PF-00610355 1200 µg|An orally inhaled dose of PF-00610355 1200 µg
62608497|NCT03572361|EXPERIMENTAL|V3-MOMMO|Oral once daily pill of tableted vaccine (V3-MOMMO) containing pooled breast cancer antigens administered for 3 months in 20 volunteers with breast cancer
62830838|NCT01107054|ACTIVE_COMPARATOR|moxifloxacin 400 mg|A single oral dose of moxifloxacin 400 mg on Day 4.
62830839|NCT01107054|PLACEBO_COMPARATOR|placebo|A single oral dose of non-matched placebo on Day 4.
62830840|NCT05039086||PDE5 inhibitors|Exposure group
62830841|NCT05039086||Endothelin receptor antagonists|Reference group
62830842|NCT02581813|EXPERIMENTAL|RDa (Recommended dairy group)|4 servings of dairy per day + exercise (3 times per week with combination of aerobic and resistance exercise).
62830843|NCT02581813|EXPERIMENTAL|LDa (Low dairy group)|0-1 serving of dairy per day + exercise (the same as the RDa group)
62608498|NCT03059199|EXPERIMENTAL|Single-Arm Feasibility Study|12-week, 1x/week, 90-minute face-to-face sessions.
62830844|NCT02581813|NO_INTERVENTION|GCon (growth controls)|This no-intervention group will serve as the control to account for growth during the study.
62830845|NCT03135600|EXPERIMENTAL|Normal|The participants from this group are healthy people.
62830846|NCT03135600|EXPERIMENTAL|ACLD|The participants from this group suffer from anterior cruciate ligament injury.
62830847|NCT04668456|PLACEBO_COMPARATOR|Group C (control group)|Group C (control group): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.
62608499|NCT01038414|PLACEBO_COMPARATOR|Brief-Duration Counseling|3-Month Duration
62250633|NCT05827055|EXPERIMENTAL|Proglumide TID with Gemcitabine and Nab-Paclitaxel|Proglumide given three times a day with gemcitabine and nab-paclitaxel
62250634|NCT05827055|EXPERIMENTAL|Placebo TID with Gemcitabine and Nab-Paclitaxel|Placebo given three times a day with gemcitabine and nab-paclitaxel
62830848|NCT04668456|ACTIVE_COMPARATOR|Group SD (subtenon dexmedetomiine)|Group SD ( subtenon dexmedetomidine): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ 0.5 μg/kg dexmedetomidine (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.
62250635|NCT05166915|EXPERIMENTAL|UVA Light Emitting Catheter|Experimental Device intended to eliminate microorganisms using UV-A light, thereby reducing the viral burden of SARS-CoV-2.
62250636|NCT05166915|SHAM_COMPARATOR|Sham Control Device|Sham Control Device
62250637|NCT03618784|EXPERIMENTAL|FURESTEM-RA Inj.|
62250638|NCT03618784|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|
62250639|NCT00453648|PLACEBO_COMPARATOR|White-fleshed Sweet Potato|0 ug retinol activity equivalents (RAE)/d as boiled white-fleshed sweet potatoes (WFSP) and a corn oil capsule, 6d/wk for 10 wk
62608500|NCT01038414|ACTIVE_COMPARATOR|Moderate Duration Counseling|6-Month Duration
62830849|NCT04668456|ACTIVE_COMPARATOR|Group ID (iv dexmedetomidine)|Group ID (iv dexmedetomidine): received received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of 0.5 μg/kg dexmedetomidine over 10 min. before subtenon block.
62830850|NCT03096288|EXPERIMENTAL|Evolocumab|Evolocumab (Repatha) 420 mg s.c. single injection
62830851|NCT03096288|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride s.c. single injection
62830852|NCT06491277|ACTIVE_COMPARATOR|Flossband Group|Our study began by applying flossband to the football players. The players were first assessed without the flossband, and then reassessed with the flossband to measure its effectiveness. This group was referred to as the 'Study Group.'
62830853|NCT06491277|SHAM_COMPARATOR|Controlled Group|After the specified rest period, the football players were evaluated prior to the foam roller application. Seventy-two hours later, they were reassessed with the foam roller to measure the effectiveness of the application. This group was referred to as the 'Control Group.
62048306|NCT04218448|EXPERIMENTAL|Somatosensory evoked potentials with hypnorelaxation|As part of this research, the patient must complete a pain scale and a Spielberger Stay-A anxiety self-assessment questionnaire before the PES examination. Hypno-relaxation is induced by following VAKOG: external sensory identification, fixation of attention, bodily sensation, breathing, sensory perceptions, closing of the eyes. The work phase follows induction and allows deepening of the hypnotic trance. It corresponds to a metaphorical narrative associated with post-hypnotic suggestions and is fueled by the construction of suggestions and metaphors. The protocol is adapted to each patient. The investigator who remains present throughout the duration of the examination, maintains a hypnotic, empathetic, attentive attitude, and makes it possible to recover this material. The investigator, thanks to hypnosis, allows the development of a creative imagination which allows a modification of the relation to space and time.
62830854|NCT02435992|EXPERIMENTAL|RPC1063 (Ozanimod)|1mg, daily oral administration during Induction and Maintenance periods.
62830855|NCT02435992|PLACEBO_COMPARATOR|Placebo|Daily oral administration during Induction and Maintenance periods.
62830856|NCT06654427|EXPERIMENTAL|Implementation of OBTIC|The OB-TIC intervention toolkit will be pilot tested in outpatient obstetrics clinics. OB-TIC will be implemented for 9 months during which time I will assess providers' and patients' perceptions of acceptability, appropriateness, and feasibility of OB-TIC. Adoption of OB-TIC, attitudes towards TIC, appointment adherence and care choices, maternal-infant health outcomes, and patient mental health will be assessed before, during, and after the pilot.
62830857|NCT02324101|EXPERIMENTAL|Breast cancer|Detect plasma Hsp90α concentration of breast cancer patients
62048307|NCT01602406|EXPERIMENTAL|LJM716 in combination with trastuzumab|
62830858|NCT00628667|EXPERIMENTAL|1|
62830859|NCT00628667|PLACEBO_COMPARATOR|2|
62830860|NCT04557891|EXPERIMENTAL|Low Intensity Focused Ultrasound|"Device: Low Intensity Focused Ultrasound Device~Low Intensity Focused Ultrasound Pulsation (LIFUP) of amygdala (a key area for anxiety) will be performed during two sessions. The proposed experiment will involve behavioral (e.g. HAM-A) and paramedical (i.e., MRI/fMRI) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session). The device does not produce a sound when operating and as such, the active group will well blinded."
62830861|NCT04557891|SHAM_COMPARATOR|Sham|Sham Treatment consists of placing the device but not turning it on. The device does not produce a sound when operating and as such, the sham group will well blinded.
62830862|NCT03044106|ACTIVE_COMPARATOR|CLRT, Then Sham|Subjects performed the KEA, HHD, PPT functional tests on their right hamstring before and after the CLRT intervention.
62830863|NCT03044106|SHAM_COMPARATOR|Sham, Then CLRT|The Sham procedure was identical to CLRT except the laser device was placed in placebo mode: all device indicator lights and sounds will be functional but no laser light will be emitted from probe aperture.
62830864|NCT02194335|EXPERIMENTAL|BIBN 4096 BS - in single rising doses|
62048308|NCT05613738|EXPERIMENTAL|1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
62250640|NCT00453648|EXPERIMENTAL|Orange-fleshed Sweet Potato (boiled)|600 ug RAE/d as boiled orange-fleshed sweet potato and a corn oil capsule, 6d/wk for 10 wk
62830865|NCT02194335|PLACEBO_COMPARATOR|Placebo|
62830866|NCT04337645|EXPERIMENTAL|Test group|resective surgical treatment of peri-implantitis (decontamination performed with titanium brushes and sterile saline) combined with implantoplasty
62830867|NCT04337645|ACTIVE_COMPARATOR|Control group|resective surgical treatment of peri-implantitis (decontamination performed with titanium brushes and sterile saline)
62830868|NCT00912808|EXPERIMENTAL|Donepezil|
62830869|NCT00912808|PLACEBO_COMPARATOR|Sugar Pill|
62830870|NCT03848728|EXPERIMENTAL|Intervention Clinics|SEARCH Youth combination intervention, which includes life-stage assessment and counseling, rapid VL feedback, structured choice clinic access, and e-collaboratives chat-based discussion among providers
62830871|NCT03848728|NO_INTERVENTION|Control Clinics|Optimized country standard of care
62830872|NCT05200403|EXPERIMENTAL|Crisaborole 2%|Adult caregivers of children participants will be asked to apply a thin even-layer of Crisaborole (2%) twice daily for 2 weeks.
62830873|NCT05200403|ACTIVE_COMPARATOR|Vehicle Arm|Adult caregivers of children participants will be asked to apply a thin even-layer of vehicle treatment twice daily for 2 weeks.
62830874|NCT01532596|EXPERIMENTAL|Mindfulness-Based Stress Reduction|A standardized 8-week mindfulness meditation training program
62830875|NCT01532596|NO_INTERVENTION|Wait-List|
62830876|NCT03428984|EXPERIMENTAL|EXPAREL 20 + 20|20 mL EXPAREL with 20 mL normal saline
62830877|NCT03428984|EXPERIMENTAL|EXPAREL 20 + 10|20 mL EXPAREL with 10 mL normal saline
62830878|NCT00859196|EXPERIMENTAL|Arm 1|
62830879|NCT00859196|PLACEBO_COMPARATOR|Arm 2|
62608501|NCT01038414|ACTIVE_COMPARATOR|Extended Duration Counseling|12-Month Duration
62608502|NCT01772680|EXPERIMENTAL|Zinc Supplementation|25 mg elemental Zinc as Zn sulfate in capsule form taken daily for 3 months
62608503|NCT03406000|EXPERIMENTAL|Insulin glargine (U300)|Self-administered subcutaneously once daily in the morning, at the same time.The initial dose for patients switching from insulin glargine is 80% of the total daily dose of basal insulin agent that was discontinued. Thereafter, insulin glargine (U300) will follow a titration algorithm for dose adjustment.
62608504|NCT01577719|ACTIVE_COMPARATOR|Multimedia Lifestyle Improvement|Multimedia lifestyle intervention
62608505|NCT01577719|PLACEBO_COMPARATOR|Usual Care|usual care
62830880|NCT03346538|EXPERIMENTAL|Continuous infusion high-dose group (Group H)|High-dose MCI-186 will be administered as a bolus, and then as a continuous infusion. In addition, a placebo will be administered as an intravenous infusion twice a day over 30 minutes.
62830881|NCT03346538|EXPERIMENTAL|Continuous infusion low-dose group (Group L)|Low-dose MCI-186 will be administered as a bolus, and then as a continuous infusion. In addition, a placebo will be administered as an intravenous infusion twice a day over 30 minutes.
62830882|NCT03346538|EXPERIMENTAL|Approved dosing regimen group (control group)|A placebo will be administered as a bolus, and then as a continuous infusion. In addition, MCI-186 30 mg will be administered as an intravenous infusion twice a day over 30 minutes.
62830883|NCT04962763||Heart Failure|
62830884|NCT04962763||Control|
62830885|NCT06375967|EXPERIMENTAL|EUS-GBD with LAMS-Pigtail|"Biliary drainage using EUS-guided Cholecystostomy with lumen apposing metal stent~Echoendoscopy-guided Cholecystostomy (EUS-GBD) with deployment of a lumen-apposing metal stent (LAMS) and axis-orienting double-pigtail plastic stent throug LAMS.~EUS-GBD technique: Diagnostic EUS. Classic or free-hand with preloaded guidewire cholecystostomy with LAMS. Pneumatic dilation whithin LAMS is allowed. 'push' technique ___ ??? Deployment of a pigtail coaxial to LAMS."
62830886|NCT06375967|ACTIVE_COMPARATOR|EUS-CDS with LAMS-Pigtail|"Echoendoscopy-guided Choledochoduodenostomy (EUS-CDS) with deployment of a lumen-apposing metal stent (LAMS) and axis-orienting double-pigtail plastic stent throug LAMS.~EUS-CDS technique: Diagnostic EUS. Classic or free-hand with preloaded guidewire choledochoduodenostomy with LAMS. Pneumatic dilation whithin LAMS is allowed. In case of bile duct \< 15mm is mandatory the 'push' technique. Deployment of a pigtail coaxial to LAMS."
62830887|NCT06654635|EXPERIMENTAL|Rhomboid intercostal plane block group|The patients in this group will receive ultrasound -guided rhomboid intercostal plane block after induction of general anesthesia. The rhomboid intercostal block will be performed at the T6 levels, bilaterally.
62830888|NCT06654635|EXPERIMENTAL|Erector spinae plane block group|The patients in this group will receive ultrasound -guided Erector spinae plane block after induction of general anesthesia. ESP block will be performed at the level of T9 bilaterally.
62830889|NCT06654635|EXPERIMENTAL|Control group|No block will be performed, and patient will receive general anesthesia (GA) only.
62440446|NCT03366285||Preterm infants with skin to skin contact|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the delivery room skin to skin study (deisy) who were randomized into the skin to skin contact group. The study was conducted from 2012 to 2015."
62440447|NCT03366285||Preterm infants with visual contact|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the delivery room skin to skin study (deisy) who were randomized into the visual contact group. The study was conducted from 2012 to 2015."
62440448|NCT04550468|EXPERIMENTAL|Low-Carb High-Fat Breakfast|Participants will follow a daily low carbohydrate high fat breakfast intervention for 3 months.
62440449|NCT04550468|ACTIVE_COMPARATOR|"Low fat Standard Care Control Breakfast"|"Participants will follow a daily low fat standard care control breakfast intervention for 3 months."
62608506|NCT03215407|EXPERIMENTAL|Intra-articular Tocilizumab|Tocilizumab, solution, 80mg intra-articular.
62608507|NCT03215407|ACTIVE_COMPARATOR|Intra-articular Compound Betamethasone|Compound betamethasone, solution, 14mg intra-articular
62608508|NCT06534086|EXPERIMENTAL|Cystoscopy VR intervention|Local anesthetic and VR intervention
62608509|NCT06534086|ACTIVE_COMPARATOR|Cystoscopy treatment as usual|Local anesthetic only
62608510|NCT06534086|EXPERIMENTAL|Vasectomy VR intervention|Local anesthetic and VR intervention
62608511|NCT06534086|ACTIVE_COMPARATOR|Vasectomy treatment as usual|Local anesthetic only
62608512|NCT06244459|EXPERIMENTAL|Hemiplegia Group|Participants diagnosed with stroke will be evaluated with the Box and Block Test, 360 degree rotation test and 5 times squat test. These tests will be presented to the participants first in the real world and then in virtual reality.
62830890|NCT05990010||Patients with AF|
62830891|NCT05990010||Patients without AF|
62830892|NCT03788213|ACTIVE_COMPARATOR|3 week RT|Adjuvant Radiotherapy delivered over 3 weeks
62830893|NCT03788213|EXPERIMENTAL|1 Week RT|Adjuvant Radiotherapy delivered over 1 week
62830894|NCT03406312||Gastric Bypass Surgery population|liquid mixed meal tolerance test, solid mixed meal tolerance test, continuous glucose monitoring
62608513|NCT05958654|EXPERIMENTAL|with DETECT-RPC screening tool|
62608514|NCT05958654|NO_INTERVENTION|without DETECT-RPC screening tool|
62608515|NCT03424629|EXPERIMENTAL|Low-Dose UC-MSCs|Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 1 x 10\^6 cells/kg in normal saline injection
62608516|NCT03424629|EXPERIMENTAL|High-Dose UC-MSCs|Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 3 x 10\^6 cells/kg in normal saline injection
62608517|NCT03424629|ACTIVE_COMPARATOR|Methotrexate|5-25mg Methotrexate orally
62608518|NCT03654105|EXPERIMENTAL|Smoking cessation and Antinflammatory|Smoking cessation through the administration of Cytisine (in standard and prolonged administration) + reduction of inflammatory status through the administration of Acetylsalicylic acid, diet modification and physical activity increase + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
62608519|NCT03654105|EXPERIMENTAL|Smoking cessation|Smoking cessation through the administration of Cytisine (in standard and prolonged administration) + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
62608520|NCT03654105|EXPERIMENTAL|Antinflammatory|reduction of inflammatory status through the administration of Acetylsalicylic acid, diet modification and physical activity increase + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
62608521|NCT03654105|OTHER|Control Group|standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
62830895|NCT03406312||Control population|liquid mixed meal tolerance test, solid mixed meal tolerance test, continuous glucose monitoring
62830896|NCT02161016|OTHER|map3 allogeneic bone graft|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
62830897|NCT04244292|OTHER|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
62830898|NCT05023642|EXPERIMENTAL|resistance training|"Participants will not be offered the exercise program in the three months before data collection.~From then on, participants will perform exercises during the resistance training protocol intervention."
62830899|NCT05023642|NO_INTERVENTION|control group|Individuals in the control group will not be offered the exercise program in the three months before data collection and during the entire period corresponding to the 12-week intervention.
62048309|NCT05613738|EXPERIMENTAL|1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
62440450|NCT01208558|ACTIVE_COMPARATOR|Diet A and physiotherapy|"Behavioral: Diet A Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people, i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid junk food and juice. In order to match carbohydrate intake between the arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Behavioral: Physiotherapy Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end."
62440451|NCT01208558|ACTIVE_COMPARATOR|Diet B and physiotherapy|"Behavioral: Diet B Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A.~Other Name: Whole grains Behavioral: Physiotherapy Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end.~Other Name: Exercise"
62440452|NCT01208558|ACTIVE_COMPARATOR|Diet A only|"Behavioral: Diet A Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains as much as possible. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. In order to match carbohydrate intake between the intervention arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Other Name: No grains"
62048310|NCT05613738|EXPERIMENTAL|2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
62250641|NCT00453648|EXPERIMENTAL|Orange-fleshed Sweet Potato (fried)|600 ug RAE/d as fried orange-fleshed sweet potato and a corn oil capsule, 6d/wk for 10 wk
62250642|NCT00453648|ACTIVE_COMPARATOR|White-fleshed Sweet Potato and retinyl palmitate capsule|0 ug RAE/d as white-fleshed sweet potato and 600 ug retinol/d as retinyl palmitate, 6d/wk for 10 wk
62608522|NCT03349281|EXPERIMENTAL|Dose Level 1: Pevonedistat 15 + VXLD|"* Pevonedistat: 15 mg/m2 intravenously (IV)~* Vincristine: 1.5 mg/m2/dose IV push~* Dexamethasone: 10 mg/m2/day divided twice daily~* PEG-asparaginase: 2000 IU's/m2/day, capped at maximal dose of 3750 IU's.~* Doxorubicin: 60 mg/m2/day IV~* Intrathecal (IT) chemotherapy via injection per protocol:~  * All subjects: Cytarabine 70 mg ;~ * For central nervous system (CNS) negative subjects: Methotrexate 15 mg;~ * For CNS positive subjects (Triple IT Therapy): Cytarabine 30 mg, Methotrexate 15 mg, and Hydrocortisone 15 mg."
62048311|NCT00990717|EXPERIMENTAL|NK-92 cells|Preparation of irradiated NK-92 cells suspended in a saline and plasma solution. NK-92 working cell bank was established from a master cell bank supplied by Conkwest Inc. (San Diego CA).
62608523|NCT03349281|ACTIVE_COMPARATOR|Dose Level -1: Pevonedistat 10 + VXLD|"* Pevonedistat: 10 mg/m2 IV~* Vincristine: 1.5 mg/m2/dose IV push~* Dexamethasone: 10 mg/m2/day divided twice daily~* PEG-asparaginase: 2000 IU's/m2/day, capped at maximal dose of 3750 IU's.~* Doxorubicin: 60 mg/m2/day IV~* Intrathecal (IT) chemotherapy via injection per protocol:~  * All subjects: Cytarabine 70 mg ;~ * For CNS negative subjects: Methotrexate 15 mg;~ * For CNS positive subjects (Triple IT Therapy): Cytarabine 30 mg, Methotrexate 15 mg, and Hydrocortisone 15 mg."
62830900|NCT04428853|EXPERIMENTAL|exercise|A schedule has designed by the researcher for group yoga therapy of the participant twice a week, each session lasting for 75- minutes for the duration of 8 weeks
62830901|NCT05609292||Study group|Infants will get their temperature measured with the liquid crystal thermometer. We are not providing any interventions as they will be in the care of a healthcare team.
62830902|NCT02303496|EXPERIMENTAL|PRP Cream Application|Application of Cream Containing Platelet Rich Plasma and Oleaginous Base
62830903|NCT02303496|ACTIVE_COMPARATOR|SW Cream Application - Placebo|Application of Cream Containing Sterile Water and Oleaginous Base
62830904|NCT06533787||Group 1|Hemodynamically unstable neonates
62608524|NCT03349281|ACTIVE_COMPARATOR|Dose Level 2: Pevonedistat 20 + VXLD|"* Pevonedistat: 20 mg/m2 IV~* Vincristine: 1.5 mg/m2/dose IV push~* Dexamethasone: 10 mg/m2/day divided twice daily~* PEG-asparaginase: 2000 IU's/m2/day, capped at maximal dose of 3750 IU's.~* Doxorubicin: 60 mg/m2/day IV~* Intrathecal (IT) chemotherapy via injection per protocol:~  * All subjects: Cytarabine 70 mg ;~ * For CNS negative subjects: Methotrexate 15 mg;~ * For CNS positive subjects (Triple IT Therapy): Cytarabine 30 mg, Methotrexate 15 mg, and Hydrocortisone 15 mg."
62608525|NCT03894215|EXPERIMENTAL|AGEN2034 + Placebo|AGEN2034 administered with placebo monotherapy: approximately 100 patients.
62608526|NCT03894215|EXPERIMENTAL|AGEN2034 + AGEN1884|AGEN2034 administered in combination with AGEN1884 (combination therapy): approximately 100 patients.
62608527|NCT03674697|EXPERIMENTAL|Active Treatment Group (Green LED)|Subjects will be exposed to a Green LED light for 8 weeks prior to surgery, during their hospital stay and for an additional 2 weeks after hospital discharge.
62608528|NCT03674697|PLACEBO_COMPARATOR|Control Group (White LED)|Subjects will be exposed to a White LED light for 8 weeks prior to surgery, during their hospital stay and for an additional 2 weeks after hospital discharge.
62608529|NCT06695247|EXPERIMENTAL|Home-Based Exercise Training|
62608530|NCT06695247|NO_INTERVENTION|Standard therapy (Standard of Care)|
62250643|NCT03868852|EXPERIMENTAL|Radiotherapy plus apatinib mesylate|All eligible patients signed informed consent. Three-dimensional conformal intensity modulation (IMRT) technique was used to treat the patients with radiation doses 45 Gy - 54 Gy. All patients took apatinib mesylate tablets 250 mg QD orally from 1 week before radiotherapy to the whole radiotherapy period. They were required to take apatinib mesylate tablets with warm boiling water half an hour after meal. The daily medication time should be as consistent as possible.
62250644|NCT04666350||Study Volunteers|"Participants provided a blood sample on Day 1 for DMFA testing and then participated in the mosquito feeding assay. On Day 2 participants underwent a second DMFA and DSFA assay (within 24 hours of the first assays).~Upon completion of Day 2 DSFA participants will receive one dose of primaquine and the first dose of a 3-day regiment of artemether/lumefantrine."
62608531|NCT05331781|EXPERIMENTAL|transversus abdominis plain block group|post-cesarean section tap block will be given by ultrasound guidance using 20 ml bupivacaine local anesthetic 0.25% concentration for each side as an adjuvant to spinal anesthesia
62440453|NCT01208558|ACTIVE_COMPARATOR|Diet B only|"Behavioral: Diet B Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A. The goal is that carbohydrate intake, as a proportion of total energy intake, should not differ between the groups.~Other Name: Whole grains"
62608532|NCT05331781|EXPERIMENTAL|intrathecal morphia group|intrathecal 150 microgram morphine in a 0.5 ml volume as an adjuvant to spinal anesthesia
62608533|NCT03391232|EXPERIMENTAL|PolyPEPI1018 CRC Vaccine|The vaccine contains 6 synthetic peptides mixed with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 cancer testis antigens (CTAs), which are the most frequently expressed CTAs in colorectal cancer. The 6 peptides were optimized to induce long lasting CRC specific T cell responses.
62608534|NCT03410212|ACTIVE_COMPARATOR|Ketorolac Tromethanine|In the experimental group, 30mg/mL, ketorolac tromethamine will be injected as same as the first IANB and 5 minutes following it.
62048312|NCT03233802|EXPERIMENTAL|Individualized Assess & Treatment (IATP)|Intervention: Cognitive-Behavioral IATP consists of 12 weekly visits of individual treatment. IATP employs cellphone-based experience sampling via interactive voice response (IVR) to assess drinking, plus craving, thoughts, feelings, and coping behaviors to develop near a real-time picture of patients' high-risk situations and the ways they use to deal with them. This information will be used by the therapist and client together to problem-solve and devise adaptive coping responses to these specific high-risk situations, and develop generalized solutions to deal with other situations in the future.
62440454|NCT01208558|NO_INTERVENTION|Control|Only follow-up. No intervention.
62440455|NCT03740698|NO_INTERVENTION|SAP, open-loop|Sensor augmented pump (combination of insulin pump and continuous glucose monitoring) (open-loop system)
62608535|NCT03410212|SHAM_COMPARATOR|No injection|In the control group, 5 minutes following the IANB, the sham injection will be provided at the same place of the first injection.
62608536|NCT05673096|EXPERIMENTAL|PACT + Management as usual|"PACT + management (MAU - see comparator intervention). PACT is a parent-mediated and video-aided intervention designed to improve socio-communicative functioning in children with ASD. The intervention is based on theory and research on pre-linguistic and early social interaction and language development. The programme focuses on changing the interaction in the parent-child dyad in order to enhance communication and language development and skills in children with ASD.~The overall focus of the intervention is to guide parents to provide a sensitive, highly adapted interaction context in which their own responses and language are matched to the child's communication competence and language comprehension. Parents learn to identify windows of opportunity to facilitate joint interactions, enhance emerging communication, elicit child intentionality and support language comprehension, thereby aiming to ameliorate abnormal developmental pathways."
62623502|NCT04962087|EXPERIMENTAL|Health enSuite Insomnia - Deprescribing|All participants in Trial 2 will be initiating a gradual medication tapering schedule recommended to them by their physician. The module physicians use to refer their patients to the study includes a section where they fill out a brief drug history for sleep medications. This information is then used to generate a tapering schedule that the health care provider will review with their patient. Health care providers are responsible for providing appropriate medication counselling and follow-up care to supervise deprescribing. This study does not place any restriction on the usual care participants will receive.
62830905|NCT06533787||Group 2|Hemodynamically stable neonates
62830906|NCT03298334|ACTIVE_COMPARATOR|Receives Vaginal Seeding|
62830907|NCT03298334|SHAM_COMPARATOR|No Vaginal Seeding|
62608537|NCT05673096|ACTIVE_COMPARATOR|Management as usual|"Enhanced management as usual (MAU). MAU is delivered by the regional Child and Adolescent Mental Health Center (CAMHS). All participants will have equal access to seek advice via a telephone hotline in the trial period (12 months).~Following the diagnosis of ASD, the parents will be offered psychoeducation as usual in the local CAMHS. A telephone hotline open to all participants will offer pedagogical advice and try to help the parents to collaborate and engage with their professional partners in the municipality. The parents will also be able to contact the CAMHS when needed. The hotline team will be able to consult with the responsible clinician at the CAMHS. The clinician should always be notified within the same day, if a parent describes acute worsening of the child's condition, risk of suicidality, or severe aggression. The responsible clinician will be able to refer the child to further assessment and treatment within the CAMHS without any significant delay."
62608538|NCT01578226||Decompensated cirrhotic patients|Cirrhotic patients presenting with clinically detectable ascites (Grade 2 o Grade 3)
62608539|NCT03050112|EXPERIMENTAL|Congenital cardiopathy|Patients having had surgery in adulthood for a congenital heart disease, at the Brugmann University Hospital. The group consists in patients aged 16 years or older, having had surgery between 01/01/1998 and 31/12/2015.
62608540|NCT06557733|EXPERIMENTAL|Prevention (TPST-1495)|Patients receive TPST-1495 PO QD for 6 months in the absence of unacceptable toxicity. Patients also undergo EGD and GI endoscopy with biopsy at baseline and end of treatment and undergo blood sample collection throughout the study.
62608541|NCT06588166||Study cohort consists of patients enrolled in the national colorectal cancer (CRC) screening program|Participants will be selected among those enrolled in the national colorectal cancer (CRC) screening program and among who refer to all centers involved in this study for screening colonoscopy. Patients with all inclusion criteria and none of the exclusion criteria will be considered for this study. In this cohort 1006 patients will be enrolled (838 patients by sample size + 168 patients as validation cohort)
62608542|NCT01861418|PLACEBO_COMPARATOR|Sham manipulation|Each participant will lie in a supine position. The treating investigator (TI) will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The TI will side bend the participant's spine towards the non-painful side, reach through the participant's hands and perform a spinal rotation away from the painful side. The TIs other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side. Lastly, the TI will take up the slack and maintain the pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If the participant can tolerate the pressure for at least 5 seconds. Then, the subjects will be re-positioned to the starting position.
62608543|NCT01861418|EXPERIMENTAL|Lumbopelvic Manipulation, Chicago|Each participant will lie in supine position. The treating investigator (TI) will stand opposite of the low back pain. Participant will clasp his/her hand behind the neck. TI will side bend the participant's spine toward non-painful side, reach through participant's hands and perform a spinal rotation away from the painful side. TI's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side. The TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from the participant and the TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
62608544|NCT06271278|EXPERIMENTAL|Emotional Freedom Techniques group|The Nurse Introduction Form, Subjective Discomfort Unit, Alarm Fatigue Scale, and Work Stress Scale were administered to the experimental group prior to patient care. The Emotional Freedom Technique was explained, and the nurses were instructed to apply it before and after their shifts for one week. One week later, the Subjective Discomfort Unit, Alarm Fatigue Scale, and Work Stress Scale were applied again.
62608545|NCT06271278|NO_INTERVENTION|Control group|No applications were administered to nurses working in the surgical intensive care unit. In the control group, data was collected before patient care using the Nurse Introduction Form, Subjective Discomfort Unit, Alarm Fatigue Scale, and Work Stress Scale. No interventions were performed. One week later, the Subjective Discomfort Unit, Alarm Fatigue Scale, and Work Stress Scale were applied again.
62608546|NCT03595358|EXPERIMENTAL|Arm|"Ellume Home Flu Test and ellume.lab Flu A+B Test~Upper respiratory tract samples from participants will be tested with:~Ellume Home Flu Test; ellume.lab Flu A+B Test; Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and viral culture."
62608547|NCT03768024|EXPERIMENTAL|Treatment A: GRT0151Y 100 mg|Treatment A: GRT0151Y 100 mg free base: 2 × GRT0151Y 50 mg capsules and 6 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
62608548|NCT03768024|EXPERIMENTAL|Treatment B: GRT0151Y 200 mg|Treatment B: GRT0151Y 200 mg free base: 4 × GRT0151Y 50 mg capsules and 4 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
62608549|NCT03768024|EXPERIMENTAL|Treatment C: GRT0151Y 400 mg|Treatment C: GRT0151Y 400 mg free base: 8 × GRT0151Y 50 mg capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
62608550|NCT03768024|EXPERIMENTAL|Treatment D: Matching placebo|Treatment D: Matching placebo to GRT0151Y and hydromorphone IR: 8 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
62608551|NCT03768024|EXPERIMENTAL|Treatment E: Hydromorphone IR 4 mg|Treatment E: Hydromorphone IR 4 mg: 1 × hydromorphone IR 4 mg tablet (encapsulated) and 7 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
62048313|NCT03233802|ACTIVE_COMPARATOR|Packaged Cognitive-Behavioral (PCBT)|Intervention: Cognitive-Behavioral PCBT consists of 12 weekly visits of individual treatment. PCBT is designed to remediate deficits in skills for coping with interpersonal (e.g., social pressure, conflict with others) and intrapersonal (e.g., craving, anger) antecedents to drinking. The treatment consists of 6 mandatory modules (e.g., managing cravings) plus 6 electives from a list of 10 (e.g., receiving criticism; scheduling pleasant activities).The treatment, based on manuals developed for our previous clinical research provides a structured experience using didactic presentations, behavioral rehearsal, and homework practice exercises.
62250645|NCT01732796|EXPERIMENTAL|Allocated 24 weeks BI 207127 + BI 201335|24 weeks of BI 207127 and BI 201335 in combination with Ribavirin
62608552|NCT03768024|EXPERIMENTAL|Treatment F: Hydromorphone IR 8 mg|Treatment F: Hydromorphone IR 8 mg: 2 × hydromorphone IR 4 mg tablet (encapsulated) and 6 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
62608553|NCT03768024|EXPERIMENTAL|Treatment G: Hydromorphone IR 16 mg|Treatment G: Hydromorphone IR 16 mg: 4 × hydromorphone IR 4 mg tablet (encapsulated) and 4 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
62608554|NCT01772849|EXPERIMENTAL|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors"
62608555|NCT01772849|NO_INTERVENTION|Standard educational programme|The children receive the standard of care with respect to education this include education in the hospitals school or at home without a class mate and no specific activity to secure continuous linkage with community school and class mates
62048314|NCT03233802|ACTIVE_COMPARATOR|Case Management (CaseM)|Intervention: Social and Instrumental Support CaseM is included to control for cohort and other common factors in treatment. During the 12 individual CaseM sessions the therapist and participant will identify problems in daily living that may be of concern, and consider community resources that might help in dealing with them (e.g., contacting a psychiatrist for depression, or finding a better place to live). The therapist's role is to explore the patient's concerns, help to identify goals and resources, provide verbal support, and troubleshoot difficulties that may arise in obtaining or following through with services. The support and attention to ancillary services has proven effective in reducing drinking in previous studies.
62048315|NCT06490757|OTHER|Ancillary study|PET CT with 18 FDG will be performed in 12 patients in selected centers (Avicenne hospital, Beaujon hospital, Henri Mondor hospital, Bordeaux hospital, Paul brousse hospital, Saint Antoine hospital with nuclear medicine department available and should be done at baseline and 3 months (+/- one week).
62048316|NCT04679402|EXPERIMENTAL|Respiratory Muscle Training Breathing Low Dose Carbon Monoxide|Carbon monoxide 200 ppm in air breathing during daily 30 minute inspiratory loading training sessions. Subjects will breathe the experimental gas through a mouthpiece with nose-clip in place.
62048317|NCT04679402|SHAM_COMPARATOR|Respiratory Muscle Training Breathing Air|Air breathing during daily 30 minute inspiratory loading training sessions. Subjects will breathe air through a mouthpiece with nose-clip in place.
62608556|NCT02993354||Pregnant women|Pregnant women with singleton pregnancy with gestational age greater than or equal to 24 weeks.
62048318|NCT02342886|EXPERIMENTAL|MDR-TB|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg for 26 weeks.
62608557|NCT05651438||E-Athletes|E-Athletes who are over the age of 18, have participated in professional matches for at least one year, and have an E-sports license were evaluated.
62048319|NCT02342886|ACTIVE_COMPARATOR|DS-TB (HRZE), HR|"26 consecutive weeks to DS-TB subjects only, as follows:~HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination) Weeks 1-8 with daily dose per the subjects weight~HR (Rifampicin plus isoniazid combination tablets) Weeks 9 - 26 with daily dose per the subjects weight~Daily dose per the subjects weight as follows: 30-39kg: 2 tablets; 40-54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets."
62440456|NCT03740698|EXPERIMENTAL|BiAP, fixed bolus calculator|Bio-inspired Artificial Pancreas (closed-loop system) with a fixed bolus calculator
62608558|NCT05019885|EXPERIMENTAL|IV Ketamine Hydrochloride|dose 0.5mg/kg of IV Ketamine Hydrochloride over 40 min
62608559|NCT04977362|EXPERIMENTAL|ERAS protocol (intervention group)|The innovative care process in the intervention group is characterized by an interdisciplinary approach according to the previously established enhanced recovery after surgery protocol. This process aims at improving the clinical outcome after cardiac surgery, increasing patient satisfaction and quality of life, enabling early professional reentry and participation, and optimizing the cost-effectiveness of service provision. In addition, intersectoral barriers are being broken down in order to establish an interdisciplinary and cross-sectoral overall care process for patients with heart valve surgery as a new form of care in the future.
62623503|NCT04962087|NO_INTERVENTION|Psychoeducation Control - Deprescribing|Participants allocated to the Control group will receive a version of the Health enSuite Insomnia app that contains a static psychoeducation module. It will contain information related to insomnia and its treatment. Topics covered will include a brief description of cognitive behavioural therapy for insomnia and information about the benefits of medication de-prescribing for those in Trial 2.
62250646|NCT01732796|EXPERIMENTAL|Randomized 16 weeks BI 7127+BI1335 + RBV|16 weeks of BI 207127 and QD BI 201335 RBV, followed by additional 8 weeks of placebo BI 207127+ placebo BI 201335 in combination with placebo RBV
62250647|NCT01732796|EXPERIMENTAL|Randomized 24weeks BI 7127+ BI1335 + RBV|24 weeks of BI 207127and BI 201335 in combination with RBV
62250648|NCT04243850|EXPERIMENTAL|Empagliflozin|Empagliflozine 7 days
62250649|NCT04243850|PLACEBO_COMPARATOR|Placebo|Placebo 7 days
62250650|NCT02958007|EXPERIMENTAL|Peer Education on Exercise for Recovery|A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
62440457|NCT03740698|EXPERIMENTAL|BiAP, ABC4D|Bio-inspired Artificial Pancreas (closed-loop system) with the Advanced Bolus Calculator for Diabetes (ABC4D)
62440458|NCT03309891|EXPERIMENTAL|Cohort 1|GX-H9 subcutaneous injections (weekly)
62440459|NCT03309891|EXPERIMENTAL|Cohort 2|GX-H9 subcutaneous injections (weekly)
62440460|NCT03309891|EXPERIMENTAL|Cohort 3|GX-H9 subcutaneous injections (twice-monthly)
62440461|NCT03309891|ACTIVE_COMPARATOR|Cohort 4|Genotropin subcutaneous injections (daily)
62830908|NCT05557188|PLACEBO_COMPARATOR|Sham Grounding|Each pregnant woman in the placebo group is going to be informed about the Sham grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
62440462|NCT03522584|EXPERIMENTAL|Treatment (tremelimumab, durvalumab, HIGRT, SBRT)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1, week 1. Treatment repeats every 4 weeks for up to 4 cycles or every 6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes on day 1, week 16. Treatment repeats every 4 weeks for up to 9 cycles or every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo hypofractionated radiation therapy using either HIGRT or SBRT over 3 fractions QOD during week 3.
62440463|NCT02044978|ACTIVE_COMPARATOR|Bisphosphonate implant|Dental implant coated with zoledronate Note: Both arms in each patient (2 implants)
62440464|NCT02044978|PLACEBO_COMPARATOR|control|Dental implant without coating Note: Both arms in each patient (2 implants)
62440465|NCT04636528|EXPERIMENTAL|Digital Rehabilitation|Home-based 8-week rehabilitation sessions using SWORD Phoenix®, under remote monitoring by a physical therapist
62440466|NCT04636528|ACTIVE_COMPARATOR|Conventional Rehabilitation|Outpatient clinic-based 8 week rehabilitation program with face-to-face PT sessions
62440467|NCT02124109||Control|Control group
62440468|NCT02124109||rheumatic heart disease|Patients with rheumatic heart disease
62440469|NCT01607138||Total laryngectomy|A group of patients who underwent total laryngectomy with trechea esophageal puncture (TEP)
62608560|NCT04977362|ACTIVE_COMPARATOR|Treatment as usual (control group)|The control group undergoes standard heart valve surgery. In this case, no preoperative interventions take place, the patient is operated on the affected heart valve in a minimally invasive procedure without prehabilitation. After surgery, the patient is transfered to an intensive care unit (not a specialized postanesthesia care unit) depending on the individual condition and then transfered to the general ward. Patients receive medical, nursing, and physiotherapeutic care in accordance with current hospital standards.
62608561|NCT04686266|EXPERIMENTAL|ViCCY: Health Information + Health Coaching|This group will receive 10 front-loaded sessions of virtual health coaching by trained Health Coaches over 6 months with content based on the theoretical framework our prior research. Sessions are provided using tablets. Initially, sessions are weekly to build the relationship, but the frequency of sessions decreases over time
62250651|NCT02958007|ACTIVE_COMPARATOR|Enhanced supervised fitness training|A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
62250652|NCT02560363|EXPERIMENTAL|Treatment sequence 1|Period 1:Fast ER formulation of AZD9977 Period 2:Intermediate ER formulation of AZD9977 Period 3:Slow ER formulation of AZD9977 Period 4:IR formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
62250653|NCT02560363|EXPERIMENTAL|Treatment sequence 2|Period 1:Intermediate ER formulation of AZD9977 Period 2:IR formulation of AZD9977 Period 3:Fast ER formulation of AZD9977 Period 4:Slow ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
62440470|NCT00312000|ACTIVE_COMPARATOR|1Capecitabine-irinotecan|1st line- 2nd line (3rd line oxaliplatin plus capecitabine)
62440471|NCT00312000|EXPERIMENTAL|2capecitabine plus irinotecan|1st line (2nd line oxaliplatin plus capecitabine)
62440472|NCT03956433|EXPERIMENTAL|Docosahexaenoic Acid enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) to be consumed daily for 4 weeks.
62440473|NCT03956433|EXPERIMENTAL|Beta-glucan enriched pancakes|One portion of pancakes enriched with 3 g beta-glucan (BG) to be consumed daily for 4 weeks.
62440474|NCT03956433|EXPERIMENTAL|Anthocyanin enriched pancakes|One portion of pancakes enriched with 320 mg anthocyanins (AC) to be consumed daily for 4 weeks.
62830909|NCT05557188|ACTIVE_COMPARATOR|Grounding|Each pregnant woman in the placebo group is going to be informed about the grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
62830910|NCT01028820|EXPERIMENTAL|Open-Label, Flexible-Dose Aripiprazole|This is a single group assignment pharmacodynamics study in which all study participants are given an open-label, flexible dose of aripiprazole for up to 8 weeks.
62608562|NCT04686266|NO_INTERVENTION|Health Information|Caregivers in the Health Information group are asked to spend at least 30 minutes weekly using the computer tablet provided to you by the study team to access recommended websites
62048320|NCT02342886|EXPERIMENTAL|DS-TB PA-824 200mg 26 weeks|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once daily for 26 weeks
62048321|NCT02342886|EXPERIMENTAL|DS-TB PA-824 200mg 17 weeks|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once a day for 17 weeks
62250654|NCT02560363|EXPERIMENTAL|Treatment sequence 3|Period 1:Slow ER formulation of AZD9977 Period 2:Fast ER formulation of AZD9977 Period 3:IR formulation of AZD9977 Period 4:Intermediate ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
62250655|NCT02560363|EXPERIMENTAL|Treatment sequence 4|Period 1:IR formulation of AZD9977 Period 2:Slow ER formulation of AZD9977 Period 3:Intermediate ER formulation of AZD9977 Period 4:Fast ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
62250656|NCT06493344|EXPERIMENTAL|Spastic Cerebral Palsy Group|Conventional physiotherapy and training with applying additional weight
62048322|NCT02342886|EXPERIMENTAL|DS-TB PA-824 100mg 17 weeks|moxifloxacin 400 mg + PA-824 100 mg + pyrazinamide 1500 mg orally once daily for 17 weeks
62440475|NCT03956433|EXPERIMENTAL|DHA+BG enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) plus 3 g beta-glucan (BG) to be consumed daily for 4 weeks.
62440476|NCT03956433|EXPERIMENTAL|DHA+AC enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) plus 320 mg anthocyanins (AC) to be consumed daily for 4 weeks.
62440477|NCT00525967|ACTIVE_COMPARATOR|1|Methadone plus Placebo
62440478|NCT00525967|EXPERIMENTAL|2|Methadone plus Acetaminophen
62440479|NCT03325647|EXPERIMENTAL|Visit 1 Drug, Visit 2 Placebo|Subjects in this group will be randomized to receive Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution every 4 weeks x 3 doses, beginning at visit 1, and Placebo Injectable Saline beginning at visit 2.
62440480|NCT03325647|EXPERIMENTAL|Visit 1 Placebo, Visit 2 Drug|Subjects in this group will be randomized to receive Placebo Injectable Saline beginning at visit 1, and Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution every 4 weeks x 3 doses beginning at visit 2.
62440481|NCT00564174|EXPERIMENTAL|a|
62440482|NCT00564174|ACTIVE_COMPARATOR|b|Low dose aspirin only
62440483|NCT04480411|EXPERIMENTAL|COVID-19 Patients|Patients that are admitted to the hospital with COVID 19.
62440484|NCT01518452|EXPERIMENTAL|working memory training|Cogmed JM working memory training
62440485|NCT01518452|EXPERIMENTAL|delayed working memory training|Cogmed JM working memory training after 8 weeks waiting
62440486|NCT04766918|EXPERIMENTAL|High molecular weight hyaluronic acid|Ultrasound-guided hydrodissection with high molecular weight hyaluronic acid between carpal tunnel and median nerve (total 2 times with one-week interval)
62440487|NCT04766918|ACTIVE_COMPARATOR|Low molecular weight hyaluronic acid|Ultrasound-guided hydrodissection with low molecular weight hyaluronic acid between carpal tunnel and median nerve (total 2 times with one-week interval)
62048323|NCT05399680|EXPERIMENTAL|Interventional|Treatment with SMART RADIANZ, BRITE TIP RADIANZ and SABERX RADIANZ devices
62440488|NCT05965193|EXPERIMENTAL|NBO group|Normobaric Hyperoxia combined with intravenous thrombolysis
62250657|NCT00963755||Primary prostate cancer|Patients referred with a suspicion of prostate cancer based on elevated PSA and rectal examination in whom a prostate biopsy is planned and radical prostatectomy is envisioned in the event of a positive biopsy finding
62250658|NCT00963755||Prostate cancer relapse|Patients previously treated for prostate cancer and being investigated for biochemical relapse, (mostly in the Urology and Radiation Therapy Department, but not exclusively), for whom surgical or radiation therapy is envisioned in the event of a positive FCH-PET finding
62440489|NCT05965193|PLACEBO_COMPARATOR|Control group|Nasal oxygen combined with intravenous thrombolysis
62440490|NCT03055533|EXPERIMENTAL|Immediate intervention with Headsprout reading program|Participants randomized to this study arm will begin treatment with the Headsprout program right away. Reading assessments will occur at the beginning and end of 12 weeks of treatment. Participation may be in clinic or via telehealth.
62830911|NCT04013477|EXPERIMENTAL|Cohort1|"drug : DA-5207 80mg/40cm²~placebo : 40cm²"
62048324|NCT06217757|EXPERIMENTAL|Low-dose radiotherapy combined with sugemalimab, olaparib, etoposide and cisplatin|Participants will receive the following treatment regimens: LDRT cisplatin + etoposide + sugemalimab+olaparib. Induction treatment will be administered on a 21-day cycle for four cycles. LDRT will be conducted from Day 1 - Day 5 in the first cycle. Following the induction phase, participants will continue maintenance therapy with sugemalimab and olaparib. Participants will be treated until loss of clinical benefit, or unaccepted toxicity, or withdrawal of consent, or death (whichever occurs first).
62048325|NCT04444037||OCT-guided PCI|PCI procedure was done with intra-coronary imaging OCT.
62048326|NCT04444037||Angiography-guided PCI|PCI procedure was done without any intra-coronary imaging assistance, guided by angiography alone
62048327|NCT03751631|OTHER|1-TR/PE, 2-TR, 3-PE|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
62048328|NCT03751631|OTHER|1-TR/PE, 2-PE, 3-TR|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
62048329|NCT03751631|OTHER|1-TR, 2-TR/PE, 3-PE|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
62048330|NCT03751631|OTHER|1-TR, 2-PE, 3-TR/PE|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
62048331|NCT03751631|OTHER|1-PE, 2-TR/PE, 3-TR|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
62440491|NCT03055533|NO_INTERVENTION|Delayed intervention|Participants randomized to this study arm will have reading assessments at the beginning and end of the study, but they will not begin treatment with the Headsprout program until after their participation in the study ends (12 weeks). Participation may be in clinic or via telehealth.
62440492|NCT03036033|EXPERIMENTAL|SaeboGlove Therapy|All participants will be given a SaeboGlove for a 4-week period to use along side their routine functional based training program.
62440493|NCT05644691||Lipikar Baume AP+M|The group applies Lipikar Baume AP+M twice daily for 3 months. Participants have 4 visits (Day0, Day 28, Day56, Day84) with different outcome measures including self-evaluations).
62440494|NCT05644691||Usual emollient|The group applies their usual emollient twice daily for 3 months. Participants have 4 visits (Day0, Day28, Day56, Day84 with different outcome measures including self-evaluations).
62440495|NCT01312610|EXPERIMENTAL|High flavonone orange juice drink|
62440496|NCT01312610|PLACEBO_COMPARATOR|Control orange juice drink|Juice drink matched for sugar content
62440497|NCT02482805|EXPERIMENTAL|Power Posing|Individuals hold two, 1-minute postures associated with dominance and high power prior to exposure therapy.
62048332|NCT03751631|OTHER|1-PE, 2-TR, 3-TR/PE|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
62048333|NCT02316522||Group I: T2D nephropathy|Individuals with type 2 diabetes and nephropathy
62048334|NCT02316522||Group II: T2D and no nephropathy|Individuals with type 2 diabetes and no nephropathy
62048335|NCT02316522||Group III: Control, non-diabetic|Non-diabetic individuals with normal kidney function
62048336|NCT02316522||Group IV: Controls, non-diabetic|Non-diabetic individuals with hypertensive nephropathy
62048337|NCT03509974|EXPERIMENTAL|Bone Anchored Hearing Device (OSIA)|All subjects will receive the Bone Anchored Hearing Device (OSIA)
62048338|NCT03778879|EXPERIMENTAL|Group 1:With CCX872-B|Concurrent SBRT 25 Gy in 5 fractions over 5-7 days, and 21 days of CCX872-B therapy. CCX872-B 150 mg by mouth twice daily approximately 12 hours apart.
62048339|NCT03778879|NO_INTERVENTION|Group 2:Without CCX872-B|SBRT Alone: 25 Gy in 5 fractions over 5-7 days
62048340|NCT05864664|EXPERIMENTAL|WALANT procedure|"Patient awake with no form of sedation or analgesia~A mixture of lidocaine, adrenaline, normal saline, bicarbonate is used to get 40-50ml solution Injection is performed around incision site - superficial to deep including periosteum Incision is performed in the normal fashion Plate and screws are removed and incision is closed"
62440498|NCT02482805|EXPERIMENTAL|Submissive Posing|Individuals hold two, 1-minute postures associated with submissiveness and low power prior to exposure therapy.
62440499|NCT02482805|EXPERIMENTAL|Rest|Individuals rest (no postures) for 2 minutes prior to exposure therapy.
62440500|NCT06545136|EXPERIMENTAL|Dosed with FLT201|
62830912|NCT04013477|EXPERIMENTAL|Cohort2|"drug : DA-5207 120mg/60cm²~placebo : 60cm²"
62830913|NCT04013477|EXPERIMENTAL|Cohort3|"drug : DA-5207 160mg/80cm²~placebo : 80cm²"
62830914|NCT04013477|ACTIVE_COMPARATOR|Cohort4|drug : Aricept
62830915|NCT04181658|EXPERIMENTAL|Real tDCS and Physical Therapy|This arm combines tDCS and Physical Therapy intervention. The real tDCS will be delivered before each physical therapy visit for up to 10 combined sessions. The tDCS montage was designed to target the left dorsal lateral prefrontal cortex (DLPFC) for around 20 minutes. The direct current delivered by any electrode will not exceed 2.0 milliamp(mA) and the total amount of current from all electrodes will not exceed 4 mA.
62830916|NCT04181658|SHAM_COMPARATOR|Sham stimulation and Physical Therapy|This arm combines sham stimulation and Physical Therapy intervention. The sham stimulation will be delivered before each physical therapy visit for up to 10 combined sessions. We will use an active sham stimulation in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This montage was designed to deliver currents not significantly influence their cortical tissue, but still, mimic the cutaneous sensations induced by tDCS over the same brain site (i.e. left DLPFC).
62830917|NCT06139120||Chronic subacromial pain|Patients with central sensitization associated with chronic pain syndrome
62440501|NCT03719183||Acute Myeloid Leukemia (AML) group|"Patients who are diagnosed as Acute Myeloid Leukemia based on peripheral blood, bone marrow aspiration and immunophenotyping and fulfill WHO criteria for diagnosis.~Fluorescent in Situ Hybridization (FISH) Panels for AML, Multiplex FISH (M-FISH) and Conventional Cytogenetics Studies will be performed for AML patients."
62830918|NCT06139120||Control|Healthy participants
62830919|NCT04050735|EXPERIMENTAL|Alcohol, ethyl, moderate dose|0.6 gram ethyl alcohol per kilogram of body weight
62830920|NCT04050735|PLACEBO_COMPARATOR|Placebo|0 gram ethyl alcohol per kilogram of body weight
62830921|NCT06239675|EXPERIMENTAL|tDCS+CIMT|Participants will receive concurrent anodal tDCS (20 minutes, 1mA\~2mA) and CIMT (2 hours) five days a week for three weeks in a row.
62830922|NCT06239675|SHAM_COMPARATOR|sham+CIMT|Participants will receive concurrent sham tDCS and CIMT (2 hours) five days a week for three weeks in a row.
62830923|NCT05562895||Subjects with biopsy of pulmonary nodule using Ion Endoluminal System and Cios Spin|Subjects in which a pulmonary nodule biopsy was attempted or performed with the integrated Ion Endoluminal System and Cios Spin
62830924|NCT00568022|EXPERIMENTAL|Ixabepilone + Capecitabine|
62440502|NCT02493725|ACTIVE_COMPARATOR|Eculizumab|Eculizumab, 900 mg intravenously once a week
62440503|NCT02493725|PLACEBO_COMPARATOR|Placebo|Matched placebo, intravenously once a week
62440504|NCT03169777|EXPERIMENTAL|Nant CRC Vaccine|avelumab, bevacizumab, capecitabine, cetuximab, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
62608563|NCT06302023|EXPERIMENTAL|DHA supplement|DHA supplement 1000mg per day
62608564|NCT06302023|NO_INTERVENTION|no DHA supplement|no DHA supplement
62830925|NCT01341353|ACTIVE_COMPARATOR|Antiarrythmic Drugs|
62830926|NCT01341353|EXPERIMENTAL|ablation|
62830927|NCT03469414||Wheelchair Mobility and Speed|This group will participate in activity-based measures employed in routine occupational and physical therapy practice to assess participants' wheelchair speed, maneuverability, and endurance. These measures include: the Life Space Assessment Scale, 6-Minute Push Test, Forward Push Test, Wheelchair Slalom Test, Craig Handicap Assessment and Reporting Technique, and PART-O.
62830928|NCT03469414||GPS Tracking|A GPS tracker will be placed on the wheelchairs of 25 individuals who consent to participate in this arm of the project. Using a GPS tracker will provide a direct measure of the community locations these participants go. The GPS location is collected every minute, and mapped to Google Maps, which would allow calculation of speed of movement.
62830929|NCT03860649|EXPERIMENTAL|Nordic Walking|The patient walk program consists of 3 moments: warm up, walk and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed - SSWS (3 'SSWS), then walk according to the training cycle, the intensity will be between 60 to 80% of the Heart of Ratio reserve. In addition, the intensity of the classes will be measured in each phase by the Borg Scale of Perceived Exertion.
62830930|NCT03860649|EXPERIMENTAL|Jogging|This group will undergo 24 Dance sessions. Aquatic therapy patients will receive deep water running intervention with the use of flotation vests. The exercises will consist of: immersion, balance, strength, agility, and movement within the water. The intensity of the classes will be measured in each moment and by the Borg Scale of Perceived Exertion.
62048341|NCT05864664|ACTIVE_COMPARATOR|General anesthesia|The surgery is performed in the standard fashion. The patient received general anesthesia The surgery is performed normally and the plate/screws are removed
62048342|NCT05174663|EXPERIMENTAL|Almond-enriched diet dose 1|Participants will be instructed to ingest 1.5 oz of almonds daily for 16 weeks. The 1.5 oz of almonds can be split into a morning and afternoon snack. Participants will be advised not to exceed 2 doses of almonds daily. If a dose is missed, participants should take the missed dose as soon as the participants remember.
62048343|NCT05174663|EXPERIMENTAL|Almond-enriched diet dose 2|Participants will be instructed to ingest 2.5 oz of almonds daily for 16 weeks. The 2.5 oz of almonds can be split into a morning and afternoon snack. Participants will be advised not to exceed 2 doses of almonds daily. If a dose is missed, participants should take the missed dose as soon as the participants remember.
62048344|NCT05174663|OTHER|Nut-free diet|Participants will be instructed to ingest the control snack (Iso-caloric \[to 1.5 oz of almonds\] control snack of chocolate chip cookies or Oreo cookies) daily for 16 weeks. The control snack can be split into a morning and afternoon snack. Participants will be advised not to exceed 2 doses of snack daily. If a dose is missed, participants should take the missed dose as soon as the participants remember.
62048345|NCT04487067|EXPERIMENTAL|Atezolizumab + Bevacizumab|Participants will receive atezolizumab 1200 mg intravenous (IV) infusions Q3W (dosed in 3-week cycles) + bevacizumab 15 mg/kg IV Q3W (dosed in 3-week cycles)
62048346|NCT02264522|EXPERIMENTAL|Single Arm|"All patients will be enrolled in the same intervention arm. Interventions are implemented based in 1-4 event levels on the device. Interventions include: Place dialysis chair into position 3, Decrease dialysate temperature, Decrease ultrafiltration rate by 25%, and Decrease ultrafiltration rate by 50%."
62440505|NCT03179683|ACTIVE_COMPARATOR|Diode laser application|An 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side (treatment group)
62048347|NCT02748187|EXPERIMENTAL|Intervention|Cognitive Behavioural Analysis System of Psychotherapy
62048348|NCT01826240|EXPERIMENTAL|MBCT+SPI|Note: There is only one condition in this study. Mindfulness-Based Cognitive Therapy (MBCT) is combined with Safety Planning Intervention (SPI). All individuals who choose to participate will receive MBCT+SPI.
62048349|NCT04609267|EXPERIMENTAL|Paper Baseline|Half of the participants will complete the PHQ-9 in the traditional paper format at their first appointment. At their second appointment 1-month later, they will complete the PHQ-9 on the Mirror device equipped with Amazon Alexa.
62048350|NCT04609267|EXPERIMENTAL|Mirror Baseline|Half of the participants will complete the PHQ-9 on the Mirror device equipped with Amazon Alexa at their first appointment. At their second appointment 1-month later, they will will complete the PHQ-9 in the traditional paper format.
62048351|NCT05541016|ACTIVE_COMPARATOR|Group 1 (observation)|Patients undergo observation following standard of care surgery. Patients undergo modified barium swallow study (MBSS) at pre-op, 2 weeks post-op, and 3 months follow-up. Patients also undergo CT, PET/CT, or magnetic MRI at baseline and 3 months and 1, 2 and 5 years post treatment. Patients undergo blood specimen collection for NavDx testing at pre-op, 1-2 days post-op, 2 weeks post-op, and 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48, and 60 months as well as saliva sample collection at pre-op, end of RT, and any clinical recurrence.
62048352|NCT05541016|EXPERIMENTAL|Group 2 (DART, docetaxel)|Patients undergo DART with/without mucosal sparing BID on days 1-12 Monday-Friday for a total of 20 fractions within 8 weeks of standard of care surgery. Patients receive concurrent docetaxel IV over 1 hour on days 1 and 8 (Mondays preferred). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo MBSS at pre-op, 2 weeks post-op, and 3 and 12 months post-treatment. Patients also undergo CT, PET/CT, or MRI at baseline and 3 months and 1, 2 and 5 years post treatment. Patients undergo blood specimen collection for NavDx testing at pre-op, 1-2 days post-op, 2 weeks post-op, end of RT, and 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48, and 60 months as well as saliva sample collection at pre-op, end of RT, and any clinical recurrence.
62440506|NCT03179683|NO_INTERVENTION|No application|no treatment were aplied
62440507|NCT00832078|OTHER|Group A|SCCM (SpeediCath Compact Male catheter) then SC (SpeediCath cathter) on test day 1. SC then SCCM on test day 2
62608565|NCT04045899|ACTIVE_COMPARATOR|ProSeal Laryngeal Mask Airway Group|ProSeal LMA was inserted in 50 patients
62608566|NCT04045899|EXPERIMENTAL|Air-Q LMA Group|Air-Q LMA was inserted in 50 patients
62608567|NCT04045899|EXPERIMENTAL|Ambu AuraGain LMA Group|Ambu AuraGain was inserted in 50 patients
62608568|NCT04996511|EXPERIMENTAL|Colorectal Surgery Patients|
62048353|NCT05541016|EXPERIMENTAL|Group 3 (IMRT/IMPT, with/without cisplatin)|Patients undergo IMRT or IMPT QD on days 1-40 Monday-Friday for a total of 30 fractions within 6 weeks of standard of care surgery. Depending on risk status, patients may also receive concurrent cisplatin IV over 1-2 hours once a week QW on Monday, Tuesday, or Wednesday or once every 3 weeks for 6 doses (or accepted alternate regimen when drug shortage applies per physician discretion). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo MBSS at pre-op, 2 weeks post-op, and 3 and 12 months post-treatment. Patients also undergo CT, PET/CT, or MRI at baseline and 3 months and 1, 2 and 5 years post treatment. Patients undergo blood specimen collection for NavDx testing at pre-op, 1-2 days post-op, 2 weeks post-op, end of RT, and 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48, and 60 months as well as saliva sample collection at pre-op, end of RT, and any clinical recurrence.
62608569|NCT06255717|EXPERIMENTAL|The observation group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
62048354|NCT05541016|EXPERIMENTAL|Group 4 (IMRT/IMPT, cisplatin)|Patients undergo IMRT or IMPT therapy QD on days 1-40 Monday-Friday for 28 or 35 fractions based on biomarker response along with concurrent cisplatin IV over 1-2 hours QW on Monday, Tuesday, or Wednesday or once every 3 weeks for 6 doses (or accepted alternate regimen when drug shortage applies per physician discretion). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo MBSS prior to RT and at 3 and 12 months post RT. Patients undergo CT, PET/CT, or MRI at baseline and 3 months and 1, 2 and 5 years post treatment. Patients undergo blood specimen collection for NavDx testing pre-RT, 4 weeks into RT, anticipated fraction 20, end of RT, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48, and 60 months as well as saliva sample collection at pre-op, end of RT, and any clinical recurrence.
62830931|NCT03860649|EXPERIMENTAL|Dance|This group will undergo 24 Dance sessions inspired by Forró dance rhythm and Samba dance rhythm. Classes will be divided into four stages: Joint warm up and stretching on the chairs; strengthening, balance and rhythm exercises with the support of the barre; exercises inspired by the Samba and Forró dance (Brazilian ballroom dance) basic steps; and Final cool down. The intensity of the classes will be measured according to the beats per minute (BPMs) of the songs used in each moment and by the Borg Scale of Perceived Exertion.
62048355|NCT01293058|OTHER|Intravenous|The investigators administered intravenous naloxone for our opioid overdose patients
62048356|NCT01293058|OTHER|Intranasal|The investigators administered intranasal naloxone for treatment of our patients
62048357|NCT04517864|EXPERIMENTAL|Treatment Arm: PF-06651600|ritlecitinib 200 milligram (mg) once per day (QD) (four 50 mg tablets) for 4 weeks then ritlecitinib 50 mg tablet QD through month 24. At Month 9, participants assigned to this treatment arm will also receive 3 tablets of placebo for 4 weeks to maintain the blind with the other arm. After month 24, participants switch to 50 mg capsules, 1 QD, up to month 60.
62048358|NCT04517864|OTHER|Control Arm (Placebo) followed by active therapy extension|matching comparator: placebo QD (4 tablets x 4 weeks then 1 tablet x 8 months) then ritlecitinib 200 mg QD (four 50 mg tablets) for 4 weeks then ritlecitinib 50 mg tablet QD through month 24. After month 24, participants switch to 50 mg capsules, 1 QD, up to month 60.
62048359|NCT02007005|EXPERIMENTAL|Dose escalation|intravesical instillation of abnobaVISCUM Fraxini
62048360|NCT03118024|ACTIVE_COMPARATOR|Fluid restriction|Crystalloid fluid max. 2.0 ml/kg/h, no administration of colloids, noradrenaline max. 0.15 µg/kg/min
62048361|NCT03118024|ACTIVE_COMPARATOR|Catecholamine restriction|Noradrenaline max. 0.04 µg/kg/min, fluids max. 8.0 ml/kg/h
62048362|NCT02445040|EXPERIMENTAL|Babylog VN500 in HFOV mode|Subjects will be treated with HFOV provided by the Babylog VN500 - the investigational device - for up to 14 days.
62048363|NCT02172625|PLACEBO_COMPARATOR|Placebo Group|Corn starch and food coloring is the placebo comparator. Each subject will ingest 675 mg (1 pill) per day of the placebo comparator
62048364|NCT02172625|EXPERIMENTAL|Protandim Dietary Supplement|Each subject will ingest 675 mg per day (1 pill) of Protandim for about 90 days. Each pill contains 5 botanicals (Bacopa extract 150 mg, milk thistle 225mg, ashwagandha 150 mg, green tea 75 mg, turmeric 75 mg).
62048365|NCT03323619||GA|No intervention. General anesthesia is decided by the physicien according to his usual practice
62608570|NCT06255717|ACTIVE_COMPARATOR|The control group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
62608571|NCT05413122|EXPERIMENTAL|Intensive Behavioral Counselling|Participants randomized to the Intensive Behavioural Counselling condition will receive in-person intensive (\~45 minutes) behavioural counselling in the clinic at screening and at weeks 2, 4, 8, and 12. Additionally, on non-clinic visit weeks participants will receive (1) one phone call each week from the clinic counsellor, and (2) two text messages each week providing encouragement and advice. \].
62608572|NCT05413122|EXPERIMENTAL|Peer Support|Participants randomized to receive Peer Support will be engaged by participants' own peer counsellor over weeks -2 to 12. Peer counselling will follow a flexible framework for contact with participants, which will include in-person and phone-based check-ins, depending upon individual participant preference. Peer counsellors will visit the counsellors' assigned participant in-person at participants' home, workplace, or other setting based on participant preference at least during weeks -2, 2, 4, 8 and 12; additional in-person contact will be provided upon participant request.
62608573|NCT05413122|EXPERIMENTAL|c-NRT|A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package. Participants will be provided with education on its use, including where and how to place a patch, strength of patches to use and how to taper, not smoking while using the patch, and using gum ad hoc; the investigators will also discuss possible side effects. Participants will be given a number to call should the participants require assistance, and weekly calls will be made to participants to screen for adverse events and monitor adherence; calls will taper to every other week after four weeks.
62608574|NCT05413122|EXPERIMENTAL|Varenicline|At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician according to randomization into the varenicline condition and participants will be provided with education on its use. Participants will be instructed to begin taking varenicline one week prior to participants' quit date and for 11 weeks following quit date. Participants will be given a number to call should the participants require assistance, and weekly calls will be made to participants to screen for adverse events and to monitor adherence; calls will taper to every other week after four weeks.
62830932|NCT03860649|EXPERIMENTAL|Pilates Training|"Classes composed of three phases: Warming up, main part and back to calm. Warming up will begin with pre-Pilates training exercises for 5 minutes (eg. breathing exercises, hip joint mobilization, shoulder girdle, etc.), the main part of the lesson will be the Pilates training drill sequence for the beginner level that will be conducted for 50 minutes in which all exercises will be performed on the floor.~The sequence of the eighteen exercises of the main part of the lesson is described in the table below. Back to Calm: will be carried out for 5 final minutes with standing exercises with the subject reclining on the wall to reconnect the subject with orthostatic posture.~In the each of the phases of the lesson will be shown to the subject the table of BORG with the objective of measuring the intensity of perceived exertion, using the Borg Scale of Perceived Exertion."
62830933|NCT06310031|EXPERIMENTAL|BrioVAD System|BrioVAD® Left Ventricular Assist System (BrioVAD® System) by BrioHealth Solutions, Inc.
62830934|NCT06310031|ACTIVE_COMPARATOR|HeartMate 3|HeartMate 3 System by Abbott
62830935|NCT06592937||Patients receiving invasive ventilation|Patients receiving invasive ventilation, included in PRoVENT, PRoVENT-iMiC, and ENIO
62830936|NCT04870047|EXPERIMENTAL|p64 MW HPC Flow Diverter + SAPT|
62830937|NCT04870047|EXPERIMENTAL|p64 MW Flow Diverter + DAPT|
62048366|NCT03323619||LASed|No intervention. Local anesthesia with sedation is decided by the physicien according to his usual practice
62440508|NCT00832078|OTHER|Group B|SC (SpeediCath cathter)then SCCM (SpeediCath Compact Male catheter) on test day 1. SCCM then SC on test day 2
62440509|NCT02404740||VP shunt functioning|No intervention, just a physiological category--patients with VP shunts that are functioning normally.
62440510|NCT02404740||VP shunt malfunctioning|No intervention, just a physiological category--patients with VP shunts that are malfunctioning.
62440511|NCT02404740||No known intracranial pathology|No intervention, just a physiological category--patients without VP shunts that have no known intracranial pathology.
62048367|NCT04793919|ACTIVE_COMPARATOR|Standard Risk (SR)|Patient with APL and WBC less than 10x10e9/L at presentation before start treatment
62048368|NCT04793919|EXPERIMENTAL|High Risk (HR)|Patient with APL, with the highest pre-treatment WBC count equal to or greater than 10x10e9/L at presentation
62440512|NCT05305521||Injectable TSFE|partially edentulous patients needing unilateral sinus floor elevation (residual crestal height \<5 mm) for the placement of a single implant
62440513|NCT03139214|EXPERIMENTAL|Intervention|Parenting intervention, 7 weekly sessions, each session 2 hours in length.
62440514|NCT03139214|NO_INTERVENTION|Control|3 mailings about child development and stress management.
62440515|NCT03917628|EXPERIMENTAL|SCT630|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing SCT630
62440516|NCT03917628|ACTIVE_COMPARATOR|adalimumab-EU source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-EU source
62440517|NCT00270374|EXPERIMENTAL|001|nesiritide
62440518|NCT02870712|EXPERIMENTAL|suture directed|The suture of the perineum is headed by obtaining hemostasis by digital compression 5 minutes; If hemostasis is obtained, the perineum will not be sutured. In case of failure of hemostasis, suture of the perineum will be realized.
62440519|NCT02870712|ACTIVE_COMPARATOR|systematic suture|systematic suture tears following current recommendations
62440520|NCT04822766|ACTIVE_COMPARATOR|Chemotherapy|
62440521|NCT04822766|EXPERIMENTAL|Allogeneic Hematopoietic Cell Transplantation|Time of transplant procedure The best available treatments of AML
62440522|NCT00088777|EXPERIMENTAL|MET|
62440523|NCT00088777|EXPERIMENTAL|CSE|
62608575|NCT05413122|NO_INTERVENTION|Control|No intervention
62608576|NCT05413122|EXPERIMENTAL|Varenicline & c-NRT|Varenicline \& c-NRT
62608577|NCT05413122|EXPERIMENTAL|Peer Support & Varenicline|Peer Support \& Varenicline
62440524|NCT03840746|NO_INTERVENTION|Habitual diet|participants remain on their habitual diet
62440525|NCT03840746|EXPERIMENTAL|Tomato, onion and lovage soup (TOL)|One tin of soup containing Tomato onion and lovage daily for 6 weeks
62830938|NCT03773224|ACTIVE_COMPARATOR|Irrigation|Layer by layer irrigation of the surgical wound with gentamicin-saline solution
62830939|NCT03773224|NO_INTERVENTION|Control|The surgical wound is closed layer by layer without irrigation
62440526|NCT03840746|EXPERIMENTAL|TOL soup with inulin|One tin of Tomato, onion and lovage soup with added inulin for 6 weeks
62440527|NCT05551078||pregnant women with severe IUGR|
62440528|NCT03111979|EXPERIMENTAL|Beta-alanine supplementation|Participants will be supplemented with 4.8g·d-1 β-alanine (CarnoSyn™, NAI, USA). The β-alanine dosing regimen will consist of two 800 mg tablets three times per day at 3-4 hour intervals or the same regimen for placebo tablets. The use of multiple small doses throughout the day has been used in numerous studies using β-alanine in solutions or gelatine capsules (Hoffman et al., 2008; Sale et al., 2011; Saunders et al., 2012; Sale et al., 2012; Tobias et al., 2013) in order to circumvent potential symptoms of paraesthesia (see box xii for possible risks and discomforts). Overall increases have been shown to be between 40% and 80% depending upon dose (between 3.2 and 6.4 g·d-1) and duration of administration (between 4 and 10 weeks) (Sale et al., 2012).
62440529|NCT03111979|PLACEBO_COMPARATOR|Placebo|Participants will be supplemented with 4.8 g·d-1 placebo (maltodextrin; NAI, USA). The regimen will consist of two 800 mg tablets three times per day at 3-4 hour intervals the same regimen for beta-alanine tablets
62440530|NCT03773328|EXPERIMENTAL|CK0801, 50ml|"All subjects will receive adoptive therapy with an infusion of unrelated cord blood-derived regulatory T cells: CK0801. Subjects will receive one 50mL intravenous dose of CK0801 (Treg cells) on study Day 0. A total of three cohorts will be evaluated.~Cohort dosing will be as follows:~Dose level 1 = 1x10e6/kg Treg cells per kg recipient ideal body weight (IBW); Dose level 2 = 3x10e6/kg Treg cells per kg recipient ideal body weight (IBW); Dose level 3 = 1x10e7/kg Treg cells per kg recipient ideal body weight (IBW)."
62440531|NCT02666430|EXPERIMENTAL|Mylan's insulin glargine|Patients will be administered either Mylan insulin glargine or Lantus® subcutaneously, once daily in combination with lispro and titrated based on blood glucose readings per standard of care for a total of thirty-six (36) weeks, split into three cycles of twelve (12) weeks each.
62440532|NCT02666430|ACTIVE_COMPARATOR|Lantus®|Patients will be administered either Mylan insulin glargine or Lantus® subcutaneously, once daily in combination with lispro and titrated based on blood glucose readings per standard of care for a total of thirty-six (36) weeks, split into three cycles of twelve (12) weeks each.
62440533|NCT03135379|EXPERIMENTAL|Heated gel|Patient undergoes ultrasound study using the intervention of heated ultrasound gel.
62440534|NCT03135379|PLACEBO_COMPARATOR|Room temperature gel|Patient undergoes ultrasound study using the intervention of room temperature gel.
62440535|NCT00419926|EXPERIMENTAL|Intensified Mycophenolate Sodium (Myfortic) dosing regimen|In patients randomized to the intensified Myfortic dosing regimen, the initial dose was 2-fold of the labeled dose (i.e. 2880 mg/day). The dosage was reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
62440536|NCT00419926|ACTIVE_COMPARATOR|Standard Mycophenolate Sodium (Myfortic) dosing regimen|In patients randomized to the standard Myfortic dosing regimen, the initial dose of 1440 mg/day had to be maintained throughout the whole study.
62440537|NCT01654146|ACTIVE_COMPARATOR|Arm 1 (Control Arm)|Carboplatin and paclitaxel on day 1 of a 21-day cycle for 6 cycles
62440538|NCT01654146|EXPERIMENTAL|Arm 2 (Research arm)|Carboplatin on day 1 and dose-fractionated weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles
62440539|NCT01654146|EXPERIMENTAL|Arm 3 (Research arm)|Dose-fractionated weekly carboplatin and weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles.
62449437|NCT03869749|EXPERIMENTAL|Learning to BREATHE Plus|It is a 6-week manualized program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University. Adolescents will be sent ecological momentary intervention text messages several times a day (with reminders, encouragement, and guides to practice mindfulness), and also have access to an on demand online library of mindfulness resources.
62608578|NCT05413122|EXPERIMENTAL|c-NRT & Peer Support|c-NRT \& Peer Support
62608579|NCT05413122|EXPERIMENTAL|c-NRT & Peer Support & Varenicline|c-NRT \& Peer Support \& Varenicline
62608580|NCT05413122|EXPERIMENTAL|Intensive Behavioral Counseling & Varenicline|Intensive Behavioral Counseling \& Varenicline
62608581|NCT05413122|EXPERIMENTAL|Intensive Behavioral Counseling & c-NRT|Intensive Behavioral Counseling \& c-NRT
62608582|NCT05413122|EXPERIMENTAL|Intensive Behavioral Counseling & Varenicline & c-NRT|Intensive Behavioral Counseling \& Varenicline \& c-NRT
62608583|NCT05413122|EXPERIMENTAL|Intensive Behavioral Counseling & Peer Support|Intensive Behavioral Counseling \& Peer Support
62608584|NCT05413122|EXPERIMENTAL|Intensive Behavioral Counseling & Peer Support & Varenicline|Intensive Behavioral Counseling \& Peer Support \& Varenicline
62608585|NCT05413122|EXPERIMENTAL|Intensive Behavioral Counseling & Peer Support & c-NRT|Intensive Behavioral Counseling \& Peer Support \& c-NRT
62608586|NCT05413122|EXPERIMENTAL|Intensive Behavioral Counseling & Peer Support & c-NRT & Varenicline|Intensive Behavioral Counseling \& Peer Support \& c-NRT \& Varenicline
62608587|NCT02927041||OR-Trauma|Patients presenting with hemodynamic instability with expected intubation greater than 24 hours. Hemodynamic monitoring with transesophageal echo and hemodynamic support/ interventions include volume resuscitation, vasopressors, and positive inotropes. The Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
62830940|NCT03839160|ACTIVE_COMPARATOR|SAPB group. Group S|In this group, serratus anterior plane block (SAPB) was performed before extubation with injection of 30 ml of 0.25% bupivacaine hydrochloride followed by 0.1ml/kg/hr of 0.12% bupivacaine hydrochloride. In addition to SAPB, intravenous patient-controlled-analgesia morphine was used. Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
62048369|NCT06083025|EXPERIMENTAL|CleaRing device for cataract patients|"All subjects who meet eligibility requirements will be asked to participate. Subjects will be considered enrolled into the study after:~1. A signed Informed Consent has been obtained.~2. The subject has met all of the inclusion and none of the exclusion criteria.~3. The ability of the subject to safely undergo cataract surgery under local anesthesia was confirmed by the investigator, according to standard procedure of the medical center."
62048370|NCT00101933|EXPERIMENTAL|1|Active Stimulation
62608588|NCT02927041||OR-Cardiovascular|Requiring non-isolated cardiac surgery for repair of thoracic aortic aneurysm. Hemodynamic monitoring with transesophageal echo and hemodynamic support/ interventions include volume resuscitation, vasopressors, and positive inotropes. The Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
62608589|NCT03233204|EXPERIMENTAL|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
62608590|NCT02567864|EXPERIMENTAL|Healthy Beat Accupunch|The HBA exercise program includes: 1) warm-up: 5 slow and gentle exercises to regulate qi, loosen up the body, and elevate the energy for a safe transition to the next phase, 2) accupunch: 14 low-to-medium speed exercises to punch the 14 meridians to enhance the cardiovascular-respiratory workout, and 3) relaxation: 5 low-speed, muscle relaxing exercises with deep breaths to sooth the body and mind. It is conducted 3 times per week and 40 minutes per practice.
62608591|NCT02567864|ACTIVE_COMPARATOR|control|The control group maintains daily activities.
62608592|NCT06526078|EXPERIMENTAL|Cognitive Training|Web-based cognitive training
62608593|NCT06526078|SHAM_COMPARATOR|Sham Training|Web-based sham training
62608594|NCT06494306||Patients with PTSD|They are outpatients receiving psychological and medical treatment in the clinical department connected to the inclusion site
62608595|NCT06494306||Control group|Data from subjects without PTSD included in a previous study
62608596|NCT01826370||Linagliptin|
62608597|NCT03237780|EXPERIMENTAL|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and CT with contrast throughout the trial. Patients may undergo biopsy during screening and on study.
62608598|NCT03237780|EXPERIMENTAL|Arm II (atezolizumab, eribulin mesylate)|Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle and eribulin mesylate IV over 2-3 minutes on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and CT with contrast throughout the trial. Patients may undergo biopsy during screening and on study.
62608599|NCT01398410|EXPERIMENTAL|Rabeprazole 5 mg|
62608600|NCT01398410|EXPERIMENTAL|Rabeprazole 10 mg|
62608601|NCT06629584|EXPERIMENTAL|Asciminib|Patients will receive asciminib 80 mg once daily continuously for 28-day cycles for 2 years.
62608602|NCT04240964||Dd group|Patients with diabetic foot osteomyelitis
62608603|NCT04240964||ND group|Foot osteomyelitis without diabetes
62608604|NCT02360202|EXPERIMENTAL|Bullous pemphigoid patient treated with clobetasol propionate|Impedance analysis in patient with bullous pemphigoid treated by Clobetasol Propionate cream treatment.
62608605|NCT06731764|ACTIVE_COMPARATOR|Levothyroxine alone|Patients in this arm will be administered Levothyroxine/Placebo
62608606|NCT06731764|EXPERIMENTAL|Combination therapy liothyronine once daily|Patients in the arm will be administered Levothyroxine/Liothyronine with Liothyronine administered once daily plus placebo
62608607|NCT06731764|EXPERIMENTAL|Combination therapy liothyronine twice daily|Patients in this arm will be administered Levothyroxine/Liothyronine with Liothyronine administered twice daily.
62608608|NCT05688254|EXPERIMENTAL|Intervention group|The intervention group will get a 4-week online stress recovery intervention.
62608609|NCT05688254|NO_INTERVENTION|Control group|The control group will take care as usual.
62608610|NCT01676818|EXPERIMENTAL|Eribulin mesylate|Eribulin mesylate 1.4 mg/m2 IV bolus over 2-5 minutes on days 1 and 8 every 21 days in the absence of disease progression or unacceptable toxicity.
62608611|NCT05704777|EXPERIMENTAL|exercise|The intervention (endurance + resistance training) group will perform 48 training sessions (24 weeks, twice per week). In each session, they will perform the leg and arm cycling exercises during the first half of the session (15 minutes of leg cycling and 15 minutes of arm cycling) and resistance training exercises involving the lower-body (e.g., squat) and upper-body (e.g., a variety exercises performed against the resistance imposed by elastic bands) during the second half of the session.
62608612|NCT05704777|NO_INTERVENTION|control|The control group will not perform any supervised training program, and will follow standard care.
62608613|NCT03491631|EXPERIMENTAL|2 drugs combination group|
62608614|NCT03491631|EXPERIMENTAL|3 drugs combination group|
62608615|NCT02987569|EXPERIMENTAL|Group One|Intervention
62608616|NCT02987569|ACTIVE_COMPARATOR|Group Two|Control
62608617|NCT03541109|EXPERIMENTAL|Polypill|Polypill group will receive a fixed dose combinations of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg), prescribed once daily by moth for 34 months
62608618|NCT03541109|NO_INTERVENTION|Control|The usual care arm will receive regular drug order at the time of discharge from the hospital.
62608619|NCT06276244||Congenital Myotonic Dystrophy (CDM)|"CDM group:~1. Age 0-17 years, 11 months of age~2. A diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (\&lt;30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4\&gt;1,500)."
62608620|NCT06276244||Childhood Muscular Dystrophy (ChDM)|"ChDM group:~1. Age 0-17 years, 11 months of age~2. A diagnosis of ChDM, which is defined as children having symptoms of myotonic dystrophy after day 30 from birth. These may include any delay in psychomotor development, attention deficit disorder, behavioral abnormalities within the spectrum of autistic spectrum disorders, gastrointestinal dysfunction such as persistent constipation or diarrhea and gastroesophageal reflux; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats."
62608621|NCT02400866|PLACEBO_COMPARATOR|Control|palonosetron + dexamethasone + placebo
62608622|NCT02400866|EXPERIMENTAL|Experimental|palonosetron + dexamethasone + olanzapine
62608623|NCT00622804|OTHER|1|Billroth-II (B-II)reconstruction
62608624|NCT00622804|OTHER|2|Roux en Y gastrojejunostomy (RY-GJ)
62608625|NCT00622804|OTHER|3|uncut Roux en Y gastrojejunostomy (uncut RY-GJ)
62608626|NCT01562249|EXPERIMENTAL|Experimental group|Inclusion criteria were: Skeletal Class III orthognathic surgery patients; adults (age above 18 years), agreement to perform orthognathic surgery and to undergo all of the necessary procedures determined by the multidisciplinary team (i.e. orthodontic preparation, clinical orofacial myofunctional and electromyographic assessment, surgery, post surgery orthodontic treatment, post surgery clinical orofacial myofunctional and electromyographic assessment and orofacial myofunctional treatment when necessary). Exclusion criteria were: previous orthognathic surgery; previous head and neck surgery; neurologic and/or systemic diseases; facial trauma; syndromes; cognitive impairment; and communication and hearing deficits.
62608627|NCT01562249|ACTIVE_COMPARATOR|Instruction Group|Inclusion criteria were: Skeletal Class III orthognathic surgery patients, adults (age above 18 years), agreement to perform orthognathic surgery and to undergo all of the necessary procedures determined by the multidisciplinary team (i.e. orthodontic preparation, clinical orofacial myofunctional and electromyographic assessment, surgery, post surgery orthodontic treatment, post surgery clinical orofacial myofunctional and electromyographic assessment and orofacial myofunctional treatment when necessary). Exclusion criteria were: previous orthognathic surgery; previous head and neck surgery; neurologic and/or systemic diseases; facial trauma; syndromes; cognitive impairment; and communication and hearing deficits.
62608628|NCT01562249|NO_INTERVENTION|Control group|Inclusion criteria for this group were: adults (age above 18 years); absence of stomatognathic system alterations; absence of alterations in the scapular region; complete permanent dentition (absence/extraction of the third molar was accepted); Skeletal and Angle's Class I facial pattern; and absence of malocclusion. Exclusion criteria were: previous orthodontic treatment; and history of previous oral motor intervention.
62608629|NCT04233671|EXPERIMENTAL|Mindfulness based relapse prevention and peer mentoring|MiMP is a twelve week program, meeting once per week for 12 weeks for approximately two hours. Eight weeks are facilitated by a licensed counselor, and four weeks are facilitated by a peer mentor.
62608630|NCT04233671|NO_INTERVENTION|12 Step Treatment Program Control|The control group will meet for 12 weeks for standard 12 Step Facilitation meetings.
62608631|NCT04242992|EXPERIMENTAL|CETA (Common Elements Treatment Approach)|CETA is a modular, multi-problem, flexible psychotherapy approach that trains a lay provider in nine evidence-based cognitive behavioral therapy (CBT) elements so the provider can treat a variety of common problems, including violence, substance use, depression, anxiety, risky behaviors (sexual, non-adherence), and other trauma-related symptoms. Patients randomized to CETA will meet weekly with a lay provider or community health worker member of the study staff for about an hour once each week, approximately 6-12 times depending on presentation and symptom level. This treatment arm will include Short Message Service (SMS) text reminders of their HIV care appointments, similar to the active control group. As of October 12, 2022 participants can elect to have CETA delivered by telephone.
62608632|NCT04242992|ACTIVE_COMPARATOR|Active control|Our comparison arm will be an active control receiving usual care for intimate partner violence. Short Message Service (SMS) text messages will be sent monthly to our control group participants to remind them of HIV care appointments.
62608633|NCT01855282|EXPERIMENTAL|Behavioral intervention|Behavioral intervention consisting of 10 educational sessions promoting healthy diet and increased physical activity.
62608634|NCT01855282|ACTIVE_COMPARATOR|Control|Control arm received no behavioral intervention
62608635|NCT04060459|EXPERIMENTAL|Treatment plan|Paclitaxel-binding albumin 260 mg/m2，d1，ivgtt；cisplatin 75 mg/m2，d1，ivgtt
62608636|NCT03451110|EXPERIMENTAL|Part 1: Lemborexant plus Loestrin|Healthy female participants will receive a single oral dose of Loestrin 1.5/30 (containing ethinyl estradiol \[EE\] 0.030 milligrams \[mg\] and norethindrone \[NE\] 1.5 mg) in the evening of Day 1 after a fast of at least 3 hours. After a washout period of at least 4 days, participants will receive 10 mg lemborexant orally for 10 days. Lemborexant will continue to be administered in the evening on Days 15 through 18, followed by a single oral dose of Loestrin on Day 15 when administered with lemborexant after fasting in the evening for at least 3 hours.
62608637|NCT03451110|EXPERIMENTAL|Part 2: Lemborexant plus Famotidine|Healthy participants will receive a single oral dose of 10 mg lemborexant in the morning of Day 1 after an overnight fast of at least 10 hours. On Day 15, participants will receive a single oral dose of 40 mg famotidine, followed at least 2 hours later by a single dose of 10 mg lemborexant. After a washout period of up to 14 days participants will receive 10 mg lemborexant orally for 10 days.
62048371|NCT00101933|SHAM_COMPARATOR|2|No Stimulation
62830941|NCT03839160|PLACEBO_COMPARATOR|Control group. Group C|In this group, intravenous patient-controlled-analgesia morphine was used. Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
62608638|NCT03451110|EXPERIMENTAL|Part 3: Lemborexant plus Fluconazole|Healthy participants will receive a single oral dose of 10 mg lemborexant in the morning of Day 1 after an overnight fast of at least 10 hours. After a washout interval of approximately 10 days, on Day 11, participants will be administered 400 mg fluconazole followed by 200 mg fluconazole once daily from Days 12 to 26. During this time a single dose of 10 mg lemborexant will be administered following an overnight fast of at least 10 hours along with fluconazole on Day 15 only.
62608639|NCT04074382||Prospective Cohort|Prospective cohort (Phase 1, and Phase 2 Group A: explained in detailed description earlier) We will recruit and consent patients on the ward in the first few weeks following their admission for major trauma when the consultant in charge of their care feels that they are physically and emotionally/mentally ready and appropriate to take part in the study. A member of the research team will ask whether they want to take part in the study and offer them the participant information sheet. If happy to take part, the patient will have an account set up on the online questionnaire service we will be using called QTool. The consent form will be completed online at baseline along with the initial baseline PROM questionnaires. This group of people will then be sent reminders at 3, 6, 9 and 12 months to complete follow-up questionnaires, up to 28 days before or after these timepoints. They will then enter Phase 2 (Group A).
62608640|NCT04074382||Retrospective Cohort|"Retrospective cohort (Phase 1/2):~Patients between 1 to 10 years following their major trauma will be identified using a database. We will randomly select which of these patients to include in our study, using computer software, to reduce selection bias, and those selected will be sent a recruitment pack in the post. We have calculated that we need at least 320 patients in the retrospective cohort to show any important changes.~This group of patients will only complete the questionnaires once in phase 1, and once per year up to 10 years after their trauma in phase 2 (Group B)."
62608641|NCT05029804|EXPERIMENTAL|Intervention Group|"After the initial assessment, patients in this group will be educated by the researcher on walking exercise by using the transtheoritical model. The data will be collected from the patients in the experimental group at baseline, 1st, 3rd, and 6th months of the programme.~The data will be collected by using Exercise Stages of Change Questionnaire, Exercise Processes of Change Scale, Pedometer, Patient Compliance in Type 2 Diabetes Mellitus Treatment Scale, and patient identification that includes five domain. These domains include questions about the patients' sociodemographic characteristics, habits, knowledge of diabetes and its treatment, exercise status, and the evaluation of the metabolic control variables."
62830942|NCT02405078|EXPERIMENTAL|Diagnostic (PET/CT, clonotype, metabolic profile)|"Patients receive standard salvage chemotherapy as determined by the treating physician.~Patients undergo FDG PET/CT scans at baseline (between days -21 to 0), on day 4 after completion of first high-dose chemotherapy, on day 21 after completion of the first course of chemotherapy, and on day 42 after the end of the second course of chemotherapy. Blood samples are also collected for tumor-specific clonotype and metabolic profile at baseline (days -5 to 0) and on days 4, 8, 21, and 42."
62440540|NCT02044471|EXPERIMENTAL|Intervention|"Our intervention will be ischemic conditioning (IC) remotely applied using a sphygmomanometer. We will use the standard, validated protocol, which is inflation of the sphygmomanometer to 200 mmHg for 5 minutes, then deflation with 5 minutes of reperfusion, repeated for 3 cycles (total 30 minutes). This will be done in the dominant arm, twice daily.~Once patients are discharged home on a stable pharmacotherapy regimen, they will be expected to follow the above intervention for 6 weeks, followed by another 6 weeks in the control (no intervention) phase. Patients will be randomized as to which phase they begin the study."
62830943|NCT06042205|EXPERIMENTAL|Hernia repair|There is no comparator for this study. All patients are in the treatment allocated group for hernia repair with TISSIUM™ Atraumatic Hernia Repair System (TAHRS)
62830944|NCT03697252|EXPERIMENTAL|KarXT|
62830945|NCT03697252|PLACEBO_COMPARATOR|Placebo|
62830946|NCT01696110|EXPERIMENTAL|Bivalirudin|Bivalirudin will be started in the cath lab, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; if ACT\<225s 5min after bolus, an additional dose of 0.3mg/kg bolus should be given. After procedure, a prolonged infusion (1.75mg/kg per h) will be given for at least 30 min (totally no more than 4 h) followed by a reduced dose infusion (0.2mg/kg per h) up to 20 h.
62830947|NCT01696110|ACTIVE_COMPARATOR|Heparin monotherapy|100 IU/kg intravenous bolus. If ACT \<225s 5 min after bolus injection, additional dose of heparin (20U/kg) will be given.
62830948|NCT01696110|ACTIVE_COMPARATOR|heparin plus tirofiban|heparin 60 IU/kg intravenous bolus and Tirofiban: 10μg/kg intravenous bolus followed by 0.15μg/kg per min infusion for up to 36h.
62440541|NCT02044471|NO_INTERVENTION|Control|standard care
62440542|NCT02788123|EXPERIMENTAL|bismuth tripotassium dicitrate and pantoprazole|Participants will receive bismuth tripotassium dicitrate (twice daily) and pantoprazole (once daily) as single tablets
62440543|NCT02788123|ACTIVE_COMPARATOR|pantoprazole|Participants will receive pantoprazole (once daily) as single tablet
62440544|NCT01847573|EXPERIMENTAL|Cohort 1: HT-100 tablet, Dose 1|"* Single dose administration: Dose 1~* Multiple dose administration: Dose 1"
62440545|NCT01847573|EXPERIMENTAL|Cohort 2: HT-100 tablet, Dose 2|"* Single dose administration: Dose 2~* Multiple dose administration: Dose 2"
62440546|NCT01847573|EXPERIMENTAL|Cohort 3: HT-100 tablet, Dose 3|"* Single dose administration: Dose 3~* Multiple dose administration: Dose 3"
62440547|NCT01847573|EXPERIMENTAL|Cohort 4a: HT-100 tablet, Dose 4|"* Single dose administration: Dose 4~* Multiple dose administration: Dose 4"
62440548|NCT01847573|EXPERIMENTAL|Cohort 4b: HT-100 tablet, Dose 5|\* Multiple dose administration: Dose 5
62440549|NCT01847573|EXPERIMENTAL|Cohort 5: HT-100 tablet, Dose 6|\* Multiple dose administration: Dose 5
62440550|NCT02537132|EXPERIMENTAL|Home Group|Adaptation and training to Non Invasive Ventilation (NIV) (not less than five sessions), at home
62608642|NCT05029804|NO_INTERVENTION|Control|"No intervention will be applied to this group. The data will be collected from the patients in the control group at baseline, 1st, 3rd, and 6th months.~The data will be collected by using Exercise Stages of Change Questionnaire, Exercise Processes of Change Scale, Pedometer, Patient Compliance in Type 2 Diabetes Mellitus Treatment Scale, and patient identification that includes five domain. These domains included questions about the patients' sociodemographic characteristics, habits, knowledge of diabetes and its treatment, exercise status, and the evaluation of the metabolic control variables."
62608643|NCT05020418|EXPERIMENTAL|Cardiac Device Cohort|This study is open to any adult VA patient with data about a cardiac device procedure performed in the electrophysiology laboratory entered into the national VA EHR. During FY 20-FY 24, we anticipate that this will include approximately 9,000 patients per year, or a total of 50,000 patients. In addition, cases that were previously accessed and used to develop the infection monitoring system, and the quality metric monitoring system, may also be included. This includes all patients entered in the VA Clinical Assessment Reporting and Tracking - Electrophysiology Cohort (CART-EP) database during the period from 2006-2016, and all VA patients who received a cardiac device procedure during the period from 2010-2019. This includes another approximately 50,000 patients, for a total of 100,000 patients.
62608644|NCT06432309|OTHER|nOPC: Duodopa (Levodopa/carbidopa intestinal gel) in monotherapy|Levodopa carbidopa intestinal gel infusion. Diurnal infusion from 7.a.m to 11 p.m.
62608645|NCT06432309|ACTIVE_COMPARATOR|add-OPC: Duodopa plus OPC therapy|Levodopa carbidopa intestinal gel infusion (Diurnal infusion from 7 a.m to 11 p.m) plus Opicapone 50 mg 1 tablet at nighttime (11 p.m)
62608646|NCT01500213|PLACEBO_COMPARATOR|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
62608647|NCT01500213|EXPERIMENTAL|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
62608648|NCT03840551|OTHER|Subjects|Subjects involved are required to do some specific motor tasks, commonly found in all main sports. Evaluated with inertial sensors (XSENS) and marker-based motion capture (BTS)
62608649|NCT06347445||Patients with diabetes mellitus|Patients with type 1 or type 2 diabetes who were under follow-up in the same center for at least a year.
62608650|NCT04134520||Generally healthy subjects with no known cancer disorder|
62608651|NCT04134520||Subjects with a pathological diagnosis of cancer|
62608652|NCT02160522||Cuffed ETT|Patients that are intubated with a cuffed endotracheal tube.
62830949|NCT05442853|ACTIVE_COMPARATOR|Continuous Glucose Monitoring|Study subjects in this arm will receive glycemic management based on continuous glucose monitoring with CGM device. CGM readings will be available to patients, nurses, and the treating team. All treatment decisions for this group will be based on CGM readings, confirmatory POC readings (as necessary), and venipuncture.
62608653|NCT04015518|OTHER|Placebo & Spesolimab|Subcutaneous injections of placebo matching Spesolimab, with subcutaneous injections of Spesolimab starting at week 16, for a total treatment time of 52 weeks.
62608654|NCT04015518|EXPERIMENTAL|Spesolimab 'Speso Low'|Subcutaneous injections of Spesolimab in a low dose scheme for a total treatment time of 52 weeks.
62608655|NCT04015518|EXPERIMENTAL|Spesolimab 'Speso Medium-low'|Subcutaneous injections of Spesolimab in a medium-low dose scheme for a total treatment time of 52 weeks.
62608656|NCT04015518|EXPERIMENTAL|Spesolimab 'Speso Medium-high'|Subcutaneous injections of Spesolimab in a medium-high dose scheme for a total treatment time of 52 weeks.
62830950|NCT05442853|ACTIVE_COMPARATOR|Point of Care Glucose Monitoring|Study subjects in this arm will receive glycemic management based on point of care blood glucose readings. CGM will be placed in blinded mode and used for study comparison only. Patients, nurses, and other treatment team will be blinded to the CGM readings. All treatment decisions for this group will be based on POC readings and venipuncture
62830951|NCT00224575|EXPERIMENTAL|1|Diagnosis strategy and subsequent therapeutic reassessment All patients are in that arms. They all receive the diagnosis reassessment strategy.
62830952|NCT05494385|PLACEBO_COMPARATOR|Preoperative Gabapentin/Postoperative Placebo|
62830953|NCT05494385|ACTIVE_COMPARATOR|Preoperative Gabapentin/Postoperative Gabapentin|
62440551|NCT02537132|ACTIVE_COMPARATOR|Outpatient Group|Adaptation and training to Non Invasive Ventilation (NIV) (not less than five sessions), at the outpatient clinic
62440552|NCT04108377|EXPERIMENTAL|Roflumilast|Roflumilast 500mcg by mouth, once daily, for 70 days (10 weeks).
62440553|NCT04108377|PLACEBO_COMPARATOR|Placebo|Placebo by mouth, once daily, for 70 days (10 weeks).
62440554|NCT04090996|EXPERIMENTAL|DT patients|
62440555|NCT05427565|EXPERIMENTAL|Cortical hemodynamic variability of four weeks iTBS|"One healthy participant will be included in this study, which lasts for 4 weeks, 5 visits per week, involving 20 visits in total.~The participant will receive the following instructions the night before: to take 200 mg of caffeine one hour before the visit (no other caffeine intake since the wake-up) or avoid caffeine intake at all before the visit; to attend the visit in the morning or afternoon. These assignments will be randomized in a counterbalanced manner."
62440556|NCT01836718||HCV RNA (-) on anti-viral therapy|Patients undergoing liver transplantation who are documented HCV viral load undetectable while on antiviral therapy
62440557|NCT01836718||HCV RNA (+) on anti-viral therapy|Patients undergoing liver transplantation who are receiving anti-viral therapy and who have a documented detectable HCV viral load
62440558|NCT01836718||HCV RNA (+) not on anti-viral therapy|Patients undergoing liver transplantation who are not currently receiving anti-viral therapy and are documented viral load positive will be included and serve as a comparison group
62830954|NCT06071078|EXPERIMENTAL|DISCUSS announcement protocol|Model protocol for announcing decision of withholding and withdrawing life-sustaining treatments, with human simulation and the intervention of partner families in a simulation center and in situ, on the reduction of family stress following the announcement of a decision of withholding and withdrawing life-sustaining treatments in the emergency departments
62830955|NCT06071078|NO_INTERVENTION|Control|Individuals will receive the usual practices.
62048372|NCT00045305|EXPERIMENTAL|Arm I|"Preparative Regimen: Patients underwent photopheresis on two consecutive days and received pentostatin 4 mg/m2/d (total dose = 8 mg/m2) by continuous IV infusion on two consecutive days following photopheresis. Total body irradiation was administered on two consecutive days following pentostatin for a total of 600 cGy given in three 200 cGy fractionated doses.~Transplantation: Unmanipulated allogeneic bone marrow or G-CSF mobilized peripheral blood stem cells were infused on day 0 within 48 hours of completion of TBI. Minimum cell dose was 2 ×106 CD34 cells/kg recipient.~Acute graft-vs-host-disease (GVHD) prophylaxis: Patients received Cyclosporine or Tacrolimus per institutional preference or protocol beginning no later than day -1. Methotrexate (MTX) was administered on day +1 and +3. Mycofenolate mofetil (MMF) was introduced on day 100 and could be tapered and discontinued after 12 months if no active cGVHD."
62048373|NCT01238055|EXPERIMENTAL|Docetaxel + Sunitinib|Docetaxel and Sunitinib
62048374|NCT01238055|ACTIVE_COMPARATOR|Docetaxel|Docetaxel only
62048375|NCT04167605||Breast cancer metastatic to bone|No direct intervention(s) will be administer to the patients. We will use the sample (slides) recovered from the surgery on primary tumor (breast cancer responsible for metastatic disease).
62608657|NCT04015518|EXPERIMENTAL|Spesolimab 'Speso High'|Subcutaneous injections of Spesolimab in a high dose scheme for a total treatment time of 52 weeks.
62608658|NCT03871725|EXPERIMENTAL|Sonodynamic therapy(SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure.
62608659|NCT00829816|EXPERIMENTAL|Dimebon|20 mg dimebon by mouth 3 times per day
62608660|NCT00829816|PLACEBO_COMPARATOR|Placebo|20 mg placebo by mouth 3 times per day
62608661|NCT05037539|EXPERIMENTAL|Injectable Fentanyl in Sublingual Route|Injectable Fentanyl in Sublingual Route that given after the first time Breakthrough Pain is occurred 50 mcg in sublingual route
62608662|NCT05037539|ACTIVE_COMPARATOR|Oral Morphine Syrup|Oral Morphine Syrup 2.5 ml ( 5 mg) in oral router that first time given after Breakthrough Pain is occurred
62608663|NCT05622721||Pet owner|Pet owners
62608664|NCT05622721||Non pet owner|Non pet owners
62830956|NCT03208010|EXPERIMENTAL|Diabetes Prevention Intervention|The intervention is 12 weeks of education on diet and physical activity, followed by 15 biweekly support groups for problem solving. Then, 3 booster sessions are scheduled, each one at 6-month intervals. Further, motivational interviewing is infused into all group sessions.
62830957|NCT03208010|ACTIVE_COMPARATOR|Enhanced Usual Care|"The comparator is an enhanced usual care control group that receives health care from personal physicians plus has access to: a) data collection sessions; b) individualized exit interviews with program staff after each data collection session to receive immediate feedback on lab results and trends in personal health indicators (e.g., BMI, A1C) and to ask questions; c) referral to a local physician or clinic, if needed; and d) Spanish-language materials on diabetes prevention."
62830958|NCT02768857|EXPERIMENTAL|Early sensorimotor reeducation intervention|The experimental group received 15 minutes of touch-observation and task-based mirror therapy program, followed by 20 minutes of regular hand therapy and 20 minutes of physiotherapy in each treatment session before the returning of the touch of a Semmes-Weinstein monofilament marked 4.31. Once the patients had regained the protective sense (SWM \< 4.31), the mirror therapy program was replaced with a discriminative sensory reeducation program. Treatment duration was 12 weeks, at a frequency of three sessions per week.
62830959|NCT02768857|ACTIVE_COMPARATOR|Traditional sensorimotor reeducation intervention|The control group received received 15 minutes traditional sensory reeducation program, 20 minutes of regular hand therapy and 20 minutes of physiotherapy in each treatment session before the returning of the touch of a Semmes-Weinstein monofilament marked 4.31. Once the patients had regained the protective sense (SWM \< 4.31), the protective sensory reeducation program was replaced with a discriminative sensory reeducation program. Treatment duration was 12 weeks, at a frequency of three sessions per week.
62830960|NCT00267059|EXPERIMENTAL|Lenalidomide|
62830961|NCT03586492|OTHER|Patient with myocardial ischemia|
62830962|NCT05050318|EXPERIMENTAL|Group 1: Fluzone Quadrivalent Influenza Vaccine: 6 to <36 Months|Participants aged 6 to \<36 months received a 0.5-milliliters (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 1. Participants for whom 2 doses of influenza vaccine were recommended per Advisory Committee on Immunization Practices (ACIP), a second dose was administered at Day 28.
62830963|NCT05050318|EXPERIMENTAL|Group 2: Fluzone Quadrivalent Influenza Vaccine: 3 to <9 Years|Participants aged 3 to \<9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 1. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
62830964|NCT05050318|EXPERIMENTAL|Group 3: Fluzone High-Dose Quadrivalent Influenza Vaccine: >=65 Years|Participants aged \>= 65 years received a 0.7-mL dose of Fluzone High-Dose Quadrivalent vaccine intramuscularly at Day 1.
62048376|NCT04167605||Bone metastasis|No direct intervention(s) will be administer to the patients. Waste material will be analysed for the expression of specific proteins
62048377|NCT01189968|EXPERIMENTAL|Carboplatin and Pemetrexed plus demcizumab|Carboplatin and Pemetrexed plus demcizumab
62048378|NCT01189968|EXPERIMENTAL|Pemetrexed plus demcizumab|Pemetrexed plus demcizumab
62048379|NCT02057874|EXPERIMENTAL|Diagnostic (3T MRI)|Patients undergo 3T MRI at baseline (=\< 2 weeks before TACE) and at 2-4 weeks, 4-8 weeks, and 12 weeks after TACE. Each 3T MRI session will utilize a sequence of the following modalities: CEST-MRI, MT-MRI, DW-MRI, and DCE-MRI.
62608665|NCT03448939|EXPERIMENTAL|S5G4T-1|Participants will topically apply S5G4T-1 cream, once daily to face for 12 weeks.
62608666|NCT03448939|PLACEBO_COMPARATOR|S5G4T-2 Vehicle Cream|Participants will topically apply S5G4T-2 vehicle cream, once daily to face for 12 weeks.
62608667|NCT02798120|EXPERIMENTAL|SB204 4%|All subjects received SB204 4% once daily (QD) in this open label study. Subjects assigned to SB204 4% QD in the parent study (NI-AC301/302) continued to receive SB204 for 40 more weeks. Subjects assigned to Vehicle Gel in the parent study (NI-AC301/302) received SB204 4% QD in this open label study.
62608668|NCT03910530|EXPERIMENTAL|INCMGA00012|Single-agent INCMGA00012.
62608669|NCT03910530|EXPERIMENTAL|INCB001158 75 mg|Single-agent INCB001158.
62048380|NCT05455905||Main Study Cohort|"A web-based audio recording tool will be used to record voice sample answering the prompt, How are you feeling today? Participants are asked to speak for 1-minute. Following the recording, participants are asked to complete the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 questions."
62048381|NCT05455905||Selected Self-Reported Depression Cohort|The Researcher will review Patient Health Questionnaire-9 scores of all the participants and select the subset that self-reported a scored greater than 20, on a scale from 0 to 27. Participants will be approached via email to complete an additional administration of the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 questionnaires and be offered resources for depression and anxiety and how to set up an appointment with a mental health professional.
62048382|NCT04123067|EXPERIMENTAL|Pioglitazone treatment group|oral administration of 45mg Pioglitazone daily for three subsequent days, initiated within 12h of stroke symptom onset
62048383|NCT04123067|PLACEBO_COMPARATOR|Placebo group|Oral administration of placebo daily for three subsequent days, initiated within 12h of stroke symptom onset
62048384|NCT01931280|EXPERIMENTAL|Lifestyle Counseling|Participants will obtain access to an internet-based educational intervention.
62048385|NCT01931280|NO_INTERVENTION|Usual Care (Self-Directed)|Participants receive information via email on health related topics that surround pregnancy, physical activity, nutrition, and gestational diabetes.
62048386|NCT05508230|EXPERIMENTAL|Experimental|
62048387|NCT00811343|EXPERIMENTAL|1|
62048388|NCT00784394|EXPERIMENTAL|Arm I (diindolylmethane)|Participants receive a single dose of diindolylmethane PO on day 1.
62048389|NCT00784394|PLACEBO_COMPARATOR|Arm II (placebo)|Participants receive a single dose of placebo orally (PO) on day 1.
62048390|NCT05184257||Study Drugs|The study drug is Zoladex® 10.8 mg. The maximum observation time window for effectiveness analysis is 28 (24+4) weeks.
62048391|NCT05184257||Comparison Drugs|The comparison drug is Zoladex® 3.6 mg. The maximum observation time window for effectiveness analysis is 28 (24+4) weeks.
62048392|NCT05065489||Schizophrenia patients|patients who diagnosed with schizophrenia in accordance with DSM-5 criteria
62048393|NCT05065489||Bipolar disorder patients|patients who diagnosed with bipolar disorder in accordance with DSM-5 criteria
62608670|NCT03910530|EXPERIMENTAL|INCB001158 100 mg|Single-agent INCB001158.
62048394|NCT05065489||Depression patients|patients who diagnosed with major depression disorder in accordance with DSM-5 criteria
62048395|NCT05065489||Health control|health participants who have not diagnosed with any psychological or psychiatric disease.
62048396|NCT00972348|EXPERIMENTAL|Access to Personal Health Record|Full access to the Personal Health Record including lists of diagnoses, medications and laboratory values.
62048397|NCT00972348|ACTIVE_COMPARATOR|No access to the PHR|No access to the PHR but patients will complete surveys.
62449438|NCT03869749|ACTIVE_COMPARATOR|Health and wellness|It is a 6-week program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University.
62449439|NCT00778947|ACTIVE_COMPARATOR|1|
62608671|NCT03910530|EXPERIMENTAL|INCMGA00012 + INCB001158|Combination of INCMGA00012 and INCB001158.
62048398|NCT04886492||NMO|Pts presenting to enrolling sites across the northern America are invited to enroll if eligible
62048399|NCT02578979|EXPERIMENTAL|ECG for 5 days|Patients will receive 12-lead electrocardiogram for 5 days during their hospitalization.
62608672|NCT01576003|EXPERIMENTAL|Glutamine|Infants randomized to the Glutamine group will receive L-Glutamine (GLN) administered enterally at a dose of 0.6g/kg body weight/day (0.3g/kg/dose) in 2 divided daily doses for 6 months. GLN will be dissolved in water, breast milk or formula and administered to the subject orally or through their enterostomy tube approximately every 12 hours (twice a day).
62608673|NCT01576003|PLACEBO_COMPARATOR|L-alanine|Infants randomized to the placebo group will receive L-alanine (ALA) administered enterally at a dose of 0.6g/kg body weight/day in 2 divided doses (0.3g/kg/day twice a day) for 6 months. ALA will be dissolved in water, breast milk or formula and administered to the subject orally or through their enterostomy tube approximately every 12 hours (twice a day).
62608674|NCT01576003|NO_INTERVENTION|Healthy Control|Healthy age-matched infants (n=12) will have serial stools collected on 4 occasions, each separated by 60 days.
62830965|NCT06651840|ACTIVE_COMPARATOR|"Group A: patients in this group will be managed with bipolar diathermy Standard technique."|"The bipolar technique for group A:~A bipolar with straight blade will be used with a footplate-operated switch to control the coagulation time, and the length, width and depth of penetration of the thermal power.~The lesion will be coagulated in a distal-to-proximal direction to achieve a uniform gray-white coagulation zone in the lesion and surrounding tissue. Multiple ablations at the same area should be avoided to avoid septal perforation. After finishing coagulation small gauze impregnated with antibiotic ointment will be applied for 2 hours postoperatively."
62830966|NCT06651840|EXPERIMENTAL|Group B: patients in this group will be managed with coblation technique.|"The coblation technique for group B:~An coblator with tonsillar blade will be used with a footplate-operated switch to control the coagulation time, and the length, width and depth of penetration of the thermal power.~The lesion will be coagulated in a distal-to-proximal direction to achieve a uniform gray-white coagulation zone in the lesion and surrounding tissue. Multiple ablations at the same area should be avoided to avoid septal perforation. After finishing coagulation small gauze impregnated with antibiotic ointment will be applied for 2 hours postoperatively."
62830967|NCT04318353||early enteral feeding|start enteral feeding within 2 days postoperative
62830968|NCT04318353||control|start enteral feeding after 2 days postoperative according to clinician discretion based on clinical progress(ranging from 1-5 days after passage of flatus or stool.
62830969|NCT03415685|ACTIVE_COMPARATOR|Group A: PicoPlus for unwanted tattoos.|Subjects receiving PicoPlus laser system treatment for unwanted tattoos.
62830970|NCT03415685|ACTIVE_COMPARATOR|Group B: PicoPlus for other dermatological conditions|Subjects receiving PicoPlus laser system treatment for unwanted benign pigmented lesions, melasma or other dermatological conditions such as skin rejuvenation.
62830971|NCT05099952|EXPERIMENTAL|Arm I - BBT-CI|Patients participate in BBT-CI over 60 minutes for 2 sessions and phone calls over 15 minutes once weekly for 4 weeks.
62830972|NCT05099952|ACTIVE_COMPARATOR|Arm II- therapist|Patients meet with therapist over 60 minutes for 2 sessions and phone calls over 15 minutes once weekly for 4 weeks.
62830973|NCT05099952|EXPERIMENTAL|Observational Study|Patients wear actigraphy watch and complete sleep log at baseline (over the weekend prior to first day of CRT), and weeks 1, 3, and 6 during treatment. Patients also undergo collection of cheek cell samples and may undergo collection of blood samples at weeks 1, 3 and 6 during treatment. Patients' medical records are also reviewed.
62830974|NCT02643914|EXPERIMENTAL|Nicotine Cravings|
62830975|NCT01703234|EXPERIMENTAL|Ramipril|
62830976|NCT02864784|EXPERIMENTAL|Amorphous calcium carbonate|Subjects in this arm of the study will receive ACC tablets, containing 200 mg elemental calcium in addition to the standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab)
62830977|NCT02864784|PLACEBO_COMPARATOR|Placebo|Subjects in this arm of the study will receive Placebo tablets in addition to standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab)
62048400|NCT02578979|ACTIVE_COMPARATOR|24-h Holter|Patients will receive a 24-h Holter during their hospitalization.
62048401|NCT06442618|ACTIVE_COMPARATOR|Extracorporeal Shokwave Theraphy (Group A)|Group A participants were invited to come to our department's outpatient clinics, wearing comfortable clothing. Meetings were held every six days, for a total of 5 sessions (30 days), lasting about 20 minutes each.
62449440|NCT00778947|ACTIVE_COMPARATOR|2|
62608675|NCT01440569|EXPERIMENTAL|COBI-boosted DRV|Participants will receive DRV+COBI+2 investigator-selected NRTIs for 48 weeks, and may continue their regimen in the open-label rollover phase.
62608676|NCT06078722||Study Cohort|Patients taking Carnitine-Orotate Complex and BDD regardless of study participation. The duration of observation for taking COCs and BDD is 6 months, and the duration of follow-up is 6 months.
62608677|NCT06078722||Control cohort|Patients who do not take Carnitine-Orotate Complex and BDD, regardless of study participation. Duration of patient observation - 12 months.
62608678|NCT01323036|EXPERIMENTAL|Krill Oil|
62608679|NCT01323036|EXPERIMENTAL|Fish Oil|
62440559|NCT00746668|EXPERIMENTAL|Control Group|Subjects randomly assigned to this group had their training delayed for 18 weeks. These subjects underwent four assessments: baseline and at three 6-week intervals' but, they were not given any training during this time. After this data collection period, these control subjects were given training on the three modules. However, their performance after each period of training was not assessed.
62440560|NCT00746668|EXPERIMENTAL|Group 1|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 2: Module 2 (Control of Reading Eye Movements) Training Session 3: Module 3 (Reading Practice with RSVP)"
62440561|NCT00746668|EXPERIMENTAL|Group 2|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 2 (Control of Reading Eye Movements) Training Session 2: Module 3 (Reading Practice with RSVP) Training Session 3: Module 1 (Visual Awareness and Eccentric Viewing)"
62440562|NCT00746668|EXPERIMENTAL|Group 3|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 3 (Reading Practice with RSVP) Training Session 2: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 3: Module 2 (Control of Reading Eye Movements)"
62440563|NCT00746668|EXPERIMENTAL|Group 4|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 2: Module 3 (Reading Practice with RSVP) Training Session 3: Module 2 (Control of Reading Eye Movements)"
62440564|NCT00746668|EXPERIMENTAL|Group 5|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 2 (Control of Reading Eye Movements) Training Session 2: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 3: Module 3 (Reading Practice with RSVP)"
62440565|NCT00746668|EXPERIMENTAL|Group 6|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 3 (Reading Practice with RSVP) Training Session 2: Module 2 (Control of Reading Eye Movements) Training Session 3: Module 1 (Visual Awareness and Eccentric Viewing)"
62440566|NCT01672346|ACTIVE_COMPARATOR|Arm I|PVAI with ablation of posterior wall contained within pulmonary veins using energy up to 30 watts and post-ablation adenosine challenge
62440567|NCT01672346|ACTIVE_COMPARATOR|Arm II|AF ablationPVAI with ablation of posterior wall contained within pulmonary veins using energy up to 40 watts and post-ablation adenosine challenge
62440568|NCT02565342|EXPERIMENTAL|Interscalene brachial plexus block|
62440569|NCT02400320|ACTIVE_COMPARATOR|Topical Spray|Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
62440570|NCT02400320|EXPERIMENTAL|Topical Gel|Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
62440571|NCT02400320|OTHER|Saline|Saline
62608680|NCT01839305|EXPERIMENTAL|Hidrotherapy|Patients performed hydrotherapy 2 twice a week, for 16 weeks, to check if there was any effect on the outcome measures for women with fibromyalgia
62608681|NCT03289806||Cases|Glaucoma surgery
62608682|NCT03289806||Controls|Strabismus surgery
62608683|NCT03858894|EXPERIMENTAL|Drug Arm: DE-117 QD|DE-117 Ophthalmic Solution QD (20:00) and Vehicle (8:00; no active DE-117 ingredient) QD
62608684|NCT03858894|EXPERIMENTAL|Test Arm: DE-117 BID|DE-117 Ophthalmic Solution BID Twice daily (20:00 and 8:00)
62830978|NCT03505502|PLACEBO_COMPARATOR|placebo arm|group receive i/v saline plus irrigation of the myoma bed with normal saline
62608685|NCT04332731|EXPERIMENTAL|Renal angiography and Renal denervation|"Symplicity Spyral™ multi electrode renal denervation system~After renal angiography, participants in the experimental group will be immediately treated with renal denervation procedure using standard techniques. The participants will remain blinded throughout the procedure."
62048402|NCT06442618|ACTIVE_COMPARATOR|Nutraceutical Supplementation (Group B)|Participants in Group B performed home therapy with nutraceutical supplementation containing: hyaluronic acid (200 mg), collagen (5,000 mg), manganese (10 mg) and vitamin C (250 mg), daily for 30 days; they were advised to always take it at the same time and independently of meals, so as not to interfere with absorption.
62048403|NCT06442618|ACTIVE_COMPARATOR|Combined Treatment (Group C)|Participants in group C were invited to come to our department's outpatient clinics to perform treatment with focal ESWT; they had one session every six days for a total of 5 sessions lasting about 20 minutes each. Patients in this group took also additional nutraceutical therapy every day or 30 days.
62608686|NCT04332731|SHAM_COMPARATOR|Renal angiography|In the control group, the sham procedure will consist of only a renal angiogram. Participants will undergo diagnostic renal angiogram but will not receive any therapeutic endovascular treatment. Participants will remain on the procedure table for at least 20 min after the angiogram to prevent possible unblinding of randomization allocation.
62608687|NCT02811380|EXPERIMENTAL|BIP CVC|Bactiguard Infection Protection Central Venous Catheter
62608688|NCT02811380|PLACEBO_COMPARATOR|Uncoated standard CVC|Uncoated standard Central Venous Catheter
62608689|NCT03317457|EXPERIMENTAL|Durvalumab and Tremelimumab|"Cycles/courses 1-3:~Durvalumab 1.5g q4wks Tremelimumab 75 mg q4wks~Cycles/courses ≥4:~Durvalumab 1.5g q4wks Tremelimumab 75 mg q12wks"
62608690|NCT03317457|ACTIVE_COMPARATOR|Doxorubicin|Doxorubicin 75 mg/qm q3wks for 6 courses
62048404|NCT05084417||Cohort 1: Alopecia Areata|Cohort 1 is limited to patients clinically diagnosed with Alopecia Areata. Patients in this cohort will receive the universal ClinROs and PROs (i.e. not disease specific) as well as additional AA-specific measures throughout the length of the study.
62440572|NCT02303561|EXPERIMENTAL|CHAMP|Families assigned to this arm will receive tailored asthma education and behavioral skills focused on improving asthma and weight management.
62440573|NCT02303561|ACTIVE_COMPARATOR|Health education|Families assigned to this arm will receive tailored asthma education and general health education on a variety of topics.
62440574|NCT04853810||Major diabetic subjects having used a system with adhesives|Major diabetic subjects, whatever the etiology of diabetes, using or having used in the last 10 years a system with skin adhesives, i.e. insulin patch pump (e.g. OMNIPOD®, cell Novo®), pump with externalized catheter (e.g. MINIMED 640G®, YpsoPump®) or continuous glucose measurement system (Free Style®, DexCom® sensors, Enlite® sensors).
62440575|NCT00809809|ACTIVE_COMPARATOR|Zinc gluconate|Oral swabs containing homeopathic Zinc gluconate
62440576|NCT00809809|PLACEBO_COMPARATOR|Placebo|placebo
62440577|NCT00301106|EXPERIMENTAL|adenovirus-mediated human interleukin-12|starting dose of ADV-hIL12 - 1 x 10 to the 10th power vp (virus particles) per patient, escalating in half-log increments up to 1 x 10 to the 13th power vp per patient, after which dose escalation will be at lower increments of 2 x 10 to the 13th power vp, to a maximum of 3.0 x 10 to the 13th power vp per patient.
62830979|NCT03505502|EXPERIMENTAL|IV tranexamic acid group|group received IV tranexamic 1gm in normal saline
62830980|NCT03505502|ACTIVE_COMPARATOR|topical tranexamic acid group|group received topical tranexamic 2gm in normal saline
62440578|NCT02639208|EXPERIMENTAL|PatientsLikeMe (PLM)|"After the screening procedures confirm eligibility.~* Baseline Survey Assessment and PatientsLikeMe Introduction~* Treatment Evaluation on PLM website at predetermined times per protocol~* Final Survey"
62440579|NCT05267574|EXPERIMENTAL|REN001|100 mg once daily
62440580|NCT05999981|ACTIVE_COMPARATOR|Transversalis Fascia Plane Block (TFPB) Group|At TFPB group, the block will be performed by ultrasound guidance after completion of surgery. TFPB will be performed under ultrasonography guidance using a linear 6 to 13 megahertz ultrasound probe by the anesthesiologist. In TFPB group patients will receive 40 ml %0.25 bupivacaine divided into 2 equal doses between transversus abdominis muscle and transversalis fascia bilaterally.
62440581|NCT05999981|ACTIVE_COMPARATOR|Transversus Abdominis Plane (TAP) Block Group|At TAP block group, the block will be performed by ultrasound guidance after completion of surgery. TAP blocks will be performed under ultrasonography guidance using a linear 6 to 13 megahertz ultrasound probe by the anesthesiologist. In TAP block group patients will receive 40 ml %0.25 bupivacaine divided into 2 equal doses in the fascial plane between internal oblique muscle and transversus abdominis muscle bilaterally.
62440582|NCT03192683|ACTIVE_COMPARATOR|Regular sling|
62048405|NCT05084417||Cohort 2: Atopic Dermatitis|Cohort 2 is comprised of patients that have been clinically diagnosed with Atopic Dermatitis. Patients in this cohort will receive the universal PROs and ClinROs, but will also receive additional AD-specific measures throughout the length of the study.
62440583|NCT03192683|EXPERIMENTAL|Cast-sling|
62440584|NCT02524028||Case Participant Cohort|Participants with atrial fibrillation
62440585|NCT02524028||Control Participant Cohort|Participants without atrial fibrillation or any other heart disease
62440586|NCT05144620|EXPERIMENTAL|Preoperative Imaging|
62440587|NCT04485000|EXPERIMENTAL|Immediate Treatment|The experimental (immediate workshop) group will receive the online workshop at baseline (T1) in addition to receiving standard postnatal care.
62440588|NCT04485000|OTHER|Waitlist Cpntrol|The waitlist control group will receive standard postnatal care for 12 weeks and will participate in the online 1-day CBT-based workshop at T2 (12 weeks post baseline).
62440589|NCT03131999|EXPERIMENTAL|Imatinib Mesylate 400mg capsule|56 days of Imatinib mesylate 400 mg oral daily with or without co-administration of an mTOR inhibitor for 28 days. A dose reduction to 200 mg daily is allowed for toxicity.
62608691|NCT01923844|EXPERIMENTAL|poractantalfa|preterm infants who received poractantalfa for respiratory distress syndrome
62608692|NCT01923844|EXPERIMENTAL|beractant|preterm infants who received beractant for respiratory distress syndrome
62608693|NCT01923844|NO_INTERVENTION|Control|Preterm infants without respiratory distress syndrome
62048406|NCT05084417||Cohort 3: Hidradenitis Suppurativa|Cohort 3 is limited to patients clinically diagnosed with Hidradenitis Suppurativa. Patients in this cohort will receive the universal ClinROs and PROs (i.e. not disease specific) as well as additional HS-specific measures throughout the length of the study.
62608694|NCT05268354|EXPERIMENTAL|Training group|6-week neuromuscular training program
62608695|NCT05268354|NO_INTERVENTION|Control group|
62048407|NCT05084417||Cohort 4: Psoriasis|Cohort 4 is limited to patients clinically diagnosed with Psoriasis. Patients in this cohort will receive the universal ClinROs and PROs (i.e. not disease specific) as well as additional PsO-specific measures throughout the length of the study.
62048408|NCT05084417||Cohort 5: Vitiligo|Cohort 5 is limited to patients clinically diagnosed with Vitiligo. Patients in this cohort will receive the universal ClinROs and PROs (i.e. not disease specific) as well as additional VL-specific measures throughout the length of the study.
62048409|NCT02213562|EXPERIMENTAL|200 mg CFO|200 mg of chrysanthemum flower oil
62048410|NCT02213562|EXPERIMENTAL|300 mg CFO|300 mg of chrysanthemum flower oil
62048411|NCT02213562|EXPERIMENTAL|400 mg CFO|400 mg of chrysanthemum flower oil
62048412|NCT05934968|EXPERIMENTAL|Mad Dog cooking class intervention group|This 6-week series consists of a once-weekly cooking class and educational session where a group of individuals with neuromuscular disability can come together to learn about the health benefits of an anti-inflammatory diet, receive instruction on how to cook selected anti-inflammatory recipes, and experiment with various pieces of accessible kitchen equipment that may increase their meal preparation skills. This series will also allow participants to share a meal together once per week.
62440590|NCT03131999|PLACEBO_COMPARATOR|Placebo Capsule|56 days of Placebo with or without co-administration of an mTOR inhibitor for 28 days. A dose reduction is allowed for toxicity.
62048413|NCT05934968|NO_INTERVENTION|Control group|The control group will be given the Mad Dog recipes but will not take part in the Mad Dog cooking class series.
62608696|NCT06539533|EXPERIMENTAL|Group A (Experimental group):22 subjects|22 subjects will receive Pilates training. twice a week for 5 consecutive weeks, with The duration of Pilates is 30 minutes. 10 repetitions for each exercise with 10 seconds of rest between each Pilates.And short feet exercises daily 3 minutes per time, for a total of five weeks
62048414|NCT05211388|EXPERIMENTAL|arm 1: generator-controlled RFA|In up to 6 patients (arm 1: generator-controlled RFA), RFA will be performed directly following manufacturer-specified algorithms, with recording of 3D ultrasound echo decorrelation images during ablation.
62048415|NCT05211388|EXPERIMENTAL|arm 2: imaging-controlled RFA|In up to 6 additional patients (arm 2: imaging-controlled RFA), real-time, 3D echo decorrelation imaging during ablation will provide an additional treatment end point.
62048416|NCT05070247|EXPERIMENTAL|Dose Escalation: TAK-500 Single Agent (SA)|TAK-500 dose escalation starting at 8 microgram per kilogram (mcg/kg), infusion, intravenously, once on Day 1 of each 21-day treatment cycle (once every 3 weeks, Q3W) or once on Day 1, 15 and 29 of each 42-day treatment cycle (once every 2 weeks, Q2W), for up to 1 year.
62440591|NCT01200082||Healthy Controls|Male or female, age 19-65, no apparent signs of hepatobiliary diseases
62440592|NCT01200082||Patients with hepatobiliary diseases|Male or female, age 19-65, visiting the UNMC hepatology clinic for treatment from hepatobiliary diseases
62440593|NCT06054906|EXPERIMENTAL|sintilimab+metronomic PLOF|sintilimab therapy(200mg, iv,d1,Q3W, 2cycles)and PLOF chemotherapy (Paclitaxel 60 mg/m2, oxaliplatin 50 mg/m2, 5-fluorouracil 425mg/m2, d1, QW, 6cycles) followed by adjuvant sintilimab therapy(200mg, iv,d1,Q3W, 2cycles)and PLOF chemotherapy (Paclitaxel 60 mg/m2, oxaliplatin 50 mg/m2, 5-fluorouracil 425mg/m2, d1, QW, 6cycles) neoadjuvant chemotherapy (8 weeks) preceding surgery (3 weeks after completion of chemotherapy) followed by adjuvant chemotherapy (16 weeks, begin within 12 weeks after surgery)
62440594|NCT06135285|EXPERIMENTAL|Control subjects|The subject will lie down on the Korus smart mattress. Korus will detect when the subject is in a prone (face-down) position and reposition the subject into a recovery (sideways) position.
62440595|NCT02480010|EXPERIMENTAL|Pertuzumab 1050 mg (Cohort B)|Participants in Cohort B will receive 1050 mg pertuzumab via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
62449441|NCT03139968|EXPERIMENTAL|Radiation absorbing drape|Conventional protection measurements. Additionally, a lead-free protective, disposable drape containing bismuth and antimony (RADPAD®) is placed onto the sterile drape on the patient between the operator and the image intensifier.
62608697|NCT06539533|ACTIVE_COMPARATOR|Group B (control group):22 subjects|22 subjects will receive short feet exercise daily 3 minutes per time for a total of five weeks.
62608698|NCT01770067|EXPERIMENTAL|Infected CIED and Infection-Prone Patients Prior to CIED Implantation|Administration of high-dose antibiotics (CITA)
62608699|NCT01770067|ACTIVE_COMPARATOR|Infected CIED extraction|Extraction of infected CIED
62608700|NCT04549376|EXPERIMENTAL|PVP-I 0.4% NI|Arm-1 will receive Povidone iodine (PVP-I) nasal irrigation (NI) at concentration of 0.4% single time
62608701|NCT04549376|EXPERIMENTAL|PVP-I 0.5% NI|Arm-2 will receive Povidone iodine (PVP-I) nasal irrigation at concentration of 0.5% single time
62608702|NCT04549376|EXPERIMENTAL|PVP-I 0.6% NI|Arm-3 will receive Povidone iodine (PVP-I) nasal irrigation at concentration of 0.6% single time
62608703|NCT04549376|EXPERIMENTAL|PVP-I NS 0.5% NS|Arm-4 will receive will receive PVP-I nasal spray (NS) at concentration of 0.5% single time
62608704|NCT04549376|EXPERIMENTAL|PVP-I 0.6% NS|Arm-5 will receive will receive PVP-I nasal spray at concentration of 0.6% single time
62608705|NCT04549376|PLACEBO_COMPARATOR|DW NI|Arm-6 will receive distilled water through nasal irrigation
62608706|NCT04549376|PLACEBO_COMPARATOR|DW NS|Arm-7 will receive distilled water through nasal spray
62608707|NCT02176083|EXPERIMENTAL|Intervention|Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness
62048417|NCT05070247|EXPERIMENTAL|Dose Escalation: TAK-500 + Pembrolizumab|TAK-500, infusion, intravenously, once on Day 1 of each 21-day treatment cycle (once every 3 weeks, Q3W) or once on Day 1, 15 and 29 of each 42-day treatment cycle (once every 2 weeks, Q2W), for up to 1 year, along with pembrolizumab 200 milligram (mg) infusion, intravenously, once on Day 1 of each 21-day treatment cycle or on Days 1 and 22 in a 42-day cycle (Q3W) for up to 1 year. The exact starting dose of TAK-500 will be determined from the results of the TAK-500 SA arm dose escalation.
62440596|NCT02480010|EXPERIMENTAL|Pertuzumab 420 mg (Cohort A)|Participants in Cohort A will receive an IV loading dose of 840 milligrams (mg) pertuzumab followed by 420 mg via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
62440597|NCT01211847|EXPERIMENTAL|DCCR|DCCR Treatment with 290 mg Diazoxide Choline
62608708|NCT02176083|NO_INTERVENTION|Control|Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness
62608709|NCT04833231||High eGFR group (eGFR ≥60 mL/ min/1.73 m2)|Patients with estimated glomerular filtration rate (eGFR) ≥60 mL/ min/1.73 m2 as high eGFR group
62608710|NCT04833231||Low eGFR group (eGFR <60 mL/min/1.73 m2)|Patients with estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m2 as low eGFR group
62608711|NCT03433313|EXPERIMENTAL|EG12014|Epirubicin and cyclophosphamide followed by EG12014 plus paclitaxel. All patients will be scheduled for surgery (breast and axillary lymph nodes) at 3 to 6 weeks after completion of neoadjuvant chemotherapy.
62440598|NCT01211847|PLACEBO_COMPARATOR|Placebo|Placebo matching DCCR
62440599|NCT05621538|EXPERIMENTAL|Neurofeedback-active + TMS-active|4 sessions of: TMS (protocol: 10 Hz pulses delivered at 110% of MT in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of own brain activity from multiple ROIs measured using fMRI)
62608712|NCT03433313|ACTIVE_COMPARATOR|Herceptin|Epirubicin and cyclophosphamide followed by Herceptin plus paclitaxel. All patients will be scheduled for surgery (breast and axillary lymph nodes) at 3 to 6 weeks after completion of neoadjuvant chemotherapy.
62608713|NCT03761225|EXPERIMENTAL|Masitinib & docetaxel|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus docetaxel 75 mg/m2 by intravenous infusion during 1 hour, once every 3 weeks (1 cycle = 21 days) for 6 cycles (8 to 10 cycles can be performed according to patient's tolerance) plus prednisone according to usual practice.
62608714|NCT03761225|PLACEBO_COMPARATOR|Placebo & docetaxel|Participants receive placebo (6 mg/kg/day), given orally twice daily, plus docetaxel 75 mg/m2 by intravenous infusion during 1 hour, once every 3 weeks (1 cycle = 21 days) for 6 cycles (8 to 10 cycles can be performed according to patient's tolerance) plus prednisone according to usual practice.
62608715|NCT01100216|ACTIVE_COMPARATOR|Nicotine Lozenge|4 mg nicotine lozenge (LOZ
62608716|NCT01100216|ACTIVE_COMPARATOR|Camel Snus Frost|
62608717|NCT01100216|ACTIVE_COMPARATOR|Stonewall Spearment Tablet|
62608718|NCT01100216|ACTIVE_COMPARATOR|Skoal Wintergreen|
62608719|NCT03597828||DEXMEDETOMIDINE|Dexmedetomidine infusion for pleuroscopy sedation. Rescue drugs will be midazolam for inadequate sedation and fentanyl for pain control
62608720|NCT03597828||MIDAZOLAM/FENTANYL|Midazolam for sedation and fentanyl for pain will be used for pleuroscopy monitored anesthesia care
62608721|NCT02248974|ACTIVE_COMPARATOR|LVAD Decision Aid|Decision aid presented to subjects was developed from patient and clinician feedback to increase patient knowledge on the risks, benefits, misconceptions or mispredictions regarding LVADs to help patients make an informed decision on accepting or declining LVAD placement.
62608722|NCT02248974|NO_INTERVENTION|No LVAD Decision Aid|The standard education processis institution-specific and unstandardized. The education consists of viewing education pamphlets that are created by device manufacturers. The traditional informed consent process may also include viewing and manipulating the actual device and meeting a patient with a device already implanted. Additionally, the LVAD coordinator describes the device and answers any questions LVAD candidates have.
62608723|NCT05279768|EXPERIMENTAL|WJ-MSCs|Patients will be given tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
62440600|NCT05621538|ACTIVE_COMPARATOR|Neurofeedback-active + TMS-sham|4 sessions of: TMS (protocol: 10 Hz pulses delivered using the Sham TMS coil in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of own brain activity from multiple ROIs measured using fMRI)
62440601|NCT05621538|ACTIVE_COMPARATOR|Neurofeedback-sham + TMS-active|4 sessions of: TMS (protocol: 10 Hz pulses delivered at 110% of MT in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of other's brain activity from multiple ROIs measured using fMRI)
62440602|NCT05621538|SHAM_COMPARATOR|Neurofeedback-sham + TMS-sham|4 sessions of: TMS (protocol: 10 Hz pulses delivered using the Sham TMS coil in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of other's brain activity from multiple ROIs measured using fMRI)
62440603|NCT05621538|NO_INTERVENTION|Check-In Only|4 sessions of: Completing typical pre-TMS/MRI procedures Being prompted to reflect on outside treatment (TAU)
62608724|NCT05279768|EXPERIMENTAL|Secretomes|Patients will be given tablet (placebo) once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.
62608725|NCT05279768|EXPERIMENTAL|WJ-MSCs and Secretomes|Patients will be given tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.
62608726|NCT05279768|PLACEBO_COMPARATOR|Control|Patients will be given Metformin once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
62608727|NCT03083431|EXPERIMENTAL|Propranolol|Oral propranolol (1.6 mg propranolol-HCl/kg/d in 3-4 divided dosages) given for a maximum of 10 weeks (depending on postmenstrual gestational age at birth)
62608728|NCT03083431|PLACEBO_COMPARATOR|Placebo|Placebo (same duration as oral propranolol solution)
62608729|NCT02791438|EXPERIMENTAL|Azilsartan 2.5 - 20 mg (Weight < 50 kg)|Following a 2-week placebo run-in period, azilsartan 2.5 mg (titrated as needed to the highest dose of 20 mg) was administered orally once daily before or after breakfast, for the participants weighing \< 50 kg.
62440604|NCT04385810|EXPERIMENTAL|Ophthalmologic exam|
62440605|NCT01683253|EXPERIMENTAL|Levodopa/Carbidopa(200mg/50mg)|
62440606|NCT01683253|EXPERIMENTAL|Control A (dopaminergic agonist )|Parkinson patients treated with anti-Parkinson drug over 6 months.
62440607|NCT01683253|NO_INTERVENTION|Control B (no drug)|Parkinson diseased patients not treated.
62440608|NCT02122094|EXPERIMENTAL|Sexual Health Promotion Intervention|The SHP Intervention consists of seven core and five optional modules covering topics related to sexual health. It is delivered in both community (outreach) settings and i clinic-based settings.
62440609|NCT01522833||Cohort A|EGFR Wild Type patients
62440610|NCT01522833||Cohort B|EGFR mutation patients
62440611|NCT01954875||Subjects with ALS|subjects diagnosed with amyotrophic lateral sclerosis
62440612|NCT01954875||subjects with non-ALS neurodegenerative disease|subjects diagnosed with non-ALS neurodegenerative disease
62440613|NCT01954875||healthy controls|healthy subjects as controls
62608730|NCT02791438|EXPERIMENTAL|Azilsartan 5 - 40 mg (Weight ≥ 50 kg)|Following a 2-week placebo run-in period, azilsartan 5 mg (titrated as needed to the highest dose of 40 mg) was administered orally once daily before or after breakfast, for the participants weighing ≥ 50 kg.
62608731|NCT01759836|EXPERIMENTAL|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
62608732|NCT01759836|PLACEBO_COMPARATOR|Placebo|Placebo daily for 1 year
62608733|NCT05958719|EXPERIMENTAL|interim evaluation of CR group|Untreated patients with TFH-derived peripheral T-cell lymphoma will be treated with chidamide combined with azacitidine for four cycles. For patients with interim-PET evaluation of CR, consolidation therapy with ASCT or another eight cycles with chidamide combined with azacitidine can be obtained. Subsequently, cidarbenamide monotherapy was given as maintenance therapy for 12 months. Patients with interim evaluation of SD or PD withdrew from this study.
62623504|NCT02186158|EXPERIMENTAL|Vitamin C|Each patient of this group will be received a direct intravenous injection of 2,5 ml ascorbic acid twice a day (at the morning and the lunchtime) from d1 to d2 included. From d3 to d7 included, ascorbic acid's capsules produced by the University Hospital Bordeaux's central pharmacy to keep the double blind way of this study will be given at patient at the morning and at the lunchtime.
62608734|NCT05958719|EXPERIMENTAL|interim evaluation of PR group|Untreated patients with TFH-derived peripheral T-cell lymphoma will be treated with chidamide combined with azacitidine for four cycles. For patients with interim-PET evaluation of PR, another two cycles of chidamide combined with azacitidine will be continued, followed by the second PET-CT efficacy evaluation, and those who achieve CR receive consolidation therapy with ASCT or another six cycles of chidamide combined with azacitidine. Subsequently, cidarbenamide monotherapy was given as maintenance therapy for 12 months. Patients with second efficacy evaluation of PR or SD or PD withdrew from this study.
62608735|NCT03488225|EXPERIMENTAL|Treatment (hyper-CVAD, inotuzumab ozogamicin)|See detailed description.
62608736|NCT05073354||Full-implementation|Patients experiencing shock without trauma once all training is in place and devices are deployed
62608737|NCT06730516|EXPERIMENTAL|Latanoprost (Xalatan)|Group (1) included 23 patients (46 eyes) treated with Latanoprost 0.005 %
62608738|NCT06730516|EXPERIMENTAL|Brimonidine 0.2%|24 patients (48 eyes) received treatment with Brimonidin tartrate 0.2% in group (2)
62608739|NCT01797159|EXPERIMENTAL|Hippocampal-sparing PCI|Hippocampal-sparing PCI 25 Gy in 10 fractions
62608740|NCT05502991|EXPERIMENTAL|Cohort 1|Subjects with ctDNA-level-relapse glioblastoma before clinical relapse, determined according to the dynamics of TISF ctDNA.
62608741|NCT05502991|EXPERIMENTAL|Cohort 2|Subjects with clinical-relapse glioblastoma, determined according to the response assessment in neuro-oncology (RANO) criteria for gliomas.
62608742|NCT05505318||parotid gland neoplasm in upper Egypt|
62440614|NCT00788957|EXPERIMENTAL|Part 1: Panitumumab + Rilotumumab|Participants received panitumumab 6 mg/kg and rilotumumab 10 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
62440615|NCT00788957|ACTIVE_COMPARATOR|Part 2: Panitumumab Alone|Participants received panitumumab 6 mg/kg and placebo by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
62440616|NCT00788957|EXPERIMENTAL|Part 2: Panitumumab + Rilotumumab|Participants received panitumumab 6 mg/kg and rilotumumab 10 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
62440617|NCT00788957|EXPERIMENTAL|Part 2: Panitumumab + Ganitumab|Participants received panitumumab 6 mg/kg and ganitumab 12 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
62608743|NCT03447600|EXPERIMENTAL|Alternate day fasting|Participants randomised to Alternate Day Fasting weight loss intervention. One day fasting of 25% total energy requirements alternated with one day ad libitum intake until study completion at \>/=5% weight loss which is an average of 12 weeks.
62608744|NCT03447600|ACTIVE_COMPARATOR|Continuous caloric restriction|Participants randomised to continuous caloric restriction weight loss intervention. Every day intake of 75% total energy requirements until study completion at \>/=5% weight loss which is an average of 12 weeks.
62608745|NCT05858164|EXPERIMENTAL|Dose Escalation|Participants will take BAY2862789 oral doses.
62608746|NCT05858164|EXPERIMENTAL|Dose Expansion|Participants will take BAY2862789 oral doses. Dose Expansion starts after Dose Escalation.
62830981|NCT02876432|EXPERIMENTAL|Device: Electroacupuncture|"The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes"
62830982|NCT02876432|SHAM_COMPARATOR|Device: Sham Electroacupuncture|In sham electroacupuncture (Sham) the investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
62608747|NCT01830998||control,MCI, Olfactory dsfunction|There are different groups:control,MCI, Olfactory dsfunction.
62608748|NCT01830998||control, MCI|control and MCI group.Glycaemic control
62608749|NCT01830998||control and MCI|treatment and without treatment
62608750|NCT01830998||MCI and Olfactory function|observation between MCI and Olfactory function groups.
62830983|NCT02876432|ACTIVE_COMPARATOR|Drug: Diclofenac sodium|100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.
62830984|NCT02033395||Participants exposed to tramautic event|
62830985|NCT01392339|EXPERIMENTAL|CPAP|CPAP - Continuous Positive Airway Pressure, gold standard treatment to Obstructive Sleep Apnea
62830986|NCT03371069||users of methylphenidate|Children and adolescents who are users of methylphenidate, 2010 to 2015
62830987|NCT01281514|EXPERIMENTAL|Treatment|See Detailed Description
62048418|NCT05070247|EXPERIMENTAL|Dose Expansion: 2L NSCLC: TAK-500 + Pembrolizumab (RDE 1)|Participants with second-line (2L) non-small cell lung cancer (NSCLC) will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) with pembrolizumab 200 mg infusion, intravenously, in a 42-day treatment cycle (Q3W) for up to 1 year. The recommended dose (RDE 1) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 in combination with pembrolizumab Dose Escalation arm.
62048419|NCT05070247|EXPERIMENTAL|Dose Expansion: 2L NSCLC: TAK-500 + Pembrolizumab (RDE 2)|Participants with 2L NSCLC will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) with pembrolizumab 200 mg infusion, intravenously, in a 42-day treatment cycle (Q3W) for up to 1 year. The recommended dose (RDE 2) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 in combination with pembrolizumab Dose Escalation arm.
62608751|NCT05547607||definite or high suspicion endocarditis|All consecutive patients referred for an echocardiography (transthoracic or transesophageal approach) with a high suspicion of endocarditis and those with a confirmed diagnosis of endocarditis independently by the request will be eligible for the study.
62608752|NCT05547607||negative examination with low suspicion of endocarditis|For patients with no evidence of endocarditis on their echocardiogram, data on the following will be collected: i) risk factors for endocarditis; i) size, type and position of valve prosthesis or other devices if present; iii) Duke criteria verification.
62608753|NCT06030830|EXPERIMENTAL|Intervention|Participants will be instructed not to use the smartphone during breastfeeding for a week
62608754|NCT06030830|NO_INTERVENTION|Control|Participants will not be instructed not to use the smartphone during breastfeeding for a week
62608755|NCT04047849|EXPERIMENTAL|Antibiotics|This will include those subjects randomized into the treatment arm, receiving the outpatient antibiotic course of azithromycin and amoxicillin prior to re-admission at viability (23 0/7 weeks gestation). They will receive a single, 500mg dose of Azithromycin given prior to discharge to home, followed by 250mg daily for 4 more days, and Amoxicillin 500mg orally TID for 7 days (first dose also being given prior to discharge home).
62830988|NCT04467203|EXPERIMENTAL|Fadanafil fast to fat meal|"Seven subjects in group A will receive treatment in the following order:~At Day 1, a single dose of Fadanafil 100mg will be administered orally after overnight fasting-\> At Day 8, a single dose of Fadanafil 100mg will be administered orally with high fat meal"
62440618|NCT00788957|EXPERIMENTAL|Part 3: Rilotumumab|Participants randomized to Panitumumab Alone in Part 2 who had disease progression (radiographic or clinical) or intolerability were re-randomized in Part 3 to receive rilotumumab 10 mg/kg every 2 weeks until disease progression, intolerability, withdrawal, death, or sponsor decision.
62440619|NCT00788957|EXPERIMENTAL|Part 3: Ganitumab|Participants randomized to Panitumumab Alone in Part 2 who had disease progression (radiographic or clinical) or intolerability were re-randomized in Part 3 to receive ganitumab 12 mg/kg every 2 weeks until disease progression, intolerability, withdrawal, death, or sponsor decision.
62830989|NCT04467203|EXPERIMENTAL|Fadanfil fat meal to fat|"Seven subjects in group B will receive treatment in the following order:~At Day1, a single dose of Fadanafil 100mg will be administered orally with high fat meal-\> At Day 8, a single dose of Fadanafil 100mg will be administered orally after overnight fasting"
62048420|NCT05070247|EXPERIMENTAL|Dose Expansion: 3L NSCLC: TAK-500 (RDE 1) SA|Participants with third-line (3L) NSCLC will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) for up to 1 year. The recommended dose (RDE 1) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 as single agent in Dose Escalation arm.
62830990|NCT06586710|OTHER|Activation of interferon pathway|Assessment activation of interferon pathway on biological samples (blood and kidney biopsy) in cSLE patients
62048421|NCT05070247|EXPERIMENTAL|Dose Expansion: 3L NSCLC: TAK-500 (RDE 2) SA|Participants with 3L NSCLC will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) for up to 1 year. The recommended dose (RDE 2) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 as single agent in Dose Escalation arm.
62830991|NCT05698550|EXPERIMENTAL|EZTG group|
62830992|NCT05698550|PLACEBO_COMPARATOR|Control group|
62830993|NCT03843814|EXPERIMENTAL|APT MRI|"Participants will have the standard MRI of the brain that is performed for radiation planning for brain tumors.~1. Addition of the additional MRI sequences to the standard MRI before radiation therapy. This typically adds 10-15 minutes to the length of the scan.~2. An additional MRI scan to be scheduled during one of the final five radiation treatment days that would not otherwise occur. There will be no contrast injection as part of this second scan. This may typically take 40-45 minutes.~3. Collection of information about participants' tumor, including copies of their MRIs and later outcome of treatment."
62830994|NCT06064721|EXPERIMENTAL|Buerger-Allen Exercise Group|"The researcher will conduct training sessions on the BAE for the study group (how to perform these exercises, duration, and frequency of exercise).~Firstly researcher practically demonstrate the BAE technique lasting 15-20 minutes, and secondly will encourage each participant to re-demonstrate the following technique.~The researcher will ensure that the study group practices the exercise until they demonstrate competence in its execution. Additionally, the study group will be provided with a photographic brochure illustrating the exercise.~The buerger Allen exercise will consist of three steps step 1. Elevation step 2. Dependency step 3. Horizontal The intervention group will continue for 51 days, with a 6-8 hour gap between the two sessions, in addition to receiving routine care.~To ensure exercise continuity, participants will receive reminders via phone calls/messages"
62830995|NCT06064721|NO_INTERVENTION|Routine Care Group|the control group participants will receive routine care.
62830996|NCT03113461|EXPERIMENTAL|CPAP adherent|Study participants in this arm are using the CPAP intervention consistently
62830997|NCT03113461|ACTIVE_COMPARATOR|CPAP non-adherent|Study participants in this arm are not using the CPAP intervention consistently
62608756|NCT04047849|NO_INTERVENTION|No antibiotics|This will include those subjects randomized into the control arm and will not receive outpatient antibiotics prior to re-admission at viability (23 0/7 weeks gestation).
62608757|NCT06729983|ACTIVE_COMPARATOR|Control|Standard reverse shoulder arthroplasty
62608758|NCT06729983|EXPERIMENTAL|Treatment|Prophylactic conjoint tendon lengthening in addition to reverse shoulder arthroplasty
62440620|NCT03814109|EXPERIMENTAL|LENINGRADO|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:~1 tablet Leningrado association,1 tablet indapamide placebo, 1 tablet levamlodipine placebo, oral, once a day."
62608759|NCT01267084|EXPERIMENTAL|Part 1|Patients will receive trabectedin+ketoconazole followed by trabectedin alone. Each cycle will be will be separated by 21 days. Patients will receive 6 total consecutive doses of ketoconazole. Dexamethasone or equivalent steroid will be administered before trabectedin in each cycle.
62608760|NCT01267084|EXPERIMENTAL|Part 2|Patients will receive 1 of 2 treatment sequences; Sequence 1: trabectedin+ketoconazole followed by trabectedin alone or Sequence 2: trabectedin alone followed by trabectedin+ketoconazole. Each cycle will be separated by 21 days. Patients will receive 15 total consecutive doses of ketoconazole. Dexamethasone or equivalent steroid will be administered before trabectedin in each cycle.
62608761|NCT06697093||cardiogenic shock patients|The registry will include all patients presenting with primary cardiogenic shock. All medical interventions will be conducted based on established clinical indications.
62608762|NCT01810705|EXPERIMENTAL|GRASPA|"patients will receive one injection of GRASPA (100 IU/kg) after each course of low-dose cytarabine (see Arm Control)"
62048422|NCT05070247|EXPERIMENTAL|Dose Expansion: 2L Pancreatic Adenocarcinoma: TAK-500 + Pembrolizumab (RDE 1)|Participants with 2L Pancreatic Adenocarcinoma will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) with pembrolizumab 200 mg infusion, intravenously, in a 42-day treatment cycle (Q3W) for up to 1 year. The recommended dose (RDE 1) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 in combination with pembrolizumab Dose Escalation arm.
62440621|NCT03814109|ACTIVE_COMPARATOR|Indapamide|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:~1 tablet indapamide 1,5 mg, 1 tablet Leningrado association placebo, and 1 tablet levamlodipine placebo, oral, once a day."
62440622|NCT03814109|ACTIVE_COMPARATOR|Levamlodipine|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:~1 tablet levamlodipine 2.5/ 5 mg, 1 tablet indapamide placebo, and 1 tablet Leningrado association placebo, oral, once a day."
62440623|NCT01918111|EXPERIMENTAL|RD group|Renal denervation group
62440624|NCT01918111|ACTIVE_COMPARATOR|Control group|Control group
62440625|NCT05205785|EXPERIMENTAL|Human Milk Oligosaccharide (HMO) mix|The HMO blend to be used in this trial is a mix of the three milk oligosaccharides produced by fermentation of lactose. The blend is provided as white powder and mixed in a single serve stick packs containing 5.5 g of HMOs. The final product contains less than 0.03 g lactose per serving. The participants will be instructed to mix the product in a 4-6 oz glass of water and consume in the morning once a day for 12 weeks.
62440626|NCT05205785|PLACEBO_COMPARATOR|Placebo|The placebo to be used in this trial is 5.5 g of powdered dextrose powder in a single-serve stick pack. The participants will be instructed to mix the product in a 4-6 oz glass of water and consume in the morning once a day for 12 weeks.
62440627|NCT03626610|EXPERIMENTAL|Interventional|Participants will be given a monitored exercise program during their treatment starting before chemotherapy
62440628|NCT03626610|NO_INTERVENTION|Non-interventional|Patients will have standard care.
62440629|NCT01190683|ACTIVE_COMPARATOR|cholecalciferol|cholecalciferol 60,000IU/week for first eight weeks followed by 60,000 IU every 15 days for four months along with calcium placebo
62440630|NCT01190683|ACTIVE_COMPARATOR|Calcium carbonate|two tablets of calcium carbonate daily equivalent to 1 gm of elemental calcium for six months along with vitamin D placebo
62440631|NCT01190683|ACTIVE_COMPARATOR|oral calcium and cholecalciferol|60,000 IU of cholecalciferol every week for ist eight week and then 60,000IU every 15 days for next four months along with 1 gm of elemental calcium ever day for six months
62440632|NCT01190683|PLACEBO_COMPARATOR|lactose|identical placebos
62440633|NCT01133392|EXPERIMENTAL|Insulin Lispro A|20 units (U) subcutaneously (SC)
62440634|NCT01133392|ACTIVE_COMPARATOR|Insulin lispro B|20 units (U) subcutaneously (SC)
62440635|NCT03584737||Symptomatic for bacterial sinusitis|Samples from participants showing symptoms of bacterial sinusitis tested by rapid in vitro diagnostic test, bacterial culture, and PCR assay
62440636|NCT04915586|EXPERIMENTAL|Treatment Arm|"Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg for total 3 doses within 24 hours~Intervention Drug: Combination Alteplase and pulmozyme (DNase)"
62440637|NCT03114189|ACTIVE_COMPARATOR|Footbath, care of sleep|"Warm water (37°C) filled up to the level of the ankle. Water has to be heated up to 42°C and increased to the calf 's half height within 15 minutes.~Information about wrong and correct behaviour."
62440638|NCT03114189|ACTIVE_COMPARATOR|Care of sleep|Information about wrong and correct behaviour.
62440639|NCT06528262|EXPERIMENTAL|Enavogliflozin|Enavogliflozin as a study group
62440640|NCT06528262|PLACEBO_COMPARATOR|Placebo|Placebo as a comparison group
62440641|NCT04979130|EXPERIMENTAL|SC semaglutide|Participants receive a once weekly, subcutaneous, Semaglutide injection for 16 weeks in addition to the participants background metformin monotherapy. The participants in this arm will begin at a 0.25 mg dose during the randomization visit, at week 4 this will be escalated to a 0.5 mg dose and at week 8 it will be escalated again to a 1.0 mg dose if tolerable by the participant. If the participant cannot tolerate the 0.25 mg dose at randomization or the 0.5 mg dose at week 4 they will be withdrawn from the study.
62440642|NCT04979130|PLACEBO_COMPARATOR|Placebo|Participants in this arm will be given a once weekly, subcutaneous, placebo injection matching the Semaglutide experimental arm in addition to their background metformin monotherapy.
62440643|NCT03016559|OTHER|releasing muscle|The physical therapist placed thumbs on the quadratus lumborum to release muscle.
62440644|NCT04559295|EXPERIMENTAL|Stem Cells (BMC)|Subjects in the BMC arm received an injection of bone marrow concentrate
62048423|NCT05070247|EXPERIMENTAL|Dose Expansion: 2L Pancreatic Adeno: TAK-500 (RDE 1) SA|Participants with 2L Pancreatic Adenocarcinoma will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) for up to 1 year. The recommended dose (RDE 1) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 as single agent in Dose Escalation arm.
62048424|NCT05070247|EXPERIMENTAL|Dose Expansion: 3L RCC: TAK-500 + Pembrolizumab (RDE 1)|Participants with 3L renal clear cell carcinoma (RCC) will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) with pembrolizumab 200 mg infusion, intravenously, in a 42-day treatment cycle (Q3W) for up to 1 year. The recommended dose (RDE 1) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 in combination with pembrolizumab Dose Escalation arm.
62048425|NCT05838807|EXPERIMENTAL|Group A: Thermal Ultrasound Group|
62608763|NCT01810705|NO_INTERVENTION|Control|patients will receive successive courses of low intensive chemotherapy, as subcutaneous low-dose cytarabine 20mg twice daily for 10 days per course (from day 1 to day 10), each course occurring every 28 days, for a duration up to 24 months
62830998|NCT03113461|NO_INTERVENTION|No OSA|Study participants who do not have OSA
62830999|NCT02372188|EXPERIMENTAL|Water|125 mL water are administered during or before gastric pH measurement
62831000|NCT02372188|EXPERIMENTAL|Caffeine|150 mg Caffeine and 125 mL water are administered during or before gastric pH measurement
62831001|NCT02372188|EXPERIMENTAL|Caffeine + homoeriodictyol sodium salt|150 mg Caffeine + 30 mg homoeriodictyol sodium salt and 125 mL water are administered during or before gastric pH measurement
62440645|NCT04559295|NO_INTERVENTION|Control|Subjects in the control arm received no treatment for their condition
62831002|NCT02372188|EXPERIMENTAL|homoeriodictyol sodium salt|30 mg homoeriodictyol sodium salt and 125 mL water are administered during the gastric pH measurement
62440646|NCT05821712|EXPERIMENTAL|0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash|mouthwash
62440647|NCT05821712|ACTIVE_COMPARATOR|0.057% sodium fluoride Mouthwash|mouthwash
62440648|NCT03962933||Flexcystoscopy/Uromonitor|Control cystoscopy every 4 - 8 and 12 months as a standard procedure, And Urine test (Uromonitor) every 4 months
62048426|NCT05838807|EXPERIMENTAL|Group B: Pulsed Ultrasound Group:|
62608764|NCT03219086|ACTIVE_COMPARATOR|Group M|combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%
62608765|NCT03219086|ACTIVE_COMPARATOR|Group P|A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)
62048427|NCT05838807|EXPERIMENTAL|Group C: Combination Group|
62048428|NCT05838807|PLACEBO_COMPARATOR|Group D: Placebo Group|
62048429|NCT05100290||HVS+|Subjects without documented respiratory or cardiac disease, with a spirometry and metacholine tests within expected values AND with complaints documented by a Nijmegen questionnaire score of ≥23/64 (suspected of idiopathic hyperventilation)
62048430|NCT05100290||HVS-|Healthy controls without documented respiratory or cardiac disease, with a spirometry and metacholine tests within expected values AND without complaints documented by a Nijmegen questionnaire score of \<23/64
62440649|NCT05030090|ACTIVE_COMPARATOR|Control group|"1. Consulted by the dietitian using communication software (Line) or telephone.~2. At 0.5, 1, 1.5, 2, 2.5, and 3 months will track the biochemical data, assess nutritional status and quality of life.~3. The nutrition care plan period will be three months."
62440650|NCT05030090|EXPERIMENTAL|Nutrition care plan group A|"1. Consulted by the dietitian using communication software (Line) or telephone.~2. Implement a daily diet with a concentrated high-calorie and high-protein liquid supplement~3. At 0.5, 1, 1.5, 2, 2.5, and 3 months will track the biochemical data, assess nutritional status and quality of life.~3.The nutrition care plan period will be three months."
62831003|NCT01334450|ACTIVE_COMPARATOR|High Frequency TMS to prefrontal cortex|
62831004|NCT01334450|ACTIVE_COMPARATOR|Low Frequency TMS to Prefrontal cortex|
62831005|NCT01334450|SHAM_COMPARATOR|Sham TMS on Prefrontal Cortex|
62831006|NCT05681182|OTHER|Single Arm|All patients who are enrolled into the study will receive the treatment. This includes the CardiaMend which should be used according to the Instructions for Use with the exception that device hydration is performed with 3 ampules of amiodarone (150mg/3ml) instead of room temperature saline. For best results, the device should be fixed in place using a continuous or interrupted stitch (approximately 1 stitch per cm) to approximate the edge of the pericardial defect. The closed defect should not put pressure on the underlying structures. A non-absorbable monofilament suture is preferred such as 5-0 or 4-0 prolene. A small edge may be left open for drain placement and a small slit for LIMA in case of CABG
62831007|NCT04762602|EXPERIMENTAL|Part 1 Dose Escalation Cohorts|Patients from each cohort will be administered HMPL-306 orally QD
62831008|NCT04762602|EXPERIMENTAL|Part 2 Dose Expansion Cohorts|Patients from each cohort will be administered HMPL-306 orally QD at the recommended phase 2 dose
62831009|NCT05993858|OTHER|Neoadjuvant therapy+Surgery+Adjuvant therapy+Consolidation therapy|Participants receive totally 3 cycles of neoadjuvant therapy (Toripalimab+cetuximab), then radical treatment(surgery). After surgery, Participants receive radiotherapy or chemoradiotherapy according to the pathological results of the operation. Then, participants receive consolidation therapy of Toripalimab.
62048431|NCT03901196||Interstitial Lung Disease|Ex : sarcoidosis, IPF
62048432|NCT05461976|EXPERIMENTAL|Home-based self-management exercise program|A home-based self-management exercise program will be implemented based on behaviour change techniques on the approach of Social-Cognitive Theory and Control Theory. In the present study, we will use the following behaviour changes techniques: health consequences, action planning, graded tasks, problem-solving/coping planning, modelling of the behaviour, vicarious reinforcement and non-specific encouragement, feedback on behaviour, self-monitoring on behaviour, review behaviour goals and goal setting (behaviour). The program will include six sessions of self-management with an average duration of 60 minutes. The intervention will be delivered individually and face-to-face in the participant's home by a physical therapist over 10 weeks.
62048433|NCT05461976|NO_INTERVENTION|Control Group|This group will receive one session about education on risk factors after stroke and usual care.
62440651|NCT05030090|EXPERIMENTAL|Nutrition care plan group B|"1. Consulted by the dietitian using communication software (Line) or telephone.~2. Implement a daily diet with a concentrated high-calorie and high-protein liquid supplement and powdered supplement 1 and nutritional products and powdered supplement 2~3. At 0.5, 1, 1.5, 2, 2.5, and 3 months will track the biochemical data, assess nutritional status and quality of life.~4. The nutrition care plan period will be three months."
62831010|NCT06587087|EXPERIMENTAL|Investigational Glucose level device- Smartest-AE|The Smartest's System is intended to measure blood glucose levels in home environment. The Smartest's System consists of a disposable single-use device and a mobile app.
62440652|NCT01106872|EXPERIMENTAL|Treatment|Bevacizumab Combined with Gemcitabine, Docetaxel and Valproic Acid in Advanced Sarcoma
62440653|NCT03848585|EXPERIMENTAL|Pilloxa Pillbox|
62831011|NCT06587087|ACTIVE_COMPARATOR|Commercial Glucometer|
62440654|NCT03848585|SHAM_COMPARATOR|Non active Pilloxa Pillbox|
62831012|NCT02170571|EXPERIMENTAL|Dabigatran etexilate|
62831013|NCT05690802|EXPERIMENTAL|Palonosetron hydrochloride capsules|The recommended dose for adults is 0.5mg (1 capsule) for a single oral dose about 1 hour before chemotherapy.
62831014|NCT04684836||High Telemedicine|Patients in practices that had high telemedicine use, based on the percent of visits the practice delivered via telemedicine from April 2020 to December 2021 (the study post-period)
62831015|NCT04684836||Low Telemedicine|Patients in practices that had some telemedicine use, based on the percent of visits the practice delivered via telemedicine from April 2020 to December 2021 (the study post-period)
62831016|NCT05663606|ACTIVE_COMPARATOR|Happy Bob Arm|Subjects, who are using Happy Bob App in addition to CGM
62831017|NCT05663606|PLACEBO_COMPARATOR|Controls|Subjects, who are using CGM only
62831018|NCT04363970||group A- early catheter removal)|in group A, we will remove the catheter after 24 h.
62831019|NCT04363970||Group B- delayed catheter removal|In group B, we will remove the catheter after 48 h.
62831020|NCT01373840||healthy controls|
62048434|NCT00652158|EXPERIMENTAL|A|
62440655|NCT05480917|OTHER|IRIS|
62440656|NCT01764620|OTHER|Control|In this session, the athletes will be evaluated before and after the fatigue protocol, without any taping application.
62831021|NCT01373840||patients with focal dystonias|
62831022|NCT06593119|EXPERIMENTAL|Telemedicine management of Hypertension intervention group|BP monitor and telehealth application Home BP monitoring Pharmacotherapy Telemedicine-based self-management support Additional support in-person training
62831023|NCT06593119|PLACEBO_COMPARATOR|control group|This includes usual clinic based Hypertension care using routinely available clinic resources (e.g., community health worker, social worker). Clinicians can offer self-management support (e.g., dietician referral) or recommend a home BP monitor. These activities mirror current primary care practice.
62831024|NCT04664686|ACTIVE_COMPARATOR|AF catheter ablation|
62831025|NCT04664686|ACTIVE_COMPARATOR|AV node ablation|
62831026|NCT00003469|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62048435|NCT01922492|EXPERIMENTAL|Autologous islet transplantation|Autologous islet transplantation arm: autologous islet transplantation
62440657|NCT01764620|EXPERIMENTAL|Kinesio taping|A kinesio taping technique for facilitating lower trapezius muscle function will be applied just before fatigue protocol and removed after in the end of the evaluation session.
62440658|NCT01764620|SHAM_COMPARATOR|Sham|A similar technique, using the same tape, will be applied but without any tension (tension is considered to be the therapeutic effect). The tape will be applied just before the fatigue protocol and removed in the end of the session.
62449442|NCT03139968|ACTIVE_COMPARATOR|Dummy group|Conventional protection measurements. Additionally, a dummy, silicone, disposable drape (appearing identical to the experimental arm) is placed onto the sterile drape on the patient between the operator and the image intensifier.
62449443|NCT03139968|NO_INTERVENTION|Control goup|Only conventional protection measurements.
62831027|NCT01831388|EXPERIMENTAL|The breath training program|Approximately 30-minutes of group instruction session on breathing techniques delivered at a Main Campus outpatient clinic, followed by approximately 15 minutes twice daily home practice for six weeks with weekly telephone coaching. The intervention will conclude at about week 6. Patients will be encouraged to continue the practice, but there will be no further phone calls to remind patients or to confirm their continuing practice.
62831028|NCT04488614||Early Stage Breast Cancer (Stage I and II)|Consecutive early stage breast cancer patients who are treated according to the national guidelines. Observation over 11 years.
62048436|NCT01922492|ACTIVE_COMPARATOR|Oral anti-diabetic drugs|Metformin (starting from 500mg qd with dose adjustment thereafter) with or without vildagliptin (starting from 50mg qd with dose adjustment thereafter)
62608766|NCT03922204|EXPERIMENTAL|MCLA-145|In Part 1, the dose escalation phase, patients with advanced or recurrent/metastatic solid tumors or B-cell lymphomas will receive escalating doses of MCLA-145 (either Q2W for those patients in treatment at the time of Amendment #4 or Q3W with Amendment #4 approval). Treatment will be with MCLA-145 (monotherapy) for Group A, or in combination with pembrolizumab for Group B, until MTD or RDE is reached. In Part 2, the expansion phase, participants with advanced or metastatic solid tumors will receive intravenous infusion of MCLA-145 either in monotherapy (Group A) or in combination with pembrolizumab (Group B) at the recommended phase II dose every 3 weeks. The duration of each treatment cycle is 21 days
62608767|NCT03922204|EXPERIMENTAL|Group B Combination Treatment|Patients in Group B will be treated with MCLA-145 in Combination with pembrolizumab 200mg Q3W.
62608768|NCT06062953|EXPERIMENTAL|Melatonin|
62608769|NCT06062953|EXPERIMENTAL|Quetiapine|
62608770|NCT06062953|PLACEBO_COMPARATOR|Placebo|
62608771|NCT05929079|EXPERIMENTAL|Retatrutide Dose 1|Participants will receive retatrutide subcutaneously (SC).
62608772|NCT05929079|EXPERIMENTAL|Retatrutide Dose 2|Participants will receive retatrutide SC.
62048437|NCT06509126|ACTIVE_COMPARATOR|CONTINUOUS ARM|Patients will receive Panitumumab plus FOLFIRI until progressive disease, unacceptable toxicity or informed consent withdrawal
62608773|NCT05929079|EXPERIMENTAL|Retatrutide Dose 3|Participants will receive retatrutide SC.
62048438|NCT06509126|EXPERIMENTAL|INTERMITTENT ARM|Patients will have a treatment free interval until progressive disease (PD), when they will receive up to 8 cycles of Panitumumab plus FOLFIRI. In the presence of complete or partial response, or stable disease, non-progressing patients will undergo again to treatment free interval until PD, when they will restart treatment. Treatment cycling will continue till any PD on treatment.
62048439|NCT05842226|EXPERIMENTAL|Intervention group|Micro-teaching enriched with standard patient will be applied.
62440659|NCT06080984|EXPERIMENTAL|Treatment Cohort 1|"This arm includes 6 head and neck squamous cell carcinoma patients. Patients in the study receive intratumoral treatment with a novel oncolytic virus SDJ001 at two dose levels: 5x10\^11 and 1x10\^12 pfu per person. At the current dose levels, intratumoral injection is administered on the first day of each treatment cycle. Each treatment cycle consists of three weeks, continuing until tumor growth is observed following injection or until the patient experiences intolerable toxic effects.~Ultrasound-guided injection may be used when necessary (2.0 mL for tumors with a diameter \>2.5 cm, 1.0 mL for diameters of 1.5-2.5 cm, 0.5 mL for diameters of 0.5-1.5 cm, and 0.1 mL for diameters \<0.5 cm, with a maximum of 4 mL)."
62440660|NCT06080984|EXPERIMENTAL|Treatment Cohort 2|This arm includes 9 melanoma patients. Patients in the study receive intratumoral treatment with a novel oncolytic virus YD06-1 at a concentration of 10\^6 pfu/mL to 10\^8 pfu/ml following a dose escalation plan. Each subject receives only one injection at the corresponding concentration, with the dose determined based on the size of the tumor mass. (Diameter ≤1.5 cm, maximum of 1 mL; diameter 1.5-2.5 cm, maximum of 2 mL; diameter greater than 2.5 cm, maximum of 4 mL). The second dose is administered three weeks after the first dose, followed by subsequent doses at two-week intervals.
62608774|NCT05929079|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62048440|NCT05842226|NO_INTERVENTION|Control group|The control group will receive palliative care brochure for patients and their relatives.
62608775|NCT02849067|EXPERIMENTAL|Group Treatment|Patients in this group will watch a comedy show that will will not exceed 30 minutes. This group will have until five patients.
62608776|NCT02849067|OTHER|Group Control|patients in this group will watch a documentary that will not exceed 30 minutes. This will have until five patients
62831029|NCT04893369|EXPERIMENTAL|The Low Back Pain and Disability Drivers Management model|Participating clinicians in the intervention arm will use the PDDM model to guide assessment and treatment of their patients and data will be collected over a 12-weeks period.
62831030|NCT04893369|ACTIVE_COMPARATOR|Low back pain clinical practice guidelines|Participating clinicians in the active comparator arm will perform assessment and treatment of their patients based on the recommendations from the most recent and high-quality clinical practice guidelines (CPGs) and data will be collected over a 12-weeks period.
62831031|NCT04225897|EXPERIMENTAL|RV521|"sisunatovir is formulated as a dry powder blend of RV521 drug substance with mannitol as excipient. The RV521 dry powder blend will be supplied in capsules containing 10, 20, or 50 mg RV521. The Investigational Medicinal Product (IMP) will be dispersed in a defined volume of suspending diluent prior to oral administration on a mg/kg basis. Instructions for opening the capsule(s) and dispersing the contents in a fixed volume of suspending diluent prior to administration will be provided in the Pharmacy Manual.~The proposed dosing regimen for Part A is a single open label dose of RV521. Part B and C is RV521 or placebo administered BID, 12 hours apart, for a period of 5 consecutive days with a total of 10 doses. However, this is subject to the recommendation of the DSMC."
62831032|NCT04225897|PLACEBO_COMPARATOR|Placebo|The placebo capsules administered in Part B and C will contain mannitol and microcrystalline cellulose (vehicle). The placebo dry powder will be dispersed in suspending diluent and given orally BID. Instructions for opening the capsule(s) and dispersing the contents in a fixed volume of suspending diluent prior to administration will be provided in the Pharmacy Manual.
62831033|NCT05922917|ACTIVE_COMPARATOR|PVI|Pulmonary vein isolation
62831034|NCT05922917|EXPERIMENTAL|PVI+|Pulmonary vein isolation supplemented by the additional lesions: left atrial posterior wall isolation, mitral and cavotricuspid isthmus lines
62831035|NCT01047358||ajuvant group|adjuvant setting after two to three years of tamoxifen
62831036|NCT01047358||palliative group|palliative setting after progression of disease with anti-estrogen therapy
62831037|NCT03430284|EXPERIMENTAL|Integrated Treatment|
62831038|NCT03430284|OTHER|General Treatment|
62831039|NCT03651479|EXPERIMENTAL|real boxing group|In the real boxing (RB) group in addition to the NDT program, real boxing training will be given.
62831040|NCT03651479|EXPERIMENTAL|virtual boxing group|In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing.
62831041|NCT02153086||Ramelteon 8 mg Tablets|
62608777|NCT03693469|EXPERIMENTAL|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during immunization.
62608778|NCT03693469|NO_INTERVENTION|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
62048441|NCT05589870||Clinical pharmacists group|A group of patient files that were evaluated by the clinical pharmacists, Insights Insights were categorized according to five categories: 1) duplication of therapy, 2) age-related issues, 3) incorrect dose, 4) current side effects and 5) future side effects risks. An external judging committee comprised of two (2) senior clinical pharmacy doctors, who were blinded to the source of the conclusion sheets, adjudicated the MDI system and clinical pharmacist insights.
62048442|NCT05589870||MDI system group|A group of patient files that were evaluated by the MDI system. Insights were categorized according to five categories: 1) duplication of therapy, 2) age-related issues, 3) incorrect dose, 4) current side effects and 5) future side effects risks. An external judging committee comprised of two (2) senior clinical pharmacy doctors, who were blinded to the source of the conclusion sheets, adjudicated the MDI system and clinical pharmacist insights.
62048443|NCT03300791||Admitted|We will include patients who had beeb admitted by an acute heart failure in hospitalization ward
62048444|NCT05886400|EXPERIMENTAL|Distracted|Visual and audio distraction via sports video clips or a game will be playing during the testing session.
62048445|NCT05886400|SHAM_COMPARATOR|Not Distracted|No visual or auditory distractions will be used during testing session. Testing area will be in a controlled environment.
62048446|NCT01201395||Dental caries assessment|
62440661|NCT06080984|EXPERIMENTAL|Treatment Cohort 3|This arm includes 9 sarcoma patients. Patients in the study receive intratumoral treatment with a novel oncolytic virus YD06-1 at a concentration of 10\^6 pfu/mL to 10\^8 pfu/ml following a dose escalation plan. Each subject receives only one injection at the corresponding concentration, with the dose determined based on the size of the tumor mass. (Diameter ≤1.5 cm, maximum of 1 mL; diameter 1.5-2.5 cm, maximum of 2 mL; diameter greater than 2.5 cm, maximum of 4 mL). The second dose is administered three weeks after the first dose, followed by subsequent doses at two-week intervals.
62440662|NCT06101121||Urethral catherisation|Observation time will start with placement of catheter and will end with catheter removal or if any complication appears, whatever occurs first. In this case, the observational time will be 1 day when a bladder catheterization is undergone.
62440663|NCT06101121||Cytoscopy|Observation time will start with placement of catheter and will end with catheter removal or if any complication appears, whatever occurs first. In this case, the observational time will be the time which the catheterization lasts.
62048447|NCT00453986|EXPERIMENTAL|Nimenrix A Group|subjects received 1 dose of Nimenrix™ Lot A at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
62048448|NCT00453986|EXPERIMENTAL|Nimenrix B Group|subjects received 1 dose of Nimenrix™ Lot B at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
62048449|NCT00453986|EXPERIMENTAL|Nimenrix C Group|subjects received 1 dose of Nimenrix™ Lot C at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
62048450|NCT00453986|ACTIVE_COMPARATOR|Mencevax ACWY Group|subjects received 1 dose of Mencevax™ ACWY vaccine at Month 0. Mencevax™ ACWY vaccine was administered by subcutaneous injection in the non-dominant upper arm.
62608779|NCT06676735|EXPERIMENTAL|Intraoperative hypothermia low risk group|Patients included this group are determined by prediction model. Operating room environment temperature was set at not less than 21°C, with a relative humidity of 50% to 60%. Patients are covered from neck to feet with a cotton blanket and the area to be disinfected and operated on is uncovered after induction of anesthesia. All patients will be administered intravenous fluid warmers and irrigation fluid prewarming (37℃\~43℃).The estimated sample size calculated using SPSS is 362 cases.
62623505|NCT02186158|PLACEBO_COMPARATOR|Placebo|Each patient of this group will be received a direct intravenous injection of 2,5 ml NaCl 9% twice a day (at the morning and the lunchtime) from d1 to d2 included. From d3 to d7 included, mannitol's capsules produced by the University Hospital Bordeaux's central pharmacy will be given at patient at the morning and at the lunchtime.
62623506|NCT04424472|EXPERIMENTAL|Ultrasonography|Patient will be scheduled to undergo an additional US by a blinded sonographer within 4 weeks of their most recent cross-sectional imaging that indicated a recurrence
62623507|NCT06202274|EXPERIMENTAL|Treatment|Treatment will be performed with commercial products manufactured by Candela and may also include non-Candela products. All devices will be used per the manufacturer's instructions.
62440664|NCT03324126||Targeted fortification|In the targeted protein fortification group, breast milk samples were analyzed daily via mid-infrared spectroscopy and additional protein was provided to maintain an intake of 4.5 g/kg/day.
62440665|NCT03324126||Adjustable fortification|"In the adjustable protein fortification group, blood urea nitrogen (BUN) levels were monitored weekly, and if the level was \< 5 mg/dL, the amount of protein fortification was gradually increased to an estimated maximum level of 4.5 g/kg/day"
62608780|NCT06676735|EXPERIMENTAL|Intraoperative hypothermia high risk group|"Patients included this group are determined by prediction model. In addition to the measures taken in intraoperative hypothermia low risk group, an inflatable warming system, including a forced air warming system (IOB, WU505) and forced air warming blanket (IOB-001, IOB-006, IOB-011), is employed for prewarming before anesthesia initiation and for maintaining body temperature throughout the operation. During the surgery, the insulation blanket will be applied to non surgical areas, and the host temperature will be adjusted to 38 ℃ for warming. If the temperature of the patient is lower than 36 ℃, the temperature of the system can be adjusted to 43 ℃; if the temperature of the patient is higher than 37 ℃, the temperature of the system can be adjusted to 32 ℃. After the patient's temperature is normal, it can be adjusted back to 38 ℃.~The estimated sample size calculated using SPSS is 362 cases."
62623508|NCT01449864|EXPERIMENTAL|Proton RT|Subjects receive proton radiation
62048451|NCT00453986|EXPERIMENTAL|Nimenrix+Fluarix Group|subjects received 1 dose of Nimenrix™ Lot A co-administered with Fluarix™ vaccines at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm. Fluarix™ vaccine was administered by intramuscular injection in the deltoid region of the dominant arm.
62440666|NCT00974883||Suspected GCA|Patients who present with new onset of headache and suspected diagnosis of GCA. They will all require a temporal artery biopsy to assist in the diagnosis
62440667|NCT00974883||Training cohort|Patients with any condition or healthy volunteers who are willing to consent ot have their temporal and axillary arteries examined using ultrasound, for training purposes
62623509|NCT01408719|EXPERIMENTAL|5g LMW beta glucan|5 gram low molecular weight barley beta-glucan diet for 35 days
62440668|NCT03511352|NO_INTERVENTION|Control Condition (Protocol A)|Following a one-hour sitting run-in period, participants will sit for a 5-hour period including a mid-point bathroom break.
62440669|NCT03511352|EXPERIMENTAL|Frequent Sit-to-Stands (Protocol B)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period and a mid-point bathroom break.
62608781|NCT06676735|OTHER|Model optimization group|Only observe the patient's baseline, intraoperative hypothermia, postoperative complications, and other indicators, and collect data through the electronic Data Capture System to optimize existing intraoperative hypothermia prediction model. The estimated sample size is 1000 cases by the incremental learning curve calculating.
62608782|NCT06676735|NO_INTERVENTION|Group of model benefit evaluation|Data of this group is medical records before the application of the intraoperative hypothermia prediction model, which will be collected from the electronic medical record system. Estimated sample size is 700 cases.
62831042|NCT02678026|EXPERIMENTAL|Cervical Pessary|"Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early).~Women will receive pessary soon after UIC"
62831043|NCT02678026|NO_INTERVENTION|No intervention|No treatment
62608783|NCT04159168|EXPERIMENTAL|Arm 1: R61 FAST|Individuals in this Arm will receive the FAST intervention, as described in the Intervention section of the Clinical Trials form below, with a focus on demonstrating target (facial affect sensitivity) engagement.
62608784|NCT04159168|NO_INTERVENTION|Arm 2: R61 No-Treatment Control|Individuals in this Arm will not receive any intervention.
62608785|NCT04159168|EXPERIMENTAL|Arm 3: R33 FAST|Individuals randomized this Arm of the R33 phase will receive the FAST intervention, with the aim of replicating FAST target engagement (as demonstrated in the R61 phase) with a new high-CU sample, and to evaluate the FAST intervention in comparison to an active control condition (Arm 4, implicit eye gaze training).
62250659|NCT00929604|NO_INTERVENTION|Standard of care|Standard of care arm: utilizes the current standard of care per Zambian national guidelines to determine treatment failure and eligibility for second-line ART. HIV-1 viral load measurement is performed if the criteria for either immunologic (i.e., CD4+ lymphocyte count-based) or clinical treatment failure are fulfilled. If both immunologic and clinical treatment failure criteria are fulfilled, the ART regimen is changed to second-line without VL testing.
62608786|NCT04159168|ACTIVE_COMPARATOR|Arm 4: R33 Active Control|Individuals in this Arm will receive the active control component, which is an implicit gaze training intervention.
62440670|NCT03511352|EXPERIMENTAL|Stand More (Protocol C)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 8-minute standing breaks, 1 per hour, and a mid-point bathroom break.
62831044|NCT06112808|EXPERIMENTAL|BCD-263|
62250660|NCT00929604|EXPERIMENTAL|Routine HIV-1 viral load testing|Routine viral load testing arm: Routine HIV viral load testing at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30 and 36 months thereafter.
62831045|NCT06112808|ACTIVE_COMPARATOR|Opdivo|
62831046|NCT00400465|ACTIVE_COMPARATOR|Control group|Pressure dressing
62440671|NCT01858246|ACTIVE_COMPARATOR|Bonebridge|Implantation with a Bonebridge
62440672|NCT01858246|ACTIVE_COMPARATOR|Bone Anchored Hearing Aid|Implantation with a Bone Anchored Hearing Aid
62831047|NCT00400465|EXPERIMENTAL|Experimental group|Normal dressing
62831048|NCT03787511|OTHER|Diabetic patients with chronic cough|Diabetic patients with chronic cough defined by cough lasting for more than 8 weeks. Cough assessment, neurological tests and cardiovascular tests and skin biopsy.
62831049|NCT03787511|OTHER|Diabetic patients without chronic cough|Diabetic patients without chronic cough defined by cough lasting for more than 8 weeks. Cough assessment, neurological tests and cardiovascular tests and skin biopsy.
62831050|NCT01353898|EXPERIMENTAL|MK-1972 50 mg once daily (Part I)|Ten capsules containing a total daily dose of 50 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
62831051|NCT01353898|EXPERIMENTAL|MK-1972 200 mg once daily (Part I)|Ten capsules containing a total daily dose of 200 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
62250661|NCT05761054|EXPERIMENTAL|A|
62440673|NCT05655702|OTHER|community-based TB intervention|
62440674|NCT01617564|ACTIVE_COMPARATOR|Bupivacain|
62440675|NCT01617564|SHAM_COMPARATOR|Sodium Chloride|
62608787|NCT05904119|ACTIVE_COMPARATOR|Control group|Lomustine alone
62608788|NCT05904119|EXPERIMENTAL|Experimental group|Lomustine plus reirradiation
62608789|NCT02804906|EXPERIMENTAL|Home-Based Physical Therapy|
62831052|NCT01353898|EXPERIMENTAL|MK-1972 800 mg once daily (Part I)|Ten capsules containing a total daily dose of 800 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
62831053|NCT01353898|EXPERIMENTAL|MK-1972 25 mg twice daily (Part I)|Ten capsules containing a total daily dose of 25 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part I)
62608790|NCT02804906|ACTIVE_COMPARATOR|Control-30-minute counseling session|Participants in the control arm will be provided with a 30-minute counseling session on risk factor modification prior to discharge.
62608791|NCT02303990|EXPERIMENTAL|Single arm|Hypofractionated RT and Pembro
62608792|NCT03337035|ACTIVE_COMPARATOR|oral probiotics and oxytocin spray|Subjects will receive oral probiotics, 2 pills per day, for 28 weeks. For the last 12 weeks, subjects will also receive intranasal oxytocin spray at the following dose: 4 IU in week 1, 8 IU in week 2, 16 IU in week 3, and 24 IU in weeks 4-12.
62831054|NCT01353898|EXPERIMENTAL|MK-1972 100 mg twice daily (Part I)|Ten capsules containing a total daily dose of 100 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part I)
62250662|NCT04352192|EXPERIMENTAL|Kinesiotaping Group|The group in which kinesiotaping is going to be applied to biceps brachii muscle of participants and will assess EMG activities before KT, immediately after KT, after 30 minutes and 24 hours of KT. The EMG analysis will be performed during maximum isometric voluntary contraction of biceps brachii muscle.
62449444|NCT02772536|OTHER|Visual Stimulus Condition Set|"In this single arm study all participants are subject to a set of three visual stimulus conditions.~These are: Low ambient light; Self selected tinted light; White light"
62449445|NCT01484821|ACTIVE_COMPARATOR|Arm A|Volunteers (18 -30 years)
62449446|NCT01484821|ACTIVE_COMPARATOR|Arm B|Volunteers (70 years or older)
62608793|NCT03337035|PLACEBO_COMPARATOR|oral placebo and oxytocin spray|Subjects will receive oral placebo, 2 pills per day, for 28 weeks. For the last 12 weeks, subjects will also receive intranasal oxytocin spray at the following dose: 4 IU in week 1, 8 IU in week 2, 16 IU in week 3, and 24 IU in weeks 4-12.
62608794|NCT01889355|OTHER|Enhanced meter feature usability|Home diabetes monitoring by patient using provided blood glucose monitoring system.
62608795|NCT05580328|EXPERIMENTAL|treatment group|"Hematoporphyrin injection is a new drug for tumor photodynamic therapy approved by the State Food and Drug Administration of China. It is a representative drug of domestic photosensitizer with independent intellectual property rights developed and produced by Chongqing Huading Modern Biological Pharmaceutical Co., Ltd.~In the third phase clinical trial, the dosage of hematoporphyrin injection (5mg/kg) should be given intravenously 48-72 hours before laser irradiation for diagnosis and treatment, and skin test should be conducted before injection. Diagnostic laser wavelength is 514.5nm, power density is 10mW/cm2, therapeutic laser wavelength is 630-690nm, average output power density is 400mW/cm, and optical dose density is 200-400J/cm2 The chemical structure formula of hematoporphyrin is: C34H38N4O6, molecular weight: 598.70"
62831055|NCT01353898|PLACEBO_COMPARATOR|Placebo twice daily (Part I)|Ten capsules containing placebo were taken orally, twice per day for 10 days (Part I)
62831056|NCT01353898|EXPERIMENTAL|MK-1972 800 mg twice daily (Part II)|Ten capsules containing a total daily dose of 800 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part II)
62831057|NCT01353898|PLACEBO_COMPARATOR|Placebo twice daily (Part II)|Ten capsules containing placebo were taken orally, twice per day for 10 days (Part II)
62831058|NCT02007096|EXPERIMENTAL|Transabdominal Plane Block|Receiving Transabdominal Plane Block with 0.25% bupivacaine
62250663|NCT04352192|NO_INTERVENTION|Control Group|The group in which kinesiotaping is not going to be applied. EMG activities will be assessed first assessment and after 10th minutes, 30th minutes and 24th hours of the first assessment. The EMG analysis will be performed during maximum isometric voluntary contraction of biceps brachii muscle.
62250664|NCT01721876|EXPERIMENTAL|Volasertib and Cytarabine|
62250665|NCT01721876|PLACEBO_COMPARATOR|Placebo and Cytarabine|
62831059|NCT02007096|PLACEBO_COMPARATOR|Non Transabdominal Plane Block|Receiving placebo saline injection
62048452|NCT06181864|EXPERIMENTAL|Experimental group|Twenty children from the experimental group will undergo the treatment using Robot Nao.
62048453|NCT06181864|OTHER|Control group|Twenty children belonging to the control group will be subjected to the same training but in a traditional way.
62608796|NCT06680076||Disease group|Patients who have inflammation bowel disease.
62608797|NCT06680076||Health group|Healthy people who volunteered to participate.
62608798|NCT05942924|ACTIVE_COMPARATOR|Selective stimulation|At the start of the study, selective tactile stimulation will be performed at each participating centre in accordance with international guidelines. Clinicians will gently rub the back, chest, extremities or soles of the feet if they consider the breathing of the infant to be insufficient or absent. All other procedures in the delivery room and NICU will be performed according to international and local guidelines.
62608799|NCT05942924|EXPERIMENTAL|Repeated stimulation|"For each centre, a lot will be drawn which indicates the month in which the protocol for tactile stimulation changes from selective stimulation to repetitive stimulation.~Repetitive stimulation is defined as gently rubbing the soles of the feet, back, chest, or extremities for 10 seconds. To prevent extinction of the stimulatory effect (reflex), every 10 second period of stimulation will be followed by 10 seconds rest (no stimulation). The repetitive stimulation will be performed for the first 5 minutes after birth, or longer if the breathing is still considered insufficient or absent. All other procedures in the delivery room and NICU will be performed according to international and local guidelines."
62608800|NCT02707406|EXPERIMENTAL|NEOX®CORD 1K|Intervention Other: hct/p human cell or tissue product: NEOX®CORD 1K Intervention other: human tissue application of of NEOX®CORD 1K on subject wound
62608801|NCT02707406|ACTIVE_COMPARATOR|Standard of Care|Intervention Other: standard of care alone Other intervention of Standard dressing with a non-adherent wound contact layer, a classic foam pad or gauze for moderately draining wounds, a secondary bandage, and institution of an investigator-approved off-loading device
62608802|NCT03563664|EXPERIMENTAL|Study group|38 ovulatory patients with unexplained recurrent implantation failure were recruited. Pre-treatment endometrial biopsy and immunohistochemical examination for endometrial αvβ3 integrin expression (using immunohistochemically stained endometrial biopsy) was done. After treatment with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in daily dosage of 400 mg for 12 weeks, post-treatment endometrial biopsy and immunohistochemical examination was repeated and compared with previous results.
62608803|NCT04541602||Dysphagia-positive|"* critically ill patients more than 17 years of age~* matching study inclusion criteria~* confirmed newly acquired swallowing dysfunction using FEES at study day 10 or later~* ICU-AW positive (MRC-ss \<48) or ICU-AW negative (MRC-ss ≥48)"
62608804|NCT04541602||Dysphagia-negative|"* critically ill patients more than 17 years of age~* matching study inclusion criteria~* newly acquired swallowing dysfunction ruled out using FEES at study day 10 or later~* ICU-AW positive (MRC-ss \<48) or ICU-AW negative (MRC-ss ≥48)"
62608805|NCT04541602||Controls|"* healthy volunteers without any neuromuscular disease~* swallowing dysfunction ruled out using FEES"
62048454|NCT04837300|EXPERIMENTAL|Experimental-1|Resisted Sprint Training
62608806|NCT05861102|EXPERIMENTAL|Jaktinib 100mg BID (twice daily)|
62608807|NCT05861102|PLACEBO_COMPARATOR|Placebo|
62608808|NCT02454374|EXPERIMENTAL|Knee Loading|Progressive joint loading intervention will be taught by a program of exercises by the treating physiotherapist. The intervention consists of knee flexion (bending) and knee extension (straightening). Participants will be assessed for their immediate response to treatment during each assessment or treatment session and advised on the appropriate level of self-directed exercises to be performed twice daily. The clinician will review the patient at follow up appointments during the treatment period, progressing to the next level of exercises or by increasing intensity, duration or repetitions as appropriate. The physiotherapist will encourage compliance during the treatment period and beyond
62623510|NCT01408719|EXPERIMENTAL|3g HMW beta glucan|3 gram high molecular weight barley beta-glucan diet for 35 days
62623511|NCT01408719|EXPERIMENTAL|3g LMW beta glucan|3 grams of low molecular weight beta-glucan diet for 35 days
62623512|NCT01408719|PLACEBO_COMPARATOR|Control|control diet containing negligible amount of beta glucan
62831060|NCT04985123||Silicone Block patients|All subjects who received a successful penile implantation with the Silicone Block by the surgeons at the centers in this study.
62831061|NCT03390946|EXPERIMENTAL|four-drug interval-compressed regimen|"Interventions for 'four-drug interval-compressed regimen': Drug: methotrexate, cisplatin, doxorubicin, ifosfamide.~Newly diagnosed oseteosarcoma patients under 40 years are eligible. Neoadjuvant chemotherapy with four drugs in an interval-compressed schedule will be done as a single arm.~Duration of neoadjuvant chemotherapy will be 10 weeks like that of conventional three-drug regimen, although four-drugs are employed in the current protocol.~After tumor resection operation, participants will be divided to poor responder group and good responder group based on 90% necrosis rate of a tumor specimen.~Poor responder group and will be assigned to 'Poor responder group adjuvant chemotherapy' and good responder will be assigned to 'Good responder group adjuvant chemotherapy'."
62048455|NCT04837300|EXPERIMENTAL|Experimental-2|Plyometric Training
62048456|NCT04837300|NO_INTERVENTION|Control|No Training
62048457|NCT00742638|EXPERIMENTAL|The arm 1|Quetiapine fumarate tablet:25mg and 200mg
62048458|NCT00742638|ACTIVE_COMPARATOR|The arm 2|Sodium valproate tablet 200mg
62831062|NCT06530446||one group|observational study of this group
62831063|NCT02490098|ACTIVE_COMPARATOR|Single-hormone closed-loop strategy with full boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
62048459|NCT04511754|EXPERIMENTAL|Experiential Training Condition|Trainees will be taught the following skills during a single session: 1) Therapist in-session emotional-awareness and self-regulation; 2) Facilitating client disclosure of traumas and other difficult experiences; and 3) Helping clients access and experience adaptive emotions. In the experiential training condition, the trainees will receive information about the skills with examples and will have opportunity to practice using short video clips of actors portraying clients. The trainees will be asked to respond to the short clips using the skills they learned. A trainer (a graduate student in clinical psychology) will pause and process the trainees' reactions after they respond to each practice video clip and will provide feedback to the trainees about their performance on the practice.
62048460|NCT04511754|ACTIVE_COMPARATOR|Standard Training Condition|Trainees will be taught the following skills during a single session: 1) Therapist in-session emotional-awareness and self-regulation; 2) Facilitating client disclosure of traumas and other difficult experiences; and 3) Helping clients access and experience adaptive emotions. In the standard training condition, the trainee will receive a lecture about the skills including rationale and research background, examples, and opportunities to ask questions. The standard training condition will not include opportunities for practice or live discussion and feedback from the trainer.
62048461|NCT03623087|EXPERIMENTAL|SIMPLE|cisplatin, gemcitabine, ifosfamide, etoposide (VP-16), L-asparaginase, dexamethasone
62831064|NCT02490098|ACTIVE_COMPARATOR|Dual-hormone closed-loop strategy with full boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) and Glucagon (Eli Lilly) will be infused using two separate subcutaneous infusion pumps (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
62831065|NCT02490098|ACTIVE_COMPARATOR|Single-hormone closed-loop strategy with partial boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). For this strategy, meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO. The meal size assessment will be done by the patient.
62831066|NCT02490098|ACTIVE_COMPARATOR|Dual-hormone closed-loop strategy with partial boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) and Glucagon (Eli Lilly) will be infused using two separate subcutaneous infusion pumps (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). For this strategy, meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO. The meal size assessment will be done by the patient.
62831067|NCT02490098|ACTIVE_COMPARATOR|Sensor-augmented pump therapy|Subjects will use sensor-augmented pump therapy and freely implement their usual basal rate and CHO-matching full prandial bolus to regulate glucose levels. Patient's usual fast acting insulin analog will be infused using a subcutaneous insulin infusion pump. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
62048462|NCT02635048|OTHER|Group 1|Patients in Group 1 undergo mini percutaneous nephrolithotomy
62048463|NCT02635048|OTHER|Group 2|Patients in Group 2 undergo percutaneous nephrolithotomy
62048464|NCT01064297||Women exposed to lamotrigine during pregnancy|
62608809|NCT02454374|ACTIVE_COMPARATOR|Routine physiotherapy care|Normal care delivered to the control group will be based on current NICE guidelines (2014) for non-pharmacological management of OA which includes verbal and written advice/education; education regarding weight loss; exercise to include local muscle strengthening and general aerobic fitness; with or without manual therapy. Clinicians will be asked to refrain from using the progression of techniques specifically documented in the progressive loading protocol (not currently considered to constitute 'normal care'). Treating clinicians will be asked to record specific exercises and manual therapy techniques employed in the patient's records. Participants will be asked to complete a home treatment record sheet.
62250666|NCT04180748||Normal skin|
62250667|NCT04180748||Oily skin|
62440676|NCT01664052|EXPERIMENTAL|ESS505-A (Essure, BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert with minimal polyethylene terephthalate (PET) fibers (investigational device model ESS505-A) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement.
62449447|NCT01484821|EXPERIMENTAL|Arm C|70 years patient or older with curative cares for cancer
62608810|NCT04895995|EXPERIMENTAL|Digital Cognitive Behavior Therapy (dCBT) for Generalized Anxiety Disorder|
62608811|NCT04895995|NO_INTERVENTION|Waitlist Control|
62608812|NCT00950560||inpatient|
62608813|NCT00950560||outpatient|
62608814|NCT00950560||emergency patient|
62608815|NCT06368882|ACTIVE_COMPARATOR|Treatment Group|Treatment Group \[PEG-IFNα-based antiviral therapy (combined with NAs or PEG-IFNα monotherapy)\]: PEG IFNα injection 180 μg is administrated subcutaneously on the first day of the first week, weekly; If HBsAg is negative within 48 weeks of treatment, Peg IFNα combined with NAs or PEG-IFNα monotherapy was continued for 12 weeks, with a maximum of 96 weeks, and the patients are followed up to 240 weeks after the end of treatment. If the patient doesn't achieve HBsAg negative conversion within 48 weeks of treatment, the maximum duration of Peg-IFNα treatment is 96 weeks, and the NAs treatment can be continued until the time of discontinuation where combined treatment programme is used (if HBsAg negative, the consolidation treatment for not less than 24 weeks, and if HBsAg positive still, the treatment with NAs continue). The total of duration of treatment or follow-up is 240 weeks after the end of treatment.
62608816|NCT06368882|NO_INTERVENTION|Control Group|Control group (receiving NAs monotherapy) : on the first day of the first week, daily, according to the standard dosage of each drug, until the time when the drug can be stopped (if HBsAg negative conversion is achieved, NAs should be ended after consolidation treatment for not less than 24 weeks; if HBsAg negative conversion is not achieved, NAs therapy should be continued), and follow-up up to 240 weeks after the end of treatment.
62831068|NCT05964582||Healthy children aged 6 months to < 22 months|No vaccine will be administered. All enrolled participants will have a blood sample collected at enrollment (visit 01) and a nasal swab collected each time they have an RSV-like illness visit
62831069|NCT06026917|EXPERIMENTAL|Toludesvenlafaxine hydrochloride sustained-release tablets|40 mg/tablet, 80mg/tablet, 40 mg\~160mg each time, once a day, for 42 days
62831070|NCT03711513|EXPERIMENTAL|Exposure only|Psycho-education (PE) (plus homework) + 4 x Exposure (EX) (plus homework): 20 participants will receive four exposure group sessions after the psycho-education session. In the four sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
62608817|NCT04020081|EXPERIMENTAL|Effect of yoga exercises in COPD patients after 12 weeks.|Yoga group
62831071|NCT03711513|EXPERIMENTAL|Cognitive restructuring plus exposure|PE (plus homework) + Cognitive Restructuring (CR) (plus homework) + CR (plus homework) + EX (plus homework) + EX: 20 participants will receive two cognitive restructuring group sessions after the psycho-education session. In these two session they will practice identifying dysfunctional cognitions and formulating more functional (alternative/helping) cognitions. After the cognitive sessions they will receive two exposure group sessions. In these two sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
62250668|NCT04180748||Dry skin|
62250669|NCT04180748||Combination skin|
62250670|NCT04180748||Sensitive skin|
62250671|NCT04543799||A1|"Group A1 consists of patients with prostate cancer receiving ADT as part of their standard care for either locally advanced or metastatic disease.~Group A1 consists of a combination of two groups; B1, metastatic patients receiving ADT both with and without an oral AR targeted agent, and not receiving radiotherapy and B2, locally advanced patients receiving ADT alongside radiotherapy"
62250672|NCT04543799||A2|patients with localised prostate cancer receiving radiotherapy only
62250673|NCT04543799||YET|Breast cancer survivors receiving endocrine therapy
62250674|NCT04543799||NET|Breast cancer survivors not receiving endocrine therapy
62250675|NCT04246801|EXPERIMENTAL|Clobetasol propionate|"Clobetasol propionate (Clobetasol propionate ophthalmic nanoemulsion 0.05%)~First dose of the drug will be dispensed at the end of the Baseline visit at the study center. Then, study medication will be dispensed to the participant for self-administration at a dosage of one drop four (4) times a day during 14 days."
62250676|NCT04246801|PLACEBO_COMPARATOR|Vehicle|First dose of the drug will be dispensed at the end of the Baseline visit at the study center. Then, study medication will be dispensed to the participant for self-administration at a dosage of one drop four (4) times a day during 14 days.
62250677|NCT04468789||Comparison group|Patients eligible for six-month dispensing receiving care at comparison sites.
62250678|NCT04468789||Intervention group|Patients eligible for six-month dispensing receiving care at intervention sites.
62250679|NCT01056172|ACTIVE_COMPARATOR|A. 24 weeks in RVR patients.|Peginterferon alfa-2a and weight-based ribavirin (800-1200mg/day) for 24 weeks in patients with RVR.
62250680|NCT01056172|EXPERIMENTAL|B. 16 weeks in RVR patients.|Peginterferon alfa-2a and weight-based ribavirin (800-1200mg/day) for 16 weeks in patients with RVR.
62831072|NCT03711513|EXPERIMENTAL|Relaxation plus exposure|PE (plus homework) + Relaxation (RE) (plus homework) + RE (plus homework) + EX (plus homework) + EX: 20 participants will receive two relaxation exercises group sessions after the psycho-education session. In these two session they will practice muscle relaxation and breathing exercises. After the relaxation sessions they will receive two exposure group sessions. In these two sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
62608818|NCT04020081|NO_INTERVENTION|COPD patients lung functions without yoga excercises.|Control group
62608819|NCT05143216||Chronic subdural haematoma post burr-hole drainage|Chronic subdural haematoma post burr-hole drainage
62608820|NCT06372418|EXPERIMENTAL|Breastfeeding peer support intervention.|In addition to support as currently recommended by the World Health Organization (WHO) and National IMAM guidelines, the intervention arm will receive a homebased individualized face to face support breastfeeding by peer supporters and phone support for 7 weeks post hospital discharge.
62608821|NCT06372418|ACTIVE_COMPARATOR|Standard of care|The Control arm will receive post-discharge support as currently recommended by the World Health Organization (WHO) and national IMAM guidelines, including providing linkage to available local breastfeeding support groups.
62608822|NCT00556738|EXPERIMENTAL|nHFPV|Intrapulmonary Percussive Ventilation
62831073|NCT00321620|ACTIVE_COMPARATOR|zoledronic acid|
62831074|NCT00321620|EXPERIMENTAL|denosumab|
62831075|NCT01857817|EXPERIMENTAL|VT-122 with physician's choice therapy|Participants will receive oral doses of 66 mg propranolol and 680 mg etodolac daily. Propranolol will be administered 44 mg with breakfast and 22 mg in the mid-afternoon (3PM). Etodolac will be administered 340 mg with breakfast and 340 mg with dinner.
62831076|NCT01857817|PLACEBO_COMPARATOR|Placebo with physician's choice therapy|Participants will receive physician's choice therapy as the standard of care as well as the placebo capsules that are of the same weight as propranolol and etodolac.
62831077|NCT02726568|EXPERIMENTAL|Icotinib 375mg Tid|The human subject gets icotinib 375mg, Tid until intracranial PD or intolerable toxicity reaction.
62831078|NCT00066157|EXPERIMENTAL|1|estradiol patch and medroxyprogesterone
62831079|NCT00066157|ACTIVE_COMPARATOR|2|estradiol patch and placebo pill
62831080|NCT00066157|ACTIVE_COMPARATOR|3|placebo patch and medroxyprogesterone
62831081|NCT00066157|PLACEBO_COMPARATOR|4|placebo patch and placebo pill
62831082|NCT01615120|EXPERIMENTAL|GTx-758 125mg|one GTx-758 tablet orally administered daily
62831083|NCT01615120|EXPERIMENTAL|GTx-758 250 mg|two GTx-758 tablets orally administered daily
62831084|NCT04442295|EXPERIMENTAL|Single Ascending Doses|Enrollment of patients in two age groups. A Sentinel group of 2 patients aged 13 to 18 years of age, inclusive, and an expanded group of 2 patients 2 to 12 years of age to receive single doses. There will be an option to dose up to 6 additional patients at each dose level and an option to expand the maximum tolerated dose level with 5 additional patients.
62831085|NCT04442295|EXPERIMENTAL|Multiple Ascending Doses|Enrollment of patients in two age groups. A Sentinel group of 2 patients aged 13 to 18 years of age, inclusive, and an expanded group of 2 patients 2 to 12 years of age to receive multiple doses. There will be an option to dose up to 6 additional patients at each dose level and an option to expand the maximum tolerated dose level with 10 additional patients.
62831086|NCT01189032|EXPERIMENTAL|High concentration|
62831087|NCT01189032|EXPERIMENTAL|Low concentration|
62449448|NCT02563509|EXPERIMENTAL|HIV-specific CD8 cells|Transfusing HIV-specific CD8 cells 50-100mlonce a week for four times.
62831088|NCT01189032|PLACEBO_COMPARATOR|Placebo|
62449449|NCT02563509|NO_INTERVENTION|Regualar therapy|Only receiving Highly active anti-retroviral therapy(HAART).
62449450|NCT03845309|EXPERIMENTAL|Nutritional intervention for CHF|
62449451|NCT00536926|ACTIVE_COMPARATOR|A|home spirometry alone
62831089|NCT04434937|EXPERIMENTAL|parsaclisib|parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits
62831090|NCT01300754|ACTIVE_COMPARATOR|Dextrose|
62831091|NCT01300754|ACTIVE_COMPARATOR|Lidocaine|
62831092|NCT01300754|ACTIVE_COMPARATOR|Usual Care|
62831093|NCT01697917|OTHER|Total Gastrectomy or Proximal Gastrectomy|
62831094|NCT01967940|EXPERIMENTAL|Part 1 Sentinel Cohort (TAF)|TAF + their current failing ARV regimen for 10 days in Part 1
62831095|NCT01967940|EXPERIMENTAL|Part 1 Randomized Cohort (TAF)|Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive TAF + their current failing ARV regimen for 10 days in Part 1.
62831096|NCT01967940|PLACEBO_COMPARATOR|Part 1 Randomized Cohort (Placebo)|Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive placebo + their current failing ARV regimen for 10 days in Part 1.
62449452|NCT00536926|EXPERIMENTAL|B|Home spirometry with data transfer via cellphone to clinical database
62608823|NCT00556738|ACTIVE_COMPARATOR|nCPAP|Nasal Continuous Positive Airway Pressure ventilation
62608824|NCT05075993|EXPERIMENTAL|Regimen A: LVGN3616 + LVGN6051 + Nab-Paclitaxel|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
62608825|NCT05075993|EXPERIMENTAL|Regimen B: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
62608826|NCT05075993|EXPERIMENTAL|Regimen C: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
62608827|NCT05075993|EXPERIMENTAL|Regimen D: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
62608828|NCT02904551|EXPERIMENTAL|Experimental|Free gingival grafts
62608829|NCT02904551|ACTIVE_COMPARATOR|Control|Oral prophylaxis
62608830|NCT05903313||Software diagnosis|Software diagnosis with gold standard of 3 cardiologists' interpretation.
62608831|NCT00717275|EXPERIMENTAL|Temozolomide|
62608832|NCT05693545|EXPERIMENTAL|Oral Pencillin|Oral phenoxymethyl penicillin (Pen V) prophylaxis 250mg twice daily.
62608833|NCT05693545|ACTIVE_COMPARATOR|IM Penicillin|Intramuscular benzathine benzylpenicillin G (BPG) prophylaxis (600,000 IU for children \<30kg, 1.2 million IU for children ≥30kg), every 28 days
62608834|NCT04947995||Gastric cancer group|
62831097|NCT01967940|EXPERIMENTAL|Part 2 E/C/F/TAF+ATV|Following a 14-day period to confirm eligibility, participants in the Randomized Cohort TAF group with a \> 0.5 log10 decline in HIV-1 RNA and all participants completing the Randomized Cohort Placebo group will receive E/C/F/TAF+ATV for 48 weeks in Part 2. After completion of Part 2, all participants will be eligible to continue to receive E/C/F/TAF plus ATV in the extension phase until E/C/F/TAF becomes commercially available, or until Gilead Sciences terminates development of E/C/F/TAF in the applicable country.
62831098|NCT06499064|EXPERIMENTAL|mHealth|Structured follow-up in the basis of using mHealth-based solution. mHealth will include daily signs and symptoms telemonitoring and structured follow-up by the means of video or audio-conference.
62048465|NCT01134146|EXPERIMENTAL|Intensity Modulated Radiation Therapy (IMRT)|Intensity Modulated Radiation Therapy (IMRT) Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
62449453|NCT04050488|ACTIVE_COMPARATOR|Treatment Group|Participants who receive the intervention.
62608835|NCT04947995||Precancerous lesion group|
62608836|NCT04947995||Healthy group|
62831099|NCT06499064|NO_INTERVENTION|Usual care|Patients with usual care follow-up in a heart failure due to ATTR-CM program.
62831100|NCT03021785|EXPERIMENTAL|0.5mg|In the core study, patients will receive 0.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
62831101|NCT03021785|EXPERIMENTAL|1.0mg|In the core study, patients will receive 1.0mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
62831102|NCT03021785|EXPERIMENTAL|1.5mg|In the core study, patients will receive 1.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
62048466|NCT04769726|EXPERIMENTAL|treatment|premeal load of almonds
62048467|NCT04769726|NO_INTERVENTION|control|standard diet
62449454|NCT04050488|PLACEBO_COMPARATOR|Control Group|Participants who receive the placebo.
62608837|NCT03438526|EXPERIMENTAL|Melatonin (Circadin ®)|
62608838|NCT03438526|PLACEBO_COMPARATOR|Placebo|
62608839|NCT03193658|ACTIVE_COMPARATOR|Group T|Will receive bilateral US guided Thoracolumbar Interfascial Plane (TLIP) block at the proposed level of surgery before the start of the surgery
62608840|NCT03193658|ACTIVE_COMPARATOR|Group O|Will not receive the block and postoperative pain control will be managed by I.V drug based multi-modal approach (Opioid \& acetaminophen) only.
62608841|NCT01399970|OTHER|Outpatient Consultation Arm (OCA)|Conventional in Office Care
62608842|NCT01399970|EXPERIMENTAL|Mobile Teleconsultation Arm (MTA)|Mobile Teledermatology Care
62608843|NCT00240825|EXPERIMENTAL|001|Acetaminophen
62608844|NCT00240825|EXPERIMENTAL|002|Ibuprofen
62608845|NCT00240825|PLACEBO_COMPARATOR|003|Placebo
62608846|NCT04395274||Current E-Cigarette Users|Monitoring current e-cigarette users
62608847|NCT04395274||Never E-Cigarette / Tobacco Users|Monitoring never users of any tobacco or e-cigarette products.
62608848|NCT05792995|EXPERIMENTAL|Immunomonotherapy plus Chemotherapy plus Anti-angiogenesis Therapy|Any first-line treatment that includes immunotherapy.
62608849|NCT05792995|EXPERIMENTAL|Chemotherapy plus Immunomonotherapy|Any first-line treatment that includes immunotherapy.
62608850|NCT05792995|EXPERIMENTAL|Immunomonotherapy plus Anti-angiogenesis Therapy|Any first-line treatment that includes immunotherapy.
62608851|NCT05792995|EXPERIMENTAL|Immunomonotherapy|Any first-line treatment that includes immunotherapy.
62608852|NCT00623051|EXPERIMENTAL|1|Male circumcision by experimented doctor or nurse
62608853|NCT05264519|EXPERIMENTAL|intervention|foot bath intervention
62608854|NCT05264519|NO_INTERVENTION|control|follow-up
62608855|NCT01805973|NO_INTERVENTION|Control|Standard pre-operative care, no active intervention
62608856|NCT01805973|EXPERIMENTAL|Exercise Training|"Supervised Exercise Training Programme Patients will be required to attend three 50 minute exercise sessions per week for 18 weeks. They will exercise in groups of 8-12 and will be supervised by an experienced exercise physiologist. Each session will comprise a 15 minute warm up, 30 minutes of moderate intensity aerobic exercise followed by a 10 minute cool down period.~The patients will have the option to choose from three different exercise programmes tailored to individuals of mixed abilities (and co-morbidities)."
62608857|NCT01606202|EXPERIMENTAL|GW-1000-02|Active treatment.
62608858|NCT01606202|PLACEBO_COMPARATOR|Placebo|Placebo control.
62608859|NCT06730295|EXPERIMENTAL|The study group|Patients in the study group will receive online adaptive stereotactic body radiotherapy (without PTV expansion margin). The total dose will be 39-42Gy/3fractions, administered once daily. Both FBCT and 4DCT will be acquired before initiating treatment at each fraction.
62048468|NCT04848428|EXPERIMENTAL|Online Mindfulness-based intervention|Four weekly sessions are planned. The first session will focus on providing feedback regarding post-surgical pain. The second session will focus on teaching mindfulness strategies. The third session will focus on practicing one of the two strategies. Of note, sessions 2 and 3 will start with cognitive restructuring strategies. The 4th session consists in a booster providing feedback and reminders about cognitive reactions to pain and mindfulness meditation. The participants will be asked to practice meditation 5 days a week, for a total of 4 weeks
62608860|NCT03242642|EXPERIMENTAL|Primary Cohort- TMVR|Treatment of mitral regurgitation with the Medtronic Transcatheter Mitral Valve Replacement System (TMVR)
62048469|NCT04848428|ACTIVE_COMPARATOR|Online standardized education|In addition to usual care, the CG will have access to one 15-minute standardized educational online session on persistent post-surgical pain, how pain and stress may interact and their potential impact on recovery.
62048470|NCT04035057|EXPERIMENTAL|Behaviorally Enhanced Training Strategies|Both training conditions will receive a 1.5 day training followed by ongoing supervision while they implement exposure therapy with patients recruited to the study. The first full day will consist of the same foundational information in both conditions. The two conditions will differ in their training focus during the subsequent half-day training. The Behaviorally Enhanced condition will involve therapist engagement in repeated self-exposure and partner-exposure exercises with the goal of targeting and reducing therapists' reservations about using exposure with their patients. The focus of ongoing supervision following the initial 1.5 day training workshop will also differ by condition. The Behaviorally Enhanced condition will include regular sampling and feedback on therapists' remaining reservations about exposure in additional to counseling the implementation of exposure with therapists' patients.
62048471|NCT04035057|ACTIVE_COMPARATOR|Standard Didactic Training|Both training conditions will receive a 1.5 day training followed by ongoing supervision while they implement exposure therapy with patients recruited to the study. The first full day will consist of the same foundational information in both conditions.The two conditions will differ in their training focus during the subsequent half-day training. The Standard Didactic condition will involve additional didactic instruction related to common barriers and more advanced delivery concepts than will be presented in the half-day training for the Behaviorally Enhanced condition. The focus of ongoing supervision following the initial 1.5 day training workshop will also differ by condition. The Standard Didactic condition will involve counseling on the implementation of exposure with therapists' patients without explicit focus on therapists' remaining reservations about exposure.
62048472|NCT03055143|EXPERIMENTAL|SPARC-08-038|2 mg/ml
62048473|NCT03055143|ACTIVE_COMPARATOR|Ref-08-038|
62048474|NCT04814836|OTHER|Group I|Total-etch mode with 35% phosphoric acid
62048475|NCT04814836|OTHER|Group II|Selective-etch mode with 35% phosphoric acid
62048476|NCT04814836|OTHER|Group III|Total-etch mode with laser (Er,Cr:YSGG)
62048477|NCT04814836|OTHER|Group IV|Selective-etch mode with laser (Er,Cr:YSGG)
62048478|NCT04814836|OTHER|Group V|Self-etch mode
62608861|NCT03242642|EXPERIMENTAL|Mitral Annular Calcification -TMVR|Treatment of mitral regurgitation with the Medtronic Transcatheter Mitral Valve Replacement System (TMVR)
62608862|NCT03241537|NO_INTERVENTION|Hormonal therapy alone|total androgen ablation or antiandrogen therapy alone for 2-3 years
62608863|NCT03241537|ACTIVE_COMPARATOR|Hormonal therapy with radiotherapy|total androgen ablation or antiandrogen therapy for 2-3 years combined with radiotherapy on whole pelvis
62608864|NCT03862768|EXPERIMENTAL|Surgery following imatinib|Surgery requires at least removal of all drug-resistant lesions. Imatinib 400 MG/d should be taken once the patients resume oral diet.
62048479|NCT03713528|OTHER|Treatment Group|The treatment group includes any patient with an acute perioperative periprosthetic infection, acute hematogenous infection, or unresectable infection with a gram positive organism sensitive to vancomycin and treated with intraoperative intraosseous vancomycin. Additionally, patients will be treated with at least 4 weeks of IV antibiotics under guidance of an infectious disease specialist, and indefinite antibiotic chronic suppression.
62048480|NCT04816513|ACTIVE_COMPARATOR|Ustekinumab (Using Reference Device)|Participants will receive a single subcutaneous (SC) injection of ustekinumab in Device 1 as a reference device on Day 1.
62048481|NCT04816513|EXPERIMENTAL|Ustekinumab (Using Test Device)|Participants will receive a single SC injection of ustekinumab in Device 2 as a test device on Day 1.
62048482|NCT01588626|EXPERIMENTAL|AZD6140|single administration of 90 mg dose of AZD6140
62048483|NCT05816070|EXPERIMENTAL|IVIEW-1201|
62048484|NCT05816070|ACTIVE_COMPARATOR|Ofloxacin Eye Drops|
62250681|NCT02479945|OTHER|Selective internal iliac vein sampling|
62449455|NCT03112057|EXPERIMENTAL|Healthy subjects|Healthy subjects of different ages (20 persons), Interventions: harmonic generation microscopy
62608865|NCT03862768|ACTIVE_COMPARATOR|Imatinib escalation or sunitinib|Escalation of imatinib or replacement of sunitinib are both conventional salvage treatments for imatinib-resistant GISTs. There is no high-level evidence to suggest which method is better. So patients are free to choose imatinib 600 MG/d or sunitinib 37.5 MG/d
62608866|NCT04666844||Survey|Clinicians will be asked to provide responses to the two surprise questions for each of their PD patients.
62608867|NCT06505083|SHAM_COMPARATOR|control grops|stepping on stable step
62608868|NCT06505083|EXPERIMENTAL|experimental group|stepping on unstable step
62608869|NCT00410059|EXPERIMENTAL|Erlotinib|Erlotinib 150 mg by mouth daily x 28 days.
62608870|NCT06608693|EXPERIMENTAL|PNF stretching group|PNF and static stretching methods were applied 2 days a week and 6 repetitions in each session for 4 weeks to the hip flexors. In addition to stretching, both of the groups received a routine treatment program consisting of gluteus maximus and quadriceps strengthening, balance, and walking exercises.
62608871|NCT06608693|EXPERIMENTAL|Static stretching group|PNF and static stretching methods were applied 2 days a week and 6 repetitions in each session for 4 weeks to the hip flexors. In addition to stretching, both of the groups received a routine treatment program consisting of gluteus maximus and quadriceps strengthening, balance, and walking exercises.
62608872|NCT06523439|ACTIVE_COMPARATOR|Standard SAINT®|10 daily sessions (50 total over 5-days) of SAINT® stimulation (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds), delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
62608873|NCT06523439|EXPERIMENTAL|Truncated SAINT®|5 daily sessions (25 total over 5-days) of SAINT® stimulation (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds), delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
62831103|NCT00436696||Ancillary-correlative (SNP analysis)|DNA samples are derived from participants' banked blood or uninvolved bone marrow. A whole genome scan of DNA samples is employed to identify candidate single nucleotide polymorphisms (SNPs). The candidate SNPs are investigated, using a gene-centric haplotyping approach, to identify 10-20 true disease-associated alleles. The disease-associated alleles are again investigated, using a gene-centric haplotyping approach, to validate 5-10 disease-associated SNPs. SNPs are then analyzed for heritable predisposition.
62608874|NCT01541670|EXPERIMENTAL|Open-label Dose-Escalation Arm|Conducted in an ascending dose manner, subjects will be assigned to single- or multiple-dose administration of the investigational product
62608875|NCT04312282|EXPERIMENTAL|Cohort 1, Sequence 1A: Fed then fasted|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle under fed conditions~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle under fasted conditions"
62608876|NCT04312282|EXPERIMENTAL|Cohort 1, Sequence 1B: Fasted then fed|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle under fasted conditions~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle under fed conditions"
62608877|NCT04312282|EXPERIMENTAL|Cohort 2: Tesetaxel plus itraconazole|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle and itraconazole on Day -3 through Day 14 of a 21-day cycle"
62608878|NCT04312282|EXPERIMENTAL|Cohort 3: Tesetaxel plus rifampin|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle and rifampin on Day -6 through Day 14 of a 21-day cycle"
62608879|NCT02322450|EXPERIMENTAL|A: P1-QGC001 - Washout-placebo - P2-placebo|The first period (P1) will correspond either to QGC001 or placebo, the second period (P2) will correspond either to QGC001 or placebo.
62608880|NCT02322450|EXPERIMENTAL|B: P1-placebo - Washout-placebo - P2-QGC001|The first period (P1) will correspond either to QGC001 or placebo, the second period (P2) will correspond either to QGC001 or placebo.
62608881|NCT03933020|EXPERIMENTAL|Exercise Group|
62608882|NCT03933020|ACTIVE_COMPARATOR|Control Group|
62608883|NCT06238713|EXPERIMENTAL|Single-port extraperitoneal RARP|Single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy (VIP) techniques
62608884|NCT06238713|ACTIVE_COMPARATOR|Multi-port transperitoneal RARP|Multi-port transperitoneal RARP with bilateral intrafascial nerve-sparing techniques
62608885|NCT06167642||People with RMS due to commence or already receiving ofatumumab therapy|75 people with RMS due to commence or already receiving ofatumumab therapy within 60 days of baseline.
62608886|NCT02858180|EXPERIMENTAL|Heart Failure Cohort|"Harvoni (sofosbuvir/ledipasvir fixed dose combination)~1 pill once daily Includes 400 mg sofosbuvir (SOF) and 90 mg ledipasvir (LDV)"
62608887|NCT02858180|EXPERIMENTAL|Lung Disease Cohort|"Harvoni (sofosbuvir/ledipasvir fixed dose combination)~1 pill once daily Includes 400 mg sofosbuvir and 90 mg ledipasvir"
62608888|NCT06731322||Fontan operation group|Adults (\>18 years old) after Fontan operation and without active protein-losing enteropathy
62608889|NCT06731322||Control group|Adults (\>18 years old) with simple congenital heart defects without significant residual lesions or comorbidities
62608890|NCT03099772|EXPERIMENTAL|CBT-IU|Cognitive-behavioral therapy for intolerance of uncertainty
62608891|NCT06344325|EXPERIMENTAL|Youth group|Youth group (18-45 years old)
62608892|NCT06344325|EXPERIMENTAL|middle-aged group|middle-aged group (46-65 years old)
62608893|NCT06344325|EXPERIMENTAL|elderly group|elderly group (66-80 years old)
62608894|NCT03697564|EXPERIMENTAL|gemcitabine +nivolumab + cabiralizumab|
62831104|NCT02633514|EXPERIMENTAL|Radiochemotherapy|adjuvant radiochemotherapy after incomplete resection: Cisplatin + Etoposide + Radiotherapy (60Gy / 30FX)
62449456|NCT03112057|EXPERIMENTAL|peripheral neuropathy|the participant have symptoms and diagnosed with peripheral neuropathy (90 persons), Interventions:harmonic generation microscopy
62608895|NCT02613715|EXPERIMENTAL|Blackberry juice with 12% ethanol|250 ml of blackberry juice freshly prepared with 250 g fresh blackberries, 80 ml alcohol beverage (38%) and 17 g sugar.
62608896|NCT02613715|EXPERIMENTAL|Blackberry juice|250 ml of blackberry juice freshly prepared with 250 g fresh blackberries, 80 ml water and 17 g sugar.
62608897|NCT04263636||Study group|Patients that underwent uneventful bilateral pseudophakic presbyopic correction with trifocal diffractive IOLs (PanOptix or PanOptix toric, Alcon Laboratories, Inc., Fort Worth, TX, USA)
62608898|NCT04263636||Control group|Patients of similar age without cataract that their crystalline lens has not been replaced.
62608899|NCT01281267|EXPERIMENTAL|Face transplantation|
62608900|NCT05621304||Foreign Born subjects w/Chronic HBV|foreign born (FB) chronic hepatitis B subjects
62608901|NCT03327961||scaffold|Patients receiving during PCI the implantation of at least one scaffold
62608902|NCT05892016|NO_INTERVENTION|spontaneous healing|No treatment after tooth extraction
62608903|NCT05892016|EXPERIMENTAL|Bone particle + subepithelial connective tissue graft|Alveolar ridge preservation grafted with bone particle and covered with a subepithelial connective tissue graft
62608904|NCT05892016|EXPERIMENTAL|Bone particle + Vascularized interpositional periosteal connective tissue graft|Alveolar ridge preservation grafted with bone particle and covered with vascularized interpositional periosteal connective tissue graft
62048485|NCT03240731|EXPERIMENTAL|bone marrow transplant|"All the included patient will receive an haploidentical bone marrow transplant with the following protocol concerning the conditioning and GvHD prevention~Conditioning~* THYMOGLOBULINE : 0.5mg/kg at D-9 and 2 mg/kg at D-8 and D-7~* THIOTEPA: 10mg/kg/j at D-7~* CYCLOPHOSPHAMIDE (Endoxan®):14.5mg/kg/j at D-6 and D-5~* FLUDARABINE (Fludara®): 30mg/m2 per Day from D-6 to D-2~* TBI : 2GY : D -1 Graft : Injection at D0 of G-CSF-stimulated bone marrow transplant.~Prophylaxis of GvHD~* CYCLOPHOSPHAMIDE (Endoxan®): 50mg/Kg per Day from D+3 to D+4~* Sirolimus and MycophénolateMofétil (MMP) from D+5. In the absence of acute GvHD (aGvHD), stop of MMP to D35 and pursuit of sirolimus 1 year after the graft."
62608905|NCT05892016|EXPERIMENTAL|Bone particle + collagen membrane|Alveolar ridge preservation grafted with bone particle and covered with a collagen membrane
62608906|NCT05892016|EXPERIMENTAL|Bone particle + Cytoplast|Alveolar ridge preservation grafted with bone particle and covered with a Cytoplast.
62831105|NCT02633514|SHAM_COMPARATOR|radiotherapy|adjuvant radiotherapy after incomplete resection: Radiotherapy (60Gy / 30FX)
62831106|NCT06595563|EXPERIMENTAL|"HER2 PET/CT positive"|Subjects classified as HER2-PET/CT positive (cohort A) will receive T-DM1, IV 3.6mg/kg every 3 weeks, as monotherapy. HER2-PET/CT positive pattern: The entire or majority of the tumour load shows significant tracer uptake.
62831107|NCT06595563|NO_INTERVENTION|"HER2 PET/CT negative"|Subjects classified as HER2 PET/CT negative (cohort B) will receive treatment of physician's choice (TPC) as per the best local clinical practice. Subsequent treatment will be collected and the subject will enter survival follow-up. HER2-PET/CT negative pattern: The dominant part or all of the tumour load lacks significant tracer uptake.
62048486|NCT04879290|ACTIVE_COMPARATOR|Control Group FiO2=1|FiO2 = 1 (100%) 10mn before emergence of general anesthesia
62048487|NCT04879290|EXPERIMENTAL|Intervention Group FiO2 0.5|Fi02 = 0.5 (50%) 10mn before emergence of general anesthesia
62831108|NCT05236582|EXPERIMENTAL|50 subjects with chemotherapy-induced thrombocytopenia|50 enrolled subjects will be picked up to take Herombopag at the indicated dose.
62048488|NCT06294496||CEA group|The patient with carotid stenosis underwent CEA surgery.
62440677|NCT01664052|EXPERIMENTAL|ESS 305/ESS 505 (Essure, BAY1454032/Essure, BAY1454033)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) and contralateral placement of the current commercially approved Essure device, model ESS305 followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
62440678|NCT00593138|EXPERIMENTAL|1|
62440679|NCT05219396||mobile bearing (MB)|
62440680|NCT05219396||medial congruent (MC)|
62440681|NCT05219396||posterior stabilized (PS)|
62440682|NCT00704223||A|
62440683|NCT02655172|EXPERIMENTAL|Patients|patients suffering schizophrenic disorders and who will perform cognitive tasks + PANSS+ IQ
62608907|NCT02397291|PLACEBO_COMPARATOR|Part 1: Measurements of maternal and fetal concentrations|"At the time of the elective cesarean section, a blood sample of 0.5 ml will be obtained from a maternal heated hand vein at the time the umbilical cord is clamped. Then, the umbilical cord will be doubly clamped to isolate a segment. The umbilical artery and vein will be sampled for 0.5 ml of blood. There are no stable isotopes infused. Heating the maternal hand vein allows it to be arterialized. These patients are separate from those required for the stable isotope studies listed below."
62831109|NCT01389596|PLACEBO_COMPARATOR|Placebo|
62831110|NCT01389596|EXPERIMENTAL|Pregabalin Level 1 (max 150 mg/day)|
62048489|NCT06294496||CAS group|The patient with carotid stenosis underwent CAS treatment.
62440684|NCT02655172|ACTIVE_COMPARATOR|Control group|healthy patients who will perform cognitive tasks
62440685|NCT03170206|EXPERIMENTAL|Binimetinib Combine with Palbociclib Phase 1|"* Palbociclib will be administered orally once daily~* Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle~* Binimetinib will be administered orally twice daily~* Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
62440686|NCT06347757|EXPERIMENTAL|laparoscopic proximal gastrectomy with single-tract jejunal interposition reconstruction|
62440687|NCT06347757|ACTIVE_COMPARATOR|laparoscopic proximal gastrectomy with double-tract reconstruction|
62440688|NCT06347757|ACTIVE_COMPARATOR|laparoscopic proximal gastrectomy with tube-like stomach reconstruction|
62440689|NCT01877928|EXPERIMENTAL|Boussignac CPAP device|Patients previously diagnosed with obstructive sleep apnea and who are undergoing abdominal or peripheral surgery will have the Boussignac CPAP mask applied for 1 hour starting immediately post-extubation
62440690|NCT01877928|ACTIVE_COMPARATOR|standard CPAP|Patients previously diagnosed with obstructive sleep apnea who are undergoing peripheral or abdominal surgical procedures will receive the standard-of-care for obstructive sleep apnea. This typically involves CPAP application only at night
62440691|NCT01117064|ACTIVE_COMPARATOR|NMTD adjustment testing|We will determine effective NMTD device settings for reducing AHI.
62440692|NCT01117064|ACTIVE_COMPARATOR|CPAP vs NMTD device|We will randomly assign previously titrated CPAP vs. NMTD to each subject then compare the resultant AHI between the two devices.
62831111|NCT01389596|EXPERIMENTAL|Pregabalin Level 2 (max 600 mg day)|
62831112|NCT04587284||Patients with robot-assisted laparoscopic radical prostatectomy|
62831113|NCT04587284||Patients with open retropubic radical prostatectomy|
62831114|NCT04587284||Patients with laparoscopic radical prostatectomy|
62831115|NCT04081103|EXPERIMENTAL|Nexagon® (lufepirsen) High Dose Concentration|
62831116|NCT04081103|EXPERIMENTAL|Nexagon® (lufepirsen) Low Dose Concentration|
62831117|NCT04081103|PLACEBO_COMPARATOR|Vehicle|
62831118|NCT05313555|ACTIVE_COMPARATOR|Ultraviolet lights (UV-B)|
62831119|NCT05313555|EXPERIMENTAL|Ultraviolet lights (UV-C)|
62608908|NCT02397291|ACTIVE_COMPARATOR|Part 2: Stable Isotope Studies|Prior to the elective cesarean section, 2 samples from the patient's heated hand vein are obtained to establish a baseline for the compounds. Next, a primed constant infusion containing the stable isotopes of mannose and myoinositol is begun in a peripheral IV of the mother. This is continued approximately 2 hours until the Cesarean section is complete and the umbilical cord samples are obtained. An additional 3 samples are obtained from the patient's heated hand vein: 1 at the start of the cesarean section, 1 at the time the fetus is delivered, and 1 at the time the umbilical cord samples are obtained.
62608909|NCT00619164|EXPERIMENTAL|1|
62608910|NCT00619164|EXPERIMENTAL|2|
62608911|NCT00619164|EXPERIMENTAL|3|
62250682|NCT04726384||Observed group|The group was monitored for physical activity levels using the SenseWear Armband device. The group was informed of the purpose of the study and asked to wear the device 24 hours a day for the next 4 days (Friday-Monday) excluding bath time, no more than 30 minutes. Patients received the device on Thursday afternoon and returned it on Tuesday. However, the days Friday-Monday were analyzed to have a record of the entire days
62250683|NCT03372850|EXPERIMENTAL|Sequence Group 1|Period 1: Reference Drug(HGP1705) Period 2: Test Drug(HIP1601)
62250684|NCT03372850|EXPERIMENTAL|Sequence Group 2|Period 1: Test Drug(HIP1601) Period 2: Reference Drug(HGP1705)
62440693|NCT01117064|ACTIVE_COMPARATOR|NMTD efficacy and tolerability|Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
62608912|NCT00619164|PLACEBO_COMPARATOR|4|
62608913|NCT05848596|ACTIVE_COMPARATOR|Hand hygiene training|Hand hygiene theoretical training and simulation application
62608914|NCT05848596|PLACEBO_COMPARATOR|Observation group|Hand hygiene theoretical training was given.
62608915|NCT02888353|EXPERIMENTAL|Device: MRI no pre-screen|"Clinically Indicated MRI will be done in patients with cardiac devices (pacemakers and defibrillators).~Patients will not be pre-screened prior to hospital visit."
62608916|NCT00287677|EXPERIMENTAL|A|growth hormone + vaccination + HAART
62608917|NCT00287677|EXPERIMENTAL|B|growth hormone + HAART
62608918|NCT00287677|EXPERIMENTAL|C|vaccination + HAART
62440694|NCT00398359|EXPERIMENTAL|1|
62449457|NCT03112057|EXPERIMENTAL|diabetic neuropathy|the participant have symptoms and diagnosed with diabetic neuropathy (20 persons), Interventions:harmonic generation microscopy
62608919|NCT00287677|ACTIVE_COMPARATOR|D|control healthy HIV negative + vaccination
62608920|NCT04769505|EXPERIMENTAL|Intervention group|Participants receive a digital mindfulness-based intervention (MBI) + treatment as usual.
62608921|NCT04769505|NO_INTERVENTION|Wait list control group|Participants receive treatment as usual during the intervention period. They are provided with the digital mindfulness-based intervention (MBI) after the intervention period. The waitlist control group receives the same intervention as the intervention group, with the exception of using not using the exercises via the software on the smartphone, but receiving the exercises as audio files.
62608922|NCT04477733|EXPERIMENTAL|Butorphanol group|
62608923|NCT04477733|PLACEBO_COMPARATOR|control group|
62608924|NCT05079776||Children aged 0-18 months of age|Children aged 0-18 months of age with no structural abnormalities of the lower limbs or orthopedic conditions
62048490|NCT06084858|EXPERIMENTAL|Dialysate Bicarbonat modification|Dialysate bicarbonate prescription will be modified from low (27 mmol/l) to high (37 mmol/l) in a step-wise fashion
62250685|NCT05031845||COVID-19 positive, Hospitalized with ARDS|"1. Patients with chest imaging at the time of the first COVID-positive PCR test will have their first LDCT within 3 to 4 months after COVID 19 diagnosis. A second LDCT between 3 to 6 months after the initial LDCT.~2. Patients without chest imaging at the time of the first COVID-positive PCR test or with a negative COVID PCR test will have their first LDCT within 2 weeks to 1 month after their recovery from COVID 19, or testing. A second LDCT may be performed between 3 to 6 months after the initial LDCT."
62608925|NCT05815485|EXPERIMENTAL|Phase 2 azeliragon|
62608926|NCT05815485|PLACEBO_COMPARATOR|Phase 2 placebo|
62250686|NCT05031845||COVID-19 positive, not hospitalized with ARDS|"1. Patients with chest imaging at the time of the first COVID-positive PCR test will have their first LDCT within 3 to 4 months after COVID 19 diagnosis. A second LDCT between 3 to 6 months after the initial LDCT.~2. Patients without chest imaging at the time of the first COVID-positive PCR test or with a negative COVID PCR test will have their first LDCT within 2 weeks to 1 month after their recovery from COVID 19, or testing. A second LDCT may be performed between 3 to 6 months after the initial LDCT."
62440695|NCT03772639|EXPERIMENTAL|Experimental group|The experimental group received a standard medical and pharmacological care in a daily format and shared decision making (SDM). The general framework of SDM was developed focusing on self-management goals which include education that addresses continuous use of medication, behavioral change, breathing training, learning to interpret changes in the disease and its consequences, and use of medical and community resources.
62440696|NCT03772639|NO_INTERVENTION|Control Group|The control group received standard care and pharmacological care including systemic steroids, antibiotics, inhaled bronchodilators, and oxygen therapy.
62608927|NCT05815485|EXPERIMENTAL|Phase 3 azeliragon|
62608928|NCT05815485|PLACEBO_COMPARATOR|Phase 3 placebo|
62608929|NCT05155449|ACTIVE_COMPARATOR|Probiotics|Two capsules per day for 8 weeks
62608930|NCT05155449|PLACEBO_COMPARATOR|Placebo|Two capsules per day for 8 weeks
62608931|NCT05255250|EXPERIMENTAL|PLAYshop Intervention|Participants will receive a 60 minute virtual physical literacy workshop, an equipment goody-bag with basic play equipment and printed resources, and access to a digital app with an online toolkit and four bi-weekly boosters lessons.
62608932|NCT05255250|NO_INTERVENTION|Control|Participants will receive the 60 minute virtual physical literacy workshop, equipment goody-bag, and access to the digital app after completing 2-month follow-up measures.
62608933|NCT04970472||patients with Urothelial bladder carcinoma|collection of blood, urines, stool and tumor samples
62608934|NCT04407416|ACTIVE_COMPARATOR|Healthy subjects|The breath of all patients with positive FIT (fecal immunochemical test) but negative colonoscopy will be sampled using a breath sampler
62608935|NCT04407416|ACTIVE_COMPARATOR|Colorectal Cancer patients|The breath of all patients with positive FIT (fecal immunochemical test) and a colorectal cancer detected by colonoscopy will be sampled using a breath sampler
62608936|NCT04407416|ACTIVE_COMPARATOR|Colonic Polyps patients|The breath of all patients with positive FIT (fecal immunochemical test) and a colonic polyp detected by colonoscopy will be sampled using a breath sampler
62608937|NCT03827902||Intervention Group|A Telcare 2.0 BGM, which is FDA cleared, will be used to upload blood glucose measurements to a cloud server accessible by providers. Intervention group will participate in an integrated care model where they will attend Diabetic Clinic and Foot Wound appointments on the same day.
62608938|NCT03827902||Control Group|Control Group will receive usual care (a non-integrated care model where Diabetes Clinic and Foot Wound appointments are on separate days.) These patients will not receive a blood monitoring glucose device.
62608939|NCT05843201|EXPERIMENTAL|Patients are hospitalized with chronic heart failure symptoms and fluid overloaded|"Phase 1: 'In Hospital' Phase: chronic heart failure (CHF) patients are enrolled in the study when admitted to the hospital with fluid overload.~Study procedures performed, alongside diuretic therapy, in the hospital. Phase 2: 'At Home' Phase: Upon investigator's decision at discharge, the patients are enrolled in the second phase of the study for additional treatment sessions at home."
62608940|NCT02073318|EXPERIMENTAL|Balance training|
62608941|NCT02073318|ACTIVE_COMPARATOR|Control|Control group received 4 weeks upper extremities exercise in sitting position
62608942|NCT00962936|EXPERIMENTAL|CT-011|
62608943|NCT04930614||Transgender and non-binary people|Adult transgender and non-binary people in Flanders and Brussels (Belgium)
62608944|NCT05242133|EXPERIMENTAL|CinnaGen peginterferon beta-1a|Pegylated interferon beta-1a (CinnaGen) autoinjector (Physioject™),125 mcg, subcutaneous (SC) injection, every 2 weeks, for 24 months
62608945|NCT05242133|ACTIVE_COMPARATOR|CinnoVex®|Interferon Beta-1A Prefilled Syringe, CinnoVex® (CinnaGen), 30 mcg, intramuscular injection, once a week, for 24 months
62608946|NCT00957749|EXPERIMENTAL|cPMP|
62048491|NCT00567190|EXPERIMENTAL|Pertuzumab + Trastuzumab + Docetaxel|Participants randomized to this arm received pertuzumab 420 milligrams (mg) intravenously (IV) once every 3 weeks (q3w) and trastuzumab 6 milligrams per kilogram (mg/kg) IV q3w, plus docetaxel 75 milligrams per square metre of body surface (mg/m\^2) IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.
62608947|NCT01963650||No treatment|
62623513|NCT06236113|PLACEBO_COMPARATOR|Placebo/Control|Pharmacist will check randomization schedule. For placebo/control subject they will prepare an infusion bag of saline with no added medication. The Study Drug Bag will be released with a label that includes: Name of Study, Study Subject #, Patient (Pt) Name, Pt Medical record number (MR#), Pt Date of birth (DOB), and INFUSION RATE.
62831120|NCT03656289|EXPERIMENTAL|Etonogestrel Contraceptive|Etonogestrel contraceptive implant; consists of a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel, pre-loaded in the needle of a disposable applicator. The implant must be removed no later than by the end of the third year.
62831121|NCT00959855|EXPERIMENTAL|Pulmonary Rehabilitation|Pulmonary rehabilitation classes based on the British Thoracic Society guidelines will be undertaken for two hours for 16 sessions within an eight week period.
62250687|NCT05031845||COVID-19 negative, not hospitalized with ARDS|"1. Patients with chest imaging at the time of the first COVID-positive PCR test will have their first LDCT within 3 to 4 months after COVID 19 diagnosis. A second LDCT between 3 to 6 months after the initial LDCT.~2. Patients without chest imaging at the time of the first COVID-positive PCR test or with a negative COVID PCR test will have their first LDCT within 2 weeks to 1 month after their recovery from COVID 19, or testing. A second LDCT may be performed between 3 to 6 months after the initial LDCT."
62831122|NCT00959855|NO_INTERVENTION|Pulmonary Rehabiliation|The control group will be assessed in the same time frame without participating in the rehabilitation class. They will avail of the next available class after the 12 month assessment.
62608948|NCT04756128|EXPERIMENTAL|Colchicine-Only Arm|"Patients randomized to a colchicine-containing treatment arm will receive colchicine 0.6 mg twice daily for up to 28 days. On the day of enrollment, provided the first dose can be given prior to 16:00 that day, patients are eligible to receive two doses; the second dose will be scheduled for 22:00. Patients experiencing gastrointestinal side effects (nausea, vomiting, and diarrhea) on twice daily dosing may have the dose decreased to 0.6 mg daily. Dosing will continue twice daily unless there is a change that requires a dose adjustment or an exclusion criterion is met. Dosing deviations above the study protocol will be allowed if medically necessary for the treatment of an additional indication (e.g. colchicine for viral pericarditis).~Patients in this arm will also receive the investigating institution's current standard of care (described in detail in the standard of care arm) for patients with COVID-19."
62608949|NCT04756128|EXPERIMENTAL|"Colchicine and Naltrexone (Combined) Arm"|"Patients randomized to a colchicine-containing treatment arm (including the combined arm) will receive colchicine 0.6 mg twice daily for up to 28 days. On the day of enrollment, provided the first dose can be given prior to 16:00 that day, patients are eligible to receive two doses; the second dose will be scheduled for 22:00.~Patients in the combined arm will also receive naltrexone. Patients randomized to an LDN-containing treatment arm (including the combined arm) will receive naltrexone 4.5 mg once daily. The first dose can be given at any time during the day of enrollment/randomization, and will be timed at 08:00 daily thereafter (with AM colchicine dose, if in combined colchicine/LDN arm) for up to 28 days (unless new contraindication or exclusion criteria met).~Patients in this arm will also receive the investigating institution's current standard of care (described in detail in the standard of care arm) for patients with COVID-19."
62250688|NCT01466530|PLACEBO_COMPARATOR|Placebo|sublingual two moistened white coated placebo tablets
62831123|NCT01872416|EXPERIMENTAL|Refractory and relapsed SCLC|Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
62831124|NCT02933749|ACTIVE_COMPARATOR|The sitting|The sitting position Device sCtO2 Device BIS
62831125|NCT02933749|ACTIVE_COMPARATOR|The prone|The prone position Device sCtO2 Device BIS
62831126|NCT06590233||Acute pancreatitis|
62831127|NCT02547818|ACTIVE_COMPARATOR|Group I|ALZT-OP1a active capsules for inhalation and ALZT-OP1b placebo capsules for oral administration.
62048492|NCT00567190|PLACEBO_COMPARATOR|Placebo + Trastuzumab + Docetaxel|Participants randomized to this arm received placebo IV q3w and trastuzumab 6 mg/kg IV q3w, plus docetaxel 75 mg/m\^2 IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.
62048493|NCT00303199|EXPERIMENTAL|Single Arm|
62048494|NCT06468319||Community Census Cohort|Women of child-bearing aged (WOCBA) identified within the community.
62250689|NCT01466530|ACTIVE_COMPARATOR|Misoprostol|sublingual misoprostol (400 µg)
62250690|NCT01811784|EXPERIMENTAL|Use skirt on raw sap consumption|"Phase one: Test the effectiveness of a single message of do not drink raw sap."
62250691|NCT01811784|EXPERIMENTAL|Ask people not to drink sap|Test the effectiveness of a risk reduction approach, encouraging people to avoid drinking sap, if they do, they should only drink sap from skirt protected trees.
62250692|NCT01811784|NO_INTERVENTION|Phase 1: Routine raw sap consumption among household members.|"Test the effectiveness of a single message of do not drink raw sap"
62250693|NCT01811784|NO_INTERVENTION|Phase 2:|Raw sap consumption from skirt protected trees
62250694|NCT02629796||CIDP treated (IVIG)|patients with a diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) according to European criteria, treated with IVIG (intravenous immunoglobulin as a first line of treatment) as a usual treatment
62250695|NCT02629796||control|healthy subjects
62250696|NCT03502239|EXPERIMENTAL|Treatment group|Subjects randomly assigned to this arm will train on the Mega Team video game.
62831128|NCT02547818|ACTIVE_COMPARATOR|Group II|ALZT-OP1a active capsules for inhalation and ALZT-OP1b active tablets for oral administration.
62831129|NCT02547818|ACTIVE_COMPARATOR|Group III|ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b active tablets for oral administration.
62048495|NCT06468319||Health Facility Cohort|Pregnant women presenting at the health facility for antenatal care or referred in from the Community Consensus Cohort.
62250697|NCT03502239|NO_INTERVENTION|Control- wait list group|Subjects randomly assigned to this arm will be the wait-list group. They are allowed to play the video games that they usually play.
62250698|NCT01971502|EXPERIMENTAL|BI 1060469 single rising dose part|single rising doses given as tablet
62250699|NCT01971502|EXPERIMENTAL|BI 1060469 food effect part|given as tablet fasted and fed
62250700|NCT04700384|NO_INTERVENTION|Control Group|"Control Group - Baseline Training~25 Participants allocated. Individuals receive introductory information on using the simulator and the scenario. They perform 5 simple subpial tumour resections for practice and have 5 minutes per trial. After each attempt, the student takes a 5-minute break with no assessment or feedback on their performance. On their 6th attempt they have 13 minutes to perform a different realistic scenario."
62608950|NCT04756128|EXPERIMENTAL|Naltrexone-Only Arm|"Patients randomized to an LDN-containing treatment arm (including the combined arm) will receive naltrexone 4.5 mg once daily. The first dose can be given at any time during the day of enrollment/randomization, and will be timed at 08:00 daily thereafter (with AM colchicine dose, if in combined colchicine/LDN arm) for up to 28 days (unless new contraindication or exclusion criteria met).~Patients in this arm will also receive the investigating institution's current standard of care (described in detail in the standard of care arm) for patients with COVID-19."
62608951|NCT04756128|NO_INTERVENTION|Standard of Care Arm|Patients in this arm will receive the investigating institution's current standard of care for patients with COVID-19. For example, all patients requiring supplemental oxygen (assuming no contraindications) would be candidates for both remdesivir 200 mg x 1 IV dose followed the next day by 100 mg q24h IV x up to 4 doses, as well as dexamethasone 6 mg q24h x 10 up to 10 doses.
62608952|NCT05659069||Control group|10 patients with dental implant placement without inferior alveolar nerve lateralization
62608953|NCT05659069||Lateralization group|10 patients with dental implant placement with inferior alveolar nerve lateralization.
62608954|NCT05842564|EXPERIMENTAL|Crohn's Disease Group|Patients followed for a Crohn's Disease in consultation or in day hospital aged between 6 and 18 years old.
62608955|NCT05842564|OTHER|Control Group|Patients followed for functional abdominal disorders
62608956|NCT03027206|EXPERIMENTAL|Vibration technique|Rhythmic and rapid movements of isometric contraction of the forearm, applied manually over the anterior region of the thorax
62831130|NCT02547818|PLACEBO_COMPARATOR|Group IV|ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b placebo tablets for oral administration.
62831131|NCT01476111||Group 1|Patients with primary invasive breast cancer
62831132|NCT02354898|EXPERIMENTAL|BBI503, BBI503 and Sorafenib|
62831133|NCT03784586||Positive EPS - ICD|Patients with inducible sustained ventricular tachycardia or ventricular fibrillation at EPS evaluation underwent ICD implantation
62831134|NCT03784586||Negative EPS - PMK|All non inducible patients underwent PMK implantation
62831135|NCT03410706||Rivaroxaban|Anticoagulation with rivaroxaban
62831136|NCT06233136|EXPERIMENTAL|Leg Pedalling exercise and designed physical therapy program|"Each child in the experimental group will be positioned in semi-reclined position with 45 degree trunk flexion during the application of cycling Sessions will be 30 minutes per session, three times per week, for two successive months The designed physical therapy program It will be applied for all participated children in both groups. It includes;~1. Flexibility exercises~2. Static and dynamic balance exercises~3. Functional training Sessions will be 45 minutes per session, three times per week, for two successive month"
62831137|NCT06233136|ACTIVE_COMPARATOR|Designed physical therapy program|"The designed physical therapy program It will be applied for all participated children in both groups. It includes;~1. Flexibility exercises~2. Static and dynamic balance exercises~3. Functional training Sessions will be 45 minutes per session, three times per week, for two successive month"
62831138|NCT02233777|EXPERIMENTAL|Pregabalin capsules 150 mg of Dexa Medica|Each capsule contains 150 mg pregabalin.
62831139|NCT02233777|ACTIVE_COMPARATOR|Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland|Each capsule contains 150 mg pregabalin.
62831140|NCT00565188|EXPERIMENTAL|I|
62048496|NCT06468319||Offspring from Health Facility Cohort|Children born to women in the health facility cohort.
62048497|NCT01162681|EXPERIMENTAL|A-623 high dose weekly|
62831141|NCT00565188|NO_INTERVENTION|C|
62831142|NCT03483857|EXPERIMENTAL|Peer Navigation|Individuals assigned to the PN condition will be assigned to one of 10 PN case managers who will follow an SOP described for initial intake and follow up visits with each participant. Participants will be asked to provide contact information for themselves and up to 3 individuals whom study staff can contact in case they cannot make direct contact with the study participant assigned to PN. PN will meet with their clients at least once monthly to discuss treatment related issues including medication access, side effects, adherence, stigma or discrimination related to HIV or their taking ART medication, etc. Participants will have contact information for their assigned PN and may contact them for reasons related to their treatment between scheduled monthly visits if they choose. All visits with PN will be recorded by the PN. and participants who fail to attend up to 3 scheduled PN appointments will be considered LTFU for the intervention.
62048498|NCT01162681|EXPERIMENTAL|A-623 low dose weekly|
62048499|NCT01162681|EXPERIMENTAL|A-623 high dose every 4 weeks|
62048500|NCT01162681|PLACEBO_COMPARATOR|Placebo|
62608957|NCT03027206|EXPERIMENTAL|Acceleration of expiratory flow|Soft compression of the thorax applied with one hand on the lower ribs and the other using the ulnar border on the supramammary line
62608958|NCT04982172|EXPERIMENTAL|Interventional arm|Model-informed precision dosing of infliximab (intravenously administered) using a Bayesian forecasting software tool. Doses and dosing intervals will be derived from the software tool, aiming to maintain adequate exposure (trough concentration target 5 mg/L).
62608959|NCT04982172|ACTIVE_COMPARATOR|Historical control arm|The treating physician adjusted the intravenously administered infliximab doses and dosing intervals without being guided by a model-informed precision dosing software tool. The primary objective was to extend the dosing interval. Therefore, dose de-escalation (interval extension with/without dose adjustment) were performed following a scheme at the treating physician's discretion.
62608960|NCT03704116|ACTIVE_COMPARATOR|Expedition: Strategic Advantage|Software-based intervention simulating daily life cognitive challenges. Delivered 1 hour per day, 5 days per week for 4 weeks. Includes 8 check-in phone calls with an experimenter. Includes escalating challenge levels.
62608961|NCT03704116|PLACEBO_COMPARATOR|Expedition: Informational Advantage|Software-based intervention simulating daily life cognitive challenges. Delivered 1 hour per day, 5 days per week for 4 weeks. Includes 8 check-in phone calls with an experimenter. Includes capped challenge levels.
62608962|NCT06523543||Pregnant women|Women who are pregnant between 7 and 16 weeks of amenorrhea (WA)
62608963|NCT05674318|EXPERIMENTAL|Alpha-lactalbumin|
62608964|NCT00310466|ACTIVE_COMPARATOR|Sublingual immunotherapy|sublingual immunotherapy with drops applied once daily by single dose containers (200 STU per dose)
62048501|NCT04723823|EXPERIMENTAL|Individuals with spinal cord injury (SCI)|Individuals will be asked to imagine movements or sensations while fMRI is used to measure brain activity.
62831143|NCT03483857|NO_INTERVENTION|Standard of Care|Individuals assigned to SOC will be referred directly to the NCHC/RLS staff for treatment initiation or continuation. At intake they will receive standard treatment information per MPDOH guidelines, as well as information about Anova's RLS and Health4Men clinical and psychosocial services available at the NCHC. They will receive monthly text message reminders from study staff to refill ART prescriptions, and a separate reminder in month 6 to schedule complete their 6-month clinical visit. Study staff will verify that participants have picked up medications and attended all scheduled clinical visits by means of chart review and data extraction. Per MPDOH guidelines, individuals who fail to collect medications 3 months in a row, or who fail to attend their 6-month HIV clinical follow-up appointment, will be considered non-engaged and lost to follow up (LTFU).
62831144|NCT05182593|EXPERIMENTAL|Diet 1: moderate/high FODMAP diet. Diet 2: low FODMAP diet.|The subjects will follow the moderate/high FODMAP diet as the first intervention, and the low FODMAP diet as the second intervention. The subjects will follow both interventions for seven days.
62250701|NCT04700384|EXPERIMENTAL|Experimental Group - Virtual Operative Assistance Training|"Experimental Group - Virtual Operative Assistance Training~25 participants allocated. Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. In the 5-minutes between attempts, participant receive the Virtual Operative Assistance Training assessment of their performance and audiovisual feedback."
62250702|NCT04700384|EXPERIMENTAL|Experimental Group - remote-based expert Instructor Training|25 participants allocated. Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. Meanwhile, a trained instructor observes the participant's on-screen performance, that is live-streamed, remotely. Instructors are senior neurosurgery residents with extensive experience in performing and assessing this scenario. During the 5-minute feedback session, they chat with the student, discussing the performance and help in setting goals for the next trial.
62048502|NCT04723823|EXPERIMENTAL|Individuals with amotrophic lateral sclerosis (ALS)|Individuals will be asked to imagine movements or sensations while fMRI is used to measure brain activity.
62048503|NCT03536286|EXPERIMENTAL|Encouragement Zone 3|"Encouragement households will be randomly sampled based on location, and a team of 2 local community champions/data collectors (hired from within the community) will visit each of the encouragement arm homes. Community champions will be responsible for visiting each home, going door-to-door and speaking with each family individually in order to avoid contamination/cross-over with control households.~The Asili intervention involves membership into a program; households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention."
62048504|NCT03536286|NO_INTERVENTION|Control Zone 3|Control households will still have equal access to the Asili intervention and can gain membership into a program at any time. Regardless of membership status, households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention.
62250703|NCT01172197|ACTIVE_COMPARATOR|Ropivacaine|Local anaesthetic bolus and infusion
62250704|NCT01172197|ACTIVE_COMPARATOR|Levobupivacaine|Local anaesthetic bolus and infusion
62608965|NCT00310466|PLACEBO_COMPARATOR|Placebo|placebo sublingual drops
62250705|NCT02887014|EXPERIMENTAL|Group A|Participants getting SPECIFIC VERBAL INSTRUCTIONS before starting bowel preparation (Group A).
62250706|NCT02887014|NO_INTERVENTION|Group B|Participants getting ordinary instructions as usual in each of the participating centers (Group B).
62831145|NCT05182593|EXPERIMENTAL|Diet 1: low FODMAP diet. Diet 2: moderate/high FODMAP diet.|The subjects will follow the low FODMAP diet as the first intervention, and the moderate/high FODMAP diet as the second intervention. The subjects will follow both interventions for seven days.
62250707|NCT04115579|EXPERIMENTAL|Biscuit 1 Control|Consumption of control biscuit for breakfast and afternoon snack and impact on postprandial glucose and insulin
62831146|NCT05761782||University of California, Davis Comprehensive Cancer Center's Catchment Area Population|Behavioral Intervention: Education and Training on Cancer Prevention and Education
62831147|NCT02066181|EXPERIMENTAL|Arm I (sorafenib tosylate)|Patients receive sorafenib tosylate PO QD on days 1-28.
62831148|NCT02066181|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Patients may crossover to Arm I upon disease progression.
62831149|NCT05577507|ACTIVE_COMPARATOR|Test group|"Group 1:~(cholestyramine 12 gram), 40 patients will take a dose of cholestyramine 4-gram sachets three times daily within meals with (Calcimate).~Dosage: one sachet on 150 ml water three times daily duration : 8 weeks"
62831150|NCT05577507|PLACEBO_COMPARATOR|Control group|Group 2: Control group, 40 patients will take only (Calcimate).
62831151|NCT03969212|EXPERIMENTAL|Baloxavir Marboxil|Participants who are IPs will receive a single oral dose of baloxavir marboxil. HHCs of the IPs will not receive study medication.
62831152|NCT03969212|PLACEBO_COMPARATOR|Placebo|Participants who are IPs will receive a single oral dose of placebo. HHCs of the IPs will not receive study medication.
62831153|NCT02729532||Xpert cohort|HIV-positive presumptive TB patients tested for TB using Xpert MTB/RIF assay (fluorescence microscopy and TB culture also done to serve as reference standard)
62831154|NCT02729532||Standard of Care cohort|HIV-positive presumptive TB patients tested for TB using standard of care testing (sputum smear microscopy plus clinical evaluation)
62831155|NCT03184168|EXPERIMENTAL|treatment|\[14C\]lorlatinib
62831156|NCT04330118||20 patients with DRESS syndrome|
62831157|NCT04330118||20 patients with drug induced MPE with eosinophilia|patients with drug induced maculopapular exanthema (MPE) with eosinophilia
62831158|NCT04330118||20 patients with drug induced MPE without eosinophilia|
62831159|NCT04330118||20 Healthy subjects|
62831160|NCT00459316|EXPERIMENTAL|Group 1|Participants ≤11 to \<25 years of age with CD4% at screening ≥15%. All received Quadrivalent meningococcal conjugate vaccine at entry, those who were eligible were randomized at week 24, with Group 1B receiving a second Quadrivalent meningococcal conjugate vaccine at week 24. Those who were eligible received a booster dose of Quadrivalent meningococcal vaccine at 3.5 years.
62831161|NCT00459316|EXPERIMENTAL|Group 2|Participants ≤11 to \<25 years of age with CD4% at screening \<15%; All receiving Quadrivalent meningococcal conjugate vaccine at entry, with those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24 and 3 years.
62250708|NCT04115579|EXPERIMENTAL|Biscuit 2 Test|Consumption of test biscuit for breakfast and afternoon snack on postprandial glucose and insulin
62250709|NCT06417320|ACTIVE_COMPARATOR|Group 1|Group 1 (ACEI group)
62250710|NCT06417320|ACTIVE_COMPARATOR|Group 2|Group 2 (combined ACEI and SGLT-2i group)
62608966|NCT02920177|EXPERIMENTAL|platelet-rich plasma|platelet-rich plasma injection into the head-neck junction of the hip joint
62831162|NCT00459316|EXPERIMENTAL|Group 3|Participants \>=2 to \<11 years of age with CD4% at screening ≥ 25%; All received Quadrivalent meningococcal conjugate vaccine at entry, with those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24 and 3 years.
62831163|NCT06609577|NO_INTERVENTION|Control group|Received standard mechanical ventilation withdrawal protocol without diaphragmatic external pacing
62250711|NCT05570591|ACTIVE_COMPARATOR|Active laser|Application of the active 2RT sub threshold laser
62250712|NCT05570591|SHAM_COMPARATOR|Sham laser|Application of sham laser (i.e. flashing lights which replicate the look of active laser to the participant)
62250713|NCT01728415|EXPERIMENTAL|A: Exercise|High intensity interval exercise training (3 x 3 minutes of intensity abow 85% og Heart rate peak)
62250714|NCT01728415|ACTIVE_COMPARATOR|B: Execise|Moderate continuous exercise training
62250715|NCT01728415|NO_INTERVENTION|C: Controll|Usual care without exercise training
62608967|NCT02920177|ACTIVE_COMPARATOR|Kenalog 10 mg/mL Injectable Suspension|corticosteroid injection into the head-neck junction of the hip joint
62831164|NCT06609577|EXPERIMENTAL|Invention group|Diaphragm function was monitored by diaphragmatic ultrasound to personalize the intensity of diaphragm extracorporeal pacing.
62831165|NCT02891499|EXPERIMENTAL|LLLT + immediate force|Use of Low-level laser therapy and not mediate orthodontic force application (150 gF the day of the implantation).
62831166|NCT02891499|EXPERIMENTAL|LLLT + mediate force|Use of Low-level laser therapy and mediate orthodontic force application (150 gF 4 weeks after the day of the implantation).
62831167|NCT02891499|NO_INTERVENTION|Immediate force application|Not mediate orthodontic force application (150 gF the day of the implantation), without use of Low-level laser therapy.
62250716|NCT04146779|EXPERIMENTAL|Video and Written Yoga Instruction|Videos and written instructions on Hatha yoga will be provided
62250717|NCT04146779|EXPERIMENTAL|Video, Written Yoga Instruction Plus Guided Yoga Sessions|Videos and written instructions on Hatha yoga and instructor guided session on Hatha yoga will be provided
62440697|NCT05084690|ACTIVE_COMPARATOR|Resistance training control group|The resistance training control group will perform unilateral resistance training on their dominant arm. The training will be performed twice per week for four weeks totaling eight training sessions.
62608968|NCT00659542|NO_INTERVENTION|1|mesh fixation by absorbable sutures
62608969|NCT00659542|EXPERIMENTAL|2|mesh fixation by cyanoacrylate glue
62831168|NCT02891499|EXPERIMENTAL|Mediate force application|Mediate orthodontic force application (150 gF 4 weeks after the day of the implantation), without use of Low-level laser therapy.
62831169|NCT00710697|EXPERIMENTAL|Single Arm|Picoplatin
62831170|NCT05442957|EXPERIMENTAL|BRIGHT|BRIGHT is a manualized theory-based video tele-cognitive behavioral therapy (CBT) intervention delivered one-on-one by a licensed clinical psychologist.
62440698|NCT05084690|EXPERIMENTAL|Resistance training with mirror illusion group|The resistance training with mirror illusion group will perform unilateral resistance training on their dominant arm. During training, they will view a mirror illusion of their exercising arm over their opposite, non-exercising arm. The training will be performed twice per week for four weeks totaling eight training sessions.
62608970|NCT01785849|EXPERIMENTAL|Etelcalcetide|Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session three times a week, for 26 weeks.
62608971|NCT01785849|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
62608972|NCT03046992|EXPERIMENTAL|YH25448|"* Dose Escalation Phase: Consists of 7 Cohorts~* Dose Expansion Phase: Consists of 5 Cohorts~* Dose Extension Phase: Consists of 2 Cohorts"
62831171|NCT05442957|ACTIVE_COMPARATOR|Attention Control|The attention control arm is a manualized video tele-supportive care intervention that addresses non-body image aspects of HNC survivorship.
62608973|NCT05071716|EXPERIMENTAL|Rifaximin SSD-40mg IR|
62608974|NCT05071716|PLACEBO_COMPARATOR|Placebo|
62608975|NCT04633239|EXPERIMENTAL|Treatment (abemaciclib, olaparib, biospecimen collection)|Patients receive olaparib PO BID on days 1-28 and abemaciclib PO BID on days 8-28 of cycle 1 and days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and undergo tumor biopsy on study.
62608976|NCT03146871|EXPERIMENTAL|Treatment (sEphB4-HSA, azacitidine, decitabine)|Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62608977|NCT04775550|EXPERIMENTAL|Daratumumab, Bortezomib,Lenalidomide,Dexamethasone|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. Cycle Length is 28 days.~The names of the study drugs involved in this study are:~* Daratumumab~* Bortezomib~* Lenalidomide~* Dexamethasone"
62608978|NCT06520514|ACTIVE_COMPARATOR|Reference group|Reference treatment using the standard administration mode
62608979|NCT06520514|EXPERIMENTAL|Test 1 group|Treatment 1 using the test administration mode
62608980|NCT06520514|EXPERIMENTAL|Test 2 group|Treatment 2 using the test administration mode
62623514|NCT06236113|EXPERIMENTAL|Low Dose Ketamine Infusion (LDKI)|Infusion Bag will receive 100 mg of ketamine (Ketamine Infusion Subject). The Study Drug Bag will be released with a label that includes: Name of Study, Study Subject #, Patient Name, Pt MR#, Pt DOB, and INFUSION RATE. (Note: infusion rate is 0.1 mg/kg/hr and concentration of standard ketamine infusion bag is 1 mg/mL. That is, 100 mg of ketamine added to 100 mL saline).
62623515|NCT00884260|EXPERIMENTAL|Arm 1|
62831172|NCT01458392|EXPERIMENTAL|Dalantercept|dalantercept
62831173|NCT01526863|PLACEBO_COMPARATOR|Placebo|
62831174|NCT01526863|ACTIVE_COMPARATOR|HA egg|
62831175|NCT06049849|EXPERIMENTAL|Treatment Group|Active Biophoton Generators are placed under the hotel bed.
62831176|NCT06049849|PLACEBO_COMPARATOR|Control Group|Placebo-products are placed under the hotel bed.
62831177|NCT01113086|EXPERIMENTAL|Left active anodal DLPFC|We will place the anodal electrode on the left dorsolateral prefrontal cortex. Stimulation will be given at 2 mA for a total of 20 mins for 10 consecutive sessions (Monday through Friday).
62831178|NCT01113086|EXPERIMENTAL|Right active anodal DLPFC|We will place the anodal electrode on the right dorsolateral prefrontal cortex. Stimulation will be given at 2 mA for a total of 20 mins for 10 consecutive sessions (Monday through Friday).
62440699|NCT05482984|EXPERIMENTAL|Lectures with video-recorded role-play and guided reflection|The learning method used with the intervention group was role-playing with videos and guided reflection.
62831179|NCT01113086|PLACEBO_COMPARATOR|Sham tDCS|Sham tDCS: For sham-controlled tDCS subjects, the same montage will be used; however current will be applied for only 30 seconds.
62831180|NCT01113086|OTHER|Open-Label Arm|In addition to this study we will have an open label arm in which subjects who received sham stimulation through the course of the study will have the opportunity to receive active stimulation free of charge. The same parameters and identical procedures as is done in the original study will be used. Data will be collected as an open label, which will therefore provide additional information. Data obtained from this open label portion of the study will be kept separate.
62831181|NCT06011187|ACTIVE_COMPARATOR|Routine care|"During the pre-implementation period, fluid therapy will be done as routine care.~Mean arterial pressure (MAP) will be maintained between 65-70 mmHg per standard of care"
62048505|NCT03536286|EXPERIMENTAL|Encouragement Zone 4|"Encouragement households will be randomly sampled based on location, and a team of 2 local community champions/data collectors (hired from within the community) will visit each of the encouragement arm homes. Community champions will be responsible for visiting each home, going door-to-door and speaking with each family individually in order to avoid contamination/cross-over with control households.~The Asili intervention involves membership into a program; households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention."
62048506|NCT03536286|NO_INTERVENTION|Control Zone 4|Control households will still have equal access to the Asili intervention and can gain membership into a program at any time. Regardless of membership status, households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention.
62048507|NCT00990639|EXPERIMENTAL|candesartan+UDCA group|oral candesartan(8 mg/day) in addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months
62048508|NCT00990639|PLACEBO_COMPARATOR|UDCA group|ursodeoxycholic acid(UDCA,600 mg/day)only for 6 months
62048509|NCT02758353|EXPERIMENTAL|Community distribution of SP|All the eligible pregnant women were reached with SP either at health clinic and/or at community/household level with sulphadoxine-pyrimethamine (SP). Alerts and reminders were sent to them by community-based health volunteers ahead of subsequent SP doses.
62440700|NCT05482984|NO_INTERVENTION|Lectures without video-recorded role-play and guided reflection|The control group was exposed to classroom lectures without video-recorded role-play and guided reflection.
62440701|NCT06544018|ACTIVE_COMPARATOR|Patients with cryopyrin-associated periodic syndrome (CAPS)|Confirmed by genetic analysis of NLRP3
62440702|NCT06544018|PLACEBO_COMPARATOR|Control group|Healthy participant (absence of CAPS, verified by NLRP3 gene analysis) living in the same household as a CAPS participant included in the protocol
62440703|NCT01991587|EXPERIMENTAL|Low dose of quadrivalent VLP vaccine|Biological: A single low dose of quadrivalent VLP vaccine
62440704|NCT01991587|EXPERIMENTAL|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
62440705|NCT01991587|EXPERIMENTAL|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
62440706|NCT01991587|PLACEBO_COMPARATOR|Placebo|A single dose of Placebo
62440707|NCT01688037|EXPERIMENTAL|NBI-98854 50 mg|NBI-98854 50 mg administered as two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
62440708|NCT01688037|EXPERIMENTAL|NBI-98854 100 mg and 50 mg|NBI-98854 100 mg administered as two (2) 50 mg capsules taken every morning between 7:00am - 10:00am for 2 weeks. After 2 weeks, NBI-98854 50 mg administered by two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for remaining 4 weeks.
62623516|NCT06336811|NO_INTERVENTION|Control|"No additional intervention will be performed on the patient in the control group, and until the intervention begins, How old are you? Which grade are you in? What is the name of your favorite friend? Which sport do you enjoy doing more? His attention was distracted by asking questions such as."
62831182|NCT06011187|EXPERIMENTAL|Assisted fluid management system|"In the post-implementation period, fluid bolus administration will be guided by the AFM recommandation.~MAP will be maintained between 65-70 mmHg per standard of care"
62440709|NCT01688037|PLACEBO_COMPARATOR|Placebo|Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.
62440710|NCT04682275|OTHER|Female Group|Females with periodontal disease (71 subjects with gingivitis, 100 subjects with periodontitis)
62440711|NCT04682275|NO_INTERVENTION|Male Group|males with periodontal disease (72 subjects with gingivitis, 96 subjects with periodontitis)
62440712|NCT04193891||Diet Group|Participants choosing to newly initiate the modified Atkins diet, a high fat low carb diet, for improved epilepsy control.
62440713|NCT04193891||Control Group|Participants not choosing to initiate dietary therapy for epilepsy. The participants in the control group will continue with the treatment regimen they have chosen together with their physician.
62440714|NCT04288050||Diabetic subjects under dialysis|Diabetic subjects under dialysis
62440715|NCT02854566||periprosthetic fractures of the femur|periprosthetic fractures of the femur treated by osteosynthesis
62440716|NCT00130520|EXPERIMENTAL|open label|
62440717|NCT01618305|EXPERIMENTAL|Arm A (Women)|Pregnant women received ZDV/3TC + EFV
62440718|NCT01618305|EXPERIMENTAL|Arm B (Women)|Pregnant women received ZDV/3TC + RAL
62440719|NCT01618305|NO_INTERVENTION|Arm A (Infants)|Infants born to women in Arm A; infants received no study intervention.
62440720|NCT01618305|NO_INTERVENTION|Arm B (Infants)|Infants born to women in Arm B; infants received no study intervention.
62440721|NCT01152281|ACTIVE_COMPARATOR|Maximal Control|Basic awareness messages with stories of people living with AIDS
62440722|NCT01152281|EXPERIMENTAL|Instrumental|Instrumental messages with stories of people living with HIV
62440723|NCT01152281|EXPERIMENTAL|Empowering|Empowering messages with stories of people living with HIV
62440724|NCT01152281|EXPERIMENTAL|Instrumental and Empowering|Instrumental and empowering messages with stories of people living with HIV
62440725|NCT01152281|ACTIVE_COMPARATOR|Minimal Control|Basic awareness messages with stories of people who are not infected with HIV
62831183|NCT06201026|ACTIVE_COMPARATOR|Traditional exercise group in newly diagnosed patients with MS (SEP-R-TEM)|Newly diagnosed patients with MS who will be part of the group doing traditional exercises
62831184|NCT06201026|EXPERIMENTAL|Individualized exercise group in newly diagnosed patients with MS (SEP-R-IND)|Newly diagnosed patients with MS who will be part of the group doing individualized exercises
62831185|NCT06201026|ACTIVE_COMPARATOR|Traditional exercise group in advanced diagnosed patients with MS (SEP-A-TEM)|Advanced diagnosed patients with MS who will be part of the group doing traditional exercises
62831186|NCT06201026|EXPERIMENTAL|Individualized exercise group in advanced diagnosed patients with MS (SEP-A-IND)|Advanced diagnosed patients with MS who will be part of the group doing individualized exercises.
62831187|NCT01928212||healthy control|Sex- and agematched healthy subjects
62831188|NCT01928212||Parkinson group|Patients with Parkinson's disease
62831189|NCT03141827|EXPERIMENTAL|Insulin|Nasal spray, insulin 40 IU, single dose
62831190|NCT03141827|PLACEBO_COMPARATOR|Placebo|Nasal spray, placebo, single dose
62831191|NCT00791505|ACTIVE_COMPARATOR|Ciprofloxacin|750 mg a day during 10 days
62831192|NCT00791505|ACTIVE_COMPARATOR|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
62440726|NCT04767789|EXPERIMENTAL|NZ-GHMH-01|Dietary supplement in shape of capsule to be taken once per day in the evening.
62440727|NCT04767789|PLACEBO_COMPARATOR|Placebo|The placebo is in shape of capsule to be taken once per day in the evening and in which only the active ingredients are not present.
62440728|NCT05661929||Users of medical internet resources|This group includes people older 18 years who are looking for medical information at the Internet-resources
62440729|NCT02351128|EXPERIMENTAL|Only one arm|All patients receive Lanreotide.
62623517|NCT06336811|EXPERIMENTAL|active Virtual reality|The remote control of the virtual glasses will be given to the hand that will not be interfered with, and the child will start, slow down or stop the application herself. Samsung Gear Oculus Guest 2 headset allows watching virtual reality applications.
62831193|NCT03621475|EXPERIMENTAL|Novel restraint first, then traditional restraint|Participants will be randomized to wear the novel arm restraint bilaterally for 4 hours on study day #1, followed by traditional soft bilateral wrist restraints for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
62831194|NCT03621475|EXPERIMENTAL|Traditional restraint first, then novel restraint|Participants will be randomized to wear traditional soft bilateral wrist restraints for 4 hours on study day #1, followed by the novel arm restraint bilaterally for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
62831195|NCT00224640|EXPERIMENTAL|1|Iron chelating intervention
62831196|NCT03516630|EXPERIMENTAL|TRZ 20|Product is administered as single dose in the morning, under fasting conditions. 10 drops for the dose of 20 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
62831197|NCT03516630|EXPERIMENTAL|TRZ 60|Product is administered as single dose in the morning, under fasting conditions. 30 drops for the dose of 60 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
62831198|NCT03516630|EXPERIMENTAL|TRZ 140|Product is administered as single dose in the morning, under fasting conditions. 70 drops for the dose of 140 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
62608981|NCT06511362|EXPERIMENTAL|Functional stabilization training (Group 1))|The participants will perform Lateral bridge and ventral bridge(6 weeks protocol,5 sets 30 sec, 5 sec hold of each rep), Isometric hip abduction/lateral rotation in standing (first 2 weeks 2 sets 20 reps), Hip abduction/lateral rotation/extension in sidelying ( 6 week 2 sets 20 reps), Hip abduction/lateral rotation with slight knee and hip flexion in sidelying ( 6 week , 2 sets , 20 reps), Pelvic drop in standing ( 6 weeks , 3 sets 12 reps ) Hip lateral rotation in closed kinetic chain ( 6 weeks, 3 sets , 12 reps ) Single-leg deadlift (6-8 weeks , 3 sets , 12 reps) Single-leg squat ( last 2 weeks ,3 sets 12 reps) Prone knee flexion (6 weeks 2-3 sets , 12 reps) Seated knee extension (90°-45° of knee flexion)( 6 weeks ,2-3 sets 12 reps ) Single-leg standing on unstable platform ( 3 sets)
62608982|NCT06511362|EXPERIMENTAL|Perturbation training(Group 2)|Perform perturbation exercises that involve double leg foam balance activity (30-second hold), tilt board balance training (30-second hold), and roller board (30-second hold).
62608983|NCT05654090|EXPERIMENTAL|cefoperazone sodium and sulbactam sodium (Product name:Burotam)|Single dose Burotam
62831199|NCT03516630|PLACEBO_COMPARATOR|Placebo|Product is administered as single dose in the morning, under fasting conditions. Trazodone-matching placebo corresponding to 70 drops is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
62831200|NCT03516630|ACTIVE_COMPARATOR|Moxifloxacin|Product is administered as single dose in the morning, under fasting conditions. One 400 mg tablet is swallowed (without chewing) with 240 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
62831201|NCT01639378|EXPERIMENTAL|Renal Denervation|Subjects are treated with renal denervation after randomisation and maintained on heart failure medications
62831202|NCT01639378|NO_INTERVENTION|Control group|Subject will have a sham procedure and not receive renal denervation. They will continue with the heart failure medications
62048510|NCT02320292|ACTIVE_COMPARATOR|Arm A (rituximab)|Patients receive rituximab IV on days 1, 8, 15, and 22.
62048511|NCT02320292|EXPERIMENTAL|Arm B (rituximab, yttrium Y-90 ibritumomab tiuxetan)|Patients receive rituximab IV on days 1 and 8 and yttrium Y-90 ibritumomab tiuxetan over 10 minutes on day 8.
62048512|NCT02200874||before NST-implementation (group A)|Patients with a NRS of 3 or more than 3 or NUTRIC score of 4 or more than 4 within the first three days after admittance to hospital. Time point: Before implementation of Nutrition Support Team (NST).
62048513|NCT02200874||After NST-implementation (group B)|Patients with a NRS of 3 or more than 3 or NUTRIC score of 4 or more than 4 within the first three days after admittance to hospital. Time point: After implementation of Nutrition Support Team (NST).
62048514|NCT06454032|EXPERIMENTAL|Fitness walking group|
62048515|NCT06454032|SHAM_COMPARATOR|Control group|
62048516|NCT00644631|ACTIVE_COMPARATOR|Arm 1|
62048517|NCT00644631|PLACEBO_COMPARATOR|Arm 2|
62440730|NCT03782857|EXPERIMENTAL|Intervention group|Initiation/stepwise escalation of antihypertensive medication in case of blood pressure above individual target Initiation/stepwise escalation of cholesterol lowering medication in case of LDL-cholesterol above individual target Advice on healthy lifestyle and life long adherence to preventive medication
62048518|NCT04274920|EXPERIMENTAL|Bioactive Glass|18 teeth were capped indirectly with dental adhesive containing bioactive glass applied according to the manufacturer's instructions and cured for 20 seconds and then resin composite restoration containing bioactive glass applied by golden plated composite applicator in increments 2 mm each and cured for 40 seconds for each increment.
62440731|NCT03782857|NO_INTERVENTION|Control group|Participants had the usual treatment: all patients were invited to one visit in the outpatient clinic three months after discharge with a diagnosis of stroke/TIA
62440732|NCT00892827|EXPERIMENTAL|Single Arm Study|Rituximab
62440733|NCT05678621|EXPERIMENTAL|ARM A: Stop immunoglobulin (Ig) and commence prophylactic oral antibiotics|"Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg. Nb: Doxycycline 100mg daily as an alternative for participants with hypersensitivity to co-trimoxazole.~Duration: 12 months. Route: PO"
62440734|NCT05678621|EXPERIMENTAL|ARM B: Stop immunoglobulin (without prophylactic antibiotics)|"Participants will be prescribed amoxycillin/clavulanic acid 1750-2000mg/250mg and ciprofloxacin 750 mg, to keep at home for initial use if symptoms of infection develop, with immediate review by their treating clinical team, or nearest emergency department or medical practitioner with phone contact to treating team if most practical.~Nb: clindamycin 600 mg is permitted as an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.~Duration: 12 months. Route: PO"
62449458|NCT03112057|EXPERIMENTAL|chemotherapy induced neuropathy|before chemotherapy, during chemotherapy, after peripheral nerve lesions were cured (30 persons). Interventions:harmonic generation microscopy
62449459|NCT03112057|EXPERIMENTAL|Polydactyly|Abandoned extra digit specimen of polydactyly(10 persons): the normal skin and nerve endings in extra digit: Interventions: harmonic generation microscopy
62831203|NCT05795036|EXPERIMENTAL|Hope Clinic|Participants will be recruited from clients admitted to the Phase III CR program at Hope Clinic. An information sheet introducing this study will be provided to clients by the assigned therapist at the Hope clinic after admission.
62831204|NCT05183360|EXPERIMENTAL|BI 706321 single dose|
62831205|NCT05183360|EXPERIMENTAL|BI 706321 multiple dose|
62831206|NCT05183360|PLACEBO_COMPARATOR|Placebo|
62831207|NCT05917197||Medical students|
62449460|NCT02210351|EXPERIMENTAL|MRI test|
62608984|NCT05654090|ACTIVE_COMPARATOR|cefoperazone sodium and sulbactam sodium (Product name:Brosym)|Single dose Brosym
62608985|NCT02444975|EXPERIMENTAL|Increased water intake+coaching program|Women in the intervention group will be asked to increase their mineral water intake of 1.5L/day
62831208|NCT05670886|EXPERIMENTAL|uterine artery ligation + carbetocin|Group (A) , study group (N=55) : patients with multiple pregnancy undergoing cesarean section underwent bilateral uterine artery ligation and received carbetocin.
62831209|NCT05670886|ACTIVE_COMPARATOR|carbetocin only|Group (B ) , control group (N=55) : patients with twin pregnancy undergoing cesarean section received carbetocin only.
62831210|NCT05373459||Health care workers without third COVID-19 booster|Health care workers received less than 3 doses of COVID-19 vaccine
62831211|NCT05373459||HCWs with third COVID-19 booster|Health care workers received at least 3 doses of COVID-19 vaccine
62608986|NCT02444975|OTHER|No intervention|No intervention
62608987|NCT05155722|EXPERIMENTAL|Single group|First Phase: dose escalation study. It was divided into three dose groups: 100mg, 300mg and 600mg. The safety, tolerance and pharmacokinetics of BAT1308 injection were explored according to the 3+3 dose increasing mode. It is expected that 12-18 cases will be included in the group. Second Phase: dose expansion study. After the completion of dose increment, 300mg tolerated doses were selected for extended research on advanced non-small cell lung cancer, advanced hepatocellular carcinoma and cervical cancer (80-130 cases), so as to provide recommended doses for subsequent clinical trials.
62831212|NCT02835287|EXPERIMENTAL|Protocol-based Integrated Care|The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by care team (trained primary care physicians, health managers, and nurses supported by diabetes specialists) and assisted by a clinical decision support systems.
62831213|NCT02835287|ACTIVE_COMPARATOR|Enhanced Control|A usual team-based care delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
62831214|NCT06498076|ACTIVE_COMPARATOR|Group E: ephedrine|Group E : parturients will received ephedrine boluses (6 mg) ; systematic bolus after the induction of spinal anesthesia and therapeutic boluses if hypotention (systolic blood pressure falls to ≤ 20% of baseline).
62831215|NCT06498076|ACTIVE_COMPARATOR|Group N: norepinephrine|Group N : patients will received norepinephrine boluses (8 µg) ; prophylactic bolus immediately after spinal anesthesia induction and therapeutic boluses when systolic blood pressure falls to ≤ 20% of baseline
62831216|NCT03963817||Normals|Imaging normal subjects for equipment refinement
62831217|NCT03963817||Subjects with AMD|Imaging subjects with AMD
62831218|NCT00445042|EXPERIMENTAL|A|Intrapatient dose escalation study of sorafenib
62831219|NCT05318586|EXPERIMENTAL|Individualized rTMS based on fNIRS|Low-frequency rTMS will be given to the most active brain regions assessed by fNIRS.
62831220|NCT05318586|ACTIVE_COMPARATOR|Traditional rTMS strategy|The control group will always be given low-frequency rTMS to contralesional M1
62048519|NCT04274920|ACTIVE_COMPARATOR|Light cured calcium hydroxide|18 teeth were capped indirectly with light cured calcium hydroxide (control group) applied according to the manufacturer's instructions by calcium hydroxide applicator and light cured for 20 seconds then resin composite restoration was applied by golden plated composite applicator in increments 2 mm each and cured for 40 seconds for each increment.
62449461|NCT01621464|PLACEBO_COMPARATOR|Control|Pacemaker implanted but NO pacing (mode DDI, 30 bpm and sub-threshold)
62449462|NCT01621464|EXPERIMENTAL|CLS group|pacemaker implanted programmed with the contractility sensor activated (mode DDD-CLS)
62449463|NCT05840809||Participants|"Women who require first-line treatment for drug-sensitive tuberculosis whilst breastfeeding and their babies.~This regimen consists of rifampicin, isoniazid, ethambutol and pyrazinamide for 2 months (intensive phase) followed by a further four months of rifampicin and isoniazid (continuation phase)"
62608988|NCT02379273|EXPERIMENTAL|Hybrid L24 pivotal study subjects|Subjects implanted with the Nucleus Hybrid L24 Implant as part of the pivotal IDE study and who still have the device implanted will continue to be followed for 5 years post activation
62831221|NCT03238378|EXPERIMENTAL|Therapy|Brachytherapy d1-5(6) Hyperthermia d2 + 5
62831222|NCT00669734|EXPERIMENTAL|Treatment (vaccine therapy, sargramostim)|Patients receive falimarev vaccine intratumorally using endoscopic ultrasound guidance on day 1. Patients also receive inalimarev vaccine SC on day 1 and sargramostim SC on days 1-4. Patients then receive falimarev vaccine SC on days 15 and 29 and sargramostim SC on days 15-18 and 29-32 in the absence of unacceptable toxicity. Beginning on day 43, patients with stable or improving pancreatic cancer receive falimarev vaccine SC and sargramostim SC (given on the day of and for 3 days after each falimarev vaccination) monthly in the absence of disease progression or unacceptable toxicity. Beginning on day 71, patients with no irreversible or dose limiting toxicity, receive falimarev vaccine SC and sargramostim SC (given on the day of and for 3 days after each falimarev vaccination) monthly in the absence of disease progression or unacceptable toxicity.
62831223|NCT06061926|EXPERIMENTAL|Celery seed|14 patients to receive homologated intervention capsule (celery seed 150 mg) one capsule with 75 mg of celery seed, every 12 hours (before breakfast and before dinner) along 12 weeks.
62831224|NCT06061926|PLACEBO_COMPARATOR|Placebo|14 patients to receive homologated placebo capsule (calcinated magnesia) one capsule with calcinated magnesia, every 12 hours (before breakfast and before dinner) along 12 weeks.
62831225|NCT01184963|OTHER|Controls|Women in reproductive age regular ovulatory cycles
62831226|NCT01184963|OTHER|PCOS patients|Patients with anovulatory cycles, hyperandrogenism with or without polycystic ovarian appearance
62608989|NCT01076751||CRPC patients|
62608990|NCT00901784|EXPERIMENTAL|1|25 mg Topiramate tablets of Ranbaxy Laboratories, Ltd
62608991|NCT00901784|ACTIVE_COMPARATOR|2|(Topamax®) 25 mg Topiramate tablets of Ortho-McNeil Pharmaceutical, Inc. New jersey 08869
62623518|NCT06336811|EXPERIMENTAL|passive virtual reality|It was said that he could watch videos by wearing virtual headset glasses during the procedure. A virtual reality application that will attract the attention of children was determined by the researchers.
62250718|NCT03482557|EXPERIMENTAL|CESM VS MRI|"Each enrolled participant will receive both a CESM and MRI exam prior to the breast biopsy, if they had not been performed already as part of clinical care.~MRI: Breast MRI will be performed, if not already performed as part of clinical care.~CESM: After the MRI is complete, patients will be brought to the mammography department for the contrast enhanced mammogram. The CESM will only occur if not already performed as part of the patient's clinical care.~Biopsy: Patients will then have their biopsy. Any additional findings seen on the CESM or MRI will be worked up also.~Reader Study: The CESM and the MRI images will be included in a case set that is ready by 10 study radiologists at a later date, after the biopsy is performed. These radiologists will look at the images to see if CESM and MRI find the same number of breast cancers."
62608992|NCT05541900|ACTIVE_COMPARATOR|TEC-Sacredness|Active condition of the intervention. For the active intervention group, the three match types are as follows: (1) a self-related word paired with a life-related stimulus; (2) a sacredness of life-related stimulus paired with a pleasant stimulus; and (3) a neutral stimulus paired with a neutral stimulus.
62608993|NCT05541900|PLACEBO_COMPARATOR|TEC-Control|Control condition of the intervention. The control paradigm maintains the same parameters, however, all three match pairings will be neutral.
62608994|NCT04746261|EXPERIMENTAL|ASSIP plus treatment as usual|ASSIP according to manual. Treatment as usual will be multidisciplinary and combine psychotherapy, pharmacotherapy and other treatments as well as referral to specialist psychiatry or primary care as required.
62250719|NCT05508009|EXPERIMENTAL|Cohort 1b: Conditioning Regimen A|An initial cohort of 4 patients will be enrolled as part of the initial Phase 1b safety run-in evaluation. Patients will undergo an αβdepleted hematopoietic stem cell transplant (HSCT) after receiving conditioning regimen A (conditioning regimen type is dependent on underlying disease and not part of the experimental goals). In the presence of donor myeloid engraftment, at least 3 months post-HSCT, patients will undergo a living donor kidney transplant (KT) using same donor as HSCT. In the absence of any clinical signs of kidney rejection, pharmacological immunosuppression (used for KT) will be tapered off by Day +90 post-KT.
62250720|NCT05508009|EXPERIMENTAL|Cohort 2a: Conditioning Regimen A|If the intervention is determined to be safe and non-futile, the study will continue to enroll eight more patients under Phase 2a following the same treatment as Phase 1b.
62250721|NCT05508009|EXPERIMENTAL|Cohort 1b: Conditioning Regimen B|An initial cohort of 4 patients will be enrolled as part of the initial Phase 1b safety run-in evaluation. Patients will undergo an αβdepleted hematopoietic stem cell transplant (HSCT) after receiving conditioning regimen B (conditioning regimen type is dependent on underlying disease and not part of the experimental goals). In the presence of donor myeloid engraftment, at least 3 months post-HSCT, patients will undergo a living donor kidney transplant (KT) using same donor as HSCT. In the absence of any clinical signs of kidney rejection, pharmacological immunosuppression (used for KT) will be tapered off by Day +90 post-KT.
62440735|NCT05678621|ACTIVE_COMPARATOR|ARM C: Continue immunoglobulin|"Participants will continue treatment with their current Ig replacement schedule. Participants will receive either Intravenous Ig (IVIg) or Subcutaneous Ig (SCIg)~* IVIg: Participants will be treated in accordance with the Criteria for Clinical Use of Immunoglobulin in Australia. Monthly (every 4 weeks ± 1 week) dose of 0.4g/kg, modified to achieve an Immunoglobulin G (IgG) trough level of at least lower limit of age-specific serum IgG reference range. In the first month of therapy, if IgG \<4g/L then an additional (loading) dose of 0.4g/kg may be given at the clinician's discretion.~* SCIg: Subcutaneous immunoglobulin weekly may be used in patients who meet local criteria for home based self-administration in centres with established SCIg programs. A loading IVIg dose may be given in the first month if required. Thereafter, dosing at 100mg/kg/week, modified to achieve an IgG steady state level of at least the lower limit of the serum reference range.~Duration: 12 months."
62440736|NCT06436924||Subjects undergoing LAAO device implant|Watchman LAAO device implant
62440737|NCT02300025|EXPERIMENTAL|Cohort 1: Normal function|
62440738|NCT02300025|EXPERIMENTAL|Cohort 2: Mild Hepatic Impairment|
62440739|NCT02300025|EXPERIMENTAL|Cohort 3: Moderate Hepatic Impairment|
62440740|NCT02300025|EXPERIMENTAL|Cohort 4: Severe Hepatic Impairment|
62440741|NCT00653497|EXPERIMENTAL|1|Community-based aquatic exercise program (Arthritis Foundation Aquatics Program). Two classes per week, 45-60 minutes in duration.
62440742|NCT00653497|NO_INTERVENTION|2|Usual care; abstention from initiation of new exercise programs. Invited to participate in Arthritis Foundation Aquatics Program after study completion.
62440743|NCT02916381|EXPERIMENTAL|PEC block|Ultrasound-guided PEC block after induction of general anaesthesia.
62440744|NCT02916381|SHAM_COMPARATOR|Control|No ultrasound-guided PEC block; only general anaesthesia will be provided.
62440745|NCT00876278|OTHER|*AT.Smart 46LC|The \*AT.Smart 46LC is indicated for primary implantation for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the \*AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
62440746|NCT02248337|ACTIVE_COMPARATOR|4 Liter PEG|Colon preparation for colonoscopy: PEG 4 Liter before endoscopy
62440747|NCT02248337|EXPERIMENTAL|2 Liter PEG plus bisacodil|Colon preparation for colonoscopy: PEG 2 L before endoscopy
62608995|NCT04746261|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual will be multidisciplinary and combine psychotherapy, pharmacotherapy and other treatments as well as referral to specialist psychiatry or primary care as required.
62608996|NCT01276691|ACTIVE_COMPARATOR|Acute, Aspirin|81 mg asprin provided 30 minutes prior to firefighting- Acute single dosage
62608997|NCT01276691|PLACEBO_COMPARATOR|Acute, Placebo|Acute single dosage of placebo provided 30 minutes prior to firefighting
62608998|NCT01276691|ACTIVE_COMPARATOR|Chronic, Aspirin|81 mg asprin provided prior to firefighting- 14 day dosage
62608999|NCT01276691|PLACEBO_COMPARATOR|Chronic, Placebo|14 day dosage of placebo provided prior to firefighting
62609000|NCT05136534|EXPERIMENTAL|group A|subarachnoid anesthesia wit hyperbaric prilocaine
62609001|NCT05136534|ACTIVE_COMPARATOR|group B|local anesthesia + mild sedation
62440748|NCT04183790|EXPERIMENTAL|Triple Combination Arm|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
62048520|NCT06174584|ACTIVE_COMPARATOR|Cow Milk|Cow Milk was injected as sclerosing agent in one group
62831227|NCT05969496|EXPERIMENTAL|Combination Pembrolizumab and Axitinib|Neoadjuvant therapy with the combination of Pembrolizumab and Axitinib will be given for eligible RCC patients with an IVC TT for a total of 12 weeks. Patients will then undergo imaging with a contrast enhanced, diffusion weighted imaging MRI of the abdomen to evaluate the IVC TT response. A CT chest will also be done to ensure there is no progression of disease. Patients can undergo definitive surgery per treating Urologist within 2 weeks (+/- 7 days) after end of treatment scan.
62609002|NCT02938234|EXPERIMENTAL|Single-arm study|High caloric, high protein ONS, single dose of 400 kcal/day for 7 consecutive days, oral administration
62048521|NCT06174584|ACTIVE_COMPARATOR|15% Hypertonic Saline|Hypertonic Saline 15% used as sclerosing agent in other half.
62048522|NCT05228899|EXPERIMENTAL|Group 1: Zofin|Group 1 (15 subjects) Fifteen subjects will receive 1 mL of Zofin diluted with 100ml of sterile saline on day 0, day 4 and day 8, containing 2-5 x 10\^11 particles/ml intravenously.
62048523|NCT05228899|PLACEBO_COMPARATOR|Group 2: Placebo|Group 2 (15 subjects) Fifteen subjects will receive 1mL of placebo diluted with 100ml of sterile saline on day 0, day 4 and day 8, containing sterile saline intravenously.
62048524|NCT05164575|EXPERIMENTAL|eRP-LOw Intensity (eRP-LO)|an 8-week intervention that includes FOUR virtual visits with a physiotherapist
62048525|NCT05164575|EXPERIMENTAL|eRP-HIgh Intensity (eRP-HI)|an 8-week intervention that includes EIGHT virtual visits with a physiotherapist
62048526|NCT00430248|EXPERIMENTAL|Febuxostat 40 mg QD|
62048527|NCT00430248|EXPERIMENTAL|Febuxostat 80 mg QD|
62048528|NCT00430248|ACTIVE_COMPARATOR|Allopurinol 200 mg or 300 mg QD|(dependent on renal function)
62048529|NCT02487810|EXPERIMENTAL|Intuitive|Patients in each arm will be asked all of the same questions. The only difference between the arms will be the instructions regarding how and when to answer the series of hypothetical questions regarding medical interventions. The instructions will be designed to influence patients to think either intuitively or deliberatively about the questions regarding life-sustaining interventions.
62250722|NCT05508009|EXPERIMENTAL|Cohort 2a: Conditioning Regimen B|If the intervention is determined to be safe and non-futile, the study will continue to enroll eight more patients under Phase 2a following the same treatment as Phase 1b.
62250723|NCT03537859|EXPERIMENTAL|Augmented Reality (AR)|Books with augmented reality plus an electronic tablet.
62250724|NCT03537859|OTHER|Non Augmented Reality (NoAR)|Conventional children book. No electronic device will be given to children.
62250725|NCT06144775||Children with autism spectrum condition|Thirty ASC children with medium-high functioning, aged 7 to 13 years, IQ \> 80, in the absence of motor deficits due to another clinical condition.
62250726|NCT06144775||Children with typical development|Thirty TD children, aged 7 to 13 years, IQ \> 80, in the absence of motor deficits due to clinical condition.
62831228|NCT03959514|EXPERIMENTAL|AT247|Single subcutaneous injection 0.3 U/Kg
62250727|NCT04722120|ACTIVE_COMPARATOR|Conventional liver CT|Underwent conventional liver CT on HCC high-risk patient
62250728|NCT04722120|EXPERIMENTAL|Double low dose CT|Underwent double low dose liver CT with 30% lower radiation dose and 20% contrast media on HCC high-risk patient
62831229|NCT03959514|ACTIVE_COMPARATOR|NovoRapid|Single subcutaneous injection 0.3 U/Kg
62831230|NCT03959514|ACTIVE_COMPARATOR|Fiasp|Single subcutaneous injection 0.3 U/Kg
62048530|NCT02487810|EXPERIMENTAL|Deliberative|Patients in each arm will be asked all of the same questions. The only difference between the arms will be the instructions regarding how and when to answer the series of hypothetical questions regarding medical interventions. The instructions will be designed to influence patients to think either intuitively or deliberatively about the questions regarding life-sustaining interventions.
62048531|NCT04492579|EXPERIMENTAL|Supplementation of Gentle-UHT donor milk|Supplementation of Gentle-UHT donor milk in addition to mother's own milk, as recommended by the health care providers.
62048532|NCT04425005|NO_INTERVENTION|Control group|
62048533|NCT04425005|EXPERIMENTAL|Exercise training group|
62250729|NCT01735279|PLACEBO_COMPARATOR|Placebo|The placebo group will receive 3g per day of mineral oil during 90 days treatment
62250730|NCT01735279|EXPERIMENTAL|Omega3|The omega 3 group will receive 3g per day of fish oil during 90 days treatment
62250731|NCT00959998|ACTIVE_COMPARATOR|Relaxation acupressure|
62250732|NCT00959998|EXPERIMENTAL|High Intensity Stimulating Acupressure|
62250733|NCT00959998|EXPERIMENTAL|Low Intensity Stimulating Acupressure|
62250734|NCT00021151|EXPERIMENTAL|Alemtuzumab|
62250735|NCT01689675|EXPERIMENTAL|Computer based pain management|The computer-based self-management program (CBSM) intervention will be administered over 8 sessions during the average 4 week period patients are receiving their standard on-site rehabilitation care. Patients will come to the center to receive their standard care and then interact with the computer for the 25-30 minute CBSM intervention. The primary goals of treatment include developing skills for managing acute injury and related pain including: reducing fear avoidance beliefs and catastrophizing, improving mood, increasing perceptions of control and self-efficacy, maintaining activity and reducing pain. Skills are presented and modeled by computer-based video during sessions, audio will be used to explain models and teach skills such as relaxation training.
62250736|NCT01689675|ACTIVE_COMPARATOR|Education control|The computer exposure will be administered over 8 sessions during the average 4-week period patients are receiving their standard on-site rehabilitation care. Patients will come to the center to receive their standard care and then interact with the computer for the 25-30 minute control condition. The primary goal of this condition is to provide a control for computer exposure. Briefly, the first session will concentrate on establishing the patient's ability to interact with the computer. The materials will provide general education regarding the injury and methods for preventing re-injury. This condition will not provide teaching and practice of specific pain management and coping management skills. This control computer education activity will equalize the computer exposure of the two groups and the duration of time devoted to injury care.
62250737|NCT05586048||Exposed group|patients who received YQFM
62609003|NCT03172364|EXPERIMENTAL|Test product 1|All the participants in this arm will receive test product 1 (micellar cleanser) at home twice a day (morning and evening) for 21 (±2) days.
62831231|NCT05367466||Newborn with thrombossis|All admitted newborns in NICU during the study period
62831232|NCT05893784|EXPERIMENTAL|END|Use of progressive relaxation exercises education
62250738|NCT05586048||Non-exposed group|patients who didn't receive YQFM
62250739|NCT01961206||Case Patients|Case Patients with Community-Onset Bacteremia Due toESBL producing E.coli or K.pneumoniae
62250740|NCT01961206||control group|bacteremia caused by ESBL producing E.coli or K.pneumoniae
62609004|NCT03172364|EXPERIMENTAL|Test product 2|All the participants in this arm will receive test product 2 (micellar foaming cleanser) at home twice a day (morning and evening) for 21 (±2) days.
62831233|NCT05893784|NO_INTERVENTION|END free|patient witout of progressive relaxation exercises education
62449464|NCT00748293|NO_INTERVENTION|A|PEG-ELS 2000 ml ingestion in the morning of colonoscopy
62623519|NCT01393418||Subjects undergoing cardiac surgery|
62831234|NCT02939911||Paediatric patients after NMBA administration|Paediatric patients undergoing surgery with neuromuscular blockade
62831235|NCT06071247|EXPERIMENTAL|Use 3D printed models group|This group will use 3D printed models for preoperative simulation planning and then undergo surgery
62831236|NCT06071247|NO_INTERVENTION|Not use 3D printed models group|This group will undergo surgery directly without using 3D printed models.
62831237|NCT05940220|ACTIVE_COMPARATOR|acetazolamid|We will administer injectable and oral furosemide in infusion ward based on the dosage determined by the specialist on day zero. After that, we continue oral furosemide administration for three days. The prescribed dose of injectable and oral furosemide is determined by the specialist based on previous visits and hospitalizations in such a way that the patient has the least symptoms. The intervention group will receive acetazolamide 500 mg on day zero, then 250 mg bd for two days and 250 mg on the third day. The control group will receive placebo equivalent to acetazolamide.
62048534|NCT02609165|ACTIVE_COMPARATOR|study group|rhNGF 180 µg/ml eye drops solution
62048535|NCT02609165|PLACEBO_COMPARATOR|control group|vehicle eye drops solution
62048536|NCT02709668|PLACEBO_COMPARATOR|placebo|gel cap with placebo
62048537|NCT02709668|EXPERIMENTAL|enlyte|gel cap of B vitamins brand Enlyte
62048538|NCT02483897|EXPERIMENTAL|Tetracaine 0.5% ophthalmic drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
62048539|NCT02483897|PLACEBO_COMPARATOR|placebo (Normal Saline placebo drops)|0.8 mls. drops provided to be used hourly p.r.n. for pain control
62048540|NCT06181110|EXPERIMENTAL|TranS-C Group|TranS-C is a personalized, non-pharmacological transdiagnostic intervention that addresses psychosocial, behavioural, and cognitive contributors to sleep and circadian dysfunction. It references the sleep health framework and integrates evidence-based elements, including CBT for insomnia, interpersonal and social rhythm therapy (IPSRT), chronotherapy, and motivation enhancement.
62048541|NCT06181110|NO_INTERVENTION|Care-As-Usual Group|The participants in this group will not receive the TranS-C treatment but will have access to usual care based on their needs and preferences, including but not limited to pharmacological interventions, psychological interventions, and complementary and alternative medicine. A treatment tracking log will be used to monitor the care the participants receive during the study period. The CAU group will receive self-help TranS-C materials after completing all of the assessments. We will monitor the participants' weekly depression severity using PHQ-9 and refer those who have serious suicidal risk to the PI for further assessment and professional mental health services if deemed necessary.
62250741|NCT05439161|ACTIVE_COMPARATOR|XEN Glaucoma Gel Microstent (AbbVie) Device|Implantation of XEN Glaucoma Gel Microstent (Device, AbbVie) for the treatment of glaucoma will be performed in this arm. It is a newer filtering glaucoma surgery. XEN Glaucoma Gel Microstent implantation accounts to the filtering glaucoma surgeries.
62440749|NCT04832074|EXPERIMENTAL|Dry Needling|"Dry needling will be performed with 'solid filiform needles'. The procedure is as follows: The participant will lie in the prone position. The overlying skin will be cleaned with antiseptic spray. The taut band and MTrP, will be localized manually.~After measuring the Pain Pressure Thresholds in this location and the control (located 3 cm lateral to the MTrP), the needle within its plastic guide tube will be placed over the MTrP. After a tapping movement to insert the needle, the needle will be moved to the muscle around the bundle and moved forward and backward to the tissue to elicit a small muscle twitch. After eliciting LTR, needling will be stopped. If no twitch were elicited, needling will stopped after two or three stellate movements"
62449465|NCT00748293|OTHER|B|Low-reside diet on previous day (breakfast, lunch and dinner), PEG-ELS 1500 mL in the morning of colonoscopy
62449466|NCT02939274|OTHER|Open Label|Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin
62048542|NCT05673239|EXPERIMENTAL|Test group|The patients in the test group were injected with levocarnitine on each dialysis day, and other conventional treatment drugs such as hemodialysis drugs were maintained in the original scheme and recorded in detail on the CRF form.
62048543|NCT05673239|NO_INTERVENTION|Control group|The patients in the control group were the same as those in the test group, except that they were not treated with L-carnitine.
62048544|NCT03382964|ACTIVE_COMPARATOR|VLA1553 low dose|VLA1553 with 3.2x10\^3 TCID50/ 100 µL (microliter). Re-vaccination at Month 12 with VLA1553 with 3.2x10\^5 TCID50/ 1 mL (milliliter)
62048545|NCT03382964|ACTIVE_COMPARATOR|VLA1553 medium dose|VLA1553 with 3.2x10\^4 TCID50/ 1 mL Re-vaccination at Month 12 with VLA1553 with 3.2x10\^5 TCID50/ 1 mL
62048546|NCT03382964|ACTIVE_COMPARATOR|VLA1553 high dose|VLA1553 with 3.2x10\^5 TCID50/ 1 mL Re-vaccination at Month 6 or Month 12 with VLA1553 with 3.2x10\^5 TCID50/ 1 mL
62048547|NCT03788538|NO_INTERVENTION|group 1 with no dexmedetomidine|
62048548|NCT03788538|EXPERIMENTAL|group 2 with dexmedetomidine 0.25μg/kg/h|
62048549|NCT03788538|EXPERIMENTAL|group 2 with dexmedetomidine 0.5μg/kg/h|
62048550|NCT01000168|EXPERIMENTAL|Treadmill therapy|"Patients assigned to the Treadmill therapy group received daily 30 minutes specific walking training on treadmill with body weight support alternatively overground, and 30 minutes functional training, treated by a physiotherapist."
62609005|NCT00772005|ACTIVE_COMPARATOR|150 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
62048551|NCT01000168|ACTIVE_COMPARATOR|Conventional walking therapy|Patients assigned to the comparative conventional walking therapy group received daily 30 minutes specific traditional walking training overground and 30 minutes functional training, treated by a physiotherapist.
62048552|NCT03505281||Patients|
62250742|NCT05439161|ACTIVE_COMPARATOR|Trabeculectomy|Trabeculectomy will be performed in this arm. Trabeculecomy is the classic filtering glaucoma surgery since more than 50 years for the treatment of glaucoma (gold standard within the filtering glaucoma surgery group).
62250743|NCT05045898|EXPERIMENTAL|Control group|plantar massage
62250744|NCT05045898|EXPERIMENTAL|Intervention group|plantar massage and textured insoles
62250745|NCT04960020||ACL injuries with e-scooter trauma|
62250746|NCT05204823|EXPERIMENTAL|Experimental Product 1|Consumption of 221.24 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
62609006|NCT00772005|ACTIVE_COMPARATOR|200 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
62831238|NCT05940220|PLACEBO_COMPARATOR|placebo|Acetazolamide placebo add-on a standard therapy of iv furosemide in one day and oral furosemide during three consecutive days will be used for the comparator arm.
62831239|NCT03213691|EXPERIMENTAL|Treatment (selumetinib)|Patients receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62831240|NCT05717153|EXPERIMENTAL|Arm I (MRI, resection, DFMO, AMXT 1501)|Patients undergo magnetic resonance imaging (MRI) and surgical resection at baseline. Patients receive eflornithine PO in combination with AMXT 1501 PO on days 1-5 post-surgery. Patients also undergo CT after surgery and collection of blood on study.
62048553|NCT03505281||Healthy volunteers|
62048554|NCT03639701|EXPERIMENTAL|Open label thymidine and deoxycytidine|All patients will receive open label thymidine and deoxycytidine
62048555|NCT05012800|EXPERIMENTAL|COVID-19 Vaccines in older adults|Healthy people between the ages of 60 and 80 inoculated coronavirus vaccine on day 0 and day 21, respectively.
62250747|NCT05204823|EXPERIMENTAL|Experimental Product 2|Consumption of 282.81 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
62250748|NCT05204823|EXPERIMENTAL|Experimental Product 3|Consumption of 589,62 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
62250749|NCT05204823|EXPERIMENTAL|Experimental Product 4|Consumption of 573,39 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
62250750|NCT05204823|ACTIVE_COMPARATOR|Control product|Consumption of 25g of glucose. Subjects will take this amount only on the day of the visit that they are to consume this product.
62250751|NCT01070121||RA patients/participants|
62250752|NCT02116504|OTHER|Global population|"All included patients :~Sampling of blood"
62831241|NCT05717153|PLACEBO_COMPARATOR|Arm II (MRI, resection, placebo, DMFO, AMXT 1501)|Patients undergo magnetic MRI and surgical resection at baseline. Patients receive placebo PO on days 1 and 2 post-surgery, and then receive eflornithine PO and AMXT 1501 PO on days 3-5 post-surgery. Patients also undergo CT after surgery and collection of blood on study.
62250753|NCT04213027|ACTIVE_COMPARATOR|SSLF-CSI|native tissue repair procedure with conventional surgical instruments in Chinese apical prolapse female patients randomized to Sacrospinous ligament fixation (SSLF) .
62250754|NCT04213027|ACTIVE_COMPARATOR|ISFF-CSI|native tissue repair procedure with conventional surgical instruments in Chinese apical prolapse female patients randomized to Ischial spinous fascia fixation (ISFF)
62250755|NCT01582295|EXPERIMENTAL|Treatment Arm|Cabozantinib ( XL 184)
62048556|NCT05012800|EXPERIMENTAL|COVID-19 Vaccines in young adults|Healthy people between the ages of 20 and 59 inoculated coronavirus vaccine on day 0 and day 21, respectively.
62048557|NCT06580535||group 1 (patients)|50 patients assigned to receive treatment of bipolar disorder
62048558|NCT06580535||Group 2 recrutied blood from patients|GroupII:50 blood sample will be recruited from G1for in vitro tissue culture to study the effect of tamoxifen on the WBCs of patients
62449467|NCT02142764|EXPERIMENTAL|Multiple Sclerosis|Human Leukocyte Antigen (HLA)-A2 patients whose Multiple Sclerosis has just been diagnosed
62048559|NCT06580535||group 3 control|GroupIII:50 healthy control will be recruited (age and sex will be matched
62831242|NCT05717153|ACTIVE_COMPARATOR|Arm III (MRI, resection, DMFO, AMXT 1501)|Patients undergo magnetic MRI and surgical resection at baseline. Patients receive eflornithine PO alone on days 1 and 2 post-surgery, then receive eflornithine PO in combination with AMXT 1501 PO on days 3-5 post-surgery. Patients also undergo CT after surgery and collection of blood on study.
62831243|NCT03182049||GPA (Wegener's granulomatosis) patients|
62831244|NCT00863278|ACTIVE_COMPARATOR|Arm A|"All patients will be treated by stabilized Kligman's trio with daily application during 4 months.~After one month, the left side of the face will be treated with pulsed dye laser at the rate of 3 sessions (one every weeks).~Applications of cream will be stopped on both side of the face for the 3 days following each laser session. Final visit will be scheduled 1 month after the end of applications of stabilized Kligman's trio.~All the patients will used a sunscreen indication 50 + for the duration of the entire study.~The patient is her own witness. They compare the hemiface treated without laser and the hemiface treated with the laser."
62048560|NCT02119260|EXPERIMENTAL|Cohort 1|Eight subjects will be randomized to 1 of 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2798745 + 1 placebo dose). GSK2798745 will be administered in a liquid form (suspension or solution) in this cohort. In each treatment period, the subjects will be fasting from the prior midnight to four hours post-dose (Day 1).
62440750|NCT04832074|SHAM_COMPARATOR|Sham Dry Needling|"The same approach will be used with the exception of piercing the skin. The guide tube will press against the tissue and the sham needle will be allowed to drop against the skin. The handle will be tapped briskly but not breaking the skin. The sham needle will stay within the guide tube and will be pressed against the skin twice so as to mimic the quick in and out technique."
62440751|NCT01847313|ACTIVE_COMPARATOR|Liraglutide|Liraglutide 0.6 mg daily
62831245|NCT00863278|ACTIVE_COMPARATOR|Arm B|"All patients will be treated by stabilized Kligman's trio at the rate of application in the evening during 4 months.~After one month, the side of the right face will be treated by pulsed dye laser at the rase of 3 sessions spaced out by 3 weeks each.~Applications will be stopped in the 3 days which will follow every session by laser with blown colouring agent. The patients will be seen again 1 month after the stopping of applications of stabilized Kligman's trio~All patients will be used a sunscreen indication 50 + for the duration of study.~The patient is her own witness. They compare the cheek treated without laser and the cheek treated with the laser."
62831246|NCT03594630|ACTIVE_COMPARATOR|Group I (surgical resection)|Participants who have achieved clinical complete response undergo standard surgical resection.
62831247|NCT03594630|EXPERIMENTAL|Group II (active surveillance)|Participants who have achieved clinical complete response receive active surveillance and consolidated chemotherapy for up to 4 months in the absence of disease progression or unacceptable toxicity. Participants with incomplete response or regrowth of tumor, undergo surgical resection as in Group I.
62048561|NCT02119260|EXPERIMENTAL|Cohort 2|Twelve subjects will receive GSK2798745 in three single-dose treatment periods in a fixed sequence. The actual dose-selected will be determined based on review of emerging safety and exposure data from Cohort 1. The dosing will be done in 3 study periods for investigating bioavailability and food effects. In Period 1, subjects will be fasting from midnight to four hours post-dose and will receive GSK2798745 in a liquid form (suspension or solution). In Period 2, subjects will be fasting from midnight to four hours post-dose and will receive a capsule formulation of GSK2798745. In Period 3, subjects will receive GSK2798745 capsule following a standard high fat/high calorie meal.
62831248|NCT01198795|EXPERIMENTAL|1|Flexible-dose 10mg-20mg once-daily oral (10mg tablets) dose of escitalopram
62831249|NCT04002232|EXPERIMENTAL|CPP-ACP-NaF|Dental varnish that contains calcium phosphoprotein stabilized amorphous calcium phosphate and sodium fluoride (CPP-ACP-NaF) is applied to the teeth with orthodontic brackets on one side of the mouth immediately after the teeth have received the bracket.
62250756|NCT03712748|EXPERIMENTAL|Imaginal Exposure Session|
62250757|NCT01194583||NO NICOTINE|Well characterized group of 100 regular smokers experimenting the E-Cigarette without nicotine cartridges (NO nicotine group).
62440752|NCT01847313|NO_INTERVENTION|Control|Standard diabetes care including renin angiotensin aldosterone system inhibitor or antagonist
62440753|NCT01653574|EXPERIMENTAL|Famitinib Malate|Famitinib 25mg/d
62831250|NCT04002232|PLACEBO_COMPARATOR|Placebo|Dental varnish base that does not contain calcium phosphoprotein stabilized amorphous calcium phosphate and sodium fluoride (CPP-ACP-NaF) is applied to the teeth with orthodontic brackets on one side of the mouth immediately after the teeth have received the bracket.
62623520|NCT03478085|ACTIVE_COMPARATOR|Traditional exercise therapy|Training will be performed three times a week for 12 weeks. Each session will take place on a GaitKeeper treadmill (Sammons Preston, IL) treadmill and will last 45 minutes with a 5 minute warm up and cool down of either cycling or walking.
62609007|NCT00772005|ACTIVE_COMPARATOR|250 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
62609008|NCT00772005|PLACEBO_COMPARATOR|Matching Placebo|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
62250758|NCT06405711|EXPERIMENTAL|Test group A (strong higher-order aberrations group)|Simultaneous myopic defocus and strong higher-order aberrations lenses
62048562|NCT02119260|EXPERIMENTAL|Cohort 3|Sixteen subjects will be randomized to 2 repeat dose cohorts with 8 subjects in each cohort in a ratio of 6:2 (treatments: placebo). Food intake timing will be determined based on data from Cohorts 1 and 2 (if Cohort 2 is conducted before Cohort 3). Doses will be administered once daily from Day 1 through Day14. Based on data from Cohort 1, the second dose in the repeat-dose period may be skipped to estimate the time invariance in PK. Dosing may be altered to twice daily based on the results obtained in the initial study cohort. Subjects will be fasted from midnight to 4 hours after dosing on Day 1 and Day 14 that entail serial PK sampling. Meal timings on other days will be based on previous cohort data.
62048563|NCT02119260|EXPERIMENTAL|Cohort 4|Eighteen stable HF subjects will be randomized in this cohort with a treatment:placebo ratio of 1:1. If required, an additional number of subjects (up to 24 total) will be randomized. An additional separate dose group of approximately 18 to 24 subjects may be randomized to GSK2798745 or placebo to gain additional safety, tolerability,pharmacokinetic and pharmacodynamic information, if needed. The subjects will receive GSK2798745 in a single dose (at least the first 6 subjects) followed by a 7 -days repeat dose. Based on data from the cohorts 1, 2 and 3, the dose will be 2.4 mg (initial) in the first group utilizing the capsule formulation administered with or without food.
62250759|NCT06405711|EXPERIMENTAL|Test group B (medium higher-order aberrations group)|Both myopic defocus and medium higher-order aberrations lenses
62250760|NCT06405711|ACTIVE_COMPARATOR|control groups（HOYA MiYOSMART）|HOYA MiYOSMART lenses
62250761|NCT00504907|EXPERIMENTAL|Cohort A|Placebo or BTA9881 -10mg
62250762|NCT00504907|EXPERIMENTAL|Cohort B|Placebo or BTA9881 - 10mg
62831251|NCT01446055|EXPERIMENTAL|ResQ process group|Autologous BM-MNC is enriched with ResQ process(an automatic cell separator). Then the cell product is transplanted into the ischemia limbs of a patient.
62250763|NCT00504907|EXPERIMENTAL|Cohort C|Placebo or BTA9881 - 25mg
62250764|NCT00504907|EXPERIMENTAL|Cohort D|Placebo or BTA9881 - 50mg
62250765|NCT00504907|EXPERIMENTAL|Cohort E|Placebo or BTA9881 - 100mg
62250766|NCT00504907|EXPERIMENTAL|Cohort F|Placebo or BTA9881 - 200mg
62250767|NCT00504907|EXPERIMENTAL|Cohort G|Placebo or BTA9881 - 400mg
62250768|NCT06216184||CRI|Patients with suspected catheter-related infection (CRI) and with one central venous catheter for at least 7 days were included. The area under the curve (AUC) of the Maki technique, the vortexing technique and the combination of both techniques for the diagnosis of catheter tip colonization (CTC) and diagnosis of catheter-related bloodstream infection (CRBSI) were compared.
62250769|NCT03083847|EXPERIMENTAL|Pilot (1a): 1 injection of 5x10^4 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 5x10\^4 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
62250770|NCT03083847|EXPERIMENTAL|Pilot (1b):1 injection of 1x10^5 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 1x10\^5 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
62250771|NCT03083847|EXPERIMENTAL|Pilot (1d):1 injection of 2x10^5 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 2x10\^5 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
62250772|NCT03083847|EXPERIMENTAL|Pilot (5a): 1 injection of 1x10^5 PfSPZ Challenge+chloroquine|Pilot Phase - 1 injection of 1x10\^5 sporozoites of PfSPZ Challenge (NF54) with 1000mg of chloroquine (loading dose) 2 days prior to injections and 500mg (maintenance dose) 5 days post injection
62250773|NCT03083847|EXPERIMENTAL|Pilot (5b): 1 injection of 2x10^5 PfSPZ Challenge+chloroquine|Pilot Phase - 1 injection of 2x10\^5 sporozoites of PfSPZ Challenge (NF54) with 1000mg of chloroquine (loading dose) 2 days prior to injections and 500mg (maintenance dose) 5 days post injection
62250774|NCT03083847|EXPERIMENTAL|Main (2a):3 doses of 2x10^5 PfSPZ Challenge+pyrimethamine+NF54|Main Phase - 3 monthly doses of 2x10\^5 sporozoites of PfSPZ Challenge + pyrimethamine on days 2 and 3 post injection + homologous controlled human malaria infection (CHMI) with 3.2x10\^3 PfSPZ Challenge (NF54) at 12 weeks after third injection
62250775|NCT03083847|EXPERIMENTAL|Main (2b):3 doses of 2x10^5 PfSPZ Challenge+pyrimethamine+7G8|Main Phase - 3 monthly doses of 2x10\^5 sporozoites of PfSPZ Challenge + pyrimethamine on days 2 and 3 post injection + heterologous CHMI with 3.2x10\^3 PfSPZ Challenge (7G8) at 12 weeks after third injection
62250776|NCT03083847|EXPERIMENTAL|Main (3):3 doses of 2x10^5 PfSPZ Challenge+chloroquine+7G8|Main Phase - 3 monthly doses of 2x10\^5 sporozoites of PfSPZ Challenge + weekly chloroquine (1000mg given 2 days prior to injections and 500mg given 5 days post injection and weekly thereafter until 5 days post third injection) + heterologous controlled human malaria infection (CHMI) with 3.2x10\^3 PfSPZ Challenge (7G8) at 12 weeks after third injection
62440754|NCT04123041|EXPERIMENTAL|Virginia Tobacco|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Virginia Tobacco ENDS, JUUL 3% Virginia Tobacco ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
62609009|NCT02832141||Group A|Group A: immediate effects: T0, Grade 3 central thoracic mobilization from posterior-to-anterior on thoracic vertebrae from T5 to T12, immediate (T1), after 2 (T2), 4 (T3), 6 (T4), 8 (T5) and 10 (T6) minutes, 1 days wash-out period; T7, a grade 3 central thoracic mobilization from anterior-to-posterior on all thoracic vertebrae, immediate T8, after 2 (T9), 4 (T10), 6 (T11), 8 (T12) and 10 (T13) minutes.
62609010|NCT02832141||Group B|Group B: immediate effects: T0, 3 central thoracic mobilization from anterior-to-posterior on thoracic vertebrae from T5 to T12, immediate (T1), after 2 (T2), 4 (T3), 6 (T4), 8 (T5) and 10 (T6) minutes, 1 days wash-out period; T7, a grade 3-4 central thoracic mobilization from posterior-to-anterior on all thoracic vertebrae, immediate T8, after 2 (T9), 4 (T10), 6 (T11), 8 (T12) and 10 (T13) minutes.
62609011|NCT06241924|EXPERIMENTAL|Epilepsy|
62831252|NCT01446055|ACTIVE_COMPARATOR|Ficoll-based conventional method|A conventional method based on Ficoll cell separation is used to process bone marrow.
62831253|NCT01322945||Endonasal surgery|Single cohort of patients undergoing endonasal surgery
62831254|NCT02900378|EXPERIMENTAL|LCZ696 (Sacubitril/Valsartan)|After randomization, patients in this arm received LCZ696 (Sacubitril/Valsartan) twice daily and matching placebo of Enalapril depending on the patient's previous ACEI/ARB dose (enalapril equivalent dose) for 2 weeks. Patients could start study medication at dose level 1 (24 mg/26 mg LCZ), 2 (49 mg/51 mg LCZ) or 2a (49 mg/51 mg LCZ) or matching placebo bid. After 2 weeks (visit 3) the doses were up-titrated: patients, who started on dose level 2 or 2a received the target dose of study medication (level 3) at this point. After another 2 weeks (visit 4) all patients were to achieve the target dose of 97 mg/103 mg bid LCZ696(sacubitril/valsartan) and matching placebo, provided no safety and tolerability issues arised during uptitration.
62831255|NCT02900378|ACTIVE_COMPARATOR|Enalapril|After randomization, patients in this arm received Enalapril twice daily and matching placebo of LCZ696 (Sacubitril/Valsartan) depending on the patient's previous ACEI/ARB for 2 weeks. Patients could start study medication at dose level 1 or 2a or matching placebo bid. After 2 weeks (visit 3) the doses were up-titrated: patients, who started on dose level 2 or 2a received the target dose of study medication (level 3) at this point. After another 2 weeks (visit 4) all patients were to achieve the target dose of 10 mg bid enalapril and matching placebo, provided no safety and tolerability issues arised during uptitration
62831256|NCT03251495|EXPERIMENTAL|Vaxchora Vaccination|Healthy participants will receive a single dose of oral live cholera vaccine.
62831257|NCT06654453|EXPERIMENTAL|Thrombectomy + PCI Arm|This group will receive thrombectomy combined with percutaneous coronary intervention.
62831258|NCT06654453|ACTIVE_COMPARATOR|PCI-only Arm|PCI is an established treatment for STEMI, and you are comparing it to the experimental group that receives an additional thrombectomy procedure.
62831259|NCT03694353|EXPERIMENTAL|Pegvaliase|Beginning on Day 1, subjects will receive the same dose and regimen of pegvaliase they were receiving in 165-302 or PAL-003 (pegvaliase dosing should continue without interruption from the previous study). Subsequent revisions to dosing regimens are allowed following consultation with the medical monitor.
62831260|NCT04551547|EXPERIMENTAL|Experimental Vaccine-low dosage|low dosage inactivated SARS-CoV-2 vaccine
62831261|NCT04551547|EXPERIMENTAL|Experimental Vaccine-medium dosage|medium dosage inactivated SARS-CoV-2 vaccine
62831262|NCT04551547|PLACEBO_COMPARATOR|Placebo|No active ingredient in the placebo
62831263|NCT06053502||Masked condition|Participants who underwent the graded exercise test with the respirator.
62831264|NCT06053502||Unmasked condition|Participants who underwent the graded exercise test without the respirator.
62831265|NCT03779295|EXPERIMENTAL|Pulse laser therapy|Pulse laser therapy will be randomly applied to right side or left side of face in addition to Clindamycin
62831266|NCT03779295|EXPERIMENTAL|Clindamycin|Clindamycin only applied to side of face that does not receive pulse laser therapy.
62831267|NCT05816889||Patients|"Upper extremity exercise capacity (6 minutes pegboard and ring test), muscle oxygenation (moxy monitor), functional exercise capacity(6 minutes walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), respiratory muscle endurance (incremental threshold loading test), peripheral muscle strength (dynamometer), physical activity level (multi-sensor activity monitor) and fatigue (Parkinson's fatigue scale) will be evaluated."
62831268|NCT05816889||Healthy Controls|"Upper extremity exercise capacity (6 minutes pegboard and ring test), muscle oxygenation (moxy monitor), functional exercise capacity(6 minutes walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), respiratory muscle endurance (incremental threshold loading test), peripheral muscle strength (dynamometer), physical activity level (multi-sensor activity monitor) and fatigue (Parkinson's fatigue scale) will be evaluated."
62831269|NCT01419964|EXPERIMENTAL|Group 01|ACH24
62831270|NCT01419964|PLACEBO_COMPARATOR|Group 02|Placebo
62831271|NCT05935124|OTHER|First withdrawal - White light endoscopy|white light (WLE) high definition colonoscope (Olympus 190 series) first and then B-NBI
62831272|NCT05935124|OTHER|First withdrawal - Bright Narrow Band Imagin|B-NBI first and then WLE with the same colonoscope.
62831273|NCT04226599|EXPERIMENTAL|Dissolve AVF Group|This group treated with Peripheral scoring drug balloon.Dissolve AVF
62831274|NCT04226599|ACTIVE_COMPARATOR|PTA Group|This group treated with plain balloon catheter.Armada 35
62048564|NCT02119260|EXPERIMENTAL|Cohort 5|Eight HF subjects will be randomized in this cohort with a treatment: placebo ratio of 3:1. This cohort will evaluate safety, pharmacokinetics, and lung permeability (DLco and DLno) in a boarder, more general population of patients with HF, NYHA Class II or III. Subjects will receive GSK2798745 or placebo (based on randomization) for 7 days. The dose will be 2.4 mg utilizing the capsule formulation administered with or without food. Subjects will remain in house from Day -1 until Day 4 and be fitted with a remote monitoring device; Day 5, 6 and 8 visits will be in home (on Days 5 and 6, they will receive study medication, collect samples for pharmacokinetic analysis, and assess vital signs); and subjects will return to the clinic for Day 7 visit.
62048565|NCT02278068|EXPERIMENTAL|Metabolic Neuromodulation System (MNS)|Hepatic sympathetic denervation therapy to aid in glycemic control
62048566|NCT01925833|EXPERIMENTAL|Both insertion and withdrawal|
62440755|NCT04123041|EXPERIMENTAL|Mint|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Mint ENDS, JUUL 3% Mint ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
62609012|NCT06241924|EXPERIMENTAL|parkinson disease|
62609013|NCT01578954|EXPERIMENTAL|Drug|Lenalidomide (25, 35, or 50 mg induction/10mg maintenance)
62609014|NCT05366218|EXPERIMENTAL|Tafasitamab|All patients will receive MOR00208 over 2-3 hours i.v. MOR00208 will be administered on a bi-weekly (every fourteen days) basis with infusions on Days 1 and 15 of each 28-day cycle. Additional doses will be administered on Day 4, Day 8 and Day 22 of Cycle 1 as well as Day 8 and Day 22 of Cycle 2 and Cycle 3.
62831275|NCT05471323|EXPERIMENTAL|RC1012 injection (allo-DNT Cells)|Experimental: RC1012 injection (allo-DNT Cells) The trial is divided into two parts: Part A1 is a single- dose escalation trial with three dose groups (5×10\^7 cells/kg, 1.5×10\^8 cells/kg, 4.5×10\^8 cells/kg), with 9-18 patients planned to be enrolled. Part A2 is a multiple-dose escalation trial consisting of 2 dose groups (1.5×10\^8 cells/kg and 4.5×10\^8 cells/ kg at day 0, day 7 and day 14), with 9-12 patients planned to be enrolled. Part B is a multiple-dose extension trial in which the Safety Review Committee evaluates whether to extend an additional 3-6 patients to receive the multiple cell infusions based on available PK and safety data.
62048567|NCT01925833|ACTIVE_COMPARATOR|Only withdrawal|
62250777|NCT03083847|EXPERIMENTAL|Main Phase (4a) - Infectivity Control: NF54 (homologous) CHMI|Main Phase - Infectivity Control with one dose of 3.2x10\^3 sporozoites of PfSPZ Challenge (NF54) (homologous) controlled human malaria infection (CHMI)
62250778|NCT03083847|EXPERIMENTAL|Main Phase (4b) - Infectivity Control: 7G8 (heterologous) CHMI|Main Phase - Infectivity Control with 3.2x10\^3 sporozoites of PfSPZ Challenge 7G8 (heterologous) controlled human malaria infection (CHMI)
62250779|NCT04182633|EXPERIMENTAL|Group A - Treatment Group|This group will receive vancomycin for 14 days, then Miralax for 1 day, then intestinal microbiota for 2 days at high dose, then intestinal microbiota for 12 weeks at a maintenance dose
62440756|NCT04123041|EXPERIMENTAL|Menthol|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Menthol ENDS, JUUL 3% Menthol ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
62440757|NCT04123041|EXPERIMENTAL|Mango|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Mango ENDS, JUUL 3% Mango ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
62609015|NCT01921738|EXPERIMENTAL|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
62609016|NCT01921738|EXPERIMENTAL|Azithromycin capsule|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
62609017|NCT01921738|PLACEBO_COMPARATOR|Placebo Gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
62609018|NCT01921738|PLACEBO_COMPARATOR|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
62609019|NCT05482165|EXPERIMENTAL|Intervention group|The students of this group will receive multi-faceted intervention activities toward weight management.
62609020|NCT05482165|NO_INTERVENTION|Usual practice group|The students of this group will receive regular health education.
62609021|NCT05209711|OTHER|FN blockade under ultrasound control with a peripheral nerve stimulator 7.5 ml 1% lidocaine|Patients undergoing surgery on the shin, ankle or foot
62831276|NCT01970293|OTHER|Introduction to AA volunteer|
62048568|NCT05580848|EXPERIMENTAL|Examined group|28 patients with indication for distal radius fracture (DRF) osteosynthesis : 14 patients with extraarticular DRF and 14 patients with intraarticular DRF with associated wrist arthroscopy
62048569|NCT05580848|NO_INTERVENTION|Control group|28 patients with indication for distal radius fracture (DRF) osteosynthesis : 14 patients with extraarticular DRF and 14 patients with intraarticular DRF without associated wrist arthroscopy.
62831277|NCT01970293|NO_INTERVENTION|AA materials offered|
62831278|NCT06245343|EXPERIMENTAL|Functional inspiratory muscle training group|Patients in the training group will be performed functional inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure.
62831279|NCT06245343|SHAM_COMPARATOR|Control group|The control group will not be given any training during the study period.
62831280|NCT02485873||Rivaroxaban|Non-valvular Atrial Fibrillation (NVAF) patients who were initiated on rivaroxaban for stroke prevention
62250780|NCT04182633|PLACEBO_COMPARATOR|Group B - Control Group (Miralax only for 1 day)|This group will receive placebo vancomycin for 14 days, then Miralax for 1 day, then placebo intestinal microbiota for 2 days at high dose, then placebo intestinal microbiota for 12 weeks at a maintenance dose
62250781|NCT05304650|OTHER|iTEAR100 Therapy|Treatment Arm. Assessment of usability of generation 2 connected devices
62831281|NCT02485873||Vitamin K antagonists (VKA)|NVAF patients who were initiated on VKA (predominately phenprocoumon in Germany) for stroke prevention
62831282|NCT06598709||Mechanically ventilated adult ARDS patients|Adult mechanically ventilated patients (≥ 16 years old) expected to receive invasive mechanical ventilator for more than 48 hours
62831283|NCT06595862|EXPERIMENTAL|EA-Avatar|The avatar-guided digital intervention includes monitoring of alcohol use and common triggers suicidal thoughts, skills to manage alcohol use and suicidal thoughts, resources on how to access outpatient care and crisis hotlines for suicidal thoughts, and achievements for milestones. In addition, text messages provide reminders to access the avatar platform to learn or practice skills and provide encouragement. EA-Avatar is given in addition to emergency department care as usual.
62831284|NCT03351725||Peripheral venous catheter indwell time more than 48 hours|
62831285|NCT03354195|ACTIVE_COMPARATOR|Group 1|"Group 1 - intact ACL ligament will be accepted as functionally intact~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
62831286|NCT03354195|ACTIVE_COMPARATOR|Group 2|"Group 2 - intact but fibrillated (frayed) ligament) will be accepted as functionally intact~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
62831287|NCT03354195|ACTIVE_COMPARATOR|Group 3|"Group 3 - nearly completely torn ligament (\>50% and disrupted) will be deemed as having functionally absent ACLs~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
62831288|NCT06594679|EXPERIMENTAL|ARM 1|Niraparib+Abemaciclib
62831289|NCT03473054||Web-based Mindfulness Course|Participants will complete a 2 week baseline phase, followed by the four week web-based mindfulness course intervention phase, and a four week follow-up period.
62831290|NCT00551408||A|20 patients with idiopathic pulmonary arterial hypertension in the WHO functional class II to III, and had a mean pulmonary artery pressure \>30 mm Hg on right heart catheterization able to walk \>50 m during a standardized 6-min walk test.
62831291|NCT02336152|EXPERIMENTAL|Body suit|The patients will receive a body suit at least 30 min before start of general anaesthesia, and will keep the suit on until warm and comfortable in the post-operative unit. The suit is supplied with multiple snap openings to allow for draping, washing and surgery.
62250782|NCT04838665|ACTIVE_COMPARATOR|Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI)|20 infants were enrolled in Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI)
62250783|NCT04838665|EXPERIMENTAL|Single instillation of 0.5% tropicamide + 0.5% phenylephrine (SI)|Single instillation of 0.5% tropicamide + 0.5% phenylephrine (SI)
62831292|NCT02336152|ACTIVE_COMPARATOR|Forced warm air|The patients will receive forced warm air on their lower body when placed on operating table, ready for surgery.
62831293|NCT04744246|ACTIVE_COMPARATOR|Without Load|5 kilometer walk with no load carried
62250784|NCT04838665|EXPERIMENTAL|1 instillation of 0.5% tropicamide +0.5% phenylephrine w/a cotton wick placed in the inferior fornix|Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick placed in the inferior fornix (SIW)
62440758|NCT06144359|EXPERIMENTAL|concussed patients|"Patients will be included :~* Sports patients with concussion in sport,~* Consultation with Sports Medecine within 7 days of concussion.~* affiliated to a social security scheme."
62250785|NCT04807855|EXPERIMENTAL|the experimental arm|All subjects, the ptosis group and the normal group receive the same intervention.
62831294|NCT04744246|EXPERIMENTAL|With Load|5 kilometer walk with load
62048570|NCT00743769|ACTIVE_COMPARATOR|2|"Thymosin Beta 4~A single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD (once a day)"
62831295|NCT01203202|PLACEBO_COMPARATOR|PED 0|placebo
62831296|NCT01203202|EXPERIMENTAL|PED 1|PED-1 (clomipramine 15mg)
62831297|NCT01203202|EXPERIMENTAL|PED-2|PED-2 (Clomipramine 30mg)
62048571|NCT00743769|PLACEBO_COMPARATOR|1|Placebo A single bolus injection of 0.0 mg QD of thymosin beta 4
62440759|NCT06144359|EXPERIMENTAL|Control subjects|"* major case matched subjects by sex and age (± 5 years).~* affiliated to a social security scheme.~* written consent."
62831298|NCT00949169||Carrotid IMT group according to maximal IMT|We defined increased IMT group as whom had maximal IMT ≥ 1.0 mm.
62831299|NCT00103896||HIV Infected Youth in Treatment/Care|HIV infected youth in treatment/care will be interviewed using Audio Computer-Assisted Self-Administered Interview ACASI technology to reveal possible venues where youth at high risk for acquiring the disease may be found (N = 20-30 individuals per ATN site).
62048572|NCT00815282|OTHER|Patients|patients were girls aged 15 to 18 immunised with the HPV vaccine according to dutch vaccination guidelines
62048573|NCT00502255|EXPERIMENTAL|telemonitoring|Health Buddy in patients home situation
62048574|NCT00502255|EXPERIMENTAL|usual care|patients receive care as usual
62048575|NCT00768820|EXPERIMENTAL|1|
62609022|NCT05209711|OTHER|FN blockade under ultrasound control without a peripheral nerve stimulator 7.5 ml 1% lidocaine|Patients undergoing surgery on the shin, ankle or foot
62609023|NCT05470816|ACTIVE_COMPARATOR|Tranexamic Acid|12 mg/kg, before surgical incision, and then an infusion of 3 mg/kg/h until the end of surgery.
62048576|NCT00960180|EXPERIMENTAL|1|
62048577|NCT00960180|PLACEBO_COMPARATOR|2|
62048578|NCT00022412|PLACEBO_COMPARATOR|Observation, then prostatectomy|Arm 2: Patients undergo observation for 28 days. Patients then undergo prostatectomy.
62048579|NCT00022412|ACTIVE_COMPARATOR|Doxercalciferol once daily for 28 days|Dietary supplement once daily to treat prostate cancer for 28 days
62831300|NCT00103896||BVI Individuals|Additional data will be gathered on potential recruitment venues by administering a brief venue interview (BVI) to individuals who appear to be between 12 and 24 years old (N = unlimited individuals during 3-5 assessment periods per venue each lasting 5 hours).
62831301|NCT00103896||HIV Serosurvey Individuals|HIV Serosurvey Individuals Anonymous structured interview using ACASI technology and an anonymous HIV antibody assay will be administered to 20-30 young women at 2-3 targeted locations and 20-30 young men at 2-3 targeted locations whose HIV status is unknown (N = 160-360 individuals per ATN site)..
62048580|NCT04356833|EXPERIMENTAL|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - cohort 1|For patients in the rt-PA group, 10 mg of rt-PA dissolved in 5 ml of diluent will be given every 6 hrs for 66 hrs, in addition to standard of care for COVID-19 acute respiratory distress syndrome (ARDS). 6 patients will be receiving Invasive mechanical ventilation and another six will be receiving Non Invasive ventilation.
62048581|NCT04356833|NO_INTERVENTION|Historical matched controls - cohort 1|"Matched historical controls who received standard of care were also recruited at a ratio of 2 controls to every 1 treatment arm patient. Matching will be done according to the following criteria in the order stated:~1. Ventilation and oxygen type (IMV and non-invasive oxygen support)~2. Severity as determined by PaO2/FiO2 ratio~3. Gender~4. Age (+/- 2 years, up to a maximum of 10 years)~5. Ethnicity"
62048582|NCT04356833|EXPERIMENTAL|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - cohort 2|In cohort 2, fewer timepoints will be collected, which will allow for more rapid recruitment while at the same time not compromising safety monitoring. A more flexible dosing regimen for rtPA will be utilised. 30 patients will be recruited in total, with an aim to recruit a minimum of 10 IMV patients and 10 patients on non-invasive oxygen support.
62831302|NCT01607710||Generalized Anxiety Disorder|The group of participants diagnosed with generalized anxiety disorder.
62048583|NCT06430840|ACTIVE_COMPARATOR|Arm A: Enhanced Usual Care (EUC)|Usual care + pre-screening for financial hardship and social risks
62048584|NCT06430840|EXPERIMENTAL|Arm B: CostCOM|Usual care + two 1-hour phone or video sessions with a remote financial counselor including out-of-pocket cost communication, financial navigation and counseling.
62048585|NCT06430840|EXPERIMENTAL|Arm C: FinEd|Usual care + access to local and national resources including (1) a detailed list of local and national resources for financial navigation, and social needs where patients can self-refer and (2) video and online /printed educational materials to improve financial health literacy
62609024|NCT05470816|PLACEBO_COMPARATOR|Placebo|12 mg/kg, before surgical incision, and then an infusion of 3 mg/kg/h until the end of surgery.
62831303|NCT01607710||Nonclinical Control Group|The comparison group of participants with no psychiatric diagnoses.
62831304|NCT06346418|EXPERIMENTAL|healthy women with offspring affected by BWS|healthy women with offspring affected by BWS and peculiar reproductive history from our population of clinically and molecularly diagnosed BWS families
62831305|NCT06346418|EXPERIMENTAL|women under 35 undergoing ART|women under 35 undergoing ART for infertility (defined as failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourses) and unable to obtain a live birth after three completed cycles or after the transfer of at least 6 blastocysts
62831306|NCT06346418|EXPERIMENTAL|women under 35, with RPL|women under 35, with RPL (defined as the loss of two or more pregnancies before 24 weeks of gestation)
62831307|NCT04318873|EXPERIMENTAL|Packed Promise Demonstration Benefits|Treatment households (n=2,143) received one food box per eligible child, per month, delivered to the household, which contained (1) shelf-stable foods, including 6 protein-rich items, 2 dairy items, 4 grain foods, 4 cans of fruit, and 12 cans of vegetables; (2) a nutrition education handout (e.g., a recipe); and (3) a $15 Fresh Check for frozen or fresh fruits and vegetables that participants could redeem at any of 38 Special Supplemental Nutrition Program for Women, Infants, and Children (WIC)-authorized stores or farmers' markets in the study counties.
62048586|NCT04392505|EXPERIMENTAL|The whole study population|All patients will receive durvalumab for up to 1 months after standard treatment With chemoradiotherapy.
62048587|NCT01559454|ACTIVE_COMPARATOR|Methadone|10-60 mg/day divided by 2-4 times a day
62048588|NCT01559454|EXPERIMENTAL|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day
62048589|NCT03568266||Biospecimen Collection|Buccal swabs of prospective participants' saliva will be collected when participant achieves complete remission (during regular clinical visit) from their asparaginase treatment.
62048590|NCT06200103|ACTIVE_COMPARATOR|Arm I (177Lu-PSMA-617 standard)|Patients receive 177Lu-PSMA-617 IV over 10-15 minutes on day 1 of each cycle. Cycles repeat every 42 days for 5 cycles in the absence of disease progression or unacceptable toxicity. Patients with a near complete response may receive 1 additional cycle. Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo PET/CT and a bone scan during screening and on the trial. Patients also undergo SPECT/CT and blood sample collection on the trial.
62250786|NCT03611868|EXPERIMENTAL|APG-115+pembrolizumab open label, two-part phase Ib/II|single arm dose escalation and dose expansion
62609025|NCT00684632|EXPERIMENTAL|1|KW-2246
62609026|NCT00684632|PLACEBO_COMPARATOR|2|Placebo
62609027|NCT00847431||STN DBS Group|PD patients with deep brain stimulators in the subthalamic nucleus. Subjects within this group will be placed into either a 1 contact group, or 2 contact group, depending on contact location requirements for this study.
62048591|NCT06200103|EXPERIMENTAL|Arm II (177Lu-PSMA-617 treatment pause)|Patients receive 177Lu-PSMA-617 IV over 10-15 minutes on day 1 of each cycle. Cycles repeat every 42 days for 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo clinical observation until documented first progression. After progression, patients resume treatment with 77Lu-PSMA-617 for another cycle. Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo PET/CT and a bone scan during screening and on the trial. Patients also undergo SPECT/CT and blood sample collection on the trial.
62250787|NCT02485990|EXPERIMENTAL|Arm A: Tremelimumab Alone|25 patients will receive tremelimumab alone at 10 mg/kg IV every 4 weeks for 7 doses then every 12 weeks until disease progression.
62609028|NCT00847431||Control Group|PD patients without deep brain stimulator surgery, with similar symptoms to the study group.
62609029|NCT03368404|EXPERIMENTAL|CBL-102 eye drops|CE marked medical device, tear substitute containing 0.24% hyaluronic acid salt, carbomer and medium chain triglycerides
62831308|NCT04318873|NO_INTERVENTION|Control Group|Control households (n=2,607) did not receive the treatment benefits but still could participate in other available nutrition assistance programs.
62250788|NCT02485990|EXPERIMENTAL|Arm B1: DESE Tremelimumab and Olaparib|18 patients will receive tremelimumab (3 or 10 mg/kg IV) every 4 weeks for 7 doses then every 12 weeks and olaparib (150 or 300 mg orally twice a day) until disease progression.
62831309|NCT06497270|EXPERIMENTAL|BRCAmut patients|germinal BRCA1/2 mutated (BRCAmut) patients undergoing risk reducing salpingo-oophorectomy whose ovaries will be used to select theca and granulosa cells for the 3D bioprinted device.
62831310|NCT05414409|NO_INTERVENTION|Comparison of microbiome by BMI Category|The gut microbiome and metabolites of 42 lean and 42 obese youth with type 1 diabetes will be evaluated cross-sectionally.
62831311|NCT05414409|EXPERIMENTAL|Metformin|This is a group of 30 youth with type 1 diabetes and obesity who will receive metformin for 6 months.
62250789|NCT02485990|EXPERIMENTAL|Arm B2: Tremelimumab and Olaparib|25 patients will receive tremelimumab (every 4 weeks for 7 doses then every 12 weeks) and olaparib (daily) until disease progression. Dose of tremelimumab and olaparib will be determined during the DESE (Arm B1).
62440760|NCT02394132|EXPERIMENTAL|Imiquimod|"Topical imiquimod 5% cream~* application to treatment area for 5 days/week for a total of 12 weeks~* dispensed at baseline visit along with patient diary"
62449468|NCT02142764|OTHER|Control|HLA-A2 patients hospitalized in the neurology department who are not affected with a neuroimmunological disorder
62609030|NCT03368404|ACTIVE_COMPARATOR|Vismed Multi eye drops|CE marked medical device, tear substitute containing 0.18% sodium hyaluronate
62609031|NCT05114057|OTHER|PICU Patients|Prospectively enrolled patients admitted to the PICU will be assessed by the RAI calibration for sepsis in the PICU and including additional risk factors.
62609032|NCT05114057|OTHER|CICU Patients|Prospectively enrolled patients admitted to the CICU will be assessed by the RAI calibration specific to the CICU, especially post cardiac bypass
62609033|NCT05114057|OTHER|NICU Patients|Prospectively enrolled patients admitted to the NICU will be assessed by the RAI calibration for neonatal patients with sepsis or post abdominal surgeries
62609034|NCT02509975|EXPERIMENTAL|Prostate Artery Embolization|Transarterial administration of OCL 503 to the arteries feeding the prostate.
62609035|NCT06068283|EXPERIMENTAL|LOTUS Intervention Arm|A mobile, WebApp-based platform to access the LOTUS intervention content.
62609036|NCT06068283|ACTIVE_COMPARATOR|Informational Control Arm|An information-only website, with content on HIV transmission, PrEP, harm reduction, and resources for women.
62048592|NCT06200103|EXPERIMENTAL|Arm III (Treatment pause 177Lu-PSMA-617)|Patients undergo clinical observation until documented first progression. After progression, patients receive 177Lu-PSMA-617 IV over 10-15 minutes on day 1 of each cycle. Cycles repeat every 42 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo PET/CT and a bone scan during screening and on the trial. Patients also undergo SPECT/CT and blood sample collection on the trial.
62250790|NCT03109379|EXPERIMENTAL|TAR-302-5018 (42-day Indwelling)|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
62831312|NCT05621434|EXPERIMENTAL|Inetetamab, pyrotinib, chemotherapy|"Inetetamab: was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~pyrotinib: 400 mg once daily orally within 30 minutes after a meal at the same time each day.~chemotherapy:Taxanes (paclitaxel, docetaxel, liposomal paclitaxel, nabpaclitaxel), vinorelbine, capecitabine, eribulin, and other chemotherapeutic agents indicated in advanced breast cancer are permitted. Refer to the appropriate package insert for dosage and administration recommendations."
62250791|NCT03109379|EXPERIMENTAL|TAR-302-5018 (84-day Indwelling)|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 84. TAR-302-5018 releases trospium gradually during the 84 day indwelling time.
62831313|NCT06599541|EXPERIMENTAL|HE group|Participants with AD who are going to perform hypopressive exercises
62250792|NCT03086395|EXPERIMENTAL|Obinutuzumab|Patients will be treated with a total of 2 cycles of obinutuzumab.
62250793|NCT01309139|EXPERIMENTAL|Treatment A: Tiotropium medium dose|Oral inhalation daily for 21 days
62831314|NCT06599541|EXPERIMENTAL|Pilates group|Participants with AD who are going to perform pilates exercises.
62831315|NCT01851642||AAT Deficiency|Those diagnosed with Alpha-1 Antitrypsin (AAT) Deficiency. At every study visit, a history and physical exam (H\&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
62831316|NCT01851642||Cystic Fibrosis|Those diagnosed with Cystic Fibrosis (CF) with mutation Delta F508. At every study visit, a history and physical exam (H\&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
62831317|NCT01851642||Without Lung Disease Diagnosis|Those without the diagnosis of AAT Deficiency or CF. At every study visit, a history and physical exam (H\&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
62831318|NCT02713893|EXPERIMENTAL|Econazole nitrate 1% plus Benzydamine HCl 0.12%|5 grams of Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream, once daily for 15 consecutive days
62831319|NCT02713893|ACTIVE_COMPARATOR|Placebo plus Econazole nitrate 1%|5 grams of Placebo plus Econazole nitrate 1% intravaginal cream, once daily for 15 consecutive days
62250794|NCT01309139|EXPERIMENTAL|Treatment A: BI 54903 high dose|Oral inhalation daily for 21 days
62250795|NCT01309139|EXPERIMENTAL|Treatment B: Tiotropium medium dose|Oral inhalation daily for 21 days
62831320|NCT02713893|ACTIVE_COMPARATOR|Placebo plus Benzydamine HCl 0.12%|5 grams of Placebo plus Benzydamine HCl 0.12% intravaginal cream, once daily for 15 consecutive days.
62831321|NCT02713893|PLACEBO_COMPARATOR|Placebo|5 grams of Placebo intravaginal cream, once daily for 15 consecutive days.
62048593|NCT05334498|EXPERIMENTAL|Motor dual-task gait training|Motor dual task gait training was the protocol which performed by the patients after the measurement of the balance and gait ability
62048594|NCT05334498|EXPERIMENTAL|Cognitive dual-task gait training|Cognitive dual task gait training was the protocol which performed by the patients after the measurement of the balance and gait ability
62831322|NCT01599637|EXPERIMENTAL|IGE025|Patients will receive omalizumab administered subcutaneously every 4 weeks at the study center.
62831323|NCT01599637|PLACEBO_COMPARATOR|Placebo to IGE025|Placebo administered subcutaneously every 4 weeks at the study center.
62831324|NCT02936596|EXPERIMENTAL|Ursodeoxycholic acid + immunosuppressive agents group|Ursodeoxycholic acid + immunosuppressive agents
62831325|NCT02936596|ACTIVE_COMPARATOR|Ursodeoxycholic acid group|Ursodeoxycholic acid
62831326|NCT01271946|OTHER|Diagnostic Procedure|
62048595|NCT01786928|EXPERIMENTAL|resistance training|resistance training of the upper and lower limbs, two series of 80% of repetition maximum test
62048596|NCT01786928|NO_INTERVENTION|Control|Traditional Respiratory Therapy for bronchial hygiene
62048597|NCT02629991|EXPERIMENTAL|Intranasal Oxytocin|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
62048598|NCT02629991|PLACEBO_COMPARATOR|Matched Placebo|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
62048599|NCT04063774|EXPERIMENTAL|Dengue diagnostic algorithm|single arm of consecutive enrolled subjects with fever in whom the dengue diagnostic algorithms were applied by study physician and blood sample taken for hemogram and dengue reference tests (gold standard)
62048600|NCT05000567|NO_INTERVENTION|Control Group|No intervention.
62048601|NCT05000567|EXPERIMENTAL|Experimental Older group|12 week strength training program: Nordic Hamstring Exercise
62831327|NCT05893745|ACTIVE_COMPARATOR|Control Group|Supervised Exercise Program
62831328|NCT05893745|EXPERIMENTAL|Study Group|Combination of Exercise and Dermoneuromodulation Techniques
62831329|NCT04119414|EXPERIMENTAL|S&S + LFLS Group|300 expecting couples totaling 600 participants will be completing the S\&S program followed by the LFLS Program.
62831330|NCT06294106|EXPERIMENTAL|eTMS|The active side of a TMS coil will be used to administer eTMS application.
62831331|NCT06294106|SHAM_COMPARATOR|eTMS sham|The sham side of a TMS coil will be used to administer a sham dosage of eTMS application.
62831332|NCT05116852||Both grieving a loved one to opioid-related death and have an actively using loved one|These individuals will complete the study survey for their designated experience both supporting a loved one in treatment for Opioid Use Disorder, and having lost a loved one to opioid-related death.
62831333|NCT05116852||Individuals supporting a loved one in treatment for Opioid Use Disorder|These individuals will complete the study survey for their designated experience supporting a loved one in treatment for Opioid Use Disorder.
62831334|NCT05116852||Individuals grieving a loved one to opioid-related death|These individuals will complete the study survey for their designated experience losing a loved one to opioid-related death.
62831335|NCT01403532|ACTIVE_COMPARATOR|Traditional|
62831336|NCT01403532|EXPERIMENTAL|Sequential|
62831337|NCT01403532|EXPERIMENTAL|Sequential Plus|
62048602|NCT05000567|EXPERIMENTAL|Experimental Younger group|12 week strength training program: Nordic Hamstring Exercise
62048603|NCT02450331|EXPERIMENTAL|Atezolizumab|Participants will receive intravenous (IV) atezolizumab on Day 1 of each 21-day cycle for 16 cycles (up to 1 year).
62048604|NCT02450331|NO_INTERVENTION|Observation|Participants will undergo observation starting on Day 1 for 16 cycles (up to 1 year).
62048605|NCT03948750||Patients with Ocular Toxoplasmosis|
62048606|NCT03948750||Patients without Ocular Toxoplasmosis|
62831338|NCT05902247|EXPERIMENTAL|225Ac-PSMA I&T|225Ac-PSMA I\&T
62831339|NCT01312532|OTHER|fixed-bearing|fixed-bearing device is a kind of prosthesis
62831340|NCT01312532|OTHER|mobile-bearing|mobile-bearing device is a kind of prosthesis
62250796|NCT01309139|EXPERIMENTAL|Treatment C: BI 54903 high dose|Oral inhalation daily for 21 days
62831341|NCT05740072|EXPERIMENTAL|Drying before wrapping|Immediately after birth, the infant's body will be dried before wrapping in a plastic bag
62250797|NCT04824638|EXPERIMENTAL|Group 1: SARS-CoV-2 naive participants|participants without antecedent of SARS-CoV-2 infection
62831342|NCT05740072|ACTIVE_COMPARATOR|No drying before wrapping|Immediately after birth, the infant will be wrapped in a plastic bag without drying
62048607|NCT06495788|EXPERIMENTAL|High-intensity laser therapy group|Patients will receive pulsed high-intensity laser therapy in addition to conventional treatment
62048608|NCT06495788|PLACEBO_COMPARATOR|placebo high-intensity laser therapy group|Patients will receive placebo high-intensity laser therapy in addition to conventional treatment
62048609|NCT05654896|NO_INTERVENTION|No Antibiotic Prophylaxis Group|No antibiotic will be administered prophylactically for TACE.
62048610|NCT05654896|EXPERIMENTAL|Antibiotic Prophylaxis Group|Antibiotic will be administered prophylactically (i.e., Inj. Ceftriaxone 1g, intravenous × stat)
62048611|NCT00814424|ACTIVE_COMPARATOR|1|ERCP patients monitored using currently marketed smart biteblock o2
62250798|NCT04824638|EXPERIMENTAL|Group 2: Previously SARS CoV-2 infected participants|participants with antecedent of SARS-CoV-2 infection (more than 5 months)
62250799|NCT03194178||Pierre Robin sequence patients|Patients presenting a Pierre Robin sequence, and who have been cared in their early childhood by either the Necker or Trousseau hospitals teams, and who are between 12 and 18 years old at the beginning of the study.
62250800|NCT03241199|EXPERIMENTAL|Imatinib Mesylate|imatinib 400mg daily
62250801|NCT02269787|EXPERIMENTAL|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one 15-minute telephone call per week for 12 weeks.
62250802|NCT02269787|NO_INTERVENTION|Usual Care|Patients in the usual care condition will receive the care they would receive in the absence of a research project.
62250803|NCT00041301||QoL in prostate cancer|The study sample will be composed of a consecutive series of prostate cancer patients, stratified by stage of disease, local and locally advanced versus advanced (metastatic) disease, and undergoing active anti-tumor therapy. In order to increase sample homogeneity, and to facilitate evaluation of the responsiveness of the quality of life instruments to changes in patients' health status and symptoms experience over time, the subsample of patients with local or locally advanced disease will be restricted to those undergoing surgery (radical prostatectomy) or radiation therapy, and the subsample of metastatic disease patients will be limited to those receiving hormonal therapy.
62048612|NCT00814424|EXPERIMENTAL|2|ERCP patients monitored using experimental biteblock delivering up to 10 lit/min oxygen
62048613|NCT04649502|EXPERIMENTAL|Metformin combined with doxycycline|
62048614|NCT04649502|PLACEBO_COMPARATOR|Doxycyline combined with placebo|
62831343|NCT04336774|EXPERIMENTAL|Echocardiogram patients|Patients scheduled to have an echocardiogram (echo) and who are also being evaluated for, or are positive for COVID-19.
62831344|NCT03256461|EXPERIMENTAL|Lactate clearance 10% target group|Lactate clearance falls by 10-percent every two hours.
62609037|NCT01675154|PLACEBO_COMPARATOR|SLx-4090 placebo/Orlistat Placebo|"Slx-4090(placebo) is dosed as 4 tablets of 50 mg, three times per day with meals.~Orlistat (placebo) is dosed as 2 capsules of 60 mg, three times per day with meals.~This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment."
62609038|NCT01675154|EXPERIMENTAL|Orlistat/placebo|Orlistat two capsules 60mg each, three times per day with meals. Placebo for SLx-4090, 4 tablets 50mg each, three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
62609039|NCT01675154|EXPERIMENTAL|Orlistat placebo /SLx-4090|Orlistat placebo 2 capsules, 60mg each three times per day with meals. Slx-4090 4 tablets, 50mg each. three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
62609040|NCT01675154|EXPERIMENTAL|Orlistat/SLx-4090|Orlistat, 2 capsules 60 mg each, three times per day with meals. SLx-4090 4 tablets 50mg each, three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
62609041|NCT06401343|EXPERIMENTAL|Study group|Use of Empagliflozin+guideline directed medical treatment of HCM
62609042|NCT06401343|NO_INTERVENTION|Control group|Guideline directed medical treatment of HCM
62609043|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 1, version A|Medical Illustration Design Distinction 1, version A
62609044|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 1, version B|Medical Illustration Design Distinction 1, version B
62048615|NCT01235546|PLACEBO_COMPARATOR|Placebo and standard of care|250 cc normal saline
62048616|NCT01235546|EXPERIMENTAL|Azithromycin and Standard of care|500 mg Azithromycin in 250 cc normal saline
62609045|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 2, version A|Medical Illustration Design Distinction 2, version A
62609046|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 2, version B|Medical Illustration Design Distinction 2, version B
62609047|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 3, version A|Medical Illustration Design Distinction 3, version A
62609048|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 3, version B|Medical Illustration Design Distinction 3, version B
62609049|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 4, version A|Medical Illustration Design Distinction 4, version A
62609050|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 4, version B|Medical Illustration Design Distinction 4, version B
62609051|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 5, version A|Medical Illustration Design Distinction 5, version A
62609052|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 5, version B|Medical Illustration Design Distinction 5, version B
62609053|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 6, version A|Medical Illustration Design Distinction 6, version A
62609054|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 6, version B|Medical Illustration Design Distinction 6, version B
62609055|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 7, version A|Medical Illustration Design Distinction 7, version A
62609056|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 7, version B|Medical Illustration Design Distinction 7, version B
62609057|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 8, version A|Medical Illustration Design Distinction 8, version A
62609058|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 8, version B|Medical Illustration Design Distinction 8, version B
62609059|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 9, version A|Medical Illustration Design Distinction 9, version A
62609060|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 9, version B|Medical Illustration Design Distinction 9, version B
62609061|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 10, version A|Medical Illustration Design Distinction 10, version A
62609062|NCT06435806|EXPERIMENTAL|Medical Illustration Design Distinction 10, version B|Medical Illustration Design Distinction 10, version B
62609063|NCT06528145||S-|Individuals who have not had symptoms for 6-18 months after Covid infection
62048617|NCT04237506|EXPERIMENTAL|Intervention group|All participants in this group will take the one-hour ballet dance class twice per week for six weeks
62048618|NCT06495203||nAMD patients, anti-VEGF naïve on treatment after July 2015|"* Cluster A: Likely to require frequent injections~* Cluster B: Probable to extend treatment interval~* Cluster C: Likely to extend treatment interval"
62250804|NCT02179671|EXPERIMENTAL|Gefitinib with a Seq. Switch to a MEDI4736|Gefitinib once daily followed by MEDI4736
62609064|NCT06528145||S+|Individuals with ongoing symptoms 6-18 months after Covid infection
62831345|NCT03256461|EXPERIMENTAL|Lactate clearance 20% target group|Lactate clearance falls by 20-percent every two hours.
62831346|NCT03256461|PLACEBO_COMPARATOR|Standard EGDT group|Refer to the Surviving Sepsis Campaign(SSC) 2012 sepsis guidelines within 6 h liquid resuscitation.
62609065|NCT02667626|EXPERIMENTAL|SCPR Intervention|"Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information, including resource lists of helpful websites, followed by regular reproductive health prompts and study adherence reminders for 24 weeks.~Healthcare providers of young breast cancer participants randomized to the intervention arm will receive their patient's SCPR and access to the same additional web-based educational reproductive health information as their patient, including resource lists of helpful websites."
62831347|NCT04498832|EXPERIMENTAL|Group 1: QIV-HD|Participants received a single injection of 0.7 milliliters (mL) high dose quadrivalent influenza vaccine (QIV-HD), intramuscularly (IM) at Day 0.
62609066|NCT02667626|ACTIVE_COMPARATOR|Control|"Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders. At completion of the 24 weeks of follow up, they will have access to their SCPR.~Healthcare providers of young breast cancer participants randomized to the waitlist control arm will receive access to the same web-based resources as their patient."
62609067|NCT01962545|EXPERIMENTAL|OAC alone|OAC includes warfarin or NOAC. The dose of warfarin should be adjusted with the target international normalized ratio (INR) range of 2.0-3.0 for those \<70 years and 1.6-2.6 for those =\>70 years, which is recommended in the Japanese guidelines. NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice daily, and edoxaban 60mg daily with the reduced dose of 30mg daily.
62831348|NCT04498832|ACTIVE_COMPARATOR|Group 2: QIV-SD|Participants received a single injection of 0.5 mL standard-dose quadrivalent influenza vaccine (QIV-SD), subcutaneously (SC) at Day 0.
62831349|NCT04934540||Patients undergoing ERBT|Patients who are diagnosed with bladder tumors and planning for ERBT.
62831350|NCT04301960|EXPERIMENTAL|Single task group|The single task group includes balance gaining and cognitive training. The single task group will have 30-40 minutes of single-task training for 3 sessions per week for 8 weeks.
62831351|NCT04301960|EXPERIMENTAL|Dual-task|The dual-task group includes CSRT Mat training. The dual-task group will have CSRT Mat training for 30-40 minutes of dual-task training for 3 sessions per week for 8 weeks.
62440761|NCT02394132|EXPERIMENTAL|Radiotherapy|"Radiotherapy~* treatment regimen determined by treating radiation oncologist and as per standard practice at local institution~* treatment to commence within 8 weeks of randomisation"
62831352|NCT03606902|ACTIVE_COMPARATOR|(Group f):|"Intervention:~1. Procedure: Epidural catheter insertion~2. Drug: Epidural 15 ml of 0.0625%bupivacaine with 1 µg /Kg Fentanyl ,then continuous epidural infusion of fixed volume 10 ml of 0.0625% bupivacaine +1 µg/Kg/h Fentanyl for the next 6 hours ."
62831353|NCT03606902|ACTIVE_COMPARATOR|(Group Lf):|"Intervention:~1. Procedure:Epidural catheter insertion~2. Drug: Epidural injection 15 ml of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then 1st hour continuous IV infusion of 10ml of 0.0625%bupivacaine +1 µg/Kg/h Fentanyl ,2nd hour 10ml of 0.0625%bupivacaine + 0.5 µg/Kg/h Fentanyl , then next 4 hours10 ml of 0.0625%bupivacaine with + 0.25 µ g/Kg/h Fentanyl."
62831354|NCT05506124|EXPERIMENTAL|group 1|Propose a novel airbag-type stretchable electrode array (ASEA) device for training of the female pelvic floor muscle (PFM) for the treatment of UI
62831355|NCT05506124|ACTIVE_COMPARATOR|group 2|Propose a two-channel hard electrode device for training of the female pelvic floor muscle (PFM) for the treatment of UI
62831356|NCT02628912||long-term survivors of HPV-related oropharyngeal cancer|This is a cross-sectional pilot study of long-term survivors of HPV-related oropharyngeal cancer treated with CTRT who are at least three years from treatment completion. This study consists of a onetime assessment of cardiopulmonary fitness, physical function status, measurement of lean body mass, endothelial function quality of life assessment, medical history and blood laboratory evaluation for traditional cardiac risk factors, endocrine derangement and inflammation.
62831357|NCT01302652||GH deficient after acromegaly cure (on GH replacement)|Men and women with growth hormone deficiency following cure of acromegaly who are receiving growth hormone treatment.
62831358|NCT01302652||GH deficient after acromegaly cure (not on GH replacement)|Men and women with growth hormone deficiency following cure of acromegaly who are not receiving growth hormone treatment.
62831359|NCT01134185|ACTIVE_COMPARATOR|Group I|Moderate hepatic impairment (grade B)
62048619|NCT06495203||nAMD patients, anti-VEGF naïve on treatment before July 2015|"* Cluster D: Likely to require frequent injections~* Cluster E: Probable to extend treatment interval~* Cluster F: Likely to extend treatment interval"
62048620|NCT06495203||nAMD patients, anti-VEGF experienced on treatment after July 2015|"* Cluster G: Likely to require frequent injections~* Cluster H: Likely to extend treatment interval"
62048621|NCT06495203||CRVO patients, anti-VEGF naïve on treatment after July 2015|"* Cluster A: Likely to require continued anti-VEGF treatment~* Cluster B: Likely to be off anti-VEGF treatment"
62831360|NCT01134185|ACTIVE_COMPARATOR|Group II|Severe hepatic impairment (grade C)
62831361|NCT01134185|ACTIVE_COMPARATOR|Group III|healthy subjects
62048622|NCT06495203||BRVO patients, anti-VEGF naïve on treatment after March 2017|"* Cluster C: Likely to require continued anti-VEGF treatment~* Cluster D: Likely to be off anti-VEGF treatment"
62831362|NCT02158442|EXPERIMENTAL|Treatment Group|The Treatment Group received intravenous Timentin prior to their PILP procedure.
62831363|NCT02158442|ACTIVE_COMPARATOR|Control Group|The Control Group received standard dosings of intravenous Timentin plus other standard care.
62831364|NCT04883008||Intervention|CorPath GRX with technIQ automated movements enabled (technIQ ON)
62831365|NCT04883008||Control|CorPath GRX with technIQ automated movements disabled (technIQ OFF).
62048623|NCT02937272|EXPERIMENTAL|LY3200882 Schedule 1 Escalation|
62440762|NCT03109990|EXPERIMENTAL|Dexmedetomidine|Patients of dexmedetomidine group will receive a loading dose of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.
62440763|NCT03109990|PLACEBO_COMPARATOR|saline|Same amount of saline will be administrated.
62440764|NCT00542516|EXPERIMENTAL|HES 130/04|Pre-expansion with HES
62440765|NCT00542516|ACTIVE_COMPARATOR|Ringer's lactate|Pre-expansion with Ringer's lactate
62449469|NCT02142764|EXPERIMENTAL|Multiple Sclerosis patients treated|HLA-A2 Multiple Sclerosis patients treated by Natalizumab therapy
62449470|NCT06094556|EXPERIMENTAL|SHR-1826|Dose escalation; Dose expansion; Therapeutic effect expansion.
62831366|NCT03352102|EXPERIMENTAL|Diaphragm Group (DG)|"subjects who received conventional physical therapy once a day, plus a daily session of electrical stimulation in the diaphragm.~Intervention: Electrical stimulation of the diaphragm."
62831367|NCT03352102|ACTIVE_COMPARATOR|Quadriceps Group (QG)|"subjects who also received conventional physical therapy once a day, plus a daily session of electrical stimulation in the quadriceps.~Intervention: Electrical stimulation of the quadriceps."
62831368|NCT03352102|NO_INTERVENTION|Control Group (CG)|subjects who received regular treatment, i.e., conventional physical therapy, which included gross motor therapy and respiratory therapy twice a day every day, including weekend, during their stay in the ICU.
62831369|NCT03329157|OTHER|Rebuilding Bridges|This is a one-group study and the group will receive the Rebuilding Bridges intervention
62831370|NCT03834545||cycling group|They attended three sessions of exercise on three different conditions : a classic ergometric bicycle without chairback, an ergometric bicycle with chairback with virtual environment and the other session without virtual environment
62831371|NCT06310876|EXPERIMENTAL|Sequence 1|Subjects will receive ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg tablet
62831372|NCT06310876|EXPERIMENTAL|Sequence 2|Subjects will receive ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg tablet
62831373|NCT06310876|EXPERIMENTAL|Sequence 3|Subjects will receive ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg tablet
62831374|NCT06310876|EXPERIMENTAL|Sequence 4|Subjects will receive ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg tablet
62831375|NCT01081652|EXPERIMENTAL|Crinone 8% group|Female subjects undergoing IVF/ET treated with Crinone 8% intravaginally
62831376|NCT01081652|ACTIVE_COMPARATOR|Intramuscular progesterone group|Female subjects undergoing IVF/ET treated with 60 mg progesterone intramuscularly once daily
62831377|NCT04178668|EXPERIMENTAL|20-40 years old|33 patients between 20 and 40 years old
62831378|NCT04178668|EXPERIMENTAL|70-90 years old|33 patients between 70 and 90 years old
62831379|NCT04336553|EXPERIMENTAL|Intervention: Social prescribing in sweden (SPiS)|Patients (older adults experiencing loneliness) at a Health care clinic are invited to an optional additional internal referral for social prescribing (SPiS) within four working days. SPiS is a means of enabling the professionals to refer people to a range of local, non-clinical services. SPiS will involve a variety of activities, tailored to the patients needs and desires) which are typically provided by voluntary and community sector organisations.
62831380|NCT04336553|NO_INTERVENTION|Control: Social prescribing in sweden (SPiS)|Patients (older adults experiencing loneliness) at a Health care clinic are invited to an optional additional internal referral for social prescribing (SPiS) within three months. SPiS is a means of enabling the professionals to refer people to a range of local, non-clinical services. SPiS will involve a variety of activities, tailored to the patients needs and desires) which are typically provided by voluntary and community sector organisations.
62831381|NCT03747861|OTHER|Arm for HRV monitoring|For monitoring HRV each subject will put Wristband for registration of ECG RR intervals for one hand, SenceBand in the left wrist and Holter monitor electrodes will be placed in standard configurations places.
62831382|NCT06654583|EXPERIMENTAL|Interactive Play Mat|
62831383|NCT06654583|EXPERIMENTAL|Conventional Physical Therapy|
62831384|NCT00888134|EXPERIMENTAL|Treatment (selumetinib)|Patients receive selumetinib PO BID for 3 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62831385|NCT04824924|EXPERIMENTAL|HVAG regimen|
62048624|NCT02937272|EXPERIMENTAL|LY3200882 Schedule 2 Escalation|
62250805|NCT02179671|EXPERIMENTAL|AZD9291 with a Seq. Switch to a MEDI4736|AZD9291 once daily followed by MEDI4736
62831386|NCT01314313|EXPERIMENTAL|PIIA - SAPIEN XT|PIIA is operable group
62048625|NCT02937272|EXPERIMENTAL|LY3200882 Schedule 1 Expansion|
62048626|NCT02937272|EXPERIMENTAL|LY3200882 Schedule 2 Expansion|
62048627|NCT02937272|EXPERIMENTAL|LY3200882 + LY3300054|
62048628|NCT02937272|EXPERIMENTAL|LY3200882 + Gemcitabine + nab-Paclitaxel|
62831387|NCT01314313|ACTIVE_COMPARATOR|Control: SAVR|SAVR (surgical aortic valve replacement) is the control arm
62048629|NCT02937272|EXPERIMENTAL|LY3200882 + Cisplatin + Radiation|
62048630|NCT02937272|EXPERIMENTAL|Japanese Arm LY3200882|
62250806|NCT02179671|EXPERIMENTAL|Selumetinib+Docetaxel with a Seq. Switch to a MEDI4736|Selumetinib twice daily + docetaxel, followed by MEDI4736
62250807|NCT02179671|EXPERIMENTAL|Tremelimumab with a Seq. Switch to a MEDI4736|Tremelimumab every 4 weeks followed by MEDI4736
62250808|NCT00897806||Genetic Markers|
62831388|NCT01712477|ACTIVE_COMPARATOR|Intravenous sedation with propofol|Traumatic brain injured patient, already requiring sedation. Intervention is sedation with intravenous propofol during mechanical ventilation
62250809|NCT00112931|ACTIVE_COMPARATOR|Watch and Wait|Watch and Wait - no treatment
62831389|NCT01712477|ACTIVE_COMPARATOR|Intravenous sedation with midazolam|Patients with traumatic brain injury requiring mechinical ventilation. Intervention is intravenous midazolam for sedation at variable doses to achieve adequite sedation levels
62831390|NCT04169217|NO_INTERVENTION|Control arm|This arm will not be in the prehabilitation group- as is current standard practice
62831391|NCT04169217|ACTIVE_COMPARATOR|Group 2|This arm will be subject to a one off prehabilitation workshop and provided with a prehab booklet
62831392|NCT04169217|EXPERIMENTAL|Group 3- Mentored group|This arm will be subject to a one off workshop and provided with a prehab booklet- and additional mentoring by means of 1. an educational app, 2. push notifications,3. weekly communication with physiotherapy team member.
62831393|NCT02310698||Breast Cancer Screening Patients|"* Women presenting for screening full field digital mammography (FFDM) and WBUS on the same day or within 30 days of one another.~  o These women will be offered CEDM instead of the FFDM.~* Women that are scheduled for CEDM alone.~  o These women will be offered WBUS in addition to the CEDM.~* Women scheduled for both CEDM and WBUS on the same day or within 30 days of one another."
62831394|NCT01723384|ACTIVE_COMPARATOR|Naltrexone|Intermittent oral naltrexone to be taken on an as-needed basis for 8 weeks.
62831395|NCT01723384|PLACEBO_COMPARATOR|Placebo|Intermittent oral placebo to be taken on an as-needed basis for 8 weeks
62831396|NCT00873483|EXPERIMENTAL|Arm 1|
62831397|NCT05739721|EXPERIMENTAL|Zoom meeting (camera off)|participants will be randomly assigned to a Zoom (San Jose, CA, USA) video conference meeting with another participant of the opposite gender
62831398|NCT05739721|EXPERIMENTAL|In person meeting (blindfolded)|Once all subjects have been selected and enrolled in the study, participants will be randomly assigned for an in-person meeting.
62831399|NCT05739721|EXPERIMENTAL|Zoom meeting (camera on)|participants will be randomly assigned to a Zoom (San Jose, CA, USA) video conference meeting with another participant of the opposite gender
62831400|NCT05739721|EXPERIMENTAL|In person meeting (no blindfold)|Once all subjects have been selected and enrolled in the study, participants will be randomly assigned for an in-person meeting.
62831401|NCT05405803|EXPERIMENTAL|Intervention Group|Participants will be asked to visit WPAPP-K at least two times a week for 12 months.
62831402|NCT05405803|ACTIVE_COMPARATOR|Control group|Participants will have access to a link of the CDC website from baseline and during the duration of the study (12 months).
62831403|NCT02032732||suspected infection|leukocyte esterase test on fluid removed by intra-articular aspiration for suspected infection
62831404|NCT02032732||no suspected infection|leukocyte esterase test on fluid removed by intra-articular aspiration for reason other than suspected infection
62831405|NCT04689607|EXPERIMENTAL|Mulligan Traction Straight Leg Raise (TSLR)|This technique involves sustained traction applied to the limb. Patient actively does the SLR and both the therapist and the patient note the range. Therapist now grasp patient lower leg proximal to the ankle joint and raise it off the bed to a position just short of the painful range. Therapist flexes his knees and holds the clasped leg to his (therapist's) chest. When the therapist extends his knees this will effectively apply a longitudinal traction to the leg provided the bed is low enough and the therapist is tall enough. Sustain this traction and undertake a straight leg raise as far as it will go provided there is no pain.When pain free SLR with traction is given for three times.
62831406|NCT04689607|ACTIVE_COMPARATOR|Post Isometric Relaxation technique (PIR):|The patient is placed in the supine position with the non-affected leg lying flat on the table. The knee of the affected leg is gently placed in extension, and the affected hip is then flexed. The calf of the patient is then placed on the shoulder of the practitioner The practitioner stands on the side of the affected leg. The hands of the practitioner are then placed over the upper leg, just proximal to the knee. The hip of the affected leg is then passively flexed until resistance is felt. The patient is instructed to gently attempt to push down on the practitioner's shoulder with the leg against the practitioner's resistance. The practitioner resists hip extension to create an isometric contraction and then, after appropriate time and breathing instructions. The patient is instructed to relax and the practitioner gently flexes the hip until the next barrier is reached. After a period of relaxation, the technique will be repeated three to four times.
62831407|NCT02004093|EXPERIMENTAL|Chemotherapy + Pertuzumab|
62831408|NCT02004093|ACTIVE_COMPARATOR|Chemotherapy|
62831409|NCT03315663|ACTIVE_COMPARATOR|Sweetch App + DBWS|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app plus weight monitoring via digital body weight scale (DBWS).
62831410|NCT03315663|ACTIVE_COMPARATOR|Sweetch App Alone|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app alone.
62831411|NCT03771924|EXPERIMENTAL|inorganic phosphate|"Experimental intervention:~Single dose of orally administered 700 mg inorganic phosphate as sodium phosphate in combination with a standardized meal and blood sampling"
62831412|NCT03771924|PLACEBO_COMPARATOR|Placebo|Single dose of Sodium chloride in combination with a standardized meal and blood sampling
62831413|NCT03524976||Embolization with Squid|All patients with DAVFs are treated with SQUID™ aiming at complete occlusion of the fistula. Each participating center will include patients with DAVFs in whom the liquid embolic agent SQUID™ is planned to be used consecutively in the study. The
62831414|NCT03968393|EXPERIMENTAL|Non-vitamin K oral anticoagulant (NOAC)|Participants randomized to the intervention arm will be prescribed one of the following NOACs for the duration of follow-up, unless they are undergoing a procedure with an increased risk of bleeding, have an adverse event or low calculated creatinine clearance, or decide to discontinue their use.
62048631|NCT04503525||COVID 19 hospitalized patients|COVID 19 infected patients admitted in conventional hospitalization for less than 72 hours
62048632|NCT01016080|ACTIVE_COMPARATOR|oral glutathione|glutathione, 500 mg, taken orally twice daily
62048633|NCT01016080|PLACEBO_COMPARATOR|placebo capsules|identical-appearing placebo capsules
62048634|NCT03721575|ACTIVE_COMPARATOR|Scarpa's preserving hernio-abdominoplasty|Hernio-abdominoplasty is performed with preservation of Scarpa's fascia.
62048635|NCT03721575|ACTIVE_COMPARATOR|Classical hernio-abdominoplasty|Hernio-abdominoplasty is performed with removalof Scarpa's fascia.
62048636|NCT02408575|EXPERIMENTAL|Notched filtering (verum)|"The Hearing aid with notched amplification filters frequencies in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.~Intervention: Device: Conventional hearing aid type Carat 7bx with M-Receiver; Adjustment by Connexx 7.3"
62048637|NCT02408575|EXPERIMENTAL|No filtering (placebo)|"Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3~No notched filtering~Intervention: Device: Conventional hearing aid type Carat 7bx with M-Receiver; Adjustment by Connexx 7.3"
62609068|NCT01962545|NO_INTERVENTION|OAC plus single APT|"OAC includes warfarin or NOAC. The dose of warfarin should be adjusted with the target INR range of 2.0-3.0 for those \<70 years and 1.6-2.6 for those =\>70 years, which is recommended in the Japanese guidelines. NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice daily, and edoxaban 60mg daily with the reduced dose of 30mg daily.~Single APT includes aspirin or clopidogrel. The dose of aspirin is 81-324mg/day and the dose of clopidogrel is 75mg/day."
62609069|NCT06730698||Early stage osteoarthritis|Early stage osteoarthritis according to Eaton-Litter classification (stage 1 and 2)
62609070|NCT06730698||Advanced stage osteoarthritis|Advanced stage osteoarthritis according to Eaton-Litter classification (stage 3 and 4)
62609071|NCT04531982|EXPERIMENTAL|Drug - Pimavanserin|Pimavanserin 34 mg taken as two tablets + background antipsychotic, once daily by mouth
62609072|NCT04531982|PLACEBO_COMPARATOR|Placebo|Placebo + background antipsychotic, taken as two tablets, once daily by mouth
62609073|NCT04205344|EXPERIMENTAL|Bupivacaine 5 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg
62609074|NCT04205344|EXPERIMENTAL|Bupivacaine 10 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg
62609075|NCT04940416||Cirrhosis|These will include patients with cirrhosis. They will perform the paper-based standard psychometric tests (number connection test A, number connection test B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes). After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes.
62609076|NCT04940416||Non-cirrhosis|These will include patients without cirrhosis seen in the general gastroenterology clinic. Participants will perform the paper-based standard psychometric tests (number connection test A, number connection test B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes). After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes.
62048638|NCT04967235|ACTIVE_COMPARATOR|Conventional Exercise-based Cardiac Rehabilitation|This interventional arm consists of a conventional exercise-based cardiac rehabilitation, composed of initial rest, warm-up, treadmill aerobic exercise, orthostatic passive recovery, and supine passive recovery.
62048639|NCT04967235|EXPERIMENTAL|Dance-Based Cardiac Rehabilitation|This interventional arm consists of a new dance-based cardiac rehabilitation, composed of initial rest, warm-up, dance therapy, orthostatic passive recovery and supine passive recovery.
62048640|NCT05666453|EXPERIMENTAL|Treatment group|LIV-GAMMA SN Inj. administration after ABO-incompatible liver transplantation
62609077|NCT03213197|EXPERIMENTAL|CPR video|Patient watches a short CPR video
62609078|NCT00673426|EXPERIMENTAL|A|
62048641|NCT05666453|OTHER|Comparator group|No administration after ABO-incompatible liver transplantation
62048642|NCT05666453|OTHER|Reference group|No administration after ABO-compatible liver transplantation
62048643|NCT03881306|EXPERIMENTAL|D-TACE|D-TACE for inoperable NEN liver metastases. Embolization agent: CalliSpheres Drug-Eluting Beads Chemotherapy agent: Oxaliplatin
62609079|NCT03277716|EXPERIMENTAL|TACE+MWA|Transcatheter arterial chemoembolization combined with microwave ablation: 2-3 times of TACE treatment, then followed by ablation treatment using MWA system.
62609080|NCT06052306|EXPERIMENTAL|Dose escalation of BAY3546828|Participants with advanced metastatic castration-resistant prostate cancer (mCRPC) will receive 225Ac-pelgi dose in a stepwise fashion, according to a predefined dose escalation scheme.
62609081|NCT06052306|EXPERIMENTAL|Dose expansion group A of BAY3546828|Participants with advanced mCRPC with at least 1 but no more than 2 prior taxane regimens. No prior radionuclide therapy
62609082|NCT06052306|EXPERIMENTAL|Dose expansion group B of BAY3546828|Participants with advanced mCRPC who have not received taxane chemotherapy since becoming castration-resistant. No prior radionuclide therapy.
62609083|NCT06052306|EXPERIMENTAL|Dose expansion group C of BAY3546828|Participants with advanced mCRPC after prior Lutetium-177 labeled PSMA ligand (177Lu-PSMA) treatment.
62609084|NCT04408508|OTHER|Amoxicillin administration|Oral amoxicillin administered to study patients
62609085|NCT06091592||Patient ( cancer)|. The colorectal cancer patient group included clinical stage 1-3 patients of both sexes. Patients with metastatic disease, those who received neoadjuvant therapy, those who received systemic chemoradiotherapy, those who had any known systemic inflammatory or autoimmune disease, those with another concurrent malignancy, and those who had been previously diagnosed and treated for another malignancy were excluded from the study.
62609086|NCT06091592||Control (healthy volunteer)|The control group included healthy volunteers who had undergone screening colonoscopy within the last month, had no pathology, had not been diagnosed with any malignant disease before, had no known systemic inflammatory or autoimmune disease, and had not been diagnosed with inflammatory bowel disease.
62609087|NCT04575259|EXPERIMENTAL|ANAVEX2-73 Active|Oral capsules
62609088|NCT04122755|EXPERIMENTAL|Cohort1|Subjects receive a single subcutaneous injection of 1-fold ALA-1000 dose (first in human dose).
62609089|NCT04122755|EXPERIMENTAL|Cohort2|Subjects receive a single subcutaneous injection of 2-fold ALA-1000 dose
62831415|NCT03968393|NO_INTERVENTION|No anticoagulation|Participants randomized to the control arm will not be prescribed an oral anticoagulant unless they develop a clear indication for one during follow-up (e.g., recurrent nonoperative AF). They can be newly prescribed or continue taking low dose aspirin or another single antiplatelet agent as per the protocol. This will be decided by the participant's physician.
62831416|NCT01815970|EXPERIMENTAL|Pulmonary Rehabilitation|8 weeks of Pulmonary Rehabilitation
62831417|NCT02858622|ACTIVE_COMPARATOR|dual TAB group|22 patients will receive unilateral dual transversus abdominis plane (TAB) block USING bupivacaine 0.25% at a dose of 2 mg/kg
62831418|NCT02858622|SHAM_COMPARATOR|control group|22 patients who will not receive dual TAB block
62831419|NCT06173102|EXPERIMENTAL|Early Cranial Orthosis|Early cranial orthosis (reception 1 week after initial visit)
62048644|NCT02063334|ACTIVE_COMPARATOR|Vitamin D3|2000 micrograms of vitamin D3 in two doses during one day
62831420|NCT06173102|OTHER|Usual Cranial Orthosis|Usual cranial orthosis (reception 7 weeks after initial visit)
62831421|NCT00785785|EXPERIMENTAL|Nilotinib|nilotinib 400 mg twice a day
62831422|NCT00785785|ACTIVE_COMPARATOR|Imatinib|imatinib 400 mg once daily
62831423|NCT05962060|EXPERIMENTAL|Electrical Muscle Stimulation|"This group will receive PNF techniques (rhythmic initiation to stabilizing reversals and then then followed by dynamic reversals) with EMS to improve their spasticity, gait and lower limb functions. PNF exercises involved PNF pelvic patterns, PNF lower extremity D1 Flexion and PNF lower extremity D1 extension, repeated 10 to 20 times or up to patient's tolerance, up to 4 weeks.~When patients will perform PNF pattern electrodes of EMS will be placed at desired points of upper- extremity such that there will movement by patient effort and EMS will produce contraction of muscles simultaneously thus enhancing the function of extremity. Daily this combination will be used for patients to find the desired results. the time for period of 6 weeks for 5 days a week on regular basis. EMS Parameters to be implemented; Stimulus pulse: Symmetric Biphasic. Amplitude: 0-60mA. Pulse width: 300µsec Frequency: 25 to 50 H. Duty cycle: 10sec off 10 sec on."
62831424|NCT05962060|ACTIVE_COMPARATOR|Proprioceptive Neuromuscular Facilitation|"This group will receive PNF techniques (rhythmic initiation to stabilizing reversals and then followed by dynamic reversals) to improve their spasticity, gait and lower limb functions.~PNF exercises involved PNF pelvic patterns, PNF lower extremity D1 Flexion and PNF lower extremity D1 extension, each exercise was repeated 10 to 20 timesor up to patient's tolerance, progressed from rhythmic initiation to stabilizing reversals and then the followed by dynamic reversals up to 4 weeks of 10 therapy session. The treatment was provided 3 days per week on alternate basis, for 6 weeks (18 sessions). Participants were re-assessed on the outcome scale at end of 6 weeks."
62831425|NCT01099722|ACTIVE_COMPARATOR|Inhaler|
62831426|NCT01099722|ACTIVE_COMPARATOR|inhaler|Symbicort
62831427|NCT06463808||patients who take Recombinant Human Brain Natriuretic Peptide|
62831428|NCT06463808||patients who do not take Recombinant Human Brain Natriuretic Peptide|
62831429|NCT02545088|EXPERIMENTAL|Study group Hybrid Assistive Limb (HAL)|
62831430|NCT02545088|ACTIVE_COMPARATOR|1st control group|
62831431|NCT02545088|ACTIVE_COMPARATOR|2nd control group|
62831432|NCT03217071|EXPERIMENTAL|Pembrolizumab + Surgery|Patients will receive 200mg pembrolizumab on Day 1 of each 3 week cycle, for 2 cycles, prior to surgery. Pembrolizumab will be administered via IV infusion for 30 minutes. Surgery will occur no later than 6 weeks following the last dose of pembrolizumab.
62831433|NCT03217071|EXPERIMENTAL|Pembrolizumab + Radiation + Surgery|Patients will receive 200mg pembrolizumab on Day 1 of each 3 week cycle, for 2 cycles. Pembrolizumab will be administered via IV infusion for 30 minutes.Within the week (7 days +/- 3 days) following administration of the second cycle, a single 12 Gy dose of stereotactic radiation therapy (SRT) will be delivered to 50% of the primary tumor only. Definitive surgical resection will occur no later than 6 weeks following the last dose of pembrolizumab.
62831434|NCT05077202||ultra sound|lung ultrasound
62831435|NCT05077202||ct chest|patients had done CT chest already and we receive it from hospital files
62831436|NCT02643212|PLACEBO_COMPARATOR|Placebo|
62048645|NCT02063334|PLACEBO_COMPARATOR|Placebo|Placebo in two doses during one day
62250810|NCT00112931|EXPERIMENTAL|Arm C Rituximab 4 and Rixuximab Maintenance|4 infusions - 375mg/m2 every 2 months. A single dose of rituximab (375mg/m2 will then be given at 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92 and 100 weeks
62831437|NCT02643212|EXPERIMENTAL|Rivaroxaban|Rivaroxaban 10mg, 1 once a day
62048646|NCT05025969||Glioma|(20 grade II gliomas, 20 grade III gliomas and 20 glioblastomas)
62048647|NCT05025969||Brain metastasis|"The brain metastasis cohort consists of 80 patients, including 30 patients for whom the matched primary tumour is available"
62048648|NCT00936442||Group A|Standard treatment: 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
62250811|NCT02321930|OTHER|tofacitinib 5mg po bid|Open label with tofacitinib 5mg po bid
62831438|NCT05765916|EXPERIMENTAL|Online mindfulness and acceptance intervention|Participants of the intervention group will receive an intervention manual and videos. The duration of the intervention will be six weeks. Participants will be asked for a minimum time investment of 60 min per week. The intervention will be delivered via WeChat video call. The intervention will be conducted following the intervention manual to ensure consistency of intervention content that delivered.
62831439|NCT05765916|NO_INTERVENTION|Standard of care|Participants of the control group will be received usual follow-up care including regular medical checkups, which may include a physical exam, blood tests, and imaging tests.
62831440|NCT03013270|EXPERIMENTAL|ARIS group|Aerobic-Resistance-Inspiratory
62831441|NCT03013270|ACTIVE_COMPARATOR|AT/RT group|Aerobic-Resistance
62831442|NCT03013270|ACTIVE_COMPARATOR|AT/IMT group|Aerobic-Inspiratory
62831443|NCT03013270|ACTIVE_COMPARATOR|AT group|Aerobic Training
62831444|NCT02147639|EXPERIMENTAL|Sodium Nitrate|Patients will ingest a single oral dose of sodium nitrate (\~8.4 mmol)
62831445|NCT02147639|NO_INTERVENTION|Baseline|This is a baseline study visit, which will serve to assess inclusion and exclusion criteria, as well as provide untreated measurments of skeletal muscle blood flow and perfusion.
62831446|NCT02147639|EXPERIMENTAL|Dose-escalation trial|This is an optional study visit, where subjects will ingest twice the dose of sodium nitrate (\~16.8 mmol).
62609090|NCT04122755|EXPERIMENTAL|Cohort3|Subjects receive a single subcutaneous injection of 4.7-fold ALA-1000 dose
62048649|NCT00936442||Group B|Standard treatment + educational material: 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice plus reception of educational material on regular basis.
62048650|NCT03968432|SHAM_COMPARATOR|Standard Care|Be Sweet to Babies Videos and Pamphlet. Be Sweet to Babies vaccination pain management videos showing parents how to use breastfeeding, upright secure holding, and a small volume of the sweet solution during vaccination will be used.
62048651|NCT03968432|ACTIVE_COMPARATOR|Intervention|Be Sweet to Babies Videos, pamphlet, and MIAS\&Q. MIAS\&Q includes five questions and statements based on MI approach which was developed by the researcher and was reviewed further by a panel of parent representatives and HCPs representatives and the research team consisting of the supervisor and two Ph.D. committee members. This MIAS\&Q intervention consists of four scaled questions and two open-ended questions and presents brief informative and affirmative questions and statements. This aims to help the parents reflect on their own thoughts, and support them to advocate for the use of the recommended pain management strategies during their infant's vaccination.
62048652|NCT04834791|EXPERIMENTAL|Letrozole|These patients were treated with letrozole (Femara®, Novartis New York, NY, USA) in a dose 2.5 mg (one tablet daily) orally began on the 3rd day to the 7th day of the cycle. If ovulation is not achieved dose is increased by 2.5 mg in next cycle till 3 cycles.
62250812|NCT01653964|EXPERIMENTAL|Molecular breast imaging|Molecular Breast Imaging at 4 mCi dose and at 8 mCi dose, consecutively.
62609091|NCT04122755|EXPERIMENTAL|Cohort4|Subjects receive a single subcutaneous injection of 9.4-fold ALA-1000 dose
62609092|NCT04122755|EXPERIMENTAL|Cohort5|Subjects receive a single subcutaneous injection of 18.8-fold ALA-1000 dose
62609093|NCT04122755|EXPERIMENTAL|Cohort6|Subjects receive a single subcutaneous injection of 18.8-fold ALA-1000 dose after 7 days of buprenorphine sublingual film dosing
62609094|NCT06109272|EXPERIMENTAL|Stage 1: Cohort 1|Participants will receive livmoniplimab Dose 1 in combination with budigalimab every 3 weeks until disease progression or until discontinuation criteria are met.
62831447|NCT02147639|PLACEBO_COMPARATOR|Placebo-control trial|This is an optional study visit, where patients will ingest a placebo.
62831448|NCT02147639|EXPERIMENTAL|Increased exercise intensity|This is an optional study visit, where patients will be asked to repeat all of the blood flow assessments, but the exercise intensity will be increased.
62831449|NCT01510483|EXPERIMENTAL|Obesity prevention|Orthodontist promotion of physical activity and healthy diet
62831450|NCT01510483|ACTIVE_COMPARATOR|Tobacco prevention|Orthodontist promotion of tobacco and second hand smoke avoidance
62831451|NCT04616456|EXPERIMENTAL|Multiple System Atrophy (MSA)|Twenty to twenty-five subjects with probable MSA diagnosis will be recruited for this study. Each subject will undergo an \[F-18\]PBR06 PET and MRI scan at baseline, and will receive the experimental drug, verdiperstat (BHV-3241) under supervision of clinic staff. A follow-up \[F-18\]PBR06 PET and MRI scan will be performed after 6 months (26 weeks) of taking verdiperstat.
62831452|NCT01986426|EXPERIMENTAL|Arm A: LTX-315 monotherapy singe lesion|"Cohort 1-3: First induction treatment (6 weeks): In week 1 the first index lesion will be injected Twice daily on 3 consecutive days. During week 2-6 the injection will be once a week.~Second induction treatment (6 weeks) and Maintenance treatment (20 weeks)- At week 7 the second index lesion will be injected with same dosing schedule as the first index lesion.~Cohort 4 and above: Once daily on 3 consecutive days week 1. Week 2-6 one injection per week. From week 8, one dosing days every 2 weeks."
62831453|NCT01986426|EXPERIMENTAL|Arm B: LTX-315 monotherapy in multiple concurrent lesions|"Patients with at least one injectable lesion and one bystander lesion will receive LTX-315 to one or more lesions:~Once daily on 2 consecutive days week 1-3."
62831454|NCT01986426|EXPERIMENTAL|Arm C|Patients with melanoma and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with ipilimumab given for 4 cycles every 3 weeks.
62831455|NCT01986426|EXPERIMENTAL|Arm D|Patients with TNBC and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with pembrolizumab given every 3 weeks.
62048653|NCT04834791|ACTIVE_COMPARATOR|Gonadotropins|These patients were given urofollitropin (fostimon ®, IBSA, Lugano, Switzerland) in a dose of 75 IU/mL I.M from day 3rd to day 7th of the cycle beginning by one ampoule per day and the dose had been modulated according to response.
62048654|NCT03887338|OTHER|NIV settings titration|Transnasal Fiberoptic Laryngoscopy will be used during ongoing NIV setting titration. Aim is to titrate NIV setting to be more optimal for laryngeal responses.
62048655|NCT03344679|OTHER|Control group|Bupivacaine 0.25% for pectoral nerve block.
62250813|NCT00350584|EXPERIMENTAL|Mindfulness Telehealth for PTSD|Participants receive two in-person sessions and 6 sessions over the phone. Participants are introduced to mindfulness concepts. CDs with guided meditation exercises are given to participants and they are asked to practice between sessions.
62609095|NCT06109272|EXPERIMENTAL|Stage 1: Cohort 2|Participants will receive livmoniplimab Dose 2 in combination with budigalimab every 3 weeks until disease progression or until discontinuation criteria are met.
62609096|NCT06109272|ACTIVE_COMPARATOR|Stage 1: Cohort 3 - Group 1 (Control)|Participants will receive atezolizumab in combination with bevacizumab every 3 weeks until disease progression or until discontinuation criteria are met.
62609097|NCT06109272|ACTIVE_COMPARATOR|Stage 1: Cohort 3 - Group 2 (Control)|Participants will receive a single dose of tremelimumab in combination with durvalumab every four weeks until disease progression or until discontinuation criteria are met.
62609098|NCT06109272|EXPERIMENTAL|Stage 2: Arm 1|Participants will receive livmoniplimab (optimized dose) in combination with budigalimab every 3 weeks until disease progression or until discontinuation criteria are met.
62609099|NCT06109272|ACTIVE_COMPARATOR|Stage 2: Arm 2 (Control)|Participants will receive a single dose of tremelimumab in combination with durvalumab every 4 weeks until disease progression or until discontinuation criteria are met.
62048656|NCT03344679|OTHER|Adenosine|Bupivacaine 0.25% with added Adenosine 12mg for pectoral nerve block.
62048657|NCT03344679|OTHER|Magnesium sulphate|Bupivacaine 0.25% with Magnesium sulphate 500 mg for pectoral nerve block.
62048658|NCT03580889|ACTIVE_COMPARATOR|Atropine sulphate|Atropine 5 mcg/kg diluted in normal saline to total volume of 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blood pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly
62048659|NCT03580889|ACTIVE_COMPARATOR|Glycopyrrolate|Glycopyrrolate 2.5 mcg / kg diluted in normal saline to total volume of 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blold pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly.
62048660|NCT03580889|ACTIVE_COMPARATOR|Normal Saline|Normal saline 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blold pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly.
62048661|NCT01144026|EXPERIMENTAL|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
62609100|NCT05729828||Observation group|Neonates with PMA 33 weeks, 0 days or more, present in NICU. No intervention was done.
62609101|NCT02461797|OTHER|healthy controls|biopsy of nasal mucosa healthy controls
62048662|NCT01144026|EXPERIMENTAL|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
62609102|NCT02461797|OTHER|AR patients with use of nasal corticoid spray|biopsy of nasal mucosa allergic rhinitis to house dust mite with nasal corticosteroid spray
62609103|NCT02461797|OTHER|AR patients without medication|biopsy of nasal mucosa allergic rhinitis to house dust mite without any use of medication for symptom control
62048663|NCT03089892||Gynecologic cancer patients|Gynecologic cancer patients under chemotherapy
62048664|NCT05499390|EXPERIMENTAL|AK112|Subjects receive AK112 monotherapy intravenously (IV), selected dose.
62609104|NCT04010864||SHARP-2|ShangHai At Risk for Psychosis-Phase 2
62609105|NCT03383692|EXPERIMENTAL|Cohort 1: DS-8201a + Ritonavir|DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Ritonavir twice daily (BID) on Day 17 of Cycle 2 until Day 21 of Cycle 3
62609106|NCT03383692|EXPERIMENTAL|Cohort 2: DS-8201a + Itraconazole|DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Itraconazole BID on Day 17 of Cycle 2 followed by 200 mg daily (QD) until Day 21 of Cycle 3
62609107|NCT05123976|EXPERIMENTAL|Treatment A|Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine)
62609108|NCT05123976|ACTIVE_COMPARATOR|Treatment B|Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)
62609109|NCT02446262|OTHER|Substudy 1: Instructed subjects|Participants are instructed about outcomes
62609110|NCT02446262|OTHER|Substudy 1: Uninstructed subjects|Participants learn through experience
62609111|NCT02446262|OTHER|Substudy 2: heat group|Participants learn about heat outcomes through conditioning
62048665|NCT05499390|ACTIVE_COMPARATOR|Pembrolizumab|Subjects receive Pembrolizumab monotherapy intravenously (IV), 200mg q3w.
62048666|NCT03300947|EXPERIMENTAL|High-dose Psilocybin|Psilocybin 300 mcg/kg once per week, every week, for 8 weeks
62048667|NCT03300947|EXPERIMENTAL|High- or Low-dose Psilocybin|Psilocybin 100 mcg/kg or psilocybin 300 mcg/kg once per week, every week, for 8 weeks
62048668|NCT03300947|PLACEBO_COMPARATOR|High-dose Psilocybin or Lorazepam|Psilocybin 300 mcg/kg or Lorazepam 1 mg once per week, every week, for 8 weeks
62048669|NCT02380625|EXPERIMENTAL|Azithromycin|Azithromycin, IV fluids and laboratory testing
62048670|NCT02380625|EXPERIMENTAL|Sunitinib and Erlotinib|Sunitinib, Erlotinib, IV fluids and laboratory testing
62048671|NCT02380625|EXPERIMENTAL|Atorvastatin and Irbesartan|Atorvastatin, Irbesartan, IV fluids and laboratory testing
62048672|NCT02380625|OTHER|IV fluids and laboratory testing|no additional treatment
62048673|NCT04799626||Treatment|The use of antimicrobial agents depends on the clinical practice.
62048674|NCT05505877|EXPERIMENTAL|BR790+Tislelizumab dose escalation|Dose escalation part
62609112|NCT02446262|OTHER|Substudy 2: salt group|Participants learn about salt outcomes through conditioning
62609113|NCT02446262|OTHER|Substudy 2: sugar group|Participants learn about sugar outcomes through conditioning
62609114|NCT02446262|NO_INTERVENTION|Substudy 3: healthy volunteers|All participants experience all outcomes, within subjects designs
62609115|NCT02446262|OTHER|Substudy 4: healthy volunteers|Participants are instructed to attend toward or away from the stimulus
62609116|NCT02446262|OTHER|Substudy 5: healthy volunteers|Participants experience both placebo and cue-based expectations within subjects
62609117|NCT02879708|NO_INTERVENTION|Control|40 (of 120) randomly selected villages receive no intervention
62609118|NCT02879708|OTHER|Information Only|"40 randomly selected villages are assigned to the information only arm where households will receive information regarding their rights and entitlements pertaining to healthcare, certain health outcomes specific to their village, as well as health-related activities happening in their village."
62609119|NCT02879708|OTHER|Information and Facilitation|The remaining 40 villages will receive similar information as the villages in the Information Only Arm, but will also have facilitators present that ensure the existence of the VHSNC at the village level as well as the occurrence of VHSNC monthly meetings.
62048675|NCT05505877|EXPERIMENTAL|BR790+Tislelizumab dose expansion|Dose expansion part
62048676|NCT03012464||Pathologic and functional assessment|Patients of both genders, aging below 45 years with internal or external rectal prolapse
62048677|NCT05897567|EXPERIMENTAL|ketogenic diet|Participants will perform a single exercise bout after 4 weeks of resistance training combined with a ketogenic diet (KD group).
62048678|NCT05897567|ACTIVE_COMPARATOR|western diet|Participants will perform a single exercise bout after 4 weeks of resistance training combined with a western diet (WD group).
62048679|NCT02898779|EXPERIMENTAL|Cohort 1 ( Primaquine Low Dose)|"Interventions: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine A single center, prospective, cross-over, randomized phase 1 trial. Thirty-six participants, enrolled into a two cohort pharmacokinetic study evaluating two dose levels of primaquine isomers.~Cohort 1 (Low Dose Level)- single dose of 15 mg of S-Primaquine and 15 mg of R-Primaquine compared to 30 mg RS-Primaquine over 24 hours. Participants will cross-over after a one week wash-out period."
62609120|NCT05668104|EXPERIMENTAL|Jing Si Herbal Tea Liquid Packet|Participants received Jing Si Herbal Tea Liquid Packet 15 mg tablet orally twice daily for 28 days.
62609121|NCT05668104|PLACEBO_COMPARATOR|Jing Si Herbal Tea Liquid Packet Placebo|Participants received Jing Si Herbal Tea Liquid Packet Placebo 15 mg tablet orally twice daily for 28 days.
62609122|NCT05189522|EXPERIMENTAL|Innova Breeze®-based roadmap|"An Innova Breeze® bolus chase acquisition is realized prior to the revascularization to assess the lesions of the entire target limb. Guidance to the different lesions is done using a 2D roadmap based on the Innova Breeze® bolus acquisition frames if the patient position has not moved on the table.~An Innova Breeze® bolus chase acquisition is realized to assess the final result of the revascularization of the target limb. Both Innova Breeze® bolus chases are required at field of view 30-cm. Finally, the sheath is retrieved and the hemostasis at the puncture site is realized via a manual compression or using a vascular closure device.~DSAs are performed with the injector set at 7mL/s and the volume at 7mL (pressure limit 1000psi) for femoropopliteal assessment. Innova Breeze® bolus chase acquisitions are performed with the injector set at 4mL/s and the volume at 24mL (pressure limit 1000psi). An injector with iodinated contrast (50% of dilution) will be used."
62048680|NCT02898779|EXPERIMENTAL|Cohort 2 (Primaquine High Dose)|"Interventions: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine A single center, prospective, cross-over, randomized phase 1 trial. Thirty-six participants, enrolled into a two cohort pharmacokinetic study evaluating two dose levels of primaquine isomers.~Cohort 2 (High Dose Level)-single dose of 22.5 mg of S-Primaquine and 22.5 mg of R-Primaquine compared to 45 mg RS-Primaquine over 24 hours. Participants will cross-over among the treatment arms following a one week wash-out period between each."
62048681|NCT04675450|PLACEBO_COMPARATOR|Placebo|Interventions: Placebo (NBP placebo softgel capsules, 0 mg NBP, BID)
62048682|NCT04675450|ACTIVE_COMPARATOR|NBP|Interventions: 800 mg NBP softgel capsules daily (400 mg BID)
62048683|NCT00915031|ACTIVE_COMPARATOR|Hypothermia Only OR|Use of Hypothermia Cooling device only in the operating room. Intervention is Hypothermia Cooling Device.
62250814|NCT00350584|ACTIVE_COMPARATOR|Psychoeducation Telehealth for PTSD|Participants receive two in-person sessions and six telehealth sessions with education about symptoms of PTSD and coping strategies. In addition, participants are asked to read short homework assignments and think about them during the week; these are discussed in weekly sessions.
62250815|NCT02238951|EXPERIMENTAL|Mobile Health (mHealth)|Care coordination using mHealth technology enhancements
62831456|NCT01777386|ACTIVE_COMPARATOR|preexpanded flap|Fourteen patients were treated with fifteen '' preexpanded perforator flap surgery '' interventions. The last six cases were evaluated in terms of perforator artery diameter before and after expansion process. The preexpanded flap donor sites' perforator artery diameters were also compared with their anatomic equivalents located in the symmetric side of the body.
62831457|NCT01777386|NO_INTERVENTION|control side|In six of the 14 patients, perforator artery diameter of the nonexpanded symmetric anatomical side of the body (equivalent to the expanded site)were measured.
62048684|NCT00915031|ACTIVE_COMPARATOR|Hypothermia in OR + Recovery|Use of hypothermia cooling device in the operating room and up to five hours after surgery is intervention.
62048685|NCT00512148|EXPERIMENTAL|1|Receipt of autologous neo-bladder construct consisting of a device regenerated in the laboratory from the patient's own muscle and urothelial cells
62048686|NCT04154202|EXPERIMENTAL|Bone inaction patients|Three months or more post joint replacement, or post tibial ORIF, or last surgical intervention adult patients suspected of bone infection and or mechanical loosening.
62048687|NCT05771909|EXPERIMENTAL|NeurodigitX|"After randomization, the NeurodigitX Group receiving this program will follow the recommendations for a period of three months (2 sessions of 2 minutes per day).~At this visit and at the 1/2/3 and 6 month visits, staff will complete the following scales and questionnaires (15 minutes in length): Visual Anxiety Analog Scale (VAS), Spielberger Anxiety Scale - State (STAI form Y-A) and SF-12 Quality of Life Questionnaire.~All participants will be called in at 3 months for a visit to measure HRV via the app."
62048688|NCT05771909|OTHER|Control|"After randomization, the Control Group does not receive the NeurodigitX application.~At this visit and at the 1/2/3 and 6 month visits, staff will complete the following scales and questionnaires (15 minutes in length): Visual Anxiety Analog Scale (VAS), Spielberger Anxiety Scale - State (STAI form Y-A) and SF-12 Quality of Life Questionnaire.~All participants will be called in at 3 months for a visit to measure HRV via the app."
62048689|NCT05599009|EXPERIMENTAL|RIC group|RIC+Standard medical treatment. Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg.
62048690|NCT05599009|SHAM_COMPARATOR|control group|Sham RIC+Standard medical treatment. Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg.
62048691|NCT01216930||All colorectal cancer patients|
62048692|NCT03280134|NO_INTERVENTION|predictive nSLN-|No further axillary lymph node dissection (ALND)
62048693|NCT03280134|ACTIVE_COMPARATOR|predictive nSLN+|axillary lymph node dissection (ALND)
62048694|NCT01220700|EXPERIMENTAL|Triclosane|triclosan coated suture material
62048695|NCT01220700|ACTIVE_COMPARATOR|Control|ordinary suture material
62048696|NCT01981733|EXPERIMENTAL|Device|
62831458|NCT01808456|EXPERIMENTAL|High Dose Flu Vaccine|influenza trivalent inactive vaccine high dose. IM (intramuscular) injection one time administration
62831459|NCT01808456|ACTIVE_COMPARATOR|Flu Vaccine|influenza trivalent inactive vaccine IM injection one time administration
62048697|NCT02763514|ACTIVE_COMPARATOR|DHA-enriched oil|3 g PronovaPure 150:500 EE EU
62048698|NCT02763514|ACTIVE_COMPARATOR|EPA-enriched oil|3 g PronovaPure 500:200 EE EU
62048699|NCT02763514|PLACEBO_COMPARATOR|Placebo|3 g Olive oil
62048700|NCT00004070|EXPERIMENTAL|IL-12 Injection 3mg/ml [Phase I]|The dosing schedule will consist of eight injections 3 mg/ml of formulated plasmid over a seven week period.
62048701|NCT00004070|EXPERIMENTAL|IL-12 Injection 6mg/ml [Phase I]|The dosing schedule will consist of eight injections 6mg/ml of formulated plasmid over a seven week period.
62048702|NCT00004070|EXPERIMENTAL|IL-12 Injection MTD [Phase II]|The dosing schedule will consist of eight injections over a seven week period of formulated plasmid at the MTD established in the phase I portion.
62250816|NCT02238951|ACTIVE_COMPARATOR|No mHealth|Care coordination without mHealth enhancements
62250817|NCT03276377||Exposed to VKA|VKA intake Patients who have been taking VKA for at least 3 months
62250818|NCT03276377||Non-exposed to VKA|DOAC intake Patients who have been taking DOAC for at least 3 months
62609123|NCT05189522|OTHER|control group|"2D roadmap guidance is used based on DSA. The treatment of the target lesion is let at the physician discretion. Treatment result of each lesion is checked by a DSA with 1 incidence.~After treatment overall limb assessment will be done through multiple staged DSA.~Finally, the sheath is retrieved and the hemostasis at the puncture site is realized via a manual compression or using a vascular closure device.~DSAs are performed with the injector set at 7mL/s and the volume at 7mL (pressure limit 1000psi) for femoropopliteal assessment. An injector with iodinated contrast (50% of dilution) will be used.~For hospitalized patients, three to five days after the procedure, a blood test is performed to assess the eGFR, as part of the usual care of patients. If the patient is no longer hospitalized, at the time of this examination, the investigating physician has given him an order before his discharge to perform this examination in an analysis laboratory."
62609124|NCT01916902|ACTIVE_COMPARATOR|Ticagrelor- Delayed Administration|Subjects receive 180 mg of ticagrelor during cardiac catheterization after diagnostic angiography and prior to stenting. OCT is performed prior to and after coronary artery stenting.
62609125|NCT01916902|ACTIVE_COMPARATOR|Ticagrelor- Immediate Administration|Subjects receive 180 mg of ticagrelor immediately after study enrollment. OCT is performed prior to and after coronary artery stenting.
62831460|NCT00637975|EXPERIMENTAL|A|oxycodone 20 mg/day plus pregabalin at increasing dose starting from 50 mg/day for 15 days or until unacceptable toxicity develops
62831461|NCT00637975|ACTIVE_COMPARATOR|B|pregabalin 50 mg/day plus oxycodone at increasing dose starting from 20 mg/day. For 15 days or until unacceptable toxicity develops
62831462|NCT01578486|EXPERIMENTAL|salsalate|open-label trial of salsalate 3g/day
62831463|NCT04871126||LVT group|left ventricular thrombus in acute anterior myocardial infarction patients with left ventricular dysfunction
62831464|NCT04871126||non-LVTgroup|acute anterior myocardial infarction patients with left ventricular dysfunction while without LVT
62831465|NCT03281798|EXPERIMENTAL|Fetal Cystoscopy Group|Participants in this group will receive the fetal cystoscopy procedure around 16 weeks 0 days to 25 weeks and 6 days of gestation.
62831466|NCT04950647|EXPERIMENTAL|Test group 1|Nitroketazine tablet 600 mg group
62831467|NCT04950647|EXPERIMENTAL|Test group 2|Nitroketazine tablets 1200 mg group
62831468|NCT04950647|PLACEBO_COMPARATOR|Control group|placebo group
62831469|NCT06516380|NO_INTERVENTION|lower extremity strength|A 30 s sit and stand test was performed to evaluate lower extremity strength.
62831470|NCT06516380|NO_INTERVENTION|walking test|The 10-metre walking test (10 MWT) and timed up and walk test (TUG) were performed.
62831471|NCT06516380|EXPERIMENTAL|ROM|Hip ROM, knee ROM, trunk flexion ROM were measured with TecnoBody Walker View 3.0 SCX device.
62831472|NCT04166422|ACTIVE_COMPARATOR|Conventional group|Conventional rehabilitation treatment
62831473|NCT04166422|EXPERIMENTAL|Experimental group|Virtual reality plus conventional rehabilitation treatment
62831474|NCT00188344|ACTIVE_COMPARATOR|1|pneumatic dilatation
62831475|NCT00188344|ACTIVE_COMPARATOR|2|Laparoscopic myotomy
62831476|NCT01100619|EXPERIMENTAL|All subjects|All subjects will receive daily XL184, and two single doses of rosiglitazone, 3 weeks apart
62831477|NCT04698369|EXPERIMENTAL|low frequency low amplitude|The vibration frequency is 60 Hz and amplitude is 0.2 mm
62831478|NCT04698369|EXPERIMENTAL|low frequency high amplitude|The vibration frequency is 60 Hz and amplitude is 2 mm
62831479|NCT04698369|EXPERIMENTAL|high frequency low amplitude|The vibration frequency is 120 Hz and amplitude is 0.2 mm
62831480|NCT04698369|EXPERIMENTAL|high frequency high amplitude|The vibration frequency is 120 Hz and amplitude is 2 mm
62831481|NCT05026593|ACTIVE_COMPARATOR|Sintilimab+EP|During each 21-day cycle, participants receive Sintilimab 200 mg intravenously (IV) Day 1 PLUS etoposide 100 mg/m\^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an area under the plasma drug concentration-time curve \[AUC\] 5 IV on Day 1 OR cisplatin 75 mg/m\^2 IV on Day 1). After the induction phase, participants will begin maintenance therapy with Sintilimab 200 mg intravenously (IV) Day 1 every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or other protocol-allowed reasons, whichever occurs first.
62440766|NCT02957409||sacubitril/valsartan|Patients diagnosed with HFrEF being treated with sacubitril/valsartan according to the Canadian product label and treatment initiation with sacubitril/valsartan within the last 3 months. The usual recommended starting dose is one tablet of 49 mg sacubitril / 51 mg valsartan taken twice daily. The target dose is one tablet of 97 mg sacubitril / 103 mg valsartan taken twice daily. Investigator/designated will document sacubitril/valsartan treatment adherence throughout the 3 years study period
62831482|NCT05026593|EXPERIMENTAL|IBI110+Sintilimab+EP|During each 21-day cycle, participants receive IBI110 PR2D intravenously (IV) Day 1 PLUS Sintilimab 200 mg intravenously (IV) Day 1 PLUS etoposide 100 mg/m\^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an area under the plasma drug concentration-time curve \[AUC\] 5 IV on Day 1 OR cisplatin 75 mg/m\^2 IV on Day 1). After the induction phase, participants will begin maintenance therapy with IBI110 PR2D intravenously (IV) Day 1 PLUS Sintilimab 200 mg intravenously (IV) Day 1 every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or other protocol-allowed reasons, whichever occurs first.
62831483|NCT03719079||Heart Failure Patients|Patients with primary diagnosis as heart failure
62831484|NCT06392477|EXPERIMENTAL|DL1 of DR-0201|Subjects in this arm will receive up to 12 months of dosing with 0.3 mg DR-0201
62831485|NCT06392477|EXPERIMENTAL|DL2 of DR-0201|Subjects in this arm will receive up to 12 months of dosing with 1 mg DR-0201
62831486|NCT06392477|EXPERIMENTAL|DL3 of DR-0201|Subjects in this arm will receive up to 12 months of dosing with 3 mg DR-0201
62831487|NCT06392477|EXPERIMENTAL|DL4 of DR-0201|Subjects in this arm will receive up to 12 months of dosing with 10 mg DR-0201
62831488|NCT06392477|EXPERIMENTAL|DL5 of DR-0201|Subjects in this arm will receive up to 12 months of dosing with 30 mg DR-0201
62831489|NCT06392477|EXPERIMENTAL|DL6 of DR-0201|Subjects in this arm will receive up to 12 months of dosing with 100 mg DR-0201
62831490|NCT06392477|EXPERIMENTAL|DL7 of DR-0201|Subjects in this arm will receive up to 12 months of dosing with 300 mg DR-0201
62831491|NCT06392477|EXPERIMENTAL|DL8 of DR-0201|Subjects in this arm will receive up to 12 months of dosing with 500 mg DR-0201
62831492|NCT03824249|EXPERIMENTAL|Spontaneous breathing|Performance of indirect calorimetry in spontaneously breathing children through the use of indirect calorimetry.
62831493|NCT03824249|EXPERIMENTAL|NIV-CPAP|Performance of indirect calorimetry in children undergoing Non-invasive continuous positive airway pressure (CPAP) of 4 centimeters of water (cmH2O). CPAP will be applied via single-limb circuit with intentional leak.
62048703|NCT03144414|ACTIVE_COMPARATOR|LAVH|Laparoscopic Assisted Vaginal Hysterectomy
62048704|NCT03144414|ACTIVE_COMPARATOR|LADH|Laparoscopic Assisted Doderlin Vaginal Hysterectomy
62048705|NCT02993445|EXPERIMENTAL|Alternate Nostril Breathing|The procedure for ANB begins by bringing the right hand up to the nose; with the ring finger over the left nostril and the thumb over the right nostril, so that the nostrils may be closed by the fingers. The first step in the cycle is to hold the right nostril closed with the thumb, and exhale completely through the left nostril in a slow and controlled fashion, free from exertion and jerkiness. At the end of the exhalation, the patient will inhale slowly and completely back through the left nostril. At this point the patient will close the left nostril with the ring finger, open the right nostril by releasing the thumb, and repeat the exhale-inhale process through the right nostril, completing one cycle. Then the patient will switch back to the left nostril and begin the cycle again. This cycle will be performed for one session lasting approximately 5 minutes.
62440767|NCT05729750|EXPERIMENTAL|Lable litter A (Study group)|The sealed opaque brown envelope contains a case record form and the letter A paper for listening to the music before and during the BPP assessment (study group), which cannot be visible from the outside.
62440768|NCT05729750|PLACEBO_COMPARATOR|Lable litter B (control group)|The sealed opaque brown envelope contains a case record form and the letter B for not listening to the music before and during the BPP assessment (control group), which cannot be visible from the outside.
62440769|NCT03834584|EXPERIMENTAL|AG-636|AG-636 dosed orally.
62609126|NCT06534385|EXPERIMENTAL|Single group|Participants receive HEPA purifiers and air monitoring equipment to operate daily for 12-weeks.
62831494|NCT03824249|EXPERIMENTAL|NIV-PS|Performance of indirect calorimetry in children undergoing Non-invasive continuous positive airway pressure (CPAP) of 4 cmH2O and Pressure support (PS) of 8 cmH2O. Non-invasive ventilation will be applied via single-limb circuit with intentional leak.
62831495|NCT02057250|EXPERIMENTAL|Sarilumab 150 mg by AID|Sarilumab 150 mg subcutaneous (SC) injection every 2 weeks (q2w) administered by AID with one or a combination of non-biologic disease-modifying anti-rheumatic drug (DMARD) (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
62831496|NCT02057250|EXPERIMENTAL|Sarilumab 150 mg by PFS|Sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
62831497|NCT02057250|EXPERIMENTAL|Sarilumab 200 mg by AID|Sarilumab 200 mg SC injection q2w administered by AID with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
62440770|NCT06168955|EXPERIMENTAL|alzheimer's disease patients|Alzheimer's disease patients with positive biomarkers who started their disease before age 75 and benefited from genetic research.
62440771|NCT06168955|OTHER|Control group|control cell lines from patients free of alzheimer's disease
62440772|NCT03462329|ACTIVE_COMPARATOR|patients with erythema migrans|Patients will be treated with antibiotics for Lyme disease.
62609127|NCT03605849|EXPERIMENTAL|Centanafadine|400 mg total daily dose
62609128|NCT06731517||Classical group|In the classical group, Double Lumen Tube selection was based on gender and height. For males, a 41 F tube was chosen if height \>170 cm, and a 39 F tube if height ≤170 cm. For females, a 37 F tube was used if height \>160 cm, and a 35 F tube if height ≤160 cm. The depth was determined using the formula: 12 + (patient height/10). The calculated depth was marked on the DLT, and after intubation, the mark was positioned at the level of the upper teeth.
62831498|NCT02057250|EXPERIMENTAL|Sarilumab 200 mg by PFS|Sarilumab 200 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
62048706|NCT02993445|EXPERIMENTAL|Foot Reflexology|The procedure for FR focuses on activating specific reflex areas on the foot linked with the eye and eye disease, via massage. Although in the interest of repeatable precision, we have decided to use a FR board (fig.1) to conduct the procedure. This board has two foot shaped pieces of wood mounted on a flat board with springs. On top of these wooden feet are small wooden nodes, which are organized at precise locations to activate the reflexology of the foot by stimulation certain pressure points. The patient will be instructed to rest their feet on these boards with a comfortable pressure for a period of 5 minutes.
62048707|NCT05706766|EXPERIMENTAL|Exercise Group (PARE)|"Participants will be randomly assigned to the Exercise Group (PARE) and will complete study procedures as outlined:~* 8 weeks of 3x weekly sessions of virtually supervised aerobic and resistance exercise performed at home using study-provided stationary bike, resistance equipment, heart-rate monitor, and a wi-fi enabled tablet.~* Clinic visits at week 1, week 10, and 30 days post Autologous Stem Cell Transplantation (ASCT).~* Questionnaires and surveys."
62048708|NCT05706766|ACTIVE_COMPARATOR|Waitlist Control Group|"Participants will be randomly assigned to the Waitlist Control Group and will complete study procedures as outlined:~* 8 weeks of continuing with normal daily activities.~* Option to participate in PARE exercise program after study completion.~* 3 clinic visits with option of 5 visits. The two additional visits are for evaluation and testing for those who choose to participate in exercise program after study completion."
62250819|NCT02849197||Primary Closure|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.~Technique: primary closure. Technical details: An elliptical incision was made, and the excision included sinus openings at the median line and extended down to the pre-sacral fascia. One suction drain was placed in the wound cavity. Subcutaneous tissue was approximated with interrupted 2-0 absorbable suture, and skin was closed with interrupted 2-0 silk suture."
62609129|NCT06731517||Ultrasonography group|In the Ultrasonography (USG) group, Double Lumen Tube selection was based on the transverse cricoid cartilage diameter measured preoperatively using ultrasound. A 41 F tube was selected if the cricoid diameter was ≥18 mm, 39 F for 16-17.9 mm, 37 F for 15-15.9 mm, 35 F for 13-14.9 mm, and 32 F for \<13 mm (Table 5) (5). To determine placement depth, the distance between the vocal cords and the Louis angle was measured (the Louis angle was used as a guide as it anatomically aligns with the carina). The position of the vocal cords was identified using USG. The measured length was marked starting from the bronchial cuff line, and this mark was positioned at the level of the vocal cords during intubation.
62831499|NCT02700906|ACTIVE_COMPARATOR|Corticosteroid injection|For corticosteroid injection, triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
62831500|NCT02700906|ACTIVE_COMPARATOR|Lidocaine injection|For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.
62609130|NCT06731517||Computed Tomography|In the Computed Tomography (CT) group, Double Lumen Tube selection was based on CT measurements. Radiologists measured the cricoid diameter and the distance between the carina and the vocal cords. A 41 F tube was selected if the cricoid diameter was ≥18 mm, 39 F for 16-17.9 mm, 37 F for 15-15.9 mm, 35 F for 13-14.9 mm, and 32 F for \<13 mm (Table 5) (5). The calculated depth was marked starting from the bronchial cuff line, and this mark was positioned at the level of the vocal cords during intubation.
62440773|NCT03462329|NO_INTERVENTION|controls|Control subjects will not be given antibiotics.
62609131|NCT03802435|EXPERIMENTAL|Two-sessions of ultrasound-guided PIT|two-sessions of ultrasound-guided PIT with 10cc 5% dextrose (3 months interval)
62609132|NCT03802435|ACTIVE_COMPARATOR|One-session of ultrasound-guided PIT|one-session of ultrasound-guided PIT with 10cc 5% dextrose and 10cc normal saline separately (3 months interval)
62831501|NCT05647317|OTHER|Digital technology-based system for heart failure management|This is a single-arm study to assess the feasibility and preliminary effectiveness of a digital technology-based system for heart failure management
62831502|NCT02815501||women|"attending the emergency room and/or hospitalised or followed for: Spontaneous and/or repeated miscarriage Foetal death Pre-eclampsia Retroplacental haematoma Post-partum haemorrhage Premature delivery~Blood samples"
62831503|NCT03413488|EXPERIMENTAL|Kinesio taping|subject with shoulder impingement syndrome
62831504|NCT03413488|ACTIVE_COMPARATOR|Exercise|subject with shoulder impingement syndrome
62831505|NCT01595542|EXPERIMENTAL|Intervention|Parents served by experimental school sites received intervention packets including modified vaccine consent form
62831506|NCT01595542|NO_INTERVENTION|Control|Did not receive intervention materials
62831507|NCT02904278|EXPERIMENTAL|Teen Pocket PATH® Mobile Application|"Participants in this group will receive the mobile application for improving adherence to their post-transplant medications, along with standard post-transplant care, in accordance with the CTOTC-10 Cardiac Consortium Clinical Care Guidelines.~The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken. Additionally, the mobile app. will inform the investigators, by way of automated text messaging, of treatment adherence.~Duration of participation: up to 12 months post heart transplantation."
62831508|NCT02904278|OTHER|Control Group: Standard of Care|"Participants in the control group will receive standard post-transplant care, in accordance with the CTOTC-10 Cardiac Consortium Clinical Care Guidelines.~Duration of participation: up to 12 months post heart transplantation."
62831509|NCT00855881|EXPERIMENTAL|Treatment arm|Treated with tegafur-uracil for 1 year
62831510|NCT03397810|EXPERIMENTAL|Singe arm|Subjects will receive a low dose radiotherapy focused to the heart
62831511|NCT01574469|ACTIVE_COMPARATOR|1 = Tested product|
62831512|NCT01574469|PLACEBO_COMPARATOR|2 = Control product|
62831513|NCT04889638|EXPERIMENTAL|Cessation intervention|Participants will undergo pre-/post-comparisons of a personalized, remote smoking cessation intervention composed of two main elements: a) prescription and monitoring of nicotine (e.g., replacement therapy) and/or non-nicotine pharmacotherapies (e.g., varenicline) and b) cessation-centered motivational messaging.
62440774|NCT04948190||SARS-CoV-2 Infected/ positive group|Has tested positive for SARS-CoV-2 within appropriate timeframe (criteria vary for different study stages). Aged 16 years or older, willing and able to provide informed consent.
62440775|NCT04948190||SARS-CoV-2 negative group|Has tested negative for SARS-CoV-2 within appropriate timeframe (criteria vary for different study stages, and in phase 2 part 1, 2 and 4 enrolment may be accepted using symptoms-based criteria). Aged 16 years or older, willing and able to provide informed consent.
62831514|NCT00437229|EXPERIMENTAL|Subjects in Part A|In PART A, subjects received Regimen A: oral casopitant alone (150 mg once daily \[QD\] Day 1, 50 mg QD Days 2 and 3); Regimen B: oral dexamethasone (20 mg QD Day 1 and 8 mg twice daily \[BID\] Days 2 and 3) and intravenous (IV) ondansetron (32 mg single-dose Day 1); and Regimen C: oral casopitant as in Regimen A, IV ondansetron as in Regimen B and a lower dose oral dexamethasone than in Regimen B (12 mg QD Day 1, 8 mg QD Days 2 and 3).
62831515|NCT00437229|EXPERIMENTAL|Subjects in Part B|In PART B, subjects received Regimen D: oral casopitant alone (150 mg QD Day 1, 50 mg QD Days 2 and 3); Regimen E: IV dexamethasone (8 mg single-dose Day 1 only) and oral ondansetron (8 mg BID Days 1 to 3); and Regimen F: oral casopitant regimen as in Regimen D, and IV dexamethasone and oral ondansetron as in Regimen E.
62831516|NCT03340675|EXPERIMENTAL|Oral Ifetroban - Low Dose|Weight based, once daily oral ifetroban
62831517|NCT03340675|EXPERIMENTAL|Oral Ifetroban - High Dose|Weight based, once daily oral ifetroban
62831518|NCT03340675|PLACEBO_COMPARATOR|Placebos|Matching Placebo
62440776|NCT01021150|EXPERIMENTAL|Ombrabulin/cisplatin|AVE8062 combined with 75 mg/m2 of cisplatin will be administered once in every 3 weeks, with 30-minute intravenous infusion
62440777|NCT01816152|ACTIVE_COMPARATOR|Active Intervention|Light levels, primary and secondary measurements are obtained after a 4-week intervention period where active lighting is experienced by patients.
62440778|NCT01816152|PLACEBO_COMPARATOR|Inactive intervention|Light levels, primary and secondary measurements are obtained after a 4-week intervention period where an inactive lighting is experienced by patients
62440779|NCT02207621|EXPERIMENTAL|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) \& 1 drop placebo in the morning (AM) in both eyes (OU)
62440780|NCT02207621|ACTIVE_COMPARATOR|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
62440781|NCT02207621|EXPERIMENTAL|AR-13324 Ophthalmic Solution 0.02% BID|1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
62440782|NCT05172856|EXPERIMENTAL|IBI321 in advanced solid tumors|
62440783|NCT04948684||Patients with dystonia secondary to atypical Parkinsonism or Parkinson's disease|Patients with dystonia secondary to idiopathic Parkinson's disease or atypical parkinsonism and treated with BoNT
62440784|NCT04948684||Patients with atypical Parkinsonism or Parkinson's disease and no dystonia|Patients with idiopathic Parkinson's disease or atypical parkinsonism and without reported dystonia
62440785|NCT02345278|PLACEBO_COMPARATOR|Placebo|once daily sublingual administration for 1 month
62440786|NCT02345278|ACTIVE_COMPARATOR|SUBLIVAC FIX Mite mixture 10,000 AU/mL|once daily sublingual administration for 1 month
62831519|NCT01434212||Interferon and ribavirin|All the patients followed the standard treatment protocol.
62440787|NCT02345278|ACTIVE_COMPARATOR|SUBLIVAC FIX Mite mixture 25,000 AU/mL|once daily sublingual administration for 1 month
62831520|NCT04235608|EXPERIMENTAL|inhaled sedation with sevoflurane|Inhaled sedation with sevoflurane, as vaporized via the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
62831521|NCT04235608|ACTIVE_COMPARATOR|intravenous sedation with propofol|intravenous sedation with propofol, as already routinely used in participating ICUs
62831522|NCT02106598|EXPERIMENTAL|Phase 2 - Head and Neck Cancer|Patients with early oral cavity squamous cell carcinoma, and prior to standard of care wide local resection of the primary tumor and elective neck dissection, will receive a locally-administered, peritumoral injection of fluorescent cRGDY-PEG-Cy5.5-C dots (0.25 - 1 ml) around the primary lesion while under standard-of-care anesthesia for identification of optically-avid SLNs and to assess for metastatic disease. After completion of the neck dissection, nodal specimens will be examined ex vivo for fluorescence signal. Any fluorescent and non-fluorescent nodes will be compared to determine the true positive and false positive rates for cancer detection in this pilot study. No change in standard of care surgical practice will occur.
62831523|NCT05114954|EXPERIMENTAL|Experiment group|Patients treated with PFA catheter.
62831524|NCT03755778|EXPERIMENTAL|EDP-938 and itraconazole interaction (Part 1)|
62440788|NCT02345278|ACTIVE_COMPARATOR|SUBLIVAC FIX Mite mixture 50,000 AU/mL|once daily sublingual administration for 1 month
62831525|NCT03755778|EXPERIMENTAL|EDP-938 and rifampin interaction (Part 2)|
62440789|NCT02345278|ACTIVE_COMPARATOR|SUBLIVAC FIX Mite mixture 100,000 AU/mL|once daily sublingual administration for 1 month
62440790|NCT05396820|EXPERIMENTAL|Experimental pain|Experimental pain will be induced at the level of the dominant delto-pectoral groove of the participant (between the shoulder stump and the pectoral).
62440791|NCT00439608|EXPERIMENTAL|Treatment|Cetuximab, paclitaxel, and carboplatin weekly for 6 weeks with 50.4 Gy radiation.
62440792|NCT04283578|EXPERIMENTAL|Oxytocin|intranasal administration of OT
62440793|NCT04283578|PLACEBO_COMPARATOR|Placebo|intranasal administration of placebo
62440794|NCT00621179|ACTIVE_COMPARATOR|Group 1|Positive endometrial alpha v, beta 3 vitronectin expression. Standard controlled ovarian stimulation protocol followed by in vitro fertilization Intervention: No intervention
62831526|NCT03755778|EXPERIMENTAL|EDP-938 and quinidine interaction (Part 3)|
62831527|NCT02061488|ACTIVE_COMPARATOR|open-loop night|
62831528|NCT02061488|EXPERIMENTAL|closed-loop night|
62831529|NCT06044779|ACTIVE_COMPARATOR|Transversus Abdominis Plane (TAP) Anesthestic Block|Ultrasound-guided TAP block is done using 20 mL of 0.25% Bupivacaine administered at the lateral abdominal wall between the costal margin and the iliac crest
62831530|NCT06044779|ACTIVE_COMPARATOR|Erector Spinae Plane (ESP) Anesthetic Block|Ultrasound-guided ESP block is done using 20 mL of 0.25% Bupivacaine administered at the tip of the transverse process at the T9 level
62831531|NCT04613648||Group A|Painful and stiff hemiplegic side shoulders of stroke patients
62831532|NCT04613648||Group B|Asymptomatic non-hemiplegic side shoulders of stroke patients
62831533|NCT04613648||Group C|Non-dominant side shoulders of healthy volunteers
62831534|NCT00131079|EXPERIMENTAL|PEPAF|General Practitioner's assessment of physical activity level and minimal advice in routine clinical practice supplemented by physical activity prescription to those who accepted an additional 15 minutes appointment.
62831535|NCT00131079|ACTIVE_COMPARATOR|Control|
62831536|NCT04046913|ACTIVE_COMPARATOR|Low food additive diet|Dietary advice, given by a dietitian, will be discussed at trial baseline.
62831537|NCT04046913|PLACEBO_COMPARATOR|Habitual food additive diet|Dietary advice, given by a dietitian, will be discussed at trial baseline.
62831538|NCT04240535|EXPERIMENTAL|Active- onabotulinumtoxinA|BOTOX Cosmetic (onabotulinumtoxinA) for injection, is a sterile, vacuum-dried purified botulinum toxin type A, produced from fermentation of Hall strain Clostridium botulinum type A intended for intramuscular use. It is purified from the culture solution by dialysis and a series of acid precipitations to a complex consisting of the neurotoxin, and several accessory proteins. The complex is dissolved in sterile sodium chloride solution containing Albumin Human and is sterile filtered (0.2 microns) prior to filling and vacuum-drying.
62831539|NCT04240535|PLACEBO_COMPARATOR|Placebo-Bacteriostatic 0.9% Sodium Chloride|Placebo subjects will have injections in the same manner, but will be injected with Bacteriostatic 0.9% Sodium Chloride.
62831540|NCT00842335|EXPERIMENTAL|JI-101|
62831541|NCT04114760|ACTIVE_COMPARATOR|Group A : defibrillator ECG to patchy-type ECG|"Group A subject will performing ECG examination to a mock patient in the ambulance.~First ECG performance will be using defibrillator which contain 12-lead ECG checking function. And taking a 15 minutes wash out period. Second ECG performance after wash out period, will be using patchy-type wireless device.~when ECG examination performance ended, survey of patchy-type wireless ECG device usability will be collect."
62831542|NCT04114760|EXPERIMENTAL|Group B : patchy-type ECG to defibrillator ECG|"Group B subject will performing ECG examination to a mock patient in the ambulance.~First ECG performance will be using patchy-type wireless device.~And taking a 15 minutes wash out period. Second ECG performance after wash out period, will be using defibrillator which contain 12-lead ECG checking function.~when ECG examination performance ended, survey of patchy-type wireless ECG device usability will be collect."
62831543|NCT06409546|ACTIVE_COMPARATOR|Tocopherol 75% and pentoxifilline 5% gel|Patients treated with a topical gel of tocopherol 75% and pentoxifilline 5%
62831544|NCT06409546|PLACEBO_COMPARATOR|Placebo gel|Patients treated with a topical placebo gel control
62831545|NCT02686749|ACTIVE_COMPARATOR|AF catheter Ablation|Pulmonary Vein Isolation catheter ablation for treatment of AF. AF catheter ablation is an FDA approved treatment for AF
62831546|NCT02686749|ACTIVE_COMPARATOR|FDA approved anti arrhythmic drug|FDA approved anti arrhythmic drug for the treatment of AF will be based on treating physicians' preference in accordance to guidelines.
62831547|NCT01238068|ACTIVE_COMPARATOR|Gamma nail, fracture stabilization, better walking|
62831548|NCT04254458||PACG group|Cases who had first acute attack of primary angle closure glaucoma
62831549|NCT00761995|ACTIVE_COMPARATOR|Azopt|topical eye drop dosed 1 drop 3 times daily
62609133|NCT03802435|PLACEBO_COMPARATOR|Two-session of ultrasound-guided nerve hydrodissection|two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline (3 months interval).
62831550|NCT00761995|ACTIVE_COMPARATOR|Cosopt|topical eye drop
62048709|NCT05482048|NO_INTERVENTION|Usual Care|In line with current guidelines \[4\], participants will continue chest physiotherapy as advised by their physiotherapist (at least one session of ACT/day) and continue to undertake exercise and physical activity at their usual levels.
62440795|NCT00621179|EXPERIMENTAL|Group 2|Intervention: Positive endometrial alpha v beta 3 vitronectin expression, 3 months of leuprolide acetate in depot suspension administration prior to initiation of controlled ovarian stimulation followed by in vitro fertilization
62440796|NCT00621179|EXPERIMENTAL|Group 3|Negative endometrial alpha v, beta 3 vitronectin and administration of leuprolide acetate in depot suspension for 3 months prior to initiation of controlled ovarian stimulation
62609134|NCT05893069|EXPERIMENTAL|Treatment group|Oxandrolone
62440797|NCT00621179|ACTIVE_COMPARATOR|Group 4|Negative endometrial alpha v, beta 3 vitronectin expression and standard controlled ovarian stimulation protocol followed by in vitro fertilization. Intervention: No intervention
62440798|NCT02260492|EXPERIMENTAL|OT329 Solis|OT329 Solis (twice daily inhalation throughout the study)
62440799|NCT02260492|ACTIVE_COMPARATOR|Advair Diskus|Advair Diskus (twice daily inhalation throughout the study)
62440800|NCT02260492|PLACEBO_COMPARATOR|Placebo|Placebo (twice daily inhalation throughout the study)
62609135|NCT05893069|PLACEBO_COMPARATOR|Placebo Group|Placebo
62609136|NCT03232164|EXPERIMENTAL|18F-DCFPyL PET|Four separate substudies evaluating 18F-DCFPyL PET imaging of prostate cancer in four prostate cancer clinical scenarios under the following subheadings: (1) primary prostate cancer, (2) biochemical recurrence post-prostatectomy prior to radiation therapy, (3) androgen-resistant metastatic disease and (4) detection of clinically significant prostate cancer in low to intermediate risk primary prostate cancer
62609137|NCT01641705||Control Group|Group of nonsmokers individuals without respiratory disease.
62609138|NCT01641705||RA patients 1|RA patients nonsmokers with up to five years of disease.
62609139|NCT01641705||RA group 2|RA patients nonsmokers with six to ten years of disease.
62831551|NCT04757168|EXPERIMENTAL|NOGA TM probe|
62831552|NCT05468996|ACTIVE_COMPARATOR|young-old group|a group of patients who are 60 to 74 years old
62609140|NCT01641705||RA group 3|RA patients nonsmokers with eleven to fifteen years of disease.
62609141|NCT01641705||RA group 4|RA patients nonsmokers with sixteen or more years of disease
62831553|NCT05468996|ACTIVE_COMPARATOR|old-old group|a group of patients who are equal or older than 75 years
62831554|NCT05468996|ACTIVE_COMPARATOR|young adult group|a group of patients who are 20-59 years old
62250820|NCT02849197||Limberg Flap Technique|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.~Technique: Limberg Flap Technique. Technical details: A rhomboid incision was made as to include all sinus openings, and an excision was made down to the pre-sacral fascia. A bisector drawn in the rhombohedron was extended laterally to a length similar to that of a corner of the rhombohedron. Then, the flap was prepared by removing gluteal muscle with its fascia. One suction drain was placed at the wound cavity. The base of the flap was approximated with the presacral fascia at the excised area with interrupted 2-0 absorbable sutures. Subcutaneous tissue was approximated with interrupted 2-0 absorbable sutures, and the skin was closed with interrupted 3-0 prolene suture."
62440801|NCT06175195|EXPERIMENTAL|Treatment Group|"Experimental Group:~Participants in the experimental group would receive 8-10 session of psychoeducational based Program.~Waitlist control Group:~Participants in the Control group would not receive psychoeducational Intervention."
62831555|NCT02382536||Infusion set|Each subject will receive a total of 4 simultaneous subcutaneous infusions of insulin diluent, two using the investigational device (BD Scarlett Infusion Set) and two using the the comparator (Medtronic QuickSet Infusion Set).
62831556|NCT03160443|OTHER|Participants|"All participants performed the same evaluation: clinical and neuropsychological assessment.~All of them are patients with an eating disorder."
62440802|NCT06175195|NO_INTERVENTION|Control Group|"Control Group:~Participants in the control group did not receive the said psychoeducational intervention."
62831557|NCT04942821|EXPERIMENTAL|Platelet rich fibrin and coronally advanced flap|Coronally advanced flap and platelet rich fibrin were used in treatment arms.
62831558|NCT04942821|ACTIVE_COMPARATOR|Connective tissue graft and coronally advanced flap|Coronally advanced flap and connective tissue graft were used in treatment arms.
62831559|NCT00491634|EXPERIMENTAL|1|treosulfan
62440803|NCT02918838|EXPERIMENTAL|Own Adherence Group|Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
62440804|NCT02918838|EXPERIMENTAL|Fixed Adherence Group|Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
62440805|NCT02918838|ACTIVE_COMPARATOR|Control Group|Participants do not receive a lottery incentive conditional on adherence. Participants will however, continue to receive weekly messaging with airtime top-up contingent on response.
62440806|NCT01606566|EXPERIMENTAL|Amphinex induced PCI of bleomycin|"Drug: Amphinex induced PCI of bleomycin~Intervention:Intravenous administration of Amphinex (day 0) followed by intravenous administration of bleomycin and laser light application (day 4). Laser light application could be both interstitial and/or superficial depending on the tumour location."
62440807|NCT00903383|EXPERIMENTAL|Low Dose|A low dose of LX3305; daily oral intake for 12 weeks
62440808|NCT00903383|EXPERIMENTAL|Mid Dose|A mid dose of LX3305; daily oral intake for 12 weeks
62440809|NCT00903383|EXPERIMENTAL|High Dose|A high dose of LX3305; daily oral intake for 12 weeks
62440810|NCT00903383|PLACEBO_COMPARATOR|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
62440811|NCT01773577||Physician Pract. Employee and Off. Staff|The office staff and providers and physician practices enrolled in the RHIO
62440812|NCT05743296||Cross-sectional study, no arm|"Experimental: Training with the virtual reality program (MOTOCOG)~Training consists of 26 minutes task-specific training."
62440813|NCT03433001||Ixazomib + Lenalidomide + Dexamethasone|Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.
62440814|NCT00006425||1|25 women undergoing ductal lavage
62440815|NCT03640936||Healthy|Healthy controls, without asthma or allergy (negative prick test)
62440816|NCT03640936||Allergic asthma|Patients with allergic asthma sensitized to Dermatophagoides pteronyssinus, tested by prick test or specific IgE
62440817|NCT03640936||Non-allergic asthma|Patients with asthma not sensitized to Dermatophagoides pteronyssinus, with negative prick test or specific IgE
62440818|NCT03445559|NO_INTERVENTION|Control|No intervention
62440819|NCT03445559|EXPERIMENTAL|Intervention|The intervention is comprised of three components: 1) Clinical Order Check, 2) Academic Detailing, and 3) Audit and Feedback.
62440820|NCT05542537|EXPERIMENTAL|BB Produce Distribution + BB Nutrition Education + CHF Weekly Wellness Groups + CHF Web-Based Module|BB is Brighter Bites. CHF is Create Healthy Futures.
62440821|NCT05542537|ACTIVE_COMPARATOR|CHF Web-Based Module|CHF is Create Healthy Futures.
62440822|NCT05431309|ACTIVE_COMPARATOR|CCTA-based strategy group|Patients will be managed following the CCTA -based coronary heart disease prevention strategy for statin initiation and follow-up.
62440823|NCT05431309|SHAM_COMPARATOR|Traditional strategy group|Patients will be managed following the Traditional cardiovascular disease prevention strategy based on Chinese guideline for statin initiation and follow-up.
62609142|NCT06349005|ACTIVE_COMPARATOR|Group Storz VL|Patients will undergo intubation with the Storz Videolaryngoscope®, during which their hemodynamic responses will be documented.
62831560|NCT02936804|EXPERIMENTAL|Screening Arm|Low Dose Computed Tomography (LDCT) was performed at baseline + 2 rounds of biennial repeated LDCT. Management of positive screening test will be carried out by a pre-specified protocol.
62831561|NCT01614886|EXPERIMENTAL|1 step|
62831562|NCT01614886|ACTIVE_COMPARATOR|3 step|
62831563|NCT01435382|EXPERIMENTAL|Group A|
62831564|NCT01435382|EXPERIMENTAL|Group B|
62831565|NCT01435382|EXPERIMENTAL|Group C|
62831566|NCT01435382|EXPERIMENTAL|Group D|
62831567|NCT00879502||1|Men with the fragile X premutation
62831568|NCT00879502||2|Healthy men
62831569|NCT00879502||3|Brothers of men with the fragile X premutation
62831570|NCT06655129|EXPERIMENTAL|Intense Pulsed Light Treatment|Patients will be treated at different visits, and according to the IFU, with the Anthelia Medical Device (Intense Pulsed Light).
62048710|NCT05482048|EXPERIMENTAL|Exercise as Airway Clearance Therapy (ExACT)|"Arm-2 (ExACT): Participants will be advised to replace routine chest physiotherapy sessions with exercise combined with coughs and huffs - also referred to as forced expiratory techniques (FET) - agreed in our e-Delphi exercise REF and wider PPI discussion as possible alternatives for airway clearance. This intervention we term ExACT\*.~The undertaking of ExACT at least once per day is expected of those randomised to Arm 2.~\*Although routine chest physiotherapy is being replaced by ExACT, chest physiotherapy is permissible in the event of a chest exacerbation and a protocol deviation will be recorded."
62250821|NCT02849197||Modified Limberg Technique|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.~Technique: Modified Limberg Flap Technique. Technical details: As in Limberg flap technique, a rhomboid incision was made. Upper and lower corners of the excision were lateralized 2 cm away from the midline in order to keep the suturing line at the inferior from overlapping the midline. An excision was made down to the pre-sacral fascia. One suction drain was placed at the wound cavity, and the base of the flap was approximated with the pre-sacral fascia at the excised area with interrupted 2-0 absorbable sutures. Subcutaneous tissue was approximated with interrupted 2-0 absorbable suture, and the skin was closed with 3-0 prolene."
62440824|NCT05957718|EXPERIMENTAL|TKTX Group|In this group, We will use TKTX cream as a local anesthesia
62440825|NCT05957718|PLACEBO_COMPARATOR|Control Group|In this group, we will use a Vasalin as Placebo
62440826|NCT03896490|EXPERIMENTAL|ACT|
62440827|NCT03896490|PLACEBO_COMPARATOR|Control|
62609143|NCT06349005|ACTIVE_COMPARATOR|Group MacGrath VL|Patients will undergo intubation with the McGrath Videolaryngoscope®, during which their hemodynamic responses will be documented.
62609144|NCT06349005|ACTIVE_COMPARATOR|Group EzVision VL|Patients will undergo intubation with the EzVision Videolaryngoscope®, during which their hemodynamic responses will be documented.
62831571|NCT01660048|EXPERIMENTAL|SILS TEP repair|Half of the patients will undergo laparoscopic total extraperitoneal inguinal hernia repair using a single port (Triport)
62831572|NCT01660048|ACTIVE_COMPARATOR|Multiports TEP repair|Half of the patients will undergo the conventional multiports total extraperitoneal inguinal hernia repair
62831573|NCT03426891|EXPERIMENTAL|Combination Therapy|Pembrolizumab and Vorinostat Combined with Temozolomide and Radiotherapy. There are two parts to this study: Part 1 (dose escalation) and Part 2 (dose expansion). Dose Expansion: Twenty participants will be treated with vorinostat at the maximum tolerated dose (MTD) from dose escalation phase, pembrolizumab, temozolomide and radiation. During the maintenance phase, participants will receive Temozolomide (for the first 6 months), vorinostat (for 12 months), and pembrolizumab (for 12 months).
62609145|NCT06349005|ACTIVE_COMPARATOR|Group Traditional|Patients will undergo intubation with the traditional (Macintosh) laryngoscopy, during which their hemodynamic responses will be documented.
62831574|NCT05784493|EXPERIMENTAL|Washing by heated saline group|
62831575|NCT05784493|ACTIVE_COMPARATOR|Washing by normal room temperature saline group|
62831576|NCT04393454|EXPERIMENTAL|Sirolimus|Participants will be instructed to take 2 milligrams (mg) every day for 28 days (1 cycle). They will be evaluated in the oncology clinic every 2 weeks to make sure they are tolerating the medication well.
62831577|NCT01181063|EXPERIMENTAL|400/12 μg D94-2BF (60/40) inhaler|
62831578|NCT01181063|EXPERIMENTAL|320/9 μg D94-2BF (20/80) inhaler|
62048711|NCT01326858|EXPERIMENTAL|Olopatadine, 0.7%|Olopatadine hydrochloride ophthalmic solution, 0.7%, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic vehicle and ketotifen fumarate ophthalmic solution, 0.025%, Periods 2 and 3, as randomized
62831579|NCT01181063|ACTIVE_COMPARATOR|Symbicort 320/9 μg inhaler|
62831580|NCT01181063|EXPERIMENTAL|320/9 μg D94-2F (60/40) inhaler|
62440828|NCT05730985|EXPERIMENTAL|Intevention group|Experimental formula (Miotrof®) to take 1 sachet per day for 4 months
62440829|NCT05730985|PLACEBO_COMPARATOR|Placebo group|Placebo formula to take 1 sachet per day for 4 months
62440830|NCT00624767|EXPERIMENTAL|1|Insulin Nasal Spray
62440831|NCT00624767|ACTIVE_COMPARATOR|2|NovoLog
62831581|NCT01181063|EXPERIMENTAL|320/9 μg D94-2BF (60/40) inhaler|
62250822|NCT02780050|NO_INTERVENTION|chest compression before physical fitness|"The subjects consist of 25 medical school students and interns had experienced in cardiopulmonary resuscitation (CPR) education.~2 instructors, they had physical therapy (PT) certificate, take an exam for subject's muscle strength of each muscle. After that time, subjects take a rest for 10 minutes. Researchers educate to subjects for high quality CPR including 5 to 6cm compression depth, 100 to 120 beat per minute (bpm) rate, complete chest recoil. Subjects perform chest compression to manikin with skill reporting system during 4min under guidance of 110 bpm metronome sound (first chest compression). Researchers record subject's chest compression depth and rate in 1st chest compression."
62609146|NCT00925652|EXPERIMENTAL|Lifestyle: Diet|The dietary intervention focuses on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber. Patients receive a series of 13 telephone calls over the course of one-year with a dedicated and trained counselor.
62831582|NCT06526039|EXPERIMENTAL|Intervention|Patients will be treated with a novel short regimen
62831583|NCT00914316|ACTIVE_COMPARATOR|Phase 1-Ranolazine, Phase 2-Ranolazine|This group will participate in the Phase 1 -12 week supervised exercise program and will additionally receive ranolazine 1000 mg orally, twice daily, by mouth. In Phase 2, the group will exercise independently and also receive ranolazine 1000 mg orally twice daily by mouth.
62250823|NCT02780050|EXPERIMENTAL|after core muscle activation using physical fitness|"The subjects consist of 25 medical school students and interns had experienced in cardiopulmonary resuscitation (CPR) education.~After 1st chest compression, subjects take a rest during an hour and carry out PT. PT consist of 30 second plank for 3 sets, 12 times bridge for 3 sets and 20 times leg extension for 3 sets. Subjects take a rest during 30 seconds between sets, 1 minute every 3 sets.~After PT completion, subjects take a rest during 10 minutes, and then perform 2nd chest compression in the same way of 1st chest compression. Researchers record subject's chest compression depth and rate in 2nd chest compression."
62831584|NCT00914316|ACTIVE_COMPARATOR|Phase 1 -Ranolazine, Phase 2 -Placebo|This group will participate in the Phase 1 -12 week supervised exercise program and will additionally receive ranolazine 1000 mg orally, twice daily, by mouth. In Phase 2, the group will exercise independently and will receive a sugar pill in place of the study drug.
62831585|NCT00914316|ACTIVE_COMPARATOR|Phase 1 -Placebo, Phase 2 -Ranolazine|This group will participate in the Phase 1 -12 week supervised exercise regimen and will receive a sugar pill in place of the study drug. In Phase 2, the group will exercise independently and also receive ranolazine 1000 mg orally twice daily by mouth.
62831586|NCT00914316|PLACEBO_COMPARATOR|Phase 1 -Placebo, Phase 2 -Placebo|This group will participate in the Phase 1 -12 week supervised exercise regimen and will receive a sugar pill in place of the study drug. In Phase 2, the group will exercise independently and will receive a sugar pill in place of the study drug.
62831587|NCT03678493|EXPERIMENTAL|AML Patients undergoing Intensive Chemotherapy|
62831588|NCT03678493|PLACEBO_COMPARATOR|AML Patients undergoing Intensive Chemotherapy Control|
62831589|NCT03678493|EXPERIMENTAL|Patients undergoing Allo-HCT Patients|
62831590|NCT03678493|PLACEBO_COMPARATOR|Patients undergoing Allo-HCT Patients Control|
62831591|NCT04418648|EXPERIMENTAL|Toripalimab Consolidation|Patients in experimental group will receive toripalimab consolidation (240 mg) via iv infusion Q3W.
62831592|NCT04418648|NO_INTERVENTION|Observation|Patients in this group will receive observation.
62831593|NCT01063751|OTHER|Tritanium® Primary Acetabular Shell|Tritanium® Primary Acetabular Shell
62831594|NCT05338346|EXPERIMENTAL|ATG-018|"Dose Escalation Phase:~For Solid Tumors Group: A maximum of 44 subjects with solid tumors will be enrolled during the Dose Escalation Phase.~For Hematological Malignancies Group: Subjects with hematological malignancy will be enrolled.~Dose Expansion Phase:~The tumor types in Dose Expansion Phase may involve other tumor types based on the signals from the Dose Escalation Phase. Each tumor type is planned to enroll at least 12 subjects, and a further expansion (up to 40 subjects in each tumor type) may be triggered if 2 or more confirmed responses are observed in this cohort."
62831595|NCT05379374|ACTIVE_COMPARATOR|Bupivacaine group|0.25% bupivacaine 20 ml in TAP block
62831596|NCT05379374|EXPERIMENTAL|Bupivacaine morphine group|0.25% bupivacaine 20 ml with 3 mg morphine in TAP block
62440832|NCT05621083|EXPERIMENTAL|Fish oil (the omega-3 fatty acid supplement)|"Participants will be randomized to either start to receive fish oil (the omega-3 fatty acid supplement) for 6 weeks. Followed by a wash-out period of a minimum of 12 weeks before the treatment is changed.~Once the classical Randomized Controlled Trial (RCT) has finished, all the participants will repeat the fish oil intervention period (adaptive design) to determine if those the investigators defined as responders continue to be defined in the same category."
62609147|NCT00925652|EXPERIMENTAL|Lifestyle: Diet+Exericise|The dietary intervention focuses on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber. The exercise intervention is comprised of a target physical activity goal of 180 minutes of moderate-intensity activity each week. Patients receive a series of 13 telephone calls over the course of one-year with a dedicated and trained counselor.
62831597|NCT01025726|EXPERIMENTAL|Full Intervention|Police Patrolled Walking Program plus Social Marketing Intervention
62831598|NCT01025726|EXPERIMENTAL|Walking Only|Police Patrolled Walking Only Intervention
62831599|NCT01025726|ACTIVE_COMPARATOR|General Health|General Health Education Intervention
62831600|NCT01082016|NO_INTERVENTION|Control|Monitor sleep in ICU without attempts at promotion
62831601|NCT01082016|EXPERIMENTAL|Sleep promotion|Measure sleep in ICU with sleep promotion program in effect
62831602|NCT03549182|EXPERIMENTAL|male TPH2-GG carriers with ATD then placebo group|male TPH2-GG carriers will first receive ATD, then will receive placebo at least 5 weeks later.
62831603|NCT03549182|EXPERIMENTAL|male TPH2-GG carriers with placebo then ATD group|male TPH2-GG carriers will first receive placebo, then will receive ATD at least 5 weeks later.
62250824|NCT03929081|EXPERIMENTAL|Inference Based Approach (IBA)|The IBA treatment, a focused form of psychotherapy consists of twenty 45-minutes sessions, delivered weekly. The IBA model is based on the assumption that patients with OCD feel the need to perform compulsive acts because they misjudge the actual state of affairs, for example fearing that an appliance is on when it is visibly off. It is assumed that certain reasoning processes lead to these erroneous conclusions and distract the patient's attention from observable reality. IBA teaches patients how to defend themselves against the absorbing and confusing effect of obsessive reasoning processes and how to stay in touch with reality by actively relying on the sensory information of the very moment. As a consequence, the patient realizes that any compulsive act is superfluous and feels able to omit it.
62831604|NCT03549182|EXPERIMENTAL|male TPH2-TTcarriers with ATD then placebo group|male TPH2-TT carriers will first receive ATD, then will receive placebo at least 5 weeks later.
62250825|NCT03929081|ACTIVE_COMPARATOR|Cognitive Behavior Therapy (CBT)|In the control condition, the patients will receive twenty 45-minutes sessions of CBT consisting of self-guided exposure in vivo with response prevention (ERP) and cognitive therapy (CT), both standardized according to evidence-based session-by-session protocols, containing standardized forms for exercises and homework assignments.
62250826|NCT03929081|NO_INTERVENTION|No intervention (healthy controls)|The healthy control group will receive no intervention.
62250827|NCT06041399|EXPERIMENTAL|diabetic peripheral neuropathy group with hypoglycemic or lipid-lowering drugs.|Patients with type 2 diabetic peripheral neuropathy were categorized into the diabetic peripheral neuropathy group with hypoglycemic or lipid-lowering drugs group.The group treated with specific drug,like hypoglycemic or lipid-lowering drugs.
62250828|NCT06041399|NO_INTERVENTION|diabetic peripheral neuropathy group without hypoglycemic or lipid-lowering drugs.|Patients with type 2 diabetic peripheral neuropathy were categorized into the diabetic peripheral neuropathy group without hypoglycemic or lipid-lowering drugs group.No hypoglycemic or lipid-lowering drugs were used in this group.
62250829|NCT06041399|EXPERIMENTAL|Diabetic group with hypoglycemic or lipid-lowering drugs.|Patients with type 2 diabetes mellitus but not with diabetic peripheral neuropathy were distributed into the Diabetic group with hypoglycemic or lipid-lowering drugs group. group.The group treated with specific drug,like hypoglycemic or lipid-lowering drugs.
62250830|NCT06041399|NO_INTERVENTION|Diabetic group without hypoglycemic or lipid-lowering drugs.|Patients with type 2 diabetes mellitus but not with diabetic peripheral neuropathy were distributed into the Diabetic group without hypoglycemic or lipid-lowering drugs group.No hypoglycemic or lipid-lowering drugs were used in this group.
62250831|NCT03588988|EXPERIMENTAL|Dexmedetomidine group|
62250832|NCT03588988|PLACEBO_COMPARATOR|Control group|
62250833|NCT06455592|ACTIVE_COMPARATOR|standard|practice only once adapted physical activity in hospital and at home during four days
62250834|NCT06455592|EXPERIMENTAL|daily adapted physical activity|practice adapted physical activity daily in hospital and at home during four days
62250835|NCT01743924|EXPERIMENTAL|Raw|Broccoli,200 grams
62440833|NCT05621083|PLACEBO_COMPARATOR|High-oleic sunflower oil (HOSO) containing no omega-3 fatty acids|Participants will be randomized to either start to receive high-oleic sunflower oil (HOSO) for 6 weeks. Followed by a wash-out period of minimum 12 weeks, before the treatment is changed.
62609148|NCT00925652|EXPERIMENTAL|Lifestyle: Diet and Bevicizumab+CM|"The dietary intervention focuses on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber. Patients receive a series of 13 telephone calls over the course of one-year with a dedicated and trained counselor.~Bevicizumab: 15 mg/kg administered intravenously day 1 of a 3-week cycle for 6 months and day 1 of a 6 week cycle up to 2 years Cyclophosphamide: 50 mg orally each day of a 3-week cycle for 6 months Methotrexate: 2.5 mg orally twice daily of a 3-week cycle for 6 months"
62250836|NCT01743924|EXPERIMENTAL|cooked|Microwaved, 200 grams
62250837|NCT01861028||Phase I|A series of 50 consecutive primary iTotal patients will be compared to assess the fit of the tibial tray intra-operatively. These patients will have a series of tibial templates from Standard TKR implant sets trialed on the operative knee. Each template will be optimally sized and positioned based on the surgeon's judgment. Implant fit data (overhang and underhang) on the tibia for all templates will be taken from intra-operative measurements
62250838|NCT01861028||Phase II|The Phase I (50 consecutive primary iTotal patients) will also have implant fit data assessed for the femur. After final implantation is complete measurement will be assessed and recorded. A series of 25 primary knees that are scheduled for Standard TKR implants will then undergo the same measurements of the femur.
62440834|NCT00681408|ACTIVE_COMPARATOR|Omega 3 recipient arm|
62440835|NCT00681408|PLACEBO_COMPARATOR|Placebo|Placebo fish oil
62831605|NCT03549182|EXPERIMENTAL|male TPH2-TTcarriers with placebo then ATD group|male TPH2-TT carriers will first receive placebo,then will receive ATD at least 5 weeks later.
62831606|NCT01929317|EXPERIMENTAL|Ropinirole CR high-dose group|The subjects will receive Ropinirole CR 16mg/day for 4 weeks in screening phase. After randomization the subject will enter dose increase effect verification phase, where Ropinirole CR dose will titrated (2 mg /day/week) from 18 mg/day up to a maximum 24mg/day at intervals of 1 week or longer for 8 weeks, till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose for 4 weeks. This will be followed by a down titration phase of one week and long term phase of 39 weeks in which the subjects will receive incremental doses (2 mg /day/week) of Ropinirole CR from 18 mg/day till to a maximum of 24 mg/day till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose. Subjects completing the long term phase will undergo a down titration phase of 1 to 2 weeks.
62440836|NCT05868057|EXPERIMENTAL|Treatment group ARM 1|SHR7280 dry suspension then SHR7280 tablets
62831607|NCT01929317|EXPERIMENTAL|Ropinirole CR maintenance group|The subjects will receive Ropinirole CR 16mg/day for 4 weeks in screening phase. After randomization the subject will enter dose increase effect verification phase and Ropinirole CR dose will maintained at 16mg/day and placebo will be increased at intervals of 1 week for 8 weeks till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose for 4 weeks. This will be followed by a down titration phase of one week and long term phase of 39 weeks in which the subjects will receive incremental doses (2 mg/day/week) of Ropinirole CR from 18 mg/day till to a maximum of 24 mg/day till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose. Subjects completing the long term phase will undergo a down titration phase of 1 to 2 weeks.
62831608|NCT06530147||Transversalis Fascia Plane Block|One-side ultrasound (US)-guided Transversalis fascia plane (TFP) block with 0.25% bupivacaine will performe after placement laryngeal mask airway before surgery.
62831609|NCT06530147||Transversus Abdominis Plane Block|One-side ultrasound (US)-guided Transversus abdominis plane (TAP) block with 0.25% bupivacaine will performe after placement laryngeal mask airway before surgery.
62831610|NCT04681443|ACTIVE_COMPARATOR|Successful treatment|Patients with successfully treated pilonidal sinus disease
62831611|NCT04681443|ACTIVE_COMPARATOR|Treatment failure|Pilonidal sinus disease patients with treatment failure
62831612|NCT06232304|EXPERIMENTAL|TEACH|Participants will undergo a cognitive behavioral coping skills program and continue medical treatment as usual.
62831613|NCT06232304|NO_INTERVENTION|Control|Participants will only continue medical treatment as usual.
62831614|NCT05373407|EXPERIMENTAL|moderate intensity aerobic training|The exercises were conducted at a heart rate of 50-70% of maximum heart rate for 30 minutes. Exercises were included strengthening muscles groups (shoulder flexors, extensors, abductor's muscles, hip flexors, extensor muscles, knee flexors, extensor muscles, abdominal muscles, and back muscles).
62831615|NCT05373407|EXPERIMENTAL|low intensity aerobic training|"Exercises were performed at 40-50% of the maximum heart rate Starting by 15 minutes of Warm-up time included static stretching of upper and lower body muscles.~After that, participants performed 30 minutes of low-intensity aerobic training exercises, which included 20 minutes on the treadmill, followed by 10 minutes of cooling down.~A set of 5-10 exercises was performed by each muscle group, three sets per exercise were performed, and 10-15 repetitions per series were performed 4 days per week"
62831616|NCT02928042||Lactobacillus bacteria|Pseudomonas aeruginosa, Acinetobacter baumanii, Staph aureus and Klebsiella pneumoniae will be isolated from tracheal aspiration cultures. 80 isolates associated with pneumonia will be identified and made antibiogram with VITEK. Then antimicrobial effects of Lactobacillus bacteria (LAB) (Lc. lactis subsp. lactis (IL 1403), Lc. lactis subsp. lactis (ATCC 11454), Lactobacillus plantarum (FI8595), Leuconostoc mesenterodies subsp. cremoris (DSMZ 20346), Streptococcus thermophilus (NCFB2392), Pediococcus acidophilus (ATCC 25741)) and nisin bacteriocin will be investigated on the bacteria's growth rate in the laboratory.
62831617|NCT06379204|EXPERIMENTAL|the maximum physiological value standardized group|
62831618|NCT06379204|ACTIVE_COMPARATOR|the ventilatory threshold individualized group|
62831619|NCT06127030|EXPERIMENTAL|Brief behavioral teacher training and optional practice as usual|A brief, individualized, three-session teacher training that exists of two (bi)weekly individually tailored training sessions of 120 minutes, and a third session of 60 minutes. Teachers and children may receive practice as usual as well. The practice as usual may include any support or treatment as regularly provided by mental health care centers, schools, school collaborations and/or other organizations, except from pharmacological treatment for children's behavioral difficulties and/or behavioral teacher training/support. Practice as usual can also imply that there is no support or treatment.
62831620|NCT06127030|ACTIVE_COMPARATOR|Practice as usual only (PAU)|PAU may include any support or treatment as regularly provided by mental health care centers, schools, school collaborations and/or other organizations, except from pharmacological treatment for children's behavioral difficulties and/or behavioral teacher training/support. PAU can also imply that there is no support or treatment. There are no criteria for professionals providing PAU.
62831621|NCT02952404||Before workshop|October 2014 to October 2015 Cohort which is the time frame before the educational workshop
62831622|NCT02952404||After workshop|December 2015 to December 2016 Cohort which is the time after the educational workshop
62048712|NCT01326858|PLACEBO_COMPARATOR|Vehicle|Olopatadine hydrochloride ophthalmic solution vehicle, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic solution, 0.7% and ketotifen fumarate ophthalmic solution, 0.025%, Periods 2 and 3, as randomized
62440837|NCT05868057|EXPERIMENTAL|Treatment group ARM 2|SHR7280 tablets, then SHR7280 dry suspension
62440838|NCT05226520|EXPERIMENTAL|Probiotic NCC3001|Sachets of NCC3001 and excipient (maltodextrin) to be administered orally every day for 6 weeks
62440839|NCT05226520|PLACEBO_COMPARATOR|Matched Placebo Comparator|Sachets of matching placebo containing maltodextrin, yeast extract, cystein HCl and pea flour to be administered orally every day for 6 weeks
62440840|NCT00786071||Rett syndrome girls|The study population consists of a well-defined group of Dutch RTT thirteen girls with complete clinical, molecular and neurophysiological work-up.
62440841|NCT05287984|EXPERIMENTAL|ZFCR regimen|Patients aged 65 years or younger who can tolerate FCR： Patients in this group will receive zanubrutinib monotherapy for 12 months, then receive 4 cycles of zanubrutinib, fludarabine, cyclophosphamide and rituximab(ZFCR). Efficacy evaluation and MRD test of peripheral blood and bone marrow were performed at the 17th cycle after 16 cycles to obtain study end point data. Patients with CR/CRi and MRD negative could stop taking zanubrutinib, and other patients could stop taking zanubrutinib or continue treatment. Follow-up and efficacy assessment were conducted every three months.
62449471|NCT03196024|EXPERIMENTAL|Family-focused intervention arm|Family-focused intervention arm: Educational sessions will be provided to family pairs that include participants who are at-risk for type 2 diabetes or CVD and their co-participating family member.
62048713|NCT01326858|ACTIVE_COMPARATOR|Zaditor|Ketotifen fumarate ophthalmic solution, 0.025%, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic solution, 0.7% and olopatadine hydrochloride ophthalmic solution vehicle, Periods 2 and 3, as randomized
62048714|NCT04437238|EXPERIMENTAL|Intervention - KeepWell tool|KeepWell is standalone eHealth application aimed at supporting the self-management of older adults with multimorbidity, and it has the following features: (i) lifestyle advice for any combination of the top 10 chronic conditions affecting older adults); (ii) an avatar health coach that walks users through a health prioritization and goal setting exercise; (iii) a health risk questionnaire (HRQ) covering health (chronic diseases), lifestyle (physical activity, diet, smoking, alcohol, caffeine, bladder health), and social and emotional well-being (social frailty, isolation, loneliness) dimensions; (iv) an evidence-based, customized Action plan; (v) an interactive lifestyle tracker; (vi) journaling; (vii) and a health resources library. A health coach avatar leads users through a health priority and goal setting exercise that allows them to create a customized action plan based on guideline recommendations for lifestyle changes.
62048715|NCT04437238|PLACEBO_COMPARATOR|Control|Participants allocated to the control condition will receive care as usual but will be asked to complete the health risk questionnaire at baseline, 3- and 6-month follow-up via an online survey to collect outcomes data. The control group will receive full access to KeepWell at the conclusion of the study.
62048716|NCT06108375|OTHER|Live then recording|During the first visit music will be played live, during the second visit a recording will play.
62048717|NCT06108375|OTHER|Recording then live|During the first visit a recording will play, during the second visit music will be played live.
62250839|NCT02508051|NO_INTERVENTION|No daily emails|The usual care group will receive no intervention except for a reminder every six months to take a test of journal-based CME questions from 2 anesthesiology journals
62250840|NCT02508051|PLACEBO_COMPARATOR|Article email links|The email link group will get e-mailed web links to different specific articles, including articles on which the CME questions are based, published in 2 anesthesiology journals Monday through Friday with a reminder to take the same test every six months
62831623|NCT01812252|OTHER|Arm A (decitabine or azacitidine)|Patients receive decitabine or azacitidine IV or SC per standard of care. Treatment repeats per standard of care, every 28 days for 4 cycles of decitabine or 6 cycles of azacitidine in the absence of disease progression or unacceptable toxicity.
62831624|NCT01812252|OTHER|Arm B (induction-like chemotherapy regimen)|Patients receive physician choice of standard of care or other experimental protocol using induction-like chemotherapy regimen. No one specific regimen is required. Several regimens are listed in the protocol for example only.
62831625|NCT01246596|ACTIVE_COMPARATOR|chronic periodontitis|
62831626|NCT01246596|ACTIVE_COMPARATOR|aggressive periodontitis|
62831627|NCT01246596|ACTIVE_COMPARATOR|healthy patient (orthodontics extraction)|
62831628|NCT05304195||DLB patients|Dementia with lewy bodies according to the revised criteria of Mc Keith 2017
62831629|NCT05304195||Control|Absence of cognitive impairment and clinical element for a neurodegenerative disease
62831630|NCT00169897|EXPERIMENTAL|Hospital-based|This group has to go at the hospital 3 times per week to do the exercise program.
62831631|NCT00169897|ACTIVE_COMPARATOR|Home-Based|The group had to do the exercise program at home with indirect supervision (Polar watches and a phone call per week).
62831632|NCT02252003|EXPERIMENTAL|Pain scales testing|
62831633|NCT03837223||"patients underwent rescue protocols and fresh embryotransfer"|they were patients with good prognosis with a mean age of 34.13 ± 4.42 years, with a good ovarian reserve
62250841|NCT02508051|EXPERIMENTAL|Blog email links|The experimental group will get e-mailed web links to blogs Monday through Friday based on the same specific articles as in group 2; each daily blog will focus on a specific article, including articles on which CME questions are based, the blogs will have web links to the articles on which they are based and every six months group 3 will get a reminder to take the same test.
62250842|NCT05091749|EXPERIMENTAL|chronic coronary syndromes|
62831634|NCT03343912|EXPERIMENTAL|Test 1 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.400 mg/day and Trimegestone 0.06 mg/day (Test 1) over 21 days
62831635|NCT03343912|EXPERIMENTAL|Test 2 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.300 mg/day and Trimegestone 0.12 mg/day (Test 2) over 21 days
62831636|NCT03343912|EXPERIMENTAL|Test 3 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.200 mg/day and Trimegestone 0.18 mg/day (Test 3) over 21 days
62440842|NCT05287984|EXPERIMENTAL|ZBR regimen|For patients older than 65 years or who cannot tolerate FCR regimens: Patients in this group will receive zanubrutinib monotherapy for 12 months, then receive 4 cycles of bendamostine and rituximab(BR). Efficacy evaluation and MRD test of peripheral blood and bone marrow were performed at the 17th cycle after 16 cycles to obtain study end point data. Patients with CR/CRi and MRD negative could stop taking zanubrutinib and other patients could stop taking zanubrutinib or continue treatment.
62831637|NCT00658385|EXPERIMENTAL|1|GCSF (human recombinant granulocyte colony stimulating factor)Neupogen(Amgen), Filgrastim, Central venous line placement, Stem cell Collection (leukapheresis)
62831638|NCT05956015|EXPERIMENTAL|Patients with liver disease|"patients with chronic liver disease will receive a oral dose of a stable isotope labeled amino acid, 2H5-Phenylalanine, (45 mg/kg body weight 50% MPE).~Blood samples will be taken over 12 weeks."
62831639|NCT05956015|EXPERIMENTAL|Healthy volunteers with no signs of liver disease|"Healthy volunteers with no signs of liver disease will receive a oral dose of a stable isotope labeled amino acid, 2H5-Phenylalanine, (45 mg/kg body weight 50% MPE).~Blood samples will be taken over 12 weeks."
62831640|NCT02751723||lung cancer|validated questionnaires
62831641|NCT02751723||malignant melanoma|validated questionnaires
62048718|NCT05523414|EXPERIMENTAL|SKY|In-person SKY sessions will be 3 hours long on each of 3 consecutive days, and participants must be willing to attend all 3 sessions. Each session comprises a combination of breathwork, emotional resilience training, yoga, and leadership skills. The SKY technique includes a unique set of standardized breathing techniques to rapidly reduce neuroendocrine stress responses and the autonomic imbalance due to sympathetic overdrive. 8 weeks of online and/or in-person sessions will be delivered to participants in the follow-up period after the initial in-person intervention. They will receive intermittent reminders about their daily practice during the 8-week follow-up period. The participants will be asked to engage in daily 30 minute SKY sessions remotely, that is led by an instructor. Each participant will be required to log in the number of times a week they practice. In addition, weekly 60-minute reinforcement sessions will be conducted, in-person.
62048719|NCT05523414|NO_INTERVENTION|Control|Waitlist control participants will not be provided any intervention. However, they will have the same schedule for data and biological specimen collection as the SKY intervention participants. They will be provided an opportunity to take the SKY retreat free of charge at the end of the follow up period.
62048720|NCT06579495|EXPERIMENTAL|Peer involvement in Two player mode(peer involvement) in Competitive Exergame play|The peer participation group requires a classmate to accompany the child to complete the experiment task.
62048721|NCT06579495|EXPERIMENTAL|Single player mode in Competitive Exergame play|Single player mode play the single-person model and the child need to complete the experimental task under the teacher's supervision.
62048722|NCT06579495|ACTIVE_COMPARATOR|Children did not engage in any Competitive Exergame play|Children did not engage in any Competitive Exergame play nor any other structured school-based PA programs beyond physical education, and maintained just for a normal school life.
62831642|NCT02751723||cancer of the hepatobiliary system|validated questionnaires
62831643|NCT02751723||head and neck cancer|validated questionnaires
62831644|NCT02751723||breast cancer|validated questionnaires
62048723|NCT04398212|PLACEBO_COMPARATOR|Non-complaining group|the students in this group are not complaining of CVS symptoms but will be examined to diagnose CVS or exclude it
62048724|NCT04398212|EXPERIMENTAL|Complaining group|the students in this group are complaining of CVS symptoms but will be examined to document their complains and correlate to clinical findings
62449472|NCT03196024|ACTIVE_COMPARATOR|Individual-focused intervention arm|Individual-focused intervention arm: Educational sessions will be provided to the individual members of the family pairs who are at-risk for type 2 diabetes or CVD.
62449473|NCT05056142|ACTIVE_COMPARATOR|Epidural Anesthesia|Patients will receive epidural analgesia with 15 ml isobaric bupivacaine 0.125% plus fentanyl 2 μg/mL
62831645|NCT02751723||ovarian carcinoma|validated questionnaires
62831646|NCT02751723||pancreatic cancer|validated questionnaires
62831647|NCT02751723||stomach cancer|validated questionnaires
62831648|NCT02751723||oesophageal cancer|validated questionnaires
62831649|NCT02751723||colorectal cancer|validated questionnaires
62831650|NCT05201313|EXPERIMENTAL|lidocaine spray|nebulization 3 puffs of 10 mL Lidocaine hydrochloride 10% spray at a distance of 4-5 cm
62048725|NCT00617292||Category 1, Group 1|Children who have 21OHD and received prenatal dexamethasone treatment
62250843|NCT01660321|EXPERIMENTAL|Natroba|Natroba (Spinosad) Topical Suspension, 0.9%
62250844|NCT05983549|NO_INTERVENTION|Standard of care group|Patients will receive fluids according to clinical practice
62048726|NCT00617292||Category 1, Group 2|Children who have 21OHD and did not receive prenatal dexamethasone treatment (control)
62609149|NCT00925652|EXPERIMENTAL|Lifestyle: Diet+Exericise and Bevicizumab+CM|"The dietary intervention focuses on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber. The exercise intervention is comprised of a target physical activity goal of 180 minutes of moderate-intensity activity each week. Patients receive a series of 13 telephone calls over the course of one-year with a dedicated and trained counselor.~Bevicizumab: 15 mg/kg administered intravenously day 1 of a 3-week cycle for 6 months and day 1 of a 6 week cycle up to 2 years Cyclophosphamide: 50 mg orally each day of a 3-week cycle for 6 months Methotrexate: 2.5 mg orally twice daily of a 3-week cycle for 6 months"
62609150|NCT00078949|EXPERIMENTAL|Salvage arm I|Patients receive cisplatin IV over 60 minutes on day 1, dexamethasone IV or orally on days 1-4, and gemcitabine IV over 30 minutes on days 1 and 8.
62609151|NCT00078949|EXPERIMENTAL|Salvage arm II|Patients receive cisplatin IV over 24 hours on day 1, dexamethasone as in arm I, and cytarabine IV over 3 hours every 12 hours for a total of 2 doses on day 2.
62609152|NCT00078949|EXPERIMENTAL|Maintenance arm I|Beginning on day 28 posttransplantation, patients receive rituximab IV once every 2 months for 6 doses (a total of 12 months) in the absence of disease progression or unacceptable toxicity.
62609153|NCT00078949|NO_INTERVENTION|Maintenance arm II|Patients undergo observation only.
62609154|NCT04761159|ACTIVE_COMPARATOR|Ketofol1/1|Propofol 1 mg/kg + ketamin1 mg/kg (1/1 ratio) for group I to anesthesia induction.
62609155|NCT04761159|ACTIVE_COMPARATOR|Ketofol1/2|propofol 1,5 mg/kg + ketamin 0,75 mg/kg (2/1 ratio) for group II to anesthesia induction
62609156|NCT04761159|ACTIVE_COMPARATOR|Ketofol1/3|propofol 2 mg/kg +ketamin 0,66 mg/kg (3/1 ratio) for group III to anesthesia induction
62609157|NCT04761159|ACTIVE_COMPARATOR|propofol|propofol 3 mg/kg will perform for anesthesia induction
62609158|NCT03362801|OTHER|Sarcopenic|sarcopenic status the day before cystectomy.
62048727|NCT00617292||Category 2|Mothers of children who received prenatal dexamethasone treatment
62048728|NCT01774747|EXPERIMENTAL|DSP-1053|DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
62048729|NCT01774747|PLACEBO_COMPARATOR|Placebo|Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
62048730|NCT02745665||1-Elite Cyclist|"10 symptomatic cyclists with unilateral diagnosis of iliac EF,~FLOW MEDIATED DILATION Ankle brachial pressure index (ABPI) PULSE WAVE VELOCITY AND AUGMENTATION INDEX Blood pressure RAMP Test"
62048731|NCT02745665||2-Amateur Cyclist|"10 asymptomatic cyclists with no evidence of EF~FLOW MEDIATED DILATION ABPI PULSE WAVE VELOCITY AND AUGMENTATION Blood pressure RAMP Test"
62250845|NCT05983549|ACTIVE_COMPARATOR|Neutral balance|Patients will receive fluids aiming to a neutral balance
62449474|NCT05056142|ACTIVE_COMPARATOR|Spinal Anesthesia|Patients will receive Spinal analgesia with 5 mg bupivacaine and 25 μg of fentanyl in a 2 ml volume.
62609159|NCT03362801|OTHER|not sarcopenic|sarcopenic status the day before cystectomy.
62609160|NCT05920135|EXPERIMENTAL|Phase 1a; Dose escalation at various dose levels in patients with EGFR TKI sensitizing mutation|
62609161|NCT05920135|EXPERIMENTAL|Phase 1b; At 2 recommended dose levels of BBT-207 in patients with EGFR C797S mutation|
62609162|NCT05920135|EXPERIMENTAL|Phase 2; At the recommended phase 2 dose of BBT-207 in patients with EGFR C797S mutation|
62609163|NCT06235697|ACTIVE_COMPARATOR|EBRT + Brachy Boost|
62609164|NCT06235697|EXPERIMENTAL|SBRT|
62609165|NCT03988673|NO_INTERVENTION|decision aid with information only (control)|decision aid with information only, without values clarification method (VCM)
62609166|NCT03988673|ACTIVE_COMPARATOR|decision aid with implicit VCM|decision aid with information plus an implicit VCM
62609167|NCT03988673|ACTIVE_COMPARATOR|decision aid with explicit VCM|decision aid with information plus an explicit VCM
62609168|NCT01864213|EXPERIMENTAL|Ametop cream|
62609169|NCT00572975|EXPERIMENTAL|1|
62609170|NCT04877444|EXPERIMENTAL|Aerobic exercise (AEx) + upper extremity rehabilitation|Subject will receive a total of 24 intervention sessions. In each session, subjects will perform 15 minutes of AEx followed by 200 repetitions of an upper extremity rehabilitation program.
62609171|NCT04877444|EXPERIMENTAL|Stretching (CON) + upper extremity rehabilitation|Subjects will perform 15 minutes of lower extremity stretching. Following lower extremity stretching subjects will receive 200 repetitions of DDP.
62048732|NCT02745665||3-Control|"10 age-matched healthy male group~FLOW MEDIATED DILATION ABPI PULSE WAVE VELOCITY AND AUGMENTATION Blood pressure RAMP Test"
62048733|NCT04620187|EXPERIMENTAL|Standard of Care + T-DM1 in HER2-Positive Salivary Gland Cancer|"Participants will undergo standard of care surgery followed by standard of care radiation and chemotherapy with the addition of T-DM1.~Study cycles are 21 days (3 weeks):~* Participants will be given the study treatment T-DM1 at a predetermined dose (3.6 mg/kg) intravenously once (1x) every 3 weeks for up to 52 weeks (or about 1 year).~* Participants will be given standard of care radiation and chemotherapy~  * Radiation will be given on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, and Cycle 3 Day 1~ * Chemotherapy (cisplatin 40 mg/m2 intravenously or carboplatin AUC 2 intravenously) will be given on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, and Cycle 3 Day 1~Participants will be followed for 3 years."
62048734|NCT05651776|EXPERIMENTAL|Intervention of golf and rehab|2x/week x 6 weeks participation in a golf and PD rehab program
62048735|NCT04775914|ACTIVE_COMPARATOR|PCI standard|
62250846|NCT02401321|EXPERIMENTAL|Supportive care (Taking Care of Her program)|Patients and spouse caregivers complete the Taking Care of Her Program comprising 5 telephone-delivered intervention sessions over 45-60 minutes every 2 weeks. The intervention sessions are designed to provide training for spouse caregivers and patients to better manage the impact and emotional toll of recently diagnosed ovarian cancer, including its impact on their interpersonal communication and support about the cancer.
62250847|NCT03520959|PLACEBO_COMPARATOR|Placebo|A sequential regimen of LV305-matching placebo and G305-matching placebo.
62250848|NCT03520959|EXPERIMENTAL|CMB305|A sequential regimen of LV305 and G305.
62609172|NCT04878458|EXPERIMENTAL|PEI+GSL+GT|Sixty-two patients with advanced primary angle-closure glaucoma will receive phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.
62048736|NCT04775914|EXPERIMENTAL|PCI standard + ischemic conditioning|
62048737|NCT04775914|EXPERIMENTAL|Stent with ultrasound|
62048738|NCT04775914|ACTIVE_COMPARATOR|Stent without ultrasound|
62048739|NCT04245280|ACTIVE_COMPARATOR|PENG and LFCN blocks with ropivacaine|For the PENG block, and after negative aspiration, 20 ml of a solution of ropivacaine 0.5% with epinephrine 2.5 mcg/ml will be injected in 5 ml aliquots. Then, for the LFCN block, the lateral femoral cutaneous nerve will be localized, infero-medially to the antero-superior iliac spine, superficially to the sartorius muscle and 5 ml of the same solution will be injected with the same needle.
62250849|NCT02846350|ACTIVE_COMPARATOR|Experimental condition|The proposed intervention training utilizes a structured, sustainable MI training and supervision program designed to improve retention, adherence and persistence in challenging patients.
62250850|NCT02846350|NO_INTERVENTION|Standard of Care (SOC)|Physicians providing SOC will attend 3 time-matched video presentations over 2 years on research on optimizing entry into and retention in care and adherence, from materials available at the International Association for Providers of AIDS Care
62250851|NCT05560282|EXPERIMENTAL|Fenfluramine|"Fenfluramine, oral,~1. starting at 0.1mg/kg twice daily, maximum 26mg/day in patients not taking concomitant stiripentol~2. starting at 0.1mg/kg twice daily, maximum 17mg/day in patients taking concomitant stiripentol"
62831651|NCT05201313|ACTIVE_COMPARATOR|mepivacaine infiltration|subcutaneous / submucosal infiltration depending on the type of perineal tear of 10 ml of 1% mepivacaine hydrochloride
62831652|NCT03826303|EXPERIMENTAL|E-cigarette with ethanol, 1 puff|
62250852|NCT01996813|EXPERIMENTAL|Prospective Case|Patients with a BMI of 30 kg/m\^2 or greater who underwent shoulder arthroscopy in the beach chair position and were monitored intraoperatively using near-infrared spectroscopy while wearing thigh-high compression stockings.
62250853|NCT01996813|NO_INTERVENTION|Historical Control|Patients with a BMI of 30 kg/m\^2 or greater who underwent elective shoulder arthroscopy in the beach-chair position and were monitored intraoperatively using near-infrared spectroscopy but without wearing compression stockings.
62831653|NCT03826303|PLACEBO_COMPARATOR|E-cigarette without ethanol, 1 puff|
62831654|NCT03826303|EXPERIMENTAL|E-cigarette with ethanol, 10 puffs|
62831655|NCT03826303|PLACEBO_COMPARATOR|E-cigarette without ethanol, 10 puffs|
62831656|NCT04146948||COPD group|No intervention 40 years or older, clinical diagnosis of COPD (Global Initiative for Chronic Obstructive Lung Disease stages I to IV)
62831657|NCT04146948||healthy group|40 years or older, not with the clinical diagnosis of COPD
62250854|NCT05222971|EXPERIMENTAL|Olaparib plus durvalumab|"Olaparib 300 mg twice daily Durvalumab 1,500 mg IV on Day 1~Every 4 weeks"
62250855|NCT05222971|ACTIVE_COMPARATOR|Olaparib|"Olaparib 300 mg twice daily~Every 4 weeks"
62250856|NCT01637909|ACTIVE_COMPARATOR|general management|
62250857|NCT01637909|EXPERIMENTAL|The treatment group1|Korean DASH diet with sodium reduction intervention
62250858|NCT01637909|EXPERIMENTAL|The treatment group2|Korean DASH diet with sodium reduction intervention and excersize intervention
62831658|NCT05505955|EXPERIMENTAL|Part 1|single ascending dose, randomized, double-blind study，with 6 dose groups preset, of which 1 group will be administered under fasted and fed conditions. The food impact study consisted of 10 subjects, 8 of whom received HRS-5965 tablets and 2 of whom received placebo. The remaining cohorts required 8 subjects each, with 6 receiving HRS-5965 tablets and 2 receiving placebo.
62831659|NCT05505955|EXPERIMENTAL|Part 2|Multiple ascending dose, randomized, double-blind study，with 4 dose groups preset; Each dose group consisted of 8 healthy adult subjects randomly assigned 6:2 to HRS-5965 tablets or placebo.
62831660|NCT05505955|EXPERIMENTAL|Part 3|an open-label, nonrandomized, single-dose study to evaluate the effect of severe renal impairment (RI) on the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS -5965 compared to demographically-matched healthy participants with normal renal function. Subjects took HRS5965 tablets.
62831661|NCT03461835|ACTIVE_COMPARATOR|M4|High risk classification if the chance of the PUL being an EP ≥5 %; a calculation based on the average value of the two hCG and the ratio of these two hCG (0 h/48 h). Otherwise a low risk classification is made and a predicted outcome of either an IUP or failed PUL is presented.
62048740|NCT04245280|PLACEBO_COMPARATOR|PENG and LFCN blocks with saline solution|For the PENG block, and after negative aspiration, 20 ml of a saline solution will be injected in 5 ml aliquots. Then, for the LFCN block, the lateral femoral cutaneous nerve will be localized, infero-medially to the antero-superior iliac spine, superficially to the sartorius muscle and 5 ml of the same saline solution will be injected with the same needle.
62048741|NCT02561494|PLACEBO_COMPARATOR|Control|Intravenous normal saline 2 ml is given slowly as a placebo before the anesthesia induction and after finishing anesthesia.
62048742|NCT02561494|EXPERIMENTAL|Nefopam|Intravenous nefopam 20 mg is given slowly before the anesthesia induction and after finishing anesthesia.
62048743|NCT03214367|EXPERIMENTAL|LY900014|LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
62048744|NCT03214367|ACTIVE_COMPARATOR|Insulin Lispro (Humalog)|Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
62048745|NCT03214367|EXPERIMENTAL|LY900014 Postmeal (Open Label)|LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
62250859|NCT01766271|EXPERIMENTAL|Standard Risk Assessment (SRA) Only|
62250860|NCT01766271|EXPERIMENTAL|SRA plus Health Coaching|
62250861|NCT01766271|EXPERIMENTAL|SRA plus Genetic Testing|
62250862|NCT01766271|EXPERIMENTAL|SRA plus Health Coaching plus Genetic Testing|
62250863|NCT02713165|EXPERIMENTAL|Raisins Enhanced Diet|Participants will be provide with a Raisin Enhanced Diet over a short term period of time.
62250864|NCT04924569||Standard of Care|Individuals using an intermittent catheter to void urine through the urethra. Participants use their currently prescribed intermittent catheter per their clinician's standard of care.
62048746|NCT03214367|EXPERIMENTAL|LY900014 - Maximum Extended Enrollment (MEE)|LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
62048747|NCT03214367|ACTIVE_COMPARATOR|Insulin Lispro (Humalog)-MEE|Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
62250865|NCT01473979|ACTIVE_COMPARATOR|Arm A) Secondary closure with the vacuum-assisted system (VAC|"after the diagnosis of the poststernotomy wound infection is established the clinical procedure is obtained as follows: firstly the empiric antibiotic therapy with vancomycin is induced. The lab samples including bacteriology test are obtained. Surgical debridement is made until occurrence of tissue bleeding. Finally VAC sponge is implanted wit the negative suction pressure of 75 mmHg.~The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 48/72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done."
62250866|NCT01473979|ACTIVE_COMPARATOR|Arm B) Surgical procedure by delayed primary closure|In the first step, after the diagnosis of the infection was done, and the empiric antibiotic therapy is induced with vancomycin in the first surgical intervention the sternal wires will be removed, the mediastinum is explored and extensive surgical debridement is performed until occurrence of tissue bleeding.The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed.
62831662|NCT03461835|ACTIVE_COMPARATOR|NICE|High risk classification if the change in rising hCG levels ≤ 63 % or the change in declining hCG ≤ 50 %. If these cut-offs are exceeded the PUL is classified as low risk and predicted to be either an IUP or failed PUL depending on rising or declining hCG levels.
62831663|NCT02348749|EXPERIMENTAL|pts with primary or metastatic neuroendocrine tumors|For phase I, a single dose of 18F-MFBG will be injected intravenously in patients. For all patients, pharmacokinetics and bio distribution will be evaluated using non invasive PET scanning and blood assays at multiple time points post injection. In the expansion phase, a single dose of 18F-MFBG will be injected intravenously followed by a single time point imaging using PET MR scanner or PET/CT. In expansion cohort, an additional 50 patients with NB will be imaged. Patients will receive a single dose of 18F-MFBG intravenously, followed by a whole body PET scan on PET/CT or PET/CT scanner at 60-90 minutes post injection. Patients who show lesion detection by MFBG may be eligible for repeat imaging scan with 18 F- MFBG, at the discretion of PI or study investigator(s). All parameters and technical details of scanning will be as per the study and first imaging.
62831664|NCT02352896|EXPERIMENTAL|EPI-743|Participants will receive EPI-743 at a dose of 15 milligrams/kilogram (mg/kg) up to a total 200 mg 3 times daily (TID) orally with meal or by using nasogastric (NG) or gastrostomy feeding tubes with liquid food for at least 36 months.
62831665|NCT05813600|NO_INTERVENTION|lianhua qingwen granule|Patients were given Lianhua Qingwen Capsule orally, 3 times/day, 6 g/time. oral antipyretic (ibuprofen suspension 10ml) and symptomatic supportive treatment for body temperature \>38.5 ℃.
62831666|NCT05813600|EXPERIMENTAL|lianhua qingwen granule+Nirmatrelvir/Ritonavir|Patients were given Lianhua Qingwen Capsule orally, 3 times/day, 6 g/time. oral antipyretic (ibuprofen suspension 10ml) and symptomatic supportive treatment for body temperature \>38.5 ℃. And given Nirmatrelvir 300mg/Ritonavir 100mg orally, q12h, for 5 days.
62831667|NCT00684021|ACTIVE_COMPARATOR|1|Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).
62831668|NCT00684021|ACTIVE_COMPARATOR|2|Participants will receive active adult stem cell infusion 7 days after PCI.
62831669|NCT00684021|PLACEBO_COMPARATOR|3|Participants will receive placebo infusion (5% human serum albumin \[HSA\]) 3 days after PCI.
62048748|NCT03214367|EXPERIMENTAL|LY900014 Postmeal (Open Label)-MEE|LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
62048749|NCT01896882|EXPERIMENTAL|Intervention|Nutritional education on sodium restriction diet.
62048750|NCT01896882|NO_INTERVENTION|Control|Standard treatment.
62048751|NCT03325244||All participants|All participants will use a portable EEG monitor and FITBIT to monitor sleep and activity before and after night call
62250867|NCT01619111|ACTIVE_COMPARATOR|standard therapy|standard chemo- or endocrine therapy
62250868|NCT01619111|EXPERIMENTAL|standard therapy + lapatinib|standard chemo- or endocrine therapy + lapatinib
62609173|NCT04878458|EXPERIMENTAL|PEI+Trab|Sixty-two patients with advanced primary angle-closure glaucoma will receive phacoemulsification with intraocular lens implantation combined with trabeculectomy.
62609174|NCT04032951|EXPERIMENTAL|Adominal neoplasms patients|Patients in whom EUS-FNTA is performed with a novel type of biopsy neede.
62609175|NCT03025347|EXPERIMENTAL|Control|Experimental day where participants rest.
62609176|NCT03025347|EXPERIMENTAL|Exercise|Experimental day where participants complete a run.
62609177|NCT01078298|EXPERIMENTAL|varenicline|
62250869|NCT06209554|EXPERIMENTAL|control group|Eight patients to be treated with only Scaling and root planning .
62609178|NCT01078298|PLACEBO_COMPARATOR|placebo|placebo
62250870|NCT06209554|EXPERIMENTAL|erythritol group|Eight patients to be treated with erythritol air polishing as an adjunct to Scaling and root planning .
62250871|NCT06209554|EXPERIMENTAL|laser group|Eight patients to be treated with dioad laser as an adjunct to Scaling and root planning .
62250872|NCT02061566||Acute kidney injury|Acute kidney injury in ICU
62609179|NCT06255028|EXPERIMENTAL|Arm A: CNTY-101 in SLE Participants|"During Part 1 (Dose Confirmation Phase), participants with SLE will undergo lymphodepleting chemotherapy (LDC) followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental human recombinant interleukin 2 (IL-2).~After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2.~During Part 2 (Dose Expansion Phase), participants will receive treatments using the recommended phase 2 regimen (RP2R) confirmed during Part 1."
62609180|NCT06255028|EXPERIMENTAL|Arm B: CNTY-101 in LN Participants|"During Part 1 (Dose Confirmation Phase), participants with LN will undergo LDC followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental IL-2.~After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2.~During Part 2 (Dose Expansion Phase), participants will receive treatments using the RP2R confirmed during Part 1."
62250873|NCT02061566||Non acute kidney injury|Non acute kidney injury
62440843|NCT03877055|EXPERIMENTAL|Copanlisib and Ibrutinib|Copanlisib is given intravenously on days 1, 8, and 15 of 28 day cycles. Ibrutinib is given orally every day on 28 days cycles. The maximum duration of treatment is 36 cycles not exceeding 36 months. In the phase II study, the cohort will expand and accrue patients at the recommended phase II dose of copanlisib and ibrutinib determined during phase I dose escalation. In a simon two stage mini-max design, an initial 18 patients will be enrolled, inclusive of 6 patients treated at MTD or RP2D from phase I study, in first stage.
62609181|NCT06255028|EXPERIMENTAL|Arm C: CNTY-101 in IIM Participants|"During Part 1 (Dose Confirmation Phase), participants with IIM will undergo LDC followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental IL-2.~After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2.~During Part 2 (Dose Expansion Phase), participants will receive treatments using the RP2R confirmed during Part 1."
62609182|NCT06255028|EXPERIMENTAL|Arm D: CNTY-101 in DcSSC Participants|"During Part 1 (Dose Confirmation Phase), participants with DcSSC will undergo LDC followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental IL-2.~After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2.~During Part 2 (Dose Expansion Phase), participants will receive treatments using the RP2R confirmed during Part 1."
62609183|NCT02370069|ACTIVE_COMPARATOR|Previous immunization with PPV23|Participants who have received a previous vaccination with 1 or more dose of PPV23 at least 12 months previously will receive one dose of 0.5 mL Prevnar 13 study vaccine.
62609184|NCT02370069|ACTIVE_COMPARATOR|Naive to PPV23|Participants who have never received a previous vaccination with PPV23 will receive one dose of 0.5 mL Prevnar 13 study vaccine.
62609185|NCT00194194|ACTIVE_COMPARATOR|moderate|moderate behavioral management
62609186|NCT00194194|EXPERIMENTAL|intensive|intensive behavioral management
62609187|NCT04798872|EXPERIMENTAL|web-based educational program|Consist of 6 education session during 1 month and will be followed up by telephone counselling at 2, 4, and 6 weeks postpartum.
62250874|NCT02604953||Ocular Hypertension patients|Ocular hypertension patients are recruited from the Wills Eye Hospital Glaucoma Service. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
62250875|NCT02604953||Healthy Controls|Healthy adults are recruited from staff, family and friends of Wills Eye Hospital Glaucoma Research Center. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
62250876|NCT02604953||Glaucoma patients|Glaucoma patients are recruited from the Wills Eye Hospital Glaucoma Service. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
62250877|NCT04930809|EXPERIMENTAL|VER-01 single dose (2.5 mg THC)|PK profile is investigated after oral intake of a single dose VER-01 corresponding to 2.5 mg THC (Group A).
62250878|NCT04930809|EXPERIMENTAL|VER-01 single dose (5 mg THC)|PK profile is investigated after oral intake of a single dose VER-01 corresponding to 5 mg THC (Group B).
62250879|NCT04930809|EXPERIMENTAL|VER-01 single dose (10 mg THC)|PK profile is investigated after oral intake of a single dose VER-01 corresponding to 10 mg THC (Group C).
62250880|NCT04930809|EXPERIMENTAL|VER-01 single dose (20 mg THC)|PK profile is investigated after oral intake of a single dose VER-01 corresponding to 20 mg THC (Group D).
62250881|NCT04930809|EXPERIMENTAL|VER-01 multiple dose (5 mg THC)|PK profile is investigated after oral intake of VER-01 corresponding to 5 mg THC in the morning and 5 mg THC in the evening on 4 consecutive days (Group E).
62250882|NCT04930809|EXPERIMENTAL|VER-01 multiple dose (10 mg THC)|PK profile is investigated after oral intake of VER-01 corresponding to 10 mg THC in the morning and 10 mg THC in the evening on 4 consecutive days (Group F).
62250883|NCT04930809|EXPERIMENTAL|VER-01 multiple dose (12.5 / 20 mg THC)|PK profile is investigated after oral intake of VER-01 corresponding to 12.5 mg THC in the morning and 20.5 mg THC in the evening on 4 consecutive days (Group F).
62250884|NCT00784290|EXPERIMENTAL|1|Orantinib
62250885|NCT04503304|EXPERIMENTAL|HAS group|"hip abductors strengthening group~1. Hip abduction -standing\[Ferber et al.,2015\].~2. Sidelying hip abduction(clamshell)\[Schache et al.,2016\].~3. lateral leg raise: in brief, the patients lie down on bed on the unaffected side, with the resistance band positioned around the distal thigh of the affected limb.;later, they raise the above lower limbs upwards for about 30 degrees, stay for 5- 10 s and slowly lay down\[Xie et al.,2018\].~4. pelvic lift training, specifically, patients stand single-leg off the side at a 10-cm step. Later, they begin with the other limb that is lower than the step level, and contract the stance-limb hip abductor to raise the free leg to the step level while keeping the stance knee extended\[Xie et al.,2018\].~5. Stretching Hamstrings \[Fukuda et al.,2012\]. Number of sets = 3, Repetitions =10 repetitions for each set"
62250886|NCT04503304|ACTIVE_COMPARATOR|KES group|"knee extensors strengthening group~1. Isometric quadriceps setting~2. Knee extensions from sitting with knee bend to 90~3. Terminal knee extension from sitting.~4. Stretching Hamstrings Number of sets = 3, Repetitions =10 repetitions for each set"
62609188|NCT04798872|NO_INTERVENTION|control (usual care)|Mothers in the control group will receive standard treatment with pamphlets during the prenatal period. After delivery, standard postpartum care will be provided by the midwife, including pamphlets, rooming in and encourage mothers to breastfeed the baby.
62440844|NCT04877392|NO_INTERVENTION|Control (usual measures to control pain)|The neonate was taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. The neonate was swaddled, administered 1 mL of oral sucrose, and allowed to suck for 2 minutes prior to the procedure.
62440845|NCT04877392|EXPERIMENTAL|Case (usual measures to control pain plus inhaled lavender essential oil)|The neonate was taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. The neonate was swaddled, administered 1 mL of oral sucrose, and allowed to suck for 2 minutes prior to the procedure. The neonate also had a 7 x 7 cm gauze pad with 1 drop (43.75 mg) of 100% pure LEO (Pranarôm España S.L.) placed 2 cm under their nose for 2 minutes prior to starting the frenotomy and for the duration of the procedure.
62440846|NCT04735237|EXPERIMENTAL|Autogenous fat injection|Fat will first be harvested from the abdomen, then injected into the lip
62440847|NCT04735237|ACTIVE_COMPARATOR|Surgical revision with orbicularis oris muscle reconstruction|
62440848|NCT01868009|EXPERIMENTAL|ELLIPTA Period 1 and DISKUS Period 2 Arm|Subjects will use the ELLIPTA inhaler once daily for 5 to 9 days during the first period followed by the DISKUS inhaler twice daily for 5 to 9 days during the second period.
62440849|NCT01868009|EXPERIMENTAL|DISKUS Period 1 and ELLIPTA Period 2 Arm|Subjects will use the DISKUS inhaler twice daily for 5 to 9 days during the first period followed by the ELLIPTA inhaler once daily for 5 to 9 days during the second period.
62831670|NCT00684021|PLACEBO_COMPARATOR|4|Participants will receive placebo infusion (5% HSA) 7 days after PCI.
62831671|NCT02785549|EXPERIMENTAL|Symptomatic treatment with NSAID|1 g/8 h acetaminophen alternating with 600 mg/8 h ibuprofen
62609189|NCT04645134||Inactive|Older adults who have a sedentary or under-active lifestyle.
62609190|NCT04645134||Highly Active|Older adults who have a highly active lifestyle.
62831672|NCT02785549|ACTIVE_COMPARATOR|Antibiotic+symptomatic treatment with NSAID|875/125mg /8h amoxicillin/clavulanic acid and symptomatic treatment with 1 g/8 h acetaminophen alternating with 600 mg/8 h ibuprofen
62831673|NCT02070536||ARDS (Acute Respiratory Distress Syndrome)|
62831674|NCT03975985|EXPERIMENTAL|Core stability exercises|This group will be divided in two: core stability exercises (CSE) plus conventional therapy (CP) and CSE with transcutaneous electrical nerve stimulation (TENS) plus CP.
62831675|NCT03975985|ACTIVE_COMPARATOR|Conventional physiotherapy (CP)|CP consists in a variety (or combination) of multiple components such as tone normalization, exercises for maintain range of motion, passive mobilization of hemiparetic side, postural control, gait re-education to walking/standing between parallel bars or with a therapist, rehabilitation of the activity of daily living, etc.
62831676|NCT01656408|EXPERIMENTAL|Panel A: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
62609191|NCT05147701|EXPERIMENTAL|Treatment Group (AlloRx)|intravenous and sub-tenon delivery (total dose of 100 million cells)
62609192|NCT06730308|EXPERIMENTAL|Study arm|Methylprednisolone combined with concurrent chemoradiotherapy
62609193|NCT03662815|EXPERIMENTAL|iNeo-Vac-P01|"Personal Cancer Vaccine: iNeo-Vac-P01 (peptides)+ GM-CSF;~Peptides: 0.1 or 0.3 mg per peptide given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses. Additional booster vaccines might be administered depending on ethics and patients' potential benefit.~GM-CSF: 40 mcg given 30 minutes before iNeo-Vac-P01."
62831677|NCT01656408|EXPERIMENTAL|Panel B: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
62831678|NCT01656408|EXPERIMENTAL|Panel C: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
62831679|NCT01656408|EXPERIMENTAL|Panel D: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
62831680|NCT01656408|EXPERIMENTAL|Panel E-Elderly|Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days
62831681|NCT01656408|EXPERIMENTAL|Panel F - Elderly|Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days
62831682|NCT01656408|EXPERIMENTAL|Panel G - Healthy - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
62048752|NCT05340855|EXPERIMENTAL|Facebook Intervention|In Phase 3, all participants will receive the same intervention.
62048753|NCT02753855|EXPERIMENTAL|Telavancin Administration|Single dose of telavancin administered as a 1-hour intravenous infusion
62048754|NCT03008967||Total Knee and Hip Arthroplasty|Rehabilitation, observational. Identification of risk factors for poor response to rehabilitation programs after TJR and use these to identify patients who are most susceptible to poor outcomes
62048755|NCT05291780|EXPERIMENTAL|SABR in unresectable LA-NSCLC|Patients fit for chemotherapy will be enrolled to sequential chemotherapy-stereotactic ablative radiotherapy (SABR), while patients unfit for chemotherapy will be enrolled to exclusive stereotactic ablative radiotherapy (SABR).
62048756|NCT06579820|EXPERIMENTAL|experimental group|The experimental group consisted of the group to which a tubular bandage was placed over the routinely applied peripheral intravenous catheters.
62449475|NCT06314321|EXPERIMENTAL|Baduanjin exercise group|Before starting dialysis，Patients perform Baduanjin exercises. All Baduanjin training is provided by a professional doctor who has received training on BaduanJin and obtained certificate. Each session is approximately 30 minutes in duration, consisting of 5 minutes of warm-up exercises, 20 minutes of Baduanjinpractice, and 5 minutes of cool-down exercises.
62609194|NCT01126866|EXPERIMENTAL|preoperative chemotherapy|
62609195|NCT01512459|EXPERIMENTAL|Venlafaxine MR Capsules 150|Venlafaxine MR Capsules 150 of Dr.Reddy's Laboratories Limited
62048757|NCT06579820|NO_INTERVENTION|control group|The routine practice used for the application of peripheral intravenous catheters in the ward constituted the control group.
62048758|NCT01047592|ACTIVE_COMPARATOR|sarcosine|
62048759|NCT01047592|ACTIVE_COMPARATOR|sarcosine+ BE|
62048760|NCT01047592|PLACEBO_COMPARATOR|Placebo|
62048761|NCT06049264|EXPERIMENTAL|Thoracic Spine Manual Traction with Mobilization|Thoracic Spine Manual Traction with Mobilization
62048762|NCT06049264|ACTIVE_COMPARATOR|Thoracic Spine Manual Traction with Manipulation|Thoracic Spine Manual Traction with Manipulation
62048763|NCT05258786|EXPERIMENTAL|Intervention group|Transabdominal ultrasound will be applied to optimize the training program of contracting pelvic floor muscles, aiming to decrease postpartum urinary and fecal incontinence. Transperineal ultrasound will be used for pre-labor-coached maternal pushing aiming to improve pushing during the second stage of labor, reduce operative deliveries, the incidence of perineal tears, and urinary and fecal incontinence.
62048764|NCT05258786|NO_INTERVENTION|Control group|A pelvic floor physiotherapist will provide the participants with a verbal explanation of how to contract pelvic floor muscles. without ultrasound.
62048765|NCT05258786|NO_INTERVENTION|Standard care|Questionnaires only at four timeline points - before delivery at recruitment (T0), a week later (T2), immediately postpartum (T3), and two months postpartum (T4)
62449476|NCT06314321|NO_INTERVENTION|Control group|Patients in this group maintain their conventional therapy and daily life activities, and there is no intervention given.
62609196|NCT01512459|ACTIVE_COMPARATOR|Effexor XR 150 mg Capsules|Effexor XR 150 mg Capsules of Wyeth Laboratories Philadelphia, PA, USA
62609197|NCT05770336||Patient with previous hospitalization for Covid-19 infection|
62609198|NCT04128124||self-extubation|patients receiving invasive mechanical ventilation who develops an episode of self-removal (voluntary) of the endotracheal tube. Excluding those accidentally removed.
62609199|NCT04128124||spontaneous breathing trial|patients who, according to the attending physician, are clinically ready to initiate and begin a protocolized test (acording to the institutions or unit) to evaluate the readiness to be liberated from mechanical ventilation.
62609200|NCT01630356|EXPERIMENTAL|Intervention group|
62609201|NCT01630356|ACTIVE_COMPARATOR|Control group|
62831683|NCT01656408|EXPERIMENTAL|Panel H - Crossover|MK-8150 or matching placebo for 10 consecutive days in 2-period crossover with minimum 3 weeks washout period between the 2 treatment periods
62048766|NCT04636489|EXPERIMENTAL|Highland barley β-glucan group|Participants will be given oral liquids mainly containing highland barley β-glucan once daily for 8 weeks followed by comprehensive physical and clinical examinations.
62048767|NCT04636489|PLACEBO_COMPARATOR|Placebo group|Participants will be given oral liquids mainly containing Corn starch once daily for 8 weeks followed by comprehensive physical and clinical examinations.
62250887|NCT04122404|OTHER|Intervention|"Routine TB diagnostic care (sputum smear microscopy, sputum Xpert MTB/Rif / sputum Xpert MTB/Rif Ultra, sputum culture) + Intervention~Intervention: LF-LAM is made available at the study site for the clinical staff to use; Training of clinical staff in national TB guidelines and LF-LAM use together with staff from the National TB Programme in Ghana"
62609202|NCT03667027||Patients undergoing LTx with respiratory failure (cases)|Patients are receiving a respiratory support modality (mechanical ventilation and/or extracorporeal life support) as a bridge to lung transplantation (LTx).
62831684|NCT01656408|EXPERIMENTAL|Panel I - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
62831685|NCT01656408|EXPERIMENTAL|Panel J - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
62831686|NCT03119987||UGIB|Those who was diagnosed as UGI bleeding at emergency department during the study periods. Red cell distribution widths wers checked at all patients.
62831687|NCT02282618||heart failure with HTEA|Heart failure patients are treated with the world-wide accepted medicine, plus HTEA for 4 weeks.
62048768|NCT06200844|EXPERIMENTAL|Rotavac 5D|Rotavirus Vaccine (ROTAVAC 5D), is a monovalent vaccine containing suspension of live attenuated rotavirus 116E prepared in Vero cells, containing NLT 10 power 5.0 FFU and administered as a three-dose regimen, 4 weeks apart.
62048769|NCT06200844|PLACEBO_COMPARATOR|Placebo|Placebo administered as a three-dose regimen, 4 weeks apart.
62048770|NCT04021303|EXPERIMENTAL|Experimental Cereal|Experimental cereal with probiotics, prebiotic fiber and low carbohydrates through all the duration of the study.
62048771|NCT04021303|ACTIVE_COMPARATOR|Conventional cereal|Conventional gluten free cereal between 4 and 6 months old, and conventional gluten cereal between 7 and 12 months old.
62048772|NCT00586404||A|Patients with confirmed Barrett's Esophagus
62048773|NCT00244790|EXPERIMENTAL|low protein|
62831688|NCT02282618||heart failure with medicine|Heart failure patients are treated with the world-wide accepted medicine.
62831689|NCT00784914|ACTIVE_COMPARATOR|Cohort 1|Patients do not receive temsirolimus.
62048774|NCT02276885|EXPERIMENTAL|PBI Radiotherapy 6 Gy|Prone partial breast irradiation of 6 Gy x 5 over 5 days, on five consecutive days
62048775|NCT02276885|EXPERIMENTAL|PBI Radiotherapy 8 Gy|Prone partial breast irradiation of 8 Gy x 3 over 5 days, every other day
62048776|NCT05306041|EXPERIMENTAL|Inavolisib|Inavolisib for 6 cycles (18 weeks) Neoadjuvant endocrine therapy in combination with dual anti-HER2 blockade consisting of ready-to-use fixed-dose combination of pertuzumab and trastuzumab as subcutaneous (PH-FDC SC) formulation q3w for 6 cycles (18 weeks)
62250888|NCT04122404|NO_INTERVENTION|Standard of care|Routine TB diagnostic care (sputum smear microscopy, sputum Xpert MTB/Rif / sputum Xpert MTB/Rif Ultra, sputum culture)
62250889|NCT05057260||Long Covid cohort|Long Covid patients managed in the 10 participating sites
62831690|NCT00784914|EXPERIMENTAL|Cohort 2|48 hours after surgery, patients receive one 200 mg dose of temsirolimus IV.
62831691|NCT01266629||capsule patients|All patients that will undergo endoscopic capsule
62831692|NCT02267837|EXPERIMENTAL|OrthoPulse™|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment in conjunction with receiving daily OrthoPulse™ treatments.
62831693|NCT02267837|NO_INTERVENTION|Control|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment only, and no OrthoPulse™ treatments.
62831694|NCT04855851|EXPERIMENTAL|PAIN NEUROSCIENCE EDUCATION AND STRENGTH TRAINING|Subjects will receive 6 PAIN NEUROSCIENCE EDUCATION (PNE) sessions and 12 weeks (3 times/week) of STRENGTH TRAINING (ST)
62250890|NCT05831748|EXPERIMENTAL|Experimental Group|15 Transfemoral and Transtibial amputees will be included in this group. Patients will be treated with classic physiotherapy exercises for 12 weeks. Patients will practice exercises 3 times a week, one time in clinics with a physiotherapist and 2 times as home exercise.
62048777|NCT05306041|OTHER|without Inavolisib|Neoadjuvant endocrine therapy in combination with dual anti-HER2 blockade consisting of ready-to-use fixed-dose combination of pertuzumab and trastuzumab as subcutaneous (PH-FDC SC) formulation q3w for 6 cycles (18 weeks)
62250891|NCT05831748|ACTIVE_COMPARATOR|Active Comparator group|15 Transfemoral and Transtibial amputees will be included in this group. Patients will be treated with Clinical pilates exercises for 12 weeks. Patients will practice exercises 3 times a week, one time in clinics with a physiotherapist and 2 times as home exercise.
62440850|NCT04434313|EXPERIMENTAL|Delivery of iStride™ device gait treatment using telemedicine|"Treatment with the gait device will be adapted to remote delivery using the telemedicine platform. Participants and caregivers will be guided through an adapted treatment protocol remotely by physical therapists. Training will include platform navigation, device instruction, treatment guidelines, safety precautions, and assessment performance. Understanding will be verified through a caregiver quiz.~Gait patterns will be monitored before, during, and after treatment using gait sensors and outcome measures. Assessments include the 10-Meter Walk Test, Six Minute Walk Test, Timed Up and Go Test, Geriatric Depression Scale, Activities-Specific Balance Confidence Scale, and Stroke Impact Scale-16. Treatment will consist of 12 sessions of walking on the device for a goal of 30 minutes per session. Assessments will be repeated one-week, one-month, three-months, six-months, and 12-months after treatment. Feasibility and safety of the delivery method will be measured throughout the trial."
62440851|NCT05871697||Patients with spinal cord injury|Patients who have spinal cord injury.
62609203|NCT03667027||Patients undergoing LTx without prior respiratory support|Patients undergoing lung transplantation but do not require prior bridging respiratory support.
62609204|NCT03667027||Elective thoracic surgical patients|Patients undergoing elective thoracic surgery for planned lung or esophageal resection.
62609205|NCT03818776|EXPERIMENTAL|Arm 1 - 60 CGyE in 20 fractions|"Proton based external beam radiation therapy with concurrent Durvalumab starting one week before RT.~Radiation will follow dose escalation scheme:~60 CGyE in 20 fractions (3+3 participants, 3-6 total)"
62609206|NCT03818776|EXPERIMENTAL|Arm 2 - 69 CGyE in 23 fractions followed by expansion cohort a|"Proton based external beam radiation therapy with concurrent Durvalumab starting one week before RT.~Radiation will follow dose escalation scheme:~69 CGyE in 23 fractions (3+3 participants, 3-6 total) Followed by expansion cohort at identified RP2 dose (12 participants)"
62609207|NCT04935008|EXPERIMENTAL|Effect of recruitment maneuver on intracranial pressure|A recruitment maneuver will be performed in patients with decreased oxygen saturation due to atelectasis by applying 30 cm H2O positive pressure support for 30 seconds. The effect of the recruitment maneuver on intracranial pressure will be investigated by measuring the optic nerve sheath diameter with the help of ultrasonography before and after the recruitment maneuver.
62609208|NCT02869841|ACTIVE_COMPARATOR|Continuous rectus sheath analgesia|Local anesthetic continuous infusion with infusion pumps
62609209|NCT02869841|ACTIVE_COMPARATOR|Bolus rectus sheath analgesia|Bolus administration of local anesthetic
62609210|NCT02869841|ACTIVE_COMPARATOR|Single dose rectus sheath analgesia|single dose administration of local anesthetic
62609211|NCT02869841|PLACEBO_COMPARATOR|Placebo|no rectus sheath analgesia
62609212|NCT05212480|ACTIVE_COMPARATOR|Zinc arm|patients received a pill containing 25 mg of zinc twice a day for 15 days
62609213|NCT05212480|PLACEBO_COMPARATOR|Placebo|patients received identical shape, smell, taste and color pill like the protocol treatment twice a day for 15 days
62048778|NCT00957294||Schizophrenia|Patients with first-episode schizophrenia age 18-45 years
62048779|NCT00957294||Depression|First-time hospitalized patients with depression age 18-45 years
62048780|NCT00957294||healthy controls|Healthy controls matched on age and gender (18-45 years)
62250892|NCT05926388|EXPERIMENTAL|Video-assisted training group|The researcher will train the patients with video-assisted on insulin therapy and administration.
62250893|NCT06429384|EXPERIMENTAL|Y-3 low-dose group (20 mg/dose, qd)|Y-3 injection 20mg diluted with about 250 ml normal saline, intravenous infusion, qd, continuous medication for 10 days.
62440852|NCT06454500|EXPERIMENTAL|Stop Orders|For participants in this arm, a clinical decision support tool consisting of stop orders and an expiring alert that was displayed to care team clinicians.
62440853|NCT06454500|NO_INTERVENTION|Continuous Orders|For participants in this arm, no clinical decision support or alerts were displayed to care team clinicians and the urinary catheter order was continuous.
62440854|NCT01760278|EXPERIMENTAL|Study Arm|Subjects would receive recombinant Follicle Stimulating Hormone (rFSH) by S.C. injection 150 - 225 IU/day for 9 days. The embryos of subjects would be cultured by time-lapse imagery technique (embryoscope) and analysis would be done using patients receive rFSH (Gonembryo viewer equipped with latest software.
62440855|NCT01760278|ACTIVE_COMPARATOR|Control Arm|Subjects would receive recombinant Follicle Stimulating Hormone (rFSH) by S.C. injection 150 - 225 IU/day for 9 days. The embryos of subjects would be cultured in conventional culture environment and analysis would be done using established subjective morphological criteria.
62440856|NCT01264211|EXPERIMENTAL|Diacerein|
62440857|NCT01264211|PLACEBO_COMPARATOR|Placebo|
62440858|NCT02254733|EXPERIMENTAL|ACT + CBSST|Implementing Cognitive Behavioral Social Skills Training in an Assertive Community Treatment model
62440859|NCT02254733|ACTIVE_COMPARATOR|ACT only|Assertive Community Treatment only
62440860|NCT02223975||Vulval Disease|Patients who have undergone vulval skin biopsy or surgery for a vulval condition within Gloucestershire Hospitals NHS Foundation Trust.
62440861|NCT01593527|EXPERIMENTAL|Arm 1|Canakinumab 150 mg s.c.
62440862|NCT01593527|EXPERIMENTAL|Arm 2|Triamcinelone acetonide 40 mg i.m.
62440863|NCT04138849|EXPERIMENTAL|BBT-877 Low Dose|
62831695|NCT04855851|ACTIVE_COMPARATOR|USUAL CARE|The subjects of this group will receive Usual Care. In Spain, the treatment provided is mainly pharmacological, adjusted to the symptomatic profile of theses patients, and recommendation of aerobic and flexibility exercise
62831696|NCT05153616|EXPERIMENTAL|Diagnostic Polysomnography|
62831697|NCT06337123||Physica Porous KR femoral component|"Devices: Physica TT Tibial Plate and Physica Porous KR femoral component~Total knee arthroplasty with Physica TT Tibial Plate and Physica Porous KR femoral component"
62831698|NCT06337123||Physica Porous PS femoral component|"Devices: Physica TT Tibial Plate and Physica Porous PS femoral component~Total knee arthroplasty with Physica TT Tibial Plate and physica Porous PS femoral component"
62831699|NCT06373965|EXPERIMENTAL|CINTAI|Participants randomized to the Jom-TestPlus group will have access to all Jom-TestPlus features, including: assessment center; online registration; risk calculator; HIVST kit order, management, and monitoring; automated reminders; real-time e-counseling (eHIVST, active referral services); chemsex-related harm reduction services (screening, chemsex e-counseling, PartyPack ordering), chat function (ability to chat with counselors and research staff); and knowledge center (multimedia library on information and resources on HIV testing, PrEP, treatment, risks, and chemsex). Participants will follow a defined pathway to accessing HIVST kit ordering, e-counseling, and subsequent O2O linkage to clinical services.
62831700|NCT06373965|ACTIVE_COMPARATOR|Control|The TAU group will have access to the assessment center (risk assessment, follow-up surveys), knowledge center (multimedia library on information and resources on HIV testing, PrEP, treatment, risks, and chemsex), and a voucher for no-cost community-based HIV testing (sent via secure, encrypted email or can be downloaded on the Jom-TestPlus).
62831701|NCT05755516|EXPERIMENTAL|experimental group|Self-expanding Intracranial Stent (Tonbridge)
62831702|NCT05755516|ACTIVE_COMPARATOR|control group|LVIS and LVIS Jr. (MicroVention)
62250894|NCT06429384|EXPERIMENTAL|Y-3 medium dose group (40 mg/dose, qd)|Y-3 injection 40mg diluted with about 250 ml normal saline, intravenous infusion, qd, continuous medication for 10 days.
62440864|NCT04138849|EXPERIMENTAL|BBT-877 Mid Dose|
62831703|NCT02762916|EXPERIMENTAL|1- Telemedicine arm|"The intervention arm (IA), telehealth control, were followed up by himself helped by CONTECI program. They have to use every three months and if somethings was wrong the patient have to send mail to the doctor.~The intervention consisted to use the CONTECI program (included test) for the following of the patients."
62831704|NCT02762916|NO_INTERVENTION|2- Control arm|The Control Arm (CA) were followed up as usual every 6 months in outpatient vascular visits in the clinical hospital. If some patient have a complications or and emergency they have to do usual protocol, go to primary care or emergency.
62440865|NCT04138849|EXPERIMENTAL|BBT-877 High Dose|
62831705|NCT02556177|ACTIVE_COMPARATOR|mTBI patient group (Segment 1)|"1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit~Patients in the acute period following recent diagnosis of mild traumatic brain injury (mTBI)"
62831706|NCT02556177|ACTIVE_COMPARATOR|non-TBI patients (Segment 2)|Control subjects with no recent mild traumatic brain injury. 1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit
62831707|NCT02704364|EXPERIMENTAL|NGM282 Dose 1|NGM282 Dose 1
62440866|NCT04138849|PLACEBO_COMPARATOR|Placebo|
62440867|NCT05886699|EXPERIMENTAL|PRP combined with DFDBA|Open flap debridement, followed by placement of PRP combined with DFDBA
62440868|NCT05886699|ACTIVE_COMPARATOR|DFDBA|Open flap debridement, followed by placement of DFDBA
62440869|NCT03397628|NO_INTERVENTION|Control|
62250895|NCT06429384|EXPERIMENTAL|Y-3 high-dose group (60 mg/dose, qd)|Y-3 injection 60mg diluted with about 250 ml normal saline, intravenous infusion, qd, continuous medication for 10 days.
62250896|NCT06429384|PLACEBO_COMPARATOR|Blank control group|Y-3 blank injection 10ml was diluted with about 250 ml normal saline, intravenous infusion, qd, and continuous medication for 10 days.
62250897|NCT00572026|EXPERIMENTAL|1|Daytrana
62440870|NCT03397628|EXPERIMENTAL|Intervention|
62440871|NCT06483958|EXPERIMENTAL|Intervention|Palliative care protocol
62440872|NCT06483958|NO_INTERVENTION|Standard care|None intervention
62440873|NCT00533520|ACTIVE_COMPARATOR|0.5mg ranibizumab|Subjects will be treated with 0.5mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
62440874|NCT00533520|ACTIVE_COMPARATOR|1.0mg ranibizumab|Subjects will be treated with 1.0mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
62449477|NCT04253431|EXPERIMENTAL|L01|Finger pricking using lancing device with personal lancets
62048781|NCT00002587|EXPERIMENTAL|Arm I|"Patients receive paclitaxel IV over 3 hours on day 1 followed 2-6 hours later by topotecan IV continuously on days 1-14. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan and paclitaxel until the maximum tolerated dose (MTD) of each drug is determined. The MTD is defined as the highest dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
62048782|NCT03111056|EXPERIMENTAL|Web-Based Intervention|In an effort to reduce heavy drinking, participants will be asked to complete a daily monitoring assessment each morning for 14 days. Based on their responses, they will be provided a coping skill to either directly address their alcohol use or attempt to improve their emotion regulation and distress tolerance skills.
62048783|NCT03111056|NO_INTERVENTION|Assessment Only Control|Participants will be asked to complete only the daily monitoring assessment each morning for 14 days.
62048784|NCT02068495||Candesartan cilexetil/Amlodipine besilate|8 milligram (mg)/2.5 mg or 8 mg/5 mg, orally, once daily
62048785|NCT05047055||Single Group - 4 months moxifloxacin group|"Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E), Moxifloxacin (M)~Isoniazid, rifampicin, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by isoniazid, rifampicin, ethambutol and moxifloxacin daily for 2 months (2 HRZEM daily / 2HREM daily) - Duration 4 months~Drug dosages The Fixed-dose Combination (FDC) for HRZE(75/150/400/275mg) used under NTEP according to weight category will be used.~The patients enrolled in the study will receive an additional tablet of moxifloxacin(M) 400mg (body weight \<64 Kg) / 600mg (body weight \>65 Kg) along with the FDC both in the intensive and continuation phase."
62048786|NCT00733980|EXPERIMENTAL|GSK561679 arm|Double blind GSK561679
62048787|NCT00733980|PLACEBO_COMPARATOR|placebo arm|Double blind placebo
62048788|NCT03660579|NO_INTERVENTION|HIIT-CON|No intervention: Control
62048789|NCT03660579|EXPERIMENTAL|HIIT-AB Group|"Intake:~330ml (women) or 2x300 ml (men) of beer with 5.4% alcohol. The beverage intakes will be programmed from Monday to Friday.~Training:~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
62048790|NCT03660579|EXPERIMENTAL|HIIT-NAB Group|"Intake:~330 ml (women) or 2x300 ml (men) of beer without alcohol (0.0%). The beverage intakes will be programmed from Monday to Friday.~Training:~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
62250898|NCT00572026|NO_INTERVENTION|2|No treatment for ADHD
62609214|NCT06333405|EXPERIMENTAL|Experimental: Fecal Microbiota Transplantation|
62250899|NCT03571529|ACTIVE_COMPARATOR|Robotic rehabilitation|"Active Comparator: Robotic rehabilitation~Protocol with EMG-driven hand exoskeleton (Hand of Hope):~Warm-up: 10 min passive mode 2 min resting~Training: According to residual muscle power:~* 10 min active-assistive, 2 min resting, 10 min Active-assistive or~* 5 min active, 2 min resting, 15 min active assistive or~* 10 min active, 2 min resting, 10 min active and~* 10 min window cleaning game Robotic rehabilitation will be applied 5 times a week; Totally 15 sessions (3 weeks). Conventional physiotherapy also will be performed to the robotic rehabilitation group."
62449478|NCT04253431|EXPERIMENTAL|L02|Finger pricking using lancing device with personal lancets
62449479|NCT04253431|EXPERIMENTAL|L03|Finger pricking using lancing device with personal lancets
62609215|NCT02214862|EXPERIMENTAL|[F18]-FDDNP|2-(1-{6-\[(2-\[F-18\]fluoroethyl) (methyl)amino\]-2-naphthyl} ethylidene) malononitrile Radiopharmaceutical tracer, intravenous, single dose of 360+/-20 megabecquerel
62609216|NCT06193148|EXPERIMENTAL|Jaktinib 100mg|6 Participants will receive Jaktinib 100 mg, orally; 2 Participants will receive placebo, orally.
62831708|NCT02704364|EXPERIMENTAL|NGM282 Dose 2|NGM282 Dose 2
62831709|NCT02704364|ACTIVE_COMPARATOR|Placebo|Placebo
62831710|NCT06016504|EXPERIMENTAL|Arm 1 (AVCT)|Patients participate in an adaptive virtual consultation on trial.
62831711|NCT06016504|ACTIVE_COMPARATOR|Arm 2 (non-AVCT)|Patients participate in a non-adaptive virtual consultation on trial.
62831712|NCT06016504|ACTIVE_COMPARATOR|Arm 3 (information-only)|Patients receive information-only on trial.
62831713|NCT05647798|ACTIVE_COMPARATOR|Usual care glycemic management arm|Blood glucose will be checked every 2 hours during labor and glucose target will be 75-110 mg/dl
62831714|NCT05647798|ACTIVE_COMPARATOR|More liberalized glycemic management arm|Blood glucose will be checked every 4 hours during labor and glucose target will be 70-126 mg/dl
62831715|NCT06164002|EXPERIMENTAL|Group (I)|"Patients will be prepared with vertical feather edge margin design."
62831716|NCT06164002|EXPERIMENTAL|Group (II)|"Patients will be prepared with horizontal shoulder margin design."
62831717|NCT06164002|EXPERIMENTAL|Subgroup (A)|Patients will receive zirconia ceramic crowns
62831718|NCT06164002|EXPERIMENTAL|Subgroup (B)|Patients will receive hybrid ceramic crowns.
62831719|NCT02917096|EXPERIMENTAL|Treatment (ruxolitinib phosphate, chemotherapy,allogeneic HCT)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV on days -9 to -5, melphalan IV over 20 minutes on day -4, and ruxolitinib phosphate PO BID on days -3 to 30 with a taper for 2-3 weeks in the absence of disease progression or unacceptable toxicity. Patients being treated with ruxolitinib phosphate prior to allogeneic HCT as standard therapy may continue receiving ruxolitinib phosphate.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously beginning on day -3 and convert to PO daily when the patient is able to tolerate and absorb oral medications. Patients also receive sirolimus PO daily beginning on day -3. Treatment continues in the absence of GVHD.~STEM CELL TRANSPLANT: Patients undergo allogeneic HCT on day 0."
62831720|NCT00416910|ACTIVE_COMPARATOR|FCM|Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) q28d, max. 6 cycles
62831721|NCT00416910|EXPERIMENTAL|FCM + G-CSF|Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) Filgrastim (G-CSF) s.c. (5 µg/kg/d beginning on day +6 until neutrophil recovery above 1500/µl.) q28d, max. 6 cycles
62831722|NCT06298799|OTHER|Collection of DNA/RNA samples|Type 2 Diabetic participants cohort or Healthy participants cohort who will perform Collection of DNA/RNA samples
62831723|NCT06047015|EXPERIMENTAL|IRE plus Checkpoint Inhibitor|"Nivolumab: Patients will receive 240 mg nivolumab (dissolved in 250 mL NaCl 0.9%) administered intravenously over 30 minutes. The first dose will take place one or two days before the IRE treatment. The second and third doses will be given 2 and 4 weeks post-IRE. Bloodwork will be done just prior to each treatment.~IRE is performed in the CT scanner. Patients will receive a general anesthetic, and an ultrasound will be performed to locate the designated metastasis. Ultrasound-guided electrode placement (3 or 4 depending on cancer size, shape, and location) will be performed by interventional radiologist Dr. Chris Wall and the IRE device will be activated and used as per the technique of Martin et al."
62831724|NCT06047015|EXPERIMENTAL|IRE plus Checkpoint Inhibitor plus CpG Oligodeoxynucleotides (CpG-ODN)|"Patients will receive 240 mg nivolumab as above and also receive 8 mg of CpG-ODN dissolved in 1 mL normal saline administered peritumorally just before the IRE treatment. Three or four electrodes will be placed using a combination of ultrasound and CT guidance in preparation for treatment. Then using the electrodes as landmarks, injection of ¼ or 1/3 cc of the CpG-ODN solution will be performed near each of the 3 or 4 electrodes to achieve a peritumoral administration of the drug.~IRE is performed in the CT scanner. Patients will receive a general anesthetic and an ultrasound will be performed to locate the designated metastasis. Ultrasound-guided electrode placement (3 or 4 depending on cancer size, shape, and location) will be performed by interventional radiologist Dr. Chris Wall and the IRE device will be activated and used as per the technique of Martin et al."
62831725|NCT02874040|EXPERIMENTAL|Experimental|endoresection of the tumor scar or, when surgery is not possible, transpupillary thermotherapy on the tumor scar
62831726|NCT03856788|PLACEBO_COMPARATOR|Saline|Patients will undergo general anesthesia with a post-induction, post-intubation, pre-procedural subcostal TAP block with normal saline on the ipsilateral side as the extraction site.
62831727|NCT03856788|ACTIVE_COMPARATOR|Bupivacaine|Patients will undergo general anesthesia with a post-induction, post-intubation, pre-procedural subcostal TAP block with bupivacaine on the ipsilateral side as the extraction site.
62831728|NCT04815941|EXPERIMENTAL|Soft ball tissue release exercises|
62609217|NCT06193148|EXPERIMENTAL|Jaktinib 400mg|6 Participants will receive Jaktinib 400 mg, orally; 2 Participants will receive placebo, orally.
62831729|NCT01112917|EXPERIMENTAL|VenaTech Convertible Vena Cava Filter|Implantation of the VenaTech Convertible Filter. The filter is pre-loaded in a cartridge (syringe) and provided as a system with introducer accessories and instructions to accommodate delivery and implantation either using the femoral or jugular approach.
62609218|NCT06193148|EXPERIMENTAL|Jaktinib 600mg|6 Participants will receive Jaktinib 600 mg, orally; 2 Participants will receive placebo, orally.
62831730|NCT02868593|EXPERIMENTAL|Patient with clinical meningitis or meningo-encephalitis|
62831731|NCT04324437|OTHER|eRAPID online symptom monitoring in lung cancer|Two groups of patients with differing internet access: access from home or access in clinic only
62250900|NCT03571529|ACTIVE_COMPARATOR|conventional physiotherapy|"Conventional Physiotherapy will be performed to the both group 5 sessions a week and totally 15 sessions (3 weeks).~Conventional physiotherapy will include neurophysiological approaches. Each session will last around 1,5 hours."
62250901|NCT06372938||Pregnant Women with Fetal Growth Restriction|120 patients will be included diagnosed with late-onset Fetal Growth Restriction.
62250902|NCT06372938||Healthy Pregnancies|120 patients will be included in a control group of developing fetuses according to gestational age.
62250903|NCT01444482|EXPERIMENTAL|Matrix M adjuvanted influenza vaccine|1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M
62250904|NCT01444482|ACTIVE_COMPARATOR|Seasonal influenza vaccine|1 human dose of seasonal influenza vaccine
62440875|NCT00533520|ACTIVE_COMPARATOR|2.0mg ranibizumab|Subjects will be treated with 2.0 mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
62440876|NCT04960475||A/D group|Chronic ankle sprain patient with anxity or depression
62440877|NCT04960475||Control group|Chronic ankle sprain patient with no emotional issues
62609219|NCT06193148|EXPERIMENTAL|Jaktinib 800mg|6 Participants will receive Jaktinib 800 mg, orally; 2 Participants will receive placebo, orally.
62609220|NCT04532411||Pre-Booth Testing|This cohort was comprised of samples acquired as a component of outpatient SARS-CoV-2 (COVID-19) testing prior to implementation of the Hexapod personal protective booths.
62831732|NCT00494676|EXPERIMENTAL|Real prism glasses first, then sham|Participants in this arm will receive high power (57 prism diopter) peripheral prism glasses in the first period of the crossover and low power sham peripheral prism glasses in the second period
62831733|NCT00494676|EXPERIMENTAL|Sham prism glasses first, then real|Participants in this arm will receive low power sham peripheral prism glasses in the first period of the crossover and high power (57 prism diopter) peripheral prism glasses in the second period
62831734|NCT01520506|EXPERIMENTAL|Rapid Renal Denervation|
62831735|NCT05876182|EXPERIMENTAL|Oral Vancomycin 750|28 subjects with PSC will be randomized to this arm. They will take 2 tablet (1 of vancomycin 250 mg and 1 of placebo), three times a day administered orally (total dose 750 mg/daily).
62440878|NCT00927459|EXPERIMENTAL|PRO-040201|PRO-040201 with placebo control in each cohort
62440879|NCT00927459|PLACEBO_COMPARATOR|Placebo|PRO-040201 with placebo control in each cohort
62440880|NCT06547593|EXPERIMENTAL|Nutritional Intervention Group|"In this group, based on routine health management, a 3-month multifaceted nutrition intervention and a 9-month follow-up will be conducted. The specific content is as follows:~1. Anti-inflammatory dietary management: the elderly will receive an anti-inflammatory dietary menu designed based on the Chinese Dietary Guidelines for the Elderly (2022 Edition) provided by researchers.~2. Personalized nutritional intervention management: To ensure the compliance and participation of the elderly, a variety of health intervention materials will be provided. WeChat groups will be established to record the dietary status of the research subjects.~3. Health education: Nutrition and health knowledge lecture will be held for elderly family caregivers and the elderly themselves every two weeks."
62440881|NCT06547593|EXPERIMENTAL|Nutritional and Exercise Combined Intervention Group|To investigate the combined effects of nutrition and exercise, this group added exercise intervention in addition to the corresponding intervention measures of the nutrition intervention group. The subjects were required to exercise 3 times a week, 1 hour each time. The project included 10 minutes of warm-up exercises (stretching), 10-20 minutes of aerobic exercise (balance ability, leg and core muscle strength, etc.), 10-20 minutes of muscle resistance strength training (legs, buttocks, feet, upper limbs, etc.) and 10 minutes of relaxation training. All exercise programs were uniformly trained by professional coaches, and compliance was ensured by uploading photos to punch the clock. The intervention period is 3 months, with a follow-up of 9 months.
62449480|NCT04253431|EXPERIMENTAL|L04|Finger pricking using lancing device with personal lancets
62449481|NCT04253431|EXPERIMENTAL|L05|Finger pricking using lancing device with personal lancets
62831736|NCT05876182|EXPERIMENTAL|Oral Vancomycin 1500|28 subjects with PSC will be randomized to this arm.They will take 2 tablet of 250 mg of vancomycin three times a day administered orally (total dose 1500mg/daily)
62250905|NCT03054922|ACTIVE_COMPARATOR|Normal Saline|0.9% Sodium Chloride
62250906|NCT03054922|ACTIVE_COMPARATOR|Lactated Ringers|"Each 100 mL of Lactated Ringer's Injection USP contains:~Sodium Chloride USP 0.6 g; Sodium Lactate USP 0.31 g; Potassium Chloride USP 0.03 g; Calcium Chloride Dihydrate USP 0.02 g; Water for Injection USP qs"
62250907|NCT03054922|ACTIVE_COMPARATOR|Normosol-R|Each 100 mL of Normosol-R contains sodium chloride, 526 mg; sodium acetate, 222 mg; sodium gluconate, 502 mg; potassium chloride, 37 mg; magnesium chloride hexahydrate, 30 mg.
62250908|NCT00006392|EXPERIMENTAL|Vitamin E + selenium placebo|vitamin E and selenium placebo daily for 7-12 years
62250909|NCT00006392|EXPERIMENTAL|Selenium + vitamin E placebo|selenium and vitamin E placebo daily for 7-12 years
62831737|NCT05876182|PLACEBO_COMPARATOR|Placebo|28 subjects with PSC will be randomized to this arm. They will take 2 tablet (placebo-to-match oral vancomycin) administered orally three times a day.
62831738|NCT06284889|EXPERIMENTAL|Treatment|Brief Behavioral Activation
62831739|NCT06284889|PLACEBO_COMPARATOR|Treatment as usual (TAU)|Treatment as usual regarding depression received at their primary care centre.
62831740|NCT02141295|EXPERIMENTAL|Part 1 (Induction): Vanucizumab + mFOLFOX-6|Participants will receive vanucizumab at a dose of 2000 milligram (mg) as intravenous (IV) infusion; oxaliplatin at a dose of 85 mg per meter-squared (mg/m\^2) as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
62048791|NCT03660579|EXPERIMENTAL|HIIT-SW Group|"Intake:~330 ml (women) or 2x300 ml (men) of sparkling water. The beverage intakes will be programmed from Monday to Friday.~Training:~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
62048792|NCT03660579|EXPERIMENTAL|HIIT-ASW Group|"Intake:~330 ml (women) or 2x300 ml (men) of sparkling water with 5.4% alcohol.The beverage intakes will be programmed from Monday to Friday.~Training:~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
62250910|NCT00006392|EXPERIMENTAL|Vitamin E + selenium|vitamin E and selenium placebo daily for 7-12 years
62831741|NCT02141295|EXPERIMENTAL|Part 1 (Maintenance): Vanucizumab + 5-FU + Folinic acid|Participants will receive vanucizumab at a dose confirmed during induction as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
62831742|NCT02141295|ACTIVE_COMPARATOR|Part 2 (Induction): Bevacizumab + mFOLFOX-6|Participants will receive bevacizumab at a dose of 5 milligram per kilogram (mg/kg) as IV infusion; oxaliplatin at a dose of 85 mg/m\^2 as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
62831743|NCT02141295|EXPERIMENTAL|Part 2 (Induction): Vanucizumab + mFOLFOX-6|Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; oxaliplatin at a dose of 85 mg/m\^2 as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
62831744|NCT02141295|ACTIVE_COMPARATOR|Part 2 (Maintenance): Bevacizumab + 5-FU + Folinic acid|Participants will receive bevacizumab at a dose of 5 mg/kg as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
62831745|NCT02141295|EXPERIMENTAL|Part 2 (Maintenance): Vanucizumab + 5-FU + Folinic acid|Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
62831746|NCT05689476|EXPERIMENTAL|NAVA group|Nava ventilation
62831747|NCT05234307|EXPERIMENTAL|Treatment (PBF-1129, nivolumab)|Patients receive PBF-1129 PO QD and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62831748|NCT00912535|ACTIVE_COMPARATOR|Quetiapine extended release tablet|Quetiapine orally at a flexible dose fo 50-300mg/day according to the judgment by the investigator for 8 weeks, as adjunct to the same antidepressant at the same dose.
62831749|NCT00912535|PLACEBO_COMPARATOR|Placebo|Placebo orally, as adjunct to the same antidepressant at the same dose.
62831750|NCT02987686|EXPERIMENTAL|Topical Infliximab|Additionally to standard treatment, patients with all inclusive criteria and none exclusive criteria will be included in the therapeutic group and will receive topical infliximab QID for 4 weeks.
62831751|NCT02987686|NO_INTERVENTION|Observational group|Patients with all inclusive criteria and one exclusive criteria will receive the standard treatment, without topical infliximab.
62831752|NCT02585856|EXPERIMENTAL|PDT+stent|Patients with unresectable CCA are performed PDT and biliary stent with ERCP
62250911|NCT00006392|PLACEBO_COMPARATOR|Vitamin E placebo + selenium placebo|vitamine E placebo and selenium placebo daily for 7-12 years
62449482|NCT04253431|EXPERIMENTAL|L06|Finger pricking using lancing device with personal lancets
62449483|NCT04253431|EXPERIMENTAL|L07|Finger pricking using lancing device with personal lancets
62449484|NCT04253431|EXPERIMENTAL|L08|Finger pricking using lancing device with personal lancets
62449485|NCT04253431|EXPERIMENTAL|L09|Finger pricking using lancing device with personal lancets
62831753|NCT02585856|PLACEBO_COMPARATOR|stent|Patients with unresectable CCA are performed biliary stent with ERCP alone
62048793|NCT01071564|EXPERIMENTAL|Treatment (RO4929097 and vismodegib)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on day 1 or days -2, -1, and 1 of course 1 and days 1-3 and 8-10 of course 2 and all subsequent courses. Patients also receive vismodegib PO QD beginning day 8 of course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62609221|NCT04532411||Post-Booth Testing|This cohort was comprised of samples acquired as a component of outpatient SARS-CoV-2 (COVID-19) testing after implementation of the Hexapod personal protective booths.
62609222|NCT03268018|OTHER|Single arm|
62609223|NCT01967095|EXPERIMENTAL|erlotinib|"This protocol is a phase 1, single arm, open label study of combination daily low dose erlotinib plus twice weekly high dose erlotinib in patients with EGFR-Mutant lung cancer who have not yet received erlotinib or gefitinib. Six dose levels are planned for escalation, with the pulse dose erlotinib increasing.~Expansion cohort A: Treat an additional 19 pts at the MTD with CNS involvement at diagnosis"
62609224|NCT05637112||Prospective Cohort|All patients aged ≥18 years diagnosed with SLE who initiate anifrolumab as prescribed by their healthcare provider (HCP) per the approved country-specific label and are treated at the study sites will be eligible for inclusion.
62609225|NCT06482333|ACTIVE_COMPARATOR|Late Resumption|The first group will recommence DOACs on Day 2 as recommended by current guideline (Late Resumption)
62609226|NCT06482333|EXPERIMENTAL|Early Resumption|The second group will resume DOACs on the same day of the procedure (Early Resumption).
62609227|NCT04189133|EXPERIMENTAL|Study group|The study group will receive the daily administration sc of Luveris with increasing dosages two weeks (Treatment phase) as follows: Rec-LH 75 IU daily for 2 weeks; Rec-LH 150 IU daily for 2 weeks; Rec-LH 300 IU daily for 2 weeks; Rec-LH 600 IU daily for 2 weeks.
62609228|NCT04189133|ACTIVE_COMPARATOR|Control group|"The control group will receive the administration im of Gonasi HP as follows:~hCG 500 IU two times weekly, for 2 weeks; hCG 1000 IU two times weekly, for 2 weeks; hCG 1500 IU two times weekly, for 2 weeks; hCG 2000 IU two times weekly, for 2 weeks."
62609229|NCT06731387|EXPERIMENTAL|PTAs dispensing medications|
62609230|NCT05691244|ACTIVE_COMPARATOR|Normal Saline + Standard of care|Normal saline will be used as a comparator. It will be available in a 5.0 mL vial. Three doses will be administered as an IV bolus over one minute every 3 hours ± 1 hour on day 1. The dose will be repeated on days 3 and 6 post randomization. The study drug will be administered as an IV bolus dose over 1 minute within 24 hours of the stroke onset.
62609231|NCT05691244|EXPERIMENTAL|Sovateltide + Standard of care|The test product is sovateltide. It is available as a lyophilized injection containing 30 µg of sovateltide in a 5.0 mL vial. Three doses of 0.3 μg/kg will be administered as an IV bolus over one minute every 3 hours ± 1 hour on day 1. The dose will be repeated on days 3 and 6 post randomization. The study drug will be administered as an IV bolus dose over 1 minute within 24 hours of the stroke onset.
62250912|NCT04669340|EXPERIMENTAL|Intervention group|"Participants in the intervention group will receive patient education through an e-learning program at home. A study nurse will introduce patients to the program and they will be asked to accomplish the program within four weeks. Furthermore, they will be encouraged to go through the program as many times as necessary and involve family and relatives if they like.~Both groups will receive one planned phone call regarding medication 2-3 weeks after they started taking the medicine. Furthermore, both groups will be referred to a physiotherapist if needed. All patients have access to contact the out-patient clinic as needed throughout the study period."
62609232|NCT05495217|EXPERIMENTAL|Gasless Laparoscopy-assisted Gastrectomy|Patients receive Gasless Laparoscopy-assisted Gastrectomy with D2 Lymphadenectomy for Distal Gastric Cancer.
62609233|NCT05495217|OTHER|Conventional Laparoscopy-assisted Gastrectomy|Patients receive Conventional Laparoscopy-assisted Gastrectomy with D2 Lymphadenectomy for Distal Gastric Cancer.
62609234|NCT00655603|EXPERIMENTAL|1|10 patients with Type 2 Diabetes Mellitus
62609235|NCT00655603|EXPERIMENTAL|2|10 healthy, matched control participants
62831754|NCT06110026|EXPERIMENTAL|Brunkow exercise program|Brunkow program includes Push up and stabilization against the wrists and heels,brunkow- from plank to a standing position ,plank from lying on the stomach to a sitting in a tilted position, Turning from the back to the position on all four
62831755|NCT06110026|EXPERIMENTAL|Lumbar stabilization exercises|lumbar stabilization exercises protocol includes Diaphragmatic breathing and abdominal bracing, bridging, side plank on knees, bird dog
62048794|NCT06425328||Underweight|"BMI calculation was calculated with the equation body weight (kg) / height (m)2 using body weight and height measurement results. BMI was evaluated according to the World Health Organization's BMI Z score classification for ages 5-19. Accordingly, those with a BMI z score below -1 SD are defined as underweight."
62609236|NCT00597012|EXPERIMENTAL|Surgical|Participants will undergo arthroscopic partial menisectomy (APM) surgery and offered postoperative rehabilitative physical therapy.
62609237|NCT00597012|ACTIVE_COMPARATOR|Nonoperative|Participants will undergo standard physical therapy that will include strengthening and stretching sessions one to three times a week for 8 weeks.
62609238|NCT04842591||kidney transplant candidates|Patients listed for first kidney transplantation
62831756|NCT01626469|ACTIVE_COMPARATOR|Arm A|Captopril 25 mg (Admission 1, Day 1, low salt diet) Matched Placebo (Admission 1, Day 2, low salt diet) Captopril 25 mg (Admission 2, Day 1, high salt diet) Matched Placebo (Admission 2, Day 2, high salt diet)
62440882|NCT06547593|PLACEBO_COMPARATOR|Control Group|"The control group will undergo routine community health management, including regular chronic disease health education lectures, provision of health education materials, health counseling services, and comprehensive health examinations by qualified medical professionals.~At the beginning and end of the intervention, as well as at a 9-month follow-up, the study subjects were evaluated to understand the sustainability of the intervention after the project was completed, and to explore the management mode of sustainable intervention."
62609239|NCT06433934|EXPERIMENTAL|Oxy2mask|Change oxymask to oxy2mask
62609240|NCT03832504|EXPERIMENTAL|38°C and 60% RH + No intervention|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
62609241|NCT03832504|EXPERIMENTAL|38°C and 60% RH + Fan|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
62609242|NCT03832504|EXPERIMENTAL|38°C and 60% RH + Skin wetting|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
62831757|NCT01626469|PLACEBO_COMPARATOR|Captopril|Matched Placebo (Admission 1, Day 1, low salt diet) Captopril 25 mg (Admission 1, Day 2, low salt diet) Matched Placebo (Admission 2, Day 1, high salt diet) Captopril 25 mg (Admission 2, Day 2, high salt diet)
62831758|NCT01840241|EXPERIMENTAL|BIVON group|
62831759|NCT01840241|PLACEBO_COMPARATOR|Placebo group|normal saline infusion
62831760|NCT05318417|OTHER|Children and adults with unilateral hearing loss/single-sided deafness|
62831761|NCT06055946||Symmcora® Long bidirectional|Symmcora® Long-term bidirectional barbed suture for vesicourethral anastomosis in patients undergoing robotic assisted radical prostatectomy.
62831762|NCT04004988|EXPERIMENTAL|Tirzepatide Test|Participants received single dose of 5 milligram (mg) Tirzepatide by subcutaneous injection (SC) via an autoinjector (AI) in one of two study periods.
62831763|NCT04004988|EXPERIMENTAL|Tirzepatide Reference|Participants received single dose of 5mg Tirzepatide by subcutaneous injection (SC) via a prefilled syringe (PFS) in one of two study periods.
62831764|NCT00419406|EXPERIMENTAL|A: UVA1|
62831765|NCT00419406|EXPERIMENTAL|B: NB UVB|
62831766|NCT06654362|EXPERIMENTAL|Arfa's company workers|all interventions administer to this arm
62831767|NCT03909789|ACTIVE_COMPARATOR|plant based bioequivalent dietary nitrate supplement|The nitrate supplement consists of nitrate-rich beetroot extract 20mg, thiamine mononitrate 90mg, potassium nitrate 480mg, ascorbic acid 150mg, folic acid 200mcg, methylcobalamin 200mcg, calcium 115mg, pomegranate fruit extract 5mg and green coffee bean extract 115mg.
62831768|NCT03909789|PLACEBO_COMPARATOR|placebo|The Placebo does not contain any nitric oxide supplement.
62831769|NCT00872820|ACTIVE_COMPARATOR|1|Participants will receive standard cognitive behavioral therapy.
62831770|NCT00872820|EXPERIMENTAL|2|Participants will receive acceptance- and commitment-based behavioral therapy.
62831771|NCT00872820|NO_INTERVENTION|3|Participants will be placed on a waitlist for 3 months before being offered treatment.
62831772|NCT06600893|SHAM_COMPARATOR|Sham Arm 1-Simulated Low Intensity Shockwave Therapy|Using the shockwave device, 5000 simulated low intensity shockwave therapy delivered week 0, week 3, week 6
62831773|NCT06600893|EXPERIMENTAL|Active Arm 1- Low Intensity Shockwave Therapy|Using the shockwave device, 5000 low intensity shockwave therapy delivered week 0, week 3, week 6
62831774|NCT06600893|SHAM_COMPARATOR|Sham Arm 2 - Simulated Low Intensity Shockwave Therapy|Using the shockwave device, 5000 simulated low intensity shockwave therapy delivered week 0, 3000 week 1, 3000 week 3, 5000 week 6, 3000 week 7, 3000 week 8
62831775|NCT06600893|EXPERIMENTAL|Active Arm 2 - Low Intensity Shockwave Therapy|Using the shockwave device, 5000 low intensity shockwave therapy delivered week 0, 3000 week 1, 3000 week 3, 5000 week 6, 3000 week 7, 3000 week 8
62831776|NCT06514625|EXPERIMENTAL|splint and exercise|The patient was asked to wear the fabricated splint that fixes the wrist in the neutral position every night and during the day as much as possible
62831777|NCT06514625|EXPERIMENTAL|kinesiotaping and exercise|"Kinesiotaping was applied twice a week for a total of 8 sessions for 4 weeks. Taping was performed with a neural technique for the median and field correction technique for releasing the carpal tunnel. The elbow was positioned in full extension, the forearm in supination, and the wrist in 30 extension. I tape was used for neural technique. Tape was applied to the skin along the median nerve from the second and third metacarpophalangeal joints to five centimetres distal to the medial epicondyle. For the area correction technique, the I tape, which is half of the wrist circumference, was heavily stretched to the volar side of the wrist and the middle 1/3 part was taped without stretching the edges."
62250913|NCT04669340|ACTIVE_COMPARATOR|Control group|"Participants in the control group will receive conventional patient education from a nurse in the out-patient clinic within four weeks after inclusion. Relatives can take part in the conversation.~Both groups will receive one planned phone call regarding medication 2-3 weeks after they started taking the medicine. Furthermore, both groups will be referred to a physiotherapist if needed. All patients have access to contact the out-patient clinic as needed throughout the study period."
62250914|NCT01621542|EXPERIMENTAL|WT2725|WT2725; injection
62250915|NCT06023316|EXPERIMENTAL|mGain system|mGain system: passive, noninvasive, Bluetooth-enabled, wire-free, surface electromyography measurement device that provides input to a mobile app for an interactive gaming platform
62440883|NCT05473156|EXPERIMENTAL|Dose-Escalation|
62440884|NCT05473156|EXPERIMENTAL|Dose-Expansion (Non Small Cell Lung Cancer, NSCLC)|
62609243|NCT03832504|EXPERIMENTAL|38°C and 60% RH + Fan + Skin wetting|Tthe participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
62609244|NCT03832504|EXPERIMENTAL|46°C and 10% RH + No intervention|The participant will enter an environmental chamber maintained at 46°C and 10% relative humidity.
62250916|NCT04048265|EXPERIMENTAL|Pain in PD Arm one|This arm will receive a total 5 sessions of TMS stimulation in a week. Pre and post intervention scales will be performed on week one, week 2 and week 4.
62831778|NCT06514625|ACTIVE_COMPARATOR|exercise|Nerve tendon gliding exercises were taught practically by an experienced physiotherapist. Participants were asked to do three sets of 10 repetitions every day for one month. Tendon gliding exercises were performed by bringing the hand into five different positions: regular grip, hook grip, punch, tabletop, and regular punch. Nerve gliding exercises were performed by bringing the fingers and wrist into six different positions: fingers and thumb in flexion with the wrist in neutral position, fingers and thumb in extension with the wrist in neutral position, thumb in neutral position with the wrist and fingers in extension, wrist, fingers, and thumb in extension, forearm in supination, and gentle stretching of the thumb with the other hand. Patients were given a thirty day exercise diary.
62250917|NCT04048265|SHAM_COMPARATOR|Pain in PD Arm two|This arm will receive a total 5 sessions of sham-TMS stimulation in a week. Pre and post intervention scales will be performed on week one, week 2 and week 4.
62250918|NCT04533490|EXPERIMENTAL|SHR-1210|After the subjects were enrolled in the study, the patients were treated with SHR-1210 (200mg ivgtt q3w) from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months
62250919|NCT01950247|EXPERIMENTAL|Injectafer|2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
62250920|NCT01950247|ACTIVE_COMPARATOR|IV Iron Standard of Care (SOC)|At a dose and administration regimen as determined by the study site investigator
62250921|NCT00853749|OTHER|Single|All subjects will receive a single dose of 13vPnC
62250922|NCT01146704|ACTIVE_COMPARATOR|Standard Diet|Standard protein diet group as control based on 0.5 gram protein per pound of lean body mass with same calories: 15% protein and 55% carbohydrate.
62250923|NCT01146704|ACTIVE_COMPARATOR|High Protein Diet|High protein diet group based on 1 gram of protein per pound of lean body mass: 30% protein and 40% carbohydrate.
62250924|NCT03522051|EXPERIMENTAL|Patients with carious teeth|female or male patients with permanent teeth and deep caries will receive pulpotomy treatment and dressing with calcium silicate based material (Neo MTA plus material) followed by restoration.
62250925|NCT05699265||Fabry Disease Follow-Up Patients|
62250926|NCT01810653|EXPERIMENTAL|Macrogol (Transipeg)|
62250927|NCT01810653|ACTIVE_COMPARATOR|Macrogol (Forlax)|
62250928|NCT05573776|EXPERIMENTAL|Exercise Therapy, High Protein supplement|
62250929|NCT00227292|PLACEBO_COMPARATOR|A, 2, II|Placebo 10mg per day for the first week, then 20mg per day till the end of study.
62250930|NCT00227292|EXPERIMENTAL|A, 1|Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
62440885|NCT05473156|EXPERIMENTAL|Dose-Expansion (Head and Neck Squamous Cell Carcinoma, HNSCC)|
62609245|NCT03832504|EXPERIMENTAL|46°C and 10% RH + Skin wetting|The participant will enter an environmental chamber maintained at 46°C and 10% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
62250931|NCT05082376|EXPERIMENTAL|Test Arm|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg/centimeter\^2) of ChapStick Lip Moisturizer (CLM) Original will be applied to the assigned test site using a fingercot. The test product will be evenly spread over the test site using light pressure.
62609246|NCT02450552|EXPERIMENTAL|Oral ezogabine 600 mg/day|
62250932|NCT05082376|NO_INTERVENTION|Control Arm|No treatment will be applied to the assigned control site.
62609247|NCT02450552|EXPERIMENTAL|Oral ezogabine 900 mg/day|
62609248|NCT02450552|PLACEBO_COMPARATOR|Placebo|
62609249|NCT05691764|EXPERIMENTAL|Cyclosporin + RIPC|This group received cyclosporin intravenously 2 hours pre-induction of anesthesia, with the dose of 3 mg/ kg body weight. RIPC was performed preoperatively after induction of anesthesia by inflating pressure cuff on the extremity 30 mmHg higher than systolic blood pressure of the patient for 5x5 minutes with 5 minutes reperfusion interval.
62250933|NCT00946504|EXPERIMENTAL|1|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)
62250934|NCT00946504|ACTIVE_COMPARATOR|2|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)
62250935|NCT03480568|EXPERIMENTAL|alirocumab|Alirocumab 150 mg q 2 weeks for 12 weeks
62440886|NCT05473156|EXPERIMENTAL|Dose-Expansion (Esophageal Squamous Cell Carcinoma, ESCC)|
62440887|NCT02165228|EXPERIMENTAL|Mindfulness-based stress reduction|Stress reduction class and behavioral intervention
62440888|NCT02165228|ACTIVE_COMPARATOR|Nutrition Enhancement|Nutrition education class and behavioral intervention
62440889|NCT02165228|NO_INTERVENTION|Control|No class or behavioral intervention
62609250|NCT05691764|PLACEBO_COMPARATOR|Control|This group received placebo intravenously 2 hours pre-induction of anesthesia.
62250936|NCT03410459|ACTIVE_COMPARATOR|Gastric Bypass|Patients ≥ 5 years after laparoscopic gastric bypass receive DEXA (= Dual-energy x-ray absorptiometry) in order to measure bone mass density
62250937|NCT03410459|ACTIVE_COMPARATOR|Sleeve gastrectomy|Patients ≥ 5 years after laparoscopic sleeve gastrectomy receive DEXA (= Dual-energy x-ray absorptiometry) in order to measure bone mass density
62250938|NCT06030336|EXPERIMENTAL|Intervention|The Home Health Report will provide quantitative information about health-relevant pollutants (fine particulate matter, carbon dioxide, nitrogen dioxide, and volatile organic compounds), their levels compared to health-based guidelines, their potential sources, as well as no- and low-cost actions occupants could take to improve indoor air quality. The Home Health Report will be designed to maximize utility to residents. Each Home Health Report will be provided after the corresponding Home Health Box deployment. The second Home Health Box deployment will occur after the household receiving their first Home Health Report. The third and final Home Health Box deployment will occur within one month of the household receiving their second Home Health Report.
62440890|NCT05547230||teachers|4 basic components will be examined posture analysis body awareness work motivation quality of life
62440891|NCT01211574|EXPERIMENTAL|peer coach|Participants will be coached by a peer between treatment visits.
62440892|NCT01211574|EXPERIMENTAL|mentor|Participants will be coached by a mentor between treatment visits
62440893|NCT01211574|EXPERIMENTAL|Professional|Participants will be coached by an interventionist between treatment visits
62440894|NCT03723291|ACTIVE_COMPARATOR|Arm A|The current best standard of care \[rehabilitation exercises\]
62440895|NCT03723291|EXPERIMENTAL|Arm B|The current best standard of care \[rehabilitation exercises\] + the experimental intervention
62440896|NCT05464290|EXPERIMENTAL|Nanofat grafting|The nanofat in a 10 cc syringe connected with a 23 gauge needle is used to create a lot of tunnels in the plane of the sclerotic tissues and the nanofat is delivered into the tunnels.
62449486|NCT04253431|EXPERIMENTAL|L10|Finger pricking using lancing device with personal lancets
62609251|NCT01524822||Artillery personnel|exposure to a significant number of concussive evolutions, specifically, exposure to 400 or more within a career, will be considered experienced by the investigators.
62609252|NCT01524822||Breachers|exposure to a significant number of breaching blasts, specifically, exposure to 400 breaching blasts or more within a career, will be considered experienced by the investigators
62609253|NCT01524822||Companions|The criterion is met by a person who has both some historical knowledge of the participant and routine interactions outside a work environment.
62609254|NCT01524822||Unexposed|People not exposed to repeated blasts
62831779|NCT04785313||Retrievable Inferior Vena Cava Filters (IVCF)|The population study includes patients with a Retrievable Inferior Vena Cava Filters (IVCF) placed because of temporary contraindication to curative anticoagulation and that was been removed by the radiology department at the University Hospital of Saint-Etienne, between January 1, 2010 and December 31, 2014. All the Inferior Vena Cava Filters (IVCF) were been sent for histological examination.
62250939|NCT06030336|NO_INTERVENTION|Control|Households in the control group will also receive three Home Health deployments spaced over several months, but will not receive Home Health Reports after the first and second deployments. At the close of their participation in the study, households in the control group will receive a comprehensive Home Health Report, including results from all three Home Health Box deployments and recommended actions occupants could take to improve their home air quality.
62250940|NCT05071365|EXPERIMENTAL|Videos|"Single Arm study: All participants recruited to the study will be allocated to a single arm- videos in which participants will be able to access self help videos for plantar fasciitis"
62440897|NCT03101163|EXPERIMENTAL|Intervention|Subjects randomized to the intervention group will undergo subchondral drilling surgery according to standard protocol, and will also receive a regimen of PBSC and HA intra-articular injections and postoperative physiotherapy.
62250941|NCT00864890|EXPERIMENTAL|A|Citalopram HBr 40 mg tablets, single dose
62440898|NCT03101163|ACTIVE_COMPARATOR|Standard treatment|Subjects randomized to the standard treatment-controlled parallel group will receive intra-articular HA injections and a physiotherapy regimen.
62440899|NCT01814761||Pts with POAG or OH (Previously Treatment Naive)|Previously treatment naïve patients with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).
62609255|NCT01634659|OTHER|Delefilcon A, then narafilcon B|Delefilcon A contact lenses (DAILIES TOTAL1®) worn first, followed by narafilcon B contact lenses (1-DAY ACUVUE® TruEye®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
62250942|NCT00864890|ACTIVE_COMPARATOR|B|CelexaTM 40 mg tablets, single dose
62250943|NCT02375542||Cardiac Reoperation|Patients who have previously undergone a cardiac operation with the use of BioGlue and are now undergoing a reoperation
62250944|NCT00073528|PLACEBO_COMPARATOR|Placebo + Letrozole 2.5 mg|Letrozole (2.5 mg once daily orally) with Placebo (which matched with Lapatinib tablet)
62440900|NCT01814761||Pts with POAG or OH (Switched Monotherapy)|Patients previously on another monotherapy treatment with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).
62440901|NCT02168270|EXPERIMENTAL|Treatment (ascorbic acid, temozolomide)|Patients receive ascorbic acid IV over 90-120 minutes three times per week and temozolomide orally days 1-28. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62831780|NCT00668278|ACTIVE_COMPARATOR|A|Laryngeal Mask Airway insertion
62831781|NCT00668278|ACTIVE_COMPARATOR|B|I-gel insertion
62831782|NCT04268667|EXPERIMENTAL|Upper cervical spine manipulation group|Spinal thrust joint manipulation on the atlantoaxial joint
62250945|NCT00073528|EXPERIMENTAL|Lapatinib 1500 mg + Letrozole 2.5 mg|Lapatinib (1500 mg once daily orally) with Letrozole (2.5 mg once daily orally)
62250946|NCT06243731||All Participants With Kidney Failure|Participants aged 18 years or older treated with maribavir for a refractory CMV infection and who have comorbid ESRD or severe chronic renal disease requiring peritoneal dialysis or hemodialysis will be assessed from index date (Day 0: the day of initiation of the first maribavir treatment course during the eligibility period) until, end of treatment (treatment completion, discontinuation, or addition of another antiviral regimen for CMV) +7 days post-treatment, death, or end of data availability whichever occurs earliest.
62250947|NCT01079273|ACTIVE_COMPARATOR|Vaccine|All Subjects enrolled in this study will receive the study vaccine (single-arm)
62250948|NCT04133454|EXPERIMENTAL|subjects treated with LGT|subjects will be treated with a single dose of LGT (AAV-hTERT)
62609256|NCT01634659|OTHER|Narafilcon B, then delefilcon A|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®) worn first, followed by delefilcon A contact lenses (DAILIES TOTAL1®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
62831783|NCT04268667|ACTIVE_COMPARATOR|Cervicothoracic spine manipulations group|Different spinal thrust joint manipulations on the thoracic spine (T6), mid-cervical spine (C3-C4) and cervicothoracic junction (C7-T1).
62048795|NCT06425328||Normal weight|"BMI calculation was calculated with the equation body weight (kg) / height (m)2 using body weight and height measurement results. BMI was evaluated according to the World Health Organization's BMI Z score classification for ages 5-19. Accordingly, BMI z scores between -1 SD +1 SD are defined as normal weight."
62250949|NCT00681174|ACTIVE_COMPARATOR|Control|Control intervention will be intraoperative i.v. morphine administration 30 minutes before the end of anesthesia.
62250950|NCT00681174|EXPERIMENTAL|CROxy|The intervention group will receive controlled-release oxycodone 1 h pre-operatively
62440902|NCT01943461|EXPERIMENTAL|Dose-escalation Cohort: Avelumab 3 mg/kg|
62440903|NCT01943461|EXPERIMENTAL|Dose-escalation Cohort: Avelumab 10 mg/kg|
62440904|NCT01943461|EXPERIMENTAL|Dose-escalation Cohort: Avelumab 20 mg/kg|
62440905|NCT01943461|EXPERIMENTAL|Expansion Cohort: Avelumab 10 mg/kg|
62440906|NCT01680731||Forceps assisted vaginal delivery|Forceps assisted vaginal delivery within 1-5 years without any interval delivery
62440907|NCT01680731||Vacuum assisted vaginal delivery|Vacuum assisted vaginal delivery within 1-5 years without any interval delivery
62440908|NCT01680731||Elective cesarean delivery|Elective cesarean vaginal delivery within 1-5 years without any interval delivery done prior to labor
62440909|NCT01680731||Spontaneous vaginal delivery|Spontaneous vaginal delivery within 1-5 years without any interval delivery
62440910|NCT06400849|ACTIVE_COMPARATOR|Cryotherapy only|Single group, same patient, Homolateral wearing of cryotherapy devices only on hands and feet
62609257|NCT03727295|EXPERIMENTAL|The control group 1|60 cases, idebenone 180mg/d, 3 times / day, oral
62609258|NCT03727295|EXPERIMENTAL|The control group 2|60 cases, idebenone 360mg/d, 3 times / day, oral
62609259|NCT03727295|PLACEBO_COMPARATOR|The placebo group|60 cases, placebo, 3 times / day, oral
62831784|NCT02732574|EXPERIMENTAL|OPEP Device Treatment|Patients randomized to OPEP will receive the device on postoperative day (POD) 1 or day of extubation, whichever comes first. Patients will be seen on POD #1 by a blinded physiotherapist (PT) for mobility and education on supported coughing. The OPEP device group will also be instructed to complete 15 breaths twice per waking hour in a seated position and receive education on proper use of the device. The OPEP device will be set to the highest pressure setting unless deemed inappropriate by the PT, at which time the most appropriate pressure setting will be selected and then increased daily until the OPEP device is set to the highest pressure setting by POD #3 if able. The PT will reassess the patients on POD 2 and 3 to assess for proper technique and continued use of the device, as well as usual care. Patients will use the OPEP device up to POD#5 pressure settings and compliance will be recorded and measure by use of a daily log.
62048796|NCT06425328||Overweight|"BMI calculation was calculated with the equation body weight (kg) / height (m)2 using body weight and height measurement results. BMI was evaluated according to the World Health Organization's BMI Z score classification for ages 5-19. Accordingly, those with a BMI z score between +1 SD +2 SD are defined as overweight"
62440911|NCT06400849|EXPERIMENTAL|Cryptherapy and compression|Single group, same patient, Homolateral wearing of cryotherapy and compression devices on hands and feet
62609260|NCT04594941|EXPERIMENTAL|Treatment Sequence: SPE-SPE|"Participants received 2 intravenous (IV) boluses of Flurpiridaz (18F) Injection manufactured by SPE process at Visit 1 and 2.~The targeted dose to the body of Flurpiridaz (18F) Injection was to be in the range of 1.7 to 2.5 millicurie (mCi) (63 to 93 megabecquerel \[MBq\]) for each administration and not exceed a total of 6 mCi (222 MBq) for an individual participant."
62609261|NCT04594941|EXPERIMENTAL|Treatment Sequence: HPLC-HPLC|"Participants received 2 IV boluses of Flurpiridaz (18F) Injection manufactured by HPLC process at Visit 1 and 2.~The targeted dose to the body of Flurpiridaz (18F) Injection was to be in the range of 1.7 to 2.5 mCi (63 to 93 MBq) for each administration and not exceed a total of 6 mCi (222 MBq) for an individual participant."
62609262|NCT04594941|EXPERIMENTAL|Treatment Sequence: SPE-HPLC|"Participants received 2 IV boluses of Flurpiridaz (18F) Injection manufactured by 2 different processes (1 dose manufactured by SPE followed by 1 dose manufactured by HPLC) at Visit 1 and 2.~The targeted dose to the body of Flurpiridaz (18F) Injection was to be in the range of 1.7 to 2.5 mCi (63 to 93 MBq) for each administration and not exceed a total of 6 mCi (222 MBq) for an individual participant."
62440912|NCT04755322|OTHER|hydroxychloroquine group|hydroxychloroquine 400 mg+ Folic Acid 5 mg+ Low-dose aspirin 75 mg
62440913|NCT04755322|OTHER|control group|Folic Acid 5 mg+ Low-dose aspirin 75 mg
62440914|NCT03730324|ACTIVE_COMPARATOR|Standard care|Study subject will undergo sampling of plasma and urine biomarkers.
62440915|NCT03730324|EXPERIMENTAL|Magnetic Resonance Imaging.|Prior to biopsies a magnetic resonance imaging scan will be performed.
62440916|NCT04485247|ACTIVE_COMPARATOR|Conventional group|conventional laparoscopic appendectomy with 3-ports
62440917|NCT04485247|EXPERIMENTAL|TULAA group|An operator extracts and ligates appendix through umbilical port.
62440918|NCT02934828|EXPERIMENTAL|Neoadjuvant chemotherapy|Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d\*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d\*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year. RECIST is used once every 2 cycles. Patients will finish 6 cycles preoperative chemotherapy when CR/partial response(PR)/stable disease(SD) by RECIST without serious adverse events.
62440919|NCT02934828|ACTIVE_COMPARATOR|postoperative chemotherapy|Postoperative Chemotherapy:Standard chemotherapy regiments according to risk of recurrence: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
62440920|NCT05072691||Patients with Multiple sclerosis and Optic Neuritis|Patients ≥ 18 year-old at the time of enrollment, with newly diagnosed multiple sclerosis according to 2017 McDonald diagnostic criteria Patients ≥ 18 year-old at the time of enrollment with first episode of optic neuritis, fulfilling or not (i.e. CIS, clinically isolated syndrome) 2017 McDonald diagnostic criteria for multiple sclerosis
62048797|NCT06425328||Obese|"BMI calculation was calculated with the equation body weight (kg) / height (m)2 using body weight and height measurement results. BMI was evaluated according to the World Health Organization's BMI Z score classification for ages 5-19. Accordingly, those with a BMI z score above +2 SD are defined as obese."
62831785|NCT02732574|SHAM_COMPARATOR|SHAM Device|Patients randomized to the sham treatment will receive the sham device on postoperative day (POD) 1 or day of extubation, whichever comes first. Patients will be seen on POD #1 by a blinded physiotherapist (PT) for mobility and education on supported coughing. The sham group will also be instructed to complete 15 breaths twice per waking hour in a seated position and receive education on proper use of the device. The sham device is identical in exterior appearance to the OPEP device but does not contain the internal mechanism providing expiratory pressure. As such, the device will be set to the highest setting and will not need to be adjusted at all for patient tolerance. The PT will reassess the patients on POD 2 and 3 to assess for proper technique and continued use of the device, as well as usual care. Patients will use the OPEP device up to POD#5 pressure settings and compliance will be recorded and measure by use of a daily log.
62831786|NCT01874899||Manual, then Automatic Stimulation|The RestoreSensor neurostimulator will be programed for manual stimulation adjustments and the patients will crossover to automatic stimulation group after 1.5 months
62048798|NCT03381755|EXPERIMENTAL|half-dose ticagrelor|
62831787|NCT01874899||Automatic, then Manual Stimulation|The RestoreSensor neurostimulator will be programed for automatic stimulation adjustments and the patients will crossover to manual stimulation group after 1.5 months.
62831788|NCT02237417|OTHER|Healthy Control|
62831789|NCT02237417|ACTIVE_COMPARATOR|Individuals with Schizophrenia (Group A)|
62048799|NCT03381755|ACTIVE_COMPARATOR|standard-dose ticagrelor|
62831790|NCT02237417|ACTIVE_COMPARATOR|Individuals with Schizophrenia (Group B)|
62831791|NCT04139018|EXPERIMENTAL|Timolol Gel Arm|Participants in the timolol gel arm (active medication arm) will receive timolol nasal gel 0.1% with 0.5 mL applied to each nostril twice daily via a syringe that will amount to a 2 mg total daily dose.
62048800|NCT05858138|EXPERIMENTAL|Jing-Si Herbal Tea group|Each patient will receive Jing-Si Herbal Tea two times (after breakfast and lunch) in a day for 24 weeks.
62048801|NCT05858138|PLACEBO_COMPARATOR|Placebo group|Each patient will receive placebo two times (after breakfast and lunch) in a day for 24 weeks.
62048802|NCT04497792|EXPERIMENTAL|Treatment group|The treatment group are patients with stable coronary artery disease before planned percutaneous coronary intervention. All of them will receive empagliflozin additionally to previously taken hypoglycemic treatment.
62048803|NCT04497792|OTHER|Control group|patients continue previously prescribed medication intake
62048804|NCT00180635|EXPERIMENTAL|Healthy volunteers non smoker|Control group
62831792|NCT04139018|PLACEBO_COMPARATOR|Placebo Gel Arm|Participants in the placebo gel arm will receive the gel itself with no active medication.
62048805|NCT00180635|EXPERIMENTAL|Healthy volunteers smoker|More than 10 pack-years
62048806|NCT00180635|EXPERIMENTAL|Chronic Obstructive Pulmonary Disease COPD|COPD diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease guidelines
62048807|NCT06054659|EXPERIMENTAL|Real time - Continuous glucose monitoring|Participants will wear a CGM sensor in the abdomen or arm placed by a study team prior to hospital discharge. Participants will have instructions on how to monitor BG with the CGM device and will use their own glucometer and do fingersticks as needed including for CGM calibration.
62048808|NCT06054659|ACTIVE_COMPARATOR|Fingerstick blood glucose (FBG) monitoring|Participants randomized to this group will monitor blood glucose by performing fingersticks, they will also have the application of CGM but will not be given the receiver to allow for self-monitoring. CGM will only be applied by the research team for monitoring over a 14-day interval at baseline, week 4, week 8, and week 12. Blinding will continue throughout the study. This group will receive training only in home BG monitoring with FBG.
62831793|NCT02951377|NO_INTERVENTION|Control|Wait list control - usual care - free to pursue other treatments prescribed by the patients family physician
62048809|NCT02434510||Sterile Water bath|Standard of Care group using a sterile water instrument bath
62048810|NCT02434510||CHG group|Study group using the 0.05% CHG solution in the instrument bath
62048811|NCT00687921||A|patients over the age of 18 who had knee trauma, intent to or had MRI assessment and are scheduled for arthroscopy.
62048812|NCT01256567|EXPERIMENTAL|ramucirumab and docetaxel combination|
62048813|NCT00835848|ACTIVE_COMPARATOR|Exenatide|25 μg Byetta (Lilly, Exenatide) is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
62048814|NCT00835848|PLACEBO_COMPARATOR|Saline|Isotonic saline infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
62449487|NCT03936400|EXPERIMENTAL|Randomized controlled trial|Experimental group receiving a couple-based intervention
62048815|NCT03651648|EXPERIMENTAL|SENSITACT System ON|As soon as the early signs of an apnea-bradycardia are detected, the SENSITACT controller sends a trigger signal to the PASITHEA stimulator that immediately activates kinesthetic stimulation
62048816|NCT03651648|SHAM_COMPARATOR|SENSITACT System OFF|The SENSITACT controller doesnt send any trigger signal to the PASITHEA stimulator even if an early sign of an apnea-bradycardia is detected.
62048817|NCT03684148|EXPERIMENTAL|Motor imagery practice|In addition to routine physical therapy patients that will be included in the motor imagery practice (MIp) group will receive an additional intervention based on motor imagery beginning immediately after the TKA procedure.
62048818|NCT03684148|NO_INTERVENTION|Control group|Patients from the control group will underwent the same post-surgery rehabilitation program, but will not be engaged in MI practice.
62048819|NCT03631446||Patients administered Picoprep® for bowel cleansing|Patients administered Sodium Picosulfate, Magnesium Oxide and Citric Acid for bowel cleansing
62831794|NCT02951377|EXPERIMENTAL|MDT +/- TESI|Exercise (MDT approach) and/or Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%). Patients will further classified into centraliser (group 2a) and non-centralising pain responses (group 2b). Group 2a: will continue with exercise (MDT approach). Group 2b: Patients with a non-centralising pain response will be offered Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under fluoroscopic guidance with contrast medium (Omni Pac 240). Two weeks after completion of the MDT or TESI intervention, patients will be reassessed and treated consistent with their response: 1) resolved: advice on remaining active; 2) centralising: daily exercises based on MDT principles; 3) non-centralising but significant less pain: advice to remain active, with respect for worsening leg pain; and 4) persisting high levels of pain and/or disability: advise to remain active as tolerated and consult family physician.
62048820|NCT02220894|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
62440921|NCT05072691||Patients with non-inflammatory neurologic diseases (NIND)|Patients ≥ 18 year-old with suspected non-inflammatory neurologic diseases (such as Alzheimer disease, intracranial hypertension, etc) receiving routine diagnostic lumbar puncture
62048821|NCT02220894|ACTIVE_COMPARATOR|SOC Treatment|Participants receive carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\^2 IV on Day 1 of every 21-day cycle (Q3W) for a maximum of 6 cycles OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\^2 IV on Day 1 Q3W for a maximum of 6 cycles; participants with non-squamous histologies may go on to receive optional treatment with pemetrexed 500 mg/m\^2 IV on Day 1 Q3W.
62048822|NCT00800969|OTHER|all patients|all patients with Adenocarcinoma
62048823|NCT02832206||hybrid ablation|60 patients with stand-alone, persistent or long-standing persistent atrial fibrillation
62048824|NCT05176275|EXPERIMENTAL|68Ga-NOTA-RP25|Intravenous injection
62048825|NCT04569630|EXPERIMENTAL|Intervention group|
62440922|NCT05072691||Patients with other inflammatory neurologic diseases (IND)|Patients ≥ 18 year-old with suspected inflammatory neurologic diseases other than multiple sclerosis (such as inflammatory peripheral neuropathies, meningitis, neuromyelitis optica spectrum disorders, etc) receiving routine diagnostic lumbar puncture
62440923|NCT02144259|ACTIVE_COMPARATOR|DMPA group|Subjects randomized to receive DepoProvera(DMPA) immediately post-partum.
62440924|NCT02144259|ACTIVE_COMPARATOR|Implanon group|Subjects randomized to receive Implanon immediately post-partum.
62048826|NCT00353587|EXPERIMENTAL|MBX-102 200 mg|MBX-102 200 mg once daily for 16 weeks
62048827|NCT00353587|EXPERIMENTAL|MBX-102 400 mg|MBX-102 400 mg once daily for 16 weeks
62048828|NCT00353587|EXPERIMENTAL|MBX-102 600 mg|MBX-102 600 mg once daily for 16 weeks
62440925|NCT02144259|NO_INTERVENTION|Control group|Subjects selecting their own method of contraception or no contraception.
62440926|NCT03004690|EXPERIMENTAL|Performance temperature 22°C|Participants wearing PPE suit A or PPE suit B perform tests I -IV at 22°C.
62440927|NCT03004690|EXPERIMENTAL|Performance temperature 28°C|Participants wearing PPE suit A or PPE suit B perform tests I -IV at 28°C.
62048829|NCT00353587|PLACEBO_COMPARATOR|Sugar Pill|Placebo comparator once daily for 16 weeks
62048830|NCT00353587|ACTIVE_COMPARATOR|Actos|Actos 30 mg once daily for 16 weeks
62048831|NCT00763958|EXPERIMENTAL|Buprenorphine|Active sublingual buprenorphine provided to participants; dose as clinically indicated up to 32 mg daily for up to 3 months
62048832|NCT00763958|PLACEBO_COMPARATOR|Placebo|Placebo sublingual medication provided to individuals randomized to control up to 3 months
62048833|NCT06111209|ACTIVE_COMPARATOR|Testosterone|Testosterone Cypionate 25-mg weekly by intramuscular injection
62048834|NCT06111209|PLACEBO_COMPARATOR|Placebo|Placebo intramuscular injections weekly
62048835|NCT00778128|EXPERIMENTAL|1|"Step 1: Dose escalation - oral CP-4126~Step 2: Oral CP-4126 on day 1 and 15 in a 4 week schedule. One dose (only) gemcitabine IV on day 8."
62048836|NCT00778128|EXPERIMENTAL|2|"Step 1: Dose escalation - oral CP-4126~Step 2: Oral CP-4126 on day 8 and 15 in a 4 week schedule. One dose (only) gemcitabine IV on day 1."
62048837|NCT06395610|EXPERIMENTAL|Treatment R|Single dose of CHF6001
62048838|NCT06395610|EXPERIMENTAL|Treatment T|Single dose of CHF6001 administered after repeated doses of oral Erythromycin
62048839|NCT01451879||Age 0 months to 65 years|Confirmed diagnosis of Pompe Disease, and clinically prescribed immune modulation regimen with agents such as rituximab, sirolimus, methotrexate, IVIg or other immunomodulatory agents such as pharmacological chaperone Miglustat, N-butyldeoxynojirimycin (NB-DNJ), alone or in combination, at the discretion of their primary/specialist caregiver.
62048840|NCT01405625|ACTIVE_COMPARATOR|AAAAI Action Plan|Asthma Action Plan from the American Academy of Allergy, Asthma, and Immunology
62048841|NCT01405625|EXPERIMENTAL|Asthma pictogram written action plan|Cartoon/pictogram-based written action plan sheet
62440928|NCT05555589|EXPERIMENTAL|0.1% RGN-259 Opthalmic Solution|It is a preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into study eye(s), five times per day for 28 days
62440929|NCT05555589|PLACEBO_COMPARATOR|Placebo Ophthalmic Solution (Vehicle for RGN-259 Ophthalmic Solution)|It is composed of the same excipients as RGN-259 but does not contain Tβ4
62048842|NCT01429636|EXPERIMENTAL|Applied Relaxation (AR)|
62048843|NCT01429636|EXPERIMENTAL|Modified Relaxation (MR)|
62048844|NCT04031144|EXPERIMENTAL|Ultrafiltration|Ultrafiltration is applied at the end of cardiopulmonary bypass. Maximal clot formation (MCF) of ROTEM-EXTEM tracing is reduced before applying the ultrafiltration.
62048845|NCT03006770|EXPERIMENTAL|PLX-PAD|PLX-PAD will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.
62048846|NCT03006770|PLACEBO_COMPARATOR|Placebo|Placebo will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.
62048847|NCT03987841|EXPERIMENTAL|Integrated MBSR/DSME intervention|Integrated mindfulness-based stress reduction/diabetes self-management education intervention. Single-arm study, a group of participants meeting eligibility requirements will be invited to participate.
62048848|NCT03381768|EXPERIMENTAL|Study group|3 vaccines of PD-L2 peptide followed by 12 vaccines of PD-L2 and PD-L1 peptide, over the course of one year.
62048849|NCT00653458|EXPERIMENTAL|A|Subjects received Kali formulated products under fed conditions
62048850|NCT00653458|ACTIVE_COMPARATOR|B|Subjects received GlaxoSmithKline's formulated products under fed conditions
62048851|NCT01520740|ACTIVE_COMPARATOR|Collateral Ventilation Positive (CV+)|
62048852|NCT01520740|ACTIVE_COMPARATOR|Collateral Ventilation Negative (CV-)|
62048853|NCT04079348|ACTIVE_COMPARATOR|Oasis ECM|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application Oasis Extracellular Matrix to their donor site wound.
62609263|NCT04594941|EXPERIMENTAL|Treatment Sequence: HPLC-SPE|"Participants received 2 IV boluses of Flurpiridaz (18F) Injection manufactured by 2 different processes (1 dose manufactured by HPLC followed by 1 dose manufactured by SPE) at Visit 1 and 2.~The targeted dose to the body of Flurpiridaz (18F) Injection was to be in the range of 1.7 to 2.5 mCi (63 to 93 MBq) for each administration and not exceed a total of 6 mCi (222 MBq) for an individual participant."
62831795|NCT03672708|OTHER|Cresyl violet|
62609264|NCT02381769|EXPERIMENTAL|Parenteral Nutrition|Soybean based lipid emulsion
62609265|NCT05548491|EXPERIMENTAL|AZR-MD-001 1.0%|AZR-MD-001 ointment/semi-solid drug (1.0%)
62609266|NCT05548491|PLACEBO_COMPARATOR|AZR-MD-001 vehicle|AZR-MD-001 vehicle
62609267|NCT06697730||Hospitalized Patients|All patients hospitalized from 01/01/2019 to 12/31/2023.
62831796|NCT03863080|EXPERIMENTAL|Regimen A|RVT-1401 680 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
62831797|NCT03863080|EXPERIMENTAL|Regimen B|RVT-1401 340 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
62831798|NCT03863080|PLACEBO_COMPARATOR|Placebo|Placebo for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
62831799|NCT02940834||patients with sodium imbalance|
62048854|NCT04079348|ACTIVE_COMPARATOR|Standard wound care|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of standard wound care to their donor site wound.
62048855|NCT00766233|ACTIVE_COMPARATOR|1|Hyperthermal treatment once per week
62048856|NCT00766233|ACTIVE_COMPARATOR|2|Hyperthermal treatment 3 times a week
62048857|NCT02116348|EXPERIMENTAL|Cerebrolysin|Nerve growth factor Cerebrolysin will be given to the intervention group
62048858|NCT02116348|NO_INTERVENTION|Conventional|These children will receive conventional treatment for cerebral palsy
62048859|NCT02388802|EXPERIMENTAL|Uterine transplant|10 patients will be appropriately selected to undergo oocyte retrieval and freezing. Subsequently deceased donor allograft excision will take place prior to uterine transplantation. Immunosuppressive agents will be used to optimise graft success until successful In-vitro fertilisation and subsequent delivery by Caesarean Section
62440930|NCT03729765|EXPERIMENTAL|hemoperfusion|The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.
62609268|NCT05629091|EXPERIMENTAL|FibDex|FibDex® is a CE-marked NFC wound dressing intended to come into contact with injured skin and specifically split-thickness skin graft wounds, which have breached the dermis.
62831800|NCT02940834||patients without sodium imbalance|
62831801|NCT02628990|EXPERIMENTAL|1.6 g plant stanols|A yoghurt drink containing plant stanol ester (1.6 grams plant stanols), consumed with a meal daily for 4 weeks
62831802|NCT02628990|EXPERIMENTAL|2 g plant stanols|A yoghurt drink containing plant stanol ester (2 grams plant stanols), consumed with a meal daily for 4 weeks
62831803|NCT02628990|EXPERIMENTAL|1.6 g plant stanols and camelina oil|A yoghurt drink containing plant stanol ester (1.6 grams plant stanols) and camelina oil (2 g), consumed with a meal daily for 4 weeks
62831804|NCT02628990|EXPERIMENTAL|2 g plant stanols and camelina oil|A yoghurt drink containing plant stanol ester (2 grams plant stanols) and camelina oil (2 g), consumed with a meal daily for 4 weeks
62831805|NCT02628990|PLACEBO_COMPARATOR|Placebo|A placebo yoghurt drink, consumed with a meal daily for 4 weeks
62831806|NCT06297369|NO_INTERVENTION|control group|a. Group 1 (Control group, N = 30 patients) which will include patients who will receive cisplatin chemotherapy starting from 75mg/m2 for 4 cycles (21-28 days and or fractionated)
62831807|NCT06297369|ACTIVE_COMPARATOR|treatment group|b. Group 2 (N = 30 patients) will receive N-acetylcysteine 600 mg twice daily (Acetylcystein ® 600 mg effervescent instant granules sachets, Sedico, Egypt) with cisplatin chemotherapy for 4 cycles (21-28 days and or fractionated)
62831808|NCT04497259|EXPERIMENTAL|Interventional|Patients in the teleconsultation arm will benefit from a tele-evaluation (a questionnaire filled through a chatbot link) and teleconsultation (skype-like connection) at 6 and 9 months after surgery.
62048860|NCT03278938|ACTIVE_COMPARATOR|bupropion added to citalopram|patients who did not remit with citalopram will continue at the same dose and have bupropion added
62048861|NCT03278938|ACTIVE_COMPARATOR|citalopram added to bupropion|Patients who did not remit with bupropion will have bupropion continued at the same dose and citalopram will be added
62440931|NCT03729765|NO_INTERVENTION|standard care|The patients in the standard care arm will not receive hemoperfusion when lextracorporeal membrane oxygenation (ECMO) is commenced.
62440932|NCT04449042||COVID19 positive|a recently performed test which is positive for coronavirus infection
62440933|NCT04449042||COVID19 negative|a recently performed test which is negative for coronavirus infection
62440934|NCT04449042||COVID19 presumed positive|patients who do not have testing or who have negative testing but whose symptoms, history, physical exam, laboratory and imaging findings are consistent with infection with COVID19 and are treated as positive
62440935|NCT04449042||COVID19 presumed negative|patients who do not have testing, but based on symptoms, history, physical exam, laboratory and imaging findings are deemed to be low risk for COVID19 infection and are treated as negative
62440936|NCT01988311|EXPERIMENTAL|Drug Only|psilocybin dose manipulation as described in the protocol
62609269|NCT05629091|ACTIVE_COMPARATOR|Epicite hydro|Epicitehydro is composed of biotechnology derived cellulose and is indicated for treatment of superficial and deep partial thermal and chemical burn wounds (1st and 2nd degree), scalds, skin graft donor sites, abrasions and lacerations
62609270|NCT05629091|ACTIVE_COMPARATOR|Epiprotect|Epiprotect is composed of biosynthetic cellulose. It contains a minimum of 95% isotonic saline solution. Epiprotect is intended for treatment of partial thickness wounds. It can also be used as a temporary coverage for full thickness wounds prior to transplantation or other surgical intervention.
62609271|NCT05437237|EXPERIMENTAL|Dry electrode cap EEG|All patients that are included in the study will undergo a dry electrode electroencephalography (EEG).
62609272|NCT02603926|EXPERIMENTAL|Allopregnanolone|Subjects will receive an intravenous infusion of Allopregnanolone at escalating doses of 2mg, 4mg, and 6mg once weekly over a three week period. The highest dose tolerated without sedation will be held stable for the remaining weekly infusions, for a total of 12 infusions.
62831809|NCT04497259|EXPERIMENTAL|Control|Patients in the consultation arm will benefit from a tele-evaluation (a questionnaire filled at home after the file was sent by secured mail) and a classical face to face consultation at 6 and 9 months after surgery.
62831810|NCT00905944|NO_INTERVENTION|Control|
62831811|NCT00905944|EXPERIMENTAL|Intervention|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
62831812|NCT06615349|EXPERIMENTAL|DigiPall|Patients receive standard of care + DigiPall intervention
62831813|NCT06615349|NO_INTERVENTION|control|Patients receive standard of care
62831814|NCT06486194|EXPERIMENTAL|Targeted breast milk fortification using preemie device|Mother's breast milk (MBM) or Donor Breast Milk (DBM) for use in a day's milk feeds will be measured using the Preemie sensor every 2-3 days, results recorded, and the amounts of breast milk fortifier (BMF), protein supplement, carbohydrate supplement and fat supplements needed to be added in order for that sample of milk to meet current 2022 European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) enteral nutrient intake recommendations calculated by the Preemie Sensor NutriNTrack software. Feeds will be made up in batches of 24hrs worth of feeds each day based on these calculations and the resulting supplement amounts used for the next 2-3 days until another sample of MBM is analysed, in line with previous work by Rochow et al
62831815|NCT06486194|ACTIVE_COMPARATOR|Standard Fortification|Mother's breast milk (MBM) or Donor Breast Milk (DBM) for use in a day's milk feeds will be measured using the Preemie sensor every 2-3 days and results recorded. Breast milk will then be fortified in the standard way according to the manufacturer's recommendations, which assume a standard macronutrient content of the milk.
62831816|NCT05642403|ACTIVE_COMPARATOR|SAD Cohort A XW001|Single inhalation of XW001
62831817|NCT05642403|PLACEBO_COMPARATOR|SAD Cohort A placebo|Single inhalation of placebo
62831818|NCT05642403|ACTIVE_COMPARATOR|MAD Cohort B XW001|Multiple inhalations of XW001
62831819|NCT05642403|PLACEBO_COMPARATOR|MAD Cohort B placebo|Multiple inhalations of placebo
62831820|NCT02531802|EXPERIMENTAL|Adult: ETVAX (Full)|Adult arm (18-45 year olds) receiving the full dose of ETVAX vaccine (10\^11 inactivated E. coli bacteria) added to bicarbonate buffer solution administered orally on Day 0 and 14
62831821|NCT02531802|EXPERIMENTAL|Adult: ETVAX (Full) + 10 ug dmLT|Adult arm (18-45 year olds) receiving the full dose of ETVAX vaccine (10\^11 inactivated E. coli bacteria) with 10 ug dmLT added to bicarbonate buffer solution administered orally on Day 0 and 14
62048862|NCT05488626|EXPERIMENTAL|Adaptive Arm|Subjects in this arm will receive their external beam radiotherapy on the Ethos Radiotherapy System version 2.0 with HyperSight cone beam computed tomography imaging, with daily online adaptation of their radiation dosimetry plan to account for day-to-day changes in the tumor and surrounding anatomical structures. All subjects will received standard concurrent chemotherapy and may receive adjuvant immunotherapy, if indicated.
62048863|NCT05488626|ACTIVE_COMPARATOR|Non-Adaptive Arm|Subjects in this arm will receive their radiotherapy using standard image-guided radiation therapy (IMRT) techniques. All subjects will receive standard concurrent chemotherapy and may receive adjuvant immunotherapy, if indicated.
62048864|NCT02680548|ACTIVE_COMPARATOR|0.9% saline (salt water)|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.9% saline injection per nerve (20cc max)
62048865|NCT02680548|ACTIVE_COMPARATOR|local anesthetic (freezing)|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.25% bupivacaine per nerve (20cc max)
62440937|NCT01988311|NO_INTERVENTION|Cognitive/Behavioral Tasks Only|
62440938|NCT01988311|NO_INTERVENTION|Imaging Only|
62440939|NCT02789111|ACTIVE_COMPARATOR|Alvimopan|12 mg alvimopan twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.
62048866|NCT02680548|ACTIVE_COMPARATOR|local anesthetic (freezing) and steroid|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.25% bupivacaine and 4mg/cc methylprednisolone per nerve (20cc max)
62250951|NCT06410690||Retrospective Cohort|For the retrospective study, we will enrol 3,000 patients \>18 years old who underwent CCTA and meet all of the inclusion and exclusion criteria, with at least 4-year follow-up. The primary endpoint and patient characteristics will be those of the CTP-PRO study. Since women are less affected by CAD, at a ratio of 35:65, to correct for this expected imbalance we will weight recruitment to obtain relatively sex-balanced cohorts. In subgroups of patients, available data from invasive coronary angiography, FFR and OCT will be collected to help develop, test and refine the diagnostic performance of the automated AI tools.
62250952|NCT06410690||Prospective Cohort|The cohort will include subjects prospectively enrolled in the CCTA arm of the CTP-PRO study. The subjects will be followed-up for 24 months after CCTA.
62609273|NCT03066856|EXPERIMENTAL|Intervention|After baseline examinations, participants are randomized to an active dietary intervention group.The intervention group is invited to attend six full days of life-style intervention activities over the next six months. These activities include six cookery courses followed by lunch, six physical activity sessions (walking for 45 minutes) and six conferences. The intervention and control groups both complete questionnaires on adherence to the Mediterranean diet (MEDAS) at baseline and at the end of the study, and are asked for at least two 24-hour recalls of the previous day's food intake, and details of their physical exercise during the six-month intervention.
62831822|NCT02531802|PLACEBO_COMPARATOR|Adult: Placebo|Adult arm (18-45 year olds) receiving a placebo on days 0 and 14
62831823|NCT02531802|EXPERIMENTAL|24-59 months: ETVAX (1/4)|24-59 month old children receiving a quarter adult dose (2.5 x 10\^10 inactivated E. coli bacteria) of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14
62831824|NCT02531802|EXPERIMENTAL|24-59 months: ETVAX (1/2)|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
62440940|NCT02789111|PLACEBO_COMPARATOR|Placebo|Placebo twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.
62440941|NCT05760014||CAS patients|"CAS patients with a conventional follow-up who will benefit from the hypnosis technique known as Place of Safety on their admission to conventional hospitalization."
62831825|NCT02531802|EXPERIMENTAL|24-59 months: ETVAX (full)|24-59 month old children receiving a full adult dose of ETVAX vaccine (10\^11 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
62831826|NCT02531802|EXPERIMENTAL|24-59 months: ETVAX (1/2) + 2.5 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
62831827|NCT02531802|EXPERIMENTAL|24-59 months: ETVAX (1/2) + 5 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
62250953|NCT03426293||Arterial procedure and ACT measurement|All patients undergoing an open or endovascular arterial procedure in which heparin is used peri-procedurally and the ACT is measured to determine effect of heparin
62250954|NCT03777150|EXPERIMENTAL|Group ICU|Group ICU:patients are admitted directly into the ICU for postoperative care
62250955|NCT03777150|EXPERIMENTAL|Group Ward|Group Ward:patients are admitted directly into the standard ward for postoperative care
62250956|NCT03707613|EXPERIMENTAL|DWT learning curve|Initial cannulation is performed with a wire-guided sphincterotome by a trainee. If the cannulation proves difficult (cannulation time \>10min, cannulation attemtps \>5 or inadvertent PD cannulation \>1) and PD is inadvertently entered, DWT will be performed by one of the two trainees. If DWT fails within 5min or 5 attempts, a trainer will take over and continue the cannulation. To prevent PEP, all patients receive prophylactic PD stent and post-ERCP rectal indomethacin. Aggressive hydartion will be administrated at the discretion of endoscopists.
62831828|NCT02531802|EXPERIMENTAL|24-59 months: ETVAX (1/2) + 10 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\^10 inactivated E. coli bacteria) plus 10 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
62831829|NCT02531802|PLACEBO_COMPARATOR|24-59 months: Placebo|24-59 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
62831830|NCT02531802|EXPERIMENTAL|12-23 months: ETVAX (1/4)|12-23 month old children receiving a quarter adult dose of ETVAX vaccine (2.5 x 10\^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
62831831|NCT02531802|EXPERIMENTAL|12-23 months: ETVAX (1/2)|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
62250957|NCT03502291|ACTIVE_COMPARATOR|Study One: LAIV + Inoculation|LAIV Nasal Spray: Inoculation (FLUMIST or FLUENZ) plus intramuscular placebo then inoculation with pneumococci bacteria
62440942|NCT05760014||TEMOINS patients|TEMOINS patients with conventional follow-up who will not benefit from the medical hypnosis technique.
62440943|NCT00652873|EXPERIMENTAL|A|Subjects received the test product, Cabergoline 0.5 mg tablets under fed conditions
62440944|NCT00652873|ACTIVE_COMPARATOR|B|Subjects received the reference product, Dostinex under fed conditions
62440945|NCT01507896|EXPERIMENTAL|BAX326 in Surgery|BAX 326 (recombinant factor IX) in Surgery
62440946|NCT06290583|ACTIVE_COMPARATOR|Group B|Patients will be given spinal anesthesia with bupivacaine (10 mg) added to morphine (100 microgram) and will be diluted with 0.9% saline to the 3 ml final volume to be injected.
62048867|NCT03014674|EXPERIMENTAL|Liquid mepolizumab in safety syringe|Subjects will receive a single dose of 100 mg liquid mepolizumab administered subcutaneously using a prefilled syringe within a safety syringe according to randomization.
62048868|NCT03014674|EXPERIMENTAL|Liquid mepolizumab in an autoinjector|Subjects will receive a single dose of 100 mg liquid mepolizumab administered subcutaneously using a prefilled autoinjector, according to randomization.
62048869|NCT03014674|ACTIVE_COMPARATOR|Lyophilised mepolizumab from vial|Subjects will receive a single dose of 100 mg reconstituted lyophilized mepolizumab manually administered subcutaneously according to randomization
62048870|NCT03574064|EXPERIMENTAL|GLP-2|Glucagon-Like Peptide-2 (GLP-2)
62250958|NCT03502291|PLACEBO_COMPARATOR|Study One: Placebo + inoculation|Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo then inoculation with pneumococci bacterial
62831832|NCT02531802|EXPERIMENTAL|12-23 months: ETVAX (1/2) + 2.5 ug dmLT|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
62831833|NCT02531802|EXPERIMENTAL|12-23 months: ETVAX (1/2) + 5 ug dmLT|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
62250959|NCT03502291|ACTIVE_COMPARATOR|Study Two: Inoculation + LAIV|Inoculation with pneumococci bacteria then Live attenuated Influenza Vaccine Nasal Spray (FLUMIST or FLUENZ) plus intramuscular placebo
62250960|NCT03502291|PLACEBO_COMPARATOR|Study Two: Inoculation + placebo|Inoculation with pneumococci bacteria then Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo
62250961|NCT02902081|PLACEBO_COMPARATOR|Placebo|Oral placebo administered once prior to subjective drug effects questionnaires and behavioral tasks.
62250962|NCT02902081|EXPERIMENTAL|Cannabidiol|(300 mg, 600 mg, 900 mg) cannabidiol administered once prior to subjective drug effects questionnaires and behavioral tasks.
62250963|NCT05962047|EXPERIMENTAL|Group 1|Augmented Reality games
62250964|NCT05962047|ACTIVE_COMPARATOR|Group 2|Traditional therapy
62250965|NCT01383980|NO_INTERVENTION|Control|Tube feeds are held night prior to elective surgery (standard of care)
62250966|NCT01383980|EXPERIMENTAL|Continuous Feeding|Tube feeds are continued up until surgery. Subjects with a nasogastric tube will have their stomach contents emptied prior to surgery.
62250967|NCT01322503|EXPERIMENTAL|Norovirus Challenge|
62250968|NCT01322503|EXPERIMENTAL|Norovirus challenge|
62831834|NCT02531802|PLACEBO_COMPARATOR|12-23 months: Placebo|12-23 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
62831835|NCT02531802|EXPERIMENTAL|6-11 months: ETVAX (1/8)|6-11 month old children receiving an eighth of an adult dose of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14
62250969|NCT05234554|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%)|
62440947|NCT06290583|ACTIVE_COMPARATOR|Group P|Patients will be given spinal anesthesia with prilocaine (50 mg) added to morphine (100 microgram) and will be diluted with 0.9% saline to the 3 ml final volume to be injected.
62831836|NCT02531802|EXPERIMENTAL|6-11 months: ETVAX (1/4)|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10\^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
62831837|NCT02531802|EXPERIMENTAL|6-11 months: ETVAX (1/2)|6-11 month old children receiving a half of an adult dose of ETVAX vaccine (5 x 10\^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
62831838|NCT02531802|EXPERIMENTAL|6-11 months: ETVAX (1/4) + 2.5 ug dmLT|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10\^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
62831839|NCT02531802|EXPERIMENTAL|6-11 month olds: ETVAX (1/4) + 5 ug dmLT|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10\^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
62831840|NCT02531802|PLACEBO_COMPARATOR|6-11 month olds: Placebo|6-11 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
62250970|NCT05234554|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution|
62250971|NCT05979376||Group I (Control group)|group I: quadratus lumborum block with 0,25% bupivacaine 0,5 ml/kg
62250972|NCT05979376||Group II|groupII: quadratus lumborum block with 0,25%bupivacaine 0,5 ml/kg and dexmedetomidine 0,5 mcg/kg as an adjuvant
62250973|NCT05979376||Group III|groupIII: quadratus lumborum block with 0,25% bupivacaine 0,5 ml/kg and dexmedetomidine 1 mcg/kg as an adjuvant
62250974|NCT06478355|EXPERIMENTAL|The patients with ESCC receive Immunotherapy combined with chemoradiotherapy|"Immunotherapy: intravenously, every 3 weeks for at least 6 months, or until progression, intolerance, or spontaneous withdrawal of the patient.~Chemotherapy drug：albumin-bound paclitaxel 110-130mg/m2,d1,d8;cis-platinum 60-75mg/m2,d1 Q3W Radiotherapy: Total dose of 60Gy/30 times, each time 2.0Gy, 5 times a week from week 7 to week 12 of radiotherapy."
62250975|NCT01102348|EXPERIMENTAL|PEP-uP Protocol (after)|PEP-uP protocol and treatment algorithm implemented for all patients in ICU.
62250976|NCT01102348|NO_INTERVENTION|Standard feeding protocol (before)|Enteral feeds are guided by a standard feeding protocol specified by pre-printed ICU admission orders. The admitting physician has the option of initiating the enteral feeding protocol or keeping the patient nil per os (NPO).
62250977|NCT04124484|EXPERIMENTAL|50mg group|Participants received one 50mg of DBPR108 tablet and two placebos matching DBPR108 100mg under fasted conditions for one day.
62250978|NCT04124484|EXPERIMENTAL|100mg group|Participants received one 100mg of DBPR108 tablet and two placebos matching DBPR108 50mg and 100mg under fasted conditions for one day.
62250979|NCT04124484|EXPERIMENTAL|200mg group|Participants received two 100mg of DBPR108 tablets and one placebo matching DBPR108 50mg under fasted conditions for one day.
62250980|NCT04124484|PLACEBO_COMPARATOR|placebo group|Participants received two placebo matching DBPR108 100mg and one placebo matching DBPR108 50mg
62250981|NCT04143360|EXPERIMENTAL|New Closed Drainage Device|We further improve the new closed thoracic drainage system by changing the material of drainage tube, adding external fixator control valve and increasing the gas flow monitoring kit for special patients, and apply it in clinical practice.
62250982|NCT04143360|EXPERIMENTAL|Traditional Closed Drainage Device|We use traditional closed drainage devices for patients with hemothorax and pneumothorax.
62250983|NCT04853836|PLACEBO_COMPARATOR|Rehabilitation therapy only (control group)|Olfactory training / stimulation through Sniffin' Sticks, administered twice every day (10 minutes session)
62609274|NCT03066856|NO_INTERVENTION|Control|All participants receive general recommendations for the dietary prevention of cancer. After baseline examinations, women randomized in the control group carry on following the baseline recommendations.
62831841|NCT06267755|EXPERIMENTAL|Extracorporeal Shockwave therapy|Thirty patients will receive Extracorporeal Shockwave therapy and Traditional physical therapy three times per week for six consecutive weeks.
62831842|NCT06267755|ACTIVE_COMPARATOR|Traditional physical therapy|Thirty patients will receive Traditional physical therapy three times per week for six consecutive weeks.
62048871|NCT03574064|EXPERIMENTAL|GIP|Glucose-dependent Insulinotropic polypeptide (GIP)
62250984|NCT04853836|ACTIVE_COMPARATOR|Rehabilitation and treatment with PEA-LUT|Olfactory training / stimulation through Sniffin' Sticks, plus daily treatment with PEA/Luteolin oral supplement
62250985|NCT04853836|ACTIVE_COMPARATOR|Treatment with PEA-LUT one sachet daily|Patients in this group only used a single dose of PEA-LUT
62250986|NCT04853836|ACTIVE_COMPARATOR|Treatment with PEA-LUT two sachet daily|Patients in this group only used two doses of PEA-LUT
62250987|NCT03874663||Oral HIV Self-testing|Evaluate the acceptability and performance of a directly assisted oral HIV self-testing (HIVST) in a youth population aged 14-24 in Nigeria
62250988|NCT01750372||Persons with lower limb amputation|Persons with amputation below the hip and at or above the ankle
62250989|NCT02064920|PLACEBO_COMPARATOR|Placebo|Placebo for donepezil hydrochloride capsule administered orally once a day for 16 weeks.
62449488|NCT03936400|ACTIVE_COMPARATOR|Active comparator: control group|A control group that receives same but delayed couple-based intervention
62449489|NCT02819674||early-onset hypertension|early-onset hypertension patients recruited in Chinese multiple centers
62609275|NCT05225571||cervical myofascial pain syndrome|The participants who diagnosed as cervical myofascial pain syndrome aged 18-64 years. The pain must last at least 3 months.
62048872|NCT03574064|EXPERIMENTAL|GLP-2+GIP|GLP-2+GIP
62048873|NCT03574064|PLACEBO_COMPARATOR|Placebo|Placebo
62250990|NCT02064920|EXPERIMENTAL|Donepezil|During the first 4 weeks, participants received placebo for donepezil. Over the following 2 weeks, participants were treated with donepezil at 5 mg per day. Then, over the remaining 10 weeks were titrated to up to 10 mg per day donepezil based on tolerability.
62609276|NCT05460234||Single Cohort|data from medical records up to 3 months prior to ERC treatment start will be retrospectively collected (if available), to provide baseline data and to serve as a basis for evaluating the treatment decision. If relevant baseline data is not available within 3 months preceding treatment start, retrospective documentation can extend to up to 6 months. The observational period of ERC (both retrospective and prospective) is scheduled up to 18 months after treatment start (Protocol v2.0,06Dec2023)
62609277|NCT03091075|EXPERIMENTAL|Treatment Group|Oxandrolone
62048874|NCT03670667||RA patients treated with abatacept|
62048875|NCT03670667||RA patients treated with anti-TNFi's|
62048876|NCT03670667||RA patients treated with other biologics|
62048877|NCT00755040|EXPERIMENTAL|Ocular Cyclosporine (Restasis)|Patients receive cyclosporine ophthalmic emulsion (Restasis®) drops in each eye twice daily for up to 1 year after transplant.
62048878|NCT00755040|PLACEBO_COMPARATOR|Placebo|Patients receive placebo ophthalmic drops in each eye twice daily for up to 1 year after transplant.
62250991|NCT06201247|EXPERIMENTAL|Experimental: Experimental: JD123 injection.|The relapsed/refractory AML patients will receive JD123 injections up to 3 dose levels (5.0×108 cells/dose，1.5×109 cells/dose，3.0×109 cells/dose) after FC chemotherapy.
62449490|NCT05492591|EXPERIMENTAL|Group 1|5 μg/kg of peginterferon α1b for injection in patients with herpes zoster.
62449491|NCT05492591|EXPERIMENTAL|Group 2|6 μg/kg of peginterferon α1b for injection in patients with herpes zoster.
62449492|NCT05492591|EXPERIMENTAL|Group 3|7 μg/kg of peginterferon α1b for injection in patients with herpes zoster.
62449493|NCT05492591|EXPERIMENTAL|Group 4|Both valacyclovir tablets and 6 μg/kg of peginterferon α1b for injection plan to be used in patients with herpes zoster.
62831843|NCT05760339|EXPERIMENTAL|Time-restricted feeding|Subjects will follow a daily time-restricted feeding regimen consisting of an 8h ad libitum eating period and a 16h water fasting period during the last two weeks before surgery, followed by routine preoperative fasting before surgery.
62831844|NCT05760339|ACTIVE_COMPARATOR|Carbohydrate loading|Subjects will follow their usual diet in the pre-surgical weeks and will receive a maltodextrin beverage on the evening before surgery, as well as two hours before induction of anaesthesia
62250992|NCT01230281|EXPERIMENTAL|Black bean seed coat extract|Daily 1000 mg oral Black bean seed coat extract is given to each subject for 2 weeks from Day2 after measuring antioxidative marker without intervention on Day1.
62250993|NCT01657474|EXPERIMENTAL|Weekly Application of EpiFix|Weekly application of EpiFix plus standard of care
62250994|NCT01657474|EXPERIMENTAL|Biweekly application of EpiFix|Biweekly application of EpiFix plus standard of care
62609278|NCT03091075|PLACEBO_COMPARATOR|Placebo Group|placebo
62048879|NCT04137692|EXPERIMENTAL|Red Blood Cell Transfusion|Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.
62048880|NCT06165783|EXPERIMENTAL|evaluate the effect of using therapeutic exercises and ultrasound|evaluate the effect of using therapeutic exercises and ultrasound for the rehabilitation of partially injured hamstring muscles.
62048881|NCT06165783|EXPERIMENTAL|analyse its effectiveness on the speedy healing|analyse its effectiveness on the speedy healing, which will be defined through some physical variables (hamstring muscle strength, the electrical activity of hamstring muscles) and pain perception.
62048882|NCT01269580||Diabetic|Adult diabetic patients type 1 or 2, with chronic critical ischemia as defined by TASC 2007 criteria
62048883|NCT01269580||Not diabetic|Adult not diabetic with chronic critical ischemia
62048884|NCT03840603|NO_INTERVENTION|Control|Usual care of patients with suspected Low RespiratoryTract Infection at the discretion of the attending physician. Care may entail a CRP and/or a PCT measurement, but no nasopharyngeal swab sampling.
62048885|NCT03840603|EXPERIMENTAL|Film Array RP2 Assay guided|In the emergency room a nasopharyngeal swab sample will be collected from subjects with a suspected Low RespiratoryTract Infection for the Film Array RP2 Assay guided plus a blood sample for the PCT assay if the PCT measurement has not been already prescribed.
62048886|NCT02963974|EXPERIMENTAL|Cochlear Implant|Pediatric patients with single sided deafness will receive a cochlear implant in the ear of loss
62250995|NCT03470038|EXPERIMENTAL|NGF condition + Control condition|"All participants will receive five injections with NGF (1ug/0.5ml) into the tibialis anterior muscle in their non-dominant leg~After 4 weeks:~All participants will receive five injections with isotonic saline (9%/0.5ml) into the tibialis anterior muscle in their non-dominant leg"
62250996|NCT03470038|EXPERIMENTAL|Control condition + NGF condition|"All participants will receive five injections with isotonic saline (9%/0.5ml) into the tibialis anterior muscle in their non-dominant leg~After 4 weeks:~All participants will receive five injections with NGF (1ug/0.5ml) into the tibialis anterior muscle in their non-dominant leg"
62250997|NCT05164055|EXPERIMENTAL|Avalglucosidase alfa|Administered intravenously every other week
62440948|NCT05610501||Patient population|"All consecutive patients (\> 18 years) undergoing a tru-cut biopsy at the participating centers during the study periof will be eligible for inclusion in the study.~All biopsies will be performed by trained operators in gynecologic ultrasound and tru-cut biopsies. Tissue samples will be assessed by experienced pathologists, dedicated in gynecologic oncology. Data will be collected by reviewing patients' electronic medical file including data concerning further treatment-strategy and pathology reports. Patients' level of pain and overall experience will be assessed by an independent investigator not present during biopsy. This will be performed from 0-72h after the biopsy using a numeric rating scale (0-100). Safety and complication-rate will be assessed by both using the collected data and via postprocedural assessment and by phone after six weeks. Inclusion and exclusion criteria can be found elsewhere."
62449494|NCT05492591|EXPERIMENTAL|Group 5|Both valacyclovir tablets and 7 μg/kg of peginterferon α1b for injection plan to be used in patients with herpes zoster.
62609279|NCT01492725|EXPERIMENTAL|Intra-arterial Clot Retrieval after iv tPA|
62609280|NCT01492725|ACTIVE_COMPARATOR|Standard care iv tPA|
62609281|NCT03386617|EXPERIMENTAL|NEPA|"Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded."
62609282|NCT03175471||Patients with autoimmune liver disease|"Patients (6-23 y.o.) with established clinical diagnosis of AIH or suspected diagnosis of AIH based on elevated serum AST or ALT, elevated IgG level \>1.1 ULN, elevated titer of autoantibodies, including ANA, SMA, LKM, LC-1 or SLA, which is consistent with the simplified criteria for the diagnosis of AIH in children will be enrolled.~Patients (6-23 y.o.) with established clinical diagnosis of PSC or Suspected diagnosis of PSC supported by abnormal cholangiogram (ERCP or MRCP) or elevated GGT\>1.5 ULN and dilated bile ducts by liver ultrasound will be enrolled."
62609283|NCT04504175|EXPERIMENTAL|Acute infusion|Acute phase: ketamine infusions twice a week for 4 weeks
62831845|NCT05760339|NO_INTERVENTION|Control group|Subjects will continue their usual diet and proceed with standard preoperative fasting (i.e., eat up until 6 hours and take clear liquids up until 2 hours before induction of anaesthesia).
62831846|NCT00936286|EXPERIMENTAL|Respiratory Muscle Training|
62250998|NCT02207998|EXPERIMENTAL|Homeopathic complex and physiotherapy|"Homeopathic complex and physiotherapy: (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of 168 tablets; 56 tablets will be issued forth nightly to assess participant's compliance in taking their medicine. Participants will be given instruction to take two tablets, dissolved under the tongue 20 minutes away from meals, twice daily, starting from day one.~Physiotherapy treatment will consist of lower back classic massage, lumber joint manipulation and the application of a hot pack. Treatment sessions will last for 30 minutes, once every two weeks at the same physiotherapy practice from the same specific and identified physiotherapist."
62250999|NCT02207998|PLACEBO_COMPARATOR|Placebo and physiotherapy|"Placebo and Physiotherapy: Placebo will comprise of 168 unmedicated lactose tablets; 56 tablets will be issued forth nightly to assess participant's compliance in taking their medicine. Participants will be given instruction to take two tablets, dissolved under the tongue 20 minutes away from meals, twice daily, starting from day one.~Physiotherapy treatment will consist of lower back classic massage, lumber joint manipulation and the application of a hot pack. Treatment sessions will last for 30 minutes, once every two weeks at the same physiotherapy practice from the same specific and identified physiotherapist ."
62251000|NCT03188562|EXPERIMENTAL|EBUS-TBNA, EUS-NA|"1. PET/CT~2. Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA)"
62251001|NCT03188562|EXPERIMENTAL|TEMLA|"1. PET/CT~2. Transcervical Extended Mediastinal Lymphadenectomy (TEMLA)"
62251002|NCT06438848|EXPERIMENTAL|Physical therapy program|group will be prescribed a usual physical therapy program three times a week for four weeks, which will be conducted in the clinic. The program consists of eight sessions comprising warm-up and cool-down, stretching activities, and strengthening exercises, and manual therapy. The program will start with 10-minute warm-up and 10-minute cool-down periods of physical therapy sessions
62831847|NCT01074814|OTHER|Metastatic Breast Cancer Patients|Blood drawn for molecular profiling
62831848|NCT06371092|EXPERIMENTAL|UltraEZ Group|Patients put in their bleaching trays the UltraEZ desensitizing gel for 30 minutes before the bleaching treatment every day during three weeks.
62831849|NCT06371092|PLACEBO_COMPARATOR|Placebo Group|Patients put in their bleaching trays the UltraEZ placebo gel for 30 minutes before the bleaching treatment every day during three weeks.
62831850|NCT04336917|ACTIVE_COMPARATOR|Group Rhomboid Intercostal and Subserratus Plane Block|In addition to routine standard perioperative and postoperative analgesic protocol participants will recieve Rhomboid Intercostal and Subserratus Plane Block under ultrasound guidence at the end of the surgery.
62251003|NCT06438848|EXPERIMENTAL|Physical therapy program with lymphedema drainage|physical therapy program three times a week for four weeks, which will be conducted in the clinic. The program consists of eight sessions comprising warm-up and cool-down, stretching activities, and strengthening exercises,And manual lymphatic drainage prescribed 20 minutes of MLD daily. The program will be prescribed five times a week, for four weeks
62251004|NCT05223660|EXPERIMENTAL|Low dose KT07|KT07 single dose (4 capsules) followed by multiple doses for 5 days (tid)
62251005|NCT05223660|EXPERIMENTAL|High dose KT07|KT07 single dose (6 capsules) followed by multiple doses for 5 days (tid)
62251006|NCT05223660|PLACEBO_COMPARATOR|Low dose placebo|Placebo single dose (4 capsules) followed by multiple doses for 5 days (tid)
62251007|NCT05223660|PLACEBO_COMPARATOR|High dose placebo|Placebo single dose (6 capsules) followed by multiple doses for 5 days (tid)
62251008|NCT03877978||Severe traumatized patients|Severe traumatized patients with an Index Severity Score (ISS) ≥ 15 admitted to the trauma center of Edouard Herriot Hospital.
62251009|NCT00317720|EXPERIMENTAL|Trastuzumab + RAD001|Trastuzumab loading dose is 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle. Starting RAD001 dose 10 mg by mouth daily.
62251010|NCT02562079|EXPERIMENTAL|subjects SSc diagnosed|
62251011|NCT02562079|EXPERIMENTAL|subjects Localised sclerosis diagnosed|
62251012|NCT02562079|EXPERIMENTAL|subjects Sc|
62251013|NCT02375724|EXPERIMENTAL|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg twice daily by inhalation
62251014|NCT02375724|PLACEBO_COMPARATOR|Placebo|placebo twice daily by inhalation
62831851|NCT04336917|NO_INTERVENTION|Control Group|Routine standard perioperative and postoperative analgesic protocol will be given.
62831852|NCT04461717||MicroNet covered stenting (interventional)|MicroNet covered stent implantation for increased risk arterial lesions beyond the carotid bifurcation
62831853|NCT01491607|EXPERIMENTAL|BioThrax (0.5 mL, on days 0, 14, and 28)|
62831854|NCT01682889|PLACEBO_COMPARATOR|Placebo|NaCl 0.9% intravenously for 24 hours after induction of anaesthesia
62251015|NCT04625842|EXPERIMENTAL|Patient focus group|Patients who received radiation treatment
62251016|NCT04625842|EXPERIMENTAL|Family focus group|Family of patients who received radiation treatment
62251017|NCT03921320|ACTIVE_COMPARATOR|Bilateral sympathectomy|Bilateral sequential (one surgical procedure) videothoracoscopic R4 sympathectomy
62609284|NCT05842005|EXPERIMENTAL|Mesh-reduced Sling|Mesh-reduced sling will improve stress urinary incontinence (SUI) symptoms in women with SUI and normal urethral closure pressure at 2 months and 12 months after surgery.
62609285|NCT06294665|ACTIVE_COMPARATOR|Group A : ( Bupivacaine + Dexmedetomidine )|Group A : will receive bupivacaine 0.25% + dexmedetomidine 1 mic/kg, total volume (20 ml)
62609286|NCT06294665|ACTIVE_COMPARATOR|Group B: ( Bupivacaine + Dexamethasone )|Group B : will receive bupivacaine 0.25% +dexamethasone (8 mg), total volume(20 ml).
62609287|NCT01903681|ACTIVE_COMPARATOR|Circadin 10 mg|Second arm higher dose
62609288|NCT01903681|ACTIVE_COMPARATOR|Circadin 2 mg|First arm lower dose
62609289|NCT04484155|EXPERIMENTAL|Minimally invasive micro sclerostomy (MIMS)|create a drainage channel at the sclera-corneal junction
62048887|NCT04917133|EXPERIMENTAL|Adapted Physical workshops|The experimental APA group will have in addition of the classic program, 6 APA workshops per week with collective care : Adapted Physical workshops, adapted cycling, therapeutic (horseback/equestrian) riding, cultural or leisure outings, situation tests
62048888|NCT04917133|OTHER|Control|"Standard of care The control group will have the classic program performed in the standard of care with : kinesitherapy, soft gym, medico-social workshop, cognitive workshop, creative workshop, individual care (rehabilitation, rest, creation)."
62048889|NCT00778479|EXPERIMENTAL|Sepraspray|Receive Sepraspray
62251018|NCT03921320|EXPERIMENTAL|Unilateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy on the right (dominant) side
62251019|NCT03921320|EXPERIMENTAL|Contralateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy on the left (contralateral) side
62251020|NCT01037491|ACTIVE_COMPARATOR|aspirin|Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD.patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks.
62251021|NCT01037491|ACTIVE_COMPARATOR|clopidogrel|Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD.patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks.
62251022|NCT04498169|EXPERIMENTAL|Once Daily Netarsudil Ophthalmic Solution|One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the evening for an 8 week period in up to 20 subjects.
62251023|NCT04498169|EXPERIMENTAL|Twice Daily Netarsudil Ophthalmic Solution|One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the morning and in the evening for an 8 week period in up to 20 subjects.
62251024|NCT00759733||1|Pregnant women with a history of cardiac disease (study group)
62609290|NCT04717388|EXPERIMENTAL|impact of tinnitus on executive cognitive functioning|
62609291|NCT04717388|EXPERIMENTAL|impact of tinnitus on reorganization of functional/ structural brain connectivity maps|
62609292|NCT02384109|EXPERIMENTAL|Intervention|Pharmacist-coordinated shared decision making about treatment for pre-diabetes (lifestyle change and/or metformin), using a decision tool
62609293|NCT02384109|PLACEBO_COMPARATOR|Usual Care|Usual care for patients with a diagnosis of pre-diabetes
62048890|NCT00778479|NO_INTERVENTION|Control|no treatment
62048891|NCT04232683|EXPERIMENTAL|Preoperative Tamsulosin|The study group will receive one oral dose .4mg of Tamsulosin prior to surgery.
62048892|NCT04232683|PLACEBO_COMPARATOR|Preoperative Placebo|The control group will receive one oral dose of placebo pill prior to surgery.
62251025|NCT00759733||2|Pregnant women with no history of heart disease (control group)
62251026|NCT05570942|ACTIVE_COMPARATOR|Probiotic group|The patients with staged III colorectal cancer receiving adjuvant chemotherapy who will be given probiotics.
62609294|NCT02356510||Culprit lesion|Patients who underwent culprit lesion only PCI during primary intervention
62609295|NCT02356510||Culprit vessel|Patients who underwent culprit lesion only PCI during primary intervention
62609296|NCT06624020||Breast Cancer Patients|HR+/HER2- metastatic breast cancer patients in in Australia
62609297|NCT06283680||Group 1|Ex patients on the lung transplant waiting list
62609298|NCT06283680||Group 2|Tansplant patients
62609299|NCT06283680||Group 3|Patients waiting on the current list
62831855|NCT01682889|ACTIVE_COMPARATOR|Arginine|L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours after induction of anaesthesia
62609300|NCT05299619|EXPERIMENTAL|Tixel Group|Tixel treatments in Dry Eye Patients
62831856|NCT00701350||1|Women presenting with preterm gestation and ruptured membranes
62609301|NCT02758873|EXPERIMENTAL|Personalised Medicine|If an add-on controller is required, young people in this arm will be prescribed personalised medicine by results of the genotyping for the adrenergic beta2-receptor gene (ADRB2). Health professional's will be advised to prescribe inhaled salmeterol as 'add-on' controller if trial participants have the Gly/Gly variant on ADRB2, and montelukast if they have Arg/Arg or Arg/Gly variant on ADRB2.
62609302|NCT02758873|ACTIVE_COMPARATOR|Standard care|If an add-on controller is required, young people will be prescribed medication as per the choice of the primary or secondary care physician, without knowledge of genotypic status.
62609303|NCT05538091|EXPERIMENTAL|vismodegib + atezolizumab|"Vismodegib: fixed dose of 150 mg PO daily~Atezolizumab: fixed dose of 1200 mg Q3W (1200 mg on Day 1 of each 21-day cycle)"
62609304|NCT03117881|EXPERIMENTAL|DirectCAM|The DirectCAM arm receives the intervention content via therapists at participating clinics.
62609305|NCT03117881|EXPERIMENTAL|TeleCAM|The TeleCAM arm receives the intervention content at home using pre-loaded tablets and Interactive Voice Response (IVR) system technology.
62831857|NCT05251480|ACTIVE_COMPARATOR|Standard of Care|The standard of care includes physical examination, wound debridement, total cast or offloading boot, non-adherent dressing (PolyMem®) for wound covering, weekly visit for ongoing assessment
62831858|NCT05251480|EXPERIMENTAL|DermGEN™|A decellularized dermal matrix created from donated human skin. This arm will receive the same care as the Standard of Care control arm-physical examination, wound debridement, total cast or offloading boot, non-adherent dressing (PolyMem®) for wound covering, weekly visit for ongoing assessment-with the addition of DermGEN™ onto the wound at the first visit.
62831859|NCT03503032||Fenestrated|Standard extracardiac fontan undergoing Fontan fenestration creation
62831860|NCT03503032||Non fenestrated|Standard extracardiac fontan without fenestration
62831861|NCT05327348|EXPERIMENTAL|Parenteral Ascorbic Acid|Intravenous ascorbic acid 1 gram 8 hourly (3 grams per day) for 7 days
62831862|NCT05327348|PLACEBO_COMPARATOR|0.9% Normal Saline|Intravenous 0.9% normal saline 10 mL 8 hourly for 7 days
62048893|NCT03834233|EXPERIMENTAL|Nivolumab|Nivolumab 3mg/kg IV every 14 days until disease progression, unacceptable toxicity or up to 12 months.
62048894|NCT00260143|EXPERIMENTAL|Testosterone enanthate|300 mg of testosterone enanthate by intramuscular injection once weekly for 16 weeks
62048895|NCT00260143|PLACEBO_COMPARATOR|Placebo|Placebo (sesame oil) by intramuscular injection once weekly for 16 weeks
62048896|NCT05043051|ACTIVE_COMPARATOR|Vagal stimulation|Vagal stimulation will be given at 20 Hz for 1 hour daily with the bipolar electrode attached to the tragus for 2 months.
62831863|NCT03959891|EXPERIMENTAL|Fulvestrant + Ipatasertib|"* Ipatasertib will be administered orally on a daily basis~* Fulvestrant would be administered as intra-muscular injection twice a month for the first cycle, and then monthly for all other cycles."
62831864|NCT03959891|EXPERIMENTAL|Aromatase Inhibitor + Ipatasertib|"* Ipatasertib will be administered orally on a daily basis~* Aromatase inhibitors will be administered orally on a daily basis"
62831865|NCT03959891|EXPERIMENTAL|Fulvestrant + Ipatasertib +Palbociclib|"* Ipatasertib will be administered orally on a 3 week on and 1 week off schedule~* Fulvestrant would be administered as intra-muscular injection twice a month for the first cycle, and then monthly for all other cycles.~* Palbociclib will be administered orally on a 3 week on and 1 week off schedule"
62609306|NCT03117881|EXPERIMENTAL|rDirectCAM|The rDirectCAM arm is being implemented in response to Covid-19. The rDirectCAM arm receives the intervention content delivered remotely in real-time by therapists via videoconferencing technology.
62609307|NCT05433480|EXPERIMENTAL|experimental group|Intervention Drug: BPI-16350, Fulvestrant
62831866|NCT05101122|ACTIVE_COMPARATOR|Dosing Period 1: Atomoxetine|3 days of atomoxetine 40 mg followed by 4 days of atomoxetine 80 mg.
62831867|NCT05101122|EXPERIMENTAL|Dosing Period 2-4: AD313|Week 2: atomoxetine 40 mg/dronabinol 2.5 mg Week 3: atomoxetine 80 mg/dronabinol 5 mg Week 4: atomoxetine 80 mg/dronabinol 10 mg
62831868|NCT03472885|EXPERIMENTAL|Group 1: 100 mg Danicopan TID + Eculizumab|Starting dose of 100 mg danicopan TID in combination with eculizumab.
62831869|NCT03472885|EXPERIMENTAL|Group 2: Initial dose 100 or 150 mg Danicopan TID + Eculizumab|Starting dose of 100 or 150 mg danicopan TID in combination with eculizumab.
62831870|NCT03472885|EXPERIMENTAL|Group 3: Initial dose of 100, 150, or 200 mg Danicopan TID + Eculizumab|Starting dose of 100, 150, or 200 mg danicopan TID in combination with eculizumab.
62609308|NCT05433480|PLACEBO_COMPARATOR|control group|Intervention Drug: Placebo, Fulvestrant
62048897|NCT05043051|SHAM_COMPARATOR|Sham stimulation|Sham stimulation will be given at 20 Hz for 1 hour daily with the bipolar electrode attached to the earlobe for 2 months.
62251027|NCT05570942|PLACEBO_COMPARATOR|Control group|The patients with staged III colorectal cancer receiving adjuvant chemotherapy who will be given placebo.
62251028|NCT06210750|ACTIVE_COMPARATOR|Arm 1 (AALL0434 regimen)|See detailed description for Arm 1
62609309|NCT02199639||Spain|Group of patients with hemophilia recruited in the Region of Murcia (Spain) and evaluated in the Universidad Católica San Antonio between June and July 2014.
62609310|NCT02199639||El Salvador|"Group of patients with hemophilia recruited in the city of San Salvador (El Salvador) and evaluated in the Hospital Nacional Rosales and the Hospital Nacional de niños Benjamín Bloom from San Salvador in April 2014."
62831871|NCT03472885|EXPERIMENTAL|Group 4: Optimal Dose of Danicopan TID + Eculizumab|Optimal dose (starting dose of either 100, 150, or 200 mg, as determined from Groups 1-3) of danicopan TID in combination with eculizumab.
62831872|NCT01735006|EXPERIMENTAL|HPV vaccine|This dosage contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant
62831873|NCT01735006|PLACEBO_COMPARATOR|HEV vaccine|commercialized HEV vaccine which contains 30μg HEV antigen adsorbed in alum-adjuvant
62831874|NCT06573879|EXPERIMENTAL|Exercise Group (EG)|Exercise Group (EG) is the first arm of the study in which volleyball athlete participants performed eccentric exercises in addition to their exercise routines.
62831875|NCT06573879|NO_INTERVENTION|Control Group (CG)|Control Group (CG) is the second arm of the study, where volleyball athletes only continued their exercise routines and no external intervention was made.
62831876|NCT02808598|EXPERIMENTAL|Clinical Trials Education Program|Breast Cancer Clinical Trials Education program is offered to women in the experimental arm. This program was designed to promote increased clinical trials literacy among African American and Hispanic American women. Increased clinical trials knowledge and a better understanding of clinical trials is anticipated to create more positive attitudes, and perceptions about clinical trials among these two groups of women who are traditionally underrepresented in breast cancer clinical trials.
62831877|NCT02808598|PLACEBO_COMPARATOR|Neighborhood Watch Education Program|The Neighborhood Watch Program created by the Bureau of Justice Assistance and the National Crime Prevention Council was selected for inclusion in the control arm of this study. It provided participants with a program of equivalent length and format, as well as an equivalent focus on improving the well-being of African American and Hispanic Americans. It also provided an opportunity to evaluate the impact of the Neighborhood Watch Program.
62831878|NCT01109472|EXPERIMENTAL|Patient Tailored Magazine|Patient responses from computer assisted telephone interviews will be used to develop a patient tailored educational magazine.
62831879|NCT03713658|EXPERIMENTAL|Oral Risperidone|Participants will receive 3 milligram (mg) oral risperidone tablets once daily for up to one Week to determine tolerability based on investigator review.
62251029|NCT06210750|EXPERIMENTAL|Arm 2 (AALL0434 regimen with venetoclax)|See detailed description for Arm 2
62831880|NCT03713658|EXPERIMENTAL|Paliperidone Palmitate Once Monthly (PP1M)|Participants will receive 50, 75, 100 or 150 mg eq. (\[paliperidone palmitate\] mg equivalent \[to paliperidone\]) long acting formulation of paliperidone palmitate once monthly (PP1M) intramuscular injection for 4 months (17 weeks) plus option to continue 3 more months if not stabilized depending on the participant's clinical safety, tolerability and efficacy requirements.
62251030|NCT06210750|EXPERIMENTAL|Arm 3 (AALL0434 regimen with navitoclax)|See detailed description for Arm 3
62609311|NCT02199639||Bolivia|Group of patients with hemophilia recruited in the city of Santa Cruz (Bolivia) and evaluated at the Hospital Nacional de niños in Santa Cruz August 2014.
62609312|NCT00507351||Cancer Pain Management|Patients receiving chemotherapy for breast, colon, lung, or prostate cancer.
62609313|NCT03084757|EXPERIMENTAL|research of druggable molecular alterations on tumor biopsy|
62831881|NCT03713658|EXPERIMENTAL|Paliperidone Palmitate Every 3 Months (PP3M)|Participants will receive 175, 263, 350 or 525 mg eq. (\[paliperidone palmitate\] mg equivalent \[to paliperidone\]) long acting formulation of paliperidone palmitate every 3 months (PP3M) intramuscular injection for 24 Weeks.
62831882|NCT04806464|EXPERIMENTAL|VG161|"Part1:~1. 1.0\*10\^8 PFU on Day 1(1.0×10\^8PFU)~2. 1.0\*10\^8 PFU on Days 1 to 2(2.0×10\^8PFU)~3. 1.0\*10\^8 PFU on Days 1 to 3(3.0×10\^8PFU)~4. 1.3\*10\^8 PFU on Days 1 to 3(4.0×10\^8PFU)~5. 1.7\*10\^8 PFU on Days 1 to 3(5.0×10\^8PFU)~Part2:~Depends on the recommended dose in Part1"
62831883|NCT04845282|EXPERIMENTAL|Graded Protein plus Resistance Training|This group will participate in a progressive resistance training program and will be instructed to consume a diet with a gradation of protein over the 12 week study duration.
62048898|NCT03393195|EXPERIMENTAL|Time-restricted eating plan|Participants in this group will be instructed to fast every day from 8pm until 12pm the following day. From 12pm until 8pm, participants can eat and drink whatever they want. During fasting hours, participants can drink water and black coffee.
62251031|NCT06210750|EXPERIMENTAL|Arm 4 (AALL0434 regimen with venetoclax and navitoclax)|See detailed description for Arm 4
62251032|NCT06210750|ACTIVE_COMPARATOR|Arm 5 (AALL0434 [no nelarabine])|See detailed description for Arm 5
62251033|NCT06210750|EXPERIMENTAL|Arm 6 (AALL0434 [no nelarabine] + navitoclax & venetoclax)|See detailed description for Arm 6
62251034|NCT06210750|ACTIVE_COMPARATOR|Arm 7 (AALL0434 regimen)|See detailed description for Arm 7
62251035|NCT06210750|EXPERIMENTAL|Arm 8 (Remission induction with venetoclax and navitoclax)|See detailed description for Arm 8
62251036|NCT03057613|EXPERIMENTAL|Pembrolizumab + post operative radiotherapy|IMRT 60-66Gy for 6 weeks in combination with Pembrolizumab every 3 weeks for 16 weeks
62251037|NCT02098265|EXPERIMENTAL|Experimental Group - Immediate BCI Therapy|EEG - BCI training (closed loop)
62251038|NCT02098265|EXPERIMENTAL|Experimental Group - Delayed BCI Therapy|Scanned and tested 4 times over a 10-week period before EEG-BCI training
62251039|NCT02098265|EXPERIMENTAL|Experimental Group - RecoveriX|Recruited from participants who have completed the study intervention
62449495|NCT05492591|ACTIVE_COMPARATOR|Group 6|Only valacyclovir tablets in patients with herpes zoster, positive drug control group.
62609314|NCT05149573|ACTIVE_COMPARATOR|4-Week Treatment with no Maintenance Period|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (full body mat) and B. Pad (targeted pelvic pad). The participant will lie the B. Body mat on any flat surface and lay on the mat with the smaller B. Pad placed directly over the pelvic area. The PEMF device (attached to the control unit) has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a 4-week period. After 4 weeks, participants will return the device and complete one set of electronic questionnaires during the last week of the month for the following 3 months.
62831884|NCT04845282|ACTIVE_COMPARATOR|RDA Protein plus Resistance Training|This group will participate in a progressive resistance training program and will be instructed to consume a diet with the recommended daily allowance of protein over the 12 week study duration.
62831885|NCT00003553|EXPERIMENTAL|1|The target for progenitor cell is \>=5 x 106 CD 34/kg.
62831886|NCT01703767||Gulf War 1 Veterans|Persian Gulf War 1 Veterans (GW1V) who are currently treated by a primary care physician at the VA Salt Lake City Health Care System. GW1V will assess their primary care satisfaction before and after their providers receive a Provider Education Workshop.
62048899|NCT03393195|ACTIVE_COMPARATOR|Consistent Meal Timing Plan|Participants in this group will be instructed to eat three daily meals during specified eating times. Their first meal will be between 7am-11am. Second meal between 11am and 3pm, and third meal between 4pm-10pm. Participants will be encouraged to eat small snacks if needed so that they can eat their next meal during the specified window.
62048900|NCT04878835|NO_INTERVENTION|Control group|No intervention was given. No intralesional ranibizumab (Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL) was given at 2 weeks prior to pterygium excision surgery
62048901|NCT04878835|EXPERIMENTAL|Intervention group|The interventional group was given intralesional ranibizumab (Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL) 2 weeks prior to pterygium excision surgery
62251040|NCT02098265|ACTIVE_COMPARATOR|Control Group 1|48 stroke patients, 48 participants with risk factors for stroke, 48 healthy controls receiving 4-6 training sessions on the EEG-BCI, pre- and post- behavioral testing, and MRI
62831887|NCT05246306||Healthy group|Healthy adolescents aged 14-24 who have not been diagnosed with any chronic disease
62048902|NCT00227617|EXPERIMENTAL|FOLFOX with Bevacizumab|"Starting on Day 1, administered every two weeks:~5-fluorouracil: 2400 mg/ m2 CIV; over 46-48 hours Leucovorin: 200 mg/ m2; over 2 hours Oxaliplatin : 85 mg/m2; over 2 hours Bevacizumab: 5 mg/kg IV over 30-90 minutes"
62048903|NCT01091948|ACTIVE_COMPARATOR|Fiberoptic Intubation|Subjects will be intubated with the Fiberoptic laryngoscope.
62048904|NCT01091948|ACTIVE_COMPARATOR|GlideScope® Video Laryngoscope|Subjects will be intubated with the GlideScope® Video Laryngoscope.
62251041|NCT02098265|ACTIVE_COMPARATOR|Control Group 2|24 Stroke Patients with UE impairment receiving standard FES only therapy
62831888|NCT05246306||Patient with PCOS group|Adolescents between the ages of 14-24 diagnosed with Polycystic Ovary Syndrome according to the Rotherdam criteria.
62251042|NCT02524548|EXPERIMENTAL|SMS reminder|Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor
62251043|NCT02524548|NO_INTERVENTION|Standard care|Routine care
62251044|NCT05097144|EXPERIMENTAL|Lens A, then Lens B|Participants wore Lens A for one month and then wore Lens B for one month.
62251045|NCT05097144|EXPERIMENTAL|Lens B, then Lens A|Participants wore Lens B for one month and then wore Lens A for one month.
62440949|NCT01387100|EXPERIMENTAL|Physical Therapist/Occupational Therapist Intervention|This group will be assigned a physical therapist or occupational therapist to meet with followed by 2 phone consultations.
62609315|NCT05149573|SHAM_COMPARATOR|4-Week Sham Treatment with no Maintenance Period|Participants will be provided with a sham B. Body and B. Pad that appears identical to the active pulsed electromagnetic field (PEMF) device. The participant will lie the sham B. Body mat on any flat surface and lay on the mat with the smaller sham B. Pad placed directly over the pelvic area. The participant will be instructed to administer this sham treatment twice a day (morning and evening) for 8-minute sessions over a 4-week period. After 4 weeks, participants will return the sham device and complete one set of electronic questionnaires during the last week of the month for the following 3 months.
62609316|NCT05149573|ACTIVE_COMPARATOR|4-Week Treatment with 1-Week-Per-Month Maintenance Period for an Additional 3 Months|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (full body mat) and B. Pad (targeted pelvic pad). The participant will lie the B. Body mat on any flat surface and lay on the mat with the smaller B. Pad placed directly over the pelvic area. The PEMF device (attached to the control unit) has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a 4-week period. After 4 weeks, participants will keep the device and use it for 1 week (7 days) during the last week of the month for the following 3 months. Each participant in this group will be asked to complete a set of electronic questionnaires immediately following their week-long maintenance treatment during the last 3 months of the study.
62831889|NCT04293406||Established Prostate Cancer Group|Established Prostate Cancer Group will consist of a qualitative study of 12 semi-structured interviews with self-identified AA patient undergoing prostate treatment (stages I-III) (N-12 patients) and 12 semi-structured interviews with H/L patient undergoing prostate treatment (stages I-III) (N=12 patients) at NYPH Queens and NYPH-BM. Interview content will focus on psycho-social and socio-cultural factors associated with prostate cancer decision making, social support, and physician-patient communication.
62831890|NCT04293406||At Risk of Prostate Cancer Group|"At Risk of Prostate Cancer Group will recruit 58 self-identified AA or H/L men at risk of prostate cancer (stages I-III) receiving care at NYPH-Queens and NYPHQ (29 at each hospital) to participate in the evaluation of the tailored DNI intervention. Men who consent to participate in the study will complete a baseline survey. After biopsy appointment, participants with a negative Prostate Cancer biopsy will receive a study closure phone call, ending study participation.~Participants with positive Prostate Cancer biopsy will proceed with study procedures and be randomly assigned to decision navigation intervention (DNI) or standard of care (SOC). Participants with a positive Prostate Cancer biopsy will be followed for 6 months and complete assessments at 2 weeks, 1 month, and 6 months (close of the study)."
62251046|NCT04301232||Fast-Track Group|After extubation, patients were evaluated using modified Aldrete Scoring System (mASS) , White's Fast- Track Scoring System (WFTSS) and SPEEDS criteria during 15 minutes with 3 min intervals. Patients who fulfilled criteria of all scoring systems were defined as eligible for PACU by-pass (fast-tracking) and transferred into phase II recovery area in the ward without observation in PACU (Group FT = Fast Track;)
62251047|NCT04301232||PACU Group|After extubation, patients were evaluated using modified Aldrete Scoring System (mASS) , White's Fast- Track Scoring System (WFTSS) and SPEEDS criteria during 15 minutes with 3 min intervals. Ineligible patients were taken into PACU where their treatments were continued until discharge criteria were achieved (Group PACU)
62251048|NCT01485341|ACTIVE_COMPARATOR|gluten|gluten is administered blindly versus placebo for 15 days at 10 g/day
62440950|NCT01387100|NO_INTERVENTION|Control|This is the control group. This group will not receive the vocational rehabilitation intervention from an occupational or physical therapist. They will receive written information regarding job accommodations and disability advocacy.
62251049|NCT01485341|PLACEBO_COMPARATOR|rice starch|placebo (rice starch) will be administered blindly versus gluten for 15 days at 10 g/day
62609317|NCT05957224|EXPERIMENTAL|Shake 1 then Shake 2|Participants will consume 1 bottle of shake 1 and take their normal morning medications. After this 3ml blood samples will be taken via the cannula at 30mins, 60mins and 120 mins post meal. During the waiting period between phlebotomy, a sensory analysis questionnaire which asks participants to rate the taste, appearance, texture and smell of the product. After a 1-week washout period, the entire protocol will be repeated using Shake 2.
62251050|NCT05526742|EXPERIMENTAL|Group 1|"Subjects will receive single-dose of CKD-510 capsule in fasted state (treatment A) on Day 1 of Period 1 and tablet in fasted state (treatment B) on Day 1 of Period 2, and then receive tablet in a fed state (treatment C) on Day 1 of Period 3.~A washout period will be at least 7 days between each treatment period."
62440951|NCT02386059|PLACEBO_COMPARATOR|PLACEBO Group|Received normal saline
62440952|NCT02386059|ACTIVE_COMPARATOR|DEXAMETHASONE Group|Received 4 mg Dexamethasone.
62440953|NCT02386059|ACTIVE_COMPARATOR|ONDANSETRON|Received 4 mg Ondansetron
62440954|NCT02386059|ACTIVE_COMPARATOR|DEXAMETHASONE + ONDANSETRON|Received 4mg Dexamethasone + 4mg Ondansetron
62251051|NCT05526742|EXPERIMENTAL|Group 2|"Subjects will receive single-dose of CKD-510 tablet in a fed state (treatment C) on Day 1 of Period 1 and tablet in fasted state (treatment B) on Day 1 of Period 2, and then receive capsule in fasted state (treatment A) on Day 1 of Period 3.~A washout period will be at least 7 days between each treatment period."
62251052|NCT00874445||ICD shocks programmed to Tuned Waveform|ICD shocks programmed to Tuned Waveform
62831891|NCT04659876||Grup S (Survivors)|Survivors in ICU follow-up
62831892|NCT04659876||Grup NS (Nonsurvivors)|Patients who died in ICU follow-up
62251053|NCT00874445||ICD shocks programmed to Fixed Tilt Waveform|ICD shocks programmed to Fixed Tilt Waveform
62831893|NCT06315712|EXPERIMENTAL|Respiratory muscle training group|Received inspiratory muscle training plus pulmonary rehabilitation program. Powerbreathe device was used for the exercise of the inspiratory muscle strength. Strengthening the inspiratory muscles with the Powerbreathe is similar to weightlifting to strengthen other muscles in the body.
62831894|NCT06315712|EXPERIMENTAL|Pulmonary rehabilitation group|Received pulmonary rehabilitation program for five sessions per week for 8 weeks. Four resistive exercises, aerobic exercise, and deep breathing exercises, aerobic conditioning exercises on the treadmill. All exercises were performed using variable resistance machines.
62831895|NCT02372955|EXPERIMENTAL|dapagliflozin 10 mg daily|dapagliflozin, 10 mg daily for 16 weeks
62048905|NCT02497287|EXPERIMENTAL|Intranasal Esketamine plus oral antidepressant|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg). Participants greater than or equal to (\>=) 65 will start at a dose of 28 mg on Day 1. Direct-entry participants will initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release \[XR\]) on Day 1; transferred-entry participants will continue the same oral antidepressant from ESKETINTRD3005. Optimization/Maintenance Phase: Participants will self-administer esketamine (56mg or 84mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years) intranasally once per week for 4 weeks; transferred entry responder subjects from ESKETINTRD3005 will start at a dose of 28 mg in the first week. All participants will continue their same oral antidepressant during this phase.
62048906|NCT03074227|ACTIVE_COMPARATOR|Allogeneic faecal transplantation|Faecal transplantation of donor stool
62251054|NCT03406143|EXPERIMENTAL|CGF injection group|Concentrate Growth Factors(CGF) will be harvested through centrifugation afte intravenous blood collection. Venous blood was collected in tube and then centrifuged in Medifuge system（Thermo Scientific）. About 2ml liquid CGF can be harvested from 9ml venous blood. Patients will receive autologous CGF injection subdermally to expanded skin at the density of 0.02 ml/cm2.
62251055|NCT03406143|SHAM_COMPARATOR|Control group|0.9% saline will be injected into expanded skin for control study. Patients will receive saline injection subdermally to expanded skin at the density of 0.02 ml/cm2.
62440955|NCT01682161|EXPERIMENTAL|Group 1 (Immediate switch)|Paliperidone palmitate will be administered immediately after randomization and will be continued throughout the treatment phase.
62440956|NCT01682161|EXPERIMENTAL|Group 2 (Delayed switch)|Current oral antipsychotics will be continued until Week 8, and later on paliperidone palmitate will be administered.
62609318|NCT05957224|EXPERIMENTAL|Shake 2 then Shake 1|Participants will consume 1 bottle of Shake 2 and take their normal morning medications. After this 3ml blood samples will be taken via the cannula at 30mins, 60mins and 120 mins post meal. During the waiting period between phlebotomy, a sensory analysis questionnaire which asks participants to rate the taste, appearance, texture and smell of the product. After a 1-week washout period, the entire protocol will be repeated using Shake 1.
62831896|NCT02372955|ACTIVE_COMPARATOR|glimpiride|glimpiride 4 mg daily for 16 weeks
62831897|NCT00013533|EXPERIMENTAL|1|Transplant with Induction Therapy
62831898|NCT02911844|OTHER|Fulvestrant|500 mg administered intramuscularly (as two 5 mL injections) on days 0, 14, 28 and 56
62831899|NCT06586983||"Standard model (treat only if)"|"HBsAg positive patients will be eligible for treatment of they fulfill one of the following criteria:~i) Clinically diagnosed cirrhosis; or ii) APRI ≥0.5; or iii) Persistently elevated ALT \>40 U/L; or iv) Co-infection with HCV or HDV; or v) Family history of HCC/cirrhosis; or vi) Relevant co-morbidity"
62831900|NCT06586983||"Inclusive model (treat all except)"|HBsAg positive patients will receive treatment, except if APRI ≤0.3 and no clinical signs/symptoms of cirrhosis and no risk factors for liver disease.
62831901|NCT06586983||"Test-and-treat model (treat all)"|All HBsAg positive patients will receive treatment.
62048907|NCT03074227|PLACEBO_COMPARATOR|Autologous faecal transplantation|Faecal transplantation of own stool
62048908|NCT00002611|ACTIVE_COMPARATOR|Stratum 1|Stage I favorable histology (FH) Wilms' tumor, under 24 months of age, and tumor weight less than 550 g: After conventional surgery (nephrectomy), patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
62449496|NCT05448677|EXPERIMENTAL|Experimental|Ezurpimtrostat+Atezolizumab-Bevacizumab
62449497|NCT05448677|ACTIVE_COMPARATOR|Control|Atezolizumab-Bevacizumab
62831902|NCT03052075||Parathyroidectomy Data Review|The research plan is for a retrospective review to be performed of a prospectively maintained parathyroid database within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center.
62048909|NCT00002611|ACTIVE_COMPARATOR|Stratum 2|Stage I FH Wilms' tumor and age 24 months and over or tumor weight at least 550 g; stage I focal anaplastic (FA) or diffuse anaplastic (DA) Wilms' tumor: Patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
62048910|NCT00002611|ACTIVE_COMPARATOR|Stratum 3|Stage II FH Wilms' tumor: Patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
62048911|NCT00002611|ACTIVE_COMPARATOR|Stratum 4|Stage III FH Wilms' tumor; stage II or III FA Wilms' tumor: After conventional surgery (nephrectomy), patients receive regimen DD-4A comprising dactinomycin DACT IV weekly on weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weekly on weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weekly on weeks 1-10, 12, 15, 18, 21, and 24. Patients also undergo abdominal radiation therapy.
62251056|NCT02452905|ACTIVE_COMPARATOR|Nitazoxanide|Nitazoxanide 7.5mg/kg oral/nasogastric/nasoenteric tube three times per day for five days.
62440957|NCT02872402|EXPERIMENTAL|Intervention group|"At 2-mo postpartum, women will start the 1-yr lifestyle intervention that will consist of 7 face-to-face individual sessions of 1-hr (at 2, 3, 4, 5, 6, 9, 12 mo postpartum and a follow-up at 18 mo). Metabolic and anthropometric measurements will be assessed at 2,6,12 and 18 mo postpartum. In addition, 7 individual sessions of 30 min between face-to-face sessions will be carried out on the phone.~Benefits of exclusive breastfeeding, healthy eating and physical activity will be portrayed at each visit ."
62440958|NCT02872402|ACTIVE_COMPARATOR|Active control lifestyle intervention|Women in the control group will come to the testing unit at 2, 6, 12 and 18 mo postpartum for metabolic and anthropometric measurements and at 3, 4, 5, 9 mo for weight measurements only. They will receive standard lifestyle recommendations in the form of written information at each visit.
62831903|NCT06655597|EXPERIMENTAL|Reds Powder|Reds Powder
62048912|NCT00002611|ACTIVE_COMPARATOR|Stratum 5|Stage IV FH or FA Wilms' tumor: patients receive regimen DD-4A comprising dactinomycin DACT IV weekly on weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weekly on weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weekly on weeks 1-10, 12, 15, 18, 21, and 24. Patients also undergo abdominal radiation therapy, and whole lung radiation therapy (at the discretion of the investigator).
62251057|NCT02452905|PLACEBO_COMPARATOR|Placebo|The placebo is identical to the active drug described above except that it does not contain the active compound nitazoxanide. It is reconstitutes, administered and dosed as per the active study drug.
62251058|NCT05149183|EXPERIMENTAL|cervical stability training|cervical stability training will be received three times a week for eight weeks
62251059|NCT05149183|ACTIVE_COMPARATOR|traditional treatment|traditional treatment will be received three times a week for eight weeks
62440959|NCT01480856|ACTIVE_COMPARATOR|Cobedding|Newborn twins are settled in a single bed : this is cobedding
62440960|NCT01480856|PLACEBO_COMPARATOR|Single -bedding|Newborn twins are settled in two beds : this is single-bedding
62831904|NCT06655597|NO_INTERVENTION|Standard|Usual Diet
62251060|NCT01244295|EXPERIMENTAL|Complicated Grief Treatment|Targeted psychotherapy for complicated grief
62251061|NCT01244295|ACTIVE_COMPARATOR|Interpersonal Therapy|Standard IPT is a comparator treatment
62251062|NCT03457545|EXPERIMENTAL|Intervention|Eligible participants will take part in the home-based pulmonary rehabilitation using the Aidcube platform in-person assessment and training with a research coordinator (i.e. physical exercise capacity assessment, SPPB, disability survey, exercise prescription determination, exercise training, dyspnea control techniques) and complete an follow-up assessment at the 8th week.
62251063|NCT03457545|NO_INTERVENTION|No Intervention|Ineligible participants will receive standard of care
62440961|NCT02345486|ACTIVE_COMPARATOR|0.9% sodium chloride|Participants in the '0.9% sodium chloride' arm will receive 0.9% sodium chloride ('normal saline') any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
62609319|NCT04529850|EXPERIMENTAL|Open Label Active Arm|90mg GC4419 by IV
62831905|NCT01590719|EXPERIMENTAL|Onartuzumab (MetMAb) with mFOLFOX6|Onartuzumab (MetMAb) in combination with mFOLFOX6 (modified 5-fluorouracil, folinic acid \[leucovorin\], and oxaliplatin)
62831906|NCT01590719|PLACEBO_COMPARATOR|Placebo with mFOLFOX6|Placebo in combination with mFOLFOX6 (modified 5-fluorouracil, folinic acid \[leucovorin\], and oxaliplatin)
62048913|NCT00002611|ACTIVE_COMPARATOR|Stratum 6|Stage V FH, FA, or DA Wilms' tumor: After bilateral conventional surgery (biopsy), patients with FH receive chemotherapy as in stratum 1 (dactinomycin IV weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate IV weeks 1-10, 12, 15, and 18) or 4 (dactinomycin IV weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weeks 1-10, 12, 15, 18, 21, and 24). Patients with FA or DA receive chemotherapy as in stratum 7 (vincristine sulfate VCR IV weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy.
62048914|NCT00002611|ACTIVE_COMPARATOR|Stratum 7|Stages I-IV clear cell sarcoma): After conventional surgery (nephrectomy), patients receive vincristine sulfate VCR IV weekly on weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weekly on weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy and continuing until blood counts recover. Patients also undergo abdominal radiotherapy and whole lung radiotherapy (if pulmonary metastases are present).
62048915|NCT00002611|ACTIVE_COMPARATOR|Stratum 8|Stages II-IV DA Wilms' tumor: After conventional surgery (nephrectomy), Patients receive treatment as in stratum 7 (patients receive vincristine sulfate VCR IV weekly on weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weekly on weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy and continuing until blood counts recover. Patients also undergo abdominal radiotherapy and whole lung radiotherapy (if pulmonary metastases are present).
62048916|NCT00002611|ACTIVE_COMPARATOR|Stratum 9|Stages I-IV rhabdoid tumor: After conventional surgery (nephrectomy), patients receive carboplatin IV on days 1-2 and VP-16 IV over 1 hour (beginning after carboplatin infusion) on days 1-3 of weeks 0, 3, 9, 12, 18, and 21 and CTX IV over 1 hour on days 1-5 of weeks 6, 15, and 24. Filgrastim G-CSF is administered as on stratum 7. Patients also undergo radiation therapy. After completion of chemotherapy, patients undergo second-look conventional surgery (laparotomy) and conventional surgery (partial nephrectomy or wedge excision if feasible). After conventional surgery (second-look surgery), patients without persistent or residual disease resume chemotherapy.
62831907|NCT03912194|EXPERIMENTAL|Early Withdrawal Exposure plus NAW Regulation Training|The development, application, modification, and repeated practice of individualized withdrawal regulation strategies (e.g., behavioral and cognitive strategies for allaying withdrawal symptoms) across the first 4 hours of abstinence over 4 separate sessions.
62048917|NCT04026165|EXPERIMENTAL|Selonsertib|"Run-in Period (5 Weeks): Participants will receive placebo-to-match SEL for at least one week and then SEL 18 mg for at least 4 weeks.~Randomized Period: Participants will be randomized to receive SEL 18 mg for at least 48 weeks."
62048918|NCT04026165|PLACEBO_COMPARATOR|Placebo|"Run-in Period (5 Weeks): Participants will receive placebo-to-match SEL for at least one week and then SEL 18 mg for at least 4 weeks.~Randomized Period: Participants will be randomized to receive placebo-to-match SEL for at least 48 weeks."
62251064|NCT06025890|EXPERIMENTAL|Language Disorder|The language disorder group had to complete a two-year follow-up and intervention. Collect blood samples from 600 cases of language disorder.
62251065|NCT06025890|EXPERIMENTAL|Attention Deficit Hyperactivity Disorder|The ADHD group had to complete a two-year follow-up and intervention.Collect blood samples 800 cases of ADHD, and complete a fNIRS task test from 800 ADHD patients.
62251066|NCT06025890|NO_INTERVENTION|Normal children|For children aged 1-4, 2 developmental behavioral specialists with associate professor titles or above exclude language barriers.
62251067|NCT06025890|NO_INTERVENTION|Healthy children|Children aged 3-6, except ADHD with 2 developmental behavioral and/or psychiatrists with associate professor titles or above.
62251068|NCT01877915|EXPERIMENTAL|Rivaroxaban 2.5 mg|Each participant will receive 2.5 mg of rivaroxaban twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
62440962|NCT02345486|ACTIVE_COMPARATOR|Physiologically balanced fluid|Participants in the 'physiologically balanced fluid' arm will receive physiologically balanced fluid (Lactated ringers or Plasmalyte-A) any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
62440963|NCT05085314|EXPERIMENTAL|Ngenuity digital 3D microscope|
62440964|NCT05085314|ACTIVE_COMPARATOR|Conventional microscope|
62440965|NCT03496454|OTHER|PfSPZ Challenge|this is a basic sciences protocol designed to study the effect of pre-exposure to Plasmodium falciparum (Pf) on malaria parasite kinetics, clinical symptoms and immunity after Controlled Human Malaria Infection by administration of an injection PfSPZ Challenge in Gambian adults. Based on a well-defined serological profile representing the extremes of current malaria exposure in The Gambia, two cohorts will be identified to study the impact of naturally acquired immunity on susceptibility for a Controlled Human Malaria Infection. The classification as a clinical trial results from the administration of the PfSPZ Challenge to the healthy volunteers
62831908|NCT03912194|ACTIVE_COMPARATOR|Early Withdrawal Exposure plus Relaxation Control Training|The development, application, modification, and repeated practice of relaxation strategies across the first 4 hours of abstinence over 4 separate sessions.
62831909|NCT03912194|ACTIVE_COMPARATOR|NAW Regulation Training Only|The development, application, modification, and repeated practice of individualized withdrawal regulation strategies (e.g., behavioral and cognitive strategies for allaying withdrawal symptoms) over 4 separate sessions involving smoking as usual.
62831910|NCT03912194|ACTIVE_COMPARATOR|Relaxation Control Training Only|The development, application, modification, and repeated practice of relaxation strategies over 4 separate sessions involving smoking as usual.
62831911|NCT00260975||Chemotherapy patients|Breast cancer patients treated with adjuvant chemotherapy of various types.
62831912|NCT00260975||Hormonal patients|Breast cancer patients treated with adjuvant hormonal therapy but not chemotherapy.
62440966|NCT05381259|OTHER|hortitherapy intervention versus control|"Horticultural therapy refers to physical and psychic therapy by nature by focusing on the action of gardening on the body, intellect, psych and mind.~Horticultural in the form of therapeutic gardening serves as a support to help and treat various pathologies in the brain.~It is a form of curative treatment exploiting the planting and maintenance of garden. The term is a contraction of  horticultural  and  therapy."
62440967|NCT03746678||C-Care Mobile Application|
62440968|NCT03645226||Early PD subjects converted from iRBD|"1. Chinese aged 50 or above~2. Being capable of giving informed consent for participation of the study~3. PD diagnosis confirmed by neurologists according to the United Kingdom Parkinson's Disease Survey Brain Bank. Assessment tools including Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn \& Yahr Staging will be used for severity grading.~4. Onset of PD symptoms of \<5 years~5. In view of the heterogeneity of PD, we will only include those patients with RBD preceding the onset of motor symptom of PD."
62440969|NCT03645226||iRBD subjects|"1. Age-and sex-matched with PD subjects~2. Chinese aged 50 or above~3. Being capable of giving informed consent for participation of the study~4. RBD diagnosis according to the International classification of sleep disorder 3rd edition (ICSD 3rd), fulfilling both the clinical and video-polysomnography (vPSG) criteria."
62440970|NCT03645226||First degree relatives of patients with iRBD|"1. First degree relatives of patients with iRBD;~2. Age-and sex-matched with PD subjects~3. Chinese aged 40 or above;~4. Absence of dream enactment behaviors;~5. Not cohabiting with proband"
62831913|NCT03631992|EXPERIMENTAL|Low Sweet|"Children in intervention group will be provided with daily snacks lower in added sugar and sweetness and their mothers will receive educational lessons on dental care, reading food labels, and nutrition that support the goals of reducing sweet exposure and added sugar intake."
62440971|NCT03645226||Healthy Controls|"1. Age-and sex-matched with PD subjects;~2. Chinese aged 50 or above;~3. Being capable of giving informed consent for participation of the study;~4. Without a personal history or a family history of PD or RBD;~5. Absence of dream enactment behaviors;~6. A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~7. Absence of RSWA as measured by v-PSG."
62440972|NCT01978106||a WTR corneal astigmatism group|Corneal astigmatism was defined as WTR when the steep corneal cylinder axis was within 30 degrees of the horizontal axis.
62831914|NCT03631992|SHAM_COMPARATOR|Regular Sweet|Children in the regular sweet control group will be provided with common snacks fed to children of this age and mothers will be given education lessons on portion size, physical activity, sleep, screen time and, at the end of the trial, dental care.
62831915|NCT03859934|ACTIVE_COMPARATOR|Melatonin|10 mg melatonin each day 1 hour before bedtime for 3 months
62831916|NCT03859934|PLACEBO_COMPARATOR|Placebo|Placebo each day 1 hour before bedtime for 3 months
62831917|NCT01087463|EXPERIMENTAL|single arm|In this single arm study, the Quantum nailing system will be used in all patients.
62831918|NCT04949997||control|patients without heart failure
62831919|NCT04949997||HF|patients with heart failure
62831920|NCT06655116||Control Group|
62831921|NCT06655116||Study Grup|
62831922|NCT04804384|EXPERIMENTAL|Experimental|
62831923|NCT02266511|EXPERIMENTAL|Sequence 1|Flomax®, Nishine facility followed by Flomax®, Norman II facility
62831924|NCT02266511|EXPERIMENTAL|Sequence 2|Flomax®, Norman II facility followed by Flomax®, Nishine facility
62831925|NCT00494728|OTHER|CBASP + ST|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) + Smoking Cessation Treatment (ST)
62831926|NCT00494728|OTHER|ST|Smoking Cessation Treatment (ST)
62831927|NCT05689996|EXPERIMENTAL|Infective keratitis|"Preparation of nanostructure lipid carriers (NLCs):~The emulsification-solvent evaporation technique was used to prepare the NLCs. The method was followed by ultrasonication as reported \[1\]. In brief, the lipid phase was composed of stearic acid (solid lipid, 300 mg and oleic acid (liquid lipid, 300 mg) dissolved in ethanol (2 mL, 1:1, v/v) at 70oC. In total, 20 mL of the distilled water containing 2% of the Tween® 80 were heated at 70 oC to prepare the aqueous phase. Then, both phases, aqueous and lipid phases, were mixed at the same temperature using 2000 rpm stirring for 15 min. The resulting pre-emulsion obtained from the mixture of the aqueous and lipid phases was sonicated by a probe-type sonicator (Cole-Parmer, Vernon Hills, IL, USA) for 10 min at pulse-ON for 3 s and pulse-OFF for 5 s (40 W). The obtained dispersion was allowed to cool to RT under continuous stirring for 60 min at 1000 rpm for 1 h to obtain the NLCs dispersions."
62048919|NCT05040555|EXPERIMENTAL|R-CDOP|Rituximab 375mg/m2, D0; Cyclophosphamide 750mg/ m2, D1; Doxorubicin hydrochloride liposome 30-35mg/ m2, D1; Vindesine 3mg/ m2, D1; Prednisone 60mg/ m2, D1\~5.
62048920|NCT00522626||Observational|Opioid exposed pregnancies
62048921|NCT05979831|EXPERIMENTAL|DS-2325a|"Participants will be randomized to receive a single initial (loading) dose of DS-2325a (Week 1) followed by (maintenance) doses for a total of 12 weeks (Main Phase).~Participants will receive DS-2325 doses for a total of 24 weeks (Extension Phase)."
62048922|NCT05979831|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive a single initial loading dose of placebo followed by maintenance doses of placebo for a total of 12 weeks (Main Phase).
62048923|NCT03087565|ACTIVE_COMPARATOR|subtotal hystrectomy|"Careful examination under anesthesia. Catheterization by N. 18 Foley's catheter . A transverse lower abdominal incision (Pfannenstiel incision) . the corpus is amputated just below the level of the isthmus and then the endocervical canal is electrocoagulated using monopolar electrocautery. The cervical stump is closed using vicryl 0 sutures.~Intraoperative antibiotics The abdomen is closed in layers; the wound is covered with a sterile dressing. All specimens were sent for pathological examination ."
62048924|NCT03087565|ACTIVE_COMPARATOR|Total hyterectomy|examination under anesthesia. Catheterization by N. 18 Foley's catheter A transverse lower abdominal incision (Pfannenstiel incision) The urinary bladder is dissected off the lower uterine segment of the uterus and cervix by blunt or sharp dissection. Blunt dissection is done . Sharp dissection using Metzenbaum scissors is performed in patients with previous cesarean sections Revision of all pedicles to ensure hemostasis. Intraoperative antibiotics The abdomen is closed in layers; the wound is covered with a sterile dressing. All specimens were sent for pathological examination .
62048925|NCT05293561||COVID-19 cases|O2 saturation readings, Mini-mental state examination (MMSE), Hamilton's anxiety (HAM-A) Hamilton's depression rating scales (HAM-D)
62048926|NCT05293561||control|O2 saturation readings, Mini-mental state examination (MMSE), Hamilton's anxiety (HAM-A) Hamilton's depression rating scales (HAM-D)
62048927|NCT01440400|NO_INTERVENTION|Conventional spinal anesthesia|
62048928|NCT01440400|EXPERIMENTAL|Ultrasound guided spinal anesthesia|
62251069|NCT01877915|PLACEBO_COMPARATOR|Placebo|Each participant will receive matching placebo twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
62048929|NCT00795457|EXPERIMENTAL|1|Patients must have undergone surgery or biopsy alone ≤16 weeks prior to study entry (no postoperative radiation or chemotherapy).
62048930|NCT00795457|EXPERIMENTAL|2|Patients received surgery or biopsy and radiation therapy (RT) (including fractionated external beam radiation therapy and/or stereotactic radiosurgery), which was completed ≥6 months prior to enrollment, and have a baseline MRI scan (within 4 weeks of the first vaccine) that shows stable disease or regression.
62048931|NCT02128464|ACTIVE_COMPARATOR|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
62048932|NCT02128464|ACTIVE_COMPARATOR|Patient specific cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
62048933|NCT03625401|EXPERIMENTAL|AD-35 60 mg|AD-35 60 mg group: 2 AD-35 30 mg tablets and 1 placebo tablet
62048934|NCT03625401|PLACEBO_COMPARATOR|Placebo of AD-35 30 mg|Placebo group: 3 placebo tablets
62048935|NCT01814748|EXPERIMENTAL|Omarigliptin 25 mg|Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
62048936|NCT01814748|PLACEBO_COMPARATOR|Placebo|Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
62251070|NCT03486886|EXPERIMENTAL|PSMA -PET/CT scanning|
62251071|NCT05140122||Primary caregivers of individuals with Dravet Syndrome|
62251072|NCT00872976|EXPERIMENTAL|Cohort #1|
62440973|NCT01978106||an ATR corneal astigmatism group|Corneal astigmatism was defined as ATR when the cylinder axis was within 30 degrees of the vertical axis.
62440974|NCT03089632|EXPERIMENTAL|Gluten-free diet|All patients will follow a strict gluten-free diet for 1 month. Measurement will be conducted at baseline and after the intervention.
62251073|NCT00872976|EXPERIMENTAL|Cohort #2|
62251074|NCT03447938|ACTIVE_COMPARATOR|CABG with sternotomy|Patients in this group will undergo coronary artery bypass grafting (CABG) in the usual way, through an incision in the middle of the chest, through the breastbone or sternum (conventional CABG).
62251075|NCT03447938|EXPERIMENTAL|Minimally-invasive CABG|Patients in this group will undergo coronary artery bypass grafting (CABG) using a minimally-invasive approach (MICS CABG), through smaller incisions between the ribs.
62251076|NCT00505596|EXPERIMENTAL|Computerized decision aid|Participants instructed to view the updated PT Tool and told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study (Informed free choice). They also participate in a baseline pre-randomization interview and one follow-up telephone interview.
62251077|NCT00505596|NO_INTERVENTION|Usual care|Control group, in which participants receive no intervention beyond a baseline pre-randomization interview and one follow-up telephone interview.
62831928|NCT05371652|EXPERIMENTAL|Rimegepant 75mg Orally Disintegrating Tablets (ODT)|One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day)
62251078|NCT04825171|EXPERIMENTAL|Bryophyllum pinnatum 50% chewing tablets|Bryophyllum is administered for 3 weeks. Bryophyllum is given in form of chewing tablets, 350mg per tablet, 0-2-2-2/d: 2 tablets at midday, 2 tablets in the evening, 2 tablets before bedtime.
62251079|NCT01667536|EXPERIMENTAL|Drug: 99mTc-MIP-1404|20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
62251080|NCT06469099|EXPERIMENTAL|research group|active exercises for few weeks
62251081|NCT06469099|NO_INTERVENTION|control|control group - no intervention, continue their routine
62251082|NCT05242042|EXPERIMENTAL|Arm 1|
62251083|NCT05242042|PLACEBO_COMPARATOR|Arm 2|
62251084|NCT06065176|ACTIVE_COMPARATOR|Novavax COVID-19 booster|Participants will receive a single dose (0.5 ml) of study vaccine Novavax COVID-19 vaccine, 2023-2024 formula (XBB containing) in the deltoid muscle of the arm.
62251085|NCT06065176|ACTIVE_COMPARATOR|Pfizer COVID-19 booster|Participants will receive a single dose (0.3 ml) of study vaccine Pfizer mRNA COVID-19 vaccine, 2023-2024 formula (XBB containing) in the deltoid muscle of the arm.
62251086|NCT06065176|NO_INTERVENTION|Non-boosted comparison group|Participants will not receive a dose of the study vaccine.
62251087|NCT01177436|EXPERIMENTAL|Patients treated for prostatic pathology|Patients treated for prostatic pathology (benign or malign)in the hospital department.
62831929|NCT02040324|ACTIVE_COMPARATOR|Endotracheal Intubation|Clinical routine for longer lasting procedures
62831930|NCT02040324|EXPERIMENTAL|Laryngeal Mask|Laryngeal mask with gastric access and drainage as airway management instead of endotracheal intubation
62831931|NCT02132026|ACTIVE_COMPARATOR|Alendronic Acid|50 patients will receive once weekly Alendronic Acid tablets (70mg).
62048937|NCT06223412|EXPERIMENTAL|interventional group|The participants in this group received a series of short videos, ranging between 30- 45 minutes/ each video revolved around five core themes including The road start to green planet, The ripple effect climate change on Health, Climate Change Literacy, Strengthen resilience to overcome climate related- psychological impacts, and Sustaining phase: closing session..
62251088|NCT02729740|OTHER|Penumbra Smart System|
62440975|NCT01254045|EXPERIMENTAL|placebo, oxytocin 24IU, oxytocin 48IU|intranasal placebo (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
62831932|NCT02132026|PLACEBO_COMPARATOR|Alendronic Acid placebo|25 patients will receive alendronic acid placebo tablets.
62831933|NCT02132026|ACTIVE_COMPARATOR|Denosumab|50 patients will receive 6 monthly denosumab injections
62251089|NCT06114277||Patients with low ETCO2 levels|Intraoperative ETCO2 values between 26 and 35 in laparoscopic robotic prostatectomy patients were included in this group.
62251090|NCT06114277||Patients with high ETCO2 levels|Intraoperative ETCO2 values between 36 and 45 in laparoscopic robotic prostatectomy patients were included in this group.
62251091|NCT02873936|EXPERIMENTAL|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg + stable dose of permitted csDMARD(s)
62251092|NCT02873936|EXPERIMENTAL|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg + stable dose of permitted csDMARD(s)
62251093|NCT02873936|PLACEBO_COMPARATOR|Placebo|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + stable dose of permitted csDMARD(s)
62251094|NCT04195035|EXPERIMENTAL|Air-Q intubating laryngeal airway mask|"Where Air-Q intubating laryngeal airway will be used for ventilation \& intubation through fiberoptic bronchoscope.~After complete muscle relaxation a suitable sized (according to the patient's weight and BMI) Air-Q will be lubricated inserted and the ventilator circuit will be connected to the device to ventilate the patient. The ventilator will be set with tidal volume 4-6 ml/kg at a respiratory rate 12-15 breath/minute to keep normocapnia (ETCO2=30-35 mmHg). Vitals (HR, ABP and O2 saturation) and ET CO2were recorded 5 minutes after device insertion.~Then intubation using the fiberoptic bronchoscope will be started through the supraglottic device, laryngeal view grade will be recorded, success of endotracheal intubation through the device and time of intubation (time starting from disconnection of the circuit from the device to use the fiberoptic brochoscope for intubation till tube insertion in the trachea)."
62609320|NCT00412594|EXPERIMENTAL|Treatment (cladribine and rituximab)|Patients receive cladribine IV over 2 hours QD on days 1-5 and rituximab IV once weekly for 8 weeks beginning on day 28 in the absence of disease progression or unacceptable toxicity.
62609321|NCT02476370|NO_INTERVENTION|Usual care|Does not receive a specific study intervention
62831934|NCT02132026|PLACEBO_COMPARATOR|Denosumab Placebo|25 patients will receive a 6 monthly placebo injection.
62831935|NCT00119184|EXPERIMENTAL|External cephalic version with spinal anesthesia|External cephalic version with spinal anesthesia
62831936|NCT00119184|ACTIVE_COMPARATOR|External cephalic version without spinal anesthesia|External cephalic version without spinal anesthesia
62831937|NCT05590923|EXPERIMENTAL|OLA then crossover to DEX|"OLA group: olanzapine (Zyprexa) 10 mg oral each night after chemotherapy cycle 1 on days 1-4 after HEC (or days 1-3 after MEC).~DEX group: dexamethasone (Decadron) 8 mg oral daily after chemotherapy cycle 2 on days 2-4 after HEC (or days 2-3 after MEC)"
62831938|NCT05590923|ACTIVE_COMPARATOR|DEX then crossover to OLA|"DEX group: dexamethasone (Decadron) 8 mg oral daily after chemotherapy cycle 1 on days 2-4 after HEC (or days 2-3 after MEC)~OLA group: olanzapine (Zyprexa) 10 mg oral each night after chemotherapy cycle 2 on days 1-4 after HEC (or days 1-3 after MEC)."
62251095|NCT04195035|EXPERIMENTAL|Ambu-Aura intubating laryngeal mask|"Ambu-Aura intubating laryngeal mask will be used for ventilation \& intubation through fiberoptic bronchscope.~After complete muscle relaxation a suitable sized (according to the patient's weight and BMI) Ambu-Aura laryngeal mask will be lubricated inserted and the ventilator circuit will be connected to the device to ventilate the patient. The ventilator will be set with tidal volume 4-6 ml/kg at a respiratory rate 12-15 breath/minute to keep normocapnia (ETCO2=30-35 mmHg). Vitals (HR, ABP and O2 saturation) and ET CO2 will be recorded 5 minutes after device insertion.~Then intubation using the fiberoptic bronchoscope will be started through the supraglottic device, laryngeal view grade will be recorded, success of endotracheal intubation through the device and time of intubation (time starting from disconnection of the circuit from the device to use the fiberoptic brochoscope for intubation till tube insertion in the trachea)."
62251096|NCT06280222|NO_INTERVENTION|Routine management|Usual care of patients prior to a surgical procedure : oocyte retrieval
62251097|NCT06280222|EXPERIMENTAL|Virtual reality management|20 minutes of scenery VR movies prior to the surgical procedure (oocyte retrieval)
62440976|NCT01254045|EXPERIMENTAL|oxytocin 24IU, placebo, oxytocin 48IU|intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
62609322|NCT02476370|EXPERIMENTAL|preoperative relaxation program|preoperative relaxation program
62831939|NCT00389038|ACTIVE_COMPARATOR|Coping Skills Training + Amitriptyline|Behavioral coping skills training--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.
62609323|NCT02476370|EXPERIMENTAL|preoperative surgery education|single education unit to understand the complete surgical procedures
62048938|NCT06223412|PLACEBO_COMPARATOR|control group|The participants in this group received routine care such as received flyers related to climate change across the globe.
62609324|NCT02476370|EXPERIMENTAL|preoperative relaxation program+preoperative surgery education|preoperative relaxation program AND single education unit
62609325|NCT04353388||CBC-Diff Monocyte Volume Width Distribution|Monocyte Volume Width Distribution (MDW) is part of the CBC with Differential
62609326|NCT04643964|EXPERIMENTAL|Entrée: Cognitive Skills|
62831940|NCT00389038|ACTIVE_COMPARATOR|Headache Education + Amitriptyline|Behavioral headache education
62831941|NCT03529032|NO_INTERVENTION|Fentanyl group|Drug: Fentanyl Fentanyl group 3µg/kg to start surgery TIVA: general anesthesia will be based on Fentanyl an Propofol, titrated to achieve bispectral index (BIS) between 40-60.
62831942|NCT03529032|EXPERIMENTAL|methadone group|Drug: methadone methadone group 0.2mg/kg to start surgery TIVA: general anesthesia will be based on Fentanyl an Propofol, titrated to achieve bispectral index (BIS) between 40-60.
62831943|NCT01839955|EXPERIMENTAL|Arm I (Dose Escalation Group)|Erlotinib hydrochloride and quinacrine dihydrochloride. The first three or six patients will be entered in this part of the study. Then this part will end.
62831944|NCT01839955|EXPERIMENTAL|Arm II (Extension Group)|Erlotinib hydrochloride and quinacrine dihydrochloride. The next 12 patients will enter into the second part of this study.
62831945|NCT05365425|EXPERIMENTAL|Tgfenon|Choline fenofibrate (135mg as fenofibric acid) 1 tablet once daily oral administration regardless of diet
62831946|NCT05365425|ACTIVE_COMPARATOR|Policosanol 10|Policosanol 10mg 1 tablet once daily oral administration
62251098|NCT06001996||Pericapsular nerve group (PENG) block|"Group 1:Pericapsular nerve group (PENG) block: Using an in-plane approach with ultrasonographic imaging, the block needle reaches the fascial plane between the psoas muscle and the upper pubic ramus, and patients injected with local anesthetic solution.~* After the patients were sedated with intravenous 1 mg midazolam and 50 mcg fentanyl in the preoperative preparation room, 15 ml of 0.375% bupivacaine was administered to the fractured hip side under ultrasound guidance.~* After the block application, the patient will be taken to the operating room and standard spinale anaesthesia will be applied.~* Each patient will receive 15 ml of 0.375% bupivacaine 0.375% on the side of the broken hip only one time approximately 15-20 minutes before the operation.~* Plane block applications will be applied only once in the preoperative period~* Plane block applications will be performed by anaesthesiologists with at least 5 years of experience"
62609327|NCT04643964|EXPERIMENTAL|Entrée: Behavioral Skills|
62609328|NCT04643964|EXPERIMENTAL|Entrée: Interpersonal Skills|
62831947|NCT01099176|EXPERIMENTAL|Atorvastatin|10mg of Atorvastatin
62831948|NCT01099176|EXPERIMENTAL|Fenofibrate|267mg of Fenofibrate
62831949|NCT01099176|EXPERIMENTAL|Fenofibrate and atorvastatin|10mg of Atorvastatin and 267mg of fenofibrate
62831950|NCT01099176|PLACEBO_COMPARATOR|Therapeutic Lifestyle Change|Placebo and Therapeutic Lifestyle Change
62831951|NCT05929300|EXPERIMENTAL|Yoga|The study design entails randomizing \~34 Veterans who are undergoing RP for PCa to either usual care or a twice-weekly hybrid (in-person and virtual) yoga program that includes up to 4 weeks of pre-habilitation yoga and 8 weeks of post-RP yoga. Participants will provide data at three time points: baseline/pre-yoga (T1), completion of\~ 4 weeks of pre-RP yoga (T2), and completion of 8 weeks of post-RP yoga (T3). Data collection for the control group will parallel that of the yoga group. Times of data collection are consistent with other yoga trials. Veterans randomized to the intervention will be asked to routinely practice yoga (at least 15 min/day).
62609329|NCT04643964|EXPERIMENTAL|Sampler Skills|
62609330|NCT04643964|NO_INTERVENTION|Control|Participants are not given videos to watch until their involvement in the study ends.
62831952|NCT05929300|ACTIVE_COMPARATOR|Usual Care|"The control group will consist of usual care patients. It is current practice for all patients to: 1) receive a handout that covers Kegel exercises; and, 2) instruction from a nurse who teaches the patient how to perform the exercises. There is no referral to a physical therapist unless progression indicates a need for it."
62831953|NCT05333198|OTHER|Traditional physical therapy using Epley's maneuver|Epley's maneuver was performed once a week for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes.
62609331|NCT05490134|EXPERIMENTAL|ABVN Only Stimulation|30 minutes of ABVN Only stimulation (15Hz stimulation of cymba conchae).
62609332|NCT05490134|EXPERIMENTAL|ATN Only Stimulation|30 minutes of ATNS Only stimulation (100Hz stimulation adjacently anterior to the tragus)
62609333|NCT05490134|EXPERIMENTAL|Combination (ABVN + ATN) Stimulation|30 minutes of Combo stimulation (stimulation of both the 15Hz cymba conchae and 100HZ adjacently anterior to the tragus)
62609334|NCT05490134|EXPERIMENTAL|Sham Stimulation|30 minutes of Sham (15Hz stimulation of the earlobe)
62609335|NCT03304184|PLACEBO_COMPARATOR|Photac-fil|Participants will have a restoration placed with photac-fil in the lesion near the gum line.
62609336|NCT03304184|EXPERIMENTAL|Biodentine|Participants will have a restoration placed with Biodentine in the lesion near the gum line.
62831954|NCT05333198|ACTIVE_COMPARATOR|Oculomotor and Vestibular Ocular Reflex (VOR) exercises|oculomotor and VOR exercises after Epley's maneuver. The exercises were performed for approximately 5 minutes daily or 1 to 2 minutes, 3 to 4 times a day, in sitting position. The exercises were continued for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes. Saccadic exercises were performed by moving eyes between two stationary targets. Smooth pursuit exercises were performed by tracking a moving target while keeping head still and VOR exercises were performed by moving head left to right while maintaining eyes on stationary target
62251099|NCT06001996||Suprainguinal fascia iliaca plane block|"Group 2: Suprainguinal fascia iliaca plane block: Patients in whom the needle entered in plane from the caudal end of the ultrasound probe passes through the musculus iliacus and fascia iliaca and local anesthetic solution has been injected immediately under the fascia.~After the patients were sedated with intravenous 1 mg midazolam and 50 mcg fentanyl in the preoperative preparation room, 15 ml of 0.375% bupivacaine was administered to the fractured hip side under ultrasound guidance. After the block application, the patient will be taken to the operating room and standard spinale anaesthesia will be applied.~Each patient will receive 15 ml of 0.375% bupivacaine 0.375% on the side of the broken hip only one time approximately 15-20 minutes before the operation.~* Plane block applications will be applied only once in the preoperative period~* plane block applications will be performed by anaesthesiologists with at least 5 years of experience"
62251100|NCT03104075|ACTIVE_COMPARATOR|Prevnar 13|Prevnar 13 (Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein) will be administered at the single 0.5 ml dose, by intramuscular injection with routine clinical care.
62831955|NCT01444612||Cancer-related surgery patient records|Healthcare claims records from patients aged 18 years or older with at least one primary inpatient discharge diagnosis of cancer and a cancer-related surgery during the hospitalization
62048939|NCT05590208|EXPERIMENTAL|sleeve gastrectomy+ cruroplasty + omental rape|sleeve gastrectomy+ cruroplasty + omental rape
62048940|NCT04274452|EXPERIMENTAL|efgartigimod|Patients receiving an intravenous infusion of efgartigimod
62048941|NCT04274452|PLACEBO_COMPARATOR|placebo|Patients receiving an intravenous infusion of placebo
62251101|NCT03104075|ACTIVE_COMPARATOR|Pneumovax 23|Pneumovax 23 (Pneumococcal Vaccine Polyvalent) will be administered at the single 0.5ml dose, by intramuscular injection with routine clinical care.
62251102|NCT00955812|EXPERIMENTAL|OPB-31121|OPB-31121 50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
62251103|NCT01062139|EXPERIMENTAL|Petasites extract, levocetirizine|Cosalin (Petasites hybridus CO2 extract), Xarlin (levocetirizine) combination therapy group
62251104|NCT01062139|ACTIVE_COMPARATOR|Cosalin (Petasites hybridus CO2 extract)|Cosalin monotherapy
62251105|NCT02219321|ACTIVE_COMPARATOR|Lidocaine infusion|A continuous intravenous infusion of lidocaine
62831956|NCT00519753|EXPERIMENTAL|DuoTrav|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
62831957|NCT00740038|ACTIVE_COMPARATOR|1|Active Control: Usual Care
62831958|NCT00740038|EXPERIMENTAL|2|Stress Management Intervention
62831959|NCT00740038|EXPERIMENTAL|3|Exercise Intervention
62831960|NCT00740038|EXPERIMENTAL|4|Combined Stress Management and Exercise Intervention
62831961|NCT03715348|ACTIVE_COMPARATOR|Fresh Frozen Plasma (FFP)|"Patients randomised to the comparator arm will receive Fresh Frozen Plasma (FFP)~FFP will be provide as a solution for intravenous administration, once thawed.~The dose of the FFP will be \~ 15 mL/kg.~Subjects may receive multiple doses of FFP as required if bleeding continues, as per usual care"
62831962|NCT03715348|EXPERIMENTAL|Prothrombin Complex Concentrate (PCC)|"Patients randomised to the experimental arm will receive PCC at \~15 IU/kg. PCC will be reconstituted into a solution for intravenous administration.~Subjects will receive a single dose of PCC, and if bleeding continues, standard treatment will be administered"
62831963|NCT06590298|EXPERIMENTAL|Intervention group|The intervention group will be added 5 mg of aripiprazole as an adjunct with the usual antipsychotic treatment to the females on antipsychotic treatment
62831964|NCT06590298|NO_INTERVENTION|Control|No intervention will be given except usual antipsychotic treatment
62831965|NCT01115413||young maternal age|maternal age of \< 18 years
62831966|NCT01115413||adult maternal age|maternal age \>/= 18 years
62831967|NCT02317471|EXPERIMENTAL|gp96 group|autologous gp96 vaccination + basal treatment for gastric cancer
62831968|NCT02317471|OTHER|control group|Oxaliplatin+S-1
62831969|NCT06602947||low-flow sevoflurane (LFS)|"Anaesthesia will be administered according to the recommendations of ASA Enviornment Sustainability Committee.~Three strategies to reduce the fresh gas flow and enviornmental contamination are~1. Induction: Set the Vaporizer to Deliver a Concentration Greater than Intended~2. Intubation: Turn Off the Fresh Gas Flow, Not the Vaporizer.~3. Maintanance: Minimize Fresh Gas Flow During Maintenance."
62831970|NCT06602947||low- flow desflurane (LFD)|"Anaesthesia will be administered according to the recommendations of ASA Enviornment Sustainability Committee.~Three strategies to reduce the fresh gas flow and enviornmental contamination are~1. Induction: Set the Vaporizer to Deliver a Concentration Greater than Intended~2. Intubation: Turn Off the Fresh Gas Flow, Not the Vaporizer.~3. Maintanance: Minimize Fresh Gas Flow During Maintenance."
62048942|NCT00789815|ACTIVE_COMPARATOR|BIS-guided propofol infusion|In the study group, induction was started using alfentanil 4\~5μg/kg bolus following repeated propofol boluses (0.5\~1.5 mg/kg) until the BIS level reached 70. During maintenance, propofol infusion (3\~12 mg/kg/hour) was given using a syringe pump (Injectomat Agilia, Fresenius Kabi, France), which was titrated to keep the BIS level between 65 and 75.
62048943|NCT00789815|ACTIVE_COMPARATOR|Clinical-judged midazolam administration|In the control group, induction was started using alfentanil 4\~5μg/kg bolus following 2 mg midazolam bolus. After 2 minutes, if the patient was not well sedated, midazolam boluses were repeat by increments of 2 mg/2min until conscious sedation was achieved
62048944|NCT04450537|EXPERIMENTAL|Vape Messaging Intervention|Participants will be exposed to 10 vape education messages
62048945|NCT04450537|NO_INTERVENTION|Sun Safety Control|Participants will be exposed 10 sun safety messages
62251106|NCT02219321|PLACEBO_COMPARATOR|Saline infusion|A continuous intravenous infusion of saline
62440977|NCT01254045|EXPERIMENTAL|oxytocin 48IU, oxytocin 24IU, placebo|intranasal oxytocin (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
62609337|NCT03745040|EXPERIMENTAL|Group A: Exparel|"Standard of Care plus Liposomal bupivacaine (Exparel®). Dosage: Exparel® 20 mL single use vial, 1.3% (13.3 mg/mL), Maximum dose of 266 mg (20 mL).~Frequency: Single intraoperative administration"
62609338|NCT03745040|NO_INTERVENTION|Group B: No Exparel|Standard of Care
62609339|NCT05347290|EXPERIMENTAL|Lead Apron + Rampart IC, M1128|Consented providers will perform catherization procedures utilizing both lead apron and Rampart system. Radiation will be measured by dosimeters worn by the providers.
62609340|NCT05347290|EXPERIMENTAL|Rampart M1128 IC, Only|Consented providers will perform catherization procedures utilizing only the Rampart system. Radiation will be measured by dosimeters worn by the providers.
62609341|NCT05347290|ACTIVE_COMPARATOR|Lead Apron Only|This is the control group. Consented providers will perform catherization procedures utilizing only the lead apron and ancillary shields (lead skirt, vest, thyroid collar (all at least 0.5mm Pb) with use of under table lead per lab operating policy and mobile suspended lead-acrylic shield and lead glasses). Radiation will be measured by dosimeters worn by the providers.
62609342|NCT01374477||Adolescent with preeclampsia|Patients \< 19 years old who delivered in our institution (vaginal birth or cesarean) that developed a hypertensive disorder of pregnancy.
62609343|NCT01374477||Normal adolescent|Patients \< 19 years old who delivered in our institution (vaginal birth or cesarean) without developing a hypertensive disorder of pregnancy.
62609344|NCT00904839|EXPERIMENTAL|BIBF 1120 + mFolfox6|BIBF1120 medium dose twice daily
62609345|NCT00904839|ACTIVE_COMPARATOR|Bevacizumab + mFolfox6|Bevacizumab 5mg/kg once daily every other week
62609346|NCT05657457|EXPERIMENTAL|TNK group|
62609347|NCT05657457|NO_INTERVENTION|control group|
62831971|NCT02651675|EXPERIMENTAL|Cohort 1|2.5E12 (genome copies)/kg (kilogram) body weight (E means the exponential constant)
62440978|NCT01254045|EXPERIMENTAL|oxytocin 24IU, oxytocin 48IU, placebo|intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
62609348|NCT03138200|OTHER|Blood transfusion based on central venous oxygen saturation|
62609349|NCT00540904|ACTIVE_COMPARATOR|sodium bicarbonate|Solution 154 mEq/L of sodium bicarbonate
62609350|NCT00540904|ACTIVE_COMPARATOR|Sodium chloride|Solution of 154 mEq/L of NaCl
62831972|NCT02651675|EXPERIMENTAL|Cohort 2|7.5E12 GC/kg body weight
62609351|NCT05353634||Infected patients with mNGS|If the patient is suspected of infection, mNGS is performed for testing.
62609352|NCT05353634||Infected patients without mNGS|The patient is suspected of being infected, and no mNGS test was performed, only other tests were performed.
62609353|NCT03102307||CNB biopsy/clip placement not done|Clinically affected lymph nodes cannot be biopsied or clip labeled. Patients are not suitable for TAD
62609354|NCT03102307||CNB/clip placement done - benign|Clinically affected lymph nodes can be biopsied and clip labeled. Needle biopsy reveals no axillary tumor spread. Patients are suitable for TAD
62609355|NCT03102307||CNB/clip placement done - malignant|Clinically affected lymph nodes can be biopsied and clip labeled. Needle biopsy reveals axillary tumor spread. Patients are suitable for TAD
62609356|NCT06712615|EXPERIMENTAL|Cohort A1 (T2DM/PG-102)|PG-102(MG12) Dose 1, 2 and 3 (N=16), Placebo (N=8) Subcutaneous injection
62609357|NCT06712615|EXPERIMENTAL|Cohort A2 (T2DM/PG-102)|PG-102(MG12) Dose 1, 2 and 3 (N=16), Placebo (N=8) Subcutaneous injection
62609358|NCT06712615|EXPERIMENTAL|Cohort B11 (OB Group/PG-102)|PG-102(MG12) Dose 1, 2 and 3 (N=16), Placebo (N=8) Subcutaneous injection
62609359|NCT06712615|EXPERIMENTAL|Cohort B12 (OB Group/PG-102)|PG-102(MG12) Dose 1, 2 and 3 (N=16)Subcutaneous injection
62831973|NCT02651675|EXPERIMENTAL|Cohort 2 Expansion|"7.5E12 GC/kg body weight~DSMB (Data Safety Monitoring Board) approved expansion of Dose 2 cohort, 3 additional subjects enrolled and received prophylactic corticosteroids"
62831974|NCT05257850|ACTIVE_COMPARATOR|Fan first|Patients use the fan first and high-flow nasal therapy thereafter
62831975|NCT05257850|ACTIVE_COMPARATOR|High-flow nasal therapy first|Patients use high-flow nasal therapy first and the fan thereafter
62831976|NCT05322681|EXPERIMENTAL|Pregabalin|Experimental group will take medicine for 10 weeks from 2 weeks before surgery to 8 weeks after surgery. The group takes one pill of pregabalin 150mg after breakfast and one pill of pregabalin 150 mg after dinner.
62831977|NCT05322681|NO_INTERVENTION|Active Comparator|Active Comparator group will take no medicine
62251107|NCT00537498|EXPERIMENTAL|1|Interventional group
62609360|NCT06712615|EXPERIMENTAL|Cohort B21 (OB with T2DM/PG-102)|PG-102(MG12) Dose 1, 2 and 3 (N=16) Subcutaneous injection
62609361|NCT06712615|EXPERIMENTAL|Cohort B22 (OB with T2DM/PG-102)|PG-102(MG12) Dose 1, 2 and 3 (N=16) Subcutaneous injection
62609362|NCT06712615|PLACEBO_COMPARATOR|Cohort A1 (T2DM/PL)|PG-102(MG12) Dose 1, 2 and 3 (N=16), Placebo (N=8) Subcutaneous injection
62609363|NCT06712615|PLACEBO_COMPARATOR|Cohort A2 (T2DM/PL)|PG-102(MG12) Dose 1, 2 and 3 (N=16), Placebo (N=8) Subcutaneous injection
62609364|NCT06712615|PLACEBO_COMPARATOR|Cohort B11 (OB Group/PL)|PG-102(MG12) Dose 1, 2 and 3 (N=16), Placebo (N=8) Subcutaneous injection
62831978|NCT00260533|EXPERIMENTAL|1|Atomoxetine
62831979|NCT00260533|PLACEBO_COMPARATOR|2|Placebo
62609365|NCT06712615|PLACEBO_COMPARATOR|Cohort B12 (OB Group/PL)|PG-102(MG12) Dose 1, 2 and 3 (N=16), Placebo (N=8) Subcutaneous injection
62609366|NCT06712615|PLACEBO_COMPARATOR|Cohort B21 (OB with T2DM/PL)|PG-102(MG12) Dose 1, 2 and 3 (N=16), Placebo (N=8) Subcutaneous injection
62609367|NCT06712615|PLACEBO_COMPARATOR|Cohort B22 (OB with T2DM/PL)|PG-102(MG12) Dose 1, 2 and 3 (N=16), Placebo (N=8) Subcutaneous injection
62609368|NCT02679989|EXPERIMENTAL|Intermittent Energy Restriction|Weight loss intervention: Intermittent Energy Restriction
62609369|NCT02679989|ACTIVE_COMPARATOR|Continuous Energy Restriction|Weight loss intervention: Continuous Energy Restriction
62609370|NCT06472999||Critically ill patients|
62609371|NCT04373798||Suspected COVID-19|Individuals with symptoms who are seen at covid19 check points for covid19 diagnosis.
62609372|NCT05359510|EXPERIMENTAL|patient with various abdominal incisions to be operated|patients with various abdominal incisions for closure either by primary suturing or by mesh
62609373|NCT05947227|EXPERIMENTAL|manual chest physical therapy and Buteyko breathing technique|Group A will be treated with manual chest physical therapy and Buteyko breathing technique
62831980|NCT03510546|EXPERIMENTAL|Active|"De-novo: Each capsule contains 60 mg. pyridostigmine. 1 capsule is administered twice within 4 hours.~Chronic: Each capsule contains 60 mg. pyridostigmine. Number of administered capsules per dosage depend on the patient's usual dosage. Study drug is administered twice within 4 hours.~Patients are examined/rated before 1st dose, 1 hour after 1st dose, 1 hour after 2nd dose (Visit 1). After cross-over (Visit 2), patients will be rated open-label at 1 month (Visit 3) and 3 months (Visit 4)."
62048946|NCT02563496|EXPERIMENTAL|Tafenoquine 50 mg|Subjects with weight band of \>=5 to \<=10 kilogram (kg) will receive 50 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
62251108|NCT04012879|EXPERIMENTAL|study group|After 6 days of pre-chemotherapy, patients in study group will be injected with CD19CART cell at the dose of 5×10\^4 cells/kg in 36-96 hours
62440979|NCT01254045|EXPERIMENTAL|oxytocin 48IU, placebo, oxytocin 24IU|intranasal oxytocin (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles ; intranasal oxytocin (24 international units) and intranasal placebo (24 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
62609374|NCT05947227|EXPERIMENTAL|manual chest physical therapy and Diaphragmatic breathing technique.|Group-B will be treated with manual chest physical therapy and Diaphragmatic breathing technique.
62609375|NCT04226495|ACTIVE_COMPARATOR|Sufentanil Bolus|medication in scheduled doses (bolus)
62609376|NCT04226495|EXPERIMENTAL|Sufentanil Infusion|medication in a slow trickle (infusion)
62831981|NCT03510546|PLACEBO_COMPARATOR|Placebo|"Same as Active, however capsules contain placebo."
62831982|NCT01161277|ACTIVE_COMPARATOR|aripiprazole|
62831983|NCT01161277|ACTIVE_COMPARATOR|haloperidol|
62831984|NCT01161277|PLACEBO_COMPARATOR|suger pill|
62251109|NCT00657865|ACTIVE_COMPARATOR|1|Ramipril
62251110|NCT00657865|PLACEBO_COMPARATOR|2|Placebo
62251111|NCT04819256|EXPERIMENTAL|Intervention arm|Providers use PACE-It mobile application as a care co-ordination platform
62609377|NCT05104424|ACTIVE_COMPARATOR|adult post covid-19 recovered 22 patients with smell and taste dysfunction take quadruple therapy|adult patients recovered postcovid-19 taking the quadruple therapy zinc 50 mg , gabapentin 300 mg , 40 I.U rapid insulin , 3 times small cube of ice in the mouth Questionnaires will be administered pre- and post-treatment to assess the change in measures. The mean values between groups will be compared.
62831985|NCT04277897|EXPERIMENTAL|Drug SAD Cohorts|Hepenofovir Fumarate Tablets Dose 1, Dose 2, Dose 3, Dose 4 and Dose 5 orally, once daily in one single administration.
62048947|NCT02563496|EXPERIMENTAL|Tafenoquine 100 mg|Subjects with weight band of \>10 to \<=20 kg will receive 100 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
62048948|NCT02563496|EXPERIMENTAL|Tafenoquine 150 mg|Subjects with weight band of \>10 to \<=20 kg will receive 150 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
62048949|NCT02563496|EXPERIMENTAL|Tafenoquine 200 mg|Subjects with weight band of \>20 to \<=35 kg will receive 200 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
62251112|NCT04819256|NO_INTERVENTION|Usual care|Providers use usual modes of communication (e.g., phone calls, emails)
62609378|NCT05104424|PLACEBO_COMPARATOR|patients taking zinc only with smell training on volatile oils|these 22 adult patients on zinc 50 mg and smell training on 4 volatile oils
62609379|NCT06625411|EXPERIMENTAL|VRDN-003 every 4 weeks|6 subcutaneous administrations of VRDN-003
62609380|NCT06625411|EXPERIMENTAL|VRDN-003 every 8 weeks|3 subcutaneous administrations of VRDN-003 and 3 subcutaneous administrations of placebo
62609381|NCT06625411|PLACEBO_COMPARATOR|Placebo every 4 weeks|6 subcutaneous administrations of placebo
62609382|NCT05260424||non-invasive ventilation failure|babies who will be intubated in the first 72 hours
62609383|NCT05260424||non-invasive ventilation success|babies who will not intubated in the first 72 hours
62609384|NCT01238094|EXPERIMENTAL|FOLFIRI or XELIRI/simvastatin|FOLFIRI or XELIRI/simvastatin
62831986|NCT04277897|PLACEBO_COMPARATOR|Placebo SAD Cohorts|Matching placebo, orally, once daily in one single administration.
62831987|NCT04277897|EXPERIMENTAL|Drug MAD Group|Hepenofovir Fumarate Tablets Dose 3 orally, once daily for 7 days.
62831988|NCT04277897|PLACEBO_COMPARATOR|Placebo MAD Group|Matching placebo, orally, once daily for 7 days.
62831989|NCT04277897|EXPERIMENTAL|Food-influnced Group|Hepenofovir Fumarate Tablets Dose 4 orally, once daily in one single administration in fast condition,cross-over 7 days later in fed condition.
62831990|NCT06655766|EXPERIMENTAL|Socket-plug technique with putty bone|"* Patients will be anesthetized at the surgical site by infiltration, using Articaine Hydrochloride 4%.~* Atraumatic extractions after careful surgical preparation of the soft and hard tissues using periotomes sulcular incision may be done with the aid of number 15c scalpel to dissect the crestal fibers and avoid trauma to soft tissue, care should be taken not to raise the flap.~* Careful curettage and debridement of the socket is performed with hand instruments to remove granulation tissue.~* The socket walls are then inspected for the presence of buccal defects.~* putty bone is injected into the socket up to the crest of the bone.~* Collagen plug or sponge is adapted over the graft to occlude the socket~* The plug is then stabilized with absorbable suture material."
62831991|NCT06655766|ACTIVE_COMPARATOR|Ice cream cone technique|"* Patients will be anesthetized at the surgical site by infiltration, using Articaine Hydrochloride 4%.~* Atraumatic extractions after careful surgical preparation of the soft and hard tissues using periotomes sulcular incision may be done with the aid of number 15c scalpel to dissect the crestal fibers and avoid trauma to soft tissue, care should be taken not to raise the flap.~* Careful curettage and debridement of the socket is performed with hand instruments to remove granulation tissue.~* The socket walls are then inspected for the presence of buccal defects.~* A Collagen barrier membrane is then shaped as an ice-cream cone and placed in the extraction socket lining the buccal tissues.~* The socket is then filled with particulate bone graft.~* The upper part of the membrane is then used to cover the socket.~* Absorbable suture is then used to close the socket and stabilize the barrier membrane"
62831992|NCT03758053||Individuals with alcohol use disorder + ACE|Individuals with AUD and varying levels of adverse childhood experiences (ACE)
62831993|NCT03758053||Healthy controls|Healthy individuals without AUD
62831994|NCT03758053||Individuals with alcohol use disorder, no ACE|Individuals with AUD and no adverse childhood experiences (ACE)
62831995|NCT06520917|EXPERIMENTAL|Performing temporomandibular joint arthroscopy with the aid of the Locator-Positioner (LOPO) Device|The patients underwent the arthroscopic procedure of the temporomandibular joint with the guidance of the Locator-Positioner Device
62831996|NCT04074889|ACTIVE_COMPARATOR|Group A|Patients will be given Lactobacillus \& Bifidobacterium containing probiotics \[Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg\], to be taken 1 sachet twice daily for 6 months.
62048950|NCT02563496|EXPERIMENTAL|Tafenoquine 300 mg|Subjects with weight band of \>35 kg will receive 300 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
62048951|NCT03433989|EXPERIMENTAL|Diagnosis and follow up arm|
62048952|NCT06579053|EXPERIMENTAL|Test product|Spironolactone Tablets, 100 mg/tablet, to be orally administered.
62048953|NCT06579053|ACTIVE_COMPARATOR|Reference product|ALDACTONE® Tablets,100 mg/tablet, to be orally administered.
62831997|NCT04074889|PLACEBO_COMPARATOR|Group B|Patients will be given placebo sachet (exactly the same packaging as active comparator) to be taken 1 sachet twice daily for 6 months.
62048954|NCT01825629|EXPERIMENTAL|Multidisplinary Therapy|The multidisciplinary therapy involves the application of physical therapy, manual therapy and deontology therapy. This multidisciplinary therapy will be administered twice a week for 15 weeks.
62048955|NCT01825629|PLACEBO_COMPARATOR|One technique of myofascial release|"A physiotherapist administered 15 sessions of induction occipital once a week."
62048956|NCT02336243|EXPERIMENTAL|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA) 200 mg capsules, 3 capsules by mouth every day, from early gestation until the end of pregnancy
62831998|NCT04718155|ACTIVE_COMPARATOR|statin group|will receive atorvastatin for 48 hours
62831999|NCT04718155|PLACEBO_COMPARATOR|control|will receive placebo tablets for 48 hours
62048957|NCT02336243|PLACEBO_COMPARATOR|Placebo|Placebo 200 mg capsules, 3 capsules by mouth every day, from early gestation until the end of pregnancy
62048958|NCT06328764|EXPERIMENTAL|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
62048959|NCT00066482|EXPERIMENTAL|combination chemotherapy|"Induction therapy: bleomycin sulfate IV over 10-20 minutes on day 1, etoposide IV over 1 hour and cisplatin IV over 4 hours on days 1-5, and cyclophosphamide IV over 1 hour on day 1. MESNA \& Filgrastim (G-CSF) subcutaneously once daily beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. 6 patients receive escalating doses of cyclophosphamide until the maximum tolerated dose (MTD) is determined.~Evaluated after 4 courses of therapy. Partial response or stable disease undergo second-look conventional surgery \& receive 2 more courses of induction therapy then re-evaluated. Those who do not achieve complete response (CR) after a total of 6 courses may undergo a third conventional surgery. Tumor that cannot be removed are removed from study therapy. Achievement of a CR at anytime are followed monthly for 1 year, every 6 months for 1 year, and then annually for 3 years."
62048960|NCT04152902||PULL-DOWN HELLER-DOR|The PD-HD procedure aimed to restore the vertical axis of the intraabdominal portion of the oesophagus as much as possible. In brief, before performing the myotomy and the anterior fundoplication according to Dor, at least 6 cm of the mediastinal oesophagus was fully isolated; two or more U intramuscular stitches were applied on the curling of the right side of the oesophagus, pulled down and rotated towards the right side of the gastro-oesophageal junction. The PD-HD operation was performed under manometric control
62832000|NCT05703711|NO_INTERVENTION|Enhanced Usual Care|In the Enhanced Usual Care arm, all healers are invited to participate in an interactive session reviewing ways to reduce inhumane and potentially harmful treatments in practices at their camps.
62048961|NCT04152902||OESOPHAGECTOMY|OE was performed with open technique, or recently, with a minimally invasive technique. The stomach was always the oesophageal substitute, and the oesophagogastric anastomosis was preferably located at the thoracic dome or at the neck to minimize the risk of postoperative reflux oesophagitis or cancer growth in the residual dilated oesophagus
62048962|NCT02773550|EXPERIMENTAL|Velcadito|Bortezomib 1.3 mg/m2 days 1,4,8 and 11 first cycle, the 1.0 mg/m2 days 1 and 4. Melphalan 9 mg/m2 days 1 to 4 Prednisone 60 mg/m2 days 1 to 4 Cycles of 28 days
62048963|NCT01474213|ACTIVE_COMPARATOR|dexmedetomidine|a loading dose (1.5mcg/kg) infused over10 min followed by a continuous infusion of 0.7 μg/kg/h
62048964|NCT01474213|ACTIVE_COMPARATOR|remifentanil|The initial target was 3.0 ng/ml and the TCI was adjusted by 0.5 ng/ml after the target concentration at the effect site had equilibrated with the plasma concentration, until the desired level of sedation was acheived.
62832001|NCT05703711|EXPERIMENTAL|M&M Intervention Package|M\&M is a 8-week long combination of mHealth designed to train healers to deliver basic psychosocial interventions while preserving human rights with pharmacotherapy delivered directly to their patients via visiting nurse.
62048965|NCT00335452|EXPERIMENTAL|Clopidogrel high dose treatment regimen + ASA high dose|
62609385|NCT04181268|ACTIVE_COMPARATOR|Rotational Atherectomy|"The procedure is performed by using a Rotablator system, which consists of a spring coil shaft with a burr at the tip. The front edge of the burr is the ablating portion, oval shaped, and covered with fine diamond crystals.~The rotational atherectomy catheter is introduced into the coronary artery over a dedicated long rotational atherectomy wire, which consists of a monofilament stainless steel 0.09-inch wire.~The device is connected to a console that houses the turbine that rotates the burr with pressurized nitrogen gas. Typically the rpm is set at 150,000 to 180,000 rpm.~After the lesion is crossed with the wire, the lesion is crossed with multiple pecking movements of the burr, with each run lasting not more than 20 seconds. After successful rotational atherectomy with one or more burrs, the procedure is completed with balloon angioplasty and stent placement. This can be achieved by exchanging the rota wire with a workhorse wire and using standard equipment."
62048966|NCT00335452|EXPERIMENTAL|Clopidogrel high dose treatment regimen + ASA low dose|
62048967|NCT00335452|ACTIVE_COMPARATOR|Clopidogrel standard treatment regimen + ASA high dose|
62048968|NCT00335452|ACTIVE_COMPARATOR|Clopidogrel standard treatment regimen + ASA low dose|
62048969|NCT05072457|EXPERIMENTAL|Experimental|All participants in the study fit with Phonak Audeo P hearing aids and compatible Phonak Roger receivers.
62609386|NCT04181268|ACTIVE_COMPARATOR|Intravascular Lithotripsy|"The procedure is perforemed with a Coronary intravascular lithotripsy (IVL) System that consists of a generator, a connector cable with a push button to allow manually controlled delivery of electric pulses, and semi-compliant balloon catheter.~The balloon integrates two radiopaque lithotripsy emitters 6 mm that receive electrical pulses from the generator vaporising the fluid within the balloon and creating a rapidly expanding and collapsing bubble. This bubble can transmit unfocused circumferential pulsatile mechanical energy into the vessel wall, in the form of sonic pressure waves equivalent to approximately 50 atmospheres (atm). The IVL therapy consists on a maximun of 8 runs of 10 pulses (80 pulses). The number of therapies needed per lesion will depend on lesion resistance; however, a mínimum of 20 pulses is recommended.~Alter IVL, an optional additional post-dilatation with non-compliant balloons, a stent is implanted"
62048970|NCT04050774|EXPERIMENTAL|Age group 1|6-9 years old
62048971|NCT04050774|EXPERIMENTAL|Age group 2|15-17 years old
62609387|NCT04181268|ACTIVE_COMPARATOR|Excimer Laser|"Excimer laser is pulsed gas laser that use Xenon chloride (XeCl) as the active medium to generate pulses of short wavelength, high-energy ultraviolet (UV) light.~Excimer laser tissue ablation is mediated through three distinct mechanisms: photochemical, photo-thermal and photomechanical. UV laser light is absorbed by intra-vascular material and breaks carbon-carbon bonds (photochemical). It elevates the temperature of intra-cellular water, causing cellular rupture and generates a vapor bubble at the catheter tip (photo-thermal). Expansion and implosion of these bubbles disrupts the obstructive intra-vascular material (photomechanical). The laser catheter is advanced slowly over a conventional wire while the therapy is aplied and saline is inffused. After laser, balloon dilatation is usually performed finishing the procedure with stent implantation"
62609388|NCT04840524|OTHER|Conventional preparation design (Chamfer finish line with Butt joint incisal preparation design)|conventional treatment
62609389|NCT04840524|EXPERIMENTAL|New preparation design (Feather edge finish line with feather edge incisal preparation design)|New preparation design
62609390|NCT01792323|EXPERIMENTAL|1 bolus of insulin lispro with short bolus duration|Subcutaneous administration of insulin lispro as a bolus of 15 IU over a period of 30 seconds
62048972|NCT04050774|EXPERIMENTAL|Age group 3|18 - 24 years old
62048973|NCT04050774|EXPERIMENTAL|Age group 4|65-80 years old
62048974|NCT00921986||Arrhythmias|Patients with arrhythmias
62048975|NCT00921986||Control Subjects|Subjects that do not have a history of cardiac arrhythmias.
62048976|NCT02252419|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone will be administered 30 minutes before the anesthetic induction.
62048977|NCT02252419|EXPERIMENTAL|Dexamethasone+ Paracetamol (DP)|Dexamethasone will be administered 30 minutes before the anesthetic induction. Paracetamol will be administered at the end of the surgery.
62048978|NCT03983187|NO_INTERVENTION|Control|
62048979|NCT03983187|EXPERIMENTAL|Rotating Magnetic Therapy group|
62048980|NCT01053195|EXPERIMENTAL|Lifestyle counseling|In the project areas, lifestyle counseling will be given every three months to individuals having prediabetes and every six months to those with normal glucose levels.
62048981|NCT01053195|NO_INTERVENTION|Control|No intervention activity will be assigned for participants enrolled from the control areas.
62048982|NCT02221167|NO_INTERVENTION|Exclusive breastfeeding|Infants in the exclusive breastfeeding group will continue to breastfeed.
62048983|NCT02221167|ACTIVE_COMPARATOR|Donor Milk|"Infants in this arm will continue to breastfeed and will be given 10 ml of donor breast milk by syringe after each breastfeeding until their mother's milk comes in. (until the onset of lactogenesis II)"
62048984|NCT02623322|EXPERIMENTAL|MHAA4549A 3600 milligrams (mg)|Participants will receive single-dose MHAA4549A, 3600 mg, by intravenous (IV) administration.
62048985|NCT02623322|EXPERIMENTAL|MHAA4549A 8400 mg|Participants will receive single-dose MHAA4549A, 8400 mg, by IV administration.
62832002|NCT01735162||Very high risk|Very high risk PICU patients are on mechanical ventilation and at least one inotrope or vasopressor at time of admission
62048986|NCT02623322|PLACEBO_COMPARATOR|Placebo|Participants will receive single-dose placebo by IV administration.
62048987|NCT01328301|EXPERIMENTAL|Speed-dependent treadmill training (SDT)|Subjects underwent short interval of walking trials with stepwise increases in the treadmill speed
62048988|NCT01328301|ACTIVE_COMPARATOR|speed-stable treadmill training|Control subjects received gait training on the treadmill with a steady speed.
62048989|NCT04894201||All patients with relevant dental findings|
62048990|NCT01887080|EXPERIMENTAL|Exercise|Experimental group 1 performed cardiovascular rehabilitation home-based program
62048991|NCT01887080|EXPERIMENTAL|Exercise afther Microcurrent|Experimental group 2 performed cardiovascular rehabilitation home-based program just after microcurrent.
62048992|NCT01887080|OTHER|Cardiovascular Risk Factors|Education about risk factors
62048993|NCT00590902|EXPERIMENTAL|1 - OSI-774|
62048994|NCT01012232|ACTIVE_COMPARATOR|low volume local anesthetic|bolus injection of local anesthetic in low volume/high concentration (10 mL, 10 mg/mL)
62048995|NCT01012232|EXPERIMENTAL|high volume local anesthetic|bolus injection of ropivacaine in high volume/low concentration (20 ml, 5 mg/mL)
62832003|NCT01735162||High Risk|High risk PICU patients have a history of transplantation (solid organ or bone marrow)
62251113|NCT02876120|OTHER|Pre- and post-implementation phases|"Pre-implementation phase: during the pre-implementation period persons with hip or knee osteoarthritis will receive usual care as it is currently delivered by physiotherapists and general practitioners.~Post-implementation phase: during the post-implementation phase the GPs and PTs will treat persons with hip or knee osteoarthritis according to the START treatment model including providing information/patient education program, supervised exercise and advice/support to loose weight and other non-surgical evidence based treatments modalities prior to being referred to an orthopaedic surgeon"
62251114|NCT05799599|ACTIVE_COMPARATOR|Stay-Play_Talk Basic Followed by Stay_Play_Talk Basic - (SPT Basic Responders)|After being randomly assigned to the SPT Basic condition, these participants responded and therefore remained in this condition
62251115|NCT05799599|ACTIVE_COMPARATOR|Stay_Play_Talk Basic Followed by Randomization to Stay_Play_Talk Basic (SPT Basic - SPT BASIC)|After being randomly assigned to the SPT Basic condition, these participants did not respond but were randomized to stay in this condition to examine longer duration in this treatment.
62251116|NCT05799599|EXPERIMENTAL|Stay_Play_Talk Basic Followed by Randomization to Stay_Play_Talk Plus (SPT Basic - SPT Plus)|After being randomly assigned to the SPT Basic condition, these participants did not respond and were randomized to Stay_Play_Talk Plus in the second stage.
62609391|NCT01792323|EXPERIMENTAL|1 bolus of insulin lispro with long bolus duration|Subcutaneous administration of insulin lispro as a bolus of 15 IU over a period of 10 minutes
62832004|NCT01735162||Moderate risk|Moderate risk PICU patients are all other admissions to the ICU (may have either mechanical ventilation or inotropy/vasopressor use but not both). Cannot have a history of transplant. Minimum expected stay 48 hours.
62832005|NCT05846984|EXPERIMENTAL|Learning Skills Together Intervention|Complex care psychoeducation training intervention for family caregivers
62832006|NCT05846984|ACTIVE_COMPARATOR|Caregiver Healthy Living Intervention|Healthy living intervention for family caregivers
62832007|NCT01131832|EXPERIMENTAL|Plant sterol|Plant sterol supplementation, 2 grams per day of plant sterols in a margarine
62048996|NCT03209323|EXPERIMENTAL|sevoflurane - increasing concentrations|The patient was breathing spontaneously via the face mask and the sevoflurane concentration in the inhaled gas was doubled every 10 breaths starting from 0.3 vol. % in a sequence 0.3-0.6-1.2-2.4-4.8-8 vol. % until a minimal alveolar concentration (MAC) of 2 was obtained in the exhalation gas. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
62048997|NCT03209323|EXPERIMENTAL|sevoflurane - vital capacity|The anaesthetic circuit was prefilled with 8% sevoflurane. The patients were asked to exhale to the residual volume. Then the patients were explained to perform a vital-capacity breath with a face mask applied tightly to their faces. Then the patients were encouraged to hold their breaths as long as possible. Thereafter, the patients were asked to breathe spontaneously. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
62609392|NCT01230684|OTHER|Endoleak imaging|In the single arm all participants are recieving both imaging techniques; CEUS and CTA
62832008|NCT00999804|EXPERIMENTAL|24-week arm|Participants will receive 24-weeks of lapatinib plus trastuzumab. Participants who are estrogen receptor (ER) and/or progesterone receptor (PR) positive will also receive endocrine therapy.
62048998|NCT03209323|EXPERIMENTAL|propofol - intravenous induction|the patients were preoxygenated with 100% oxygen following which propofol was intravenously administered at a single dose of 2.5 mg/kg of body weight, after which it was infused with an infusion speed of 4 mg/kg body weight/h. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
62048999|NCT03163355|ACTIVE_COMPARATOR|pureed rice with a gelling agent|3 ml of pureed rice containing a gelling agent is attempted to swallow under endoscopic examination of swallowing
62049000|NCT03163355|PLACEBO_COMPARATOR|standard pureed rice|3 ml of standard pureed rice is attempted to swallow under endoscopic examination of swallowing
62049001|NCT05016154|EXPERIMENTAL|Online group CBT intervention|Online group CBT delivered via Microsoft Teams (a secure web-based video conferencing platform) in 10 weekly workshops of 60-75 minutes.
62049002|NCT05016154|ACTIVE_COMPARATOR|SilverCloud guided|"The SilverCloud app is a set of programs and courses that can be completed on a phone, tablet or computer. Students are also contacted by the SilverCloud support team which offers them guidance and support while using the app.~Silvercloud uses principles borrowed from both a popular type of counseling called Cognitive Behavioral Therapy (CBT) and Mindfulness. Each module takes approximately 40minutes to complete. Students are encouraged to complete at least one module per week."
62049003|NCT05016154|ACTIVE_COMPARATOR|SilverCloud unguided|"The SilverCloud app is a set of programs and courses that can be completed on a phone, tablet or computer. Students are encouraged to use the app as they see fit, although guidelines to using the app are provided.~Silvercloud uses principles borrowed from both a popular type of counseling called Cognitive Behavioral Therapy (CBT) and Mindfulness. Each module takes approximately 40minutes to complete. Students are encouraged to complete at least one module per week."
62049004|NCT05016154|ACTIVE_COMPARATOR|Mood Flow|The Moodflow app is a mood tracker and journal that helps students figure out what changes their mood. Students are encouraged to use the app as they see fit, although guidelines to using the app are provided.
62251117|NCT05799599|EXPERIMENTAL|Stay_Play_Talk Plus Followed by Stay_Play_Talk Plus (SPT Plus Responders)|After being randomly assigned to the SPT Plus condition, these participants responded and therefore remained in this condition
62251118|NCT05799599|EXPERIMENTAL|Stay_Play_Talk Plus Followed by Randomization to Stay_Play_Talk Plus (SPT Plus - SPT Plus)|After being randomly assigned to the SPT Plus condition, these participants did not respond and were randomized to Stay_Play_Talk Plus in the second stage.
62440980|NCT01254045|EXPERIMENTAL|placebo, oxytocin 48IU, oxytocin 24IU|intranasal placebo (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
62251119|NCT05799599|EXPERIMENTAL|Stay_Play_Talk Plus Followed by Randomization to Stay_Play_Talk Advanced (SPT Plus - SPT Advanced)|After being randomly assigned to the SPT Plus condition, these participants did not respond and were randomized to Stay_Play_Talk Advanced condition in the second stage which incorporates direct instruction.
62251120|NCT04557319|EXPERIMENTAL|GNR-038, 25 МЕ/kg|Recombinant C1-esterase (25 ME/kg) inhibitor intravenous infusion
62251121|NCT04557319|EXPERIMENTAL|GNR-038, 50 МЕ/kg|Recombinant C1-esterase (50 ME/kg) inhibitor intravenous infusion
62251122|NCT04557319|EXPERIMENTAL|GNR-038, 100 МЕ/kg|Recombinant C1-esterase (100 ME/kg) inhibitor intravenous infusion
62440981|NCT02570165|EXPERIMENTAL|Batefenterol 37.5 mcg|Each subject will receive batefenterol 37.5 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
62609393|NCT02271724||CIDP/MMN newly diagnosed (drug naive)|"Patients, who are suspected to suffer from CIDP or MMN, will undergo a lumbar puncture as a part of the diagnostic procedure. We expect to include 5-10 patients.~Lumbar puncture Blood sample"
62609394|NCT02271724||CIDP/MMN treated|"All patients with established CIDP in maintenance treatment with SCIG or IVIG are recruited from local registries at the outpatient clinic at Department of Neurology, Aarhus University Hospital.~We expect that 10-15 patients with CIDP and MMN treated with SCIG or IVIG eligible for inclusion. Furthermore, we expect to include 10 CIDP and MMN patients in maintenance therapy from the outpatient clinics at Department of Neurology, Odense University Hospital and Department of Neurology, Aalborg University Hospital."
62832009|NCT00999804|ACTIVE_COMPARATOR|12-week arm|Participants will receive 12-weeks of lapatinib plus trastuzumab. Participants who are estrogen receptor (ER) and/or progesterone receptor (PR) positive will also receive endocrine therapy.
62832010|NCT00722072|EXPERIMENTAL|Fulvestrant/ Sorafenib|"Fulvestrant: A loading dose will be administered intramuscularly to all subjects during cycle 1 of treatment as follows:~* 500 mg IM on Day 1~* 250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of Fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or unacceptable toxicity occurs requiring discontinuation.~Sorafenib: Subjects will take Sorafenib 800 mg/day administered as 400 mg bid (twice daily)each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until unacceptable toxicity occurs."
62832011|NCT02048670|EXPERIMENTAL|Chronic Subjective Dizziness Syndrome Subjects|Subjects diagnosed with Chronic Subjective Dizziness Syndrome (CDS) will wear the BalanceBelt while performing test involving walking and balance.
62832012|NCT02048670|ACTIVE_COMPARATOR|Healthy Subjects|Age matched healthy subjects without complaints of balance or dizziness problems will wear the BalanceBelt while performing test involving walking and balance.
62832013|NCT03612934||patients under the age of 65 years|patients under the age of 65 years
62832014|NCT03612934||patients at the age of 65 years and over|patients at the age of 65 years and over
62440982|NCT02570165|EXPERIMENTAL|Batefenterol 75 mcg|Each subject will receive batefenterol 75 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
62440983|NCT02570165|EXPERIMENTAL|Batefenterol 150 mcg|Each subject will receive batefenterol 150 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
62049005|NCT06580379||Spine Surgery Patients|non-vulnerable adults undergoing spine surgery, with a posterior approach
62440984|NCT02570165|EXPERIMENTAL|Batefenterol 300 mcg|Each subject will receive batefenterol 300 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
62251123|NCT01467349||Raltegravir group|"This study will include subjects who received raltegravir and were previously exposed to NRTIs, NNRTIs, PIs, regardless of the stage of HIV disease at the start of the treatment.~A control group will be used for the evaluation of the primary and secondary objectives in comparison to patients treated with raltegravir (study patients). The control group will be constituted by subjects who never received raltegravir, matched (in a ratio 1:3) with the study subjects by gender, age (± 3 years), CD4+ cells counts (± 50 cells) and HCV co-infection status yes/no). For control patients, the last antiretroviral regimen prescribed will be considered."
62251124|NCT01433757|ACTIVE_COMPARATOR|Ampicillin|Patients who are randomly selected to receive the active drug will receive Ampicillin (2mg daily for adults and 1 mg daily for children).
62251125|NCT01433757|PLACEBO_COMPARATOR|Placebo|Patients who are randomly selected to receive the placebo will be given a sugar pill that resembles the active drug.
62609395|NCT02271724||Other peripheral neuropathies|Patients who are diagnosed with other causes of peripheral neuropathies than CIDP. We expect to include 20 patients
62609396|NCT02271724||Syptomatic controls|Controls include patients with unspecified neurological symptoms or diseases who will undergo a lumbar puncture at the Department of Neurology at Aarhus University Hospital as part of their diagnostic work up irrespective of this study plus healthy controls. We expected to include 40-50 symptomatic controls
62609397|NCT05830669|EXPERIMENTAL|Intervention Group|Remote ischemic preconditioning (RIPC) Three Cycles of 5-min upper limb ischemia. If there is no response this will be followed by 2 cycles of 10-min upper-limb ischemia.
62609398|NCT05830669|SHAM_COMPARATOR|Control Group|Three cycles of 5- min upper limb sham ischemia.
62251126|NCT01881945|EXPERIMENTAL|Physiological measurments|
62251127|NCT01111942|ACTIVE_COMPARATOR|radiation and weekly carboplatin|
62832015|NCT02563652||Major abdominal surgery|Patients undergoing major abdominal surgery (laparotomy). Surgical procedures considered for inclusion include, but are not restricted to, procedures such as gastrectomy, pancreatic surgery, liver resection, open prostatectomy, colonic surgery, radical cystectomy with ileal conduit, open nephrectomy and vascular abdominal aortic surgery.
62832016|NCT03367793|EXPERIMENTAL|Clinical, then Metric #1, then Metric #2|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the clinically derived prescription first, followed by the metric-derived #1, and lastly the metric-derived #2.
62832017|NCT03367793|EXPERIMENTAL|Clinical, then Metric #2, then Metric #1|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the clinically derived prescription first, followed by the metric-derived #2, and lastly the metric-derived #1.
62251128|NCT01111942|OTHER|conservation surgery|
62251129|NCT03947450|EXPERIMENTAL|Autologous skin fibroblasts|"For whole stump participants: The investigators will be comparing whole stump injection sites that receive autologous skin fibroblasts to vehicle (placebo) injections. This subject receives autologous skin fibroblast whole stump injections.~For localized injection participants: The investigators are comparing two injection sites in the same individual. This site receives autologous skin fibroblasts."
62440985|NCT02570165|EXPERIMENTAL|Batefenterol 600 mcg|Each subject will receive batefenterol 600 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
62609399|NCT03329248|EXPERIMENTAL|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: ALT-803, ETBX-011, GI-4000, haNK, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ethyl esters, oxaliplatin, SBRT
62609400|NCT00825656|EXPERIMENTAL|1|Sinol-M
62609401|NCT00825656|ACTIVE_COMPARATOR|2|Sinol
62609402|NCT05537649|ACTIVE_COMPARATOR|Oatmeal porridge|Cold-stored oatmeal porridge (38 g oats) and stored for 24 h at 4 degrees Celsius
62609403|NCT05537649|ACTIVE_COMPARATOR|Oatmeal porridge treated with amylomaltase|Cold-stored oatmeal porridge (38 g oats) treated with 30 enzyme units/g oats of amylomaltase and stored for 24 h at 4 degrees Celsius
62251130|NCT03947450|PLACEBO_COMPARATOR|Control|"For whole stump participants: The investigators will be comparing whole stump injection sites that receive autologous skin fibroblasts to vehicle (placebo) injections. This subject receives vehicle (placebo) whole stump injections.~For localized injection participants: The investigators are comparing two injection sites in the same individual. This site receives a placebo."
62251131|NCT05738811|EXPERIMENTAL|TENS treatment group|Group A was given exercise protocol along with TENS treatment protocol.
62251132|NCT05738811|EXPERIMENTAL|EMS treatment group|Group B received exercise protocol along with EMS treatment protocol.
62251133|NCT04786457|EXPERIMENTAL|Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)|open-label injection of DENV-1-LVHC to 15-20 adults who were previously vaccinated and 5 adults who have never received a dengue vaccination
62440986|NCT02570165|EXPERIMENTAL|UMEC/VI 62.5/25 mcg|Each subject will receive UMEC/VI 62.5/25 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
62440987|NCT02570165|EXPERIMENTAL|Placebo|Each subject will receive placebo (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
62440988|NCT06126042|EXPERIMENTAL|DRL_AB|Drug: Abatacept Prefilled Syringe Each pre-filled syringe contains 125 mg of abatacept in 1 mL Other Name: Dr. Reddy's Abatacept
62440989|NCT06126042|ACTIVE_COMPARATOR|RP|Drug: Abatacept Prefilled Syringe Each pre-filled syringe contains 125 mg of abatacept in 1 mL Other Names: Orencia
62609404|NCT04411147||Close Contacts|Individuals without COVID-19 diagnosis, lived in same home as a survivor during illness, were within 6 feet of a COVID-19 case for a prolonged period of time or had direct contact with secretions
62609405|NCT04411147||COVID-19 Survivor|Individuals with documented prior COVID-19 infection and who have recovered
62609406|NCT05652400||Individuals diagnosed with HIV infection|People with HIV
62609407|NCT02647255|EXPERIMENTAL|PE and methylprednisolone pulse|Plasma exchange(PE) and methylprednisolone pulse therapy: plasma exchange \>7 within 3ws, Volume: 60ml/kg/course; Replacement fluid: 5% albumin or fresh frozen plasma and methylprednisolone pulse therapy Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.
62609408|NCT02647255|ACTIVE_COMPARATOR|Methylprednisolone pulse|Methylprednisolone pulse alone: methylprednisolone 7-15mg/kg/d 3 times on consecutive or alternate days Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.
62609409|NCT00649233|EXPERIMENTAL|1|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
62609410|NCT00649233|ACTIVE_COMPARATOR|2|Lopressor HCT® Tablets 100/50 mg
62609411|NCT00303212|NO_INTERVENTION|UC|Usual HF guideline-base care
62609412|NCT00303212|EXPERIMENTAL|TM|Telemonitoring group plus usual guideline-based HF care
62609413|NCT02564406|EXPERIMENTAL|hypercapnic patients|patients with acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease, refused endotracheal intubation after failing NIV and were treated withLow flow etracorporeal CO2 removal
62832018|NCT03367793|EXPERIMENTAL|Metric #1, then Clinical, then Metric #2|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #1 prescription first, followed by the clinically derived prescription, and lastly the metric-derived #2 prescription.
62049006|NCT05030779|EXPERIMENTAL|Treatment of SLE|Experimental：Administration of CD19/BCMA CAR T-cells A dose levels of 1-4\*10E6/kg are administrated for each subject.
62049007|NCT05099926|EXPERIMENTAL|Reducing Exercise Sensitivity with Exposure Training|Participants in this group complete 2, at-home reducing exercise sensitivity with exposure training (RESET) intervention visits with research-trained personnel via video visits. They complete psychoeducation, and a brief walking activity (i.e., interoceptive exposure), followed by a session reflecting upon their walking experience with research-trained personnel (i.e., interoceptive counseling). Participants also complete weekly physical activity journals throughout the intervention. Each RESET intervention visits can occur once or twice per week over the course of 2 weeks, based on patient preference.
62440990|NCT06126042|ACTIVE_COMPARATOR|RMP|Drug: Abatacept Prefilled Syringe Each pre-filled syringe contains 125 mg of abatacept in 1 mL Other Names: Orencia
62440991|NCT00729196|EXPERIMENTAL|1|Low-Glycemic Load Diet
62609414|NCT01032070|EXPERIMENTAL|Erlotinib|Erlotinib was administered orally at a dose of 85 mg/m\^2 per day continuously until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity.
62049008|NCT05627102|EXPERIMENTAL|Percutaneous Electrolysis and neuromodulation.|The intervention for this group consisted of Therapeutic Percutaneous Electrolysis and neuromodulation. Patient received once week for four weeks associated with eccentric exercises device at home.
62049009|NCT05627102|ACTIVE_COMPARATOR|Conventional group|"The multimodal physical therapy program includes 10 sessions of:~ultrasound pulsatil therapy (US) for 10 minutes , transcutaneous electric nerve stimulation (TENS) for 20 minutes ans associated with eccentric exercises device at home."
62049010|NCT01578811|PLACEBO_COMPARATOR|Placebo|
62049011|NCT01578811|EXPERIMENTAL|SK-MS10 160mg t.i.d|
62049012|NCT01578811|EXPERIMENTAL|SK-MS10 320mg t.i.d|
62049013|NCT01783418|EXPERIMENTAL|Mindfulness intervention|
62049014|NCT01783418|ACTIVE_COMPARATOR|Wait-list control|
62440992|NCT00729196|ACTIVE_COMPARATOR|2|Low-Fat Diet
62440993|NCT04277195||NUH Adjuvant Breast Cancer Cohort: Historical|This is a series of breast cancer patients treated with adjuvant therapy, who were identified and samples selected for inclusion in the Nottingham Tenovus Breast research project by Prof Ian Ellis's research group (1986-1999; n=1650). The clinical dataset for this cohort of breast cancer patients has been collected in a master clinical database by the team supporting Professor Ian Ellis. The study research team will work with a pseudo-anonymised copy of this dataset.
62609415|NCT01032070|ACTIVE_COMPARATOR|Etoposide|Etoposide 50 mg/m\^2 per day was administered orally for 21 days followed by a 7-day rest period until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity.
62609416|NCT03844594|EXPERIMENTAL|Eptifibatide Drug: Eptifibatide Injection|
62609417|NCT02966119|EXPERIMENTAL|Start antiplatelet drug(s)|If the patient is randomized in this arm, an antiplatelet agent (aspirin or clopidogrel or dypyridamole), chosen by the patient's physician before the randomisation, will be prescribed to the patient during the study period
62609418|NCT02966119|NO_INTERVENTION|Avoid antiplatelet drug(s)|If the patient is randomized in this arm, antiplatelet drugs will not be prescribed to the patient during the entire study period
62609419|NCT01195181|ACTIVE_COMPARATOR|peginterferon alfa-2a plus ribavirin|patients will receive a fixed dose of 180ug/week of peginterferon alfa-2a plus ribavirin at 15mg/kg/daily.
62609420|NCT01195181|ACTIVE_COMPARATOR|peginterferon alfa-2b plus ribavirin|patients will receive a weight adjusted dose (1,5ug/kg) from 50 to 150ug/week of peginterferon alfa-2b (standard dose) or a lower dose (1,0ug/kg) at physician discretion (randomization list available only for 100 cases) plus ribavirin at 15mg/kg/daily.
62609421|NCT01395173|PLACEBO_COMPARATOR|Control|Subject will undergo standard colonoscopy.
62049015|NCT04111003|EXPERIMENTAL|SFRC direct filling|Restoration of endodontically treated tooth Endodontically treated molars are restored with direct composite restorations, using a short-FRC base filling.
62609422|NCT01395173|ACTIVE_COMPARATOR|Position change|Subject will under go standard colonoscopy, but also with position changes during colonoscope withdrawal.
62832019|NCT03367793|EXPERIMENTAL|Metric #2, then Clinical, then Metric #1|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #2 prescription first, followed by the clinically derived prescription, and lastly the metric-derived #1 prescription.
62049016|NCT04111003|ACTIVE_COMPARATOR|CEREC endocrown|Restoration of endodontically treated tooth Endodontically treated molars are restored with indirect ceramic CAD/CAM restorations.
62049017|NCT02080429|ACTIVE_COMPARATOR|Immediate Pushing|Patient's will begin to push when they are determined to be completely dilated.
62832020|NCT03367793|EXPERIMENTAL|Metric #1, then Metric #2, then Clinical|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #1 prescription first, followed by the metric-derived #2 prescription, and lastly the clinically derived prescription.
62049018|NCT02080429|EXPERIMENTAL|Passive Descent|Patient's will wait 90 minutes prior to begin pushing
62049019|NCT00455975|EXPERIMENTAL|Weekly Avastin|Bevacizumab 15mg/kg IV weekly until progressive disease or toxicity
62049020|NCT00455975|EXPERIMENTAL|Bi-weekly Avastin|Bevacizumab 15mg/kg IV every 2 weeks until progressive disease or toxicity
62049021|NCT00694005|ACTIVE_COMPARATOR|bifurcation stent techniqe|"cross over stenting without kissing balloon angioplasty leave alone"
62440994|NCT04277195||NUH Adjuvant Breast Cancer Cohort: New|A series of breast cancer patients treated with adjuvant therapy, who were identified and samples selected for inclusion in the Nottingham Tenovus Breast research project by Prof Ian Ellis's research group (2000-2006; n=2000). The clinical dataset for this cohort of breast cancer patients has been collected in a master clinical database by the team supporting Professor Ian Ellis. The study research team will work with a pseudo-anonymised copy of this dataset.
62832021|NCT03367793|EXPERIMENTAL|Metric #2, then Metric #1, then Clinical|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #2 prescription first, followed by the metric-derived #1 prescription, and lastly the clinically derived prescription.
62049022|NCT00694005|EXPERIMENTAL|bifurcation stent technique|kissing balloon angioplasty
62049023|NCT05072925|ACTIVE_COMPARATOR|Combustible Cigarette|The usual brand of combustible cigarette smoked by study subjects, with a minimum Federal Trade Commission tar yield of 8mg
62049024|NCT05072925|EXPERIMENTAL|BIDI Stick ENDS Arctic flavor|BIDI Stick ENDS containing 6% nicotine and Arctic flavor
62049025|NCT05072925|EXPERIMENTAL|BIDI Stick ENDS Classic flavor|BIDI Stick ENDS containing 6% nicotine and Classic flavor
62609423|NCT02339155|EXPERIMENTAL|Anthrax Vaccine Adsorbed|Subjects will be administered subcutaneous (SC) 0.5 mL AVA doses on Days 1, 15, and 29 (0, 2, and 4 weeks).
62609424|NCT02339155|EXPERIMENTAL|AVA + Raxibacumab|Subjects will be administered SC 0.5 mL AVA doses on Days 1, 15, and 29 (0, 2, and 4 weeks), with the first AVA dose administered immediately after completion of a single intravenous (IV) infusion 40 milligram (mg)/kilogram (kg) raxibacumab dose. Subjects will be premedicated with 25-50 mg of diphenhydramine up to 1 hour prior to the raxibacumab infusion to reduce the risk of infusion reactions.
62609425|NCT06731712|EXPERIMENTAL|Physical Function Group|Physical function interventions including strength, balance, and mobility exercises
62609426|NCT06731712|NO_INTERVENTION|Control Group|Will continue their normal lives
62609427|NCT04394793|EXPERIMENTAL|Study Arm|
62049026|NCT05072925|EXPERIMENTAL|BIDI Stick ENDS Zest flavor|BIDI Stick ENDS containing 6% nicotine and Zest flavor
62049027|NCT05072925|EXPERIMENTAL|BIDI Stick ENDS Regal flavour|BIDI Stick ENDS containing 6% nicotine and Regal flavor
62049028|NCT05072925|EXPERIMENTAL|BIDI Stick ENDS Winter flavour|BIDI Stick ENDS containing 6% nicotine and Winter flavor
62609428|NCT03127813|EXPERIMENTAL|Treated glaucoma|POAG patients established on treatment
62609429|NCT03127813|EXPERIMENTAL|Untreated|Newly diagnosed treatment naïve POAG patients
62049029|NCT05072925|EXPERIMENTAL|BIDI Stick ENDS Solar flavor|BIDI Stick ENDS containing 6% nicotine and Solar flavor
62049030|NCT05072925|ACTIVE_COMPARATOR|JUUL ENDS Virginia Tobacco flavor|JUUL ENDS containing 5% nicotine and Virginia Tobacco flavor
62049031|NCT05050149|EXPERIMENTAL|Experimental: PTX-022|PTX-022 QTORIN
62049032|NCT02095275||Acute kidney injury|ICU patients with Acute kidney injury
62049033|NCT00785408|EXPERIMENTAL|1|
62049034|NCT00785408|EXPERIMENTAL|2|
62049035|NCT00785408|EXPERIMENTAL|3|
62049036|NCT00785408|PLACEBO_COMPARATOR|4|
62049037|NCT00785408|PLACEBO_COMPARATOR|5|
62049038|NCT00785408|PLACEBO_COMPARATOR|6|
62609430|NCT03127813|ACTIVE_COMPARATOR|Control|Control subjects without glaucoma
62832022|NCT02129699|OTHER|None, standard chemotherapy only|"4 - 6 cycles of standard chemotherapy + best supportive care including any bone protective agent except denosumab.~Standard chemotherapy consis of a combination of platinum-based doublet agents plus gemcitabine or pemetrexed."
62832023|NCT02129699|EXPERIMENTAL|Standard chemotherapy + Denosumab|"4 - 6 cycles of standard chemotherapy + denosumab 120 mg, administered subcutaneously every 3-4 weeks until unacceptable toxicity, patient refusal, or patient's death. Denosumab should be administered on day 1 of each cycle, before or after the administration of chemotherapy. After stop of first-line chemotherapy, denosumab must be continued life-long, regardless of tumour progression and concomitantly with subsequent lines of systemic treatment, as long as tolerable for the patient.~Standard chemotherapy consis of a combination of platinum-based doublet agents plus gemcitabine or pemetrexed."
62049039|NCT05711979|EXPERIMENTAL|AARC Intervention|Participants in the AARC Intervention Arm will receive a 10 week intervention.
62049040|NCT02080975|EXPERIMENTAL|Data Collection During Atrial Flutter Ablation|
62049041|NCT04790058||Physicians using CSRS practice recommendation to treat syncope patients in ED.|During the control period, there will be no interventions. The intervention is the knowledge translation of the CSRS practice recommendations. The components of the practice recommendations include: 1) evidence-informed systematic clinical evaluation with appropriate history, physical examination and in-ED investigations (e.g. troponin testing, work-up for pulmonary embolism and CT head) for detecting serious underlying conditions and predicting 30-day serious outcomes; 2) application of the CSRS for risk-stratification at the end of ED visit after no serious underlying conditions for the syncope were identified; 3) use of patient information materials to aid in disposition; 4) the use of 15-day outpatient cardiac monitoring for CSRS medium and high-risk patients upon ED discharge. The ED physician or non-ED physician performing consultation on the patient can apply all the components of the practice recommendation and decide disposition of the patients who are eligible to be studied.
62049042|NCT05200130|ACTIVE_COMPARATOR|Home exercise group|The home exercise program will be explained to the patients in the control group by the physiotherapist and the relevant brochures will be delivered to the patients. Home exercise program will take 30-45 min. İt will be applied 5 days a week for 8 weeks. Patients will receive a reminder message from the physiotherapist once a week.
62049043|NCT05200130|ACTIVE_COMPARATOR|Manual Therapy Group|Patients in the Manual Therapy Group will receive one-to-one physiotherapy sessions in the hospital 2 days a week for 8 weeks. In these sessions, soft tissue and joint mobilizations and exercises will be applied by physiotherapist.
62049044|NCT05200130|EXPERIMENTAL|Telerehabilitation Supported Group|Telerehabilitation program will be applied 2 days a week for 8 weeks to patients in the telerehabilitation group. İt will take 30-45 min. A physiotherapist will meet with patients via videoconferencing over the internet and guide the program.
62049045|NCT05452655|EXPERIMENTAL|Intensive Outpatient Integrated Motor-Cognitive and Aerobic Exercises Rehabilitation Program|Intervention of highly challenging motor and cognitive training for 6 consecutive weeks.
62049046|NCT05452655|ACTIVE_COMPARATOR|Home-Based Stretching Exercises|Home-based self-treatment program for 40 '/ day for 6 consecutive weeks
62251134|NCT01628107|EXPERIMENTAL|Epoetin Hospira|Epoetin Hospira will be administered by IV bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.
62251135|NCT02741804|ACTIVE_COMPARATOR|BBH-1001 Brain Health Supplement|Patients will be given supplement containing ingredients all approved by the FDA: Turmeric (125mg), fisetin (16.65mg), green tea leaf extract (17.5mg), EPA (75mg), DHA (150mg) and Vitamin D3 (250IU). Patients will take 4 softgels once per day for entire study duration (18 months).
62251136|NCT02741804|PLACEBO_COMPARATOR|Brain Health Placebo|Patients will be given a pill resembling the study supplement, but instead consisting of Soybean oil (608mg). Patients will take 4 softgels once per day for the entire study duration (18 months).
62251137|NCT00058474|ACTIVE_COMPARATOR|Arm 1: 5-FU + RT|Patients receive fluorouracil IV continuously and undergo radiation therapy (RT) once daily 5 days a week for 5-6 weeks.
62251138|NCT00058474|EXPERIMENTAL|Arm 2: 5-FU + RT + Oxaliplatin|Patients receive fluorouracil and undergo RT as in arm 1. Patients also receive oxaliplatin IV over 1 hour once weekly for 5 weeks.
62832024|NCT02557139|EXPERIMENTAL|Regimen A|Single-dose belumosudil 200 mg tablet in the fasted state
62832025|NCT02557139|EXPERIMENTAL|Regimen B|Single-dose belumosudil 200 mg tablet in the fed state
62251139|NCT00058474|EXPERIMENTAL|Arm 3: Capecitabine + RT|Patients receive oral capecitabine twice daily and undergo RT once daily 5 days a week for 5-6 weeks.
62251140|NCT00058474|EXPERIMENTAL|Arm 4: Capecitabine + RT + Oxaliplatin|Patients receive capecitabine and undergo RT as in arm 3. Patients also receive oxaliplatin as in arm 2.
62832026|NCT02557139|EXPERIMENTAL|Regimen C|Single-dose belumosudil capsules (administered as two 100-mg capsules) in the fed state
62832027|NCT01054989|ACTIVE_COMPARATOR|Fat intravenously|Intravenous application of fat
62832028|NCT01054989|ACTIVE_COMPARATOR|Fat orally|Oral fat load
62832029|NCT01054989|ACTIVE_COMPARATOR|LPS intravenously|Lipopolysaccharide (LPS; US Standard Reference endotoxin)
62832030|NCT01054989|PLACEBO_COMPARATOR|Glycerol intravenously|Intrevenous glycerol infusion
62832031|NCT05931302|EXPERIMENTAL|68Ga-FAPI-46 PET scan + 18-FDG PET scan|
62832032|NCT06654661|EXPERIMENTAL|TKA Patients|TKA patients will undergo total knee replacement as part of standard of care. The 3D printed mechanical balancer will be used at one timepoint during surgery while the patient is under anesthesia during their scheduled TKA surgery.
62832033|NCT02510521|PLACEBO_COMPARATOR|in rest situation|No intervention during one week. Daily usual activities are allowed.
62609431|NCT01857700|EXPERIMENTAL|Conditional economic compensation|A scratch off card will be used to randomly determine which of the compensations will be offered: compensation for transport cost, compensation for lost wages, or compensation for transport cost and lost wages
62609432|NCT01857700|PLACEBO_COMPARATOR|Standard of Care|
62609433|NCT02631902|EXPERIMENTAL|Exercise|Community-based exercise program
62609434|NCT02631902|EXPERIMENTAL|Exercise plus dietary intervention|Community-based exercise and dietary intervention program
62609435|NCT02631902|NO_INTERVENTION|Control|Habitual physical activity and habitual dietary pattern
62609436|NCT06731075|OTHER|ORMD-0801 8 mg once-daily at night - QD|Double-Dummy; the subject receives both experimental drug and placebo. 1 x 8 mg capsule between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 2 placebo capsules (1 in the morning and 1 at night).
62251141|NCT04654520|EXPERIMENTAL|Drug therapy combined with radiotherapy for primary tumor omitted CTV|"* IMRT (omitted CTV) concurrent with systemic chemotherapy on paticipants of kown negative gene mutation .After it, the paticipants may choose immunotherapy.~* IMRT (omitted CTV) concurrent with targeted drug on paticipants of kown sensitive gene mutation."
62251142|NCT04654520|NO_INTERVENTION|Drug therapy combined with radiotherapy for primary tumor with CTV|"* IMRT (with CTV) concurrent with systemic chemotherapy on paticipants of kown negative gene mutation .After it, the paticipants may choose immunotherapy.~* IMRT ((with CTV) concurrent with targeted drug on paticipants of kown sensitive gene mutation."
62251143|NCT04296279|ACTIVE_COMPARATOR|"Part A - Low Dose"|"Part A vaccinees in the low dose arm will receive the lower dosing (20 μg FMP014 per 0.5 mL ALFQ) approximately 2 weeks prior to each vaccination. Vaccination to be delivered on 0,1,2 month."
62440995|NCT04277195||NUH Neoadjuvant Breast Cancer Cohort|For many years clinical data on this cohort of breast cancer patients has been collected in a master clinical database by the clinical team supporting Dr Chan (1996-2021; n=900 patients). This has been used for internal audits and reviews of clinical practice. The study research team will work with a pseudo-anonymised copy of this dataset.
62440996|NCT04277195||NUH Oncotype DX tested Adjuvant Breast Cancer Cohort|A list of patients tested with Oncotype DX as part of their standard treatment pathway (2015-2021; n=200) will be collected and will form the basis of a master clinical database for this cohort. The database will be managed and populated by the clinical team supporting Dr Chan. The study research team will work with a pseudo-anonymised copy of this dataset.
62440997|NCT02648373|EXPERIMENTAL|Education|Patients receive an educational video about low back pain based on the Consumer Reports Choosing Wisely recommendation for patients with back pain to avoid early imaging and remain as active as possible. After the video the evaluator and patient discussed key themes from the video and the patient was able to ask any questions. Previously scheduled physical therapy then began with treatment at the therapist's discretion.
62440998|NCT02648373|ACTIVE_COMPARATOR|Control|Previously scheduled physical therapy was provided with treatment at the therapist's discretion. No educational intervention was provided before beginning physical therapy
62440999|NCT04083339|EXPERIMENTAL|AT-001 High dose|The total daily doses will be of 3g. The dose selection and the frequency of dosing was based on the results of the phase 1/2 study demonstrating that 3g/day of AT-001 is capable of producing the maximum inhibition of the production of sorbitol (a pharmacodynamic biomarker of biological activity).
62441000|NCT04083339|EXPERIMENTAL|AT-001 Low Dose|The total daily doses will be of 2g. The dose selection and the frequency of dosing was based on the results of the phase 1/2 study demonstrating that 2g/day of AT-001 is capable of producing a sufficient inhibition of the production of sorbitol (a pharmacodynamic biomarker of biological activity).
62441001|NCT04083339|PLACEBO_COMPARATOR|Placebo Comparator|Placebo capsules will be used as comparator
62441002|NCT06200961|ACTIVE_COMPARATOR|Transnasal Endoscopy (TNE)|Unsedated endoscopic evaluation of the esophagus and stomach through the nose with a transnasal endoscope.
62441003|NCT06200961|ACTIVE_COMPARATOR|Sedated Esophagogastroduodenoscopy (EGD)|Sedated endoscopic evaluation of the esophagus and stomach through the mouth with a standard upper endoscope.
62441004|NCT04111133|EXPERIMENTAL|Carvedilol + Ivabradine|
62441005|NCT04111133|ACTIVE_COMPARATOR|Carvedilol|
62609437|NCT06731075|OTHER|ORMD-0801 8 mg twice daily - BID|Double-Dummy; the subject receives both experimental drug and placebo. 1 x 8 mg capsule each morning approximately 45 minutes (±15 minutes) prior to breakfast and 1 x 8 mg capsule each night prior to bedtime (between 8 PM to 12 Midnight and no sooner than 1 hour after dinner) and 1 placebo capsule at night.
62609438|NCT06731075|OTHER|ORMD-0801 16 mg once-daily at night - QD|Double-Dummy; the subject receives both experimental drug and placebo. 2 x 8 mg capsules between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 1 placebo capsule in the morning.
62609439|NCT06731075|PLACEBO_COMPARATOR|Placebo|The subject receives 3 placebo capsules.
62609440|NCT06730178|EXPERIMENTAL|Relaxation training in patients with insomnia|The goals and processes of relaxation training were explained by therapists. The patients were asked to record data before relaxation training, inclusive of all sleep durations, the frequency of night waking, the time needed to fall asleep, and medication history. The insomnia scales were completed again one week later, and the relaxation training started in the second week. The patients recorded their sleep conditions every day and underwent relaxation training intervention for 4 weeks.
62609441|NCT05605509|ACTIVE_COMPARATOR|RP-6306 + Gemcitabine|
62609442|NCT05605509|ACTIVE_COMPARATOR|RP-6306 + FOLFIRI|
62609443|NCT05605509|ACTIVE_COMPARATOR|RP-6306 + Trastuzumab|
62609444|NCT05605509|ACTIVE_COMPARATOR|RP-6306 + RP-3500|
62609445|NCT06285084||Training Cohort|455 Athletes already evaluated for sports participation clearance, whom ECG and clinical evaluation (cleared - not cleared for competitive sports participation) will be fed into the DL model
62609446|NCT06285084||Validation Cohort|76 Athletes evaluated using standard sports eligibility clearance tests and our DL model
62441006|NCT02619604|OTHER|Clinician education|
62441007|NCT04510220|EXPERIMENTAL|Subjects diagnosed with relapsing forms of multiple sclerosis|We plan to enroll 10 subjects with relapsing MS. All enrolled subjects will receive Ofatumumab 20 mg every 4 weeks, subcutaneously for 9 months during the study. Loading doses will be administered initially at 1, 7 and 14 days. During the study period, all enrolled subjects will undergo five PET scans using \[F-18\] PBR06 at 0, 5, 28, 90 and 273 days after starting treatment with Ofatumumab.
62441008|NCT04625920|EXPERIMENTAL|Virtual reality|women allocated to undergo hysteroscopy with Vr System
62441009|NCT04625920|EXPERIMENTAL|Standart care|women allocated to undergo hysteroscopy without VR
62441010|NCT04633759|EXPERIMENTAL|Blood Flow Restriction Exercise|Participant will participate in a supervised low load blood flow restriction exercise program twice a week for 8 weeks.
62441011|NCT04568928|EXPERIMENTAL|OLTP/PE+FES|"3-5 familiarization sessions + 12 training sessions (3 blocks of 4 training sessions; 60-90 min each session, 2-3 sessions per week) of an overground locomotor training program using a powered exoskeleton combined with functional electrical stimulation (OLTP/PE+FES).~The training sessions are divided into 3 blocks. Each block will take place over a period of approximately 2 weeks (2-3 sessions/week) and will consist of 3 training sessions with exoskeleton combined with FES and a fourth session with exoskeleton alone, without FES.~For each participant, FES intensity will be set for each muscle in order to elicit a palpable muscle contraction. FES timing and duration is already built into the device. For each participant, specific level of assistance for each hip and knee, and gait parameters will be set and adjusted during a familiarization period with the PE. Level of PE assistance will then be adjusted weekly to ensure training progression."
62609447|NCT01249833|ACTIVE_COMPARATOR|Oseltamivir|Added to standard of care for influenza
62609448|NCT01249833|NO_INTERVENTION|Standard of care alone|Standard of care for influenza
62832034|NCT02510521|EXPERIMENTAL|after acute muscle exercise by NMES|"A working session of 20 minutes with three sequences electrostimulation:~* warming-up sequence~* work sequence (starting at 50% of the intensity achieved during warm-up)~* relaxation sequence~Electrostimulation relates both quadriceps are stimulated simultaneously and jointly. During the sessions, the patient sits on a chair or on a chair, legs bent at 90 °. So that there is no extension of the legs when electrostimulation (which could be painful), a strap is placed behind the legs of the chair or armchair and holds the pegs."
62832035|NCT02510521|EXPERIMENTAL|after a daily workout sequence with NMES in one week|"Working sessions of 20 minutes 7 days in a row, including :~* warming-up sequence~* work sequence (starting at 50% of the intensity achieved during warm-up)~* relaxation sequence~Electrostimulation relates both quadriceps are stimulated simultaneously and jointly. During the sessions, the patient sits on a chair or on a chair, legs bent at 90 °. So that there is no extension of the legs when electrostimulation (which could be painful), a strap is placed behind the legs of the chair or armchair and holds the pegs."
62832036|NCT05860946|EXPERIMENTAL|RIC group|Patients in RIC group and control group will achieve RIC intervention and sham RIC intervention three times daily from 5 days before operation and 7 days post operation
62832037|NCT05860946|SHAM_COMPARATOR|Control group|Patients in control group, bilateral upper arm cuffs were inflated to a pressure of 60 mm Hg for 5 minutes, followed by 5 minutes of relaxation of the cuffs
62832038|NCT00391586|EXPERIMENTAL|Erlotinib followed by chemotherapy|"Erlotinib: 150 mg orally once daily,~Platinum-based chemotherapy regimen selections include:~Carboplatin (Carbo) area under the curve (AUC) 6, or cisplatin (Cis) 60-100 mg/m2, day (D)1, administered with one of the following:~1. Docetaxel 75 mg/m2, D1~2. Docetaxel 35 mg/m2, D1,8,15~3. Paclitaxel 200-225 mg/m2, D1~4. Paclitaxel 80-100 mg/m2, D1,8,15~Carbo AUC 5-6, or Cis 60-100 mg/m2, D1, administered with one of the following:~1. Etoposide 100 mg/m2 D1-3~2. Etoposide 200 mg/m2 orally D1-3~3. Pemetrexed 500 mg/m2, D 1~4. Irinotecan 50 mg/m2 D1,8,15~Other regimens:~1. Gemcitabine 1000 mg/m2-1250 mg/m2, D1,8 + Carbo AUC 6, or Cis 60-100 mg/m2, D1 or 8~2. Vinorelbine 25 mg/m2 D1,8 + Carbo AUC 5, or Cis 80 mg/m2 D1"
62832039|NCT05072600|EXPERIMENTAL|arm 1|All participants will receive pembrolizumab monotherapy per 21 days no longer than 17 cycles until disease progression or death.
62049047|NCT06286605|EXPERIMENTAL|A-oss and autogenous bone|In these group a GBR will be performed using only A-oss and autologous bone will be added and then will be covered with a membrane.
62441012|NCT04574778|ACTIVE_COMPARATOR|Group 1: IV acetaminophen and PO placebo|Group 1 will receive 1000 mg of IV acetaminophen approximately 30 minutes prior to skin closure and will receive oral placebo in the holding area prior to surgery
62441013|NCT04574778|ACTIVE_COMPARATOR|Group 2: PO acetaminophen|Group 2 will receive 1000 mg of PO acetaminophen in the holding area and will not receive an IV placebo.
62441014|NCT04596501|EXPERIMENTAL|Early postmenopausal women|Healthy sedentary early postmenopausal women
62441015|NCT04596501|EXPERIMENTAL|Late postmenopausal women|Healthy sedentary late postmenopausal women
62441016|NCT01004770|EXPERIMENTAL|1 (AH113111 Injection)|
62441017|NCT01004770|ACTIVE_COMPARATOR|2 (Visipaque Injection)|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
62609449|NCT02007044|EXPERIMENTAL|Arm I (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62832040|NCT01547611|ACTIVE_COMPARATOR|Customary treatment|Group A (physiotherapy as usual), customary treatment. The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
62609450|NCT02007044|EXPERIMENTAL|Arm II (ibrutinib, rituximab)|Patients receive ibrutinib as in Arm I beginning on day 1 or 2. Patients also receive rituximab IV over 3-8 hours on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 2-6. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62609451|NCT06731114|EXPERIMENTAL|Group A|On group A we will perform suboccipital muscle release (3 repititions 3 mins)9 minutes along with conventional physical therapy including TENS and hot pack for 10 mins 6 days a week for consective 2 weeks.
62609452|NCT06731114|EXPERIMENTAL|Group B|On group B we will perform sternocleidomastoid release for 5 mins along with suboccipital muscle release and coventional physical therapy including TENS and hot pack for 10 mins 6 days a week for consective 2 weeks .
62609453|NCT01440387|EXPERIMENTAL|FLULAVAL QUADRIVALENT Adult Group|Subjects 18-60 years of age received 1 dose of FLULAVAL® QUADRIVALENT vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
62609454|NCT01440387|EXPERIMENTAL|FLULAVAL QUADRIVALENT Elderly Group|Subjects above 60 years of age received 1 dose of FLULAVAL® QUADRIVALENT vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
62441018|NCT04079842|EXPERIMENTAL|INVSENSOR00029|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00029 sensor
62441019|NCT01859325|EXPERIMENTAL|Vaccine|HIV-MAG pDNA vaccine prime will be administered at a dose of 3000 g (1500 g of the HIV-1 gag/pol plasmid and 1500 g of the HIV-1 net/tat/vif, env plasmid) at week 0, 4, 12, and 36. Each construct of HIV-MAG pDNA vaccine (1500 g each) will be mixed and combined with 1000 g of the IL-12 pDNA adjuvant. The resulting mixture will be divided into 2 IM injections and administered as 0.75 mL IM injection in the left deltoid and 0.75 mL IM injection in the right deltoid with EP using the TDS device. IL-12 pDNA adjuvant will be mixed with the HIV-MAG pDNA vaccine prime, as noted above, and administered at a dose of 1000 g (500 g in each IM injection) at week 0, 4, 12, and 36. rVSV HIV gag booster vaccine--The total dose, 1x107 pfu, will be administered as 1 mL (5x106 pfu) IM injection in the left deltoid and 1 mL (5x106 pfu) IM injection in the right deltoid at week 24 and 48.
62441020|NCT01859325|PLACEBO_COMPARATOR|Placebo|Placebo for the IL-12 pDNA adjuvant and HIV-MAG pDNA vaccine (sodium chloride for injection, USP 0.9%) will be administered as 0.75 mL IM injection in the left deltoid and 0.75 mL IM injection in the right deltoid at weeks 0, 4, 12, and 36 with EP using the TDS device. Placebo for the rVSV HIV gag (sodium chloride for injection, USP 0.9%) will be administered as 1 mL IM injection in the left deltoid and 1 mL IM injection in the right deltoid at week 24 and 48.
62441021|NCT02501239|EXPERIMENTAL|Accept Yourself! Intervention|Combined Health At Every Size and Acceptance and Commitment Therapy Psychotherapy Group
62609455|NCT05161078||All Patients Enrolled|Patients will be treated with CARPEDIEM per standard of care.
62609456|NCT04747990||Baseline (Pre-Covid19) group|All patients admitted to the participating surgical departments with a clinical and radiological diagnosis of biliary acute pancreatitis in 2019
62609457|NCT04747990||Pandemic (During Covid-19) group|All patients admitted to the participating surgical departments with a clinical and radiological diagnosis of biliary acute pancreatitis in 2020
62609458|NCT05245045|EXPERIMENTAL|Shengtaibufen Photodynamic Therapy(STBF-PDT)|The Shengtaibufen photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying 0.5mg/ml Shengtaibufen solution for 45min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
62609459|NCT05245045|PLACEBO_COMPARATOR|Red light|The Shengtaibufen photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying normal saline solution for 45min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
62609460|NCT03062995|EXPERIMENTAL|Active product: partially hydrolysed formula + synbiotics|partially hydrolysed formula + synbiotics
62609461|NCT03062995|ACTIVE_COMPARATOR|Control product: standard formula (intact protein)|standard formula (intact protein)
62609462|NCT01451554|ACTIVE_COMPARATOR|Portion Control Intervention|Individuals will be given a portion control plate and dietary counseling
62609463|NCT01451554|PLACEBO_COMPARATOR|Usual Care|Provided with self-help booklets on diet and exercise.
62609464|NCT03907930|ACTIVE_COMPARATOR|conventional|this arm will have both nephrostomy tube and ureteric catheter after completing the operation
62609465|NCT03907930|ACTIVE_COMPARATOR|tubeless|the arm will have only ureteric catheter rafter completing the operation
62609466|NCT03986554|OTHER|Randomization Visit A|Participants enrolled in this arm will consume 300ml of water over 60 minutes. Each session will consist of 30 swallows broken into three 10-swallow sequences of 10ml of water. Each sequence will be use VFSS to visualize swallows.
62049048|NCT06286605|ACTIVE_COMPARATOR|A-oss and LCR-A|In these subjects a GBR will be performed using only A-oss and LCR-A and then will be covered with a membrane.
62441022|NCT02501239|ACTIVE_COMPARATOR|Behavioral Weight Loss|Weight Watchers groups
62441023|NCT04370145|EXPERIMENTAL|moderate cholangitis|Meropenem injection, iv. drip,20mg/Kg，Q12h; Tinidazole injection, iv. drip,20mg/Kg,Qd.
62609467|NCT03986554|OTHER|Randomization Visit B|Participants enrolled in this arm will consume 300ml of water over 60 minutes. Each session will consist of 30 swallows broken into three 10-swallow sequences of 10ml of water. Sequences 1 and 3 will use videofluoroscopy only, while sequence 2 will use VFSS with simultaneous pharyngeal high resolution manometry in order to visualize swallows.
62609468|NCT05740345||Hyperglycemia/Normoglycemia|
62609469|NCT05740345||Treated/No treated|
62832041|NCT01547611|EXPERIMENTAL|structured behavioural medicine program|Group B (extended physiotherapy treatment), customary treatment (please see above) plus a standardised and structured behavioural medicine program. The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
62832042|NCT02915822|EXPERIMENTAL|Minimally Invasive Chevron/Akin osteotomy|Minimally invasive technique to surgically correct Hallux Valgus
62832043|NCT02915822|ACTIVE_COMPARATOR|Open Scarf/Akin osteotomy|Open technique to surgically correct Hallux Valgus
62251144|NCT04296279|ACTIVE_COMPARATOR|"Part A - High Dose"|"Part A vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,2 month."
62251145|NCT04296279|ACTIVE_COMPARATOR|"Part B - Standard Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 4,5,6 month."
62609470|NCT03386604|EXPERIMENTAL|Whey protein + Rehabilitation|Pulmonary rehabilitation will last 8 weeks covering 3 weekly sessions of supervised exercise and a weekly educational session. Patients will receive whey protein and will be instructed to take it daily for breakfast, diluted in milk or water (if they do not drink milk).
62609471|NCT03386604|PLACEBO_COMPARATOR|Placebo + Rehabilitation|Pulmonary rehabilitation will last 8 weeks covering 3 weekly sessions of supervised exercise and a weekly educational session. Patients will receive placebo (maltodextrin) and will be instructed to take it daily for breakfast, diluted in milk or water (if they do not drink milk).
62609472|NCT03386604|NO_INTERVENTION|Control|Patients without pulmonary rehabilitation nor whey protein supplementation.
62609473|NCT02219776|ACTIVE_COMPARATOR|Chlorhexidine Standard of Care Arm|Use of Chlorhexidine to cleanse pre-operative surgery site
62609474|NCT02219776|EXPERIMENTAL|Benzoyl Peroxide Experimental Arm|Use of Chlorhexidine scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient
62609475|NCT03568032||the post-radiation group|patients diagnosed as non-metastatic nasopharyngeal carcinoma who received definitive IMRT more than 3 years ago
62609476|NCT03568032||the pre-radiation group|untreated patients diagnosed as non-metastatic nasopharyngeal carcinoma
62609477|NCT03226678|EXPERIMENTAL|270mg or 360mg APL-2 administered subcutaneously daily (CAD)|
62609478|NCT03226678|EXPERIMENTAL|270mg or 360mg APL-2 administered subcutaneously daily (wAIHA)|
62609479|NCT04767854|EXPERIMENTAL|OA school + Virtual Training mobile health application|"After a clinical examination by the physiotherapist, all patients will receive a 1-2-hour group session of patient education according to guidelines.~The intervention group will receive an individually tailored exercise program through the Virtual Training mobile health application. After each exercise the patient score his/her execution of the exercise on a Likert-scale of 1 to 5, judging their effort from very poor to very good. After the session, patients rate their pain on a Numeric Rating Scale from 0 to 10. The patients in the intervention group will be instructed to exercise 3 times per week for 6 weeks. If the patients want to exercise more than 3 times per week, the exercise program will be available in the app once every day."
62609480|NCT04767854|ACTIVE_COMPARATOR|OA school + usual care|"After a clinical examination by the physiotherapist, all patients will receive a 1-2-hour group session of patient education according to guidelines.~The control group will receive individually tailored supervised exercise therapy by a physiotherapist individually or in a group setting, twice a week for 6 weeks. Additionally, the patients will be motivated to perform one session of home exercise a week, a total of 3 sessions per week"
62609481|NCT06730347|EXPERIMENTAL|PROC Cohort|Lorigerlimab IV every 21 days
62609482|NCT06730347|EXPERIMENTAL|CCGC Cohort|Lorigerlimab IV every 21 days
62609483|NCT02539134|EXPERIMENTAL|Part 1, Cohort 1: TAK-935 100 mg QD|TAK-935 100 milligram (mg), solution, orally, once daily (QD) or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
62609484|NCT02539134|EXPERIMENTAL|Part 1, Cohort 2: TAK-935 300 mg QD|TAK-935 300 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
62251146|NCT04296279|ACTIVE_COMPARATOR|"Part B - Delayed Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,6 month."
62251147|NCT04296279|ACTIVE_COMPARATOR|"Part B - Delayed Fractional Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,6 month."
62251148|NCT04296279|NO_INTERVENTION|Control|Up to 6 subjects will be enrolled (defined as receiving malaria challenge) later in the trial to serve as challenge controls. Additional subjects may be recruited as alternates to ensure that 6 control subjects undergo the challenge. Any alternates not challenged will be released from the study at day of challenge.
62609485|NCT02539134|EXPERIMENTAL|Part 1, Cohort 3: TAK-935 300 mg BID|TAK-935 300 mg, solution, orally, twice daily (BID) or TAK-935 placebo-matching solution, orally, BID for up to 10 days.
62609486|NCT02539134|EXPERIMENTAL|Part 1, Cohort 4: TAK-935 600 mg QD|TAK-935 600 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 10 days.
62609487|NCT02539134|EXPERIMENTAL|Part 1, Cohort 5: TAK-935 400 mg QD|TAK-935 400 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
62609488|NCT02539134|EXPERIMENTAL|Part 2, Cohort 6: TAK-935 Dose 1|TAK-935 first decided dose as determined from other TAK-935 trials and Cohorts 1 to 4 of Part 1, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
62609489|NCT02539134|EXPERIMENTAL|Part 2, Cohort 7: TAK-935 Dose 2|TAK-935 second decided dose as determined from other TAK-935 trials and Cohorts 1 to 4 of Part 1, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
62609490|NCT06710457|ACTIVE_COMPARATOR|Erector spinae plane (ESP) block|Patients will receive an erector spinae plane (ESP) block in addition to standard medical treatment to prevent PONV and postoperative pain.
62609491|NCT06710457|ACTIVE_COMPARATOR|No Erector spinae plane (ESP) block|Patients will receive standard medical treatment to prevent PONV and postoperative pain.
62609492|NCT01323504|EXPERIMENTAL|Music therapy group|Local care with music
62609493|NCT01323504|NO_INTERVENTION|control group|Local care without music
62609494|NCT06718036||Adults participating in the therapeutic rehabilitation process|
62609495|NCT04512365|PLACEBO_COMPARATOR|Placebo oral capsule|Participants will receive a placebo at their first or second laboratory visit.
62609496|NCT04512365|EXPERIMENTAL|THC|Participants will receive THC (7.5 mg) at their first or second laboratory visit.
62609497|NCT05922813|EXPERIMENTAL|BMI2004 Inj.|hyaluronidase, recombinant
62609498|NCT05922813|PLACEBO_COMPARATOR|0.9% NaCl|Normal Saline
62609499|NCT04544943|EXPERIMENTAL|Cohort 1|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa. The total body surface area (BSA) dosed will be either 9% or 27% BSA. Part A will include both an active-control (lotion base + 0.1% gentamicin) and a placebo control, applied at 9% or 27% BSA.
62609500|NCT04544943|PLACEBO_COMPARATOR|Cohort 2|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa. The minimum % BSA dosed will be 3% BSA and the maximum will be 27% BSA for patients in Cohort 2. Part B will include both an active-control (lotion base + 0.1% gentamicin) and a placebo control.
62609501|NCT04544943|EXPERIMENTAL|Open-Label|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa. The minimum % BSA dosed will be 3% BSA and the maximum will be 27% BSA for patients
62609502|NCT05604326|EXPERIMENTAL|Pathways Intervention|Twenty-four weeks of a manualized Naturalistic Developmental Behavioral Intervention (NDBI) parent-mediated early autism intervention that uses a coaching model.
62609503|NCT05604326|ACTIVE_COMPARATOR|Parent Education Intervention (PEI)|Twenty-four weeks of individual caregiver training without the child being present.
62609504|NCT04072731||thyroid cancer|the thyroid cancer was determined by the the Pathology Department based on the pathological evidence.
62609505|NCT04072731||the adjacent thyroid tissues|the adjacent thyroid tissues was collected from the tissue that 3 centimeters from the thyroid cancer.
62609506|NCT01643798|PLACEBO_COMPARATOR|Saline|Participants received intravenous saline immediately prior to sham and real rTMS of the left dorsolateral prefrontal cortex. The parameters of the stimulation paradigm are as follows: 10 Hz, 5 seconds on, 10 seconds off, 20 minutes, 4000 pulses).
62609507|NCT01643798|ACTIVE_COMPARATOR|Naloxone|Participants received intravenous naloxone (0.1mg/kg) immediately prior to sham and real rTMS of the left dorsolateral prefrontal cortex. The parameters of the stimulation paradigm are as follows: 10 Hz, 5 seconds on, 10 seconds off, 20 minutes, 4000 pulses).
62609508|NCT06132113|EXPERIMENTAL|Part A: BI 764532 low dose + carboplatin + etoposide|
62609509|NCT06132113|EXPERIMENTAL|Part A: BI 764532 medium dose + carboplatin + etoposide|
62609510|NCT06132113|EXPERIMENTAL|Part A: BI 764532 high dose + carboplatin + etoposide|
62609511|NCT06132113|EXPERIMENTAL|Part B: BI 764532 + carboplatin + etoposide|
62609512|NCT06132113|EXPERIMENTAL|Part B: BI 764532 + cisplatin + etoposide|
62251149|NCT06188819||Cryopreserved arterial allograft|Aortic infection treated by cryopreserved arterial allograft
62609513|NCT06291740|EXPERIMENTAL|Continuous nebulization|continuous nebulization using the MiniHEART-HiFlo® nebulizer containing Budesonide 1000 microgram/2 ml (3 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) and Normal saline 12 ml in the nebulizer chamber. Patients in this group will receive continuous aerosol therapy over a period of 1 hour at an oxygen flow rate of 8 L/min
62251150|NCT06188819||Rolled pericardium patch|Aortic infection treated by Pericardium patch rolled
62251151|NCT01375257|ACTIVE_COMPARATOR|Guideline treatment with parenteral antibiotics|Guideline treatment with parenteral antibiotics
62441024|NCT04370145|EXPERIMENTAL|severe cholangitis|Meropenem injection, iv. drip,20mg/Kg，Q8h; Teicoplanin injection, iv. drip,10mg/Kg,Qd; Tinidazole injection, iv. drip,20mg/Kg,Qd.
62441025|NCT04370145|ACTIVE_COMPARATOR|control group|Sulperazon, iv.,drip,100mg/Kg,Bid; Tinidazole injection, iv. drip,20mg/Kg,Qd
62609514|NCT06291740|ACTIVE_COMPARATOR|intermittent nebulization|intermittent nebulization using a nebulizer containing Budesonide 1000 microgram/2 ml (1 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) at an oxygen flow rate of 10 L/min every 20 minutes, thrice within 1 hour
62609515|NCT02607280|EXPERIMENTAL|DS-5565 group|DS-5565 15 mg (for moderate renal impairment) or 7.5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
62251152|NCT01375257|EXPERIMENTAL|Oral treatment with antibiotics|Oral treatment with antibiotics based on resistens pattern
62609516|NCT05703464|EXPERIMENTAL|Elobixibat|10mg Elobixibat administration for 4 weeks
62609517|NCT04693468|EXPERIMENTAL|Arm I (talazoparib, palbociclib)|Patients receive talazoparib PO QD on days 1-21 or 1-28 and palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion.
62609518|NCT04693468|EXPERIMENTAL|Arm II (talazoparib, axitinib)|Patients receive talazoparib PO QD on days 1-28 and axitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion.
62609519|NCT04693468|EXPERIMENTAL|Arm III (talazoparib, crizotinib)|Patients receive talazoparib PO QD on days 1-28 and crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion.
62251153|NCT01025596|EXPERIMENTAL|CYT107|
62441026|NCT04228302|EXPERIMENTAL|EC5026|Single Ascending Doses of oral EC5026
62441027|NCT04228302|PLACEBO_COMPARATOR|Placebo|Single doses of matching oral placebo
62609520|NCT06512883|EXPERIMENTAL|EGPA Cohort: Benralizumab|Participants with greater than or equal to (\>=) 35 kg weight will receive benralizumab dose-1 and participants with less than (\<) 35 kg weight will receive benralizumab dose-2 as SC injection Q4W during the 52-week treatment period. All participants, who complete the 52-week treatment period, will be offered the opportunity to continue into an extension period.
62609521|NCT01656187|EXPERIMENTAL|Memantine, Then Placebo|Participants first received Memantine 10 mg capsule twice a day for 24 weeks. After a washout period of 4 weeks, they then received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks.
62609522|NCT01656187|EXPERIMENTAL|Placebo, Then Memantine|Participants first received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks. After a washout period of 4 weeks, they then received Memantine 10 mg capsule twice a day for 24 weeks.
62832044|NCT03219723||Vonoprazan 20 mg|For adults, the following three-drug regimen will be administered orally at the same time twice daily for 7 days: 20 mg dose of vonoprazan, 750 mg (potency) dose of amoxicillin hydrate, and 200 mg (potency) dose of clarithromycin. The dose of clarithromycin may be increased as clinically warranted. However, dosage should not exceed 400 mg (potency)/dose twice daily. If H. pylori eradication with a three-drug regimen comprising vonoprazan or proton pump inhibitor + amoxicillin hydrate + clarithromycin has been unsuccessful, as an alternative treatment, the following three drugs will be administered orally twice daily for 7 days to adults: 20 mg dose of vonoprazan, 750 mg (potency) dose of amoxicillin hydrate, and 250 mg dose of metronidazole. Participants will receive interventions as part of routine medical care.
62251154|NCT05510921|NO_INTERVENTION|Control group|The control group will not receive any intervention
62251155|NCT05510921|EXPERIMENTAL|Minimalist music group|a live session of minimalist music piano piece
62251156|NCT05510921|EXPERIMENTAL|Minimalist music plus birdsongs group|a live session of minimalist music piano piece with the superposition of bird song sounds
62251157|NCT05629429|EXPERIMENTAL|Arm 1: olaparib treatment|Olaparib 300mg BID PO
62251158|NCT05629429|ACTIVE_COMPARATOR|Arm2: continuation of the chemotherapy|continuation of the current platinum based chemotherapy
62251159|NCT05479279|EXPERIMENTAL|Neck Stabilization Training Program|Patient education Tens Hot pack Cervical muscle stretching trigger/ tender point release postural re-education cranio-cervical isometrics training of intrascapular, shoulder and upper extremity musculature resistance training with theraband
62251160|NCT05479279|ACTIVE_COMPARATOR|Conventional physical therapy|Patient education Tens Hot pack Cervical muscle stretching trigger/ tender point release
62251161|NCT00517322|EXPERIMENTAL|1|treatment with ramipril
62251162|NCT00517322|EXPERIMENTAL|2|treatment with irbesartan
62609523|NCT03743480|NO_INTERVENTION|standard care|Patients in this arm will receive standard hematological care and palliative care on demand
62609524|NCT03743480|EXPERIMENTAL|early palliative care|early palliative care: patients in this arm will receive integrated palliative care
62251163|NCT02903251|EXPERIMENTAL|oxytocin|"intranasal oxytocin spray Day 1-3: Twice daily intranasal oxytocin spray administered by health personnel.~Day 3-30: Self-administered intranasal spray as needed, max thrice daily intranasal spray without oxytocin"
62441028|NCT02333409|ACTIVE_COMPARATOR|Electroacupuncture|A Hong Kong registered Chinese Medicine practitioner will give Electroacupuncture treatments. Patients will be treated in a comfortable prone position. Jiaji (Ex-B2) points form T8 to T12 bilaterally are chosen based on traditional Chinese medicine (TCM) theory and neurophysiologic basis of Jiaji points. After De Qi sensation is achieved, the handles of needles on homolateral T8-T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1 mA with a disperse-dense waveform. The needles remained for 30 min. The treatment was given twice weekly on week 1 and week 3.
62441029|NCT02333409|SHAM_COMPARATOR|Sham|For placebo acupuncture, sham placebo acupuncture needles (DongBang AcuPrime Acupuncture Inc., South Korea) will be used. Its validity and credibility have been well demonstrated. The needles with blunt tips are quickly put onto the same points used in the electroacupuncture group without inserting into the skin. The needles on homolateral T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
62441030|NCT01677455|EXPERIMENTAL|HER2+ breast cancer|
62609525|NCT00694720|EXPERIMENTAL|Dose Level 1|
62832045|NCT05623878|EXPERIMENTAL|68Ga-Anti-PSMA mAbs|
62832046|NCT05567783|EXPERIMENTAL|VIR-2482 (Dose 1)|
62832047|NCT05567783|EXPERIMENTAL|VIR-2482 (Dose 2)|
62832048|NCT05567783|PLACEBO_COMPARATOR|Placebo|
62832049|NCT00871975|EXPERIMENTAL|Urodynamics + Tetra|All patients were recruited to the same arm and receive Urodynamics testing as part of the routine diagnostic work-up, plus the Tetra-NIRS intervention.
62832050|NCT06129708|EXPERIMENTAL|Group (A) Aquatic Exercise Group|They participated in an aqua aerobic exercise program, 3 days per week, for 8 weeks
62251164|NCT02903251|PLACEBO_COMPARATOR|Placebo|"intranasal spray without oxytocin Day 1-3: Twice daily intranasal spray without oxytocin, administered by health personnel.~Day 3-30: Self-administered intranasal spray as needed, max thrice daily"
62251165|NCT03662672|EXPERIMENTAL|Rib-raising Intervention|We will do daily rib raising and lumbar release from the 5th thoracic vertebra to the 2nd lumbar vertebra for 2 minutes per side for rib raising and 2 minutes for lumbar release.
62441031|NCT01677455|EXPERIMENTAL|Triple negative breast cancer|Closed to enrollment
62441032|NCT01677455|EXPERIMENTAL|ER/PR+ Refractory to Prior Hormonal Treatment|
62441033|NCT01583387|OTHER|1= Intervention|
62441034|NCT01583387|OTHER|2= Control|
62609526|NCT00694720|EXPERIMENTAL|Dose Level 2|
62609527|NCT00694720|EXPERIMENTAL|Dose Level 3|
62251166|NCT03662672|SHAM_COMPARATOR|Sham Intervention|We will do daily sham intervention from the 5th thoracic vertebra to the 2nd lumbar vertebra where we place our hands under the ribs for 2 minutes per side and under the lumbar area for 2 minutes without applying any pressure (or applying pressure into the bed).
62251167|NCT01918423||Children of obese women from a RCT|Children born to obese women who were in the active intervention arm of the randomized controlled trial LiP. The lifestyle intervention during pregnancy consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
62251168|NCT01918423||Children of obese mothers from a RCT, controls|Children born to obese mothers who were in the control arm of the randomized controlled trial LiP.
62609528|NCT00694720|EXPERIMENTAL|Dose Level 4|
62441035|NCT06234852|ACTIVE_COMPARATOR|Glucocorticoid maintenance group|Maintenance of 5-mg of prednisolone daily over 24 weeks
62441036|NCT06234852|PLACEBO_COMPARATOR|Glucocorticoid withdrawal group|Gradual withdrawal of daily 5-mg prednisolone to daily 0-mg prednisolone over 20-24 weeks
62609529|NCT00694720|PLACEBO_COMPARATOR|Placebo|12 subjects: 3 subjects per dose level
62609530|NCT03398239|ACTIVE_COMPARATOR|BPAP ST/T|Non-invasive Ventilation with BPAP ST/T mode
62609531|NCT03398239|EXPERIMENTAL|AVAPS|Non-invasive Ventilation with AVAPS mode
62609532|NCT03284112|PLACEBO_COMPARATOR|Control|School population without the Old SCHOOL Hip-Hop program, but with the My Plate program.
62609533|NCT03284112|EXPERIMENTAL|Intervention|School population with the Old SCHOOL Hip-Hop program.
62609534|NCT04267159|ACTIVE_COMPARATOR|Conventional treatment by acute cardioversion|Participants in the conventional treatment arm will be returned to sinus rhythm in the emergency department within 48 hours of symptom onset unless they convert to sinus rhythm spontaneously.
62609535|NCT04267159|EXPERIMENTAL|Elective treatment by delayed cardioversion|Participants in the elective treatment arm will be returned to sinus rhythm in an out-patient clinic approximately one week after randomizatio unless they convert to sinus rhythm spontaneously.
62832051|NCT06129708|EXPERIMENTAL|Group (B) Aerobic Exercise Group|They participated in an aerobic exercise program on a treadmill, 3 days per week, for 8 weeks.
62832052|NCT02864290|EXPERIMENTAL|Dose Escalation of ASP1235 (AGS62P1) Schedule A|Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion once every three weeks (Q3W) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose. A cycle is 21 days.
62832053|NCT02864290|EXPERIMENTAL|Dose Escalation of ASP1235 (AGS62P1) Schedule B|Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion every other week of a 4-week cycle (Q2W) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose. A cycle is 28 days.
62832054|NCT02864290|EXPERIMENTAL|Dose Expansion of ASP1235 (AGS62P1) Schedule A|Once the maximum tolerated dose (MTD) or recommended Phase 2 dose has been determined, an expansion cohort of up to 25 subjects may be enrolled. Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion once every three weeks (Q3W).
62049049|NCT02604290|EXPERIMENTAL|Kinesio Taping method|"The tape is applied depending on the physical examination:~* Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.~* Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.~* Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers."
62609536|NCT06628388|ACTIVE_COMPARATOR|Minimal intervention|Participants allocated to the control group condition will be given minimal intervention in standard practices at baseline and 3-month. It consist of general health education and advice, where the health information is open resources available for the public. No risk-stratified services nor active referral will be conducted by nurse until 6-month assessment is completed. After that, they will immediately receive intervention based on their 6-month assessment, and booster interventions at 7-month contact and 12-month follow-up.
62832055|NCT02864290|EXPERIMENTAL|Dose Expansion of ASP1235 (AGS62P1) Schedule B|Once the maximum tolerated dose (MTD) or recommended Phase 2 dose has been determined, an expansion cohort of up to 25 subjects may be enrolled. Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion every other week of a 4-week cycle (Q2W).
62832056|NCT02864290|EXPERIMENTAL|Dose Escalation of ASP1235 (AGS62P1) Schedule C|Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion once weekly for three weeks of a 4-week cycle to determine the MTD or recommended Phase 2 dose. A cycle is 28 days.
62832057|NCT02864290|EXPERIMENTAL|Dose Expansion of ASP1235 (AGS62P1) Schedule C|Once the MTD or recommended Phase 2 dose has been determined, an expansion cohort of up to 25 subjects may be enrolled. Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion once weekly for three weeks pf a 4-week cycle.
62832058|NCT04491318||Experimental group|Hemophilic arthropathy patients who will not receive any intervention. The dependent variables (frequency of hemarthrosis, pain, joint state and range of movement) in the joints will be evaluated: elbows, knees and ankles.
62832059|NCT04668755|ACTIVE_COMPARATOR|Charcot Restraint Orthotic Walker 3d printed sole|the group fit with Charcot Restraint Orthotic Walker 3d printed sole for 12 week. the protocol of gait analysis testing starts with a reacclimation period during which the subject walked usual freely walking across the path for a duration of four minutes and then the testing session data collection done by four acceptable force platform strikes for the feet fitted with the CROW.
62832060|NCT04668755|ACTIVE_COMPARATOR|Generic Charcot Restraint orthotic walker|the group fit with Generic Charcot Restraint Orthotic Walker for 12 week.the protocol of gait analysis testing starts with a reacclimation period during which the subject walked usual freely walking across the path for a duration of four minutes and then the testing session data collection done by four acceptable force platform strikes for the feet fitted with the CROW.
62832061|NCT03854266|EXPERIMENTAL|Catheter directed thrombolysis|Low dose alteplase (4/8 milligram) will be infused over 2 hours locally in the pulmonary arteries at the site of the thrombus through an infusion catheter with sideholes (Unifuse, AngioDynamics, US)
62832062|NCT03854266|ACTIVE_COMPARATOR|Unfractionated heparin|Initial dose of unfractionated heparin is 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time is 1.5-2.3 times control value.
62832063|NCT02243995|EXPERIMENTAL|Physical training|
62832064|NCT06598176|EXPERIMENTAL|Sample collection|Women will collect one first-void urine sample and one vaginal self-sample at home, one day prior to a scheduled appointment at the hospital. During the hospital visit, an additional clinician collected cervical smear and a blood sample will be collected for the study. In case, the patient also undergoes a surgical intervention for their standard treatment plan, the tissue that is collected there, will also be used and analysed for our study. Cytology and histology results will be used as reference test.
62832065|NCT03109964|ACTIVE_COMPARATOR|Hemostasis with bipolar coagulation|Patients undergoing laparoscopic ovarian cystectomy with bipolar coagulation hemostasis.
62832066|NCT03109964|EXPERIMENTAL|Hemostasis with SURGIFLO|Patients undergoing laparoscopic ovarian cystectomy with SURGIFLO hemostasis.
62832067|NCT02917122|PLACEBO_COMPARATOR|sertraline + sham tDCS|Patients will take sham tDCS.
62832068|NCT02917122|ACTIVE_COMPARATOR|sertraline + active tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
62049050|NCT02604290|SHAM_COMPARATOR|Kinesio Taping sham|The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
62049051|NCT01254123|ACTIVE_COMPARATOR|Exenatide|
62049052|NCT01254123|PLACEBO_COMPARATOR|Placebo|
62049053|NCT02771444|EXPERIMENTAL|Tomo Assessment|Subjects will have a 4-view tomosynthesis examination with the study device.
62832069|NCT06380491|EXPERIMENTAL|Usual care for nocturnal non-dipping Blood Pressurem in OSA|1. Group of participants receives an intervention/treatment considered to be usual care
62049054|NCT03222193|EXPERIMENTAL|TRP group|Snoring subjects treated with the Tongue Right Positioner (TRP) medical device
62049055|NCT03084926|EXPERIMENTAL|MP0274|
62049056|NCT04922346||Healthy Pregnant|All volunteer pregnant women who were in the 2nd and 3rd trimesters (between 14-40 weeks) and who met the inclusion criteria in the study
62049057|NCT02672254||Shams|Samples without any type of treatment
62251169|NCT01918423||Children born to normal weight women|Children born to women with a pregestationally normal BMI and who were not part of a lifestyle intervention programme during pregnancy.
62251170|NCT03846999||Long-term breast cancer survivors|"Analyze comorbidities and patterns of use of health services. Describe the specific use of health services in primary care vs. specialized care.~Analyze comorbidities and patterns of use of health services by tumor characteristics."
62832070|NCT06380491|EXPERIMENTAL|Oral administration of 3 mg/day of melatonin for 30 days in non-dipping Blood Pressure in OSA|2. Group of participants receives oral Melatonin 3 mg/day during 30 days plus usual care
62832071|NCT05722392||Two-step Radical Prostatectomy|Two-step Radical Prostatectomy
62049058|NCT02672254||Samples with 1 treatment|These samples will be treated with only one therapy: chemical agents such as cisplatin or other metallic compounds, or with superficial radiotherapy. These results will help us understand the effectiveness of each treatment by itself on cSCC cells.
62251171|NCT03846999||Women without history of cancer|Analyze comorbidities and patterns of use of health services. Describe the specific use of health services in primary care vs. specialized care.
62251172|NCT01514097||Fractures reduced|
62251173|NCT01514097||Fractures splinted|
62251174|NCT01887951|ACTIVE_COMPARATOR|Tramadol|Tramadol HCL. Dosage form: Injection Strength: 50mg/ampoule Frequency: 1 time
62251175|NCT01887951|EXPERIMENTAL|Penthrox|Dosage form: Inhalation; Strength: 3ml/bottle; Frequency: Up to 6ml per day. Total weekly dose should not exceed 15ml.
62251176|NCT02960178|EXPERIMENTAL|Perturbation-based training|Participants will practice standing and walking activities while secured in an overhead harness attached to an overhead track. While practicing these tasks, the trainer will apply pushes and pulls to the harness at unexpected times, causing a reactive step to be practiced.
62251177|NCT02960178|ACTIVE_COMPARATOR|Conventional walking training|Participants will practice standing and walking activities while secured in an overhead harness attached to an overhead track. No external perturbations will be applied.
62251178|NCT00797836|EXPERIMENTAL|Quantiferon Gold|
62251179|NCT01471314||Spontaneous migraine|
62251180|NCT01358890|EXPERIMENTAL|B|Subjects will be supplied with low carbohydrate diet for 12 weeks.
62251181|NCT01358890|EXPERIMENTAL|A|Subjects will be supplied with calories restricted diet for 12 weeks
62609537|NCT06628388|EXPERIMENTAL|Nurse-led Risk-based 5As Intervention Arm|Participants allocated to the intervention condition will receive the nurse-led 5As model intervention at baseline, 1- and 3-month boosters, and 6- and 12-month follow-ups. The current model includes risk assessments and stratification, general health education booklet, consultations and active referrals based on personal risk stratification at baseline and 3-month booster, with additional booster session at 1-month, and follow-up sessions at 6- and 12-month from baseline. For participants with high risk of any target health conditions at baseline and 3-month booster, medical referral and service utilization (e.g., GPs/network doctors/specialist consultation at health centres/hospitals/clinics, screening, therapies, corresponding District Health Centre schemes, etc.) will be arranged at the visits. Such medical resource utilization among participants will be encouraged and motivated at 1-month booster session.
62832072|NCT05682716|EXPERIMENTAL|Intervention group|Controlled low central venous pressure (CLCVP) technology
62251182|NCT06465251|EXPERIMENTAL|Home-based CIMT|Participants and their families will be required to attend clinic to practice 3 times (Monday, Wednesday and Friday) during the first week, 2 times (Monday and Friday) during the second week and once (Monday) during the 3rd week under the supervision of a trained research assistant. They will be allowed to practice exclusively at home during the 4th week under the supervision of their family members.
62441037|NCT03369756|OTHER|Prontosan Solution and Gel|Treatment with Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel over 4 week period
62049059|NCT02672254||Samples with 2 treatments|These samples will be treated with both, chemical agents followed by superficial radiotherapy. These results will provide us information concerning the effectiveness of both treatments, wich is expected to be enhanced by the concomitant effects.
62441038|NCT05485428|EXPERIMENTAL|Exercise|High-intensity interval training plus usual care
62441039|NCT05485428|NO_INTERVENTION|Usual care|Usual care / treatment. Usual physical activity.
62441040|NCT01706198|EXPERIMENTAL|FF/VI|fluticasone furoate (FF) + vilanterol (VI) once daily via a Novel Dry Powder Inhaler
62441041|NCT01706198|ACTIVE_COMPARATOR|ICS or ICS/LABA maintenance therapy|inhaled corticosteroid (ICS) alone or in combination with a long acting beta2-agonist (LABA)
62441042|NCT02217722|EXPERIMENTAL|Ulcerative Colitis Diet counseling|Patients will receive a structured novel diet termed the UCD for 6 weeks. . patients that completed induction phase with remission(PUCAI\<10) will be asked if they are willing to adhere to the UCD for an additional 20 weeks.
62832073|NCT05682716|NO_INTERVENTION|control group|
62832074|NCT06249802|EXPERIMENTAL|Nebivolol arm|Patients randomly assigned to receive active treatment with escalating doses of nebivolol.
62049060|NCT05907382|EXPERIMENTAL|JMKX003002 SAD experimental group|Participants will be randomized into 5 cohorts to receive single oral dose of JMKX003002 on Day 1. The doses in each cohort will be escalated based on the safety and pharmacokinetics (PK) / Pharmacodynamics (PD) data of the previous cohort.
62049061|NCT05907382|EXPERIMENTAL|JMKX003002 MAD experimental group|Participants will be randomized into 2 cohorts to receive orally twice -daily of JMKX003002 for 7 consecutive days. The second cohort will be escalated based on the safety and pharmacokinetics (PK)/ Pharmacodynamics (PD) data of the previous cohort.
62441043|NCT02217722|EXPERIMENTAL|Antibiotic Treatment|Patients failing to enter or maintain remission by 6 weeks, or with worsening disease at any time after week 2 will be considered failures on an intention to treat basis. Eligible patients at this time at aged 10 or above may receive a 14 day antibiotic course with Doxycycline, amoxicillin and metronidazole.In addition to the description above children who refused to UCD or with low adherence to UCD may be enrolled directly to this arm.
62441044|NCT04066179|EXPERIMENTAL|Prednisolone+G-CSF|Prednisolone 40 mg/day for initial 7 days G-CSF300 microgram daily for 7 days
62441045|NCT04066179|ACTIVE_COMPARATOR|Prednisolone|Prednisolone 40 mg/day for 7 days
62441046|NCT04066179|EXPERIMENTAL|Granulocytes-Colony Stimulating Factor|Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days
62251183|NCT06465251|EXPERIMENTAL|Clinic-based CIMT|Participants in both groups will perform 5 tasks with the affected upper limb, each 100 times, making it 500 repetitions in total within a duration of 2 hours every day, five days a week for 4 weeks at home and in the clinic respectively. Details of the tasks to be performed are presented in table 1. We chose 2 hours because, patients with stroke can perform about 300 repetitions of tasks practice within one hour (Birkinmeier et al., 2014). Similarly, we chose 500 repetitions because the number of repetitions of tasks practice required for motor recovery ranges between 300 and 600 repetitions per day
62251184|NCT06465251|PLACEBO_COMPARATOR|Control|Participants will attend 45 minutes health talk provided by a research assistant twice in a week (Mondays and Fridays) in the clinic for 4 weeks. They will receive each talk in either a group of 3 or 5 patients. Similar control intervention was used in previous study
62251185|NCT04612036||Journey II Bi-Cruciate Stabilized|Subjects who have received a Journey II Total Knee Arthroplasty with both the ACL and PCL resected
62832075|NCT06249802|PLACEBO_COMPARATOR|Placebo arm|Patients randomly assigned to receive matching placebo tablets.
62441047|NCT04224779|EXPERIMENTAL|Tumors and blood collection|"For all the patients included in the study :~* Blood samples will be collected at different times T1 (Baseline), T2 (1 or 2 weeks after the beginning of the treatment), T3 (3 or 4 weeks before the surgery) and T4 (1 month after the surgery).~* Tumors biopsy will be collected for some patients who will benefit from an initial biopsy in the course of his management care in our Institute (before the surgery).~In parallel to this biological collection, imaging and clinical data will be entered into a database treatment."
62441048|NCT02523365|EXPERIMENTAL|HepaSphere|cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
62441049|NCT02523365|PLACEBO_COMPARATOR|control|cervical carcinoma patients received traditional therapy
62832076|NCT01004068|EXPERIMENTAL|SET-diet plus clomiphene|Structured exercise program plus hypocaloric diet for two months and received one-cycle of clomiphene citrate for one cycle
62441050|NCT01525706|EXPERIMENTAL|Ethanol and Paclitaxel Injection|All patients will receive at least one treatment with alcohol and paclitaxel.
62441051|NCT02945462|EXPERIMENTAL|autologous mesenchymal stem cells|"Intervention:~Autologous bone marrow derived stem cells will be injected twice intracavernously to enrolled erectile dysfunction patients"
62609538|NCT06721637||Group A (n = 20): received core stability exercise trained three times a week for 8 weeks.|"1. Abdominal hollowing exercise:~   Woman was in crook lying position with feet flat on the treatment table. The therapist put his two thumbs on the anterior superior iliac spines then, asked the woman to contract the abdominal muscle, hold the contraction for 10 seconds, then, asked her to relax for 10 seconds \[29\].~2. Quadruped abdominal hollowing exercise:~   Woman was in a quadruped position on the treatment plinth with her hips, knees and shoulders flexed 90 degrees, the spine parallal to the table. The woman instructed to inhale allowing her abdomen to drop, as she exhale, she was pulling her abdominal toward her spine without moving her spine with holding for 10 seconds while maintaining her normal breathing patterns. Then asked the woman to relax for 10 seconds \[29\].~3. Bilateral knee raise exercise:~Woman was in crook lying position .She instructed to contract her lower abdomen while continuing to breathe in a normally. While maintaining the contraction"
62832077|NCT01004068|ACTIVE_COMPARATOR|Clomiphene citrate|One month of observation followed by one-cycle of clomiphene citrate therapy
62832078|NCT01004068|EXPERIMENTAL|SET plus diet|Lifestyle modifications for two months.
62832079|NCT01203969|EXPERIMENTAL|Single port laparoscopic surgery|
62832080|NCT01203969|ACTIVE_COMPARATOR|Conventional laparoscopic surgery|
62251186|NCT04612036||Journey II Cruciate Retaining|Subjects who have received a Journey II Total Knee Arthroplasty with only the ACL resected (therefore PCL retained)
62832081|NCT03378986||Unilateral THA|Patients who underwent to unilateral total hip arthroplasty
62251187|NCT04612036||Journey II Bi-Cruciate Retaining|Subjects who have received a Journey II Total Knee Arthroplasty with both the ACL and PCL retained
62251188|NCT02114268|EXPERIMENTAL|MEDI8897 300 milligram (mg) Intravenous (IV)|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
62832082|NCT03378986||Bilateral THA|Patients who underwent to simultaneous bilateral total hip arthroplasty
62832083|NCT04603599||benign endometrial changes|
62832084|NCT04603599||endometrial hyperplasia|
62832085|NCT04603599||endometrial cancer|
62832086|NCT05183035|ACTIVE_COMPARATOR|Arm A: Control Arm without Venetoclax|"During cycle 1 (each cycle is 42 days), participants will receive 30 mg/m\^2 of fludarabine followed by 2 g/m\^2 of cytarabine on Days 1-5. Gemtuzumab 3 mg/m\^2 will be given on Day 6 (only for participants with CD33 expression on leukemia blasts).~During cycle 2 participants will receive 30 mg/m\^2 of fludarabine followed by 2 g/m\^2 of cytarabine on Days 1-5.~After cycle 2 participants are assessed for hematopoietic stem cell transplantation (HSCT) or azacitidine maintenance therapy."
62832087|NCT05183035|EXPERIMENTAL|Arm B: Experimental Arm with Venetoclax|"During cycle 1 (each cycle is 42 days), participants will receive 300 mg adult dose equivalent of venetoclax once on Day 1 followed by 600 mg adult dose equivalent of venetoclax on Days 2-21. Participants will also receive 30 mg/m\^2 of fludarabine followed by 2 g/m\^2 of cytarabine on Days 8-12. Gemtuzumab 3 mg/m\^2 will be given on Day 13 (only for participants with CD33 expression on leukemia blasts).~During cycle 2, participants will receive 600 mg adult dose equivalent of venetoclax on Days 1-21. Participants will receive 30 mg/m\^2 of fludarabine followed by 2 g/m\^2 of cytarabine on Days 1-5.~After cycle 2 participants are assessed for HSCT or azacitidine maintenance therapy in combination with venetoclax."
62832088|NCT06587373||traumatic childbirth|
62832089|NCT06587373||non traumatic childbirth|
62832090|NCT05471466|ACTIVE_COMPARATOR|Diathermy- Electrosurgical Unit Cutting Settings|One half of the neck incision in each participant was made using diathermy (electrosurgical unit cutting settings at 15 watts Blend One mode).
62832091|NCT05471466|ACTIVE_COMPARATOR|Scalpel- Surgical Blade|One half of the neck incision in each participant was made using a scalpel (size 10 surgical blade).
62251189|NCT02114268|EXPERIMENTAL|MEDI8897 1000 mg IV|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
62251190|NCT02114268|EXPERIMENTAL|MEDI8897 3000 mg IV|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
62251191|NCT02114268|EXPERIMENTAL|MEDI8897 100 mg Intramuscular (IM)|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
62251192|NCT02114268|EXPERIMENTAL|MEDI8897 300 mg IM|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
62251193|NCT02114268|PLACEBO_COMPARATOR|Placebo|Participants received placebo on Day 1.
62251194|NCT00488111|ACTIVE_COMPARATOR|1|Participants were treated with normal Ringer's solution 15 min before the operation.
62251195|NCT00488111|ACTIVE_COMPARATOR|2|6% Starch was used 15min before operation followed epidural anesthesia.
62251196|NCT05147064|EXPERIMENTAL|group A|randomly allocated
62251197|NCT05147064|EXPERIMENTAL|group B|randomly allocated
62251198|NCT01873417|EXPERIMENTAL|Dimethyl Fumarate|120 mg DMF twice daily (BID) for the first 7 days and 240 mg DMF BID thereafter for 12 weeks of treatment. Participants will be instructed to take the DMF dose with food (with a meal or within 1 hour after a meal).
62609539|NCT06721637||Group B (n = 20): received whole body vibration trained three times a week for 8 weeks|The woman assumed a full squat position on a vibration platform. The apparatus was set at a frequency of 30 Hz, amplitude of 2 mm, and duration of 5 min. The women were instructed to remain in the squatting position with holding hand rail after turning on the vibration and to report any discomfort that might arise. At the end of 5 min, the vibration turned off automatically. Thereafter, the women took a 1-min rest. They were then asked to stand on the vibration platform for 5 min, with the same parameters as those used in the squatting position. Thus, the total time for the application of WBV in each session was 10 min
62609540|NCT06446349|EXPERIMENTAL|Brief motivational intervention|identification followed by a brief motivational intervention in pharmacies (BMI) based on the mobilisation of patients' psychosocial skills and the integration of tools to help reduce consumption of BZD/Z prescribed over the long term (≥ 6 months).
62251199|NCT00904631|EXPERIMENTAL|Treatment|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
62251200|NCT00344565|PLACEBO_COMPARATOR|Placebo|Placebo, was matched to modafinil up to 400 mg/day. Patients also receive motivational interviewing and Cognitive Behavioral Therapy-Relapse Prevention (CBT-RP)
62609541|NCT06446349|NO_INTERVENTION|Control|Standard of care in case of benzodiazepine prescription
62609542|NCT00829829|PLACEBO_COMPARATOR|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
62609543|NCT00829829|ACTIVE_COMPARATOR|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.
62251201|NCT00344565|ACTIVE_COMPARATOR|Modafinil|Modafinil (Active comparator). Patients received motivational interviewing and Cognitive Behavioral Therapy--relapse prevention (CBT-RP)
62251202|NCT01038804|EXPERIMENTAL|A. YM155 plus docetaxel|
62251203|NCT01038804|ACTIVE_COMPARATOR|B. docetaxel alone|
62251204|NCT05800340|EXPERIMENTAL|Toripalimab plus chemotherapy|3 cycles of neoadjuvant Toripalimab (240mg every 3 weeks) with nab-paclitaxel + carboplatin, or pemetrexed + carboplatin (decided by investigators; nab-paclitaxel 135 mg/m2, d1, 8 and carboplatin AUC 5, d1 every 3 weeks; pemetrexed, 500mg/m2 d1 every 3 weeks) will be administered before surgery, followed by optional adjuvant treatment including chemotherapy for 3-4 cycles or rare mutations-TKIs for up to 2 years or till disease progression or unacceptable toxicity.
62251205|NCT02221349|OTHER|oxalate liquid & gel plus SnF2 paste|Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Stannous fluoride paste, self applied
62251206|NCT02221349|OTHER|oxalate liquid & gel plus NaF paste|Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Sodium fluoride paste, self applied
62251207|NCT04158544||Checkpoint Inhibitors|Patients with metastatic melanoma receiving systemic therapy with checkpoint inhibitors
62609544|NCT00829829|ACTIVE_COMPARATOR|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
62609545|NCT03734900|PLACEBO_COMPARATOR|Saline injection|Sodium Chloride injection into the study knee joint every 4 weeks for a total of 3 injections
62251208|NCT04158544||Kinase Inhibitors|Patients with metastatic melanoma receiving systemic therapy with kinase inhibitors
62251209|NCT03378323|ACTIVE_COMPARATOR|Multiple injection local anesthetic|Ultrasound guided axillary plexus block with multiple injections of local anesthetic
62251210|NCT03378323|EXPERIMENTAL|Single injection local anesthetic|Ultrasound guided axillary plexus block with a single injection of local anesthetic
62251211|NCT04128345||SBN arm|We will evaluate the feasibility of using an integrated navigation system incorporating pre-operative MRI and intraoperative ultrasound images
62609546|NCT03734900|EXPERIMENTAL|PRP injection|PRP injection into the study knee joint every 4 weeks for a total of 3 injections
62609547|NCT03734900|EXPERIMENTAL|PL injection|PL injection into the study knee joint every 4 weeks for a total of 3 injections Platelet lysate is the product of nature activation from autologous platelet.
62609548|NCT05844150|EXPERIMENTAL|PM8002+Etoposide＋platinum|Subjects will be administered with PM8002 plus Etoposide and platinum via intravenously (IV) Q3W for 4 cycles, followed by PM8002 until progression or for a maximum of 2 years.
62609549|NCT05844150|ACTIVE_COMPARATOR|Atezolizumab+Etoposide＋platinum|Subjects will be administered with Atezolizumab plus Etoposide and platinum via intravenously (IV) Q3W for 4 cycles, followed by Atezolizumab until progression or for a maximum of 2 years.
62609550|NCT05961345|EXPERIMENTAL|early mobilization|The patients in the experimental group were mobilized at the 4th postoperative hour.
62609551|NCT05961345|NO_INTERVENTION|control group (late mobilization)|The patients in the control group were mobilized at the 6th hour as in the routine of the clinic.
62832092|NCT05929482|EXPERIMENTAL|Infección de Amor (Infectious Love)|71 Latinas will view four IA intervention episodes, one per week immediately after the baseline survey and orientation. Participants will receive an email to their preferred email address with a password to access to the episode on the IA's website: www.telenoveladeamor.com Each 10-minute episode can be watched more than once during the week and presents a situation with notable HIV risk and ways the characters avoided risk (e.g., condom use) or confronted consequences of poor practices (e.g., HIV infection). The one week time frame for each episode is needed to provide time to review and reflect about IA's content and modify HIV prevention behaviors. It will also allow Latinas to obtain information and support from the team and referral if needed. This time frame was effective to improve behaviors in previous studies.
62251212|NCT04349163||Caregivers|Physicians and nurses working at the Emergency Department, Intensive care Unit, infectious disease Department, Anaesthesiology.
62251213|NCT03092206|EXPERIMENTAL|Group 1|F/TAF ; oral; Dose: 25/200 mg; Frequency: QD
62251214|NCT03092206|EXPERIMENTAL|Group 2|Group 2: E/C/F/TAF; oral; Dose: 150/150/200/10 mg; Frequency: QD
62251215|NCT03092206|EXPERIMENTAL|Group 3|Group 3: R/F/TAF; oral; Dose: 25/200/25 mg; Frequency: QD
62609552|NCT06111872|EXPERIMENTAL|Ketamine - Midazolam arm|Initial IV Ketamine of 0.5mg/kg with IV Midazolam 0.02mg/kg given over 1 minute. If depth of sedation not adequate, to give another bolus of IV ketamine 0.25mg/kg after 2 minutes with IV Midazolam 0.01mg/kg. If depth of sedation not adequate, to give another bolus of IV Ketamine 0.25mg/kg after 2 minutes and IV Midazolam 0.01mg/kg. Failure of sedation: inadequate sedation for the intention to treat: patient will be arranged for MAC (monitored anaesthesia care) with anaesthesia team
62609553|NCT06111872|ACTIVE_COMPARATOR|Midazolam - Pethidine arm|Initial IV Midazolam 0.05mg/kg given over 1 minute with IV Pethidine 0.7mcg/kg. If depth of sedation not If adequate, to give another bolus of IV Midazolam 0.02mg/kg after 2 minutes and IV Pethidine 0.7mcg/kg. If depth of sedation not adequate, to give another bolus of IV Midazolam 0.02mg/kg after 2 minutes. Failure of sedation: inadequate sedation for the intention to treat: patient will be arranged for MAC (monitored anaesthesia care) with anaesthesia team.
62832093|NCT05929482|EXPERIMENTAL|Wait-listed|A wait-listed control group of 71 Latinas will receive IA in the same manner as the intervention group. Latinas will start watching the telenovela episodes 7 months after their baseline survey (after T3 survey). Latinas will be informed at recruitment of this group condition and the study randomization. During the waiting time, participants will be called on a monthly basis to encourage participation and refer to services if needed.
62832094|NCT03212742|EXPERIMENTAL|IMRT - Temozolomide - Olaparib|"The therapeutic regimen will be divided into 2 different periods:~* Radiotherapy period The patient will start IMRT (60Gy/30fr/6 weeks), TMZ(Temozolomide) chemotherapy (75mg/m²/day), and olaparib on the same day, on a Monday (day 1), within 6 weeks after surgery. The daily dose of TMZ (75 mg/m²) will be continued until the end of radiotherapy (6 weeks) and olaparib will be continued with the same dose until 4 weeks after the end of IMRT, as a single agent.~* Maintenance period TMZ will then be re-introduced 4 weeks after the end of IMRT at the dose of 150 mg/m2/day on days 1 to 5 every 28 days, for a total of 6 cycles. Concomitantly, olaparib will be daily given at the maintenance dose level up to confirmed disease progression or unacceptable toxicities.~We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously"
62049062|NCT05907382|EXPERIMENTAL|JMKX003002 FE experimental group|Participants will receive 3 Sequence regimens, with a washout period between treatments.
62609554|NCT00370097|EXPERIMENTAL|Subjects receiving HFA|Subjects in Session 1 will receive two inhalations of placebo HFA by meter-dose inhaler (MDI) twice daily and in Session 2 subjects will receive two inhalations of fluticasone propionate (FP) HFA MDI 44 mcg twice daily
62251216|NCT05221905|ACTIVE_COMPARATOR|Acute High-Intensity Exercise|Subjects will exercise at an intensity of 75% of the difference between the lactate threshold and VO2peak until 200 kcal are expended. Pre- and post-testing measures of vascular health will be completed at baseline (0 min) and again 60, 90, 120, 150, 180 min post-baseline testing, with exercise taking place during time points 0-60 min.
62609555|NCT01756508|EXPERIMENTAL|eculizumab|Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
62609556|NCT01756508|NO_INTERVENTION|control|No intervention will be applied instead eculizumab infusion
62832095|NCT05344313|EXPERIMENTAL|Sarcopenic patients|Ensure Plus Advance + resistance training (Prehab) Rehabilitation 2months post surgery
62049063|NCT05907382|PLACEBO_COMPARATOR|Placebo in Cohorts 1 to 5|Participants in Cohorts 1 to 5 will receive single oral dose of matching placebo on Day 1.
62251217|NCT05221905|ACTIVE_COMPARATOR|Acute Moderate-Intensity Exercise|Subjects will exercise at an intensity at the lactate threshold until 200 kcal are expended. Pre- and post-testing measures of vascular health will be completed at baseline (0 min) and again 60, 90, 120, 150, 180 min post-baseline testing, with exercise taking place during time points 0-60 min.
62251218|NCT05221905|PLACEBO_COMPARATOR|Non-Exercise Control|Measures of vascular health will be completed at baseline (0 min) and again 60, 90, 120, 150, 180 min post-baseline testing, without exercise taking place during time points 0-60 min.
62251219|NCT01178320||Simvastatin|Participants in the main AIM-HIGH study who are receiving simvastatin.
62609557|NCT04291495|EXPERIMENTAL|ANDROSITOL®TEST|At least 45 patients (13 for each category: low, medium, and high responders, + 15% of hypothetical drop-outs)
62609558|NCT06147089|NO_INTERVENTION|Control Group|The control group will receive no behavioral intervention and is instructed to continue with their normal sleep and nutritional habits.
62609559|NCT06147089|EXPERIMENTAL|Sleep intervention|The sleep intervention group will receive personalised sleep advice to promote better sleep during night shift periods. This intervention will last 3 months.
62049064|NCT05907382|PLACEBO_COMPARATOR|Placebo in 2 Cohorts|Participants in 2 Cohorts will receive orally twice -daily of matching placebo for 7 consecutive days.
62251220|NCT01178320||Simvastatin and Extended-Release Niacin|Participants in the main AIM-HIGH study who are receiving simvastatin and extended-release niacin.
62441052|NCT00551122|EXPERIMENTAL|Paclitaxel, gemcitabine, cisplatin, ifosfamide|"Day 1 Dexamethasone sodium phosphate 25mg I/V ) before Chlorphenamine 10mg I/V 30 - 60 mins ) paclitaxel Ranitidine 50mg I/V ) Paclitaxel - 175 mg m2 I/V in 500ml normal saline over 3 hours Gemcitabine - 1200mg per m2 I/V in 500ml normal saline over 30 mins Days 1-5 Cisplatin 20mg per m2 in 1 litre normal saline over 4 hours 2 litres normal saline over 16 hours, each litre containing 10 mmol MgSO4 and 20mmol KCL.~If urine output is insufficient (less than 600ml per 6 hours) or if excessive weight gain (greater than 2kg) 100 - 200ml 10% mannitol should be used. Alternatively, low dose frusemide (20mg I/V) can be used.~Days 2 - 6 Ifosfamide 1G per m2 + MESNA 0.5G m2 in 500 ml normal saline over 1 hour after the cisplatin infusion.~MESNA 0.5G m2 to be included in first 1 litre post cisplatin hydration bag Pegylated G-CSF will be given on day 7 as an alternative to daily G-CSF."
62832096|NCT05344313|NO_INTERVENTION|Healthy individuals|"To make meaningful comparison of muscle quality, 10 healthy non-sarcopenic individuals from the same age range would also be recruited and will undergo muscle quality assessment using MuscleSound® once upon recruitment so that an objective comparison for IMAT can be made with our sarcopenic study cohort. This is to aid the study team to identify normal IMAT vs an IMAT for sarcopenic individuals. Any improvement of our cohort's muscle quality can be benchmarked against healthy muscle quality so that more meaningful comparison can be made. This control group would not be undergoing surgery, nor will they have any ONS supplied."
62832097|NCT04652752|EXPERIMENTAL|CONNETTIVINA HI TECH patch|CONNETTIVINA HI TECH patch will be applied to eligible patients. CONNETTIVINA HI TECH will be renewed every two day, according with general principles of wound management
62832098|NCT03944577|EXPERIMENTAL|Evolocumab|Patients who will receive the study drug.
62832099|NCT02784548|EXPERIMENTAL|Virtual reality|Using a Virtual reality (VR) headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
62832100|NCT02338596|EXPERIMENTAL|Conventional stem|total hip replacement operated with conventional stem (Profile; DePuy, Leeds, United Kingdom)
62832101|NCT02338596|ACTIVE_COMPARATOR|Ultra-Short stem|total hip replacement operated with ultra-short stem (Proxima; DePuy, Leeds, United Kingdom)
62832102|NCT04958473|EXPERIMENTAL|Patients with advanced RCC|Patients with a diagnosis of kidney cancer (renal cell carcinoma, advanced or metastatic, previously treated or untreated)
62832103|NCT05874635|EXPERIMENTAL|Signos digital health app and CGM|For all consented participants, the Signos app will use CGM data to provide recommendations customized to users for promoting general health and wellness.
62832104|NCT06655064||Group 1: Newly Diagnosed|Patients who have been newly diagnosed with prostate cancer and have not received any prior treatment for prostate cancer and have undergone a 68Ga-PSMA-11 PET/CT imaging evaluation to evaluate potential spread of the disease.
62049065|NCT05159089|ACTIVE_COMPARATOR|Nordic Walking Group|Each group will be received 26 sessions of nordic walking. In each session, the intensity will be controlled and expected to be between 3 to 5 in the Borg scale adaptation. Patients will receive a schedule with all three-month sessions.
62049066|NCT05159089|EXPERIMENTAL|Physical activity base on SEM (Socioecological models)|The intervention group based on SEM will apply nordic walking in the same way as the Nordic Walking group. However, in this group, instructors will apply a SEM (instructors will not be the same as in the Nordic Walking group): in each session, the instructors in charge of the Nordic Walking will be also in charge to prescribe the PA.
62049067|NCT05159089|NO_INTERVENTION|Congrol group|Control group outcomes assessment will be the same as the intervention group. However, they will receive common health care professional advice. A common health care professional advice used to recommend patients to walk more and do more PA or physical exercise at the gym. Visits with doctors and nurses will be the same as the intervention group. The difference will be that at intervention group nurses will refer participants to the instructor's physiotherapist to promote PA throughout nordic walking and use the SEM to apply it.
62049068|NCT00173108|NO_INTERVENTION|Term group|
62251221|NCT00182832|EXPERIMENTAL|1|
62251222|NCT00182832|ACTIVE_COMPARATOR|2|
62049069|NCT00173108|NO_INTERVENTION|Usual care program group|
62049070|NCT00173108|EXPERIMENTAL|Clinic-based interveniton program group|
62049071|NCT00173108|EXPERIMENTAL|Home-based interveniton program group|
62251223|NCT01457391|EXPERIMENTAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a non-exposure based manual-guided individual therapy. CBT for PTSD consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Breathing retraining: A behavioral anxiety reduction skill; and 3) Cognitive restructuring: A cognitive approach and functional analysis of the link among emotions, cognitions and situations.
62251224|NCT01457391|ACTIVE_COMPARATOR|Individual Addiction Counseling|Individual Addiction Counseling (IAC) was adapted from the Individual Drug Counseling (IDC) manual used in the NIDA Cocaine Collaborative Study. IAC is a manual-guided treatment that focuses on substance use and history of use, consequences of use and denial, developing strategies for relapse prevention, and facilitation of connection with peer recovery support groups, specifically twelve step groups. The current adaptation of IAC modified the IDC manual by broadening the focus to include drugs other than cocaine, as well as alcohol.
62049072|NCT04274894|EXPERIMENTAL|AndroGel 1.62%|AndroGel 1.62% was applied topically once daily in the morning beginning at the Day 1 Visit after confirmed valid ambulatory blood pressure monitoring (ABPM) assessment and was applied at approximately the same time each day after that during the study, for approximately 16 weeks. The starting dose of AndroGel 1.62% was 40.5 mg of T (2 pump actuations, applied to the upper arms and shoulders) and was titrated up or down by 20.25 mg or remained the same as assessed by morning serum T levels at Weeks 2 and 4.
62049073|NCT01543243|EXPERIMENTAL|Group 1|"Group 1: immediate effects: T0, Stochastic resonance whole-body vibration A intervention, immediate T1 (one minute after Stochastic resonance whole-body vibration B intervention), 7 days wash-out period; T2, Stochastic resonance whole-body vibration intervention, immediate T3 (one minute after Stochastic resonance whole-body vibration intervention)~long term effect: T4, Stochastic resonance whole-body vibration A intervention over four weeks, three time a week;T5, 16 days wash-out period; T6, Stochastic resonance whole-body vibration B intervention over four weeks, three times week, T7"
62251225|NCT01457391|ACTIVE_COMPARATOR|Treatment-as-usual|Treatment-as-usual (TAU) is the typical intensive outpatient (IOP) treatment that the patient would receive ordinarily at the identified addiction treatment program. Each TAU service operates using the American Society of Addiction Medicine criteria for Level II Intensive Outpatient services: 9-12 hours per week; group and individual sessions focused on motivation to address substance use, education about the consequences of substance use on major life areas, education about the disease concept and brain changes associated with addiction, exposure to information about social and family relationships and recovery, and relapse prevention skills.
62251226|NCT04960540||impaired speech comprehension processing in ALS|Brain functional network mechanism of impaired speech comprehension processing in ALS
62832105|NCT06655064||Group 2: Previously Treated|Patients who have received previous treatment for prostate cancer and have and have undergone 68Ga-PSMA-11PET/CT imaging evaluation for suspected recurrence (demonstrated by elevated PSA levels).
62832106|NCT06655064||Group 3: RLT Candidates|Patients who have metastatic prostate cancer and undergone a 68Ga-PSMA-11 PET/CT imaging evaluation for the initiation of RLT.
62832107|NCT04588064|EXPERIMENTAL|18F-FDG PET/CT scan|Each subject receives a single intravenous injection of 18F-FDG, and undergo PET/CT imaging within the specified time.
62832108|NCT01454102|EXPERIMENTAL|Arm A: Nivolumab + Gemcitabine + Cisplatin|"Nivolumab solution intravenously every 3 weeks until progressive disease (PD) or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Gemcitabine solution intravenously on Day 1 and Day 8 of every cycle for 4 cycles~Cisplatin solution intravenously on Day 1 of each cycle for 4 cycles"
62832109|NCT01454102|EXPERIMENTAL|Arm B: Nivolumab + Pemetrexed + Cisplatin|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Pemetrexed solution intravenously on Day 1 of every cycle for 4 cycles~Cisplatin solution intravenously on Day 1 of each cycle for 4 cycles"
62832110|NCT01454102|EXPERIMENTAL|Arm C: Nivolumab + Paclitaxel + Carboplatin|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Paclitaxel solution intravenously on Day 1 of every cycle for 4 cycles~Carboplatin area under curve (AUC) 6 solution intravenously on Day 1 of every cycle for 4 cycles"
62832111|NCT01454102|EXPERIMENTAL|Arm D: Nivolumab + Bevacizumab maintenance|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Bevacizumab administered prior to intravenous infusion on Cycle 1 Day 1 followed by intravenous infusion every 3 weeks on Cycle 2 onwards and until PD or discontinuation due to toxicity"
62832112|NCT01454102|EXPERIMENTAL|Arm E: Nivolumab + Erlotinib|"Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Erlotinib tablet by mouth daily until PD or discontinuation due to toxicity"
62832113|NCT01454102|EXPERIMENTAL|Arm F: Nivolumab|Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered over 60 minutes
62832114|NCT01454102|EXPERIMENTAL|Arm G: Nivolumab + Ipilimumab|"In Squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered until PD or discontinuation due to toxicity"
62832115|NCT01454102|EXPERIMENTAL|Arm H: Nivolumab + Ipilimumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
62251227|NCT04960540||language use processing injury in ALS|Brain functional network mechanism of language use processing injury in ALS
62251228|NCT04960540||motor executive processing injury in ALS|Brain functional network mechanism of motor executive processing injury in ALS
62251229|NCT04960540||anguage cognitive impairment in ALS|Brain structural network mechanism of language cognitive impairment in ALS
62251230|NCT02715336|EXPERIMENTAL|Study group: High Responders|1000 units hCG
62251231|NCT02715336|NO_INTERVENTION|Control group: High Responders|1000 units hCG
62251232|NCT02715336|EXPERIMENTAL|Study group: Normal Responders|5000 units hCG
62251233|NCT02715336|NO_INTERVENTION|Control group: Normal Responders|5000 units hCG
62251234|NCT02715336|EXPERIMENTAL|Study group: Low Responders|10000 units hCG
62251235|NCT02715336|NO_INTERVENTION|Control group: Low Responders|10000 units hCG
62251236|NCT02874560||Schizophrenia|350 patients will be included in the study. The centers selection is planned with 100 hospital-based psychiatrists, in centers for preventive medicine (CMP) or in private settings. Each investigator should consecutively enroll patients fulfilling the selection criteria to participate in the study (mean expected number of participants per center is around 10).
62251237|NCT01925352|EXPERIMENTAL|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection in patients with ischemic heart disease into five left ventricular sites once.
62609560|NCT06147089|EXPERIMENTAL|Nutritional Intervention|The nutritional intervention group will receive personalised nutrition advice to promote better metabolic health during night shift periods. This intervention will last 3 months.
62609561|NCT03174288|EXPERIMENTAL|Exercise alone|24 weeks of exercise treatment
62609562|NCT03174288|EXPERIMENTAL|spironolactone alone|24 weeks of Spironolactone treatment
62609563|NCT03174288|EXPERIMENTAL|Exercise + Spironolactone|24 weeks of exercise + Spironolactone treatment
62609564|NCT01349933|EXPERIMENTAL|Treatment (Akt inhibitor MK2206)|Patients receive 200 mg Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62609565|NCT00792116|EXPERIMENTAL|Gum Chewing|
62609566|NCT00792116|NO_INTERVENTION|Non-gum chewing|
62609567|NCT04108949|EXPERIMENTAL|Tuning in to Kids|Eight weekly two-hour sessions delivered in groups of up to six parents.
62832116|NCT01454102|EXPERIMENTAL|Arm I: Nivolumab + Ipilimumab|"In squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
62832117|NCT01454102|EXPERIMENTAL|Arm J: Nivolumab + Ipilimumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
62251238|NCT00729378|EXPERIMENTAL|Exercise Intervention|Implementation of intervention program designed to provide skeletal loading through high impact activities. All activities performed by subjects in exercise intervention arm will be assessed by physical activity questionnaire and use of pedometer. Have baseline anthropometric measurements, total body DXA scans and peripheral quantitative computed tomography (pQCT) scans of the tibia and femur.
62251239|NCT00729378|NO_INTERVENTION|Control|Participants in this arm will not take part in exercise intervention. All activities performed by subjects in control arm will be assessed by physical activity questionnaire and use of pedometer. Have baseline anthropometric measurements, total body DXA scans and peripheral quantitative computed tomography (pQCT) scans of the tibia and femur.
62441053|NCT06544486|EXPERIMENTAL|Device: Hybrid Glass-ionomer Cement (Equia Forte HT)|The material in capsule form was placed in the mixer (Ultramat 2, SDI, Australia) and mixed for 10 seconds, and applied to the cavity in a single step. The restorative material was polymerized for 20 seconds using an LED light device (VALO, Ultradent, Utah, USA). Equia Forte Coat was applied and polymerized for 20 seconds.
62441054|NCT06544486|EXPERIMENTAL|Device: Resin-Modified Glass-ionomer Cement (Fuji II LC)|The material in capsule form was mixed in the mixer (Ultramat 2, SDI, Australia) for 10 seconds, and applied to the cavity in a single step. Polymerization was achieved using an LED light device (VALO, Ultradent, Utah, USA) for 20 seconds.
62609568|NCT04108949|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual, may consist of any psychosocial intervention the therapist sees fit, which is the type of intervention the participants ordinarily receives in the participating clinics. No limit on number of sessions or format of delivery.
62609569|NCT05629767||Patients with ASCVD|Patients with ASCVD on statins and LDL-C more than 70 mg/dl
62609570|NCT01160835|EXPERIMENTAL|Quadriceps-sparing total knee arthroplasty|Quadriceps-sparing arthrotomy with side-cutting instruments
62609571|NCT01160835|ACTIVE_COMPARATOR|Medial parapatellar total knee arthroplasty|Medial parapatellar arthrotomy with front-cutting instruments
62609572|NCT02634710|EXPERIMENTAL|Hypofractionated Radiation Therapy|Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given every other day. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
62609573|NCT00524173|ACTIVE_COMPARATOR|Tenofovir only|Tenofovir 300mg by mouth daily for 192 weeks
62609574|NCT00524173|EXPERIMENTAL|Tenofovir & emtricitabine|Tenofovir 300mg in combination with emtricitabine 200mg by mouth daily for 192 weeks
62609575|NCT06444425||Heart Failure|"Patients with stable heart failure were defined as those with structural heart disease and a history of heart failure episodes but no current symptoms or signs of heart failure after receiving anti-heart failure treatment during hospitalization, such as decreased exercise tolerance (dyspnea, fatigue), fluid retention, etc. Additionally, according to the 2024 Chinese guidelines for the diagnosis and treatment of heart failure consensus, patients eligible for this study will be classified based on ejection fraction into the following categories:~* Reduced ejection fraction heart failure (HFrEF): HFrEF is defined by LVEF \< 40%~* Preserved ejection fraction heart failure (HFpEF): HFpEF is defined by LVEF ≥ 50%~* Heart failure with mid-range ejection fraction (HFmrEF): HFmrEF refers to heart failure characterized by LVEF between 40% and 49%."
62609576|NCT06444425||Normal|There were no structural or functional abnormalities in the cardiac system, and no symptoms or signs of heart failure were observed. Alternatively, the patient has developed organic heart disease without exhibiting any symptoms or signs of heart failure.
62609577|NCT04156945|EXPERIMENTAL|Intervention I: behavioural intervention|Participants will receive the behavioural Intervention in addition to standard of care.
62609578|NCT04156945|EXPERIMENTAL|Intervention II: home-based testing intervention|Participants will receive the home-based testing intervention in addition to standard of care.
62609579|NCT04156945|EXPERIMENTAL|Intervention III: combined intervention|Participants will receive the behavioural intervention and the home-based testing intervention in addition to standard of care.
62609580|NCT05008393|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo orally once daily for 10 days.
62609581|NCT05008393|EXPERIMENTAL|PJS-539 Dose 1|Patients will receive PJS-539 dose 1 orally once daily for 10 days.
62609582|NCT05008393|EXPERIMENTAL|PJS-539 Dose 2|Patients will receive PJS-539 dose 2 orally once daily for 10 days.
62609583|NCT04230356|EXPERIMENTAL|VSTs to Prevent|VSTs are given through an IV infusion 21-30 days after transplant to see if the VSTs will help prevent a viral infection.
62609584|NCT04230356|EXPERIMENTAL|VSTs to Treat|VSTs will be given only if a viral infection develops.
62609585|NCT02893111|EXPERIMENTAL|Bortezomib (Velcade)|A proteasome inhibitor
62609586|NCT02706171|EXPERIMENTAL|A: pre-operative|"Radiation- CyberKnife:~35-40 Gy over 5 fractions~Surgery:~Surgical resection of sarcoma"
62609587|NCT02706171|EXPERIMENTAL|B: Post-operative|"Radiation- CyberKnife:~40 Gy over 5 fractions"
62609588|NCT02706171|EXPERIMENTAL|C: Non-resectable|"Radiation- CyberKnife:~50 Gy over 5 fractions"
62609589|NCT06533631||pMRI and 3T MRI|Participants will receive both a pMRI and high-field 3T MRI at a single study visit for the purpose of comparing WMH measurements against a gold standard (3T MRI).
62609590|NCT00394134|OTHER|Interview|Interviews to describe the sun exposure and sun protection practices of patients and their children.
62609591|NCT01881087|EXPERIMENTAL|Levo-7.5 mg|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 7.5 mg. Single Dose.
62609592|NCT01881087|EXPERIMENTAL|Levo-9.37|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 9.37 mg. Single Dose.
62832118|NCT01454102|EXPERIMENTAL|Arm K: Nivolumab|"In squamous histology subjects (NSCLC)~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered as switch maintenance therapy. A cycle is 2 weeks"
62832119|NCT01454102|EXPERIMENTAL|Arm L: Nivolumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered over 60 minutes as switch maintenance therapy. A cycle is 2 weeks"
62832120|NCT01454102|EXPERIMENTAL|Arm M: Nivolumab|"NSCLC subjects with untreated, asymptomatic brain metastases and have no evidence of cerebral edema~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered for up to an hour as monotherapy. A cycle is 2 weeks"
62251240|NCT01033552|EXPERIMENTAL|RDEB Mac|Recessive Dystrophic EB (RDEB) - Myeloablative conditioning (MAC) Participants receive Myeloablative Busulfan (targeting AUC 1000 umol/min), Fludarabine 75 mg/m2, and Cyclophosphamide 200 mg/kg
62251241|NCT01033552|EXPERIMENTAL|RDEB RIC|Recessive Dystrophic EB (RDEB) - Reduced Intensity Condition Participants received Fludarabine 500 mg/m2, Cyclosphosphamide 50 mg/kg, equine Anti-thymocyte globulin 90 mg/kg, and low dose total body irradiation (either 200 or 300 cGy)
62441055|NCT06544486|EXPERIMENTAL|Device: Bioactive Glass-Containing Alkasite (Cention N)|The material was mixed using a plastic spatula on a mixing pad or glass with a powder-to-liquid ratio of 1:1 until it reached a homogeneous consistency, which took approximately 45 -60 seconds. Then the material was applied to the cavity and allowed to set for its self-curing time of 4 and a half minutes.
62441056|NCT06544486|EXPERIMENTAL|Device: Zinc-Reinforced High-Viscosity Glass-ionomer Cement (ChemFil Rock)|The material in capsule form was placed in the mixer (Ultramat 2, SDI, Australia) and mixed for 12 seconds, and applied to the cavity in a single step. In addition to the 90-second working time, an additional 4 and a half minutes were allowed for the material to cure.
62441057|NCT04900233||Control group|
62441058|NCT04900233||Pandemic group|
62441059|NCT06161597|EXPERIMENTAL|Informational Support|Parents will be told that they have the option of contacting an informational support specialist any point while completing the program to address questions and discuss the program. Parents will be informed that their questions can be addressed via e-mail or alternatively they can schedule a time to talk with their coach via phone or Zoom. The informational support specialist will not initiate contact with parents in this condition.
62441060|NCT06161597|EXPERIMENTAL|Guidance Coaching|Parents will be informed that they have been assigned a guidance coach who will contact them via email to schedule 1-3 check-in meetings over the phone or via Zoom while they complete the online program. These meetings are structured to help establish parental goals for the program, offer emotional support, and help motivate parents to implement new parenting skills. During these contacts, coaches use motivational interviewing techniques to help promote and support behavioral change. These coaching contacts are designed to be brief and focused, and typically last for less than 30 minutes. Coach contacts are scheduled based on the parents' availability and interest, and additional coaching sessions can be requested by the parent at any point during the program.
62441061|NCT02888769|EXPERIMENTAL|Intervention-Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week.
62609593|NCT01881087|ACTIVE_COMPARATOR|Levo-11.25|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 11.25 mg. Single Dose.
62609594|NCT00555126|ACTIVE_COMPARATOR|Warming with Forced Air|Forced Air Warming
62609595|NCT00555126|EXPERIMENTAL|Endovascular Warming|Warming with Endovascular Catheter
62609596|NCT00711607|EXPERIMENTAL|1|Group 1: NOMAC-E2 (days 1-24 and day 35)
62609597|NCT00711607|PLACEBO_COMPARATOR|2|Group 2: NOMAC-E2 (days 1-24) followed by Placebo (day 35)
62609598|NCT06075810|EXPERIMENTAL|MBQ-167 oral capsule|A dose ranging from 10mg to 400mg BID following a standard 3+3 cohort design
62609599|NCT01724801|EXPERIMENTAL|icotinib|icotinib administered orally at a dose of 125 mg 3 times daily
62609600|NCT01724801|ACTIVE_COMPARATOR|Whole brain irradiation|Whole brain irradiation 30Gy/3Gy/10 fractions plus concurrent or sequential chemotherapy for 4-6 cycles
62609601|NCT03006068|EXPERIMENTAL|Participants receiving Upadacitinib (ABT-494) Dose A|The participants in this arm will receive Upadacitinib (ABT-494) dose A.
62609602|NCT03006068|EXPERIMENTAL|Participants receiving Upadacitinib (ABT-494) Dose B|The participants in this arm will receive Upadacitinib (ABT-494) dose B.
62251242|NCT01033552|EXPERIMENTAL|JEB MAC|Junctional EB (JEB) - Myeloablative conditioning (MAC) Participants receive Myeloablative Busulfan (targeting AUC 1000 umol/min), Fludarabine 75 mg/m2, and Cyclophosphamide 200 mg/kg
62609603|NCT03006068|EXPERIMENTAL|Participants receiving Upadacitinib (ABT-494) Dose C|The participants in this arm will receive Upadacitinib (ABT-494) dose C.
62609604|NCT03006068|EXPERIMENTAL|Participants receiving Placebo|The participants in this arm will receive placebo until study is unblinded.
62609605|NCT03006068|EXPERIMENTAL|Participants receiving Upadacitinib (ABT-494) Dose A or Dose B|The participants in this arm will receive Upadacitinib (ABT-494) dose A or dose B.
62609606|NCT00667186|ACTIVE_COMPARATOR|Targeted Screening|"Targeted Screening~Participants approached at ED for voluntary HIV counseling and testing based on risk for HIV"
62609607|NCT00667186|ACTIVE_COMPARATOR|Routine Screening|"Routine Screening~Participants approached at ED for voluntary HIV counseling and testing regardless of established risk according to age criteria"
62609608|NCT00752869|PLACEBO_COMPARATOR|B|This group will meet the same inclusion and exclusion criteria as the group receiving the study drug
62609609|NCT00752869|ACTIVE_COMPARATOR|A|This arm will receive the active medication dutasteride
62609610|NCT06731166|EXPERIMENTAL|Videomonitoring Group|Videomonitoring by cardiovascular nursing
62609611|NCT06731166|NO_INTERVENTION|Voice call group|Voice call by cardiovascular nurses
62609612|NCT04652700|EXPERIMENTAL|Islatravir (ISL) Once Monthly (QM) Group|Participants receive 60 mg tablet of ISL QM, orally plus Placebo to Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) tablet once daily (QD) or Placebo to Emtricitabine/Tenofovir Alafenamide (FTC/TAF) tablet QD, orally for up to 24 months of treatment duration.
62609613|NCT04652700|ACTIVE_COMPARATOR|FTC/TDF or FTC/TAF QD Group|Participants receive 200/245 mg or 200/300 mg of FTC/TDF combination tablet, QD, orally or 200/25 mg of FTC/TAF combination tablet, QD, orally at investigator's discretion plus Placebo to ISL tablet QM, orally for up to 24 months of treatment duration.
62609614|NCT01594398|EXPERIMENTAL|entinostat C1D1 fed|Entinostat: Beginning C1D1 fed; C1D15 fasted. Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd. Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
62609615|NCT01594398|EXPERIMENTAL|entinostat C1D1 fasted|Entinostat: Beginning C1D1 fasted; C1D15 fed. Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd. Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
62251243|NCT01033552|EXPERIMENTAL|JEB RIC|Junctional EB (JEB) - Reduced Intensity Condition Participants received Fludarabine 500 mg/m2, Cyclosphosphamide 50 mg/kg, equine Anti-thymocyte globulin 90 mg/kg, and low dose total body irradiation (either 200 or 300 cGy)
62609616|NCT05853211||Clear aligner|Patient with class II malocclusion, treated with class II elastics on aligners
62609617|NCT05853211||Fixed appliance|Patient with class II malocclusion, treated with class II elastics on fixed appliance
62609618|NCT05216458|EXPERIMENTAL|Control|Households in the control group did not receive any messages during the intervention period from June 2021 to August 2021
62609619|NCT05216458|EXPERIMENTAL|Generic Outreach|"Households in the generic outreach group were assigned to receive a letter and two email reminders in June 2021 and thereafter received the standard messages Covered California sends to prospective enrollees, which explain that nearly all Covered California members get subsidies to pay for health insurance and encourage them to explore their plan options using an online Shop \& Compare tool.~For the generic arm, the outreach materials described new financial assistance under the American Rescue Plan and noted the availability of plans as low as $1/month."
62609620|NCT05216458|EXPERIMENTAL|Personalized Outreach|"Households in the personalized outreach group were assigned to receive a letter and two email reminders in June 2021 and thereafter received the standard messages Covered California sends to prospective enrollees.~For the personalized arm, the outreach explicitly informed the household that they were eligible for a $1/month CSR Silver 94 plan and described the benefits this plan confers. The outreach materials for the personalized group were not only designed to increase enrollment, but also to simplify the search process by providing households with a clear recommendation to pick a CSR Silver plan; this included highlighting the low out-of-pocket costs these plans provide when accessing care, a screenshot of what the plan would look like when they entered the shopping portal and peer comparison language that noted 9 out of 10 consumers like them choose CSR Silver plans"
62251244|NCT00263029|EXPERIMENTAL|1|
62609621|NCT04853108||Remote Monitoring of COVID-19|Patients with COVID-19 who completed acute clinical monitoring of at least 30 days from symptom onset or positive COVID-19 test.
62609622|NCT00893906|EXPERIMENTAL|TIV|Children living in villages randomized to influenza vaccine
62609623|NCT00893906|EXPERIMENTAL|IPV|Children living in villages randomized to polio vaccine
62251245|NCT00585611|EXPERIMENTAL|Atorvastatin|Heart failure patients assigned to atorvastatin
62251246|NCT00585611|PLACEBO_COMPARATOR|2|
62049074|NCT01543243|EXPERIMENTAL|Group 2|"Group 2: immediate effect: T0, Stochastic resonance whole-body vibration B intervention, immediate T1 (one minute after intervention), 7 days wash-out period; T2, Stochastic resonance whole-body vibration A intervention, immediate T3 (one minute after intervention)~Long term effect: T4, Stochastic resonance whole-body vibration B intervention over four weeks, three time a week;T5, 16 days wash-out period;T6, Stochastic resonance whole-body vibration A intervention over four weeks, three times week, T7"
62251247|NCT02650999|EXPERIMENTAL|Pembrolizumab|Single arm, pembrolizumab 200mg IV every 3 weeks until progression/toxicity
62049075|NCT00346021|EXPERIMENTAL|Sun Protection Intervention|School based sun protection education, provision of free hats.
62251248|NCT01688284|ACTIVE_COMPARATOR|No treatment|patients with recurrent miscarriages
62441062|NCT02888769|NO_INTERVENTION|Control|Participants in the control group will receive 2 thank-you messages per month and undertake routine clinical practice.
62609624|NCT06731621|EXPERIMENTAL|Open-label|"Safety Dosing Session (V3): 10mg of psilocybin + therapy + safety evaluations~Active Treatment Session (V4): 25mg of psilocybin + therapy + safety evaluations"
62609625|NCT06221813|EXPERIMENTAL|Cohort 1 (first 60 subjects) PHV02 high dose|
62609626|NCT06221813|EXPERIMENTAL|Cohort 1 (first 60 subjects) PHV02 medium dose|
62609627|NCT06221813|EXPERIMENTAL|Cohort 1 (first 60 subjects) PHV02 low dose|
62609628|NCT06221813|PLACEBO_COMPARATOR|Cohort 1 (first 60 subjects) Placebo|
62609629|NCT06221813|EXPERIMENTAL|Cohort 2 (next 60 subjects) PHV02 high dose|
62832121|NCT01454102|EXPERIMENTAL|Arm N: Nivolumab + Ipilimumab|"In subjects with any histology (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
62832122|NCT01454102|EXPERIMENTAL|Arm O: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
62832123|NCT01454102|EXPERIMENTAL|Arm P: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
62832124|NCT01454102|EXPERIMENTAL|Arm Q: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
62832125|NCT01454102|EXPERIMENTAL|Arm R: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
62832126|NCT01454102|EXPERIMENTAL|Arm S: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
62832127|NCT04663009||Mechanical chest compression|Patients recieving LDB CPR
62832128|NCT04663009||Manual chest compressions|Patients recieving manual CPR
62609630|NCT06221813|EXPERIMENTAL|Cohort 2 (next 60 subjects) PHV02 medium dose|
62609631|NCT06221813|EXPERIMENTAL|Cohort 2 (next 60 subjects) PHV02 low dose|
62832129|NCT04195763||Participants with Pediatric-onset HPP|Adult participants diagnosed with pediatric-onset HPP, newly prescribed treatment with asfotase alfa, and registered in the patient support program managed by OneSource.
62049076|NCT00346021|NO_INTERVENTION|Control arm|Usual sun protection practices
62049077|NCT04838990|ACTIVE_COMPARATOR|conventional visit|Regular outpatient visit
62049078|NCT04838990|EXPERIMENTAL|phone visit|Remote visit via phone
62049079|NCT04838990|EXPERIMENTAL|video visit|Remote visit via videochat
62049080|NCT06449131|OTHER|patients referred to the cardiac surgery clinic|This clinical trial focused on patients referred to the cardiac surgery clinic of Imam Reza Hospital in Mashhad 2023 who were diagnosed with unilateral or bilateral pleural effusion resistant to conservative management.
62049081|NCT00642187|EXPERIMENTAL|1|Pulmicort
62049082|NCT00642187|PLACEBO_COMPARATOR|2|Placebo
62251249|NCT01688284|ACTIVE_COMPARATOR|OFFICE HYSTEROSCOPY|Office hysteroscopic endometrial biopsy at the luteal phase of the menestrual cycle
62251250|NCT02546765|EXPERIMENTAL|IV acetaminophen & IV propofol|"20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU~1g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively"
62609632|NCT06221813|PLACEBO_COMPARATOR|Cohort 2 (next 60 subjects) Placebo|
62832130|NCT01287702|EXPERIMENTAL|Early feeding|patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
62832131|NCT01287702|ACTIVE_COMPARATOR|Dealyed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL.
62832132|NCT01523366|EXPERIMENTAL|Ticagrelor|
62832133|NCT01523366|ACTIVE_COMPARATOR|Clopidogrel|
62832134|NCT00525161|EXPERIMENTAL|Sorafenib & Endocrine Therapy|Sorafenib \& Endocrine Therapy
62832135|NCT03367988|EXPERIMENTAL|Opioid-free Anesthesia|Patients will receive no intraoperative narcotics as part of their anesthesia regimen
62832136|NCT03367988|ACTIVE_COMPARATOR|Opioid Anesthesia|Patients will receive intraoperative narcotics as part of their anesthesia regimen
62832137|NCT05494515|EXPERIMENTAL|the early swallowing rehabilitation program|swallowing problem eveluated by high resolution impedance manometry (HRIM). The early swallowing rehabilitation program based on the results of HRIM evaluation
62832138|NCT05494515|NO_INTERVENTION|the routine care group|patients recieve swallowing education
62832139|NCT06130488|EXPERIMENTAL|KMC implementation|KMC phases implemented as per the protocol
62832140|NCT00567814|ACTIVE_COMPARATOR|1|Lower dose combination of metyrapone with oxazepam
62609633|NCT06358430|EXPERIMENTAL|Dose Escalation + Dose Expansion|"Up to 5 dose levels of TROP2-CAR-NK cells will be tested in the Dose Escalation phase. Up to 12 participants maximum will be enrolled at any dose level, in groups of 3 participants at a time. The first group of participants will receive the lowest dose level.~Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the recommended dose of TROP2-CAR-NK cells is found. When that dose level is confirmed, the final group of 12 participants will be enrolled at that dose level."
62049083|NCT05605054|EXPERIMENTAL|Coach-guided|In person or phone call with an assigned Health Coach for about 1 hour per week for 12 weeks to complete the Health Literacy course, and with an assigned Service Navigator for 30 minutes per week for 12 weeks to address health and social service needs.
62049084|NCT05605054|ACTIVE_COMPARATOR|Self study|Self-guided printed or online version of the Health Literacy course (approximately 1 hour per week for 12 weeks) and comprehensive Service Navigation report with recommended referrals to services, providers, and contact information for service providers so that the participant can access these resources independently (i.e., without Navigator assistance).
62609634|NCT03383952|EXPERIMENTAL|ICAR19 CAR-T cells|Immunotherapy offers an extremely precise approach with the potential to eliminate cancer cells specifically. The newly designed CD19 targeted ICAR19 T cells can specifically kill CD19+ tumor cells. ICAR19 CART used the second generation of CART designation. In this study, the participants will receive several doses of autologous ICAR19 CAR-T cells and the investigators will determine the safety and therapeutic effects of these cells.
62049085|NCT06008574|EXPERIMENTAL|MBCR (mindfulness-based cancer survivorship group) (AmDTx-PCSP)|Patients randomized to the MBCR group will receive remote AmDTx-PCSP in the perioperative period (initiated at least 2 weeks before surgery). AmDTx-PCSP will be continued after surgery, for a minimum of 6 weeks total. AmDTx-PCSP is a step-by-step program including meditation training and other activities relevant for people living with cancer. The participants are asked to use AmDTx for about 20-30 minutes per day, at least 4 days per week, for 6 weeks. The participants are free to proceed at a faster pace and use AmDTx more than 20-30 per day if they choose. The first 3 modules of the program are required, and then the participant will be able to pick 3 additional modules based on topics that are most meaningful to them.
62251251|NCT02546765|EXPERIMENTAL|IV acetaminophen & IV dexmedetomidine|"A loading infusion of 0.5 - 1 µg/kg given over 10 minutes will be administered. After the loading infusion, a maintenance infusion of 0.1-1.4 µg/kg/hr will be initiated.~1 g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively"
62251252|NCT02546765|ACTIVE_COMPARATOR|IV propofol & placebo|20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl.
62609635|NCT03790605|EXPERIMENTAL|1% curcumin chip|Following routine full mouth scaling and root planing within 48 hours, a single chip of 1% curcumin will be placed locally within a single isolated periodontal pocket(the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip(second placement)
62832141|NCT00567814|ACTIVE_COMPARATOR|2|Higher dose combination of metyrapone with oxazepam
62832142|NCT00567814|PLACEBO_COMPARATOR|3|
62832143|NCT03126591|EXPERIMENTAL|15 milligrams per kilogram (mg/kg) Olaratumab + 200 milligrams (mg) Pembrolizumab - Dose Escalation|Participants received15 mg/kg Olaratumab administered IV on Day 1 and Day 8 in addition to 200 mg Pembrolizumab administered IV on Day 1 of a 21-day cycle.
62832144|NCT03126591|EXPERIMENTAL|20 mg/kg Olaratumab + 200 mg Pembrolizumab - Dose Escalation|Participants received 20 mg/kg Olaratumab administered IV on Day 1 and Day 8 in addition to 200 mg Pembrolizumab administered IV on Day 1 of a 21-day cycle.
62832145|NCT03126591|EXPERIMENTAL|20 mg/kg Olaratumab + 200 mg Pembrolizumab - Dose Expansion|Participants received 20 mg/kg Olaratumab administered IV on Day 1 and Day 8 in addition to 200 mg Pembrolizumab administered IV on Day 1 of a 21-day cycle.
62832146|NCT04396756|EXPERIMENTAL|Placebo|Placebo
62251253|NCT02546765|ACTIVE_COMPARATOR|IV dexmedetomidine & placebo|0.1-1.0 µg/kg/hour IV dexmedetomidine given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of i.v. acetaminophen at 100ml 0.9% NaCl.
62251254|NCT03950349||"Anterior cervical discectomy group"|
62251255|NCT03612362|EXPERIMENTAL|"Improved Injera Baking Biomass Stove"|"2750 eligible households with in 50 randomly selected clusters/Gotes are allocated into the improved Injera backing stove intervention arm."
62251256|NCT03612362|NO_INTERVENTION|Control arm|"Similarly 2750 eligible households with in 50 randomly selected clusters/Gotes will continue to use the traditional Injera baking biomass stove and will be used as control arm."
62251257|NCT04795297||recurrent BCC|recurrent BCC
62251258|NCT04795297||resected BCC|resected BCC
62251259|NCT03175354|EXPERIMENTAL|ALX-101 Gel 1.5% vs. ALX-101 Gel Vehicle|ALX-101 Gel 1.5% applied twice daily for 42 days to one treatment area and ALX-101 Gel Vehicle applied twice daily for 42 days to a second treatment area. Treatments will be randomly assigned to bilateral target areas.
62251260|NCT03175354|EXPERIMENTAL|ALX-101 Gel 5% vs. ALX-101 Gel Vehicle|ALX-101 Gel 5% applied twice daily for 42 days to one treatment area and ALX-101 Gel Vehicle applied twice daily for 42 days to a second treatment area. Treatments will be randomly assigned to bilateral target areas.
62832147|NCT04396756|EXPERIMENTAL|PLN-74809 Dose Level 1 (Part A)|PLN-74809 Dose Level 1 (Part A) - 4 weeks
62832148|NCT04396756|EXPERIMENTAL|PLN-74809 Dose Level 2 (Part A)|PLN-74809 Dose Level 2 (Part A) - 4 weeks
62049086|NCT06008574|ACTIVE_COMPARATOR|CI (control) group (AmDTx-2048)|"Patients randomized to the CI group will use a game called 2048, a cognitive training app, which is used as an control condition to control for expectancy and daily engagement. The participants will use AmDTx-2048 to engage in cognitive training with a puzzle game. The participants are asked to use AmDTx for about 20-30 minutes per day, at least 4 days per week, for 6 weeks. The participants are free to proceed at a faster pace and use AmDTx more than 20-30 per day if you choose. In this puzzle game, the participants will slide numbered tiles around a grid, matching tiles of the same value to combine them into one new tile displaying the sum of the previous two numbers. The goal is to match tiles until the sum of 2048 is reached on a single tile. There is no time limit."
62049087|NCT05717556|ACTIVE_COMPARATOR|single attempt catheterization|successful catheterization with a single attempt number
62049088|NCT05717556|ACTIVE_COMPARATOR|multiple attempts catheterization|successful catheterization after multiple attempts
62049089|NCT01265355|EXPERIMENTAL|Anti-rotavirus protein|
62251261|NCT05102578|NO_INTERVENTION|Standard Care|Usual care. Consultation with pharmacist with no decision aid tool.
62251262|NCT05102578|EXPERIMENTAL|Digital Decision Aid Tool|Consultation with pharmacist using the digital decision aid tool.
62832149|NCT04396756|EXPERIMENTAL|PLN-74809 Dose Level 2 (Part B)|PLN-74809 Dose Level 2 (Part B) - 12 weeks
62832150|NCT04396756|EXPERIMENTAL|PLN-74809 - Dose Level 3 (Part C)|PLN-74809 Dose Level 3 (Part C) - 12 weeks
62049090|NCT01265355|PLACEBO_COMPARATOR|Maltodextrin|
62049091|NCT01750606||pre-THA|Patients who are planned but have not yet received a total hip arthroplasty. No intervention or treatment - blood draw only to be used as a surrogate baseline for metal ion exposure.
62049092|NCT01750606||Metal-on-Poly|Patients receiving a Biomet metal on poly hip implanted between January 1, 2003 and December 31, 2006.
62049093|NCT01750606||M2a Magnum hip|Patients receiving a Biomet M2a Magnum hip implanted between January 1, 2006 and January 1, 2011.
62049094|NCT01750606||M2a38 hip|Patients receiving a Biomet metal on metal M2a38 hip implanted between January 1, 2004 and December 31, 2006.
62049095|NCT01750606||M2a Ringloc hip|Patients receiving a Biomet M2a Ringloc metal on metal hip implanted between January 1, 2002 and December 31, 2004.
62441063|NCT04996810|EXPERIMENTAL|PROTOXIN (Phase I/II)|PROTOXIN will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL).
62441064|NCT04996810|ACTIVE_COMPARATOR|Botox® (Phase II)|Botox® will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL).
62441065|NCT04657510||Proximal femur fracture AND COVID-19|Surgical treatment of femur fracture
62441066|NCT04657510||Proximal femur fracture NO COVID|Surgical treatment of femur fracture
62441067|NCT02749019|EXPERIMENTAL|68Ga-NOTA-BBN-RGD PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-BBN-RGD in one dose intravenously and underwent PET/CT scan 15-30 min later.
62441068|NCT01584778||Behçet patients|
62441069|NCT01584778||Healthy controls|
62049096|NCT01750606||M2a Taperloc hip|Patients receiving a Biomet M2a Taperloc metal on metal hip implanted between January 1, 2002 and December 31, 2003.
62049097|NCT04392466||Transtibial amputees|People who use transtibial prosthesis.
62049098|NCT04392466||Transfemoral amputees|People who use transfemoral prosthesis.
62049099|NCT04392466||Healty individuals|Healty individuals
62049100|NCT01410058||Nevirapine|HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder
62251263|NCT04667000|EXPERIMENTAL|lower extremities|the women's lower extremities will be heated with Forced Air Warming
62251264|NCT04667000|EXPERIMENTAL|upper extremities|the women's upper extremities will be heated with Forced Air Warming
62251265|NCT04667000|EXPERIMENTAL|whole body|the women's whole body will be heated with Forced Air Warming
62251266|NCT04667000|NO_INTERVENTION|control group|there is no intervention for this group
62251267|NCT04785170|EXPERIMENTAL|amino acid|"Dose: 1000 mg/day (500 mg/Capsule) Regimen: One capsule after breakfast \& one capsule after dinner to be taken with a glass of water.~Duration: 14 Days"
62441070|NCT01584778||Allergic rhinitis (diseased) controls|
62441071|NCT00006081|EXPERIMENTAL|Bryostatin-1 + Taxol|
62441072|NCT03982758|EXPERIMENTAL|isometric handgrip exercise|Isometric session with handgrip: 4 sets of 2 minutes of contractions sustained at 30% of CVM, for each arm. The time between sets and between arms will be 1 minute rest.
62832151|NCT04396756|EXPERIMENTAL|PLN-74809 - Dose Level 4 (Part C)|PLN-74809 Dose Level 4 (Part C) - 12 weeks
62609636|NCT03790605|PLACEBO_COMPARATOR|Placebo chip|Following routine full mouth scaling and root planing within 48 hours, a single placebo chip will be placed locally within a single isolated periodontal pocket (the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip (second placement)
62609637|NCT02181569||Treatment seeking participants with alcohol dependence|Treatment seeking individuals with alcohol dependence who are admitted into a 28-day inpatient treatment program.
62609638|NCT06730464||Patients with non ischemic cardiomyopathies|"Patients will only be recruited if they fulfill ALL the inclusion criteria:~1. Age \> 18 years.~2. Diagnosis of non-ischemic heart disease involving the left ventricle, irrespectively of LVEF. This diagnosis includes:~   1. Dilated cardiomyopathy (DCM)~  2. Non-dilated left ventricular cardiomyopathy (NDLVC)~  3. Post-myocarditis cardiomyopathy~3. Life expectancy of \> 1 year with a good functional status.~4. Signed informed consent.~5. CMR already performed or scheduled for clinical purpose (standard clinical practice).~6. No VA events at the time of the 1st LGE-CMR study."
62609639|NCT05677230|EXPERIMENTAL|Balloon Occluded/plug assisted Retrograde Transvenous Obliteration.|Balloon occluded/plug assisted retrograde transvenous obliteration will be done one time only.
62609640|NCT05677230|ACTIVE_COMPARATOR|Endoscopic Variceal Obturation|endoscopic variceal glue therapy will be done till obturation every 3 weekly.
62609641|NCT03715231|EXPERIMENTAL|Glaucoma & Glaucoma Suspect Patients|Patients with Glaucomatous optic neuropathy
62832152|NCT04396756|EXPERIMENTAL|PLN-74809 - Dose Level 5 (Part D)|PLN-74809 Dose Level 5 (Part D) - ≥ 24 weeks
62609642|NCT02671825|EXPERIMENTAL|PUR0217a|PUR0200 formulation 1
62609643|NCT02671825|EXPERIMENTAL|PUR0228a|PUR0200 formulation 2
62609644|NCT02671825|EXPERIMENTAL|PUR0228b|PUR0200 formulation 3
62609645|NCT02671825|EXPERIMENTAL|PUR0228c|PUR0200 formulation 4
62609646|NCT02671825|EXPERIMENTAL|PUR0230c|PUR0200 formulation 5
62609647|NCT02671825|ACTIVE_COMPARATOR|Reference Product 1|Reference Product formulation with active charcoal
62609648|NCT02671825|ACTIVE_COMPARATOR|Reference Product 2|Reference Product without active charcoal
62609649|NCT03442374|EXPERIMENTAL|Exercise|A single bout of moderate intensity lumbar extensor muscle exercise.
62609650|NCT03442374|NO_INTERVENTION|Non-exercise|No exercise intervention.
62609651|NCT01093651|EXPERIMENTAL|DPPIV inhibition|Four to six months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count \>350 cells/µL) and virologic (plasma HIV RNA \<50 copies/mL) status.
62609652|NCT01093651|PLACEBO_COMPARATOR|Placebo|Four to six months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count \>350 cells/µL) and virologic (plasma HIV RNA \<50 copies/mL) status.
62609653|NCT06241066||Surgery alone group|Patients who were diagnosed with esophageal squamous cell carcinoma and underwent esophageal squamous cell carcinoma resection without any prior treatment are included in this group. These patients had not been diagnosed with any other cancer. Finally, 96 patients were included.
62609654|NCT06241066||Neoadjuvant chemotherapy group|Patients who were diagnosed with esophageal squamous cell carcinoma and underwent esophageal squamous cell carcinoma resection, and underwent routine chemotherapy before surgery were included in this group. These patients were not diagnosed with any other cancers Finally, 89 patients were included.
62609655|NCT06241066||Neoadjuvant chemotherapy combined with immunotherapy group|Patients who were diagnosed with esophageal squamous cell carcinoma and underwent esophageal squamous cell carcinoma resection, and underwent routine chemotherapy combined with immunotherapy before surgery were included in this group. These patients were not diagnosed with any other cancers Finally, 81 patients were included.
62609656|NCT06241066||Neoadjuvant chemotherapy combined with radiotherapy group|Patients who were diagnosed with esophageal squamous cell carcinoma and underwent esophageal squamous cell carcinoma resection, and underwent routine chemotherapy combined with radiotherapy before surgery were included in this group. These patients were not diagnosed with any other cancers Finally, 93 patients were included.
62609657|NCT06731296||Abdominal surgery|Patients admitted to the ICU after an abdominal surgery.
62609658|NCT06731296||Older adults|Older adults (65+) surgical patients admitted to the ICU.
62832153|NCT06116669|EXPERIMENTAL|Pre-treatment group|Participants assigned to this group will receive 100 mg oral iron daily on study days 1-56.
62832154|NCT06116669|EXPERIMENTAL|Simultaneous treatment group|Participants assigned to this group will receive placebo daily on study days 1-28 and 100 mg oral iron daily on study days 29-56.
62832155|NCT06116669|PLACEBO_COMPARATOR|Control group|Participants assigned to this group will receive placebo daily on study days 1-56.
62609659|NCT01507714|NO_INTERVENTION|control arm|vaginal wall repair surgery will be done to women in this arm, with no treatment for stress incontinence
62609660|NCT01507714|ACTIVE_COMPARATOR|TVT-O arm|the women in this arm will have a TVT-O procedure in addition to the vaginal wall repair
62609661|NCT03946228|EXPERIMENTAL|Behavioral Intervention|The intervention will use behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts to target a 2-4 hour/day reduction in sedentary behavior.
62609662|NCT03946228|NO_INTERVENTION|Control Condition|Participants randomized to the control condition will receive no intervention during the study. After the 3-month assessment, control participants will be provided with a wrist-worn activity monitor and will be offered the 3-month delayed intervention if desired to aid in retention and recruitment.
62609663|NCT04266704|EXPERIMENTAL|Intervention|Along with providing education on a low sodium diet (Dietary Approaches to Stop Hypertension or DASH), exercise, and medication adherence, the intervention arm is designed to promote information sharing and stimulate broad cortical neural networks, the default mode (DMN), which focuses on emotion-management and self-awareness.
62609664|NCT04266704|ACTIVE_COMPARATOR|Control|education on a low sodium diet (Dietary Approaches to Stop Hypertension or DASH), exercise, and medication adherence
62049101|NCT01410058||Efavirenz|HIV positive patients on efavirenz containing regimen, taking Moringa oleifera
62609665|NCT06274710|EXPERIMENTAL|ODYSSEE-KH|Participants in the intervention arm of the trial will have full access to digital counselling materials for CKD self-care and RRT education. Program engagement is dynamic with videos, digital handouts, animated charts, infographics, interactive digital trackers, and self-assessment forms. Patients will receive weekly email links to digital sessions (Supplements 1 and 2). Initial sessions will build motivation for therapeutic change. Subsequent sessions follow CBT guidelines. Finally, a monthly video posted on ODYSSEE will address common challenges and patient comments or queries.
62832156|NCT05642364|EXPERIMENTAL|Virtual Reality Treatment|VR-delivered JovialityTM Sessions: Treatment Group. Participants will interact with a newly-developed VR environment over a 5-week period, during regularly scheduled maintenance HD treatment. Each week, enrollees will be introduced to a new skill, all taught in distinctive VR environments-with immersive sessions lasting no more than 30 minutes. The investigators' 5-week positive psychological intervention covers the following topics: (1) noticing positive events, (2) amplifying positive events, (3) gratitude, (4) behavioral activation, (5) mindfulness/meditation, (6) positive reappraisal, (7) personal strengths, and (8) acts of kindness. Delivery of intervention content will require VR immersion for no more than 30 minutes during each HD session (i.e., 30-min. sessions thrice weekly). VR immersion will only occur chairside when patients are already sedentary and in a seated position during regularly scheduled HD treatment, thus avoiding increased sedentarism.
62049102|NCT01382394||Sepsis Group, Heart failure group|"The first group will include 60 patients with the diagnosis of acute decompensated heart failure.~The second group will include 60 patients with the diagnosis of sepsis."
62049103|NCT04189692||Patients with Inflammatory Bowel Disease and fatigue|Patients with Inflammatory Bowel Disease and fatigue that participated in the two studies (1,2).
62251268|NCT01984164|ACTIVE_COMPARATOR|Candesartan|To achieve blood pressure control, we will use a stepwise protocol as follows: candesartan (blinded) 8mg→ 16mg→ 32mg. Both groups will also receive (unblinded) , if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg →10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg. Antihypertensive medications will be increased every 2 weeks until control is achieved.
62251269|NCT01984164|ACTIVE_COMPARATOR|Lisinopril|To achieve blood pressure control we will use a stepwise protocol as follows: lisinopril (blinded) 10mg→ 20mg→ 40mg. Both groups will also receive (unblinded), if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg→ 10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg. Antihypertensive medications will be increased every 2 weeks until control is achieved.
62251270|NCT03202823||Diabetics|
62609666|NCT06274710|NO_INTERVENTION|Usual care (UC)|UC is the standard of usual care which provides patients with conventional digital CKD education
62609667|NCT05654545|OTHER|Chatbot coaching|Due to the single-group design there will only be one arm. All participants will be exposed to four different chatbot relapse prevention coaching dialogs, which are presented in a random order.
62609668|NCT04151745|OTHER|study group|When a hemodynamically stable state is achieved, the external pacemaker will be switched off for 30 minutes. Hemodynamic parameters will be acquired directly prior to switching off, 15 respectively 30 minutes after switching off, and 15 minutes after switching back on. To gain insight in the natural course of stunning, this routine will be repeated the next morning.
62251271|NCT03202823||Non-diabetics|
62251272|NCT02372565|EXPERIMENTAL|Facebook and Text Message|Participants randomized to the technology-based physical activity intervention will receive a culturally-relevant physical activity promotion intervention delivered via text messages and the social media website Facebook. The purpose of the intervention materials is to encourage participants to achieve a minimum of 150 minutes/week of moderate-intensity aerobic physical activity each week.
62251273|NCT02372565|ACTIVE_COMPARATOR|Standard Print-based Intervention|Participants randomized to the standard print-based physical activity intervention group will be mailed 4 self-help booklets promoting physical activity produced by the American Heart Association. Booklets will be mailed one at a time in 2 week intervals over the 1st 6-weeks of the intervention. These high quality booklets provide general information on the benefits of physical activity, tips and strategies to increase daily physical activity, and encourage recipients to perform a minimum of 10,000 steps per day.
62251274|NCT02794142|EXPERIMENTAL|HD patient|
62609669|NCT06221098|ACTIVE_COMPARATOR|congenital esotropia|will be defined as that type of esotropia with an onset prior to 6 months of age \& characterized by a large stable angle
62609670|NCT06221098|ACTIVE_COMPARATOR|accommodative esotropia|Fully accommodative esotropia will be defined as an esotropia which is controlled for distance and near with full hypermetropic correction. Partially accommodative esotropia will be defined as a reduction in the angle of esotropia of 10 dioptres or more for distance or near, using the full hypermetropic correctionAccommodative esotropia with convergence excess occurs when the near angle exceeded the distance angle by 15 dioptres or more when fixating an accommodative target, using the full hypermetropic correction.
62049104|NCT04394364||BIS monitor group|Patients under monitoring of BIS
62049105|NCT02579954|NO_INTERVENTION|control group|
62049106|NCT02579954|EXPERIMENTAL|intervention|Rehabilitation
62049107|NCT05596175|NO_INTERVENTION|Usual Care|Patients will continue Usual Care, which will include having medication optimised for adequate heart-rate control, anti-arrhythmic therapy, and anti-coagulation (for stroke-risk) instituted by their treating Cardiologist if indicated by their CHA₂DS₂-VASc Score. Patients who remain significantly symptomatic despite attempts to optimise medical therapy may be referred for further rhythm management strategies, including cardioversion(s) and/or ablation(s) - as per current standard clinical practice. The Cardiologist will also provide routine, verbal one-off lifestyle advice in line with guidance.
62049108|NCT05596175|EXPERIMENTAL|Super Rehab plus Usual Care|12-month Super Rehab programme involving supervised dietary review sessions, 1-to-1 high-intensity exercise sessions and 3-monthly clinical review of AF risk factors, alongside Usual Care (defined above)
62049109|NCT05493774|EXPERIMENTAL|Experimental group|Virtual reality
62251275|NCT02794142|OTHER|Healthy volunteers|
62832157|NCT05642364|ACTIVE_COMPARATOR|Inert Virtual Reality|Participants randomized to the control arm will receive a rigorous placebo following clinical trial guidelines of VR-CORE, which consists of 2-dimensional (2D) non-immersive visual content displayed on the head-mounted display. Footage of wildlife and nature-based settings are visually displayed as part of the 'Sham' VR with inert music that does not promote high levels of relaxation or distraction. The 'Sham' VR experience has very passive features, such that it mimics viewing content on a large flatscreen television. Passive viewing during the 'Sham' VR experience rotates content using twenty different videos and has a duration time that is matched to that of JovialityTM over the 5-week intervention period.
62609671|NCT06221098|ACTIVE_COMPARATOR|non-accommodative esotropia|neither congenital nor accommodative esotropia
62609672|NCT06657170|EXPERIMENTAL|PV reconnection + HSC ablation|Patients undergoning pulmunary veins (PV) reconnection checking and ablation plus identification and ablation of hidden sites of slow conduction (HSC)
62251276|NCT01368536|EXPERIMENTAL|Valturna|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks.
62251277|NCT01368536|ACTIVE_COMPARATOR|Valturna + Amlodipine|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks.
62251278|NCT01368536|ACTIVE_COMPARATOR|Valturna + chlorthalidone|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks.
62609673|NCT06657170|ACTIVE_COMPARATOR|PV reconnection ablation only|Patients undergoning PV reconnection checking and ablation only.
62832158|NCT05019144|ACTIVE_COMPARATOR|Face-to-face arm|Standard face-to-face burn care.
62609674|NCT06099431|OTHER|Surgery/Device|Mandibular marginal resection and reconstruction using a mandibular osteosynthesis a 2.3mm reconstruction bone plate
62049110|NCT05493774|ACTIVE_COMPARATOR|Control group|High Fidelity Simulation Training
62609675|NCT02616718|EXPERIMENTAL|Ventral incisional hernia|Repeated computed tomography scan of abdomen
62609676|NCT04794010||Cohort 1|Participants with Metastatic Non-Small Cell Lung Cancer
62049111|NCT01896869|EXPERIMENTAL|Ipilimumab + Vaccine (Arm A)|Ipilimumab and vaccine will be administered every 3 weeks for 4 doses, then every 8 weeks.
62049112|NCT01896869|EXPERIMENTAL|FOLFIRINOX (Arm B)|Administered every 14 days (one cycle)
62609677|NCT06362031||Participants Receiving Venetoclax|Participants with AML receiving venetoclax undergoing chart review.
62049113|NCT02218827|EXPERIMENTAL|dry eye patients|Loteprednol Etabonate (FML) topical treatment 1 drop 4 times daily for 1 month then Loteprednol Etabonate (FML) 1 drop 2 times daily for 1 month
62049114|NCT02360319|ACTIVE_COMPARATOR|Clinician's Choice|Prescribers are not limited in the choice of treatment they can administer to their clients to alleviate the symptoms of schizophrenia. Any FDA approved antipsychotic agent can be used. Clients in the study wil be followed for 2 years
62609678|NCT02736591|ACTIVE_COMPARATOR|DHEA|Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI
62609679|NCT02736591|ACTIVE_COMPARATOR|Growth hormone|Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
62609680|NCT02612350||Increased Risk for Cancer Development|The group is to include at least 1000 individuals who are at high risk for the development of cancer. Risk is assessed through the completion of a clinical history questionnaire. Examples of such subjects include those with known hereditary cancer syndrome pathogenic variants without a diagnosis of cancer, with significant family history of breast, ovarian, colon, or lung cancer or melanoma, or another strong history of cancer but no prior molecular diagnosis, heavy smokers or those exposed to carcinogens and mutagens. The individuals who meet criteria for inclusion will undergo cell-free DNA isolation and circulating-tumor DNA (ctDNA) analysis for the detection of genetic mutations associated with the possible development of a malignancy.
62049115|NCT02360319|EXPERIMENTAL|Aripiprazole Once Monthly|Aripiprazole long acting injectable formulation, 400mg per dose is to be administered once monthly. Clients in the study will be followed for 2 years
62609681|NCT04145024||Pulmonary arterial hypertension|Group 1 PH
62049116|NCT03220490|EXPERIMENTAL|Short term: interval no-interval eye|"On the first day of the study, in the selected eye the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval.~One drop of two types of IOP reduction drugs (Brimonidine and Timolol) will be given with a 5 minutes interval between the first (Brimonidine) and the second (Timolol) drop. IOP measurements will be taken every hour up to 6 hours after treatment.~On the second day of the study (two weeks after the first day) the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol no time interval. Again one drop of the same two types of drugs will be given at the same order but with no time interval between them. IOP measurements will be taken in the same manner as on the first day."
62049117|NCT03220490|EXPERIMENTAL|Short term: No-interval interval eye|"On the first day of the study, in the selected eye the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval.~One drop of two types of IOP reduction drugs (Brimonidine and Timolol) will be given with no waiting period between the first (Brimonidine) and the second (Timolol) drop. IOP measurements will be taken every hour up to 6 hours after treatment.~On the second day of the study (two weeks after the first day) the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval. Again one drop of the same two drugs will be given at the same order but with a five minute time interval between the first and second drop. IOP measurements will be taken in the same manner."
62049118|NCT03220490|EXPERIMENTAL|Long term: interval no-interval eye|"In the first phase the effect of 5 minute interval between regular glaucoma drops - long term will be examined. The patients will be asked in this eye to wait 5 minutes after taking one of their IOP reduction drugs, before instilling the second type for a total duration of 1 month.~After the one month has passed IOP measurement will be taken and the patients will be asked to switch to the no interval between regular glaucoma drops - long term phase in which they will be asked to take the drops for this eye at the same order but with no waiting period for a duration of 1 month. After the second month has passed IOP measurements will be repeated."
62049119|NCT03220490|EXPERIMENTAL|Long term: No-interval interval eye|"In the first phase no interval between regular glaucoma drops - Long term will be examined. The patients will be asked in this eye to take both IOP reduction drugs, with no waiting period between them for a total duration of 1 month.~After the one month has passed IOP measurement will be taken and the patient will be asked to switch to the to 5 minute interval between regular glaucoma drops - Long term phase and take the drops for the same eye at the same order but with a five minute waiting period for a duration of 1 month. After the second month has passed IOP measurements will be repeated."
62049120|NCT00498979|EXPERIMENTAL|recombinant interferon alfa-2b|recombinant interferon alfa-2b
62049121|NCT02479568|ACTIVE_COMPARATOR|Control|Control drink (placebo)
62049122|NCT02479568|EXPERIMENTAL|Natural Florida orange juice|100% Florida orange juice (OJ) (natural content of hesperidin)
62609682|NCT04145024||Pulmonary hypertension due to left heart disease|Group 2 PH
62609683|NCT04145024||Pulmonary hypertension due to lung disease|Group 3 PH
62609684|NCT04145024||Chronic thromboembolic pulmonary hypertension|Group 4 PH
62609685|NCT04145024||Miscellaneous|Group 5 PH
62609686|NCT04145024||Exclusion PH|Patient with invasively excluded PH
62049123|NCT02479568|EXPERIMENTAL|Enriched Florida orange juice|100% Florida orange juice (OJ) (enriched hesperidin content)
62049124|NCT02159248|EXPERIMENTAL|Tolfenamic acid + gemcitabine + radiation|
62049125|NCT02608866|EXPERIMENTAL|SF-SSRS|Single-Fraction (SF) Stereotactic Spine Radiosurgery
62049126|NCT02608866|EXPERIMENTAL|MF-SSRS|Multiple-Fraction (MF) Stereotactic Spine Radiosurgery
62609687|NCT04550845|EXPERIMENTAL|Prostate Cancer Genetic Literacy Application (PCGLA) Educational Video.|Focus group discussions about the PCGLA educational video post-study. Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14. A data dictionary will be created for each technical term to establish acceptable and unacceptable responses. Trained coders will evaluate comprehension of the technical terms independently and then resolve disagreement by consensus.
62251279|NCT01129050|EXPERIMENTAL|Low-dose Flaxseed Oil|2.2 g ALA (alpha-linolenic acid) per day
62251280|NCT01129050|EXPERIMENTAL|High-dose Flaxseed Oil|6.6 g ALA (alpha-linolenic acid) per day
62251281|NCT01129050|EXPERIMENTAL|Low-dose Fish Oil|1.2 g EPA+DHA (700 mg EPA and 500 mg DHA) per day
62609688|NCT04550845|EXPERIMENTAL|Prostate Cancer Genetic Literacy Application (PCGLA) Educational Video plus Communication Coaching.|"Focus group discussions about the PCGLA educational plus nurse-navigated, tailored, prostate cancer education and communication coaching post-study.~Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14. A data dictionary will be created for each technical term to establish acceptable and unacceptable responses. Trained coders will evaluate comprehension of the technical terms independently and then resolve disagreement by consensus. post-study. Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14. A data dictionary will be created for each technical term to establish acceptable and unacceptable responses. Trained coders will evaluate comprehension of the technical terms independently and then resolve disagreement by consensus."
62609689|NCT06390761|EXPERIMENTAL|The Acupuncture Group|The intervention is going to be executed using the acupoints EX-HN1（Sishencong),LI4 (Hegu),ST25 (Tianshu),ST37(Shangjuxu),ST36(Zusanli),ST44 (Neiting), ST44 (Taichong), SP6 (Sanyinjiao) and CV4 (Shuangyuan).The acupuncture needles will be inserted to a depth of 0.8 to 1 cm in the acupuncture group.
62609690|NCT06390761|SHAM_COMPARATOR|The Sham Acupuncture Group|The sham acupuncture group's needles will be inserted to a depth of 0.2 to 0.3 cm with nonacupuncture points located 0.5 cm in lateral to the real acupoint or to the right for midline points.
62609691|NCT05920785||Metabolically healthy obesity|"Patients diagnosed with exogenous constitutional obesity, but without complications of this disease"
62609692|NCT05920785||Metabolically unhealthy obesity|"Patients diagnosed with Exogenous constitutional obesity with the presence of complications of this disease: arterial hypertension, dyslipidemia, impaired carbohydrate metabolism, type 2 diabetes hyperuricemia"
62609693|NCT05920785||Control group|Healthy children with normal body weight
62609694|NCT03784859||All patients in study|5 consecutive patients with breast cancer or a breast cancer-causing gene that elect to undergo bilateral breast reconstruction will be Insertion of Tissue Expander with Fluid Reservoir as the first stage of reconstruction. Post-surgical care will be similar as patients with conventional expanders, except that during office visits, fluid will be transcutaneously aspirated from the fluid reservoir on each side.
62251282|NCT01129050|EXPERIMENTAL|High-dose Fish Oil|3.6 g EPA+DHA (2.1 g EPA and 1.5 g DHA) per day
62251283|NCT01129050|PLACEBO_COMPARATOR|Placebo|4 g or 6 g soybean oil per day
62609695|NCT06602167|EXPERIMENTAL|True electroacupuncture + True self-administered acupressure plus doctor-prescribed treatment group|"True electroacupuncture: Participants will receive two electroacupuncture treatments within the first week of each treatment cycle. The acupuncturist inserts the needle into the point and manipulates the needle until the feeling of deqi is achieved and reported by the participant. The electrical stimulation will be administered at a sustained frequency of 2Hz for 30 minutes. True self-administered acupressure: In weeks 2 and 3 of each treatment cycle, participants performed true self-administered acupressure, pressing each acupoint with their thumb to achieve deqi for three minutes. Doctor-prescribed treatment: At the beginning of capecitabine, patients will be treated with doctor-recommended medications, including oral celecoxib, topical diclofenac, and other skin protectants."
62049127|NCT05478980|EXPERIMENTAL|Active Tea - Good Sleepers|
62049128|NCT05478980|ACTIVE_COMPARATOR|Control Tea - Good Sleepers|
62049129|NCT05478980|EXPERIMENTAL|Active Tea - Poor Sleepers|
62049130|NCT05478980|ACTIVE_COMPARATOR|Control Tea - Poor Sleepers|
62049131|NCT01974167|EXPERIMENTAL|Eldecalcitol group|Eldecalcitol 0.75 microgram once daily orally
62049132|NCT01974167|ACTIVE_COMPARATOR|Alfacalcidol group|Alfacalcidol 1 microgram once daily orally
62049133|NCT01922076|EXPERIMENTAL|Treatment (adavosertib, radiation therapy)|Patients undergo radiation therapy 5 days a week for 6 weeks (up to 30 fractions). Patients also receive adavosertib PO on days 1-5 of weeks 1, 3, and 5; days 1-5 of weeks 1, 3, and 5 AND days 1, 3, and 5 of weeks 2, 4, and 6; OR days 1-5 of weeks 1-6 depending on dose level assignment. Treatment continues in the absence of disease progression or unacceptable toxicity.
62049134|NCT00598026|EXPERIMENTAL|1|Tele- follow-up: remote transmission to the implantation centre every 3 months
62049135|NCT00598026|ACTIVE_COMPARATOR|2|Conventional follow-up: visits at the implantation centre every 3 months
62049136|NCT04349280|EXPERIMENTAL|Participants receiving bintrafusp alfa|Participants will receive bintrafusp alfa.
62049137|NCT04107922|ACTIVE_COMPARATOR|Glicoset|Glicoset is a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate
62049138|NCT04107922|PLACEBO_COMPARATOR|Placebo|
62049139|NCT03293576|EXPERIMENTAL|Intervention|Volitional help sheet
62441073|NCT03982758|EXPERIMENTAL|isometric of lower limbs|Isometric session for lower limbs: 4 series with 2 minutes of contractions sustained at 30% of 1RM. The rest interval will be 1 minute.
62049140|NCT03293576|NO_INTERVENTION|Control|Short Zimbardo's time perspective inventory (Orosz et al. 2017)
62049141|NCT02695355|EXPERIMENTAL|ADHD medication effects|Single dose methylphenidate (Ritalin tablets); 10 mg for ages 8-13; 15 mg for ages 13-17
62049142|NCT02465840|PLACEBO_COMPARATOR|Immobilization programs|custom-made protective hand splint physical therapy and occupational therapy
62049143|NCT02465840|EXPERIMENTAL|Kleinert programs|custom-made dynamic hand splint physical therapy and occupational therapy
62049144|NCT04954599|EXPERIMENTAL|Module 1A Monotherapy Multiple Ascending Dose|Multiple ascending dose cohorts dosing CP-506 monotherapy in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506
62049145|NCT04954599|EXPERIMENTAL|Module 1B Monotherapy Dose Expansion Cohort|Expansion cohort dosing CP-506 monotherapy in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506
62049146|NCT04954599|EXPERIMENTAL|Module 2A Combination with carboplatin Multiple Ascending Dose|Multiple ascending dose cohorts dosing CP-506 in combination with carboplatin in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506
62049147|NCT04954599|EXPERIMENTAL|Module 2B Combination with carboplatin Dose Expansion Cohort|Expansion cohort dosing CP-506 in combination with carboplatin in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506
62441074|NCT05031481|EXPERIMENTAL|VENUS 20 + 0,064|Venus association vaginal cream, single dose.
62441075|NCT05031481|EXPERIMENTAL|VENUS 20 + 1|Venus association vaginal cream, single dose.
62049148|NCT04954599|EXPERIMENTAL|Module 3A Combination with Immune Checkpoint Inhibitor Multiple Ascending Dose|Multiple ascending dose cohorts dosing CP-506 in combination with Immune Checkpoint Inhibitor in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506
62049149|NCT04954599|EXPERIMENTAL|Module 3B Combination with carboplatin Dose Expansion Cohort|Expansion cohort dosing CP-506 in combination with Immune Checkpoint Inhibitor in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506
62049150|NCT05100186|EXPERIMENTAL|Dexamethasone Ophthalmic Insert|Day of surgery, in OR placement versus Day 1 Post-Op, In-office (HOPD)
62049151|NCT02403180|OTHER|DACP MF, then PROCLEAR 1D MF|DACP MF (nelfilcon A) multifocal contact lenses worn in Period 1, followed by PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
62049152|NCT02403180|OTHER|PROCLEAR 1D MF, then DACP MF|PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 1, followed by DACP MF (nelfilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
62049153|NCT05862922||lumbosacral plexus block group|
62049154|NCT05862922||sacral plexus + suprainguinal fascia iliaca plane block group|
62049155|NCT01291498|OTHER|HIFU Treatment|High Intensity Focused Ultrasound. This is not a comparative study
62049156|NCT04788901|EXPERIMENTAL|Online therapeutic game|Participants in this group will have access to the evaluation module of the REThink game.
62251284|NCT06476522|EXPERIMENTAL|Intervention|The exercises were taught to the patients in the intervention group practically by the physiotherapist so that they could do their exercises at home.
62251285|NCT06476522|ACTIVE_COMPARATOR|Control|The control group patients continued with their routine chemotherapy treatment determined by their doctor. No intervention was made other than routine treatments.
62441076|NCT05031481|EXPERIMENTAL|VENUS 20 + 4|Venus association vaginal cream, single dose.
62441077|NCT05031481|ACTIVE_COMPARATOR|Butoconazole nitrate 100 mg|Butoconazole nitrate vaginal cream, single-dose containing 100 mg.
62832159|NCT05019144|EXPERIMENTAL|TOBI arm|A novel smartphone application for burn wound care, called the Telemedicine Optimized Burn Intervention (TOBI), was recently developed to enable burn experts to direct burn wound care while the patient and caregiver are home through text messaging and video-conferencing. The app was designed to bring expert wound care directly to the patient's home to address barriers to healthcare, including high cost burden and time commitment (e.g., geographic limitations, transportation to burn centers, parking, lodging, meals, time away from school and work), particularly for patients/families in rural and medically underserved communities. TOBI is synced with a portal used by providers, as an adjunct to standard therapy. This burn app provides education through frequently asked questions, instructional burn dressing change videos in addition to direct communication between patient and burn expert through store-and-forward pictures and videoconferencing.
62049157|NCT03434327|EXPERIMENTAL|Strength Training|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2s concentric and 3s eccentric. All training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for12 consecutive weeks, for a total of 24 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
62049158|NCT03434327|EXPERIMENTAL|Power Training|For power training the subjects will perform the concentric phase at high speed, while eccentric portion will last approximately 2 sec. Loads will vary from 30-80% of the subject's maximum depending on the biomechanical nature of the joints involved in the exercise. All training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 24 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
62049159|NCT06188793|EXPERIMENTAL|Virtual reality-directed BGBT|
62049160|NCT05452928|ACTIVE_COMPARATOR|Active arm|Randomisation to 7 days of active treatment with IV aciclovir 10 mg/kg q8h and possibility for oral step-down therapy with valaciclovir 1g q8h, or placebo (IV q8h and/or oral q8h).
62049161|NCT05452928|PLACEBO_COMPARATOR|Placebo|Randomisation to 7 days of IV and/or oral placebo.
62441078|NCT06480448|EXPERIMENTAL|Traditional physical therapy|This group will only getting conventional therapy which include core stability training, strength training, gait training through Parallel bar etc.
62832160|NCT04978675|EXPERIMENTAL|Diagnostic (F-18 rhPSMA-7.3, PET/MRI)|Patients receive F-18 rhPSMA-7.3 IV and after approximately 60 minutes of uptake time, will undergo PET/MRI over 60 minutes. Patients with evidence of F-18 rhPSMA-7.3 disease in the first PET/MRI scan undergo a second F-18 rhPSMA-7.3 PET/MRI at 6 months after the second dose of standard hormonal therapy.
62049162|NCT05980208||Inetetamab|Inetetamab-based treatment for first-line treatment of HER2-positive MBC
62049163|NCT06580366|ACTIVE_COMPARATOR|"Sennoside A+B Group for bowel preparation."|"This study will compare two bowel preparation methods in patients undergoing colonoscopy:~Sennoside A+B Group~Intervention: Patients will take Sennoside A+B, a stimulant laxative derived from the senna plant.~Purpose: To cleanse the colon by increasing bowel movements and reducing water absorption."
62049164|NCT06580366|ACTIVE_COMPARATOR|"PM/Ca Group for bowel preparation."|"PM/Ca Group (Sodium Picosulfate/Magnesium Oxide/Citric Acid)~Intervention: Patients will take a combination of sodium picosulfate (a stimulant laxative) and magnesium oxide/citric acid (osmotic agents).~Purpose: To promote bowel movements by stimulating the bowel and drawing water into the colon."
62049165|NCT01410955|EXPERIMENTAL|Probiotics|Patients receiving probiotics.
62049166|NCT01410955|PLACEBO_COMPARATOR|Placebo|Patients receiving placebo
62049167|NCT04023240|EXPERIMENTAL|68Ga-FAPI PET/CT|Patients receive 68Ga-FAPI IV and then undergo PET/CT approximately 1 hour later.
62441079|NCT06480448|ACTIVE_COMPARATOR|Treadmill training|This group will getting treadmill training will be started along with conventional therapy group. Training protocol will be standardized and follow FITT protocol for 12 weeks.
62441080|NCT00881959|EXPERIMENTAL|Group 1: Puros Dermis|Experimental treatment group of subjects who each have a single non-adjacent Miller's Class I or II gingival recession defect, greater than or equal to 2 mm, located on the buccal aspect of the maxillary incisor, canine, or premolar.
62441081|NCT00881959|ACTIVE_COMPARATOR|Group 2: Alloderm|Control group of subjects who each have a single non-adjacent Miller's Class I or II gingival recession defect, greater than or equal to 2 mm, located on the buccal aspect of the maxillary incisor, canine, or premolar.
62441082|NCT01541462|ACTIVE_COMPARATOR|Pressure support|Patients randomized to the pressure support arm will wean using pressure support ventilation. The level of pressure support will be decreased by 2 cm H2O every 6 hours. The maximum decrement in pressure support permitted in one day will be 6 cm H2O.
62441083|NCT01541462|ACTIVE_COMPARATOR|Spontaneous Breathing|Patients randomized to spontaneous breathing arm will be disconnected from the ventilator and allowed to breathe spontaneously through the tracheostomy. Duration of the trial will be increased sequentially as tolerated.
62441084|NCT02223026|EXPERIMENTAL|Linagliptin/metformin fed|
62441085|NCT02223026|ACTIVE_COMPARATOR|Linagliptin/metformin fasted|
62441086|NCT04305223|EXPERIMENTAL|Dry needling and upper extremity stretching program Arm|"Participants will receive a combination of dry needling and upper extremity stretching.~* Dry needling in regions of the head and cervical spine will be positioned supine, sidelying or prone with the relevant myofascial trigger points treated using a Seirin L- type 30 mm needle (Seirin America, Inc., Weymouth, MA). The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 5 minutes.~* A standard home exercise program consisting of strengthening and stretching exercises for the upper quarter."
62832161|NCT01096875|ACTIVE_COMPARATOR|Atorvastatin|Hydroxymethylglutaryl-CoA Reductase Inhibitors
62832162|NCT01096875|PLACEBO_COMPARATOR|Placebo|Atorvastatin like pill
62832163|NCT00551811|EXPERIMENTAL|Subjects receiving treatment sequence 1|Eligible subjects will receive single doses of placebo in period 1, SB-656933-AAA with a dose of 50 milligrams in period 2 and 150 milligrams in period 3.
62441087|NCT04305223|ACTIVE_COMPARATOR|Dry Needling Arm|Dry needling in regions of the head and cervical spine will be positioned supine, sidelying or prone with the relevant myofascial trigger points treated using a Seirin L- type 30 mm needle (Seirin American, Inc., Weymouth, MA). The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 5 minutes.
62832164|NCT00551811|EXPERIMENTAL|Subjects receiving treatment sequence 2|Eligible subjects will receive single doses of SB-656933-AAA with a dose of 50 milligrams in period 1, placebo in period 2 and SB-656933-AAA 150 milligrams in period 3.
62441088|NCT01900873|EXPERIMENTAL|Inspiratory Muscle Strength Training|High intensity inspiratory muscle training
62049168|NCT03063697||patients who check the safety data after taking Dilatrend SR|
62049169|NCT02508987||Group 1|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as periodontally healthy.Periodontal status was determined by evaluating the following clinical parameters: Silness \& Löe plaque index; Löe \& Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index. 18.50-24.99 kg/m2: Normal-weight"
62049170|NCT02508987||Group 2|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as gingivitis. Periodontal status was determined by evaluating the following clinical parameters: Silness \& Löe plaque index; Löe \& Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index.~18.50-24.99 kg/m2: Normal-weight"
62049171|NCT02508987||Group 3|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'generalized chronic periodontitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness \& Löe plaque index; Löe \& Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index.18.50-24.99 kg/m2: Normal-weight"
62049172|NCT02508987||Group 4|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as either 'periodontally healthy'. Periodontal status was determined by evaluating the following clinical parameters: Silness \& Löe plaque index; Löe \& Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
62049173|NCT02508987||Group 5|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'gingivitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness \& Löe plaque index; Löe \& Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
62049174|NCT02508987||Group 6|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'generalized chronic periodontitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness \& Löe plaque index; Löe \& Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
62049175|NCT00975910|PLACEBO_COMPARATOR|Saline|
62049176|NCT00975910|ACTIVE_COMPARATOR|Lidocaine|
62049177|NCT05239130|EXPERIMENTAL|Auralya 1|Sixteen patients will be administered Auralya® 1 (Cross-linked Hyaluronic Acid) for the treatment of minor facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
62832165|NCT00551811|EXPERIMENTAL|Subjects receiving treatment sequence 3|Eligible subjects will receive single doses of SB-656933-AAA with a dose of 50 milligrams in period 1, 150 milligrams in period 2 and placebo in period 3.
62832166|NCT00560989||1|CBD cases
62832167|NCT00560989||2|Beryllium-exposed, non-diseased control subjects
62832168|NCT00560989||3|Sarcoidosis cases
62049178|NCT05239130|EXPERIMENTAL|Auralya 2|Sixteen patients will be administered Auralya® 2 (Cross-linked Hyaluronic Acid) for the treatment of medium-sized facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
62049179|NCT05239130|EXPERIMENTAL|Auralya 3|Sixteen patients will be administered Auralya® 3 (Cross-linked Hyaluronic Acid) for the treatment of major facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
62049180|NCT02785341|OTHER|Immediate adaptated physical activity (Group A)|"Group A began a physical activity program for 12 consecutive weeks from inclusion in the protocol, then underwent the usual care for 12 additional weeks.~Then to complete five evaluations with several questionnaires, and 6-minute walk test every 6 weeks (T0, T1, T2, T3 and T4) and leptin level with a blood test every 12 weeks (T0, T2 and T4)."
62609696|NCT06602167|SHAM_COMPARATOR|Sham electroacupuncture + sham self-administered acupressure plus doctor-prescribed treatment group|"Sham electroacupuncture: The sham electroacupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive acupuncture treatment without electrical stimulation same the intervention group. And avoid deqi sensation. Sham self-administered acupressure: administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of deqi. Doctor-prescribed treatment: All the drugs used are the same as those in the experimental group."
62609697|NCT00738062|ACTIVE_COMPARATOR|Droxidopa|Study medication
62609698|NCT00738062|PLACEBO_COMPARATOR|Placebo|Placebo
62609699|NCT03342131||STEMI group|The study population consists of 150 patients with ST-elevated acute myocardial infarction (STEMI) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded. Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA at 0 , 7days and 12 months after admission.
62609700|NCT03342131||NST-ACS group|The study population consists of 150 patients with non-ST elevated acute myocardial infarction (NST-ACS) including unstable angina pectoris (UAP),who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA at 0 , 7days and 12 months after admission.
62049181|NCT02785341|OTHER|Without immediate adaptated physical activity (Group B)|"Group B followed the usual care for 12 weeks then started the physical activity program for 12 additional weeks.~Then to complete five evaluations with several questionnaires, and 6-minute walk test every 6 weeks (T0, T1, T2, T3 and T4) and leptin level with a blood test every 12 weeks (T0, T2 and T4)."
62049182|NCT00438880|EXPERIMENTAL|Arm I|See Detailed Description
62049183|NCT00652782|EXPERIMENTAL|1|rolofyline 2.5 mg IV QD
62251286|NCT06441045|EXPERIMENTAL|Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed|
62251287|NCT06441045|ACTIVE_COMPARATOR|Double Dose of Third-generation EGFR-TKI|
62832169|NCT00560989||4|Sarcoidosis control subjects
62049184|NCT00652782|EXPERIMENTAL|2|rolofyline 15 mg IV QD
62049185|NCT00652782|EXPERIMENTAL|3|rolofyline 30 mg IV QD
62251288|NCT05708950|EXPERIMENTAL|KVA12123 Monotherapy Dose Escalation|Part A will consist of dose escalation with KVA12123 administered as a single agent in participants with advanced solid tumors.
62251289|NCT05708950|EXPERIMENTAL|KVA12123 Plus Pembrolizumab Dose Escalation|Part B will consist of dose escalation with KVA12123 administered in combination with a fixed dose of pembrolizumab.
62251290|NCT05708950|EXPERIMENTAL|KVA12123 Monotherapy Dose Expansion|Part C will consist of dose expansion with KVA12123 administered as a single agent at the RP2D in participants with advanced solid tumors.
62251291|NCT05708950|EXPERIMENTAL|KVA12123 Plus Pembrolizumab Dose Expansion|Part D will consist of dose expansion with KVA12123 administered at the RP2D in combination with a fixed dose of pembrolizumab.
62049186|NCT00652782|EXPERIMENTAL|4|rolofyline 60 mg IV QD
62049187|NCT00652782|PLACEBO_COMPARATOR|5|placebo for rolofyline IV QD
62049188|NCT05093049|ACTIVE_COMPARATOR|Gynecomastia Surgery Followed by Renuvion|Patients receiving gynecomastia correction surgery followed by Renuvion treatment were randomly assigned to the left or the right side of the chest in a split-body randomized design. The gynecomastia surgery and Renuvion APR System use will be as per investigator's standard clinical practice.
62049189|NCT05093049|ACTIVE_COMPARATOR|Gynecomastia Surgery Only|Patients receiving gynecomastia correction surgery followed by Renuvion treatment were randomly assigned to the left or the right side of the chest in a split-body randomized design. The gynecomastia surgery will be as per investigator's standard clinical practice.
62049190|NCT00579280|ACTIVE_COMPARATOR|Quetiapine SR|Quetiapine SR (Quetiapine Sustained Release)
62049191|NCT00579280|ACTIVE_COMPARATOR|Divalproex Sodium ER|Divalproex Sodium ER (Divalproex Sodium Extended Release)
62049192|NCT00579280|PLACEBO_COMPARATOR|Placebo|placebo
62251292|NCT06396585|EXPERIMENTAL|Tislelizumab combined with anlotinib chemotherapy|
62441089|NCT01900873|SHAM_COMPARATOR|Inspiratory Muscle Endurance Training|Sham inspiratory muscle training at low intensity
62832170|NCT03583814|ACTIVE_COMPARATOR|CASE Program only|"During the Active Trial Phase, families of children with asthma status defined as not well controlled will complete the CASE program. Outcomes for participants assigned to the CASE program will be compared in a pre-post within subject comparison. Regardless of intervention arm assignment, children are expected show improvement in asthma outcomes. The stepped wedge trial design of the overall study allows for comparison of outcomes of communities in the pre-active trial baseline control period, active trial phase, and post-active trial phase follow-up period."
62049193|NCT01089374|OTHER|Partial breast radiation after lumpectomy|Radiation per NSABP B-39/R0413 protocol.
62251293|NCT03747042|EXPERIMENTAL|Treatment|"Drug: letrozole Take by mouth at a dose of 2.5 mg on days 7-30~Other: Blood Collection Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction~Procedure: biopsy/lumpectomy/mastectomy Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis"
62049194|NCT02054806|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 10 mg/kg, intravenously (IV), once every 2 weeks (Q2W) for up to \~2 years
62441090|NCT03804645|EXPERIMENTAL|Cohort 1|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
62609701|NCT03342131||Control group|150 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Control group. Circulation wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission.
62609702|NCT05936541|EXPERIMENTAL|Probiotic Bifidobacterium Bifidum PRL2010|Participants in this group will receive probiotic Bifidobacterium Bifidum PRL2010 supplementation from the time of discharge to a daily for the 6 months
62832171|NCT03583814|ACTIVE_COMPARATOR|CASE and HARP Programs|"During the Active Trial Phase, families of children with asthma status that is defined as poorly controlled will complete the CASE and HARP programs. Outcomes for participants assigned to this arm (CASE and HARP) will be compared in a pre-post within subject comparison. Regardless of intervention arm assignment, children are expected show improvement in asthma outcomes. The stepped wedge trial design of the overall study allows for comparison of outcomes of communities in the pre-active trial baseline control period, active trial phase, and post-active trial phase follow-up period."
62832172|NCT03583814|NO_INTERVENTION|Standard Care|Cluster-based randomization in the Stepped Wedge Trial allows for comparison of Community Based Outcomes for clusters (communities defined by school catchment areas) who are not yet in the active trial phase and are receiving Standard of Care at that time.
62832173|NCT02633904|ACTIVE_COMPARATOR|Osteotomy|Femoral osteotomy are applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
62049195|NCT01090570|EXPERIMENTAL|PLX3397 25 mg|
62049196|NCT01090570|EXPERIMENTAL|PLX3397 50 mg|
62251294|NCT04838223||Neuropathic Corneal Pain with Ocular Surface Discomfort|Participants diagnosed with neuropathic corneal pain with ocular surface discomfort
62251295|NCT04838223||Neuropathic Corneal Pain with Dry Eye Disease|Participants diagnosed with dry eye disease and neuropathic corneal pain
62441091|NCT03804645|EXPERIMENTAL|Cohort 2|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
62049197|NCT01090570|EXPERIMENTAL|PLX3397 100 mg|
62049198|NCT01090570|EXPERIMENTAL|PLX3397 200 mg|
62049199|NCT01090570|EXPERIMENTAL|PLX3397 300 mg|
62049200|NCT01090570|PLACEBO_COMPARATOR|Placebo|
62441092|NCT03804645|EXPERIMENTAL|Cohort 3|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
62049201|NCT00140205|EXPERIMENTAL|Fed state or fasting state|"1-day fed studies with administration of r-metHuLeptin at three different doses (0.01 mg/kg, 0.1 mg/kg, 0.3 mg/kg). All subjects participated in 3 studies in the fed condition (Part A) and 3 separate 72-hour fasting studies.~Intervention administered was-r-metreleptin in 3 different doses"
62049202|NCT05606757|EXPERIMENTAL|Cohort 1, BOTOX Dose A|Participants will receive BOTOX Dose A
62049203|NCT05606757|EXPERIMENTAL|Cohort 1, BOTOX Dose B|Participants will receive BOTOX Dose B.
62049204|NCT05606757|PLACEBO_COMPARATOR|Cohort 1, Placebo|Participants will receive placebo for BOTOX.
62049205|NCT05606757|EXPERIMENTAL|Cohort 2, BOTOX Dose A|Participants will receive BOTOX Dose A
62049206|NCT05606757|EXPERIMENTAL|Cohort 2, BOTOX Dose B|Participants will receive BOTOX Dose B
62049207|NCT05606757|EXPERIMENTAL|Cohort 2, BOTOX Dose C|Participants will receive BOTOX Dose C
62049208|NCT05606757|PLACEBO_COMPARATOR|Cohort 2, Placebo|Participants will receive placebo for BOTOX
62441093|NCT03804645|EXPERIMENTAL|Cohort 4|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
62609703|NCT05936541|ACTIVE_COMPARATOR|Control|Participants in this group will not receive probiotic probiotic supplementation
62832174|NCT02633904|EXPERIMENTAL|Non-osteotomy|Femoral osteotomy are not applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
62609704|NCT02817698|EXPERIMENTAL|Drug of dependence|There is only one arm to the study. All subjects will receive their drug of dependence in this study. Nicotine dependent subjects will receive tobacco cigarettes, cannabis dependent subjects will receive cannabis cigarettes, and cocaine dependent subjects will receive IV cocaine.
62049209|NCT05606757|EXPERIMENTAL|Cohort 3, BOTOX Dose A|Participants will receive BOTOX Dose A
62049210|NCT05606757|EXPERIMENTAL|Cohort 3, BOTOX Dose B|Participants will receive BOTOX Dose B.
62049211|NCT05606757|EXPERIMENTAL|Cohort 3, BOTOX Dose C|Participants will receive BOTOX Dose C.
62049212|NCT05606757|EXPERIMENTAL|Cohort 3, Placebo|Participants will receive placebo for BOTOX.
62049213|NCT00520858|NO_INTERVENTION|C|
62049214|NCT00520858|ACTIVE_COMPARATOR|RE|Resistance Exercise
62049215|NCT00520858|ACTIVE_COMPARATOR|AE|Aerobic Exercise
62049216|NCT00520858|ACTIVE_COMPARATOR|RAE|Resistance and Aerobic
62049217|NCT01312870|EXPERIMENTAL|postoperative nutritional supplements|postoperative nutritional supplements in addition to standard hospital diet
62609705|NCT00005624|EXPERIMENTAL|CI-994 Treatment|Patients receive CI-994 orally daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for 30 days and then every 2 months.
62251296|NCT04838223||NCP or Dry Eye in patients with ocular surface discomfort|Participants diagnosed with neuropathic corneal pain or with a neuropathic component of dry eye in patients with ocular surface discomfort
62251297|NCT04248387|EXPERIMENTAL|Toripalimab group|The subjects in this group receive intravenous drip infusion of Toripalimab at a dose of 3 mg / kg once every 2 weeks for a total of two cycles
62251298|NCT00376337|ACTIVE_COMPARATOR|1|infusion for 3-12 weeks
62251299|NCT00376337|EXPERIMENTAL|2|infusion for 3-12 weeks
62251300|NCT00794495|EXPERIMENTAL|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
62609706|NCT06061211|EXPERIMENTAL|Treadmill with TENS training|SIDEA-Germany treadmill \& MH8001 Portable tens Treadmill walking initially will begin exercising at 2 mph (3.2 km/h) at a 0% grade. They will walk until their claudication pain and determine site of pain then we will apply TENS on pain site and starting frequency at 2 HZ, then will increase inclination of treadmill gradually together with increasing frequancy of TENS up to 120 HZ if patient will report any feeling of pain, pain became moderately severe (4 of 5 on the claudication scale), throughout 45-minute exercise session. When a participant will be able to walk for 8 minutes at the initial workload without having to stop because of moderately severe claudication, the treadmill grade will be increased by increments of 0.5% until an 8-10% grade will be achieved. Subsequently, exercise intensity will be increased during training sessions by increasing the treadmill speed by increments of 0.1-0.2 mph (0.2-0.3 km/h) as tolerated
62832175|NCT05595213|EXPERIMENTAL|Group 1 Wrist Cooling Devices|Participants randomized into Group 1 will be provided two wrist cooling devices that are worn like watches. Group 1 participants will be instructed to first use the skin cooling watch device with a cooling plate for 2 weeks and then stop using it and switch to using the watch device that activates the fan without the cooling plate for 2 weeks.
62609707|NCT06061211|OTHER|Treadmill training|Over the past 30 years, treadmill-based SET programs have been shown to be consistently beneficial in improving walking ability as assessed by graded treadmill testing and to be effective in patients with PAD both with and without classic symptoms of claudication. Treadmill-based exercise therapy for patients with PAD consists of intermittent bouts of walking exercise to moderate to moderately severe discomfort (4 of 5 on the claudication scale) followed by short periods of rest until symptoms resolve. These exercise/rest bouts are repeated over a 30- to 45-minute exercise session. Exercise capability is most commonly measured as COT/COD and PWT/PWD.
62609708|NCT06514521||Lutetium vipivotide tetraxetan|Patients prescribed with Lutetium vipivotide tetraxetan in real world practice
62609709|NCT05094544|EXPERIMENTAL|Non-ablative SBRT|Non-ablative SBRT (800 cGy X 3 fractions) given 5-7 days preoperatively in selected patients with stage I-II NSCLC
62251301|NCT00794495|EXPERIMENTAL|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
62049218|NCT01312870|PLACEBO_COMPARATOR|standard hospital diet|patients receiving standard hospital diet
62049219|NCT01830114|EXPERIMENTAL|Web app evaluation group|
62609710|NCT02035397|EXPERIMENTAL|Botulinum toxin A|Botulinum toxin type A injection in muscles of stomach wall
62609711|NCT02035397|PLACEBO_COMPARATOR|Saline solution|Placebo (saline solution) injection first 6 months, then active treatment
62832176|NCT05595213|EXPERIMENTAL|Group 2 Wrist Cooling Devices|Participants randomized into Group 2 will be provided two wrist cooling devices that are worn like watches. Group 2 participants will be instructed to first use the cooling watch device that activates the fan without the cooling plate for 2 weeks and then stop using it and switch to using the skin cooling watch device with the cooling plate.
62832177|NCT03203096|PLACEBO_COMPARATOR|Placebo|identically tasting and looking Placebo
62049220|NCT05996666||Liver cancer arm|Participants with new diagnosis of liver cancer, from whom blood samples will be collected.
62049221|NCT05996666||Benign diseases arm|Participants with benign diseases of cancer, from whom blood samples will be collected.
62049222|NCT05996666||Healthy arm|Participants without known presence of malignancies or benign diseases of liver, from whom blood samples will be collected.
62251302|NCT04646681|EXPERIMENTAL|Group 1|
62049223|NCT05996666||Interfering cancer arm|Participants with new diagnosis of interfering cancer types, from whom blood samples will be collected.
62049224|NCT06580522|EXPERIMENTAL|Prone Position Group|Children in this group were given the prone position after weaning from noninvasive mechanical ventilation and its effect on the physiologic symptoms of the children was examined.
62049225|NCT06580522|EXPERIMENTAL|Supine Position Group|Supine position group children were given supine position after weaning from noninvasive mechanical ventilation and the effects on physiologic symptoms were examined.
62049226|NCT05695781|ACTIVE_COMPARATOR|BRM421 Ophthalmic Solution|
62049227|NCT05695781|PLACEBO_COMPARATOR|Vehicle|
62049228|NCT00999466|EXPERIMENTAL|1|AZD8848 (30 μg PILOT part and 60 μg MAIN part)
62049229|NCT00999466|PLACEBO_COMPARATOR|2|Placebo
62049230|NCT03069092|EXPERIMENTAL|Aerobic exercise (AE)|AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.
62049231|NCT03069092|EXPERIMENTAL|Resistance exercise (RE)|RE will consist of 3 sets of 8-15 repetitions at 50-80% of 1 rep-max of each exercise for 12 exercises (chest press, shoulder press, pull-down, back extension, abdominal crunch, torso rotation, biceps curl, triceps extension, leg press, leg extension, leg curl, and calf raise). Weight loads will be increased gradually. With one minute of rest between sets, this plan is estimated to take approximately 60 minutes per session. Sessions will occur 3 times per week for the duration of the 1 year trial.
62049232|NCT03069092|EXPERIMENTAL|Combined Resistance and Aerobic Exercise|Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
62609712|NCT02002416||Metastatic gastric cancer patients|Selecte 100 cases of eligible metastatic gastric cancer patients with primary and metastatic lesion (1:1). Use the immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH) to detect the status of C-met.
62609713|NCT02002416||Early stage gastric cancer|Selected 100 cases of eligible gastric cancer patients with previously early stage gastric cancer
62251303|NCT04646681|NO_INTERVENTION|Group 2|
62832178|NCT03203096|ACTIVE_COMPARATOR|Magnesium|Supplementation with 400 mg Magnesium from Magnesium Citrate / Magnesium Oxide once daily
62832179|NCT02156076|PLACEBO_COMPARATOR|Arm A: Placebo (Matching with BMS-919373)|Placebo (Matching with BMS-919373) 0 mg tablets orally once daily for approximately 28 Days
62832180|NCT02156076|EXPERIMENTAL|Arm B: BMS-919373|BMS-919373 3 mg tablets orally once daily for approximately 28 days
62832181|NCT02156076|EXPERIMENTAL|Arm C: BMS-919373|BMS-919373 5 mg tablets orally once daily for approximately 28 days
62832182|NCT02156076|EXPERIMENTAL|Arm D: BMS-919373|BMS-919373 12 mg tablets orally once daily for approximately 28 days
62832183|NCT00826202|EXPERIMENTAL|D serine|60 mg/kg/day
62832184|NCT00826202|PLACEBO_COMPARATOR|Placebo|
62832185|NCT06655311|EXPERIMENTAL|Enlicitide Chloride|Participants receive enlicitide chloride titrated orally from Dose 1, Dose 2, or Dose 3 once daily (QD) over the course of a 14-day treatment for each dose based on the safety and tolerability of the previous starting dose. The total treatment duration is up to approximately 6 weeks.
62832186|NCT06655311|PLACEBO_COMPARATOR|Placebo|Participants receive placebo orally for up to approximately 6 weeks.
62832187|NCT06655688|EXPERIMENTAL|Experimental: ACT|''Acceptance and Commitment Therapy (ACT) Based Intervention Program was applied to the intervention group.
62832188|NCT06655688|NO_INTERVENTION|Control|Arm Description: Only data collection was carried out. No attempt was made by the researcher during the study.
62832189|NCT04479995|EXPERIMENTAL|Horizon Program|"Eight weekly, audio recorded telehealth videoconferencing sessions. Sessions are 90 minutes.~Questionnaire assessments at 8 and 16 weeks after end of videoconferencing sessions"
62832190|NCT04479995|EXPERIMENTAL|Usual Care|"Standard medical visits to address chronic GVHD, with an additional standardized booklet, in electronic or paper format, containing information on the management of chronic GVHD and stem cell transplant survivorship recommendations.~Questionnaire assessment at 8 weeks and 16 weeks after Horizons Program group starts"
62832191|NCT06016049|ACTIVE_COMPARATOR|EMLA®|adjuvant forearm anesthesia cream (EMLA®) and sensibility training in a program involving 15 sessions (8 weeks) of guided plasticity
62832192|NCT06016049|PLACEBO_COMPARATOR|Skin cream|skin cream and sensibility training in a program involving 15 sessions (8 weeks) of guided plasticity training
62832193|NCT06654115|ACTIVE_COMPARATOR|WIP|wireless biosensor arm
62832194|NCT06654115|NO_INTERVENTION|SOC|Standard of care
62832195|NCT01152424||Acute eosinophilic pneumonia|
62832196|NCT01152424||Community acquired pneumonia|
62832197|NCT04941209||Case|Inpatients/Outpatients with confirmed COVID-19 with and without pulmonary symptoms.
62251304|NCT02887235|NO_INTERVENTION|Standard of Care (SOC) Meals|Patient assigned in this arm will receive standard of care nutritional services including nutrition consult, evaluation, and as needed follow-ups.
62441094|NCT03804645|EXPERIMENTAL|Cohort 5|In Part B, each subject will receive one formulation from Part A chosen for further development, dose under fed conditions, followed by dose under fasted condition.
62609714|NCT00532272|EXPERIMENTAL|letrozole|letrozole(2.5mg orally daily)
62832198|NCT04941209||Matched-Control|Outpatients without COVID-19 without known non-pulmonary diagnoses or symptoms.
62832199|NCT02015637|EXPERIMENTAL|Delafloxacin|900mg orally (2 x 450 mg tablets) administered once
62832200|NCT02015637|ACTIVE_COMPARATOR|ceftriaxone|Ceftriaxone 250 mg intramuscular injection administered once
62832201|NCT06074341|EXPERIMENTAL|Mindfulness-based relapse prevention|"The MBRP condition will be based on an existing rolling group treatment manual, which consists of eight 60-minute sessions. Each session will begin with a brief mindfulness practice and a discussion of what is mindfulness? and the role mindfulness may play in recovery. The themes are repeated every eight sessions, but in every session the participant is bringing a new direct moment experience to the practices in that session. The groups will also consist of people in various stages of recovery and familiarity with the material, which can make for richer discussions of the material led by the group members themselves. Participants who are randomized to receive rolling MBRP treatment will also have access to the Thrive Recovery smart phone app, which includes audio-guided MBRP meditations for participants to practice in daily life."
62609715|NCT00532272|ACTIVE_COMPARATOR|goserelin plus letrozole|goserelin (3.6mg subcutaneously every 28 days) plus letrozole(2.5mg orally daily)
62832202|NCT06074341|ACTIVE_COMPARATOR|Referral to online mutual support groups|The referral group will consist of a brief 1:1 meeting with a research team member who will provide an orientation to online mutual support and discuss the SMART Recovery, Alcoholics Anonymous (AA), and other virtual meeting options and to discuss how to access mutual support via these platforms. Individuals will also have an opportunity to review the process of attending online groups, and will discuss technology issues that might arise during groups. The session will be 20-30 minutes in length.
62049233|NCT03069092|NO_INTERVENTION|No training control|Participants in this group will be asked to maintain their current level of activity during the 1 year study period. After 1 year, they will be offered the training program of their choice (AE, RE, or combined).
62049234|NCT01085838|EXPERIMENTAL|Cohort 1|The first cohort of 5 patients will start with a dosage of 100 mg erlotinib daily
62049235|NCT01085838|EXPERIMENTAL|Cohort 2|The second cohort of patients will receive 150 mg of erlotinib daily
62049236|NCT01085838|EXPERIMENTAL|Cohort 3|The third cohort of five patients will be enrolled to receive 300 mg of erlotinib daily
62049237|NCT05929469|EXPERIMENTAL|Fully Automated Kick-Off + App|"This arm includes participants who respond to the Fully Automated Kick-Off + App in stage 1.~In stage 1, participants will receive a Fully Automated Kick-Off and an mHealth program.~In stage 2, responders to the Fully Automated Kick-Off + App will continue with the mHealth program, alone, for the remainder of the study."
62049238|NCT05929469|EXPERIMENTAL|Human-Enhanced Kick-Off + App|"This arm includes participants who respond to the Human-Enhanced Kick-Off + App in stage 1.~In stage 1, the participant's kick-off will include a session with a study interventionist. They will also receive an mHealth program.~In stage 2, responders to the Human-Enhanced Kick-Off + App will continue with the mHealth program, alone, for the remainder of the study."
62251305|NCT02887235|ACTIVE_COMPARATOR|Medically tailored meals|Patient assigned in this arm will receive home delivered, medically tailored meals (HDMTM) in addition to the standard nutritional care.
62251306|NCT02386748|EXPERIMENTAL|Chewing gum|Chewing sugarless gum
62251307|NCT02386748|ACTIVE_COMPARATOR|Oral fluids|Clear oral fluids
62251308|NCT02386748|OTHER|Intravenous fluids|No chewing gum No oral fluids Only intravenous fluids (Lactated Ringer's solution)
62251309|NCT01088464|EXPERIMENTAL|Cohort 1|
62251310|NCT01088464|EXPERIMENTAL|Cohort 2|
62251311|NCT01088464|EXPERIMENTAL|Cohort 3|
62251312|NCT05392504|EXPERIMENTAL|Core stability exercise|"The core stability training consist of three phases. The first and second phases each will last for three weeks in total, and the third phase will take place in four weeks. Each training session will begin with 10 minutes of warm-up exercises and finish with 10 minutes of cool-down exercises; both warm-up and cool-down exercises includes breathing and stretching exercises. The number of repetitions will be adjusted according to the participant's exercise tolerance.~During the first week of each phase, the number of repetitions of each exercise will be 7-10, and this will progress to 10-15 based on the patient's physical tolerance."
62251313|NCT05392504|ACTIVE_COMPARATOR|Scroth's program|The Schroth program include exercises for rotational breathing, spinal elongation, de-flexion, stretching, de-rotation, and strengthening, and these exercises are performed to improve the curvature, muscle strength, and endurance of postural muscles. During the Schroth exercises, rice bags, foam blocks, a stool, and long sticks will be used to adjust the posture and give passive support. The intensity of the Schroth exercises will gradually increased depending on the patient's improvement in exercise performance by decreasing the amount or degree of passive support, changing the patient's position, and adjusting the sets and repetitions of exercises
62609716|NCT02425033|EXPERIMENTAL|Intervention|Patients undergoing POEM for spastic esophageal disorders such as achalasia at the University Health Network, Toronto, Canada
62609717|NCT03009383|EXPERIMENTAL|A bedside portable endoscopy|
62609718|NCT04724031||One cohort|women with advanced epithelial ovarian cancer who received PARP inhibitors at any line of treatment
62251314|NCT04643080|NO_INTERVENTION|Control|Subjects were asked to avoid consuming fermented foods for 12 weeks.
62251315|NCT04643080|EXPERIMENTAL|Yogurt|Subjects were asked to consume 6 oz. of yogurt daily for 12 weeks.
62251316|NCT01505270||Autistic Children|
62441095|NCT06205303|EXPERIMENTAL|intervention arm using PDA|The intervention arm participants will watch the PDA which is estimated to take 10 minutes, after their consultation with the physician. The participants will be directed to a private room to watch the PDA.
62049239|NCT05929469|EXPERIMENTAL|Fully Automated Kick-Off + App + Check-In|"This arm includes participants who do not respond to the Fully Automated Kick-Off + App in stage 1.~In stage 1, participants will receive a Fully Automated Kick-Off and an mHealth program.~In stage 2, they will continue with the mHealth program, but will also receive a check-in with a study interventionist."
62049240|NCT05929469|EXPERIMENTAL|Fully Automated Kick-Off + App + Counseling|"This arm includes participants who do not respond to the Fully Automated Kick-Off + App in stage 1.~In stage 1, participants will receive a Fully Automated Kick-Off and an mHealth program.~In stage 2, they will continue with the standard mHealth program, but will also receive counseling from a study interventionist."
62049241|NCT05929469|EXPERIMENTAL|Human-Enhanced Kick-Off + App + Check-In|"This arm includes participants who do not respond to the Human-Enhanced Kick-Off + App in stage 1.~In stage 1, the participant's kick-off will include a session with a study interventionist. They will also receive an mHealth program.~In stage 2, they will continue with the mHealth program, but will also receive a check-in with a study interventionist."
62049242|NCT05929469|EXPERIMENTAL|Human-Enhanced Kick-Off + App + Counseling|"This arm includes participants who do not respond to the Human-Enhanced Kick-Off + App in stage 1.~In stage 1, the participant's kick-off will include a session with a study interventionist. They will also receive an mHealth program.~In stage 2, they will continue with the standard mHealth program, but will also receive counseling from a study interventionist."
62049243|NCT00440869|EXPERIMENTAL|N-acetylcysteine|Active
62441096|NCT06205303|NO_INTERVENTION|Control arm|The control arm participants will receive a thyroxine replacement pamphlet at their routine clinic appointment but will not attend the health education session using the PDA.
62609719|NCT06725667|EXPERIMENTAL|Transversalis fascia plane block group|Patients will receive transversalis fascia plane block after the induction of general anesthesia.
62832203|NCT04845568|NO_INTERVENTION|Video|This is the control condition, which views a short video and online interactive game with psychoeducational material on healthy eating and consideration of future consequences.
62832204|NCT04845568|EXPERIMENTAL|Virtual Reality|This is the intervention condition, which participates in the virtual reality experience; the experience includes psychoeducational material on healthy eating and consideration of future consequences.
62832205|NCT03879772|EXPERIMENTAL|MFNS 25 mcg QD|Mometasone furoate nasal spray 12.5 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
62832206|NCT03879772|EXPERIMENTAL|MFNS 100 mcg QD|Mometasone furoate nasal spray 50 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
62832207|NCT03879772|EXPERIMENTAL|MFNS 200 mcg QD|Mometasone furoate nasal spray 100 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
62832208|NCT03879772|ACTIVE_COMPARATOR|BDP 84 mcg BID|Beclomethasone dipropionate nasal spray 42 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
62832209|NCT03879772|PLACEBO_COMPARATOR|Placebo|Matching placebo nasal spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
62832210|NCT04053777||NIV group|Patients receiving non-invasive ventilation in the hospital or at home
62832211|NCT03674853|EXPERIMENTAL|Wuling Capsule group|Patients who were treated with Wuling Caspule
62832212|NCT03674853|ACTIVE_COMPARATOR|Oryzanol group|Patients who were treated with oryzanol
62251317|NCT02020057|ACTIVE_COMPARATOR|Conventional|knee receiving Total knee arthroplasty with conventional polyethylene inserts
62251318|NCT02020057|EXPERIMENTAL|Prolong|knee receiving total knee arthroplasty with highly cross linked polyethylene insert
62251319|NCT01876251|EXPERIMENTAL|PF-03084014 plus docetaxel|PF 03084014 will be administered orally, continuously, twice daily at doses from 80 to 150 mg in combination with docetaxel given every 3 weeks at doses from 75 to 100 mg/m\^2
62251320|NCT01998620|EXPERIMENTAL|Ademetionine 1|Ademetionine 2000mg
62441097|NCT00891774|EXPERIMENTAL|Device|Treatment with EVOLENCE®
62441098|NCT04813900|EXPERIMENTAL|Patient suspected to suffer from interstitial syndrome needing an arterial blood gas analysis|
62609720|NCT06725667|ACTIVE_COMPARATOR|Caudal block group|Patients will receive caudal block after the induction of general anesthesia.
62049244|NCT00440869|PLACEBO_COMPARATOR|placebo|placebo
62609721|NCT04583358|ACTIVE_COMPARATOR|AMT-101|AMT-101 Tablet
62609722|NCT04583358|PLACEBO_COMPARATOR|Placebo|Placebo Tablet
62049245|NCT05260996|EXPERIMENTAL|Pilot Group|
62049246|NCT05260996|NO_INTERVENTION|Control Group|
62609723|NCT00902980||1. Community Based Clinics|Patient charts from community based nephrology clinics
62609724|NCT00902980||2. Regional Clinics|Patient charts from regional transplant clinics
62609725|NCT00235066|EXPERIMENTAL|1|Cypher Sirolimus-Eluting Stent
62609726|NCT04698421||patients with rare autoimmune neurological diseases|
62049247|NCT00131014||Next of Kin of deceased subj by lymphoma|Next of Kin of deceased subject by lymphoma
62609727|NCT01380691|EXPERIMENTAL|LY, Alc, Pl-Match Alc, Then Pl-Match LY, Alc, Pl-Match Alc|"Period 1: 18 milligrams (mg) LY2216684 (LY) administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic (Alc) beverage (with an alcohol dose of 0.6 grams per kilograms \[g/kg\] for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching (Pl-Match) alcoholic beverage, taken orally, one time.~Period 2: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
62049248|NCT00131014||Subject unaffected by lymphoma|Subject unaffected by lymphoma
62049249|NCT00131014||Subject affected by lymphoma|Subject affected by lymphoma
62832213|NCT00157131|EXPERIMENTAL|FS 4IU VH S/D|"FS 4IU VH S/D was administered intraoperatively to the wound bed by spray application using the TISSOMAT and Spray Set. Only the DUPLOJECTvii system and Spray Set (connection tube with sterile filter and spray head) device was used for simultaneous spray application of the study product. A thin layer of FS 4IU VH S/D was applied to the wound bed using a painting motion from side to side to achieve coverage. The recommended dosing volume was 2.0 to 4.0 mL/100 cm2. One 2-mL pack (4 mL total volume) of FS 4IU VH S/D applied using the TISSOMAT and Spray Set was sufficient to coat a wound bed of 100-200 cm2."
62049250|NCT00977665|EXPERIMENTAL|rasagiline mesylate|rasagiline tablet, 1 mg/day for up to 48 weeks.
62049251|NCT00977665|PLACEBO_COMPARATOR|placebo|placebo tablet for up to 48 weeks.
62049252|NCT05024851||Patients with Psychogenic pruritus|
62049253|NCT05024851||Patients with Neuropathic Pruritus|
62049254|NCT02037048|ACTIVE_COMPARATOR|Positive Pathologic Response|Patients with ≤50% viable tumor cells remaining in the surgical specimen will receive postoperative chemo-radiotherapy with the mFOLFOX6 regimen
62049255|NCT02037048|EXPERIMENTAL|Negative Pathologic Response|Patients with \>50% viable tumor cells remaining in the surgical specimen, will receive postoperative chemo-radiotherapy with weekly carboplatin and paclitaxel.
62049256|NCT05751512|EXPERIMENTAL|MRG003|MRG003 will be administrated via intravenous infusion at 2.3 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
62049257|NCT05751512|ACTIVE_COMPARATOR|cetuximab/ methotrexate|cetuximab (400 mg/m2 for the first week and 250 mg/m2 for subsequent weeks, QW) or methotrexate (40 mg/m2, IV, QW)
62049258|NCT00929162|EXPERIMENTAL|ZD4054 + paclitaxel + carboplatin|ZD4054 10mg oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks
62049259|NCT00929162|PLACEBO_COMPARATOR|Placebo + paclitaxel + carboplatin|Placebo oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks
62049260|NCT01127282|EXPERIMENTAL|Vitamin|Vitamin(vitamin A 15mg,C 500mg,E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics
62049261|NCT01127282|PLACEBO_COMPARATOR|Control|Placebo(digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
62049262|NCT05699330|EXPERIMENTAL|Bilateral subgenual cingulate deep brain stimulation (SGC DBS)|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone. All patients will receive deep brain stimulation (DBS) targeting the subgenual cingulate (SGC) bilaterally. No other changes to pre-existing treatment will be made. This is the only arm in this experiment.
62049263|NCT02701985|PLACEBO_COMPARATOR|Placebo|Matching-placebo capsules will be administered orally, 2 times a day, for up to 12 weeks.
62049264|NCT02701985|EXPERIMENTAL|RO5459072|RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day, for up to 12 weeks.
62049265|NCT03488368||Supportive-care group|Observation of IgAN patients who received supportive care measures (without additional immunosuppression) during the first three years after randomization, i.e. trial phase of the original STOP-IgAN trial.
62049266|NCT03488368||Immunosuppression group|Observation of IgAN patients who received supportive care measures and additional immunosuppression during the first three years after randomization, i.e. trial phase of the original STOP-IgAN trial.
62049267|NCT01511822|ACTIVE_COMPARATOR|Drospirenone + Ethinyl estradiol|
62049268|NCT01511822|EXPERIMENTAL|Drospirenone + Ethinyl estradiol + Myo-inositol|
62049269|NCT01511822|PLACEBO_COMPARATOR|Placebo|
62049270|NCT02673398|EXPERIMENTAL|Treatment (neratinib)|Patients receive neratinib 240mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62609728|NCT01380691|EXPERIMENTAL|Pl-Match LY, Alc, Pl-Match Alc, Then LY, Alc, Pl-Match Alc|"Period 1: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.~Period 2: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
62832214|NCT00157131|ACTIVE_COMPARATOR|Staples|Staples are the current standard of care in burn surgery and are well accepted as the control in this type of study.
62832215|NCT02633098|EXPERIMENTAL|Artesunate|Artesunate 200mg oral tablets once daily for 14 days.
62049271|NCT05592054|EXPERIMENTAL|Intervention group|Balloon guide catheters (BGCs)
62049272|NCT05592054|ACTIVE_COMPARATOR|Control group|Standard guide catheter
62049273|NCT02616887||Vertebral metastases|Selected patients with spine metastases are treated with ablative single dose SBRT and VMAT technique in various solid tumors .
62049274|NCT03619460|EXPERIMENTAL|piezoelectric extraction|The flap will be raised using a Piezoelectric elevator, the eventual bone around the third molar crown will be removed with the same piezoelectric lever used for luxation and root extraction. The eventual rizectomy will be performed using a piezoelectric saw.
62049275|NCT03619460|ACTIVE_COMPARATOR|conventional extraction|The flap will be raised using a manual elevator and the eventual bone around the third molar crown will be removed with a bone bur with a straight handpiece while the eventual rizectomy will be performed using a bone bur. Manual levers will be used for luxation and tooth extraction
62832216|NCT02633098|PLACEBO_COMPARATOR|Matching placebo|Matching placebo oral tablets once daily for 14 days.
62832217|NCT04705831|ACTIVE_COMPARATOR|RUCONEST|IV Ruconest
62832218|NCT04705831|PLACEBO_COMPARATOR|Placebo|Placebo
62832219|NCT00768014||1|Healthy term pregnant women in labor without any pain relief
62832220|NCT00768014||2|Healthy term pregnant women received TENS
62049276|NCT01349920||Infliximab 5 mg/kg|Infliximab treatment and endoscopy.
62049277|NCT03651050|EXPERIMENTAL|intervention FBOs receive the P-MHDT|
62049278|NCT03651050|EXPERIMENTAL|control FBOs receive no P-MHDT|
62049279|NCT02470494|EXPERIMENTAL|Sound amplificatoin via EarLens CHD|Sound amplification provided via the EarLens CHD for subjects with hearing impairment.
62049280|NCT03963154|EXPERIMENTAL|Implantation of a therapeutical patch|All the patients will receive a single central subretinal implantation in one eye of a monolayer of Human Embryonic Stem Cells-derived Retinal Pigmented Epithelium (hESC-derived RPE). The implanted eye will be the one with the worst visual acuity.
62049281|NCT01534325|EXPERIMENTAL|Study arm|The Arm who uses the real study device Daily use of SD device
62049282|NCT01534325|SHAM_COMPARATOR|Control Arm|Daily use of Sham comperator
62049283|NCT01534325|EXPERIMENTAL|Staudy2 arm|Uses the under study device in a different time frames Daily use of SD device in a different time frames than of Study Arm
62049284|NCT04284345|EXPERIMENTAL|Saline Pd/Pa|Eligible subjects will undergo invasive coronary physiology measurements including whole cycle resting Pd/Pa, iFR, RFR, cFFR, Saline Pd/Pa and FFR
62049285|NCT05085587|EXPERIMENTAL|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
62049286|NCT05085587|ACTIVE_COMPARATOR|Reference Product|ADVAIR DISKUS 250/50
62832221|NCT00768014||3|Healthy term pregnant women received epidural anesthesia
62832222|NCT00763035|ACTIVE_COMPARATOR|A|Arm A will get Dobutamine Stress test with cardiac MR (CMR). Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.
62832223|NCT00763035|ACTIVE_COMPARATOR|B|Arm B will get Regadenoson stress test with CMR. Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.
62832224|NCT00994513|ACTIVE_COMPARATOR|ALA|alpha lipoic acid 1200 mg/day
62832225|NCT00994513|PLACEBO_COMPARATOR|Placebo|placebo 1200 mg/day
62049287|NCT05969457|EXPERIMENTAL|Experienced group|Administration of Naropeine
62609729|NCT01380691|EXPERIMENTAL|LY, Pl-Match Alc, Alc, Then Pl-Match LY, Pl-Match Alc, Alc|"Period 1: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~Period 2: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
62609730|NCT01380691|EXPERIMENTAL|Pl-Match LY, Pl-Match Alc, Alc, Then LY, Pl-Match Alc, Alc|"Period 1: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~Period 2: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
62609731|NCT01948583|ACTIVE_COMPARATOR|Arm I: vaginal gel new formulation|"Application once a day at evening during the first study week of the vaginal gel new formulation (hyaluronic acid).~One week of wash-out (second week). Application once a day at evening during the third study week of the vaginal gel on the market (hyaluronic acid)."
62049288|NCT05969457|PLACEBO_COMPARATOR|Control group|Administration of a saline solution
62049289|NCT02552628|EXPERIMENTAL|"Stimulation on"|"The deep brain stimulation is on"
62049290|NCT02552628|SHAM_COMPARATOR|"Stimulation off"|"The deep brain stimulation is off"
62049291|NCT02679040|EXPERIMENTAL|Immediate Mammary Reconstruction|Chemotherapy, radiation therapy, mastectomy with immediate mammary reconstruction
62609732|NCT01948583|ACTIVE_COMPARATOR|Arm II: vaginal gel on the market|"Application once a day at evening during the first study week of the vaginal gel on the market (hyaluronic acid).~One week of wash-out (second week). Application once a day at evening during the third study week of the vaginal new formulation (hyluronic acid)."
62609733|NCT03291470|ACTIVE_COMPARATOR|Active Treatment (TG-C)|TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
62049292|NCT00545961|PLACEBO_COMPARATOR|1|placebo Ora-Plus (registered trademark) mixture with an strawberry sweetening agent to make the placebo mixture similar in appearance and taste to active drug
62609734|NCT03291470|PLACEBO_COMPARATOR|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
62609735|NCT05777941|EXPERIMENTAL|Eccentric Training|This Group will train on the KREHA for 20 Trainings
62832226|NCT00539591|EXPERIMENTAL|Temozolomide/peginterferon alfa-2b|"Stratum B: Resected Stage IIIC, unresectable Stage III, Stage IV, and recurrent patients~Stratum B is divided into 2 groups based on the presence (Stratum B1) or absence (Stratum B2) of measurable disease. Subjects will receive 8 weekly doses of peginterferon alfa-2b 0.5 mcg/kg/dose subcutaneously (SQ) in combination with temozolomide 75mg/m2/dose by mouth (PO) daily for 6 weeks followed by 2 week break. The duration of each treatment course will be 8 weeks. Strata B2 (no measurable disease) will proceed with 7 courses as outlined."
62609736|NCT01442727|PLACEBO_COMPARATOR|Placebo|Patients who receive control (placebo)
62049293|NCT00545961|ACTIVE_COMPARATOR|2|amoxicillin-clavulanate acid
62049294|NCT02340741|OTHER|conventional prophylaxis of aeroembolism|"Procedure: cardiac surgery with opening of heart chambers.~Will be including 167 patients to undergo cardiac surgery. After the main operation phase all heart cavities are sealed, left vent drainage is stopped, ascending aorta is punctured and cardiac massage is performed, ventilation is started and the heart is filled with volume. Operating table is positioned in the Trendelenburg position, and aorta is opened. The amount of air in the cavities is evaluated by transesophageal echocardiography."
62049295|NCT02340741|OTHER|conventional prophylaxis plus CO2 insufflation|"Procedure: cardiac surgery with opening of heart chambers.~Will be including 167 patients to undergo cardiac surgery. After the main phase of the operation standard measures of aeroembolism prevention are carried out. The amount of air in the cavities is evaluated by transesophageal echocardiography."
62049296|NCT01155154|ACTIVE_COMPARATOR|clindamycin|clindamycin 300 mg (two 150 mg capsules) every 6 hours for 7 days
62049297|NCT01155154|ACTIVE_COMPARATOR|cepahlexin|
62609737|NCT01442727|ACTIVE_COMPARATOR|Selenium|Patients who receive treatment (selenium)
62609738|NCT05141006|EXPERIMENTAL|BOTOX|Participants will receive BOTOX on Day 1 and will be followed for at least 12 weeks in treatment period 1. An optional dose of BOTOX in Treatment 2 can be requested between Weeks 12 and 24.
62609739|NCT05141006|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo on Day 1 and will be followed for at least 12 weeks in treatment period 1. An optional dose of BOTOX in Treatment 2 can be requested between Weeks 12 and 24.
62609740|NCT05753501|EXPERIMENTAL|Dose Escalation ABBV-101|Participants with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) will receive escalating doses of ABBV-101, until the maximum administered dose (MAD)/Maximum tolerated dose (MTD) is determined, as part of the approximately 60 month study duration.
62609741|NCT05753501|EXPERIMENTAL|Dose Expansion ABBV-101 R/R Chronic Lymphocytic Lymphoma (CLL)|Participants with R/R CLL will receive ABBV-101 at the dose determined in the dose escalation arm, as part of the approximately 60 month study duration.
62251321|NCT01998620|EXPERIMENTAL|Ademetionine 2|Ademetionine 1000mg
62251322|NCT01998620|ACTIVE_COMPARATOR|Ademetionine 3|no treatment in first 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
62049298|NCT01155154|PLACEBO_COMPARATOR|Placebo|
62049299|NCT05857787|ACTIVE_COMPARATOR|With nerve track function(group A)|trained in the live demo method with nerve track function
62049300|NCT05857787|ACTIVE_COMPARATOR|Without nerve track function(group B)|trained in the existing live demo method without nerve track function
62049301|NCT02612987|EXPERIMENTAL|iCBT|
62049302|NCT02073695|OTHER|Neutral Rotation Brace|Neutral Rotation Brace
62251323|NCT04032704|EXPERIMENTAL|Part A: Non-randomized LV monotherapy|Monotherapy dosing schedule 1.
62049303|NCT02073695|OTHER|Standard polysling (Current practice)|Standard polysling (Current practice)
62049304|NCT03850652|ACTIVE_COMPARATOR|Prebiotic (Synergy-1)|Prebiotic (Synergy-1) + Iron supplement
62049305|NCT03850652|PLACEBO_COMPARATOR|Maltodextrin|Placebo (Maltodextrin) + Iron Supplement
62049306|NCT06119984|EXPERIMENTAL|Community mobilization|a six-month community mobilization intervention that consisted of advocacy to stakeholders, community workshops and small group discussions in intervention communities
62049307|NCT06119984|NO_INTERVENTION|No intervention|
62251324|NCT04032704|EXPERIMENTAL|Part B: Non-randomized LV monotherapy|Monotherapy dosing schedule 2.
62251325|NCT04032704|EXPERIMENTAL|Part C - Arm 1: Randomized LV monotherapy|Monotherapy dosing schedule 3.
62251326|NCT04032704|EXPERIMENTAL|Part C - Arm 2: Randomized LV combination therapy|Combination dosing schedule 1.
62609742|NCT05753501|EXPERIMENTAL|Dose Expansion ABBV-101 R/R non-GCB DLBCL|Participants with R/R non-germinal center B cell (GCB) diffuse large B-cell lymphoma (DLBCL) will receive ABBV-101 at the dose determined in the dose escalation arm, as part of the approximately 60 month study duration.
62832227|NCT00539591|EXPERIMENTAL|Peginterferon alfa-2b/non-pegylated interferon alfa-2b|Stratum A: Resected Stages IIC, IIIA, and IIIB patients will receive recombinant interferon alfa-2b 20 million units/m2/day intravenously (IV) 5 consecutive days per week for 4 weeks followed by peginterferon alfa-2b 1mcg/kg subcutaneously (SQ) once a week for 48 weeks.
62832228|NCT05003843|OTHER|Single Arm|Use of Indigo Aspiration System in patients with obstruction due to DVT
62832229|NCT04280510||Active coeliac patients|Patients with active coeliac disease
62832230|NCT04280510||Treated coeliac patients|Patients with coeliac disease on gluten free diet
62832231|NCT04280510||Sprue type I|Patients with refractory coeliac disease of type I
62609743|NCT04245202|ACTIVE_COMPARATOR|Active Comparator: HFNCOT|Set between 2 to 25 l/min, adjusted to obtain peripheral oxygen saturation \>92%.
62609744|NCT04245202|ACTIVE_COMPARATOR|Active Comparator: St-FMOT|To obtain oxygen saturation \>92%
62609745|NCT03023540|ACTIVE_COMPARATOR|PXT3003 dose 1|Period 1, PXT3003 : Liquid oral solution (0.6 mg/mL baclofen, 0.07 mg/mL naltrexone HCl and 210 mg/mL D-sorbitol), 5 mL bid (taken morning and evening with food) for 9 consecutive months
62832232|NCT04280510||Sprue type II|Patients with refractory coeliac disease of type II
62832233|NCT04280510||Intestinal Lymphoproliferations|Patients with intestinal lymphoproliferations
62832234|NCT04280510||Non coeliac enteropathies|Patients with non coeliac immune-mediated enteropathy
62832235|NCT04280510||Patients without neoplastic or inflammatory intestinal disease|Patients without neoplastic or inflammatory intestinal disease
62832236|NCT02545985|EXPERIMENTAL|Prolim stent implantation|In patients with symptomatic coronary artery disease Prolim stent was implanted in coronary arteries
62832237|NCT01185210|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo (mix of sugar and salt).
62832238|NCT01185210|EXPERIMENTAL|Alanine - 12.5|Subjects will receive 12.5 grams of alanine
62832239|NCT01185210|EXPERIMENTAL|Alanine - 25|Subjects will receive 25 grams of alanine.
62832240|NCT02121535|EXPERIMENTAL|T80/A5/H12.5 mg FDC|A Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination (FDC) tablet
62832241|NCT02121535|ACTIVE_COMPARATOR|T80/A5 mg FDC+H12.5 mg mono|A Telmisartan 80 mg/ Amlodipine 5 mg fixed dose combination (FDC) tablet and a Hydrochlorothiazide 12.5 mg tablet
62832242|NCT05327907||Training cohort|Training cohort consists of the patients diagnosed with intrahepatic cholangiocarcinoma who collected from January 2010 to July 2021 retrospectively.
62832243|NCT05327907||Internal validation cohort|Internal validation cohort consists of the intrahepatic cholangiocarcinoma patients who enrolled from September 2021 of Qilu Hospital prospectively.
62832244|NCT05327907||External validation cohort|External validation cohort consists of the intrahepatic cholangiocarcinoma patients who enrolled from September 2021 of Shandong Province Hospital, Jinan Military General Hospital and Jinan Central Hospital prospectively.
62049308|NCT01969110|ACTIVE_COMPARATOR|Perioperative|Oral IMPACT (1 L/day) for 5 days before surgery and by enteral feeding after surgery
62049309|NCT01969110|ACTIVE_COMPARATOR|Preoperative|Oral IMPACT 1000ml/day for 5 days (1 L/day) before surgery
62049310|NCT01393782|ACTIVE_COMPARATOR|Angiotensin|The angiotensin arm will receive angiotensin II acetate at an initial dose of 20ng/kg/min, titratable during the study (6 hours) for mean arterial pressure (MAP) goals as outlined in the protocol.
62049311|NCT01393782|PLACEBO_COMPARATOR|Control|Control patients will receive placebo intravenously equal in duration, color and volume to the intervention arm's angiotensin II.
62049312|NCT02660723|OTHER|Healthy Volunteers|A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
62049313|NCT05025657|EXPERIMENTAL|Program|
62251327|NCT04032704|EXPERIMENTAL|Part C - Arm 3: Randomized LV combination therapy|Combination dosing schedule 2.
62251328|NCT05435170|EXPERIMENTAL|Treatment sequence AB|Participants will receive linerixibat in fed state (Treatment A) in period 1 followed by linerixibat in fasted state (Treatment B) in period 2. The washout period will be of at least 7 days.
62251329|NCT05435170|EXPERIMENTAL|Treatment sequence BA|Participants will receive linerixibat in fasted state (Treatment B) in period 1 followed by linerixibat in fed state (Treatment A) in period 2. The washout period will be of at least 7 days.
62251330|NCT04450667|NO_INTERVENTION|Fasting|"Patient will be nil per os from midnight before their cesarean section"
62832245|NCT05294549|EXPERIMENTAL|Caring Contact|
62832246|NCT01662765|EXPERIMENTAL|Surgery|"Circular incision 2-3 mm below the skin level in the umbilicus through the subcutaneous fat towards the linea alba. Dissection of the subcutaneous tissue within the umbilicus and its deep connection to preperitoneal fat through the linea alba. Excision of the umbilical complex containing pilonidal cyst 3 mm below the umbilical ostium.~Approximation of the subcutaneous tissue with a single purse-string absorbable suture. The specimen, including the umbilical complex (pilonidal cyst, and involved skin and subcutaneous tissue), was transferred to department of pathology for histopathological examination."
62832247|NCT01662765|ACTIVE_COMPARATOR|Conservative|"Conservative treatment described as follow:~Under local anesthesia, extracting all protruding hair, and curetting the granulation tissue and pilonidal cyst deep in the umbilicus.~postoperative management include antibiotic treatment with ampicilline plus sulbactam and ornidazole, shaving surrounding skin, washing twice daily, and keeping umbilicus dry."
62832248|NCT02433418|ACTIVE_COMPARATOR|Tubal flushing with Urografin®|Women will have HSG using water soluble media
62832249|NCT02433418|NO_INTERVENTION|Control group|Women will not receive any intervention
62832250|NCT05609552||Tuberculosis patients|Patients with confirmed TB \[culture confirmed or positive by genotypic testing with GeneXpert, Accuporobe, etc.\] by genotype and/or culture testing positive for M. tuberculosis
62832251|NCT06066320|EXPERIMENTAL|MMST|
62832252|NCT06066320|ACTIVE_COMPARATOR|TSST|
62832253|NCT06404450|EXPERIMENTAL|Digital cognitive behavioral therapy (dCBT)|"The experimental group participants will receive immediate access to the Daylight program."
62049314|NCT05025657|PLACEBO_COMPARATOR|Control|
62049315|NCT04613908|ACTIVE_COMPARATOR|standard care or usual rehabilitation|It will consist of the usual treatment performed by the intensive care physiotherapist, it will be applied every day that the study lasts.
62832254|NCT06404450|NO_INTERVENTION|Waitlist Control|The waitlist control group participants do not have access to the Daylight program during the study, which lasts from pregnancy to 8-weeks after delivery. However, they will be given access to Daylight after completing the 10-week follow-up survey.
62832255|NCT02622126|ACTIVE_COMPARATOR|Normotensive pregnant women group|"Preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6% 130/0.4) (Voluven).~Sub arachnoid 10-12 mg hyperbaric bupivacaine Sub arachnoid 200 meg morphine Isotonic 0.9 sodium chloride (NaCl) solution ( 10 ml/kg) will be used as co loading during the duration of the operation Ephedrine 6 me intravenous will be used to treat severe hypotension (fall of \> 20% of mean arterial pressure from baseline) Atropine 0.5 mg intravenous will be used to treat bradycardia (fall of \>30% of heart rate from baseline or \<50 beats /minute and when associated with hypotension)"
62832256|NCT02622126|ACTIVE_COMPARATOR|Mild preeclampsia pregnant women group|"Preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6% 130/0.4) (Voluven).~Sub arachnoid 10-12 mg hyperbaric bupivacaine Sub arachnoid 200 meg morphine Isotonic 0.9 sodium chloride (NaCl) solution (NaCl) solution ( 10 ml/kg) will be used as co loading during the duration of the operation Ephedrine 6 me intravenous will be used to treat severe hypotension (fall of \> 20% of mean arterial pressure from baseline) Atropine 0.5 mg intravenous will be used to treat bradycardia (fall of \>30% of heart rate from baseline or \<50 beats /minute and when associated with hypotension)"
62832257|NCT02254135|EXPERIMENTAL|BEA 2180 BR solution - rising dose|
62832258|NCT02254135|PLACEBO_COMPARATOR|Placebo|
62832259|NCT06587425|EXPERIMENTAL|LM-302+Cadonilimab+Capecitabine|LM-302: 1.8mg/kg ivgtt d1, q2w; Canonilimab: 6mg/kg ivgtt d1, q2w; Capecitabine: 1000mg/m\^2 po bid d1-10, q2w.
62832260|NCT04316845|EXPERIMENTAL|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT
62832261|NCT06594614||Patients with Progressive Multifocal Leukoencephalopathy|
62049316|NCT04613908|EXPERIMENTAL|neuro muscular electro stimulation|They received 5 sessions per week (except weekends) of neuromuscular electrostimulation of 30 minutes duration. Also, every day that the study is carried out in the morning and in the afternoon, the subjects will receive the usual treatment performed by the intensive care physiotherapist.
62049317|NCT04613908|EXPERIMENTAL|early mobilization protocol|Throughout the duration of the study, an early mobilization protocol will be applied to apply a specific treatment based on different levels of treatment for each subject of the group; It differs from the usual procedure in protocolized progression according to the objectives reached by the patient, unlike the usual treatment, where the progression is in accordance with the clinical criteria of the treatment professional.
62832262|NCT06004739|OTHER|Antibiotics|Participants will be randomized to start or continue with antibiotics. Antibiotic type and duration targeted to lower urinary tract infection as directed by the Most Responsible Physician (MRP).
62832263|NCT06004739|OTHER|No Antibiotics|Participants will be randomized to no antibiotics
62832264|NCT06516900|NO_INTERVENTION|Own Shoe|Patients wearing their own appropriate shoes
62832265|NCT06516900|EXPERIMENTAL|OrthoFeet shoe|Patients wearing OrthoFeet shoes with standard inserts
62832266|NCT00632814|EXPERIMENTAL|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg qw|rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 70 IU/kg, dosing by injection once per week \[qw\] (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
62049318|NCT05808738|ACTIVE_COMPARATOR|therapeutic game group|therapeutic play will be played 10 minutes before the hydrotherapy treatment.
62049319|NCT05808738|NO_INTERVENTION|control group|No intervention was given to the children prior to hydrotherapy treatment.
62832267|NCT00632814|EXPERIMENTAL|rFVIII-FS (Kogenate FS, BAY14-2222), biw (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 70 IU/kg, dosing by injection twice per week \[biw\] (30 IU/kg \[day 1\] + 40 IU/kg \[day 4\]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
62049320|NCT03281473|EXPERIMENTAL|Arms A|Strategy 1 - Washout period - Strategy 2
62049321|NCT03281473|EXPERIMENTAL|Arms B|Strategy 2 - Washout period - Strategy 1
62049322|NCT01089231|PLACEBO_COMPARATOR|Placebo - healthy subjects|Dietary Supplement: corn oil capsules (6 per day) about 3 months
62049323|NCT01089231|PLACEBO_COMPARATOR|Placebo - hyperlipedemic subjects|Dietary Supplement: corn oil capsules (6 per day) about 3 months
62049324|NCT01089231|EXPERIMENTAL|Fish oil - hyperlipidemic subjects|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months
62049325|NCT01089231|EXPERIMENTAL|Fish oil - healthy subjects|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months.
62049326|NCT04000152|ACTIVE_COMPARATOR|Control group (group 1)|Deferred single day 6/7 blastocyst transfer with blastocyst selection according to morphology.
62049327|NCT04000152|EXPERIMENTAL|Intervention group (group 2)|Deferred single day 6/7 blastocyst transfer with blastocyst selection according to the analysis of the spent culture media (niPGT-A).
62609746|NCT03023540|ACTIVE_COMPARATOR|PXT3003 dose 2|"Period 1, PXT3003: Liquid oral solution (1.2 mg/mL baclofen, 0.14 mg/mL naltrexone HCl and 420 mg/mL D-sorbitol), 5 mL bid (taken morning and evening with food) for 9 consecutive months~Period 2, PXT3003: Liquid oral solution (0.6 mg/mL baclofen, 0.07 mg/mL naltrexone HCl and 210 mg/mL D-sorbitol), 10 mL bid (taken morning and evening with food)"
62609747|NCT01053520|EXPERIMENTAL|Sequence I|
62049328|NCT05152732|EXPERIMENTAL|VGB-R04|Single intravenous (i.v.) infusion of VGB-R04 Intervention: Gene Therapy / Gene Transfer
62049329|NCT01054417||Appendicitis|Patients with suspected appendicitis who are to be operated upon by diagnostic laparoscopy
62049330|NCT04920864|EXPERIMENTAL|Active 10 Hz dlPFC rTMS|10 Hz dorsolateral prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
62049331|NCT04920864|SHAM_COMPARATOR|Sham dlPFC rTMS|inactive dorsolateral prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
62049332|NCT04920864|EXPERIMENTAL|Active 1 Hz mPFC rTMS|1 Hz medial prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
62049333|NCT04920864|SHAM_COMPARATOR|Sham mPFC|inactive medial prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
62049334|NCT00778583|EXPERIMENTAL|1|Nitrofurantoin 100 mg capsules of Ranbaxy
62049335|NCT00778583|ACTIVE_COMPARATOR|2|Macrobid 100 mg capsules
62049336|NCT03513757|ACTIVE_COMPARATOR|propofol|Each patient will receive 1 mg/kg lidocaine followed by 2 mg/kg propofol IV once prior to continuous propofol infusion for MRI sedation at 200 mcg/kg/min. Dose will be increased by 50 mcg/kg/min up to 300 mcg/kg/min for movement and decreased to 150 mcg/kg/min if no movement after 30 minutes. Additional 1 mg/kg propofol bolus administered at time of each movement. Study to be terminated if movement persists despite above interventions.
62049337|NCT03513757|EXPERIMENTAL|propofol dexmedetomidine|Each patient will receive: 1 mg/kg lidocaine, 2 mg/kg propofol, 4 mcg/kg glycopyrrolate and single dose dexmedetomidine administered prior to scan. Dexmedetomidine dose is dependent on expected duration of scan and will be equal to 1 mcg/kg/hour x duration of scan in hours. 1 mg/kg propofol will be administered for movement up to 2 times. For continued movement after that, begin propofol infusion at 150 mcg/kg/min. Study to be terminated if movement persists despite above interventions.
62251331|NCT04450667|ACTIVE_COMPARATOR|Rehydration|Patient will receive 400 mL of Nutricia Preop ® 2 hours before their cesarean section
62609748|NCT01053520|EXPERIMENTAL|Sequence II|
62609749|NCT01053520|EXPERIMENTAL|Sequence III|
62609750|NCT06718673|EXPERIMENTAL|virtual delivery room visit|Participants were informed about the study, the Participant Information Form was provided during the initial interview, and the Belief Scale for Normal Delivery pre-test was administered. Following, participants in the intervention group were provided with a link to a virtual delivery room introduction video (https://www.youtube.com/watch?v=EyCt-jTDCVs), created using the actual delivery room environment, and were encouraged to watch it., a second interview was conducted four days after the initial interview, during which post-test data were collected using the Belief Scale for Normal Delivery form. After all participants completed their birth processes, a third interview was conducted, and the data collection process was finalized using the Birth Adaptation Self-Assessment Scale and Birth Adaptation Midwife Assessment Scale forms.
62609751|NCT06718673|OTHER|Standard of care|Participants were informed about the study, the Participant Information Form was provided during the initial interview, and the Belief Scale for Normal Delivery pre-test was administered. However, no intervention related to the virtual delivery room visit was conducted with the control group. This group was only subjected to a monitoring process after the pre-test. Four days after the initial interview, a second interview was conducted with participants in the control group, during which post-test data were collected using the BSND form. After the birth processes of the participants in the control group were completed, a third interview was conducted, and the data collection process was completed using the Birth Adaptation Self-Assessment Scale and Birth Adaptation Midwife Assessment Scale forms.
62609752|NCT04907500|EXPERIMENTAL|Multifocal IOL|Implantation of a multifocal intraocular lens
62609753|NCT00379431|EXPERIMENTAL|Administration of rituximab and methylprednisolone|
62609754|NCT02799173|EXPERIMENTAL|Systemic lupus erythematosus|RANKL/OPG ratio bone densitometry fan beam CT scan Doppler ultrasound
62609755|NCT06531629||Kidney cancer patients with second primary malignancy (SPM)|Patients diagnosed with first primary kidney cancer and second primary malignancy between 2000 and 2020
62609756|NCT06531629||Kidney cancer patients without SPM|Patients diagnosed with only first primary kidney cancer between 2000 and 2020
62609757|NCT05260216|EXPERIMENTAL|Experimental subgroup of Cariostat|Use Cariostat as the caries risk assessment tool to divide the children into different risk levels. Based on the results, children with low risk of caries will receive twice fluoride foam each year and oral hygiene guidance, children with middle or high risk of caries will receive forth fluoride applications each year, oral hygiene guidance and professional caries treatment.
62609758|NCT05260216|EXPERIMENTAL|Experimental subgroup of Cariogram|Use Cariogram as the caries risk assessment tool to divide the children into different risk levels. Based on the results, children with low risk of caries will receive twice fluoride foam each year and oral hygiene guidance, children with middle or high risk of caries will receive forth fluoride applications each year, oral hygiene guidance and professional caries treatment.
62609759|NCT05260216|PLACEBO_COMPARATOR|Control group|Use Cariogram and as the caries risk assessment tool to divide the children into different risk levels. All children will receive routine prevention including wice fluoride foam each year and oral hygiene guidance.
62609760|NCT01538849|EXPERIMENTAL|YH4808 A mg (Twice daily)|YH4808 A mg (Twice daily, Oral administration)
62609761|NCT01538849|EXPERIMENTAL|YH4808 B mg (Once daily)|YH4808 B mg (Once daily, Oral administration)
62609762|NCT01538849|EXPERIMENTAL|YH4808 B mg (Twice daily)|YH4808 B mg (Twice daily, Oral administration)
62609763|NCT01538849|EXPERIMENTAL|YH4808 C mg (Once daily)|YH4808 C mg (Once daily, Oral administration)
62609764|NCT01538849|ACTIVE_COMPARATOR|Esomeprazole 40mg (Once daily)|Esomeprazole 40mg (Once daily, Oral administration)
62609765|NCT03280225||VAMC's receiving implementation support for REACH VET|This cohort consists of 28 VA Medical Centers (VAMC's) needing additional implementation support to fully implement REACH VET as identified by Veteran Integrated Service Network (VISN) leadership, and that agreed to participate.
62609766|NCT03725774|EXPERIMENTAL|Quasi-experimental uncontrolled, before-and-after|The intervention will consist of the use of the GRIP (Getting Research into Practice) model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action
62609767|NCT00986986|EXPERIMENTAL|Active Drug (extended release niacin)|Subjects in this arm will be given 12 weeks of extended release niacin. Intervention: extended release niacin (Niaspan) starting at 500 mg by mouth daily and titrated to a maximum dose of 1500 mg by mouth daily. Titration will depend on patient tolerability.
62609768|NCT00986986|NO_INTERVENTION|Observation|Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin
62609769|NCT03707834|NO_INTERVENTION|WIC Standard Care (SC)|Participants assigned to the WIC standard care arm will receive usual care offered to pregnant women at WIC.
62609770|NCT03707834|EXPERIMENTAL|Antenatal Obesity Treatment (AO)|The AO arm consists of a multi-component, theory- and evidence-based intervention and includes weight-related behavior change through goal setting and self-monitoring, behavioral skills training, interpersonal support, and social modeling strategies.
62049338|NCT05307770|EXPERIMENTAL|Immediate Release Melatonin, Then Extended Release Melatonin|Subjects will receive immediate release melatonin 5 mg orally at 9 pm every night for 4 weeks. After a washout period of 2 weeks, they then receive extended release melatonin 5 mg orally at 9 pm every night for 4 weeks.
62049339|NCT05307770|EXPERIMENTAL|Extended Release Melatonin, Then Immediate Release Melatonin|Subjects will receive extended release melatonin 5 mg orally at 9 pm every night for 4 weeks. After a washout period of 2 weeks, they then receive immediate release melatonin 5 mg orally at 9 pm every night for 4 weeks.
62609771|NCT04848259|PLACEBO_COMPARATOR|Control|No drug given before surgery
62049340|NCT05180708|ACTIVE_COMPARATOR|Active|
62049341|NCT05180708|PLACEBO_COMPARATOR|Vehicle|
62049342|NCT02418247|ACTIVE_COMPARATOR|low dose RAI|Low dose RAI (radioactive iodine I-131, 30mCi) will be given to ablate remnant thyroid tissue.
62049343|NCT02418247|SHAM_COMPARATOR|diagnostic RAI|Diagnostic RAI (radioactive iodine I-123, 2-6mCi) will be given to achieve postRAI scan.
62049344|NCT02944084|EXPERIMENTAL|Rice bran extract|2 g of unprocessed rice bran extract
62049345|NCT02944084|EXPERIMENTAL|Porridge in water|35 g of porridge containing 2 g of rice bran extract mixed with 95 ml of warm water
62049346|NCT02944084|EXPERIMENTAL|Porridge in milk|35 g of porridge containing 2 g of rice bran extract mixed with 95 ml of warm milk (3.8% fat)
62049347|NCT05504226|EXPERIMENTAL|Teneligliptin 20 mg|Once daily for 24 weeks
62049348|NCT05504226|PLACEBO_COMPARATOR|Teneligliptin placebo|Once daily for 24 weeks
62049349|NCT04160325|EXPERIMENTAL|3 months exclusive enteral nutrition plus azathioprine|patients underwent surgery in this arm will given 3 months exclusive enteral nutrition,and free diet after 3 months. All patients will be adminsrated with oral azathioprine to preventing disease recurrence.
62049350|NCT04160325|ACTIVE_COMPARATOR|normal diet plus azathioprine|patients underwent surgery in this arm will given free diet all through. All patients will be adminsrated with oral azathioprine to preventing disease recurrence.
62049351|NCT04563468|EXPERIMENTAL|Strength inspiratory muscle training group|Strength IMT
62049352|NCT04563468|SHAM_COMPARATOR|Endurance inspiratory muscle training group|Endurance IMT
62441099|NCT02300376|EXPERIMENTAL|Calcium edetate de sodium versus inulin|The designing a Bayesian model of the plasma clearance of Calcium edetate de sodium is compared to the renal clearance of Inulin.
62609772|NCT04848259|ACTIVE_COMPARATOR|Dexamethason|Dexamethason will be given IV before surgery
62049353|NCT02647606|EXPERIMENTAL|McGrath Group|MgGrath videolaryngoscope will be used for nasotracheal intubation with MILS
62049354|NCT02647606|EXPERIMENTAL|Pentax-AWS Group|Pentax-AWS videolaryngoscope will be used for nasotracheal intubation with MILS
62049355|NCT02647606|EXPERIMENTAL|Macintosh Laryngoscope Group|Macintosh Laryngoscope will be used for nasotracheal intubation with MILS
62049356|NCT03504163|EXPERIMENTAL|High Risk T1 Bladder Cancer Cohort|Pts will receive pembrolizumab/MK-3475 after transurethral resection of bladder tumor/TURBT in comb w/BCG as initial therapy. Pembrolizumab (MK-3475) will be administered as a 400 mg IV infusion at 6-wk intervals for 9 doses over a 48-wk period, unless there is unacceptable toxicity or other reasons to discontinue treatment occur. Intravesical BCG therapy (TICE strain, 50 mg) will be given 1x-weekly for 6 consecutive wks as a standard induction course, followed by maintenance BCG consistent w/standard clinical practice. BCG will start on wk 3 after the first infusion of pembrolizumab (400 mg) to allow for initial priming of T cells to further enhance the effects of BCG treatment.
62049357|NCT03504163|EXPERIMENTAL|Exploratory cohort for high-grade non-muscle-invasive upper tract urothelial carcinoma|Pts will receive pembrolizumab (MK-3475) administered after ureteroscopy/laser ablation in comb w/BCG as initial therapy. Pembrolizumab (MK-3475) will be administered as 400 mg IV infusion at 6-week intervals for 9 doses over a 48-week period, unless there is unacceptable toxicity or other reasons that would warrant the discontinuation of treatment. Pts will receive once-weekly BCG therapy (TICE strain, 50 mg) for 6 consecutive wks as a standard induction course administered through a percutaneous nephrostomy tube in antegrade fashion for patients with high-grade NMI-UTUC, consistent with standard clinical practice. BCG will start on wk 3 after the first infusion of pembrolizumab (400 mg) to allow for initial priming of T cells to further enhance the effects of BCG treatment.
62441100|NCT01097356|NO_INTERVENTION|common care|HPV+ patients with LSIL on their PAP smear, waiting for 6 months to receive a new PAP smear
62441101|NCT01097356|EXPERIMENTAL|probiotic drinkers|HPV+, LSIL patients who will drink the study drink for 6 months
62609773|NCT04848259|ACTIVE_COMPARATOR|Natural honey|Honey will be placed locally after impaction removal
62609774|NCT04848259|ACTIVE_COMPARATOR|Dexamethason and natural honey|Dexamethason will be given IV before surgery and Honey will be placed locally after impaction removal
62049358|NCT01787448|EXPERIMENTAL|Ibuprofen 5% topical gel|
62049359|NCT01787448|EXPERIMENTAL|Topical gel vehicle|
62049360|NCT01787448|ACTIVE_COMPARATOR|Sodium lauryl sulfate 0.1%|
62049361|NCT01787448|SHAM_COMPARATOR|Sodium chloride solution 0.9% (saline)|
62049362|NCT05670379|EXPERIMENTAL|Exenatide Implant|One Exenatide Implant that delivers approximately 52 microgram/day of exenatide will be inserted subdermally just under the skin of the upper outer arm for the 9-week treatment period.
62049363|NCT05670379|ACTIVE_COMPARATOR|Bydureon BCise (exenatide extended release)|2 mg subcutaneous injection every week for a duration of 9 weeks
62609775|NCT04946552|ACTIVE_COMPARATOR|Individuals with normal BMI|(BMI 18-25 kg/m2)
62609776|NCT04946552|ACTIVE_COMPARATOR|Individuals with obesity|(BMI 30-40 kg/m2)
62609777|NCT06545942|EXPERIMENTAL|MOMA-313 Monotherapy (Treatment Arm 1)|MOMA-313 administered as a single-agent in 21-day cycles.
62609778|NCT06545942|EXPERIMENTAL|MOMA-313 in Combination with Olaparib (Treatment Arm 2)|MOMA-313 administered together with twice daily (BID) olaparib in 28-day cycles.
62609779|NCT04808518||Bx reg group|
62609780|NCT04808518||non-Bx reg group|
62832268|NCT00632814|EXPERIMENTAL|rFVIII-FS (Kogenate FS, BAY14-2222), tiw (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 75 IU/kg, dosing by injection three times per week \[tiw\] (3 x 25 IU/kg \[day 1, 3, 5\]) for 9 months. No escalation opportunity for participants in this group
62609781|NCT03410901|EXPERIMENTAL|Treatment (radiation therapy, SD-101, BMS-986178)|Patients receive radiation therapy on days 1-2, TLR9 agonist SD-101 and anti-OX40 antibody BMS-986178 intratumorally on days 2, 9, 16, 23, and 30, and anti-OX40 antibody BMS-986178 IV on days 2, 30, 58, 86, 114, and 142 in the absence of disease progression or unacceptable toxicity.
62609782|NCT04172428||Healthy volunteers|Young healthy volunteers between the ages of 18-55.
62609783|NCT01199822|EXPERIMENTAL|Olaratumab|
62609784|NCT04297475||rheumatoid arthritis|The patients are diagnosed with RA according to the American College of Rheumatology (ACR) criteria, and the current clinical state was in-active or relapse. The patients receive final diagnosis and disease evaluation by two experienced rheumatologists
62609785|NCT02600767|OTHER|Artemether-Lumefantrine|Three days of standard treatment. This is a standard combination therapy for the treatment of P. falciparum malaria.
62609786|NCT01324570|EXPERIMENTAL|Overall BTDS|Buprenorphine transdermal system
62609787|NCT01573754|EXPERIMENTAL|Hydroxychloroquine|Low-dose hydroxychloroquine 100 mg by mouth twice weekly
62609788|NCT01573754|ACTIVE_COMPARATOR|Phlebotomy|Phlebotomy 450 mL biweekly
62609789|NCT06304740|EXPERIMENTAL|IMG-007 Cohort 1 (Healthy Participant)|Cohort 1 will receive a single subcutaneous dose of IMG-007 Dose 1 or matching placebo.
62609790|NCT06304740|EXPERIMENTAL|IMG-007 Cohort 2 (Healthy Participant)|Cohort 2 will receive a single subcutaneous dose of IMG-007 Dose 2 or matching placebo.
62609791|NCT06304740|EXPERIMENTAL|IMG-007 Cohort 3 (Healthy Participant)|Cohort 3 will receive a single subcutaneous dose of IMG-007 Dose 3 or matching placebo.
62609792|NCT02430103||Chemotherapy plus GnRHa|Patients of the group will receive (neo)chemotherapy plus GnRHa ( Goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration).
62609793|NCT02430103||Chemotherapy|Patients of the group will receive (neo)chemotherapy merely.
62049364|NCT05670379|ACTIVE_COMPARATOR|Semaglutide|1.0 mg subcutaneous injection every week for a duration of 9 weeks
62049365|NCT04989127||group 1|platelet-rich fibrin placed into the socket of the extracted tooth.+ Augmentin 1 gr tablet prescribed 3 times a day
62049366|NCT04989127||group 2|platelet-rich fibrin + 0.5 ml amoklavin I.V. 1.2 gr placed into the socket of the extracted tooth.
62609794|NCT01167556|EXPERIMENTAL|Family Motivational Intervention|An intervention provided to parents consisting of 6 sessions of training in Interactions Skills and 6 sessions training in Motivational Interviewing.
62609795|NCT01167556|ACTIVE_COMPARATOR|Routine care for parents|Routine care for parents consisting of 2 sessions psycho-education and individual support
62609796|NCT06498687|EXPERIMENTAL|Intranasal Theophylline|Theophylline Intranasal Spray strength 3.1mg/mL, providing a per spray dose of 140 microgram and total daily dose of 1120 microgram per day (2 sprays per naris BID). Intervention is self-administered.
62609797|NCT02230540|EXPERIMENTAL|Sequence A|"Catheterization with SelfCath (comparator) followed by measurement of residual urine.~Then catheterization with Product A in different positions. Measurement of residual urine at different positions."
62609798|NCT02230540|EXPERIMENTAL|Sequence B|"Based on results from sequence A, sequence B may or may not be initiated.~Catheterization with SelfCath (comparator) followed by measurement of residual urine.~Then catheterization with Product B in different positions. Measurement of residual urine at different positions."
62609799|NCT06731738|EXPERIMENTAL|HFpEF with HCM|"Heart failure patients with preserved ejection fraction caused by hypertrophic cardiomyopathy.~Participants will have 2 cardiac MRIs (gadolinium- and manganese-enhanced) at Visit 2 and Vist 3, respectively."
62609800|NCT06731738|EXPERIMENTAL|HFpEF with CA|"Heart failure patients with preserved ejection fraction caused by cardiac amyloidosis.~Participants will have 2 cardiac MRIs (gadolinium- and manganese-enhanced) at Visit 2 and Vist 3, respectively."
62609801|NCT06731738|EXPERIMENTAL|Healthy Volunteers|Participants will have 2 cardiac MRIs (gadolinium- and manganese-enhanced) at Visit 2 and Vist 3, respectively.
62609802|NCT00634049|EXPERIMENTAL|Isavuconazole|Administration of isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days followed by daily administration of isavuconazole (IV) or oral
62609803|NCT04108780||CBD exploration with T-tube|repair of CBD after CBD exploration over T-tube
62609804|NCT04108780||CBD exploration with primary repair|primary repair of CBD after CBD exploration
62609805|NCT04056000|EXPERIMENTAL|Exercising following the ingestion of a high-carbohydrate br|60 minutes of cycling, with the ingestion of a high-carbohydrate breakfast and 200 mg of caffeine.
62609806|NCT04056000|EXPERIMENTAL|Exercising following the ingestion of caffeine only|60 minutes of cycling, with the ingestion of 200 mg of caffeine.
62609807|NCT04056000|EXPERIMENTAL|Exercising in the absence of breakfast or caffeine ingestion|60 minutes of cycling, without the ingestion of breakfast, or caffeine.
62609808|NCT04927494|EXPERIMENTAL|Black women cervical cancer screening|Participants in this group with receive the Health is Wealth intervention.
62609809|NCT05367882||critically ill COVID-19 patients in ICU|critically ill COVID-19 patients who are recommended to receive IL-6R antagonist as tocilizumab at the dosage of 8 mg/kg with a second dose 12 hours after the first dosage, or sarilumab at the dosage of 200 mg subcutaneously or 200 to 800 mg intravenously.
62609810|NCT06239779|EXPERIMENTAL|Education Group|"The Education Group is comprised of study participants who receive an educational intervention aimed at enhancing their understanding and management of fibromyalgia. This group is designed to assess the impact of fibromyalgia education on various aspects of participants' well-being, including pain levels, quality of life, smart phone addiction, and daily activities.~Participants in the Education Group will attend a brief educational session. The educational content covers the following key topics: an overview of fibromyalgia, coping strategies and potential harmful effects of smart phone addiction on fibromyalgia.~The primary objective of the Education Group is to evaluate the influence of fibromyalgia education on pain levels, quality of life and physical function (measured using the FIQR) and smart phone addiction (measured using the SAS-SV) and socialization frequency, exercise frequency, sleep quality and daily screen time based on participant diaries."
62609811|NCT06239779|NO_INTERVENTION|Control Group|"The Control Group is a vital component of this study, serving as a reference group for evaluating the impact of the Education Group's intervention. Participants in this group do not receive the structured educational intervention. Instead they follow their usual routines and receive standard care for fibromyalgia, which may include any recommendations typically offered by their healthcare providers but they are monitored similarly to the participants in the Education Group.~The primary objective of the Control Group is to provide a baseline against which the effects of the educational intervention received by the Education Group can be compared. By not receiving the intervention, this group helps assess whether the educational program has a measurable impact on various aspects of participants' well-being when compared to standard care."
62609812|NCT04592627||Simulated home environment visit with the dyad participants|The cohort consists of six stroke survivor-informal caregiver (e.g., spouse or family member) dyads. Individual dyads will participate in the simulated home environment visit while the investigative team collects the data.
62609813|NCT06731088|ACTIVE_COMPARATOR|Midazolam|
62609814|NCT06731088|ACTIVE_COMPARATOR|Remazolam benzenesulfonate|
62609815|NCT00655512|ACTIVE_COMPARATOR|1|
62609816|NCT00655512|ACTIVE_COMPARATOR|2|
62609817|NCT00655512|ACTIVE_COMPARATOR|3|
62609818|NCT00655512|ACTIVE_COMPARATOR|4|
62609819|NCT00655512|PLACEBO_COMPARATOR|5|
62609820|NCT01635907|EXPERIMENTAL|Dovitinib|
62609821|NCT06464926|EXPERIMENTAL|ON Group|"Participants assigned to the ON treatment group will begin with specified device programming values at the randomization visit. Device programming values may be adjusted at follow-up study visits during the blinding period.~At the conclusion of the 4-month visit, participants will have their devices programmed to individualized therapy as determined by the Investigator. Investigators may adjust programming values at additional follow-up study visits."
62609822|NCT06464926|EXPERIMENTAL|OFF Group|"Participants assigned to the OFF treatment group will begin with device programming values set to off at the randomization visit. These settings will continue until the 4-month visit.~At the conclusion of the 4-month visit, participants will receive specified device programming values. Device programming values may be adjusted at follow-up study visits. At the conclusion of the 8-month visit, participants will have their devices programmed to individualized therapy as determined by the Investigator."
62609823|NCT05572372|EXPERIMENTAL|ACT group|Psychological intervention will consist in an 8-session individual on line-delivered ACT-based treatment.
62609824|NCT04140240|EXPERIMENTAL|İntervention group|Experimental: İntervention group
62609825|NCT04140240|NO_INTERVENTION|Control group|Control group: No intervention
62609826|NCT00677573|ACTIVE_COMPARATOR|UrFSH|
62609827|NCT02608008||Data analysis transfemoral aortic valve implantation|Periinterventional data analysis during structural heart procedures like transfemoral aortic valve implantation with and without the use of EchoNavigator System Release II.
62609828|NCT02608008||Data analysis MitraClip|Periinterventional data analysis during structural heart procedures like MitraClip Implantations with and without the use of EchoNavigator System Release II.
62049367|NCT04989127||group 3|platelet-rich fibrin placed into the socket of extracted tooth + Clin 150 mg capsule prescribed 4 times a day
62049368|NCT04989127||group 4|platelet-rich fibrin + 0.5 ml Clin 600 mg/4 ml IM/IV, 0.5 ml placed into the socket of the extracted tooth.
62441102|NCT05296512|EXPERIMENTAL|PEMBROLIZUMAB and LENVATINIB|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~The names of the study drugs involved in this study are:~* Lenvatinib~* Pembrolizumab~Treatment will continue until progression of disease or unacceptable toxicity. Participants will be followed for up to 36 months after discontinuation of study treatment."
62609829|NCT02608008||Data analysis PFO|Periinterventional data analysis during structural heart procedures like PFO implantations with and without the use of EchoNavigator System Release II.
62609830|NCT02608008||Data analysis ASD|Periinterventional data analysis during structural heart procedures like ASD implantations with and without the use of EchoNavigator System Release II.
62609831|NCT01110213|EXPERIMENTAL|Physical activity|Participants received individual tailored telephone counseling and group-tailored newsletters encouraging leisure time physical activity. Content was based on goal setting theory and decisional balance.
62609832|NCT01110213|EXPERIMENTAL|Fruit and vegetable|Participants received individual tailored telephone counseling and group-tailored newsletters encouraging fruit and vegetable intake. Content was based on goal setting theory and decisional balance.
62049369|NCT04989127||control group|platelet-rich fibrin placed into the socket of extracted tooth and no antibiotic is prescribed.
62049370|NCT04610931|EXPERIMENTAL|Cybertherapy|use of cybertherapy (6 sessions) in addition to cognitive behavioral therapy (6 sessions) + pharmacological treatment
62049371|NCT04610931|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual is a cognitive behavioral therapy (6 sessions) + pharmacological treatment
62441103|NCT02788331||Hospitals with increasing activity|Hospitals experiencing an increase in the volume of surgical procedures over the study period
62441104|NCT02788331||Hospitals with decreasing activity|Hospitals experiencing a decrease in the volume of surgical procedures over the study period
62441105|NCT02788331||Hospitals with stable activity|Hospitals experiencing no change in the volume of surgical procedures over the study period
62441106|NCT02727140|EXPERIMENTAL|Yoga with Asana (yoga postures)|
62609833|NCT01931241|EXPERIMENTAL|Cohort 1, 500 mg|Cohort 1 receives SDD 500 mg AHRO-001; one week later receives MDD of 500 mg bid 7 days, then 500 mg tid 7 days
62832269|NCT05603702|EXPERIMENTAL|Dose Escalation Level|In the first 3-patient cohort, the dose of lacosamide given is 50mg/d BID. Enrollment to the next higher dose cohort will be initiated only if none of the 3 participants exhibits a DLT in the 21 ±3 days following completion of the 7 day drug therapy. Dose escalation will proceed according to the Bayesian optimal interval (BOIN) design at incremental increase of 100mg/day in two divided doses. The maximum daily dose of lacosamide will be 400mg/day.
62832270|NCT03210194|ACTIVE_COMPARATOR|Standard Neonatal Resuscitation Training|Standard training will be conducted through a theoretical-practical course, which will be administered once during the study period, to all health professionals of the selected facilities, according to the randomization. It is an 8-hour course, with 3 hours of theory and 5 hours of practice, which will take place during a single day. The course will be performed by staff of the Neonatal Unit of the Instituto Nacional de Salud del Niño (National Institute of Child Health, Lima, Peru), and will be coordinated by an NRP instructor accredited by the American Academy of Pediatrics. Participants who have completed their attendance to theoretical sessions, participated in the simulated practices and approved the printed exams taken the same day will we granted a Standard Certification.
62049372|NCT03432923|EXPERIMENTAL|Benzocaine 8 mg|Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
62049373|NCT03432923|PLACEBO_COMPARATOR|Placebo|Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
62049374|NCT03189784|EXPERIMENTAL|mobilization group|this group will receive mobilization with movement techniques.
62609834|NCT01931241|EXPERIMENTAL|Cohort 2, 750 mg|Cohort 2 receives SD of 750 AHRO-001, then 7 days of 750 mg BID AHRO-001, then 7 days of 750 mg TID AHRO-001.
62049375|NCT03189784|NO_INTERVENTION|Control group|The control group will receive no intervention
62049376|NCT04992351||WALANT group|WALANT was used exclusively as anesthesia method for the operation
62049377|NCT04992351||control|tourniquet with regional or general anesthesia was used for the operation
62049378|NCT01972529|EXPERIMENTAL|Group A (avatrombopag, lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
62441107|NCT02727140|EXPERIMENTAL|Yoga without Asana (yoga postures)|
62441108|NCT02727140|NO_INTERVENTION|Wait-list control group|
62609835|NCT01931241|EXPERIMENTAL|Cohort 3, 1000 mg|Cohort 3 identical design as Cohorts 1 and 2, but SD is 1000 mg AHRO-001.
62609836|NCT01931241|EXPERIMENTAL|Cohort 4, 21 day dosing|Cohort 4 receives 21 days tid administration of AHRO-001 using the best tolerated dose as determined by cohorts 1, 2 \& 3
62609837|NCT01931241|EXPERIMENTAL|Cohort 5, 12 weeks dosing|Cohort 5 receives 12 weeks tid administration of AHRO-001 using the best tolerated dose as determined by the first 4 cohorts.
62049379|NCT01972529|PLACEBO_COMPARATOR|Group B (placebo, lower baseline platelet count)|placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5
62049380|NCT01972529|EXPERIMENTAL|Group C (avatrombopag, higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5
62049381|NCT01972529|PLACEBO_COMPARATOR|Group D (placebo, higher baseline platelet count)|placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
62049382|NCT05700084|EXPERIMENTAL|Utidelone Capsule (Part 1)|Utidelone Capsule, available as 10 mg/capsule and 15 mg /capsule. Doses between 50 mg/m2/d and 120 mg/m2/d administered orally will be explored. Patients will be dosed for 5/7 consecutive days in a 21 day cycle.
62049383|NCT05700084|EXPERIMENTAL|Utidelone Capsule/Utidelone Injection (Group A-B, Part 2)|At cycle 0, patients will take Utidelone Capsule in fasted status at 60 mg/m2/d. At cycle 1, patients will be administered Utidelone Injection by iv drip at 30 mg/m2/d. At Cycle 2, patients will take Utidelone Capsule (after meals) at 60 mg/m2/d.
62049384|NCT05700084|EXPERIMENTAL|Utidelone Injection/Utidelone Capsule (Group B-A, Part 2)|At cycle 0, patients will be administered Utidelone Injection by iv drip at 30 mg/m2/d. At cycle 1, patients will take Utidelone Capsule in fasted status at 60 mg/m2/d. At cycle 2, patients will take Utidelone Capsule (after meals) at 60 mg/m2/d.
62441109|NCT02024828|EXPERIMENTAL|Early/Slow|Infants were offered oral feedings beginning at 32 weeks PMA. They were offered 2 oral feedings per day for 3 days (Days 1-3). The number of oral feedings offered per day increased by 1 feeding every other day until day 14 when they were offered 8 oral feedings each day (Days 4-5, 3 oral feeds offered; Days 6-7, 4 oral feeds offered; Days 8-9, 5 oral feeds offered; Days 10-11, 6 oral feeds offered; Days 12-13, 7 oral feeds offered; Day14, 8 oral feeds offered). Any feedings not offered orally were provided by gavage.
62441110|NCT02024828|EXPERIMENTAL|Early/Fast|Infants were first offered oral feedings beginning at 32 weeks PMA. They were offered 8 oral feedings every day, at each of 8 scheduled daily feedings.
62609838|NCT05166720|EXPERIMENTAL|NIDCAP care|The training core group was formed by the project team. After a one-month clinical unified training on the best evidence of NIDCAP for the VLBW nursing professional group, the best evidence of NIDCAP was applied to the intervention group.
62609839|NCT05166720|NO_INTERVENTION|routine nursing care|routine nursingPerform routine care for NICU infants according to the nursing routine of each hospital
62609840|NCT00678470|EXPERIMENTAL|Single Arm|Investigational intervention without random assignment
62609841|NCT02535169|EXPERIMENTAL|Health Education and Coaching|1. To evaluate whether a health education and coaching strategy in overweight and obese adolescents (≥85th percentile) with high risk for type 2 diabetes is superior to usual care (single nutrition consultation) for weight management, clinical health outcomes (measures of glucose tolerance), lifestyle behavior outcomes (diet and physical activity) and outcomes of importance to patients such as satisfaction with the health care team, treatment goals, and psychosocial functioning.
62609842|NCT02535169|PLACEBO_COMPARATOR|Usual Care|1. Dietary consult only
62609843|NCT03650296||Resusci Baby|Resusci Baby used for the simulated emergency scenario
62609844|NCT03650296||MegaCode-Kid|MegaCode-Kid used for the simulated emergency scenario
62251332|NCT04649957||Cohort Observation|"Study investigators will identify eligible participants within 72 hours of expected discharge from hospital. Eligibility will be determined using the criteria outlined in section 5.1 which incorporates the Post-COVID-19 Functional Status (PCFS) Scale, a tool which has been developed and endorsed by the European Respiratory Society to measure functional status over time following COVID-19 infection. Patients graded 2, 3 or 4 on the PCFS will be eligible for participation. Eligible patients will be provided with a detailed explanation of the study including the provision of written information (PIS). Patients will be given time to consider participation in the research study before being approached again by the research team.~If the patient expresses an interest in study participation the research team will invite participants to a baseline data collection session that will be held at the University of Derby (Kedleston Road campus) in the days following discharge."
62251333|NCT06174051|EXPERIMENTAL|FF EMDR|Subjects in this group will receive two EMDR treatment sessions following the flashforward protocol.
62441111|NCT02024828|EXPERIMENTAL|Late/Slow|Infants were offered oral feedings beginning at 34 weeks PMA. They were offered 2 oral feedings per day for 3 days (Days 1-3). The number of oral feedings offered per day increased by 1 feeding every other day until day 14 when they were offered 8 oral feedings each day (Days 4-5, 3 oral feeds offered; Days 6-7, 4 oral feeds offered; Days 8-9, 5 oral feeds offered; Days 10-11, 6 oral feeds offered; Days 12-13, 7 oral feeds offered; Day14, 8 oral feeds offered). Any feedings not offered orally were provided by gavage.
62441112|NCT02024828|EXPERIMENTAL|Late/Fast|Infants were offered oral feedings beginning at 34 weeks PMA. They were offered 8 oral feedings every day, at each of 8 scheduled daily feedings.
62441113|NCT04443322|EXPERIMENTAL|Durvalumab and Lenvatinib|"Participants receive intravenous (IV) durvalumab at 1500mg on Day 1 of each 28-day cycle. Number of cycles: until unacceptable toxicity develops or \>42 days before liver transplantation (If patients with locally advanced HCC would undergo liver transplant).~Patients receive Lenvatinib 8-12mg(basing on weight), once a day, oral at least 38 days of each 6 weeks cycle until \>7 days before liver transplantation(If patients with locally advanced HCC would undergo liver transplant)."
62609845|NCT03650296||Ambu® Junior|Ambu® Junior used for the simulated emergency scenario
62609846|NCT05854043|EXPERIMENTAL|ERAS group|In this group, patients will be treated with modified ERAS protocol.
62609847|NCT05854043|OTHER|control group|In this group, patients will be treated with routine protocol.
62609848|NCT01891318|EXPERIMENTAL|Treatment (radiosurgery, surgery)|Patients undergo radiosurgery on day 0. Within 2 weeks, patients undergo surgical resection.
62441114|NCT02448628|EXPERIMENTAL|CS-3150|CS-3150 1.25 to 5.0 mg , orally, once daily after breakfast for 12 weeks
62441115|NCT00325533|EXPERIMENTAL|Screening & Enhanced Intervention|After an intensive 10-week baselne screening, the enhanced intervention group barbers will be trained to measure blood pressure and deliver health messages related to blood pressure control during each customer's visit.
62441116|NCT00325533|ACTIVE_COMPARATOR|Screening|After the intensive 10-week baseline BP screening (an intervention in itself), the barbershops in the comparison arm received a continual supply of American Heart Association pamphlets on Hypertension in African Americans.
62609849|NCT04910672|ACTIVE_COMPARATOR|Control Group|The control group (n = 30) will only carry out a bilateral global pelvic manipulation
62609850|NCT04910672|EXPERIMENTAL|Experimental Group|The experimental group (n = 30) will be treated following an osteopathic treatment, through a bilateral global pelvic manipulation and a specific internal technique for mobility of the cervix
62609851|NCT06220409|EXPERIMENTAL|Dance|The patients persuading dance classes two times a wek for 3 months .
62609852|NCT06220409|NO_INTERVENTION|Passive|The patients engage in no structured or self-induced physical exercise or activity (sedentary individuals)
62609853|NCT06220409|NO_INTERVENTION|Healthy subjects|The subjects engage in sports recreationally
62609854|NCT05342428|EXPERIMENTAL|Cohort 1|TLL018 tablets, 1piece,BID
62609855|NCT05342428|EXPERIMENTAL|Cohort 2|TLL018 tablets, 2pieces, BID
62609856|NCT05342428|EXPERIMENTAL|Cohort 3|TLL018 tablets, 3pieces, BID
62609857|NCT05342428|PLACEBO_COMPARATOR|Cohort 4|TLL018 placeboes, 3pieces, BID
62049385|NCT05700084|EXPERIMENTAL|Utidelone Capsule combination with Capecitabine|"Dosage:~Utidelone capsule: 60 mg/m2/d, administered once a day on an empty stomach, continuously for 5 days from day 1 to day 5, with a treatment cycle of 21 days.~Capecitabine: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals. It is administered continuously for 14 days from day 1 to day 14, with a 21 day treatment cycle."
62049386|NCT03172702|EXPERIMENTAL|Sodium Zirconium Cyclosilicate|Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
62609858|NCT04736732||COVID-19 positive patients|"1. Patients who had previous asymptomatic or mild COVID-19 (mild=never required supplemental oxygen during the acute phase of the infection)~2. Patients who had previous moderate or severe COVID-19 (moderate=required supplemental oxygen by nasal cannula during the acute phase of the infection; severe=required supplemental oxygen by either high-flow nasal cannula, non-invasive positive pressure ventilation or intubation~3. Patients who had COVID-19 but did not have signs or symptoms related to COVID-19 lasting beyond 4 weeks from the date of COVID-19 symptom-onset or diagnosis"
62609859|NCT04736732||COVID-19 negative patients|Patients who have not had COVID-19 (i.e., patients who tested negative for COVID-19 and who never had symptoms consistent with COVID-19)
62609860|NCT05800496|EXPERIMENTAL|SesZen-Bio™|SesZen-Bio™ is specially formulated for healthy hairs and healthy skin. Fortified with Sesbania Agati for 2X Hair Follicle Stimulation \& Hair Fall Control, to Promote Shiny Hair, biotin that Supports Hair Growth.
62609861|NCT05800496|PLACEBO_COMPARATOR|Placebo (Tapioca based starch Capsules)|tapioca starch, is a starchy white flour that has a slight sweet flavor to it and is prepared by extrusion and coating process.
62609862|NCT03769597|EXPERIMENTAL|Iohexol administration|After injecting a loading dose of 5ml of Iohexol Inj 300 MG/ML bolus, blood samples will be taken at given times for 24 hours. The urinary samples will be taken at each urination, with measurement of the exact volume and times
62609863|NCT03418194|EXPERIMENTAL|TAES group|Patients in group TAES group received transcutaneous acupoint electrical stimulation (disperse-dense waves, frequency 4/20Hz) at the points of PC6 (Neiguan) and PC4 (Ximen) from 30 min before anesthesia induction to the end of surgery,
62609864|NCT03418194|PLACEBO_COMPARATOR|control group|Patients in group C received electrode plate atthe points of PC6 (Neiguan) and PC4 (Ximen) without any electrical stimulation.
62609865|NCT06528509|EXPERIMENTAL|AI-Generated Informative Videos|Participants in this arm will receive an AI-generated informative video. The video will provide comprehensive information about cataract surgery, including the procedure, risks, benefits, and postoperative care. The content will be generated using the Synthesia platform, which uses artificial intelligence to create realistic, photo-realistic digital avatars to deliver the information. The aim is to improve patient understanding, satisfaction, and reduce preoperative anxiety compared to traditional information delivery methods. The video will be produced in English for Cohort A, and translated into Bengali for Cohort B.
62609866|NCT06528509|ACTIVE_COMPARATOR|Standard Written Information Brochures|Participants in this arm will receive the standard information provided to patients undergoing cataract surgery, which consists of written information brochures. These brochures include comprehensive details about the cataract surgery procedure, potential risks, benefits, and postoperative care. The brochures are designed to provide all necessary information to help patients make an informed decision regarding their surgery. The leaflet will be supplied in English for Cohort A, and Bengali for Cohort B.
62832271|NCT03210194|EXPERIMENTAL|MP-ICT Neonatal Resuscitation Training|The Multi-platform ICT (MP-ICT) training includes continuous certification in neonatal resuscitation and is being developed for online and offline access, and will be complemented with simulated practices on every site. The platform is being improved and adjusted to the needs of the fieldwork in Ayacucho and Cusco. The adaptations include increasing hosting; ameliorate friendly usability, uploading packages and videos, improvement of examination and certifications, and tests for readiness. The MP-ICT resource will be accessed from remote Peruvian locations through computers, personal portable devices and cell phones. To be granted an MP-ICT Certification the trainee needs to have passed the online theoretical exam, assist to the practice and approve practical skills assessment.
62832272|NCT05679752|ACTIVE_COMPARATOR|control group|massage therapy will be given to this group of participants
62832273|NCT05679752|EXPERIMENTAL|experimental group|Facial PNFtechnique will be given to this group of participants
62609867|NCT03745105|EXPERIMENTAL|dexamethasone|Pretreatment intraligamentary injection of 0.4 mL of 8 mg/2 mL dexamethasone (Dexamethasone, AMRIYA pharmaceutical, Egypt)
62609868|NCT03745105|EXPERIMENTAL|piroxicam|Pretreatment intraligamentary injection of 0.4 mL of 20 mg mL-1 piroxicam (Feldene, Pfizer, Egypt)
62832274|NCT02368834|EXPERIMENTAL|intervention group|A psychoeducation program was delivered to the parents/caregivers
62832275|NCT02368834|NO_INTERVENTION|control group|This group waited for 3 months, only receiving general consultation.
62832276|NCT00495352|ACTIVE_COMPARATOR|High-dose NRT, Low-dose NRT, bupropion|
62832277|NCT01868997|PLACEBO_COMPARATOR|Placebo|A placebo infusion (normal saline) administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions.
62049387|NCT02844699|EXPERIMENTAL|Mobilan (M-VM3) on both Day 1 and on Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Investigational Drug Product (Mobilan (M-VM3)) administered 2 weeks apart. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
62251334|NCT06174051|ACTIVE_COMPARATOR|FB EMDR|Subjects in this group will receive two EMDR treatment sessions following the flashback protocol.
62609869|NCT03745105|ACTIVE_COMPARATOR|Mepivacaine HCL|Pretreatment Intraligamentary injection of 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml (Mepecaine - L, Alexandria Co.-Egypt)
62832278|NCT01868997|EXPERIMENTAL|Teprotumumab|Teprotumumab administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions. All participants start treatment at a dose of 10 mg/kg. At Week 3, the dose is escalated to 20 mg/kg and kept constant for the remainder of the study.
62609870|NCT05729581|NO_INTERVENTION|Control group|This group of pregnant women (24-32 SG) will not be provided educational programme and information on sustainlably and healthy diet and sustainable breastfeeding. It is a control group.
62609871|NCT05729581|EXPERIMENTAL|Experimental group|This group of pregnant women (24-32 SG) will be provided educational programme and information on sustainlably and healthy diet and sustainable breastfeeding
62609872|NCT06048575||Number of patients with early therapy|Patients with early surgery (\<72 hours of admission).
62609873|NCT06048575||Number of patients with subacute therapy|Patients with surgery for three days or more.
62609874|NCT06048575||Number of patients with late therapy|Patients with surgery beyond ten days.
62832279|NCT05355246|EXPERIMENTAL|assisted sit-up exercises Group|Group A patients will be instructed to perform assisted sit-up exercises by lying on their back and lifting their torso. They will use their body weight to strengthen and tone the core stabilizing abdominal muscles. This exercise will perform a minimum of five and a maximum of 10 repetitions, two times a day and two days a week.
62441117|NCT00621686|EXPERIMENTAL|Sorafenib + Bevacizumab/Group A|"Patients receive oral sorafenib 400 mg (200 mg twice daily) days 1-5 and 8-12 and 5 mg/kg bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days.~Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies.~Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment.~After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years."
62441118|NCT00621686|EXPERIMENTAL|Sorafenib + Bevacizumab /Group B|"Patients receive oral sorafenib 200 mg once daily on days 1-14 and 5 mg/kg bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days.~Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies.~Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment.~After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years."
62441119|NCT01702350|EXPERIMENTAL|Study Drug Formulation A|Enterric Coated Tablet Formulation of GSK2251052
62441120|NCT01702350|EXPERIMENTAL|Study Drug Formulation B|Modified Release Table Formulation of GSK2251052
62441121|NCT01702350|EXPERIMENTAL|Study Drug Formulation C|Enterric Coated Powder for Oral Suspension Formulation of GSK2251052
62441122|NCT01702350|EXPERIMENTAL|Study Drug Formulation D|Immidiate Release Table Formulation of GSK2251052
62441123|NCT01702350|EXPERIMENTAL|Study Drug Formulation E|Oral Solution Formulation of GSk2251052
62441124|NCT06106503|OTHER|patients will not underwent chest x-ray|
62441125|NCT06106503|OTHER|patients underwent chest x-ray|patients underwent chest x-ray
62441126|NCT01129999|EXPERIMENTAL|Cognitive-Behavioral Therapy|
62441127|NCT01129999|EXPERIMENTAL|Hypnotherapy|
62441128|NCT06480617||LNM(+)|Postoperative pathology suggests lymph node metastasis
62609875|NCT06048575||Number of patients with no therapy|Patients discharged with no surgical therapy.
62609876|NCT01074723|EXPERIMENTAL|b-cryptoxanthin|
62609877|NCT01074723|EXPERIMENTAL|phytosterols|
62609878|NCT01074723|EXPERIMENTAL|b-cryptoxanthin plus phytosterols|
62609879|NCT02065063|EXPERIMENTAL|Part 1|Part 1 is a dose finding phase in which subjects will be initially administered 75 milligram (mg) of palbociclib (21 days on/7 days off) and 1.5 mg of trametinib (once daily continuous dosing) in each 28-day cycle. Dose escalations will continue based on predefined parameters until the RCR is identified. The RCR will not exceed the maximum tolerated dose (MTD).
62609880|NCT02065063|EXPERIMENTAL|Part 2|Once the MTD and schedule have been determined, two expansion cohorts of up to 20 subjects each will be enrolled. The cohorts will enroll subjects with BRAF-WT (wild type) cutaneous melanoma that are either NRAS-WT or NRAS-MUT (mutated). Subjects will be dosed at or below the RCR to determine the inhibition of selected tumor biomarkers at each dose level.
62609881|NCT02065063|EXPERIMENTAL|Part 3|Part 3 will be a randomized Phase II study in which subjects will be administered the RCR as previously identified. Part 3 will be initiated only if an RCR is identified, and sufficient anticancer activity is observed in Parts 1 and 2.
62609882|NCT03938688|OTHER|Transfascial sutures for mesh fixation|Mesh will be placed in the retromuscular space, with wide overlap on all sides. Full thickness transfascial sutures will be placed circumferentially to secure the mesh using slowly absorbable no. 1 sutures. A total of at least six transfascial sutures will be placed universally for all patients with additional sutures allowed according to each surgeon's discretion. Additional bone or ligament sutures for mesh fixation will be allowed according to each surgeon's discretion.
62609883|NCT03938688|NO_INTERVENTION|No mesh fixation|Mesh will be placed in the retromuscular space, with wide overlap on all sides. No fixation method will be used. Bone or ligament sutures for mesh fixation will not be allowed.
62609884|NCT03240406|ACTIVE_COMPARATOR|Anti-inflammatory dietary intervention|18 month intervention of dietary counseling to adhere to the Multicultural Healthy Diet or the anti-inflammatory diet,
62049388|NCT02844699|EXPERIMENTAL|Placebo on Day 1 and Mobilan (M-VM3) on Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Placebo (Glucose 5%) first on Day 1 and Investigational Drug Product (Mobilan (M-VM3)) in two weeks on Day 15. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
62609885|NCT03240406|PLACEBO_COMPARATOR|Usual Diet plus Self-Care|18 month intervention of usual diet plus self-care modules
62832280|NCT05355246|ACTIVE_COMPARATOR|swiss ball pikes exercises Group|Group B patients will be instructed to perform swiss ball pikes by getting into the pushup position, the rest of the tops of their feet on a swiss ball. Each patient should keep her legs as straight as possible, bend their hips and try to pull their feet towards their chest so that the ball rolls forward. Hold at the top for three to four seconds, then slowly roll back to the starting position. This exercise will perform a minimum of one or two and a maximum of 10 repetitions, two times a day and two days a week. Both exercises will be performed for 12 weeks in both groups.
62832281|NCT03481595|NO_INTERVENTION|Group A|Group A will receive standard, routine medical care. If you are randomized to standard, routine medical care you will need to communicate with your Doctor and clinical care team through conventional methods such as over the phone or through MyChart.
62832282|NCT03481595|EXPERIMENTAL|Group B|Group B will be asked to use the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care. Patients randomized to use the Health Loop app will be able to communicate with their Doctor and clinical care team directly through the app. Patients will also participate in mobile and web-based surveys, receive reminders related to their healthcare, and receive information personalized to their treatment plan.
62832283|NCT04748198|EXPERIMENTAL|Study group|Intracorneal ring segments are implanted for treatment of keratoconus, and posterior corneal surface is assessed preoperatively and postoperatively.
62832284|NCT06614790||Patients with advanced, high-grade ovarian cancer who respond on the first line therapy (NED, CR,PR)|
62832285|NCT06418802|EXPERIMENTAL|Experiment 1: Experimental group 1|PD Patient's gait were followed up at 1 month,3 months,6 months, and 1 year after bilateral STN-DBS surgery.
62832286|NCT06418802|ACTIVE_COMPARATOR|Experiment 1: Comparator group 1|PD patient's gait with optimal medical therapy before bilateral STN-DBS surgery.
62832287|NCT06418802|EXPERIMENTAL|Experiment 2: Experimental group 2|PD patient's gait with a short pulse width (30s) with bilateral STN-DBS.
62049389|NCT02844699|PLACEBO_COMPARATOR|Placebo on both Day 1 and Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Placebo (Glucose 5%) administered 2 weeks apart. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
62049390|NCT03484598|EXPERIMENTAL|SPEAC Treatment Arm|All study participants will be provided with a SPEAC System to use in their home environment.
62832288|NCT06418802|ACTIVE_COMPARATOR|Experiment 2: Comparator group 2|PD patient's gait with the conventional pulse width (60 s) with bilateral STN-DBS.
62832289|NCT06418802|EXPERIMENTAL|Experiment 3: Experimental group 3|PD patient's gait with frequency parameters(60,100, and 130HZ) with bilateral STN-DBS.
62832290|NCT06418802|ACTIVE_COMPARATOR|Experiment 3: Comparator group 3|PD patient's gait with the conventional frequency parameters with bilateral STN-DBS.
62832291|NCT02981446|EXPERIMENTAL|DE-117 ophthalmic solution|
62832292|NCT02981446|ACTIVE_COMPARATOR|Latanoprost ophthalmic solution 0.005%|
62832293|NCT05357651|EXPERIMENTAL|Dose Escalation|Up to 9 dose cohorts will be sequentially enrolled in the dose escalation part using an accelerated titration combined with the standard 3+3 dose escalation algorithm approach.
62832294|NCT05357651|EXPERIMENTAL|Safety Expansion|2-3 doses were initially selected for safety expansion, with patients with advanced solid tumors as the main research population. Each dose cohort is expected to enroll 9-12 patients.
62832295|NCT05357651|EXPERIMENTAL|Exploratory Expansion|The Cohort Exploratory Expansion will enroll subjects by cohort at the RP2D dose, and a total of 4 cohorts (cohorts A, B, C, D) are expected.
62049391|NCT03440749|EXPERIMENTAL|Children with Cerebral Palsy (PC)|Serial reaction time task: repeating a sequence of movements according to the luminous stimuli
62049392|NCT03440749|ACTIVE_COMPARATOR|Control Group|Serial reaction time task: of movements according to the luminous stimuli
62049393|NCT05189626|EXPERIMENTAL|Group A|Muscle energy technique
62049394|NCT05189626|EXPERIMENTAL|Group B|Kaltonborn mobilizations
62049395|NCT06296095|EXPERIMENTAL|Single arm|cell therapy
62049396|NCT02836223|EXPERIMENTAL|Interdental device|Water Flosser
62609886|NCT05133414|EXPERIMENTAL|Participants will receive stimulation of the left subclavian ansae.|Participants as self-controlled cases for the study. Human cardiac haemodynamics and electrophysiological in response to left subclavian ansae stimulation will be studied.
62832296|NCT04436757|EXPERIMENTAL|IPS (Self-image and body-representation program)|"The IPS program (Self-image and body representation) was designed by Dr PLAZAT and coll. for specific use with patients with severe mental disorders suffering of low self- and body-esteem and aiming at  reinsert themselves in the society."
62832297|NCT04436757|ACTIVE_COMPARATOR|TAU|Treatment As Usual : the usual care proposed by the health service (SUR/CL3R).
62251335|NCT06174051|NO_INTERVENTION|Control group|Subjects in this group will not receive any treatment until the wait list period (4 weeks) is over
62832298|NCT03107871|EXPERIMENTAL|Arm A|Valganciclovir 16 mg/kg PO twice daily (BID) x 6 months
62832299|NCT03107871|PLACEBO_COMPARATOR|Arm B|Flavored Simple Syrup, volume equivalent to active arm dose, PO BID x 6 months
62251336|NCT06273384||Intervention group|Patients aged 18 years and older who present with peptic ulcer hemorrhage, confirmed by esophagogastroduodenoscopy (EGD).
62251337|NCT04173884|ACTIVE_COMPARATOR|Live Surgical Peer Coaching|Coaches will facilitate an initial, individual, introductory phone call with participants prior to the first formal coaching session. The objective of this call is to develop rapport, explore each other's background, experience, and motivation for participation in the program, set overall goals for the program, set specific goals for the first coaching session, develop an action plan including identification of the key characteristics of the first case for review, and develop a timeline and plan for meetings. Peer coaching sessions will be scheduled at three national meetings that are commonly attended by ACHQC surgeons. In advance of each meeting, participants will record and upload a self-selected video to a secure server maintained by the study team, and coaches will have the opportunity to review the video if they wish to prepare. A live coaching session will be organized at the meeting where the coaches and participants will have parallel one-hour coaching sessions.
62441129|NCT06480617||LNM(-)|Postoperative pathology did not suggest lymph node metastasis
62609887|NCT03875976|ACTIVE_COMPARATOR|Fast Track Protocol|Patients treated using Fast Track Care Protocol
62049397|NCT02836223|OTHER|Toothbrush|Control
62049398|NCT01881139|EXPERIMENTAL|experimental 1|men with exercise training for 3 months
62609888|NCT03875976|ACTIVE_COMPARATOR|Standard Protocol|Patients treated using Standard Care Protocol
62609889|NCT01393132|EXPERIMENTAL|Thymosin Beta 4 eye drops|It is a preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, six times daily for 28 days
62049399|NCT00409682|ACTIVE_COMPARATOR|Open-label adalimumab (Week 0 to Week 4)|All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
62441130|NCT03252288|NO_INTERVENTION|No intervention|No intervention
62441131|NCT03252288|EXPERIMENTAL|Reminders only|Reminders are sent 1 week and 1 day before each scheduled vaccination date
62441132|NCT03252288|EXPERIMENTAL|Reminders + Conditional financial transfer|Reminders are sent 1 week and 1 day before each scheduled vaccination date; and conditional financial transfers are made for each on-time vaccination visit
62609890|NCT01393132|PLACEBO_COMPARATOR|Vehicle Control|It is composed of the same excipients as RGN-259 but does not contain Tβ4 for direct instillation into each eye, six times daily for 28 days.
62832300|NCT06318949|EXPERIMENTAL|experimental arm|
62832301|NCT01269021|EXPERIMENTAL|mycophenolate mofetil|
62832302|NCT01269021|ACTIVE_COMPARATOR|Prednisone|
62832303|NCT03902353|OTHER|Adults without diagnosis of PH|Adults without diagnosis of PH carrying an heterozygous EIF2AK4
62832304|NCT03497195|ACTIVE_COMPARATOR|Community level screening; Arm 1|use of chest X-ray plus Xpert Ultra for community level TB screening
62832305|NCT03497195|ACTIVE_COMPARATOR|Community level screening: Arm 2|use of C-reactive Protein and Xpert Ultra for community level TB screening
62832306|NCT03420599||health control|healthy controls are all from normal volunteers
62832307|NCT03420599||splenectomy|Traumatic patients after total splenectomy
62832308|NCT06109571|EXPERIMENTAL|Group 1: mHealth Implementation|First 2 sites begin enrollment. Research participants will be asked to complete weekly-check-in, 4 research surveys and engage in content available in the Connections app and with peer mentors over the course of a year.
62251338|NCT04173884|ACTIVE_COMPARATOR|Asynchronous Video-based Constructive Feedback|There will be no real-time interpersonal contact between coaches and participants in this arm. Participants will upload their self-selected procedural video to the video review platform, together with a short description of the case and any specific questions. The coach will review the video within one week of its posting and provide time-stamped feedback on the video platform. Participants will then review the coach's feedback within one week with the ability to respond to the comments. The coach and participant will continue communication via the internet-based review platform until no further comments are made by either party. Coach-participant dyads are expected to review three videos during the 6 month intervention period.
62251339|NCT04173884|ACTIVE_COMPARATOR|Wait-List Control|One-third of participants will be randomized to an intervention, but wait-listed to provide a control group. These surgeons will submit two videos for technical skill evaluation during each of the baseline and follow-up periods, and ACHQC data will be tracked for short-term outcomes prior to their crossover to the intervention for long-term follow-up. Selecting the control group using the identical sampling frame of ACHQC surgeons participating in the interventions affords the opportunity for a comparable group with outcome metrics recorded systematically.
62251340|NCT00741572||1|
62251341|NCT00741572||2|
62251342|NCT02813278|EXPERIMENTAL|simo decoction and acupuncture with vitamin B1|Patients will receive simo decoction (10 mL/piece,three times per day) and bilateral tsusanli acupoint injections with vitamin B1 two times per day, starting in the first day after resection for 5 days or until flatus.
62251343|NCT02813278|ACTIVE_COMPARATOR|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection for 5 days or until flatus.
62049400|NCT00409682|ACTIVE_COMPARATOR|Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52)|Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
62049401|NCT00409682|ACTIVE_COMPARATOR|High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52)|Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
62049402|NCT06384248|EXPERIMENTAL|PHASE 1|Enrollment of 10 consecutive evaluable sarcoma subjects with failure of existing standard therapy or lack of effective treatment Treated with LTC004 in Phase I
62832309|NCT06109571|EXPERIMENTAL|Group 2: mHealth Implementation|Next 2 sites begin enrollment 6 months after Group 1. Research participants will be asked to complete weekly-check-in, 4 research surveys and engage in content available in the Connections app and with peer mentors over the course of a year.
62832310|NCT06109571|EXPERIMENTAL|Group 3: mHealth Implementation|Next 2 sites begin enrollment 6 months after Group 2. Research participants will be asked to complete weekly-check-in, 4 research surveys and engage in content available in the Connections app and with peer mentors over the course of a year.
62832311|NCT06109571|EXPERIMENTAL|Group 4: mHealth Implementation|Next 2 sites begin enrollment 6 months after Group 3. Research participants will be asked to complete weekly-check-in, 4 research surveys and engage in content available in the Connections app and with peer mentors over the course of a year.
62832312|NCT05417516|ACTIVE_COMPARATOR|Whole Breast Irradiation (WBI)|26 Gy in 5 fractions to the whole breast
62832313|NCT05417516|EXPERIMENTAL|Partial Breast Irradiation (PBI)|26 Gy in 5 fractions to the tumour bed with a margin of normal tissue
62832314|NCT04434443|EXPERIMENTAL|trunk exercise on unstable surface|trunk exercise training in supine and sitting positions, with unstable surfaces
62832315|NCT04434443|SHAM_COMPARATOR|upper limb range of motion exercise|upper limb range of motion exercise in sitting with back fully supported
62832316|NCT00597220|EXPERIMENTAL|1|Omega 3
62832317|NCT00597220|PLACEBO_COMPARATOR|2|
62832318|NCT05464342|EXPERIMENTAL|Evening LGI Carbohydrate Consumption|Dietary Intervention: Consumption of Low Glyceamic Index (LGI) carbohydrates intake post-workout/evening.
62832319|NCT05464342|EXPERIMENTAL|Evening HGI Carbohydrate Consumption|Dietary Intervention: Consumption of High Glyceamic Index (HGI) carbohydrates intake post-workout/evening.
62049403|NCT06384248|EXPERIMENTAL|PHASE 2|If ≥2 subjects experience objective remission or SD lasting \>12 weeks in PHASE 1, proceed to Phase II to enroll an additional 20 evaluable subjects to further evaluation of the safety and efficacy of LTC004
62049404|NCT01494584|EXPERIMENTAL|ezogabine/retigabine|ezogabine dose escalation
62049405|NCT02877511|EXPERIMENTAL|Arm 1|2/3 of subjects testing the test article
62049406|NCT02877511|ACTIVE_COMPARATOR|Arm 2|1/3 of subjects testing the marketed control
62049407|NCT00441090|EXPERIMENTAL|Avatrombopag tablets|"2.5, 5, 10 or 20 mg tablets~1 tablet taken orally once daily for 28 days"
62049408|NCT00441090|PLACEBO_COMPARATOR|Placebo tablet|"2.5, 5, 10, or 20 mg tablets~1 tablet taken orally once daily for 28 days"
62049409|NCT05782257|ACTIVE_COMPARATOR|Zinc Supplementation|Those allocated in this arm will be provided with 90 capsules of gluten-free Zn gluconate 25 mg (7 mg of elemental Zn; Jamieson®) and will be instructed to take 1 tablet daily with a meal and at least 2 hrs apart from other medications, and iron or copper supplements
62251344|NCT02813278|NO_INTERVENTION|empty control|Patients only receive best support care.
62441133|NCT03432299|EXPERIMENTAL|RFA for PTMC|Group who will undergo RFA after diagnosis of PTC
62832320|NCT05464342|EXPERIMENTAL|Evening NO-CHO Carbohydrate Consumption|Dietary Intervention: No consumption of carbohydrates intake post-workout/evening.
62832321|NCT03989258|ACTIVE_COMPARATOR|Cohort 1|High monogenic breast cancer risk
62832322|NCT03989258|ACTIVE_COMPARATOR|Cohort 2|High polygenic breast cancer risk
62832323|NCT03989258|NO_INTERVENTION|Cohort StMG|Standard mammography screening in age 50-69
62832324|NCT01930006|EXPERIMENTAL|MGCD265|
62832325|NCT04257448|EXPERIMENTAL|Romidepsin/nab-Paclitaxel/Gemcitabine (Arm A)|Part 1a: Romidepsin (2 mg/m² or 3.3 mg/m² or 7 mg/m²) will be administered in combination with nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle. Study treatment is given until intolerable toxicity or will escalate until the recommended dose for expansion for a maximum of 3 cycles.
62049410|NCT05782257|EXPERIMENTAL|Zinc Optimized Diet|Instructions provided by a dietitian to establish a target of 11 mg/day (female) and 14 mg /day (male) provided by Zn-rich food sources, adjusted for dietary phytate intake.
62609891|NCT03643913|ACTIVE_COMPARATOR|Comparison group|"Neuromuscular Blocking Agents and reversing agents: The comparison group will receive anesthesia top up Esmeron dose to maintain a Train Of Four (TOF) count of maximum 2 during the whole procedure. This represents moderate neuromuscular block conditions. A neuromuscular monitor (PHILIPS integrated) will be used to evaluate TOF count.~To maintain TOF at 2 and according to our practice a bolus injection of 0,1 mg/kg Rocuronium will be given when TOF count returns to 3. This dose will be repeated if TOF does not go back to 2 within 2 minutes after bolus injection. TOF guard and TOF tube will be used at the ulnar nerve at the contralateral side and will be checked continuously during surgery.~Reversal of the TOF=2 will be done by Sugammadex 2 mg/kg at end of procedure (Time of last suture)"
62609892|NCT03643913|EXPERIMENTAL|Deep group|Neuromuscular Blocking Agents and reversing agents: The deep group will receive deep neuromuscular block, using a infusion of Esmeron at 0,1mg/kg/hour. A post tetanic count will be performed and our target will be to have a PTC 1-2. The standard infusion will be adjusted as such. Reversal will be achieved by Sugammadex 4 mg/kg depending on reversal speed at the end of procedure (Time of last suture)
62609893|NCT02795845|EXPERIMENTAL|Primary prevention- probiotic capsules|"patients with normal vaginal flora in the experimental arm will be treated with Probiotic capsules (containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus, Bifidobacterium bifidum and B. Lactis).~one capsule twice a day until delivery."
62832326|NCT04257448|EXPERIMENTAL|Azacitidine/nab-Paclitaxel/Gemcitabine (Arm B)|Part 1a: Azacitidine (20 mg/m² or 30 mg/m² or 40 mg/m²) will be administered on Days -7 to Day -3 of each treatment cycle. Additionally nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) will be given on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle. Study treatment is given until intolerable toxicity or will escalate until the recommended dose for expansion for a maximum of 3 cycles.
62832327|NCT04257448|EXPERIMENTAL|Romidepin/Azacitidine/nab-Paclitaxel/Gemcitabine (Arm C)|Part 1a: The intervention to be administered depends on the determined dose in Arm A and Arm B. Additionally nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) will be given on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle. Study treatment is given until intolerable toxicity or will escalate until the recommended dose for expansion for a maximum of 3 cycles.
62049411|NCT03804710|EXPERIMENTAL|Test Product 1|Participants will apply 2 pumps of the test product (approximately 0.3ml x 2= 0.6ml) to the randomly assigned side of the face, including forehead and chin, and 6 pumps of test product (approximately 0.3 ml x 6 = 1.8 ml) to the randomly assigned lower leg (below the knee; above the ankle) topically twice-daily (in the morning and evening) after cleansing.
62049412|NCT03804710|EXPERIMENTAL|Test Product 2|Participants will apply pea-sized amount of the test product (approximately 0.6ml) to the randomly assigned side of the face, including forehead and chin, and walnut-sized amount of the test product (approximately 1.8 ml) to the randomly assigned lower leg (below the knee; above the ankle) twice-daily (in the morning and evening) after cleansing.
62832328|NCT04257448|ACTIVE_COMPARATOR|nab-Paclitaxel/Gemcitabine (Standard Arm)|nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) will be administered on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle.
62251345|NCT04607148|EXPERIMENTAL|Galegenimab 20 mg Q4W|Participants will receive 20 milligrams (mg) galegenimab via ITV injection every 4 weeks (Q4W).
62441134|NCT00560183|EXPERIMENTAL|1|
62441135|NCT00560183|PLACEBO_COMPARATOR|2|
62832329|NCT04257448|EXPERIMENTAL|Arm C or B or A|In Part 1b (expansion part) of the study, one of the treatment arms (Arm C over Arm B over Arm A) will be continued. Treatment will only be performed with the study drug that were tolerable in Part 1a (dose escalation).
62832330|NCT04257448|EXPERIMENTAL|Durvalumab/Lenalidomide|Part 2: All patients from Part 1 who have not progressed after three cycles receive standard fixed dose Durvalumab (1500 mg) on Day 1 of each 28-day treatment cycle by IV infusion in combination with orally administered low-dose Lenalidomide (10 mg) on Days 1 to 21 until documented disease progression. Study treatment is given for a maximum of 13 cycles.
62832331|NCT05505084||Collatape (Zimmer Dental)|This material is a resorbable collagen wound dressing. They are made from bovine Achilles tendons and are a source of Type I collagen. The resorbable wound dressings are sterilized after purification with ethylene oxide.
62441136|NCT01227668|EXPERIMENTAL|Aripiprazole|
62441137|NCT01227668|PLACEBO_COMPARATOR|Placebo|
62441138|NCT02371083|NO_INTERVENTION|Routine|Subjects will continue with regular pessary care every 12 weeks.
62441139|NCT02371083|EXPERIMENTAL|Extended|Subjects will have extended time between pessary care visits which will occur every 24 weeks.
62441140|NCT04659733|EXPERIMENTAL|Anlotinib hydrochloride|
62441141|NCT03754491|EXPERIMENTAL|One stage stone removal in mild cholangitis|one-stage stone removal at the first session of ERCP in mild cholangitis patients. The indomethacin 100mg anal route will be administered for all patients without allergy history
62441142|NCT03754491|EXPERIMENTAL|One stage stone removal in moderate cholangitis|one-stage stone removal at the first session of ERCP in moderate cholangitis patients. The indomethacin 100mg anal route will be administered for all patients without allergy history
62609894|NCT02795845|PLACEBO_COMPARATOR|Primary prevention - Placebo|patients with normal vaginal flora in the placebo arm will be treated with a capsule without active ingredient, one capsule twice a day until delivery.
62832332|NCT05505084||Cytoplast Barrier Membranes TXT-200 Singles (Osteogenics Biomedical)|Cytoplast Barrier membranes are manufactured from high-density Polytetrafluoroethylene (PTFE) which allows them to withstand exposure to the oral environment. The textured surface increases the surface area available for cellular attachment during dental bone grafting procedures thereby aiding in stabilizing the PTFE membrane. It can be removed non-surgically after at least 21 days.
62832333|NCT05505084||Ossix Plus (dantum dental)|OssixPlus is a resorbable collagen dental membrane used for Guided Bone Regeneration and Guided Tissue Regeneration. It contains a patented GLYMATRIX cross-linking technology that allows it to maintain barrier functionality for 4 to 6 months. The collagen is derived from porcine.
62832334|NCT05505084||Renovix-Plus (Salvin)|Renovix Plus is a non-cross-linked extracellular matrix containing Type I, II, and III Collagen, Fibronectin, Laminin, and Elastin. It provides architecture and barrier protection for bone regeneration and soft tissue esthetics. This membrane resorbs within six months.
62832335|NCT05505084||BioXclude (Snoasis)|BioXclude is a minimally manipulated allograft amnion chorion tissue. It is obtained from consenting mothers who donate their placentas after elective caesarian section delivery. The tissue is processed to cleanse and maintain the tissue. Following processing and dehydration, the allografts are packaged and terminally sterilized.
62609895|NCT02795845|EXPERIMENTAL|Secondary prevention - probiotic capsules|Patients with abnormal vaginal flora/bacterial vaginosis or vaginal candidiasis in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if necessary) or antimycotic treatment. Once the infection was eradicated, the patient will be given probiotic capsules.
62609896|NCT02795845|PLACEBO_COMPARATOR|Secondary prevention - Placebo|Patients with abnormal vaginal flora/bacterial vaginosis or vaginal candidiasis in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if necessary) or antimycotic treatment. Once the infection was eradicated, the patient will be given placebo without active ingredient.
62832336|NCT06213857|EXPERIMENTAL|A (silymarin)|silymarin capsules (140 mg\\day) for 6 months + mesalamine
62832337|NCT06213857|NO_INTERVENTION|B (No silymarin)|mesalamine only
62832338|NCT05856617|EXPERIMENTAL|Remimazolam|Anesthesia induction with remimazolam
62832339|NCT05856617|NO_INTERVENTION|Propofol|Anesthesia induction with propofol
62832340|NCT03095859|ACTIVE_COMPARATOR|Control|Standard care (once daily physical rehabilitation, approx. 30 minutes). Standard care will consist of physical exercise, such as early mobility, endurance training, upper limb, lower limb and trunk activity. This will involve non-physical interventions including respiratory therapy, airway clearance and patient and carer education.
62832341|NCT03095859|EXPERIMENTAL|Experimental|Early intensive physical rehabilitation, which will consist of standard care plus one additional treatment per day. The additional early intensive physical rehabilitation session provided to the experimental group will allow for progression of aerobic, strength and flexibility exercise and / or completion of a more comprehensive physical rehabilitation program.
62832342|NCT06404385|ACTIVE_COMPARATOR|Conventional surgical guide|Implants (Straumann®) placed with an analogic laboratory surgical guide
62832343|NCT06404385|EXPERIMENTAL|Computer aided design - computer aided manufacturing (CAD-CAM) surgical guide|Implants (Straumann®) placed with static computer-assisted implant surgery
62832344|NCT02955667|EXPERIMENTAL|invivo microscopy group|patients receive invivo micro-colposcopy examination and do not have to receive the biopsies
62832345|NCT02955667|OTHER|normal group|patients receive normal colposcopy examination and the biopsy specimens are sent for pathological HE staining and analysis
62832346|NCT00893438|EXPERIMENTAL|FitNet treatment|FitNet treatment: web-based cognitive behaviour therapy
62832347|NCT00893438|ACTIVE_COMPARATOR|Usual care|waiting list for FitNet intervention (usual care allowed)
62049413|NCT03804710|PLACEBO_COMPARATOR|Standard soap cleanser|Participants will use wet soap with warm water and form lather. Participants will cleanse their entire face and both lower legs (between the knees and ankles) twice daily (morning and evening).
62609897|NCT05297110|ACTIVE_COMPARATOR|atherolive group|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
62049414|NCT05011968|EXPERIMENTAL|No Intervention: (control group)|The control group was assigned to crop lettuce without any biofortification but with the same characteristic of bioforticated lettuce (soil, water, harvesting time)
62049415|NCT05011968|EXPERIMENTAL|Experimental: intervention group|The intervention group was assigned to biofortificated Iodine crop lettuce.
62832348|NCT03812731|ACTIVE_COMPARATOR|Caudal Group|"Children will receive oral midazolam 0.25 mg/kg thirty minutes before induction. Inhalational induction will be carried with incremental concentration of sevoflurane upto 8% in 50% oxygen and nitrous oxide mixture. As soon as the child will be asleep, ASA standard monitors (SPO2, HR, ECG and NIBP) will be attached. Intravenous access with age appropriate IV cannula will be secured. Injection fentanyl citrate 2 mcg/ kg followed by injection atracurium 0.5 mg/kg will be administered. Appropriate size LMA Pro SealTM will be inserted and pressure controlled ventilation will be instituted.~Children in will then receive CEB with 0.2 % ropivacaine 1-ml/kg for maintaining analgesia"
62832349|NCT03812731|ACTIVE_COMPARATOR|Non- Caudal Group|"Children will receive oral midazolam 0.25 mg/kg thirty minutes before induction. Inhalational induction will be carried with incremental concentration of sevoflurane upto 8% in 50% oxygen and nitrous oxide mixture. As soon as the child will be asleep, ASA standard monitors (SPO2, HR, ECG and NIBP) will be attached. Intravenous access with age appropriate IV cannula will be secured. Injection fentanyl citrate 2-mcg/ kg followed by injection atracurium 0.5 mg/kg will be administered. Appropriate size LMA Pro SealTM will be inserted and pressure controlled ventilation will be instituted.~Children in will then receive fentanyl citrate 1-mcg/kg/hr for maintaining analgesia"
62832350|NCT02286349|EXPERIMENTAL|Real rTMS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 5 blocks of real stimulation intensity of 10 Hz, each block containing 15 series of repetitive transcranial magnetic stimulation with 1 second duration and presenting interval of 10 seconds between sets + 20 minutes of neuropsychological reassessment (on average).
62832351|NCT02286349|SHAM_COMPARATOR|Sham rTMS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 5 stimulation sham blocks, each block containing 15 series of repetitive transcranial magnetic stimulation with 1 second duration and presenting interval of 10 seconds between sets + 20 minutes of neuropsychological reassessment (on average)
62832352|NCT02286349|EXPERIMENTAL|Real tDCS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 10 minutes of real anodal transcranial direct current stimulation with intensity of 1 mA + 20 minutes of neuropsychological reassessment (on average).
62832353|NCT02286349|SHAM_COMPARATOR|Sham tDCS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 10 minutes of sham transcranial direct current stimulation + 20 minutes of neuropsychological reassessment (on average)
62832354|NCT04307329|EXPERIMENTAL|Monalizumab + trastuzumab - low TILs (<5%)|trastuzumab 4 mg/kg and monalizumab 750 mg every two weeks.
62832355|NCT04307329|EXPERIMENTAL|Monalizumab + trastuzumab - high TILs (>=5%)|trastuzumab 4 mg/kg and monalizumab 750 mg every two weeks.
62832356|NCT00251732|ACTIVE_COMPARATOR|Standard dose (PPI) plus low dose TCA|Standard dose Rabeprazole(PPI) plus low dose tricyclic antidepressant(TCA)
62832357|NCT00251732|ACTIVE_COMPARATOR|Double dose PPI|Double dose proton pump inhibitor plus placebo
62832358|NCT00251732|PLACEBO_COMPARATOR|Standard dose PPI plus placebo x 2|Standard dose 20 mg. once daily plus Placebo before dinner and placebo before bedtime
62832359|NCT05609591|EXPERIMENTAL|Liquid diet group|From 8:00 on the day before colonoscopy, oral fluids including juice, rice soup, filtered vegetable juice/broth, lotus root powder and milk and egg soup were taken to ensure energy intake and blood glucose stability. The fasting starts at 9:00 AM on the day of colonoscopy.
62832360|NCT05609591|EXPERIMENTAL|Enteral nutrition group|Oral administration of 100% short peptide enteral nutrition preparation from 8:00 on the day before colonoscopy. The fasting starts at 9:00 AM on the day of colonoscopy.
62609898|NCT05297110|PLACEBO_COMPARATOR|placebo group|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
62832361|NCT05609591|EXPERIMENTAL|Low residual diet group|From 8:00 on the day before colonoscopy, the patients were given oral administration of less residue food included gruel with grain only, peeled carrot, white gourd, powdered skin, tofu, vegetable, mud and fruit. The fasting starts at 9:00 AM on the day of colonoscopy.
62832362|NCT05061511||Healthy gingival tissue|healthy patients with absence of gingivitis (full-mouth bleeding score \<10%), no history of periodontal disease, having ≥20 teeth, and ≤1 tooth with interdental clinical attachment loss.
62049416|NCT05952635|EXPERIMENTAL|Tip bendable suction ureteral access sheath (S-UAS) group|Patients will use S-UAS during flexible ureteroscopy.
62832363|NCT05061511||Periodontitis patients|patients with stage III or IV periodontitis, which means that these patients would have deep periodontal lesions that extend at least to the mid portion of the roots and whose management is complicated by the presence of intrabony defects, furcation involvement, history of periodontal tooth loss and localized ridge defects.
62832364|NCT05061511||Peri-implantitis patients|patients affected by peri-implantitis, defined as radiographic evidence of bone loss ≥3 mm and probing pocket depth ≥6 mm around implants in conjunction with bleeding on probing; or defined as bleeding and/or suppuration on probing, increased probing pocket depth from a previous examination and loss of peri-implant bone.
62832365|NCT00135551|ACTIVE_COMPARATOR|angiotensin receptor blockers|benidipine+angiotensin receptor blockers, titlation scheme
62832366|NCT00135551|ACTIVE_COMPARATOR|β-blockers|benidipie+β-blockers, titlation scheme
62832367|NCT00135551|ACTIVE_COMPARATOR|thiazide diuretics|benidipine+thiazide diuretics, titlation scheme
62832368|NCT06514066|OTHER|Group A|Subjects will receive placebo for the first three months. After transitioning from the placebo, subjects will be titrated with 200 mg CBD for the first two weeks. Subsequent to this period, they will be administered 400 mg CBD for the remaining two and a half months.
62609899|NCT01287000||1|Workers and volunteers engaged or potentially engaged in oil spill clean-up operations in the Gulf of Mexico
62609900|NCT02320682|ACTIVE_COMPARATOR|Exeter femur component and Delta TT acetabular component|
62609901|NCT02320682|ACTIVE_COMPARATOR|SP-CL femur component and Delta TT acetabular component|
62832369|NCT06514066|OTHER|Group B|For the initial two weeks, subjects will be given 200 mg CBD. Following this titration period, they will receive 400 mg CBD for the remaining two and a half months. Then, subjects will receive placebo for the remaining of the study.
62832370|NCT03058146|EXPERIMENTAL|Mobile Health Walking Condition|Physically inactive older adults in this condition will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
62832371|NCT03058146|ACTIVE_COMPARATOR|Healthy Aging Education Condition|The education control condition will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
62832372|NCT04429711|PLACEBO_COMPARATOR|IVERMECTIN|
62832373|NCT04429711|ACTIVE_COMPARATOR|PLACEBO|
62832374|NCT04476797|EXPERIMENTAL|Phase 1 GC4711 + SBRT|
62049417|NCT05952635|NO_INTERVENTION|Traditional ureteral access sheath group|Patients will use traditional UAS during flexible ureteroscopy.
62609902|NCT02320682|ACTIVE_COMPARATOR|SP-CL femoral component and Delta PF acetabular component|
62609903|NCT02320682|ACTIVE_COMPARATOR|Exeter femoral component and Delta PF acetabular component|
62832375|NCT04476797|PLACEBO_COMPARATOR|Phase 2 Placebo + SBRT|
62832376|NCT04476797|EXPERIMENTAL|Phase 2 GC4711 +SBRT|
62049418|NCT04803110|EXPERIMENTAL|Immediate Implant with SST (SST)|Patients who will receive immediate implant placement using the Socket-Shield Technique.
62049419|NCT04803110|ACTIVE_COMPARATOR|Immediate Implant with biomaterial (GAP)|Patients who will receive immediate implant placement using bone biomaterials to fill the gap after complete extraction of the tooth.
62609904|NCT06553885|EXPERIMENTAL|Cohort 1: Colorectal Cancer|Enfortumab vedotin at a dose of 1.25 mg/kg will be administered as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of every 28-day cycle.
62832377|NCT06095063|EXPERIMENTAL|20 sessions of dTMS and Cognitive Training|"Participants will receive dTMS followed by computerized cognitive training.~dTMS: The motor threshold (MT) will be measured by delivering single stimulations to the motor cortex with gradually increased intensity. After defining the MT, the coil will be positioned anterior to the hot spot using the ruler on the participant's cap, and a dTMS session will be performed with the dosing of the stimulus intensity titrated slowly to approximately 120% of the motor threshold. On Day 1 of the treatment, stimulation will be delivered at an intensity ranging from 80% to 100% of the participant's MT depending on their initial tolerance to the stimulation. Stimulation intensity will then be slowly titrated by sequentially increasing the intensity by 10% over the remaining days of the first week until a maximum intensity of 120% of MT is achieved depending on the tolerability of the patient.~Immediately following dTMS, participants will complete 20-30 minutes of cognitive training."
62251346|NCT04607148|EXPERIMENTAL|Galegenimab 20 mg Q8W|Participants will receive 20 mg galegenimab via ITV injection every 8 weeks (Q8W).
62609905|NCT06553885|EXPERIMENTAL|Cohort 2: Hepatocellular Carcinoma|Enfortumab vedotin at a dose of 1.25 mg/kg will be administered as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of every 28-day cycle.
62609906|NCT06712901|PLACEBO_COMPARATOR|Control (no exposure)|Participants in the Control Arm will not be shown any messages.
62609907|NCT06712901|EXPERIMENTAL|Median Ranked|Participants in the Median Ranked Arm will be shown four Median Ranked messages.
62609908|NCT06712901|EXPERIMENTAL|Overall Preferred|Participants in the Overall Preferred arm will be shown four Overall Preferred messages.
62832378|NCT06095063|SHAM_COMPARATOR|20 sessions of sham/control stimulation and Cognitive Training|"Participants will receive sham intervention followed by computerized cognitive training.~The sham intervention consists of treatment with similar technical parameters which induce scalp sensations but do not penetrate into the brain.~Immediately following dTMS, participants will complete 20-30 minutes of cognitive training."
62832379|NCT05434286||Cirrhosis/ACLF of any etiology|Cirrhosis with hepatorenal syndrome-acute kidney injury (HRS-AKI) as per International Ascites Club criteria.
62832380|NCT05019326|EXPERIMENTAL|Andrographis extract|Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.
62832381|NCT05019326|EXPERIMENTAL|Boesenbergia extract|Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.
62832382|NCT05019326|OTHER|Standard supportive treatment|Standard supportive treatment, as recommended by guideline from Ministry of Public Health, Thailand, there will be no antivirus given in this asymptomatic group
62832383|NCT00460616||1|Patients already receiving treatment with cabergoline.
62832384|NCT00460616||2|healthy controls sex and age-matched with the patients
62832385|NCT02191735||Troponin I|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI). Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
62832386|NCT02191735||Myoglobin|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI) and who have a RAMP Myoglobin test result that is within the test reportable range. Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
62609909|NCT06712901|EXPERIMENTAL|Black American Preferred|Participants in the Black American Preferred arm will be shown four Black American Preferred messages.
62832387|NCT02191735||CK-MB|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI) and who have a RAMP CK-MB test result that is within the test reportable range. Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
62832388|NCT02191735||NT-proBNP|Subjects who have undergone a routine test order of NT-proBNP or BNP for suspected Heart Failure (HF). Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
62832389|NCT05605002|ACTIVE_COMPARATOR|Waiting list group|This group will include 30 patients with MDD who will be treated with oral SSRIs only, the dosage of which will be determined by the psychiatrist. After 6 weeks, patients could choose 6 weeks' intradermal acupuncture treatments free of charge.
62832390|NCT05605002|SHAM_COMPARATOR|SIA+SSRIs group|This group will include 30 patients with MDD who will be treated with sham intradermal acupuncture combined with SSRIs. Acupoints related to MDD will be stimulated by acupuncturists and the dosage of oral SSRIs will be determined by the psychiatrist.
62832391|NCT05605002|EXPERIMENTAL|AIA+SSRIs group|This group will include 30 patients with MDD who will be treated with active intradermal acupuncture combined with SSRIs. Acupoints related to MDD will be stimulated by acupuncturists and the dosage of oral SSRIs will be determined by the psychiatrist.
62832392|NCT01143376|ACTIVE_COMPARATOR|Moderate intensity exercise|Moderate intensity exercise
62832393|NCT01143376|EXPERIMENTAL|High Intensity training|High Intensity intermittent training
62049420|NCT03166943|EXPERIMENTAL|study group|Systolic function by echocardiography to100 Hepatitis C virus infected patients on continuous regimen ( sofosbuvir and daclatasvir )
62609910|NCT06712901|EXPERIMENTAL|White American Preferred|Participants in the White American Preferred arm will be shown four White American Preferred messages.
62251347|NCT04607148|EXPERIMENTAL|Galegenimab 10 mg Q4W|Participants will receive 10 mg galegenimab via ITV injection Q4W.
62609911|NCT03606694|EXPERIMENTAL|Dihydromyricetin|Dihydromyricetin capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
62609912|NCT03606694|EXPERIMENTAL|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
62609913|NCT04339010|EXPERIMENTAL|Hypopressive|"1. st session: the meetings were provided by a physiotherapist, who also discussed the location and function of the pelvic organs, PFM, and the transversus abdominis (TrA) muscles. The participants learned how to activate TrA muscles. The training was performed during full expiration, the physiotherapist check and coordinate the group to maintain the Tra contraction. The women were also trained to inhale through the nose and exhale through the mouth maintaining an apical breathing pattern.~2. nd session: The contractions were executed during six different positions the ones which they will keep following through the whole treatment.~3. rd session: The patients were exposed to all the six positions (supplementary material) and their three variations (positions 1, 3, 5 and 6 ). Every meeting obeyed the same schedule through the five weeks of treatment and was accompanied by two physiotherapists."
62832394|NCT01143376|EXPERIMENTAL|Short springs|short springs training
62832395|NCT05867238||Student nurse anaesthetists with no training in stress management|Student nurse anaesthetists who participated in the previous study: stress of anaesthesia professionals in the operating theatre and did not receive stress management training.
62609914|NCT04339010|ACTIVE_COMPARATOR|Hypopressive + PFMC|This group receives the same protocol than the Hypopressive group, but with a verbal command to realize the PFM contraction during the activation of the deep abdominal muscle.
62609915|NCT05628298||Experimental group|Women in their 2nd and 3rd trimester of pregnancy who have significant pregnancy related pain (\>5/10). Subjects will be allowed to use the device during labor and one month postpartum.
62609916|NCT06469697|EXPERIMENTAL|Intervention|Musical pieces developed by the Ministry of Education and Vocational Training will be played at intervention schools using compact discs. These will be broadcast once during morning assembly, once during recess, and once before school ends on Mondays and Fridays for 3 months. After this period, a popular local radio station will broadcast the music pieces three times a day during peak hours.
62609917|NCT06469697|ACTIVE_COMPARATOR|Comparator|A popular local radio station will broadcast the music pieces three times a day during peak hours, coinciding with the times when the intervention group is receiving the same program (community broadcast).
62609918|NCT02562235|EXPERIMENTAL|Riociguat|Participants with age ≥6 to \<18 years received riociguat up to 2.5 mg three times a day (titration between 1.0 mg and 2.5 mg) for up to 8 weeks during the individual dose titration (IDT) phase, and followed with the last dose administered in the IDT phase for up to 16 weeks during the maintenance phase. Down-titration (up to 0.5 mg) of the dose for safety reasons was allowed at any time.
62609919|NCT05679180|EXPERIMENTAL|micropulse laser|treatment with confluent spots over the area of focal leak on the earliest phase of fundus fluorescein angiography on Navilas® system using 5% duty cycle with 100 micron spot size with 200 ms envelope. Thirty percent of threshold laser burn power was used.
62609920|NCT06531499|EXPERIMENTAL|AAA617|All participants will receive the investigational product AAA617 (7.4 GBq ±10%).
62609921|NCT06098716|NO_INTERVENTION|Education|The Education condition package will consist of Canada's PA guidelines, information about the benefits of child and adult PA, and a breakdown of ways for the parent to help their child achieve this PA.
62609922|NCT06098716|EXPERIMENTAL|Self Regulation|"The SR condition will receive all of the same education material as the standard condition in addition to skill training content (how to plan for family PA) based on our prior family trials. Families will be instructed to plan for when, where, how, and what PA will be performed, and to create back-up plans commensurate with the creation of action and coping planning"
62609923|NCT06098716|EXPERIMENTAL|Identity & Family Functioning|The ID condition will receive the same content as the other groups but with two additional virtual workshop sessions. Session 1 involves only the parent(s) and focuses on parental support identity. The content is based on the behaviour change principles of self-identity theory that should lead to increases in self-identity.97-100 This session's activities include: 1) bringing awareness to the concept of identity and being a role model, 2) an activity on finding the meaning and value of parental support of child PA, 3) an activity on setting prioritization rules around parental support for child PA in comparison to other parenting responsibilities and values (brainstormed), 4) developing an affirmation for parental support self-talk, and 5) planning ways to visually demonstrate the parental support identity for self-categorization (e.g., on social media, pictures in frames101)
62609924|NCT04310475|EXPERIMENTAL|Active Treatment|This is a case series
62609925|NCT02722161|EXPERIMENTAL|[14C]BI 1482694|
62609926|NCT03279354|EXPERIMENTAL|Intervention group|Family Move app intervention
62832396|NCT05867238||Student nurse anaesthetists with training in stress management|Volunteer nurse anaesthetist students who have received training in stress management this year.
62251348|NCT04607148|EXPERIMENTAL|Galegenimab 10 mg Q8W|Participants will receive 10 mg galegenimab via ITV injection Q8W.
62251349|NCT00841204|EXPERIMENTAL|Arm I|Participants receive oral sulindac twice daily for 8 weeks
62251350|NCT00841204|PLACEBO_COMPARATOR|Arm II|Participants receive oral placebo twice daily for 8 weeks
62251351|NCT03032406|EXPERIMENTAL|HCQ alone (Arm A)|
62251352|NCT03032406|EXPERIMENTAL|EVE alone (Arm B)|
62251353|NCT03032406|EXPERIMENTAL|combination HCQ and EVE (Arm C)|
62609927|NCT03279354|PLACEBO_COMPARATOR|Control group|"HK FitNuts app intervention"
62609928|NCT05615636|EXPERIMENTAL|Safety Run In|During the safety run-in, the study team will first test a recommended dose of mosunetuzumab, polatuzumab vedotin, tafasitamab, and lenalidomide.
62609929|NCT05615636|EXPERIMENTAL|Dose Expansion Cohort|Participants will receive mosunetuzumab, polatuzumab vedotin, tafasitamab, and lenalidomide at the dose level that was found tolerated in the safety run-in.
62609930|NCT01449513|ACTIVE_COMPARATOR|PEP005 Gel 0.05%|active ingredient of PEP005: Ingenol mebutate
62609931|NCT01449513|PLACEBO_COMPARATOR|Placebo Gel|Vehicle of PEP005 Gel
62609932|NCT00090584|EXPERIMENTAL|Combination therapy|Women randomly assigned to this condition receive 10 weeks of anti-cholinergic medication (tolterodine) and behavioral training.
62609933|NCT00090584|ACTIVE_COMPARATOR|Drug therapy alone|Women assigned to this arm received 10 weeks of anti-cholinergic medication (tolterodine), only.
62609934|NCT02972749|EXPERIMENTAL|Intervention|Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
62609935|NCT02972749|NO_INTERVENTION|Control|No intervention. patients are instructed to continue prescribed medical therapy.
62251354|NCT03032406|EXPERIMENTAL|observation (Arm D)|
62251355|NCT04143399|ACTIVE_COMPARATOR|holmium laser enucleation of the prostate|holmium laser enucleation of the prostate (HoLEP)
62251356|NCT04143399|ACTIVE_COMPARATOR|bipolar resection of the prostate|bipolar resection of the prostate (BPEP)
62609936|NCT06276452|EXPERIMENTAL|Supporting resilience psychoeducational group|This group-based psychoeducational intervention will take place once weekly for eight weeks and will be centered upon building older adults' knowledge, skills, and motivation to manage chronic disease.
62832397|NCT01286480|EXPERIMENTAL|Clinic-based Educational Intervention|This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
62832398|NCT01286480|NO_INTERVENTION|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies. Time-pressured clinic visits limit the opportunity to discuss many of the topics noted above.
62609937|NCT04129528|ACTIVE_COMPARATOR|CFZ533|Randomized in a 2:1 ratio: 2 Active / 1 Placebo
62609938|NCT04129528|PLACEBO_COMPARATOR|Placebo|Similar in appearance to active study drug
62049421|NCT03166943|ACTIVE_COMPARATOR|Control group|Diastolic function by echocardiography age and sex matched group of 30 patients with Hepatitis C virus who did not receive antiviral treatment ( sofosbuvir and daclatasvir )
62049422|NCT01872533|EXPERIMENTAL|Hypoxia Exposure|There was only one study arm: All participants slept in moderate hypoxia (see description below).
62049423|NCT05597501|ACTIVE_COMPARATOR|CBT (cognitiv behavioural-therapy)-based|weekly psychosocial group-intervention (8 weeks) based on a CBT-manual
62251357|NCT01882842|EXPERIMENTAL|Endometrial biopsy arm|Participants randomised to this arm arm will undergo an endometrial biopsy procedure using Pipelle endometrial sampler (Pipelle de Cornier, Laboratoire CCD, Paris, France) or Wallace/ Wallach endometrial sampler as an alternative device on cycle day LH+7 to LH+9 of the cycle directly preceding commencement of down-regulation prior to IVF or ICSI treatment. A transvaginal ultrasound scan will be performed prior to the biopsy.
62049424|NCT05597501|ACTIVE_COMPARATOR|integrative therapy|weekly psychosocial group-intervention (8 weeks) based on a integrative therapy manual
62049425|NCT05597501|ACTIVE_COMPARATOR|Existential Analysis and Logotherapy|weekly psychosocial group-intervention (8 weeks) based on a Existential Analysis and Logotherapy manual
62251358|NCT01882842|NO_INTERVENTION|Control group|Participants randomised to control group will undergo a transvaginal ultrasound scan on day LH+7 to LH+9 of the cycle directly preceding commencement of IVF/ICSI treatment.
62609939|NCT03759145|EXPERIMENTAL|Intervention arm, usual rehabilitation + Jintronix exergame|On top of the usual out-patient rehabilitation sessions planned for the participant, participants attend sessions to use the Jintronix system for up 30 minutes up to 3 times per week
62609940|NCT03759145|OTHER|Control group|Participants continue their prescribed rehabilitation sessions
62609941|NCT05477628|PLACEBO_COMPARATOR|Control Group|Participants who are randomized to the control group will receive usual care from their health care practitioners.
62049426|NCT03283579||Pregnant women|
62049427|NCT04322123|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine after randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] for 07 days.
62049428|NCT04322123|EXPERIMENTAL|Hydroxychloroquine + azithromycin|Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] + azithromycin \[500mg 1x/day\]) for 07 days.
62049429|NCT04322123|NO_INTERVENTION|Control|standard treatment protocol for 2019-nCoV infection.
62049430|NCT01113502|EXPERIMENTAL|Phase 1 DL1|50 mg; Taken daily by mouth
62049431|NCT01113502|EXPERIMENTAL|Phase 1 DL 2|100 mg; Taken daily by mouth
62049432|NCT01113502|EXPERIMENTAL|Phase 1 DL3|200 mg; Taken daily by mouth
62049433|NCT01113502|EXPERIMENTAL|Phase 1 DL 4|300 mg; Taken daily by mouth
62049434|NCT01113502|EXPERIMENTAL|Phase 2|200 mg taken daily by mouth for 2 weeks; then 300 mg taken daily by mouth
62049435|NCT06571448|EXPERIMENTAL|SR750 high dose|
62049436|NCT06571448|EXPERIMENTAL|SR750 low dose|
62049437|NCT06571448|PLACEBO_COMPARATOR|Placebo|
62049438|NCT03070496|EXPERIMENTAL|STEMI cohort|"Patients recruited in the cohort will have 4 additional interventions compared to the usual follow-up :~* an additional blood sampling at 6 months~* an additional electrocardiogram (ECG) at 6 months~* Magnetic Resonance Imaging (MRI)~* Quality of life questionnaire"
62049439|NCT04042857|EXPERIMENTAL|Next Science|Patients will apply Next Science treatment to the study target hallux nail for 48 weeks daily.
62049440|NCT05114655|EXPERIMENTAL|Intervention 1|Participants apply an herbaceous, earthy based essential oil blend diluted in fractionated coconut oil to the jawline three times each day for 7 days.
62609942|NCT05477628|EXPERIMENTAL|Intervention Group|"Participants who are randomized to Intervention Group will receive one of three possible scenarios: 1) Childcare Navigator Support, 2) Breastfeeding support via Lactation Consultant, 3) both Childcare Navigator Support and Breastfeeding support via Lactation."
62609943|NCT05497232|EXPERIMENTAL|the homolateral simultaneous pancreas and kidney transplantation|SPK using the surgical technique was performed in our department from September 2016 to January 2023 in the Department of Transplantation of the Second Affiliated Hospital of Guangzhou Medical University.
62832399|NCT03228225|EXPERIMENTAL|Tele cardiac rehabilitation|Following a standard intake process, patients will begin exercise in the institute and will gradually over a period of 6 months reduce the number of institution visits and will concomitantly increase the number of home \\ community exercise sessions. During the entire period we will monitor program, coach and fine-tune the exercise program. Weekly exercise data will be securely transmitted to the rehabilitation team (heart rate zones, duration of exercise and type, step count, caloric expenditure, blood pressure and patients reported impressions)
62609944|NCT03379792||Type 1 Diabetes: BMI Classified as Lean|Participants with type 1 diabetes with a BMI between 18.0-24.9 kg/m\^2.
62832400|NCT01371396|OTHER|Hispanic subjects|Subjects will identify as Hispanic ethnicity.
62832401|NCT01371396|OTHER|African American subjects|Subjects will self-identify as African American in origin.
62251359|NCT02774395||endometrioid adenocarcinoma grade I|
62049441|NCT05114655|EXPERIMENTAL|Intervention 2|Participants apply a light, citrus-based essential oil blend diluted in fractionated coconut oil to the jawline three times each day for 7 days.
62049442|NCT05114655|PLACEBO_COMPARATOR|Placebo|Participants apply an inert blend including fractionated coconut oil to the jawline three times each day for 7 days.
62251360|NCT02774395||endometrioid adenocarcinoma grade II|
62251361|NCT02774395||endometrioid adenocarcinoma garde III|
62251362|NCT02774395||healthy endometrioid|obtain after hysterectomia provided for
62251363|NCT00958945||FloSeal - Knee - control|100 Historical Control Patients, knees - no FloSeal (retrospective)
62251364|NCT00958945||FloSeal - Knee - 5ml|100 Patients, knees - 5mL FloSeal (retrospective)
62832402|NCT00306501|OTHER|Button Press|Training with button press
62251365|NCT00958945||FloSeal - Knee - 10ml|100 Patients, knees- 10mL FloSeal (prospective)
62251366|NCT00958945||FloSeal - Hip - Control|100 Historical Control patients, hips-no FloSeal (retrospective)
62251367|NCT00958945||FloSeal - Hip - 5ml|100 retrospective patients, hips-5mL of FloSeal (retrospective)
62251368|NCT03035695|EXPERIMENTAL|Axiostat® Size|"Device: Axiostat® Size: 8 x 5 cm Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.~Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
62251369|NCT03035695|ACTIVE_COMPARATOR|Cotton Gauze|Cotton Gauze Size: 8 x 5 cm
62251370|NCT03163784|PLACEBO_COMPARATOR|Arm A|Weekly placebo (for Fecal Inoculum Capsule) treatment with placebo pre-treatment.
62251371|NCT03163784|EXPERIMENTAL|Arm B|Weekly Fecal Inoculum Capsule treatment with placebo pre-treatment.
62251372|NCT03163784|EXPERIMENTAL|Arm C|Weekly Fecal Inoculum Capsule treatment with antibiotic pre-treatment.
62251373|NCT01535495|EXPERIMENTAL|Complete laser|Patients who have had complete panretinal photocoagulation laser treatment and active retinal neovascularization
62251374|NCT01535495|EXPERIMENTAL|Laser naive|"Patients who have not had panretinal photocoagulation laser treatment and active retinal neovascularization without so called high-risk characteristics"
62251375|NCT02860195|EXPERIMENTAL|healthy volunteers|
62609945|NCT03379792||Type 1 Diabetes: BMI Classified as Overweight|Participants with type 1 diabetes with a BMI between 25.0-29.9 kg/m\^2.
62609946|NCT03379792||Type 1 Diabetes: BMI Classified as Obese|Participants with type 1 diabetes with a BMI between 30.0-39.9 kg/m\^2.
62609947|NCT03379792||Control: BMI Classified as Lean|Control participants without diabetes with a BMI between 18.0-24.9 kg/m\^2.
62609948|NCT03379792||Control: BMI Classified as Overweight|Control participants without diabetes with a BMI between 25.0-29.9 kg/m\^2.
62609949|NCT03379792||Control: BMI Classified as Obese|Control participants without diabetes with a BMI between 30.0-39.9 kg/m\^2.
62832403|NCT00306501|OTHER|Vibtrotactile|Sensory Stimulation - Vibrotactile device with button press to initiate swallowing during retraining
62832404|NCT00306501|OTHER|Cortical Stimulation|Training with Cortical stimulation - cortical stimulation during training with button press
62832405|NCT00306501|OTHER|Combined|Combined vibrotactile and cortical stimulation with button press training
62832406|NCT00684931|EXPERIMENTAL|1|patients with Attention Deficit Disorder with or without Hyperactivity
62832407|NCT00684931|SHAM_COMPARATOR|2|healthy volunteer without Attention Deficit Hyperactivity Disorder
62832408|NCT05447780|EXPERIMENTAL|General anesthesia|induction: propofol 1.5-2.5 mg\\kg IV bolus and fentanyl 1-2 mcg\\kg maintenance anesthesia: sevoflurane, doses of the inhalation agent according to bispectral index (BIS) monitor ( target BIS level 40-60) and fentanyl 1-5 mcg\\kg\\h.
62832409|NCT05447780|EXPERIMENTAL|Combined anesthesia: general anesthesia and Erector spinae plane block (ESP block)|"induction: propofol 1.5-2.5 mg\\kg IV bolus and fentanyl 1-2 mcg\\kg ESP- block with US control with single shot of local anesthetic ( bupivacaine 0.375% or 0.25% 20-30 ml) is performed after induction.~maintenance anesthesia: sevoflurane, doses of the inhalation agent according to BIS monitor ( target BIS level 40-60) and fentanyl 0.5-1.5 mcg\\kg\\h."
62832410|NCT05447780|EXPERIMENTAL|Combined anesthesia: General anesthesia and Thoraco-lumbar interfacial plane block (TLIP block)|"induction: propofol 1.5-2.5 mg\\kg IV bolus and fentanyl 1-2 mcg\\kg TLIP- block with US control with single shot of local anesthetic ( bupivacaine 0.25% 15 ml or mixed bupivacaine 0.25% 7.5 ml and lidocaine 2% 7.5 ml) is performed after induction.~maintenance anesthesia: sevoflurane, doses of the inhalation agent according to BIS monitor ( target BIS level 40-60) and fentanyl 0.5-1.5 mcg\\kg\\h."
62832411|NCT03687060|OTHER|Organization Level|
62832412|NCT03687060|OTHER|Provider Level|
62832413|NCT03687060|OTHER|Patient Level|
62832414|NCT06361069|NO_INTERVENTION|Control group|20 children in the control group
62832415|NCT06361069|EXPERIMENTAL|Experimental group|22 in the finger puppet, 21 in the distraction cards intervention group, and 22 in the kaleidoscope intervention group
62832416|NCT03527108|EXPERIMENTAL|Patients with prior IO therapy|
62832417|NCT03394820|ACTIVE_COMPARATOR|dexamethasone 1 hour prior to block|The patient will receive dexamethasone through IV one hour prior to receiving their block. During the patient's block, 1 hour after and 2 hours after the block the patient will receive infusions of normal saline to maintain the blind.
62832418|NCT03394820|EXPERIMENTAL|dexamethasone during the block|The patient will receive dexamethasone through IV at the same time the patient has the SCB done. One hour prior to the block, one hour after the block and 2 hours after the block the patient will receive infusions of normal saline to maintain the blind.
62832419|NCT03394820|ACTIVE_COMPARATOR|dexamethasone 1 hour after block|The patient will receive dexamethasone through IV one hour after the block has been administered. One hour prior to block, during the block and two hours after the block the patient will receive normal saline to maintain the blind.
62832420|NCT03394820|ACTIVE_COMPARATOR|dexamethasone 2 hours after block|The patient will receive dexamethasone 2 hours after the block has been administered. One hour prior to the block, during the block and one hour after the block the patient will receive normal saline to maintain the blind.
62251376|NCT00290290|ACTIVE_COMPARATOR|povidone-iodine|preoperative skin preparation with povidone-iodine
62251377|NCT00290290|EXPERIMENTAL|chlorhexidine-alcohol|preoperative skin preparation with scrub and paint technique
62251378|NCT05518227||The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
62832421|NCT04046809|EXPERIMENTAL|Study Treatment|500 ml oral solution containing citicoline free acid 50 mg/ml.
62251379|NCT00189618|PLACEBO_COMPARATOR|1|
62251380|NCT00189618|ACTIVE_COMPARATOR|2|
62251381|NCT01978535|EXPERIMENTAL|Iron infusion|Iron Sucrose (Venofer (R))
62251382|NCT01978535|PLACEBO_COMPARATOR|Normal saline infusion|Equal volume to intervention of normal saline
62251383|NCT01411020|EXPERIMENTAL|Grupo 1|Doses of induction: propofol 4 mcg/ml and fentanyl 3 mcg/kg
62251384|NCT01411020|EXPERIMENTAL|Grupo 2|Dose of induction: propofol 4.5 mcg/ml and fentanyl 3 mcg/kg
62251385|NCT01411020|EXPERIMENTAL|Grupo 3|Doses of propofol: propofol 5 mcg/ml and fentanyl 3 mcg/kg
62251386|NCT01411020|EXPERIMENTAL|Grupo 4|Doses of induction: propofol 5.5 mcg/ml and fentanyl 3 mcg/kg
62251387|NCT01411020|EXPERIMENTAL|Grupo 5|Doses of induction: propofol 6 mcg/ml and fentanyl 3 mcg/kg
62251388|NCT01411020|EXPERIMENTAL|Grupo 6|Doses of induction: propofol 4 mcg/ml and fentanyl 5 mcg/kg
62251389|NCT01411020|EXPERIMENTAL|Grupo 7|Doses of induction: propofol 4.5 mcg/ml and fentanyl 5 mcg/kg
62251390|NCT01411020|EXPERIMENTAL|Grupo 8|Doses of induction: propofol 5 mcg/ml and fentanyl 5 mcg/kg
62251391|NCT01411020|EXPERIMENTAL|Grupo 9|Doses of induction: propofol 5.5 mcg/ml and fentanyl 5 mcg/kg
62251392|NCT01411020|EXPERIMENTAL|Grupo 10|Doses of induction: propofol 6 mcg/ml and fentanyl 5 mcg/kg
62832422|NCT04046809|PLACEBO_COMPARATOR|Placebo|500 ml oral solution indistinguishable from active product in appearance and taste
62832423|NCT06177496||Group A|HCC patients underwent local ablation
62832424|NCT06177496||Group B|HCC patients underwent TACE
62832425|NCT06177496||Group C|HCC patients received sorafenib
62832426|NCT02157025|EXPERIMENTAL|Cartoon Intervention|Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry
62832427|NCT02157025|ACTIVE_COMPARATOR|Usual Care|Usual care procedures for Humphrey perimetry in young children
62832428|NCT03675997||Autografted patients|Patients hospitalized in the hematological department of the Institute will complete the first day of conditioning and then weekly HAD (Hospital Anxiety and Depression) scale.
62832429|NCT04684277|EXPERIMENTAL|antidepressant treatment|recieve antidepressant treatment
62609950|NCT06621576|EXPERIMENTAL|HM2002 Injection group|First sentinel enrollment, no DLT events followed by re-enrollment after 2 cases
62609951|NCT01733459|EXPERIMENTAL|Treatment I|1 DLBS3233 capsule 100 mg (once daily) and 1 placebo caplet of Metformin XR (twice daily)
62609952|NCT01733459|ACTIVE_COMPARATOR|Treatment II|1 Metformin XR caplet 750 mg (twice daily) and 1 placebo capsule of DLBS3233 (once daily)
62609953|NCT03918278|EXPERIMENTAL|Part 1: MK-0482 Monotherapy|Participants receive escalating doses of MK-0482 via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 administrations (up to approximately 2 years).
62609954|NCT03918278|EXPERIMENTAL|Part 1: MK-0482 + Pembrolizumab Combination Therapy|Participants receive escalating doses of MK-0482 via IV infusion + pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 administrations (up to approximately 2 years).
62609955|NCT03918278|EXPERIMENTAL|Part 2: Cohort A|Participants with metastatic triple negative breast cancer (TNBC) first line treatment (1L) receive MK-0482 via IV infusion plus pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) up to 35 administrations (up to approximately 2 years) and paclitaxel 90 mg/m\^2 via IV infusion until PD or discontinuation.
62609956|NCT03918278|EXPERIMENTAL|Part 2: Cohort B|Participants with recurrent non-operable glioblastoma (GBM) current treatment of second line (2L) receive MK-0482 via IV infusion plus pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) up to 35 administrations (up to approximately 2 years).
62609957|NCT03918278|EXPERIMENTAL|Part 2: Cohort C|Participants with metastatic pancreatic ductal adenocarcinoma (PDAC) (1L) receive MK-0482 via IV infusion plus pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) up to 35 administrations (up to approximately 2 years), Nab-Paclitaxel 125 mg/m\^2 via IV infusion and gemcitabine 1000 mg/m\^2 via IV infusion until PD or unacceptable toxicity that requires discontinuation.
62251393|NCT01378260||Surgical Bypass|use of synthetic or endogenous (vein) or composite graft to treat lesions in the superficial femoral, common femoral, or popliteal artery
62251394|NCT01378260||Endovascular Therapy|angioplasty and/or stent to treat lesions in the superficial femoral or popliteal artery
62251395|NCT01378260||Medical Management|"Documentation of the following in the medical record:~i. Walking/physical therapy to improve endurance was recommended; ii. For tobacco users, tobacco cessation was recommended; iii. Prescribing pentoxifylline (Trental) or cilostazol (pletal) iv. Ongoing care by physician for treatment of claudication"
62251396|NCT06419192|EXPERIMENTAL|dietary advice + food supplied|Eat 7 dates a day from 37 weeks' gestation (SA) until delivery. Women will be provided with the quantity of dates they need.
62609958|NCT03918278|EXPERIMENTAL|Part 2: Cohort D|Participants with metastatic soft tissue sarcoma (STS) (2L) receive MK-0482 via IV infusion plus pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) up to 35 administrations (up to approximately 2 years).
62609959|NCT03918278|EXPERIMENTAL|Part 2: Cohort E|Participants with metastatic non-squamous non-small cell lung carcinoma (NSCLC) (1L) receive MK-0482 via IV infusion plus pembrolizumab 200 mg via IV infusion plus Pemetrexed 500 mg/m\^2 via IV infusion on Day 1 of each 21-day cycle (Q3W) up to 35 administrations (up to approximately 2 years) plus carboplatin with desired dose of area under the curve (AUC) 5 and pemetrexed 500 mg/m\^2, both administered via IV infusion, followed by maintenance therapy with pemetrexed 500 mg/m\^2 via IV infusion for up to a total of 35 administrations (up to approximately 2 years).
62609960|NCT04002778|ACTIVE_COMPARATOR|ROSE by endosonographer|Submitted to fine-needle aspiration. Endosonographer's on-site evaluation of sample adequacy and categorization
62609961|NCT04002778|OTHER|non-ROSE|Submitted to fine-needle aspiration.
62609962|NCT00853515|EXPERIMENTAL|1|Goal-directed fluid resuscitation with lactated Ringer's solution
62609963|NCT00853515|EXPERIMENTAL|2|Goal-directed fluid resuscitation with normal saline
62609964|NCT00853515|NO_INTERVENTION|3|Standard fluid resuscitation with lactated Ringer's solution
62609965|NCT00853515|NO_INTERVENTION|4|Standard fluid resuscitation with normal saline
62609966|NCT06731413|EXPERIMENTAL|Reduced Dose Combination Therapy|"Squamous cell histology:~1. Carboplatin AUC 3 every 21 days IV for 4 cycles~2. Paclitaxel 135 mg/m2 every 21 IV days for 4 cycles~3. Pembrolizumab 200 mg every 21 days IV until disease progression or unacceptable toxicity up to 35 cycles~Non-squamous histology:~1. Carboplatin AUC 3 every 21 days IV for 4 cycles~2. Pemetrexed 375 mg/m2 every 21 IV days for 4 cycles~3. Pembrolizumab 200 mg every 21 days IV until disease progression or unacceptable toxicity up to 35 cycles"
62832430|NCT04684277|EXPERIMENTAL|antidepressant treatment combined with Internet-based interventions|recieve antidepressant treatment combined with Internet-based interventions
62832431|NCT06019702|EXPERIMENTAL|Personalized mRNA Vaccine iNeo-Vac-R01|The traditional 3+3 design will be used in dose escalation. In dose escalation phase, subjects are expected to be enrolled at 50 μg, 100 μg and 150 μg (3-6 subjects in each group). The low dose group will be enrolled first. Subjects will receive iNeo-Vac-R01 administered via a hypodermic (IH) injection on Day 1 of each 21-day cycle for up to 9 cycles. The investigators will choose the optimal clinical dose for dose expansion phase.
62832432|NCT04690023|ACTIVE_COMPARATOR|PENG block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided PENG block. Patients in PENG group receive multimodal postoperative analgesia techniques coupled with morphine PCA pump.
62251397|NCT06419192|EXPERIMENTAL|dietary advice alone|Advise to eat 7 dates a day from 37 weeks' gestation (SA) until delivery. The food will not be provided.
62251398|NCT06419192|NO_INTERVENTION|usual care|No specific dietary advice
62251399|NCT05490836|ACTIVE_COMPARATOR|continuous treatment arm|
62251400|NCT05490836|EXPERIMENTAL|pulse treatment arm|
62251401|NCT03770091|EXPERIMENTAL|Foam and Compression Wrap|Patients will use Theraworx foam and a compression wrap
62251402|NCT03770091|PLACEBO_COMPARATOR|Placebo Foam and Compression Wrap|Patients will use placebo foam and a compression wrap
62251403|NCT03770091|EXPERIMENTAL|Foam alone|Patients will use Theraworx foam without compression wrap
62251404|NCT03569046|ACTIVE_COMPARATOR|group l|ear block by local anaesthetic injection 0.25% bupivacaine. general anesthetic by: midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 µg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air. hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
62251405|NCT03569046|PLACEBO_COMPARATOR|Group II|ear block by Normal Saline Flush, 0.9% Injectable Solution . general anesthetic by: midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 µg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air. hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
62251406|NCT01200004|EXPERIMENTAL|Azacitidine + Lenalidomide|Azacitidine 75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle. Lenalidomide starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
62251407|NCT01200004|EXPERIMENTAL|Azacitidine + Lenalidomide + Grifola Frondosa|Once Lenalidomide MTD identified in combination with azacitidine, Grifola frondosa added. Cycle 1, azacitidine on day 1, lenalidomide on day 2 and Grifola frondosa on day 3. Azacitidine daily for 5 days every 28 days while lenalidomide and Grifola frondosa on days 1-21 of subsequent cycles.
62251408|NCT01200004|EXPERIMENTAL|Expansion Group A|Azacitidine + Lenalidomide MTD, then 2 weeks later Grifola frondosa
62251409|NCT01200004|EXPERIMENTAL|Expansion Group B|Azacitidine + Grifola Frondosa, then 2 weeks later Lenalidomide
62251410|NCT01961375||Group 1|BAY 86-5028; Levonorgestrel- Intra Uterine System
62251411|NCT01698866|EXPERIMENTAL|vaccin GenHevac B Pasteur|vaccin GenHevac B Pasteur (Suspension for injection in pre-filled syringe / 20 μg microgram(s)Per day). In total, 3 injections at M0, M1 and M6
62251412|NCT03043521|EXPERIMENTAL|CJ-12420 50mg|T1=CJ-12420 50mg QD evening (9PM)
62251413|NCT03043521|EXPERIMENTAL|CJ-12420 100mg|T2=CJ-12420 100mg QD evening (9PM)
62251414|NCT03043521|EXPERIMENTAL|CJ-12420 200mg|T3=CJ-12420 200mg QD evening (9PM)
62251415|NCT03043521|ACTIVE_COMPARATOR|Dexlansopazole 60mg|R=dexlansoprazole 60mg QD evening (9p.m)
62251416|NCT00467779|EXPERIMENTAL|Stage 1: Cobimetinib Dose Escalation (21/7 Schedule)|Participants will receive cobimetinib (GDC-0973/XL518) at the starting dose of 0.05 mg/kg via solution or capsule, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment \[21/7 schedule\]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
62251417|NCT00467779|EXPERIMENTAL|Stage 1A: Cobimetinib Dose Escalation (14/14 Schedule)|Participants will receive cobimetinib at the starting dose of 60 mg via solution or capsule, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment \[14/14 schedule\]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
62251418|NCT00467779|EXPERIMENTAL|Stage 2: Cobimetinib Expansion (21/7 Schedule)|Participants will receive cobimetinib at the maximum tolerated dose (MTD) established in Stage 1, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment \[21/7 schedule\]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
62251419|NCT00467779|EXPERIMENTAL|Stage 2 A: Cobimetinib Expansion (14/14 Schedule)|Participants will receive cobimetinib at the MTD established in Stage 1A, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment \[14/14 schedule\]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
62251420|NCT00467779|EXPERIMENTAL|Stage 3: Cobimetinib+Midazolam+Dextromethorphan|Participants will receive a single dose of midazolam (2 mg of midazolam syrup) and dextromethorphan (30 mg tablet) on Cycle 1 Day 1, in the absence of cobimetinib. After a 2-day washout period, participants will receive 21 consecutive daily doses of cobimetinib (60-mg) followed by a 7-day washout period. Participants will receive another single dose of midazolam and dextromethorphan on Cycle 1 Day 15, in the presence of steady-state cobimetinib concentrations. In Cycle 2 and beyond participants will receive cobimetinib alone, administered as a 60-mg daily dose for 21 consecutive days in 28-day cycles (21/7 schedule).
62251421|NCT01611064|ACTIVE_COMPARATOR|Oxygen|Volunteer receives oxygen at a rate of 10litres/minute by mask
62251422|NCT01611064|PLACEBO_COMPARATOR|Air|Volunteer receives normal air at a rate of 10litres/minute by mask
62251423|NCT04643756|ACTIVE_COMPARATOR|Conventional Physiotherapy|Classical electrotherapy method consisting of tens, hotpack and ultrasound. Procedure/Device: Conventional Physiotherapy Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in prone and supported with a pillow under the abdomen, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm2 and duration of 5 minute. TENS was applied to the lumbar region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
62609967|NCT01935245|EXPERIMENTAL|Mini extracorporeal circulation|Patients undergoing coronary artery bypass surgery on minimal extracorporeal circulation
62609968|NCT01935245|ACTIVE_COMPARATOR|Conventional extracorporeal circulation|Patients undergoing coronary artery bypass surgery on conventional extracorporeal circulation
62832433|NCT04690023|ACTIVE_COMPARATOR|SFICB block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided supra-inguinal fascia iliaca compartment block. Patients in SFICB group receive multimodal postoperative analgesia techniques coupled with morphine PCA pump.
62049443|NCT01043432||Moderate/severe TBI and history of suicidal behavior Group 1|Moderate/severe TBI and history of suicidal behavior
62049444|NCT01043432||Moderate/Severe TBI and no history of suicidal behaviorGroup|Moderate/Severe TBI and no history of suicidal behavior
62049445|NCT01043432||No TBI and a history of suicidal behavior Group 3|No TBI and a history of suicidal behavior
62609969|NCT03050541|EXPERIMENTAL|MDMA at Memory Encoding|20 healthy adult volunteers will be randomly assigned to the encoding group (MDMA at Encoding). This group will receive capsules before viewing the study materials, and at retrieval two days later, but they will receive MDMA only in the capsule appropriate to their condition, and the next session capsule will contain placebo.
62832434|NCT00549835|ACTIVE_COMPARATOR|Real Acupuncture|Participants will have acupuncture performed at a rate of 3 times (Mon, Wed, Fri) / week for total of 2 weeks (total of 6 sessions). We will follow Saam Acupuncture methods, which have been the mainstream of acupuncture methodology in most Korean Oriental Medical Colleges and among clinical practitioners \>400 years. Standardized acupuncture prescriptions for mucositis will be acupuncture points tonifying Spleen Meridian (R side) and Small Intestine Meridian (L side). In Oriental Medicine, the spleen has functions of promoting water metabolism, transporting nutrients, and controlling blood. Mouth belongs to the spleen system according to Five element theory. Small intestine is related with mucositis symptoms including thirst and tongue ulcers. We will use sterile, disposable, filiform needles, size 0.16 (40Gauge) - 0.30 mm (30Gauge) in diameter and 15-40 mm long. Total number of acupuncture needles will be 8 (4 needles each side) and needles will be retained for 20 minutes.
62832435|NCT00549835|SHAM_COMPARATOR|Sham Acupuncture|Newly diagnosed leukemia patients will be recruited from the large patient population on the Leukemia Inpatient Services who will be receiving high dose preperative regimens such as Busulfan + Cytarabine for marrow transplantation.
62832436|NCT05661617||Czech healthy women tested in normative study|"Czech healthy women aged 20-24 years tested in study called Establishing Czech Norms of Selected Standardized Tests."
62832437|NCT05661617||Czech healthy women (experimental group)|Czech healthy women aged 20-24 years (inclusive) who participated in the research in the period from January 2023.
62832438|NCT06341478|ACTIVE_COMPARATOR|Radical cystectomy|Radical cystectomy and pelvic lymphadenectomy upfront, according to the standar-of-care management
62832439|NCT06341478|EXPERIMENTAL|Sacituzumab Govitecan|SURE-01 trial: 4 courses of sacituzumab Govitecan, intravenously, at the dose of 7.5 mg/Kg on Day 1 and 8, every 21 days.
62251424|NCT04643756|ACTIVE_COMPARATOR|Conventional Physiotherapy + Kinesiotaping|Kinesiotaping application in addition to classical electrotherapy method consisting of tens, hotpack and ultrasound.It will be applied to reduce pain, increase proprioception and awareness. Kinesiotaping will be re-applicated every day. Space taping will be applied to the waist area. Space taping creates a vacuum effect on the skin, loosening the adhesions in the tissue layers. With this lifting effect, it creates a space under the skin, causing an increase in circulation and a decrease in pain. Four pieces of I-tape will be used for taping. The middle point of the first tape will be attached with maximum tension. The ends of the tape will be tensionless. The second tape will also be applied at a 90 degree angle. The third and fourth tapes will be taped at an angle of 45 degrees.
62609970|NCT03050541|EXPERIMENTAL|MDMA at Memory Retrieval|20 healthy adult volunteers will be randomly assigned to the retrevial group (MDMA at Retrevial). This group will receive placebo before viewing the study materials, and MDMA at retrieval two days later..
62609971|NCT03050541|PLACEBO_COMPARATOR|Placebo at both sessions|20 healthy adult volunteers will be randomly assigned to the placebo group (no drug at either session). This group will receive only placebo during study, session before viewing the study materials, and at retrieval two days later.
62049446|NCT01043432||No TBI and no history of suicidal behavior Group 4|No TBI and no history of suicidal behavior
62832440|NCT06341478|EXPERIMENTAL|Sacituzumab Govitecan + pembrolizumab|SURE-02 trial: 4 courses of sacituzumab Govitecan, intravenously, at the dose of 7.5 mg/Kg on Day 1 and 8, every 21 days, added to pembrolizumab, intravenously, at the dose of 200 mg every 21 days, followed by radical cystectomy. After cystectomy, 13 courses of 200 mg pembrolizumab, intravenously, every 21 days.
62832441|NCT06341478|EXPERIMENTAL|Nivolumab + abraxane|NureCombo trial: 4 cycles of 360 mg nivolumab, every 3 weeks, added to nab-paclitaxel 125 mg/m2 on days 1 and 8, every 21 days, before radical cystectomy. After cystectomy, 13 courses of 360 mg nivolumab, intravenously, every 21 days.
62832442|NCT02397577|OTHER|gastric emptying measurements|
62609972|NCT04400981|EXPERIMENTAL|Intervention arm: RIC plus standard medical therapy|"Remote ischemic conditioning (RIC) will be applied immediately after randomization in the Emergency Department, through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 4 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure) and 5 minutes of deflation.~Patients randomized to remote ischemic conditioning will also receive standard medical therapy"
62609973|NCT04400981|ACTIVE_COMPARATOR|Control arm: Standard medical therapy alone|"Standard medical therapy will be administered immediately after randomization in the Emergency Department. Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction."
62609974|NCT06070753|EXPERIMENTAL|Participants undergo EVT plus Cerebrolysin|one group of patients should receive intravenous treatment with Cerebrolysin (30 ml/day) starting post EVT CT-Perfusion that will be performed not later than 3 hours from completion of EVT. Treatment will be continued for 10 consecutive days as one single daily infusion.
62609975|NCT00933114||Functional Imaging|Functional imaging with MRI and PET
62609976|NCT03108872||LAAO group|One-hundred consecutive patients who underwent left atrial appendage occlusion from October 2010 to March 2015 in 5 Korean tertiary cardiovascular centers will be retrospectively registered.
62609977|NCT03108872||NOAC group|Two-hundred age-, sex-, CHA2DS2-VASc score- and HAS-BLED score- matched control will be selected with a 1:2 ratio among all patients treated with new oral anticoagulants to prevent ischemic events from 5 centers during same periods
62609978|NCT03152994||COPD patients with T2DM|"For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who will develope T2DM during the follow-up will be divided into the groupCOPD patients with T2DM."
62609979|NCT03152994||COPD patients without T2DM|"For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who won't develope T2DM during the follow-up will be divided into the groupCOPD patients without T2DM."
62609980|NCT04877158|EXPERIMENTAL|Self-Blame and Perspective-Taking Intervention|These participants are enrolled with intent to participate in the group therapy intervention.
62609981|NCT02368210|EXPERIMENTAL|122-0551 Foam|122-0511 Foam, topically applied twice daily
62251425|NCT05126186|EXPERIMENTAL|haplo-SCT with PTCy|haploidentical (haplo) related donor Stem Cell Transplantation (haplo-SCT) with administration of post-transplantation cyclophosphamide (PTCy, which targets alloreactive T cells generated early after an HLA-mismatched transplant, sparing regulatory T cells and leaving unaffected the non-dividing hematopoietic stem cells)
62251426|NCT02959528|ACTIVE_COMPARATOR|Control|ADHD group treated with visual-perceptual training
62251427|NCT02959528|EXPERIMENTAL|Experiment|ADHD group treated with working memory training
62251428|NCT01353508|EXPERIMENTAL|LCZ696 to Valsartan - Heart Failure (HF) cohort|Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.
62251429|NCT01353508|EXPERIMENTAL|Valsartan to LCZ696 - HF Cohort|Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.
62251430|NCT01353508|EXPERIMENTAL|LCZ696 to Valsartan - Hypertension (HTN) cohort|Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.
62251431|NCT01353508|EXPERIMENTAL|Valsartan to LCZ696 - HTN cohort|Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.
62251432|NCT03755570||CRT: Main Arm|"Cardiac Resynchronisation Therapy (CRT): Main Arm \~98 participants~Prior to CRT Implantation \& Post-Implant 6-Month Device Follow-Up Clinic:~- Battery of 5 questionnaire-based cognitive tests, including the Test of Premorbid Functioning, Repeatable Battery for the Assessment of Neuropsychological Status, Hospital Anxiety and Depression Scale, Frontal Assessment Battery and Trail Making Test Part A and B~Please note, the Test of Premorbid Functioning will only be performed ONCE at Pre-Assessment as results reflect IQ prior to disease onset."
62441143|NCT03929224|ACTIVE_COMPARATOR|Bacitracin|Standard care: Bone-anchored hearing aid (BAHI) abutment incision is coated in bacitracin. A healing cap is placed over the abutment and left for a week. The healing cap is removed on postoperative day 7. Patient is instructed to apply bacitracin ointment to the area for 2 weeks.
62609982|NCT02368210|PLACEBO_COMPARATOR|Vehicle Foam|Vehicle Foam, topically applied twice daily
62609983|NCT06392386|EXPERIMENTAL|Efgartigimod PH20 SC|Participants aged 12 to \<18 years receiving efgartigimod PH20 SC treatment
62609984|NCT06308588|EXPERIMENTAL|Blinatumomab + Asciminib|"Participants found to be eligible to take part in this study will receive 5 cycles of blinatumomab and asciminib, followed by asciminib alone for as long as it benefits the participant.~Participants will receive blinatumomab as a continuous (non-stop) infusion on Days 4-31 of Cycle 1 and on Days 1-28 of Cycles 2-5.~Participants will take asciminib by mouth 2 times every day during this study."
62832443|NCT00240513|ACTIVE_COMPARATOR|Minocycline 3 mo|Minocycline 3 mo
62609985|NCT05822206|EXPERIMENTAL|Treatment|Participants in the Treatment arm receive 2 therapy sessions on LifeSteps and sexual decision-making, as well at 8 sessions of Cognitive Behavioral Therapy for Trauma and Self-Care (CBT-TSC). Participants then participate in 3-, 6-, and 9-month follow-up assessments.
62609986|NCT05822206|OTHER|Control|Participants in the Control arm receive 2 therapy sessions on LifeSteps and sexual decision-making. Participants then participate in 3-, 6-, and 9-month follow-up assessments.
62609987|NCT06719232||Catheter-Free Intravesical Instillation Patients|This group consists of patients receiving catheter-free intravesical instillation treatments with a special syringe adapter, called UroDapter for any conditions, including interstitial cystitis/bladder pain syndrome (IC/BPS), recurrent urinary tract infections (UTIs), post-chemotherapy cystitis, post-radiation cystitis, and non-muscle invasive bladder cancer.
62832444|NCT00240513|EXPERIMENTAL|Minocycline plus Tretinoin|Minocycline plus Tretinoin for 3 months
62049447|NCT04584034|ACTIVE_COMPARATOR|Salbutamol|Salbutamol inhalation 4x200ug daily for 7 days, delivered using a Babyhaler
62251433|NCT03755570||ICD and PPM: Control Arm|"Implantable Cardioverter-Defibrillator (ICD) and Permanent Pacemaker (PPM): Control Arm \~98 participants~Prior to ICD or PPM Implantation \& Post-Implant 6-Month Device Follow-Up Clinic:~- Battery of 5 questionnaire-based cognitive tests, including the Test of Premorbid Functioning Repeatable Battery for the Assessment of Neuropsychological Status, Hospital Anxiety and Depression Scale, Frontal Assessment Battery and Trail Making Test Part A and B~Please note, the Test of Premorbid Functioning will only be performed ONCE at Pre-Assessment as results reflect IQ prior to disease onset."
62251434|NCT04416399|EXPERIMENTAL|Inhaled budesonide|Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
62251435|NCT04416399|NO_INTERVENTION|Standard of care|Standard of care
62251436|NCT03611283|EXPERIMENTAL|Test group|"Patients had to use:~Mouthwash treatment (250 ml): Aqua, Betaine, Glycerin, PEG-40, Hydrogenated Castor Oil, Propylene Glycol, Xylitol, Aroma, Potassium Phosphate, Diazolidinyl Urea, Allantoin, Olea Europaea Fruit Oil, Sodium Methylparaben, Sodium Propylparaben, Sodium Fluoride, CI75810, Panthenol, Tocopheryl Acetate, Sucralose, Carum Petroselinum Seed Oil, Limonene.~Toothpaste treatment (50 ml): Glycerin, Aqua, Hydrated Silica, Xylitol, Betine, Tetrapotassium Pyrophosphate, Olea Europaea Fruti Oil, Xanthan Gum, Titanium Dioxide, Potassium Phosphate, Aroma, Sodium Fluoride, Diazolidinyl Urea, Papain, Carum Petroselinum Seed Oil, Panthenol, Tocopheryl Acetate, Limonene"
62251437|NCT03611283|PLACEBO_COMPARATOR|Placebo group|"Patients had to use:~Mouthwash placebo(250 ml): Aqua, Glycerin, PEG-40 Hydrogenated Castor Oil, Propylene Glycol, flavoring, Potassium Phospate, Diazolidinyl Urea, Sodium Methylparaben, Sodium Propylparaben, Sodium Fluoride, CI75810, Tocopheryl Acetate, Sucralose, LImonene.~Toothpaste placebo (50 ml): Aqua, Sorbitol, Hydrated Silica, Glycerin, Tetrapotassium Pyrophosphate, Xanthan Gum Titanium Dioxide, Sodium Lauryl Sulphate, Potassium Phosphate, flavoring, Sodium Fluoride, Diazolidinyl Urea, Sucralose, Limonene"
62251438|NCT02616614|ACTIVE_COMPARATOR|Onexton gel|Clindamycin 1.2% and benzoyl peroxide 3.75% topical gel Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
62609988|NCT03722407|EXPERIMENTAL|Ruxolitinib|All patients will be given their first dose of oral Ruxolitinib, 20 mg at first scheduled visit. After that dose and on all other days patients will self-administer oral Ruxolitinib at a dose of 40 mg daily divided into two equal doses approximately 12 hours apart. Patients will be treated for a total of 16 weeks. After treatment, patients will be followed monthly.
62609989|NCT03538067||Paired sample group|Patients with symptomatic coronary artery disease (stable, NSTEACS) undergoing planned percutaneous coronary intervention with intravascular ultrasound (IVUS) guidance
62832445|NCT02659254|EXPERIMENTAL|Firesorb Implantation|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）in patients with coronary artery lesions.
62832446|NCT01919502|OTHER|Semi-quantitative urine pregnancy test|Semi-quantitative urine pregnancy test (Quanti5 Multilevel hCG Pregnancy Test)
62049448|NCT04584034|PLACEBO_COMPARATOR|Placebo|Placebo 4 x 2 inhalations daily for 7 days, delivered using a Babyhaler
62049449|NCT04851548|ACTIVE_COMPARATOR|Group A (control)|"preoperative cone-beam computed tomography (CBCT) scans N=9~* open flap debridement.~* use membrane without hyaluronic acid. (The first monitor will be done after three months. The data will be recorded. After another three months, the patients will undergo an x-ray check again, and the data will be registered. The goal is to have the patients exposed to x-ray twice not to be compromised to a high radiation dose. The evaluation to be done for the 3-month interval will only be clinical assessments\|)"
62251439|NCT02616614|EXPERIMENTAL|Clindamycin/benzoyl peroxide gel|Generic clindamycin 1.2% and benzoyl peroxide 3.75% topical gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
62609990|NCT06651476|EXPERIMENTAL|oxytocin|Two 30 minute infusions of oxytocin, 10 International Units (IU) separated by 30 minutes. To avoid potential unmasking by facial flushing which can occur at the beginning of high rates of oxytocin administration, the first infusion will consist of two steps beginning with a rate of 0.125 IU oxytocin per minute for 5 minutes, then increased to 0.375 IU oxytocin for 25 minutes. The second infusion will be a constant rate of 0.333 IU oxytocin per minute for 30 minutes.
62832447|NCT02057185||Study population|"Patients diagnosed with Chronic Myeloid Leukaemia, Chronic Lymphocytic Leukaemia, Myelodysplastic Syndromes (low risk), Chronic Thrombocytopenia or Hodgkin Disease in complete remission, who have signed written informed consent according to ICH/EU/GCP and Italian laws, aged between 15 and 74 years old.~The study excludes non Italian speaking patients or unable to fully understand the study's forms."
62832448|NCT05024019|EXPERIMENTAL|Study group|The study group received nimotuzumab (200mg, weekly, for 6 weeks) combined with concurrent radiotherapy.
62609991|NCT06651476|PLACEBO_COMPARATOR|placebo|Two 30 minute infusions of placebo separated by 30 minutes. The first infusion will consist of two steps, using an equivalent volume of placebo fluid infusion as in the oxytocin arm. This will consist of a slower rate in the first 5 minutes and more rapid rate for the last 25 min. The second placebo solution infusion will be a constant rate and volume equivalent to that used in the oxytocin arm.
62049450|NCT04851548|ACTIVE_COMPARATOR|Group B (test)|"preoperative cone-beam computed tomography (CBCT )scans N= 9~* open flap debridement.~* use membrane and 8% hyaluronic acid gel (The first monitor will be done after three months. The data will be recorded. After another three months, the patients will undergo an x-ray check again, and the data will be registered. The goal is to have the patients exposed to x-ray twice not to be compromised to a high radiation dose. The evaluation to be done for the 3-month interval will only be clinical assessments\|)."
62251440|NCT02616614|PLACEBO_COMPARATOR|Placebo|A vehicle gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
62251441|NCT01538628|EXPERIMENTAL|SpaceOAR|Men meeting the study eligibility criteria will be scheduled for fiducial marker placement using a transperineal approach with ultrasound guidance. Following successful fiducial marker placement, subjects will be randomized (2:1) to the treatment group or control group. Subjects randomized to the treatment group will undergo placement of 10 mL of SpaceOAR hydrogel
62251442|NCT01538628|NO_INTERVENTION|Control|Men meeting the study eligibility criteria will be scheduled for fiducial marker placement using a transperineal approach with ultrasound guidance. Following successful fiducial marker placement, subjects will be randomized (2:1) to the treatment group or control group. Subjects randomized to the control group will not receive injection of the SpaceOAR hydrogel.
62832449|NCT05024019|NO_INTERVENTION|Control group|The control group received radiotherapy alone.
62832450|NCT00613873||1|Women participating in a community based mammography or cervical screening program will also participate in colonoscopy screening. Participation will be measured by stating an interest in colorectal cancer screening and then following through with colonoscopy screening. Furthermore we will assess whether those complying with colonoscopy will also recommend colonoscopy screening for their spouses or household members.
62609992|NCT03592498|ACTIVE_COMPARATOR|Sulfadiazine, Silver|Intervention: Treatment with silver sulfadiazine ointment. Procedures: wound washing, application of silver sulfadiazine ointment, bandage covered with gauze and bandage. These patients undergone the change of dressings on alternate days.
62832451|NCT02098785|EXPERIMENTAL|Caffeine citrate (Peyona) 400mg|Caffeine Citrate (Peyona) 400mg single dose (20ml oral solution)
62832452|NCT00643747|EXPERIMENTAL|A|Injection of vector
62832453|NCT03848026||Group 1|middle ear fluid viscosity \<439 centipoise (cP), Tympanostomy tube extrusion time of the all patients recorded prospectively
62832454|NCT03848026||Group 2|middle ear fluid viscosity \>439 centipoise (cP), Tympanostomy tube extrusion time of the all patients recorded prospectively
62251443|NCT02591381|EXPERIMENTAL|STANDARD AUS Placement|Standard placement of an artificial urinary sphincter involves a small incision made in the patient's perineum or scrotum and a fluid-filled cuff is placed around the bulbar urethra (the portion of the urethra between the bladder neck and penis). Connected to the cuff with tubing, is a balloon filled with fluid that is placed behind the pubic bone or in the space between the peritoneum and abdominal muscles. A control pump is placed in the scrotum and allows the device to cycle, thus either exerting pressure to close off the urethra or releasing pressure to allow the urethra to open and the patient to void.
62832455|NCT03022552||MINOCA|Women with myocardial infarction (MI) with demonstrated non-obstructive coronary artery disease during cardiac catheterization (less than 50% blockage in any major vessel).
62832456|NCT03022552||MI-CAD|Women with myocardial infarction (MI) with demonstrated obstructive coronary artery disease during cardiac catheterization (50% or greater blockage in any major vessel) or previous history of percutaneous coronary intervention (PCI) or or coronary artery bypass graft (CABG).
62832457|NCT03022552||CATH-NOCA|Women with stable angina that are age and race matched to women in the MINOCA arm that are clinically referred for cardiac catheterization
62832458|NCT03957577||All participants|Participants with COPD or Asthma-COPD overlap syndrome (ACOS)
62832459|NCT02507232|ACTIVE_COMPARATOR|Arm A|NovoTTF-200A
62832460|NCT02507232|ACTIVE_COMPARATOR|Arm B|NovoTTF-200A + Temozolomide 50 mg/m2 daily (oral)
62832461|NCT00918255|EXPERIMENTAL|Adalimumab 40 mg qwk|Initial dose of adalimumab 160 mg at Week 0, adalimumab 80 mg at Week 2, followed by 40 mg weekly (qwk) starting at Week 4 through Week 15.
62832462|NCT00918255|EXPERIMENTAL|Adalimumab 40 mg eow|Initial dose of adalimumab 80 mg at Week 0, followed by adalimumab 40 mg eow (every other week) starting at Week 1 through Week 15.
62049451|NCT04115111|EXPERIMENTAL|Durvalumab arm|"Patients will receive Durvalumab at the dose and regimens described above every 4 weeks until evidence of disease progression or occurrence of unacceptable toxicity.~Patients who show evidence of disease progression but appear to tolerate Durvalumab well, for whom no other treatment options exist and who, at the judgement of the investigator, may still enjoy clinical benefit, will be classified as failures and offered the possibility to continue treatment with extended follow up."
62049452|NCT03883815||Assesment treatment intensity|Assesment treatment intensity during neurodevelopmental therapy session and active video games therapy session
62049453|NCT06059027||Plain Cohort|Plain Community Children
62049454|NCT06059027||Madison Cohort with Asthma|Madison-area Children with Asthma
62251444|NCT02591381|EXPERIMENTAL|TRANSCORPORAL AUS Placement|Transcorporal placement has been introduced as a way to reduce risk of erosion and involves tunneling the cuff through the erectile bodies. The same incision is made as for the standard approach, and then an incision is made in each corpus cavernosum (cylinders of tissue that allow for erection). This allows the cuff to be placed around both the urethra and through the lining of the corporal bodies, increasing the bulk of tissue behind the urethra to protect it from erosion.
62441144|NCT03929224|EXPERIMENTAL|Medicinal honey|Medicinal honey: Medicinal honey will be applied to the abutment site immediately after surgery. The healing cap will be placed on the BAHI site. The healing cap is removed on postoperative day 7. Patient is instructed to apply medicinal honey daily to the area for 2 weeks.
62449498|NCT03354247|NO_INTERVENTION|Healthy Control|Participants in this group will attend small group sessions providing basic education about NAFLD/NASH, and about principles of healthy eating, physical activity and weight control. These sessions occur every 12 weeks and are conducted by a Master's level nutritionist or health educator. Providing basic education about diet and exercise has produced minimal weight loss in other clinical trials. The educational sessions will be included in this study in order to provide standard care to these patients and to maximize subject retention.
62609993|NCT03592498|EXPERIMENTAL|Skin of Nile tilapia|"Intervention: treatment with skin of Nile tilapia (Oreochromis niloticus), as a biological occlusive dressing.~Procedures: wound washing, application of tilapia skin and dressing with gauze and bandage. These dressings were changed if the skin of the tilapia was loose (not adhered)."
62832463|NCT00918255|PLACEBO_COMPARATOR|Placebo|Matching placebo for adalimumab, administered weekly starting at Week 0 through Week 15.
62049455|NCT06059027||Madison Cohort without Asthma|Madison-area Children without Asthma
62049456|NCT06059027||Madison Cohort with Active Respiratory Illness|Madison-area children with active respiratory illness, with or without asthma
62049457|NCT01309529||thoracic surg, epidural, urine retention|
62049458|NCT03726255||Stromal Vascular fraction|31 patients were treated with one injection of Stromal Vascular Fraction from adipose tissue obtained by liposuction. Procedure: curettage, closure of the internal opening (IO) and SVF injection in IO (50%) and fistula tract (50%)
62049459|NCT03726255||Autologous mesenchymal stem cells|9 patients were treated with one injection of autologous mesenchymal stem cells from adipose tissue. Procedure: curettage, closure of the internal opening (IO) and autologous cell injection in IO (50%) and fistula tract (50%)
62251445|NCT04506814|ACTIVE_COMPARATOR|Endocardial PVI|Endocardial complete PVI
62251446|NCT04506814|EXPERIMENTAL|Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI|Minimally invasive surgical hybrid ablation using the convergent approach plus LAA exclusion using the clip
62251447|NCT04862533|EXPERIMENTAL|Beta-alanine + PFMT|Participants will ingest an active supplement containing beta-alanine for a period of maximum 6 months. During the whole period, participants will take part in a structured program of PMFT. After first month, the participants will undergo radical prostatectomy.
62251448|NCT04862533|EXPERIMENTAL|Placebo + PFMT|Participants will ingest a placebo supplement containing no beta-alanine for a period of maximum 6 months. During the whole period, participants will take part in a structured program of PMFT. After first month, the participants will undergo radical prostatectomy.
62251449|NCT04532216|EXPERIMENTAL|Study group|
62251450|NCT04532216|OTHER|Control group|
62832464|NCT00716417|EXPERIMENTAL|A. BIBW 2992-cisplatin-paclitaxel|daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-paclitaxel
62832465|NCT00716417|EXPERIMENTAL|B. BIBW 2992-cisplatin-5FU|daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-5FU
62832466|NCT01507259||100 g containing 70% or 34% cocoa|Healthy controls
62832467|NCT00384670|EXPERIMENTAL|Dengue and Japanese Encephalitis vaccine|1 mL subcutaneous injection Dengue Vaccine Formulation 17 on Day 0 and Day 60. 0.5 mL subcutaneous injection Licensed Japanese Encephalitis (JE) Vaccine on months 7 and 7.5.
62832468|NCT02873416|EXPERIMENTAL|Precision cells combined with Chemotherapy treatment:|Once a week with a total of six times before 60 days prior to the start of drawing blood. Precision cells：once per 3 weeks with a total of three periods.
62832469|NCT02873416|ACTIVE_COMPARATOR|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
62832470|NCT04465708|OTHER|Homework, Organization, and Planning Skills (HOPS)|"The Homework, Organization, and Planning Skills (HOPS) intervention is delivered through a series of 16 frequent but brief sessions between the HOPS provider and student. The HOPS intervention will be delivered by either a member of the school team (HOPS-ST), referred to as a school provider, or a member of the research team (HOPS-RT), referred to as a research provider. Each session is approximately 20 minutes. The three main skill areas covered as part of the program are: (1) school materials organization, (2) homework management and (3) time management and planning. A reward system is utilized in effort to change behavior patterns by making rewards available when a student engages in productive organizing and planning behaviors. The intervention also includes two parent meetings and one teacher meeting."
62832471|NCT04465708|NO_INTERVENTION|Treatment-As-Usual Waitlist (WL-TAU)|The Treatment-As-Usual Waitlist (WL-TAU) will be enacted for study participants attending the enrolled schools assigned to this arm. After providing post data (and in some cases, follow-up data as well), participants will then receive the HOPS intervention.
62832472|NCT01303016|EXPERIMENTAL|Nutrition supplement|Receives a month's supply of the nutrition supplement, Chispuditos, in addition to a voucher for 1lb of powdered milk each month and a voucher for 1lb of sugar every other month.
62832473|NCT01303016|NO_INTERVENTION|Control|Receives a voucher for 1lb of powdered milk each month and a voucher for 1lb of sugar every other month. Participants in the control group will receive the nutrition supplement, Chispuditos, for one year after the study is complete.
62049460|NCT03726255||Allogenic mesenchymal stem cells|12 patients were treated with one injection of allogenic mesenchymal stem cells of healthy donors: Procedure: curettage, closure of the internal opening (IO) and allogenic cell injection in IO (50%) and fistula tract (50%)
62832474|NCT00335036|ACTIVE_COMPARATOR|Thin leads|Thin (less than or equal to 7 French introducer) isodiametric ICD leads
62832475|NCT00335036|ACTIVE_COMPARATOR|Gore PTFE-coated|ICD lead with PTFE-coated coils
62832476|NCT04979312|EXPERIMENTAL|LabClasp+Standard of care|
62832477|NCT04979312|NO_INTERVENTION|Standard of care|
62832478|NCT05540938|EXPERIMENTAL|treatment group|Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules 12.0g tid, treatment course 3 months.
62832479|NCT05540938|ACTIVE_COMPARATOR|control group|Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules simulant 12.0g tid, treatment course 3 months.
62832480|NCT02695108|EXPERIMENTAL|classical approach for neck pain|patients in this arm received classical approaches for neck pain. Cervical manual therapy was performed on patients in this arm and they were also instructed to to perform cervical endurance, strength and stretching exercises. Rehabilitation period was lasted for 6 weeks. Pain, quality of life and scapular kinematics were assessed before and after rehabilitation program.
62832481|NCT02695108|EXPERIMENTAL|scapular exercise on neck pain|patients in this arm received cervical manual therapy and cervical exercises too. Apart from cervical manual therapy and cervical exercises,patients also performed scapular stabilization exercise targeting trapezius, serratus anterior and rhomboid muscles. Rehabilitation period was lasted for 6 weeks. The same assessment parameters was conducted on this arm too.
62049461|NCT03346811|EXPERIMENTAL|Experimental: icotinib|Patients diagnosed with lung cancer with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
62832482|NCT04579107|OTHER|Contrast Enhanced Mammography|All included women go through a Contrast Enhanced Mammography added to the standard of care examinations.
62441145|NCT02751333|ACTIVE_COMPARATOR|FCSEMS with Endostitching (ES)|General anesthesia or conscious sedation will be started and an upper endoscope will be inserted into the participants mouth and advanced into the stomach. Endoscopic stenting with a fully covered self-expanding metal stents (FCSEMS) will then be performed. Once the stent is in place, the endoscope will be withdrawn from the participant to set-up the endostitch device unto the endoscope. Bites are taken separately with the first on the esophageal mucosa followed by a second on the stent itself and finishing with a last bite on esophageal mucosa. A cinch is then used to secure the deployed suture. An attempt at placing 2 sutures will be performed. Stent removal will then be performed at 8-weeks post-stent insertion.
62049462|NCT05389579|NO_INTERVENTION|Control Group|After the patients were taken to their own beds after surgery, the researcher covered them with a wool blanket from the top of clavicle to the bottom of their feet, put the sphygmomanometer on the arm without an IV line, positioned the sphygmomanometer so that the instrument panel was on the blanket and measured blood pressure. the SPO2 probe was put on the patients' fingers after blood pressure measurements and counted respiratory rates for one minute while waiting for the SPO2 measurements. After this measurement, the researcher evaluated shivering by observation, and recorded these data on the DCIF. the temperature and humidity in the room on a thermohygrometer were read and recorded on the evaluation form. Body temperature, pulse rate, respiration rate, arterial blood pressure, pulse pressure, oxygen saturation, feeling cold and shivering were examined both experimental and control group before their surgeries, every 15 minutes after surgeries until being 36 0C.
62832483|NCT03252379|EXPERIMENTAL|Group A|Patients undergoing modified hepaticojejunostomy with gastric access loop
62832484|NCT03252379|EXPERIMENTAL|Group B:|Patients undergoing modified hepaticojejunostomy with subcutaneous access loop
62832485|NCT03252379|EXPERIMENTAL|Group C:|Group C: Patients undergoing standard hepaticojejunostomy with no endoscopic access loop
62832486|NCT01601236|EXPERIMENTAL|Acthar 8 U (0.1 mL) daily|Repository Corticotropin Injection
62832487|NCT01601236|PLACEBO_COMPARATOR|Placebo (0.1 mL) daily|Placebo
62832488|NCT01601236|EXPERIMENTAL|Acthar 16 U (0.2 mL) daily|Repository Corticotropin Injection
62832489|NCT01601236|PLACEBO_COMPARATOR|Placebo (0.2 mL) daily|Placebo
62832490|NCT01601236|EXPERIMENTAL|Acthar 32 U (0.4 mL) daily|Repository Corticotropin Injection
62832491|NCT01601236|PLACEBO_COMPARATOR|Placebo (0.4 mL) daily|Placebo
62832492|NCT06266247|OTHER|patients|"1. Group: Behcet patients~2. Group: Healty people"
62832493|NCT05085938||Gonadal veins embolisation|This group includes patients who have undergone coil embolization of gonadal vein
62832494|NCT03520829||Patient treated for Gamma Knife|
62049463|NCT05389579|EXPERIMENTAL|Intervention Group|"After the patients were taken to their own beds after surgery, the researcher covered them with a wool blanket from the top of clavicle to the bottom of their feet, put the sphygmomanometer on the arm without an IV line, positioned the sphygmomanometer so that the instrument panel was on the blanket and measured the patients' blood pressure. Then, the electric blanket was operated at the warm level for the experimental group, and it was turned off and unplugged when their body temperature reached 36.0 °C."
62049464|NCT03802123|EXPERIMENTAL|⁸⁹Zr-Df-IAB22M2C Infusion|A dose of 3 mCi (±20%) of ⁸⁹Zr-Df-IAB22M2C between 0.5 mg to 1.5 mg of API will be administered intravenously over 5-10 minutes, within one week prior to the onset of immunotherapy, and 5 to 6 weeks after start of IOT.
62251451|NCT01687179|EXPERIMENTAL|"Sirolimus and Hydroxychloroquine"|"Subjects will take Sirolimus at an initial dose of 2mg followed by dose adjustment to keep Sirolimus trough levels between 5-15ng/ml consistent with the effective dose in the MILES trial. In addition to Sirolimus subjects will receive Hydroxychloroquine at 200 mg daily for 6 months. Once safety is established at the lower dose (Sirolimus and Hydroxychloroquine 200 mg), subjects enrolled henceforth will receive Sirolimus and Hydroxychloroquine 400 mg (200 mg twice a day) for 6 months."
62832495|NCT03038100|EXPERIMENTAL|Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab|Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
62832496|NCT03038100|PLACEBO_COMPARATOR|Placebo With Paclitaxel, Carboplatin and Bevacizumab|Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and placebo for additional 16 cycles.
62832497|NCT06649578||Metabolic-Bariatric Surgery|Patients undergoing Metabolic-Bariatric Surgery are divided into either Laparoscopic Sleeve Gastrectomy (LSG), Roux-en-Y Gastric Bypass (RYGB) or One-Anastomosis Gastric Bypass (OAGB).
62832498|NCT02951000|ACTIVE_COMPARATOR|platysma suture|running suture of the platysma with 3/0 polyglactin
62832499|NCT02951000|ACTIVE_COMPARATOR|no platysma suture|no platysma suture
62832500|NCT05403346||SARS COv-2 RT-PCR AND Self collected CoviDx Covid-19 Antigen Self-Test|Sequentially enrolled symptomatic patients will have a nasal swab collected for high-sensitive SARS-CoV-2 RT-PCR testing as comparator and self collect a nasal swab for CoviDx™ Covid-19 Antigen self-testing. Order of tests will be performed following a randomization scheme.
62832501|NCT04248426|EXPERIMENTAL|ATI-2173|
62832502|NCT04248426|PLACEBO_COMPARATOR|ATI-2173 Placebo|
62832503|NCT02144896|EXPERIMENTAL|Ankle splinting|Older adults will have one leg randomly assigned to ankle splinting for 4 weeks. The non-splinted leg will serve as the control.
62832504|NCT02144896|NO_INTERVENTION|No Ankle Splinting|The non splinted leg will serve as the control
62251452|NCT01837069|ACTIVE_COMPARATOR|Treatment|Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
62832505|NCT01853670|EXPERIMENTAL|definitive radiation + concomitant chemo|"Concurrent chemo + IGRT:~These patients will have chemotherapy during the time of radiation treatment"
62832506|NCT01853670|EXPERIMENTAL|neoadjuvant chemo|"Neoadjuvant chemo + IGRT:~These patients will have chemotherapy prior to other radiation treatment."
62832507|NCT02032017|EXPERIMENTAL|Percutaneous assisted approach|In this technique, a second small incision (1 cm) at the anterior border of the femur is made. A canulla is placed underneath the muscle and used to pass the reamers in the direction of the acetabulum. There's no need to enlarge the skin incision or to release more muscle insertion to achieve good working access to the acetabulum. Two advantages can be defined: sparing of the gluteus medius muscle and safe access to the acetabulum to obtain perfect positioning of the implants.
62832508|NCT02032017|ACTIVE_COMPARATOR|Anterolateral approach|A standard transgluteal approach is used. This means a large part of the gluteus medius muscle is released to obtain good access to the acetabulum.
62049465|NCT04110405|EXPERIMENTAL|Stepped Care|To assess the effectiveness of the stepped care model with 420 women who have depression and potential co-occurring anxiety, recruited from 12 primary care clinics in Tajikistan.
62832509|NCT04154904|EXPERIMENTAL|Aerobic exercise|
62049466|NCT04110405|ACTIVE_COMPARATOR|Standard of Care plus Healthy Lifestyle|To compare standard of care plus healthy lifestyle materials with 210 women recruited from 6 primary care clinics in Tajikistan.
62049467|NCT05256108|EXPERIMENTAL|Cebranopadol 600 µg|Single oral dose of 6 capsules containing 3 cebranopadol 200 µg tablets and placebo
62251453|NCT01837069|NO_INTERVENTION|Control|Standard of care
62251454|NCT02867124|EXPERIMENTAL|Vivitrol at place of residence|One injection of long-acting naltrexone (XR-NTX) in prison, followed by 6 monthly injections post-release at the participants's place of residence utilizing mobile medical treatment
62832510|NCT04154904|EXPERIMENTAL|Resistance exercise|
62832511|NCT04154904|EXPERIMENTAL|High intensity interval exercise|
62832512|NCT02501291|EXPERIMENTAL|Thalidomide|Thalidomide was administered at a daily dose of 50 mg to the patients. Dosage adjustment of thalidomide from 25mg daily to 100mg daily was tailored individually according to patients' tolerance to thalidomide. To minimize the sedative effect of thalidomide, the investigators recommended patients take a single dose of the study drug in the evening before bedtime.
62832513|NCT03197896|EXPERIMENTAL|Group I (prostate cancer information)|The educator reviews general information about the prostate Cancer
62832514|NCT03197896|ACTIVE_COMPARATOR|Group II (general health information)|The educator reviews topics about health promotion actions.
62832515|NCT03739268|ACTIVE_COMPARATOR|sevelamer|Patients with type 2 diabetes treated with sevelamer
62251455|NCT02867124|ACTIVE_COMPARATOR|Vivitrol at opioid treatment program|One injection of long-acting naltrexone (XR-NTX) in prison, followed by 6 monthly injections post-release at a community opioid treatment program.
62251456|NCT06537739|EXPERIMENTAL|Group A (test intervention + placebo communication)|Participants who will undergo the joint manipulation of the lumbar spine region and receive positive communication - placebo.
62251457|NCT06537739|EXPERIMENTAL|Group B (test intervention + nocebo communication)|Participants who will undergo the joint manipulation of the lumbar spine region and receive negative communication - nocebo.
62251458|NCT06537739|OTHER|Group C (test intervention + neutral communication)|Participants who will undergo the joint manipulation of the lumbar spine region and receive neutral communication.
62251459|NCT03128970|NO_INTERVENTION|frozen/thawed|blastocysts with three or less grade of expansion will be thawed and then subsequently transferred into women uterus three hours post-thawing.
62251460|NCT03128970|EXPERIMENTAL|synchronized frozen/thawed hatching blastocysts|blastocyst thawing (with three or less grade of expansion) will take place the day before embryo transfer in order to reach hatching stage
62832516|NCT03739268|PLACEBO_COMPARATOR|placebo|Patients with type 2 diabetes treated with placebo
62832517|NCT01798771|OTHER|Control arm|5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.
62832518|NCT01798771|OTHER|Interventional arm|5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.
62832519|NCT04077216|EXPERIMENTAL|Group A|Initially received the test meal with EVOO, then on crossover, received the meal without EVOO
62832520|NCT04077216|NO_INTERVENTION|Group B|Initially received the test meal without EVOO, then on crossover, received the meal without EVOO
62832521|NCT03253952||Traumatic Spinal Cord Injury|Observational study - monitoring immune response and heart rate variability
62832522|NCT03253952||Traumatic Spine Fracture, Control Group|Observational study - monitoring immune response and heart rate variability acting as a control group.
62832523|NCT03056872||AUD only|AUD treatment inpatients without a co-occurring AnxD receiving AUD treatment as usual
62049468|NCT05256108|EXPERIMENTAL|Cebranopadol 1000 µg|Single oral dose of 6 capsules containing 5 cebranopadol 200 µg tablets and placebo
62832524|NCT03056872||AnxD+AUD-Cognitive Behavioral Therapy (CBT)|AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual in addition to CBT for co-occurring AUD+AnxD
62251461|NCT04346498|EXPERIMENTAL|CB-SSC|The participant received CB-SSC for 2 hours per day for three consecutive days
62251462|NCT04346498|PLACEBO_COMPARATOR|CC-SSC|Following a 30 minute washout time, the same participant would continue to receive chest-to-chest (CC) SSC for 2 hours. This was also conducted for three consecutive days
62441146|NCT02751333|ACTIVE_COMPARATOR|FCSEMS with No Suturing (NS)|The procedure will be done in the same manner with same endoscopic technique, stent deployment, and timing of stent removal. The only difference would be the lack of suturing and naturally the need for suture cutting at stent removal.
62609994|NCT02397434|EXPERIMENTAL|Adjuvant EBRT|Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to positive lymph nodes will be delivered.
62832525|NCT03056872||AnxD+AUD- No CBT|AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual only.
62251463|NCT06386965||propofol|General anesthesia will maintain with propofol in this group.
62251464|NCT06386965||sevoflurane|General anesthesia will maintain with sevoflurane in this group.
62251465|NCT02834169||pseudomyxoma peritonei|Data from pseudomyxoma peritonei cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
62441147|NCT01809314||NeoRecormon in Symptomatic Anemia|Participants with symptomatic anemia who are receiving epoetin beta (NeoRecormon) according to standard of care and the Summary of Product Characteristics will be observed for 4 months. Treatment must be selected at the discretion of the prescriber prior to enrollment and will not be chosen by the Sponsor in this non-interventional study.
62441148|NCT01664195|OTHER|Group A|Epoetin alfa Test drug in the first period and comparator drug in the second period.
62441149|NCT01664195|OTHER|Group B|Epoetin alfa Comparator Drug in the first period and test drug in the second period
62441150|NCT04014959|EXPERIMENTAL|All Participants|All participants follow the same procedures.
62441151|NCT06243978|EXPERIMENTAL|liebria|"Participants allocated to the intervention group will receive access to liebria in addition to treatment as usual (TAU).~reviga is a digital health application designed for individuals with hypertension, accessible through a web browser. The application focuses on evidence-based psychological and psychotherapeutic methods combined with psychoeducation and health behavior change. Topics addressed by liebria include clarifying and strengthening motivation, training the parasympathetic nervous system, recognizing and overcoming obstacles, strengthening impulse control, development of an individualized day plan, and relapse prevention.~The program operates through interactive dialogues, which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 360 days."
62441152|NCT06243978|OTHER|brochure on hypertension|Participants allocated to the control group will receive a brochure from the Deutsche Hochdruckliga (German Hypertension League) in addition to TAU.
62441153|NCT03175237|EXPERIMENTAL|Group of Motor Patterns|For the mirror therapy protocol applied to the Motor Standard, each patient was treated with 15 mirror therapy sessions, 3 times a week for a total duration of 50 minutes. There were 4 exercises of voluntary range of motion involving the extension and mass flexion of the fingers, adduction and abduction of the fingers, pronation and supination of the forearm and elbow extension with associated shoulder elevation.
62609995|NCT05886998|EXPERIMENTAL|Group A (Nebulized Heparin)|Heparin is nebulized via endotracheal tube
62609996|NCT05886998|PLACEBO_COMPARATOR|Group B (Nebulized Saline)|Normal saline is nebulized via endotracheal tube
62609997|NCT00463294|ACTIVE_COMPARATOR|On Pump Arm|
62609998|NCT00463294|EXPERIMENTAL|Off Pump Arm|
62251466|NCT02834169||peritoneal mesothelioma|Data from peritoneal mesothelioma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
62251467|NCT02834169||desmoplastic small round cell tumor|Data from desmoplastic small round cell tumor cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
62251468|NCT02834169||psammocarcinoma|Data from primary peritoneal serous carcinoma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
62251469|NCT02834169||primary peritoneal serous carcinoma|Data from primary peritoneal serous carcinoma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
62609999|NCT03947931||General group|Patient with extremely severe ulcerative colitis
62610000|NCT04673435|EXPERIMENTAL|Permeaderm as temporary coverage|A: temporary coverage with PermeaDerm until autografting: After randomization of study site, study dressing will be applied as temporary coverage on freshly excised full-thickness burn wounds.
62610001|NCT04673435|ACTIVE_COMPARATOR|FHCA as temporary coverage|B: temporary coverage with FHCA until autografting: After randomization of study site, study dressing will be applied as temporary coverage on freshly excised full-thickness burn wounds.
62610002|NCT04673435|EXPERIMENTAL|Permeaderm over widely meshed autograft|C: temporary coverage of widely meshed autograft with PermeaDerm until healing occurs and PermeaDerm can remove
62832526|NCT03056872||Healthy Controls|Community sample
62832527|NCT02512783|ACTIVE_COMPARATOR|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine immediately prior to propofol induction.
62832528|NCT02512783|PLACEBO_COMPARATOR|Normal Saline|Administration of 1ml of pre-treatment normal saline immediately prior to propofol induction.
62049469|NCT05256108|ACTIVE_COMPARATOR|Oxycodone 40 mg|Single oral dose of 6 capsules containing 2 oxycodone 20 mg and placebo
62441154|NCT03175237|EXPERIMENTAL|Group of Functional Activities|For the mirror therapy protocol applied to functional activities, four functional exercises were performed: fitting of pieces stimulating fine and thick gripping, stacking of cubes / cups and transfer of objects of different shapes and sizes. Each patient was treated with 15 mirror therapy sessions, 3 times a week with a total duration of 50 minutes
62441155|NCT02081261||Coronary artery bypass surgery|patients who underwent coronary artery bypass surgery between 2010 and 2012 in Samsung Medical Center
62610003|NCT04673435|ACTIVE_COMPARATOR|FHCA over widely meshed autograft|D: temporary coverage of widely meshed autograft with FHCA until healing occurs
62610004|NCT02954822|EXPERIMENTAL|(Group A)|Evogliptin→Evogliptin+Glimepiride→Glimepiride
62610005|NCT02954822|EXPERIMENTAL|(Group B)|Glimepiride→Evogliptin→Evogliptin+Glimepiride
62832529|NCT06655662|EXPERIMENTAL|β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q|This arm involves the transduction of autologous hematopoietic stem cells with a lentiviral vector carrying the β-globin gene modified with LentiHBBT87Q. Subjects aged 6-35 years with transfusion-dependent β-thalassaemia will receive a infusion of these modified stem cells.
62441156|NCT06483672|EXPERIMENTAL|Furmonertinib combine with anlotinib|Furmonertinib 80mg, once daily, orally Anlotinib 12mg, once daily (days 1-14, 21 days per cycle), orally
62441157|NCT02610049|ACTIVE_COMPARATOR|Control|Subjects will receive 8 sessions of Cognitive Processing Therapy.
62441158|NCT02610049|EXPERIMENTAL|Experimental|Subjects will receive 8 sessions of CPT + Art Therapy 8 sessions of individual therapy.
62441159|NCT02610049|EXPERIMENTAL|Experimental 2|Subject to receive 8 sessions of individual therapy for Art + CPT Cognitive Processing Therapy intervention pre-specified to be administered separately.
62441160|NCT05496088|ACTIVE_COMPARATOR|Group 1: Re-PVI only|Repeat ablation of pulmonary veins (Re-PVI), followed by electrical cardioversion if AF persists, n=100 pts
62441161|NCT05496088|ACTIVE_COMPARATOR|Group 2: Re-PVI + substrate ablation|Repeat ablation of pulmonary veins (Re-PVI) + mapping \& ablation of areas of continuous, complex activity, n=100 pts
62441162|NCT03605615|NO_INTERVENTION|CONTROL|In this group parturients will be attended in standardized manner, which in our hospital means a humanized approach with choice of position in socond stage and without routine episiotomy.
62610006|NCT03535532|EXPERIMENTAL|unilateral laparoscopic adrenalectomy|subjects allocated in this group will be given unilateral laparoscopic adrenalectomy as treatment.
62610007|NCT03535532|ACTIVE_COMPARATOR|standard medical treatment|subjects allocated in standard medical treatment group will be given conservative medicine treatment.
62610008|NCT05575336|EXPERIMENTAL|Intervention group|Use of the ADLIFE system
62610009|NCT05575336|NO_INTERVENTION|Control group|Patients will receive the Standard of Care
62610010|NCT04946019|EXPERIMENTAL|MR-Linac Guided Adaptive FSRT|Patients will receive FSRT (30Gy in 5 fractions) on the MR-Linac treatment machine.
62610011|NCT04016246|EXPERIMENTAL|Propofol|"Propofol (Propofol LIPURO 1% 100mL), Pharmacologic form: 10mg/ml. Considering the birthweight of most preterm babies, Propofol will be diluted to a final concentration of 1mg/ml by the nurse.~Treatment initiation: the 1st dose will be injected following usual management of LISA procedure included the installation of the newborn and the atropine and caffeine injections and sugar solution administration Dose per administration: 0.5mg/kg per dose of Propofol. Number of administrations: Several administrations of 0.5 mg/kg are possible, according the level of sedation achieved, as evaluated by the FANS score. If the FANS score is ≥6, a new dose will be injected up to a total of two (before 28 wGA) or 3 (between 28 - 31 wGA) administrations of the drug. (See paragraph 5.3)"
62832530|NCT04509726|EXPERIMENTAL|EBV TCR-T|
62832531|NCT06459206||Healthy Adult Volunteers|Minimum of ten (10) subjects meeting the eligibility criteria.
62832532|NCT02817048|ACTIVE_COMPARATOR|Tubeless|Interventions: VATS without chest tube placement
62832533|NCT02817048|ACTIVE_COMPARATOR|Chest tube|VATS with chest tube placement
62049470|NCT05256108|ACTIVE_COMPARATOR|Tramadol 600 mg|Single oral dose of 6 capsules containing 6 tramadol 100 mg tablets
62049471|NCT05256108|PLACEBO_COMPARATOR|Placebo|Single oral dose of 6 capsules containing placebo
62049472|NCT01093950||PROSPECTIVE BODY CONTOURING SUBJECTS|"It is anticipated that the participants will undergo body contouring procedures including lipoplasty \[internal fat suction removal\], abdominoplasty \[surgical removal of lower abdominal skin and fat\], breast reduction \[surgical removal of breast skin, fat, and breast tissue to reduce breast size\], breast augmentation \[surgical breast enlargement\], thigh lift \[surgical removal of upper thigh tissue\], and brachioplasty \[surgical removal of upper arm tissue\].~These procedures will be evaluated by pre- and post-operative digital scans, analog measurements, and clinical examinations and photographs."
62049473|NCT06219564|ACTIVE_COMPARATOR|Total placenta previa (t-PP) patients who underwent placental MRI (p-MRI).|"The study compares clinical factors and p-MRI findings between two surgical procedures: Caesarean Section (C/S) and Peripartum Total Abdominal Hysterectomy (p-TAH). The study analyzes both univariate and multivariate associations with surgical procedures.~This arm presents the results of a study assessing risk factors affecting peripartum hysterectomy in placenta previa patients, focusing on the impact of MRI screening. Peripartum hysterectomy (p-TAH) refers to the surgical removal of the uterus around the time of childbirth.~The arm does not explicitly mention specific interventions to be administered. However, it provides information on clinical and p-MRI factors that might influence the surgical procedure (C/S or p-TAH) choice in placenta previa patients. The interventions, if any, would likely be based on assessing these risk factors and involve decisions on the type of surgery, additional procedures, or use of certain medical interventions based on the patient's condition."
62251470|NCT02834169||diffuse peritoneal leiomyomatosis|Data from diffuse peritoneal leiomyomatosis cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
62251471|NCT02834169||appendiceal mucinous neoplasms|Data from appendiceal mucinous neoplasms cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
62441163|NCT03605615|EXPERIMENTAL|VOCALIZATION|In this group parturients will besides being be attended with our standar care, will receive training to vocalize during second stage.
62610012|NCT04016246|PLACEBO_COMPARATOR|medialipide|"Name of treatment for placebo: Medialipide® (B. BRAUN) Pharmacological form: 20g/100ml Medialipide 20% will be used as the placebo. This is an emulsion of medium and long triglycerides based on soya oil and having same appearance organoleptic characteristics as Propofol.~Dose per administration: Same volume as for the Propofol administration~Number of administrations: according the same protocol that for the Propofol administration.~Modalities of preparation : The same dilution procedure as Propofol lipuro 1% SPC (Summary of Product Characteristics):1 part of Medialipide 20% with 9 parts of 5% w/v glucose solution or 0.9% w/v sodium chloride solution as shown in parenteral nutrition which is in accordance with medialipide 20% SPC"
62832534|NCT06440616|NO_INTERVENTION|CT images without spectral information available|Reported without access to spectral information in a normal clinical practice. Supplemental examinations suggested as per the ACR white papers for incidental findings.
62610013|NCT02774005|EXPERIMENTAL|Raxone|
62832535|NCT06440616|EXPERIMENTAL|CT images with spectral information available|Reported with access to spectral information in a normal clinical practice. Supplemental examinations suggested as per the ACR white papers for incidental findings.
62441164|NCT06389279||PENG block group|Before the spinal anesthesia, PENG block will be performed under the guidance of ultrasound.
62441165|NCT06389279||FIC block group|Before the spinal anesthesia, FIC block will be performed under the guidance of ultrasound.
62610014|NCT01120132|EXPERIMENTAL|Cyclosporine low dose , Prednisolone Acetate|Administration of a solution of Cyclosporine (low dose) and a suspension of Prednisolone Acetate
62610015|NCT01120132|EXPERIMENTAL|Cyclosporine high dose, Prednisolone Acetate|Administration of a solution of Cyclosporine (high dose) and a suspension of Prednisolone Acetate
62610016|NCT01120132|EXPERIMENTAL|Cyclosporine high dose|Administration of a solution of Cyclosporine (high dose) and Placebo
62832536|NCT03429114||Binge eating/purging|Adolescents engaging in recurrent binge eating and/or purging behavior.
62441166|NCT06389279||Femoral block group|Before the spinal anesthesia, femoral block will be performed under the guidance of ultrasound.
62441167|NCT06389279||Control group|No intervention
62610017|NCT01120132|EXPERIMENTAL|Cyclosporine low dose|Administration of a solution of Cyclosporine (low dose) and Placebo
62610018|NCT01120132|ACTIVE_COMPARATOR|Prednisolone Acetate|Administration of a suspension of Prednisolone Acetate and Placebo
62610019|NCT01120132|PLACEBO_COMPARATOR|Placebo|Administration of Placebo
62610020|NCT03148717|ACTIVE_COMPARATOR|Preoperative|"Group no.1 will receive preoperative rectal 400 microgram of misoprostol (Sigma) 2 tablets and postoperative rectal placebo2 tablets."
62610021|NCT03148717|ACTIVE_COMPARATOR|Postoperative|"Group no.2 will receive preoperative rectal placebo 2 tablets and postoperative rectal 400 microgram of misoprostol (Sigma)  2 tablets ."
62610022|NCT04320953|EXPERIMENTAL|Non-contact MCE examination|Study subject in this arm receives non-contact MCE examination.
62610023|NCT06505278|EXPERIMENTAL|Night medication group|Participants receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide between 10:00 pm and 12:00 pm.
62832537|NCT03429114||Healthy comparison|Adolescents who do not have a history of eating disorders
62832538|NCT03337477|EXPERIMENTAL|ZS+insulin+glucose|ZS will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
62832539|NCT03337477|PLACEBO_COMPARATOR|Placebo+insulin+glucose|Placebo will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
62832540|NCT00107341|EXPERIMENTAL|bortezomib + paclitaxel + carboplatin|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, and 8 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years."
62610024|NCT06505278|NO_INTERVENTION|Daytime medication group|Participants receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide between 7:00 am and 9:00 am.
62832541|NCT02699749|EXPERIMENTAL|TAK-931|"TAK-931 30 mg, capsules, orally, QD or BID on Days 1-14 of each 21-day treatment cycle in dosing schedule A followed by dosing schedule B, C, D, E and F. In dosing schedules B through F, starting doses and dosing escalations will vary depending on the dosing data obtained from dosing in the previous schedule.~Dose escalation of TAK-931 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data. 3-4 dose cohorts are expected for each dosing schedule.~If the PK from the early cohorts support BID dosing, then study drug administration in subsequent cohorts may transition to a BID dosing schedule."
62832542|NCT01655485|EXPERIMENTAL|Patient teaching|ipad application for social script book
62832543|NCT02202200|EXPERIMENTAL|PD-0332991|
62832544|NCT03131570|EXPERIMENTAL|Group 1|6 months of Secukinumab at a dose of 300 mg with injections administered once weekly at baseline and at weeks 1, 2, 3, and 4 and then every 4 weeks for 6 months of period.
62832545|NCT03131570|PLACEBO_COMPARATOR|Group 2|Placebo followed by Secukinumab. 3 months of placebo followed by 3 months of Secukinumab at a dose of 300 mg with injections administered once weekly at week 12 and at weeks 13, 14, 15, and 16 and then every 4 weeks for 3 months of period.
62832546|NCT03114683|EXPERIMENTAL|IBI308|
62832547|NCT04448535|EXPERIMENTAL|Gingko Biloba|oral intake of gingko biloba for 4 weeks
62832548|NCT06277427|EXPERIMENTAL|CAR-T treatment|"Lymphocyte clearance before PRG-1801 cells' infusion; Plan to design two dose levels (2.5x10\^6 CAR-T/kg and 5.0x10\^6 CAR-T/kg), with 3-6 AAV and LN subjects included in each dose group, totaling 12-24 subjects. Within each dose group, the next subject can be administered after the previous subject has completed at least 14 days of safety observation.~Dose group 1: with a dosage of 2.5x10\^6 (cells/kg) per dose Dose group 2: with a dosage of 5.0x10\^6 (cells/kg) per dose"
62049474|NCT06219564|ACTIVE_COMPARATOR|Total placenta previa (t-PP) patients who did not undergo placental MRI (p-MRI).|"The study compares clinical factors without p-MRI between two surgical procedures: Cesarean Section (C/S) and Peripartum Total Abdominal Hysterectomy (p-TAH). The study analyzes both univariate and multivariate associations with surgical procedures.~This arm presents the results of a study assessing risk factors affecting peripartum hysterectomy (p-TAH) in placenta previa patients, focusing on the impact of clinical factors.~The arm does not explicitly mention specific interventions to be administered. However, it provides information on clinical factors that might influence the surgical procedure (C/S or p-TAH) choice in placenta previa patients. The interventions, if any, would likely be based on assessing these risk factors and involve decisions on the type of surgery, additional procedures, or use of certain medical interventions based on the patient's condition."
62610025|NCT05096572|EXPERIMENTAL|Group 1|Subjects will receive VIM stimulation for two weeks, followed by VIM+PSA stimulation for two weeks, and finally PSA stimulation for two weeks.
62832549|NCT02211807||Patients initiating an Efavirenz|Patients initiating an Efavirenz-containing antiretroviral regimen
62832550|NCT02211807||Patients initiating an Efavirenz-free regimen|
62610026|NCT05096572|EXPERIMENTAL|Group 2|Subjects will receive VIM+PSA stimulation for two weeks, followed by PSA stimulation for two weeks, and finally VIM stimulation for two weeks.
62610027|NCT05096572|EXPERIMENTAL|Group 3|Subjects will receive PSA stimulation for two weeks, followed by VIM stimulation for two weeks, and finally VIM+PSA stimulation for two weeks.
62610028|NCT06314451||Patients with respiratory, gastroenterology and dermatology inflammatory conditions|Patients will be purposively sampled to include a spectrum of participants with a range of different diseases and demographics (age, gender, country) for each indication. Sample size will also be led by the point at which no further issues are emerging during the cognitive interview process.
62049475|NCT03868865|EXPERIMENTAL|Integrative mind-body-medicine group program|The 66 hour program encompasses mindfulness training, yoga, moderate exercise, nutrition, naturopathic self-help strategies, cognitive restructuring and acupuncture for the management of side effects caused by chemotherapy.
62049476|NCT05604924|EXPERIMENTAL|Participants who received virtual reality training|
62049477|NCT05604924|PLACEBO_COMPARATOR|Participants who received similar contents in a standard PowerPoint presentation on a laptop|
62049478|NCT00282893|EXPERIMENTAL|pTBA|Prophylactic Transluminal Ballooning Angioplasty
62049479|NCT00282893|ACTIVE_COMPARATOR|Control|currently existing therapies for the treatment of vasospasm
62049480|NCT03659448|ACTIVE_COMPARATOR|Treatment|"Patients will receive a single dose of the study drug, SGM-101, and subsequently undergo surgical resections under both standard white light conditions and then NIR."
62049481|NCT03659448|NO_INTERVENTION|No Treatment|"Patients will not be administered the study drug, SGM-101, and will undergo surgical resections under standard :white light conditions only."
62049482|NCT04123678||All|Patients attending a Medical Photography facility with at least 1 suspicious skin lesion will be approached to participate in the study. Participants will have an additional macro and dermoscopic image of each suspicious skin lesions suitable for photography. Photographs will be taken by a healthcare professional using an iPhone XR smart phone camera with a DL1 dermoscopic lens attachment. The images will be encrypted and electronically transmitted to Skin Analytics' cloud servers for analysis by DERM. The suspected diagnosis determined by DERM will be compared with dermatologist review and histologically confirmed diagnosis, where obtained. Healthcare resource utilization information and patient satisfaction data will also be collected
62049483|NCT05675046|EXPERIMENTAL|CTR-US|Ultrasound Guided Carpal Tunnel Release (CTR-US)
62049484|NCT02313857|EXPERIMENTAL|Viralym-C|"Partially HLA-matched Viralym-C cells will be thawed and given by intravenous injection. Patients will receive 2 x 10\^7 partially HLA-matched Viralym-C/m2 as a single infusion.~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
62049485|NCT03295318|EXPERIMENTAL|Adjuvanted study formulation NmCV-5|"Subjects in this arm will receive adjuvanted formulation of polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W \& X.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
62049486|NCT03295318|EXPERIMENTAL|Non-adjuvanted study formulation NmCV-5|"Subjects in this arm will receive non-adjuvanted formulation of polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W \& X.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
62251472|NCT04630587|EXPERIMENTAL|Indirect restorations|For the indirect technique, the cavities are prepared according to the common principles for inlays/onlays. Digital impressions are taken of each tooth with a digital impression system (3Shape TRIOS® Intraoral Scanner).The dentist, utilizing the scanner's CAD SW, designs the 3D restoration. The design is imported from the scanner SW into the Rayo 3DToothFill SW to manufacture the mould and the restoration. After printing the mould, it is transferred to the Rayo robot which manufactures the restoration by casting filling material layers in the mould. The automated filling and curing procedures in the Rayo 3DToothFill robot are directed by Rayo 3DToothFill SW. After the manufacturing process is finished, the dentist cements the finished restoration into the cavity with a dual-cure resin cement (G-CEM LinkAce®).The indirect fillings are manufactured chair-side from the same composite material as in the direct technique.
62610029|NCT06314451||Clinicians and researchers skilled in inflammatory diseases|Clinician researchers from each country (UK, USA) will be purposively sampled to include a spectrum of participants with a range of clinical experience and demographics (age, gender, country). Sample size will also be led by the point at which no further issues are emerging during the cognitive interview process.
62610030|NCT04311281||Suspected AD|"Participants with suspected AD enrolling in the trial must meet all of the following criteria:~* Cognitive deficits do not occur exclusively in the context of a delirium.~* Cognitive deficits are not better explained by another mental disorder (e.g., major depressive disorder, schizophrenia).~* There is insidious onset and gradual progression of impairment in one or more cognitive domains.~* The participant has documented memory problems in one or more other cognitive domains, such as language, visual-spatial functioning, executive functioning, etc. (Busse et al., 2006)."
62049487|NCT03295318|ACTIVE_COMPARATOR|Menactra|"Subjects in this arm will licensed quadrivalent conjugated vaccine against meningococcal serogroups A,C,Y, \& W viz. Menactra.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
62049488|NCT05841355|OTHER|Educate (Education + Navigation) Sessions|Session 1 BC knowledge, BC disparities, USPSTF guidelines, barriers and preferred solutions to BC screening, Community Health Workers (CHW) testimonials, empirical data, individual action plans for BC screening Session 2 \&3 Health knowledge (diet and physical activity guidelines), barriers and preferred solutions to dietary and physical activity change, CHW testimonials, empirical data, individual action plans for diet
62610031|NCT04311281||Suspected CTE / TES|"Required Features:~* Persistence of symptoms for longer than 2 years; no other neurologic disorder that is more likely to account for all the clinical features; history of head trauma exposure; progressive course; and at least 1 supportive feature~* History of head trauma exposure, typically associated with history of concussion, although may be limited to subconcussive trauma~* Head trauma exposure is repetitive in nature~* Demonstrated progressive course~* Delayed symptom onset~* Self-report or observer report of cognitive dysfunction, confirmed with objective cognitive decline documented by results of formal neuropsychological testing. Cognitive decline typically affects more than 1 domain (executive, visuospatial, memory, and language).~Supportive Features (only 1 required):~* Emotional dysregulation~* Behavioral change~* Motor disturbance"
62610032|NCT02664922|EXPERIMENTAL|Sedation - Group 1|Sedation - monitored anesthesia with propofol.
62610033|NCT02664922|EXPERIMENTAL|Sedation - Group 2|Sedation - monitored anesthesia with ketamine + propofol
62610034|NCT02664922|EXPERIMENTAL|Sedation - Group 3|Sedation - monitored anesthesia with remifentanil + propofol
62610035|NCT02664922|EXPERIMENTAL|General Anesthesia - Group 1|General anesthesia (GA) with Sevoflurane + O2
62610036|NCT05040100|NO_INTERVENTION|Textbook Cohort|Trainees underwent a 10-minute lecture using two-dimensional (2D) images of the mediastinum selected from standard textbook resources. The lecture carefully reviewed the mediastinal anatomy reflected in the prosected cadaver and provided a variety of 2D axial, coronal, and sagittal images.
62610037|NCT05040100|EXPERIMENTAL|3D Model Cohort|Trainees underwent a 10-minute lecture using two-dimensional (2D) images of the mediastinum selected from standard textbook resources. The lecture carefully reviewed the mediastinal anatomy reflected in the prosected cadaver and provided a variety of 2D axial, coronal, and sagittal images. Upon completion of the didactic session, the 3D model cohort was provided with an additional 10-minute interactive lecture reviewing the same focused mediastinal anatomical structures using the 3D model.
62610038|NCT02064465|EXPERIMENTAL|Lamotrigine Dispersable/Chewable|lamotrigine dispersible/chewable tablet 100mg
62610039|NCT02064465|EXPERIMENTAL|Lamotrigine Compressed|lamotrigine compressed tablet 100mg
62610040|NCT05201066|EXPERIMENTAL|sabatolimab + azacitidine|Patients will take sabatolimab 800 mg i.v and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w or sabatolimab 400 mg i.v/q2w and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w.
62610041|NCT05201066|EXPERIMENTAL|sabatolimab + decitabine|Patients will take Sabatolimab 400 mg i.v/q2w and decitabine 20 mg/m2/d d1-5 i.v.
62610042|NCT05201066|EXPERIMENTAL|sabatolimab + venetoclax + azacitidine|Patients will take sabatolimab 200 mg i.v./q2w and venetoclax 400 mg p.o. d1-14/q4wk and azacitidine 75 mg/m2/d d1-7/q4w.
62610043|NCT05201066|EXPERIMENTAL|sabatolimab + spartalizumab + decitabine|Patients will take sabatolimab 400 mg i.v./q2w and decitabine 20 mg/m2/d d1-5 i.v. and spartalizumab 100 mg i.v/q2w.
62832551|NCT02364570|ACTIVE_COMPARATOR|Oral Glucose Tolerance Test|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (100 g). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
62251473|NCT04630587|ACTIVE_COMPARATOR|Direct restorations|The direct composite restorations are performed based on normal treatment practices. For both direct and indirect restorations, commercially available short-fibre reinforced composite material (everX Flow, GC) is used for core material (replacing dentin) and flowable composite material (G-ænial® Universal Injectable, GC) for surface (replacing enamel), according the manufacturer´s instructions. The occlusion and articulation are checked and adjusted, and the restoration is finished with polishing instruments.
62251474|NCT00630851|EXPERIMENTAL|1|
62251475|NCT00630851|PLACEBO_COMPARATOR|2|
62251476|NCT06258889|EXPERIMENTAL|reward-focused intervention + exposure|Psychoeducation reward-focused interventions based on Positive Affect Treatment (Finding the silver lining, taking ownership, imagining the positive) Exposure \& reward-focused interventions before and after exposure trials
62251477|NCT06258889|ACTIVE_COMPARATOR|Cognitive flexibility intervention + exposure|Psychoeducation Cognitive Flexibility based on Unified Protocol of emotional disorders Exposure \& cognitive flexibility interventions before and after exposure trials
62610044|NCT05201066|EXPERIMENTAL|sabatolimab + HMA|"Patients will take sabatolimab 800 mg and azacitidine 75 mg/m2/d d1-7 or decitabine 20 mg/m2/d d1-5/ all q4w~HMA means hypomethylating agents. Hypomethylating agents are azacitidine and decitabine."
62610045|NCT05201066|EXPERIMENTAL|sabatolimab|Patients will take sabatolimab 800 mg i.v q4w.
62610046|NCT05075044|EXPERIMENTAL|Experimental Group|A total 400 HIV-infected subjects receive three doses inactivated COVID-19 vaccine on day 0, day 21 and day 111, respectively .
62610047|NCT04636294||COVID-19 suspected by symptoms, after high-risk contact or after a borderline PCR result.|
62610048|NCT03093051|EXPERIMENTAL|UPT Treatment|Investigational therapy (UPT)
62610049|NCT01037816|ACTIVE_COMPARATOR|FS-67 patch|One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
62610050|NCT01037816|PLACEBO_COMPARATOR|Placebo Patch|One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
62610051|NCT04777656|EXPERIMENTAL|CDED/Modulen™IBD®|Strategy combining CD exclusion diet plus Modulen™IBD® on top of ongoing maintenance therapy.
62610052|NCT04777656|ACTIVE_COMPARATOR|Unrestricted food access|Stop CDED and Modulen™IBD®, but continue maintenance therapy with unrestricted food access.
62610053|NCT04777656|OTHER|Not randomized|Patient not in remission at M2 or refusing randomisation
62610054|NCT00348036|EXPERIMENTAL|Group therapy|Participants will receive interpersonal group therapy.
62610055|NCT00348036|ACTIVE_COMPARATOR|Control|Participants will receive information only on PTSD.
62049489|NCT05841355|OTHER|Empower (Empowerment + Navigation) Sessions|"Session 1 BC knowledge, BC disparities, USPSTF guidelines, barriers and preferred solutions to BC screening CHW testimonials, Empirical data, Individual action plans for BC screening Sessions 2 \& 3 BC screening as leading by example, BC promotion strategies that reflect personal and network members' preferences, opportunities to volunteer/be a part of tight-knit initiatives, partnerships with navigators/CHWs to serve as bridges for network members CHW testimonials , resource guides for BC promotion, individual action plans for promoting BC, role playing activities (session 2) Participant testimonials, participant relays empirical data, group discussion and plans for promoting BC (session 3)"
62049490|NCT04237805|EXPERIMENTAL|SAF-189s|The phase I dose study will enrol patients with advanced malignant solid tumors that are ALK-positive, and the phase II study will be divided into two parts, Part I Some patients with ALK/ROS1 positive advanced non-small cell lung cancer were enrolled in the 210m,80mg,120mg and 160mg dose groups for safety evaluation.In the second part, two cohorts will be included and 110 ROS1 patients will be enrolled. Except for the PK induction period, all patients will receive oral administration of SAF189s once a day for a continuous period of 21 days.
62049491|NCT06335264||Case group (HF)|"1. Clinical signs and/or symptoms of heart failure caused by a structural and/or functional cardiac abnormality, as defined by Bozkurt et al. \[2021\], diagnosed at the cardiovascular clinic~2. NT-proBNP levels \> 125 pg/L or objective evidence of cardiogenic pulmonary or systemic congestion~3. One of the following;~i. For HFpEF, LVEF ≥ 50% ii. For HFmrEF, LVEF 41-49% iii. For HFrEF, LVEF ≤ 40%"
62049492|NCT06335264||Control group (non-HF)|"1. Absence of known clinical heart failure history.~2. Absence of criteria in the case group."
62049493|NCT02921529|EXPERIMENTAL|TEAS|Patients were given 30min of TEAS(transcutaneous electrical acupoint stimulation) before anesthesia and 1,2,3 day after surgery
62049494|NCT02921529|SHAM_COMPARATOR|false stimulation|Attach electrodes without electric current
62610056|NCT02772276|EXPERIMENTAL|Normal-CKD Stage 2/QuantumLeap|MB-102 and iohexol administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the QuantumLeap ORFM device. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. In order to determine the optimal dose of MB-102, participants may have received different doses.
62049495|NCT01928355||metabolically healthy|
62049496|NCT01928355||Unhealthy|
62049497|NCT05692622|EXPERIMENTAL|Early start group|Participants in this group will receive a baseline monitoring period of 1 week, an active remotely supervised and monitored intervention period of 8 weeks and then an unsupervised but monitored follow up period of 4 months. They will be assessed at baseline (T0) and after one week (T1) to determine the sensitivity of the measures. They will then begin their intervention (T2) for a period of 8 weeks. At the end of the intervention phase (T3), assessment will be repeated that will also mark the beginning of a 16 weeks follow up period (T4), during this time they will have the choice to continue the exercises or stop them. At the end of the follow up period, assessment will be carried out again to measure any carry over effects.
62610057|NCT02772276|EXPERIMENTAL|CKD Stage 3-4/QuantumLeap|MB-102 and iohexol administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-4), and fluorescence measured by the QuantumLeap ORFM device. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. In order to determine the optimal dose of MB-102, participants may have received different doses.
62610058|NCT02772276|EXPERIMENTAL|Normal-CKD Stage 2/Radiance|MB-102 and iohexol administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Radiance ORFM device. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
62832552|NCT02364570|EXPERIMENTAL|Glucose with Whole Eggs|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 1.5 whole eggs (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
62049498|NCT05692622|EXPERIMENTAL|Delayed start group|Participants in this group will receive a baseline monitoring period of 1 week, a control period of 8 weeks, an active remotely supervised and monitored intervention period of 8 weeks and then an unsupervised but monitored follow up period of 2 months. They will be assessed at baseline (T0) and after one week (T1) to determine the sensitivity of the measures. While the early start group receives their 8-week intervention, this group will not receive any intervention during this control period. At the end of 8 weeks, an assessment will be carried out for this group as well (T2). The participants will then begin their intervention (T3) for a period of 8 weeks. At the end of the intervention phase (T4), assessment will be repeated that will mark the beginning of an 8 weeks follow up period (T5), during this time they will have the choice to continue the exercises or stop them. At the end of the follow up period (T6), assessment will be carried out again to measure any carry over effects.
62049499|NCT03826290|EXPERIMENTAL|Intervention arm|When patients are seen in clinics in this arm, the clinical providers will have access to the intervention (EHR-integrated diabetes dashboard).
62049500|NCT03826290|NO_INTERVENTION|Control arm|When patients are seen in clinics in this arm, the clinical providers will not have access to the intervention (EHR-integrated diabetes dashboard). The providers will have access to the usual decision support tools and information sources.
62049501|NCT02999828|EXPERIMENTAL|3.0 EU in Children|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
62610059|NCT02772276|EXPERIMENTAL|CKD Stage 3-5/Radiance|MB-102 and iohexol administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Radiance ORFM device. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
62832553|NCT02364570|EXPERIMENTAL|Glucose with Egg Whites|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 7 egg whites (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
62049502|NCT02982525|EXPERIMENTAL|No Mussels|The control group will continue to consume their normal habitual diet
62610060|NCT02772276|EXPERIMENTAL|Normal-CKD Stage 2/Brilliance algorithm optimization|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Algorithm optimization of the Brilliance sensor was conducted. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
62610061|NCT02772276|EXPERIMENTAL|CKD Stage 3-5/Brilliance algorithm optimization|MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. Algorithm optimization of the Brilliance sensor was conducted. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
62610062|NCT02772276|EXPERIMENTAL|Normal-CKD Stage 2/Brilliance sensor optimization|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Sensor optimization of the Brilliance device was conducted. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
62832554|NCT02364570|EXPERIMENTAL|Glucose with Egg Yolks|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 2 egg yolks (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
62832555|NCT02119377||Transgender and Transsexual People|Transgender and transsexual (trans) people aged 18 years or older living in Australia were invited to complete a questionnaire assessing a range of mental and physical health domains.
62832556|NCT04382040|EXPERIMENTAL|ArtemiC|Active study treatment + Standard care
62832557|NCT04382040|PLACEBO_COMPARATOR|PLACEBO|Placebo + Standard care
62832558|NCT03763838|EXPERIMENTAL|Acupressure plus standard of care|Using AcuWand, participants will apply acupressure to points that are known to affect physiology. Participants will also receive standard of care.
62832559|NCT03763838|SHAM_COMPARATOR|Sham acupressure plus standard of care|Using AcuWand, participants will apply acupressure to points that are not known to affect physiology. Participants will also receive standard of care.
62832560|NCT03763838|OTHER|Standard of care|Participants will receive standard of care only.
62049503|NCT02982525|EXPERIMENTAL|One mussel portion|One 75g portion of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption.
62049504|NCT02982525|EXPERIMENTAL|Two mussel portions|Two 75g portions of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption
62049505|NCT02982525|EXPERIMENTAL|Three mussel portions|Three 75g portion of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption
62049506|NCT02430402|EXPERIMENTAL|Climate therapy|Climate therapy consisting of 3 week stay at rehabilitation facility in Spain
62441168|NCT01464359|EXPERIMENTAL|Patients with Acute Myelogenous Leukemia|Patients with chemotherapy refractory Acute Myelogenous Leukemia (AML) after a double T-cell depleted (TCD) umbilical cord blood (UCB) transplantation where the smaller unit is activated overnight in interleukin-2 (IL-2). IL-2 will be given three times weekly for 6 doses beginning on days+3 and days +60 to expand UCB-derived natural killer (NK) cells in vivo.
62441169|NCT00226694|ACTIVE_COMPARATOR|Citalopram Group|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
62049507|NCT02430402|NO_INTERVENTION|Usual care|Usual care provided as needed / agreed between patient and health care providers
62049508|NCT04296487|EXPERIMENTAL|Autologous Chondrocyte Injection|Autologous chondrocytes were isolated and expanded in laboratory, then injected at 2x10\^6 of cells per cm\^2 of the cartilage defect.
62049509|NCT03663686|PLACEBO_COMPARATOR|25mg single doses|Intervention Drug: 25mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
62049510|NCT03663686|PLACEBO_COMPARATOR|50mg single doses|Intervention Drug: 50mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
62049511|NCT03663686|PLACEBO_COMPARATOR|100mg single doses|Intervention Drug: 100mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
62049512|NCT03663686|PLACEBO_COMPARATOR|200mg single doses|Intervention Drug: 200mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
62049513|NCT03663686|PLACEBO_COMPARATOR|400mg single doses|Intervention Drug: 400mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
62049514|NCT03663686|PLACEBO_COMPARATOR|600mg single doses|Intervention Drug: 600mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
62441170|NCT00226694|PLACEBO_COMPARATOR|Placebo Group|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
62049515|NCT03663686|PLACEBO_COMPARATOR|800mg single doses|Intervention Drug: 800mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
62441171|NCT04497610||Positive TeraSystem test|Patients having positive PCR tests will undergo TeraSystem test
62441172|NCT04497610||Negative TeraSystem test|Patients having negative PCR tests will undergo TeraSystem test
62441173|NCT02229032||Dravet Sydrome|Patients with Dravet Syndrome who are self-seeking therapy with Charlotte's Web strain of medical marijuana with the assistance of a medical marijuana doctor, but are still naïve to therapy
62441174|NCT04604483|EXPERIMENTAL|PTNS|Treatment with PTNS for chronic anal fissure, treatment to be given for 30 minutes during 10 consecutive work Days.
62441175|NCT00377052|EXPERIMENTAL|Bortezomib + Gemcitabine|
62441176|NCT02743442|EXPERIMENTAL|Transoral surgery|
62441177|NCT00887003|EXPERIMENTAL|LV/LD 1|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
62441178|NCT00887003|EXPERIMENTAL|LV/HD 2|Low Volume, High Dose (5cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
62610063|NCT02772276|EXPERIMENTAL|Normal-CKD Stage 2/Brilliance sensor validation|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Validation of the Brilliance sensor was conducted. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
62832561|NCT01549899|ACTIVE_COMPARATOR|In-person CBT of Insomnia|CBTi consisted of 6 weekly 60-minute sessions and included identical informational material. The treatments contained the following efficacious and commonly used modules of cognitive behavioral treatments for insomnia: Stimulus Control, Sleep Restriction, Sleep Hygiene, Relaxation Training, Cognitive Restructuring.
62251478|NCT05232851|EXPERIMENTAL|Arm A (PDS0101)|Patients receive PDS0101 SC on day 1 of each cycle. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or FDG-PET/CT and blood sample collection throughout the trial. Patients may undergo a biopsy during screening and on the trial.
62251479|NCT05232851|EXPERIMENTAL|Arm B (PDS0101, pembrolizumab)|Patients receive PDS0101 SC on day 1 and pembrolizumab intravenously (IV) over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or FDG-PET/CT and blood sample collection throughout the trial. Patients may undergo a biopsy during screening and on the trial.
62251480|NCT03017638||Patients receiving QLB and questionaires|Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours and 48 hours and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
62251481|NCT03017638||Historical control|"The control subjects' data will be assessed reviewing patient records. Data will include:~* Maximal PACU VAS pain score (per nursing charts)~* Overall POD 24 hours and 48 hours and 4 weeks opioid consumption (overall morphine mg/kg equivalent dose)~* POD 24 and 48 hours and 4 weeks Respiratory complications"
62251482|NCT02730052|ACTIVE_COMPARATOR|Omron 9200T without Telemonitoring|In the control group doctors will receive information on the self-measured blood pressure as recorded at home via a diary card.
62251483|NCT02730052|EXPERIMENTAL|Omron 9200T plus Telemonitoring|In the intervention group, doctors will receive weekly reports via telemonitoring of self-measured blood pressure.
62251484|NCT02252536|PLACEBO_COMPARATOR|Sugar Pill|Matching placebo, sugar pill
62251485|NCT02252536|ACTIVE_COMPARATOR|Gabapentin Enacarbil|600 mg Gabapentin Enacarbil (Horizant)
62251486|NCT04344301|EXPERIMENTAL|AUDIO|"Participant clinic visits will be audio recorded locally on a secure, HIPAA-compliant server. Patient access to recordings will be performed via a secure web-based platform.~Additionally, participants will be offered the After Visit Summary (AVS) prior to clinic departure, per Usual Care (UC)"
62251487|NCT04344301|NO_INTERVENTION|Usual Care|During the trial, patients will be offered to receive the AVS prior to clinic departure as is the current standard at each site.
62251488|NCT00404820|EXPERIMENTAL|Zoledronic acid 5 mg|Patients received zoledronic acid 5 mg in 100 ml solution in a 15 minute intravenous (iv) infusion once per year. The peripheral iv infusion was preceded by and followed by a 10 ml normal saline flush of the intravenous line. In addition to study therapy, all participants received 1200 mg elemental calcium and 800 IU of vitamin D daily. Calcium and vitamin D were supplied in a chewable tablet that was to be taken twice daily.
62441179|NCT00887003|EXPERIMENTAL|HV/LD 3|High Volume, Low Dose (10cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
62441180|NCT00887003|EXPERIMENTAL|HV/HD 4|High Volume, High Dose (10cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
62832562|NCT01549899|ACTIVE_COMPARATOR|Internet CBT of Insomnia|The I-CBTi protocol was developed by the National Center for Telehealth and Technology with the first author (DJT) serving as the subject matter expert, and administered on the afterdeployment.org website. The information and instructions for I-CBTi were identical to in-person CBTi; however, their mode of delivery in I-CBTi is considerably different due to the constraints of its automated, online format. The lessons were presented as audio recordings accompanied by visual graphics and animations and several lessons, had interactive components such as games, quizzes, and prompts for participants to schedule healthy sleep habits.
62049516|NCT02674217|EXPERIMENTAL|Multiple sclerosis autografted patients|Individuals with a relapsing-remitting (RRMS) course, secondary progressive (SPMS) or primary progressive (PPMS) were included. Patients should have a Karnofsky performance status (18) above 70% and a EDSS score (1) of 6 or below. The study is approved by the Etichs Committee of the Clinica RUIZ and all patients signed a consent form after being fully informed about procedure an possible complications. Patients included will de treated with Hematopoietic stem cell transplantation
62610064|NCT02772276|EXPERIMENTAL|CKD Stage 3-5/Brilliance sensor validation|MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. Validation of the Brilliance sensor was conducted. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
62610065|NCT02772276|EXPERIMENTAL|Normal-CKD Stage 2/Brilliance (1-2 sensors)|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device (1-2 sensors). The optimized algorithm and final device design of the Brilliance device was tested. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. A subset of participants in this arm received two doses of MB-102, 12 hours apart.
62049517|NCT04692402|OTHER|open label|open label prospective feasibility trial.
62049518|NCT00790283|EXPERIMENTAL|Numen|
62049519|NCT00790283|ACTIVE_COMPARATOR|Vision/MiniVision|
62049520|NCT02782702|EXPERIMENTAL|Botulism Toxin treatment|Injection of 50 UI Botulism toxin for the treated zone
62049521|NCT02089230|EXPERIMENTAL|Phase I Cohort 1 - MEK 162|Phase I Starting Dose of MEK 162: 30 mg by mouth twice a day in a 28 day cycle.
62049522|NCT02089230|EXPERIMENTAL|Phase I Cohort 2 - MEK 162|Phase I Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.
62049523|NCT02089230|EXPERIMENTAL|Phase II Cohort 3 - MDK 162|Phase II Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.
62049524|NCT01514526|EXPERIMENTAL|Dovitinib|Dovitinib (TKI-258) f 500 mg / day (5 x 100mg) once daily. The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal.
62049525|NCT00825422|EXPERIMENTAL|A|first bolus of 20 ml of ropivacaine(5mg/ml) and continuous infiltration (8ml/h)of ropivacaine (2mg/ml)
62049526|NCT00825422|PLACEBO_COMPARATOR|B|first bolus of 20 ml of physiological saline solution(9%) and continuous infiltration (8ml/h)of physiological saline solution(9%)
62049527|NCT03915639|EXPERIMENTAL|Cocktail|Participants in Group Cocktail are planned to infiltrate the head fixation sites after intubation and peri-incisionally prior to skin incision. The infiltration will be performed by the attending neurosurgeon. The muscle and the subcutaneous tissue beneath the fixation sites and incision site will be fully irrigated with the multimodal cocktail.
62049528|NCT03915639|ACTIVE_COMPARATOR|Ropivacaine|Participants in Group Ropivacaine are planned to infiltrate the head fixation sites after intubation and peri-incisionally prior to skin incision. The infiltration will be performed by the attending neurosurgeon. The muscle and the subcutaneous tissue beneath the fixation sites and incision site will be fully irrigated with ropivacaine.
62049529|NCT00289887|EXPERIMENTAL|1|Losartan
62049530|NCT00289887|PLACEBO_COMPARATOR|2|Placebo
62049531|NCT00424125|EXPERIMENTAL|Enhanced Pharmacy Care|Received enhanced community pharmacy based services.
62251489|NCT00404820|ACTIVE_COMPARATOR|Alendronate 70 mg|Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal. Patients were to remain in an upright position for 30 minutes after swallowing the tablet. In addition to study therapy, all participants received 1200 mg elemental calcium and 800 IU of vitamin D daily. Calcium and vitamin D were supplied in a chewable tablet that was to be taken twice daily.
62441181|NCT06367556|EXPERIMENTAL|Treatment|Participants randomized to the intervention group will receive the Emotion and Symptom-focused Engagement (EASE) intervention and usual care. EASE consists of 8-12 psychotherapeutic sessions (\~30-60 minutes each) delivered by a trained mental health clinician over 12 weeks.
62441182|NCT06367556|NO_INTERVENTION|Usual Care|Participants randomized to the control group will receive usual care.
62441183|NCT06103526|ACTIVE_COMPARATOR|Immunonutrition and ERAS|Immunonutrition supplements will be provided to patients in the form of oral supplements given twice daily for 3 days pre-surgery and 3 days post-surgery.
62441184|NCT06103526|NO_INTERVENTION|ERAS without immunonutrition|Typical ERAS protocol will be followed for patients in that group
62441185|NCT01271114|EXPERIMENTAL|Hypertonic Saline and Terlipressin|
62049532|NCT02845401|EXPERIMENTAL|HBeAg-CHB patients who stop NA Therapy|"Patients with early antigen negative form of disease (HBeAg-CHB) who are already taking standard oral HBV antiviral therapy for at least 192 weeks that stop treatment.~Intervention: Cases will stop antiviral therapy"
62049533|NCT02845401|NO_INTERVENTION|HBeAg-CHB patients continue NA Therapy|"Patients with early antigen negative form of disease (HBeAg-CHB) who are already taking standard oral HBV antiviral therapy for at least 192 weeks that continue to stay on treatment.~Intervention: None. Controls will continue antiviral therapy."
62441186|NCT01271114|ACTIVE_COMPARATOR|Normal Saline and norepinephrine|
62441187|NCT06109662||Healthy volunteers|Normal renal function with no kidney disease. Participants with other comorbidities can be included as long as not listed on the exclusion criteria. They will have body composition measured, and eGFR measured.
62441188|NCT06109662||Chronic Kidney Disease Stage 3|People with CKD Stage 3 (eGFR 30-59). They will have body composition measured, and eGFR measured.
62441189|NCT06109662||Chronic Kidney Disease Stage 4|People with CKD 4 (eGFR 15-29). They will have body composition measured, and eGFR measured.
62441190|NCT06109662||Chronic Kidney Disease Stage 5|People with CKD 5 (eGFR \<15), but not on dialysis. They will have body composition measured, and eGFR measured.
62441191|NCT04487756|EXPERIMENTAL|Atezo+DCvac|"- Induction (4 cycles, every 3 weeks): Carboplatin area under the curve (AUC) 5 (5 mg per milliliter per minute, administered intravenously on day 1 of each cycle) and etoposide (100 mg per square meter of body-surface area, administered intravenously on days 1 through 3 of each cycle) Atezolizumab, 1200 mg administered intravenously every 3 weeks on day 1 of each cycle)~- Maintenance (only patients without PD after 4 induction cycles, up to PD): Atezolizumab iv (1200 mg/IV on day 1 every 3 weeks) DCV intradermally (max. 6 doses) on weeks 1, 3, 6, 9, 21, 33."
62610066|NCT02772276|EXPERIMENTAL|Normal-CKD Stage 2/Brilliance (1-2 sensors and Brilliance 2-part sensor)|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device (1-2 sensors and 2-part sensor). The optimized algorithm and final device design of the Brilliance device was tested. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. A subset of participants in this arm received two doses of MB-102, 12 hours apart.
62832563|NCT01549899|NO_INTERVENTION|Minimal Contact|Those assigned to the MC control group will be asked to not work with another therapist or seek additional treatment for insomnia-related difficulties during the 6-week MC period. They will be called every other week to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MC participants will also be given contact information to use in case of worsening of symptoms or increasing distress. At the end of six weeks, they will complete the baseline assessments again, which will serve as the post-treatment assessment for the MC period. They will then be randomly assigned to either the CBTi or ICBTi groups.
62832564|NCT02794909|EXPERIMENTAL|CPUS group|The group of patients in the CPUS group will be those who receive a cardiopulmonary ultrasound exam in accordance with a specified CPUS scanning protocol in addition to their routine care. Patients will be in this group if their treating physician has received specific training in the CPUS protocol.
62832565|NCT02794909|NO_INTERVENTION|Control group|The group of patients in the control group will be those who do not receive an ultrasound exam in accordance with a specified CPUS scanning protocol in addition to their routine care. Patients will be in this group if their treating physician has not received specific training in the CPUS protocol.
62441192|NCT01869322|EXPERIMENTAL|Sling and Swathe|In this arm, study subjects will receive sling and swathe immobilization for humeral shaft fracture.
62441193|NCT01869322|ACTIVE_COMPARATOR|Coaptation Splint|In this arm participants receive a coaptation splint for humeral shaft fracture.
62441194|NCT05875415|EXPERIMENTAL|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point|
62441195|NCT05875415|SHAM_COMPARATOR|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|
62441196|NCT04044846|EXPERIMENTAL|The recipients of the home-based physical activity program|Frail OAs will be asked to fill out the Vitality Plus Scale at the beginning of the implementation phase (baseline) by a research assistant over the telephone. At the end of the 6-month implementation phase, the research assistant will administer the survey again (post-intervention).
62441197|NCT04372498|EXPERIMENTAL|Treatment|This is a pivotal trial in members of the same family carrying the V282M nutation in the Gardos channel (KCNN4) and other patients with V282 mutations with demonstrated in-vitro sensitivity to senicapoc. These mutations lead to hyperactivation of the channel and red cell dehydration. Up to 6 patients are eligible to enroll in this study, which will assess effectiveness based on individual changes of primary endpoints over individually established baselines.
62441198|NCT03720184|EXPERIMENTAL|HAR group|Treated group is exposed to an haematic antegrade autologous repriming of the MiECC CLass IV circuit, reducing the haemodilution related to CPB initiation to a fix amount of 300ml
62441199|NCT03720184|NO_INTERVENTION|Control Group|Control group is not exposed to HAR. The extracorporeal circuit is a MiECC primed with 1000ml of Isofundin (crystalloid balanced solution) as an standard circuit
62441200|NCT00632671||Obese persons cohorte|constitution of a prospective data collection (biological, clinical, paraclinical and questionnaires) in morbidly obese persons.
62049534|NCT00708916|EXPERIMENTAL|Apremilast|CC-10004 20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
62049535|NCT06141330|EXPERIMENTAL|Vitamin D|
62441201|NCT03256513|EXPERIMENTAL|model controlling|an statistical model for periprocedural blood pressure control
62441202|NCT03256513|ACTIVE_COMPARATOR|conventional controlling|an conventional strategy for periprocedural blood pressure control
62610067|NCT02772276|EXPERIMENTAL|Normal-CKD Stage 2/Brilliance (1-2 sensors and Brilliance 2-part sensor) and 2 doses MB-102|Two doses of MB-102 administered to participants 12 hours apart, with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device (1-2 sensors and 2-part sensor). The optimized algorithm and final device design of the Brilliance device was tested. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
62441203|NCT01247688|EXPERIMENTAL|Umbilical Cord Blood Transplant Treatment Plan|Cytoxan, Fludarabine, Total Body Irradiation (TBI), Cord Blood Stem Cell Infusion
62441204|NCT02099461|OTHER|No treatment|Participants received no treatment and underwent percutaneous core needle breast biopsies on Day 1 and Day 28.
62832566|NCT03024476|EXPERIMENTAL|Intensive management arm|"Description:~* Interventions in the intensive management arm consist of 1) behavioral intensification and 2) pharmacological intensification based on olmesartan~* Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups).~* Regarding behavioral intensification, an automated texting and call for breakthrough visit will be sent from the main server to encourage regular measurements of BP and maintain a desirable goad of BP.~* Regarding pharmacological intensification, a specific algorithm for BP-lowering medication prescription will be provided to the responsible physicians by the steering committee."
62441205|NCT02099461|EXPERIMENTAL|Denosumab 60 mg|Participants received 60 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.
62441206|NCT02099461|EXPERIMENTAL|Denosumab 120 mg|Participants received 120 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.
62441207|NCT01465776|EXPERIMENTAL|Treatment (chemoprevention)|
62441208|NCT00410410|EXPERIMENTAL|Abatacept (ABA)|"Induction Period; 3 arms for Cohort 1: ABA 30/\~10 mg/kg (ABA administered at 30 mg/kg followed by ABA at \~10 mg/kg), ABA \~10 mg/kg, ABA 3 mg/kg~Induction Period; 2 arms for Cohort 2: ABA 30/\~10 mg/kg and Second Cohort ABA \~10 mg/kg~1 arm for maintenance period (ABA \~10 mg/kg)"
62441209|NCT00410410|PLACEBO_COMPARATOR|Placebo|"1 arm for induction period~1 arm for maintenance period"
62441210|NCT00410410|OTHER|abatacept|1 arm for open-label extension phase (ABA \~10 mg/kg)
62441211|NCT02370706|EXPERIMENTAL|Dose Escalation Arm 1|
62441212|NCT02370706|EXPERIMENTAL|Dose Escalation Arm 2|
62441213|NCT02370706|EXPERIMENTAL|Dose Escalation Arm 3|
62441214|NCT02370706|EXPERIMENTAL|Dose Expansion Arm 1|
62441215|NCT02370706|EXPERIMENTAL|Dose Expansion Arm 2|
62441216|NCT02370706|EXPERIMENTAL|Dose Expansion Arm 3|
62441217|NCT03718156|EXPERIMENTAL|PREPARED Trial Intervention|Participating nursing staff will be trained to apply the PREPARED Trial interventions, and will apply this knowledge to modify the therapeutic nursing plans of residents under their care who are enrolled in the study, accordingly.
62441218|NCT03718156|NO_INTERVENTION|Care as Usual|Participating nursing staff will only be provided with general information about delirium, but will not be trained or instructed to modify the therapeutic nursing plans that are in place for residents enrolled in the study. However, at the end of the follow-up period, nursing staff in the control arm will be provided with the PREPARED Trial intervention training program (including bedside coaching), which they can then use after the study has ended at their facility.
62441219|NCT05108883|NO_INTERVENTION|standard care arm|decision whether a patient will be hospitalized or be treated as out-patient is based on routine clinical assessment and usual protocols
62441220|NCT05108883|EXPERIMENTAL|MR-proADM guided arm|decision whether a patient will be hospitalized or be treated as out-patient is based on routine clinical assessment, usual protocols and MR-proADM levels
62441221|NCT04413747|EXPERIMENTAL|Yoga-based breathing support|Three daily yoga pranayama breathing cycles within existing home-care provision of Covid19's patients (protocols shared dated 27 March 2020 by Italian Society of Infectious and Tropical Diseases - Italian General Practitioners Physician - Italian Society of General Medicine, Italy)
62441222|NCT03892681|OTHER|contrast agents for liver MRI|
62441223|NCT01671787|EXPERIMENTAL|GS-7340 8mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
62441224|NCT01671787|EXPERIMENTAL|GS-7340 25mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
62832567|NCT03024476|ACTIVE_COMPARATOR|Control arm|"Description:~* Other than a bluetooth-equipped sphygmomanometer, standard managements abiding by the most current guideline will be provided from the responsible physicians.~* Participants will be given a Bluetooth-equipped sphygmomanometer, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups)."
62832568|NCT02083354|EXPERIMENTAL|Arm 1|All subjects will receive the combination of dabrafenib (150 mg) and trametinib (2 mg) in the morning at approximately the same time every day. The second dose of dabrafenib (150 mg) alone will be administered approximately 12 hours after the morning dose. Subjects will continue study treatment until disease progression, death, unacceptable toxicity, withdrawal of consent, or study closure
62832569|NCT00106483||Coronary Artery Risk Development in Young Adults|There were no interventions.
62441225|NCT01671787|EXPERIMENTAL|GS-7340 40mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
62441226|NCT01671787|EXPERIMENTAL|GS-7340 120mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
62441227|NCT01671787|EXPERIMENTAL|Tenofovir disoproxil fumarate 300mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
62441228|NCT05127083|EXPERIMENTAL|toluidine blue-mediated photodynamic therapy|The number of points will be variable according to the lesion size. Patients will be treated with localized PBM with a diode laser with continuous wave +toluidine blue
62441229|NCT05127083|ACTIVE_COMPARATOR|photodynamic therapy + gel|The number of points will be variable according to the lesion size.atients will be treated with localized PBM with a diode laser with continuous wave
62441230|NCT05127083|SHAM_COMPARATOR|acetonide triamcinolone 0.2%+sham|Patients will be treated with acetonide triamcinolone 0.2% for 30 consecutive days. Laser device will be positioned over the lesion but will be switched off to mask the treatment. Patients will be instructed to apply the gel in the entire lesion three times/days.The number of points will be variable according to the lesion size.
62441231|NCT04958083|EXPERIMENTAL|aortopathy patient|Patients who have proximal aortic conditions and are referred to the aortic team in Royal Brompton and Harefield Hospitals will be screened for eligibility. For this pilot study and in view of the volume of aortic surgery in the Trust (approx. 100 cases per year), 30 patients will be recruited in the first year of this project to be followed for at least one year for clinical outcomes.
62441232|NCT02501850|EXPERIMENTAL|Group A|Type 2 diabetic patients whom were prescribed GLP-1R agonists by the endocrinologist, according to usual clinical practice (liraglutide, exenatide, lixisenatide). The intervention is the prescription of an GLP-1R agonist (liraglutide, exenatide, lixisenatide)
62441233|NCT02501850|ACTIVE_COMPARATOR|Group B|Type 2 diabetic patients whom were prescribed metformin and/or sulphonilurea, according to usual clinical practice.
62441234|NCT03522779|PLACEBO_COMPARATOR|High-fat meal + placebo|Participants will complete a high-fat meal challenge with a placebo beverage.The placebo will be designed to match the tart cherry juice for volume and macronutrient content, but without the phytonutrient content of the tart cherries.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
62441235|NCT03522779|EXPERIMENTAL|High-fat meal + tart cherry|Participants will complete a high-fat meal challenge with a tart cherry juice concentrate. 60 mL of montmorency tart cherry concentrate will be diluted with 100 mL of water.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
62441236|NCT03522779|PLACEBO_COMPARATOR|Exercise + high-fat meal + placebo|Participants will perform an acute bout of submaximal aerobic exercise 15 hours prior to the high-fat meal test. The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve. The following morning participants will complete a high-fat meal challenge with a placebo beverage.The placebo will be designed to match the tart cherry juice for volume and macronutrient content, but without the phytonutrient content of the tart cherries.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
62441237|NCT03522779|EXPERIMENTAL|Exercise + high-fat meal + tart cherry|Participants will perform an acute bout of submaximal aerobic exercise 15 hours prior to the high-fat meal test. The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.The following morning participants will complete a high-fat meal challenge with a tart cherry juice concentrate. 60 mL of montmorency tart cherry concentrate will be diluted with 100 mL of water.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
62832570|NCT03408392|EXPERIMENTAL|Test followed by Reference Formulation|Subjects will be randomized to receive single dose of Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 1 and Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
62832571|NCT03408392|EXPERIMENTAL|Reference followed by Test Formulation|Subjects will be randomized to receive single dose of Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 1 and Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
62832572|NCT05233306||GTS patient group|Cohort of adult GTS patients, males and females, age range 18 to 50 years
62832573|NCT05233306||Control group|Cohort of healthy control subjects, males and females, age range 18 to 50 years
62049536|NCT06141330|ACTIVE_COMPARATOR|Placebo|
62832574|NCT02346058|EXPERIMENTAL|Esarin Gel|"Dosage form:One tube of Esarin Gel contains 20 gm of compound. Each gm contains:10 mg Heparinoid, 10 mg Escin, 50 mg Diethylamine Salicylate.~Dosage and frequency: Approx. 3-5 cm Gel was applied topically on skin.twice daily.~Duration: 28 days."
62832575|NCT02524782|EXPERIMENTAL|MEDI-4166|MEDI-4166 administered subcutaneously
62832576|NCT02524782|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously
62832577|NCT03499483|EXPERIMENTAL|Open Label Biktarvy|Single arm all participants receive open label study product intervention.
62832578|NCT00767364|EXPERIMENTAL|Infants with bowel resection|Infants with bowel resection who will receive the oral rotavirus vaccine, RotaTeq(R).
62832579|NCT00767364|ACTIVE_COMPARATOR|Healthy Infants|Healthy infants that are gest. age and age-matched controls within 14 days will be given the oral rotavirus vaccine, RotaTeq(R).
62832580|NCT01702311|ACTIVE_COMPARATOR|Bedtime supplementation|Patients in this arm will have acqhs (before meals and at bedtime) and 3 am blood glucose testing and will receive sliding scale insulin supplementation as needed.
62832581|NCT01702311|NO_INTERVENTION|no bedtime supplementation|Patients in this arm will have ac (before meals), qhs (at bedtime) and 3 am blood glucose testing; however, subjects in this group will NOT receive sliding scale insulin bedtime supplementation.
62832582|NCT06166615|ACTIVE_COMPARATOR|Pyllium group|"Take 2 sachets (12 g) orally once daily. Increase or decrease the dose as needed to treat your symptoms, with a maximum daily dose of 18 grams (6 grams in the morning and 12 grams in the evening). Do not chew this medication and take it with 1 to 2 cups of water.~Take it for 1 month"
62832583|NCT06166615|EXPERIMENTAL|Ramosetron group|"Men: 5 μg orally once daily. Increase or decrease the dose as needed based on symptoms, with a minimum daily dose of 2.5 μg and a maximum daily dose of 10 μg.~Women: 2.5 μg orally once daily. Women: 2.5 μg orally once daily, titrated up or down as needed, with a maximum daily dose of 5 μg.~Take it for 1 month"
62832584|NCT05393440|EXPERIMENTAL|Dose-escalation cohort|Three subjects will be enrolled in this cohort. First subject will receive first injection in dose level of 1 million CCID50/mL. If tolerated, second injection for this subject will be accelerated to 10 millions CCID50/mL. If tolerated, the third injection will be further accelerated to 100 million CCID50/mL. The maximum volume for per injection time point is 8 mL. Injection will repeat every two weeks until disease progression or unacceptable toxicity or withdrawn of consent or no lesion suitable for injection or death. If dose limiting toxicity (DLT) happens in any dose level, the injection dose will be decrease to the last tolerable level.
62832585|NCT05393440|EXPERIMENTAL|Dose-expansion cohort|Fifteen subjects will be enrolled in this cohort. The maximal tolerable dose (MTD) confirmed in the first stage will be utilized in 15 patients. This stage should not be initiated before the completion of dose escalation of all three subjects in the first stage. Treatment will be repeated every two weeks until disease progression or unacceptable toxicity or withdrawn of consent or no lesion suitable for injection or death. Dose interruption, not reduction, is permitted. Treatment will be terminated if toxicity-related treatment interrupt is longer than 28 days. Radiology assessment will be conducted every six weeks.
62832586|NCT01686919|EXPERIMENTAL|milk-free|morbidly obese patients with irritable bowel syndrome (IBS) eligible for gastric bypass surgery
62832587|NCT02131259||Afatinib|
62832588|NCT03873142|EXPERIMENTAL|Mindful parenting intervention|There is only one arm in this study. A range of variables will first be measured (daily and weekly) over a baseline period in a group of participants. Following this baseline period, participants will be take part in a mindful parenting intervention whilst the same variables are measured. Following the intervention, there will be an 8-week follow-up period, and mindful parenting groups will not run during this time.
62832589|NCT01387477|EXPERIMENTAL|Lactate|infusion of 66 mmol of lactate
62832590|NCT01387477|ACTIVE_COMPARATOR|glucose|infusion of 33 mmol of glucose
62441238|NCT01347710|EXPERIMENTAL|Flurpiridaz F18|Open-label study of a single dose of Flurpiridaz F18 injection for PET MPI compared to a single dose of 99mTc sestamibi or tetrofosmin for SPECT MPI in patients with suspected or known coronary artery disease referred for coronary catheterization
62441239|NCT06044558||Combined with voriconazole group|Methylprednisolone sodium succinate was administered intravenously the day after transplantation at an initial dose of 500 mg/day, with the dose being tapered evenly to 40 mg/day during the first week. During the second week, methylprednisolone tablets were administered continuously at a dose of 40 mg/day, after which the dose was tapered to 16 mg/day as a maintenance dose. Immunosuppression was maintained with oral mycophenolate sodium 720 mg twice daily. For renal transplant patients, the initial oral tacrolimus dose should be 0.15 - 0.30 mg/kg per day divided into morning and evening doses. The starting dose of voriconazole should be 400 mg twice a day, which should be changed to 200 mg twice a day from the next day as a maintenance dose.
62441240|NCT06044558||Combined with caspofungin group|Methylprednisolone sodium succinate was administered intravenously the day after transplantation at an initial dose of 500 mg/day, with the dose being tapered evenly to 40 mg/day during the first week. During the second week, methylprednisolone tablets were administered continuously at a dose of 40 mg/day, after which the dose was tapered to 16 mg/day as a maintenance dose. Immunosuppression was maintained with oral mycophenolate sodium 720 mg twice daily. For renal transplant patients, the initial oral tacrolimus dose should be 0.15 - 0.30 mg/kg per day divided into morning and evening doses. The dosage of caspofungin was 70 mg intravenous injection once on the first day after surgery and 50 mg intravenous injection once a day starting from the second day.
62441241|NCT06044558||Tacrolimus-alone treatment group|Methylprednisolone sodium succinate was administered intravenously the day after transplantation at an initial dose of 500 mg/day, with the dose being tapered evenly to 40 mg/day during the first week. During the second week, methylprednisolone tablets were administered continuously at a dose of 40 mg/day, after which the dose was tapered to 16 mg/day as a maintenance dose. Immunosuppression was maintained with oral mycophenolate sodium 720 mg twice daily. For renal transplant patients, the initial oral tacrolimus dose should be 0.15 - 0.30 mg/kg per day divided into morning and evening doses.
62610068|NCT02772276|EXPERIMENTAL|CKD Stage 3-5/Brilliance 1-2 sensors|MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. The optimized algorithm and final device design of the Brilliance device was tested. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
62832591|NCT00732030|EXPERIMENTAL|AcrySof Toric T3|Each enrolled eye receives AcrySof Toric Model SN60T3 Intraocular Lens (IOL)
62832592|NCT00670254|EXPERIMENTAL|Hydrocortisone|
62832593|NCT00670254|PLACEBO_COMPARATOR|Placebo|
62832594|NCT02878343|ACTIVE_COMPARATOR|Incentives|Daily lottery type incentives tied to achievement of weight loss goals
62832595|NCT02878343|ACTIVE_COMPARATOR|Environmental strategies|Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform
62832596|NCT02878343|ACTIVE_COMPARATOR|Incentive and environmental strategies|A combination of incentives and environmental strategies
62832597|NCT02878343|NO_INTERVENTION|Usual care|Standard employee wellness benefits
62832598|NCT00402948|EXPERIMENTAL|TPI ASM8|ASM8 0.25mg
62832599|NCT00402948|EXPERIMENTAL|ASM8 as TPI ASM8|TPI ASM8 0.5mg
62832600|NCT04144790||ADHD+RLS|Twelve participants between the ages of 5 and 18 years with a clinical diagnosis of either RLS or ADHD, and iron deficiency.
62832601|NCT00739869||1|Participants will include women who participated in the Women's Health Initiative Memory Study.
62832602|NCT05114421|EXPERIMENTAL|Cohort A (pembrolizumab, lenvatinib)|Beginning cycle 0, patients receive pembrolizumab IV over 30 minutes on day 1. Beginning cycle 1, patients also receive lenvatinib PO QD on days 1-21. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
62832603|NCT05114421|EXPERIMENTAL|Cohort B (pembrolizumab, lenvatinib)|Beginning cycle 0, patients receive lenvatinib PO QD on days 1-21. Beginning cycle 1, patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
62832604|NCT01475760|ACTIVE_COMPARATOR|K2CG chewing gum (20 mg chitosan)|
62832605|NCT01475760|ACTIVE_COMPARATOR|K2CG chewing gum (60 mg chitosan)|
62832606|NCT01475760|NO_INTERVENTION|Standard of Care|
62049537|NCT06022835|EXPERIMENTAL|Chlorhexidine Gluconate-gel (CHG) Dressing group|Participants used Tegaderm™ CHG dressing for 4 months. The dressing was changed every seven days or soiled.
62441242|NCT02406833|EXPERIMENTAL|TGF-β2 antisense oligonucleotide|"Core Study: Administered intravitreally at the time of trabeculectomy at escalating doses~Post-Study Follow-up: until 1 year after administration"
62441243|NCT00395707|ACTIVE_COMPARATOR|1|Lucentis 0.3mg/0.05 ml
62441244|NCT00395707|ACTIVE_COMPARATOR|2|Lucentis 0.5mg/0.05 ml
62441245|NCT05723640|EXPERIMENTAL|177Lu-LNC1004 Injection group 1|177Lu-LNC1004 Injection, a single dose of 30mCi will be administered every 6 weeks, for a total of 2 cycles.
62441246|NCT05723640|EXPERIMENTAL|177Lu-LNC1004 Injection group 2|177Lu-LNC1004 Injection, a single dose of 60mCi will be administered every 6 weeks, for a total of 2 cycles.
62441247|NCT05723640|EXPERIMENTAL|177Lu-LNC1004 Injection group 3|177Lu-LNC1004 Injection, a single dose of 80mCi will be administered every 6 weeks, for a total of 2 cycles.
62441248|NCT05723640|EXPERIMENTAL|177Lu-LNC1004 Injection group 4|177Lu-LNC1004 Injection, a single dose of 100mCi will be administered every 6 weeks, for a total of 2 cycles.
62441249|NCT01765556|EXPERIMENTAL|Ketoconazole treatment|
62441250|NCT01765556|EXPERIMENTAL|Vemurafenib treatment|
62441251|NCT05198128|EXPERIMENTAL|Calcium intravenous infusion|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes"
62441252|NCT05198128|PLACEBO_COMPARATOR|saline|0.9 % saline intravenous infusion
62441253|NCT06220461|EXPERIMENTAL|Experimental group|Oral folic acid 50 mcg daily starts at 14 days of age
62441254|NCT06220461|NO_INTERVENTION|Control|No additional folic acid supplementation
62441255|NCT05772299|EXPERIMENTAL|Er:Yag laser treatment|"The experimental (test) group will receive the following treatment:~The submucosal debridement will be performed with an Er:Yag laser (AdvErL EVO, Morita Corporation, Japan). The P-400 tip is placed into the peri-implant mucositis pockets mesially, lingually, distally and buccally while rinsing water. Careful attempts are to cover the full circumference of the implant."
62441256|NCT05772299|ACTIVE_COMPARATOR|Ultrasonic device treatment|"The active comparator (control) group will receive the following treatment:~The submucosal debridement will be performed by a piezoelectric ultrasonic device with a PEEK coated tip (EMS, Switzerland). The tip is placed into the peri-implant mucositis pockets mesially, lingually, distally and buccally while rinsing water. Careful attempts are to cover the full circumference of the implant."
62441257|NCT01475383|ACTIVE_COMPARATOR|PF-03654746|Subjects are randomized to either active drug or placebo in Period 1; in Period 2 the sequence is reversed.
62441258|NCT01475383|PLACEBO_COMPARATOR|Placebo|Subjects are randomized to either active drug or placebo in Period 1; in Period 2 the sequence is reversed.
62441259|NCT04373109||Single-group study|Assessment of intensity of rehabilitation therapy, daily life upper limb use, physical activi-ty engagement, patient-reported quality of life, and motor outcome after stroke
62441260|NCT00403286|EXPERIMENTAL|C 10/1|
62441261|NCT00403286|EXPERIMENTAL|C 5/2|
62441262|NCT00403286|EXPERIMENTAL|C 5/1|
62441263|NCT00403286|EXPERIMENTAL|FP 1000|
62610069|NCT06055023|EXPERIMENTAL|ZL-82 12.5mg|2 case，The starting dose，Take the medicine once on D1 ，D1 through 7.
62610070|NCT06055023|EXPERIMENTAL|ZL-82 25mg|8 case，The starting dose，Take the medicine once on D1 ，D1 through 7.
62610071|NCT06055023|EXPERIMENTAL|ZL-82 50mg|8 case，The starting dose，Take the medicine once on D1 ，D1 through 7.
62832607|NCT00910416||patients receiving iv anesthesia|
62832608|NCT00910416||patients receiving balanced anesthesia|
62610072|NCT06055023|EXPERIMENTAL|ZL-82 100mg|8 case，The starting dose，Take the medicine once on D1 ，D1 through 7.
62610073|NCT06055023|EXPERIMENTAL|ZL-82 200mg|8 case，The starting dose，Take the medicine once on D1 ，D1 through 7.
62610074|NCT06055023|EXPERIMENTAL|ZL-82 300mg|8 case，The starting dose，Take the medicine once on D1 ，D1 through 7.
62610075|NCT06055023|EXPERIMENTAL|ZL-82 450mg|8 case，The starting dose，Take the medicine once on D1 ，D1 through 7.
62441264|NCT00403286|EXPERIMENTAL|FF 20|
62441265|NCT00403286|ACTIVE_COMPARATOR|AD 250/50|
62441266|NCT00403286|PLACEBO_COMPARATOR|Plc|
62610076|NCT06055023|EXPERIMENTAL|ZL-82 600mg|8 case，The starting dose，Take the medicine once on D1 ，D1 through 7.
62610077|NCT01500044|ACTIVE_COMPARATOR|Conventional Rehabilitation Program|The conventional program consists in cervicothoracic mobilizations and stabilization exercises. This program is based on the intervention used in clinical practice, and on programs proposed in two RCTs evaluating individuals with neck and arm pain that do not include any specific mobilization or exercise leading to the opening of the intervertebral foramen. Four mobilisation techniques will be executed at each treatment session. However, the therapists will not be allowed to use techniques that specifically open the intervertebral foramen of the affected segment, two segments above and two segments below.
62610078|NCT01500044|EXPERIMENTAL|Program targeting the opening of foramen|"The same interventions as for the conventional rehabilitation program will be applied, except:~Of the four mobilisation techniques, there will be two mandatory techniques targeting the opening of the intervertebral foramen on the same side and at the same level as the radiculopathy: global contralateral rotation mobilisation and ipsilateral lateral shearing in a flexion position. The therapist, according to the biomechanical evaluation results, will choose the two other mobilisation techniques."
62610079|NCT04280458|EXPERIMENTAL|Intervention group|patients will receive intensive care of rehabilitation of psychomotor
62610080|NCT04280458|ACTIVE_COMPARATOR|Control group|patients will receive standard care
62610081|NCT03858283|EXPERIMENTAL|Mindfulness Based Health Care Program|
62610082|NCT03858283|NO_INTERVENTION|Control|
62610083|NCT05039320|EXPERIMENTAL|Group 1 - probiotic|"The use of Streptococcus salivarius K12 containing tablets (Bactoblis, registration number: AM.01.06.01.003.Е.000024.07.18; 20.07.18, MEDICO DOMUS, d.d.o.; 18116, Nis, Serbia)) once a day for 4 weeks (before bedtime after evening brushing).~Ingredients: basic active ingredient - Streptococcus salivarius K12 (≥1×109 CFU in 1 tablet), excipients - fructose (sweetener), maltodextrin, silicon dioxide, magnesium stearate (vegetable), strawberry flavouring."
62832609|NCT03125395|EXPERIMENTAL|LUM/IVA|LUM/IVA granules or tablets were administered orally every 12 hours (Participants aged 2 through 5 years received LUM 100 mg/IVA 125 mg granules or LUM 150 mg/IVA 188 mg granules based on body weight. Participants ≥6 years of age were to receive LUM 200 mg/IVA 250 mg tablets). Doses were adjusted upward for changes in weight and age.
62832610|NCT05395975||Group I|Preoxygenation with 100% oxygen for 3 minutes
62832611|NCT05395975||Group II|4 deep breaths with 100% oxygen in 30 seconds
62832612|NCT00497081|ACTIVE_COMPARATOR|Mirtazapine|mirtazapine 30 mg daily
62832613|NCT00497081|PLACEBO_COMPARATOR|Placebo|placebo 30 mg daily
62832614|NCT05482126||Deep Brain Stimulation Surgery Patients|The investigators will seek to enroll people with Parkinson's disease (PD) who have been approved for deep brain stimulation surgery (DBS) as part of their routine clinical
62441267|NCT00403286|EXPERIMENTAL|C 10/2|
62610084|NCT05039320|PLACEBO_COMPARATOR|Group 2 - placebo|"The use of placebo tablets once a day for 4 weeks (before bedtime after evening brushing).~Ingredients: fructose (sweetener), maltodextrin, silicon dioxide, magnesium stearate (vegetable), flavouring (strawberry)."
62441268|NCT01961791||TNM 7th edition|staged by the current TNM 7th edition of AJCC/UICC
62441269|NCT01961791||new TNM stage|staged by new TNM stage with new lymph node staging concept
62610085|NCT06517550|NO_INTERVENTION|PEEP 5 cmH2O|During the surgical mechanical ventilation process, a constant PEEP value of 5 cmH2O is set.
62832615|NCT05482126||Healthy controls|The investigators will seek to enroll a cohort of age- and sex-matched healthy individuals to act as a control group. This group will NOT undergo DBS surgery
62832616|NCT02555267||Elderly patients with DLBCL|Elderly patients (age\>=65 years) with DLBCL treated with R-CHOP chemotherapy
62832617|NCT06025214|EXPERIMENTAL|Test|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
62832618|NCT06025214|ACTIVE_COMPARATOR|Reference|ADVAIR DISKUS® 500/50
62832619|NCT04171843|EXPERIMENTAL|PBCAR269A at Dose Level 1 (Cohort A)|The starting dose of PBCAR269A will be 6 x 10\^5 CAR T cells/kg body weight.
62832620|NCT04171843|EXPERIMENTAL|PBCAR269A at Dose Level 2|2 × 10\^6 CAR T cells/kg body weight.
62832621|NCT04171843|EXPERIMENTAL|PBCAR269A at Dose Level 3|6 × 10\^6 CAR T cells/kg body weight.
62832622|NCT04171843|EXPERIMENTAL|PBCAR269A at Dose Level 2 (Cohort B)|2 × 10\^6 CAR T cells/kg body weight.
62832623|NCT04171843|EXPERIMENTAL|PBCAR269A at Dose Level 1 (Cohort B)|6 x 10\^5 CAR T cells/kg body weight.
62832624|NCT04171843|EXPERIMENTAL|PBCAR269A at Dose Level 3 (Cohort B)|6 × 10\^6 CAR T cells/kg body weight.
62049538|NCT03658564|EXPERIMENTAL|Oral carbohydrate|fast from midnight the night before surgery, and patients consume 400 ml Preoperative oral carbohydrate preOp®(12.5% carbohydrates, 0.5%kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, the Netherlands) 3 hours prior to induction of anesthesia and finished the ingestion within 20 minutes.
62251490|NCT00806676|OTHER|1. Chronic Kidney Disease, NKF Stage 1-4|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with chronic kidney disease will be compared to titers in the general population measured during Phase III clinical studies by Merck \& Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
62251491|NCT00806676|OTHER|2. ESRD (dialysis)|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with ESRD will be compared to titers in the general population measured during Phase III clinical studies by Merck \& Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
62832625|NCT02869152|EXPERIMENTAL|Intraoperative sentinel lymph node mapping|Subjects will come to the OR and undergo a flexible sigmoidoscopy after induction of anesthesia and receive separate endoscopic injections of Spot (up to 5 cc), 99mTc-sulfur colloid (up to 0.5 mCi), and Indocyanine green (ICG) (1 ml). Patient will undergo the standard transanal endoscopic surgery (TES) to remove the rectal neoplasm, exposing the lymph node basin. The sentinel node(s) will be identified using a combination of the gamma probe and fluorescence imaging endoscopically, dissected out, and removed through a transanal approach.
62832626|NCT04367974||1|The dose of cefazolin and Ceftazidime co-administered were 20 mg /kg，they were given intraperitoneal twice daily in the first bag and the fourth bag for 5 days，and given 1g once daily in the fourth bag for 9 days. Total treatment duration was 2 weeks.
62049539|NCT03658564|NO_INTERVENTION|Fasting|fast from midnight the night before surgery, and no preoperative oral carbohydrate loading
62441270|NCT03281421|EXPERIMENTAL|Group from posterior to anterior (GPA)|Participants in group GPA will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense from posterior to anterior. The physiotherapist will be positioned in front the participant's ankle, and a belt will be posicioned above the participant's malleolus and around physiotherapist's pelvis. The therapist applies with belt a anterior slip sustained in the tibia of the participant, while the talus are secured with the space between the thumb and the second finger of the hand of both hands on the physiotherapist´s. The participant will be instructed to perform a slow dorsiflexion movement at its maximum amplitude and hold five seconds in that position, returning to the initial position at the end of the five seconds.
62610086|NCT06517550|EXPERIMENTAL|Personalized PEEP|During surgical mechanical ventilation, individualized PEEP values are set based on each patient's lung condition.
62049540|NCT05381935|EXPERIMENTAL|Part 1 dose escalation|ES014 doses will be escalated in patients with advanced solid tumors with approximately 30 subjects.
62251492|NCT00806676|OTHER|3. Kidney Transplant Recipient|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with a kidney transplant will be compared to titers in the general population measured during Phase III clinical studies by Merck \& Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
62610087|NCT01853696|ACTIVE_COMPARATOR|Loteprednol|Loteprednol etabonate 0.5% gel applied topically 4 times daily for 2 months, 3 times daily for 1 month, twice daily for one month and once daily for 7 months
62832627|NCT04367974||2|The dose of cefazolin and Ceftazidime co-administered were 20 mg /kg，and were given once daily in the fourth bag. Total treatment duration was 2 weeks.
62832628|NCT00408317|EXPERIMENTAL|Ultrase® MT20|
62832629|NCT00408317|PLACEBO_COMPARATOR|Placebo|
62832630|NCT04677088|EXPERIMENTAL|HBV/ TCR T cell infusion|Autologous T cells with HBV antigen-specific TCR
62832631|NCT03500718|EXPERIMENTAL|Pediatric patients with bilateral sensorineural hearing loss|One group will be studied: Patients undergoing cochlear implantation surgery between age 1 and 6 years who meet the above inclusion and exclusion criteria seen in JIPMER during the study period.
62832632|NCT04124809|EXPERIMENTAL|Study group (artificially laser-collapsed blastocysts)|laser was used as an intervention before blastocyst vitrification to assist rapid blastocyst collapse with vitrification
62832633|NCT04124809|NO_INTERVENTION|& control group (blastocysts were vitrified, no laser collapse|blastocyst were vitrified without laser assisted collapse
62251493|NCT03947983|EXPERIMENTAL|Intervention Group|The intervention group will receive a sensor-controlled digital game (SCDG) app and weight monitoring and physical activity sensors
62251494|NCT03947983|ACTIVE_COMPARATOR|Control group|The control group will receive only the weight monitoring and physical activity sensors
62251495|NCT01109342||Vaccine Recipients|Participants received HIV preventive vaccine VRC-HIV ADV014-00-VP in previous trials RV 156A/WRAIR 1078A or RV 172/WRAIR 1218.
62251496|NCT01109342||Placebo Recipients|Participants received a placebo vaccine in previous trials RV 156A/WRAIR 1078A or RV 172/WRAIR 1218.
62251497|NCT00842231||Visual performance measures|Collection of visual performance measures in subjects with low levels of astigmatism.
62832634|NCT05173558|EXPERIMENTAL|Uninterrupted motionless standing|20minutes of uninterrupted motionless standing
62251498|NCT00646906|EXPERIMENTAL|Phase 1a: Acetaminophen 1000mg / aspirin|"All subjects in this arm (smokers (n=8) and non-smokers (n=8) will receive 81 mg aspirin at approximately 8 am followed by 1000 mg acetaminophen at approximately 10 am during one crossover period (see Crossover period: Aspirin first intervention). During the other crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 1000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see Crossover Period: Aspirin last intervention). The occurrence of the two crossover periods will be randomized by order. Smokers and non-smokers will be matched for age and gender."
62251499|NCT00646906|EXPERIMENTAL|Phase 1a: Acetaminophen 2000mg / aspirin|"All subjects in this arm (smokers (n=8) and non-smoking volunteers (n=8)) will receive 81 mg aspirin at approximately 8 am followed by 2000 mg acetaminophen at approximately 10 am during one crossover period (see Crossover Period: Aspirin first intervention). During the other crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 2000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see Crossover Period: Aspirin last intervention). The occurrence of the two crossover periods will be randomized by order. Smokers and non-smokers will be matched for age and gender."
62441271|NCT03281421|ACTIVE_COMPARATOR|Group from anterior to posterior (GAP)|Participants in group GAP will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense from anterior to posterior. The physiotherapist will be positioned behind the participant's ankle. An belt will be posicioned above the participant's malleolus and around physiotherapist's trunk. The therapist applies with belt a posterior slip sustained in the tibia of the participant, while the heel and rearfoot are secured with the space between the thumb and the second finger of the hand of both hands on the physiotherapist´s. The participant will be instructed to perform a slow dorsiflexion movement at its maximum amplitude and hold five seconds in that position, returning to the initial position at the end of the five seconds.
62441272|NCT03281421|ACTIVE_COMPARATOR|Group GPA-AP|Participants in group GAP will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense both from posterior to anterior and anterior to posterior. In the group GPA-AP, will be apllied both the procedure described for the group GPA as for the group GAP. To standardized the sequence of mobilization, the first two sets will be performed with slip sense from posterior to anterior, and the last two sets will be performede with slip sense from anterior to posterior.
62832635|NCT05173558|EXPERIMENTAL|Uninterrupted motionless sitting|20 minutes of uninterrupted motionless sitting
62832636|NCT05173558|EXPERIMENTAL|Sit-to-stand transitions|20 minutes of sit-to-stand transitions (1 minute sitting with 1 minute standing)
62832637|NCT03743168|EXPERIMENTAL|Intermittent stretching protocol|Intermittent stretching protocol including five sets at 1 minute and 15 second rest.
62832638|NCT03743168|EXPERIMENTAL|Continuous stretch|2 minutes continuous stretch
62832639|NCT02851615|OTHER|SCThrive|SCThrive Intervention for Adolescents with SCD - 6 week self-management group
62832640|NCT02851615|NO_INTERVENTION|Attention Control|6 weekly 15-20 minute individual phone calls on educational topics. No interventions are included in this arm.
62832641|NCT02476253|EXPERIMENTAL|Intervention|Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
62832642|NCT02476253|NO_INTERVENTION|Control|No intervention
62832643|NCT03857867|EXPERIMENTAL|Tactile Stimulation Glove|Patient will receive active stimulation for a minimum of 3 months and a maximum of 13 months
62832644|NCT02756559||sepsis, severe sepsis and septic shock|Septic patients were divided into sepsis, severe sepsis and septic shock
62832645|NCT04881994|EXPERIMENTAL|Mild hepatic impairment (Child Pugh A)|Participants with mild hepatic impairment (Child Pugh A) received single oral dose of finerenone.
62832646|NCT04881994|EXPERIMENTAL|Moderate hepatic impairment (Child Pugh B)|Participants with moderate hepatic impairment (Child Pugh B) received single oral dose of finerenone.
62832647|NCT04881994|EXPERIMENTAL|Healthy participants|Healthy age-, weight-, and gender- matched participants received single oral dose of finerenone.
62832648|NCT06431152|EXPERIMENTAL|Low-Dose|"Intra-articular knee injection of exosomes (2 x 10e9 particles/dose) derived from allogeneic mesenchymal stromal cells. Single dose.~4 patients"
62832649|NCT06431152|EXPERIMENTAL|Medial-Dose|"Intra-articular knee injection of exosomes (6 x 10e9 particles/dose) derived from allogeneic mesenchymal stromal cells. Single dose.~4 patients"
62832650|NCT06431152|EXPERIMENTAL|High-Dose|"Intra-articular knee injection of exosomes (2 x 10e10 particles/dose) derived from allogeneic mesenchymal stromal cells. Single dose.~4 patients"
62832651|NCT01322620||A|
62832652|NCT04725578|EXPERIMENTAL|Telehealth Single Session Consultation|
62832653|NCT01021020|EXPERIMENTAL|1|Colchicine (fasted)
62832654|NCT01021020|EXPERIMENTAL|2|Colchicine (fed)
62832655|NCT01021020|ACTIVE_COMPARATOR|3|Colchicine/Probenecid (fasted)
62049541|NCT05381935|EXPERIMENTAL|Part 2 dose expansion|Part 2 of the study will consist of 3 expansion cohorts for pancreatic ductal adenocarcinoma (Cohort 2A), NSCLC (Cohort 2B), and colorectal adenocarcinoma (Cohort 2C) with 10 subjects per expansion cohort respectively at the recommended optimal biological dose determined in Part 1 dose escalation.
62049542|NCT03329287|EXPERIMENTAL|SCBT + Drug|Participants receive SCBT at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
62049543|NCT03329287|ACTIVE_COMPARATOR|Psychological Placebo + Drug|Participants receive supportive and relaxation therapy at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
62049544|NCT03329287|ACTIVE_COMPARATOR|Drug|Participants only take SSRIs and/or SNRIs through the trial at a recommended dosage.
62049545|NCT00549757|EXPERIMENTAL|Aliskiren|"In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.~With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment"
62610088|NCT01853696|ACTIVE_COMPARATOR|Prednisolone acetate|Prednisolone acetate 1% ophthalmic solution applied 4 times daily for two months, 3 times daily for one month, twice daily for one month, and once daily for 7 months
62251500|NCT00646906|EXPERIMENTAL|Phase 1b: Acetaminophen 1000 mg alone|"Eight male and non-pregnant female subjects who are healthy and non-smoking will be recruited. They will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM (see Acetaminophen 1000 mg/d intervention). Study assessments will be performed on day 1 and on day 6. This is not a crossover design. Just one treatment period."
62251501|NCT00646906|EXPERIMENTAL|Phase 2: Acetaminophen vs. Ibuprofen|"Eight male and non-pregnant female subjects who are healthy and non-smoking will be recruited. In one period of this crossover study acetaminophen (1000 mg p.o.) will be administered orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days (see Crossover Period: Acetaminophen 4000 mg/d intervention). The last dose will be administered on day four at 8 AM In the other crossover period, after a washout period of at least 14 days, the subjects will receive ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days (see Crossover Period: Ibuprofen 800 mg/d intervention). The last dose will be administered on day four at 8 AM Study assessments will be performed on day 1 and day 4 of each crossover period. The occurrence of the two crossover periods will be randomized by order."
62251502|NCT03244514|EXPERIMENTAL|Intervention group|"Implementation of the cardiovascular surgery AKI bundle~1. discontinuation of all nephrotoxic agents when possible~2. optimization of volume status and hemodynamic parameters~3. close monitoring of serum creatinine, fluid balance and urinary output~4. avoidance of hyperglycemia~5. considerations of alternatives to radiocontrast agents~6. discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period~7. avoidance of HES, gelatin, and chlorid-rich solutions"
62441273|NCT00386724|EXPERIMENTAL|Precision Spinal Cord Stimulation|Single arm Precision Spinal Cord Stimulation System with Artisan Surgical Lead
62441274|NCT00782002|EXPERIMENTAL|IMC-18F1|
62610089|NCT06292013|EXPERIMENTAL|Lepodisiran Sodium|Lepodisiran sodium administered subcutaneously (SC).
62610090|NCT06292013|PLACEBO_COMPARATOR|Placebo|Placebo administered SC.
62610091|NCT01254721|EXPERIMENTAL|1|Seroquel XR tablet
62251503|NCT03244514|NO_INTERVENTION|Control group|The patients will receive standard of care (according to each center)
62251504|NCT02194530||Peanut allergic individuals|20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
62251505|NCT02194530||Allergic/atopic individuals (not peanut)|Subjects should not be allergic to peanut. 20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
62441275|NCT02768623|ACTIVE_COMPARATOR|Control Group|Patients in the control group will receive standard, dispensing services they currently receive from pharmacists. Control group pharmacists will continue to provide these services in accordance with the standards of practice adopted by the Ontario College of Pharmacists. They will not provide either of the 3 intervention components outlined above. Should a control group patient request additional information and/or services, the pharmacist will comply and provide these as deemed necessary for the particular patient. This could include the full range of educational and drug therapy optimization services outlined for the intervention group. If this occurs then the pharmacists will document all services provided in order for the research team to account for this in the analysis.
62610092|NCT01254721|ACTIVE_COMPARATOR|2|Seroquel XR + lithium
62832656|NCT00940771|EXPERIMENTAL|boosted Atazanavir|Boosted Atazanavir was switched for the PI or NNRTI in the patients regimen
62832657|NCT02796599|EXPERIMENTAL|CWLT with facial mask|This study has a cross-over design. Patients will achieve CWLT with non-invasive ventilation using facial or nasal mask in a randomised order.
62832658|NCT02796599|EXPERIMENTAL|CWLT with nasal mask|This study has a cross-over design. Patients will achieve CWLT with non-invasive ventilation using facial or nasal mask in a randomised order.
62832659|NCT02919995|EXPERIMENTAL|Higher Dose RPL554|Single dose of inhaled 6 mg RPL554
62832660|NCT02919995|EXPERIMENTAL|Lower dose RPL554|Single dose of inhaled 1.5 mg RPL554
62832661|NCT02919995|PLACEBO_COMPARATOR|Placebo|Inhaled placebo dose
62832662|NCT01254617|EXPERIMENTAL|Treatment (lenalidomide and cetuximab)|Patients receive lenalidomide PO QD on days 1-21 and cetuximab IV over 1-2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62251506|NCT02194530||Non-allergic individuals|20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
62251507|NCT00436618|EXPERIMENTAL|Relapsed aggressive non-Hodgkin lymphoma|Study 1. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
62251508|NCT00436618|EXPERIMENTAL|Relapsed indolent non-Hodgkin lymphoma|Study 2. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
62251509|NCT00436618|EXPERIMENTAL|Uncommon lymphomas|Study 3. Includes Hodgkin's lymphomas. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
62832663|NCT06431997|EXPERIMENTAL|TRE(Time-restricted eating group)|Participants assigned to the TRE group will be instructed to consume prescribed calories in a 10-hour eating window (from 8:30 am to 18:30 pm) each day and only noncaloric beverages were permitted outside of the eating window over 3 months (from 14-26 gestational weeks).
62251510|NCT01639768|PLACEBO_COMPARATOR|SUBLIVAC FIX Birch 0 AUN/ml|
62832664|NCT06431997|NO_INTERVENTION|SOC (standard of care group)|Participants in the SOC group will be instructed to consume prescribed calories following habitual daily eating schedule over 3 months.
62832665|NCT06588946|EXPERIMENTAL|Ketone monoester (KME) supplement|Participants will be instructed to consume a bottle of the ketone monoester (KME) supplement, containing the KME of β-hydroxybutyrate (β-OHB), 15-min prior to each meal (3x/day) for 14 days. This dosing protocol raises plasma β-OHB consistently during the waking hours. Oral KME will be provided in opaque bottles labelled A or B to maintain condition blinding. Each bottle will contain a drink providing 15g of a KME supplement: \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (ΔG®, TDeltaS, Oxford, UK).
62832666|NCT06588946|PLACEBO_COMPARATOR|Placebo supplement|Participants will be instructed to consume a bottle of placebo supplement 15-min prior to each meal (3x/day) for 14 days. Oral placebo will be provided in opaque bottles labelled A or B to maintain condition blinding. Each bottle will contain a 50mL taste-match inert calorie-free placebo.
62251511|NCT01639768|ACTIVE_COMPARATOR|SUBLIVAC FIX Birch 3,333 AUN/ml|
62251512|NCT01639768|ACTIVE_COMPARATOR|SUBLIVAC FIX Birch 10,000 AUN/ml|
62251513|NCT01639768|ACTIVE_COMPARATOR|SUBLIVAC FIX Birch 20,000 AUN/ml|Evaluation of the SUBLIVAC FIX Birch 20,000 AUN/ml by an independent safety committee
62251514|NCT01639768|ACTIVE_COMPARATOR|SUBLIVAC FIX Birch 40,000 AUN/ml|Start of SUBLIVAC FIX Birch 40,000 AUN/ml arm depends on safety in the SUBLIVAC FIX Birch 20,000 AUN/ml arm evaluated by an independent safety committee
62251515|NCT02247960|ACTIVE_COMPARATOR|Ciprofloxacin|Antibiotic
62251516|NCT02247960|NO_INTERVENTION|No Antibiotic|No Antibiotic
62251517|NCT05948007|EXPERIMENTAL|Neurofeedback group|12 training sessions within 6 weeks, starting with FAA modulation followed by the frontal midline theta upregulations.
62251518|NCT05948007|SHAM_COMPARATOR|Sham neurofeedback group|Same dosage as the neurofeedback group
62251519|NCT05948007|ACTIVE_COMPARATOR|Pain management protocol|The PMP includes cognitive behavioral therapy techniques, and pain neuroscience education.
62251520|NCT05948007|NO_INTERVENTION|Care as usual|Providing medical care as they would normally receive, including a post-surgery exercise program.
62251521|NCT00502814||1|Patients with Breast Cancer.
62049546|NCT00549757|PLACEBO_COMPARATOR|Placebo|"In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.~With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment."
62251522|NCT03056950|NO_INTERVENTION|non-oclusion training group|The control (non-occlusion training) group will follow the standard s/p distal radius fracture rehabilitation protocol. Treatment will include passive, active assistive,active range of motion (P/AA/AROM) to wrist, forearm and hand; desensitization as needed; edema control as needed; heat/cold modalities as needed; and strengthening exercises.
62610093|NCT05840328|PLACEBO_COMPARATOR|plan group|bupivacaine will be administered epidurally as a loading dose then epidural continuous infusion with 0.125 % bupivacaine at rate 10 ml will be a maintainance for analgesia .IV placebo (normal saline) infusion will be connected to each patient at a rate of 10 ml \\hr.
62610094|NCT05840328|ACTIVE_COMPARATOR|epidural group|10 ml of 0.125 % buoivacaine with 0.5 µg\\ml dexmetomidine as a loading dose then continuous epidural infusion of 0.125% bupivacaine with 0.5µ/ml dexmetomidine at a rate of 10 ml\\hr will be used as maintainance . IV placebo (normal saline) infusion will be connected to each patient at a rate of 10 ml\\hr
62610095|NCT05840328|ACTIVE_COMPARATOR|intravenous group|continuous intravenous dexmetomidine infusion at rate of 0.5 µg / kg / hour in addition to same epidural infusion of 0.125% bupivacaine
62610096|NCT01490697|EXPERIMENTAL|Mifepristone plus d-Cycloserine (DCS)|DCS 100 mg capsule orally followed by mifepristone1800 mg tablet orally 4 hours later and 90 minutes prior to traumatic memory retrieval via the traumatic event script preparation procedure, all on Day 7.
62610097|NCT01490697|PLACEBO_COMPARATOR|Placebo plus Placebo|Placebo-matching DCS 100 mg capsule orally followed by placebo-matching mifepristone1800 mg tablet orally 4 hours later and 90 minutes prior to traumatic memory retrieval via the traumatic event script preparation procedure, all on Day 7.
62832667|NCT01383356|EXPERIMENTAL|Linagliptin/Metformin medium dosecombo|patient to receive a single medium dose combination tablet containing Linagliptin and Metformin once daily
62832668|NCT01383356|ACTIVE_COMPARATOR|Linagliptin plus Metformin medium dose|patient to receive two individual tablets: Linagliptin and Metformin (medium dose)
62832669|NCT05588921||Aging group|Participants with baseline information, medical history of diseases, and lens photographs
62832670|NCT04793217|EXPERIMENTAL|Improving AIDS Care after Trauma+|ImpACT+ (Improving AIDS Care after Trauma+), is an individual-level coping intervention to address traumatic stress and HIV care engagement among South African women with sexual trauma histories. The ImpACT+ individual sessions will focus on coping skills and care engagement during an early critical period, while maintenance check-ins will serve to reinforce positive change and support the ongoing implementation of skills as new challenges arise.
62832671|NCT04793217|ACTIVE_COMPARATOR|Adapted Problem-Solving Therapy|Participants randomly assigned to the control condition will receive a brief adapted version of problem-solving therapy (PST), based on Problem Management Plus, a component of the World Health Organization (WHO) Mental Health Gap Action Programme (mhGAP). PST is a psychoeducational treatment focused on managing the negative effects of stressful life events. PST has been found to be effective for a range of problems, such as depression, and is recommended for implementation in low-resource settings.
62832672|NCT01875653|ACTIVE_COMPARATOR|Autologous PBMCs in GM-CSF (MC)|"DOSE/ROUTE/REGIMEN:~1. Treatment Duration: Doses of MC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.~2. Dosage: Each dose of MC contains approximately 10 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.~3. Mode of Administration: Subcutaneous (SC) injections."
62832673|NCT01875653|EXPERIMENTAL|Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|"DOSE/ROUTE/REGIMEN:~1. Treatment Duration: Doses of DC-TC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.~2. Dosage: Each dose of DC-TC contains approximately 10-20 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.~3. Mode of Administration: Subcutaneous (SC) injections."
62049547|NCT06231238|EXPERIMENTAL|Balance ACT|Participants randomised to Balance ACT will receive 10 therapy sessions with a therapist.
62049548|NCT06231238|NO_INTERVENTION|Treatment as usual|Information leaflet about PCS/LC.
62049549|NCT01992510||silicone oil fiiled eye|those with a condition
62610098|NCT00921011||Perimenopausal women|Women at the beginning stages of menopause
62610099|NCT01288092|EXPERIMENTAL|BEZ235|
62610100|NCT06044272||Escherichia coli producing ESBL|Ceftazidime or cefotaxime resistance.
62610101|NCT06044272||Klebsiella pneumoniae producing ESBL|Ceftazidime or cefotaxime resistance.
62610102|NCT06044272||Klebsiella pneumoniae resistant to carbapenem|Ertapenem resistance.
62610103|NCT06044272||Pseudomonas aeruginosa resistant to carbapenems|Imipenem or meropenem resistance.
62610104|NCT06044272||Staphylococcus aureus resistant to methicillin|Methicillin resistance.
62610105|NCT03684551|ACTIVE_COMPARATOR|No dashboard supervision tool|CHWs received monthly individual supervision from a dedicated CHW supervisor. The supervisory feedback session for CHWs in the control arm was not facilitated by a visual Dashboard tool or any personalised quantitative feedback on quantity, speed, or quality of care. CHW supervisors were instructed to continue providing CHWs in the control arm with feedback informed by patient perspectives and direct observation during the individual supervision visit.
62049550|NCT01992510||fellow eye|the contralateral eye in the same patient
62832674|NCT01532986|OTHER|Usual Care (Arm 1)|"Veterans randomized to the usual care arm will continue to receive care they would have received if they had not enrolled in the study; no care or resources that are made available in general by VA will be withheld from participants in either arm or to any Veterans who wish to use those resources.~Educational handout: brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook."
62832675|NCT01532986|EXPERIMENTAL|Intervention (Arm 2)|"A delivery system redesign, with nurse care managers, using standardized assessment tools and care coordination protocols to address unmet needs of Veterans with Parkinson's Disease (PD) by collaborating with these Veterans and their families, providers, and community partners.~Educational handout: brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook."
62832676|NCT05606445||1|Healthy young (18-30 years old) (n = 40). This group will be used to assess the development of paratonia in healthy conditions.
62832677|NCT05606445||2|Healthy middle aged (40-55y) (n = 40). This group will be used to assess the development of paratonia in healthy conditions.
62832678|NCT05606445||3|Healthy old (\>65y) (n = 40). This group will be used to assess the development of paratonia in healthy conditions.
62832679|NCT05606445||4|People with mild cognitive impairment (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
62832680|NCT05606445||5|People with mild dementia according to the Clinical Dementia Rating (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
62049551|NCT04001179||Presence of pulmonary embolism|≥ 1 noninfused and normoventilated segment(s) by pulmonary tomoscintigraphy
62049552|NCT04001179||No pulmonary embolism|Pulmonary perfusion without anomaly (segmental or sub-segmental) by pulmonary tomoscintigraphy
62049553|NCT02764710|EXPERIMENTAL|Short treatment|Short course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily for a total of 2 doses.
62049554|NCT02764710|ACTIVE_COMPARATOR|Long treatment|Long course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily up until and including postoperative day 7.
62049555|NCT01726881|EXPERIMENTAL|Fresh Spinal Cord Injury patients|Spinal Cord Injury patients that are currently admitted to the rehabilitation unit with three weeks or less since injury that will over go several tests and will fill out several questionnaires.
62832681|NCT05606445||6|People with moderate dementia according to the Clinical Dementia Rating (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
62832682|NCT05606445||7|People with severe dementia according to the Clinical Dementia Rating (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
62832683|NCT01711840||Symbicort|
62049556|NCT01726881|EXPERIMENTAL|Chronic Spinal Cord Injury patients|Spinal Cord Injury patients with one year or more since injury that will over go several tests and will fill out several questionnaires
62251523|NCT03056950|ACTIVE_COMPARATOR|occlusion traingn with tourniquet|The occlusion training group will follow the same protocol as described above but will utilize occlusion training with the strengthening exercises. Investigators will use an established occlusion training protocol already being used. Intervention: Occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
62832684|NCT02202759|EXPERIMENTAL|MLN0264 1.8 mg/kg|MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 14 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
62832685|NCT02755246|EXPERIMENTAL|Polyamine supplementation|750 mg polyamine-rich plant extract per day
62251524|NCT03130062|EXPERIMENTAL|Exercise|Volunteers underwent a supervised resistance exercise program for 16 weeks. The subjects performed 10 exercises with 3 sets of 10 maximum repetitions in each. The training sessions were held twice a week.
62251525|NCT03130062|NO_INTERVENTION|Control|Volunteers in this group were instructed not to perform systematic physical exercises for 16 weeks (the same period of the GEX group training program), and only the SSP medication treatment was maintained, and they were followed up during the study period.
62251526|NCT00615472|EXPERIMENTAL|Group 1|Inhaled Anesthesia - isoflurane
62832686|NCT02755246|PLACEBO_COMPARATOR|Placebo|750 mg potato starch per day
62832687|NCT01834989|ACTIVE_COMPARATOR|Insulin-like growth factor I|3 injection (1 mg), once a week the first 3 weeks of the 12 weeks of intervention
62049557|NCT01726881|ACTIVE_COMPARATOR|Healthy volunteers|Healthy subjects that will over go several tests and will fill out several questionnaires
62251527|NCT00615472|EXPERIMENTAL|Group 2|Intravenous Anesthesia - propofol, remifentanil
62832688|NCT01834989|PLACEBO_COMPARATOR|Placebo injections|3 Injections of saline into the patellar tendon 3 times during the first 3 weeks of the 12 weeks interventions period
62049558|NCT04497402||female COVID19 patients|Females with COVID19 disease
62049559|NCT04497402||male COVID19 patients|Males with COVID19 disease
62049560|NCT04497402||female matched COVID19-free patients|Free from disease COVID19 Females matched.
62049561|NCT04497402||male matched COVID19-free patients|Free from disease COVID19 males matched.
62049562|NCT05470114|EXPERIMENTAL|LEO 138559|Participants will receive injections of LEO 138559 from Week 0 (baseline) to Week 16 (end of treatment).
62049563|NCT05470114|ACTIVE_COMPARATOR|Dupixent®|Participants will receive injections of Dupixent® from Week 0 (baseline) to Week 16 (end of treatment).
62049564|NCT03766022|EXPERIMENTAL|Heavy smoker patients|Marginal bone changes after 1 year after implant installation using Neo dental implant Alpha Bio Tec. Ltd.
62049565|NCT03766022|ACTIVE_COMPARATOR|non Smokers patients|Marginal bone changes after 1 year after implant installation using Neo dental implant Alpha Bio Tec. Ltd.
62049566|NCT02726802|EXPERIMENTAL|Physical Therapy route of entry|The subject will see a physical therapist as their initial encounter into the healthcare system
62049567|NCT02726802|ACTIVE_COMPARATOR|Primary Care Provider rout of entry|The subject will see a primary care provider as their initial encounter into the healthcare system
62049568|NCT02447822|ACTIVE_COMPARATOR|6.0ATG|Recipients who have 6.0 mg/kg Thymoglobulin as induction therapy
62049569|NCT02447822|ACTIVE_COMPARATOR|4.5ATG|Recipients who have 4.5 mg/kg Thymoglobulin as induction therapy
62049570|NCT06064084||Psoriasis|
62049571|NCT06064084||Control|Age, Sex and BMI matched
62049572|NCT01291979|ACTIVE_COMPARATOR|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
62049573|NCT01291979|PLACEBO_COMPARATOR|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
62049574|NCT05217238|EXPERIMENTAL|Age range of 18 to 44 years olds|The initial dose of lidocaine for pre-injection was set at 1ug/kg according to previous literature and preliminary test results. The dose of remifentanil was according to the patients' pain level. If there is no pain (negative reaction), the dose of remifentanil in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of remifentanil will be increased in the next patient until the patient is painless.
62251528|NCT06490705|EXPERIMENTAL|Tongue resistance exercises|"Participants received tongue resistance exercises 6 days a week, 3 times a day (before meals), with each session lasting 30 minutes.~The exercise intervention is divided into two stages. After completing the pre-test (T1), the first stage of 12 weeks of exercise begins, with evaluations conducted at the 4th week (T2), 8th week (T3), and 12th week (T4). After a 12-week rest period (T5), the second phase of Boosters exercise is conducted for another 12 weeks, followed by an immediate post-test (T6) and a final evaluation after another 12 weeks of rest (T7)."
62251529|NCT06490705|EXPERIMENTAL|Tongue strengthening exercises and tongue resistance exercises|"Participants received tongue strengthening exercises and tongue resistance exercises 6 days a week, 3 times a day (before meals), with each session lasting 30 minutes.~The exercise intervention is divided into two stages. After completing the pre-test (T1), the first stage of 12 weeks of exercise begins, with evaluations conducted at the 4th week (T2), 8th week (T3), and 12th week (T4). After a 12-week rest period (T5), the second phase of Boosters exercise is conducted for another 12 weeks, followed by an immediate post-test (T6) and a final evaluation after another 12 weeks of rest (T7)."
62441276|NCT02768623|EXPERIMENTAL|Intervention Group|"Pharmacists in the intervention group will provide patients with a comprehensive disease management program for asthma. The 3 major components of pharmacists' intervention are outlined below. The services delivered will be customized based on each patient's case.~1. Medication review and drug therapy optimization~2. Patient education~3. Improving patient adherence"
62832689|NCT00425802|OTHER|treatment|This is a phase 2 study of a treatment regimen consisting of a non-myeloablative (NMA) conditioning regimen incorporating low dose chemotherapy and low dose radiation as well as peri-transplant Rituximab and the transplantation of peripheral blood stem cells (PBSC) or bone marrow if PBSC collection not possible from an HLA compatible related or unrelated donor in patients with B cell lymphoid malignancies including diffuse large cell (DLC) and mantle cell non-Hodgkin's lymphoma (NHL), indolent B cell NHL, or chronic lymphocytic leukemia (CLL).
62049575|NCT05217238|EXPERIMENTAL|Age range of 45 to 59 years olds|The initial dose of lidocaine for pre-injection was set at 1ug/kg according to previous literature and preliminary test results. The dose of remifentanil was according to the patients' pain level. If there is no pain (negative reaction), the dose of remifentanil in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of remifentanil will be increased in the next patient until the patient is painless.
62049576|NCT05217238|EXPERIMENTAL|Age range of 60 to 80 years olds|The initial dose of lidocaine for pre-injection was set at 1ug/kg according to previous literature and preliminary test results. The dose of remifentanil was according to the patients' pain level. If there is no pain (negative reaction), the dose of remifentanil in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of remifentanil will be increased in the next patient until the patient is painless.
62441277|NCT00146770|ACTIVE_COMPARATOR|Placebo/Aldurazyme|Patients received placebo for 26 weeks in the Double-Blind Study then received 182 weeks of Aldurazyme (0.58 mg/kg every week) in this Extension Study; patients received a total of 182 weeks of Aldurazyme.
62441278|NCT00146770|ACTIVE_COMPARATOR|Aldurazyme/Aldurazyme|Patients received 26 weeks of Aldurazyme in the Double-Blind Study and then received 182 weeks of Aldurazyme in this Extension Study; patients received a total of 208 weeks of Aldurazyme.
62441279|NCT03480503||study group|Patients with acne vulgaris , measurement of serum apelin12 by using ELISA technique ,complete lipid profile and fasting blood glucose.
62441280|NCT03480503||Control group|Healthy control volunteers, measurement of serum apelin12 by using ELISA technique ,complete lipid profile and fasting blood glucose.
62832690|NCT05072236|PLACEBO_COMPARATOR|normal saline|intravenous normal saline 5 mL 1 minute before bronchoscope insertion
62832691|NCT05072236|ACTIVE_COMPARATOR|lidocaine|intravenous lidocaine 1.5 mg/kg 1 minute before bronchoscope insertion
62832692|NCT05072236|EXPERIMENTAL|alfentanil|intravenous alfentanil 10 ug/kg 1 minute before bronchoscope insertion
62832693|NCT03408093||Interferon beta-1b|Patients with CIS, RRMS or SPMS who had more than 6 months in treatment
62832694|NCT04819542|EXPERIMENTAL|drain + compression bandage|
62832695|NCT04819542|ACTIVE_COMPARATOR|drain without compression bandage|
62832696|NCT04646421||Motivational intervention - clients reached|Gamblers successfully reached with the motivational telephone intervention.
62832697|NCT04646421||Control group: clients not reached for the motivational intervention|Clients aimed to be reached for the same intervention, but who were not reached and therefore were not exposed to the intervention.
62832698|NCT04646421||Prospective intervention group|Clients subject to the prospective study part (target N 200), who are successfully reached by the intervention from November, 2020, and who provide informed consent to the web survey study. Studied as a cohort without control group, but with the pre-intervention situation as their own control condition.
62832699|NCT01497496|EXPERIMENTAL|Immunotherapy|Combination regimen consisting of high dose methylprednisolone combined with ofatumumab, followed by consolidative therapy with lenalidomide in combination with ofatumumab.
62832700|NCT04436952|EXPERIMENTAL|H7 coil only|patients undergoing DTMS treatment using the H7 coil
62832701|NCT04436952|ACTIVE_COMPARATOR|Cool D-B80 coil only|20 patients undergoing rTMS treatment using the cool D-B80 coil
62049577|NCT04602312|EXPERIMENTAL|Mindfulness meditation|"focussed attention mindfulness meditation technique taught as means to reduce coronavirus-related catastrophizing."
62049578|NCT04602312|SHAM_COMPARATOR|Specific sham mindfulness meditation|a training session designed to specifically match the real mindfulness training while lacking the proposed active elements of mindfulness training. Delivered as a means to elicit expectancy-mediated (but not mindfulness-mediated) reductions in coronavirus-related catastrophizing.
62049579|NCT04602312|SHAM_COMPARATOR|General sham mindfulness meditation|a training session designed to generally match focussed-attention mindfulness meditation while maintaining greater distance from proposed mindfulness mechanisms. Delivered as a means to elicit expectancy-mediated (but not mindfulness-mediated) reductions in coronavirus-related catastrophizing.
62049580|NCT04602312|NO_INTERVENTION|Book listening control|"this group completes no meditation training. They listen to a spoken excerpt from the audiobook The Natural History and Antiquities of Selborne"
62251530|NCT06490705|ACTIVE_COMPARATOR|cheek bulging exercises|"Participants received cheek bulging exercises6 days a week, 3 times a day (before meals), with each session lasting 30 minutes.~The exercise intervention is divided into two stages. After completing the pre-test (T1), the first stage of 12 weeks of exercise begins, with evaluations conducted at the 4th week (T2), 8th week (T3), and 12th week (T4). After a 12-week rest period (T5), the second phase of Boosters exercise is conducted for another 12 weeks, followed by an immediate post-test (T6) and a final evaluation after another 12 weeks of rest (T7)."
62441281|NCT05937113|EXPERIMENTAL|Safety of a 3-dose regimen of RABIVAX-S in healthy participants aged 5 to 60 years|RABIVAX-S is a pure, sterile inactivated rabies vaccine produced on vero cells. RABIVAX-S vaccine is lyophilized and is supplied with rehydration solution (1 vial containing 1 dose of lyophilized vaccine and 1 vial of rehydration solution).
62832702|NCT04436952|ACTIVE_COMPARATOR|DTMS treatment using the H7 coil + ERP|20 patients undergoing DTMS treatment using the H7 coil + ERP
62832703|NCT04436952|ACTIVE_COMPARATOR|rTMS treatment using the cool D-B80 coil + ERP|20 patients undergoing rTMS treatment using the cool D-B80 coil + ERP
62832704|NCT04436952|ACTIVE_COMPARATOR|ERP only|20 patients undergoing ERP only
62049581|NCT04805060|EXPERIMENTAL|TQB2858 injection|TQB2858 administered intravenously (IV) once every 3 week
62049582|NCT01733732|EXPERIMENTAL|Systane Balance|SYSTANE® BALANCE Lubricant Eye Drops, 1 drop in each eye 4 times a day for 30 days
62049583|NCT01733732|ACTIVE_COMPARATOR|Systane Gel|SYSTANE® Gel, 1 drop in each eye 4 times a day for 30 days
62049584|NCT03758170|EXPERIMENTAL|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
62049585|NCT03758170|ACTIVE_COMPARATOR|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
62251531|NCT05125094||Non-Gadoxetic MRI for diagnosis|the patients with HCC follow up with Non-Gadoxetic MRI for diagnosis
62251532|NCT05125094||Gadoxetic MRI for diagnosis|the patients with HCC follow up with Gadoxetic MRI for diagnosis
62832705|NCT02655120|EXPERIMENTAL|Bone Marrow +BMP7|The drilling is completed by a joint supply of autologous marrow unconcentrated and recombinant BMP7 (OP1)
62832706|NCT02655120|PLACEBO_COMPARATOR|Drilling|Group I: a simple drill is practiced
62049586|NCT00314548|EXPERIMENTAL|Cases|PGE1 drug
62049587|NCT00314548|PLACEBO_COMPARATOR|Placebo|normal saline via same nebulizer
62049588|NCT02737800|ACTIVE_COMPARATOR|1A endometrioma more than 5cm|Endometrioma aspiration GnRh agonist :Decapeptyl 3.75mg intramuscular Standard long stimulation protocol \& ICSI
62049589|NCT02737800|SHAM_COMPARATOR|1B endometrioma more than 5cm control|Endometrioma aspiration Standard long stimulation protocol \& ICSI
62049590|NCT02737800|ACTIVE_COMPARATOR|2A endometrioma less than 5cm|Decapeptyl 3.75mg intramuscular Standard long stimulation protocol \& ICSI
62049591|NCT02737800|SHAM_COMPARATOR|2B endometrioma less than 5cm control|Standard long stimulation protocol \& ICSI
62049592|NCT03509740|EXPERIMENTAL|tramadol|Intravenous 100 mg tramadol in 100 ml saline with slow infusion over 10 minutes.
62049593|NCT03509740|ACTIVE_COMPARATOR|paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with slow infusion over 10 minutes.
62049594|NCT01008267||SWL under general anesthesia|Patients who failed in SWL under sedation(a standard protocol), will undergo a second SWL process under general anesthesia.
62049595|NCT01008267||SWL under general selective anesthesia|Patients who failed in SWL under sedation(a standard protocol), will undergo a second SWL process under general selective anesthesia, using a bronchial blocker.
62251533|NCT00621751|EXPERIMENTAL|Carbamazepine|Carbamazepine 800 mg daily
62251534|NCT00621751|PLACEBO_COMPARATOR|Placebo|Placebo
62251535|NCT02809131|EXPERIMENTAL|Saline irrigation|Saline irrigation
62832707|NCT06469034|OTHER|Control group|The operators in the control group will perform the procedure by visualizing the conventional ultrasound images displayed directly on the ultrasound screen. Each operator will perform an internal jugular vein cannulation via the short-axis approach. To standardize the approach, the ultrasound machine will be placed just to the right of the patient and operators will be asked to stand at the head of the patient and perform the procedure on the patient's internal jugular vein. Each operator could determine the height of the surgical table, and the posture during the procedure that will be most familiar to him/her to increase the success rate. Every procedure will be recorded by focusing on the participant's hands and faces.
62832708|NCT06469034|EXPERIMENTAL|MR+HMD group|In the MR + HMD group, the ultrasound machine will be located behind the operator to remove the distraction, and the operator will not be allowed to see the ultrasound screen during the procedure. The operators randomized into the MR+HMD group will use a MR ultrasound machine. Images from the MR ultrasound machine will be transmitted to HMD via a novel connection developed specifically for this purpose. The operator will wear a pair of HMD and perform the procedure by visualizing the ultrasound images displayed on their HMD screen instead of the ultrasound screen. Each operator will perform an internal jugular vein cannulation via the short-axis approach. Every procedure will be recorded by focusing on the participant's hands and faces.
62832709|NCT06256406|ACTIVE_COMPARATOR|kangaroo care|Kangaroo care Arm subjected to Kangaroo care, a practice involving skin-to-skin contact between the infant and a caregiver.
62049596|NCT01520818|EXPERIMENTAL|BIAsp 50 or 70|
62251536|NCT02809131|ACTIVE_COMPARATOR|Antibiotic irrigation and PO antibiotics|Antibacterial irrigant (polymyxinB/bacitracin) and postoperative oral antibiotics (cephalexin, clindamycin, or levofloxacin)
62251537|NCT00528164|EXPERIMENTAL|Team PLAY Group|6-month family-centered intervention to increase physical activity and healthy eating patterns, primarily directed at parents. Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
62049597|NCT01520818|ACTIVE_COMPARATOR|BHI 30|
62251538|NCT00528164|NO_INTERVENTION|Standard Care Group|Participants receive standard care by primary care physician.
62251539|NCT01793805||Metastatic Colorectal Cancer Patients|
62251540|NCT01210170|EXPERIMENTAL|mometasone 400 mcg - 30 min|randomly assigned intervention
62251541|NCT01210170|EXPERIMENTAL|mometasone 400 mcg simultaneous|randomly assigned intervention
62251542|NCT01210170|PLACEBO_COMPARATOR|placebo- 30 min|randomly assigned intervention
62251543|NCT01210170|PLACEBO_COMPARATOR|placebo simultaneous|randomly assigned intervention
62251544|NCT01210170|EXPERIMENTAL|mometasone 400 mcg - 60 min|randomly assigned intervention
62049598|NCT05333354|EXPERIMENTAL|Experimental(simulation education group)|The experimental group (simulation teaching group), the content of simulation teaching is based on the simulation model, and includes five important elements: Instructor, student, educational practice, simulation situation design and characteristics, and result that design covering the four stages of learning, concrete experience, reflective observation, abstract conceptualization and action experience, and design lesson plans, which include delirium assessment and delirium risk factor detection. Delirium prevention and management (PADIS guidelines). The main objectives of the teaching plan design of the experimental group are: to be able to confirm delirium by assessment of the Delirium Assessment Scale; to confirm the risk factors by the history taking; to propose treatment and measures according to the assessment results. Secondary goals: Be able to perform handovers.
62049599|NCT05333354|NO_INTERVENTION|Control(traditional group)|Nurses in the control group did not receive simulated situational teaching, but received classroom teaching 3 times (once every other week) (delirium assessment, risk factor assessment; PADIS treatment), each session of about 2 hours. In order to avoid inconsistent teaching content, the control group and the experimental group are not to be together in classroom.
62251545|NCT01210170|PLACEBO_COMPARATOR|placebo- 60 min|randomly assigned intervention
62251546|NCT01210170|EXPERIMENTAL|mometasone 200 mcg - 30 min|randomly assigned intervention
62251547|NCT01210170|EXPERIMENTAL|mometasone 200 mcg - 60 min|randomly assigned intervention
62251548|NCT01210170|EXPERIMENTAL|mometasone 200 mcg simultaneous|randomly assigned intervention
62251549|NCT01089998|EXPERIMENTAL|Arm 1|
62251550|NCT01089998|EXPERIMENTAL|Arm 2|
62251551|NCT01089998|EXPERIMENTAL|Arm 3|
62251552|NCT01089998|EXPERIMENTAL|Arm 4|
62251553|NCT03951051|OTHER|Sequence AB|16 subjects assigned to the sequence AB will receive a single 40 mg dose of the test product Olmesartan Medoxomil (1 x 40 mg film-coated tablet), marked as A in the sequence, in Period 1 and a single 40 mg dose of the reference product Olmetec® (1 x 40 mg film-coated tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62251554|NCT03951051|OTHER|Sequence BA|16 subjects assigned to the sequence BA will receive a single 40 mg dose of the reference product Olmetec® (1 x 40 mg film-coated tablet), marked as B in the sequence, in Period 1 and a single 40 mg dose of the test product Olmesartan Medoxomil (1 x 40 mg film-coated tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62251555|NCT01236105|EXPERIMENTAL|6 mg LY2624803 Alone Morning Dosing|Participants received 6 milligrams (mg) LY2624803 alone orally (po) at approximately 0800 hours following an overnight fast.
62049600|NCT01247402|ACTIVE_COMPARATOR|Paclitaxel eluting balloon|Freeway 0.035 Paclitaxel eluting balloon (3 microgram Paclitaxel/mm2)
62251556|NCT01236105|EXPERIMENTAL|6 mg LY2624803 Morning Dosing + Activated Charcoal|Participants received 6 mg LY2624803 po at approximately 0800 hours following an overnight fast, followed 1 hour later by a single po dose of 1 gram per kilogram (g/kg) body weight of activated charcoal, mixed with caffeine-free diet cola.
62832710|NCT06256406|ACTIVE_COMPARATOR|Music therapy|Music therapy Arm subjected to music therapy, a practise improving perception of newborns
62832711|NCT03426748|ACTIVE_COMPARATOR|Low dose rate brachytherapy|Device: Radiation. Low dose rate prostate brachytherapy is delivered under anesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.
62832712|NCT03426748|EXPERIMENTAL|High dose rate brachytherapy|"Device: Radiation. High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anesthesia, but no follow-up imaging visit is required.~HDR brachytherapy is also accomplished as an out-patient."
62832713|NCT05669274|EXPERIMENTAL|Old World milk|Old World milk containing only a2 beta-casein vs. New World milk that includes both a1 and a2 beta-casein
62832714|NCT05669274|EXPERIMENTAL|New World milk|Old World milk containing only a2 beta-casein vs. New World milk that includes both a1 and a2 beta-casein
62832715|NCT06654596|EXPERIMENTAL|Telitacicept+ACEI/ARB|
62049601|NCT01247402|ACTIVE_COMPARATOR|Standard balloon angioplasty|standard balloon angioplasty
62049602|NCT04704518|EXPERIMENTAL|Group 1; Lagricel® Ofteno PF|Lagricel® Ofteno PF, multidose presentation (sodium hyaluronate 0.4%) Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.
62251557|NCT01236105|EXPERIMENTAL|6 mg LY2624803 Alone Evening Dosing|Participants received 6 mg LY2624803 alone po at approximately 2200 hours following a 4-hour fast.
62832716|NCT06654596|ACTIVE_COMPARATOR|Glucocorticoids+ACEI/ARB|
62832717|NCT03581279|ACTIVE_COMPARATOR|EM present|All patients must display signs/symptoms of Lyme disease as well as exhibit an EM lesion.
62049603|NCT04704518|ACTIVE_COMPARATOR|Group 2; Thealoz® Duo|Thealoz® Duo, (trehalose 3%/sodium hyaluronate 0.15%). Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.
62251558|NCT00151983|ACTIVE_COMPARATOR|Methylphenidate Transdermal System|Methylphenidate 27.5mg, 41.3mg, 55mg, and 82.5mg patches applied daily for 8 weeks
62832718|NCT03581279|ACTIVE_COMPARATOR|No EM present|All patients must display signs/symptoms of Lyme disease but do not have an EM lesion.
62832719|NCT05738486|EXPERIMENTAL|Donanemab Dose Level 1|"Participants will receive donanemab by intravenously (IV) infusion.~Participants will receive placebo at certain intervals to preserve the blind."
62832720|NCT05738486|EXPERIMENTAL|Donanemab Dose Level 2|"Participants will receive donanemab by IV infusion.~Participants will receive placebo at certain intervals to preserve the blind."
62049604|NCT05773560|EXPERIMENTAL|Patients receiving rehabilitation with virtual reality.|Single Group Assignment Patients after a major amputation would received at least 10 days of rehabilitation with the assistance of virtual reality. Before the operation, patients consent, life quality, pain score and motivation score were be evaluated. The rehabiliation with virtual reality started on the second postoperative day. The pain score would be evaluated everyday before and after the rebilitation. On the fifth and tenth day, motivation, life quality and functional index would be carried out again as the evaluation of the outcome of training.
62251559|NCT00151983|PLACEBO_COMPARATOR|Placebo patch|Placebo patch applied daily for 8 weeks
62251560|NCT03877562|EXPERIMENTAL|Olanzapine plus CORT118335|Participants will receive olanzapine 10 mg oral tablets and double-blind CORT118335 600 mg after breakfast once daily for 14 days.
62251561|NCT03877562|PLACEBO_COMPARATOR|Olanzapine plus Placebo|Participants will receive olanzapine 10 mg oral tablets and double-blind placebo matching CORT118335 oral tablets after breakfast once daily for 14 days.
62251562|NCT01624259|EXPERIMENTAL|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 26 weeks~Metformin: at least 1500 mg/day, oral, for 26 weeks"
62251563|NCT01624259|ACTIVE_COMPARATOR|Liraglutide|"Liraglutide 0.6 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.2 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.8 mg, SC, once daily for 24 weeks~Metformin: at least 1500 mg/day, oral, for 26 weeks"
62251564|NCT02047539|EXPERIMENTAL|1000 mg/day aspirin|1000 mg/day aspirin
62251565|NCT02047539|PLACEBO_COMPARATOR|sugar pill|sugar pill
62251566|NCT01395251|OTHER|Prednisolone|Patients with suspicious of rheumatoid arthritis will undergo a prednisolone test with 20 mg per day for 3 days after 2 days of therapy with paracetamol 500 mg twice for 2 days.
62251567|NCT03347981|EXPERIMENTAL|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
62251568|NCT03347981|ACTIVE_COMPARATOR|IOL implantation active comparator|hydrophilic, trifocal intraocular lens POD F
62832721|NCT05738486|EXPERIMENTAL|Donanemab Dose Level 3|"Participants will receive donanemab by IV infusion.~Participants will receive placebo at certain intervals to preserve the blind."
62832722|NCT05738486|EXPERIMENTAL|Donanemab Dose Level 4|"Participants will receive donanemab by IV infusion.~Participants will receive placebo at certain intervals to preserve the blind."
62832723|NCT01075529|NO_INTERVENTION|fluoxetine|
62832724|NCT02239419|EXPERIMENTAL|CO2-Enriched Tap Water (Carbothera)|CO2-enriched tap water (CO2 concentration, 1000-1200 ppm) maintained at a temperature of 37˚C. Tap water will be enriched with CO2 by the investigational Carbothera device.
62049605|NCT06509256|ACTIVE_COMPARATOR|Tumescent solution only (Control group)|"The operative site will be injected with a standard tumescent solution prepared by adding 20ml of 2% lignocaine and 1ml of 1 in 1000 adrenaline to 500 ml of ringer lactate. No tranexamic acid will be used in this group.~- All patients will undergo suction-assisted liposuction through an infra-areolar incision, followed by glandular excision using the orange peel excision technique. The surgical intervention will be performed as a day-care procedure. Patients will wear pressure garments continuously for 3 days post-operatively and intermittently and by the 3rd day we estimate the ecchymosis in the chest area then pressure garment will be reapplied for 7 to 10 days. Follow-up evaluations will be conducted immediately post-op, at 10 days."
62049606|NCT06509256|ACTIVE_COMPARATOR|Tumescent solution with tranexamic acid added|"The operative site will be injected with a tumescent solution prepared as in Group A (Control group), with the addition of 500 mg tranexamic acid to the tumescent solution.~- All patients will undergo suction-assisted liposuction through an infra-areolar incision, followed by glandular excision using the orange peel excision technique. The surgical intervention will be performed as a day-care procedure. Patients will wear pressure garments continuously for 3 days post-operatively and intermittently and by the 3rd day we estimate the ecchymosis in the chest area then pressure garment will be reapplied for 7 to 10 days. Follow-up evaluations will be conducted immediately post-op, at 10 days."
62049607|NCT06509256|ACTIVE_COMPARATOR|Tumescent solution with intravenous tranexamic acid|"The standard tumescent solution as in the control group, with 500 mg tranexamic acid administered intravenously ( well-injected IV directly).~- All patients will undergo suction-assisted liposuction through an infra-areolar incision, followed by glandular excision using the orange peel excision technique. The surgical intervention will be performed as a day-care procedure. Patients will wear pressure garments continuously for 3 days post-operatively and intermittently and by the 3rd day we estimate the ecchymosis in the chest area then pressure garment will be reapplied for 7 to 10 days. Follow-up evaluations will be conducted immediately post-op, at 10 days."
62251569|NCT01723215|ACTIVE_COMPARATOR|Active ABMT8|Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
62441282|NCT05937113|EXPERIMENTAL|immunogenicityof a 3-dose regimen of RABIVAX-S in subgroup of participants|RABIVAX-S is a pure, sterile inactivated rabies vaccine produced on vero cells. RABIVAX-S vaccine is lyophilized and is supplied with rehydration solution (1 vial containing 1 dose of lyophilized vaccine and 1 vial of rehydration solution).
62441283|NCT01211769|EXPERIMENTAL|PUFAs|Polyunsaturated fatty acids (PUFAs): borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram; along with 1 gram of fish oil - rich in omega 3 PUFA;
62441284|NCT01211769|ACTIVE_COMPARATOR|Naltrexone|Naltrexone chlorhydrate 50 mg
62610106|NCT03684551|EXPERIMENTAL|Dashboard supervision tool|CHWs received monthly individual supervision from a dedicated CHW supervisor. For CHWs randomised to the intervention arm, a visual feedback tool, the CHW Performance Dashboard, was employed during individual supervision, starting in January 2016. During the individual supervisory feedback session, this personalised and relative (to the highest performer) quantitative performance feedback helped orient the discussion of strengths and weaknesses, and allowed the CHW to see quantitatively and visually how his/her performance fared the previous month. The feedback provided to CHWs in the intervention arm, therefore, was both quantitative, informed by the Dashboard, and qualitative, informed by patient perspectives and direct observation of CHW service provision during the individual supervision visit.
62610107|NCT05306236|EXPERIMENTAL|LLL therapy and postural correction ex (study group)|study group will be treated by low level laser therapy and postural correction exercises
62610108|NCT05306236|EXPERIMENTAL|postural correction ex (control group)|control group will be treated by postural correction exercises only
62832725|NCT02239419|PLACEBO_COMPARATOR|Non-CO2-Enriched Tap Water|Non-CO2-enriched tap water (i.e. normal tap water) maintained at a temperature of 37˚C.
62832726|NCT04466319|EXPERIMENTAL|intervention arm|The individuals in the intervention group in the rocking chair three times a day, 20 minutes, a total of 60 minutes after the first day after surgery.They did this intervention until they first defecation .
62832727|NCT04466319|NO_INTERVENTION|Control arm|The individuals in the control group sat in a standard chair in the same time as the intervention group in the non-rocking chair.
62832728|NCT04402372||Group 1|30 patients undergoing aortic valve replacement with minimally invasive technique prospectively randomized to receive 19 F bidirectional (BiflowTM, LivaNova, Italy) for femoral artery cannulation
62832729|NCT04402372||Group 2|30 patients undergoing aortic valve replacement with minimally invasive technique prospectively randomized to receive 19 F conventional (HLS, Maquet, Germany cannula with downstream line (6F) for femoral artery cannulation
62832730|NCT02481219|ACTIVE_COMPARATOR|Bowel preparation regimen -Control|"Regimen includes administration of:~Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of polyethylene glycol (PEG) on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository."
62832731|NCT02481219|EXPERIMENTAL|Bowel preparation regimen-Test|"Regimen includes administration of:~Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository."
62049608|NCT06346314|EXPERIMENTAL|Intervention arm|Participants who underwent intervention.
62610109|NCT03233594||Chiropractic Group|Participants receiving a chiropractic care technique Neuro Emotive Technique (NET) will complete initial pain evaluations and questionnaires for chronic pain symptoms. After approximately 8 weeks participants will receive follow evaluation for pain. Pre and Post PET-MRI scan will be conducted to evaluate changes.
62610110|NCT03233594||Healthy Control Group|Participants will receive initial evaluations and questionnaires followed by a PET-MRI scan.
62049609|NCT00198484|EXPERIMENTAL|Vitrase|ovine hyaluronidase injection 150 USP Units in 1 mL solution. Single dose of Vitrase will be administered as an adjuvant prior to ophthalmologic surgery
62049610|NCT03155789||Low Back Pain emanating from L4-5|"1. S TLIF at L4-5 (n=10)~2. MI TLIF at L4-5 (n=10)~3. XLIF at L4-5 (n=10)"
62049611|NCT03155789||Low Back Pain emanating from L5-S1|"1. S TLIF at L5-S1 (n=10)~2. MI TLIF at L5-S1 (n=10)~3. XLIF at L5-S1 (n=10)"
62049612|NCT03155789||Low Back Pain emanating from L4-5 and L5-S1|"1. S TLIF at L4-5 and L5-S1 (n=10)~2. MI TLIF at L4-5 and L5-S1 (n=10)~3. XLIF at L4-5 and L5-S1 (n=10)"
62049613|NCT06451900|EXPERIMENTAL|fenofibrate single dose|full term neonates will receive a single oral dose of 10 mg/kg of non- micronized fenofibrate
62610111|NCT06246149|EXPERIMENTAL|Tebentafusp|Participants will receive tebentafusp 20 mcg on week 1, 30 mcg on week 2, 68 mcg on week 3, and 68 mcg weekly thereafter for 6 months i.e., maximum 26 infusions.
62610112|NCT06246149|NO_INTERVENTION|Observation|
62610113|NCT05796648|EXPERIMENTAL|Food is Medicine approach|Groups of 10 will attend a 12 week intervention that includes cooking classes, grocery delivery and nutrition education.
62738693|NCT00392834|EXPERIMENTAL|Regimen B (rituximab and IVAC chemotherapy)|Patients receive rituximab IV on day 1, ifosfamide IV continuously and etoposide IV continuously over 24 hours on days 1-5, and high-dose cytarabine IV over 1-3 hours twice daily on days 1-2. Patients receive CNS prophylaxis comprising methotrexate IT and hydrocortisone IT on day 5. Patients also receive pegfilgrastim SC once 24-48 hours after completion of chemotherapy OR G-CSF SC beginning on day 6 and continuing until blood counts recover. Patients with CNS involvement (leptomeningeal and/or intraparenchymal) at diagnosis do not receive CNS prophylaxis as above. Instead, these patients receive a combination of sequential liposomal cytarabine and methotrexate IT or via an Ommaya reservoir on day 1 and then every 14 days as tolerated until completion of systemic chemotherapy.
62049614|NCT06451900|EXPERIMENTAL|fenofibrate double dose|full term neonates will receive two oral doses of 10 mg/kg of non - micronized fenofibrate.
62251570|NCT01723215|ACTIVE_COMPARATOR|Active ABMT4|Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
62738694|NCT05365997|NO_INTERVENTION|Control|Clinicians will receive no further interventions beyond usual practice.
62738695|NCT05365997|EXPERIMENTAL|Intervention|Clinicians receive a nudge consisting of an electronic health record in-basket message indicating a patient has a default pended order for palliative care.
62738696|NCT02516982||Screening - Scrolling layout|"Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:~* Section 1: Demographic information survey~* Section 2: Whooley questions~* Section 3: Edinburgh Postnatal Depression Scale~All questions will be presented on a single screen. This means that participants will have to scroll vertically in order to answer all the questions."
62049615|NCT06451900|PLACEBO_COMPARATOR|placebo|full term neonates will receive equivalent amount of distilled water.
62049616|NCT02459730|EXPERIMENTAL|ART with GIC containing 1.25% CHX|The cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
62049617|NCT02459730|ACTIVE_COMPARATOR|ART with GIC|The cavities were filled with the press finger technique using KetacMolar Easymix® (control group).
62049618|NCT02027402|EXPERIMENTAL|Drain insertion|Laparoscopic cholecystectomy with drain insertion is performed in this arm.
62049619|NCT02027402|NO_INTERVENTION|no drain insertion|In this arm, investigators perform only laparoscopic cholecystectomy, and not insert a drain
62049620|NCT03169803|EXPERIMENTAL|Single arm, NeuroTronik CANS Therapy System|
62049621|NCT05665933|EXPERIMENTAL|THE EFFECT OF ACCEPTANCE AND COMMITMENT THERAPY-BASED PSYCOEDUCATION|PSYCHOEDUCATION PROGRAM Total Duration: 6 Weeks Session Duration: 90 min Frequency: 1 day per week Number of People: 30
62049622|NCT05665933|NO_INTERVENTION|THE EFFECT OF ACCEPTANCE AND COMMITMENT THERAPY-BASED PSYCOEDUCATION ON EXAM ANXIETY IN ADOLESCENTS|Similar training will be provided after the study is completed. Number of People: 30
62049623|NCT03595332|EXPERIMENTAL|Immediate intervention|Summer activity program: Children will receive the summer scorecard program during the first summer of the 2-year study.
62049624|NCT03595332|EXPERIMENTAL|Delayed intervention|Summer activity program: Children will receive the summer scorecard program during the second summer of the 2-year study.
62251571|NCT01723215|NO_INTERVENTION|Control|Control: will not receive any intervention
62610114|NCT04520139|EXPERIMENTAL|Phase 1 Dose Escalation|Patients will receive NAC beginning at Cohort 1. If, at a given dose, none of the 3 patients shows a dose-limiting toxicity during the first cycle of PBT, then the dose is escalated 1 step for subsequent subjects. If, at a given dose, only 1 of 3 shows a dose-limiting toxicity, then up to 3 additional participants will be enrolled at that dose.If, at a given dose, the first 2, or any 2 of 3 subjects show a dose-limiting toxicity, then the dose will be de-escalated 1 step for future participants. At a dose where enrollment is expanded to between 4 and 6, if only 1 of 6 subjects shows a dose-limiting toxicity, then the dose will be escalated 1 step for future participants. However, if 2 or more of 4, 5, or 6participants show a dose-limiting toxicity, then the dose will be reduced one step for future participants. The maximum tolerated dose is defined as the highest dose not requiring deescalation. This is the dose to be used for the NAC arm of Phase II study.
62610115|NCT04520139|EXPERIMENTAL|Phase 2 Dose Expansion|Patients will be randomized to receive NAC at the maximum tolerated dose or placebo.
62610116|NCT06730581|EXPERIMENTAL|Gastric cancer group|
62832732|NCT06603519|EXPERIMENTAL|Dietary Intervention Group|Participants in this arm will follow a modified plant-based Mediterranean diet following their colonoscopies. The dietary intervention aims to reduce inflammation and improve gut microbiome composition. Participants' gut bacteria and overall health will be monitored through blood and stool sample collections, focusing on inflammation reduction and metabolic health improvement.
62832733|NCT01295814|EXPERIMENTAL|adalimumab|Adalimumab 80mg subcutaneous loading dose followed by 40 mg subcutaneous every 2 weeks for 12 weeks
62832734|NCT01295814|PLACEBO_COMPARATOR|Inactive drug|Placebo in identical syringe subcutaneous every 2 weeks for 12 weeks
62832735|NCT05265429||Data/Biospecimen Collection|Tumor and saliva specimens from participants with non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) diagnosed at age 45 or younger
62832736|NCT00422682|EXPERIMENTAL|1|BSI-201 + topotecan
62832737|NCT00422682|EXPERIMENTAL|2|BSI-201 + temozolomide
62832738|NCT00422682|EXPERIMENTAL|3|bsi-201 + gemcitabine
62832739|NCT00422682|EXPERIMENTAL|4|bsi-201 + carboplatin/paclitaxel
62832740|NCT06002880|EXPERIMENTAL|Post/Core-Total Etch|Endodontic posts and/or cores-Total etch
62832741|NCT06002880|EXPERIMENTAL|Ceramic-Total Etch|Glass-ceramics-Total etch
62832742|NCT06002880|EXPERIMENTAL|Metal/Zi-Total Etch|Metal-Zi-Total etch
62832743|NCT06002880|EXPERIMENTAL|Composite-Total Etch|Composite-Total etch
62832744|NCT06002880|EXPERIMENTAL|Post/Core-Self Etch|Endodontic posts and/or cores-Self etch
62832745|NCT06002880|EXPERIMENTAL|Ceramic-Self Etch|Glass-ceramics-Self etch
62832746|NCT06002880|EXPERIMENTAL|Metal/Zi-Self Etch|Metal-Zi-Self etch
62832747|NCT06002880|EXPERIMENTAL|Composite-Self Etch|Composite-Self etch
62832748|NCT00643864|OTHER|Mirror training|"Training will be performed one-on-one by an investigator in a quiet room, one hour a day, five days a week, for four weeks. The mirror-box apparatus consists of an 18 x 24 vertical mirror secured in the center of a wooden platform. During training, the mirror-box will be placed on a table in front of the subject so that the mirror is perpendicular to the chest, slightly lateral of midline. Subjects will be asked to attend to the mirror reflection of their unaffected hand performing a series of tasks, while keeping their affected limb still. At the end of the four week training period, posttests will be administered by the same therapist who performed the pretests."
62832749|NCT02982746|EXPERIMENTAL|gPCC-G (Gothenburg Person Centred Care) Group|gPCC-G Patients randomized to the intervention group were contacted and scheduled to attend a meeting at the oncology clinic with the nurse specialist in oncology
62832750|NCT02982746|NO_INTERVENTION|Control group|Control Group Patients randomized to the control group received usual care and return visits were scheduled according to the treatment procedure described under the previous heading and based on the Regional care program for patients with HNC. CG patients were recruited at the same time and in the same way as those in the intervention group
62251572|NCT01723215|PLACEBO_COMPARATOR|Placebo|Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns
62832751|NCT06316102|NO_INTERVENTION|Control|This group will not receive an intervention; however, provider training in gender affirmation will be conducted at the clinic level, so control participants may be exposed to changes in provider attitudes and practices.
62832752|NCT06316102|EXPERIMENTAL|Gender Affirming Abriendo Puertas (Opening Doors) (GAP)|"This group will be exposed to all four components of the multilevel intervention.~1) individual counseling and education; 2) peer navigation; 3) provider capacity building; and 4) community support building."
62251573|NCT05281796||healthy patient|Full-mouth clinical periodontal measurements recorded, saliva and GCF obtained
62610117|NCT06730581|EXPERIMENTAL|Ovarian and cholangiocarcinoma groups|
62610118|NCT06730581|EXPERIMENTAL|Other oncology indications (including esophageal cancer, liver cancer, colorectal cancer, cervical c|
62610119|NCT05320198|EXPERIMENTAL|Phase 1b: Dose Escalation|In the Phase 1b (dose-escalation) portion of the study, DISC-0974 will be administered subcutaneously every 4 weeks.
62610120|NCT05320198|EXPERIMENTAL|Phase 2: Expansion|In the Phase 2 (expansion) portion of the study, DISC-0974 will be administered subcutaneously every 4 weeks.
62610121|NCT05345769|EXPERIMENTAL|Phase I- All|Subjects with neovascular AMD
62610122|NCT01429064|EXPERIMENTAL|ODM-201|
62610123|NCT00583102|EXPERIMENTAL|Lovastatin followed by Cytarabine|The subject will receive high dose cytarabine as well as lovastatin. The subject will take doses of lovastatin twice a day, about 12 hours apart. On the third day, the subject will begin high-dose cytarabine IV over 3 hours, twice a day, starting 1 hour after the lovastatin dose for 5 days.
62610124|NCT05416645|ACTIVE_COMPARATOR|Patients in group I (G1) had GERD|Patients developed GERD after LSG
62610125|NCT05416645|ACTIVE_COMPARATOR|Patients in group I (G2) had no GERD|Patients not developed GERD after LSG
62610126|NCT06401044|EXPERIMENTAL|Part A: AMG 732|Participants in 6 cohorts will receive either AMG 732 or placebo in Single Ascending Doses (SAD).
62610127|NCT06401044|PLACEBO_COMPARATOR|Part A: Placebo|Participants in 6 cohorts will receive either AMG 732 or placebo in Single Ascending Doses (SAD).
62832753|NCT04087109|EXPERIMENTAL|Intervention: MedSafer|In the intervention phase, the MedSafer feature will become accessible in MED e-care for the physicians, pharmacists and nurses. This feature will provide health care professionals with individualized and prioritized deprescribing opportunities: a) identifying the medication, b) explaining why that medication is potentially inappropriate and c) providing instructions on how to safely stop/taper the medication. The user will review these opportunities and appropriate candidate medications for deprescribing can then be tapered or stopped directly in the EMR. During the intervention phase, all patients will receive the educational (EMPOWER) brochures as applicable to the medications they are taking (PPI, sedative-hypnotic, antihistamine, antipsychotic, sulfonylurea, NSAID, opioid/narcotic).
62832754|NCT04087109|NO_INTERVENTION|Control: Baseline (no MedSafer)|During the control phase, the MedSafer application programming interface will not be accessible to the caretakers at the aged care facilities (ACF). This serves to obtain baseline deprescribing levels for each ACF.
62832755|NCT02118584|EXPERIMENTAL|Part 1: Open-label Extension|Participants with moderate to severe UC who were enrolled in the Phase II OLE study or the Phase III studies, and who meet the eligibility criteria for enrollment will receive open-label etrolizumab in Part 1 (OLE).
62832756|NCT02118584|NO_INTERVENTION|Part 2: Safety Monitoring|All participants from Part 1 (OLE), participants whose PML follow-up is not completed within the Phase II OLE study, and participants transferring from the Phase III double-blind studies after the 12-week safety follow-up will be monitored for PML (92 weeks).
62832757|NCT00912197|EXPERIMENTAL|Oligofructose|Participants received 10g of Oligofructose powdered supplements in sachets each containing 10 g dietary fiber) three times per day. Volunteers were instructed to take the supplement with their main meals.The 8-week supplementation period took place between visits 3 and 4 and included a 2-week run-in period to allow the bowel to adapt to the 30 g of dietary fiber.
62832758|NCT00912197|PLACEBO_COMPARATOR|Cellulose and maltodextrin|Participants received 10g of Cellulose powdered supplements in sachets each containing 10 g dietary fiber) three times per day. Volunteers were instructed to take the supplement with their main meals. Maltodextrin was added to the cellulose supplement. The 8-week supplementation period took place between visits 3 and 4 and included a 2-week run-in period to allow the bowel to adapt to the 30 g of dietary fiber.
62832759|NCT04255238|EXPERIMENTAL|Gemigliptin 50 mg and Dapagliflozin 10 mg|"* Subject shoud took 1 tablet of Gemigliptin 50 mg and 1 tablet of Dapagliflozin 10 mg per day~* Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day"
62832760|NCT04255238|ACTIVE_COMPARATOR|Gemigliptin 50 mg and Dapagliflozin placebo|"* Subject shoud took 1 tablet of Gemigliptin 50 mg and 1 tablet of Dapagliflozin placebo per day~* Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day"
62832761|NCT04255238|ACTIVE_COMPARATOR|Gemigliptin placebo and Dapagliflozin 10mg|"* Subject shoud took 1 tablet of Gemigliptin placebo and 1 tablet of Dapagliflozin 10 mg per day~* Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day"
62832762|NCT02844569|EXPERIMENTAL|Test|Extraction treated with xenograft bone substitute (BioOss Collagen®) + 3D-collagen matrix (Mucograft Seal®).
62832763|NCT02844569|ACTIVE_COMPARATOR|Control|Extraction treated with xenograft bone substitute (BioOss Collagen®) + collagen dressing (HeliPlug®).
62832764|NCT04693819||Hyperacusis|Abnormally reduced tolerance to sound
62832765|NCT05087004|EXPERIMENTAL|Teen Council Pogram|Teens assigned to the intervention group received a 1-year long Teen Council Program.
62832766|NCT05087004|NO_INTERVENTION|Control Group|Teens assigned to the control group did not receive any intervention.
62832767|NCT00400166|EXPERIMENTAL|1|Recovery Mentor: peer-based supportive care
62832768|NCT00400166|NO_INTERVENTION|0|No Recovery Mentor, services as usual
62832769|NCT01590355|ACTIVE_COMPARATOR|Radiotherapy plus or minus Chemotherapy|Radiotherapy plus or minus chemotherapy with surgical treatment for salvage of persistent disease
62832770|NCT01590355|EXPERIMENTAL|Transoral Robotic Surgery + Neck Dissection|Transoral robotic excision will be carried out using the da Vinci surgical robot. The spatula cautery will be used to remove the tumours with 1 cm margins. At the time of surgery circumferential margins will be taken and sent for frozen section analysis. The resection will proceed until negative margins are obtained if feasible.
62832771|NCT01498068|EXPERIMENTAL|Treatment-naïve|Treatment naïve participants will receive telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual ontreatment virologic response in this study.
62832772|NCT01498068|EXPERIMENTAL|Treatment-experienced|Treatment-experienced participants received telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual on-treatment virologic response in this study.
62832773|NCT00638677|PLACEBO_COMPARATOR|1|Sorbitol tablet
62832774|NCT00638677|PLACEBO_COMPARATOR|2|Xylitol tablet
62832775|NCT00638677|ACTIVE_COMPARATOR|3|Xylitol + BB12 tablet
62832776|NCT01544257|EXPERIMENTAL|OMT|patients under standard medical care plus OMT.
62251574|NCT05281796||gingivitis patient|Full-mouth clinical periodontal measurements recorded, saliva and GCF obtained
62610128|NCT00323037|ACTIVE_COMPARATOR|1|
62832777|NCT01544257|NO_INTERVENTION|Control|patients under standard medical care plus only osteopathic evaluation
62832778|NCT01765933|EXPERIMENTAL|DMAA|Single oral dose 25 mg DMAA
62832779|NCT02839200|EXPERIMENTAL|ACT-541468 5 mg|Each subject receives one 5-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks
62832780|NCT02839200|EXPERIMENTAL|ACT-541468 10 mg|Each subject receives one 10-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks
62832781|NCT02839200|EXPERIMENTAL|ACT-541468 25 mg|Each subject receives one 25-mg ACT-541468 capsule (+ one placebo capsule), once daily in the evening) for 4 weeks
62832782|NCT02839200|EXPERIMENTAL|ACT-541468 50 mg|Each subject receives two 25-mg ACT-541468 capsules, once daily in the evening for 4 weeks
62610129|NCT00323037|ACTIVE_COMPARATOR|2|
62049625|NCT02611739|EXPERIMENTAL|Intervention Group|"Children in the experimental treatment condition will sit in front of the nurse and beside (or on the lap) of a parent. Medi-Port (humanoid robot) will be positioned beside the child (at eye-level) and will execute a pre-programmed series of behaviours to distract the child before, during, and after the SCP needle insertion. The nurse will insert the needle according to hospital procedures, using minimal distraction (e.g., What's on TV?). The estimated time for port procedures and completion of the needle insertion will range from 10-30 minutes. The total estimated time which includes the completion of surveys and questionnaires on the pain intensity of the SCP needle insertion procedure and acceptability of Medi-port will be approximately 1 hour. There will be no follow-up visits."
62441285|NCT01211769|PLACEBO_COMPARATOR|Placebo|"Naltrexone Placebo: pill with 50mg of talcum powder, identical to the pill of naltrexone;~Polyunsaturated fatty acids Placebo (PUFAs Placebo): yellow liquid paraffin identical to the pills of borage seed and fish oil."
62049626|NCT02611739|ACTIVE_COMPARATOR|Control Group|"Following consent and randomization, children in the (control) usual care condition will sit in front of the nurse and beside (or on the lap) of a parent. Medi-Port (humanoid robot) will be positioned beside the child (at eye-level) and will execute a standard set of dancing movements only. The nurse will insert the needle according to hospital procedures, using minimal distraction (e.g., What's on TV?). The estimated time for port procedures and completion of the needle insertion will range from 10-30 minutes. The total estimated time which includes the completion of surveys and questionnaires on the pain intensity of the SCP needle insertion procedure and acceptability of Medi-port will be approximately 1 hour. There will be no follow-up visits."
62049627|NCT01949311|EXPERIMENTAL|Dupilumab|Participants will receive repeat doses of dupilumab
62251575|NCT05281796||patients with Stage III periodontitis|Full-mouth clinical periodontal measurements recorded, saliva and GCF obtained
62251576|NCT05060705|EXPERIMENTAL|Efesovir|The patients of experimental arm take study drug Efesovir twice a day as an antiviral therapy in dose 0.125 ml / kg. Daily dose of Efesovir: 0.250 ml / kg. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
62251577|NCT05060705|ACTIVE_COMPARATOR|Remdesivir|"The patients are treated with the antiviral drug Remdesivir in dose 200 mg intravenously on the 1st day, then by 100 mg intravenously daily for 5 - 10 days, depending on the severity of the disease."
62251578|NCT04903925|EXPERIMENTAL|Group 1|All patients will undergo an impacted tooth extraction; patients allocated to group 1 will receive an antibiotic therapy with amoxicillin for 6 days (2 g/day) and a probiotic for 21 days (2 tablets/day).
62441286|NCT01211769|OTHER|Naltrexone + PUFAs|"Polyunsaturated fatty acids (PUFAs): borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram; along with 1 gram of fish oil - rich in omega 3 PUFA;~Naltrexone chlorhydrate 50 mg"
62610130|NCT05797155|EXPERIMENTAL|CoQuit App - Cognitive Dissonance Based Smoking Cessation|This group will receive daily smoking cessation tips and will be asked to complete activities within the app that are designed to induce cognitive dissonance, create and share videos related to the activities with an online group, and provide support to other group members
62610131|NCT05797155|ACTIVE_COMPARATOR|Comparison App - Smoking Cessation Support without Cognitive Dissonance Activities|This group will use an app that consists of tips for quitting cigarettes but does not include the cognitive dissonance component.
62610132|NCT00425893|ACTIVE_COMPARATOR|1|health education
62610133|NCT00425893|EXPERIMENTAL|2|hand hygiene
62610134|NCT00425893|EXPERIMENTAL|3|masks and hand hygiene
62610135|NCT05611996|OTHER|Peer support|Peer mentors who have experienced depression provide social support through video chats and texting for 8 weeks.
62610136|NCT05035225|EXPERIMENTAL|Specialty Pharmacy Patient|Patients who have been prescribed at least one selected specialty medication
62610137|NCT05995249|EXPERIMENTAL|Part 1, Treatment A + Treatment B: TAK-279 50 mg + Erythromycin 500 mg|Participants will receive single oral dose of TAK-279 50 mg, on Day 1 of Period 1. Following Period 1 participants will receive single oral dose of TAK-279 50 mg, on Day 5 and erythromycin 500 mg orally thrice daily (TID) on Day 1 through Day 10 of Period 2 in Part 1 of the study.
62610138|NCT05995249|EXPERIMENTAL|Part 2, Treatment C + Treatment D: TAK-279 50 mg + Phenytoin 100 mg|Participants will receive single oral dose of TAK-279 50 mg, on Day 1 of Period 1. Following Period 1 participants will receive single oral dose of TAK-279 50 mg on Day 14 and phenytoin 100 mg orally TID on Day 1 through Day 18 of Period 2 in Part 2 of the study.
62610139|NCT05995249|EXPERIMENTAL|Part 3, Treatment E + Treatment F: TAK-279 50 mg + Efavirenz 600 mg|Participants will receive single oral dose of TAK-279 50 mg, on Day 1 of Period 1. Following Period 1 participants will receive single oral dose of TAK-279 50 mg on Day 11 and efavirenz 600 mg orally once daily (QD) on Day 1 through Day 15 of Period 2 in Part 3 of the study.
62610140|NCT05070468|ACTIVE_COMPARATOR|Group A|Prescribing Vaginally Dexamethasone tablets to the Group A
62049628|NCT03791580|EXPERIMENTAL|Commitment nudge|Primary care clinicians in the practice assigned to this arm will receive only the commitment nudge.
62049629|NCT03791580|EXPERIMENTAL|Justification nudge|Primary care clinicians in the practice assigned to this arm will receive only the justification nudge.
62049630|NCT03791580|EXPERIMENTAL|Commitment + Justification nudges|Primary care clinicians in the practice assigned to this arm will receive both the commitment nudge and the justification nudge.
62441287|NCT00225199|EXPERIMENTAL|Arm 1|
62441288|NCT00225199|PLACEBO_COMPARATOR|Arm 2|
62441289|NCT05338086|EXPERIMENTAL|MB09-MB09|Subjects randomised into MB09-MB09 group will receive MB09 (60 mg in 1 mL) SC injection every 6 months.
62610141|NCT05070468|PLACEBO_COMPARATOR|Group B|Prescribing Vaginally placebo tablets to the Group B
62610142|NCT03514979|EXPERIMENTAL|AAV patients treated with rituximab|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
62049631|NCT03791580|NO_INTERVENTION|Non-participating|Primary care clinicians in Northwestern-affiliated practices other than the 3 pilot-participating practices will not receive any study interventions.
62049632|NCT04051164|EXPERIMENTAL|Progressive Muscle Relaxation Technique|Progressive muscle relaxation technique
62049633|NCT04051164|ACTIVE_COMPARATOR|Conventional treatment|Conventional Treatment: (Strengthening exercises of residual limb, Gait training, Deep Breathing exercise)
62610143|NCT03514979|EXPERIMENTAL|AAV patients - never received rituximab|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
62610144|NCT03514979|EXPERIMENTAL|Healthy controls|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
62251579|NCT04903925|PLACEBO_COMPARATOR|Group 2|All patients will undergo an impacted tooth extraction; patients allocated to group 1 will receive an antibiotic therapy with amoxicillin for 6 days (2 g/day) and a placebo of the probiotic for 21 days (2 tablets/day).
62610145|NCT01190111|EXPERIMENTAL|CYT107 (r-hIL-7)|
62251580|NCT03171844|EXPERIMENTAL|Skin to skin|Implement of skin to skin
62610146|NCT00437372|EXPERIMENTAL|Sunitinib plus Radiation|Sunitinib plus Radiation
62832783|NCT02839200|ACTIVE_COMPARATOR|Zolpidem|Each subject receives one 10-mg zolpidem capsule (+ one placebo capusle), once daily in the evening for 4 weeks
62832784|NCT02839200|PLACEBO_COMPARATOR|Placebo|Each subject receives two placebo capsules, once daily in the evening for 4 weeks
62832785|NCT01213472|EXPERIMENTAL|NY-ESO 1 Group|Patients with non-operable and progressing metastatic cutaneous melanoma, received up to 24 doses of GSK2241658A Cancer Immunotherapeutic, provided that at each tumor evaluation time point, the clinical criteria to continue the treatment were met, including patients having a clinical response.
62832786|NCT01238926|EXPERIMENTAL|PD vitamin supplementation|
62832787|NCT01238926|EXPERIMENTAL|PD exercise intervention|
62049634|NCT02925910|OTHER|softwheels at second round|Begining with regular wheelchair for 2 days and then changing for shock absorbing wheelchair for 2 days
62049635|NCT02925910|OTHER|softwheels at first round|starting with Shock absorbing wheelchair for 2 days and then changing for regular wheelchair for 2 days
62049636|NCT02703350|EXPERIMENTAL|LY900014 - Test (Part A)|Individualized doses of LY900014 administered by injection under the skin once in each of 3 periods
62049637|NCT02703350|ACTIVE_COMPARATOR|Insulin Lispro - Reference (Part A)|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
62049638|NCT02703350|EXPERIMENTAL|LY900014 - Test (Part B)|Individualized doses of LY900014 administered by injection under the skin immediately before each meal for 14 days
62251581|NCT05345535|EXPERIMENTAL|Study group|Participants of study group will perform 45 minutes of trampoline exercises. Evaluations are going to be done immediately before and after trampoline session.
62251582|NCT05345535|EXPERIMENTAL|Control group|Participants of control group will perform 45 minutes of walking. Evaluations are going to be done immediately before and after walking session.
62251583|NCT04863079|EXPERIMENTAL|Pembrolizumab for Postoperative Adjuvant Treatment of ESCC|Participants receive pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance as postoperative adjuvant treatment of ESCC with pN+.
62251584|NCT01700270|EXPERIMENTAL|dovitinib (TKI258)|dovitinib, 5 days on / 2 days off dose schedule
62610147|NCT05760300|EXPERIMENTAL|Group A: Bulevirtide (BLV), Severe Renal Impaired Participants|"Participants with severe renal impairment will receive BLV 2 mg once daily for 6 days.~Following completion and evaluation of pharmacokinetics (PK) and safety data from all participants in Group A, additional participant groups (Groups B, C, and D) and BLV doses (2 mg or 10 mg) may be initiated."
62610148|NCT05760300|EXPERIMENTAL|Group A: BLV, Normal Renal Function (Matched Control Participants)|"Participants with normal renal function will receive BLV 2 mg once daily for 6 days.~Following completion and evaluation of PK and safety data from all participants in Group A, additional participant groups (Groups B, C, and D) and BLV doses (2 mg or 10 mg) may be initiated."
62610149|NCT06731439|EXPERIMENTAL|Early feeding arm|
62610150|NCT06731439|ACTIVE_COMPARATOR|Control arm|
62610151|NCT04935086||MACE Group|MACE Group includes the patients suffered from any component of MACE after RA-CABG until the latest follow-up.
62610152|NCT04935086||Non-MACE Group|Non-MACE Group includes the patients freed from any component of MACE after RA-CABG until the latest follow-up.
62610153|NCT05671419|EXPERIMENTAL|Mindful Self-Compassion|Mindful Self-Compassion (MSC) is a weekly class given for 8 weeks. The individual classes last about 2 hours each. The class is provided in a group setting.
62610154|NCT05671419|NO_INTERVENTION|Treatment as Usual (TAU)|The TAU arm will not receive the additional treatment from the study. Subjects will receive psychiatric treatment from their usual providers.
62610155|NCT04480567|EXPERIMENTAL|Dose 1 of BMN 307|
62610156|NCT04480567|EXPERIMENTAL|Dose 2 of BMN 307|
62610157|NCT04480567|EXPERIMENTAL|Dose 3 of BMN 307|
62610158|NCT01097070|EXPERIMENTAL|Bevirimat 200 mg twice daily, 15 days|
62049639|NCT02703350|ACTIVE_COMPARATOR|Insulin Lispro - Reference (Part B)|Individualized doses of insulin lispro reference formulation administered by injection under the skin immediately before each meal for 14 days
62610159|NCT01097070|EXPERIMENTAL|Bevirimat 300 mg once daily, 15 days|
62610160|NCT01097070|EXPERIMENTAL|Bevirimat 400 mg once daily, 15 days|
62610161|NCT05666921||Pediatric patients|The group is made up of pediatric patients, and an accompanying caregiver, belonging to the functional chronic pain clinic of Pain Therapy and Palliative Care, to the Gastroenterology and Nutrition Unit, to the Bronchopneumology Unit and Medical Pediatrics as well as to the Pediatric Psychology Unit, who present with somatic symptom disorders.
62832788|NCT01238926|EXPERIMENTAL|PD vitamin + exercise|
62832789|NCT01238926|NO_INTERVENTION|PD control|
62832790|NCT02875236|PLACEBO_COMPARATOR|Control|Ringer-acetat
62832791|NCT02875236|ACTIVE_COMPARATOR|Intervention|OctaplasLG®
62832792|NCT00756899||Obese|Chilren with BMI of \>95th percentile
62832793|NCT00756899||Non-obese|Children with BMI of \<85th percentile
62610162|NCT05666921||Control group|The population of the control group, recruited through informal channels according to a sampling of convenience, will be enrolled on the basis of the expected inclusion criteria.
62610163|NCT05563506|EXPERIMENTAL|Healthy Kids +|Three times a week for 30 weeks with each session lasting 1 hour.
62049640|NCT01826812||Dry Eye|"The patients with Sjogren Syndrome related or non-Sjogren Syndrome related dry eye. The participants will be asked some questions. Before and after reading a text silently in 30 minutes 30 minutes sustained reading, a detailed dry eye exam will be performed."
62049641|NCT01826812||Controls|"The patients without dry eye. The participants will be asked some questions. Before and after reading a text silently in 30 minutes 30 minutes sustained reading, a detailed dry eye exam will be performed."
62049642|NCT02863484|ACTIVE_COMPARATOR|Conventional surgery intra-dural|This arm will be surgically operated by direct attack of the tumour after opening the dura
62049643|NCT02863484|EXPERIMENTAL|Pealing surgery extra-dural|This arm the pealing of the outer layer of the lateral wall of the cavernous sinus will be done before the dura is opened. After the pealing is completed, the middle meningeal artery will be divided at the foramen spinosum. Then, the dura will be opened and the tumour attacked.
62049644|NCT04873648|EXPERIMENTAL|food addiction and binge eating follow caloric reduced -intermitted fasting diet|Obese women diagnosed with binge eating disorder and food addiction follow caloric reduced -intermitted fasting diet
62832794|NCT01658436|EXPERIMENTAL|BEZ235 300 mg/400 mg bid (Stage 1)|Stage 1 consisted of a single arm where patients received BEZ235 300mg or 400mg bid. Initially the study started with a dose of 400mg bid. However, following an amendment after the preliminary safety and tolerability data from the first 3 patients treated at the 400mg dose, the dosage was changed to 300mg bid.
62832795|NCT05021406|EXPERIMENTAL|Carvedilol+ NUCs therapy|Patients randomized to Carvedilol combined with NUCs group during the previous 2-year treatment of RCT study; Patients showed the progression of esophageal varices in NUCs group during the 2-year treatment of RCT study. Based on nucleoside analogue (NUCs), carvedilol will be added to the patients. Carvedilol is started at a dose of 6.25 mg once per day, and will increase to a dose of 12.5 mg once per day after 1 week. Target dose will be maintained at 12.5 mg once per day if patients with systolic blood pressure not lower than 90 mm Hg and HR no less than 50 beats/min.
62049645|NCT04873648|ACTIVE_COMPARATOR|food addiction and binge eating follow caloric restriction diet|Obese women diagnosed with binge eating disorder and food addiction follow caloric restriction diet
62049646|NCT04873648|EXPERIMENTAL|binge eating disorder follow follow caloric reduced -intermitted fasting diet|Obese women diagnosed with binge eating disorder follow caloric reduced -intermitted fasting diet
62049647|NCT04873648|ACTIVE_COMPARATOR|binge eating disorder follow caloric restriction diet|Obese women diagnosed with binge eating disorder follow a caloric restriction diet
62049648|NCT04873648|PLACEBO_COMPARATOR|obese women without food addiction and binge eating follow caloric restriction diet|Obese women without eating disorder follow a caloric restriction diet
62049649|NCT05845268|EXPERIMENTAL|CRT+concurrent PD-1 inhibition|Long-course chemoradiation plus PD-1 inhibition (Tislelizumab 200mg, 3 times, 3-week interval) starting on Day 8 of radiation therapy. TME surgery is scheduled in 10\~13 weeks after completion of radiation.
62049650|NCT05845268|ACTIVE_COMPARATOR|CRT without PD-1 inhibition|Long-course chemoradiation plus PD-1 inhibition with no PD-1 inhibition. TME surgery is scheduled in 10\~13 weeks after completion of radiation.
62049651|NCT05541055|EXPERIMENTAL|Digital CBT-I|Digitally-delivered CBT for insomnia accessed via web and/or mobile app
62049652|NCT05541055|ACTIVE_COMPARATOR|Sleep hygiene education|This group will receive access to sleep hygiene education delivered via digital written materials
62610164|NCT00673725|EXPERIMENTAL|1|
62610165|NCT03493022|EXPERIMENTAL|Test Granola|50.5 g Test Granola
62610166|NCT03493022|PLACEBO_COMPARATOR|Control Granola|54.3 Control Granola
62251585|NCT04973579||Simultaneous cardiac surgery and carotid stenting|Patients with Heart Team and NeuroVascular Team recommendation to perform simutaneous (single anaesthesia) carotid artery stenting with MicroNet covered stent (CGuard) including proximal or distal neuroembolic protection and cardiac surgery (CABG or surgical valve replacement / repair procedure)
62610167|NCT06731660|EXPERIMENTAL|Education with personalized performance feedback|Education about proper otitis media diagnosis following criteria from the American Academy of Pediatrics with personalized performance feedback on otitis media diagnosis and treatment rates delivered via email
62832796|NCT05021406|NO_INTERVENTION|NUCs therapy|Continuing take single or combined nucleoside analogue (NUCs) including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).
62610168|NCT06731660|EXPERIMENTAL|Use of digital otoscope|Use of the Wispr digital otoscope to diagnose otitis media in place of a traditional visual otoscope
62049653|NCT04137848|EXPERIMENTAL|Experimental|Osteopathic Manipulative Treatment (OMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT) Osteopathic Manipulative Treatment (OMT) is manipulative therapy that was performed once a week along 30 days.
62049654|NCT04137848|SHAM_COMPARATOR|Control|Sham Osteopathic Manipulative Treatment (SOMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT) Osteopathic Manipulative Treatment (OMT) is manipulative therapy that was performed once a week along 30 days.
62049655|NCT06578884||877PTY|100 patients/eyes implanted with 877PTY IOL
62832797|NCT05849493|EXPERIMENTAL|IU-ICBT|10 week program of internet delivered cognitive behavior therapy with written support by licensed clinical psychologist. Based on the Intolerance of uncertainty model of worry.
62832798|NCT05849493|EXPERIMENTAL|Meta-ICBT|10 week program of internet delivered cognitive behavior therapy with written support by licensed clinical psychologist. Based on the Metacognitive model of worry.
62049656|NCT03288610||With inflammatory response|"Patients with postoperative inflammatory response as defined by the occurrence of severe SIRS and/or postoperative vasodilation syndrome.~Severe SIRS is defined by meeting at least 2 SIRS criteria during 6 consecutive hours or at least 3 SIRS criterias. Classical SIRS criteria include: temperature \>38,3 or \<36°C, heart rate \>90/min, respiratory rate \>20/min or PaCO2 \<32mmHg, GB\>12000 ou \<4000 c/mm3.~Postoperative vasodilation syndrome is defined by the need of continuous infusion of norepinephrine (whatever the dose) to maintain the mean arterial pressure above 60 mmHg associated to a cardiac index above or egal to 2.2 L/min/m2.~Patients without postoperative severe SIRS and without postoperative vasodilation syndrome"
62049657|NCT05180292|EXPERIMENTAL|Acute on Chronic Liver failure|
62049658|NCT05130879|EXPERIMENTAL|BRAW intervention group|BRAW is designed as an online intervention comprising of six sessions over six weeks. The six sessions are: (1) happiness and positivity, (2) cognitive restructuring, (3) behavioural activation, (4) emotion regulation, (5) positive work climate and (6) problem solving.
62049659|NCT05130879|NO_INTERVENTION|Waitlist control group|Participants will receive the intervention after the follow-up assessment.
62049660|NCT03255824|ACTIVE_COMPARATOR|Propofol Group|Group of patients to be administered a standard Propofol, Midazolam, Fentanyl anesthesia combination.
62049661|NCT03255824|EXPERIMENTAL|Dexmedetomidine Group|Group of patients to be administered the Dexmedetomidine and Midazolam anesthesia combination.
62832799|NCT01881828|EXPERIMENTAL|Metformin|Metformin 2000 mg per day
62832800|NCT01881828|PLACEBO_COMPARATOR|Oral Placebo|"A central pharmacy will compound a placebo to match the metformin tablets.~The placebo product will contain the following components:~* Micosolle™, silica based excipient~* Silicified Micro Crystalline Cellulose, National Formulary~* Safflower Oil, United States Pharmacopeia~* K-30 Povidone Powder~* Magnesium Stearate, National Formulary (Vegetable source)~* Fumed Silica, National Formulary"
62049662|NCT05204810|EXPERIMENTAL|Night_1dosis|"* anticoagulation at dialysis start~* blood sampling 5min after start dosis, and at 1h, 4h and 8h after dialysis start~* microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62049663|NCT05204810|EXPERIMENTAL|Night_2doses|"* anticoagulation split over dialysis start and halfway dialysis (after 4h)~* blood sampling 5min after start dosis, and at 1h, 4h (1 sample before and 1 sample after the extra anticoagulant dosis) and 8h after dialysis start~* microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62049664|NCT02219893|EXPERIMENTAL|MOC31PE Immunotoxin|Drug to be instilled on day 1 after cytoreductive surgery and HIPEC.
62049665|NCT05374902|EXPERIMENTAL|Procedural informational animation group|Children and parents have watched procedural informational animation before venipuncture. Afterward, the children and their parents entered the blood drawn unit, and the procedure was performed as in standard care.
62049666|NCT05374902|EXPERIMENTAL|Buzzy group|Buzzy® was placed on the injection site and cold application and vibration were turned on 60 s before the procedure. Then, the nurse moved Buzzy® about 3-5 cm above the injection site. The procedure was performed with buzzy®. The Buzzy® intervention and phlebotomy were terminated at the same time.
62441290|NCT05338086|ACTIVE_COMPARATOR|Prolia-MB09|Subjects randomised into Prolia- MB09 group will receive Prolia® (60 mg in 1 mL) SC injection every 6 months.
62441291|NCT05338086|ACTIVE_COMPARATOR|Prolia-Prolia|Subjects randomised into Prolia-Prolia group will receive Prolia® (60 mg in 1 mL) SC injection every 6 months.
62441292|NCT01930084|EXPERIMENTAL|Combination intervention + incentives|"1. Point of care CD4+ after HIV diagnosis~2. Accelerated ART initiation~3. SMS appointment reminders~4. Non-cash financial incentives (FI)"
62441293|NCT01930084|EXPERIMENTAL|Combination intervention strategy(CIS)|"1. Point of care (POC) CD4+ after HIV diagnosis~2. Accelerated ART initiation~3. SMS appointment reminders"
62832801|NCT04866784|EXPERIMENTAL|High Sensation TENS|"Active TENS is delivered for 30mins at a frequency of 100 Hz and pulse duration of 100μsec using the EMPI Select TENS unit (calibrated using an oscilloscope prior to study). The intensity will be increased until patients feel a maximally strong but comfortable sensation to ensure an analgesic effect."
62832802|NCT04866784|PLACEBO_COMPARATOR|Low Sensation TENS|Placebo TENS parameters will be identical to Active TENS (100 Hz and 100 μsec), but a novel placebo TENS unit, previously tested and validated will be used (Rakel et al., 2010). The placebo device provides a current for 30sec and ramps off over 15sec to zero output. An indicator light remains on so it appears to the subject that the unit is still producing current. This unit has demonstrated nearly 100% blinding of investigators such that the investigator applying the TENS is unable to distinguish between the active and the placebo unit; approximately \~50% of subjects are successfully blinded using this unit.
62832803|NCT04866784|NO_INTERVENTION|No Treatment Control|The No Treatment Control includes application of TENS electrodes identical to the other 2 conditions, but the unit remains off. This condition will control for potential effects of repeat testing and any placebo effect.
62832804|NCT05287906|EXPERIMENTAL|Normal Weight Group|The normal weight group incudes men and women with BMI 18.5 - 24.9 kg/m2, and will receive all interventions.
62832805|NCT05287906|EXPERIMENTAL|Overweight Group|The overweight group includes men and women with BMI 25.0 - 29.9 kg/m2, and will receive all interventions.
62832806|NCT05287906|EXPERIMENTAL|Type 2 Diabetes Mellitis Group|The T2DM group includes men and women with BMI 25.0 - 34.9 kg/m2, HbA1c \<8%, and will receive all interventions.
62832807|NCT04135417|EXPERIMENTAL|HAV|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. HAV for this study will be manufactured using the commercial manufacturing system.It will be implanted in the forearm or upper arm using standard vascular surgical techniques. All subjects will be required to start taking daily aspirin (75 or 325 mg) on Day 1 after surgical implantation of HAV unless they are already taking another antiplatelet agent. If low molecular weight heparin (LMWH) is administered post-operatively, aspirin or other antiplatelet agents should be initiated after stopping LMWH. Subjects who are known to be aspirin-sensitive should take another antiplatelet agent at the discretion of the Principal Investigator.
62832808|NCT01017302|EXPERIMENTAL|1|
62832809|NCT01017302|PLACEBO_COMPARATOR|2|
62832810|NCT01017302|EXPERIMENTAL|3|
62832811|NCT01017302|PLACEBO_COMPARATOR|4|
62832812|NCT02892344|EXPERIMENTAL|QMF149 150/80 μg|QMF149 150/80 microgram o.d. delivered via Concept1
62832813|NCT02892344|ACTIVE_COMPARATOR|MF 200 µg|MF 200 microgram o.d. delivered via Twisthaler®
62832814|NCT02074501|OTHER|training capacity in caregivers|"The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put hands on caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge; (iii) using telephone support, counselling caregivers on 3rd, 6th, 8th and 10th weeks post discharge. It aims at facilitating the caregivers 'adjustment to stroke demands, increasing knowledge and practical skills to support their decision-making."
62832815|NCT01745458|EXPERIMENTAL|SB-659032|250 mg non-enteric coated SB-659032
62832816|NCT01745458|PLACEBO_COMPARATOR|Placebo|matched placebo QD for 14 days
62832817|NCT04284228|EXPERIMENTAL|Safety Evaluation Phase|Treatment with NEXI-001 T cells, derived from PBMCs of original HLA- matched HCT donor.
62049667|NCT05374902|EXPERIMENTAL|Multiple interventions group|Children and parents have watched procedural informational animation before venipuncture. Afterward, the children and their parents entered the blood drawn unit. Buzzy® was placed on the injection site and cold application and vibration were turned on 60 s before the procedure. Then, the nurse moved Buzzy® about 3-5 cm above the injection site. The procedure was performed with buzzy®. The Buzzy® intervention and phlebotomy were terminated at the same time.
62049668|NCT05374902|NO_INTERVENTION|Control group|Children in this group received standard care. A local anesthetic is not used, and the parents are with their children during the procedure in the standard care of the blood collection unit
62049669|NCT01258634|OTHER|Pre-op treatment|
62049670|NCT05181852|EXPERIMENTAL|IP2015_dose 1|Active
62049671|NCT05181852|EXPERIMENTAL|IP2015_dose 2|Active
62049672|NCT05181852|PLACEBO_COMPARATOR|Placebo|Placebo
62251586|NCT05328726|EXPERIMENTAL|Drug:GZR-18 administered via subcutaneous injection|For Assigned Interventions: GZR-18 administered once via subcutaneous injection at doses of 1.0 ug/kg, 5.0 ug/kg, 10.0 ug/kg, 20.0 ug/kg, 30.0 ug/kg, 40.0 ug/kg \& 50.0 ug/kg
62441294|NCT01930084|NO_INTERVENTION|Standard of care (SOC)|Standard of care, no intervention
62441295|NCT01467063|ACTIVE_COMPARATOR|Glutamine|
62441296|NCT01467063|PLACEBO_COMPARATOR|Placebo|
62832818|NCT04284228|EXPERIMENTAL|Dose Expansion Phase|Dose Expansion Phase to further define the safety, tolerability and initial anti-tumor efficacy of the NEXI-001 T cell product at the dose established from the Safety Evaluation Phase.
62832819|NCT01829958|EXPERIMENTAL|Pre-Phase Arm|They will be treated with a single dose of rituximab 375mg/m2, once, by intravenous infusion 3-10 days prior to initiation of planned R-CHOP-like chemoimmunotherapy, and prednisone 50mg to 100 mg (preferred dose is 100mg) PO daily for 5-7 days (preferred duration is 7 days) of the 14 days prior to initiation of planned R-CHOP, R-EPOCH or R-CEPP chemoimmunotherapy. Pre-phase therapy may be given in either the inpatient or outpatient setting. After completion of a single course of pre-phase rituximab and prednisone as described above, further treatment will be according to the choice of the attending physician, in accordance with appropriate medical practice. It is expected, based on the inclusion criteria, that patients enrolled on the pre-phase arm will most often receive initial therapy consisting of R-CHOP, R-EPOCH or RCEPP chemoimmunotherapy for ≥ 2 cycles, but alternative therapies as deemed appropriate by the treating physician will not be considered violations of this protocol.
62832820|NCT01829958|EXPERIMENTAL|Geriatric Assessment (GA) only arm|Patients enrolled on the GA only arm of the study will be treated according to the choice of the attending physician. This arm of the study is non-therapeutic.
62832821|NCT00926770||Pretem infants (GG < 37+0)|
62049673|NCT05181852|ACTIVE_COMPARATOR|Pregabalin|Comparator
62049674|NCT02732379|EXPERIMENTAL|Lavender Aromatherapy|Aromatherapy with lavender essential oil.
62049675|NCT02732379|EXPERIMENTAL|Rose Aromatherapy|Aromatherapy with rose essential oil
62049676|NCT02732379|EXPERIMENTAL|Ginger Aromatherapy|Aromatherapy with ginger essential oil
62049677|NCT02732379|PLACEBO_COMPARATOR|Placebo Aromatherapy|Aromatherapy with pure water
62049678|NCT03786861|ACTIVE_COMPARATOR|42 eyes in aberration free group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing aberration free in aberration free group provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
62049679|NCT03786861|ACTIVE_COMPARATOR|24 eyes in corneal WFG group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing corneal WFG patterns in corneal WFG group provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
62049680|NCT01490502|ACTIVE_COMPARATOR|Low-dose vitamin D3|
62049681|NCT01490502|ACTIVE_COMPARATOR|High-dose vitamin D3|
62049682|NCT06459648||Patients with migraine under treatment with monoclonal antibodies against CGRP|Patients with diagnosis of episodic or chronic migraine who, under the criteria of their neurologist and according to the clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (Galcanezumab, Fremanezumab, Eptinezumab) or else its receptor (Erenumab) will be included.
62049683|NCT05753787|ACTIVE_COMPARATOR|preservatives-free dexamethasone 0.1% eye drops|
62049684|NCT05753787|PLACEBO_COMPARATOR|preserved dexamethasone 0.1% eye drops|
62049685|NCT04519086|EXPERIMENTAL|Low-dose CT for acute appendicitis in patients with BMI >30|Low-dose computed tomography (CT) vs. standard CT for diagnosing acute uncomplicated appendicitis in patients with BMI \> 30 Laparoscopic appendectomy
62049686|NCT00932776|EXPERIMENTAL|TBA|
62049687|NCT00932776|ACTIVE_COMPARATOR|Control|
62251587|NCT05328726|PLACEBO_COMPARATOR|Placebo control|Commercially obtained sterile, normal saline for injection will be used as the matching placebo. Placebo will be dosed in an identical manner to active study drug. The volume of placebo will be calculated according to body weight using active drug dose for volume calculation in order to maintain the study blind.
62251588|NCT02019225|EXPERIMENTAL|Dialysis session of at least 4.25 hours|Dialysis facilities randomized to the Intervention arm will adopt an approach of recommending that all patients who are initiating treatment with maintenance hemodialysis have a treatment session duration of at least 4.25 hours.
62251589|NCT02019225|NO_INTERVENTION|Usual care|There will be no trial-driven approach to dialysis session duration in the Usual Care arm.
62251590|NCT06194513|EXPERIMENTAL|Intervention 1: Twice a day for 1 week PIOMI|Mothers of preterm babies in this group who have oral feeding difficulties will be taught Oral Motor Intervention (PIOMI) and asked to apply it. During the applications, visual monitoring of the application will be provided via video call, and objective monitoring of the application will be provided with the PIOMI Reliability Assessment Tool.
62610169|NCT06731660|EXPERIMENTAL|Education with personalized performance feedback plus use of a digital otoscope|Education about proper otitis media diagnosis following criteria from the American Academy of Pediatrics with personalized performance feedback on otitis media diagnosis and treatment rates delivered via email plus use of the Wispr digital otoscope to diagnose otitis media in place of a traditional visual otoscope
62251591|NCT06194513|EXPERIMENTAL|Intervention 2: Once a day for 2 weeks PIOMI|Mothers of preterm babies in this group who have oral feeding difficulties will be taught Oral Motor Intervention (PIOMI) and asked to apply it. During the applications, visual monitoring of the application will be provided via video call, and objective monitoring of the application will be provided with the PIOMI Reliability Assessment Tool.
62251592|NCT06194513|NO_INTERVENTION|Control|In the control group, no extra intervention will be given to preterm babies who have difficulty in oral feeding, and oral activation will be provided only with a pacifier.
62251593|NCT01231256|EXPERIMENTAL|preventive health consultation|Half participants randomized to a one hour preventive health consultation with their own general practitioner and a follow up consultation 3 months later
62610170|NCT06731660|NO_INTERVENTION|Control|Control arm, no intervention
62049688|NCT01151800|EXPERIMENTAL|IVR group|
62049689|NCT01151800|NO_INTERVENTION|Usual care|
62049690|NCT03813238|EXPERIMENTAL|TEV-50717|administered as oral tablets at a starting dose of 6 mg once daily
62049691|NCT03813238|PLACEBO_COMPARATOR|Placebo|Matching placebo
62049692|NCT04389450|EXPERIMENTAL|PLX-PAD interval high dose|PLX-PAD will be administered via 15 IM injections (1 mL each). Each subject will be treated twice, with an interval of 1 week between treatments.
62049693|NCT04389450|EXPERIMENTAL|PLX-PAD low dose|PLX-PAD 300, single administration, second administration of placebo after 1 week.
62049694|NCT04389450|PLACEBO_COMPARATOR|Control Group A|Placebo, two administrations, 1 week apart
62049695|NCT04389450|EXPERIMENTAL|PLX-PAD high dose|PLX-PAD, single administration
62049696|NCT04389450|PLACEBO_COMPARATOR|Control Group B|Placebo, single administration
62049697|NCT00783731|EXPERIMENTAL|Low dose midazolam|
62049698|NCT02601989|EXPERIMENTAL|Tadalafil|Per oral intake of tadalafil 20 mg o.d. for six weeks
62049699|NCT02601989|PLACEBO_COMPARATOR|Placebo|Per oral intake of placebo
62049700|NCT04431193|EXPERIMENTAL|Oxytocin 4 picogram/millilitre|Oxytocin infused to maintain serum concentration of 4 picogram/millilitre
62049701|NCT04431193|EXPERIMENTAL|Oxytocin 16 picogram/millilitre|Oxytocin infused to maintain serum concentration of 16 picogram/millilitre
62049702|NCT04431193|EXPERIMENTAL|Oxytocin 64 picogram/millilitre|Oxytocin infused to maintain serum concentration of 64 picogram/millilitre
62049703|NCT04431193|EXPERIMENTAL|Oxytocin 256 picogram/millilitre|Oxytocin infused to maintain serum concentration of 256 picogram/millilitre
62049704|NCT03392584||APR|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR)
62049705|NCT03392584||APR with VRAM|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR) and subsequent reconstruction of the perineum with a vertical rectus abdominis myocutaneous flap (VRAM)
62049706|NCT06272422||total hip arthroplasty (THA)|Standard THA, the head and neck of the femur are cut.
62049707|NCT06272422||Total hip prosthesis with femoral neck preservation|A total hip replacement is performed, but the neck of the femur is preserved and the head of the femur is cut off.
62610171|NCT00096993|PLACEBO_COMPARATOR|Placebo + gemcitabine|Participants received placebo intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). In addition, participants received gemcitabine 800 mg/m\^2 intravenously on Days 1 and 8 of every 3 week cycle for up to 1 year (up to 17 treatment cycles).
62610172|NCT00096993|ACTIVE_COMPARATOR|Pertuzumab + gemcitabine|Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). Participants received pertuzumab at a loading dose of 840 mg in Cycle 1 followed by a dose of 420 mg in Cycles 2 and beyond. In addition, participants received gemcitabine 800 mg/m\^2 intravenously on Days 1 and 8 of every 3 week cycle for up to 1 year (up to 17 treatment cycles
62610173|NCT03330366|EXPERIMENTAL|Allium hookeri extract|take two capsules per day (486 mg/day) for 8 weeks
62610174|NCT03330366|PLACEBO_COMPARATOR|Placebo|take two capsules per day for 8 weeks
62049708|NCT06272422||Hip resurfacing|the head and neck of the femur are preserved.
62049709|NCT05114317||Women with Lipoedema|No interventions administered.
62049710|NCT03351855|EXPERIMENTAL|HPV-CTLs|Autologous or allogenic HPV specific cytotoxic lymphocytes
62049711|NCT04710745||Study Group|Patients in sinus rhythm without history of AF, with high risk for ischemic stroke and AF. CHA2DS2-VASc score \> 2 (for females \> 3) and with more than 3 specific criteria for inclusion.
62049712|NCT03099993|OTHER|A: Healthy volunteers|
62441297|NCT04505410|EXPERIMENTAL|Tofacitinib plus FMD group|Participants in this group with UC consuming a standard, regular low-fiber diet will be provided Tofacitinib for eight consecutive weeks with the addition of two, five-day cycles of Fast Mimicking Diet (FMD) daily meals on weeks 2 and 6.
62610175|NCT00507650|ACTIVE_COMPARATOR|Prescribed|Fluid volume and type prescribed by MD or provider.
62610176|NCT00507650|EXPERIMENTAL|Supplemental|Fluid volume and type prescribed by physician or provider plus 10 ml/kg X 5 days.
62610177|NCT06465914|EXPERIMENTAL|9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine|Participants in this arm would receive 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha). Follow-up for the study encompassed Month 7 through Month 72.
62610178|NCT06465914|PLACEBO_COMPARATOR|Placebo|Participants in this arm would receive Placebo. Follow-up for the study encompassed Month 7 through Month 72.
62610179|NCT03634241|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab IV over 30 minutes on day 1. Treatment repeat every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans and collection of blood samples throughout the trial.
62738697|NCT02516982||Screening - Paging layout|"Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:~* Section 1: Demographic information survey~* Section 2: Whooley questions~* Section 3: Edinburgh Postnatal Depression Scale~Only one question will be presented at any given time. This means that participants will have to navigate through multiple pages in order to answer all the questions."
62738698|NCT02516982||Retrospective plus momentary assessment|Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of 6 consecutive days, once a month for 6 months. During the 6 assessment days, participants will be required to complete the Edinburgh Postnatal Depression Scale, 5 momentary questions on a 5-point pictorial scale, and 2 contextual questions.
62049713|NCT03099993|OTHER|B: Patient with heamiplegia|
62049714|NCT03099993|OTHER|C: Patient with heamiplegia and constraint induced therapy|arm with constraint induced therapy (done before the protocol)
62049715|NCT04852874|EXPERIMENTAL|Ultrasound-guided Quadratus Lumborum Block|
62049716|NCT02650050|EXPERIMENTAL|Micropulsed laser photocoagulation|
62049717|NCT02650050|SHAM_COMPARATOR|Sham micropulsed laser photocoagulation|
62441298|NCT04505410|ACTIVE_COMPARATOR|Tofacitinib only group|Participants in this group with UC consuming a standard, regular low-fiber diet will be provided Tofacitinib for eight consecutive weeks.
62049718|NCT05365750||Case|"The COVID-19 case group is a random sample of individuals who are enrolled in KPCO's health plan who are cases or likely cases. These individuals may have positive antibodies to COVID-19."
62049719|NCT05365750||Control|A random stratified sample of the general KPCO membership with similar age, gender, race/ethnicity and co-morbidities as case group
62049720|NCT04864574|EXPERIMENTAL|Group 1 - Intervention|Participating children have daily access to the fruit and vegetable garden beginning Year 1.
62049721|NCT04864574|EXPERIMENTAL|Group 2 - Wait-list control (delayed intervention)|Participating children have daily access to the fruit and vegetable garden beginning Year 2.
62049722|NCT04864574|NO_INTERVENTION|Group 3 - Control|No intervention
62049723|NCT06070155|EXPERIMENTAL|Aerobic exercise three times a week|The participants will receive mild to moderate aerobic exercise for three weeks for 12 sessions.
62049724|NCT06070155|NO_INTERVENTION|No Exercise group|This group will act as a control group.
62049725|NCT02572557|EXPERIMENTAL|Spray cryotherapy using liquid nitrogen|Device: TruFreeze Spray CryoTherapy Drug: Liquid nitrogen
62049726|NCT03087344|EXPERIMENTAL|Chronic liver disease|patient who will undergo liver biopsy will undergo liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
62251594|NCT01231256|NO_INTERVENTION|Control|Controls are not offered preventive health consultations, but had questionnaires as the intervention arm
62610180|NCT06729541|EXPERIMENTAL|Guided|"In the Guided group, clinicians selected or maintained treatment based on patients' symptoms, incorporating pharmacogenomic testing. Patients underwent pharmacogenomic testing and received the results within 3 to 5 working days. Following this, drug dose adjustments or changes were made within the subsequent week (dose adjustments or changes were completed within 2 weeks of enrollment to ensure a stable dose). For schizophrenia (SCH), antipsychotic monotherapy was employed; for major depressive disorder (MDD), antidepressant monotherapy was initiated; and for bipolar disorder (BPD), mood stabilizer therapy was started with lithium or a single-agent valproic acid salt, along with regular monitoring of blood lithium levels. If symptoms remained uncontrolled after 2 to 4 weeks, consideration was given to adding a second mood stabilizer or psychiatric medication in combination with lithium or valproic acid salt.~After 10 weeks of clinical observation, patients were assessed using standar"
62610181|NCT06729541|NO_INTERVENTION|Unguided|In the Unguided group, clinicians selected or maintained treatment based on patients' symptoms, without the use of pharmacogenomic guidance. Patients underwent pharmacogenomic testing, and the results were provided at the end of the 12-week follow-up period. During the 12 weeks of clinical observation, patients were assessed using standardized scales at 4, 8, and 12 weeks. Clinical doctors adjusted the treatment plan based on the patients' clinical manifestations and assessment results at these intervals. The pharmacogenomic test report was delivered to patients at the conclusion of the 12-week follow-up period.
62832822|NCT02233517|EXPERIMENTAL|Cognitive Behavioral Therapy|"Cognitive-Behavioral Therapy for Anger and Aggression in Combat Veterans with PTSD (CBT-A) is a 12-week manualized group treatment protocol that is grounded in up-to-date research, and that specifically addresses the Energy and Drive Functions, Attention Functions, Emotion Functions, and Thought Functions that are hypothesized to underlie the limitations to Activities and Participation associated with PTSD-related anger and aggression. Each session lasts 90 minutes. The first session orients participants to the structure and philosophy of the program, provides a historical overview of PTSD, and introduces the concept of the survival mode of functioning (Chemtob et al., 1997). The remaining 11 sessions follow a standard format: 1) practice relaxation training (15-20 minutes); 2) review homework, introduce new material, and engage in group activities focused on implementing new skills and behaviors (70-80 minutes); and 3) review problems or concerns of group members."
62832823|NCT02233517|ACTIVE_COMPARATOR|Present Centered Therapy|"Present Centered Therapy (PCT) is an active, manualized treatment comparison condition for psychotherapy trials. PCT is designed to control for nonspecific factors of therapy such as contact with a trained therapist, rationale for treatment, and instillation of expectancy for therapeutic gains. The therapeutic approach was drawn from Yalom's group therapy model, which utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now. Previous large-scale randomized clinical trials of Veterans with PTSD have found reduced PTSD symptoms in the PCT comparison condition (Schnurr et al., 2003), and a survey of practice patterns within the VA suggests that similar present-focused approaches are routinely employed by VA mental health providers (Rosen et al., 2004). Consistent with recommendations in the PCT manual, training will emphasize the approach rather than specific interventions."
62049727|NCT03126825|OTHER|Conventional CI|The conventional CI group will receive the noise reduction on and off signal processing test programs. This is a within subject repeated measures design, so all subjects will receive the same testing but in a counterbalanced order.
62049728|NCT03126825|OTHER|Hybrid CI|The Hybrid CI group will receive the noise reduction on and off signal processing test programs. This is a within subject repeated measures design, so all subjects will receive the same testing but in a counterbalanced order.
62049729|NCT05132608|EXPERIMENTAL|Social Media|social media based health education program developed using Health belief model
62049730|NCT05132608|NO_INTERVENTION|Usual care|physical assessment of maternal and foetal wellbeing, screening, treatment, and receiving preventive measures
62251595|NCT01460953|EXPERIMENTAL|training intervention|Students participating in didactic training
62251596|NCT01256151|ACTIVE_COMPARATOR|Alprazolam conventional tablet|Alprazolam conventional tablet
62251597|NCT01256151|EXPERIMENTAL|Alprazolam sublingual tablet|Alprazolam sublingual tablet
62049731|NCT04858698|EXPERIMENTAL|Reduced fluoroscopy arm|Patients exposed to 20 seconds or less of fluoroscopy to implant a single chamber device with aid of ultrasound / echocardiography.
62049732|NCT04858698|ACTIVE_COMPARATOR|Conventional arm|Patients exposed to more than 20 seconds of fluoroscopy to implant a single chamber device with/without the aid of ultrasound / echocardiography.
62049733|NCT00652223|EXPERIMENTAL|1|
62049734|NCT06562894|EXPERIMENTAL|SYHX1901 dose 1|
62049735|NCT06562894|EXPERIMENTAL|SYHX1901 dose 2|
62251598|NCT02081404|ACTIVE_COMPARATOR|Esomeprazole|proton pump inhibitor
62251599|NCT02081404|PLACEBO_COMPARATOR|Placebo|placebo
62049736|NCT06562894|EXPERIMENTAL|SYHX1901 dose 3|
62049737|NCT06562894|PLACEBO_COMPARATOR|Placebo|
62049738|NCT05428605|EXPERIMENTAL|GEM patients|
62049739|NCT00614081|EXPERIMENTAL|1|Renal transplant recipients
62049740|NCT04332523|EXPERIMENTAL|Group 1: Participants with Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
62049741|NCT04332523|EXPERIMENTAL|Group 2: Participants with Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
62251600|NCT04203745|EXPERIMENTAL|Nonablative Fractional Diode Laser|Single Group - single arm study. Group was treated with Nonablative Fractional Diode Laser
62251601|NCT01316185|EXPERIMENTAL|Group 1|Low Dose for 28 days: n=4
62251602|NCT01316185|EXPERIMENTAL|Group 2|High Dose for 28 days; n=4
62610182|NCT02155075|EXPERIMENTAL|Arm 1|"Testing phase (Phase II) Arm 1 - 180 participant will be enrolled for this arm. Participants will be enrolled to undergo MIRA device imaging. Following the MIRA device imaging procedure, the optimized risk model will assign a binary result to the participant.~All participants will recive standart of care, participants with negative screening exams and a positive MIRA device imaging result will additionally undergo MRI."
62610183|NCT02155075|EXPERIMENTAL|Arm 2|Testing phase (Phase II) Arm 2 - 150 participant will be enrolled for this arm. Participants will be enrolled to undergo MIRA device imaging. Following the MIRA device imaging procedure all participants in arm 2 will be following standard of care, MIRA device imaging will NOT change their clinical path.
62610184|NCT01329432|SHAM_COMPARATOR|take care|In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing
62610185|NCT01329432|EXPERIMENTAL|InSurE|infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration
62610186|NCT04365478|EXPERIMENTAL|rSWT group|Radial Extracorporeal Shock Wave Therapy on spastic muscles of upper limb
62610187|NCT04365478|ACTIVE_COMPARATOR|Control group|conventional physiotherapy
62441299|NCT04505410|EXPERIMENTAL|Infliximab plus FMD group|Participants in this group with UC consuming a standard, regular low-fiber diet and will have initiated second line biologic therapy with infliximab with the addition of two, five-day cycles of Fast Mimicking Diet (FMD) daily meals on weeks 2 and 6.
62610188|NCT01618110|ACTIVE_COMPARATOR|Treatment Group|
62441300|NCT04505410|ACTIVE_COMPARATOR|Infliximab only|Participants in this group with UC consuming a standard, regular low-fiber diet for 8 consecutive weeks and will have initiated second line biologic therapy with infliximab
62610189|NCT01618110|SHAM_COMPARATOR|Sham group|Sham TMS coil (same noise, minimal magnetic field)
62049742|NCT04332523|EXPERIMENTAL|Group 3: Participants with Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
62441301|NCT04505410|EXPERIMENTAL|Ustekinumab plus FMD group|Participants in this group with UC consuming a standard, regular low-fiber diet and will have initiated second line biologic therapy with ustekinumab with the addition of two, five-day cycles of Fast Mimicking Diet (FMD) daily meals on weeks 2 and 6.
62441302|NCT04505410|ACTIVE_COMPARATOR|Ustekinumab only|Participants in this group with UC consuming a standard, regular low-fiber diet for 8 consecutive weeks and will have initiated second line biologic therapy with ustekinumab
62441303|NCT00634179|EXPERIMENTAL|Treatment (VR-CHOP regimen)|"INDUCTION: Patients receive bortezomib IV on days 1 and 8; rituximab IV, doxorubicin hydrochloride IV over 3-5 minutes, cyclophosphamide IV over 60 minutes, and vincristine sulfate IV over 10 minutes on day 1; and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression.~MAINTENANCE: Patients achieving complete response (CR) receive rituximab IV once every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or partial response (PR) receive rituximab IV and bortezomib once weekly for 4 weeks every 6 months for up to 2 years in the absence of disease progression or unacceptable toxicity."
62610190|NCT03557684|EXPERIMENTAL|PO leucine & IV LPS|Oral (PO) leucine 6 g twice a day for 2 weeks followed by a single intravenous (IV) bolus of lipopolysaccharide (LPS) 0.8 ng/kg of body weight
62610191|NCT03557684|EXPERIMENTAL|PO placebo & IV LPS|PO maltodextrin (placebo) twice a day for 2 weeks followed by a single IV bolus of LPS 0.8 ng/kg of body weight
62610192|NCT03557684|EXPERIMENTAL|PO leucine & IV placebo|PO leucine 6 g twice a day for 2 weeks followed by a single IV bolus of 0.9% saline
62610193|NCT03557684|PLACEBO_COMPARATOR|PO placebo & IV placebo|PO maltodextrin (placebo) twice a day for 2 weeks followed by a single IV bolus of 0.9% saline
62610194|NCT01443325|EXPERIMENTAL|lidocaine patch|
62610195|NCT01900431|PLACEBO_COMPARATOR|Placebo|Placebo (for Sarilumab) subcutaneous (SC) injection every 2 weeks (q2w) for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and \<80 mg/day as single therapy or in combination with Methotrexate (MTX) 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
62610196|NCT01900431|EXPERIMENTAL|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and \<80 mg/day as single therapy or in combination with MTX 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
62610197|NCT01192724|ACTIVE_COMPARATOR|Triple antiplatelet therapy (TAPT) group|3-month use of cilostazol in addition to dual antiplatelet agent
62610198|NCT01192724|ACTIVE_COMPARATOR|Dual antiplatelet therapy (DAPT) group|Aspirin and clopidogrel (dual antiplatelet therapy, DAPT) for 1 year
62049743|NCT04332523|EXPERIMENTAL|Group 4: Participants with Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of JNJ-53718678 suspension on Day 1.
62441304|NCT01452529|EXPERIMENTAL|Hydrocodone bitartrate|Hydrocodone bitartrate (HYD) once daily (q24h) tablets
62049744|NCT05682911|EXPERIMENTAL|Zingiber Officinale L (Ginger) treated group n=20|Ginger tablets 500mg twice a day (BD) for two month
62049745|NCT05682911|ACTIVE_COMPARATOR|Simvastatin treated group n=20|Simvastatin 20 mg tablet once a day (OD) for two month
62049746|NCT03577067||Patients submitted to liver resection|Patients underwent liver resection for primary and secondary disease
62441305|NCT01452529|PLACEBO_COMPARATOR|Placebo|Placebo to match hydrocodone bitartrate once daily tablets
62441306|NCT03980795|EXPERIMENTAL|Intervention|The intervention (I) group received monthly exercise physiologist consultations, exercise prescription (resistance and aerobic exercise program using exercise bands) and weekly phone calls over 12 weeks.
62441307|NCT03980795|NO_INTERVENTION|Control|Usual care
62610199|NCT06020196|ACTIVE_COMPARATOR|Rectus sheath block group|The participants will receive bilateral surgical rectus sheath block
62610200|NCT06020196|ACTIVE_COMPARATOR|Subdermal group|The participants will receive subdermal infiltration of local anaesthetics.
62610201|NCT01917357|EXPERIMENTAL|Quinvaxem in Uniject|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), whole-cell inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using the Uniject pre-filled injection device"
62610202|NCT01917357|ACTIVE_COMPARATOR|Quinvaxem in single dose vials|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), whole-cell inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using a needle and syringe from single dose vials"
62610203|NCT06199349|EXPERIMENTAL|GMDTC group|The subjects assigned to the GMDTC group will be administered once every morning after eating a standard breakfast on D1-D3 and D8-D10.
62610204|NCT06199349|PLACEBO_COMPARATOR|Normal saline group|The subjects assigned to the placebo group will be administered once every morning after eating a standard breakfast on D1-D3 and D8-D10.
62610205|NCT01618019|EXPERIMENTAL|N-3 PUFA|5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
62049747|NCT03205228|EXPERIMENTAL|Flupentixol + Melitracen & placebo|Deanxit® (Flupentixol + Melitracen) 5 mg/D\*4 weeks will be given
62610206|NCT01618019|PLACEBO_COMPARATOR|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
62610207|NCT04247568|EXPERIMENTAL|Hypnosis|
62610208|NCT04247568|PLACEBO_COMPARATOR|Control|
62049748|NCT03205228|ACTIVE_COMPARATOR|Proton pump inhibitor & placebo|Miracid® (Omeprazole) 20 mg/D\*4 weeks will be given
62610209|NCT03427268|EXPERIMENTAL|PM060184|PM060184
62049749|NCT03205228|ACTIVE_COMPARATOR|Psychoeducation&placebo|Psychoeducation by psychologists will be advised on Day 1 and Day 14 of the study time frame
62049750|NCT04670133|EXPERIMENTAL|Inulin|Supplementation with inulin for 4 weeks prior to and 10 weeks after sanative therapy. 10 g daily, divided into two equal doses.
62610210|NCT02348359|EXPERIMENTAL|50 mg of X-82 plus ivt anti-VEGF prn|Subject will administer one 50 mg tablet of X-82 and one placebo tablet once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
62049751|NCT04670133|PLACEBO_COMPARATOR|Placebo|Supplementation with maltodextrin (as placebo) for 4 weeks prior to and 10 weeks after sanative therapy. 10 g daily, divided into two equal doses.
62049752|NCT01670981|EXPERIMENTAL|ixmyelocel-T|Ixmyelocel-T delivered by catheter-based intramyocardial injection procedure.
62049753|NCT01670981|PLACEBO_COMPARATOR|Placebo|Placebo delivered by catheter-based intramyocardial injection procedure.
62610211|NCT02348359|EXPERIMENTAL|100 mg of X-82 plus ivt anti-VEGF prn|Subject will administer two 50 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
62610212|NCT02348359|EXPERIMENTAL|200 mg of X-82 plus ivt anti-VEGF prn|Subject will administer two 100 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
62610213|NCT02348359|PLACEBO_COMPARATOR|Placebo plus ivt anti-VEGF prn|Subject will administer two placebo tablets once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
62610214|NCT01831323||mesalazine|10 female patients with first diagnosis of SUDD will take mesalazine 1,6g per day for 14 days (1 tablet 800mg twice daily)
62610215|NCT01831323||VSL#3|10 female patients with first diagnosis of SUDD will take VSL#3 2 sachets a day for 14 days (1 sachet twice a day, for a total of 900 billion bacteria per day)
62610216|NCT01831323||Rifaximin|10 female patients with first diagnosis of SUDD will take 800mg/day of rifaximin (2 tablets of 200mg twice a day)
62610217|NCT01831323||fiber|10 female patients with first diagnosis of SUDD will take fibers for 14 days (psyllium 10grams per day)
62610218|NCT04026932|PLACEBO_COMPARATOR|Unmodified music group|34 participants in Group 1 will listen to the music without any modification for at least two hours a day in total.
62251603|NCT04049955|EXPERIMENTAL|endoscopy|In the case of a well-organized abscessed collection responsible for sepsis instability, or poorly organized collection, an external drainage is carried out, by a radiological or a surgical way. The endoscopy is performed 7 days later. If there is no hemodynamic instability and in presence of a well-organized abscessed collection, a first-line endoscopy is carried out. After laying 2 double pig tail stents, the external drainage is removed 2 to 7 days later.
62251604|NCT02882542|EXPERIMENTAL|Visible light exposure Orange 30 lux|The participants will be exposed to orange LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62251605|NCT02882542|EXPERIMENTAL|Visible light exposure Orange 120 lux|The participants will be exposed to orange LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62251606|NCT02882542|EXPERIMENTAL|Visible light exposure Cyan 30 lux|The participants will be exposed to cyan LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62251607|NCT02882542|EXPERIMENTAL|Visible light exposure Cyan 120 lux|The participants will be exposed to Cyan LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62610219|NCT04026932|EXPERIMENTAL|Modified tinnitus relieving sound group|34 participants in Group 2 will listen to the music modified according to the matched dominant tinnitus pitch for at least two hours a day in total.
62610220|NCT03248414|EXPERIMENTAL|Lactobacillus sakei|2 packs per day
62610221|NCT03248414|PLACEBO_COMPARATOR|Control|2 packs per day
62610222|NCT04369235|EXPERIMENTAL|tCES & upper extremity rehabilitation|The experiment group will receive tCES combined with upper extremity rehabilitation of affected side.
62610223|NCT04369235|SHAM_COMPARATOR|Sham tCES & upper extremity rehabilitation|The sham control group will receive sham tCES combined with upper extremity rehabilitation of affected side.
62610224|NCT02921633|EXPERIMENTAL|Intervention letter|Centrally-sent behavioural-insight informed invitation letter.
62610225|NCT02921633|NO_INTERVENTION|Control|No centrally-sent invitation letter.
62610226|NCT05705271|EXPERIMENTAL|Finerenone|Participants will receive study treatment for 18 months ± 7 days.
62832824|NCT05306535|EXPERIMENTAL|occlusal reduction|Performing occlusal reduction on the experimental tooth until absence of occlusal contact is confirmed following completion of the endodontic treatment
62832825|NCT05306535|NO_INTERVENTION|control|No occlusal reduction or modification of the occlusal anatomy will be performed
62832826|NCT01894893||Breastfeeding mothers|
62610227|NCT04592289|EXPERIMENTAL|Full bowel preparation (MBP+OA)|"Rifaximin 400 mg twice daily for three days prior to surgery~Day prior to surgery:~17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml~18.00 - 19.00 Clear fluids 500 ml~19.00 - 20.00 17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml~20.00 - 21.00 Clear fluids 500 ml"
62610228|NCT04592289|ACTIVE_COMPARATOR|Mechanical bowel preparation only|"Day prior to surgery:~17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml~18.00 - 19.00 Clear fluids 500 ml~19.00 - 20.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml~20.00 - 21.00 Clear fluids 500 ml"
62610229|NCT00257205|ACTIVE_COMPARATOR|B|Choice of one or the other Dacarbazine or Temozolomide(CP-675,206) (choice)
62610230|NCT00257205|EXPERIMENTAL|A|
62610231|NCT06623448||Nursing students|
62832827|NCT01523912|EXPERIMENTAL|gastric RFA|Ablation of gastric dysplastic mucosa
62832828|NCT03366896|EXPERIMENTAL|Delirium|Diagnosis of delirium according to 5th Edition of The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) by Psychiatrist.
62832829|NCT06373367|EXPERIMENTAL|Illustration|This study arm will receive education via an illustration based application
62832830|NCT06373367|ACTIVE_COMPARATOR|Text|This study arm will receive education via text based application
62832831|NCT00462995|ACTIVE_COMPARATOR|Erlotinib|Erlotinib 150mg once a day p.o
62832832|NCT01249261|PLACEBO_COMPARATOR|Placebo/Risedronate|Placebo years 1-5, Risedronate 5mg/day years 6 \& 7, no drug year 8
62832833|NCT01249261|ACTIVE_COMPARATOR|Risedronate|Risedronate 5mg years 1-7, no drug year 8
62832834|NCT00013221|OTHER|Arm 1|
62832835|NCT06306716||Chronic and acute wounds|Subjects hospitalized due to chronic and acute wounds
62832836|NCT00095888|EXPERIMENTAL|Treatment (triapine, gemcitabine hydrochloride)|Patients receive 3-AP (Triapine®) IV over 2 hours followed by gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62832837|NCT00612144|EXPERIMENTAL|1|Amaryl M group
62832838|NCT00612144|ACTIVE_COMPARATOR|2|Metformin group
62832839|NCT01197118|ACTIVE_COMPARATOR|2|chemotherapy alone following radical resection
62832840|NCT01197118|EXPERIMENTAL|1|sequence chemoradiotherapy following radical resection
62251608|NCT02882542|EXPERIMENTAL|Visible light exposure White 30 lux|The participants will be exposed to white LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62441308|NCT02981797||Radium 223 Standard of Care|Standard of Care and Blood Collection for Baseline Circulating Tumor Cells (CTCs) Numeration and H2AX Assay. Participants who have chosen Radium 223 treatment for their prostate cancer that has spread to the bone and causing pain. Week 1 starts with the first Radium 223 treatment and week 24 ends 4 weeks after the last or sixth Radium 223 treatment. The circulating prostate cancer cell analysis will be performed within 24 hours of blood draw. Any unused blood samples for circulating prostate cancer cell analysis will be disposed per lab protocol.
62832841|NCT01487343||breast or gastrointestinal cancer pts taking capecitabine|This is a mixed-methodology pilot study of patients currently taking oral chemotherapy for breast or gastrointestinal cancer. The quantitative portion of the study consists of self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions.
62832842|NCT02351622|EXPERIMENTAL|caffeic acid tablet and dexamethasone|Oral administration of caffeic acid tablet 0.3g three times per day for 1 year. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
62441309|NCT01830556|ACTIVE_COMPARATOR|Arm A: cetuximab with 5FU and carboplatin or cisplatin|Arm A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h maintenance treatment thereafter with cetuximab 500 mg/m2 every second week until PD or toxicity
62832843|NCT02351622|ACTIVE_COMPARATOR|Placebo and dexamethasone|Oral administration of placebo tablet 0.3g three times per day for 1 year. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
62832844|NCT03834181|EXPERIMENTAL|Monitoring evaluation|"Monitoring evaluation by connected devices: Wristband activity tracker Garmin Vivosmart® 3, Fora® Scale 550, Terraillon® Tensioscreen, Pulse oximeter Nonin® 3230, thermometer Fora® IR20b"
62832845|NCT05827172|EXPERIMENTAL|AF ablation|The aim of the ablation procedure was to achieve isolation of all pulmonary veins and to restore sinus rhythm.Additional ablation strategies were made at the discretion of the operators.
62832846|NCT05827172|OTHER|Medical therapy (rate or rhythm control)|The medical therapy for atrial fibrillation was administered in accordance with the guidelines that were available at the time of the trial.Efforts to maintain sinus rhythm were recommended. Among patients who were treated for rate control, the recommended criteria varied according to the age of the patient. The aim of the treatment was a ventricular rate of 60 to 80 beats. per minute at rest
62832847|NCT04279717||Subjects with von Willbrand Disease Acquired|
62832848|NCT04279717||Subjects with von Willbrand Disease Congenital|
62832849|NCT04321213||Healthcare professionals in the Region of Västmanland|Healthcare professionals of all professions working in-hospital with patient contact at two hospitals in the Region of Västmanland, Sweden. Data is collected by questionnaires.
62832850|NCT04321213||Healthcare professionals in the Region of Dalarna|Healthcare professionals of all professions working in-hospital with patient contact at three hospitals in the Region of Dalarna, Sweden. Data is collected by questionnaires.
62832851|NCT03136510|OTHER|Newly diagnosed NVAF: apixaban 5 mg|blood collection for biological analyses of 30 patients new diagnosis of NVAF (VKA treatment ≤1 week) initiated with apixaban 5 mg
62832852|NCT03136510|OTHER|Previously diagnosed NVAF: apixaban 5 mg|blood collection for biological analyses of 30 patients previously treated by VKA for more than 3 months switched to apixaban 5 mg
62832853|NCT04220463|EXPERIMENTAL|Hypnosis group|For the hypnosis group, hypnotic support is set up by a doctor/IDE previously trained and dedicated during the implementation of the NIV. The dedicated doctor/IDE will be presented before the start of the NIV setup procedure and will start the hypnosis session a few minutes before the mask is put on. The procedure for setting up the NAV may begin after agreement from the dedicated doctor/IDE.
62832854|NCT04220463|PLACEBO_COMPARATOR|Control group|In the control group, in order to preserve the knowledge of the evaluator, the doctor/IDE dedicated to hypnosis is present in the service but does not intervene in the care so as not to be tempted to involuntarily put hypnosis in place. The assessor will be chosen from the two other teams present in the other two modules (each module is a seven-bed unit and has no physical communication with the other two) after the start of the procedure for setting up the NIV, with or without hypnosis, in order to be certain that he had no visual contact with the patient and the caregivers present before the evaluation. The implementation of the NAV will take place as usually carried out in the service.
62610232|NCT06731101|EXPERIMENTAL|Stellate ganglion block|Local anesthetic + dexamethasone injection into stellate ganglion
62610233|NCT06731101|EXPERIMENTAL|Drugs|Anticholinergic and Antidepressant Drugs
62251609|NCT02882542|EXPERIMENTAL|Visible light exposure White 120 lux|The participants will be exposed to white LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62251610|NCT05059158||Alzheimer's Disease|Patients with a Alzheimer's Disease diagnosis
62610234|NCT03889119|ACTIVE_COMPARATOR|Elekta Versa HD|This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Elekta machines, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.
62610235|NCT03889119|OTHER|Agility Systems|This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Agility Systems, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.
62610236|NCT06718270|EXPERIMENTAL|CAR-T cells Infusion|chimeric antigen receptor T cells
62251611|NCT05059158||Mild Cognitive Impairment|Patients with a mild cognitive impairment diagnosis
62610237|NCT01752634|EXPERIMENTAL|Secukinumab (AIN457) 75 mg s.c.|Secukinumab 75 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4.
62832855|NCT01198496|EXPERIMENTAL|Blood pressure|"The incidence of recurrent stroke will be lower in a strict BP control group having lower BP target: less than 120/80 mmHg\* than in a standard BP control group having BP target less than 140/90 mmHg or less than 130/80 mmHg for current DM/CKD/old MI in patients with hypertension.~* This study uses BP target: less than 120/80 mmHg that is sat up for this study rather than the BP target recommended in the Guidelines for the management of hypertension, Japanese Society of Hypertension 2009.~* BP management is strongly recommended in patients with hypertension, DM, and/or CKD for prevention of recurrent stroke in the Japanese guidelines for the management of stroke 2009."
62832856|NCT02148874||Flu Shot|pregnant women receive a seasonal influenza virus vaccination
62832857|NCT00472576|EXPERIMENTAL|Placebo then MK-0657|Double-blind crossover administration of placebo then MK-0657 (4-8 mg/day)
62832858|NCT00472576|EXPERIMENTAL|MK-0657 then Placebo|Double-blind crossover administration of MK-0657 (4-8 mg/day) then placebo
62832859|NCT03086811|EXPERIMENTAL|intervention group|First time mothers, when infants were ages 4-6 months old, took part in a training program in small group setting (10-12 mother-infants). the program continued for a month, with 4 weekly meetings. group coordinators were a highly experienced pediatric dietitian, and a social worker. Training topics addressed were infant healthy nutrition and growth, feeding skills, obesity and emotional feeding prevention, parenting. Thereafter, mothers were encouraged to stay in contact with the trainers, till infants reached age 12 months and data was collected using video taping of mealtime feeding interactions at home setting environment. Mother Infant Feeding Interaction very early training
62832860|NCT03086811|NO_INTERVENTION|control group|Control group first time mothers were recruited when infants were around 11-12 months of age for data collection of mealtime feeding interactions taping at home setting environment. They received during this year the official support and training given in municipality care centers.
62832861|NCT01356628|EXPERIMENTAL|PD-0332991|PD-0332991 in the Treatment in Patients with Advanced Hepatocellular Carcinoma
62832862|NCT02902289|EXPERIMENTAL|Ibuprofen 200 mg/5 mL oral suspension|Single dose of 1 ibuprofen 200 mg/5 mL stick administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
62251612|NCT05059158||Subjective Cognitive Decline|Patients with a subjective cognitive decline diagnosis
62251613|NCT04609813||Screening population|Participants underwent opportunistic endoscopic screening for esophageal cancer in high-risk regions in China will be enrolled in this study. Esophageal cell specimen will be collected by esophageal sponge cell collection device (Esoheal 1.0) prior to endoscopic examinations.
62610238|NCT01752634|EXPERIMENTAL|Secukinumab (AIN457) 150 mg s.c.|Secukinumab 150 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4.
62610239|NCT01752634|EXPERIMENTAL|Secukinumab (AIN457) 300 mg s.c.|Secukinumab 300 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4
62441310|NCT01830556|EXPERIMENTAL|Arm B: cetuximab paclitaxel and carboplatin|Arm B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter maintenance treatment day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
62441311|NCT01073020|ACTIVE_COMPARATOR|Gastric Band vs Intensive Diabetes & Weight Management|"Patients will be randomized to receive either 1) laparoscopic placement of an adjustable gastric band (LAGB) or 2) treatment with an intensive medical and weight management (IMWM) program.~LAGB will be placed using the pars flaccida technique. The Allergan laparoscopic band LAP BAND system will be utilized. LAGB ports will be placed in subcutaneous pockets in the right upper abdomen.~The IMWM group will participate in the Weight Achievement and Intensive Treatment (Why WAIT) program, which is a multidisciplinary program for weight control and intensive diabetes management designed by Joslin Diabetes Center. Key aspects include: 1) Intensive and interactive medication adjustments, 2) Structured modified dietary intervention, 3) Graded, balanced, and individualized exercise intervention, 4) Cognitive behavioral intervention and 5) Group education."
62449499|NCT03354247|EXPERIMENTAL|NAFLD Intervention|Participants randomized to the Lifestyle Intervention will receive an intensive, state-of-the-art weight loss intervention based on a Mediterranean diet and physical activity. The intervention will focus on changing both eating and exercise habits with a goal of producing a 7-10% weight loss within the first 6 months and then maintaining this weight loss. Participants who are able to lose more than 10% of their body weight will be encouraged to do so. Participants will be seen weekly for the first 6 months and then biweekly for months 7-12. The lifestyle intervention focused on diet, exercise, and behavior modification.
62832863|NCT02902289|ACTIVE_COMPARATOR|MOMENT 200 mg coated tablet|Single dose of 1 MOMENT 200 mg coated tablet administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
62832864|NCT06654336|EXPERIMENTAL|Recurrence-directed therapy (RDT) + ADT x 12 months|Local, regional or distant oligometastatic RDT in addition to treatment with ADT for 12 months in the form of ELIGARD®.
62832865|NCT06654336|ACTIVE_COMPARATOR|Recurrence-directed therapy (RDT) alone|Local, regional, and distant oligometastatic RDT.
62832866|NCT01470521|EXPERIMENTAL|Hookworm larvae (Necator americanus)|Participants will receive 25 live hookworm larvae
62832867|NCT01470521|PLACEBO_COMPARATOR|Placebo|Participant will receive pharmacopoeial grade water
62832868|NCT03768934|NO_INTERVENTION|Control|No airtime incentive for completing the survey
62832869|NCT03768934|EXPERIMENTAL|1X Incentive|1X airtime incentive
62832870|NCT03768934|EXPERIMENTAL|2X incentive|2X airtime incentive
62832871|NCT03768934|EXPERIMENTAL|Lottery Incentive|Lottery airtime incentive where odds of winning lottery are 1 out of 20
62251614|NCT04588194|EXPERIMENTAL|Romiplostim, Rituximab, Dexamethasone|Each patient will receive Rituximab 100 mg weekly days 1, 7, 14, 21, Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21 and Dexamethasone 40 mg IV/PO days 1-4.
62251615|NCT04472143|EXPERIMENTAL|Granisetron Transdermal Delivery System|The patch will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days
62832872|NCT05330286|EXPERIMENTAL|Pediatric Formulation|Part 1 - healthy participants receiving pediatric formulation
62832873|NCT05330286|EXPERIMENTAL|Adult Formulation|Part 1 - healthy participants receiving adult formulation
62832874|NCT05330286|EXPERIMENTAL|Adult formulation fasted state|Part 2- healthy participants receiving adult formulation in fasted conditions
62832875|NCT05330286|EXPERIMENTAL|Adult formulation Fed state|Part 2- Part 2- healthy participants receiving adult formulation in fed conditions
62832876|NCT05799885|EXPERIMENTAL|31 players with ankle instability|2 sessions per week for 8 weeks, total training time 30 min
62832877|NCT05799885|EXPERIMENTAL|30 players with ankle instability|2 sessions per week for 8 weeks, total training time 30-40 min
62832878|NCT03925285|EXPERIMENTAL|IV fluorescent tracer bevacizumab-800CW|Patients will be administered with 10 or 25 bevacizumab-800CW.
62832879|NCT04591613|OTHER|Standardized clinical and paraclinical follow-up|"Standardized clinical and paraclinical follow-up will be offered in one of the referring investigator centers. Patients will be able to benefit from additional biological samples. Questionnaires will be completed by the patient or with the help of clinical research staff in paper format.~All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID.~Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits.~Total serum, plasma and naso-paaryngeal samples will be collected."
62832880|NCT00587314||1|Patients with Barrett's Esophagus or early esophageal adenocarcinoma who will or have had ablation therapy will be enrolled in this long term follow up study
62610240|NCT01752634|PLACEBO_COMPARATOR|Placebo s.c.|Placebo at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4. Non-responder (assessed at Week 16) were re-randomized to receive AIN457 150mg or AIN457 300 mg starting at Week 16. Responder (assessed at Week 16) were re-randomized to receive AIN457 150mg or AIN457 300 mg starting at Week 24.
62251616|NCT01715220|ACTIVE_COMPARATOR|Sublingual nitroglycerine|Sublingual nitroglycerine followed by pain assessment and if necessary second dose of sublingual nitroglycerine
62251617|NCT01715220|PLACEBO_COMPARATOR|placebo|sublingual placebo followed by pain assessment and if necessary second dose of sublingual placebo
62610241|NCT05167279|PLACEBO_COMPARATOR|JS026/placebo 30 mg|4 patients will be enrolled in this arm.
62251618|NCT01484899||PAH|Patients with pulmonary arterial hypertension (PH). PH defined as mean pulmonary artery pressure \>25mmHg with a pulmonary capillary occlusion pressure ≤ 15mmHg
62251619|NCT01484899||CTEPH|Patients with chronic thromboembolic pulmonary hypertension. CTEPH defined as mean pulmonary artery pressure \>25mmHg with a pulmonary capillary occlusion pressure ≤ 15mmHg.
62251620|NCT01484899||Controll group|Data from 16322 (10336 females) participants of the Swiss health survey (SHS) 2007 will serve as control. The SHS was performed in 2007, a representative sample of 30000 Swiss citizens were asked to participate, 66% answered per telephone to detailed health question.
62449500|NCT05371522|EXPERIMENTAL|[18F]DPA-714|All individuals included will undergo a \[18F\]DPA-714 positron emission tomography (PET) scan, irrespective of the existence of post-COVID-19 complaints.
62449501|NCT01946165|EXPERIMENTAL|Abiraterone Acetate + Prednisone + Enzalutamide + LHRHa|Patients receive abiraterone acetate (1,000 mg daily) plus prednisone (5mg once daily) in combination with enzalutamide (160 mg daily) and LHRHa. Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
62610242|NCT05167279|PLACEBO_COMPARATOR|JS026/placebo 100 mg|4 patients will be enrolled in this arm.
62610243|NCT05167279|PLACEBO_COMPARATOR|JS026/placebo 300 mg|8 patients will be enrolled in this arm.
62610244|NCT05167279|PLACEBO_COMPARATOR|JS026/placebo 600 mg|8 patients will be enrolled in this arm.
62610245|NCT05167279|PLACEBO_COMPARATOR|JS026/placebo 1000 mg|8 patients will be enrolled in this arm.
62610246|NCT05167279|PLACEBO_COMPARATOR|JS026/placebo 300 mg + JS016/placebo1200 mg|8 patients will be enrolled in this arm.
62610247|NCT05167279|PLACEBO_COMPARATOR|JS026/placebo 600 mg + JS016/placebo 1200 mg|8 patients will be enrolled in this arm.
62049754|NCT05387824|ACTIVE_COMPARATOR|Group 1: Bladder Training - Control group|BT, consisting of four stages, won't contain any PFMT programs in all groups. In these stages, including urgency supression strategies, it was aimed to delay urination, to inhibit detrusor contraction and to prevent urgency; by squeezing the PFM several times in a row (women will be encouraged to pause/ stop their work, sit down if possible, relax the entire body and squeeze PFM repeatedly), breathing deeply, giving their attention to another job for a while and self-motivating (I can do it, I can check the urination, etc.).
62049755|NCT05387824|EXPERIMENTAL|Group 2: Bladder Training + TTNS|Two self-adhesive surface electrodes will be positioned according to the protocol which previously explained, with the negative electrode 2 cm behind the medial malleolus and positive electrode 10 cm proximal. Correct positioning wil be determined by noting a hallux reaction (plantar flexion of great toe or fanning of all toes). The stimulation protocol will be delivered at fixed 20 Hz and pulse width 200 ms in continous mode in accordance with the PTNS stimulation protocol. The intensity of the stimulation current (range 0-50 mA) will be determined once correct positioning are established, according to the comfort level of the person. TTNS sessions will be performed twice a week for 6 weeks. Every session will be lasted 30 min. Treatment will consist of 12 sessions of stimulation.
62049756|NCT05387824|EXPERIMENTAL|Group 3: Bladder Training + MStim|Patients are told to sit on the chair with a magnetic coil below the chair. When a volume conductor is in serted by this magnetic field, an eddy current flow is generated. This eddy current stimulates nerve or muscle of the pelvic floor. To apply MS, the device will be set to generate its maximum stimuli, with a stimulation pulse width of 200 μs and a stimulation repetition cycle of 10 Hz in accordance with the literature. When setting the device at each treatment session, patients will be interviewed so that they receive the stimuli at the maximum stimulation intensity (maximum tolerable stimulation intensity) .
62049757|NCT00596843|EXPERIMENTAL|1|Motivational intervention
62049758|NCT00596843|ACTIVE_COMPARATOR|2|Educational intervention
62049759|NCT03799068|ACTIVE_COMPARATOR|suprazygomatic maxillary nerve block|the group were given a bilateral suprazygomatic maxillary nerve block with 0.125% bupivacaine, 2 ml on each side, the total dose of bupivacaine not exceeding 2 mg/kg.
62049760|NCT03799068|ACTIVE_COMPARATOR|surgical site infiltraion|the group were given peri-incisional infiltration with 0.125% bupivacaine, 2 ml on each side. In all cases the block was given by the anaesthetist and the infiltration by the surgeon.
62049761|NCT05339932|EXPERIMENTAL|Manual wheelchair skills training|
62610248|NCT01587469||HIV-infected and -uninfected individuals|HIV-infected and -uninfected individuals with suspected TB infection
62610249|NCT03959696|ACTIVE_COMPARATOR|Notification only arm|Clinician participants will be notified of their patients aged 76-85 with an upcoming visit who are due for colorectal cancer screening.
62049762|NCT01648270|EXPERIMENTAL|Study Arm|"Subjects will be studied on four occasions. Sessions and drugs are:~1. Intravenous buprenorphine~2. Sublingual buprenorphine~3. Cyclosporine plus intravenous buprenorphine~4. Cyclosporine plus sublingual buprenorphine"
62049763|NCT06076720|EXPERIMENTAL|New head-mounted visual aids|Wearing different head-mounted visual aids
62449502|NCT01946165|EXPERIMENTAL|Abiraterone Acetate + Prednisone + LHRHa|Patients receive abiraterone acetate (1,000 mg daily) plus prednisone (5mg once daily) and LHRHa. Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
62449503|NCT01922349|PLACEBO_COMPARATOR|Placebo (Multiple dose)|Placebo
62449504|NCT01922349|EXPERIMENTAL|Dose 1, Single dose|Low dose
62449505|NCT01922349|EXPERIMENTAL|Dose 2, Single dose|Medium dose
62449506|NCT01922349|EXPERIMENTAL|Dose 3, Single dose|High dose
62449507|NCT01922349|EXPERIMENTAL|Dose 4, Multiple dose|Low dose
62449508|NCT01922349|EXPERIMENTAL|Dose 5, Multiple dose|Medium dose
62610250|NCT03959696|EXPERIMENTAL|Training and Notification arm|Clinician participants will be notified of their patients aged 76-85 with an upcoming visit who are due for colorectal cancer screening and will complete a two-hour shared decision making communication skills training course that includes case studies, interactive exercises, and lecture content.
62610251|NCT03950141|EXPERIMENTAL|Apatinib and S1 group|Combined with Apatinib (250mg qd po) and S-1 (40-60mg bid d1-14) as maintenance therapy in advanced HER-2 negatived GC
62610252|NCT06379568||Aspergillus pneumonia group|According to diagnostic criteria , patients diagnosed with IPA and CPA and were assigned to the Aspergillosis pneumonia group
62610253|NCT06379568||control group|The remaining patients without IPA and CPA were included in the Aspergillus colonization group
62610254|NCT03796715||Red Cell Distribution Width (RDW)|RDW was assessed as part of complete blood count analysis using SYSMEX XN-550 automated analyzer
62610255|NCT03796715||Presepsin (sCD14-ST)|Presepsin analysis was done by utilising Elisa technique using kits from (MyBioSource, San Diego, CA 92195-3308 USA)
62610256|NCT06426134|EXPERIMENTAL|dGK|1x50 g dGK ketone drink
62832881|NCT05073874|OTHER|Functional Near-Infrared Spectroscopy (fNIRS)|"Subjects will be guided to walk at a normal pace while maintaining the required attentional focus:~1. no instructions about the attentional focus~2. internal focus on their feet movements,~3. external focus on two lines drawn on the floor,~4. divided attention (walking while performing an arithmetic task).~A fNIRS system will be used for the prefrontal cortex activation evaluation and connected soles for gait analyses."
62832882|NCT01642576|EXPERIMENTAL|diet modification|counselling on caloric restriction and healthy eating
62449509|NCT01922349|EXPERIMENTAL|Dose 6, Multiple dose|High dose
62449510|NCT01922349|PLACEBO_COMPARATOR|Placebo (Single dose)|Placebo
62251621|NCT03961217||Gynecological Cases|"Gynecological Cancer survivors with treatment induced survivorship syndroms treated pelvic radiotherapy at~1. Radiumhemmat, Karolinska University Hospital and~2. Jubileumskliniken at Sahlgrenska University Hospital in Sweden."
62251622|NCT03961217||Prostate Cases|Prostate Cancer survivors treated with radiotherapy for localized prostate cancer at Sahlgrenska University Hospital, Gothenburg, Sweden
62610257|NCT06426134|ACTIVE_COMPARATOR|isocaloric carb control|1x isocaloric carbohydrate control drink
62610258|NCT00083720|EXPERIMENTAL|cetuximab|Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes
62610259|NCT01068626|ACTIVE_COMPARATOR|Rosuvastatin|
62832883|NCT01642576|EXPERIMENTAL|weight management program|dietician and sports trainer, physician counselling on weight loss
62449511|NCT04407819||diabetes mellitus type 2|36 patients with diabetes mellitus type 2, aged 20-80 years, attending endocrinology outpatient clinics were studied for the assessment of muscle mass and function compared to controls.
62449512|NCT04407819||CONTROLS|14 community people who visited the endocrinology outpatient hospital clinic for a routine checkup, or with a non-related to diabetes disease.
62610260|NCT01068626|PLACEBO_COMPARATOR|Placebo for Rosuvastatin|
62610261|NCT01897766||Somatropin|Patients administered Somatropin.
62832884|NCT06242652|EXPERIMENTAL|608 Dose A|608 Dose A subcutaneous (SC) injection.
62832885|NCT06242652|EXPERIMENTAL|608 Dose B|608 Dose B subcutaneous (SC) injection.
62832886|NCT06242652|EXPERIMENTAL|608 Dose C|608 Dose C subcutaneous (SC) injection.
62832887|NCT06242652|ACTIVE_COMPARATOR|Positive control group|Adalimumab subcutaneous (SC) injection.
62610262|NCT03168490|ACTIVE_COMPARATOR|1.5g low gluten friendly bread|1.5g low gluten friendly bread as15g bun/day to be consumed as 250 ml beverages at breakfast for 14 days
62610263|NCT03168490|ACTIVE_COMPARATOR|3g medium gluten friendly bread|3g medium gluten friendly bread as 30g bun to be consumed as 250 ml beverages at breakfast for 14days
62610264|NCT03168490|ACTIVE_COMPARATOR|6g high gluten friendly bread|6g high gluten friendly bread as 60g bun to be consumed as 250 ml beverages at breakfast for 14 days
62610265|NCT03168490|PLACEBO_COMPARATOR|Control bread|Placebo control bread as 15g bun to be consumed as 250 ml beverages at breakfast for 14 days
62610266|NCT03168490|PLACEBO_COMPARATOR|Gluten free bread|Gluten bread as 15g bun to be consumed as 250 ml beverages at breakfast for 14 days
62610267|NCT02778841|EXPERIMENTAL|XBox Kinact Exercise|Kinact game intervention group performed three times per week on non-consecutive days for eight weeks
62251623|NCT03961217||Gynecological Rehab Cases|Gynecological Cancer survivors with treatment induced survivorship syndroms treated pelvic radiotherapy
62610268|NCT02778841|EXPERIMENTAL|conventional balance exercises|conventional balance exercises group performed three times per week on non-consecutive days for eight weeks
62610269|NCT02778841|EXPERIMENTAL|concurrent exercise group|Concurrent group performed mixed conventional balance and Xbox Kinact exercises three times per week on non-consecutive days for eight weeks
62610270|NCT02778841|NO_INTERVENTION|control Group|There is no exercise for this group
62610271|NCT05103436|NO_INTERVENTION|Control Group|Participants will not receive intervention for the first 2 months. This period will be used for comparison with the intervention group. At the end of the 2-month delay, they will receive TENS (1 hr AM, 1 hr PM/day, 50 Hz, below pain/motor threshold, using an EMS 7500 TENS unit).
62251624|NCT01752660|EXPERIMENTAL|Endurance training|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
62610272|NCT05103436|EXPERIMENTAL|Intervention Group|Participants will receive 2 months of TENS (1 hr AM, 1 hr PM/day, 50 Hz, below pain/motor threshold, using an EMS 7500 TENS unit) immediately upon entry to the study.
62610273|NCT05032456|EXPERIMENTAL|Virtual Reality Group|Investigators used Oculus Quest All-in-one Virtual Reality Gaming Headset (128 GB) VR system. Before the intervention, the investigators introduced the equipment and instructed study participants on how to wear and activate the headsets. The laboring women who enrolled in the virtual reality group first wore the headsets in early labor (Cervical dilation 3 cm) for 20 minutes. The patients were offered to choose among several virtual environments including orange sunset, green meadows, black beginning, red savannah, blue deep, blue moon, blue ocean, white winter, and red fall. Cards printed out from the images of the Nature Trek application representing these novel immersion options were provided to the patients to help them pick up their preferred environment in advance. The second implementation of virtual reality headsets was after the epidural analgesia in the active phase of labor for another 20 minutes (Cervical dilation 6-7cm).
62251625|NCT01752660|ACTIVE_COMPARATOR|Standard care|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center
62251626|NCT01386918|EXPERIMENTAL|Low frequency left (LFL) sided rTMS|LFL rTMS was administered at an intensity of 115% resting motor threshold at 1HZ for 20 minutes. The treatment targeted the left temporoparietal cortex (TPC).
62251627|NCT01386918|EXPERIMENTAL|Priming stimulation|Priming stimulation was administered as follows: 10 minutes of 6 Hz at 90% resting motor threshold (RMT) administered to the left temporoparietal cortex followed by 10 minutes of 1 Hz stimulation at 115% RMT.
62610274|NCT05032456|NO_INTERVENTION|Control Group|For participants randomized to the control group, virtual reality headsets were not used and the clinic's standard of care in laboring women was followed. Participants in this group filled out a visual pain rating scale both in the latent and active phases of labor.
62610275|NCT05459194|ACTIVE_COMPARATOR|Test|Fluticasone/Salmeterol Elpenhaler active vs Fluticasone/Salmeterol Diskus placebo
62610276|NCT05459194|PLACEBO_COMPARATOR|Refere|Fluticasone/Salmeterol Elpenhaler placebo vs Fluticasone/Salmeterol Diskus active
62610277|NCT01275703||patients with PH undergoing exercise testing|
62610278|NCT03945994|NO_INTERVENTION|Connecting People Control Group|CMHTs (Community Mental Health Teams) will continue to support people with mental health problems using their standard care.
62610279|NCT03945994|EXPERIMENTAL|Connecting People Intervention Group|CMHTs will receive training on how to implement Connecting People programme. They will receive implementation toolkit to improve their practice in contrast to standard care.
62610280|NCT06467994|ACTIVE_COMPARATOR|Cashew Oral Immunotherapy|Oral immunotherapy with boiled cashews followed by roasted cashews taken daily for 12 months
62832888|NCT06242652|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous (SC) injection.
62610281|NCT06467994|PLACEBO_COMPARATOR|Placebo Oral Immunotherapy|Placebo oral immunotherapy taken daily for 12 months
62610282|NCT02939482|ACTIVE_COMPARATOR|Group 1: 40 ml/min|Triamcinolone acetonide (80 mg)/2 ml and normal saline solution 18 ml infusion in 0.5 min
62610283|NCT02939482|EXPERIMENTAL|Group 2: 20 ml/min|Triamcinolone acetonide (80 mg)/2 ml and normal saline solution 18 ml infusion in 1 min
62832889|NCT00577304|OTHER|2|Placebo - Topical AmphiMatrix
62832890|NCT00577304|ACTIVE_COMPARATOR|1|Topical AmphiMatrix with Nitroglycerin
62832891|NCT01162096|EXPERIMENTAL|Transplantation|
62251628|NCT01386918|SHAM_COMPARATOR|Sham Control|Sham stimulation was applied with identical parameters to those for the LFL condition but with the coil angled at 90 degrees off the scalp in a single wing tilt position.
62251629|NCT02607592|EXPERIMENTAL|Nedaplatin and Pemetrexed|nedaplatin 90mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
62251630|NCT02607592|ACTIVE_COMPARATOR|Cisplatin and Pemetrexed|cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
62610284|NCT02732405|EXPERIMENTAL|MK5172 /MK8742|
62832892|NCT05847946|EXPERIMENTAL|Kinesiotape application|In addition to core stabilization and pelvic floor exercises, kinesiotape will be applied to the paraspinal muscles in the lumbar region 2 times a week for a total of 8 times.
62832893|NCT05847946|ACTIVE_COMPARATOR|Core stability and pelvic floor exercises group|Participants will perform core stabilization and pelvic floor exercises 5 days a week for 4 weeks.
62610285|NCT02466607|OTHER|RETeval color flicker ERG|Compare implicit times and amplitudes of electroretinograms obtained from series of color flashes to those obtained from white flashes.
62610286|NCT02466607|OTHER|RETeval dilated versus un-dilated flicker ERG|Compare implicit times and amplitudes of ERGs obtained from cd/m2/sec stimulation (used with dilated pupils) to those obtained from troland stimulation (used with un-dilated pupils).
62610287|NCT05289024||MABT utilizers|Chronic pain patients receiving MABT in an interdisciplinary clinic as part of their standard of care.
62610288|NCT01902355|EXPERIMENTAL|modified Seldinger technique|Use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
62610289|NCT01902355|ACTIVE_COMPARATOR|Seldinger technique|The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
62610290|NCT00775853||Individuals at risk for developing PD|Individuals who may be at risk for developing PD because of genetic risk, olfactory dysfunction, symptomatic rapid eye movement sleep behavior disorder, or orthostatic hypotension
62610291|NCT00306787|EXPERIMENTAL|Famciclovir|Patients received Famciclovir 1000 mg (2 x 500 mg tablets) twice a day for one day. The first dose was to be taken within 6 hours after onset of prodromal symptoms or genital herpes lesions and the second dose approximately 12 hours later. Patients also received 1 valacyclovir placebo capsule, beginning with the first famciclovir dose, twice a day for 3 days, each taken about 12 hours apart.
62610292|NCT00306787|ACTIVE_COMPARATOR|Valacyclovir|Patients received Valacyclovir 500 mg capsule twice a day approximately 12 hours apart for 3 consecutive days. The first dose was to be taken within 6 hours after onset of prodromal symptoms or genital herpes lesions. On the first day patients also received 2 famciclovir placebo tablets taken with the first 2 doses of Valacyclovir.
62610293|NCT06509672|EXPERIMENTAL|Combined Plyometric and Endurance Training|will receive both below mentioned trainings with alternative timings
62738699|NCT02516982||Retrospective assessment|Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of one day a month for 6 months. The assessment days will consist of a single administration of the Edinburgh Postnatal Depression Scale.
62738700|NCT02400606|EXPERIMENTAL|Intervention|The intervention group were presented with a short case overview introducing four cardiopulmonary VP cases as well as the final diagnosis and had to complete the history, physical findings, and lab results, i.e. constructing VP cases.
62738701|NCT02400606|ACTIVE_COMPARATOR|Control|The participants were presented with a short case overview introducing four cardiopulmonary VP cases to be solved, i.e. solving VP cases.
62738702|NCT05489354|EXPERIMENTAL|mHealth psychoeducational intervention|The intervention group will receive six weeks mHealth psychoeducational intervention (mPEI) delivered through a mobile application.
62049764|NCT01638325|ACTIVE_COMPARATOR|Insulin Lispro|15 international units (IU) insulin lispro administered once subcutaneously (SC) during 1 of 3 dosing periods. There is a minimum 7 day washout between dosing periods.
62441312|NCT01073020|ACTIVE_COMPARATOR|RYGB vs Intensive Diabetes & Weight Management|"Patients will be randomized to receive either 1) Roux-en-Y gastric bypass (RYGB) surgery or 2) treatment with an intensive medical and weight management (IMWM) program.~RYGB will be performed using a 75 cm antecolic, ante-gastric Roux limb created with a 50 cm pancreaticobiliary limb. A 15-20 cc gastric pouch will be created lying along the lesser curve of the stomach, with division of the vagal trunks at the lower border of the pouch.~The IMWM group will participate in the Weight Achievement and Intensive Treatment (Why WAIT) program, which is a multidisciplinary program for weight control and intensive diabetes management designed by Joslin Diabetes Center. Key aspects include: 1) Intensive and interactive medication adjustments, 2) Structured modified dietary intervention, 3) Graded, balanced, and individualized exercise intervention, 4) Cognitive behavioral intervention and 5) Group education."
62441313|NCT02469974|EXPERIMENTAL|Ruxolitinib / INC 424|Ruxolitinib, Jakafi ®, will be given orally at standard dose daily for 16 weeks pre ASCT and up to 3 months post-ASCT for 10 patients (allowing for 2 additional screen failures). Patients will restart ruxolitinib at 100 days after the ASCT as long as their platelet count is at least 50 x103. For patients whose platelet count is below 50 x103 at day 100, ruxolitinib should be restarted once platelet count reaches 50 x103. The dose of ruxolitinib can be titrated up as per clinical guidelines. PBSC mobilization will include G-CSF 10 mcg/kg/day. HDC for ASCT will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2.
62738703|NCT05489354|NO_INTERVENTION|Control Group|No psychoeducational intervention will be given.
62738704|NCT01376622||Chronically Transfusion Patients|Patients with transfusion dependent anemia (excluding sickle cell disease), ages 2-25, on Deferasirox chelation therapy, to be monitored over 2 years.
62738705|NCT01376622||Controls|Normal controls, ages 2-25, with no known brain abnormality or endocrine dysfunction.
62738706|NCT05596461|EXPERIMENTAL|Transcranial magnetic stimulation|
62738707|NCT05596461|EXPERIMENTAL|Transcranial direct-current stimulation|
62738708|NCT05289492|EXPERIMENTAL|A: Participants will receive EOS884448|EOS884448 will be administered
62738709|NCT05289492|EXPERIMENTAL|B: Participants will receive EOS884448 and iberdomide|EOS884448 and iberdomide will be administered
62738710|NCT05289492|EXPERIMENTAL|C: Participants will receive EOS884448, iberdomide and dexamethasone|EOS884448, iberdomide and dexamethasone will be administered
62610294|NCT06509672|ACTIVE_COMPARATOR|Plyometric Training|First of all, the training session will be started with a warm-up period of 10min. the athlete will be asked to do gentle warm-up exercises. In the next step of training Counter movement jump for Plyometric training (CMJ will be performed with a squat starting position, that is, knees flexed to 90 ° and hands on hips. From this position, the hockey players will be required to bend their knees to a freely chosen angle and perform a maximal vertical thrust. The hands are held on the hips during the jump to avoid any effect of arm-swinging. Participants will be instructed to keep their body vertical throughout the jump, avoiding undue lateral and frontal movements, and to land with knees fully extended.) The CMJ period will be in 2 rounds each round of 8 min with 4 min break between the rounds. The training session will end with a 10min cooling period. The complete plyometric training session will be of 40mins.
62610295|NCT06509672|ACTIVE_COMPARATOR|Endurance Training|Endurance training will be done on a cycle ergometer. Subjects will initially do six 3-min bouts of exercise with 3-min rest periods between bouts. The bouts will be done at power outputs corresponding to that which require 60 and 80% VO₂ max respectively. After 4 weeks a seventh bout will be added and after 8 weeks an eight bout. After 10 weeks 10 bouts will be done till the end of the training. Each endurance training sub-session will last for 35-45 min.
62610296|NCT01623024|EXPERIMENTAL|Vitamin D and Lifestyle counseling|
62610297|NCT01623024|ACTIVE_COMPARATOR|Lifestyle counseling|
62610298|NCT00405743|EXPERIMENTAL|Arm A|CP4055, 2 and 4 hour IV infusion
62610299|NCT00405743|EXPERIMENTAL|Arm B|CP-4055, Continuous IV infusion
62610300|NCT03350308||Patients with chronic end-stage renal failure|
62610301|NCT06519097|EXPERIMENTAL|Vitamin E Delta-tocotrienol (DT3)|Patients will be given DT3 orally (by mouth) twice daily for 3 years
62610302|NCT06519097|ACTIVE_COMPARATOR|Placebo|Patients will be given a placebo (a substance that looks like the study drug, but contains not active ingredients) orally (by mouth) twice daily for 3 years
62610303|NCT05454254|ACTIVE_COMPARATOR|Adults with Fontan circulation|Individualised muscle strengthening exercise training protocol.
62610304|NCT05454254|ACTIVE_COMPARATOR|Healthy controls|Individualised muscle strengthening exercise training protocol.
62610305|NCT05635097|OTHER|One group intervention|One group without comparator
62610306|NCT06730568|ACTIVE_COMPARATOR|Mechanical Instrumentation (M)|The participants in the mechanical instrumentation (M) group were treated with conventional submarginal instrumentation using titanium curettes.
62610307|NCT06730568|EXPERIMENTAL|Mechanical Instrumentation with Chlorhexidine (MC)|Participants in the mechanical instrumentation with chlorhexidine (MC) group were treated with conventional submarginal instrumentation using titanium curettes followed by adjunctive chlorhexidine irrigation.
62610308|NCT06730568|EXPERIMENTAL|Mechanical Instrumentation with Ozone (MO)|Participants in the mechanical instrumentation with chlorhexidine (MC) group were treated with conventional submarginal instrumentation using titanium curettes followed by gaseous ozone
62610309|NCT06730568|EXPERIMENTAL|Mechanical Instrumentation with Air Abrasion (MA)|The participants in the mechanical instrumentation with glycine powder air abrasion (MA) group were treated with conventional submarginal instrumentation using titanium curettes and followed by adjunctive glycine air-abrasion.
62610310|NCT06730568|EXPERIMENTAL|Air Abrasion Monotherapy (A)|The participants in the air abrasion monotherapy (A) group were treated exclusively with glycine powder-based air abrasion.
62610311|NCT03218605|EXPERIMENTAL|healthy active participants|
62610312|NCT00539032|EXPERIMENTAL|Group 1: Menactra® Booster Group|Participants who had received 2 doses of quadrivalent (A, C, Y, and W-135) meningococcal polysaccharide vaccine before age 2 years received a booster vaccination with Menactra® vaccine.
62610313|NCT00539032|EXPERIMENTAL|Group 2: Menactra® Primary Vaccine (Control) Group|Participants who had not previously been given any meningococcal vaccine (meningococcal vaccine naive) received a primary vaccination with Menactra® vaccine.
62610314|NCT04003454|OTHER|Nontargeted Screening|The nontargeted HCV screening arm will consist of implementing non-risk-based rapid opt-out HCV screening.
62738711|NCT06192472|EXPERIMENTAL|1% Sodium Tetradecyl Sulphate|Superficial leg veins will be removed by phlebectomy operations. Sections of vein 3-5cm in length will be filled with sclerosant.
62441314|NCT00319449|EXPERIMENTAL|Ezetimibe 10 mg|Participants treated with 10 mg/day ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.
62441315|NCT00319449|PLACEBO_COMPARATOR|Placebo 10 mg|Participants treated with 10 mg/day matching placebo to ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.
62738712|NCT06192472|EXPERIMENTAL|3% Sodium Tetradecyl Sulphate|Superficial leg veins will be removed by phlebectomy operations. Sections of vein 3-5cm in length will be filled with sclerosant.
62738713|NCT06192472|EXPERIMENTAL|0.5% Polidocanol|Superficial leg veins will be removed by phlebectomy operations. Sections of vein 3-5cm in length will be filled with sclerosant.
62738714|NCT06192472|EXPERIMENTAL|3% Polidcanol|Superficial leg veins will be removed by phlebectomy operations. Sections of vein 3-5cm in length will be filled with sclerosant.
62738715|NCT03540706|EXPERIMENTAL|Care with C-reactive protein assay in micro method|During a visit to the general practitioner for a clinical suspicion of respiratory infection, the doctor will practice a C-reactive protein assay in micro method. He will prescribe antibiotics according to the result of the dosage
62738716|NCT03540706|NO_INTERVENTION|Care without C-reactive protein assay in micro method|Simple management of a patient coming for a suspicion of respiratory infection without dosage of the C-reactive protein in micro method
62738717|NCT02661737||YVOIRE volume s|Treatment with YVOIRE volume s
62738718|NCT00610857|EXPERIMENTAL|Anti-CTLA4 monoclonal antibody and HDI|Specific Aim #1: Test the hypothesis that the combination of IFNa-2b and anti-CTLA-4 monoclonal antibody will improve the response rate in patients with recurrent inoperable AJCC stage III and stage IV melanoma. Our therapeutic target is achieving, with acceptable toxicity, a 20% or better rate of objective response, CR or PR by RECIST criteria, as compared to the 5% to 10% expected in patients eligible for study. Study size is planned in terms of our primary efficacy endpoint, objective response.
62610315|NCT04003454|OTHER|Targeted Screening|"The targeted HCV screening arm will consist of implementation of risk-based rapid opt-out HCV screening using current recommendations for HCV screening by the CDC, USPSTF, and AASLD-IDSA. Targeted HCV screening will consist of offering HCV testing to those identified with the following specific risk characteristics, adapted from the above recommendations: born between 1945 - 1965 (birth cohort); injection drug use (IDU); intranasal drug use;tattoo or piercing in an unregulated setting; or blood transfusion or organ recipient before 1992."
62610316|NCT03946670|EXPERIMENTAL|MBG453 + hypomethylating agents|Patients are taking MBG453 plus hypomethylating agents
62610317|NCT03946670|PLACEBO_COMPARATOR|Placebo + hypomethylating agents|Patients are taking placebo plus hypomethylating agents
62610318|NCT00864136||Group 1|
62610319|NCT00864136||Group 2|
62610320|NCT00864136||Group 3|
62610321|NCT01822951|EXPERIMENTAL|Cerebrolysin Verum|"Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). For the infusion 2x10 ml Cerebrolysin (215.2 mg/ml) is diluted with 80 ml 0.9% NaCl (saline) to a total volume of 100 ml, i.v.~Placebo for donepezil: 1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o."
62832894|NCT02922322|ACTIVE_COMPARATOR|Pilates Group|The Pilates Group was composed by 15 participants evaluated before and after 16 sessions of intervention with mat Pilates exercises.
62832895|NCT02922322|NO_INTERVENTION|Control Group|The control group was composed by 15 participants that received no intervention
62049765|NCT01638325|EXPERIMENTAL|BC106 Insulin Lispro|15 up to 30 IU BC106 insulin lispro administered once SC during 2 of 3 dosing periods. There is a minimum 7 day washout between dosing periods.
62049766|NCT04604002||Subjects with Normal Eyes|OCT, Color Fundus Photography and OCT Angiography as per protocol in subjects without ophthalmic pathology
62610322|NCT01822951|ACTIVE_COMPARATOR|Donepezil Verum|"5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Placebo for Cerebrolysin: 100 ml 0.9% NaCl (saline), i.v. infusion. Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly)."
62610323|NCT04760379|ACTIVE_COMPARATOR|Conventional Therapy|Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
62610324|NCT04760379|EXPERIMENTAL|Vibration Therapy|Focal muscle vibrator (FMV) (120 Hz) for 10 minutes on paraspinal muscles. Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
62610325|NCT03776071|ACTIVE_COMPARATOR|RT plus TMZ and ENZ; ENZ alone; TMZ and ENZ|Radiotherapy (RT) plus temozolomide (TMZ) and enzastaurin (ENZ) (Concurrent Phase) followed by enzastaurin alone (Single-Agent Phase), then temozolomide and enzastaurin (Adjuvant Phase)
62049767|NCT04604002||Subjects with Pathology|OCT, Color Fundus Photography and OCT Angiography as per protocol in subjects with retinal vascular pathology
62049768|NCT00338598|EXPERIMENTAL|Glycine|Glycine, 0.8 gr per kg given in two daily doses
62049769|NCT00338598|PLACEBO_COMPARATOR|placebo|placebo will be administered.
62049770|NCT03376815||prostate ,traditional sample method|Samples from 100 patients with prostate carcinoma were obtained by traditional sampling method
62251631|NCT05997433|EXPERIMENTAL|7 days|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid
62610326|NCT03776071|PLACEBO_COMPARATOR|RT plus TMZ and placebo; placebo; TMZ and placebo|Radiotherapy (RT) plus temozolomide (TMZ) and placebo followed placebo then by temozolomide and placebo
62610327|NCT05948839|EXPERIMENTAL|active rTMS treatment|3 sessions of active rTMS would be delivered to the left DMPFC daily, with a session of 1800 pulse.
62610328|NCT05948839|SHAM_COMPARATOR|sham control|3 sessions of sham rTMS would be delivered to the left DMPFC daily, with a session of 1800 pulse.
62610329|NCT06729931||Tuberculous Pleural Effusion|Patients diagnosed with tuberculous pleural effusion based on pleural fluid ADA, AFB/GeneXpert, or pleural/lung tissue biopsy.
62610330|NCT06729931||Malignant Pleural Effusion|Patients diagnosed with malignant pleural effusion through pleural fluid cytology or pleural/lung tissue biopsy, supported by radiological findings.
62610331|NCT00586287|EXPERIMENTAL|A|Algorithm which uses serum albumin and weight to determine the loading dose of phenprocoumon within the first 5 days
62610332|NCT00586287|EXPERIMENTAL|B|Algorithm which uses serum age and weight to determine the loading dose of phenprocoumon within the first 5 days
62610333|NCT00586287|ACTIVE_COMPARATOR|C|The physician chooses the loading dose of phenprocoumon according to his/her experience
62610334|NCT01237327|ACTIVE_COMPARATOR|1|
62610335|NCT01237327|EXPERIMENTAL|2|
62049771|NCT03376815||prostate ,landscape sample method|Samples from 100 patients with prostate carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
62610336|NCT05362695|EXPERIMENTAL|Cohort 1: 100 μg IW-3300|100 μg dose of active drug (IW-3300) once daily for 7 days
62610337|NCT05362695|PLACEBO_COMPARATOR|Cohort 1: Placebo|matching placebo once daily for 7 days
62610338|NCT05362695|EXPERIMENTAL|Cohort 2: 300 μg IW-3300|300 μg dose of active drug (IW-3300) once daily for 7 days
62610339|NCT05362695|PLACEBO_COMPARATOR|Cohort 2: Placebo|matching placebo once daily for 7 days
62251632|NCT05997433|ACTIVE_COMPARATOR|14 days|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid
62251633|NCT01878526|EXPERIMENTAL|Omeprazole plus alginic acid and placebo of domperidone|
62610340|NCT05362695|EXPERIMENTAL|Cohort 3 (optional): Dose 3|Active drug (IW-3300) once daily for 7 days
62049772|NCT03376815||liver, traditional sample method|Samples from 100 patients with liver cancer were obtained by traditional sampling method.
62251634|NCT01878526|EXPERIMENTAL|Omeprazole plus domperidone and placebo of alginic acid|
62610341|NCT05362695|PLACEBO_COMPARATOR|Cohort 3 (optional): Placebo|Matching placebo once daily for 7 days
62610342|NCT02189655|NO_INTERVENTION|Group Control|Hyperbaric bupivacaine 0.5% 2.5 mL was administered intrathecally in 30 seconds.
62610343|NCT02189655|EXPERIMENTAL|Group Diluting with cerebrospinal fluid|Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
62610344|NCT04603794|ACTIVE_COMPARATOR|1% Hydrogen Peroxide Mouth Rinse|30 second oral rinse with 1% Hydrogen Peroxide
62049773|NCT03376815||liver,landscape sample method|Samples from 100 patients with liver cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
62049774|NCT03376815||esophageal ,traditional sample method|Samples from 100 patients with esophageal carcinoma were obtained by traditional sampling method.
62049775|NCT03376815||esophageal ,landscape sample method|Samples from 100 patients with esophageal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
62049776|NCT03376815||GIST,traditional sample method|Samples from 100 patients with gastrointestinal stromal tumor were obtained by traditional sampling method.
62251635|NCT03059095|EXPERIMENTAL|Yoga and Meditation|Yoga and Meditation online sessions 2x's a week.
62251636|NCT04206995||Evaluation of odour capturing techniques|To evaluate two odour capturing techniques to compare VOC profiles of cancerous and healthy skin cancer.
62251637|NCT00943579|EXPERIMENTAL|Kuvan®|Kuvan® (sapropterin) will be administered to all subjects at 20 mg/kg/day for 16 weeks.
62251638|NCT01410682|EXPERIMENTAL|0.12% Chlorhexidine Digluconate|Oral care included use of an oral gel containing chlorhexidine digluconate 0.12% as an active ingredient (chlorhexidine digluconate 0.12%; methylcellulose gel 2.12%, 25 g; gooseberry syrup, 4 drops; menthol solution 50%,3 drops; and distilled water, to 30 g).The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular,lingual, occlusal, and incisal). After each quadrant was cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto- anterior movements.
62441316|NCT01577095|EXPERIMENTAL|EA + Rosiglitazone|
62441317|NCT01577095|PLACEBO_COMPARATOR|Rosiglitazone|
62441318|NCT04929496|NO_INTERVENTION|Angiographical guidance only|Standard of care
62610345|NCT04603794|ACTIVE_COMPARATOR|0.12% Chlorhexidine Gluconate Mouth Rinse|30 second oral rinse with 0.12% Chlorhexidine Gluconate
62610346|NCT04603794|ACTIVE_COMPARATOR|0.5% Povidone Iodine Mouth Rinse|30 second oral rinse with 0.5% Povidone Iodine Mouth wash
62610347|NCT04603794|PLACEBO_COMPARATOR|0.9% Normal Saline Mouth Rinse|30 second oral rinse with 0.9% Normal Saline
62610348|NCT03202069|EXPERIMENTAL|Even protein intake|Menu to provide 90 g of protein per day in an even distribution of 30 g at each meal.
62610349|NCT03202069|EXPERIMENTAL|Skewed protein intake|Menu to provide 90 g of protein per day in a skewed distribution of 10 g at breakfast, 15 g at lunch and 65 g at dinner.
62610350|NCT05400395|EXPERIMENTAL|GNX|GNX / 80mg / BID / PO
62610351|NCT05400395|PLACEBO_COMPARATOR|Placebo|Placebo / BID / PO
62610352|NCT01438372|EXPERIMENTAL|Intravenous iron sucrose arm|
62610353|NCT01438372|ACTIVE_COMPARATOR|Oral ferrous sulfate|
62610354|NCT01534780|EXPERIMENTAL|fixation with Protack|
62610355|NCT01534780|EXPERIMENTAL|fixation with Securestrap|
62610356|NCT01534780|EXPERIMENTAL|fixation with Glubran|surgery
62610357|NCT03059251||Obinutuzumab|All participants with chronic lymphocytic leukemia (CLL) who have received the indication for treatment with Obinutuzumab, as per routine clinical practice in Argentina.
62610358|NCT05055934|EXPERIMENTAL|SHR-1314 injection|
62610359|NCT05055934|PLACEBO_COMPARATOR|placebo|
62610360|NCT05876871|OTHER|Diagnostic Intervention|
62610361|NCT01836809|EXPERIMENTAL|Total Artificial Heart|Nesiritide
62610362|NCT01836809|PLACEBO_COMPARATOR|Total Artificial Heart: Placebo|Control arm for subjects receiving the Total Artificial Heart and randomized to receive placebo
62610363|NCT01836809|ACTIVE_COMPARATOR|LVAD: Nesiritide|Active arm of the LVAD group
62610364|NCT01836809|PLACEBO_COMPARATOR|LVAD: Placebo|Control arm for subjects receiving LVAD and randomized to placebo
62610365|NCT00932451|EXPERIMENTAL|PF-0231066|
62610366|NCT01057797|EXPERIMENTAL|Upper Body Strength Training with Self-Efficacy|16 weeks of upper body strength training combined with an exercise-specific self-efficacy enhancing intervention
62610367|NCT01057797|ACTIVE_COMPARATOR|Upper body strength training|16 weeks of upper body strength training with weekly health education sessions
62610368|NCT01057797|SHAM_COMPARATOR|Chair exercise|16 wks of gentle chair exercise with weekly health education
62610369|NCT06258317|EXPERIMENTAL|Mesh fixation|Procedure/Surgery: fixation of conventional polypropylene mesh. This group includes patients with fixation of conventional polypropylene mesh.
62610370|NCT06258317|EXPERIMENTAL|Non-mesh fixation|Procedure/Surgery: non-fixation of the mesh. This group includes patients without fixation of the mesh.
62049777|NCT03376815||GIST,landscape sample method|Samples from 100 patients with gastrointestinal stromal tumor were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
62610371|NCT02612610|PLACEBO_COMPARATOR|Placebo|Participants received one matching placebo tablet administered by mouth twice daily for 12 weeks.
62610372|NCT02612610|EXPERIMENTAL|Gefapixant 7.5 mg|Participants received one 7.5 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
62610373|NCT02612610|EXPERIMENTAL|Gefapixant 20 mg|Participants received one 20 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
62610374|NCT02612610|EXPERIMENTAL|Gefapixant 50 mg|Participants received one 50 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
62832896|NCT05048277|EXPERIMENTAL|Single Arm Study|"The intervention will consist of one 60-minute long session conducted through NYU ZOOM. Each session will be between one parent and one study consultant. The session is goal-oriented and solution-focused. During the SSC, consultants will identify the participant's hope for the session and a specific modifiable goal. From this, the consultant will discuss the smallest-possible step participants can take toward overcoming their identified problem and work together in creating an Action Plan, which will present three specific actions the participant can take to accomplishing the session's established goals. Following completion of the two-week follow-up assessment, additional resources personalized to participants will also be provided (i.e., referrals for further services and online resources for parents/children). Ultimately, this intervention is a way to potentially jumpstart progress and facilitate hope and agency."
62832897|NCT04876820|EXPERIMENTAL|Pharmacist-led intervention|
62832898|NCT04876820|SHAM_COMPARATOR|Standard of care|
62049778|NCT03376815||colorectal ,traditional sample method|Samples from 100 patients with colorectal carcinoma were obtained by traditional sampling method.
62441319|NCT04929496|EXPERIMENTAL|Post-PCI FFR guidance|Post-PCI Fractional Flow Reserve and non-hyperemic pressure ratios measurement
62441320|NCT01573923|SHAM_COMPARATOR|Conventional therapy|only apply for conventional medical therapy without any cell therapy
62441321|NCT01573923|ACTIVE_COMPARATOR|mesenchymal stem cells|combination of conventional therapy with umbilical mesenchymal stem cells intravenous injection, (4x107/40ml, once per three months, four times in one year)
62441322|NCT02896660|EXPERIMENTAL|ActiGraph Link|Study participants will wear an actigraphy device, the ActiGraph Link, continuously for 90 days
62441323|NCT06528444|PLACEBO_COMPARATOR|Placebo|placebo 1 capsule (6 mg) /day for 7 days.
62441324|NCT06528444|ACTIVE_COMPARATOR|dexamethasone|dexamethasone 1 capsule (6 mg)/day for 7 days
62610375|NCT04684875||Long-Term Study Subjects|All subjects who were treated with the Aerin Medical InSeca/RhinAer Stylus in the 50-subject TP668 interventional study, who consent to continue to provide quality of life data.
62832899|NCT04341246||Cases|Cases are defined as those patients who have undergone liver biopsy and have confirmed NASH and fibrosis
62832900|NCT04341246||Controls|Controls are patients have undergone a liver biopsy with neither significant NASH nor significant fibrosis
62832901|NCT02910479|EXPERIMENTAL|temperature measurements with 4 devices|temperature measurements with e-device Celsius, esophageal probe and a rectal probe and vital sense capsule
62441325|NCT06113523||Patient cohort|Patients already tested for monogenic obesity with the 71 genes panel.
62441326|NCT06113523||Control cohort|Patients tested for other indication than monogenic obesity in the lab. The DNA samples will be sequenced for the 71 obesity genes especially for the study.
62441327|NCT05497011|NO_INTERVENTION|Control|This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.
62449513|NCT00002965|EXPERIMENTAL|Arm 1: Benign Meningiomas|INF alpha as a subcutaneous injection Monday to Friday for 8 weeks.
62832902|NCT03824769|ACTIVE_COMPARATOR|Behavioral Weight Loss Maintenance + Healthy Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
62610376|NCT03493581|EXPERIMENTAL|NSCLC patients|
62610377|NCT03441282||ASA Patients I|"Age 18-80 years old, English-speaking, not on current Fentanyl/opioid therapy, no use of opioid medications in the 3 months prior to surgery, scheduled for elective surgery at UAB main.~A normal healthy patient Healthy, non-smoking, no or minimal alcohol use"
62610378|NCT03441282||ASA Patients III|"Age 18-80 years old, English-speaking, not on current Fentanyl/opioid therapy, no use of opioid medications in the 3 months prior to surgery, scheduled for elective surgery at UAB main.~A patient with severe systemic disease Substantive functional limitations; One or more moderate to severe diseases. Examples include (but not limited to): poorly controlled DM or HTN, COPD, morbid obesity (BMI ≥40), active hepatitis, alcohol dependence or abuse, implanted pacemaker, moderate reduction of ejection fraction, ESRD undergoing regularly scheduled dialysis, premature infant PCA \< 60 weeks, history (\>3 months) of MI, CVA, TIA, or CAD/stents."
62832903|NCT03824769|EXPERIMENTAL|Behavioral Weight Loss Maintenance Treatment + Future Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
62251639|NCT01410682|PLACEBO_COMPARATOR|tothbrushing|This group received the same oral care that experimental group with the use of a similarly formulated gel without the antiseptic agent.The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
62441328|NCT05497011|EXPERIMENTAL|PiCSO|This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).
62441329|NCT03216330||Case|"* Consented to participate in the Data Registry (H16-00264) prior to their physician appointment at the BC Women's Health Centre.~* New or re-referred to the BC Women's Health Centre for Pelvic Pain and Endometriosis.~* Endometriosis (previously surgically diagnosed, or current endometrioma, or current nodule)~* Willing and committed to indicating pain scores and menstrual data on a REDCap survey every day for 6 weeks after the test date.~* At least 18 years old"
62441330|NCT03216330||Control|"* Reproductive aged female with no suspected or diagnosed endometriosis.~* Have not experienced any sexual pain scores over 4/10 on a 11-point numeric rating scale, as determined on an online questionnaire prior to test day.~* At least 18 years old"
62441331|NCT05925101|EXPERIMENTAL|Clinical (Human) Study on Effects of Reinforcement-Rate Drop|Based on the TWML, we hypothesize that a large drop in reinforcement rate at the start of treatment with extinction alone or with FCT will increase the probability of an extinction burst. Preventing such drops will lessen the probability of an extinction burst. We will test the effects of eliminating reinforcement in the extinction-only condition and the effects of substantially decreasing the rate of reinforcement in the rate-drop condition. We will compare these two suboptimal treatments with one in which we ensure that the rate of reinforcement remains equal to baseline, called the rate-hold condition, which the TWML predicts will prevent an extinction burst.We will equate reinforcement magnitude (i.e., each reinforcer delivery will be 20 s) and quality (i.e., the functional reinforcer identified during the functional analysis) across the baseline and the rate-drop and rate-hold conditions (no reinforcement will be delivered in the extinction-only condition).
62610379|NCT05017025|EXPERIMENTAL|Treatment (osimertinib, aurora A kinase inhibitor LY3295668)|Patients receive osimertinib PO QD and aurora A kinase inhibitor LY3295668 PO BID on days 1-28. Treatment repeats every 28 days for 24 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
62610380|NCT04482166|EXPERIMENTAL|Candidates|Training of fiberoptic-guided tracheal intubation through supraglottic airway device to pediatric airway manikin
62610381|NCT03031041|EXPERIMENTAL|Short-axis hydrodissection|Ultrasound-guided short-axis hydrodissection with normal saline between carpal tunnel and median nerve
62441332|NCT05925101|EXPERIMENTAL|Clinical (Human) Study on Effects of Reinforcement-Magnitude Drop|Based on the TWML, we hypothesize that a large drop in reinforcement magnitude at the start of treatment will increase the probability of an extinction burst. Preventing drops will lessen the probability of an extinction burst. We will test the effects of eliminating reinforcement in the extinction-only condition and the effects of substantially decreasing the magnitude of reinforcement in the magnitude-drop condition. We will compare these two suboptimal treatments with one in which we ensure that the magnitude of reinforcement remains equal to baseline, called the magnitude-hold condition, which the TWML predicts will prevent an extinction burst. We will equate reinforcement rate (i.e., independent, VI 1.5-s schedules) and quality (i.e., the functional reinforcer identified during the functional analysis) across baseline and both FCT conditions (no reinforcement will be delivered in the extinction-only condition).
62441333|NCT05925101|EXPERIMENTAL|Clinical (Human) Study on Effects of Reinforcement-Quality Drop|Note: We will conduct Ex 3 with participants who display destructive behavior reinforced by access to tangible items so that we can vary reinforcement quality using the results of a paired-stimulus preference assessment. Based on the TWML, we hypothesize that a large drop in reinforcement quality at the start of FCT will increase the probability of an extinction burst. Preventing such drops will lessen the probability of an extinction burst. Therefore, we will program a large drop in the quality of reinforcement in our quality-drop condition and ensure that the quality of reinforcement remains equal to the quality of reinforcement in baseline in the quality-hold condition. In Experiment 3, we will equate reinforcement rate (i.e., independent, VI 1.5-s schedules) and magnitude (i.e., each reinforcer delivery will be 20 s) across baseline and both FCT conditions.
62441334|NCT05925101|EXPERIMENTAL|Clinical (Human) Study on Counteracting Reinforcement-Rate Drop with Quality Increase|Based on the TWML, we hypothesize that a large drop in reinforcement rate at the start of FCT will increase the probability of an extinction burst but that simultaneously increasing reinforcement quality will counteract the negative effects of a drop in reinforcement rate. We will program a large drop in the rate of reinforcement in the rate-drop-only condition, and in the rate-drop/quality-increase condition we will program the same drop in reinforcement rate but also program a large increase in reinforcement quality.
62441335|NCT00002806|EXPERIMENTAL|procarbazine + lomustine + vincristine + radiation|PCV followed by external-beam cranial irradiation using at least 6 MV photons.
62441336|NCT01252654||1 IntraLase flaps|Patients who have undergone flap creation with IntraLase laser
62441337|NCT01252654||2 Visumax flaps|Patients who have undergone flaps created with Visumax laser
62610382|NCT03031041|ACTIVE_COMPARATOR|Long-axis hydrodissection|Ultrasound-guided long-axis hydrodissection with normal saline between carpal tunnel and median nerve
62832904|NCT04591808|EXPERIMENTAL|S05167|
62832905|NCT04591808|ACTIVE_COMPARATOR|Lipitor®|
62832906|NCT04591808|ACTIVE_COMPARATOR|Coversyl®|
62251640|NCT02600104|EXPERIMENTAL|all subjects|will receive up to four (4) facial treatments in 3-8 weeks interval, with the PicoWayTM device-fractional hand piece 1064nm and/or 532nm according to the study protocol. Subjects will be followed by phone 7 days post first treatment by study staff, and will return for follow-up (FU) visits at the clinic at: 6 weeks and 12 weeks following the last treatment.
62251641|NCT03372928|EXPERIMENTAL|Standard EAA Dose|EAA dose provided at 0.10 g/kg body mass
62610383|NCT05370508|EXPERIMENTAL|Cohort 1|10 mg/kg IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy Level 1
62610384|NCT05370508|EXPERIMENTAL|Cohort 2|10 mg/kg IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy Level 2
62610385|NCT05370508|EXPERIMENTAL|Cohort 3|10 mg/kg IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy Level 3
62610386|NCT05370508|EXPERIMENTAL|Cohort 4|10 mg/kg IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy Level 4
62610387|NCT05370508|EXPERIMENTAL|Cohort 5|Recommended Phase 2 Dose (RP2D) IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy Level 5
62251642|NCT03372928|EXPERIMENTAL|High EAA Dose|EAA dose provided at 0.30 g/kg body mass
62610388|NCT05716217|EXPERIMENTAL|Training group|
62610389|NCT05716217|NO_INTERVENTION|Normal care|
62610390|NCT01880567|EXPERIMENTAL|Treatment (ibrutinib, rituximab)|Patients receive ibrutinib PO daily on days 1-28 and rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of course 1; on day 1 of courses 3-8; and on day 1 of every other course for all subsequent courses. Treatment with rituximab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Courses with ibrutinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62832907|NCT03638193|EXPERIMENTAL|CART-meso cells|A single dose of CART-meso T cells will be administered intravenously.The dose is 1-3×10\^7/m\^2 CART positive cells(chort 1)or 1-3×10\^8/m\^2 CART positive cells(chort 2).
62832908|NCT00942604|ACTIVE_COMPARATOR|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
62251643|NCT02722382|NO_INTERVENTION|Usual Nephrology Care|Nephrology care at Geisinger Health System.
62251644|NCT02722382|ACTIVE_COMPARATOR|Patient-Centered Kidney Transitions Care|Health system intervention which will implement informatics tools (including a disease registry, predictive modeling, and advance directives) and a disease specific care manager who will provide services and navigate patients through kidney disease transitions.
62251645|NCT06321289|EXPERIMENTAL|Allogeneic TRAC locus-inserted CD19-targeting STAR T cells|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide (FC regimen) will be administered followed by investigational treatment, allogeneic targeting CD19 synthetic T-cell receptor antigen receptor T cells.
62251646|NCT05692856|EXPERIMENTAL|Clenbuterol|Participants are randomized to daily ingestion of clenbuterol for a period of 8 weeks, with or without supervised resistance training.
62251647|NCT05692856|PLACEBO_COMPARATOR|Placebo|Participants are randomized to daily ingestion of placebo for a period of 8 weeks, with or without supervised resistance training.
62251648|NCT04202523|EXPERIMENTAL|RT&RFA|
62251649|NCT04202523|ACTIVE_COMPARATOR|RFA|
62251650|NCT06508918||group 1 (with central sensitization)|"Group: group 1 (with central sensitization) 8 mg betamethasone, 3 cc bupivacaine, 5 cc serum will be injected in the neck, and caudal force pressure, pressure pain thresholds will be evaluated with a manual algometer, accompanied by ultrasonography.~Group: group 2 (without central sensitization) 8 mg betamethasone, 3 cc bupivacaine, 5 cc serum will be injected in the neck, and caudal force pressure, pressure pain thresholds will be evaluated with a manual algometer, accompanied by ultrasonography."
62251651|NCT06508918||group 2 (without central sensitization)|"Group: group 1 (with central sensitization) 8 mg betamethasone, 3 cc bupivacaine, 5 cc serum will be injected in the neck, and caudal force pressure, pressure pain thresholds will be evaluated with a manual algometer, accompanied by ultrasonography.~Group: group 2 (without central sensitization) 8 mg betamethasone, 3 cc bupivacaine, 5 cc serum will be injected in the neck, and caudal force pressure, pressure pain thresholds will be evaluated with a manual algometer, accompanied by ultrasonography."
62251652|NCT04271085||Patients in the last phase of life|Patients in the last phase of life and their families
62251653|NCT03337542|OTHER|Treatment arm description|Subjects will receive maintenance dosing with AR101. Maintenance doses are provided in sachets, where each sachet contains 300 mg of peanut protein. Subjects are to ingest 300 mg orally once a day during maintenance.
62251654|NCT06191432|EXPERIMENTAL|NCWS Packets A-B|NCWS patients will undergo a Double-Blind Wheat Challenge DBWC with an ancient diploid wheat (TM) or a modern hexaploid wheat (TA). This DBWC will be performed with flour packets coded A or B, each containing respectively one of the wheat varieties. Packets A or B will be given for 1 week and then, after 1 week of washout (or until patients report complete well-being), the patients will receive the other packets for another 1 week (cross-over design).
62441338|NCT00119977|ACTIVE_COMPARATOR|1|
62441339|NCT05261113||Intervention cohort|Patients that were operated due to liver neoplasms with use of CE-IOUS
62441340|NCT05261113||Control cohort|Patients that were operated due to liver neoplasms without use of CE-IOUS
62441341|NCT00788528|EXPERIMENTAL|Arm A|1600 mg S-2367 (velneperit)
62441342|NCT01592799|OTHER|Influenza Group|Children \<15 years of age hospitalized for or presenting to an ER for acute ARI and/or isolated fever during the influenza season.
62610391|NCT01923337|EXPERIMENTAL|Treatment (irinotecan, alisertib)|Patients receive irinotecan hydrochloride IV over 30 minutes on days 1 and 8 and alisertib PO BID on days 1-3 and 8-10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62610392|NCT05428384||mono arm|Each subject will have at baseline and at 3 month follow-up CardioMEMS readings paired with cardiac MRI scans and measurements completed for each subject will be under nominally the same conditions.
62610393|NCT05735275|EXPERIMENTAL|SHR-A2102 Does Escalation and Expansion|
62832909|NCT00942604|PLACEBO_COMPARATOR|Vehicle gel|Vehicle gel once daily for 2 consecutive days
62610394|NCT02380118|EXPERIMENTAL|Olanzapine|intramuscular olanzapine injection (zyprexa), 5 mg/dose, first dose and an optional second dose.
62832910|NCT05216549|EXPERIMENTAL|Water-based exercise|The water-based exercise group will be held twice a week, 45 min per session for 8 weeks. Supervised exercise will be led by the experienced physiotherapist and water-based exercise by physiotherapist with aquatic exercise expertise.Each session will consist of warm up (10 min), main part (30 min) and cool-down (5 min). During warm up children will perform lower and upper limbs aerobics and breathing exercises. The main part will consist of endurance exercises of upper and lower limbs with focus on breathing pattern. During cool-down focus will be on upper limb and thoracic cage stretches and breathing control.
62251655|NCT06191432|EXPERIMENTAL|NCWS Packets B-A|NCWS patients will undergo a Double-Blind Wheat Challenge DBWC with an ancient diploid wheat (TM) or a modern hexaploid wheat (TA). This DBWC will be performed with flour packets coded A or B, each containing respectively one of the wheat varieties. Packets A or B will be given for 1 week and then, after 1 week of washout (or until patients report complete well-being), the patients will receive the other packets for another 1 week (cross-over design).
62049779|NCT03376815||colorectal ,landscape sample method|Samples from 100 patients with colorectal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
62251656|NCT01508195|EXPERIMENTAL|Treatment Sequence AB|Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 1 followed by Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between treatment periods.
62251657|NCT01508195|EXPERIMENTAL|Treatment Sequence BA|Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 1 followed by Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between treatment periods.
62441343|NCT03562403|EXPERIMENTAL|DBS on patients with abnormal movement disorders|16 patients with intractable abnormal movement disorders (Parkinson's disease, Essential tremors and Dystonia)
62441344|NCT00698022|EXPERIMENTAL|Risperidone plus mifepristone|risperidone plus mifepristone daily for 28 days
62610395|NCT02380118|ACTIVE_COMPARATOR|Haloperidol|intramuscular haloperidol injection, 5 mg/dose, first dose and an optional second dose.
62610396|NCT02380118|ACTIVE_COMPARATOR|Midazolam|intramuscular midazolam injection, 5 mg/dose, first dose and an optional second dose.
62610397|NCT05812092||DePuy Synthes Cervical Plating System|All enrolled patients will receive CONDUIT Interbody Cervical System with supplemental fixation using a DePuy Synthes Cervical Plating System.
62832911|NCT05216549|EXPERIMENTAL|Land-based exercise|The land-based exercise group will be held twice a week, 45 min per session for 8 weeks. Supervised exercise will be led by the experienced physiotherapist and water-based exercise by physiotherapist with aquatic exercise expertise.Each session will consist of warm up (10 min), main part (30 min) and cool-down (5 min). During warm up children will perform lower and upper limbs aerobics and breathing exercises. The main part will consist of endurance exercises of upper and lower limbs with focus on breathing pattern. During cool-down focus will be on upper limb and thoracic cage stretches and breathing control.
62832912|NCT05216549|NO_INTERVENTION|Control|The control group will be asked not to change their physical activity for 8 weeks. After that period and post-test the control group will receive the exercise.
62832913|NCT04374669||patients with lumbar spinal stenosis|Patients with lumbar spinal stenosis will be scheduled for neuroplasty.
62049780|NCT03376815||pancreatic ,traditional sample method|Samples from 100 patients with pancreatic carcinoma were obtained by traditional sampling method.
62049781|NCT03376815||pancreatic,landscape sample method|Samples from 100 patients with pancreatic carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
62049782|NCT03376815||lung cancer,traditional sample method|Samples from 100 patients with lung cancer were obtained by traditional sampling method.
62049783|NCT03376815||lung cancer,landscape sample method|Samples from 100 patients with lung cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
62049784|NCT03376815||Renal ,traditional sample method|Samples from 100 patients with renal carcinoma were obtained by traditional sampling method.
62049785|NCT03376815||Renal carcinoma,landscape sample method|Samples from 100 patients with renal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
62251658|NCT04964713||type 2 diabetes|T2DM was defined according to the WHO 2006 criteria. Assessing the left heart and right heart structure and function of T2DM by speckle tracking echocardiography.
62832914|NCT03414983|EXPERIMENTAL|Arm A|Nivo + SOC
62832915|NCT03414983|ACTIVE_COMPARATOR|Arm B|SOC
62049786|NCT03376815||Breast cancer,traditional sample method|Samples from 100 patients with breast cancer were obtained by traditional sampling method.
62049787|NCT03376815||Breast cancer,landscape sample method|Samples from 100 patients with breast cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
62049788|NCT03376815||cervical ,traditional sample method|Samples from 100 patients with cervical carcinoma were obtained by traditional sampling method.
62251659|NCT04964713||Prediabetes|According to the WHO 2006 criteria, combining impaired fasting glucose and impaired glucose tolerance as prediabetes. Assessing the left heart and right heart structure and function of prediabetes by speckle tracking echocardiography.
62251660|NCT04964713||normal glucose metabolism(NGM)|Assessing the left heart and right heart structure and function of NGM by speckle tracking echocardiography.
62251661|NCT03827382|ACTIVE_COMPARATOR|Intervention|Patients with intensive Lifestyle intervention
62251662|NCT03827382|NO_INTERVENTION|Control|Patients with Standard Diabetes care
62832916|NCT01849991|ACTIVE_COMPARATOR|Lactobacillus reuteri|The first arm of the cohort will include 30 patients on LR (5x10\^8 cfu's orally once daily.)
62049789|NCT03376815||cervical ,landscape sample method|Samples from 100 patients with cervical carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
62049790|NCT01751555|EXPERIMENTAL|TDF/3TC/EFV Treatment HIV/HBV Co-infection|TDF+3TC+EFV treatment regimen in Adults with HIV/HBV Coinfection
62049791|NCT04252742|EXPERIMENTAL|Erenumab|"The 4-month DBTP has 2 phases:~* Main double-blind treatment phase (M-DBTP, months 1 to 3) that will assess the effect of erenumab on metrics such as time spent in at least moderate pain, peak migraine severity, and functional impairment.~* Exploratory DBTP (E-DBTP, month 4) that will assess the impact of erenumab on the acute response to treatment with oral triptan therapy as well as non-ictal burden."
62049792|NCT04252742|EXPERIMENTAL|Placebo|"The 4-month DBTP has 2 phases:~* Main DBTP (M-DBTP, months 1 to 3) that will assess the effect of erenumab on metrics such as time spent in at least moderate pain, peak migraine severity, and functional impairment.~* Exploratory DBTP (E-DBTP, month 4) that will assess the impact of erenumab on the acute response to treatment with oral triptan therapy as well as non-ictal burden."
62049793|NCT05203484|EXPERIMENTAL|Multielectrode mapping|Participants assigned to the Multielectrode Mapping arm will undergo VT ablation within 48 hours after baseline evaluation. The Mapping procedure will be performed with either a Pentaray or Octaray catheter (Biosense Webster; each 45 catheters, randomly allocated). Catheter ablation of potential diastolic pathways and Scar homogenisation will be performed with a irrigated 3.5mm tip catheter (QDot; Biosense Webster).
62049794|NCT05203484|ACTIVE_COMPARATOR|Point-by-Point Mapping|Participants assigned to the Point-by-Point Mapping arm will undergo VT ablation within 48 hours after baseline evaluation. The Mapping procedure will be performed with a QDot catheter (Biosense Webster). Catheter ablation of potential diastolic pathways and scar homogenisation will also be performed with the QDot catheter.
62251663|NCT03514030||positive|serum AQP4-antibody is positive
62251664|NCT03514030||negtive|serum AQP4-antibody is negtive
62251665|NCT05732662|EXPERIMENTAL|SBRT combined with PD-1/CTLA-4 dual antibody|
62832917|NCT01849991|PLACEBO_COMPARATOR|Sunflower Oil|The second arm includes 15 subjects on placebo (sunflower oil.)
62610398|NCT03105921|EXPERIMENTAL|Electrodes|Electrodes
62832918|NCT00610298|EXPERIMENTAL|I|Subjects who receive whole body vibration
62251666|NCT02706704|ACTIVE_COMPARATOR|Intravitreal|Intravitreal injection of 1.5mg/0.03ml adalimumab given at zero, 2 weeks, and then every 4 weeks.
62251667|NCT02706704|ACTIVE_COMPARATOR|Systemic|Subcutaneous injection of 40 mg adalimumab (Humira) given every 2 weeks.
62251668|NCT05769023|EXPERIMENTAL|Experimental|behavioral intervention
62832919|NCT00610298|NO_INTERVENTION|N|Subjects do not receive whole body vibration intervention
62832920|NCT05104138||Half fluence photodynamic therapy|Patients with central serous chorioretinopathy, treated by half-fluence photodynamic therapy
62832921|NCT05104138||Oral Eplerenone|Patients with central serous chorioretinopathy, treated by oral eplerenone
62832922|NCT01371357|EXPERIMENTAL|TEST1|2.4 g/day of guanidinoacetic acid
62832923|NCT01371357|EXPERIMENTAL|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogen citrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
62049795|NCT05936931|OTHER|Aim 3: Single arm, open-label, pre-test/post-test design pilot trial|Single arm, open-label, pre-test/post-test design pilot trial
62251669|NCT04762641|EXPERIMENTAL|ABL503|ABL503 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
62610399|NCT05191589|EXPERIMENTAL|Intervention Group|In the intervention group trainees will train in an already validated laparoscopic training program with haptic devices.
62049796|NCT04201457|EXPERIMENTAL|Phase 1 Stratum 1 BRAF V600E LGG or HGG|LGG or HGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the assigned dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
62049797|NCT04201457|EXPERIMENTAL|Phase 1 Stratum 2 BRAF aberration or LGG with NF1|LGG with BRAF duplication or fusion with any partner or LGG with NF1 will received Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the assigned dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
62832924|NCT01371357|EXPERIMENTAL|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
62832925|NCT01371357|EXPERIMENTAL|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
62251670|NCT02575053||Latex group|patients who report ( a high risk for) latex allergy and will be operated on
62251671|NCT03891342|EXPERIMENTAL|Patients with sepsis/septic shock|Comaprison of fast or slow fluid bolus administration in patients with sepsis/septic shock 48hours before admission to ICU requiring fluid challenge as assessed by clinical examination
62251672|NCT03891342|EXPERIMENTAL|Major surgical patients|Comaprison of fast or slow fluid bolus administration in patients undergoing major surgery requiring fluid challenge as assessed by clinical examination
62610400|NCT05191589|NO_INTERVENTION|Control|In the control group trainees will complete the same validated training program in the conventional non-haptic setting.
62610401|NCT05375084|EXPERIMENTAL|Dose Escalation Level 1|Level 1 oral capsules administered in combination with nivolumab
62832926|NCT06654193|PLACEBO_COMPARATOR|Placebo|Normal saline
62832927|NCT06654193|EXPERIMENTAL|Treatment|Allogeneic adipose-derived HB-adMSCs
62832928|NCT05490225|EXPERIMENTAL|Ark Implantation|Single arm study. Depending on the clinical needs of the patient, the physician will decide if a single return Ark is needed (ex. easily cannulatable arterial pull site but the venous return access site is poorly accessible for cannulation) or two Arks (both arterial pull and venous return are poorly accessible for cannulation).
62832929|NCT02559141|OTHER|Study group (SG)|"Before induction of anaesthesia:~* Arterial line~* Nexfin Monitoring System~* Measurement of cardiac index (CI), pulse pressure variation (PPV) and mean arterial pressure (MAP)~* Baseline blood samples. Induction of anaesthesia~Study Group:~* PPV ≤10%, 500 ml of crystalloids/colloids as long as CI was ≥2.5 l/min/m²~* Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min)."
62610402|NCT05375084|EXPERIMENTAL|Dose Escalation Level 2|Level 2 oral capsules administered in combination with nivolumab
62610403|NCT05375084|EXPERIMENTAL|Dose Escalation Level 3|Level 3 oral capsules administered in combination with nivolumab
62610404|NCT05375084|EXPERIMENTAL|Dose Expansion|RP2D defined dose. Oral capsules administered in combination with nivolumab
62832930|NCT02559141|NO_INTERVENTION|Control group (CG)|"* MAP ≥65 mmHg~* CVP ≤12 mmHg~* Haemoglobin level ≥8 g/dl.~* Maintenance of MAP ≥65 mmHg by using crystalloids/colloids, bolus injection of theodrenaline/cafedrine or continuous infusion of norepinephrine (0.03 µg/kg/min) according to clinical evaluation."
62251673|NCT00489814||1|Patients who are planned to undergo local proton radiotherapy for biopsy-proven, untreated, prostate adenocarcinoma.
62251674|NCT04297813|ACTIVE_COMPARATOR|Control|The gold standard; Bone block from the ramus of the nation will be transplanted to the alveolar ridge.
62251675|NCT04297813|EXPERIMENTAL|Test|Expanded, autologous mesenchymal stem cells in combination with biphasic calcium phosphate
62441345|NCT00698022|PLACEBO_COMPARATOR|Risperidone plus mifepristone-matched placebo|risperidone plus mifepristone-matched placebo daily for 28 days
62441346|NCT00698022|PLACEBO_COMPARATOR|Risperidone-matched placebo plus mifepristone|risperidone-matched placebo plus mifepristone daily for 28 days
62441347|NCT04938206|EXPERIMENTAL|management reduction strategy|Patients classified as low risk by the DRC who will have a reduction in the management of their post-chemotherapy NF.
62441348|NCT04938206|ACTIVE_COMPARATOR|standard management|Patients classified as low risk by the DRC who will have standard management of post-chemotherapy NF.
62441349|NCT01518491|EXPERIMENTAL|NanoDOX Hydrogel plus VAC|NanoDOX™ Hydrogel in conjunction with serial wound debridement and irrigation on open traumatic orthopedic and soft tissue wounds in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.
62441350|NCT01518491|ACTIVE_COMPARATOR|VAC Alone|Serial wound debridement and irrigation alone in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.
62441351|NCT00943800|EXPERIMENTAL|Good Risks patients|For patients transplanted in remission.
62441352|NCT00943800|EXPERIMENTAL|High Risk Patients eligible for radiation|
62441353|NCT00943800|EXPERIMENTAL|High Risk Patients not eligible for radiation|
62441354|NCT03639597|EXPERIMENTAL|Study device|VytronUS Ablation System
62441355|NCT01768000|EXPERIMENTAL|Family Cognitive Adaptation Training|Participants in this group will receive the Family CAT manual and DVD
62441356|NCT01768000|NO_INTERVENTION|Control group|Participants in this arm will support their family members as usual, and will not receive the Family CAT manual and DVD provided to those in the experimental arm of the study.
62832931|NCT06589323||Group 1|adult patients undergoing coronary artery bypass surgery
62251676|NCT06048107|EXPERIMENTAL|a prospective single-arm clinical study|
62251677|NCT03021148||High-school children|"High-school children, age range from 13 to 18 years, from Liceo Classico and Liceo Artistico Tommaso Fazello of Sciacca, Agrigento, Italy"
62441357|NCT01736410|OTHER|IHC method|
62610405|NCT05993026|EXPERIMENTAL|Mental health course|A mental health-promoting student course offered to lower secondary school classes delivered by their teacher or another employee of the school. T
62610406|NCT06481488|EXPERIMENTAL|Part A, Cohort 1: E2086 Dose 1 or Placebo|Healthy participants will receive E2086 Dose 1 or two E2086 matched placebo, tablets, orally, once daily after an overnight fast of 10 hours.
62610407|NCT06481488|EXPERIMENTAL|Part A, Cohort 2: E2086 Dose 2 or Placebo|Healthy participants will receive E2086 Dose 2 or one E2086 matched placebo, tablets, orally, once daily after an overnight fast of 10 hours.
62610408|NCT06481488|EXPERIMENTAL|Part A, Cohort 3: E2086 Dose 3 or Placebo|Healthy participants will receive E2086 Dose 3 or two E2086 matched placebo, tablets, orally, once daily after an overnight fast of 10 hours.
62610409|NCT06481488|EXPERIMENTAL|Part B: E2086 Dose 2 Fasted + E2086 Dose 2 Fed|Healthy participants will receive E2086 Dose 2, tablets, orally, once on Day 1 of Treatment Period 1 in fasted state, followed by E2086 Dose 2, tablets, orally, once on Day 4 of Treatment Period 2 in fed state.
62251678|NCT05351983|EXPERIMENTAL|Organoid generation|All patients will included in a single-arm. Participants will undergo biopsy of tumor tissue for subsequent organoid generation.
62251679|NCT03649282|EXPERIMENTAL|HFNC/NCPAP|HFNC will be provided for 45 minutes followed by NCPAP for 45 minutes. Cardiorespiratory signals including electrocardiogram (ECG), respiratory inductive plethysmography (RIP), oxygen saturation (SpO2) and Pulse rate will be recorded continuously during the interventions and analyzed offline.
62441358|NCT01736410|OTHER|FISH method|
62441359|NCT05958277|EXPERIMENTAL|Vitamin B3|Vitamin B3 group
62441360|NCT05958277|EXPERIMENTAL|Vitamin B12 group|Vitamin B12 group
62449514|NCT00002965|EXPERIMENTAL|Arm 2: Other Pathologies|INF alpha as subcutaneous injection Monday to Friday for 8 weeks.
62610410|NCT06481488|EXPERIMENTAL|Part B: E2086 Dose 2 Fed + E2086 Dose 2 Fasted|Healthy participants will receive E2086 Dose 2, tablets, orally, once on Day 1 of Treatment Period 1 in fed state, followed by E2086 Dose 2, tablets, orally, once on Day 4 of Treatment Period 2 in fasted state.
62049798|NCT04201457|EXPERIMENTAL|Phase 2 Stratum 3 LGG with BRAF V600 mutation|LGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
62049799|NCT04201457|EXPERIMENTAL|Phase 2 Stratum 4 HGG with BRAF V600 mutation|HGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria
62049800|NCT04201457|EXPERIMENTAL|Phase 2 Stratum 5 LGG with BRAF aberration|LGG with BRAF duplication or fusion with any partner will receive Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
62049801|NCT04201457|EXPERIMENTAL|Phase 2 Stratum 6 LGG with NF Type 1|LGG with Neurofibromatosis Type 1 will receive Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
62049802|NCT05899686|EXPERIMENTAL|Tetanic Stimulus|all participants receive the same intervention, which is three tetanic stimuli applied to three different anatomical locations. The three anatomical locations are identical in all subjects.
62049803|NCT01822587|PLACEBO_COMPARATOR|Placebo|Administered once orally following cue exposure on each of the first two days of testing.
62049804|NCT01822587|ACTIVE_COMPARATOR|Propranolol 40mg|Administered once orally following cue exposure on each of the first two days of testing.
62049805|NCT01822587|ACTIVE_COMPARATOR|Propranolol, 80mg|Administered once orally following cue exposure on each of the first two days of testing.
62049806|NCT03496519|EXPERIMENTAL|Dose Escalation|"Dose escalation will occur following a 3+3 design in all advanced tumor types meeting the inclusion and exclusion criteria.~* Cohort -1 (if necessary): Durvalumab 1125mg with Trabectedin 0.5mg/m2~* Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2~* Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2~* Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2~* Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2"
62049807|NCT03496519|EXPERIMENTAL|Dose Expansion|Patients at this level will receive the safest dose of Durvalumab and Trabectedin that was determined during the Dose Escalation Phase. There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be fixed dosage of Trabectedin for each cohort, given through intravenous infusion as an outpatient, over a 24 hour period on Day 1 every 21 days.
62049808|NCT03883867||Normal|The subject population will involve 10 non-pregnant women. The tactile imaging reprifucibility sub-group will include 5 non-pregnant subjects with 2 tactile imaging examinations completed in one session. All other subjects will have a single tactile imaging examination.
62049809|NCT03883867||Pregnant|The subject population will involve 10 pregnant women without known complications at 36-37 weeks of pregnancy scheduled for a regular examination. All pregnant subjects should be examined weekly after completing 36th week of an uncomplicated pregnancy. Routine gynecologic examination includes external and internal obstetrical examination.
62049810|NCT02355028|EXPERIMENTAL|LHA510|LHA510 ophthalmic suspension administered topically in the study eye as specified in the protocol for 84 days, with ranibizumab ophthalmic solution for IVT injection as standard of care rescue therapy.
62251680|NCT03649282|EXPERIMENTAL|NCPAP/HFNC|NCPAP will be provided for 45 minutes followed by HFNC for 45 minutes. Cardiorespiratory signals including electrocardiogram (ECG), respiratory inductive plethysmography (RIP), oxygen saturation (SpO2) and Pulse rate will be recorded continuously during the interventions and analyzed offline.
62251681|NCT00627783|EXPERIMENTAL|Intervention|Patients are referred to a cardiologist for a systematic detection of silent ischemia by a bicycle exercise test performed according to the French Society of Cardiology protocol after washout of cardiovascular medications likely to interfere with the test. Dipyridamole Single Photon Emission Computed Tomography (SPECT) is used in patients unable to perform the exercise test, with a sub-maximal negative exercise test result or with electrocardiographic abnormalities impairing the interpretation of the exercise test. Subsequent investigations (such as coronary angiography) and treatments (such as revascularization procedures) are left at the cardiologist's decision.
62610411|NCT04392830|EXPERIMENTAL|ALZ002 DS|"SAD: 6 cohorts of subjects are planned to be orally dosed, ranging from 15 mg - 800 mg.~MAD: 3 cohorts of subjects are planned to be orally dosed once or twice daily for 7 consecutive days, ranging from 300 mg - 600 mg."
62832932|NCT05432440|EXPERIMENTAL|Intervention group (the digital asthma education program)|"The intervention group receives the digital asthma education program (MIRACLE program). It consists of an asthma interactive narrative, a serious game, and an asthma action plan. It mainly covers asthma self-management and asthma attack prevention, such as asthma definition, asthma triggers and how to prevent asthma triggers exposures, asthma medications, proper inhaler technique, and asthma written action plan.~The time schedule will be described as:~1. Explain study purposes, program, procedures, and instructions (10 minutes).~2. Accompany children and parents to download and install the MIRACLE program on Google Play Store for free on their personal computers, tablets, or smartphones (5 minutes).~3. Asthma education will take place over one session lasting approximately 45 minutes."
62251682|NCT00627783|NO_INTERVENTION|Control|Patients are treated according current guidelines but are not referred to a cardiologist
62251683|NCT06010498|EXPERIMENTAL|Eye Mask Group|
62251684|NCT06010498|NO_INTERVENTION|Standart Care|
62610412|NCT04392830|PLACEBO_COMPARATOR|Placebo|Placebo
62610413|NCT05439928|EXPERIMENTAL|DEXCOM G6 CGM|Continuous glucose monitoring by DEXCOM G6 (glucose monitoring device) in a step-down unit in participants with DKA
62610414|NCT05439928|NO_INTERVENTION|Hourly Finger Stick Point of Care (Historical Control)|Retrospective chart review of DKA patients that received hourly glucose monitoring by finger stick while in the ICU
62610415|NCT01075399|EXPERIMENTAL|[F 18]HX4|\[F18\]HX4, 10 mCi, is administered in a single intravenous bolus injection, followed by a saline flush.
62610416|NCT03065036|EXPERIMENTAL|Hydrus Aqueous Implant|Hydrus implanted into Schlemm's Canal.
62610417|NCT03065036|OTHER|IOL placement and Hydrus implant|Cataract Extraction with IOL placement and Hydrus implant into Schlemm's canal
62251685|NCT05973552||All participants|Women (n=250), are followed throughout their pregnancy. Mother-infant pairs are followed throughout the first 6-months postpartum. Women receive daily oral iron supplementation during pregnancy in accordance with local standards of care. Using the stable iron isotopes dilution methodology, concentration of the stable iron isotope tracer (57Fe) in circulation will be measured throughout pregnancy and up to 6 months postpartum in both, mother and infant.
62832933|NCT05432440|ACTIVE_COMPARATOR|Control group (the booklet asthma education program)|"For the control group, a pharmacist (same personnel) will provide an asthma education using a booklet for 45-60 minutes to children and parents. Patients will be asked to read the booklet at home for 15 minutes in 7 days. It mainly covered the same content as the MIRACLE program. The time schedule will be described as:~1. Explain study purposes, booklet, procedures, and instructions (10 minutes).~2. Asthma education will take place over one session lasting approximately 45 minutes."
62832934|NCT05462522|EXPERIMENTAL|MAD Stage|Participants will be randomized in a ratio of 4:1 to receive RO7303509 or placebo, as subcutaneous (SC) injection, one time per month for 3 months. You have a 20% chance of getting placebo.
62832935|NCT05462522|EXPERIMENTAL|OSE Stage|Every participant in the OSE stage will receive study drug and no participant will receive placebo. Participants will receive RO7303509 as SC injection at the same dose as that administered during the MAD stage, one time per month for up to a year.
62832936|NCT00432172|ACTIVE_COMPARATOR|Group 1 (Luminal A) Standard treatment|Standard treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv every 21 days for 4 cycles.
62832937|NCT00432172|EXPERIMENTAL|Group 1 (Luminal A) Selective treatment|"Selective treatment:~Postmenopausal patients: exemestane x 6 months Premenopausal patients: goserelin x 6 months + exemestane x 6 months"
62251686|NCT05973552||Randomly selected sub-group|To directly assess dietary iron absorption, in a randomly selected subset of women (n=35), oral and intravenous stable iron isotope tracers (54Fe, 58Fe) will be administered. Oral iron absorption and erythrocyte iron incorporation will be measured 14 days after tracer administration.
62441361|NCT01858714|ACTIVE_COMPARATOR|Behavior Therapy (BT)|"Active Comparator: Behavior Therapy~Behavioral treatment strategies will be utilized to facilitate adherence to the treatment goals in all three treatments. Participants in the BT condition will receive only the BT intervention. Strategies that will be emphasized are listed below:~Self monitoring Stimulus control Changing eating behaviors Goal setting Problem solving Social support Cognitive restructuring Relapse prevention"
62441362|NCT01858714|EXPERIMENTAL|Behavior Therapy + Environment|Participants will receive standard behavioral therapy with an emphasis on environmental strategies.
62441363|NCT01858714|EXPERIMENTAL|Acceptance-based BT + Environment|Participants will receive acceptance-based behavioral therapy with an emphasis on environmental strategies.
62441364|NCT01962883|NO_INTERVENTION|Control group|Osteopathic evaluation Cognitive and Physical Rest
62441365|NCT01962883|EXPERIMENTAL|Osteopathic Treatment Group|4 osteopathic treatments following a set protocol to which only the osteopathic lesions found within the subjects assessment will be treated.
62441366|NCT00831727|EXPERIMENTAL|Expressive Writing|
62049811|NCT02355028|PLACEBO_COMPARATOR|Vehicle|LHA510 vehicle administered topically in the study eye as specified in the protocol for 84 days, with ranibizumab ophthalmic solution for IVT injection as standard of care rescue therapy.
62049812|NCT04866615||50 patients newly diagnosed SLE with no treatment|OCT \& OCTA for newly diagnosed SLE patients
62441367|NCT00831727|PLACEBO_COMPARATOR|Control|
62441368|NCT02232048||Corticosteroid Treatment|Patients in the internal medicine department who are being treated with corticosteroids will undergo Transthoracic Echocardiogram to determine change in heart function.
62441369|NCT02739984|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injection once every month (QM) for 12 weeks.
62441370|NCT02739984|EXPERIMENTAL|Evolocumab|Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks.
62441371|NCT02658409|EXPERIMENTAL|GC3106(quadrivalent)|0.5ml, intramuscular, a single dosing
62441372|NCT02658409|ACTIVE_COMPARATOR|Fluarix™tetra Syringe Inj.(Quadrivalent)|0.5ml,intramuscular,a single dosing
62049813|NCT04866615||50 patients SLE on treatment by (HCQ) at doses of less than 6.5 mg/kg per day for less than 5 years|OCT \& OCTA for on treatment SLE patients
62049814|NCT04866615||50 normal subjects as control group of similar age and gender|OCT \& OCTA for normal subjects
62049815|NCT04284449||Enrolled Participants|This is a whole-practice precision medicine model in which a participant-specific Naturopathic treatment program is developed and implemented for older adults with cognitive complaints.
62049816|NCT01719484||Healthy|Subjects deemed to be medically healthy
62049817|NCT01719484||Obese|Subjects deemed to be medically obese
62251687|NCT05040724|EXPERIMENTAL|Ivermectin|Ivermectin 3mg, on tablet. As a single dose of 400 µg / kg orally (rounded down to the nearest unit). T+ usual care
62441373|NCT01167920|ACTIVE_COMPARATOR|Virtual Hypertension Clinic Group|In the VHC group, patients will be ask to regularly measure blood pressure with the Stabil-o-Graph so that these readings are transmitted to Virtual Hypertension Clinic. The data will be reviewed weekly and the patient will receive feedback and intervention if needed at every 2 week interval to achieve blood pressure goal. Once they reach goal, the feedback will be less intense and given at four week intervals till the end of the study.
62832938|NCT00432172|ACTIVE_COMPARATOR|Group 2 (Basal) Standard treatment|Standard treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv every 21 days for 4 cycles.
62832939|NCT00432172|EXPERIMENTAL|Group 2 (Basal) Selective treatment|Selective treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv and carboplatin (Cb) (area under the curve = 6 mg/mL) iv every 21 days for 4 cycles.
62832940|NCT03771664|PLACEBO_COMPARATOR|Placebo|Participants received SAGE-217 matching placebo capsules (single-blind), orally, once daily prior to Day 1 (Days -2 and -1) followed by self-administration of SAGE-217 matching placebo capsules, orally, once daily for 12 days. Thereafter participants received SAGE-217 matching placebo capsules, orally, once daily, 30 minutes prior to lights out \[polysomnography (PSG)\] on Days 13 and 14 (double-blind). Thereafter participants self-administered SAGE-217 matching placebo capsules (single-blind), orally, once daily on Days 15 to 21.
62049818|NCT03367039|EXPERIMENTAL|ProDisc-C vivo|This group of patients will be treated with ProDisc-C vivo disc replacement (single segment).
62049819|NCT03367039|ACTIVE_COMPARATOR|Anterior cervical discectomy fusion|This group of patients will be treated with anterior cervical discectomy fusion (ACDF) procedure (single segment).
62049820|NCT03087955|EXPERIMENTAL|Acoziborole (SCYX-7158)|Acoziborole (SCYX-7158), in 320-mg tablets, administered by the oral route to patients in the fasting state according to the following dosing regimen: 960 mg (3 tablets) in a single intake on Day 1.
62049821|NCT01281202|ACTIVE_COMPARATOR|CPP-109 Vigabatrin Tablets|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -2 to -4 week Screening/Baseline Phase~During treatment, subjects received 3 CPP-109 Vigabatrin 500 mg Tablets, bid, for 9 weeks~Subjects were provided with on-site, supervised, standardized, manualized Individual Drug Counseling 1x per week for 9 weeks and the first 4 weeks for the follow-up phase (weeks 10-13)"
62049822|NCT01281202|PLACEBO_COMPARATOR|Placebo|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -2 to -4 week Screening/Baseline Phase~During treatment, subjects received Vigabatrin matching placebo tablets, bid, for 9 weeks~Subjects were provided with on-site, supervised, standardized, manualized Indivdiual Drug Counseling 1x per week for 9 weeks and the first 4 weeks for the follow-up phase (weeks 10-13)"
62049823|NCT01899313|EXPERIMENTAL|CBT- based SMS text messaging intervention|cognitive behavioral therapy- (CBT-) based short message service (SMS) text messaging intervention
62049824|NCT01899313|PLACEBO_COMPARATOR|Placebo Texts|Placebo texts will be given instead of interventional texts
62049825|NCT00863252|EXPERIMENTAL|1|MMF
62049826|NCT00863252|ACTIVE_COMPARATOR|2|Control
62049827|NCT00554008|ACTIVE_COMPARATOR|1|children randomized to open appendectomy
62049828|NCT00554008|ACTIVE_COMPARATOR|2|children randomized to laparoscopic appendectomy
62049829|NCT05997264|EXPERIMENTAL|Full Dose Schedule 1|"This study group will receive full dose AV7909 (0.5mL) at study days 1, 15, 181 and 366. A placebo full dose (0.5 mL) will be administered between the second and third dose of AV7909 at study day 29.~Update: Enrollment to this treatment arm was closed on 13 May 2024."
62251688|NCT05040724|PLACEBO_COMPARATOR|control|placebo of ivermectin administered in the same manner as the active drug in experimental arm + usual care
62251689|NCT06423482|EXPERIMENTAL|PEEK bar|
62251690|NCT06423482|EXPERIMENTAL|Titanium bar|
62251691|NCT05022394|EXPERIMENTAL|Treatment (sapanisertib, nivolumab)|Patients receive PO QD on days 1, 8, 15, and 22 and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62832941|NCT03771664|EXPERIMENTAL|SAGE-217|Participants received SAGE-217 matching placebo capsules (single-blind), orally, once daily prior to Day 1 (Days -2 and -1) followed by self-administration of SAGE-217, 30 milligrams (mg) capsules, orally, once daily for 12 days. Thereafter participants received SAGE-217, 30 mg capsules, orally, once daily, 30 minutes prior to lights out (PSG) on Days 13 and 14 (double-blind). Thereafter participants self-administered SAGE-217 matching placebo capsules (single-blind), orally, once daily on Days 15 to 21.
62610418|NCT01172964|EXPERIMENTAL|Arm I|Patients undergo debulking craniotomy and receive injections of HB1.F3.CD neural stem cells directly into brain tissue on day 0. Patients then receive oral 5-fluorocytosine every 6 hours on days 4-10 in the absence of disease progression or unacceptable toxicity.
62049830|NCT05997264|EXPERIMENTAL|Full Dose Schedule 2|"This study group will receive of AV7909 full dose (0.5 mL) at study days 1, 29, 181 and 366. A placebo full dose (0.5 mL) will be administered between the first and second dose of AV7909 at study day 15.~Update: Enrollment to this treatment arm was closed on 13 May 2024."
62049831|NCT05997264|EXPERIMENTAL|Half Dose Schedule 1|This study group will receive of AV7909 half dose (0.25 mL) at study days 1, 15, 181 and 366. A placebo half dose (0.25 mL) will be administered between the second and third dose of AV7909 at study day 29.
62049832|NCT05997264|EXPERIMENTAL|Half Dose Schedule 2|This study group will receive of AV7909 half dose (0.25 mL) at study days 1, 29, 181 and 366. A placebo full dose (0.25 mL) will be administered between the first and second dose of AV7909 at study day 15.
62610419|NCT01060709||elective colonoscopy and requiring sedation|
62832942|NCT01080079|ACTIVE_COMPARATOR|Group A -Terbinafine HCl|Terbinafine HCl
62049833|NCT06425549|EXPERIMENTAL|bimekizumab|Study participants randomized to this arm receive bimekizumab dosage regimen 1 at pre-specified timepoints during the Initial Treatment Period (16 weeks). They continue to receive bimekizumab dosage regimen 2 in the Maintenance Period (32 weeks). Under certain conditions study participants may be offered to continue on bimekizumab dosage regimen 2 in the Open-label Extension (OLE) Period (104 weeks).
62251692|NCT04759261|OTHER|Study group|
62832943|NCT01080079|ACTIVE_COMPARATOR|Group B - Terbinafine HCl|Terbinafine HCl
62832944|NCT01080079|ACTIVE_COMPARATOR|Group C - Terbinafine HCl|Terbinafine HCl
62832945|NCT01080079|ACTIVE_COMPARATOR|Group D Terbinafine HCl|Terbinafine HCl
62049834|NCT06425549|ACTIVE_COMPARATOR|ustekinumab|Study participants randomized to this arm receive ustekinumab at pre-specified timepoints during the Initial Treatment Period (16 weeks) and during the Maintenance Period. Under certain conditions participants may switch to bimekizumab dosage regimen 1 (16 weeks) and continue with bimekizumab dosage regimen 2 in the last 16 weeks of the Maintenance Period. Under certain conditions study participants may be offered to participate in the OLE Period also receiving bimekizumab dosage regimen 2.
62251693|NCT04163900|EXPERIMENTAL|A - NUC-1031 and cisplatin|725 mg/m\^2 NUC-1031 administered in combination with 25 mg/m\^2 cisplatin on Days 1 and 8 of a 21-day cycle
62251694|NCT04163900|ACTIVE_COMPARATOR|B - gemcitabine and cisplatin|1000 mg/m\^2 gemcitabine administered in combination with 25 mg/m\^2 cisplatin on Days 1 and 8 of a 21-day cycle
62441374|NCT01167920|NO_INTERVENTION|Usual Care Group|The Usual Care Group (UCG) patients will be told their BP is not in control and encouraged to work with their physician to improve it. There will be no further structured intervention during the rest of the study.
62441375|NCT03863275|OTHER|No intervation|Children between the ages of 7 and 12 diagnosed with class II dental classification, who attend the Leonardo Da Vinci School after carrying out an intraoral and extraoral photography study and diagnostic impressions with study models accepting participation in the study, Children over the age of 12 who have an agreement according to the results of medical care. Patients with Pierre Robin syndrome or any form of cleft.
62610420|NCT02200991|EXPERIMENTAL|Lixisenatide|"Lyxumia solostar: Initially started with 10 μg once-daily and increased up to 20 μg once daily (dose increased by 5 μg every week), subcutaneous injection in the abdomen, administered 30 minutes before breakfast. The period of administration is 4 weeks.~Lantus solostar as base treatment: Subcutaneous injection in the abdomen."
62832946|NCT01080079|ACTIVE_COMPARATOR|Group E|Terbinafine HCl
62832947|NCT01080079|PLACEBO_COMPARATOR|Group F - Placebo|Placebo application
62832948|NCT00686712|EXPERIMENTAL|1 - Insulin glargine QHS|Insulin glargine injected subcutaneously once daily at bedtime
62832949|NCT00686712|EXPERIMENTAL|2 - Insulin glargine QAM|Insulin glargine injected subcutaneously once daily in the morning
62049835|NCT02423681|ACTIVE_COMPARATOR|Heated humidification as first intention (HH1st)|Subjects receive heated humidification as first intention with ThermoSmart
62049836|NCT02423681|PLACEBO_COMPARATOR|Non-heated humidification|Subjects will receive no humidification. However they can be switched to the humidification group if patients complains of nasal dryness, congestion, nose bleed or if they had significant leak that cannot be resolved by two changes of mask.
62049837|NCT03062722|EXPERIMENTAL|keyhole approach|open minimally invasive approach
62049838|NCT04668196||High-flow nasal cannula treatment|
62049839|NCT04668196||Continuous positive airway pressure (CPAP) treatment|
62251695|NCT03723317||Training liver transplantation|Patients consecutively transplanted in four European collaborative LT Centres (Ancona, Brussels, Rome Sapienza, and Padua) (N=1,262)
62610421|NCT02200991|ACTIVE_COMPARATOR|Sitagliptin - Januvia|"50 mg tablet, administered orally once-daily, 30 minutes before breakfast. The period of administration is 4 weeks.~Lantus solostar as base treatment: Subcutaneous injection in the abdomen."
62251696|NCT03723317||Validation liver transplantation|Patients consecutively transplanted in the Karolinska Institute (N=520)
62610422|NCT04688398|EXPERIMENTAL|Seal oil|Daily intake of 15 ml of seal oil containing 534 mg of EPA + 1129 mg of DHA + 530 mg of DPA during 12 weeks
62049840|NCT04668196||Noninvasive ventilation treatment|
62049841|NCT04220177|EXPERIMENTAL|treatment arm|SETA LATECBA Stent Grafts, are tube shaped implantable devices, delivered by balloon catheter system which are intended to the treatment of infrarenal AAA by sealing the affected areas, avoiding the bleeding or perfusion inside the aneurysm and restoring the normal hemodynamics in the affected vessels. The product family is composed by a set of endovascular stent grafts, that can be used alone or in combination, according to the treatment strategy, extension and complexity of the AAA. One aortic bifurcated stent graft, ABK SETA LATECBA model, is the aortic trunk and two straight iliac stent grafts, RIK SETA LATECBA model, are the connections to both iliac arteries.
62049842|NCT00617981|EXPERIMENTAL|ThermoDox + RFA|ThermoDox 50 mg/m2 start infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
62049843|NCT00617981|SHAM_COMPARATOR|Sham + RFA|Sham infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
62049844|NCT04049630|EXPERIMENTAL|LEV 1 mg/kg|Tablets of LEV at 1 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
62049845|NCT04049630|EXPERIMENTAL|LEV 1,5 mg/kg|Tablet of LEV at 1,5 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
62251697|NCT04227886||Good response|TRG of 0-1 is defined as good response.
62251698|NCT04227886||Poor response|TRG of 2-3 is defined as poor response.
62251699|NCT04227886||Light toxicity|No grade 3-4 toxicities occur during neoadjuvant therapy.
62251700|NCT04227886||Heavy toxicity|Grade 3-4 toxicities occur during neoadjuvant therapy.
62251701|NCT05635968|EXPERIMENTAL|Low-dose whole brain irradiation group 1 (4cGy/day)|Low-dose whole brain irradiation with general AD medication treatment (4cGy/day, 2times/1wk, total 24cGy, 6 times/3wks)
62251702|NCT05635968|EXPERIMENTAL|Low-dose whole brain irradiation group 2 (50cGy/day)|Low-dose whole brain irradiation with general AD medication treatment (50cGy/day, 2times/1wk, total 300cGy, 6 times/3wks)
62251703|NCT05635968|SHAM_COMPARATOR|Sham RT group|Sham RT wtih general AD medication treatment (0cGy/day, 2times/1wk, total 0cGy, 6 times/3wks)
62251704|NCT02777697||cancer patients|
62251705|NCT01011439|EXPERIMENTAL|Milciclib Maleate (PHA-848125AC)|100 and 50 mg Capsule 150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle
62251706|NCT01112020|EXPERIMENTAL|CHG Catheter Dressing Patch|
62251707|NCT01112020|ACTIVE_COMPARATOR|Biopatch|Biopatch Protective Disk with CHG
62251708|NCT01112020|ACTIVE_COMPARATOR|Tegaderm CHG|Tegaderm CHG IV Securement Dressing
62251709|NCT03250936||Trampoline group|Child patients with trauma due to trampoline from june 2016 to december 2016 consulting in emergencies unit of Rennes' hospital
62610423|NCT04688398|ACTIVE_COMPARATOR|Control|Daily intake of vegetable oil during 12 weeks
62610424|NCT01277809|NO_INTERVENTION|Usual Care|Participants will receive care as usual (Usual Care Group; UCG) that is provided by their long-term care unit.
62832950|NCT00686712|ACTIVE_COMPARATOR|3 - NPH Insulin QHS|NPH insulin injected subcutaneously once daily at bedtime
62832951|NCT01219881|ACTIVE_COMPARATOR|Desflurane|Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Desflurane.
62832952|NCT01219881|ACTIVE_COMPARATOR|Sevoflurane|Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Sevoflurane.
62832953|NCT05110924|OTHER|Treatment arm (T-arm)|"Patients in the T-arm will receive diagnostic investigation(s) as in standard care. This includes clinical and dermoscopic examination and (in most cases) a biopsy to confirm the diagnosis of a BCC. Patients will be asked to fill out a questionnaire (Q) concerning their HrQoL. Important is the possible exclusion of patients (when the biopsy shows the lesion is not a BCC) in this step.~Patients will receive treatment of their BCC in accordance with the standard treatment regimen. The treatment will be performed by an independent dermatologist of the investigator's department who is blinded and not aware of the patient's participation in this study. After the treatment, a new Q will be sent out to capture the HrQoL and possible patient-reported side effects. Afterwards, the patients will be followed every 6 to 12 months for 36 months with a clinical evaluation of the previously treated skin site, evaluation of possible complications and the HrQoL and complications Qs."
62610425|NCT01277809|ACTIVE_COMPARATOR|Interpersonal Interaction|Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program. This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the walking group. This interaction time will occur with the participant stationary, rather than walking with the researcher.
62610426|NCT01277809|EXPERIMENTAL|Walking Program|Participants will walk five times per week under the supervision of a licensed physiotherapist.
62610427|NCT01702532|EXPERIMENTAL|Nicotine Mouth Film|mint nicotine mouth film, buccal administration
62610428|NCT01702532|ACTIVE_COMPARATOR|Nicotine Lozenge|nicotine lozenge, buccal administration
62610429|NCT02766452|EXPERIMENTAL|Pre-operative educational DVD preparation|"After their pre-assessment clinic (PAC) appointment, parents in the intervention group took the hospital's 20 minute surgical virtual tour in the hospital's family library. Parents in the intervention group also watched the 12 minute DVD entitled, You and Your Child in the RR. This pre-operative educational tool was developed and tested in a previous study (Chartrand 2014). It was designed to enable parents to gain knowledge about the equipment and procedures related to the RR, and about nurses' and parents' roles in supporting their child in the RR. The DVD also focused on potential reactions of children waking up after a general anesthesia and strategies parents can use to support their child in the RR. The DVD included images of RR equipment and positive nurse-family and parent-child interactions."
62251710|NCT03250936||Control group|Child patients with trauma related to sport from june 2016 to december 2016 consulting in emergencies unit of Rennes' hospital
62251711|NCT01833962||Actifuse|Patients who recieved Actifuse synthetic bone brafting material
62251712|NCT02580942|EXPERIMENTAL|Acupoint sticking therapy group|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
62251713|NCT02580942|SHAM_COMPARATOR|Sham sticking therapy group|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
62251714|NCT01050452|PLACEBO_COMPARATOR|1|albendazole treatment
62251715|NCT01050452|ACTIVE_COMPARATOR|2|mebendazole treatment
62251716|NCT01050452|ACTIVE_COMPARATOR|3|ivermectin treatment
62610430|NCT02766452|PLACEBO_COMPARATOR|Standard pre-operative preparation|After their PAC appointment, parents in the control groups took the hospital's 20 minute surgical virtual tour in the hospital's family library.
62610431|NCT04952207||DAA Group|Chronic hepatitis C patients treated with DAA
62610432|NCT02604355|EXPERIMENTAL|Healthy Participants (Multiple-Ascending Dosing)|
62610433|NCT02604355|EXPERIMENTAL|Healthy Participants (Single-Ascending Dosing)|
62610434|NCT02604355|EXPERIMENTAL|Healthy Participants (Study of Food Effect)|
62610435|NCT02604355|EXPERIMENTAL|Participants with Chronic Hepatitis B (Proof of mechanism)|
62610436|NCT03318081|ACTIVE_COMPARATOR|cognitive function rehabilitation group|The main content of cognitive function rehabilitation esecutive function,including working memory,sustained attention, response inhibition function and cognitive flexibility, 45 minutes a day over 6 weeks period.
62251717|NCT01050452|ACTIVE_COMPARATOR|4|albendazole + ivermectin treatment
62251718|NCT01050452|ACTIVE_COMPARATOR|5|mebendazole + ivermectin treatment
62251719|NCT06021899|ACTIVE_COMPARATOR|Classic CIMT group|Total session of 6 hours a day, 5 days per week for 3 weeks to Classic CIMT groups will be given.
62251720|NCT06021899|EXPERIMENTAL|mCIMT group|Session of 6 hours a day, 5 session per week for first 2 weeks (CIMT), session of 2 hours a day, 5 days per week for last 1 week (BIT) to modified CIMT group will be given.
62251721|NCT05296642|EXPERIMENTAL|Cycling at a Moderate Intensity Aerobic Exercise (AE) group|All participants will be asked to cycle during the first phase at a moderate intensity for 20 minutes.
62610437|NCT03318081|ACTIVE_COMPARATOR|cognitive bias modification group|The main content of cognitive bias modification groups were changing ATS related attention bias, 45 minutes a day over 6 weeks period.
62251722|NCT05296642|EXPERIMENTAL|Blood Flow restriction training with cycling at a moderate intensity (BFR+AE) group|All participants will be asked to wear an automated personalize tourniquet system to restrict blood flow. Participants will be asked to lie in supine and a non-shedding stockinette protection sleeve will be placed at bilateral proximal thighs. Then, participants will be asked to cycle at a moderate intensity for 20 minutes during the second phase.
62251723|NCT02486653|EXPERIMENTAL|Tamsulosin|
62251724|NCT02486653|PLACEBO_COMPARATOR|Placebo|
62251725|NCT05916781|EXPERIMENTAL|steroid tapering group|0\~6th month: mycophenolate mofetil (1g/d) + tacrolimus (2.0mg/d) + steroid (1 pill/d) 6th\~18th month: mycophenolate mofetil (1g/d) + tacrolimus (2.0mg/d) 18th\~30th month: Participants who stop steroid treatment and do not flare will be randomly assigned to monotherapy with mycophenolate mofetil or tacrolimus
62610438|NCT03318081|NO_INTERVENTION|control group|Participants only accept the regular scheduled in the compulsory isolated detoxification center
62610439|NCT00431067|EXPERIMENTAL|BIBW 2992|BIBW 2992 (Afatinib) once daily until progression
62251726|NCT05916781|ACTIVE_COMPARATOR|steroid maintenance group|0\~18th month: mycophenolate mofetil (1g/d) + tacrolimus (2.0mg/d) + steroid (1 pill/d) 18th\~24th month: Participants who do not flare will stop the use of steroid. 24th\~30th month: Participants who do not flare will be randomly assigned to monotherapy with mycophenolate mofetil or tacrolimus
62251727|NCT04434599|ACTIVE_COMPARATOR|Fluoroscopically guided ablation|These patients will receive one catheter ablation of typical atrial flutter by fluoroscopically guided radiofrequency ablation catheters
62441376|NCT03863275|EXPERIMENTAL|Myofunctional apparatus|Boys and girls between 7 and 12 years skeletal class II, for the study group the individuals will be selected from the UNICIEO postgraduate clinic of orthopedic clinic orthodontics after conducting a full clinical case study exposed to a board of specialist teachers in orthodontics, where by means of several diagnostic methods a skeletal class II is confirmed that involves a treatment with myofunctional apparatus SN1; patients presenting syndromes that generate craniofacial alterations, patients with previous orthopedic treatment, patients with signs of condyle lesions, patients with Pierre Robin syndrome or any form of slit will be excluded.
62441377|NCT04013256|EXPERIMENTAL|Dermal Exposure to Thirdhand Cigarette Smoke|Participants will wear clothing that has been exposed to cigarette smoke, for 3 hours while breathing filtered, temperature and humidity controlled air.
62441378|NCT04013256|ACTIVE_COMPARATOR|Inhalational Exposure to Thirdhand Cigarette Smoke|Participants will breathe cigarette smoke aerosol that has been aged for 22 hours, for 3 hours while wearing clean clothing.
62610440|NCT04148963|EXPERIMENTAL|Inhaled loxapine|Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours
62832954|NCT05110924|OTHER|non-Treatment arm (n-T-arm)|"Patients allocated to the n-T-arm will receive diagnostic investigations by non-invasive imaging techniques to confirm the diagnosis of a BCC. Patients will be asked to fill out a Q concerning their HrQoL. Important to point out is the possible exclusion of certain patients (when the imaging shows the lesion is not a BCC) in this step.~The patients in this arm will be followed every 6 to 12 months for 36 months. Every study visit there will be a clinical evaluation of the tumor. At the follow-up visits of 6, 12, 24 and 36 months a new documentation of the tumor will take place with in vivo imaging. At these time-points, patients will also be asked to fill out the HrQoL Q and complications Q.~Because of ethical reasons, a maximum tolerable diameter of the tumor has been defined in advance: BCCs in the non-treatment arm that reach a diameter of 4cm will be excluded and will receive treatment."
62832955|NCT00518102||001|REGRANEX (becaplermin) A cohort of REGRANEX (becaplermin) users (ie patients treated with REGRANEX (becaplermin) a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
62832956|NCT00518102||002|REGRANEX (becaplermin) comparators A cohort of REGRANEX (becaplermin) nonusers (ie patients who are not treated with REGRANEX \[becaplermin\]) but are similar in characteristics to patients in the REGRANEX \[becaplermin\] user cohort)
62049846|NCT04049630|EXPERIMENTAL|LEV 2,5 mg/kg|Tablet of LEV at 2,5 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
62049847|NCT04049630|PLACEBO_COMPARATOR|Placebo|Tablets of placebo will be administrated to the participant in single dose only one time.
62251728|NCT04434599|ACTIVE_COMPARATOR|Contact force guided ablation|These patients will receive one catheter ablation of typical atrial flutter by contact force guided radiofrequency ablation catheters using the CARTO 3D electroanatomic mapping system
62251729|NCT04434599|ACTIVE_COMPARATOR|Local impedance guided ablation|These patients will receive one catheter ablation of typical atrial flutter by local impedence guided radiofrequency ablation catheters using the Rhythmia Ultra-high density 3D electroanatomic mapping system
62251730|NCT06090851|ACTIVE_COMPARATOR|verum|pralines containing nitrate 3x day (200mg nitrate per day)
62251731|NCT06090851|PLACEBO_COMPARATOR|placebo|pralines without nitrate
62441379|NCT04013256|ACTIVE_COMPARATOR|Inhalational Exposure to Secondhand Cigarette Smoke|Participants will breathe cigarette smoke aerosol that has been aged for 30 minutes, for 3 hours while wearing clean clothing.
62441380|NCT04013256|SHAM_COMPARATOR|Clean Air Exposure|Participants will breathe filtered, temperature and humidity controlled air while wearing clean clothing for 3 hours.
62441381|NCT00671671|EXPERIMENTAL|Cohort B|
62441382|NCT00671671|EXPERIMENTAL|Cohort A|Dose study drug in subjects who have previously failed to respond to interferon based therapies
62441383|NCT04047212||Smokers|
62441384|NCT04047212||non-Smokers|
62441385|NCT02002247|PLACEBO_COMPARATOR|Placebo|Normal saline will be administered to subjects intravenously pre-operatively, upon admission to the ICU, then daily up to post-operative day 10 or ICU discharge, whichever occurs first.
62610441|NCT04148963|PLACEBO_COMPARATOR|Inhaled placebo|Inhaled placebo, may repeat x 1 or 2 after 2 hours
62832957|NCT04634253|EXPERIMENTAL|LY3462817 300 mg|Participants received Intravenous (IV) infusion of 300 mg LY3462817 solution.
62832958|NCT04634253|EXPERIMENTAL|LY3462817 700 mg|Participants received IV infusion of 700 mg LY3462817 solution.
62832959|NCT04634253|PLACEBO_COMPARATOR|Placebo|Participants received IV infusion of 0.9% sodium chloride solution (Placebo).
62832960|NCT01780740|EXPERIMENTAL|Atorvastatin|Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
62251732|NCT05872490||Older 80 people|Semi-structured interviews were conducted for the qualitative research. In addition, a driving habits questionnaire was administered. To complete this questionnaire, medical data from the PROOF cohort were collected.The PROOF cohort is a prospective study for which enrollment began in 2001. The main objective is to evaluate the predictive value of Autonomic Nervous System (ANS) activity and its decline during follow-up on the occurrence of serious and cerebral events, and on all-cause mortality, in a general population of subjects of homogeneous age. Participants were included in the study if they were 65 years of age (plus or minus 2 years) at the time of inclusion and registered on the electoral list of the city of St Etienne, had not had a previous myocardial infarction or stroke and were non-insulin dependent.
62610442|NCT02262156|EXPERIMENTAL|Cognitive behavioral Therapy|"CBT program to be used in group modality that focused on managing symptoms of depression in patients with epilepsy.~12 CBT sessions, consisting of one weekly 90-minute session for 12 consecutive weeks."
62610443|NCT02262156|ACTIVE_COMPARATOR|Selective serotonin euptake inhibitor|Patients will receive a SSRI (sertraline or citalopram) for 12 weeks. Dose will be adjusted every 4 weeks according to medical criteria.
62251733|NCT05872490||Attending physicians|Semi-structured interviews were conducted for the qualitative research
62251734|NCT05872490||law enforcement|Semi-structured interviews were conducted for the qualitative research
62251735|NCT05872490||certified driver's license physicians|Semi-structured interviews were conducted for the qualitative research
62251736|NCT05872490||geriatricians|Semi-structured interviews were conducted for the qualitative research
62251737|NCT05872490||driving instructors|Semi-structured interviews were conducted for the qualitative research
62610444|NCT06050330|ACTIVE_COMPARATOR|cases group|patients with psoriasis
62610445|NCT06050330|ACTIVE_COMPARATOR|control group|Healthy
62610446|NCT06406413||DoC patients|patients with disorders of consciousness
62610447|NCT06406413||healthy controls|healthy participants matched by gender and age
62738719|NCT00559104|ACTIVE_COMPARATOR|Irradiation in conditioning|total-body irradiation, etoposide, cyclophosphamide, infusion of peripheral blood stem cells, granulocyte-colony stimulating factor (G-CSF), autologous hematologic stem cell transplantation, peripheral blood stem cell transplantation
62738720|NCT00559104|ACTIVE_COMPARATOR|Carmustine in conditioning|Carmustine, etoposide, cyclophosphamide, infusion of peripheral blood stem cells, granulocyte-colony stimulating factor (G-CSF), autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
62738721|NCT06040385|ACTIVE_COMPARATOR|• Group I (control group)|Final impression will be done by conventional one-step impression technique. For the same patient, another final impression using unmodified scan bodies will be done by direct intraoral scan technique.
62738722|NCT06040385|ACTIVE_COMPARATOR|• Group II (Test Group)|Final impression will be done by conventional one-step impression technique. For the same patient another final impression using subtractive modified scan bodies will be done by direct intraoral scan technique
62738723|NCT03082911|EXPERIMENTAL|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group).~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention.~Each phone call will last approximately 5 minutes."
62738724|NCT03082911|ACTIVE_COMPARATOR|Standard procedure|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample.
62738725|NCT01393483||patients endoscopically resected|In patients with endoscopically resected T1 disease (40 patients in 2 years) if available, we will stain the initial endoscopic tumor specimen, as well as any subsequent specimen obtained at each routine 3(+/- 2) month interval endoscopy.
62738726|NCT01393483||patients treated primarily with surgery|In patients who undergo surgery as their primary therapy, serum will be obtained at the time of surgical resection, and at each subsequent long-term disease status follow-up visit every 4 (+/- 2) months.
62738727|NCT01393483||patients who undergo chemo-radiation prior to surgery|a serum sample will be obtained : 1) prior to initiation of therapy, 2) following the completion of induction chemotherapy, 3) at the time of surgical resection, and 4) at each subsequent long-term disease status follow-up visit every 4 (+/- 2) months. The availability of tissue for staining will determine whether or not patients are evaluable for Group 3.
62738728|NCT05655533||Adult patients who clinically suspected to have early spondyloarthropathy|"Adult patients who clinically suspected to have early spondyloarthropathy in acute stage.~At least 4 of 5 criteria for inflammatory low back pain have to be fulfilled"
62738729|NCT01762384|ACTIVE_COMPARATOR|LSC|procedure: laparoscopic sacral colpopexy.
62738730|NCT01762384|ACTIVE_COMPARATOR|Modified PFRS|procedure: modified pelvic floor reconstructive surgery with mesh.
62738731|NCT04469387|ACTIVE_COMPARATOR|NS Group|NS Group includes patients who simply receive responsible segments fused (L4-S1).
62738732|NCT04469387|EXPERIMENTAL|LD Group|LD Group includes patients who receive responsible segments fused (L4-S1) plus limited decompression at adjacent segment (L3/4).
62738733|NCT01465867|EXPERIMENTAL|Selenium|
62738734|NCT01465867|PLACEBO_COMPARATOR|Sugar Pill Placebo|
62738735|NCT01465867|EXPERIMENTAL|Selenium + L-Thyroxine (LT4)|
62049848|NCT04488263||Cohort 1|Subjects with confirmed/suspected NENs.
62049849|NCT06252103|ACTIVE_COMPARATOR|group I|the first group 20 patients will receive one tab of ferrous gluconate 300mg administered orally twice per day for 4 weeks (Ferrous-Gluconate®, tab.300mg glucofer, Egypt) two times daily.
62049850|NCT06252103|ACTIVE_COMPARATOR|group II|20 patients were given lactoferrin 100mg (Pravotin-sachets®,100mg, Hygint, Egypt) with ferrous gluconate twice daily for 4 weeks Patients were assigned to take the medication orally; once daily before breakfast, and Pravotin (100 sachets were be dissolved each in ¼ glass of water and taken before breakfast). Patients were advised to avoid the intake of tea, coffee, milk, milk products, antacids and calcium preparation within 2 hours before or after iron capsules.
62049851|NCT01901107||Kiklin group|
62049852|NCT03664466|EXPERIMENTAL|Astaxanthin|Astaxanthin 12mg twice daily by mouth
62251738|NCT05872490||personal assistance services|Semi-structured interviews were conducted for the qualitative research
62441386|NCT02002247|ACTIVE_COMPARATOR|sodium selenite|"High-dose sodium-selenite will be administered to subjects intravenously:~1) pre-operatively (2000 ug); 2) upon admission to the ICU (2000 ug), 3) then daily (1000 ug) up to post-operative day 10 or ICU discharge, whichever occurs first."
62610448|NCT03765424||GCA cases|"GCA cases were patients with a clinical diagnosis of GCA based on a rheumatologists evaluation of history taking, physical examination, laboratory screening and initial PET report (reporting potential large vessel inflammation but not considering cranial artery inflammation).~GCA was considered large vessel (LV) and/or cranial (c) GCA cases:~LV-GCA cases were patients with a clinical diagnosis of GCA and verified LV inflammation by 18F-FDG PET/CT with or without concomitant c-GCA.~C-GCA cases, for the exploratory analysis of the performance of US and PET in c-GCA, were patients with a clinical diagnosis of GCA fulfilling the 1990 American College of Rheumatology (ACR) criteria, with or without concomitant LV-GCA."
62610449|NCT03765424||controls|Controls were GCA suspected patients in whom GCA diagnosis was dismissed.
62441387|NCT02585258|EXPERIMENTAL|prednisolone|prednisolone 5 mg per day
62441388|NCT02585258|PLACEBO_COMPARATOR|placebo|placebo capsules once per day
62610450|NCT05627752|EXPERIMENTAL|Group of Combination|Docetaxel plus Enzalutamide
62049853|NCT03664466|PLACEBO_COMPARATOR|Placebo|Placebo twice daily by mouth
62049854|NCT03086304|EXPERIMENTAL|TEAS group|Choose several acupoints,give 2/10 hz dilatational wave stimulation.Complete the 30 minutes intervention after extubation and 1-3 days after surgery.Give a health education on the first postoperative day.
62049855|NCT03086304|EXPERIMENTAL|no TEAS group|The choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation,the others steps are same with TEAS group.
62441389|NCT03867591|EXPERIMENTAL|Gastro-AD® Group|The participants randomized to this group 1 g of Gastro-AD® powder per sachet + flavoring agents.
62441390|NCT03867591|PLACEBO_COMPARATOR|Placebo Group|Participants in this arm will take a sachet containing maltodextrin (1 g) and exactly the same flavoring and coloring agents as Gastro-AD® powder flavored sachets.
62049856|NCT04131569||ESBL-E fecal carriers|Patients with a positive ESBL-E fecal carriage according to routine screening
62049857|NCT04131569||non ESBL-E fecal carriers|Patients without positive ESBL-E fecal carriage according to routine screening
62049858|NCT05139875|EXPERIMENTAL|Betamethasone (Diprospan)|Participant received single intra-articular Betamethasone Dipropionate / Betamethasone Sodium Phosphate 1 ml
62049859|NCT05139875|ACTIVE_COMPARATOR|Triamcinolone acetonide|Participant received single intra-articular Triamcinolone acetonide 40 mg
62251739|NCT03726606|EXPERIMENTAL|Extended depth of focus intraocular lens|Bilateral implantation of extended depth of focus intraocular lenses.
62251740|NCT03726606|ACTIVE_COMPARATOR|Trifocal intraocular lens|Bilateral implantation of trifocal intraocular lenses.
62251741|NCT02508142|ACTIVE_COMPARATOR|Hyoscine-N-Butylbromide|20 mg Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL)
62251742|NCT02508142|PLACEBO_COMPARATOR|Placebo|100 mL normal saline
62610451|NCT05627752|PLACEBO_COMPARATOR|Group of Docetaxel|Docetaxel plus placebo
62610452|NCT06710860|EXPERIMENTAL|Intervention group|ScreenTalk AI-based tailored communication intervention
62610453|NCT06710860|NO_INTERVENTION|Control group|Targeted communication
62251743|NCT05544188|EXPERIMENTAL|individual outpatient physiotherapy|individual outpatient physiotherapy (7 times in two and a half months, approx. 90 minutes) aimed at correcting functional pathologies of the musculoskeletal system assessed by differential diagnosis (removal of trigger points, stretching of shortened muscles and mobilization of joint blockages) and changing of motor program that led to the occurrence of the functional disorder by means of Motor Programmes Activating Therapy
62251744|NCT05544188|ACTIVE_COMPARATOR|Without changing the current habits|It will not change the existing habits. At the same time, however, these are physiotherapy students who will participate in the classes. Their motor behaviour can thus be influenced in a natural way.
62251745|NCT06467162||observational group|Research participants were interviewed using structured questionnaires, including demographic characteristics information, clinical characteristics information, and the chronic obstructive pulmonary disease assessment test.
62251746|NCT03590015|OTHER|old letter of invitation|"Old invitation letter written by researchers/doctors in The coronary project sent to patients in order to recruit to an ongoing project"
62251747|NCT03590015|OTHER|New letter of invitation|New invitation Letter written with consideration of impaired language comprehension and has therefore been written in simple sentences with a sequential structure of basic information sent to patients in an ongoing project.
62251748|NCT05608382|PLACEBO_COMPARATOR|sterile Phosphate Buffer Saline (PBS)|
62251749|NCT05608382|EXPERIMENTAL|SGW13|
62251750|NCT03259750||professional athletes|athlete who volunteered in this study that should be a member of a professional sport team, All athletes must complete self reported outcome instrument (FAAM-T)
62251751|NCT01329250|EXPERIMENTAL|Moxifloxacin|Moxifloxacinin escalating dose
62251752|NCT02703415|ACTIVE_COMPARATOR|Bupivacaine|caudal Bupivacaine
62251753|NCT02703415|ACTIVE_COMPARATOR|Tramadol|caudal Tramadol
62251754|NCT04666467|EXPERIMENTAL|Single-arm study of PLAR Implant and Delivery System|All enrolled patients will receive the study device
62251755|NCT01611948|ACTIVE_COMPARATOR|Active Drug|125mg/d aprepitant for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
62610454|NCT03765112|EXPERIMENTAL|OCTA|Patients with diabetes and healthy controls will be imaged with optical coherence tomography (OCT) angiography, Spectral domain OCT and ultra wide-field imaging.
62049860|NCT05439798|ACTIVE_COMPARATOR|Group OD (Group ondansetron+dexamethasone)|The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg-1).
62251756|NCT01611948|PLACEBO_COMPARATOR|Placebo pill|Placebo pill daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
62049861|NCT05439798|ACTIVE_COMPARATOR|Group PD (Group palonosetron+dexamethasone)|The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).
62441391|NCT03871400|OTHER|NanoMetalene/PEEK|
62441392|NCT03871400|OTHER|NanoMetalene/Allograft|
62610455|NCT00387049|EXPERIMENTAL|Anxiety-specific smoking cessation care|
62610456|NCT00387049|ACTIVE_COMPARATOR|Standard smoking cessation care|
62610457|NCT06731816|ACTIVE_COMPARATOR|Neck and stabilization exercise group|In addition to neck stretching, range of motion, and isometric exercises, spinal stabilization exercises will be applied.
62610458|NCT06731816|ACTIVE_COMPARATOR|Neck exercise group|Neck stretching, range of motion, and isometric exercises will be applied.
62738736|NCT01465867|EXPERIMENTAL|Sugar Pill Placebo + L-Thyroxine (LT4)|
62738737|NCT01022710||Group 1|Veterans with sensorineural hearing loss
62738738|NCT03092999|EXPERIMENTAL|Healthy subjects|healthy subjects
62049862|NCT05439798|PLACEBO_COMPARATOR|Group D (Group Dexamethasone)|The patients in Group D (Group Dexamethasone) will be given intravenous (iv) dexamethasone (0.5 mg.kg-1).
62251757|NCT04006496|EXPERIMENTAL|Experimental: Intervention|In-patient, Chemotherapy patients in this arm will receive the expressive writing intervention twice each week for two weeks. These writing samples will be reviewed and analyzed. These patients will receive coaching from an expert expressive writing coach and will be allowed to ask questions and receive guidance. All patients will receive standard of care treatment in addition to the intervention.
62251758|NCT04006496|NO_INTERVENTION|Control|Patients in the control group will not interface with the expressive writing coach for guidance nor have their writing samples reviewed and analyzed. All patients in the control arm will still receive standard care
62251759|NCT03052504||Cx prospective|Cystectomy patients followed with prospective registration of complications
62251760|NCT03052504||Cx retrospective|Cystectomy patients followed with retrospective registration of complications
62251761|NCT03052504||Nx prospective|Nephrectomy patients followed with prospective registration of complications
62251762|NCT03052504||Nx retrospective|Nephrectomy patients followed with retrospective registration of complications
62441393|NCT03818737|EXPERIMENTAL|Bone Marrow Derived MSCs|Participants randomized to this arm will undergo bone marrow aspiration and then will be further randomized to receive a standard orthobiologic injection into the knee joint of autologous bone marrow concentrate (BMAC).
62441394|NCT03818737|EXPERIMENTAL|Adipose-derived MSCs|Participants randomized to this arm will undergo small volume lipoplasty, and then will be further randomized to receive an injection into the knee joint of adipose-derived stromal vascular fraction (SVF).
62738739|NCT03092999|EXPERIMENTAL|Subjects with mild hepatic impairment|hepatically impaired patients (classified as Child Pugh A)
62738740|NCT03092999|EXPERIMENTAL|Subjects with moderate hepatic impairment|hepatically impaired patients (classified as Child Pugh B)
62738741|NCT00277810|EXPERIMENTAL|A|
62738742|NCT00277810|EXPERIMENTAL|B|
62738743|NCT00277810|EXPERIMENTAL|C|
62610459|NCT04261127|EXPERIMENTAL|experimental arm|"The analysis of phenotypic data in RADIAL and the analysis of DNA (analysis of the Friedreich gene ± PMDA panel) will be performed for all patients in order to meet the main objective and the secondary objectives.~Specifically for the secondary objectives (N ° 3, 4 and 5), randomization via eCRF (electronic case report form) will be performed for the interpretation of genetic analyzes (PMDA panel) without inducing any change for the patients. This randomization, by block and by center, will allow the attribution of one of the following two groups:~* Control group: interpretation of genetic analyzes without the use of RADIAL;~* Experimental group: interpretation of genetic analyzes using RADIAL.~Genome analysis (secondary objective n ° 6) will be carried out for all the patients who remained without diagnosis at the end of the first part, and for whom the DNA of relatives is available."
62049863|NCT02943850|EXPERIMENTAL|Stem cell implantation|Subjects meeting all Eligibility Criteria and providing Informed Consent will be enrolled in one of two sequential dosing groups (Group A and B). Subjects will be treated sequentially with a minimum of one month interval between surgeries for the first three subjects in each dosing cohort. The remaining subjects in the cohort will be treated with a minimum interval of at least one week between surgeries. There will be 9 subjects in each group. No control group is included. All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
62251763|NCT03462420|EXPERIMENTAL|PT+ walking|Participants in this group will be referred to a physical therapy facility according to their preferences and the intervention will be chosen by the treating physical therapist. In addition, participants will be asked to perform free walking at their own pace for 30-45 min, 5 days per week for 6 consecutive weeks and to record their walking date/time on a diary form provided by the research team before commencing the study. Participants in PT+ group will also be provided with accelerometer to accurately estimate their physical activity level.
62610460|NCT06720246||Bariatric Surgery|Patients submitted to bariatric surgery
62832961|NCT01780740|PLACEBO_COMPARATOR|Sugar pill|Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included.
62251764|NCT03462420|ACTIVE_COMPARATOR|Regular PT|Participants in this group will be referred to a physical therapy facility according to their preferences and the intervention will be chosen by the treating physical therapist. Participants in this group will not be notified about the walking program.
62251765|NCT05212506||vaccinated and unvaccinated|
62441395|NCT03818737|EXPERIMENTAL|Umbilical Cord Tissue (UCT) MSCs|Participants randomized to this arm will receive an injection into the knee joint of cryopreserved doses of umbilical cord tissue MSCs.
62441396|NCT03818737|ACTIVE_COMPARATOR|Corticosteroid Injection|Participants randomized to the bone marrow derived MSC, adipose-derived MSC, or umbilical cord tissue MSC study arms will be further randomized within the arm in a 3:1 ratio to receive either MSCs derived from the study arm of the initial randomization or a corticosteroid (CS) injection. Participants randomized to the control group will receive an injection of corticosteroid into the knee joint.
62441397|NCT04417790||Study population|Children under 12 years of age, Undergoing elective cardiac surgery for cyanotic or acyanotic congenital heart disease, Aristotle score ≤9, Giving prior written informed consent.
62441398|NCT02902731|PLACEBO_COMPARATOR|placebo|PLACEBO + Usual use of tapering doses of oral prednisone
62832962|NCT00242502|EXPERIMENTAL|Bevacizumab + Erlotinib|Bevacizumab 10 mg/kg intravenous every 14 days, repeat cycle every 28 days; Erlotinib 150 mg orally every day continuous dosing.
62832963|NCT01621269|EXPERIMENTAL|Fingolimod|
62441399|NCT02902731|EXPERIMENTAL|anakinra|"ANAKINRA : dose of anakinra is 100 mg/day by subcutaneous injection from day 1 until the end of week 16 (W16). The dose of Anakinra will be adapted to that recommand according to renal function.~Intervention Anakinra in add on Therapy."
62832964|NCT04247685|EXPERIMENTAL|12-Lead ECG|The study group patients will have MRI with 12-lead ECG monitoring device produced by a Massachusetts-based medical device company MiRTLE Medical
62832965|NCT04247685|ACTIVE_COMPARATOR|3-lead ECG gating system|the control group will have MRI with 3-lead ECG gating which is standard of care.
62832966|NCT04588038|EXPERIMENTAL|Treatment (efineptakin alfa)|Patients receive one dose of efineptakin alfa IM.
62832967|NCT06025864|EXPERIMENTAL|Intervention Group|Support for breastfeeding and depletion of breast milk throughout the 6 months. Free and professional support through monthly consultations and videos on the subject.
62610461|NCT06720246||Liraglutide|Patients submitted to liraglutide treatment
62610462|NCT06504888||Patients allergic to penicillin|Patients who cannot take any type of penicillin, who have undergone a lateral sinus lift with simultaneous or delayed dental implant.
62610463|NCT06504888||Patients who are not allergic to penicillin|Patients who can take some type of penicillin, who have had a lateral sinus lift with simultaneous or delayed dental implant.
62610464|NCT01116076|EXPERIMENTAL|DECISION+ Program|Exposure to the Decision+ Program
62610465|NCT01116076|NO_INTERVENTION|Control|Usual Care
62251766|NCT03920553|EXPERIMENTAL|Test Group|Preoperatively all patients gargled for 1 min with 0.2% chlorhexidine mouthwash. Local anaesthesia was applied to the area where the surgical procedure was to be applied. Then the frenectomy operation was performed with a continuous 970nm wavelength of the diode laser at power setting of 1,5W for approximately 60 seconds from the base to the apex of the frenum, thereby excising it. No bleeding was observed after the frenectomy performed with laser. Then, commercially available Hiyaluronic acid was topically applied to the relevant area to completely cover the surgical field to the test group. Following the frenectomy performed with laser, no application was made to the control group patients.
62441400|NCT02779582|EXPERIMENTAL|Progesterone|Oral micronized progesterone, 300 mg po daily, taken as three capsules daily before sleep for three months
62441401|NCT02779582|PLACEBO_COMPARATOR|Placebo|Placebo, each taken as three capsules daily before sleep for three months
62441402|NCT05237700||Trendelenburg with lithotomy positioning on the operating table.|The patient is positioned in Trendelenburg with lithotomy positioning on the operating table.
62441403|NCT05237700||Trendelenburg without lithotomy positioning on the operating table.|The patient is positioned in Trendelenburg without lithotomy positioning on the operating table.
62441404|NCT01814579|EXPERIMENTAL|V-Loc Vaginal Cuff Closure|Patients in this arm will receive vaginal cuff closure with unidirectional barbed suture at time of their robotic hysterectomy.
62441405|NCT01814579|ACTIVE_COMPARATOR|Vicryl Vaginal Cuff Closure|Patients enrolled in this arm will have their vaginal cuff closed with polyglactin 910 (Vicryl) at the time of their robotic hysterectomy.
62441406|NCT04936620|ACTIVE_COMPARATOR|Duroplasty|Duroplasty (includes Surgery with Laminectomy)
62441407|NCT04936620|ACTIVE_COMPARATOR|No duroplasty|No duroplasty (but includes surgery with Laminectomy)
62610466|NCT01522235|ACTIVE_COMPARATOR|IVIg group|Double blinded IVIg and single blinded IVIg
62610467|NCT01522235|OTHER|Placebo Group|Double blinded Placebo and single blinded IVIg
62610468|NCT03358316||cuff tear patients|Patients with cuff tear
62610469|NCT05775328||Patients with hypertrichosis|Patients suffering from hypertrichosis or hirsutism according to Ferriman-Galway scale criteria and treated with intense pulse light for a total of 5 sessions.
62610470|NCT02716766|EXPERIMENTAL|SECOX|Sorafenib 400 mg twice daily from Day 1 to 14, Capecitabine 850 mg/m2 twice daily from Day 1 to 7, Oxaliplatin 85 mg/m2 on Day 1
62610471|NCT02716766|ACTIVE_COMPARATOR|Sorafenib|Sorafenib 400 mg twice daily from Day 1 to 14
62610472|NCT05808816|EXPERIMENTAL|Arm A|Patient with oral supplementation of Lactobacillus Crispatus M247
62610473|NCT05808816|NO_INTERVENTION|Arm B|Patients without oral supplementation of Lactobacillus Crispatus M247
62441408|NCT06429098|EXPERIMENTAL|Venetoclax, Azacitidine/Decitabine/, Cytarabine|"INDUCTION: Patients receive 2 cycles of VEN/HMA as induction therapy. Venetoclax orally (PO) once daily (QD) on days 1-28, azacitidine subcutaneously (SC) on days 1-7 or decitabine intravenously (IV) over 30-60 minutes on days 1-5.~CONSOLIDATION: Fit patients will receive four cycles of consolidation therapy with high-dose cytarabine (2g/m2 every 12 hours, on days 1-3) combined with venetoclax (on days 1-7). Unfit patients will continue to receive VEN/HMA until disease progression."
62610474|NCT02370030|ACTIVE_COMPARATOR|Intervention|Oral or nasogastric administration of 10 g citrulline malate daily. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
62610475|NCT02370030|PLACEBO_COMPARATOR|Placebo|10 g of maltodextrin will be substituted for the citrulline. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
62049864|NCT00251095|ACTIVE_COMPARATOR|Taxol|Taxol 80mg/m2/week
62049865|NCT00251095|EXPERIMENTAL|TOCOSOL|TOCOSOL Paclitaxel
62610476|NCT06730243|EXPERIMENTAL|RS-RARP-S|"Retzius-sparing robot-assisted radical prostatectomy and Sandwich Technique of Total Urethral Reconstruction"
62049866|NCT00486421|EXPERIMENTAL|PRED & RITUX|
62049867|NCT03031964||revision multihole acetabular cup|Revision total hip arthroplasty using multihole revision acetabular cup
62610477|NCT06730243|EXPERIMENTAL|S-RARP|Standard RARP
62610478|NCT06730243|SHAM_COMPARATOR|LRP|Laparoscopic Radical Prostatectomy
62610479|NCT05859022|EXPERIMENTAL|Roux-en-Y gastric By-pass (RYGB)|RYGB procedure requires 1-2 hours of operating time and two to three days length of hospital stay. Use the Kit-RYGB by J\& company.
62610480|NCT05859022|EXPERIMENTAL|Bariatric Arterial Embolization (BAE)|Embosphere Microspheres (EM) are designed to offer controlled, target embolization. BAE procedure requires 1hour of operating time and one day length of hospital stay. Use the Kit by Merit MedicalCompany.
62610481|NCT02175381|EXPERIMENTAL|Carbo/GEM|
62610482|NCT05627726|EXPERIMENTAL|PelviSense-assisted pelvic floor muscle training group|Women allocated to the PelviSense-assisted pelvic floor muscle training (PFMT) group will perform PFMT to contract their urethras while the wearable sensors are positioned close to the vagina (to measure pubococcygeus muscle activation). Exercises will be performed in antigravity (supine or side-lying) positions and will progress to against-gravity positions (sitting/ standing).
62832968|NCT06025864|NO_INTERVENTION|Control Group|"All mothers were followed up for 6 months and received a breastfeeding support booklet virtually, through a cell phone application. The booklet provides basic information about breastfeeding and possible complications. The recruited mothers also received a notebook to record the date, duration, volume and frequency of breastfeeding and/or milk collections, and the use of alternative routes such as a bottle, cup or enteral nutrition. At the initial visit, all mothers were given a standard measuring cup to measure the volume of milk used up in the household each day.~In addition, all mothers received a call 7 days after delivery to apply the Portuguese version of the Breastfeeding Self-Efficacy Survey - Short Form: BSES-SF. This questionnaire was reapplied after 90 days."
62832969|NCT02096302|EXPERIMENTAL|Experimental Formula|Infant formula with a novel probiotic CECT7210
62832970|NCT02096302|ACTIVE_COMPARATOR|Standard Formula|Standard infant formula without probiotics
62832971|NCT05511584|EXPERIMENTAL|VO2 and SEVOup|Estimation of VO2 and SEVOup (ml/min) followed by estimation of O2 and sevoflurane supply (DO2 and SEVOsuppl, respectively) through a closed-circuit anesthesia administration system.
62049868|NCT00877279|EXPERIMENTAL|Belotero® Soft|Comparator will be given into the opposite side of the face that Belotero® Soft was administered for facial wrinkles, such as nasolabial folds.
62049869|NCT00877279|ACTIVE_COMPARATOR|CosmoDerm1|
62049870|NCT06369779|EXPERIMENTAL|Test group (TM Fill in combination with TM Flow)|TM Fill an TM Flow are used for restoration of class I and class II cavities
62049871|NCT00117676|EXPERIMENTAL|TDF-TDF|TDF plus ADV placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.
62610483|NCT05627726|ACTIVE_COMPARATOR|Pelvic floor muscle training (PFMT) alone group|Pelvic floor muscle training (PFMT) alone group: Women allocated to the PFMT alone group will perform unassisted PFMT. Exercise parameters, technique, and progression will be similar to those for the PelviSense-assisted PFMT group, but exercises will be performed without the PelviSense.
62610484|NCT02140983|ACTIVE_COMPARATOR|Liraglutide|90 days of liraglutide treatment at adjusting dose, up to 1.8mg/day
62610485|NCT02140983|PLACEBO_COMPARATOR|Placebo|90 days of placebo pen, up to 1.8mg/day.
62610486|NCT01901861|ACTIVE_COMPARATOR|Sitagliptin|Sitagliptin 100mg is given before meal ingestion
62610487|NCT01901861|PLACEBO_COMPARATOR|Placebo|Placebo is given before meal ingestion
62832972|NCT01394796|ACTIVE_COMPARATOR|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
62832973|NCT01394796|PLACEBO_COMPARATOR|Placebo|No active substance is given.
62832974|NCT01192191|EXPERIMENTAL|Fluticasone Furoate/GW642444 100/25mcg|Combination inhaled corticosteroid and long-acting beta2-agonist
62832975|NCT01192191|EXPERIMENTAL|Fluticasone Furoate/GW642444 200/25mcg|Combination inhaled corticosteroid and long-acting beta2-agonist
62610488|NCT06107153|ACTIVE_COMPARATOR|basal insulin plus glucose lowering drugs|"New diagnosed T2DM with an age of 18 years and above. HbA1c of equal to or more than 9% and or random serum glucose equal to or more than 300 mg/dl.~Agree to start basal insulin for two weeks"
62049872|NCT00117676|ACTIVE_COMPARATOR|ADV-TDF|ADV plus TDF placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of FTC/TDF FDC tablet) to their treatment regimen in the open-label period.
62049873|NCT03925701|EXPERIMENTAL|vildagliptin|vildagliptin 50 mg twice daily
62610489|NCT06107153|ACTIVE_COMPARATOR|glucose lowering drugs only|"New diagnosed T2DM with an age of 18 years and above. HbA1c of equal to or more than 9% and or random serum glucose equal to or more than 300 mg/dl.~Refuse to start basal insulin."
62610490|NCT01860144||bevacizumab|Patients with metastatic colorectal cancer who accept treatment with chemotherapy and bevacizumab
62049874|NCT03925701|ACTIVE_COMPARATOR|vildagliptin\metformin|vildagliptin\\metformin twice daily
62049875|NCT04924283|EXPERIMENTAL|Cognitive Interference Task|Participants in this arm will complete random assessments of alcohol use and cravings on their phone, and be prompted to play Tetris on their phone after reporting cravings for alcohol.
62049876|NCT04924283|ACTIVE_COMPARATOR|Assessment Only|Participants in this arm will complete random assessments of alcohol use and cravings on their phone.
62049877|NCT03388567|EXPERIMENTAL|Staff pharmacy whith intervention|Staff pharmacy who will receive continuous education through technology and communication tools, as well as accompaniment and advice from a pharmaceutical chemist
62049878|NCT03388567|NO_INTERVENTION|Staff pharmacy without intervention|Staff pharmacy who will receive only pharmacy information
62049879|NCT06022757|EXPERIMENTAL|Dose escalation and Safety of XNW5004 in combination with KEYTRUDA® (pembrolizumab) (Phase Ib)|Dose escalation and safety with repeated administrations of XNW5004 in combination with infusions of KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors.
62049880|NCT06022757|EXPERIMENTAL|HNSCC：XNW5004 in combination with KEYTRUDA® (pembrolizumab) (Phase II - cohort 1)|Repeated administrations of XNW5004 in combination with infusions of KEYTRUDA® (pembrolizumab) in patients with head and neck squamous cell carcinoma (including nasopharyngeal carcinoma), urothelial carcinoma, metastatic castration-resistant prostate adenocarcinoma, small cell lung cancer, non-small cell lung cancer, other solid tumor (including cervical cancer)
62049881|NCT06022757|EXPERIMENTAL|Urothelial carcinoma：XNW5004 in combination with KEYTRUDA® (pembrolizumab) (Phase II - cohort 2)|Repeated administrations of XNW5004 in combination with infusions of KEYTRUDA® (pembrolizumab) in patients with urothelial carcinoma
62610491|NCT03026933|EXPERIMENTAL|Treatment|KI1107
62049882|NCT06022757|EXPERIMENTAL|mCRPC：XNW5004 in combination with KEYTRUDA® (pembrolizumab) (Phase II - cohort 3)|Repeated administrations of XNW5004 in combination with infusions of KEYTRUDA® (pembrolizumab) in patients with metastatic castration-resistant prostate adenocarcinoma
62610492|NCT03026933|ACTIVE_COMPARATOR|Control|Rosuvastatin calcium
62610493|NCT03979183|EXPERIMENTAL|Intervention|Therapeutic exercise
62049883|NCT06022757|EXPERIMENTAL|Small cell lung cancer：XNW5004 in combination with KEYTRUDA® (pembrolizumab) (Phase II - cohort 4)|Repeated administrations of XNW5004 in combination with infusions of KEYTRUDA® (pembrolizumab) in patients with small cell lung cancer
62049884|NCT06022757|EXPERIMENTAL|non-small cell lung cancer:XNW5004 in combination with KEYTRUDA®(pembrolizumab)(PhaseII-cohort5)|Repeated administrations of XNW5004 in combination with infusions of KEYTRUDA®(pembrolizumab) in patients with non-small cell long cancer
62049885|NCT06022757|EXPERIMENTAL|：XNW5004 in combination with KEYTRUDA® (pembrolizumab) (Phase II - cohort 6)|Repeated administrations of XNW5004 in combination with infusions of KEYTRUDA® (pembrolizumab) in patients with other solid tumor (including cervical cancer)
62049886|NCT06435104|OTHER|neoadjuvant chemotherapy|Patients will receive effective neoadjuvant chemotherapy for at least 2 courses.
62049887|NCT06435104|EXPERIMENTAL|neoadjuvant chemotherapy+aromatherapy|Patients will receive effective neoadjuvant chemotherapy for at least 2 courses, and the aromatherapy is recommended to continue throughout neoadjuvant chemotherapy.
62049888|NCT01833143|EXPERIMENTAL|Bortezomib|Bortezomib will be administered by subcutaneous injection twice weekly for 2 weeks (Days 1, 4, 8, and 11) at 1.3 mg/m2/dose followed by a 10-day rest period for a 21 day cycle. Dose modifications are permitted as per a prescribed algorithm. Acyclovir at 400mg daily is recommended as prophylaxis for herpes zoster. Restaging scans, with evaluation of response, will be done every 2 cycles (6 weeks of treatment ± 7 days). Treatment will continue until clinical disease progression, unacceptable toxicity, treatment delay \> 2 weeks, or at the discretion of the treating physician or patient.
62049889|NCT04370925|ACTIVE_COMPARATOR|Matched control|Patients undergo radical resection of primary colorectal cancer and receive standard adjuvant systemic chemotherapy
62049890|NCT04370925|EXPERIMENTAL|HIPEC|Patients undergo radical resection of colorectal cancer and HIPEC simultaneously or within 2 days after primary tumor resection. Followed by standard adjuvant systemic chemotherapy
62049891|NCT01599052||Brain Tumour Patients|Newly diagnosed brain tumour patients aged between 5 and 13 years
62049892|NCT01599052||Cystic Fibrosis patients|Patients diagnosed with Cystic Fibrosis aged between 5 and 13 years
62049893|NCT01599052||Healthy control group|Healthy children aged between 5 and 13 years
62049894|NCT03426202|EXPERIMENTAL|modafinil group|a single dose of p.o. modafinil (200mg)
62049895|NCT03426202|EXPERIMENTAL|placebo group|a single dose of p.o. placebo (200mg)
62049896|NCT02580708|EXPERIMENTAL|Rociletinib and Trametinib|
62610494|NCT03979183|NO_INTERVENTION|Control|Usual care
62610495|NCT04953507|EXPERIMENTAL|Thermal Radiofrequency|T2, T3 block by thermal radiofrequency lesioning at 80°c for 60-90 seconds
62610496|NCT04953507|ACTIVE_COMPARATOR|Chemical Neurolysis|T2, T3 block by chemical neurolysis using 2-3 ml of phenol in glycerin 6%
62610497|NCT03197194|EXPERIMENTAL|A : Alteplase|Intravenous injection of Alteplase and one tablet of placebo
62610498|NCT03197194|ACTIVE_COMPARATOR|B : Acetylsalicylic Acid|one tablet of Acetylsalicylic Acid and one dose of IV placebo
62610499|NCT06731283||Vitiligo|Patients diagnosed with vitiligo
62610500|NCT06731283||Controls|Patients that do not have vitiligo
62610501|NCT01180556|EXPERIMENTAL|Probiotics supplementation|Supplementation by probiotics for 4 weeks
62049897|NCT05584852||with myosteatosis|
62610502|NCT01180556|PLACEBO_COMPARATOR|Placebo|Supplementation of placebo for 4 weeks
62610503|NCT03865589|EXPERIMENTAL|Patients Undergoing HCT|All patients enrolled will undergo US SWE at specific time points as outlined in the protocol based on disease course.
62049898|NCT05584852||without myosteatosis|
62049899|NCT04547010|EXPERIMENTAL|Intervention group|In four weeks of intervention study the participants instructed to receive (60 mg) of soy-isoflavone supplement per day, after this period the Bone Mineral Density was assessed by Dual X-ray Absorptiometry scan to evaluate the effect of soy-isoflavone supplement on Bone mineral density.
62049900|NCT03204955|EXPERIMENTAL|Sodium chloride /sodium acetate (16.4%)|50cc doses of sodium-chloride/sodium-acetate (16.4%) along with 30cc bag of dummy solution (PlasmaLyte).
62610504|NCT04663087|EXPERIMENTAL|Treatment with XSTAT|Participants randomized to the treatment arm will be treated using the study device - XSTAT.
62610505|NCT04663087|OTHER|Standard Care|Participants assigned to the control group receive standard prehospital care, consisting of direct pressure/dressings.
62832976|NCT02260687||Group 1|Decision of treatment is made by attending investigator according to the Japanese Package Insert
62832977|NCT02071394|EXPERIMENTAL|72h cooling + 18h xenon inhalation|Babies in poor condition at birth and referred to our neonatal unit for standard therapy of cooling to 33.5 degree C body temperature will be randomised to receive xenon gas at 50% concentration for 18 hours
62832978|NCT02071394|ACTIVE_COMPARATOR|Standard 72 h whole body cooling therapy|Whole body cooling therapy to rectal temperature of 33.5 degree Centigrade (standard therapy)
62251767|NCT03920553|NO_INTERVENTION|Control Group|Preoperatively all patients gargled for 1 min with 0.2% chlorhexidine mouthwash. Local anaesthesia was applied to the area where the surgical procedure was to be applied. Then the frenectomy operation was performed with a continuous 970nm wavelength of the diode laser at power setting of 1,5W for approximately 60 seconds from the base to the apex of the frenum, thereby excising it.
62441409|NCT06019325|EXPERIMENTAL|Study Group|After endotracheal intubation, patients will be positioned in lateral decubitus position. A linear ultrasound probe will be placed at the edge of scapula at the level of T5-T6. Under sterile conditions, the landmark points (rhomboid major muscle, 5th and 6th ribs, and intercostal muscles) will be observed and a block needle will be directed to the interfacial plane between rhomboid major muscle and intercostal muscle. RIB will be performed by injecting 30 ml of bupivacaine 0.25%.
62832979|NCT03891381|EXPERIMENTAL|Tetragraph|Patients will be randomized to receive quantitative monitoring in the operating room. Neuromuscular management will be guided by information provided by the monitor
62049901|NCT03204955|ACTIVE_COMPARATOR|Sodium chloride (23.4%)|30cc per dose of sodium chloride (23.4%) along with 50cc dummy solution bag (PlasmaLyte)
62441410|NCT06019325|NO_INTERVENTION|Control Group|No block procedure will be performed in this group.
62610506|NCT05527847|ACTIVE_COMPARATOR|Healthy Living with Diabetes (HLWD)|Participants will have a 6-week self-management program, followed by the option to work with a Community Health Worker for the remaining 4 months.
62832980|NCT03891381|ACTIVE_COMPARATOR|Qualitative monitoring|The screen of the Tetragraph will be covered so that information is not provided to the clinician. The monitor will therefore function as a standard peripheral nerve monitor (clinicians will only observe the response to nerve stimulation)
62832981|NCT00760032|EXPERIMENTAL|Active|Ciprofloxacin
62832982|NCT00760032|PLACEBO_COMPARATOR|Placebo|Placebo
62049902|NCT03872479|EXPERIMENTAL|Adults Low Dose|Single dose of EDIT-101 administered by subretinal injection surgery
62049903|NCT03872479|EXPERIMENTAL|Adults Middle Dose|Single dose of EDIT-101 administered by subretinal injection surgery
62049904|NCT03872479|EXPERIMENTAL|Adults High Dose|Single dose of EDIT-101 administered by subretinal injection surgery
62049905|NCT03872479|EXPERIMENTAL|Pediatric Middle Dose|Single dose of EDIT-101 administered by subretinal injection surgery
62251768|NCT01688128|EXPERIMENTAL|Intervention_Control group|Phase I: U-SMART for 4 weeks (2 session/week); Washout: for 2 weeks; Phase II: No intervention for 4 weeks
62441411|NCT02275988|EXPERIMENTAL|K-877|K-877
62441412|NCT02275988|EXPERIMENTAL|K-877 with Clarithromycin|K-877 with Clarithromycin
62441413|NCT00673361|EXPERIMENTAL|"Chemo-Switch Regimen"|
62441414|NCT00878345|ACTIVE_COMPARATOR|1|Dexmedetomidine sedation protocol
62610507|NCT05527847|EXPERIMENTAL|Peers EXCEL|Participants will have an 8-week self-management program, and will participate in phone calls with a peer for the remaining 4 months.
62610508|NCT01036633||Control Group no mucositis|Control patients with multiple myeloma who are not currently receiving chemotherapy and who do not suffer from oral mucositis
62610509|NCT01036633||Non-control Group Mucositis|Patients with multiple myeloma suffering from WHO Grade 3/4 Oral Mucositis
62610510|NCT03336723|EXPERIMENTAL|Experimental Group|Two piece zirconia dental implants place subcrestally with a healing abutment at baseline (T0) and rehabilitated with a zirconia dental crown T3 3 Measures on the IL1b and IL6 at T0 baseline , T2 2 month and T3 at crown placement.Microbiological samples at T2 and T3.
62049906|NCT03872479|EXPERIMENTAL|Pediatric High Dose|Single dose of EDIT-101 administered by subretinal injection surgery
62049907|NCT06324929|OTHER|Aim 1 Survey|We will enroll up to 300 Native women ages 18-44 to complete a 35-minute survey to characterize demographics, parity, literacy, AEP risk, drinking levels, knowledge of FASD, location, Tribal affiliation, cultural preferences for tailoring, preferred digital platforms, methods of access to mobile devices/Internet, and interest in a digital women's health study about alcohol and birth control
62049908|NCT05407454||Study Group|Patients with diabetes (all types)
62251769|NCT01688128|EXPERIMENTAL|Control_Intervention group|Phase I: No intervention for 4 weeks; Washout: for 2 weeks; Phase II: U-SMART for 4 weeks (2 session/week)
62441415|NCT00878345|ACTIVE_COMPARATOR|2|Pentobarbital sedation protocol
62049909|NCT04547374||Cohort 1 - GaH Intervention|Cohort 1 - GaH intervention group
62049910|NCT04547374||Cohort 2 - Standard-of-care control group|"Cohort 2 - Standard-of-care control group~\*Importantly, these individuals are eligible for referral to GaH at the discretion of their physicians.\*"
62049911|NCT04749589||iron deficient|ferritin\<30 or Transferine saturation\<.2
62610511|NCT03336723|ACTIVE_COMPARATOR|Control Group|Two piece titanium dental implants place subcrestally with a healing abutment at baseline (T0) and rehabilitated with a zirconia dental crown T3 3 Measures on the IL1b and IL6 at T0 baseline , T2 2 month and T3 at crown placement.Microbiological samples at T2 and T3.
62832983|NCT04299607||AFI patients|"Blood will be collected from patients presenting with an undifferentiated fever.~Samples will be tested with:~* the Malaria Ag Pf/Pan test SD Bioline~* the SD Bioline Dengue Duo IgM/IgG/NS1~* the DPP Zika Chikungunya Dengue test from Chembio~* the DPP Fever Panel II assay~* the Leptospira IgM ELISA test from Serion~* an in-house ELISA tests for scrub and murine typhus IgM~* blood culture for detection of Burkholderia pseudomallei"
62832984|NCT01958372|EXPERIMENTAL|Group I (squamous cell histology)|Patients receive etoposide IV over 1 hour on days 1-5 and 29-33, cisplatin IV over 1 hour on days 1, 8, 29, and 36, and undergo RT 5 days a week for 6.6 weeks. Within 48 hours of initiating treatment, patients receive soy isoflavones PO daily on days 1-90.
62832985|NCT01958372|EXPERIMENTAL|Group II (non-squamous cell histology)|Patients receive pemetrexed disodium IV over 10 minutes on days 1, 22, and 43 and cisplatin IV over 1 hour on days 1, 22, and 43. Patients also undergo RT and receive soy isoflavones as in Group I.
62049912|NCT04749589||iron replete|opposite of the other group
62049913|NCT00114179|EXPERIMENTAL|Treatment (capecitabine, radiation, bevacizumab, gemcitabine)|"Chemoradiotherapy and bevacizumab: Patients receive oral capecitabine twice daily and undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-38. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29. Patients undergo reevaluation 3-4 weeks after completion of chemoradiotherapy and bevacizumab.~Patients with no evidence of disease progression proceed to maintenance therapy. Patients with a marked response may undergo surgery at the discretion of the attending surgeon and then proceed to maintenance therapy approximately 4-8 weeks later.~Maintenance therapy: Beginning within 4-7 weeks after completion of chemoradiotherapy and bevacizumab, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30 minutes on days 1 and 15 provided that blood counts have returned to normal. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62049914|NCT01155752|EXPERIMENTAL|PULMOZYME|active drug
62049915|NCT01155752|PLACEBO_COMPARATOR|placebo|cross over to placebo
62049916|NCT00980070|EXPERIMENTAL|Positioning Device|use of positioning device
62049917|NCT00980070|ACTIVE_COMPARATOR|Control|institutional standard of care
62832986|NCT02132988|EXPERIMENTAL|OPT-822/OPT-821|
62832987|NCT00068692|EXPERIMENTAL|Group I, Arm I|Patients receive 1 of 3 preoperative chemo and radiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive irinotecan IV over 90 minutes and leucovorin calcium IV over 2 hours followed immediately by fluorourcil IV bolus on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.
62049918|NCT01865955|NO_INTERVENTION|Palpation|Palpation will be used to determine placement of the spinal needle.
62049919|NCT01865955|EXPERIMENTAL|Ultrasound|Ultrasound will be used prior to placement of the spinal needle.
62049920|NCT05768685||Cases|Right-handed women diagnosed with obesity will be consecutively recruited during their rehabilitative treatment at the Istituto Auxologico Italiano, IRCCS, San Giuseppe Hospital (Italy). Concurrent neurological, neurodevelopmental (e.g., autism), motor, somatosensory and/or psychiatric disorders will be exclusion criteria, as well as the evidence of any skin-related condition possibly affecting sensitivity on the participants' forearm (e.g., eczema, scars)
62441416|NCT05757492|ACTIVE_COMPARATOR|Dose Optimization Phase - Arm A|Advanced solid tumor participants will receive CHS-006 in combination with toripalimab Q3W
62441417|NCT05757492|ACTIVE_COMPARATOR|Dose Optimization Phase - Arm B|Advanced solid tumor participants will receive CHS-006 in combination with toripalimab Q3W
62441418|NCT05757492|ACTIVE_COMPARATOR|Indication-specific Expansion Phase - Cohort 1 NSCLC-NS|NSCLC-NS participants will receive CHS-006 in combination with toripalimab Q3W
62441419|NCT05757492|ACTIVE_COMPARATOR|Indication-specific Expansion Phase - Cohort 2 HCC|HCC participants will receive CHS-006 in combination with toripalimab Q3W
62049921|NCT05768685||Controls|Age-matched, right-handed, healthy women (i.e., with no history of eating disorders) will be recruited outside the hospital through personal contacts of the researchers and word-of-mouth.
62049922|NCT03657498|EXPERIMENTAL|Study group|Combined orthodontic-orthognathic treatment
62049923|NCT03657498|NO_INTERVENTION|Control Group I|No intervention
62049924|NCT03657498|ACTIVE_COMPARATOR|Control Group II|Standard orthodontic treatment
62049925|NCT02529150|EXPERIMENTAL|exercise|
62049926|NCT05522374||NBIA Patients|Patients with suspected or confirmed NBIA
62441420|NCT01626885|EXPERIMENTAL|MP-214 1.5-9 mg|
62251770|NCT01810133||Anesthesia patients|All patients undergoing general anesthesia between January 2006 and December 2011 in Charité - University Berlin
62251771|NCT04446962|ACTIVE_COMPARATOR|Arm A: R-MPV with Lenalidomide|Lenalidomide in association with R-MPV as a targeted induction treatment
62251772|NCT04446962|ACTIVE_COMPARATOR|Arm B: R-MPV with Ibrutinib|Ibrutinib in association with R-MPV as a targeted induction treatment
62251773|NCT05489692||FOLFOX-HAIC plus targeted therapy and/or PD-1 inhibitors|"FOLFOX-HAIC as the following dosage: 130 mg/m2 oxaliplatin infusion for 2 hours; 400 mg/m2 of leucovorin infusion for 2 hours; and 400 mg/ m2 of 5-FU bolus and 1200 of mg/m2 continuous infusion of 5-FU for 23 hours.~Patients received targeted therapy, three different targeted therapy were applied including: 1. lenvatinib 2. sorafenib; 3. apatinib. A portion of patients received PD-1 inhibitor administered intravenously every three weeks."
62251774|NCT05058417|EXPERIMENTAL|Empagliflozin group|participants will receive 10 mg Empagliflozin for 8 consecutive weeks in addition to the standard therapy
62049927|NCT02753595|EXPERIMENTAL|Eribulin mesylate plus PEGPH20 (Phase 1b)|"Recommended Phase 2 dose (RP2D) will be determined from the below dose levels:~* Dose level 1: PEGPH20 (3.0 microgram per kilogram (mcg/kg)) followed by eribulin mesylate (1.4 milligrams per square meter (mg/m\^2)) or~* Dose level 0: PEGPH20 (1.6 mcg/kg) followed by eribulin mesylate (1.4 mg/m\^2) or~* Dose level -1: PEGPH20 (1.6 mcg/kg) followed by eribulin mesylate (1.1 mg/m\^2)~Dose level 1 can be selected as the RP2D if no more than 1 out of 6 participants has a DLT; DLT was only observed from the first treatment cycle; otherwise, Dose level 0 will be assessed in a second cohort of 6 subjects and will be selected as the RP2D if no more than 1 subject has a DLT. Otherwise, Dose level - 1 will be assessed in a third cohort of 6 subjects. Upon determination of the RP2D, study Phase 1b Expansion Part will proceed to confirm the RP2D, and thereafter Phase 2 part will proceed."
62251775|NCT05058417|PLACEBO_COMPARATOR|Placebo|participants will receive placebo for 8 consecutive weeks in addition to the standard therapy
62251776|NCT03007979|EXPERIMENTAL|Palbociclib + letrozole or + fulvestrant|"* Palbociclib should be taken by mouth with food on a 5 days on/2 days off schedule (meaning: on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle).~* Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle.~* Patients who are receiving fulvestrant will receive it as two intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.~* Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- or peri-menopausal women only.~* Optional research biopsy at baseline and progression~* Blood for research at baseline, cycle 1 day 15, cycle 2 day 1, every 2-3 months (to coincide with imaging studies), and time of progression"
62251777|NCT02025842||Chronic hepatitis B patients|Chronic hepatitis B patients treated with nucleoside/nucleotide
62251778|NCT02025842||Compensated cirrhosis patients|Compensated cirrhosis patients treated with nucleoside/nucleotide
62251779|NCT02277977|EXPERIMENTAL|Contrast enhanced ultrasound|Contrast enhanced ultrasound during septic shock
62251780|NCT00809419|EXPERIMENTAL|A|NeoVista Ophthalmic System procedure + Lucentis
62251781|NCT02730273|EXPERIMENTAL|Trial Nasal Mask|Participants to use nasal mask in-home for a week and one night in lab overnight polysomnography.
62251782|NCT00288990||1|subjects who are NAb positive
62251783|NCT00288990||2|Subjects who are antibody negative
62251784|NCT00288990||3|subjects who are BAb positive
62251785|NCT01687140|PLACEBO_COMPARATOR|Placebo|Participant takes one pill of placebo a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
62251786|NCT01687140|ACTIVE_COMPARATOR|DCS|Participant takes one pill of D-Cycloserine a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
62251787|NCT03805997|EXPERIMENTAL|Experimental Group|consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day
62251788|NCT03805997|PLACEBO_COMPARATOR|Control Group|no consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day. This group will receive Système U vouchers.
62441421|NCT05962177|EXPERIMENTAL|Relapsing-remitting Multiple sclerosis benefiting from a moderately effective treatment|Moderately effective treatment includes interferon beta, glatiramer acetate, Teriflunomide, dimethyl Fumarate and monomethyl fumarate n= 175 patients
62441422|NCT05962177|EXPERIMENTAL|Relapsing-remitting Multiple sclerosis benefiting from a highly effective treatment|Highly effective treatment includes Natalizumab, Ocrelizumab, Rituximab, Ofatumumab, Fingolimod and Cladribine n= 175 patients
62441423|NCT05962177|EXPERIMENTAL|Untreated relapsing-remitting Multiple sclerosis|Patients untreated for relapsing-remitting Multiple sclerosis n= 50 patients
62441424|NCT01541956|ACTIVE_COMPARATOR|metformin up titration|metformin 500 mg bid will be up titrated (total daily dose up to 2000 mg)
62441425|NCT01541956|EXPERIMENTAL|vildagliptin add on to metformin|Vildagliptin 50 mg twice daily + Metformin 500mg twice daily
62441426|NCT02041494|ACTIVE_COMPARATOR|Synthetic|Patients in this arm will have their ventral hernia repaired utilizing Ventralight, a synthetic prosthetic mesh made of polypropylene.
62441427|NCT02041494|ACTIVE_COMPARATOR|Biologic|Patients in this arm will have their ventral hernia repaired utilizing Strattice, a biologic prosthetic mesh derived from porcine dermis.
62441428|NCT04776174|EXPERIMENTAL|standard and telerobotic ultrasound|Included patients will have both ultrasound examination: standard ultraosound (abdominal, cardiac or pulmonary depending on the prescription and telerobotic ultrasound
62441429|NCT04912466|EXPERIMENTAL|IBI322|Singal arm
62441430|NCT01517724|EXPERIMENTAL|Bortezomib consolidation|Bortezomib administered once a week 1.3mg/sq m; maximum of 8 cycles (each cycle is 4 weeks)
62610512|NCT04547231||Deferral of PCI group|Patients with a vessel determined to defer revascularization after FFR measurement who undergo CCTA within 90 days before FFR measurement will be included.
62251789|NCT03686098|EXPERIMENTAL|Dietary Soy Arm|Participants will be asked to increase soy in their diet by an equivalent of 50mg/day for 12 months
62251790|NCT03686098|ACTIVE_COMPARATOR|Soy Supplement Arm|Participants will consume 2 tablets of 50mg each per day for 12 months
62251791|NCT03686098|NO_INTERVENTION|Control Arm|No diet or supplement changes
62251792|NCT02124395||Primary Hyperoxaluria|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
62251793|NCT02124395||Cystinuria|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
62441431|NCT05480618|EXPERIMENTAL|Spinal Cord Injury Subjects|20 medically stable male and female subjects between 18 and 60 years old, BMI between 18.5-35 kg/m2, with a history of SCI and who use a wheelchair were included. Participants that did not speak English or with a history of renal, neurological, or coronary artery disease, cancer, diabetes, significant arrhythmia smoking, or using cardioactive medications were excluded.
62441432|NCT05851235|EXPERIMENTAL|Colorectal cancer patients|Patients with colon or rectal cancer awaiting surgery
62441433|NCT03946215|EXPERIMENTAL|well-trained athletes|A cardiorespiratory stress test
62049928|NCT02753595|EXPERIMENTAL|Eribulin mesylate plus PEGPH20 (Phase 2)|Participants will receive eribulin mesylate and PEGPH20 at the established RP2D level achieved in the Phase 1b.
62049929|NCT02753595|EXPERIMENTAL|Eribulin mesylate (Phase 2)|Participants will receive eribulin mesylate at 1.4 mg/m\^2.
62049930|NCT03139422|ACTIVE_COMPARATOR|Tranexamic Acid|Tranexamic Acid oral tablets 500 mg every six hour with the onset of the first day of menstrual cycle till the end of bleeding for 3 cycles
62610513|NCT04547231||PCI group|Patients with a vessel that undergo stent implantation and FFR measurement both before and after revascularization (pre-PCI FFR and post-PCI FFR) with available coronary CT angiography within 90 days before FFR measurement will be included.
62049931|NCT03139422|EXPERIMENTAL|Calcium Dobesilate|Calcium Dobesilate oral tablets 500 mg (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.
62049932|NCT03765840||POCD group|patients occur cognitive decline after surgery according to scores in this group.
62049933|NCT03765840||NO POCD group|patients do not occur cognitive decline after surgery according to scores in this group.
62251794|NCT02124395||Dent Disease|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
62251795|NCT02124395||APRT deficiency|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
62251796|NCT02171273|EXPERIMENTAL|Chronic circadian disruption|Following a baseline of adequate time in bed, study participants will spend 3 weeks on a daily jet-lag schedule (where each day is longer than 24 hours).
62251797|NCT02171273|EXPERIMENTAL|Chronic sleep restriction|Following a baseline of adequate time in bed, study participants will have a shortened opportunity for sleep during each 24-hour day (for three weeks).
62251798|NCT02171273|ACTIVE_COMPARATOR|Control (sleep extension)|Following a baseline of adequate time in bed, study participants will continue to have adequate time in bed and opportunity for sleep during each 24-hour day, for 3 weeks.
62251799|NCT00517153|EXPERIMENTAL|1|OGT-918 - Zavesca (miglustat)
62251800|NCT00517153|NO_INTERVENTION|2|Standard treatment
62610514|NCT02211092|EXPERIMENTAL|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
62251801|NCT04457180|EXPERIMENTAL|treatment|"In phase A, subjects receiving a single dose of Repaglinide orally on day 1 , a single dose of Bupropion orally on day 2 and wash-out for 10 days, then apatinib once daily will be conducted on D5 through D16~# In addition, In phase B, subjects receiving a single dose of Repaglinide (in combination with apatinib) orally on day 12 , a single dose of Bupropion (in combination with apatinib) orally on day 13."
62251802|NCT05932836||Pancancer corhor|No interventions to be administered.
62251803|NCT05932836||Hepatocellular carcinoma patients who undergo hepatic artery infusion with mFOLFOX6|No interventions to be administered.
62251804|NCT01444742|EXPERIMENTAL|Clofarabine + Cytarabine|"Induction:~Clofarabine 10 mg/m2 1-2 hours by vein daily for 5 days (days 1-5) Cytarabine 20 mg subcutaneously twice daily for 7 days (days 1-7)~Consolidation:~Clofarabine 10 mg/m2 1-2 hours by vein daily for 3 days (days 1-3) Cytarabine 20 mg subcutaneously twice daily for 5 days (days 1-5)"
62251805|NCT03382015|ACTIVE_COMPARATOR|Group 1|Receives 28 days of active test product (BKR-013) in Part 1 of the study and receives 28 days of placebo in Part 2 of the study, following a washout period.
62049934|NCT04803448|NO_INTERVENTION|Control|No statement is provided before asking the health care question. Example: What is your weight in pounds?
62049935|NCT04803448|EXPERIMENTAL|Benefit Statement|A statement of benefit will be given (see intervention) after the health question.
62049936|NCT04803448|EXPERIMENTAL|Risk Statement|A statement of risk will be given (see intervention) after the health question.
62049937|NCT04803448|EXPERIMENTAL|Privacy Statement|A statement of privacy will be given (see intervention) after the health question.
62049938|NCT04803448|EXPERIMENTAL|Benefit + Privacy statement|A statement of benefit and privacy will be given (see intervention) after the health question.
62049939|NCT04803448|EXPERIMENTAL|Risk + privacy statement|A statement of risk and privacy will be given (see intervention) after the health question.
62049940|NCT05364775||Focus Groups with International Nurses|It is anticipated that there will be four focus groups, each comprised of 6-8 participants
62049941|NCT05364775||Interviews with Nursing Staff|Interviews with qualified and unqualified staff who work with international nurses
62049942|NCT02548455|EXPERIMENTAL|Treatment|Subjects implanted with the Quartet 1457Q LV lead
62049943|NCT04586725|ACTIVE_COMPARATOR|Encouragement every minute|Patients will be randomised to six tests at one week apart
62049944|NCT04586725|ACTIVE_COMPARATOR|Encouragement every two minutes|Patients will be randomised to six tests at one week apart
62610515|NCT02211092|OTHER|Usual care|Access to usual community resources but no active lifestyle coaching.
62610516|NCT04916314|EXPERIMENTAL|Low Carbohydrate Diet|". The intervention, provided by Second Nature, involves diet, activity and behaviour change components. It comprises a three-month remote behavioural change programme with mentoring from a registered dietitian or nutritionist (health coach), peer group support, structured education articles and activity tracking technology. These elements are accessed via a smartphone or web-based application. Each participant will also receive a hard copy of an instructional handbook and a recipe book."
62610517|NCT04916314|NO_INTERVENTION|Standard NHS type 2 diabetes care|Participants randomised to the control group will receive no additional intervention, and will continue to receive their usual NHS diabetes care from their general practice.
62610518|NCT05202275|EXPERIMENTAL|OPA regimen|All patients were given orally olanzapine 10mg once on d1-5; intravenously palonosetron 0.25mg once on d1; aprepitant 125 mg once on d1, then 80mg once on d2-5.
62251806|NCT03382015|PLACEBO_COMPARATOR|Group 2|Receives 28 days of placebo in Part 1 of the study and receives 28 days of active test product (BKR-013) in Part 2 of the study, following a washout period.
62251807|NCT05553483|EXPERIMENTAL|pranayama and acupoint stimulation by laser|"for 6 weeks,This 30-children group will receive 2-session per-week laser stimulation to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for six weeks) will be (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama)"
62049945|NCT03247790|EXPERIMENTAL|Lasmiditan (Period 1)|200 mg Lasmiditan tablet given once orally during migraine attack.
62049946|NCT03247790|EXPERIMENTAL|Lasmiditan (Period 2)|200 mg Lasmiditan tablet given once orally during inter-ictal period.
62049947|NCT01620567|PLACEBO_COMPARATOR|chickpeas/potatoes|1 potato/day or 1 cup chickpeas
62049948|NCT01620567|ACTIVE_COMPARATOR|avocados|1 avocados/day
62049949|NCT05877950|EXPERIMENTAL|Smartphone-based speech therapy with usual stroke care|"Smartphone-based speech therapy: Participants will be instructed to use smartphone-based speech therapy (application), including oro-motor exercises, phonation, articulation, resonance, syllable repetition, and reading exercises.~Usual stroke care: Participants will follow the treatment as usual, including conventional stroke therapy if needed based on the medical guidelines."
62049950|NCT05877950|ACTIVE_COMPARATOR|Home-based speech therapy with usual stroke care|"Home-based speech therapy: Participants will receive treatment such as oro-motor exercises and reading tasks from a workbook.~Usual stroke care: Participants will follow the treatment as usual, including conventional stroke therapy if needed based on the medical guidelines."
62049951|NCT00249106|EXPERIMENTAL|HIV vaccine|dosage escalation of ADVAX
62049952|NCT00249106|PLACEBO_COMPARATOR|Placebo|Sodium phosphate
62251808|NCT05553483|ACTIVE_COMPARATOR|acupoint stimulation by laser|for six weeks, This 30-children group will receive 2-session per-week laser stimulation to some selected acupoints. The stimulated bilateral points will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
62610519|NCT04312945|EXPERIMENTAL|Primary Parent|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
62610520|NCT04312945|EXPERIMENTAL|Close Friend|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
62049953|NCT06471634|EXPERIMENTAL|CBTi and Sedentary Behaviour support|Participants will be counselled in how to improve their sleep and decrease sedentary behaviour using CBTi and behaviour change techniques.
62049954|NCT06471634|ACTIVE_COMPARATOR|Control - usual care|Participants will be given a leaflet containing brief information on good sleep hygiene practice and the benefits of decreasing sedentary behaviour.
62049955|NCT02969525|PLACEBO_COMPARATOR|Placebo|Subjects will receive for 12 Weeks Placebo and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.
62049956|NCT02969525|EXPERIMENTAL|Bimekizumab dosage regimen 1|Subjects will receive for 12 Weeks Bimekizumab dosage regimen 1 and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.
62610521|NCT04312945|EXPERIMENTAL|Experimenter|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
62610522|NCT04312945|EXPERIMENTAL|No Social Partner|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
62049957|NCT02969525|EXPERIMENTAL|Bimekizumab dosage regimen 2|Subjects will receive for 48 Weeks Bimekizumab dosage regimen 2.
62610523|NCT01819948|EXPERIMENTAL|single-arm|Two capsules in the morning, one at night, every day for a month, taken with a glass of water.
62251809|NCT02669966|EXPERIMENTAL|Study Arm|Donor candidates with their intended recipients who meet criteria will be enrolled into this, the sole arm of our study. Donor-recipient pairs will be screened to meet criteria, and will proceed to kidney transplantation and post-transplant monitoring
62049958|NCT02969525|EXPERIMENTAL|Bimekizumab dosage regimen 3|Subjects will receive for 48 Weeks Bimekizumab dosage regimen 3.
62049959|NCT02969525|EXPERIMENTAL|Bimekizumab dosage regimen 4|Subjects will receive for 12 Weeks Bimekizumab dosage regimen 4 and will then be re-randomized to Bimekizumab dosage regimen 2 for 36 Weeks.
62049960|NCT04257266|EXPERIMENTAL|Cryo Cooling Pack|Cryo cooling pack will be placed on subjects for 30 mins after exercise-induced hyperthermia is achieved.
62049961|NCT04257266|ACTIVE_COMPARATOR|Commerical Ice Pack|The commercial ice pack will be placed on subjects for 30 mins after exercise-induced hyperthermia is achieved.
62251810|NCT02432222|EXPERIMENTAL|Music Training|Music training
62251811|NCT02432222|EXPERIMENTAL|Visual Arts Training|Visual arts training
62251812|NCT02432222|NO_INTERVENTION|Control|Waitlist control
62049962|NCT05385458|EXPERIMENTAL|ACT Intervention|Participants will attend 6-8 individual psychotherapy sessions via telephone, text or videoconference. Sessions will last approximately 1 hour and occur every 3-4 weeks. Participants will be enrolled in the Intervention Group for 18-36 weeks. All sessions will be audio recorded. Participants will also be able to attend all available usual care services such as: support groups, First Link, education classes at the Alzheimer Society. Any services utilized will be documented by Alzheimer Society staff.
62049963|NCT05385458|ACTIVE_COMPARATOR|Usual Care|Participants will be enrolled as an Alzheimer Society client. Participants will receive 1 First Link 'check-in' telephone call from a staff member at the time of enrolment. Participants will receive a 2nd 'check-in' First Link telephone call from a staff member 3-4 months following enrolment. Participants will be enrolled in the Usual Care Group 12-16 weeks. Participants will also be able to attend all available usual care services such as: support groups, etc. Any services utilized will be documented by Alzheimer Society staff.
62049964|NCT00665574|EXPERIMENTAL|1|ActaVisc
62251813|NCT01671020|ACTIVE_COMPARATOR|(R)(T)|Period 1: Fimasartan 60mg → Period 2: Fimasartan 30mg
62251814|NCT01671020|ACTIVE_COMPARATOR|(T)(R)|Period 1: Fimasartan 30mg → Period 2: Fimasartan 60mg
62251815|NCT00664495|NO_INTERVENTION|C|Control
62441434|NCT03787745|ACTIVE_COMPARATOR|Ischemic postconditioning|In addition to state of the art primary PCI in patients with TIMI0-1 ischemic postconditioning with an adequately sized balloon (60 reperfusion/60 seconds re-occlusion, four cycles) will be performed, however thrombectomy will not be allowed
62049965|NCT00665574|EXPERIMENTAL|2|ActaVisc Mx Intra-articular Injection
62049966|NCT00665574|PLACEBO_COMPARATOR|3|Saline
62049967|NCT00665574|ACTIVE_COMPARATOR|4|Corticosteroid
62049968|NCT01862705|EXPERIMENTAL|Thoracic spine manipulation thrust|Thoracic spine manipulation thrust
62251816|NCT00664495|ACTIVE_COMPARATOR|DWL|Diet Weight Loss
62251817|NCT00664495|ACTIVE_COMPARATOR|EWL|Exercise Weight Loss
62251818|NCT00664495|ACTIVE_COMPARATOR|EWS|Exercise Without Weight Loss
62441435|NCT03787745|PLACEBO_COMPARATOR|Conventional|State of the art primary PCI in patients with TIMI0-1 will be performed, however thrombectomy will not be allowed
62441436|NCT01280370||1|1.patients treated in a laparoscopic manner
62441437|NCT01280370||2.|2. patients treated in open operative manner
62441438|NCT05887830|EXPERIMENTAL|Interventional drug treatment group|The participants receive Nivolumab treatment. The active drug Nivolumab will be administered at a standard dose (5mg/kg) dissolved in 100ml 0.9%NaCl solution. Nivolumab was given at a rate of 15-25 drops per minute, and the intravenous infusion time exceeded 1 hour.
62441439|NCT05887830|PLACEBO_COMPARATOR|Placebo treatment group|The participants receive placebo treatment. Patients assigned to the placebo treatment group will receive an intravenous infusion of 100 ml 0.9% NaCl solution at a rate of 15-25 drops/min for an IV infusion duration of more than 1 hour.
62441440|NCT03140306|EXPERIMENTAL|Low dose CT abdomen and pelvis|Low dose computed tomography
62441441|NCT03140306|EXPERIMENTAL|Control dose CT abdomen and pelvis|Control dose CT abdomen and pelvis
62441442|NCT00631111|EXPERIMENTAL|1|
62441443|NCT00631111|ACTIVE_COMPARATOR|2|
62251819|NCT03279185||Infected Cohort|Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment.
62251820|NCT03227471|PLACEBO_COMPARATOR|Part A: Pooled Placebo (Except Cohort A7)|Participants without CF who received single dose of placebo matched to VX-445 in Cohort A1 to A5.
62441444|NCT00631111|ACTIVE_COMPARATOR|3|
62441445|NCT00631111|PLACEBO_COMPARATOR|4|
62610524|NCT06412458|EXPERIMENTAL|IM83 CAR-T Cells|After preconditioning with chemotherapy, IM83 CAR-T Cells will be evaluated
62049969|NCT01862705|SHAM_COMPARATOR|Thoracic spine manipulation non-thrust|Thoracic spine manipulation non-thrust
62049970|NCT00387673|EXPERIMENTAL|Arm 1|6 weeks of upper extremity training for 3 sessions/week, as follows: a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session);
62049971|NCT00387673|ACTIVE_COMPARATOR|Arm 2|a 6-week period of 2 hours somatosensory stimulation of the hand, without training
62610525|NCT06154174|EXPERIMENTAL|C-RUTF (Ready-to-Use Therapeutic Food with added choline)|A daily dose of 500mg choline will be added to RUTF. 2 sachets (daily dose) of RUTF will provide approximately 1000 Kcal, 14g of protein, 28g of fat, and 1 RDA of 14 micronutrients.
62610526|NCT06154174|ACTIVE_COMPARATOR|S-RUTF (Ready-to-Use Therapeutic Food without added choline)|A daily dose of 5mg choline will be added to RUTF for masking. 2 sachets (daily dose) of RUTF will provide approximately 1000 Kcal, 14g of protein, 28g of fat, and 1 RDA or 14 micronutrients.
62610527|NCT03751436|EXPERIMENTAL|Treatment (venetoclax, enzalutamide)|Patients receive venetoclax PO QD and enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62610528|NCT06038929|EXPERIMENTAL|vagal nerve stimulant|The aim is to measure gastric emptying and gastric accommodation in response to a caloric meal before and 3 months after activation of VNS. Therefore, prior to surgery, subjects will undergo combined gastric emptying/accommodation test. Subsequently, participants will undergo a second identical study approximately 3 months after insertion of the VNS.
62049972|NCT00387673|PLACEBO_COMPARATOR|Arm 3|a 6-week period of 2 hours sham somatosensory stimulation of the hand, followed by 1 hour of activity-based training
62049973|NCT03995108|EXPERIMENTAL|Mavorixafor|Participants (adults and adolescents \[12 to 17 years of age weighing \>50 kilograms \[kg\]) will receive mavorixafor 400 milligrams (mg) once daily (QD) orally for 52 weeks in the Randomized Placebo-Controlled Period. Adolescents weighing ≤50 kg will receive mavorixafor 200 mg QD. Participants who complete the Randomized Placebo-Controlled Period or are granted Early Release due to recurrent or significant infections, as adjudicated by a blinded, independent adjudication committee (AC), will be offered the opportunity to enroll in the Open-Label Period and receive treatment with mavorixafor 400 mg once daily orally until commercial availability or study termination by the Sponsor.
62049974|NCT03995108|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to mavorixafor QD orally for 52 weeks in the Randomized Placebo-Controlled Period. Participants who complete the Randomized Placebo-Controlled Period or are granted Early Release due to recurrent or significant infections, as adjudicated by a blinded, independent AC, will be offered the opportunity to enroll in the Open-Label Period and receive treatment with mavorixafor 400 mg once daily orally until commercial availability or study termination by the Sponsor.
62049975|NCT04657744|EXPERIMENTAL|A test|Test drug (Sphingomod ) 1 capsule contains 0.5 mg Fingolimod
62049976|NCT04657744|ACTIVE_COMPARATOR|B reference|Reference drug (Gilenya) 1 capsule contains 0.5 mg Fingolimod
62049977|NCT06413836|EXPERIMENTAL|aPDT Therapy|antimicrobial photodynamic therapy using methylene blue in surfactant solution
62251821|NCT03227471|EXPERIMENTAL|Part A: VX-445 (Except Cohort A7)|Participants without CF who received single ascending dose of VX-445 tablet starting from 20 milligrams (mg) to 360 mg in Cohort A1 to A5.
62251822|NCT03227471|EXPERIMENTAL|Part A: VX-445 (Cohort A7)|Participants without CF who received single dose of VX-445 100 mg tablet on Day 1 in fasted state and on Day 7 in fed state, followed by VX-445 20 mg intravenous (IV) injection on Day 13 in fed state in Cohort A7.
62251823|NCT03227471|PLACEBO_COMPARATOR|Part B: Pooled Placebo (Cohort B1 to B4)|Participants without CF who received multiple doses of placebo matched to VX-445 once daily (qd) for 10 days in Cohort B1 to B4.
62049978|NCT06413836|SHAM_COMPARATOR|conventional treatment|Endodontic treatment conventional treatment
62049979|NCT02070484|EXPERIMENTAL|NuCel|Stemcell allograft
62049980|NCT02070484|ACTIVE_COMPARATOR|Demineralized Bone Matrix (DBM)|Demineralized Bone Matrix (DBM) bone graft substitute
62049981|NCT03944525|ACTIVE_COMPARATOR|Intervention|Intervention consists of HFA using standard equipment at the department. A gas flow of 60L/min and a FiO2 as clinically feasible will be used. Therapy will be continued until a pCO2-level of 50mmHg or less is reached, or therapy has to be aborted because of lack of tolerance by the pati ent or indication for intubation.
62049982|NCT03944525|ACTIVE_COMPARATOR|Control|Control consists of non-invasive CPAP ventilation support using a tight mask and standard respirator equipment of the Department of Emergency Medicine. A positive airway pressure of 5cm H2O and a FiO2 as clinically feasible will be used. Therapy will be continued until a pCO2-level of 50mmHg or less is reached, or therapy has to be aborted because of lack of tolerance by the patient or indication for intubation.
62251824|NCT03227471|EXPERIMENTAL|Part B: VX-445 (Cohort B1 to B4)|Participants without CF who received VX-445 tablet qd for 10 days in Cohort B1 (60 mg), B2 (120 mg), B3 (240 mg) and B4 (340 mg).
62251825|NCT03227471|PLACEBO_COMPARATOR|Part C: Pooled Placebo (Cohort C1 to C3)|Participants without CF who received placebo matched to VX-445/TEZ/IVA triple combination (TC) qd in the morning and placebo matched to IVA in the evening for 14 days.
62251826|NCT03227471|EXPERIMENTAL|Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3)|Participants without CF who received VX-445 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C1; VX-445 280 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C2 and VX-445 100 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C3 for 14 days.
62610529|NCT06712849|SHAM_COMPARATOR|Sham Stimulation|40-minute sessions of sham stimulation for 5 consecutive days.
62610530|NCT06712849|ACTIVE_COMPARATOR|hf-tRNS Stimulation|40-minute sessions of hf-tRNS stimulation for 5 consecutive days.
62610531|NCT02519816|EXPERIMENTAL|Intervention|Open-label phase II study. After signing informed consent, patients will undergo 6 times an apheresis during the 6-month treatment period. These cells will be manufactured into the Rhitol and frozen in aliquots. Then re-infused.
62610532|NCT05710094|EXPERIMENTAL|Group 1|Single dose of 500ppm HOCl + 1 % HAc, or placebo
62610533|NCT05710094|EXPERIMENTAL|Group 2|Single dose of 500ppm HOCl + 2 % HAc, or placebo
62610534|NCT05710094|EXPERIMENTAL|Group 3|Single dose of 500ppm HOCl + 3 % HAc, or placebo
62610535|NCT05710094|EXPERIMENTAL|Group 4|Single dose of 1000ppm HOCl + 3 % HAc, or placebo
62610536|NCT05710094|EXPERIMENTAL|Group 5|Multiple doses (OD for 5 days) of xppm HOCl + x% HAc#
62610537|NCT05710094|EXPERIMENTAL|Group 6|Multiple doses (BID for 5 days) of xppm HOCl + x% HAc#
62251827|NCT03227471|PLACEBO_COMPARATOR|Part D: Placebo|Participants with CF, F/MF genotype who received placebo matched to VX-445/TEZ/IVA TC qd in the morning and placebo matched to IVA qd in the evening for 4 weeks in the TC treatment period.
62441446|NCT01689610||Adult female patients with MBC|This is an observational study, no interventions are specified
62441447|NCT03940313||Subjects|Participants \>18 years old who meet inclusion and exclusion criteria, and have findings on physical exam and ultrasound that suggest potential benefit from prolotherapy.
62441448|NCT03940313||Controls|Participants \>or =18 years old who do not complain of lower back pain, but consent to have physical examination testing and musculoskeletal ultrasound of the lower back to evaluate these areas.
62441449|NCT02413073|SHAM_COMPARATOR|Sham of Whole Body Vibration|This group will receive placebo treatment on the platform we'll use a little engine that will produce a very small vibration stimulus in the platform.
62441450|NCT02413073|EXPERIMENTAL|Whole body vibration Group|This group will be a training na vibratory platform with 12 weeks (3 months), held twice a week on alternate days
62441451|NCT02976012|ACTIVE_COMPARATOR|IAI q8 week Group|"Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q8 week Group) where 4 additional mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up. Starting at week 20 in the q8week group eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment"
62441452|NCT02976012|ACTIVE_COMPARATOR|IAI q16 week Group|Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q16week Group) where 2 additional mandatory postoperative q4weeks IAI will be followed by mandatory q16weeks IAI for 52 weeks follow-up. Starting at week 12 in the q16 group, eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment.
62441453|NCT03220685||1.normal persons|normal persons include 25 person
62441454|NCT03220685||2.CKD pt with anemia|includes 25 previously diagnosed CKD patients with or without treatment of anemia.
62441455|NCT03363282|EXPERIMENTAL|Mini-SLET|Simple Limbal Epithelial Transplantation
62441456|NCT03363282|EXPERIMENTAL|Limbal-Conjunctival Autograft|Patients treated with limbal-conjunctival autograft
62610538|NCT05710094|EXPERIMENTAL|Group 7|Multiple doses (TID for 5 days) of xppm HOCl + x% HAc#
62610539|NCT04984278|EXPERIMENTAL|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides. Study dependent: Each spray delivers 100 microliters (μL) of nabiximols. A pre-determined number of sprays, but no less than 4 sprays, of nabiximols will be self-administered by participants as an oromucosal spray, under supervision of trial staff during 2 study visits to the trial site after they temporarily discontinued treatment with prescribed nabiximols (Sativex) as part of their regular medication.
62251828|NCT03227471|EXPERIMENTAL|Part D: VX-445/TEZ/IVA TC - Low Dose|Participants with CF, F/MF genotype who received VX-445 50 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.
62251829|NCT03227471|EXPERIMENTAL|Part D: VX-445/TEZ/IVA TC - Medium Dose|Participants with CF, F/MF genotype who received VX-445 100 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.
62251830|NCT03227471|EXPERIMENTAL|Part D: VX-445/TEZ/IVA TC - High Dose|Participants with CF, F/MF genotype who received VX-445 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.
62049983|NCT00005810|EXPERIMENTAL|Estramustine + docetaxel + carboplatin+ filgrastim|Patients receive oral estramustine 3 times daily on days 1-5. Patients receive docetaxel IV over 1 hour followed by carboplatin IV over 1 hour on day 2. Filgrastim (G-CSF) SC is administered beginning on day 6 and continuing until hematopoietic recovery. Treatment continues every 21 days in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for a maximum of 2 years.
62049984|NCT00881179|EXPERIMENTAL|1|Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)
62049985|NCT00881179|ACTIVE_COMPARATOR|2|Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)
62049986|NCT06350890|EXPERIMENTAL|HTD1801|Administered orally twice daily (BID)
62049987|NCT06350890|PLACEBO_COMPARATOR|Placebo|Administered orally BID
62049988|NCT06185998|EXPERIMENTAL|plated balloon tracheostomy cannulas|4 interfaces are tested: cap, ventilator, filter and phonation valve
62049989|NCT06185998|ACTIVE_COMPARATOR|low pressure balloon tracheotomy cannulas|4 interfaces are tested: cap, ventilator, filter and phonation valve
62049990|NCT04296695|EXPERIMENTAL|B/F/TAF|50mg/600mg/300mg
62049991|NCT04296695|ACTIVE_COMPARATOR|TDF/3TC/EFV|300mg/300mg/400mg
62049992|NCT05592795||Patients with Gallbladder polyp or gallbladder adenomyosis|Patients with Gallbladder polyp or gallbladder adenomyosis In view of the difficulty in obtaining bile from normal people, our research team plans to select bile samples from patients undergoing laparoscopic cholecystectomy and patients with pathological diagnosis of gallbladder polyps or gallbladder adenomyosis as physiological bile of normal people.
62049993|NCT05592795||Patients with choledocholithiasis|Patients with choledocholithiasis The research group plans to select bile samples from patients with first episode choledocholithiasis, patients receiving ERCP treatment for the first time, and patients undergoing duodenal papillary incision during EST operation to study the biliary flora of patients with choledocholithiasis. Compared with the normal group, analyze whether there are differences, similarities and uniqueness between the groups, dynamically track changes in the structure of biliary flora before and after treatment, and whether there is specific flora related to the type of disease, and compared with the existing biliary microbiome database, to study whether there are new bacterial species.
62049994|NCT05592795||Patients with previous ERCP and/or EST operations and duodenal papilla incision during operation|Patients with previous ERCP and/or EST operations and duodenal papilla incision during operation Bile from patients who had undergone ERCP and EST duodenal papillary incision was collected, and the long-term impact of duodenal papillary incision on biliary microecology was discussed by comparing with that of normal patients.
62049995|NCT02465281||Stroke patients|20 patients who are at least 6 months post stroke. Device: 3T scanner with MRI-compatible robot
62049996|NCT02465281||Healthy volunteers|80 age-matched healthy volunteers
62251831|NCT03227471|ACTIVE_COMPARATOR|Part E: TEZ/IVA|Following run-in period of 4 weeks with TEZ/IVA, participants with CF, F/F genotype who received TEZ 100 mg qd/IVA 150 mg q12h and placebo matched to VX-445 for 4 weeks in the TC treatment period.
62441457|NCT03070210|OTHER|EUS-celiac plexus block (EUS-CPB)|"This is the standard technique. In this approach, the needle is passed through the body of the stomach adjacent the celiac artery into the retroperitoneal space in 1 or 2 passes. The injectate (bupivacaine or alcohol) is injected and spreads through the retroperitoneal space, effectively bathing all the ganglia."
62049997|NCT00772590|EXPERIMENTAL|Raltegravir, bovine colostrum|Raltegravir and hyper-immune bovine colostrum
62049998|NCT00772590|EXPERIMENTAL|Hyper-immune bovine colostrum|Hyper-immune bovine colostrum and Raltegravir placebo
62049999|NCT00772590|EXPERIMENTAL|Raltegravir|Raltegravir and Hyper-immune Bovine Colostrum Placebo
62050000|NCT00772590|PLACEBO_COMPARATOR|Placebo|Raltegravir placebo and hyper-immune bovine colostrum placebo
62050001|NCT01573936|EXPERIMENTAL|rehabilitation program|Rehabilitation program from January 2008 through July 2010, which consists of 40-minutes of many therapies for 1-2 days a week
62050002|NCT06472817||Observational|"AIM I: Participants complete a survey and participate in an interview in person, over the phone, or via zoom on study.~AIM II: Participants complete an interview in person, over the phone, or via zoom on study."
62050003|NCT02526043|EXPERIMENTAL|laparoscopic hepatectomy|The HCC patients who meet the Louisville consensus will be underwent the liver resection by laparoscopic surgery
62050004|NCT02526043|EXPERIMENTAL|Open hepatectomy|The HCC patients who meet the Louisville consensus will be underwent the liver resection by open surgery
62050005|NCT02974790||Circulatory failure|Patients with a circulatory failure due to a sepsis or not
62050006|NCT01888393|EXPERIMENTAL|Group A|Approximately 12 subjects (male and female) with moderate hepatic impairment
62050007|NCT01888393|EXPERIMENTAL|Group B|Approximately 12 healthy subjects (male and female)
62050008|NCT03275025|EXPERIMENTAL|YRA-1909 low dose|
62050009|NCT03275025|EXPERIMENTAL|YRA-1909 medium does|
62050010|NCT03275025|EXPERIMENTAL|YRA-1909 high dose|
62050011|NCT03275025|PLACEBO_COMPARATOR|YRA-1909 Placebo|
62050012|NCT05834114|EXPERIMENTAL|McKenzie protocol|In this group, 20 participants will be included. the interventions will be given for 15 mint. The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week.
62251832|NCT03227471|EXPERIMENTAL|Part E: VX-445/TEZ/IVA TC|Following run-in period of 4 weeks with TEZ/IVA, participants with CF, F/F genotype who received VX-445 200 mg qd/TEZ 100 mg qd /IVA 150 mg q12h for 4 weeks in the TC treatment period.
62251833|NCT03227471|PLACEBO_COMPARATOR|Part F: Placebo|Participants with CF, F/MF genotype who received placebo matched to VX-445/TEZ/VX-561 for 4 weeks in the TC treatment period.
62251834|NCT03227471|EXPERIMENTAL|Part F: VX-445/TEZ/VX-561 TC|Participants with CF, F/MF genotype who received VX-445 200 mg qd/TEZ 100 mg qd/VX-561 150 mg qd for 4 weeks in the TC treatment period.
62050013|NCT05834114|ACTIVE_COMPARATOR|Rhythmic stabilization technique|In this group, 20 participants will be included. Rhythmic Stabilization with traditional physical therapy will be given for 3 sessions of 45 minutes a week, over a period of 10 weeks.
62251835|NCT05937308|OTHER|NEUROMARK Treatment|Interventional registry to collect real world data - Subjects will undergo treatment with the NEUROMARK System.
62610540|NCT04984278|PLACEBO_COMPARATOR|Placebo|Placebo to match nabiximols is presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray delivers 100 μL containing no active ingredients.
62832988|NCT00068692|EXPERIMENTAL|Group I, Arm II|Patients receive 1 of 3 preoperative chemo and radiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours followed immediately by fluorourcil IV bolus on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 8 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
62832989|NCT00068692|EXPERIMENTAL|Group I, Arm III|Patients receive 1 of 3 preoperative chemo and radiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV over 1 hour on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 8 weeks for 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
62050014|NCT06200454||Guillain-Barré syndrome patients|neuromuscular ultrasound of cranial nerves
62050015|NCT06200454||normal participants|neuromuscular ultrasound of cranial nerves
62050016|NCT04959058|OTHER|Volunteer|This study has only one arm for the brachial plexus evaluation with ultrasound
62050017|NCT05519280|EXPERIMENTAL|the Biopsychosocial-Spiritual Group Intervention|The experimental group received 8 sessions of weekly BPS-S group therapy for 80 minutes each.
62050018|NCT05519280|NO_INTERVENTION|weekly general chatting activities|The Control group received weekly general chatting activities for 30 minutes.
62251836|NCT04103489|EXPERIMENTAL|HELLP Syndrome at less than 30 weeks gestation|Women diagnosed with HELLP syndrome at 23-30 weeks gestation will receive eculizumab.
62251837|NCT00282178|ACTIVE_COMPARATOR|1|Candesartan 16-32 mg once daily
62251838|NCT00282178|ACTIVE_COMPARATOR|2|Hydrochlorothiazide 25-50 mg once daily
62251839|NCT00282178|PLACEBO_COMPARATOR|3|
62251840|NCT03042104|EXPERIMENTAL|TAVR|Transcatheter aortic valve replacement (TAVR)
62050019|NCT01982149||Group 1|Non-smokers (n=20)
62050020|NCT01982149||Group 2|Non-smokers (n=20), Smokers (n=20) and Individuals with lung cancer (n=20)
62050021|NCT01982149||Group 3|Subjects with abnormalities (nodules) detected on CT (n=20)
62050022|NCT03979196|ACTIVE_COMPARATOR|Inpatient Management|Women in this arm will follow the standard of care for admission to high-risk units at Sunnybrook Health Sciences Centre or North York General Hospital.
62251841|NCT03042104|NO_INTERVENTION|CS|Clinical surveillance (CS)
62251842|NCT05895162|EXPERIMENTAL|JUVIA zinc-containing vaginal gel and Fluconazole|JUVIA zinc containing vaginal gel group. Receive oral fluconazole treatment (150 mg) and after that participants will use a zinc containing- vaginal gel for 12 weeks.
62251843|NCT05895162|ACTIVE_COMPARATOR|Fluconazole|Control group. Receive oral fluconazole treatment.
62251844|NCT01825642|ACTIVE_COMPARATOR|Control Group|nerve-sparing radical prostatectomy
62251845|NCT01825642|ACTIVE_COMPARATOR|Treatment Group|seminal vesicle-sparing radical prostatectomy
62050023|NCT03979196|ACTIVE_COMPARATOR|Outpatient Management|Women in this arm will be encouraged to follow the standard of care established in the high-risk clinics at Sunnybrook Health Sciences Centre or North York General Hospital.
62050024|NCT01177423|ACTIVE_COMPARATOR|Quicksleeper intraosseous anesthesia|Pulpal and periapical molar and premolar sedation is managed by Quicksleeper intraosseous anesthesia.
62050025|NCT01177423|ACTIVE_COMPARATOR|Inferior alveolar nerve block|Pulpal and periapical molar and premolar sedation is managed by inferior alveolar nerve block.
62050026|NCT04211922|EXPERIMENTAL|Alkotinib 400mg QD|400mg orally once daily. Take Alkotinib at least 1 hour before or at least 2 hours after a meal.
62050027|NCT00801801|EXPERIMENTAL|Metronomic Docetaxel + Sorafenib|"Subjects with advanced non-squamous cell non-small cell lung cancer with poor performance status will receive treatment in this non-randomized, open-label Phase II Study of Metronomic Chemotherapy (docetaxel) plus sorafenib as first-line therapy.~Subjects will be treated with metronomic chemotherapy with low dose docetaxel weekly for 3 out of 4 weeks, and sorafenib will be administered continuously 400 mg bid on a 28 day cycle. Treatment with metronomic chemotherapy will be expressed as a 4-week cycle."
62050028|NCT01735201|EXPERIMENTAL|AGN-199201 Dose A Once Daily|AGN-199201 Dose A applied once daily to the face for 28 days.
62050029|NCT01735201|EXPERIMENTAL|AGN-199201 Dose B Once Daily|AGN-199201 Dose B applied once daily to the face for 28 days.
62050030|NCT01735201|EXPERIMENTAL|AGN-199201 Dose C Once Daily|AGN-199201 Dose C applied once daily to the face for 28 days.
62050031|NCT01735201|PLACEBO_COMPARATOR|AGN-199201 Vehicle Once Daily|AGN-199201 Vehicle applied once daily to the face for 28 days.
62050032|NCT01735201|EXPERIMENTAL|AGN-199201 Dose A Twice Daily|AGN-199201 Dose A applied twice daily to the face for 28 days.
62050033|NCT01735201|EXPERIMENTAL|AGN-199201 Dose B Twice Daily|AGN-199201 Dose B applied twice daily to the face for 28 days.
62050034|NCT01735201|EXPERIMENTAL|AGN-199201 Dose C Twice Daily|AGN-199201 Dose C applied twice daily to the face for 28 days.
62050035|NCT01735201|PLACEBO_COMPARATOR|AGN-199201 Vehicle Twice Daily|AGN-199201 Vehicle applied twice daily to the face for 28 days.
62050036|NCT06423755|EXPERIMENTAL|Swimming programme|Participants allocated to the swimming programme will be invited to complete three short questionnaires to assess general health, back pain, and swimming ability and experience, see Appendix H, I and J. Both the swimming and physiotherapy groups will complete the three outcome measures, the Oswestry low back pain disability index (ODI), the pain self-efficacy questionnaire (PSEQ), and the EQ-5D-3L, before the intervention, after the last appointment and 6 months later. Data will be collected to report participant characteristics: including age, gender, and length of time with LBP. A follow up participant feedback questionnaire will be distributed to the participants in the swimming arm on completion of the programme and 6 months later.
62251846|NCT04326699|ACTIVE_COMPARATOR|Sacroiliac joint injection group|The active group will receive bilateral sacroiliac joint injection of 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) under ultrasound guidance.
62251847|NCT04326699|NO_INTERVENTION|control group|The other group will not receive the sacroiliac joint injection
62441458|NCT03070210|ACTIVE_COMPARATOR|EUS-celiac ganglia block (EUS-CGB)|This is a more recent technique which has been often used. In this procedure, the needle is inserted under EUS guidance directly into as many ganglia as possible. For celiac ganglia \<1cm in diameter, the solution is injected into the central point; for those ≥1 cm, a needle is advanced to the deepest point into the ganglia and solution is injected as the needle is slowly withdrawn. Injections are continued until an echogenic pattern is produced over the entire celiac ganglia.
62441459|NCT05751655||Drowning patients|Process of experiencing respiratory impairment from submersion/immersion in liquid
62050037|NCT06423755|ACTIVE_COMPARATOR|Standard Physiotherapy care|The participants in the physiotherapy arm will attend the physiotherapy department in the hospital. Treatment delivered by the physiotherapist could include exercise, advice, education, and manual therapy; they will be offered up to 6 sessions. Some appointments will be delivered in a cubicle and others in the physiotherapy gym. The time between appointments varied from person to person.
62050038|NCT05056779|EXPERIMENTAL|Nemolizumab|
62050039|NCT05056779|EXPERIMENTAL|Placebo|
62050040|NCT02216344||Pulse Oximeter (the device)|The pulse oximetry devices were placed on subjects per the protocol. The subjects underwent gradual hypoxia and the output of the devices under test was compared to the SaO2 value as measured by a CO-Oximeter (the reference value), as outlined by ISO 80601, to ensure that the devices meet the specified performance claims.
62441460|NCT02778178|EXPERIMENTAL|TAP block with ropivacaine|Bilateral single shot TAP block under ultrasound guidance: 20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
62050041|NCT03716310||septic shock patients|Inclusion criteria of the study were diagnosis of septic shock and a platelet count \>150\*103/mcL.
62251848|NCT03525106|EXPERIMENTAL|Participants: Positive Psychology Intervention|Participants receive a positive psychology exercise manual, complete positive psychology exercises every week, and participate in phone sessions over 30 minutes every week for 8 weeks.
62251849|NCT03525106|EXPERIMENTAL|Caregivers: Positive Psychology Intervention|Caregivers receive a positive psychology exercise manual, complete positive psychology exercises every week, and participate in phone sessions over 30 minutes every week for 8 weeks.
62251850|NCT02632396|EXPERIMENTAL|Treatment (ixazomib, rituximab)|Beginning between 70-180 days after stem cell transplant, patients receive ixazomib PO on days 1, 8, and 15, and rituximab IV (or SC after first dose if deemed appropriate) on day 1 of courses 1, 3, 5, 7, and 9. Treatment repeats every 28 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
62441461|NCT02778178|PLACEBO_COMPARATOR|TAP block with placebo|Placebo administration: bilateral single shot TAP block under ultrasound guidance: 20 mL saline 0.9%, per side
62441462|NCT03787446||Multiple Sclerosis (MS) patients|3 Primary Progressive MS patients on no disease modifying therapy and 3 Relapsing-Remitting MS patients on no disease modifying therapy
62441463|NCT03787446||Healthy Controls (HC)|3 Healthy volunteers aged between 18-60 years of age
62441464|NCT01104233||The soft spreading|Patients with lung cancer underwent Video-assisted Thoracoscopic Surgery (VATS) with soft spreading (using LAP Protector).
62441465|NCT01104233||The rigid spreading|Patients with lung cancer underwent Video-assisted Thoracoscopic Surgery (VATS) with rigid spreading.
62050042|NCT06072703|ACTIVE_COMPARATOR|Active rTMS|1 Hz (LF) and 10 Hz (HF) rTMS stimulation will be delivered at 90% of the resting motor threshold for 40 min each week day for two weeks.
62050043|NCT06072703|SHAM_COMPARATOR|Sham rTMS|"Low-frequency (1Hz) active rTMS stimulation will be delivered with an inert sham stimulation coil for 40 min each week day for two weeks."
62050044|NCT03077490||Single center vs. multicenter|Both Groups operated on by the same device (Transvaginal mesh Uphold TM Vaginal Support System) and in the same manner.
62610541|NCT06731855||Study Population|Infants born \>35 weeks gestation and have a condition requiring major gastrointestinal surgery within 5 days (120 hours) of birth. This is expected to include predominantly congenital gut malformations such as gastroschisis, gut atresias, volvulus and congenital diaphragmatic hernia (who are stable enough for surgery in this time frame).
62610542|NCT01344317||Caffeine group|Premature infants below 30 weeks of gestation who receive Caffeine treatment
62610543|NCT01344317||Caffeine and Doxapram group|Premature infants below 30 weeks of gestation who receive Caffeine and Doxapram treatment
62610544|NCT01344317||Group with no treatment|Premature infants below 30 weeks of gestation with no stimulating treatment
62050045|NCT04357314||Patients with STEMI in 2019|Patient with acute myocardial infarction between March 17, 2019 and April17, 2019
62251851|NCT05454436|EXPERIMENTAL|Healing rate of intra oral sinus tract in single visit by SCT with bioceramic sealer|When a patient comes with intra oral sinus tract will treat in a single visit. The treatment protocol will be: cleaning and shaping by NITI file ( pro taper gold ) with Naocl 5.25%, EDTA 17% and saline then the canal will be obturate by single cone technique with bioceramic sealer.
62050046|NCT04357314||Patients with STEMI in 2020|Patient with acute myocardial infarction between March 17, 2020 and April17, 2020.
62050047|NCT01323530|EXPERIMENTAL|Dose-escalation Phase (Phase 1b)|Participants with advanced and/or metastatic tumors will receive eribulin mesylate as a 2 to 5 min Intravenous (IV) bolus or infusion in two different schedules (Schedule 1 \[1.2, 1.6, 2.0 mg/m2\], given on Day 1 only, and Schedule 2 \[0.7, 1.1, 1.7 mg/m\^2\], given on Days 1 and 8) and oral capecitabine 1000 mg/m2 bid on Days 1-14 (21-day cycles) in both schedules. If maximum tolerated dose (MTD) is not observed at dose level 3 the dose of capecitabine might be escalated to 1250 mg/m\^2 bid on Days 1-14 (21-day cycles) depending on the Dose limiting toxicities (DLTs) observed and/or pharmacokinetic (PK) data when available. Based on the data and safety monitoring board review of dose escalation phase data (DLTs that will be observed in first cycle), Dose-Confirmation Phase (Phase 2) will may get initiated.
62251852|NCT05454436|EXPERIMENTAL|Healing rate of intra oral sinus tract in multi visit by SCT with bioceramic sealer|When a patient comes with intra-oral sinus tract will treat in a multi-visit. The treatment protocol will : cleaning and shaping by NITI file ( pro taper gold ) with Naocl 5.25%, EDTA 17%, and saline then ca(oh)2 use as Intracanal medication the after disappear the sinus tract the canal will obturate by single cone technique with bioceramic sealer.
62251853|NCT06026748|EXPERIMENTAL|XJ103 Injection|Participants will receive a single dose of XJ103 intravenously.
62251854|NCT06026748|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo intravenously.
62251855|NCT05768581|EXPERIMENTAL|Concurrent Training|Experimental: home-based concurrent training composed by strength and aerobic exercises within the same training session
62251856|NCT05768581|EXPERIMENTAL|Strength Training|Experimental: home-based resistance training mode
62251857|NCT05768581|EXPERIMENTAL|Aerobic Training|Experimental: home-based endurance training mode
62251858|NCT06057584|EXPERIMENTAL|somatosensory-motor integration training|
62610545|NCT06731127||People with HIV (PWH) Immune responders (n=35)|undetectable viral load for 1+ year, CD4 \>500/uL, CD4/CD8 ratio \>1 including individuals with a historical, low CD4 nadir
62610546|NCT06731127||People with HIV (PWH) Immune non-responders (n= 10)|undetectable viral load, CD4 \<350/uL or CD4/CD8 ratio \<0.75 for 1+ year
62610547|NCT06731127||People with HIV (PWH) Low-level viremics (n= 10)|low-level viremia (\<1,000 copies/mL) for 1+ year, any CD4, any CD4/CD8 ratio
62050048|NCT01323530|EXPERIMENTAL|Dose-confirmation Phase (Phase 2)|Participants with advanced and/or metastatic tumors will receive Eribulin mesylate at the MTD for the selected schedule of dose escalation phase based on safety/PK data.
62050049|NCT02283281|EXPERIMENTAL|Cannabis oil high dose|Single-dose, before anesthetic induction: 21.6 mg tetrahydrocannabinol + 20 mg cannabidiol, Sub-linguistic
62050050|NCT02283281|EXPERIMENTAL|Cannabis oil low dose|Single-dose, before anesthetic induction: 10.8 mg tetrahydrocannabinol + 10 mg cannabidiol, Sub-linguistic.
62050051|NCT02283281|PLACEBO_COMPARATOR|Control|Single-dose, before anesthetic induction: Dummy oromucosal spray containing alcohol vehicle without Cannabis oil .
62050052|NCT03814798|EXPERIMENTAL|Cohort 1|IGSC 20% daily push versus every 2 weeks pump or the reverse sequence
62050053|NCT03814798|EXPERIMENTAL|Cohort 2|IGSC 20% daily push versus once a week pump or the reverse sequence
62441466|NCT03776851|EXPERIMENTAL|Erythropoietin|Erythropoietin plus standard of care (RBC transfusions if Hb ≤7 mg/dl and/or hemodynamic instability)
62441467|NCT03776851|NO_INTERVENTION|No Intervention|Standard of care: RBC transfusions if Hb ≤7 mg/dl and/or hemodynamic instability
62441468|NCT05668871|EXPERIMENTAL|Danning Tablet and lifestyle intervention group|Under lifestyle intervention, Danning Tablet will be taken orally from baseline to weeks 12±1.
62441469|NCT05668871|NO_INTERVENTION|Lifestyle intervention group|Lifestyle intervention only.
62610548|NCT06731127||HIV-negative control (n= 20)|age and sex matched
62610549|NCT02172040|EXPERIMENTAL|Amlodipine+Celecoxib|Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
62050054|NCT03814798|EXPERIMENTAL|Cohort 3|IGSC 20% daily push versus 2 times per week pump or the reverse sequence
62050055|NCT03814798|EXPERIMENTAL|Treatment-Naive IGSC 20% pump dosing|IGSC 20% 150 mg/kg
62050056|NCT01060202||Bortezomib|
62050057|NCT01558479||Case|Has a diagnosis of Parkinson's disease
62050058|NCT01558479||Control|No diagnosis of Parkinson's disease
62050059|NCT01558479||Family Member|Has a family history of Parkinson's disease. Can be affected or unaffected with Parkinson's disease
62050060|NCT02334566|EXPERIMENTAL|NET TX|Behavioral intervention for PTSD (NET/KIDNET) with 8-12 sessions administered on a weekly basis.
62251859|NCT06057584|ACTIVE_COMPARATOR|pure somatosensory training|
62832990|NCT00068692|EXPERIMENTAL|Group II, Arm I|"Patients receive irinotecan, leucovorin calcium, and fluorouracil as in group 1, arm I for 4 courses. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemo and radiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III.~Treatment continues in the absence of disease progression or unacceptable toxicity."
62251860|NCT06057584|ACTIVE_COMPARATOR|pure motor training|
62832991|NCT00068692|EXPERIMENTAL|Group II, Arm II|"Patients receive oxaliplatin, leucovorin calcium, and fluorouracil as in group 1, arm II for 4 courses. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemo and radiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III.~Treatment continues in the absence of disease progression or unacceptable toxicity."
62832992|NCT00068692|EXPERIMENTAL|Group II, Arm III|Patients receive leucovorin calcium and fluorouracil as in group 1, arm III for 1 course. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemo and radiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III. Treatment continues in the absence of disease progression or unacceptable toxicity.
62832993|NCT05656144|EXPERIMENTAL|Cadonilimab|Cadonilimab monotherapy
62832994|NCT02195102||transcatheter aortic valve Replacement|Patients with symptomatic severe aortic stenosis who are not candidates for surgical aortic valve replacement because of coexisting illnesses.
62832995|NCT02343640||Baseball players|Members of the baseball team, both pitchers and fielders, who participate in repetitive baseball throwing and are exposed to damage of the ulnar collateral ligament in the arm that is used for throwing.
62832996|NCT06591338|ACTIVE_COMPARATOR|Ticagrelor and aspirin arm|The ticagrelor arm will receive (a 180 mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90 mg twice daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
62050061|NCT02334566|ACTIVE_COMPARATOR|Delayed TX|Behavioral intervention for PTSD (NET/KIDNET) with 8-12 sessions administered on a weekly basis, started following a three-month wait period
62050062|NCT05831111|EXPERIMENTAL|Part A: mRNA-1195.1 Dose Level 1|Participants will receive 3 intramuscular (IM) injections of mRNA-1195.1 at Dose Level 1 on Days 1, 57, and 169.
62050063|NCT05831111|EXPERIMENTAL|Part A: mRNA-1195.2 Dose Level 1|Participants will receive 3 IM injections of mRNA-1195.2 at Dose Level 1 on Days 1, 57, and 169.
62251861|NCT05080972|EXPERIMENTAL|in-the-kNOW mobile app.|Participants will be assigned to the in-the-kNOW mobile app for four (4) months.
62251862|NCT05080972|ACTIVE_COMPARATOR|Control condition.|Participants will be randomized to receive a one-time virtual women's health counseling session with a healthcare provider.
62251863|NCT00966420|EXPERIMENTAL|mucosa resection|
62251864|NCT05102084|EXPERIMENTAL|Experimental group|Patients listening to music during CPAP application
62251865|NCT05102084|NO_INTERVENTION|Control group|Patients not listening to music during CPAP application
62251866|NCT01265615|ACTIVE_COMPARATOR|Paricalcitol treatment|6-8 μg daily per os (orally) without special diet
62251867|NCT01265615|ACTIVE_COMPARATOR|Calcitriol treatment|2-4 μg daily orally under with dietary restrictions of vitamin D
62251868|NCT01265615|ACTIVE_COMPARATOR|Cholecalciferol|alendronate sodium/ cholecalciferol capsules with recommended daily allowance equals 1200-2400 IU per day
62251869|NCT01265615|OTHER|Supplemental|intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
62832997|NCT06591338|ACTIVE_COMPARATOR|clopidogrel and aspirin|The clopidogrel arm will receive (a 300 mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
62832998|NCT02220543|EXPERIMENTAL|Back on Track intervention|Back on Track intervention is a biopsychosocial primary care intervention
62832999|NCT02220543|ACTIVE_COMPARATOR|Primary care as usual|Primary care as usual comprises maximally 12 individual regular physical therapy sessions for a maximum of 8 weeks.
62833000|NCT01704599|EXPERIMENTAL|Humira then Humira plus 3 B vitamins|"Humira then Humira plus 3 B vitamins~The only arm: After 16 weeks on adalimumab, modulators of homocysteine (oral vitamin B12, oral vitamin B6 or pyridoxine, and oral folic acid) will be added to adalimumab therapy for an additional 12 weeks. At end of this therapy can stop or continue. Telephone call day 70 after formal end of in person study the investigators will assess general health of each subject."
62833001|NCT02863419|EXPERIMENTAL|Oral Semaglutide|
62833002|NCT02863419|ACTIVE_COMPARATOR|Liraglutide|
62833003|NCT02863419|PLACEBO_COMPARATOR|Placebo|
62833004|NCT04892381||Lichen Planus group|Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels using ELISA in lesional and non lesional skin
62251870|NCT03636620|ACTIVE_COMPARATOR|TACE group|Transcatheter arterial chemoembolization
62251871|NCT03636620|EXPERIMENTAL|TACE+RFA/MV group|Transcatheter arterial chemoembolization and radiofrequency /microwave ablation
62251872|NCT01499784|EXPERIMENTAL|Pelvic Floor muscle Training|educational class for behavioral modification and group exercise class for pelvic floor muscle training
62251873|NCT00932360|EXPERIMENTAL|Active TENS Placebo TENS No TENS|Active TENS: 100 Hz, 200 μs at maximal tolerable intensity Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor
62251874|NCT00932360|EXPERIMENTAL|Placebo TENS Active TENS No TENS|Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off Active TENS: 100 Hz, 200 μs at maximal tolerable intensity Participants wore a TENS unit that was turned off for blinding of the outcome assessor
62441470|NCT00038883|EXPERIMENTAL|Campath-1H|10 mg/day x 5
62050064|NCT05831111|EXPERIMENTAL|Part A: mRNA-1195.1 Dose Level 2|Participants will receive 3 IM injections of mRNA-1195.1 at Dose Level 2 on Days 1, 57, and 169.
62050065|NCT05831111|EXPERIMENTAL|Part A: mRNA-1195.2 Dose Level 2|Participants will receive 3 IM injections of mRNA-1195.2 at Dose Level 2 on Days 1, 57, and 169.
62050066|NCT05831111|EXPERIMENTAL|Part A: mRNA-1195.1 Dose Level 3|Participants will receive 3 IM injections of mRNA-1195.1 at Dose Level 3 on Days 1, 57, and 169.
62050067|NCT05831111|EXPERIMENTAL|Part A: mRNA-1195.2 Dose Level 3|Participants will receive 3 IM injections of mRNA-1195.2 at Dose Level 3 on Days 1, 57, and 169.
62050068|NCT05831111|EXPERIMENTAL|Part A: mRNA-1195.1 Dose Level 4|Participants will receive 3 IM injections of mRNA-1195.1 at Dose Level 4 on Days 1, 57, and 169.
62050069|NCT05831111|EXPERIMENTAL|Part A: mRNA-1195.2 Dose Level 4|Participants will receive 3 IM injections of mRNA-1195.2 at Dose Level 4 on Days 1, 57, and 169.
62050070|NCT05831111|ACTIVE_COMPARATOR|Part A: mRNA-1189|Participants will receive 3 IM injections of mRNA-1189 on Days 1, 57, and 169.
62050071|NCT05831111|PLACEBO_COMPARATOR|Part A: Placebo|Participants will receive IM injection of study drug-matching placebo on Days 1, 57, and 169.
62050072|NCT05831111|EXPERIMENTAL|Part B: mRNA-1195.1 or mRNA-1195.2 Low Dose|Participants will receive 3 IM injections of mRNA-1195.1 or mRNA-1195.2 (at a dose level selected based on the Part A interim analysis) low dose on Days 1, 57, and 169.
62050073|NCT05831111|EXPERIMENTAL|Part B: mRNA-1195.1 or mRNA-1195.2 Middle Dose|Participants will receive 3 IM injections of mRNA-1195.1 or mRNA-1195.2 (at a dose level selected based on the Part A interim analysis) middle dose on Days 1, 57, and 169.
62050074|NCT05831111|EXPERIMENTAL|Part B: mRNA-1195.1 or mRNA-1195.2 High Dose|Participants will receive 3 IM injections of mRNA-1195.1 or mRNA-1195.2 (at a dose level selected based on the Part A interim analysis) high dose on Days 1, 57, and 169.
62251875|NCT00932360|EXPERIMENTAL|No TENS Active TENS Placebo TENS|No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor Active TENS: 100 Hz, 200 μs at maximal tolerable intensity Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off
62251876|NCT00932360|EXPERIMENTAL|Active TENS No TENS Placebo TENS|Active TENS: 100 Hz, 200 μs at maximal tolerable intensity No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off
62251877|NCT00932360|EXPERIMENTAL|Placebo TENS No TENS Active TENS|Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off Participants wore a TENS unit that was turned off for blinding of the outcome assessor Active TENS: 100 Hz, 200 μs at maximal tolerable intensity
62610550|NCT02172040|ACTIVE_COMPARATOR|Amlodipine+Placebo|Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
62610551|NCT02172040|PLACEBO_COMPARATOR|Placebo+Celecoxib|Matched placebo capsule for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
62050075|NCT05831111|ACTIVE_COMPARATOR|Part B: mRNA-1189|Participants will receive 3 IM injections of mRNA-1189 on Days 1, 57, and 169.
62441471|NCT03355742|EXPERIMENTAL|XIENCE|XIENCE + Short duration (1 month) of DAPT
62441472|NCT02933983||Control group (healthy)|Participants who do not suffer from acute or chronic airway infections
62610552|NCT02172040|SHAM_COMPARATOR|Placebo+Placebo|Matched placebo capsule for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
62050076|NCT05831111|PLACEBO_COMPARATOR|Part B: Placebo|Participants will receive IM injection of study drug-matching placebo on Days 1, 57, and 169.
62050077|NCT06511336|EXPERIMENTAL|children using Alkaline water as mouthwash (FLO- bottled natural drinking water - made in Egypt)|Children in this group will be asked to use alkaline water as mouthwash once daily for 3 weeks
62441473|NCT02933983||CRS patients|Patients who suffer from chronic rhinosinusitis
62050078|NCT06511336|ACTIVE_COMPARATOR|children using chlorohexidine mouthwash (Orovex- MARCO Pharmaceuticals- made in Egypt)|Children in this group will be asked to use chlorohexidine as mouthwash once daily for 3 weeks
62050079|NCT06511336|PLACEBO_COMPARATOR|children using tap water as mouthwash|Children in this group will be asked to use tap water as mouthwash once daily for 3 weeks
62050080|NCT00654719|ACTIVE_COMPARATOR|NutriDrink|Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
62050081|NCT00654719|PLACEBO_COMPARATOR|Placebo|
62050082|NCT05523622|OTHER|IOP Measurement|These are the measurements of the intraocular pressure.
62050083|NCT05968001||Cohort 1|the younger cohort (aged ≥ 18 and \< 60 years at the start of treatment)
62050084|NCT05968001||Cohort 2|the older cohort (aged ≥ 60 years at the start of treatment)
62050085|NCT02274389||Bedaquiline Patient Registry (BPR)|
62050086|NCT05712694|EXPERIMENTAL|ADIGemDoc|ADI-PEG 20: 36 mg/m2 on Day -7 of Cycle 1, and Days 1, 8, and 15 of each 21-day cycle Gemcitabine: 600 mg/m2 on days 1 and 8 of each 21-day cycle Docetaxel: 60 mg/m2 on day 8 of each 21-day cycle
62050087|NCT05712694|PLACEBO_COMPARATOR|PBOGemDoc|Placebo: matched PBO on Day -7 of Cycle 1, and Days 1, 8, and 15 of each 21-day cycle Gemcitabine: 900 mg/m2 on days 1 and 8 of each 21-day cycle Docetaxel: 75 mg/m2 on day 8 of each 21-day cycle
62441474|NCT02026661||those that did not receive ICSI or LAH|
62441475|NCT02026661||those that received ICSI only|
62441476|NCT02026661||those that received LAH only|
62441477|NCT02026661||those that received both ICSI and LAH|
62441478|NCT04619433|EXPERIMENTAL|Treatment group A|Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib
62441479|NCT04619433|PLACEBO_COMPARATOR|Treatment group B|Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo
62610553|NCT03729323|EXPERIMENTAL|Experimental: Motivational Interviewing|INTERVENTION GROUP: In this group, Diabetics and Hypertensives will attend two Nursing Consultation sessions based on the assumptions and techniques of Motivational Interviewing with a certified nurse with specific 20-hour theoretical and practical training for this approach style.
62050088|NCT02265614|EXPERIMENTAL|PGS|blastocyst biopsy and chromosomal analysis
62050089|NCT02265614|NO_INTERVENTION|control|regular IVF
62833005|NCT04892381||Control group|Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels using ELISA
62050090|NCT03251625|PLACEBO_COMPARATOR|To assess the effect of multistrain probiotics on abdominal|To assess the effect of multistrain probiotics on abdominal pain using a validated symptom severity score in IBS patients.
62050091|NCT03251625|PLACEBO_COMPARATOR|To assess the efficacy of a multistrain probiotic supplement|To assess the efficacy of a multistrain probiotic supplement as a treatment option for IBS in a tertiary referral centre
62050092|NCT00734630|ACTIVE_COMPARATOR|Nebivolol|Nebivolol 5 mg, 5 mg nontrade tablets, oral administration Nebivolol 10 mg, 10 mg nontrade tablets, oral administration Nebivolol 20 mg, 20 mg nontrade tablets, oral administration Nebivolol 40 mg (two 20 mg nontrade tablets), oral administration
62050093|NCT00734630|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets, oral administration
62610554|NCT03729323|ACTIVE_COMPARATOR|Nursing Consultation|CONTROL GROUP: In this group, Diabetics and Hypertensives will attend two conventional nursing consultation sessions aimed at self-care, with a untrained nurse for the use of motivational interviewing, based on the recommendations of the Primary Care Strategy Notebooks for the care of chronic conditions in Diabetes Mellitus and Arterial Hypertension and the SSC-GHC Institutional Protocol for SAH and DM2 Patient Care.
62610555|NCT05665140|ACTIVE_COMPARATOR|Arm A (Control)|"Three cycles of induction (isatuximab, bortezomib, lenalidomide, dexamethasone, I-VRD), followed by standard of care therapy (e.g. stem cell mobilization, and apheresis with a subsequent high-dose melphalan and autologous stem cell transfusion).~Both groups will receive subsequently an isatuximab- and lenalidomide-based maintenance therapy."
62050094|NCT05030831|EXPERIMENTAL|INZ-701|"The study design of the Dose Evaluation Period is a MAD 3 + 3 with 3 dose cohorts.~Based on nonclinical findings and nonclinical pharmacology modeling, the initial planned doses will be 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg, with a twice weekly dose regimen.~During the Extension Period, INZ-701 administration will initially be at the dose and dose schedule assigned in the Dose Evaluation Period; however, the Sponsor may modify the assigned dose and/or dosing regimen in the Extension Period post-Week 48 based on cumulative review of safety and PK/PD data, including population PK.~Study visits will be in-clinic every 4 weeks until Week 48 of the Extension Period and then every 12 weeks (remote or in-clinic) until the subject leaves the study. Subjects will complete an End of Study (EOS) Visit (Safety Follow-up Visit) 30 days after their last dose of INZ-701."
62050095|NCT04887025|EXPERIMENTAL|Dose Escalation|Subjects will be treated with RGV004 as a single injection, one time.
62050096|NCT01232010|EXPERIMENTAL|Healthy Volunteers|
62050097|NCT01232010|EXPERIMENTAL|Patients with severe renal impairment|
62050098|NCT01267292|EXPERIMENTAL|Buspirone plus Methylphenidate|\[week 1: Buspirone 30 mg twice a day (9am and 6pm) on Monday through Sunday; no Methylphenidate or Methylphenidate placebo\] \[week 2: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday; 0mg Methylphenidate (placebo) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday; Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]
62050099|NCT01267292|PLACEBO_COMPARATOR|Placebo for Buspirone plus Methylphenidate|\[week 1: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; no Methylphenidate or Methylphenidate placebo\] \[week 2: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]
62050100|NCT02003508||Pre-school based vaccination program (not vaccine eligible)|Young (17-19 years) men who were not eligible for school based vaccination due to their age at the time of the programs roll out.
62050101|NCT02003508||Post-school based vaccination program (vaccine eligible)|Young men (17-19 years) who were eligible for school based vaccination due to their age at the time of the programs roll out.
62050102|NCT04026529|EXPERIMENTAL|walking at incline|Subjects will walk on treadmill at slope and speed to equal 60% of their peak work rate as determined on baseline cardiopulmonary exercise test.
62050103|NCT03403348|EXPERIMENTAL|Part 1: Single Ascending Dose (SAD)|Participants will be enrolled in 7 cohorts and receive one of the 7 corresponding SADs of JNJ-64417184, starting from 40 milligram (mg), or placebo in a fasted state. Dose escalation in the subsequent cohorts will depend on the human maximum observed plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) in previous cohorts.
62050104|NCT03403348|EXPERIMENTAL|Part 2A: Food Effect|Participants enrolled in cohort 4 of part 1 will roll-over in Part 2A and will receive a single oral dose (the same dose as received in Part 1) of JNJ-64417184 or placebo with a high-fat meal.
62610556|NCT05665140|EXPERIMENTAL|Arm B (Experimental)|"Three cycles of induction (I-VRD), stem cell mobilization, and apheresis followed by three cycles of consolidation (I-VRD).~Both groups will receive subsequently an isatuximab- and lenalidomide-based maintenance therapy."
62050105|NCT03403348|EXPERIMENTAL|Part 2B: Relative Bioavailability (Optional)|Participants enrolled in cohorts 5, 6, 7 or any other optional cohorts of Part 1 will roll-over in Part 2B and will receive a single oral dose (the same dose as received in Part 1) of JNJ-64417184 or placebo under fasted state. Dosing may be changed from fasted to a fed state, depending on emerging pharmacokinetics (PK) data from Part 2A.
62050106|NCT03403348|EXPERIMENTAL|Part 3: Multiple Ascending Dose (MAD)|Participants will be enrolled in 3 cohorts and will receive one of the 3 corresponding MADs of JNJ-64417184 or placebo, dosed once daily for 7 days. There will be 3 optional cohorts and participants in these cohorts will follow 7- to 14-day dosing schedule. Dosing will either occur in the fasted or the fed state, depending on the outcome of Part 2A. Dose selection and dose escalation in the MAD cohorts will depend on the observed human Cmax and AUC in previous (SAD) cohorts. Additional cohorts may be evaluated at the discretion of the Sponsor and the Principal Investigator (PI).
62251878|NCT00932360|EXPERIMENTAL|No TENS Placebo TENS Active TENS|No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off Active TENS: 100 Hz, 200 μs at maximal tolerable intensity
62251879|NCT04000789|EXPERIMENTAL|NPDR|
62833006|NCT03053817|EXPERIMENTAL|Exercise group|The 45 minute exercise program will be performed 3 times a week and will consist of aerobic exercise and resistance training for 12 weeks.
62050107|NCT03403348|EXPERIMENTAL|Part 4: Human RSV Challenge (Proof-of-Concept Study Part)|Based on emerging PK and safety data from Part 3 (MAD), the participants inoculated with respiratory syncytial virus (RSV) -A Memphis 37b and confirmed positive by polymerase chain reaction (PCR) will either receive JNJ-64417184 or placebo once daily OR receive JNJ-64417184 (low dose), JNJ-64417184 (high dose) or placebo once daily.
62050108|NCT03403348|EXPERIMENTAL|Part 5: SAD/Japanese|Participants of Japanese descent will be enrolled in 3 cohorts and will receive one of the corresponding SADs of JNJ-64417184 or placebo in a fasted state. Dosing may be changed from fasted to a fed state, depending on emerging PK data from Part 2A. The starting dose and formulation will be selected based on the outcome of Parts 1 and 2. Dose escalation in the subsequent cohorts will depend on the observed human Cmax and AUC in previous cohorts.
62050109|NCT03403348|EXPERIMENTAL|Part 6: MAD/Japanese (Optional)|Participants of Japanese descent may be enrolled in 3 cohorts and will receive one of the corresponding MADs of JNJ-64417184 or placebo, dosed once daily for 7 to 14 days. Dosing will either occur in the fasted or the fed state, depending on the outcome of Part 2A. Dose selection and dose escalation in the MAD cohorts will depend on the observed human Cmax and AUC in previous (Parts 1, 2, 3, and 5) cohorts.
62050110|NCT02355743|EXPERIMENTAL|rtPA lock therapy Recipients|rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks
62050111|NCT03426384|ACTIVE_COMPARATOR|Intervention Group|"The Intervention Group will enter daily tasks into the Mymee app. After the first intake session, the subject will participate in weekly 20-30-minute coaching sessions with the Health Coach. At the second session, the Health Coach will review the symptoms and the free text entered by the subject to determine which dietary and environmental factors will be monitored in the Mymee app.~Each subsequent week, the Health Coach will review and discuss with the subject the food diary and the data entered into the Mymee app during the previous week. Based on this discussion and the subject's medical records, the Health Coach will determine or revise which symptoms will continue to be monitored using the Mymee App."
62050112|NCT03426384|NO_INTERVENTION|Control Group|The Control Group subjects will receive no training, coaching, or other intervention services from Mymee. The Control Group subjects will complete the same battery of assessments at the same intervals as the Intervention Group subjects.
62050113|NCT02557841|EXPERIMENTAL|anodal ctDCS|Volunteers will be submitted to anodal ctDCS + motor learning assessments (SRTT and Handwriting test).
62050114|NCT02557841|EXPERIMENTAL|cathodal ctDCS|Volunteers will be submitted to cathodal ctDCS + motor learning assessments (SRTT and Handwriting test).
62251880|NCT04000789|ACTIVE_COMPARATOR|NPDR Comparator|
62251881|NCT04000789|EXPERIMENTAL|PDR|
62251882|NCT04000789|ACTIVE_COMPARATOR|PDR Comparator|
62251883|NCT02782936|EXPERIMENTAL|Baseline|Randomised baseline without and with gas mask.
62251884|NCT02782936|EXPERIMENTAL|Induced Hypoxemia|Randomised hypoxemia: i. without gas mask; ii. with gas mask; and iii. correction with FreeO2 and gas mask.
62251885|NCT02782936|EXPERIMENTAL|Effort|Randomised effort without and with gas mask
62251886|NCT02008279|EXPERIMENTAL|Group 1A|100 mg CNTO 3157 or placebo in healthy male Japanese participants
62251887|NCT02008279|EXPERIMENTAL|Group 1B|100 mg CNTO 3157 or placebo in healthy male Caucasian participants
62251888|NCT02008279|EXPERIMENTAL|Group 2A|300 mg CNTO 3157 or placebo in healthy male Japanese participants
62251889|NCT02008279|EXPERIMENTAL|Group 2B|300 mg CNTO 3157 or placebo in healthy male Caucasian participants
62833007|NCT03053817|NO_INTERVENTION|Control|No treatment
62251890|NCT02008279|EXPERIMENTAL|Group 3A|600 mg CNTO 3157 or placebo in healthy male Japanese participants
62251891|NCT02008279|EXPERIMENTAL|Group 3B|600 mg CNTO 3157 or placebo in healthy male Caucasian participants
62251892|NCT02008279|EXPERIMENTAL|Group 4|300 mg CNTO 3157 in healthy male Caucasian participants
62251893|NCT04946279|EXPERIMENTAL|Arm I (conversation tool)|Patients receive the conversation tool.
62251894|NCT04946279|ACTIVE_COMPARATOR|Arm II (usual care)|Patients receive usual care.
62251895|NCT01089920|EXPERIMENTAL|High dose coffee|High dose of polyphenols from soluble coffee
62251896|NCT01089920|EXPERIMENTAL|Medium dose coffee|Medium dose of polyphenols from soluble coffee
62833008|NCT03303976|EXPERIMENTAL|Pneumo1-low dose|Arm A: intramuscular injection monovalent bioconjugate pneumococcal vaccine
62833009|NCT03303976|EXPERIMENTAL|Pneumo1-mid dose|Arm B: intramuscular injection monovalent bioconjugate pneumococcal vaccine
62833010|NCT03303976|EXPERIMENTAL|Pneumo1-target dose|Arm C: intramuscular injection monovalent bioconjugate pneumococcal vaccine
62050115|NCT02557841|SHAM_COMPARATOR|sham ctDCS|Volunteers will be submitted to sham ctDCS + motor learning assessments (SRTT and Handwriting test)
62610557|NCT05065736|EXPERIMENTAL|18F-Clofarabine|18F-Clofarabine as PET imaging agent for measuring the activity of deoxycytidine kinase (DCK) in various normal and abnormal tissues in cancer participants before and after therapy
62050116|NCT01946542|PLACEBO_COMPARATOR|placebo|placebo drink, single dose, taste and color-matched to experimental drink
62050117|NCT01946542|EXPERIMENTAL|beet juice concentrate|single dose of beet juice concentrate, roughly 70 mL
62251897|NCT01089920|EXPERIMENTAL|Low dose coffee|Low dose of polyphenols from soluble coffee
62050118|NCT03848403|EXPERIMENTAL|Ixekizumab (Reference)|Reference formulation 80 milligram (mg) ixekizumab administered as a subcutaneous (SC) injection in a prefilled syringe in one of three study periods.
62610558|NCT06731244|ACTIVE_COMPARATOR|Control arm|Anticoagulant treatment management according to usual practice and international guidelines
62050119|NCT03848403|EXPERIMENTAL|Ixekizumab (Test 1)|Test 1 formulation 80 mg ixekizumab administered as an SC injection in a prefilled syringe in one of three study periods.
62050120|NCT03848403|EXPERIMENTAL|Ixekizumab (Test 2)|Test 2 formulation 80 mg ixekizumab administered as an SC injection in a prefilled syringe in one of three study periods.
62251898|NCT01089920|EXPERIMENTAL|High dose green tea|High dose of green tea polyphenols from infusion
62251899|NCT01089920|EXPERIMENTAL|Medium dose green tea infusion|Medium dose of green polyphenols from infusion
62610559|NCT06731244|EXPERIMENTAL|Experimental arm|Shared decision-making process integrating time-dependent multicomponent risk prediction scores and socio-anthropological scales (TDMI)
62833011|NCT03303976|ACTIVE_COMPARATOR|Pneumovax23|Arm D: intramuscular injection multivalent plain polysaccharide vaccine
62833012|NCT00923793|ACTIVE_COMPARATOR|Titanium|Titanium implant for cranioplasty. Titanium implants are used since 10 years in Germany because of their high biocompatibility and accuracy of fit.
62833013|NCT00923793|EXPERIMENTAL|Hydroxylapatite|Hydroxylapatite (CustomBone) implant Hydroxylapatite implants are used since about 3 years in Germany. As this material is very similar to human bone structure an improved osteointegration has been observed.
62833014|NCT03623165||Arm|Cordella™ Heart Failure System
62833015|NCT03835195|EXPERIMENTAL|Diabetes Disease Management Program|Diabetes Disease Management Program
62833016|NCT03835195|ACTIVE_COMPARATOR|Usual Care Process|Usual care process
62833017|NCT04690049|EXPERIMENTAL|Neuromuscular resistance exercise group|Subjects will develop an innovator program consisting in the performance of exercises of increasing difficulty, with movements based on functional tests to analyze the subjects' neuromuscular capacities. Participants will attend to 80 individual, face-to-face physiotherapy sessions, including both supervised and semi-supervised monitoring. From the total, a minimum of 15 sessions will be supervised, including 6 sessions to teach and monitor the exercises, and 9 sessions to perform the tests in order to quantify the load; 37 sessions will be semi-supervised, where subjects will perform the exercises independently, but with the presence of an instructor; additionally, the remaining 28 sessions will consist in non-supervised aerobic work at a 70-80% from maximum heart rate, obtained according to the methodology of Tanaka et al.
62050121|NCT04589533||EDUCATIONAL PROGRAM GROUP|This group will receive an educational program based . This group, as the other group, during phase 1 and phase 3, will review the medical records of the last 40 patients (for each phase) with known T2DM and hospitalized for any cause.
62050122|NCT04589533||CONTROL GROUP|Control group will not receive educational program. This group, as the other group, during phase 1 and phase 3, will review the medical records of the last 40 patients (for each phase) with known T2DM and hospitalized for any cause.
62251900|NCT01089920|EXPERIMENTAL|Low dose green tea infusion|low dose of polyphenols from an infusion of green tea
62251901|NCT01462136|EXPERIMENTAL|ACHN-490 Injection|
62050123|NCT00948779|OTHER|antibiotics|antibiotic education for children in an emergency care unit: Patient and family's therapeutic education to improve the use of antibiotics at home.
62050124|NCT00948779|EXPERIMENTAL|the antipyretic therapy|antibiotic education for children in an emergency care unit: Patient and family's therapeutic education to improve the antipyretic therapy at home.
62251902|NCT05803408|EXPERIMENTAL|Early introduction of gluten free oats|Early introduction of oats (starting GF oats immediately after the diagnosis, within 3 months)
62251903|NCT05803408|ACTIVE_COMPARATOR|Late introduction of gluten free oats|Late introduction of oats (starting GF oats 6 months after diagnosis of celiac disease)
62610560|NCT00002756|EXPERIMENTAL|Chemo (Reduced Induction) No BMT (Open February 2004)|
62610561|NCT02160028|ACTIVE_COMPARATOR|Standard information|This group is given anesthetics and standard information before dental treatment about the anesthetics.
62050125|NCT02009202|ACTIVE_COMPARATOR|picosulphate|Picosulphate is given orally
62050126|NCT02009202|ACTIVE_COMPARATOR|polyethylene glycol|Polyethylene glycol is given orally
62251904|NCT00780819|EXPERIMENTAL|PoleStar N20 intraoperative MRI|PoleStar N20 intraoperative MRI
62251905|NCT02101021|EXPERIMENTAL|Momelotinib|Participants will receive momelotinib plus nab-paclitaxel and gemcitabine.
62251906|NCT02101021|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo to match momelotinib plus nab-paclitaxel and gemcitabine.
62610562|NCT02160028|EXPERIMENTAL|Extended information|This group is given anesthetics and extended information before dental treatment about the anesthetics.
62050127|NCT05115448|OTHER|Bevel Up|In the patients who participated in the study, cannulation was applied to the fistula with the needle direction antegrade and the needle pointing upwards for the first 6 sessions, and the needle direction antegrade and the needle tip facing down for the next 6 sessions. The cannulation procedure was performed by the same nurse for each patient who participated in the study.
62050128|NCT05115448|OTHER|Bevel Down|In the patients who participated in the study, cannulation was applied to the fistula with the needle direction antegrade and the needle pointing downwards for the next 6 sessions. The cannulation procedure was performed by the same nurse for each patient who participated in the study.
62050129|NCT02132845|ACTIVE_COMPARATOR|Arm A (standard of care therapy)|Patients undergo collection of tissue and blood samples for analysis via next generation sequencing. Patients receive standard of care therapy based on the discretion of the treating physician.
62050130|NCT02132845|EXPERIMENTAL|Arm B (target-directed therapy)|Patients undergo collection of tissue and blood samples for analysis via next generation sequencing. Based on the results of the next generation sequencing, patients receive target-directed therapy.
62050131|NCT01559948|EXPERIMENTAL|Lumbopelvic stabilization exercises plus sacroiliac joint belt|The participants will be instructed in the lumbopelvic stabilization program. Additionally, during the initial session, these participants receive a sacroiliac compression belt and be instructed to wear the belt during all waking hours for the first four weeks of the study.
62050132|NCT01559948|ACTIVE_COMPARATOR|Lumbopelvic stabilization exercise|The participants will be instructed in the lumbopelvic stabilization program.
62050133|NCT02708979|ACTIVE_COMPARATOR|University Exam Period|This visit takes place the week before an exam at the university assuming that this will induce a stress response. Measurements (see description elsewhere) are being taken within 1-2 weeks prior to an university exam.
62050134|NCT02708979|PLACEBO_COMPARATOR|University Non-exam Period|This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period. Measurements (see description elsewhere) are being taken in a control-period without exams (at least 4 weeks after and 4 weeks prior to an exam)
62050135|NCT05810168|ACTIVE_COMPARATOR|Traditional Dietary Advice|Recommended to eat smaller, regular meals and reduce the intake of caffeine/alcohol/fizzy drinks, fatty/processed/spicy foods, and fibre
62833018|NCT04690049|ACTIVE_COMPARATOR|Control exercise group|This program will be based on a home exercise protocol considering painful sensation and self-perceived stability as progression criteria: regarding pain management, exercises will be planned in a way that increased pain after their performance reverts to before-exercise levels prior to the next session; regarding self-perceived stability, participants will be asked to maintain a constant sensation of joint stability and control during the execution of the exercises. Participants will perform shoulder rotations (external and internal) and abduction up to 30º by using elastic bands. The resistance of the band will be adjusted by the physiotherapist so that participants perceive the exercises as demanding enough but not too unpleasant, being able to complete the 10 repetitions before taking the rest. Likewise, exercises will progress until a maximum of 90º of shoulder abduction.
62833019|NCT05205122|EXPERIMENTAL|Infants with primary congenital glaucoma|
62833020|NCT02994446|EXPERIMENTAL|SERF Catheter Ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
62833021|NCT00960882|EXPERIMENTAL|DMMET-01|
62833022|NCT02647619|ACTIVE_COMPARATOR|Needle aponeurotomy|percutaneous transection or pretendinous palmar dupytren cord
62833023|NCT02647619|ACTIVE_COMPARATOR|Xiapex|Injection of 0.58 mg collagenase into pretendinous palmar dupytren cord
62833024|NCT05987553||General practitioners|All participants were general practitioners (in training).
62833025|NCT02242526|ACTIVE_COMPARATOR|Parietex™ Composite Hiatal Mesh, North Haven, CT|Synthetic prosthetic mesh Parietex™ Composite Hiatal (PCO 2H) Mesh (Covidien, North Haven, CT) designed for hiatal hernia repair.
62833026|NCT02242526|ACTIVE_COMPARATOR|Biodesign™ Surgisis® Graft, Cook Medical, Bloomington|Biologic mesh Biodesign™ Surgisis® Graft Reinforcement in Hiatal, Cook Medical, Bloomington, IN which will be placed for repair of hiatal hernia
62833027|NCT01512615|EXPERIMENTAL|Intervention group|Complex Cardiac Rehabilitation
62833028|NCT01512615|EXPERIMENTAL|Control group|Usual care
62833029|NCT00755053|ACTIVE_COMPARATOR|Clotrimazole tablet (Canesten, BAY-B5097)|Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
62833030|NCT00755053|EXPERIMENTAL|Clotrimazole ovule (Canesten, BAY-B5097)|Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
62833031|NCT02446522|ACTIVE_COMPARATOR|Open vein harvesting|Patients with IHD, who were underwent open vein harvest method (OVH)
62833032|NCT02446522|ACTIVE_COMPARATOR|Endoscopic vein harvesting|Patients with IHD, who were underwent edoscopic vein harvestingopen vein harvest method (EVH).
62833033|NCT06595212||affected twins|
62833034|NCT06595212||unaffected twins|
62833035|NCT01281124|EXPERIMENTAL|Treatment (azacitidine)|Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62833036|NCT03760042|OTHER|Group A (Crisaborole RIGHT SIDE / Vehicle LEFT SIDE)|Crisaborole ointment 2% applied to sensitive skin locations on right side of body. Crisaborole placebo vehicle ointment applied to sensitive skin locations on left side of body
62251907|NCT03838055|EXPERIMENTAL|SLN only|Pelvic SLN's defined by ICG injected cervically
62251908|NCT01516840|EXPERIMENTAL|Arm 1|
62833037|NCT03760042|OTHER|Group B (Crisaborole LEFT SIDE / Vehicle RIGHT SIDE)|"Crisaborole placebo vehicle ointment applied to 7 sensitive skin sites on right side of body.~Crisaborole ointment 2% applied to 7 sensitive skin locations on left side of body"
62833038|NCT05536401|OTHER|Optical Coherence Tomography (OCT)|
62833039|NCT05950815|EXPERIMENTAL|PM1015|Subjects will be administered PM1015 via intravenously (IV) once in first cycle, then administered PM1015 every 2 weeks (Q2W ) after 3 weeks
62833040|NCT02079246|EXPERIMENTAL|Idalopirdine (Lu AE58054) 60 mg|Idalopirdine 60 mg adjunct to 10 mg donepezil. The dose of idalopirdine could be decreased from 60 mg to 30 mg if 60 mg was not well tolerated. The dose of donepezil was to be maintained throughout the study.
62610563|NCT03774134||CME group|The CME group consisted of patients, who underwent elective CME for sigmoid colon adenocarcinoma at Nordsjaellands Hospital Hillerød from 1 June 2008 to 31 December 2014.
62610564|NCT03774134||Non-CME group|The non-CME group comprised patients having a elective conventional colon cancer resection for sigmoid adenocarcinoma at the other three colorectal centers in the Capital Region of Denmark from 1 June 2008 to 31 December 2013.
62833041|NCT02079246|EXPERIMENTAL|Idalopirdine 60 mg + memantine|Idalopirdine 60 mg as adjunct to 10 mg donepezil and memantine (patient's individualised maintenance dose, either immediate-release (IR) 20 mg/day (recommended target dose) or extended release (XR) 28 mg/day (recommended target dose). Memantine was administered to approximately 100 patients included in the OLEX-MEM. The dose of idalopirdine could be decreased from 60 mg to 30 mg if 60 mg was not well tolerated. The dose of donepezil was to be maintained throughout the study. The dose of memantine could be changed at any time throughout the study.
62833042|NCT04033497|EXPERIMENTAL|TRAMs I|"* Magnetic resonance imaging (MRI)-based treatment response assessment maps (TRAMs)~* Patients with an enlarging lesion in the site of a brain metastasis treated with stereotactic radiation for which neurosurgical resection is planned will undergo preoperative TRAMs"
62833043|NCT02664935|EXPERIMENTAL|Arm A: AZD4547|AZD4547 - FGFR Inhibitor Route \& Formulation: Oral, Tablets Strengths: 20 \& 80mg Trial Dose \& Schedule: 80 mg BD, Continuous dosing, 21 day cycle.
62833044|NCT02664935|EXPERIMENTAL|Arm B: Vistusertib (AZD2014)|Vistusertib (AZD2014) - MTORC1/2 Inhibitor Route \& Formulation: Oral, Tablets Strengths: 25mg Trial Dose \& Schedule: 125 mg BD, Intermittent dosing (2 continuous days in 7), 28 day cycle.
62050136|NCT05810168|ACTIVE_COMPARATOR|Low FODMAP diet|FODMAPs are fermentable carbohydrates that increase intestinal water and gas production that, in those with visceral hypersensitivity, induces gastrointestinal symptoms. The low FODMAP diet therefore excludes fermentable carbohydrates, which are present in wheat-based products, many fruits/vegetables, pulses, beans, dairy, and sweeteners.
62050137|NCT00892502|ACTIVE_COMPARATOR|1|Bismuth tablets
62441480|NCT01313728|EXPERIMENTAL|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks - all subjects participate in both arms in a split-face model
62050138|NCT00892502|PLACEBO_COMPARATOR|2|Placebo tablets, containing no active substance
62050139|NCT00765232|EXPERIMENTAL|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
62050140|NCT00765232|PLACEBO_COMPARATOR|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
62441481|NCT01313728|ACTIVE_COMPARATOR|Tretinoin Gel Alone|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks - all subjects participate in both arms in a split-face model
62441482|NCT02224521|EXPERIMENTAL|Cohort 1|Subjects will be assigned to any of the 4 dosage regimen (A, B, C, D) in four periods. A= GSK2190915 Solution, 50mg single dose, fasted; B = GSK2190915 Capsule Formulation A, 50mg single dose (1 x 50mg capsule), fasted; C= GSK2190915 Capsule Formulation B, 50mg single dose (1 x 50mg capsule), fasted; D= GSK2190915 Capsule Formulation C, 50mg single dose (1 x 50mg capsule), fasted.
62610565|NCT01877551|ACTIVE_COMPARATOR|tauroursodeoxycholic acid|This group will receive 1.75 grams per day of tauroursodeoxycholic acid given once daily for 30 days.
62050141|NCT03479697|ACTIVE_COMPARATOR|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
62050142|NCT03479697|OTHER|Continued Current Care|Participants will continue their current care.
62610566|NCT01877551|PLACEBO_COMPARATOR|placebo|This group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
62610567|NCT01178814|EXPERIMENTAL|Revlimid|Revlimid (Lenalidomide) capsule taken orally once a day
62610568|NCT06201455|EXPERIMENTAL|PEI+GT|Experimental group: Phacoemulsification with intraocular lens implantation (PEI) and goniotomy (GT).
62050143|NCT05417880|ACTIVE_COMPARATOR|Group 1 (Control group)|Continue with current oral anti-hyperglycemic regime
62050144|NCT05417880|ACTIVE_COMPARATOR|Group 2 (Voreta group)|Empagliflozin 10 mg OD
62251909|NCT01516840|EXPERIMENTAL|Arm 2|
62251910|NCT01516840|ACTIVE_COMPARATOR|Arm 3|
62251911|NCT01516840|ACTIVE_COMPARATOR|Arm 4|
62251912|NCT05615051|EXPERIMENTAL|Group electrolytic approach (EA)|Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) during 2 minutes
62251913|NCT05615051|ACTIVE_COMPARATOR|Group hydrogen peroxide (HP)|Group hydrogen peroxide (HP): Mechanical detoxification using curettes + NiTi brushes + hydrogen peroxide 5% for 2 minutes soaked in a gauze
62610569|NCT06201455|ACTIVE_COMPARATOR|PEI+MED|Controll group: Phacoemulsification with intraocular lens implantation (PEI) and medication therapy (MED).
62050145|NCT05417880|EXPERIMENTAL|Group 3 ( Voreta + SunnyD PRO group )|Empagliflozin 10 mg OD + Vitamin D3 (2000 IU) + Vitamin K2 (100 mcg)
62050146|NCT03547843|EXPERIMENTAL|Educational intervention|Patients randomized to the intervention group will start with a group-based educational program immediately after the randomization.
62050147|NCT03547843|ACTIVE_COMPARATOR|Waiting list|Participants randomized to the waiting list control group receive no educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment, consisting of diagnostic treatment with medication.
62050148|NCT01690091|EXPERIMENTAL|Metformin|500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening), duration: 3 months
62050149|NCT01690091|PLACEBO_COMPARATOR|Placebo|500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening), duration:3 months
62050150|NCT02239380|EXPERIMENTAL|Lorazepam|Lorazepam intravenous formulation
62050151|NCT05019664|EXPERIMENTAL|Treatment Group|Subject target population suffers from fractures or osteotomies of the humerus which require temporary fixation and stabilization.
62050152|NCT00217646|EXPERIMENTAL|Arm I|Patients receive oral sorafenib once or twice daily on days 1-5, 8-12, and 15-19.
62050153|NCT00217646|EXPERIMENTAL|Arm II|Patients receive oral sorafenib once or twice daily on days 1-14.
62050154|NCT06550336|EXPERIMENTAL|Chidamide maintenance arm|20 mg (4 tablets) twice a week, specifically on days 1, 4, 8, 11, 15, 18, 22, and 25. It should be administered orally 30 minutes after meals.
62050155|NCT05596643||Patients diagnosed with Familial Mediterranean Fever|
62050156|NCT05596643||Healthy Controls|
62050157|NCT01086748|EXPERIMENTAL|160 mg LY2140023|80 mg LY2140023 administered orally, twice daily (BID) for up to 7 weeks.
62050158|NCT01086748|ACTIVE_COMPARATOR|4 mg Risperidone|2 mg risperidone administered orally, BID for up to 7 weeks.
62050159|NCT01086748|PLACEBO_COMPARATOR|Placebo|Placebo administered orally, BID for up to 7 weeks.
62050160|NCT01086748|EXPERIMENTAL|80 mg LY2140023|40 mg LY2140023 administered orally, BID for up to 7 weeks.
62610570|NCT04405622|EXPERIMENTAL|Toripalimab plus gemcitabin arm|Subjects receive gemcitabine and toripalimab.
62050161|NCT01941732|EXPERIMENTAL|Sildenafil|motor function to be tested before and after challenge with 100 mg sildenafil after taking normal anti-PD medication, and Again after discontinuation of anti-PD medication for 12 h
62050162|NCT02834156|OTHER|LP in a seated position then LP in a lying position|Patients will have first a lumbar puncture (LP) in a seated position then a LP in a lying position
62050163|NCT02834156|OTHER|LP in a lying position then LP in a seated position|Patients will have first a lumbar puncture (LP) in a lying position then a LP in a seated position
62050164|NCT04889001|OTHER|Before/After|Before and after comparison- one arm study
62050165|NCT04667299|EXPERIMENTAL|BMT group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid and metronidazole 0.4 g qid for 14 days
62441483|NCT02224521|EXPERIMENTAL|Cohort 2|The selected formulation will be dosed with GSK2190915 capsule formulation at 20mg (fasted), 100mg (fasted), 100mg (fed) and 200mg (fasted).
62610571|NCT01714609|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo will take two tablets of placebo by mouth twice daily.
62610572|NCT01714609|EXPERIMENTAL|Sorafenib|Subjects randomized to Sorafenib will take Sorafenib 400 mg by mouth twice daily.
62610573|NCT05633277|ACTIVE_COMPARATOR|Arm 1: Combination Sclerotherapy & Ablation|"Standard Practice:~Arm 1 will be patients receiving sclerotherapy and ablation at the start of treatment along with compression therapy. The patients in arm 1 will not receive any further treatment during the duration of the study."
62050166|NCT04667299|ACTIVE_COMPARATOR|BMQ group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and amoxicillin 1 g bid for 14 days
62050167|NCT02563457|EXPERIMENTAL|case|diabetic patients who will receive periodontal treatment blood sampling
62050168|NCT02563457|EXPERIMENTAL|control|diabetic patients without periodontal treatment (no periodontal treatment) blood sampling
62441484|NCT02224521|EXPERIMENTAL|Cohort 3|Cohort 3 will be a 4-way complete crossover study with single doses of 20mg and 200mg of up to two capsule formulations taken forward from cohort 2 in 10 healthy adult subjects in the fasted state.
62050169|NCT03372122|ACTIVE_COMPARATOR|SAGE Chlorhexidine Gluconate Cloth|Ready to use disinfectant cloth
62050170|NCT03372122|ACTIVE_COMPARATOR|HUBS with Hibiclens|Dry cloths to be used with water and disinfectant
62050171|NCT01172769|EXPERIMENTAL|Temsirolimus|
62050172|NCT06579482|EXPERIMENTAL|Aesculus hippocastanum, Polygonum acre, Smilax Pepyracea, and Rutina|Aesculus hippocastanum 50mg, Polygonum acre 10mg, Smilax Pepyracea 40mg, Rutina 20mg
62050173|NCT06579482|ACTIVE_COMPARATOR|Diosmina, and Hesperidina|Diosmina 450mg e Hesperidina 50mg
62050174|NCT03061565||Erythropoietin|Patients were treated with EPO during the EPO-TBI study in 2010-2014.
62050175|NCT03061565||Placebo|Patients were treated with placebo during the EPO-TBI study in 2010-2014.
62441485|NCT02224521|EXPERIMENTAL|Cohort 4|The regimen for Cohort 4 will be either the highest dose (200mg) of the capsule formulation (A, B or C) taken forward from the previous cohorts or the solution formulation (200mg).
62833045|NCT02664935|EXPERIMENTAL|Arm C: Palbociclib|Palbociclib - CDK4/6 Inhibitor Route \& Formulation: Oral, Capsules Strengths: 75, 100 \& 125mg Trial Dose \& Schedule: 125 mg OD, Intermittent dosing (21 days on, 7 days off), 28 day cycle.
62050176|NCT03077191||Quality of life|Quality of life of breast cancer patients treated with conservative surgery (quadrantectomy) and adjuvant hypofractionated whole breast radiotherapy according to the institutional standard regimen, to a total dose of 40 Gy in 15 fraction over 3 weeks will be measured with EORTC quality of life questionnaires QLQ-C30 and QLQ-BR23, before the start of the radiotherapy, at the end of the radiotherapy and subsequently at every follow-up visit (the first at 6 months after the end of the treatment, then annually for 5 consecutive years after the first follow up visit).
62251914|NCT02801136|EXPERIMENTAL|ReACT for PNES|ReACT consists of 8 weekly sessions of therapy focused on teaching adolescents to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. It teaches parents how to respond to PNES in a manner that encourages the adolescents to regain control of their body. The PNES is explained as behaviors learned through classical and operant conditioning .
62251915|NCT02801136|ACTIVE_COMPARATOR|Supportive Therapy|The supportive therapy treatment consists of 8 weekly sessions of therapy focused on discussing daily difficulties and/or stressors they experience and identifying stress triggers for PNES. The PNES is explained as physical manifestations of psychological stress.
62251916|NCT02801136|NO_INTERVENTION|Healthy Control|Healthy controls are matched to patients with PNES based on age (+ or - 1 year), gender, race and family income. They come to one laboratory visit to complete initial visit questionnaires and computer tasks.
62251917|NCT03429881|ACTIVE_COMPARATOR|Laparoscopic stripping ovarian endometriomas|
62251918|NCT03429881|ACTIVE_COMPARATOR|Laser CO2 treatment ovarian endometriomas|
62050177|NCT03077191||Breast cancer, retrospective|"In the observational retrospective cohort patients with histologically confirmed breast cancer treated with hypofractionated/ultrahypofractionated radiotherapy to:~* whole breast +/- Simultaneous Integrated Boost (SIB) to surgical bed,~* breast/chest wall and lymph node areas +/- SIB to surgical bed,~* surgical bed only, with accelerated partial breast irradiation,~using 3D conformal radiotherapy or advanced radiotherapy techniques (IGRT, IMRT, SBRT) will be included."
62251919|NCT00005036|EXPERIMENTAL|Arm I (irinotecan)|Patients receive irinotecan IV over 90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
62251920|NCT00005036|EXPERIMENTAL|Arm II (oxalipatin, fluorouracil, leucovorin calcium)|Patients receive oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on days 1 and 2, and fluorouracil IV bolus followed by IV infusion over 22 hours on days 1 and 2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
62251921|NCT02862405||Patients with loss of central vision|Patients coming in ophthalmic consultation will be selected for the study. The diagnosis of this disease is based on clinical examination, and imaging of the retina.Patients with only loss of central vision will be selected.
62251922|NCT02862405||Patients with loss of peripheral vision|Patients coming in ophthalmic consultation will be selected for the study. Patients with loss of peripheral vision will be selected on the bases of presence of tunnel vision.
62251923|NCT02862405||Control group|Patients without loss of vision.
62251924|NCT04638959||GC|patients diagnosed with GC
62251925|NCT04638959||HC|patients diagnosed with chronic gastritis by histopathology
62833046|NCT02664935|EXPERIMENTAL|Arm D: Crizotinib|Crizotinib - ALK Inhibitor Route \& Formulation: Oral, Capsules Strengths: 200 \& 250mg Trial Dose \& Schedule: 250 mg BD, Continuous dosing, 21 day cycle.
62833047|NCT02664935|EXPERIMENTAL|Arm E: Selumetinib & Docetaxel|"AZD6244 (Selumetinib) - MEK Inhibitor Route \& Formulation: Oral, Capsules Strengths: 25mg Trial Dose \& Schedule: 75 mg BD, Continuous dosing, 21 day cycle.~Docetaxel - Chemotherapy Route \& Formulation: IV infusion over 30-60 minutes, concentrate for solution for infusion.~Trial Dose \& Schedule: 75 mg/m2, 3-weekly, 21 day cycle."
62833048|NCT02664935|EXPERIMENTAL|Arm F: AZD5363|AZD5363 - AKT Inhibitor Route \& Formulation: Oral, Tablets Strengths: 80 \& 200mg Trial Dose \& Schedule: 480 mg BD, Intermittent dosing (4 days on, 3 days off), 28 day cycles.
62833049|NCT02664935|EXPERIMENTAL|Arm G: Osimertinib (AZD9291)|Osimertinib (AZD9291) - EGFRM+ and T790M+ Inhibitor Route \& Formulation: Oral, Tablets Strengths: 80mg Trial Dose \& Schedule: 80 mg OD, Continuous dosing, 21 day cycles.
62833050|NCT02664935|EXPERIMENTAL|Arm NA: Durvalumab (MEDI4736)|Durvalumab (MEDI4736) - Anti-PDL1 Route \& Formulation: IV Infusion, Lyophilized powder for solution for infusion Strengths: Vial containing 200mg Trial Dose \& Schedule: 10 mg/kg IV, 2-weekly.
62833051|NCT02664935|EXPERIMENTAL|Arm H: Sitravatinib|Sitravatinib - VEGFR Inhibitor Route \& Formulation: Oral, Capsules Strengths: 10 \& 40mg Trial Dose \& Schedule: 120 mg OD, Continuous dosing, 21 day cycles.
62833052|NCT02664935|EXPERIMENTAL|Arm J: AZ6738 & Durvalumab|"AZD6738 - ATR Inhibitor Route \& Formulation: Oral, Tablets Strengths: 20mg, 80mg, 100mg Trial Dose \& Schedule: 240 mg twice daily (BD) on days 15-28 of 28 day cycle.~Durvalumab (MEDI4736) - Anti-PDL1 Route \& Formulation: IV Infusion, Lyophilized powder for solution for infusion Strengths: Vial containing 500mg Trial Dose \& Schedule: 1500mg on day 1 of each 28 day cycle"
62833053|NCT01337960|EXPERIMENTAL|Arm 1|Seated robot training group. Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
62441486|NCT02224521|EXPERIMENTAL|Cohort 5|Subjects will take milled and micronised tablet formulations of GSK2190915 in the fasted state in periods 1 and 2, and will take milled and micronised tablet formulations of GS2190915 in the fed state in periods 3 and 4.
62441487|NCT02224521|EXPERIMENTAL|Cohort 6|Tablet formulations (milled and micronised, different to the Cohort 5 formulations) of GSK2190915 will be dosed in the fasted and fed (after a light breakfast) states.
62441488|NCT00783679|OTHER|1|Twenty adult spontaneously breathing patients without intubation and mechanical ventilation recruited from the cardiac catheterization laboratory. All will be post-heart-transplant patients coming for yearly evaluation.
62441489|NCT02346539|EXPERIMENTAL|Nicotine|"2mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time.~4mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time."
62441490|NCT02346539|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62441491|NCT01497938|EXPERIMENTAL|Low Glucose Suspend feature (LGS)|According to randomization, Low Glucose Suspend (LGS) will be turned ON in the treatment arm of the study
62441492|NCT01497938|EXPERIMENTAL|Control Arm|The Low Glucose Suspend feature will not be available to subjects in the control arm
62441493|NCT02397200|EXPERIMENTAL|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
62050178|NCT03500614|EXPERIMENTAL|Cohort 1|Participants (n=57) will receive either true or sham air cleaner treatment for 1 week and then alternate the treatment after a wash out interval (Air cleaner use method 1). Exposure monitoring for PM2.5 will continue throughout the treatment period and air and fine particle phase phthalates samples will be collected during the last day (24 hours) of the treatment period; and health variables will be measured and biological samples will be collected immediately after the completion of each intervention period.
62050179|NCT03500614|EXPERIMENTAL|Cohort 2|Participants (n=32) will undergo extended treatment period covering the start, peak and end phases of smog episodes in Beijing, with either true or sham air cleaner treatment and then alternate the treatment after a wash out interval (Air cleaner use method 2). Exposure monitoring for PM2.5 will continue throughout the treatment period and repeated health examinations will be conducted at time points corresponding to the start, peak and end phases of the smog episodes.
62050180|NCT02381054||Translation and cross-cultural adaptation phase|In this phase 96 Italian-speaking patients who are receiving cancer treatment or who have completed treatment for cancer within the past six months at one of the participating sites will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the interviewer will elicit participants' feedback regarding item comprehension, symptomatic adverse event terms, attribute terms, 7-day recall period, and response options, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.
62050181|NCT02381054||Test-retest phase|In this phase a minimum of 59 Italian-speaking patients who are receiving cancer treatment will be asked to independently complete the Italian version PRO-CTCAE questionnaire on 2 consecutive business days.
62050182|NCT05697874||CNS Sarcoma|Patients diagnosed with Central nervous system (CNS) sarcomas
62050183|NCT05697874||BCOR-altered|Patients diagnosed with tumors characterized by alterations in the BCOR gene.
62050184|NCT05697874||Astroblastoma/MN-1- altered|Patients diagnosed with Astroblastomas/MN-1 alterations
62050185|NCT05697874||Unclassifiable tumors|Patients diagnosed with histologically ambiguous tumors or tumors that fail to classify with the current diagnostic methods.
62050186|NCT05697874||Other Rare Brain tumors|Patients diagnosed with other rare brain tumors that do not meet the criteria for cohorts 1-4.
62833054|NCT01337960|EXPERIMENTAL|Arm 2|Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
62050187|NCT04167501||Non exposed|Women born between 1972 and 1982 who were not exposed to HPV vaccination
62050188|NCT04167501||exposed|Women born between 1983 and 1993 who were potentially exposed to HPV vaccination
62050189|NCT03166150|EXPERIMENTAL|Multi-modal rehabilitation program|12 weeks of various exercises
62833055|NCT01337960|ACTIVE_COMPARATOR|Arm 3|Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
62050190|NCT03166150|ACTIVE_COMPARATOR|Pelvic Floor Physical therapy|12 weeks of standard pelvic floor physical therapy
62050191|NCT03578003|EXPERIMENTAL|Morning Bright Light Therapy|Subjects who engage in morning bight light therapy
62050192|NCT03578003|NO_INTERVENTION|Control|Subjects who do not engage in morning bright light therapy
62050193|NCT06308679|EXPERIMENTAL|Generic Empagliflozin 10 mg tablets|Generic Empagliflozin 10 mg tablets (test drug)
62050194|NCT06308679|ACTIVE_COMPARATOR|ARDIANCE®|ARDIANCE® (Empagliflozin 10 mg tablets (reference drug))
62050195|NCT02136472||Subfertile women|"Women who visit the fertility clinic of the Maastricht University Medical Centre who start with a basic fertility work-up. Women diagnosed with an unexplained subfertility or with (signs of) a decreased ovarian reserve are asked for further participation in the study of the cardiovascular profile.~As a control group parous women with an uncomplicated pregnancy more than 6 months ago will be asked for participation."
62050196|NCT03958084|EXPERIMENTAL|Massage group|The deep massage will be applied for three minutes in the ischiotíbial muscles, only in the left limb, towards the muscular fibers. The volunteers will be placed in a ventral decubitus position on the stretcher.
62441494|NCT02397200|PLACEBO_COMPARATOR|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and minerals.
62441495|NCT05296681|EXPERIMENTAL|NM108 Drinks|"NBT-NM108 Drinks four times daily before meals and 2 hours after dinner for 56 days.~Beginning 5 days before starting chemotherapy, patients receive NBT-NM108 PO QID for 56 days. Patients receive irinotecan-based chemotherapy per standard of care."
62833056|NCT05618977|ACTIVE_COMPARATOR|Control|In-class case studies will be conducted.
62833057|NCT05618977|EXPERIMENTAL|Experimental|Case studies will be done in the form of dramatization simulation.
62050197|NCT03958084|EXPERIMENTAL|Ventosa therapy group|The negative pressure ventosa therapy slide winds will be applied for three minutes in the oval direction in the posterior region of the thigh to contemplate the full extent of the ischiotíbial muscles, only in the left limb. The volunteers will be placed in a ventral decubitus position on the stretcher.
62050198|NCT03958084|EXPERIMENTAL|Foam roller group|The foam roller is a self-applied intervention for three minutes where the volunteers will be positioned on bench press on the floor of the room, with the left thigh posteriorly on the foam roller and the leg extended, the right lower limb will be in flexion of hip and knee, only the right foot and the right and left hands will touch the ground. Volunteers will be instructed to move so that they move forward and backward, causing the roller to travel the full length of the hamstring muscles.
62050199|NCT03958084|EXPERIMENTAL|Lumbar mobilization group|Unilateral lumbar mobilization of grade III at the frequency of 2Hz at the joint L4 / L5 of the ipsilateral side of the limb tested. The frequency was guaranteed by a metronome set at 120 beats per minute. Three sets of 1 minute of mobilization were performed with a 30 second interval, totaling a time of 4 minutes and 30 seconds of intervention. The technique was performed with the patient in the ventral decubitus position.
62251926|NCT01758458|EXPERIMENTAL|Treatment (autologous T cells and aldesleukin)|"Patients undergo radiation therapy or recombinant interferon beta intralesional injection within day -3 to day -1.~Patients receive MCPyV TAg-specific polyclonal autologous CD8-positive T cell infusion IV on day 1 and aldesleukin SC every 12 hours on days 1-14. Treatment repeats at least every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~Patients with continued presence of detectable metastatic disease 8 weeks after the first infusion may repeat the treatment regimen including radiation therapy or recombinant interferon beta injection."
62251927|NCT01409213||All Enrolled Participants|
62610574|NCT05633277|EXPERIMENTAL|Arm 2: Sclerotherapy Only|"Experimental Timeline:~Arm 2 will be patients who receive sclerotherapy at the start of treatment along with compression therapy, and ablation 3 months later. All patients in arm 2 will receive ablation at their 3 month appointment. After ablation, the patients in arm 2 will not receive any further treatment for the remainder of the study."
62610575|NCT01483989|EXPERIMENTAL|SYSTANE® Gel Drops Lubricant eye gel|SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
62610576|NCT04862663|EXPERIMENTAL|Capivasertib Plus Palbociclib and Fulvestrant|Capivasertib Plus Palbociclib and Fulvestrant (Ph 1b)
62251928|NCT04196738|EXPERIMENTAL|Dual Mode first|Four consecutive steps (45 min per step) in the following order: APRV (A), Dual Mode (B) , APRV (A) and VAC (C). (ABAC)
62251929|NCT04196738|EXPERIMENTAL|VAC fist|Four consecutive steps (45 min per step) in the following order: APRV (A), VAC (C) , APRV (A) and Dual Mode (B). (ACAB)
62441496|NCT05296681|NO_INTERVENTION|No Microbiome Support|"No microbiome~Patients receive irinotecan-based chemotherapy per standard of care."
62441497|NCT05025332|EXPERIMENTAL|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
62441498|NCT00472446|EXPERIMENTAL|cervical block before surgery|bilateral superficial cervical block, placed before surgery (just before skin incision)
62610577|NCT04862663|EXPERIMENTAL|Capivasertib Plus Ribociclib and Fulvestrant|Capivasertib Plus Ribociclib and Fulvestrant (Ph 1b)
62833058|NCT05604170|EXPERIMENTAL|Ganaxolone (GNX) oral suspension, 3 times a day (TID)|
62050200|NCT03958084|EXPERIMENTAL|Proprioceptive neuromuscular facilitation group|Patient in dorsal decubitus, the examiner lifted the participant's leg up to the referred maximum amplitude. He then asked the patient for an isometric contraction of the hamstring muscles against the researcher's resistance for 10 seconds. After contraction, the researcher asked the patient to relax for 10 seconds. Then the member is repositioned passively by the researcher until the new amplitude limit reached. The technique was performed in 2 sets of 4 repetitions with an interval of 1 minute, totaling in an approximate time of 4 minutes of intervention.
62050201|NCT03958084|NO_INTERVENTION|Control group|The patient remained lying down in the ventral position for 4 minutes. the patient remained lying down in the ventral position for 4 minutes.
62050202|NCT04381520|EXPERIMENTAL|Heat-sensitive moxibustion plus antihypertensive drugs|
62050203|NCT04381520|ACTIVE_COMPARATOR|Antihypertensive drugs|
62050204|NCT00975559||Normal volunteers|Normal study volunteers with no prior history of coronary artery disease
62050205|NCT00975559||Apical Ballooning Syndrome|Women who have had a documented Apical Ballooning event as shown by coronary angiogram
62050206|NCT00975559||Coronary Endothelial Dysfunction|Patients who have been diagnosed with Endothelial Dysfunction via a coronary angiogram with acetylcholine challenge
62050207|NCT00975559||Myocardial Infarction|Women diagnosed with a Myocardial Infarction who subsequently had a Percutaneous Intervention
62050208|NCT02693938|EXPERIMENTAL|luteal phase clamp|Luteal euglycemic clamp administered during luteal phase of menstrual cycle.
62050209|NCT02693938|ACTIVE_COMPARATOR|follicular phase clamp|Follicular euglycemic clamp administered during follicular phase of menstrual cycle.
62050210|NCT05321680|EXPERIMENTAL|Treatment withdrawal|discontinuation of treatment (anti-cholinesterase inhibitors including donepezil, rivastigmine and galantamine; and/or memantine)
62610578|NCT04862663|EXPERIMENTAL|Capivasertib Plus Abemaciclib and Fulvestrant|Capivasertib Plus Abemaciclib and Fulvestrant (Ph 1b)
62050211|NCT05321680|NO_INTERVENTION|Treatment continuation|treatment continuation (anti-cholinesterase inhibitors including donepezil, rivastigmine and galantamine; and/or memantine)
62050212|NCT05288660|EXPERIMENTAL|ALXN1210 200 mg|ALXN1210 was administered intravenously.
62050213|NCT05288660|EXPERIMENTAL|ALXN1210 400 mg|ALXN1210 was administered intravenously.
62610579|NCT04862663|EXPERIMENTAL|Capivasertib Plus Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib)|Capivasertib Plus Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib) (Ph III)
62610580|NCT04862663|ACTIVE_COMPARATOR|Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib)|Fulvestrant and investigator's choice of CDK4/6i (palbociclib or ribociclib) (Ph III)
62050214|NCT05288660|PLACEBO_COMPARATOR|Placebo|Placebo was administered intravenously.
62050215|NCT04156165|ACTIVE_COMPARATOR|VLCD-Control|Very low calorie diet, 600 kcal pr day for eight weeks.
62050216|NCT04156165|EXPERIMENTAL|VLCD-Active|Very low calorie diet plus additional 25 g protein powder, 700 kcal pr day for eight weeks.
62050217|NCT04156165|ACTIVE_COMPARATOR|Maintenance-Control|"12-week weight maintenance diets: Moderate protein weight maintenance diet (MP-WMD): Recommended healthy diet including 25 g beef daily.~The diet is ad libitum and will be high in fibre (40 g/10 MJ) and whole grain (150 g/day) and allow inclusion of free/added sugar up to the recommended level (\<10E% sugar)."
62050218|NCT04156165|EXPERIMENTAL|Maintenance-Active|12-week weight maintenance diets: High protein weight maintenance diet (HP-WMD): The macronutrient distribution will be 25 energy percentage (E%) from protein, 45 E% from carbohydrate and 30 E% from fat. The diet will include 150 g beef as a daily source of protein, The diet is ad libitum and will be high in fibre (40 g/10 MJ) and whole grain (150 g/day) and allow inclusion of free/added sugar up to the recommended level (\<10E% sugar).
62050219|NCT01791920|ACTIVE_COMPARATOR|Botulinum toxin type A(Botox®)|Botulinum toxin type A
62050220|NCT01791920|EXPERIMENTAL|Botulinum toxin type A (Botulax®)|Botulinum toxin type A
62251930|NCT00613444|EXPERIMENTAL|LumaCare LC-122M non-coherent light source|"Split Face Comparison. One half of subject's face will receive topical photosensitizer applications followed by LumaCare LC-122M non-coherent light source illumination. Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.~The other half of the face will not receive any treatment and will serve as internal control."
62251931|NCT01128361|EXPERIMENTAL|Aerobic Exercise|
62251932|NCT01128361|ACTIVE_COMPARATOR|Stretching|
62251933|NCT06292572||Initial Retinal Detachment|First of both eyes of the same patient that underwent retinal detachment repair
62251934|NCT06292572||Subsequent Retinal Detachment|Subsequent eye undergoing retinal detachment repair
62251935|NCT01805596|EXPERIMENTAL|clopidogrel-ticagrelor|21 days clopidogrel followed by 21 days ticagrelor
62251936|NCT01805596|EXPERIMENTAL|ticagrelor-clopidogrel|ticagrelor for 21 days followed by clopidogrel for 21 days
62610581|NCT00833118||Intubation|
62050221|NCT05950334|EXPERIMENTAL|Regimen A|Participants receive FT522 in combination with rituximab (or a rituximab biosimilar approved by a local health authority) with chemotherapy.
62050222|NCT05950334|EXPERIMENTAL|Regimen B|Participants receive FT522 in combination with rituximab (or a rituximab biosimilar approved by a local health authority) without chemotherapy.
62050223|NCT01448564|ACTIVE_COMPARATOR|Laser therapy|Recently has been using the LED, known by its acronym in English LED (Light Emitting Diode), devices that are light-emitting non-coherent and monochromatic, having a longer wavelength (± 10 - 30 nm) compared to lasers. The difference between the fundamental radiation emitted by a laser and an LED is the coherence of the beam.
62050224|NCT01448564|PLACEBO_COMPARATOR|Placebo Laser therapy|
62251937|NCT00699803|ACTIVE_COMPARATOR|T-Pred|Tobramycin prednisolone acetate combination
62251938|NCT00699803|ACTIVE_COMPARATOR|Pred Forte|Prednisolone acetate
62610582|NCT03707366|EXPERIMENTAL|FHF-T Intervention Group|9 months of 1:1 youth mentoring by graduate-student mentors; workshops; educational advocacy
62610583|NCT03707366|NO_INTERVENTION|Control group|Services as usual
62833059|NCT00898781||Metastatic Breast Cancer|
62833060|NCT00898781||Metastatic Ovarian Cancer|
62833061|NCT00898781||Metastatic Pancreatic Cancer|
62050225|NCT04805255||Hypofractionated Stereotactic Radiotherapy (HF-SRT)|"A prospective cohort study addressing both neurocognitive outcome measures and oncological endpoints will be carried out for treating newly-diagnosed brain oligometastases with a pre-defined course of hypofractionated stereotactic radiotherapy (HF-SRT) in cancer patients with a fair/satisfactory performance status.~Either a limited number of brain metastases or oligometastatic brain disease refers to that the number of brain metastatic lesions (both post-resected and intact) at enrollment should be limited to three or fewer and that the greatest diameter of any metastatic lesion (either a tumor bed post-surgical resection or an intact brain metastasis) should be no more than 4 cm."
62050226|NCT06180304|EXPERIMENTAL|Indoor training group|Exercise group in a gym.
62050227|NCT06180304|EXPERIMENTAL|outdoor training group|Exercise group in an outdoor space.
62050228|NCT06180304|NO_INTERVENTION|Control group|No exercise group.
62610584|NCT04164823|EXPERIMENTAL|Medical Taping|"Medical taping will be applied as a self-treatment. All participants will be instructed in an indvidual session and will receive a tutorial video to remember the kinesiotaping procedure. 3 band of a special and hypoallergenic tape (Kinematix Tex) will be attached to the abdominal (2 strips) and lower back (1 strip).~Patients will be taped for four days. It will start at the beginning of pain associated to the menstruation."
62050229|NCT05204589|EXPERIMENTAL|Group A|Subjects in safety cohort will receive one heterologous booster dose of aerosolized Ad5-nCoV
62251939|NCT04969445||Vaccine group|Participants in this arm have received 3 doses of HPV 16/18 bivalent vaccine that contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant.
62251940|NCT04969445||Control group|Participants in this arm have received 3 doses of HEV vaccine that contains 30μg HEV virus-like particle antigen adsorbed in alum-adjuvant.
62251941|NCT00943891||Tumor biopsies|
62251942|NCT02941874||Healthy volunteers IRAP measurement|
62441499|NCT00472446|PLACEBO_COMPARATOR|placebo cervical block before surgery|placebo bilateral superficial cervical block with saline, placed before surgery (just before skin incision)
62610585|NCT04164823|ACTIVE_COMPARATOR|Analgesic self-medication (OTC)|"Participants will use the usual analgesic self-treatment for primary dysmenorrhea.It will start at the beginning of pain associated to the menstruation.~They will note the treatment indicating the analgesic and the dosage in a calendar."
62833062|NCT00898781||Metastatic Colon Cancer|
62833063|NCT00898781||Stage 3 Ovarian Cancer|
62833064|NCT00898781||Locally Advanced Pancreatic Cancer|
62833065|NCT06203743|NO_INTERVENTION|control group|Patients in this group will not undergo any block after LMA. PI, PVI, pulse, saturation, noninvasive arterial pressure values will be recorded before induction, after induction, after LMA, at 0, 5, 10, 15, 20, 25 and 30 minutes after the surgical incision and at the end of anesthesia. PI, PVI will be monitored with Radical-97TM Pulse CO-OximeterTM (Masimo Corp, Irvine, CA, USA) probe.
62833066|NCT06203743|ACTIVE_COMPARATOR|caudal block group|Patients in this group will receive a caudal block in the lateral decubitus position after LMA with 0.25% Buvasin® 0.5ml/kg. PI, PVI, pulse, saturation, noninvasive arterial pressure values before induction, after induction, after LMA, before applied block, after applied block (after surgical incision) 0., 5., 10., 15., 20., 25. It will be recorded at the 30th and 30th minutes and at the end of anesthesia. PI, PVI will be monitored with Radical-97TM Pulse CO-OximeterTM (Masimo Corp, Irvine, CA, USA) probe.
62833067|NCT06203743|ACTIVE_COMPARATOR|ilioinguinal-iliohypogastric nerve block group|Patients in this group will undergo an ilioinguinal-iliohypogastric nerve block in the supine position under ultrasound guidance after LMA with 0.25% Buvasin® 0.5ml/kg. PI, PVI, pulse, saturation, noninvasive arterial pressure values before induction, after induction, after LMA, before applied block, after applied block (after surgical incision) 0., 5., 10., 15., 20., 25. It will be recorded at the 30th and 30th minutes and at the end of anesthesia. PI, PVI will be monitored with Radical-97TM Pulse CO-OximeterTM (Masimo Corp, Irvine, CA, USA) probe.
62833068|NCT02930824|EXPERIMENTAL|Adult Genotype guided treatment|For adults randomized to the genotype-supported arm a CYP2C19 genotype will be provided to physicians to assist in dosing.
62833069|NCT02930824|NO_INTERVENTION|Adult Conventional treatment|For adults randomized to the conventional arm no genotype will be provided to physicians to assist in dosing.
62833070|NCT02930824|EXPERIMENTAL|Pediatric Genotype guided treatment|For children randomized to the genotype-supported arm a CYP2C19 genotype will be provided to physicians to assist in dosing.
62833071|NCT02930824|NO_INTERVENTION|Pediatric Conventional treatment|For children randomized to the conventional arm no genotype will be provided to physicians to assist in dosing.
62833072|NCT06237985|EXPERIMENTAL|ProTaper Gold file system|Sx-S1-S2-F1-F2 files for mesial canals and F3 file for distal canal with 350 rpm speed and 2 Ncm torque will be used via an endodontic motor.
62833073|NCT06237985|EXPERIMENTAL|OneShape file system|25/.06 file for mesial canals with 350 rpm and 4 Ncm torque will be used via an endodontic motor.
62833074|NCT06237985|EXPERIMENTAL|TruNatomy file system|17/.02, 20/.04 ve 26/.04 files for mesial canals and 36/.03 file for distal canal with 500 rpm speed and 1.5 Ncm torque will be used via an endodontic motor.
62833075|NCT02015910|EXPERIMENTAL|Januvia (Sitagliptin)|Sitagliptin 100 mg a day for 12 weeks
62833076|NCT02015910|PLACEBO_COMPARATOR|Placebo|Placebo
62050230|NCT05204589|EXPERIMENTAL|Group B|Subjects in immunogenicity cohort will receive one heterologous booster dose of aerosolized Ad5-nCoV
62610586|NCT05705258||Aflibercept treatment|The patients will be included in this study by investigators who are prescribing Aflibercept (AFL) routinely in their clinical practice. The enrollment of each patient in this study is able to accept at latest in 6 months from initiation of treatment.
62610587|NCT01909726||Interactive media|ScreenPlay
62050231|NCT05204589|EXPERIMENTAL|Group C|Subjects in immunogenicity cohort will receive one homologous booster dose of ICV.
62610588|NCT01909726||Passive media|Silent nature video
62050232|NCT04702633||Confirmed diagnosis group|Patients with a diagnosis of prostate cancer (metastatic or advanced) before prostatectomy.
62610589|NCT01909726||No media|Standard care
62610590|NCT05587426|ACTIVE_COMPARATOR|Glucose - Control|20 g of glucose mixed with 250 ml of cold water
62610591|NCT05587426|EXPERIMENTAL|SFF|20 g of SFF mixed with 250 ml of cold water
62610592|NCT05587426|ACTIVE_COMPARATOR|Regular chocolate chips - Control|50 g of regular chocolate chips
62610593|NCT05587426|EXPERIMENTAL|SFF chocolate chips|50 g of SFF chocolate chips
62610594|NCT05984693|EXPERIMENTAL|Experimental group|Experimental group students determined by randomization will be shown videos containing examples of health education prepared by the researchers. After watching each video, the right and wrong aspects of health education will be critically evaluated, discussed with the group, and the group's suggestions for improving education will be taken.
62610595|NCT05984693|NO_INTERVENTION|Control groups|Control group students will not receive any training other than theoretical training.
62050233|NCT04702633||Pre-diagnosis group|Patients undergoing prostate biopsy in the context of prostate cancer diagnosis: PSA increases, and / or abnormal digital rectal examination (DRE) and / or an MRI detected signal.
62050234|NCT01982435|OTHER|Group I - Monthly|Enrolled subjects will receive multiple open-label intravitreal injections of 0.3 mg ranibizumab administered every 28 days (+/- 7 days from the last treatment) for 12 months in the monthly group.
62050235|NCT01982435|OTHER|Group II - Treat-and-Extend|Enrolled subjects will initially receive 3 loading doses of open-label Ranibizumab 0.3 mg given via intravitreal injection every 28 days (+/- 7 days from the last treatment). After the third loading dose, the follow-up interval is determined by the Principal Investigator based on OCT results as stated in the protocol. The follow-up interval is increased by 2 weeks (+/- 7 days) at each visit up to a maximum interval of 12 weeks (+/- 7 days). There is criteria built into the protocol in case a reduction in the follow-up intervals becomes necessary based upon worsening OCT results.
62050236|NCT03574597|EXPERIMENTAL|Semaglutide|Participants will receive semaglutide as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
62610596|NCT02779660|EXPERIMENTAL|RIPC-Group|After randomization patients will undergo 3 sessions of RIPC (Remote ischemic preconditioning) intervention: I) on preoperative day, II) 1 h before and III) directly before the blood sample collection and invasive measurement of electrophysiological parameters.
62610597|NCT02779660|PLACEBO_COMPARATOR|Control-Group|After randomization patients will undergo 3 sessions of sham-intervention: I) on preoperative day, II) 1 h before and III) directly before the blood sample collection and invasive measurement of electrophysiological parameters.
62610598|NCT04288817|ACTIVE_COMPARATOR|Cryotherapy and intralesional tuberculin PPD|Efficacy of cryotherapy combined with intralesional tuberculin purified protein in treatment of multiple common warts
62610599|NCT04288817|ACTIVE_COMPARATOR|Intralesional tuberculin PPD|Efficacy of Intralesional tuberculin purified protein deravative monotherapy in the treatment of multiple common warts
62610600|NCT02598011|EXPERIMENTAL|Toca 511/Toca FC at 170 mg/kg/day|"Toca 511: 4 mL administered by intracranial parenchymal injection into the walls of the resection cavity following tumor resection or, for those subjects who are not candidates for resection, via stereotactic injection into their tumor using a standard Nashold-type side cutting biopsy needle.~Toca FC: Approximately 4 to 6 weeks after tumor resection, subjects will begin temozolomide concurrent with radiation therapy. During concurrent chemoradiation at the start of the second and sixth week of concurrent chemoradiation and every 28 days thereafter, a 7-day course of oral Toca FC will be dosed at 170 mg/kg/day"
62738792|NCT06346431|EXPERIMENTAL|App Intervention group|A project coordinator will meet with the participant to assist in installing the app on device and provide instruction in use. Participants will be able to access support from the app continuously. When in proximity, during service hours to an organization meeting needs identified by the individual, the app will prompt to take action. Data will be collected on symptoms at baseline, three and six months post.
62050237|NCT03574597|PLACEBO_COMPARATOR|Placebo (semaglutide)|Participants will receive placebo (semaglutide) as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
62050238|NCT02507518|EXPERIMENTAL|Experimental|Two Pet scan Imaging will be done : 14 days before and 16 days after the beginning of maintenance therapy
62251943|NCT05380258|EXPERIMENTAL|chewing gum|Pregnant women with 4-5 cm cervical dilatation started chewing gum as soon as their contractions came and they chewed gum for 20 minutes. and when the cervical dilation was 6-8 cm, they chewed gum again for 20 minutes.
62738793|NCT06346431|NO_INTERVENTION|Control group|"Data will be collected on symptoms at baseline, three and six months post. As individuals have a diagnosis of mental illness they may be receiving Treatment as usual for their reservation/ service provider, but no additional services will be provided by the sponsor."
62738794|NCT00437957|EXPERIMENTAL|Temazolomide, Valproic Acid and Radiation|Temazolomide, Valproic Acid and Whole Brain Radiation Therapy
62441500|NCT00472446|EXPERIMENTAL|cervical block after surgery|bilateral superficial cervical block, placed after surgery (just after skin closure)
62738795|NCT04457791|EXPERIMENTAL|Intervention phase|From week 5-8, participants will receive the intervention, namely personalized dietary advice.
62738796|NCT04457791|NO_INTERVENTION|Observational phase|From week 1-4, participants will not receive any intervention, but just will be observed, to form as their own control
62738797|NCT01191645|EXPERIMENTAL|Primperan|
62738798|NCT01191645|ACTIVE_COMPARATOR|Naloxon|
62833077|NCT02199184|EXPERIMENTAL|Treatment (DA-EPOCH and ofatumumab or rituximab)|Patients receive DA-EPOCH regimen comprising doxorubicin hydrochloride IV, vincristine sulfate IV, and etoposide IV continuously over 96 hours on days 1-4; cyclophosphamide IV over 1-2 hours on day 5; and prednisone PO BID on days 1-5. Patients also receive ofatumumab IV over 2 hours on days 1, 2, and 11 of cycle 1; on days 1 and 8 of cycles 2 and 4; and on days 1 and 11 of cycle 3 for a total of 9 injections. Patients may receive rituximab instead of ofatumumab if their insurance provider does not cover the cost of ofatumumab. Patients receive rituximab IV over 2 hours on days 1 and 11 of cycles 1 and 3 and on days 2 and 8 of cycles 2 and 4. Treatment repeats every 21-28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
62050239|NCT01974115|ACTIVE_COMPARATOR|Radial extracorporeal shock wave therapy|All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
62050240|NCT03169218|EXPERIMENTAL|Mirror therapy group|Mirror therapy group: exercises looking at the reflection in the mirror of the hand moving
62050241|NCT03169218|PLACEBO_COMPARATOR|Placebo group|Placebo group: exercises performed with the mirror turned to avoid the reflection of the hand and looking at the hand that did not remain hidden.
62050242|NCT05995028|EXPERIMENTAL|Universal 4SCAR7U cells to treat CD7-positive hematological malignancies|
62050243|NCT05453825|EXPERIMENTAL|Combination navicixizumab + paclitaxel|Gastric/GEJ and TNBC cancer patients will be assigned to this treatment arm.
62050244|NCT05453825|EXPERIMENTAL|Combination navicixizumab + irinotecan|CRC patients will be assigned to this treatment arm.
62050245|NCT05453825|EXPERIMENTAL|Navicixizumab monotherapy|CRC,TNBC and ovarian cancer patients will be assigned to this treatment arm.
62050246|NCT05660200|EXPERIMENTAL|IBSA Iron ODF|A single dose of IBSA Iron ODF containing 30mg Iron and 400ug folic acid will be admistered to healthy female volounteers in one of the two consecutive study periods with a 7-day washout interval between the two administrations.
62050247|NCT05660200|ACTIVE_COMPARATOR|SiderAL® FORTE|A single dose of SiderAL® FORTE containing 30mg Iron and 70mg vitamin C will be admistered to healthy female volounteers in one of the two consecutive study periods with a 7-day washout interval between the two administrations.
62050248|NCT00187226|OTHER|Stratum 1|Ependymoma, craniopharyngioma, low-grade glioma
62050249|NCT00187226|OTHER|Stratum 2|High-grade glioma
62050250|NCT02232308|EXPERIMENTAL|Nizatidine|Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
62050251|NCT02232308|EXPERIMENTAL|Lisinopril|Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
62050252|NCT02232308|EXPERIMENTAL|Nizatidine plus Lisinopril|Nizatidine (150 mg) and Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
62050253|NCT02232308|PLACEBO_COMPARATOR|Placebo|Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
62050254|NCT00168038|EXPERIMENTAL|IgPro10|
62050255|NCT05885698||Non-small Cell Lung Cancer|
62050256|NCT00361439|ACTIVE_COMPARATOR|Mometasone|Mometasone intranasal steroid therapy daily for 2 weeks
62050257|NCT00361439|PLACEBO_COMPARATOR|Placebo|2 puffs of placebo spray in each nostril once daily
62050258|NCT00772785|EXPERIMENTAL|Probuphine|buprenorphine implant
62441501|NCT00472446|PLACEBO_COMPARATOR|placebo cervical block after surgery|placebo bilateral superficial cervical block with saline, placed after surgery (just after skin closure)
62833078|NCT03475147|ACTIVE_COMPARATOR|eyeFusion Control Subjects|Healthy normal controls with no known eye disorders age 18-80.
62050259|NCT03617744|EXPERIMENTAL|Surgical Intervention|Open Sleeve gastrectomy procedure will be performed immediately following liver transplantation (as a single surgery) or within 2 weeks of transplantation (as a second open surgery)
62050260|NCT03617744|NO_INTERVENTION|No Surgical Intervention|Liver transplantation will proceed as per routine practice
62050261|NCT01017354|EXPERIMENTAL|High-dose vitamin D3|monthly high-dose vitamin D3 supplement dose (60'000 IU/month, equivalent to 2000 IU daily)
62050262|NCT01017354|EXPERIMENTAL|standard vitamin D + 25(OH)D|standard vitamin D3 supplement dose combined with 25(OH)D (24'000 IU/month, equivalent to 800 IU daily PLUS 300 mcg 25(OH)D, equivalent to 10 mcg per day)
62050263|NCT01017354|ACTIVE_COMPARATOR|standard vitamin D|standard vitamin D3 supplement dose (24'000 IU/month, equivalent to 800 IU daily)
62050264|NCT01966003|EXPERIMENTAL|ABP 215|Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.
62050265|NCT01966003|ACTIVE_COMPARATOR|Bevacizumab|Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.
62050266|NCT04895865|EXPERIMENTAL|Self-selected|"Participants in the self-selected arm will choose the initial resistance in view of their preferences, and complete as many repetitions as they wish in order to reach the target rating of perceived exertion RPE of 7/10"
62050267|NCT04895865|ACTIVE_COMPARATOR|Predetermined|"Participants in the predetermined arm will be instructed to complete ten repetitions per set and exercise, while aiming to reach a rating of perceived exertion (RPE) of 7/10 by the 10th repetition. This means that participants will need to select and adjust the resistance of each exercise (e.g., band's resistance) to achieve this goal."
62050268|NCT02170025|EXPERIMENTAL|Riociguat (Adempas, BAY63-2521)|Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
62050269|NCT02170025|EXPERIMENTAL|Placebo|Participants received matching placebo tid.
62050270|NCT04536246|ACTIVE_COMPARATOR|BQT Group|Procedure on this arm = bone quadriceps tendon reconstruction
62050271|NCT04536246|OTHER|SBHT Group|Procedure on this arm = single-bundle hamstring tendon reconstruction
62050272|NCT03365154|EXPERIMENTAL|Treatment Group|Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.
62050273|NCT05061875||Cases|Patients treated with ceftriaxone doses equal to or higher 4 grams / day.
62050274|NCT03823781|EXPERIMENTAL|milrinone|milrinone milrinone will be administered intravenously at a rate of 0.75ug/kg/min for 35 hours, and baseline catecholamines will be administered at the discretion of the physician.
62050275|NCT03823781|PLACEBO_COMPARATOR|normal saline|placebo placebo (normal saline) will be administered intravenously for 35 hours, and baseline catecholamines will be administered at the discretion of the physician.
62050276|NCT04608175|EXPERIMENTAL|Acupuncture group|"The experimental group will receive the standard treatment administered in these cases (analgesic regimen and nursing care procedures), in addition to the following acupuncture therapy.~In the first visit (preoperative), the anamnesis and energy diagnosis of each patient will be carried out following the practices of Traditional Chinese Medicine (TCM) to design a personalized treatment based on the patient's medical history. A treatment of approximately 10 to 12 acupuncture points will be designed considering the TCM diagnosis and medical history of each patient. Both TCM diagnosis and the points used will be reassessed in each session. The points belonging to the upper extremity of the affected breast will be treated on the contralateral side, taking care not to insert any needle in the limb on the affected side. No points in the operated region will be used."
62050277|NCT04608175|NO_INTERVENTION|Control group|The control group will only receive standard care procedures (analgesic regimen and nursing care procedures), although they will have the same follow up visits as the patients in the intervention group to facilitate analysis of the study variables.
62050278|NCT01066325|EXPERIMENTAL|NET|This arm will receive two 20-minutes sessions of NET 1 week apart. NET (Neuro Emotional Technique) is a non-invasive stress reduction technique.
62050279|NCT01066325|ACTIVE_COMPARATOR|Active Controls|This arm will receive two 20-minute sessions of stretching instructions 1 week apart.
62050280|NCT01066325|NO_INTERVENTION|Inactive Controls|This arm will receive no intervention and no instructions.
62738799|NCT01191645|PLACEBO_COMPARATOR|Natriumklorid|
62050281|NCT01408355|EXPERIMENTAL|50 microgram PF-06273588 intravenous|Subjects will receive a single intravenous microdose of PF-06273588 in period one
62050282|NCT01408355|EXPERIMENTAL|50 microgram PF-06273588 oral|Subjects will receive a single oral microdose of PF-06273588 in period two
62050283|NCT06168812|EXPERIMENTAL|Cohort 1|Participants in this cohort will receive glipizide for up to 4 months and participate in continuous glucose monitoring for as long as they are receiving the drug.
62050284|NCT06168812|NO_INTERVENTION|Cohort 2a|Participants in this cohort will include people who have received various types of treatment for their hyperglycemia and pancreatic cancer. People's medical records will be reviewed to compare the effects of glipizide with the effects of other standard medications used to treat hyperglycemia.
62050285|NCT06168812|NO_INTERVENTION|Cohort 2b|Participants in this cohort will complete a questionnaire about their use of hyperglycemia medications. Participants from Cohort 2a will take part in this group.
62050286|NCT01939873|EXPERIMENTAL|KRISTELLER|Uterine fundal pressure
62050287|NCT01939873|NO_INTERVENTION|Control group|
62050288|NCT01839006||patients with supranormal renal function|Patients with preoperative HN and supranormal renal function in DTPA renography
62050289|NCT05134766||PCR positive|Those with a condition of the first SARS-CoV-2 PCR test result was positive. Based on data recorded in the period between 01 January 2021 to 30 June 2021
62738800|NCT01191645|EXPERIMENTAL|Ultiva|
62833079|NCT03475147|EXPERIMENTAL|eyeFusion Patients|Scotoma subjects aged 18-80.
62833080|NCT06516679|EXPERIMENTAL|Low risk group|KMT2A wild type \& minimal residual disease(MRD) (-) after consolidation 1
62833081|NCT06516679|EXPERIMENTAL|Intermediate risk group|"ntermediate risk (If one of the two cases below applies)~* KMT2A: MLL mutation (+) \& minimal residual disease (MRD) (-) after consolidation 1~  * KMT2A: wild type \& minimal residual disease (MRD) (+) after consolidation 1"
62050290|NCT05134766||PCR negative|Those with a condition of the first SARS-CoV-2 PCR test result was negative. Based on data recorded in the period between 01 January 2021 to 30 June 2021
62050291|NCT05134766||IgA/IgG positive|Those with a condition of the first IgA or IgG test result was at least once positive.
62050292|NCT05134766||IgA/IgG negative|Those with a condition of the first IgA and IgG test results were both negative
62050293|NCT05134766||Prevention only|Those with a condition of the first SARS-CoV-2 PCR test result was negative AND IgG /IGA negative.
62050294|NCT05134766||W/Symptoms|Those that reported at least one positive symptom. Based on data recorded in the period between 01 January 2021 to 30 June 2021
62050295|NCT00511017|EXPERIMENTAL|Doxercalciferol|
62050296|NCT03967431|EXPERIMENTAL|Narrative Enhancement and Cognitive Therapy group|The patients in the experimental group received narrative enhancement and cognitive therapy which contains 20 times group meetings.
62050297|NCT03967431|NO_INTERVENTION|Control group|The patients in the control group received routine care.
62050298|NCT06069050|EXPERIMENTAL|Surgical group|SALT operation plan for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
62050299|NCT05095805|EXPERIMENTAL|Test group|additional weight-bearing exercise
62050300|NCT05095805|ACTIVE_COMPARATOR|Control group|standard weight-bearing exercise
62050301|NCT01756950|EXPERIMENTAL|Cohort 1 - CR8020|2 mg/kg CR8020
62050302|NCT01756950|PLACEBO_COMPARATOR|Cohort 1 - Placebo|5% dextrose in water
62050303|NCT01756950|EXPERIMENTAL|Cohort 2 - CR8020|5 mg/kg CR8020
62050304|NCT01756950|PLACEBO_COMPARATOR|Cohort 2 - Placebo|5% dextrose in water
62050305|NCT01756950|EXPERIMENTAL|Cohort 3 - CR8020|15 mg/kg CR8020
62050306|NCT01756950|PLACEBO_COMPARATOR|Cohort 3 - Placebo|5% dextrose in water
62050307|NCT01756950|EXPERIMENTAL|Cohort 4 - CR8020|30 mg/kg CR8020
62050308|NCT01756950|PLACEBO_COMPARATOR|Cohort 4 - Placebo|5% dextrose in water
62050309|NCT01756950|EXPERIMENTAL|Cohort 5 - CR8020|50 mg/kg CR8020
62251944|NCT05380258|EXPERIMENTAL|stress ball|Pregnant women with 4-5 cm cervical dilatation were asked to tighten the ball for 5 seconds and relax for 2 seconds within 20 minutes when their contractions came, and when the cervical opening was 6-8 cm, they were asked to tighten the ball for 5 seconds and relax for 2 seconds within 20 minutes.
62050310|NCT01756950|PLACEBO_COMPARATOR|Cohort 5 - Placebo|5% dextrose in water
62050311|NCT01756950|EXPERIMENTAL|Cohort 6 - CR8020|30 mg/kg CR8020
62050312|NCT01756950|PLACEBO_COMPARATOR|Cohort 6 - Placebo|5% dextrose in water
62050313|NCT00817492||1|Subjects with mild to moderate kidney disease
62050314|NCT00817492||2|Healthy Control Subjects
62050315|NCT06083870|EXPERIMENTAL|Oba01|
62050316|NCT05711537|EXPERIMENTAL|Intervention Auricular Acupressure (AA) Group|Participants will participate in the Auricular Acupressure intervention over 3 days in addition to the Standard of Care treatment for Chronic Pain and complete questionnaires
62050317|NCT03339479|EXPERIMENTAL|dielectric property test|The patient with lung nodules/mass is firstly arranged to be tested for dielectric property after the nodules/mass resection and cutting open.
62050318|NCT03339479|PLACEBO_COMPARATOR|frozen pathological examination|The resected lung nodules/mass will be sent for frozen pathological examination after dielectric property test.
62050319|NCT03339479|OTHER|final pathological examination|The resected lung nodules/mass will undergo the final pathological examination for final diagnosis after dielectric property test and frozen pathological examination.
62050320|NCT06566326|ACTIVE_COMPARATOR|Group (PK)|Patients received intravenous sedation using prepared mixture of propofol and ketamine (in the ratio 4:1)
62050321|NCT06566326|ACTIVE_COMPARATOR|Group (OPETA)|Patients underwent modified Oropharyngeo-esophygeal Topical Anesthesia by OPETA Prototype tool
62050322|NCT00072761|ACTIVE_COMPARATOR|Transfusion Group|Participants allocated to the transfusion arm will receive blood transfusion therapy every 4-6 weeks for 36 months.
62050323|NCT00072761|NO_INTERVENTION|Observation Group|Participants allocated to the observation arm will be treated according to standard care and will receive a quarterly physical examination by a study hematologist for 36 months.
62050324|NCT03767179||Study Group|The study group consisted of 30 fertile, under 35 years old women who were included in the study for the first time missed abortus diagnosis.
62251945|NCT05380258|NO_INTERVENTION|Control Group|standard care
62833082|NCT06516679|EXPERIMENTAL|High risk group|Somatic KMT2A mutation (+) \& minimal residual disease (MRD) (+) after consolidation 1
62050325|NCT03767179||Control Group|30 cases with the same trimester, fertile, and under 35 years old who were referred to Obstetrics clinic, who had no systemic disease, were included in the study.
62050326|NCT01245465|EXPERIMENTAL|Profermin|Daily oral intake of a food for special medical purposes (Profermin)
62050327|NCT04684225|EXPERIMENTAL|Telerehabilitation|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients via telerehabilitation for 3 sessions per week.
62610601|NCT02598011|EXPERIMENTAL|Toca 511/Toca FC at 220 mg/kg/day|"Toca 511: 4 mL administered by intracranial parenchymal injection into the walls of the resection cavity following tumor resection or, for those subjects who are not candidates for resection, via stereotactic injection into their tumor using a standard Nashold-type side cutting biopsy needle.~Toca FC: Approximately 4 to 6 weeks after tumor resection, subjects will begin temozolomide concurrent with radiation therapy. During concurrent chemoradiation at the start of the second and sixth week of concurrent chemoradiation and every 28 days thereafter, a 7-day course of oral Toca FC will be dosed at 220 mg/kg/day"
62050328|NCT04684225|EXPERIMENTAL|Home-exercises|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied by their own at home for 3 sessions per week.
62251946|NCT01181076|EXPERIMENTAL|Individualized Nutrition|
62610602|NCT06731790|EXPERIMENTAL|Mutant RANBP2 associated with predisposition to ANE1|"Subjects aged 1 to 90 with a T585M mutation in RANBP2 for the RANBP2 mutation arm. During a single visit, 2 tubes of blood will be sampled, demographic data and clinical history collected, and a clinical examination performed."
62610603|NCT06731790|ACTIVE_COMPARATOR|Healthy control subjects|"For healthy control subjects related to a person from the mutant RANBP2 arm: During a single visit, 2 tubes of blood will be sampled, demographic data and clinical history collected, and a clinical examination performed. Healthy control subjects related to a person from the mutant RANBP2 arm will be included in the third Secondary Outcome (whole exome sequencing).~For healthy control subjects unrelated to a person from the mutant RANBP2 arm: During a routine epilepsy consultation for children, or a family disease screening for adults, an additional blood tube will be sampled, demographic data collected and a clinical examination performed. Healthy control subjects unrelated to a person from the mutant RANBP2 arm will not be included in the third Secondary Outcome (whole exome sequencing)."
62610604|NCT05352919|EXPERIMENTAL|Litifilimab Low Dose|"Participants who are receiving background nonbiologic lupus standard of care (SOC) therapy and received litifilimab low dose, subcutaneously (SC), every 4 weeks (Q4W) during the parent Phase 3 studies (i.e. studies 230LE303 \[NCT04895241\] or 230LE304 \[NCT04961567\]) will continue to receive litifilimab low dose, SC, Q4W from Day 1 up to 152 weeks with an additional dose of litifilimab-matching placebo at Week 2.~Participants who are receiving background nonbiologic lupus SOC therapy and received litifilimab-matching placebo in the parent Phase 3 studies (i.e. studies 230LE303 \[NCT04895241\] or 230LE304 \[NCT04961567\]) will be randomized to receive litifilimab low dose, SC, Q4W from Day 1 up to 152 weeks with an additional dose at Week 2."
62738801|NCT01846962|EXPERIMENTAL|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
62833083|NCT01499355|PLACEBO_COMPARATOR|Placebo|Placebo intravenous (IV) infusion on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48, plus background therapy including oral steroids (prednisone or equivalent) and mycophenolate mofetil (MMF)
62738802|NCT01846962|EXPERIMENTAL|fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
62738803|NCT01846962|EXPERIMENTAL|Budesonide|The administered dose of topical steroid was 400mcg/day or 800 mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
62050329|NCT04684225|NO_INTERVENTION|Control|They will have no intervention for 8 weeks. After the period, they will do home exercises.
62050330|NCT05840848|ACTIVE_COMPARATOR|Control plus Placebo|B-carotene supplement (15 mg) consumed in the morning after a \>10 hour overnight fast.
62050331|NCT05840848|EXPERIMENTAL|Control plus iron Supplement|B-carotene supplement (15 mg) and iron sulphate supplement (25 mg) consumed in the morning after a \>10 hour overnight fast.
62050332|NCT05840848|EXPERIMENTAL|Control plus zinc Supplement|B-carotene supplement (15 mg) and zinc sulphate supplement (30 mg) consumed in the morning after a \>10 hour overnight fast.
62251947|NCT01181076|NO_INTERVENTION|Control group|The patients in the control group will be nourished after established routine, first by the oral route, later by the PN route. Naso-jejunal tube will not be inserted and enteral nutrition will not be given.
62050333|NCT02846090|EXPERIMENTAL|D50 Dexmedetomidine 50 micrograms group|peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
62050334|NCT02846090|EXPERIMENTAL|D25 Dexmedetomidine 25 micrograms group|peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine + 4.5 ml of 2% lidocaine +0.5ml of 25 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
62050335|NCT02846090|PLACEBO_COMPARATOR|control|peribulbar block was given using 10 ml of a mixture of local anesthetics without Dexmedetomidine. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml with 150 IU hyaluronidase.
62050336|NCT03322280|EXPERIMENTAL|TACE+I-125 seeds|TACE combined with iodine-125 seeds implantation
62050337|NCT03322280|ACTIVE_COMPARATOR|TACE alone|TACE alone
62738804|NCT01846962|EXPERIMENTAL|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1 or mg/day (\<150 cm or \>150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
62050338|NCT02231177|EXPERIMENTAL|BI 1744 CL/Tiotropium FDC|
62050339|NCT02231177|ACTIVE_COMPARATOR|BI 1744 CL|
62050340|NCT02231177|ACTIVE_COMPARATOR|Tiotropium|
62050341|NCT01509781|ACTIVE_COMPARATOR|Suction drain|Patients in Arm A undergo simplex mastectomy or modified radical mastectomy. One plastic Redon drain (16 Ch) is placed after simplex mastectomy and two plastic Redon drains (16 Ch each) following modified radical mastectomy.
62251948|NCT06072989|EXPERIMENTAL|B4T2-001 CAR T|Single Arm and Open Label study consisting of dose escalation study design followed by dose expansion phase at determined MTD.
62441502|NCT00275028|EXPERIMENTAL|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62441503|NCT06302712|EXPERIMENTAL|Intervention|
62441504|NCT06302712|NO_INTERVENTION|TAU|
62441505|NCT02783391|EXPERIMENTAL|BRAINSPEAK|Electrocorticographical (ECoG) and intracortical electrodes
62441506|NCT00647049|EXPERIMENTAL|A|first diagnosis of PCNSL: combined chemotherapy with methotrexate
62441507|NCT00647049|EXPERIMENTAL|B|Patients with relapse or progressive disease of PCNSL after methotrexate containing chemotherapy
62251949|NCT03745833|EXPERIMENTAL|Intervention|Participants will be shown a brief VR-based mindfulness intervention after meals.
62050342|NCT01509781|EXPERIMENTAL|Adaptive suture|Following mastectomy, wound cavity is closed with adaptive skin sutures. No suction drain is inserted.
62251950|NCT04042168|EXPERIMENTAL|Intervention|Inappropriate use of inhalers and medication change. Pre-post intervention data will be compared.
62251951|NCT05464706|EXPERIMENTAL|Interventional|
62251952|NCT05464706|PLACEBO_COMPARATOR|Control|
62251953|NCT00955279|PLACEBO_COMPARATOR|Placebo|Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
62251954|NCT00955279|EXPERIMENTAL|Golimumab|Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
62251955|NCT00955279|EXPERIMENTAL|Ustekinumab|Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
62251956|NCT05197348|EXPERIMENTAL|Meaning-Centered Group Psychotherapy (MCP).|The intervention lasts two months and includes eight sessions that follow a two-hour group format on a weekly basis. The investigators will follow the manualized MCP for patients with advanced cancer.
62251957|NCT05197348|ACTIVE_COMPARATOR|Cognitive Behavioral Psychotherapy (CBT).|The intervention lasts two months and includes eight sessions that follow a two-hour group format on a weekly basis, with the following sessions. The investigators will follow the manualized CBT or patients with advanced cancer.
62251958|NCT02823795|EXPERIMENTAL|sPATH|Motivational Interviewing in five sessions post hospital discharge
62251959|NCT02823795|NO_INTERVENTION|Control|Care as usual
62251960|NCT00998049|EXPERIMENTAL|Plerixafor|"Plerixafor 160mg/kg/dose by IV on days 5-8~Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8."
62251961|NCT05273879|OTHER|decompression group|minimally invasive decompression without fusion
62251962|NCT05273879|OTHER|fusion group|minimally invasive decompression with trans-foraminal interbody fusion
62251963|NCT02319668|EXPERIMENTAL|Test product|Mouthwash containing 0.2% w/v Chlorhexidine digluconate
62251964|NCT02319668|PLACEBO_COMPARATOR|Control|Sodium fluoride toothpaste (Aquafresh Mild \& Minty)
62251965|NCT04502004|NO_INTERVENTION|Control Group (CG)|"Receive the recommendations of the Clinical Practice Guidelines which consist of: advice on smoking cessation smoking, leaflet with information (tobacco components, treatments to reduce withdrawal syndrome).~Follow-up after discharge by the hospital tabacco service: at one month, at three months, at six months and at one year."
62050343|NCT03409666|EXPERIMENTAL|Taperloc Complete Microplasty stem|Subjects in need of a total hip artthroplasty who received the Taperloc Complete Microplasty stem.
62050344|NCT03409666|ACTIVE_COMPARATOR|Taperloc Complete Reduced Distal stem|Subjects in need of a total hip arthroplasty who received the Taperloc Complete Reduced Distal stem.
62050345|NCT00954148|ACTIVE_COMPARATOR|PET/CT follow-up|PET/CT with history and physical exams at 3,9,18,36,60 months only
62050346|NCT00954148|OTHER|conventional follow-up|NCCN recommendations
62050347|NCT04700501|OTHER|EYB Implementation study|All participants will have the opportunity to access an online CBT life skills learning programme.
62050348|NCT05205902|OTHER|Low-dose total-skin electron-beam therapy|Low-dose total skin electron beam therapy (12 Gy) will be delivered to the patient in 4 Gy/week, 1 Gy/day over 3 weeks by symmetrical electron beams of 6 MeV energy via a linac accelerator.
62050349|NCT05205902|OTHER|Phototherapy|"Phototherapy will be given 3 times a week during 2 months, then twice a week during one month, then once a week during one month, or until disease progression or unacceptable side effect, whatever comes first.~Patients with plaques will receive PUVA therapy and patients with patches only will receive narrow-band UVB therapy."
62050350|NCT01223482||Miscarriage with genetic testing|This is a study population of women that have had a miscarriage and had genetic testing performed. The investigators would like to know what their experiences were following their miscarriage and testing.
62050351|NCT01223482||Miscarriage without genetic testing|This cohort is considered the control group. These women have not had genetic testing done, but are asked questions regarding their miscarriage experience.
62050352|NCT02157779|EXPERIMENTAL|Cognitive Behavioral Intervention (CBI)|12 weekly individual sessions consisting of psychoeducation, and cognitive and behavioral anger management strategies
62050353|NCT02157779|ACTIVE_COMPARATOR|Supportive Intervention (SI)|12 weekly individual sessions consisting of psychoeducation, problem-solving strategies, and support
62050354|NCT01965405|EXPERIMENTAL|Phase 1: Standard of Care (A)|Brief counseling and bupropion
62050355|NCT01965405|EXPERIMENTAL|Phase 1: Standard of Care (B)|Brief counseling, bupropion, and brief high-magnitude prize contingency management.
62050356|NCT01965405|EXPERIMENTAL|Phase 2a Non-Responders (A)|Bupropion, continued counseling, monitored support to quit smoking.
62050357|NCT01965405|EXPERIMENTAL|Phase 2a: Non-Responders (B)|Bupropion, monitored support to quit smoking, prize contingency management for abstinence.
62441508|NCT03011463|ACTIVE_COMPARATOR|trospium intravenous|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o.
62833084|NCT01499355|EXPERIMENTAL|BIIB023 3 mg/kg|BIIB023 3 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
62833085|NCT01499355|EXPERIMENTAL|BIIB023 20 mg/kg|BIIB023 20 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
62050358|NCT01965405|EXPERIMENTAL|Phase 2b: Responders (A)|Bupropion, no additional treatment.
62050359|NCT01965405|EXPERIMENTAL|Phase 2b: Responders (B)|Bupropion, continued monitoring and low intensity prize contingency management.
62050360|NCT04827485|ACTIVE_COMPARATOR|Gluteal squeeze|Patients behind pressed together during part of the colonoscopy (The technicians arms will be covered with a towel to mask the provider of any pressure being applied)
62050361|NCT04827485|SHAM_COMPARATOR|Non-squeeze|When the doctor asks for gluteal pressure, a technician will not administer the pressure but their arms will be covered with a towel and the doctor will not know if the pressure is being administered or not.
62050362|NCT01756352|EXPERIMENTAL|GBM Avastin receiving 18F-FET|Recurrent GBM patients receiving Avastin, imaged twice with 18F-FET PET before and approximately 8 weeks after receiving Avastin
62050363|NCT05684627|EXPERIMENTAL|Fast mimicking diet group|The patients in this group will be assigned to follow one cycle of a fasting mimicking diet (FMD) the same day after receiving the full-mouth non-surgical periodontal treatment.
62050364|NCT05684627|ACTIVE_COMPARATOR|Normal diet group|The patients in this group will be assigned to normal diet after receiving the full-mouth non-surgical periodontal treatment.
62050365|NCT01414621||CABG patients|atrial tissue samples from CABG patients
62441509|NCT03011463|ACTIVE_COMPARATOR|trospium oral|Oral administration of 30 mg trospium chloride with 240 ml tap water
62251966|NCT04502004|EXPERIMENTAL|Experimental Group (EG)|"Receive codes to download the App NoFumo+ . Is a mHealth that offer a CBT program. Follow-up after discharge by the hospital tabacco service: at one month, at three months, at six months and at one year."
62833086|NCT05006638|PLACEBO_COMPARATOR|control group|will receive the traditional supportive treatment according to (PCC-ASUH) protocol
62833087|NCT05006638|ACTIVE_COMPARATOR|case group|will receive the traditional supportive treatment plus administration of ILE (20%) 1.5 ml/kg as a bolus over 2-3 minutes. Followed immediately by an infusion of 20 % lipid emulsion at a rate of 0.25 mL/kg/min. After 3 minutes of this infusion rate, response to the bolus and initial infusion should be assessed. If there has been a significant response, the infusion rate can be adjusted to 0.025 mL/kg/min with monitoring of blood pressure, heart rate, and other available hemodynamic parameters during the infusion with a maximum dose of 10 mL/kg
62833088|NCT04180761|EXPERIMENTAL|HIPEC-Treatment|"Doxorubicin (15 mg/m²/body surface) Cisplatin (75 mg/m²/body surface) applied as hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy.~All drugs used are approved."
62833089|NCT03632889|NO_INTERVENTION|Control Arm|Subjects randomized to the control group will receive a sleep hygiene handout .
62833090|NCT03632889|OTHER|Computerized Group|Subjects randomized to GoToSleep program will receive a sleep hygiene handout and a unique code for home access to the GoToSleep program.
62833091|NCT06654180|ACTIVE_COMPARATOR|Orthokeratology|To wear Orthokeratology at night to slow down progressing myopia
62050366|NCT00941226||Cerebral Palsy|Those kids who have cerebral palsy and are helped by carers
62251967|NCT00797875|EXPERIMENTAL|1|PNF stretching x 5 repetitions for 3 days
62251968|NCT00797875|ACTIVE_COMPARATOR|2|passive stretching
62441510|NCT03011463|ACTIVE_COMPARATOR|trospium intravenous with ranitidine|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and oral administration of 300 mg ranitidine with 240 ml tap water
62441511|NCT03011463|ACTIVE_COMPARATOR|trospium intravenous with clarithromycin|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and oral administration of 500 mg clarithromycin with 240 ml tap water
62441512|NCT03011463|ACTIVE_COMPARATOR|trospium oral with ranitidine|Oral administration of 30 mg trospium chloride together with 300 mg ranitidine with 240 ml tap water
62441513|NCT03011463|ACTIVE_COMPARATOR|trospium oral with clarithromycin|Oral administration of 30 mg trospium chloride together with 500 mg clarithromycin with 240 ml tap water
62441514|NCT00623623|EXPERIMENTAL|Tenecteplase|Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention
62441515|NCT00623623|OTHER|primary PCI|Standard primary PCI
62441516|NCT01162083||Mitral Valve disease|Patients with mitral valve disease, deemed suitable and ready for elective valve repair or replacement. No significant arrhythmias, other valvular disease or LV dysfunction present. We shall also be recruiting patients undergoing a Mitraclip procedure.
62441517|NCT01162083||COPD|Patients with isolated chronic obstructive pulmonary disease and no cardiac disease.
62441518|NCT01162083||Mixed Lesions|Patients with proven limitation from both cardiac and respiratory disease.
62441519|NCT01162083||CRT|Patients with symptomatic heart failure who have responded to cardiac resynchronisation therapy (biventricular pacemaker).
62833092|NCT06654180|EXPERIMENTAL|defocus-incorporated multiple segment lenses (DIMS) spectacles|To wear defocus-incorporated multiple segment lenses (DIMS) spectacles at daytime
62833093|NCT06654180|EXPERIMENTAL|defocus incorporated soft contact (DISK) lenses|To wear defocus incorporated soft contact (DISK) lenses at daytime
62833094|NCT06654180|PLACEBO_COMPARATOR|single-vision spectacles (SVS)|To wear SVS at daytime and at night before sleep
62833095|NCT05670067|ACTIVE_COMPARATOR|immediate implant with bone graft (autogenous)|with immediate implant placement autogenous grafting using maxillary tuberosity will be done
62833096|NCT05670067|ACTIVE_COMPARATOR|immediate implant with bonegraft (xenograft)|with immediate implant placement grafting with xenograft will be done
62050367|NCT03613805|ACTIVE_COMPARATOR|Dexcom G5 - Eversense|Patients will wear first Dexcom G5 (Dexcom San Diego, CA, USA) transcutaneous sensor for 3 months, then Eversnese(Senseonics Inc, MD, USA) implantable sensor for 3 months Accuracy and efficacy will be evaluated
62251969|NCT02957591|EXPERIMENTAL|Probiotic Group|Over a period of 4 weeks, depressive patients will ingest a probiotic food supplementation (Vivomixx®) 4 times a day. Primary and secondary endpoints will be assessed before and after the intervention.
62833097|NCT04687982|EXPERIMENTAL|mDLI infusion|"The planned number of mDLI is 3.~1. Day +50 (+/- 7 days) from allogenic transplant, 1st mDLI 5x105CD3+/kg of recipient.~2. 4-6 weeks after 1st DLI, 2nd mDLI 1x106CD3+/kg of recipient.~3. 4-6 weeks after 2nd DLI, 3rd mDLI 5x106CD3+/kg of recipient."
62833098|NCT04005131|EXPERIMENTAL|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 10 weeks
62833099|NCT04005131|ACTIVE_COMPARATOR|Robot and tDCS on-line after sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 weeks, followed by combined tDCS on-line and upper extremity rehabilitation robot for 5 weeks
62050368|NCT03613805|EXPERIMENTAL|Eversense- Dexcom G5|Patients will wear first Eversense (Senseonics Inc, MD, USA) implantable sensor for 3 months, then Dexcom G5 (Dexcom San Diego, CA, USA) transcutaneous sensor for 3 months accuracy and efficacy will be evaluated
62251970|NCT02957591|PLACEBO_COMPARATOR|Placebo Group|Subjects in the placebo group will receive a placebo 4 times a day over 4 weeks. Primary and secondary endpoints will be assessed before and after the intervention.
62251971|NCT01368042||Chronic Kidney Disease, Secondary Hyperpathyroidism|All eligible participants treated with paricalcitol iv according to the approved Summary of Product Characteristics (SmPC)
62050369|NCT00877084|EXPERIMENTAL|1|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
62050370|NCT00877084|PLACEBO_COMPARATOR|2|Usual care according to clinical pathway for COPD exacerbations + NO training
62050371|NCT04604080||single group|Respondents will be given survey form, filled and will be collected back
62050372|NCT02493296||Observational|The cohort will have their central aortic pressure, and carotid-femoral and brachio-femoral pulse-wave velocities measured. These measurements will take place pre-operatively, within a week of surgery, 6-weeks and 1-year post-operatively also. The surgery will be abdominal aortic aneurysm repair.
62050373|NCT04000568||Study Population|All the infants enrolled in the study will receive 1 h of NAVA-NIV and 1h PC-NIV in a cross-over study design
62050374|NCT04119895|EXPERIMENTAL|NMES and exercise|Neuromuscular electrical stimulation and core stabilization exercise
62050375|NCT04119895|SHAM_COMPARATOR|Sham NMES and exercise|Sham neuromuscular electrical stimulation and core stabilization exercise
62050376|NCT01070901||Organ transplant recipients|
62251972|NCT05575037|EXPERIMENTAL|Dupilumab|Subjects will receive dupilumab (300mg every-other-week for 8 weeks).
62251973|NCT01039077|ACTIVE_COMPARATOR|Single incision laparoscopic gastric banding|Patients in this group will undergo laparoscopic gastric banding through a single periumbilical incision.
62251974|NCT01039077|ACTIVE_COMPARATOR|Five port laparoscopic gastric banding|Patients in this group will undergo conventional laparoscopic gastric banding using 5 small incisions.
62251975|NCT06289322|OTHER|Digital Toolkit for assessment of pain and distress|a digital toolkit will be developed using facial emotional recognition and other instruments as well as questionnaires for the assessment of pain and distress in patients with dementia
62251976|NCT00122681|EXPERIMENTAL|Cervarix Group|Subjects received 3 doses of Cervarix™ (GSK Biologicals' human papillomavirus \[HPV\] vaccine) at Months 0, 1 and 6.
62251977|NCT00122681|ACTIVE_COMPARATOR|Havrix Group|Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine \[HAV\] (Havrix™-based investigational formulation) at Months 0, 1 and 6.
62441520|NCT01162083||Cardiomyopathy|Heart Failure of primarily myopathic origin, without rhythm disturbance, ongoing ischaemia or significant valvular disease.
62441521|NCT03349606|EXPERIMENTAL|Cocaine dependence|\[C-11\]FLB 457 PET at baseline and post d-amphetamine
62441522|NCT03349606|EXPERIMENTAL|Controls|\[C-11\]FLB 457 PET at baseline and post d-amphetamine
62833100|NCT03420118|EXPERIMENTAL|Tumor tissue and blood samples collection|
62833101|NCT02757209|ACTIVE_COMPARATOR|Spiromax Inhaler|"Evaluation of correct use of Spiromax inhaler - DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup"
62251978|NCT04551222|ACTIVE_COMPARATOR|Probenecid|1 gr. orally of probenecid twice daily for 180 days
62251979|NCT04551222|PLACEBO_COMPARATOR|Placebo|identical placebo (to probenecid tablets) for 180 days
62251980|NCT06460675|EXPERIMENTAL|Autogenic Inhibition Muscle Energy Technique|This group will receive Autogenic Inhibition Muscle Energy Technique
62251981|NCT06460675|ACTIVE_COMPARATOR|Reciprocal Inhibition Muscle Energy Technique|This group will receive Reciprocal Inhibition Muscle Energy Technique
62251982|NCT00956774|ACTIVE_COMPARATOR|Balloon Catheter|
62251983|NCT00956774|ACTIVE_COMPARATOR|Cervical Vacuum Cup|
62251984|NCT00956774|ACTIVE_COMPARATOR|acorn-tipped cannula|
62251985|NCT02967705|EXPERIMENTAL|Pain management group|6 + 1 meetings 2 hours each
62251986|NCT02967705|NO_INTERVENTION|Treatment as usual|Waiting list - will receive treatment as usual
62251987|NCT02932995||DXR stent group|Patients who undergo coronary intervention with DXR stent
62251988|NCT02043548|ACTIVE_COMPARATOR|Group A: Tocilizumab|Tocilizumab will be given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
62251989|NCT02043548|PLACEBO_COMPARATOR|Group B: Placebo|Placebo arm - no active drug
62441523|NCT03205514||NSTE-ACS with intermediate stenosis and negative FFR|Patients hospitalized because of an acute coronary syndrome without ST segment elevation and with intermediate culprit lesion with negative fractional flow reserve evaluation (\>0.80).
62833102|NCT02757209|ACTIVE_COMPARATOR|Turbohaler inhaler|"Turbohaler® - Symbicort® 160/4.5 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate). Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup"
62050377|NCT02592538|EXPERIMENTAL|RFA+stent+S-1|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement, and be treated with S-1 began within 1 month after RFA.
62251990|NCT02161575|EXPERIMENTAL|Ranibizumab|All patients received 3 monthly intraveal injections of 0.5mg ranibizumab followed by monthly injections of ranibizumab 0.5mg for a further 3 months on a prn (as required) basis, as determined by the study doctor.
62833103|NCT02757209|ACTIVE_COMPARATOR|Diskus Inhaler|"Diskus® inhaler - Seretide Diskus 50/250 mcg ® or 50/500 mcg (50 mcg salmeterol \& 250/500 mcg fluticasone propionate). Dose of one inhalation twice a day for 1 week.~Additional 8 weeks in one subgroup"
62251991|NCT00878111|EXPERIMENTAL|A: escalating dose levels of NGR-hTNF|NGR-hTNF administered at high doses
62251992|NCT03824470||Group E(rocuronium)|E, after the administration of 1 mg / kg lidocaine, 2 mg / kg propofol, 1 mcg / kg remifentanil and 0.6 mg / kg rocuronium intravenously, patients will be intubated and general anesthesia will be performed when the Tof value is 0.
62251993|NCT03824470||Group R (remifentanil)|1 mg / kg lidocaine, 4 mcg / kg remifentanil and 2 mg / kg propofol intravenously.patients will be intubated and general anesthesia will be performed when the Tof value is 0
62251994|NCT03270072||Photon Therapy|The patients being treated on the Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) at Massachusetts General Hospital that were randomized to receive photon therapy.
62251995|NCT03270072||Proton Therapy|The patients being treated on the Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) at Massachusetts General Hospital that were randomized to receive proton therapy
62610605|NCT05352919|EXPERIMENTAL|Litifilimab High Dose|"Participants who are receiving background nonbiologic lupus SOC therapy and received litifilimab high dose, SC, Q4W during the parent Phase 3 studies (i.e. studies 230LE303 \[NCT04895241\] or 230LE304 \[NCT04961567\]) will continue to receive litifilimab high dose, SC, Q4W from Day 1 up to 152 weeks with an additional dose of litifilimab-matching placebo at Week 2.~Participants who are receiving background nonbiologic lupus SOC therapy and received litifilimab-matching placebo in the parent Phase 3 studies (i.e. studies 230LE303 \[NCT04895241\] or 230LE304 \[NCT04961567\]) will be randomized to receive litifilimab high dose, SC, Q4W from Day 1 up to 152 weeks with an additional dose at Week 2."
62833104|NCT06655584|EXPERIMENTAL|Group A|Experimental Group A: The patient will be installed in a reception room and will benefit from Bliss DTx digital therapy via a video headset and an audio headset for a duration of 13 minutes
62833105|NCT06655584|NO_INTERVENTION|group B|Group B control: The patient will be installed in a reception room and will be seated and wait for the doctor to arrive (no material)
62833106|NCT01957007|EXPERIMENTAL|Docetaxel|Drug: Docetaxel - administered intravenously
62833107|NCT01957007|EXPERIMENTAL|vantictumab|Drug: vantictumab - administered intravenously
62833108|NCT04594980|OTHER|Minimally invasive TLIF|Patients will undergo a single level decompression and fusion using a minimally invasive technique. Followed posterior screw fixation is mandatory.
62833109|NCT04594980|OTHER|Open TLIF|Patients will undergo a single level decompression and fusion using an open traditional technique. Followed posterior screw fixation is mandatory.
62833110|NCT00570830|OTHER|1|single armed case series in which all patients underwent the same treatment.
62833111|NCT05623046|EXPERIMENTAL|Treatment|8 one-on-one teletherapy training sessions to enhance emotional skills. Teletherapy sessions will last approximately 60-90 minutes.
62833112|NCT04388969||Gaucher disease patients|Patients with type 1,2,3 Gaucher disease.
62833113|NCT04388969||GBA carriers with Parkinson disease|Patients with Parkinson disease GBA related (carriers)
62833114|NCT02630615||Cohort A (one-time blood sample)|"Blood samples will be collected from eligible patients only once at baseline. These samples will be immediately processed for CTCs and CTC derived xenografts.~For Cohorts A \& B: Patients can participate in both cohorts simultaneously, or only one cohort per patient preference."
62050378|NCT02592538|PLACEBO_COMPARATOR|RFA+stent|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will only receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement
62050379|NCT02475252|ACTIVE_COMPARATOR|Experts|Surgically experienced gynecologists with a personal history of at least 50 hysteroscopy procedures will perform a hysteroscopy on a training model.
62610606|NCT03973255|PLACEBO_COMPARATOR|Home based vestibular rehabilitation program|Home-based vestibular rehabilitation program including vestibular adaptation exercises, oculomotor exercises, static and dynamic balance exercises was given to each group in the form of a booklet. All exercises were demonstrated and performed first time at hospital under supervision. Booklet with descriptions and pictures of each exercise were given to patients in order to enable them to perform exercises at home. Vestibular rehabilitation exercises were prescribed as once daily with 10 repetitions at home for one month and wanted to mark a chart if the exercises were performed daily. A diary was used to monitor adherence with the program.
62610607|NCT03973255|ACTIVE_COMPARATOR|Biofeedback training|"Biofeedback training was performed five days a week during a month for 20 minutes for a total of 20 sessions with Tetrax ® (Sunlight Medical Ltd) static posture analysis device. Biofeedback training including catch, speedball, sky ball, gotcha exercises which requires following a visual target during weight transfer movements, capturing fast-moving objects by changing the center of gravity or quickly escaping from incoming objects, were applied to the patients in biofeedback training. There is a 30 seconds pause between each exercise."
62833115|NCT02630615||Cohort B (multiple blood samples)|Blood samples will be collected from eligible patients at baseline just prior to initiation of therapy. Samples will also be collected on day 1 of every cycle of therapy for 4 cycles (typical cycles are 21 days for chemotherapy, 28 days for targeted therapy and 14 days for immune therapy). At the time of initiation of the treatment break, blood samples will be collected. During the treatment break, patients will be followed every 6-12 weeks with imaging studies, and we will collect blood samples at each visit. At the time of disease progression in the event patient goes on best supportive care, the last blood draw will be at the time of this decision as there will unlikely be any further imaging studies going forward. If a patient is found to have disease progression while on active therapy, the next blood draw will be on the first day of the next therapy and time point of subsequent blood draws will depend on the type of therapy the patient receives.
62050380|NCT02475252|EXPERIMENTAL|Novices|Medical students will perform a hysteroscopy on a training model.
62610608|NCT03973255|ACTIVE_COMPARATOR|Whole body vibration|Whole body vibration training was also performed five days a week during a month for 20 minutes for a total of 20 sessions with Power Plate Pro 5 (MDD CE 0086). In whole body vibration, single leg, squat and deep squat positions were applied respectively with 35 Hz frequency, including rest periods of 30 seconds between each application.
62050381|NCT01534026|ACTIVE_COMPARATOR|Aspirin|Current dose of aspirin for 12 weeks
62050382|NCT01534026|EXPERIMENTAL|Withdrawal arm|Withdrawal of aspirin for 12 weeks
62610609|NCT06247072||low IOP|having low IOP in one eye
62610610|NCT06247072||intermediate IOP|having intermediate IOP in one eye
62833116|NCT03703284||LHI Hernia|Acute (\<=48h) large hemispheric infarction (LHI) patients who developed cerebral hernia in 5 days post-stroke
62833117|NCT03703284||LHI Non-Hernia|Acute (\<=48h) large hemispheric infarction (LHI) patients without cerebral hernia in 5 days post-stroke
62833118|NCT03703284||Healthy control|Healthy individuals
62050383|NCT00604032|PLACEBO_COMPARATOR|1|
62610611|NCT06247072||high IOP|having high IOP in one eye
62050384|NCT02969720|EXPERIMENTAL|Phytosterol|Daily consumption of 2 grams (8 ml) nano-phytosterols per 180 days.
62050385|NCT02969720|PLACEBO_COMPARATOR|Placebo|Daily consumption of 8 ml of a solution with Titanium Dioxide per 180 days.
62050386|NCT05982184|EXPERIMENTAL|Music|Music intervention at home. Patients will be asked to listen to music using their own equipment three times a day. Starting approximately a week prior to surgery up to the day of surgery.
62610612|NCT03212391|EXPERIMENTAL|Diet+Walking|52 weeks of Diet+26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking
62610613|NCT03212391|EXPERIMENTAL|Diet+Nordic Walking|52 weeks of Diet+26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
62833119|NCT00506363|EXPERIMENTAL|A|pulsed dye laser and dynamic cooling device on the day of suture removal
62833120|NCT00506363|ACTIVE_COMPARATOR|B|pulsed dye laser and dynamic cooling device 2 months after suture removal
62833121|NCT00506363|SHAM_COMPARATOR|C|dynamic cooling device
62050387|NCT05982184|NO_INTERVENTION|Standard Care|Treatment as usual.
62050388|NCT04211064|OTHER|Deep neuromuscular block|Patients undergoing deep neuromuscular blockade with rocuronium (TOF -- PTC 1-5)
62050389|NCT04211064|ACTIVE_COMPARATOR|Moderate neuromuscular block|Patients undergoing moderate neuromuscular blockade with rocuronium (TOF 1-3)
62050390|NCT00853164|EXPERIMENTAL|aerobic exercise|Subjects who are randomly assigned to this arm will be assigned a walking program to participate in 3 times a week for eight weeks
62050391|NCT00853164|EXPERIMENTAL|resistence training|Subjects who are randomly assigned to this arm will be assigned a weight training program to participate in 3 times a week for eight weeks
62050392|NCT00853164|ACTIVE_COMPARATOR|Usual Care|Subjects who are randomly assigned to this arm will not participate in any exercise program and will continue with usual care treatment
62050393|NCT01560325|EXPERIMENTAL|CKD-516 inj.|CKD-516 Inj, 3.3\~13mg/m2/day, D1, 4, 8, 11 every 3 weeks
62050394|NCT05098054|EXPERIMENTAL|Arm 1, Moderate HI: Soticlestat 300 mg|Soticlestat 300 mg, tablets, orally, once on Day 1 to participant with moderate HI.
62050395|NCT05098054|EXPERIMENTAL|Arm 2, Mild HI: Soticlestat 300 mg|Soticlestat 300 mg, tablets, orally, once on Day 1 to participant with mild HI.
62050396|NCT05098054|EXPERIMENTAL|Arm 3, Normal hepatic function: Soticlestat 300 mg|Soticlestat 300 mg, tablets, orally, once on Day 1 to healthy participants.
62050397|NCT04082299||Pregnant women|pregnant women expected to be vaccinate with Tdap vaccine during their 3th trimester
62050398|NCT04082299||Non pregnant women|Non pregnant women expected to be vaccinate with Tdap vaccine
62050399|NCT03419364|EXPERIMENTAL|Nicotinamide - pre-eclampsia|All participants will receive study agent
62050400|NCT03419364|EXPERIMENTAL|Nicotinamide - healthy pregnant|All participants will receive study agent 1000mg in single dose
62050401|NCT03419364|EXPERIMENTAL|Healthy Non-Pregnant|All participants will receive study agent 1000mg in single dose
62050402|NCT06433531|EXPERIMENTAL|TQH2929 Injection (900 mg)|TQH2929 Injection is administered as a single dose.
62050403|NCT02899494|OTHER|Group A|Antenatal classes
62050404|NCT02899494|EXPERIMENTAL|Group B|Physical and psychic preparation
62610614|NCT06034379|EXPERIMENTAL|Clinical prototype (CP1) device|15 subjects will be randomly assigned to use the eSpectacle Clinical Prototype (CP1) device 2 hours per day, at least 6 days per week. Standard single vision correction will be used during other waking hours. The eSpectacle clinical prototype (CP1) device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights onto the peripheral retina.
62610615|NCT06034379|EXPERIMENTAL|CP1 and 0.01% atropine|15 subjects will be randomly assigned to use the eSpectacle Clinical Prototype (CP1) device 2 hours per day, at least 6 days per week, in addition to nightly instillation of one drop of 0.01% atropine. Standard single vision correction will be used during other waking hours. The eSpectacle clinical prototype (CP1) device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights onto the peripheral retina. Atropine is an anticholinergic medication which can be used for dilation and cycloplegia and has been evaluated for slowing the progression of myopia.
62610616|NCT06034379|EXPERIMENTAL|0.01% atropine|15 subjects will be randomly assigned to nightly instillation of one drop of 0.01% atropine without use of the eSpectacle clinical prototype (CP1) device. Standard single vision correction will be used during waking hours. Atropine is an anticholinergic medication which can be used for dilation and cycloplegia and has been evaluated for slowing the progression of myopia.
62050405|NCT03211364|ACTIVE_COMPARATOR|Angular mobilization|Angular mobilization of the shoulder joint in the frontal plane.
62610617|NCT06098144|EXPERIMENTAL|Tobacco Quit-line (TQL) Group|Participants will be referred to the TQL and will be followed up for up to 12 months.
62050406|NCT03211364|ACTIVE_COMPARATOR|Angular mobilization with soft tissue techniques|Angular mobilization performed in the scapular plane. Additional soft tissue techniques to eliminate limitations created by tensed muscles in order to perform capsular stretch.
62610618|NCT06098144|EXPERIMENTAL|Brief Behavioral Counseling Group|Participants will receive one brief behavioral counseling session and be followed up for 12 months.
62610619|NCT06098144|EXPERIMENTAL|Intensive Behavioral Counseling Group|Participants will receive four behavioral counseling sessions and be followed up for 12 months.
62050407|NCT03211364|PLACEBO_COMPARATOR|Scapular mobilization|Scapular mobilization without glenohumeral movement.
62050408|NCT02701010|ACTIVE_COMPARATOR|Group 1|Structured training and leaflet
62050409|NCT02701010|ACTIVE_COMPARATOR|Group 2|Structured training
62050410|NCT02701010|ACTIVE_COMPARATOR|Group 3|Leaflet
62050411|NCT02701010|SHAM_COMPARATOR|Group 4|Control group
62050412|NCT04732091||Subproject 1 - acute STEMI|Participants with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. Treatment will continue after procedure until complete a total of 50 minutes.
62050413|NCT04732091||Subproject 2 - acute STEMI initially treated with fibrinolytic|Participants with acute STEMI initially treated with fibrinolytic therapy within 12 hours will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (\<0.2) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI; High MI will continue after PCI procedure until complete a total of 50 minutes.
62610620|NCT03134885||VigilanS Nord-Pas de Calais cohort|All patients leaving in the Nord-Pas de Calais region and entering in the VigilanS program after a suicide attempt
62610621|NCT00455520|PLACEBO_COMPARATOR|Placebo|placebo matching placebo twice daily for 12 weeks
62050414|NCT04732091||Subproject 3 - NSTEMI|Participants with NSTEMI or with high-risk unstable angina will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (\<0.2) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI. High MI will continue after PCI procedure until complete a total of 50 minutes.
62050415|NCT04732091||Subproject 4 - No reflow|Participants with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (\<0.2 MI) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI. High MI will continue after PCI procedure until complete a total of 50 minutes.
62050416|NCT04732091||Subproject 6 - Pre-hospital care (ambulance)|Participants with acute STEMI routing from the ambulance to the emergency department will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (\<0.2) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI. High MI will continue after PCI procedure until complete a total of 50 minutes.
62050417|NCT04697264|EXPERIMENTAL|Patients with endometrial cancer|"Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.~Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.~Blood sample will be collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 3/6 months post-surgery follow-up in clinic.~For the women undergoing chemotherapy, blood sample will be procured prior to commencing chemotherapy and after 3rd (with the blood test before the fourth cycle of chemotherapy) and 6th cycles of chemotherapy."
62050418|NCT03866941||synthetic cannibinoids users|
62050419|NCT02599415|OTHER|TL01 light treatment|routine treatment with a CE marked device that has been used for this disease for many years
62610622|NCT00455520|EXPERIMENTAL|CG5503|CG5503 100, 150, 200, 250mg twice daily given for up to 15 weeks
62610623|NCT03178630||Patients with autoimmune liver disease|"Patients with autoimmune liver disease~Patients (6-23 y.o.) with established clinical diagnosis of AIH or suspected diagnosis of AIH based on elevated serum AST or ALT, elevated IgG level \>1.1 ULN, elevated titer of autoantibodies, including ANA, SMA, LKM, LC-1 or SLA, which is consistent with the simplified criteria for the diagnosis of AIH in children will be enrolled.~Patients (6-23 y.o.) with established clinical diagnosis of PSC or Suspected diagnosis of PSC supported by abnormal cholangiogram (ERCP or MRCP) or elevated GGT\>1.5 ULN and dilated bile ducts by liver ultrasound will be enrolled."
62610624|NCT06730646|EXPERIMENTAL|Health effects|Participants will receive messages with information about smoking-related diseases.
62610625|NCT06730646|EXPERIMENTAL|Tobacco industry manipulation|Participants will receive messages with information about how the tobacco industry uses targeted marketing and manipulative tactics aimed at youth and young adults.
62610626|NCT06730646|EXPERIMENTAL|Secondhand smoke|Participants will receive messages with information about secondhand smoke exposure.
62610627|NCT06730646|EXPERIMENTAL|Mental Health|Participants will receive messages with information about the effects of smoking on mental health.
62610628|NCT06730646|EXPERIMENTAL|Social acceptability|Participants will receive messages that portray smoking as socially unacceptable in China.
62833122|NCT00928239|EXPERIMENTAL|1|Arm1: Laparoscopic repair of vaginal vault prolapse. Laparoscopic sacropexy procedure as described in previous publication(Sarlos D, Brandner S, Kots L, Gygax N, Schaer G. Laparoscopic sacrocolpopexy for uterine and post-hysterectomy prolapse: anatomical results, quality of life and perioperative outcome-a prospective study with 101 cases. Int Urogynecol JPelvic Floor Dysfunct. 2008 Oct;19(10):1415-22. Epub 2008 Jun 7. PubMed PMID: 18536861) with attachment to the caudal part of the vagina and the apex.
62610629|NCT06730646|OTHER|Control|Participants will receive messages about bottled water which should have no impact on the outcomes of interest.
62610630|NCT01768091|EXPERIMENTAL|POEM|POEM for patients with esophageal achalasia
62610631|NCT01768091|ACTIVE_COMPARATOR|Pneumatic dilation|Pneumatic dilation for patients with esophageal achalasia
62050420|NCT05297955||The number of CTC in HCC patient great than or equal to two|According to the cutoff of CTC, the number of CTC in HCC patient great than or equal to two
62610632|NCT06730100|EXPERIMENTAL|Treatment (CBX-12)|Patients receive CXB-12 IV over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo x-rays during screening and biopsy, CT, MRI, and blood collection throughout the study.
62050421|NCT05297955||The number of CTC in HCC patient less than two|According to the cutoff of CTC,the number of CTC in HCC patient less than two
62050422|NCT00808587||No Treatment|
62050423|NCT03418116|EXPERIMENTAL|Argus II|"Implantation of the Argus II Retinal Prosthesis in patients with advanced Retinitis Pigmentosa who have a measurable central residual visual field smaller than or equal to 5 degrees radius. The array will be placed parafoveally, adjacent to the preserved central visual field (i.e., tunnel vision) in these subjects."
62610633|NCT03617861|EXPERIMENTAL|Healthy Controls: Secretin Then Placebo|Healthy subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.
62610634|NCT03617861|EXPERIMENTAL|Healthy Controls: Placebo Then Secretin|Healthy subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.
62050424|NCT01995487|EXPERIMENTAL|BioNIR|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:~* Stent - a mounted Cobalt Chromium (CoCr) alloy based stent~* Delivery System - Rapid Exchange (RX) Coronary System~* Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~* Ridaforolimus drug - CAS Registry Number: 572924-54-0~The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
62050425|NCT01995487|ACTIVE_COMPARATOR|Resolute|"The Endeavor Resolute Zotarolimus-Eluting Stent System consists of four subsystems:~1. Endeavor Resolute Stent- a pre-mounted cobalt alloy based stent~2. Delivery system (Rapid Exchange \[RX\] Coronary System)~3. Polymer system~4. Zotarolimus - drug The Resolute has a nominal drug dose of 1.6µg Zotarolimus per mm2 of the stent surface area."
62050426|NCT05727410|EXPERIMENTAL|nivolumab, docetaxel, cisplatin Group|nivolumab, docetaxel, cisplatin (IV infusion every 3 weeks)
62050427|NCT01878929|ACTIVE_COMPARATOR|Allergen(Tree, Grass, Weeds) -Held|"Allergen(Tree, Grass, Weeds)-Held~Weekly administration of Greer manufactured allergen extract at same dose and concentration patient was on prior to allergen season for the duration of patients allergen season."
62050428|NCT01878929|ACTIVE_COMPARATOR|Allergen(Tree, Grass, Weeds) -Build-up|"Allergen(Tree, Grass, Weeds) -Build-up~Weekly administration of Greer manufactured allergen extract at escalating dose and concentration patient for the duration of patients allergen season."
62050429|NCT03861910||extensively hydrolyzed casein formula+LGG|subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG as exclusion diet
62050430|NCT03861910||extensively hydrolyzed whey formula;|subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed whey formula as exclusion diet
62441524|NCT02036281|EXPERIMENTAL|SP-SAP ARM|The first subject will be enrolled in the 1-mcg SP-SAP cohort. A percutaneous intraspinal catheter will be placed at the L5-S1 interspace and the catheter advanced 4-5 cm into the intrathecal space under fluoroscopic guidance. To confirm location, CSF will be aspirated and radioopaque contrast dye injected. 1-mL study drug will be mixed with 1-mL patient CSF fluid and administered intrathecally via the catheter. The catheter will be flushed with 1 mL bolus of saline. Four hours after injection (+15 min), the catheter will be removed and the exit site treated with Neosporin ointment and sterilely dressed. Subjects will be monitored in the recovery room for 4 hours and in the hospital for 24 hours and discharged home. Patients only receive a single IT dose.
62610635|NCT03617861|EXPERIMENTAL|Functional Dyspepsia: Secretin Then Placebo|Functional Dyspepsia subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.
62610636|NCT03617861|EXPERIMENTAL|Functional Dyspepsia: Placebo Then Secretin|Functional Dyspepsia subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.
62610637|NCT06286475|EXPERIMENTAL|Part 1: VRG50635 Sequence A, B, C|Participants will receive a single dose of VRG50635 in each of 3 treatment periods separated by 14-day washout periods.
62610638|NCT06286475|EXPERIMENTAL|Part 1: VRG50635 Sequence B, A, C|Participants will receive a single dose of VRG50635 in each of 3 treatment periods separated by 14-day washout periods.
62610639|NCT06286475|EXPERIMENTAL|Part 2: Cohort 1 VRG50635|Participants will receive VRG50635 (Dose X) for 14 consecutive days.
62610640|NCT06286475|PLACEBO_COMPARATOR|Part 2: Cohort 1 Placebo|Participants will receive VRG50635-matching placebo for 14 consecutive days.
62050431|NCT03861910||hydrolyzed rice formula|subjects with IgE mediated cow milk allergy treated with hydrolyzed rice formula as exclusion diet
62050432|NCT03861910||soy based formula|subjects with IgE mediated cow milk allergy treated with soy based formula as exclusion diet
62050433|NCT03861910||amino-acid based formula|subjects with IgE mediated cow milk allergy treated with amino-acid based formula as exclusion diet
62050434|NCT06186141|ACTIVE_COMPARATOR|Intravenous (IV) Morphine Patient controlled analgesia (PCA)|Morphine PCA IV 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout- as per current RCH Children's Pain Management Service (CPMS) dosing and use.
62050435|NCT06186141|ACTIVE_COMPARATOR|IV Oxycodone PCA|Oxycodone PCA IV 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout- as per current RCH Children's Pain Management Service (CPMS) dosing and use.
62050436|NCT01559233|EXPERIMENTAL|FPlus|
62050437|NCT01751126|EXPERIMENTAL|Ciclosporin|One drop of ciclosporin (NOVA22007) 1 mg/ml 4 times a day as monotherapy (morning, noon, afternoon and evening).
62050438|NCT01751126|EXPERIMENTAL|Ciclosporin/Placebo|One drop of ciclosporin (NOVA22007) 1 mg/ml twice a day and one drop of placebo twice a day (active study treatment morning and evening and placebo noon and afternoon) as monotherapy.
62050439|NCT01751126|PLACEBO_COMPARATOR|Placebo|One drop of placebo 4 times a day as monotherapy (morning, noon, afternoon and evening).
62050440|NCT02929433|EXPERIMENTAL|Cycloergometer group|Training at home with the cycloergometer per 20 minutes twice a day. The protocol suggested a continous use of the cycloergometer for a period of 6 months after 2 weeks of rehabilitation as outpatient.
62050441|NCT02929433|NO_INTERVENTION|Control group|Usual care after a period (2 weeks) of rehabilitation as outpatient.
62610641|NCT06286475|EXPERIMENTAL|Part 2: Cohort 2 VRG50635|Participants will receive VRG50635 (Dose Y) for 14 consecutive days.
62610642|NCT06286475|PLACEBO_COMPARATOR|Part 2: Cohort 2 Placebo|Participants will receive VRG50635-matching placebo for 14 consecutive days.
62610643|NCT00831909||1|All NSCLC patients attending the responsible department of treating this type of patients (e.g. Oncology Department, Pneumology Department) for the first time (regardless of whether the patient is diagnosed with locally, advanced or metastatic disease) at the participating sites from the first of January 2009 to the end of March 2009. Patients diagnosed, or even treated, in other departments within the same hospital or in another hospital are susceptible to be included in the study if full access to the patient's medical record is made available.
62050442|NCT05294796|ACTIVE_COMPARATOR|Short course of antibiotherapy|Patients enrolled in this arm, will receive 8 weeks of antibiotherapy in case of early infection (\< 2 week), and 12 weeks of antibiotherapy in case of delayed infection (2-10 weeks)
62050443|NCT05294796|ACTIVE_COMPARATOR|Long course of antibiotherapy|Patients enrolled in this arm, will receive 12 weeks of antibiotherapy in case of early infection (\< 2 week), and until fracture healing of antibiotherapy in case of delayed infection
62050444|NCT04188379|EXPERIMENTAL|efgartigimod|Patient receiving efgartigimod
62050445|NCT04188379|PLACEBO_COMPARATOR|Placebo|Patients receiving placebo
62050446|NCT01964326|EXPERIMENTAL|Atorvastatin calcium 10 mg|
62050447|NCT04382105||Control|observation of salivary IL-6 levels
62050448|NCT04382105||Periodontitis|observation of salivary IL-6 levels
62050449|NCT02694705|EXPERIMENTAL|CPAP|3 minutes of preoxygenation with a portable ventilator providing Continuous Positive Airway Pressure (CPAP) at 5 cmH20 and an FiO2 of 100%.
62050450|NCT02694705|EXPERIMENTAL|BVM|3 minutes of preoxygenation with a bag-valve-mask (BVM) device and oxygen flow rate of 15 litres / minute.
62050451|NCT02694705|EXPERIMENTAL|NRM|3 minutes of preoxygenation with a non-rebreather mask (NRM) device and oxygen flow rate of 15 litres / minute.
62050452|NCT04843787|EXPERIMENTAL|Experimental: Multiple Ascending Dose Cohort 1|Intervention: SLV213, 8 subjects will receive 200mg oral doses twice a day for seven consecutive days.
62050453|NCT04843787|PLACEBO_COMPARATOR|Placebo Comparator: Multiple Ascending Dose Cohort 1|Intervention: Placebo, 4 subjects will receive an equivalent number of oral doses twice a day for seven consecutive days.
62050454|NCT04843787|EXPERIMENTAL|Experimental: Multiple Ascending Dose Cohort 2|Intervention: SLV213, 8 subjects will receive 400mg oral doses twice a day for seven consecutive days.
62050455|NCT04843787|PLACEBO_COMPARATOR|Placebo Comparator: Multiple Ascending Dose Cohort 2|Intervention: Placebo, 4 subjects will receive the equivalent number of oral doses twice a day for seven consecutive days.
62050456|NCT04843787|EXPERIMENTAL|Experimental: Multiple Ascending Dose Cohort 3|Intervention: SLV213, 8 subjects will receive 800mg oral doses once a day for seven consecutive days.
62050457|NCT04843787|PLACEBO_COMPARATOR|Placebo Comparator: Multiple Ascending Dose Cohort 3|Intervention: Placebo, 4 subjects will receive the equivalent number of oral doses once a day for seven consecutive days.
62441525|NCT01723956|ACTIVE_COMPARATOR|Arm B|LEEP treatment of CIN 2/3 cervical lesion in HIV positive women (standard of Care)
62610644|NCT04893200||Lung adenocarcinoma|Imaging from patients with surgically treated lung adenocarcinoma were collected and processed for the construction of the radiomics-based prediction model
62610645|NCT06152744||High-altitude group|
62050458|NCT04843787|EXPERIMENTAL|Experimental: Multiple Ascending Dose Cohort 4|Intervention: SLV213, 30 subjects will receive the MTD (200mg twice a day, 400mg twice a day or 800 mg once a day) oral doses for seven consecutive days.
62050459|NCT04843787|PLACEBO_COMPARATOR|Placebo Comparator: Multiple Ascending Dose Cohort 4|Intervention: Placebo, 15 subjects will receive the equivalent number of oral doses once a day or twice a day for seven consecutive days.
62050460|NCT03224182|EXPERIMENTAL|Qapzola|Participants were randomized to receive a single dose of Qapzola 8 mg by intravesical administration into the bladder at 60 ± 30 minutes post transurethral resection of bladder tumor (TURBT) on Day 1 via an indwelling 100% Silicone Foley catheter and retained in the bladder for 60 ± 5 minutes.
62050461|NCT03224182|PLACEBO_COMPARATOR|Placebo|Participants were randomized to receive a single dose of Qapzole-matching placebo by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter and retained in the bladder for 60 ± 5 minutes.
62050462|NCT01367028|OTHER|A: Trastuzumab+Docetaxel|
62050463|NCT01367028|EXPERIMENTAL|B: Trastuzumab+Docetaxel+Bevacizumab|
62050464|NCT01367028|EXPERIMENTAL|C: Trastuzumab+Docetaxel+NPLD|
62050465|NCT01367028|EXPERIMENTAL|D: Trastuzumab+Docetaxel+NPLD+Bevacizumab|
62050466|NCT01270269|NO_INTERVENTION|Patients (Controls)|Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
62441526|NCT01723956|EXPERIMENTAL|Arm A|Cryotherapy treatment of CIN 2/3 cervical lesions
62441527|NCT05612347|ACTIVE_COMPARATOR|FIT|FIT (annual)
62441528|NCT05612347|ACTIVE_COMPARATOR|Colonoscopy|Surveillance colonoscopy (one time)
62050467|NCT01270269|EXPERIMENTAL|Behavioral: Phys & Func Rehab|A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.
62610646|NCT06152744||Low-altitude group|
62833123|NCT00928239|ACTIVE_COMPARATOR|2|Arm 2: Laparoscopic repair of vaginal vault prolapse. Laparoscopic sacropexy procedure as described in previous publication(Sarlos D, Brandner S, Kots L, Gygax N, Schaer G. Laparoscopic sacrocolpopexy for uterine and post-hysterectomy prolapse: anatomical results, quality of life and perioperative outcome-a prospective study with 101 cases. Int Urogynecol JPelvic Floor Dysfunct. 2008 Oct;19(10):1415-22. Epub 2008 Jun 7. PubMed PMID: 18536861) with attachment of the dorsal mesh at distal end of vagina at dorsal vaginal wall
62833124|NCT05448196|EXPERIMENTAL|Intervention|Patients randomized to the intervention arm will be enrolled in a four-month coordinated financial navigation program. This program will take a more proactive, coordinated, and systematic approach and includes concrete action plans, and frequent and standardized follow-ups. All patients randomized to the intervention arm will meet with the nurse navigator (NN) for an intake. The NN will introduce navigation services and navigator's NN role and describe the financial navigation program (e.g., goals and expectations of the financial advocacy and social work programs). Next, the navigator will elicit from the patient their potential and current barriers to completing the diagnostic test or treatment. The navigator will then perform proactive outreach to these resources and coordinate an action plan with the patient.
62833125|NCT05448196|NO_INTERVENTION|Usual Care|Patients are connected to financial advocacy and social work on an ad hoc basis, rather than systematically. We hypothesize that many patients who would qualify and benefit from these services are not using them or are being referred late in their treatment course, which is contributing to their financial hardship and adversely affecting their healthcare.
62441529|NCT03797976|EXPERIMENTAL|Parkinson's Disease Group|MIP and MEP Respiratory Function Test Strength Test
62441530|NCT03418883|EXPERIMENTAL|Mirror therapy|Patient is sitting on a conventional chair and placed her/his forearms on a table. A mirror (45 cm × 40 cm) is positioned between the two arms, at right angle with the patient's trunk. The reflective surface is oriented so that the participant could easily see the mirror image of his/her sound arm. Patient practises his/her sound arm with exercises, ranging from the simple elbow flexion-extension to complex tasks.
62610647|NCT02638129|OTHER|Lead-In: Naltrexone/Bupropion + Placebo|Naltrexone hydrochloride (HCl) 8 mg/bupropion HCl 90 mg extended release (ER) combination tablets, orally, once daily for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, once daily for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
62610648|NCT02638129|OTHER|Lead-In: Placebo + Naltrexone/Bupropion|Naltrexone/bupropion placebo-matching tablets, orally, once daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, once daily, for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
62050468|NCT01270269|EXPERIMENTAL|Behavioral: Cog/Phys/Func Rehab|A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
62050469|NCT03769779|EXPERIMENTAL|Treatment|Lutein (FloraGLO™) in safflower oil
62050470|NCT03769779|PLACEBO_COMPARATOR|Placebo|safflower oil
62050471|NCT00673309|EXPERIMENTAL|Growth Hormone|Growth Hormone administered daily until 95% wound healing. Stable Isotope Infusion Study with collection of blood and tissue
62050472|NCT00673309|EXPERIMENTAL|Insulin High Dose|Insulin IV administered continuously to 95% healing. Stable Isotope Infusion Study with collection of blood and tissue
62050473|NCT00673309|EXPERIMENTAL|Oxandrolone|Oxandrolone administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
62050474|NCT00673309|EXPERIMENTAL|Propranolol|Propranolol administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
62050475|NCT00673309|EXPERIMENTAL|IGF-1/IGFBP-3|IGF-1/IGFBP-3 will be administered until 95% wound healing
62050476|NCT00673309|EXPERIMENTAL|Insulin Low Dose|Insulin Low Dose will be administered until 95% wound healing.
62050477|NCT00673309|EXPERIMENTAL|Itraconazole|Itraconazole will be administered until 95% wound healing.
62050478|NCT00673309|EXPERIMENTAL|Growth Hormone and Propranolol|Growth Hormone and Propranolol will be administered until 95% wound healing.
62050479|NCT00673309|EXPERIMENTAL|Oxandrolone and Propranolol|Oxandrolone and Propranolol will be administered until 95% wound healing
62251996|NCT06452966|EXPERIMENTAL|intervention group|"patients in the group will recived one of or a combination of the following intervantions:~1. Oral Chinese medicine decoction:~   The Chinese medicine practitioner will personally examine the patient and judge the patient's condition through the four diagnostic methods of traditional Chinese medicine(TCM): sight, smell, inquiry, and incision. Based on the syndrome differentiation and treatment of the patient's condition, he or she will prescribe an oral Chinese herbal decoction, two to three times a day, for two weeks.~2. Acupuncture or low level laser acupuncture treatment:~Chinese medicine practitioners select acupuncture points for treatment based on the patient's condition and treat them twice a week for 20 minutes each time for a total of two weeks.~the intervantion depents on the TCM doctor decision based on the patient's diagnosis and needs.~in addition, the patients will recive ICU care and medication based on patient's needs."
62251997|NCT06452966|ACTIVE_COMPARATOR|control group|the patients in this group will receive routine ICU care. the patients will be recruted during the study period. the patients will not recive TCM intervantions.
62251998|NCT06452966|OTHER|Historical control|Patients admitted to the same ICU in the period of 01.2019 to 12.2023. the patients did not recivied TCM intervantions
62251999|NCT00856960|ACTIVE_COMPARATOR|1|Aliskiren 600 mg
62252000|NCT00856960|ACTIVE_COMPARATOR|2|Aliskiren 150 mg
62833126|NCT00533117|EXPERIMENTAL|Dialectical Behavior Therapy Fluoxetine|Dialectal behavior therapy (DBT) is a form of Cognitive behavior therapy (CBT) targeting suicidal and non-suicidal self injury in borderline personality disorder and is delivered over a 12 month period,and fluoxetine, a selective serotonin reuptake inhibitor (SSRI) that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
62050480|NCT00673309|PLACEBO_COMPARATOR|Control/Placebo|Placebo or Control will be administered until 95% wound healing
62050481|NCT03511911|EXPERIMENTAL|GROUP A1|In GROUP A1, participants are all healthy women.A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the participant her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,participants in group A1 will be tested by inspector B twice in the same way as what they have done the first day.
62050482|NCT03511911|EXPERIMENTAL|GROUP A2|In GROUP A2,participants are all healthy women.A gynecological physician evaluates participant's pelvic floor muscle strength by vaginal palpation without telling the participant her result, and records it on a unique paper other than in the Case Report Form as what GROUP A1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,participants in group A2 will be tested by inspector A twice in the same way as what they have done the first day.
62252001|NCT00856960|ACTIVE_COMPARATOR|3|Losartan 100 mg
62252002|NCT00856960|PLACEBO_COMPARATOR|4|Placebo
62252003|NCT01848184||PARIETEX™ Composite Ventral Patch|PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra-peritoneal positioning
62252004|NCT04651543||no control X-Ray|patients with a proximal humeral fracture without one-week X-Ray control
62252005|NCT04651543||one-week X-Ray control|patients with a proximal humeral fracture with one-week X-Ray control
62252006|NCT01932242|EXPERIMENTAL|Sequence A|An intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Days 1 and 14 and an intravenous dose of ETI-204-Placebo infused over 90 minutes on Day 120.
62252007|NCT01932242|EXPERIMENTAL|Sequence B|An intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Days 1 and 120 and an intravenous dose of ETI-204-Placebo infused over 90 minutes on Day 14.
62252008|NCT00498160|EXPERIMENTAL|Living or Deceased Donor Kidney Allograft|Recipients with the need for a living kidney allograft are treated with an enriched hematopoetic stem cell infusion from the same living donor. Recipients with the need for a deceased donor kidney allograft are treated with an enriched hematopoetic stem cell infusion from the same deceased donor
62610649|NCT02638129|ACTIVE_COMPARATOR|Naltrexone/Bupropion|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet, in the morning (AM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet in the AM and one in the evening (PM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
62050483|NCT03511911|EXPERIMENTAL|GROUP B1|In GROUP B1,patients are all with pelvic floor disorders.A gynecological physician evaluates the patient's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the patient her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,patients in group B1 will be tested by inspector B twice in the same way as what they have done the first day.
62050484|NCT03511911|EXPERIMENTAL|GROUP B2|In GROUP B2,patients are all with pelvic floor disorders.A gynecological physician evaluates the patient's pelvic floor muscle strength by vaginal palpation without telling patient her result, and records it on a unique paper other than in the Case Report Form as what GROUP B1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,patients in group B2 will be tested by inspector A twice in the same way as what they have done the first day.
62610650|NCT02638129|PLACEBO_COMPARATOR|Placebo|Naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
62050485|NCT03511911|EXPERIMENTAL|GROUP C1|In GROUP C1,participants are all female who give birth to a child within a year(compliance and twice assessment are guaranteed,but PFMT are not allowed during the interval).A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the participant her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,participants in group C1 will be tested by inspector B twice in the same way as what they have done the first day.
62050486|NCT03511911|EXPERIMENTAL|GROUP C2|In GROUP C2,participants are all female who give birth to a child within a year(compliance and twice assessment are guaranteed,but PFMT are not allowed during the interval).A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation without telling patient her result, and records it on a unique paper other than in the Case Report Form as what GROUP C1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,participants in group C2 will be tested by inspector A twice in the same way as what they have done the first day.
62610651|NCT03924505|EXPERIMENTAL|Organize and Mobilize for Implementation Effectiveness|Our approach was based on the Implementation Sustainment Facilitation (ISF), which is grounded in the theory of implementation effectiveness, and added discrete strategies from the Addiction Technology Transfer Center (ATTC), which were considered necessary elements from the original ISF trial. In addition to receiving the OEND best practice recommendations, our multi-component approach used external facilitation as the overarching strategy, by which seven other strategies were leveraged to support SSP staff and leadership. In addition to external facilitation, the multi-faceted approach included: organize implementation team meetings, identify and prepare champions, develop and organize quality monitoring system, assess for readiness and identify barriers, distribute educational materials and resources, conduct educational meetings, and provide ongoing consultation.
62610652|NCT03924505|ACTIVE_COMPARATOR|Dissemination of Best Practice Recommendations|This arm will receive the best practice recommendations for implementing overdose education and naloxone distribution within syringe services programs.
62610653|NCT01537276|EXPERIMENTAL|real-time fluoroscopy|evaluating the tubal patency and pathology under fluoroscopy real-timely
62610654|NCT01537276|NO_INTERVENTION|respective image|evaluating the tubal patency and pathology by Two supine and two oblique static images.
62050487|NCT00717639|EXPERIMENTAL|1|single arm study, all patients will undergo Vasovist-enhanced MRA
62610655|NCT06080906|EXPERIMENTAL|Tolldlers (7-71 months old, two-dose)|Inactivated Rotavirus vaccine (Vero cell) in toddlers aged 7-71 months old on Day 0, 28
62610656|NCT06080906|EXPERIMENTAL|Infants (2-6 months old, three-dose)|Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on Day 0, 28, 56
62610657|NCT06080906|PLACEBO_COMPARATOR|Placebo in Tolldlers (7-71 months old, two-dose)|Two doses of placebo at the vaccination schedule of Day 0, 28
62050488|NCT05736341|EXPERIMENTAL|Remimazolam|Patient group who receives remimazolam for sedation after delivery
62610658|NCT06080906|PLACEBO_COMPARATOR|Placebo in Infants (2-6 months old, three-dose)|Three doses of placebo at the vaccination schedule of Day 0, 28, 56
62610659|NCT00382395|EXPERIMENTAL|1|SOLX Gold Shunt
62610660|NCT00382395|ACTIVE_COMPARATOR|2|Control Ahmed FP7 Shunt
62050489|NCT05736341|ACTIVE_COMPARATOR|Midazolam|Patient group who receives midazolam for sedation after delivery
62610661|NCT02918643|ACTIVE_COMPARATOR|Application|7 physicians will receive an application to tablet device with information about potentially inappropriate medications for elderly and access for consultation of the portal of evidence-based health
62610662|NCT02918643|SHAM_COMPARATOR|Control|7 physicians will receive a tablet with internet access for consultation of the portal of evidence-based health
62610663|NCT04279782||Exclusion group|Patients with two consecutive negative results of detection for 2019 Novel Coronavirus nucleic acid from pharyngeal swabs
62610664|NCT04279782||Confirmed group|Patients with positive result of detection for 2019 Novel Coronavirus nucleic acid from pharyngeal swab
62610665|NCT04022356|EXPERIMENTAL|Connected soles|Number of steps recorded by the soles (activation per smartphone)
62610666|NCT04022356|ACTIVE_COMPARATOR|Gold Standard|Number of steps counted by two observers viewing the film
62610667|NCT06040502|EXPERIMENTAL|The DICE Approach|Training of clinic staff to work with caregivers in the approach.
62610668|NCT03211429|ACTIVE_COMPARATOR|Cognitive behavioural therapy|The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity, in order to increase their physical, social and functional activities. The cognitive behavioural intervention program, provides by psychologists, consists of eight group sessions, 60 minutes each. During each session a main theme is addressed. The themes of the program are: concerns about falls; thoughts about falling; physical exercise; asserting oneself; overcoming personal barriers; safe behaviour; and managing concerns about falls.
62833127|NCT00533117|PLACEBO_COMPARATOR|Dialectical Behavior Therapy placebo|Dialectal behavior therapy and placebo Dialectal behavior therapy (DBT) is a form of Cognitive behavior therapy targeting suicidal and non-suicidal self injury in borderline personality disorder and is delivered over a 12 month period, and placebo for fluoxetine, an SSRI that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
62833128|NCT00533117|EXPERIMENTAL|Supportive therapy Fluoxetine|Supportive psychotherapy and fluoxetine Supportive therapy is a manualized psychotherapy aimed at strengthening coping skills and is delivered over a 12 month period, and fluoxetine, an SSRI that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
62833129|NCT00533117|ACTIVE_COMPARATOR|Supportive therapy placebo|Supportive psychotherapy and placebo See above for descriptions.
62833130|NCT02928614|EXPERIMENTAL|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
62833131|NCT02928614|PLACEBO_COMPARATOR|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
62833132|NCT03918837|SHAM_COMPARATOR|Sham rTMS|"The investigators will perform sham rTMS at 30% of the Motor Threshold, with a 1Hz frequency and 1200 pulses during one session. The target will be the right Orbito Frontal Cortex, localized using Neuronavigation. Sessions will last fifteen minutes; subjects will perform two sessions a day during five days. The coil will have a 180° rotation compared to the active coil position, thus making the magnetic field ineffective on the patient's cortex.~Participants will undergo a MRI with anatomical and ASL sequences one week before and four weeks after treatment.~All participants of this group will have the opportunity to undergo an active rTMS treatment right after the end of each one's participation in the study."
62050490|NCT03171701||maturation of arteriovenous fistula|
62050491|NCT01876290|EXPERIMENTAL|Dexamethasone and Ondansetron|Each patient will receive Dexamethasone and Ondansetron
62050492|NCT01876290|PLACEBO_COMPARATOR|Placebo|Each patient will receive placebo instead of Dexamethasone and Ondansetron
62610669|NCT03211429|ACTIVE_COMPARATOR|Tai chi|Subjects in the Tai Chi group undertook supervised Tai Chi training in the Yang style of 24 movements, for one hour, once a week for 8 weeks. The first 5 min was allocated for warm-up, with the rest of the time for Tai Chi practice.
62610670|NCT03211429|ACTIVE_COMPARATOR|Postural control exercise|Individually adjusted progressive and specific postural control training, provided by physiotherapists for one hour, one time per week for 8 weeks. The exercise is progressive and specific to functional postural control tasks. It comprises elements that represent activities included in, and required for, independent daily living, such as maintaining balance when sitting, standing and walking; and also reacting to loss of balance.
62252009|NCT02841098|EXPERIMENTAL|Carotid endarterectomy combined with optimal medical therapy|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)
62833133|NCT03918837|ACTIVE_COMPARATOR|Active rTMS|"The investigators will perform active rTMS at 120% of the Motor Threshold, with a 1Hz frequency and 1200 pulses during one session. The target will be the right Orbito Frontal Cortex, localized using Neuronavigation. Sessions will last fifteen minutes; subjects will perform two sessions a day during five days.~Participants will undergo a MRI with anatomical and ASL sequences one week before and four weeks after treatment"
62050493|NCT03493230|EXPERIMENTAL|Patient with malignant melanoma|Patient with advanced or metastatic malignant melanoma (stage IIIB inoperable or IIIC or stage IV) will have a first blood test before any treatment, then at day 15 or 30 after initiation of therapy, and every two months until recurrence or progression for a maximum of 22 months.
62050494|NCT04467385|EXPERIMENTAL|Experimental Group|Virtual Reality training(VR) + Sensory Integration therapy + conventional therapy
62050495|NCT04467385|EXPERIMENTAL|Control Group|VR training + conventional therapy
62050496|NCT04995848|EXPERIMENTAL|Telepalliation group|"The intervention group will participate in the telepalliation program. The patients will lent a tablet during the RCT study to access the TelePal.dk platform an video consultations. The patients will participate from the time they are referred to palliative care, and are enrolled in the telepalliation program for up to six months or until:~1. They stop being followed by the Palliative Team due to lack of symptoms~2. They are diagnosed with delirium based upon clinical guidelines and the Confusion Assessment Method (CAM). The assessment of delirium will be done by either:~   * The project nurse or the clinical responsible doctor at the patients' home OR~  * A district nurse under video supervision by the project nurse or the clinical responsible doctor~3. Death of the patient"
62050497|NCT04995848|NO_INTERVENTION|Conventional palliation program|"The control group will follow a conventional palliation program. The patients will participate from the time they are referred to palliative care, and are enrolled in the telepalliation program for up to six months or until:~1. They stop being followed by the Palliative Team due to lack of symptoms~2. They are diagnosed with delirium based upon clinical guidelines and the Confusion Assessment Method (CAM). The assessment of delirium will be done by either:~   * The project nurse or the clinical responsible doctor at the patients' home OR~  * A district nurse under video supervision by the project nurse or the clinical responsible doctor~3. Death of the patient"
62050498|NCT00529490|EXPERIMENTAL|HL|Hypertonic lactate group
62050499|NCT00529490|ACTIVE_COMPARATOR|RL|Ringer's lactate
62050500|NCT00316173|EXPERIMENTAL|Single-arm|HYCAMTIN at a dose of 2.0 - 2.5mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1, every 21 days
62050501|NCT06525766|EXPERIMENTAL|Treatment (capecitabine)|See Detailed Description.
62252010|NCT02841098|ACTIVE_COMPARATOR|Optimal medical therapy (OMT)|Optimal medical therapy (OMT)
62833134|NCT04605172||Lockdown Group|newborn born prematurely during confinement (1st March - 1st June 2020)
62833135|NCT04605172||Control group|newborn born prematurely in comparative years over the same period (1st March - 1st June from 2015 to 2019)
62833136|NCT05461209|EXPERIMENTAL|Arm A: Talquetamab|Participants will receive talquetamab subcutaneously (SC).
62833137|NCT05461209|ACTIVE_COMPARATOR|Arm B: Belantamab Mafodotin|Participants will receive belantamab intravenously (IV).
62833138|NCT02416336|EXPERIMENTAL|Sentinella intraoperative use|"Standard of care intraoperative protocol~1. Localize SLN with the Gamma Probe for In vivo count~2. Optional (time permitting during surgical prep). Image same SLN with Sentinella (Pre-incision)~3. Surgically remove/excise localized SLN~4. Ex vivo count - excised SLN with Gamma Probe~5. In vivo background/roaming count with Gamma Probe~6. Repeat step 1-5, until no SLNs are found with the Gamma Probe (negative reading)~Sentinella intraoperative imaging protocol~1. Survey surgical field/Post-excision control with Sentinella for remaining SLNs~2. If focal uptake seen in step 1, search for these occult SLNs with Gamma Probe and remove localized additional SLNs~3. Record information on data sheet for each excised SLN with Gamma Probe and Sentinella"
62050502|NCT04526535||No B-lines|Patients with no significant B lines in the lung ultrasound at first 24 hours after acute myocardial infarction (any field with 3 or more B-lines)
62050503|NCT04526535||B lines|Patients with significant B lines in the lung ultrasound at first 24 hours after acute myocardial infarction (3 or more B-lines in at least one lung field)
62252011|NCT01415011|EXPERIMENTAL|Afatinib (BIBW 2992)|All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
62252012|NCT06091085|EXPERIMENTAL|Acetazolamide|Acetazolamide administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2x250mg pills) for 2 nights
62252013|NCT06091085|PLACEBO_COMPARATOR|Placebo|Placebo sugar pills administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2 pills) for 2 nights
62833139|NCT05955248|PLACEBO_COMPARATOR|Control (CTRL)|Participants will be treated following Enhanced Recovery After Surgery (ERAS) protocols + placebo supplements containing maltodextrin and sunflower oil
62252014|NCT00518999||1|Schizophrenia patients who performed earlier cognitive assessment as part of routine assessment for patients in the Shalvata Mental Health Center.
62833140|NCT05955248|ACTIVE_COMPARATOR|Mixed-nutriend supplement (NUT)|Mixed nutrient supplement containing whey protein, leucine, vitamin D and omega 3 fatty acids
62833141|NCT05955248|ACTIVE_COMPARATOR|Multi-modal intervention (MM)|Multimodal prehabilitation including structured exercise (1 supervised exercise session per week + home-based exercise program), nutritional optimization with dietician, NUT intervention, and relaxation strategies.
62833142|NCT06097494||People with Vitiligo|Children and adults with new onset Vitiligo registered with OPCRD during the study period.
62833143|NCT06097494||People without Vitiligo|Children and adults without Vitiligo registered with OPCRD during the study period
62050504|NCT04050241|EXPERIMENTAL|Videolaryngoscope|Anesthetists performing intubation with the Glidescope videolaryngoscope.
62610671|NCT06093867||allogeneic HSCT|Up to 30 men or women, 18 - 70 years of age, who are being treated with allogeneic HSCT for a hematologic malignancy, blood, or immune system disorder at the NIH Clinical CenterUp to 10 children 5 - 17 years of age who are being treated with allogeneic HSCT for a hematologic malignancies, blood, or immune system disorder at the NIH Clinical CenterNIH Clinical Center
62610672|NCT02071602|PLACEBO_COMPARATOR|Placebo|Placebo infused for up to 72 hours IV
62833144|NCT00519441|OTHER|I|All patients in the study will have pH studies done in order to determine the degree of reflux after laparoscopic Heller myotomies.
62050505|NCT04050241|EXPERIMENTAL|Direct laryngoscope|Anesthetists performing intubation with the Mcintosh laryngoscope.
62050506|NCT00350974||End-stage Renal Disease|on maintenance hemodialysis 3 x per week for more than 12 months
62050507|NCT00350974||No kidney disease|eGFR greater than 60 ml/Min
62610673|NCT02071602|ACTIVE_COMPARATOR|CD-NP 5 ng/kg/min|CD-NP 5 ng/kg/min infused for up to 72 hours IV
62610674|NCT02071602|PLACEBO_COMPARATOR|CD-NP 10 ng/kg/min|CD-NP 10 ng/kg/min infused for up to 72 hours IV
62833145|NCT00112996|EXPERIMENTAL|Arm I: Alpha-Lipoic Acid|Oral alpha-lipoic acid three times daily for at least 24 weeks in the absence of unacceptable toxicity.
62833146|NCT00112996|PLACEBO_COMPARATOR|Arm II: Placebo|Oral placebo three times daily for at least 24 weeks in the absence of unacceptable toxicity.
62833147|NCT00936767|EXPERIMENTAL|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
62050508|NCT00350974||Hypertensive group|Blood pressure greater than 130/80
62050509|NCT00648128|ACTIVE_COMPARATOR|2|
62050510|NCT00648128|EXPERIMENTAL|1|
62833148|NCT00936767|ACTIVE_COMPARATOR|Artesunate/Mefloquine (MAS3)|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
62833149|NCT03218046|EXPERIMENTAL|EMDR group|This is the treatment arm that will receive EMDR therapy
62050511|NCT02062359|EXPERIMENTAL|All Participants|Patients will receive the standard National Cancer Institute (NCI) Surgery Branch non-myeloablative, lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of the anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ engineered peripheral blood lymphocyte (PBL) and aldesleukin
62050512|NCT03027648|OTHER|patients with LNG-IUS|Placement of levonorgestrel-releasing intrauterine system
62610675|NCT00217737|ACTIVE_COMPARATOR|Arm A (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
62610676|NCT00217737|EXPERIMENTAL|Arm B (combination chemotherapy, bevacizumab)|Patients receive oxaliplatin, leucovorin calcium, and fluorouracil as in Arm A and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone for 12 additional courses in the absence of disease progression or unacceptable toxicity.
62050513|NCT01116492|ACTIVE_COMPARATOR|Lap Group|Patients in this group are operated for uncomplicated cholelithiasis with standard 4 port laparoscopic cholecystectomy
62610677|NCT00217737|NO_INTERVENTION|Arm C (observation)|Patients undergo observation.
62610678|NCT06709014|EXPERIMENTAL|buntanetap|
62610679|NCT06709014|PLACEBO_COMPARATOR|Placebo|
62833150|NCT03905018|EXPERIMENTAL|tadalafil|Male patients aged 25-60 years, BMI ≥30, without comorbidities will be included. They should not be under treatment with iPDE5 or statins, nor should they have uncontrolled ischemic heart disease. To carry out this test, two groups will be created: the first will receive a single dose of tadalafil 20 mg orally
62833151|NCT03905018|PLACEBO_COMPARATOR|calcined magnesia (placebo)|Male patients aged 25-60 years, BMI ≥30, without comorbidities will be included. They should not be under treatment with iPDE5 or statins, nor should they have uncontrolled ischemic heart disease. To carry out this test, two groups will be created: the second will receive 20 mg of calcined magnesia (placebo),after a single administration
62050514|NCT01116492|ACTIVE_COMPARATOR|SILS group|Patients in this group are operated for uncomplicated cholelithiasis with Single Incision Laparoscopic Cholecystectomy
62050515|NCT05374564|EXPERIMENTAL|18F-flutemetamol|All clinical trial subjects will receive 18F-flutemetamol
62050516|NCT03346720||Participants recruited into biomedical research|Participants recruited into biomedical research where data collected may be shared with the wider research community.
62610680|NCT02380391||People living with HIV (HIV+)|Adults experiencing first episode of ACS treated with percutaneous coronary intervention.
62050517|NCT03346720||Frontline research staff|Frontline research staff directly involved in obtaining consent from participants in the above studies e.g. study nurses, investigators
62610681|NCT02380391||People without HIV (HIV-)|Adults experiencing first episode of ACS treated with percutaneous coronary intervention, matched to HIV+ on age, sex, known diabetes mellitus, and anti-platelet therapy.
62610682|NCT01731769|ACTIVE_COMPARATOR|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
62050518|NCT03346720||Research related staff and other stakeholders|Research related staff and other stakeholders involved in the implementation of the data sharing policy e.g. study managers, data access committee members, ethics committee members, study nurses, investigators, research collaborators, data managers and other clinical trials support staff.
62610683|NCT01731769|EXPERIMENTAL|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
62610684|NCT05702411|EXPERIMENTAL|Protocol 1|Closed system aspiration with an expiratory pause of 10 seconds followed by hyper insufflation maneuver with the Air Stacking technique.
62610685|NCT05702411|EXPERIMENTAL|Protocol 2|Closed system aspiration with an expiratory pause of 10 seconds.
62610686|NCT03404258||Study Patients|Infants between 1 month and 2 years of age undergoing evaluation for SCPA candidacy.
62610687|NCT03404258||Control Patients|Infants between 3 months and 12 months of age with no known cardio-pulmonary disease, no active infection, and no known genetic abnormality undergoing elective surgery for a non-cardiac indication.
62833152|NCT00059462|EXPERIMENTAL|Arm 1|
62833153|NCT00059462|ACTIVE_COMPARATOR|Arm 2|
62833154|NCT06414629|EXPERIMENTAL|Intervention Group/ Intervention Birthing Center|The nurses working in the Intervention Birthing Centers received the Simulation Based Mentorship Program.
62833155|NCT06414629|NO_INTERVENTION|Control Group/ Control Birthing Center|The nurses working in the Intervention Birthing Centers did not receive the Simulation Based Mentorship Program.
62050519|NCT03346720||Community advisory board members|Community advisory board members and other community members
62050520|NCT02464813|ACTIVE_COMPARATOR|Pregabalin|Pregabalin in hard capsule 2mg/kg rounded up to next 25mg twice daily, max 150mg x 2, for 5 days.
62050521|NCT02464813|PLACEBO_COMPARATOR|Sugar pill|Same hard capsule and same amount of tablets twice daily for 5 days.
62050522|NCT03570398|OTHER|Abdominal CT|
62050523|NCT03570398|OTHER|Abdominal Ultrasound|
62050524|NCT03297203|EXPERIMENTAL|groupe1|patients in septic shock (group 1) in the medical intensive care unit of the Timone Hospital.
62050525|NCT03297203|ACTIVE_COMPARATOR|groupe 2|patients with a bacterial sepsis alone, during a 6 months period.
62610688|NCT04559035|OTHER|Betadine|"Intervention - twice-a-day nasal lavage Twice-a-day virucidal group: Participants randomized to betadine will receive 2 gallon jugs of distilled water, two NeilMed Sinus Irrigation bottles and 28 salination packets (with some extras), OR one Navage unit with 28 SaltPods (and some extras), and a cardboard receptacle labeled used saline containers to keep track of adherence.~Those randomized to receive betadine will also receive one bottle of povidone-iodine, a one-sheet instruction with photographs demonstrating how to add ½ tsp betadine in addition to the salination packet to the sinus irrigation bottle or Navage unit reservoir prior to SaltPod, along with a ½ tsp measuring spoon."
62610689|NCT04559035|OTHER|Baking Soda|"Twice-a-day alkalinized group: Participants randomized to alkalinization will receive 2 gallon jugs of distilled water, two Neilmed bottles with 28 saline packets, OR one Navage unit with 28 SaltPods, and a cardboard receptacle labeled used saline containers to keep track of adherence. Those randomized to alkalinization will also receive a box of baking soda, ½ tsp measuring spoon and instructions on how to add the baking soda."
62610690|NCT04812795|EXPERIMENTAL|Culturally tailored (Non-smokers)|"The anti-smoking and anti-industry messages will be culturally tailored to specifically reach out to young adult SMW. They will receive only messages that are culturally tailored at baseline and weeks 1, 2, and 3.~Culturally tailored anti-smoking messages: Anti-smoking messages that are culturally tailored for sexual minority women."
62610691|NCT04812795|ACTIVE_COMPARATOR|Non-culturally tailored (Non-smokers)|"The anti-smoking and anti-industry messages will not be culturally tailored. They will receive only messages that are not culturally tailored at baseline and weeks 1, 2 and 3.~Non-culturally tailored interventions: Anti-smoking messages that are not culturally tailored for sexual minority women."
62610692|NCT04812795|EXPERIMENTAL|Culturally Tailored (Smokers)|"The anti-smoking and anti-industry messages will be culturally tailored to specifically reach out to young adult SMW. They will receive only messages that are culturally tailored at baseline and weeks 1, 2, and 3.~Culturally tailored anti-smoking messages: Anti-smoking messages that are culturally tailored for sexual minority women."
62050526|NCT04493931|EXPERIMENTAL|Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg|This is a fixed sequence (Sequence AB) cohort. Participants will receive gepotidacin 1500 milligrams (mg) single dose (SD) on Day 1 of Period 1 (Treatment A); and Cimetidine 400 mg 4 times daily on Days 1 through 4 of Period 2 and gepotidacin 1500 mg single dose (Treatment B). Gepotidacin will be administered 1 hour after the first dose of cimetidine on Day 2 of Period 2. There will be a washout of at least 3 days between Treatment A and Treatment B, and a follow-up visit 5 to 7 days after the last dose of cimetidine.
62050527|NCT04493931|EXPERIMENTAL|Cohort 2: Gepotidacin 1500 mg + Rifampicin 600 mg|This is a fixed sequence (Sequence CDE) cohort. Participants will receive gepotidacin 1500 mg single dose on Day 1 of Period 1 (Treatment C), rifampicin 600 mg (administered in the evenings) once daily for 7 days (Days 1 through 7 of Period 2, to elicit maximal enzyme induction) (Treatment D); and gepotidacin 1500 mg single dose administered in the morning on Day 8 and rifampicin 600 mg administered in the evening on Days 8 and 9 of Period 2 (Treatment E). There will be a washout of at least 3 days between Treatment C and Treatment D, and a follow-up visit 7 to 10 days after the last dose of rifampicin.
62252015|NCT05520437|EXPERIMENTAL|Physically active males|Half of the study population will consist of long-distance runners with 2-5 years of experience in running and similar times in covering the half-marathon distance.
62252016|NCT05520437|EXPERIMENTAL|Physically inactive males|The other half of the study population will consist of age-matched individuals involved in no regular physical activity.
62610693|NCT04812795|ACTIVE_COMPARATOR|Non-culturally Tailored (Smokers)|"The anti-smoking and anti-industry messages will not be culturally tailored. They will receive only messages that are not culturally tailored at baseline and weeks 1, 2 and 3.~Non-culturally tailored interventions: Anti-smoking messages that are not culturally tailored for sexual minority women."
62610694|NCT01902875||TP regimen + CIK group|This group are treated with Preconditioning Chemotherapy （Paclitaxel + Cisplatin） Combined with Cytokine Induced Killer Cell Immunotherapy （CIK cell therapy）.
62252017|NCT02589496|EXPERIMENTAL|pembrolizumab|"Cohort A :gastric cancer patients Cohort B : MSI-H gastric cancer patients All Chort receive the following treatment.~* Pembrolizumab 200 mg every 3 weeks"
62252018|NCT00314626|EXPERIMENTAL|A|abacavir 600 mg + lamivudine (3TC) 300 mg in 1 tablet + efavirenz 600 mg 1/24h
62252019|NCT00314626|NO_INTERVENTION|B|efavirenz + 2 NUCS
62252020|NCT04564963|EXPERIMENTAL|Cryotherapy|Cold therapy
62610695|NCT01902875||TP regimen group|This group are treated with Chemotherapy （Paclitaxel + Cisplatin） only.
62610696|NCT02295761|ACTIVE_COMPARATOR|Lifestyle counseling|12-weeks
62610697|NCT02295761|ACTIVE_COMPARATOR|Lifestyle counseling + activity watch|12-weeks
62610698|NCT06730529||Patients diagnosis of thyroid cancer with lymph node metastases|
62610699|NCT02195726|SHAM_COMPARATOR|Sham remote ischemic preconditioning'|In the control group Sham remote ischemic preconditioning will be performed with inflation of 10 mmHg more than baseline
62833156|NCT06655649|EXPERIMENTAL|Ketone Intervention|Participants with sleep apnea using CPAP will undergo open-label procedures. They will ingest (1) nothing, (2) Ketone IQ 20 g or (3) Ketone IQ 40 g before bedtime and undergo objective and subjective sleep assessments.
62252021|NCT04564963|NO_INTERVENTION|No cryotherapy|Standard practices for pain management
62252022|NCT02036632|OTHER|Eye Patching|Intervention
62252023|NCT03150862|EXPERIMENTAL|Arm A (Dose Escalation)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.
62252024|NCT03150862|EXPERIMENTAL|Arm B (Dose Escalation)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib, radiation therapy (RT) and temozolomide (TMZ).
62252025|NCT03150862|EXPERIMENTAL|Arm A (Dose Expansion)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.
62252026|NCT03150862|EXPERIMENTAL|Arm C (Dose Escalation)|Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.
62252027|NCT03150862|EXPERIMENTAL|Arm C (Dose Expansion-Cohorts C1 and C2)|Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.
62252028|NCT04662944||Licensed anti-VEGFs|Patients being treated for nAMD with licensed anti-VEGFs
62833157|NCT02511548|EXPERIMENTAL|Intervention|Financial incentive
62833158|NCT02511548|NO_INTERVENTION|Control|No financial incentive
62610700|NCT02195726|EXPERIMENTAL|Remote ischemic preconditioning|"In the experimental group, patients will receive for four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg upper than baseline), followed by 5-minute intervals of reperfusion.~In subjects presenting with BMI \> 30 a dedicated blood pressure cuff for obese patients will be used. Coronary angiography will be performed in 45 minutes from last inflation"
62610701|NCT04128488||Transgender women and non-binary individuals without HIV|
62050528|NCT04493931|EXPERIMENTAL|Cohort 3: Digoxin 0.5mg+Midazolam 2mg then Gepotidacin 3000mg|Participants will receive digoxin 0.5 mg and midazolam 2 mg (Treatment F) in Period 1 on Day 1 then gepotidacin two 3000 mg doses (given 12 hours apart) co-administered with digoxin 0.5 mg and midazolam 2 mg in Period 2 on Day 1, with the 2 probe drugs administered with the second daily dose of gepotidacin only (Treatment G). There will be a washout of at least 10 days between treatments. In Sequence 2, these regimens are reversed. A follow-up visit will occur 7 to 10 days after the last dose of study intervention in Period 2.
62252029|NCT02056054||Subjects with d-AIH|Pediatric transplant patients with de novo autoimmune hepatitis (d-AIH) will be enrolled at an outside center.
62252030|NCT02056054||Subjects with Acute Rejection|Pediatric transplant patients with acute rejection will be enrolled at an outside center.
62252031|NCT02056054||Subjects with Chronic Rejection|Pediatric transplant patients with chronic rejection will be enrolled at an outside center.
62252032|NCT02056054||Control Subjects|Healthy pediatric patients will be enrolled at the coordinating center (Yale).
62252033|NCT02056054||Subjects with Auto-immune Hepatitis|Adult non-transplant patients with auto-immune hepatitis will be enrolled at the coordinating center (Yale).
62441531|NCT03418883|SHAM_COMPARATOR|Sham therapy|Patient is sitting on a conventional chair and placed her/his forearms on a table. A box (45 cm × 40 cm) is positioned between the two arms, at right angle with the patient's trunk. The opaque surface replaces the mirror reflecting surface. Patient practises his/her sound arm with exercises,ranging from the simple elbow flexion-extension to complex tasks.
62610702|NCT04128488||Transgender women and non-binary individuals with HIV|
62610703|NCT05903040||Episodic migraine|Patients affected by an episodic pattern (\< 15 monthly headache days) migraine with or without aura according to ICHD-III criteria.
62252034|NCT02056054||Subjects with Chronic Hepatitis C Virus|Adult non-transplant patients with chronic hepatitis C will be enrolled at the coordinating center (Yale).
62252035|NCT02056054||Adult Subjects with d-AIH|Adult transplanted patients with de novo autoimmune hepatitis will be enrolled at the coordinating center (Yale).
62252036|NCT00575536||Rhizotomy for children with spasticity|Children with spasticity needing Rhizotomy surgery
62441532|NCT06484023||Overactive bladder TENSI+ patients|Patients monitored for overactive bladder and using the TENSI + device for at least 3 months
62441533|NCT01172353|EXPERIMENTAL|sodium bicarbonate|hydration with sodium bicarbonate
62610704|NCT05903040||Chronic migraine|Patients affected by chronic migraine according to ICHD-III criteria.
62610705|NCT05595408||adjuvant chemotherapy group|muscle invasive upper tract urothelial carcinoma after radical nephroureterectomy receiving adjuvant chemotherapy
62833159|NCT04444726|EXPERIMENTAL|"Phototherapy PUVA +traditional medical treatmentn"|"patient sock his hands in a bath containing water with the constitution of psoralen meladinine  capsule for 20 minutes then irradiated at the UVA device for 3 sessions per week for 8 weeks Plus the traditional medical treatment. which is the betamethasone dipropionate 0.05%  diprolene for 2 times a day for 8 weeks."
62441534|NCT01172353|ACTIVE_COMPARATOR|saline|hydration with saline 1ml/Kg/h for 6 hours
62441535|NCT03315156||Patients|patients with AOM
62610706|NCT05595408||adjuvant immunotherapy group|muscle invasive upper tract urothelial carcinoma after radical nephroureterectomy receiving adjuvant immunotherapy
62050529|NCT04493931|EXPERIMENTAL|Cohort 3: Gepotidacin 3000mg then Digoxin 0.5mg+Midazolam 2mg|Participants will receive gepotidacin two 3000 mg doses (given 12 hours apart) co-administered with digoxin 0.5 mg and midazolam 2 mg in Period 1 on Day 1, with the 2 probe drugs administered with the second daily dose of gepotidacin only (Treatment G) followed by digoxin 0.5 mg and midazolam 2 mg (Treatment F) in Period 2 on Day 1. A follow-up visit will occur 7 to 10 days after the last dose of study intervention in Period 2.
62050530|NCT04493931|EXPERIMENTAL|Cohort 4: Gepotidacin 1500 mg fed then fasted then 3000 mg fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of gepotidacin 1500 mg under fed conditions in Period 1 (Treatment H), then a single dose of gepotidacin 1500 mg under fasted conditions in Period 2 (Treatment I), followed by two doses of gepotidacin up to 3000 mg (given 12 hours apart) under fed conditions in Period 3 (Treatment J). There will be a washout of at least 3 days between each treatment, and a follow-up visit 5 to 7 days after the last dose of gepotidacin.
62610707|NCT06018545||Readers|30 readers will be recruited across four NHS trusts including ten general radiologists, fifteen emergency medicine clinicians, and five CT radiographers of varying seniority. Readers will interpret each scan first without, then with, the assistance of the AI tool, with an intervening 4-week washout period. Using a panel of neuroradiologists as ground truth, the stand-alone performance of qER will be assessed, and its impact on the readers' performance will be analysed as change in accuracy, mean review time per scan, and self-reported diagnostic confidence. Subgroup analyses will be performed by reader professional group, reader seniority, pathological finding, and neuroradiologist-rated difficulty.
62610708|NCT06018545||Ground truthers|Two Consultant neuroradiologists will independently review the images to establish the 'ground truth' findings on the CT scans which will be used as the reference standard. In the case of disagreement, a third senior neuroradiologist's opinion will be sought for arbitration. A difficulty score will be assigned to each scan by the ground truthers using a 5-point Likert scale.
62610709|NCT05808790|ACTIVE_COMPARATOR|Minimally invasive pulmonary metastasectomy|Minimally invasive parenchymal sparing pulmonary metastasectomy Surgical approach by means of video-assisted thoracic surgery (VATS), robot-assisted (RATS), or uniportal VATS
62252037|NCT04029220|EXPERIMENTAL|Parent Peer Navigation (PPN) by Family Run Organization|In this arm, families receive PPN services from a trained provider with lived experience whose role is to effectively engage parents/caregivers in necessary treatment for their children by helping them connect with assessment, treatment and community-based resources and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support once the PPN is no longer involved. PPN providers use the foundational competencies and skills to educate, inform and support families who are just entering the child-serving systems due to emerging behavioral health issues of their child.
62441536|NCT03158337|EXPERIMENTAL|Aerobic exercise|Participants took part in a supervised 6-month long aerobic (walk/jog) training program held 3 days/week. Each session included a 5-min warm-up, 20-40 min of aerobic exercise (walking, jogging), 5-min cool-down, and stretching. Exercise prescriptions follow current principles and guidelines established by ACSM/AHA, including sufficient warm-up, cooldown, and ongoing provision of safety precautions/exercise tips. As participants progress, the duration of aerobic exercise increased from 20 (month 1) to 30 (months 2-3) and 40 min (months 4-6), with proportional increases to warm-up and cool-down periods. Exercise intensity is based on individual maximal oxygen uptake (VO2 max), measured at baseline. Intensity builds from 30-45% (months 1-3) to mitigate the risk of injury and will progress to 60-70% (months 4-6) heart rate reserve (HRR).
62610710|NCT05808790|EXPERIMENTAL|Stereotactic ablative radiotherapy|Gross tumor volume = tumor visible on CT (+/- PET) No CTV margin will be added (Clinical target volume (CTV) = Gross target volume (GTV)) Planning Target Volume (PTV): GTV plus margins of 3-5mm (varying depending on site, motion, SABR delivery approach)
62441537|NCT03502629|EXPERIMENTAL|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
62441538|NCT00947427|PLACEBO_COMPARATOR|Placebo|Placebo solution given by subcutaneous injection on monthly basis for 12 months
62441539|NCT00947427|EXPERIMENTAL|Canakinumab|Subcutaneous injection of canakinumab at dose of 2.0 mg/kg given monthly of 12 months
62441540|NCT00945425|EXPERIMENTAL|1|Low dose or placebo, twice daily
62441541|NCT00945425|EXPERIMENTAL|2|Low dose or placebo, once daily
62610711|NCT01179789|ACTIVE_COMPARATOR|Optimal Diet|Diet advices will receive the Optimal Diet for Elderly
62050531|NCT04493931|EXPERIMENTAL|Cohort 4: Gepotidacin 1500 mg fasted then fed then 3000 mg fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of gepotidacin 1500 mg under fasted conditions in Period 1 (Treatment I), then a single dose of gepotidacin 1500 mg under fed conditions in Period 2 (Treatment H), followed by two doses of gepotidacin up to 3000 mg (given 12 hours apart) under fed conditions in Period 3 (Treatment J). There will be a washout of at least 3 days between each treatment, and a follow-up visit 5 to 7 days after the last dose of gepotidacin.
62610712|NCT01179789|EXPERIMENTAL|VSL#3|Diet advices + VSL-3: will receive the Optimal Diet for Elderly + VSL#3® probiotic blend
62610713|NCT01179789|EXPERIMENTAL|AISA-5203-L|Diet advices + 5203-L: will receive the Optimal Diet for Elderly + AISA-5203-L fruit extracted terpene
62610714|NCT01179789|EXPERIMENTAL|Argan oil|Diet advices + Argan oil: will receive the Optimal Diet for Elderly + Argan
62610715|NCT03266575|ACTIVE_COMPARATOR|Pulmonary Rehabilitation|Participants will participate in formal Pulmonary Rehabilitation Exercise program
62610716|NCT03266575|ACTIVE_COMPARATOR|Home based program|Participants will participate in a Home based Exercise program
62441542|NCT00945425|EXPERIMENTAL|3|Middle dose or placebo, twice daily
62441543|NCT00945425|EXPERIMENTAL|4|High dose or placebo, once daily
62610717|NCT06004492|PLACEBO_COMPARATOR|blended learning program|8 hours of workshops and four months of practical learning on technology platforms
62610718|NCT06004492|NO_INTERVENTION|conventional education|conventional education
62833160|NCT04444726|EXPERIMENTAL|Tap Water Iontophoresis + Traditional medical treatment|"Tap-water iontophoresis was given 3 times weekly for 10 min The direct current level was slowly increased, guided by the occurrence of tingling sensations. The maximum level was 30mA. Plus the traditional medical treatment. which is the betamethasone dipropionate 0.05%  diprolene for 2 times a day for 8 weeks."
62833161|NCT04444726|ACTIVE_COMPARATOR|traditional medical treatment|"Traditional medical treatment. which is the betamethasone dipropionate 0.05%  diprolene for 2 times a day for 8 weeks."
62833162|NCT01910363|EXPERIMENTAL|A2NTX|single intramuscular injection of 300 units of A2NTX, a purified low molecular weight (150 kDalton) botulinum toxin preparation of type A2
62050532|NCT04493931|PLACEBO_COMPARATOR|Cohort 4: Placebo fed then fasted then fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of placebo under fed conditions in Period 1, then a single dose of placebo under fasted conditions in Period 2, followed by two doses of placebo (given 12 hours apart) under fed conditions in Period 3. There will be a washout of at least 3 days between each period, and a follow-up visit 5 to 7 days after the last dose of placebo.
62252038|NCT04029220|ACTIVE_COMPARATOR|Resources provided by Family Support Organization|"The active comparator is service provided by Family Support Organizations (FSOs), which provide information and resources for families about disabilities, special education and other services as well as workshops and parent support groups. Unlike PPN services, FSO staff members are not veteran caregivers of a child with mental health challenges, do not provide personalized service delivery, do not provide a comprehensive assessment of family needs, and do not prepare families to make use of services through support for their initial and continued involvement in them. Finally, whereas PPNs participate in comprehensive training and coaching, training for FSO staff tends to be more general and consists primarily of being aware of local resources to which families may be referred."
62252039|NCT02742597|ACTIVE_COMPARATOR|Group A|Intervention group (n = 86) Intervention: Participates in Telemedicine Impact Plus (TIP)/ IMPACT Plus Care Coordination meeting
62252040|NCT02742597|ACTIVE_COMPARATOR|Group B|Before/After Intervention group (n = 10) Intervention: Participates in TIP / IMPACT Plus Care Coordination meeting
62252041|NCT02742597|NO_INTERVENTION|Group C|Control group (n = 77)
62252042|NCT02742597|NO_INTERVENTION|Group D|Health Administrative Data Group (n = 430) Number of matched data controls. Not taking part in intervention.
62252043|NCT03568045|ACTIVE_COMPARATOR|Usual care, standard light|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), but otherwise have usual care."
62441544|NCT05890456|EXPERIMENTAL|Treatment Arm|The SWIFT Program is a 9-12 month intervention that includes four components: (a) behavioral progress monitoring, (b) clinical supervision of the intervention elements and coordination with the school, (c) parent support to promote parent engagement/collaboration with the school and study routines in the home, and (d) behavioral skills coaching for students. SWIFT students will continue to receive any school-based services that were receiving prior to entering the study.
62252044|NCT03568045|EXPERIMENTAL|10,000 lux bright light, 4 hours|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 8am to noon starting on study day 2 and continuing through study day 5. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor if the patient is transferred.~Feasibility metrics will be collected."
62441545|NCT05890456|ACTIVE_COMPARATOR|Services As Usual Control|The SAU students and families will continue to receive any services that they were receiving prior to their entry into the study. These may include school-based interventions and supports and related services as required in the student's Individualized Education Program.
62441546|NCT03603236||preeclampsia|18-40 aged diagnosed with preeclampsia
62441547|NCT03603236||control|18- 40 aged healthy females over 37. weeks of pregnant with no history of preeclampsia
62441548|NCT02649231|EXPERIMENTAL|Ketamine+Psychological Therapy|Ketamine with psychological therapy
62441549|NCT02649231|ACTIVE_COMPARATOR|Ketamine+Education|ketamine with alcohol education
62610719|NCT01823172|EXPERIMENTAL|Methylene Blue|1% Methylene Blue - 1 ml. Methylene blue dye injection of sentinel lymph node
62833163|NCT01910363|ACTIVE_COMPARATOR|BOTOX|single intramuscular injection of 300 units of BOTOX®, a commercially available botulinum toxin preparation of type A1
62833164|NCT06268275|EXPERIMENTAL|Group S|Receive 30 ml of 0.25% bupivacaine with 1% lidocaine (1:1) with adrenaline 1:200,000 infiltration for 10 minutes before skull pins application.
62833165|NCT06268275|ACTIVE_COMPARATOR|Group E|Receive intravenous esmolol 1 mg/kg bolus over 1 minute before skull pins application.
62833166|NCT05862077|SHAM_COMPARATOR|Overground walking exercise without EX1|Exercise consists of 30 minutes of overground walking.
62441550|NCT02649231|ACTIVE_COMPARATOR|Placebo+Psychological Therapy|placebo with psychological therapy
62441551|NCT02649231|PLACEBO_COMPARATOR|Placebo+Education|placebo with simple alcohol education
62441552|NCT02495597||Subject-Group|Patients suffering from doctors diagnosed bronchiolitis obliterans
62441553|NCT02495597||Control Group|age- and sex matched to subject-group
62610720|NCT05517434|EXPERIMENTAL|For STUDY 1 (ARM A): Bone Marrow Aspirate (BMA)|This group will undergo a bone marrow aspiration and receive an ultrasound guided intra-articular injection of BMA (a single dose of cellular suspension of 9 mL or less)
62833167|NCT05862077|EXPERIMENTAL|Exercise program 1 with EX1|Exercise program 1 consists of 30 minutes of overground walking.
62833168|NCT05862077|EXPERIMENTAL|Exercise program 2 with EX1|Exercise program 2 consists of 30 minutes of overground walking.
62833169|NCT05064215||injection behind NAC|in 7 breasts dye was injected behind the nipple areola complex before breast reduction
62833170|NCT05064215||Injection into lateral upper quadrant|in 5 breasts dye was injected into upper lateral glandular tissue before breast reduction
62833171|NCT05064215||injection into medial upper quadrant|in 2 breasts dye was injected into upper medial glandular tissue before breast reduction
62833172|NCT00988806|ACTIVE_COMPARATOR|Levosimendan|infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours.
62833173|NCT00988806|PLACEBO_COMPARATOR|Placebo|infusion of placebo for 24 hours.
62441554|NCT02231320||Chronic Obstructive Pulmonary Disease patients|
62833174|NCT04874246|ACTIVE_COMPARATOR|Diluted Vasopressin Group 1|During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 50 ml of normal saline to make a total of 100 ml) was injected before uterine serosal incision.
62252045|NCT03568045|EXPERIMENTAL|10,000 lux bright light, 8 hours|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 8am to 4pm starting on study day 2 and continuing through study day 5. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor if the patient is transferred.~Feasibility metrics will be collected."
62252046|NCT06141850|EXPERIMENTAL|Project PEACH2 Intervention|In addition to a text-based reporting tool for reporting COVID-19 testing, participants randomized to the Project PEACH2 intervention will be sent weekly behavioral nudges via mobile phone text message to encourage adherence to COVID-19 testing and preventive behaviors.
62441555|NCT02073955||Pakistani adults|"Men and women aged 40 and above, residing in Ibrahim Hyderi (periurban Pakistani community)~Consenting to Interview about stroke symptoms"
62441556|NCT00681863|ACTIVE_COMPARATOR|pramipexole 0.0625 mg BID (twice daily)|all patients to receive one tablet of pramipexole 0.0625 mg BID for first 4 weeks (flexible dosing for all other arms)
62610721|NCT05517434|PLACEBO_COMPARATOR|For STUDY 1 (ARM C): Saline Injection|This group will undergo a bone marrow aspiration and receive an ultrasound guided intra-articular injection of saline solution (9 mL)
62610722|NCT05517434|EXPERIMENTAL|For STUDY 2 (ARM B): Lipoaspirate Micronized + Leukocyte-Poor Platelet-Rich Plasma (LAM + LP-PRP)|This group will undergo a blood collection plus lipoaspiration and receive an ultrasound guided intra-articular injection of LAM (a single dose of cellular suspension of 9 mL or less) followed by LP-PRP (a single dose of cellular suspension of 2 mL or less)
62610723|NCT05517434|PLACEBO_COMPARATOR|For STUDY 2 (ARM D): Saline Injection|This group will undergo a blood collection plus lipoaspiration and receive ultrasound guided intra-articular injections of saline solution (9 mL followed by 2 mL)
62252047|NCT06141850|ACTIVE_COMPARATOR|Control Group|Participants randomized to the control group will receive access to the text-based COVID-19 reporting tool and receive weekly texts on diabetes prevention, management or care.
62252048|NCT05104645|EXPERIMENTAL|Patients after a Stroke|
62441557|NCT00681863|ACTIVE_COMPARATOR|pramipexole 0.0625 mg QD (once daily)|patients to receive one tablet of pramipexole 0.0625 mg QD
62441558|NCT00681863|ACTIVE_COMPARATOR|pramipexole 0.125 mg BID|patients to receive one tablet of pramipexole 0.125 mg BID
62441559|NCT00681863|ACTIVE_COMPARATOR|pramipexole 0.125 mg TID (three times daily)|patients to receive one tablet of pramipexole 0.125 mg TID
62610724|NCT03255252|EXPERIMENTAL|Cisplatin|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
62833175|NCT04874246|ACTIVE_COMPARATOR|Diluted Vasopressin Group 2|During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 200 ml of normal saline to make a total of 100 m) was injected before uterine serosal incision.
62441560|NCT00681863|ACTIVE_COMPARATOR|pramipexole 0.25 mg BID|patients to receive one tablet of pramipexole 0.25 mg BID
62441561|NCT02505776||GLASH VISTA™|Patients with eyelash hypotrichosis prescribed bimatoprost cutaneous solution 0.03% (GLASH VISTA™) as per local standard of care in clinical practice.
62441562|NCT01165814|ACTIVE_COMPARATOR|Tramadol at fixed intervals|
62441563|NCT01165814|ACTIVE_COMPARATOR|Tramadol on request|
62050533|NCT01613638|OTHER|Congenital malformations|"All livebirths, fetal deaths with gestational age (GA) ≥22 weeks and terminations of pregnancy (at any gestational age) after prenatal diagnosis of malformation.~* born from mothers living in Brittany at delivery~* with a congenital anomaly according to Eurocat criteria, diagnosed or suspected (and then confirmed) at birth~* or with mild congenital heart defects, genital anomalies or hip dislocation diagnosed after birth (and before the age of one)"
62252049|NCT05104645|ACTIVE_COMPARATOR|Healthy Volunteering|
62252050|NCT02728661|EXPERIMENTAL|PACE|PACE participants will begin up to 6 weeks prior to their scheduled TKR and continue until 12 weeks after their TKR. Participants will be given personalized weight, dietary, and physical activity goals. Participants will be encouraged to monitor their dietary intake and physical activity using their preferred method of self-monitoring. Participants will have regular contact with their coaches either in-person or over the telephone on a weekly or bi-weekly basis, based on preference during the first 14 weeks (from up to 6 weeks pre-op to 12 weeks post-op). Further, participants may opt to receive regular text messages or emails from coaches if they prefer. At 12 weeks, PACE participants will enter a maintenance period and not have any contact with coaches.
62441564|NCT01165814|ACTIVE_COMPARATOR|Naproxen at fixed intervals|
62441565|NCT01165814|ACTIVE_COMPARATOR|Naproxen on request|
62441566|NCT00814320|EXPERIMENTAL|1|Efficacy and tolerability of subcutaneous (SC) infusions of immune globulin intravenous (IGIV), 10% with hyaluronidase (rHuPH20) after ramp-up
62610725|NCT05289167|EXPERIMENTAL|Participants with hematological malignancies|Participants undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will receive a combination of cyclophosphamide, known commercially as Cytoxan®, abatacept, known as Orecia® and bortezomib commercially known as Velcade®, to reduce the rate of graft-versus-host disease (GvHD). These medications will be given for GvHD prevention during the transplant process.
62833176|NCT04874246|ACTIVE_COMPARATOR|Diluted Vasopressin Group 3|During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 400 ml of normal saline to make a total of 100 m) was injected before uterine serosal incision.
62833177|NCT02290769|EXPERIMENTAL|Short guide wire rapid exchange|Use of short guide wire rapid exchange to guide the cannulation during primary ERCP
62833178|NCT02290769|ACTIVE_COMPARATOR|Long guide wire|Use of long wire to guide the cannulation during primary ERCP
62833179|NCT03338192||African American/Black QST|This group will consist of a full range of socioeconomic status in African American/Black individuals with chronic low back pain.
62833180|NCT03338192||Caucasian/White QST|This group will consist of a full range of socioeconomic status in Caucasian/White individuals with chronic low back pain.
62833181|NCT06207591|EXPERIMENTAL|ECoG (electrocorticography) sensing|Use implantable ECoG-based Brain Computer interface to control assistive technology
62833182|NCT03862326|OTHER|Group Training|Group Training of the women with incontinence - with 5-8 women in each group. This is also Usual Care
62833183|NCT03862326|EXPERIMENTAL|Individual training|Individual pelvic floor exercises one-to-one with the physiotherapist
62833184|NCT03862326|EXPERIMENTAL|Individual training with biofeedback|Individual pelvic floor exercises one-to-one with the physiotherapist but with ultrasound used as biofeedback, and to check if the women are contracting the right muscles.
62441567|NCT00814320|EXPERIMENTAL|2|Pharmacokinetics of intravenous (IV) infusions of immune globulin intravenous (IGIV), 10% and efficacy and tolerability of subcutaneous (SC) infusions of immune globulin intravenous (IGIV), 10% with hyaluronidase (rHuPH20) after ramp-up
62833185|NCT00120302|EXPERIMENTAL|1|Pimecrolimus
62050534|NCT01613638|OTHER|control|2 controls per case will be included, corresponding to the first 2 births without congenital anomalies, with same sex and same birth place, following the case.
62050535|NCT00265980|NO_INTERVENTION|Weight initial|Subjects undergo studies at their usual body weight which is used as a baseline against which to compare subjects following weight loss with or without leptin repletion.
62050536|NCT00265980|PLACEBO_COMPARATOR|Weight -10% placebo|Subjects are studied while at a 10% reduced body weight and receiving placebo injections for 5 weeks.
62050537|NCT00265980|EXPERIMENTAL|Weight -10% leptin|Subjects are studied while at a 10% reduced body weight and receiving leptin injections for 5 weeks.
62610726|NCT06368323|EXPERIMENTAL|AB Group|First choir, then usual care
62610727|NCT06368323|EXPERIMENTAL|BA Group|First usual care, then choir
62833186|NCT00120302|PLACEBO_COMPARATOR|2|Vehicle
62833187|NCT03079622|ACTIVE_COMPARATOR|Electric vacuum aspiration|Electric vacuum aspiration will be performed with Synevac® Vacuum Curettage System 10 (Richmond, CA, USA) with a rigid cannula.
62833188|NCT03079622|ACTIVE_COMPARATOR|Manual vacuum aspiration|Manual vacuum aspiration will be performed using the 60-mL double valve aspirator, manufactured by Ipas (Chapel Hill, NC, USA) with a flexible cannula.
62833189|NCT03112603|EXPERIMENTAL|Ruxolitinib|Ruxolitinib for the treatment period and extension period.
62833190|NCT03112603|ACTIVE_COMPARATOR|Best Available Therapy|Best available therapy for the treatment period and extension period, with optional crossover to ruxolitinib after Cycle 6.
62833191|NCT03524729|ACTIVE_COMPARATOR|Ankle osteoarthritis patients|Ambulatory adult patients (18+) with ankle osteoarthritis.
62050538|NCT02745821|EXPERIMENTAL|Coronary physiology|Non-target and target vessels of patients with diabetes mellitus referred for PCI will be assessed for FFR, CFR and IMR. Intravenous adenosine at 140 micrograms/kg/min will be used to induce maximal hyperemia.
62050539|NCT03637543|EXPERIMENTAL|PD-L1 Positive|-Nivolumab will be given on day 1 of a 28-day cycle intravenously
62050540|NCT03637543|EXPERIMENTAL|PD-L1 Negative|-Nivolumab will be given on day 1 of a 28-day cycle intravenously
62050541|NCT01266850|ACTIVE_COMPARATOR|Group 1, RotaTeq® x 3|2, 4 and 6 months of age: RotaTeq®
62050542|NCT01266850|EXPERIMENTAL|Group 5, Rotarix®, RotaTeq® x2|2 months of age: Rotarix®; 4 and 6 months of age: RotaTeq®
62050543|NCT01266850|ACTIVE_COMPARATOR|Group 4, Rotarix® x 2|2 and 4 months of age: Rotarix®
62833192|NCT03524729|OTHER|Healthy control subjects|Ambulatory adults (18+) with no known ankle osteoarthritis.
62833193|NCT01118182||Traumatic Brain Injury (TBI)|Veterans with a positive history of TBI
62833194|NCT01118182||No Traumatic Brain Injury (TBI)|Veterans with a negative history of TBI
62833195|NCT02233686|EXPERIMENTAL|XEN-D0501|4mg BID Days 1-13, 4mg once daily (OD) Day 14
62833196|NCT02233686|PLACEBO_COMPARATOR|Placebo to Match|BID Days 1-13, once daily (OD) Day 14
62833197|NCT06365424|ACTIVE_COMPARATOR|UDCA|
62050544|NCT01266850|EXPERIMENTAL|Group 2, RotaTeq®, Rotarix® x 2|2 months of age: RotaTeq®; 4 and 6 months of age: Rotarix®
62050545|NCT01266850|EXPERIMENTAL|Group 3, RotaTeq® x 2, Rotarix®|2 and 4 months of age: RotaTeq®; 6 months of age: Rotarix®
62050546|NCT04757987||Pain-free|Report persistent pain at enrolment
62050547|NCT04757987||Persistent pain|Report no pain at enrolment
62050548|NCT06332079|EXPERIMENTAL|COHORT A/B|"Eligible patients will receive Scout dose procedure. After 1-2 weeks, patients eligible for radioembolization will receive 166Ho-TARE and at least after 3 weeks, maintenance treatment with fluoropyrimidine plus target agents (anti-EGFR or bevacizumab) according to the respective study cohort.~Maintenance treatment:~Cohort A:~* CETUXIMAB iv day1, over 1 hours, 500 mg/sqm or PANITUMUMAB iv over 1 hours, 6 mg/kg, every 14 days~* LED 200 mg/sqm iv over 1 hour, day 1~* 5-FLUOROURACIL ic 48 h, starting on day 1 every 14 days; 2400 mg/sqm and 400 mg/sqm bolus if FOLFOX/FOLFIRI in the induction treatment~Cohort B:~* BEVACIZUMAB 5 mg/kg iv biweekly day1, over 30 minutes~* LED 200 mg/sqm iv over 1 hour, day 1~* 5-FLUOROURACIL ic 48 h, starting on day 1 every 14 days; 2400 mg/sqm and 400 mg/sqm bolus if FOLFOX/FOLFIRI in the induction treatment~CAPECITABINE, 1000 mg/sqm orally twice daily, day 1-14, plus bevacizumab 7,5 mg/kg iv every 21 days is allowed."
62610728|NCT04775498|ACTIVE_COMPARATOR|Face-to-face psychoeducation group|The group of face-to-face psychoeducation or standard intervention will consist of the participation by the patients include in all the sessions of a therapeutic education programme of the investigator center.
62833198|NCT06365424|EXPERIMENTAL|UDCA+Fenofibrate|
62833199|NCT05592106||PHLF group and non-PHLF group|group with and without PHLF
62833200|NCT02516241|EXPERIMENTAL|Combination Therapy|MEDI4736 (Durvalumab) + Tremelimumab
62050549|NCT05382260|EXPERIMENTAL|Disorders of consciousness(DOC)|The participants in this arm are disorders of consciousness, containing of vegetative state(VS) and minimally conscious state(MCS).
62050550|NCT05382260|OTHER|Health control|They are health people with normal hearing, acting as a control for DOC group.
62050551|NCT02685644||Laparoscopic removal|Patients with endometrioma who will undergo laparoscopic removal of cysts.
62050552|NCT03682835|PLACEBO_COMPARATOR|Placebo treatment arm|Placebo: 2 capsules per dose, 2 doses per study day.
62050553|NCT03682835|EXPERIMENTAL|POCO treatment arm|FDGard Capsule containing a combination of peppermint oil (41,5mg) and caraway oil (50mg); 2 capsules per dose, 2 doses per study day.
62833201|NCT02516241|EXPERIMENTAL|Monotherapy|MEDI4736 (Durvalumab)
62833202|NCT02516241|ACTIVE_COMPARATOR|Standard of Care|Standard of Care Chemotherapy Treatment
62833203|NCT06655402|EXPERIMENTAL|CARE-CITE- CarePartners (Intervention Group)|The CP will receive virtual Collaborative Integrated Therapy (CARE-CITE), a post-stroke family education program.
62833204|NCT06655402|EXPERIMENTAL|CARE-CITE- Stroke Survivors (Intervention Group)|This study arm consists of stroke survivors (SS) of carepartners receiving the virtual Collaborative Integrated Therapy (CARE-CITE), a post-stroke family education program.
62050554|NCT05849779|EXPERIMENTAL|Inhaled sedation with sevoflurane|Sevoflurane as vaporized via the Anesthesia Conserving Device (Sedaconda-ACD-S, Sedana Medical, Danderyd, Sweden).
62050555|NCT05849779|ACTIVE_COMPARATOR|Intravenous sedation|The investigators will not mandate the sedative type, but rather encourage the use of sedatives that are already routinely used in participating ICUs (typically a benzodiazepine, propofol, or dexmedetomidine, i.e. drugs approved for sedation).
62050556|NCT05738993|EXPERIMENTAL|BCD-178 group|single IV infusion of BCD-178 at a dose of 420 mg
62050557|NCT05738993|ACTIVE_COMPARATOR|Perjeta Group|single IV infusion of Perjeta at a dose of 420 mg
62252051|NCT02728661|EXPERIMENTAL|Delayed PACE|After being notified of their randomized condition at baseline (up to 6 weeks prior to surgery), Delayed PACE participants will not have contact with coaches until 12 weeks after surgery. At 12 weeks after surgery, Delayed PACE participants will be given personalized weight, dietary, and physical activity goals. Participants will be encouraged to monitor their dietary intake and physical activity using their preferred method of self-monitoring. Participants will have regular contact with their coaches either in-person or over the telephone on a weekly or bi-weekly basis, based on preference during the first 14 weeks. Further, participants may opt to receive regular text messages or emails from coaches if they prefer.
62610729|NCT04775498|EXPERIMENTAL|SIMPLe mobile application|The experimental intervention consists of the use of the SIMPLe application during 1 year: answers of 5 daily questions and to the weekly questions. Moreover, daily and personalized psychoeducation messages (adapted to the answers to the tests carried out) will be sent to user by notifications.
62833205|NCT06655402|ACTIVE_COMPARATOR|Attention Control Group-CarePartners|CP in this group will receive traditional written family educational materials to review during the 4-week intervention period.
62833206|NCT06655402|ACTIVE_COMPARATOR|Attention Control Group-Stroke Survivors|This study arm consists of stroke survivors (SS) of carepartners receiving the traditional written family educational materials to review during the 4-week intervention period.
62441568|NCT06057298|EXPERIMENTAL|Cytoreductive surgery and patient-tailored Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|"* Preliminary laparoscopic exploration of the whole abdominal cavity is performed to stage the peritoneal disease, and obtain samples of peritoneal tumor to confirm the diagnosis of colorectal peritoneal metastases, and develop tridimensional cell cultures (organoids).~* Preoperative systemic chemotherapy (s-CT) is performed at the discretion of treating medical oncologists, according to current guidelines.~* Cytoreductive surgery and patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC) is scheduled within 6 weeks and at least 4 weeks after the completion of preoperative s-CT (at least 6 weeks after the last administration of bevacizumab). Cytoreductive surgery is aimed at removing all the macroscopic tumor by means od peritonectomy procedures and organ resections, as needed."
62441569|NCT01923246|EXPERIMENTAL|Single WEB intervention|Web intervention recieved once.
62833207|NCT03633032|OTHER|UTE MRI|
62833208|NCT02134158|EXPERIMENTAL|sham and then anodal|visit 2 sham stimulation (120 seconds) and visit 3 anodal stimulation (30 minutes)
62833209|NCT02134158|EXPERIMENTAL|anodal and then sham|visit 2 anodal stimulation (30 minutes) and visit 3 sham stimulation (120 seconds)
62833210|NCT00740649|EXPERIMENTAL|1|HSD-016
62252052|NCT02510092|ACTIVE_COMPARATOR|Coronary artery diseae with revascularization indicated|Subjects with coronary artery disease, that require and are eligible for percutaneous revascularization.
62833211|NCT00740649|OTHER|2|placebo
62833212|NCT05839301|EXPERIMENTAL|Experimental Group1|Single subcutaneous injection of the investigational vaccine (0.5ml)
62252053|NCT02510092|NO_INTERVENTION|Coronary artery disease not requiring revascularization|Subjects with coronary artery disease that do not require revascularization.
62252054|NCT03045445|EXPERIMENTAL|Double Low-Dose protocol CT|Low radiation dose + low amount of iodine contrast media at spectral CT (Philips Healthcare)
62252055|NCT03045445|ACTIVE_COMPARATOR|Standard protocol CT|Standard protocol quadriphasic liver CT according to current liver CT protocol in our institution, at spectral CT (Philips Healthcare)
62252056|NCT05520346|EXPERIMENTAL|Device|Patients use toilet device to measure fluid output and self-report event types
62252057|NCT05520346|NO_INTERVENTION|Control|Collection in standard hats + nurses visually assessing fluid volumes
62252058|NCT01854320|EXPERIMENTAL|Acceptance-based treatment|Behavioral therapy for weight loss focusing on acceptance-based cognitive strategies and techniques.
62441570|NCT01923246|EXPERIMENTAL|Repeated WEB intervention|Web intervention recieved twice.
62441571|NCT01923246|EXPERIMENTAL|Single IVR intervention|IVR intervention recieved once
62441572|NCT01923246|EXPERIMENTAL|Repeated IVR intervention|IVR intervention recieved twice
62833213|NCT05839301|EXPERIMENTAL|Experimental Group2|Single subcutaneous injection of the investigational vaccine (0.5ml)
62833214|NCT05839301|EXPERIMENTAL|Experimental Group3|Single subcutaneous injection of the investigational vaccine (0.5ml)
62833215|NCT04713241|ACTIVE_COMPARATOR|Group A: SOC|Participants will receive the SOC and will also be asked to complete questionnaires to rate their symptoms
62833216|NCT04713241|EXPERIMENTAL|Group B: Electro-Acupuncture|Participants will receive the SOC + a daily 20-30 minute electro-acupuncture treatment from the time of randomization until the return of bowel function. The first treatment will be provided within 48 hours after the diagnosis of postoperative ileus. Participants will receive acupuncture every day until normal bowel movement function returns.
62833217|NCT05064436|EXPERIMENTAL|Part A - Healthy Participants|
62833218|NCT05064436|EXPERIMENTAL|Part B - Participants with MS|
62833219|NCT03290885|EXPERIMENTAL|Combined use of contact aspiration and stent retriever|Combined use of contact aspiration and stent retriever mechanical thrombectomy for recanalization
62833220|NCT03290885|ACTIVE_COMPARATOR|Stent retriever mechanical thrombectomy alone|Stent retriever mechanical thrombectomy alone for recanalisation
62833221|NCT04731818|EXPERIMENTAL|ZB-06|All participants will receive a single ZB-06 film for intravaginal administration prior to intercourse.
62441573|NCT01923246|NO_INTERVENTION|Control group|Untreated Control Group.
62833222|NCT05973032||MRD positive and MRD negative groups|"MRD postive: NGS-MRD\>=0.01% at the end of induction or \>=0.0001% at the end of consoidation.~MRD negative: NGS-MRD\<0.01% at the end of induction or \<0.0001% at the end of consoidation."
62833223|NCT06654843|NO_INTERVENTION|Control Arm: No Intervention: Control Arm: Fitness classes only|"There will be 21 Shape Up NYC classes offered weekly for one hour free of charge to consenting participants in all three arms with a total of 12 classes offered per participant.~Weekly reminders for each class will be sent via automated text messages to individuals."
62252059|NCT01854320|ACTIVE_COMPARATOR|Standard behavioral treatment|"Standard behavioral therapy for weight loss, the gold standard treatment."
62833224|NCT06654843|ACTIVE_COMPARATOR|Comparator Arm: Fitness classes + childcare|"There will be 21 Shape Up NYC classes offered weekly for one hour free of charge to consenting participants in all three arms with a total of 12 classes offered per participant.~Weekly reminders for each class will be sent via automated text messages to individuals."
62441574|NCT02758054|NO_INTERVENTION|Usual Care|Participants will experience standard practice for lung cancer early detection.
62833225|NCT06654843|EXPERIMENTAL|Enhanced intervention arm: Fitness classes + childcare + peer support|There will be 21 Shape Up NYC classes offered weekly for one hour free of charge to consenting participants in all three arms with a total of 12 classes offered per participant.
62833226|NCT03319147|PLACEBO_COMPARATOR|Placebo|4g of maltodextrin
62833227|NCT03319147|ACTIVE_COMPARATOR|Active|4g of essential amino acids
62833228|NCT06064214|EXPERIMENTAL|block|33 patients will receive bilateral u/s guided intermediate cervical plexus block with general anesthesia
62833229|NCT06064214|ACTIVE_COMPARATOR|morphine|33 patients will receive morphine in a dose of 0.1-0.2 mg/kg to maintain intraoperative analgesia
62252060|NCT05452330|EXPERIMENTAL|Group 1|Connective tissue massage
62252061|NCT05452330|EXPERIMENTAL|Group 2|Classical massage
62441575|NCT02758054|EXPERIMENTAL|Usual Care + Patient Navigation|Participants will experience standard practice for lung cancer early detection plus the intervention.
62441576|NCT02742779|EXPERIMENTAL|High-Fat Meal SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a high-fat meal after a 8-hour/overnight fast using PIC on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
62833230|NCT02134496|NO_INTERVENTION|no assessment of motorfunction in PACU|no assessment of motorfunction after spinal anesthesia in PACU
62833231|NCT02134496|ACTIVE_COMPARATOR|motorfunction assessment in PACU|Assesment of motorfunction after spinal anesthesia
62833232|NCT00852449|EXPERIMENTAL|restrictive fluid|Restrictive fluid administration: 6 ml kg-1 h-1 of crystalloids (lactated Ringer's solution)
62833233|NCT00852449|EXPERIMENTAL|liberal fluid|Liberal fluid administration: 12 ml kg-1 h-1 of crystalloids (lactated Ringer's solution)
62833234|NCT04921644||patient cohort|Newly diagnosed patients with colon, rectum, liver, pancreas or lung cancer, malignant melanoma, breast or other gynecological cancers, prostate, kidney, bladder or thyroid gland cancer, non-Hodgkin lymphoma or leukemia recruited approximately 6 months after diagnosis and followed up to 2 years post-diagnosis. No intervention.
62833235|NCT01698840|EXPERIMENTAL|Investigational Nutrition|Starting between post menstrual age (PMA) 34 0/7 to 38 6/7 weeks, infants in the Investigational Nutrition group will receive vitamin D drops that are added to transitional formula daily through hospital discharge and at home until the outpatient follow-up visit at 52 weeks PMA.
62833236|NCT01698840|PLACEBO_COMPARATOR|Routine Nutrition|Starting between post menstrual age (PMA) 34 0/7 to 38 6/7 weeks, infants in the Routine Nutrition group will receive placebo drops that are added to transitional formula daily through hospital discharge and at home until the outpatient follow-up visit at 52 weeks PMA.
62833237|NCT03265314|EXPERIMENTAL|LeadHer|The LeadHer curriculum is presented to the target population over a total of 30 hours. The program addresses the following adult preparation subjects: Healthy relationships, Adolescent development, Healthy life skills, Educational and career success. The LeadHer curriculum is also accompanied by a mobile application.
62833238|NCT03265314|PLACEBO_COMPARATOR|Sassy Science|The Sassy Science curriculum is presented to the target population over a total of 30 hours. The program addresses the following subjects: States of Matter, Math, Engineering, Chemistry, Arts and Crafts, Sweet Treats and Celebrations. The curriculum does not have a mobile application.
62833239|NCT01772316|EXPERIMENTAL|Tocilizumab Subcutaneous (SC)|Participants received Tocilizumab 162 milligram (mg) given as 0.9 milliliter (mL) of a 180 milligram per milliliter (mg/mL) solution administered once a week (for participants entering from NCT01194414) or once every two weeks (for participants entering from NCT01232569) by SC injection and as a single fixed dose irrespective of body weight.
62833240|NCT06104800|EXPERIMENTAL|Red meat diet|Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (including red meat), 50% carbohydrates, and 25-30% fats.
62833241|NCT06104800|ACTIVE_COMPARATOR|Red meat free diet|Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (excluding red meat), 50% carbohydrates, and 25-30% fats
62833242|NCT06091488|EXPERIMENTAL|Experimental|Patients with anterior cruciate ligament injury, in which the patient's own autologous tendons cannot be used, will be treated with the ligamentous reconstruction device.
62050558|NCT03921814|EXPERIMENTAL|Treatment with IPL device|This study will be conducted in women, aged 18 to 65 years, with skin types I up to and including V, and measured melanin values of ≤ 553 Melanin index in each qualifying treatment area in face (upper lip), axilla, bikini line, and leg. Each of the 2cm x 4cm treatment area bilateral located in axilla, bikini line and leg should count a minimum of 24 hairs. In face (upper lip) on upper lip, a minimum of 10 hairs should be available in each of the 1cm x 2cm selected treatment area bilateral located. The procedure to define the treatment area is described in the Training Manual \[5\]. Skin type must be determined based on an evaluation by a dermatologist or designee at site according to the Fitzpatrick Skin Type Scale.
62050559|NCT02432989|NO_INTERVENTION|Resting Control Group|Patients will receive standard concussion management, but will be asked not to exercise for the first 7 days after their concussion.
62252062|NCT03633526|EXPERIMENTAL|VX-659/TEZ/IVA|Participants who received VX-659 120 milligram (mg)/TEZ 50 mg/ IVA 75 mg as fixed-dose combination (FDC) in the morning and IVA 75 mg as a mono tablet in the evening in the triple combination (TC) treatment period.
62252063|NCT00187096|EXPERIMENTAL|Stratum 1|"Stratum 1 (AML in complete remission)~Cyclophosphamide 60 mg/kg IV Day -7 Fludarabine 25 mg/m2/day IV Days -6 through -2 Donor pheresis Day -1 Start IL-2 on Day -1, then 3 times per week x 2 weeks NK Cell purification and infusion on Day 0"
62252064|NCT00187096|EXPERIMENTAL|Stratum 2|"Stratum 2 (AML that is refractory or relapsed or AML with increasing minimal residual disease)~Clofarabine 40 mg/m2 IV, days -6 through -2 Etoposide 100 mg/m2 IV, days -6 through -2 Cyclophosphamide 400 mg/m2 IV, days -6 through 02 Donor pheresis Day -1 Start IL-2 Day -1, and then 3 times per week x 2 weeks NK Cell purification and infusion on Day 0."
62441577|NCT02742779|EXPERIMENTAL|High-Fat Meal SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a high-fat meal after a 8-hour/overnight fast using solution on Day 1 of the treatment period (5 days) in an additional cohort of Part 3.
62441578|NCT02742779|EXPERIMENTAL|Low-Fat Meal SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose given orally using PIC based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a low-fat meal after an 8-hour/overnight fast using PIC on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
62441579|NCT02742779|EXPERIMENTAL|Low-Fat Meal SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose given orally using PIC based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a low-fat meal after an 8-hour/overnight fast using solution on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
62441580|NCT02742779|EXPERIMENTAL|MD Cohort: PIC (Part 2)|Participants will receive multiple ascending dose administered orally using PIC from Day 1 to Day 13 twice daily (BID) or may even be thrice daily (TID) or four times a day (QD) depending on clinical PK, followed by morning dose on Day 14 in 7 cohorts of Part 2.
62441581|NCT02742779|EXPERIMENTAL|MD Cohort: Solution Formulation (Part 4)|Participants will receive multiple ascending dose in fed or fast condition, administered orally using solution from Day 1 to Day 13 BID or may even be TID or QD depending on clinical PK, followed by morning dose on Day 14 in 7 cohorts of Part 2.
62833243|NCT05408078|EXPERIMENTAL|Intervention group - Treatment as Usual (TAU) + SLEEPexpert|"SLEEPexpert is a behavioral programme for insomnia.~The TAU + SLEEPexpert group will receive a specific treatment for insomnia. This treatment will consist of the following three phases:~1. a face-to-face treatment initiation (kick-off) guided by a medical doctor/ psychologist in a group format~2. self-managed implementation of behavioral changes supported by the nursing team (individual brief contact during the week)~3. self-management by the patients, potentially assisted by the Webapplication after discharge from the hospital."
62050560|NCT02432989|EXPERIMENTAL|Exercise Group|Patients will receive standard concussion management, but will be asked to exercise on a stationary bike on two different occasions (once for 15 minutes and again for 30 minutes) in their first week of recovery. This group will also be asked to complete a 30 minute leisurely walk at their convenience on the two days they are not tested at UBC or Fortius.
62610730|NCT04201678|ACTIVE_COMPARATOR|CLIA (conventional local anesthesia infiltration) Group|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the CLIA group, the needle (50 mm 22 Gauge) was directed towards the laminar periosteum at the pedicular projection point at the 10-15 ° angle with the sagittal plane. A mixture of 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be applied bilaterally."
62610731|NCT04201678|ACTIVE_COMPARATOR|EPIAA (Extrapedicular infiltration anesthesia) Group|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~The anesthesia process of the CLIA + EPIA group also includes the third step called EPIA. For this stage, the anesthetic needle (50 mm 22 Gauge) is first drawn into the subcutaneous tissue, then through the lateral superior articular process to the lateral half of the pedicle and the upper border of the transverse process (5-10 degrees with sagittal plane and 5-10 with coronal plane), and after negative aspiration 3 mL 2% Lidocaine Hydrochloride and 7 mL 0.5% bupivacaine mixture will be applied bilaterally"
62252065|NCT05765266|EXPERIMENTAL|ACP Max™|Single 4-6 ml intra-articular (IA) injection of the output of ACP Max™
62252066|NCT05765266|ACTIVE_COMPARATOR|40 mg of methylprednisolone acetate|Single IA injection of 40 mg of methylprednisolone acetate (1 ml of solution) mixed with 5 ml of Normal Saline for a total of 6 ml.
62252067|NCT02000076|EXPERIMENTAL|Sleep deprivation|Partial sleep deprivation allowing 3 h sleep at night
62252068|NCT02000076|EXPERIMENTAL|Full sleep|Sleep with no restriction
62610732|NCT04201678|ACTIVE_COMPARATOR|ESP (Erector Spina Plane Block) Group|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the ESP group, a high-frequency-50 15-6 Megahertz (MHz) linear ultrasound probe will be placed vertically approximately 3 cm laterally at the point of application. Once the erector spinae muscle and transverse process have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane was opened. Bilateral 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be administered."
62610733|NCT00478699|ACTIVE_COMPARATOR|1 Control group|"Control group:~\*Docetaxel 75 mg/m2, and cisplatin 75 mg/m2, both on day 1, every 21 days. Total cycles: Four."
62610734|NCT00478699|EXPERIMENTAL|2 Experimental group|"Experimental group, according to the BRAC1 levels of the tumor tissue, will be assigned one of the following treatments:~* Low expression of BRCA1 → gemcitabine 1250 mg/m2, days 1 and 8, and cisplatin 75 mg/m2, day 1. Cycles every 21 days. Total cycles: 4~* Intermediate expression levels of BRCA1 → docetaxel 75 mg/m2, and cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total cycles: 4.~* High expression levels of BRCA1 → docetaxel 75 mg/m2, day 1. Cycles every 21 days. Total cycles: 4."
62610735|NCT04350814|EXPERIMENTAL|Self-Compassion Intervention Arm|Participants randomized to this condition will receive access to the audio Mindful Self-Compassion self-help intervention. The intervention is 7 weeks in duration (with a pacing of one lesson per week) and participants are asked to complete study measures once each week of the intervention.
62610736|NCT04350814|ACTIVE_COMPARATOR|Self-Reflection|Participants randomized to this active control condition will be asked to complete study measures at the same assessment intervals as those in the experimental arm. In addition to completing the measures, participants in the Self-Reflection Active Control condition will be asked to reflect on their self-reported symptoms and changes they may have experienced between assessment intervals.
62610737|NCT00055679|ACTIVE_COMPARATOR|6 FEC|6 cycles of CYCLOPHOSPHAMIDE + EPIRUBICINE + 5-FLUOROURACILE
62610738|NCT00055679|EXPERIMENTAL|4 FEC|4 cycles of CYCLOPHOSPHAMIDE + EPIRUBICINE + 5-FLUOROURACILE
62833244|NCT05408078|OTHER|Control group - TAU + sleep monitoring|"In addition to TAU, patients in the control group (TAU + sleep monitoring) receive a smartphone app (sleep monitoring). No further interventions will be provided through this app.~TAU comprises standard clinical care, including intensive daily contacts with health care providers on the wards, medical treatment, pharmacotherapy, psychotherapy in individual and group setting, nurse support, additional therapies such as music or ergotherapy and social support, informed by current guidelines for the respective disorder and adapted to individual needs. Of note, no change to any aspects of TAU will be made. Sleep monitoring will consist of daily sleep diary entries with the help of a smartphone app."
62833245|NCT00787644|ACTIVE_COMPARATOR|1|
62252069|NCT04650282|EXPERIMENTAL|Lidocaine in SphenoCath device|One treatment will be given.
62833246|NCT00787644|PLACEBO_COMPARATOR|2|
62050561|NCT03026023|EXPERIMENTAL|Treatment with grazoprevir + elbasvir +/- ribavirin|12 to 16 weeks of treatment with combination tablet of grazoprevir + elbasvir +/- ribavirin
62252070|NCT04650282|PLACEBO_COMPARATOR|Saline Solution in SphenoCath device|One treatment will be given.
62252071|NCT03778567|OTHER|lamivudine + nucleotide analogue|At the time of recruitment (0 month, baseline), lamivudine is switched to telbivudine while adefovir or tenofovir disoproxil fumarate was continued
62252072|NCT04540549|EXPERIMENTAL|intervention group|Jogging or cycling ≥5 days/week, 30-60 min/d
62252073|NCT04540549|NO_INTERVENTION|control group|The control group was encouraged to maintain their lifestyle.
62252074|NCT04677673|EXPERIMENTAL|NAC PLUS SURGERY|Patients receive three cycles of the modified dose of TGO plus oxaliplatin before curative gastrectomy.
62252075|NCT04677673|ACTIVE_COMPARATOR|SURGERY FIRST|Patients undergo curative gastrectomy without any prior chemotherapy.
62252076|NCT05168748|EXPERIMENTAL|IMJ995 in ALL|Dose escalation and expansion of IMJ995 single agent in ALL
62441582|NCT02742779|PLACEBO_COMPARATOR|Placebo PIC|Participants will receive placebo matched to GDC-0310 single or multiple ascending dose administered orally in the fasted (SD cohorts) or fed state using PIC on Day 1 of the treatment period (5 days) to the SD cohorts and from Day 1 to 14 BID or may even be TID or QD depending on clinical PK, to the MD cohorts.
62252077|NCT03389295|EXPERIMENTAL|Reduced Target Delineation and Radiation Doses|All patients were assigned to receive induction chemotherapy (IC) followed by IMRT with adjuvant chemotherapy (AC). IMRT was administered 2 weeks after IC, and AC was administered 1 month after IMRT. IC or AC (TPF regimen) comprised docetaxel (60 mg/m2/day, day 1), cisplatin (25 mg/m2/day, days 1-3), and 5-fluorouracil (500 mg/m2/day with a 120-h infusion) administered once every 3 weeks for two cycles. During radiotherapy, involved retropharyngeal lymph nodes and intracavity lesions of the primary tumor were delineated according to the post-IC volume, whereas the remainder of the involved tissues (eg, pterygopalatine fossa) of the primary tumor were delineated according to the pre-IC volume of the primary tumor as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for delineation. The prescribed dose was 66 Gy to tumors above the slices of skull base or below the orapharynx with less than 5 mm retropharyngeal lymph nodes, or 70.4 Gy to tumors in other slices.
62610739|NCT03283917|EXPERIMENTAL|Treatment (daratumumab, ixazomib, dexamethasone)|Participants receive daratumumab IV over 3.5-6.5 hours on days 1, 8, 15, and 22 of courses 1-2, on days 1 and 15 of courses 3-6, and on day 1 of courses 7-12. Participants also receive ixazomib PO on days 1, 8, and 15, and dexamethasone IV over 15 minutes or PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unaccepted toxicity.
62050562|NCT01055548||Parents of babies born before 33 weeks gestation|
62050563|NCT03474302|EXPERIMENTAL|Physical Activity|The intervention will be a 12-week community-based physical activity promotion program
62252078|NCT05520151|EXPERIMENTAL|ORAL impact group|This group of patients will receive a 7-days course of IMPACT ORAL 20 days before the surgery
62252079|NCT05520151|OTHER|control|a retrospective cohort of patients operated between 2016 and 2019 by nephrectomy cystectomy and laparotomy who did not receive oral impact
62252080|NCT02495844|EXPERIMENTAL|UCB0942|UCB0942/UCB0942
62252081|NCT02495844|PLACEBO_COMPARATOR|Placebo|Placebo/UCB0942 (after 2-week inpatient period, placebo subjects will receive the experimental medicine, UCB0942).
62252082|NCT02491957|EXPERIMENTAL|LOFT Therapy|LOFT therapy twice weekly for 4 weeks
62441583|NCT02742779|PLACEBO_COMPARATOR|Placebo Solution|Participants will receive placebo matched to GDC-0310 single or multiple ascending dose administered orally in the fasted (SD cohorts) or fed state using PIC on Day 1 of the treatment period (5 days) to the SD cohorts and from Day 1 to 14 BID or may even be TID or QD depending on clinical PK, to the MD cohorts.
62738805|NCT03013387|EXPERIMENTAL|PRRT with 90Y--DOTA-tyr3-Octreotide|"The 90Y--DOTA-tyr3-Octreotide initial, Cycle 1 dose will be 50 mCi/m2 in children; 120 mCi in adults. Treatment consists of 3 cycles, 6-8 weeks apart. Cycle 1 dose is fixed. Cycles 2 and 3 doses will be determined by dosimetry-based calculation of renal doses from previous cycles; total renal dose ≤ 23Gy. 90Y-DOTA-tyr3-Octreotide will be administered with an amino acid solution to prevent radiation damage to kidneys. Amino acid infusion will begin 30 min prior to infusion of 90Y-DOTATOC and continue 3.5 hrs after infusion of study drugs.~68Ga-DOTATOC will be administered intravenously to perform the PET/CT scan. The dose will be 3-5 mCi (target 4mCi). The pediatric dose will be 0.043 mCi/kg with a minimum dose of 0.3 mCi and a maximum dose of 3 mCi in children \<18 years old."
62738806|NCT04667598|EXPERIMENTAL|Experimental group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given modified Wenxin Tang granules, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
62738807|NCT04667598|PLACEBO_COMPARATOR|Control group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given placebo, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
62738808|NCT01318135|ACTIVE_COMPARATOR|Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID|
62738809|NCT01318135|ACTIVE_COMPARATOR|Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID|
62738810|NCT01318135|ACTIVE_COMPARATOR|Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID|
62738811|NCT01318135|ACTIVE_COMPARATOR|Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID|
62050564|NCT03474302|ACTIVE_COMPARATOR|Successful Aging|Those randomized to the successful aging group will receive health information pertinent to African Americans over the 12 weeks
62050565|NCT06344390|EXPERIMENTAL|Pentoxifylline|Pentoxifylline
62050566|NCT06344390|NO_INTERVENTION|No intervention|No intervention
62050567|NCT04717414|EXPERIMENTAL|Experimental Arm: Luspatercept (ACE-536)|Luspatercept will be given to participants via subcutaneous injection (administered on Day 1 of each 21-day treatment cycle)
62050568|NCT04717414|PLACEBO_COMPARATOR|Control Arm: Placebo|Placebo starting dose with volume equivalent to experimental arm subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
62610740|NCT05585125|ACTIVE_COMPARATOR|Beta-Blocker ABAB Sequence|This arm will follow an ABAB sequence: ON beta-blockers (A) and OFF beta-blockers (B). Participants start with their home beta-blocker dose in Period 1 (A), and then switch to Period 2 (B), where the dose is slowly reduced until they are off their beta-blocker (or the lowest tolerable dose). Participants are then asked if they have enough information to clarify their preference about continuing or discontinuing their beta-blocker. Participants can choose to engage in 2-6 periods based on whether they need more information to make a preference. These extra phases follow the same ON-OFF pattern (ABABAB), meaning if the participant chooses to continue into Period 3 (A), the study team will restart the participant's beta-blocker, and slowly up-titrate until they reach their home dose, or their highest tolerable dose. This continues until the participant has enough information to clarify their preference about their beta-blocker, with a limit of 6 periods.
62738812|NCT04580836|EXPERIMENTAL|Treatment (MRI-guided SBRT)|Patients undergo an MRI scan to check the status and location of the disease, including the motion of the tumor during breathing. Two weeks after MRI, patients undergo SBRT over 1-2 hours on 3 non-consecutive weekdays in the absence of disease progression or unacceptable toxicity.
62050569|NCT04279314|EXPERIMENTAL|Trofinetide|
62050570|NCT01351298|PLACEBO_COMPARATOR|Saline spray|
62050571|NCT01351298|EXPERIMENTAL|Decongestant|
62441584|NCT02742779|EXPERIMENTAL|SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose administered orally in the fasted state using PIC on Day 1 of the treatment period (5 days) in the 9 cohorts of Part 1.
62441585|NCT02742779|EXPERIMENTAL|SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose administered orally in the fasted state using solution formulation on Day 1 of the treatment period (5 days) in the 9 cohorts of Part 3.
62738813|NCT06661811|EXPERIMENTAL|CAR-T treatment|
62738814|NCT02295631|EXPERIMENTAL|ETI during immobilized spine (oral intubation)|intubation with immobilized cervical spine endotracheal intubation with immobilized cervical spine
62050572|NCT01351298|EXPERIMENTAL|Decongestant and local anesthetic|
62050573|NCT03475849||RYGB subjects|Morbidly obese patients who has undergone an uncomplicated gastric bypass surgery more than 12 months before study start.
62050574|NCT03475849||Control subjects|Age, sex and BMI-matched healthy controls
62738815|NCT02295631|EXPERIMENTAL|ETI during immobilized spine (nasal intubation)|intubation with immobilized cervical spine endotracheal intubation with immobilized cervical spine
62738816|NCT01908491|ACTIVE_COMPARATOR|IV PCA|hydromorphone with ketorolac
62050575|NCT03475849||SG subjects|Morbidly obese patients who has undergone an uncomplicated sleeve gastrectomy surgery more than 12 months before study start.
62738817|NCT01908491|EXPERIMENTAL|Continuous wound infusion|ON-Q Painbuster with ropivacaine
62738818|NCT06503848||episodic migraine|Patients with episodic migraine will be asked to treat four spontaneous migraine attacks with sumatriptan 50 milligrams. They will register the headache characteristics and whether or not the treatment was effective.
62738819|NCT00361231|EXPERIMENTAL|Bevacizumab, Gemcitabine, Oxaliplatin|"* The chemotherapy drugs are given twice every 28 days. This 28 day period is called a cycle of study treatment.~* Bevacizumab will be administered by IV over 90 minutes on day 1 and day 15. Gemcitabine will be administered by IV over 1 hour and 40 minutes on days 1 and 15 of each cycle. Oxaliplatin will be administered by IV for 2 hours on days 1 and 15 of each cycle.~* Participants will continue to receive cycles of study treatment as long as their disease does not progress and they are not experiencing any serious side effects."
62050576|NCT01742377||Patients with GerdQ positive|Gerd Q positive was defined as score equal or more than eight.
62050577|NCT01742377||Patients with GerdQ negative|Gerd Q neegative was defined as score less than eight.
62050578|NCT01742377||Normal volunteers|Normal volunteers was defined as population without dyspeptic symptom.
62050579|NCT02083016|OTHER|Conventional Mapping|Both pre and post-ablation mapping will be performed firstly by conventional point by point mapping using a Navistar Thermocool catheter, and secondly by multielectrode contact mapping using a Pentaray catheter. In this group, ablation will be guided by conventional mapping.
62050580|NCT02083016|OTHER|Multielectrode mapping.|Both pre and post-ablation mapping will be performed firstly by multielectrode contact mapping using a Pentaray catheter, and secondly by conventional point by point mapping using a Navistar Thermocool catheter. In this group ablation will be guided by multielectrode contact mapping.
62050581|NCT04750967|EXPERIMENTAL|Active|Greater occipital nerve and supraorbital nerve block with 1% lidocaine once a week for first four weeks then once a month for 5 months
62441586|NCT02245776|EXPERIMENTAL|Stem Cell|Bone marrow mononuclear cell transplantation
62441587|NCT04160078|EXPERIMENTAL|Mindfulness Intervention Arm|A stress reduction plus sleep education intervention to improve sleep health
62441588|NCT01982383|EXPERIMENTAL|Micropulse Laser Treatment|Patient's randomized to ML treatment would be treated with the following settings: 200 micron spot size, 0.2 second duration, 15% duty cycle, and 300 milliWatt power. Their eyes would be dilated prior to treatment with standard mydriatic medications, including Tropicamide and Phenylephrine
62738820|NCT06653764|EXPERIMENTAL|Rehabilitation|
62738821|NCT04333888|EXPERIMENTAL|Treatment|
62738822|NCT04333888|NO_INTERVENTION|Control|
62738823|NCT01016717|ACTIVE_COMPARATOR|Omeprazole|Patients will be taking omeprazole tablets 40 mg QD for 30 days
62738824|NCT01016717|ACTIVE_COMPARATOR|Pantoprazole|Patients will be taking Pantoprazole tablets 40 mg QD for 30 days
62738825|NCT06625515|EXPERIMENTAL|Dose escalation|Subjects will be enrolled at various doses or schedules of ATX-559 to identify the RP2D
62050582|NCT04750967|ACTIVE_COMPARATOR|Control|Amitriptyline 25 mg daily for 6 months
62050583|NCT01160848|OTHER|Part 1|Three areas will be randomized to either a pre-treatment cleaning using a wipe containing an ethyl alcohol solution(one area) or a cleansing wipe containing saline water (two areas), before application of the Visonac cream. One of the areas cleaned with saline wipe will also be occluded with a transparent dressing (Tegaderm) during the incubation time. In vivo fluorescence spectroscopy will be performed in the three areas before cream application, and at 1h, 1.5h, 2h, 2.5h and 3 h after cream application
62050584|NCT01160848|OTHER|Part 2|For each patient, 3 areas were randomized to treatment with Visonac for 24 hours (2 areas) or Visonac for 1 hour (1 area)
62050585|NCT04076410|EXPERIMENTAL|5 Lenses|"The five lenses will be tested in each patient following always the same specific order, with the most protective lenses tested first (Z1).~Z1F133 (Zeiss Clarlet Z1) is a CE marked device manufactured by Carl Zeiss Vision International GmBH (Aalen, Germany).~Our lenses are CE marked devices manufactured by Cerium Optical Products (Kent, UK)."
62050586|NCT05429970|EXPERIMENTAL|PSRB|Participants will receive mind-body resilience training/MBRT, music therapy, propranolol and etodolac pre and post operatively. Postoperative Psychological Interventions may occur between POD 1-7 if needed.
62610741|NCT05585125|ACTIVE_COMPARATOR|Beta-Blocker BABA Sequence|This arm will follow a BABA sequence: OFF beta-blockers (B) and ON beta-blockers (A). Participants start Period 1 (B) by slowly reducing the participant's beta-blocker home dose by 50% each week until they are off (or the lowest tolerable dose), then switch to Period 2 (A), where they restart their beta-blocker and slowly up-titrate until they reach their home dose (or the highest tolerable dose). Participants are then asked if they have enough information to clarify their preference about continuing or discontinuing their beta-blocker. Participants can choose to engage in 2-6 periods based on whether they need more information. The extra phases follow the same OFF-ON pattern (BABABA), meaning if they choose to continue into Period 3 (B), the participant will slowly reduce their beta-blocker until they are off (or the lowest tolerable dose). This continues until the participant has enough information to clarify their preference about their beta-blocker, with a max of 6 periods.
62610742|NCT03345628||sedated|infants requiring intubation and ventilation who received sedatives for at least 3 days
62833247|NCT03405194|EXPERIMENTAL|Elvitegravir-Cobicistat-TAF-FTC|Elvitegravir 150mg po QD Cobicistat 150 mg po QD TAF 10 mg po QD FTC 200 mg QD
62833248|NCT03405194|ACTIVE_COMPARATOR|EFV-TDF-3TC|EFV 600 mg po QD TDF 300 mg po QD 3TC 300 mg po QD
62833249|NCT05060367|EXPERIMENTAL|Liposomal multivitamin/mineral condition|Ingestion of novel, liposomal multivitamin/mineral.
62833250|NCT05060367|ACTIVE_COMPARATOR|Standard multivitamin/mineral condition|Ingestion of standard multivitamin/mineral.
62050587|NCT05429970|NO_INTERVENTION|Standard of Care|Participants will receive usual care (study interventions not specifically recommended)
62050588|NCT05959343|EXPERIMENTAL|ERAS group|The experimental group will be implemented with the ERAS Clinical Pathway (ERAS CP)
62833251|NCT01238367|EXPERIMENTAL|recombinant factor VIII (N8)|
62833252|NCT05973617||Glaucoma|Patients with diagnosis of glaucoma, that are receiving or had surgery to treat glaucoma
62833253|NCT05973617||Ocular hypertension|Patients with diagnosis of ocular hypertension, that are receiving or had surgery to treat ocular hypertension
62833254|NCT05973617||Keratoconus|Patients with diagnosis of keratoconus, that are receiving or had surgery to treat keratoconus
62833255|NCT05973617||Healthy controls|Healthy
62833256|NCT05991271|EXPERIMENTAL|procedure|implant valve by TAVR
62441589|NCT01982383|PLACEBO_COMPARATOR|No Treatment|Patients randomized to this treatment arm, will not receive treatment for CSC. They will continue to be observed at month 1 and month 3. If any worsening of pathology is found during the follow up visits, the patient will be removed from the study and given appropriate standard of care by the attending
62441590|NCT06503796|EXPERIMENTAL|the antiviral group|HBV-infected infants in the treatment group were treated with LAM (4 mg/kg/d) before 1 year of age, and then combined with regular interferon (intramuscular or subcutaneous injection, 3-6 million U/m2 body surface area, every other day, with a starting dose of 3 million U/m2 body surface area, which was adjusted according to the specific tolerances of the children during the course of the treatment) if they were still HBV DNA and/or HBsAg-positive at the end of the 1st year of age. The course of interferon treatment is 52 weeks.
62441591|NCT06503796|NO_INTERVENTION|the control group|synchronized follow-up visits without intervention
62833257|NCT06143332|EXPERIMENTAL|Moderate-intensity continuous training|\~50 min of constant-power output cycling, 3 x per week at 85% of gas exchange threshold
62833258|NCT06143332|EXPERIMENTAL|Heavy-intensity continuous training|30 min of constant-power output cycling, 3 x per week at 70% of the difference between gas exchange threshold and respiratory compensation point
62050589|NCT05959343|NO_INTERVENTION|Control group|The control group will not be implemented with the ERAS CP
62441592|NCT01423435|EXPERIMENTAL|Japanese|
62610743|NCT03345628||non-sedated|infants who received respiratory support by non-invasive ventilation and were not sedated
62050590|NCT02017054||Cath patients|Patients with previous cardiac cath via the radial access who are planned for additional radial access cardiac cath
62050591|NCT01185444|EXPERIMENTAL|Hya-Joint|The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.
62050592|NCT01185444|ACTIVE_COMPARATOR|Hyalgan|the control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.
62441593|NCT01423435|EXPERIMENTAL|Chinese|
62441594|NCT01423435|EXPERIMENTAL|South Korean|
62610744|NCT05220748|EXPERIMENTAL|RM-1995 Photoimmunotherapy (Phase 1a Monotherapy)|Patients with locally advanced cuSCC or HNSCC or metastatic disease that has recurred or progressed, despite all available standard therapies.
62833259|NCT06143332|EXPERIMENTAL|High (severe)-intensity interval training|intervals; 4 x 4 min on - 3 min off at 115% of respiratory compensation point (work) and 50-70% gas exchange threshold (recovery)
62833260|NCT01440777|ACTIVE_COMPARATOR|Go! to Sleep|Participants access and utilize the 6-week online program that provides a set of various psycho-educational materials and behavioral techniques to treat insomnia.
62050593|NCT02492854|ACTIVE_COMPARATOR|Standard Sterile Gauze Dressings|In this arm, pts. will be randomized to receive standard sterile gauze dressing post-operatively.
62050594|NCT02492854|EXPERIMENTAL|PICO Negative Pressure Dressings|In this arm, pts. will be randomized to receive PICO single-use negative pressure dressings.
62050595|NCT05085925|EXPERIMENTAL|Cognitive behavioral mindfulness intervention at entry|Cognitive behavioral mindfulness intervention at entry
62252083|NCT03579420|EXPERIMENTAL|Brief lifestyle program|3-session lifestyle group intervention program focussed on physical activity and eating habits, using interactive methods and a behavioral approach
62252084|NCT03579420|ACTIVE_COMPARATOR|Traditional lifestyle longer program|6-session lifestyle group intervention program focussed on physical activity and eating habits, using traditional lessons and interactive methods
62252085|NCT00036751|EXPERIMENTAL|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
62252086|NCT04311736|ACTIVE_COMPARATOR|Exergame|Moderate intensity cycling only 3 times per week for 12 weeks + concurrent virtual reality cognitive training, supervised by an exercise specialist
62610745|NCT05220748|EXPERIMENTAL|RM-1995 Photoimmunotherapy + Pembrolizumab (Phased 1b Combination Therapy)|Patients with locally advanced cuSCC or HNSCC or metastatic disease that has recurred or progressed, despite all available standard therapies.
62050596|NCT05085925|ACTIVE_COMPARATOR|Cognitive behavioral mindfulness intervention after 3 months|Cognitive behavioral mindfulness intervention after 3 months of wait list
62050597|NCT01989143|EXPERIMENTAL|SAD Cohorts 1-8 Experimental Arm|
62050598|NCT01989143|PLACEBO_COMPARATOR|SAD Cohorts 1-8 Placebo Arm|
62050599|NCT01989143|EXPERIMENTAL|MAD Cohorts 9-11 Experimental Arm|
62050600|NCT01989143|PLACEBO_COMPARATOR|MAD Cohorts 9-11 Placebo Arm|
62050601|NCT01989143|EXPERIMENTAL|MAD Cohort 12 Experimental Arm|
62050602|NCT01989143|PLACEBO_COMPARATOR|MAD Cohort 12 Placebo Arm|
62050603|NCT02139098|EXPERIMENTAL|Amitriptyline flexible dosing|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights/placebo
62050604|NCT02139098|EXPERIMENTAL|Zolpidem flexible dosing|5 mg capsule zolpidem before going to bed on 8 out of 17 nights/placebo
62050605|NCT02139098|ACTIVE_COMPARATOR|Amitriptyline fixed dosing|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
62050606|NCT02139098|ACTIVE_COMPARATOR|Zolpidem fixed dosing|5 mg capsule zolpidem before going to bed on 8 out of 17 nights
62050607|NCT02139098|ACTIVE_COMPARATOR|Amitriptyline continuous dosing|50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
62252087|NCT04311736|ACTIVE_COMPARATOR|Cycling|Moderate intensity cycling only 3 times per week for 12 weeks, supervised by an exercise specialist
62252088|NCT04311736|SHAM_COMPARATOR|Stretching|Stretching 3 times per week for 12 weeks, supervised by a therapist
62252089|NCT03422679|EXPERIMENTAL|CB-103|CB-103 capsules will be administered orally in treatment cycles of 28-days each.
62252090|NCT01168973|EXPERIMENTAL|Ramucirumab + Docetaxel|
62050608|NCT05001360|EXPERIMENTAL|XBI-302 + Nivolumab|FMT capsules XBI-302 will be administered orally every two weeks for 12 weeks and then every four weeks for 12 weeks. Nivolumab will be intravenously infused every two weeks for 24 weeks.
62050609|NCT04334265|EXPERIMENTAL|Anluohuaxian combined with regular treatment group|Anluohuaxian: 6g each time, twice a day
62050610|NCT04334265|NO_INTERVENTION|regular treatment group|
62050611|NCT02298361||Intervention patients|Community Health Centers that implemented health insurance outreach IT tools: active patients on whom tools were used
62050612|NCT02298361||Within-clinic comparison patients|Community Health Centers that implemented health insurance outreach IT tools: active patients on whom tools were not used
62252091|NCT01168973|PLACEBO_COMPARATOR|Placebo + Docetaxel|
62252092|NCT03281967|OTHER|Minimally Invasive Ponto Surgery|Surgical method for installation of a bone anchored hearing system for hearing rehabilitation
62738826|NCT06625515|EXPERIMENTAL|Dose Expansion: MSI-H/dMMR solid tumors|
62738827|NCT06625515|EXPERIMENTAL|Dose Expansion: BRCA1- or BRCA2-deficient HER2-negative breast cancer|
62738828|NCT04164433|EXPERIMENTAL|Workplace-based HIV Self-Testing|"i. Explain the procedure of conducting HIVST \& interpret HIV self- test result to the user.~ii. Demonstrate how to perform the self-test and how to interpret the self-test result.~iii. Provide appointment card including information on linkage for HIV prevention services and further testing for diagnosis among those with a reactive self-test. Participants with a non-reactive self-test will be referred to HIV prevention services.~iv. Provide a toll free number for continued consultation"
62738829|NCT04164433|NO_INTERVENTION|Workplace-based standard HIV Testing Services (HTS)|Standard of care following the HIV testing algorithm .
62738830|NCT06644833|EXPERIMENTAL|Transcranial magnetic stimulation|Participants will receive repetitive Transcranial Magnetic Stimulation (rTMS) sessions, targeting the dorsolateral prefrontal cortex, at a frequency of 10 Hz. Each session will last approximately 30 minutes, with 5 sessions per week for 4 to 6 weeks. TMS will be administered by certified professionals, and patients will be monitored for any adverse events during each session. Follow-up evaluations will occur at regular intervals over the 3-year study period.
62050613|NCT02298361||Control clinic comparison patients|Matched Community Health Centers that did not implement health insurance outreach IT tools: active patients
62050614|NCT01334749||Acute Stroke|Patients over 18 years and without pre-stroke dementia, displaying an ischemic or hemorrhagic stroke, onset within the last 72 hours, language German
62050615|NCT06453655|EXPERIMENTAL|Intervention|This group was interviewed face to face one week before the day of the procedure and the nursing process was started to be applied. In the 3-day period before the procedure, the nursing process was continued with daily telephone follow-up. In the first face-to-face interview, nursing diagnoses and nursing outcome scales appropriate to the needs of the individual were determined and NOCs baseline measurements were made. NICs selected according to the nursing process were applied for 7 days. The last measurement of NOCs was made on the day of the procedure. In addition, BBPS scores calculated by the endoscopist during the procedure were taken from the patient file and recorded in the data collection form
62050616|NCT06453655|NO_INTERVENTION|Control Group|This grup nursing diagnoses and expected nursing outcomes (NOC) appropriate to the needs of the individual were selected in a face-to-face interview 1 week before the procedure. The baseline measurements of NOCs were made. On the trading day, the after measurement of NOCs was made. But nursing process was not applied to this group.
62252093|NCT02067195|ACTIVE_COMPARATOR|Guideline Hydration|No hydration for patients without chronic kidney disease(CrCl\<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
62441595|NCT03154320|ACTIVE_COMPARATOR|Standard Group|On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and provide a sputum specimen for spot Xpert Ultra testing (48-hour results). Those with high clinical/radiographic suspicion for TB will start same-day TB treatment. On Day 2, participants will return for results of Xpert Ultra testing (spot specimen) and to provide a specimen for early morning Xpert Ultra testing. Those who are Xpert Ultra positive will start TB treatment. Those who are not diagnosed with TB will start ART on Day 7, after testing and treatment for other opportunistic infections. A liquid TB culture will be performed on both the spot and early morning specimens.
62610746|NCT06730217|ACTIVE_COMPARATOR|Control|Participants randomized to the control group will receive standard care. The patient is then assessed by a first physiotherapist evaluator, who measures the data described in the study setting section. The physiotherapist then performs a manual bronchial decongestion session, using the Expiratory Flow Augmentation technique with abdominal and thoracic counter-pressure.
62610747|NCT06730217|EXPERIMENTAL|Experimental|Participants randomized to the intervention group will benefit from a mechanical insufflator during airway clearance sessions (EOVE-70®, Air Liquide Medical Systems France).
62610748|NCT06730841|ACTIVE_COMPARATOR|DOS-tDCS: A dose-optimized and spaced form of tDCS|On each treatment day, participants will receive 5 tDCS sessions, each lasting 20 minutes, with a 20-minute intersession interval. The dose-optimized and spaced tDCS (DOS-tDCS) group will be treated using a stimulation intensity of up to 4 mA.
62610749|NCT06730841|ACTIVE_COMPARATOR|Spaced tDCS: A spaced form of tDCS only|On each treatment day, participants will receive 5 tDCS sessions, each lasting 20 minutes, with a 20-minute intersession interval. The spaced tDCS only group will receive stimulation at the standard 2 mA dose.
62610750|NCT06730841|SHAM_COMPARATOR|Sham tDCS|On each treatment day, participants will receive 5 sham tDCS sessions, each lasting 20 minutes, with a 20-minute intersession interval.
62610751|NCT05676476|EXPERIMENTAL|Intervention|Antihypertensive treatment for a BP goal of less than 140/90 mmHg
62610752|NCT05676476|NO_INTERVENTION|Usual Care|Antihypertensive treatment only if BP ≥ 160/110 mmHg
62610753|NCT05983575|EXPERIMENTAL|LIPUS-Brain|
62610754|NCT05983575|PLACEBO_COMPARATOR|Placebo|
62050617|NCT05742828|ACTIVE_COMPARATOR|Virtual Seating Coach|The Virtual Seating Coach is a context-aware reminding system that when set up by a clinician, directly benefits a user by reminding him or her to change position with the chair's power seating function.. Regular position changes increase independent function, reduce the risk of pressure ulcers, manage pain, and reduce swelling.
62050618|NCT05742828|NO_INTERVENTION|Non Virtual Seating Coach|power wheelchairs that tilt, recline, and have leg elevation for maximal pressure management and to encourage repositioning to reduce the risk of skin breakdown/pressure injury as well as decrease pain.
62050619|NCT03846102|EXPERIMENTAL|Levobupivacaïne|"Fascia Iliaca Compartment Block with Levobupivacaine Hydrochloride (weight based dosage and volume)~Ideal Body Weight : Levobupivacaïne dose (mg) : Dose/kilogram (mg/kg) : Total volume (ml)~* \[\<64 kg : 100 mg : 2.0 mg/kg : 40 ml\]~* \[65-74 kg : 125 mg : 1.9 mg/kg : 45 ml\]~* \[≥ 75 kg : 150 mg : 2.0 mg/kg : 50 ml\]~Acetaminophen 1 gram (tablets) 4 times daily.~Patient Controlled Analgesia Pump with morphine 1 milligram per dose."
62050620|NCT03846102|PLACEBO_COMPARATOR|Placebo|"Fascia Iliaca Compartment Block with placebo (Sodium Chloride 0.9%), similar volume to experimental arm.~Ideal Body Weight : Total volume (ml)~* \[\<64 kg : 40 ml\]~* \[65-74 kg : 45 ml\]~* \[≥ 75 kg : 50 ml\]~Acetaminophen 1 gram (tablets) 4 times daily.~Patient Controlled Analgesia Pump with morphine 1 milligram per dose."
62610755|NCT05467670|EXPERIMENTAL|ALX148 + Doxorubicin (PLD) + Pembrolizumab|"Given on Day 1 of each 21 day cycle, in the following order of administration:~200 mg IV pembrolizumab\* (maximum of 2 years (approximately 35 cycles)~45 mg/kg IV ALX148~30 mg/m\^2 IV doxorubicin (Pegylated Liposomal Doxorubicin (PLD)\*~\*standard of care"
62610756|NCT00782691||Head-and-neck cancer patients.|Head-and-neck cancer patients eligible for therapeutic lymph node dissection of cervical nodes.
62252094|NCT02067195|ACTIVE_COMPARATOR|Adequate Hydration|Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP \<13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and \>1.5 ml/kg/hr for LVEDP \>18 mmHg, whereas,0.5 ml/kg/hr for LVEDP \>20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
62252095|NCT00812799|ACTIVE_COMPARATOR|Grass pollen extract|Subjects will receive 19.000 BU grass pollen extract daily sublingually
62610757|NCT05119569|EXPERIMENTAL|Fenebrutinib|Participants will receive oral fenebrutinib.
62610758|NCT05119569|PLACEBO_COMPARATOR|Placebo|Participants will receive oral placebo.
62610759|NCT04140916|EXPERIMENTAL|Midline catheter|Insertion of a Midline catheter in patients scheduled for insertion of a catheter for intravenous fluids or medicines with an expected length of treatment between 5 and 28 days will
62050621|NCT01844271|PLACEBO_COMPARATOR|Placebo Low Level Laser|Application of low level laser without any dose (0 Joule) before strenuous exercise. A laser device with a cluster of 5 diodes (810 nm, 200 mW) each diode was used for this study.
62252096|NCT00812799|PLACEBO_COMPARATOR|Placebo control|Subjects will receive matching placebo control daily sublingually
62252097|NCT03713034|EXPERIMENTAL|Active Game|"PlayTest! is an interactive world in which the player, using an avatar they have created, travels through life in high school. They face challenges that bring different risks and benefits, requiring them to practice decision-making skills. The player learns skills that aim to empower them to make safe choices in situations that may otherwise increase their risk for HIV/STI infection. The game also provides opportunities for the player to practice advocating for their health by modeling a conversation with a medical professional. PlayTest! incorporates evidence-based tools for behavior change including social learning theory and self-efficacy. message framing, motivational interviewing to identify the variables that must be targeted to increase HTC among adolescents."
62252098|NCT03713034|ACTIVE_COMPARATOR|Control Game|Some examples of control games that participants could play are: The Sims, Harry Potter, Subway Surfer, Tetris. The control games contained not relevant content related to HIV Testing and Counseling.
62252099|NCT02067442|ACTIVE_COMPARATOR|oral acetaminophen|Patients in this arm of the study will receive oral acetaminophen and an IV placebo
62441596|NCT03154320|EXPERIMENTAL|Same-Day Treatment Group|On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and Xpert Ultra testing with same-day results. Based on clinical symptoms, Xpert Ultra results, and chest x-ray, physician will determine whether or not the participant has tuberculosis. Those who are diagnosed with TB will start same-day TB treatment. Those who are not diagnosed with TB will start same-day ART.
62050622|NCT01844271|EXPERIMENTAL|2 Joules Low Level Laser|Application of 2 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
62252100|NCT02067442|ACTIVE_COMPARATOR|intravenous acetaminophen|Patients in this arm of the study will receive IV acetaminophen and an oral placebo
62441597|NCT03945565|ACTIVE_COMPARATOR|FiO2 0.3|Patients allocated to this group are going to receiving FiO2 of 0.3 during surgery
62441598|NCT03945565|ACTIVE_COMPARATOR|FiO2 0.8|Patients allocated to this group are going to receiving FiO2 of 0.8 during surgery
62441599|NCT03015142||New image-guidance software|Patients in this group had spine surgery with new image-guidance software application.
62441600|NCT01752920|EXPERIMENTAL|Low Dose Group|Patients who received derazantinib orally at dose levels from 25 mg every other day (QOD) - 200 mg daily (QD) on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
62610760|NCT04140916|ACTIVE_COMPARATOR|PICC-line catheter|Insertion of a Midline catheter in patients scheduled for insertion of a catheter for intravenous fluids or medicines with an expected length of treatment between 5 and 28 days will
62610761|NCT00919542|ACTIVE_COMPARATOR|prednisolone|standard course of prednisolone given in a reducing regimen over 16 weeks
62610762|NCT00919542|EXPERIMENTAL|Ciclosporin|ciclosporin reducing regimen lasting 16 weeks (additional prednisolone given for the first four weeks)
62610763|NCT02984514|EXPERIMENTAL|Type 1 diabetes|Positron emission tomography with tracer 18F-deoxy glucose
62610764|NCT06730191|OTHER|conventional|conventional without anything only immediate dental implant covering by soft tissue graft
62610765|NCT06730191|OTHER|Split thickness|split thickness graft before covering immediate implant
62610766|NCT03385369|PLACEBO_COMPARATOR|Placebo Japanese Descent|Participants of Japanese descent will receive a single subcutaneous injection of placebo matching to MEDI0382.
62050623|NCT01844271|EXPERIMENTAL|6 Joules Low Level Laser Therapy|Application of 6 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
62050624|NCT01844271|EXPERIMENTAL|10 Joules Low Level Therapy|Application of 10 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
62610767|NCT03385369|EXPERIMENTAL|MEDI0382 50 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 50 mcg MEDI0382.
62610768|NCT03385369|EXPERIMENTAL|MEDI0382 100 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 100 mcg MEDI0382.
62610769|NCT03385369|EXPERIMENTAL|MEDI0382 150 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 150 mcg MEDI0382.
62610770|NCT03385369|EXPERIMENTAL|Placebo Chinese Descent|Participants of Chinese descent will receive a single subcutaneous injection of placebo matching to MEDI0382.
62610771|NCT03385369|EXPERIMENTAL|MEDI0382 100 mcg Chinese Descent|Participants of Chinese descent will receive a single subcutaneous dose of 100 mcg MEDI0382.
62833261|NCT01440777|NO_INTERVENTION|Control Group|No intervention provided. These participants will receive the Go! to Sleep program after the research trial has been completed (10 weeks after registration).
62833262|NCT03604302|EXPERIMENTAL|Functional Magnetic Resonance Imaging (fMRI)|The interventions for this study are non-invasive. For patients, routine pre-operative MRI that includes task based fMRI and perfusion data acquisition will be performed on a 3T scanner. Patients who participate in this study, will have approximately 5 minutes added to their scan time for the below described breath holding fMRI (BH fMRI) paradigm, which will be done for research purposes. For healthy volunteers, participation will involve having a high resolution anatomical MRI done with the same paradigms which patients will have, listed below. the total scanner time will be approximately 25 minutes, and the scan will not be billed to the healthy volunteer.
62833263|NCT02809482|OTHER|Eucaloric Feeding|
62833264|NCT02809482|OTHER|Overfeeding|
62441601|NCT01752920|EXPERIMENTAL|Middle Dose Group|Patients who received derazantinib orally at dose levels from 250 mg QD - 325 mg QD on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
62833265|NCT01068847|EXPERIMENTAL|1|Receives 2-4 of the drugs listed under Intervention
62833266|NCT06374563|EXPERIMENTAL|Group 1|Group 1 received topical application of Bee Venom gel, 3 times per week
62833267|NCT06374563|EXPERIMENTAL|group 2|Group 1 received phonophoresis of Bee Venom gel using low intensity ultrasound, 3 times per week
62441602|NCT01752920|EXPERIMENTAL|High Dose Group|Patients who received derazantinib orally at dose levels from 400 mg QD - 425 mg QD on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
62441603|NCT01752920|EXPERIMENTAL|Expanded Cohort Group|Patients who received derazantinib orally at the recommended phase 2 dose of 300 mg QD on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
62441604|NCT02462421|ACTIVE_COMPARATOR|Wild type genotype|Research subjects with wild type genotypes at three candidate genes encoding sodium-dependent glucose transporter-3, sodium-dependent glucose transporter-4, and glucose transporter-9 (abbreviated as SLC5A4, SLC5A9, SLC2A9, respectively) will be studied before and after canagliflozin treatment.
62441605|NCT02462421|EXPERIMENTAL|Nonsense mutation in SLC5A4|Research subjects who are homozygous for nonsense mutation in SLC5A4 (sodium-dependent glucose transporter-3) will be studied before and after canagliflozin treatment.
62441606|NCT02462421|EXPERIMENTAL|Nonsense mutation in SLC5A9|Research subjects who are homozygous for nonsense mutation in SLC5A9 (sodium-dependent glucose transporter-4) will be studied before and after canagliflozin treatment.
62441607|NCT02462421|EXPERIMENTAL|Missense variant in SLC2A9|Research subjects who are homozygous for nonsynonymous variant in glucose transporter-9 (SLC2A9) will be studied before and after canagliflozin treatment.
62441608|NCT00667927|OTHER|1|
62441609|NCT02543333||Asthma|Patients attending outpatient clinic as part of their clinical care who have FEV1 less than 80% of predicted and are referred by their clinician for a bronchodilator test
62610772|NCT03365453|EXPERIMENTAL|frailty evaluation|all consecutive patients admitted to hospital for valvular disorders more than 69 years will be evaluated with several frailty and comorbidities scores.
62610773|NCT05366010|EXPERIMENTAL|Intervention|Intervention time period, during which all subjects receive OLE therapy as their airway clearance intervention
62610774|NCT04856631|EXPERIMENTAL|Experimental group|Toripalimab Injection (JS001) + Cetuximab
62833268|NCT03585764|EXPERIMENTAL|Cohort 1: MOv19-BBz CAR T cells without chemo|Cohort 1: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy.
62610775|NCT02818426|EXPERIMENTAL|UCPVax|"UCPVax is a therapeutic cancer vaccine composed of two peptides called UCP2 and UCP4 derived from telomerase combined with Montanide ISA 51 VG as adjuvant.~The two peptides UCP2 and UCP4 will be emulsified in Montanide ISA 51 and injected subcutaneously in separate sites (one site per peptide), at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination every 8 weeks for 12 months."
62610776|NCT03661216|PLACEBO_COMPARATOR|Placebo|3g of non-GMO maltodextrin
62050625|NCT01844271|EXPERIMENTAL|Power of 100mW|After assigning ideal dose of application it was delimited two experimental groups which was irradiated with the dose established by the first part of the study and power of 100mW.
62050626|NCT01844271|EXPERIMENTAL|Power of 400mW|After assigning ideal dose of application it was delimited two experimental groups which were irradiated with the dose established by the first part of the study and power of 400mW.
62050627|NCT02658630|EXPERIMENTAL|Device: Robot + TTT Exercise|All participants will be enrolled in this group to receive the same 60 minute study intervention consisting of wrist and shoulder-elbow robot training and TTT arm exercises.
62050628|NCT02606279|PLACEBO_COMPARATOR|Placebo control|20 HIV-infected participants will be randomized into a blinded arm where they will receive 24 weeks of placebo therapy. During this time, they will undergo the same study procedures as the intervention arm.
62050629|NCT02606279|EXPERIMENTAL|Valsartan|20 HIV-infected participants will be randomized into a blinded arm where they receive 24 weeks of valsartan therapy. For those subjects randomized to the valsartan group, they will receive valsartan 40 mg by mouth daily for 2 weeks, then increase to 80 mg by mouth daily for the remaining 22 weeks. During this time, they will undergo the same study procedures as the placebo arm.
62610777|NCT03661216|ACTIVE_COMPARATOR|Nephure|3g of Nephure
62610778|NCT00858715|ACTIVE_COMPARATOR|1|75 mg clopidogrel + 100 mg aspirin
62610779|NCT00858715|ACTIVE_COMPARATOR|2|150 mg clopidogrel + 100 mg aspirin
62610780|NCT05276011|ACTIVE_COMPARATOR|Active Treatment (TG-C)|TG-C at 1.0 x 10e7 cells per single 2 mL intraarticular injection
62610781|NCT05276011|ACTIVE_COMPARATOR|Active Treatment 2 (TG-C)|TG-C at 3.0 x 10e6 cells per single 2 mL intraarticular injection
62610782|NCT05276011|PLACEBO_COMPARATOR|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
62050630|NCT04791280||patients with systemic sclerosis|"On the day of inclusion, the faeces collection will be carried out by the patient using adapted equipment, either at the hospital or at home. In the case of a home collection, it will be carried out on the day of a planned hospital and preserved using equipment provided and tested to maintain the quality of the collection before storage.~6 months after inclusion (+/- 2 months) a follow-up visit will be carried out and the patient will perform a second faecal sample.~At the inclusion visit and at M6 the UCLA SCTC GIT 2.0 questionnaire will be completed by the patient."
62050631|NCT03021356|ACTIVE_COMPARATOR|Trifecta aortic xenograft|The Trifecta aortic xenograft is implanted in these patients.
62050632|NCT03021356|ACTIVE_COMPARATOR|Magna Ease aortic xenograft|The Magna Ease aortic xenograft is implanted in these patients.
62050633|NCT00290862|EXPERIMENTAL|CORTOSS|Patients prospectively randomized to be treated with Cortoss constitute treatment group.
62050634|NCT00290862|ACTIVE_COMPARATOR|PMMA|Patients prospectively randomized to be treated with PMMA constitute active control group.
62050635|NCT05446324|EXPERIMENTAL|68Ga-tilmanocept PET/CT|All participants receive 68Ga-tilmanocept PET/CT imaging in adjunct to standard-of-care (SLN mapping with intraoperative ICG).
62050636|NCT03893721||malnourished under five children|children from 2 to 5 years with malnutrition
62441610|NCT02543333||Acute Asthma|Inpatients admitted for an acute asthma exacerbation
62050637|NCT03893721||well nourished under five children|children from 2 to 5 years without malnutrition
62050638|NCT01705496|EXPERIMENTAL|[124I]FIAU|Single dose study of \[124I\]FIAU in patients presenting with pain in a prosthetic knee or hip joint who will undergo PET-CT scanning.
62441611|NCT02543333||Normal|Participants with no current or previous diagnosis of a respiratory condition
62441612|NCT01214330|EXPERIMENTAL|Patient-Collected Cervical Pap Smear|women will receive a self Papanicolaou Smear test (SoloPap) in addition to their physician-collected Papanicolaou Smear
62441613|NCT02104518||G6PD testing|Blood samples will be tested for G6PD activity levels
62441614|NCT01045499|EXPERIMENTAL|laparoscopic gastric banding|Adolescent patients who have undergone laparoscopic adjustable gastric banding. Weight, BMI, and co-morbidity data will be compared to patient's pre-operative values.
62610783|NCT04667533|EXPERIMENTAL|Desidustat tablet|
62610784|NCT03953625|NO_INTERVENTION|no delivery of the low back pain booklet|"When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.~if the patient is included and depending on the week of inclusion, he will then be randomized to either the no booklet or the booklet group.~If it is randomized to the arm 1 no booklet group, the patient will have classic management.~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection."
62610785|NCT03953625|EXPERIMENTAL|delivery of the low back pain booklet|"When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.~If the patient is included and depending on the week of inclusion, the patient will then be randomized to either the no booklet or the booklet group.~If it is randomized in the arm 2 with booklet group, the management will be the same as for the without booklet group but with the hand delivery of the booklet in addition.~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection."
62610786|NCT02604173|EXPERIMENTAL|Budesonide|Budesonide inhaler as experimental treatment along with placebo pill.
62610787|NCT02604173|ACTIVE_COMPARATOR|Acetazolamide|Acetazolimide pill as active comparator along with sham inhaler.
62050639|NCT00406003|EXPERIMENTAL|Subjects receiving treatment sequence ABC|Eligible subjects will receive treatment sequence ABC; A= paroxetine 12.5 milligrams, B= paroxetine 25 milligrams, and C= paroxetine 37.5 milligrams separated by a wash-out period of 10 days.
62050640|NCT00406003|EXPERIMENTAL|Subjects receiving treatment sequence BAC|Eligible subjects will receive treatment sequence BAC; B= paroxetine 25 milligrams, A= paroxetine 12.5 milligrams and C= paroxetine 37.5 milligrams separated by a wash-out period of 10 days.
62610788|NCT02604173|SHAM_COMPARATOR|Control|Sham inhaler as control for budesonide inhaler along with placebo pill as control for acetazolamide comparator.
62833269|NCT03585764|EXPERIMENTAL|Cohort 2: MOv19-BBz CAR T cells after chemo|Cohort 2: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
62833270|NCT03585764|EXPERIMENTAL|Cohort 3: MOv19-BBz CAR T cells after chemo|Cohort 3: (n=3 to 6 subjects): Single infusion of 1-3x108 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
62833271|NCT03585764|EXPERIMENTAL|Cohort-1: without chemo;only if dose de-escalation required|Cohort -1: (n= 3 to 6 subjects): Single Infusion of 1-3x106 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy. Up to 6 subjects will be infused in Cohort -1 with ≤ 1 DLT/6 subjects to establish the MTD.
62833272|NCT02194543||HD 3D|The patients received surgeries with HD 3D on their left eyes.
62833273|NCT02194543||Conventional|The patients received surgeries with conventional method on the other eye.
62833274|NCT02648919|EXPERIMENTAL|Noni 6,000 mg/day|Noni extract 6,000 mg/day (4 capsules with breakfast, 4 capsules with lunch and 4 capsules with dinner)
62050641|NCT00406003|EXPERIMENTAL|Subjects receiving treatment sequence CBA|Eligible subjects will receive treatment sequence CBA; C= paroxetine 37.5 milligrams, B= paroxetine 25 milligrams and A= paroxetine 12.5 milligrams separated by a wash-out period of 10 days.
62050642|NCT00406003|EXPERIMENTAL|Subjects receiving treatment sequence BCA|Eligible subjects will receive treatment sequence BCA; B= paroxetine 25 milligrams, C= paroxetine 37.5 milligrams and A= paroxetine 12.5 milligrams separated by a wash-out period of 10 days.
62050643|NCT00406003|EXPERIMENTAL|Subjects receiving treatment sequence CAB|Eligible subjects will receive treatment sequence CAB; C= paroxetine 37.5 milligrams, A= paroxetine 12.5 milligrams and B= paroxetine 25 milligrams separated by a wash-out period of 10 days.
62050644|NCT00406003|EXPERIMENTAL|Subjects receiving treatment sequence ACB|Eligible subjects will receive treatment sequence ACB; A= paroxetine 12.5 milligrams, C= paroxetine 37.5 milligrams and B= paroxetine 25 milligrams separated by a wash-out period of 10 days.
62050645|NCT01774864|EXPERIMENTAL|DA-8159 dose 1|Udenafil
62050646|NCT01774864|EXPERIMENTAL|DA-8159 dose 2|Udenafil
62050647|NCT01774864|PLACEBO_COMPARATOR|Placebo|
62050648|NCT05391750|EXPERIMENTAL|Treatment (venetoclax, tocilizumab)|Patients receive tocilizumab IV on day -7 of cycle 1, and on day 1 of subsequent cycles. Patients also receive venetoclax PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62833275|NCT01795053|EXPERIMENTAL|playtraining|playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and intensity and thereby reduce ADHD symptoms
62050649|NCT04439643||Development / training|Selected by stratified partitioning
62833276|NCT01795053|PLACEBO_COMPARATOR|open play session|the open play sessions are conducted in the same rooms, by the same staff and in the same time frame as the experimental sessions. The therapist plays with the child without structuring the sitauation through behavioral tecniques. The play situation is designed to be ineresting and comfortable for the child.
62833277|NCT02846025|OTHER|Folate|diet rich in folate
62833278|NCT02846025|OTHER|placebo|placebo
62610789|NCT06731270|EXPERIMENTAL|Treatment (diclofenac, immunotherapy)|Patients receive diclofenac PO BID and standard of care immunotherapy with pembrolizumab, atezolizumab, nivolumab or cemiplimab on day 1 of each cycle. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and CT, PET, or MRI on study.
62610790|NCT05170230|ACTIVE_COMPARATOR|intracapsular myomectomy Terlipressin injection|intracapsular myomectomy Terlipressin injection in women undergoing laparoscopic myomectomy procedure
62833279|NCT02846025|OTHER|diet antioxidant|diet antioxidant
62833280|NCT02846025|OTHER|Hazelnut Oil|hazelnut oil capsule
62050650|NCT04439643||Sequestered / test|Selected by stratified partitioning
62050651|NCT02591134|EXPERIMENTAL|Non Nutritive Sweetened Beverages|Non-nutritive sweeteners (NNS) beverages will be provided to participants using a home delivery system and they are expected to consume at least two portions (330ml) per day.
62050652|NCT02591134|PLACEBO_COMPARATOR|Control Water Beverages|Water beverages will be used as a comparator to NNS beverages during the trial. These beverages will encompass a range of water-based drinks that contain no NNS. Including water as a comparator is vital to understand whether NNS beverages are equally as effective as water during phases of weight loss and weight maintenance.
62050653|NCT02184754||MEI|
62050654|NCT01525316|EXPERIMENTAL|Bovine Lactoferrin|Lactoferrin is a freeze-dried protein purified directly from fresh bovine milk.
62050655|NCT01525316|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin is an inert sugar.
62833281|NCT01875094|EXPERIMENTAL|Self-Management / MTM via Health IT|Stroke survivors are trained to measure and enter BP into an online health management tool
62833282|NCT01875094|NO_INTERVENTION|Usual Care|
62833283|NCT03997188|EXPERIMENTAL|Hepilor arm|patients received ZLC solution. The prescribed dose was 10 ml, in the morning and evening, between meals.
62833284|NCT03997188|PLACEBO_COMPARATOR|Placebo arm|Patients received a placebo solution. The prescribed dose was 10 ml, in the morning and evening, between meals
62833285|NCT06137937|EXPERIMENTAL|Interventional Group|subjects in the treatment group underwent routine hemodialysis by committing to an intradialysis aerobic exercise program
62833286|NCT06137937|NO_INTERVENTION|Control Group|subjects in the control group underwent routine hemodialysis without a physical exercise program
62833287|NCT05199103|EXPERIMENTAL|Rabbit antithymocyte globulin (rATG)|
62833288|NCT03013803|EXPERIMENTAL|Nutricomp Drink Plus Fibre|Nutricomp® Drink Plus Fibre (flavours vanilla, coffee, peach-apricot and chocolate)
62833289|NCT02902237|EXPERIMENTAL|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
62833290|NCT03347721|ACTIVE_COMPARATOR|Lidocaine gel|
62050656|NCT06579274|EXPERIMENTAL|Active - Parecoxib|"Parecoxib 40 mg/100 ml will be injected into a peripheral or central venous catheter within 12 hours of the patient's inclusion in the study (from when informed consent is signed). Parecoxib 40 mg/100 ml is administered every 12 hours for 5 days. The maximum daily dose is 80 mg.~In patients with moderate hepatic impairment (Child-Pugh score 7-9), parecoxib is started at 20 mg/50 mL and continued at this dose every 12 hours. The maximum daily dose is 40 mg.~Participants will be monitored for six months for adverse events and changes in subjective status. In the event of adverse events, patients will be followed until resolution. After that, their participation in this clinical trial will be terminated. The total duration of the patient's participation in the clinical trial will be six months."
62833291|NCT03347721|PLACEBO_COMPARATOR|Lubricant Gel|
62833292|NCT04746677|EXPERIMENTAL|Complex abdominal aortic aneurysm (AAA)|Includes juxtarenal AAA, suprarenal AAA, and type IV thoracoabdominal aortic aneurysm
62833293|NCT04746677|EXPERIMENTAL|Thoracoabdominal aortic aneurysm (TAAA)|Includes Type I, Type II, and Type III TAAA
62833294|NCT04746677|EXPERIMENTAL|Type B aortic dissection|Includes all Type B dissections
62833295|NCT04746677|EXPERIMENTAL|Expanded Selection Arm|Includes high risk subjects who do not meet inclusion criteria for Arms !-3
62833296|NCT03743181||intervention|will be supplied by pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.
62833297|NCT03743181||control|will received standard care by physician in attendance
62833298|NCT00897234||Healthy Volunteers|Non-smoking healthy volunteers
62833299|NCT00897234||Non-Small Cell Lung Cancer|Patients with non-small cell lung cancer.
62441615|NCT04638985|EXPERIMENTAL|group 1 (sIPV+DTaP+MMR)|150 subjects; simultaneously administration of sIPV+DTaP+MMR as booster immunization at the age of 18 months old, 0.5 ml each, respectively
62833300|NCT02417766||Family Members|Family members to the patients
62833301|NCT02417766||Patient|Patients here at NIH
62833302|NCT05871216||Joint Hypermobility Syndrome|Patients suffering from Joint Hypermobility Syndrome with a moderate/severe degree of joint hypermobility (Beighton-Horan Joint Mobility Index score 3-9)
62833303|NCT01662102|EXPERIMENTAL|Zevalin Regimen Consolidation (Group A)|"90Y-Ibritumomab tiuxetan administered 8 to 12 weeks after the last chemotherapy infusion. Each participant randomized to this treatment group was to receive a therapeutic dose of 14.8 MBq/kg (0.4 mCi/kg of total body weight) of 90Y ibritumomab tiuxetan (maximum 1,184 MBq or 32 mCi). Participants with a pre-treatment platelet count between 100 and 149 x10\^9/L were to receive 0.3 mCi/Kg 90Y-ibritumomab tiuxetan. (Body weight ≤80 kg: 14.8 MBq \[0.4 mCi\] yttrium-90/kg and Body weight \>80 kg: 1,184 MBq \[32 mCi\] maximum dose).~The 90Y ibritumomab tiuxetan regimen is as follows: Day 1 rituximab (250 mg/m\^2); Day 7,8, or 9 rituximab (250 mg/m\^2) followed by 90Y ibritumomab tiuxetan within 4 hours of the end of the rituximab infusion. (Maximum duration of study was up to approximately 2.7 months)."
62833304|NCT01662102|ACTIVE_COMPARATOR|Rituximab Maintenance (Group B)|Participants were to receive 375 mg/m\^2 of rituximab, administered by intravenous (I.V.) infusion every 8 weeks, starting 8 to 12 weeks after the last R-chemotherapy cycle. (Maximum duration of study was up to approximately 2.7 months).
62833305|NCT06333912|EXPERIMENTAL|study group treated with guided ridge splitting.|virtual surgical planning using planning software Blue Sky Bio (BSB) and 3D printed surgical guide are fabricated to guide the ridge splitting procedure and implant drilling and placement.
62833306|NCT06333912|ACTIVE_COMPARATOR|control group treated with conventional ridge splitting.|Freehand surgery is done including ridge splitting and implant plaement
62833307|NCT00438009|EXPERIMENTAL|CAVATAK|
62833308|NCT04575948|EXPERIMENTAL|Moringa Oleifera mouth wash|According to part I of the study, we will select the most effective (Non-toxic, anti-bacterial effect) Moringa extract to prepare the mouth wash.
62833309|NCT04575948|PLACEBO_COMPARATOR|Base formula of mouth wash|Base formula of mouthwash
62833310|NCT04575948|ACTIVE_COMPARATOR|Chlorhexidine|Commercial 0.12% chlorhexidine digluconate mouthwash
62833311|NCT05976412|EXPERIMENTAL|RNI group|
62833312|NCT05976412|PLACEBO_COMPARATOR|non-RNI group|
62833313|NCT02341677|EXPERIMENTAL|Biopsy|Single Arm Study. Biopsy Intervention.
62833314|NCT03262480|ACTIVE_COMPARATOR|Stroke volume optimization|Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4 (Voluven) will be administered within 10 minutes and stroke volume response will be recorded .If stroke volume increase by more than 10 % for 20 minutes, the aliquot will be repeated.
62833315|NCT03262480|SHAM_COMPARATOR|Central venous pressure dynamic|Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4(Voluven) will be administered within 10 minutes and CVP response will be recorded. If CVP failed to rise sustainably for more than 2 mmHg for 20 minutes, the aliquot will be repeated.
62833316|NCT02556385|EXPERIMENTAL|High frequency rTMS|Most activated area from fNIRS with language task: Perileisional Broca's area
62833317|NCT02556385|ACTIVE_COMPARATOR|Low Frequency rTMS|Most activated area from fNIRS with language task: Contralesional homologs of Broca's area
62833318|NCT02454517|EXPERIMENTAL|Arm I (diet and exercise lifestyle intervention)|The goals of the diet and exercise lifestyle intervention is for patients to lose 7% total body weight. Patients meet with a nutritionist 11 times during the first 6 months to receive the structured diet and exercise instruction. Participants complete exercise sessions supervised by an exercise specialist, and will wear a heart rate monitor periodically during the study.
62833319|NCT02454517|ACTIVE_COMPARATOR|Arm II (control)|Patients receive an informational intervention along with a 20-30 minute individual session with a dietitian and a goal of 30 minutes of physical activity 5 days a week.
62833320|NCT01177371|EXPERIMENTAL|Arm I|"HIGH-DOSE CHEMOTHERAPY: Patients receive oral busulfan every 6 hours on days -8 to -5 and cyclophosphamide IV over 2 hours on days -4 and -3, or -4 to -2.~TRANSPLANTATION: Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine IV over 6 hours on day -1, over 10 hours twice daily on days 0-20, and then orally every 12 hours beginning on day 21 and continuing for 12 months with taper at 9 months. Patients also receive methylprednisolone IV or orally beginning on day 8 and continuing for 7 months with taper at 4 months. Some patients may also receive methotrexate IV on days 1, 3 and 6."
62610791|NCT05170230|ACTIVE_COMPARATOR|intracapsular myomectomy Carbetocin injection|intracapsular myomectomy Carbetocin injection in women undergoing laparoscopic myomectomy procedure
62610792|NCT05170230|PLACEBO_COMPARATOR|intramyometrial saline|intracapsular myomectomy saline injection in women undergoing laparoscopic myomectomy procedure
62610793|NCT04343365||Participants Reviewed by ETB|Participants clinical history, available therapeutic options, and outcome expectations will be presented to the Evolutionary Tumor Board (ETB) along with images and pathology. Strategies and models will be presented regarding additional evolutionary ideas that can be applied.
62610794|NCT05582187|EXPERIMENTAL|Cohort 1: Fosmanogepix participants with mild hepatic impairment|Participants with mild hepatic impairment will receive a single dose of fosmanogepix, administered orally as 1 fosmanogepix tablet under fasted conditions.
62610795|NCT05582187|EXPERIMENTAL|Cohort 2: Fosmanogepix Participants with moderate hepatic impairment|Participants with moderate hepatic impairment will receive a single dose of fosmanogepix, administered orally as 1 fosmanogepix tablet under fasted conditions.
62833321|NCT02865447||PRESERVE total hip arthroplasty implant|Subjects to be prospectively implanted with the PROFEMUR PRESERVE total hip arthroplasty implant
62833322|NCT00361348|ACTIVE_COMPARATOR|Palifermin|A single 60µg/kg IV bolus dose of palifermin on Day 1 of the treatment period
62833323|NCT00361348|EXPERIMENTAL|Palifermin + Heparin|A single 60µg/kg IV bolus dose of palifermin on Day 1 of the treatment period + unfractionated heparin for a 2 to 3 day heparin titation/maintenance period and continuing through a 3 day treatment period
62610796|NCT05582187|EXPERIMENTAL|Cohort 3: Fosmanogepix Participants with severe hepatic impairment|Participants with severe hepatic impairment will receive a single dose of fosmanogepix, administered orally as 1 fosmanogepix tablet under fasted conditions.
62610797|NCT05582187|EXPERIMENTAL|Cohort 4: Fosmanogepix Participants with normal hepatic function (control group)|Participants with normal hepatic function will receive a single dose of fosmanogepix, administered orally as 1 fosmanogepix tablet under fasted conditions.
62610798|NCT04893460|EXPERIMENTAL|Intervention|All participants will use the CoQuit App for Smoking Cessation
62610799|NCT04126642|OTHER|Assessment only group|Standard care + Daily ecological momentary assessments (EMAs)
62833324|NCT00361348|ACTIVE_COMPARATOR|Heparin|unfractionated heparin for a 2 to 3 day heparin titation/maintenance period and continuing through a 3 day treatment period
62833325|NCT01721044|PLACEBO_COMPARATOR|Placebo|"Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.~Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study."
62833326|NCT01721044|EXPERIMENTAL|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
62833327|NCT01721044|EXPERIMENTAL|Baricitinib 4 mg|"Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
62441616|NCT04638985|ACTIVE_COMPARATOR|group 2 (sIPV)|150 subjects; vaccination of 0.5 ml sIPV as booster immunization at the age of 18 months old
62441617|NCT04638985|ACTIVE_COMPARATOR|group 3 (DTaP)|150 subjects; vaccination of 0.5 ml DTaP as booster immunization at the age of 18 months old
62833328|NCT06210217|EXPERIMENTAL|Dobutamine group|In the dobutamine group, 3\~6μg/kg/min dobutamine will be injected intravenously after anesthesia induction until hemostasis is completed. To ensure preload, TEE will be used to monitor LVEDV and SV.
62833329|NCT06210217|PLACEBO_COMPARATOR|Control group|In the control group, 3mL/h normal saline will be injected intravenously after anesthesia induction until hemostasis is completed, and the liquid will be restricted according to the currently commonly used principle of LCVP, nitroglycerin can be used if necessary.
62833330|NCT05894915|EXPERIMENTAL|open surgery group|Patients who met the inclusion criteria and excluded the exclusion criteria, and did not have high mutational burden characteristics after molecular testing, were randomly divided into open surgery group or laparoscopic surgery group according to 1:1.
62833331|NCT05894915|EXPERIMENTAL|laparoscopic surgery group|Patients who met the inclusion criteria and excluded the exclusion criteria, and did not have high mutational burden characteristics after molecular testing, were randomly divided into open surgery group or laparoscopic surgery group according to 1:1.
62833332|NCT03694886|ACTIVE_COMPARATOR|Caffeine with small sucrose pill|Participants will be given one dose of 90 milligrams caffeine anhydrous dissolved in 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
62833333|NCT03694886|ACTIVE_COMPARATOR|Caffeine with large sucrose pill|Participants will be given one dose of 90 milligrams caffeine anhydrous dissolved in 8 ounces of water and a 5 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
62833334|NCT03694886|PLACEBO_COMPARATOR|No caffeine with small sucrose pill|Participants will be given 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
62833335|NCT03694886|PLACEBO_COMPARATOR|No caffeine with large sucrose pill|Participants will be given 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
62833336|NCT03553355|EXPERIMENTAL|Infrared Laser Moxibustion Therapy|Each patient will receive this treatment twice per week for six weeks (12 sessions total).
62833337|NCT03553355|SHAM_COMPARATOR|Sham Infrared Laser Moxibustion Therapy|The patients will receive treatment from sham laser moxibustion instrument.
62833338|NCT03553355|NO_INTERVENTION|Waitlist Controls|The patients maintain their usual treatment and self-care,
62833339|NCT03327662|EXPERIMENTAL|Interventional|Active CTC assessment: Patients will receive first line docetaxel until progression by CTC, and/or disease progression according to treating clinician or completion of 10 cycles. CTC results will be available to the treating clinician to guide decision-making. A progressing CTC count on Day 1 will require confirmation with a second CTC count performed on Day 15 (-/+ 5 days) of that cycle. If a patient is found to have two successive CTC determinations showing progression by CTCs, the clinician will receive a recommendation to discontinue docetaxel on the following cycle.
62833340|NCT03327662|NO_INTERVENTION|Control|Patients will receive first line docetaxel until disease progression according to treating clinician or completion of 10 cycles. Patients and treating clinicians will not be disclosed to the results of CTC determinations.
62833341|NCT05960071|ACTIVE_COMPARATOR|Group S|patients received protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and steady PEEP (10) cm H2O in between RM till end of surgery.
62833342|NCT05960071|ACTIVE_COMPARATOR|Group D|patients received protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and decreasing PEEP (15, 10, and 5) cm H20 (10 minutes for each level) in between RM till end of surgery.
62833343|NCT00705016|EXPERIMENTAL|Cilengitide 2000 mg once weekly+Cetuximab+5-FU+Cisplatin|
62833344|NCT00705016|EXPERIMENTAL|Cilengitide 2000 mg twice weekly+Cetuximab+5-FU+Cisplatin|
62833345|NCT00705016|ACTIVE_COMPARATOR|Cetuximab+5-FU+Cisplatin|
62833346|NCT03290066|ACTIVE_COMPARATOR|Kinesiotape|"Kinesiotape will be applied as a self-treatment. All participants will be instructed in an indvidual session and will receive a tutorial video to remember the kinesiotaping procedure. 3 band of a special and hypoallergenic tape (Kinematix Tex) will be attached to the abdominal (2 strips) and lower back (1 strip).~Patients will be taped for four days , ıt will start at the beginning of the menstruation."
62833347|NCT03290066|ACTIVE_COMPARATOR|Usual care|"Participants will use the usual self-care for primary dysmenorrhea. It will start at the beginning of the menstruation.~They will note the treatment indicating the dosage in a calendar."
62252101|NCT06365866|EXPERIMENTAL|"Add-on of intraluminal brachytherapy with BRAXX Esophageal Brachytherapy Applicator."|"Brachytherapy protocol starts 3 weeks after EBRT (This is week 1). After transnasal insertion of the applicator into the esophagus, CT simulation scan(s) with a dummy source in place will be done for further planning procedures, including adjustment of the applicator and 3D treatment planning."
62441618|NCT04638985|ACTIVE_COMPARATOR|group 4 (MMR)|150 subjects; vaccination of 0.5 ml MMR as booster immunization at the age of 18 months old
62441619|NCT05042336|EXPERIMENTAL|camrelizumab/lenvatinib combined with TACE|"Phase Ib trial： Ib-A group \[camrelizumab q3w group\]: TACE d1, camrelizumab 200mg, d1, 22, 43; Lenvatinib d7-43; Surgery d50; Group Ib-B \[camrelizumab q2w group\]: TACE d1, camrelizumab 200mg, d1, 15, 29; Lenvatinib d7-43; Surgery d50.~Phase II trial： The enrolled patients received camrelizumab/lenvatinib combined with TACE treatment (a relatively safer treatment plan based on phase Ib), and the first imaging efficacy evaluation was performed at 6-8 weeks to evaluate surgical resection"
62833348|NCT06299059|EXPERIMENTAL|the observation group|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups
62441620|NCT05048732|EXPERIMENTAL|Cohort 1 = Healthy Volunteers|"* Healthy volunteers (N=6, three male, three female) will be recruited to undergo a single 18F-FAT PET/CT imaging session for radiation dosimetry estimates.~* 18F-FAT administration followed by body imaging at 3 time points~  * 0-60 min = multiple quick body scans~ * 120 min post injection = body scan~ * 240 min post injection = body scan"
62610800|NCT04126642|EXPERIMENTAL|Intervention group|"Intervention group will receive same measures and interventions as the assessment only group AND will receive messaging that is tailored to patient responses on EMAs. When participants provide a pattern of responses that are suggestive of heightened emotional distress, they will receive feedback and/or a prompt to complete one of the self-management exercise. The app will prompt participants to complete a brief educational video on relaxation strategies and guided relaxation exercises. Participants will have access to: 1) a Help me Cope button in the app that contains links to evidenced-based self-management techniques, and 2) a Contact Counselor button that will send a secure email to a study psychologist requesting a call. Participants will receive a coping focused message at the completion of the Report Distress EMAs. Participants can access these on demand intervention components and review them at any time in addition to receiving the tailored intervention messages."
62441621|NCT05048732|EXPERIMENTAL|Cohort 2a: Newly Diagnosed DLBCL patients being treated with R-CHOP|-N= 6 : 18F-FAT imaging session at baseline and Day 2-4 following Cycle 1 standard of care therapy.
62441622|NCT05048732|EXPERIMENTAL|Cohort 2b: Newly Diagnosed DLBCL patients being treated with R-CHOP|-N=9: 18F-FAT imaging session at baseline and best time point determined from Cohort 2a (2 days post Cycle 1 standard of care therapy)
62441623|NCT06354244||Electroacupuncture of 2 sessions per week|
62833349|NCT06299059|ACTIVE_COMPARATOR|the control group|the control group was given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements.
62252102|NCT05577286|OTHER|control group|15 Children with type 1 Diabetes mellitus in this group will receive the regular medical treatment without change of their daily activity routine
62252103|NCT05577286|EXPERIMENTAL|plyometric group|15 Children with type 1 Diabetes mellitus in this group will receive the regular medical treatment as in control group in addition to a designed plyometric training program for 30 minutes, three times a week for two successive months.
62252104|NCT00356083|EXPERIMENTAL|switch from morphine to methadon|
62441624|NCT06354244||Electroacupuncture of 3 sessions per week|
62610801|NCT05393934|PLACEBO_COMPARATOR|PNC (Pediatric Nutrition Care)|This first group will be given pediatric nutrition care (PNC) in visit 0. In this group parents will receive nutritional advice about how many calories are needed, the type and form of food that can be given so that the baby can gain weight accordingly.
62833350|NCT05484752|EXPERIMENTAL|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation 1 session
62252105|NCT01640912|EXPERIMENTAL|RXI-109|
62252106|NCT01640912|PLACEBO_COMPARATOR|Placebo|
62441625|NCT06354244||Electroacupuncture of 4 sessions per week|
62441626|NCT01566292|EXPERIMENTAL|BOTOX|
62441627|NCT05558722|EXPERIMENTAL|Anlotinib|Anlotinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that strongly inhibits VEGFR, PDGFR, FGFR, and c-kit. Anlotinib (12 mg qd, d1-14; 21 days per cycle; total 5 cycles) Combined TAC×6 cycles.
62441628|NCT05511285|EXPERIMENTAL|Behavioural: Digital cognitive behavioural therapy for insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online.
62441629|NCT05511285|NO_INTERVENTION|Treatment as usual|Participants will receive treatment as usual.
62441630|NCT02056899|EXPERIMENTAL|Gabapentin|
62441631|NCT05710302||Patients diagnosed with acute heart failure in the emergency department|Patients with acute heart failure.
62441632|NCT06343051||Fetal Growth Restriction diagnosed > 27w6d gestation|Patients with a new diagnosis of fetal growth restriction after 27 weeks 6 days' gestation.
62833351|NCT05484752|SHAM_COMPARATOR|Sham Repetitive Peripheral Magnetic Stimulation|Sham Repetitive Peripheral Magnetic Stimulation 1 session
62833352|NCT02341183|ACTIVE_COMPARATOR|A: Treatment order: tPAD treatment, then no treatment|Subjects will receive one overnight treatment with 7% hypertonic saline administered via the tPAD device. They will then have one overnight stay without treatment.
62833353|NCT02341183|ACTIVE_COMPARATOR|B: Treatment order: no treatment, then tPAD treatment|Subjects will have overnight stay w/o treatment, and one overnight treatment with 7% hypertonic saline administered via the tPAD device.
62833354|NCT00638014|ACTIVE_COMPARATOR|1|Conventional wires only
62833355|NCT00638014|EXPERIMENTAL|2|Rapid Sternal Closure System supplemented with wires
62833356|NCT02353975|EXPERIMENTAL|SHR3824 10mg fasted to fed|SHR3824 tablet, fasting conditions day 1, visit 2, 7 days wash-out, SHR3824 tablet, high fat, high calorie breakfast day 1, visit 3.
62610802|NCT05393934|ACTIVE_COMPARATOR|FSMP (Food for Special Medical Purposes) & PNC (Pediatric Nutrition Care)|In this second group, subject will receive PNC in visit 0 and food for special medically purposes/FSMP that will be given according to daily calorie needs which are determined based on ideal body weight (BB) according to body length. In general, FSMP will be given 3 times a day, according to the needs of each subject. Parents will be taught about preparation of FSMP e.g. dissolving and the correct amount of product (image will be attached in the appendix). FSMP will be given during the research period and will be discontinued when not needed anymore.
62610803|NCT05976035|ACTIVE_COMPARATOR|Exercise & Supplement Group|Exercise \& Supplement group will take supplements that are prescribed by the orthopedist every day for 8 weeks in addition to a structured exercise program under the supervision of a physiotherapist 3 days per week for 8 weeks.
62252107|NCT04886648|EXPERIMENTAL|Mother Voıce|Premature baby group with mother voıce application.
62252108|NCT04886648|EXPERIMENTAL|Lullably|Premature baby group with lullably application.
62610804|NCT05976035|ACTIVE_COMPARATOR|Exercise Group|Exercise group will follow a structured exercise program under the supervision of a physiotherapist 3 days per week for 8 weeks.
62610805|NCT06730230|EXPERIMENTAL|Latinx patients with uncontrolled hypertension (HTN)|Patients will be exposed to the RPM-enabled CHW support, this will be carried out through the step-wedge design, meaning that over the course of the study (\~18 months), all clinics will carry out standard HTN care and also have exposure to the intervention (though at varying time intervals).
62610806|NCT04116541|EXPERIMENTAL|HDM201 + Ribociclib|Patient with documented amplification of Cyclin-dependent kinase 6 (CDK6) and/or Cyclin-dependent kinase 4 (CDK4), and/or cyclin dependent kinase inhibitor 2A (CDKN2A) homozygous deletion, and/or amplification of Cyclin D1 (CCND1) and/or Cyclin D3 (CCND3) with no deletion/losses more than single copy of retinoblastoma 1 (RB1) by copy number and P53 wild-type detected on tumor sample from primary tumor or metastatic lesion.
62610807|NCT04116541|EXPERIMENTAL|Cabozantinib|Patient with AXL, MET, vascular endothelial growth factor receptor (VEGFR), vascular endothelial growth factor (VEGF), RET, ROS1, MER, Tropomyosin receptor kinase B (TRKB),TIE-2 and/or Tyro3 activating mutations and/or amplification, and/or NTRK translocation and/or ROS1 translocation, and/or MET translocation detected on tumor sample from primary tumor or metastatic lesion.
62833357|NCT02353975|EXPERIMENTAL|SHR3824 10mg fed to fasted|SHR3824, high fat, high calorie breakfast day 1, visit 2, 7 days wash-out, SHR3824, fasting conditions day 1, visit 3.
62833358|NCT01495403|EXPERIMENTAL|hydroxychloroquine|
62833359|NCT00169065|ACTIVE_COMPARATOR|Clozapine|Clozapine or olanzapine in treatment resistant schizophrenia
62252109|NCT04886648|NO_INTERVENTION|Control|Premature baby group with no application
62252110|NCT00003765|EXPERIMENTAL|Arm I|Patients receive O6-benzylguanine IV over 1 hour, then, 1 hour later, carmustine IV is administered over 1 hour. Treatment is repeated every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each receive escalating doses of carmustine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose level at which fewer than 2 of 6 patients experience dose limiting toxicity (DLT). If myelosuppression is the DLT, stratum 1 is closed and patients are accrued to stratum 2. If neutropenia is the DLT in stratum 2, patients receive filgrastim (G-CSF) subcutaneously beginning on day 2 and continuing until blood counts recover.
62252111|NCT03831061|EXPERIMENTAL|Cognitive stimulation|"10 sessions of 45 minutes/week during 10 weeks. Each session included : (a) temporo-spatial orientation , (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises.~There are 54 participants subdivided into two groups of 27 participants that perform the same intervention in different days of the week."
62252112|NCT03831061|NO_INTERVENTION|Control group (No intervention)|There are 68 participants in total. These participants did not receive intervention.
62252113|NCT03559036||Locomotor Training|Assessments for bladder function will be conducted pre-training and following 80 sessions of locomotor training. Locomotor training consists of body-weight supported stepping on a treadmill for one hour.
62610808|NCT04116541|EXPERIMENTAL|Alectinib|Activating ALK alterations: translocation, or selected mutations
62610809|NCT04116541|EXPERIMENTAL|Regorafenib|Patient with activating mutation and/or amplification of VEGFR1-3, TIE-2, KIT, RET, RAF1, BRAF (other than V600 mutations), CRAF, HRAS, Platelet Derived Growth Factor Receptor (PDGFR), Fibroblast Growth Factor Receptor 1-2 (FGFR1-2), FLT3 and/or Colony Stimulating Factor 1 Receptor (CSF1R), and/or amplification of the ligands, and/or biallelic inactivation of SMAD4
62610810|NCT04116541|EXPERIMENTAL|Trametinib|Patient with activating mutation and/or amplification of KRAS (except all KRAS G12 mutations), NRAS, HRAS and/or Mitogen-Activated Protein Kinase Kinase (MAP2K); and/or biallelic inactivation of Neurofibromin 1 (NF1); and/or activating mutation Protein Tyrosine Phosphatase Non-Receptor Type 11 (PTPN11); and/or amplification or translocation of BRAF ; and/or translocation RAF1
62833360|NCT00169065|ACTIVE_COMPARATOR|olanzapine|clozapine or olanzapine in treatment resistant schizophrenia
62833361|NCT04636268|EXPERIMENTAL|FIB Grifols|"FIB Grifols is the IP and will be administered via slow intravenous (IV) infusion at a rate not to exceed 5 mL/minute.~Dosing will be individually calculated for each subject based on the target plasma fibrinogen level according to the type of bleeding, measured actual plasma fibrinogen level before infusion, and body weight. The IP will be administered according to the nominal potency of the product."
62833362|NCT04641182||Prone position|Prone position per institutional protocol and as indicated by the treating physician
62833363|NCT04641182||No prone position|The control group will not be in prone position
62833364|NCT05609331|EXPERIMENTAL|Stage I-(Simulated Online Adaptive Planning)|Participants will receive treatment with the conventional CT-based radiation therapy and receive additional MRI scans.
62833365|NCT05609331|EXPERIMENTAL|Stage II (Stereotactic MRI-guided adaptive radiotherapy-SMART)|Participants will receive treatment with the investigational MRI-guided radiation therapy.
62050657|NCT06579274|PLACEBO_COMPARATOR|Control - Placebo|"A placebo is a substance administered to a participant as a comparison without any pharmacological effect. However, unlike conventional medicines, it does not contain any active ingredients. In this clinical trial, the placebo is an isotonic sodium chloride solution.~The placebo is injected into a peripheral or central venous catheter within 12 hours of the patient's enrollment in the study (from when informed consent is signed). Placebo 100 mL per dose will continue to be administered every 12 hours for five days.~Participants will be followed for six months for any adverse events and changes in subjective status. In the event of adverse effects, patients will be followed until resolution. After that, their participation in this clinical trial will be terminated. The total duration of the patient's participation in the clinical trial will be six months."
62050658|NCT05145387|EXPERIMENTAL|TEAMSS Intervention in the RCT|Students randomly assigned to the TEAMSS intervention will receive the 5th and 6th grade components.
62833366|NCT06507189|EXPERIMENTAL|Interrogation|In Interrogation, all participants will exercise train using an exercise prescription that is in accordance with current public health recommendations19. At the end of Phase I participants will be classified into one of the four categories listed in Fig. A: (1) CRF-/fMQ-, 2) CRF-/fMQ+, 3) CRF+/fMQ- and 4) CRF+/fMQ+).
62050659|NCT05145387|NO_INTERVENTION|Enhanced Usual Care in the RCT|Enhanced Usual Care (EUC) will serve as the comparison group. EUC will be comprised of written materials (given all at once after randomization by study team) for parents and children that include: 1) a specialty mental health referral list; 2) a list of websites and books on child anxiety; and 3) tip sheets on successful transitions to MS. Families in this condition will not be prohibited from seeking treatment (though this will be monitored) for their children. These students will visit and meet with the 6th grade clinician in the spring of 5th grade.
62050660|NCT03984370|EXPERIMENTAL|80 ug of sc dasiglucagon|80 ug of dasiglucagon in a 0.4 mL fluid (saline) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
62050661|NCT03984370|EXPERIMENTAL|200 ug of sc dasiglucagon|200 ug of dasiglucagon in a 0.4 mL fluid (saline) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
62050662|NCT03984370|PLACEBO_COMPARATOR|0.4 mL of sc saline (placebo)|0.4 mL fluid (saline/placebo) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
62050663|NCT01259050|EXPERIMENTAL|Zinc and Copper|
62050664|NCT00415610|OTHER|Tier 1|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 170 to 200 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
62252114|NCT06476574|EXPERIMENTAL|Vacuum-formed retainer|An alginate impression will be taken to be poured into a working model for fabrication of the Vacuum-formed retainer; 1mm Hard vacuum sheet will be used.
62441633|NCT01426256|EXPERIMENTAL|Cholecalciferol (Vitamin D3)|Patients will be given 250,000 IU cholecalciferol in one bolus oral dose while they are in the hospital. Three months after the initial bolus dose, patients will take 50,000 IU oral cholecalciferol every other week for 9 months.
62441634|NCT01426256|NO_INTERVENTION|Placebo|Patients will be given placebo pills in one bolus oral dose while they are in the hospital. Three months after the initial bolus dose, patients will take a placebo pill every other week for 9 months.
62441635|NCT03999125|ACTIVE_COMPARATOR|Group 1|Aflibercept intravitreal injection for CSME
62441636|NCT03999125|OTHER|Group 2|Ranibizumab Intravitreal Injection for CSME
62441637|NCT03999125|EXPERIMENTAL|Group 3|Dexamethasone Implant for CSME
62441638|NCT01612000|EXPERIMENTAL|PanBlok 15µg in 2% SE|15µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
62833367|NCT06507189|EXPERIMENTAL|Mitigation|Based on these categories of responsiveness, exercise training will be boosted in the three groups that are nonresponsive in one or both outcomes. CRF-/fMQ+ will receive boosted ET, CRF+/fMQ- will receive boosted RT, and CRF-/fMQ- will receive boosting in both. All three of these classifications will also receive education on wearable device data and other free-living recommendations four times during Mitigation
62833368|NCT06236269|EXPERIMENTAL|Sacituzumab Govitecan|Sacituzumab govitecan will be given on Days 1, 8 of a 21-day cycle at a dose of 10 mg/kg intravenously, continuously until progression of the disease or unacceptable toxicity.
62610811|NCT04116541|EXPERIMENTAL|Trametinib + Dabrafenib|Patient with BRAF V600 mutation
62610812|NCT04116541|EXPERIMENTAL|Avapritinib|Activating mutations of KIT exon 17 or PDGFRA exon 18 associated or not to mutation on KIT exon 11 or PDGFRA exon 12/14
62610813|NCT06308536|ACTIVE_COMPARATOR|bone powder + collagen membrane|Fill the extraction socket with bone powder, and cover the extraction wound with collagen membrane.
62610814|NCT06308536|EXPERIMENTAL|bone powder + collagen membrane + CGF membrane|Fill the extraction socket with bone powder, and cover the extraction wound with collagen membrane and CGF membrane.
62610815|NCT06308536|EXPERIMENTAL|bone powder mixed wih CGF gel + collagen membrane + CGF membrane|Fill the extraction socket with bone powder mixed with CGF gel, and cover the extraction wound with collagen membrane and CGF membrane.
62610816|NCT06308536|EXPERIMENTAL|bone powder + CGF membrane|Fill the extraction socket with bone powder, and cover the extraction wound with CGF membrane.
62610817|NCT01531595|EXPERIMENTAL|Chemotherapy plus bevacizumab|Bevacizumab plus alternating XELOX x3 cycles (capecitabine + oxaliplatin) and XELIRI x3 cycles (capecitabine + irinotecan)
62610818|NCT02658383|EXPERIMENTAL|Cleaner cookstove received after visit 2|This arm receives the cleaner cookstove earlier in the study (after visit 2 which is approximately after 6 months)
62610819|NCT02658383|EXPERIMENTAL|Cleaner cookstove received after visit 4|This arm receives the cleaner cookstove later in the study (thus acting as a control arm until after visit 4 which is after approximately 1 yr and 6 months)
62610820|NCT04492072|EXPERIMENTAL|Oxytocin with Mechanical Dilation|"If the patient is randomized to Cook Balloon and Oxytocin - The balloon inflated to 60cc will be placed and oxytocin 2 mu/min will be initiated, and increased incrementally by 2mu/min every 30 minutes. If the cook cannot be placed initially, it will be reattempted and placed within 6 hours of oxytocin starting. The Cook catheter will remain in place until spontaneously expelled, or if not, after 12 hours of placement.~If a Cook Balloon is not available, a Foley catheter can be used in its place as alternate and equivalent form of mechanical dilation."
62610821|NCT04492072|ACTIVE_COMPARATOR|Misoprostol with Mechanical Dilation|If the patient is randomized to Misoprostol and Cook balloon - she will be given 25mcg of misoprostol orally or buccal and a Cook Balloon inflated to 60cc will be placed. She will subsequently receive 50mcg oral or buccal misoprostol every 4 hours up to 4 doses. If regular contractions occur (three or more contractions in a 10-minute period), the patient will be switched to Oxytocin 2 mu/min, and increased incrementally by 2mu/min every 30 minutes. If the cook balloon cannot be placed initially, it will be reattempted and placed within 6 hours of induction start. The Cook catheter will remain in place until spontaneously expelled, or at the fourth misoprostol administration. At this point, oxytocin will be started if not already initiated and artificial rupture of membranes will occur
62610822|NCT06124586|EXPERIMENTAL|PTA within 48h|A study participant in this group will receive a PTA in 'readiness', which means within 48 hours after diagnosis of a flow-limiting leg artery stenosis.
62610823|NCT06124586|ACTIVE_COMPARATOR|PTA within 6 weeks|A study participant in this group will receive a PTA according to the international guidelines, which means within 6 weeks after diagnosis of a flow-limiting leg artery stenosis.
62610824|NCT05833828||on-pump coronary artery bypass graft surgery|"Due to the observational design of the study, no study-specific interventions are performed. Except for the above mentioned laboratory analyses, the treatment of the patients is completely guided by the responsible ICU physicians.~Study participation does not influence the determination of surgical procedure (on- vs off-pump)."
62610825|NCT05833828||off-pump coronary artery bypass graft surgery|"Due to the observational design of the study, no study-specific interventions are performed. Except for the above mentioned laboratory analyses, the treatment of the patients is completely guided by the responsible ICU physicians.~Study participation does not influence the determination of surgical procedure (on- vs off-pump)."
62610826|NCT01649908||sectional cross clamping|
62610827|NCT01649908||simultaniously cross clamping|
62252115|NCT06476574|EXPERIMENTAL|Combined Vacuum-formed and Lingual bonded retainer from canine-to-canine.|A multistrand rectangular stainless steel retainer wire will be bonded to the lingual surface of the lower anterior teeth, from the canine-to-canine bonded to all six anteriors; followed by an alginate impression; the impression will be poured into a working model for fabrication of the Vacuum-formed retainer; 1mm Hard vacuum sheet will be used.
62252116|NCT06476574|ACTIVE_COMPARATOR|Lingual bonded retainer from canine-to-canine|A multistrand rectangular stainless steel retainer wire will be bonded to the lingual surface of the lower anterior teeth, from the canine-to-canine bonded to all six anteriors.
62252117|NCT02237963||Posterolateral thoracotomy|Surgeons perform a posterolateral thoracotomy
62441639|NCT01612000|EXPERIMENTAL|PanBlok 3.8µg in 2% SE|3.8µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
62441640|NCT01612000|EXPERIMENTAL|PanBlok 7.5µg No Adjuvant|7.5µg recombinant hemagglutinin, no adjuvant. 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
62441641|NCT01612000|EXPERIMENTAL|PanBlok 7.5µg in 2% SE|7.5µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
62441642|NCT01725815|EXPERIMENTAL|HARP Intervention|
62441643|NCT01725815|NO_INTERVENTION|No Intervention: Control|Participants in usual care will continue to obtain any mental health or peer-support services that they would otherwise be receiving.
62441644|NCT02355145||Patient group in moment 1 of evaluation|Study group enrolled in moment 1 of evaluation (Feb - Mar 2015)
62441645|NCT02355145||Patient group in moment 2 of evaluation|Study group enrolled in moment 2 of evaluation (Feb - Mar 2016) - 1 year distance from moment 1
62441646|NCT05297747|EXPERIMENTAL|Apical periodontitis|Radiography of the patients in the apical periodontitis group was evaluated and blood samples were collected from those patients
62441647|NCT05297747|EXPERIMENTAL|Chronic periodontitis|Radiography of the patients in the chronic periodontitis group was evaluated and blood samples were collected from those patients
62441648|NCT05297747|NO_INTERVENTION|Control|Radiography of the participants in the healthy, control group was evaluated and blood samples were collected from those participants
62441649|NCT00631176|NO_INTERVENTION|1|
62610828|NCT01649908||EVAR|
62252118|NCT02237963||Axillary thoracotomy|Surgeons perform an axillary thoracotomy
62252119|NCT04647877|EXPERIMENTAL|Phenytoin 10 percent cream|Phenytoin 10 percent cream, 2 to 4 times daily application, 2 weeks long
62252120|NCT04647877|EXPERIMENTAL|Phenytoin 20 percent cream|Phenytoin 20 percent cream, 2 to 4 times daily application, 2 weeks long
62833369|NCT00874510|NO_INTERVENTION|Standard Schedule|interns work standard schedule, being on duty for 30 continuous hours
62610829|NCT06083480|EXPERIMENTAL|GlyNAC (combination of glycine and n-acetylcysteine)|GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively. The preparation will be a commercially available product of 1:1 ratio of glycine and N-acetyl-cysteine.
62050665|NCT00415610|OTHER|Tier 2|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 140 to 170 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
62252121|NCT04647877|PLACEBO_COMPARATOR|Placebo cream|Placebo cream, 2 to 4 times daily application, 2 weeks long
62050666|NCT00415610|OTHER|Tier 3|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 110 to 140 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
62050667|NCT06326827||In'Oss™ (MBCP® Putty)|Participants will be recruited from a population who are undergoing orthopaedic bone trauma surgery at the investigational site. All admitted patients will be screened and assessed to determine whether patients may be eligible to take part based on the inclusion and exclusion criteria. Patient participation in this study will include a screening visit within 48 hours of admission to hospital prior the surgery.
62050668|NCT01250990|ACTIVE_COMPARATOR|Niacin|Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
62050669|NCT01250990|PLACEBO_COMPARATOR|Placebo|Placebo tablet with 50 mg niacin for the first 4 weeks to maintain blinding of the study team and subjects, changed to pure placebo after that.
62050670|NCT06011772|EXPERIMENTAL|Cohort A1|"LOADING PHASE: Patients receive CIMAvax-EGF IM on days 1 and 15. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive CIMAvax-EGF IM on day 15. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive mFOLFOX6 chemotherapy consisting of leucovorin IV, oxaliplatin IV over 2 hours, and fluorouracil IV and bevacizumab IV over 10 minutes on days 1 and 15. Treatment repeats every 2 weeks for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples throughout the trial."
62050671|NCT06011772|EXPERIMENTAL|Cohort B1|"LOADING PHASE: Patients receive CIMAvax-EGF IM on days 1 and 15. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive CIMAvax-EGF IM on day 15. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive FOLFIRI consisting of irinotecan IV, leucovorin IV over 90 minutes, and fluorouracil IV and cetuximab IV over 120 minutes on days 1 and 15. Treatment repeats every 2 weeks for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples throughout the trial."
62050672|NCT06011772|EXPERIMENTAL|Cohort B2|"LOADING PHASE: Patients receive CIMAvax-EGF IM on days 1 and 15. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive CIMAvax-EGF IM on day 15. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive mFOLFOX6 chemotherapy and cetuximab IV over 120 minutes on days 1 and 15. Treatment repeats every 2 weeks for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples throughout the trial"
62252122|NCT03016936||Subgroup for NTproBNP Substudy|Planned subgroup analyses in patients undergoing vascular, orthopaedic, thoracic surgery, and in patients aged 65 years or older with a RCRI \<2 and NSQIP- MICA \<1%
62252123|NCT00516048|EXPERIMENTAL|Exenatide:Treatment-Emergent Antibody Negative|This arm will receive 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks.
62252124|NCT00516048|EXPERIMENTAL|Exenatide:Treatment-Emergent Antibody Positive|This arm will receive 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks.
62252125|NCT03422419|EXPERIMENTAL|TIPS+Anticoagulation|
62252126|NCT03422419|ACTIVE_COMPARATOR|Anticoagulation|
62252127|NCT04651621|EXPERIMENTAL|Open label active cTBS|Four consecutive days with 40s cTBS, 100% MT over the SMA, five times a day with 50 minutes between stimulations
62252128|NCT04651621|EXPERIMENTAL|active cTBS|One test session with 40s active cTBS, 100% MT, over the SMA in the initial double blind cross-over phase
62610830|NCT06083480|PLACEBO_COMPARATOR|Placebo (alanine)|Placebo (alanine) 200 mg/kg/day will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.
62252129|NCT04651621|SHAM_COMPARATOR|Sham cTBS|One test session with 40s sham cTBS, 100% MT, over the SMA in the initial double blind cross-over phase with a special sham coil that diverts the magnetic field to be only superficial
62252130|NCT06231420|ACTIVE_COMPARATOR|Encourage using pedometer group.|Sarcopenic cirrhotic patient who received pedometer recording and was encouraged to use actively.
62252131|NCT06231420|PLACEBO_COMPARATOR|Discourage using pedometer group.|Sarcopenic cirrhotic patient who received pedometer recording but without encouraged to use.
62252132|NCT03677596|EXPERIMENTAL|Dose Level 2|Inotuzumab ozogamicin at starting dose 1.2 mg/m2/cycle (administered in 3 divided doses). Most patients expected to receive 2 or 3 cycles (cycle length 21 to 28 days)
62252133|NCT03677596|ACTIVE_COMPARATOR|Dose Level 1|Inotuzumab ozogamicin at starting dose 1.8 mg/m2/cycle (administered in 3 divided doses). Most patients expected to receive 2 or 3 cycles (cycle length 21 to 28 days)
62252134|NCT01292382|SHAM_COMPARATOR|rTMS versus Sham|rTMS: active coil Sham: inactive coil
62252135|NCT01292382|ACTIVE_COMPARATOR|rTMS versus sham|rTMS group: active coil Sham group: inactive coil
62610831|NCT02826577|ACTIVE_COMPARATOR|Pregnenolone 175mg|- Single dose of 175mg
62610832|NCT02826577|ACTIVE_COMPARATOR|Pregnenolone 400mg|- Single dose of 400mg
62610833|NCT02826577|PLACEBO_COMPARATOR|Placebo|- Single dose of placebo
62610834|NCT02826577|NO_INTERVENTION|Matched healthy controls|- No intervention
62610835|NCT06731335|EXPERIMENTAL|Intervention Arm with Psilocybin|Intervention Arm with Psilocybin 25 mg single dose PO + psychological support
62610836|NCT06731335|PLACEBO_COMPARATOR|Placebo|Placebo (Active) Dextromethorphan 400 mg single dose PO + psychological support
62610837|NCT04057664||Multidisciplinary Group Therapy|Multidisciplinary group therapy for women with chronic pelvic or belly pain
62610838|NCT00763516|EXPERIMENTAL|Proton radiation and chemotherapy|"Proton radiation~Capecitabine chemotherapy on radiation days~Surgery~Gemcitabine chemotherapy"
62610839|NCT02777281|OTHER|Shoulder pain and SCI|Manual wheelchair users with SCI
62610840|NCT02777281|OTHER|Shoulder pain and able bodies|No SCI or wheelchair use but presence of shoulder pain
62610841|NCT06729957|EXPERIMENTAL|Care Navigation|Mental health care coordinators are able to offer and refer patients to a care navigator in addition to offering substance use resources and treatment options as usual.
62252136|NCT06171620|OTHER|Control group (SOC)|Standard of care
62441650|NCT00631176|EXPERIMENTAL|2|
62441651|NCT02950753|EXPERIMENTAL|Lactated Ringer|Intravenous bolus of Lactated Ringer solution (30ml/kg) via 18ga IV catheter at wide open.
62441652|NCT02950753|PLACEBO_COMPARATOR|Normal Saline|Intravenous bolus of Normal Saline (30ml/kg) via 18ga IV catheter at wide open.
62610842|NCT06729957|NO_INTERVENTION|Services as Usual|Mental health care coordinators will continue offering substance use resources and treatment options to patients as usual.
62738831|NCT06644833|ACTIVE_COMPARATOR|Treatment as usual|Participants in this group will continue receiving standard care, which includes pharmacological management and psychotherapy based on clinical standards for MDD. Common medications may include selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants, with dose adjustments made based on clinical response. Psychotherapy will involve cognitive-behavioral therapy or supportive therapy sessions as determined by the attending psychiatrist.
62738832|NCT05336734|EXPERIMENTAL|Main group|The group underwent a psychotherapy course combining CBT and imagery work. (For full protocol see Prinz et al., 2019)
62738833|NCT04155619|ACTIVE_COMPARATOR|No change in eating or light exposure habits|
62738834|NCT04155619|EXPERIMENTAL|Early Time-Restricted Feeding|
62738835|NCT04155619|EXPERIMENTAL|Timed Light Therapy|
62738836|NCT04155619|EXPERIMENTAL|Early Time-Restricted Feeding and Timed Light Therapy|
62738837|NCT03218449||1/NC|noninfective complication
62738838|NCT03218449||2/IC|infective complication
62050673|NCT06011772|EXPERIMENTAL|Cohort C|"Description LOADING PHASE: Patients receive CIMAvax-EGF IM on days 1 and 15. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive CIMAvax-EGF IM on day 15. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive mFOLFOX6 and cetuximab, FOLFOX6 and bevacizumab, or mFOLFOX6 per investigators preference. Treatment repeats every 2 weeks for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo metastasectomy 4-8 weeks after first maintenance phase dose. Patients undergo collection of blood samples throughout the trial."
62050674|NCT06011772|EXPERIMENTAL|Cohort A2|"LOADING PHASE: Patients receive CIMAvax-EGF intramuscularly (IM) on days 1 and 15. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive CIMAvax-EGF IM on day 15. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive mFOLFOX6 chemotherapy consisting of leucovorin IV, oxaliplatin IV over 2 hours, and fluorouracil IV, as well as cetuximab IV over 120 minutes on days 1 and 15, or panitumumab IV over 60 minutes on days 1 and 15. Patients undergo collection of blood samples and CT throught the trial"
62252137|NCT06171620|EXPERIMENTAL|Intervention Group (VR)|Standard of care with addition of the Virtual reality headset
62252138|NCT00761787||1|Heart transplanted subjects.
62252139|NCT00121836|EXPERIMENTAL|1|
62252140|NCT03193762||Painful hospitalized patient|The anxiety of those patients will be measured with an Anxiety VAS
62252141|NCT05865444|EXPERIMENTAL|Values alignment wise intervention|1 hour wise intervention (based on a values alignment approach) consisting on several tasks (online and paper-based tasks) to be completed individually.
62441653|NCT01572961|ACTIVE_COMPARATOR|Aspirin|Aspirin
62441654|NCT01572961|PLACEBO_COMPARATOR|Placebo|Placebo
62441655|NCT03919955|EXPERIMENTAL|Atomoxetine and Oxybutynin|Participants will take Atomoxetine and Oxybutynin nightly for one month. Half doses will be given on the first three nights.
62441656|NCT03919955|PLACEBO_COMPARATOR|Placebo|Participants will take Placebos nightly for one month. Half doses will be given on the first three nights.
62441657|NCT03179982|EXPERIMENTAL|Intervention|"Male adolescents (15-17 years) will be randomly allocated to an intervention arm based on permuted blocked randomization. The intervention arm will receive the HIV-IPV intervention called Safe South Africa.~Safe South Africa is a group-based, facilitated behavioral intervention for prevention of HIV risk and IPV perpetration specifically tailored for male adolescents. The behavioral intervention is comprised of 2-hour sessions, held once a week for a total of two weeks."
62441658|NCT03179982|NO_INTERVENTION|Control|Male adolescents (15-17 years) will be randomly allocated to a control arm based on permuted blocked randomization. The control arm will consist of ordinary usual care. The ordinary usual care condition will consist of a packet of existing available brochures on HIV and other sexually transmitted diseases including testing, prevention, and treatment; IPV prevention and intervention; and places to access prevention, care, and support for these outcomes and related health outcomes.
62441659|NCT03876522||Lafora Disease Patients|Documented genetic diagnosis of Lafora disease; clinical diagnosis of Lafora disease and a sibling with a known mutation in EPM2A or EPM2B; clinical diagnosis of Lafora disease and a previously undescribed mutation in EPM2A or EPM2B; asymptomatic siblings if mutation positive prior to enrollment.
62738839|NCT06652178||Study Group|Children with lower urinary tract dysfunction
62050675|NCT06576882|ACTIVE_COMPARATOR|14-days Vonoprazan-based triple therapy|Vonoprazan tablets 20 mg twice daily plus Amoxicillin 50 mg/kg/day capsules or suspension \[maximum daily dose 2 g\] plus Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose 1 g\]. The triple combination will be given for 14 days .
62050676|NCT06576882|EXPERIMENTAL|7-days Vonoprazan-based triple therapy|Vonoprazan tablets 20 mg twice daily plus Amoxicillin 50 mg/kg/day capsules or suspension \[maximum daily dose 2 g\] plus Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose 1 g\]. The triple combination will be given for 7 days.
62050677|NCT02987075|OTHER|Early compaction embryo group|patients have compacting embryos at 66±2 hours after ICSI
62050678|NCT02987075|OTHER|Cleavage stage embryo group|patients have non-compacting embryos with 7-9 cells, under 20% fragmentation. at 66±2 hours after ICSI
62050679|NCT03702842|EXPERIMENTAL|Immediate effects|All participants will complete 2 sessions of walking with tsDCS separated by at least 72 hours. The only difference between sessions will be the dosage of stimulation (higher or lower dosage tsDCS using the Soterix Medical tsDCS stimulator). During each session, participants will be asked to walk for up to 30 minutes on a treadmill while the stimulation is delivered. Assessments will be completed before and after the bout of treadmill walking.
62050680|NCT03702842|EXPERIMENTAL|Interventional effects: Higher dosage|After completing the 2 sessions of the first part of the study, the participants will be randomized to two groups for the second part of the study. Those in the higher dosage group will receive 16 sessions of locomotor training with tsDCS stimulation applied at the higher dosage for up to 30 minutes using the Soterix Medical tsDCS stimulator. The training sessions will be scheduled 4 days per week for 4 weeks. All training will be overseen by a physical therapist with experience in SCI walking rehabilitation and will involve the use of an overhead support harness.
62252142|NCT05865444|ACTIVE_COMPARATOR|Traditional educational intervention|1 hour traditional educational intervention on nutrition and physical exercise. This will also include reading and writing exercises.
62252143|NCT04868721|NO_INTERVENTION|control side|Conventional side Canine retraction was commenced without micro-osteoperforations.
62252144|NCT04868721|EXPERIMENTAL|single Micro-osteoperforations side|Three flapless micro-osteoperforations (MOPs) was performed for one time only distal to the maxillary canine before starting retraction.
62252145|NCT04868721|EXPERIMENTAL|Multiple Micro-osteoperforations side|Three flapless micro-osteoperforations (MOPs) was performed on repeated basis distal to the maxillary canine evey 28 days before canine retraction.
62252146|NCT00005950|EXPERIMENTAL|Treatment|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62441660|NCT06352320||HCM group|Patients were diagnosed with HCM.
62738840|NCT06652178||Control Group|Healthy peers
62441661|NCT06352320||DCM group|Patients were diagnosed with DCM.
62441662|NCT06352320||ARVC group|Patients were diagnosed with ARVC.
62441663|NCT06352320||NDLVC group|Patients were diagnosed with NDLVC.
62441664|NCT06352320||RCM group|Patients were diagnosed with RCM.
62738841|NCT03839849|EXPERIMENTAL|i-PRF (Test)|injected subgingivally i-PRF after scaling and root planing
62441665|NCT06352320||LVNC group|Patients were diagnosed with LNVC.
62441666|NCT02891200|EXPERIMENTAL|Healthcare professional (HCP) Arm|Healthcare professional (HCP) Arm includes a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
62738842|NCT03839849|ACTIVE_COMPARATOR|saline (Control)|injected subgingivally saline after scaling and root planing
62738843|NCT06315673||Patient|Individuals with diagnosis of definite, probable, probable laboratory-supported, or possible ALS by revised El Escorial research criteria \[2\], primary lateral sclerosis (PLS), or progressive muscular atrophy (PMA).
62738844|NCT06315673||Control|Individuals with no neurological or orthopedic problems that affects their speech or handwriting AND age-matched to the existing patient cohort.
62738845|NCT06249152|EXPERIMENTAL|Experimental: QLS-111 ophthalmic solution|Qlaris' IP, QLS-111 ophthalmic solution, provided in 3 concentrations (0.015%, 0.03%, and 0.075%), preservative free (PF), single-use units, masked.
62738846|NCT06249152|PLACEBO_COMPARATOR|Placebo comparator: Vehicle ophthalmic solution|Inactive control (0.00%), PF, single-use units, masked.
62738847|NCT05207644|OTHER|Letrozole followed by misoprostol|There is only one arm in this study.
62050681|NCT03702842|ACTIVE_COMPARATOR|Interventional effects: Lower dosage|After completing the 2 sessions of the first part of the study, the participants will be randomized to two groups for the second part of the study. Those in the lower dosage group will receive 16 sessions of locomotor training with tsDCS stimulation applied at the lower dosage for up to 30 minutes using the Soterix Medical tsDCS stimulator. The training sessions will be scheduled 4 days per week for 4 weeks. All training will be overseen by a physical therapist with experience in SCI walking rehabilitation and will involve the use of an overhead support harness.
62252147|NCT02536768|EXPERIMENTAL|Intervention|Minimum package of interventions to improve ART adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
62252148|NCT02536768|NO_INTERVENTION|Comparison|Standard of care HIV treatment
62252149|NCT06186713||Pulmonary hypertension (PH) group|The PH group comprised of patients with systolic pulmonary artery pressure (sPAP) ≥ 35mmHg measured by echocardiology.
62252150|NCT06186713||Control group|The control group included patients with systolic pulmonary artery pressure (sPAP) \<35mmHg measured by echocardiology.
62623521|NCT03478085|EXPERIMENTAL|Oxygen guided exercise therapy|Training will be performed three times a week for 12 weeks. Each session will take place on a GaitKeeper treadmill (Sammons Preston, IL) treadmill and will last 45 minutes with a 5 minute warm up and cool down of either cycling or walking. All patients will be outfitted during exercise with the PortaMon NIRS device on the most affected calf (including subjects in the symptom-driven exercise cohort). The intensity of training will be adjusted to either pain (claudication) rating or oxygen tension. In preliminary studies, a 50% reduction in the tissue saturation index is typically not associated with severe claudication and will be used as the lower level threshold to gauge physical effort (i.e., if subjects do not desaturate by \>50% then the intensity of training - the walking pace - will be increased). The training duration, intensity, pain rating, and oxygen tension will be recorded.
62050682|NCT03757221|EXPERIMENTAL|Combination ixazomib + daratumumab without dexamethasone|Elderly Relapse Refractory Multiple Myeloma Patients treated by Combination ixazomib + daratumumab without dexamethasone
62252151|NCT03492528|EXPERIMENTAL|Cardiovascular patients treated for a cancer|
62252152|NCT00492427|ACTIVE_COMPARATOR|2|
62252153|NCT00492427|EXPERIMENTAL|1|
62252154|NCT00574145|EXPERIMENTAL|Radiotherapy/Supportive Care (A)|Patients receive radiotherapy and healing touch therapy from a healing touch therapist once a week for the duration of their radiotherapy
62252155|NCT00574145|SHAM_COMPARATOR|Control ARM (B)|Patients receive radiotherapy and sham healing touch therapy from a sham healing touch therapist once a week for the duration of their therapy
62252156|NCT01184222|ACTIVE_COMPARATOR|Arm Active SENGO|The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.
62252157|NCT01184222|PLACEBO_COMPARATOR|Arm sham SENGO|The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted.
62252158|NCT02131675||Boost shake|children that have had type 1 diabetes for more than 1 year
62252159|NCT05500820|EXPERIMENTAL|Cohort 1: 2.5 mg CIN-107|Subjects on a low salt diet
62252160|NCT05500820|EXPERIMENTAL|Cohort 2: 5.0 mg CIN-107|Subjects on a low salt diet
62252161|NCT05500820|EXPERIMENTAL|Cohort 3: 1.5 mg CIN-107|Subjects on a normal salt diet
62441667|NCT02891200|EXPERIMENTAL|HCP plus Peer arm|HCP plus Peer arm involves delivering of HCP support as in HCP Arm , along with adding Peer Support Program services. This program is offered to participants by especially trained 'peer mentors' with oversight from a social worker.
62050683|NCT05272566||Infants|"30 healthy, term infants are recruited for 2 purposes:~1. To study the development of gut bacteria and viruses over time~2. To use as donors in a separate trial"
62050684|NCT05272566||Mothers|"30 healthy pregnant women are recruited along with their infants~1. To compare gut bacteria and viruses with those of their children~2. To screen for disease transferrable by breastfeeding"
62050685|NCT06218225|EXPERIMENTAL|Verum|Partecipants received a food supplement with the innovative IMMUREMEDY®-B complex and Lactobacillus rhamnosus CRL1505.
62050686|NCT06218225|PLACEBO_COMPARATOR|Placebo|Partecipants received a food supplement in the same primary packaging of the verum, but without active substances
62050687|NCT05602051|EXPERIMENTAL|Virtual reality+Mindfulness|Intervention method combining virtual reality technology and mindfulness therapy, twice a week, lasting for 7 weeks
62050688|NCT05602051|NO_INTERVENTION|Mindfulness|Intervention method of mindfulness therapy, twice a week, lasting for 7 weeks
62050689|NCT04027348|EXPERIMENTAL|Treatment (octreotide, dexamethasone, metoclopramide)|IV octreotide 300 mcg TID + IV dexamethasone 4 mg BID (first dose 9am and second at 2pm) + IV metoclopramide 10 mg q6h.
62050690|NCT00855062|ACTIVE_COMPARATOR|Minocycline|Minocycline 100 mg orally every 12 hours
62050691|NCT00855062|PLACEBO_COMPARATOR|Placebo|Placebo minocycline capsules every 12 hours
62050692|NCT03924479|EXPERIMENTAL|Breathing muscle training|The breathing muscle training will consist of 7 sessions per week (1 per day) for 8 weeks. Each training session will consist of breathing \~15 times each minute for 30 minutes at 40% of maximal breathing muscle strength, while using the breathing muscle trainer. During the inhalation, participants will be instructed to inhale as fast as they can, while exhalations will be performed at the participants discretion.
62050693|NCT03924479|SHAM_COMPARATOR|Sham breathing muscle training|The breathing muscle training will consist of 7 sessions per week (1 per day) for 8 weeks. Each training session will consist of breathing \~15 times each minute for 30 minutes at 2%% of maximal breathing muscle strength, while using the breathing muscle trainer. During the inhalation, participants will be instructed to inhale as fast as they can, while exhalations will be performed at the participants discretion.
62252162|NCT05500820|EXPERIMENTAL|Cohort 4: 2.5 mg CIN-107|Subjects on a normal salt diet
62623522|NCT03478085|PLACEBO_COMPARATOR|Control|Patients will be advised to walk independently.
62623523|NCT05930171|ACTIVE_COMPARATOR|Group A: L-ESPB and PENG|receiving after end of hip surgery (PENG) block first and (LESPB) at lumber 4 vertebrae level
62623524|NCT05930171|ACTIVE_COMPARATOR|Group B: conventional analgesia|receiving postoperative conventional analgesia in form of acetaminophen 15 mg/kg/6hrs
62050694|NCT06236867|EXPERIMENTAL|Kaleidoscope Group|In order for the patients in the kaleidoscope group to recognize the device and increase their compliance during the procedure, a practice was performed using the device before the AVF cannulation procedure. Kaleidoscope application was performed during cannulation.
62050695|NCT06236867|EXPERIMENTAL|Ice Application Group|Ice application application was made with non-melting ice molds to the area where the index finger and thumb of the hand with fistula are joined (HOKU point).
62050696|NCT06236867|EXPERIMENTAL|Control Group|In the control group, the vital signs of the patients before AVF cannulation will be recorded. Before, during and after AVF cannulation, VAS pain scores will be evaluated after cannulation without any intervention.
62050697|NCT03062462|ACTIVE_COMPARATOR|clopidogrel|To observe double standard-dose clopidogrel on platelet aggregation in clopidogrel resistance's patients with coronary heart disease
62050698|NCT03062462|EXPERIMENTAL|ticagrelor|To observe low-dose of ticagrelor on platelet aggregation in clopidogrel resistance's patients with coronary heart disease
62050699|NCT02379182|ACTIVE_COMPARATOR|Control group|Will not receive any treatment procedure. Patients allocated in the control group will be treated according to the standard clinical care of patients with dysphagia at our center, that includes: adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary.
62252163|NCT05500820|EXPERIMENTAL|Cohort 5: 0.5 mg CIN-107|Subjects on a normal salt diet
62252164|NCT05500820|PLACEBO_COMPARATOR|Cohort 1: 2.5 mg matching placebo|Subjects on a low salt diet
62252165|NCT05500820|PLACEBO_COMPARATOR|Cohort 2: 5.0 mg matching placebo|Subjects on a low salt diet
62252166|NCT05500820|PLACEBO_COMPARATOR|Cohort 3: 1.5 mg matching placebo|Subjects on a normal salt diet
62252167|NCT05500820|PLACEBO_COMPARATOR|Cohort 4: 2.5 mg matching placebo|Subjects on a normal salt diet
62623525|NCT04818203|EXPERIMENTAL|Test Group|Participants receive 1 mL of clusters of autologous dermal fibroblast to three spots around the left eye and three spots around the right eye along the periorbital wrinkles on both sides, perpendicularly to the wrinkles.
62252168|NCT05500820|PLACEBO_COMPARATOR|Cohort 5: 0.5 mg matching placebo|Subjects on a normal salt diet
62252169|NCT06354582|EXPERIMENTAL|Group C1|The vitamin C1 group will receive 1 g of vitamin C intravenously administered after the induction of epidural labor anesthesia. The infusion speed will be set at 5ml/min.
62441668|NCT04259411|EXPERIMENTAL|MitraClip|Subject will receive MitraClip procedure with MitraClip NTR System or MitraClip XTR System.
62050700|NCT02379182|EXPERIMENTAL|Sensory Group|Patients allocated in the sensory group will be treated with transcutaneous electrical stimulation at sensory level. In addition, they will receive the standard clinical care described in the control group. The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
62833370|NCT00874510|EXPERIMENTAL|Mandatory Naps|interns on overnight extended duty shifts have mandatory sign out of cell phones and cross-coverage responsibilities for 5 hours roughly between 12 and 5 am. For Year 2, this will be two 3 hour shifts, the first between 12am-3am and the 2nd between 3am-6am.
62833371|NCT02529969|ACTIVE_COMPARATOR|intervention|500 mg curcumin capsule
62833372|NCT02529969|PLACEBO_COMPARATOR|placebo|500 mg placebo
62833373|NCT00724698||Group|Patients diagnosed with Allergic Rhinitis or Chronic Idiopathic Urticaria
62833374|NCT06595875|NO_INTERVENTION|control group|
62833375|NCT06595875|ACTIVE_COMPARATOR|m-tapa block|
62833376|NCT01545492||Tight|"Children born to women in the CHIPS RCT randomized to Tight blood pressure control \[target diastolic BP 85mmHg\]"
62833377|NCT01545492||Less Tight|"Children born to women in the CHIPS RCT randomized to Less Tight \[target diastolic BP 100mmHg\]."
62833378|NCT04411498||Group of Systemic Sclerosis|Patients who were followed-up with the diagnosis of diffuse systemic sclerosis in the Hospital of Rheumatology Clinic were evaluated in terms of inclusion criteria. 44 female patients who met the inclusion criteria were included in the study. All patients were evaluated by a rheumatologist with detailed history and physical examination. Scleroderma patient group was evaluated for the presence of other rheumatic diseases that may accompany.
62833379|NCT04411498||Group of control|The healthy control group (96 female ) was evaluated for rheumatic diseases \[undiagnosed connective tissue diseases and additional rheumatological diseases\] that may accompany secondary FMS exclusion.
62833380|NCT00335777|EXPERIMENTAL|Migranal treatment first treatment phase|All subjects were asked to treat one headache at 1 hour (early) and one headache at 4 hours after onset of throbbing (late). Dose of nasal spray constant for both time points. The subject could determine the order in which they could treat the headaches (early (first treatment phase) then late (second treatment phase), or late (first treatment phase) then early (second treatment phase).
62252170|NCT06354582|EXPERIMENTAL|Group C2|The vitamin C2 group will receive 2 g of vitamin C intravenously administered after the induction of epidural labor anesthesia. The infusion speed will be set at 5ml/min.
62623526|NCT04818203|PLACEBO_COMPARATOR|Placebo|Participants receive 1 mL of placebo solution to three spots around the left eye and three spots around the right eye along the periorbital wrinkles on both sides, perpendicularly to the wrinkles.
62833381|NCT00335777|EXPERIMENTAL|Migranal second treatment phase|All subjects were asked to treat one headache at 1 hour (early) and one headache at 4 hours after onset of throbbing (late). Dose of nasal spray constant for both time points. The subject could determine the order in which they could treat the headaches (early (first treatment phase) then late (second treatment phase), or late (first treatment phase) then early (second treatment phase).
62833382|NCT03094325|EXPERIMENTAL|Septal myectomy|
62833383|NCT02656771|ACTIVE_COMPARATOR|Echo Bi-Metric THA stem|"Uncemented titanium alloy press-fit stem with a proximal plasma spray porous titanium coating designed for bone ingrowth and the distal part of the stem has a roughened titanium surface for bone on-growth.~It is a relatively new implant that is now in routine clinical use. The stem uses many of the features of the known and used Integral® and Bi-Metric® hip stems while integrating new design features to further enhance clinical performance such as a reduced neck geometry to allow for increased ROM and decreased risk of neck impingement, a polished neck designed to reduce debris should impingement occur and a polished bullet-shape distal tip to reduce distal stresses."
62833384|NCT02656771|NO_INTERVENTION|Bi-Metric Porous Primary THA stem|"Uncemented titanium alloy press-fit stem with a proximal plasma spray porous titanium coating designed for bone ingrowth and the distal part of the stem has a roughened titanium surface for bone on-growth.~It was introduced in 1984 and have shown good clinical results and excellent stem survival in register studies"
62833385|NCT00512213|ACTIVE_COMPARATOR|1|Immunonutrition containing RNA, omega-3-FAs, arginine
62833386|NCT00512213|ACTIVE_COMPARATOR|2|Standard enteral nutrition: isocaloric and isonitrogeneous but w/o active ingredients
62252171|NCT06354582|EXPERIMENTAL|Group C3|The vitamin C3 group will receive 3 g of vitamin C intravenously administered after the induction of epidural labor anesthesia. The infusion speed will be set at 5ml/min.
62252172|NCT06354582|PLACEBO_COMPARATOR|Group P|The control group P will receive normal saline and be administered after the induction of epidural labor anesthesia. The infusion speed will be set at 5ml/min.
62252173|NCT05726851|EXPERIMENTAL|Part A, Cohort 1: E2025 Dose 1 or Placebo|Participants will receive E2025 Dose 1 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
62833387|NCT02575638|EXPERIMENTAL|Treatment population|The study drug, CZ48, is administered orally in capsule form t.i.d. Capsules in 30mg and 50mg of drug are available for dosing. This is a dose escalation study so dosage has not yet been determined. Study drug is take on day 1 - 5 and then no drug on day 6 and 7. This is repeated for 4 weeks, or one course.
62441669|NCT00566709|EXPERIMENTAL|RBCT based on rSO2 value|Intervention: In the rSO2 - strategy group, patients will be transfused to attain a post-transfusion rSO2 values higher than 60%.
62623527|NCT02393131|EXPERIMENTAL|Hippocampal avoidance WBRT|Conformal whole brain radiotherapy with hippocampal avoidance
62623528|NCT02393131|ACTIVE_COMPARATOR|Conformal WBRT|Conformal whole brain radiotherapy without hippocampal avoidance
62623529|NCT04923932|EXPERIMENTAL|Savolitinib|GC
62623530|NCT00835835|PLACEBO_COMPARATOR|Control group|The placebo group did not receive treatment during the matched period yet did undergo all assessments. The MS Placebo group received equal treatment following the study intervention period.
62050701|NCT02379182|EXPERIMENTAL|Motor Group|Patients allocated in the motor group will be treated with transcutaneous electrical stimulation at motor level. In addition, they will receive the standard clinical care of patients with dysphagia described in the control group. The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
62050702|NCT01519492|EXPERIMENTAL|AFN-12520000|100 mg tablet
62050703|NCT05308550|OTHER|Phase 1|"Version 1 of the rapid test:~The clinician taking the nasopharyngeal / oropharyngeal swab for standard PCR testing for Covid-19 collected a second swab directly afterwards for the rapid RNA test. The swab was placed in a dry tube, labelled with the patient's ID, date and time of taking the sample, and was taken to the microbiology laboratory for processing.~In the laboratory, 2ml of RNase-free water was added to the tube and shaken with the swab. Twenty-five microlitres of the swab solution was transferred into a PCR tube containing the dried reagents for the rapid RNA test. This tube was then incubated for 45 minutes at 65'C, then taken out to cool down. The colour of the tube was recorded by the laboratory technician."
62050704|NCT05308550|OTHER|Phase 2|"Version 2 of the rapid test:~The clinician taking the nasopharyngeal / oropharyngeal swab for standard PCR testing for Covid-19 collected a second swab directly afterwards for the rapid RNA test. The swab was placed in a tube containing 1ml of normal saline (instead of a dry tube). If the patient was eligible but the standard swab had already been taken \>12 hours before, we asked them for their consent to take a second standard swab alongside the swab for the rapid RNA test, to ensure that the samples were comparable.~In the laboratory, the swab was heated to 95'C for 5 minutes to inactivate the virus. Nine ml of RNase-free water was added to the tube and shaken with the swab, before transferring 25ul of the swab solution into the PCR tube containing the dried reagents. This tube was then incubated for 30 minutes at 65'C, then the colour of the tube was recorded and photographed by the laboratory technician at 30 minutes (primary reading) and 45 minutes (secondary reading)."
62050705|NCT04398537|EXPERIMENTAL|5mm retraction of clip deployment apparatus|The participants in this group will have clip placement 5mm in front of the biopsy site site.
62050706|NCT04398537|ACTIVE_COMPARATOR|no retraction of clip deployment apparatus|These participants will the clip delivered at the biopsy site.
62050707|NCT04457557|EXPERIMENTAL|Low concentration|Interscalene block with 0.15% ropivacaine 15 ml
62050708|NCT04457557|ACTIVE_COMPARATOR|Usual concentration|Interscalene block with 0.5% ropivacaine 15 ml
62050709|NCT03958838|EXPERIMENTAL|Intervention Group|"Subjects will receive usual care from community health center staff. In addition, they will also receive a variety of community-level and individual-level interventions, categorized broadly into three levels.~At the community level, subjects will receive the 5 Key Diabetes Messages that Everyone Should Know and the 6 Modules of Basic Diabetes Education. At the individual level, subjects and their families will be invited to participate in group activities, co-organized by community health staff, CHC staff, and CSMG peer leaders. Subjects will receive in-person peer support through these group activities, with follow up through telephone calls and text messaging. For subjects that have poorly controlled diabetes or are experiencing emotional distress related to their diabetes, CSMG peer leaders will work closely with them to help them solve problems around their diabetes."
62623531|NCT00835835|EXPERIMENTAL|Combination Treadmill training group|Subjects randomized to Combination therapy received 20 minutes of Lokomat assisted treadmill training followed by up to 20 minutes of BWS treadmill training (without robotic assistance) twice a week.
62623532|NCT04773821|EXPERIMENTAL|Experimental Arm|All men patients with low and intermediate risk prostate cancer (ISUP 1 and 2) who has already chosen to undergo focal treatment, in the referral centers and responding to the inclusion criteria will be included after obtaining their writing consent. Follow-up visits are planned at 3, 6,12 and 13 month from the date of the focal treatment consistently with usual care. All patients will have a MpMRI and MpMRI targeted biopsy in the presence of a lesion suggestive of recurrence at 12 months. The subject will be his own control
62833388|NCT04731558|EXPERIMENTAL|Preoperative thromboprophylaxis|Preoperatively initiated tromboprophylaxis
62833389|NCT04731558|OTHER|Postoperative thromboprophylaxis|Postoperatively initiated thromboprophylaxis
62833390|NCT04137640|OTHER|endocrine group|76 postmenopausal estrogen receptor-positive LABC patients with low Ki67 expression will beassigned into endocrine group.
62833391|NCT04137640|OTHER|chemotherapy group|76 postmenopausal estrogen receptor-positive LABC patients with low Ki67 expression will beassigned into chemotherapy group
62050710|NCT03958838|NO_INTERVENTION|Control Group|Subjects in the control group will receive usual care from community health center staff.
62050711|NCT03154489|OTHER|Acenocoumarol|
62050712|NCT03154489|OTHER|control group|
62050713|NCT05473754||Experimental Group|Families, teachers, and clinicians use SUPER digital platform in addition to usual rehabilitative and educative interventions.
62050714|NCT05473754||Control Group|Families, teachers, and clinicians perform usual rehabilitative and educative interventions.
62050715|NCT01620905|EXPERIMENTAL|Cervical spine manipulation|Subjects received cervical spine manipulation
62610843|NCT02472626|EXPERIMENTAL|Treatment (CPI-613, cytarabine, daunorubicin hydrochloride)|"INDUCTION: Patients receive cytarabine IV continuously on days 1-7, daunorubicin hydrochloride IV on days 1-3, and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 3-7. Patients then undergo biopsy on day 14. Patients experiencing significant residual disease receive cytarabine IV continuously on days 1-5, daunorubicin hydrochloride IV on days 1-2, and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5.~CONSOLIDATION: Beginning 42 days later, patients receive cytarabine IV continuously on days 1-16 and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 2-6. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients not undergoing transplant after consolidation receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
62610844|NCT06719765||60 Jordanian university students|"Age range will between 18 to 25 years old~- The study design will be observational cross sectional study"
62833392|NCT05445271|ACTIVE_COMPARATOR|Group 1|30 patients who will be intubated with a video laryngoscope and who meet the inclusion criteria are randomly selected by lottery method. After obtaining the consent of the patient's family, the patient is taken to the operating room and monitored. 5 minutes after sedation with 1 mg midazolam, the optic nerve sheath diameter of both eyes is measured with a linear ultrasound probe and recorded (T0). 5 minutes after the patient is intubated with a video laryngoscope, the optic nerve sheath diameter of both eyes is measured and recorded (T1). After the patient's extubation at the end of the case, the optic nerve sheath diameter of both eyes is measured and recorded (T2). Vitals (pulse, blood pressure, saturation) involved in T0, T1 and T2 processes are recorded.
62833393|NCT05445271|ACTIVE_COMPARATOR|Group 2|30 patients who will be intubated with a normal laryngoscope and who meet the inclusion criteria are randomly selected by lottery method. After obtaining the consent of the patient's family, the patient is taken to the operating room and monitored. 5 minutes after sedation with 1 mg midazolam, the optic nerve sheath diameter of both eyes is measured with a linear ultrasound probe and recorded (T0). 5 minutes after the patient is intubated with a normal laryngoscope, the optic nerve sheath diameter of both eyes is measured and recorded (T1). After the patient's extubation at the end of the case, the optic nerve sheath diameter of both eyes is measured and recorded (T2). Vitals (pulse, blood pressure, saturation) involved in T0, T1 and T2 processes are recorded.
62833394|NCT05445271|ACTIVE_COMPARATOR|Group 3|30 patients who will be ventilated with a laryngeal mask airway (LMA) and who meet the inclusion criteria are randomly selected by lottery method. After obtaining the consent of the patient's family, the patient is taken to the operating room and monitored. 5 minutes after sedation with 1 mg midazolam, the optic nerve sheath diameter of both eyes is measured with a linear ultrasound probe and recorded (T0). The optic nerve sheath diameter of both eyes is measured and recorded 5 minutes after LMA is placed on the patient (T1). After the patient's extubation at the end of the case, the optic nerve sheath diameter of both eyes is measured and recorded (T2). Vitals (pulse, blood pressure, saturation) involved in T0, T1 and T2 processes are recorded.
62833395|NCT04069702|EXPERIMENTAL|VR Blue|VR Blue is a protocol for patients with advanced stage colorectal cancer who experience persistent pain. Participants will complete a single 30-minute laboratory-based virtual reality underwater/sea environment (VR Blue) session. VR Blue is an immersive computer-generated environment featuring calming scenic graphics and relaxing nature music.
62833396|NCT04782869|EXPERIMENTAL|tDCS (transcranial direct current stimulation)|Patient will be treated for 3 cycles. A cycle is composed of 5 bi-sessions (one per day) of 20 minutes each.
62833397|NCT01747876|EXPERIMENTAL|LEE011|
62833398|NCT03754621||Pregnants|400 pregnant women with a singleton pregnancy, free of pre-existing thyroid disease, that do not use thyroid interfering medication, that did not undergo IVF treatment and are TPOAb negative. Serum thyroid functions tests will be obtained on the first visit.
62610845|NCT02245113|EXPERIMENTAL|Test Fat P|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
62610846|NCT02245113|EXPERIMENTAL|Test Fat Q|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
62833399|NCT03121053|ACTIVE_COMPARATOR|sodium bicarbonate|250ml 1.4% sodium bicarbonate 1 h before TAVR
62833400|NCT03121053|ACTIVE_COMPARATOR|hypotone saline|0.65% sodiumchloride 1 ml/kg/h for 12 h before and 12 h after TAVR
62833401|NCT01043419|EXPERIMENTAL|LENOXe™ (xénon 100 % v/v)|Influence of LENOXe™ (xénon 100 % v/v) anesthesia on Sympathetic Nervous Activity and Security under LENOXe™ (xénon 100 % v/v) anesthesia
62833402|NCT04674423|EXPERIMENTAL|TAF Treatment|TAF treatment for 144 weeks and followed for 48 weeks after 144-week TAF treatment
62833403|NCT04674423|NO_INTERVENTION|Observation arm|Observation for 144 weeks
62833404|NCT04380285|ACTIVE_COMPARATOR|Group 1. Custom heel pads and modified soft molded orthotics|Modified soft custom orthotics supported in the medial longitudinal arches and medial shock absorbing heel pads with customized cutout at the point corresponding to the heel pain
62833405|NCT04380285|ACTIVE_COMPARATOR|Group 2. Custom hard orthotics|Custom hard orthotics made from a positive mold of a foot in neutral position, with arch support and medial heel postings.
62050716|NCT01458470|ACTIVE_COMPARATOR|Memantine|NMDA Receptor Antagonist
62050717|NCT01458470|PLACEBO_COMPARATOR|Sugar pill|
62050718|NCT02803554|EXPERIMENTAL|Young donor plasma|An infusion of plasma derived from donors aged 25 years or younger
62252174|NCT05726851|EXPERIMENTAL|Part A, Cohort 2: E2025 Dose 2 or Placebo|Participants will receive E2025 Dose 2 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
62833406|NCT05521308|EXPERIMENTAL|Participants with Hearing Loss|Individuals with hearing loss that meet the candidacy to wear hearing aids. All interventions are associated with the fitting of binaural hearing aids with various coupling methods. All participants will be assessed under all interventions.
62833407|NCT03144154|EXPERIMENTAL|Experimental group : Hypnosis-based intervention|Groupal intervention combining self-care techniques and self-hypnosis exercises
62833408|NCT03144154|NO_INTERVENTION|Control group : Usual care|Control group receiving usual care but not the intervention
62833409|NCT03821402|EXPERIMENTAL|DAXI 250 U|DAXI for injection for the treatment of Upper Limb Spasticity (ULS) in Adults with 250 U dose
62833410|NCT03821402|EXPERIMENTAL|DAXI 375 U|DAXI for injection for the treatment of Upper Limb Spasticity (ULS) in Adults with 375 U
62833411|NCT03821402|EXPERIMENTAL|DAXI 500 U|DAXI for injection for the treatment of Upper Limb Spasticity (ULS) in Adults with 500 U
62252175|NCT05726851|EXPERIMENTAL|Part A, Cohort 3: E2025 Dose 3 or Placebo|Participants will receive E2025 Dose 3 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
62441670|NCT00566709|ACTIVE_COMPARATOR|RBCT based on hemoglobin level value|Intervention: In the hemoglobin - strategy group, patients will be transfused to reach post-transfusion hemoglobin levels between 8.5 g/dL and 10 g/dL.
62833412|NCT03821402|PLACEBO_COMPARATOR|Placebo|Placebo group
62833413|NCT01194856|ACTIVE_COMPARATOR|Efavirenz 600 mg|Serving as the Control Arm - patients will maintain EFV-containing antiretroviral regimen
62441671|NCT02818556|OTHER|Restylane Right, Belotero Left|Patients will receive one treatment with Restylane® Silk (right side of the face) and one treatment of Belotero Balance® (left side)
62441672|NCT02818556|OTHER|Restylane Left, Belotero Right|Patients will receive one treatment with Restylane® Silk (left side of the face) and one treatment of Belotero Balance® (right side)
62441673|NCT01897597|EXPERIMENTAL|BI 144807 PfoS Treatment A|intermediate dose of BI 144807
62441674|NCT01897597|EXPERIMENTAL|BI 144807 PfoS Treatment C|high dose of BI 144807
62441675|NCT01897597|EXPERIMENTAL|BI 144807 Tab Treatment B|intermediate dose of BI 144807
62441676|NCT01897597|EXPERIMENTAL|BI 144807 Tab Treatment D|high dose of BI 144807
62833414|NCT01194856|EXPERIMENTAL|Arm B - Atazanavir/Ritonavir|Atazanavir 300 mg orally with Ritonavir 100 mg orally once daily for 96 wks
62833415|NCT06654375|EXPERIMENTAL|Endovascular thrombectomy|
62050719|NCT06452056||Clinical Evaluation|Participants (N=170) will be divided into three categories: known to be COVID+ symptomatic (n=50); known to be COVID+ asymptomatic (n=20) and not known to have COVID n=100
62441677|NCT01897597|EXPERIMENTAL|BI 144807 Tab Treatment E|intermediate dose of BI 144807, fasted
62441678|NCT01897597|EXPERIMENTAL|BI 144807 Tab Treatment F|intermediate dose of BI 144807, fed
62441679|NCT01897597|EXPERIMENTAL|BI 144807 Tab Treatment G|intermediate dose of BI 144807, fasted
62441680|NCT05658042||rivaroxaban 10mg qd|nonintervention
62441681|NCT05658042||rivaroxaban 10mg qd+rifampicin|nonintervention
62833416|NCT06654375|NO_INTERVENTION|Best Medical Management|
62833417|NCT03879161|EXPERIMENTAL|Device Arm|Study participants will be enrolled in the Device Arm and the Vu-Path™ Device will be used to access the femoral artery for intra-arterial chemoembolization.
62833418|NCT03619382||Healthy|Subjects identified to have a healthy foot/ankle
62833419|NCT02992795||Cohort Ia|Athletes in this cohort serve as control subjects participating in Division 1 Athletics at the University of Wyoming. They will be enrolled once they meet eligibility. Upon enrollment, all athletes will have an initial BrainPulse recording. Once a subject from this cohort sustains an injury, they crossover to Cohort II. Also, a matched control for every concussed subject will be selected from Cohort Ia.
62833420|NCT02992795||Cohort Ib|Athletes in this cohort are subjects currently subscribed to the Head Health Network. They will have a BrainPulse recording completed every week through the entire season. Similarly, if subjects in this cohort sustain an injury, they will crossover to Cohort II.
62050720|NCT06452056||Human Usability|"Participants not known to have COVID (n=180) will be observed by a trained observer either in person or by videomonitoring when performed in non laboratory, actual or simulated use environments.~We will split our usability study into two sections including participants testing themselves (n=90) and participants testing another person (child or adult) (n=90)."
62833421|NCT02992795||Cohort IIa|Athletes from Cohort I will be assigned to cohort IIa once they sustain an injury other than concussion. They will have been pulled out of the game by the athletic trainer and removed from play until at least the end of the game. Once the subjects have been assigned to Cohort IIa, they will have a BrainPulse recording and a symptom evaluation within 3 days of their injury. After two weeks of recovery, subjects in this cohort will return to Cohort 1 and resume their participation in the study in their respective sub-cohort.
62833422|NCT02992795||Cohort IIb|Athletes in this cohort are injured subjects who sustain a non-penetrating head injury and are confirmed to have had a concussion according to the protocol reference standard and by their physician. All subjects enrolled in this cohort are required to have a BrainPulse recording within 3 days of their injury. Each BrainPulse recording will be accompanied by a symptoms evaluation and medical data collection documented in the case report forms. Subjects will complete 3 weeks of follow-up visits post injury.
62833423|NCT04237116|EXPERIMENTAL|Investigational Arm - secukinumab|secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind
62833424|NCT04237116|PLACEBO_COMPARATOR|Control Arm - placebo|placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20
62833425|NCT03033095|EXPERIMENTAL|etanercept|"The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.~Modality of administration :~Etanercept : 50 mg / week subcutaneously, every 7 days The clinical response will be evaluated after 6 months of etanercept treatment, at the M6 visit."
62833426|NCT06175884|EXPERIMENTAL|Good communication skills|Participants will watch a video about the pain neuroscience education in which physiotherapist will develop qualities of good communication while he will be giving information and explanation about chronic musculoskeletal pain.
62833427|NCT06175884|EXPERIMENTAL|Poor communication skills|Participants will watch a video about the pain neuroscience education in which physiotherapist will not develop qualities of good communication while he will be giving information and explanation about chronic musculoskeletal pain.
62833428|NCT06175884|NO_INTERVENTION|Control|Participants will not watch any video
62833429|NCT01493739||lymphadenopathy|
62833430|NCT03980054|EXPERIMENTAL|Arm Pyrotinib|Intervention: Drug: Pyrotinib
62252176|NCT05726851|EXPERIMENTAL|Part A, Cohort 4: E2025 Dose 4 or Placebo|Participants will receive E2025 Dose 4 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
62833431|NCT03980054|PLACEBO_COMPARATOR|Arm Placebo|Intervention: Drug: Placebo
62252177|NCT05726851|EXPERIMENTAL|Part B, Cohort 5: E2025 Dose 2|Participants will receive E2025 Dose 2 administered as an IV infusion on Day 1.
62252178|NCT05726851|EXPERIMENTAL|Part B, Cohort 6: E2025 Dose 3|Participants will receive E2025 Dose 3 administered as an IV infusion on Day 1.
62252179|NCT05726851|EXPERIMENTAL|Part B Cohort 7: E2025 Dose 4|Participants will receive E2025 Dose 4 administered as an IV infusion on Day 1.
62441682|NCT05658042||rivaroxaban 20mg qd+rifampicin|nonintervention
62252180|NCT03851003|EXPERIMENTAL|Endometrial suturing|Uterine incision repair including suturing of the endometrium
62441683|NCT05658042||rivaroxaban 15mg bid+rifampicin|nonintervention
62441684|NCT04818021|EXPERIMENTAL|Adaptation to Altered Auditory Feedback|Adaptation to Altered Auditory Feedback
62441685|NCT04818021|EXPERIMENTAL|Adaptation to Altered Auditory Feedback + Forward Skin Stretch|Adaptation to Altered Auditory Feedback + Forward Skin Stretch
62441686|NCT04818021|EXPERIMENTAL|Adaptation to Altered Auditory Feedback + Backward Skin Stretch|Adaptation to Altered Auditory Feedback + Backward Skin Stretch
62441687|NCT04818021|EXPERIMENTAL|Speech Repetition Control|Speech Repetition Control
62050721|NCT06452056||Demonstration Project|Our demonstration project in the Columbia University community will offer COV-SCAN and paired app to undergraduate students housed on the Columbia campus and to graduate students living in Columbia-owned residences on the Morningside campus.
62050722|NCT02327962||Hemodialysis|Hemodynamic measurements with PWV
62050723|NCT02327962||Control|Hemodynamic measurements with PWV
62610847|NCT02245113|EXPERIMENTAL|Test Fat R|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
62833432|NCT05204277|ACTIVE_COMPARATOR|In-office bleaching|40% hydrogen peroxide in-office bleaching (Opalescence™ boost™ PF 40%, Ultradent Products, Inc., South Jordan, UT, USA)
62441688|NCT01754259|EXPERIMENTAL|Ranolazine|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
62050724|NCT06214845|EXPERIMENTAL|Automated REX|Automated REX
62610848|NCT06654297|EXPERIMENTAL|Camrelizumab+Palbociclib(100mg) 3 patients|For palbociclib, there is 2 dose levels, 100mg qd and 125 mg qd, and if no patients experience DLT on 100mg level, 125mg level will be administered.
62610849|NCT06654297|EXPERIMENTAL|Camrelizumab+Palbociclib(125mg) 3 patients|For palbociclib, there is 2 dose levels, 100mg qd and 125 mg qd, and if no patients experience DLT on 100mg level, 125mg level will be administered.
62610850|NCT06035939|EXPERIMENTAL|Intervention|Study participants randomized to receive the intervention.
62610851|NCT06035939|ACTIVE_COMPARATOR|Control|Study participants randomized to receive enhanced usual care (control).
62610852|NCT03913104|EXPERIMENTAL|Medication Abortion Patients|Oral Mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone)
62050725|NCT06214845|ACTIVE_COMPARATOR|Manual REX|First manual REX will be performed as soon as possible after randomisation, and the patient will be re-assessed every 24 hours (repeated manual REX will be allowed in case of clinical worsening after 24 or 48 hours or in the absence of clinical improvement after 72 hours)
62610853|NCT02615392|EXPERIMENTAL|Park prescription|The participants in this group will receive a brief counseling on physical activity together with a park prescription that highlights the importance of engaging in at least 150 minutes of physical activity per week and the possibility of engaging in physical activity in the park. In addition, they are invited to join in a structured and supervised physical activity program in the park. The structured physical activity program will take place in public parks located in the participants' neighbourhood. Participants will receive text messages for reminder and registration purposes approximately once a week. Also, participants will receive a sheet to monitor their weekly physical activity, information about parks in their neighborhood, and a counseling phone call half-way through the study.
62050726|NCT04147039|EXPERIMENTAL|Intervention|Receives the MINISTOP 2.0 mobile phone app for 6 months
62050727|NCT04147039|NO_INTERVENTION|Control|Receives standard care through primary child health care
62050728|NCT02273830|ACTIVE_COMPARATOR|oxygen adjusted|oxygen adjusted to get SpO2\> 90% during the walking test
62441689|NCT01754259|PLACEBO_COMPARATOR|Placebo|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
62050729|NCT02273830|PLACEBO_COMPARATOR|control group|oxygen at 3L/min
62050730|NCT00869479||1|subjects with a histologically-proven diagnosis of NSF
62050731|NCT00869479||2|subjects with other fibrosing skin diseases
62610854|NCT02615392|NO_INTERVENTION|Control|The participants in this group will not be given any park prescription or be invited to participate in the weekly program in the park. However, they will receive all the information materials provided to the experimental group after the study has ended.
62050732|NCT00869479||3|subjects with non-fibrosing skin diseases
62050733|NCT00869479||4|subjects without skin diseases
62050734|NCT06532318|EXPERIMENTAL|Group A|Patients here will have one milliliter of freshly prepared autologus platelet rich plasma injection for the treatment of their trigger finger.
62252181|NCT03851003|EXPERIMENTAL|Non - Endometrial suturing|Uterine incision repair without suturing of the endometrium
62610855|NCT04129840|ACTIVE_COMPARATOR|Intervention 1: dual combination|dual combination of half-dose Calcium Channel Blocker (CCB) and Angiotensin II Receptor Blocker (ARB), dosage increases at 4 and 8 weeks if target blood pressure is not reached at the respective time point
62610856|NCT04129840|ACTIVE_COMPARATOR|Intervention 2: triple combination|triple combination of quarter-dose of Calcium Channel Blocker (CCB), Thiazide diuretic (TZD) and Angiotensin II Receptor Blocker (ARB) with dosage increases of all drugs at 4 and 8 weeks, if target blood pressure is not reached at the respective time point
62833433|NCT05204277|ACTIVE_COMPARATOR|microabrasion|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste (Opalustre™, Ultradent Products, Inc., South Jordan, UT, USA)
62050735|NCT06532318|ACTIVE_COMPARATOR|Group B|Patients here will have one milliliter(20mg) injection of pfizer Depo-medrol(methylprednisolone acetate) injection for the treatment of their trigger finger.
62610857|NCT04129840|PLACEBO_COMPARATOR|Standard of care|start normal dose Calcium Channel Blocker (CCB), add Thiazide diuretic (TZD) after 4weeks and increase of TZD dosage after 8 weeks, if target blood pressure is not reached at the respective time point
62610858|NCT01915524|EXPERIMENTAL|CV9202 and local radiation|"CV9202 consisting of 6 RNActive-derived molecules coding for 6 different NSCLC associated antigens.~local radiation (4x5 Gy)"
62833434|NCT05204277|ACTIVE_COMPARATOR|Remineralization|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème (MI-Paste Plus®, GC America Inc., USA).
62833435|NCT05204277|ACTIVE_COMPARATOR|Microabrasion + In-office bleaching|teeth were treated with enamel microabrasion followed by in-office bleaching.
62833436|NCT05204277|ACTIVE_COMPARATOR|In-office bleaching + Remineralization|In-office bleaching was applied followed by MI-Paste Plus®
62833437|NCT05204277|ACTIVE_COMPARATOR|Microabrasion + Remineralization|microabrasion was applied followed by MI-Paste Plus®
62833438|NCT05204277|ACTIVE_COMPARATOR|Microabrasion + In-office bleaching + Remineralization|teeth were treated with microabrasion followed by inoffice bleaching and lastly MI-Paste Plus®
62833439|NCT05204277|NO_INTERVENTION|Control|no treatment (control)
62833440|NCT03904914||AIS group|Patients confirmed with adolescent idiopathic scoliosis (AIS)
62833441|NCT06087653|EXPERIMENTAL|Study ARM1 - Vld (Velcade-lenalidomide-dexamethasone)|Bortezomib SC at 1.3 mg/m2 on Days 1, 8, 15, and 22 of each 28-day cycle Lenalidomide 400 mcg/hr continuously for 28 of 28-day cycle Dexamethasone 40mg orally on Days 1, 8, 15 and 22 of each 28-day cycle (age 75 or over 20 mg.
62833442|NCT06217510|EXPERIMENTAL|Test Brace|A 3D printed brace designed automatically from a digital twin of the participant.
62833443|NCT02153320|EXPERIMENTAL|HBsAg + adjuvant 1 Group|Single blood sample taken from subjects who had received GSK candidate vaccine containing HBsAg together with an adjuvant 1 in study 287615 (NCT00508833).
62833444|NCT02153320|EXPERIMENTAL|HBsAg + adjuvant 2 Group|Single blood sample taken from subjects who had received GSK candidate vaccine containing HBsAg together with an adjuvant 2 in study 287615 (NCT00508833).
62050736|NCT06105242||Retrospective Cohort Aim 1|Aims 1 and 2 are retrospective and will be conducted with the same dataset, just at two different time points (at diagnosis of CTEPH and after PTE surgery). For simplicity, aims 1 and 2 will be combined into one section throughout the protocol.
62050737|NCT06105242||Retrospective Cohort Aim 2|Aims 1 and 2 are retrospective and will be conducted with the same dataset, just at two different time points (at diagnosis of CTEPH and after PTE surgery). For simplicity, aims 1 and 2 will be combined into one section throughout the protocol.
62050738|NCT06105242||Prospective Cohort Aim 3|Aim 3 is prospective and will enroll a distinct set of patients from Aim 1 and 2.
62441690|NCT01798459|ACTIVE_COMPARATOR|Methylphenidate|Methylphenidate 0.3 mg/kg per os is given before performing a continuous performance test.
62610859|NCT04612972|EXPERIMENTAL|Investigational vaccine 1. Wuhan|Inactivated SARS-CoV-2 vaccine (Vero cell); 200WU/dose for per human use, 0.5 mL/ dose; Intramuscular injection; Two doses: one dose/21-28 days; 4000 participants per arm
62610860|NCT04612972|EXPERIMENTAL|Investigational vaccine 2. Beijing|Inactivated SARS-CoV-2 vaccine (Vero cell); 4μg/dose for per human use, 0.5 mL/ dose; Intramuscular injection; Two doses: one dose/21-28 days; 4000 participants per arm
62610861|NCT04612972|PLACEBO_COMPARATOR|Placebo/Aluminum Adjuvant of Inactivated SARS CoV|Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine; Active Ingredient: None; Virus Contents: None; Adjuvant: aluminum hydroxide; Specification: 0.5 mL/ dose, 0.5mL for per human use; Intramuscular injection; Two doses: one dose/21-28 days; 4000 participants per arm
62833445|NCT02153320|EXPERIMENTAL|HBsAg + adjuvant 3 Group|Single blood sample taken from subjects who had received GSK candidate vaccines containing HBsAg together with an adjuvant 3 in study 287615 (NCT00508833).
62833446|NCT05812729|EXPERIMENTAL|Intervention|"Participants in the intervention group will receive access to the 6-week online resilience intervention resiLIR Basic consisting of 8 modules of about 45-60 minutes addressing evidence-based resilience factors, such as optimism or sense of coherence."
62833447|NCT05812729|NO_INTERVENTION|Waitlist control group|Participants will receive the intervention after the first follow-up assessment (3 months after post-assessment).
62833448|NCT03531346|EXPERIMENTAL|Hyperosmolarity group|Healthy, young, habitual contact lens wearers with initial increased tear osmolarity (hyperosmolarity)
62833449|NCT03531346|EXPERIMENTAL|Normal osmolarity|Healthy, young, habitual contact lens wearers with initial tear osmolarity reported as normal
62833450|NCT01973764|OTHER|Ultrasound guided arm|
62833451|NCT01973764|OTHER|Landmark-based arm|
62833452|NCT05859503||Perclose-Proglide system|
62833453|NCT05859503||Figure-of-8|
62252182|NCT02613845||Cardiac surgery|Study subjects are all patients who underwent cardiac surgery with cardiopulmonary bypass at the University Hospital Basel during the year 2013.
62441691|NCT01798459|PLACEBO_COMPARATOR|Placebo|Placebo is given before performing a continuous performance test.
62610862|NCT05675514|EXPERIMENTAL|İntervention Group|The intervention group; (n=30) at the beginning of the study, after the initial evaluations (demographic information, functional movement screening test (FMS), t agility test, vertical jump test, muscle strength test, muscle viscoelasticity and star balance test) were made, twice a week for 6 weeks, pre-training myofascial release technique will be applied. Final evaluations will be made when the intervention period is over.
62610863|NCT05675514|NO_INTERVENTION|Control Group|The control group; (n=30) will do their routine training for 6 weeks after initial evaluations (demographic information, FMS, t agility test, vertical jump test, muscle strength test, muscle viscoelasticity and star balance test).No action will be taken. Final evaluations will be made at the end of 6 weeks.
62610864|NCT00776620|EXPERIMENTAL|1|Glimepiride 1 MG Tablets of Ranbaxy
62610865|NCT00776620|ACTIVE_COMPARATOR|2|AMARYL® 1 mg tablets
62610866|NCT04587024|OTHER|mHealth intervention|mHealth intervention
62050739|NCT06352372|EXPERIMENTAL|Near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - to the brain of autistic child|This is a prospective, open level study comparing 15 individuals with active seizures and 15 individuals with EEG abnormalities before and after, near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) will be the active arm and the second arm will receive a placebo (no intervention).
62050740|NCT03376867||Healthy volunteers|Conditioned pain modulation (2 stimuli test: heat and pressure points) before and after conditioning stimuli (cold water bath).
62050741|NCT03376867||Volunteers with chronic pain|Conditioned pain modulation (2 stimuli test: heat and pressure points) before and after conditioning stimuli (cold water bath).
62050742|NCT00900874|ACTIVE_COMPARATOR|1|Salbutamol + steroid
62050743|NCT00900874|ACTIVE_COMPARATOR|2|Formoterol + steroid
62610867|NCT04587024|PLACEBO_COMPARATOR|standard of care|post-transplant standard of care
62610868|NCT03381963||Aromatase inhibitors|
62610869|NCT03381963||Tamoxifen|
62610870|NCT03963180|NO_INTERVENTION|control group|the control group received 3 cups hot water on the 6th, 12th and 18th hours after the operation
62610871|NCT03963180|EXPERIMENTAL|study group|drank 3 cups of caffeinated coffee on the 6th, 12th and 18th hours after the operation.
62610872|NCT05731167|ACTIVE_COMPARATOR|Regular follow up|Subjects underwent routine outpatient care after assessment and will receive outcomes follow up for 1 year.
62833454|NCT05952466||COVID-19 infection group|School-age children infected recently with COVID-19
62833455|NCT05952466||control group|School-age children without COVID-19
62833456|NCT03470389|EXPERIMENTAL|HVPG|Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
62833457|NCT04387604||non vitrectomized eyes|ranibizumab injections (0.5 mg/0.05ml) following a PRN regimen
62833458|NCT04387604||vitrectomized eyes|ranibizumab injections (0.5 mg/0.05ml) following a PRN regimen
62833459|NCT00736762|EXPERIMENTAL|GPR|Global postural re-education intervention
62833460|NCT03519633|EXPERIMENTAL|SUG|
62833461|NCT03519633|ACTIVE_COMPARATOR|NEO|
62833462|NCT03979287|EXPERIMENTAL|IFC and Therapeutic Exercise Program|Patients will receive 10 sessions for two weeks. The duration of each session will be of approximately one hour. Participants will receive treatment with Interferential current therapy plus a program of therapeutic exercise focused on the neck region
62833463|NCT03979287|ACTIVE_COMPARATOR|Therapeutic Exercise Program|Patients will receive 10 sessions for two weeks. The duration of each session will be of approximately one hour.This group will only receive the same therapeutic exercise program.
62833464|NCT05528315|EXPERIMENTAL|Single dose, ABX-002|Single Dose (solution) dose escalating
62833465|NCT05528315|EXPERIMENTAL|Multiple dose, ABX-002|Multiple Dose (solution) dose escalating
62050744|NCT03151681|EXPERIMENTAL|Propranolol pill + mismatch memory reactivation|Prediction-error will be incorporated into each treatment sessions.
62050745|NCT03151681|EXPERIMENTAL|Propranolol pill + standard memory reactivation|
62050746|NCT03151681|NO_INTERVENTION|Waitlist|
62050747|NCT02296554|EXPERIMENTAL|SLAP Repair|Patient will receive SLAP repair for their SLAP tear.
62050748|NCT02296554|EXPERIMENTAL|Biceps Tenodesis Repair|Patient will receive biceps tenodesis repair for their SLAP tear.
62050749|NCT04928963|EXPERIMENTAL|Fasting mimicking diet|Fasting mimicking diet will be provided with all food to be consumed during each of the 2 cycles. The components of the diet will be approximately 30% calorie restricted and 50% protein restricted but supplemented with 50% of the RDA in vitamins and minerals and also supplemented with both nonessential and essential amino acids identified in animal studies to be effective.
62050750|NCT04928963|PLACEBO_COMPARATOR|Placebo diet|One meal which substitute or lunch or dinner for 5 days, without calories restriction.
62050751|NCT05666219|EXPERIMENTAL|Treatment group|Patients receiving Injection Aminophylline
62050752|NCT04481295|ACTIVE_COMPARATOR|High SpO2 group|In this group, patients have undergone 4 weeks of pulmonary rehabilitation under the HFNC (FIO2 value that the minimum SpO2 value during pulmonary rehabilitation is 94-96%, and a flow of 10 L/min).
62050753|NCT04481295|ACTIVE_COMPARATOR|Low SpO2 group|In this group, patients have undergone 4 weeks of pulmonary rehabilitation under the HFNC (FIO2 value that the minimum SpO2 value during pulmonary rehabilitation is 84-86%, and a flow of 10 L/min).
62050754|NCT02926248|EXPERIMENTAL|Colchicine|Manipulation under Anesthesia (MUA) will be performed prior to 12 weeks after the index TKA. Patients will be randomized to oral colchicine 0.6 mg twice daily for 6 weeks. All patients will follow a standardized post-MUA physical therapy protocol.
62252183|NCT02224313|NO_INTERVENTION|1.Premenopausal women|No treatment
62833466|NCT05528315|EXPERIMENTAL|Formulation Comparison Solution or Capsule|ABX-002 Single Dose TBD - Solution ABX-002 Single Dose TBD - Capsule
62050755|NCT02926248|PLACEBO_COMPARATOR|Placebo|Manipulation under Anesthesia (MUA) will be performed prior to 12 weeks after the index TKA. Patients will be randomized to oral placebo twice daily for 6 weeks. All patients will follow a standardized post-MUA physical therapy protocol.
62050756|NCT06371131|EXPERIMENTAL|Right stellate ganglion block|Right -stellate ganglion block was given 30minutes before anesthesia induction.
62050757|NCT06371131|NO_INTERVENTION|Blank control group|No treatment was given 30 minutes before anesthesia induction
62050758|NCT04744857|EXPERIMENTAL|A single set of test|The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.
62050759|NCT04876222|ACTIVE_COMPARATOR|Acute CAG|The patient is triaged directly to the catheterization laboratory for acute evaluation including ECHO, acute CAG and PCI if indicated according to guidelines.
62252184|NCT02224313|EXPERIMENTAL|2.Postmenopausal women with hormones|"Oral hormone therapy will be given to women in this group. Daily dose of oral estradiol 1 mg will be given the first 14 days after enrollment. Then a daily dose of oral estradiol 1 mg and progesterone 100 mg for 14 days will be given during the following 14 days."
62833467|NCT00494793|OTHER|VAWC and mesh mediated fascial traction|This is a study aiming to evaluate one technique for temporary abdominal closure for open abdomen therapy in all patients applicable according to the inclusion criteria
62833468|NCT00006461|OTHER|Chemotherapy, surgery, radiation therapy|Patients receive induction chemotherapy consisting of vincristine sulfate IV on days 1, 8, and 15; cisplatin IV over 6 hours on day 1; cyclophosphamide IV over 30 minutes on day 2; and oral etoposide daily on days 2-22. Treatment repeats every 28 days for a total of 4 courses. After completion of induction chemotherapy, patients with residual disease undergo a therapeutic conventional surgery (second resection). Within 4 weeks after completion of induction chemotherapy or second resection, patients receive 3-dimensional conformal radiation therapy daily, 5 days a week, for 6 weeks. Four weeks after completion of 3-dimensional conformal radiation therapy, patients receive alternating treatments of maintenance chemotherapy. Patients receive vincristine sulfate IV on days 1, 8, and 15 and cyclophosphamide IV over 30 minutes on day 1 of courses 1, 3, 5, and 7 and oral etoposide daily on days 1-21 of courses 2, 4, 6, and 8. Treatment continues every 28 days for 8 courses.
62050760|NCT04876222|NO_INTERVENTION|Subacute CAG|The patient is triaged to the coronary care unit (CCU) for rhythm surveillance, and additional diagnostics, and in case there is found indication for CAG, it is planned for the coming day in daytime (12-24 hours after cardiac arrest). Revascularization is performed if indicated according to guidelines.
62050761|NCT01100554|EXPERIMENTAL|all patients|
62050762|NCT03431402|OTHER|Acute stroke receive hyperbaric oxygen|
62050763|NCT03431402|NO_INTERVENTION|Acute stroke receive only conventional treatment|
62050764|NCT06579976||psoriasis lesion area|Assessment of lesions in patients with plaque psoriasis using high-frequency ultrasound and local PASI scores
62050765|NCT06579976||non-psoriasis lesion area|Assessment of 2 cm next to lesions in patients with plaque psoriasis using high-frequency ultrasound
62252185|NCT03672370||Alloclassic® Variall® Cup|Subjects who received the Alloclassic® Variall® Cup Ceramic Bearing System
62610873|NCT05731167|EXPERIMENTAL|Multidomain intervention|The intervention group will receive multi-faceted frailty prevention programs such as physical training, nutritional advice, cognitive training, and drug education and receive outcomes follow up for 1 year.
62050766|NCT05602649|PLACEBO_COMPARATOR|Placebo Gummy|Participants will self-administer a gummy containing 0mg THC
62050767|NCT05602649|EXPERIMENTAL|Low Dose Gummy|Participants will self-administer a gummy containing 10mg THC
62252186|NCT00403676|EXPERIMENTAL|Follow up by nurse|Patient randomized for follow-up by a nurse
62252187|NCT00403676|EXPERIMENTAL|follow up by medical doctor|Patients randomized for follow up by a medical doctor
62252188|NCT03975920|NO_INTERVENTION|Usual Care (UC)|The study control is UC, which involves the dental assistant supporting the jaw during the extractions with concurrent use of a bite block.
62050768|NCT05602649|EXPERIMENTAL|High Dose Gummy|Participants will self-administer a gummy containing 25mg THC
62050769|NCT05602649|PLACEBO_COMPARATOR|Placebo Chocolate|Participants will self-administer chocolate containing 0mg THC
62050770|NCT05602649|EXPERIMENTAL|Low Dose Chocolate|Participants will self-administer chocolate containing 10mg THC
62050771|NCT05602649|EXPERIMENTAL|High Dose Chocolate|Participants will self-administer chocolate containing 25mg THC
62050772|NCT05602649|PLACEBO_COMPARATOR|Placebo Beverage|Participants will self-administer a beverage containing 0mg THC
62050773|NCT05602649|EXPERIMENTAL|Low Dose Beverage|Participants will self-administer a beverage containing 10mg THC
62050774|NCT05602649|EXPERIMENTAL|High Dose Beverage|Participants will self-administer a beverage containing 25mg THC
62050775|NCT01952184|ACTIVE_COMPARATOR|closed vitrification with closed storage|Half of the oocytes of every donor will be vitrified with the Cryo Bio Systems High Security vitrification (CBSvit HS) device; the standard device in our lab.
62610874|NCT05640661|EXPERIMENTAL|Terminal visual feedback therapy plus Immersive Virtual reality|"Active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement.~The brief intervention will last 3 sessions of 15 minutes during a week, thus taking a total duration of one week of treatment. Within the intervention will consist of a pill of education in pain neuroscience (PNE) of 1 minute duration, followed by an exposure level that will last 2:30 minutes where a progression will be made in number of ranges of motion and speed. Each session will consist of 2 intervention blocks (PNE + Gradual Exposure pill). The content of the PNE educational pills have been selected according to the objective of the study. Subjects will be recorded through an Ipad Tablet, and after performing the entire intervention a terminal visual feedback therapy will be performed by observation of actions in holocentric vision."
62623533|NCT04064515||Cervical Cancer|Participants with advanced or recurrent cervical cancer will provide 15 mL of whole blood. Participants will then be followed prospectively for three years to document oncologic outcome.
62050776|NCT01952184|EXPERIMENTAL|open vitrification with closed storage|Half of the oocytes of every donor will be vitrified with the Cryotop closed system (Cryotop SC).
62050777|NCT04358003|EXPERIMENTAL|Plasma Adsorption Cartridge|Subjects will receive one treatment per day with the D2000 Cartridge for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) for up to 4 hours (treatment cycle) for up to seven (7) days.
62252189|NCT03975920|EXPERIMENTAL|Experimental Care (EC)|The study intervention for EC is use of the Restful Jaw version 2 (RJ2) device, which supports the jaw during the extractions, with concurrent use of a bite block.
62623534|NCT04064515||Control|Participants without a history of cervical cancer or high grade pre-cancer of the cervix
62623535|NCT02878200|EXPERIMENTAL|reactive treatment|Household members; defined as those sharing the same sleeping area, in the intervention villages, will be treated with a full course of dihydroartemisinin-piperaquine (DHAP)
62050778|NCT05815654|EXPERIMENTAL|Warm Palace Analgesic Point Sticker Group|Participants in the EG group will be provided test sticker, containing Ding Xiang, Rou Gui, Gan Jiang, Huang Jie Zi, Rou Cong Rong, Xiao Hui Xiang, Hua Jiao, Ai Ye, Xiang Fu, Wu Zhu Yu, Graphene（0.01%）The acupoints for applying the sticker are Guanyuan (CV4), Zigong (EX-CA1), and Sanyinjiao (SP6). The subjects will be reminded to closely observe their skin during the process and remove the sticker in time if the subjects feel itchy or painful, and record the adverse event.
62050779|NCT05815654|PLACEBO_COMPARATOR|Control Group|Participants in the CG group will be provided control sticker containing flour.The acupoints for applying the sticker are the same with experimental group
62050780|NCT03323879|EXPERIMENTAL|LDR/HDR|MRI planned LDR boost to DIL with concurrent whole gland 19 Gy HDR. LDR dose will be sequentially escalated from 50 Gy to 80 Gy
62050781|NCT06574802|ACTIVE_COMPARATOR|test group|Er:YAG laser (ERL) plus sub-gingival air polishing treatment
62833469|NCT04522232|PLACEBO_COMPARATOR|group A|women that underwent conventional Total laparoscopic hysterectomy
62252190|NCT02663271|EXPERIMENTAL|Optune+Pulsed Bevacizumab|The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI.
62833470|NCT04522232|EXPERIMENTAL|group B|women that underwent Total laparoscopic hysterectomy with prior uterine artery ligation at its origin
62833471|NCT03631888||patients scheduled for elective laparoscopic surgery|
62833472|NCT02575157|NO_INTERVENTION|Discontinuing usage|Patients will discontinue use of bisphosphonates. Bone markers and BMD will be monitored until a need for reinitiation of treatment within 2-years is identified or needed.
62833473|NCT00984217|EXPERIMENTAL|Panitumumab|Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-8 doses).
62833474|NCT05612477|EXPERIMENTAL|Autotransfusion|patients in this arm will receive their salvaged and washed RBCs via transfusion
62833475|NCT05612477|NO_INTERVENTION|No Autotransfusion|patients in this arm will have their salvaged and washed RBCs discarded.
62833476|NCT03841604|EXPERIMENTAL|Experimental|"Safinamide methanesulfonate film coated tablets once daily, 50 mg and 100 mg. Safinamide methanesulfonate 50 mg and 100 mg tablets was administered orally, OD, with or without food, at breakfast time when the subject was taking their morning dose of L-DOPA.~Subjects received study drug 50 mg (from Day 1 to Day 7) and then 100 mg (from Day 8 onwards). The dose of 100 mg/day (titrated from 50 mg/day after 1 week) was selected based on the results of previous studies in patients with PD and from the results of a post hoc analysis that investigated the effects of safinamide on pain."
62833477|NCT03841604|PLACEBO_COMPARATOR|Placebo|Safinamide methanesulfonate matching placebo film coated tablets once daily. The matching placebo was administered orally, OD, in tablets, with or without food, at breakfast time when the subject was taking their morning dose of L-DOPA.
62833478|NCT00456222||Luteal|
62833479|NCT00456222||Follicular|
62833480|NCT02877407|OTHER|laparoscopic/robotic-assisted hysteropexy|patient who undergo laparoscopic/robotic-assisted hysteropexy
62833481|NCT02877407|OTHER|vaginal hysterectomy|patient who undergo vaginal hysterectomy
62833482|NCT05565625|EXPERIMENTAL|Sunscreen|Participants will receive two of six sunscreens (A, B, C, D, E, and F) at Visit 1 (Day 1) to apply to whole lower legs (1 sunscreen per lower leg), between the knee and ankle. Participant will then select one of the two sunscreens randomly assigned to lower legs and apply the selected sunscreen to full face. After lower legs and facial applications are completed, a trained designee will delineate six 4 centimeters (cm)\*4 cm test sites on the participants' volar forearms (3 test sites per volar forearm). The six sunscreens will be randomly assigned to the six test sites at a dose of 2.00 +- 0.05 milligrams per centimeter square (mg/cm\^2) using a 1cc tuberculin syringe (without a needle) and a clean finger cot for approximately 20 to 50 seconds and applied by a trained designee.
62833483|NCT06603688|EXPERIMENTAL|experimental group：Minocycline+Berberine quadruple therapy|40mg of esomeprazole, 220mg of colloidal bismuth tartrate, 500mg of berberine hydrochloride, and 100mg of minocycline, taken orally twice daily for 14 days.
62833484|NCT06603688|ACTIVE_COMPARATOR|control group：Amoxicillin+clarithromycin quadruple|40mg of esomeprazole, 220mg of bismuth tartrate colloid, 500mg of clarithromycin, and 1000mg of amoxicillin, taken orally twice a day for 14 days.
62252191|NCT01910376||Control cohort|Nursing home residents without cancer
62252192|NCT01910376||Cancer patient cohort|Patients in nursing homes with suspected or diagnosed active invasive cancer where a diagnostic or treatment decision has to be taken
62252193|NCT01910376||Biomarker cohort|Subgroup of individuals in the control cohort willing to provide a blood sample
62050782|NCT06574802|PLACEBO_COMPARATOR|control group|ERL treatment only
62833485|NCT00218868||skin scrape|
62833486|NCT05385770|ACTIVE_COMPARATOR|AZM Xmg|1. AZM Xmg (4 weeks) Non-responder -\> AZM Xmg (8 weeks)
62833487|NCT05385770|ACTIVE_COMPARATOR|AZM X'mg|1. AZM X'mg (4 weeks) Non-responder -\> AZM X'mg (8 weeks)
62623536|NCT02878200|NO_INTERVENTION|standard care|In control villages, no household treatment will be done
62833488|NCT05385770|ACTIVE_COMPARATOR|AML Ymg|1. AML Ymg (4 weeks) Non-responder -\> AML Ymg (8 weeks)
62833489|NCT05385770|ACTIVE_COMPARATOR|AML Y'mg|1. AML Y'mg (4 weeks) Non-responder -\> AML Y'mg (8 weeks)
62623537|NCT02328482|EXPERIMENTAL|Arm 1|Trehalose 30 g for IV infusion administered every week over an additional 52 weeks
62833490|NCT05385770|ACTIVE_COMPARATOR|AZM/AML X/Ymg|"1. AZM Xmg (4 weeks) Non-responder -\> AZM Xmg + AML Ymg (8 weeks)~2. AML Ymg (4 weeks) Non-responder -\> AZM Xmg + AML Ymg (8 weeks)"
62833491|NCT05385770|ACTIVE_COMPARATOR|AZM/AML X'/Ymg|"1. AZM X'mg (4 weeks) Non-responder -\> AZM X'mg + AML Ymg (8 weeks)~2. AML Ymg (4 weeks) Non-responder -\> AZM X'mg + AML Ymg (8 weeks)"
62833492|NCT05385770|ACTIVE_COMPARATOR|AZM/AML X/Y'mg|"1. AZM Xmg (4 weeks) Non-responder -\> AZM Xmg + AML Y'mg (8 weeks)~2. AML Y'mg (4 weeks) Non-responder -\> AZM Xmg + AML Y'mg (8 weeks)"
62252194|NCT03687645|EXPERIMENTAL|Prostate Cancer|Patients with biopsy-proven prostate cancer will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
62441692|NCT04330300|EXPERIMENTAL|Alternative anti-hypertensive medication|Switch to an alternative BP medication (specifically a Calcium channel blocker \[CCB\] or Thiazide/Thiazide-like diuretic at an equipotent blood pressure lowering dose). The choice of either CCB or Thiazide/Thiazide-like anti-hypertensive provided as alternative therapy will be at the discretion of the patient's treating physician.
62610875|NCT05640661|ACTIVE_COMPARATOR|Immersive Virtual Reality|"Active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.~The brief intervention will last 3 sessions of 15 minutes during a week, thus taking a total duration of one week of treatment. Within the intervention will consist of a pill of education in pain neuroscience (PNE) of 1 minute duration, followed by an exposure level that will last 2:30 minutes where a progression will be made in number of ranges of motion and speed. Each session will consist of 2 intervention blocks (PNE + Gradual Exposure pill). The content of the PNE educational pills have been selected according to the objective of the study."
62610876|NCT02226926|EXPERIMENTAL|Aggrenox|Dipyridamole extended release / Acetylsalicylic acid
62833493|NCT05385770|ACTIVE_COMPARATOR|AZM/AML X'/Y'mg|"1. AZM X'mg (4 weeks) Non-responder -\> AZM X'mg + AML Y'mg (8 weeks)~2. AML Y'mg (4 weeks) Non-responder -\> AZM X'mg + AML Y'mg (8 weeks)"
62441693|NCT04330300|ACTIVE_COMPARATOR|Continue ACEi/ARB antihypertensive|Continue with either the ACEi (Angiotensin Converting Enzyme Inhibitor) or the Angiotensin Receptor Blocker (ARB) that had already been prescribed for the treatment of hypertension.
62833494|NCT05949333|ACTIVE_COMPARATOR|Day1 Group|Eflapegrastim administration on day 1 (24 hours after completion of chemotherapy)
62050783|NCT05970965|EXPERIMENTAL|Child patient consulting the service|"* Trisomy 21 patient with gingival inflammation (subgroup 1)~* Trisomy 21 patient with healthy gingiva on intact periodontium with no history of periodontitis (subgroup 2)~* Patient with psychomotor retardation with no known repercussions on the orofacial sphere or immunity, presenting gingival inflammation (subgroup 1)~* Patients with psychomotor retardation and no known repercussions on orofacial health or immunity, presenting gingival health on intact periodontium with no history of gingival inflammation (subgroup 2).~* Patients with no known general pathology and gingival inflammation (subgroup 3)~* Patients with no known general pathology and healthy gingiva on intact periodontium with no history of gingival inflammation (subgroup 4)"
62050784|NCT05557331|NO_INTERVENTION|Pre-intervention (no app)|Participants before (12-month retrospective period) the implementation of the app in the emergency department.
62050785|NCT05557331|ACTIVE_COMPARATOR|Post-intervention (PIMPmyHospital app)|Participants that will use the mobile heath PIMPmyHospital app during the prospective 6-month period after the implementation of the app in the emergency department.
62441694|NCT03449056|EXPERIMENTAL|TREATMENT|salbutamol nebulization
62833495|NCT05949333|EXPERIMENTAL|Day 3 Group|Eflapegrastim administration on day 3 (the third day after completion of chemotherapy
62833496|NCT05710237|EXPERIMENTAL|Risperidone 1 mg plus Psilocybin 25 mg|
62050786|NCT04979975|EXPERIMENTAL|Placebo|placebo matching UB-621
62050787|NCT04979975|EXPERIMENTAL|UB-621 low-dose|low-dose of UB-621
62050788|NCT04979975|EXPERIMENTAL|UB-621 high-dose|high-dose of UB-621
62050789|NCT05871710||Patients in need of pulmonary rehabilitation or already receiving pulmonary rehabilitation.|Native Turkish-speaking patients in need of pulmonary rehabilitation or already receiving pulmonary rehabilitation.
62252195|NCT03687645|EXPERIMENTAL|Renal Cancer|Patients with biopsy-proven renal cell carcinoma will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
62252196|NCT03687645|EXPERIMENTAL|Breast Cancer|Patients with biopsy-proven breast cancer will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
62252197|NCT03687645|EXPERIMENTAL|Lymphoma|Patients with biopsy-proven lymphoma will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
62252198|NCT01087099|EXPERIMENTAL|Albendazole|Treatment with albendazole
62252199|NCT02198339|EXPERIMENTAL|BIBN 4096 BS - ranging dose|"sequential adaptive design, allocation of verum treated patients to dose groups not fixed in advance~IV infusion over 10 minutes"
62050790|NCT05871710||Health personnel working in the field of pulmonary rehabilitation.|Native Turkish-speaking health personnel working in the field of pulmonary rehabilitation.
62050791|NCT05598801||VersaWrap|All enrolled patients will received VersaWrap applied prior to surgical closure on the affected tendon.
62441695|NCT01565083|EXPERIMENTAL|Pertuzumab + Trastuzumab + Vinorelbine: Separate Infusion|Pertuzumab will be administered as IV infusion on Day 1 of the first treatment cycle (1 cycle = 21 days) as a loading dose of 840 milligrams (mg), followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab will be administered as IV infusion on Day 2 of the first treatment cycle as a loading dose of 8 mg per kilogram (mg/kg), followed by 6 mg/kg on Day 2 of each subsequent cycle. Vinorelbine IV infusion (will be administered after trastuzumab) on Day 2 and Day 9 of the first treatment cycle at a dose of 25 mg per meter-squared (mg/m\^2) followed by 30-35 mg/m\^2 on Day 2 and Day 9 of each subsequent cycle. Pertuzumab and trastuzumab will be administered sequentially in separate infusion bags, followed by vinorelbine until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end (up to 47 cycles).
62610877|NCT02226926|ACTIVE_COMPARATOR|Persantin Retard|Dipyridamole extended release
62610878|NCT02226926|ACTIVE_COMPARATOR|Acetylsalicylic acid|
62610879|NCT03069456|ACTIVE_COMPARATOR|BIS group|Combined sigmoidal Emax models from the BIS data
62252200|NCT02198339|PLACEBO_COMPARATOR|Placebo|IV infusion over 10 minutes
62252201|NCT02522676|ACTIVE_COMPARATOR|Conventional PCNL|Endoscopic kidney stone surgery: Patients will undergo conventional percutaneous nephrolithotripsy.
62252202|NCT02522676|ACTIVE_COMPARATOR|Mini PCNL|Endoscopic kidney stone surgery: Patients will undergo mini percutaneous nephrolithotripsy.
62252203|NCT02522676|ACTIVE_COMPARATOR|Ultra-mini PCNL|Endoscopic kidney stone surgery: Patients will undergo ultra-mini percutaneous nephrolithotripsy.
62252204|NCT02522676|ACTIVE_COMPARATOR|Micro PCNL|Endoscopic kidney stone surgery: Patients will undergo micro percutaneous nephrolithotripsy.
62252205|NCT02522676|ACTIVE_COMPARATOR|Retrograde intrarenal surgery|Endoscopic kidney stone surgery: Patients will undergo retrograde intrarenal surgery.
62252206|NCT02522676|ACTIVE_COMPARATOR|Extracorporeal shock wave lithotripsy|Non-invasive kidney stone treatment: Patients will undergo extracorporeal shock wave lithotripsy.
62050792|NCT02697279|ACTIVE_COMPARATOR|Traditional Incision and Drainage|Treatment of a simple cutaneous abscess with traditional incision and drainage with or without packing, decision made at the discretion of the provider.
62050793|NCT02697279|EXPERIMENTAL|Loop drainage|Treatment of a simple cutaneous abscess with incision and drainage using the loop drainage technique.
62050794|NCT05334303||epigenetic MMR deficiency|Tumors with MMR abnormalities by IHC and MLH1 methylation
62050795|NCT05334303||probable MMR mutations|Tumors with MMR abnormalities by IHC and without MLH1 methylation
62050796|NCT05334303||MMR proficient|without MMR abnormalities by IHC
62050797|NCT00608010|EXPERIMENTAL|1|Vitrification
62050798|NCT00608010|ACTIVE_COMPARATOR|2|Slow freezing
62252207|NCT00940381|EXPERIMENTAL|Sirolimus + Cetuximab|Sirolimus beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle. Cetuximab Beginning dose 100 mg/m\^2 by vein over two hours on Day 1, and 65 mg/m\^2 on Days 8, 15 and 22 for a 28 day cycle.
62610880|NCT03069456|EXPERIMENTAL|ADMS group|Combined sigmoidal Emax models from the ADMS data
62610881|NCT04412642|OTHER|methoxyflurane|methoxyflurane
62610882|NCT00865267|EXPERIMENTAL|A|Ultravate® 0.05% ointment, single exposure
62610883|NCT06729996|EXPERIMENTAL|Pioglitazone (PIO)|PIO (Actos) is a thiazolidinedione and an agonist for peroxisome proliferator activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 DM in multiple clinical settings. Its use has limitation for type 1 DM or for treatment of diabetic ketoacidosis. It is contraindicated to use in established NYHA class III or IV heart failure.
62610884|NCT06729996|EXPERIMENTAL|Empagliflozin (EMPA)|EMPA is a sodium-glucose co-transporter 2 inhibitor, FDA approved drug. It is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, to reduce the risk of cardiovascular death in adults with type 2 DM and established cardiovascular disease and as an adjunct to diet and exercise to improve glycemic control in adults with type 2 DM. It is not recommended in patients with type 1 DM. It may increase the risk of diabetic ketoacidosis. Not recommended for use to improve glycemic control in adults with type 2 DM with an eGFR less than 30mL/min/1.73m2.
62050799|NCT01649830|EXPERIMENTAL|Radiotherapy plus adjuvant temozolomide|Radiation therapy will start within 8 weeks after neurosurgical procedures. The residue gliomas will receive a total dose of 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks. Four weeks after radiotherapy, patients will then receive 6 cycle of temozolomide dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
62050800|NCT01649830|ACTIVE_COMPARATOR|Radiotherapy|Radiation therapy will start within 8 weeks after neurosurgical procedures. The residue gliomas will receive a total dose of 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
62050801|NCT02945384|EXPERIMENTAL|Creating Connections|Dual-generation intervention: child component delivered in classroom setting, parent component delivered in small-group setting
62050802|NCT02945384|NO_INTERVENTION|Head Start as usual|Regular Head Start curriculum
62610885|NCT02428894||LVAD recipients|
62610886|NCT00417638|EXPERIMENTAL|patients with acute STEMI - treatment with Hypothermia +PCI|"Hypothermia using endovascular cooling with the Celsius Control System as an adjunct therapy.~Hypothermia before reperfusion by a combination of infusion of cold saline and endovascular catheter cooling as an adjunct therapy in patients with a STEMI scheduled to undergo primary percutaneous coronary intervention (PCI)."
62833497|NCT05710237|EXPERIMENTAL|Placebo plus Psilocybin 25 mg|
62833498|NCT05710237|ACTIVE_COMPARATOR|Risperidone 1 mg plus Placebo|
62833499|NCT05393102||Malignant liver nodules cohort|Participants with malignant liver nodules diagnosed by pathological biopsy.
62833500|NCT05393102||Benign liver nodules cohort|Participants with benign liver nodules diagnosed by pathological biopsy or imaging examination.
62833501|NCT05393102||Uncertain benign or malignant liver nodules cohort|Participants with liver nodules could not be diagnosed definitely by imaging examination and serum protein markers.
62833502|NCT01094847|EXPERIMENTAL|Treatment A|DWJ1252 given by oral administration under fasting conditions
62833503|NCT01094847|ACTIVE_COMPARATOR|Treatment B|DWJ1252 given by oral administration, 30 minutes after a meal
62833504|NCT01094847|NO_INTERVENTION|Treatment C|mosapride by oral administration 30 minutes before meals
62050803|NCT05543291||healthy controls|
62050804|NCT05543291||mild CKD|
62610887|NCT00417638|ACTIVE_COMPARATOR|Patients with an acute STEMI eligible for primary PCI|Standard of care treatment or the control group Patients with an acute STEMI eligible for primary PCI
62610888|NCT01564641||iDuo G2|iDuo G2 to be implanted in the patient.
62610889|NCT00931827||Group 1|
62610890|NCT00931827||Group 2|
62610891|NCT02914041||Kyphosis group|Subjects are community-dwelling elderly with different degrees of kyphosis, aged at least 60 years with a body mass index between 18.5-29.9 kg/m2 and OWD \>0 cm.
62441696|NCT01565083|EXPERIMENTAL|Pertuzumab + Trastuzumab + Vinorelbine: Single Infusion|Pertuzumab will be administered as IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab will be administered as IV infusion on Day 2 of the first treatment cycle as a loading dose of 8 mg/kg, followed by 6 mg/kg on Day 1 of each subsequent cycle. Vinorelbine IV infusion on Day 2 and Day 9 of the first treatment cycle at a dose of 25 mg/m\^2 followed by 30-35 mg/m\^2 on Day 1 and Day 8 of each subsequent cycle. If administration of all 3 drugs is well tolerated in Cycle 1, then on Day 1 of each subsequent cycle, pertuzumab 420 mg and trastuzumab 6 mg/kg will be administered in a single infusion bag, followed by vinorelbine until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end (up to 47 cycles).
62610892|NCT05681871|EXPERIMENTAL|Iron-deficiency anaemia|Participants will receive oral iron supplementation for a minimum of 6 weeks prior to surgery
62610893|NCT04477694||type II diabetic patients|
62833505|NCT03155906|EXPERIMENTAL|Integrated treatment|Patients randomised to receive integrated treatment will be counselled on treatment by physician working at MAR outpatient clinic where patient receive OST care, and will receive medication and follow-up at the same MAR outpatient clinic. Treatment medication will be given in line with national guidelines with a close and integrated follow-up.
62833506|NCT03155906|ACTIVE_COMPARATOR|Standard treatment|Those randomised to receive standard treatment will be offered referral for standard HCV treatment at a medical ward hospital clinic. Treatment medication will be given in line with national guidelines.
62833507|NCT05651503|EXPERIMENTAL|Experimental group 1: patients, age 12-18, conventional brackets, Oral probiotics lozenges|30 patients, age 12-18,with conventional brackets,will get Oral probiotics lozenges
62833508|NCT05651503|EXPERIMENTAL|Experimental group 2: patients, age ≥18, Invisalign™ appliances, Oral probiotics lozenges|30 patients, age ≥18, Invisalign™ appliances,wil get Oral probiotics lozenges
62833509|NCT05651503|PLACEBO_COMPARATOR|Control group 1: patients, age 12-18, conventional brackets, placebo lozenges|30 patients, age 12-18, conventional brackets,will get placebo lozenges
62833510|NCT05651503|PLACEBO_COMPARATOR|Control group 2: patients, age ≥18, Invisalign™ appliances, placebo lozenges|30 patients, age ≥18, Invisalign™ appliances,will get placebo lozenges
62833511|NCT02690948|EXPERIMENTAL|Pembrolizumab Monotherapy|Participants who previously received vismodegib and subsequently progressed will receive pembrolizumab IV over 30 minutes on day 1. Cycles are every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
62833512|NCT02690948|EXPERIMENTAL|Pembrolizumab plus Vismodegib Combination Therapy|Participants who have not progressed while receiving vismodegib will receive pembrolizumab IV over 30 minutes on day 1 and take vismodegib 150 mg by mouth daily. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
62833513|NCT05166772|EXPERIMENTAL|Donafenib combined with Sintilimab and HAIC|Donafenib：200mg bid； Sintilimab：200mg Q3D； HAIC：Q3W；
62833514|NCT01228097||Gastric Bypass|Participants who receive gastric bypass surgery.
62833515|NCT01228097||Principally Restrictive Surgery|Participants who receive gastric banding or sleeve gastrectomy surgery.
62833516|NCT01228097||Weight Stable|Participants who remain weight stable.
62833517|NCT06592456|EXPERIMENTAL|Live Attenuated Varicella vaccine candidates|freezedried live attenuated VarV developed by Beijing Minhai Biotechnology Co., LTD., which are derived from the Oka strain, cultured and harvested from inoculated MRC-5 human diploid cells inoculated human diploid cells (MRC-5), and then lyophilized with appropriate stabilizers.
62610894|NCT04477694||non-diabetic patients|
62623538|NCT02328482|NO_INTERVENTION|Arm 2|no-treatment concurrent control; follow-up over 52 weeks
62050805|NCT05543291||Moderate CKD|
62050806|NCT05543291||ESRD|
62050807|NCT04999878|EXPERIMENTAL|treatment group|"All enrolled patients will receive a regimen containing Ruxilitinib, Etoposide, Dexamethasone, Gemcitabine, Pasparase and Platinum for 28 days. The specific medication is as follows:~Ruxilitinib 10 mg, bid, d1-28, P.O. Etoposide 100mg per week, two weeks, ivgtt Dexamethasone, 15mg/(m²·d)，d1-12，10 mg/ (m²·d) ，d13-14，5 mg/ (m²·d) ，d15-21，2.5mg/(m²·d)，d22-28，ivgtt or P.O.~Gemcitabine, 0.5 g/m², d8, ivgtt Pegaspargase, 2500IU/m², d9, im Platinum, 20mg/m² d10 d11, ivgtt After the treatment, patients will be given disease specific chemotherapy regimen to treat lymphoma according to patient's different lymphoma subtype."
62050808|NCT00836082|EXPERIMENTAL|Cohort 1 (N=10)|Placebo-controlled, escalating multiple doses of 0.5mg per day for 14 days.
62441697|NCT01466686|EXPERIMENTAL|Temozolomide with Low Dose Fractionated Radiation Therapy|"All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.~All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If \> 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below. Otherwise, following a 1 month waiting period after the first cycle of adjuvant LDFRT plus temozolomide for the first cohort of patients, the phase 2 study will open for full accrual. Patients will receive radiation with the first six 28-day cycles of temozolomide."
62610895|NCT06721221|EXPERIMENTAL|SVtag arm. Point-by-point PVI with the Svtag software|PVI will be performed with QDot Micro catheter in QMODE plus with the Svtag software.
62610896|NCT03121573|OTHER|intervention|medication: duloxetine 30 to 60 mg tablets by mouth, QD to BID.
62610897|NCT00958412|EXPERIMENTAL|Proellex®|25 mg Proellex®
62610898|NCT04978077|EXPERIMENTAL|High fat test meal first, high carbohydrate test meal second|Consumption of a high fat challenge first, consumption of a high carbohydrate challenge after two weeks wash out
62833518|NCT06592456|ACTIVE_COMPARATOR|Marketed Live Attenuated Varicella vaccine|the active control group received VarV produced by Changchun BCHT Biotechnology Co.,which are derived from human diploid cellsinoculated human diploid cells (MRC-5), and then lyophilized with appropriate stabilizers
62833519|NCT04657393|ACTIVE_COMPARATOR|Alternative Ventilation Rate|ventilation is performed at 20 breaths/min
62833520|NCT04657393|ACTIVE_COMPARATOR|Conventional Ventilation Rate|ventilation is performed at 10 breaths/min
62833521|NCT05979246|EXPERIMENTAL|Diabetic patients|undergo implant installation
62833522|NCT03822117|EXPERIMENTAL|Pemigatinib|"Cohort A (Solid tumor malignancies with FGFR1-3 in frame fusions; any FGFR2 rearrangement; FGFR1/3 rearrangement with known partner\*). Cohort B (Solid tumor malignancies with known or likely activating mutations (excluding kinase domain) in FGFR1-3) Cohort C (Solid tumor malignancies with FGFR1-3 known activating mutations in kinase domain; FGFR1-3 putatively activating mutations; other FGFR1/3 rearrangements\* (not eligible for Cohort A)).~\*Only FGFR fusions or rearrangements with an intact kinase domain are eligible"
62833523|NCT06555549|EXPERIMENTAL|DEH113|The patient must take two (2) DEH113 tablets in a single dose, if pain.
62833524|NCT06555549|PLACEBO_COMPARATOR|Placebo|The patient must take two (2) placebo tablets in a single dose, if pain.
62833525|NCT02264249||Split dose colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - split dose - ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)
62833526|NCT02264249||Evening before colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - Evening before (4L, 2L or miralax bowel preparation)
62833527|NCT02264249||Same day prep colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - Same day prep (4L volume or 2L volume or Miralax bowel preparation)
62833528|NCT03367663|EXPERIMENTAL|low dose|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
62833529|NCT03367663|EXPERIMENTAL|high dose|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
62833530|NCT06171243||PK/PDLido|Patients over 50 years old, with neuropathic pain who are hospitalized at UC-Christus Clinical Hospital, will be candidates for recruitment to the study.
62833531|NCT03258385|ACTIVE_COMPARATOR|Vitamin B12-fortified UHT milk|Supplementation group (N=74) that will receive vitamin B12 fortified UHT milk daily
62833532|NCT03258385|PLACEBO_COMPARATOR|Plain UHT milk|Placebo group (N=74) that will receive plain UHT milk daily
62833533|NCT04072900|EXPERIMENTAL|Intervention/Treatment|"Personalized NeoAntigen Cancer Vaccine- Neo-Vac-Mn (peptides + rhGM-CSF+anti-PD1+Imiquimod 5% Topical Cream)~NeoAntigen peptides:4 x 2 mg the total peptides given on days 84，87，91，98，105，133，and 161~Anti-PD-1 Toripalimab: 3mg/kg, ivgtt, Q2w~rhGM-CSF: 3μg/kg given on Days 81，82，83，95，96，97，102，103，104，130，131，132，158，159，and 160~Imiquimod 5% Topical Cream:topical application on the injection site 6 hours before each NeoAntigen peptides injection"
62050809|NCT00836082|EXPERIMENTAL|Cohort 2 (N=10)|Placebo-controlled, escalating multiple doses of 1mg per day for 14 days.
62252208|NCT04993534|EXPERIMENTAL|Psychological First Aid + Stepped-care intervention (DWM/PM+)|"All participants will be offered individual Psychological First Aid (PFA), a WHO developed support strategy that involves humane, supportive and practical help for individuals suffering from serious humanitarian crises.~The treatment group will receive the stepped-care program consisting of DWM (step 1) and Problem Management Plus (PM+).~The DWM program has been developed by WHO and collaborators working in the humanitarian field. DWM was designed to be relevant for large segments of adversity-affected populations: it is intended to be transdiagnostic, and easily adaptable to different cultures and languages.~PM+ is a new, brief, psychological intervention program based on cognitive-behavioral therapy (CBT) techniques that are empirically supported."
62833534|NCT02874378|EXPERIMENTAL|study group|Dexmedetomidine will be pumped at 0.3μg/kg•h during the operation till 30 minutes before the operation complete. Standard anaesthesia and standard cure are given for all patients.
62833535|NCT02874378|PLACEBO_COMPARATOR|control group|0.9%NaCl solution 0.1ml/kg•h during the operation till 30 minutes before the operation complete. Standard anaesthesia and standard cure are given for all patients.
62833536|NCT03002337|EXPERIMENTAL|Aromatherapy massage|Ten aromatherapy group received 70 minutes of aromatherapy massage once biweekly by certified aromatherapy therapist for 20 weeks.
62833537|NCT03002337|EXPERIMENTAL|Yoga exercise|The yoga group participated in two weekly 70-minute yoga sessions led by a midwife certified as a yoga instructor for 20 weeks
62833538|NCT03002337|NO_INTERVENTION|Control|the control group received only routine prenatal care.
62833539|NCT03308071|EXPERIMENTAL|Hypnosis Group|Participants will undergo a brief hypnotic assessment, a single hypnosis session with an MD trained in hypnosis, and be given a phone number to listen to a guided self-hypnosis recording for 1 week pre-op until 2 weeks post-op.
62833540|NCT03308071|NO_INTERVENTION|Usual care|These patients will be enrolled in the study and usual care will be provided.
62833541|NCT05352503|EXPERIMENTAL|watching video with virtual reality glasses|
62833542|NCT05352503|NO_INTERVENTION|routine maintenance, no intervention|
62833543|NCT06088121|ACTIVE_COMPARATOR|ATNC MDD-V1|ATNC MDD-V1 treatment, synchronized TMS and cognitive training stimulation
62833544|NCT06088121|SHAM_COMPARATOR|Sham TMS + Real Cog|The Control arm subjects will receive daily treatments five days a week for 6 consecutive weeks of Sham treatment of TMS and real cognitive training which is similar to the real treatment in visit frequency and procedure.
62833545|NCT06651866|EXPERIMENTAL|D-CMG|"Liposomal mitoxantrone hydrochloride injection (Doxorubicin®): Used after dilution with 250mL of 5% glucose injection (50mg/mL), with an intravenous drip time of at least 60 minutes.~* Level 1: 12mg/m2, IV drip, day 4;~* Level 2: 18mg/m2, IV drip, day 4; Decitabine: 25mg, IV drip, days 1-3; Cytarabine: 10mg/m2, every 12 hours, IV drip, days 4-10; G-CSF: 300 ug, IV drip, days 1-5; Each cycle is 4 weeks, with a total of 2 cycles, and DLT is observed in the first cycle.~Note: Patients who achieve CR (Complete Remission) and PR (Partial Remission) in the first cycle can continue with the original dose for one more cycle, and then the investigator decides whether to continue this regimen or choose another regimen for maintenance therapy; Patients with NR (No Remission) in the first cycle will be withdrawn from this study."
62610899|NCT04978077|EXPERIMENTAL|High carbohydrate test meal first, high fat test meal second|Consumption of a high carbohydrate challenge first, consumption of a high fit challenge after two weeks wash out
62833546|NCT03023397|OTHER|Der f treated Non-smoker|
62833547|NCT03023397|OTHER|Der f treated Cigarette smoker|
62050810|NCT00836082|EXPERIMENTAL|Cohort 3 (N=10)|Placebo-controlled, escalating multiple doses of 4mg per day for 14 days.
62623539|NCT02742025|OTHER|Standard Care|"Patients randomized to this arm will have standard care with no extra interventions.~Intervention: Inclusion visit~Intervention: Coronarography on day 0"
62833548|NCT03023397|OTHER|Der f treated E-cig user|
62833549|NCT02516761|EXPERIMENTAL|Low-impact aerobic exercise combined with music therapy|Intervention consists in working the muscles which are mostly affected by fibromyalgia through group exercises, which are dynamic, smooth and aim functionality. This exercise is done to the rhythm of melodic music, adapted to the tastes of the participants and also adapted on the way to perform the exercise.
62833550|NCT02516761|EXPERIMENTAL|Low-impact aerobic exercise|Then intervention is like the previous group but with the difference that physical activity is not performed to the rhythm of chosen melodic music. Therefore, exercises are done with general chill-out music throughout the session, without adaptation of the exercise to the music.
62833551|NCT02516761|ACTIVE_COMPARATOR|Control group|With this group no intervention is done, but they are assessed like the other groups.
62833552|NCT04078906|NO_INTERVENTION|Control group|Conventional IVLE (Intralipid) from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
62833553|NCT04078906|EXPERIMENTAL|Experimental group|n3-LCPUFA enriched IVLE (SMOFlipid) from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
62050811|NCT00836082|EXPERIMENTAL|Cohort 4 (N=10)|Placebo-controlled, escalating multiple doses of 8mg per day for 14 days.
62050812|NCT01444157|EXPERIMENTAL|Palliative homecare nursing group|In addition to the standard homecare nursing the families will receive six home visits from a research nurse with at least 1 year specialised palliative care experience. During the first 2 hour visit a family assessment is obtained containing identification of family roles, resources and coping strategies. The first home visit takes place no later than one week after randomization. The visits continues every third week up to 16 weeks, each visit with a duration of 1,5 hours. At every visit the EORTC-QLQ-C30 patient administered questionnaire is used to identify the nature, frequency and intensity of the patients physical and psychosocial problems.
62050813|NCT01444157|NO_INTERVENTION|Standard homecare nursing group|Patients continue to receive the standard homecare nursing. They can contact municipality services for visitation to homecare nursing if they feel that additional homecare is needed or if they do not yet receive this service and feel they need homecare nursing.
62610900|NCT06232434|EXPERIMENTAL|Experimental arm|"after diagnostic laparotomy/laparoscopy, a single intraperitoneal administration of the study drug Prospidelong, produced by UNITEHPROM BSU, Republic of Belarus, further in accordance with the protocols of the Ministry of Health of the Republic of Belarus for the treatment of patients with the corresponding pathology, systemic chemotherapy in accordance with the clinical protocol Diagnosis and treatment of malignant neoplasms\&#34; (approved by Resolution of the Ministry of Health of the Republic of Belarus No. 60 of 07/06/2018)."
62610901|NCT06232434|PLACEBO_COMPARATOR|Comparison group|"after diagnostic laparotomy/laparoscopy, systemic chemotherapy in accordance with the clinical protocol Algorithms for the diagnosis and treatment of malignant neoplasms (approved by Resolution of the Ministry of Health of the Republic of Belarus No. 60 of 07/06/2018), namely the section regulating the treatment of patients suffering from metastatic gastric cancer with the degree of prevalence of the tumor process corresponding to sT1-4N0-3M1."
62610902|NCT04498598|EXPERIMENTAL|A/Z Airway|Patients under general anesthesia for surgical procedures who need airway management for ventilation.
62610903|NCT04474613|EXPERIMENTAL|Liquid biopsy|A liquid biopsy is a test will be done on a sample of blood to look for cancer cells
62610904|NCT01075906|EXPERIMENTAL|Colchicine|Colchicine Sprinkle Capsules, 0.3 mg - dose administered according to age range on Day 1
62610905|NCT01075906|EXPERIMENTAL|colchicine at steady state|colchicine sprinkle capsules 0.3 mg - dose administered according to age range on Day 15 following once daily dosing of colchicine on Days 2 - 14
62610906|NCT06319872|EXPERIMENTAL|All participants|Participants will receive either drug or placebo for 180 days.
62610907|NCT03357900|EXPERIMENTAL|Orthotopic liver transplantation|
62833554|NCT04842812|EXPERIMENTAL|TILs/CAR-TILs treatment|Obtain TILs/CAR-TILs from advanced solid tumor patients and infuse them back to evaluate safety and clinical efficacy of the treatment.
62833555|NCT04237597|EXPERIMENTAL|K-877 & CSG452|K-877 Single dose on Day 1 and Day 15 CSG452 Repeat dose on Day 2 Through Day 15
62610908|NCT01846806|EXPERIMENTAL|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
62610909|NCT06725680|EXPERIMENTAL|Retrolaminar block group|Patients will receive retrolaminar block after the induction of general anesthesia.
62610910|NCT06725680|EXPERIMENTAL|Erector spinae plane block group|Patients will receive erector spinae plane block after the induction of general anesthesia.
62833556|NCT00629070|EXPERIMENTAL|ST|Traditional strength training
62833557|NCT00629070|EXPERIMENTAL|VT|Velocity-enhanced training
62833558|NCT04346381|EXPERIMENTAL|camrelizumab combined with famitinib|Participants will receive camrelizumab on Day 1of each cycle and famitinib qd up to 2 years.
62833559|NCT03074513|EXPERIMENTAL|Treatment (atezolizumab, bevacizumab)|Patients receive atezolizumab and bevacizumab IV over 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62833560|NCT06655038|EXPERIMENTAL|Advocacy coalition|Feedback + advocacy coalition
62833561|NCT06655038|ACTIVE_COMPARATOR|Control|Only feedback
62833562|NCT00395031|OTHER|Ziprasidone|Open label
62050814|NCT05549401|EXPERIMENTAL|Sequence 1|Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition Period 3: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition
62050815|NCT05549401|EXPERIMENTAL|Sequence 2|Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition Period 3: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition
62610911|NCT03205098||Runners|To assess the evolution of biological markers of mesenteric ischemia during ultratrail.
62610912|NCT01687387|EXPERIMENTAL|IPH2102 at 1 mg/kg|lirilumab (IPH2102/BMS986015) at 1 mg/kg
62610913|NCT01687387|EXPERIMENTAL|IPH2102 at 0.1 mg/kg|lirilumab (IPH2102/BMS986015) at 0.1 mg/kg
62610914|NCT01687387|PLACEBO_COMPARATOR|Placebo (Normal saline solution)|Normal saline solution
62610915|NCT02897063|EXPERIMENTAL|Droxidopa and Placebo|Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of either droxidopa 300 mg or placebo after the first tilt table test, followed two hours later by a single oral dose of placebo.
62610916|NCT02897063|EXPERIMENTAL|Midodrine and Placebo|Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of placebo after the first tilt table test, followed two hours later by a single oral dose of either midodrine 10 mg or placebo.
62610917|NCT03623633|ACTIVE_COMPARATOR|Denosumab and Raloxifene|denosumab and raloxifene
62050816|NCT05549401|EXPERIMENTAL|Sequence 3|Period 1: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition
62050817|NCT05549401|EXPERIMENTAL|Sequence 4|Period 1: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition Period 2: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
62050818|NCT05549401|EXPERIMENTAL|Sequence 5|Period 1: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition
62050819|NCT05549401|EXPERIMENTAL|Sequence 6|Period 1: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition Period 2: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
62050820|NCT05618548||Cohort A: Pregnant women vaccinated with a mRNA COVID-19 vaccine|Pregnant women who will be offered a mRNA COVID-19 vaccine (brand will depend on the vaccine available at the time of inclusion). Gestational age at vaccination will depend on the timing when the vaccine is offered to the specific participant, this being subject to the national recommendations for vaccination of priority groups.
62252209|NCT04993534|OTHER|Psychological First Aid + usual care|"All participants will be offered individual Psychological First Aid (PFA), a WHO developed support strategy that involves humane, supportive and practical help for individuals suffering from serious humanitarian crises.~In addition, both the groups will receive care-as-usual (CAU); they will be allowed to receive any usual care. CAU may include community care, social/legal support, and psychoeducation."
62610918|NCT03623633|ACTIVE_COMPARATOR|Denosumab and Alendronate|denosumab and alendronate
62610919|NCT05292482|EXPERIMENTAL|pharmacopunture therapy|The physicians will choose the type and volume of pharmacopuncture according to participants' conditions and inject it at the proper acupoints they choose.
62610920|NCT05292482|ACTIVE_COMPARATOR|physical therapy|The physicians will choose the type and time of physical therapy according to participants' conditions.
62610921|NCT05328388|EXPERIMENTAL|Lycomato|Lycomato soft gel
62610922|NCT03535194|EXPERIMENTAL|250mg Q4W/250mg Q8W Mirikizumab|Participants received 250 Milligrams (mg) Mirikizumab once every four weeks (Q4W) by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab once every eight weeks (Q8W) in maintenance period. Participants received matching placebo to blind Secukinumab.
62610923|NCT03535194|EXPERIMENTAL|250mg Q4W/125mg Q8W Mirikizumab|Participants received 250mg Mirikizumab once every four weeks (Q4W) by subcutaneous injection during blinded induction period followed by 125mg Mirikizumab once every eight weeks (Q8W) in maintenance period. Participants received matching placebo to blind Secukinumab.
62833563|NCT04670978|EXPERIMENTAL|albumin-bound paclitaxe combined with bevacizumab biosimilar|albumin-bound paclitaxel, 260mg/m2，ivdrip，D1，once every three weeks bevacizumab biosimilar, 10mg/kg，ivdrip，D1, once every three weeks
62050821|NCT05618548||Cohort B: Pregnant women vaccinated with an adenoviral vector COVID-19 vaccine|Pregnant women who will be offered an adenoviral vector COVID-19 vaccine (Astra Zeneca). Gestational age at vaccination will depend on the timing when the vaccine is offered to the specific participant, this being subject to the national recommendations for vaccination of priority groups.
62050822|NCT05618548||Cohort C: Postpartum lactating women vaccinated with a mRNA COVID-19 vaccine|Non-pregnant women during lactation (postpartum) will be offered a mRNA COVID-19 vaccine (brand will depend on the vaccine available at the time of inclusion). Duration of lactation at vaccination will depend on the timing when the vaccine is offered to the specific participant, this being subject to the national recommendations for vaccination of priority groups.
62050823|NCT05618548||Cohort D: Postpartum lactating women vaccinated with an adenoviral vector COVID-19 vaccine (N=40)|Non-pregnant women during lactation (postpartum) will be offered an adenviral vector COVID-19 vaccine (brand will depend on the vaccine available at the time of inclusion). Duration of lactation at vaccination will depend on the timing when the vaccine is offered to the specific participant, this being subject to the national recommendations for vaccination of priority groups.
62050824|NCT06015815||stage III non-small cell lung cancer|A total of 21 patients with stage III NSCLC who received definitive CRT were prospectively evaluated. The expression levels of miRNA-21 and miRNA-155 in serum at the beginning and end of the treatment
62050825|NCT03050502|ACTIVE_COMPARATOR|Chest tube drain|A chest tube placed with the intent of draining all intra-pleural blood.
62050826|NCT03050502|SHAM_COMPARATOR|Expectant management|No chest tube, but will undergo standard observation/conservative management by the trauma service.
62050827|NCT04923113|EXPERIMENTAL|patients who meet the inclusion criteria|5 different methods will be performed to detect H. pylori infection in patients who meet the inclusion criteria，and patients with Hp positive will be further treated with 10-day minocycline-based quadruple therapy,to observe the efficacy and safety of minocycline-based regimen for H.pylori eradication as a first-line therapy.
62050828|NCT03308825|EXPERIMENTAL|Group 1: 6 to < 36 Months|Children aged 6 to \< 36 months received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered on Day 28.
62050829|NCT03308825|EXPERIMENTAL|Group 2: 3 to < 9 Years|Children aged 3 to \< 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered on Day 28.
62441698|NCT06546605|EXPERIMENTAL|Plyometric Training to WB-EMS Training Group (PTG-ETG)|"Participants in the PTG-ETG will undergo a progressive plyometric training program in the first 8-week intervention period, followed by a WB-EMS training program in the second 8-week intervention period after the crossover. The plyometric training will include exercises such as box jumps, depth jumps, split squat jumps, and single-leg hops to enhance lower extremity power, speed, and agility.~After the crossover, participants will engage in a WB-EMS training program that combines dynamic exercises with concurrent electrical stimulation using the miha bodytec® device. Each WB-EMS session will consist of a warm-up followed by 4-6 exercises lasting 4-6 seconds each, with 4 seconds of rest between exercises. The intensity of the electrical stimulation will be set at 70-85% of the participant's maximal comfort level and adjusted based on individual tolerance. The WB-EMS training will be performed twice a week for 20-25 minutes per session during the second intervention period."
62610924|NCT03535194|EXPERIMENTAL|Placebo/250mg Mirikizumab|Participants received matching placebo at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab Q4W from week 16 to 32 followed by 250mg Mirikizumab Q8W from week 32 to 48 in maintenance period. Participants received matching placebo to blind Secukinumab.
62833564|NCT03351452|EXPERIMENTAL|Real tDCS|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the VLPFC (current density: 0.057 mA/cm2) and cathodal 10x10 rubber electrode over supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
62833565|NCT03351452|EXPERIMENTAL|Real tACS|20 min of 2 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm and 10x10 cm rubber electrodes over the VLPFC (current density: 0.057 mA/cm2) and supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
62050830|NCT03308825|EXPERIMENTAL|Group 3: 18 to < 65 Years|Adults aged 18 to \< 65 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
62050831|NCT03308825|EXPERIMENTAL|Group 4: >= 65 Years|Adults aged \>= 65 years received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
62050832|NCT02781948||Normal|Not having any history of refractive surgery, contact lens, dry eye or pathology
62050833|NCT02781948||Corneal condition|History of refractive surgery, contact lens, dry eye or keratoconus
62050834|NCT04789265|EXPERIMENTAL|Combined Therapy (Instrumented Soft Tissue Mobilization)|
62050835|NCT04789265|NO_INTERVENTION|Control Group (Exercise Therapy)|
62050836|NCT04811430||Randomized Traditional|Randomized to traditional ultrasound guided peripheral insertion placement vs placement with Cue needle tracking technology
62050837|NCT04811430||Radomized Cue Needle Tracking technology|Randomized to traditional ultrasound guided peripheral insertion placement vs placement with Cue needle tracking technology
62050838|NCT06437379|EXPERIMENTAL|effect of infection control on patient outcomes undergoing PCNL|Effect of Teaching Protocol on Nurse's Knowledge and Practice regarding Infection Control Measures for Patients undergoing Percutaneous Nephrolithotomy
62610925|NCT03535194|ACTIVE_COMPARATOR|300mg Secukinumab|Participants received 300mg Secukinumab at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during induction period followed by 300mg Secukinumab Q4W from week 16 to 52 in maintenance period.
62050839|NCT05741580||peri-urethral bulk agent injection of Bulkamid® for urinary incontinence|patients who received a first injection of Bulkamid® in the context of urinary incontinence
62833566|NCT03351452|SHAM_COMPARATOR|Sham tES|30 s of 2 mA sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the VLPFC (current density: 0.057 mA/cm2) and supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase of the memory task.
62833567|NCT05663658|ACTIVE_COMPARATOR|Control group|The patients in Control Group will be received patient controlled analgesia with morphine for postoperative analgesia
62050840|NCT05122390|EXPERIMENTAL|Contraction Coper|The digital application Contraction Coper is provided from pregnancy week 25. The application contains two different modules. One is an informational module about the method (about 60 minutes), the other is a contraction module to be used in early labour (in total 6 hours).
62050841|NCT05122390|ACTIVE_COMPARATOR|Contraction Coper Plus|The digital application Contraction Coper with additionally support from a midwife in two different occasions during pregnancy.
62050842|NCT05122390|NO_INTERVENTION|Control|Conventional antenatal care.
62050843|NCT04644042|EXPERIMENTAL|Glenohumeral arthroscopy and arthroscopic subacromial decompression|The intervention group will receive a glenohumeral arthroscopy and ASAD. Participants are discharged with an arm sling and referred to 3 months physiotherapy in a municipally setting. Participants are given a rehabilitation program containing progressive exercises to guide the rehabilitation.
62833568|NCT05663658|ACTIVE_COMPARATOR|External oblique intercostal plane block group|The patients in external oblique intercostal plane block group will be received EOI plane block and patient controlled analgesia with morphine for postoperative analgesia
62441699|NCT06546605|EXPERIMENTAL|Functional Training to Plyometric Training Group (FTG-PTG)|"Participants in the FTG-PTG will engage in a functional training program tailored to their specific sport in the first 8-week intervention period, followed by a progressive plyometric training program in the second 8-week intervention period after the crossover. The functional training will incorporate sport-specific movements, such as multidirectional lunges, rotational medicine ball throws, and single-leg balance drills.~After the crossover, participants will undergo a progressive plyometric training program designed to enhance their lower extremity power, speed, and agility. The program will include a variety of plyometric exercises such as box jumps, depth jumps, split squat jumps, and single-leg hops.~Each session will begin with a dynamic warm-up, then proceed to the main exercise, and then cool down with stretching."
62833569|NCT05701995|EXPERIMENTAL|Deucravacitinib|
62610926|NCT03535194|EXPERIMENTAL|Japan GPP/EP|Participants received 250mg Mirikizumab Q4W in induction period followed by 250mg Q8W in maintenance period by subcutaneous injection.
62610927|NCT02295267|EXPERIMENTAL|walnut allergy provocation|inclusion of walnut allergic patients, food provocation with walnut
62610928|NCT06731309|EXPERIMENTAL|Punch Debdridement|After local anesthesia, a punch biopsy tool is positioned over the inflamed follicular unit, and a small circle of skin (4 to 8 mm in diameter) is excised. A firm twisting motion is necessary to ensure adequately deep excision. Similar to I\&D, this is followed by applying digital pressure and gauze scraping to eliminate the fluid contents. The wound is then left open to allow free drainage and heal by secondary intention.
62623540|NCT02742025|EXPERIMENTAL|HEARTLINK|"Patients randomized to this arm will participate in the HEARTLINK program, which includes a specific nurse consultation and telephone contact.~Intervention: Inclusion visit~Intervention: Nurse consultation~Intervention: Telephone contact~Intervention: Coronarography on day 0"
62833570|NCT05701995|PLACEBO_COMPARATOR|Placebo then Deucravacitinib|
62833571|NCT04542317|EXPERIMENTAL|REACH VN|A multi-component behavioral intervention to support family caregivers of persons with dementia. Participants will receive 4-6 sessions in-person or by phone over the course of 2-3 months.
62833572|NCT04542317|PLACEBO_COMPARATOR|Enhanced control|A single session focused on education about the nature of dementia.
62833573|NCT01649778||Pazopanib|Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
62050844|NCT04644042|ACTIVE_COMPARATOR|Glenohumeral arthroscopy and skin incision|The control group will receive a glenohumeral arthroscopy, but no treatment concerning the subacromial structures. To allow for the best possible blinding, a 7-10 mm incision, mimicking the one used for ASAD, is performed on the lateral side of the arm 2-3 distal to the acromion. Participants are discharged with an arm sling and referred to 3 months physiotherapy in a municipally setting. Participants are given a rehabilitation program containing progressive exercises to guide the rehabilitation.
62050845|NCT02662725|EXPERIMENTAL|ipilimumab + Stereotactic Radiosurgery|ipilimumab combined with a Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases
62050846|NCT00816465|EXPERIMENTAL|1|Patients receiving Hoodia
62050847|NCT00816465|PLACEBO_COMPARATOR|2|Patients receiving placebo
62050848|NCT04035213|EXPERIMENTAL|Behavior of Sleep Course|A semester-long course focused on sleep improves college students' sleep patterns over one semester. The listed aims of this course are to: 1) provide students with a comprehensive understanding of sleep; 2) afford an overview of the multiple ways sleep impact health, performance and well-being; and 3) to assist students in discovering how their own sleep-wake patterns impact their day to day functioning.
62833574|NCT05226806||Healthy adults|"Inclusion criteria: both, mals and female, age 45 years and older. Exclusion criteria: Medical contraindications for a maximum stress test and endurance test by the attending physician~Pathologies in the context of the preliminary examinations:~* Acute and chronic cardiovascular diseases except arterial hypertension (systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg in untreated and drug-treated participants) and minor valve insufficiency~* Acute and chronic lung diseases~* Liver and kidney diseases~* diabetes mellitus~* Alcohol (\> 30g / day) or drug abuse~* Obesity from grade 2 (body mass index\> 35 kg / m²)~* Orthopedic diseases with reduced physical performance~* Existing pregnancy"
62833575|NCT03595683|EXPERIMENTAL|Cohort 1: Anti-PD1 naive|Participants that have not received prior anti-PD1 therapy for their cancer will be enrolled to this arm.
62833576|NCT03595683|EXPERIMENTAL|Cohort 2: Anti-PD1 refractory|Participants that have received prior anti-PD1 therapy for their cancer will be enrolled to this arm.
62833577|NCT01075490|PLACEBO_COMPARATOR|prematurely born, bupivacaine, placebo|
62833578|NCT01075490|EXPERIMENTAL|prematurely born, bupivacaine, clonidine|
62833579|NCT01075490|PLACEBO_COMPARATOR|term neonate, bupivacaine, placebo|
62050849|NCT04035213|NO_INTERVENTION|Control|Students from other upper level departmental courses with content that does not include a focus on or discussion of sleep
62050850|NCT05372770|EXPERIMENTAL|Group 1: Transgender women using Flourish|"After gender-confirming surgery, this group will use the Flourish Vaginal Care System for six months, ramping up usage with healing. They will use Balance external wash beginning day 6 after surgery; Restore® vaginal moisturizing gel on dilators beginning day 6 after surgery; Restore every other day at bedtime with BiopHresh homeopathic/probiotic suppository every 3rd day at bedtime beginning week 6 after surgery through end of study at 6 months."
62050851|NCT05372770|NO_INTERVENTION|Group 2: Transgender women not using Flourish|After gender-confirming surgery, this group will use only KY jelly on dilators beginning day 6 after surgery according to routine care; they will use any standard hygiene product (soap, body wash, etc) of their choice except products used by Group 1 through the end of the study at 6 months.
62050852|NCT05372770|OTHER|Group 3: Cisgender women|This group will use the Flourish Vaginal Care system for 6 months: Balance external wash daily; Restore intravaginal gel every other day at bedtime; BiopHresh homeopathic/probiotic suppository every 3rd day at bedtime through the end of study.
62050853|NCT03968757||Obese patients eligible for laparoscopic RYGB surgery.|
62050854|NCT03350334|ACTIVE_COMPARATOR|Duloxetine|The patients who will be given 60 mg duloxetine 2 hours before surgery and 24 hours after surgery.
62050855|NCT03350334|PLACEBO_COMPARATOR|Placebo Control|The patients who will be given 60 mg placebo 2 hours before surgery and 24 hours after surgery.
62050856|NCT03182699|EXPERIMENTAL|Etelcalcetide|Patients will receive Etelcalcetide i.v. 3 times per week after dialysis Dose titration will take plac every 4 weeks in the first 16 weeks Dose adaptation is based on PTH, SerumCa++, SerumPhosphate, T-50-time
62050857|NCT03182699|ACTIVE_COMPARATOR|Alfacalcidol|Patients will receive Alfacalcidol i.v. 3 times per week after dialysis Dose titration will take plac every 4 weeks in the first 16 weeks Dose adaptation is based on PTH, SerumCa++, SerumPhosphate, T-50-time
62833580|NCT01075490|EXPERIMENTAL|term neonate, bupivacaine, clonidine|
62833581|NCT02960581|EXPERIMENTAL|Group 1A|HIV-uninfected participants
62050858|NCT06276933|EXPERIMENTAL|Camrelizumab+Chemotherapy+Thalidomide|
62441700|NCT06546605|EXPERIMENTAL|WB-EMS Training to Functional Training Group (ETG-FTG)|"Participants in the ETG will participate in a training program that combines dynamic exercises with concurrent WB-EMS. The WB-EMS device (miha bodytec®, Augsburg, Germany) will be used to apply electrical stimulation to major muscle groups while participants perform exercises such as squats, lunges, and trunk rotations. Each session will consist of a warm-up followed by 4-6 WB-EMS exercises lasting 4-6 seconds each, with 4 seconds of rest between exercises. The intensity of the electrical stimulation will be set at 70-85% of the participant's maximal comfort level and adjusted based on individual tolerance. The WB-EMS training will be performed twice a week for 20-25 minutes per session.~After the crossover, participants will engage in a functional training program that simulates game-specific movements, such as multidirectional lunges, rotational medicine ball throws, and single-leg balance drills.The program will also include core stability and injury prevention exercises."
62623541|NCT03715452||DyeVert Plus Contrast Reduction System|DyeVert Plus Contrast Reduction System
62833582|NCT02960581|EXPERIMENTAL|Group 1B|HIV-uninfected participants
62833583|NCT02960581|EXPERIMENTAL|Group 1C|HIV-uninfected participants
62833584|NCT02960581|EXPERIMENTAL|Group 2A|HIV-infected on ART, (\<50 cp/ml)
62833585|NCT02960581|EXPERIMENTAL|Group 2B|HIV-infected on ART, (\<50 cp/ml)
62833586|NCT02960581|EXPERIMENTAL|Group 2C|HIV-infected on ART, (\<50 cp/ml)
62833587|NCT02960581|EXPERIMENTAL|Group 3A|HIV-Infected off ART (VL 2x10\^3 - 1x10\^5 cp/ml)
62833588|NCT02960581|EXPERIMENTAL|Group 3B|HIV-Infected off ART (VL 1x10\^2 - 2x10\^3 cp/ml)
62833589|NCT02960581|EXPERIMENTAL|Arm 1D|HIV-uninfected participants
62833590|NCT05537662|EXPERIMENTAL|Subjects using Neuromodulation Therapy (SCS or DRG)|Patients will trial standard of care neuromodulation therapy (SCS or DRG), and if successful will proceed to a permanent implant.
62050859|NCT06276933|ACTIVE_COMPARATOR|Camrelizumab + chemotherapy+placebo|
62050860|NCT00969384|EXPERIMENTAL|waist circumferences|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
62050861|NCT00969384|EXPERIMENTAL|Lifestyle counseling|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
62050862|NCT04061434||Cardiac resynchronisation therapy recipients|
62441701|NCT06546605|NO_INTERVENTION|Control Group (CG)|Participants in the CG will maintain their usual team training routines and practices throughout the study period, without receiving any additional training interventions. They will serve as a reference to compare the effects of the plyometric, functional, and WB-EMS training programs on athletic performance and health-related outcomes. Participants in this group will undergo all scheduled assessments at baseline, after each 8-week intervention period, and during the follow-up to track changes in their performance and health status over time. The control group will help determine the extent to which changes in the intervention groups can be attributed to the specific training programs, rather than other factors such as natural progression or regular team training.
62441702|NCT01465542||Oral NAC|Patients receiving oral NAC treatment after an acute acetaminophen ingestion.
62623542|NCT03634527|EXPERIMENTAL|Auricular Point Acupressure|Auricular points related to Chemotherapy-induced peripheral neuropathy (CINP) will be used for the intervention.
62833591|NCT06653179|ACTIVE_COMPARATOR|Sacral Erector Spinae Plane Block Group|Sacral Erector Spinae Plane Block for Chronic Coccydynia
62833592|NCT06653179|ACTIVE_COMPARATOR|Caudal Epidural Injection Gropu|Caudal Epidural Injection for Chronic Coccydynia
62050863|NCT04061434||Other cardiac implantable electronic devices recipients|
62441703|NCT01465542||IV NAC|Patients receiving IV NAC after an acute Acetaminophen ingestion.
62623543|NCT03634527|SHAM_COMPARATOR|Control Auricular Point Acupressure|Auricular points not related to CINP will be used for the intervention.
62623544|NCT00777062|EXPERIMENTAL|1|VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6
62833593|NCT02064023|EXPERIMENTAL|insulin pump|subjects will use an insulin pump for the duration of the pregnancy. The intervention is that they will control their diabetes using an insulin pump
62833594|NCT02064023|ACTIVE_COMPARATOR|Multiple Daily Insulin injections|subjects will continue their usual insulin treatment with multiple daily injections of sc insulin
62833595|NCT00679900|EXPERIMENTAL|1|
62833596|NCT00679900|ACTIVE_COMPARATOR|2|
62833597|NCT05895292|EXPERIMENTAL|CAD/CAM Milled Methacrylate Complete Removable Dentures based on bone-support concept.|The patient will be provided by a complete removable denture designed according to bone-support concept to restore his missing teeth which will be manufactured by CAD/CAM milling of monolithic methacrylate blanks.
62441704|NCT05455749|EXPERIMENTAL|holoBLG|
62623545|NCT00777062|PLACEBO_COMPARATOR|2|Placebo injection, 380 mg injection at the start of weeks 2 and 6.
62050864|NCT05151068|EXPERIMENTAL|Group A,traditional|"The control group is given conventional nursing care: ①Preoperative education, informing patients of the importance of the tube and the adverse effects of unauthorised extubation after the operation on the recovery of the disease. ②Pipe care: The nose wing is fixed with modified human elastic tape, and the same side cheek bridge is fixed to keep the duct unobstructed and pour gastric juice in time. ③Oral care: routinely brush teeth and gargle with mouthwash daily. ④Skin care: Observe the condition of the nose, cheek skin and oral and nasal mucosa. Replace the tape as needed, and clean the skin before fixing. ⑤ Pain care: assess the degree of pain, follow the doctor's prescription for medication, and observe the efficacy of medication. ⑥Psychological care: pay attention to the emotional changes of patients and provide psychological support.This group is planned to enroll 100 patients."
62050865|NCT05151068|EXPERIMENTAL|Group B,Precise|On the basis of conventional nursing, the experimental group adopted a precision nursing program of acupoint application combined with ear acupoint embedding.This group is planned to enroll 100 patients.
62050866|NCT03045406|EXPERIMENTAL|Apixaban|orally administered, at the dose of 10 mg bid for 7 days, followed by 5 mg bid (total period of treatment: six months)
62050867|NCT03045406|ACTIVE_COMPARATOR|Dalteparin|subcutaneously administered, at a dose of 200 IU/kg SC o.i.d for 1 month. Thereafter, dalteparin will be administered at a dose of 150 IU/kg o.i.d. for 5 months
62441705|NCT05806359|EXPERIMENTAL|Japanese Cohort - Dose 1|
62610929|NCT06731309|ACTIVE_COMPARATOR|Gold standard: Incision and Drainage|Incision and Drainage is a minimally invasive surgical procedure often employed for the treatment of intensely painful, tense, and fluctuant abscesses that are too deep to drain spontaneously. After administration of a broad circumferential local anesthetic, a small linear incision is made using a standard scalpel blade. Digital pressure is applied to expel the fluid collection. Saline rinses can be used to flush out the remaining contents. This method offers instant pain relief, commonly performed in acute settings by dermatologists, emergency department physicians and general practitioners.
62610930|NCT06730048|EXPERIMENTAL|experimental group|An appointment will be made to meet with the students in the experimental group in a suitable classroom of the school. After the pre-test data, the students in the experimental group will be shown the preeclampsia case with virtual glasses for about 5-10 minutes. Then the post-test will be applied. A scenario including preeclampsia case and nursing care practices will be created in the virtual reality environment, and 10 experts will be consulted about the scenario before the students are shown it. This application will not have any side effects.
62610931|NCT06730048|OTHER|control group|After the pre-test data, the preeclampsia case will be explained to the students in the control group with the classical lecture method in the Women's Health and Diseases Nursing course and the post-test will be applied.
62610932|NCT01094782|ACTIVE_COMPARATOR|Healthy - True Acupuncture|Healthy volunteers with no neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7.This group received true acupuncture treatment (the needles punctured the skin).
62050868|NCT00492609||1|PATIENTS WITH COMPUTER-ASSISTED
62050869|NCT00492609||2|PATIENTS WITHOUT COMPUTER-ASSISTED
62050870|NCT02256670|EXPERIMENTAL|Text Message Application Intervention|The study intervention will include a mobile phone two-way text message application. Each prompt described below will generate either a yes (Y)/no (N) or ABCDE(F) response from patients. Each response will generate further prompts resulting in either notification for providers to call patients or relevant phone numbers for patients to call for assistance.
62050871|NCT02216773|ACTIVE_COMPARATOR|Portal vein embolization (PVE)|"Patients allocated to the PVE group will receive pre-intervention blood tests and a contrast enhanced CT scan of the abdomen. They will then have their portal vein embolized radiologically once their pre-intervention investigations have been completed and reviewed by the clinical team.~Post-intervention investigations (blood tests and CT scan) will take place 4 weeks after the completion of the PVE. At this point, they will be listed to receive their definitive surgical hepatectomy."
62441706|NCT05806359|EXPERIMENTAL|Japanese Cohort - Dose 2|
62441707|NCT05806359|EXPERIMENTAL|Japanese Cohort - Dose 3|
62441708|NCT05806359|EXPERIMENTAL|Caucasian Cohort - Dose 3|
62050872|NCT02216773|EXPERIMENTAL|Radiofrequency assisted liver partition and ligation (RALPP)|"Patients allocated to the RALPP group will receive pre-intervention blood tests and a contrast enhanced CT scan of the abdomen. They will then have their right portal vein surgically ligated followed by radiofrequency ablation in situ splitting of the liver. Certain patients may additionally have a tumourectomy or wedge resection of the left liver lobe if clinically indicated. The RALPP procedure will occur once the patient's pre-intervention investigations have been completed and reviewed by the clinical team.~Post-intervention investigations (blood tests and CT scan) will take place 2 weeks after the completion of the RALPP. At this point, they will be listed to receive their definitive surgical hepatectomy."
62050873|NCT01505387|PLACEBO_COMPARATOR|Placebo|Identical to Litramine 2 tablets 3 times daily (oral consumption, after meal)
62050874|NCT01505387|EXPERIMENTAL|Litramine|Fibre complex of plant origin n tablet form 2 tablets 3 times daily (oral consumption, after meal)
62050875|NCT04179721|EXPERIMENTAL|The PES-4-BPSD Model|The intervention arm consists of PES and NAs who work on the intervention unit which consists of: I. Cohorting of patients with cognitive impairment AND past or present indication of BPSD, acutely admitted to the medicine or telemetry service, are cohorted on a 10-bed medical unit. II. PES staff. III. Staff Support: The PI will hold monthly 20 minute group sessions to reinforce training and discuss challenging patient behaviors; meant to improve the attitude and empathy of hospital caregivers towards patients. IV. Staff Training
62050876|NCT04179721|ACTIVE_COMPARATOR|The attention control condition|The control group consists of NAs that work on a 40-bed medicine unit, staffed with 39 nurses (1:6 ratio) and 26 NA (1:8 ratio), that primarily cohorts older patients with geriatric syndromes. All components of the intervention arm are the same with the exception of the PES staff. The control arm (NAs) will receive the same training as the intervention arm.
62050877|NCT04632602|OTHER|patients in prone position followed by dorsal decubitus|patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours.
62050878|NCT04632602|OTHER|dorsal decubitus followed by prone decubitus|patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours.
62050879|NCT04413292||Group A|21 patients with lung cancer
62050880|NCT04413292||Group B|21 patients with various benign lung diseases
62050881|NCT04413292||Group C|Healthy controls
62050882|NCT04413292||Group D|15 patients with malignant pleural mesothelioma (MPM)
62050883|NCT04413292||Group E|16 patients having various benign pleural diseases
62050884|NCT06580288|EXPERIMENTAL|Finerenone|
62252210|NCT01068197|EXPERIMENTAL|Low glycemic load dietary plan|"The subjects and their parents will be given instructions, and specific examples, to lower the glycemic load of their diets by replacing high-GI sources of carbohydrates with low-GI food sources, replacing energy from carbohydrate with energy from protein and fat, and attempt to balance meals and snacks with low-GI carbohydrate, proteins and low-fat food sources. The objective will be to achieve macronutrient composition for the low-GL diet of 45-50% low-GI carbohydrates, 20-25% protein, and 30-35% fat. All subjects will receive sessions on behavior modification, increasing physical activity and reducing sedentary behavior.~At 3 months, subjects will be admitted to the GCRC for a 24 hour period for a meal study. They will be given standardized low-glycemic load diet for dinner, breakfast and lunch, followed by an ad lib snack platter. Their subjective, hormonal and metabolic responses will be serially measured."
62050885|NCT06580288|PLACEBO_COMPARATOR|placebo|
62050886|NCT01865708|OTHER|Ethanol lock|Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
62050887|NCT06221202|EXPERIMENTAL|Stories in the Moment Dance Intervention|12 weeks online dance program - 1hour/week for 12 weeks
62050888|NCT04618666|EXPERIMENTAL|laparoscopic and open appendectomy|comparative study between laparoscopic and open appendectomy
62050889|NCT04419844|ACTIVE_COMPARATOR|TAR with Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect Botox injection .
62050890|NCT04419844|ACTIVE_COMPARATOR|TAR without Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect without Botox injection .
62050891|NCT02723942|EXPERIMENTAL|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen by infusion.
62050892|NCT02723942|NO_INTERVENTION|no intervention|no intervention
62050893|NCT03440684|EXPERIMENTAL|Healthy individuals|Forty-one healthy individuals were volunteer to participate in the study and 39 of them had no neurological disease, were from 18 to 65 years old, and had no upper extremity injuries. And they have joined to exercise training during 6 weeks.
62050894|NCT05152173|EXPERIMENTAL|EN3835 Group|Participant will receive a maximum dose of up to 1.8mg of EN3835 injection
62050895|NCT05152173|PLACEBO_COMPARATOR|Placebo Group|Participant will receive a maximum dose of up to 1.8mg of Placebo injection
62050896|NCT04756557|EXPERIMENTAL|Tooth Brushing HAP Toothpaste|"Experimental: Tooth Brushing HAP HAP-Toothpaste Tooth Brushing HAP Prophylactic cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated toothpaste containing microcrystalline hydroxylapatite two x daily over the duration of the study (18 months).~Procedure: Tooth Brushing HAP"
62050897|NCT04756557|ACTIVE_COMPARATOR|Tooth Brushing F Toothpaste|Cleaning teeth using a standardized electric tooth brush and a fluoridated tooth paste containing amino fluoride (1450 ppm F-), (two x daily over the duration of the study (18 months).
62050898|NCT01980407|EXPERIMENTAL|SOL, single arm|S-1 combined with leucovorin and oxaliplatin
62050899|NCT02080871|EXPERIMENTAL|Gore VIABAHN BX|Balloon expandable stenting of iliac occlusive disease
62050900|NCT02770781|EXPERIMENTAL|Personal Trainer|All subjects will meet a set amount of times with a personal trainer over the course of the study to participate in an exercise regimen.
62050901|NCT05565729|EXPERIMENTAL|LY3471851 (Test formulation)|LY3471851 administered subcutaneously (SC).
62050902|NCT05565729|EXPERIMENTAL|LY3471851 (Test) + Levocetirizine|LY3471851 administered SC in combination with levocetirizine given orally.
62050903|NCT05565729|ACTIVE_COMPARATOR|LY3471851 (Reference formulation)|LY3471851 administered SC.
62050904|NCT05565729|PLACEBO_COMPARATOR|Placebo|Placebo administered SC.
62441709|NCT01038557|ACTIVE_COMPARATOR|Refrigerated RBCs 0-14 days old|Standard, refrigerated RBC units stored up to 14 days
62610933|NCT01094782|SHAM_COMPARATOR|Healthy - Sham Acupuncture|Healthy with no neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received sham acupuncture treatment (the needles did not puncture the skin).
62050905|NCT05934812|EXPERIMENTAL|Oxytocin|24IU oxytocin liquid delivered with a pump-actuated nasal spray device, administered twice-daily
62050906|NCT05934812|PLACEBO_COMPARATOR|Placebo|Placebo delivered with a pump-actuated nasal spray device, administered twice-daily
62050907|NCT00758238|EXPERIMENTAL|myBP intervention|participants will receive access to hypertension self-management tools and support via a personal patient electronic health record
62050908|NCT00758238|NO_INTERVENTION|usual care|participants allocated to usual care may still opt to use the personal patient electronic health record, but will not have access to the hypertension self-management tools until after the intervention period. The usual care group will be given a web-link for patient hypertension management resources
62050909|NCT04484974|EXPERIMENTAL|Pecan snack condition|In this crossover condition, a mid morning snack consisting of 250 kcal of lightly salted roasted pecan nuts will be administered.
62050910|NCT04484974|ACTIVE_COMPARATOR|Tortilla chip snack condition|In this crossover condition, a mid morning snack consisting of 250 kcal of lightly salted pretzels will be administered.
62050911|NCT00578955|EXPERIMENTAL|1|
62050912|NCT00578955|ACTIVE_COMPARATOR|2|
62050913|NCT00578955|ACTIVE_COMPARATOR|3|
62050914|NCT03020225|ACTIVE_COMPARATOR|White cheese|Reference group- animal protein food source: White cheese (contains 30g protein), intact, plus 250ml mineral water
62050915|NCT03020225|EXPERIMENTAL|Green peas|Plant food source: Green peas (contains 30g protein), intact, cooked, plus 250ml mineral water
62050916|NCT03020225|EXPERIMENTAL|Mankai|Plant food source: Wolffia globosa (Mankai, contains 30g protein), intact, cooked, plus 250ml mineral water
62050917|NCT04835818|EXPERIMENTAL|Reporting|check point-of-care Multiplex PCR for pneumonia pathogens and report results to primary care physician
62441710|NCT01038557|ACTIVE_COMPARATOR|Refrigerated RBCs 15-42 days old|Standard, refrigerated RBC units stored 15-42 days
62050918|NCT04835818|NO_INTERVENTION|Usual Care|check point-of-care Multiplex PCR for pneumonia pathogens but do NOT report results to primary care physician. Let primary care physician provide usual standard care
62441711|NCT01038557|EXPERIMENTAL|Frozen RBCs|RBC units stored frozen at -80 degrees Celsius, then thawed and deglycerolized using the ACP 215.
62252211|NCT01068197|ACTIVE_COMPARATOR|Low fat diet|"For the low fat diet, subjects and their parents will be given instructions, and specific examples, to lower the fat content of their diet. The composition of the low-fat diet will be targeted to achieve 55-60% carbohydrates (with no discrimination by their glycemic index), 15-20% protein and 25-30% fat. All recruited children will receive sessions on behavior modification, increasing physical activity and reducing sedentary behavior.~At 3 months, subjects will be admitted to the GCRC for a 24 hour period for a meal study. They will be given standardized high-glycemic load diet for dinner, breakfast and lunch, followed by an ad lib snack platter. Their subjective, hormonal and metabolic responses will be serially measured."
62252212|NCT03366090||IBD patients|Biopsies for immunological analyses
62252213|NCT03366090||healthy controls|Biopsies for immunological analyses
62610934|NCT01094782|NO_INTERVENTION|Healthy - No Treatment|Healthy volunteers with no neck or back pain who attended 3 visits over 4 weeks and received no sham or true acupuncture treatment.
62833598|NCT05895292|ACTIVE_COMPARATOR|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patient will be provided with a complete removable denture designed according to the neutral-concept to restore his missing teeth, which will be manufactured by CAD/CAM milling of monolithic methacrylate blanks.
62050919|NCT01938651|EXPERIMENTAL|Diagnostic (7T ultra high-field MRI/MRS)|Patients undergo measurement of tumor perfusion and permeability using DCE-MRI, tumor cellularity using DW-MRI, phospholipid metabolism using 31P MRS, macromolecular content using MT-MRI, and cellular protein content using CEST-MRI. All of these procedures are integrated into a single MRI exam lasting under 60 min.
62050920|NCT01948635|EXPERIMENTAL|tapered PVC-cuffed tracheal tubes|Patients in this arm will be intubated with tapered PVC-tracheal tubes
62252214|NCT00571844|EXPERIMENTAL|DASH diet|
62252215|NCT00571844|EXPERIMENTAL|DASH diet plus Weight loss|
62441712|NCT03657199||Bypass graft failure|Patients with at least one detected graft failure after routine cardiac computed tomography before discharge
62252216|NCT00571844|NO_INTERVENTION|Usual Care|Usual Care Control Group: Patients in the Usual Care control group will be asked to maintain their usual dietary and exercise habits for 4 months until they are re-evaluated. At biweekly intervals we will ask patients to describe any spontaneous changes in their eating habits or food preferences. To ensure patient safety, BPs will also be monitored biweekly by our staff.
62441713|NCT03657199||No bypass graft failure|Patients without occluded bypass grafts after routine cardiac computed tomography before discharge
62610935|NCT01094782|ACTIVE_COMPARATOR|Pain - True Acupuncture|Volunteers with radiating neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received true acupuncture treatment (the needles punctured the skin).
62610936|NCT01094782|SHAM_COMPARATOR|Pain - Sham Acupuncture|Volunteers with radiating neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received sham acupuncture treatment (the needles did not puncture the skin).
62833599|NCT00035243|EXPERIMENTAL|EPO906|
62833600|NCT03873077|NO_INTERVENTION|intravenous analgesia|Patient receives intravenous analgesia: paracetamol 30 mg/kg, diclofenac 75 mg, clonidine 1 µg/kg and morfine 0,05 mg/kg
62833601|NCT03873077|OTHER|intravenous analgesia + LIA|Patient receives intravenous analgesia and a local infiltration analgesia in the knee
62441714|NCT04281069||"patients visiting the centre de santé"|Women visiting to the selected health centres in the Oujda province will be invited to participate
62833602|NCT03387085|EXPERIMENTAL|NANT triple negative breast cancer (TNBC) Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, SBRT.
62610937|NCT01094782|NO_INTERVENTION|Pain - No Treatment|Volunteers with radiating neck or back pain who attended 3 visits over 4 weeks and received no sham or true acupuncture treatment.
62050921|NCT01948635|ACTIVE_COMPARATOR|Standard PVC-cuffed tracheal tube|Patients in this arm will be intubated with standard (barrel-shape cuffed) PVC tracheal tubes
62050922|NCT05900284|EXPERIMENTAL|Metformin 500 mg|One 500mg tablet will be administered twice a day for the first (5) days of study treatment.
62610938|NCT02393105||Breast cancer survivor|Females finished primary breast cancer treatment including surgical operation, radiation therapy and chemotherapy.
62050923|NCT05900284|PLACEBO_COMPARATOR|Placebo|One inactive tablet will be administered twice a day for the first (5) days of study treatment.
62050924|NCT05900284|EXPERIMENTAL|Metformin 1,000 mg|One 1,000mg tablet will be administered twice a day for the first (5) days of study treatment.
62050925|NCT02241941|EXPERIMENTAL|Daptomycin|
62050926|NCT01383265|EXPERIMENTAL|Water method and chromoendoscopy|Combined water method with chromoendoscopy using 0.008% IC solution for screening colonoscopy
62050927|NCT01383265|ACTIVE_COMPARATOR|Water method|Control method will use plain water with the water method for screening colonoscopy
62610939|NCT04454710|ACTIVE_COMPARATOR|Real Pulsed Radiofrequency|The participant will receive real pulsed radiofrequency for 2 minutes at a frequency of 2 pulses per second (2Hz) while lie in the supine position with their leg of interest partially flexed about 45 degrees and externally rotated. The full procedure will take eight minutes, composed of four sessions of 2 minutes in which the temperature was maintained below 42°C.
62050928|NCT04834310|EXPERIMENTAL|Intraoperative and Postoperative Antibiotics|The experimental group will receive an intraoperative dose of antibiotics, which is standard protocol at our institution, followed by oral antibiotics for 5 days postoperatively.
62252217|NCT05298189|EXPERIMENTAL|Audio-visual Group|
62252218|NCT05298189|EXPERIMENTAL|Auditory-only Group|This group will recover in the relaxation room with only auditory stimuli.
62610940|NCT04454710|SHAM_COMPARATOR|Sham Pulsed Radiofrequency|Identical to the real pulsed radiofrequency, except the participants will only receive the initial 2 seconds of ramp-up, after which the device will switch-off for the rest of the session and will turn-on again at the end of the session.
62623546|NCT06492382|EXPERIMENTAL|Home oxygen monitor|Infant will be on a home oxygen weaning guideline for their pediatrician to used based on information form the home oxygen monitor
62833603|NCT04948372|EXPERIMENTAL|The terlipressin group|Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.
62050929|NCT04834310|PLACEBO_COMPARATOR|Intraoperative Antibiotics and Placebo|The control group will receive an intraoperative dose of antibiotics, which is standard protocol at our institution, followed by a placebo for 5 days postoperatively
62050930|NCT04523155|EXPERIMENTAL|Treatment Sequence AB|Participants randomized to sequence AB will receive 3 months of meals, followed by a 3 month washout period and a 3 month intervention period with no meals.
62050931|NCT04523155|EXPERIMENTAL|Treatment Sequence BA|Participants randomized to sequence BA will receive 3 months of no meals followed by a 3 month washout period and a 3 month intervention period with meals.
62050932|NCT01529125||Kwashiorkor|HIV-positive children aged 6-59 months with kwashiorkor receiving nutritional rehabilitation and who are started on HAART.
62050933|NCT01529125||Marasmus|HIV-positive children aged 6-59 months with marasmus receiving nutritional rehabilitation and who are started on HAART.
62050934|NCT01529125||Control|HIV-positive children aged 6-59 months who are not severely malnourished and who are started on HAART for a non-nutritional reason.
62252219|NCT05298189|EXPERIMENTAL|Visual-only group|
62252220|NCT05298189|NO_INTERVENTION|Control Group|
62252221|NCT04126083|EXPERIMENTAL|Lofexidine|Patients will receive lofexidine 0.54 mg 4 times daily and the baseline opioid dose will be reduced by 10% daily.
62252222|NCT04559191|NO_INTERVENTION|HbA1c-guided group|Glycemic control is controlled by guideline-recommended HbA1c control.
62252223|NCT04559191|ACTIVE_COMPARATOR|CGM-guided group|Glycemic control is controlled by CGM-guided control.
62252224|NCT01583933|EXPERIMENTAL|Essix retainer|
62050935|NCT04386525|EXPERIMENTAL|Omega-3|Fish oil will be administered to this group. We will administer 4g per day of fish oil in three times with meals for one month with monitoring the health status regularly
62610941|NCT06323317|EXPERIMENTAL|Frailty-Specific Prehabilitation Program|Participants in the frailty-specific prehabilitation program (intervention group) will participate in a comprehensive prehabilitation programme comprising the following components: 1) structured preoperative education; 2) nutritional optimization; 3) stress management; and 4) exercise training. These four components are recommended by the international association as core elements of prehabilitation to optimize cardiac patients' physical and psychological capacity to withstand the challenges of cardiac surgical procedures. The prehabilitation will last for at least 4 weeks, and it will continue throughout the preoperative period.
62610942|NCT06323317|PLACEBO_COMPARATOR|Routine Preoperative Care|Participants in the control group will receive routine preoperative care provided by the clinical team, which includes unstructured patient education on the surgeries/procedures, and a brief session on the use of an incentive spirometer, breathing, and coughing exercise. Other perioperative care procedures will be implemented according to the existing clinical protocols.
62610943|NCT06219018|ACTIVE_COMPARATOR|Medical grade honey formulation (MGH) (L-Mesitran®) for CIN II group 1|Group 1, pt 0-20: daily application of 5 grams (with applicator) for 1 month. Followed by weekly applications (5 grams withapplicator) for 5 months.
62610944|NCT06219018|ACTIVE_COMPARATOR|Medical grade honey formulation (MGH) (L-Mesitran®) for CIN II group 2|Group 2, pt 20-40: daily application of 5 grams (with applicator) for 3 months. Then weekly applications (5 grams with applicator) for3 months.
62610945|NCT06219018|ACTIVE_COMPARATOR|Medical grade honey formulation (MGH) (L-Mesitran®) for CIN II group 3|Group 3, pt 40-60: daily application of 5 grams (with applicator) for 6 months
62610946|NCT00758654||1|Patients with suspected or known stable coronary artery disease
62833604|NCT04948372|PLACEBO_COMPARATOR|The usual care group|Patients in the usual care group were treated with standard care.
62833605|NCT06299332|EXPERIMENTAL|Device Treatment|Eligible subjects will receive 6 weekly treatments with the Forma Applicator according to the study protocol and will return for two follow up visits 1- and 3-months post treatment. Two further telephone feedback checks will be carried out 6 months and 12 months following the last treatment visit.
62833606|NCT05513534|EXPERIMENTAL|Standard Hatha Yoga|A yoga program adapted for those with PD will be used in the current study. It will be conducted over a 16-week period and consists of twice-weekly sessions lasting approximately one hour. The program will be based on principles of Hatha yoga which incorporate longer holds and deep breathing. Each session will include a warm-up, three yoga flows, a balance training section, and a cooldown phase. The first four weeks will emphasize proper alignment, breathing, and technique. Additionally, the classes will be led by a certified yoga instructor and include multiple on-site assistants to ensure a safe training environment. Participants will also be provided with assistive devices (i.e. chairs, yoga blocks, and blankets) if they are required.
62833607|NCT05513534|EXPERIMENTAL|Power Resisatnce Training|: A high-velocity resistance (power) will be conducted over a 16-week period and consists of twice-weekly sessions lasting approximately one hour. Each training session will begin with a brief warm-up. Each session will consist of three sets of 10 repetitions each with 1.5 to 2- to minute rest periods between sets. Participants will be instructed to control the concentric and eccentric velocity of each exercise, with each phase lasting approximately two to three seconds. Exercise order will be randomized during each session and upper and lower body exercises will be alternated whenever possible.
62833608|NCT05022576|EXPERIMENTAL|PSMA PET/CT guided biopsy arm|Ga-68 PSMA PET/CT imaging is now routinely done in patients with prostate cancer with biochemical recurrence, response evaluation and even in patients with clinical suspicion of prostate cancer. In the present study, we aim to plan robotic arm-assisted Ga-68 PSMA guided transgluteal prostatic biopsies.
62833609|NCT04467684|EXPERIMENTAL|Cohort 1|Cohort 1: 100 mg CB-0406 (n=6)
62833610|NCT04467684|EXPERIMENTAL|Cohort 2|Cohort 2: 200 mg CB-0406 (n=6). Dose initiated following review of all safety data from Cohort 1 by a Safety Review Committee
62833611|NCT04467684|EXPERIMENTAL|Cohort 3|Cohort 3: 400 mg CB-0406 (n=6). Dose initiated following review of all safety data and PK data from Cohort 2 by a Safety Review Committee.
62833612|NCT04467684|EXPERIMENTAL|800 mg|Cohort 4: 800 mg CB-0406 (n=6). Dose initiated following review of all safety data and PK data from Cohort 3 by a Safety Review Committee.
62833613|NCT04467684|EXPERIMENTAL|1000 mg|Cohort 5: 1000 mg CB-0406 (n=6). Dose initiated following review of all safety data and PK data from Cohort 4 by a Safety Review Committee
62833614|NCT04467684|PLACEBO_COMPARATOR|Matched placebo|Two subjects in each Cohort (1, 2, 3, 4, 5) are randomized to matched placebo
62833615|NCT05063058|EXPERIMENTAL|Molecular guided therapy|
62833616|NCT04763369|EXPERIMENTAL|Sub-tenon injection group|In total twenty five subjects will be treated by injecting UMSCs in sub-tenon space of eye.
62833617|NCT04763369|EXPERIMENTAL|Suprachoroidal injection group|A total of twenty five subjects will be treated by suprachoroidal injection of UMSCs.
62833618|NCT04053803|EXPERIMENTAL|Open Label|
62833619|NCT02965014|EXPERIMENTAL|Face-to-Face Young Women's CoOp (YWC)|Participants in this arm will be offered a two-session face-to-face Young Women's CoOp (YWC) intervention.
62050936|NCT04386525|NO_INTERVENTION|Controle|for comparison with interventional arm
62610947|NCT00758654||2|Healthy subjects as a control group
62050937|NCT03457519|ACTIVE_COMPARATOR|Intervention Group A|"CHWs trained in ChARM and using ChARM as a self-monitoring tool for 8 months while counting respiratory rate of children under 5 visually using a timer.~Intervention: The Children's Respiration Monitor (also known as ChARM) device is routinely used to diagnose Pneumonia cases but in this study it will be used as a self-monitoring and teaching aide for strengthening CHWs skills."
62050938|NCT03457519|ACTIVE_COMPARATOR|Intervention Group B|"CHWs trained in ChARM and using ChARM as a self-monitoring tool for 4 months while counting respiratory rate of children under 5 visually using a time; then discontinue using ChARM and continue to monitor the respiratory rate visually using a timer only for the remaining 4 months.~Intervention: The Children's Respiration Monitor (also known as ChARM) device is routinely used to diagnose Pneumonia cases but in this study it will be used as a self-monitoring and teaching aide for strengthening CHWs skills."
62050939|NCT03457519|NO_INTERVENTION|Control Group C|CHWs who did not receive the ChARM training and will be monitoring the respiratory rate of children under 5 visually using a timer only, as per the MoH traditional training.
62050940|NCT06575777||Married Couples with Newborns|No intervention was applied to the group. The surveys planned to be examined in the postpartum period have been completed.
62252225|NCT01583933|ACTIVE_COMPARATOR|Hawley retainer|"Hawley retainer is a device composed of an acrylic base with built-in hooks and a labial arch wire 0.022 x0.036 and attached to the teeth. Its metal component consists of two adams hooks positioned from the first permanent molar right to left, a labial bow that progresses from lingual superface to distal of canine to integrate with the acrylic base."
62252226|NCT05514704|ACTIVE_COMPARATOR|Synchronous Telerehabilitation Group|Synchronous Telerehabilitation Group will receive exercise therapy via video conference.
62252227|NCT05514704|EXPERIMENTAL|Asynchronous Telerehabilitation Group|Asynchronous Telerehabilitation Group will receive exercise therapy via mobile application.
62252228|NCT03469583|EXPERIMENTAL|EYP001 dose1|EYP001 capsules by mouth
62252229|NCT03469583|ACTIVE_COMPARATOR|Entecavir 1mg|2 tablets of 0.5mg, by mouth
62252230|NCT03469583|EXPERIMENTAL|EYP001 dose 1 + Entecavir 1mg|EYP001 capsules and 2 tablets of Entecavir 0.5mg by mouth
62252231|NCT04537546|EXPERIMENTAL|Elasto compression belt|all patients must wear the belt 2 months after laparoscopic digestive surgery.
62252232|NCT04754750|ACTIVE_COMPARATOR|INVEGA Sustenna|INVEGA Sustenna is a one month long-acting injection (PP1M)
62252233|NCT04754750|ACTIVE_COMPARATOR|INVEGA Trinza|INVEGA Trinza is a three month long-acting injection (PP3M)
62252234|NCT05289050|PLACEBO_COMPARATOR|sodium chloride (NaCl; 0.9%)|For patients in the control group,anaesthesia will be maintained with intravenous sodium chloride (NaCl; 0.9%) infusion.while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h),analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient. The assessment of the depth of anesthesia was based on clinical evaluation,placebo-controlled infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
62441715|NCT02330081|EXPERIMENTAL|Mirasol|"Subject will be infused with two products at the same time:~1. radio-labeled platelets derived from subjects stored whole blood which has been treated with Mirasol.~2. radio-labeled platelets derived from subjects untreated fresh whole blood."
62441716|NCT04117308|ACTIVE_COMPARATOR|Control group|Patients who received a classic information.
62050941|NCT06580431|ACTIVE_COMPARATOR|Active Comparator|Saliva and serum collection of patients and samples molecules analysis Saliva and serum sampling Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Saliva and serum were then stored at -80 °C until analysis.
62050942|NCT06580431|EXPERIMENTAL|Salivary and serum TMAO observation|"TNF-α levels in collected saliva and serum samples were measured by commercial ELISA kits (ELISA Cloud Immunoassay, Cloud Clone Corp; cat #SEA079Hu) and analyzed according to manufacturers\&#39; instructions. The standard curve of the assay was used to determine the analyte concentrations in each sample. All samples were analyzed in duplicate, and the mean values were used in subsequent calculations.~TMAO levels in saliva and serum were determined by a liquid chromatography-mass spectrometry (LC MS/MS) method (LC-MS/MS, ESI Source, Thermo Scientific Accessmax), which was a modification of the method by Li et al and similar as our previous study.(Yufei Li, Kang, Lee, Chung, \&amp; Cho, 2021) To identify and quantify TMAO, samples were analyzed by an LC-MS/MS 1 system equipped with a Thermo Dionex Ultimate 3000 UHPLC system and an TSQ Quantum Access Max quadrupole mass spectrometer (USA)."
62050943|NCT01274052||Gestational Diabetes Mellitus|Women with Gestational Diabetes Mellitus
62050944|NCT01274052||Normal Glucose Tolerance|Women with Normal Glucose Tolerance
62050945|NCT03829124|EXPERIMENTAL|ketamine + propofol group|use ketamine + propofol for ECT induction
62441717|NCT04117308|EXPERIMENTAL|Educated group|Who have been educated to the active fetal movements count.
62833620|NCT02965014|EXPERIMENTAL|mHealth Young Women's CoOp (YWC)|Participants in this arm will be offered training on the mobile health application mHealth Young Women's CoOp (YWC) and offered tablets with the mHealth application to complete the two-session intervention.
62441718|NCT04437693|EXPERIMENTAL|Hydroxychloroquine|400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks.
62441719|NCT04437693|PLACEBO_COMPARATOR|Placebo|2 tablets (Placebo White tablets) twice daily on day 1 followed by 2 tablets weekly for 7 weeks
62610948|NCT05499078|EXPERIMENTAL|SULFEX 13081.22|Patients with dry or irritated nose treated with SULFEX 13081.22 nasal spray for 6 days (with at least 1 spray use a day).
62833621|NCT02965014|ACTIVE_COMPARATOR|HIV Counseling and Testing|Participants will be offered standard HIV counseling and testing services.
62833622|NCT02778737|EXPERIMENTAL|ACT-based intervention|The Acceptance and Commitment Therapy + MTAU consists of an unpublished manual developed for the purposes of the project (Karekla et al., 2013). The 8, 90-min weekly group sessions focus in fostering psychological flexibility or the capacity to engage or change behaviors based on what a situation affords and an individual's goals, needs, and desires (Hayes et al., 2004). The ACT protocol involves helping patients to engage in values-based behaviors while remain in contact with pain, especially, when efforts to control or reduce it fail or contribute to suffering.
62050946|NCT03829124|ACTIVE_COMPARATOR|propofol group|use propofol only for ECT induction
62050947|NCT04180644||Atopic Dermatitis|Participants with atopic dermatitis active lesions
62441720|NCT02325700||Open aortic repair|145 patients with open aortic repair for abdominal aortic aneurysmal disease (n=139) or abdominal aortic occlusive disease (n=89)
62441721|NCT02325700||Laparoscopic aortic repair|83 patients with Laparoscopic aortic repair for abdominal aortic aneurysmal disease (n=30) or abdominal aortic occlusive disease (n=53)
62610949|NCT01678703|ACTIVE_COMPARATOR|Laminaria group|Patients in this group will have cervical preparation with laminaria MedGyn Products, Inc. USA overnight the day before the abortion
62050948|NCT04180644||Healthy Control|Participants without a history of atopic dermatitis
62050949|NCT05423925||monopolar|monopolar electrodes, and have their corresponding distension media.
62050950|NCT05423925||bipolar|bipolar electrodes, and have their corresponding distension media.
62050951|NCT00079001|EXPERIMENTAL|Zoledronic acid + androgen deprivation therapy|4mg by IV over 15 minutes every 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progression on blinded treatment before having a skeletal event may continue on open label Zoledronic acid (4 mg by IV over 15 minutes every 3 weeks).
62050952|NCT00079001|ACTIVE_COMPARATOR|Placebo + androgen deprivation therapy|Placebo bu IV over 15 minutes for 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progress on blinded treatment before having a skeletal event may continue on open label Zoledronic acid.
62441722|NCT03393442|EXPERIMENTAL|1. Gd-exposed subjects|Diagnostic Test: Brain MRI scan Female subjects at high risk for breast cancer that previously underwent more than 6 Gd-based contrast enhanced MRI exams of the breast.
62610950|NCT01678703|ACTIVE_COMPARATOR|Misoprostol group|Patients in this group will have cervical preparation with vaginal Misoprostol 600 mcg overnight the day before the abortion
62610951|NCT01580176|EXPERIMENTAL|GlucoseMonitor|
62050953|NCT04299880|OTHER|Napabucasin monotherapy|Patients in this arm will receive napabucasin administered orally, twice daily
62050954|NCT04299880|OTHER|Napabucasin in combination with Gemcitabine and Nab-paclitaxel|Patients in this arm will receive napabucasin administered orally, twice daily in combination with weekly nab-paclitaxel and gemcitabine administered intravenously once weekly, on 3 of every 4 weeks.
62050955|NCT04299880|OTHER|Napabucasin in combination with Nivolumab|Patients in this arm will receive napabucasin administered orally, twice daily in combination with biweekly nivolumab 3mg/kg administered intravenously over 60 minutes.
62050956|NCT04299880|OTHER|Napabucasin in combination with paclitaxel|Patients in this arm will receive napabucasin administered orally, twice daily in combination with weekly paclitaxel administered intravenously once weekly, on 3 of every 4 weeks.
62050957|NCT04299880|OTHER|Napabucasin in combination with FOLFIRI|Patients in this arm will receive napabucasin administered orally, twice daily in combination with biweekly FOLFIRI. Addition of bevacizumab, per Investigator choice, will be permissible.
62610952|NCT06731829|EXPERIMENTAL|HRS-9231 dose 1|
62610953|NCT06731829|EXPERIMENTAL|HRS-9231 dose 2|
62050958|NCT04376554|EXPERIMENTAL|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will be sequentially randomized to receive either 600mg TBPM-PI-HBr every 8 hours (PO q8h \[±1 hour\]) or 500/125mg amoxicillin-clavulanate PO q8h (±1 hour) for 10 days.
62050959|NCT04376554|ACTIVE_COMPARATOR|amoxicillin-clavulanate|Healthy subjects meeting eligibility criteria will be sequentially randomized to receive either 500/125mg amoxicillin-clavulanate PO q8h (±1 hour) or 600mg TBPM-PI-HBr every 8 hours (PO q8h \[±1 hour\]) or for 10 days.
62050960|NCT03390868|EXPERIMENTAL|Intervention arm|Phase 1, participants in the intervention group will take part in an web-based training for staff working with people with intellectual disabilities and challenging behaviour aiming to in a more effective way communicate to prevent challenging behaviour. The participants (staff) will by their own, go through the web-based training program during working hours. Measurement are conducted before intervention, at intervention completion an average of 12 weeks, and for a 3 month follow up after completed intervention
62610954|NCT06731829|EXPERIMENTAL|HRS-9231 dose 3|
62050961|NCT03390868|OTHER|control arm|Control arm: participants in the control-group will maintain regular care and have the opportunity to receive the web-based training for staff working with people with intellectual disabilities and challenging behaviour in phase 2.
62050962|NCT02178566|PLACEBO_COMPARATOR|Inhaled Treprostinil Placebo|A dose of placebo resembling inhaled treprostinil will be administered to all study participants in the placebo comparator arm prior to each of their Pulmonary Rehab sessions. A dose of inhaled albuterol will be administered prior to each inhaled agent. Vitals signs will be taken prior to administering the dose and no medication will be given if the systolic blood pressure in \< 85 mm Hg. Three puffs of inhaled trepostinil dose will be administered each time to all patients .
62441723|NCT03393442|ACTIVE_COMPARATOR|2. Healthy subjects|Diagnostic Test: Brain MRI scan Age-matched female control subjects that never received Gd-based contrast agents.
62833623|NCT02778737|ACTIVE_COMPARATOR|CBT-based intervention|The Cognitive Behavioral group + MTAU consists of an unpublished manual developed by Kalantzi-Azizi \& Karademas (2003). It includes 8, 90-min weekly group session and primarily focuses on teaching patients to manage their pain by utilizing various techniques, such as activity pacing, muscle relaxation(i.e., progressive muscle relaxation, diaphragmatic breathing, guided imagery), pain recording, thought challenging, problem solving skills, relapse prevention, etc. The CBT protocol involves helping patients to learn to control their pain and to modify dysfunctional thoughts that accompany it.
62833624|NCT05533736|EXPERIMENTAL|Community based strategy to follow-up pactientes with Cutaneous Leishmaniasis|Patients with cutaneous leishmaniasis are followed with the Guaral+ST app by Community Health Leaders. This intervention was not randomized
62441724|NCT00359437|EXPERIMENTAL|Satavaptan|
62441725|NCT00359437|PLACEBO_COMPARATOR|Placebo|
62441726|NCT00050661|ACTIVE_COMPARATOR|Narrow Band Ultraviolet B|312nm
62441727|NCT00050661|EXPERIMENTAL|anti-TAC or placebo|
62441728|NCT02497391|EXPERIMENTAL|Evacetrapib Reference (R)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
62441729|NCT02497391|EXPERIMENTAL|Evacetrapib Test 1 (T1)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
62441730|NCT02497391|EXPERIMENTAL|Evacetrapib Test 2 (T2)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
62441731|NCT04938778|EXPERIMENTAL|Intervention Arm|8 week 14 hour prolonged nightly fasting intervention.
62610955|NCT06731829|ACTIVE_COMPARATOR|Gadobutrol|
62441732|NCT05085613|ACTIVE_COMPARATOR|Vaccine Corrective Control|A message that explains why people are hesitant to accept the FDA authorized COVID vaccines are safe and effective and how the vaccines are evaluated as safe and effective by FDA.
62441733|NCT05085613|EXPERIMENTAL|Vaccine corrective with economic recovery framing|"The content of the control message with the addition of the text, If everyone gets vaccinated, we can keep schools, stores, and other businesses open so more Americans can keep working and supporting their families. The message will also include a picture of an open for business sign."
62441734|NCT05085613|EXPERIMENTAL|Vaccine corrective with freedom framing|"The content of the control message with the addition of the text, Everyone getting vaccinated is the key to freedom! A vaccine can give us the freedom to hang out with friends, shop, and worship together again safely. The message will also include a picture of an American flag."
62833625|NCT05533736|NO_INTERVENTION|Control group: Standard of care|Control group: Standard of Care: Registers historical patients with cutaneous leishmaniasis is followed in the health facility by physicians according to national guidelines.
62050963|NCT02178566|ACTIVE_COMPARATOR|Inhaled Treprostinil|A dose of inhaled treprostinil will be administered to all study participants prior to each of their Pulmonary Rehab sessions. A dose of inhaled albuterol will be administered prior to each inhaled agent. Vitals signs will be taken prior to administering the dose and no medication will be given if the systolic blood pressure in \< 85 mm Hg. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
62050964|NCT06457828|SHAM_COMPARATOR|No apical patency|
62610956|NCT02415062|EXPERIMENTAL|high dose donepezil (23mg)|Patients with dementia in Parkinson's disease, who are treated with high dose donepezil (23mg)
62050965|NCT06457828|ACTIVE_COMPARATOR|Apical patency|
62050966|NCT04806828||HF|Preoperative classification of inguinal hernia
62050967|NCT03403868|OTHER|Conductance catheter|Contractility-measurement with conductance catheter (pressure-volume-catheter)
62050968|NCT02536365|EXPERIMENTAL|Sensory Integration Therapy|Children receive manualized SIT intervention that follows principles of sensory integration. SIT directly addresses the specific sensory factors hypothesized to underlie the child's functional skills difficulties and follows the Data Driven Decision Making Process, to tailor the intervention to the child's specific sensory issues.
62050969|NCT02536365|ACTIVE_COMPARATOR|Applied Behavioral Analysis|This involves examination of environmental variables that influence behavior and altering those variables to improve the child's skills. Intervention is individualized based on identified needs of the child, assessment of environmental variables impacting their performance of specific functional skills, and their abilities.
62050970|NCT02536365|NO_INTERVENTION|No Treatment|Treatment as usual will occur through the treatment period. As with the other treatment conditions, the participant agrees to refrain from beginning new treatments during participation in this study.
62050971|NCT02070068|EXPERIMENTAL|Group 1|ICG administered 10 minutes prior to time of visualization
62050972|NCT02070068|EXPERIMENTAL|Group 2|ICG administered 45 min prior to time of visualization
62050973|NCT03224013|ACTIVE_COMPARATOR|Hyperopic LASIK with crosslinking|group 1:hyperopic customized LASIK with concurrent prophylactic high-fluence cross-linking
62050974|NCT03224013|ACTIVE_COMPARATOR|Hyperopic LASIK only|group 2: hyperopic customized LASIK only
62441735|NCT05085613|EXPERIMENTAL|Vaccine corrective with humor|"The content of the control message with the addition of the text, Unfortunately, everyone getting vaccinated means leaving the house again. The message will include a meme of a cat being pulled/rescued from a window with text boxes labeling the cat as People at home working in sweatpants and the rescuer as COVID Vaccines."
62441736|NCT00152321|EXPERIMENTAL|A|Multifaceted intervention
62441737|NCT00152321|ACTIVE_COMPARATOR|B|Usual Care
62441738|NCT03995069|EXPERIMENTAL|3D|The participant's voluntary grip forces in all 3 dimensions will be shown to the participant via computer screen.
62050975|NCT03791164|EXPERIMENTAL|Pain Toolkit plus the Back Book|Participants who are being discharged from the regional back pain pathway who are allocated the 'Pain Toolkit' booklet along with the control intervention 'the Back Book'. They follow the interventions in the 'PainToolkit' for 12 months and are followed up 6 months and 1 year.
62050976|NCT03791164|ACTIVE_COMPARATOR|Back Book|Participants who are being discharged from the regional back pain pathway who are allocated 'the Back Book'. They are followed up 6 months and 1 year. This is the control group.
62441739|NCT03995069|ACTIVE_COMPARATOR|1D|The participant's voluntary grip force in 1 dimension will be shown to the participant via computer screen.
62441740|NCT05103956||Group A (Study Group)|HEMOPATCH® (Sealing / hemostatic patch of collagen and e polyethylene glycol)
62441741|NCT05103956||Group B (Control Group)|No hemostatic or the standard (ligatures and oxidized cellulose regenerated).
62441742|NCT01405820|ACTIVE_COMPARATOR|Natalizumab 300 mg Intravenous (IV) Every 4 Weeks|Natalizumab 300 mg IV every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
62610957|NCT02415062|ACTIVE_COMPARATOR|standard dose denepezil (10mg)|Patients with dementia in Parkinson's disease, who are treated with standard dose donepezil (10mg)
62610958|NCT02636439|ACTIVE_COMPARATOR|dietary, and aerobic exercise|"Intervention for diet-A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb.) weight loss per week.~Intervention for aerobic exercise-Based on initial evaluations and the stress testing results, (HR, VO2, RPE) an individual exercise prescription will be developed for aerobic training."
62833626|NCT05808231|OTHER|Control Group|Standard of Care alone
62833627|NCT05808231|OTHER|Experimental Group|Standard of Care + Quinine Sulfate
62833628|NCT01698398|EXPERIMENTAL|CF-LVAD pumpspeed.|Optimal pumpspeed setting of CF-LVAD during exercise on ergometric bicycle.
62833629|NCT00536419|PLACEBO_COMPARATOR|2|4 days of placebo
62833630|NCT00536419|EXPERIMENTAL|1|MPH-SODAS at day 1 (0.3/mg/kg/day); day 2 (0.7/mg/kg/day);days 3 and 4 (1.0 mg/kg/day)
62050977|NCT03116984|ACTIVE_COMPARATOR|Transcatheter arterial chemoembolization|TACE group: The frequency of treatment is determined based on the disease condition for patients who are randomly assigned to group of TACE treatment.TACE is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery, and micro-embolization superselective catheterization is preferred.Adriamycin(30 to 60mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion.The dose of ultra fluid lipiodol was determined by diameter and blood supply type of HCC,generally 5-20ml, and no more than 30ml once.The boundary is considered whether there are large amounts of lipiodol to deposit in the tumor and tiny branches shadow of portal veins in paracarcinoma under fluoroscopic guidance. Embolizing agents(gelatin sponge particles 350um-560um) are added after lipiodol emulsion embolization.It has a possibility of observeation alone if tumor achieves a complete response after two times TACE.
62050978|NCT03116984|EXPERIMENTAL|External-beam radiotherapy|EBRT group: Patients who were randomized to the external- beam radiotherapy (EBRT) 3-5 weeks after the completion 2 times TACE.Radiotherapy equipment is based on the conditions of the cooperative units. 3-DCRT, IMRT or IGRT will be opted based on hospital. IGRT can also be used via helical tomotherapy, Rapid Arc or VMAT. The target volume should include the visible tumor.
62050979|NCT04387630|EXPERIMENTAL|metformin group|"metformin 850 mg once daily increased within 3 weeks to a maximum dose of 2550 mg on three divided daily doses.~Neoadjuvant cytotoxic chemotherapy as per MDT (multi-disciplinary team) decision. Patients scheduled for AC-T (adriamycin, Cyclophosphamide, paclitaxel) or AC (adriamycin, cyclophosphamide) will be eligible to randomization."
62610959|NCT02636439|ACTIVE_COMPARATOR|dietary, aerobic and resistance training|"Intervention for diet-A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb.) weight loss per week.~Intervention for aerobic exercise-Based on initial evaluations and the stress testing results, (HR, VO2, RPE) an individual exercise prescription will be developed for aerobic training.~Intervention for resistance training- Additional weight resistant exercise will be added to this arm."
62833631|NCT00887536|ACTIVE_COMPARATOR|Group 1: TAC then pegfilgrastim|docetaxel, doxorubicin, cyclophosphamide, and pegfilgrastim/filgrastim
62833632|NCT00887536|ACTIVE_COMPARATOR|Group 2: TC|docetaxel and cyclophosphamide
62833633|NCT00887536|EXPERIMENTAL|Group 3: TC + bevacizumab|docetaxel, cyclophosphamide, and bevacizumab
62833634|NCT02721329|ACTIVE_COMPARATOR|APAP without SensAwake|Auto CPAP delivered from the ICON+ CPAP device.
62833635|NCT02721329|EXPERIMENTAL|APAP with SensAwake|Auto CPAP with SensAwake turned on and set at a pressure of 4cmH2O. SensAwake is a pressure relief function that reduces the CPAP pressure on the transition from sleep to wake.
62833636|NCT02558296|ACTIVE_COMPARATOR|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.
62833637|NCT02558296|PLACEBO_COMPARATOR|Placebo tablets|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
62833638|NCT01244893|OTHER|Acuvue Advance Plus prePQ/Acuvue Advance Plus postPQ|Acuvue Advance Plus silicone hydrogel contact lens manufactured prior to process qualification will be worn first and Acuvue AdvancePlus silicone hydrogel contact lens manufactured after process qualification will be worn second.
62833639|NCT01244893|OTHER|Acuvue Advance Plus postPQ/Acuvue Advance Plus prePQ|Acuvue Advance Plus silicone hydrogel contact lens manufactured prior to process qualification worn first and Acuvue Advance Plus silicone hydrogel contact lens manufactured after process qualification worn second.
62833640|NCT02689661||Obese participants|Obese participants recruited from the University of Michigan Investigational Weight Management Clinic. Subjects in this group complete the five surveys, undergo extensive metabolic phenotyping, and a comprehensive neuropathy assessment at study entry and again at 2 years.
62833641|NCT02689661||Lean participants|Healthy lean age and gender matched controls recruited via the umclinicaltrials.org complete the five surveys, complete an oral glucose tolerance test and cholesterol panel, as well as the complete comprehensive neuropathy assessment.
62050980|NCT04387630|PLACEBO_COMPARATOR|Placebo group|placebo. Neoadjuvant cytotoxic chemotherapy as per MDT(multi-disciplinary team) decision. Patients scheduled for AC-T (adriamycin, Cyclophosphamide, paclitaxel) or AC (adriamycin, cyclophosphamide) will be eligible to randomization.
62441743|NCT01405820|EXPERIMENTAL|Natalizumab 300 mg Subcutaneous (SC) Every 4 Weeks|Natalizumab 300 mg SC every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
62833642|NCT04347122|ACTIVE_COMPARATOR|Bony tumor treated with Tranexamic acid (TXA)|This group of participants will undergo a bony tumor resection of the femur or proximal tibia and endoprosthetic reconstruction with TXA.
62833643|NCT04347122|NO_INTERVENTION|Bony tumor treated without TXA|This group of participants will undergo a bony tumor resection of the femur of proximal tibia and endoprosthetic reconstruction.
62833644|NCT04347122|ACTIVE_COMPARATOR|Soft tissue sarcoma treated with Tranexamic Acid (TXA)|This group of participants will undergo soft tissue sarcoma resection of the lower extremity with TXA
62833645|NCT04347122|NO_INTERVENTION|Soft tissue sarcoma treated without TXA|This group of participants will undergo soft tissue sarcoma resection of the lower extremity.
62833646|NCT01732289|EXPERIMENTAL|A|
62833647|NCT01123902|EXPERIMENTAL|hand-held fan|
62610960|NCT05490433|EXPERIMENTAL|robot assisted nipple sparing mastectomy(RNSM)|Robotic nipple sparing mastectomy, robotic mastectomy, hybrid robotic nipple sparing mastectomy, robotic nipple mammary complex and skin sparing mastectomy, robot nipple sparing mastectomy
62610961|NCT05490433|ACTIVE_COMPARATOR|Conventional nipple sparing mastectomy(CNSM)|Total mastectomy, mastectomy, nipple sparing mastectomy, skin sparing mastectomy, nipple sparing breast resection, open nipple sparing mastectomy, general nipple sparing Mammastectomy, an open-window nipple sparing mastectomy
62610962|NCT04910243||Physicians|Physicians managing patients with COVID-19 admitted at ICU during period of COVID-19 pandemic.
62610963|NCT04910243||Nurses|Nurses providing care to patients with COVID-19 admitted at ICU during period of COVID-19 pandemic.
62610964|NCT04607980|EXPERIMENTAL|Treatment Group A (ABP 654)|Participants will receive subcutaneous (SC) injection of ABP 654, 45 mg (baseline BW less than equal to \[\<=\] 100 kg) or 90 mg (baseline BW greater than \[\>\] 100 kg) at weeks 0, 4, and 16. Further from week 28 participants will receive ABP 654 (same dose) every 12 weeks (Q12W) at weeks 28 and 40 or may receive dose intensification Q8W at weeks 28, 36, and 44, depending on PASI score.
62610965|NCT04607980|EXPERIMENTAL|Treatment Group B (Ustekinumab - ABP 654)|Participants will receive SC injection of ustekinumab,45 mg (baseline BW \<= 100 kg) or 90 mg (baseline BW \> 100 kg) at weeks 0, 4, and 16. At week 28, participants will be re-randomized to continue on ustekinumab (Treatment group B1), or to receive ABP 654 (Treatment group B2) on weeks 28 and 40. Depending on PASI score, some participants may not be re-randomized and may receive dose intensification with ustekinumab Q8W at weeks 28, 36, and 44.
62833648|NCT01123902|PLACEBO_COMPARATOR|wristband|
62833649|NCT06177548||Minimally invasive Group|Patients who underwent minimally invasive Bentall procedure will be included. The minimally invasive Bentall procedure is performed through a small incision in the right intercostal space.
62833650|NCT06177548||Control Group|Patient who underwent Bentall procedure through median sternotomy will be included.
62252235|NCT05289050|EXPERIMENTAL|S-ketamine|For patients in the s-ketamine group, anaesthesia will be maintained with s-ketamine infusion（0.3mg/kg/h),while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h) ,analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient.The assessment of the depth of anesthesia was based on clinical evaluation.S-ketamine infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
62252236|NCT00396994|EXPERIMENTAL|Low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz
62833651|NCT05183867|EXPERIMENTAL|Healthy Minds Program (HMP) app|Participants will receive access to the 4-week HMP Foundations module. The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). The full HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose. At post-treatment, participants will be given access to additional HMP content to support their continued practice.
62833652|NCT05183867|ACTIVE_COMPARATOR|Psychoeducation app|Participants will receive access to the 4-week HMP Foundations module with guided meditation practices removed. The active control will include only the didactic content included in HMP without the guided meditation practices.
62833653|NCT05183867|NO_INTERVENTION|Usual Care|Participants will receive access to HMP at the end of the study and will be encouraged to continue with their usual care.
62833654|NCT00843596|EXPERIMENTAL|vacuum device - suction cup|
62833655|NCT06655844|EXPERIMENTAL|Real Arm|This group will experience the active device settings.
62833656|NCT06655844|SHAM_COMPARATOR|Sham Arm|This group will experience the sham device settings.
62833657|NCT03029871|EXPERIMENTAL|Arm 1|Nine subjects (3 cohorts, 3 subjects/cohort) with medically inoperable stage I/IIA (T1a - T2b) NSCLC with tumors measuring \> 2 to ≤ 5 cm will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-ADP adenovirus at one of three dose levels (1 x 1011 vp, 3 x 1011 vp, 1 x 1012 vp). Depending on the location of the target lesion, the adenovirus will be injected either transbronchially (central tumors) or percutaneously under computed tomography (CT)-guidance (peripheral tumors). Two days later, subjects will be administered (orally) a 10 day course of 5-fluorocytosine (5-FC) and valganciclovir (vGCV) prodrug therapy along with 48 Gy (4 fractions of 12 Gy) of SBRT. Prior to and following the adenovirus injection, subjects will be administered \[18F\]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify HSV-1 TK gene expression.
62050981|NCT01572389|EXPERIMENTAL|Arm 1: HOPE|The Healthy Outcomes through Patient Empowerment (HOPE) intervention group is the intervention arm which will employ behavioral health coaching telephone sessions. Tele-coaching is a theoretically grounded, structured processes guided by intervention manuals.
62050982|NCT01572389|ACTIVE_COMPARATOR|Arm 2: EUC|The Enhanced Usual Care (EUC) group will serve as a concurrent control group to compare to the intervention arm of the study. Participants are screened for diabetes self-management behaviors and control and for active depressive and anxiety symptoms. Primary care providers are alerted of the patients' status and given decision support to enhance care for these uncontrolled conditions.
62050983|NCT04510675|EXPERIMENTAL|Test Article (Omeza Collagen Matrix)|"Repetitive and continuous patch applications of the test article to the same test sites on the back approximately 48 hours on weekdays and for approximately 72-hour periods over weekends over 3 weeks, for a total of 9 induction applications. During a subsequent challenge phase 10-17 days after the induction phase, the test article and negative control will be applied for 48 hours.~Each subject will receive both the test article and negative control at the same time."
62050984|NCT04510675|EXPERIMENTAL|Negative Control (0.9% aqueous sodium chloride)|"Repetitive and continuous patch applications of the negative control to the same test sites on the back approximately 48 hours on weekdays and for approximately 72-hour periods over weekends over 3 weeks, for a total of 9 induction applications. During a subsequent challenge phase 10-17 days after the induction phase, the test article and negative control will be applied for 48 hours.~Each subject will receive both the test article and negative control at the same time."
62050985|NCT05320055||IPOM|receiving laparoscopic intraperitoneal onlay mesh repair
62050986|NCT05320055||rTARUP|recieving robotic assited retromuscular repair
62050987|NCT02216266|ACTIVE_COMPARATOR|Physostigmine|Physostigmine administered intravenously at a dose of 24 mg + 25 min a 0,04 mg/kg milligram(s)/kilogram
62050988|NCT02216266|PLACEBO_COMPARATOR|Sodium Chloride solution|solution administered intravenously 24 mg + 25 min a 0,04 mg/kg milligram(s)/kilogram
62050989|NCT01257776|ACTIVE_COMPARATOR|Mesenchymal stem cells 0,5 million * weight (kg)|Group of low dose of Mesenchymal stem cells.
62050990|NCT01257776|ACTIVE_COMPARATOR|Mesenchymal stem cells 1 million * weight (kg)|Group of mid dose of mesenchymal stem cells
62050991|NCT01257776|NO_INTERVENTION|Controlled group|Controlled group with no intervention
62610966|NCT06150768|ACTIVE_COMPARATOR|Control group Cobalt Chromium Removable Partial Denture|The patient will receive a Cobalt Chromium Removable Partial Denture to restore missing posterior teeth in Kennedy Class II cases. The denture will be fabricated by conventional lost-wax and processing techniques.
62050992|NCT04227574|EXPERIMENTAL|Zero Time Exercise training + WhatsApp anti-inertia reminders|Subjects in this group will receive daily WhatsApp anti-inertia reminders from the research assistant to remind and encourage them to practice Zero Time Exercise.
62050993|NCT04227574|ACTIVE_COMPARATOR|Zero Time Exercise training alone|Subjects in this group will not receive any WhatsApp reminders from week 8 to 24.
62050994|NCT06070402|EXPERIMENTAL|Experimental group|Participants randomly assigned to this group will test the DIAL device for four weeks
62050995|NCT06070402|NO_INTERVENTION|Control group|Participants randomly assigned to this group will not use the DIAL device
62050996|NCT01010425|EXPERIMENTAL|ACP-001, dose-level 1|
62050997|NCT01010425|EXPERIMENTAL|ACP-001, dose-level 2|
62050998|NCT01010425|EXPERIMENTAL|ACP-001, dose-level 3|
62050999|NCT01010425|EXPERIMENTAL|ACP-001, dose-level 4|
62051000|NCT03248765||Chronic pain group|post-surgical opioid use measured at 1 day and 1 week.
62051001|NCT03248765||No chronic pain|post-surgical opioid use measured at 1 day and 1 week.
62051002|NCT03305523|EXPERIMENTAL|Thermocautery|Circumcision with thermocautery technique was applied all participants
62441744|NCT01405820|EXPERIMENTAL|Natalizumab 300 mg IV Every 12 Weeks|Natalizumab 300 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
62051003|NCT02059967|EXPERIMENTAL|Treatment (IGART using ABC, SIVAB, paclitaxel, carboplatin)|Patients undergo IGART using ABC 5 days a week for 7 weeks, for a total of 33 fractions with SIVAB during fractions 26-33. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once a week for 6 weeks.
62051004|NCT05008783|EXPERIMENTAL|AK104 + Oxaliplatin + Capecitabine|AK104 in combination with Oxaliplatin and Capecitabine
62051005|NCT05008783|PLACEBO_COMPARATOR|Placebo + Oxaliplatin + Capecitabine|Placebo in combination with Oxaliplatin and Capecitabine
62051006|NCT01867099||Post-successful ablation|Patients who had undergone PVI ablation for AF and were free of AF for at least one year
62051007|NCT05080062|EXPERIMENTAL|Painrehabilitation + Demand and ability protocol|Will receive pain-rehabilitation and the intervention ( an interview called Requirements and functional Schedule, with the patients employer and an occupational therapist)
62051008|NCT05080062|ACTIVE_COMPARATOR|Painrehabilitation|Will receive pain-rehabilitation
62051009|NCT02460692|PLACEBO_COMPARATOR|Placebos|The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
62051010|NCT02460692|ACTIVE_COMPARATOR|Dronabinol|A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
62051011|NCT02460692|EXPERIMENTAL|Vaporized Cannabis 3.7% THC/5.6% CBD|The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
62051012|NCT03537079|PLACEBO_COMPARATOR|normoxia conditioning|exercise training in normoxia and rest conditioning in normoxia
62051013|NCT03537079|ACTIVE_COMPARATOR|exercise hypoxia|exercise training in hypoxia and rest conditioning in normoxia
62051014|NCT03537079|ACTIVE_COMPARATOR|rest hypoxia|exercise training in normoxia and rest conditioning in hypoxia
62051015|NCT05296499||Venous outflow obstruction extending to inferior vena cava, symptomatic with dyspnoea|Baseline assessments Post-operative assessments if applicable
62051016|NCT05296499||Venous outflow obstruction extending to inferior vena cava, not symptomatic with dyspnoea|Baseline assessments Post-operative assessments if applicable
62051017|NCT05296499||Unilateral iliac venous outflow obstruction|Baseline assessments Post-operative assessments if applicable
62051018|NCT05296499||Age and sex matched controls|Baseline assessments
62051019|NCT04596202|EXPERIMENTAL|Supine Position|It is the supine position. The body parts of the patient stand as if the patient is standing upright. The head, neck and shoulders should be supported with a pillow placed under the head. Arms are aside and body muscles are relaxed. The upper arms should lie on both sides of the body, should slightly be moved away from the body and should be supported by a pillow.
62051020|NCT04596202|EXPERIMENTAL|Prone Position|It is the position where the patient lies face down with his/her head turned to the side. Arms are stretched to both sides of the head. The prone position (prone lying) is a relaxing and resting position.
62051021|NCT04596202|EXPERIMENTAL|Lateral position|Lateral position is the left or right lateral lying position. The lateral position is given to the patient to provide proper anatomical lying and to reduce lateral flexion of the back and the strain of the large back muscles. This position prevents pressure on the bones in the back.
62051022|NCT02026180|ACTIVE_COMPARATOR|Micropuncture Access|Vascular access using micropuncture needle kit
62051023|NCT02026180|ACTIVE_COMPARATOR|Standard 18G vascular access needle|Vascular access using standard 18G needle
62051024|NCT00026143|EXPERIMENTAL|Arm I|Patients receive interleukin-12 IV over 5-15 seconds on day 1 and interferon alfa subcutaneously on days 2-6. Treatment repeats every 2 weeks in the absence of unacceptable toxicity. Patients are reassessed after 6 courses. Patients with a complete response receive 2 additional courses. Patients with a partial response or stable disease continue treatment in the absence of disease progression.
62051025|NCT05415800|EXPERIMENTAL|Interventional Arm|Intervention
62051026|NCT01648348|EXPERIMENTAL|Arm I (bevacizumab and TRC105)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 8 and 11 of course 1 and days 1 and 8 of all subsequent courses. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62051027|NCT01648348|ACTIVE_COMPARATOR|Arm II (bevacizumab)|Patients receive bevacizumab as in arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62051028|NCT03535064|EXPERIMENTAL|Schools received hand hygiene workshop|Schoolgirls of randomly assigned schools attended one-hour Arabic handwashing workshop conducted by the principal investigator one week after submitting all baseline questionnaires. Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
62051029|NCT03535064|NO_INTERVENTION|Schools with did not receive hand hygiene workshop|Schoolgirls in control group followed their usual hand washing procedure. When the study ended, schoolgirls of control school were exposed to the same intervention by the same investigator.
62051030|NCT03687567||HBA|alpha-Thalassemia
62051031|NCT03687567||HBB|beta-Thalassemia
62252237|NCT00396994|PLACEBO_COMPARATOR|2|10 minutes per day standing on sham low mechanical stimulation platform
62252238|NCT03972579|ACTIVE_COMPARATOR|Graded exposure therapy|Weekly 60-min sessions with an occupational therapist and psychologist over 8 weeks.
62252239|NCT03972579|ACTIVE_COMPARATOR|Pacing + mindfulness|Weekly 60-min sessions with an occupational therapist and psychologist over 8 weeks.
62252240|NCT01937936|EXPERIMENTAL|CBT|Cognitive Behavioral Therapy (CBT)
62252241|NCT01937936|ACTIVE_COMPARATOR|Education|Health Education
62252242|NCT03275571|EXPERIMENTAL|cCBT intervention|Over the course of 9 weeks, 30 min online sessions, once per week, with a fictive therapist.
62252243|NCT04623372|EXPERIMENTAL|suture|
62252244|NCT04623372|EXPERIMENTAL|Directed wound healing|
62252245|NCT02057796|EXPERIMENTAL|Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|"Arm1 Extensive TB screening:~In this arm, point-of-care tests for TB will be used at randomization (in all patients) and at each scheduled or unscheduled follow-up visit (in patients with signs or symptoms suggestive of TB and no clear alternative diagnosis); TB treatment will only be prescribed to patients with a diagnosis of TB"
62441745|NCT01405820|EXPERIMENTAL|Natalizumab 300 mg SC Every 12 Weeks|Natalizumab 300 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
62610967|NCT06150768|EXPERIMENTAL|Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture|Two dental implants will be placed to restore missed posterior teeth (second mandibular premolar and second mandibular molar) in Kennedy Class II cases by using a two-stage surgical technique with the help of a radiographic and surgical stent. After a three-month osseointegration period, implants will be loaded with three units of anatomical Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture
62051032|NCT01701986|EXPERIMENTAL|Treatment (gemcitabine, clofarabine, busulfan, BMT or PBSCT)|"PREPARATIVE REGIMEN: Patients receive gemcitabine hydrochloride IV over 40-180 minutes on days -6 and -4, clofarabine IV over 1 hour on days -6 to -3, and busulfan IV over 3 hours on days -6 to -3. Patients with matched unrelated donors also receive antithymocyte globulin IV on days -3 to -1 and patients with CD20-positive disease also receive rituximab IV on days -14, -7, 1, and 8.~TRANSPLANT: Patients undergo allogeneic BMT or PBSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously over 24 hours or PO beginning on day -2 for up to 6 months and mycophenolate mofetil IV over 2 hours or PO TID beginning day 0."
62610968|NCT06150768|EXPERIMENTAL|Implant-Supported Zirconia fixed partial denture|Two dental implants will be placed to restore missed posterior teeth (second mandibular premolar and second mandibular molar) in Kennedy Class II cases by using a two-stage surgical technique with the help of a radiographic and surgical stent. After a three-month osseointegration period, implants will be loaded with three units of anatomical implant-supported Zirconia fixed partial dentures
62610969|NCT02945254|ACTIVE_COMPARATOR|Background noise|Overnight sleep study with filtered white noise
62610970|NCT02945254|NO_INTERVENTION|Silence|Overnight sleep study with normal environmental noise
62610971|NCT06397989|EXPERIMENTAL|Ready-to-use school food|Provision of peanut paste-based, milk-containing ready-to-use school food (PM-RUF)
62610972|NCT06397989|ACTIVE_COMPARATOR|Standard school meal|Provision of flour made from millet + rice (local food) as school food
62610973|NCT02223364|ACTIVE_COMPARATOR|Peripheral Nerve Block (PNB)|This group received a continuous femoral nerve block and a single injection sciatic nerve block consisting of the following: Peripheral nerve blocks with Bupivacaine.
62610974|NCT02223364|ACTIVE_COMPARATOR|Ropivacaine (PAI-R)|This group received intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
62610975|NCT02223364|ACTIVE_COMPARATOR|Liposomal Bupivacaine (PAI-L)|This group received Intra articular injection with liposomal bupivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
62610976|NCT04373850|EXPERIMENTAL|Home visit group|Will receive a home visit after discharge in addition to the standard discharge planning.
62610977|NCT04373850|NO_INTERVENTION|Control group|Will receive only the standard discharge planning.
62610978|NCT03871959|EXPERIMENTAL|Pembrolizumab + Debio 1143|"Pembrolizumab : 200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.~Debio 1143 : 3 escalating dose level (100 mg, 150 mg, 200 mg) administered daily for 14 days over a 21-day cycle period."
62252246|NCT02057796|EXPERIMENTAL|Rifampin, isoniazid, pyrazinamide, ethambutol|"Arm 2: Systematic Empiric treatment (Rifampicin,isoniazid, pyrazinamide, ethambutol) ART~In this arm, all patients will start a systematic 6-month TB treatment at randomization. TB screening tests will not systematically be used neither at randomization nor while patients are on TB treatment."
62252247|NCT02522507|EXPERIMENTAL|Empowering youth towards employment|This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
62610979|NCT02851979|EXPERIMENTAL|S0 - S1 - S2|S0 = no stimulation; washout; S1 = vehicle; washout; S2 = olfactory stimulation
62610980|NCT02851979|EXPERIMENTAL|S0 - S2 - S1|S0 = no stimulation; washout; S2 = olfactory stimulation; washout; S1 = vehicle
62610981|NCT02851979|EXPERIMENTAL|S1 - S0 - S2|S1 = vehicle; washout; S0 = no stimulation; washout; S2 = olfactory stimulation
62610982|NCT02851979|EXPERIMENTAL|S1 - S2 -S0|S1 = vehicle; washout; S2 = olfactory stimulation; washout; S0 = no stimulation
62610983|NCT02851979|EXPERIMENTAL|S2 - S0 - S1|S2 = olfactory stimulation; washout; S0 = no stimulation; washout; S1 = vehicle
62610984|NCT02851979|EXPERIMENTAL|S2 - S1 - S0|S2 = olfactory stimulation; washout; S1 = vehicle; washout S0 = no stimulation
62610985|NCT02638051|EXPERIMENTAL|Study Group|Modulated Electro-Hyperthermia (mEHT): 150 Watt x 60 min/session every 2nd day for 4 weeks (14 sessions); TCM Herbal Decoction: Shi Pi Decoction administered orally twice a day (200 mL x 2) 30 min after breakfast and supper, for 4 weeks.
62610986|NCT02638051|ACTIVE_COMPARATOR|Control Group|IPCI: CDDP (30-60 mg) with 5FU (500-600 mg/sqm of body surface), both dissolved in 100 mL of normal saline, after abdominal paracentesis and catheterization with following closed drainage of the ascites up to small amount of remaining liquid. After IPCI, the catheter occluded. Administered biweekly during four weeks of the course, totally two times.
62610987|NCT01520194||psychosocial burden|122 women attending reproductive health clinics were interwied using HPV Impact Profile (HIP) and a socio-economic characteristics questionnaire.
62610988|NCT01520194||economic burden|Medical records of 102 patients diagnosed with genital warts were reviewed in the six BEMFAM's participating reproductive health clinics
62610989|NCT05015543|EXPERIMENTAL|Patients paticipating in the Personal Training Program|The study patients complete two training sessions per week (60 minutes each) under supervision (16 weeks)
62610990|NCT01731470|EXPERIMENTAL|Liposomes|Liposomes
62610991|NCT02706353|EXPERIMENTAL|APX005M + Pembrolizumab|"Dose Escalation Phase:~Starting dose level of APX005M is 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses. Tumor site chosen based on volume to be injected.~All participants receive Pembrolizumab at 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.~Dose Expansion Phase:~Starting dose level of APX005M is maximum tolerated dose from Dose Escalation Phase.~Participants receive same dosage of Pembrolizumab as in Dose Escalation Phase."
62833658|NCT04029402||Diabetic kidney disease|Patients with archived biopsies with a pathologic diagnosis of diabetic kidney disease, interstitial fibrosis/tubular atrophy, or nephrosclerosis.
62833659|NCT04029402||Healthy controls|Potential living donors with archived biopsies performed as part of their donor workup and with no diagnostic abnormalities
62051033|NCT02573402|EXPERIMENTAL|Transcutaneous Tibial Nerve Stimulation|Transcutaneous Tibial Nerve Stimulation (TTNS) applied to subjects for 2-week protocol.
62051034|NCT02573402|SHAM_COMPARATOR|Control|Sham stimulation.
62051035|NCT05087381|EXPERIMENTAL|Fluvoxamine Arm|The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime.
62051036|NCT05087381|EXPERIMENTAL|Fluvoxamine in Combination with Bromhexine Arm|The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.
62051037|NCT05087381|EXPERIMENTAL|Fluvoxamine in Combination with Cyproheptadine Arm|The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with cyproheptadine 4 mg, 1 tablet, three times, orally after meals and should be taken every 8 hours apart, for 14 days.
62051038|NCT05087381|EXPERIMENTAL|Niclosamide Arm|The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days.
62051039|NCT05087381|EXPERIMENTAL|Niclosamide in Combination with Bromhexine Arm|The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days. Co-administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.
62051040|NCT05087381|NO_INTERVENTION|Usual Care Arm|The control group received treatment according to the latest usual care medical guidelines provide by ministry of Thailand at that time.
62051041|NCT04420468||Possible COVID-19 infection and acute myocarditis|"Children presented with an acute myocarditis, fever and shock with a possible COVID-19 infection cared between April 2020 till the end of the main SARS-Cov-2 outbreak in 4 AP-HP Parisian hospitals :~* Necker-Enfants Malades~* Armand Trousseau~* Robert Debré~* Kremlin Bicêtre"
62051042|NCT03704155|EXPERIMENTAL|Experimental group (EG)|The EG was treated with Botulinum toxin type A and physiotherapy (stretching, balancing training, functional walking training).
62051043|NCT03704155|ACTIVE_COMPARATOR|Control group (CG)|GC was treated with physiotherapy (stretching, balancing training, functional walking training).
62051044|NCT03577860|ACTIVE_COMPARATOR|Bupivacaine 4ml|The interscalene brachial plexus block is performed with 4ml at level of C5-6 roots
62051045|NCT03577860|ACTIVE_COMPARATOR|Bupivacaine 15ml|The interscalene brachial plexus block is performed with 15ml at level of C5-6
62051046|NCT04351503||SARSCoV-infected patients (cases)|
62610992|NCT06622291|EXPERIMENTAL|Nitric Oxide|Patients in this group receive treatment with exogenous nitric oxide (NO) via the CPB machine. After CPB, NO is administered through the inspiratory limb of the anesthetic or ventilator circuit and then via the mechanical ventilator in the ICU. Once patients are extubated, they will breathe NO through a facemask or nasal cannula. NO administration begins at the start of CPB and continues for 12 hours post-operation.
62833660|NCT04818853||COVID Patients with Aspergillosis and Other fungal Infections|All patients have been diagnosed with COVID-19. The purpose of this study is to look at this group of patients in the potential to develop Aspergillosis and other fungal infections.
62051047|NCT04351503||non-SARS-CoV-2 infected patients (control)|non-SARS-CoV-2 infected patients with or without other respiratory viruses (control).
62051048|NCT01732848||Subjects treated with BMS-986094/INX-08189|Subjects who participated in a clinical trial in which at least 1 dose of BMS-986094/INX-08189 was administered
62051049|NCT01732848||Subjects treated with Placebo matching BMS-986094/INX-08189|Subjects who participated in a clinical trial in which at least 1 dose of Placebo matching BMS-986094/INX-08189 was administered
62051050|NCT03202381|EXPERIMENTAL|Degarelix|
62051051|NCT00667472|EXPERIMENTAL|Ranibizumab|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
62051052|NCT00667472|EXPERIMENTAL|Pulsed Dye Laser|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
62051053|NCT03532802|ACTIVE_COMPARATOR|Metoprolol Succinate|Metoprololsuccinat
62051054|NCT03532802|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo
62051055|NCT00677235|EXPERIMENTAL|FLAIR|FLAIR Endovascular Stent Graft
62051056|NCT00677235|ACTIVE_COMPARATOR|PTA Only|Percutaneous Transluminal Angioplasty
62051057|NCT02565563|ACTIVE_COMPARATOR|Eye Movements|Eye Movement Desensitisation Reprocessing with eye movements (measuring Heart Rate Variability using HeartMath)
62051058|NCT02565563|ACTIVE_COMPARATOR|No Eye Movements|Eye Movement Desensitisation Reprocessing without eye movements (measuring Heart Rate Variability using HeartMath)
62051059|NCT03852043|EXPERIMENTAL|High-intensity interval training|
62051060|NCT03852043|ACTIVE_COMPARATOR|Moderate-intensity continuous training|
62051061|NCT02138045|PLACEBO_COMPARATOR|Placebo treatment|"Placebo solution will be slowly titrated to maximum tolerable dose in order to minimize potential side-effects, hence treatment will follow:~First and second week: 0.6 mg/day; Third and fourth week: 1.2 mg/day and Fifth and to sixth week: 1.8 mg/day."
62252248|NCT02522507|NO_INTERVENTION|Control group|The control group will have access to the employment activities during the 12-week employment readiness learning but will not have access to a mentor.
62252249|NCT05850754|EXPERIMENTAL|CBD Capsule|Participants will take capsules containing 50 mg of CBD daily for 4 weeks.
62252250|NCT05850754|PLACEBO_COMPARATOR|Placebo Capsule|Participants will take placebo capsules containing 0 mg of CBD daily for 4 weeks.
62252251|NCT02398448|EXPERIMENTAL|Zyloprim® 300 mg and three dissolution test formulations|Regimen A: Zyloprim® 300 mg; Regimen B: Allopurinol 300 mg; undergranulated, high hardness condition; Regimen C: Allopurinol 300 mg; alternative condition 2; Regimen D: Allopurinol 300 mg; alternative condition 3
62252252|NCT00698932|EXPERIMENTAL|Saxagliptin 5mg|
62252253|NCT00698932|PLACEBO_COMPARATOR|Placebo|
62252254|NCT04603105||Single Study Cohort|Patients will be recruited from the main study after being determined to having COVID-19 and Cancer
62252255|NCT00884325|EXPERIMENTAL|Xyzal|
62252256|NCT00884325|PLACEBO_COMPARATOR|Placebo|
62833661|NCT01887535|EXPERIMENTAL|Cohort 1: JNJ-54861911 3 mg|Participants will be administered single doses of JNJ-54861911 on Days 1 to 14. Initially the doses will be once per day, but the frequency of daily dosing (eg, once-daily, twice-daily, three times daily) may change prior to or during study conduct depending on the pharmacokinetic data from the ongoing single-ascending dose study (54861911ALZ1001) or ongoing cohorts in this current study. Actual dose levels as well as the magnitude of dose escalation will depend on the results of the ongoing single-ascending dose study, the observed safety and tolerability profile as well as the observed exposures.
62252257|NCT03974399|OTHER|study enrollment|all participants will take dietary supplement, Bacopa Monnieri, daily for 3 months
62252258|NCT05926154|EXPERIMENTAL|LOP + 50 mmHg|As a result of randomization, the surgical tourniquet pressure is 50 mmHg higher than the limb occlusion pressure. Limb occlusion pressure is calculated using the formulation by Graham: LOP = \[(Systolic Pressure - Diastolic Pressure)× (Limb Diameter) / 3 Cuff Width)\] + Diastolic Pressure
62252259|NCT05926154|EXPERIMENTAL|LOP + 100 mmHg|As a result of randomization, the surgical tourniquet pressure is 100 mmHg higher than the limb occlusion pressure. Limb occlusion pressure is calculated using the formulation by Graham: LOP = \[(Systolic Pressure - Diastolic Pressure)× (Limb Diameter) / 3 Cuff Width)\] + Diastolic Pressure
62252260|NCT03228355|ACTIVE_COMPARATOR|Levcromakalim|
62610993|NCT06622291|PLACEBO_COMPARATOR|Usual care|Patients in this group receive a sham treatment without the supply of nitric oxide during CPB and for 12 hours post-operation.
62610994|NCT01574677||Screening FIT positive|Patients aged 49-80, with a positive screening FIT, who are referred to colonoscopy, and who meet inclusion criteria.
62833662|NCT01887535|EXPERIMENTAL|Cohort 2: JNJ-54861911 10 mg|
62833663|NCT01887535|EXPERIMENTAL|Cohort 3: JNJ-54861911 30 mg|
62051062|NCT02138045|ACTIVE_COMPARATOR|Liraglutide treatment|"Liraglutide will be slowly titrated to maximum tolerable dose in order to minimize potential side-effects, hence treatment will follow:~First and second week: 0.6 mg/day; Third and fourth week: 1.2 mg/day and Fifth and to sixth week: 1.8 mg/day."
62252261|NCT03228355|PLACEBO_COMPARATOR|Saline|
62252262|NCT02065167|EXPERIMENTAL|Cultured autologous Mesenchymal Cells|"Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.~20x106 cells per cc in a single administration of 7cc"
62252263|NCT06303284|EXPERIMENTAL|Teriparatide|20 µg subcutaneous Teriparatide injection once daily for 3 months in the post-operative ankle fracture population.
62252264|NCT06303284|SHAM_COMPARATOR|placebo|20 µg subcutaneous saline placebo injection once daily for 3 months in the post-operative ankle fracture population.
62252265|NCT00592033|NO_INTERVENTION|2|Rehabilitation, no supplemental oxygen
62252266|NCT00592033|EXPERIMENTAL|1|Rehabilitation plus supplemental oxygen
62252267|NCT01414699|ACTIVE_COMPARATOR|One-Course, Variety|Participants will receive a snack in one course with a variety of fruit.
62252268|NCT01414699|ACTIVE_COMPARATOR|Two-Course, Variety|Participants will receive a snack in two courses with a variety of fruit.
62252269|NCT01414699|ACTIVE_COMPARATOR|One-course, Non-Variety|Participants will receive a snack in one course with no variety of fruit.
62252270|NCT01414699|ACTIVE_COMPARATOR|Two-Course, Non-Variety|Participants will receive a snack in two courses with no variety of fruit.
62252271|NCT02452281|EXPERIMENTAL|ipilimumab + HSPPC-96|"* Ipilimumab is administered intravenously at a dose of 3 mg/kg one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.~* HSPPC-96 is administered at a dose of 25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab.~* Length of Treatment: 4 cycles of ipilimumab and at least 6 cycles of HSPPC-96 up to 12 doses.~* Booster doses of HSPCC-96 following 6 administrations on subsequent cycles will be administered every 21-23 days according to availability of vaccine."
62252272|NCT01247987|ACTIVE_COMPARATOR|Blastocyst cryopreservation|Subjects randomly assigned to this arm of the study will have all of their embryos cryopreserved at the blastocyst stage, followed by thaw and transfer in a subsequent menstrual cycle.
62610995|NCT05524246|EXPERIMENTAL|Pravastatin Prophylactic Treatment|
62610996|NCT03729622|ACTIVE_COMPARATOR|Immediate Intervention|Participants in this arm will receive an immediate low FODMAP dietary intervention on their second visit after they have been screened, consented and enrolled during visit 1.
62610997|NCT03729622|PLACEBO_COMPARATOR|Delayed Intervention|Participants in this arm will receive a delayed Low FODMAP dietary intervention during their third visit after they have been been screened, consented and enrolled during visit 1.
62623547|NCT06492382|ACTIVE_COMPARATOR|No Home oxygen monitor|Infant will have a home oxygen weaning guideline for their pediatrician to use based on parameters other than a home oxygen monitor
62623548|NCT04972422|EXPERIMENTAL|Single Agent Dose Escalation|Participants with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
62252273|NCT01247987|EXPERIMENTAL|Bipronuclear oocyte cryopreservation|Subjects randomly assigned to this arm of the study will have all of their bipronuclear oocytes cryopreserved, followed by thaw, extended culture, and transfer in a subsequent menstrual cycle.
62252274|NCT02800408|EXPERIMENTAL|Whole grain high-BCX maize|Whole grain, high-beta-cryptoxanthin (BCX; orange) maize will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
62252275|NCT02800408|EXPERIMENTAL|Refined grain high-BCX maize|Refined (degermed) grain, high-beta-cryptoxanthin (BCX; orange) maize will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
62252276|NCT02800408|PLACEBO_COMPARATOR|Whole grain white maize|Whole grain, white maize (low in beta-cryptoxanthin) will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
62252277|NCT06401720||Patients|Patients with airway infection. Enrolled while seeking health care or when hospitalized.
62252278|NCT06401720||Controls|Subjects without airway infection.
62252279|NCT01468220|PLACEBO_COMPARATOR|normoxic training|6 weeks of endurance training under normoxia
62833664|NCT01887535|EXPERIMENTAL|Cohort 4: JNJ-54861911 80 mg|
62833665|NCT01887535|EXPERIMENTAL|Cohort 5: JNJ-54861911 25 mg|
62051063|NCT02915848||PC+S group|PC+S group gets Medtronic, Activa PC+S DBS device,
62610998|NCT06721559|EXPERIMENTAL|Empower@Home supported by aging service providers|Participants will be provided with access to a 9-session online program called Empower@Home, a self-help intervention based on cognitive behavioral therapy principles. The intervention has three components: 9 interactive self-paced online sessions, printed workbook that goes along the online sessions for exercises and homework, and telephone coaching by a trained staff from a social service agency serving older adults. Participants will have up to 12 weeks to try to complete the program with the support of a trained coach.
62610999|NCT06721559|OTHER|Attention call with friendly visitors|Participants will receive enhanced care as usual, including care as usual from their social service provider and a psycho-educational handout. In addition, they will receive telephone friendly calls from a research staff every other week to mimic the human interactions provided by coaches in the experimental group.
62611000|NCT06719869|EXPERIMENTAL|Midline catheter|
62611001|NCT06719869|ACTIVE_COMPARATOR|Central venous catheter|Centrally inserted CVC
62833666|NCT01887535|PLACEBO_COMPARATOR|Cohorts 1-4: Placebo|Participants in Cohorts 1-4 will receive matching placebo.
62833667|NCT04057326|ACTIVE_COMPARATOR|Oryz-Aspergillus Enzyme and Pancreatin Tablet Arm|Oryz-Aspergillus Enzyme and Pancreatin Tablet ,2 tablets/time, 3 times daily. Study drug will be administered orally.
62833668|NCT04057326|PLACEBO_COMPARATOR|Placebo Arm|Placebo,2 tablets/time, 3 timesdaily. Study drug will be administered orally.
62051064|NCT05840861||MDD|Participants with major depressive disorder (MDD), unmedicated and currently depressed to participate in MRI and \[18F\]FPEB PET scans
62051065|NCT05840861||Bipolar|Participants with bipolar disorder, unmedicated and currently depressed to participate in MRI and \[18F\]FPEB PET scans
62611002|NCT04885400|EXPERIMENTAL|iJobs|All the participants will be included in the program.
62611003|NCT03012763|PLACEBO_COMPARATOR|non-caloric water|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml non-caloric water 3 h thereafter
62611004|NCT03012763|ACTIVE_COMPARATOR|caloric drink|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml caloric drink 3 h thereafter
62611005|NCT03012763|ACTIVE_COMPARATOR|grapefruit juice|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml grapefruit juice 3 h thereafter
62833669|NCT03530072||Cases|Subjects with Fever and Neutropenia
62833670|NCT06654570|EXPERIMENTAL|Intravaginal estradiol during adjuvant letrozole|Eligible patients were treated with Vagifem® (17β-estradiol hemihydrate) 10 μg vaginal tablets for 12 weeks. Patients were instructed to insert one vaginal tablet daily using the provided applicator for 14 consecutive days, followed by one tablet twice weekly (Monday and Thursday evenings).
62051066|NCT05840861||Healthy Control|Healthy participant with no MDD or other psychiatric condition to participate in MRI and \[18F\]FPEB PET scans
62051067|NCT02159599|ACTIVE_COMPARATOR|Darunavir/Ritonavir + 2 nucleos(t)idos|Darunavir/Ritonavir ( (800mg/100mg) + Tenofovir/emtricitabine (300mg/200mg) or Abacavir/lamivudine (600 mg/300mg)
62051068|NCT02159599|EXPERIMENTAL|Darunavir/ritonavir + Lamivudine|Darunavir/Ritonavir (800mg7100mg) + lamivudine (300mg)
62051069|NCT03420781|PLACEBO_COMPARATOR|Treatment Period: Placebo|Placebo-matching relamorelin injected subcutaneously twice daily for up to 40 weeks.
62833671|NCT04077879|EXPERIMENTAL|Single ascending dose of ASP1617|This is composed of 5 sequential cohorts (cohorts 1.1 to 1.5), 6-9 participants for each cohort, consisting of either only non-Asians in cohorts 1.1 and 1.2; or non-Asians plus Japanese in cohorts 1.3, 1.4 and 1.5). Participants in cohorts 1.1, 1.2, 1.3, 1.4 and 1.5 will receive a single dose of 2, 10, 30, 100 and 300 milligrams (mg) ASP1617 capsules respectively under fasting conditions
62833672|NCT04077879|PLACEBO_COMPARATOR|Single ascending dose of Placebo|Participants (2-3 for each cohort, consisting of either only non-Asians in cohorts 1.1 and 1.2; or non-Asians plus Japanese in cohorts 1.3, 1.4 and 1.5) will receive a single dose of matching placebo under fasting conditions.
62051070|NCT03420781|EXPERIMENTAL|Treatment Period: Relamorelin 10 μg|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 40 weeks.
62611006|NCT05330468||Abbott Regent MHV|Subjects implanted with an Abbott Regent MHV replacement of the aortic valve.
62051071|NCT03420781|EXPERIMENTAL|Randomized Withdrawal Period: Placebo then Relamorelin 10 μg|Participants who received placebo-matching relamorelin injected subcutaneously twice daily for 40 weeks, followed by relamorelin 10 μg injected twice daily for up to 6 weeks in the Randomized Withdrawal (RW) Period.
62051072|NCT03420781|EXPERIMENTAL|Randomized Withdrawal Period: Relamorelin 10 μg then Relamorelin 10 μg|Participants who received relamorelin 10 μg injected subcutaneously twice daily for 40 weeks, followed by relamorelin injected twice daily for up to 6 weeks in the RW Period.
62051073|NCT03420781|EXPERIMENTAL|Randomized Withdrawal Period: Relamorelin 10 μg then Placebo|Participants who received relamorelin 10 μg injected subcutaneously twice daily for 40 weeks, followed by placebo-matching relamorelin injected twice daily for up to 6 weeks in the RW Period.
62051074|NCT04088370||Alcoholic Hepatitis|No intervention-blood draw only
62051075|NCT04088370||Healthy Controls|No intervention- blood draw only
62051076|NCT04088370||Healthy Heavy Drinkers|No intervention- blood draw only
62051077|NCT02190292||PANS group|All current Swedish cases investigated with the Cunningham panel (approximately 150 individuals) will be invited to participate in the study. 50 of these will be re-assessed with the Cunningham panel.
62051078|NCT02190292||Psychiatric controls|60 individuals with psychiatric disorder (eg. ADHD, autism spectrum disorder, psychosis, major depression, obsessive-compulsive disorder) will be recruited.
62611007|NCT05207722|EXPERIMENTAL|Phase I Dose Escalation|Up to two dosing cohorts of CYNK-101 in combination with rhIL2 will be evaluated following an initial induction and lymphodepletion regimen.
62833673|NCT04077879|EXPERIMENTAL|Single dose of ASP1617 (Food Effect)|Participants (6 Japanese and 3 non-Asian) will receive a single dose of 100 mg ASP1617 with a high-fat meal. Dosing of the Food Effect cohort will commence after having established the safety and tolerability of the dose tested in cohort 1.4.
62833674|NCT04077879|EXPERIMENTAL|Multiple ascending dose of ASP1617|"This is composed of 3 sequential cohorts (cohorts 2.1 to 2.3, 9 participants for each cohort, consisting of only non-Asians in cohort 2.1, or non-Asians plus Japanese in cohorts 2.2 and 2.3). Participants in cohorts 2.1, 2.2 and 2.3 will receive 30, 60 and 110 mg ASP1617 capsules respectively twice daily for 14 consecutive days at the same dose level.~Based on safety, tolerability and pharmacokinetic data of Part 1, once daily or twice daily dosing will be selected."
62833675|NCT04077879|PLACEBO_COMPARATOR|Multiple ascending dose of Placebo|Participants (3 for each cohort, consisting of either only non-Asians in cohort 2.1, or non-Asians plus Japanese in cohort 2.2 and 2.3) will receive matching Placebo for 14 consecutive days at the same dose level in cohort 2.1 to 2.3.
62833676|NCT06170047|EXPERIMENTAL|Chicago Parent Program for Foster Care|The Chicago Parent Program for Foster Care (CPP-FC) is a caregiver-directed prevention program to strengthen parenting skills and confidence in foster and kinship caregivers and prevent or reduce behavior problems in children 2-8 years old. CPP-FC was designed to specifically meet the unique needs of children ages 2-8 who are placed with foster and kinship caregivers. Participants assigned to CPP-FC will receive CPP-FC and the services typically offered from the county, Cincinnati Children's Hospital Medical Center Comprehensive Health Evaluations for Cincinnati's Kids (CHECK) clinic, and for licensed caregivers, their licensing agency.
62833677|NCT06170047|ACTIVE_COMPARATOR|Usual Care|Usual Care control will receive standard care offered from the county, Cincinnati Children's Hospital Medical Center Comprehensive Health Evaluations for Cincinnati's Kids (CHECK) clinic, and for licensed caregivers, their licensing agency.
62833678|NCT00735436|OTHER|Gliadel/Avastin/CPT-11|Gliadel/Avastin/CPT-11
62051079|NCT02190292||Healthy controls|25 age and sex matched children to the PANS group will be recruited.
62051080|NCT01965210|EXPERIMENTAL|Rye + high dose inulin + low dose gluten|Rye porridge supplemented with a high dose of the fermentable dietary fibre inulin and low dose of the plant protein gluten.
62051081|NCT01965210|EXPERIMENTAL|Rye + equal doses of inulin & gluten|Rye porridge supplemented with equal doses of the fermentable dietary fibre inulin and the plant protein gluten.
62051082|NCT01965210|EXPERIMENTAL|Rye + low dose inulin + high dose gluten|Rye porridge supplemented with a low dose of the fermentable dietary fibre inulin and a high dose of the plant protein gluten.
62051083|NCT01965210|EXPERIMENTAL|Large non-supplemented rye|Large portion of rye porridge without supplements.
62833679|NCT03531112|EXPERIMENTAL|Appetite Awareness Treatment (AAT) + Lifestyle Modification (LM)|Participants will receive an 8-week Appetite Awareness Training (AAT) program using a group format, will be provided a smart scale (with bluetooth connection) and instructions to weigh themselves daily. Participants will also be provided with weekly tailored feedback on self-weighing frequency and weight change. Assessment will be conducted at 0, 2, and 6 months.
62833680|NCT03531112|NO_INTERVENTION|Control|Control group participants will receive no intervention in months 1-6, but will be offered the chance to receive an abbreviated form of AAT (4 weeks) following the 6-month assessment.
62833681|NCT03769519|NO_INTERVENTION|Control (Group 1)|This group is considered the control group. This group will have scheduled texts and emails for the monthly surveys after the participant completes the baseline questionnaires.
62833682|NCT03769519|EXPERIMENTAL|ARICA Intervention (Group 2)|This group is considered the intervention group. Participants in this group will receive weekly texts and emails containing asthma facts and myths. They will also complete monthly surveys and participate in asthma education sessions.
62833683|NCT06628830|EXPERIMENTAL|Intervention Group|"The intervention consists of an indicated prevention program delivered through a mobile app. The program will last 6 weeks and includes the following:~1. Psychoeducation on depression and anxiety~2. CBT skills training~3. mood and symptom monitoring and feedback: mood tracker and the application every two weeks of the PHQ-4 and question 9 of the PHQ-9~4. Chat with a psychologist (on demand)~5. Optional modules on other related mental health topics (e.g. healthy habits, relaxation, mindfulness)~Additionally, participants will be able to access additional help resources that include a speed dial button for a suicide prevention hotline and a web link to access contact information for mental health services. Finally, the intervention protocol also includes the eventual referral to face-to-face mental health care if required."
62051084|NCT01965210|EXPERIMENTAL|Small non-supplemented rye|Small portion of rye porridge without supplements.
62051085|NCT01965210|ACTIVE_COMPARATOR|Refined wheat bread|Refined wheat bread.
62252280|NCT01468220|ACTIVE_COMPARATOR|hypoxic training|6 weeks of endurance training under hypoxia
62252281|NCT05383404||mild dehydration|(3-5)% according to change in body weight.
62252282|NCT05383404||moderate dehydration|(6-9)% according to change in body weight.
62252283|NCT05383404||severe dehydration|(6-9)% according to change in body weight.
62252284|NCT04016831|OTHER|Mapping Enhanced Counseling (MEC) only|a motivational enhancement clinical intervention derived from cognitive-behavioral models that addresses problem recognition, treatment motivation, thoughtful and objective decision making, and therapeutic engagement
62252285|NCT04016831|EXPERIMENTAL|Mapping Approaches to Prepare for Implementation Transfer|an implementation intervention to explore and address agency preparation needs in order to promote implementation success (includes MEC training)
62611008|NCT05207722|EXPERIMENTAL|Phase IIa Expansion|Once the Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D) is determined in Phase I, the Phase IIa portion of the study will commence.
62611009|NCT02103257|EXPERIMENTAL|Sequential icotinib plus chemotherapy|Sequential icotinib plus chemotherapy : pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
62611010|NCT02103257|ACTIVE_COMPARATOR|Icotinib|Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
62051086|NCT06103825|EXPERIMENTAL|Strengths of solriamfetol (JZP-110) strengths: 37.5 mg，75 mg, 150 mg|"subject will first enter a 2-week Titration Phase, during which the initial dose will be 37.5mg. The dose will be increased from 37.5mg QD to 75mg QD after 3 days, and then to 150mg QD at the first day of the second week if well-tolerated. subjects will then enter the 10-week Maintenance Phase on 150mg QD if well-tolerated.~If a subject tolerability issues after titration up to 150mg at the second week, the dose can be reduced to 75mg QD following instructions of the investigators. This subject will then enter the 10-week Maintenance Phase on 75mg QD.~If a subject experiences tolerability issues after titration up to 75mg at the first week, the dose can be reduced to 37.5mg QD following instructions of the investigators. The dose will be increased to 75mg QD again at the first day of the second week. Subject will then enter the 10-week Maintenance Phase on 75mg QD if well-tolerated.~All subjects should be maintained on either 75mg QD or 150mg QD during the Maintenance Phase."
62441746|NCT01405820|EXPERIMENTAL|Natalizumab 150 mg IV Every 12 Weeks|Natalizumab 150 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
62833684|NCT06628830|ACTIVE_COMPARATOR|Control Group|Participants in the enhanced control group will receive a web link (https://concienciasaludable.uchile.cl/) with information about places to go to seek mental health care both inside and outside the respective university and psychoeducational material on depression and anxiety
62833685|NCT03244332|EXPERIMENTAL|Decompensated cirrhosis|Children suffering from decompensated cirrhosis and needing an orthotopic liver transplantation.
62833686|NCT03244332|EXPERIMENTAL|Compensated cirrhosis|Children suffering from a compensated cirrhosis (compensated cirrhosis with kasai surgery in biliary atresia patients e.g) or from portal hypertension without cirrhosis (portal vein thrombosis e.g)
62833687|NCT04221867|EXPERIMENTAL|Esophageal stricture patients|Patients suffering from benign esophageal stricture are treated with through-the scope CRE dilation balloon. Free fat graft is gathered from the abdominal subcutaneous fat. Fat graft is prepared and injected to the stricture site.
62833688|NCT04308291||MiniMed™ 780G System|Subject will use the MiniMed™ 780G System as per standard of care.
62833689|NCT01465919|EXPERIMENTAL|mirtazapine|mirtazapine
62833690|NCT01465919|OTHER|Supportive psychotherapy|Supportive psychotherapy will be given by a specialized psychiatrist.
62833691|NCT02437344|EXPERIMENTAL|CI-581aa|CI-581aa will be administered 24 hours after last opioid use, and followed by naltrexone dosing
62833692|NCT05512156|EXPERIMENTAL|Intervention Group|All children in the intervention arm of the study will be receiving daily supervised toothbrushing in kindergartens for two years. All children are exposed to background water fluoridation.
62833693|NCT05512156|NO_INTERVENTION|Control Group|All children in the control arm of the study will be receiving TAU which is awareness sessions in the school about importance of the daily brushing, healthy diet and demonstrating how to brush correctly and efficiently. All children are exposed to background water fluoridation.
62833694|NCT04277338|EXPERIMENTAL|The tested injected doses of 99mTc-HE3-G3 1000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 1000 μg.~Subjects withdrawn from the study for any reason will be replaced."
62833695|NCT04277338|EXPERIMENTAL|The tested injected doses of 99mTc-HE3-G3 2000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 2000 μg.~Subjects withdrawn from the study for any reason will be replaced."
62833696|NCT04277338|EXPERIMENTAL|The tested injected doses of 99mTc-HE3-G3 3000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 3000 μg.~Subjects withdrawn from the study for any reason will be replaced."
62833697|NCT04243720||Immune Resistance Interrogation Study (IRIS)|Patients with a histological or cytological diagnosis of solid malignancies. Patients must have progressed on immunotherapy as their most recent line of therapy.
62833698|NCT03533049|EXPERIMENTAL|myFAMI intervention|"All participants will receive the standard discharge education from their transplant and inpatient care team.~Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge."
62833699|NCT03533049|ACTIVE_COMPARATOR|Control|Family members assigned to the control group (standard care) will receive standard post-discharge follow-up care consisting of discharge education during the transplant hospitalization and at regularly scheduled appointments instructing families to contact the research nurse with problems or questions.
62051087|NCT06103825|PLACEBO_COMPARATOR|matching Placebo|
62051088|NCT02612064|EXPERIMENTAL|Stannous Fluoride dentifice|Participants will apply (under supervision) a pea-sized dose of experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm) to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted
62833700|NCT00651690|EXPERIMENTAL|1|Botulinum Toxin Type A
62611011|NCT05869110|EXPERIMENTAL|Experimental Intervention|Olfactory stimulation
62611012|NCT05869110|PLACEBO_COMPARATOR|Placebo|Propylene glycol
62611013|NCT06444828|NO_INTERVENTION|non operative treatment|Proximal humeral fractures (PHF) treated non-operative, Rehabilitation only
62833701|NCT00651690|PLACEBO_COMPARATOR|2|Saline
62611014|NCT06444828|ACTIVE_COMPARATOR|Reverse Shoulder Arthroplasty (RSA)|RSA 135/ 155 inclination
62833702|NCT06128759|EXPERIMENTAL|Maryam's Flower Group|Maryam's flower will place in a bowl of water and left in the room of the pregnant women who will at 1 cm cervical dilatation and in the first phase of the labor. It will explain to the pregnant women that the leaves of the plant would open up in the water, and they will ask to imagine that the birth canal would simultaneously open up. In effect, they will told to focus on the opening of these leaves during the course of the labor.. After birth, the flower used only as a focusing method will be removed from the water and its water will be poured.
62051089|NCT02612064|OTHER|Sodium Monofluorophosphate dentifrice|Participants will apply (under supervision) a pea-sized dose of dentifrice containing Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted.
62051090|NCT03688061|EXPERIMENTAL|Group 1 (low dose/healthy volunteers)|5 healthy volunteers receiving 1 dose ChAd3-hliNSmut (5x10\*9 vp) IM at week 0 and 1 dose of MVA-hliNSmut (5 X10\*7 pfu) IM at week 8
62051091|NCT03688061|EXPERIMENTAL|Group 2 (higher dose/healthy volunteers)|10 healthy volunteers receiving 1 dose ChAd3-hliNSmut (2.5 x10\*10 vp) IM at week 0 and 1 dose of MVA-hliNSmut (2 X 10\*8 pfu) IM at week 8
62051092|NCT03688061|EXPERIMENTAL|Group 3 (higher dose/HCV cured volunteers)|10 DAA treated volunteers (previously HCV positive) receiving 1 dose ChAd3-hliNSmut (2.5 x10\*10 vp) IM at week 0 and 1 dose of MVA-hliNSmut (2 X10\*8 pfu) IM at week 8
62051093|NCT02013492|EXPERIMENTAL|Treatment (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO BID for 4 months in the absence of disease progression or unacceptable toxicity. Propranolol will be administered on an out-patient basis. Blood for correlative studies (30 ml - green top tube) will be drawn at baseline and at each clinic visit. Tumor tissue for analysis will be obtained via core needle biopsy (or other appropriate modality) pre-study and at approximately the two month time point.
62051094|NCT00663325|EXPERIMENTAL|1|Lactic acid in small quantity during 21 days
62051095|NCT01800773|EXPERIMENTAL|Written Exposure Therapy|Written exposure treatment is a 5 session treatment in which participants write about their trauma event in a specified manner.
62051096|NCT01800773|ACTIVE_COMPARATOR|Cognitive Processing Therapy|cognitive processing therapy will be included as the evidence-based treatment for PTSD in this study.
62051097|NCT05421338|EXPERIMENTAL|BI 456906 (C-14)|
62051098|NCT05786222|EXPERIMENTAL|Cluster 1|"Buildings randomized to Cluster 1 will receive the CSH-delivered intervention at Months 2-7. Tenant surveys will be administered 1 month prior to and 12 months following the start of the intervention period.~At all clusters, an all-staff survey will be administered at Months 1, 8, 15, 22, and 29. A sustainment survey will be administered to selected staff-leaders in the 8th month following the end of the intervention period."
62051099|NCT05786222|EXPERIMENTAL|Cluster 2|"Buildings randomized to Cluster 2 will receive the CSH-delivered intervention at Months 9-14. Tenant surveys will be administered 1 month prior to and 12 months following the start of the intervention period.~At all clusters, an all-staff survey will be administered at Months 1, 8, 15, 22, and 29. A sustainment survey will be administered to selected staff-leaders in the 8th month following the end of the intervention period."
62833703|NCT06128759|NO_INTERVENTION|control group|will provided with standard midwifery care.
62833704|NCT03421483|ACTIVE_COMPARATOR|Folic Acid supplementation|Participants receive an adult multivitamin supplement along with a folic acid supplement
62833705|NCT03421483|PLACEBO_COMPARATOR|No supplementation|Participants only receive an adult multivitamin supplement
62051100|NCT05786222|EXPERIMENTAL|Cluster 3|"Buildings randomized to Cluster 3 will receive the CSH-delivered intervention at Months 16-21. Tenant surveys will be administered 1 month prior to and 12 months following the start of the intervention period.~At all clusters, an all-staff survey will be administered at Months 1, 8, 15, 22, and 29. A sustainment survey will be administered to selected staff-leaders in the 8th month following the end of the intervention period."
62051101|NCT05786222|EXPERIMENTAL|Cluster 4|"Buildings randomized to Cluster 3 will receive the CSH-delivered intervention at Months 23-28. Tenant surveys will be administered 1 month prior to and 12 months following the start of the intervention period.~At all clusters, an all-staff survey will be administered at Months 1, 8, 15, 22, and 29. A sustainment survey will be administered to selected staff-leaders in the 8th month following the end of the intervention period."
62252286|NCT03700580|ACTIVE_COMPARATOR|Hydrogel treatment|It refers to the standard treatment currently applied for foot ulcers at the Health Center where the study was conducted. The intervention was applied to the cohort, three times a week during 16 weeks or when the wound attained full epithelization. The wound bed was cleaned with physiological serum before application of Hydrogel.
62252287|NCT03700580|EXPERIMENTAL|P1G10 treatment|It refers to the experimental parallel intervention consisting of three weekly applications of 0.1% P1G10 dispersed in the hydrosoluble vehicle during a 16-week period, or until full epithelization of the wound. The wound bed was cleaned with physiological serum before application of the drug.
62833706|NCT05267613|ACTIVE_COMPARATOR|Nexium - high dose|Arm 1 (High dose = Healing dose)
62833707|NCT05267613|ACTIVE_COMPARATOR|Nexium - Low dose|Arm 2 (Low dose = ½ healing dose)
62252288|NCT01083524|EXPERIMENTAL|Group 1|Dichloroacetate Sodium 3.0 mg/kg, BID
62833708|NCT02765750|EXPERIMENTAL|BIS 40-60|Patient with intraoperative Bispectral Index (BIS) 40-60.
62833709|NCT02765750|EXPERIMENTAL|BIS 20-40|Patient with intraoperative Bispectral Index (BIS) 20-40.
62833710|NCT02765750|PLACEBO_COMPARATOR|Placebo|Placebo group
62833711|NCT06492642|EXPERIMENTAL|Patient Education for Chronic Low Back Pain|Patients will access online patient education materials on chronic low back pain five times after completing baseline questionnaires on days 5, 8, 11, 14, and 17.
62833712|NCT01001325|EXPERIMENTAL|Seasonal influenza vaccination|Receipt of Fluviral seasonal (2009-2010, Canadian) influenza vaccination as per manufacturers specification
62833713|NCT01001325|PLACEBO_COMPARATOR|Placebo|0.5 mL normal saline
62833714|NCT06322628|EXPERIMENTAL|VSA006 low dose|
62833715|NCT06322628|PLACEBO_COMPARATOR|VSA006 low dose comparator|
62833716|NCT06322628|EXPERIMENTAL|VSA006 high dose|
62833717|NCT06322628|PLACEBO_COMPARATOR|VSA006 high dose comparator|
62833718|NCT06096467|EXPERIMENTAL|Comprehension exercise training combined with protein supplementation (CET+PS)|CET+PS: the comprehension exercise training combined with protein supplementation
62833719|NCT06096467|PLACEBO_COMPARATOR|Comprehension exercise training combined with placebo milk (CET+PC)|CET+PC: the comprehension exercise training combined with placebo milk
62833720|NCT04126005||Cohort 1 (Age < 18 Months)|"* Motor function assessments (remote or in-clinic) every 2 months~* Clinic assessments every 6 months"
62833721|NCT04126005||Cohort 2 (Age ≥ 18 Months - 3 Years)|"* Motor function assessments (remote or in-clinic) every 4 months~* Clinic assessments every 6 months"
62833722|NCT04126005||Cohort 3 (Age > 3 - 5 Years)|"* Motor function assessments (remote or in-clinic) every 6 months~* Clinic assessments every 6 months"
62833723|NCT04126005||Cohort 4 (Age > 5 Years)|"* Motor function assessments (remote or in-clinic) 12 months~* Clinic assessments every 12 months"
62051102|NCT05399745||Children with biliary atresia|
62833724|NCT04126005||Cohort 5 (Deceased)|• The patient's medical history records will be reviewed. In addition, a parent interview will be performed.
62833725|NCT04554680|EXPERIMENTAL|Treatment Group|Patients with progressive, metastatic or locally advanced, unresectable radioiodine (RAI)-refractory thyroid cancer of follicular cell origin with mutation involving MAPK signalling pathway, including BRAFV600E mutation or RAS mutation.
62833726|NCT00823017|EXPERIMENTAL|1|Patient-preferred music
62833727|NCT00823017|EXPERIMENTAL|2|Relaxation Music
62051103|NCT05399745||Children with Tetralogy of Fallot|
62051104|NCT05399745||Healthy control children|
62051105|NCT05700188||Resectable|Patients with resectable pancreatic cancer
62051106|NCT05700188||Borderline resectable|Patients with borderline resectable pancreatic cancer
62051107|NCT05700188||Locally advanced|Patients with locally advanced unresectable pancreatic cancer
62252289|NCT01083524|EXPERIMENTAL|Group 2|Dichloroacetate Sodium 6.25 mg/kg, BID
62252290|NCT01083524|EXPERIMENTAL|Group 3|Dichloroacetate Sodium 12.5 mg po bid
62441747|NCT01405820|EXPERIMENTAL|Natalizumab 150 mg SC Every 12 Weeks|Natalizumab 150 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
62441748|NCT00252187|ACTIVE_COMPARATOR|B-type Natriuretic Peptide (BNP)|BNP (nesiritide) administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
62441749|NCT00252187|PLACEBO_COMPARATOR|Placebo|Placebo self-administered subcutaneously twice daily for 8 weeks.
62441750|NCT06316583|EXPERIMENTAL|dry-needling trigger points treatment (TrP-DN)|Firstly, use pressure techniques to diagnose trigger points on the rectus abdominis and oblique muscles, which typically present as distinct tender points and palpable muscle tension bands. Deep pressure on these points may induce referred pain. Procedure: Begin by disinfecting the treatment sites. Use a traditional acupuncture needle (0.35×50mm) to repeatedly stimulate the designated point until muscle soreness and localized twitching are felt. If participants experience lower back pain, trigger points on the back can also be targeted, located bilaterally from the twelfth thoracic vertebra to the third lumbar vertebra
62441751|NCT06316583|EXPERIMENTAL|acupuncture group|Acupuncturists use acupuncture point needling for treating PD, focusing primarily on key acupoints from the Foot Taiyin Spleen Meridian, Conception Vessel, Foot Taiyang Bladder Meridian, Foot Yangming Stomach Meridian, and Foot Shaoyin Kidney Meridian. Commonly selected points include Taichong, Xuehai, Zusanli, Yanglingquan, Guanyuan, Uterus, and Sanyinjiao. After routine disinfection, a #32 fine needle is quickly inserted and retained for 30 minutes per session
62441752|NCT06316583|SHAM_COMPARATOR|placebo control group|Subjects undergo the same diagnostic and therapeutic procedures as the TrP-DN group but using a 'sham' needling technique. The sham needling is administered by the same expert as the real needling, with retention time and treatment frequency matching those of the genuine needling group. A retractable sham needle apparatus is used without piercing the skin.
62441753|NCT02959775|EXPERIMENTAL|60 µg dose hepatitis B vaccine|Receive three intramuscular injections of 60 µg recombinant hepatitis B vaccine at months 0, 1 and 6
62441754|NCT02959775|EXPERIMENTAL|20 µg dose hepatitis B vaccine|Receive three intramuscular injections of 20 µg recombinant hepatitis B vaccine at months 0, 1 and 6
62441755|NCT02959775|NO_INTERVENTION|Control|Receive no vaccination during the study period
62833728|NCT00823017|PLACEBO_COMPARATOR|3|Standard of Care
62252291|NCT03621865|EXPERIMENTAL|subject sequence 1|subject allocation sequence 1. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
62441756|NCT00112489|EXPERIMENTAL|Taxol-Carbo|Paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC = 6 IV over 30 minutes every 21 days until disease progression or adverse effects prohibit further therapy
62833729|NCT01980537|EXPERIMENTAL|Stereotaxis|Magnetic wire navigation
62833730|NCT01980537|ACTIVE_COMPARATOR|Conventional|Conventional wire navigation
62833731|NCT01715740|EXPERIMENTAL|Chinese herbal medicine (CHM)|Subject in CHM group will receive CHM capsules, 8 capsules (4 gm) four times a day, total 16 gm a day, combined with levocetiricine 1PC once a day for 1 month.
62833732|NCT01715740|PLACEBO_COMPARATOR|Control|Subjects in control group will receive the placebo capsules, which has the similar look, smell and taste. The dosage, frequency and duration are the same as CHM group, in which 8 placebo capsule (4gm) 4 times a day, total 16 gm a day, combined with levocetiricine 1PC once a day, for 1 month.
62051108|NCT05700188||Metastatic|Patients with metastatic pancreatic cancer
62051109|NCT02719990|EXPERIMENTAL|Somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly in adult participants with GHD
62051110|NCT00948298|PLACEBO_COMPARATOR|Placebo|
62051111|NCT00948298|EXPERIMENTAL|Vitamin D|
62051112|NCT04972448||Group1|Chemotherapy+endocrine therapy+radiotherapy
62051113|NCT04972448||Group2|Chemotherapy+endocrine therapy
62051114|NCT04972448||Group3|endocrine therapy+radiotherapy
62051115|NCT04972448||Group4|endocrine therapy
62051116|NCT05995314|PLACEBO_COMPARATOR|PLACEBO|placebo (0 mg/kg of body mass of caffeine). The capsule will be filled with 3 mg/kg of body mass of cellulose.
62051117|NCT05995314|EXPERIMENTAL|3mg/kg|3 mg/kg of body mass of caffeine (99% caffeine, Bulkpowders, United Kingdom).
62051118|NCT05995314|EXPERIMENTAL|6mg/kg|6 mg/kg of body mass of caffeine (99% caffeine, Bulkpowders, United Kingdom).
62051119|NCT05295966|EXPERIMENTAL|Intervention Group|Subjects in the intervention group will perform 20 sessions of multisensory training
62051120|NCT05295966|ACTIVE_COMPARATOR|Control Group|Subjects in the Control Group will not perform 20 sessions of multisensory training and they will keep doing the current therapy
62252292|NCT03621865|EXPERIMENTAL|subject sequence 2|subject allocation sequence 2. IIntervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
62051121|NCT01843543|EXPERIMENTAL|MBSR participants|Subjects in this arm will participate in an 8 week Mindfulness Based Stress Reduction Course
62051122|NCT01843543|NO_INTERVENTION|No MBSR Participants|Subjects in this arm will not participate in the Mindfulness Based Stress Reduction Course.
62051123|NCT05887505|EXPERIMENTAL|Vitamin D group|Oral supplementation of 1,728,000 IU vitamin D3 in 3 days
62051124|NCT05887505|PLACEBO_COMPARATOR|Placebo Group|Oral supplementation of placebo in 3 days
62051125|NCT05030402|EXPERIMENTAL|Maitland group|31 patients receives tens, SW, Maitland, and exercises. An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
62611015|NCT03004924|EXPERIMENTAL|SHP640|Participants will instill 1 drop of SHP640 (povidone-iodine \[PVP-I\] 0.6 percent \[%\] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) for 7 days.
62051126|NCT05030402|ACTIVE_COMPARATOR|Control group|32 receives tens, SW, conventional physiotherapy and exercises as treatment. An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
62051127|NCT04849286|EXPERIMENTAL|Group 1|10 mg dose, CSF sample 2 hours post-dose
62051128|NCT04849286|EXPERIMENTAL|Group 2|10 mg dose, CSF sample 6 hours post-dose
62611016|NCT03004924|ACTIVE_COMPARATOR|PVP-I 0.6%|Participants will instill 1 drop of PVP-I 0.6% ophthalmic solution in each eye 4 times QID for 7 days
62051129|NCT04849286|EXPERIMENTAL|Group 3|20 mg dose, CSF sample 2 hours post-dose
62441757|NCT04009330||Adults in the Intensive Care Setting|Adults in the Intensive Care Setting
62611017|NCT03004924|PLACEBO_COMPARATOR|Placebo|Participants will instill 1 drop of placebo ophthalmic solution in each eye 4 times QID for 7 days.
62611018|NCT04302740|ACTIVE_COMPARATOR|LEAP|Housing First plus LEAP
62611019|NCT04302740|NO_INTERVENTION|Service-As-Usual|Housing First
62833733|NCT00624598|EXPERIMENTAL|SMART Group|The experimental group will have a nutrition program based solely on measured resting metabolic rate. The nutrition plan will be a specific calorie level that will promote a 1-2.5 lb per week weight reduction. No experimental participants' nutrition plan will be below 1200 Kcal/day for women or 1600 Kcal/day for men. Second, the experimental group will receive a downloadable copy of a computerized nutrition software program (BalanceLog: Microlife USA, Inc. Golden, CO) that functions s on a Windows 2000-XP or Palm operating system.
62833734|NCT00624598|ACTIVE_COMPARATOR|Usual Care|Standard 1200 kcal/day diet (women) 1600 kcal/day diet (men) using a sample 3-day menu program. The diet will be follow current government based recommendations for carbohydrates (i.e. 55%), fat (30%), and protein (15%). Study participants will receive a standard paper-based food and exercise journal
62833735|NCT05556837|PLACEBO_COMPARATOR|Control Cereal|A portion of cereal (25g available carbohydrate) that contains no beta-glucan
62833736|NCT05556837|EXPERIMENTAL|OBG Cereal|A portion of cereal (25g available carbohydrate) that contains approximately 1.4g of oat beta-glucan (OBG)
62833737|NCT05556837|EXPERIMENTAL|BBG Cereal|A portion of cereal (25g available carbohydrate) that contains approximately 1.4g of barley beta-glucan (BBG)
62833738|NCT05342077|EXPERIMENTAL|Virtual Reality-Reward Training (VR-RT)|7 sessions of positive VR immersion and positive memory specificity training exercises designed to savor rewarding features of immersion followed by memory specificity training exercises to savor rewarding features of autobiographical memory.
62833739|NCT05342077|ACTIVE_COMPARATOR|Virtual Reality-Memory Training (VR-MT)|7 sessions of neutral VR immersion and neutral memory specificity training exercises, designed to train memory of objective non-emotional stimuli followed by memory exercises to neutral autobiographical memories.
62833740|NCT03610269|EXPERIMENTAL|INVSENSOR00026|All enrolled subjects receive INVSENSOR00026 Pulse CO-Oximeter and sensor for the noninvasive measurement of hemoglobin (SpHb).
62833741|NCT05033782||MS patients|"This group includes patients living in Ile de France, followed in the neurology department of the Pitié Salpêtrière Hospital in Paris for relapsing-remitting MS.~Clinical examination will be performed to evaluate the disability (EDSS scale), as part of the care (systematic for all MS consultations)~- A paper questionnaire is given to the patient during the consultation. The patient will be contacted by telephone within 15 days after the consultation by a health care staff to collect the answers to the questionnaire."
62051130|NCT04849286|EXPERIMENTAL|Group 4|20 mg dose, CSF sample 6 hours post-dose
62051131|NCT03128424|EXPERIMENTAL|PQ Bypass Stent Graft System|The PQ Bypass™ Stent Graft System is intended for patients with atherosclerotic lesions of the SFA
62051132|NCT02489786|ACTIVE_COMPARATOR|Regimen 1|patient takes 0.25mg of digoxin daily except friday
62051133|NCT02489786|ACTIVE_COMPARATOR|Regimen 2|patient takes 0.25mg of digoxin daily except Thursday and Friday
62051134|NCT02489786|ACTIVE_COMPARATOR|Regimen 3|patient takes 0.125mg of digoxin daily
62051135|NCT02489786|ACTIVE_COMPARATOR|Regimen 4|digoxin dose is calculated using Jusko-Koup method and given daily
62441758|NCT03662386||Patients with suspicion of hereditary retinal dystrophy|
62441759|NCT04083014|EXPERIMENTAL|study group|The treatment regimen is a single dose anti-CD20 antibody injection (500mg iv drip，day0) combined with bortezomib injection (1.3mg/m2 subcutaneous injection，twice a week for two weeks，day1，4，8，11). The treatment course will be repeated three months later.
62051136|NCT02787707|ACTIVE_COMPARATOR|intervention|2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour from 24 hour before to fifth day after chemotherapy.
62051137|NCT02787707|PLACEBO_COMPARATOR|control|2.7 grams Lactose every 8 hour from 24 hour before to fifth day after chemotherapy.
62051138|NCT04209478|EXPERIMENTAL|TAP Block|Cases were assessed transversus abdominis plane block for postoperative analgesia
62051139|NCT04209478|EXPERIMENTAL|QL Block|Cases were assessed quadratus lumborum block for postoperative analgesia
62611020|NCT02371564|ACTIVE_COMPARATOR|High flow humidified oxygen first|High flow humidified oxygen then standard oxygenotherapy with a two-hour non invasive ventilation session in between.
62611021|NCT02371564|ACTIVE_COMPARATOR|Standard oxygen therapy first|Standard oxygenotherapy then high flow humidified oxygen with a two-hour non invasive ventilation session in between.
62051140|NCT01904864|ACTIVE_COMPARATOR|NovaFerrum®|Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks.
62051141|NCT01904864|ACTIVE_COMPARATOR|Ferrous Sulfate|Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, ferrous sulfate, for 12 weeks.
62833742|NCT00967070|EXPERIMENTAL|Both Treatments Applied on Lower Back|Treatments were applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
62051142|NCT00560612|ACTIVE_COMPARATOR|Paroxetine|Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
62252293|NCT03621865|EXPERIMENTAL|subject sequence 3|subject allocation sequence 3. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
62252294|NCT03621865|EXPERIMENTAL|subject sequence 4|subject allocation sequence 4. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
62252295|NCT03621865|EXPERIMENTAL|subject sequence 5|subject allocation sequence 5. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
62252296|NCT03621865|EXPERIMENTAL|subject sequence 6|subject allocation sequence 6. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
62252297|NCT03621865|EXPERIMENTAL|subject sequence 7|subject allocation sequence 7. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
62252298|NCT03621865|EXPERIMENTAL|subject sequence 8|subject allocation sequence 8. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
62833743|NCT02885701|EXPERIMENTAL|No splint|
62252299|NCT03621865|EXPERIMENTAL|subject sequence 9|subject allocation sequence 9. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
62252300|NCT03621865|EXPERIMENTAL|subject sequence 10|subject allocation sequence 10. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
62252301|NCT03975101|EXPERIMENTAL|VSEL Max|A mean volume of 5.5 mL platelet-rich plasma containing approximately 120,000 cells were prepared and injected into the selected knee of the patient
62252302|NCT03975101|EXPERIMENTAL|VSEL Medium|A mean volume of 5.5 mL platelet-rich plasma containing approximately 90,000 cells were prepared and injected into the selected knee of the patient
62252303|NCT03975101|EXPERIMENTAL|VSEL Mini|A mean volume of 5.5 mL platelet-rich plasma containing approximately 60,000 cells were prepared and injected into the selected knee of the patient
62252304|NCT03975101|NO_INTERVENTION|Control|A mean volume of 5.5 mL platelet-rich plasma containing no VSELs injected into the selected knee of the patient
62252305|NCT05273476|EXPERIMENTAL|strip|apically repositioned flap+ xenogeneic collagen matrix +free gingival graft
62252306|NCT01898897|ACTIVE_COMPARATOR|robot general anesthesia|"General anesthesia for robot assisted laparoscopic urogenital surgery includes premedication with alprazolam (0.5 mg per os), induction with sufentanil, propofol (1-2 mg/kg), neuromuscular blocking agents (rocuronium 0.5 mg/kg) to facilitate tracheal intubation. Anesthesia is maintained with volatile agents (sevoflurane, desflurane) and reinjection of rocuronium and sufentanil as needed.~Robotic assisted laparoscopic interventions are realised with Da Vinci surgical robot, known to assure a minimally invasive approach with good results in urologic surgery. The system consists of an ergonomic surgeon console, a patient cart with four interactive robotic arms, a 3D high resolution visualization interface and specific EndoWrist articulated tools."
62252307|NCT01898897|EXPERIMENTAL|robot combined anesthesia|Combined anesthesia is defined as association of epidural analgesia to general anesthesia. Epidural catheter is inserted at low thoracic level in the operation theatre before the induction of anesthesia. Correct position is verified with 15 mg bupivacaine plain 0.5%. Infusion is started after the incision at a rate of 6-8 ml/ hour.Epidural continuous infusion of local anesthetic is maintained 12 hours postoperative in the postoperative anesthesia care unit.
62252308|NCT02418780|EXPERIMENTAL|Tai Chi|6-month Tai Chi training program combined with usual medical care
62833744|NCT02885701|EXPERIMENTAL|Removable Splint|
62833745|NCT02885701|EXPERIMENTAL|Non-removable Splint|
62051143|NCT00560612|PLACEBO_COMPARATOR|Placebo|
62051144|NCT00992667|EXPERIMENTAL|Asthmatics|Ten nonsmoking patients, suffering from mild bronchial asthma participated in the study (mean age 30±9 years, 5 men, 5 women). Asthma was diagnosed based on GINA 2008 criteria. The patients were free of any medication, at least 7 days before, and had not suffered from any infectious diseases including upper respiratory tract infections for at least 3 months prior to the study. Patients who did not meet these criteria were excluded from the study.
62051145|NCT05179967|EXPERIMENTAL|WeFlow-JAAA Stent Graft System|
62051146|NCT04069325|EXPERIMENTAL|simiaowan 6g + febuxostat 40mg|
62051147|NCT04069325|PLACEBO_COMPARATOR|placebo 6g + febuxostat 40mg|
62252309|NCT02418780|NO_INTERVENTION|Usual Care|Waitlist control group receiving usual medical care alone
62252310|NCT00382239|EXPERIMENTAL|Exenatide 5 mcg/exenatide 10 mcg|
62252311|NCT00382239|EXPERIMENTAL|Exenatide 5 mcg/exenatide 5 mcg|
62252312|NCT00382239|EXPERIMENTAL|Exenatide 2.5 mcg/exenatide 2.5 mcg|
62252313|NCT00382239|PLACEBO_COMPARATOR|Placebo/placebo|
62833746|NCT05079308|EXPERIMENTAL|Filtering face piece with peripheral sealing device|Individuals using the Filtering face Piece (FFP2) with the Peripheral Sealing Device (AMS).
62833747|NCT05079308|ACTIVE_COMPARATOR|Filtering face piece without peripheral sealing device|Individuals using the Filtering face Piece (FFP2) without the AMS;
62051148|NCT04107831|EXPERIMENTAL|Pulmonary rehabilitation|Participants who are participating in a 6-week pulmonary rehabilitation program are enrolled in the study.
62833748|NCT05079308|EXPERIMENTAL|IIR surgical mask with peripheral sealing device|Individuals using the Surgical mask (SM) with the AMS;
62051149|NCT02077764||Controls, healthy individuals|controls
62611022|NCT05228886|ACTIVE_COMPARATOR|Call + Resources|Participants receive standard care typically provided to 211 callers, including ad hoc follow-up.
62833749|NCT05079308|ACTIVE_COMPARATOR|IIR surgical mask without peripheral sealing device|Individuals using the Surgical mask (SM) without the AMS;
62833750|NCT05079308|EXPERIMENTAL|Filtering face piece with IIR surgical mask|individuals using a FFP2 with a SM over it, simultaneously, without the AMS.
62833751|NCT01724099|EXPERIMENTAL|Euiiyin-tang|powder type, 3 times per day before the meal, 12 weeks total
62833752|NCT01724099|PLACEBO_COMPARATOR|Placebo|powder type, 3 times per day before the meal, 12 weeks total
62833753|NCT06176079||Part 1 (Cohort A): No injection of hyperpolarized (HP) 13C|Participants who are comprised of, primarily, healthy volunteers will undergo a standard MRI scan.
62833754|NCT06176079||"Part 1 (Cohort B): Injection of hyperpolarized (HP) 13C or HP13C-pyruvate+HP13C-urea copol"|"Participants will receive HP 13C injection, and receive an MRI scan. Imaging results will be used to optimize the hyperpolarized 13C part of the imaging procedure. Participants will also have the option of undergoing repeated dose imaging studies of HP 13C-pyruvate or HP13C-pyruvate+HP13C-urea copol, (up to a total of two injections per imaging visit separated by 15-60 minutes). Participants may be asked to fast up to 6 hours prior to the scan and the initial HP 13C MRI scan may be taken while participants are in a fasted state. Participants who have fasted will be offered up to 20 ounces (oz) of an oral glucose, fructose, or other high calorie drink (i.e. Gatorade, Coca-Cola, Ensure, etc.) to increase blood glucose levels, and a second HP 13C MRI scan will be performed after caloric intake."
62833755|NCT06176079||Part 2 (Group 1): NAFLD|"Participants with diagnosed NAFLD will receive HP 13C-pyruvate or HP13C-pyruvate+HP13C-urea copol injection optimized in Part 1 of the study as well as standard liver MRI pulse sequences."
62833756|NCT06176079||Part 2 (Group 2): NASH|"Participants with diagnosed NASH will receive HP 13C-pyruvate or HP13C-pyruvate+HP13C-urea copol injection optimized in Part 1 of the study as well as standard liver MRI pulse sequences."
62833757|NCT06176079||Part 2 (Group 3): Healthy Volunteers|"Healthy volunteers without known liver disease will receive HP 13C-pyruvate or HP13C-pyruvate+HP13C-urea copol injection optimized in Part 1 of the study as well as standard liver MRI pulse sequences."
62833758|NCT01369888|EXPERIMENTAL|IL-15 following Young TIL (0.25 mcg)|0.25 mcg/kg/day x 10
62833759|NCT01369888|EXPERIMENTAL|IL-15 following Young TIL (0.50 mcg)|0.50 mcg/kg/day x 10
62833760|NCT01369888|EXPERIMENTAL|IL-15 Following Young TIL (1 mcg)|1 mcg/kg/day x 10
62833761|NCT01369888|EXPERIMENTAL|IL-15 Following Young TIL (2 mcg)|2 mcg/kg/day x 10
62833762|NCT02989597|EXPERIMENTAL|Intra-operative Methadone Hydrochloride|Patient who will be given a single dose of intra-operative methadone, and having standard care otherwise
62833763|NCT02989597|ACTIVE_COMPARATOR|Control|Patients administered standard of care
62833764|NCT04489836|EXPERIMENTAL|Meal A + Glutalytic®|350 mg Glutalytic® capsule, taken by mouth, once, with Meal A
62833765|NCT04489836|EXPERIMENTAL|Meal A + DE111®|350 mg DE111® capsule, taken by mouth, once, with Meal A
62833766|NCT01448980|ACTIVE_COMPARATOR|Physical therapy|The control group will receive physical therapy 2 time per week for 6 weeks
62833767|NCT01448980|EXPERIMENTAL|Thai Traditional Massage|The experimental group will receive Thai traditional massage program 2 times per week for 6 weeks.
62833768|NCT06194331|EXPERIMENTAL|iCHART/cASAP|"An intervention previously studied in the ETUDES Center along with a computerized version of our As Safe As Possible intervention.~1. Safety Planning App for suicidal youth which enables a primary care provider to streamline the gold standard of care for those with current suicidality symptoms through an app;~2. Mental Health Screener questionnaire that gathers additional mental health symptoms, treatment preferences, and family's readiness for treatment engagement to help a primary care provider make a personalized, tailored treatment plan a suicidal youth is more likely to adhere to;~3. Text Messages which aims to provide texts for 2-3 weeks to motivate you to engage with the safety plan and recommended treatment following the patient visit.~4. cASAP is a computerized version of the As Safe As Possible intervention that offers self-led modules with psychoeducation about safety planning, cognitive-behavioral skills to cope with distress, and facilitate collaboration with parents."
62051150|NCT02077764||Heart transplanted patients|Patients
62051151|NCT05775588|EXPERIMENTAL|Lung volume reduction surgery group|
62051152|NCT01005342|EXPERIMENTAL|Mixture of fiber|Single intake of a mixture of spray-dried oat drink, rye bran and sugar beet fiber
62051153|NCT01005342|EXPERIMENTAL|Sugar beet fiber|Single intake of sugar beet fiber
62051154|NCT01005342|EXPERIMENTAL|Rye bran|Single intake of rye bran
62051155|NCT01005342|EXPERIMENTAL|Oat bran|Single intake of oat bran
62051156|NCT01005342|EXPERIMENTAL|Spray-dried oat drink|Single intake of spray-dried oat drink
62051157|NCT01005342|PLACEBO_COMPARATOR|Control|Single intake of a meal with no added fiber
62051158|NCT05797064||Training set|The training set is a dataset used to train the model, which includes randomly enrolled patients with colon and rectal cancer. The inputs include data such as gender, age, height, weight, BMI, tumor stage, tumor pathology type, and the output information is whether NOSES surgery was successful or not. During training, the model learns from this dataset to make predictions on whether new patients with colon and rectal cancer can undergo NOSES surgery successfully.
62611023|NCT05228886|EXPERIMENTAL|Call + Resources + Scheduled Follow-Up|Participants receive standard care typically provided to 211 callers plus scheduled follow-up calls according to the Scheduled Follow-Up intervention description.
62833769|NCT06194331|ACTIVE_COMPARATOR|Treatment as usual|When patients disclose suicidal ideation on the PHQ-9, a treatment as usual approach will be given to the patient and their parent by the pediatrician which includes a paper safety plan will be completed and given to the patient and a referral placed for the patient to begin behavioral health services.
62833770|NCT04396418|EXPERIMENTAL|Intervention arm|A 16-week blended learning programme targeting stroke prevention and rhythm control therapy at the healthcare professional level, with controlled assessments, a commitment to change plan, and reinforcement actions
62833771|NCT04396418|OTHER|Control arm|No added education of healthcare professionals
62833772|NCT01592357|EXPERIMENTAL|Tai Chi|
62833773|NCT01592357|SHAM_COMPARATOR|Sham Exercise|
62833774|NCT02683577|EXPERIMENTAL|Telotristat etiprate 500 mg|1 single oral dose (2 x 250-mg tablets)
62833775|NCT04441892|EXPERIMENTAL|QTc Meter|Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device
62833776|NCT04441892|EXPERIMENTAL|QTc Meter - Healthy Controls|Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device.
62051159|NCT05797064||test set|The test set is a dataset used to evaluate the performance of a trained machine learning model. It includes another randomly enrolled group of patients with colon and rectal cancer, as well as their clinical and pathological data and surgical outcomes. The outputs are not used during training, but are used to test the trained model to evaluate its predictive ability on unknown data. The purpose is to evaluate the model's generalization ability, that is, its performance on new and unknown data.
62441760|NCT02753400|EXPERIMENTAL|Emixustat hydrochloride|"Week 1- Four tablets (2 placebo, 2 emixustat HCl Strength A)~Week 2- Four tablets (2 placebo, 2 emixustat HCl Strength B)~Week 3- Four tablets (2 placebo, 2 emixustat HCl Strength C)~Week 4- Four emixustat HCl tablets (Strength C)~All tablets are administered orally once daily. After week 4, all subjects will be held at a stable dose for the remainder of the 12-week dosing regimen."
62441761|NCT02753400|PLACEBO_COMPARATOR|Placebo|Four placebo tablets are administered orally once daily for 12 weeks; Subjects in the placebo group will be mock-titrated on the same schedule as those in the active arm.
62833777|NCT06120985|ACTIVE_COMPARATOR|Treatment|Households randomized to the treatment group will be provided countertop pitcher water filters
62051160|NCT00018434||Group 1|
62051161|NCT04471155|ACTIVE_COMPARATOR|Holep|patient underwent laser prostatectomy
62051162|NCT04471155|ACTIVE_COMPARATOR|open prostatectomy|patient underwent open prostatectomy
62441762|NCT05484375|EXPERIMENTAL|Capecitabine plus toripalimab maintenance therapy|capecitabine and toripalimab were used as maintenance therapy every 3 weeks until toxicity was unacceptable, disease progression, consent withdrawal, or withdrawal was determined by the investigator, or a maximum of 2 years of treatment had been reached.
62441763|NCT02786498|EXPERIMENTAL|High Loading Dose|150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.
62441764|NCT02786498|EXPERIMENTAL|High Daily Dose|Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.
62441765|NCT02786498|EXPERIMENTAL|Low Daily Dose|Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.
62441766|NCT02786498|PLACEBO_COMPARATOR|Control Group|Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.
62051163|NCT00742092|EXPERIMENTAL|1|miglustat
62051164|NCT00742092|PLACEBO_COMPARATOR|2|placebo
62051165|NCT05362565||Patient with salivary sampling|
62252314|NCT00807326|EXPERIMENTAL|Loperamide/simeticone Caplets|Drug (including placebo)
62441767|NCT04577274|EXPERIMENTAL|smoothie with regular formulas (SM)|Participants were given 300 kcal smoothie with regular formulas within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
62441768|NCT04577274|EXPERIMENTAL|smoothie with low carbohydrate formulas (SMLS)|Participants were given 300 kcal smoothie with low carbohydrate formulas within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
62441769|NCT04577274|ACTIVE_COMPARATOR|conventional diabetic enteral drinks (Glucerna)|Participants were given 300 kcal Glucerna within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
62441770|NCT00627718|OTHER|A|All patients with possible neovascular ARMD are assessed with HRT to determined the positive predictive value of the test
62441771|NCT04014998|EXPERIMENTAL|Virtual Reality|Virtual Reality + Exercise
62441772|NCT04014998|OTHER|Exercise|Exercise Only
62441773|NCT05057156|EXPERIMENTAL|"application supervised by a psychologist via teleconsultations"|patient have app, and teleconsultation with psychologist
62441774|NCT05057156|PLACEBO_COMPARATOR|"application in total autonomy"|patients have app, they play when they want
62833778|NCT06120985|NO_INTERVENTION|Control|Households randomized to the control group will be provided water filters at the completion of the study
62833779|NCT00720915|OTHER|No Anticoagulant Therapy|No Anticoagulant Therapy
62833780|NCT00720915|OTHER|Anticoagulant Therapy|Continue on anticoagulant therapy
62833781|NCT02266888|EXPERIMENTAL|Rituximab Induction|Rituximab (Rituxan®) Induction Therapy Plus Standard of Care Immunosuppression (thymoglobulin induction, tacrolimus or equivalent, mycophenolate mofetil (MMF) or equivalent, and steroids)
62833782|NCT02266888|PLACEBO_COMPARATOR|Placebo Induction|Placebo Induction Therapy Plus Standard of Care Immunosuppression (Thymoglobulin® induction, tacrolimus or equivalent, mycophenolate mofetil (MMF) or equivalent, and steroids)
62252315|NCT00807326|ACTIVE_COMPARATOR|Loperamide/simeticone Chewable Tablets|Drug (including placebo)
62441775|NCT05057156|NO_INTERVENTION|"control group without using the application"|patients haven't app
62441776|NCT02786199||Hepatocellular carcinoma|patients HCC who are going to receive surgical resection
62833783|NCT05134428|EXPERIMENTAL|ADAM Cohort 1|The first 5 subjects will be reviewed for safety by a Data Safety Monitoring Board (DSMB) at 30 days post-implantation. The 5 subjects will then be followed up to 24 months or until their semen analyses is ≥ 15 million sperm/mL.
62833784|NCT05134428|EXPERIMENTAL|ADAM Cohort 2|An additional 13 subjects will be enrolled and implanted with ADAM. They will be followed up to 24 months or until or until their semen analyses is ≥ 15 million sperm/mL.
62833785|NCT05134428|EXPERIMENTAL|ADAM Cohort 3|An additional 4 subjects will be enrolled and implanted with ADAM. They will be followed up to 24 months or until or until their semen analyses is ≥ 15 million sperm/mL.
62833786|NCT05134428|EXPERIMENTAL|ADAM Cohort 4|An additional 3 subjects will be enrolled and implanted with ADAM. They will be followed up to 24 months or until or until their semen analyses is ≥ 15 million sperm/mL.
62833787|NCT03127007|EXPERIMENTAL|Arm A|"Protracted IV 5-FU 225 mg/m2 is given from day 1 to 5 in parallel with radiotherapy 1.8 to 2 Gy from day 1 to 5 during 5 consecutive weeks.~Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV. Rectal surgery is planned during week 15"
62833788|NCT03127007|ACTIVE_COMPARATOR|Arm B|"Protracted IV 5-FU 225 mg/m2 is given from day 1 to 5 in parallel with radiotherapy 1.8 to 2 Gy from day 1 to 5 during 5 consecutive weeks.~Rectal surgery is planned during week 15"
62833789|NCT02444767|EXPERIMENTAL|13mg Bimatoprost Insert|Subjects in this arm have 13mg Bimatoprost Ocular Inserts placed in both eyes for 7 days.
62833790|NCT03603353|EXPERIMENTAL|Intervention group|
62252316|NCT00807326|ACTIVE_COMPARATOR|Probiotic Capsules|Drug (including placebo)
62252317|NCT04357873|EXPERIMENTAL|pembrolizumab + vorinostat|"Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations~Vorinostat: 400 mg once daily, until progression"
62252318|NCT02991742||Iodixanol|Iodixanol contrast media
62252319|NCT02991742||Ioxaglate|Ioxaglate contrast media
62252320|NCT02241382|ACTIVE_COMPARATOR|External Electrocardioversion|"Cardioversion with an external cardioverter-defibrillator with a step-up energy protocol (100, 150, 200, 360 J biphasic) in antero-posterior orientation, maintaining a \> 8 cm distance between shock electrodes and device and complying with a cool-down phase of 2 minute between shocks, if more than one shock is required."
62833791|NCT03603353|ACTIVE_COMPARATOR|Control group|
62833792|NCT06591078|EXPERIMENTAL|experimental group|"1.Carrilizumab for injection; 200mg; Q14d; 2.Apatinib; 250mg Qd or Bid or chemotherapy; 3.electropuncture; 4/Q28d.~Use up to 2 years/ patient disease progression(about 1 year)/ unacceptable toxic effects, use of prohibited therapies (such as antitumor therapy other than chemotherapy and beva or non-palliative radiotherapy)/ investigator's decision to discontinue the regimen/ or patient's withdrawal of consent treatment may be discontinued. If a patient with a confirmed complete response has received at least eight cycles of immunotherapy, including at least two cycles beyond a complete response, treatment will be discontinued."
62252321|NCT02241382|EXPERIMENTAL|Internal Electrocardioversion|Cardioversion via the implanted ICD with a maximum energy synchronized shock (41 J, with a RV -\> SVC+can shock orientation in pts with SVC leads). After 1 ineffective internal shock, the patient will be counted as internal CV failure and cardioverted externally, following the same protocol as the external CV group.
62252322|NCT04211636||Complete SCI, AIS A|Patients with complete spinal cord injury (AIS A)
62252323|NCT04211636||Incomplete SCI, AIS B, C, D|Patients with incomplete spinal cord injury (AIS B, C, D)
62252324|NCT04211636||Vertebral injuries without SCI|Patients with vertebral injuries without spinal cord injury (control)
62441777|NCT01694615|ACTIVE_COMPARATOR|Cryoprobe biopsy|All patients enrolled will undergo standard forceps biopsies followed by cryoprobe biopsies and results will be compared
62441778|NCT01694615|ACTIVE_COMPARATOR|Forceps Biopsy|All patients enrolled will undergo standard forceps biopsies followed by cryoprobe biopsies and results will be compared
62611024|NCT05228886|EXPERIMENTAL|Call + Resources + SINCERE|Participants receive standard care typically provided to 211 callers plus scheduled follow-up calls according to the SINCERE intervention description (scheduled follow up with active collaborative goal setting).
62611025|NCT04616001|EXPERIMENTAL|IVIG|IVIG 0.5gram/kg IVPB using actual body weight daily x 4 days
62611026|NCT00701480|EXPERIMENTAL|1|skin cleanser contained Hibiscus sabdariffa
62051166|NCT04186013|EXPERIMENTAL|Experimental arm|Atezolizumab 1200 mg intravenous infusion every 3 weeks for a total of 6 doses combined with External Beam Radiation Therapy (EBRT) (dosage: 60 Gy in 30 fractions overs 6 weeks at 2Gy/day)
62051167|NCT03227211||COPD exacerbated patients admitted|No specific intervention
62051168|NCT02546934|EXPERIMENTAL|ABX, cisplatin|AP (ABX and cisplatin combination)
62051169|NCT02546934|ACTIVE_COMPARATOR|Gemcitabine, Cisplatin|GP (Gemcitabine and Cisplatin combination)
62051170|NCT05374954|EXPERIMENTAL|A1：one dose, 18-59 years old, from 3 months to 6 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive one dose from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
62051171|NCT05374954|ACTIVE_COMPARATOR|A2：one dose, 18-59 years old, from 3 months to 6 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive one dose from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
62051172|NCT05374954|EXPERIMENTAL|A3：one dose, 18-59 years old, from 6 months to 12 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive one dose from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
62051173|NCT05374954|ACTIVE_COMPARATOR|A4：one dose, 18-59 years old, from 6 months to 12 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive one dose from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
62252325|NCT02267603|EXPERIMENTAL|Treatment (pembrolizumab)|"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression\* or unacceptable toxicity.~\* NOTE: Patients with confirmed disease progression may continue to receive treatment if they are otherwise clinically stable until there is an increase in tumor burden of 25% or more following initial confirmation of progression. Under exceptional circumstances, and with protocol P.I. and CITN P.I. approval, patients may receive treatment beyond 2 years."
62252326|NCT01366261|EXPERIMENTAL|semirigid thoracoscopy|Semirigid instrument which we compare was autoclavable Olympus LTF-160 (Olympus Tokyo, Japan). Handle and its controls were similar to flexible fiberoptic bronchoscope, with the insertion portion composed of 22 cm long rigid part and distal 5 cm flexible tip with angulation range 1600 up / 1300 down. The external diameter of insertion portion was 7 mm with 2,8 mm inner channel diameter. The instrument was compatible with Olympus EVIS Exera 160 and 145 and EVIS 100 and 140 video processors and light sources, otherwise employed in video-bronchoscopy. Forceps, which we used was flexible FB-55CD-1 Olympus forceps with 5 mm long cusps and diameter, which fitted the diameter of inner channel of semirigid thoracoscope.
62252327|NCT01366261|ACTIVE_COMPARATOR|rigid thoracoscopy|The rigid instrument was autoclavable OP EndoEYE WA50120A (Olympus Tokyo, Japan) video thoracoscope. The length of the instrument was 29 cm with 00 direction of view and 700 field of view. The external diameter of the instrument was 10 mm with 5,2 mm inner channel diameter. The instrument was compatible with Olympus Visera OTV-S7V and EVIS Exera II CV-180 video processors. Cusps of rigid forceps had outer diameter 5 mm and length 10 mm.
62252328|NCT04572880|ACTIVE_COMPARATOR|Trabeculectomy|
62252329|NCT04572880|ACTIVE_COMPARATOR|XEN®|
62441779|NCT03819933|OTHER|Pregnant women and their partners|"For the qualitative arm of this mixed method study, using an exploratory sequential design, investigators will enroll \~ 30 adult pregnant women admitted estimated 22 0/7-25 6/7 weeks' estimated gestation and their partners to participate in a post-counseling semi-structured interview to explore preferred language and approaches, and better inform questionnaire development. Sample size will be up to 30 families, or until thematic saturation is achieved (total up to 60 if all partners agree to participate).~For the quantitative arm of this study, investigators will enroll \~100 adult pregnant women admitted between estimated 22 0/7-25 6/7 weeks' estimated gestation and their partners (up to total \~200 if all partners present and agree to participate)."
62441780|NCT03819933|OTHER|Counseling MFM and Neonatology providers|Investigators will enroll \~100 counseling Maternal-Fetal Medicine (MFM) specialists and 100 counseling Neonatologists (total \~200 providers), who provided counseling to the enrolled pregnant women between 22 0/7-25 6/7 weeks' estimated gestation for anticipated extremely preterm delivery. This assumes 1 counseling provider from MFM and 1 from Neonatology per pregnant woman, although there could be more if a consult is performed by both an attending physician and a training fellow or practitioner, or less, if a counseling provider declines to participate in the study. There will be anticipated repetition of counseling providers, accounted for in the statistical analysis. Providers will be asked to complete educational interventions to improve counseling at extreme prematurity.
62051174|NCT05374954|EXPERIMENTAL|B1：one dose, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive one dose from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
62051175|NCT05374954|ACTIVE_COMPARATOR|B2：one dose, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive one dose from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
62252330|NCT04572880|ACTIVE_COMPARATOR|Preserflo®|
62252331|NCT03437564|EXPERIMENTAL|Vortioxetine one 20 mg tablet + two 10 mg tablets|Vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 2 in a fasted state.
62252332|NCT03437564|EXPERIMENTAL|Vortioxetine two 10 mg tablets + one 20 mg tablet|Vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 2 in a fasted state.
62441781|NCT04984850|EXPERIMENTAL|Intervention plus usual care|
62441782|NCT04984850|NO_INTERVENTION|Usual care only|
62611027|NCT00701480|ACTIVE_COMPARATOR|2|marketed skin cleanser
62611028|NCT05989776|NO_INTERVENTION|Usual care|Usual care information to fertility preservation counseling
62623549|NCT02814383||ELBW Infants|This study seeks to collect data on premature ELBW infants (less than or equal to 2.2 lbs) at high risk of developing brain injury.
62611029|NCT05989776|ACTIVE_COMPARATOR|Intervention: informational brochure for patients and brief training for oncologists|The intervention is based on information provided to different target populations, using a variety of media, including brochures and videos.
62833793|NCT06591078|NO_INTERVENTION|control group|1.Carrilizumab for injection; 200mg; Q14d; 2.Apatinib; 250mg Qd or Bid or chemotherapy; Use up to 2 years/ patient disease progression(about 1 year)/ unacceptable toxic effects, use of prohibited therapies (such as antitumor therapy other than chemotherapy and beva or non-palliative radiotherapy)/ investigator's decision to discontinue the regimen/ or patient's withdrawal of consent treatment may be discontinued. If a patient with a confirmed complete response has received at least eight cycles of immunotherapy, including at least two cycles beyond a complete response, treatment will be discontinued.
62611030|NCT03513900||cirrhosis|In this cross-sectional study , we will collect all patients with cirrhosis who meet the inclusion and exclusion criteria criteria coming to The Second Affiliated Hospital, Xi'an Jiaotong University since March 2018 to December 2018.
62611031|NCT04698174|EXPERIMENTAL|Transepithelial Photorefractive keratectomy (tPRK) without laser polishing|
62611032|NCT04698174|EXPERIMENTAL|Transepithelial Photorefractive keratectomy (tPRK) with laser polishing|
62611033|NCT04698174|ACTIVE_COMPARATOR|Standard Photorefractive keratectomy (PRK)|
62611034|NCT00190372|OTHER|A|
62611035|NCT06730165|ACTIVE_COMPARATOR|Transcutaneous Auricular Vagus Nerve Stimulation|Transcutaneous vagus nerve stimulation through the tragus and concha in the ear, Frequency: 25 Hertz, Duration: 20 minutes
62252333|NCT03584828|EXPERIMENTAL|Tele-Rehabilitation - intervention|Following the standard rehabilitation intake process the subjects in the Tele-rehaab arm will receive physiologic consultation based on clinical stress tests and clinical data passed from the physician. The Tele-rehab arm will receive an exercise prescription and execution will be assessed and periodically adjusted in accordance to data received from the wearable device. Intensity and type of exercise will be moderate and will comply with exercise recommendations provided by ESC guidelines. A dedicated application will be installed on the mobile phone for patients in the research group and they will receive a smart sports watch.
62611036|NCT06730165|ACTIVE_COMPARATOR|Transcutaneous Auricular Trigeminal Nerve Stimulation|Transcutaneous auricular trigeminal nerve stimulation, Frequency: 25 Hertz, Duration: 20 minutes
62611037|NCT06730165|SHAM_COMPARATOR|Sham Transcutaneous Auricular Vagus Nerve Stimulation|Sham Transcutaneous Auricular Vagus Nerve Stimulation, The device is switched on but the current intensity is off, Duration: 20 minutes
62611038|NCT06730165|SHAM_COMPARATOR|Sham Transcutaneous Auricular Trigeminal Nerve Stimulation|Sham Transcutaneous Auricular Trigeminal Nerve Stimulation, The device is switched on but the current intensity is off, Duration: 20 minutes
62611039|NCT00312572|EXPERIMENTAL|BTDS10/20|Initial doses (Level 1) of BTDS 10. Subjects were allowed to have their doses adjusted to BTDS 20 (Level 2) on or after day 4.
62611040|NCT00312572|EXPERIMENTAL|BTDS 20|Initial doses (Level 1) of BTDS 20.
62611041|NCT05039801|EXPERIMENTAL|Part A (IACS-6274)|Patients receive IACS-6274 PO throughout the study.
62611042|NCT05039801|EXPERIMENTAL|Part B (IACS-6274, bevacizumab, paclitaxel)|Patients receive IACS-6274 PO, paclitaxel IV, and bevacizumab IV throughout the study.
62611043|NCT05039801|EXPERIMENTAL|PART C: (IACS-6274) with capivasertib|Patients receive IACS-627 PO, with capivasertib PO throughout the study.
62611044|NCT06436833|EXPERIMENTAL|2-Liter polyethylene glycol plus elobixibat|Take Elobixibat 10 mg, one day before colonoscopy at 8 a.m. Take Polyethylene glycol 1 Liter, one day before colonoscopy at 8 p.m. Take polyethylene glycol 1 Liter, at day of colonoscopy at 5 a.m.
62833794|NCT03891108|ACTIVE_COMPARATOR|Treatment A: BMS-986231 Formulation A|Participants will be administered Treatment A: BMS-986231 Formulation A as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
62833795|NCT03891108|EXPERIMENTAL|Treatment B: BMS-986231 Formulation B|Participants will be administered Treatment B: BMS-986231 Formulation B as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
62833796|NCT03891108|EXPERIMENTAL|Treatment C: BMS-986231 Formulation C|Participants will be administered Treatment C: BMS-986231 Formulation C as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
62833797|NCT03891108|EXPERIMENTAL|Treatment D: BMS 986231 Formulation D|Participants will be administered Treatment D: BMS 986231 Formulation D as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
62611045|NCT06436833|ACTIVE_COMPARATOR|4-Liter polyethylene glycol|Take Polyethylene glycol 2 Liter, one day before colonoscopy at 8 p.m. Take polyethylene glycol 2 Liter, at day of colonoscopy at 5 a.m.
62833798|NCT01193244|EXPERIMENTAL|Orteronel + prednisone|
62833799|NCT01193244|PLACEBO_COMPARATOR|Placebo + prednisone|
62833800|NCT00614432||1|Women who are anticoagulated.
62833801|NCT00614432||2|Matched case controls.
62833802|NCT03486834|EXPERIMENTAL|V160 3-Dose Regimen|Participants received 3 doses of vaccine V160 (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant \[MAPA\], 4°C stable formulation) administered by intramuscular (IM) injection on Day 1, Month 2, and Month 6.
62833803|NCT03486834|EXPERIMENTAL|V160 2-Dose Regimen|Participants received 2 doses of vaccine V160 (100 Units/0.5 mL dose with MAPA, 4°C stable formulation) administered IM on Day 1 and Month 6 and a placebo-saline solution at Month 2.
62833804|NCT03486834|PLACEBO_COMPARATOR|Placebo|Participants received placebo (saline solution) by IM injection on Day 1, Month 2, and Month 6.
62833805|NCT03189004|ACTIVE_COMPARATOR|Identification and registration of pregnant women and servic|Pregnant women will receive auto reminder through their mobile for ANC visit prior to their scheduled date for each visit via voice message followed by text message. The schedule visit date will be calculated by the system automatically from the LMP. The reminder will include the date, time, available facilities and services for ANC, and will be sent to the women several times to ensure their ANC visits. The system will also send auto reminder through text message to the concerned service provider to check whether the pregnant woman has received ANC or not. The service provider will provide and update the ANC services and status of the particular pregnant woman. Apart from ANC reminders, the pregnant women will also receive voice message on healthcare during pregnancy, danger signs and birth preparedness.From the LMP, the expected date of delivery (EDD) will be calculated by the system and reminder will be sent to the pregnant women automatically.
62611046|NCT00618241|EXPERIMENTAL|A|"Group A: day 1-5 Raltegravir 400 mg oral BD (twice daily). Lamotrigine one oral dose 100 mg on day 4. Wash-out 6-31. Followed by one oral dose Lamotrigine 100 mg on day 34.~5 days Raltegravir 400 mg oral BD. Lamotrigine one oral dose 100mg on day 34."
62611047|NCT00618241|ACTIVE_COMPARATOR|B|"Group B: day 4 Lamotrigine one oral dose on day 4. Wash-out day 6-28 followed by Raltegravir 400 mg oral BD day 29-33. One dose Lamotrigine 100 mg oral on day 32.~One dose Lamotrigine 100 mg oral."
62611048|NCT01069315|EXPERIMENTAL|Normal saline and High pressure|Irrigation with normal saline delivered at high pressure
62611049|NCT01069315|EXPERIMENTAL|Soap solution and High pressure|Irrigation with soap solution delivered at high pressure
62611050|NCT01069315|EXPERIMENTAL|Normal saline and Low pressure|Irrigation with saline solution delivered at low pressure
62611051|NCT01069315|EXPERIMENTAL|Soap solution and Low pressure|Irrigation with soap solution delivered at low pressure
62611052|NCT05156645|EXPERIMENTAL|SCTA01 and SCTA01C+SOC|
62611053|NCT05156645|PLACEBO_COMPARATOR|Placebo+SOC|
62833806|NCT03189004|ACTIVE_COMPARATOR|Birth notification|The pregnant women will be encouraged and trained to notify immediately after the delivery through SMS by themselves or by anyone on behalf of the delivered women. After receiving birth notification, system will automatically update the particulars of newborns including date of birth, PNC schedule, EPI vaccination due dates for the newborn and location of service centre. The system will also send auto reminder to the mothers with a specific time schedule for PNC visit, newborn care visit and schedule of receiving vaccines for the newborn.
62252334|NCT03584828|NO_INTERVENTION|Usual care|The usual care arm will receive general recommendations for a healthy and active lifestyle and community cardiologist and primary care physician according to local guidelines.
62441783|NCT05014386|ACTIVE_COMPARATOR|Ahmed Glaucoma Valve Implantation|A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.
62441784|NCT05014386|ACTIVE_COMPARATOR|Ologen augmentation group|In addition to what is planned for the other Arm;, a round 12 × 1 mm circular Ologen disc will be placed over the FP7 or FP8 AGV-plate immediately before conjunctival closure.
62441785|NCT01876862|EXPERIMENTAL|STOP ART|"Antiretroviral treatment interruption in 3 successive groups of 5 patients.~Zero-risk strategy If after 8 weeks of treatment interruption, at least 1 patient from group 1 does not present any of the failure criteria, patients from group 2 will be included and their treatment interrupted. If after 8 weeks of treatment interruption, at least 2 patients from groups 1 and 2 do not present any failure criteria, patients from group 3 will be included and their treatment interrupted."
62441786|NCT03810833|EXPERIMENTAL|Participants with Brilliance sensor placement|Brilliance device sensors placed on the left and right pectoralis major, remaining for 48 hours
62441787|NCT06344442|EXPERIMENTAL|Arginine vasopressin|low-dose arginine-vasopressin supplementation group: Vasopressin will be administered by continuous infusion. AVP will be used to a final concentration of 0.12 U/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that AVP doses ranged from 0.01 to 0.06 U/min
62441788|NCT06344442|ACTIVE_COMPARATOR|Norepinephrine|Norepinephrine will be administered by continuous infusion. Norepinephrine will be used with final concentrations of 120 microg/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that NE doses ranged from10 to 60 microg/min.
62441789|NCT01759381|NO_INTERVENTION|No Negative Pressure Wound Therapy Device|This control group will not receive the negative pressure wound therapy device. Post operative dressings will be per the surgeon's standard routine.
62611054|NCT04154514|EXPERIMENTAL|Delivering FES to stroke survivors|"In stroke survivors, normal and abnormal muscle synergies will also be determined from their walk EMGs. Our proposed FES intervention involves delivering stimulations to muscles with waveforms generated from the activations of all the normal synergies not observed in each stroke survivor. We are going to employ the wearable to deliver personalized muscle-synergy-based FES stimulations to multiple groups of leg muscles on the stroke-affected side of elderly chronic stroke survivors as they walk on a treadmill/overground for gait rehabilitation. We hypothesized that the subject will essentially be walking with his/her abnormal muscle pattern superimposed with the artificially introduced normal muscle pattern coming from FES."
62611055|NCT04154514|EXPERIMENTAL|Delivery no current FES to stroke survivors (Sham group)|In stroke survivors, normal and abnormal muscle synergies will also be determined from their walk EMGs. Our proposed FES intervention involves delivering stimulations to muscles with waveforms generated from the activations of all the normal synergies not observed in each stroke survivor. Additionally, we are going to introduce a sham group. We are going to employ the wearable to multiple groups of leg muscles on the stroke-affected side of elderly chronic stroke survivors without any stimulation as they walk on a treadmill or overground for gait rehabilitation. The purpose of the sham group is to empirically validate the effectiveness of the FES wearable.
62611056|NCT02722837|EXPERIMENTAL|SOF/VEL|SOF/VEL for 12 weeks
62611057|NCT03623971|EXPERIMENTAL|Artificial Intelligence|A universal diagnostic system. An artificial intelligence to make comprehensive evaluation and treatment decision of cataract.
62623550|NCT04862975||Drug of Interest|Lactating moms receiving one or more antiretroviral drugs and their breastmilk fed infants per standard of care.
62051176|NCT05374954|EXPERIMENTAL|B3：one dose, 18-59 years old, from 6 months to 12 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive one dose from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
62051177|NCT05374954|ACTIVE_COMPARATOR|B4：one dose, 18-59 years old, from 6 months to 12 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive one dose from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
62051178|NCT05374954|EXPERIMENTAL|C1：two doses, 18-59 years old, from 3 months to 6 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
62051179|NCT05374954|ACTIVE_COMPARATOR|C2：two doses, 18-59 years old, from 3 months to 6 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
62051180|NCT05374954|EXPERIMENTAL|C3：two doses, 18-59 years old, from 6 months to 12 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
62051181|NCT05374954|ACTIVE_COMPARATOR|C4：two doses, 18-59 years old, from 6 months to 12 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
62051182|NCT05374954|EXPERIMENTAL|C5：two doses, 18-59 years old, more than 12 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart more than 12 months after 2 doses of inactivated COVID-19 vaccine
62051183|NCT05374954|ACTIVE_COMPARATOR|C6：two doses, 18-59 years old, more than 12 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart more than 12 months after 2 doses of inactivated COVID-19 vaccine
62051184|NCT05374954|EXPERIMENTAL|D1：two doses, 60 years old and above, from 3 months to 6 months after 2 doses of vaccination|subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
62051185|NCT05374954|ACTIVE_COMPARATOR|D2：two doses, 60 years old and above, from 3 months to 6 months after 2 doses of vaccination|subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
62051186|NCT05374954|EXPERIMENTAL|D3：two doses, 60 years old and above, from 6 months to 12 months after 2 doses of vaccination|subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
62051187|NCT05374954|ACTIVE_COMPARATOR|D4：two doses, 60 years old and above, from 6 months to 12 months after 2 doses of vaccination|subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
62051188|NCT05374954|EXPERIMENTAL|E1：two doses, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
62051189|NCT05374954|ACTIVE_COMPARATOR|E2：two doses, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
62051190|NCT05374954|EXPERIMENTAL|E3：two doses, 18-59 years old, from 6 months to 12 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
62441790|NCT01759381|EXPERIMENTAL|NPWT Arm Therapy|This group will receive NPWT as opposed to the standard incisional dressing following complex spinal surgery.
62833807|NCT03189004|ACTIVE_COMPARATOR|Childhood vaccination services under EPI|After the outcome of the delivery of the registered pregnant women, the system will receive the birth notification as mentioned in the birth notification process. Mothers/caregivers of the newborn will receive auto voice/text messages one day prior to their visit to the vaccination centres. A second reminder will be sent to the parents of all the targeted children through their own phones or their family's numbers collected earlier on the vaccination day at the beginning of the vaccination session for bringing their children for vaccination. A third reminder will be sent to the mothers/caregivers of the children who were not vaccinated after receiving the second reminder as scheduled on that day. The system will also provide auto reminder to the concerned service provider including EPI session wise list of targeted children. The service providers will update the status of vaccination of session using their Smartphone
62441791|NCT05480397|EXPERIMENTAL|• Group (1) will receive (TENS , cryotherapy and conventional physical therapy program).|
62611058|NCT00934856|EXPERIMENTAL|MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (over 2 days)|Participants with human epidermal growth factor receptor 2 (HER2)-positive MBC will receive docetaxel (Doc) 75 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Day 1 and T-DM1 2.4 milligrams per kilogram (mg/kg) IV infusion on Day 2 of Cycle 1 followed by T-DM1 75 mg/m\^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 75 mg/m\^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
62611059|NCT00934856|EXPERIMENTAL|MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (over 2 days)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m\^2 IV infusion on Day 1 and T-DM1 2.4 mg/kg IV infusion on Day 2 of Cycle 1 followed by T-DM1 60 mg/m\^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m\^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
62611060|NCT00934856|EXPERIMENTAL|MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (same day)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m\^2 IV infusion and T-DM1 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m\^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
62833808|NCT03189004|ACTIVE_COMPARATOR|Newly married couple identification|The Smartphones will contain specific software for newly married couple registration where some necessary information (names of newly married couple, age, address, LMP, current contraceptive use, future fertility plan and mobile phone number) can be updated and sent to the server. A unique ID number will be automatically created. This unique ID will ensure her to get necessary family planning services within the study area. Based on the information gathered through couple registration process, the system will automatically generate the most suitable family planning options for a couple and send the information to the concerned service providers. The service provider will motivate the client for the most suitable FP method option generated by the system and after taking the consent they provide the method accordingly.
62051191|NCT05374954|ACTIVE_COMPARATOR|E4：two doses, 18-59 years old, from 6 months to 12 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
62051192|NCT05374954|EXPERIMENTAL|E5：two doses, 18-59 years old, more than 12 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart more than 12 months after 3 doses of inactivated COVID-19 vaccine
62441792|NCT05480397|EXPERIMENTAL|•Group (2) receive (distractive techniques , cryotherapy and conventional physical therapy)|
62051193|NCT05374954|ACTIVE_COMPARATOR|E6：two doses, 18-59 years old, more than 12 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart more than 12 months after 3 doses of inactivated COVID-19 vaccine
62441793|NCT05480397|EXPERIMENTAL|• Group (3) will receive (cryotherapy and conventional physical therapy program).|
62441794|NCT06527911||Mako robot assisted TKA|Patients with osteoarthritis (OA) who underwent Mako robot-assisted TKA at the Chinese PLA General Hospital between September 2024 and September 2026.
62441795|NCT06527911||Manual TKA|Patients with OA who underwent manual TKA at the Chinese PLA General Hospital between September 2024 and September 2026.
62441796|NCT04110795||Cases|Atypical Femur fracture cases
62441797|NCT04110795||Control|matched to AFF cases by race, age, length of ART use
62051194|NCT05374954|EXPERIMENTAL|F1：two doses, 60 years old and above, from 3 months to 6 months after 3 doses of vaccination|subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
62441798|NCT01508585|ACTIVE_COMPARATOR|Pre-Op CBT|This group will receive CBT (Telephone Based Cognitive Behavioral Therapy) before bariatric surgery
62441799|NCT01508585|ACTIVE_COMPARATOR|Post-Op CBT|This group will receive CBT (Telephone Based Cognitive Behavioral Therapy) after bariatric surgery
62441800|NCT02733237|EXPERIMENTAL|male oxytocin group|male subjects with oxytocin treatment
62441801|NCT02733237|EXPERIMENTAL|female oxytocin group|female subjects with oxytocin treatment
62441802|NCT02733237|PLACEBO_COMPARATOR|male placebo group|male subjects with placebo treatment
62441803|NCT02733237|PLACEBO_COMPARATOR|female placebo group|female subjects with placebo treatment
62833809|NCT03189004|ACTIVE_COMPARATOR|e-Referral|There will be online referral system for the registered women and their children for ANC, PNC, delivery care, neonatal management, IMCI and other complication management in which healthcare providers from lower facilities can refer a patient to the higher facilities. The women will be identified in the higher facilities by their unique ID. The service providers will enter referral data to the system during the referral process and the patients and providers from higher facilities will get system generated reminders about the referral. The service providers in higher facilities will be able to check the health status and cause of referral using patient's unique ID number from the system and will manage accordingly as well as update the given management to the system. If the referred woman does not visit the referral facility, she will receive repeated reminders auto-generated by the system to comply the referral
62611061|NCT00934856|EXPERIMENTAL|MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (same day)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m\^2 IV infusion and T-DM1 3.6 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m\^2 will be stopped and T-DM1 3.6 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
62833810|NCT03189004|ACTIVE_COMPARATOR|e-monitoring|There will be web based monitoring system to oversee the progress and status of all the activities under this study for policy makers, programme peoples and other supervisors from national to the union levels. All these data will be available in the central database which will be visualized and accessible at all concerned levels through internet in particular website. They can constantly follow up the progression and healthcare delivery system of the respective area and provide regular feedback, when necessary. There will be provision of auto-generation of reports for each and every activity through the system by area and service provider specific.
62833811|NCT02097264|EXPERIMENTAL|NNC0109-0012|
62051195|NCT05374954|ACTIVE_COMPARATOR|F2：two doses, 60 years old and above, from 3 months to 6 months after 3 doses of vaccination|subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
62051196|NCT05374954|EXPERIMENTAL|F3：two doses, 60 years old and above, from 6 months to 12 months after 3 doses of vaccination|subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
62051197|NCT05374954|ACTIVE_COMPARATOR|F4：two doses, 60 years old and above, from 6 months to 12 months after 3 doses of vaccination|subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
62051198|NCT01869790|EXPERIMENTAL|Meal challenge|Different fat types
62051199|NCT02686034|ACTIVE_COMPARATOR|gammaCore-S|Treatment of up to 5 migraine attacks with the Active gammaCore-S non-invasive vagus nerve stimulator device which delivers a mild electrical signal in the vicinity of the vagus nerve
62051200|NCT02686034|SHAM_COMPARATOR|gammaCore-S Sham|Treatment of up to 5 migraine attacks with the Sham gammaCore-S non-invasive vagus nerve stimulator device which delivers a mild electrical signal in the vicinity of the vagus nerve
62051201|NCT01633554||Chronic Hepatitis B Group|Patients with chronic hepatitis B
62051202|NCT01633554||Cirrhosis|Patients with liver cirrhosis
62051203|NCT01633554||Control Group|Control Group: Healthy Volunteers
62051204|NCT01639937||1|Subjects with palliated congenital heart disease including, but not limited to, d TGA, ccTGA, single ventricles, hypoplastic left heart syndrome and tricuspid atresia will be recruited
62833812|NCT02097264|ACTIVE_COMPARATOR|Adalimumab|
62051205|NCT04845048||Health care professionals between 18 and 59 years old|Health care professionals
62051206|NCT04845048||General population 75 years old or more|Elderly 75y plus
62051207|NCT04845048||General population 60 and 74 years old|Elderly between 60-74y
62051208|NCT04225533|EXPERIMENTAL|SP16|Patients will receive a single dose of SP16 0.2 mg/kg by subcutaneous injection
62051209|NCT02908308|ACTIVE_COMPARATOR|Normothermia|Standard care with early treatment of fever. Active temperature control with a device will be used if the patient develops a temperature greater than or equal 37.8°C.
62611062|NCT00934856|EXPERIMENTAL|LABC: T-DM1 + Doc (Doublet Regimen)|Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg IV infusion and docetaxel 60/75/100 mg/m\^2 IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.
62833813|NCT03155841|EXPERIMENTAL|Life Skills Coaching|Participants in the experimental arm will receive access to HIV prevention and life skills content, including opportunities for goal setting, a directory of local resources in their community, and the ability to discuss their goals with Youth Navigators through a video-chat function.
62051210|NCT02908308|EXPERIMENTAL|Hypothermia|Targeted temperature management to 33°C for up to 28h.
62252335|NCT04063241|NO_INTERVENTION|Parent: Pre-implementation|Parents in the pre-implementation group will receive standard care: verbal counseling by the doctor/nurse using text-based instructions they have prepared (not standardized).
62833814|NCT03155841|ACTIVE_COMPARATOR|Community Resources|Participants in the control arm will receive access to a directory of local resources in their community.
62611063|NCT00934856|EXPERIMENTAL|LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)|Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg Iv infusion, docetaxel 60/75 mg/m\^2 IV infusion, and pertuzumab 840 mg (for Cycle 1) or 420 mg (for remaining cycles) IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.
62611064|NCT05269589|SHAM_COMPARATOR|Thermoneutral|Participants will immerse their feet in a foot bath with water maintained at 36°C
62611065|NCT05269589|EXPERIMENTAL|Heat|Participants will immerse their feet in a foot bath with water maintained at 42°C
62611066|NCT05529316|EXPERIMENTAL|Part 1 Cohort A: Botensilimab|Participants refractory to PD-(L)1 therapy will receive botensilimab intravenously (IV).
62611067|NCT05529316|EXPERIMENTAL|Part 1 Cohort B: Botensilimab|Participants refractory to PD-(L)1 and anti-CTLA-4 therapies will receive botensilimab IV.
62833815|NCT03632473||clinically isolated syndrome (CIS)|"Multiple sclerosis (MS) with a clinically isolated syndrome (CIS) within six months of first clinical event.~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
62833816|NCT03632473||early relapsing-remitting late disease course (RRMS)|"MS with relapsing-remitting early disease course (RRMS) \</= 10 years, Expanded Disability Status Scale (EDSS) \</=3.5~EDSS:~1.0: No disability, minimal signs in 1 functional System (FS) 1.5: No disability, minimal signs in more than one FS 2.0: Minimal disability in one FS 2.5: Mild disability in one FS or minimal disability in two FS 3.0: Moderate disability in one FS, or mild disability in three or four FS. No impairment to Walking 3.5: Moderate disability in one FS and more than minimal disability in several others. No impairment to Walking.~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
62252336|NCT04063241|EXPERIMENTAL|Parent: Post-Implementation|Doctors and nurses will be able to customize the web-based disease-specific instructions with the research team's help. They will reference these instructions as they perform discharge counseling and will give parents a copy of the instructions to refer to at home.
62441804|NCT00685919|EXPERIMENTAL|Carbidopa then Placebo|Carbidopa 200 mg every 6 hours orally for 5 doses followed by Placebo every 6 hours for 5 doses
62441805|NCT00685919|EXPERIMENTAL|Placebo then Carbidopa|Placebo matching carbidopa given every 6 hours orally for 5 doses followed by Carbidopa
62441806|NCT03346395|EXPERIMENTAL|Problem solving based intervention|The problem solving based intervention contains a problem solving process and cooperation between the person on sick leave, his/her employer and health care professionals. The intervention consists of five steps: 1) Making an inventory of problems and/or opportunities related to return to work; 2) brainstorming about solutions; 3) writing down solutions, identifying the support needed to implement the solutions; 4) a three-party meeting with the person on sick leave, his/her employer and the rehabilitation coordinator; 5) evaluation of the action plan and implementation of solutions, relapse prevention. The intervention takes the form of two to five consultations. The first and fourth steps are key elements.
62441807|NCT03346395|ACTIVE_COMPARATOR|Care as usual|Medical treatment, or behavioral therapy or in combination. Meeting with a rehabilitation coordinator if that is a part or care as usual within primary health care.
62611068|NCT05529316|EXPERIMENTAL|Part 2 Cohort A: Botensilimab + Balstilimab|Participants refractory to PD-(L)1 will receive botensilimab IV in combination with balstilimab IV.
62611069|NCT05529316|EXPERIMENTAL|Part 2 Cohort B: Botensilimab + Balstilimab|Participants refractory to PD-(L)1 and CTLA-4 will receive botensilimab IV in combination with balstilimab IV.
62611070|NCT05641662|EXPERIMENTAL|Exergame group|"Patients will be introduced to the exergame and the exergame will be installed following a protocol either by the patients themselves or an instructor of the study.~Patients will be advised to exergame daily based on their activity monitor reading at baseline and based on their current activity level and preferences.~During the 3 months of active intervention patients will receive feedback on their activity level and data will also be shared with the coach who will use it to adapt the gaming advice. A clear exergaming goal will be set together by patient and coach. In the first month, they will receive weekly feedback on their performance based on the readings from the activity monitor and the reading from the exergame. In the rest of the active study team the frequency of the contact with the coach will be personalized."
62611071|NCT05641662|NO_INTERVENTION|Control group|Patients will receive a protocol-based activity advice (one time) from the HF team (nurse, cardiologist and/or physiotherapist) that corresponds to the intervention group in terms of time and effort. Participants in the control group are encouraged to decrease their sedentary behaviour to the same extent as the intervention group, and if possible be physical active 30 minutes for 5 days a week.
62051211|NCT03839342|EXPERIMENTAL|Binimetinib + Encorafenib|Binimetinib and encorafenib are administered orally on a twice daily or once daily schedule, respectively in 28-day cycles. Treatment will continue until it is discontinued due to unacceptable toxicity, clinical or radiological disease progression as per RECIST 1.1, investigator decision, and/or withdrawal of consent.
62051212|NCT00644202|EXPERIMENTAL|Group 1|Intervention Group
62611072|NCT06474650|EXPERIMENTAL|Fed condition|Period in which subjects receive a single oral dose of LPM3770164 sustained-release tablets in fed condition
62051213|NCT00644202|NO_INTERVENTION|Group 2|Usual Care Group
62051214|NCT06176599|EXPERIMENTAL|Shenxiao Yuning decoction|"* Diabetes education~  * control of blood glucose; ③Control blood lipids；~    * Control blood pressure； ⑤Other symptomatic treatment； ⑥Shenxiao Yuning decoction：Astragalus 30g, Radix Pseudostellariae 15g, Rehmannia glutinosa 15g, Rhodiola rosea 12g，Cimicifuga 15g，Cuttlebone 15g，Poria 15g，Cicada degeneration 9g，Rheum palmatum 6g.~Usage: Decoct by the Traditional Chinese Medicine Pharmacy of the First Affiliated Hospital of Shandong First Medical University. Put 14 doses of Chinese medicine into the decoction bag, then put it into the automatic decoction machine, add 8 L of water and soak for 30 minutes, follow the standard decoction process Decoct 28 bags of Chinese medicine liquid, each bag is 200ml. Take 200ml warmly half an hour after breakfast and dinner."
62051215|NCT06176599|ACTIVE_COMPARATOR|Symptomatic treatment|* Diabetes education: all study participants were given dietary guidance for diabetic nephropathy, low-fat, high-quality, low-protein diet, and restricted sodium intake; maintain emotional stability, quit smoking and alcohol, and exercise appropriately; ② control of blood glucose: all study participants routinely received hypoglycaemic treatment, hypoglycaemic measures are not limited (including oral hypoglycaemic drugs or insulin injection); (iii) Control of lipids: study participants with substandard lipids routinely receive lipid-lowering treatment; (iv) Control of blood pressure: those with blood pressure \&amp;gt;140/90 mmHg should be treated with antihypertensive drugs to control blood pressure, and antihypertensive measures are not limited (CCB class, ACEI or ARB class, α, β-blockers, diuretics, etc.); ⑤ Other symptomatic treatment.
62051216|NCT06395181|EXPERIMENTAL|Diet Group: Whole Food Plant Based Diet|Subjects with follow a whole food plant-based diet for 8 weeks.
62051217|NCT06395181|NO_INTERVENTION|Control Group: Usual Care|Subjects will not change their diet for 8 weeks.
62051218|NCT01730885|OTHER|BGStar|Comparision
62051219|NCT01044576||Multiple Sclerosis|Patients with relapsing-remitting or secondary progressive multiple sclerosis
62051220|NCT00546780|ACTIVE_COMPARATOR|Arm A|Tanespimycin + Bortezomib
62051221|NCT00546780|ACTIVE_COMPARATOR|Arm B|Bortezomib
62051222|NCT01103310|EXPERIMENTAL|Arm 1|Cancer patients, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, PET/CT
62051223|NCT01103310|EXPERIMENTAL|Arm 2|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY94-9392 in blood
62051224|NCT03546894||Brigatinib|The dosage and regimen of brigatinib (ALK inhibitors) will be decided by participant's prescribing physician and will not be determined by participation in the study.
62051225|NCT03546894||Any FDA Approved ALK Inhibitor Other Than Crizotinib|The dosage, regimen of any Food and Drug Administration (FDA) approved ALK inhibitor (at any point in therapy) other than crizotinib will be decided by participant's prescribing physician and will not be determined by participation in the study.
62051226|NCT04734548|ACTIVE_COMPARATOR|Phase Ib ApTOLL|ApTOLL is administered intravenously in a single ascending dose pattern in four dose levels (0.025mg/kg - 0.2mg/kg). All levels include six patients.
62051227|NCT04734548|PLACEBO_COMPARATOR|Phase Ib Placebo|Placebo is administered intravenously in a single ascending dose pattern in four dose levels (0.025mg/kg - 0.2mg/kg). All levels include two patients.
62051228|NCT04734548|ACTIVE_COMPARATOR|Phase IIa ApTOLL|ApTOLL is administered intravenously (two doses selected in Phase Ib). The two dose levels include 35 patients each one.
62051229|NCT04734548|PLACEBO_COMPARATOR|Phase IIa Placebo|Placebo is administered intravenously in one arm which includes 49 patients.
62051230|NCT06510582|EXPERIMENTAL|Phase 1 Unilateral cSDH/ 2mg/kg Arm|During phase 1, single 2mg/kg dose of bevacizumab to treat unilateral cSDH
62051231|NCT06510582|EXPERIMENTAL|Phase 1 Bilateral cSDH/ 4mg/kg Arm|During phase 1, two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH
62611073|NCT06474650|EXPERIMENTAL|Fasted condition|Period in which subjects receive a single oral dose of LPM3770164 sustained-release tablets in fasted condition
62611074|NCT01153620|PLACEBO_COMPARATOR|Ringer's Solution|
62611075|NCT01153620|ACTIVE_COMPARATOR|Lavasept 0.04%|
62051232|NCT06510582|EXPERIMENTAL|Phase 2 Unilateral cSDH/ 2mg/kg Arm|During phase 2, single 2mg/kg dose of bevacizumab to treat unilateral cSDH
62051233|NCT06510582|EXPERIMENTAL|Phase 2 Bilateral cSDH/ 4mg/kg Arm|During phase 2, two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH
62051234|NCT05278780|EXPERIMENTAL|Asynchronous screening|Participants will be screened for medication abortion eligibility using written or online materials and questionnaires, without a synchronous conversation between the prescribing clinician and the patient.
62051235|NCT04108000|EXPERIMENTAL|SPIRIT-Dementia|Patients and their surrogates randomized to this study arm will receive the SPIRIT-dementia intervention.
62623551|NCT05430477||Cohort 1 Biopsy|Subjects recruited to Cohort I will include patients who are scheduled to undergo oral lesion biopsy as well as patients who are determined to need a biopsy at the time of visual examination, which often occurs in-clinic. Cohort I will consist of 125 oral lesion biopsy patients total. Prior to the start of enrollment in this Cohort, up to 5 additional subjects will be enrolled to optimize the data acquisition process.
62051236|NCT04108000|ACTIVE_COMPARATOR|Usual Care|Patients and surrogates randomized to this study arm will receive the standard information about advance directives that is provided at the time of diagnosis.
62833817|NCT03632473||late relapsing-remitting late disease course (RRMS)|"MS with relapsing-remitting late disease course (late RRMS) of 5 to 15 years, EDSS: 2.0-5.5 inclusive~EDSS:~4.0: Significant disability but self-sufficient and up and about some 12 hours a day. Able to walk without aid or rest for 500m 4.5: Significant disability but up and about much of the day, able to work a full day, may otherwise have some limitation of full activity or require minimal assistance. Able to walk without aid or rest for 300m 5.0: Disability severe enough to impair full daily activities and ability to work a full day without special provisions. Able to walk without aid or rest for 200m 5.5: Disability severe enough to preclude full daily activities. Able to walk without aid or rest for 100m.~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
62051237|NCT05018884||Patients without SSI|Patients who underwent surgery and who developed a surgical site infection (SSI) during 30 days after surgery
62051238|NCT05018884||Patients with SSI|Patients who underwent surgery and who didn't develop a surgical site infection (SSI) during 30 days after surgery
62051239|NCT02137525|ACTIVE_COMPARATOR|Morphine 6 mg|Placebo Sublingual Spray (PSS) + Intravenous Morphine (IVM 6 mg), every 30 minutes for two hours as needed (or until rescue), maximum exposure morphine 30 mg
62051240|NCT02137525|EXPERIMENTAL|Fentanyl 100 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 100 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 500 µg
62051241|NCT02137525|EXPERIMENTAL|Fentanyl 200 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 200 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 1000 µg
62051242|NCT02137525|EXPERIMENTAL|Fentanyl 400 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 400 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 2000 µg
62051243|NCT01947465||Healthy controls|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 319 healthy controls will be enrolled and will receive hepatitis A and/or tetanus vaccination
62441808|NCT02362906|EXPERIMENTAL|Injection,medications and application|"Intravenous injection:~bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules; external application: Fu-xiong San."
62833818|NCT03632473||primary progressive disease course (PPMS)|"MS with a primary progressive disease course (PPMS) up to 15 years, EDSS: 2.0-6.5 inclusive~EDSS:~6.0: Requires a walking aid - cane, crutch, etc. - to walk about 100m with or without resting 6.5: Requires two walking aids - pair of canes, crutches, etc. - to walk about 20m without resting.~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
62833819|NCT04015544|EXPERIMENTAL|Watermelon|Watermelon puree 710 mL per day for six weeks
62833820|NCT04015544|NO_INTERVENTION|Control|No intervention
62833821|NCT01096069||Rituximab|Rheumatoid arthritis patients undergoing treatment with rituximab.
62833822|NCT04600596||Roux-en-Y gastric bypass patients|Severely obese non-diabetic adult female patients scheduled for RYGB.
62833823|NCT04600596||Obese (BMI ≥ 35) controls|Severely obese non-diabetic adult female patients not undergoing surgery.
62833824|NCT04600596||Lean (BMI ≤ 25) controls|Lean healthy non-diabetic adult females.
62833825|NCT05777252|EXPERIMENTAL|Training Group|Circuit training will be applied to the participants for a total of 16 weeks, with an average of 40 minutes a day, 3 days a week, taking into account the recommendations of the American College of Sports Medicine (ACSM).
62051244|NCT01947465||Patients with rheumatoid arthritis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with rheumatoid arthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
62833826|NCT06055270|PLACEBO_COMPARATOR|Placebo Group|The placebo sham injection will be performed in an identical fashion as the stellate ganglion block, with the exception of using 8 mL of 0.9% saline injection instead of Lidocaine.
62833827|NCT06055270|EXPERIMENTAL|Stellate Ganglion Block|The ultrasound-guided stellate ganglion blocks will be performed by a pain management specialist with extensive experience performing these blocks. The first SGB at the initial visit will be performed on the right side, and the second SGB will be on the left side 5-10 days after the first SGB, given that the patient tolerated the first SGB.
62051245|NCT01947465||Patients with axial spondylarthritis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with axial spondylarthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
62833828|NCT01460693|ACTIVE_COMPARATOR|Arm A - Imatinib|Imatinib 400mg daily
62833829|NCT01460693|EXPERIMENTAL|Arm B - Dasatinib|Dasatinib 100mg daily
62833830|NCT05336162|EXPERIMENTAL|Patients with non-cavitated pits and fissures in permanent molars will be treated with BeautiSealant|Young adults (16-22 y) who have existing pits and fissures that are anatomically deep and caries susceptible or with Stained pits and fissures with minimum decalcification of opacification and no softness at the base of the fissure (ICDAS 1 and 2).
62833831|NCT05336162|ACTIVE_COMPARATOR|Patients with non-cavitated pits and fissures in permanent molars will be treated with UltraSeal XT|Young adults (16-22 y) who have existing pits and fissures that are anatomically deep and caries susceptible or with Stained pits and fissures with minimum decalcification of opacification and no softness at the base of the fissure (ICDAS 1 and 2).
62833832|NCT04057417|EXPERIMENTAL|Urban Trail Expansion|Neighbourhoods within 400m to 800m of a neely built greenway, defined as a multi-use concrete/asphalt trail that was \>4km in length)
62051246|NCT01947465||Patients with vasculitis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with vasculitis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
62051247|NCT03535142|EXPERIMENTAL|Intervention|The intervention is bariatric surgery (Roux en Y gastric bypass or gastric sleeve operation).
62051248|NCT03535142|NO_INTERVENTION|Control|Age, BMI and co-morbidity matched group who do not undergo surgery.
62051249|NCT06524011|EXPERIMENTAL|SVF enriched PRP vs PRP|
62051250|NCT06524011|ACTIVE_COMPARATOR|SVF enriched PRP vs SVF|
62051251|NCT06524011|ACTIVE_COMPARATOR|PRP vs SVF|
62441809|NCT02362906|EXPERIMENTAL|Injection and medications|"Intravenous injection:~bacterial pneumonia：second generation cephalosporin; mycoplasma pneumonia：erythromycin or azithromycin; viral pneumonia：Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules."
62441810|NCT02362906|EXPERIMENTAL|Injection and application|"Intravenous injection:~bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; external application: Fu-xiong San."
62441811|NCT01720186|EXPERIMENTAL|SPI Medical device|SPI medical device used during PET/CT 4D imaging in a synchronized mode centered on the thorax.
62051252|NCT01910168||Cohort|
62051253|NCT00509834|EXPERIMENTAL|hLF1-11|hLF1-11 0.5mg
62051254|NCT00509834|PLACEBO_COMPARATOR|Placebo|Placebo formulation is Similar to hLF1-11 iv formulation except for the active component
62051255|NCT05267392|EXPERIMENTAL|Durvalumab|All subjects enrolled in the study will receive open-label neoadjuvant durvalumab 1500 mg followed by standard of care RT/RCT
62051256|NCT01373762|EXPERIMENTAL|Exercise Videogame Bike|Families in this group will receive an interactive exercise videogame bike (ie. the Active Cycle) to keep in their home for three months.
62738848|NCT03683420|EXPERIMENTAL|Group I (music)|The intervention is a behavioral intervention, which consists of giving patients and caregivers iPods to listen to music for up to 60 minutes while the patient is receiving a chemo infusion. The study consists of a presurvey, active listening period, and a post-survey.
62738849|NCT03683420|NO_INTERVENTION|Group II (control)|The intervention is a behavioral intervention, which consists of giving patients and caregivers iPods to listen to music for up to 60 minutes while the patient is receiving a chemo infusion. Participants and caregivers in the control condition complete a presurvey and post survey but do not listen to music during infusion session .
62738850|NCT03828097|EXPERIMENTAL|Experimental supplement|Participants in this arm will receive two capsules per day containing a total of 1 mg boron, 600 mcg folate, 8 mg iron, 50 mg magnesium, 320 mg omega-3 (DHA+EPA), 8 mcg vitamin B12, 50 mcg vitamin D3, and 7 mg vitamin E
62051257|NCT01373762|OTHER|Stationary Bike|Families will receive a stationary bike to keep in their home for three months. It is required that the family places the stationary bike (Active Cycle without video game controllers) in front of a television.
62051258|NCT03388749|EXPERIMENTAL|Liposomal annamycin|
62051259|NCT00683709||Counselling as Usual|Discussing Clozapine medication, diet and exercise as per clinical protocol potential weight changes
62051260|NCT00683709||Cognitive Behavoural Therapy|Counselling about Clozapine medication, diet and exercise in a structured fashion using Cognitive Behavioural Therapy about potential weight changes
62738851|NCT03828097|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive two capsules per day containing safflower oil
62051261|NCT03115294|EXPERIMENTAL|Study group|Patients undergo procedure with stepwise measurements and ventilator + volume adjustment + iv theophylline Myocardial movement recording using videoscanning
62252337|NCT04063241|OTHER|Provider|Baseline measures will be assessed for providers. They will then take part in a 20-minute training session, including information about health literacy, advanced counseling strategies, results of prior studies, and pre-implementation data. At the end of the study, assessments will be performed for those who use the health literacy-informed tool at least once during the study period.
62252338|NCT03558165||Stage IV Lung Adenocarcinoma|
62252339|NCT04204863||SE patients|
62252340|NCT00774280|NO_INTERVENTION|ArmI(BuCy)|"* Intravenous busulfan (Busulfex®; Orphan Medical, Minnetonka, MN) 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4~* Cyclophosphamide 60 ㎎/㎏ in D5W 200 ㎖ i.v. over 1-2 hours on days -3 and -2"
62252341|NCT00774280|NO_INTERVENTION|Arm II (BuFlu)|"* Intravenous busulfan 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4.~* Fludarabine (Fludara®, Schering AG, Berlin, Germany) 30 ㎎/㎡ i.v. over 30 minutes in D5W 100 ㎖ on days -6 to -2"
62252342|NCT00533143|EXPERIMENTAL|2|Non-invasive ventilation
62441812|NCT01720186|ACTIVE_COMPARATOR|reference medical device : RPM|Reference medical device (RPM) used simultaneously during PET/CT 4D imaging in a synchronized mode centered on the thorax.
62441813|NCT04670757|EXPERIMENTAL|CPL409116|"PART A. IMP is to be administered orally in single ascending dose in the groups consisting of 3 volunteers according to '3+3' design'. Dose escalation scheme is to be determined based on preclinical results and due to dose limiting observation (DLT).~PART A additional. Assessing the effect of food on bioavailability of CPL409116. IMP is to be administered orally in single dose in fasted and fed state in the group of 12 volunteers.There is to be one week wash-out between two treatment periods for this cohort."
62738852|NCT06027814|NO_INTERVENTION|Treatment-as-usual (TAU)|TAU will be usual care that the Addiction Consult Service provides. It is comprised of a multidisciplinary team of professionals, including addiction medicine and addiction psychiatry physicians, nurses specializing in the treatment of OUD, substance use disorder counselors, peer recovery supports, and program coordinators.
62833833|NCT04057417|NO_INTERVENTION|Control|Neighbourhoods that are located beyond 400 to 800m of a newly built greenway
62051262|NCT03286751|EXPERIMENTAL|LY900014|Single dose of 7 units (U), 15 U, and 30 U of LY900014 administered subcutaneously (SC) in three of six periods.
62051263|NCT03286751|ACTIVE_COMPARATOR|Insulin Lispro (Humalog)|Single dose of 7 U, 15 U, and 30 U of insulin lispro administered SC in three of six periods.
62051264|NCT05322148|ACTIVE_COMPARATOR|cyclosporine 0.1% / loteprednol 0.2% group|60 total patients will be randomized in a 2 to 1 proportion with 40 in the cyclosporine 0.1% / loteprednol 0.2% group and 20 in the cyclosporine 0.05% group. All patients will undergo treatment in both eyes.
62252343|NCT01163812|EXPERIMENTAL|Laparoscopic D2 gastrectomy|
62252344|NCT03228472|EXPERIMENTAL|real stimulation|Cranial - electrical or magnetic stimulation. Stimulation will be different according to clinical conditions, as specified elsewhere.
62252345|NCT03228472|PLACEBO_COMPARATOR|sham stimulation|"Patients will be treated as in the Real stimulation arm, but no electrical or magnetic stimulation will be induced."
62252346|NCT04013789|OTHER|DACP FreshTech, then DACP|DACP FreshTech contact lenses worn first, followed by DACP contact lenses, as randomized. Each product was worn in both eyes for approximately 8 hours per day for 1 week with a new pair of lenses worn each day.
62252347|NCT04013789|OTHER|DACP, then DACP FreshTech|DACP contact lenses worn first, followed by DACP FreshTech contact lenses, as randomized.. Each product was worn in both eyes for approximately 8 hours per day, for 1 week with a new pair of lenses worn each day.
62611076|NCT05638516|EXPERIMENTAL|Vira Self-Care|"The Vira app is installed on the participant's phone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also so prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Users will be asked to use Vira for 12 weeks.~The Vira app can be used as a standalone product. After an initial 10-day period, during which the app assesses the relationship between the user's patterns of behavior and their day-to-day variations in mental health and wellbeing using passive mobile sensing, the user is able to access a personalized behavior change goal that is support by in app information and functionality."
62611077|NCT05638516|EXPERIMENTAL|Vira + Coaching|"The Vira app can also be supported by a health coach. The health coach interacts with the user (via an instant messaging platform) and who also schedules just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan. The Vira Health Coach Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the coach's workflow."
62611078|NCT05441891|NO_INTERVENTION|Control group|Participants assigned to the control group are cited to the Health centre, but they do not suffer any intervention. These subjects followed the same evaluation and data collection process.
62611079|NCT05441891|ACTIVE_COMPARATOR|Auditory intervention filter-modulated|Participants assigned to this group listened classical music modulated by an equalizer for 30 minutes, 2 sessions a day separated by at least 3 hours, for 10 days (Monday to Friday for 2 weeks).
62611080|NCT01499641|ACTIVE_COMPARATOR|Epidural steroid|1.0 mL methylprednisolone acetate 40 mg/mL instilled at the decompressed nerve root
62611081|NCT01499641|EXPERIMENTAL|None epidural steroid|
62611082|NCT04709341|EXPERIMENTAL|Group A|
62611083|NCT04709341|ACTIVE_COMPARATOR|Group B|
62611084|NCT05322356|EXPERIMENTAL|Intervention|Interstitial Brachytherapy of the Prostate With Iodine 125 Implant With Target Dose Supplementation in the Tumor Volume Guided by the TRINITY® PERINE 3D system
62611085|NCT05030636|EXPERIMENTAL|EX starts at 9:30 am|A warm-up, 30 min at 70% VO2 max and a cool-down performed at 9:30 am.
62611086|NCT05030636|EXPERIMENTAL|EX starts at 11:00 am|A warm-up, 30 min at 70% VO2 max and a cool-down performed at 11:00 am.
62611087|NCT05030636|NO_INTERVENTION|No EX|Control condition. A choice of 30 minutes sedentary activities.
62611088|NCT06419010|EXPERIMENTAL|Experimental group|Patients will benefit from surgery with the use of L-PRF.
62611089|NCT06419010|OTHER|Control group|Patients will benefit from standard surgical treatment.
62611090|NCT06191302||SARS-CoV-2 positive patients|a cohort of former patients hospitalized with COVID-19
62611091|NCT06191302||SARS-CoV-2 negative patients|a control group of former patients hospitalized with other respiratory diseases
62611092|NCT04714762|EXPERIMENTAL|Intervention (eMOM GDM application)|Participants in the intervention group will use the eMOM GDM -application one week/month. The participants will also receive regular antenatal care in maternity clinics and hospitals. In addition they will meet a study nurse three times during study period (at GW 24-28, at GW 35-37 and 3 mo postpartum).
62611093|NCT04714762|NO_INTERVENTION|Control|Participants in the control group will meet a study nurse 3 times during study period (at GW 24-28, at GW 35-37 and 3 mo postpartum). They also receive regular antenatal care in maternity clinics and hospitals.
62611094|NCT01505179|ACTIVE_COMPARATOR|Ranolazine|Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
62611095|NCT01505179|PLACEBO_COMPARATOR|Placebo|Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
62611096|NCT05786612|ACTIVE_COMPARATOR|Mepilex Border with Aquacel Extra Hydrofiber|Standard of care (filler, that functions as a primary dressing to manage exudate and the gap/space between the wound bed and the dressing, covered by a secondary dressing on top) defined in this study as Mepilex® Border with AQUACEL® Extra Hydrofiber Dressing
62611097|NCT05786612|EXPERIMENTAL|Biatain® Silicone|The investigational test product is Biatain® Silicone. Biatain® Silicone is intended to be used for moist wound healing and exudate management.
62611098|NCT06204120|PLACEBO_COMPARATOR|Placebo|
62611099|NCT06204120|ACTIVE_COMPARATOR|morphine hydrochloride injection|
62611100|NCT06204120|EXPERIMENTAL|LPM3480392 injection group 1|
62611101|NCT06204120|EXPERIMENTAL|LPM3480392 injection group 2|
62611102|NCT06204120|EXPERIMENTAL|LPM3480392 injection group 3|
62611103|NCT06204120|EXPERIMENTAL|LPM3480392 injection group 4|
62611104|NCT03403621|EXPERIMENTAL|Topical Pentamidine Isethionate|Subjects were randomly assigned to apply topical pentamidine isethionate to either the proximal or distal end of their incision every 48 hours for 4 weeks following surgical scar excision (14-16 treatments).
62611105|NCT03403621|PLACEBO_COMPARATOR|Placebo Control|Subjects were randomly assigned to apply topical placebo to either the proximal or distal end of their incision every 48 hours for 4 weeks following surgical scar excision (14-16 treatments). The subject served as their own control.
62611106|NCT02589834|ACTIVE_COMPARATOR|Quran group|The patients listened to Quran recitation by a compact disc player through an occlusive headphone, started after induction of spinal anesthesia and continued throughout the entire cesarean section duration.
62611107|NCT02589834|NO_INTERVENTION|Non-Quran group|Those patients did not listen to Quran and subjected to operative room noise throughout the surgery.
62611108|NCT02358772||Pre-hospital thrombolysis|Patients with acute ischemic stroke who are cared in a specialized STroke Emergency MObile (STEMO) before admission to the Hospital and receive thrombolytic therapy (either in STEMO or in Hospital).
62611109|NCT02358772||In-hospital thrombolysis|Patients with acute ischemic stroke who receive thrombolytic therapy after admission to an University Hospital.
62611110|NCT06645821|EXPERIMENTAL|Open label EVO101 topical cream 0.1%|All eligible subjects will receive open label EVO101 topical cream 0.1%
62611111|NCT04236375||Normal|Subjects over 45 years old without cognitive dysfunction
62611112|NCT04236375||Mild cognitive decline|Subjects who are diagnosed as mild cognitive decline(MCI) according to neurologists.
62611113|NCT04236375||Alzheimer's disease|Subjects who are diagnosed as Alzheimer's disease(AD) according to neurologists.
62611114|NCT04236375||Vascular dementia|Subjects who are diagnosed as vascular dementia(VD) according to neurologists.
62441814|NCT04670757|EXPERIMENTAL|PLACEBO|PART B. Two participants from each of 4 cohorts (total of 8 participants) are to receive masking placebo tablet once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
62441815|NCT05146466|OTHER|E-MATVR (intervention)|
62441816|NCT05146466|OTHER|E-MATEE (control)|
62441817|NCT05303142||Individuals with a history of EHI|Service personnel who have a history of EHI.
62441818|NCT05303142||Control participants without a history of EHI|"Matched control participants with no history of EHI. They will be matched to the experimental group for parameters that are known to influence thermoregulatory responses to exercise heat-stress.~1. Relative aerobic fitness (V̇O2max; ml∙kg-1∙min-1)~2. Body mass (kg)~3. Body surface area (m2)~4. Age~5. Sex"
62441819|NCT04057781|NO_INTERVENTION|Control|
62441820|NCT04057781|ACTIVE_COMPARATOR|Dry Needling (DN)|"Subjects will receive dry needling treatment every 2 weeks for 6 weeks (weeks 0, 2, 4, 6).~Outcomes will be measured at baseline (week 0), 4 weeks after initiation of study (week 4), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
62441821|NCT04057781|ACTIVE_COMPARATOR|Dry Needling with Intramuscular ES (DNES)|"Subjects will receive dry needling treatment with electrical stimulation every 2 weeks for 6 weeks (week 0, 2, 4, 6)~Outcomes will be measured at baseline (week 0), 4 weeks after initiation of study (week 4), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
62441822|NCT00002571|EXPERIMENTAL|ProMACE-CytaBOM + G-CSF|6 cycles of 21 days each of ProMACE-CytaBOM (cyclophosphamide 490 mg/m\^2 on day 1, doxorubicin 19 mg/m\^2 on day 1, etoposide 90 mg/m\^2 on day 1, cytarabine 225 mg/m\^2 on day 8, bleomycin 5 u/m\^2 on day 8, methotrexate 90 mg/m\^2 on day 8, leucovorin 25 mg/m\^2 q 6 hours on days 8-9, vincristine 1.4 mg/m\^2 on day 8, prednisone 60 mg/m\^2 on days 1-14, allopurinol 300 mg on days 1-21 of cycle 1 and days 1-8 of cycle 2 only) plus 1 double strength tablet TMP/SMX 3 days a week plus G-CSF 5 ug/kg on days 9-20. Patients also receive intrathecal cytarabine 30 mg/m\^2 (BM positive: 5 doses spaced evenly during 1st 2 cycles, then on day 1 of cycles 3-6; CSF cytology positive: 5 doses spaced evenly during 1st cycle, then on day 1 of cycles 2-6; BM and CSF negative: 5 doses spaced evenly within 1 month of completion of cycle 6). All patients with CR or PR after systemic therapy and IT cytarabine receive 2400 cGy RT to the whole brain in 12 fractions.
62441823|NCT03507439|EXPERIMENTAL|HFrEF|Participants with established diagnosis of heart failure with reduced ejection fraction (HFrEF; EF ≤ 35%) wore the AVIVO MPM System or VitalPatch biosensor for 5 monitoring periods with patches applied on Day 0, 9, 16, 77 and 84; and the DynaPort Move Monitor belt for 2 monitoring periods with belts applied on Day 9 and Day 77.
62611115|NCT04236375||Lewy body dementia|Subjects who are diagnosed as Lewy body demenita (DLB) according to neurologists.
62611116|NCT04236375||Frontotemporal dementia|Subjects who are diagnosed as Frontotemporal demenita (FD) according to neurologists.
62252348|NCT00814671|EXPERIMENTAL|RPT450|Rifapentine 450mg daily
62252349|NCT00814671|ACTIVE_COMPARATOR|RIF 600|Rifampin 600mg daily
62252350|NCT00814671|EXPERIMENTAL|RPT 600|Rifapentine 600mg daily
62252351|NCT01274663|EXPERIMENTAL|10 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
62252352|NCT01274663|EXPERIMENTAL|30 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
62611117|NCT04236375||Other dementia|Subjects who are diagnosed as dementia but are not as AD, VD, DLB OR FD.
62611118|NCT01526876|EXPERIMENTAL|Single Arm drug study|The effect of systemic blood pressure reduction using Clevidipine on intracranial pressure (ICP) and cerebral perfusion pressure (CCP)
62611119|NCT03602833|EXPERIMENTAL|Compound 451238|To assess the safety and tolerability of combining radiotherapy with compound 451238, treating advanced STS.
62611120|NCT00231283|EXPERIMENTAL|1|CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System
62611121|NCT02925377|EXPERIMENTAL|Neuromuscular|Neuromuscular warm-up
62611122|NCT02925377|ACTIVE_COMPARATOR|Control|Standard warm-up
62611123|NCT01701505|EXPERIMENTAL|Kovacaine Mist High Dose|400uL of Kovacaine Mist, as 2 sprays of 200uL.
62051265|NCT05322148|ACTIVE_COMPARATOR|cyclosporine 0.05% group|60 total patients will be randomized in a 2 to 1 proportion with 40 in the cyclosporine 0.1% / loteprednol 0.2% group and 20 in the cyclosporine 0.05% group. All patients will undergo treatment in both eyes.
62051266|NCT05514002|ACTIVE_COMPARATOR|Recombinant Influenza Vaccine (RIV)|
62051267|NCT05514002|ACTIVE_COMPARATOR|Standard-Dose Inactivate Influenza Vaccine (SD IIV)|
62611124|NCT01701505|EXPERIMENTAL|Kovacaine Mist Mid Dose|200uL of Kovacaine Mist, as 2 sprays of 100uL.
62051268|NCT04477187|EXPERIMENTAL|Single Group|All subjects will undergo a single treatment for skin laxity in the submentum with a dermal handpiece.
62051269|NCT02701127|ACTIVE_COMPARATOR|Niacinamide 1 gram|Oral niacinamide, 1 gram daily
62051270|NCT02701127|ACTIVE_COMPARATOR|Niacinamide 3 grams|Oral niacinamide, 3 grams daily
62051271|NCT02701127|PLACEBO_COMPARATOR|Placebo|Oral placebo pill
62051272|NCT05139667|EXPERIMENTAL|tacrolimus/corticosteroid|topical steroids ( triamcinolone acetonide 0.1 %), tacrolimus paste and tacrolimus patch
62051273|NCT05139667|ACTIVE_COMPARATOR|corticosteroids|topical corticosteroid
62051274|NCT05139667|ACTIVE_COMPARATOR|tacrolimus|topical tacrolimus patch and tacrolimus paste
62611125|NCT01701505|EXPERIMENTAL|Kovacaine Mist Low Dose|120uL of Kovacaine Mist, as 2 sprays of 60uL.
62833834|NCT03705338||Electroencephalography|Electroencephalography (EEG) for induction and emergence in pediatric patients under general anesthesia with propofol.
62833835|NCT02024919|ACTIVE_COMPARATOR|Diltiazem|intracoronary diltiazem 5 milligrams which is diluted with 5 mL of saline
62833836|NCT02024919|PLACEBO_COMPARATOR|Saline|intracoronary saline 5 mL
62833837|NCT03278171||Patients in intensive care unit|Cohort of patients leaving intensive care unit after a stay of more than 72 hours
62833838|NCT04289935|EXPERIMENTAL|single arm|"* Unicentric histologically confirmed invasive luminal B, HER2- enriched, triple negative breast cancer + Clipping + Neoadjuvant chemotherapy~* rCR / near-rCR in MRI / US~* Registration~* US-guided VAB~* Breast conserving surgery / mastectomy~* Pathology examination 1. Preoperative VAB, 2. Surgical specimen"
62833839|NCT06274736||Women who will undergo a breast augmentation or reconstruction with Motiva® Sizer during surgery.|
62833840|NCT06274736||Women who will undergo a breast augmentation or reconstruction without Motiva® Sizer during surgery.|
62833841|NCT00521404|EXPERIMENTAL|CS-1008 + gemcitabine|CS-1008 + gemcitabine
62833842|NCT04626908|EXPERIMENTAL|Administration of GC022F CAR-T cells|Each subject receive GC022F CAR T-cells by intravenous infusion
62833843|NCT01328132|ACTIVE_COMPARATOR|Saline|
62051275|NCT03610464|EXPERIMENTAL|Study patients (AMPH EROS)|All patients treated with extended-release oral suspension (AMPH EROS) that contains 2.5 mg/mL amphetamine base
62051276|NCT05760157||Modeling cohort|The first 425(425/567,75%) patients with acute ST-segment elevation myocardial infarction were used to establish a heart failure risk prediction model.
62051277|NCT05760157||Validation cohort|The latter 142(142/567,25%) patients with acute ST-segment elevation myocardial infarction were used to further validate the validity and predictive power of the risk model
62051278|NCT03485326||Safety|Safety
62051279|NCT02370433|EXPERIMENTAL|Bowel Evacuation via IV|The study design will consist of an intravenous (IV) screening visit to determine each individual's response to neostigmine and glycopyrrolate (NG).
62051280|NCT02370433|EXPERIMENTAL|Bowel Evacuation Titration|This design will consist of a dose titration for those subjects who respond positively to IV. These subjects will receive either a low dose and/or a high dose of NG via iontophoresis to determine their responsiveness.
62051281|NCT02370433|EXPERIMENTAL|Bowel Evacuation Iontophoresis|This design will consist of the incorporation of iontophoresis administration into clinical bowel care. The subject will receive the exact dose they responded to during the titration 3x per week for 2weeks.
62051282|NCT00597948|EXPERIMENTAL|1|Workshop Group: Receives Healthy Lifestyles curriculum and subsequent support.
62051283|NCT00597948|NO_INTERVENTION|2|Comparison Group: Does not receive Healthy Lifestyles curriculum and subsequent support.
62051284|NCT03396029|EXPERIMENTAL|Individually tailored lifestyle feedback|Written, standardized individually tailored lifestyle feedback based on participants responses to a lifestyle questionnaire, and a leaflet on healthy lifestyle mailed to the participant.
62051285|NCT03396029|EXPERIMENTAL|Standard leaflet|A leaflet on healthy lifestyle mailed to the participant.
62051286|NCT03396029|NO_INTERVENTION|Control|No contact with the participant.
62051287|NCT02233933|ACTIVE_COMPARATOR|argon plasma coagulation|argon plasma coagulation of radiation proctitis
62051288|NCT02233933|EXPERIMENTAL|argon plasma coagulator and hemospray|treatment of radiation proctitis with argon plasma coagulator followed by application of hemospray
62051289|NCT06085274|EXPERIMENTAL|ICG-SLNB|This is a prospective within-patient clinical study to assess the accuracy of ICG SLNB compared to standard dual-tracer SLNB in breast cancer patients treated with neoadjuvant chemotherapy. For SLNB, triple localization of the sentinel lymph nodes using blue dye, Tc-99m and ICG will be utilized in each patient.
62051290|NCT02244905|EXPERIMENTAL|Positive Deviance Intervention Arm|Three hospital wards received Positive Deviance intervention.
62051291|NCT02244905|OTHER|Control Arm|Three hospital wards randomized to control arm received the Standard-of-Care Infection Control approach.
62051292|NCT01019044||Rectal mucosa biopsy|Rectal mucosa samples collection
62051293|NCT02044848|EXPERIMENTAL|Secukinumab|Secukinumab will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year
62051294|NCT02044848|PLACEBO_COMPARATOR|Placebo|Placebo will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year
62611126|NCT03641313|EXPERIMENTAL|Treatment (irinotecan and M6620)|Patients receive irinotecan IV over 90 minutes and berzosertib IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo endoscopic or CT assisted biopsy and MRI on study.
62611127|NCT05556265|EXPERIMENTAL|Deucravacitinib Dose 1|
62611128|NCT05556265|EXPERIMENTAL|Deucravacitinib Dose 2|
62611129|NCT05556265|PLACEBO_COMPARATOR|Placebo, followed by Deucravacitinib Dose 1 or Dose 2.|
62833844|NCT01328132|EXPERIMENTAL|25% albumin|
62833845|NCT06523933||ON+|Patients with OME after NPC with a Positive Result of Bacteria Culture of Middle Ear Effusion.
62833846|NCT06523933||ON-|Patients with OME after NPC with a Negative Result of Bacteria Culture of Middle Ear Effusion.
62051295|NCT05734963||Group 1|"Patients with histologically confirmed cancer~Tissue, blood and saliva samples collected before and after surgery and before and after any adjuvant therapy. Molecular profiling, DNA sequencing, gene expression analysis"
62051296|NCT02259738|EXPERIMENTAL|Human urinary kallidinogenase and Shuxuening injection|Human urinary kallidinogenase 0.15PNA and Shuxuening injection 20mg, every day for 7 days.
62833847|NCT06523933||O+|Patients with OME with a Positive Result of Bacteria Culture of Middle Ear Effusion.
62833848|NCT06523933||O-|Patients with OME with a Negative Result of Bacteria Culture of Middle Ear Effusion.
62833849|NCT04293068||Control group|Related tests were normal, because the male factor alone required the first IVF/ICSI cycle; Follow-up of included patients was conducted to determine whether embryo transplantation was performed, and the score of transferred embryos was recorded, and the final control group would be confirmed after achieving clinical pregnancy
62833850|NCT04293068||Recurrent implantation failure|Previous ≥3 consecutive embryo transfer failures
62051297|NCT03357263|EXPERIMENTAL|GC3114|Pre-filled syringe inj., 0.5ml, Once, IM
62051298|NCT03357263|ACTIVE_COMPARATOR|GCFLU Quadrivalent|Pre-filled syringe inj., 0.5ml, Once, IM
62051299|NCT03497650|EXPERIMENTAL|Mirror Therapy + Cross-Education.|Patients performed 4 sets of 5 maximal isometric ankle dorsiflexions with their less-affected lower limb while observing the reflection of the exercising limb in the mirror which was placed in the patient's mid-sagittal plane. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
62252353|NCT01274663|EXPERIMENTAL|100 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
62833851|NCT04293068||Recurrent spontaneous abortion(miscarriage)|≥2 consecutive spontaneous abortions or embryo damage
62833852|NCT02509442|OTHER|Diffusion of direct electric stimulation|Neurosurgery awakened
62833853|NCT01597804|EXPERIMENTAL|"Supportive care (Bathing Bundle)"|"Patients undergo preoperative preparation with the Bathing Bundle comprising CHG 4% skin prep solution and disposable wash cloths to bathe or shower with the night before and morning of surgery."
62833854|NCT03520855|EXPERIMENTAL|ETP + Serious game|patients receiving the serious game additionally to the classic therapeutic education
62833855|NCT03520855|ACTIVE_COMPARATOR|ETP|patients under classic therapeutic education
62252354|NCT01274663|EXPERIMENTAL|300 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
62252355|NCT01274663|EXPERIMENTAL|600 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
62833856|NCT01035086|EXPERIMENTAL|Boregine|Intervention: Lupinus angustifolius Boregine; 25 g lupin kernel fibre per day over 4 weeks; lupin kernel fibre was incorporated in different food
62833857|NCT01035086|ACTIVE_COMPARATOR|Reference|Intervention: Reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood ingredients); 25 g citrus fibre per day over 4 weeks; the citrus fibre was incorporated in different food
62833858|NCT01035086|PLACEBO_COMPARATOR|Placebo|different food without added fibre
62833859|NCT04449250|ACTIVE_COMPARATOR|CTx-1301 Fasted|Subjects will receive CTx-1301 in a fasted state.
62833860|NCT04449250|ACTIVE_COMPARATOR|CTx-1301 Fed|Subjects will receive CTx-1301 in a fed state (high fat test meal).
62051300|NCT03497650|ACTIVE_COMPARATOR|Cross-Education of Strengthening.|Patients trained without a mirror entirely. They performed 4 sets of 5 maximal isometric ankle dorsiflexions with their less-affected lower limb. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
62252356|NCT01274663|EXPERIMENTAL|800 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
62252357|NCT01274663|EXPERIMENTAL|xxx mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
62252358|NCT03521050||implanted defibrillator lead|patients having an ICD implanted and having follow-up at the investigators center
62252359|NCT00655954||Healthy volunteers non smoker|18 volunteers
62252360|NCT00655954||Healthy volunteers smoker|15 volunteers
62833861|NCT01527097|EXPERIMENTAL|Atorvastatin|
62833862|NCT01527097|PLACEBO_COMPARATOR|Placebo|
62833863|NCT02664896||Knee Osteoarthritis Cohort|Subjects with knee osteoarthritis will be asked to participate in the knee osteoarthritis testing session. This group will participate in 1 three hour testing session.
62051301|NCT02381522|ACTIVE_COMPARATOR|Remote Ischemic Pre-conditioning|Remote Ischemic Pre-conditioning group will receive 4 cycles of lower extremity occlusion of perfusion by blood pressure cuff inflated to 20 mmHg higher than systolic and confirmed by doppler.
62833864|NCT02664896||Healthy Subject Cohort|Healthy subjects will be asked to participate in the healthy control testing session. This group will participate in 1 two hour testing session.
62051302|NCT02381522|SHAM_COMPARATOR|Sham RIPC|Sham procedure group will receive 4 cycles of inflation of lower extremity blood pressure cuff but it will be 20mmhg lower than systolic BP and hence not occlude the vessel.
62051303|NCT04535674|NO_INTERVENTION|Standard of Care|
62833865|NCT04016935||Patients with primary invasive ER+ HER2- breast cancer|Distant recurrence-free survival (DRFS) between years 5 and 10 post-diagnosis of women with ER+, HER2- breast cancer who are classified as low risk according to their EPclin score and who did not receive extended endocrine therapy
62833866|NCT05684172|ACTIVE_COMPARATOR|endovascular thrombectomy|For patients randomized to the control group, EVT has to be completed within 24 hours of stroke onset. The choice of EVT strategy will be made by the treating neurointerventionalist. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
62833867|NCT05684172|EXPERIMENTAL|endovascular thrombectomy+intra-arterial tenecteplase|For patients randomized to the endovascular treatment arm, tenecteplase will be injected according to protocol, proceeding to inject TNK through a distal access catheter or microcatheter located proximal to the residual thrombus (if still present) and distally to the origin of the lenticulostriates branches. The administration of TNK will be infused for 15 seconds.
62051304|NCT04535674|EXPERIMENTAL|Standard of Care + Asunercept 25 mg|
62051305|NCT04535674|EXPERIMENTAL|Standard of Care + Asunercept 100 mg|
62051306|NCT04535674|EXPERIMENTAL|Standard of Care + Asunercept 400 mg|
62252361|NCT00655954||Chronic Obstructive Pulmonary Disease COPD|39 volunteers
62252362|NCT05242757|EXPERIMENTAL|To evaluate the safety and reliminary efficacy of MAK immune cells in the treatment of PHC.|To evaluate the safety and reliminary efficacy of MAK immune cells in the treatment of primary hepatocellular carcinoma.
62441824|NCT03507439|EXPERIMENTAL|HFpEF|Participants with established diagnosis of heart failure with preserved ejection fraction (HFpEF; EF ≥ 45%) wore the AVIVO MPM System or VitalPatch biosensor for 5 monitoring periods with patches applied on Day 0, 9, 16, 77 and 84; and the DynaPort Move Monitor belt for 2 monitoring periods with belts applied on Day 9 and Day 77.
62441825|NCT01493297|OTHER|Retinyl palmitate|Labeled iron as FeSO4 (4 mg) added to a test meal with or without retinyl palmitate (1000 RE)
62833868|NCT00830440|EXPERIMENTAL|EndoBarrier Device|EndoBarrier Device and Diet \& Lifestyle Counseling
62833869|NCT00830440|ACTIVE_COMPARATOR|Control|Diet \& Lifestyle Counseling
62051307|NCT00799292|NO_INTERVENTION|No injection|Patients did not receive an injection at cervix prior to beginning the procedure
62051308|NCT00799292|EXPERIMENTAL|Injection of vasopressin|Patients will be randomized to receive 20cc of dilute vasopressin (20units in 50cc normal saline)injected at cervix at beginning of the hysterectomy
62051309|NCT02021175|EXPERIMENTAL|Tailored CBME Therapy via Technology|6 weeks of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones
62051310|NCT02021175|OTHER|Standard of Care|Referral to currently available resources for 6 weeks of a standard smoking cessation approach
62051311|NCT00386022|EXPERIMENTAL|Young postmenopausal women|intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
62051312|NCT00386022|EXPERIMENTAL|Older postmenopausal women|intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
62051313|NCT03151980|ACTIVE_COMPARATOR|Hamam treated skin and sun exposure|
62051314|NCT03151980|OTHER|Untreated skin and sun exposure|
62051315|NCT01868295|EXPERIMENTAL|Sleeping with denture|Sleeping with denture at night
62051316|NCT01868295|NO_INTERVENTION|Sleeping without denture|Sleeping without denture at night
62051317|NCT02048072|EXPERIMENTAL|Gilenya|Autonomic testing during first dose adminstration of Gilenya.
62051318|NCT00969501|EXPERIMENTAL|EUFLEXXA|ACTIVE CONTROL
62051319|NCT00752843|EXPERIMENTAL|1|
62051320|NCT02822625|EXPERIMENTAL|arm 1|Patients, followed in the institut and for whom a new application of QUTENZA® is required, will receive standard care.
62051321|NCT02822625|ACTIVE_COMPARATOR|arm 2|"Patients, followed in the institut and for whom a new application of QUTENZA® is required.~Patients will receive QUTENZA® according to standard procedure with a standardized hypnotic message"
62441826|NCT01493297|OTHER|Beta-carotene|Labeled iron as FeSO4 (4 mg) added to a test meal with or without beta-carotene (1000 RE)
62833870|NCT05513404|NO_INTERVENTION|Breakfast only|This is an acute intervention study to compare the health benefits, in relation to changes in postprandial glucose and cognitive performance, of consumption of 3 soft fruits, raspberries, cherries, and honeyberries. It will have a randomised controlled crossover design where the volunteers will return for 4 stand-alone study sessions. All study procedures will be carried out at the Human Nutrition Unit (HNU) of the Rowett Institute. . The first study session will be an oral glucose tolerance test (OGTT). The glucose load for the OGTT in all sessions will be given as carbohydrate meal consisting of white bread, spread, low-polyphenol jam. (meal: 75g carbohydrate total). The remaining three will be intervention sessions which will be identical in all respects except for the addition of either honeyberry, cherry, or raspberry. There will be a minimum of 1 week washout period.
62051322|NCT02822625|PLACEBO_COMPARATOR|arm 3|"Patients, followed in the institut and for whom a new application of QUTENZA® is required.~Patients will receive QUTENZA® according to standard procedure with a music therapy"
62051323|NCT05892315|EXPERIMENTAL|Repeated subgingival instrumentation|Conventional staged debridement (CSD) according to the severity of periodontitis in 2 to 4 appointments at day 0, 7, 14 and 21. Re-instrumentation at 6 weeks and 3 months after completion of step I-II.
62051324|NCT05892315|ACTIVE_COMPARATOR|Supragingival instrumentation|Conventional staged debridement (CSD) according to the severity of periodontitis in 2 to 4 appointments at day 0, 7, 14 and 21. Only supragingival instrumentation at 6 weeks and 3 months after completion of step I-II.
62051325|NCT00490282|EXPERIMENTAL|Image-Guided Adaptive Radiotherapy|Intensity Modulated Radiotherapy (IMRT) + Adaptive Radiotherapy (ART)
62051326|NCT05416957|EXPERIMENTAL|SF001 ODT administered under fasting condition|Investigational product administration under fasting condition
62051327|NCT05416957|EXPERIMENTAL|SF001 ODT administration under fed condition|Investigational product administration under fed condition
62051328|NCT04047043||Taurine > 30 μmol/L|serum taurine level
62051329|NCT04047043||Taurine 30-20 μmol/L|serum taurine level
62051330|NCT04047043||Taurine < 20 μmol/L|serum taurine level
62051331|NCT03072940||Patients with idiopathic RBD|
62833871|NCT05513404|EXPERIMENTAL|Honeyberry|This arm will be an oral glucose tolerance test (OGTT). The glucose load for the OGTT in all sessions will be given as carbohydrate meal consisting of white bread, spread, low-polyphenol jam. (meal: 75g carbohydrate total) with the addition of honeyberry. There will be a minimum of 1 week washout period.
62833872|NCT05513404|EXPERIMENTAL|Cherry|This arm will be an oral glucose tolerance test (OGTT). The glucose load for the OGTT in all sessions will be given as carbohydrate meal consisting of white bread, spread, low-polyphenol jam. (meal: 75g carbohydrate total) with the addition of cherrry. There will be a minimum of 1 week washout period.
62051332|NCT03072940||Healthy volunteers|
62051333|NCT01593202|EXPERIMENTAL|Dialectical behavior therapy|Dialectical Behavior Therapy, delivered for 19 weeks, consisted of 1 weekly session of individual therapy (60 minutes), 1 weekly session of multifamily skills training (120 minutes), and family therapy sessions and Telephone coaching with individual therapists outside therapy sessions as needed.
62051334|NCT01593202|ACTIVE_COMPARATOR|Enhanced usual care|Enhanced usual care was 19 weeks of standard care (enhanced for the purpose of the study by requiring that EUC therapists agree to provide on average no less than 1 weekly treatment session per patient throughout the trial) delivered by therapists (4 psychiatrists, 16 clinical psychologists, 6 clinical social workers, 2 clinical pedagogues, 1 specialist nurse, and 1 psychology graduate student) not trained in or practicing DBT.
62252363|NCT02717884|EXPERIMENTAL|TCP, ATRA, Cytarabine|"Phase I part:~The rolling-six phase I design will be used to determine the MTD of TCP in combination with fixed-dose of ATRA and with fixed-dose AraC in patients with AML/MDS.~Intervention: Four dose levels of TCP (20 mg, 40 mg\*\*, 60 mg\*\*, 80 mg\*\* on days 1-28) will be examined in combination with ATRA (45 mg/m2 on days 10-28) and with fixed-dose AraC (40 mg on days 1-10) in the first cycle. In case of dose-limiting toxicity (DLT) on the starting level 1 of 20 mg a de-escalation to dose level of 10 mg (level -1) will be investigated.~\*\*TCP dose will be slowly increased to achieve the necessary dose level and slowly tapered off at the end of treatment"
62252364|NCT04497116|EXPERIMENTAL|RP-3500 (camonsertib) alone|"Phase 1:~Multiple doses of RP-3500 (camonsertib) for oral administration alone"
62051335|NCT00320775|EXPERIMENTAL|Part A|Part A: An open label study in which six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye. The total volume of each injection will be 100 μL. Enrollment in new dose levels will not begin until all patients in the preceding dose level have completed Visit 5 (Day 15).
62252365|NCT04497116|EXPERIMENTAL|Expansion cohorts with RP-3500 (camonsertib)|"Phase 2:~Expansion cohorts with RP-3500 (camonsertib)"
62611130|NCT05839184|NO_INTERVENTION|CONTROL GROUP|All newborns in the study will be monitored during IV catheter placement. Newborns in the control group will not be given any therapeutic toy and IV catheter will be placed and their comfort levels and vital signs will be monitored.
62611131|NCT05839184|ACTIVE_COMPARATOR|therapeutic toy GROUP|All newborns in the study will be monitored during IV catheter placement. Newborns in the therapeutic toy group will be given an octopus-shaped therapeutic toy that they can hold in their hands throughout the procedure and IV catheter will be inserted and their comfort levels and vital signs will be monitored.
62051336|NCT00320775|ACTIVE_COMPARATOR|Part B|Part B: A controlled, prospective, randomized, double-masked study in which up to 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive a single ITV injection of2.0 mg/eye VEGF Trap (or the MTD if reached prior to 2.0 mg) followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later. Enrollment into Part B will begin 2 weeks after the last subject to receive the 2.0 mg/eye dose in Part A has been observed for 15 days and it has been determined that the safety profile of VEGF Trap at this dose level is adequate to support expansion of dosing at this dose level. The dose of pegaptanib sodium will be 0.3 mg, according to the package insert.
62051337|NCT00320775|ACTIVE_COMPARATOR|Part C|Part C: A controlled, prospective, randomized, double-masked study in which approximately 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap. Initiation of Part C is contingent upon the 4.0 mg dose being adequately tolerated in Part A.
62051338|NCT04821479|EXPERIMENTAL|Repeated MSCs treatment in ALS patients|Four intrathecal (IT) administrations of autologous MSC cells administered every 3 months in ALS patients. the IT treatment will be administered through a regular lumbar puncture at a dose of 1x10\^6 MSCs per kg body weight in 3 ml saline.
62252366|NCT04497116|EXPERIMENTAL|RP-3500 (camonsertib) with Talazoparib or Gemcitabine|"Phase 1:~Multiple doses of RP-3500 (camonsertib) for oral administration in combination with talazoparib or gemcitabine"
62252367|NCT06397755||Patients underwent prostate biopsy and/or radical prostatectomy surgery.|
62252368|NCT02996188||Patients with refractory tense ascites|
62252369|NCT04296877|EXPERIMENTAL|All study participants|All subjects are fit into daily disposable contact lenses after wearing their optimized habitual contact lenses for \~ 1 week. Subjects are requested to wear the lenses for two weeks, for a minimum of at least 6 hours per day for 10 days.
62252370|NCT00890149|EXPERIMENTAL|Ondansetron|Ondansetron + BASICS Plus
62252371|NCT00890149|PLACEBO_COMPARATOR|Placebo|Placebo + BASICS Plus
62252372|NCT02768233|EXPERIMENTAL|Educational programme|Group 1: Educational programme + standard treatment
62252373|NCT02768233|NO_INTERVENTION|Standard treatment|Standard treatment
62252374|NCT00573209|OTHER|1|
62252375|NCT03959124|EXPERIMENTAL|AD with DBS|Alzheimer's disease subjects with optimal medication therapy and with DBS treatment
62252376|NCT03959124|ACTIVE_COMPARATOR|AD without DBS|Alzheimer's disease subjects with optimal medication therapy and without DBS treatment
62252377|NCT03959124|NO_INTERVENTION|Normal control|Matched aged and demographics subjects
62252378|NCT06273007|EXPERIMENTAL|woman in labor|"All women in labour during the study period (3 months baseline and the 3rd-6th month of the intervention) will be included for this pre- vs post-study of the PartoMa intervention.~The following subgroups will be studied in-depth:~1. All stillbirths~2. 5th Minute APGAR score \<7~3. All maternal deaths~4. All women with severe obstetric complication (postpartum hemorrhage, hypertensive disorders of pregnancy, uterine rupture, obstructed labor)"
62441827|NCT02758002|EXPERIMENTAL|Firm ablation for transitional AF rotors|All subjects will undergo this ablation, in addition to their standard PVI and Firm ablation for sustained AF rotors.
62441828|NCT03475732|EXPERIMENTAL|XueBiJing injection|100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days
62611132|NCT05226234||Experimental group|
62611133|NCT02710916|SHAM_COMPARATOR|perimetric glaucoma patients|
62441829|NCT05612386|EXPERIMENTAL|"Control condition with waiting for you message"|This control condition will use the text message that the investigators found to be the best performing in their last mega-study of vaccine text messages to recommend a COVID vaccination.
62441830|NCT05612386|EXPERIMENTAL|Planning message recommending same time/location as last vaccination|This condition will use a text message recommending the same time and location as the participant's last vaccination to get a COVID vaccination.
62441831|NCT04468256||Cardiomyopathy|Heart Hive registered participants with self-reported cardiomyopathy
62441832|NCT04468256||Participants without Heart Disease|Heart Hive registered participants without cardiomyopathy or other heart disease.
62441833|NCT04125004|EXPERIMENTAL|virtual reality|Patients will use virtual reality headset during procedure
62441834|NCT04125004|NO_INTERVENTION|general anesthesia|Patients will undergo general anesthesia for their procedure
62611134|NCT02710916|ACTIVE_COMPARATOR|preperimetric glaucoma patients|
62833873|NCT05513404|EXPERIMENTAL|Raspberry|This arm will be an oral glucose tolerance test (OGTT). The glucose load for the OGTT in all sessions will be given as carbohydrate meal consisting of white bread, spread, low-polyphenol jam. (meal: 75g carbohydrate total) with the addition of raspberry. There will be a minimum of 1 week washout period.
62833874|NCT02668653|EXPERIMENTAL|Chemotherapy plus quizartinib|"Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by the experimental drug quizartinib~Consolidation: up to 4 cycles of cytarabine followed by the experimental drug quizartinib and/or hematopoeitic stem cell transplant~Continuation: up to 36 cycles with the experimental drug quizartinib"
62833875|NCT02668653|ACTIVE_COMPARATOR|Chemotherapy plus placebo|"Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by placebo~Consolidation: up to 4 cycles of cytarabine followed by placebo and/or hematopoeitic stem cell transplant~Continuation: up to 36 cycles with placebo"
62833876|NCT02877992|ACTIVE_COMPARATOR|Donors|Oocyte donors without infertility problems
62833877|NCT02877992|EXPERIMENTAL|PCOS|Patients with Polycystic Ovary Syndrome (PCOS) according to Rotterdam criteria
62833878|NCT02877992|EXPERIMENTAL|Endometriosis|Patients with endometriosis (I-IV)
62051339|NCT05756972|EXPERIMENTAL|PM8002+Chemotherapy|Subjects will be administered with PM8002 plus pemetrexed and carboplatin via intravenously (IV) Q3W for 4 cycles, followed by PM8002 and pemetrexed until progression or for a maximum of 2 years.
62051340|NCT05756972|EXPERIMENTAL|Placebo+Chemotherapy|Subjects will be administered with placebo plus pemetrexed and carboplatin via intravenously (IV) Q3W for 4 cycles, followed by placebo and pemetrexed until progression or for a maximum of 2 years.
62252379|NCT06273007|EXPERIMENTAL|Birth attendants|All health care providers (physicians and midwives) working at the department of obstetrics during the study period will be invited to participate in knowledge tests of obstetric care and qualitative study. participant observations as well as in-depth interviews regarding quality of intrapartum care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.
62441835|NCT03867383|EXPERIMENTAL|Calcium Chloride|"Non-participating anesthesiologist prepares the drug solution, which is 1 gram of calcium chloride diluted into a total volume of 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour (for a calcium infusion rate of 100 milligrams /minute until the full 1 gram dose is administered).~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol."
62441836|NCT03867383|PLACEBO_COMPARATOR|Placebo|"Non-participating anesthesiologist prepares the placebo solution, which is 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour.~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol."
62441837|NCT03831633|EXPERIMENTAL|AKYNZEO|
62441838|NCT03831633|ACTIVE_COMPARATOR|Standard of Care|
62441839|NCT04716114|EXPERIMENTAL|SKLB1028|Subjects will receive 150 mg orally twice daily (BID) in continuous 28-day cycles
62611135|NCT02710916|SHAM_COMPARATOR|perimetric glaucoma control patients|
62611136|NCT00659516||1|intubated patients
62611137|NCT00659516||2|non intubated patients
62611138|NCT05159349||Exposed group|
62611139|NCT05159349||Non-exposed group|
62611140|NCT05654675||Oncologic patients|"Lymphoma and lung cancer patients will undergo an additional dynamic FDG PET/CT examination on top of their standard care PET/CT examination.~In addition, blood samples will be drawn at three time points"
62051341|NCT04253327||BOT|Patients diagnosed and treated by surgery for borderline ovarian tumor
62611141|NCT02278887|ACTIVE_COMPARATOR|Ipilimumab|4 cycles of ipilimumab treatment, the standard treatment
62611142|NCT02278887|EXPERIMENTAL|TIL treatment|non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2
62833879|NCT02877992|EXPERIMENTAL|Age|Patients with advanced maternal age (38 years or more)
62833880|NCT02877992|EXPERIMENTAL|Low ovarian response|Patients with low ovarian response according to Bologna criteria
62051342|NCT04253327||controls|Patients after surgical treatment of benign ovarian tumor
62051343|NCT05245578|EXPERIMENTAL|KX01 ointment and Placebo ointment|
62051344|NCT02304276|ACTIVE_COMPARATOR|1 (Explanted valves)|"10 subjects who are due to undergo repeat aortic valve replacement surgery~Investigations:~1. Baseline 18F-Fluoride PET-CT scan~2. Retrieval of explanted bioprosthetic aortic valve at time of surgery for analysis"
62252380|NCT04922463|NO_INTERVENTION|Control group|
62833881|NCT02802540|EXPERIMENTAL|Nabilone|Patients start receiving a dose of 0.5 mg daily oral nabilone the first 2 weeks and then 1 mg to complete 8 weeks.
62833882|NCT02802540|PLACEBO_COMPARATOR|placebo|Patients start receiving a dose of 0.5 mg daily oral placebo the first 2 weeks and then 1 mg to complete 8 weeks.
62611143|NCT06174753|EXPERIMENTAL|Treatment|Dapagliflozin 10mg daily X 7 days
62611144|NCT06174753|PLACEBO_COMPARATOR|Placebo|Placebo daily X 7 days
62833883|NCT05705453|EXPERIMENTAL|Volitional EMG power|Assessing the change in volitional EMG power during the Brain Motor Control Assement (BMCA) between nonstimulation baseline and stimulation.
62833884|NCT02947789||Postoperative mortality within 3 days|Group 1: Patients undergoing emergency surgery with postoperative mortality within 3 days Group 2: Patients undergoing emergency surgery without postoperative mortality within 3 days
62833885|NCT04762589|EXPERIMENTAL|RT001|RT001 960 mg capsule. 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
62833886|NCT04762589|PLACEBO_COMPARATOR|Placebo|Inactive comparator capsule 960 mg (safflower oil). 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
62441840|NCT04716114|ACTIVE_COMPARATOR|Salvage Chemotherapy|"Chemotherapy will be given in 28-day cycles. Subjects on low-dose cytarabine (LoDAC) will receive 10 to 20 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injections for 7 to 14 days.~Subjects on azacitidine will receive 75 mg/m\^2 daily by SC or IV, for 5 to 7 days.~Subjects on homoharringtonine (HHT), cytarabine and aclarubicin (HAA) will receive 2 mg/m\^2 of HHT by IV, for 7 days (day 1 to 7) (or HHT 2 mg/m\^2, twice daily, day 1 to 3); 100\~200 mg/m\^2 of cytarabine by IV for 7 days (day 1\~7) and 20 mg/d of aclarubicin by IV for 7 days (day 1 to 7).~Subjects on fludarabine, cytarabine and granulocyte colony-stimulating factor (G-CSF) (FLAG) will receive 30 mg/m\^2 of fludarabine daily by IV for 5 days (day 2 to 6), 1000\~2000 mg/m2 of cytarabine daily by IV for 5 days (day 2 to 6), and 300 g/m\^2 of G-CSF daily by SC or IV for 5 days (days 1 to 5). After completion of chemotherapy, G-CSF will be administered continually until ANC\>0.5 x 10\^9 / L."
62441841|NCT06178146|EXPERIMENTAL|Tα-1 group|Subcutaneous injection with 1.6mg Thymosin alpha 1 in combination with the conventional therapy
62441842|NCT06178146|ACTIVE_COMPARATOR|Control group|Conventional therapy includes corticosteroids and other immunosuppressants according to CSCO guidelines.
62441843|NCT03141177|EXPERIMENTAL|Doublet|Nivolumab and Cabozantinib
62833887|NCT04425109|EXPERIMENTAL|tempeh steak|The subjects were received the tempeh steak meal with isocal diet containing energy 307.4Kcal
62833888|NCT04425109|EXPERIMENTAL|soybean steak|The subjects were received the soybean steak meal with isocal diet containing energy 307.4Kcal
62833889|NCT04427267||Health workers|
62833890|NCT03276624|OTHER|patients with low EF undergoing CABG|Chronic Unstable Angina patients with low ejection fraction and a viable myocardium will undergo surgical revascularization CABG
62441844|NCT03141177|ACTIVE_COMPARATOR|Monotherapy|Sunitinib
62441845|NCT03141177|EXPERIMENTAL|Triplet|"Nivolumab, Ipilimumab, Cabozantinib~\*Enrollment to the triplet arm was discontinued by protocol amendment"
62611145|NCT05935033|EXPERIMENTAL|Severe Hepatic Impairment|Participants will receive a single oral dose of 10 milligrams (mg) emraclidine.
62051345|NCT02304276|EXPERIMENTAL|2 (AVR)|"70 subjects with surgical bioprosthetic AVR, to include 10 subjects who have had a valve replacement \< 1 month; 20 at 2 years; 20 at 5 years and 20 at \>10 years.~Investigations:~1. Baseline 18F-Fluoride PET-CT scan~2. Repeat CT calcium score of aortic valve at 2 years~3. Annual clinical follow-up for 5 years (history, examination, blood tests, ECG and echocardiogram)"
62252381|NCT04922463|EXPERIMENTAL|1x PLASOMA|
62611146|NCT05935033|EXPERIMENTAL|Moderate Hepatic Impairment|Participants will receive a single oral dose of 10 mg emraclidine.
62611147|NCT05935033|EXPERIMENTAL|Mild Hepatic Impairment|Participants will receive a single oral dose of 10 mg emraclidine.
62611148|NCT05935033|EXPERIMENTAL|Normal Hepatic Function|Participants will receive a single oral dose of 10 mg emraclidine.
62611149|NCT02810015|EXPERIMENTAL|Botulinum Toxin A|BTX-A will be reconstituted as directed by the manufacturer. 2.5 mL of diluent (0.9% Saline) per 100 U vial will be used to reconstitute the solution while swirling. This creates a solution with a concentration of 4 U/0.1 mL. Patients will be seated and all usual precautions of sterility and skin preparation will be completed (i.e. alcohol wipes) Injections will be administered unilateral and/or bilaterally in accordance with the topography of the corresponding muscles (temporalis and masseter) into areas of maximal tenderness and pain. Plastic single use insulin syringes with 30 gauge needles will be used to inject 30 U intramuscularly into each masseter, divided evenly into 5 sites and 20 U will be injected into each temporalis, divided evenly over 5 sites. Injections will be completed by the principal investigator and supervisors who will be trained in botulinum toxin injections.
62611150|NCT06608602||Group I and Group II|Group I= tidal volume 7 ml/predicted body weight Group II= tidal volume FVC/8 ml
62833891|NCT05704582|EXPERIMENTAL|Avatar Intervention|The Avatar Intervention will take place over 8 consecutive weeks, with one session per week. Additional sessions (up to a maximum of 4 sessions) will be offered if needed. Each session will last approximately 60 minutes. The goal of the intervention will be to help you reduce cravings related to your cannabis use with the use of virtual reality and avatars.
62833892|NCT05704582|ACTIVE_COMPARATOR|Addiction supportive intervention|The Addiction supportive intervention will take place over 8 consecutive weeks, with one session per week. Additional sessions (up to a maximum of 4 sessions) will be offered if needed. Each session will last approximately 60 minutes. The goal of the intervention will be to help you reduce cravings related to your cannabis use.
62833893|NCT04572789|PLACEBO_COMPARATOR|placebo|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of placebo omega-6 PUFAs intervention and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
62051346|NCT02304276|EXPERIMENTAL|3 (TAVI)|"50 subjects who have undergone TAVI with the COREVALVE and 50 subjects with the SAPIEN valve. In each group this will include 10 subjects who have had TAVI \< 1 month; 20 at 2 years and 20 at 5 years.~Investigations:~1. Baseline 18F-Fluoride PET-CT scan~2. Repeat CT calcium score of aortic valve at 2 years~3. Annual clinical follow-up for 5 years (history, examination, blood tests, ECG and echocardiogram)"
62051347|NCT01348750|OTHER|Group A|This group receives 6 Healing Touch \& Guided Imagery treatments in addition to standard medical care.
62051348|NCT01348750|NO_INTERVENTION|Group B|This group receives standard medical care but NO Healing Touch and Guided Imagery.
62051349|NCT02623010|EXPERIMENTAL|Single arm|Imbruvica (ibrutinib) will be given as maintenance treatment until relapse or toxicity to 30 elderly PCNSL patients after achieving response to first line treatment
62051350|NCT04605978|EXPERIMENTAL|S95011 concentrate for solution for infusion|S95011 is administrated by one IV infusion every 2 weeks for the first month and then every 3 weeks.
62051351|NCT04605978|PLACEBO_COMPARATOR|S95011 Placebo concentrate for solution for infusion|S95011 placebo is administrated by one IV infusion every 2 weeks for the first month and then every 3 weeks.
62441846|NCT03649737|EXPERIMENTAL|Supportive care (exercise)|Participants attend supervised group exercises classes twice per week during weeks 1-6 and once per week during weeks 7-12. Participants also attend home-based unsupervised exercise sessions via an instructional DVD once per weeks over for 30 minutes during weeks 1-6 and twice per week during weeks 7-12.
62833894|NCT04572789|EXPERIMENTAL|Omega-3|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of omega-3 PUFAs intervention (EPA) and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
62833895|NCT03041181|EXPERIMENTAL|Arm A - Single Agent Chemotherapy + Nivolumab|"Single Agent Chemotherapy of choice plus nivolumab:~Taxotere Pemetrexed Gemcitabine"
62833896|NCT03041181|ACTIVE_COMPARATOR|Arm B - Single Agent Chemotherapy|Single Agent Chemotherapy of choice Taxotere Pemetrexed Gemcitabine
62833897|NCT05194644|EXPERIMENTAL|Routine physical therapy + Sensorimotor stimulation|Active and passive Range of motion exercise on upper and lower limb, Transfers from bed to chair, Sit to stand exercise Time duration will be 20 min, Rest period 5 min In Sensory Stimulation Gustatory, Tactile, Olfactory, Visual, Auditory Stimulation will be applied alternatively Time duration will be 4 min In motor stimulation first warm up session for 5-10 min, strengthening exercise, PNF techniques for upper and lower limb, abdominal curls and then different Balance exercises for 6 min 5 times a week
62833898|NCT05194644|PLACEBO_COMPARATOR|Routine physical therapy|Active and passive Range of motion exercise on upper and lower limb, Transfers from bed to chair, Sit to stand exercise Time duration will be 20 min, Rest period 5 min
62833899|NCT05027555|EXPERIMENTAL|Multisensory training group|The intervention is a 50-minute session and 2-sessions/week, totaling 6 weeks
62833900|NCT05027555|ACTIVE_COMPARATOR|Conventional training group.|The intervention is a 50-minute session and 2-sessions/week, totaling 6 weeks
62833901|NCT02850926|EXPERIMENTAL|Soccer head gear|Subjects who are wearing soccer head gear during the practices and games during the soccer season.
62833902|NCT02850926|NO_INTERVENTION|Control|Subjects who are not wearing soccer head gear during the practices and games during the soccer season.
62833903|NCT03921957|EXPERIMENTAL|stereotactic|
62833904|NCT01323101|SHAM_COMPARATOR|Control|No doxycycline
62611151|NCT05732558|EXPERIMENTAL|prospective|8 Patients who were prescribed a CT-guided percutaneous bone biopsy, performed with the aid of endosight navigation system
62051352|NCT00593567|EXPERIMENTAL|A|Daily topical gentamicin sponge and standard daily wound care
62051353|NCT00593567|ACTIVE_COMPARATOR|B|Daily oral levofloxacin 750 mg and standard daily wound care
62051354|NCT03764839|NO_INTERVENTION|Active Control Group (Digital Health Education)|"* Demographics survey~* Baseline surveys~* Participants receive a digital information sheet on nutrition and exercise that are relevant for people recovering from surgery. Participants are encouraged to incorporate healthy lifestyle choices into their daily routines as they recover from surgery~Post-surgery:~* Pain check-ins (2 times per week) (detailed above)~* Patients receive 30 second booster videos at 7, 14, and 21 days after surgery~* Follow-up surveys (4, 8, and 12 weeks after surgery)"
62051355|NCT03764839|EXPERIMENTAL|"My Surgical Success Treatment Group"|"* Demographics survey~* Baseline surveys~* Intervention:~  * 45-minute digital behavioral pain medicine intervention My Surgical Success that emphasized cognitive and emotional regulation of pain and downregulation of physiologic arousal.~ * downloadable app with an audio file~ * personalized plan that allows learners to incorporate the treatment information~* Post-video survey (detailed above)~Post-surgery:~* Pain check-ins (2 times per week) (detailed above)~* Follow-up surveys (4, 8, and 12 weeks after surgery) Intervention: Behavioral: Perioperative Digital Behavioral Pain Medicine My Surgical Success"
62051356|NCT04226222||Triple negative Breast Cancer|Triple Negative Breast Cancer operatable from the outset
62051357|NCT06115330|EXPERIMENTAL|Ear Acupuncture with Standard Medical Therapy|The intervention group was give a press needle acupuncture with standard medical therapy for gynecological cancer pain
62051358|NCT06115330|NO_INTERVENTION|Standard Medical Therapy|The control group was given standard medical therapy for gynecological cancer pain
62252382|NCT04922463|EXPERIMENTAL|2x PLASOMA|
62252383|NCT00602095|EXPERIMENTAL|1|Labour induction with misoprostol
62252384|NCT00602095|ACTIVE_COMPARATOR|2|Labour induction with dinoprostone
62833905|NCT01323101|EXPERIMENTAL|Doxycycline|
62252385|NCT00602095|EXPERIMENTAL|3|Labour induction with bard
62252386|NCT01617590|EXPERIMENTAL|leflunomide|Leflunomide 10-20 mg/d
62833906|NCT05348213|EXPERIMENTAL|R-ICE+X|R-ICE plus novel targeted drugs
62833907|NCT02738281||Rett Syndrome|This is a prospective natural history study examining the phenotypic variations of individuals with mutations in MECP2 or meeting the diagnostic criteria for classic (typical) or variant (atypical) Rett syndrome. The overwhelming majority will be female, but males meeting diagnostic criteria will be included. No interventions are planned.
62833908|NCT02738281||MECP2 Duplication|This is a prospective natural history study examining the phenotypic variations of individuals with MECP2 duplications. The majority are expected to be males, but females expressing a duplication will be included. No interventions are planned.
62051359|NCT03548883||Alzheimer subject Group|In phase I, up 50 AD patients will be recruited and screened until we obtain 6 AD subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of standard of care (SOC) medical history, labs, imaging, and cognitive assessment. Recruited subjects will be scheduled for Study Visit #1 (@TRI) and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to rule out other causes of cognitive decline.
62051360|NCT03548883||Control Group|In phase II, up to 50 age, sex, race ethnicity, group matched healthy controls will be recruited and screened until we have 6 healthy control subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of medical history (including a review of past images, current medication and labs if available). Recruited subjects will be scheduled for Study Visit #1 and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to confirm that there are no undiagnosed conditions.
62252387|NCT01617590|ACTIVE_COMPARATOR|methotrexate|MTX 7.5-15 mg/week
62252388|NCT00319280|EXPERIMENTAL|1|Minced Iliac Crest autograft in osteotomysite
62252389|NCT00319280|EXPERIMENTAL|2|Injectable calcium phosphate cement in osteotomysite
62252390|NCT00319280|ACTIVE_COMPARATOR|3|Local autograft in the osteotomysite serves as control
62252391|NCT03337360|ACTIVE_COMPARATOR|Impryl|One tablet daily for 6 months
62252392|NCT03337360|PLACEBO_COMPARATOR|Placebo|One tablet daily for 6 months
62252393|NCT03193645||Degarelix|
62252394|NCT00121784|EXPERIMENTAL|1|1
62833909|NCT02738281||RTT related disorders|This is a prospective natural history study examining individuals, both females and males who do not meet criteria for Rett syndrome, but have a mutation in MECP2, CDKL5, or FOXG1. No interventions are planned.
62833910|NCT01399541||Under and over 65 years|
62833911|NCT03511937|EXPERIMENTAL|Sugar-Sweetened Beverage Health Warning Label|
62833912|NCT03511937|OTHER|Neutral Label|
62252395|NCT04223843|EXPERIMENTAL|Active Arm|Tiotropium + Olodaterol Fixed Dose Combination (FDC) via Respimat
62252396|NCT04223843|PLACEBO_COMPARATOR|Placebo Arm|Matching placebo via Respimat
62252397|NCT03965936|PLACEBO_COMPARATOR|lipofilling|subcutaneous injection of lipoaspiate (microfat) in one temporal region
62252398|NCT03965936|ACTIVE_COMPARATOR|lipofilling enriched with adipose tissue derived stem cells|subcutaneous injection of lipoaspiate enriched with adipose tissue derived stem cells in one temporal region
62252399|NCT05092919|OTHER|Flavor|Either a sweet-flavored or a non-flavored cigarillo
62252400|NCT00474708|EXPERIMENTAL|1|1.Effexor XR Group
62252401|NCT00474708|ACTIVE_COMPARATOR|2|2.SSRI or Conventional Antidepressant Group
62252402|NCT00309465|EXPERIMENTAL|1|Patients in Group 1 will administer 80% of their usual insulin glargine dose.
62252403|NCT00309465|ACTIVE_COMPARATOR|2|Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose.
62441847|NCT03731182|EXPERIMENTAL|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.
62611152|NCT05732558|NO_INTERVENTION|retrospective|8 Patients with a bone lesion for which a percutaneous biopsy has been performed from January 2011 to May 2022
62252404|NCT00309465|EXPERIMENTAL|3|Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
62252405|NCT03629236|EXPERIMENTAL|GrafixPL|
62252406|NCT03629236|ACTIVE_COMPARATOR|Control|
62252407|NCT03592966|PLACEBO_COMPARATOR|Placebo|Freeze-dried placebo powder
62252408|NCT03592966|ACTIVE_COMPARATOR|Wild Blueberry powder|Freeze-dried whole fruit blueberry drink.
62252409|NCT01841463|EXPERIMENTAL|P1446A-05|"* The study will be conducted in two phases- Phase I ('Dose escalation' phase), and Extension phase:-~* In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of three to six patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~* In the 'Extension' phase, sixty patients with BRAF V600E/K mutations (forty patients naïve to selective BRAF inhibitor therapy, and twenty progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity"
62252410|NCT05672511|EXPERIMENTAL|İntervention group|Randomly determined experimental group students will perform eight vaginal examination scenarios different in terms of cervical effacement, cervical dilatation, presence of amniotic membrane, presenting fetus part, position of the fetus and fetal descent on the fetal monitoring and labor progress model set in the laboratory.
62441848|NCT03731182|ACTIVE_COMPARATOR|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1.
62441849|NCT06402747|EXPERIMENTAL|Clopidogrel|Clopidogrel 75mg once daily
62833913|NCT00767988|ACTIVE_COMPARATOR|A|Urex-cap-5 capsules (2x10\^9 cfu each of RC-14 and GR-1) 1:1 ratio
62833914|NCT00767988|PLACEBO_COMPARATOR|B|Capsule 1:1
62833915|NCT03488953|OTHER|Transplantation Arm|
62833916|NCT01628640|EXPERIMENTAL|Arm A (viral therapy in single tumor location)|Patients with hepatocellular carcinoma or advanced solid tumor with liver lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in a single tumor location on day 1.
62611153|NCT06174818||TN|Patients with trigeminal neuralgia
62051361|NCT03548883||Type 2 diabetes group|In phase III, up to 50 age, sex, race ethnicity, group matched T2D patients will be recruited and screened until we have 6 T2D subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of medical history (including a review of past images, current medication and labs if available). Recruited subjects will be scheduled for Study Visit #1 and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to confirm that there are no undiagnosed conditions.
62611154|NCT03996564|ACTIVE_COMPARATOR|Acupuncture Group|"Battlefield Acupuncture (BFA) has a structured administration sequence that was utilized to limit any variability between investigators administering the treatment. The BFA technique has been suggested that the needles are placed not just in an acupoint but actually acupoint zones. BFA utilizes one to ten (maximum five points per ear) ASP semi-permanent gold needles® placed in one or both ears. The ASP Gold needle® is a sterile device which inserts a small 2 mm needle into the auricle. It is comprised in single-needle applicator ensuring ease of insertion combined with excellent precision. The needles remain in the ear and fall out spontaneously as early as two hours and up to seven days. After administration of the BFA, if subjects felt that their pain was not controlled based on verbal response, rescue medication could be administered to control pain to a tolerable level for discharge."
62833917|NCT01628640|EXPERIMENTAL|Arm B (viral therapy in multiple locations)|Patients with advanced solid tumor with subcutaneous/cutaneous lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in up to 5 cutaneous, subcutaneous, or soft tissue tumor lesions on day 1.
62833918|NCT03312634|EXPERIMENTAL|Palovarotene Chronic/Flare-Up Regimen|Participants received 5 mg palovarotene once daily for up to 48 months; and 20 mg palovarotene once daily for 28 days, followed by 10 mg for 56 days for flareups. (Dosing was adjusted for weight in skeletally immature subjects.)
62833919|NCT04698863||high flow rate|After intubation, patients had fresh gas flow with 50% O2/50% air for the first 10 minutes (3/3 L/min) and 6% desflurane. Then the flow rate was set to 4 L/min for Group High flow rate.
62833920|NCT04698863||low flow rate|After intubation, patients had fresh gas flow with 50% O2/50% air for the first 10 minutes (3/3 L/min) and 6% desflurane. Then the flow rate was set to 1 L/min for Group Low flow rate.
62833921|NCT03690687||Group I. Primary anastomosis|Resection of the small bowel to place primary anastomosis into small intestine or transverse colon during relaparotomy.
62252411|NCT05672511|NO_INTERVENTION|Control group|. The control group will not receive any simulation training
62252412|NCT05260853|EXPERIMENTAL|Intervention|High-risk patients as identified by the computer model. Treating staff are supported by specialised staff from the local certified weaning-center
62441850|NCT06402747|ACTIVE_COMPARATOR|Cilostazol|Cilostazol 200mg per day
62833922|NCT03690687||Group II. Delayed anastomosis|Resection of the small intestine to place delayed anastomosis. After the closure of the afferent and efferent loops of the small intestine, anastomosis was not applied. A decompression probe was introduced into the upper small intestine. In 24-36 hours, delayed anastomosis was placed into the small intestine or transverse colon during the planned relaparotomy with arrested postoperative peritonitis.
62051362|NCT01314989|ACTIVE_COMPARATOR|Cyproheptadine|Cross-over study
62051363|NCT01314989|PLACEBO_COMPARATOR|Sugar pill|Cross-over study
62051364|NCT01815788|EXPERIMENTAL|Teo first|"* Mild and moderate presbycusis (20 to 50 dB average hearing loss at 500, 1000, 2000 Hz and 4000 Hz)~* Patient 60 years of age and older,~* No previous hearing aid"
62051365|NCT04482543|ACTIVE_COMPARATOR|Intra-silicone oil injection of 250 µg methotrexate|
62051366|NCT04482543|NO_INTERVENTION|No intra-silicone oil injection of methotrexate|
62051367|NCT00939484|EXPERIMENTAL|Treatment (vismodegib)|Patients receive vismodegib PO once daily on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
62252413|NCT05260853|NO_INTERVENTION|Control|clinical date gathered from AOK BW insured patients on invasive ventilation outside the participating centers
62252414|NCT02607683|EXPERIMENTAL|XAF5 (concentration A: 0.1%)|Participants will apply XAF5 Ointment (concentration A: 0.1%) to the lower eyelids once daily.
62252415|NCT02607683|EXPERIMENTAL|XAF5 (concentration B: 0.035%)|Participants will apply XAF5 Ointment (concentration B: 0.035%) to the lower eyelids once daily.
62441851|NCT06201624|EXPERIMENTAL|Isotretinoin|patients will receive oral isotretinoin (1 mg/kg/day) for 3 months
62441852|NCT06201624|ACTIVE_COMPARATOR|Kligman Formula arm|patients will receive topical triple combination formula at night everyday over the affected areas for 3 months
62441853|NCT03922477|EXPERIMENTAL|Atezolizumab + Hu5F9-G4|An initial safety evaluation will be performed in participants with relapsed AML. If atezolizumab in combination with Hu5F9-G4 is initially safe and tolerable in participants an additional cohort with R/R AML will be evaluated to further test the safety and anti-tumor activity. If dose-limiting toxicities (DLT) are observed in \>=33% of participants in this initial cohort, a dose de-escalation cohort will be enrolled. If less than 33% of enrolled and dosed participants in any given cohort experience a DLT, an expansion cohort of 15 participants will be enrolled at the highest tolerated dose for this combination. If a dose de-escalation cohort is needed, an expansion cohort will be enrolled at the lower tolerated dose for this combination.
62441854|NCT03341286|EXPERIMENTAL|TK3|This is a oral supplement combination of tryptophan and thiamine called TK3 to be taken three times a day
62441855|NCT03341286|PLACEBO_COMPARATOR|Placebo|Placebo orally, to be taken three times a day
62441856|NCT05619146|EXPERIMENTAL|SCI subject|Subject with SCI
62441857|NCT03441542|EXPERIMENTAL|Data-assisted Case Navigation|Patients are recruited and consented into the study by the patient navigator after which the navigator provides assistance with scheduling, reminders, and transportation. The navigator is also charged with responding to patient questions, and monitoring and documenting if and when patients achieve HCV care milestones. Each month, the project will update the Grady Liver Clinic HCV patient registry, to generate information about the patient's HCV care progress and use this information to develop instructions sheets regarding the expected care milestones to be achieved that month for each patient. During the month, the navigator will participate in project meetings and report on milestone achievement and barriers for patients assigned to the experimental arm of the study.
62051368|NCT05968222|NO_INTERVENTION|Control group|Participants in the control group will undergo a determination of glycosylated hemoglobin, blood pressure, lipid profile, weight and height, as well as functional tests such as TUG, 10MWT, 5STS. Subsequently, they will be encouraged to continue their normal life insisting on the importance of glycemic controls before and after their daily physical exercise. In addition to continuing with the dietary measures recommended by their specialist.
62833923|NCT03690687||Group III. Enterostomy|Resection of the small intestine with enterostomy. In case there was no postoperative peritonitis relief and was organ dysfunction progression, anastomosis was not placed. The surgery was completed with enterostomy to perform open abdomen.
62833924|NCT06351007|ACTIVE_COMPARATOR|Control|The control group will consist of both pre-dialysis and dialysis patients.They will receive standard nutritional care consisting of dietary prescription with follow-up for questions and adjustment of the meal plan every 2 months.
62833925|NCT06351007|EXPERIMENTAL|Intervention predialysis|"This group will consist of pre-dialysis patients in Kidney Disease Improving Global Outcomes (KDIGO) stages 3 to 5 who will receive, in addition to the meal plan, a nutritional education program with psychological support.The meal plan will have the same characteristics as in the control group.~The educational program will have a duration of 5 monthly sessions . Simultaneously, monthly sessions will be held in groups of 5 patients, with a group of clinical psychologists."
62833926|NCT06351007|EXPERIMENTAL|Intervention dialysis|"This group will consist of peritoneal dialysis and hemodialysis patients who will receive, in addition to the meal plan, a nutritional education program with psychological support.The meal plan will have the same characteristics as in the control group.~The educational program will have a duration of 5 monthly sessions . Simultaneously, monthly sessions will be held in groups of 5 patients, with a group of clinical psychologists."
62051369|NCT05968222|EXPERIMENTAL|Experimental group|"Participants in the intervention group will be subjected to the following tests:~* At the beginning of the intervention, a determination of glycosylated hemoglobin, blood pressure, lipid profile, weight, height and TUG, 10MWT, 5STS, which will be repeated after 12 weeks of intervention.~* Before each training session, participants will undergo a basal blood glucose and blood pressure measurement, which will be repeated after the end of the session.~* Each training session on the vibrating platform is composed of 6 exercises with a duration of 60 seconds with 60-second pauses between exercises and a warm-up exercise."
62051370|NCT02526355|EXPERIMENTAL|Mobile based Intervention|Mobile based Intervention (Learning Through Play Plus) comprised of both LTP and CBT
62051371|NCT02526355|NO_INTERVENTION|Waiting List Control|Waiting List Control group will receive no intervention, but intervention will be offered to interested participants at the end of the study
62051372|NCT04236193||SIRVA|Subjects with shoulder pain \>7 days after vaccination
62051373|NCT04236193||Controls|Subjects from a prospective influenza vaccine study
62611155|NCT03996564|ACTIVE_COMPARATOR|Standard Care Group|Participants randomized to the standard care group were treated with one, or a combination of selected medications to include oral Acetaminophen 500mg-1000mg, Diclofenac 50mg-75 mg orally, Diazepam 5mg-10 mg intravenous or oral, Hydrocodone 5mg/325mg-10mg/650mg mg oral, or intramuscular Ketorolac 30mg-60 mg, as deemed appropriate by the treating investigator (medical provider). Standard treatment was administered by the investigators based on the patient's presentation and driving status as many of the medications cannot be administered if the subject would operate a vehicle. No standardized algorithm was specified and the route and dose of medications was administered at the provider's discretion. After administration of the traditional standard care medications, if subjects felt their pain was not controlled based on verbal responses, rescue medication would be given to control pain to a more tolerable level for discharge.
62051374|NCT00770926|EXPERIMENTAL|Program immediately|Receives the lifestyle program as soon as possible after randomization
62051375|NCT00770926|NO_INTERVENTION|Wait list control|Wait one year and at the end of the year, is offered the option of participating in the program
62051376|NCT02582346|EXPERIMENTAL|MRI acquisition - no contrast agent|Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
62051377|NCT03083314|EXPERIMENTAL|SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)|
62252416|NCT02607683|PLACEBO_COMPARATOR|Placebo|Participants will apply Placebo Ointment to the lower eyelids once daily.
62611156|NCT02812251|EXPERIMENTAL|Part 1: Cohort 1|Participants will receive 1 milligram (mg) JNJ-61393215 or placebo.
62611157|NCT02812251|EXPERIMENTAL|Part 1: Cohort 2|Participants will receive 5 mg JNJ-61393215 or placebo.
62833927|NCT06515730|EXPERIMENTAL|Apixaban|Apixaban 5 mg twice a day, reduced to 2.5 mg twice a day for participants with any 2 of following criteria: age \> 80 years, serum creatinine \> 133 μmol/L or body weight \<60 kg. Participants with severe renal failure defined as creatinine clearance 15-29 ml/min/1.73 m2, should also receive the reduced dose of 2.5 mg twice a day.
62051378|NCT03083314|ACTIVE_COMPARATOR|COMPLETE AXILLARY DISSECTION (ALND)|
62252417|NCT02596802|EXPERIMENTAL|FETO therapy|Intervention name: FETO therapy
62252418|NCT04415957|EXPERIMENTAL|Elastic Tape Group (ETG)|The ET placement was previously described by Pinto et al. (2020). Briefly, the subject's trunk was passively extended for ET placement. The ET was placed considering the origins and insertions of the following muscles: rectus abdominis, internal oblique, and internal intercostal. ET has shown six days of durability on average, so the participants were asked to return to change the ET after seven days.
62051379|NCT00681642||1|Corneal epithelial tissue with wound cultured in human autoserum
62252419|NCT04415957|NO_INTERVENTION|Control Group (CG)|CG received instructions about the importance of becoming physical activity. Furthermore, the participants included in CG were invited to place the ETs at the end of the protocol.
62252420|NCT03969849|EXPERIMENTAL|Part A: Cohort 1|Part A: Cohort 1 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
62252421|NCT03969849|EXPERIMENTAL|Part A: Cohort 2|Part A: Cohort 2 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
62611158|NCT02812251|EXPERIMENTAL|Part 1: Cohort 3|Participants will receive 15 mg JNJ-61393215 or placebo.
62611159|NCT02812251|EXPERIMENTAL|Part 1: Cohort 4|Participants will receive 30 mg JNJ-61393215 or placebo.
62611160|NCT02812251|EXPERIMENTAL|Part 1: Cohort 5|Participants will receive 45 mg JNJ-61393215 or placebo.
62833928|NCT06515730|ACTIVE_COMPARATOR|Warfarin|Warfarin 2,5 mg once daily with individual dosing according to coagulation assays with an international normalized ratio (INR) goal of 2.0-3.0. Bridging with low-molecular-weight-heparin with a dose of dalteparin 200 units/kg but maximum 18 000 units or enoxaparin 150 units/kg, until therapeutic INR is recommended.
62833929|NCT06001203|EXPERIMENTAL|intervention group|The intervention group is received two reflexology sessions.
62051380|NCT00681642||2|Corneal epithelial tissue with wound cultured in umbilical cord serum
62051381|NCT00964834|EXPERIMENTAL|Doxycycline and Valortim|Randomized such that sixteen volunteer subjects to be renadomized to receive Doxycycline and Valortim
62051382|NCT00964834|EXPERIMENTAL|Placebo Antibiotic and Valortim|Randomized such that four volunteer subjects to receive Placebo Antibiotic and Valortim.
62252422|NCT03969849|EXPERIMENTAL|Part A: Cohort 3|Part A: Cohort 3 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
62252423|NCT03969849|EXPERIMENTAL|Part A: Cohort 4|Part A: Cohort 4 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
62252424|NCT03969849|EXPERIMENTAL|Part B|Part B: Randomized 1:1 will receive REGN5713-5714-5715 or matching placebo in Healthy Participants with birch pollen allergy
62252425|NCT00446524|EXPERIMENTAL|Valsartan + Amlodipine 80/5 mg|Valsartan 80 mg or Amlodipine 5 mg ---\> Valsartan + Amlodipine 80 / 5 mg
62252426|NCT00446524|EXPERIMENTAL|Valsartan + Amlodipine 80/5 mg + Diuretic|Valsartan + Amlodipine 80 / 5 mg + Diuretic
62252427|NCT05534906||Small HCC with Cirrhosis|200 patients diagnosed with small HCC (as defined in Eligibility Criteria) and cirrhosis
62252428|NCT05534906||Small HCC without Cirrhosis|50 patients diagnosed with small HCC (as defined in Eligibility Criteria) but without cirrhosis
62833930|NCT06001203|NO_INTERVENTION|control group|The control group is given routine care and no intervention will be performed.
62051383|NCT00964834|EXPERIMENTAL|Placebo Antibiotic and Placebo Valortim|Randomized such that four volunteer subjects to receive Placebo Antibiotic and Placebo Valortim.
62051384|NCT02621957|EXPERIMENTAL|Female Healthy Volunteers|Healthy volunteer female subjects of non-childbearing potential will be administered pravastatin once on Day 1 during Period 1 (Day -1 to Day 4). During Period 2 (Days 5-28) GDC-0810 will be administered daily on Days 5-8. Pravastatin will be co-administered on Day 7.
62051385|NCT06081764|EXPERIMENTAL|Otago Exercise Program|They participated the Otago Exercise Program, which last 3 days a week and an average of 30 minutes per day for 12 weeks in total. In addition, they did moderate-intensity walking exercise for 30 minutes a day, 2 days a week.
62051386|NCT06081764|NO_INTERVENTION|Control Group|No program were applied to the participants in the control group.
62051387|NCT04356326|EXPERIMENTAL|Aspirin 150 mg|Aspirin 150 mg / day (acetylsalicylic acid) once daily in the evening
62051388|NCT04356326|PLACEBO_COMPARATOR|Placebo|Placebo taken in the evening
62051389|NCT02579876|ACTIVE_COMPARATOR|Viaskin Milk 500 mcg|Viaskin patch containing milk protein. The patch is applied to the skin
62051390|NCT02579876|PLACEBO_COMPARATOR|Viaskin Placebo|Viaksin patch without any milk protein.
62051391|NCT05101525|EXPERIMENTAL|Patient with effective tendon healing|
62252429|NCT05534906||Imaging Subgroup|In a subgroup of patients (N=80, around 64 patients with HCC with liver cirrhosis and around 16 patients with HCC without liver cirrhosis), additional magnetic resonance liver imaging \& elastography will be performed
62252430|NCT06457295||non-diabetic|patients who are above 40 years old and don't have diabetes
62611161|NCT02812251|EXPERIMENTAL|Part 1: Cohort 6|Participants will receive 60 mg JNJ-61393215 or placebo.
62611162|NCT02812251|EXPERIMENTAL|Part 1: Cohort 7|Participants will receive 90 mg JNJ-61393215 or placebo.
62611163|NCT02812251|EXPERIMENTAL|Part 1: Cohort 8|Participants will receive 120 mg JNJ-61393215 or placebo.
62611164|NCT02812251|EXPERIMENTAL|Part 2|Participants will receive JNJ-61393215 (dose to be determined).
62611165|NCT02812251|EXPERIMENTAL|Part 3|Participants will receive JNJ-61393125 (dose to be determined) or placebo under fed conditions.
62611166|NCT05164341|ACTIVE_COMPARATOR|metreleptin|Metreleptin \[Recombinant-methionyl human Leptin; r-metHuLeptin\] for daily injection is a sterile, white, solid lyophilised cake
62611167|NCT05164341|PLACEBO_COMPARATOR|placebo|Placebo for daily injection is a sterile, white, solid lyophilised cake
62051392|NCT05101525|ACTIVE_COMPARATOR|Patient without tendon healing|
62252431|NCT06457295||diabetic (0-5y)|patients who are above 40 years old and have diabetes for less than 5 years
62252432|NCT06457295||diabetics (5-10y)|patients who are above 40 years old and have diabetes for 5-10 years
62252433|NCT06457295||diabetics (10y < )|patients who are above 40 years old and have diabetes for more than 10 years
62611168|NCT02388711|EXPERIMENTAL|Usual Care with C-TraC Intervention|Patients/caregivers randomized to this group will receive all routine hospital discharge education/materials (same as usual care group), but will also be enrolled in the C-TraC Program. C-TraC is a low-resource, telephone-based, protocol-driven program designed to reduce 30-day rehospitalizations and to improve care transitions during the early post-hospital period.
62833931|NCT04457297|EXPERIMENTAL|trifluridine and tipiracil|
62833932|NCT04457297|PLACEBO_COMPARATOR|Placebo|
62833933|NCT04134208|EXPERIMENTAL|Diagnostic (fluciclovine F18, PET-CT)|Within 4 weeks before starting SST, patients receive fluciclovine F18 IV then undergo a PET-CT scan over 30 minutes. Within 22-28 weeks after starting SST, patients receive fluciclovine F18 IV and undergo a second PET-CT scan over 30 minutes.
62051393|NCT04988802|ACTIVE_COMPARATOR|Patients taking food supplement with levothyroxine|Patients will start taking food supplement with levothyroxine in the evening, and the other tablet of the food supplement in the evening for 8 weeks.
62051394|NCT04988802|PLACEBO_COMPARATOR|Patients taking placebo with levothyroxine|Patients will start taking placebo with levothyroxine in the evening, and the other tablet of the placebo in the evening for 8 weeks.
62252434|NCT04355741||Ambulatory|Patients that are self-isolated at home
62252435|NCT04355741||Ward|Patients that are in an isolated room at the hospital
62833934|NCT02859571|ACTIVE_COMPARATOR|Continuous oxytocin|oxytocin will be used at a starting dose of 1-2 mIU/min and the dose will be increased by 2 mIU/min at every 15 minutes until regular contractions will be obtained at a rate of 3-5 contractions in a 10-minute period. The maximum dose of oxytocin will 40 mIU/min and oxytocin will be administered until delivery.
62833935|NCT02859571|EXPERIMENTAL|intermittent oxytocin|oxytocin will be discontinued when cervical dilation will 5 cm and 2 hours after discontinuation oxytocin will be reused at a starting dose of 1-2 mIU/min and will be increased as the same protocol will be used for continuation oxytocin group.
62252436|NCT04355741||ICU|Patients that are in the ICU of the hospital
62441858|NCT03441542|ACTIVE_COMPARATOR|Standard of Care|Patients are recruited and consented into the study by the patient navigator at which time they will be reminded of their infection, consequences of untreated disease, and the availability of study sponsored antiviral treatment should they seek it. Patients will not be subsequently contacted by the study. Patients who seek treatment without patient navigation services will receive the same study provided HCV pre-treatment care and study provided treatment drugs when indicated. Self-referral to care and antiviral therapy when indicated are known to be effective in curing HCV among some patients, this arm is classified as an active comparator.
62252437|NCT03221738|EXPERIMENTAL|App-Based Cognitive Behavioral Therapy|12-week Smartphone-delivered CBT for BDD.
62252438|NCT04668053|ACTIVE_COMPARATOR|Traditional training protocol|Mobility and core strengthening, The step, The Lunge, Body weight squat, Body weight split squat , Bilateral hip raise, Push-up ,Cricket related skills
62252439|NCT04668053|EXPERIMENTAL|Hip flexor resistance protocol|Mobility and core strengthening, The step, The Lunge, Body weight squat, Body weight split squat , Bilateral hip raise, Push-up ,Cricket related skills and hip flexors resistance protocol
62441859|NCT03117673||group 1|Patients with mild to moderate TI and normal RVSP (\< 40mmHg) and mean PAP (\< 25mmHg)
62441860|NCT03117673||group 2|Patients with mild to moderate TI and elevated RVSP (\> 40mmHg) and mean PAP (\> 25mmHg)
62441861|NCT03117673||group 3|Patients with severe TI (defined as Vena contracta \> or equal 7mm, reversed systolic hepatic vein flow, proximal isovelocity surface area (PISA) radius \> 9 mm, and very large central jet or eccentric wall impinging jet)
62441862|NCT05088512||Experimental group:|Patients with bronchial asthma
62252440|NCT04006340|PLACEBO_COMPARATOR|Empirical group|Patients receive conventional triple therapy containing esomeprazole 40 mg, amoxicillin 1 g and clarithromycin 500 mg twice a day for 10 days
62252441|NCT04006340|ACTIVE_COMPARATOR|Genotypic resistance-guided tailored group|"Patients receive triple or quadruple therapy by resistance-associated mutations in 23S ribosomal RNA which are identified by polymerase chain reaction (PCR).~Triple therapy contains esomeprazole 40 mg, amoxicillin 1 g and clarithromycin 500 mg twice a day for 10 days and quadruple therapy contains esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days."
62252442|NCT03111485|EXPERIMENTAL|A (drug-placebo)|Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg) followed by a washout period and placebo oral capsule, each taken at bedtime for 2 weeks
62252443|NCT03111485|EXPERIMENTAL|B (placebo-drug)|Placebo oral capsule followed by a washout period and Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg), taken at bedtime for 2 weeks
62441863|NCT05088512||Control group|Patients without bronchial asthma
62441864|NCT05723497|EXPERIMENTAL|Elderberry juice|Participants will consume elderberry juice twice/day for 1-week.
62441865|NCT05723497|PLACEBO_COMPARATOR|Placebo beverage|Participants will consume placebo beverage twice/day for 1-week.
62051395|NCT06457074|EXPERIMENTAL|Finerenone|Patients divided into Finerenone group need to be treated with finerenone.
62051396|NCT06457074|ACTIVE_COMPARATOR|Spironolactone|Patients divided into Spironolactone group need to be treated with spironolactone.
62252444|NCT05187052||Group 1 (REI group)|Group 1 included patients that were intubated using rigid endoscope-assisted orotracheal intubation (REI) (0°, 45°, and 70°), 18-cm rigid telescope (Storz, Germany), full-HD camera (Olympus, USA), and Macintosh blade.
62252445|NCT05187052||Group 2 (V-MAC Group)|Group 2 included patients that underwent endotracheal intubation using a V-MAC (Besdata, China) videolaryngoscope and Magill forceps.
62252446|NCT05187052||Group 3 (FFEI group)|Group 3 included patients that underwent flexible fiberoptic endotracheal intubation (FFEI Group, Storz, Germany).
62252447|NCT00578110|EXPERIMENTAL|Group 1|Glaucoma Patients
62252448|NCT00578110|EXPERIMENTAL|Group 2|Glaucoma suspects
62252449|NCT00578110|ACTIVE_COMPARATOR|Group 3|Controls
62252450|NCT05988268|ACTIVE_COMPARATOR|Vibration Foam Rolling Group|The vibration foam rolling method will be applied to the gluteal, tensor fascia latae, hamstring, quadriceps femoris, and gastrocnemius muscles of both lower extremities of the participants in the Vibration Foam Rolling Group, in addition to the routine warm-up protocol, 3 days a week for a total of 15 minutes a day for 6 weeks.
62441866|NCT04690413|EXPERIMENTAL|Persons tested with investigational device|Persons tested with investigational device who previously tested positive or negative for COVID-19 with an emergency use authorized or FDA cleared COVID-19 test
62441867|NCT02089828|EXPERIMENTAL|autologous purified CD34+ cell|transplantation of autologous purified CD34+ cell
62441868|NCT02089828|ACTIVE_COMPARATOR|autologous PB-MNC|transplantation of autologous peripheral blood mononuclear cells
62441869|NCT04777032||Liver transplant recipients|All liver transplant recipient in Denmark aged 18-100 years will be eligible for inclusion in the DACOLT study. Inclusion requires the individual to be able to understand the study information in either Danish or English and to be able to provide an informed consent.
62051397|NCT04792697|EXPERIMENTAL|Advance/Extend Manipulation|"For \~2 weeks, Advance/Extend participants will advance bedtime and regularize wake time. The first night of the manipulation will be conducted in the lab under tightly-controlled experimental conditions. Participants will then go home and for the next 12 days will be instructed to:~* Sleep scheduling-- advance bedtime by 1.5 hours ( + sleep duration)~* Decrease evening blue light exposure via blue blocker goggles (2 hrs before bed)~* Increase morning bright light exposure via bright light goggles (30 min after rise)~* Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
62833936|NCT05975606|EXPERIMENTAL|Treatment group|Participants of this group will receive active rTMS along with real FES cycling.
62833937|NCT05975606|SHAM_COMPARATOR|Control group|Participants of this group will receive sham rTMS along with real FES cycling.
62252451|NCT05988268|ACTIVE_COMPARATOR|Non-Vibration Foam Rolling Group|The non-vibration foam rolling method will be applied to the gluteal, tensor fascia latae, hamstring, quadriceps femoris, and gastrocnemius muscles of both lower extremities of the participants in the Non-Vibration Foam Rolling Group, in addition to the routine warm-up protocol, 3 days a week for a total of 15 minutes a day for 6 weeks.
62833938|NCT01173094|EXPERIMENTAL|PTA|The patients with short-obstruction in the below-knee artery will be included in this group.
62833939|NCT01173094|EXPERIMENTAL|bypass|The patients with long-obstruction in the below-knee artery will be included in this group.
62051398|NCT04792697|ACTIVE_COMPARATOR|Control|Control participants will complete the baseline laboratory study, then maintain their habitual sleep schedules over the next 13 days at home, with no instruction on sleep timing or light exposure. Control participants will complete smartphone-and text-based assessments, thereby controlling for effort.
62051399|NCT01445925|ACTIVE_COMPARATOR|Pulmonary vein isolation|Patients will undergo pulmonary venous isolation plus pharmacological substrate modification
62051400|NCT01445925|EXPERIMENTAL|Pulmonary vein isolation + Linear Lesions|Patients will undergo pulmonary venous isolation plus both pharmacological and interventional substrate modification
62051401|NCT03011723|EXPERIMENTAL|Music therapy|10 weekly sessions of in-home music therapy for PWDs and a caregiver, including weekly practicing of the interventions with the caregiver between the sessions. The treatment is administered individually.
62252452|NCT05988268|NO_INTERVENTION|Control Group|No intervention will be applied to the control group. This group will continue the routine warm-up protocol.
62252453|NCT02931136|ACTIVE_COMPARATOR|treatment group|Huperzine A treatment.
62252454|NCT02931136|PLACEBO_COMPARATOR|Placebo group|The placebo in 52 weeks.
62252455|NCT04660526|EXPERIMENTAL|Intervention (Enhanced Standard of Care)|Mass community CPR/AED training, optimize 911 medical dispatch, improve first responder performance
62252456|NCT04660526|NO_INTERVENTION|Control (Standard of Care)|Usual care, continuing standard quality improvement effort
62441870|NCT04777032||Control group 1_CGPS|The Copenhagen General Population Study (CGPS) is an ongoing observational population study with more than 110.000 participants from the greater Copenhagen area. All residents in the greater Copenhagen area \> 40 years and 25% of 20-40 years old are invited to participate in the study and in follow-up examinations every decade. A random sample of 10.000 participants aged ≥ 40 years had a contrast enhanced CT of the chest including CT angiography of the heart performed. Of these, 6500 had a contrast enhanced CT of the abdomen.
62441871|NCT04777032||Control group 1_CCHS|The Copenhagen City Heart Study (CCHS) includes a random population sample included from the greater Copenhagen area. Health surveys have been repeated 5 times between 1976 and 2015. Almost 4000 participants were randomly selected for echocardiography.
62441872|NCT00321711|ACTIVE_COMPARATOR|Dose level 1 500 AMG 531 (Part A - azacitidine)|500 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
62441873|NCT00321711|ACTIVE_COMPARATOR|Dose level 1 750 AMG 531 (Part B - decitabine)|750 mcg AMG 531 weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
62441874|NCT00321711|ACTIVE_COMPARATOR|Dose level 2 750 AMG 531 (Part A - azacitidine)|750 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
62441875|NCT00321711|PLACEBO_COMPARATOR|Placebo (Part A - azacitidine)|Placebo weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
62441876|NCT00321711|PLACEBO_COMPARATOR|Placebo (Part B - decitabine)|Placebo weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
62441877|NCT01567306|EXPERIMENTAL|Allergovac Depot Group 1 Active|
62441878|NCT01567306|EXPERIMENTAL|Allergovac Depot Group 2 Active|
62441879|NCT01567306|EXPERIMENTAL|Allergovac Depot Group 3 Active|
62441880|NCT01567306|EXPERIMENTAL|Allergovac Depot Group 4 Active|
62441881|NCT01567306|EXPERIMENTAL|Allergovac Depot Group 5 Active|
62441882|NCT01567306|PLACEBO_COMPARATOR|Placebo - Group 6|
62441883|NCT02035137|ACTIVE_COMPARATOR|Single-Agent 131I-MIBG|Single-agent 131I-MIBG (Arm A) 18 mCi/kg 131I-MIBG on Day 1 and autologous stem cell infusion on Day 15.
62441884|NCT02035137|ACTIVE_COMPARATOR|131I-MIBG with Vincristine/Irinotecan|Vincristine / irinotecan / 131I-MIBG (Arm B): vincristine 2 mg/m2 (maximum dose 2 mg) intravenously on Day 0; irinotecan 50 mg/m2 (maximum dose 100 mg) intravenously on Days 0 to 4. Patients will also receive diarrhea prophylaxis with cefixime 8 mg/kg/day orally on Days -1 to +6. 131I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15.
62611169|NCT02388711|NO_INTERVENTION|Usual Care|Usual care group patients will receive all routine University of Wisconsin Hospital and Clinics (UWHC) discharge education/materials. This includes pharmacy-led medication teaching, physician discussions and routine nursing education. No post hospital education/contact is performed by these providers. Caregivers are sometimes, but not always, involved. Patients may receive home health services, depending on their physician's discharge plan.
62833940|NCT05821777|EXPERIMENTAL|LB101|"Part 1~Part 1a participants will receive LB101 once every 2 weeks (Q2W) (28-day cycle), with a preliminary plan for 6 sequential dose levels. Part 1b will be a dose optimization and will include \>1 dose levels and/or dose schedules that have been deemed safe and tolerable in Part 1a.~Part 2~Dose regimen(s) for participants in Part 2 will be based on the results of Part 1."
62833941|NCT03597945|PLACEBO_COMPARATOR|Group Placebo|"For patients of this group, the intervention was a femoral nerve block with:~* 15 ml of lidocaine with epinephrine (300 mg)~* and 3 ml of normal saline as adjuvant."
62833942|NCT03597945|ACTIVE_COMPARATOR|Group Magnesium|"For patients of this group, the intervention was a femoral nerve block with:~* 15 ml of lidocaine with epinephrine (300 mg)~* and 3 ml of Magnesium sulfate 15% (450 mg) as adjuvant."
62611170|NCT04811664|EXPERIMENTAL|Immediate Vaccination|Participants will receive Moderna COVID-19 Vaccine in 100 mcg dose given as 0.5 ml Intramuscular into the deltoid muscle on Day 1 and Day 29.
62441885|NCT02035137|ACTIVE_COMPARATOR|131I-MIBG with Vorinostat|Vorinostat / 131I-MIBG (Arm C); vorinostat 180 mg/m2 (maximum dose 400 mg) orally once daily on Days -1 to +12 (14 total doses). 131I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15.
62611171|NCT04811664|EXPERIMENTAL|Standard of care|Participants will receive Moderna COVID-19 Vaccine in 100 mcg dose given as 0.5 ml Intramuscular into the deltoid muscle on Day 113 and Day 141.
62611172|NCT04811664|NO_INTERVENTION|Vaccine Declined|Participants who prefer not to be vaccinated, If requested, participant will be offered vaccine if they have not received vaccine outside of the study
62611173|NCT05061602||Diabetic Group|The patients were included if they were of 18 years or older, with a diagnosis of diabetes mellitus for more than three years.
62611174|NCT05061602||NonDiabetic Group|The healthy age-matched control group was included.
62611175|NCT01732445|EXPERIMENTAL|Supportive care (ruxolitinib phosphate and danazol)|Patients receive ruxolitinib phosphate PO BID and danazol PO TID on days 1-56. Treatment repeats every 56 days for 6 courses in the absence of disease progression or unacceptable toxicity. At the treating physician's discretion, patients may continue treatment past 6 courses if they are without disease progression.
62833943|NCT02681029|EXPERIMENTAL|Blastocyst transplantation|The infertile women who underwent intra- uterus transferring of blastocyst from thawed cleavage embryo
62051402|NCT01798394|ACTIVE_COMPARATOR|Progesterone|Take micronized natural progesterone capsule by mouth, twice daily (approximately at 8 am and 8 pm) for four weeks beginning on postpartum day 4.
62051403|NCT01798394|PLACEBO_COMPARATOR|Placebo|Take placebo capsule by mouth, twice daily (approximately at 8 am and 8 pm) for 4 weeks beginning on postpartum day 4.
62051404|NCT04434807|EXPERIMENTAL|Minimally invasive hematoma evacuation|Patients randomized to minimally invasive hematoma evacuation will have neurosurgery followed by standard medical therapy in a stroke care unit or intensive care unit, as appropriate to the patients clinical condition.
62051405|NCT04434807|NO_INTERVENTION|Standard care (medical therapy)|Patients randomized to medical management will receive the standard medical therapies for the treatment of intracerebral hemorrhage in a stroke care unit or intensive care unit, as appropriate to the patients clinical condition, with no planned surgical intervention.
62051406|NCT04174248|EXPERIMENTAL|Experimental group|Experimental group with BCSMS App using
62051407|NCT04174248|NO_INTERVENTION|Control group|Control group without BCSMS App using
62051408|NCT00791206|EXPERIMENTAL|1|
62051409|NCT00791206|OTHER|2|
62051410|NCT05559957||Isolated oligohydramnios group|Cases with oligohydramnios (amniotic fluid index less than 5) without an overt underlying reason in the third trimester
62051411|NCT05559957||Normal amniotic fluid group|Normal pregnancy cases with normal amniotic fluid index
62611176|NCT05477992|EXPERIMENTAL|Endovascular embolisation|Embolisation is an effective measure to reduce intraoperative bleeding for vascular tumours of the head and neck. It is often carried out from 24 to 72 hours prior to the surgical resection to allow time for maximal thrombosis of the occluded vessels and prevent recanalisation of the occluded arteries or formation of collateral arterial channels. Data will be collected for primary and secondary outcome measures
62611177|NCT05718141|EXPERIMENTAL|Intervention: COMET-GB|Online single session intervention via qualtrics (any internet connected device) based on cognitive and behavioural principles.
62611178|NCT05718141|NO_INTERVENTION|Waiting List Control|Participants in the control arm will be provided with information about sources of wellbeing support they can access and will also be asked to fill out additional questionnaires at baseline, which will act as a control for time spent completing online activities. These measures are a Symptom Importance Rating Questionnaire, the Chalder Fatigue Questionnaire \[32\], Pittsburgh Sleep Quality Index \[33\], Snaith-Hamilton Pleasure Scale \[34\], Fatigue Associated with Depression Scale \[35\]. These will not be completed by the intervention group nor reported as main outcomes on the RCT itself, but will be used in separate observational projects.
62611179|NCT06260475||Patients with symptomatic peripheral artery disease and aortoiliac obstrutive disease|Chronic limb-threatening ischemia or claudicants due to extensive Aortoiliac Occlusive Disease (AIOD), particularly in Trans-Atlantic Inter-Society Consensus II (TASC-II) type C and D lesions
62611180|NCT02589353|EXPERIMENTAL|Acarbose|Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain \~484 microgram acarbose; total maximum exposure of each subject to acarbose will be \~14-30 mg each session (1-20 sessions)
62833944|NCT02681029|PLACEBO_COMPARATOR|Control|The infertile women who underwent intra- uterus transferring of thawed cleavage embryo.
62051412|NCT02093325|EXPERIMENTAL|eltrombpag|Eligible patients will be enrolled randomly in 2:1 ratio to Investigational Drug (Eltrombopag) arm, 50 mg/day, or placebo arm for 7 days.
62051413|NCT02093325|PLACEBO_COMPARATOR|Eltrombopag/placebo|Eligible patients will be enrolled randomly in 2:1 ratio to Investigational Drug (Eltrombopag) arm, 50 mg/day, or placebo arm for 7 days
62051414|NCT00122642|EXPERIMENTAL|1|The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes for patients not in the hospital.
62051415|NCT00122642|PLACEBO_COMPARATOR|2|The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
62051416|NCT06491251|EXPERIMENTAL|Varicocelectomy group|Bilateral Subinguinal microscopic varicocelectomy
62051417|NCT06491251|NO_INTERVENTION|Controlled group|no intervention , follow up
62051418|NCT01217008|EXPERIMENTAL|GRNOPC1|Subjects who receive an injection of GRNOPC1
62051419|NCT04196218|OTHER|Driving assessment|All subjects will undergo a driving assessment(s) following shoulder surgery.
62441886|NCT00751374|OTHER|group A|Topical gentamicin cream
62441887|NCT00751374|ACTIVE_COMPARATOR|Group B|topical gentamicin cream alternates with mupirocin cream at monthly basis
62441888|NCT02761369|EXPERIMENTAL|A PAS protocol, right-to-left, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a PAS protocol, starting with the right DLPFC
62441889|NCT02761369|EXPERIMENTAL|A PAS protocol, left-to-right, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a PAS protocol, starting with the left DLPFC
62252457|NCT00867633||Urothelial carcinoma|The DNA samples extracted from the urothelial carcinoma tissue
62833945|NCT01538095|EXPERIMENTAL|Treatment (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62441890|NCT02761369|SHAM_COMPARATOR|A sham PAS protocol, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a sham PAS protocol, starting with the right DLPFC (@ 40% of individual MT)
62441891|NCT03520283|EXPERIMENTAL|Supportive Care (MAP)|Participants complete MAP in-clinic over 60-90 minutes.
62051420|NCT03921203||Type 2 diabetes patients|
62051421|NCT03921203||Healthy controls|
62051422|NCT05964608|EXPERIMENTAL|Treatment group|"Pre-tests were applied to the men (Personal Information Form and PEDT) and their spouses (Personal Information Form, FSFI, and SQOL-F) just before the behavioral treatment was applied to the men in the treatment group. In the first interview with the men, the researchers delivered information about behavioral therapy and set therapy days and hours. Structured interviews, consisting of a total of 6 sessions, were held once every two weeks for men with premature ejaculation problems. Behavioral therapy took place once every two weeks for a total of six 45-minute sessions. The stop-start technique was the therapy used. Behavioral therapy interviews were conducted at the urology outpatient clinic of the hospital. Post-tests were administered to men with premature ejaculation (PEDT) and their spouses (FSFI and SQOL-F) immediately after the 6th session was completed."
62441892|NCT00293956||1|Full-term and near-term infants with respiratory distress in the first 24 hours of life
62441893|NCT00745251|EXPERIMENTAL|VI-0521|15 mg Phentermine and 92 mg Topiramate
62833946|NCT06312904|EXPERIMENTAL|paravertebral block group|This group of patients will undergo postoperative paravertebral block.
62611181|NCT05451394|EXPERIMENTAL|ROAF Arm|6 one-hour workshops working on enhancing postural awareness through the use of ROAF
62833947|NCT06312904|ACTIVE_COMPARATOR|local infiltration group|This group of patients will undergo postoperative local infiltration anesthesia.
62051423|NCT02331381|EXPERIMENTAL|MRI|Participants will have a custom immobilization device created for them for the purpose of the study. They will be scanned from one to four occasions during radiation treatment. If enrolled in the study prior to the first radiation treatment, the first imaging scan may be scheduled prior to the first radiation treatment, with subsequent scans during treatment separated by at least one day. Patients will be in the scanner for approximately 30 minutes to one hour, either prior to or following their standard of care radiotherapy treatment.
62051424|NCT03238898|ACTIVE_COMPARATOR|botulinum toxin type A|Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
62051425|NCT03238898|PLACEBO_COMPARATOR|Normal saline|The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
62051426|NCT02953938|ACTIVE_COMPARATOR|mono therapy|ranibizumab alone
62252458|NCT00867633||RCC|the DNA sample extracted from RCC
62252459|NCT00867633||Non-cancer|The DNA sample extracted from the non-cancerous kidney tissue
62441894|NCT00745251|PLACEBO_COMPARATOR|Placebo|
62611182|NCT05451394|ACTIVE_COMPARATOR|Active control|6 one-hour workshops on higher cognitive processes (memory, attention...)
62252460|NCT01547585|PLACEBO_COMPARATOR|Control|- Isocaloric control muffins
62441895|NCT02038478|EXPERIMENTAL|Transplantation Arm|"Transplantation~One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects."
62441896|NCT01070641|ACTIVE_COMPARATOR|Carvedilol|Each patient will receive Carvedilol 12.5mg QD
62441897|NCT01070641|ACTIVE_COMPARATOR|Esophageal Variceal Band Ligation|Each patient will undergo for serial esophageal variceal band ligations after 3 weeks of last session till the eradication of varices
62441898|NCT05986877|EXPERIMENTAL|lowest dose group|8 subjects will be randomized to receive lowest dose of STSA-1201 or dose-matched placebo.
62441899|NCT05986877|EXPERIMENTAL|low dose group|12 subjects will be randomized to receive low dose of STSA-1201 or dose-matched placebo.
62611183|NCT01810783|EXPERIMENTAL|Brexpiprazole|
62611184|NCT00899704||Group 1|Patient tissue samples are screened using polymerase chain reaction (PCR) for human papilloma virus-specific primers. Samples are analyzed to identify a nodal-metastasis signature for oral squamous cell carcinoma. Samples also undergo microarray analysis to quantify expression levels for targeted genes. Initial data analysis is performed using Affymetrix® Microarray Suite 5.0 to quantify expression levels for targeted genes.
62611185|NCT01388504|EXPERIMENTAL|sodium nitrite|
62611186|NCT01388504|PLACEBO_COMPARATOR|placebo|sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes
62611187|NCT06404840|EXPERIMENTAL|AG+nimotuzumab|Pts with potentially resectable, treatment-naïve PCLM received nimotuzumab (400 mg, iv, d1, qw) and AG chemotherapy (gemcitabine 1000mg/m², Nab-paclitaxel 125mg/m², d1, d8, 21d cycle).
62611188|NCT05817812|EXPERIMENTAL|Efanesoctocog alfa|All patients will be treated intravenously once weekly with 50 IU/kg efanesoctocog alfa
62051427|NCT02953938|EXPERIMENTAL|combination therapy|ranibizumab with Grid\&Direct short pulse laser photocoagulation
62051428|NCT02641392|EXPERIMENTAL|GED-0301 (160 mg) followed by Placebo intermittent 160 mg|GED-0301 160 mg once daily (QD) for 12 weeks, followed by alternating Placebo (PBO) QD for 4 weeks with GED 0301 160 mg QD for 4 weeks, up to 208 weeks, if the subject previously received Placebo in the prior GED-0301 Study
62051429|NCT02641392|EXPERIMENTAL|Intermittent GED-0301 160 mg and placebo|Alternating GED-0301 160 mg once daily (QD) for 4 weeks with placebo (PBO) QD for 4 weeks, up to 208 weeks, depending on previous response in the prior GED-0301 study
62051430|NCT02641392|EXPERIMENTAL|Intermittent placebo and GED-0301 40 mg|Alternating PBO once daily (QD) for 4 weeks with GED-0301 40 mg QD for 4 weeks with, up to 208 weeks, depending on previous response in the prior GED-0301 study
62441900|NCT05986877|EXPERIMENTAL|middle dose group|12 subjects will be randomized to receive middle dose of STSA-1201 or dose-matched placebo.
62441901|NCT05986877|EXPERIMENTAL|high dose group|12 subjects will be randomized to receive high dose of STSA-1201 or dose-matched placebo.
62441902|NCT04035590|ACTIVE_COMPARATOR|With drain|Patients undergo mastectomy with flap fixation and low vacuum drainage.
62441903|NCT04035590|EXPERIMENTAL|No drain|Patients undergo mastectomy with flap fixation and low vacuum drainage is omitted.
62441904|NCT02711956|EXPERIMENTAL|DE and DC - ZEN003694 in Combination with Enzalutamide|"Dose Escalation (DE) and Dose Confirmation (DC): ZEN003694 will be administered orally once daily with enzalutamide in 28-day cycles, enrolling mCRPC patients.~Two patient populations will be enrolled in DE and DC. Cohort A: Patients with prior progression on enzalutamide or apalutamide by PCWG2 criteria who were receiving a stable dose of enzalutamide at the time of study entry. Cohort B: Patients who were enzalutamide-naïve with prior progression on abiraterone by Prostate Cancer Working Group 2 (PCWG2) criteria."
62441905|NCT00087191|EXPERIMENTAL|Diagnostic (EF5, motexafin lutetium)|Patients receive EF5 IV over 1-2.5 hours on day 1 and motexafin lutetium IV over 10-15 minutes on day 2. Patients undergo definitive surgical resection approximately 3 hours after motexafin lutetium administration. Hypoxia and motexafin lutetium levels in the resected tumors are evaluated. Tumor to normal tissue ratios are also determined.
62441906|NCT03592381|EXPERIMENTAL|Ridge expansion by osseodensification|Ridge expansion and osteotomy drilling by osseodensification in conjunction with simultaneous implant placement in narrow ridges.
62441907|NCT03592381|ACTIVE_COMPARATOR|Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
62441908|NCT00850278|EXPERIMENTAL|FLT-PET imaging|Prior to surgical resection, patient will undergo \[11C\]MET PET imaging, \[18F\]FLT PET imaging, MRI, and spectroscopy imaging.
62441909|NCT03231618|EXPERIMENTAL|Normal weight group|20 normal-weight males taking 3 types of assigned diets in random orders
62441910|NCT03231618|EXPERIMENTAL|Overweight/ obesity group|20 overweight/ obesity males taking 3 types of assigned diets in random orders
62611189|NCT02862925|NO_INTERVENTION|Pre-Intervention|A consecutive sample of 350 patients will be collected. After informed consent, data will be abstracted from the patient's record including day and time of delivery, method of delivery, parity, gestational age, meconium presence, heart rate abnormality and induction methods. For CD, the following data will be collected: decision-to-delivery time, Partogram adherence, time of each FSST, Apgar score, date and time of delivery and Comorbidities such as: Hypertension-spectrum disorders, Malaria, Postpartum Hemorrhage, Macrosomia, History of CD, Diabetes, Sickle Cell, and HIV status.
62833948|NCT04241419|EXPERIMENTAL|High Intensity Walking|Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.
62833949|NCT05479019|EXPERIMENTAL|Positive stimuli|Images/trials that contain a target
62051431|NCT02641392|EXPERIMENTAL|Continuous GED-0301 40 mg|GED-0301 40 mg once daily (QD) for up to 208 weeks
62051432|NCT02641392|EXPERIMENTAL|Intermittent placebo and GED-0301 160 mg|Alternating PBO QD for 4 weeks with GED-0301 160 mg QD for 4 weeks, through Week 208
62051433|NCT03005509|NO_INTERVENTION|Pre-intervention group|"All injured patients to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority triage category will be eligible for inclusion.~The Trauma Quality Improvement Meeting (TQIM) checklist will not be introduced during this phase."
62252461|NCT01547585|EXPERIMENTAL|Low Dose Soy|- Isocaloric muffins containing low dose of soy
62252462|NCT01547585|EXPERIMENTAL|High Dose Soy|- Isocaloric muffins containing high dose soy
62833950|NCT05479019|EXPERIMENTAL|Negative stimuli|Images/trials that do not contain a target
62833951|NCT04046120|NO_INTERVENTION|Heel included|The bandage is made by including the heel as recommended in routine.
62051434|NCT03005509|OTHER|Post-intervention group|"All injured patients to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority triage category will be eligible for inclusion.~The Trauma Quality Improvement Meeting (TQIM) checklist will be used at all Trauma Quality Improvement Meetings (TQIMs)"
62252463|NCT04169087||General anesthesia|Patients undergoing general anesthesia
62252464|NCT01550861|EXPERIMENTAL|In vitro Maturation|in vitro maturation of immature oocytes
62441911|NCT03980379|EXPERIMENTAL|experimental group|304 injection.WILL be administered single dose IV in the patients with CD20 positive B cell NHL
62441912|NCT03980379|ACTIVE_COMPARATOR|control group|Rituximab will be administered single dose IV in the patients with CD20 positive B cell NHL.
62441913|NCT02730390||Probucol Tablets|Target is 3,000 patients in the Philippines diagnosed with hyperlipidemia (including familial hypercholesterolemia and xanthoma).
62441914|NCT05427838||Intervention (training)|"Subjects undergo online CT Head interpretation training:~Summary:~The trial participants will be required to complete a baseline assessment where users will review a set of scans and provide a diagnosis before submitting the case. Users will then be given access to an online training module. Once the training is completed, the users will complete a second assessment.~They will then be asked to evaluate a minimum of 30 CT scans each during their clinical shifts over a 3-month period. They will be asked to record their scan interpretation, the time the scans was performed, and the time they reviewed the scan. They will also be asked to retrospectively document the findings of the standard clinical radiology report, and the time it was issued.~At the end of the 3 month period they will repeat the online assessment to assess their performance, and again after a further three months to assess their retention of any improvement in reporting performance."
62441915|NCT05427838||Control (no Training)|"Subjects do not undergo online CT Head interpretation training:~Summary:~To provide a control for comparison as to the relative benefits of the online training phase and the clinical interpretation phase in terms of improving reporting performance, 30 participants (6 clinicians from each site) will be randomised to undertake the clinical interpretation phase prior to the training module."
62441916|NCT01828255|EXPERIMENTAL|SENSIMED Triggerfish®|Device: portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization.
62441917|NCT03020472|EXPERIMENTAL|2008-2009 FluMist LAIV (Intranasal)|2008-2009 FluMist LAIV (Intranasal) Seasonal live, attenuated influenza vaccine
62441918|NCT01488578||Tolterodine tartrate.|Subjects taking Tolterodine tartrate.
62441919|NCT03790787|EXPERIMENTAL|Sequential arm ABC|A: Empagliflozin 25 mg QD in the morning on Days 1-5; B: Empagliflozin 25 mg in the morning and Dorzagliatin 75 mg BID (morning and evening) on Days 6-10, with only the morning dose on Day 10; C: Dorzagliatin 75 mg BID (morning and evening) on Days 11-15, with only the morning dose on Day 15.
62441920|NCT04111237|ACTIVE_COMPARATOR|Two Finger|two finger method for performing chest compressions
62441921|NCT04111237|EXPERIMENTAL|Two Thumb Technique|Two Thumb Technique
62441922|NCT01414946|EXPERIMENTAL|Glucose and amino acids|Perioperative nutrition with glucose and amino acids
62441923|NCT01414946|ACTIVE_COMPARATOR|Amino acids only|Perioperative nutrition with amino acids only
62441924|NCT05455242|EXPERIMENTAL|Habit Formation Interventions|Single subject design used for individual control (A-B design). During baseline phase (A), participants completed self-care activities ratings once per week for 4 weeks. During intervention phase (B), participants engaged in weekly sessions to address goals related to diabetes self-management and guided in habit formation. Participants engaged in intervention for 10 weeks, in accordance with habit formation recommendations by Lally et al. (2010). Each weekly session were held virtually (telephone or Zoom) and lasted 30-60 minutes, beginning with administration of the SDSCA and SRBAI. Participants were instructed in ongoing context-specific implementation intention to promote occupational participation in DSM through habit formation. This instruction included continued education and context modification recommendations. At two week intervals, additional areas of DSM were added until each were covered: blood glucose monitoring, nutrition, medication management, and physical activity.
62833952|NCT04046120|EXPERIMENTAL|Heel not included|he bandage is made by leaving the heel uncovered.
62833953|NCT04200846|EXPERIMENTAL|Exercise intervention|Private supervised strength training exercise (e.g., body weight or dumbbell exercises) will occur in the Cancer Center Exercise Medicine Unit or the Hershey Center for Applied Research (HCAR) two days a week. In addition, subjects will be instructed to exercise on their own, at home, three days a week doing 30 minutes of moderate intensity aerobic exercise (e.g., walking at 45-55% maximum heart rate determined by the formula max heart rate = 220bpm - 0.64\*age in years).
62252465|NCT04410588|NO_INTERVENTION|saline|saline for pain for nasal packing
62252466|NCT04410588|ACTIVE_COMPARATOR|levobupivacaine|levobupivacaine for pain of nasal packing
62252467|NCT04410588|ACTIVE_COMPARATOR|fentanyl +levobupivacaine|fentanyle with levobupivacaine for pain of nasal packing
62252468|NCT04883320||participants with no asthma|Have no evidence of any long term lung condition or any other disabling condition and they must not have had a chest infection in the preceding 4 weeks.
62252469|NCT04883320||participants with mild/moderate asthma|
62252470|NCT04883320||participants with severe asthma|
62252471|NCT02047136|EXPERIMENTAL|Treatment group (on low histamine diet)|78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
62252472|NCT02047136|ACTIVE_COMPARATOR|Well-balanced diet|Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
62252473|NCT04981314|EXPERIMENTAL|Treatment with echinacea|EQUINÁCEA ARKOPHARMA, 2 caplets at breakfast, 2 caplets at lunch and 2 caplets at dinner with a glass of water, for 10 days.
62252474|NCT04981314|PLACEBO_COMPARATOR|Placebo|Hard caplets indistinguishable from EQUINÁCEA ARKOPHARMA, 2 caplets at breakfast, 2 caplets at lunch and 2 caplets at dinner with a glass of water, for 10 days.
62252475|NCT02132884|ACTIVE_COMPARATOR|Arm A (standard of care treatment)|Patients receive standard of care treatment based on the discretion of the treating physician.
62252476|NCT02132884|EXPERIMENTAL|Arm B (genetic sequencing and targeted therapy)|Patients undergo collection of tissue and blood samples for analysis via sequencing. Upon disease progression following front-line treatment, patients receive specific targeted therapy based on the mutational status obtained during sequencing.
62252477|NCT04825795||DPP4-inhibitor|Patients who were prescribed DPP4-inhibitor during the period between two coronary CT scan.
62441925|NCT02203136||Muscle Invasive Bladder Cancer (MIBC)|During bladder cancer surgery, whole genome gene expression array assays obtained on tumor biopsy specimens. Analysis to determine biologic subtypes which will then be correlated with final pathology, identifying the subtype(s) associated with noc-MIBC. 3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
62441926|NCT03979209|EXPERIMENTAL|Mometasone 1mg|1mg capsule dissolved in 240mg saline solution nasal irrigation
62441927|NCT03979209|EXPERIMENTAL|Mometasone 2mg|2mg capsule dissolved in 240mg saline solution nasal irrigation
62441928|NCT03979209|EXPERIMENTAL|Mometasone 4mg|4mg capsule dissolved in 240mg saline solution nasal irrigation
62441929|NCT01093079||Laparoscopic partial nephrectomy|
62441930|NCT01093079||Open Partial nephrectomy|
62441931|NCT04184310|EXPERIMENTAL|old patient with rectal prolapse|old co-morbid patient with complete rectal prolapse unfit for abdominal operation
62441932|NCT02356965|EXPERIMENTAL|Ketamine 70 mg Sublingual Wafer|Single dose of 70 mg ketamine sublingual wafer
62441933|NCT02356965|EXPERIMENTAL|Ketamine 100 mg Sublingual Wafer|Single dose of 100 mg ketamine sublingual wafer
62441934|NCT02356965|PLACEBO_COMPARATOR|Placebo|Single dose of placebo sublingual wafer
62441935|NCT06087809|NO_INTERVENTION|Control|No intervention
62441936|NCT06087809|EXPERIMENTAL|Education and feedback|"Clinicians within practices assigned to the Education/Feedback group received a personal email from one of the authors at the outset of the project explaining that the Committee on Infectious Diseases of the American Academy of Pediatrics (the Red Book Committee) recommends limiting the duration of antibiotic treatment for uncomplicated CAP to 5 days and for uncomplicated SSTI to 5-7 days. The email also shared data on the performance of the individual PCC and their practice for CAP and SSTI for the baseline period and the goals for each-50% for CAP and 67% for SST. An infographic was also attached to the email which could be printed and displayed in the PCC's work area. One month and two months into the project period, each PCC in the Education/Feedback group received an email reminding them of the recommendations and updating them on their performance since the previous email."
62252478|NCT04825795||No DPP4-inhibitor|Patients who were not prescribed DPP4-inhibitor during the period between two coronary CT scan.
62252479|NCT04570501|EXPERIMENTAL|Angiotensin (1-7)|Participants receive treatment for 7 days.
62252480|NCT04570501|PLACEBO_COMPARATOR|Placebo|Participants receive treatment for 7 days.
62252481|NCT06343506|EXPERIMENTAL|Affected Individuals|
62252482|NCT03420794|ACTIVE_COMPARATOR|Control Group|Patients undergoing total laparoscopic hysterectomy for benign disease who will receive celecoxib 200mg, acetaminophen 1000mg, and gabapentin 600mg by mouth once just prior to surgery.
62252483|NCT03420794|EXPERIMENTAL|Study Group|Patients undergoing total laparoscopic hysterectomy for benign disease who will receive celecoxib 200mg, acetaminophen 1000mg, and gabapentin 600mg by mouth once 3-4 hours prior to surgery.
62252484|NCT04613154|ACTIVE_COMPARATOR|Magnesium|Given 1000 mg oral magnesiumcitrate once daily (4\*250mg) during the day of surgery and the next 6 Days.
62252485|NCT04613154|PLACEBO_COMPARATOR|Placebo|Given placebo once daily during the day of surgery and the next 6 Days.
62252486|NCT01247415||Anaphylaxis|Anaphylaxis: these patients will have to meet at least level 3 of diagnostic certainty according to the Brighton Collaboration criteria for anaphylaxis
62833954|NCT04200846|NO_INTERVENTION|Control|Subjects in the control condition will be instructed to continue their medical care at the discretion of their treating medical professional and to maintain their current exercise level. Weekly phone calls will be performed to ensure adherence to the protocol (no changes in activity). Subjects will report to Penn State on a monthly basis for interim history and physical to confirm self-reports. Subjects will also be given a FitBit ChargeHR3 and downloaded data review will be performed monthly at the in-person visits.
62833955|NCT05053802|EXPERIMENTAL|Microwave ablation plus Camrelizumab|Microwave ablation plus Camrelizumab (no more than 16 cycles)
62833956|NCT05053802|OTHER|Microwave ablation|Microwave ablation
62833957|NCT05458115||liver resection group|
62833958|NCT01136161|EXPERIMENTAL|RUTI 5 micrograms of FCMtb in HIV -|n=12
62833959|NCT01136161|EXPERIMENTAL|RUTI 25 micrograms of FCMtb in HIV -|n=12
62252487|NCT01247415||Allergic-like reactions|Allergic-like reactions: These patients will have to have displayed at least one sign or symptom of an allergic reaction (any of the minor or major criteria of anaphylaxis) but will exclude patients with conjunctivitis who will belong to the ORS group
62051435|NCT01287130|EXPERIMENTAL|DL 1|AZD6244 once daily on days 1, 8, 15 and 22. Cetuximab 400 mg/m2 IV loading dose over 120minutes on day 1 and cetuximab 250 mg/m2 IV loading dose over 60 minutes on days 8, 15,22
62051436|NCT01287130|EXPERIMENTAL|DL 2|AZD6244 twice daily on days 1, 8, 15 and 22. Cetuximab 400 mg/m2 IV loading dose over 120minutes on day 1 and cetuximab 250 mg/m2 IV loading dose over 60 minutes on days 8, 15,22
62252488|NCT01247415||ORS cases|ORS cases: According to the Public Health Agency case definition, these patients should have presented a bilateral conjunctivitis plus ≥1 of the seven respiratory symptoms (cough, wheeze, chest tightness, difficulty breathing, difficulty swallowing, hoarseness or sore throat) that started within 24 hrs of vaccination, with or without facial oedema (no restriction for duration) (ref: Public Health Agency of Canada: User Guide: Report of Adverse Events Following Immunization (AEFI) Appendix III National Case Definitions of AEFIs of Special Interest: oculo-respiratory Syndrome. http://www.phac-pc.gc.ca/im/aefi_guide/ann3-eng.php
62252489|NCT01247415||Controls|Controls will be individuals who received the pH1N1 vaccine but did not present any of the above mentioned adverse events after their vaccine.
62252490|NCT06070077||On ground CPR|Quality of CPR provided on the ground in a standard environment. (n=6)
62252491|NCT06070077||Via ferrata CPR|Quality of CPR provided on the via ferrata place. (n=6)
62252492|NCT04765475|EXPERIMENTAL|MotivationaI Interviewing Group|Participants in this study group will receive a brief, culturally appropriate, and age-tailored motivational interviewing (MI) intervention targeting facilitators and barriers to appropriate testing, isolation, and care-seeking among young adults and elders. This group will also receive supportive services. Participants will be provided with referrals to needed medical, mental, or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask-wearing, how to prevent the spread in the home and managing stress during COVID-19.
62441937|NCT06087809|EXPERIMENTAL|Clinical decision support|"Clinicians within practices assigned to the CDS group did not receive education or any performance feedback relative to the initiative. If they prescribed an antibiotic linked to a diagnosis of CAP with a duration of greater than 5 days, or to a diagnosis of SSTI with a duration greater than 7 days, they received a pop-up advisory when they attempted to sign the prescription alerting them to the relevant recommendation (eFigure 3). The alert was a hard stop, meaning that the prescriber was required to respond in some way to continue their work. Options included altering the prescription to comply with the recommended duration or acknowledging the alert and sending the prescription with the originally selected duration."
62441938|NCT06087809|EXPERIMENTAL|Combined group|Clinicians within practices assigned to the combined group received both interventions as described above.
62441939|NCT00395083|NO_INTERVENTION|Group 1|Patients allocated to the control arm will receive standardized care that incorporates guide-line based recommendations including influenza vaccination, a short-acting bronchodilator, and either a long-acting bronchodilator or inhaled corticosteroid inhaler.
62441940|NCT00395083|EXPERIMENTAL|Group 2|The comprehensive group will receive an initial, intense education program with development of an action plan, and regular telephone contacts by a case manager in addition to standardized COPD care.
62833960|NCT01136161|EXPERIMENTAL|RUTI 50 micrograms of FCMtb in HIV -|n=12
62833961|NCT01136161|PLACEBO_COMPARATOR|RUTI Matching Placebo in HIV -|n=12
62051437|NCT00832767|ACTIVE_COMPARATOR|SILS Port|SILS™ Port Laparoscopic Cholecystectomy
62051438|NCT00832767|ACTIVE_COMPARATOR|Four Port|Four Port Laparoscopic Cholecystectomy
62051439|NCT04994496|EXPERIMENTAL|Web-based intervention group|Two-week web-based intervention group
62833962|NCT01136161|EXPERIMENTAL|RUTI 5 micrograms of FCMtb in HIV +|n=12
62833963|NCT01136161|EXPERIMENTAL|RUTI 25 micrograms of FCMtb in HIV +|n=12
62051440|NCT04994496|SHAM_COMPARATOR|Web-based control group|Two-week web-based sham comparator
62051441|NCT05226182|EXPERIMENTAL|patients|"Implementation and visualisation of digital care path. Pre measurement: questionnaire quantifying patient involvement and experience on a 5-p Likert scale.~Post measurement: questionnaire quantifying patient involvement and experience on a 5-p Likert scale, questionnaire quantifying usability of the tool and in-depth interview."
62833964|NCT01136161|EXPERIMENTAL|RUTI 50 micrograms of FCMtb in HIV +|n=12
62833965|NCT01136161|PLACEBO_COMPARATOR|RUTI Matching Placebo in HIV +|n=12
62833966|NCT03614156|EXPERIMENTAL|Rapastinel weekly|Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration)
62833967|NCT03614156|EXPERIMENTAL|Rapastinel clinically driven schedule|Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
62611190|NCT02862925|EXPERIMENTAL|Post-intervention|The study will take place on the labor ward at KCMC in Moshi, Tanzania. It will involve women who present to the labor ward in labor or who undergo an induction of labor. A consecutive sample of 350 patients will be collected. Study investigators will be present for 24 hours a day, 7 days a week on a rotating schedule during the enrollment period. All patients who fit inclusion and exclusion criteria will be approached if they are deemed medically stable.
62611191|NCT04293835||Cancer group|All patients pathologically diagnosed with sigmoid or rectal cancer in Peking University Third Hospital from January 2010 to December 2018 were included in our study as the cancer group.
62611192|NCT04293835||Normal group|200 patients without any intestinal-related abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were reviewed as a normal group.
62833968|NCT03614156|PLACEBO_COMPARATOR|Placebo weekly|Placebo (prefilled syringe, weekly IV administration)
62611193|NCT04559425||Prospective observational cohort 1|Complete AVB (3rd degree) diagnosed ≤ 32+0 weeks with or without hydrops
62611194|NCT04559425||Prospective observational cohort 2|Incomplete AVB (2nd; 2:1; 2nd-3rd degree) diagnosed ≤ 32+0 weeks with or without hydrops
62611195|NCT05247021|EXPERIMENTAL|erector spinae block group (E)|patients will receive bilateral ultrasound guided erector spinae block before the lumbar spine surgery starts.(20ml of bupivacaine 0.25%) after receiving general anesthesia
62611196|NCT05247021|NO_INTERVENTION|control group (C)|patients will receive standard general anesthesia for lumbar spine surgery according to hospital protocol.
62252493|NCT04765475|EXPERIMENTAL|COVID-19 Symptom Monitoring System Group|Participants in this study group will receive daily COVID-19 symptom (CS) text-based monitoring system to prompt more rapid testing at the onset of symptoms. This group will also receive supportive services. Participants will be provided with referrals to needed medical, mental or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask-wearing, how to prevent the spread in the home and managing stress during COVID-19.
62611197|NCT05585554|EXPERIMENTAL|Ablative MRIdian SMART|Induction Chemotherapy + MRIdian SMART 50 Gy in 5 fractions
62611198|NCT05585554|NO_INTERVENTION|No ablative MRIdian SMART|Induction chemotherapy alone
62611199|NCT04696653|OTHER|Comprehensive unit based safety (CUSP) intervention arm|CUSP is a quality improvement strategy developed by the Johns Hopkins University Armstrong Institute for Patient Safety and Quality that is used to improve care delivery.
62611200|NCT06655701||Postmenopausal osteoporosis|Postmenopausal osteoporosis is diagnosed using Dual-X-ray Absorptiometry (DXA), which measures bone mineral density (BMD) and provides a T-score. A T-score of -2.5 or lower confirms the diagnosis of osteoporosis.
62611201|NCT06655701||Postmenopausal non-osteoporotic women|These women maintain normal bone mineral density (BMD) levels, typically assessed using Dual-X-ray Absorptiometry (DXA). A T-score above -1.0 is considered normal.
62611202|NCT04129775|EXPERIMENTAL|OTO-413|
62611203|NCT04129775|PLACEBO_COMPARATOR|Placebo|
62611204|NCT03030885|EXPERIMENTAL|131I-MIP-1095|"FirstTherapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose.~2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53"
62611205|NCT06643637|ACTIVE_COMPARATOR|MLS101|MLS101 capsule(s) administered orally as a once a day dose
62611206|NCT06643637|PLACEBO_COMPARATOR|Placebo|Active treatment matching capsules will be administered orally as a once a day dose
62611207|NCT04260386||Staff receiving the MOMS training|Delegates taking part in the routine Multidisciplinary Obstetric and Midwifery Simulation (MOMS) training course at the Chelsea and Westminster Hospital.
62611208|NCT01315652|EXPERIMENTAL|Auto DAS|"Auto-DASNumber of patients with a modification in their treatment between baseline and 6 months visits"
62611209|NCT01315652|ACTIVE_COMPARATOR|Comorbidities treatment|
62611210|NCT03796676|PLACEBO_COMPARATOR|Placebo|Placebo
62611211|NCT03796676|EXPERIMENTAL|PF-04965842 100 mg QD|active
62611212|NCT03796676|EXPERIMENTAL|PF-04965842 200 mg QD|active
62611213|NCT05337917||Case|Injury to digital nerve: thumb, digit II radial side, digit V ulnar side
62611214|NCT05337917||Control|Injury to digital nerve: digit II ulnarside, dig III, dig IV dig V radial side.
62611215|NCT03559803|EXPERIMENTAL|Cisplatin|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
62833969|NCT01263197|EXPERIMENTAL|LY2216684, albuterol, LY2216684+albuterol|LY2216684 as an 18 milligram (mg) oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
62611216|NCT03737279|EXPERIMENTAL|Meditation|"Intervention Group:~Routine care plus twice daily mindful meditation"
62611217|NCT03737279|ACTIVE_COMPARATOR|Routine care|"Control Group:~Routine care which includes ACOG educational pamphlets on day 1, 2 and 3 after randomization"
62611218|NCT03092934|EXPERIMENTAL|25 milligrams (mg) LY3295668 (Phase 1)|25 milligrams (mg) LY3295668 twice daily (BID) administered orally in 21-day cycles.
62611219|NCT03092934|EXPERIMENTAL|50 mg LY3295668 (Phase 1)|50 mg LY3295668 BID administered orally in 21-day cycles.
62611220|NCT03092934|EXPERIMENTAL|75 mg LY3295668 (Phase 1)|75 mg LY3295668 BID administered orally in 21-day cycles.
62611221|NCT03092934|EXPERIMENTAL|25 mg LY3295668 (Phase 2)|25 mg LY3295668 BID administered orally in 21-day cycles.
62611222|NCT03118479|EXPERIMENTAL|Androgen only addback|Anastrozole 10 mg orally once daily for 3 months Testosterone gel 7.5 g transdermally daily for 3 months.
62051442|NCT05226182|EXPERIMENTAL|healthcare professionals|"Implementation and visualisation of digital care path. Pre measurement: questionnaire quantifying communication needs and experiences on a 5-p Likert scale.~Post measurement: questionnaire quantifying communication needs and experiences on a 5-p Likert scale, questionnaire quantifying usability of the tool and in-depth interview."
62051443|NCT05753722|EXPERIMENTAL|PRTH-101|Mono-therapy
62051444|NCT05753722|EXPERIMENTAL|PRTH-101 with Pembrolizumab|Combo therapy
62051445|NCT02924896|OTHER|randomization 1|Palm Olein, Interesterified Palm Olein, Soybean Oil
62051446|NCT02924896|OTHER|randomization 2|Palm Olein, Soybean Oil, Interesterified Palm Olein
62051447|NCT02924896|OTHER|randomization 3|Interesterified Palm Olein, Palm Olein, Soybean Oil
62252494|NCT04765475|EXPERIMENTAL|MotivationaI Interviewing and COVID-19 Symptom Monitoring System Group|Participants in this group will receive both motivational interviewing and daily COVID-19 symptom (CS) text-based monitoring system. This group will also receive supportive services. Participants will be provided with referrals to needed medical, mental or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask-wearing, how to prevent the spread in the home and managing stress during COVID-19.
62611223|NCT03118479|EXPERIMENTAL|Combined sex steroid addback|Placebo (sugar pill) tablet once daily for 3 months Testosterone gel 7.5 g transdermally daily for 3 months.
62051448|NCT02924896|OTHER|randomization 4|Interesterified Palm Olein, Soybean Oil, Palm Olein
62051449|NCT02924896|OTHER|randomization 5|Soybean Oil, Interesterified Palm Olein, Palm Olein
62051450|NCT02924896|OTHER|randomization 6|Soybean Oil, Palm Olein, Interesterified Palm Olein
62051451|NCT01820559|ACTIVE_COMPARATOR|ESL 1200 mg|eslicarbazepine acetate 1200 mg
62051452|NCT01820559|ACTIVE_COMPARATOR|ESL 800 mg|eslicarbazepine acetate 800 mg
62051453|NCT01820559|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62252495|NCT04765475|OTHER|Control Group|Participants in this group will only receive supportive services. Participants will be provided with referrals to needed medical, mental or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask wearing, how to prevent the spread in the home and managing stress during COVID-19
62611224|NCT04087616|EXPERIMENTAL|CBIT|ICBIT. Intervention delivered through an internet platform called Managing children's' tics (www.cbteamathome.co.il), based on CBIT protocol (Woods et al., 2008) adapted to an online parent-guided self-help format.
62611225|NCT04087616|PLACEBO_COMPARATOR|Waiting List|Participants initially assigned to the wait list receive no psychosocial intervention for 9 weeks. Following post-WL assessment, all participants receive ICBIT.
62051454|NCT04290351||Band ligation and phlebotonic group|"Patients with rubber band ligation and the prescribed anti hemorrhoidal drug will be examined in this group.~(Note: The researcher has no contribution or intervention to the treatment method.)"
62252496|NCT05105555||Healthy controls|In this study, participants of the Bern Basel Infant Lung Development (BILD) cohort, a birth cohort of healthy term-born infants and their follow-up, will serve as healthy, non-vaping controls.
62252497|NCT05105555||Vaping teenagers|Vaping teenagers will be recruited independently from the BILD study through advertisements and visits to Bernese schools.
62252498|NCT03819881|EXPERIMENTAL|STMC-103H|"Oral administration of STMC-103H twice daily, randomized 3:1 (STMC-103H:Placebo) in three age-descending groups:~Part 1: 20 subjects 18-40 years of age Part 2: 20 subjects, 12-17 years of age Part 3: 20 subjects, 2-11 years of age"
62611226|NCT01831505|EXPERIMENTAL|Multiple drug microinjection|Multiple drug microinjection with locally injected rituximab, vincristine, doxorubicin, bendamustine, prednisolone, or a combination of them
62611227|NCT02166749||Subtotal abdominal hysterectomy|107 women
62611228|NCT02166749||Total abdominal hysterectomy|105 women
62611229|NCT06731491|NO_INTERVENTION|Control Group|There will be no intervention and group participants will be advised to maintain their routine as normal.
62611230|NCT06731491|EXPERIMENTAL|G1|Intervention Group - Concurrent Training for People Living with HIV who have been on Antiretroviral Therapy for 10 years or more
62611231|NCT06731491|EXPERIMENTAL|G2|Intervention Group - Concurrent Training for People Living with HIV who have been on Antiretroviral Therapy for less than 10 years
62611232|NCT06731491|EXPERIMENTAL|G3|Intervention Group - Concurrent Training for People Living with HIV who have been on Antiretroviral Therapy for less than 10 years and had CD4/CD8 \< 1
62611233|NCT06731491|EXPERIMENTAL|G4|Intervention Group - Massage Therapy for People Living with HIV who have been on Antiretroviral Therapy for 10 years or more
62611234|NCT06731491|EXPERIMENTAL|G5|Intervention Group - Massage Therapy for People Living with HIV who have been on Antiretroviral Therapy for less than 10 years
62611235|NCT06731491|EXPERIMENTAL|G6|Intervention Group - Massage Therapy for People Living with HIV who have been on Antiretroviral Therapy for less than 10 years and have CD4/CD8 \< 1
62611236|NCT01633099|OTHER|Decitabine, CR rate,OS,EFS,RFS|Therapeutic effect and safety of 10 days of decitabine. Acute myeloid leukemia,no acute promyelocytic leukemia.
62833970|NCT01263197|EXPERIMENTAL|albuterol, LY2216684+albuterol, LY2216684|Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in third intervention period. There is a minimum 7 day washout between each intervention period.
62611237|NCT04104087|EXPERIMENTAL|deepithelializ free gingival graft|performing tunneling technique with deepithelialized free gingival graft in treating RT2 gingival recession
62611238|NCT04104087|ACTIVE_COMPARATOR|subepithelial connective tissue graft|performing tunneling technique with sub epithelial connective tissue graft in treating RT2 gingival recession
62611239|NCT04517773||study group|Oncological patients
62051455|NCT04290351||Only phlebotonic group|"Patients who are prescribed the only 450mg of diosmin + 50mg of hesperidin as a treatment for bleeding internal hemorrhoids will be examined in this group.~(Note: The researcher has no contribution or intervention to the treatment method.)"
62833971|NCT01263197|EXPERIMENTAL|LY2216684+albuterol, LY2216684, albuterol|LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in second intervention period, Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
62051456|NCT05202925|EXPERIMENTAL|Musical Training|All subjects in the intervention group will receive a weekly 45-minute lesson, one-to-one musical training for 52 weeks.
62051457|NCT00716092|PLACEBO_COMPARATOR|Placebo|Patients received placebo matching 5mg linagliptin and placebo matching 100mg sitagliptin.
62051458|NCT00716092|EXPERIMENTAL|Linagliptin|Patients received 5mg linagliptin, and placebo matching 100mg sitagliptin.
62611240|NCT01000181||Patients undergoing carotid endarterectomy|
62611241|NCT01825239|OTHER|Electrophysiology Study|This is a single arm study, all study participants will be referred for an Electrophysiology Study
62611242|NCT05963451||Chronic Low Back Pain (CLBP) group|Participants who will took part in our study are people living with CLBP who will undergo facet thermal ablation treatment
62611243|NCT06415175||Dupilumab|The information will be collected during consultation as part of the patient's usual follow-up.
62611244|NCT04790097|EXPERIMENTAL|Simultaneous In-Field Boost on FET-PET positive target volumes|
62611245|NCT00189527|EXPERIMENTAL|respiratory support|a mode of ventilation in comparison
62611246|NCT00189527|ACTIVE_COMPARATOR|Assist Control|an other mode of ventilation in comparison
62611247|NCT02700698||Healthy lean|Healthy lean women, 25-35 years
62611248|NCT02700698||Overweight/obese with/without IR|Overweight/obese with/without insulin resistant women, 25-35 years
62611249|NCT03681184|PLACEBO_COMPARATOR|Placebo/Lumasiran|Lumasiran-matching placebo (normal saline \[0.9% NaCl\]) was administered subcutaneously (SC) at Day 1 and Months 1, 2 and 3 during the 6-Month Double-blind (DB) Period, followed by lumasiran SC, 3.0 mg/kg, at Months 6, 7 and 8 during the 3-Month Blinded Treatment Extension Period, followed by lumasiran SC, 3.0 mg/kg, at Month 9 and then every three months during the 51-Month Open-label Extension (OLE) period.
62611250|NCT03681184|EXPERIMENTAL|Lumasiran/Lumasiran|Lumasiran was administered SC, 3.0 mg/kg, at Day 1 and Months 1, 2 and 3 during the 6-Month DB Period, followed by lumasiran SC, 3.0 mg/kg at Month 6, and lumasiran-matching placebo SC at Months 7 and 8 during the 3-Month Blinded Treatment Extension Period, followed by lumasiran SC, 3.0 mg/kg, at Month 9 and then every three months during the 51-Month OLE period.
62611251|NCT00671125|EXPERIMENTAL|Ramelteon 8 mg QD|
62611252|NCT00671125|EXPERIMENTAL|Ramelteon 16 mg QD|
62611253|NCT00671125|PLACEBO_COMPARATOR|Placebo|
62611254|NCT05645432|EXPERIMENTAL|Brexanolone|Participants will receive a 6-hour single continuous intravenous (IV) infusion of brexanolone at 30 micrograms per kilogram per hour (mcg/kg/hour) for 0 to 0.5 hours, at 60 mcg/kg/hour for 0.5 to 1 hour, and at 90 mcg/kg/hour for 1 to 6 hours, on Day 1 of the Treatment Period.
62833972|NCT01263197|EXPERIMENTAL|LY2216684, propranolol, LY2216684+propranolol|LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
62611255|NCT04958759|EXPERIMENTAL|Functional Inspiratory Muscle Training Group|Functional inspiratory muscle training in patients with chronic kidney disease
62833973|NCT01263197|EXPERIMENTAL|propranolol, LY2216684+propranolol, LY2216684|Placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in third intervention period. There is a minimum 7 day washout between each intervention period.
62833974|NCT01263197|EXPERIMENTAL|LY2216684+propranolol, LY2216684, propranolol|LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in second intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
62833975|NCT02824341|OTHER|Parkinson's disease patients with RBD|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
62833976|NCT02824341|OTHER|Parkinson's disease without RBD|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
62833977|NCT02824341|OTHER|Healthy volunteers|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
62833978|NCT00913640||PD Group|
62833979|NCT00913640||Control Group|
62833980|NCT00318643|EXPERIMENTAL|Cohort 1: MMC plus Chemophase 20,000 U|Participants will receive 40 milligrams (mg) MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 20,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
62611256|NCT04958759|EXPERIMENTAL|Inspiratory Muscle Training Group|Inspiratory muscle training in patients with chronic kidney disease
62611257|NCT04958759|EXPERIMENTAL|Control Group|Breathing exercises in patients with chronic kidney disease
62611258|NCT02101333|EXPERIMENTAL|TOCILIZUMAB MONTHLY DURING 6|intravenous injection, 8 mg/kg, monthly during 6 months
62611259|NCT04171817|NO_INTERVENTION|Control|Dog-handler teams will follow established hospital and therapy dog program guidelines for infection control with no changes for eight sessions. Participants enrolled in the session will derive their Arm assignment from the dog-handler team with which they interact.
62611260|NCT04171817|EXPERIMENTAL|CHX Intervention A|"Dog-handler teams will follow a modified protocol for infection control, with Treatment A first for four sessions, and cross-over to Treatment B for four sessions. Participants enrolled in the session will derive their Arm assignment from the dog-handler team with which they interact.~Treatment A consists of a pre-session shampoo with a commercial veterinary chlorhexidine-based product (2-4% chlorhexidine) within 24 hours prior to the session, and wiping with a chlorhexidine-impregnated cloth (2-4% chlorhexidine) at arrival at the session and every 20 minutes during the session, or between participants if the flow of participants is structured in a way that allows this (such as visits from one room to the next to visit individual patients)."
62611261|NCT04171817|EXPERIMENTAL|CHX Intervention B|"Dog-handler teams will follow a modified protocol for infection control, with Treatment B first for four sessions, and cross-over to Treatment A for four sessions. Participants enrolled in the session will derive their Arm assignment from the dog-handler team with which they interact.~Treatment B will consist of the same pre-session shampoo with a commercial veterinary chlorhexidine-based product (2-4% chlorhexidine), with a single wipe with a chlorhexidine-impregnated cloth (2-4% chlorhexidine) at arrival. This treatment will depend on the residual activity of chlorhexidine throughout the visit."
62611262|NCT05140616|EXPERIMENTAL|Study of Chidamide in the Treatment of Steroid-resistant/Steroid-dependent Severe cGVHD|Subjects receive twice a week dose of 15mg of Chidamide tablets
62611263|NCT01630954|ACTIVE_COMPARATOR|Single evacuation of mole,|
62611264|NCT01630954|ACTIVE_COMPARATOR|Double evacuation of mole|
62833981|NCT00318643|EXPERIMENTAL|Cohort 2: MMC plus Chemophase 60,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 60,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
62833982|NCT00318643|EXPERIMENTAL|Cohort 3: MMC plus Chemophase 200,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 200,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
62833983|NCT00318643|EXPERIMENTAL|Cohort 4: MMC plus Chemophase 400,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 400,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
62833984|NCT00318643|EXPERIMENTAL|Cohort 5: MMC plus Chemophase 800,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 800,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
62833985|NCT02061410|EXPERIMENTAL|Neuromuscular Electrical Stimulation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
62833986|NCT01276210|EXPERIMENTAL|Treatment|See Detailed Description
62833987|NCT03681314|ACTIVE_COMPARATOR|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
62833988|NCT03681314|NO_INTERVENTION|Immediate Cord Clamping|The umbilical cord is clamped immediately after the delivery.
62833989|NCT00797641||1|Patients admitted to the hospital, or inpatients admitted for another reason, presenting with overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia, as well as other clinical or laboratory evidence of acute blood loss from the upper gastrointestinal tract
62611265|NCT03654391|ACTIVE_COMPARATOR|InnoSlim|Subjects ingested 2 capsules InnoSlim® (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.
62051459|NCT00716092|ACTIVE_COMPARATOR|Sitagliptin|Patients received 100mg sitagliptin, and placebo matching 5mg linagliptin.
62051460|NCT03295513|ACTIVE_COMPARATOR|veneered zirconia full coverage restorations|InCoris zirconia material (TZI-Densupply sirona)
62051461|NCT03295513|EXPERIMENTAL|Monolithic zirconia full coverage restorations|InCoris (TZI-Densupply sirona)
62441941|NCT04899856|OTHER|Control / Crossover to TransAeris Therapy|"The Control group will be treated per standard hospital policy following electrode implant. If the participant is not liberated from mechanical ventilation after 120 hours (5 days), the participant will begin using TransAeris therapy. The participant will use the study device in the ICU until liberated from the ventilator but no longer than 30 days after implant surgery."
62441942|NCT04899856|EXPERIMENTAL|Treatment with TransAeris Therapy|"The Treatment group will start TranAeris therapy shortly after arrival in the Intensive Care Unit (ICU). Participants will use the study device in the ICU until liberated from the ventilator but no longer than 30 days after implant surgery."
62441943|NCT02087046|OTHER|Stimulation|ANS Totally Implantable Deep Brain Stimulation System
62441944|NCT06456047||all patients undergoing routine spirometry|all patients undergoing routine spirometry and have GOLD or STAR negative criteria but positive RCexp
62441945|NCT00935987|EXPERIMENTAL|CYT387|
62441946|NCT02770183||Consecutive patients|"Consecutive patients waiting to have elective cardiac surgery will be eligible. Each week the principal investigator will track patients in the operating program. The day of the consultation or the day before the operation, one of the investigators will have a talk with the patient to provide information and clarify doubts, also allowing the patient to read and look good all the details before giving its approval. For the screening, the principal investigator will use the criteria of inclusion and exclusion to select patients for the study. The screening uses clinical, laboratory or without other biological information.~To minimize confounding factors, it will be taken consecutive patients, that will also be analyzed regarding all known variables that can affect the systolic function, as non-modifiable (age, cardiovascular risk factors, heart-rate variability and preoperative basal systolic function) and modifiable."
62441947|NCT03112356|EXPERIMENTAL|99mTc-Leukoscan® scintigraphy|Patients presenting a suspicions of infectious endocarditis on surgical materials and undergoing the 99mTc-Leukoscan® scintigraphy
62441948|NCT03954561|EXPERIMENTAL|endoscopist group|endoscopist-administered abdominal compression group
62441949|NCT03954561|ACTIVE_COMPARATOR|assistant group|assistant-administered abdominal compression group
62611266|NCT03654391|PLACEBO_COMPARATOR|Placebo|Subjects ingested 2 capsules placebo (Control group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.
62611267|NCT05133583|EXPERIMENTAL|intervatonal|
62611268|NCT05133583|NO_INTERVENTION|control|
62611269|NCT01544192|ACTIVE_COMPARATOR|retinal nerve fiber thickness|
62611270|NCT01544192|ACTIVE_COMPARATOR|Mean Deviation|
62051462|NCT03826095||Multiple Sclerosis|Patients with a clinically definitive diagnosis of MS, 0-5.5 Extended Disability Status Scale range.
62611271|NCT01544192|ACTIVE_COMPARATOR|Pattern Standard Deviation|
62833990|NCT03040544|EXPERIMENTAL|LTB-Curriculum|First group/arm undergo MIS training according to the LTB curriculum after the first own laparoscopic cholecystectomy in the OR as a baseline. After 6 weeks, the participants in this group/arm will perform their second CHE. The video recordings of the MIS procedures will be analysed and compared using the Global Operational Assessment of Laparoscopic Skill (GOALS) score.
62833991|NCT03040544|ACTIVE_COMPARATOR|no LTB-Curriculums|Second group/arm will not undergo any MIS trains after their first laparoscopic CHE in the OR. After 6 weeks, the participants in this group/arm will perform their second CHE. The video recordings of the MIS procedures will be analysed and compared using GOALS score.
62441950|NCT05966857|NO_INTERVENTION|Control Group (CTL)|Patients who underwent standard treatment at the institution without any wearable monitoring.
62833992|NCT05589467|EXPERIMENTAL|DASH Diet and Fried Potatoes|DASH-FP (fried potatoes) group
62833993|NCT05589467|EXPERIMENTAL|DASH Diet and Non-Fried Potatoes|DASH-NFP (non-fried potatoes) group
62051463|NCT03826095||Healthy individuals|Voluntary healthy individuals with similar age and gender
62611272|NCT01544192|ACTIVE_COMPARATOR|ganglion cell count|
62611273|NCT01544192|ACTIVE_COMPARATOR|c/d ratios|
62833994|NCT05589467|EXPERIMENTAL|DASh Diet and No Potatoes|DASH-NP (no potatoes) group
62833995|NCT03129217||Patients weaning from mechanical ventilation|
62833996|NCT06073301|EXPERIMENTAL|Treatment: Acellular Fish Skin (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT)|Eligible subjects will be randomized electronically to either the Acellular Fish Skin (AFS)arm. The subject will undergo wound bed preparation by surgical debridement. the AFS will be applied to the wound bed and secured with sutures, the size of the AFS will be determined after surgical debridement. Once the AFS is in place a Negative Pressure Wound Therapy device will be placed. the subject will be monitored weekly on scheduled intervals of +/- 4 days post AFS placement to assess the status of the wound and readiness for autografting. Once the wound is ready for autografting the subject will be monitored for autograft take, for up to 9 visits. Long term follow-up will be done at month 3, 6, 9 post autograft placement
62252499|NCT03819881|PLACEBO_COMPARATOR|Placebo|"Oral administration of placebo twice daily, randomized 3:1 (STMC-103H:Placebo) in three age-descending groups:~Part 1: 20 subjects 18-40 years of age Part 2: 20 subjects, 12-17 years of age Part 3: 20 subjects, 2-11 years of age"
62252500|NCT03289936|EXPERIMENTAL|Start ventilation with NIPPV|Alternatively vented with NIPPV and SNIPPV
62441951|NCT05966857|EXPERIMENTAL|Telemonitored Group (TLM)|Patients who received telemonitoring with a Samsung Galaxy smartwatch and FAPO SI³ platform, which is integrated with the hospital's electronic medical record system.
62441952|NCT06544798|NO_INTERVENTION|Follow-up group|Participants who were randomized to AAV2-hAQP1 treatment in Study MGT-AQP1-201 will continue in this long-term follow-up schedule to complete an additional 48 months of follow-up after their end-of-study visit in Study MGT-AQP1-201. All study participants are to be followed for a period of 60 months after vector administration.
62441953|NCT06544798|EXPERIMENTAL|Active treatment group|Participants who were randomized to placebo treatment in Study MGT-AQP1-201, will be offered to transition from the long-term follow-up schedule to an active treatment schedule at the time of unblinding. Study drug administration should be completed after unblinding and after confirmation of the participant's continued eligibility for treatment. Upon completion of the 12-month primary treatment period, participants will continue in the study according to a follow-up schedule, to complete a total of 60 months of follow-up after AAV2-hAQP1 administration.
62441954|NCT02287454|EXPERIMENTAL|Cognitive remediation program: REHACOP|Cognitive rehabilitation program (REHACOP) including intervention in: attention, memory, processing speed, language, executive functioning and social cognition during 3 months, 3 times per week
62441955|NCT02287454|NO_INTERVENTION|Control group|No intervention was administered.
62441956|NCT00790374|EXPERIMENTAL|Cohort 1|6 patients have been enrolled, the cohort has been completed.
62441957|NCT00790374|EXPERIMENTAL|Cohort 2|6 patients have been enrolled in cohort 2, the cohort has been completed.
62441958|NCT00790374|EXPERIMENTAL|Cohort 3|5 patients have been enrolled in cohort 3. The cohort was closed after the 5th patient enrolled.
62441959|NCT01396642|EXPERIMENTAL|Topical Emollient|Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
62441960|NCT01396642|NO_INTERVENTION|Routine Skin Care|Neonates in this group will receive routine skin care as per unit protocol
62833997|NCT06073301|ACTIVE_COMPARATOR|Acellular Human Cadaver with Standard of Care Negative Pressure Wound Therapy (NPWT)|.Eligible subjects will be randomized electronically to standard of care arm which is Acellular Human Cadaver (AHC) The subject will undergo wound bed preparation by surgical debridement. The AHC will be applied to the wound bed and secured with sutures, the size of the AHC will be determined after surgical debridement. Once the AHC is in place a Negative Pressure Wound Therapy device will be placed. the subject will be monitored weekly on scheduled intervals of +/- 4 days post AHC placement to assess the status of the wound and readiness for autografting. Once the wound is ready for autografting the subject will be monitored for autograft take, for up to 9 visits. Long term follow-up will be done at month 3, 6, 9 post autograft placement
62611274|NCT04262804|EXPERIMENTAL|Margetuximab & Chosen Chemotherapy|The dosage and administering of margetuximab is 15 mg/kg IV every 21 days. Investigators need to chose one of the 3 chemotherpies based on patient conditions.
62252501|NCT03289936|EXPERIMENTAL|Start ventilation with SNIPPV|Alternatively vented with SNIPPV and NIPPV
62611275|NCT04262804|ACTIVE_COMPARATOR|Trastuzumab & Chosen Chemotherapy|The dosage and administering of Trastuzumab is 8 mg/kg loading dose then 6 mg/kg IV every 21 days. Investigators need to chose one of the 3 chemotherpies based on patient conditions.
62611276|NCT01173419|ACTIVE_COMPARATOR|VenaCure EVLT NeverTouch|
62611277|NCT01173419|ACTIVE_COMPARATOR|RF ClosureFAST|
62611278|NCT03090451|EXPERIMENTAL|Moderate Aerobic Exercise|Subjects will undergo moderate aerobic physical exercise (40-45% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
62611279|NCT03090451|EXPERIMENTAL|Intense Aerobic Exercise|Subjects will undergo intense aerobic physical exercise (60-65% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
62252502|NCT02844920||Fibroid Treatment|Intrauterine ultrasound guided radio-frequency ablation
62611280|NCT03631654|PLACEBO_COMPARATOR|Control|
62611281|NCT03631654|EXPERIMENTAL|Intervention|
62833998|NCT05217693|EXPERIMENTAL|dose escalation|Drug: BB-1705 BB-1705 will be administered as an intravenous infusion by Q3W for 8cycles
62252503|NCT01377025|EXPERIMENTAL|Sorafenib blinded Phase|400 mg Sorafenib bid until PD
62441961|NCT05729100|EXPERIMENTAL|Oral carbohydrate-electrolyte solution|The intervention group who will receive 50 ml/kg of oral solution containing carbohydrate-electrolyte
62833999|NCT05217693|EXPERIMENTAL|cohort expansion|BB-1705 will be administered as an intravenous infusion by Q3W for 8cycles
62834000|NCT00711061||1|18-25 year old males, growth hormone deficient, who completed growth hormone treatment 3-5 years prior to enrollment in study
62834001|NCT00711061||2|18-25 year old males, healthy, never treated with growth hormones.
62834002|NCT02222623|ACTIVE_COMPARATOR|glargine insulin|Basal glargine given once daily in the morning before breakfast plus standard hospital corrective doses of insulin aspart before meals and at bedtime.
62834003|NCT02222623|ACTIVE_COMPARATOR|NPH insulin|Basal NPH given twice daily before breakfast and at bedtime plus standard hospital corrective doses of insulin aspart before meals and at bedtime.
62252504|NCT01377025|PLACEBO_COMPARATOR|Placebo blinded Phase|Two tbl. in the morning and two tbl. in teh evening until PD
62252505|NCT01377025|EXPERIMENTAL|Sorafenib Open Phase|400 mg Sorafenib bid until PD
62252506|NCT04541979|ACTIVE_COMPARATOR|Aerosolized DNase I|
62252507|NCT04541979|PLACEBO_COMPARATOR|NaCl|
62441962|NCT05729100|SHAM_COMPARATOR|Standard clear fluid|The control group who will receive 50 ml/kg of clear fluid (i.e. water; which does not contain carbohydrate-electrolyte)
62441963|NCT04085081|EXPERIMENTAL|Supportive care (coaching call, motivational messages)|Patients and family caregivers complete comprehensive geriatric and functional assessments before surgery. This information is used to develop a personalized walking program plus simple lower extremity strength exercises. The intervention is administered by trained coaches with physical and occupational therapy background. The sessions are delivered by telephone before surgery (30-60 minutes), and on days 2, 7, 14, and 21 after hospital discharge (20-50 minutes). Participants will also receive brief motivational text or email messages (4 times per week between telephone sessions) to provide support, promote physical activity behavior change, and to sustain participant engagement.
62441964|NCT05007691|EXPERIMENTAL|Occlusal splints|"In a clinical setting, participants test the closure of the occlusal splint with the antagonistic dentition.~Only one of the two occlusal splints (mandibular splint and maxillary splint) is used at a time. Occlusal splints are applied separately and alternately."
62441965|NCT03458507|ACTIVE_COMPARATOR|Usual interface|"Patients which begin with their usual interface for one week, home polygraphy and side effect assessment at the end of the first week.~Switch for alternative interface, seven days familiarisation, second polygraphy and side effect assessment at the end of the second week."
62441966|NCT03458507|ACTIVE_COMPARATOR|Alternative interface|"Patients which begin with the alternative interface for one week, home polygraphy and side effect assessment at the end of the first week.~Switch for usual interface, seven days with usual device, second polygraphy and side effect assessment at the end of the second week."
62441967|NCT02197728|ACTIVE_COMPARATOR|Hohl uterine manipulator ®|Total laparoscopic hysterectomy is performed using the Hohl uterine manipulator ®
62441968|NCT02197728|ACTIVE_COMPARATOR|Colpo-Probe™ Vaginal Fornix Delineator|Total laparoscopic hysterectomy is performed using the Colpo-Probe™ Vaginal Fornix Delineator
62051464|NCT02043691|EXPERIMENTAL|Cook Custom Aortic Endograft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Cook Custom Aortic Endograft. The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
62051465|NCT02043691|EXPERIMENTAL|Zenith t-Branch Endovascular Graft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the sizing of the the Zenith t-Branch Endovascular Graft. The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
62834004|NCT05378191|ACTIVE_COMPARATOR|VACCINATION|One standard dose of COMIRNATY in adult subjects (18 years old) having received prior VAXZEVRIA vaccination.
62834005|NCT05378191|NO_INTERVENTION|NO INTERVENTION|No vaccination in adult subjects (18 years old) having received prior VAXZEVRIA vaccination. If primary analysis at day 14th confirms the starting hypothesis, subjects randomized to this arm will be considered for administration of one dose of COMINARTY at day 28th according to Public Health Department of the Ministry of Health recommendations on heterologous vaccination.
62834006|NCT05429957|EXPERIMENTAL|Muscle Energy Technique|Muscle Energy Technique of Iliopsoas, Piriformis, Quadratus Lumborum and Erector Spinae muscle
62834007|NCT05429957|EXPERIMENTAL|Aerobic Exercises|aerobic exercises (walking on the treadmill)
62834008|NCT03807206||Flashmob 2019|Patients from the following hospitals will receive a questionnaire/structured intereview: Erasmus MC, Franciscus Gasthuis \& Vlietland, Ikazia, Haaglanden Medisch Centrum, Albert Schweitzer ziekenhuis, Jeroen Bosch ziekenhuis, Rijnstate ziekenhuis, Amphia ziekenhuis, Tergooi klinieken, Medisch Spectrum Twente, Reinier de Graaf gasthuis. Pending: Maasstad ziekenhuis
62834009|NCT06405191|EXPERIMENTAL|Web Based Group|For 2 weeks, a web-based education intervention was implemented.
62252508|NCT00713479|PLACEBO_COMPARATOR|Sugar pill|Sugar pill (placebo) drug dosing will begin at 0.5 mg once daily for the first 3 days of condition and will be increased to 0.5 mg twice daily for days 5-6 of this condition, and increased to 1 mg twice daily on days 7-10 of this condition.
62252509|NCT00713479|ACTIVE_COMPARATOR|Varenicline|Varenicline dosing will begin at 0.5 mg once daily for the first 3 days of condition and will be increased to 0.5 mg twice daily for days 5-6 of this condition, and increased to 1 mg twice daily on days 7-10 of this condition.
62252510|NCT06051032|EXPERIMENTAL|Balloon thrombectomy|Patients diagnosed with arteriovenous fistula (AVF) thrombosis and deemed eligible for endovascular treatment will undergo balloon thrombectomy.
62252511|NCT06051032|EXPERIMENTAL|Thromboaspiration system|Patients diagnosed with arteriovenous fistula (AVF) thrombosis and deemed eligible for endovascular treatment will undergo the thromboaspiration system.
62252512|NCT05781230|EXPERIMENTAL|HIE program|HIE program ; High Intensity Exercises Program. 3 sets of 15 repetition
62834010|NCT06405191|NO_INTERVENTION|Control Group|No intervention was applied to the students in the control group.
62252513|NCT05781230|EXPERIMENTAL|LIE Program|Low Intensity Exercises program 2 sets of 8 repetition
62834011|NCT04420312||Group 1|Enrolled the Covid-19 patients with a negative CT Pulmonary Angiogram.
62252514|NCT02933099|EXPERIMENTAL|Aprepitant arm|Aprepitant+palonosetron+dexamethasone
62252515|NCT02933099|ACTIVE_COMPARATOR|Control arm|palonosetron+dexamethasone
62834012|NCT04420312||Group 2|Enrolled the Covid-19 patients in whom only a CT was performed.
62834013|NCT00760617|EXPERIMENTAL|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A
62834014|NCT00760617|ACTIVE_COMPARATOR|Fluarix elderly Group|Subjects aged ≥65 years received 1 dose of Fluarix vaccine
62834015|NCT00760617|ACTIVE_COMPARATOR|Fluarix young Group|Subjects aged 18-40 years received 1 dose of Fluarix vaccine
62834016|NCT05045495||Healthy Volunteer|120 Healthy Volunteers will perform the 50-gram sucrose challenge test, Sucrose hydrogen methane breath test, 13C-sucrose breath test and collect buccal swab samples for genetic testing.
62834017|NCT05045495||CSID Case|50 CSID cases defined by being on Sucraid for at least 12 months will perform the 50-gram sucrose challenge test, Sucrose hydrogen methane breath test, 13C-sucrose breath test and collect buccal swab samples for genetic testing.
62834018|NCT04911452|NO_INTERVENTION|Control|Standard Neonatal Intensive Care Unit (NICU) care
62834019|NCT04911452|EXPERIMENTAL|Calmer|Calmer placed and left in infant incubator for the 3-week study period. Calmer treatment provided for minimum total of 3 hours/day (can be discontinuous).
62834020|NCT02722993|ACTIVE_COMPARATOR|Probiotics|
62252516|NCT00528515|ACTIVE_COMPARATOR|1|propofol
62252517|NCT00528515|EXPERIMENTAL|2|desflurane
62252518|NCT04961268|ACTIVE_COMPARATOR|Tramadol 50|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received tramadol 50 mg in opaque yellow size 000 capsules."
62252519|NCT04961268|ACTIVE_COMPARATOR|Tramadol 100|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received tramadol 100 mg in opaque yellow size 000 capsules."
62834021|NCT02722993|PLACEBO_COMPARATOR|Placebo|
62834022|NCT05324059|EXPERIMENTAL|Group A: Pregabalin/Tramadol|Fixed dose combination tablet of 75 mg Pregabalin and 50 mg of Tramadol, orally, every 12 hours.
62834023|NCT05324059|ACTIVE_COMPARATOR|Group B: Pregabalin|Monotherapy with 75 mg of Pregabalin, orally, every 12 hours.
62834024|NCT02518438|ACTIVE_COMPARATOR|the tramadol group|A preprepared 20 ml solution (tramadol 2 mgkg-1 within a 0.9% saline solution) was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
62834025|NCT02518438|PLACEBO_COMPARATOR|the placebo group|A preprepared 20 ml solution (0,9% saline solution) was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
62611282|NCT03219229||Prepubertal children|Healthy 7-11 year old girls and boys.
62834026|NCT02527811|EXPERIMENTAL|ulinastatin group|the ulinastatin group will be administered as follows:Ulinastatin 30,000 unit/kg will be diluted into saline solution and administered intravenously in the surgery; Postoperative administration will be 30,000unit/kg divided into 3 regimens until leave ICU.
62834027|NCT02527811|NO_INTERVENTION|control group|patients of control group received conventional therapy,eg,General anesthetic drug and monitoring during the whole process of surgery;Mechanical ventilation and close monitoring to prevent and manage respiratory acidosis and alkalosis and so on.
62611283|NCT02183909|EXPERIMENTAL|Study intervention|
62834028|NCT02185508||Lumbar spine surgery with IONM|Patients diagnosed with 1 or 2 level lumbar disk disease and radicular symptoms who underwent decompressive surgery, and for whom IONM records exist.
62834029|NCT00518765|EXPERIMENTAL|1|Various sequences of different doses of Aliskiren
62834030|NCT00518765|EXPERIMENTAL|2|Various sequences of different doses of Aliskiren plus placebo
62834031|NCT00518765|EXPERIMENTAL|3|Various sequences of different doses of Aliskiren
62834032|NCT00518765|EXPERIMENTAL|4|Various sequences of different doses of Aliskiren plus placebo
62441969|NCT05228119|EXPERIMENTAL|Oncolytic Virus Injection(RT-01)|"RT-01 will be administered either intravenously or with a combination of intravenously and intratumorally on day 1.~Nivolumab will be administered intravenously every 3 weeks starting on day 5."
62611284|NCT04061733|EXPERIMENTAL|Experimental|Subjects who will receive an injection of the hydrogel
62611285|NCT00780624|ACTIVE_COMPARATOR|NIPPV|The NIPPV group receiving NIPPV treatment.
62611286|NCT00780624|ACTIVE_COMPARATOR|Control|The Control group receiving nCPAP treatment.
62611287|NCT06014125|EXPERIMENTAL|psychoeducation program group|In addition to the usual treatment, the experimental group will receive a tele-education programme on depression in 5 individual remote sessions. During these sessions, the symptoms of the illness will be discussed, as well as health and diet measures, the destigmatisation of the illness, mobilisation of family and friends, the various treatments for depression and, finally, an assessment of what has been learned, which will be sent to the general practitioner with the patient's agreement.
62611288|NCT06014125|NO_INTERVENTION|control group|The control group will receive their usual care from their GP. An educational booklet on depression will be provided to patients at the start of the study.
62611289|NCT02628509||cardiac devices|patients receiving mechanical circulatory support patients undergoing transaortic valve replacement
62611290|NCT03516006|EXPERIMENTAL|UCMSC|infusion of aUCMSC and Ursodeoxycholic acid therapy
62611291|NCT03516006|ACTIVE_COMPARATOR|UDCA|Ursodeoxycholic acid therapy 15mg/kg/d
62834033|NCT02896803|EXPERIMENTAL|Experimental|mFLOX
62441970|NCT02386592|EXPERIMENTAL|Intervention|Infection control package consisting of alcohol hand rub hand hygiene (HH), 2% chlorhexidine gluconate (CHG) body washes, infection control training, and text messages with basic Infection control reminders via SMS text
62611292|NCT01458951|EXPERIMENTAL|tofacitinib 10 mg BID|
62611293|NCT01458951|PLACEBO_COMPARATOR|Placebo BID|
62834034|NCT02837770|ACTIVE_COMPARATOR|Pacebo pill and Diclofenac Eye Drops|Pacebo pill will be administered 4 hours before the IVI and one drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
62834035|NCT02837770|ACTIVE_COMPARATOR|Oral Diclofenac and Diclofenac Eye Drops|One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI and one drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
62834036|NCT02837770|PLACEBO_COMPARATOR|Pacebo pill and Artificial Tears|Pacebo pill will be administered 4 hours before the IVI and one drop Artificial Tears will be instilled 45' prior to the IVI.
62834037|NCT04951024|EXPERIMENTAL|Thoracolumbar interfacial plane (TLIP) Block|Thoracolumbar interfacial plane (TLIP) Block will be performed after induction of anesthesia by anesthesiologist who is not part of investigators for this study. Bilateral 20 ml 0.25 % Bupivacaine injected between multifidus and longissimus muscle with Ultrasound guidance.
62252520|NCT04961268|ACTIVE_COMPARATOR|Ibuprofen|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received ibuprofen 600 mg in opaque yellow size 000 capsules."
62441971|NCT06002295|EXPERIMENTAL|Umbilical Cord Care with Chlorhexidine (Group A)|
62441972|NCT06002295|EXPERIMENTAL|Umbilical Cord Care with Methylated Spirit (Group B)|
62441973|NCT04180345||Validation of the questionnaire|Items reduction, ajustment and psychometric validation of the questionnaire
62834038|NCT04951024|ACTIVE_COMPARATOR|Erector Spinae Plane (ESP) Block|Erector Spinae Plane (ESP) Block will be performed after induction of anesthesia by anesthesiologist who is not part of investigators for this study. Bilateral 20 ml 0.25 % Bupivacaine injected between the erector spinae muscles and transverse process with Ultrasound guidance
62834039|NCT05469659|EXPERIMENTAL|Tofogliflozin|
62834040|NCT05469659|ACTIVE_COMPARATOR|Metformin|
62834041|NCT01338740||Switch from Adalimumab to Infliximab|Moderately to severely active Crohn's disease patients with primary non-response or loss of response to Adalimumab, will switch to Infliximab.
62051466|NCT02043691|EXPERIMENTAL|Surgeon-Modified Endograft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Surgeon-Modified Endografts. These will be created in the operating room by modifying a commercially-available Cook Alpha Thoracic Endograft or Cook Zenith Infrarenal Aortic Device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
62051467|NCT01455935|ACTIVE_COMPARATOR|Medical Therapy|"Current standard of care per the latest stroke guidelines~* Permissive Hypertension up to 220~* Antipletelets therapy:~  1. ASA 81 mg PO daily or~ 2. Plavix 75 mg PO daily or~ 3. Aggrenox 225mg PO twice daily~* Anti-inflammatory therapy:~  1. Lipitor 80 mg PO daily or~ 2. Crestor 20 mg PO daily"
62051468|NCT01455935|EXPERIMENTAL|Intravenous Thrombolysis|"Full dose Intravenous thrombolysis~* 0.9 mg/kg~* Maximum dose is 90 mg~* 10% of the dose will be given over one minute~* 90% of the dose will be infused over 1 hour~* Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications~* Neuro checks every 5 minutes during the infusion~* Neuro checks every hour after the infusion for 24 hours"
62441974|NCT02631109|EXPERIMENTAL|L-DEP|Pegaspargase 2000U/m2 day5; doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered once on the first day of every week; methylprednisolone 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
62441975|NCT01373606|EXPERIMENTAL|Terlipressin|
62441976|NCT02448459|EXPERIMENTAL|COOL-COS|All women will receive Letrozole, Clomiphene, and Corifollitropin Alfa for controlled ovarian stimulation
62834042|NCT00089752|ACTIVE_COMPARATOR|Active Treatment|Continuous Positive Airway Pressure Treatment
62834043|NCT00089752|PLACEBO_COMPARATOR|Sham/Placebo Treatment|Ineffective sham continuous positive airway pressure device with leak in interface to \<1.0 cm H2O and resistance in motor to simulate normal operating noise and no compensation for leak.
62834044|NCT05650385|EXPERIMENTAL|Cohort 1|B1962 0.035mg Open Lable
62834045|NCT05650385|EXPERIMENTAL|Cohort 2|B1962 0.12mg Open Lable
62834046|NCT05650385|EXPERIMENTAL|Cohort 3|B1962 0.4mg Open Lable
62834047|NCT05650385|EXPERIMENTAL|Cohort 4|B1962 1.2mg Open Lable
62834048|NCT05650385|EXPERIMENTAL|Cohort 5|B1962 4mg Open Lable
62834049|NCT05650385|EXPERIMENTAL|Cohort 6|B1962 8mg Open Lable
62834050|NCT05650385|EXPERIMENTAL|Cohort 7|B1962 11mg Open Lable
62834051|NCT05650385|EXPERIMENTAL|Cohort 8|B1962 15mg Open Lable
62834052|NCT05650385|EXPERIMENTAL|Cohort 9|B1962 20mg Open Lable
62834053|NCT05650385|EXPERIMENTAL|Cohort 10|B1962 25mg Open Lable
62834054|NCT04389281|EXPERIMENTAL|X-PACT Treatment|Single arm consisting of a six-week treatment period with X-PACT (phosphor device and methoxsalen sterile solution and subsequently exposing the tumor to X-ray energy) administered as an intra-tumoral injection. Intra-tumoral injections will be given on D1, D3 and D5 of Week 1, on D1 of Week 2, and a booster on D1 of Week 6. After the week 8 tumor assessment subjects demonstrating stable disease, partial response or unconfirmed progression assessed by iRecist, will be eligible to receive two additional booster treatments 4-6 weeks apart.
62834055|NCT04431440||Methicillin resistant staphylococcus aureus|
62834056|NCT04431440||vancomycin resistent staphylococcus aureus|
62834057|NCT05880186|EXPERIMENTAL|Caffeine intake|"Test in the morning~A dose of 3 mg/kg of caffeine (Bulk Powders, Essex, United Kingdom) was ingested before the beginning of each test.~Test in the evening~A dose of 3 mg/kg of caffeine (Bulk Powders, Essex, United Kingdom) was ingested before the beginning of each test."
62834058|NCT05880186|PLACEBO_COMPARATOR|Placebo intake|"Test in the morning~A dose of 3 mg/kg of placebo (Cellulose, Guinama, Valencia, Spain) was ingested before the beginning of each test.~Test in the evening~A dose of 3 mg/kg of placebo (Cellulose, Guinama, Valencia, Spain) was ingested before the beginning of each test"
62834059|NCT00467116|EXPERIMENTAL|Therapeutic Intervention|
62834060|NCT01924338|EXPERIMENTAL|Skin types I and II|"Volunteers classified as skin types I and II according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
62051469|NCT01455935|EXPERIMENTAL|Intra-Arterial Therapy|"-Choice of therapy per experienced Endovascular surgeon and includes:~1. Intra arterial Activase (Maximum dose of 22 mg)~2. MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)~3. PENUMBRA device (no standard time frame for how long the procedure takes)"
62051470|NCT03945539|EXPERIMENTAL|JNJ-56136379 and Itraconazole|Participants will receive a single dose of JNJ-56136379 on Day 1 in Treatment Period 1 and itraconazole 200 mg once daily for 21 days starting on Day 34 along with a single dose of JNJ 56136379 on Day 38 in Treatment Period 2. JNJ-56136379 intake in Treatment Period 1 and the first intake of itraconazole in Treatment Period 2 will be separated by a washout period of at least 33 days. Study drug (JNJ-56136379 and itraconazole) intakes will be taken orally and under fed conditions.
62051471|NCT04309045|EXPERIMENTAL|DBT|Standard DBT treatment
62834061|NCT01924338|EXPERIMENTAL|Skin type III|"Volunteers classified as skin type III according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
62834062|NCT01924338|EXPERIMENTAL|Skin type IV|"Volunteers classified as skin type IV according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
62441977|NCT05141266|EXPERIMENTAL|Brief Intervention Medication Therapy Management (BI-MTM)|Brief Intervention Medication Therapy Management (BI-MTM) is the overarching model made up of 4 evidence-based components: Medication Therapy Management (MTM); Screening, Brief Intervention, and Referral to Treatment (SBIRT); naloxone dispensing, and Patient Navigation (PN). Each component is sequentially delivered within the model and addresses a critical aspect of opioid medication misuse and risk. The pharmacy-based portion of BI-MTM (MTM+SBIRT+naloxone) will be delivered by a PharmD level pharmacist, and PN will be delivered by a bachelor's level interventionist.
62834063|NCT01924338|EXPERIMENTAL|Skin types V and VI|"Volunteers classified as skin types V and VI according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
62834064|NCT04214938|ACTIVE_COMPARATOR|Hypertonic sea water|The patient was applied intranasal hypertonic sea water (3.5% sodium chloride) before the nasoendoscopy procedure.
62834065|NCT04214938|ACTIVE_COMPARATOR|Lidocaine|The patient was applied intranasal Vemcaine as TLA (10% lidocaine; AstraZeneca, Södertälje, Sweden) before the nasoendoscopy procedure.
62834066|NCT04214938|ACTIVE_COMPARATOR|Xylometazoline|The patient was applied intranasal Otrivine (0.1% xylometazoline hydrochloride, GlaxoSmithKline, Brentford, UK ) before the nasoendoscopy procedure.
62834067|NCT04214938|PLACEBO_COMPARATOR|0.9% Sodium chloride|The patient was applied intranasal placebo (0.9% sodium chloride) before the nasoendoscopy procedure.
62834068|NCT03879733|EXPERIMENTAL|Intervention group|The group of childcare centers that will receive the intervention during 10 months from sept 2018 - June 2019
62834069|NCT03879733|OTHER|Wait-list control|"Will receive no intervention and continue with business as usual during the primary intervention period Sept. 2018 - June 2019.~Will receive the intervention from Sept. 2019 - June 2020."
62834070|NCT05851261|PLACEBO_COMPARATOR|PA3670 5 mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 5 mg of PA3670 tablets or PA3670 placebo tablets. They will be administered a single dose and observed for four days.
62051472|NCT04309045|ACTIVE_COMPARATOR|DDP|dynamic deconstructive psychotherapy (DDP) treatment, is part of a trend of dynamic therapies to treat borderline personality disorder. DDP is a treatment specifically developed for a population with more severe symptoms those dealing with borderline personality disorder.
62051473|NCT04309045|PLACEBO_COMPARATOR|control group|patients on the waiting list for treatment, or patients in the hospital under routine care. Which will form the control group.
62051474|NCT03395405|EXPERIMENTAL|Nitazoxanide Arm|500 mg (one tablet) nitazoxanide by mouth twice daily with food for 56 consecutive doses. N=80
62051475|NCT03395405|PLACEBO_COMPARATOR|Placebo Arm|Placebo (one tablet) by mouth twice daily with food for 56 consecutive doses. N=80
62051476|NCT00606190|ACTIVE_COMPARATOR|Retrograde brain perfusion|Pt may be randomized to retrograde brain perfusion when having a repair of the ascending aortic artery (aorta) including the aortic arch. This is one of the standard methods used while the body and the brain are cooled down to sub-normal levels (hypothermia). This will take place while on the heart-lung machine.
62611294|NCT06114498||Patient with HFpEF with decompensation|"120 patients hospitalized with a clinical picture of acute decompensation of heart failure (shortness of breath, orthopnea, clinical signs of cardiac asthma and/or pulmonary edema) in the city clinical hospital named after. V.V. Veresaeva, Moscow. Patients with a confirmed diagnosis in accordance with instrumental and/or laboratory criteria"
62611295|NCT06114498||Control group|40 particularly healthy people without heart failure and acute cardiovascular diseases
62611296|NCT05610072|EXPERIMENTAL|n-Acetylcysteine|Subjects will receive 0.6 g oral n-acetylcysteine 4 times per day.
62051477|NCT00606190|ACTIVE_COMPARATOR|Antegrade brain perfusion|Pt may be randomized to antegrade brain perfusion when having a repair of the ascending aortic artery (aorta) including the aortic arch. This is one of the standard methods used while the body and the brain are cooled down to sub-normal levels (hypothermia). This will take place while on the heart-lung machine.
62611297|NCT05610072|PLACEBO_COMPARATOR|Placebo|Subjects will receive oral placebo 4 times per day.
62611298|NCT00416793|EXPERIMENTAL|Treatment|Patients receive bortezomib IV on days 1, 4, 8, and 11 and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62834071|NCT05851261|PLACEBO_COMPARATOR|PA3670 15 mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 15 mg of PA3670 tablets or PA3670 placebo tablets. They will be administered a single dose and observed for four days.
62611299|NCT03338569|SHAM_COMPARATOR|Placebo|Placebo designed to mimic intervention
62834072|NCT05851261|PLACEBO_COMPARATOR|PA3670 30 mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 30 mg of PA3670 tablets or PA3670 placebo tablets. They will be administered a single dose and observed for four days.
62834073|NCT05851261|PLACEBO_COMPARATOR|PA3670 15 mg for 9days|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either 15mg of PA3670 tablets or PA3670 placebo tablets, once daily for 9 days.
62834074|NCT05851261|OTHER|PA3670 15mg before and after meals|Ten subjects will be administered 15mg PA3670 after overnight fasting for 10 hours in the first cycle, and then will be administered 10mg PA3670 within 30 minutes after high-fat meal in the second cycle. They will receive a single dose in each cycle and will be observed for four days. The cleaning period between the two cycles is more than 7 days.
62834075|NCT05851261|OTHER|PA3670 15mg after and before meals|Ten subjects will be administered 15mg PA3670 within 30 minutes after the high-fat meal in the first cycle, and then will be administered 10mg PA3670 after overnight fasting 10 hours in the second cycle. They will receive a single dose in each cycle and will be observed for four days. The cleaning period between the two cycles is more than 7 days.
62834076|NCT02601248|EXPERIMENTAL|Theliatinib|Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 5 dose cohorts,including120mg/160mg/200mg/220mg/300mg, QD in the dose escalation stage .
62051478|NCT06495931|EXPERIMENTAL|Treatment group A: HRS-1780 tablets、HR20033 tablets、HRS-7535 tablets|
62441978|NCT05141266|OTHER|Standard of Care|Standard of Care is the treatment as usual condition, which follows federal and Utah state pharmacy requirements for pharmacists where in patients filling prescriptions receive information and opt-in counseling. Specifically, SMC in Utah requires pharmacists to: (1) offer counseling, (2) document counseling has been offered, (3) offer a counseling process for patients not present, and (4) discuss generic substitution.The duration of SMC in the current study is a single 5-10 minute session delivered by a University of Utah pharmacist other than the study pharmacist that possesses a similar level of education and professional licensing.
62611300|NCT03338569|ACTIVE_COMPARATOR|Intervention|6000 mg per day Vitamin C supplement
62611301|NCT05403528|NO_INTERVENTION|3D-3D|All items presented in 3D form
62611302|NCT05403528|EXPERIMENTAL|3D-2D|Initial items in 3D, retention and generalization in 2D
62611303|NCT05403528|EXPERIMENTAL|2D-3D|Initial items in 2D, retention and generalization in 3D
62611304|NCT05403528|EXPERIMENTAL|2D-2D|All items in 2D
62611305|NCT05370404|ACTIVE_COMPARATOR|Prescription Group for acetaminophen, NSAIDs, and magnesium|"Participants will receive prescriptions from the surgical team for non-opioid pain medications to take at home after discharge from surgery.~The non-opioid pain medications will be acetaminophen 1000 milligram (mg) four times a day (qid) for 3 days then as needed (prn) pain, ibuprofen 600 mg qid for 3 days then prn, and magnesium oxide 400 mg daily prn pain."
62611306|NCT05370404|ACTIVE_COMPARATOR|Over the Counter Group|"Participants will receive a recommendation from the surgical team to take over-the-counter non-opioid pain medications at home after discharge from surgery.~The non-opioid pain medications will be acetaminophen 1000 mg qid for 3 days then prn pain, ibuprofen 600 mg qid for 3 days then prn, and magnesium oxide 400 mg daily prn pain."
62611307|NCT05020899|EXPERIMENTAL|Quit for Life group|Participants randomized to this arm will receive a 8 week quit smoking program delivered by trained counselors and messages to their cell phones. Participants will also be offered nicotine replacement therapy (gum or patch, depending on which one is available) and a self-help guide with information about quitting smoking.
62611308|NCT05020899|ACTIVE_COMPARATOR|Control group|Participants randomized to this arm will be offered nicotine replacement therapy (gum or patch, depending on which one is available) and a self-help guide with information about quitting smoking.
62611309|NCT05343091||Pulmonary Hypertension patients|patients with diagnosis of Pulmonary Hypertension from group 1 and 4 by right heart catheterization
62834077|NCT01591525||Uncontrolled Diabetic|Individuals who were previously diagnosed with Type II Diabetes, but have a HgA1C greater than 7.0%
62611310|NCT05260775||Development Dataset|12 cataract surgery steps including(1) main incision formation, (2) side incision formation, (3) ophthalmic viscoelastic device (OVD) injection, (4) capsulorrhexis formation, (5) hydrodissection, (6) phaco, (7) cortical material removal, (8) intraocular lens (IOL) implantation, (9) OVD removal, (10) IOL centration and (11) wound closure through corneal hydration, and (12) idle phases.
62051479|NCT00464646|EXPERIMENTAL|1|"* Cohort A: Women with unresected locally advanced breast cancer (clinical Stage IIIA, IIIB, and IIIC)~* Cohort B: Women with resected pN2 or pN3 (pathologic Stage III) breast cancer"
62051480|NCT02651935|EXPERIMENTAL|Intellivent ASV|Patients in this arm will be ventilated with Intellivent ASV. Intellivent ASV is an automatic close loop ventilation mode. FiO2 setting will be automatically adjusted according to patients SpO2 and minute volume will be automatically adjusted according to patients EtCO2.
62611311|NCT05260775||Validation Dataset|12 cataract surgery steps including(1) main incision formation, (2) side incision formation, (3) ophthalmic viscoelastic device (OVD) injection, (4) capsulorrhexis formation, (5) hydrodissection, (6) phaco, (7) cortical material removal, (8) intraocular lens (IOL) implantation, (9) OVD removal, (10) IOL centration and (11) wound closure through corneal hydration, and (12) idle phases.
62611312|NCT05260775||Test Dataset|12 cataract surgery steps including(1) main incision formation, (2) side incision formation, (3) ophthalmic viscoelastic device (OVD) injection, (4) capsulorrhexis formation, (5) hydrodissection, (6) phaco, (7) cortical material removal, (8) intraocular lens (IOL) implantation, (9) OVD removal, (10) IOL centration and (11) wound closure through corneal hydration, and (12) idle phases.
62611313|NCT05054699|EXPERIMENTAL|MST|Subjects will receive 12-18 sessions of frontal Magnetic Seizure Therapy under general anaesthesia, twice a week. Clinical and cognitive measures will be assessed before, during and after the treatment
62611314|NCT05054699|ACTIVE_COMPARATOR|ECT|Subjects will receive 12-18 sessions of bilateral Electroconvulsive Therapy under general anaesthesia, twice a week. Clinical and cognitive measures will be assessed before, during and after the treatment
62611315|NCT01711775|EXPERIMENTAL|Aleglitazar|
62834078|NCT01591525||Newly diagnosed Type II Diabetic|Individuals who have never been diagnosed with Type II Diabetes, but have an HgA1c greater than 7.0%
62834079|NCT01591525||Newly diagnosised pre-diabetics|Individuals who have never been diagnosed with Type II Diabetes, but have a HgA1C of 6.0%-6.9%
62834080|NCT01591525||Controlled|Diabetic or non-diabetic individuals with RPCG of less than 130 mg/dl.
62834081|NCT02615899|ACTIVE_COMPARATOR|Matched|Administer Targeted (specific) balance exercise interventions
62834082|NCT02615899|ACTIVE_COMPARATOR|Mismatched|Administer Untargeted (non-specific) balance exercise interventions
62834083|NCT04455256||recurrent pregnancy loss group|Women between the ages of 18 and 45 who had a history of miscarriage under 3 weeks and above 22 weeks were included in this group.
62834084|NCT04455256||women who had healthy birth|Women between the ages of 18-45 who have not had a history of pregnancy loss and who have had at least one healthy birth and no known chronic diseases are included in this group.
62834085|NCT04343742||chlorine dioxide 3000 ppm. Bottle x 150 cc.|"Assignment of study medication Each patient will receive, in order of admission to the study, a consecutive patient number and the corresponding study medication. The assignment of this medication was made before the start of the study, using a computer generated list. Patients will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.~7.1 Dosage and route of administration. Medication: chlorine dioxide 3000 ppm. Fco x 150 cc. 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots).~Both the original dioxide bottle and the preparation for the day should be kept refrigerated."
62834086|NCT01753232||DALI-adsorber, hypercholesterolemia|Patients suffering from familial hypercholesterolemia treated at least twice a month with the DALI-system
62834087|NCT01753232||MONET-Filter, hypercholesterolemia|Patients suffering from familial hypercholesterolemia treated with the MONET-Lipoprotein filter
62611316|NCT02436902|EXPERIMENTAL|TACE|Transarterial chemoembolization (TACE) is performed two to four weeks after hepatic resection.
62834088|NCT05680402|EXPERIMENTAL|Group 1|Soft tissue mobilization
62834089|NCT05680402|ACTIVE_COMPARATOR|Group 2|Piriformis Stretching
62611317|NCT02436902|ACTIVE_COMPARATOR|sorafenib|Patients will receive sorafenib at a dose of 400 mg twice daily after 2 weeks of hepatic resection.
62611318|NCT02436902|OTHER|TACE plus sorafenib|Patients will receive sorafenib at a dose of 400 mg twice daily after 2 weeks of hepatic resection. At the same time, TACE is performed two to four weeks after hepatic resection.
62834090|NCT05363748||Observation group|sequential
62834091|NCT04275362||DJO subjects for surgical technique|Subjects who meet the inclusion criteria and receive a DJO Empowr total knee replacement but will not participate in motion data collection
62834092|NCT04275362||DJO subjects for data collection|Subjects who meet the inclusion criteria and consent to be in the study will receive a DJO Empowr total knee replacement and participate in motion data collections at pre-op, and 6 and 12 months post-op. Subjects will also participate in pre-op, 6 month, 1 year, 2 year, 5 year, and 10 year post-op clinical data collections
62834093|NCT04275362||Prospective control subjects|Healthy age matched subjects who did not have any knee osteoarthritis and participated in motion data collections.
62834094|NCT04275362||Stryker TKA subjects|Subjects who met the inclusion criteria and consented to be in a study whereby they received a Stryker Triathlon total knee replacement and participated in motion analysis pre-surgery and 6 and 12 months post-surgery.
62252521|NCT04961268|ACTIVE_COMPARATOR|Ibuprofen/acetaminophen|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received ibuprofen 600 mg/acetaminophen 1000 mg in opaque yellow size 000 capsules."
62834095|NCT04275362||Biomet TKA subjects|Subjects who met the inclusion criteria and consented to be in a study whereby they received a Biomet Vanguard total knee replacement and participated in motion analysis pre-surgery and 12 months post-surgery.
62834096|NCT04275362||Retrospective control subjects|Healthy age matched subjects who did not have any knee osteoarthritis and participated in motion data collections.
62834097|NCT00148317|EXPERIMENTAL|Treatment Arm|
62834098|NCT03307499|EXPERIMENTAL|Treatment|NeoPatch
62834099|NCT04193995|EXPERIMENTAL|Intermittent fasting|There are two 36h fasting periods (FP) every week, over a 12week period. Free access to water is allowed; two cups of tea or coffee are also allowed. Each 36h FP begins after the last meal, which is consumed no later than 2000h on the preceding nights. Fasting days are Sunday and Wednesday and fasting is terminated at 0800 on Monday and Thursday.
62834100|NCT01055431|PLACEBO_COMPARATOR|Control|Control bread
62834101|NCT01055431|ACTIVE_COMPARATOR|Teff bread|Teff bread
62252522|NCT04961268|PLACEBO_COMPARATOR|Placebo|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received Placebo in opaque yellow size 000 capsules."
62441979|NCT01575392||Patients coming for creatinine clearance|For this single group study, all patients presenting at the laboratory facility for a 24-hour creatinine clearance and patients in the dialysis population of the Isala Clinics who came for their periodical KT/V control, were informed about the study and asked to participate. Moreover, 20 'healthy' volunteers (including the investigators of this study and staff working at the clinical chemistry department of the Isala clinics) participated in this study.
62441980|NCT02429869|EXPERIMENTAL|Everolimus|
62834102|NCT00491842||At-risk|Individuals at-risk for HD
62834103|NCT00491842||Presymptomatic|Presymptomatic carriers of HD
62834104|NCT05975684|ACTIVE_COMPARATOR|Baclofen|Baclofen 0.5 mg/kg/day up to 15 mg/day divided three times a day in liquid formulation for 4 weeks.
62834105|NCT05975684|PLACEBO_COMPARATOR|Placebo|Matching placebo three times a day in liquid formulation for 4 weeks.
62834106|NCT05164991|EXPERIMENTAL|MR imaging|The experiment is aimed to induce a virtual rubber hand illusion, in which the individuals can potentially experience an embodiment illusion
62834107|NCT03487237|EXPERIMENTAL|All patient|Included patients will undergo a formal work up for pulmonary embolism: Ddimer testing, followed if positive by a computed tomography pulmonary angiogram or V/Q scan.
62252523|NCT00924105|EXPERIMENTAL|1|
62252524|NCT00924105|PLACEBO_COMPARATOR|2|
62252525|NCT04641299|PLACEBO_COMPARATOR|Placebo|Placebo solution for subcutaneous injection.
62252526|NCT04641299|EXPERIMENTAL|AZD8233 high dose|AZD8233 high dose for subcutaneous injection.
62252527|NCT04641299|EXPERIMENTAL|AZD8233 medium dose|AZD8233 medium dose for subcutaneous injection.
62252528|NCT04641299|EXPERIMENTAL|AZD8233 low dose|AZD8233 low does for subcutaneous injection.
62834108|NCT04207762||PET/CT Diagnostic Imaging|Each subject will have a PET/CT scan, using 18F-AmBF3-TATE. 18F-AmBF3-TATE radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada.
62834109|NCT03350685||Classic Whipple's disease (CWD)|"Classic Whipple's disease (CWD), defined as~* duodenal biopsy positive by PAS/immunohistochemistry~* or blood positive by PCR"
62834110|NCT03350685||Focal Whipple's disease (FWD)|"Focal Whipple's disease (FWD), defined as~* joint fluid positive by PCR~* but duodenal biopsy negative by PAS/immunohistochemistry"
62834111|NCT03350685||Chronic T. whipplei-associated arthritis (CTWA)|"Chronic T. whipplei-associated arthritis (CTWA) defined as chronic arthritis and~* duodenal biopsy, stool, or saliva positive by PCR~* duodenal biopsy negative by PAS/immunohistochemistry~* joint fluid negative by PCR"
62834112|NCT00478543|EXPERIMENTAL|Diuretic|Furosemide
62834113|NCT01925456|OTHER|Toviaz|Patients willingness to take Toviaz 4mg and 8mg
62252529|NCT01003210|EXPERIMENTAL|Homeopathic ear drops|Commercially available homeopathic ear drops
62441981|NCT02115191|EXPERIMENTAL|2-octylcyanoacrylate|Application of 2-octylcyanoacrylate
62441982|NCT02115191|ACTIVE_COMPARATOR|Surgical reintervention|Surgical reintervention for urethrocutaneous fistula repair
62441983|NCT05064813|EXPERIMENTAL|Mindfulness Based Stress Reduction Group|8 weeks of Mindfulness Based Stress Reduction Group (MBSR).
62441984|NCT05064813|ACTIVE_COMPARATOR|Stress Education Group|8 weeks of Stress Education Group (SE).
62252530|NCT01003210|NO_INTERVENTION|standard therapy|standard therapy for otitis media, no ear drops
62252531|NCT04857996|EXPERIMENTAL|UBX1325|
62252532|NCT04857996|SHAM_COMPARATOR|Sham Control|
62252533|NCT02372916||Dry AMD|Patients with pre-existing GA secondary to AMD NOT requiring intravitreal injections (i.e. Dry AMD)
62252534|NCT02372916||Wet AMD and treatment-naive|Patients with pre-existing GA and CNV secondary to AMD requiring intravitreal injections (i.e. Exudative AMD) and are treatment-naïve patients
62252535|NCT02372916||Wet AMD with history of intravitreal injections|Patients with pre-existing GA and CNV secondary to AMD requiring intravitreal injections (i.e. Exudative AMD) and have received previous intravitreal injections
62441985|NCT04280172|EXPERIMENTAL|Cultural Competence Education|Participants in the intervention group will attend cultural competence education
62441986|NCT04280172|ACTIVE_COMPARATOR|Standard Mentoring Education|Participants in the control group will complete standard mentoring education that does not include a cultural competence component
62834114|NCT02439437|ACTIVE_COMPARATOR|Psychosocial Intervention|Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
62252536|NCT03685383|EXPERIMENTAL|intervention group: eCPR + CytoSorb|In addition to standard treatment in patients undergoing eCPR in the intervention group the CytoSorb removal column will be added to the ECLS-system (intervention: CytoSorb removal column in eCPR).
62834115|NCT02439437|NO_INTERVENTION|Treatment as usual|Treatment as usual
62834116|NCT03699514||Subject who completed or will complete a BNA test|
62252537|NCT03685383|ACTIVE_COMPARATOR|control group: eCPR - CytoSorb|Patients in the control group will receive standard treatment established for eCPR patients on our ICU. This standard treatment includes, among others, targeted temperature management (TTM) for the first 72 hours. For the use of ECLS as well as TTM we are following well established standard operating procedures (control: standard eCPR (va-ECMO)).
62441987|NCT03008460|EXPERIMENTAL|Eziclen®/Izinova®|
62611319|NCT02436902|NO_INTERVENTION|empty control|This group patients will receive best supportive care.
62834117|NCT01104311|EXPERIMENTAL|Aggressive BP lowering|Lowering of systolic blood pressure between 110mmHg and 120mmHg during study period
62834118|NCT01104311|ACTIVE_COMPARATOR|Modest BP lowering|Lowering of systolic blood pressure between 130mmHg and 140mmHg
62441988|NCT03008460|ACTIVE_COMPARATOR|Klean-Prep®|
62441989|NCT02735083|EXPERIMENTAL|UCART19 follow-up|
62441990|NCT00820235|EXPERIMENTAL|A|
62441991|NCT00820235|ACTIVE_COMPARATOR|B|
62441992|NCT00820235|ACTIVE_COMPARATOR|C|
62611320|NCT01065064|EXPERIMENTAL|RESTOR|Patients with cataract that had phacoemulsification and AcrySof® ReSTOR IOL implantation.
62611321|NCT06281626||Young adults|people aged 18 to 25 years.
62834119|NCT01528332|EXPERIMENTAL|Pain Relief Patch|Pain Relief Patch: Light wavelength 453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm², 30 minutes
62834120|NCT01528332|ACTIVE_COMPARATOR|Control PRP device|Control PRP device: Light wavelength 531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm², light on for 5 seconds, device worn for 30 minutes
62834121|NCT02085161|PLACEBO_COMPARATOR|placebo|patient will receive placebo once daily, 2 puffs in the morning
62834122|NCT02085161|EXPERIMENTAL|tiotropium + olodaterol high dose with BM|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
62252538|NCT02443896|EXPERIMENTAL|Sealant applied to molars|"All 'sealable' permanent molars will be sealed: Occlusal fissures and where appropriate, buccal pits (on lower molars) and palatal pits (on upper molars) will be sealed.~If patient compliance is adequate, a resin based sealant will be used as the first choice material. The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard."
62834123|NCT02085161|ACTIVE_COMPARATOR|tiotropium|patient will receive tiotropium 5 mcg once daily, 2 puffs in the morning
62834124|NCT02085161|EXPERIMENTAL|tiotropium + olodaterol with exercise training and BM|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
62051481|NCT02651935|NO_INTERVENTION|PCV+PSV|PCV+PSV is a conventional ventilation strategy of pressure controlled ventilation PCV) and pressure support ventilation (PSV).In this arm, FiO2, pressure control levels, respiratory frequency and all the ventilator settings will be manually adjusted by the physicians in charge.
62051482|NCT01210430|ACTIVE_COMPARATOR|Losartan|
62051483|NCT01210430|ACTIVE_COMPARATOR|Ascorbic Acid (VItamin C)|
62252539|NCT02443896|SHAM_COMPARATOR|No sealant applied to molars.|No molars will be sealed.
62252540|NCT06238674|EXPERIMENTAL|Individualised energy and protein delivery guided by indirect calorimetry and nitrogen balance|Energy delivery will be guided by indirect calorimetry with the aim to meet 70-100% of the most recent energy expenditure measurement and protein delivery guided by nitrogen balance with the aim to positive nitrogen balance with the maximum of 1.3 g/kg/d after 72 hours of admission and continue for total of 14 days by enteral or parenteral feeding routes
62252541|NCT06238674|ACTIVE_COMPARATOR|Standard care nutrition|Energy and protein delivery will be according to predictive equation estimates and usual site practice along enteral feeding
62252542|NCT00470054|EXPERIMENTAL|Treatment (dasatinib)|Patients receive oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62252543|NCT02895620|OTHER|NMIBC patients Xpert bladder test|Xpert bladder test of urine of patients with NMIBC treated with BCG therapy
62252544|NCT05515705|EXPERIMENTAL|EUS-NS +|EUS with the navigation system first on, then off
62252545|NCT05515705|EXPERIMENTAL|EUS-NS -|EUS with the navigation system first off, then on
62252546|NCT05515705|NO_INTERVENTION|EUS group|EUS alone
62611322|NCT02261103|ACTIVE_COMPARATOR|Pramipexole IR, fasted|Pramipexole immediate release (IR) tablets
62834125|NCT00707889|ACTIVE_COMPARATOR|A|Open-label to Bevacizumab plus mFOLFOX6
62441993|NCT02643901|EXPERIMENTAL|Ic-GW003 150ug/kg 4-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
62441994|NCT02643901|EXPERIMENTAL|Ic-GW003 300ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
62441995|NCT02643901|EXPERIMENTAL|Ic-GW003 500ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
62441996|NCT02643901|EXPERIMENTAL|Ic-GW003 650ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
62834126|NCT00707889|ACTIVE_COMPARATOR|B|Open-label to High-dose ABT-869 arm plus mFOLFOX6
62834127|NCT00707889|ACTIVE_COMPARATOR|C|Open-label to low-dose ABT-869 arm plus mFOLFOX6
62834128|NCT04830332|OTHER|Study group|Women with endometrial carcinoma
62834129|NCT01654302|ACTIVE_COMPARATOR|Synera|lidocaine/tetracaine patch with heating component which consists of iron powder, activated carbon, sodium chloride, wood flour, water and filter paper.
62051484|NCT01210430|PLACEBO_COMPARATOR|Normal Saline|
62051485|NCT03262610|EXPERIMENTAL|Setmelanotide daily subcutaneous injection|Up to 18 weeks setmelanotide treatment.
62051486|NCT05158296|EXPERIMENTAL|Ultevursen 60/60 µg|60 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter
62051487|NCT05158296|EXPERIMENTAL|Ultevursen 180/60 µg|180 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter
62051488|NCT05158296|SHAM_COMPARATOR|Sham-procedure|Sham-procedure (no experimental drug administered) on Day 1, Month 3 and every 6 months thereafter
62051489|NCT03611244|EXPERIMENTAL|Experimental group|When loss of ambulation was observed in patients with Duchenne muscular dystrophy, portable seat device devised to maintain lumbar lordosis were applied within 1 year, and then compliance with the the device were evaluated at 6-month intervals for 5 years.
62611323|NCT02261103|EXPERIMENTAL|Pramipexole ER, fasted|Pramipexole extended release (ER) tablets
62611324|NCT02261103|EXPERIMENTAL|Pramipexole ER, fed|Pramipexole extended release tablets with a high-fat meal 30 min before drug administration
62834130|NCT01654302|PLACEBO_COMPARATOR|Inactive Patch|placebo patch identical in appearance and composition (namely, the heating components) to the active patch other than lacking the lidocaine and tetracaine active ingredients.
62834131|NCT04058964|EXPERIMENTAL|Treatment (pembrolizumab, PEGPH20)|Patients receive pembrolizumab IV over 10 minutes on day 1 and pegylated recombinant human hyaluronidase PH20 SC on days 1, 8, and 15. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
62834132|NCT04976400|EXPERIMENTAL|test group|Semi-individualized total knee arthroplasty
62834133|NCT04976400|ACTIVE_COMPARATOR|Control group|Zimmer standard prosthesis total knee replacement
62611325|NCT06241313|PLACEBO_COMPARATOR|Sequence 1|Participants will receive both atogepant and placebo to treat qualifying migraines.
62611326|NCT06241313|EXPERIMENTAL|Sequence 2|Participants will receive both atogepant and placebo to treat qualifying migraines.
62611327|NCT06241313|EXPERIMENTAL|Sequence 3|Participants will receive both atogepant and placebo to treat qualifying migraines.
62611328|NCT06241313|EXPERIMENTAL|Sequence 4|Participants will receive both atogepant and placebo to treat qualifying migraines.
62834134|NCT01397214|EXPERIMENTAL|Megace F|Megace F oral suspension
62834135|NCT01397214|ACTIVE_COMPARATOR|Megace OS|Megace acetate oral suspension
62051490|NCT03611244|NO_INTERVENTION|Control group|Analysis of retrospective medical records who had not been applied portable seat device devised to maintain lumbar lordosis
62051491|NCT00123032|EXPERIMENTAL|1|This group will focus on improving their diet and increasing physical activity at home and at school.
62051492|NCT00123032|NO_INTERVENTION|2|A control group will not receive any intervention.
62611329|NCT00441155|EXPERIMENTAL|Monotherapy: AMN107|initial dose of imatinib (dose level 1) was 400 mg bid was administered orally on a continuous daily schedule and was not escalated during the study
62611330|NCT00441155|ACTIVE_COMPARATOR|Combination Therapy: AMN107 + Imatinib|six possible doses of Nilotinib (100 mg once daily (qd), 200 mg qd, 400 mg qd, 200 mg bid, 300 mg bid, and 400 mg bid). four possible doses of Imatinib (0 mg, 400 mg qd, 600 mg qd, and 400 mg bid).the initial dose of nilotinib (dose level 1) was 200 mg qd and could have been escalated up to 400 mg bid
62051493|NCT06463444|EXPERIMENTAL|Combined therapy group|All patients received HAIC combined with targeted therapy and immunotherapy
62051494|NCT04132843|EXPERIMENTAL|Diagnostic (MRI, gadobutrol, gadobenate dimeglumine)|Within 21 days before standard of care chemotherapy and/or radiation therapy, patients undergo an MRI scan for the first set of images. Patients then receive either gadobutrol or gadobenate dimeglumine IV and undergo an MRI for the second set of images. All MRI scans take a total of 60 minutes to complete. Patients then repeat the MRI scans 120 days after standard of care chemotherapy and/or radiation therapy.
62051495|NCT03917784|EXPERIMENTAL|Curcumin and bioperine|This group will receive curcumin 500 mg and bioperine 5 mg oral dosing every 12 hours for 3 months
62051496|NCT03917784|PLACEBO_COMPARATOR|Placebo|This group will receive placebo (starch) 500 mg oral dosing every 12 hours for 3 months
62051497|NCT00583986|EXPERIMENTAL|1|Levalbuterol HFA MDI with top mounted actuation indicator
62252547|NCT01945502||nasal packing with dry packs|
62252548|NCT01945502||nasal packing with wet packs|
62611331|NCT05313802|EXPERIMENTAL|LY3502970 (Dose Level 1)|LY3502970 administered orally.
62611332|NCT05313802|EXPERIMENTAL|LY3502970 (Dose Level 2)|LY3502970 administered orally.
62611333|NCT05313802|EXPERIMENTAL|LY3502970 (Dose Level 3)|LY3502970 administered orally.
62834136|NCT03405597|EXPERIMENTAL|Healthy control|Commercial Hepatitis B vaccine
62834137|NCT03405597|EXPERIMENTAL|Chronic hepatitis B with vaccination|Commercial Hepatitis B vaccine
62834138|NCT03405597|ACTIVE_COMPARATOR|Chronic hepatitis B without vaccination|Standard treatment
62834139|NCT01759446|PLACEBO_COMPARATOR|Placebo taken first|Placebo powder snorted with all other arms taken crossover therafter
62834140|NCT01759446|ACTIVE_COMPARATOR|Generic H/A taken first|Generic hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter
62834141|NCT01759446|ACTIVE_COMPARATOR|Vycavert taken first|Vycavert hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter
62834142|NCT01759446|ACTIVE_COMPARATOR|Generic H/A plus i taken first|Generic hydrocodone/APAP 10/325mg plus additional inactive ingredients pulverized tablet snorted with all other arms taken crossover therafter
62051498|NCT02007434|EXPERIMENTAL|Paradigm 1 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL (based on Baseline CR-SMFRS grade 2 or 3, respectively) on Day 0 and a cold compress applied to the treatment area.
62051499|NCT02007434|PLACEBO_COMPARATOR|Paradigm 1/ Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.
62051500|NCT02007434|EXPERIMENTAL|Paradigm 2 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.
62051501|NCT02007434|PLACEBO_COMPARATOR|Paradigm 2 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.
62051502|NCT02007434|EXPERIMENTAL|Paradigm 3 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.
62051503|NCT02007434|PLACEBO_COMPARATOR|Paradigm 3 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
62051504|NCT02007434|EXPERIMENTAL|Paradigm 4 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
62252549|NCT01945502||nasal packing with Benzidamin-Clorhexsidin damped packs|
62051505|NCT02007434|PLACEBO_COMPARATOR|Paradigm 4 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
62051506|NCT04638998||Healthy Control|The healthy control group are men ages 46-70 who were present in the Persian Gulf War between 1990 and August 1991. This cohort do not experience any Gulf War Illness symptoms.
62051507|NCT04638998||Gulf War Illness|The GWI cohort are men ages 46-70 who were present in the Persian Gulf War between 1990 and August 1991. The men in this cohort will also meet the Kansas Inclusion Criteria for GWI.
62051508|NCT02320422|EXPERIMENTAL|Behavioral Telehealth|
62051509|NCT00873418|EXPERIMENTAL|Coping Skills Training|16 week telephone intervention using coping skills training to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
62051510|NCT00873418|ACTIVE_COMPARATOR|Educational Control|16 weekly telephone calls for extended (standardized) care on heart failure education.
62051511|NCT01258192|EXPERIMENTAL|nab-paclitaxel plus cisplatin|
62252550|NCT01945502||no nasal packing|
62252551|NCT04315194||clarithromycin-naproxen-oseltamivir|Efficacy of clarithromycin-naproxen-oseltamivir combination therapy vs. oseltamivir alone for hospitalised paediatric influenza patients
62252552|NCT04263064|ACTIVE_COMPARATOR|High Volume-Low Concentration without Clonidine|The control for this study will be a High Volume-Low Concentration (1.5cc/kg of 0.15% ropivacaine and 5mcg/cc epinephrine).
62252553|NCT04263064|EXPERIMENTAL|High Volume-Low Concentration with clonidine|The study intervention will be High Volume-Low Concentration with clonidine (1.5cc/kg of 0.15% ropivacaine, with 1mcg/cc of clonidine and 5mcg/cc epinephrine).
62252554|NCT05046847|EXPERIMENTAL|TQB3811|The initial dose is 2.5mg, once a day (QD), and the medication stage is divided into single administration and continuous administration. The single administration is given once a day, and the continuous administration is entered 4 days after drug withdrawal. The drug is administered continuously until the disease progresses.
62252555|NCT02198443|ACTIVE_COMPARATOR|Tenofovir+emtricitabine|
62252556|NCT02198443|EXPERIMENTAL|Elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil|
62441997|NCT02643901|EXPERIMENTAL|Ic-GW003 850ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
62441998|NCT05727267|EXPERIMENTAL|Arm A0|HEPLISAV B® and MVA-HBVac high dose
62834143|NCT01759446|ACTIVE_COMPARATOR|Generic H/A plus p taken first|Generic hydrocodone/APAP 10/325mg plus one placebo pulverized tablet snorted with all other arms taken crossover therafter
62051512|NCT03088592|OTHER|Deep Brain Stimulation|After informed consent is obtained, the patients will undergo routine DBS pre-operative evaluation and diagnostic testing. This includes a pre-operative 3T-MRI with and without gadolinium as well as pre-operative medical clearance by the patient's PCP or general practitioner and/or other medical specialist if necessary. They will also receive a baseline clinical evaluation including both motor function (Unified Parkinson's Disease Rating Scale on and off anti-parkinsonian medication) quality of life assessment (Parkinson's disease Questionnaire-39) and a full neuropsychological evaluation, if not already completed as part of the routine DBS candidacy evaluation within 2 months of surgery. Subjects will have medical clearance from their specialists and be be evaluated by an internal medicine physician prior to surgery and cleared to proceed.
62252557|NCT01194713|ACTIVE_COMPARATOR|Sleep deprivation|"13 subjects will undergo full sleep deprivation~these subjects are blind to allocation ntil they enter the study center"
62051513|NCT03735264|EXPERIMENTAL|Anlotinib Hydrochloride plus Docetaxel|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Docetaxel (75mg/m2 IV d1)
62051514|NCT02919722|EXPERIMENTAL|Music interventions|Live music will be provided on the patient's neglected side and patients will be encouraged to play music interactively with a focus towards that side whenever possible
62051515|NCT01941290||Orsiro|
62441999|NCT05727267|EXPERIMENTAL|Arm B0.1|HEPLISAV B® \& HBcoreAg low dose and MVA-HBVac low dose
62252558|NCT01194713|NO_INTERVENTION|Control night|control night of unrestricted sleep in 13 other subjects
62252559|NCT03208764|EXPERIMENTAL|Nitric Oxide treatment|
62252560|NCT00311376|EXPERIMENTAL|1|botulinum toxin Type A (200U)
62442000|NCT05727267|EXPERIMENTAL|Arm B0.2|2 x HEPLISAV B® \& HBcoreAg medium and MVA-HBVac high dose
62051516|NCT03209141||Diastolic dysfunctional hypertension|Patients with confirmed arterial hypertension and diastolic dysfunction by echocardiographic diastolic function evaluation
62051517|NCT03209141||Non diastolic dysfunctional hypertension|Patients with confirmed arterial hypertension and without diastolic dysfunction by echocardiographic diastolic function evaluation
62051518|NCT03688984|EXPERIMENTAL|Cognitive Behavioural Therapy for Insomnia|Six sessions of in person Cognitive Behavioural Therapy for Insomnia (CBT-I)
62051519|NCT03688984|NO_INTERVENTION|Treatment As Usual|Participants will receive regular care in the Treatment As Usual (TAU) condition. Participants will be offered CBT-I at the completion of the trial.
62051520|NCT04166825|ACTIVE_COMPARATOR|Long protocol|Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono) and/or urinary human menopausal gonadotropin (menotropin, Menopur®, Ferring GmbH) or mixed recombinant human FSH/LH (Pergoveris®, Merck Serono) with a starting dose of 87.5-250 IE/day
62252561|NCT00311376|EXPERIMENTAL|2|botulinum toxin Type A (300U)
62252562|NCT00311376|OTHER|3|placebo; botulinum toxin Type A (200U)
62252563|NCT00311376|OTHER|4|placebo; botulinum toxin Type A (300U)
62252564|NCT03428022|EXPERIMENTAL|Apatinib combined with EGFR-TKI|Apatinib（Tablet（Tab. ）500millgram（mg）/day（d）） combined with EGFR-TKI（as previously）
62252565|NCT01555567|EXPERIMENTAL|Electrical stimulation|Subjects placed into this group will undergo electrical stimulation following anterior cruciate ligament reconstruction (ACLr). Subjects will be required to report 2 times per week for 6 weeks following ACLr for electrical stimulation therapy. Electrical stimulation therapy post-reconstruction will commence immediately post-ACLr and end at week 6.
62252566|NCT01555567|NO_INTERVENTION|Standard of Care|This group will undergo standard ACL rehabilitation
62834144|NCT01465555|EXPERIMENTAL|Clinical Alert|Counselors in this condition will work with the modified RecoveryTrack tested in the pilot study which has been altered to provide automated Clinical Alerts at either the intake, Month 1, or Month 2 CRM interview for High Risk patients. In addition, High Risk patients will be flagged in the counselor's caseload for discussion with clinical supervisors. Counselors in this condition will receive the Clinical Alert + Cognitive Behavioral Intervention (CBI) training, as well as monthly feedback from the Principal Investigator on their delivery of the CBI Months 1-3, with a booster session at Month 6.
62834145|NCT01465555|NO_INTERVENTION|Treatment As Usual|Counselors in this condition will work with the original RecoveryTrack which has not been altered to provide automated Clinical Alerts for High Risk patients. Supervisors will receive no automated help in identifying these clients in the counselors' caseloads. The Clinical Alert feature will not be discussed in the training these counselors receive. Rather, the counselors will receive an attention-control training, a one-day training on assessment and treatment planning, with monthly tips and reminders for six months.
62051521|NCT04166825|ACTIVE_COMPARATOR|Short protocol|Ovarian hyperstimulation with a GnRH-antagonist consisted of the use of ganirelix (Orgalutran®, MSD) from the 6th day of stimulation until it's end at the daily dose of 0.25 mg
62051522|NCT04166825|ACTIVE_COMPARATOR|Clomiphene citrate|Ovarian stimulation with clomiphene citrate (Clostilbegyt®, EGIS) 50 mg daily per os form 3rd to 7th day of the cycle
62051523|NCT04166825|ACTIVE_COMPARATOR|Letrozole|Ovarian stimulation with letrozole (Lametta®, Vipharm) 2.5 mg daily per os form 3rd to 7th day of the cycle
62051524|NCT04166825|ACTIVE_COMPARATOR|Gonadotropins|Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono).
62252567|NCT01555567|EXPERIMENTAL|Eccentric Exercise|Subjects placed into this group will undergo eccentric exercise strength training following ACLr. Subjects will be required to report 2 times per week for 6 weeks following ACLr. Eccentric strengthening will begin at week 6 post-ACLr and will end at week 12 post-ACLr.
62051525|NCT01176721|ACTIVE_COMPARATOR|t-VNS verum|Active stimulation of the left auricle by t-VNS
62051526|NCT01176721|PLACEBO_COMPARATOR|Sham|Sham-simulation of the left auricle by the t-VNS device.
62051527|NCT05670483|ACTIVE_COMPARATOR|APRV group|"Group A: APRV group (30 Patients) Post operatively, Patients will be ventilated with APRV mode using GE Carescape R860 ventilator Initial Settings15~1. P high at the P plateau (or desired P mean + 3cm H2O). keep P high below 30-35 cm H2O~2. T high at 4-6 seconds~3. P low at 0~4. T low at 0.5 to 0.8 seconds.~5. ATC (automatic tube compensation) on.~6. FIO2: 40% Ventilator settings will be adjusted to keep Pco2 between 35-45 mmhg, PO2 \> 60 mmhg on FIO2 \< 50 % Once Patients are fully conscious and after complete recovery of reflexes with no postoperative bleeding nor hemodynamic instability, weaning of APRV will start as following, P-High will be lowered 2 or 3 cm of H2O pressure at a time, and T Low will be lengthened in 0.5-2.0 s increments, depending on patient tolerance. When the P-high reaches 10 cmH2O and the Thigh reaches 12-15 seconds, change the mode to pressure support (PS) mode PS of 7-8 cmH20 above PEEP of cmh2o then extubation."
62051528|NCT05670483|ACTIVE_COMPARATOR|Standard group|"Group B: Standard (control) group (30 Patients) Post-operatively, Patients will be ventilated with conventional Synchronized Intermittent Mandatory Ventilation (SIMV) volume control mode using GE Carescape R860 ventilator Initial Settings: 16~1. Tidal Volume 6-8 ml/kg predicted body weight~2. Respiratory rate (RR) 14 /min~3. Positive end expiratory pressure (PEEP)= 5 cmH2o~4. Pressure Support (PS) = 10 cmH2o~5. Inspiratory time 1.4 Sec~6. FIO2: 40% Ventilator settings will be adjusted to keep Pco2 between 35-45 mmhg, PO2 \> 60 mmhg on FIO2 \< 50 %"
62051529|NCT03233568||Indirect Calorimetry group (IC group)|Group who performed indirect calorimetry. REE measured by indirect calorimetry.
62051530|NCT03233568||NO Indirect Calorimetry group (NO-IC group)|Group who did not perform indirect calorimetry. Resting Energy Expenditure calculated by Harris-Benedict formula
62834146|NCT00996398|EXPERIMENTAL|Cold water immersion|14°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
62834147|NCT04843462|EXPERIMENTAL|edupression.com® + treatment-as-usual|Patients are receiving treatment with edupression.com® in addition to TAU (treatment-as-usual) with esketamine nasal spray
62051531|NCT04413630|EXPERIMENTAL|Study group|family workshop
62051532|NCT02456766||F0|Liver Steatosis Grade: \<5%
62051533|NCT02456766||F1|Liver Steatosis Grade: 5-33%
62051534|NCT02456766||F2|Liver Steatosis Grade: 34-66%
62051535|NCT02456766||F3|Liver Steatosis Grade: \> 66%
62051536|NCT05284864|EXPERIMENTAL|Early stoma closure|Stoma closure 2-3 weeks after rectal surgery.
62442001|NCT05727267|EXPERIMENTAL|Arm C0.1|HBsAg high dose \& HBcoreAg high dose and MVA-HBVac high dose
62442002|NCT05727267|EXPERIMENTAL|Arm C0.2|HBsAg medium dose + adjuvant low dose \& HBcoreAg medium dose and MVA-HBVac high dose
62834148|NCT04843462|ACTIVE_COMPARATOR|treatment-as-usual|Patients are receiving TAU (treatment-as-usual) with esketamine nasal spray
62834149|NCT06154213|EXPERIMENTAL|Building Habits Together|The Building Habits Together arm includes the 24-week, Facebook-delivered lifestyle intervention based on the Diabetes Prevention Program and use of the Habit app (temptation tracking, exercise planning, and problem solving features).
62834150|NCT06154213|ACTIVE_COMPARATOR|Getting Healthy Together|The Getting Healthy Together arm includes the 24-week, Facebook-delivered lifestyle intervention based on the Diabetes Prevention Program and use of the MyFitnessPal app (daily calorie tracking, exercise tracking).
62442003|NCT05727267|EXPERIMENTAL|Arm C0.3|HBsAg high dose + adjuvant high dose \& HBcoreAg high dose and MVA-HBVac high dose
62834151|NCT00072839|PLACEBO_COMPARATOR|Placebo|placebo solution injected subcutaneously daily into either thigh or abdomen.
62834152|NCT00072839|EXPERIMENTAL|teduglutide 0.05|teduglutide 0.05 mg/kg/d injected subcutaneously daily.
62051537|NCT05284864|ACTIVE_COMPARATOR|Late stoma closure|Stoma closure 16-24 weeks after rectal surgery.
62051538|NCT01355588|EXPERIMENTAL|Ketorolac Tromethamine|
62051539|NCT01355588|EXPERIMENTAL|Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)|
62834153|NCT00072839|EXPERIMENTAL|teduglutide 0.1|0.1 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen
62051540|NCT01355588|EXPERIMENTAL|Ketorolac Tromethamine with 5% Lidocaine HCl|
62051541|NCT01355588|EXPERIMENTAL|Ketorolac Tromethamine with 6% Lidocaine HCl|
62051542|NCT06508047||Informed Vital Core App|All subjects assigned to a single arm, respiration rate measurement will be collected, calculated, and displayed on the web based application. Conventional Capnography will also be used to collect and display the respiratory rate at the same time as the Informed Vital Core App.
62051543|NCT06481033|EXPERIMENTAL|Real-time fMRI Neurofeedback|This is a pilot study to collect feasibility and acceptability data regarding the utility of real-time functional magnetic resonance imaging feedback for veterans experiencing suicide-specific rumination. All study participants will receive the intervention.
62051544|NCT00266825|EXPERIMENTAL|DHA capsules|DHA capsules
62834154|NCT00072839|EXPERIMENTAL|teduglutide|0.2 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen
62051545|NCT00266825|PLACEBO_COMPARATOR|Placebo capsules|Placebo capsule
62834155|NCT00454324|EXPERIMENTAL|Arm A|Carboplatin + Abraxane (240mg/m2) on Day 1 of a 21 Day cycle, up to 6 cycles
62442004|NCT04499183|EXPERIMENTAL|non-digestible carbohydrates|fructo- and galacto-oligosaccharides
62442005|NCT04499183|PLACEBO_COMPARATOR|placebo|maltodextrin
62442006|NCT01636297|EXPERIMENTAL|Forced exercise|Exercise on stationary cycle that was controlled by a motor to augment voluntary cycling rate by 35%
62442007|NCT01636297|EXPERIMENTAL|Voluntary Exercise|Exercise on a stationary cycle without motor assistance
62442008|NCT01636297|NO_INTERVENTION|No Exercise|Participants received no exercise intervention and served as the control group
62834156|NCT00454324|EXPERIMENTAL|Arm B|Carboplatin + Abraxane (80mg/m2)given on Days 1, 8 and 15 of a 21 Day Cycle, up to 6 cycles
62051546|NCT02436811|EXPERIMENTAL|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
62051547|NCT02436811|EXPERIMENTAL|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
62051548|NCT02436811|EXPERIMENTAL|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
62051549|NCT01241695|EXPERIMENTAL|Test|Diben DRINK (200 ml) / a diabetes-specific oral nutritional supplement
62051550|NCT01241695|PLACEBO_COMPARATOR|Control|Fresubin(R) energy fibre DRINK / an isoenergetic standard oral nutritional supplement
62051551|NCT06171334|EXPERIMENTAL|RIC|
62051552|NCT06293209|PLACEBO_COMPARATOR|The control group (non-cryotherapy group)|Routine preoperative protocol ankle fracture on short leg slab compression with bandage
62834157|NCT02693366|EXPERIMENTAL|Autologous Cell Therapy|We are conducting a prospective, non-randomized, single-center longitudinal study in five patients with progressive chronic kidney disease and estimated clearance between 40 and 20 ml / min. Patients will be followed by clinical and laboratory examination for 3 months prior to the procedure. These previous results serve as a control for comparison with a second time when the same patients receive treatment with stem cells being subsequently followed up for 9 months a total of one year of clinical follow-up.
62834158|NCT03819530|EXPERIMENTAL|Supplementation Group|Receives baseline deworming medication. Intervention: receive daily micronutrient supplementation packets- 4 month supply, to be taken every day. Blood iron and anthropometric measurements taken at 0 and 4 months.
62834159|NCT03819530|NO_INTERVENTION|Control Group|Receives baseline deworming medication. Blood iron and anthropometric measurements taken at 0 and 4 months.
62834160|NCT02191358||"Tested patients (prospective)"|Patients whose providers decide to have them undergo testing via the YouScript Personalized Prescribing System will be recruited for the study. Data will be gathered at baseline and 120 days later. The decision to utilize YouScript and all treatment decisions will be made at the discretion of the provider in accordance with their usual care practice, and will be made prior to the decision to participate in the study.
62834161|NCT02191358||"Untested patients (retrospective)"|Patients for comparison to the prospectively followed patients will be derived from Inovalon's MORE2 healthcare database. Patients meeting the same enrollment criteria (excluding the YouScript testing) will be matched on key characteristics to the tested patients. Outcomes will be compared between the prospectively enrolled patients undergoing pharmacogenetic testing with the YouScript Personalized Prescribing System at the discretion of their treating physician.
62834162|NCT00604799|ACTIVE_COMPARATOR|Test (Enrollment Completed)|Patients diagnosed with a TAA of degenerative etiology that are considered candidates for open surgical repair whom are low to moderate risk (0, 1, \& 2) per the modified SVS/AAVS criteria who meet inclusion/exclusion criteria. The aneurysm must be at least 20 mm distal to the left common carotid artery \& 20 mm proximal to the origin of the celiac artery.
62834163|NCT00604799|OTHER|Registry (Enrollment Completed)|Surgical candidates of low to moderate risk (SVS 0, 1, 2) that meet the Registry Inclusion/Exclusion criteria.
62834164|NCT00604799|OTHER|High Risk (Enrollment Completed)|"Patients that meet one or more of the following:~* High Risk (SVS 3)~* Non-surgical candidates not associated with SVS scoring~* Traumatic thoracic injuries"
62834165|NCT00604799|OTHER|Talent Captivia (Recruiting)|Patients diagnosed with a TAA of degenerative etiology that are considered candidates for open surgical repair who meet inclusion/exclusion criteria.
62834166|NCT03827096|EXPERIMENTAL|Human AMSC (passage 3) 3P in 1.5 mL|Patient receiving the investigational medicinal product - suspension of human autologous MSC 3P in 1.5 mL
62834167|NCT02647996||Conscious patients|"group: TBI patients awoken from comatose state with normal level of consciousness.~intervention: fMRI (resting state) and structural (DTI)"
62834168|NCT02647996||DOC patients|"group: TBI patients awoken from comatose state with abnormal level of consciousness~intervention: fMRI (resting state) and structural (DTI)"
62834169|NCT05463484|EXPERIMENTAL|Test product|Toothpaste including an olive product, betaine and xylitol (Saliactive®).
62834170|NCT05463484|PLACEBO_COMPARATOR|Placebo product|Toothpaste with the same composition as the test product but without olive product, betaine and xylitol.
62834171|NCT05463484|ACTIVE_COMPARATOR|Control product|Toothpaste marketed for gingivitis with zinc mineral with antimicrobial activity.
62051553|NCT06293209|ACTIVE_COMPARATOR|The cold pack group|The cold pack group consists of patients with ankle fractures who receive cold therapy using ice packs sized 20x20 centimeters. The ice packs are placed in the freezer compartment for 30 seconds after they have solidified, then applied to the injured ankle for 10 minutes, followed by a 10-minute break. This process is repeated every 2 hours for a total of 6 times (from 8:00 AM to 6:00 PM).
62051554|NCT06293209|ACTIVE_COMPARATOR|The cold spray|The cold spray group consists of patients with ankle fractures who receive cold therapy using Perskindol cold spray containing Levomenthol. The spray is applied to the injured ankle 5-6 times, followed by a 10-minute break. This process is repeated every 2 hours for a total of 6 times (from 8:00 AM to 6:00 PM).
62834172|NCT04891068|EXPERIMENTAL|Single arm with previously untreated high risk early stage breast cancer|All participants will receive azacitidine 50mg/m2 SC daily for five consecutive days.
62834173|NCT00813202|EXPERIMENTAL|Nesiritide|
62834174|NCT00390143|EXPERIMENTAL|Group A|Subjects previously primed with meningococcal vaccine 134612.
62834175|NCT00390143|ACTIVE_COMPARATOR|Group B|Subjects previously primed with Mencevax™ ACWY.
62834176|NCT05628376||Cohort A|300 participants with early stage resectable I-IIIB NSCLC
62834177|NCT05628376||Cohort B|200 participants with unresectable late stage IIIB-IIIC or de novo metastatic (stage IV) NSCLC.
62834178|NCT05628376||Cohort C|50-100 participants with stage I-IV SCLC or pleural mesothelioma.
62834179|NCT00335595|ACTIVE_COMPARATOR|1|XELOXA
62051555|NCT03909984|OTHER|Intervention|All participants will be monitored for 2 months.
62051556|NCT01561859|EXPERIMENTAL|Cognitive enhancement therapy|Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups
62051557|NCT01561859|ACTIVE_COMPARATOR|Enriched Supportive Therapy|"Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis."
62051558|NCT03350425||Recently vaccinated patients|Patients who recently received pneumococcal vaccination.
62051559|NCT03350425||Patients vaccinated >2 years ago|Patients who received pneumococcal vaccination more than two years ago.
62051560|NCT02167763|EXPERIMENTAL|VeraCept Intrauterine Contraceptive|The VeraCept low-dose Intrauterine Copper Contraceptive
62051561|NCT02167763|ACTIVE_COMPARATOR|TCu380|A commercial standard T-shaped copper IUD (TCu380)
62051562|NCT06384950|EXPERIMENTAL|GPT-3.5-based educational|Patients receive additional education using a GPT-3.5-based educational robot on top of the traditional education.
62051563|NCT06384950|ACTIVE_COMPARATOR|Traditional education procedures|Patients receive standard traditional education procedures.
62252568|NCT01555567|EXPERIMENTAL|Stimulation and Eccentrics|Subjects placed into this group will undergo a combined electrical stimulation and eccentric exercise intervention following ACLr. The electrical stimulation intervention will be delivered immediately following ACLr and will end at 6 weeks post-ACLr. Subjects will receive the electrical stimulation therapy 2 times per week for the first 6 weeks post-ACLr. At six weeks post-ACLr, subjects will begin the eccentric strengthening protocol. Subjects will eccentrically train 2 times per week for 6 weeks. The eccentric strengthening will end at 12 weeks post-ACLr.
62051564|NCT03721640||Preterm neonates (< 33 weeks GA)|Preterm neonates requiring in the first week of life, an elective tracheal intubation for surfactant administration by INSURE or LISA methods.
62051565|NCT01921816|OTHER|Prismocitrate 18/0|citrate-containing replacement solution (Prismocitrate 18/0, Gambro) will be administered at pre-filter port during continuous hemodiafiltration, for the purpose as replacement solution and anticoagulation
62051566|NCT02063230|EXPERIMENTAL|Selumetinib HV|Healthy volunteers (HV)
62051567|NCT02063230|EXPERIMENTAL|Selumetinib mild impairment|Mild (Child Pugh A) hepatic impaired patients
62051568|NCT02063230|EXPERIMENTAL|Selumetinib moderate impairment|Moderate (Child Pugh B) hepatic impaired patients
62051569|NCT02063230|EXPERIMENTAL|Selumetinib severe impairment|Severe (Child Pugh C) hepatic impairment patients
62051570|NCT04433234|EXPERIMENTAL|DS-5141b 2.0 mg/kg|Participants who will receive DS-5141b 2.0 mg/kg once weekly.
62051571|NCT04433234|EXPERIMENTAL|DS-5141b 6.0 mg/kg|Participants who will receive DS-5141b 6.0 mg/kg once weekly.
62051572|NCT05341258|OTHER|Critical Care Patients whom intubated last 24 hours|Critical Care Patients whom intubated last 24 hours
62252569|NCT01058070|EXPERIMENTAL|Implantable Device|Subjects who meet eligibility criteria are implanted with the Magnetic Esophageal Sphincter device (MES)
62252570|NCT05355272|EXPERIMENTAL|Growth Hormone Replacement Therapy|"Patients will be started at a dose of 200-300 mcg/d of daily injections of GHRT. A biweekly titration period of 6 weeks will be performed in increments of 100 mcg/d as needed until IGF-1 levels are between +1 and +2 standard deviation score, up to a maximum dose of 2,000 mcg/d, provided the dose is well tolerated.~The duration of the intervention is 6-months. Participants will complete in-clinic follow-up visits at Days 14, 40, 65, 90, and 180. The primary outcome will be the change in truncal fat mass percentage from baseline to six months measured by dual-energy x-ray absorptiometry (DEXA)."
62252571|NCT00907751|EXPERIMENTAL|1|Microangiopathic hemolytic anemia (\< 12 g/dL) with thrombocytopenia (\<50 G/L)
62834180|NCT00335595|EXPERIMENTAL|2|XELOXA-A
62834181|NCT05790369|EXPERIMENTAL|New ankle machine training group (NAMTG)|home-based ankle training program consisted of 6 exercises for their general physical fitness and use a device (new ankle machine) to provide progressive resisted exercise for the ankle strength
62051573|NCT06341608|EXPERIMENTAL|Patients with OUD, eligible for treatment with buprenorphine|
62051574|NCT02510144|ACTIVE_COMPARATOR|Chlorhexidine|A preoperative Chlorhexidine gluconate solution 4.0% (i.e Hibiclens)
62051575|NCT02510144|EXPERIMENTAL|Benzoyl Peroxide|A preoperative 5% benzoyl peroxide wash prep (i.e. Brevoxyl-4 and Brevoxyl-8)
62051576|NCT04493216|EXPERIMENTAL|GSK3640254 100 mg+ Placebo+ ABC/3TC or FTC/TAF|Participants with human immunodeficiency virus type 1 (HIV-1), orally received one 100 mg tablet per day of GSK3640254 and two tablets per day of matching placebo in a blinded setting. Open label dual NRTI background therapies were given as one tablet per day of 600 mg abacavir (ABC) / 300 mg lamivudine (3TC) OR 200 mg emtricitabine (FTC) / 25 mg tenofovir alafenamide (TAF) orally.
62051577|NCT04493216|EXPERIMENTAL|GSK3640254 150 mg + ABC/3TC or FTC/TAF|Participants with HIV-1, orally received 150 mg (one 100 mg tablet + two 25 mg tablets per day) of GSK3640254 in a blinded setting. Open label dual NRTI background therapies were given as one tablet per day combination of 600 mg ABC / 300 mg 3TC OR 200 mg FTC / 25 mg TAF orally.
62051578|NCT04493216|EXPERIMENTAL|GSK3640254 200 mg+ Placebo+ ABC/3TC or FTC/TAF|Participants with HIV-1, orally received two 100 mg tablets (200 mg) per day of GSK3640254 and one tablet per day of matching placebo in a blinded setting. Open label dual NRTI background therapies were given as one tablet per day combination of 600 mg ABC / 300 mg 3TC OR 200 mg FTC / 25 mg TAF orally.
62051579|NCT04493216|ACTIVE_COMPARATOR|Dolutegravir (DTG) 50 mg + ABC/3TC or FTC/TAF|Participants with HIV-1, orally received one 50 mg tablet per day of DTG in an open label setting. Open label dual NRTI background therapies were given as one tablet per day combination of 600 mg ABC / 300 mg 3TC OR 200 mg FTC / 25 mg TAF orally.
62051580|NCT01003457||detrusor overactivity|
62051581|NCT04620967|EXPERIMENTAL|Iasp-Fiasp|First period: Insulin pump with Iasp Second period: Insulin pump with Fiasp
62051582|NCT04620967|EXPERIMENTAL|Fiasp-Iasp|First period: Insulin pump with Fiasp Second period: Insulin pump with Iasp
62051583|NCT01054261|OTHER|Normal|Normal renal function
62051584|NCT01054261|OTHER|Mild|Mild renal impairment
62051585|NCT01054261|OTHER|Moderate|Moderate renal impairment
62051586|NCT01762150|EXPERIMENTAL|sorafenib combined with chemotherapy|this trial is designed single arm. all the subjects enrolled will receive the experimental intervention,ie. sorafenib+gemcitabine+cisplatin.
62051587|NCT01855217|ACTIVE_COMPARATOR|Sugammadex total body weight|1 mg/kg total body weight
62051588|NCT01855217|ACTIVE_COMPARATOR|Sugammadex ideal body weight|1 mg /kg ideal body weight
62051589|NCT01855217|PLACEBO_COMPARATOR|placebo|placebo 0,9% NaCl
62051590|NCT01292551|ACTIVE_COMPARATOR|Bosentan|
62051591|NCT01292551|PLACEBO_COMPARATOR|Placebo|
62051592|NCT01828580|EXPERIMENTAL|AutoLap|
62051593|NCT02640872||HAPPY Cohort|A elderly cohort for chronic diseases
62051594|NCT01525602|EXPERIMENTAL|Part 1|"Open-label, sequential PLX3397 single-agent dose escalation in combination with paclitaxel in approximately 30 patients with advanced solid tumors. Enrollment completed.~(Closed to recruitment)"
62051595|NCT01525602|EXPERIMENTAL|Part 2|"Extension cohort at the RP2D of single-agent PLX3397 in combination with paclitaxel in approximately 30 patients in advanced solid tumors. Enrollment completed.~(Closed to recruitment)"
62051596|NCT01525602|EXPERIMENTAL|Part 3|"Extension cohort at the RP2D of single-agent PLX3397 in combination with paclitaxel in approximately 30 patients with advanced, metastatic, or non-resectable, platinum-resistant or -refractory epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.~(Closed to recruitment)"
62051597|NCT00975832||women with polycystic ovary syndrome|
62051598|NCT00975832||women without polycystic ovary syndrome|
62051599|NCT00975832||women from 18-40 years of age|
62051600|NCT01737957|EXPERIMENTAL|Low-fluence|Low-fluence pan-retinal photocoagulation in a single session for proliferative diabetic retinopathy
62051601|NCT01737957|ACTIVE_COMPARATOR|Full-fluence|Full-fluence pan-retinal photocoagulation for proliferative diabetic retinopathy
62051602|NCT02013310|EXPERIMENTAL|HT-0712 (50mg)|HT-0712 capsules administered once daily.
62051603|NCT02013310|PLACEBO_COMPARATOR|Placebo|Placebo capsules administered once daily.
62051604|NCT01197508|EXPERIMENTAL|0.1 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 0.1 mg BID
62051605|NCT01197508|EXPERIMENTAL|1 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1 mg BID
62051606|NCT01197508|EXPERIMENTAL|4 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 4 mg BID
62051607|NCT01197508|PLACEBO_COMPARATOR|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
62051608|NCT03291743|EXPERIMENTAL|First Degree Relative|A total of 112 high risk first-degree relatives will be enrolled in total. Patients with Crohn's Disease will be given information about the study when in clinic for routine care to share with their first degree relatives (FDR). Screening will be done using capsule endoscopy.
62051609|NCT03291743|ACTIVE_COMPARATOR|Healthy Controls|This study will also enroll 35 healthy controls who will be age and sex matched to the first degree relative (FDR) population. Enrollment will begin after 20-25 FDR's have passed screening and will continue at this interval until all controls have been enrolled. Controls will be initially screened by colonoscopy. If enrolled they will undergo capsule endoscopy as well
62051610|NCT02088151|EXPERIMENTAL|Treatment|Patients receive selective retinal pigment epithelium laser treatment
62051611|NCT02532556|EXPERIMENTAL|1|Stimulation of muscle in this order: vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius
62051612|NCT02532556|EXPERIMENTAL|2|Stimulation of muscle in this order: rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials
62051613|NCT02532556|EXPERIMENTAL|3|Stimulation of muscle in this order: vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris
62051614|NCT02532556|EXPERIMENTAL|4|Stimulation of muscle in this order: tibialis anterior, peroneus longus, and the medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis
62051615|NCT02532556|EXPERIMENTAL|5|Stimulation of muscle in this order: peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior
62051616|NCT02532556|EXPERIMENTAL|6|Stimulation of muscle in this order: medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus
62051617|NCT02532556|EXPERIMENTAL|7|Stimulation of muscle in this order: lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius,
62051618|NCT03879746|ACTIVE_COMPARATOR|tamsulosin group|the first group will include 40 patients treated with daily administration of tamsulosin 0.4 mg
62051619|NCT03879746|ACTIVE_COMPARATOR|paroxetine group|the second group will include 40 patients treated with daily administration of paroxetine 20 mg
62051620|NCT03879746|ACTIVE_COMPARATOR|combined group|the third group will include 40 patients treated with daily administration of tamsulosin 0.4 mg and paroxetine 20 mg
62051621|NCT03879746|PLACEBO_COMPARATOR|placrbo group|the fourth group will include 40 patients will be given placebo
62051622|NCT01566331|EXPERIMENTAL|Baby-guardTM|Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet.
62051623|NCT01566331|NO_INTERVENTION|no intervention|Baby-guardTM system, without inflation
62252572|NCT02822885|EXPERIMENTAL|ultrasonography|Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
62611334|NCT04691206|OTHER|standardized step-wise operative curriculum|"General surgery residents at Mayo Clinic will complete surveys measuring resident autonomy, performance, confidence and case complexity at baseline and postoperatively following laparoscopic cholecystectomy to serve as a pre-intervention baseline.~A standardized step-wise operative curriculum will then be implemented Residents will follow and graduate through this curriculum by initiating a perioperative model of briefing objectives, intraoperative teaching, and debriefing feedback (BID). The effectiveness of the intervention will then be measured by comparing survey results pre and post intervention."
62611335|NCT01715402||operated patients|this cohort includes patients who underwent a liver surgery whatever the pathology and whatever the surgical procedure
62611336|NCT02503254|EXPERIMENTAL|CHTP 1.0|Ad libitum use of the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) for 5 days in confinement
62834182|NCT05790369|ACTIVE_COMPARATOR|Elastic band training group (EBTG)|home-based ankle training program consisted of 6 exercises for their general physical fitness and use Thera band to provide progressive resisted exercise for the ankle strength
62611337|NCT02503254|ACTIVE_COMPARATOR|Conventional cigarette (CC)|Ad libitum use of subject's own preferred brand of CC for 5 days in confinement
62611338|NCT05006846||Cohort 1|Primary care physicians (PCPs) and their patients used the intervention (OARS) for 4 weeks. They completed 2 interviews to obtain their feedback on the acceptability and feasibility of using OARS in a primary care setting. Data for this cohort was collected between February 18, 2020, to May 25, 2020.
62611339|NCT05006846||Cohort 2|Primary care physicians (PCPs) and their patients used the intervention (OARS) for 4 weeks. They completed 2 interviews to obtain their feedback on the acceptability and feasibility of using OARS in a primary care setting. Data for this cohort was collected between July 17, 2020, to August 31, 2020.
62834183|NCT04302077|ACTIVE_COMPARATOR|Telemedicine Post Op|Patients with an even-ending medical record number (0,2,4,6,8) will be randomized to virtual visit/telemedicine. This will be done by using Epic and MyChart-integrated telemedicine functionality for video visits with the Principal Investigator's patients. This is considered standard of care.
62252573|NCT02282566|PLACEBO_COMPARATOR|Protein-nutrition beverage - Placebo|: 8 oz protein-nutrition beverage 1
62834184|NCT04302077|ACTIVE_COMPARATOR|In-Office Post Op|Patients with an odd-ending medical record number (1,3,5,7,9) will be randomized to the office visit.
62834185|NCT01472289|EXPERIMENTAL|BMMNC treated group|Autologous bone marrow mononuclear cell concentrate (BMMNCs) prepared using the Res-Q 60 technology (a point of care system) to be injected intramuscularly into multiple sites in the ischemic muscle tissue of the affected limb at 0.5 cc/injection for a total of 15-20 cc.
62252574|NCT02282566|EXPERIMENTAL|Protein-nutrition beverage - Beverage 2|8 oz protein-nutrition beverage 2
62252575|NCT02282566|EXPERIMENTAL|Protein-nutrition beverage - Beverage 3|8 oz protein-nutrition beverage 3
62252576|NCT02282566|EXPERIMENTAL|Protein-nutrition beverage - Beverage 4|8 oz protein-nutrition beverage 4
62611340|NCT00135902|ACTIVE_COMPARATOR|17P plus Omega-3 Supplement|Weekly 17 alpa hydroxyprogesterone caproate (17p) injections plus Omega 3 supplements, 4 capsules per day for up to 5 weeks. Each capsule contained 200 mg of docosahexaenoic acid (DHA) and 300 mg of eicosapentaenoic acid (EPA).
62611341|NCT00135902|PLACEBO_COMPARATOR|17P plus Placebo Supplement|Weekly 17 alpa hydroxyprogesterone caproate (17p) injections plus placebo capsules, 4 capsules per day for up to 5 weeks
62051624|NCT02770651||Optical Coherence Tomography|To evaluate the incidence of late incomplete stent apposition (ISA) and un-coverage by optical coherence tomography (OCT) following everolimus-eluting stent (EES) with bioabsorbable polymerversus zotarolimus-eluting stent (ZES) with permanent polymer implantation in patients with AMI at 12 months.
62252577|NCT01761825|ACTIVE_COMPARATOR|Ivabradine|Ivabradine 10 mg once
62611342|NCT06516640|PLACEBO_COMPARATOR|Control|Receives standard of care, regular education in the clinic.
62834186|NCT02170077|EXPERIMENTAL|ODG - once-daily group|BIA 2-093 once-daily; Daily doses of BIA 2-093 were increased at four-weekly periods (400 mg, 800 mg and 1200 mg).
62834187|NCT02170077|EXPERIMENTAL|TDG - twice-daily group|BIA 2-093 twice-daily; Daily doses of BIA 2-093 were increased at four-weekly periods (400 mg, 800 mg and 1200 mg).
62051625|NCT02365675|ACTIVE_COMPARATOR|Cotton gauze with petrolatum|The dressing to be used is regular cotton gauze impregnated in petrolatum (a mixture of solid hydrocarbons) creating a film that reduces the adherence of the gauze to the wound.
62051626|NCT02365675|ACTIVE_COMPARATOR|Cellulose acetate with petrolatum|The dressing to be used is a mesh or tulle base of cellulose acetate polymers that do not easily adhere to the wound impregnated in petrolatum (a mixture of solid hydrocarbons).
62252578|NCT01761825|PLACEBO_COMPARATOR|placebo|
62252579|NCT00745407|EXPERIMENTAL|fenofibrate 160 mg, placebo|
62252580|NCT03018587|EXPERIMENTAL|All subjects|All subjects will receive 1 truSculpt radiofrequency treatment in desired area.
62252581|NCT04018794|EXPERIMENTAL|Behavioral/organizational skills intervention plus mobile app|Behavioral/organizational skills intervention plus mobile application (16, 20-30 minute sessions, twice/weekly for 8 weeks)
62252582|NCT02791282|OTHER|Index test: functional dynamic contrast enhanced (DCE)-MRI|Patients with clinical suspicion for CTEPH, scheduled for SPECT
62834188|NCT02170077|PLACEBO_COMPARATOR|PLG - placebo group|placebo
62051627|NCT02365675|ACTIVE_COMPARATOR|Nanocrystalline silver|The dressing to be used consists of two layers of a silver-coated, high-density polyethylene mesh, enclosing a single layer of an apertured non-woven fabric of rayon and polyester. The three components are ultrasonically welded together to maintain the integrity of the dressing in use. Silver is applied to the polyethylene mesh by a vapour deposition process, which results in the formation of microscopic 'nanocrystals' of metallic silver.
62051628|NCT02365675|ACTIVE_COMPARATOR|Carboxymethylcellulose with ionic silver|The dressing to be used is a soft, sterile, non- woven pad dressing made from sodium carboxymethylcellulose containing 1.2% silver in an ionic form.
62051629|NCT01373931|EXPERIMENTAL|OC + LY2216684 First, Then OC + Placebo|28-day lead-in period of Ortho Cyclen (OC; 28-day packet), followed by randomization to OC administered orally once daily for 28 days + 18 milligrams (mg) of LY2216684 administered concomitantly orally once daily for 21 days, followed by OC administered orally once daily for 28 days + placebo administered concomitantly orally once daily for 21 days.
62051630|NCT01373931|EXPERIMENTAL|OC + Placebo First, Then OC + LY2216684|28-day lead-in period of OC (28-day packet), followed by randomization to OC administered orally once daily for 28 days + placebo administered concomitantly orally once daily for 21 days, followed by OC administered orally once daily for 28 days + 18 mg of LY2216684 administered concomitantly orally once daily for 21 days.
62611343|NCT06516640|EXPERIMENTAL|Continuous Glucose Monitoring Academy|Receive an interactive workbook with problem-based learning scenarios and video links about Continuous Glucose Monitoring and glucose management strategies (CGM Academy Program). Participate in four in-depth online group sessions with diabetes care and education specialists complete questionnaires three times: at the time of study enrollment, week 4 and 6 months.
62834189|NCT03611829|ACTIVE_COMPARATOR|Standard Care|Participants in the standard care condition were provided with diet and exercise counselling and psychoeducation from their physicians over the course of 8 sessions, as was routinely done at the clinic. Standard care did not involve any targeted intervention to reduce emotional eating.
62051631|NCT02539043|ACTIVE_COMPARATOR|Focused ultrasound cavitation: Lipofocus|The first group will receive only the application of focused ultrasound cavitation.
62051632|NCT02539043|ACTIVE_COMPARATOR|Focused ultrasound and drainage: Lipofocus|The second group will receive focused ultrasound cavitation followed by stereodynamic drainage.
62611344|NCT00586508|EXPERIMENTAL|Enzastaurin + Bevacizumab|
62611345|NCT03994757|EXPERIMENTAL|MRBI group|
62611346|NCT03994757|SHAM_COMPARATOR|Control group|
62611347|NCT02742675|EXPERIMENTAL|androgen deprivation therapy|Patients will receive androgen-deprivation therapy comprising luteinizing-hormone releasing-hormone (LHRH) agonist (leuprolide acetate, goserelin acetate, buserelin, or triptorelin) subcutaneously or as an injection AND an oral antiandrogen therapy (flutamide 3 times daily or bicalutamide once daily).
62834190|NCT03611829|EXPERIMENTAL|ACT Intervention|In addition to receiving standard care, participants in the ACT condition were taught techniques to reduce their emotional eating. Three overarching skills were taught over the course of the ACT intervention: (1) values clarification and commitment, (2) metacognitive awareness, and (3) distress tolerance. Throughout the sessions, physicians formed if-then plans with the patients to specify how to habitually use the ACT techniques to reduce emotional eating in their everyday lives. At the end of each session, participants were given a one-page homework sheet that asked them to monitor their behavior and their use of the ACT techniques during the week.
62051633|NCT02260453|ACTIVE_COMPARATOR|A - Coronary angiography|All the patients receive preoperative coronary angiography followed, if needed, by percutaneous intervention (PCI) or bypass (CABG)
62834191|NCT04286945|OTHER|SENSORY EXOTROPIA PATIENTS WITH LARGE ANGLES .|Patients with monocular low vision or loss of vision due to congenital or acquired cause with exodeviation of the poorly seeing eye ≥ 50PD, were included in the study.
62834192|NCT05430399|EXPERIMENTAL|Arm A|utidelone
62051634|NCT02260453|ACTIVE_COMPARATOR|B - standard cardiac workup|Standard cardiac workup
62051635|NCT02218879||Patients with relapsing MS|
62051636|NCT03298230|EXPERIMENTAL|REmotely SuPervised Exercise Training|12- week home based exercise programme consisting of bi-weekly, hourly sessions at the time and place of the participant's choosing. They will wear a fitness tracker which will automatically upload their exercise data to an online platform which can be monitored by the research team and used to provide additional motivation.
62051637|NCT03298230|ACTIVE_COMPARATOR|Supervised Exercise Training|As per NICE guidance. 12 week, bi-weekly, one hour sessions of supervised exercise training.
62051638|NCT03190551|ACTIVE_COMPARATOR|retroclavicular approach|Patients in this group will be randomized to receive an retroclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
62051639|NCT03190551|ACTIVE_COMPARATOR|costoclavicular approach|Patients in this group will be randomized to receive an costoclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
62051640|NCT01318057||Wild-Type|Wild-Type are those individuals who were non-carriers of any functional (loss-of-function)variant in CYP2C9 and/or VKORC1 genes
62051641|NCT01318057||Carriers|Those patients who were identified as having any functional CYP2C9 and/or VKORC1 polymorphism
62051642|NCT06097676|PLACEBO_COMPARATOR|Placebo|- Single oral dose
62051643|NCT06097676|ACTIVE_COMPARATOR|Alprazolam 2 mg|"* Single oral dose~* Drug: Alprazolam 2 mg capsule"
62051644|NCT06097676|EXPERIMENTAL|GE-IR 200 mg|"* Single oral dose~* Drug: GE-IR 200 mg capsule"
62051645|NCT06097676|EXPERIMENTAL|GE-IR 450 mg|"* Single oral dose~* Drug: GE-IR 450 mg capsule"
62051646|NCT06097676|EXPERIMENTAL|GE-IR 700 mg|"* Single oral dose~* Drug: GE-IR 700 mg capsule"
62051647|NCT04715516|EXPERIMENTAL|alcohol brief intervention + lifestyle health promotion|"The intervention arm will receive 4 minutes of alcohol brief intervention, and 3 minutes of lifestyle health promotion (physical activity; maintaining a healthy weight), to increase knowledge of how to improve women's health and reduce breast cancer risk. Alcohol and lifestyle information will be delivered by way of an animation on an iPad. Participant responses to questions about current alcohol use will branch to personalised feedback consistent with level of alcohol consumption (i.e. drinking within or above current Australian Alcohol Guidelines).~Take-home pamphlets - a pamphlet summarising the alcohol information presented during the animation, and a pamphlet on nutrition to maintain a healthy weight, will be provided."
62611348|NCT02742675|EXPERIMENTAL|androgen deprivation therapy plus definitive treatment|Patients will receive androgen-deprivation therapy as in arm I in addition to definitive treatment including surgery to remove prostate or radiation therapy to the prostate.
62611349|NCT00986947|EXPERIMENTAL|IvIg with Rituximab|
62834193|NCT05430399|ACTIVE_COMPARATOR|Arm B|docetaxel
62051648|NCT04715516|OTHER|lifestyle health promotion, not inclusive of alcohol information|"The control arm will receive 3 minutes of lifestyle health promotion (physical activity; maintaining a healthy weight) to increase knowledge of how to improve women's health and reduce breast cancer risk, not inclusive of alcohol information. Lifestyle information will be delivered by way of an animation on an iPad.~Take-home pamphlet - a pamphlet on nutrition to maintain a healthy weight will be provided."
62051649|NCT02031367|ACTIVE_COMPARATOR|Corticosteroid|
62051650|NCT02031367|EXPERIMENTAL|Platelet Rich Plasma|
62051651|NCT05749848|EXPERIMENTAL|[¹⁴C]-LY3372689|Single dose of \[¹⁴C\]-LY3372689 administered orally.
62051652|NCT02913664|EXPERIMENTAL|Aerobic Exercise (Ex)|Aerobic exercise training; blood and cholesterol management will be standard-care by participant's regular doctor.
62051653|NCT02913664|EXPERIMENTAL|Intensive Reduction of Vascular Risk Factors (IRVR)|Lowering SBP \< 130 mmHg, administration of atorvastatin 80 mg daily, and stretching exercise.
62834194|NCT02873377|EXPERIMENTAL|Enhanced Care|"Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling \& Smoking Quitline Referral. Participants in the Enhanced Care intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment."
62834195|NCT02873377|ACTIVE_COMPARATOR|Standard Care|"Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The Standard Care group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment."
62051654|NCT02913664|EXPERIMENTAL|IRVR+Ex|A combination of IRVR and aerobic exercise training.
62252583|NCT02483559|OTHER|Amber Lenses|Participants will be randomized to participate in the amber lens condition first or second. Outcome measures to assess the effects of wearing amber lenses to block the blue light spectrum of light includes mood and sleep rating questionnaires (Positive and Negative Affect Scale, PANAS; Leeds Sleep Evaluation Questionnaire) as well as measuring the levels of melatonin the body is producing while wearing the glasses.
62623552|NCT05430477||Cohort 2 Resection|Potential study participants will be identified through Dartmouth-Hitchcock Medical Center (DHMC)'s Head and Neck Tumor Clinic, and will be patients with diagnosed or suspected cancer of the oral cavity, oropharynx, hypopharynx, or larynx who require biopsy or resection for either diagnostic or therapeutic purposes. Cohort II will be comprised of 125 patients undergoing oral cavity cancer resections. Initially, up to 5 subjects will be enrolled in addition to the 125 patients in this Cohort in order to optimize the data acquisition process.
62834196|NCT04805034||HBeAg positive/HBsAg positive|
62051655|NCT02913664|PLACEBO_COMPARATOR|Usual Care|Blood and cholesterol management will be standard-care by participant's regular doctor, and stretching exercise.
62252584|NCT02483559|OTHER|Placebo Lenses|Participants will be randomized to participate in the placebo lens condition first or second. Outcome measures to assess the effects of wearing placebo lenses to allow all spectrums of light includes mood and sleep rating questionnaires (Positive and Negative Affect Scale, PANAS; Leeds Sleep Evaluation Questionnaire) as well as measuring the levels of melatonin the body is producing while wearing the glasses.
62252585|NCT02975427||Diet group|All participants were prescribed an appropriate diet with caloric restriction and an exercise program and underwent a follow-up examination 3±1 months later.
62252586|NCT00310804|EXPERIMENTAL|cTIV_lot 1|
62834197|NCT04805034||HBeAg seroconversion /HBsAg loss|
62834198|NCT01544010|NO_INTERVENTION|assessment only control group|Assessment at baseline, 12, and 24 months
62252587|NCT00310804|EXPERIMENTAL|cTIV_lot 2|
62252588|NCT00310804|EXPERIMENTAL|cTIV_lot 3|
62252589|NCT00310804|ACTIVE_COMPARATOR|TIV group|
62252590|NCT00693914||1: Brain Tumor Survivors (n=50)|
62834199|NCT01544010|ACTIVE_COMPARATOR|Minimal Stage Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Stage Tailored Feedback Reports based on assessments at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
62834200|NCT01544010|ACTIVE_COMPARATOR|Moderate TTM Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Moderate TTM-Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of stage of change, decisional balance and temptations at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
62834201|NCT01544010|ACTIVE_COMPARATOR|Full TTM tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Full TTM-Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of stage of change, decisional balance (pros + cons), temptations and (ten) processes of change at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
62051656|NCT03754179|EXPERIMENTAL|Arm A phase 2|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 \[programmed cell death 1\] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily and hydroxychloroquine 200 mg twice daily upfront until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment."
62834202|NCT01544010|ACTIVE_COMPARATOR|Enhanced TTM+Addiction Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Enhanced TTM+Addiction Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of addiction levels (# cigarettes/day) stage of change, decisional balance (pros + cons), temptations and (ten) processes of change at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
62834203|NCT04017663||Public group|patients who performed cardiovascular rehabilitation in a public center
62834204|NCT04017663||Private group|patients who performed cardiovascular rehabilitation in a private center
62834205|NCT03177655|EXPERIMENTAL|Guided Imagery|Guided Imagery meditation
62834206|NCT03177655|ACTIVE_COMPARATOR|Journaling|Keeping a journal
62623553|NCT05599347|EXPERIMENTAL|Azithromycin|5-day consecutive treatment with oral azithromycin 500 mg once daily
62834207|NCT01744977|EXPERIMENTAL|Adherence Packaging Intervention Group|\[MeadWestvaco Packaging Intervention Arm\] At baseline, the intervention arm will receive instructions from the RA on obtaining medication refills and the first fill of their statin medication from the VA pharmacy. At this time, the pharmacist will provide counseling including 1) use of adherence packaging, 2) to only use statin medications from the adherence packaging 3) purpose of LDL-related medications 4) how to take the medications.
62252591|NCT00693914||2: Healthy Sibling Controls (n=40)|
62442009|NCT03297359|EXPERIMENTAL|Weight adjusted dalteparin|"Participants will receive a daily subcutaneous injection of weight-adjusted dalteparin (See Table below) at a dose of approx. 200 IU/kg beginning on the day of enrolment and for a one month.~91 to 95 kg: 18,000 IU daily ( or 1 prefilled syringe of 18,000 IU) 96 to 105 kg: 20,000 IU daily ( or 2 prefilled syringes of 10,000 IU) 106 to 120 kg: 22,500 IU daily ( or 2 pre-filled syringes (10,000 and 12,500 IU)) 121 to 130 kg: 25,000 IU daily ( or 2 prefilled syringes of 12,500 IU) 131 to 145 kg: 27,500 IU daily ( or 2 pre-filled syringes (12,500 and 15,000 IU)) 146 to 150 kg: 30,000 IU daily ( or 2 prefilled syringes of 15,000 IU)~≥ 151 kg: 33,000 IU daily ( or 2 prefilled syringes (15,000 and 18,000 IU))"
62834208|NCT01744977|NO_INTERVENTION|Education Only Group|Control Arm patients will receive primary care and LDL management according to the discretion of their provider. At baseline, patients will receive similar written information on how to obtain medication refills and the importance of taking their cholesterol medications as prescribed. The 6-month interval was selected to maintain contact with patients.
62834209|NCT06447714||No aneurysm wall enhancement|The aneurysm wall did not show enhanced signal on high-resolution magnetic resonance imaging.
62834210|NCT06447714||Aneurysm wall enhancement|The aneurysm wall shows enhanced signal on high-resolution magnetic resonance imaging.
62834211|NCT02315742|EXPERIMENTAL|Let's Move Program|Patients will take part in a 12-week exercise program.
62834212|NCT01196637||Thoracic outlet syndrome|These patients have documented thoracic outlet syndrome
62834213|NCT01196637||Normal Subjects|These patients have no thoracic outlet syndrome
62834214|NCT03192735|EXPERIMENTAL|Apatinib Combined With SOX|In this group,subject will be given ApatinibMesylateTablets 500mg one time a day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 one time a day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
62834215|NCT02504151|EXPERIMENTAL|Cannabidiol, then Placebo|The subject will receive treatment with cannabidiol (CBD)(800mg/day) for four weeks, followed by a two week washout period, followed by four weeks of placebo.
62252592|NCT00693914||Solid Tumor Survivors (n=40)|
62252593|NCT00865683|ACTIVE_COMPARATOR|1|Participants will receive DHA supplements.
62252594|NCT00865683|PLACEBO_COMPARATOR|2|Participants will receive placebo capsules of corn oil.
62252595|NCT00163267|PLACEBO_COMPARATOR|ASS + Placebo|control arm
62252596|NCT00163267|ACTIVE_COMPARATOR|ASS + Plavix|active drug
62252597|NCT03442036|ACTIVE_COMPARATOR|Through-the-Needle Technique|"Perineural catheters are inserted through a straight hollow-bore needle.~The perineural catheter will then be used to infuse local anesthetic directly onto the nerve to provide postoperative pain control."
62834216|NCT02504151|EXPERIMENTAL|Placebo, then Cannabidiol|The subject will receive placebo for four weeks, followed by a two week washout period, followed by four weeks of treatment with cannabidiol (CBD)(800mg/day).
62611350|NCT04924023|EXPERIMENTAL|Kaleidoscope Group|Children in this group were told what a kaleidoscope is and how to use it before their central venous catheter dressing. The children were then asked if they would like to look into the kaleidoscope. The children looked into the kaleidoscope and slowly turned it. The researcher asked the children about the colours and shapes seen inside the kaleidoscope. This distraction procedure began immediately before the central venous catheter dressing and continued until it was finished. The kaleidoscope was disinfected before each use. A kaleidoscope was provided for all children in this group by the same researcher. Parents accompanied their children during the catheter dressing.
62611351|NCT04924023|NO_INTERVENTION|Control Group|No intervention was performed to reduce pain and anxiety for children in the control group. Parents accompanied their children during the procedure.
62252598|NCT03442036|EXPERIMENTAL|Suture-Method Technique|"Perineural catheters are attached to the back of a hollow suture-shaped needle that pulls the catheter adjacent to the target nerve.~The perineural catheter will then be used to infuse local anesthetic directly onto the nerve to provide postoperative pain control."
62611352|NCT02267213|EXPERIMENTAL|Lipotecan|Administer 40mg of Lipotecan at D1, D8, D15 of each cycles.
62442010|NCT01066494|EXPERIMENTAL|Single-arm|Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
62442011|NCT03205384||surgical management|Patient older than 65 years old, undergoing urgent abdominal surgery in our center
62611353|NCT05666479||Patients with Type 2 Diabetes Undergoing Orthopaedic Hip or Knee Replacement Surgery|
62611354|NCT05598710||Group 1|Group who have pigtail 5-26
62611355|NCT05598710||Group 2|Group who have pigtail 6-26
62611356|NCT05598710||Group 3|Group who have pigtail 5-28
62611357|NCT05598710||Group 4|Group who have pigtail 6-28
62611358|NCT06228833|EXPERIMENTAL|Test group|
62611359|NCT06228833|ACTIVE_COMPARATOR|Control group|
62611360|NCT06572943|NO_INTERVENTION|Control|Routine Antenatal Care. Brochures with dietary recommendations will be given.
62834217|NCT01896167|ACTIVE_COMPARATOR|Hypoxia|Inhalation of air with 8-12% oxygen content
62611361|NCT06572943|EXPERIMENTAL|Experimental|Detailed recommendations and brochures regarding physical activity will be given.Moreover brochures with dietary recommendations will be administrated.
62252599|NCT02050503||intranasal transmucosal fentanyl pectin|intranasal transmucosal fentanyl in pectin (100, 200, 400 or 800 microg) intranasal route titration phase 7 days treatment phase until completing treatment of 12 consecutive episodes of breakthrough pain
62252600|NCT01456650|EXPERIMENTAL|Glyburide|Patients in which the fasting glucose persisted above the treatment goal (fasting glucose \<126 mg/dl) after a 4 week diet period will receive glyburide. The dose of the medication will be adjusted based on the results of fasting glucose values. At each visit patients will return the leftover tablets; counts of the tablets will be the method for measuring the adherence to treatment. The medical study participants who decided to doses of glibenclamide will not know the allele of ABCA1 gene under study.
62442012|NCT03205384||not surgical management|Patients that presents a surgical disease, but we desestimate surgical procedure
62442013|NCT05928000||BLV-treated patients|All patients treated with daily Bulevirtide (BLV) subcutaneous injections of 2 mg, with or without concomitant use of a nucleos(t)ide analogue. Patients with concomitant use of pegylated interferon-alfa can be included.
62442014|NCT03832933|EXPERIMENTAL|High Protein Diet|
62442015|NCT03832933|ACTIVE_COMPARATOR|Standard Protein Diet|
62442016|NCT00386672|EXPERIMENTAL|Lite OJ with Ca and VitD|240ml of reduced energy (lite) OJ beverage fortified with 350mg Ca and 100U VitD, 3 times per day.
62442017|NCT00386672|ACTIVE_COMPARATOR|Lite OJ without Ca and VitD|240ml of reduced energy (lite) OJ beverage, 3 times per day.
62611362|NCT05480865|EXPERIMENTAL|Dose Escalation: BBP-398 Level 1 and sotorasib|BBP-398 dose Level 1 capsules administered once a day (QD) for a 28-day treatment cycle in combination with sotorasib tablets administered once a day (QD) for a 28-day treatment cycle
62611363|NCT05480865|EXPERIMENTAL|Dose Escalation: BBP-398 Level 2 and sotorasib|BBP-398 dose Level 2 capsules administered once a day (QD) for a 28-day treatment cycle in combination with sotorasib tablets administered once a day (QD) for a 28-day treatment cycle
62611364|NCT05480865|EXPERIMENTAL|Dose Escalation: BBP-398 Level 3 and sotorasib|BBP-398 dose Level 3 capsules administered once a day (QD) for a 28-day treatment cycle in combination with sotorasib tablets administered once a day (QD) for a 28-day treatment cycle
62834218|NCT01896167|PLACEBO_COMPARATOR|Atmospheric air|Inhalation of atmospheric air, with oxygen content at 21%
62834219|NCT01736995|EXPERIMENTAL|Motivational/Cog Beh Tx-Contingency Mgmt|The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior.
62834220|NCT01736995|EXPERIMENTAL|Functional Family Tx- Contingency Mgmt|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers to the family as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior.
62834221|NCT01736995|EXPERIMENTAL|Motivational/Cog Beh Tx|The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention.
62834222|NCT01736995|EXPERIMENTAL|Functional Family Tx|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills.
62051657|NCT03754179|ACTIVE_COMPARATOR|Arm B phase 2|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 \[programmed cell death 1\] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily until disease progression. At disease progression, add-on of hydroxychloroquine 200 mg twice daily. Treatment until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment"
62252601|NCT00068575|EXPERIMENTAL|Postoperative Chemoradiation Regimen|Postoperative Cisplatin 30 mg/m\^2 intravenous (IV) weekly for 6 doses, Interferon Alfa-2b 3 million units subcutaneous (SQ) on Monday, Wednesday and Friday days 1-19 and 29-45 for 17 total doses, and 5-fluorouracil (5-FU) 175 mg/m2/day by continuous intravenous infusion days 1-19 and 29-45 with concurrent Radiation Treatment.
62252602|NCT00299052|ACTIVE_COMPARATOR|A|Bone reamings with 5cc of DMB putty
62252603|NCT00299052|ACTIVE_COMPARATOR|B|Bone reamings
62252604|NCT05932875|ACTIVE_COMPARATOR|Peanut/Carbohydrate Consumption Exercise Training|Participants in this group will undergo 16 weeks of concurrent exercise training (4 sessions/week) consuming a peanut-based rice/oatmilk smoothie after each workout
62252605|NCT05932875|PLACEBO_COMPARATOR|Carbohydrate Consumption Exercise Training|Participants in this group will undergo 16 weeks of concurrent exercise training (4 sessions/week) consuming a rice/oatmilk smoothie after each workout
62252606|NCT01977820|EXPERIMENTAL|Sapropterin|
62252607|NCT01977820|PLACEBO_COMPARATOR|Placebo|
62252608|NCT01534013|EXPERIMENTAL|Closed-loop insulin delivery|The closed loop device (bio-inspired artificial pancreas device, subcutaneous glucose monitor and insulin pump) will be applied to participants with type 1 diabetes
62252609|NCT01534013|ACTIVE_COMPARATOR|Open-loop (Control visit)|Subcutaneous glucose monitor and pump will be applied to participants with type 1 diabetes
62442018|NCT01703741|EXPERIMENTAL|Testosterone gel (FE 999093)|Subjects received testosterone gel with initial dose as fixed on Day 56 (23 mg, 46 mg or 69 mg) during the 000023 study. The dose could further be down titrated based on serum testosterone levels at Day 90/91 of 000023 study. Testosterone gel was applied daily in morning using an applicator, to the shoulder/upper arm in a contralateral fashion for 6 months.
62623554|NCT05599347|PLACEBO_COMPARATOR|Control|5-day consecutive oral placebo once daily
62834223|NCT01588730|EXPERIMENTAL|Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours).
62834224|NCT01588730|ACTIVE_COMPARATOR|Static Splint|The control group will be treated with a static splint for a minimum of 6 4 hours each night while sleeping with the end goal of 6-8 hours.
62834225|NCT02052258|EXPERIMENTAL|oxytocin|
62834226|NCT01635296|EXPERIMENTAL|A: Previously untreated|
62834227|NCT01635296|EXPERIMENTAL|B: Relapse/Refractory|
62834228|NCT01551186|EXPERIMENTAL|Probiotic|Patients randomized to probiotic therapy will receive 1 capsule containing 1010 cells of Lactobacillus rhamnosus GG on a twice-daily basis
62834229|NCT01551186|NO_INTERVENTION|Standard of Care|Patients in the control arm will receive standard care
62051658|NCT03754179|EXPERIMENTAL|Phase 1|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 \[programmed cell death 1\] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily and hydroxychloroquine 200 mg twice daily upfront until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment."
62051659|NCT04074421|ACTIVE_COMPARATOR|Rifaximin group|Repeating treatment of Rifaximin
62051660|NCT04074421|SHAM_COMPARATOR|Probiotics group|Sequential treatment of probiotics called Bacillus subtilis and Enterococcus faecium
62051661|NCT04074421|PLACEBO_COMPARATOR|Placebo group|Placebo control group
62051662|NCT04590534|EXPERIMENTAL|study Group A|patients will receive one capsule of \[garcinia 500 mg and chromium 281 mg\] 3 times daily for 12 weeks.
62051663|NCT04590534|ACTIVE_COMPARATOR|Active control Group B|patients will receive one capsule of Sidosin 8 mg once daily for 12 weeks
62051664|NCT04590534|PLACEBO_COMPARATOR|Placebo Group C|patients will receive placebo 3 times daily for 12 weeks
62252610|NCT03226314||stool sampled community patients|community patients entering emergency ward or intensive care unit in Reunion Island university hospital and having the stools sampled for bacterial analysis.
62442019|NCT03654898|ACTIVE_COMPARATOR|VITAL Start|VITAL Start: Video-based pre-ART counseling
62834230|NCT00813241|ACTIVE_COMPARATOR|A|A single dose of 200 mg celecoxib capsule administered as 1 x 200 mg celecoxib capsule, (Reference Formulation)
62834231|NCT00813241|EXPERIMENTAL|B|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet formulation containing granule type A1
62834232|NCT00813241|EXPERIMENTAL|C|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet containing granule type B2
62834233|NCT00813241|EXPERIMENTAL|D|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet containing granule type C1
62834234|NCT04210531|EXPERIMENTAL|BJ supplementation|Acute beetroot juice (BJ) supplementation
62834235|NCT04210531|PLACEBO_COMPARATOR|PLA supplementation|Acute placebo (PLA) supplementation
62834236|NCT01427153|ACTIVE_COMPARATOR|Corticosteroid|Corticosteroid injection
62834237|NCT01427153|ACTIVE_COMPARATOR|Orthopaedic Manual Physical Therapy|OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
62834238|NCT02592798|EXPERIMENTAL|Abatacept|"* Double Blind Periods 1 and 2 (DB1 and DB2): Abatacept IV administered on Day 1, 15, 29 and then every 28 days until the end of the Double Blind Period.~* Open Label Period (OLE): Abatacept IV administered every 28 days"
62834239|NCT02592798|PLACEBO_COMPARATOR|Placebo|"* Double Blind Periods 1 and 2 (DB1 and DB2): Normal Saline or Dextrose 5% in Water (D5W) administer on Day 1, 15, 29 and then every 28 days until the end of the Double Blind Period.~* Open Label Period (OLE): Abatacept IV administered every 28 days"
62834240|NCT00288132|ACTIVE_COMPARATOR|Usual Care|
62834241|NCT00288132|EXPERIMENTAL|Intervention|
62834242|NCT05165940|ACTIVE_COMPARATOR|TAU|Treatment As Usual with a VA mental health treatment coordinator
62051665|NCT01756911|EXPERIMENTAL|Thotaco-abdominal aneurysm|MFM
62051666|NCT05388721||GDM group|Pregnant women with positive OGTT results at 24-28 gestational weeks
62442020|NCT03654898|PLACEBO_COMPARATOR|Standard of Care|pre-ART education as conducted via routine facility methods
62442021|NCT01928784|EXPERIMENTAL|Specific pain spot|Radial Extracorporeal Shock Wave Therapy 2000 impulses, Patients with specific pain spot for low back pain
62834243|NCT05165940|EXPERIMENTAL|New Health Services Intervention|Novel health services intervention with a VA mental health treatment coordinator
62834244|NCT04846426||Arm 1: MCI amyloid positive|"* Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia~* Positive amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)"
62442022|NCT01928784|EXPERIMENTAL|No specific pain spot|Radial Extracorporeal Shock Wave Therapy 4000 impulses, Patients without specific pain spot for low back pain
62442023|NCT04521400|EXPERIMENTAL|Arm1|Lopinavir /Ritonavir +high dose Interferon-β 1a
62834245|NCT04846426||Arm 2: MCI amyloid negative|"* Non-AD Mild Cognitive Impairment (MCI)~* Negative amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)"
62834246|NCT04846426||Arm 3: CN amyloid positive|"* Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Positive amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)"
62252611|NCT02773030|EXPERIMENTAL|Cohort A: CC-220 Monotherapy - Part 1|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
62252612|NCT02773030|EXPERIMENTAL|Cohort B: CC-220 in combination with Dexamethasone (DEX) - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.~For subjects ≤ 75 years old, oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, DEX will be administered at 20 mg on Days 1, 8,15, and 22 of each 28-day cycle. Subjects who surpass the age of 75 years while on treatment may be switched to the 20 mg QD dosage based on the investigator's best judgment."
62834247|NCT04846426||Arm 4: CN amyloid negative|"* Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Negative amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)"
62834248|NCT05035381|EXPERIMENTAL|Experiment Group|
62051667|NCT05388721||Control group|Pregnant women with negative OGTT results at 24-28 gestational weeks, and had baseline data that matched those in the GDM group
62252613|NCT02773030|EXPERIMENTAL|Cohort D: CC-220 in combination with Dexamethasone - Part 2|"Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle~For subjects ≤ 75 years old, oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle"
62252614|NCT02773030|EXPERIMENTAL|Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.~Intravenous DARA at dose 16mg/kg on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.~Once the MTD and/or RP2D is determined in Cohort E (CC-220Dd), subjects will be enrolled at a dose of Subcutaneous DARA at 1800 mg over 3 to 5minutes on Days 1, 8, 15,and 22 at cycle 1-2 of a 28-day cycle, Days1, and 15 at cycle 3-6 of a 28-day cycle, and Day1 at cycle ≥7 of each 28-day cycle."
62252615|NCT02773030|EXPERIMENTAL|Cohort F: CC-220 with DEX and bortezomib - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-14 of each 21-day cycle.~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, and 15 of each 21-day cycle. For subjects \>75 years old, oral DEX at 20 mg on Days 1, 8, and 15 of each 21-day cycle.~Subcutaneous BTZ at dose 1.3 mg/m\^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, and 8 at cycle ≥9 of each 21-day cycle."
62252616|NCT02773030|EXPERIMENTAL|Cohort G1: CC-220 in combination with CFZ and DEX - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle~Intravenous (IV) CFZ (Carfilzomib)administered at a starting dose of 20 mg/m2 on C1D1; and at a dose specified by cohort dose level thereafter on days 1, 8, and 15 of each 28-day cycle.~Oral DEX (Dexamethasone) on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects ≤ 75 years old, the DEX dose will be 40 mg. For subjects \> 75 years old, the DEX dose will be 20 mg"
62252617|NCT02773030|EXPERIMENTAL|Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.~Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1 and C1D2; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle.~Oral DEX on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. The DEX dose will be 20 mg."
62442024|NCT04521400|EXPERIMENTAL|Arm2|Lopinavir /Ritonavir + Low dose Interferon-β 1a
62442025|NCT00310856|EXPERIMENTAL|MenACWY-CRM_6-12 M|Subjects received 2 doses of MenACWY-CRM (1 dose at 6 and 12 months of age). Subjects also received routine vaccines: 2 doses of PC7 (1 dose at 6 and 12 months of age), 1 dose of DTaP-Hib-IPV (at 6 months of age) and 1 dose of MMR+Varicella (at 13 months of age)
62442026|NCT00310856|EXPERIMENTAL|MenACWY-CRM_12 M|Subjects received 1 dose of MenACWY-CRM at 12 months of age. Subjects also received routine vaccines: 2 doses of PC7 (1 dose at 6 and 12 months of age), 1 dose of DTaP-Hib-IPV (at 6 months of age) and 1 dose of MMR+Varicella (at 13 months of age)
62442027|NCT00310856|EXPERIMENTAL|MenC-CRM_12 M_MenACWY-CRM_18 M|"Subjects received 1 dose of MenC-CRM (at 12 months of age) and 1 dose of MenACWY-CRM (at 18 months of age).~Subjects also received routine vaccines: 1 dose of PCV7 (at 12 months), MMR+Varicella (at 13 months) and DTaP-Hib-IPV (at 18 months)"
62834249|NCT02899468|EXPERIMENTAL|Active Treatment Group|Active treatment will consist of the BrightBrainer Virtual Reality (BBVR) Rehabilitation System therapy intervention (3 sessions per week x 6 weeks). Standard validated outcome measures which assess various domains of function, will be obtained at baseline and then at 3 and 6 weeks for those randomized to the Active Treatment group.
62834250|NCT02899468|OTHER|Wait-List Control Group|Subjects randomized to the Wait-List Control (WLC) group will wait 3 weeks before beginning the Active Treatment program intervention (3 sessions per week x 6 weeks) using the BrightBrainer Virtual Reality (BBVR) Rehabilitation System. For those randomized to the WLC group, outcome measures will be assessed at baseline, completion of waiting period (3 weeks), then at 3 and 6 weeks after initiating active treatment.
62834251|NCT04961684|EXPERIMENTAL|Solver Pen|
62834252|NCT04961684|ACTIVE_COMPARATOR|Loceryl 5%|
62834253|NCT01424384|ACTIVE_COMPARATOR|Citalopram|Marketed comparitor
62834254|NCT01424384|EXPERIMENTAL|Investigational Medicinal Product|GSK424887
62834255|NCT01424384|PLACEBO_COMPARATOR|Placebo To Match Treatment|Placebo control
62834256|NCT04706455|ACTIVE_COMPARATOR|sodium hyaluronate 0.1%|First preoperative Biometry of the eye at the IOL Master® will be measured. Then, corneal topography will be measure at the Oculus pentacam®. Afterwards, sodium hyaluronate 0.1% will be installed and biometry and corneal topography will be repeated after 5 minutes.
62834257|NCT04706455|ACTIVE_COMPARATOR|sodium hyaluronate 0.3%|First preoperative Biometry of the eye at the IOL Master® will be measured. Then,corneal topography will be measure at the Oculus pentacam®. Afterwards, sodium hyaluronate 0.3% will be installed and biometry and corneal topography will be repeated after 5 minutes.
62051668|NCT03197012|EXPERIMENTAL|Main Study: 90Y-DOTA-TOC|90Y-DOTA-TOC will be administered one time over thirty minutes via the hepatic arterial catheter in the outpatient setting. The injected dose will be 85 to 115 mCi.
62442028|NCT05113225|ACTIVE_COMPARATOR|DG-ICSI|Oocytes of this arm will be injected using sperm previously processed by DG method and located in the commonly used ICSI dishes with the common PVP microdroplets
62252618|NCT02773030|EXPERIMENTAL|Cohort I: CC-220 in combination with DEX in post BCMA RRMM - Part 2|"Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle~Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle."
62834258|NCT03241901|ACTIVE_COMPARATOR|3 Days Artemether-Lumefantrine + Placebo|"Oral tablets of artemether-lumefantrine (20-120mg):~1. tablet for 5-14kg;~2. tablets for 15-24 kg;~3. tables for 25 - 34kg and~4. tablets for above 35 Kg. The full course of treatment is 6-doses for 3 days given twice daily, at 0, 8, 24, 36, 48, 60 with the dose being given as directly observed therapy.~Oral placebo after completion of the standard 3 days-six dose regimen. A fatty snack (biscuits) will be administered together with all artemether-lumefantrine doses to optimize absorption."
62834259|NCT03241901|EXPERIMENTAL|6Days Artemether/Lumefantrine+Primaquine|"Artemether-lumefantrine (20-120mg) twice daily for 6 days according to body weight as in the active comparator arm.~And in addition to that, , a single 0.25 mg/kg primaquine dose (Primaquine phosphate) will be administered concomitantly with the last (i.e. twelfth) artemether-lumefantrine dose. Primaquine will be prepared and administered in an aqueous solution."
62834260|NCT04128852|OTHER|MagnetOs Putty|MagnetOs Putty will be applied according to the latest Instructions For Use (IFU) approved in Europe. Specifically, MagnetOs Putty will be used as bone void filler.
62252619|NCT02773030|EXPERIMENTAL|Cohort J1: CC-220 in combination with DEX and BTZ in NDMM - Part 2|"Oral CC-220 at 1.0mg, 1.3mg or 1.6mg administered at cycles 1 to 8 on Days 1 to 14 of each 21-day cycle and cycles ≥ 9 on Days 1 to 21 of each 28-day cycle.~Oral DEX at Cycles 1 to 8, 20 mg (≤ 75 years old) or 10 mg (\> 75 years old) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of each 21-day cycle and Cycles ≥ 9, 40 mg (≤ 75 years old) or 20 mg (\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle.~Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-8 of each 21-day cycle."
62252620|NCT02773030|EXPERIMENTAL|Cohort J2: CC-220 in combination with DEX and BTZ in NDMM - Part 2|"Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle.~Oral DEX at 20 mg/day (≤ 75 years old) or 10 mg/day (\> 75 years old) for Cycles 1 to 6 on Days 1, 2, 4, 5, 8, 9, 11 and 12 of a 21-day cycle.~Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-6 of each 21-day cycle."
62252621|NCT02773030|EXPERIMENTAL|Cohort K: CC-220 with DEX and DARA in NDMM and not autologous stem cell transplant eligible - Part 2|"Oral CC-220 at 1.0mg, 1.3mg or 1.6mg from Days 1-21 of each 28-day cycle.~Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.~Subcutaneous DARA at 1800 mg over 3 to 5minutes on Days 1, 8, 15, and 22 at cycle 1-2 of a 28-day cycle, Days1, and 15 at cycle 3-6 of a 28-day cycle, and Day1 at cycle ≥7 of each 28-day cycle."
62834261|NCT05006963|EXPERIMENTAL|face-to-face group|The patient will be submitted to multimodal treatment, twice a week, for twelve weeks, totaling 24 face-to-face consultations lasting 40 minutes each. In the first session, the patient will be explained what is TMD, what is the correct placement of the tongue and teeth, influence of parafunctional and sleep habits in TMD signs and symptoms.Techniques of manual therapy and therapy by exercise. In general, extra-oral and intraoral massage, myofascial release in the cranio-cervical musculature, mobilization of the hyoid bone and may also receive unspecific joint mobilization. Will be mouth opening exercise will be also performed with the tongue on the palate, proprioceptive exercises with hyperboloid. In addition to these, additional exercises may be performed, according to the patient's need. The conducts will be adapted according to the needs of each patient. The use of post its may be indicated to help maintain the correct posture of the tongue and jaw, as well as sleep hygiene.
62051669|NCT03197012|EXPERIMENTAL|Sub-study: 90Y and 68Ga-DOTA-TOC|"90Y-DOTA-TOC will be administered one time over thirty minutes via the hepatic arterial catheter in the outpatient setting. The injected dose will be 85 to 115 mCi.~Patients enrolled in the correlative sub-study will also receive 111-259 MBq (3-7 mCi) of 68Ga-DOTA-TOC concurrent with 90Y-DOTA-TOC"
62252622|NCT02773030|EXPERIMENTAL|Cohort C: CC-220 Monotherapy in RRMM - Part 2|CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
62252623|NCT03837782|EXPERIMENTAL|minimally invasive surgery|"Patients were randomized to undergo minimally invasive radical resection (endoscopic surgery or robotic assisted surgery). Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery.~Patients were eligible if they had colorectal adenocarcinoma; had a disease stage of I (T1,T2), IIABC (T3-T4ab) or IIIABC (TanyN1-2) according to the staging system of NCCN; and had an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a 5-point scale, with higher values indicating greater disability)."
62611365|NCT05480865|EXPERIMENTAL|Dose Expansion/Optimization: BBP-398 Dose Regimen 1 and sotorasib|BBP-398 Dose Regimen 1 capsules administered once a day (QD) for a 28-day treatment cycle in combination with sotorasib tablets administered once a day (QD) for a 28-day treatment cycle
62252624|NCT03837782|NO_INTERVENTION|open surgery|"Patients were randomized to undergo open radical resection (laparotomy). Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery.~Patients were eligible if they had colorectal adenocarcinoma; had a disease stage of I (T1,T2), IIABC (T3-T4ab) or IIIABC (TanyN1-2) according to the staging system of NCCN; and had an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a 5-point scale, with higher values indicating greater disability).~Exclusion criteria included a history of abdominal or pelvic radiotherapy, or evidence of metastatic disease on positron-emission tomography-computed tomography, magnetic resonance imaging, or computed tomography."
62252625|NCT03410849|ACTIVE_COMPARATOR|Gastric Bypass|A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic gastric bypass
62252626|NCT03410849|ACTIVE_COMPARATOR|Sleeve Gastrectomy|A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic sleeve gastrectomy
62252627|NCT05195944|EXPERIMENTAL|Semaglutide|In the Semaglutide Arm, participants will receive daily: 1 tablet of Semaglutide and 1 tablet of Sitagliptin placebo for 26 weeks. The dosages of Semaglutide are 3 mg, 7 mg, and 14 mg.
62252628|NCT05195944|ACTIVE_COMPARATOR|Sitagliptin|In the Sitagliptin arm, participants will receive daily: 1 tablet of 100 mg Sitagliptin and 1 tablet of Semaglutide placebo for 26 weeks.
62252629|NCT04582149|EXPERIMENTAL|EyeControl Eye-tracking Device|Ventilated ICU patients using the EyeControl wearable, eye-tracking device.
62611366|NCT05480865|EXPERIMENTAL|Dose Expansion/Optimization: BBP-398 Dose Regimen 2 and sotorasib|BBP-398 Dose Regimen 2 capsules administered once a day (QD) for a 28-day treatment cycle in combination with sotorasib tablets administered once a day (QD) for a 28-day treatment cycle
62611367|NCT05042830|ACTIVE_COMPARATOR|Active group|Birch allergic subjects receiving birch pollen extract challenge
62051670|NCT04983563|EXPERIMENTAL|Actigraphy|
62051671|NCT02636270|EXPERIMENTAL|PAPP-A2 deficient patients|Patients deficient in PAPP-A2 with short stature will be treated with Increlex (rhIGF-1)
62252630|NCT05717842||People with ESLD and eGFR between >=25 and <=40ml/min|"1. \> 18 years old~2. Listed for Liver Transplant for ESLD and Kidney Transplant (not on dialysis)~3. Candidates with two native kidneys.~4. Willing to participate and sign informed consent"
62252631|NCT02247245|PLACEBO_COMPARATOR|Placebo|Subjects are given a placebo capsule (double-blinded) to take 90 minutes prior to the cardiopulmonary exercise test.
62252632|NCT02247245|ACTIVE_COMPARATOR|Ivabradine|Subjects are given an ivabradine capsule (double-blinded) to take 90 minutes prior to the cardiopulmonary exercise test.
62252633|NCT02247245|EXPERIMENTAL|Atrial fibrillation|Subjects are (double blind) randomised to either a low base pacing rate (30) or a standard base rate (60), with rate adaptive algortithms switched on.
62252634|NCT05765006|EXPERIMENTAL|Relma-cel be administrated in four dose level|
62252635|NCT02018198||Acute Respiratory Infection|Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices with a new onset, measured fever and new onset respiratory symptoms.
62252636|NCT02018198||Asymptomatic Cohort|Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices without infection.
62442029|NCT05113225|EXPERIMENTAL|H pattern-ICSI|Oocytes of this arm will be injected using sperm that directly located in a specific H pattern PVP droplets in a commonly used ICSI dishes without pre-processing of the semen
62442030|NCT05785520|OTHER|ST500 single-dose gel|The treatment is performed twice weekly for 6 weeks.
62442031|NCT02748109|EXPERIMENTAL|Vestibular Rehabilitation + audio biofeedback|Vestibular rehabilitation paired with audio biofeedback
62442032|NCT02748109|ACTIVE_COMPARATOR|Vestibular Rehabilitation|Vestibular rehabilitation
62442033|NCT02278679||Anesthitized patient|First, it will be validated on 120 anesthetized patients undergoing prostate surgery comparing responses on the digital rectal exam clinical tool (DiRECT) from both expert and novice clinicians, with surgical pathology reports.
62252637|NCT02707380|ACTIVE_COMPARATOR|Group 1 Resistance Training Group|Participants will perform 3 exercises, one of which will be a series of 7 muscle-strengthening exercises using body weight resistance and elastic resistance bands + 36 sessions of a standard cardiac rehabilitation program consisting of monitored exercise, nutritional guidance, and heart-healthy lifestyle education three times weekly.
62252638|NCT02707380|ACTIVE_COMPARATOR|Group 2 Standard of Care|Participants will perform 3 exercises that do not include the 7 muscle-strengthening exercises + 36 sessions of a standard cardiac rehabilitation program consisting of monitored exercise, nutritional guidance, and heart-healthy lifestyle education three times weekly.
62252639|NCT03924336|EXPERIMENTAL|Advanced- platelets rich fibrin plus with open flap debridement|Mucoperiosteal flaps will be elevated using an intrasulcular incision buccally and palatally or lingually. Then the defects will be thoroughly debrided using curettes and ultrasonic scalers. The clinical measurements will be then recorded. After debridement and intraoperative recordings, A-PRF+ of the required size will be filled into the intraosseous defect, the mucoperiosteal flaps will be repositioned and secured in place using 4-0 silk sutures
62834262|NCT05006963|ACTIVE_COMPARATOR|telerehabilitation|The patient will be submitted to multimodal treatment, twice a week, for twelve weeks, by telerehabilitation lasting 40 minutes each.A physiotherapist through video call via WhatsApp application. In the first session, the patient will be explained what is TMD, what is the correct placement of the tongue and teeth, influence of parafunctional and sleep habits in TMD signs and symptoms. Patients will be instructed to perform extra-oral and intra-oral self-massage and in the cranio-cervical musculature, bone mobilization hyoid, which would replace the mobilization unspecific articulation performed in person.Exercise will also be carried out mouth opening with tongue on the palate, exercises proprioceptives with hyperboloid. The conducts will be adapted according to the needs of each patient.The conducts will be adapted according to the needs of each patient.The use of post its may be indicated to help maintain the correct posture of the tongue and jaw, as well as sleep hygiene
62834263|NCT04586439|EXPERIMENTAL|Panel A: JNJ-73763989|Participants will receive single subcutaneous (SC) injection of low dose of JNJ-73763989 on Day 1.
62252640|NCT03924336|ACTIVE_COMPARATOR|Open flap debridement (OFD)|Mucoperiosteal flaps will be elevated using an intrasulcular incision buccally and palatally or lingually. Then the defects will be thoroughly debrided using curettes and ultrasonic scalers. The clinical measurements will be then recorded. After debridement and intraoperative recordings, The interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
62252641|NCT02078570||Breast Cancer ACR BI-RAD Category 3 or 4 result|
62252642|NCT02153554|EXPERIMENTAL|Trained|Training civil servants in Medellin (Colombia) on attention to violence against women.
62252643|NCT02153554|NO_INTERVENTION|Non trained|
62252644|NCT02538016|OTHER|Tolvaptan|
62834264|NCT04586439|EXPERIMENTAL|Panel B: J NJ-73763989|Participants will receive single SC injection of high dose of JNJ-73763989 on Day 1.
62834265|NCT03726580||control group|regional anesthesia
62834266|NCT03726580||general anesthesia(S)|general anesthesia with sevoflurane
62834267|NCT03726580||general anesthesia(I)|general anesthesia with isoflurane
62834268|NCT03726580||total intravenous anesthesia|total intravenous anesthesia with propofol.
62611368|NCT05042830|PLACEBO_COMPARATOR|Control group|Birch allergic subjects receiving saline
62834269|NCT06128954|EXPERIMENTAL|Once Daily Dose Formulation (Treatment A)|1 x 900mg TETA 4HCl, new once daily formulation (3x300mg trientine base tablets as a single AM dose)
62834270|NCT06128954|ACTIVE_COMPARATOR|Cuprior® comparator (Treatment B)|2 x 450mg TETA 4HCl, Marketed Cuprior® formulation (6 x150mg trientine base tablets in two equally divided doses (450mg doses 8 hours apart)
62834271|NCT05044689||Colorectal Cancer (Cases)|Based on the existing ARGO (African Colorectal Cancer Group) platform where a current colorectal cancer study is going on, 400 patients with a prior diagnosis and a new diagnosis will be recruited into this study.
62834272|NCT05044689||Controls|We will select our 400 controls from two groups of participants who are free of cancer and gastrointestinal diseases. First, we will leverage community mobilization groups to identify and recruit a target group of 200 community-based population controls. Second, we will identify and recruit the remaining 200 controls from those seeking care in the Outpatient Health Center at OAU, which sees \~50-60 patients per day as part of routine care.
62834273|NCT04640610||Adenoidectomy / tonsillectomy|Children and adults, without SARS-CoV-2 infection, in whom an adenoidectomy and/or tonsillectomy is performed for their care in the centers of the study.
62834274|NCT05410184|EXPERIMENTAL|Virtual Reality Glasses|Except for the preparation of the patient for the procedure, since the colonoscopy procedure takes approximately 30 minutes, 30-minute 360-degree VR video scenes will be watched using the phone and VR head device.
62834275|NCT05410184|EXPERIMENTAL|Mural Curtain|the mural curtain group; they will be asked to focusing the mural curtain with a nature view during the colonoscopy procedure.
62611369|NCT03747302|EXPERIMENTAL|HPV Messaging|Subjects are randomized to receive one of five messages on one of the four themes about HPV vaccination.
62611370|NCT03747302|OTHER|Control Message|Subjects are randomized to receive one of five messages about electronic cigarettes.
62611371|NCT04110717|EXPERIMENTAL|Active Device Group|25 subjects randomised to receive active device use plus lifestyle intervention for 3 months.
62611372|NCT04110717|PLACEBO_COMPARATOR|Control Device Group|25 subjects randomised to receive control device use plus lifestyle intervention for 3 months.
62611373|NCT01615978|EXPERIMENTAL|Fixed dose: 5 mcg/kg|
62611374|NCT01615978|EXPERIMENTAL|Escalated dose: 10 mcg/kg|
62611375|NCT04653623|EXPERIMENTAL|Tranexamic acid before high tibial osteotomy|"Interventions~* Procedure/Surgery: High tibial osteotomy~* Drugs: Tranexamic acid"
62611376|NCT04653623|ACTIVE_COMPARATOR|High tibial osteotomy only|"Interventions~- Procedure/Surgery: High tibial osteotomy"
62252645|NCT03409848|EXPERIMENTAL|A: Chemo-free immunotherapy|Week 1-12 Trastuzumab 6mg/kg d1 every 3 weeks (loading dose 8mg/kg) Nivolumab 1mg/kg i.v. d1 every 3 weeks Ipilimumab 3mg/kg i.v. d1 every 3 weeks Week 13 till EOT (max treatment period 12 months) Trastuzumab 4mg/kg d1 every 2 weeks Nivolumab 240mg i.v. d1 every 2 weeks
62252646|NCT03409848|EXPERIMENTAL|B: Chemo- / immunotherapy|"Trastuzumab 4mg/kg d1 every 2 weeks (loading dose 6mg/kg) Nivolumab 240mg i.v. d1 every 2 weeks mFOLFOX6 every 2 weeks Oxaliplatin at a dose of 85 mg/m2 IV over two hours (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv over two hours (day 1) 5-FU at a dose of 2400 mg/m2 IV over 46 hours (day 1-3)~Max Treatment period 12 months"
62252647|NCT01484977|EXPERIMENTAL|Lacosamide|Lacosamide will be added to levetiracetam while withdrawing the sodium channel blocking antiepileptic drug (AED)
62252648|NCT05251740|EXPERIMENTAL|Standing program|The child completes a 60-minute home standing program five days per week over eight weeks.
62611377|NCT06417866||standard informed consent|standard verbal and written informed consent form
62611378|NCT06417866||visual spinal model|standard verbal and written informed consent form + visual spinal model
62252649|NCT00931242|EXPERIMENTAL|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
62611379|NCT06016348||Good outcome|mRS of 0-3; mRS of 0-2
62442034|NCT02278679||Standardized patients|During a standardized patient exercise focusing on digital rectal exam in the University of Virginia School of Medicine curriculum, 160 second-year medical students will be given the DiRECT to document their examination. An attending physician will also attend the standardized patient exercise and document their examination for comparison with the medical students.
62252650|NCT03687073|EXPERIMENTAL|Single-dose PK study|Subjects will take the assigned dose of I3C, Sil, or I3C + Sil once at the study center. Ten mL of blood will be collected at the time points described in Section 9.14. Concurrently, urine will also be collected for 24 hours after the first dose of I3C, Sil or I3C + Sil, divided into the time intervals.
62252651|NCT03687073|EXPERIMENTAL|Multi-dose PK Study|Subjects will take the assigned dose of I3C, Sil, or I3C + Sil for 8 weeks. Ten mL of blood will be collected at the time points described in Section 9.14. Concurrently, urine will be collected for 24 hours after the first dose of I3C, Sil or I3C + Sil, divided into the time intervals.
62252652|NCT03687073|EXPERIMENTAL|Safety Study|Safety data will be generated during the multi-dose PK and PD study, as DLT is not anticipated in the single-dose PK study. Enrollment into dose cohorts 1 and 2 can occur on a continuous basis. Enrollment for dose cohorts 3 and 4 will be done sequentially using a modified 3+3 design (see Section 8.2). The first three subjects enrolled into a dose cohort must complete at least 21 days of the multi-dose PK/PD study without a DLT before the remaining 4 subjects in the cohort can be enrolled.
62442035|NCT02278679||Clinic patient|The third phase includes 8 residents and up to10 attendings in the Urology clinic, who will independently complete the DiRECT documenting their DRE in the course of usual care.
62442036|NCT04625582|EXPERIMENTAL|Face-to-face intervention|90 trainees at Vigo Family Medicine and Community Nursing Training Unit
62442037|NCT04625582|EXPERIMENTAL|Online intervention|70 trainees at Aragón Family Medicine and Community Nursing Training Unit
62442038|NCT04625582|NO_INTERVENTION|Usual training|180 trainees at Balearic Islands Family Medicine and Community Nursing Training Unit
62442039|NCT02259842|EXPERIMENTAL|BI 34021 FU2 solution|single rising doses, dose groups 3 and 5 double-dosing (fed and fasted)
62442040|NCT02259842|EXPERIMENTAL|BI 34021 FU2 tablet|dose group 4 only
62442041|NCT02259842|PLACEBO_COMPARATOR|Placebo|
62442042|NCT03339882|EXPERIMENTAL|Remifemin intervention|Using Remifemin during LHRH-a treatment in breast cancer
62442043|NCT03339882|NO_INTERVENTION|Control|No intervention during LHRH-a treatment in breast cancer
62442044|NCT05423756|ACTIVE_COMPARATOR|Arm 1: Routine Care|Continuation of routine antibiotic stewardship strategies.
62611380|NCT06016348||Unfavorable outcomes|mRS of 4-6
62611381|NCT04187040|ACTIVE_COMPARATOR|3-step hand hygiene technique|Wards assigned to this study arm will receive instructions, educational materials and tutorials about the 3-step hand hygiene technique.
62611382|NCT04187040|ACTIVE_COMPARATOR|6-step hand hygiene technique|Wards assigned to this study arm will receive instructions, educational materials and tutorials about the 6-step hand hygiene technique.
62611383|NCT05211141||Patient with knee arthroplasty|patient with HLS KneeTec Deep Dish prosthesis
62611384|NCT01715519|EXPERIMENTAL|Treatment (Viibryd)|10 mg/day 1 to 7; 20 mg/day 8 to 14; 40 mg/day week 3 to end week 12. Subjects will then be tapered off vilazodone as follows: 20 mg/day week 13, 10 mg/day, week 14 and no medication during week 15.
62611385|NCT01715519|PLACEBO_COMPARATOR|Placebo|will be compared to the treatment group (viibryd)
62611386|NCT04292639|EXPERIMENTAL|Respiratory Rate|The purpose of this study is to conduct a Respiratory Rate accuracy validation comparing the Vital USA Vital Detect to an FDA cleared End Tidal Carbon Dioxide monitor Reference Standard (GE Datex-Ohmeda). This report documents exclusively the results of the Respiratory Rate accuracy performance for the Vital USA Vital Detect.
62611387|NCT06614777|EXPERIMENTAL|investigation : biopsy and blood extraction|
62051672|NCT04021017|EXPERIMENTAL|Treatment|"Participants randomized to the treatment arm will be divided by maturational status:~* Participants who have had their first period or have a bone age greater than or equal to 14 years will receive PrClimara® 25 (estradiol hemihydrate transdermal system - 25 mcg/day) as a weekly patch, for 24 months.~  o These participants will also receive progesterone (Provera 10 mg tablet) orally every 4 weeks, for 7 days during the second half of the planned menstrual cycle, in order to induce a menstrual period.~* Participants who have not yet had their first period and have a bone age below 14 years will receive an increasing dose of estrogen. These participants will be initiated on graduated dose of transdermal 17-β estradiol patches:~  * 3.1 mcg/day (1/8 patch) for first six-months,~ * 6.2 mcg/day (1/4 patch) for second six-months,~ * 12.5 mcg/day (1/2 patch) for third six-months, and~ * 25 mcg/day (full patch) for final six-months."
62051673|NCT04021017|NO_INTERVENTION|No Treatment|The participants in this group will not receive the estrogen patch nor the oral progesterone.
62051674|NCT03460028|EXPERIMENTAL|Yoga Condition|Participants randomized to the Yoga Condition will participate in a specialized yoga intervention.
62051675|NCT03460028|NO_INTERVENTION|Wait-List Control Condition|Participants randomized to the Wait-List Control Condition will participate in a specialized yoga intervention once the Yoga Condition has completed their assigned intervention.
62051676|NCT04876079|ACTIVE_COMPARATOR|16g of carbohydrates - Plasma glucose < 4.0 mmol/L|16g of carbohydrates will be given when glucose levels are below 4.0 mmol/L (management per guidelines)
62051677|NCT04876079|ACTIVE_COMPARATOR|16g of carbohydrates - Plasma glucose ≤ 4.5 mmol/L|16g of carbohydrates will be given when glucose levels are equal or below 4.5 mmol/L.
62051678|NCT04876079|ACTIVE_COMPARATOR|16g of carbohydrates - Plasma glucose ≤ 5.0 mmol/L|16g of carbohydrates will be given when glucose levels are equal or below 5.0 mmol/L.
62611388|NCT06415396|ACTIVE_COMPARATOR|Complete Decongestive Therapy|22 breast cancer related lymphedema patients will received complete decongestive therapy
62051679|NCT04162093|EXPERIMENTAL|single trough|
62051680|NCT06370910|ACTIVE_COMPARATOR|Cryotherapy|"Cryotherapy will be performed using a glove containing crushed ice applied to the perineum region for 20 minutes, starting within 12 hours postpartum. The patients will be evaluated before the application, immediately after the application, immediately after the application and in 24 hours after the application.~A glove containing crushed ice will be used because it is more anatomical and extends throughout the perineum region. The indicates that ice on the surface has the ability to decrease the temperature of the skin and intramuscular tissue. Compared to other cryotherapy techniques like gel and frozen pea pack, ice pack is the most adopted technique for perineal pain relief.~The application time depends on the study, which indicates that 20 minutes is enough time to cause a reduction and relief of pain in the participants of their study."
62051681|NCT06370910|ACTIVE_COMPARATOR|Low-Level Laser Therapy|Within 12 hours postpartum, red light radiation will be applied at the site of the injury, with 3 joules applied promptly. The non-contact technique will be used, maintaining a distance of 2 cm between each point. Subsequently, infrared laser will be applied using conventional contact technique, around the extent of the injury. 6 joules will be applied punctually, also with a distance of 2 cm between each point. The LLLT device used will be the DMC brand Therapy EC, portable, with a lithium-ion battery. The red laser will have a wavelength of 660nm (+- 10 nm), with an emitter power of 100 mw (+- 20%). The infrared laser will have a wavelength of 808 nm (+- 10), with an emitter power of 100 mw (+- 20%).
62051682|NCT04088201|EXPERIMENTAL|Measuring glucose|Measuring glucose from interstitial fluid
62051683|NCT01592903||Patients with symptomatic uterine fibroids.|Samples of human leiomyomas are obtained from patients undergoing laparoscopic myomectomy for symptomatic uterine fibroids. These leiomyomas are isolated and cultured for stem cells.
62051684|NCT00116844|EXPERIMENTAL|Sequence 1: VALTREX 1 g once daily, Placebo|VALTREX 1 g once daily, Placebo
62051685|NCT00116844|EXPERIMENTAL|Sequence 2: Placebo, VALTREX 1 g once daily|Placebo, VALTREX 1 g once daily
62051686|NCT03879408|EXPERIMENTAL|440 mg naproxen sodium with 1000 mg acetaminophen|440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
62051687|NCT03879408|EXPERIMENTAL|220 mg naproxen sodium with 650 mg acetaminophen|220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
62611389|NCT06415396|ACTIVE_COMPARATOR|Complete Decongestive Therapy and ESWT|22 breast cancer related lymphedema patients will received ESWT added complete decongestive therapy
62051688|NCT03879408|ACTIVE_COMPARATOR|10 mg hydrocodone + 650 mg acetaminophen|10 mg hydrocodone + 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
62051689|NCT03879408|ACTIVE_COMPARATOR|440 mg naproxen sodium|440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
62051690|NCT03879408|PLACEBO_COMPARATOR|Placebo tablet|Single dose of four placebo tablets
62051691|NCT02417779|EXPERIMENTAL|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62051692|NCT02417779|EXPERIMENTAL|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size must not be less than 1% of TBSA.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62051693|NCT02417779|EXPERIMENTAL|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62611390|NCT06415396|ACTIVE_COMPARATOR|Complete Decongestive Therapy and LLLT|22 breast cancer related lymphedema patients will received LLLT added complete decongestive therapy
62611391|NCT05556642||Group 1|Patients with relapsed/ refractory Hepatoblastoma
62611392|NCT05105516|OTHER|Ablation|Comparison between different sites of ablation
62611393|NCT03652584|EXPERIMENTAL|High Protein Diet|Low glycemic index dietary plan with 1.6 g/kg/day of protein for 6 months
62611394|NCT03652584|ACTIVE_COMPARATOR|Control Diet|Low glycemic index dietary plan with 0.8 g/kg/day of protein for 6 months
62611395|NCT03370458|EXPERIMENTAL|Lactobacillus plantarum DR7|"Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum DR7, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 weeks.~Intervention: Dietary Supplement: Lactobacillus plantarum DR7"
62834276|NCT05410184|NO_INTERVENTION|control group|Patients of the control group, will not receive any intervention except for applied routine hospital colonoscopy procedures.
62834277|NCT02846506|EXPERIMENTAL|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 100 milligram (mg) and 1 canagliflozin tablet 50 mg along with 1 Extended Release (XR) tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 XR fixed dose combination \[FDC\] tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg and metformin (XR) 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62834278|NCT02846506|EXPERIMENTAL|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62051694|NCT02417779|ACTIVE_COMPARATOR|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62051695|NCT02417779|EXPERIMENTAL|Second-Degree Burn (repetitive)|"Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62051696|NCT02417779|EXPERIMENTAL|Skin Excision (for Skin Graft) (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size must not be less than 1% of TBSA.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62051697|NCT02417779|EXPERIMENTAL|Chronic Wound (repetitive)|"Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62051698|NCT02417779|ACTIVE_COMPARATOR|Intact Skin (repetitive)|"Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62051699|NCT02417779|EXPERIMENTAL|Hypertrophic burn scar|"Group I (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn scar.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62051700|NCT02417779|EXPERIMENTAL|Hypertrophic burn scar (repetitive)|"Group J (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn scar.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62252653|NCT03687073|EXPERIMENTAL|Cohort 4 PD Study|The effect of I3C, Sil, or I3C + Sil on the pharmacodynamic endpoints listed under the Secondary Objectives in Section 1.2 will be characterized. This PD study will be done concurrently with the multi-dose PK study. Subjects will take the assigned dose of I3C, Sil, or I3C + Sil for 8 weeks. Nasal epithelium, oral cavity cells, buccal cells, blood, and urine will be collected at the time points described in the study calendar in Section 4.0.
62252654|NCT03679611|EXPERIMENTAL|Interventional Arm|Interventional Arm will receive sugammadex sodium 2 mg/kg actual body weight, At the end of surgery Sugammadex will be administered when the TOF reveals at least 2 responses
62834279|NCT02846506|EXPERIMENTAL|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62252655|NCT03679611|ACTIVE_COMPARATOR|Standard drug Arm|standard drug Arm will receive neostigmine 2.5 mg and glycopyrrolate 0.4 mg, At the end of surgery neostigmine and glycopyrrolate will be administered when the TOF reveals at least 2 responses
62252656|NCT06472154|EXPERIMENTAL|experimental group|with Chinese five elements music based on midnight-noon ebb-flow theory
62834280|NCT02846506|EXPERIMENTAL|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62252657|NCT06472154|PLACEBO_COMPARATOR|control group|with Chinese five elements music
62252658|NCT01775332|EXPERIMENTAL|Educational Intervention|Educational Intervention - Access to educational materials provided (i.e. website, videos, brochure)
62252659|NCT01775332|NO_INTERVENTION|No Intervention/Use of Own Resources|No educational materials are provided to participants, but they can use their own resources
62611396|NCT03370458|PLACEBO_COMPARATOR|Placebo|"Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks.~Intervention: Dietary Supplement: Placebo"
62834281|NCT02538224|ACTIVE_COMPARATOR|experimental(case): group A|Group A: 2.5%ketoprofen gel + 3 % doxycycline gel which(0.05cc,mixed gel) be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months .
62252660|NCT04442971|EXPERIMENTAL|Music Stimulation|Patients preferred music is presented via headphones.
62252661|NCT04442971|ACTIVE_COMPARATOR|Alternative Auditory Stimulation|An audio book is presented via headphones.
62252662|NCT04442971|SHAM_COMPARATOR|No Auditory Stimulation|Silence is presented via headphones.
62442045|NCT05423756|ACTIVE_COMPARATOR|Arm 2: INSPIRE Stewardship Bundle|Use of computerized physician order entry (CPOE) smart prompts, clinician feedback, and activities to support CPOE adoption (including education and alignment of CPOE workflows) to guide empiric choice of antibiotics for skin/soft tissue infection in the first 3 days of hospitalization.
62834282|NCT02538224|SHAM_COMPARATOR|control: group B|Group B: 2.5%ketoprofen gel which (0.05cc,gel)be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months .
62834283|NCT04859738|EXPERIMENTAL|Experiment I Group (Lidocaine Spray)|Lidocaine Spray was applied to Experiment I group before peripheral intravenous catheter application.
62051701|NCT02417779|EXPERIMENTAL|Flap|"Group K (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62051702|NCT02417779|EXPERIMENTAL|Flap (repetitive)|"Group L (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62051703|NCT05255432||Group A|Selection of tasks
62834284|NCT04859738|EXPERIMENTAL|Experiment II Group (Benzokain Sprey)|Benzokain Sprey was applied to Experiment II group before peripheral intravenous catheter application.
62051704|NCT05255432||Group B|Selection of tasks
62051705|NCT01035164|EXPERIMENTAL|Arm 1|
62051706|NCT01035164|EXPERIMENTAL|Arm 2|
62051707|NCT01035164|EXPERIMENTAL|Arm 3|
62051708|NCT04780373||Development cohort|
62051709|NCT04780373||Validation cohort|
62051710|NCT02055157|EXPERIMENTAL|Cohort 1|Cohort 1: 2.5 ug/kg
62051711|NCT02055157|EXPERIMENTAL|Cohort 2|Cohort 2: 7.5 ug/kg,
62051712|NCT02055157|EXPERIMENTAL|Cohort 3|Cohort 3: 15 ug/Kg
62252663|NCT01863875||Childhood cochlear implant recipients|The sample includes all childhood cochlear implant (CI) recipients at Oslo University Hospital in Norway from 1988-2012. The participant must have at least one year of CI-user time. Possible sample size is 530 children. The age span is from 1 to 50 years.
62252664|NCT01863875||Normal hearing people|Reference group: A group of normal hearing people matching the target group on gender and age.
62252665|NCT00243386|ACTIVE_COMPARATOR|1|Standard prophylaxis
62834285|NCT04859738|PLACEBO_COMPARATOR|Placebo Group|Alcohol was administered to the placebo group prior to peripheral intravenous catheter application.
62834286|NCT04273737|EXPERIMENTAL|Amantadine|Daily regimen of amantadine hydrochloride tablets for 6 weeks: dosing of 5mg/kg divided by two daily doses (max daily dose of 300 mg)
62834287|NCT04324411|EXPERIMENTAL|treatment group|combined sirolimus(serum concentration to be 4-10ng/ml) and ATRA (20mg bid) for at least 6 months
62834288|NCT04627402|EXPERIMENTAL|Injection combo agents|Intravitreous injection of triamcinolone acetonide (TA) and conbercept.
62834289|NCT04627402|ACTIVE_COMPARATOR|Injection single agent|Intravitreous injection of conbercept only.
62834290|NCT01293734|EXPERIMENTAL|cold type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in cold type
62834291|NCT01293734|EXPERIMENTAL|heat type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in heat type.
62051713|NCT02055157|EXPERIMENTAL|Cohort 4|Cohort 4: 30 ug/kg
62051714|NCT00002558|EXPERIMENTAL|chemotherapy administered with G-CSF and PBSC support|The design of this trial is a phase I/II trial of sequential accelerated chemotherapy cycles with taxol/ifosfamide and carboplatin/etoposide administered with G-CSF and PBSC support.
62051715|NCT03920228|EXPERIMENTAL|Open label period|
62051716|NCT03920228|PLACEBO_COMPARATOR|Randomized period - Dosing A|
62051717|NCT03920228|EXPERIMENTAL|Randomized period - Dosing B|
62051718|NCT03920228|EXPERIMENTAL|Randomized period - Dosing C|
62051719|NCT04417686|EXPERIMENTAL|patient|
62051720|NCT00956566|ACTIVE_COMPARATOR|low fat hypocaloric diet|
62051721|NCT00956566|ACTIVE_COMPARATOR|Low carbohydrate hypocaloric diet|
62051722|NCT04706702|EXPERIMENTAL|Tele-EF|Tele-EnhanceFitness
62051723|NCT05518656|EXPERIMENTAL|Online emotion regulation training version 1|
62051724|NCT05518656|ACTIVE_COMPARATOR|Online emotion regulation training version 2|
62051725|NCT04352478||Elder|elderly (≥60 years old).
62051726|NCT04352478||Young|young (\<60 years old)
62051727|NCT05527366|EXPERIMENTAL|Control Group|Conservative treatment
62051728|NCT05527366|EXPERIMENTAL|Vagus Stimulation Group|Vagus Stimulation Group
62051729|NCT03252080|ACTIVE_COMPARATOR|Education (Group A)|short-intensive education for one month
62051730|NCT03252080|EXPERIMENTAL|Education & holistic management(Group B)|short-intensive education for one month followed with holistic management for 6 months
62051731|NCT02472210|PLACEBO_COMPARATOR|Placebo|Saline IM Injection
62051732|NCT02472210|ACTIVE_COMPARATOR|Onabotulinum Toxin A|IM Injection
62051733|NCT00867438|PLACEBO_COMPARATOR|1|
62051734|NCT00867438|EXPERIMENTAL|2|
62051735|NCT06387290|EXPERIMENTAL|Mindfulness Oriented Recovery Enhancement + Patient-centered chronic pain management visits|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks, in addition to patient-centered chronic pain management visits led by their primary care provider.
62051736|NCT06387290|ACTIVE_COMPARATOR|Patient-centered chronic pain management visits|Participants will attend patient-centered chronic pain management visits led by their primary care provider.
62051737|NCT03058341|SHAM_COMPARATOR|Group S|Patients will be anaesthetized by inhalational anaesthesia using sevoflurane.
62252666|NCT00243386|EXPERIMENTAL|2|PK-driven prophylaxis
62252667|NCT00771823|ACTIVE_COMPARATOR|2|
62252668|NCT00771823|ACTIVE_COMPARATOR|1|"* Maraviroc 300 mg twice daily for the first 14 days of the study.~* Placebo twice daily for the last 14 days of the study"
62252669|NCT05161533|EXPERIMENTAL|Treatment (durvalumab, chemotherapy, radiation therapy)|"INDUCTION: Patients receive standard of care chemotherapy consisting of carboplatin or cisplatin and etoposide. Patients also receive durvalumab IV on day 1 of each cycle. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive durvalumab IV on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning cycle 5 or 6 of durvalumab, patients undergo hypofractionated radiation therapy."
62252670|NCT01177683|EXPERIMENTAL|Arm 1|Bendamustine in combination with bortezomib and pegylated liposomal doxorubicin.
62834292|NCT01293734|EXPERIMENTAL|Asthenia type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in Asthenia type.
62442046|NCT04237571|EXPERIMENTAL|CANE Adult Participants|This sample population consists of an active intervention group of prior Tanglewood to Table walking program adult participants.
62051738|NCT03058341|EXPERIMENTAL|Group P|Patients will be anaesthetized using total intravenous propofol.
62051739|NCT04023071|EXPERIMENTAL|FT516 Monotherapy|FT516 monotherapy in adult subjects with r/r AML.
62834293|NCT01293734|ACTIVE_COMPARATOR|Western medicine control group|
62834294|NCT01447459|EXPERIMENTAL|Reinforced Education|"The caregivers of the subjects enrolled in this group will be administered two survey instruments at enrollment (t0), and again via telephone at 2 weeks (t1), 1 months (t2), and 3 months (t3) after enrollment.~This group will also receive reinforced asthma education via telephone at 2 weeks, 1 month, and 3 months after enrollment."
62051740|NCT04023071|EXPERIMENTAL|FT516 in Combination with Monoclonal Antibodies|FT516 in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
62252671|NCT01483716|NO_INTERVENTION|Control|NIV alone
62834295|NCT01447459|NO_INTERVENTION|No Reinforced Education|"The caregivers of the subjects enrolled in this group will be administered two survey instruments at enrollment (t0), and again via telephone at 2 weeks (t1), 1 month (t2), and 3 months (t3) after enrollment.~This group will not receive reinforcing of the asthma education at 2 weeks, 1 month, and 3 months after enrollment."
62252672|NCT01483716|EXPERIMENTAL|Intervention|Rehabilitation arm
62442047|NCT00987987|EXPERIMENTAL|1|1
62442048|NCT05628623|ACTIVE_COMPARATOR|Arm A: Cytarabine|"Patients will participate for 2 cycles. Each cycle is 28 days.~For Core Binding Factor (CBF) leukemia patients: Cytarabine 3000 mg/m2 IV twice daily (BID), 12 hours apart x 6 doses either on Days 1, 3, and 5 OR Days 1, 2, and 3 (per institutional preference)~For non-Core Binding Factor (CBF) leukemia patients: Cytarabine 1500 mg/m2 IV twice daily (BID), 12 hours apart x 6 either on Days 1, 3, and 5 OR Days 1, 2, and 3 (per institutional preference)"
62834296|NCT05642052|SHAM_COMPARATOR|10 days control diet|Participants stay on their regular diet while glucose is continuously monitored, heart rate and number of steps is measured for 10 days.
62252673|NCT00888420||Medical Management|Patient satisfaction under current operational conditions
62252674|NCT00888420||Interventional Management|Patient satisfaction under the PSDA (Plan, do, study, act) performance improvement measures
62252675|NCT00626704|EXPERIMENTAL|Arm 1|AMG 655 + Doxorubicin
62252676|NCT00626704|PLACEBO_COMPARATOR|Arm 2|Placebo + Doxorubicin
62252677|NCT00922480|ACTIVE_COMPARATOR|2|Losartan group
62442049|NCT05628623|EXPERIMENTAL|Arm B: Cytarabine + Venetoclax|"Patients will participate for 2 cycles. Each cycle is 28 days.~For Core Binding Factor (CBF) leukemia patients: Cytarabine 3000 mg/m2 IV twice daily (BID), 12 hours apart x 6 doses either on Days 1, 3, and 5 OR Days 1, 2, and 3 (per institutional preference) followed by Venetoclax 100 mg daily Day 1 through Day 8~For non-Core Binding Factor (CBF) leukemia patients: Cytarabine 1500 mg/m2 IV twice daily (BID), 12 hours apart x 6 either on Days 1, 3, and 5 OR Days 1, 2, and 3 (per institutional preference) followed by Venetoclax 100 mg daily Day 1 through Day 8"
62442050|NCT05628623|EXPERIMENTAL|Arm C: Daunorubicin + Cytarabine Liposome+ Venetoclax|"Patients will participate for 2 cycles. Each cycle is 28 days.~Daunorubicin 29 mg/m2/Cytarabine 65 mg/m2 liposome IV on Days 1 and 3 with Venetoclax 400 mg orally once daily on Days 1-14"
62442051|NCT05628623|EXPERIMENTAL|Arm D: Azacitidine + Venetoclax|"Patients will participate for 2 cycles. Each cycle is 28 days.~Azacitidine 75 mg/m2 IV/SC on Days 1-7 OR Days 1-5 and Days 8-9 (per institutional preference) with Venetoclax 400 mg orally once daily on Days 1-28"
62442052|NCT00352079|ACTIVE_COMPARATOR|Intravesicle BCG|"Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months postrandomization (cycles 2 - 8)"
62834297|NCT05642052|ACTIVE_COMPARATOR|10 days low carb diet|Participants will eat a low carb diet while glucose is continuously monitored, heart rate and number of steps is measured for 10 days.
62834298|NCT00926861||Dry AMD|male or female persons aged over 50 years with dry age-related macular degeneration
62834299|NCT04583241||BJI group|"Patients with an BJI on material (prosthesis or other implant) infected by Staphylococcus aureus\* Patients are follow-up during two years after surgery.~\*Diagnosis of staphylococcus aureus monoinfection realized a posteriori after surgery on bacteriological sample"
62834300|NCT04583241||Control Group With material|"Patients with mechanical problems on implanted equipment (control cohort), without infection\* Patient of this group are follow-up until surgery.~\*Diagnosis of staphylococcus aureus monoinfection realized a posteriori after surgery on bacteriological sample"
62834301|NCT04583241||Group osteomyelitis|"Patients with chronic osteomyelitis\* Patient of this group are follow-up until surgery.~\*Diagnosis of staphylococcus aureus monoinfection realized a posteriori after surgery on bacteriological sample"
62051741|NCT04023071|EXPERIMENTAL|FT516 in Combination with Monoclonal Antibodies on an Extended-Dosing Schedule|FT516 on an extended-dosing schedule in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
62442053|NCT00352079|ACTIVE_COMPARATOR|Iressa and Intravesicle BCG|"Intravesical BCG:~Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)~Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)"
62834302|NCT04583241||Control Group with cruciate ligament surgery|Patients having cruciate ligament surgery Patient of this group are follow-up until surgery.
62252678|NCT00922480|ACTIVE_COMPARATOR|1|Fimasartan 60mg, 120mg
62834303|NCT04263155|EXPERIMENTAL|Experimental: The Body Project for high school young women|The 4-hour Body Project workshop delivered by trained peer leaders
62834304|NCT04263155|NO_INTERVENTION|Control|The business-as-usual comparison group does not participate in the Body Project but may engage in any other programs or services they normally would
62834305|NCT01809340|EXPERIMENTAL|Minocycline|Following a 12-day open-label treatment phase (involving ketamine and minocycline), responders may receive oral minocycline twice daily for up to 6 weeks in a blinded manner. In addition, non-responders may receive oral minocycline twice daily for up to 6 weeks in an open-label manner.
62834306|NCT01809340|PLACEBO_COMPARATOR|Placebo|Following a 12-day open-label treatment phase (involving ketamine and minocycline), responders may receive placebo twice daily for up to 6 weeks in a blinded manner
62834307|NCT01809340|EXPERIMENTAL|Ketamine and Minocycline|All patients will receive 6 IV infusions of ketamine and oral minocycline twice daily during a 12-day open-label treatment phase
62834308|NCT06371781|EXPERIMENTAL|Serum Netrin-4, Resistin and Sfrp-5 level measurement|In this study, 5 ml of whole blood will be collected from the study group into a biochemistry tube and centrifuged, and the levels of Netrin-4, Resistin and Sfrp-5 in the separated serum will be measured with an ELISA kit.
62834309|NCT06371781|NO_INTERVENTION|diagnosis of the study group|Individuals who gained excessive weight during pregnancy will be diagnosed as a patient group by evaluating their pre- and post-pregnancy height, weight and BMI values. Those with normal height, weight and BMI values before and after pregnancy will be included in the control group.
62834310|NCT00209612|EXPERIMENTAL|1|Paclitaxel+Irinotecan
62834311|NCT02850913|ACTIVE_COMPARATOR|Doxycycline|"* 115 participants will be randomized to oral Doxycycline 100 mg daily for six weeks.~* Each capsule contains doxycycline hyclate equivalent to 100 mg of doxycycline base.~* Treatment will be initiated in hospital but will be continued at home.~* Scheduled study clinic and home visits will be conducted at 6, 12, 24 months and at 2, 4 and 6 weeks respectively for adherence monitoring and assessment of safety."
62834312|NCT02850913|PLACEBO_COMPARATOR|Placebo|"* 115 participants will be randomized to the placebo arm for matching capsules containing no active ingredients daily for six weeks.~* Placebo will be initiated in hospital but will be continued at home.~* Scheduled study clinic and home visits will be conducted at 6, 12, 24 months and at 2, 4 and 6 weeks respectively for adherence monitoring and assessment of safety."
62834313|NCT01957995|EXPERIMENTAL|Arm I (lowest dose NDLS)|Patients receive lowest dose nanosomal docetaxel lipid suspension IV over 1 hour.
62834314|NCT01957995|EXPERIMENTAL|Arm II (low dose NDLS)|Patients receive low dose nanosomal docetaxel lipid suspension IV over 1 hour.
62834315|NCT01957995|EXPERIMENTAL|Arm III (high dose NDLS)|Patients receive high dose nanosomal docetaxel lipid suspension IV over 1 hour.
62834316|NCT01957995|EXPERIMENTAL|Arm IV (highest dose NDLS)|Patients receive highest dose nanosomal docetaxel lipid suspension IV over 1 hour.
62442054|NCT05024461|EXPERIMENTAL|Patient with an indication for a COVID19 test|The persons included will be those who have an indication for a COVID 19 test and who present themselves at the Cayenne hospital and during the screening missions organised by the Red Cross and Médecin du Monde during the COVID 19 epidemic in the territory
62442055|NCT02473328|EXPERIMENTAL|non comparative open study|"In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4), switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.~The administration will be done once a day orally for 48 weeks."
62611397|NCT03988972|EXPERIMENTAL|diathermy group|"Diathermy incisions will be carried out using monopolar blade pen electrode, set on cutting mode and delivering a 35 continuous current. Electrosurgical cutting was performed without pressure or mechanical displacement.~'Bleeders' will be controlled by using diathermy, on coagulating mode, and will be applied to a hemostat on the vessels"
62834317|NCT00843700|EXPERIMENTAL|Interpersonal Psychotherapy|Interpersonal Psychotherapy, 16 individual sessions within 32 weeks
62834318|NCT00843700|ACTIVE_COMPARATOR|Individual Psychotherapy|Individual Psychotherapy, 16 individual sessions within 32 weeks
62834319|NCT03690297|EXPERIMENTAL|LCI|Linked Color Imaging
62834320|NCT03690297|ACTIVE_COMPARATOR|WL|White Light
62252679|NCT03040791|EXPERIMENTAL|Nivolumab|All patients will receive Nivolumab 240 mg every 14 days until progression or unacceptable toxicity
62252680|NCT04354545||Group 1|Xiidra (Lifitegrast ophthalmic solution) 5% applied to both eye (OU) for 12 weeks
62834321|NCT04204525||Patients with chronic whiplash associated disorders|Male or female, aged between 18 and 65 years. Inclusion: 1) whiplash trauma (at least three months old) and pain since at least 3 months, self-reported mild to severe pain-related disability (score of 5/50 or more on the neck disability index), classified as wad II or wad III on the modified Quebec task force scale; 2) not undertaking exercise 1 day before the experiment; 3) not starting new treatments or medication and continuing their usual care 6 weeks prior to and during study participation (to obtain a steady state); 4) native dutch speaker and 5) refraining from non-opioid analgesics 48h before the assessments, and refraining from caffeine, alcohol and nicotine 24h before the assessments
62834322|NCT04204525||Healthy controls|Male or female, aged between 18 and 65 years. Inclusion: 1) no history of whiplash trauma, no pain with a mean pain intensity of more than 2/10 on the visual analogue scale for \> 8 consecutive days in the preceding year in the neck-shoulder-arm region 2) painfree at the day of testing 3) native dutch speaker and 4) refraining from non-opioid analgesics 48h before the assessments, and refraining from caffeine, alcohol and nicotine 24h before the assessments.
62834323|NCT04570137|EXPERIMENTAL|1|This arm received the arabinoxylan/ß-glucan mix first.
62252681|NCT00282295|EXPERIMENTAL|Boostrix + Menactra Group|Subjects, 11 through 18 years of age, received a booster dose of Boostrix® co-administered with Menactra™ at Day 0. The Boostrix® vaccine was administered intramuscularly into the left deltoid region and Menactra™ vaccine was administered intramuscularly into the right deltoid region.
62252682|NCT00282295|EXPERIMENTAL|Boostrix-Menactra Group|Subjects, 11 through 18 years of age, received one dose of Boostrix® vaccine at Day 0, followed by one dose of Menactra™ vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.
62252683|NCT00282295|EXPERIMENTAL|Menactra-Boostrix Group|Subjects, 11 through 18 years of age, received one dose of Menactra™ vaccine at Day 0 followed by one dose of Boostrix® vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.
62252684|NCT02964026||Pulmonary artery catheter (PAC)|Patients received a PAC for monitoring purposes
62252685|NCT02964026||No pulmonary artery catheter (PAC)|Patients did not receive a PAC for monitoring purposes
62834324|NCT04570137|EXPERIMENTAL|2|This arm received the inulin/oligofructose mix first.
62252686|NCT05106673|EXPERIMENTAL|clinical centers that receive implementation support|These clinical centers receive support during the implementation of the CHIMPS-intervention. There are three different implementation interventions.
62252687|NCT05106673|EXPERIMENTAL|No Intervention: Treatment as usual|These clinical centers will be the control group and will not get a specific implementation support during the implementation of CHIMPS.
62252688|NCT06417359|ACTIVE_COMPARATOR|eTEP Mesh Fixation Group|In 30 patients; Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides. During the surgery, the mesh will be fixed to three absorbable tacker the Cooper ligament, süpermedially and laterally. Patients whose pain scores (VAS score) are measured on the first postoperative day and who are suitable for discharge will be discharged after a pelvis x-ray is taken. One month after the surgery and 6 months later, patients will be called to the outpatient clinic and examined, their pain scores will be measured (VAS score) and pelvic radiographs will be taken. The movement of the clips marked on the patch will be compared with previous radiographs in cm.
62834325|NCT01598506|EXPERIMENTAL|Hydromorphone|Laboring patients receive ED50 of hydromorphone one time intrathecally
62834326|NCT02088476||Candidemia|Candidemia is defined as the presence of growth of any candida species in at least one blood culture obtained by either peripheral venipuncture or through an indwelling central venous catheter.
62252689|NCT06417359|EXPERIMENTAL|eTEP No Mesh Fixation Group|In 30 patients; Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides. During the surgery, the mesh will not be fixed to the Cooper ligament. Patients whose pain scores (VAS score) are measured on the first postoperative day and who are suitable for discharge will be discharged after a pelvis x-ray is taken. One month after the surgery and 6 months later, patients will be called to the outpatient clinic and examined, their pain scores will be measured (VAS score) and pelvic radiographs will be taken. The movement of the clips marked on the patch will be compared with previous radiographs in cm.
62252690|NCT02319291||Participants|P.F.C. Sigma PS150 RP Total Knee System
62252691|NCT03846570|ACTIVE_COMPARATOR|Formoterol-beclomethasone|Formoterol (fumarate dehydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler.
62611398|NCT03988972|ACTIVE_COMPARATOR|scalpel group|Incisions made by the scalpel will be done by the traditional method, with proper hemostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeders.
62834327|NCT03475095|EXPERIMENTAL|LDH patients|"ribs and bones Tuina therapy According to the diagnostic criteria ofvertebral dislocation,determine the position,degree and direction of the dislocation,assess the activity of the affected vertebrae.Treated with combining Tuina of muscle-loosing and bone-setting such as reinforcing ribs，kneading and plucking method,20 min every treatment,twice a week for a total time of 4 weeks."
62834328|NCT06339801||GERD group|"Patients \>18 years presenting symptoms of GERD that have not adequately responded to proton pump inhibitors (PPIs) treatment after 8 weeks and have undergone upper gastrointestinal endoscopy (UGIE) without erosive esophagitis.~Patients with a broad spectrum of severity, assessed through the GERDq score, will be included"
62834329|NCT03978546|EXPERIMENTAL|Non-Glaucoma Patient Arm|All participants will complete the same assessments
62834330|NCT03978546|EXPERIMENTAL|Glaucoma Patient Arm|All participants will complete the same assessments
62834331|NCT01100801|EXPERIMENTAL|TS-1 with cisplatin|"Chemotherapy injection (60mg/m2 cisplatin) will be given on day 1.~14 days of Oral TS-1 (40mg/m²) will be prescribed. Subjects will take it after breakfast and evening meal on Day 1-14 of a 3-weekly treatment cycle. Each cycle is about 21 days."
62252692|NCT03846570|PLACEBO_COMPARATOR|Placebo|Matching placebo (identically package) administered BID
62252693|NCT00415506|EXPERIMENTAL|Scleritis|Subjects with Scleritis
62252694|NCT00415506|EXPERIMENTAL|Orbital Inflammation|Subjects with Orbital Inflammation
62252695|NCT03505047|EXPERIMENTAL|Immediate group:|The Copper Intrauterine device will be inserted within 24 hours of the expulsion of the fetus and placenta or after surgical evacuation for placental remains, and prior to discharge from the facility.
62442056|NCT03074526|ACTIVE_COMPARATOR|4mL amniotic fluid|Amniotic Fluid: 4mL dose of amniotic fluid
62611399|NCT02272933|EXPERIMENTAL|Wireless Body-Worn Sensors|Elderly patients will wear sensors (Smart Slippers and a belt-clip sensor) as they go about their daily life in a geriatric care center.
62611400|NCT04192656|EXPERIMENTAL|PAP plus medication|patients treated by both PAP and medication
62611401|NCT04192656|ACTIVE_COMPARATOR|medication|patients treated by medication only
62834332|NCT01100801|EXPERIMENTAL|TS-1 with oxaliplatin|"Chemotherapy injection (100mg/m2 oxaliplatin) will be given on day 1.~14 days of Oral TS-1 (40mg/m²) will be prescribed. Subjects will take it after breakfast and evening meal on Day 1-14 of a 3-weekly treatment cycle. Each cycle is about 21 days."
62834333|NCT01216826|EXPERIMENTAL|Everolimus|
62051742|NCT04023071|EXPERIMENTAL|FT516 in Combination with Monoclonal Antibodies following Bendamustine Conditioning|Bendamustine conditioning followed by FT516 in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
62051743|NCT02484157|EXPERIMENTAL|Patient|Patients were checked activated coagulation time by both Hemochron Jr and ACT Plus during cardiac surgery with heparin administration.
62051744|NCT05801731|EXPERIMENTAL|Experimental|Low-GI snack, administered at 10.00 and 16.00 during the test days
62051745|NCT05801731|ACTIVE_COMPARATOR|Control|Normal GI snack, administered at 10.00 and 16.00 during the test days
62051746|NCT04858919|OTHER|study group|virgins with genital tract lesion
62051747|NCT02543658|EXPERIMENTAL|Neostigmine|Intramuscular injection of neostigmine on the basis of conventional conservative treatment
62051748|NCT02543658|OTHER|Conservative treatment|Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.
62051749|NCT05655676|EXPERIMENTAL|89Zr-NY008|
62051750|NCT02486289|EXPERIMENTAL|NBMI (Emeramide) 100mg|NBMI oral capsules 100mg administered once daily. Double dummy used for blinding i.e. 2 x 50mg NBMI + 1 x 200mg placebo capsule equals in total 3 capsules administered daily.
62252696|NCT03505047|NO_INTERVENTION|Delayed Group|The Copper Intrauterine device will be inserted at a local community health centre 14-28 days after discharge.
62611402|NCT01651000|ACTIVE_COMPARATOR|CTAP101 30 μg capsules|1 CTAP101 30 μg capsule daily at bedtime for 12 weeks, with a possible increase to 2 CTAP101 30 μg capsules daily at bedtime for study duration, if needed (26 weeks total). Subjects not requiring a dose increase after 12 weeks would receive 1 CTAP101 30 μg capsule and one sugar pill (to CTAP101 30 μg capsule) for weeks 13-26.
62834334|NCT06654206|EXPERIMENTAL|Intervention Group (Therapeutic Strength Exercise Program):|The therapeutic strength exercise program focused on strength exercises, although daily aerobic exercises were also included. The intervention group will participate in a supervised therapeutic strength exercise program twice a week, combined with a physical activity promotion program to be conducted at home three days a week. All supervised strength exercise sessions will be led by a physiotherapist in a physiotherapy clinic with appropriate space for the intervention.
62834335|NCT06654206|ACTIVE_COMPARATOR|Control Group (CG), group without an exercise program|Patients in the control group (CG) will only participate in the physical activity promotion program five days a week. This will be combined with walking for 60 minutes every day of the week.
62834336|NCT01302990|EXPERIMENTAL|5 micrograms H1 VLP|
62834337|NCT01302990|EXPERIMENTAL|13 micrograms H1 VLP|
62834338|NCT01302990|EXPERIMENTAL|28 micrograms H1 VLP|
62834339|NCT01302990|ACTIVE_COMPARATOR|45 micrograms Fluzone|
62834340|NCT01302990|PLACEBO_COMPARATOR|Placebo|
62834341|NCT02019095||Acute Respiratory Failure - Bronchoalveolar lavage|Intensive care unit patients with acute respiratory failure due to ventilator-associated pneumonia or the acute respiratory distress syndrome. Bronchoalveolar lavage (BAL) fluid will be obtained on days 1 and 5 post-enrollment for the determination of biochemical markers, and microbiological studies.
62834342|NCT06387836||POCD group|Patients will be allocated to this group according to the neuropsychological tests when there are at least two Z scales greater than 1.96.
62834343|NCT00446849|EXPERIMENTAL|MMX Mesalamine|
62834344|NCT01764906|EXPERIMENTAL|Novosis|Bongros/rhBMP-2
62834345|NCT01764906|ACTIVE_COMPARATOR|Iliac crest bone graft|Iliac crest bone graft
62834346|NCT06650878|EXPERIMENTAL|Desarda Technique|Patients asigned to this arm will be treated with Desarda Technique
62834347|NCT06650878|ACTIVE_COMPARATOR|Lichtenstein Technique|Patients asigned to this arm will be treated with Lichtenstein Technique
62051751|NCT02486289|EXPERIMENTAL|NBMI (Emeramide) 300mg|NBMI oral capsules 300mg administered once daily. Double dummy used for blinding i.e. 2 x 50mg NBMI + 1 x 200mg NBMI capsule equals in total 3 capsules administered daily.
62051752|NCT02486289|PLACEBO_COMPARATOR|Placebo|Placebo oral capsules administered once daily. Double dummy used for blinding i.e. 2 x 50mg size + 1 x 200mg size placebo capsules equal in total 3 capsules administered daily.
62051753|NCT02741401|ACTIVE_COMPARATOR|Therapy standard|Patients receive usual postoperative care
62051754|NCT02741401|EXPERIMENTAL|Therapy standard + hand-foot massage|Patients receive usual postoperative care and hand-foot massage
62442057|NCT03074526|ACTIVE_COMPARATOR|4mL2x amniotic fluid|Amniotic Fluid: 4mL 2x dose of amniotic fluid
62442058|NCT03074526|PLACEBO_COMPARATOR|4mL Saline Placebo|Normal Saline
62834348|NCT04580979||Patients with ferredoxin reductase deficiency|Male and female patients from age 2 to age 65 with clinically confirmed FDXR mutations. Both living and deceased patients will be included, if eligible. For deceased patients, the patient's medical history records will be reviewed, and an interview of the parent(s) or caregiver(s) will be performed.
62252697|NCT02428712|EXPERIMENTAL|FORE8394|"Group A: Phase 1-Dose Escalation: Adult patients.~Group B: Phase 1-Dose Escalation: Pediatric patients.~Phase 2a-Dose Extension: Adult patients with advanced unresectable solid tumors will be enrolled among two cohorts.~* Cohort 1: Activating BRAF V600 mutations (glioma patients only)~* Cohort 2: Activating BRAF non-V600 mutations~Phase 2a-RP2D Confirmation: Adult patients.~Phase 2a-RP2D Redefinition and Extension:~* Cohort 3: Activating BRAF V600 or activating non-V600 mutation~* Cohort 4: Activating BRAF non-V600 mutations~Phase 2a-RP2D Redefinition:~* Cohort 6A: Advanced activating BRAF-mutated solid tumors~* Cohort 7A: Advanced activating BRAF-mutated solid tumors~* Cohort 8A: Advanced activating BRAF-mutated solid tumors"
62252698|NCT04776473|EXPERIMENTAL|Open (i.e. surgical) treatment|"This includes reduction and internal fixation of the fracture (ORIF) performed using the preferred surgical approach and bone implants of the including centre that could be associated with one or several items among the following:~* physical therapy based on exercises done by the patient himself~* physical therapy performed by a specialized/non-specialized physical therapist~* arch bars / screws / splint use for transient MMF~* arch bars / screws / splint use for passive mobilization of the mandible"
62252699|NCT04776473|OTHER|Closed (i.e. conservative) treatment|"To date, there is no consensus on which procedures should be used in case of conservative treatment, which may vary between centres and, for a same centre, between patients. This includes one or several items among the following:~* physical therapy based on exercises done by the patient himself~* physical therapy performed by a specialized/non-specialized physical therapist~* arch bars / screws / splint use for transient maxillo-mandibular fixation (MMF) (15 days max)~* arch bars / screws / splint use for passive mobilization of the mandible"
62252700|NCT05863975|EXPERIMENTAL|Interferon group|Vaginal placement of human interferon alpha 2b vaginal effervescent capsules, one pill a day daily, 10 days, for a course of treatment, a total of 3 courses
62252701|NCT05863975|EXPERIMENTAL|Promestriene group|promestriene cream vaginal medication, once a day, 1g each time, 10 days, for a course of treatment, a total of 3 courses of treatment
62442059|NCT01749176|EXPERIMENTAL|SMS texting intervention|Behavioral text messages will be sent at random times throughout the week reagarding Healthy nutrition tips, benefits of physical activity, benefits of medication adherence and requests to check blood sugar and send back results.
62834349|NCT03755258|EXPERIMENTAL|GCK 100 mg group|GCK 100 mg+ Placebo 200 mg GCK tablet 100 mg + Placebo tablet 100 mgX2 tablets, once daily for 12 weeks (oral)
62834350|NCT03755258|EXPERIMENTAL|GCK 200 mg group|GCK 200 mg + Placebo 100 mg GCK tablet 100 mg X 2 tablets+ Placebo tablet 100 mg once daily for 12 weeks (oral)
62834351|NCT03755258|EXPERIMENTAL|GCK 300 mg group|GCK tablet 300 mg GCK tablet 100 mgX3 tablets once daily for 12 weeks (oral)
62834352|NCT03755258|PLACEBO_COMPARATOR|Placebo of GCK group|Placebo 300 mg Placebo tablet 100 mgX3 tablets, once daily for 12 weeks (oral)
62834353|NCT03506152||Culture positive|
62834354|NCT03506152||Culture negative|
62834355|NCT04590521|EXPERIMENTAL|Intervention|A standard 3-dose schedule (0, 2 and 6 months) of licensed HPV vaccine (Gardasil®, Merck) will be administered to all participants intramuscularly.
62834356|NCT01055197|EXPERIMENTAL|PCI|Prophylactic Cranial Irradiation (PCI)
62252702|NCT05863975|EXPERIMENTAL|Interferon + promestriene combination group|given one human interferon alpha 2b vaginal effervescent capsule vaginal placement + promestriene cream 1g vaginal medication, once a day, for 10 days, for a course of 1, 3 courses of continuous use.
62834357|NCT01055197|EXPERIMENTAL|PCI + Consolidation RT|Prophylactic Cranial Irradiation (PCI) plus consolidative radiation therapy (RT) to locoregional and residual metastatic disease
62834358|NCT00751517|ACTIVE_COMPARATOR|A|Cyclophosphamide
62252703|NCT05311670||Single-arm|Participants will be assigned to the single-arm involving monitoring of their symptoms.
62252704|NCT03223870||Oximeters|Comparison of respiratory rates with other devices in normal subjects as observational with other pulse oximeters. No treatment of interventions will be performed.
62252705|NCT04275505|ACTIVE_COMPARATOR|treatment group|the participants were given 10 sessions of shortwave diathermy treatment and elbow splint and told to avoid symptom provoking activities
62442060|NCT01749176|PLACEBO_COMPARATOR|Control-Usual Care|Participants will continue to receive their usual care in their primary care home. They will return at months 3 and 6 to conduct behavioral and laboratory assessments to compare results with the intervention group.
62442061|NCT01056757|EXPERIMENTAL|Ribavirin|
62611403|NCT01651000|PLACEBO_COMPARATOR|Sugar pill to CTAP101 30 μg capsule|1 sugar pill to CTAP101 30 μg capsule daily at bedtime for 12 weeks, with an increase to 2 sugar pills to CTAP101 30 μg capsules daily at bedtime for weeks 13-26.
62611404|NCT04387799||Negative PCR Covid associated Pneumonia|Patients with pneumonia who test negative to RT-PCR
62834359|NCT00751517|EXPERIMENTAL|B|Methotrexate
62834360|NCT01939613||Parkland group|Extensive burn patients are resuscitated with Parkland formula.In the first 24h of resuscitation,crystalloids were infused as the main fluid.
62834361|NCT01939613||TMMU group|Extensive burn patients are resuscitated with Third Military Medical University (TMMU) formula as a modified EVANS formula routinely used in China. In the first 24h of resuscitation, crystalloids and colloids were infused together.
62834362|NCT05248152|PLACEBO_COMPARATOR|Placebo|Patients will receive a placebo capsule in the hour before surgery and two intravenous doses of saline before surgical incision.
62834363|NCT05248152|EXPERIMENTAL|Pregabalin|Patients will receive pregabalin 150 mg in the hour before surgery and two intravenous doses of saline before surgical incision.
62834364|NCT05248152|EXPERIMENTAL|Paracetamol and Ibuprofen|Patients will receive a placebo capsule in the hour before surgery and an intravenous dose of paracetamol 1 g and ibuprofen 400 mg before surgical incision.
62834365|NCT06490354|EXPERIMENTAL|Lightback group|Use of the lightback device to relax the gluteal musculature.
62051755|NCT03353064|ACTIVE_COMPARATOR|Vivify + EMS|This arm will have the Telemedicine kits and get scheduled EMS home visits. The subjects will complete daily biometrics / surveys / care plans through the telemedicine kit, as specified in the activity schedule Apart from the tablet device, EMS home visits will be scheduled on Day 7, Day 21 and Day 42 from discharge. During these home visits, the EM personnel will perform a check of the NIV/NIPPV device. They are able to adjust pressures according to your Pulmonologist / Sleep doctor's prescription, and troubleshoot any issues with the mask, the humidifier, etc. They will also measure End-tidal CO2 via nasal cannula.
62051756|NCT03353064|ACTIVE_COMPARATOR|Vivify Only|"This group will receive the telemedicine tablet and kit, with the same protocol as defined above.~No EMS home visits will be set up"
62834366|NCT06490354|ACTIVE_COMPARATOR|Conventional group|Conventional treatment to relax the gluteal musculature and prevent hamstring injuries.
62051757|NCT02130934||childhood cancer survivors|Cardiac 3D MRI
62051758|NCT02133599|OTHER|Iohexol|All patients will receive two Iohexol clearance tests, 5 mL each time before cycle 1 and 4 of HDMTX
62051759|NCT00715650|EXPERIMENTAL|Arm 1|This counseling consists of four sessions each approximately 60 minutes each. The four sessions are organized as follows: a) Orientation to Benefits Counseling: Your Benefits and Your Goals b) Work and Claims c) Financial Review: Implications of Your Work Plan and d) Your Plans After the Benefits Notice. The first session focuses on the disability application process as a non-confrontational way to explore attitudes towards work. The second session more directly addresses the claimant's attitudes about work and beliefs about whether work will prevent receipt of disability benefits. The third session addresses the same issue as the second, ambivalence about work and disability, from a financial perspective. The fourth session occurs after the disability determination has been made, and it is possible the veteran may feel differently about a benefit that has been awarded.
62252706|NCT04275505|PLACEBO_COMPARATOR|control group|the participants were given 10 sessions of placebo shortwave diathermy treatment (the device was not turned on), elbow splint and told to avoid symtpom provoking activities
62252707|NCT03593850|EXPERIMENTAL|Music group|"Patients in this arm listened through headphones to a song of 29 minutes and 32 seconds duration. The song was composed entirely by investigator Juan Martin-Saavedra and registered to copyright and authorship regulatory entities from Colombia under the name Occasio adolore (Musical piece No. 5-559-355 and Phonogram No. 12-105-295 of Colombia's Copyright authorship agency). Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Silence group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise."
62252708|NCT03593850|ACTIVE_COMPARATOR|Silence group|Patients on the silence group listened to a 29 minute and 32 second audio file that produced no sounds with headphones on. Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Music group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise.
62834367|NCT03466814||JIA participants|
62834368|NCT03533504||Variability in individual PK|Patients with hemophilia A or B, of any severity, who are registered on the web-accessible population pharmacokinetics- hemophilia (WAPPS-Hemo) database, and for whom infusion and/or PK data is available.
62834369|NCT06421532|EXPERIMENTAL|Low-sodium oxybate (LXB)|Deepening sleep
62834370|NCT06421532|EXPERIMENTAL|Non-invasive vagus nerve stimulation (nVNS)|Inhibiting cortical spreading depolarisations
62834371|NCT06421532|EXPERIMENTAL|Combination of both|Deepening sleep and inhibiting cortical spreading depolarisations
62834372|NCT05281302|NO_INTERVENTION|Control patients|Patient receiving no additional treatment to conventional occupational therapy sessions
62834373|NCT05281302|EXPERIMENTAL|left-NMV|"Patient will be equipped with vibratory stimulators during conventional occupational therapy sessions.~Only the left-side NMV vibrator will be activated."
62834374|NCT05281302|SHAM_COMPARATOR|left-NMV + sham-tDCS|"Patient will be equipped with vibratory stimulators and with electrodes form sham-tDCS during conventional occupational therapy sessions.~Only the left-side NMV vibrator will be activated."
62834375|NCT05281302|EXPERIMENTAL|left-NMV + anodal-tDCS|"Patient will be equipped with vibratory stimulators and with electrodes for tDCS during conventional occupational therapy sessions.~Only the left-side NMV vibrator will be activated."
62252709|NCT01063387|NO_INTERVENTION|Sema4c positive +Common iliac lymph nodes control|"Sema4c Positive \& Radical hysterectomy +Pelvic Radiotherapy "
62252710|NCT01063387|ACTIVE_COMPARATOR|Sema4c positive +Common iliac lymph nodes Experimental|"Sema4c Positive \& Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation) "
62252711|NCT01063387|NO_INTERVENTION|Sema4c Positive + PAN positive control arm|"Sema4c Positive \&  Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation) "
62611405|NCT04387799||Positive PCR Covid associated Pneumonia|Patients with pneumonia from Covid 19
62834376|NCT02628873|EXPERIMENTAL|Arm 1 (HyCoSy followed by HSG)|HyCoSy procedure followed by HSG procedure
62834377|NCT02628873|EXPERIMENTAL|Arm 2 (HSG followed by HyCoSy)|HSG procedure followed by HyCoSy procedure
62834378|NCT02572908|ACTIVE_COMPARATOR|Fermented wheat bread for 7 days|Long sourdough fermentation
62834379|NCT02572908|PLACEBO_COMPARATOR|Yeast baked wheat bread for 7 days|Regular toast bread
62834380|NCT02572908|OTHER|Run-in|Gluten-free diet for 7 days before entering either bread period
62834381|NCT00404144|EXPERIMENTAL|Drug Eluting Balloon|treatment of small vessel with drug eluting balloon
62834382|NCT01464437|ACTIVE_COMPARATOR|AMG 151 - Arm 1|AMG 151 - Arm 1
62834383|NCT01464437|ACTIVE_COMPARATOR|AMG 151 - Arm 2|AMG 151 - Arm 2
62834384|NCT01464437|ACTIVE_COMPARATOR|AMG 151 - Arm 3|AMG 151 - Arm 3
62834385|NCT01464437|ACTIVE_COMPARATOR|AMG 151 - Arm 4|AMG 151 - Arm 4
62834386|NCT01464437|ACTIVE_COMPARATOR|AMG 151 - Arm 5|AMG 151 - Arm 5
62834387|NCT01464437|ACTIVE_COMPARATOR|AMG 151 - Arm 6|AMG 151 - Arm 6
62834388|NCT01464437|PLACEBO_COMPARATOR|Placebo Arm|AMG 151 Placebo Arm
62611406|NCT03277612||C-Section|Infants delivered by C-section
62834389|NCT02740452|OTHER|Ligamys technique|Ligamys technique (device) or standard technique
62834390|NCT02740452|OTHER|standard technique|Ligamys technique (device) or standard technique
62834391|NCT05517252|EXPERIMENTAL|Tele-Yoga Group|OSAS patients in the Tele-Yoga group will be taken to group-based Hathastyle Tele-Yoga sessions of 60 minutes three times a week for 12 weeks, simultaneously in groups of 4-5 people, in an internet-based telerehabilitation environment.
62834392|NCT05517252|EXPERIMENTAL|Control Group|OSAS patients in the control group will be taught unilateral basal and apical chest expansion exercises in the first session and will be followed as a home program. 3-4 thoracic extension exercises and 1-2 breathing control will be repeated 10 times. The patient will be asked to do the home program four times a day and keep a diary for the home program.
62834393|NCT01453218|NO_INTERVENTION|Basiliximab|Historical comparable cohort treated with Basiliximab 20mg iv administered at 0 and 4th day post-transplant
62834394|NCT01453218|ACTIVE_COMPARATOR|ATeGe-Fresenius|
62834395|NCT00446004|OTHER|A|On an 18-day schedule, Omeprazole (PPI) once daily on days 10 through 16; and Gleevec® once daily on days 1 and 15 (i.e., Gleevec® alone on day 1, and combination of Gleevec® and PPI on day 15).
62834396|NCT00446004|OTHER|B|On an 18-day schedule, Omeprazole (PPI) once daily on days -4 through 1; and Gleevec® once daily on days 1 and 15 (i.e., combination of Gleevec® and PPI on day 1, Gleevec® alone on day 15).
62834397|NCT01392105|ACTIVE_COMPARATOR|Mesenchymal stem cell treatment group|
62834398|NCT01392105|PLACEBO_COMPARATOR|Control group|All patients were required to have successful revascularization of an infarct-related artery on coronary angiography at the time of randomization. All patients received aspirin (300 mg loading dose, then 100 mg daily) and clopidogrel (600 mg loading dose, then 75 mg daily) with optimal medical therapy according to the American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines for treatment of ST-segment elevation myocardial infarction (STEMI)
62834399|NCT01577992|EXPERIMENTAL|Group 1: MSA disease|determination of objective and subjective pain threshold before and after levodopa intake
62834400|NCT01577992|EXPERIMENTAL|Group 2: Parkinson disease|determination of objective and subjective pain threshold before and after levodopa intake
62834401|NCT01577992|OTHER|Group 3: healthy volunteers.|one determination of objective and subjective pain threshold without treatment
62834402|NCT00734500|EXPERIMENTAL|Treatment|Treatment
62834403|NCT03183297|EXPERIMENTAL|JMI-001|JMI-001 is a combination product of naproxen 220mg and fexofenadine 60mg (Dose Level one) then a combination product of naproxen 440mg and fexofenadine 120mg (Dose Level Two).
62834404|NCT03183297|ACTIVE_COMPARATOR|Naproxen|Naproxen 220mg or 440mg
62834405|NCT03183297|ACTIVE_COMPARATOR|Fexofenadine|fexofenadine 60mg or 120mg
62834406|NCT03183297|PLACEBO_COMPARATOR|Placebo|
62834407|NCT04240496|OTHER|Schizophrenic patients|"* Determination of trough plasma concentration of clozapine (C0)~* Genotyping of CYP1A2 \& CYP2C19 Drug: Leponex (Clozapine) : was started at a dose of 25 mg/j, the dose was gradually increased and was administered in one, two or three divided doses."
62834408|NCT00781703|OTHER|DIAMOND Care Model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the Patient Health Questionnaire-9 (PHQ9), treatment adjustment as indicated, psychiatric consultation, relapse prevention.
62834409|NCT00750438|EXPERIMENTAL|Propionate ester|
62834410|NCT00750438|PLACEBO_COMPARATOR|Fermentable control|
62834411|NCT00750438|PLACEBO_COMPARATOR|Non fermentable control|
62834412|NCT03311243|EXPERIMENTAL|β-Thalassemia major (TM- β)|
62834413|NCT03311243|ACTIVE_COMPARATOR|Systemically healthy controls|
62834414|NCT04708561|EXPERIMENTAL|Brain-injured participants|
62834415|NCT06038604|EXPERIMENTAL|Psychosocial Support Intervention|The psychosocial support intervention includes components such as logistical and practical support and self-care, strategies to manage cognitive changes, as well as strategies for effective communication when coping with glioblastoma.
62834416|NCT03498898|ACTIVE_COMPARATOR|Group A|American Society of Anesthesiologists (ASA) Score 2-3 with chronic use of Beta adrenergic receptor blockers planned to undergo total hip replacement
62834417|NCT03498898|NO_INTERVENTION|Group B|American Society of Anesthesiologists (ASA) Score 2-3 with no chronic use of Beta adrenergic receptor blockers planned to undergo total hip replacement
62834418|NCT03498898|ACTIVE_COMPARATOR|Group C|American Society of Anesthesiologists (ASA) Score 2-3 with chronic use of Beta adrenergic receptor blockers planned to undergo total knee replacement.
62834419|NCT03498898|NO_INTERVENTION|Group D|American Society of Anesthesiologists (ASA) Score 2-3 with no chronic use of Beta adrenergic receptor blockers planned to undergo total knee replacement
62611407|NCT03277612||Vaginal Delivery|Infants delivered by spontaneous vaginal delivery after C-section.
62252712|NCT01063387|EXPERIMENTAL|Sema4c positive+ PAN positive Experimental|Sema4c Positive \& Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation+ supraclavicular lymph nodes irradiation) '
62051760|NCT00715650|ACTIVE_COMPARATOR|Arm 2|This will consist of four-session orientation with the sessions organized as follows: a) overview of VHA services, b) Primary Care c) Pharmacy and laboratory services and d) specialty services. After the description of each service, participants will be invited to discuss which services they plan to utilize. The counselor will provide telephone numbers and directions to the sites at which these services are provided.
62051761|NCT06131580|OTHER|Participant Group/Arm|"Other: osilodrostat~open label, with patients receiving same dose as provided in the parent study"
62051762|NCT01355458|EXPERIMENTAL|CD07805/47 gel|
62051763|NCT01355458|PLACEBO_COMPARATOR|Placebo|
62051764|NCT02192970|EXPERIMENTAL|Bevacizumab|Pars plana vitrectomy will be performed in the typical manner. After laser retinopexy and prior to air-gas exchange, intravitreal bevacizumab will be administered through the trocar. Either perfluoropropane (C3F8) or sulfur hexafluoride (SF6) gas will then be administered for long-term retinal tamponade and the vitrectomy ports closed in the usual manner.
62051765|NCT02192970|NO_INTERVENTION|Chart review|Review records over the past 5 years of patients who underwent vitrectomy for retinal detachment repair to found out the percentage of those who had re-detachment of the retina within 6 months after surgery.
62051766|NCT03911648||Group B;|Patients had 0.5 ml.kg-1 bupivacaine 0.25% caudally, the maximum given volume was 20 ml. N=42
62834420|NCT03054532|EXPERIMENTAL|Durvalumab and lenalidomide|"Open-label use of 2 drugs:~* Durvalumab 1500 mg intravenously on day 1 of a 28-day cycle until progressive disease or intolerance.~* Lenalidomide orally on days 1 through 21 of each 28-day cycle for 6 cycles."
62834421|NCT03288103|EXPERIMENTAL|Growth Hormone Treatment for Participants with ACAN Deficiency|Pre-pubertal children with ACAN deficiency on daily growth hormone (Norditropin) regimen for a 3 year period.
62834422|NCT02650076|EXPERIMENTAL|Healthy|
62834423|NCT04800809||Children and young adults with SCD and stroke|"* Participants with SCD confirmed with hemoglobin electrophoresis or high pressure liquid chromatography (HPLC)~* Age 5 to 26 years old~* Present within three months of stroke event that is diagnosed as a stroke by the local health care provider~* Medical records are available for review for the stroke event that occurred within 3 months"
62834424|NCT04800809||The participants in SPIN and SPRING and SPRINT Trials|The participants enrolled in our previous primary and secondary stroke prevention trials in northern Nigeria; SPIN and SPRING (children with SCD with normal and abnormal TCD measurements; NCT02560935 and NCT01801423), SPRINT (children with SCD and strokes; NCT02675790) Trials for ascertainment of incidences rates of strokes in children and young adults receiving standard care after completion of primary stroke prevention trials. For this purpose, we will enroll these participants to follow their progress after completion of the trials. No intervention is planned, only to follow the participants with and without abnormal TCD measurements and with and without strokes.
62834425|NCT01292629|EXPERIMENTAL|Investigational intraocular lens|iSert 251 intraocular lens
62051767|NCT03911648||Group L;|Patients had 0.5 ml.kg-1 bupivacaine 0.25% with the addition of 3 mg/kg lidocaine 1% caudally, the maximum given volume was 20 ml. N=44
62051768|NCT02522858|PLACEBO_COMPARATOR|Placebo|After fixation of the block level of spinal anesthesia, and just before starting dexmedetomidine, normal saline 0.5mL would be injected intravenously.
62051769|NCT02522858|EXPERIMENTAL|Atropine|After fixation of the block level of spinal anesthesia, and just before starting dexmedetomidine, ,atropine 0.03mg/kg would be injected intravenously.
62252713|NCT00047671|ACTIVE_COMPARATOR|Citalopram|All subjects receive an FDA approved dose of Citalopram
62252714|NCT05316532||Mechanically ventilated ECCO2R group|Adult, mechanically ventilated critically ill patients with respiratory failure and incapacity to sustain lung protective ventilation
62252715|NCT05316532||Awake spontaneously breathing ECCO2R group|Awake, spontaneously breathing critically ill patients suffering from respiratory exhaustion
62252716|NCT06537648|EXPERIMENTAL|Decreasing Alzheimer's Risk Through oNline Choreographed Exercise - Down Syndrome|Participants will be asked to play attend 35 minute, remotely delivered, group exercise classes using choreographed exercise twice a week for 12 weeks.
62834426|NCT02298582|EXPERIMENTAL|Intranasal fentanyl|
62051770|NCT00184548|EXPERIMENTAL|rFVIIa, Blunt Trauma|
62051771|NCT00184548|PLACEBO_COMPARATOR|Placebo, Blunt Trauma|
62051772|NCT00184548|EXPERIMENTAL|rVIIa, Penetrating Trauma|
62051773|NCT00184548|PLACEBO_COMPARATOR|Placebo, Penetrating Trauma|
62051774|NCT04479436|EXPERIMENTAL|Cohort 1: HER3 High (IHC 3+, 2+)|Cohort 1 participants will have high tumor expression levels of human epidermal receptor 3 (HER3) in a pre-treatment biopsy specimen.
62051775|NCT04479436|EXPERIMENTAL|Cohort 2: HER3 Low/Negative (IHC 1+, 0)|Cohort 2 participants will have low or negative tumor expression levels of human epidermal receptor 3 (HER3) expression levels in a pre-treatment biopsy specimen.
62442062|NCT04606563|EXPERIMENTAL|ARBs (Losartan, Valsartan, Azilsartan, Candesartan, Eprosartan, Irbesartan, Olmesartan, Telmisartan)|Patients will initially receive initial dose of oral ARBs, increased to higher dose after 24 hours and then increased to a max dose after another 24 hours, dependent on tolerance. Patient will remain at dose for duration of hospital (max of 3 months if still hospitalized). Tolerance is defined as having no severe adverse events 24 hours after the first dose. Investigators and/or attending physicians discretion may dictate that dose will not be increased, at which point dose will stay at initial or higher dose.
62834427|NCT00600080|OTHER|etafilcon A first nelfilcon A second|etafilcon A worn daily during week 1, nelfilcon A worn daily for week 2
62252717|NCT03848754|EXPERIMENTAL|Pracinostat 45 mg with Gemtuzumab Ozogamicin|"* Gemtuzumab Ozogamicin Induction: GO 3 mg/m\^2 on Day 1, 4, and 7~* Pracinostat Induction: 45 mg administered orally 3 days a week with 48 hours between dosing for 3 consecutive weeks, followed by 1 week of rest, in 28-day cycles. We will utilize a 3+3 design to determine the safe dose of pracinostat in combination with fixed dose GO. If there are no DLTs in the first three patients, the dose of pracinostat will be escalated to 60mg. Escalation to the next dose level will be done only after the third patient on the previous dose level has been observed for 28 days, and no DLTs were noticed. If there is 1 DLT, an additional 3 patients will be tested at same dose level. If there are ≥ 2 DLTs in 3 or 6 patients, the study will be placed on hold. If there is \< 2 DLTs in the first 3 or 6 patients, the dose of pracinostat will be escalated to 60mg. If there are no DLTs in the first 3 patients at 60 mg, an additional 3 patients will be enrolled to ensure 6 patients are treated at the MTD."
62442063|NCT04606563|NO_INTERVENTION|Usual Care Control|Usual care for duration of hospitalization for up to 3 months if still hospitalized. Due to the lack of clinical guidance from this emergent disease, this may vary dependent on Institution and/or country
62611408|NCT06150469|ACTIVE_COMPARATOR|Blend of ginger and lemon essential oils|"The experimental group will benefit from conventional management of NVCI (antiemetic prophylaxis in accordance with ESMO international recommendations) plus an aromastick of ginger and lemon essential oils renewed with each course of chemotherapy.~Patients were included for 3 cycles of chemotherapy (C1, C2, C3)."
62834428|NCT00600080|OTHER|nelfilcon A first, etafilcon A second|nelfilcon A worn daily during week 1, etafilcon A worn daily for week 2
62834429|NCT05165771|EXPERIMENTAL|GS-5718 Dose A|Participants will receive GS-5718 Dose A once daily + placebo to match (PTM) GS-5718 Dose B once daily + PTM tofacitinib twice daily for up to 12 weeks.
62834430|NCT05165771|EXPERIMENTAL|GS-5718 Dose B|Participants will receive GS-5718 Dose B once daily + PTM GS-5718 Dose A once daily + PTM tofacitinib twice daily for up to 12 weeks.
62834431|NCT05165771|ACTIVE_COMPARATOR|Tofacitinib|Participants will receive tofacitinib 5 mg twice daily + PTM GS-5718 (Dose A + Dose B) once daily for up to 12 weeks.
62834432|NCT05165771|PLACEBO_COMPARATOR|Placebo|Participants will receive PTM GS-5718 (Dose A + Dose B) once daily + PTM tofacitinib twice daily for up to 12 weeks.
62834433|NCT01912170|EXPERIMENTAL|fish oil|Patients will receive fish oil capsules, at a dose of 2g/day. Each 1g capsule will contain 220mg of EPA and 170mg of DHA
62834434|NCT01912170|EXPERIMENTAL|Flaxseed Oil|Patients will receive flaxseed oil capsule, at a dose of 2g/day. Each 1g capsule will contain 550mg of ALA
62834435|NCT01912170|PLACEBO_COMPARATOR|Placebo Supplementation|Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil
62834436|NCT02909400|EXPERIMENTAL|Treatment A|Oral administration of 100 mg KH176 twice daily
62442064|NCT05751681|EXPERIMENTAL|Group (A)|will be subjected to progestin primed ovarian stimulation protocol Women in group (A), will be prescribed 20 mg oral dose of dydrogesterone (Duphaston, Abbott) from the 2nd day of the cycle and continued until the trigger day. Transvaginal follicular monitoring will be done for all patients starting the 6th day of cycle.
62442065|NCT05751681|ACTIVE_COMPARATOR|group (B)|Gonadotropin Releasing Hormone Antagonist Protocol when the size of dominant follicles reaches 12-13 mm, 0.25 mg of cetrotide (Merck-Serono Germany) will be injected subcutaneously daily and continued until the day of trigger shot.
62611409|NCT06150469|PLACEBO_COMPARATOR|Neutral oil|The control group will receive conventional management (antiemetic prophylaxis according to international recommendations, ESMO) of NVCI plus a placebo of aromastick containing a neutral, odourless oil, renewed with each course of chemotherapy.
62611410|NCT03376373|EXPERIMENTAL|active|Neurofeedback for FER
62834437|NCT02909400|PLACEBO_COMPARATOR|Treatment B|Oral administration of matching placebo twice daily
62834438|NCT03550599||patients accessing to Radiotherapy Unit|patients accessing to Radiotherapy Unit for oncologic treatment
62834439|NCT00643903|EXPERIMENTAL|1|Participants will receive five individual sessions of coping effectiveness training.
62834440|NCT00643903|ACTIVE_COMPARATOR|2|Participants will receive standard care and one delayed group workshop of coping effectiveness training.
62834441|NCT04226742|EXPERIMENTAL|Treatment|Participants randomly assigned to this condition will receive the ADAPT platform (treatment) for a treatment period of 8 weeks.
62834442|NCT04226742|ACTIVE_COMPARATOR|Control|Participants randomly assigned to this condition will receive a similar self-guided platform (control) for a treatment period of 8 weeks.
62834443|NCT06655623|EXPERIMENTAL|Schema therapy|Schema therapy will be given in 30 sessions of 45-60 minutes over the course of 10-12 months. Concurrent treatment as part of the regular psychiatric treatment at the site may include psychotropic medication and 1-2 sessions with next-to-kin.
62834444|NCT03162263|EXPERIMENTAL|Ekso training|All patients underwent twenty-four Ekso sessions, scheduled 3 times a week. Each session lasted about 1h, and included transferring into the device arranged on an office chair; donning, standing, walking, sitting, doffing; and transferring out of the exoskeleton.The user can stand up, sit down, and walk with help of a front-wheeled walker and with the exoskeleton attached to a ceiling rail tether. A physical therapist initially provides assistance to maintain the user's center of mass over the base of support to prevent falling.
62611411|NCT03376373|NO_INTERVENTION|control|waiting list
62834445|NCT03162263|ACTIVE_COMPARATOR|Overground training|Conventional gait training overground; before the training 10 min lower limb muscular exercises and stretching were performed by the physiotherapist. The overground training had the same duration of the Ekso training.
62834446|NCT03420352|OTHER|butterfly needle with valve|thromboelastography
62834447|NCT03420352|OTHER|Standard hypodermic needle|thromboelastography
62834448|NCT00936715|EXPERIMENTAL|FTC/TDF|
62834449|NCT01670487|ACTIVE_COMPARATOR|Vapocoolant (Pain Ease Medium Stream)|Application of the stream steadily 4 to 10 seconds onto the cannulation site.
62051776|NCT02489032|EXPERIMENTAL|SBIRT Training & Support Tool|The SBIRT Training \& Support Tool has two components, both of which will be evaluated: (1) online SBIRT Training for EAP and behavioral health practitioners conducting alcohol SBIRT with their adult clients and (2) mobile/web interactive alcohol screening tools and brief intervention protocols to facilitate use of SBIRT by practitioners.
62834450|NCT01670487|PLACEBO_COMPARATOR|Nature's Tears|Apply sterile water (see manufacturer above) steadily 4-10 seconds onto the cannulation site.
62051777|NCT02489032|OTHER|Waitlist control|Subjects randomized to the control condition will be placed on a wait-list and given access to the SBIRT Training \& Support Tool after 3 months and completion of the 3-month follow-up assessment.
62051778|NCT04562961|EXPERIMENTAL|Schizophrenia caregiver (relative)|
62051779|NCT06118034|EXPERIMENTAL|Experimental group (colchicine group)|The experimental group take 0.5mg of colchicine tablets orally for 3 days before surgery, and continue to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
62051780|NCT06118034|PLACEBO_COMPARATOR|Control group|The control group take 0.5mg of placebo tablets orally for 3 days before surgery, and continue to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
62051781|NCT04752449|EXPERIMENTAL|Virtual Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered virtually in the participant's home using the online platform Zoom which is PHIPA/PIPEDA compliant. If participants do not have the technology required for virtual sessions, then a tablet will be loaned to them for the duration of treatment. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
62051782|NCT04752449|NO_INTERVENTION|Treatment as Usual|Participants continue with their regular standard of care without the addition of virtual Cognitive Behavioural Therapy for Psychosis.
62051783|NCT00192309|EXPERIMENTAL|Cold-adapted influenza vaccine (CAIVT)|A single intranasal dose of 10\^7 fluorescent focus units.
62051784|NCT00192309|ACTIVE_COMPARATOR|Trivalent inactivated vaccine (TIV)|A single dose of commercially available Flushield was administered intramuscularly.
62442066|NCT00956228|EXPERIMENTAL|Radioimmunoguided IMRT|All patients recieved Intensity Modulated Radiotherapy to the prostate with 75.6 Gy in 42 fractions. Additionally, they recieve a concurrent boost to the region of the prostate which enhanced on the prostascint scan to 82 Gy.
62442067|NCT02999464|EXPERIMENTAL|Qigong|Experimental group will receive a total of 50 minutes of qigong training 3 times per week and for 16 weeks.
62442068|NCT02999464|ACTIVE_COMPARATOR|Fitness Exercise|Fitness exercise group will receive home fitness exercise 3 times per week and for 16 weeks.
62834451|NCT01977989|NO_INTERVENTION|No Vancomycin Powder|Patients who only receive IV Vancomycion prior to surgery. No Vancomycin powder is administered.
62834452|NCT01977989|ACTIVE_COMPARATOR|Vancomycin Powder|Patients who receive Vancomycin powder in the surgical site following surgery.
62834453|NCT03710499|EXPERIMENTAL|Physical activity|The program comprises the practice of resistance exercises for the main muscular groups, with free weights and with their own body weight against the action of gravity, the proposal consists of 3 weekly sessions, for 8 consecutive weeks.
62051785|NCT00192309|PLACEBO_COMPARATOR|Placebo|The 0.2 mL administered intranasally.
62442069|NCT03150121|EXPERIMENTAL|Ovarian cancer patients|High grade ovarian/fallopian tube/primary peritoneal carcinoma patients with current active disease, at any stage and histological type, who have not yet undergone debulking surgery.
62442070|NCT03150121|ACTIVE_COMPARATOR|Non-malignant controls|Patients with non-malignant gynecological conditions indicating surgical procedure, either salpingo-oophorectomy, hysterectomy or hysteroscopy.
62442071|NCT03150121|EXPERIMENTAL|High risk population|Healthy women with genetically high risk for developing ovarian cancer, who have not undergone risk reducing procedure.
62442072|NCT04712435|EXPERIMENTAL|Experimental: N-acetylcysteine|Sachets containing N-acetylcysteine 200 mg Powder for Oral Solution administered every 8 hours (Daily dose 600 mg/day). is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner
62442073|NCT04712435|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|200mg granulated solution of matching placebo administered every 8 hours (Daily dose 600 mg/day), is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner
62834454|NCT01567267|EXPERIMENTAL|Experimental educational intervention|Experimental educational intervention
62834455|NCT01567267|ACTIVE_COMPARATOR|Standard educational intervention|Standard educational intervention
62834456|NCT05188833|ACTIVE_COMPARATOR|Deep Transcranial Magnetic Stimulation|The treatment will be carried out for 6 weeks, 5 days a week, in total 30 sessions; 20 hz using Brainsway H-7 helmet. It will be applied to the mPFC and ACC simultaneously with a total of 2000 beats at a frequency of 50 beats in each string.
62834457|NCT05188833|EXPERIMENTAL|Deep Transcranial Magnetic Stimulation and Paroxetine|The treatment will be carried out for 6 weeks, 5 days a week, in total 30 sessions; 20 hz using Brainsway H-7 helmet. It will be applied to the mPFC and ACC simultaneously with a total of 2000 beats at a frequency of 50 beats in each string. In addtion to DTMMS, paroxetine will applied.
62051786|NCT06020690|EXPERIMENTAL|Novabel bioabsorbable steroid-releasing stent|
62252718|NCT03848754|EXPERIMENTAL|Pracinostat 60 mg with Gemtuzumab Ozogamicin|"* Gemtuzumab Ozogamicin Induction: GO 3 mg/m\^2 on Day 1, 4, and 7~* Pracinostat: 60 mg administered orally 3 days a week with 48 hours between dosing for 3 consecutive weeks, followed by 1 week of rest, in 28-day cycles.~We will utilize a 3+3 design to determine the safe dose of pracinostat in combination with fixed dose GO. If there are no DLTs in the first three patients, the dose of pracinostat will be escalated to 60mg. Escalation to the next dose level will be done only after the third patient on the previous dose level has been observed for 28 days, and no DLTs were noticed. If there is 1 DLT, an additional 3 patients will be tested at same dose level. If there are ≥ 2 DLTs in 3 or 6 patients, the study will be placed on hold. If there is \< 2 DLTs in the first 3 or 6 patients, the dose of pracinostat will be escalated to 60mg. If there are no DLTs in the first 3 patients at 60 mg, an additional 3 patients will be enrolled to ensure 6 patients are treated at the MTD."
62252719|NCT03848754|EXPERIMENTAL|Gemtuzumab Ozogamicin Monotherapy Maintenance|"Response will be assessed through bone marrow biopsy on Day 28. Patients achieving at least a partial remission marrow will be offered up to 5 cycles of maintenance therapy. Maintenance should begin no later than 42 days after initial induction.~\*\*Gemtuzumab Ozogamicin Maintenance: 2 mg/m\^2 intravenous administration on day 1, in a 28-day cycle."
62252720|NCT03848754|EXPERIMENTAL|Pracinostat with Gemtuzumab Ozogamicin Maintenance|"Response will be assessed through bone marrow biopsy on Day 28. Patients achieving at least a partial remission marrow will be offered up to 5 cycles of maintenance therapy. Maintenance should begin no later than 42 days after initial induction.~* Gemtuzumab Ozogamicin Maintenance: 2 mg/m\^2 intravenous administration on day 1, in a 28-day cycle.~* Pracinostat Maintenance: (In addition to GO, only if induction dose escalation occurs) 45 mg orally 3 days a week with 48 hours between dosing, for three consecutive weeks, followed by 1 week of rest, in a 28-day cycle."
62252721|NCT03260634||Voriconazole|"Patient was received voriconazole according to individual indication. The starting dose is 6 mg/kg iv twice daily for two dosages, followed by 4 mg/kg iv twice daily in intravenous form or a loading dose of 400 mg twice daily for two doses is used (for individuals \>40 kg), followed by 200 mg twice daily, and in individuals \<40 kg the maintenance dose is 100 mg twice daily in oral form.~The dosage was adjusted by drug level and toxicity. The duration of drug used was depended on indication of treatment."
62611412|NCT06351397|EXPERIMENTAL|Mixed Reality Group|Trainees will be wearing a headset displaying holograms of Intensive Care Unit (ICU) monitors with vital signs, including arterial line and central venous line waveforms, intravenous access lines, in addition to a cardiac defibrillator. Participants will conduct a self-assessment of empathy before the embodiment simulation and after the simulation debriefing.
62834458|NCT05188833|ACTIVE_COMPARATOR|Paroxetine|Paroxetine is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor). It's often used to treat depression in OCD.
62834459|NCT00099333|EXPERIMENTAL|Exenatide|The subjects will discontinue their insulin and substitute it with exenatide. Subjects will remain on their existing oral diabetic therapy.
62252722|NCT06110260|EXPERIMENTAL|AstraGin|"The 1st round: Before each study day, all subjects took a 50 mg AstraGin capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg AstraGin and 35 g of whey protein with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min to analyze the plasma concentration of amino acids.~The washout period is seven days, during which the subjects maintain a stable lifestyle and dietary habits.~The 2nd round: All subjects take a 50 mg AstraGin capsule and conduct the procedure (same as the 1st round)"
62051787|NCT06020690|ACTIVE_COMPARATOR|marketed bioabsorbable steroid-releasing stent|
62442074|NCT03449082|EXPERIMENTAL|High concentration of Allo-ASC group|High concentration of Allo-ASC 0.5cc (Total: 10 million cells) \& Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
62611413|NCT06400407|EXPERIMENTAL|Continuous Theta-burst Stimulation|Based on the map, an 8-shaped coil was used to stimulate the motor function-related targets. The stimulation intensity was RMT80%, 600 pulses, 50Hz, 40s per target, and the stimulation interval was more than 2 hours. The treatment course lasted for 7 days.
62611414|NCT06400407|SHAM_COMPARATOR|Sham stimulation|A Sham stimulation coil was used to stimulate based on the map. The sound and duration were the same as the cTBS group, ensuring no effective stimulation. The treatment course lasted for 7 days.
62834460|NCT00099333|ACTIVE_COMPARATOR|Insulin|The subjects will remain on their current insulin therapy. Subjects will also remain on their existing oral diabetic therapy.
62834461|NCT01907347||ICU patients|
62051788|NCT05138445|EXPERIMENTAL|Arm 1: FAME-W intervention|Four-week self-management education programme
62051789|NCT05138445|ACTIVE_COMPARATOR|Arm 2: FAME-W handbook|Self-guided FAME-W handbook
62051790|NCT05580666|EXPERIMENTAL|Oral Azithromycin 250 mg once daily|Active Azithromycin tablet
62051791|NCT05580666|PLACEBO_COMPARATOR|Oral matching placebo, once daily|Matching placebo tablet
62252723|NCT06110260|PLACEBO_COMPARATOR|Placebo|"The 1st round: Before each study day, all subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 35 g of whey protein with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min to analyze the plasma concentration of amino acids.~The washout period is seven days, during which the subjects maintain a stable lifestyle and dietary habits.~The 2nd round: All subjects take a 50 mg Placebo capsule and conduct the procedure (same as the 1st round)"
62834462|NCT00281242||Research subjects|All participants undergo the same testing in this observational trial. There is no randomization, and no interventions other than blood drawing.
62834463|NCT04301154|EXPERIMENTAL|Arm 1 (n=10): HIVIS DNA / MVA-CMDR|"Arm 1 (n=10) will receive 1500 micrograms (0.5ml) HIVIS DNA IM by needle-free injection at weeks 0 and 4 followed by intramuscular (IM) needle injection of 1 X 108 IU/mL (1ml) MVA-CMDR at weeks 24 and 36 in the same arm as HIVIS DNA.~Participants who have been randomized to receive HIVIS DNA and MVA-CMDR alone (ARM 1) will be administered Cervarix after week 72, the last study follow-up visit, if required."
62252724|NCT05006157|EXPERIMENTAL|ViaOne device|ViaOne device will be used for percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac
62252725|NCT04290338|EXPERIMENTAL|PIOMI Group|Patients in this group will receive the intraoral and extraoral stimulations provided by the PIOMI protocol. These stimulations will last 5 minutes and will be performed once a day for 7 consecutive days for each patient.
62252726|NCT04290338|NO_INTERVENTION|Control Group|Patients in this group will receive classic care.
62252727|NCT02551614|EXPERIMENTAL|Group 1: healthy subjects|Subjects will undergo inhaled challenge, either with lipopolysaccharide or saline in a 2:1 ratio, prior to imaging assessments. Assessments will be performed during one study day on an outpatient basis.
62252728|NCT02551614|EXPERIMENTAL|Group 2: COPD patients|Subjects will undergo imaging assessments during one study day on an outpatient basis. Approximately 10 of these COPD patients will repeat this study day 7-10 days after completion of the first study day to assess the reproducibility of the technique.
62252729|NCT05360173|EXPERIMENTAL|Experimental group|The experimental group not only have the routine treatment, but have acupressure when they back to the ward with the following 3 days . The effectiveness evaluation was carried out by the same researcher before and after intervention. There are three assessments in this study: primary outcome including postoperative pain and bowel movement. The short-form McGill Pain Questionnaire is used to measure the quality of pain, Visual Analog Scale is used to the pain intensity and stethoscope is used to listen to the bowel sound. The study, also, will be recorded postoperative exhaust time, the postoperative date of Indwelling drainage tube and postoperative length of stay.
62252730|NCT05360173|SHAM_COMPARATOR|Control group|The control group will have the same treatment and the evaluation, except received sham acupoint.
62252731|NCT03991000|EXPERIMENTAL|Intravenous iron|Intravenous iron administration in the form of ferric carboxymaltose will be carried out according to summary of product characteristics. Bolus administration (1000 mg) will be followed by an optional administration of 500-1000 mg within the first 4 weeks (up to a total of 2000 mg which is in-label) according to approved dosing rules, followed by administration of 500 mg ferric carboxymaltose at months 4 and 8, except when haemoglobin is \> 16.0 g/dL or ferritin is \> 600 µg/L. To avoid unblinding in these patients a saline infusion will be administered.
62252732|NCT03991000|PLACEBO_COMPARATOR|Placebo|Administration of i.v. NaCl according to the dosing rules for intravenous iron.
62252733|NCT02146742|EXPERIMENTAL|1. ASP1707 lowest dose|
62252734|NCT02146742|EXPERIMENTAL|2 ASP1707 higher dose|
62252735|NCT02146742|EXPERIMENTAL|3. ASP1707 Highest dose|
62252736|NCT05009927|EXPERIMENTAL|Imatinib interruption|Immediate interruption of imatinib until progressive disease. In case of 1st relapse, imatinib will be reintroduced at 400mg/d and further increased at 800mg/d in case of 2nd relapse after re-introduction.
62442075|NCT03449082|EXPERIMENTAL|Low concentration of Allo-ASC group|Low concentration of Allo-ASC 0.5cc (Total: 1 million cells) \& Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
62442076|NCT03449082|PLACEBO_COMPARATOR|Placebo Comparator (Fibrin) group|Normal saline 0.5cc \& Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
62442077|NCT00708929|OTHER|1|14 subjects homozygous HH for the Tyr402His single nucleotide polymorphism
62611415|NCT05281900|EXPERIMENTAL|Physically active volunteers|All volunteers who meet the inclusion criteria will be included in the study.
62611416|NCT02644330|ACTIVE_COMPARATOR|surgical group|The patients in Group A (surgical group) underwent surgical repair with cardiopulmonary bypass
62611417|NCT02644330|EXPERIMENTAL|closure group|The patients in Group B (closure group) underwent minimally invasive transthoracic device closure.
62611418|NCT00475878|PLACEBO_COMPARATOR|placebo|
62611419|NCT00475878|ACTIVE_COMPARATOR|escitalopram|
62611420|NCT03080584|EXPERIMENTAL|acupucture arm|all participants undergo 12 weeks of acupuncture
62252737|NCT05009927|NO_INTERVENTION|Imatinib maintenancce|Maintenance of imatinib at the last dose routinely taken by the patient in the 10-year period prior to randomization (either 300 or 400 mg once daily). In case of progressive disease imatinib will be increased up to 800mg/day.
62252738|NCT02942719||Shanghai First Maternity and Infant Hospital|
62252739|NCT02942719||Dalian Maternity and Child Health Hospital|
62442078|NCT00708929|OTHER|2|14 subjects homozygous TT for the Tyr402His single nucleotide polymorphism
62442079|NCT04612920|EXPERIMENTAL|Study Group|Participants will receive ibuprofen 800mg every eight hours and acetaminophen 1000mg every eight hours, given at the same time, along with oxycodone five mg every six hours PRN for breakthrough pain.
62611421|NCT05024526|EXPERIMENTAL|edaravone dexborneol group|
62834464|NCT04301154|EXPERIMENTAL|Arm 2 (n=10): HIVIS DNA + Cervarix/ / MVA-CMDR|Arm 2 (n=10) will receive 0.5 ml of Cervarix IM by needle injection followed by 1500 micrograms (0.5ml) per injection of HIVIS DNA IM by a needle-free injection device in the skin above (proximal to) the Cervarix injection (within 1.5 cm). They will receive 1 X 108 IU/mL (1ml) MVA-CMDR IM by needle injection at weeks 24 and 36 in the same arm as HIVIS DNA. They will also receive 0.5 ml Cervarix at the time of the first MVACMDR injection in the opposite arm from the MVA injection at week 24.
62834465|NCT04301154|EXPERIMENTAL|Arm 3 (n=5): Cervarix|Arm 3 (n=5) will receive 0.5 ml of Cervarix by IM needle injection at weeks 0, 4 and 24.
62442080|NCT04612920|NO_INTERVENTION|Standard Group|Participants will receive current OU standard of care therapy which includes ibuprofen 800mg every eight hours as needed (PRN), acetaminophen 1000mg every eight hours PRN, and oxycodone five mg every six hours PRN.
62442081|NCT03273387|PLACEBO_COMPARATOR|Sugar pill|The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
62611422|NCT05024526|ACTIVE_COMPARATOR|edaravone group|
62611423|NCT00380718|EXPERIMENTAL|Pemetrexed|
62611424|NCT04291742|EXPERIMENTAL|0: cognitive|target prostate biopsies by cognitive fusion
62611425|NCT04291742|EXPERIMENTAL|1: software|target prostate biopsies by software
62252740|NCT02942719||Beijing Obstetrics and Gynecology Hospital|
62252741|NCT02942719||Shijiazhuang Obstetrics and Gynecology Hospital|
62252742|NCT02942719||The Children and Women's Healthcare of Laiwu City|
62252743|NCT02942719||Suzhou Municipal Hospital|
62252744|NCT02942719||Wenling Women's and Children's Hospital|
62252745|NCT02942719||First Affiliated Hospital of Kunming Medical University|
62252746|NCT02942719||Changsha Hospital for Maternal and Child Health Care|
62252747|NCT02942719||Xinxiang Maternity and Child Health Hospital|
62252748|NCT02942719||Yanshi People's Hospital|
62252749|NCT02942719||The Maternal and Child Health Hospital of Guangxi|
62252750|NCT02942719||Northwest Women and Children's Hospital|
62252751|NCT02942719||Suining Central Hospital|
62252752|NCT02942719||Inner Mongolia Maternity and Child Health Hospital|
62252753|NCT02942719||Fujian Province Maternity and Child Health Hospital|
62252754|NCT02942719||Qinghai Red Cross Hospital|
62252755|NCT02942719||Xinjiang Maternity and Child Health Hospital|
62252756|NCT02942719||Jiangmen Maternity and Child Health Care Hospital|
62252757|NCT02942719||Gansu Provincial Maternity and Child-care Hospital|
62252758|NCT02435108|EXPERIMENTAL|crizotinib arm|crizotinib medication
62252759|NCT03089775|EXPERIMENTAL|BBI-2000|Cohort A
62252760|NCT03089775|PLACEBO_COMPARATOR|Vehicle|Cohort A
62252761|NCT03089775|OTHER|Multiple treatments|Cohort B
62252762|NCT03269370|EXPERIMENTAL|1: Anchors Away|Family will receive access to the basic Anchors Away mobile app to test over 6 weeks.
62442082|NCT03273387|EXPERIMENTAL|trimetazidine|The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.
62611426|NCT03941197|EXPERIMENTAL|Ready and Healthy for Kindergarten Family Literacy Program|Ready and Healthy for Kindergarten Family Literacy Program- 8 weekly parent child workshops with text message reminders
62611427|NCT01738191|ACTIVE_COMPARATOR|Atomoxetine|The study drug target dose is Atomoxetine (ATM) 80 milligram (mg) per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
62611428|NCT01738191|PLACEBO_COMPARATOR|Placebo|Patients in the placebo arm will follow the same titration schedule as those in the active arm. Patients will titrate up to target dose by starting 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose to 80mg daily.
62611429|NCT06640881|EXPERIMENTAL|ablative single-dose PBI followed by BCS after three weeks|Eligible patients with a low-risk ipsilateral recurrent breast cancer previously treated with breast-conserving surgery and postoperative radiotherapy, will be treated with re-irradiation (i.e. ablative single-dose PBI) followed by second BCS after three weeks.
62252763|NCT03269370|EXPERIMENTAL|2: Parent Enhanced Anchors Away|Family will receive access to the Parent Enhanced Anchors Away mobile app to test over 6 weeks.
62252764|NCT03269370|ACTIVE_COMPARATOR|3: Self-Help E-Book|"Group 3 will receive the Self Help e-Book as a comparative condition (families provided a kindle version copy of Helping Your Anxious Child: A Step-by-Step Guide ; Rapee, Wignall, Spence, Lyneham, \& Cobham, 2008)."
62442083|NCT02095847|EXPERIMENTAL|Hysteroscope Imaging|All patients entered in study will undergo cervical dilation after induction of general anesthesia. Once the cervix has been dilated, a hysteroscope will be introduced in the uterine cavity to evaluate for presence of tumor. Location and size of tumor documented. White-light images obtained using the High-Resolution Microendoscopy (HRME) camera introduced through the hysteroscope. Once completed; the hysteroscope will be removed and the uterine cavity will be infused with 10 mL of proflavine (an acridine dye) (0.01% Proflavine (10ml)). A resectoscope will then be introduced in the uterine cavity and fluorescent images obtained using the HRME camera. The resectoscope will then be used to remove all tumor as guided through HRME images. The entire imaging and tumor resection process is estimated to take 45 minutes or less.
62442084|NCT04972214||Very Preterm Infants|preterm infants were born at gestational age of less than 32 weeks
62442085|NCT02737306|PLACEBO_COMPARATOR|Placebo|"In this study, 60 subjects will be randomized to receive either PRO 140 or placebo in a 1:1 ratio (i.e. 30 subjects per arm). PRO 140 or placebo will be administered as a 350 mg subcutaneous injection.~Placebo will be administered -2/-3 days before the stem cell infusion, on the day of stem cell infusion (Day 0) and thereafter on days 7, 14, 21, 28, 42, 56, 70, 84 and 98 as per the study schedule of assessments.~Each vial of the Placebo contains 5mM Histidine, 15 mM Glycine, 95 mM Sodium Chloride, 0.3% (w/v) Sorbitol, 0.005% (w/v) Polysorbate 20 at a pH of 5.5.~Each 350 mg dose of placebo consist of 2 SC injections of placebo (5mM Histidine, 15 mM Glycine, 95 mM Sodium Chloride, 0.3% (w/v) Sorbitol, 0.005% (w/v) Polysorbate 20 at a pH of 5.5) of 2 X 1 mL/inj. on opposite sides of abdomen."
62611430|NCT03806023|EXPERIMENTAL|All subjects|All subjects undergo same full protocol, including PNS and TMS at rest and active hand movements (signals from thumb muscle) triggered PNS and TMS.
62611431|NCT01354548|EXPERIMENTAL|TheraBite grupp|
62611432|NCT01354548|NO_INTERVENTION|Conventional treatment|
62611433|NCT03984968|EXPERIMENTAL|CAR-T cells infusion combined with feeding T cells (FTCs)|
62834466|NCT01743222|EXPERIMENTAL|eASC|"eASC~* First cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 2.5 millions of eASCs suspended in 0.25 ml of HTS per lymph node, total dose 5 millions of cells.~* Second cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 5 millions of eASCs suspended in 0.5 ml of HTS per lymph node, total dose 10 millions of cells."
62611434|NCT00901979|EXPERIMENTAL|LCQ908 Dose 1|
62611435|NCT00901979|EXPERIMENTAL|LCQ908 Dose 2|
62611436|NCT00901979|EXPERIMENTAL|LCQ908 Dose 3|
62611437|NCT00901979|EXPERIMENTAL|LCQ908 Dose 4|
62611438|NCT00901979|EXPERIMENTAL|LCQ908 Dose 5|
62611439|NCT00901979|PLACEBO_COMPARATOR|Placebo|
62611440|NCT00901979|ACTIVE_COMPARATOR|Sitagliptin|
62834467|NCT01743222|PLACEBO_COMPARATOR|Placebo|"* First cohort (2 volunteers): injection of 0.25 ml of Hypo Thermosol (HTS) per lymph node~* Second cohort (2 volunteers): injection of 0.5 ml of Hypo Thermosol (HTS) per lymph node"
62834468|NCT04648397|EXPERIMENTAL|Short chewing|Subjects consume two starch-based foods varying in fibre content e.g. brown rice and chick-peas in duplicate following a short chewing protocol.
62834469|NCT04648397|EXPERIMENTAL|Long chewing|Subjects will consume two starch-based foods varying in fibre content e.g. brown rice and chick-peas in duplicate following a long chewing protocol.
62834470|NCT04252534|ACTIVE_COMPARATOR|Repetitive electromagnetic stimulation|Group 1 consists of 20 RP patients (40 eyes) who received combined rEMS with PRP. In this group, patients received rEMS for 30 minutes before subtenon PRP injections. In this group, 3 loading doses were applied at 3-week intervals. Then 2 booster dose were applied at 6-month intervals.
62834471|NCT04252534|ACTIVE_COMPARATOR|Platelet rich plasma|Group 2 consists of 20 RP patients (40 eyes). In this group, patients received only subtenon PRP injections. In this group, 3 loading doses were applied at 3-week intervals. Then 2 booster dose were applied at 6-month intervals.
62834472|NCT04252534|NO_INTERVENTION|Natural course|Group 3 consists of 20 RP patients (40 eyes). Patients in this group did not accept any interventional application and were only followed up. The
62834473|NCT03585751|ACTIVE_COMPARATOR|Triple antibiotic paste|Pulpectomy for primary molars, triple antibiotic mix is used as obturating material mixed with Macrogol and Polyethylene glycol \& small amount of Zinc oxide powder to obtain workable , radio opaque mix
62834474|NCT03585751|EXPERIMENTAL|3mixstatin|Pulpectomy for primary molars, 3 Mixstatin ( mix of simvastatin and triple antibiotic mix ) is used as obturating material mixed with Macrogol and Polyethylene glycol \& small amount of Zinc oxide powder to obtain workable , radio opaque mix
62834475|NCT03585751|EXPERIMENTAL|simvastatin|Pulpectomy for primary molars, simvastatin is used as obturating material mixed with Macrogol and Polyethylene glycol \& small amount of Zinc oxide powder to obtain workable , radio opaque mix
62834476|NCT00378365|EXPERIMENTAL|1|Arsenic trioxide
62834477|NCT01147874|NO_INTERVENTION|psoriatic arthritis (PsA) questionnaire|
62834478|NCT05488041|EXPERIMENTAL|UC patients with anorectal symptoms|Patients with ulcerative colitis in remission who have anorectal symptoms will undergo an anal manometry test to characterize these symptoms.
62834479|NCT05488041|ACTIVE_COMPARATOR|UC patients without anorectal symptoms|Patients with ulcerative colitis in remission without anorectal symptoms will undergo an anal manometry test to characterize their anorectal function and to compare to those with symptoms
62834480|NCT02991040|EXPERIMENTAL|Revanesse Ultra+|Revanesse Ultra+ (with lidocaine) vs Revanesse Ultra without lidocaine
62834481|NCT03561805|OTHER|Prolonged continuous ECG monitoring|Patients will undergo a prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure. The duration of the ECG monitoring will be of 1 week.
62252765|NCT03269370|NO_INTERVENTION|4: Waitlist Control|Group 4 will not receive any intervention, but will be randomized into an active study arm at 6 weeks.
62252766|NCT00555477|EXPERIMENTAL|anastrozole|
62252767|NCT02254577|EXPERIMENTAL|Endometrin® plus Progesterone in Oil (PIO)|Subjects in all arms will undergo the standard monitoring appointments and therapies involved in a frozen embryo transfer cycle. Patients randomized to the Endometrin® plus PIO arm will take progesterone as 2 100mg tablets of Endometrin® inserted vaginally twice daily. In addition, on the first day of Endometrin® therapy, patients randomized to this arm will take a 50mg intramuscular injection (1mL) of PIO and will repeat this injection every third day. Patients in this arm will undergo Frozen Embryo Transfer on the fifth day of Endometrin® therapy.
62442086|NCT02737306|EXPERIMENTAL|350 mg Pro140|"In this study, 60 subjects will be randomized to receive either PRO 140 or placebo in a 1:1 ratio (i.e.,30 subjects per arm). PRO 140 or placebo will be administered as a 350 mg subcutaneous injection.~PRO 140 will be administered -2/-3 days before the stem cell infusion, on the day of stem cell infusion (Day 0) and thereafter on days 7, 14, 21, 28, 42, 56, 70, 84 and 98 as per the study schedule of assessments.~Each vial of the PRO 140 product contains 1.4 mL antibody at 175 mg/ml in a buffer containing 5 mM L-histidine, 15.0 mM glycine, 95 mM sodium chloride, 0.3% (w/v) sorbitol, 0.005% (w/v) polysorbate 20 (Tween 20®), and sterile water for injection, at pH of 5.5.~Each 350 mg dose of PRO 140 will consist of 2 SC injections of PRO 140 (2 X 1 mL/inj.) on opposite sides of abdomen."
62252768|NCT02254577|ACTIVE_COMPARATOR|Progesterone in Oil (PIO) Alone|Subjects in all arms will undergo the standard monitoring appointments and therapies involved in a frozen embryo transfer cycle. Patients randomized to the PIO Only arm will take progesterone as a daily 50mg intramuscular injection (1mL) of PIO and will undergo Frozen Embryo Transfer on the sixth day of taking this medication.
62442087|NCT03943342|EXPERIMENTAL|Treatment (venetoclax, ibrutinib)|"OBSERVATION COHORT: Patients who are taking ibrutinib enter observation cohort and undergo screening every 3 months for development for genetic mutations. If mutations develop, patients undergo increased screening for development of clinical disease progression. Patients who develop clinical disease progression with or without mutations enter the Intervention cohort.~INTERVENTION COHORT: Patients receive venetoclax PO daily and ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve MRD negative CR after 12 or 24 cycles continue receiving ibrutinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity."
62442088|NCT03267030|EXPERIMENTAL|GRASPA|GRASPA will replace remaining PEG-asparaginase doses in case of hypersensitivity.
62442089|NCT03147651||Cystic Fibrosis (CF) bronchiectasis|Diagnosis of Cystic Fibrosis (CF), follow up in a CF center, evidence of bronchiectasis on computed tomography (CT).
62442090|NCT03147651||non-Cystic Fibrosis (CF) bronchiectasis|Negative evaluation for of Cystic Fibrosis (CF), evidence of bronchiectasis on computed tomography (CT).
62442091|NCT03419663||gastric cancer|
62442092|NCT01841606|EXPERIMENTAL|Ondansetron|4mg of IV ondansetron 5 minutes prior to initiation of spinal anesthesia
62442093|NCT01841606|PLACEBO_COMPARATOR|Placebo|10mL of IV normal saline 5 minutes prior to initiation of spinal anesthesia
62442094|NCT00712010|EXPERIMENTAL|Whey protein native|Whey protein native versus the 6 other arms
62442095|NCT00712010|EXPERIMENTAL|Whey protein microgels|Whey protein microgels versus the 6 other arms
62442096|NCT00712010|EXPERIMENTAL|Hydrolyzed whey protein|Hydrolyzed whey protein versus the 6 other arms
62442097|NCT00712010|EXPERIMENTAL|Casein native|Casein native versus the 6 other arms
62611441|NCT02179749|ACTIVE_COMPARATOR|Experimental: mifepristone 1200 mg daily|1200 mg mifepristone daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
62611442|NCT02179749|PLACEBO_COMPARATOR|Placebo daily, 1-week|Placebo pills daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
62611443|NCT04222140|EXPERIMENTAL|ERIPTO Protocol|Protocol arm actively being studied
62611444|NCT04222140|ACTIVE_COMPARATOR|BMAC only|bone marrow aspirate concentrate only arm
62252769|NCT03848689||FQ PPA Group|Fluoroquinolone Preprescription Authorization from Infection Control consult, once, prior to prescribing fluoroquinolone
62252770|NCT03848689||Control Group|No preprescription authorization needed from Infection control prior to prescribing fluoroquinolone
62252771|NCT01347424|EXPERIMENTAL|Test group|
62252772|NCT01347424|ACTIVE_COMPARATOR|control group|
62252773|NCT04968041|EXPERIMENTAL|MI-CBT KNA Program|6-week group intervention using MI and CBT strategies to promote adherence to a ketogenic nutrition program.
62252774|NCT04153773||Group 1|60 Patient
62442098|NCT00712010|EXPERIMENTAL|Hydrolyzed casein|Hydrolyzed casein versus the 6 other arms
62442099|NCT00712010|EXPERIMENTAL|Total milk protein native|Total milk protein native versus the 6 other arms
62442100|NCT00712010|EXPERIMENTAL|Hydrolyzed milk protein|Hydrolyzed milk protein versus the 6 other arms
62442101|NCT00991198|EXPERIMENTAL|A|Aria Regimens 0.5% conc
62442102|NCT00991198|EXPERIMENTAL|B|Aria Regimen (5 products) 0.25% conc
62442103|NCT00991198|PLACEBO_COMPARATOR|C|Aria Regimen Control without O2
62442104|NCT01035528|ACTIVE_COMPARATOR|insulin glargine|antidiabetic treatment with Lantus o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
62442105|NCT01035528|ACTIVE_COMPARATOR|metformin|use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
62442106|NCT02110420|EXPERIMENTAL|CC-90001 10mg (Single Dose)|
62442107|NCT02110420|EXPERIMENTAL|CC-90001 30mg (Single Dose)|
62442108|NCT02110420|EXPERIMENTAL|CC-90001 60mg (Single Dose)|
62442109|NCT02110420|EXPERIMENTAL|CC-90001 120mg (Single Dose)|
62442110|NCT02110420|EXPERIMENTAL|CC-90001 240mg (Single Dose)|
62252775|NCT04153773||Group 2|30 Control subject
62611445|NCT04341558|NO_INTERVENTION|Baseline|During this baseline period, postoperative monitoring will be continued as normal by nursing and medical staff without intervention. No training of family members will take place
62834482|NCT06654674||Study Participants|This group consists of 2,509 adult participants recruited from a metabolic health center in Rome, Italy. Data on dietary patterns, physical activity, and body composition were collected and analyzed using Principal Component Analysis (PCA) to identify trends and patterns related to gender differences in eating behaviors and physical activity. No specific intervention was applied, as this is an observational study.
62834483|NCT03739203|PLACEBO_COMPARATOR|Placebo + ADT|Cariprazine matching placebo capsules, orally, once daily in addition to their ongoing antidepressant therapy (ADT) \[same antidepressant and dose of ADT they were on at the Baseline\] during the Double-blind Treatment Period, up to Week 6.
62834484|NCT03739203|EXPERIMENTAL|Cariprazine 1.5 mg/day + ADT|Cariprazine 1.5 mg capsules, orally, once daily in addition to their ongoing ADT (same antidepressant and dose of ADT they were on at the Baseline) during the Double-blind Treatment Period, up to Week 6.
62834485|NCT03739203|EXPERIMENTAL|Cariprazine 3 mg/day + ADT|Cariprazine 1.5 mg capsules, orally, once daily for 2 weeks starting at the Baseline, titrated to 3.0 mg capsules, orally, once daily from Week 2 through Week 6 in addition to their ongoing ADT (same antidepressant and dose of ADT) during the Double-blind Treatment Period, up to Week 6.
62834486|NCT05764785|EXPERIMENTAL|MentorPRO|Participants assigned to use MentorPRO
62834487|NCT05764785|NO_INTERVENTION|Control|Participants in mentoring program as usual
62834488|NCT01655732|EXPERIMENTAL|Atraumatic Restorative Treatment|ART is Atraumatic Restorative Treatment involving removal of soft carious enamel and dentine by hand instruments only and then restore the resulting cavity and adjacent pits and fissures with an adhesive restorative material.
62834489|NCT03527433|NO_INTERVENTION|Standard arm|In the standard arm, an average of one suture will be placed at each cm length of the wound, thus the number of sutures placed should be equal to the length of the wound in cm.
62834490|NCT03527433|EXPERIMENTAL|Intervention arm|The intervention arm will undergo the alternative/new closure technique with small and close fascia sutures, where each suture will be placed only 5 mm away from the fascia edge and 5 mm apart from the adjacent fascia suture.
62834491|NCT06653387|EXPERIMENTAL|CGuard Prime 80cm stent system with ENROUTE NPS|
62834492|NCT04515316|EXPERIMENTAL|healthy adults|Any adult, who is at least eighteen (18-70) years old.
62834493|NCT04515316|EXPERIMENTAL|Patients with intractable epilepsy|Any clinical patient referred to us via the clinical MEG program, and who is at least eighteen (18-70) years old.
62834494|NCT04412629|EXPERIMENTAL|Cabozantinib|-Cabozantinib 60 mg by mouth daily on days 1-21
62834495|NCT01672580|ACTIVE_COMPARATOR|Random-Cloro|exposure to water chlorination
62834496|NCT01672580|ACTIVE_COMPARATOR|Random-Vitamin|exposure to vitamin use
62834497|NCT01672580|EXPERIMENTAL|Indegree-Cloro|high in-degree, exposure to water chlorination
62834498|NCT01672580|EXPERIMENTAL|Indegree-Vitamin|high in-degree, exposure to vitamin use
62834499|NCT01672580|EXPERIMENTAL|Nominated-Cloro|nominated by random, exposure to water chlorination
62834500|NCT01672580|EXPERIMENTAL|Nominated-Vitamin|nominated by random, exposure to vitamin use
62834501|NCT05089825|ACTIVE_COMPARATOR|Receive routine instructions|Participants will receive routine instructions included in the myLAB Box Clinical Laboratory Improvement Amendments (CLIA) certified collection kit
62834502|NCT05089825|ACTIVE_COMPARATOR|Telehealth Visit|Participants will have a telehealth-based instructional visit and receive routine instructions included in the myLAB Box commercially available, CLIA certified collection kit
62051792|NCT02090634|EXPERIMENTAL|Personalized Reminder Texting + Psychoeducation (iTAB)|Participants in the individualized Texting for Adherence Building (iTAB) arm will receive daily text messaging reminders for antiretroviral and psychotropic medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Participants will also receive a text message that assesses mood. Finally, participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications.
62252776|NCT02963038|EXPERIMENTAL|CD19 CAR T cells|Autologous CD19-targeting CAR T cells
62252777|NCT00916279|EXPERIMENTAL|Lutonix Catheter|
62252778|NCT04844684||Obese/non-diabetic patients undergoing gastric bypass surgery|
62252779|NCT04239105||Breast cancer Group|The biopsy result is breast cancer.
62252780|NCT00613353||I|Caucasian and African American females between the ages of 18 and 65.
62252781|NCT03420014|ACTIVE_COMPARATOR|Arm 1: Doxorubicin|Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
62834503|NCT03386383|EXPERIMENTAL|Intervention|Participants will receive an initial individual session, physical activity tracker, weekly behavioral lessons, tailored feedback summaries, and access to a Facebook group immediately after baseline assessments.
62834504|NCT03386383|NO_INTERVENTION|Wait List Control|Participants will receive a physical activity tracker and be advised to maintain their current activity. After 3 months, participants will receive an initial individual session, weekly behavioral lessons, tailored feedback summaries, and access to a Facebook group.
62834505|NCT02932852|ACTIVE_COMPARATOR|GROUP I|lipoaspiration and transplantation of ADAS alone without scaffold
62834506|NCT02932852|ACTIVE_COMPARATOR|GROUP II|Lipoaspiration and transplantation of scaffold (human corneal decellularized lamina) without ADAS
62834507|NCT02932852|ACTIVE_COMPARATOR|GROUP III|Lipoaspiration and transplantation of ADAS cellularized on scaffold (the human corneal decellularized lamina)
62051793|NCT02090634|ACTIVE_COMPARATOR|Psychoeducation (CTRL)|Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. They will also receive daily text messages to assess mood, but these messages will not receive the medication reminder text messages.
62834508|NCT04320316|EXPERIMENTAL|Crysvita (burosumab-twza) Treatment|"The starting dose will be 0.3 mg/kg to be given every 2 weeks. If required dose may be titrated with increments of 0.1 mg/kg/dose every 4 weeks up to a maximum of dose of 2.0mg/kg (not to exceed 90mg per dose) until phosphorus level is WNL.~Patient will receive study drug via SC injection to the abdomen, upper arms, thighs, or buttocks; the injection site will be rotated with each injection. If the dose level exceeds 1.5 mL in volume, the dose should be administered at two injection sites.~Duration of treatment is 52 weeks. Subjects that complete treatment through week 52 may have the option to continue KRN23 treatment. If this is warranted based on preliminary efficacy, the current protocol will be amended to allow for an extension."
62834509|NCT03250715|EXPERIMENTAL|Low Level Laser Therapy group|Six points of application will be defined in the quadriceps and two points of application in the gastrocnemius. The parameters adopted for the irradiation will be: 30 Joules per application point, wavelength of 660 and 850 nm and output power of 200 mW. Each point will be radiated for 30 seconds.
62834510|NCT03250715|NO_INTERVENTION|Control group|This group will receive no intervention. This group will be evaluated before the intervention, after four and eight weeks of follow up.
62834511|NCT04809480||Non-COVID19 patients|All acute invasive fungal rhinosinusitis patients managed in our hospital from January 2017 up to February 2020
62834512|NCT04809480||COVID19 patients|All acute invasive fungal rhinosinusitis patients managed in our hospital from February 2020 up to December 2020 with positive COVID19 PCR test
62834513|NCT06112509|OTHER|Radiosurgery|
62834514|NCT04377893|EXPERIMENTAL|Treatment arm|Participants will receive eye-gaze AT intervention
62834515|NCT00577174||1. Controls|Healthy children ages 8 to 18 years
62834516|NCT00577174||2. Obese childrens|Obese children, ages 8 to 18 years
62051794|NCT02174432|EXPERIMENTAL|nalbuphine HCl ER|nalbuphine HCl ER
62252782|NCT03420014|EXPERIMENTAL|Arm 2: L19TNF plus doxorubicin|"Patients will receive a fixed dose of L19TNF in combination with a fixed dose doxorubicin.~Doxorubicin will be administered as a 15 ± 5 minutes i.v. infusion on day 1 of each 21-day cycle followed by at least 30 minutes pause before starting infusion of L19TNF."
62442111|NCT02110420|EXPERIMENTAL|CC-90001 10mg (Multiple Doses)|
62442112|NCT02110420|EXPERIMENTAL|CC-90001 30mg (Multiple Doses)|
62834517|NCT06595394|EXPERIMENTAL|Interventional group|Participants were given combined exercise training 3 days a week.
62834518|NCT06595394|ACTIVE_COMPARATOR|Control group|Participants were followed with a home program 3 days a week.
62834519|NCT04643613|EXPERIMENTAL|PCNF|Totally 42 cancer patients with poor nutritional status under nasogastric (NG) tube feeding was recruited and administered with the commercial nutritional formula (PCNF; 237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks (84 days).
62834520|NCT01534702|EXPERIMENTAL|Treatment|
62834521|NCT05338619|EXPERIMENTAL|Lazertinib|Lazertinib 240mg, oral, QD
62834522|NCT03183869|ACTIVE_COMPARATOR|Early Intervention|Fecal microbiota via enema at Month 1, 2, 3. 4, 5 and month 6 along with stool, urine and blood collection. At months 7, 8, 9, 10, 11 and 12 only stool, urine and blood collection.
62051795|NCT02234544|PLACEBO_COMPARATOR|Placebo + Cholecalciferol|The groups will be randomized to ezetimibe or placebo. All participants will receive orally a cholecalciferol capsule.
62051796|NCT02234544|ACTIVE_COMPARATOR|Ezetimibe + Cholecalciferol|The groups will be randomized to ezetimibe or placebo. All participants will receive orally a cholecalciferol capsule.
62051797|NCT04230421|EXPERIMENTAL|Monsenso with feedback|Daily smartphone-based monitoring and treatment using the Monsenso system with a clinical feedback loop feedback.
62051798|NCT04230421|ACTIVE_COMPARATOR|Monsenso without feedback|Daily smartphone-based monitoring and treatment using the Monsenso system WITHOUT a clinical feedback loop feedback.
62051799|NCT04230421|ACTIVE_COMPARATOR|Control|CAG Bipolar treatment alone and daily mood monitoring using only the mood monitoring part of the Monsenso system.
62051800|NCT05740202|EXPERIMENTAL|SHR-7367|
62051801|NCT00804401|ACTIVE_COMPARATOR|Test Product|
62051802|NCT00804401|ACTIVE_COMPARATOR|Reference Product|
62252783|NCT04291248|EXPERIMENTAL|Anlotinib+AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
62442113|NCT02110420|EXPERIMENTAL|CC-90001 60mg (Multiple Doses)|
62442114|NCT02110420|EXPERIMENTAL|CC-90001 120mg (Multiple Doses)|
62442115|NCT02110420|EXPERIMENTAL|CC-90001 240mg (Multiple Doses)|
62442116|NCT02110420|EXPERIMENTAL|Placebo|
62442117|NCT02110420|EXPERIMENTAL|CC-90001 480mg (single dose)|CC-90001 480mg will be administered as a single oral dose
62051803|NCT03471169|EXPERIMENTAL|Desirable TEG|Patients receiving antiplatelet medication and desirable thrombelastogram(TEG) test results.
62051804|NCT03471169|SHAM_COMPARATOR|Undesirable TEG|Patients receiving antiplatelet medication and undesirable thrombelastogram(TEG) test results.
62252784|NCT04291248|EXPERIMENTAL|AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.
62442118|NCT02110420|EXPERIMENTAL|CC-90001 720mg (single dose)|CC-90001 720mg will be administered as a single oral dose
62442119|NCT02110420|EXPERIMENTAL|CC-90001 480mg (multiple doses)|CC-90001 480mg will be administered daily for 14 days
62611446|NCT04341558|ACTIVE_COMPARATOR|Intervention|Family carers will be trained to perform and document basic vital signs whilst they provide personal care to their relatives after surgery in order to supplement patient monitoring conducted by nursing staff.
62611447|NCT04977414|NO_INTERVENTION|Waitlist control group|Hospitals assigned to this group will be placed in on a waitlist to receive the training intervention at a later date
62834523|NCT03183869|ACTIVE_COMPARATOR|Late Intervention|At months 1, 2, 3, 4, 5 and 6, stool, urine and blood collection. Fecal microbiota via enema at month 6, 7, 8, 9, 10, 11and 12 months along with stool, urine and blood collection.
62834524|NCT00080535|EXPERIMENTAL|LMB-2 for cutaneous Tcell lymphoma|30 micrograms/kg every other day (QOD) x 3 every 4 weeks in patients with cutaneous T-cell lymphoma, a group of lymphoproliferative disorders characterized by malignant CD4+ T-lymphocytes which localize tot he skin on initial presentation.
62834525|NCT02624076|EXPERIMENTAL|Acupuncture plus expectant management|
62051805|NCT02837640|EXPERIMENTAL|Treatment|"This is a single armed study. All patients included will receive treatment. Control will happen with data from the same patients before they received treatment.~patients will receive sinemet 200/50 1/2 tablet (levodopa-carbidopa 100/25) b.i.d for two days and then will be increased to t.i.d. for 6 months."
62442120|NCT04968210||Pulmonary arterial hypertension (PAH)|Patients that have been clinically diagnosed with pulmonary arterial hypertension and fall under the category of WHO group 1 PAH.
62442121|NCT01851213||FoundationOne™ Test Ordered|Patients for whom a FoundationOne™ test was ordered and a report is delivered.
62611448|NCT04977414|EXPERIMENTAL|"Making data count intervention group"|The Making Data Count training intervention was designed by NHS-Improvement to improve knowledge about SPC charts and to increase their uptake. Training sessions are tailored for two sets of attendees: board members and data analysts. Board member and analyst training sessions are delivered as close as possible in time, typically within the same month. Training sessions for board members are usually delivered over about one-and-a-half hours and focus more heavily on the benefits of control charts compared to other charts. Training sessions for analysts are usually delivered over three hours and focus more heavily on the structure and interpretation of the individual and moving range charts (X-mR charts).
62442122|NCT03775356|NO_INTERVENTION|1 - Blinded|EEG and Entropy will be blinded. The anesthesiological management will be performed by the anesthetist according to clinical standard operations.
62611449|NCT05342493||Drug|Ajovy syringe for SC injection 225 mg.
62611450|NCT00840593|ACTIVE_COMPARATOR|1. Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
62611451|NCT00840593|ACTIVE_COMPARATOR|2 Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
62611452|NCT04977492||observation group|People suffered from excessive lateral pressure syndrome with extracapsular release of lateral retinaculum.
62611453|NCT04977492||control group|People suffered from excessive lateral pressure syndrome with conservative treatment.
62611454|NCT03689101|EXPERIMENTAL|Endometrial biopsies|Endometrial biopsy was performed precisely 7 days after LH surge (LH+7) to count endometrial CD138.
62051806|NCT05001438|ACTIVE_COMPARATOR|Hidro alone|The patient receives the Hidrodilatation guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.
62252785|NCT02336789|PLACEBO_COMPARATOR|placebo|250 ml of normal saline (sham transplantation).
62252786|NCT02336789|ACTIVE_COMPARATOR|intervention|250 ml of diluted fecal material prepared from a screened donor
62252787|NCT02026921|EXPERIMENTAL|Carboplatin and docetaxel|Intravenous infusion every 3 weeks Carboplatin plus docetaxel
62252788|NCT05896449|EXPERIMENTAL|PET/CT before surgery|\[68Ga\]Ga-PSMA-11 PET/CT before surgery
62611455|NCT04967859|PLACEBO_COMPARATOR|Group 1 (control):|Patients using placebo ointment at the exit site of the hemodialysis catheter
62611456|NCT04967859|EXPERIMENTAL|Group 2 (intervention)|Patient using 0.1% gentamicin ointment at the exit site of the hemodialysis catheter
62834526|NCT02624076|ACTIVE_COMPARATOR|expectant management|
62834527|NCT04475796|ACTIVE_COMPARATOR|Early group|
62834528|NCT04475796|ACTIVE_COMPARATOR|Delayed group|
62834529|NCT03629535|EXPERIMENTAL|Patients in SICU|Patients in the SICU with an intra-arterial blood pressure monitor already in place will be considered as subjects.
62834530|NCT03529669|EXPERIMENTAL|Cytosponge™|All participants will receive the Cytosponge™ device.
62834531|NCT04675632||The intervention group|the tibial run off would be treated through endovascular therapy
62834532|NCT04675632||the non-intervention group|the tibial run off would not be treated through endovascular therapy
62611457|NCT02431806|PLACEBO_COMPARATOR|Placebo|Participants received 2 dose matched over-encapsulated placebo capsules, once daily, orally during the Double-blind Treatment Period up to 8 weeks followed by a 1 week Taper-down Period if applicable as determined by the investigator.
62252789|NCT02894710|EXPERIMENTAL|Lidocaine 20mg/ml|Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).
62051807|NCT05001438|EXPERIMENTAL|Hidro + MUA|"The patient receives the Hidrodilatation guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.~After the Hidrodilatation the patient is sedated and then a Movilization of the glenohumeral joint is performed."
62611458|NCT02431806|EXPERIMENTAL|Levomilnacipran 40 mg|Participants received over-encapsulated levomilnacipran extended release (ER) 40 mg/day capsules orally starting at a dose of 10 mg/day on Day 1-2, 20 mg/day on Days 3-7 and 40 mg/day on Week 2 through Week 8 during the Double-Blind Treatment Period, followed by a 1-week Double-Blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule each day to maintain the blind.
62252790|NCT02894710|PLACEBO_COMPARATOR|Glucose 5% (placebo)|Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.
62252791|NCT05503784|EXPERIMENTAL|Bite Deodorant|All 38 participants apply BITE deodorant daily for four weeks.
62252792|NCT03001973||LN patients|Patients diagnosis as lupus nephritis
62252793|NCT06395233|EXPERIMENTAL|Group one: Assured Incentives|Group 1: Assured (Points only): Participants will be able to earn 10 points for each 10 minutes of walking. Every minute will count, the participant does not have to walk for 10 consecutive minutes to receive the points. Once a person has accumulated 10 minutes of walking exercise, their points will be awarded. This will be capped at 40 points per day, i.e. the participant can earn 10 BetterPoints up to four times a day by doing 40 minutes of walking.
62252794|NCT06395233|EXPERIMENTAL|Group 2: Non Assured Incentives|Group 2: Non-Assured (Lottery tickets only): Participants will be able to earn one lottery ticket for each 10 minutes of walking. This is accrued and awarded in the same way as the points condition. It is capped at four tickets per day.
62252795|NCT06395233|EXPERIMENTAL|Group 3: Combined|Group 3: Combined (Combined points/tickets): Participants in group 3 will be able to earn 5 points and one lottery ticket for 10 minutes of walking. The daily lottery in this condition will be for 500 BetterPoints (rather than 1000 BetterPoints in group 2) and therefore each ticket will have an expected value (EV) of 5 BetterPoints. Participants will be able to earn points and tickets in this way for up to 40 minutes of walking per day.
62252796|NCT03439436|EXPERIMENTAL|xylo+dex nasal spray (0.1 mg+5 mg/dose)|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
62252797|NCT03439436|ACTIVE_COMPARATOR|Nasic|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
62611459|NCT02431806|EXPERIMENTAL|Levomilnacipran 80 mg|Participants received over-encapsulated levomilnacipran ER two 40 mg/day capsules (80 mg/day) orally starting at a dose of 10 mg/day on Day 1-2, 20 mg/day on Day 3-4, 40 mg/day on Day 5-7 and 80 mg/day on Week 2 through Week 8 during the Double-blind Treatment Period, followed by a 1-week Double-blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule the first week and during the taper-down period to maintain the blind.
62611460|NCT02431806|ACTIVE_COMPARATOR|Fluoxetine 20 mg|Participants received over-encapsulated fluoxetine 20 mg/day tablets orally starting at a dose of 10 mg/day in Week 1 and 20 mg/day in Week 2 through Week 8 during the Double-blind Treatment Period, followed by a 1-week Double-blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule each day to maintain the blind.
62834533|NCT04871646|EXPERIMENTAL|CKD-314|Treatment with CKD-314 + SOC
62834534|NCT04871646|PLACEBO_COMPARATOR|CKD-314 Placebo|Treatment with CKD-314 Placebo + SOC
62834535|NCT02720419||Synergy stent|
62252798|NCT06238609|ACTIVE_COMPARATOR|Intervention Group|Subjects will receive a functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
62252799|NCT06238609|SHAM_COMPARATOR|Control group|Subjects will receive a non-functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
62611461|NCT06093971|EXPERIMENTAL|Group remimazolam|During anesthesia induction, the remimazolam group (group R) receives remimazolam (0.2 mg/kg). If necessary, an additional dose of remimazolam (0.1 mg/kg) is administered.
62611462|NCT06093971|ACTIVE_COMPARATOR|Group propofol|During anesthesia induction, the propofol group (group P) receives propofol (1.0 mg/kg). If necessary, an additional dose of propofol (0.5 mg/kg) is administered.
62834536|NCT05969158|EXPERIMENTAL|Hetrombopag|Hetrombopag 5mg/d
62834537|NCT01816035|EXPERIMENTAL|Treatment (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving response may continue treatment.
62834538|NCT04721886|EXPERIMENTAL|Diagnostic (CEUS)|Patients undergo ultrasound without contrast. Patients then receive Definity IV over 15 minutes and undergo CEUS.
62834539|NCT00749255||FFDM|a sum of at least 200 cancer cases, mammographically visible, on at least one image view (including masses and calcifications)
62834540|NCT03568227|EXPERIMENTAL|Healthy Subjects|"The study has a 2 (Intervention: Hypnosis, Control) x 2 (State: 1 \& 2) factorial within-subjects design, resulting in a total of 4 conditions. All volunteers participate at the 4 conditions in the same session.The order of the interventions is counterbalanced resulting in two possible sequences:~Sequence 1: Hypnosis State 1, Hypnosis State 2, Control State 1, Control State 2~Sequence 2: Control State 1, Control State2, Hypnosis State 1, Hypnosis State 2~Volunteers will be randomly allocated to the two sequence types."
62834541|NCT04696965|EXPERIMENTAL|Correct/recheck strategy|Patients of study arm will be asked to show how they use their two inhalers and identify errors using a device-specific checklist by research assistant. Research assistant then show the patient how to use these devices correctly and give the checklist including the steps patients did wrong. After teaching by the research assistant, patients were asked to demonstrate the correct way of wrong step(s) they made at beginning.
62834542|NCT04696965|ACTIVE_COMPARATOR|Usual verbal instruction|Patients of control arm will be asked to show how thy use their two inhalers and identify errors using specific check list by research assistant. The educational nurse will give verbal instruction.
62834543|NCT05866315|ACTIVE_COMPARATOR|Group DLR|Administer desflurane at 1 MAC, adjust the dose by 1 vol% titration to maintain MAP and BIS levels, and remifentanil at 0.025 µg/kg/min.
62611463|NCT05086341|EXPERIMENTAL|My COPD|In addition to usual care, participants in the intervention group will receive a 12-week, twice a week, physiotherapist-supported individualized exercise program and physical activity plan via the eHealth tool My COPD.
62252800|NCT02504359|EXPERIMENTAL|Treatment (BEAM allogeneic transplant, ixazomib)|"BEAM CONDITIONING REGIMEN: Patients receive carmustine on day -6, cytarabine and etoposide on days -5 to -2, and melphalan on day -1.~PERIPHERAL BLOOD STEM CELL TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO on days -2 to at least 6 months with a taper as early as 3 months post-transplant and methotrexate IV on days 1, 3, 6, and 11.~MAINTENANCE THERAPY: Beginning between days 100 and 180 post-transplant, patients receive ixazomib PO on days 1 and 14 or days 1, 8, and 15 if the principal investigator deems it medically important. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
62252801|NCT03527082||Women attending gynaecology clinics|"150 women attending gynaecology clinics that fulfil inclusion criteria~Inclusion criteria:~Inclusion criteria~1. Over the age of 18~2. attending gynaecology clinics~3. Able to read and comprehend the details of the study in patient information sheet.~4. Mentally competent at signing the consent form.~5. English -speaking, if not then translator available"
62611464|NCT05086341|NO_INTERVENTION|Usual care|Participants in the control group will receive usual care only. Usual care is recommended to include, but not restricted to, long-acting anticholinergics and long-acting ß2-antagonists with 24-hour duration and support for smoking cessation, PA and exercise, self-management and nutrition.
62611465|NCT01675375|EXPERIMENTAL|Eye shield|Eye shield place on post Laser Vision Correction eye
62611466|NCT06441422|EXPERIMENTAL|Low load resistance training with blood flow restriction|Low load resistance training routine at 30-50% of a person's 1-repetition maximum with arterial occlusion pressure at 80%
62611467|NCT06441422|ACTIVE_COMPARATOR|Low load resistance training|Low load resistance training routine at 30-50% of a person's 1-repetition maximum
62834544|NCT05866315|EXPERIMENTAL|Group DHR|Administer desflurane at 1 MAC, adjusting the dose by 1 vol% titration to maintain MAP and BIS levels, and remifentanil at 0.3 µg/kg/min.
62834545|NCT05866315|EXPERIMENTAL|Group RHR|Administer remimazolam at a dose of 6 mg/kg/h initially, followed by 1 mg/kg/h, and remifentanil at 0.3 µg/kg/min.
62623555|NCT03864003|EXPERIMENTAL|Experimental group|Participants randomized to the experimental group will receive hearing aid fitting and verification services via teleaudiology with local, hands-on support from a Community Health Worker.
62623556|NCT03864003|ACTIVE_COMPARATOR|Control Group|Participants randomized to the control group will receive hearing aid fitting and verification services via teleaudiology with local, hands-on support from a non-Community Health Worker (undergraduate student in Speech, Language, and Hearing Sciences).
62252802|NCT03511053|EXPERIMENTAL|All participants|Epidural Lavage followed by Lumbar Epidural Steroid Injection
62252803|NCT05353699|EXPERIMENTAL|Intervention groups|
62252804|NCT05353699|NO_INTERVENTION|Control groups|as same as before
62834546|NCT03791814|EXPERIMENTAL|Zepatier treatment|Open-label Zepatier (grazoprevir 100 mg and elbasvir 50 mg) will be administered in this study. Daily treatment of Zepatier for a 12-week duration will be administered.
62834547|NCT00195104|EXPERIMENTAL|All Patients|Arsenic trioxide \[TrisenoxTM Injection\], 0.25mg/kg/dose administered intravenously over 1 to 4 hours
62252805|NCT05069506|EXPERIMENTAL|Glucose as reference food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62252806|NCT05069506|EXPERIMENTAL|Goat milk as test food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62252807|NCT05069506|EXPERIMENTAL|Goat milk and currants as test food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62252808|NCT05069506|EXPERIMENTAL|Currants as test food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62252809|NCT05069506|EXPERIMENTAL|Sultanina raisins as test food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62834548|NCT04546672|EXPERIMENTAL|Sugammadex|Sugammadex 2 mg/kg IV once at the end of surgery
62834549|NCT04546672|ACTIVE_COMPARATOR|Neostigmine|Neostigmine 0.07 mg/kg to a maximum of 5 mg (+Glycopyrrolate 0.2 mg per 1 mg of neostigmine administered) IV once at the end of surgery
62834550|NCT02172885|EXPERIMENTAL|Mesenchymal stem cells|Five Mesenchymal Stem Cell infusions
62834551|NCT05624970|EXPERIMENTAL|group (A)|"Group (A):~This group will consist of 30 patients who will receive the medical treatment (oral hypoglycemic drugs), aerobic training, tobacco cessation program and nutritional advices for 12 weeks."
62834552|NCT05624970|EXPERIMENTAL|group (B)|"Group (B):~This group will consist of 30 patients who will receive the medical treatment (oral hypoglycemic drugs), tobacco cessation program and nutritional advices for 12 weeks."
62834553|NCT03252431|EXPERIMENTAL|F-627|F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.
62834554|NCT03252431|ACTIVE_COMPARATOR|Neulasta|6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles
62834555|NCT05876715|EXPERIMENTAL|Phase 1/2 study using lurbinectedin, ipilimumab and nivolumab for advanced soft tissue sarcoma|"This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.~I. Dose Escalation Phase 1 of Study: The study will employ the standard cohort of three design (Storer, 1989).~II.Phase 2 of Study: Following completion of dose escalation, an additional 28-34 previously untreated participants will receive LURBINECTEDIN at the MTD and fixed doses of IPILIMUMAB and NIVOLUMAB to assess overall safety and potential efficacy in a larger number of participants."
62834556|NCT01870518|ACTIVE_COMPARATOR|Parkinson's patients with MCI|Procedure: deep brain stimulation surgery
62252810|NCT05069506|EXPERIMENTAL|Goat milk as preload|Forty-five healthy subjects (male: 12, female: 33) were offered a standardized breakfast and 2h after consumed one of the two preloads (goat milk yogurt and milk with lactic acid) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
62252811|NCT05069506|EXPERIMENTAL|Milk with lactic acid as preload|Forty-five healthy subjects (male: 12, female: 33) were offered a standardized breakfast and 2h after consumed one of the two preloads (goat milk yogurt and milk with lactic acid) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
62252812|NCT04118270|EXPERIMENTAL|AFib 2gether(TM) App|Patients with known Atrial Fibrillation will be assigned to download and use an app targeted at determining stroke risk and increasing knowledge of Atrial Fibrillation and stroke risk along with treatment options and will use this information to facilitate a discussion with their cardiovascular provider.
62252813|NCT01120392|EXPERIMENTAL|Treatment group - Nintendo wii.|
62252814|NCT01120392|ACTIVE_COMPARATOR|conventional - Physical Therapy|
62252815|NCT05407597|ACTIVE_COMPARATOR|Icatibant and Standard of care (SOC)|Icatibant will be given as a single, subcutaneous injection
62252816|NCT05407597|PLACEBO_COMPARATOR|0.9% Sodium Chloride and Standard of care (SOC)|Placebo will be given as a single, subcutaneous injection
62252817|NCT03945591|EXPERIMENTAL|Cyclophosphamide and Bortezomib|
62252818|NCT06004648||Supraclavicular nerve block|"The high- frequency linear USG probe will be placed in the supraclavicular fossa pointing caudally, and the subclavian artery will be localized by moving it medially and laterally. A characteristic honeycomb plexus will be visualized in the lateral and superficial subclavian artery. Vascular structures will be detected using color Doppler, the first rib will be visualized as hyperechoic structure. After the pleura, which makes a~sliding movement through the patient\&#39;s breathing is detected, a 22 gauge, 80 mm scale peripheral block needle will be directed from the lateral to the medial by an in-plane technique. After the sheath punctured, nerves will be determined with triceps, biceps, and wrist motor activity by using a nerve stimulator, and then 15 ml of 0.5% bupivacaine will be injected between the 1st rib and the lower trunk."
62252819|NCT06004648||Selective Trunk Block|Sequential ultrasound imaging technique (SUIT) will be used which is shown successfully in identifying individual elements of the brachial plexus. The neural complex of the upper trunk, middle trunk, and C8 ventral ramus, which are superficial to the T1 TP-1.rip complex will be defined. The first injections contains 8 ml and 7 ml 0.5% bupivacaine will be made as, close to the upper trunk(8ml) and middle trunk(7ml) in the interscalene groove. Then the needle will be completely withdrawn.The ultrasound probe will be placed caudally in the supraclavicular fossa. After providing the optimal view of the lower trunk in the corner pocket, 10 ml of 0.5% bupivacaine will be injected between the first rib and lower trunk.
62252820|NCT04516317||Group intravenous artesunate (around 300 patients)|Period 2011-2019
62252821|NCT04516317||Group intravenous quinine (around 300 patients)|Period 2000-2010
62252822|NCT05175573|EXPERIMENTAL|SuperNO2VA Et|Continuous positive airway pressure with end-tidal CO2 monitoring
62252823|NCT05175573|ACTIVE_COMPARATOR|Supplemental Oxygen Face Mask|
62252824|NCT04977765||Transgender Males|Individuals assigned female gender at birth but considering gender-affirming testosterone therapy. May self-identify as transgender or nonbinary etc.
62834557|NCT01870518|ACTIVE_COMPARATOR|Parkinson's patients without MCI|Procedure: deep brain stimulation surgery
62834558|NCT02012413|ACTIVE_COMPARATOR|PST group|roughly 20 patients will be treated with PST protocol, outcomes will be Kujala score improvement at 3, 6 and 12 months.
62834559|NCT02012413|PLACEBO_COMPARATOR|Control group|roughly 20 patients will be submitted to a placebo PST protocol, outcomes will be Kujala score improvement at 3, 6 and 12 months.
62252825|NCT04977765||Cisgender Controls|Individuals assigned male or female at birth. May identify as cisgender or nonbinary etc. These individuals should not be undergoing or considering any form of hormone therapy.
62252826|NCT06387173||Observational|Patients have their medical records reviewed on study.
62252827|NCT00353834|ACTIVE_COMPARATOR|Glargine insulin|Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve fasting blood glucose of 100 mg/dl and avoid hypoglycemia.
62252828|NCT00353834|EXPERIMENTAL|Exenatide|Exenatide 5ug twice daily for 4 weeks followed by 10 ug twice daily for 8 weeks.
62252829|NCT05259813|EXPERIMENTAL|JWCAR029 Treatment|Dose-finding for JWCAR029 monotherapy
62252830|NCT04307160||Group I|Patients ≤ 5 years of age
62252831|NCT04307160||Group II|Patients ≥ 7 years of age
62252832|NCT01406236|OTHER|Transradial PCI|
62252833|NCT01406236|OTHER|Transfemoral PCI|
62252834|NCT04862624|EXPERIMENTAL|Story-based media|Participants will receive a link to our story-based media with Latina characters.
62252835|NCT04862624|ACTIVE_COMPARATOR|Attention control media|Participants will receive a link to non-story based media that is informational and does not involve story characters.
62252836|NCT05317884|NO_INTERVENTION|No Contact|No reminder sent
62252837|NCT05317884|EXPERIMENTAL|Reminder|Reminder email with contact information to set an appointment will be sent 12 weeks before the appointment.
62252838|NCT00652730|EXPERIMENTAL|A|Subjects received the Par formulated product under fasting conditions
62051808|NCT04999982|EXPERIMENTAL|Intervention group- PRE-CARE|Participants will receive the 1:1 PRE-CARE social needs navigation intervention with specific content and delivery strategy which was developed based on 1) quantitative analyses of the association between unmet social needs and ADHD symptoms in a large-scale nationally representative sample of children age 3-5, and 2) in-depth qualitative interviews with parents/guardians of preschoolers with inattention and/or hyperactivity symptoms to identify mechanisms by which unmet social needs exacerbate ADHD symptoms and functioning.
62051809|NCT04999982|ACTIVE_COMPARATOR|Control group- Care as Usual|Families randomly assigned to the control condition will continue to receive care as usual, which includes screening for social needs annually at well-child visits as recommended by the American Academy of Pediatrics (AAP), followed by provision of information as needed by the family. Families will also be offered the opportunity to make research assessments available to their primary care physician for best continuity of care.
62252839|NCT00652730|EXPERIMENTAL|B|Subjects received the Par formulated product under fed conditions
62252840|NCT00652730|ACTIVE_COMPARATOR|C|Subjects received the Bristol-Myers Squibb formulated product under fed conditions
62623557|NCT02844270|EXPERIMENTAL|Galaxy stent|The galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System will be implanted in all subjects.
62623558|NCT00812500|EXPERIMENTAL|1|Young men, age 21-46 years.
62834560|NCT05290714|EXPERIMENTAL|Mentalization Based Treatment for Children (MBT-C)|Mentalization Based Therapy for Children (MBT-C) is a transdiagnostic time-limited (12 weekly sessions) and manualized treatment for children aged between 5 to 12 years old with the main aim of increasing mentalization and restoring epistemic trust. Parallel parental work takes place to increase parental mentalization.
62051810|NCT03067454|OTHER|conservative group|Treatment with early mobilisation
62051811|NCT03067454|OTHER|operative group|Treatment with operation
62051812|NCT04436315|EXPERIMENTAL|Intervention|Exergame intervention
62051813|NCT04436315|SHAM_COMPARATOR|Control|Active control condition
62442123|NCT03775356|ACTIVE_COMPARATOR|2 - Unblinded|EEG and Entropy will be unblinded. The intervention starts with the start of a positive burst suppression rate. In the case of a concurrent hypotension the anesthetist treats the hypotension according to clinical standard operations in the first step. Hypotension means blood pressure values blow the baseline value which is defined by the lowest, preoperatively measured value. If after this treatment and a reevaluation of the BSR, BSR remains positive, the anesthetist is going to reduce the concentration of anesthetics in a second step. In case of positive BSR and a blood pressure value ≥ the baseline value, the concentration of anesthetics will be reduced as a first measure. The aim is to figure out whether one or both of these interventions can reduce to total, cumulative BSR.
62442124|NCT03136991|ACTIVE_COMPARATOR|Cohort 1|Participants will receive AZD4831 5 mg/placebo oral suspension.
62051814|NCT05918497||Group 1|.patients who will switch to twice weekly dosing. Their weekly dose was divided equally into those doses, given at successive fixed days of the week
62252841|NCT03276312|EXPERIMENTAL|Intervention|Lipogems - local injection of autologous micro-fragmented adipose tissue
62252842|NCT03276312|NO_INTERVENTION|Control|Routine clinical practice
62252843|NCT04603131|EXPERIMENTAL|BBV87 - 10 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths (10, 20 and 30 mcg) administered intramuscularly on Day 0, 29 and 57
62252844|NCT04603131|PLACEBO_COMPARATOR|Placebo|Placebo administered intramuscularly on Day 0, 29 and 57
62252845|NCT04603131|EXPERIMENTAL|BBV87 -30 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths administered intramuscularly on Day 0, 29 and 57
62442125|NCT03136991|ACTIVE_COMPARATOR|Cohort 2|Participants will receive AZD4831 (Additional dose 1)/placebo oral suspension.
62442126|NCT03136991|ACTIVE_COMPARATOR|Cohort 3|Participants will receive AZD4831 (Additional dose 2)/placebo oral suspension.
62442127|NCT03136991|ACTIVE_COMPARATOR|Cohort 4|Participants will receive AZD4831 (Additional dose 3)/placebo oral suspension.
62442128|NCT05097885|EXPERIMENTAL|Sub Acute (12 week) Whole Body Training|
62442129|NCT00962299|ACTIVE_COMPARATOR|Beclomethasone|Inhaled corticosteroids
62442130|NCT00962299|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62442131|NCT02572583|EXPERIMENTAL|Liugan Shuangjie Heji Group|Liugan Shuangjie Heji, take orally, 4 times a day, 100 ml each time (i.e. two doses per day), for a course of five days.
62442132|NCT02572583|ACTIVE_COMPARATOR|Shufeng Jiedu Capsule Group|Shufeng Jiedu Capsule, take orally, 3 times a day, 4 capsules each time, for a course of five days.
62442133|NCT02572583|ACTIVE_COMPARATOR|Oseltamivir Phosphate Capsule Group|Oseltamivir Phosphate Capsule, take orally, 2 times a day, 75 mg each time, for a course of five days.
62442134|NCT02724137|EXPERIMENTAL|Physical Therapy Rehab and Fitbit®|Standard outpatient physical therapy rehabilitation after total knee replacement with the addition of a Fitbit® to promote physical activity.
62442135|NCT02724137|ACTIVE_COMPARATOR|Physical Therapy Rehab|Standard outpatient physical therapy rehabilitation after total knee replacement.
62442136|NCT05945394||Patients with suspected CHD who experienced CAG|Patients with suspected coronary heart disease who experienced coronary angiography
62442137|NCT03687125|EXPERIMENTAL|Tinostamustine 180 mg/m^2|Participants received single dose of tinostamustine 180 milligrams per meter square (mg/m\^2) intravenous (IV) injection on Day -1 followed by autologous stem cell transplantation (ASCT) on Day 1.
62442138|NCT03687125|EXPERIMENTAL|Tinostamustine 220 mg/m^2|Participants received single dose of tinostamustine 220 mg/m\^2 IV injection on Day -1 followed by ASCT on Day 1.
62442139|NCT06278285|OTHER|whole blood in a GLP1|Oxytocyne assay in a GLP1 analogue or non-analogue patient population
62623559|NCT00812500|EXPERIMENTAL|2|Old Men, age 63-81 years.
62623560|NCT00812500|EXPERIMENTAL|3|Young women, age 21-46 years.
62623561|NCT00812500|EXPERIMENTAL|4|Old women, age 63-81 years.
62611468|NCT02143830|EXPERIMENTAL|Arm A: Good Risk Patients|Patients 18 years old or younger with marrow aplasia or single lineage cytopenias will be receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days), as used in our most current study that led to \> 90% survival rates . Busulfan pharmacokinetics will not be used. All patients will receive rabbit ATG (4 doses x 4 days) prior to and granulocyte-colony stimulating factor (G-CSF) after transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells for all patients will be peripheral blood stem cells mobilized by treatment of the donor with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). Enrollment on this arm will include up to 50 patients.
62611469|NCT02143830|EXPERIMENTAL|Arm B: Intermediate Risk Patients|"Patients 18 years old or younger with MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). Busulfan pharmacokinetics will be used in this arm, as the dose of busulfan is higher. All patients will receive rabbit ATG (thymoglobulin) (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for prophylaxis against GVHD. The source of the stem cells for all patients will be peripheral blood stem cells induced and mobilized by treatment of the donor. T-cell will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).~The maximum number of patients enrolled in this arm will be 10."
62611470|NCT02143830|EXPERIMENTAL|Arm C: High Risk Patients|Patients 19 years old or older with marrow aplasia or MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). In this study, we will test whether outcomes can be improved, yet engraftment maintained, with a slightly reduced dose of busulfan. Patients will receive rabbit ATG (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells will be peripheral blood stem cells collected from donors treated with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). The maximum number of patients enrolled will be 10.
62611471|NCT02561663|EXPERIMENTAL|NWT-03, followed by placebo|Dietary Supplement: NWT-03, an egg-white protein hydrolysate For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given Dietary Supplement: Placebo A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
62051815|NCT05918497||Group 2|patients who will switch to once-weekly dosing.
62051816|NCT05918497||Group 3|patients who will continue to take L T4 on a standard daily basis.
62051817|NCT02428296|EXPERIMENTAL|Patients with PIK3CA gene mutation treated with Sirolimus|This is a single-arm, non-randomized, open-label study for the treatment of segmental overgrowth disorders (somatic PIK3CA gene mutation) with Sirolimus in thirty-nine patients.
62051818|NCT03731702||General Individuals|Any adult working at the NCI who has not used antibiotics in the past 3 months.
62051819|NCT01209065|EXPERIMENTAL|Part A|Approximately 12 subjects will be enrolled. In the first treatment period, all subjects will receive GSK1349572 50 mg every 24 hours for 5 days. In Period 2, subjects will receive GSK1349572 50 mg every 24 hours in combination with fosamprenavir 700 mg plus ritonavir 100 mg every 12 hours for 10 days. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
62051820|NCT01209065|EXPERIMENTAL|Part B|Approximately 15 subjects will be enrolled and receive three single doses of GSK1349572 approximately one week apart. One will be the current tablet formulation containing micronized drug substance and 2 will be new tablet versions, one containing unmicronized drug substance and one containing an intermediate particle size drug substance. Subjects will have a screening visit within 30 days prior to the first dose of study drug, three treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
62051821|NCT06075420||complex coronary artery disease|"\<Clinical factors\>~* Age 75 or older~* History of diabetes (those who have had diabetes in the past or are taking diabetes medication)~* History of chronic kidney disease (GFR \<60ml/min/1.73m2) or dialysis~* History of stroke~* History of coronary artery bypass surgery~* Left ventricular dysfunction (LVEF \<40%)~* Severe valve disease~* Troponin positive acute coronary syndrome~\<Lesion/procedure factors\>~* Left main lesion~* Chronic total occlusion~* Bifurcation lesion with branches larger than 2 mm~* Calcified lesion (moderate to severe calcified lesion)~* Restenosis (in-stent restenosis)~* Multivessel PCI~* Three or more stents implanted (≥3 stents implanted)~* When the stent length of one lesion is more than 50 mm (total stent length \>50 mm in a lesion)"
62442140|NCT06278285|OTHER|whole blood in non analague patient population|Oxytocyne assay in a GLP1 analogue or non-analogue patient population
62611472|NCT02561663|EXPERIMENTAL|Placebo, followed by NWT-03|Dietary Supplement: NWT-03, an egg-white protein hydrolysate For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given Dietary Supplement: Placebo A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
62611473|NCT01743118|EXPERIMENTAL|Psoriasis Plaque Test|SPS4251 Ointment, 0.01%; SPS4251 Ointment, 0.1%; SPS4251 Ointment, 1%; SPS4251 Placebo, Daivonex® ointment
62252846|NCT04603131|EXPERIMENTAL|BBV87 -20 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths administered intramuscularly on Day 0, 29 and 57
62252847|NCT02413840|EXPERIMENTAL|Baduanjin qigong group|Doing exercise of Baduanjin qigong under the guidance of medical staff;psychological counseling at the same time.
62252848|NCT02413840|NO_INTERVENTION|control group|Psychological counseling only.
62252849|NCT04979689|EXPERIMENTAL|Intensive physical therapy|Intensive session
62442141|NCT01851161||Diagnostic (CT and 4D CT in supine and prone positioning)|Patients undergo conventional CT scan and 4D CT scan in both supine and prone positioning before undergoing radiation therapy.
62442142|NCT01314755|EXPERIMENTAL|immune-enhancing feed IMPACT|immune-enhancing feed IMPACT
62442143|NCT01314755|ACTIVE_COMPARATOR|control arm|iso-nitrogenous, iso-caloric control feed
62442144|NCT02489890|NO_INTERVENTION|Non-CIK|After accepting chemotherapy, patients will regularly follow up.
62611474|NCT00223730|EXPERIMENTAL|citrulline|Patients randomized to receive oral citrulline at 3.8 gm/m2 in split BID dosing
62611475|NCT00223730|PLACEBO_COMPARATOR|Placebo|Patients randomized to receive oral diluent for citrulline in BID dosing
62051822|NCT06380699|EXPERIMENTAL|Part-A SAD in healthy subjects(Cohort 1-2)|A randomized, double-blinded, positive drug and placebo-controlled, single ascending dose (SAD) study in healthy male and female subjects. Subjects will receive QHRD106 by intramuscular-injection (im).
62051823|NCT06380699|EXPERIMENTAL|Part-B MAD in healthy subjects(Cohort 3-5)|A randomized, double-blinded, positive drug and placebo-controlled, multiple ascending dose (MAD) study in healthy male and female subjects. Subjects will receive QHRD106 by intramuscular-injection (im).
62252850|NCT04979689|OTHER|Non intensive physical therapy|Non intensive session
62252851|NCT00798057||Proton Radiation|
62051824|NCT06380699|PLACEBO_COMPARATOR|Part-C Healthy subjects SAD placebo|A randomized, double-blinded, positive drug and placebo-controlled, single ascending dose (SAD) study in healthy male and female subjects. Subjects will receive placebo by intramuscular-injection (im).
62051825|NCT06380699|PLACEBO_COMPARATOR|Part-D Healthy subjects MAD placebo|A randomized, double-blinded, positive drug and placebo-controlled, single ascending dose (SAD) study in healthy male and female subjects. Subjects will receive placebo by intramuscular-injection (im).
62051826|NCT06380699|ACTIVE_COMPARATOR|Part-E Healthy subjects MAD positive drug|A randomized, double-blinded, positive drug and placebo-controlled, single ascending dose (SAD) study in healthy male and female subjects. Subjects will receive Human Urinary Kallidinogenase by Intravenous infusion (iv).
62051827|NCT04755101|ACTIVE_COMPARATOR|Righ-sided ARGP ablation|two-thirds of the patients will be randomized to procedural arm A: a diagnostic evaluation followed by cardio-neuromodulation (CardNM) and a pharmacological evaluation
62051828|NCT04755101|SHAM_COMPARATOR|Placebo|one-third of the patients will be randomized to procedural arm B: a diagnostic evaluation followed by a pharmacological evaluation.
62252852|NCT03339388|EXPERIMENTAL|Enhanced Lithotripsy System|Treatment of urinary stones with the Enhanced Lithotripsy System
62252853|NCT03302975|EXPERIMENTAL|Real time biofeedback|Real-time visual biofeedback of braking forces during a treadmill run.
62252854|NCT04069195|ACTIVE_COMPARATOR|DHA supplement|Patients in the intervention group will recieve a \~1000mg capsule containing \~400mg of DHA. This is not standard of care and is being done for research purposes only. Patients will take this capsule once daily begining between 8-14 weeks of pregnancy until delivery of their infant.
62252855|NCT04069195|PLACEBO_COMPARATOR|corn oil: Soybean oil placebo|Patients in the Placebo group will recieve a \~1000mg capusle containing no DHA and filled with 50:50 mix of corn and soybean oils. This oil is ubiquitous in the american diet and only a very small amount of additional oil will be ingested for study purposes. Giving pregnant women this oil is not standard of care and is being done for research purposes only. Patients will continue taking this placebo from enrollment at 8-14 weeks of pregnancy until time of delivery.
62611476|NCT02636803|EXPERIMENTAL|oxfendazole 6 mg/kg|patients receive 6 mg/kg oxfendazole once
62611477|NCT02636803|EXPERIMENTAL|oxfendazole 30 mg/kg|patients receive 30 mg/kg oxfendazole once
62252856|NCT01847430|EXPERIMENTAL|HBV Group|Subjects received a single dose of Engerix™-B Kinder vaccine (HBV). The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62252857|NCT03419039|EXPERIMENTAL|Anthocyanins|Medox. 2 capsules x 2 daily, 320 mg daily.
62252858|NCT03419039|PLACEBO_COMPARATOR|Placebo|2 identically appearing placebo capsules daily
62611478|NCT02636803|EXPERIMENTAL|oxfendazole 6 mg/kg 3 times|patients receive 6 mg/kg oxfendazole three times
62611479|NCT02636803|ACTIVE_COMPARATOR|albendazole 400 mg|patients receive 400 mg albendazole once
62611480|NCT03130140|ACTIVE_COMPARATOR|Macroscopic on-site evaluation|EUS-FNA perform with a 19-gauge needle with macroscopic on-site evaluation.
62611481|NCT03130140|SHAM_COMPARATOR|Control|EUS-FNA perform with a 19-gauge needle with conventional techniques.
62611482|NCT06179732|NO_INTERVENTION|Control|"1. Information and Education Campaigns (IEC) campaigns will formally encourage breeding site management through; good practice household-level water storage (covering and cleaning of water storage containers) and waste management (removal of potential breeding sites in and around the home).~2. Epidemiological surveillance: test and treat malaria cases in children 6 - 10 years of age"
62442145|NCT02489890|EXPERIMENTAL|CIK|After accepting chemotherapy, patients will receive at least 3 cycles of Cytokine-induced Killer Cells treatment per year.
62834561|NCT05290714|ACTIVE_COMPARATOR|Parenting and Social Skills Group|"Parenting groups will run for 12 weeks with 10 parents per group. They will involve activities to help parents develop effective parenting skills via working on a family genogram, providing information on child development, developing acceptance and empathy, setting boundaries and anger regulation.~The social skills groups will run for 12 weeks and will be conducted with 10 children per group. They will involve activities on self-presentation, peer communication, play skills, empathy and anger management."
62834562|NCT02911584|ACTIVE_COMPARATOR|Sacral colpopexy|Laparoscopic procedure
62834563|NCT02911584|ACTIVE_COMPARATOR|POPS|Laparoscopic procedure: Pelvic Organs Prolapse Suspension
62834564|NCT03646552|EXPERIMENTAL|THX-110|All participants will be titrated up on THX-110 (Dronabinol) dose during the first week of the trial (2.5mg Dronabinol for 3 days, 5mg Dronabinol for 3 days to 7.5mg Dronabinol for 3 days and finally increasing to 10mg for the remainder of the trial). Dronabinol will only be increased if the subject is tolerating the previous dose of Dronabinol and the Dronabinol may be reduced based on patient side-effects. Participants will be receiving 800mg PEA concomitantly.
62834565|NCT03835806|ACTIVE_COMPARATOR|Elastikon - traditional|The participant will be randomized to a treatment arm according to their racing bib number. Even bib numbers will be in the Elastikon treatment arm. The researcher will evaluate the blister and treat according to treatment arm with the following blister treatment device intervention: the blister will be prepped per routine, drained, covered with paper tape, sprayed with adhesive spray and then covered with Elastikon.
62834566|NCT03835806|EXPERIMENTAL|Rocktape - novel|The participant will be randomized to a treatment arm according to their racing bib number. Odd bib numbers will be in the Rocktape treatment arm. The researcher will evaluate the blister and treat according to treatment arm with the following blister treatment device intervention: the blister will be prepped per routine, drained, covered with paper tape and then covered with Rocktape
62834567|NCT06201780|ACTIVE_COMPARATOR|cases group|group of cases with cholinergic urticaria
62834568|NCT06201780|ACTIVE_COMPARATOR|control group|control group not have cholinergic urticaria
62834569|NCT05005117|EXPERIMENTAL|Laparoscopic operation|Laparoscopic emergency colon resection
62834570|NCT05005117|ACTIVE_COMPARATOR|Open operation|Open emergency colon resection
62834571|NCT02600234|EXPERIMENTAL|Treatment with Inter-Atrial Shunt Device|Once all study criteria have been met, if randomized to this arm, patients will receive the IASD implant.
62834572|NCT02600234|PLACEBO_COMPARATOR|Control|Once all study criteria have been met, if randomized to this arm, patients will not receive the implant. They will undergo an intracardiac echo only, with the option to crossover at 1 year.
62834573|NCT00779350|EXPERIMENTAL|1|sertraline 100 mg tablets of ranbaxy
62051829|NCT00136786|PLACEBO_COMPARATOR|Intervention 1|"Each participant receives three consecutive interventions.~1. Placebo~2. Bupropion~3. Memantine"
62051830|NCT00136786|PLACEBO_COMPARATOR|Intervention 2|"1. Bupropion~2. Memantine~3. Placebo"
62051831|NCT00136786|PLACEBO_COMPARATOR|Intervention 3|"1. Memantine~2. Placebo~3. Bupropion"
62051832|NCT06150703|ACTIVE_COMPARATOR|Ovulation triggering with hCG + Luteal phase support with vaginal progesterone|hCG 250µg subcutaneously between 36h and 38h before oocyte retrieval + Progesterone 600mg/d (200mg tid) vaginally from the evening of the oocyte retrieval until the first pregnancy test
62442146|NCT05852548|EXPERIMENTAL|Parent-Mediated Intervention with ASD|In-home intervention (1-2x/week) will occur with families with children with ASD, including direct intervention, parent coaching, and parent training.
62442147|NCT02184949||Primary Sample|All percutaneous coronary intervention patients who meet the primary eligibility criteria for this study.
62442148|NCT02184949||Subsample|Patients drawn from the main sample who specifically underwent a primary percutaneous coronary intervention procedure.
62442149|NCT01693484|EXPERIMENTAL|ICG administered|The ICG dose (10 mg/4cc per image capture) will be administered in its entirety via push injection through IV access established for standard surgical procedure, followed by 10 cc Normal Saline bolus. This ICG dose will be administered twice, 1X prior to anesthesia, and 1X after the tourniquet on operative extremity has been removed for at least 15 minutes.
62442150|NCT02140957|EXPERIMENTAL|Educational Intervention|Parents in this arm received a 5 minute educational intervention on bottle cessation plus standard nutritional counseling.
62442151|NCT02140957|PLACEBO_COMPARATOR|Control|Parents in this arm received a placebo which consisted of standard nutritional counseling alone.
62051833|NCT06150703|EXPERIMENTAL|Ovulation triggering with Triptorelin + Luteal phase support with Nafarelin|Triptorelin 0.2 mg subcutaneously between 36h and 38h before oocyte retrieval as a single dose Nafarelin 400µg /day (200µg in the morning 200µg in the evening) nasally from the evening of the oocyte retrieval until the first pregnancy test
62051834|NCT02710279|OTHER|Depressive patients|Depressive patients with or without story of suicidal behavior will pass the TSST and will have a psychological assessment to complete with a questionnaire on their smartphone
62051835|NCT05118633|EXPERIMENTAL|Experimental group - HabitAware condition|This group will receive the device which alerts the participant when performing hair pulling behavior and the app which provides psychoeducation and components of Habit Reversal Training.
62051836|NCT05118633|PLACEBO_COMPARATOR|Control group - reminder bracelet condition|This group will receive only a device that vibrates randomly several times per hour as a reminder not to pull, as well as being asked to journal about their daily activities in an app.
62051837|NCT04670900|ACTIVE_COMPARATOR|Operative|Patients will be operated according to Orthopedic Trauma Association (OTA) principles with either tension band wiring or plate fixation with an anatomical precontoured plate.
62051838|NCT04670900|EXPERIMENTAL|Non-operative|Patients will be offered a plaster cast for 1-2 weeks
62442152|NCT02598648|OTHER|ALI( acute lung injury)|Diagnostic criteria: 1.Acute onset；2.FiO2/ PaO2\< 40.0 kPa (300mmHg, ALI); 3.Chest X-ray showed that the double lung texture increased, the increase of crude, fuzzy, visible diffuse patchy infiltration shadow with compensatory emphysema, for the most early performance; B. double lung field large sheet, asymmetric, edge fuzzy infiltration shadow, the most dense in the lung；4. Echocardiography, left atrial hypertension; 5.The gestational age \>35 week, have maternal age cholestasis (severe), sepsis or meconium aspiration syndrome (MAS) understanding of history, and with the exception of the primary pulmonary surfactant (PS) lack of. FXR and RIPK3 were measured in neonate with ALI.
62442153|NCT02598648|OTHER|ARDS(respiratory distress syndrome)|"ARDS :Diagnostic criteria: 1.Acute onset；2.FiO2/ PaO2\< 26.7 kPa (200mmHg, ARDS); 3.Chest X-ray showed that the double lung transparent brightness is generally lower, the glass sample, with bronchial inflatable sign, and even double lung field common density increased, the heart shadow is not clear, a white lung, as the most important performance；4. Echocardiography, left atrial hypertension; 5.The gestational age \>35 week, have maternal age cholestasis (severe), sepsis or meconium aspiration syndrome (MAS) understanding of history, and with the exception of the primary pulmonary surfactant (PS) lack of；6.Need to use a ventilator.~FXR and RIPK3 were measured in neonate with ALI.were measured in another group neonate with ARDS"
62834574|NCT00779350|ACTIVE_COMPARATOR|2|Zoloft® 100 mg tablets
62834575|NCT02103387|EXPERIMENTAL|Cognitive Behavioral Training|Cognitive Behavioral Training 5 weekly 1.5-hour sessions of group-based cognitive behavioral training
62834576|NCT02103387|EXPERIMENTAL|Relaxation Training|Relaxation Training 5 weekly 1.5-hour sessions of group-based relaxation training
62834577|NCT02103387|ACTIVE_COMPARATOR|Health Education Control|Health Education Control 5 weekly 1.5 sessions of group-based health education training
62834578|NCT04082793|EXPERIMENTAL|Photobiomodulation group|Low-level laser therapy will be given to the PTMB group along with mandibular mobilization and stabilization exercises
62834579|NCT04082793|EXPERIMENTAL|Sonophoresis group|Ultrasonic massage with diclofenac gel will be given to the sonophoresis group along with mandibular mobilization and stabilization exercises
62051839|NCT03219385|EXPERIMENTAL|Treatment with the Mirabilis System|
62051840|NCT01188109|EXPERIMENTAL|Gemcitabine / Cisplatin|Single arm study. All patients will receive gemcitabine and cisplatin as adjuvant therapy.
62442154|NCT02598648|OTHER|control|Control group: Patients with mechanical ventilation due to external causes of the lung, no ALI-ARDS performance,FiO2/ PaO2\< 40.0 kPa (300 mmHg), such as premature apnea or HIE. FXR and RIPK3 were measured in neonate with HIE
62442155|NCT02542124|EXPERIMENTAL|NM-IL-12 and TSEBT|TSEBT and subcutaneous doses of NM-IL-12
62834580|NCT03713385||Aged group (n =49)|Determined the optimal endotracheal tube size according to age of the child (internal diameter \[ID\] in mm = \[age in years + 16\] /4) suggested by Cole
62834581|NCT03713385||Subglottic diameter group (n =49)|The subglottic transverse diameter was estimated with ultrasonography on the middle of the anterior region of the neck at the level of cricoid cartilage
62834582|NCT03713385||Epiphyseal diameter group (n =49)|The epiphyseal transverse diameter of the distal radius was estimated with ultrasonography.
62834583|NCT03739723|NO_INTERVENTION|Control Arm|Programs will continue to conduct normal educational activities.
62834584|NCT03739723|EXPERIMENTAL|Intervention Arm|The intent of the intervention arm is to provide programs with data and resources to inform and improve surgical learning environments and resident wellness.
62834585|NCT04086901|EXPERIMENTAL|Dose escalation Arm|Chemo-radiotherapy with radiotherapy dose escalation based on Flour-Deoxy-Glucose /Positron Emissions Tomografi (FDG/PET) scans
62834586|NCT04086901|NO_INTERVENTION|Standard|Standard chemo-radiotherapy
62834587|NCT00753506|ACTIVE_COMPARATOR|Artemisinin|100 mg artemisinin capsule
62834588|NCT00753506|PLACEBO_COMPARATOR|Placebo|Identical looking placebo capsule
62834589|NCT02124837|NO_INTERVENTION|Control group|Participants continue their normal lunch routine.
62834590|NCT02124837|EXPERIMENTAL|Relaxation exercise during lunch break|Participants perform relaxation exercises during each lunch break during work for a period of 2 working weeks.
62834591|NCT02124837|EXPERIMENTAL|Park walk during lunch break|Participants go for a walk in the closest park nearby each lunch break during work for a period of 2 working weeks.
62834592|NCT02871934|EXPERIMENTAL|PGx+|Patients in the PGx+ (intervention) arm will have their SLCO1B1 results reported to their ordering provider immediately.
62834593|NCT02871934|EXPERIMENTAL|PGx-|Patient in the PGx- (control) arm will have their SLCO1B1 results reported to their ordering provider at the end of the study (after 12 months).
62834594|NCT01208207|EXPERIMENTAL|etoricoxib 60 mg/etoricoxib 60 mg|The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg in Part I and Part II
62834595|NCT01208207|EXPERIMENTAL|etoricoxib 60 mg/etoricoxib 90 mg|The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg in Part I and etoricoxib 90 mg in Part II
62834596|NCT01208207|EXPERIMENTAL|etoricoxib 90 mg/etoricoxib 90 mg|The etoricoxib 90 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg in Part I and Part II
62834597|NCT01208207|ACTIVE_COMPARATOR|naproxen 1000 mg/naproxen 1000 mg|The naproxen 1000 mg/naproxen 1000 mg treatment sequence will receive naproxen 1000 mg in Part I and Part II
62051841|NCT01161368|EXPERIMENTAL|lapatinib, vinorelbine|"Drug: Lapatinib, Vinorelbine Lapatinib 1250mg orally once daily continuously~plus~Vinorelbine 20 mg/m2 intravenously (IV) once weekly \[Days 1 and 8\] for 2 weeks, followed by a rest week in a 3-week cycle."
62051842|NCT06118723||Supramaximal resection|Supramaximal resection: maximal resection of the contrast-enhancing and non-contrast-enhancing part of the tumor (FLAIRectomy)
62051843|NCT06118723||Maximal safe resection|Maximal safe resection of the contrast-enhancing part of the tumor
62252859|NCT00520455|NO_INTERVENTION|Control|Control participants were advised where they could obtain hormonal contraception on a sliding scale basis. Participants were also advised where they could obtain hormonal contraception on a sliding scale basis.
62252860|NCT00520455|EXPERIMENTAL|Intervention|Study subjects were prescribed levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and a package of 30 condoms provided via a commerical pharmacy at no cost to the study subject. The subject could refill this prescription as many times as they wanted for 12 months
62834598|NCT02379663|ACTIVE_COMPARATOR|Oral direct Factor Xa inhibitor|Rivaroxaban
62834599|NCT02379663|ACTIVE_COMPARATOR|Low molecular weight heparin|Enoxaparin
62051844|NCT06413251|EXPERIMENTAL|Boxing|The boxing training intervention will consist of three exercise sessions per week on nonconsecutive days for six weeks
62051845|NCT06413251|PLACEBO_COMPARATOR|Control|The control group will perform three days per week 10 minutes a flexibility intervention.
62834600|NCT02379663|PLACEBO_COMPARATOR|Normal Saline|Normal Saline
62834601|NCT02215252|EXPERIMENTAL|PF-05089771|
62051846|NCT04965350|EXPERIMENTAL|2vHPV Consistency Lot 1|
62051847|NCT04965350|EXPERIMENTAL|2vHPV Consistency Lot 2|
62051848|NCT04965350|EXPERIMENTAL|2vHPV Consistency Lot 3|
62051849|NCT04965350|ACTIVE_COMPARATOR|2vHPV Pilot Scale Lot|
62051850|NCT00939874|EXPERIMENTAL|Raltegravir|
62252861|NCT01214863||T3|Model SN60T3 assigned by AcrySof Toric calculator
62252862|NCT01214863||T4|Model SN60T4 assigned by AcrySof Toric calculator
62252863|NCT01214863||T5|Model SN60T5 assigned by AcrySof Toric calculator
62442156|NCT05683795||Healthcare Professionals|Members of The PelvEx Collaborative who are experts in performing pelvic exenteration surgery, and managing the complications relating to the empty pelvis syndrome as a result of this surgery.
62442157|NCT05683795||Patient Representatives|Patients that have undergone pelvic exenteration surgery and likely to have been exposed to the morbidity of the empty pelvis syndrome.
62442158|NCT05313828||group 1'|patients with viral ulcers will receive antiviral medication with antibiotics
62442159|NCT05313828||group 2|patients with viral ulcers will receive antiviral medication, tear substitutes with antibiotics
62834602|NCT02215252|EXPERIMENTAL|Placebo|
62834603|NCT02215252|EXPERIMENTAL|Pregabalin|
62834604|NCT02215252|EXPERIMENTAL|PF-05089771 + Pregabalin|
62051851|NCT01278355||Pain Patients|
62051852|NCT05604625|ACTIVE_COMPARATOR|Group A|12 patients will receive Van-Beek activator and a headgear
62051853|NCT05604625|ACTIVE_COMPARATOR|Group B|12 patients will receive Andresen activator
62051854|NCT00316810|EXPERIMENTAL|Campath|"Day 0: Before revascularisation patients are given 500 mg of Methylprednisolone i.v. followed by Campath 30 mg i.v. infusion over 3-6 hours.~Day 1: No treatment~Day 2: Initial dose of Tacrolimus 0.05 - 0.1 mg/kg/d orally.~till Month 6: Aim at blood level of 12-15 ng/ml (try to prevent the Tacrolimus trough level falling below 12 ng/ml in the first 6 months).~Month 7-12: Maintain the Tacrolimus blood level at 6-12 ng/ml after 6 months."
62442160|NCT05313828||group 3|patients with viral ulcers will receive antiviral medication, weak steroids(at the same time) with antibiotics
62834605|NCT06009133||Conservative Treatment Group|"Micronized purified flavonoid fraction, which is routinely used within indications in hemorrhoidal disease and recommended in ESCP and ASCRS guidelines, and licensed for use in hemorrhoidal disease by the Ministry of Health in our country, was given 2 g/day for one month.~Also, Conservative methods (fiber foods, warm shower, regulation of toilet habits, laxatives and nonsteroidal anti-inflammatory drugs) were recommended."
62834606|NCT06009133||Surgical Treatment Group|While the patient was in the Jack-knife position, both hips were pulled laterally with tapes, appropriate visualization was obtained, the external thrombosed pack was excised under local anesthesia, and the wound was left to heal with secondary intention.Conservative methods were recommended in the surgical group as well as in the medical group.
62611483|NCT06179732|EXPERIMENTAL|Mesh|"1. Information and Education Campaigns (IEC) campaigns will formally encourage breeding site management through; good practice household-level water storage (covering and cleaning of water storage containers) and waste management (removal of potential breeding sites in and around the home).~2. Epidemiological surveillance: test and treat malaria cases in children 6 - 10 years of age~3. Mesh product distributed to households"
62834607|NCT04216056|EXPERIMENTAL|Frailty intervention program|There will be 2 sessions per week for 12 weeks. Each session includes 1 hour exercise (including 5-10 minute warm-up and cool-down routine, 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body, and 20-30 minutes aerobic exercises); and 1 hour game training using computer video games, board games and card games. Nutrition education will be given to the subjects based on their weight status. The 1st level of nutrition information (healthy eating tips for frailty prevention and management) will be given to all subjects on regular basis during the 12-week study period via short videos, text messages or Whatsapp reminders. On top of the 1st level nutrition information, 3 nutrition heath talks (1-1.5 hours per talk) about weight management will be given to those with BMI \>=25 kg/m2, and/or waist circumference \>=90 cm (male) or \>=80 cm (female) during the 12-week study period.
62051855|NCT00316810|ACTIVE_COMPARATOR|ATG|"Day 0: Prior to revascularisation patients are given 500 mg of Methylprednisolone i.v. followed by a single shot of a polyclonal antilymphocyte preparation. Tacrolimus will be given immediately after transplantation(0.05-0.1 mg/kg/d) orally. Preoperative loading dose MMF: 2 g orally.~From Day 1: Total initial daily dose of 0.05-0.1 mg/kg administered orally in 2 doses. Blood trough levels 12-15 ng/ml during the first 6 months and maintain blood levels 6-12 ng/ml after 6 months. Total daily dose of MMF is 2 g administered orally in 2 doses. Patients will receive Methylprednisolone 250 mg IV 12h post surgery and 125 mg of Methylprednisolone 24 h post transplantation.~Steroid taper (orally):~Day 2: 100 mg of Prednisolon Day 3: 80 mg of Prednisolon Day 4: 60 mg of Prednisolon Day 5: 40 mg of Prednisolon Day 6: 25 mg of Prednisolon Day 21: 20 mg of Prednisolon~Reduction by 5 mg in two week intervals/complete withdrawal by 3 months post-tx."
62051856|NCT03274635|ACTIVE_COMPARATOR|Usual Delayed Compensation, Money|Will receive delayed monetary compensation with Amazon gift card, non performance-contingent.
62252864|NCT01766960|EXPERIMENTAL|Healthy volunteers|Subjects will be asked to fast overnight. Upon presentation, FibroScan procedure with CAP will be conducted and baseline and postprandial bile acid profile will be assessed. Then, intravenous morphine will be administered and the pharmacokinetic profile will be assessed over 8 hours.
62252865|NCT01766960|EXPERIMENTAL|Advanced nonalcoholic fatty liver disease patients|Subjects will be asked to fast overnight. Upon presentation, FibroScan procedure with CAP will be conducted and baseline and postprandial bile acid profile will be assessed. Then, intravenous morphine will be administered and the pharmacokinetic profile will be assessed over 8 hours.
62442161|NCT05313828||group 4|patients with viral ulcers will receive antiviral medication with antibiotics followed by weak steroid after epithelial healing
62442162|NCT02925767|EXPERIMENTAL|The 311-nm Ti:Sapphire laser treatment group|All lesions were treated twice weekly for a total of 12-week period.
62442163|NCT02925767|ACTIVE_COMPARATOR|The 308-nm excimer laser treatment group|All lesions were treated twice weekly for a total of 12-week period.
62834608|NCT04216056|NO_INTERVENTION|Control group|Subjects in the control group will be asked to maintain their usual diet and physical activity patterns over the 12 weeks.
62834609|NCT02077452|EXPERIMENTAL|HMS5552 dose 1|HMS5552 25\~400mg. Oral administration, twice per day.
62834610|NCT02077452|EXPERIMENTAL|HMS5552 dose 2|HMS5552 25\~400mg. Oral administration, twice per day.
62834611|NCT02077452|EXPERIMENTAL|HMS5552 dose 3|HMS5552 25\~400mg. Oral administration, twice per day.
62834612|NCT02077452|EXPERIMENTAL|HMS5552 dose 4|HMS5552 25\~400mg. Oral administration, once per day.
62834613|NCT02077452|EXPERIMENTAL|HMS5552 dose 5|HMS5552 25\~400mg. Oral administration, twice per day.
62051857|NCT03274635|ACTIVE_COMPARATOR|Usual Delayed Compensation, Food|Will receive delayed compensation with food-based gift card, non performance-contingent.
62252866|NCT05005455|ACTIVE_COMPARATOR|bevacizumab with old manufacturing process.|
62252867|NCT05005455|EXPERIMENTAL|bevacizumab with new manufacturing process.|
62442164|NCT06483581|ACTIVE_COMPARATOR|M-TAPA|Patients will have bilateral M-TAPA block with 0.25% bupivacaine (total volume of 40 ml) before the surgery for postoperative pain control.
62442165|NCT06483581|ACTIVE_COMPARATOR|TAP|Patients will have bilateral lateral-TAP block with 0.25% bupivacaine (total volume of 40 ml) before the surgery for postoperative pain control.
62442166|NCT00121654|ACTIVE_COMPARATOR|1|paresthesic SCS
62442167|NCT00121654|ACTIVE_COMPARATOR|2|subliminal SCS (75-80% of paresthesic threshold)
62834614|NCT05063799|EXPERIMENTAL|a case included pulmonary rehabilitation program|
62611484|NCT05721690|EXPERIMENTAL|UED-A|Tracheal Intubation with UED-A videolaryngoscope
62611485|NCT05721690|ACTIVE_COMPARATOR|GLIDESCOPE|Tracheal Intubation with Glidescope Titanium videolaryngoscope
62051858|NCT03274635|EXPERIMENTAL|Individual Immediate Contingent Reward, Money|Will receive daily performance-contingent monetary compensation with Amazon gift card.
62252868|NCT00993265|EXPERIMENTAL|N-acetylcysteine (NAC)|Patients randomized to this arm will receive N-Acetylcysteine, at a standard dose titrated to 2400 mg. They will receive NAC in addition to the medication regimen they are on at enrollment.
62442168|NCT00121654|SHAM_COMPARATOR|3|low stimulation, consisting of an hour of SCS a day at 0.05 mV intensity, which does not have any significant stimulator effect (sham stimulation)
62442169|NCT02295774|PLACEBO_COMPARATOR|Group A|Biopsy samples collected during standard white light colonoscopy.
62442170|NCT02295774|ACTIVE_COMPARATOR|Group B|Subjects who have had samples collected during a Group A colonoscopy, who require a second colonoscopy within 2 weeks. Prior to this second colonoscopy the subjects take Methylene Blue MMX tablets. Biopsies collected are compared to their previous group A colonoscopy for histone gamma H2AX activity.
62442171|NCT01018888|EXPERIMENTAL|Keratoprosthesis|
62442172|NCT06121869|PLACEBO_COMPARATOR|Placebo|Participants will supplement daily for 10 weeks with 2 grams rice flower placebo in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
62611486|NCT00382109|EXPERIMENTAL|Tacro-MTX/Sirolimus GVHD Prophylaxis Regimen|Preparative regimen of total body irradiation (TBI) 200 cGy BID days -8,-7, \& -6, Thiotepa IV (dose 5 mg/kg/day on days -5 \& -4) \& cyclophosphamide IV (dose 60 mg/kg/day on days -3 \& -2). Tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily on day -2 with a taper starting on day 42 - day 98 (patients undergoing matched sibling donor transplantation) OR tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily beginning on day -2 followed by a taper on day 100 through day 180 (patients undergoing other related, unrelated, or cord blood donor transplantation) in the absence of GVHD. Patients also receive methotrexate IV (5 mg/m2/dose) on days 1,3, \& 6 (patients with matched sibling and umbilical cord blood donors) OR days 1,3 6, \& 11 (patients with other related/unrelated bone marrow and peripheral blood stem cell donors) and oral sirolimus (dose 2.5mg/m2/day - 4 mg max starting dose) daily starting on day 0 followed by a taper starting on day 180 through day 207.
62834615|NCT03367520|EXPERIMENTAL|StayQuit|StayQuit offers 3 meetings during hospitalization and up 13 telephone calls. StayQuit begins in the hospital with an assessment of motivation to remain quit after discharge and a brief intervention to develop discrepancy between values and behaviors and generate change talk. Participants are also encouraged to try nicotine replacement therapy during the hospitalization and after discharge. Telephone counseling is brief and focused on managing withdrawal from nicotine, coping with cravings, and supporting use of NRT. The investigators will work with hospital staff as needed to ensure that nicotine replacement therapy is offered to participants during the inpatient stay and prescribed at discharge.
62834616|NCT03071926|EXPERIMENTAL|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin: 20 mg, qw, first 6 weeks ,every 8 weeks
62442173|NCT06121869|ACTIVE_COMPARATOR|Leucine|Participants will supplement daily for 10 weeks with 2 grams rice leucine in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
62442174|NCT06121869|EXPERIMENTAL|Dileucine|Participants will supplement daily for 10 weeks with 2 grams dileucine (RAMPS, Ingenious Ingredients, TX, USA) in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
62834617|NCT00403520|EXPERIMENTAL|Experimental 1|
62834618|NCT00403520|PLACEBO_COMPARATOR|Placebo Comparator|
62834619|NCT04198688||With cancer|Patients diagnosed with cancer (with at least one of the following ICD-10 diagnoses: C00-43; C46.1-99; D09)
62834620|NCT04198688||Without cancer|Patients without cancer (without any of the following ICD-10 diagnoses: C00-99; D09; D30.1-9; D32-33; D35.2-4; D41.1-9; D44.3-5)
62442175|NCT01092520|EXPERIMENTAL|Gabapentin|
62252869|NCT00993265|PLACEBO_COMPARATOR|Placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
62252870|NCT01025960|OTHER|Standard Inspection Colonoscopy|The colonoscope will be inserted rapidly to reach the cecum. Inspection of the large bowel will occur during the withdrawal of the colonoscope.
62252871|NCT01025960|ACTIVE_COMPARATOR|Dual Inspection Colonoscopy|The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
62442176|NCT03396718|EXPERIMENTAL|Interventional Arm A - HPV(+)|De-escalation Radio(chemo)therapy - Level 1
62442177|NCT03396718|EXPERIMENTAL|Interventional Arm B - HPV(+)|De-escalation Radio(chemo)therapy - Level 2
62442178|NCT03396718|ACTIVE_COMPARATOR|Observational Arm A - HPV(-)|Standard Radio(chemo)therapy
62442179|NCT03396718|ACTIVE_COMPARATOR|Observational Arm B - HPV(+)|Standard Radio(chemo)therapy
62442180|NCT00590356|ACTIVE_COMPARATOR|A2|AngioSeal®
62442181|NCT00590356|EXPERIMENTAL|A1|StarClose®
62442182|NCT01885637|NO_INTERVENTION|Control group|In the control group, the patients continue to be attached to the health care system in line with current practice. This means that the patient typically remains in hospital or ambulatory and may have contact with one or more hospitals, GP and possibly homecare later in the process. Caregivers in the control group may receive psychological counseling through referral from a GP.
62051859|NCT03274635|EXPERIMENTAL|Individual Immediate Contingent Reward, Food|Will receive daily performance-contingent food-based gift card.
62051860|NCT03274635|EXPERIMENTAL|Joint Immediate Contingent Reward, Money|Will receive daily performance-contingent monetary compensation with Amazon gift card, with additional compensation contingent on pedaling activity of co-worker participant.
62051861|NCT03274635|EXPERIMENTAL|Joint Immediate Contingent Reward, Food|Will receive daily performance-contingent monetary compensation with food gift card, with additional compensation contingent on pedaling activity of co-worker participant.
62051862|NCT04591028|OTHER|Intervention|Injection of Indocyamine Green.
62051863|NCT06358625||HER positive|The study will include an initial assessment and longitudinal and individual follow-up to identify the occurrence of clinical events of interest and to monitor the evolution of any tumour biomarkers on circulating tumour DNA.
62051864|NCT01920282|ACTIVE_COMPARATOR|Nebivolol|Subjects will be provided with daily 5 mg of nebivolol for the first 2 weeks. Subjects receive additional daily doses of 10 mg nebivolol for the remainder of the study period. The dose remains at 5 mg per day, however, if BP falls below 110/70 during the first 2 weeks. Subjects will continue taking the drug during the 2-week follow-up period.
62252872|NCT03069885|ACTIVE_COMPARATOR|Standard postoperative dressing group|30 patients treated with conventional post-operative dressing.
62252873|NCT03069885|EXPERIMENTAL|Prevena group|30 patients treated with PrevenaTM (incisional negative pressure wound therapy)
62252874|NCT01348932||Asthma|The relationship between single nucleotide polymorphisms of chitinase 3-like 1 gene, YKL-40 serum levels and adult asthma
62252875|NCT01907542|ACTIVE_COMPARATOR|Monocryl suture skin closure|Monocryl skin suture
62252876|NCT01907542|ACTIVE_COMPARATOR|Stapled skin closure|stapled skin closure
62252877|NCT03632590|EXPERIMENTAL|Magnesium Citrate|450 mg of Magnesium Citrate per day
62252878|NCT03632590|EXPERIMENTAL|Magnesium Sulfate|450 mg of Magnesium Sulfate per day
62834621|NCT02453321|ACTIVE_COMPARATOR|Cont. Femoral Block - Low Dose Group|Arm is named by the intervention the group receives. Continuous Femoral Block - Low Dose. The Block/catheter is placed about 5cm below groin at ultrasonographic apex of femoral triangle. Rate of 2ml/hr of bupivacaine 0.0625% until morning of POD#2.
62834622|NCT02453321|EXPERIMENTAL|Cont. Femoral Block - Higher Dose|Place the CPNB in same manner as low-dose group, but rate will be 4ml/hr. Hypothesis is that this group may experience better pain control, but likely will have more dense motor blockade of thigh and less participation in physical therapy
62834623|NCT02453321|EXPERIMENTAL|Continuous Adductor Canal|Placed at mid-thigh in proximal adductor canal near femoral artery with a bupivacaine infusion rate of 4ml/hr. Hypothesis is that this group may experience less motor blockade of thigh but may have more pain than the femoral nerve groups.
62834624|NCT01116986|EXPERIMENTAL|1, Patch, Gum, Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
62834625|NCT01116986|EXPERIMENTAL|2, Patch, Gum, Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
62834626|NCT01116986|EXPERIMENTAL|3, Patch, Gum, Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
62834627|NCT01116986|EXPERIMENTAL|4, Patch, Gum, Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
62834628|NCT01116986|EXPERIMENTAL|5, Patch, Gum, No Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
62834629|NCT01116986|EXPERIMENTAL|6, Patch, Gum, No Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
62252879|NCT03632590|EXPERIMENTAL|Magnesium Oxide|450 mg of Magnesium Oxide per day
62252880|NCT03632590|PLACEBO_COMPARATOR|Placebo|
62252881|NCT01371136|EXPERIMENTAL|Curricular Trained|"Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an easy, medium and hard level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver."
62252882|NCT01371136|NO_INTERVENTION|conventional residency training|These residents proceed through surgical residency training as usual
62252883|NCT02923661|EXPERIMENTAL|CM LOC attachment group|this group will receive CM LOC attachment and lower overdenture attached to it
62834630|NCT01116986|EXPERIMENTAL|7, Patch, Gum, No Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
62834631|NCT01116986|EXPERIMENTAL|8, Patch, Gum, No Prequit, Int In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
62834632|NCT01116986|EXPERIMENTAL|9, Patch, No Gum, Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
62834633|NCT01116986|EXPERIMENTAL|10, Patch, No Gum, Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
62834634|NCT01116986|EXPERIMENTAL|11, Patch, No Gum, Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
62252884|NCT02923661|ACTIVE_COMPARATOR|Ball attachment|this group will receive Ball attachment and lower overdenture attached to it
62252885|NCT00596661|EXPERIMENTAL|TRIMAXX|TRIMAXX Coronary Stent
62252886|NCT00688155|EXPERIMENTAL|Physical Activity Training|The Physical Activity Training ((PAT) intervention consisted of center-based and home-based sessions comprised of aerobic, strength, flexibility, and balance training with a targeted duration of 150 mins/wk.
62252887|NCT00688155|EXPERIMENTAL|Cognitive Training|The Cognitive Training (CT) intervention was developed to improve consciously-controlled memory processing or recollection of episodic memory information.
62834635|NCT01116986|EXPERIMENTAL|12, Patch, No Gum, Prequit, Int In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
62834636|NCT01116986|EXPERIMENTAL|13, Patch, No Gum, No Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
62834637|NCT01116986|EXPERIMENTAL|14, Patch, No Gum, No Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
62834638|NCT01116986|EXPERIMENTAL|15, Patch, No Gum, No Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
62834639|NCT01116986|EXPERIMENTAL|16, Patch, No Gum, No Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
62834640|NCT01116986|EXPERIMENTAL|17, No Patch, Gum, Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
62834641|NCT01116986|EXPERIMENTAL|18, No Patch, Gum, Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
62834642|NCT01116986|EXPERIMENTAL|19, No Patch, Gum, Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
62834643|NCT01116986|EXPERIMENTAL|20, No Patch, Gum, Prequit, Int In-Person, Int Phone, 16Wk|How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt
62834644|NCT01116986|EXPERIMENTAL|21, No Patch, Gum, No Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
62834645|NCT01116986|EXPERIMENTAL|22, No Patch, Gum, No Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
62051865|NCT01920282|ACTIVE_COMPARATOR|Lifestyle Modification|Subjects will receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals were instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 minutes per week of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conformed to the Dietary Approach to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contained 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein. Sodium consumption was set at 2,400 mg/day for all subjects.
62051866|NCT01920282|EXPERIMENTAL|Nebivolol plus Lifestyle Modification|Subjects begin with 5 mg/day of nebivolol and increase to 10 mg/day if brachial blood pressure is greater than 120/80 mmHg during the first 2 weeks of therapy. Subjects also receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals will be instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 min/wk of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conforms to the Dietary Approaches to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contains 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein with sodium consumption set at 2,400 mg/day for all subjects.
62252888|NCT00688155|EXPERIMENTAL|Combined Intervention|"The Combined Intervention (PACT) was designed so that participants received both cognitive and physical activity training on the same day.~."
62252889|NCT00688155|ACTIVE_COMPARATOR|Healthy Aging Education|The Healthy Aging Education control intervention consisted of weekly lectures based on health education.
62252890|NCT01963429|EXPERIMENTAL|A(radiofrequency ablation )|radiofrequency ablation
62252891|NCT01963429|EXPERIMENTAL|B(Proton)|hypofractionated proton beam therapy
62252892|NCT02476825|ACTIVE_COMPARATOR|Inhaled fluticasone|Inhaled fluticasone propionate (via dry powder inhaler \[Accuhaler\]), 500 micrograms b.i.d. for 4 weeks
62252893|NCT02476825|NO_INTERVENTION|Observational|Observation
62834646|NCT01116986|EXPERIMENTAL|23, No Patch, Gum, No Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
62834647|NCT01116986|EXPERIMENTAL|24, No Patch, Gum, No Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
62834648|NCT01116986|EXPERIMENTAL|25, No Patch, No Gum, Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
62834649|NCT01116986|EXPERIMENTAL|26, No Patch, No Gum, Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
62834650|NCT01116986|EXPERIMENTAL|27, No Patch, No Gum, Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
62834651|NCT01116986|EXPERIMENTAL|28, No Patch, No Gum, Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
62834652|NCT01116986|EXPERIMENTAL|29, No Patch, No Gum, No Prequit, Min In-Person, Min Phone, 16|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
62834653|NCT01116986|EXPERIMENTAL|30, No Patch, No Gum, No Prequit, Min In-Person, Int Phone, 8W|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
62834654|NCT01116986|EXPERIMENTAL|31, No Patch, No Gum, No Prequit, Int In-Person, Min Phone, 8W|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
62834655|NCT01116986|EXPERIMENTAL|32, No Patch, No Gum, No Prequit, Int In-Person, Int Phone, 16|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
62834656|NCT01807988|EXPERIMENTAL|iCBT|Internetbased cognitive behavior therapy (iCBT) aimed att preventing relapse into major depression.
62834657|NCT01807988|NO_INTERVENTION|Control group|The control group in the study will fill out questionnaires every month and will be interviewed every month to detect any relapses. They will also receive feedback on there self-reported symptoms.
62834658|NCT01684761|EXPERIMENTAL|Tcelna|30-45 x 10E6 total cells in 2 ml. Subjects receive two annual courses of 5 subcutaneous doses each year (at 0, 4, 8, 12 and 24 weeks).
62834659|NCT01684761|PLACEBO_COMPARATOR|Placebo|Tcelna inactive ingredients (without cells) totaling 2 ml per dose. Administered subcutaneously with same two year treatment regimen as experimental treatment arm.
62252894|NCT00685880|EXPERIMENTAL|Prolotherapy group|Subjects randomized to this arm will receive injection(s) of 10% dextrose solution in the affected thumb joint.
62252895|NCT00685880|ACTIVE_COMPARATOR|Corticosteroid Group|Subjects randomized to this arm will receive injection(s) of betamethasone solution in the affected thumb joint.
62252896|NCT02632721|EXPERIMENTAL|Phase I dose escalation: BI 836858 20 mg + decitabine (intensive)|Dose escalation.
62252897|NCT02632721|EXPERIMENTAL|Phase I dose escalation: BI 836858 40 mg + decitabine (intensive)|Dose escalation.
62252898|NCT02632721|EXPERIMENTAL|Phase I dose escalation: BI 836858 80 mg + decitabine (intensive)|Dose escalation.
62252899|NCT02632721|EXPERIMENTAL|Phase I Extension A: BI 836858 80 mg + decitabine (intensive)|Extension phase.
62252900|NCT02632721|EXPERIMENTAL|Phase I Extension B: BI 836858 80 mg + decitabine (standard)|Extension phase.
62252901|NCT05494021|EXPERIMENTAL|Whole-process management strategy|"High-risk individuls are provided with whole-process management strategy, including lung cancer education, decision-making, assisting in making and attending LCS LDCT appointments, arranging follow-up when needed, tobacco cessation support for smokers, treatment assistance if diagnosed as lung cancer.~LDCT was performed at baseline + 2 biennial repeated LDCT rounds."
62252902|NCT05494021|ACTIVE_COMPARATOR|Rountine screening strategy|LDCT was performed at baseline + 2 biennial repeated LDCT rounds.
62252903|NCT02580851|OTHER|Coronary angiography|Patients directly undergo diagnostic coronary angiography. A PCI is performed according to current guidelines in case of ≥70% stenosis in a coronary vessel with ≥2 mm diameter.
62252904|NCT02580851|OTHER|Cardiac magnetic resonance imaging|Patients receive adenosine perfusion CMR for functional testing, first. The examination is conducted on a 3.0 Tesla whole-body scanner with a 32-channel phased-array cardiac receiver coil according to a well-established standard protocol \[21-23\]. In case reversible ischemia can be detected, subjects are sent to coronary angiography and PCI afterwards.
62252905|NCT00253643|EXPERIMENTAL|Arm I (FO, GT catechin extract)|Patients receive oral fish oil (FO) 3/day and oral green tea (GT) extract 2/day
62252906|NCT00253643|EXPERIMENTAL|ArmII (FO placebo, GT catechin extract)|Patients receive a fish oil (FO) placebo 3/day and oral green tea (GT) extract 2/day
62611487|NCT00382109|ACTIVE_COMPARATOR|Tacro-MTX GVHD Prophylaxis|Preparative regimen of total body irradiation (TBI) 200 cGy BID days -8,-7, \& -6, Thiotepa IV (dose 5 mg/kg/day on days -5 \& -4) \& cyclophosphamide IV (dose 60 mg/kg/day on days -3 \& -2). Tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally (when able) daily on day -2 with a taper starting on day 42 - day 98 (patients undergoing matched sibling donor transplantation) OR tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily beginning on day -2 followed by a taper on day 100 through day 180 (patients undergoing other related, unrelated, or cord blood donor transplantation) in the absence of GVHD. Patients also receive methotrexate IV (5 mg/m2/dose) on days 1,3, \& 6 (patients with matched sibling and umbilical cord blood donors) OR days 1,3 6, \& 11 (patients with other related/unrelated bone marrow and peripheral blood stem cell donors).
62611488|NCT04006509|EXPERIMENTAL|Antenatal Education Group|Patients will receive a prenatally delivered lactation educational program.
62252907|NCT00253643|EXPERIMENTAL|Arm III (FO, GT placebo)|Patients receive oral fish oil (FO) 3/day and a placebo mimicking green tea (GT) catechins 2/day
62252908|NCT00253643|PLACEBO_COMPARATOR|Arm IV (FO placebo, GT placebo)|Patients receive a fish oil (FO) placebo mimicking fish oil 3/day and another placebo mimicking green tea (GT) catechins 2/day
62252909|NCT03755791|EXPERIMENTAL|Experimental arm|Subjects with advanced HCC will receive cabozantinib 40 mg oral, qd + atezolizumab 1200 mg infusion, q3w
62252910|NCT03755791|ACTIVE_COMPARATOR|Control arm|Subjects with advanced HCC will receive sorafenib 400 mg bid (twice a day)
62252911|NCT03755791|OTHER|Single-Agent Cabozantinib arm|Subjects with advanced HCC will receive cabozantinib 60 mg qd
62252912|NCT02520895||large B lymphoma cells (group 1)|30 patients with large B lymphoma cells at diagnosis and who will receive an immunochemotherapy treatment patients will have blood samplings
62252913|NCT02520895||indolent B-cell lymphomas (group 2)|30 patients with indolent B-cell lymphomas without invasion excess blood lymphoma 1 giga / L at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings
62252914|NCT02520895||indolent B-cell lymphomas (group 3)|20 Patients with indolent B-cell lymphomas with lymphocytosis (\> 1 Giga / L) at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings
62834660|NCT01393392|EXPERIMENTAL|Intensive, tailored intervention|Participants in the intensive intervention condition will receive eight individual counseling sessions, with a smoking cessation counselor, over three months. Each session will last approximately 45 minutes and occur in the methadone clinic. Participant treatment needs will be assessed during the first session and the intervention will be tailored to the participants' needs. Prior to quitting participants will receive nicotine replacement patches and lozenges and instructions on how to use them.
62252915|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 4)|20 patients with LLC never treated before and will receive an immunochemotherapy treatment (fludarabine +/- endoxan +/- rituximab or alemtuzumab)- patients will have blood samplings
62834661|NCT01393392|ACTIVE_COMPARATOR|Control Intervention|Participants randomized to the control intervention will receive a referral to the NJ Quitline (a telephone smoking cessation counseling service). Participants will receive a brochure and information about the referral. Study staff will contact the NJ Quitline for control participants, and a counselor from the Quitline will call control participants.
62834662|NCT02786394|EXPERIMENTAL|REACH Participant Course|This study will run twice a week over 6 weeks with 6 REACH sessions optional walking program sessions. The optional walking program will be run by SportMedBC and may consist of one or more educational sessions (e.g., nutrition). Each REACH session introduces new topics, strength and balance activities and home practices which progressively build on each other. We will ask participants to provide feedback after each session, and in two to three 30 minutes recorded interviews (in-person or over the telephone) at the end of the study.
62834663|NCT05199077|PLACEBO_COMPARATOR|placebo group|Topical administration of a drug-free placebo ointment daily for 28 days.
62834664|NCT05199077|ACTIVE_COMPARATOR|cohort A|Topical administration of a 2.5 % GM-XANTHO ointment daily for 28 days.
62834665|NCT05199077|ACTIVE_COMPARATOR|cohort B|Topical administration of a 5 % GM-XANTHO ointment daily for 28 days.
62834666|NCT05425472|EXPERIMENTAL|HR070803|HR070803 monotherapy will be administered by intravenous infusion
62834667|NCT04273776|ACTIVE_COMPARATOR|Suvorexant Arm|10 mg of Suvorexant
62611489|NCT04006509|NO_INTERVENTION|Standard of Care Group|Patients will receive standard of care and not a prenatally delivered lactation educational program.
62611490|NCT02548923|ACTIVE_COMPARATOR|dexmedetomidine group|Patients who received dexmedetomidine for sedation
62252916|NCT02520895||T-cell lymphoma (group 5)|10 Patients with T-cell lymphoma in 1st line therapy and will receive a combination of chemotherapy- patients will have blood samplings
62611491|NCT02548923|NO_INTERVENTION|propofol group|Patients who received propofol for sedation
62834668|NCT04273776|ACTIVE_COMPARATOR|Zolpidem Arm|5 mg of Zolpidem
62834669|NCT04273776|PLACEBO_COMPARATOR|Placebo|10mg of Avicel
62834670|NCT02200406|OTHER|Desvenlafaxine|"* Open-label pilot study~* Desvenlafaxine will be administered during 56 consecutive days~* Desvenlafaxine will be administered in the morning at a 50 mg dose during weeks 1 and 2, and at 50-100 mg doses (based on the study psychiatrist's judgment) during the 6 following weeks."
62051867|NCT04885556|EXPERIMENTAL|Immediate Use|Subjects in this arm will be instructed to use the study device for 2 minutes and remove
62442183|NCT01885637|OTHER|Intervention Group|Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
62834671|NCT01106690|OTHER|Placebo/Sitagliptin|Each patient will receive matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients will be switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.
62834672|NCT01106690|EXPERIMENTAL|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.
62834673|NCT01106690|EXPERIMENTAL|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.
62834674|NCT00157677|EXPERIMENTAL|1|Selective D-Dimer use
62051868|NCT04885556|EXPERIMENTAL|1 hour use|Subjects in this arm will be instructed to use the product for one hour and then remove
62442184|NCT03801733|EXPERIMENTAL|Rosuvastatin, Vadadustat|Part 1: Subjects will receive rosuvastatin 20 mg alone, vadadustat 600 mg alone, followed by rosuvastatin 20 mg in combination with vadadustat 600 mg in a fixed-sequence dosing design.
62051869|NCT01299090|EXPERIMENTAL|Treatment Group|All subjects enrolled were in the treatment group.
62051870|NCT05096156|EXPERIMENTAL|All participants are fit with the study daily disposable lenses|All subjects are re-fit into their habitual monthly replacement contact lenses. Subjects are requested to wear the lenses for one week, for a minimum of at least 6 hours per day for 5 days. Upon return, subjects are refit into the daily disposable contact lenses.
62611492|NCT01164917|ACTIVE_COMPARATOR|AMG811|All will receive AMG 811, either on Day 1 or Day 85
62611493|NCT01164917|PLACEBO_COMPARATOR|AMG811 Placebo|All will receive placebo, either on Day 1 or Day 85
62834675|NCT00157677|ACTIVE_COMPARATOR|2|Uniform D-Dimer use
62834676|NCT04963010|NO_INTERVENTION|standard withdrawal colonoscopy|Observation of conventional colonoscopy
62834677|NCT04963010|EXPERIMENTAL|second forward view|second forward view examination of the proximal colon
62834678|NCT01047488|ACTIVE_COMPARATOR|Imipramine|Imipramine tablets and placebo capsules to pregabalin
62834679|NCT01047488|ACTIVE_COMPARATOR|Pregabalin|Pregabalin capsules and placebo tablets to imipramine
62834680|NCT01047488|EXPERIMENTAL|Imipramine plus pregabalin|Imipramine tablets and pregabalin capsules
62834681|NCT01047488|PLACEBO_COMPARATOR|Placebo|Placebo tablets to imipramine and placebo capsules to pregabalin
62834682|NCT02999204|ACTIVE_COMPARATOR|Vitamin D3 5,000 units per week|Patient receive a dose that is considered within the standard dosing range for Vitamin D3 for one year.
62252917|NCT02520895||follicular lymphoma (group 6)|6 patients with follicular lymphoma in first line or relapsed and will receive a single immunotherapy treatment (rituximab)- patients will have blood samplings
62252918|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 7)|6 patients with LLC never treated and will receive a combination of rituximab, fludarabine, endoxan- patients will have blood samplings
62252919|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 8)|6 patients with LLC stage A followed for a period of 18 months without treatment- patients will have blood samplings
62252920|NCT01195090|ACTIVE_COMPARATOR|sitagliptin|add sitagliptin100mg/d to pre-study OADs
62051871|NCT02161302|EXPERIMENTAL|Active tDCS|tDCS will be applied in the head of the patients in 20 minute sessions, daily from Monday to Friday for 2 weeks (10 sessions total). The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area, and it will use a 2 mA current.
62442185|NCT03801733|EXPERIMENTAL|Sulfasalazine. Pravastatin, Vadadustat|"Part 2, Arm 1: Subjects will receive sulfasalazine 500 mg alone followed by sulfasalazine 500 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design.~Part 2, Arm 2: Subjects will receive pravastatin 40 mg alone followed by pravastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design."
62442186|NCT03801733|EXPERIMENTAL|Atorvastatin, Simvastatin, Vadadustat|"Part 3, Arm 1: Subjects will receive atorvastatin 40 mg alone followed by atorvastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design.~Part 3, Arm 2: 24 subjects will receive simvastatin 40 mg alone followed by simvastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design."
62442187|NCT00631670|EXPERIMENTAL|Single Treatment Group|15 Gy dose in one stereotactic body radiation treatment
62051872|NCT02161302|SHAM_COMPARATOR|tDCS Sham|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
62051873|NCT04010240||Retrospective cohort|For eligible subject, tumor material will be tested by immunohistochemistry (Pan-Trk ICH testing with mAb EPR17341).
62051874|NCT00953264|EXPERIMENTAL|life style intervention|
62834683|NCT02999204|EXPERIMENTAL|Vitamin D3 50,000 units per week|Patients receive a more aggressive Vitamin D3 dosing regimen of 50,000 units weekly for the first 3 months. At this point Vitamin D3 levels are measured. If the patient is Vitamin D3 replete (\>75 nmol/L) then the dose is reduced to the equivalent of 25,000 units per week for the next 9 months. If the level is below this threshold then 50,000 units per week is continued for the next 9 months
62834684|NCT03131219|EXPERIMENTAL|Ravulizumab|"Participants were administered weight-based doses of ravulizumab every 8 weeks thereafter for participants weighing ≥ 20 kg, or once every 4 weeks for participant weighing \< 20 kg, for a total of 26 weeks of study treatment in the initial Evaluation Period.~After the Initial Evaluation Period, participants rolled over into an Extension Period in which all participant continued their weight-based maintenance dose until the product was registered or approved (in accordance with country specific regulation) or for up to 4.5 years, whichever occurred first."
62834685|NCT01749332|EXPERIMENTAL|Pts having liver or colon surgery|Blood will be obtained from patients at the time of laparotomy for hepatic resection and/or hepatic arterial infusion pump placement, or pancreatic head resection . Blood will be drawn from a peripheral vein or artery (when an arterial catheter is present), the portal vein, and suprahepatic IVC and given to a research assistant and placed on ice followed by immediate processing. Total amount of blood drawn will not exceed fifty milliliters (50ml).
62834686|NCT05919173|EXPERIMENTAL|Bupivacaine 0.25%|Bupivacaine 0.25% Dose: 1mL/kg body weight
62051875|NCT02064543||ADPM and GAITRite|mobility assessments (ADPM, GAITRite) measuring gait parameters
62051876|NCT05650164||Patients with metastatic renal cell carcinoma|Patients with metastatic renal cell carcinoma
62051877|NCT04182711|EXPERIMENTAL|Device Arm|The aim in the 1st phase is to benchmark the device against manual counting of respiration (number of breaths per minute). The aim in the 2nd phase is to benchmark the device against existing technologies, namely lead-based-ECG sensing, acoustic sensing and capnography. This phase can have a mix of patients having either COPD, asthma, pneumonia or any other respiratory diseases
62051878|NCT05465057|ACTIVE_COMPARATOR|HIIT + lifestyle intervention|Allocation of HIIT training in conjuction with lifestyle intervention (TCOCT protocol) through computerbased randomization proces.
62051879|NCT05465057|ACTIVE_COMPARATOR|Lifestyle intervention|Allocation of lifestyle intervention (TCOCT protocol) through computerbased randomization proces.
62252921|NCT01195090|ACTIVE_COMPARATOR|pioglitazone|add pioglitazone 30mg/d to pre-study OADs
62252922|NCT00813644||1|uromentor training
62252923|NCT00813644||2|non uromentor training
62252924|NCT05014360|EXPERIMENTAL|JNJ-64251330|Participants will receive oral dose of JNJ-64251330 twice daily for 24 Weeks.
62252925|NCT00487136|ACTIVE_COMPARATOR|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
62252926|NCT00487136|EXPERIMENTAL|Warfarin plus ABT-335 plus Rosuvastatin|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
62051880|NCT04419402|EXPERIMENTAL|Lu-PSMA + Enzalutamide|"Lu-PSMA - 7.5 GBq (± 10%): doses 1 and 2 (Days 15 and 57). Doses 3 and 4 (Days 113 and 169) will be given following result of PSMA PET/CT scans at Day 92.~Enzalumatide - 160 mg (four 40 mg capsules): daily until participant is no longer clinically benefiting, or experiences unacceptable toxicity."
62051881|NCT04419402|ACTIVE_COMPARATOR|Enzalutamide|Enzalutamide - 160 mg (four 40 mg capsules): daily until participant is no longer clinically benefiting, or experiences unacceptable toxicity.
62051882|NCT03889626|EXPERIMENTAL|Apatinib|In this arm, patients will receive a daily oral treatment with Apatinib 500mg.
62051883|NCT03889626|EXPERIMENTAL|Capecitabine|In this arm , patients will receive capecitabine 1000mg/m2 twice for 14 days, and repeat every 3 weeks.
62051884|NCT03889626|NO_INTERVENTION|Observation|In this arm, no additional treatment will be given, and patients will be followed up at regular time
62252927|NCT00487136|EXPERIMENTAL|Warfarin plus ABT-335 mg plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
62442188|NCT00631670|EXPERIMENTAL|25 Treatments Group|25 treatments, given once a day, Monday through Friday for about five weeks; Dose: 70 Gy at 2.8 Gy/treatment
62051885|NCT00118716|EXPERIMENTAL|FSC 100/50 mcg BID|Participants received FSC 100/50 microgram (mcg) one inhalation as a combination product via DISKUS, twice daily in morning after awakening and in evening for up to 28 days
62051886|NCT00118716|EXPERIMENTAL|FP 100 mcg BID|Participants received FP 100 mcg one inhalation via DISKUS, twice daily in morning after awakening and in evening for up to 28 days.
62442189|NCT04163692|EXPERIMENTAL|Exercise Group|Progressive relaxation exercises (PRE) as 1 day supervised and 3 days home based program in a week, for 6 weeks
62442190|NCT04163692|NO_INTERVENTION|Control Group|Information was provided about pain and its treatment and the importance of relaxing exercises without any intervention, up to 6 weeks.
62611494|NCT00865241|EXPERIMENTAL|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
62611495|NCT00865241|ACTIVE_COMPARATOR|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
62051887|NCT05277675|EXPERIMENTAL|Neoadjuvant therapy+ RFA|After confirmation of HCC recurrence by imaging exam, subjects will receive neoadjuvant therapy (immune checkpoint inhibitors + targeted therapy) and then RFA
62051888|NCT05277675|ACTIVE_COMPARATOR|RFA alone|After confirmation of HCC recurrence by imaging exam, subjects will receive RFA treatment only.
62051889|NCT05176470|EXPERIMENTAL|Treatment (pembrolizumab, lifileucel)|"Patients receive pembrolizumab IV on day -14, cyclophosphamide IV QD on days -7 to -6, fludarabine IV over 30 minutes QD on days -5 to -1, and lifileucel IV infusion on day 0. Patients also receive pembrolizumab IV on day 28 and 70, and undergo surgery on day 80.~MAINTENANCE: Patients receive pembrolizumab IV every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
62051890|NCT01938248|ACTIVE_COMPARATOR|Control|Aspirin 81 mg once daily
62051891|NCT01938248|EXPERIMENTAL|Intervention|Apixaban, 5 mg twice daily (or 2.5 mg twice daily if 2 or more of: age \> 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
62252928|NCT01724333||Group 1- in active treatment|Questionnaires only
62252929|NCT01724333||Group 2 - 2-6 months post-treatment|Questionnaires only
62252930|NCT01724333||Group 3 - 6 mos-3yrs post-treatment|Questionnaires only
62252931|NCT01724333||Group 4 - Palliative treatment|Questionnaires only
62252932|NCT01724333||Group 5 - Referred to dentist/oral team|Questionnaires only
62252933|NCT01799187|EXPERIMENTAL|revascularization|revascularization is is an alternative new treatment of immature permanent teeth with necrotic pulp. The use of triple antibiotic paste is followed by Induction of bleeding from the apical root during this intervention.
62252934|NCT01799187|ACTIVE_COMPARATOR|apexification|apexification is a traditional therapy of immature permanent teeth with necrotic pulp.calcium hydroxide is served as medication to induce the developing of root .
62252935|NCT03427567||Sublobar dissection|Chinese NSCLC patients who received sublobar dissection
62252936|NCT05275348|EXPERIMENTAL|Tele-EF|Remote delivery of Enhance Fitness.
62252937|NCT05275348|ACTIVE_COMPARATOR|In-person EF|In-person delivery of Enhance Fitness.
62252938|NCT05119608|EXPERIMENTAL|CBT/ACT|Cognitive-behavioral therapy intervention with principal components of acceptance and commitment therapy (ACT)
62252939|NCT05119608|ACTIVE_COMPARATOR|TAU|Treatment as usual, defined by standard care, i.e. referral to relevant health care provider (typically primary care).
62252940|NCT02529982|ACTIVE_COMPARATOR|intervention|500 mg curcumin capsule
62252941|NCT02529982|PLACEBO_COMPARATOR|control|placebo
62252942|NCT02150148|EXPERIMENTAL|Mentored Gardening Intervention|Participants in this arm will be provided with either a raised bed garden or 4 earthboxes, gardening supplies, and plants and seeds. A master gardener from the Cooperative Extension will mentor them over the course of a year to plant three gardens (spring, summer and fall).
62252943|NCT02150148|OTHER|Wait-List|Participants in this arm will be provided with the same gardening supplies as the other group, but will receive them one year after enrollment in the study. They also will receive instruction from a master gardener from the Cooperative Extension at this time as well.
62252944|NCT03882138|ACTIVE_COMPARATOR|thin biotype|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
62252945|NCT03882138|ACTIVE_COMPARATOR|thick biotype|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
62834687|NCT05919173|EXPERIMENTAL|Bupivacaine+DEX|Bupivacaine 0.25% plus Dexmedetomidine 1microgram/kg Dose: 1mL/kg
62834688|NCT04569565|EXPERIMENTAL|PleurX catheter intervention|Participants will undergo placement and follow up monitoring of PleurX catheter.
62252946|NCT05165355|EXPERIMENTAL|Experimental group|Furmonertinib (80 mg orally, once daily) for 3 years.
62252947|NCT03995732|EXPERIMENTAL|40 mg treatment group|PC-SOD 40 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
62252948|NCT03995732|EXPERIMENTAL|80 mg treatment group|PC-SOD 80 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
62252949|NCT03995732|EXPERIMENTAL|160 mg treatment group|PC-SOD 160 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
62252950|NCT03995732|PLACEBO_COMPARATOR|placebo control group|placebo dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
62252951|NCT02114411||Dyspeptic patients|Patients (45 years and older, both genders) with dyspepsia referred for the GastroPanel test and gastroscopy with multiple bisopies at Homerton University Hospital (London, United Kingdom).
62252952|NCT03372109|ACTIVE_COMPARATOR|Modified Fasting Arm|Dietary Supplements administered daily for 52 days with a meal replacement shake administered two days per week for the study duration
62252953|NCT03372109|PLACEBO_COMPARATOR|Placebo|Multivitamin tablet administered daily for 52 days
62252954|NCT01489202|ACTIVE_COMPARATOR|platinum chromium EES|Patients undergoing PCI with stenting will have implantation of platinum chromium everolimus-eluting stents
62834689|NCT02958917|PLACEBO_COMPARATOR|pirfenidone 2403 mg/d|Subjects will be randomized in a 2:1 ratio to receive either pirfenidone 2403 mg/d or a placebo equivalent.
62834690|NCT02958917|ACTIVE_COMPARATOR|Placebo|The placebo will be visually similar to pirfenidone.
62834691|NCT03483402|EXPERIMENTAL|PEXG treated with MLT|Patients with pseudoexfoliation glaucoma (PEXG) under prostaglandine analogue monotherapy with inadequate IOP control treated with 360-degrees 532nm micropulse laser trabeculoplasty (MLT)
62252955|NCT01489202|ACTIVE_COMPARATOR|cobalt chromium everolimus-eluting stent|Patients undergoing PCI with stenting will have implantation of cobalt chromium everolimus-eluting stents
62252956|NCT03022331||Observational|
62252957|NCT03034460|EXPERIMENTAL|CD5024 1% cream|Active drug;
62252958|NCT03034460|PLACEBO_COMPARATOR|CD5024 cream placebo|Placebo of active drug;
62252959|NCT03034460|OTHER|CD0271/CD1579 gel|Positive control;
62252960|NCT03034460|OTHER|CD0271/CD1579 gel placebo|Placebo of positive control;
62252961|NCT05680571||Parkinson|Patients suffering from PD of both genders above 18 years of age and Gender- and age-matched HC without any eye- or neurological disorder.
62834692|NCT02081781||Probing, topical anesthesia|Nasolacrimal duct obstruction (NLDO) is a quite common condition among the infants. An imperforate membrane at the distal end of the nasolacrimal duct is the main cause of occlusion. Children with the signs of NLDO presenting with epiphora and/or mucous discharge were included in this study. Intervention with probing under topical anesthesia was performed on the same surgeon. And success rate was evaluated.
62834693|NCT00304551|EXPERIMENTAL|1|
62834694|NCT00304551|EXPERIMENTAL|2|
62834695|NCT00304551|NO_INTERVENTION|3|
62834696|NCT04098718|OTHER|PO open label prednisolone (in low blood eosinophils)|Standard care Prednisolone 30mg given daily for 5 days to treat an exacerbation.
62834697|NCT04098718|EXPERIMENTAL|Benralizumab SC + PO placebo|Benralizumab as a single 100mg sub cut injection and oral placebo tablet daily for 5 days
62834698|NCT04098718|EXPERIMENTAL|Benralizumab SC + PO prednisolone|Benralizumab as a single 100mg sub cut injection and oral prednisolone 30mg daily for 5 days
62834699|NCT04098718|ACTIVE_COMPARATOR|Placebo SC + PO prednisolone|Placebo sub cut injection and oral prednisolone 30mg daily for 5 days.
62834700|NCT03449667|ACTIVE_COMPARATOR|Cryoneurolysis first, then optional sham crossover treatment|"Initial treatment: Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.~Optional sham crossover treatment: Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis."
62834701|NCT03449667|SHAM_COMPARATOR|Sham Comparator first, then optional cryoneurolysis treatment|"Initial treatment: Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.~Optional cryoneurolysis treatment: Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis."
62834702|NCT03997344|EXPERIMENTAL|Nature hiking|Group hikes in a natural setting (e.g., park, wilderness area)
62834703|NCT03997344|ACTIVE_COMPARATOR|Urban hikes|Group hikes in a urban setting (e.g., downtown area)
62252962|NCT05680571||Ataxia|Patients suffering from AT of both genders above 18 years of ageand Gender- and age-matched HC without any eye- or neurological disorder.
62252963|NCT04402970|EXPERIMENTAL|Inhaled/nebulized dornase alfa|Patient to receive inhaled/nebulized dornase alfa (Pulmozyme) 2.5 mg twice daily in the ventilator circuit for 3 days, along with standard of care for ARDS.
62252964|NCT04402970|NO_INTERVENTION|Standard of care|Standard of care provided for ARDS.
62611496|NCT05907187|EXPERIMENTAL|Twalet Deba Group|Participants will receive cervical cancer prevention education, and provide self-administered vaginal or cervical specimens and provide specimens of plants, plant-products or herbs most commonly used in the intravaginal cleansing practice of twalet deba. Total expected participation is about 30 days.
62834704|NCT00404469|ACTIVE_COMPARATOR|CORT|Peritendinous corticosteroid injections at 0 and 4 weeks. 12 weeks total
62834705|NCT00404469|EXPERIMENTAL|ECC|12 weeks of eccentric unilateral decline squats
62834706|NCT00404469|EXPERIMENTAL|HSR|Heavy slow resistance training. 3/week. 12 weeks
62834707|NCT01125592|EXPERIMENTAL|Footbath|Participants in this arm of the study will receive 4 30 minutes ionic footbath sessions, one each week for 4 weeks.
62834708|NCT03754777|EXPERIMENTAL|Modified ERAS protocol group|"Laparoscopic appendectomy with modified ERAS protocol group Preadmission. Not available due to the emergency setting. Preoperative care.~1) Patient brochure with a detailed description of the type of pathology, surgery procedure, rehabilitation process, possible complications, and other.~Surgery.~1. Low pressure (8-9 mmHg) pneumoperitoneum.~2. Routinely remove of appendix mesentery in presence of any signs of its inflammation.~3. Additional local anesthesia with 0.25% ropivacaine.~4. Abdominal cavity draining only in patients with perforated appendicitis and diffuse peritonitis (Gomes 5).~Postoperative care.~1. Early mobilization (2 h after surgery)~2. Early fluid intake (2 h after surgery)~3. Early liquid food (6 h after surgery)"
62834709|NCT03754777|PLACEBO_COMPARATOR|Standard care group|"Standard care laparoscopic appendectomy. Preadmission. Not available due to emergency setting. Preoperative care. 1) Patient oral informing about the type of pathology, surgery procedure and possible complications. No brochure.~Surgery.~1. Standard pressure (12-14 mmHg) pneumoperitoneum~2. Abdominal draining for patients with perforated and not perforated appendicitis complicated by abscess, local or diffuse peritonitis (Gomez ≥ 3A).~3. Appendix mesentery removing in the appearance of its necrotic changes.~4. No intraabdominal anesthesia. Postoperative care.~1) Mobilization in 4-6 h after surgery 2) Fluid intake in 6 hours 3) Liquid food intake in 12 hours"
62834710|NCT04406857|EXPERIMENTAL|Treatment (ropidoxuridine, capecitabine, radiation therapy)|Patients receive ropidoxuridine PO QD over 7 days per week and capecitabine PO BID over 6 days per week for 6 weeks. Patients also undergo radiation therapy over 1 fraction per day for 5 days per week (Monday-Friday) during weeks 1-5 and for 3 days during week 6 in the absence of disease progression or unacceptable toxicity. Approximately 8-12 weeks after completion of treatment with ropidoxuridine, capecitabine, and radiation therapy, patients undergo standard of care surgery.
62834711|NCT02440282||Group A|patients undergo general anesthesia
62834712|NCT02440282||Group B|spinal anesthesia
62834713|NCT02440282||Group C|ultrasound-guided sciatic nerve block
62834714|NCT06212128||RAPIDO TNT|neoadjuvant therapy per RAPIDO protocol
62834715|NCT06212128||LCRT|long course chemoradiotherapy
62834716|NCT06212128||upfront surgery|directly went for surgery after diagnosis of rectal cancer
62834717|NCT01987453|EXPERIMENTAL|LDV/SOF+RBV 12 weeks (Group 1)|Participants who failed a prior SOF+RBV ± pegylated interferon (Peg-IFN) regimen will receive LDV/SOF FDC plus RBV for 12 weeks.
62834718|NCT01987453|EXPERIMENTAL|LDV/SOF 24 weeks (Group 2)|Participants who failed a prior LDV/SOF ± RBV regimen will receive LDV/SOF FDC for 24 weeks.
62834719|NCT01987453|EXPERIMENTAL|LDV/SOF+RBV 24 weeks (Group 3)|Participants with advanced compensated or decompensated cirrhosis who failed a prior SOF+RBV regimen will receive LDV/SOF FDC plus RBV for 24 weeks.
62834720|NCT03228823|ACTIVE_COMPARATOR|Radiofrequency Ablation|Radiofrequency ablation (RFA) will be performed after 3-month observation period. EPS and RFA will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study. In the event of polymorphic PVCs, all morphologies are to be targeted for ablation
62834721|NCT03228823|ACTIVE_COMPARATOR|Antiarrhythmic Drug|Antiarrhythmic drugs (AADs) will be only initiated after 3-month observation period. AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Investigators define successful PVC suppression only if ≥ 80% absolute reduction in PVC burden is achieved after a drug or intervention. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
62834722|NCT01773213|OTHER|Bladder dysfunction, ice-water-test|
62834723|NCT01773213|OTHER|Bladder dysfunction, warm water-test|
62834724|NCT01006239||Biorepository|Patients undergoing surgical resection of a solid tumor.
62834725|NCT02396199|EXPERIMENTAL|Endovascular|Endovascular treatment using the Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents
62834726|NCT00453219||1|Women ages 18-35 years with regular ovulatory menstrual cycles
62834727|NCT00453219||2|Women ages 18-35 years with irregular or absent menstrual periods due to functional hypothalamic amenorrhea (FHA) also called stress-induced anovulation
62834728|NCT00453219||3|Women ages 18-35 years with irregular or absent menstrual periods due to polycystic ovary syndrome(PCOS).
62834729|NCT03279744|EXPERIMENTAL|Single-Arm|Radion™-pdt
62051892|NCT03603210||Patients treated with DCB angioplasty|"Patient cohort is comprised of all patients who received drug coated balloon angioplasty at NNUH during the above period. Within this cohort there will be two main groups which are drug coated balloon (DCB) angioplasty for de novo coronary artery disease (CAD) and DCB angioplasty for ISR/ST. Graft cases will be reported as a small third group.~Outcomes will also be reported for three sub groups of de novo disease group, namely, dcb-only angioplasty for de novo disease, dcb-only angioplasty as primary percutaneous coronary intervention (PPCI) and dcb-only angioplasty group using a DCB with a diameter of 3mm or more in de novo disease."
62051893|NCT04259086|EXPERIMENTAL|DAXI 40 U GL / 32 U FHL / 48 U LCL|DaxibotulinumtoxinA for injection for the treatment of moderate to severe Glabellar Lines (GL), Forehead Lines (FHL), \& Lateral Canthal Lines (LCL)
62611497|NCT02464644|EXPERIMENTAL|People with HHT|"People with HHT will identify themselves within the questionnaire, first by statement of what they think is their diagnosis, and second by provision of the HHT diagnostic criteria within specific questions.~They will be directed to appropriate questions, according to answers to the previous questions."
62051894|NCT04204200|ACTIVE_COMPARATOR|Allocated to conventional vitamin C (n= 22)|"* Received allocated conventional vitamin C (n= 22)~* Did not receive allocated conventional vitamin C (n= 0)"
62834730|NCT04780646|EXPERIMENTAL|Nature therapy in urban nature|Subjects receive a 90-minute nature therapy session once per week for 8 weeks with a licensed nature therapist, who explains exercises on perceiving nature and the connection between nature and health.
62051895|NCT04204200|ACTIVE_COMPARATOR|Allocated to liposomal vitamin C (n= 22)|"* Received allocated liposomal vitamin C (n= 22)~* Did not receive allocated liposomal vitamin C (n= 0)"
62834731|NCT04780646|ACTIVE_COMPARATOR|City Walk|Subjects receive a 90-minute city walk through urban sourroundings once per week for 8 weeks with a city guide, who talks about city architecture and gives information about the history of the surroundings.
62834732|NCT04780646|NO_INTERVENTION|Waiting List|Subjects don't receive any therapy.
62834733|NCT00615303|PLACEBO_COMPARATOR|2|
62834734|NCT00615303|ACTIVE_COMPARATOR|1|
62834735|NCT02631590|EXPERIMENTAL|Combination Therapy|Treatment Plan: Cisplatin (25 mg/m\^2 ) + Gemcitabine (1000 mg/m\^2) + copanlisib (60 mg) on days 1 and 8 with day 15 off to be administered on an every 21-days schedule.
62834736|NCT04434456||CGuard stenting (interventional)|CGuard implantation in the carotid artery with aneurysm requiring intervention
62051896|NCT04204200|PLACEBO_COMPARATOR|Allocated to placebo (n= 22)|"* Received allocated intervention (n= 22)~* Did not receive allocated intervention (n= 0)"
62051897|NCT01452633|PLACEBO_COMPARATOR|Preincision Placebo|This group of patients will receive saline injection at study port site before incision
62051898|NCT01452633|ACTIVE_COMPARATOR|Preincision Marcaine|This group will receive marcaine injection at the study port site prior to incision
62051899|NCT01452633|PLACEBO_COMPARATOR|Postincision Placebo|This group of patients will receive preincisional marcaine and then saline injection at study port site prior to closure
62834737|NCT02986360|ACTIVE_COMPARATOR|Vidscrip educational video|Patients receive Vidscrip education video discussing breast density in the context of their normal mammogram result
62834738|NCT02986360|NO_INTERVENTION|Standard of care|Receive normal mammogram result and standard letter about breast density without any additional educational tools to contextualize breast density
62834739|NCT00846976|EXPERIMENTAL|200 mg Casodex|
62834740|NCT03257059|EXPERIMENTAL|Breakfast|Subject given standardized breakfast (glutinous rice) to test blood glucose response
62834741|NCT03257059|EXPERIMENTAL|No breakfast|Subject not given breakfast to test blood glucose response
62834742|NCT02477982||control group|BMI ≤ 25 kgm-2
62442191|NCT05216978|EXPERIMENTAL|PATH Intervention|"Participants in the PATH Intervention arm will receive psychosocial support phone calls during week 1 through 9 following enrollment.~After consent procedures, participants will begin an 9-week positive-psychology program involving weekly calls with an interventionist and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).~Self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
62834743|NCT02477982||obese group|BMI ≥ 30 kgm-2
62051900|NCT01452633|ACTIVE_COMPARATOR|Postincision marcaine|This group will receive preincisional marcaine and then marcaine injection at study port site prior to closure
62051901|NCT01183663|EXPERIMENTAL|Lenalidomide + Bevacizumab|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Bevacizumab starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
62442192|NCT04944602|EXPERIMENTAL|SYN008|patients received a dose of SYN008 300 mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
62442193|NCT04944602|ACTIVE_COMPARATOR|Omalizumab|patients received a dose of omalizumab 300 mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
62834744|NCT00067002|EXPERIMENTAL|Double Cord Blood Transplant Group|Two Unmanipulated Cord Blood units. Rituxan 375 mg/m2 by vein for patients with CD20 + malignancies. Melphalan 140 mg/m2 by vein on Day -8. Thiotepa 5 mg/Kg by vein on Day -7. Fludarabine 40 mg/m2 by vein on Days -6 to -3.
62834745|NCT00067002|EXPERIMENTAL|One Expanded Cord Blood Transplant Group|One Unmanipulated and One Expanded Cord Blood Unit. Fludarabine 40 mg/m2 by vein on Days -6 to -3. Cyclophosphamide 50 mg/kg by vein on Day -6. Mesna 10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg). Total body irradiation (TBI) given on Day -1 at 2 Gy.
62834746|NCT00354432|ACTIVE_COMPARATOR|Arm I - Placebo|Patients receive oral placebo pill and oral placebo powder once daily.
62834747|NCT00354432|ACTIVE_COMPARATOR|Arm II - Soy|Patients receive oral placebo pill and oral soy protein/isoflavones powder once daily.
62834748|NCT00354432|EXPERIMENTAL|Arm III - Venlafaxine|Patients receive oral Venlafaxine pill and placebo powder once daily.
62834749|NCT00354432|PLACEBO_COMPARATOR|Arm IV - Soy + Venlafaxine|Patients receive oral Venlafaxine pill and soy protein/isoflavones powder once daily.
62051902|NCT01183663|EXPERIMENTAL|Lenalidomide + Sorafenib|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Sorafenib starting dose: 200 mg by mouth daily for 28 a day cycle.
62834750|NCT01065883|EXPERIMENTAL|community health worker|community health workers will provide education in the home
62834751|NCT01065883|ACTIVE_COMPARATOR|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
62834752|NCT02497352|EXPERIMENTAL|Flaxseed|30 g milled brown flaxseed + lifestyle modification
62834753|NCT02497352|ACTIVE_COMPARATOR|control|lifestyle modification including dietary and physical activity recommendation
62834754|NCT02331888|EXPERIMENTAL|Scalp electrode, fetal doppler and EUM|Once in labor, the parturient will be connected to the routine fetal doppler and EUM. When necessary according to clinical indications, the scalp electrode will be connected. Tracing will be recorded simultaneously from all three devices until delivery.
62834755|NCT00798993|ACTIVE_COMPARATOR|Structured exercise program|Participants will be randomised at 3 months into either this group or the comparator of usual exercise.
62834756|NCT00798993|EXPERIMENTAL|Vitamin D|Cholecalciferol 2000U per day will be given to all participants for the duration of the study
62834757|NCT00798993|PLACEBO_COMPARATOR|Usual exercise|Participants randomised to this arm, at 3 months, will continue on their usual exercise routine
62834758|NCT04558034|ACTIVE_COMPARATOR|Interventioncryotherapy/control|Subjects will have one mitt/one slipper and serve as their own control
62834759|NCT04558034|NO_INTERVENTION|standard of care|Subjects will have two mitts/slippers
62834760|NCT03689621|ACTIVE_COMPARATOR|Transcutaneous vagal nerve stimulation (tVNS)|tVNS administered for 4 hours each day and behaviour is recorded.
62834761|NCT03689621|PLACEBO_COMPARATOR|Baseline|tVNS worn but not switched on whilst collecting behavioural data.
62834762|NCT04059159|EXPERIMENTAL|Connected Catheter Users|
62834763|NCT03762317|ACTIVE_COMPARATOR|clonidine|Clonidine is started at 6mcg/kg/day and increased to 12 mcg/kg/d for the duration of the study period
62834764|NCT03762317|PLACEBO_COMPARATOR|Placebo|Placebo solution will be given for the duration of the study period
62834765|NCT04214158||Professional Folk Dancers|Individuals who have been actively dancing for at least two years will be included in the study.
62834766|NCT04214158||sedentary|According to the international physical activity questionnaire, individuals with low levels of physical activity will be included in the study.
62834767|NCT05024032|EXPERIMENTAL|10 Milligrams (mg) Tirzepatide|Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).
62834768|NCT05024032|EXPERIMENTAL|15 mg Tirzepatide|Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.
62834769|NCT05024032|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo SC QW.
62442194|NCT04871217|EXPERIMENTAL|Acute ST-elevation myocardial infarction or chronic coronary artery occlusion|68-Ga-NODAGA-RGD PET after acute ST-elevation myocardial infarction or before and after re-opening of a chronic coronary artery occlusion
62834770|NCT02261701|EXPERIMENTAL|Early mobilization|Intervention is early mobilization, four weeks immobilization postsurgery with collar´n cuff only.
62834771|NCT02261701|OTHER|Post surgery shoulder lock|Post surgery shoulder lock with abduction cushion 3 weeks and after this period collar´n cuff 3 weeks
62834772|NCT02779946||CHD-positive|positive tested for coronary artery disease
62834773|NCT02779946||CHD-negative|negative tested for coronary artery disease
62834774|NCT02275234||Retrospective|Patients who survived cardiac arrest \>3 months prior to the start of the study and a close family/friend,will be invited to attend an outpatient clinic
62834775|NCT02275234||Prospective- psychological intervention|In patients who survived cardiac arrest and a close family/friend,will be invited to attend an outpatient clinic
62834776|NCT01649206|EXPERIMENTAL|Group A: RTA|Percutaneous Radiofrequency Thermal Ablation (RTA).
62834777|NCT01649206|NO_INTERVENTION|Group B: untreated|No treatment, only follow-up
62834778|NCT00722943|ACTIVE_COMPARATOR|DMT group|These infants will receive tactile stimulation and developmental massage by a licensed therapist. This intervention will be done behind a screen in order to blind the therapy to NICU staff and parents.
62834779|NCT00722943|PLACEBO_COMPARATOR|SHAM control|These infants will have no tactile stimulation or developmental massage done. The therapist will stand behind a screen but will not touch the infant. The screen will blind the NICU staff and parents to the study arm.
62834780|NCT00553891|EXPERIMENTAL|Nasonex Nasal Spray|
62834781|NCT00553891|PLACEBO_COMPARATOR|Placebo Nasal Spray|
62834782|NCT01455701|EXPERIMENTAL|Tocilizumab|Participants will receive tocilizumab intravenous (IV) infusion at a dose of 12 milligrams per kilogram (mg/kg) every two weeks (Q2W) during main evaluation period of 12 weeks (a total of 6 infusions including one at baseline visit). Participants will have the option to be treated in an optional extension period after completion of main evaluation period. In optional extension period, participants will receive tocilizumab 12 mg/kg IV infusion Q2W from Week 12 until the participant reaches 2 years of age or has been treated for one year from baseline, whichever is longer.
62442195|NCT01037166|EXPERIMENTAL|Entecavir (0.5 mg)|
62442196|NCT01037166|EXPERIMENTAL|Entecavir (1mg)|
62834783|NCT03829644|EXPERIMENTAL|Intervention|Participants in the intervention arm will be fitted with a semi-rigid prefabricated lumbar brace (Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618) in addition to their current back pain management program.
62442197|NCT01620983|EXPERIMENTAL|Pain Coping Skills Training|The pain coping skills training will be delivered by physical therapists in eight one-hour sessions by telephone over a 2-month perioperative period. Patients will be taught a variety of skills designed to improve maladaptive pain related thoughts and actions to enhance recovery following arthroplasty.
62834784|NCT03829644|NO_INTERVENTION|Control|Participants in this arm will be instructed to follow their current back pain management program.
62051903|NCT01183663|EXPERIMENTAL|Lenalidomide + Temsirolimus|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Temsirolimus starting dose: 15 mg by vein every week for a 28 day cycle.
62051904|NCT01183663|EXPERIMENTAL|Lenalidomide + Oxaliplatin + Leucovorin + 5-fluorouracil|Lenalidomide starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle. Oxaliplatin starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle. Leucovorin 400 mg/m2 by vein on day 1 of a 21 day cycle. 5-fluorouracil 400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.
62051905|NCT01557387||Patients with pseudopolyps.|No treatment involved in this study.
62051906|NCT03011632|EXPERIMENTAL|mometasone nasal|a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months,
62051907|NCT03011632|PLACEBO_COMPARATOR|placebo mometasone|a group of children without immunoglobulin E (IgE) - dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
62834785|NCT05959720||Eligible patients|All patients deemed eligible to intensive protocol of treatment are going to be included as sole group. There is no intervention or control group in this trial.
62834786|NCT03584789|NO_INTERVENTION|Standard Practice|The patients in this arm were part of usual care with their dental provider.
62834787|NCT03584789|EXPERIMENTAL|Clinical Decision Support|A clinical decision support system designed to assist dentists in providing optimal pain management for patients without resorting to opioids when a non-opioid alternative would suffice. It provides pertinent clinical information to the dentist, including point-of-care access to the Prescription Drug Monitoring Program.
62834788|NCT03584789|EXPERIMENTAL|Clinical Decision Support + Education|Patient education regarding pain management before and after dental extraction, including information about the risks and benefits of various strategies.
62834789|NCT04266145|ACTIVE_COMPARATOR|intravenous dexmedetomidine|20 mL 0.25% levobupivacaine plus 1 mL normal saline will be administrated for adductor-canal-blockade while for intravenous solution; 0.5µg.kg-1 dexmedetomidine diluted in 20 mL normal saline will be prepared
62834790|NCT04266145|ACTIVE_COMPARATOR|adductor-canal-blockade dexmedetomidine|20 mL 0.25% levobupivacaine containing 1 mL of 0.5 mcg.kg-1 dexmedetomidine will be used for adductor-canal-blockade whereas, 20 mL 0.9% saline will be prepared for intravenous infusion
62834791|NCT04030871|ACTIVE_COMPARATOR|Capsule Dome G-Tube|Capsule Dome G-Tube
62834792|NCT04030871|ACTIVE_COMPARATOR|Balloon Bolus feeding tube|Balloon Bolus feeding tube
62834793|NCT01230983|EXPERIMENTAL|Treatment 1: (No HD MTX / No Zinecard)|Closed 09/2000 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), methotrexate/cytarabine), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, IT methotrexate /cytarabine radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), IT methotrexate/cytarabine)
62834794|NCT01230983|ACTIVE_COMPARATOR|Treatment 2: (No HD MTX / Zinecard)|Closed 09/2000 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), methotrexate/cytarabine, dexrazoxane hydrochloride (Zinecard or DZR)), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, dexrazoxane hydrochloride (Zinecard or DZR), IT methotrexate /cytarabine, radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), IT methotrexate/cytarabine)
62834795|NCT01230983|ACTIVE_COMPARATOR|Treatment 3: (HD MTX / No Zinecard)|Closed 09/2001 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), leucovorin calcium (LCV), HD methotrexate/cytarabine), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, leucovorin calcium (LCV), HD methotrexate /cytarabine radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), HD methotrexate/cytarabine)
62051908|NCT01040858|EXPERIMENTAL|Cognitive Strategies Training|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study). Cognitive Strategies training consisted of interactive didactic presentations, in-class discussions, and activities that introduced participants to a variety of cognitive strategies and external aids.
62051909|NCT01040858|PLACEBO_COMPARATOR|Placebo comparison group|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
62051910|NCT03994302||Immune toxicity induced by drugs and chemotherapies|Immune toxicity induced by drugs and chemotherapies Case reported in the World Health Organization (WHO) of immune toxicities(such as Antiphospholipid syndrome) of patient treated by a drug, with a chronology compatible with the drug toxicity
62051911|NCT01730898|ACTIVE_COMPARATOR|Control capsule|2 capsules
62051912|NCT01730898|EXPERIMENTAL|Experimental capsule|2 capsules
62252965|NCT05284279||Health professionals practicing with children|"To participate, health professionals will have to speak French fluently, practice with children as a dentist (general or pediatric), a general practitioner, or a paediatrician and work in hospital or ambulatory facility. As paediatricians and general practitioners meet the child regularly during the first 6 years of life for medical follow-up, they are key stakeholders in the early detection of caries, referrals to dentist and counselling.~The participants will be recruited using a semi-random sampling method. The sample will be constituted with a maximum variation in age, gender, years in practice, occupation and types of practice (solo, group or interdisciplinary team)."
62252966|NCT04777435|EXPERIMENTAL|Patients with Thrombotic micro-angiopathy|
62252967|NCT04801875|EXPERIMENTAL|Violin Performers|Violin performers received three 40-45 minute exercise sessions each week for eight weeks. The selected exercise program designed to correct postural alignment.
62252968|NCT04801875|EXPERIMENTAL|Ney Performers|Ney performers received three 40-45 minute exercise sessions each week for eight weeks. The selected exercise program designed to correct postural alignment.
62252969|NCT03992664|EXPERIMENTAL|EDUCATION|If the patient is in the experimental team, questionnaires and printed education information will be given first and after the completion of the forms, the intervention will be followed.
62051913|NCT06579456|ACTIVE_COMPARATOR|- Negative control|participants who continued after the pre-test in this model (negative control group) proceeded with training in the described skills, adding suture training using a perforable MMA-type woven fabric
62051914|NCT06579456|ACTIVE_COMPARATOR|- Positive control|simulation in silicone models was conducted using models that emulate the rigidity, structure, dimensions, and haptic feedback of the anatomical structures to be treated, specifically a hollow viscus for enterorrhaphy training. Each model was placed inside a Pelvitrainer for training, and the participants performed cutting and suturing exercises freely for the allotted time
62051915|NCT06579456|EXPERIMENTAL|Intervention Group|training in the cadaveric model was carried out using a complete human body preserved in formaldehyde-free solution. The cadaver was positioned and covered with surgical drapes in the supine position and a pneumoperitoneum was performed for training using a Mindray HD3 laparoscopy tower
62051916|NCT00155389|ACTIVE_COMPARATOR|H pylori eradication|All enrolled subjects received chemoprevention with Helicobacter pylori eradication
62051917|NCT04167241||Patients submitted to right pneumonectomy or bi-lobectomy|Consecutive, elective surgical patients submitted to right pneumonectomy or bi-lobectomy
62252970|NCT03992664|NO_INTERVENTION|NON-INTERVENTION|The difference in this group is that it will not be explained or given a form of educational intervention for management of rash.
62252971|NCT05353049|EXPERIMENTAL|Bathing technique based on Basale Stimulation|
62252972|NCT05353049|NO_INTERVENTION|Traditional bathing technique|
62252973|NCT03055754|EXPERIMENTAL|Argon randomized arm|Endoscopic procedure with a full inventory, measurement of the anastomosis diameter, and an argon plasma coagulation. Followup of all patients by a multidisciplinary team (life, food orientations).
62252974|NCT03055754|ACTIVE_COMPARATOR|Control arm|Full inventory and measurement of the anastomosis diameter, without any intervention. Followup of all patients by a multidisciplinary team (life, food orientations).
62442198|NCT01620983|ACTIVE_COMPARATOR|Arthritis Education|The eight one-hour perioperative arthritis education sessions will be delivered by nurse educators via telephone and will use a presentation and discussion format. Figures and discussion sessions will present information on the nature of arthritis, what to expect following knee arthroplasty, treatment of osteoarthritis, the role of exercise, joint protection and making future treatment decisions.
62442199|NCT01620983|OTHER|Usual Care|Patients randomly assigned to this arm will undergo usual care following knee arthroplasty.
62834796|NCT01230983|ACTIVE_COMPARATOR|Treatment 4: (HD MTX / Zinecard)|Closed 09/2001 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), leucovorin calcium (LCV), HD methotrexate/cytarabine, dexrazoxane hydrochloride (Zinecard or DZR)), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, HD methotrexate /cytarabine, dexrazoxane hydrochloride (Zinecard or DZR), radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), HD methotrexate/cytarabine)
62051918|NCT02519101|EXPERIMENTAL|Continunous blood pressure monitoring|Patients receive continuous noninvasive blood pressure monitoring in addition to intermittent monitoring
62051919|NCT02519101|NO_INTERVENTION|Intermittent blood pressure monitoring|Control group with intermittent blood pressure monitoring
62051920|NCT02238379|EXPERIMENTAL|Oxytocin|Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
62051921|NCT02238379|PLACEBO_COMPARATOR|Placebo|Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
62051922|NCT02701712|EXPERIMENTAL|Magnetic resonance - guided radiation therapy (MRgRT)|Magnetic resonance (MR) - guided radiation therapy
62051923|NCT02720939||ASD group|ASD patients who met the diagnostic criteria of either autistic disorder or Asperger's disorder defined by the DSM-IV criteria
62051924|NCT02720939||TD group|Typically development controls without lifetime diagnosis with ASD or any psychiatric disorders
62252975|NCT03066908|EXPERIMENTAL|Single Arm|Sinopsys® Lacrimal Stent
62252976|NCT05505136||MAPS Study Patients with Medication Change Reported|No intervention will be administered. This is a retrospective study of the patients who participating in the MAPS Protocol 90D0234 completed in 2021. Patients who had a medication change reported in that study are the focus of this study MAPS II 90D0255.
62252977|NCT03451084|EXPERIMENTAL|Part 1: Dose Level 1|
62252978|NCT03451084|EXPERIMENTAL|Part 1: Dose Level 2|
62442200|NCT03888833||Veno arterial extracorporeal membrane oxygenation|
62442201|NCT00359970|ACTIVE_COMPARATOR|Azithromycin 500 mg plus Placebo|a single 500 mg dose of Azitrhomycin at the start of treatment; a single loading dose of placebo at the start of treatment and then a dose of placebo after each loose stool
62834797|NCT04195373|EXPERIMENTAL|TMV-018 + 5-FC|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with the prodrug 5-FC.
62834798|NCT04195373|EXPERIMENTAL|TMV-018 + anti-PD-1 inhibitor|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with an anti-PD-1 Inhibitor.
62834799|NCT04195373|EXPERIMENTAL|TMV-018 + 5-FC + anti-PD-1 inhibitor|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with the prodrug 5-FC and an anti-PD-1 Inhibitor.
62051925|NCT03820856|EXPERIMENTAL|acupuncture plus fire needle group|
62051926|NCT03820856|ACTIVE_COMPARATOR|acupuncture group|
62051927|NCT03649620|EXPERIMENTAL|unripe Bokbunja Extract|tablet(1 tablet/d, 600 mg/d) for 12 weeks
62051928|NCT03649620|PLACEBO_COMPARATOR|Placebo|Placebo for 12 weeks
62051929|NCT01857882|EXPERIMENTAL|Decision Support Workshop|The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.
62051930|NCT01857882|NO_INTERVENTION|Standard Care|Routine pre-consultation education
62051931|NCT00621543|EXPERIMENTAL|Observation- All subjects|Women choosing intra-uterine contraception after medical abortion.
62051932|NCT06199557|ACTIVE_COMPARATOR|Hydroxyurea (HU) + Valproic Acid (VPA) part 1|"Combination treatment 1 (T1): hydroxyurea + valproic acid, combination treatment 2 (T2): 6-mercaptopurine + valproic acid.~Each patient enrolled will receive at least one cycle with T1: hydroxyurea and valproic acid. The 1st cycle in the study always constitutes of hydroxyurea (1000 mg twice a day) plus valproic acid (300 mg + 600 mg) for 14 days; then 14 days with no medication.~Each cycle duration is 28 days. Patients who do not experience clinical benefit after 1st cycle, or experience unacceptable and unmanageable toxicity after 1st cycle, will not be eligible to continue on this regimen and they will be allocated to treatment combination 2. T2 constitutes of 6-mercaptopurine ( 50 mg once a day) plus valproic acid 300 mg + 600 mg ) for 14 days; followed by 14 days with no medication. Each cycle duration is 28 days."
62834800|NCT02725918|EXPERIMENTAL|Pem mono|Patients in arm B will receive pemetrexed (500 mg/m2, d1) every 3 weeks until PD or intolerable toxicities.
62051933|NCT06199557|ACTIVE_COMPARATOR|Hydroxyurea (HU) + Valproic Acid (VPA) part 2|"Part B consists of two cohort expansions where the setup is identical to part A: one for HU + VPA and one for 6-MP + VPA, 16 patients in each, in total 32 new patients.~In part B the same principles will apply for response, withdrawal and allocation from HU+ VPA to 6-MP + VPA. The treatment duration in all arms can last to up 6 cycles in total. Each cycle duration is 28 days."
62051934|NCT04285255|ACTIVE_COMPARATOR|Opioids anesthesia|received propofol-fentanyl induction of anaesthesia plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side
62051935|NCT04285255|ACTIVE_COMPARATOR|OFA|received preinduction with dexmeditomidine 0.1µg.kg-1 over 10 min. Induction with propofol 1.5 mg.kg-1-ketamine (ketofol 3:1 mixture) induction plus maintenance mixture of dexmedetomidine 0.5µg.kg-1.h-1, ketamine 0.5mg.kg-1.h-1, and lidocaine 1 mg.kg-1.h-1 plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side
62834801|NCT02725918|ACTIVE_COMPARATOR|Pem+Cis|Patients in arm A will receive 4 cycles of cisplatin (75 mg/m2, d1) and pemetrexed (500 mg/m2, d1) every 3 weeks, those without disease progression (PD) and being tolerable judged by investigator will continue single-agent pemetrexed (500 mg/m2, d1) every 3 weeks as maintenance until progression or intolerable toxicities.
62834802|NCT02461134|EXPERIMENTAL|Ponesimod|Study treatment consists of 3 consecutive periods: 5 mg ponesimod treatment period (including up-titration), 10 mg treatment period (including up-titration) and a 20 mg treatment period.
62834803|NCT05953623|EXPERIMENTAL|Intra-arterial albumin infusion|
62834804|NCT05996718|EXPERIMENTAL|Informal Caregivers of Persons Living with Dementia|"Participants will receive the training program, Improving Care through Improv. This involves four weekly 2-hour in-person training sessions."
62051936|NCT01631630|EXPERIMENTAL|Pioglitazone|Subjects received pioglitazone, 15mg/day for 3 days; 30mg day for 3 days; 45mg/day thereafter, for a minimum total of 13 days
62442202|NCT00359970|ACTIVE_COMPARATOR|Azithromycin 1000 mg plus Placebo|a single 1000 mg dose of Azitrhomycin at the start of treatment; a single loading dose of placebo at the start of treatment and then a dose of placebo after each loose stool
62834805|NCT03591211|EXPERIMENTAL|Qigong Training|
62834806|NCT03591211|ACTIVE_COMPARATOR|Cognitive Training|
62834807|NCT00807001|EXPERIMENTAL|Cohort A|Subjects randomized 8:2 (active:placebo) to receive one 25 milligrams (mg) capsule of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
62051937|NCT01631630|PLACEBO_COMPARATOR|Placebo|Subjects received placebo on a similar dosing schedule, for a minimum total of 13 days
62051938|NCT02624544|EXPERIMENTAL|Group A|Proton Pump Inhibitor esomeprazole 40 mg twice a day
62051939|NCT02624544|ACTIVE_COMPARATOR|Group B|desonide
62051940|NCT02792361|NO_INTERVENTION|Control Group|Subjects who did not have a suction drain placed post-operatively following a Pterional Craniotomy.
62051941|NCT02792361|EXPERIMENTAL|Treatment Group|Subjects who did have a suction drain placed post-operatively following a Pterional Craniotomy at the location of surgical incision.
62252979|NCT03451084|EXPERIMENTAL|Part 1: Dose Level 3|
62834808|NCT00807001|EXPERIMENTAL|Cohort B|Subjects randomized 8:2 (active:placebo) to receive two 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
62834809|NCT00807001|EXPERIMENTAL|Cohort C|Subjects randomized 8:2 (active:placebo) to receive three 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
62834810|NCT00807001|EXPERIMENTAL|Cohort D|Subjects randomized 8:2 (active:placebo) to receive four 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
62834811|NCT01871935|ACTIVE_COMPARATOR|Remifentanil|Anaesthesia with remifentanil/propofol
62834812|NCT01871935|ACTIVE_COMPARATOR|Sufentanil|Anaesthesia with sufentanil/propofol
62051942|NCT03584620|EXPERIMENTAL|IMT+PR Group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training. In addition standard pulmonary rehabilitation, patients received inspiratory muscle training.
62051943|NCT03584620|EXPERIMENTAL|PR group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training.
62051944|NCT02333214|EXPERIMENTAL|Exergame + conventional physiotherapy|This group will be submitted to 30 minutes of conventional physiotherapy and 20 minutes of therapy using interactive games Xbox 360 Video Game and Entertainment Microsoft System with Kinect sensor, intervention twice a week for 12 weeks. Each game has three difficulty levels that can be used according to the performance of each participant. The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain.
62051945|NCT02333214|ACTIVE_COMPARATOR|Conventional physiotherapy|The control group will receive 50 minutes of conventional physiotherapy intervention twice a week for 12 weeks. The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain.
62252980|NCT03451084|EXPERIMENTAL|Part 1: Dose Level 4|
62252981|NCT03451084|EXPERIMENTAL|Part 2:ASLAN003 at Optinum Dose Level -1 & Azacitidine|
62252982|NCT03451084|EXPERIMENTAL|Part 2:ASLAN003 at Optinum Dose Level & Azacitidine|
62442203|NCT00359970|EXPERIMENTAL|Azithromycin 500 mg plus Loperamide|a single 500 mg dose of Azitrhomycin at the start of treatment; a single 4 mg loading dose of Loperamide at the start of treatment and then 2 mg Loperamide after each loose stool
62442204|NCT02739815|PLACEBO_COMPARATOR|Placebo|Will receive a placebo (10 ml of distilled water) in Z solution \[500 ml of normal saline containing a prophylactic Antibiotic 1 g\] (At 20 minutes preoperatively).
62442205|NCT02739815|ACTIVE_COMPARATOR|T1|Will receive Tranexamic acid 15 mg/kg in Z solution \[500 ml of normal saline containing a prophylactic Antibiotic 1 g\] (At 20 minutes preoperatively).
62442206|NCT02739815|ACTIVE_COMPARATOR|T2|Will receive Tranexamic acid 20 mg/kg in Z solution \[500 ml of normal saline containing a prophylactic Antibiotic 1 g\] (At 20 minutes preoperatively).
62442207|NCT02739815|ACTIVE_COMPARATOR|T3|Will receive Tranexamic acid 25 mg/kg in Z solution \[500 ml of normal saline containing a prophylactic Antibiotic 1 g\] (At 20 minutes preoperatively).
62611498|NCT02464644|OTHER|Controls without HHT|"People without HHT will identify themselves within the questionnaire, first by statement of what they think is their diagnosis, and second by provision of the HHT diagnostic criteria within specific questions.~They will be directed to appropriate questions, according to answers to the previous questions."
62834813|NCT01597596|EXPERIMENTAL|Alglucosidase Alfa 4000 L material (Non-US participants)|Alglucosidase alfa 4000 L material for 52 weeks.
62834814|NCT01597596|ACTIVE_COMPARATOR|Alglucosidase Alfa 160 L material (US participants)|Alglucosidase alfa 160 L material for 52 weeks.
62834815|NCT01887483|ACTIVE_COMPARATOR|Vetal Laban active|Vetal Laban with L. acidophilus
62834816|NCT01887483|PLACEBO_COMPARATOR|Placebo|Vetal Laban -like product without L. acidophilus
62834817|NCT03006003|EXPERIMENTAL|Raloxifene group|Raloxifene treatment
62834818|NCT03006003|ACTIVE_COMPARATOR|Comparator group|Alendronate treatment
62834819|NCT03006003|NO_INTERVENTION|Control group|To refuse anti-osteoporosis treatment
62834820|NCT04592887|EXPERIMENTAL|FLASH radiotherapy for painful bone metastasis(-es)|
62834821|NCT02808117||Targeted initially|Children who were in the Haiti villages and targeted by the MFI program with MNP delivery initially.
62834822|NCT02808117||Targeted later|Children who were in the Haiti villages and not targeted by the MFI program with MNP delivery until later.
62834823|NCT02566421|EXPERIMENTAL|Treatment (precision medicine)|Patients receive treatment based on the results of their genomic sequencing analyses.
62834824|NCT02231359||chronic obstructive airways disease patients|
62252983|NCT01093625|EXPERIMENTAL|Narafilcon B Contact Lens|Investigational Silicone Hydrogel Contact Lens
62252984|NCT01093625|ACTIVE_COMPARATOR|Spectacles|
62252985|NCT01993212|PLACEBO_COMPARATOR|Placebo|Androxal Placebo and Gel Placebo
62252986|NCT01993212|ACTIVE_COMPARATOR|AndroGel Treatment|AndroGel 1.62% and Placebo Capsules
62252987|NCT01993212|EXPERIMENTAL|Androxal Treatment|Androxal 12.5 mg or 25mg and Placebo Gel
62252988|NCT02090413|EXPERIMENTAL|DMF + ASA 150 mg BID|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA 150 mg is taken BID from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
62252989|NCT02090413|EXPERIMENTAL|DMF + ASA 75 mg QAM|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA 75 mg is taken in the morning (QAM) and ASA-Placebo is taken in the evening (QPM) from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
62252990|NCT02090413|EXPERIMENTAL|DMF + ASA-Placebo BID|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA-Placebo is taken BID from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
62252991|NCT02445625|EXPERIMENTAL|BCI to train joint attention in ASD|We are using Brain Computer Interfaces implemented by EEG in 16 ASD subjects
62252992|NCT00777777|EXPERIMENTAL|1|Either the Circumflex Coronary Artery or the Right Coronary Artery will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
62252993|NCT04824820|EXPERIMENTAL|Vibrator|Participants will be using commercially available genital vibrator for at least 5 minutes and/or reaching an orgasm three times a week for 3-4 months.
62051946|NCT04549610|EXPERIMENTAL|HMB supplementation|"The experimental procedure for each participant in this group includes a one week HMB supplementation.~HMB will be administered in the form of blinded capsules containing 0.5 g HMB per capsule. The capsules will be ingested with at least 250 mL of water. Each athlete will ingest 8 capsules (4 x 2 capsules) of HMB in a split dose per day. On training days the supplements will be taken in the morning (2 capsules), 1.5 hours before training session (2 capsules), immediately after training (2 capsules) and before sleep (2 capsules). On rest days the supplements will be taken in the morning (2 capsules), around midday (2 capsules), in the afternoon (2 capsules) and before bedtime (2 capsules) at possibly similar (approx. 4 hours) intervals during the day."
62051947|NCT04549610|PLACEBO_COMPARATOR|Placebo treatment|The experimental procedure for each participant in this group includes a one-week placebo (PLA) administration. PLA (corn starch) will be placed in the blinded capsules form. PLA will be ingested with at least 250 mL of water. Each participant in this group will ingest 8 placebo capsules a day. On training days the PLA capsules will be taken in the morning (2 capsules), 1.5 hours before training session (2 capsules), immediately after training (2 capsules) and before sleep (2 capsules). On rest days the supplements will be taken in the morning (2 capsules), around midday (2 capsules), in the afternoon (2 capsules) and before bedtime (2 capsules) at possibly similar (approx. 4 hours) intervals.
62834825|NCT03980704|ACTIVE_COMPARATOR|High Protein|Provision of 400 ml per day of high protein oral nutritional supplements
62051948|NCT05987033|EXPERIMENTAL|NVDX3 implant|
62051949|NCT05796856|EXPERIMENTAL|Repeated low-level light therapy (wavelength: 810 nm)|"Participants will be treated with repeated low level light therapy (wavelength of 650 nm) twice per weekday with an interval of at least 4 hours, each treatment last 3 minutes.~Single-vision spectacles with power for correcting distance refraction will also be used if necessary."
62051950|NCT05796856|ACTIVE_COMPARATOR|Repeated low-level light therapy (wavelength: 650 nm)|"Participants will be treated with repeated low level light therapy (wavelength of 650 nm) twice per weekday with an interval of at least 4 hours, each treatment last 3 minutes.~Single-vision spectacles with power for correcting distance refraction will also be used if necessary."
62051951|NCT01674374|EXPERIMENTAL|Arm I (SAMITAL)|Beginning as soon as symptoms arise during chemoradiotherapy, patients receive Vaccinium myrtillus extract/Macleaya cordata alkaloids/Echinacea angustifolia extract granules PO QID. Patients may continue to receive Vaccinium myrtillus extract/Macleaya cordata alkaloids/Echinacea angustifolia extract granules for up to 4 weeks after completion of radiation therapy for a maximum of 11 weeks.
62051952|NCT01674374|PLACEBO_COMPARATOR|Arm II (placebo)|Beginning as soon as symptoms arise during chemoradiotherapy, patients receive placebo PO QID. Patients may continue to receive placebo for up to 4 weeks after completion of radiation therapy for a maximum of 11 weeks.
62051953|NCT02650219||gaucher disease type 1|"Inclusion criteria:~* Adult patients \>= 18 years old~* Gaucher disease type 1, proved by low betaglucosidase, with or without treatment~* Patients must have read, understood and signed informed consent. intervention : genetic analyses"
62252994|NCT04475575|OTHER|COVID-19 suspected|Participants where included if an oropharyngeal and nasopharyngeal swab was collected for RT-PCR and serology testing had been performed, or if participants have had a confirmed COVID-19 diagnosis in the previous days or weeks with an indication for re-testing via PCR and serology testing at the moment of inclusion
62252995|NCT06470789|EXPERIMENTAL|blood flow restriction training|blood flow restriction training (BFRT) is a popular method of sports training. It involves the use of devices such as air sleeves or elastic bands with adjustable functions during sports training that restrict blood flow to parts of the limb, resulting in an adaptive effect similar to high-intensity training in the muscles, while actually using relatively light weights. BFRT is usually combined with light exercise, such as low-load strength training or aerobic training, to build muscle strength and muscle endurance. This training method is more friendly to patients after sports injuries ， fractures, joint surgery ， etc. It can help to train the injured area with light loads to reduce muscle atrophy and speed up recovery to restore muscle function and strength. BFRT is also commonly used by athletes in different sports to improve muscle strength and endurance while reducing weight load, helping to reduce the risk of overtraining and injury.
62252996|NCT06470789|PLACEBO_COMPARATOR|Massage|Massage is a widely used traditional Chinese physical therapy technique, which uses massage, kneading, pushing, flicking, tapping and other techniques, as well as the use of the palm, fingertips, elbows, knees and other body parts to stimulate specific body areas or acupoints to achieve the purpose of treatment or relief of disease symptoms . Massage massage can relieve musculoskeletal pain by promoting blood circulation, relaxing tense muscles and reducing inflammation, and improve muscle elasticity and flexibility, helping to reduce muscle tension and stiffness . Therefore, massage massage is often used to improve the treatment of local body pain, and a large number of studies have shown that massage massage can reduce shoulder pain in the short term, restore shoulder function and improve the range of motion of shoulder joints .
62834826|NCT03980704|EXPERIMENTAL|Immuno ONS|Provision of 400 ml per day of immunostimulating oral nutritional supplements
62834827|NCT02766023|EXPERIMENTAL|LACTIN-V|Subjects receive 5-day course of metronidazole gel 7.5 mg/gm daily applied vaginally. Subjects then receive LACTIN-V 2x10\^9 cfu/dose applied vaginally for 5 days then twice weekly for 10 weeks. N=152
62051954|NCT02650219||Control|healthy subjects intervention: genetic analyses
62051955|NCT02946918|EXPERIMENTAL|Tablets|Patients in this arm will receive levothyroxine tablets (encapsulated for blinding purposes)
62252997|NCT06470789|EXPERIMENTAL|BFRT combined massage group|To observe the effect of blood flow restriction equipment combined with low-load shoulder resistance training and massage intervention on shoulder pain, function, strength and joint motion of judo athletes with shoulder joint dysfunction.
62252998|NCT03180164|OTHER|chronic lung diseases|bronchiectasis , bronchial asthma and chronic obstructive pulmonary disease assess anxiety and depression by hospital anxiety and depression scale
62252999|NCT05126472|EXPERIMENTAL|(Cohort A) anti-CD40 antibody 2141-V11|Intravesically or intratumorally) of an anti-CD40 agonist antibody (2141-V11) for the treatment of subjects with BCG-unresponsive NMIBC who are considered ineligible for or have elected not to undergo radical cystectomy.
62253000|NCT05126472|EXPERIMENTAL|(Cohort B) 2141-V11, a fixed dose of 10mg|For patients who are ineligible for radical cystectomy or have elected not to undergo the procedure.
62253001|NCT05126472|EXPERIMENTAL|(Cohort C) expansion cohort 10 mg of 2141-V11|For patients in Cohort C, 10 mg of 2141-V11 will be administered as an intratumoral injection during standard of care cystoscopy prior to and within four weeks of planned radical cystectomy.
62253002|NCT02147366|EXPERIMENTAL|Behavioral (Lifestyle)|Only standard lifestyle modifications The prehypertensives and stage I hypertensives will be randomized to receive each of the two three experimental conditions: music along with standard lifestyle modifications or only standard lifestyle modifications in random order over the course of three months.
62253003|NCT02147366|EXPERIMENTAL|Behavioral (Music & lifestyle changes)|Experimental: Music along with standard lifestyle modifications The prehypertensives and stage I hypertensives will be randomized to receive each of the two three experimental conditions: music along with standard lifestyle modifications or only standard lifestyle modifications in random order over the course of three months.
62253004|NCT01073267|EXPERIMENTAL|TSEBT|Total Skin Electron Beam Therapy (TSEBT) to dose of 12 Gy
62253005|NCT05144113||Current FES-Row Subjects|To determine user needs we will survey 10 subjects that are currently participating in FES-row training to discover their motivations, preferences and challenges pertaining to participation in physical activity in general and FES-rowing.
62253006|NCT05144113||Non-FES-Row Subjects|To determine user needs we will survey 10 subjects that have never participated in FES-row training to discover their motivations, preferences and challenges pertaining to participation in physical activity in general and FES-rowing.
62253007|NCT04595253|EXPERIMENTAL|acupressure|After recruitment, participants will be randomized to receive acupressure or control group. In the acupressure group, participants will receive acupressure treatment.
62442208|NCT02802514|EXPERIMENTAL|With Off therapy MRI in S1:Albiglutide-S1 & Exenatide-S2|In session 1, eligible subject will undergo off-therapy MRI scan Subject will receive single dose each of 50 mg albiglutide on Day 5 and exenatide placebo on Day 8 followed by a post-dose MRI. In session 2, subject will receive single dose each of albiglutide placebo on Day 1 (Week 9) and 10 microgram exenatide on Day 4 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
62834828|NCT02766023|PLACEBO_COMPARATOR|Placebo|Subjects receive 5-day course of metronidazole gel 7.5 mg/gm daily applied vaginally. Subjects then receive placebo applied vaginally for 5 days then twice weekly for 10 weeks. N=76
62253008|NCT04595253|NO_INTERVENTION|routine care|After recruitment, participants will be randomized to receive acupressure or control group. In the control group, participants will receive routine care, including routine pain control.
62253009|NCT02295345|EXPERIMENTAL|CBT for Insomnia|Participants attend 5 weekly sessions of Cognitive Behavioural Therapy for Insomnia for pregnant women, administered by licensed clinical psychologist.
62253010|NCT02361450|EXPERIMENTAL|Retrograde Colonic Irrigation with usual care|In the experimental group, retrograde colonic irrigation sessions will be scheduled in addition to conventional treatment according to a progressive volume program.
62253011|NCT02361450|ACTIVE_COMPARATOR|Usual Care|In the comparator group, patients will receive conventional care, according to each clinical center habits.
62253012|NCT05104333|EXPERIMENTAL|0-1-4 schedule group|Subjects receive the booster vaccine 3 months after the second dose.
62253013|NCT05104333|EXPERIMENTAL|0-1-6 schedule group|Subjects receive the booster vaccine 5 months after the second dose.
62253014|NCT01415128|ACTIVE_COMPARATOR|Omeprazole|Omeprazole with single dose of avanafil (200 mg)
62253015|NCT01415128|ACTIVE_COMPARATOR|Rosiglitazone|Rosiglitazone with single dose of avanafil (200 mg)
62834829|NCT05477667|ACTIVE_COMPARATOR|control group|the patients with non-malignant hematological diseases
62834830|NCT05477667|ACTIVE_COMPARATOR|the cases (A)|NHL .
62834831|NCT05477667|ACTIVE_COMPARATOR|the cases (B)|acute leukemia
62834832|NCT02964182|EXPERIMENTAL|Arm I (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)|"PHASE I: Patients smoke their usual cigarettes brand during week 1.~PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.~PHASES III-IV: Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks."
62834833|NCT02964182|EXPERIMENTAL|Arm II (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)|"PHASE I: Patients smoke their usual cigarettes brand during week 1.~PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.~PHASES III-IV: Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks."
62834834|NCT01057732||primary hyperparathyroidism|patients with primary hyperparathyroidism
62834835|NCT01057732||controls|subjects without primary hyperparathyroidism
62834836|NCT01281904|NO_INTERVENTION|Standard of Care|Participants randomized into the standard of care group will be asked to continue following the instructions of the healthcare provider throughout the 10 week study period. They will not be asked to perform any study intervention.
62834837|NCT01281904|ACTIVE_COMPARATOR|Relaxation Acupressure|In addition to their standard of care, participants will be asked to apply pressure on each of 9 acupressure points (bilaterally where indicated) that have been carefully selected for their relaxing effect. (There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes done once daily over a period of 6 weeks followed by 4 weeks of intervention wash-out where the participant will be asked to perform no acupressure at all.
62253016|NCT01415128|ACTIVE_COMPARATOR|Desipramine|Desipramine with single dose of avanafil (200 mg)
62253017|NCT00577928||1|
62253018|NCT00577928||2|
62253019|NCT06489639|EXPERIMENTAL|Developmentally Oriented Cognitive Therapy for Social Anxiety Disorder (DOCT-SAD)|Developmentally Oriented Cognitive Therapy for Social Anxiety Disorder (DOCT-SAD) is a ten-session, combined group/individual intervention program for treating social anxiety and social anxiety disorder in adolescents. It consists of four individual and six group sessions delivered during a ten-week period. The number of adolescents in each DOCT-SAD group varies between four and six. One or both parents attend two of the individual DOCT-SAD sessions.
62253020|NCT06489639|ACTIVE_COMPARATOR|Standard Counseling (SC)|Standard Counseling (SC) is an intervention consisting of counseling sessions delivered by a school health and welfare (SHWS) professional (i.e., school nurse, school social worker, or school psychologist) to support a student with social anxiety. The defined length of intervention is ten weeks. In SC, routine professional working methods and procedures available to the SHWS professional delivering the intervention are used.
62834838|NCT01281904|ACTIVE_COMPARATOR|Stimulating Acupressure|In addition to their standard of care, participants will be asked to apply pressure on each of 9 acupressure points (bilaterally where indicated) that have been carefully selected for their excitatory effect. (There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. There are 6 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 10 points to stimulate. Each of the 10 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 30 minutes done once daily over a period of 6 weeks followed by 4 weeks of intervention wash-out where the participant will be asked to perform no acupressure at all.
62253021|NCT05146245|EXPERIMENTAL|Therapeutic Drug Monitoring|Physicians receive dosing advice based on measured blood levels of risperidone and 9-OH-risperidone.
62834839|NCT06359353|EXPERIMENTAL|Pitavastatin|"Pitavastatin 2 mg or 4 mg once daily~\* The dosage is determined based on cholesterol levels and the physician's decision."
62834840|NCT03052062|EXPERIMENTAL|Lipidrive|Dose 1 : 2,6 g (4 capsules) Lipidrive per day during 12 weeks Dose 2 : 5,2 g (8 capsules) Lipidrive per day during 12 weeks, 2 weeks (wash-out period) between the 2 doses
62834841|NCT01734616|NO_INTERVENTION|Young|Young subjects to be controlled to older individuals with interventions
62834842|NCT01734616|NO_INTERVENTION|Old|Older individuals to compare to young and other older intervention groups
62834843|NCT01734616|EXPERIMENTAL|Old Exercise|Older individuals studied after an intervention of 20 weeks fully-supervised resistance exercise training
62834844|NCT01734616|EXPERIMENTAL|Old Acute Cocoa|Older individuals studied with the addition of cocoa flavanols during their acute study
62834845|NCT01734616|EXPERIMENTAL|Old 7 Day Cocoa|Older individuals studied after 7 day supplementation of cocoa flavanols
62834846|NCT04983446|EXPERIMENTAL|Foralumab Arm + Standard of Care|Subjects in this arm would receive, intranasal foralumab 100 µg (50 µg in 0.1 ml solution into each nostril).
62834847|NCT04983446|ACTIVE_COMPARATOR|Placebo Arm + Standard of Care|Subjects in this arm would receive, placebo (0.1 ml vehicle solution into each nostril).
62051956|NCT02946918|EXPERIMENTAL|Gelcaps|Patients in this arm will receive levothyroxine gelcaps (encapsulated for blinding purposes)
62253022|NCT05146245|ACTIVE_COMPARATOR|Care As Usual|Physician decides on possible dosing changes without receiving advice based on blood levels.
62834848|NCT02564835|EXPERIMENTAL|Yoga|The Yoga Program includes two 90-minute classes every week tor a total of 12 weeks.
62253023|NCT02127671|EXPERIMENTAL|IDEAL intervention|Individual cardiovascular risk reduction counseling, coordination with primary care providers to ensure appropriate management of risk factors, and collaboration with mental health staff and social supports. All participants will be offered group exercise classes, and programs will be provided with instruction to provide more healthy meals.
62051957|NCT01499732||Early Rheumatoid Arthritis|Subjects currently experiencing active early rheumatoid arthritis (duration of symptoms \< or = 2 years) according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening. Must be drug naive (no prior treatment with traditional disease-modifying antirrheumatic drugs (DMARDs), or biologic response modifying agents)
62253024|NCT02127671|OTHER|Control|All participants will be offered group exercise classes, and programs will be provided with instruction to provide more healthy meals.
62253025|NCT05529849|EXPERIMENTAL|TCMCB07|once daily subcutaneous injection
62253026|NCT05529849|PLACEBO_COMPARATOR|Placebo|once daily subcutaneous injection
62253027|NCT06268171||Study group|transplant patients with ultrasound measurement of the cross-sectional area of the rectus femoris
62253028|NCT03349099|ACTIVE_COMPARATOR|Cook Flexor|ureteral access sheath
62253029|NCT03349099|ACTIVE_COMPARATOR|Boston Scientific Navigator HD|ureteral access sheath
62253030|NCT05410444|ACTIVE_COMPARATOR|The control group|The control group received routine indwelling catheterization, the catheter was continuously opened, and the indwelling catheter was replaced every 7 days. When the bladder function returned to normal, the catheter was removed.
62253031|NCT05410444|EXPERIMENTAL|The study group|The observation group, namely intermittent catheterization group, was given one-to-one training and education to patients and their families before the implementation of the project. Frequency and timing of intermittent catheterization: it is recommended to catheterize once every 4 hours and no more than 6 times every 24 hours. If the residual urine volume decreases, the number of catheterization can be appropriately reduced; Before each catheterization, urinate by yourself. The derived urine volume is the residual urine volume. The total amount of urine shall not exceed the safe capacity of the bladder.
62611499|NCT02944435|EXPERIMENTAL|CB-839 Capsules|A single dose of 3 x 200-mg capsules of CB-839 will be administered orally with water approximately 5 minutes after consuming an entire meal
62611500|NCT02944435|ACTIVE_COMPARATOR|CB-839 Tablets|A single dose of 3 x 200-mg tablets of CB-839 will be administered orally with water approximately 5 minutes after consuming an entire meal
62611501|NCT03584516|EXPERIMENTAL|Part 1 : Dose determination of itacitinib|itacitinib administered in combination with corticosteroids.
62253032|NCT05069064|EXPERIMENTAL|music group|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
62253033|NCT05069064|OTHER|non-music group|Participants in the non-music group will undergo hysterosalpingography in the same setting and standard procedure without listening to any music.
62253034|NCT03404284||Intervention facilities|Includes 43 health facilities and their associated outreach sites
62253035|NCT04345770|SHAM_COMPARATOR|Without HIPEC|Patients will be treated with neoadjuvant chemotherapy (SOX) followed by a D2 radical gastrectomy for locally advanced gastric cancer and postoperative chemotherapy (SOX, 6 circles together with neoadjuvant chemotherapy)
62253036|NCT04345770|EXPERIMENTAL|With HIPEC|Patients will be treated with neoadjuvant chemotherapy (SOX) followed by a D2 radical gastrectomy for locally advanced gastric cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (SOX, 6 circles together with neoadjuvant chemotherapy)
62253037|NCT01878942|OTHER|Placebo, LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.
62253038|NCT00930839||Controls|Normal, healthy controls, males and females, ages 30-80
62253039|NCT00510081|EXPERIMENTAL|1|subjects will receive filler injections
62253040|NCT02390479|ACTIVE_COMPARATOR|Chronic periodontitis|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
62253041|NCT02390479|PLACEBO_COMPARATOR|clinically healthy periodontium|GCF samples were taken at baseline Intervention: oral hygiene instructions
62253042|NCT02840110||Post-ACTR|Subjects who have previously been treated with an ACTR T cell product
62611502|NCT03584516|EXPERIMENTAL|Part 1 : Dose expansion of itacitinib|itacitinib administered in combination with corticosteroids or corticosteroids alone.
62611503|NCT03584516|PLACEBO_COMPARATOR|Part 2 : itacitinib recommended dose from part 1|itacitinib or placebo administered in combination with corticosteroids
62051958|NCT01499732||Healthy subjects without rheumatoid arthritis|Healthy subjects without rheumatoid arthritis
62253043|NCT02228720|EXPERIMENTAL|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
62253044|NCT01889082|ACTIVE_COMPARATOR|Face to Face Behavioral Weight Loss|12-week treatment program consisting of weekly, in-person group meetings and brief, bi-weekly individual check-ins
62611504|NCT06250179|EXPERIMENTAL|Non-smoking patients|The patient will receive a free gingival graft for insufficient keratinized gingival height.
62611505|NCT06250179|ACTIVE_COMPARATOR|'Light' smokers who report smoking less than 5 cigarettes per day|The patient will receive a free gingival graft for insufficient keratinized gingival height.
62611506|NCT06250179|ACTIVE_COMPARATOR|Non-smoker for 5 years, quit smoking patients|The patient will receive a free gingival graft for insufficient keratinized gingival height.
62611507|NCT05391919|EXPERIMENTAL|MT in early recovery period of IS|"Patients in early recovery period of IS receive a course of rehabilitation with multimodal correction using BFB-stabilometric training, cognitive-motor training in a virtual environment (VR), functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator SensoRehab, if moderate paresis of the upper limb - the neurointerface Exokist-3 with EEG registration."
62051959|NCT01499732||Established Rheumatoid Arthritis|Subjects currently experiencing active established rheumatoid arthritis (duration fo symptoms \> or = 2 years) according to the 2010 ACR/EULAR criteria at screening. Subjects with active established RA currently receiving methotrexate, must have received it for at least 12 weeks, and at a stable dose (\> or = 15 mg/week) for at least 6 weeks prior to screening. They must be biologic naive, and must recieve at least 5mg oral folic acid weekly
62051960|NCT03891121|EXPERIMENTAL|Occlusal splint|Patients were treated with occlusal splint.
62051961|NCT03891121|EXPERIMENTAL|Botulinum toxin|Patients were treated with botulinum toxin injection.
62253045|NCT01889082|ACTIVE_COMPARATOR|Web Based Behavioral Weight Loss|12-week treatment program consisting of an initial in-person group session (weight loss 101 and intro to website), followed by weekly web-based program and e-coaching
62253046|NCT01889082|ACTIVE_COMPARATOR|Web Based Behavioral Weight Loss Plus Optional Group Sessions|12-week treatment program consisting of an initial in-person group session (weight loss 101 and intro to website), followed by weekly web-based program and e-coaching. Participants in this arm will also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training). \*New material / content is not provided in these optional sessions, rather they are meant to serve as a place to practice applying the core content from the lessons.
62253047|NCT03405805||3+1|Healthy infants will receive 4 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4,6 and 12 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
62253048|NCT03405805||3+0|Healthy infants will receive 3 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4 and 6 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
62611508|NCT05391919|EXPERIMENTAL|MT in late recovery period of IS|"Patients in late recovery period of IS receive a course of rehabilitation with multimodal correction using BFB-stabilometric training, cognitive-motor training in a virtual environment (VR), functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator SensoRehab, if moderate paresis of the upper limb - the neurointerface Exokist-3 with EEG registration."
62611509|NCT05391919|ACTIVE_COMPARATOR|No MT Intervention: Conventional IS rehabilitation|Patients in early and late recovery period of IS recieve conventional complex rehabilitation: kinesiotherapy, physiotherapy, occupational therapy.
62834849|NCT02564835|ACTIVE_COMPARATOR|Physical Activity|The Physical Activity Program includes two 90-minutes classes every week for a total of 12 weeks.The intervention is based on the Exercise for People Living with Cancer program and will include nine resistance exercises (e.g. standing push up, squats, standing leg curl) and 8 flexibility exercises (e.g. shoulder stretch, quadriceps stretch, hamstrings and lower back stretch) targeted for the whole body as well as a brief warm up and cool down (walking).
62834850|NCT02564835|NO_INTERVENTION|Usual Care|Participants randomized to this arm will receive standard care only.
62834851|NCT02331212||Ancillary-correlative (role of HAS2+ in CSCs)|Blood and bone marrow samples are collected and analyzed via flow cytometry and PCR. Cells are also transplanted into mice and studied.
62051962|NCT03891121|EXPERIMENTAL|Both|Patients were treated with occlusal splint and botulinum toxin injection together.
62051963|NCT06016530|EXPERIMENTAL|Healthy participants|"The study will involve 20 to 30 healthy participants, with approximately 15 females and 15 males. Each participant will undergo three measurements: 1) Baseline assessment, 2) Sleep Deprivation, and 3) Dexamethasone Supplementation.~The baseline measurement will be the starting point taken before any interventions are applied. It will serve as a control and reference to evaluate the impact of interventions."
62051964|NCT06519279||Freezing Of Gait Patients|15 patients with Parkinson disease with freezing of gait (group) in ON \& OFF states
62051965|NCT06519279||Non Freezing Of Gait Patients|5 patients with Parkinson disease without freezing of gait (cohort) in ON \& OFF states
62253049|NCT03405805||2+1|Healthy infants will receive 3 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4 and 12 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
62611510|NCT05954936||Blunt injury|Patients with non-penetrating injuries from falls, car accidents, or other mechanisms. Injuries that were caused by impact with a blunt object where there is no penetration of the skin.
62611511|NCT05954936||Penetrating injury|Penetrating wounds by guns, knives, and other penetrating injuries. Wounds that were caused by objects penetrating the skin.
62611512|NCT00851019|EXPERIMENTAL|DDR|"Dance Dance Revolution (DDR) Exergaming"
62611513|NCT00851019|ACTIVE_COMPARATOR|Treadmill|Treadmill exercise
62611514|NCT03099694|ACTIVE_COMPARATOR|nCPAP|nasal continuous positive airway pressure (nCPAP) - as a primary mode of ventilation in premature infants with RDS
62611515|NCT03099694|EXPERIMENTAL|nHFOV|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in premature infants with RDS
62611516|NCT06199271|EXPERIMENTAL|Treatment group|Patients with resectable locally advanced head and neck squamous carcinoma cell carcinoma receive adebrelimab plus dalpiciclib before surgery.
62442209|NCT02802514|EXPERIMENTAL|Without Off therapy MRI in S1:Albiglutide-S1 & Exenatide-S2|In session 1, eligible subject will receive single dose each of 50 mg albiglutide on Day 1 and exenatide placebo on Day 4 followed by a post-dose MRI scan. In session 2, Day 1 (Week 9) subject will undergo off-therapy MRI scan. Subject will receive single dose each of albiglutide placebo on Day 5 and 10 microgram of exenatide on Day 8 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
62611517|NCT01368107|PLACEBO_COMPARATOR|Placebo Arm|the patients will receive Placebo before the 1st and during the 3rd CT cycle (N=6)
62611518|NCT01368107|EXPERIMENTAL|CYT107 treatment before CT|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle and the placebo during the 3rd CT cycle (N=6)
62611519|NCT01368107|EXPERIMENTAL|CYT107 treatment during CT|patients will receive the placebo before the 1st CT cycle and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (N=6)
62253050|NCT04532385|EXPERIMENTAL|GTE|Green tea extract, 400 mg every 12 hours for 12 weeks
62442210|NCT02802514|EXPERIMENTAL|With Off therapy MRI in S1:Exenatide-S1 & Albiglutide-S2|In session 1, Day 1 subject will undergo off-therapy MRI scan Subject will receive single dose each of albiglutide placebo on Day 5 and 10 microgram of exenatide on Day 8 followed by a post-dose MRI scan In session 2, eligible subject will receive single dose each of 50 mg albiglutide on Day 1 (Week 9) and exenatide placebo Day 4 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
62442211|NCT02802514|EXPERIMENTAL|Without Off therapy MRI in S1: Exenatide-S1 & Albiglutide-S2|In session 1, subject will receive single dose each of albiglutide placebo on Day 1 and 10 microgram exenatide on Day 4 followed by a post-dose MRI scan. In session 2, subject will undergo off-therapy MRI scan on Day 1 (Week 9). Subject will receive single dose each of 50 mg albiglutide on Day 5 and exenatide placebo on Day 8 followed by a post-dose MRI scan.. There will be 6-9 week washout period between Session 1 and Session 2
62834852|NCT05488444|EXPERIMENTAL|Group 1 (Investigational Group)|Participants will complete an in-depth patient needs checklist to identify patient-specific barriers that could lead to a delay with starting chemotherapy.
62834853|NCT05488444|EXPERIMENTAL|Group 2 (Control Group)|Participants will follow routine clinical care, where chemotherapy start date is determined by the provider and patient.
62611520|NCT01368107|EXPERIMENTAL|CYT107 treatment before and during CT|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (N=6).
62834854|NCT00093626|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62253051|NCT04532385|PLACEBO_COMPARATOR|Placebo|Calcined magnesia, 400 mg every 12 hours for 12 weeks
62253052|NCT04336670|EXPERIMENTAL|Virtual Reality group|Immersive Virtual Reality exercise program + Usual center therapies
62611521|NCT00000448|PLACEBO_COMPARATOR|Placebo|Subjects were given an inert placebo for 2 days, followed by daily doses of matching placebo for a total of 12 weeks.
62611522|NCT00000448|EXPERIMENTAL|Naltrexone|Subjects were prescribed 25 mg naltrexone for 2 days, followed by daily doses of 50 mg of naltrexone for a total of 12 weeks.
62611523|NCT03278782|EXPERIMENTAL|Treatment (romidepsin, pembrolizumab)|Participants receive romidepsin IV over 4 hours on days 1 and 8 or day 8 of cycle 1 and days 1 and 8 of subsequent cycles and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
62611524|NCT02003963|EXPERIMENTAL|Exergame Intervention|"Participants randomly assigned to the exergame condition will participate in the intervention condition of Klub Kinect. Klub Kinect is a 12-week intervention occurring for 90-minute sessions, 3 times per week. During each 90-minute intervention session, adolescents will engage in 60-minute bouts of aerobic gaming. Adolescents attending an exergaming session will attend concurrently."
62611525|NCT02003963|NO_INTERVENTION|Control (Self-Directed Care)|The control condition will receive no contact or intervention other than telephone reminders of their final clinic visit.
62611526|NCT01933178|OTHER|Cirrus AS-OCT|
62611527|NCT05935995|EXPERIMENTAL|Microscopy confocal|
62834855|NCT06273215|EXPERIMENTAL|Non-obese T2DM|
62834856|NCT06273215|EXPERIMENTAL|Obese T2DM|
62611528|NCT06083701|EXPERIMENTAL|Linperlisib plus Chidamide|Linperlisib combined with chidamide
62834857|NCT06273215|EXPERIMENTAL|Elderly T2DM|
62834858|NCT06273215|EXPERIMENTAL|T1DM|
62834859|NCT02000440|EXPERIMENTAL|Losmapimod (GW856553X)|The subjects will be administered with 7.5 mg (1 tablet) of losmapimod following the completion of the Baseline (time zero) assessments. Subjects will continue to take one tablet in the morning and one tablet in the evening for approximately 2 weeks. After all the pre-dose assessments are completed at the Week 2 visit, subjects will be administered the first 15 mg (2 tablets) dose. Subjects will continue to take two tablets in the morning and two tablets in the evening every day for approximately 22 weeks. Doses of study treatment will be separated by at least 6 hours
62253053|NCT04336670|ACTIVE_COMPARATOR|Usual activities group|Usual center therapies
62253054|NCT04387955|OTHER|Acrovid|Cohort
62253055|NCT06313450|EXPERIMENTAL|de-escalated radiotherapy|If the primary tumour regresses by over 75% and the level of EBV DNA reduces to zero, a radiation dose of 60Gy will be administered. Additionally, three cycles of Toripalimab (240mg, every three weeks) and two cycles of cisplatin (100mg/m2, every three weeks) will be given during radiotherapy.
62253056|NCT06313450|OTHER|conventional radiotherapy|If the primary tumour regresses by less than 75% or if EBV DNA remains above zero, a conventional radiation dose of 70Gy to the primary tumor and two cycles of cisplatin (100mg/m2, every three weeks) will be administered during radiotherapy.
62611529|NCT03762005|EXPERIMENTAL|CRT guided resuscitation|Fluid resuscitation will be aimed at normalizing capillary refill time (CRT) during the intervention period. Fluid challenges will be administered at a rate of 500 ml of crystalloids over 30 minutes, with reassessment of CRT until achieving normal values, or the patient becomes fluid unresponsive, or a safety issue develops.
62611530|NCT03762005|ACTIVE_COMPARATOR|Lactate guided resuscitation|Fluid resuscitation will be aimed at normalizing or decreasing lactate levels by more than 20% every 2 hours during the intervention during the intervention period. Fluid challenges will be administered at a rate of 500 ml of crystalloids over 30 minutes, with reassessment of lactate every 2 hours until reaching target, or the patient becomes fluid unresponsive, or a safety issue develops.
62611531|NCT05038566|NO_INTERVENTION|Comparator Baseline|The subject wears their usual partial hand prosthesis while performing functional outcome measures.
62611532|NCT05038566|EXPERIMENTAL|Pointdexter|The subject wears a modified version of their usual partial hand prosthesis. The modification replaces the usual index finger of the partial hand prosthesis with the investigational Pointdexter device. Subjects will either test out this hand configuration in the lab while performing functional outcome measures or at home in their daily lives for approximately four weeks.
62611533|NCT05168072|EXPERIMENTAL|m-Health|participants receive conventional outpatient obesity management assisted with m-Health APP
62051966|NCT02802163|EXPERIMENTAL|Combination Therapy|Combination Therapy: Panobinostat, Carfilzomib, Lenalidomide, Dexamethasone (Ca-R-Pa-Diem) . Participants will receive up to 8 cycles of the combination as induction after which will proceed with consolidation therapy with transplant as per institutional standards. After transplant, participants receive maintenance with panobinostat/lenalidomide. The maintenance dose and schedule of panobinostat will be same given during induction for 1 year. The maintenance dose of lenalidomide will be 10 mg given for 21 days of 28 days cycle until disease progression.
62253057|NCT03135275|ACTIVE_COMPARATOR|Staged complete PCI|Patients randomized to staged complete PCI will have treated during the index admission only the culprit lesion and they will be hospitalized after 19-45 days, to complete the coronary revascularization on all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
62253058|NCT03135275|EXPERIMENTAL|Immediate complete PCI|Patients randomized to immediate complete PCI will have treated immediately after the revascularization of the culprit lesion during the index procedure all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
62253059|NCT03484286|OTHER|Control group|Subject to standard care. No interventions above and beyond what is deemed standard care for heart failure patients in the region where the study takes place.
62253060|NCT03484286|EXPERIMENTAL|Intervention group|Device: OPTILOGG
62253061|NCT00513110|EXPERIMENTAL|1|Endotoxin and AMPD1 polymorphism
62253062|NCT00513110|EXPERIMENTAL|2|Endotoxin and intervention with caffeine
62442212|NCT05325892||IDH|Diabetic patients with maintenance hemodialysis who developed hypotension during hemodialysis therapy.Intradialytic hypotension (IDH) is defined as a decrease in systolic blood pressure by ≥20 mm Hg or a decrease in MAP by ≥10 mm Hg associated with symptoms that include: abdominal discomfort; yawning; sighing; nausea; vomiting; muscle cramps; restlessness; dizziness or fainting; and anxiety.
62442213|NCT05325892||non-IDH|Diabetic patients with maintenance hemodialysis who did not develop hypotension during hemodialysis treatment.Intradialytic hypotension (IDH) is defined as a decrease in systolic blood pressure by ≥20 mm Hg or a decrease in MAP by ≥10 mm Hg associated with symptoms that include: abdominal discomfort; yawning; sighing; nausea; vomiting; muscle cramps; restlessness; dizziness or fainting; and anxiety.
62442214|NCT04023565|EXPERIMENTAL|perindopril + moxonidine|perindopril 10 mg + moxonidine 0.4 or 0.6 mg a day (given as two divided doses).
62442215|NCT04896385|EXPERIMENTAL|Ruxolitinib cream|Ruxolitinib cream will be administered twice a day (BID) for 24 weeks
62442216|NCT04896385|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
62442217|NCT05124691|ACTIVE_COMPARATOR|Albendazole|Albendazole 400 mg single dose
62442218|NCT05124691|EXPERIMENTAL|FDCx1. Albendazole and Ivermectin Fixed Dose Coformulation|Single dose of a tablet of FDC 400mg18mg or 400mg9mg. (i) For participants \<45 kg of body weight at baseline: FDC of 400mg ALB 9mg IVM. (ii) For participants ≥45 kg of body weight at baseline: FDC of 400mg ALB18mg IVM
62442219|NCT05124691|EXPERIMENTAL|FDCx3. Albendazole and Ivermectin Fixed Dose Coformulation 3 days|Daily dose of a tablet of FDC 400mg18mg or 400mg 9mg for 3 days. (i)For participants \<45 kg of body weight at baseline: FDC of 400mg ALB9mg IVM. (ii) For participants ≥45 kg of body weight at baseline: FDC of 400mg ALB 18mg IVM.
62442220|NCT02012647|ACTIVE_COMPARATOR|People with Parkinsons Disease|Participants have been diagnosed with Parkinson's Disease, and as recommended by their physicians, have undergone DBS surgery for both sides of the brain. These participants will undergo TMS and motor physiology testing, and results will be compared to participants without Parkinson's Disease.
62442221|NCT02012647|PLACEBO_COMPARATOR|Healthy Controls|These participants do not have Parkinson's Disease, nor have they had DBS surgery, and are a healthy controls. These participants will undergo TMS and motor physiology testing, and results will be compared to participants with Parkinson's Disease.
62051967|NCT04209946|ACTIVE_COMPARATOR|Less Invasive Surfactant Administration (LISA)|Infants that are spontaneously breathing with a normal heart rate will be randomized to receive prophylactic surfactant (Curosurf 2.5 mL/kg, based on estimated fetal weight) by the LISA procedure in the first 2 hours of life, using a conventional or video laryngoscope and a small flexible 16 gauge angiocatheter. Any repeat dosing for surfactant will be based on clinical indication at the physician discretion by the conventional endotracheal approach.
62611534|NCT05168072|ACTIVE_COMPARATOR|conventional|participants receive conventional outpatient obesity management
62611535|NCT04657367||Diabetes|Patients with diagnosed diabetes
62611536|NCT04657367||Prediabetes|Patients with diagnosed prediabetes defined as impaired fasting glucose and/or impaired glucose tolerance
62611537|NCT04657367||Normoglycemia|Patients with normoglycemia, based on the OGTT - normal fasting glucose and normal glucose tolerance
62051968|NCT04209946|ACTIVE_COMPARATOR|Continuous Positive Airway Pressure (CPAP)|Infants that are spontaneously breathing with a normal heart rate will be randomized to early Continuous Positive Airway Pressure (CPAP).
62051969|NCT00307749|PLACEBO_COMPARATOR|1|
62051970|NCT00307749|EXPERIMENTAL|2|
62051971|NCT00307749|EXPERIMENTAL|3|
62253063|NCT00513110|PLACEBO_COMPARATOR|3|Endotoxin combined with placebo
62611538|NCT05092204||Hospitalized patient in SSR geriatric service|
62051972|NCT00307749|EXPERIMENTAL|4|
62051973|NCT04108455||With Diabetes|Pregnant women with diabetes - either diagnosed beforehand or diagnosed during gestation
62051974|NCT04108455||Controls|Biobank samples will be obtained from similar age/BMI/ethnicity women who do not have evidence of diabetes.
62253064|NCT04530903|EXPERIMENTAL|Group Clonidine|Group Clonidine will benefit from the pudendal block realised with 10 ml of 0.25% levobupivacaine and 75 µg of clonidine per side.
62253065|NCT04530903|PLACEBO_COMPARATOR|Control|Group Control will benefit from the pudendal block realised with 10 ml of 0.25% levobupivacaine per side; 0.5 ml of 0.9% NaCl will be added to each syringe to homogenise the volume in order to remain blind.
62253066|NCT05407909|EXPERIMENTAL|SYHX2001|SYHX2001 will be administered orally.
62253067|NCT04534491|EXPERIMENTAL|Oxytrol|Subjects decided to purchase Oxytrol.
62253068|NCT06098625|EXPERIMENTAL|Empagliflozin|Empagliflozin 25 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus
62253069|NCT06098625|ACTIVE_COMPARATOR|Linagliptin|Linagliptin 5 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus
62611539|NCT03932929|EXPERIMENTAL|Scotchbond universal adhesive (etch-and-rinse)|Acid etch (enamel\&dentin)+adhesive agent Intervention: Device: Adhesive agent
62611540|NCT03932929|EXPERIMENTAL|Scotchbond universal adhesive (selective-etch)|Acid etch (only enamel)+adhesive agent Intervention: Device: Adhesive agent
62611541|NCT03932929|EXPERIMENTAL|Scotchbond universal adhesive (self-etch)|Adhesive agent Intervention: Device: Adhesive agent
62611542|NCT06009809||Heart Surgical Patients|Patients with cardiovascular disease, who must undergo cardiac surgery in extracorporeal circulation with continuous flow
62611543|NCT04889599|EXPERIMENTAL|BH009 (Docetaxel Injection)|Patients will receive single dose BH009 75 mg/m2, as a 1-hour IV infusion.
62611544|NCT04889599|ACTIVE_COMPARATOR|Docetaxel Injection|Patients will receive single dose Docetaxel Injection 75 mg/m2, as a 1-hour IV infusion.
62611545|NCT01039805|EXPERIMENTAL|Cohort 1|Subjects randomized to either GSK962040 (50 mg) or placebo
62611546|NCT01039805|EXPERIMENTAL|Cohort 2|Subjects randomized to either GSK962040 (75 mg) or placebo
62611547|NCT06271759|EXPERIMENTAL|Fragrance 1 Group|"At-home administration of one of the four active stimuli (fragrances), according to the following protocol:~1. Participants will complete a series of psychological scales (pre-measurements), tapping into mood, affective states, well-being.~2. Participants will inhale the fragranced stimulus for approximately 10 minutes.~3. After the completion of step 2, participants will engage in a neutral activity for about 15 minutes.~4. Participants will complete a series of psychological scales (post-measurements).~5. Participants will repeat this protocol one week apart."
62051975|NCT03406546|EXPERIMENTAL|Group DR|Patients sedated with dexmedetomidine and remifentanil.
62051976|NCT03406546|EXPERIMENTAL|Group LMA|General anesthesia was applied using laryngeal mask.
62051977|NCT01699022|EXPERIMENTAL|Injection Cyclofem|"Injection of Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.~Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection."
62051978|NCT01138670||Cardiac device group|
62051979|NCT00394355|EXPERIMENTAL|Group 1|MF DPI 400 mcg once a day (QD) in the evening (PM)
62051980|NCT00394355|EXPERIMENTAL|Group 2|MF DPI 200 mcg QD PM
62051981|NCT00394355|ACTIVE_COMPARATOR|Group 3|Fluticasone propionate (FP) metered dose inhaler (MDI) 250 mcg twice a day (BID)
62051982|NCT00394355|ACTIVE_COMPARATOR|Group 4|ML 10 mg QD PM
62051983|NCT06267885|ACTIVE_COMPARATOR|Patients with fracture neck of femur fixed by cannulated screws|Fix the fracture by two to three cannulatef screws
62051984|NCT06267885|ACTIVE_COMPARATOR|Patient with fracture neck of femur fixed by wagner's technique|Fix the fracture by three to four k-wires
62051985|NCT03706625||Non-Hodgkin-Lymphoma (after transplantation)|Immune-suppressed patients suffering from Non-Hodgkin-Lymphoma (after transplantation) and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
62253070|NCT05804643||Breast cancer related lymphedema|Breast cancer related lymphedema cases receive observational magnetic resonance imaging before and after lymphovenous anastomosis.
62253071|NCT03351790||All included participants|Patients that complete study questionnaire and have endoscopy recorded.
62051986|NCT03706625||Non-small cell lung cancer|Immune-suppressed patients suffering from HIV-related non-small cell lung cancer, followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
62051987|NCT03706625||Primary Central Nervous System Lymphoma|Patients suffering from primitive cerebral lymphomas and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
62253072|NCT04012034|EXPERIMENTAL|Radiofrequency A|Treatment with radiofrequency
62051988|NCT03706625||Gliomas|Patients suffering from Gliomas and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
62253073|NCT04012034|PLACEBO_COMPARATOR|Placebo|Treatment with radiofrequency without energy
62253074|NCT01541020||Healthy individuals|
62253075|NCT01541020||Individuals with low back pain|
62253076|NCT03179891|EXPERIMENTAL|Interictal Period|All subjects received 12.5 mg DBF during the interictal state.
62253077|NCT03179891|EXPERIMENTAL|Ictal/Peri-ictal Period|All subjects received 12.5 mg DBF during the ictal/peri-ictal state.
62253078|NCT01888120||Severe Chronic Pain|
62253079|NCT03363750|EXPERIMENTAL|mind-body-skills intervention|mind-body-skills group intervention offered weekly for 10 weeks
62253080|NCT04157920|OTHER|Patients treated with Medtronic CoreValve/ Evolut R/Pro|TAVI patients treated with Medtronic CoreValve /Evolut R - Evolut PRO Transcatheter Heart Valves, participated in the DIRECT trial
62253081|NCT04157920|ACTIVE_COMPARATOR|Patients treated with ACURATE neo/TF|TAVI patients treated with ACURATE neo/TF Transcatheter Heart Valve recruited prospectively.
62253082|NCT05798130||Oxygen Extraction Rate < 30% Group|Oxygen Extraction Rate \< 30%
62253083|NCT05798130||Oxygen Extraction Rate ≥ 30% Group|Oxygen Extraction Rate ≥ 30%
62253084|NCT06306287|EXPERIMENTAL|ePACE Experimental Condition|The experimental intervention to be administered, ePACE, is a web-based brief intervention that includes personalization and youth-centered features. Feedback is provided based on youth's responses to activities, exercises, and quizzes to guide each individual's behavior change efforts.
62253085|NCT06306287|ACTIVE_COMPARATOR|eFACE Active Comparator Condition|The eFACE active comparator arm involves the eFACE intervention and includes content that is similar to the ePACE experimental intervention, but modules are offered in a fixed order with no tailoring features. No personalized feedback based on youth responses are provided to inform individual youth's behavior change efforts.
62611548|NCT06271759|EXPERIMENTAL|Fragrance 2 Group|"At-home administration of one of the four active stimuli (fragrances), according to the following protocol:~1. Participants will complete a series of psychological scales (pre-measurements), tapping into mood, affective states, well-being.~2. Participants will inhale the fragranced stimulus for approximately 10 minutes.~3. After the completion of step 2, participants will engage in a neutral activity for about 15 minutes.~4. Participants will complete a series of psychological scales (post-measurements).~5. Participants will repeat this protocol one week apart."
62623562|NCT01648920||FeNO|Participants with suspected but undiagnosed asthma will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit. Following that they will have a Methacholine Challenge (MCC) test performed according to the ATS guidelines and the Allergy and Asthma Specialists Procedure for conducting MCC tests
62253086|NCT06306287|NO_INTERVENTION|Waiting List Comparison Group|"Youth in the waitlist comparison (WC) condition will not have access to the ePACE or eFACE modules until the final (6-month) assessment has been completed. Thus, the WC group will serve as a no intervention comparison group."
62253087|NCT04201990|EXPERIMENTAL|treatment group|Camrelizumab, iv, Q3W until progression disease or intolerable toxicity or 2 years Apatinib, po, QD until progression disease or intolerable toxicity or 2 years
62253088|NCT05339581|EXPERIMENTAL|IMRT combined with PD-1 Blockade and Lenvatinib|"Participants receive PD-1 Blockade (Pembrolizumab，Sintilimab， Camrelizumab，Tislelizumab) 200 mg intravenously on day 1 of a 21-day treatment cycle until \>42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until \>7 days before liver transplantation.~Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be ≥50 Gy and ≤60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk."
62253089|NCT05339581|ACTIVE_COMPARATOR|PD-1 Blockade and Lenvatinib|Participants receive PD-1 Blockade (Pembrolizumab，Sintilimab， Camrelizumab，Tislelizumab) 200 mg intravenously on day 1 of a 21-day treatment cycle until \>42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until \>7 days before liver transplantation.
62051989|NCT03706625||Non-Hodgkin-Lymphoma with HIV infection|Immune-suppressed patients (during HIV infection) and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
62051990|NCT03706625||Immunocompetent Non-Hodgkin-Lymphoma|Immunocompetent patients and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA).
62442222|NCT06218420|OTHER|Patients with hepatocellular carcinoma enlisted for a liver transplant and eligible for SBRT|All patients enrolled in the trial and responding to inclusion/exclusion criteria will receive SBRT (a high-precision technique allowing to deliver a precise high dose irradiation on moving intrahepatic lesions).
62442223|NCT04517656|EXPERIMENTAL|patients with hematologic malignancy|Adult patient, over 18 years old, suffering from a malignant hemopathy (without exception) for whom an allogeneic hematopoietic stem cell transplant from a related or unrelated donor is indicated
62611549|NCT06271759|EXPERIMENTAL|Fragrance 3 Group|"At-home administration of one of the four active stimuli (fragrances), according to the following protocol:~1. Participants will complete a series of psychological scales (pre-measurements), tapping into mood, affective states, well-being.~2. Participants will inhale the fragranced stimulus for approximately 10 minutes.~3. After the completion of step 2, participants will engage in a neutral activity for about 15 minutes.~4. Participants will complete a series of psychological scales (post-measurements).~5. Participants will repeat this protocol one week apart."
62051991|NCT03706625||Immunocompetent Non-small cell lung cancer|Immunocompetent patients suffering from non-small cell lung cancer and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA).
62051992|NCT03764072|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to VX-150 for 2 days.
62051993|NCT03764072|EXPERIMENTAL|VX-150 - Dose Level 1|Participants received VX-150 1500 milligrams (mg) as first dose, followed by VX-150 750 mg every 12 hours (q12h) for 2 days.
62051994|NCT03764072|EXPERIMENTAL|VX-150 - Dose Level 2|Participants received VX-150 1000 mg once daily (qd) for 2 days.
62051995|NCT03764072|EXPERIMENTAL|VX-150 - Dose Level 3|Participants received VX-150 500 mg q12h for 2 days.
62051996|NCT03764072|EXPERIMENTAL|VX-150 - Dose Level 4|Participants received VX-150 500 mg as first dose, followed by VX-150 250 mg q12h for 2 days.
62051997|NCT03764072|EXPERIMENTAL|VX-150 - Dose Level 5|Participants received VX-150 250 mg qd for 2 days.
62051998|NCT01579604|EXPERIMENTAL|Surgical arm|"Nerve reconstruction:~Early nerve transfer (around 6-9 months post cervical spine injury) will be performed in this group of patients."
62051999|NCT01579604|NO_INTERVENTION|Non-surgical (or observed)|Patients in this group will receive standard of care and be observed for up to two years post injury.
62052000|NCT00530062|EXPERIMENTAL|Albuterol-HFA-BAI|Participants will receive single actuation of albuterol 90 micrograms (mcg), administered using BAI in treatment period 1 or 2.
62611550|NCT06271759|EXPERIMENTAL|Fragrance 4 Group|"At-home administration of one of the four active stimuli (fragrances), according to the following protocol:~1. Participants will complete a series of psychological scales (pre-measurements), tapping into mood, affective states, well-being.~2. Participants will inhale the fragranced stimulus for approximately 10 minutes.~3. After the completion of step 2, participants will engage in a neutral activity for about 15 minutes.~4. Participants will complete a series of psychological scales (post-measurements).~5. Participants will repeat this protocol one week apart."
62611551|NCT06271759|NO_INTERVENTION|No Fragrance Group|"At-home administration of the neutral/no-odor stimulus, according to the following protocol:~1. Participants will complete a series of psychological scales (pre-measurements), tapping into mood, affective states, well-being.~2. Participants will inhale the non-fragranced stimulus for approximately 10 minutes.~3. After the completion of step 2, participants will engage in a neutral activity for about 15 minutes.~4. Participants will complete a series of psychological scales (post-measurements).~5. Participants will repeat this protocol one week apart."
62052001|NCT00530062|ACTIVE_COMPARATOR|Albuterol-HFA-MDI|Participants will receive single actuation of albuterol 90 mcg, administered using MDI in treatment period 1 or 2.
62052002|NCT03525548|ACTIVE_COMPARATOR|TEZ/IVA|Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.
62052003|NCT03525548|EXPERIMENTAL|VX-445/TEZ/IVA TC|Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-445 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.
62052004|NCT04205318||study|obese (BMI ≥25.00 kg/m2, n=200)
62052005|NCT04205318||control|non-obese (BMI= 18.50-24.99 kg/m2, n=200)
62052006|NCT06181721|EXPERIMENTAL|Group A with Type 1 Diabetes|Participants with Type 1 Diabetes
62052007|NCT06181721|EXPERIMENTAL|Group B with Type 2 Diabetes|Participants with Type 2 Diabetes
62052008|NCT05751122|EXPERIMENTAL|Dynamic flex cast with neurodevelopmental Group|Dynamic flex cast with neurodevelopmental treatment
62052009|NCT05751122|ACTIVE_COMPARATOR|Rigid Ankle foot Orthosis with neurodevelopmental Group|Rigid Ankle foot Orthosis with neurodevelopmental treatment
62611552|NCT03130283|ACTIVE_COMPARATOR|Home Hospitalization|Visit every day at home
62253090|NCT02705807|EXPERIMENTAL|FLOLAN arm|Subjects will receive the existing FLOLAN treatment (i.e., FLOLAN injection prepared with the currently marketed diluent) for a run-in period of a maximum of 4 weeks, the thermostable formulation of FLOLAN injection (i.e., FLOLAN injection prepared with the reformulated diluent) for a 4-week treatment period and there will be a one-week follow-up visit.
62253091|NCT04737408|ACTIVE_COMPARATOR|"Usual care"|"Usual care prevention: atorvastatin 40 mg per day for 18 months"
62611553|NCT03130283|PLACEBO_COMPARATOR|Conventional Hospitalization|Review Clinical History
62253092|NCT04737408|EXPERIMENTAL|"Intensive care"|"Intensive care prevention: rosuvastatin 40 mg + ezetimib 10 mg per day for 18 months"
62442224|NCT04039581|EXPERIMENTAL|Group 1: Kinesio Taping and Conventional treatment|"The number of participants in this group is anticipated to be 30. The treatment method for this group is the conventional treatment + KT (Kinesio Taping) relaxation technique (muscle inhibition technique).~In the conventional treatment therapeutic exercises (active and passive Range Of Motion (ROM) and strengthening exercise of the neck and shoulder) and TENS (Transcutaneous electrical nerve stimulation) applications on the painful area, every day and 2 channels with 4 electrodes in the acute period (first 72 hours) will be applied. These exercises will be taught to participants from the first treatment session and will be performed under the supervision of a physiotherapist. In KT technique, while participants are sitting on the edge of the bed, the shoulder area will be depressed and I banding will be done by applying 25-50% tension horizontally in this position on the upper trapezius muscle."
62834860|NCT00483977|ACTIVE_COMPARATOR|Oxycodone|
62834861|NCT00483977|PLACEBO_COMPARATOR|Placebo|
62834862|NCT00483977|EXPERIMENTAL|PF-00592379|
62834863|NCT04399785|EXPERIMENTAL|Arm 1|
62834864|NCT01045837|ACTIVE_COMPARATOR|Prednisolone and Gluten free diet|Gluten free diet and prednisolone in the dose of 1 mg/kg/d over a period of 4 weeks.
62834865|NCT01045837|PLACEBO_COMPARATOR|Gluten free diet|Gluten free alone will be given in this group
62834866|NCT00976560|EXPERIMENTAL|GW856553|GW856553 7.5 mg BID
62834867|NCT00976560|PLACEBO_COMPARATOR|Placebo|Matching Placebo BID
62834868|NCT00477386|EXPERIMENTAL|Carboplatin combined with Decitabine|Decitabine at escalating dose levels will be given X 5 days followed by Carboplatin given on Day 8.
62253093|NCT04656314||Healthy participants aged 18 to 40|3 identical functional MRI scans. Blood samples to quantify level of physiological stress are taken before and after each scan.
62253094|NCT04656314||Healthy participants aged 60 and above|3 identical functional MRI scans. Blood samples to quantify level of physiological stress are taken before and after each scan.
62253095|NCT01865630|EXPERIMENTAL|Etanercept|Patients with aneurysmal subarachnoid hemorrhage will be treated with etanercept, 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
62253096|NCT02445118||Adipose Allograft Matrix Injection|AAM injected to create a 2 to 3mm raised wheal on the proximal dorsal wrist of the non-dominant hand
62253097|NCT02097524|EXPERIMENTAL|Sarilumab - dose 1|Single subcutaneous (SC) injection of Sarilumab, dose 1, plus methotrexate background treatment (dispensed and dosed according to local practice)
62253098|NCT02097524|EXPERIMENTAL|Sarilumab - dose 2|Single SC injection of Sarilumab, dose 2, plus methotrexate background treatment (dispensed and dosed according to local practice)
62253099|NCT02097524|ACTIVE_COMPARATOR|Tocilizumab - dose 1|Single intravenous (IV) administration of Tocilizumab, dose 1, plus methotrexate background treatment (dispensed and dosed according to local practice)
62253100|NCT02097524|ACTIVE_COMPARATOR|Tocilizumab - dose 2|Single IV administration of Tocilizumab, dose 2, plus methotrexate background treatment (dispensed and dosed according to local practice)
62253101|NCT06215521|EXPERIMENTAL|Pirtobrutinib|Pirtobrutinib a single oral dose on Day 1, 12 and 23 following a fast of at least 8 hours prior to and 6 hours after dosing.
62253102|NCT06215521|PLACEBO_COMPARATOR|Placebo|Placebo (matched to Pirtobrutinib) a single oral dose on Day 1, 12 and 23 following a fast of at least 8 hours prior to and 6 hours after dosing.
62611554|NCT04892992|EXPERIMENTAL|Intervention group I|6 sessions of intervention DFG starting at once (baseline). After DFG treatment as usual at Helsinki University hospital. The change between before the intervention (baseline) and after the intervention (3 months later) is being assessed.
62623563|NCT06148155|EXPERIMENTAL|patients with primary and/or metastatic hepatocellular carcinoma (HCC)|The diagnosis of HCC is established by surgery or biopsy pathology.
62623564|NCT02078596|EXPERIMENTAL|Divalproex|Divalproex at 10 mgs/lb
62623565|NCT02078596|PLACEBO_COMPARATOR|Sugar Pill|Equivalent 250 mg pills titrated to 10 mgs / lb over six weeks
62834869|NCT01841411|EXPERIMENTAL|Metronidazole + N-Acetyl cysteine|the second patient group will use NAC sachets containing 200 mg as a vaginal douche once daily plus oral metronidazole 500 mg twice daily for 7 days
62834870|NCT01841411|EXPERIMENTAL|N- Acetyl cysteine|the third patient group will use NAC sachets containing 200 mg as a vaginal douche only without taking metronidazole
62834871|NCT01841411|ACTIVE_COMPARATOR|Metronidazole|the first group of patients will take oral metronidazole 500 mg twice daily for a week
62834872|NCT00889720|OTHER|Smoking cessation tratment including varenicline|
62834873|NCT03894683|EXPERIMENTAL|Melatonin|Melatonin (10 mg tablets) by oral root, ingested at bedtime for 6 months
62834874|NCT03894683|PLACEBO_COMPARATOR|Placebo|Placebo tablets in the same shape as melatonin tablets, ingested the same as the melatonin tablets.
62834875|NCT01088867|OTHER|Acupuncture|14 weeks of electroacupuncture therapy.
62052010|NCT04540874|EXPERIMENTAL|BI 894416 25mg|1 tablet of 25 milligrams (mg) BI 894416 was administered orally as single dose with 240 milliliters of water after an overnight fast of at least 10 hours on day 1, followed by at least 48 hours close medical surveillance, followed by 2 weeks of follow-up period.
62834876|NCT03692624|EXPERIMENTAL|Intervention Group|Biofeedback. Participants receiving the HRV-B intervention will complete a baseline assessment, a minimum of 4 weeks and up to 6 weekly training sessions (until the criterion of HRV coherence is met), and a final appointment (3-7 days later) where post-training HRV and symptom inventories will be recorded.
62052011|NCT04540874|PLACEBO_COMPARATOR|Placebo group|Matching placebo was administered orally as single dose with 240 milliliters of water after an overnight fast of at least 10 hours on day 1, followed by at least 48 hours close medical surveillance, followed by 2 weeks of follow-up period.
62052012|NCT02309788||RT|Resectable HCC patients adjuvant RT for PVT or NM
62052013|NCT02309788||No RT|Resectable HCC patients adjuvant other treatment for PVT or NM
62052014|NCT00883506|EXPERIMENTAL|1|Lisinopril 40 mg Tablet under fed conditions.
62052015|NCT00883506|ACTIVE_COMPARATOR|2|Lisinopril 40 mg Tablet (Zestril)
62253103|NCT06215521|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin a single oral dose on Day 1, 12 and 23 following a fast of at least 8 hours prior to and 6 hours after dosing.
62253104|NCT05690282|NO_INTERVENTION|Standard oral hydrocodone-acetaminophen post-op management|
62253105|NCT05690282|ACTIVE_COMPARATOR|Multimodal pain post-op management (Ibuprofen/Acetaminophen/GABAPentin/0.25%Bupivacaine)|
62253106|NCT05610904|NO_INTERVENTION|Surgeon evaluation|
62253107|NCT05610904|EXPERIMENTAL|Surgeon combining with model evaluation|
62623566|NCT04037800|EXPERIMENTAL|SFUR-RARP|Patients in which RARP with sustainable functional urethral reconstruction (SFUR) is performed.
62623567|NCT04037800|ACTIVE_COMPARATOR|Standard RARP|Patients in which standard RARP is performed.
62253108|NCT02741869|EXPERIMENTAL|single arm|This is a single arm, open label study. Subjects who meet eligibility criteria will be treated with photodisinfection therapy (MRSAid™).
62623568|NCT01439984|EXPERIMENTAL|PED-1|PED-1 (Clomipramine 15 mg)
62623569|NCT01439984|PLACEBO_COMPARATOR|placebo|
62052016|NCT00883506|EXPERIMENTAL|3|Lisinopril 40 mg Tablet under fasting conditions.
62052017|NCT00480701|EXPERIMENTAL|[123I]-IBVM|To assess \[123I\] IBVM and SPECT imaging
62052018|NCT03159520|ACTIVE_COMPARATOR|Advice on acupressure|Advice sheet on use of acupressure for post orthodontic pain
62052019|NCT03159520|ACTIVE_COMPARATOR|Advice on analgesics|Advice sheet on use of NSAID analgesics for post orthodontic pain
62052020|NCT01719822|NO_INTERVENTION|Usual Care|Standard 8-week pulmonary rehabilitation programme with 2 supervised sessions per week and a written home exercise plan/diary.
62052021|NCT01719822|EXPERIMENTAL|Intervention|Standard 8-week pulmonary rehabilitation programme with 2 supervised sessions per week. In addition they will receive a pedometer with a daily step count target set by a physiotherapist and a written home exercise plan/diary.
62052022|NCT04248647|EXPERIMENTAL|Intervention Group|4-week multimodal preoperative intervention (i.e., Prehabilitation) consisting of an aerobic and strength training program, nutritional counselling and psychological support to help improve physical and psychological health prior to surgical resection of colorectal cancer.
62052023|NCT03477279|NO_INTERVENTION|Individual (SOC)|HIV-infected pregnant women enrolled in the individual arm of the study will receive Standard of Care Option B+ procedures.
62253109|NCT04144270||Included patients|One-arm study. All included patients will have muscle mass and muscle function evaluated
62253110|NCT05472766|ACTIVE_COMPARATOR|Early resumption of anticoagulation|The standard of care DOAC at appropriate standard dose assigned by the MRP will start at day 30 +/- 7 after diagnosis of acute or chronic subdural hematoma.
62253111|NCT05472766|ACTIVE_COMPARATOR|Delayed resumption of anticoagulation|The standard of care DOAC at appropriate standard dose assigned by the MRP will start at day 90 +/- 14 after diagnosis of acute or chronic subdural hematoma.
62253112|NCT03922542|ACTIVE_COMPARATOR|Accelerated|Treatment with 0.1% riboflavin eye drops and 9 mW/cm2 UVA light for 10 minutes
62253113|NCT03922542|ACTIVE_COMPARATOR|Standard|Treatment with 0.1% riboflavin eye drops and 3 mW/cm2 UVA light for 30 minutes
62253114|NCT02720770|EXPERIMENTAL|norditropine simplex|
62611555|NCT04892992|EXPERIMENTAL|Intervention group II|6 sessions of intervention DFG starting 3 months after baseline (3 months on waiting list). Between baseline and 3 months waiting list families were getting treatment as usual at Helsinki University hospital. The change between baseline - after 3 months waiting list (3 months from baseline)/ before the intervention - and after intervention (6 months from baseline) is being assessed. Also the difference between Intervention group I and II is assessed.
62611556|NCT03933878||Post-transplant recipient BAL samples|No intervention will be administered
62611557|NCT03933878||Donor BAL samples|No intervention will be administered
62611558|NCT02650622||Cohort 1-Newborns aged 1-2 days|No intervention will be applied specifically for this cohort. Blood samples will be collected from this cohort by piggybacking the state-mandated newborn screening test.
62611559|NCT02650622||Cohort 2-Children aged 0-18 years|No intervention will be applied specifically for this cohort. Blood samples will be collected from this cohort by piggybacking the blood draw of patient's standard of care.
62052024|NCT03477279|EXPERIMENTAL|Couple (Intervention)|In addition to receiving standard of care procedures, HIV-infected pregnant women in the couple arm will be provided with an intervention aimed at recruiting their male partners, providing enhanced couple counseling and testing, engaging their male partners in their care, and supporting male partners to receive care and treatment services.
62052025|NCT03477279|NO_INTERVENTION|HIV-Uninfected Cohort|HIV-uninfected pregnant women will be invited to participate in a cross-sectional study. No intervention will be provided and no follow-up will be conducted.
62052026|NCT04227743|EXPERIMENTAL|patients with endobronchial lesions|flexible bronchoscoy will be performed to patients with endobronchial lesions and biopsy from the lesions by forceps and cryoprope will be obtained
62052027|NCT01786902|EXPERIMENTAL|DA-3002 Treatment group|1.11 IU(0.37mg)/kg bodyweight of DA-3002 per week given by subcutaneous injections (six or seven times per week)
62052028|NCT01786902|NO_INTERVENTION|Non-treatment control group|Height be measured with no treatment
62052029|NCT01459432||Follow-on blood sample from previous study|
62052030|NCT05347758|EXPERIMENTAL|Group A|Drug: HRS-7535
62052031|NCT05347758|PLACEBO_COMPARATOR|Group B|Drug: Placebo
62052032|NCT01562730||No previous cardiovascular disease|Individuals without any history of cardiovascular disease
62052033|NCT01562730||Previous cardiovascular disease|Individuals with history of cardiovascular disease
62052034|NCT03018964|EXPERIMENTAL|Solo-SILC|Solo surgery using a laparoscopic camera holder instead of a camera operator in SILC
62052035|NCT03018964|ACTIVE_COMPARATOR|Ca-SILC|No solo surgery, operation with a camera operator in SILC
62052036|NCT06202560|EXPERIMENTAL|Tofacitinib|taking oral Tofacitinib 5 mg twice a day for 12 weeks
62052037|NCT06439355|ACTIVE_COMPARATOR|Healthy volunteers|
62052038|NCT06439355|EXPERIMENTAL|Patients with Idiopathic Parkinson's Disease (IPD) of course ≤ 3 years|
62052039|NCT06439355|EXPERIMENTAL|Patients with Lewy body disease (LBD) progressing ≤ 3 years|
62611560|NCT02650622||Cohort 3-Diseased childrens and families|Blood samples will be collected from this cohort by piggybacking the blood draw of patient's standard of care. Skin biopsy will be performed on the proband children with the agreement from parents or guardians.
62623570|NCT06053632|NO_INTERVENTION|Control group|Control group will be asked to maintain their usual lifestyle.
62052040|NCT02146313|EXPERIMENTAL|Dose-escalation Cohort|DMUC4064A will be administered to participants at a starting dose of 1.0 milligram per kilogram (mg/kg) by IV infusion q3w and would be monitored for DLTs for 21 days after first infusion of Cycle 1 (cycle length=21 days).
62052041|NCT02146313|EXPERIMENTAL|Platinum-resistant Ovarian Cancer Dose-expansion Cohort|Platinum-resistant Ovarian Cancer participants will be administered with the identified RP2D during the Dose-escalation of DMUC4064A q3w IV for up to until disease progression or death, whichever occurs first.
62052042|NCT02146313|EXPERIMENTAL|Unresectable Pancreatic Cancer Dose-expansion Cohort|Unresectable pancreatic cancer participants will be administered with the identified RP2D during the dose-escalation of DMUC4064A q3w IV for up to until disease progression or death, whichever occurs first.
62052043|NCT02114151|EXPERIMENTAL|Arm 1 (Simeprevir/Sofosbuvir)|100 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
62253115|NCT03461172||patients operated for breast cancer|patients operated for histologically proven breast cancer
62623571|NCT06053632|EXPERIMENTAL|Experimental group|The research group performed additional low-load and high-velocity - lying prone - eccentric hamstring exercise 3 times per week for 4 weeks. 12 sessions in total.
62623572|NCT00460746|EXPERIMENTAL|001|TMC125, Darunavir; RitonavirTMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
62052044|NCT03988075|ACTIVE_COMPARATOR|Acetaminophen and hydrocodone based pain control|Patients receive acetaminophen 650mg every 4 for pain level 1-3, hydrocodone/acetaminophen 5/325mg every 4 for pain level 4-6, or hydrocodone/acetaminophen 10/650mg every 4 for pain level 7-10 on as needed basis.
62834877|NCT03692624|NO_INTERVENTION|Control Group|To control for the laboratory environment or other potential placebo effects, a control group will receive their usual follow-up care for their cancer diagnosis and will complete baseline and post-baseline outcome assessments without any HRV-B training.
62834878|NCT00823693|ACTIVE_COMPARATOR|Bimosiamose Cream|
62052045|NCT03988075|EXPERIMENTAL|Acetaminophen and ibuprofen based pain control|Patients receive standing dose of acetaminophen 650mg every 8 hours and ibuprofen 800mg every 8 hours with alternating ibuprofen and acetaminophen every 4 hours.
62052046|NCT02124265|EXPERIMENTAL|Ceralyte 90|Ceralyte® will be administered during the first 24-hours post-burn. Fluid requirements will be calculated according to the Parkland Formula with 50% administered during the first 8 hours and the second 50% administered over the next 16 hours. During the first 2 hours IV fluids will be started at the Parkland goal minus 250cc, which will be administered using Ceralyte via oral, nasogastric (NG), or dobhoff tube. ORT and IV fluids will be monitored with additional doses given hourly. Urine output will be monitored hourly and gastric residuals will be monitored every 2 hours, with adjustments made as needed to ensure adequate fluid resuscitation.
62052047|NCT03931681|EXPERIMENTAL|Experimental: Phase 1 - Dose Escalation|Dose escalation trial evaluating OKI-179 given orally on a daily basis. Patients will take OKI-179 orally (PO) on Days 1 - 4, 8 - 11 and 15 - 18 in 21-day cycles (± 3 days), under fasted conditions. The design is a modified 3+3 design to determine the maximum tolerated dose and allows for additional cohorts enrolling subjects with an alternative dosing schedule such as OKI-179 orally (PO) daily on Days 1 - 5, 8 - 12 and 15 - 19 per 21-day cycles or Days 1 - 21 per 21-day cycles to determine the maximum tolerated dose for continuous daily dosing.
62052048|NCT03056482|ACTIVE_COMPARATOR|Ondansetron 8mg|8mg Ondansetron prepared in a 100mL normal saline mini-bag
62052049|NCT03056482|EXPERIMENTAL|Haloperidol 0.05mg/kg|0.05mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag
62253116|NCT00766090|EXPERIMENTAL|GW685698X|
62611561|NCT05555602|NO_INTERVENTION|Control group: CO2 fractional laser alone|This group of patients is the treatment control group. During the treatment period, the cold-air cooling device Cryo 6 will be placed next to the laser equipment but not started. The air outlet position is about 3 to 7 centimeters away from the skin, and it will move slowly and synchronously according to the laser position. The skin temperature will be synchronously monitored and recorded by hand-held infrared thermometry. After the operation, the investigators use hospital's routine aftercare procedures, and continue to use hand-held infrared thermometry to synchronously monitor the skin temperature.
62442225|NCT04039581|ACTIVE_COMPARATOR|Group 2: Conventional treatment|The number of participants in this group are anticipated to be 30. This group will be receiving only conventional treatment. In the conventional treatment therapeutic exercises (active and passive range of motion (ROM) and strengthening exercise of the neck and shoulder) and TENS (Transcutaneous electrical nerve stimulation) applications on the painful area, every day and 2 channels with 4 electrodes in the acute period (first 72 hours) will be applied. These exercises will be taught to participants from the first treatment session and will be performed under the supervision of a physiotherapist.
62623573|NCT00807612|EXPERIMENTAL|Part 1 Cohort 1|AMG 479 at 18 mg/kg in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 at 18 mg/kg monotherapy for 24 months from study day 1
62834879|NCT00823693|PLACEBO_COMPARATOR|Placebo Cream|
62052050|NCT03056482|EXPERIMENTAL|Haloperidol 0.1mg/kg|0.1mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag
62052051|NCT05687955|EXPERIMENTAL|Hip Exercise Program|A 12-week strength exercise protocol has been specifically designed to focus on hip rehabilitation appropriate for circus performance.
62052052|NCT01747564|EXPERIMENTAL|mirabegron group|
62052053|NCT02390531|EXPERIMENTAL|Bevacizumab 0.250 mg|Dosage of injected Bevacizumab to be studied
62052054|NCT02390531|EXPERIMENTAL|Bevacizumab 0.125 mg|Dosage of injected Bevacizumab to be studied
62253117|NCT03623594|EXPERIMENTAL|Surgical repair of the diastasis|Repair of the diastasis with a double row plication using absorbable Quill suture
62253118|NCT04807699||Total participants|3500 participants that will have their medical forms checked
62253119|NCT03960073|EXPERIMENTAL|MitoQ|20mg daily oral dose of MitoQ
62834880|NCT01569607|EXPERIMENTAL|Hebbian-type Stimulation|Participants will be randomized to receive motor training with Hebbian-type stimulation.
62834881|NCT01569607|SHAM_COMPARATOR|Sham Stimulation|Participants will be randomized to receive sham stimulation.
62253120|NCT03960073|PLACEBO_COMPARATOR|Placebo|Oral TTP placebo
62834882|NCT02750917|EXPERIMENTAL|GROUP LORNOXICAM|Immediately in postoperative care unit patients received lornoxicam 8 mg PO/12 hours for 48 hours
62834883|NCT02750917|ACTIVE_COMPARATOR|GROUP ETORICOXIB|Immediately in postoperative care unit patients received etoricoxib 120 mg PO and another pill at 24 hours.
62052055|NCT02390531|EXPERIMENTAL|Bevacizumab 0.063 mg|Dosage of injected Bevacizumab to be studied
62052056|NCT02390531|EXPERIMENTAL|Bevacizumab 0.031 mg|Dosage of injected Bevacizumab to be studied
62052057|NCT02390531|EXPERIMENTAL|Bevacizumab 0.016 mg|Dosage of injected Bevacizumab to be studied
62052058|NCT02390531|EXPERIMENTAL|Bevacizumab 0.008 mg|Dosage of injected Bevacizumab to be studied
62052059|NCT02390531|EXPERIMENTAL|Bevacizumab 0.004 mg|Dosage of injected Bevacizumab to be studied
62052060|NCT02390531|EXPERIMENTAL|Bevacizumab 0.002 mg|Dosage of injected Bevacizumab to be studied
62442226|NCT04039581|ACTIVE_COMPARATOR|Group 3: Kinesio Taping|The number of participants in this group are anticipated to be 30. This group will be receiving only Kinesio Taping relaxation technique (muscle inhibition technique). In kinesio taping technique while participants are sitting on the edge of the bed, the shoulder area will be depressed and I banding will be done by applying 25-50% tension horizontally in this position on the upper trapezius muscle.
62834884|NCT01539161|EXPERIMENTAL|Reveal XT plus SOC|Standard of care treatment plus the Reveal XT Implantable Cardiac Monitor. Treatment will follow the same schedule of the standard of care arm regarding exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. The addition will be device interrogation at every 6 month exam. Participation will last 36 months.
62834885|NCT01539161|ACTIVE_COMPARATOR|Standard of Care|Standard of care arm as described by exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. Participation will last 36 months.
62834886|NCT05481086||1|Individuals with fibromyalgia syndrome
62834887|NCT02382432|ACTIVE_COMPARATOR|Pethidine 0.4mg/kg iv|interventional: Pethidine 0.4mg/kg intravenous bolus once to be repeated if shivering incompletely abolished.
62052061|NCT04504656||1|open surgery
62052062|NCT04504656||2|minimally invasive surgery
62052063|NCT00214305|EXPERIMENTAL|Range of Motion Therapy Program|The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
62052064|NCT00214305|PLACEBO_COMPARATOR|Postural Sensory Therapy Program|The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
62052065|NCT02657317|EXPERIMENTAL|FORT-A|"has been labeled FORT-A. FORT-A is provided on an outpatient basis and includes 12 daily group pain management and physical therapy sessions spanning three weeks. Group interventions are supplemented by individual psychotherapy, biofeedback, and case staffings. CBT sessions were decreased in favor of CAM components. FORT-A participants will receive 270 minutes (4½ hours) of intervention a day for 12 days over 3 weeks."
62442227|NCT04778527|EXPERIMENTAL|Over-encapsulated DPP|A single, over-encapsulated DPP taken once daily for three 28-day cycles (Regimen A) followed by two separate tablets (oral PrEP and COC) taken once daily for three 28-day cycles (Regimen B)
62052066|NCT02657317|ACTIVE_COMPARATOR|VA Treatment As Usual|"Treatment As Usual (TAU) represents usual VA Care based on as usual appointments and referrals from VA providers. TAU can include active medical interventions, psychosocial intervention, and other rehabilitation strategies."
62623574|NCT00807612|EXPERIMENTAL|Part 1 Cohort 2|AMG 479 at 12 mg/kg in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 at 12 mg/kg monotherapy for 24 months from study day 1
62834888|NCT02382432|ACTIVE_COMPARATOR|DEX. I|Interventional:Dexmedetomidine (Precedex) 0.5µg/kg intravenous bolus once to be repeated if shivering incompletely abolished.
62834889|NCT02382432|ACTIVE_COMPARATOR|DEX. II|Interventional: Dexmedetomidine (PRECEDEX) 0.3µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.
62253121|NCT02806089|EXPERIMENTAL|Muscle strength|"single evaluation (the day of inclusion) of muscle strength (by handheld dynamometer), muscle mass (by creatinine index estimation), lean body mass (by electrical bioimpedance analysis), physical activity (by Voorrips score questionnaire), inflammatory and nutritional status."
62253122|NCT03453658|ACTIVE_COMPARATOR|Manual instrumentation|Manual instrumentation: Endodontic treatment will be performed with the use of conventional endodontic manual files.
62253123|NCT03453658|EXPERIMENTAL|Reciprocating instrumentation|Mechanized instrumentation: Endodontic treatment will be performed with the use of reciprocating mechanized files. The files are activated by an engine that produces reciprocating movements.
62253124|NCT04841980|ACTIVE_COMPARATOR|Antibiotics|
62253125|NCT04841980|ACTIVE_COMPARATOR|Dietary based therapy|
62442228|NCT04778527|EXPERIMENTAL|Two Separate Tablets|Two separate tablets (oral PrEP and COC) taken once daily for three 28-day cycles followed by a single, over-encapsulated DPP taken once daily for three 28-day cycles
62442229|NCT01725113|EXPERIMENTAL|Calcitriol, then Paricalcitol|Patients randomized to an active vitamin D treatment protocol based on IV calcitriol. After 14 weeks, patients cross-over to an active vitamin D protocol based on IV paricalcitol for 14 weeks.
62834890|NCT02382432|ACTIVE_COMPARATOR|DEX III|Interventional: Dexmedetomidine (PRECEDEX) 0.2µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.
62834891|NCT02500797|EXPERIMENTAL|Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress after 10 weeks on single agent nivolumab may elect to cross over to Arm II.
62253126|NCT03200054|NO_INTERVENTION|Clinic-based Care|Clinic-based care is the current standard of care and is defined as referral of women on antiretroviral therapy (ART) to general primary care adult ART services.
62253127|NCT03200054|EXPERIMENTAL|Adherence Club Care|Adherence club care involves referral of women on ART to community-based ART services in the form of adherence clubs, which are led by community health workers and supported by ART clinic nurses.
62834892|NCT02500797|EXPERIMENTAL|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 30 minutes every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress by imaging during the first 12 weeks of therapy may continue treatment, at the discretion of the patient and treating investigator.
62834893|NCT01354314|EXPERIMENTAL|Fluconazole|Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine
62834894|NCT01354314|EXPERIMENTAL|Paroxetine|Paroxetine 20 mg orally once per day; placebo in place of fluconazole
62834895|NCT01354314|EXPERIMENTAL|Paroxetine and Fluconazole|Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
62253128|NCT05353400|EXPERIMENTAL|(Intervention group): self-removal of transurethral catheter on POD 1|Subjects will self-remove transurethral catheter at home on postop day 1
62253129|NCT05353400|ACTIVE_COMPARATOR|(Standard practice group): self-removal of transurethral catheter on POD 3|Subjects will self-remove transurethral catheter at home on postop day 3
62253130|NCT05744622|EXPERIMENTAL|chemically cured conventional glass ionomer restorative (Ketac Universal Aplicap)|For restoration of M1 group, capsule activation will be performed through loading of the KetacTM Universal AplicapTM GIC capsule into its activator keeping the applicator nozzle closed, using the ball of my hand to depress the activator lever firmly as far as it will go and hold it down for 2 to 4 seconds. Then the capsule will be mixed in a high frequency mixing device for 8 seconds. The mixed capsule will be immediately removed from the mixer and loaded into the AplicapTM Applier then application nozzle will be opened to extrude the mixture directly into the preparation as a single bulk within 1:40 minute. The preliminary contour will be done using a ball burnisher.
62253131|NCT05744622|EXPERIMENTAL|Ketac Universal Aplicap enhanced with light-emitting diode radiant heat|Restoration of M2 group will be performed following the same steps which will be carried out for M1 group but the achieved restorations will be enhanced by light-emitting diode radiant heat for 60 seconds
62253132|NCT05054647||family caregivers of palliative patients|psychometric questionnaires
62253133|NCT04288063||Early onset T1D children|25 young, prepubertal and very early pubertal (Tanner stages 1 and 2) children (13 females and 12 males) with early onset T1D
62253134|NCT03154814|EXPERIMENTAL|ulinastatin treatment|ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
62442230|NCT01725113|ACTIVE_COMPARATOR|Paricalcitol, then Calcitriol|Patients randomized to an active vitamin D treatment protocol based on IV paricalcitol. After 14 weeks, patients cross-over to an active vitamin D protocol based on IV calcitriol for 14 weeks.
62442231|NCT06359678|EXPERIMENTAL|Northstar|This is the study group
62442232|NCT05899465|EXPERIMENTAL|Tranexamic Acid|A single dose of TXA (15 mg/kg) administered intravenously 30 min (+/-15 min) before skin incision and subsequently, TXA (1000 mg) administered orally 4 and 8 hours post-surgery and TXA (1000 mg) 3 times daily through postoperative day 4.
62623575|NCT00807612|EXPERIMENTAL|Part 2|"AMG 479 in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 monotherapy for 24 months from study day 1~(AMG 479 dose in Part 2 will be the final AMG 479 dose from Part 1)"
62834896|NCT01354314|PLACEBO_COMPARATOR|Placebo|Placebo in place of both fluconazole and paroxetine
62834897|NCT03517878||Comprehensive CHW Cohort|Pregnant women who become mothers and their infants living in areas served by the comprehensive CHW program. These are areas around two primary health care clinics and matched to the Control Cohort clinic areas.
62834898|NCT03517878||Control Cohort|Pregnant women who become mothers and their infants living in areas that are not served by the comprehensive CHW program. These are areas around two primary health care clinics and matched to the Comprehensive CHW Cohort clinic areas.
62834899|NCT04840693|EXPERIMENTAL|Excess of endogenous glucoglucocorticoids (group 1)|v
62834900|NCT04840693|EXPERIMENTAL|Exogenous hypercortisolisms (group 2)|a disease justifying the up-coming start of a glucocorticoid therapy
62834901|NCT04840693|EXPERIMENTAL|Adrenal insufficiency (group 3)|chronic adrenal insufficiency
62834902|NCT04840693|OTHER|Control (group 4)|without glucocorticoid excess
62442233|NCT05899465|PLACEBO_COMPARATOR|Placebo|A single dose of saline matching the volume of the experimental arm treatment regiment (Saline) administered intravenously 30 min (+/-15 min) before skin incision and subsequently, placebo tablets (2 tabs.) administered orally 4 and 8 hours post-surgery and (2 tabs) 3 times daily through postoperative day 4.
62442234|NCT03551730|EXPERIMENTAL|Module 3 (210 mg bolus) original|210 mg PRT064445 given as a single IV bolus
62611562|NCT05555602|EXPERIMENTAL|Combination group: CO2 fractional laser combined with Cryo 6|During the CO2 fractional laser treatment, cool the skin with cold-air cooling device Cryo 6. Set the wind to level 5, and the maximum time to 30 minutes. The air outlet position is about 3 to 7 centimeters away from the skin, and it will move slowly and synchronously according to the laser position. The skin temperature will be synchronously monitored by hand-held infrared thermometry and maintained at 0°C to 5°C. After the operation, the investigators use hospital's routine aftercare procedures and cooling with Cryo 6 on the skin synchronously. The wind level can be selected by patients themselves from level 3 to 7, and the time can be set for 5 minutes. Put the air outlet about 3 to 7 centimeters away from the skin, and move it slowly and dynamically in this area of skin to monitor and record the skin temperature synchronously.
62611563|NCT03545269|EXPERIMENTAL|CartiLife®|
62611564|NCT03545269|ACTIVE_COMPARATOR|Microfracture|
62611565|NCT02393430|EXPERIMENTAL|experimental|The experimental group were treated with rebamipide 0.1g tid and optimization of life style.
62611566|NCT02393430|PLACEBO_COMPARATOR|control|The control group were only optimized their life style.
62611567|NCT03786185|EXPERIMENTAL|Adolescents with dyslexia|MusicPlast training
62611568|NCT03786185|ACTIVE_COMPARATOR|Adolescents without dyslexia|MusicPlast training
62611569|NCT03786185|EXPERIMENTAL|Young Adults|MusicPlast training
62611570|NCT03786185|ACTIVE_COMPARATOR|Young Adults Control|MusicPlast Control, in a similar design as MusicPlast
62611571|NCT03786185|EXPERIMENTAL|Seniors|MusicPlast training
62611572|NCT06336278||Knee Osteoarthritis|Patients who have knee pain at least 6 months, 45-75 years old, kellgren-lawrence grade 1-3
62611573|NCT06336278||Control|Subjects who have not knee pain, 45-75 years old
62611574|NCT01752868|EXPERIMENTAL|supplement|
62611575|NCT01752868|NO_INTERVENTION|control|
62253135|NCT03154814|PLACEBO_COMPARATOR|control|conventional CPB was applied without ulinastatin treatment
62253136|NCT01906775||Patients with PIT|Identification of patients with pacemaker-induced ventricular tachycardias
62611576|NCT03738761|EXPERIMENTAL|Amlessa® Arm|Patients allocated to treatment with Amlessa® (starting FDC of perindopril 4mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria.
62834903|NCT04266717|EXPERIMENTAL|Baby Play Parent Education Group|Baby Play Intervention involves teaching parents targeted ways they can handle, position, and play with young infants that aim to provide infants enhanced early opportunities to learn to control their bodies and interact with objects. These abilities are associated with future motor, cognitive, and language outcomes. Parents will be asked to perform the intervention activities 20 minutes daily and to log their activity performance weekly.
62253137|NCT03013673||HIV|HIV infected individuals residing in VL-endemic areas in Northern Ethiopia
62253138|NCT01582087||acute or chronic hepatic failure|All patients presenting at University of Texas Medical Branch (UTMB) with acute and chronic hepatic failure and who are developing coma
62253139|NCT02900079||travelers|persons intending to travel for 3 weeks or longer to South-East Asia, Sub-Saharan Africa or South-/ Central America; they will be trained to use a rapid diagnostic test for malaria antigen when febrile. Upon a positive test result they are recommended to use standby emergency treatment (SBET)
62253140|NCT06099899||child|The child's age ranges from 8 to 18 years old. They have undergone hematopoietic stem cell transplantation for at least one month. They do not have any mental disorders or consciousness impairments. The child is capable of independent walking. The interviewees are able to express their thoughts clearly.
62253141|NCT06099899||parent|The primary caregivers during the home care period for these children.
62611577|NCT03738761|EXPERIMENTAL|Co-Amlessa® Arm|Patients allocated to treatment with Co-Amlessa® (starting FDC perindopril 4mg/indapamide 2,5mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria. Patients on previous perindopril and amlodipine therapy will be automatically assigned to Co-Amlessa® arm.
62611578|NCT03718754|ACTIVE_COMPARATOR|En-Bloc TURB|
62611579|NCT03718754|ACTIVE_COMPARATOR|Conventional TURB|
62611580|NCT01880905|EXPERIMENTAL|female undergoing gynecological surgery|
62611581|NCT02150070|EXPERIMENTAL|Intravenous ASP2408|
62611582|NCT02150070|EXPERIMENTAL|Subcutaneous ASP2408 low dose|
62611583|NCT02150070|EXPERIMENTAL|Subcutaneous ASP2408 middle dose|
62611584|NCT02150070|EXPERIMENTAL|Subcutaneous ASP2408 high dose|
62611585|NCT02150070|PLACEBO_COMPARATOR|Intravenous Placebo|
62611586|NCT02150070|PLACEBO_COMPARATOR|Subcutaneous Placebo|
62611587|NCT03296020|NO_INTERVENTION|control group|"After the surgery, during the hospitalization ,the control group would get as is customary in our ENT department :acetaminophen syrup+ syrup oxycode( as necessary).~After the discharge from the hospital - the patients would take( as is customary in our ENT department): acetaminophen syrup ( as necessary) and other painkillers ( as necessary).~The families would ask to follow treatment protocols for 7 days and will fill a questionnarie every day during the 7 days."
62623576|NCT03968913|PLACEBO_COMPARATOR|Control|Subjects will receive two injections of sterile saline after ACL injury, prior to surgery
62623577|NCT03968913|ACTIVE_COMPARATOR|Two doses Anakinra|Subjects will receive two injections of anakinra after ACL injury, prior to surgery
62611588|NCT03296020|EXPERIMENTAL|"case group-HONEY"|"After the surgery, during the hospitalization ,the case group would instructed to use honey twice a day( 5 ml- one tea spoon each time)+acetaminophen syrup + syrup oxycode( as necessary).~After the discharge from the hospital - the patients would take:acetaminophen syrup ( as necessary) and other painkillers+honey twice a day( 5 ml- one tea spoon each time) .~The families would ask to follow treatment protocols for 7 days and will fill a questionnarie every day during the 7 days."
62834904|NCT04266717|ACTIVE_COMPARATOR|Milestone Education Group|Parents in the Milestone Education Intervention group will receive information regarding milestones expected based on infants' CA. This information is based on forms from the Centers for Disease Control and Prevention (CDC) and The American Academy of Pediatrics (AAP). This will help parents understand the milestones typically observed at the their child's CA and reflects the education parents receive from healthcare providers. Parents will be asked to provide their infants opportunities to perform these milestone behaviors 20 minutes daily and to log their activity performance weekly.
62834905|NCT00685191|EXPERIMENTAL|1|HIV-1-infected subjects initiating raltegravir-including salvage therapy
62834906|NCT04822116|NO_INTERVENTION|standard of care|"Standard of care defined as standard operating procedure, including a goal directed intraoperative haemodynamic optimization protocol."
62834907|NCT04822116|ACTIVE_COMPARATOR|goal directed intraoperative haemodynamic optimization|"Standard of care defined as standard operating procedure, including a goal directed intraoperative haemodynamic optimization protocol. Additional application of a non-invasive haemodynamic optimization protocol in the post anaesthesia care unit."
62834908|NCT06056518|NO_INTERVENTION|Routine Care|"Patients in the Routine Care arm are will undergo regular follow-up at the kidney transplant center."
62834909|NCT06056518|EXPERIMENTAL|AI-supported Care|"Patients in the AI-supported Care arm will undergo regular follow-up at the kidney transplant center. Treating physicians will be provided an AI-based risk prediction tool that predict 1-year risk of graft loss for patients in this group based on routine parameters."
62834910|NCT02334904||Aripiprazole|Participants receiving treatment of only aripiprazole, as prescribed to them by their psychiatrists, for a minimum of at least 3 continuous months.
62834911|NCT02334904||Risperidone|Participants receiving treatment of only risperidone, as prescribed to them by their psychiatrists, for a minimum of at least 3 continuous months.
62442235|NCT03551730|EXPERIMENTAL|Module 3 (420 mg bolus) original|420 mg PRT064445 given as a single IV bolus
62442236|NCT03551730|EXPERIMENTAL|Module 3 (210 mg) lyophilized|210 mg PRT064445 (lyophilized formulation) given as a single IV bolus
62442237|NCT03551730|PLACEBO_COMPARATOR|Module 3 Placebo|Placebo administered intravenously (IV) as a bolus.
62442238|NCT05824182|EXPERIMENTAL|Intervention Group|Intervention group: FACE self-help app with guidance
62442239|NCT05824182|NO_INTERVENTION|control group|Waiting list control group with questionnaires and EMA
62442240|NCT01270022|EXPERIMENTAL|Implementation|
62442241|NCT01270022|ACTIVE_COMPARATOR|dissemination|
62834912|NCT02334904||Controls|Healthy participants who are not taking any antipsychotic medications.
62834913|NCT06452576|EXPERIMENTAL|Wear vibrating watch during therapy|The watch worn on the affected wrist vibrates during therapy.
62834914|NCT06452576|PLACEBO_COMPARATOR|Wear non-vibrating watch during therapy|The watch worn on the affected wrist does not vibrate during therapy.
62834915|NCT01539421|EXPERIMENTAL|Exercise Intervention|Use of Wii computer for enhanced exercise in COPD patients.
62834916|NCT05012917|OTHER|Patient/Proxy-SSPedi Administered First|"Parent/child dyads will complete self-report SSPedi/mini-SSPedi and proxy-SSPedi as the first period and then co-SSPedi as a second period."
62834917|NCT05012917|OTHER|Co-SSPedi Administered First|"Parent/child dyads will complete co-SSPedi as the first period and then self-report SSPedi/mini-SSPedi and proxy-SSPedi as a second period."
62834918|NCT02928965|EXPERIMENTAL|Minocycline|Participants will receive capsules containing 100mg of minocycline (modified release), two per day for the first two weeks of the trial and then three per day for the remainder of the 12 month treatment period in addition to antipsychotic drug treatment and other interventions by the responsibel medical officer.
62834919|NCT02928965|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo capsules entirely matching minocycline, two per day for the first two weeks of the trial and then three per day for the reminder of the 12 month treatment period in addition to antipsychotic drug treatment and other interventions by the responsibel medical officer.
62834920|NCT02314559|EXPERIMENTAL|Propofol (manual titration)|
62253142|NCT01396226|EXPERIMENTAL|1|A single dose of AZD2927 administered as an iv infusion
62253143|NCT01396226|PLACEBO_COMPARATOR|2|A single dose of placebo administered as an iv infusion
62253144|NCT01595984|ACTIVE_COMPARATOR|Cyclosporin + Mycophenolate mofetil|
62442242|NCT03931096||children with congenital heart disease|Groupe 1: case: children with congenital heart disease aged 5 to 7 years.
62442243|NCT03931096||control children|Groupe 2: control children recruited in schools aged 5 to 7 years.
62442244|NCT04059666|ACTIVE_COMPARATOR|Control|
62442245|NCT04059666|EXPERIMENTAL|Investigational|
62442246|NCT04059666|NO_INTERVENTION|Mother's-own Breast Milk|
62442247|NCT00974493|ACTIVE_COMPARATOR|Oral antibiotics|
62442248|NCT00974493|ACTIVE_COMPARATOR|Intravenous antibiotics|
62442249|NCT01788722||Group 1|
62611589|NCT05121740|EXPERIMENTAL|Arm A: Experimental 1|In the APLICOV-PC study, patients of arm A received 1.5 mg of plitidepsin / day for 3 consecutive days (total dose 4.5 mg).
62834921|NCT02314559|ACTIVE_COMPARATOR|Propofol (target controlled infusion)|
62834922|NCT04909385||Bronchoalveolar lavage (BAL) samples for pulmonary TB|
62834923|NCT04909385||(EBUS-TBNA) samples for mediastinal TB|
62834924|NCT06035913||Salivation group|The saliva group was instructed to take dihydroergot mesylate, one tablet twice a day, and observed the improvement of salivation after 1 week, after 1 month, after March and after 6 months.
62834925|NCT03798769|EXPERIMENTAL|Supportive Oncology Care at Home|"The Supportive Oncology Care at Home intervention entails the following:~1. patient-reported symptoms, vital sign, and weight monitoring with appropriate triggers for phone calls and home visits by Medically Home based on a clinician-derived algorithm~2. scheduled nursing visits for intravenous (IV) hydration during the course of chemotherapy;~3. regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care."
62253145|NCT01595984|EXPERIMENTAL|Everolimus + mycophenolate mofetil|
62253146|NCT01442194||Fingolimod|non-interventional
62052067|NCT00668902|EXPERIMENTAL|EM of CYP2C19|CYP2C19 enzyme activity in extensive metabolizers of CYP2C19 (CYP2C19\*1/\*1 genotype, or wild type) was measured by 13C)Pantoprazole breath test.
62253147|NCT01442194||parallel cohort|non-interventional
62611590|NCT05121740|EXPERIMENTAL|Arm B: Experimental 2|In the APLICOV-PC study, patients of arm B received 2.0 mg of plitidepsin / day for 3 consecutive days (total dose 6.0 mg).
62253148|NCT03524885|ACTIVE_COMPARATOR|Short implants|2 or 3 implant 4-5 mm length and 4 mm diameter (Syra Short, Sweden \& Martina, Padua, Italy) will be positioned. The healing cap will be immediately connected and a vycril suture will be done after soft tissue reflection.
62253149|NCT03524885|EXPERIMENTAL|Bone regeneration with longer implants|"A horizontal and vertical regeneration following GBR technique will be performed using not-resorbable PTFE titanium reinforced membrane (Cytoplast Osteogenics, US) fixed by titanium pins or miniscrews to ensure the perfect stability (Pro-fix, Cytoplast Osteogenics, US).~The graft will be composed half autogenous bone harvested with a scraper (Meta, Firenze, Italy) by the same surgical site or by a second tunnel site in the mandibular ramus and half deproteinized bovine bone (Bio Oss Geislicht Pharma, Switzerland). The mucosal flaps will be sutured in a double layer with horizontal mattress and single gore-tex sutures (Cytoplast PTFE sutures 3.0, Cytoplast Osteogenics, US).~2 or 3 implant from 10 to 13 mm length putting the implant platform 2 or 3 mm apical to CEJ of the adjacent tooth will be inserted."
62253150|NCT04200235|EXPERIMENTAL|High weight group|High weight group
62253151|NCT04200235|EXPERIMENTAL|Low weight group|Low weight group
62253152|NCT03314077||Standard managed subjects|COPD patients accepted standard COPD management.
62253153|NCT03314077||Controls|COPD patients didn't accepted standard COPD management or quality control, who are from hospital subjects with a retrospective cohort study.
62442250|NCT03391297|EXPERIMENTAL|60-minute Prolonged Exposure Therapy|This condition is a modified version of Prolonged Exposure Therapy for PTSD. It consists of weekly 60-minute sessions, with at least 20 minutes imaginal exposure.
62442251|NCT03391297|ACTIVE_COMPARATOR|90-minute Prolonged Exposure Therapy|This condition is standard Prolonged Exposure Therapy. It consists of 10 to 15 weekly sessions, each lasting about 90 minutes, with 40-60 minutes imaginal exposure.
62442252|NCT03436628|EXPERIMENTAL|App Use|Kids (10-15 years old) with type 1 diabetes and one of their parents will receive the MyT1DHero app to use for a 3-month period. Participants are urged to use the app four times each day.
62442253|NCT04878406|EXPERIMENTAL|1.7 mg NNC0480-0389 + 0.5 mg Semaglutide|Participants will be co-administered single doses of 1.7 mg NNC0480-0389 and 0.5 mg semaglutide as separate injections.
62442254|NCT04878406|PLACEBO_COMPARATOR|Placebo (1.7 mg NNC0480-03899) + placebo (0.5 mg Semaglutide)|Participants will be co-administered single doses of placebo (NNC0480-0389) and placebo (semaglutide) as separate injection.
62442255|NCT04878406|EXPERIMENTAL|8.6 mg NNC0480-0389 + 0.5 mg Semaglutide|Participants will be co-administered single doses of 8.6 mg NNC0480-0389 and 0.5 mg semaglutide as separate injections.
62442256|NCT04878406|PLACEBO_COMPARATOR|Placebo (8.6 mg NNC0480-0389) + placebo (0.5 mg Semaglutide)|Participants will be co-administered single doses of placebo (NNC0480-0389) and placebo (semaglutide) as separate injection.
62442257|NCT04878406|EXPERIMENTAL|30 mg NNC0480-0389 + 0.5 mg Semaglutide|Participants will be co-administered single doses of 30 mg NNC0480-0389 and 0.5 mg semaglutide as separate injections.
62442258|NCT04878406|PLACEBO_COMPARATOR|Placebo (30 mg NNC0480-0389) + placebo (0.5 mg Semaglutide)|Participants will be co-administered single doses of placebo (NNC0480-0389) and placebo (semaglutide) as separate injection.
62442259|NCT00278512|EXPERIMENTAL|Autologous Stem Cell Transplant|Autologous Stem Cell Transplant will be performed on eligible patients
62834926|NCT00809952||Recombinat FSH|
62052068|NCT00668902|EXPERIMENTAL|IM of CYP2C19|CYP2C19 activity in heterozygous for deficient CYP2C19 alleles (\*2 and \*3, IM of CYP2C19) was measured by (13C)Pantoprazole breath test.
62052069|NCT00668902|EXPERIMENTAL|PM of CYP2C19|Homozygous for CYP2C19 null alleles (\*2/\*2, \*2/\*3 or \*3/\*3, Poor metabolizers) was measured by (13C)Pantoprazole breath test.
62052070|NCT02333279||Organ transplant recipients|Follow-ups in regular intervals following the organ transplant date.
62052071|NCT06356025|EXPERIMENTAL|Botulinum toxin injection|
62052072|NCT06356025|PLACEBO_COMPARATOR|Placebo injection|
62052073|NCT02259179|ACTIVE_COMPARATOR|Fed Group|Reference and test product naltrexone SR/bupropion SR combination trilayer tablets tested in the fed state.
62052074|NCT02259179|ACTIVE_COMPARATOR|Fasted group|Reference and test product naltrexone SR/bupropion SR combination trilayer tablets tested in the fasted state.
62052075|NCT03769402|ACTIVE_COMPARATOR|Citric acid|Citric acid PH1 and concentration 50% was used for 30 seconds on bone surface before washing it off and filling the defect with xenograft
62052076|NCT03769402|PLACEBO_COMPARATOR|Control|Control test
62253154|NCT01733966|EXPERIMENTAL|Secnidazol-Ciprofloxacin|2g(single dose) of Secnidazol associated with 1g(2 doses of 500mg)of Ciprofloxacin during 3 days
62253155|NCT01733966|ACTIVE_COMPARATOR|Amoxicillin-Clavulanic Acid|3g (3 doses of 1g) of Amoxicillin-Clavulanic acid during 10 days
62253156|NCT02470026|EXPERIMENTAL|Yohimbine-Placebo|single low dose treatment with yohimbine on test day 1, placebo on test day 2
62253157|NCT02470026|EXPERIMENTAL|Placebo-Yohimbin|placebo on test day 1, single low dose treatment with yohimbine on test day 2
62253158|NCT02023242|EXPERIMENTAL|Hydrus Microstent|Patients randomized to the Hydrus Microstent .
62442260|NCT00278512|EXPERIMENTAL|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant will be performed on eligible patients
62611591|NCT05121740|EXPERIMENTAL|Arm C: Experimental 3|In the APLICOV-PC study, patients of arm C received 2.5 mg of plitidepsin / day for 3 consecutive days (total dose 7.5 mg).
62611592|NCT06730789|EXPERIMENTAL|Lateral Epicondylitis (treatment with epicondylitis bandage)|Patients with diagnosis of lateral epicondylitis.
62611593|NCT06730789|EXPERIMENTAL|Lateral Epicondylitis (treatment with wrist dorsiflexion orthesis)|Patients with diagnosis of lateral epicondylitis.
62611594|NCT06730789|EXPERIMENTAL|Lateral Epicondylitis (treatment with kinesio tape)|Patients with diagnosis of lateral epicondylitis.
62611595|NCT01794598|EXPERIMENTAL|Educational materials|Receiving educational materials of depression care
62611596|NCT01794598|SHAM_COMPARATOR|No educational materials|Receiving an envelope but no inclusion of educational materials of depression care
62611597|NCT00743288|EXPERIMENTAL|Melphalan and Panobinostat|"Schedule A: 10mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 of a 28-day cycle and melphalan PO at 0.05 mg/kg on days 1-5 of week 1.~Toxicity led to the following changes in dose and schedule Schedule B1: 10mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule B2: 20mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 and 0.05 mg/kg melphalan POon days 1, 3 and 5 of week 1.~Schedule C: 20mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1 and 2 and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1 Schedule D1: 15 mg/daily LBH589 PO and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule D2: 15 mg/daily LBH589 PO and 0.10 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule D3: 20 mg/daily LBH589 PO and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1."
62611598|NCT03702491|EXPERIMENTAL|Apatinib with SOX(Tegafur,Oxaliplatin)|Patients 3-4 weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate
62611599|NCT03702491|ACTIVE_COMPARATOR|SOX( Tegafur,Oxaliplatin)|3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.
62834927|NCT03450122|EXPERIMENTAL|Cohort 0 (cyclophosphamide, T cells, aldesleukin)|Participants receive cyclophosphamide IV over 30-60 minutes on day -2 and autologous NY-ESO-1-specific CD8-positive T lymphocytes IV over 60 minutes on day 0. Then, 6 hours later and twice a day for 14 days, receive aldesleukin SC in the absence of disease progression or unacceptable toxicity.
62834928|NCT03450122|EXPERIMENTAL|Cohort 1 (cyclophosphamide, T cells, aldesleukin, LV305)|Participants receive cyclophosphamide, autologous NY-ESO-1-specific CD8-positive T lymphocytes, and aldesleukin as in Cohort 0. Participants also receive dendritic cell-targeting lentiviral vector ID-LV305 ID on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
62052077|NCT00870857||1|Subjects will be 300 HIV+ subjects and 300 HIV- controls selected by random sampling stratified by age and smoking history. Subjects will be recruited from the University of Pittsburgh and the University of Washington (UW) MACS sites. The University of California San Francisco (UCSF) will serve as the recruiting center for the WIHS cohort
62052078|NCT02388503|PLACEBO_COMPARATOR|Reference|No added fruit extract
62052079|NCT02388503|ACTIVE_COMPARATOR|Active 1|lowest dose of fruit extract
62052080|NCT02388503|ACTIVE_COMPARATOR|Active 2|low dose of fruit extract
62052081|NCT02388503|ACTIVE_COMPARATOR|Active 3|medium dose of fruit extract
62052082|NCT02388503|ACTIVE_COMPARATOR|Active 4|high dose of fruit extract
62253159|NCT02023242|ACTIVE_COMPARATOR|iStent Trabecular Micro Bypass|Patients randomized to the iStent Trabecular Micro Bypass
62253160|NCT01299376|EXPERIMENTAL|L50/H12.5/A5→L50/H12.5/A5|One combination tablet containing L50 mg, H12.5 mg, and A5 mg, orally, once daily, for up to 8 weeks (double-blind treatment period). Participants continue with once daily L50/H12.5/A5 for 44 weeks during open label extension.
62253161|NCT01299376|ACTIVE_COMPARATOR|L50/H12.5→L50/H12.5/A5|One combination tablet containing L50 mg and H12.5 mg, orally, once daily, for up to 8 weeks during double-blind treatment period. Participants then receive once daily L50/H12.5/A5 for 44 weeks during open-label extension
62253162|NCT00161460|ACTIVE_COMPARATOR|1|Study nurse contacts subjects who enroll in the intervention to provide detailed education about screening tests, to assess their risk for colorectal cancer, and to facilitate screening.
62442261|NCT01424956||Asymptomatic Women who have Dense Breast Tissue|Women who have no signs or symptoms of breast cancer who have \> 50% parenchymal density on mammography.
62052083|NCT02660801|EXPERIMENTAL|Spinal manipulation|Twenty-six participants with chronic nonspecific back pain will participate in two experimental sessions. During the first session, each participant will received either a spinal manipulation of a spinal mobilization of their thoracic spine preceded and followed by the assessment of their thoracic spine stiffness. The second session (24 to 48h after) will be identical but with the other experimental condition (spinal manipulation or spinal mobilization).
62052084|NCT02660801|EXPERIMENTAL|Spinal mobilization|Twenty-six participants with chronic nonspecific back pain will participate in two experimental sessions. During the first session, each participant will received either a spinal manipulation of a spinal mobilization of their thoracic spine preceded and followed by the assessment of their thoracic spine stiffness. The second session (24 to 48h after) will be identical but with the other experimental condition (spinal manipulation or spinal mobilization).
62253163|NCT00161460|NO_INTERVENTION|2|Patients who do not enroll receive usual care from their primary care providers.
62253164|NCT02169050||No intervention|There is no intervention to subjects in this study. All subjects are morbidly women seeking bariatric surgeries.
62253165|NCT03305289|ACTIVE_COMPARATOR|pulsed radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then pulsed radiofrequency will be applied for 10 patients for 10 mins
62442262|NCT05864625|EXPERIMENTAL|Remimazolam|Induction dose of 6 mg/kg/h of remimazolam with remifentanil TCI 1\~4 nanogram/mL are injected together. When patient loses consciousness, rocuronium 0.8 mg/kg is given and endotracheal intubation is performed after confirming that TOF count is less than one. Anesthesia is maintained by using remimazolam dose of 1mg/kg/h\~2mg/kg/h with remifentanil to maintain optimal depth of anesthesia, which will checked by Sedline value between 25 to 50.
62442263|NCT05864625|ACTIVE_COMPARATOR|Propofol/sevoflurane|1% propofol 1-2mg/kg is injected with remifentanil TCI 1\~4, and when patient loses consciousness, sevoflurane is started and rocuronium 0.8mg/kg is given. After confirming that TOF count is less than one, intubation is performed and anesthesia is maintained with sevoflurane and remifentanil to keep the Sedline value between 25 and 50.
62253166|NCT03305289|ACTIVE_COMPARATOR|thermal Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then Thermal lesion will be applied for 10 patients for 2 cycles of 90 seconds
62253167|NCT06388850|EXPERIMENTAL|Intervention Group|Schools receiving HRP programming in pre-k through 5th-grade classrooms.
62611600|NCT05871671|ACTIVE_COMPARATOR|Control group|The control group shall consist of a minimum of 40 patients with a confirmed diagnosis of COPD and osteoporosis or osteopenia. This group which shall consist of patients who do not wish to participate in Pulmonary Rehabilitation but show the wish to form part of this study, or participants who are on the waiting list to be enrolled into the Rehabilitation classes, shall act as a control for the study and therefore not undergo PR and the following maintenance home exercise programme until completion of the study. All patients were medically stable and referred by their caring respiratory consultant.
62834929|NCT02980393|EXPERIMENTAL|Lifestyle intervention|Participants are guided by a fitness specialist who will help the participants to incorporate physical activity into their daily life. Based on the cardiologist assessment, an individual home-based exercise program will be developed. Participants are also guided and advised on nutrition with emphasis on low fat content and increased fiber. The nutrition counseling will focus on sustainable changes and will help participants to make healthy food choices.
62834930|NCT04112719||Control arm/pregnant patients at term|Control arm where the term pregnant patient will be lying on the bed at 45 degrees.
62834931|NCT04112719||Experimental/Supine|Term pregnant patient will be positioned in supine. Changes in hemodynamics will be measured.
62834932|NCT04112719||Experimental/15 degrees lateral tilt|Term pregnant patient will be positioned at 15 degrees in lateral tilt. Changes in hemodynamics will be measured.
62834933|NCT04112719||Experimental/30 degrees lateral tilt|Term pregnant patient will be positioned at 30 degrees in lateral tilt. Changes in hemodynamics will be measured.
62834934|NCT02405832|EXPERIMENTAL|Zinc - active arm|Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
62834935|NCT02405832|PLACEBO_COMPARATOR|Placebo|Placebo lozenge, with sweetener and citrus flavor, administered orally
62834936|NCT03537404|ACTIVE_COMPARATOR|Treatment A (Part 1/ Part 2)|Narlaprevir 200 mg once daily with Ritonavir 100 mg once daily for 5 days
62834937|NCT03537404|ACTIVE_COMPARATOR|Treatment B (Part 1)|Tenofovir disoproxil fumarate 300 mg once daily for 5 days
62834938|NCT03537404|ACTIVE_COMPARATOR|Treatment B (Part 2)|Raltegravir 400 mg twice daily for 5 days
62834939|NCT03537404|EXPERIMENTAL|Treatment C (Part 1)|Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and Tenofovir disoproxil fumarate 300 mg once daily for 5 days
62834940|NCT03537404|EXPERIMENTAL|Treatment C (Part 2)|Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and 400 mg raltegravir twice daily for 5 days
62834941|NCT01153932|EXPERIMENTAL|Continuous regimen; 6mg/kg once weekly|Once Weekly
62834942|NCT01153932|EXPERIMENTAL|Intermittent regimen; 6mg/kg twice weekly|Twice weekly on 1st, 3rd and 5th weeks, once weekly on 2nd, 4th and 6th weeks, and no active drug on 7th to 10th week of each 10 week cycle
62834943|NCT01213628|EXPERIMENTAL|Standard heating|Standard intraoperative warming measures including heated sheets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
62834944|NCT03868657|ACTIVE_COMPARATOR|Moxifloxacin|Per os, 800 mg, once daily for 4 days
62834945|NCT03868657|PLACEBO_COMPARATOR|Placebo|Per os, 800 mg, once daily for 4 days
62834946|NCT05038982|EXPERIMENTAL|Prurigo Nodularis|Prurigo Nodularis (PN) patients only: Study Design: Subjects meeting study criteria will undergo a 4-week washout period of other therapies that could impact pruritus through the end of the study (including antihistamines, topical steroids, systemic antipruritic therapies or immunosuppressants).
62052085|NCT02243280|EXPERIMENTAL|Arm A|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 1-infected participants without cirrhosis
62052086|NCT02243280|EXPERIMENTAL|Arm B|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 1- infected participants without cirrhosis
62253168|NCT06388850|NO_INTERVENTION|Control Group|Schools that have not received HRP programming. Schools in the control group will continue their normal standard of care for CSA prevention.
62834947|NCT05038982|EXPERIMENTAL|Chronic Pruritus of Unknown Origin|Chronic Pruritus of Unknown Origin (CPUO) patients only: Study Design: Subjects meeting study criteria will undergo a 4-week washout period of other therapies that could impact pruritus through the end of the study (including antihistamines, topical steroids, systemic antipruritic therapies or immunosuppressants).
62834948|NCT04567992|EXPERIMENTAL|SCPB|
62834949|NCT04567992|PLACEBO_COMPARATOR|Control|
62834950|NCT02453308|ACTIVE_COMPARATOR|ACT-arms|"1.1 Artemether-lumefantrine for 3 days.~1.2 Dihydroartemisinin-piperaquine for 3 days~1.3 Artesunate-Mefloquine for 3 days"
62834951|NCT02453308|ACTIVE_COMPARATOR|TACT-arms|"2.1: Artemether-lumefantrine for 3 days.plus: Amodiaquine for 3 days.~2.2: Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days.~2.3 Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days."
62253169|NCT03832803|EXPERIMENTAL|Empty Bladder|Empty bladder prior to treatment.
62834952|NCT05795608|EXPERIMENTAL|intervention group|The intervention group received respiratory exercise with incentive spirometry before surgery
62834953|NCT05795608|NO_INTERVENTION|control group|The control group were given standard preoperative care.
62834954|NCT05633758|PLACEBO_COMPARATOR|SOC heart failure therapy and placebo pill (Arm A)|This group will receive all standard heart failure therapy and placebo pill.
62834955|NCT05633758|ACTIVE_COMPARATOR|SOC heart failure therapy with addition of metolazone (Arm B)|This group will receive all standard heart failure therapy with addition of metolazone.
62834956|NCT02682524|ACTIVE_COMPARATOR|test|
62834957|NCT02682524|ACTIVE_COMPARATOR|reference|
62834958|NCT03588585|ACTIVE_COMPARATOR|Tension|foley balloon will be placed on tension and taped to thigh at 10 cm. Misoprostil will be placed in posterior vaginal vault.
62834959|NCT03588585|ACTIVE_COMPARATOR|No tension|The foley balloon will be loosely taped without tension to the patient's thigh. Misoprostil will be placed in the posterior vaginal vault.
62611601|NCT05871671|EXPERIMENTAL|Active group|The active group shall consist of a minimum of 40 patients with a confirmed diagnosis of COPD and osteoporosis or osteopenia. All patients shall receive a 16-week twice weekly PR programme which shall be followed by a 36-week maintenance home exercise programme. All patients were medically stable and referred by their caring respiratory consultant.
62611602|NCT03394417|NO_INTERVENTION|standard clinical practice (control)|aqueous cream normally prescribed by radiation oncologists
62253170|NCT03832803|OTHER|Full Bladder|Conventional drinking protocol - 200ml water prior to treatment.
62253171|NCT04611971|ACTIVE_COMPARATOR|Active Arm: Benlysta + Candin|Participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% sodium chloride (NaCl), and a single dose of Benlysta injection subcutaneously.
62253172|NCT04611971|NO_INTERVENTION|Control Arm: Candin|All participants will receive a single dose of Candin injection intradermally along with a single dose of saline solution of 0.9% NaCl administered intradermally and no Benlysta.
62611603|NCT03394417|ACTIVE_COMPARATOR|StrataXRT (intervention)|silicon-based gel for radiation dermatitis
62611604|NCT01413074|ACTIVE_COMPARATOR|ESRD patients receiving HD treatment|no investigational drug involved. Only oberseve therapy treatment
62611605|NCT01413074|EXPERIMENTAL|ESRD patients receiving PD treatment|no investigational drug involved. Only oberseve therapy treatment
62611606|NCT04542434|EXPERIMENTAL|Niclosamide|
62611607|NCT04542434|PLACEBO_COMPARATOR|Placebo|
62834960|NCT01558804||Rapid Strep Positive|Children will be eligible for this study if they are ages 5 to 15 years and have been diagnosed to have acute pharyngitis caused by GAS with a positive Rapid Antigen Detection Test (RADT).
62834961|NCT01820988||Sarcopenic vs. non-sarcopenic|Participants are classified as sarcopenic/non-sarcopenic according to the criteria of the European Working Group of Sarcopenia in Older People (EWGSOP).
62834962|NCT02224560|EXPERIMENTAL|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
62834963|NCT02224560|EXPERIMENTAL|GWP42003-P 10 mg/kg/day Dose|Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
62052087|NCT02243280|EXPERIMENTAL|Arm C|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 8 weeks in HCV genotype 1-infected participants without cirrhosis (never opened - Sponsor decision)
62052088|NCT02243280|EXPERIMENTAL|Arm D|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 8 weeks in HCV genotype 1-infected participants without cirrhosis (never opened - Sponsor decision)
62052089|NCT02243280|EXPERIMENTAL|Arm E|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD + ribavirin (RBV) 800 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
62052090|NCT02243280|EXPERIMENTAL|Arm F|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 1- infected participants with compensated cirrhosis
62052091|NCT02243280|EXPERIMENTAL|Arm G|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD + ribavirin (RBV) 800 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
62253173|NCT05275075||Pancreatic Cancer Cohort|All eligible adenocarcinoma pancreatic cancer patients with operable cancer.
62442264|NCT01953783|EXPERIMENTAL|IXAZOMIB|"Part A: Participants will receive a single dose of 4.1-milligram (mg) \[14C\]-IXAZOMIB oral solution containing approximately 500-nCurie (nCi) of total radioactivity on Day 1 and remain at the clinic for 8 days. On Days 14 and 21, participants may be administered a single 4.0-mg capsule of IXAZOMIB. Participants will return to the clinic in the evening before Days 14, 21, 28, and 35 for a 24-hour overnight clinic visit.~Part B: Eligible participants from Part A may continue into Part B once they have completed their Day 35 assessments in Part A. Participants may receive IXAZOMIB capsules administered orally at a dose of 4.0-mg once weekly on Days 1, 8, and 15 of 28-day cycles. Participants will continue in this study until disease progression or unacceptable toxicity."
62611608|NCT03758105|EXPERIMENTAL|Usual care and tDCS (Arm A)|Arm A patient receives a first tDCS treatment in association with usual care (medication, psychotherapy...). If the patient is responding to tDCS, he can have other tDCS treatments in case of relapse.
62611609|NCT03758105|ACTIVE_COMPARATOR|Usual care without tDCS (Arm B)|Arm B patient receives usual care: medication management and psychotherapy.
62253174|NCT01764542|OTHER|Endoscopy and biopsy|Endoscopy with biopsy taken Endoscopy and biopsy Blood samples Questionnaire
62253175|NCT06037642|EXPERIMENTAL|Intervention group|
62253176|NCT06037642|ACTIVE_COMPARATOR|Control group|
62253177|NCT00482703|EXPERIMENTAL|A|
62611610|NCT06428032|EXPERIMENTAL|Double period|Subjects will receive 130 hours of HABIT-ILE performed in two intervention periods as camp format for 6,5-hours/day, 5 days/week for two weeks. Each intervention period will be 6-months apart.
62253178|NCT00482703|EXPERIMENTAL|B|
62611611|NCT06428032|EXPERIMENTAL|Single period|Subjects will receive 65 hours of HABIT-ILE performed in one intervention period as camp format for 6,5-hours/day, 5 days/week for two weeks
62611612|NCT04492917|EXPERIMENTAL|Cranial Technique CV4|"All subjects received a combination of the active technique (CV4) and the corresponding sham technique (shamCV4).~CV4: the lateral angles of the occipital squama are manually approximated slightly exaggerating the posterior convexity of the occiput and taking the cranium into sustained extension. The technique ended when the osteopath perceived the still point, a condition in which the balanced membranous or ligamentous tension is achieved.~ShamCV4: sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch"
62611613|NCT04492917|ACTIVE_COMPARATOR|Sacral Technique ST|"All subjects received a combination of the active technique (ST) and the corresponding sham technique (sST).~ST: The subject was lying in the supine position, while the osteopath positioned the index and middle fingers of the caudal hand on either side of the subject's sacrum. Then establishes a point of balance between the coccyx and the vertex facilitating the sacral extension until the achievement of the still point.~ShamST: sham intervention was performed by placing the hands in the same position of the corresponding active technique, applying a light touch"
62611614|NCT00985426|EXPERIMENTAL|HEPLISAV-B|0.5 mL HEPLISAV-B and 0.5 mL Placebo
62834964|NCT02224560|PLACEBO_COMPARATOR|Placebo|Participants received placebo (0 mg/mL CBD) volume matched to 1 of the 2 dose levels (10 or 20 mg/kg/day) administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 7 to 11 days according to the matched IMP group (7 or 11 days for the 10 or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
62834965|NCT02051413|OTHER|Venlafaxine extended release|Venlafaxine extended-release, flexible dose
62253179|NCT05038254|ACTIVE_COMPARATOR|Arm I (standard of care)|Patients receive standard of care consisting of oncology care provided via telemedicine.
62253180|NCT05038254|EXPERIMENTAL|Arm II (standard of care, remote monitoring)|Patients receive standard of care consisting of oncology care provided via telemedicine. Patients also undergo remote monitoring.
62253181|NCT05038254|EXPERIMENTAL|Arm III (standard of care, remote monitoring, biometrics)|Patient receive standard of care consisting of oncology care provided via telemedicine. Patients also undergo remote monitoring and biometric monitoring.
62253182|NCT06432829|ACTIVE_COMPARATOR|UP in online group format|The participants assigned to this condition will receive the UP in group format through 8 sessions of 2 hours duration, once a week, in online format through the Google Meet platform. Participants will receive a brief manual with the important contents of each session, the exercises to be performed and the corresponding records.
62442265|NCT04340232|EXPERIMENTAL|Baricitinib Arm|This study is an Adaptive Phase 2/3 trial designed to test the safety (Phase 2) and efficacy (Phase 2 and 3) of baricitinib to treat COVID-19. Phase 2 consists of a single-arm, open-label assignment of 20 participants receiving 2 mg baricitinib once daily for 14 days. Phase 3 consists of a single-arm, open-label assignment of 60 additional participants receiving baricitinib at the same dose. In both phases, participants will be monitored daily while hospitalized for 29 days, or until discharge, whichever occurs first. Participants who are discharged will be followed up with via phone on Day 15 and Day 29.
62442266|NCT02492958|EXPERIMENTAL|SA4Ag|Staphylococcus aureus 4-antigen vaccine
62442267|NCT02492958|PLACEBO_COMPARATOR|Placebo|a lyophile match to the vaccine, consisting of excipients of SA4Ag formulation minus the active ingredients
62442268|NCT06524791||immunocompetent|immunocompetent patients with digestive symptoms (n=150)
62442269|NCT06524791||immunocompromised|immunocompromised patients with digestive symptoms (n=150)
62442270|NCT02875171||Anthracycline therapy|Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
62442271|NCT06546878|EXPERIMENTAL|Intervention Group|
62442272|NCT04178915||Patients with severe bacterial infections|
62611615|NCT00985426|ACTIVE_COMPARATOR|Engerix-B|2.0 mL Engerix-B
62834966|NCT00531661|ACTIVE_COMPARATOR|TREATMENT Group|Standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System
62834967|NCT00531661|PLACEBO_COMPARATOR|CONTROL Group|Standard of care HF management
62253183|NCT06432829|EXPERIMENTAL|UP in blended format (UP online group + UP App)|Participants assigned to this condition will receive the PU in a blended group format (4 online group sessions, of two hours duration in modules 1,4,6 and 7 of the PU + autonomous work through the UP-APP). Thus, participants will receive a combined intervention format, working some contents in online group sessions and others through the PU-APP.
62253184|NCT00795249|EXPERIMENTAL|smoker|Individuals who have a habit of chronic smoking without any coronary risk factors
62253185|NCT00795249|NO_INTERVENTION|non-smoker|the age-matched healthy volunteers
62442273|NCT02363010|ACTIVE_COMPARATOR|Standard Behavior Therapy for Weight Loss|Eighteen months of standard, group-based behavioral treatment for weight loss and weight loss maintenance.
62442274|NCT02363010|EXPERIMENTAL|Behavior Therapy for Weight Loss with PA emphasis|Six months of standard, group-based behavioral treatment for weight loss and weight loss maintenance, followed by 12 months of standard, group-based behavioral treatment for weight loss and weight loss maintenance with a larger emphasis on physical activity goals.
62834968|NCT01247662||ASD group|
62834969|NCT01247662||ADHD group|
62834970|NCT01247662||Normally developing control group|
62834971|NCT04230031|EXPERIMENTAL|1: Daratumumab|Pre-ASCT and Post-ASCT: Daratumumab
62834972|NCT03548948|OTHER|High heme iron diet|
62834973|NCT03548948|OTHER|Low iron diet|
62834974|NCT03548948|OTHER|Plant-based high non-heme iron diet|
62834975|NCT02168244|ACTIVE_COMPARATOR|Ice pack|Pre-treatment with ice - Ice applied to the skin 2-3 minutes before injecting biologic drug injection
62834976|NCT02168244|ACTIVE_COMPARATOR|Heating Pack|Pre-treatment with heat - Heat applied to the skin 2-3 minutes before injecting biologic drug injection
62834977|NCT02168244|NO_INTERVENTION|No treatment before injection|No treatment applied to the skin 2-3 minutes before injecting biologic drug injection
62442275|NCT02363010|EXPERIMENTAL|Acceptance-based Behavior Therapy with PA emphasis|Six months of standard, group-based behavioral treatment for weight loss and weight loss maintenance, followed by 12 months of group-based behavior therapy with acceptance-based strategies, and a larger emphasis on physical activity goals.
62442276|NCT04799210|EXPERIMENTAL|Human Factors Actual Use|Confirm device use safety and effectiveness of the Eximis CS (Contained Segmentation) System in actual use
62611616|NCT05952713||SSRI|"Group 1: Selective serotonin reuptake inhibitors (reference: sertraline)~Comparisons of the following with sertraline:~Citalopram, Fluoxetine, Paroxetine, Escitalopram"
62611617|NCT05952713||NARI|Group 2: Noradrenaline reuptake inhibitors (reference: sertraline) Comparisons of the following with sertraline: Reboxetine
62052092|NCT02243280|EXPERIMENTAL|Arm H|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
62052093|NCT02243280|EXPERIMENTAL|Arm I|ABT-493 300 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 4-, 5-, and 6-infected participants without cirrhosis
62052094|NCT02243280|EXPERIMENTAL|Arm J|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 4-, 5-, and 6-infected participants without cirrhosis (never opened - Sponsor decision)
62253186|NCT05445284|EXPERIMENTAL|Group education sessions for parents plus usual diabetes care|"≥3 in-person/virtual one-hour group education sessions for parents plus usual diabetes care, every 3 months for 12 months and ≥3 check-in virtual 15-20 minute sessions in-between the group sessions. Each group session (3-8 parents per group) will be facilitated by a diabetes social worker and will consist of parent-driven discussions on topics relevant to adolescence and transition care. Each one-hour session will commence with an ice-breaker activity and then move to a parent-driven, facilitator-mediated discussion. The group session content will be guided by the needs of the participants; however, the facilitator will actively promote discussion on adolescent- and transition-related topics. The group discussion will end with participants setting goals for their next session."
62253187|NCT05445284|OTHER|Usual diabetes care|Usual diabetes care, every 3 months for 12 months, which consists of visits with their diabetes care physician. In addition, as per usual care, individual sessions and meetings related to transition care with the diabetes social worker will be provided to parents, as needed.
62253188|NCT00312221|ACTIVE_COMPARATOR|BTDS 5|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
62052095|NCT02243280|EXPERIMENTAL|Arm K|ABT-493 300 mg once daily (QD) + ABT-530 120 mg QD for 8 weeks in HCV genotype 1- infected participants without cirrhosis
62052096|NCT04810117||COVID-19 PCR positive patients who are not yet vaccinated|Patients test positive with PCR and recovered from COVID-19
62442277|NCT04038970|EXPERIMENTAL|KN019 5mg/kg|Intravenous (IV) solution, 5 mg/kg, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months
62611618|NCT05952713||SNRI|Group 3: Serotonin and noradrenaline reuptake inhibitors (reference: venlafaxine) Comparisons of Duloxetine with venlafaxine
62834978|NCT01717027|EXPERIMENTAL|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62442278|NCT04038970|EXPERIMENTAL|KN019 10mg/kg|Intravenous (IV) solution, 10 mg/kg, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months
62442279|NCT04038970|PLACEBO_COMPARATOR|Placebo|Intravenous (IV) solution, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months
62442280|NCT01125995|ACTIVE_COMPARATOR|late CCRT|radiotherapy start on day one of the third cycle of chemotherapy
62442281|NCT01125995|EXPERIMENTAL|Early CCRT|Radiotherapy start on day 1 of 1st cycle of chemotherapy
62442282|NCT05107284|PLACEBO_COMPARATOR|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Any follow-up emails sent to them later contain only a reminder to participate in follow-up surveys.
62442283|NCT05107284|EXPERIMENTAL|Intervention plus delayed feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive a series of feedback booster emails. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
62442284|NCT01957683|EXPERIMENTAL|Single Arm|
62442285|NCT03027336|EXPERIMENTAL|coleosoma|coleosoma 500mg tablet daily
62442286|NCT03027336|PLACEBO_COMPARATOR|placebo|placebo tablets
62834979|NCT01717027|EXPERIMENTAL|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62834980|NCT01717027|EXPERIMENTAL|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62611619|NCT05952713||ARI|Group 4: Adrenergic receptor inhibitors (reference: Mirtazapine) Comparisons of Mianserin with Mirtazapine
62834981|NCT01717027|EXPERIMENTAL|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62834982|NCT00616759|ACTIVE_COMPARATOR|1|ECT as usual
62834983|NCT00616759|EXPERIMENTAL|2|ECT-induced seizures terminated with propofol
62052097|NCT04810117||COVID-19 patients with obvious symptoms who are not yet vaccinated|COVID-19 patients with obvious symptoms but PCR test was not conducted for them
62052098|NCT04810117||COVID-19 suspected patients with no symptoms who are not yet vaccinated|COVID-19 suspected patients with no symptoms but came in obvious contact with infected environmental/biological samples
62253189|NCT00312221|EXPERIMENTAL|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
62253190|NCT00312221|EXPERIMENTAL|Oxycodone Immediate-Release (Oxy IR) 40 mg|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
62442287|NCT01717456|ACTIVE_COMPARATOR|Educational-Medical-Behavioral|Educational-Medical-Behavioral intervention includes education, fiber supplements \[Metamucil 1-4 packets (3.4-13.6 g)/day\], laxatives or anti-diarrheals \[Miralax 1-2 packets (17-34 g)/day or Imodium 0.5-2 tablets (1-4 mg)/day\], pelvic floor muscle exercises \[100 10-second squeezes/day\], tips on how to prevent fecal incontinence, daily diary, and protective pads or garments \[as needed\].
62442288|NCT01717456|PLACEBO_COMPARATOR|Standard Care|Standard care includes fiber supplements 1-4 packets (3.4-13.6 g)/day\], daily diary, and protective pads or garments \[as needed\].
62442289|NCT03905291|EXPERIMENTAL|MT921 60mg Group|MT921 60 mg
62442290|NCT03905291|EXPERIMENTAL|MT921 120mg Group|MT921 120 mg
62442291|NCT03905291|EXPERIMENTAL|MT921 150mg Group|MT921 150 mg
62442292|NCT03905291|PLACEBO_COMPARATOR|Placebo Group|Placebo
62442293|NCT05170828|OTHER|Regmin A (RIC)|Pre-transplant conditioning treatment with Fludarabine, Cyclophosphamide, and Total Body Irradiation (TBI)
62611620|NCT05952713||Other drugs|Group 5: Other drugs (reference: sertraline) Comparisons of Vortioxetine and Agomelatine with sertraline
62611621|NCT05952713||TCA|"Group 6: Tricyclic antidepressants (reference: amitriptyline)~Comparisons of Nortriptyline, Imipramine, Clomipramine and Dosulepin with amitriptyline"
62253191|NCT03715842|EXPERIMENTAL|Tub shaped design|The tub-shaped preparation design this consists of an occlusal proximal reduction featuring a 3.5-4 mm width bucco-lingually, 3-3.5mm depth occluso-gingivally and 7-7.5 mm length mesio distally for molars and 2.3-2.8mm width buccolingually, 3-3.5 mm depth occluso gingivally and 3.5-4mm length mesiodistally for premolars. when necessary, superficial extensions may also be made on the preparations so that the occlusal fossa included in the preparation area and then the susceptibility for plaque accumulation will be diminished.
62253192|NCT03715842|ACTIVE_COMPARATOR|Inlay shaped design|The occlusal inlay had a preparation depth that allowed a thickness of 2.0 mm for the ceramic. The occlusal preparation was 4 mm wide and extended 4 or 6 mm mesio-distally for the premolar or molar models, respectively. The proximal box was 1 mm wide and had approximately 5˚ divergence, extending 2 mm apical to the isthmus floor . The preparations corresponded to a proximal connector area of 3 mm × 3 mm for molars and premolars.
62253193|NCT03555513||living kidney transplanted patients|Any patients over 18 who received kidney transplantation from living donor
62611622|NCT06290804|OTHER|Children aged 60-72 months-before|"As a data collection tool, two separate questionnaires were prepared for parents and children by utilizing the literature. The questionnaire form prepared for children consists of 3 parts. The first part includes some variables thought to be related to climate change and sustainability, the second part includes the questions '' Environmental Sustainability Scale for 60-72 Month-old Children and the third part includes questions about health effects of climate change.~The questionnaire form prepared before the intervention will be applied to children who agree to participate in the study."
62611623|NCT06290804|OTHER|Children aged 60-72 months-after|In the intervention phase, the effectiveness of the training program and training videos to be applied to children will be evaluated in terms of sustainable behaviors towards the environment and awareness of the health effects of climate change in 60-72 month old children.
62834984|NCT03992248|EXPERIMENTAL|Time Restricted Feeding|Participants are instructed to eat within a limited time frame during the day. They are also instructed to keep record of their eating and sleeping record with eat- and sleep diaries.
62834985|NCT03992248|OTHER|Control|Participants are instructed to spread their habitual food intake over at least 14hrs per day. They are also instructed to keep record of their eating and sleeping record with eat- and sleep diaries.
62253194|NCT00908024|EXPERIMENTAL|BMS-754807 + cetuximab|Combination
62253195|NCT01672567|EXPERIMENTAL|Egg supplementation|Daily consumption of 2 eggs for breakfast for 6 weeks
62834986|NCT03708276|EXPERIMENTAL|My MS Toolkit|20 Participants asked to use My MS Toolkit.
62834987|NCT03537521||DOA|N= 130 patients treated with direct oral anticoagulants (DOAC) with acute bleeding N= 65 patients treated with direct oral anticoagulants (DOAC) with urgent surgical intervention
62834988|NCT03537521||VKA|N= 130 patients treated with vitamin K antagonists (VKA) with acute bleeding N= 65 patients treated with vitamin K antagonists (VKA) with urgent surgical intervention
62834989|NCT01658319|EXPERIMENTAL|Treatment (chemotherapy)|Patients receive fludarabine phosphate IV over 30 minutes on days 1-5 and methoxyamine IV over 1 hour on day 1 (day 2 of course 1). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62253196|NCT01672567|EXPERIMENTAL|Egg substitute|Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
62253197|NCT01672567|EXPERIMENTAL|Control diet|Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
62834990|NCT01523756|EXPERIMENTAL|test product 1 first|"own product (baseline) - test product 1 - test product 2~test product 1 = New ostomy base plate. Due to company confidentiality the product is just called test product 1"
62253198|NCT04993235||Sotos Syndrome|Children and adolescents with Sotos Syndrome
62834991|NCT01523756|EXPERIMENTAL|test product 2 first|"own product (baseline) - test product 2 - test product 1~test product 2 = New ostomy base plate. Due to company confidentiality the product is just called test product 2"
62834992|NCT06229275|EXPERIMENTAL|Pap smear collection using the Personal Pap Smear (PPS) Device|
62834993|NCT06229275|ACTIVE_COMPARATOR|Pap smear collection using the Rovers Cervex-Brush|
62834994|NCT00530972|EXPERIMENTAL|Peginterferon alfa-2a plus ribavirin|
62834995|NCT01690156||Parallel Probe Position|Performing the simulated interscalene block with the ultrasound probe parallel to the shoulders of the person performing the block
62834996|NCT01690156||Perpendicular Probe Position|Performing the simulated interscalene block with the ultrasound probe perpendicular to the shoulders of the person performing the block
62834997|NCT06654388||Survive|
62834998|NCT06654388||Death|
62834999|NCT01876017|OTHER|BMMNC|Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
62835000|NCT02130843||MALE PATIENTS BEFORE UDS|MALE PATIENTS BEFORE UDS WITH DIFFICULT CATHETERIZATION
62052099|NCT04810117||COVID-19 PCR positive patients who are vaccinated|COVID-19 suspected patients who have got either one or two doses of vaccine
62052100|NCT04810117||Healthy Individuals who are vaccinated|Control group
62835001|NCT05824819|ACTIVE_COMPARATOR|Endometriosis|Women subjected to laparoscopy due to endometriosis. Before the procedure: collection of a stool sample for NGS testing (2 ml); During the procedure: collection of fluid/ washings from the peritoneal cavity (2 ml) and fluid from the endometrial cyst (2 ml), and collection of endometrial tissue by aspiration biopsy of the uterine cavity (1 ml) for NGS examination.
62052101|NCT04810117||Healthy Individuals who are not vaccinated|Control group
62835002|NCT05824819|ACTIVE_COMPARATOR|Idiopathic infertility|Women subjected to laparoscopy due to idiopathic infertility. Before the procedure: collection of a stool sample for NGS testing (2 ml); During the procedure: collection of fluid/ washings from the peritoneal cavity (2 ml) and collection of endometrial tissue by aspiration biopsy of the uterine cavity (1 ml) for NGS examination.
62052102|NCT05766917|NO_INTERVENTION|control group|this group will receive the routine hospital care provided in burn center
62835003|NCT02416206|EXPERIMENTAL|BeEAM|Bendaumustine, Etoposide, Cytrabine and Melphalan in autologous transplant for multiple myeloma
62052103|NCT05766917|EXPERIMENTAL|peer education group|this group will receive the routine hospital care, in addition to the proposed peer education by trained peer.
62052104|NCT06006988|EXPERIMENTAL|trunk disorder scale|It is a 17-parameter scale developed for the evaluation of trunk control. Existing sections in the scale; static sitting balance (GBÖ Static), dynamic sitting balance (GBÖ Dynamic) and coordination (GBÖ Coordination). The total score is a minimum of 0 and a maximum of 23 points and it is accepted that the higher score shows better performance.
62052105|NCT04028349|EXPERIMENTAL|Single Arm|Ad26.ZEBOV/ MVA-BN-Filo Vaccines
62052106|NCT00580814|EXPERIMENTAL|methylphenidate|intervention is methylphenidate once daily for 12 months, doses individually titrated
62052107|NCT00580814|NO_INTERVENTION|No medication|no methylphenidate treatment for non ADHD
62253199|NCT04993235||Beckwith-Wiedemann Syndrome|Children and adolescents with Beckwith-Wiedemann Syndrome
62835004|NCT01837121|OTHER|the SMS group|the diabetic retinopathy patient in the SMS group will receive a SMS reminder message about the revisit time,address 1 week and 3 day before the appointment.
62835005|NCT01837121|NO_INTERVENTION|the control group|the diabetic retinopathy patient in the control group won't get any reminder message before the appointment.
62052108|NCT01925664|EXPERIMENTAL|Doula|Mothers received doula home visiting services in addition to normal prenatal and obstetric clinical care and had access to social work case management.
62052109|NCT01925664|NO_INTERVENTION|Usual Care|Mothers received normal prenatal and obstetric clinical care and had access to social work case management.
62052110|NCT03627884|ACTIVE_COMPARATOR|Normal Saline Catheter Lock Solution Group|Patients receiving normal saline catheter locking solution
62253200|NCT04993235||Control group|Adolescents with typical development
62253201|NCT00659620|EXPERIMENTAL|1|transplantation of mesenchymal stem cell
62253202|NCT02289170|EXPERIMENTAL|Heating and cooling combination therapy|The patients in this group received heating and cooling combination therapy by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. Doctor press 8 acupuncture points which is treated in LBP patients and select the most painful 2 acupuncture points. Device's probe is attached to the acupuncture points in 15 minutes. Probe's temperature is changed 5 cycles from maximum 45℃ to minimum 15℃.
62052111|NCT03627884|ACTIVE_COMPARATOR|Sodium Bicarbonate Catheter Lock Solution|Patients receiving sodium bicarbonate catheter locking solution
62052112|NCT05810246|EXPERIMENTAL|Diagnostic imaging arm|68Ga-NY104 PET/CT Contrast-enhanced MRI of the brain and contrast-enhanced CT of abdomen and pelvis 68Ga-NODAGA-LM3 PET/CT (exploratory)
62052113|NCT05842902|EXPERIMENTAL|mPRISM|The Experimental (mPRISM) arm will receive mPRISM upon completion of their baseline study surveys.
62052114|NCT05842902|OTHER|Waitlist control|Usual Care (UC) available to both study arms consists of standard non-directed supportive care provided for all patients including an assigned social worker throughout cancer treatment. In a waitlist design, the UC arm will receive mPRISM upon completion of 3-month follow-up surveys.
62052115|NCT03912454|EXPERIMENTAL|BMAC Injection|
62052116|NCT00700726||A.|participants with atopic and non-atopic asthma
62052117|NCT02317926|ACTIVE_COMPARATOR|Levothyroxine Plus Liothyronine Group|Levothyroxine Plus Liothyronine Group
62052118|NCT02317926|ACTIVE_COMPARATOR|Levothyroxine Group|Levothyroxine Group
62052119|NCT02317926|ACTIVE_COMPARATOR|Desiccated Thyroid Extract Group|Desiccated Thyroid Extract Group
62052120|NCT02272725|PLACEBO_COMPARATOR|Placebo|tasteless and inert tablets
62052121|NCT02272725|ACTIVE_COMPARATOR|Ibuprofen|Each tablet containing 400mg of ibuprofen
62052122|NCT01738620|EXPERIMENTAL|psychological counseling+prevention of sleep disorders in ICU|patients will receive both psychological counseling and interventions to prevent sleep disorders during their ICU stay
62052123|NCT01738620|EXPERIMENTAL|psychological counseling|patients will receive psychological counseling
62253203|NCT02289170|SHAM_COMPARATOR|Sham heating and cooling therapy|The patients in this group received sham heating and cooling combination therapy in same conditions of treatment group except the temperature. Before the treatment begin, caregiver measure the patient's skin temperature. Then probe's temperature is changed 5 cycles from 1℃ over the skin temperature to 1℃ under the skin temperature.
62253204|NCT01129921|ACTIVE_COMPARATOR|Decompression with mild® Device Kit|Fluoroscopically guided percutaneous lumbar decompression using the Vertos mild® Device Kit for bone and tissue removal to decompress the targeted stenosed level(s).
62253205|NCT01129921|SHAM_COMPARATOR|Sham lumbar decompression|Sham procedure of fluoroscopically guided percutaneous placement of mild® Device Kit instrumentation with no removal of bone or tissue.
62253206|NCT03071614|ACTIVE_COMPARATOR|News with Spin|News items reporting results of animal studies with spin.
62052124|NCT01738620|EXPERIMENTAL|prevention of sleep disorders in ICU|interventions to prevent sleep disorders during their ICU stay
62611624|NCT00718484|EXPERIMENTAL|A|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
62611625|NCT00718484|ACTIVE_COMPARATOR|B|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
62611626|NCT06055920|ACTIVE_COMPARATOR|FlowTriever|Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
62611627|NCT06055920|ACTIVE_COMPARATOR|Anticoagulation|"Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.~Anticoagulants are a group of medications that decrease your blood's ability to clot."
62611628|NCT03140956|EXPERIMENTAL|Levodopa formulation D|Levodopa formulation D
62835006|NCT04126941||Teriparatide|Patients with hypoparathyroidism treated by teriparatide
62835007|NCT00956319|EXPERIMENTAL|Zolpidem group|
62835008|NCT00956319|ACTIVE_COMPARATOR|Estazolam group|
62611629|NCT03140956|EXPERIMENTAL|Levodopa formulation E|Levodopa formulation E
62835009|NCT01935778|ACTIVE_COMPARATOR|capecitabine and oxaliplatin|Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1
62253207|NCT03071614|EXPERIMENTAL|News without spin|News items reporting results of animal studies without spin.
62253208|NCT03072784|ACTIVE_COMPARATOR|group S|short time \<90 m aortic cross clamping
62253209|NCT03072784|ACTIVE_COMPARATOR|group L|\> 90 minutes aortic cross clamping
62253210|NCT03360097|NO_INTERVENTION|Fresh ET|The best available embryo is at expansion grade \<4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and transferred regardless of expansion grade. Arrested blastocysts are discarded.
62442294|NCT05170828|OTHER|Regimen B (FIC)|Pre-transplant conditioning treatment with Busulfan and Cyclophosphamide OR Fludarabine
62835010|NCT01935778|EXPERIMENTAL|Docetaxel and capecitabine and oxaliplatin|"* Docetaxel 60 mg/m² will be intravenously infused over at least 1 hour on Day 1 every 3 weeks.~* Oxaliplatin 100 mg/m² will be intravenously infused over at least 2 hours on Day 1 every 3 weeks.~* Capecitabine 800 mg/m² will be orally administered twice daily from Day 1 evening to Day 15 morning every 3 weeks. (Total 1,600 mg/m² daily)"
62052125|NCT01738620|NO_INTERVENTION|standard care|patients will receive standard care
62052126|NCT00692094|EXPERIMENTAL|1|Subjects will be given 0.5 mg at a time when melatonin should delay the timing of their body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
62052127|NCT00692094|EXPERIMENTAL|2|Subjects will be given 0.5 mg at a time when melatonin should advance the timing of their body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
62442295|NCT05170828|OTHER|Regimen C (FIC)|Pre-transplant conditioning treatment with Cyclophosphamide and Total Body Irradiation (TBI)
62442296|NCT04512768|ACTIVE_COMPARATOR|Standard ICBT|Participants in the Standard ICBT condition will receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia.
62442297|NCT04512768|EXPERIMENTAL|Sleep-Enhanced ICBT|Participants in the Sleep-Enhanced ICBT condition will receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia. In addition, participants in the Sleep-Enhanced ICBT condition will also receive a newly developed lesson designed to target insomnia.
62442298|NCT03128593|EXPERIMENTAL|Experimental: JR-141|
62442299|NCT02114931|EXPERIMENTAL|ABP 501|Participants received ABP 501 40 mg subcutaneously (SC) every other week for up to 18 months.
62442300|NCT04104646|EXPERIMENTAL|CHF6563|Sublingual dose of CHF6563 and the corresponding oral dose of morphine matched placebo
62442301|NCT04104646|ACTIVE_COMPARATOR|Morphine|Oral dose of morphine and the corresponding sublingual dose of CHF6563 matched placebo.
62835011|NCT01326949|ACTIVE_COMPARATOR|ET+NSBB|"Endoscopic treatment(ET)- Endoscopic variceal ligation (EVL)~Non-selective beta blocker(NSBB)-Propranolol.~Anticoagulation(AT)- Heparin followed by warfarin."
62835012|NCT01326949|ACTIVE_COMPARATOR|TIPS|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS.
62442302|NCT04919928|EXPERIMENTAL|Bimodal solution with cochlear implant and hearing aid (CI+HA)|"This Arm will serve as the intervention group. Patients referred for evaluation of cochlear implant candidacy at Odense University Hospital will be screened for eligibility in this study and invited to participate. All patients receive new replacement HAs that can later be fitted with the CI in a bimodal solution. The patients will use the new replacement HAs for one month and are then randomized to either the intervention group with CI+HA or to the control group with continuous use of HA+HA (bilateral) for another two months. Patients randomized to the intervention group CI+HA will undergo surgery as soon as possible after randomization.~Patients with the bimodal solution CI+HA will undergo follow-up one, three, six and twelve months after CI fitting."
62611630|NCT03140956|EXPERIMENTAL|Levodopa formulation F|Levodopa formulation F
62611631|NCT03140956|ACTIVE_COMPARATOR|Sinemet IR 100/25mg|Sinemet IR 100/25MG
62611632|NCT03140956|ACTIVE_COMPARATOR|Sinemet CR 100/25mg|Sinemet IR 100/25MG
62611633|NCT03140956|EXPERIMENTAL|ODM-104 100mg|ODM-104 100MG
62611634|NCT03140956|ACTIVE_COMPARATOR|Carbidopa 20mg|Carbidopa 20MG
62611635|NCT03140956|ACTIVE_COMPARATOR|Carbidopa 65mg|Carbidopa 65MG
62611636|NCT05277350|ACTIVE_COMPARATOR|Cohort 1|6 participants on SNIPR001 (Dose 1 BID for 7 days) and 2 participants on placebo
62611637|NCT05277350|ACTIVE_COMPARATOR|Cohort 2|6 participants on SNIPR001 (Dose 2 BID for 7 days) and 2 participants on placebo
62611638|NCT05277350|ACTIVE_COMPARATOR|Cohort 3|12 participants on SNIPR001 (Dose 3 BID for 7 days) and 8 participants on placebo
62611639|NCT06059157|EXPERIMENTAL|Single Arm|Single Arm
62052128|NCT00692094|EXPERIMENTAL|3|Subjects will be given a larger dose (up to 10 mg) at a time when the melatonin should advance the timing of the body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
62835013|NCT01318460|ACTIVE_COMPARATOR|Levosimendan|Patients treated with prophylactic administration of levosimendan
62052129|NCT00692094|EXPERIMENTAL|4|Subjects will be given a larger dose (up to 20 mg) at a time when the melatonin should advance the timing of the body clock. If the subject successfully responds to the treatment, the dose will be reduced gradually until the lowest effective dose is determined (down to 0.025 mg). If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
62052130|NCT05535049|NO_INTERVENTION|Periodontally healthy group|24 participants were included in this group.
62052131|NCT05535049|ACTIVE_COMPARATOR|Periodontitis group|24 participants were included in this group.
62052132|NCT01146314|EXPERIMENTAL|Lifestyle intervention|A 6-month 14 session lifestyle intervention led by a psychologist and a dietitian for 90 minutes group sessions. Intervention sessions were help weekly, biweekly, and monthly over the course of 6 months.
62052133|NCT03808779|EXPERIMENTAL|Radiofrequency Ablation|Eligible participants with PTMC will be randomly assigned to this group and undergo radiofrequency ablation(RFA) procedure.
62611640|NCT04136275|EXPERIMENTAL|CAR-37 T cells|"* CAR-37 will be administered intravenously on day 0~* Enrolled subjects will undergo a leukapheresis procedure processing approximately two times the subject's total blood volume.~* Subjects will receive 3 days of lymphodepleting chemotherapy starting Day -5, before the infusion of CAR-37 T cells on Day 0"
62052134|NCT03808779|ACTIVE_COMPARATOR|Conventional Surgery|Eligible participants with PTMC will be randomly assigned to this group and undergo total/thyroid lobectomy procedure.
62052135|NCT03178279|EXPERIMENTAL|Use of the Physical Health Plan|Use of the Physical Health Plan
62052136|NCT02533869|EXPERIMENTAL|Low-dose CT for acute appendicitis|Low-dose computed tomography for diagnosing acute uncomplicated appendicitis Laparoscopic appendectomy
62052137|NCT02386657||Emergency admitted sickle cell disease patients|Sickle Cell Disease Patients admitted inside the Emergency Department of the Brugmann Hospital for a vaso-occlusive crisis.
62052138|NCT02855307|ACTIVE_COMPARATOR|Unannounced exercise|The target blood glucose of the algorithm will be as usual. A pre-meal full insulin bolus will be given.
62052139|NCT02855307|ACTIVE_COMPARATOR|Announced exercise with pre-meal full bolus|The target blood glucose of the algorithm will be increased and a pre-meal full bolus will be given
62052140|NCT02855307|ACTIVE_COMPARATOR|Announced exercise with reduced insulin bolus|The target blood glucose of the algorithm will be increased and the pre-meal insulin bolus will be reduced by 33%.
62253211|NCT03360097|EXPERIMENTAL|Frozen Embryo Transfer|The best available embryo is at expansion grade \<4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and vitrified regardless of expansion grade. Arrested blastocysts are discarded. The single best available embryo is transferred under a cryo-synthetic cycle.
62253212|NCT05066321|EXPERIMENTAL|Mindfulness Oriented Recovery Enhancement (MORE) Arm|During hospitalization, participants will receive brief mindfulness training individually in person and complete a series of quantitative baseline questionnaires. Participants will complete 1 MORE session weekly for 8 sessions delivered in small groups of up to 10 people. These sessions will be delivered by a social worker in-person at baseline, and via telehealth after discharge. Follow-up surveys will be conducted at 3-, 6-. 9-, and 12- weeks, and an audio-recorded qualitative exit interview (45-60 minutes) will be completed upon completion of the intervention and the 12-week follow-up survey.
62253213|NCT04057534|EXPERIMENTAL|CB-CRT AUD group|experimental group AUD: patients receive standard clinical therapy and an add-on chess based - cognitive remediation treatment (CB-CRT)
62253214|NCT04057534|ACTIVE_COMPARATOR|Control group AUD|control group: patients with AUD receive standard clinical therapy
62442303|NCT04919928|EXPERIMENTAL|Bilateral new replacement Hearing Aids (HA+HA)|This Arm will serve as the control group. The patients in the control group will use the new replacement HAs for one month like the intervention group and then for another three months, if they complete the study. The control group using the new replacement HAs for three months after randomization, will be offered the bimodal solution with CI to the poorer hearing ear and have the same follow-up period as the intervention group after a total of four months with new replacement HAs.
62442304|NCT02844374|OTHER|Partial Epilepsy Drug Resistant|Patients with partial Epilepsy Drug Resistant , justifying a SEEG exploration.
62442305|NCT01873859|ACTIVE_COMPARATOR|On-metformin|Diabetic patients receiving contrast media without discontinuing metformin.
62442306|NCT01873859|NO_INTERVENTION|Off-metformin|Diabetic patients receiving contrast media with discontinuation of metformin.
62442307|NCT06437132||Participants|Persons with dementia
62611641|NCT04136275|EXPERIMENTAL|CAR-37 T cells Dose Escalation|"* CAR-37 will be administered intravenously on day 0~* Enrolled subjects will undergo a leukapheresis procedure processing approximately two times the subject's total blood volume.~* CAR-37 will undergo dose escalation"
62835014|NCT01318460|PLACEBO_COMPARATOR|Placebo group|Patients managed with placebo administration
62835015|NCT06295484|OTHER|Traditional CPAP, then NIPPV, then high CPAP.|The participant will stay for 2 hours on Traditional CPAP, then 2 hours on NIPPV, then 2 hours on high CPAP. The investigators will continue to record the Edi signals during the 3 methods.
62253215|NCT04057534|EXPERIMENTAL|CB-CRT TUD group|experimental group TUD: patients receive standard smoking cessation therapy and an add-on CB-CRT
62253216|NCT04057534|ACTIVE_COMPARATOR|Control group TUD|control group: patients with TUD receive standard smoking cessation therapy
62253217|NCT00003865|EXPERIMENTAL|Toremifene|All enrolled patients
62253218|NCT02098512|EXPERIMENTAL|Allogeneic Transplant and Immunotherapy|We intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from HLA matched sibling or unrelated adult donor followed by post-AlloSCT Brentuximab Vedotin in patients with poor risk Hodgkin Lymphoma.
62253219|NCT02327052||Chagas disease|The study comprised 58 subjects with Chagas disease, confirmed by two positive serologic tests.
62052141|NCT01922050|EXPERIMENTAL|Part 1: LEO 43204 Formulation 1|Open-Label, Dose-Escalation, Once-Daily, 2-Day Treatment
62052142|NCT01922050|EXPERIMENTAL|Part 1: LEO 43204 Formulation 2|Open-Label, Dose-Escalation, Once-Daily, 2-Day Treatment
62052143|NCT01922050|EXPERIMENTAL|Part 2: LEO 43204 Formulation 1 Dose X|Double-Blind, Once-Daily, 2-Day Treatment
62052144|NCT01922050|EXPERIMENTAL|Part 2: LEO 43204 Formulation 1 Dose Y|Double-Blind, Once-Daily, 2-Day Treatment
62052145|NCT01922050|EXPERIMENTAL|Part 2: LEO 43204 Formulation 2 Dose XX|Double-Blind, Once-Daily, 2-Day Treatment
62052146|NCT01922050|EXPERIMENTAL|Part 2: LEO 43204 Formulation 2 Dose YY|Double-Blind, Once-Daily, 2-Day Treatment
62052147|NCT01922050|PLACEBO_COMPARATOR|Part 2: Placebo Formulation 1|Double-Blind, Once-Daily, 2-Day Treatment
62052148|NCT01922050|PLACEBO_COMPARATOR|Part 2: Placebo Formulation 2|Double-Blind, Once-Daily, 2-Day Treatment
62052149|NCT05795413||PECS Block with Liposomal Bupivacaine|The patients in this cohort will undergo a PECS block with Liposomal Bupivacaine before their mastectomy. Patients will receive Liposomal Bupivacaine in combination with 0.25% Bupivacaine in a 1:1 mixture for the purpose of post-operative pain control.
62052150|NCT05795413||No PECS block|The patients in cohort will not undergo a PECS block. Pain will be controlled in the usual fashion with IV and oral medications.
62052151|NCT05807113|EXPERIMENTAL|Atopi intensive care BNO 3731 for topical use|
62052152|NCT05807113|ACTIVE_COMPARATOR|Benchmark skin care product for topical use|
62052153|NCT05519384|EXPERIMENTAL|JK500 cell injection|"They were divided into three dose groups: 10\^6, 5x10\^6 and 3x10\^7 JK500 cells injection /kg/ time, three times a week, a total of 6 times.~According to the principle of dose escalation, 3 patients were assigned to each dose group. After completing the treatment of 3 patients in each dose group, the Safety Review Committee (SRC) discussed whether to enter the next dose group."
62052154|NCT03357614|EXPERIMENTAL|Sulopenem|Sulopenem 1000 mg IV once daily for a minimum of 5 days, followed by sulopenem-etzadroxil/probenecid 500 mg PO twice daily to complete 7-10 total days of treatment
62052155|NCT03357614|ACTIVE_COMPARATOR|Ertapenem|Ertapenem 1000 mg IV once daily for a minimum of 5 days, followed by ciprofloxacin 500 mg PO twice daily or amoxicillin-clavulanate 500 mg PO twice daily to complete 7-10 total days of treatment
62052156|NCT04646655|ACTIVE_COMPARATOR|Enoxaparin at prophylactic dose|Enoxaparin at prophylactic dose: standard 4.000 IU QD via subcutaneous injection (6000 IU if body weight\>100 kg)
62052157|NCT04646655|EXPERIMENTAL|Enoxaparin at therapeutic dose|"Enoxaparin at therapeutic dose : 70 U/Kg b.i.d. (every 12 h)~In order to easily calculate the correct therapeutic dose of enoxaparin for each patient, a simplified categorization will be applied, as follows:~* weight \< 65 Kg: 4.000 IU b.i.d. (every 12 h)~* weight ≥ 65 Kg: 6.000 IU b.i.d. (every 12 h)~* weight ≥ 100 Kg: 8.000 IU b.i.d. (every 12 h) The most appropriate dose will be evaluated in patients with creatinine clearance between 30 and 50 ml/min"
62052158|NCT02052310|EXPERIMENTAL|Roxadustat|Participants will receive roxadustat tablets, administered orally 3 times weekly (TIW). Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low weight \[≤70 kilograms (kg)\] and high weight \[\>70 to 160 kg\] participants will receive 70 and 100 milligrams \[mg\] roxadustat, respectively). Dose adjustment to achieve correction and subsequent maintenance of target hemoglobin (Hb) values (10-12 grams \[g\]/deciliter \[dL\]) will be based upon regular monitoring of Hb. The maximum roxadustat dose is 3.0 mg/kg per dose or 400 mg per administration (whichever is lower).
62052159|NCT02052310|ACTIVE_COMPARATOR|Epoetin Alfa|Participants on hemodialysis (HD) will receive epoetin alfa, administered intravenously (IV) TIW, with starting doses and dose adjustment rules as per United States Package Insert (USPI) or summary of product characteristics (SmPC). Participants on home HD or peritoneal dialysis (PD) will receive epoetin alfa, administered subcutaneously (SC) as per the country-specific product label (USPI or SmPC) or local standard of care (SOC).
62052160|NCT05362981|EXPERIMENTAL|CAT|induction of cognitive dissonance
62052161|NCT05362981|EXPERIMENTAL|MBCT|TCA-specific mindfulness approach
62052162|NCT05362981|NO_INTERVENTION|TAU|usual support
62835016|NCT06295484|OTHER|Traditional CPAP, then high CPAP, then NIPPV|The participant will stay for 2 hours on Traditional CPAP, then 2 hours on high CPAP, then 2 hours on NIPPV. The investigators will continue to record the Edi signals during the 3 methods.
62835017|NCT06295484|OTHER|NIPPV, then traditional CPAP, then high CPAP|The participant will stay for 2 hours on NIPPV, then 2 hours on traditional CPAP, then 2 hours on high CPAP. The investigators will continue to record the Edi signals during the 3 methods.
62835018|NCT06295484|OTHER|NIPPV, then high CPAP, then traditional CPAP.|The participant will stay for 2 hours on NIPPV, then 2 hours on high CPAP, then 2 hours on traditional CPAP. The investigators will continue to record the Edi signals during the 3 methods.
62835019|NCT06295484|OTHER|High CPAP, then traditional CPAP, then NIPPV.|The participant will stay for 2 hours on High CPAP, then 2 hours on traditional CPAP, then 2 hours on NIPPV. The investigators will continue to record the Edi signals during the 3 methods.
62052163|NCT03309839||neonates with cardiac surgery under cardiopulmonary bypass|
62052164|NCT00656604|EXPERIMENTAL|Women with breast cancer|Patients undergo DCE-MRI and MRS prior to their breast cancer surgery.
62835020|NCT06295484|OTHER|High CPAP, then NIPPV, then traditional CPAP.|The participant will stay for 2 hours on High CPAP, then 2 hours on NIPPV, then 2 hours on traditional CPAP. The investigators will continue to record the Edi signals during the 3 methods.
62835021|NCT01129596||1|
62835022|NCT02751853|EXPERIMENTAL|HFPEF|Patient with heart failure with preserved ejection fraction (HFPEF)
62835023|NCT02751853|EXPERIMENTAL|HFREF|Patient with heart failure with reduced ejection fraction (HFREF)
62835024|NCT02751853|ACTIVE_COMPARATOR|No HFPEF/HFREF|Patient without heart failure with preserved ejection fraction (HFPEF) or heart failure with reduced ejection fraction (HFREF)
62052165|NCT00656604|NO_INTERVENTION|Healthy volunteers|Women without breast cancer undergo DCE-MRI and MRS.
62052166|NCT01287611|ACTIVE_COMPARATOR|Purse string closure technique|Eighty four patients were allocated to the study group. Due to expanded Kerr incisions 4 patients in study group did not receive their allocated intervention. In addition, 29 patients in the study group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 51 study group.
62052167|NCT01287611|ACTIVE_COMPARATOR|Continuously locked closure technique|Eighty four patients were allocated to the control group. Due to expanded Kerr incisions 3 patients in control group did not receive their allocated intervention. In addition, 16 patients in the control group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 65 study group.
62052168|NCT06328530|EXPERIMENTAL|1st pruritogen|"The subproject consists of 2 sessions 3 days apart. Each session consists of 3 parts.~In the first session, 3 test areas (4x4 cm) will be selected on the subject's forearms. In part 1, we will apply cowhage in one area. In part 2, we will apply cowhage in two areas on the same arm. In part 3, we will again apply cowhage in 2 areas, one on each arm. In each part, the itch intensity will be measured using a VAS (visual analog scale) for 10 min from the cowhage application. After removal of the cowhage, alloknesis and mechanically evoked itch will be measured in the area selected in part 1."
62052169|NCT06328530|OTHER|2nd pruritogen|The second session will take place 3 days after the first one and will follow the same procedure as session 1. However, histamine will be applied instead of cowhage. The order of the two sessions will be randomized.
62052170|NCT04813380|ACTIVE_COMPARATOR|Oraltek Sublingual immunotherapy group|one drops under tongue for ten days then three Drops for another ten days then five drops for another ten days for three successive months then five drops every two days per week for two months then five drops one day per week for one months
62052171|NCT04813380|PLACEBO_COMPARATOR|Placebo|one drops under the tongue then three drops then five drops for three successive months then five drops every two days per week for two months then five drops one day per week for one months
62052172|NCT02274454|ACTIVE_COMPARATOR|1.25mM Calcium-NO oxytocin pretreatment|
62052173|NCT02274454|ACTIVE_COMPARATOR|2.5mM Calcium-NO oxytocin pretreatment|
62442308|NCT03760393|EXPERIMENTAL|HAPA-treatment|(SB-related planning + daily text messages)
62442309|NCT03760393|NO_INTERVENTION|Control|(No Treatment) Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaires.
62442310|NCT01934374|EXPERIMENTAL|Stroke|On the 30th day post stroke (D30), the exjperimental group will start to receive the task-oriented lower extremity strengthening training (TOLEST) program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.
62442311|NCT01934374|NO_INTERVENTION|Control|The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity.
62442312|NCT00671879|EXPERIMENTAL|Carisprodol SR 700 mg|Carisoprodol 700 mg twice daily
62442313|NCT00671879|EXPERIMENTAL|Carisoprodol SR 500mg|Carisoprodol SR 500 mg twice daily
62052174|NCT02274454|ACTIVE_COMPARATOR|5.0mM Calcium-NO oxytocin pretreatment|
62052175|NCT02274454|ACTIVE_COMPARATOR|1.25mM Calcium-WITH oxytocin pretreatment|
62052176|NCT02274454|ACTIVE_COMPARATOR|2.5mM Calcium-WITH oxytocin pretreatment|
62052177|NCT02274454|ACTIVE_COMPARATOR|5.0mM Calcium-WITH oxytocin pretreatment|
62052178|NCT04767867|EXPERIMENTAL|Facemask oxygen (FM)|100% oxygen administered via facemask through circle system with adjustable pressure-limiting valve at 0 cmH20. Participant instructed to 'breathe normally'
62442314|NCT00671879|PLACEBO_COMPARATOR|Placebo|Placebo
62442315|NCT04665323||People living with FOP|
62442316|NCT04665323||Parent or legal guardian primary caregivers|
62442317|NCT04665323||Parent or legal guardian|
62442318|NCT04665323||Siblings|
62835025|NCT04198558|EXPERIMENTAL|Dose Level 1|MEDI0618 or placebo
62835026|NCT04198558|EXPERIMENTAL|Dose Level 2|MEDI0618 or placebo
62835027|NCT04198558|EXPERIMENTAL|Dose Level 3|MEDI0618 or placebo
62835028|NCT04198558|EXPERIMENTAL|Dose Level 4|MEDI0618 or placebo
62835029|NCT04198558|EXPERIMENTAL|Dose Level 5|MEDI0618 or placebo
62835030|NCT04198558|EXPERIMENTAL|Dose Level 6|MEDI0618 or placebo
62835031|NCT04198558|EXPERIMENTAL|Dose Level 7|MEDI0618 or placebo
62835032|NCT04198558|EXPERIMENTAL|Dose Level 8|MEDI0618 or placebo
62835033|NCT04198558|EXPERIMENTAL|Dose Level 9|MEDI0618 or placebo
62623578|NCT01404949|EXPERIMENTAL|Tretinoin and Arsenic Trioxide|This is a multicenter, phase II trial to study the efficacy of combined tretinoin and ATO in the treatment of newly diagnosed APL in an effort to reduce or eliminate the amount of standard chemotherapy required for long-term remission.
62835034|NCT01216553|ACTIVE_COMPARATOR|hypertonic inhalation + O2|oxygen for 30 minuets after inhalation of 3% saline 4 times daily
62835035|NCT01216553|ACTIVE_COMPARATOR|Epinephrine & bromhexine nebulized + O2|oxygen for 30 minuets after inhalation of racemic epinephrine with bromhexine 4 times daily
62835036|NCT01352000|ACTIVE_COMPARATOR|Usual Care (UC)|Receive Quitline services
62835037|NCT01352000|ACTIVE_COMPARATOR|Repeated Mailings (RM)|Receive the 8 Forever Free booklets sent by mail at regular intervals over a period of 12 months
62052179|NCT04767867|ACTIVE_COMPARATOR|High-flow nasal oxygen (HFNO)|100% oxygen administered via high-flow nasal cannulae at 50 L/min. Participant instructed to 'keep the mouth closed and breathe normally'
62052180|NCT04767867|ACTIVE_COMPARATOR|High-flow nasal oxygen plus mouthpiece oxygen (HFNO+MP)|100% oxygen administered via high-flow nasal cannulae at 50 L/min. Additionally, 100% oxygen administered via mouthpice through circle system with adjustable pressure-limiting valve at 0 cmH20. Participant instructed to 'keep the mouth closed and breathe normally'.
62442319|NCT02251587|ACTIVE_COMPARATOR|Standard Weight Management Program|Participants will be given information on diet and exercise. Participants will attend meetings to discuss barriers to exercise and nutrition and ways to solve these problems. Participants will be given healthy snack ideas and planning tools.
62442320|NCT02251587|EXPERIMENTAL|$ensible Weigh Program|Participants will be given information on diet and exercise with an emphasis on food security. Participants will be provided with additional information on community resources such as those for food, transportation, and safe places to exercise. A weekly cooking demonstration will be provided using inexpensive ingredients and common food pantry items.
62442321|NCT05045729||OHCA SPORTS|All OHCA, where the patient was engaged in sports at the time of the event
62442322|NCT03069079|EXPERIMENTAL|Non surgical Periodontal therapy|"All children will be offered an oral hygiene and tooth scaling and polishing session. For children affected by periodontal disease, subgingival debridement will also be performed according to needs, with the aim to disrupt the subgingival biofilm responsible for the onset and progression of the periodontal pathology. This can be accompanied, when appropriate, by the use of local anaesthesia and adjunctive antimicrobials (systemic or locally applied subgingivally), according to the clinical presentation and the child's medical conditions. In addition, when required, nitrous oxide sedation (NOS) could be used before treatment.~Caries will be treated as necessary (shared care with the general dental practitioners / community dental services). Children with mucosal lesions requiring treatment will be given a letter for their GDP suggesting referral to a collaborating expert in Oral Medicine (Prof. Stephen Porter)."
62442323|NCT03027570|EXPERIMENTAL|Control|Five-month program at two centers for the treatment of overweight children.
62442324|NCT03027570|EXPERIMENTAL|Exergame activity_EXG|Adding an exergame activity application to the regimen at a center for the treatment of overweight children.
62442325|NCT05092061|EXPERIMENTAL|Moderate-repetition resistance training|The participants will undergo a full-body resistance training protocol with moderate repetitions (6-12), moderate load (70-85% of 1RM), and moderate rest between sets (60-90s). Training will be undertaken three times per week.
62442326|NCT05092061|EXPERIMENTAL|High-repetition resistance training|The participants will undergo a full-body resistance training protocol with high repetitions (15+), low load (\<60% of 1RM), and short rest between sets (30s). Training will be undertaken three times per week.
62442327|NCT04161794|EXPERIMENTAL|Intervention group|2 g EPA/DHA via fish oil daily Regular dietary counselling Twice weekly strength and cardiovascular exercise
62442328|NCT04161794|NO_INTERVENTION|Historical control group|Standard of Care
62442329|NCT04622384||ICU patients|Patients who are treated with dialysis as CRRT and planned to undergo dialysis weaning.
62442330|NCT03336983|OTHER|LHRH-A + Enzalutamide|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide until patient's progression, consent withdrawal or unacceptable toxicity
62442331|NCT03336983|EXPERIMENTAL|LHRH-A + Enzalutamide + Zoledronic Acid|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide + Zoledronic Acid until patient's progression, consent withdrawal or unacceptable toxicity
62442332|NCT03974594|EXPERIMENTAL|Trifluridine and Tipiracil Tablets|
62442333|NCT03974594|ACTIVE_COMPARATOR|TAS-102|
62442334|NCT00384033|EXPERIMENTAL|Desvenlafaxine succinate sustained-release 50 mg|
62442335|NCT00384033|EXPERIMENTAL|Desvenlafaxine succinate sustained-release 100 mg|
62442336|NCT00384033|PLACEBO_COMPARATOR|Placebo|
62442337|NCT00384033|OTHER|Duloxetine 60mg|Active control to assess assay sensitivity
62442338|NCT02669264|EXPERIMENTAL|Part 1: ADCT-402 dose escalation|"Weekly administration - Participants will receive an intravenous (IV) infusion of ADCT-402, on Days 1, 8, and 15 of each 3-week (21-day) cycle.~3-week administration - Participants will receive an IV infusion of ADCT-402, on Day 1 of each 3-week (21-day) cycle.~The dose escalation will be conducted according to a 3+3 design."
62442339|NCT02669264|EXPERIMENTAL|Part 2: ADCT-402 expansion|All participants will be assigned to the recommended dose and/or schedule of ADCT-402 identified in Part 1 by the Dose Escalation Steering Committee
62623579|NCT03923049|OTHER|PET/MRI|Diagnostic testing with simultaneous PET/MRI for cardiac sarcoidosis diagnosis
62835038|NCT01352000|ACTIVE_COMPARATOR|Massed Mailings (MM)|Receive all 8 booklets in a single mailing
62835039|NCT01887457|EXPERIMENTAL|Voriconazole|Standard adult Voriconazole (VFEND) Loading (1 hr infusion): 6mg/kg at 1 hour and 12 hours on day 1. Followed by standard maintenance dose 4mg/kg at 1 hour and 12 hours on day 2 (1 hour infusion). Day 3 follows the same schedule, expect the dose is adjusted, this dose is used on Day 4 and a further dose adjustment is made that is administered as above on Day 5.
62835040|NCT03297112|EXPERIMENTAL|contrast-enhanced subharmonic ultrasound imaging|Patients receive perflutren lipid microspheres IV. After 15 minutes, patients receive perflutren lipid microspheres IV again over 5 minutes and undergo contrast-enhanced subharmonic ultrasound imaging over 60 minutes.
62835041|NCT06519669|EXPERIMENTAL|GT201 treatment group|
62835042|NCT02180100|EXPERIMENTAL|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
62611642|NCT00003178|EXPERIMENTAL|1st Untreated Relapse for AML|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
62052181|NCT04859582|EXPERIMENTAL|Pembrolizumab + FP or CAPOX|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m\^2 IV on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m\^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m\^2 IV on Day 1 Q3W + capecitabine 1000 mg/m\^2 orally twice a day (BID) on Days 1 to 14 Q3W. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).
62835043|NCT02180100|ACTIVE_COMPARATOR|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
62442340|NCT00991770|EXPERIMENTAL|Massage Therapy|Massage therapy provided by a certified Massage Therapist
62442341|NCT00991770|ACTIVE_COMPARATOR|Control|Empathic support conversation
62442342|NCT02456233|ACTIVE_COMPARATOR|Conventional AF Ablation with PVI|These patients will be treated by conventional AF ablation by pulmonary vein isolation (PVI) alone.
62442343|NCT02456233|EXPERIMENTAL|FIRM-guided ablation plus PVI|These patients will be treated by ablation of patient-specific rotors and focal sources (FIRM). Conventional ablation (PVI) will then be performed as part of the standard of care procedure.
62442344|NCT00368537|ACTIVE_COMPARATOR|1|Arm 1: Tigecycline
62442345|NCT00368537|ACTIVE_COMPARATOR|2|Arm 2: Ampicillin-Sulbactam or Amoxicillin-Clavulanate plus or minus a glycopeptide
62442346|NCT00843453|OTHER|1|Comparison of serum vitamin and B12 concentrations of PPI and non-PPI groups
62442347|NCT00843453|EXPERIMENTAL|2|Comparison of baseline and end of treatment serum vitamin B12 and MMA concentrations.
62442348|NCT00701428|ACTIVE_COMPARATOR|1|Hypertensive Men and Women Without OSA on Losartan (n=30)
62442349|NCT00701428|ACTIVE_COMPARATOR|2|Hypertensive Men and Women With OSA on Losartan (n=30)
62442350|NCT00701428|EXPERIMENTAL|3|Hypertensive Men and Women with OSA on Losartan and CPAP (n=30)
62623580|NCT01569698||extrarenal replacement therapy|Intermittent Hemodialysis, Continuous Renal Replacement Therapies, and Peritoneal Dialysis
62623581|NCT00667914|EXPERIMENTAL|Orthogeriatric unit|Geriatric work-up on hip-fracture patients
62442351|NCT03801837|ACTIVE_COMPARATOR|Macadamia Nut Diet|This group will have their habitual diet supplemented with appropriate portion of Macadamia Nuts (15% of daily calories or 30-45 grams based on Kcal requirement of the individual)
62442352|NCT03801837|PLACEBO_COMPARATOR|Control Diet|This group will continue with their Habitual Diet
62442353|NCT01532245|ACTIVE_COMPARATOR|two-lung ventilation (TLV)|During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
62442354|NCT01532245|ACTIVE_COMPARATOR|one lung ventillation (OLV) without PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
62442355|NCT01532245|ACTIVE_COMPARATOR|one lung ventilation (OLV) with PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2Opositive end-expiratory pressure (PEEP) were alternated
62442356|NCT02796196||Supportive care (monitoring device, medical chart review)|Data including demographics, type of HCT (e.g., allogeneic or autologous), preexisting physical conditions (e.g., chronic joint injury), CRF, steroid use data, ECOG and KPS scores are collected from patients' medical charts at time of enrollment. Patients are prescribed participation in a primarily self-directed physical activity program which encourages them to spend 6 hours out of bed daily and to perform 30 minutes of light-to-moderate daily aerobic activity. Patients who are able to maintain independent mobility undergo physical therapist assessment 2 times a week until hospital discharge. Patients wear a physical activity monitoring device and daily activity and sleep data are collected continuously during hospital LOS.
62442357|NCT03929211|EXPERIMENTAL|CPI-613 and hydroxychloroquine|The initial phase of the study will be a dose escalation of hydroxychloroquine from 600 mg to 1,200 mg orally flat dose given 2 hours before the CPI-613 infusion on days 1-5 of every 28 days. CPI-dose will be 2,000 mg/m² and will not be escalated.
62623582|NCT00667914|ACTIVE_COMPARATOR|Orthopedic care as usual|Traditional care in the orthopedic unit
62835044|NCT05969834||uHCG group|Trigger intramuscular (IM) administration of 10000 IU of uHCG
62835045|NCT05969834||rHCG group|Trigger with subcutaneous (SC) administration of 6500 IU of rHCG
62835046|NCT05969834||Dual trigger group|Combined SC administration of 0.1 mg of GnRHa and IM administration of 2500 IU of uHCG
62835047|NCT04016623|EXPERIMENTAL|1-day toric test contact lens|Each subject will wear the 1-day toric test (Test) lens in one eye and 1-day toric control (Control) contact lens in the other eye. Patient will wear as an unmatched pair, per predetermined randomization schedule (to determine which eye receives the Test or Control contact lens).
62835048|NCT04016623|ACTIVE_COMPARATOR|1-day toric control contact lens|Each subject will wear the 1-day toric test (Test) lens in one eye and 1-day toric control (Control) contact lens in the other eye. Patient will wear as an unmatched pair, per predetermined randomization schedule (to determine which eye receives the Test or Control contact lens).
62442358|NCT02668783|EXPERIMENTAL|ENG-E2 125 μg/300 μg|Participants will receive 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
62442359|NCT02668783|PLACEBO_COMPARATOR|Placebo|Participants will receive 4 cycles (or 6 cycles if also participating in the extension) of placebo. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
62442360|NCT01857193|EXPERIMENTAL|L-R-E arm|Participants who took ribociclib (LEE011), everolimus (RAD001) and exemestane triple combination
62442361|NCT01857193|EXPERIMENTAL|L-E arm|Participants who ribociclib (LEE011) and exemestane double combination
62442362|NCT04248855|EXPERIMENTAL|SAD Cohort 1|All enrolled patients will receive one dose of KAN-101 Dose A
62442363|NCT04248855|EXPERIMENTAL|SAD Cohort 2|All enrolled patients will receive one dose of KAN-101 Dose B
62835049|NCT03294252|EXPERIMENTAL|Oxaliplatin|The experimental drugs used in this protocol are Oxaliplatin, 5-Fluorouracil and L-Folinic acid. All are used as part of their marketing authorization, with the exception of Oxaliplatin as regards its mode of administration specific to the PIPAC procedure (injection and nebulisation in intraperitoneal).
62835050|NCT06209307|EXPERIMENTAL|Arm 1: Preoperative and postoperative pelvic floor physical therapy|Pelvic floor physical therapy (PFPT) will be initiated 1 month before surgery in patients randomized to Arm 1.
62835051|NCT06209307|NO_INTERVENTION|Arm 2: Postoperative pelvic floor physical therapy only.|At 1-3 days follow-up after surgery pelvic floor physical therapy (PFPT) will be initiated in the post-operative PFPT-only group as part of standard of care.
62835052|NCT05198596|EXPERIMENTAL|MVC-COV1901|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
62835053|NCT05198596|ACTIVE_COMPARATOR|AZD1222|ChAdOx1 nCoV-19 vaccine
62835054|NCT05326490|EXPERIMENTAL|Test arm|"Double-blinded treatment period:~PB201 100 mg, one tablet in the morning and one tablet in the evening;Basic treatment with stable dose of Glucophage~Open-label extended period:~PB201 100 mg, one tablet in the morning and one tablet in the evening;Basic treatment with stable dose of Glucophage"
62835055|NCT05326490|PLACEBO_COMPARATOR|Placebo arm|"Double-blinded treatment period:~PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;Basic treatment with stable dose of Glucophage~Open-label extended period:~PB201 100 mg, one tablet in the morning and one tablet in the evening;Basic treatment with stable dose of Glucophage"
62835056|NCT04852926||A prospective cohort of patients|Female patients treated for non-metastatic breast cancer and followed up in the Observatory of fertility at Jeanne de Flandre Hospital
62442364|NCT04248855|EXPERIMENTAL|SAD Cohort 3|All enrolled patients will receive one dose of KAN-101 Dose C
62442365|NCT04248855|EXPERIMENTAL|SAD Cohort 4|All enrolled patients will receive one dose of KAN-101 Dose D
62835057|NCT00933452|EXPERIMENTAL|low dose group|single oral administer 15mg duloxetine
62611643|NCT00003178|EXPERIMENTAL|Primary Refractory AML|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
62611644|NCT00003178|EXPERIMENTAL|MDS|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
62611645|NCT00701844|EXPERIMENTAL|Experimental Writing Type 1|
62611646|NCT00701844|EXPERIMENTAL|Experimental Writing type 2|
62611647|NCT00701844|ACTIVE_COMPARATOR|Control writing type 1|
62611648|NCT00701844|PLACEBO_COMPARATOR|Control writing type 2|
62611649|NCT03793374||Axillary osmidrosis patients|Patients with axillary malodor and require surgical intervention. The subcutaneous apocrine glands shaving were used.
62611650|NCT05974956|NO_INTERVENTION|Control group|The control group exposed to routine care.
62611651|NCT05974956|EXPERIMENTAL|Study group|"The study group received the sessions of mastitis care teaching protocol."
62052182|NCT04859582|ACTIVE_COMPARATOR|Placebo + FP or CAPOX|Participants receive placebo for pembrolizumab IV on Day 1 Q3W for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m\^2 IV on Day 1 Q3W and 5FU 800 mg/m\^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m\^2 IV on Day 1 Q3W + capecitabine 1000 mg/m\^2 orally BID on Days 1 to 14 Q3W.
62052183|NCT02964676|EXPERIMENTAL|AIT group|PACG in AIT group will receive ab interno trabeculectomy with Trabectome and before AIT, Laser Peripheral Iridectomy (LPI) will be performed first.
62442366|NCT04248855|EXPERIMENTAL|MAD Cohort 5|All randomized patients will receive 3 doses of either KAN-101 Dose A or placebo
62052184|NCT02964676|ACTIVE_COMPARATOR|Trab group|PACG in AIT group will receive trabeculectomy.
62442367|NCT04248855|EXPERIMENTAL|MAD Cohort 6|All randomized patients will receive 3 doses of either KAN-101 Dose B or placebo
62442368|NCT04248855|EXPERIMENTAL|MAD Cohort 7|All randomized patients will receive 3 doses of either KAN-101 Dose C or placebo
62442369|NCT02352506||AKI|Patients developing AKI during the ICU stay
62052185|NCT05323461|EXPERIMENTAL|Cohort 1: SCTV01C|one dose of SCTV01C on D0
62052186|NCT05323461|EXPERIMENTAL|Cohort 1: SCTV01E|one dose of SCTV01E on D0
62442370|NCT02352506||No AKI|Matched controls not developing AKI during the ICU stay
62052187|NCT05323461|ACTIVE_COMPARATOR|Cohort 1: Active comparator|one dose of Sinopharm inactivated COVID-19 vaccine on D0
62052188|NCT05323461|EXPERIMENTAL|Cohort 2: SCTV01C|one dose of SCTV01C on D0
62052189|NCT05323461|EXPERIMENTAL|Cohort 2: SCTV01E|one dose of SCTV01E on D0
62052190|NCT05323461|ACTIVE_COMPARATOR|Cohort 2: Active comparator|one dose of Comirnaty on D0
62052191|NCT03547401||General anesthesia|Patient (15 to 40 years old) undergoing elective surgery requiring general anesthesia in supine position.
62052192|NCT01959425|EXPERIMENTAL|Off OAT Group (Test)|Discontinuation of OAT Therapy
62052193|NCT01959425|OTHER|On OAT Group (Control)|Continuation of OAT Therapy
62052194|NCT02344043||Critical illness|This prospective cohort of critically ill patients will have brain tissue oxygen levels recorded for 24 hours after admission with near infrared spectroscopy.
62052195|NCT06497218|EXPERIMENTAL|Children formally diagnosed with Autism Spectrum Disorder|Children aged between 3 and 12 years with Autism Spectrum Disorder who received a formal DSM-5 diagnosis will be tested with Blinklab smart phone based diagnostic tool
62052196|NCT02449668|SHAM_COMPARATOR|Acupuncture on sham points (SA)|The control group received treatment with acupuncture needles on sham points (SA).
62442371|NCT01576757||Heart failure|Patients with heart failure from any cause will be considered as potential participants given their clinical background meets eligibility criteria.
62442372|NCT03244956|EXPERIMENTAL|patients with RAS mutation|
62442373|NCT03244956|EXPERIMENTAL|patients with BRAFV600E mutation|
62442374|NCT01241409|EXPERIMENTAL|Treatment sequence ABC|
62442375|NCT01241409|EXPERIMENTAL|Treatment sequence ACB|
62442376|NCT01241409|EXPERIMENTAL|Treatment sequence BAC|
62442377|NCT01241409|EXPERIMENTAL|Treatment sequence BCA|
62442378|NCT01241409|EXPERIMENTAL|Treatment sequence CAB|
62442379|NCT01241409|EXPERIMENTAL|Treatment sequence CBA|
62442380|NCT03192059|EXPERIMENTAL|experimental arm|Pembrolizumab, immune modulatory cocktail composed of Vitamin D, Lansoprazole Teva, Cyclophosphamide and Aspirine, radiation and Curcumin
62611652|NCT00811993|EXPERIMENTAL|1|
62611653|NCT00811993|EXPERIMENTAL|10|
62611654|NCT00811993|EXPERIMENTAL|11|
62611655|NCT00811993|EXPERIMENTAL|12|
62611656|NCT00811993|EXPERIMENTAL|13|
62611657|NCT00811993|EXPERIMENTAL|2|
62611658|NCT00811993|EXPERIMENTAL|3|
62611659|NCT00811993|EXPERIMENTAL|4|
62611660|NCT00811993|EXPERIMENTAL|5|
62611661|NCT00811993|EXPERIMENTAL|6|
62611662|NCT00811993|EXPERIMENTAL|7|
62611663|NCT00811993|EXPERIMENTAL|8|
62611664|NCT00811993|EXPERIMENTAL|9|
62611665|NCT03564795|EXPERIMENTAL|KeraStat Gel|Each enrolled subject will have at least one eligible burn randomized to the KeraStat Gel arm. This burn will be dressed with KeraStat Gel and covered by a secondary dressing. Subjects will be instructed to change the dressing and re-apply the KeraStat Gel per the instructions for use (at least every 3 days).
62623583|NCT03472937|ACTIVE_COMPARATOR|Inpatient cervical ripening group|Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.
62052197|NCT02449668|EXPERIMENTAL|True acupuncture (TA)|The intervention group received treatment with true acupuncture techniques (TA) on a selection of points described as effective in the literature.
62253220|NCT04021199|ACTIVE_COMPARATOR|T1D Group|"* Retrospective analysis of data from active and historical diabetic patients within diabetes care conventions of pediatric endocrinology services; screening of patients with atypical diabetes; use of tests used in clinical routine to allow referral to the genetic diagnosis of the condition.~* Prospective analysis of the evolution of new diabetic patients followed in pediatric endocrinology services of diabetes care conventions; screening of patients with atypical diabetes; use of tests used in clinical routine to allow the genetic diagnosis of the condition.~* Screening of patients with atypical diabetes: first evaluated according to the MODY probability calculator. In addition, other clinical criteria will be used to improve the sensitivity and specificity of pediatric monogenic diabetes screening."
62253221|NCT04021199|EXPERIMENTAL|MODY Group|"* Retrospective analysis of data from active and historical diabetic patients within diabetes care conventions of pediatric endocrinology services; screening of patients with atypical diabetes; use of tests used in clinical routine to allow referral to the genetic diagnosis of the condition.~* Prospective analysis of the evolution of new diabetic patients followed in pediatric endocrinology services of diabetes care conventions; screening of patients with atypical diabetes; use of tests used in clinical routine to allow the genetic diagnosis of the condition.~* Screening of patients with atypical diabetes: first evaluated according to the MODY probability calculator. In addition, other clinical criteria will be used to improve the sensitivity and specificity of pediatric monogenic diabetes screening."
62052198|NCT03498638|EXPERIMENTAL|Couples Therapy|Couples Therapy
62253222|NCT00593944|EXPERIMENTAL|1|Patients will receive active MDX-1342.
62253223|NCT03540225|EXPERIMENTAL|Early Low-dose Arm|Start from 11-14 week: 200 mg self-administered vaginal progesterone daily
62253224|NCT03540225|EXPERIMENTAL|Early High-dose Arm|Start from 11-14 week: 400 mg self-administered vaginal progesterone daily
62253225|NCT03540225|EXPERIMENTAL|Late Low-dose Arm|Start from 20-24 week: 200 mg self-administered vaginal progesterone daily
62253226|NCT03540225|EXPERIMENTAL|Late High-dose Arm|Start from 20-24 week: 400 mg self-administered vaginal progesterone daily
62253227|NCT01084915||SAGB VC group|Retrospectively patients with a SAGB-VC gastric band are inventorized. They will also be interviewed and BAROS scores will be taken.
62253228|NCT03543111|EXPERIMENTAL|Zest|Zest is an internet-based psychological health enhancement program for women with spinal cord injury. The intervention will occur in Second Life (SL), which is an online virtual word simulator with a group of women with spinal cord injury.The Zest program will consist of 10 weekly 2-hour group sessions with approximately 8 women using avatars to represent themselves.
62253229|NCT03543111|NO_INTERVENTION|Control|No intervention - Control participants are provided intervention materials at the end of the study.
62253230|NCT00314353|EXPERIMENTAL|1|
62253231|NCT00314353|EXPERIMENTAL|2|
62253232|NCT01665547|ACTIVE_COMPARATOR|l-carnitine|adding 3gm l-carnitine from day 1 to day 12 of induced the menstrual cycle by 50 mg clomiphene
62253233|NCT04350255|ACTIVE_COMPARATOR|Trident II Hemispherical cup (Stryker Orthopaedics)|Total hip arthroplasty using non cemented Trident II Hemispherical acetabular cup
62442381|NCT03249090|EXPERIMENTAL|Patient Self-Reporting of Symptoms|Patients report symptoms weekly via web or automated telephone system. Email alerts to nurses for severe/worsening symptoms; printouts for clinicians at visits. Evidence based symptom management pathways provided to patients and clinicians.
62442382|NCT03249090|ACTIVE_COMPARATOR|Usual Care Delivery|Evidence-based symptom management pathways provided to patients and clinicians
62442383|NCT04739449|NO_INTERVENTION|Control|Two facilities will follow their local protocols for infection prevention, including COVID-19 precautions. We will swab environmental surfaces at these sites to compare outcomes.
62611666|NCT03564795|ACTIVE_COMPARATOR|Silver Sulfadiazine|Each enrolled subject will have at least one eligible burn randomized to the Silver Sulfadiazine arm. This burn will be dressed with the Silver Sulfadiazine and covered by a secondary dressing. Subjects will be instructed to change the dressing and re-apply the Silver Sulfadiazine per the institution's Standard of Care instructions.
62052199|NCT03498638|PLACEBO_COMPARATOR|Control|Couples Therapy after an 8 week waiting period
62052200|NCT05241964|EXPERIMENTAL|PRP|PRP injection
62052201|NCT03043079|EXPERIMENTAL|Ventral Hernia|Twenty-five patients diagnosed with ventral hernia
62052202|NCT03043079|OTHER|Healthy Volunteers|Twenty-five volunteers without ventral hernia
62052203|NCT03043079|OTHER|Active Health Volunteers|Ten healthy volunteers with an International Physical Activity Questionnaire (IPAQ) with the scoring result of High or Vigorous Intensity
62052204|NCT02975570|EXPERIMENTAL|DAZZLE-24 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 24 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
62253234|NCT04350255|ACTIVE_COMPARATOR|Trident II Tritanium cup (Stryker Orthopaedics)|Total hip arthroplasty using non cemented Trident II Tritanium acetabular cup
62253235|NCT05811715|EXPERIMENTAL|Group A|WBS-Whole body stretching exercise group
62253236|NCT05811715|ACTIVE_COMPARATOR|Group B|control group
62253237|NCT01249820|EXPERIMENTAL|group A|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
62253238|NCT01249820|EXPERIMENTAL|group B|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
62253239|NCT01213875|EXPERIMENTAL|Experimental: Intervention and control|"I: Experimental Routine monitoring by health team in the reference institution, four home visits and four telephone contacts with trained nurses.~II: Control Routine monitoring by health team in the reference institution."
62253240|NCT01213875|NO_INTERVENTION|Control|
62253241|NCT04285242||Participants with Cancer - Group A|Assessments and observations for up to 40 days with one overnight hospital stay.
62253242|NCT04285242||Healthy Volunteers - Group A|Assessments and observations for up to 2 days with one overnight hospital stay.
62253243|NCT04285242||Healthy Volunteers - Group B|Assessments and observations for up to 2 days.
62253244|NCT04285242||Participants with Cancer - Group B|Assessments and observations for up to 40 days, with most assessments and observations being optional and no overnight hospital stay.
62052205|NCT02975570|EXPERIMENTAL|DAZZLE-32 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 32 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
62611667|NCT06056362|EXPERIMENTAL|Arm A: Al18F-NOTA-LM3 and 68Ga-DOTATATE group|Patients will perform an Al18F-NOTA-LM3 PET/CT as well as a 68Ga-DOTATATE PET/CT.
62611668|NCT06056362|EXPERIMENTAL|Arm B: Al18F-NOTA-LM3 and 68Ga-NODAGA-LM3 group|Patients will perform an Al18F-NOTA-LM3 PET/CT as well as a 68Ga-NODAGA-LM3 PET/CT.
62611669|NCT00486707||Patients with ovarian cancer|
62052206|NCT02975570|EXPERIMENTAL|DAZZLE-40 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen: delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 40 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
62052207|NCT02975570|EXPERIMENTAL|DAZZLE-48 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 48 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
62253245|NCT02539420|NO_INTERVENTION|Control|"Patients assigned to the control group will receive any treatment for status asthmaticus that does not entail use of positive pressure ventilation."
62253246|NCT02539420|EXPERIMENTAL|Late BiPAP treatment|"Patients assigned to the late treatment group will be started on BiPAP greater than 6 hours after randomization."
62253247|NCT02539420|EXPERIMENTAL|Early BiPAP treatment|"Patients assigned to the early treatment group will be started on BiPAP as soon as possible after randomization."
62052208|NCT02975570|EXPERIMENTAL|DAZZLE-56 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 56 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
62253248|NCT03441334|EXPERIMENTAL|High Frequency rTMS|The High Frequency rTMS group will receive real repetitive transcranial magnetic stimulation (rTMS) in 5Hz at 90% of resting motor threshold delivered to the bilateral motor areas via a figure of 8 air-filmed coil. The stimulation is structured as 24 10-second trains with a inter-train interval of 30 second.
62611670|NCT06731868|EXPERIMENTAL|LPM3770164 sustained release tablet 5 mg|
62611671|NCT06731868|EXPERIMENTAL|LPM3770164 sustained release tablet 10 mg|
62611672|NCT06731868|EXPERIMENTAL|LPM3770164 sustained release tablet 20 mg|
62611673|NCT06731868|PLACEBO_COMPARATOR|Placebo|
62611674|NCT05369689||spinal tumors, CT, MRI, PET-CT stereotactic radiosurgery|Patients who had spinal tumors and completed the CT, MRI or PET-CT examination before and after stereotactic radiosurgery.
62835058|NCT00933452|EXPERIMENTAL|moderate dose group/multiple dose group|single oral duloxetine 30mg, after that repeat 7 oral duloxetine 30mg/d
62835059|NCT00933452|EXPERIMENTAL|high dose group/crossover group|single oral duloxetine 60mg, after that single oral innovator duloxetine 60mg
62835060|NCT05506033|NO_INTERVENTION|Standard GCs taper group|After a complete response (PLT ≥100x10\^9/L) was confirmed, the dose of prednisone (or equivalent dose of glucocorticoids) would be reduced by 2 tablets every two weeks. When it reaches 6 tablets /d, the dose would be reduced by 1 tablet every 2 weeks, and when it reaches 15mg/d, the dose would be reduced by half tablet every 2 weeks.
62835061|NCT05506033|EXPERIMENTAL|rapid GCs taper group|After a complete response (PLT ≥100x10\^9/L) was confirmed, the dose of prednisone (or equivalent dose of glucocorticoids) would be cut in half (25mg/d for weight less than 50kg, 30mg/d for weight 50-75kg , 40mg/d for weight more than 75kg ). After that, the dose would be reduced by 2 tablets every two weeks. When it reaches 6 tablets /d, the dose would be reduced by 1 tablet every 2 weeks, and when it reaches 15mg/d, the dose would be reduced by half tablet every 2 weeks.
62052209|NCT02975570|ACTIVE_COMPARATOR|WHO MDR-TB regimen- 9 mos or 20-24 mos|MDR-TB treatment with 9-month or 20-24 month WHO approved regimen. The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine.
62253249|NCT03441334|SHAM_COMPARATOR|Sham rTMS|The Sham rTMS group will receive the same protocol but delivered via a sham coil which generates the same auditory and cutaneous feedback as the real stimulation. However, there will be no active stimulation.
62253250|NCT05968898|NO_INTERVENTION|Usual care (clinician assessment)|In the usual care arm, clinicians will evaluate individuals with indeterminate pulmonary nodules as part of routine clinical care. No specific guidance regarding pulmonary nodule risk stratification will provided to evaluating clinicians.
62611675|NCT04420819|EXPERIMENTAL|IPC-LOP|this group will carry out the baseline assessments, perform the ischemic preconditioning using exactly the limb occlusion pressure , then perform post-IPC assessments and start the excentric exercise, and the post-exercise assessments will take place immediately after the end of the EE and will be repeated in 24h, 48h, 72h and 96h.
62611676|NCT04420819|EXPERIMENTAL|IPC-40%|this group will carry out baseline assessments, perform IPC using 40% more occlusion than LOP, then perform assessments after IPC protocol and start EE, and post exercise assessments will take place immediately after the end of EE and will be repeated in 24h, 48h, 72h and 96h.
62611677|NCT04420819|PLACEBO_COMPARATOR|IPC-10mmHg:|this group will perform baseline assessments, perform occlusion-perfusion intervention with 10 mmHg restriction characterizing the placebo, then perform post-IPC assessments and initiate EE, and post-exercise assessments will take place immediately after completion of EE and if will repeat in 24h, 48h, 72h and 96h.
62611678|NCT04420819|NO_INTERVENTION|CONTR|this group will carry out the baseline assessments, immediately after starting the EE, and the post-exercise assessments will happen immediately after the end of the EE and will be repeated in 24h, 48h, 72h and 96h.
62611679|NCT06082882|EXPERIMENTAL|In-Person Delivered Breast and Cervical Cancer Behavioral Intervention|Community health worker delivered behavioral education and referrals to low-cost services. Delivered in person to participants in community and clinic settings. Participants are followed up by health coach navigators to address barriers and connect to safety-net clinics.
62835062|NCT00867672|EXPERIMENTAL|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
62835063|NCT00867672|EXPERIMENTAL|Decitabine+VPA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks, and VPA (p.o.) from day 6 of first cycle continuously throughout all treatment cycles
62052210|NCT05044013|EXPERIMENTAL|JomPrEP App Group|Participants in the JomPrEP group will be provided with full app access and will be encouraged to use all features of the app.
62253251|NCT05968898|EXPERIMENTAL|Clinician assessment + CAD-based risk stratification|In the experimental arm, evaluating clinicians will receive a Lung Cancer Prediction report from an artificial intelligence radiomics-based computer-aided diagnosis tool for risk stratification of pulmonary nodules.
62052211|NCT05044013|ACTIVE_COMPARATOR|Control Group|Participants in the control group will receive the JomPrEP app with major intervention features inactivated.
62052212|NCT06579079|EXPERIMENTAL|Implementation Strategy - Intervention Condition|Schools in the intervention condition will be assigned to receive coaching and logistical support to develop and tailor an implementation strategy across 1 academic year. This strategy will then be implemented in the following academic years (2- year pilot).
62442384|NCT04739449|EXPERIMENTAL|Intervention|"Using a cluster-randomized design, we will test a multimodal aging-friendly intervention including four components (4Cs):~1. Coaching staff~2. Cleaning protocols, standardized~3. Communication with staff and leadership~4. Collaboration with local expertise~We hypothesize that the implementation of this organizational QI educational program will be associated with lower odds of SARS-CoV-2 transmission to the environment."
62052213|NCT06579079|ACTIVE_COMPARATOR|Waitlist Control|Schools in the waitlist control will wait 1 academic year before developing and testing an implementation strategy (1-year pilot)
62052214|NCT05413980||Moxifloxacin hydrochloride ophthalmic solution|patients prescribed with 0.5% Moxifloxacin hydrochloride ophthalmic solution during the perioperative (preoperative and postoperative) period of ophthalmic surgery.
62253252|NCT00063570|EXPERIMENTAL|A|
62253253|NCT00063570|EXPERIMENTAL|B|
62442385|NCT01266174|EXPERIMENTAL|Eltoprazine|eltoprazine pill 2.5mg bid, eltoprazine pill 5mg bid, eltoprazine 7.5mg bid
62442386|NCT01266174|PLACEBO_COMPARATOR|Placebo|placebo pill 2.5mg bid, placebo pill 5mg bid, placebo 7.5mg bid
62442387|NCT00192296|EXPERIMENTAL|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
62442388|NCT00192296|EXPERIMENTAL|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, IV dose
62442389|NCT00192296|EXPERIMENTAL|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, IV dose
62442390|NCT00192296|EXPERIMENTAL|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, IV dose
62442391|NCT00557882|ACTIVE_COMPARATOR|mesh|Vaginal reconstructive surgery with synthetic polypropylene mesh
62442392|NCT00557882|ACTIVE_COMPARATOR|no mesh|Vaginal reconstructive surgery without mesh
62442393|NCT03758833|ACTIVE_COMPARATOR|SET|patients receiving the elective single embryo transfer
62442394|NCT03758833|EXPERIMENTAL|SET+NGS|patients receiving the elective single embryo transfer evaluated genetically by NGS
62442395|NCT03758833|ACTIVE_COMPARATOR|DET|patients receiving the elective double embryo transfer
62442396|NCT03758833|EXPERIMENTAL|DET+NGS|patients receiving the elective double embryo transfer evaluated genetically by NGS
62442397|NCT06355739|OTHER|CD19 autotransfusion for B-cell acute lymphoblastic leukemia in children|
62442398|NCT04711525|EXPERIMENTAL|Interactive Malaysian Childhood Healthy Lifestyle Program (i-MaCHeL)|The preschool children in the experimental group will be exposed to interactive classroom instruction, and their parents will be exposed to the Web-based program. In the experimental group, apart from the standard preschool health education curriculum, the preschool children will also be exposed to the interactive activities and quizzes using Web 2.0 tools, educational videos of a healthy lifestyle, sensory-based food education activities, cooking demonstrations, fun, and active games, and exercises. Whereas the parents will be exposed to Web-based healthy lifestyle educational materials, videos, and pictures sharing, quizzes, and communication through the WhatsApp and closed Facebook groups. Besides, a total of 3 messages per week will be delivered to the parents in the experimental group. The messages will be included announcing the release of a new topic, a reminder to log in to the website and read the health information, and a reminder to participate in the online activities.
62835064|NCT00867672|EXPERIMENTAL|Decitabine+ATRA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
62052215|NCT02437656|EXPERIMENTAL|Metformin treatment|"J1 : dosimetric scan~J3 : initiation of the Metformin therapy (at a dosage of 1700 mg / day)~J10 : increasing the dose of Metformin (2550 mg / day) + initiation of the radiochemotherapy~J44 : end of the radiochemotherapy~Between J86 and J100 : surgery (discontinuation of the Metformin therapy 48 hours before surgery)"
62253254|NCT01683279|EXPERIMENTAL|CAR+ T cells|Subjects will receive two days of cyclophosphamide for a total of 3g/m\^2 followed several days later by a single dose of Autologous CD19 CAR+ EGFTt + T cells
62253255|NCT02806128|EXPERIMENTAL|Treatment group|"Injection of Human Urinary Kallidinogenase for Injection (KLK) three times a day, 14 days .~Patients need to complete laboratory tests within a specified time."
62253256|NCT02806128|EXPERIMENTAL|Control group|"Injection of Human Urinary Kallidinogenase for Injection (KLK) Once times a day, 14 days .~Patients need to complete laboratory tests within a specified time."
62253257|NCT04366050|EXPERIMENTAL|Ramipril 2.5mg orally daily|"Total 2.5 mg Ramipril per day once a day orally for 14 days~Intervention: Ramipril"
62253258|NCT04366050|PLACEBO_COMPARATOR|Placebo|Placebo in the form of a capsule, taken orally for 14 days
62835065|NCT00867672|EXPERIMENTAL|Decitabine+VPA+ATRA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and VPA (p.o.) from day 6 continuously throughout all treatment cycles and ATRA (45 mg/m² p.o.), from day 6 to day 28 of each treatment cycle
62611680|NCT06082882|EXPERIMENTAL|Telephone Delivered Breast and Cervical Cancer Behavioral Intervention|Community health worker delivered behavioral education and referrals to low-cost services. Delivered by telephone to individual participants. Participants are followed up by health coach navigators to address barriers and connect to safety-net clinics.
62253259|NCT01342484|EXPERIMENTAL|linagliptin low dose|linagliptin low dose for children once daily
62253260|NCT01342484|EXPERIMENTAL|linagliptin high dose|linagliptin high dose for children once daily
62253261|NCT01342484|PLACEBO_COMPARATOR|placebo|matching placebo for each linagliptin dose once daily
62253262|NCT02363348|PLACEBO_COMPARATOR|Placebo (A)|"were administered 5 capsules per day each capsule contained 600 mg of magnesia calcinada. Duration: from week 20th of pregnancy until the end of the same.~dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner."
62253263|NCT02363348|EXPERIMENTAL|L arginine (B)|were administered 5 capsules per day each capsule contained 600 mg of L arginine. Duration: from week 20th of pregnancy until the end of the same dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner.
62253264|NCT04935398|EXPERIMENTAL|Manual therapy|Football players with adductor tendinopathy undergoing treatment consisting of manual therapy and therapeutic exercise.
62253265|NCT04935398|EXPERIMENTAL|Electrotherapy|Footballers with adductor tendinopathy undergoing electrotherapy treatment
62442399|NCT04711525|ACTIVE_COMPARATOR|Standard health education|The children in the control group do not have exposed to the i-MaCHeL interactive classroom instruction, and their parents do not have access to the i-MaCHeL website materials. Thus, the children will be continued with standard health education only in the preschool setting, and their parents will be received Web-based health newsletters. The Web-based newsletters consist of general health information that are relevant to the preschool life stage. In ensuring that the experimental and control groups appear the same, the topics in the Web-based newsletters will have a look and feel similar nature to the experimental group condition. But still, the topics will not be included the interactive components such as videos and pictures sharing activities, quizzes, individualized feedback, and communication through WhatsApp and closed Facebook groups. Only one message (announcement of the release of a new topic) per week will be delivered to parents of the control group.
62253266|NCT05913154||Cognitive/executive apathy|
62253267|NCT05913154||Behavioural/inhibition apathy|
62253268|NCT05913154||Emotional apathy|
62253269|NCT05913154||Social apathy|
62253270|NCT04622332|EXPERIMENTAL|SIR1-365|SIR1-365 dose 1 daily for 14 days
62253271|NCT04622332|PLACEBO_COMPARATOR|Matching placebo|Matching placebo dose 1 daily for 14 days
62253272|NCT00609193||1|Study subjects receiving lithium
62253273|NCT00609193||2|Study subjects receiving quetiapine
62253274|NCT02430350|EXPERIMENTAL|Compound Edaravone|Compound Edaravone Injection 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days
62253275|NCT02430350|ACTIVE_COMPARATOR|Edaravone|Edaravone Injection 30 mg/dose, one dose every 12 hours, continues for 14 days
62253276|NCT00649259|EXPERIMENTAL|1|Oxybutynin Chloride ER Tablets 10 mg
62253277|NCT00649259|ACTIVE_COMPARATOR|2|Ditropan XL® Tablets 10 mg
62253278|NCT04288986|EXPERIMENTAL|Keep Achieving (KA) group|Participants in the experimental group will take part in a 8-week group based activity programme. The activity programme will consist of 1, 50 minute session each week for the duration of 8-weeks. The activity sessions will include semi-structured free play sessions, sport specific sessions facilitated by local sports teams and swimming sessions.
62253279|NCT04027699|EXPERIMENTAL|Mini-bolus|"* First injection of 2ml/kg (saline solution)~* Second injection of 18ml/kg (saline solution)"
62253280|NCT01022996|EXPERIMENTAL|RAD001|"Patients with a history of classical Hodgkin lymphoma (ie, nodular sclerosing, mixed cellularity, lymphocyte-rich, lymphocyte-depleted) whose disease had progressed after receiving high-dose chemotherapy with AHSCT (if eligible) and/or after therapy with a gemcitabine- or vinorelbine- or vinblastine-containing regimen, were enrolled into this study. All patients were assigned to a daily dose of everolimus 10 mg (two 5-mg tablets), selfadministered orally and continuously from Cycle 1 Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death, or discontinuation from the study for any other reason.~A treatment cycle consisted of 28 days."
62253281|NCT00823849|EXPERIMENTAL|1|
62611681|NCT06082882|EXPERIMENTAL|Zoom Delivered Breast and Cervical Cancer Behavioral Intervention|Community health worker delivered behavioral education and referrals to low-cost services. Delivered by Zoom to individual participants. Participants are followed up by health coach navigators to address barriers and connect to safety-net clinics.
62611682|NCT05691621||septic AKI: S-AKI|Septic patients with AKI
62253282|NCT00823849|EXPERIMENTAL|2|
62253283|NCT00823849|EXPERIMENTAL|3|
62253284|NCT00823849|NO_INTERVENTION|4|Control Group
62253285|NCT06450249||Healthcare professionals|Healthcare professionals working in Continuous Care Units before and after participation in Humanitude® Care Methodology (HCM) training sessions in the Ile-de-France region in France
62253286|NCT02301663|EXPERIMENTAL|Women w/microvascular disease|10 women with microvascular disease
62253287|NCT02301663|EXPERIMENTAL|Normal controls|10 age-matched women with no evidence of microvascular disease
62253288|NCT02301663|EXPERIMENTAL|calibration|10 healthy individuals who will help to synchronize our imaging and stress testing maneuvers.
62253289|NCT00121108|PLACEBO_COMPARATOR|Placebo|Participants will receive IM dose of placebo matched to motavizumab every 30 days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the the RSV season.
62253290|NCT00121108|ACTIVE_COMPARATOR|Motavizumab|Participants will receive IM dose of motavizumab 15 milligram/Kilogram (mg/kg) every 30 Days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the RSV season.
62253291|NCT03953430||study group|Patients with clubfoot recurrence undergoing Tibialis Anterior tendon transfer with a minimum age of three years from a prospective, consecutive database of patients with clubfoot treated with the Ponseti method.
62611683|NCT05691621||non-septic AKI: non-S AKI|Non-septic critically ill patients with AKI.
62611684|NCT05691621||non-AKI Non-AKI|Critically ill patients without sepsis and AKI.
62611685|NCT02979080|EXPERIMENTAL|Oral Iron Supplementation|Eisensulfat LOMAPHARM 50 mg administration for 120 days
62052216|NCT03205371|EXPERIMENTAL|South Korea(Group1):MenACYW Conjugate + MMR+ Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.
62052217|NCT03205371|EXPERIMENTAL|South Korea (Group 2): MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
62611686|NCT04317924|EXPERIMENTAL|Reinforcement of air leak|Participants in this arm will receive reinforcement with the NEOVEIL (polyglycolic acid felt) which will be impregnated with human fibrinogen and thrombin.
62611687|NCT04317924|ACTIVE_COMPARATOR|No reinforcement of air leak|Participants in this arm will receive standard of care for air leak post lung resection.
62611688|NCT00006486|EXPERIMENTAL|Arm I (carboxyaminoimidazole)|"Patients receive oral CAI daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.~Patients receive oral CAI as above."
62611689|NCT00006486|EXPERIMENTAL|Arm II (carboxyamidotriazole, placebo)|"Patients receive oral CAI daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.~Patients receive a placebo."
62611690|NCT00625404|EXPERIMENTAL|Truvada Arm|Daily single oral tablet of Truvada (TDF/FTC), a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
62611691|NCT00625404|PLACEBO_COMPARATOR|Placebo Arm|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
62611692|NCT05539261||HVD|Heart Valve Disease
62052218|NCT03205371|ACTIVE_COMPARATOR|South Korea (Group 3): MMR + Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.
62253292|NCT03953430||control group|healthy children of employees of our hospital
62052219|NCT03205371|EXPERIMENTAL|Thailand (Group 10):MenACYW Conjugate +MMR+Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.
62052220|NCT03205371|EXPERIMENTAL|Thailand (Group 11):MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
62052221|NCT03205371|ACTIVE_COMPARATOR|Thailand (Group 12): MMR + Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.
62052222|NCT03205371|EXPERIMENTAL|Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and diphtheria, tetanus, acellular pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type-b (DTaP-IPV-HB-Hib) vaccine on Day 0.
62253293|NCT05065372|ACTIVE_COMPARATOR|Metformin plus automated insulin delivery system|Some participants with type 1 diabetes using an automated insulin delivery system will be randomized to receive treatment with metformin and will undergo RPF (Aminohippurate Sodium Injections 20%), GFR (Iohexol Inj 300 MG/ML), and insulin sensitivity (hyperinsulinemic-euglycemic clamp) assessments, in additional to assessments of cardiovascular and endothelial function.
62442400|NCT05252416|EXPERIMENTAL|BLU-222 Monotherapy|Dose Escalation: Multiple doses for BLU-222 for oral administration Dose Expansion: Oral dose of BLU-222 as determined during Dose Escalation
62442401|NCT05252416|EXPERIMENTAL|BLU-222 + Carboplatin|"Dose Escalation: Multiple doses for BLU-222 for oral administration at doses deemed appropriate based on BLU-222 Monotherapy arm and multiple doses of Carboplatin at the approved dose.~Dose Expansion: Oral dose of BLU-222 as determined during Dose Escalation and Carboplatin IV infusion at approved dose"
62442402|NCT05252416|EXPERIMENTAL|BLU-222 + Ribociclib + Fulvestrant|"Dose Escalation: Multiple doses for BLU-222 for oral administration at doses deemed appropriate based on BLU-222 Monotherapy arm along with Ribociclib and Fulvestrant at the approved doses.~Dose Expansion: Oral dose of BLU-222 as determined during dose escalation and approved doses of Ribociclib and Fulvestrant"
62442403|NCT05252416|EXPERIMENTAL|BLU-222 + Fulvestrant|Dose Expansion: Oral dose of BLU-222 as determined during Dose Escalation + fulvestrant at the approved dose
62611693|NCT05539261||HC|Healthy controls
62611694|NCT03968055|OTHER|Patients with Type 1 Diabetes|Participants will wear a continuous glucose monitor (CGM) and receive remote monitoring of the CGM data by the clinical care team.
62611695|NCT04038554||Acute Pancreatitis|Patients older than 18 years old diagnosed of acute pancreatitis according to Atlanta 2012.
62611696|NCT04038554||Healthy Control|Healthy people with a proximity relationship with case patients and similar age (+/- 5 years).
62611697|NCT04908111|EXPERIMENTAL|Safety Run In|Six evaluable patients will receive the trial vaccines with standard of care treatment to confirm they are safe before opening the next stage of the trial. These patients will not be randomised.
62611698|NCT04908111|EXPERIMENTAL|Arm A: Trial vaccines with standard of care treatment|Approximately 40 patients will be randomised to receive the trial vaccines with standard of care treatment in this arm.
62611699|NCT04908111|OTHER|Arm B: Standard of care treatment|Approximately 40 patients will be randomised to receive standard of care treatment alone in this arm.
62835066|NCT05069493||Tension-free|Hiatal hernia repair by tension-free mesh closure
62253294|NCT05065372|PLACEBO_COMPARATOR|Placebo plus automated insulin delivery system|Some participants with type 1 diabetes using an automated insulin delivery system will be randomized to receive treatment with a placebo pill which is identical in appearance to the metformin pill and will undergo RPF (Aminohippurate Sodium Injections 20%), GFR (Iohexol Inj 300 MG/ML), and insulin sensitivity (hyperinsulinemic-euglycemic clamp) assessments, in additional to assessments of cardiovascular and endothelial function.
62253295|NCT05065372|OTHER|Multiple daily insulin injections plus continuous glucose monitor|Participants with type 1 diabetes using multiple daily injections plus a continuous glucose monitor will not be randomized to receive medication treatment but will undergo RPF (Aminohippurate Sodium Injections 20%), GFR (Iohexol Inj 300 MG/ML), and insulin sensitivity (hyperinsulinemic-euglycemic clamp) assessments, in additional to assessments of cardiovascular and endothelial function.
62253296|NCT03574753|EXPERIMENTAL|ABBV-399|"C-MET overexpression is seen in 30% of patients with lung squamous cell carcinoma (SCCA). ABBV-399 (Process II) is a first-in-class antibody-drug conjugate (ADC) comprised of ABT-700, an anti-c-Met monoclonal antibody linked to monomethyl auristatin E (MMAE), which is a potent microtubule inhibitor. This delivers a direct anti-mitotic effect without relying on MET pathway inhibition.~ABBV-399 will be administered intravenously on day 1 of each 21-day cycle. Treatment will continue in consenting patients until disease progression or intolerable toxicity."
62253297|NCT06350838|EXPERIMENTAL|Medium/high-risk non-muscle invasive bladder cancer (NMIBC)|Medium/high-risk NMIBC (Ta, T1 or Tis) suitable for intravesical BCG treatment.Three phases included: screening period (28 days before the first dose), observation period (6 weeks) and safety follow-up period (7 days after the last dose).
62835067|NCT05069493||Suturing|Hiatal hernia repair by simple suturing of the diaphragmatic
62835068|NCT01376258||Patients adherent to 5-alpha reductase inhibitor (5ARI)|Patients with benign prostate hyperplasia (BPH) who are adherent (as measured by a medication possession ratio (MPR)) based on 3 MPR threshold values of 70%, 75% and 80%
62253298|NCT05903248||Amateur American Football Team|
62442404|NCT04388059||Transection at 2 cm from the pylorus|the effect of transection at 2 cm from the pylorus during Laparoscopic sleeve gastrectomy on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
62442405|NCT04388059||Transection at 5 cm from the pylorus|the effect of transection at 5 cm from the pylorus during Laparoscopic sleeve gastrectomy on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
62253299|NCT02349594|ACTIVE_COMPARATOR|treatment order A|Participants in this arm first receive 'Omegaven 10%' and after crossing over the 'Intralipid 20%'
62442406|NCT02397681|EXPERIMENTAL|Experimental|
62253300|NCT02349594|ACTIVE_COMPARATOR|treament order B|Participants in this arm first receive 'Intralipid 20%' and after crossing over the 'Omegaven 10%'
62253301|NCT01929239|EXPERIMENTAL|Anti PSMA Designer T Cells|Open Label, subjects receive anti PSMA designer T cells, plus IL2, low or moderate dose.
62442407|NCT02153047|EXPERIMENTAL|Spirometry|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
62442408|NCT02153047|NO_INTERVENTION|Brief smoking cessation advice|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
62442409|NCT03389984|EXPERIMENTAL|Adalimumab|
62442410|NCT06064253|OTHER|intervention group|health education program explaining the nature of the condition(KOA causes, pathological changes, and natural course of the disease), we explained the recommendations for the treatment of KOA, teaching the patient a home exercise program of 5 exercises (targeting knee extensor and hip muscle ), selection of a physiotherapy program suitable to the patient clinical condition, recommendations to increase daily physical activity ( e.g. brisk walking) with joint protection measures along with a weight reduction regimen proposed in overweight and obese patients and prescribing a suitable pharmacological treatment to the patients
62442411|NCT06064253|NO_INTERVENTION|control group|were assigned the traditional approach for KOA management, they were told their diagnosis if they were not already familiar with it, received the treatment for KOA according to ACR guidelines, they were offered physical therapy modalities if their condition required but they were not given the health education program or the other interventional steps.
62442412|NCT01514266|EXPERIMENTAL|Curcumin+bioprine|The study involves active arm of Curcumin+Bioprine
62442413|NCT01514266|PLACEBO_COMPARATOR|Placebo|
62442414|NCT05765955|ACTIVE_COMPARATOR|POLB 001 30 mg|
62442415|NCT05765955|ACTIVE_COMPARATOR|POLB 001 70 mg|
62442416|NCT05765955|ACTIVE_COMPARATOR|POLB 001 150 mg|
62442417|NCT05765955|PLACEBO_COMPARATOR|Placebo|
62442418|NCT00406978|EXPERIMENTAL|MPTD|
62442419|NCT01519128|EXPERIMENTAL|Treatment sequence AB|In Treatment A, digoxin 0.5 mg (single oral dose) will be administered on Day 1. In Treatment B, TMC278 at 25 mg, once daily will be administered for 16 days, with digoxin 0.5 mg (single oral dose) administered in the morning on Day 11.
62835069|NCT01376258||Patients who are non-adherent to 5ARI therapy|Patients with BPH who are not adherent to 5ARI therapy as measured by 3 MPR threshold values of 70%, 75%, and 80%
62835070|NCT00071058|EXPERIMENTAL|Surgery plus chemotherapy|"Surgical resection can be performed at the time of study entry, when patients have a mixed response, or if their tumors respond to chemotherapy.~Surgical resection will be followed by chemotherapy with 2 grams oral dose daily of mitotane on cycle 1, day 1, 6 mg/m\^2 continuous intravenous infusion doxorubicin over 96 hours days 1-4, 0.18 mg/m\^2 continuous intravenous infusion vincristine over 96 hours days 1-4, and 36 mg/m\^2 continuous intravenous infusion etoposide over 96 hours days 1-4, and 150 mg tariquidar through central venous catheter over 30 minutes on days 1 and 3."
62835071|NCT04987333|EXPERIMENTAL|Group 1: Chinese participants - efavaleukin alfa dose level 1|Chinese participants will receive a single dose of efavaleukin alfa at dose level 1.
62835072|NCT04987333|EXPERIMENTAL|Group 2: Chinese participants - efavaleukin alfa dose level 2|Chinese participants will receive a single dose of efavaleukin alfa at dose level 2.
62835073|NCT04987333|EXPERIMENTAL|Group 3: Japanese participants - efavaleukin alfa dose level 2|Japanese participants will receive a single dose of efavaleukin alfa at dose level 2.
62611700|NCT04908111|EXPERIMENTAL|Squamous Oesophageal Cancer Cohort|Approximately 17 patients with squamous oesophageal cancer will received the trial vaccines with standard of care treatment
62611701|NCT02694458|EXPERIMENTAL|Modeling arm|Early vancomycin monitoring and bayesian dosage adjustment
62611702|NCT02694458|SHAM_COMPARATOR|Control arm|Usual vancomycin dose and monitoring strategy
62835074|NCT04987333|EXPERIMENTAL|Group 4: Caucasian participants - efavaleukin alfa dose level 2|Caucasian participants will receive a single dose of efavaleukin alfa at dose level 2.
62835075|NCT03071107|ACTIVE_COMPARATOR|Multi-disciplinary intervention arm|Multi-disciplinary intervention on frailty parameters including input from dietitian, physiotherapist and medical team
62835076|NCT03071107|NO_INTERVENTION|Control arm|Standard of care
62835077|NCT01040962||Falls Risk Assessment, Diabetic Peripheral Neuropathy Patients|
62835078|NCT03254797|EXPERIMENTAL|Stepping training with feedback|"Subjects will be instructed to perform the stepping task with external feedback continuously until 20 minutes (excluding resting periods) but without fatigue. Then they continue a training program of overground walking for 10 minutes.~They have to be involved in a training program of their groups 5 times/week, for 4 weeks in total."
62442420|NCT01519128|EXPERIMENTAL|Treatment sequence BA|In Treatment B, TMC278 at 25 mg, once daily will be administered for 16 days, with digoxin 0.5 mg (single oral dose) administered in the morning on Day 11. In Treatment A, digoxin 0.5 mg (single oral dose) will be administered on Day 1.
62442421|NCT04615442|EXPERIMENTAL|All subjects|Subjects that undergo a clinical video EEG are asked to additionally wear a wearable EEG headband for up to 2 periods of 4h during the video EEG.
62442422|NCT01615081|ACTIVE_COMPARATOR|Sucrose solution|75 g sucrose (75 g carbohydrate) desolved in 750 ml water
62442423|NCT01615081|EXPERIMENTAL|Malt extract solution|183 g malt extract (corresponding to 75 g carbohydrate and 103 ml water) desolved in 647 ml water
62442424|NCT06141915|EXPERIMENTAL|Aerobic training and diet protocol group|30 patients received aerobic training and diet protocol for 12 weeks.
62442425|NCT06141915|EXPERIMENTAL|Aerobic training group|30 patients will receive aerobic training for 30 minutes, three times per week for 12 weeks.
62442426|NCT06141915|ACTIVE_COMPARATOR|Diet protocol group|30 patients will receive diet protocol for 12 weeks.
62442427|NCT03776409||vancomycin plus piperacillin/tazobactam|Critically ill patients who received the combination of VAN (vancomycin) and PTZ (piperacillin/tazobactam) for at least 48 hours during an ICU (intensive care unit) admission, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and PTZ were adjusted based on clinical practice and patient characteristics. This is an observational study without any intervention.
62442428|NCT03776409||vancomycin plus other beta-lactams|Critically ill patients who received the combination of VAN (vancomycin) and other beta-lactams (cefoperazone/sulbactam, meropenem, imipenem/siastatin, ceftriaxone, ceftazidime, et al) for at least 48 hours during an ICU (intensive care unit) admission, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and other beta-lactams were adjusted based on clinical practice and patient characteristics. This is an observational study without any intervention.
62442429|NCT02611284|EXPERIMENTAL|Treatment Cohort (LISA)|All preterm infants born at \< 32 WG between October 2013 and November 2014 who met inclusion criteria were managed by the new LISA technique.
62442430|NCT02611284|OTHER|Historical Cohort (INSURE)|The control group was collected from the period immediately before the study's initiation (from Jun 2012 to September 2013). This cohort was comprised of preterm infants of less than 32 WG who met the inclusion criteria.
62442431|NCT02701075|EXPERIMENTAL|MC5-A Scrambler Therapy|MC5-A Scrambler Therapy is an electroanalgesia device that interferes with pain signal transmission by using nerve fibers as a passive means to convey a no pain message to the central nervous system. Electrodes are placed on dermatomes that correspond to the area of pain. Patient is treated for 30 minutes and given up to 10 treatment sessions.
62442432|NCT02701075|SHAM_COMPARATOR|MC5-A Scrambler Therapy Sham Device|The MC5-A Scrambler Therapy Device will be used as an active sham device in this randomized double blind study. Participants assigned to this arm will not receive active therapy.
62442433|NCT01738581|EXPERIMENTAL|rTMS + SMR, then rTMS + CTL|First phase of treatment: Repetitive transcranial magnetic stimulation (rTMS) and sensorimotor retraining (SMR). Second phase of treatment: rTMS and control treatment (CTL) (CTL therapy consisted of non-specific therapy that includes stretching, massage, range of motion).
62442434|NCT01738581|EXPERIMENTAL|rTMS + CTL, then rTMS + SMR|First phase of treatment: Repetitive transcranial magnetic stimulation (rTMS) with non-specific therapy that includes stretching, massage, range of motion. Second phase of treatment: rTMS and sensorimotor retraining (SMR).
62442435|NCT04989062||Healthy children|Apparently healthy children at Year 1 to Year 6 in the primary school in Taiwan. Exclusion criteria are children with metal implant or splint, pacemaker implantation, limb defect or injury and pregnant.
62442436|NCT05379543||ICU-Severely ill group|Patients requiring transfer to the intensive care unit (ICU), and presenting with severe symptoms (dyspnea, respiratory rate ≥30/min, blood oxygen saturation ≤93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio \<300, or lung infiltrates \>50% within 24 to 48 hours)
62442437|NCT05379543||ICU-Critically ill group|Patients requiring transfer to the ICU, and presenting with respiratory failure, septic shock, multiple organ dysfunction, or failure)
62442438|NCT05379543||Mildly ill group|Patients presenting with fever, mild to moderate respiratory symptoms, and with or without imaging presentations of pneumonia
62442439|NCT05379543||Healthy control group|Healthy volunteers, matched for gender and age, without any signs or evidence of COVID-19 infection
62611703|NCT01010399|EXPERIMENTAL|Boosted Lexiva with Lovaza|
62611704|NCT03436199|EXPERIMENTAL|ADS-5102, 137 mg|ADS-5102, administered once daily at bedtime from Week 4 through Week 16
62611705|NCT03436199|EXPERIMENTAL|ADS-5102, 274 mg|ADS-5102, administered once daily at bedtime from Week 4 through Week 16
62611706|NCT03436199|OTHER|Placebo|placebo, administered once daily at bedtime from Week 4 through Week 16
62611707|NCT00822224|EXPERIMENTAL|1|Use of MEOPA during the painful care
62835079|NCT03254797|ACTIVE_COMPARATOR|Stepping training without feedback|"Subjects will be instructed to perform the stepping task without external feedback continuously until 20 minutes (excluding resting periods) but without fatigue. Then they continue a training program of overground walking for 10 minutes.~They have to be involved in a training program of their groups 5 times/week, for 4 weeks in total."
62835080|NCT02374528|EXPERIMENTAL|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
62835081|NCT02374528|ACTIVE_COMPARATOR|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
62835082|NCT02717923|EXPERIMENTAL|Maintenance Treatment|A single arm of maintenance treatment with capecitabine plus cetuximab after first-line 5-fluorouracil based standard chemotherapy plus cetuximab.
62835083|NCT00286468|EXPERIMENTAL|Alogliptin 12.5 mg QD|
62835084|NCT00286468|EXPERIMENTAL|Alogliptin 25 mg QD|
62835085|NCT00286468|ACTIVE_COMPARATOR|Placebo|
62835086|NCT00545454|EXPERIMENTAL|SSR150106 QD|90 micro grams oral solution once daily (QD)
62835087|NCT00545454|EXPERIMENTAL|SSR150106 OEQD|90 micro grams oral solution once every other day (OEQD)
62835088|NCT00545454|PLACEBO_COMPARATOR|Placebo|oral solution QD or OEQD
62835089|NCT05824234|OTHER|Arm number one (2023)|Arm number one: services formed the first year with the REFOCUS formation Arm number two: services formed the second year with the REFOCUS formation Stepped wedge methodology
62052223|NCT03205371|EXPERIMENTAL|Mexico (Group 5): MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
62835090|NCT05824234|OTHER|Arm number two (2024)|Arm number one: services formed the first year with the REFOCUS formation Arm number two: services formed the second year with the REFOCUS formation Stepped wedge methodology
62052224|NCT03205371|ACTIVE_COMPARATOR|Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib vaccine on Day 0.
62052225|NCT03205371|EXPERIMENTAL|Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate vaccine and pneumococcal Conjugate vaccine (PCV13) on Day 0.
62052226|NCT03205371|EXPERIMENTAL|Russian Federation (Group 8): MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
62253302|NCT02131441|OTHER|laparoscopic hepatectomy|laparoscopic hepatectomy
62835091|NCT01814267|EXPERIMENTAL|Telemedicine|care and follow-up through telemedicine.
62835092|NCT01814267|ACTIVE_COMPARATOR|Conventional care|care and follow-up through iterative diabetes physician consultations (conventional care and follow-up)
62835093|NCT01635439|ACTIVE_COMPARATOR|Propess|Propess insert is a preparation of PGE2 packaged in a hydrogel polymer matrix and designed for slow intravaginal release of 10 mg dinoprostone at a rate of 0.3 mg/h.
62835094|NCT01635439|ACTIVE_COMPARATOR|Prostin E2|PROSTIN E2 Vaginal Suppository, an oxytocic, contains dinoprostone as the naturally occurring prostaglandin E2 (PGE2)3 mg/suppository.
62835095|NCT04355169|EXPERIMENTAL|Naldemedine 1.25 mg|Participants will receive 1.25 milligrams (mg) naldemedine twice daily (BID) beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
62835096|NCT04355169|EXPERIMENTAL|Naldemedine 2.5 mg|Participants will receive 2.5 mg naldemedine BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
62835097|NCT04355169|EXPERIMENTAL|Naldemedine 5 mg|Participants will receive 5 mg naldemedine BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
62835098|NCT04355169|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
62835099|NCT01502774|EXPERIMENTAL|Cyclosporin|Injection of Cyclosporin A : one single intravenous bolus injection of 2.5 mg/Kg Echocardiography
62835100|NCT01502774|PLACEBO_COMPARATOR|Control|one single intravenous bolus injection of Placebo Echocardiography
62052227|NCT03205371|ACTIVE_COMPARATOR|Russian Federation (Group 9): PCV13 Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 15 to 23 months) received single dose of PCV13 vaccine on Day 0.
62611708|NCT03646149|EXPERIMENTAL|Housing Skills Training Group Patients|Homeless Veterans with serious mental illness who are inpatient at the VA Greater Los Angeles Domiciliary or enrolled in a VA Supported Housing (VASH) program and participating in a Housing Skills Training Group as part of routine clinical care. The intervention was 12 sessions long, with one session per week.
62611709|NCT05543031|EXPERIMENTAL|Study group|"There are 9 (35,8%) female and 14 (64,2%) male preschool cochlear implant users in the study group.~Children ranging in age from 5 to 7 who also have 5-6 years old language skills."
62835101|NCT03767413|ACTIVE_COMPARATOR|PNF group|It will be consisted of 15 -25 healthy subjects receiving only proprioceptive nueromuscular facilitation training for 5 weeks with 17 days follow up after completion of program.
62835102|NCT03767413|EXPERIMENTAL|PNFMP|It will be consisted of 15 -25 healthy subjects receiving proprioceptive nueromuscular facilitation training and mental practice technique for 5 weeks with 17 days follow up after completion of program.
62835103|NCT02270294|EXPERIMENTAL|Thai traditional massage|
62835104|NCT02270294|SHAM_COMPARATOR|No massage|
62835105|NCT05386771|EXPERIMENTAL|Whey and collagen protein blend|A blend of 25g of whey protein and 5g of collagen protein
62835106|NCT05386771|PLACEBO_COMPARATOR|Placebo|Water, same volume as the experimental study beverage
62052228|NCT04699955|NO_INTERVENTION|Assessment only Control|Participants received no intervention content. They provided assessments of past week protective strategy use, alcohol use, and alcohol problems. All assessments were delivered via an online survey.
62052229|NCT04699955|EXPERIMENTAL|Positive Message Condition|Participants received information on the positive aspects of individuals that used protective strategies and were encouraged to report why these individuals were viewed so much more positively. They provided assessments of past week protective strategy use, alcohol use, and alcohol problems. All assessments and messaging was delivered via an online survey.
62052230|NCT04699955|EXPERIMENTAL|Negative Message Condition|Participants received information on the negative aspects of individuals that did not used protective strategies and were encouraged to report why these individuals were viewed so much more negatively. They provided assessments of past week protective strategy use, alcohol use, and alcohol problems. All assessments and messaging was delivered via an online survey.
62052231|NCT02157480|NO_INTERVENTION|control|usual follow-up for 6 weeks
62253303|NCT02131441|OTHER|open liver resection|open liver resection
62442440|NCT04658056||WATER AQUABEAM Robotic System cohort|WATER Study subjects previously-treated with Aquablation of the prostate with the AQUABEAM Robotic System for lower urinary tract symptoms associated with BPH.
62442441|NCT04658056||WATER TURPS cohort|WATER Study subjects previously-treated with standard transurethral resection of the prostate (TURP) for lower urinary tract symptoms associated with BPH.
62442442|NCT03903484|EXPERIMENTAL|Deprescribing intervention|Included patient participants will meet with their clinical pharmacist to complete a survey about medication use and quality of life. Then working with the pharmacist, patients will prioritize medications that are no longer needed for discontinuing. A deprescribing plan will be created and the pharmacist will work with the patient to complete this plan. The patient will also be provided resources from the study toolbox to support the patients as they work through deprescribing the targeted drugs. Once the deprescribing plan is completed there will be a patient survey that will capture satisfaction with the deprescribing experience and patient quality of life.
62442443|NCT03836781|ACTIVE_COMPARATOR|ketorolac 3%|ketorolac 3% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
62442444|NCT03836781|OTHER|chlorhexidine 2%|chlorhexidine 2% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
62442445|NCT05361148||DIVIDS (Delhi Infant Vitamin D Supplementation) study, India|"The DIVIDS cohort were born low birth weight (LBW, \<2.5 kg) at term in 2007-2010. They had monthly follow-up until 6m then at 5 and 11 years. Anthropometry was collected at all visits, body composition in the 5 and 11 years, and blood samples at 6 months and 5 and 11 years. For SAMPA, the DIVIDS cohort acts as a positive control since we expect adverse long-term non-communicable disease consequences of being born LBW.~Sample numbers at previous follow-ups and expected:~* Birth: 2079 total, all LBW~* Age 5 y: 911 total, 764 (84%) BMIZ\>-2, 138 (15%) BMIZ -2 to -3, 9 (1%) BMIZ\<-3~* Age 11 y (ongoing): 647 total, 482 (75%) BMIZ\>-2, 117 (18%) BMIZ -2 to -3, 48 (7%) BMIZ\<-3~* Expected for SAMPA: 800 total"
62835107|NCT01048619|EXPERIMENTAL|ON 01910.Na|The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
62835108|NCT02497170|OTHER|Life style changes|Pre and post after education intervention Education program
62835109|NCT01035801|EXPERIMENTAL|IN105|Prandial Oral Insulin
62835110|NCT01035801|ACTIVE_COMPARATOR|Insulin Lispro Injection|
62835111|NCT05694416|EXPERIMENTAL|Etoposide Plus Cisplatin group|Etoposide 100mg/m2 d1-5 Cisplatin 20mg/mCisplatin d1-5
62835112|NCT05694416|NO_INTERVENTION|Temozolomide group|Temozolomide 150-200mg/m2 d1-5
62835113|NCT05744674|EXPERIMENTAL|HR18034|
62835114|NCT05744674|ACTIVE_COMPARATOR|Ropivacaine Hydrochloride Injection|
62835115|NCT01737437|EXPERIMENTAL|group L|10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
62835116|NCT01737437|PLACEBO_COMPARATOR|group C|0.9% normal saline was applied to trachea and laryngoscope blade in Group C.
62835117|NCT01737437|EXPERIMENTAL|group V|0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
62835118|NCT01737437|EXPERIMENTAL|group LV|10% Lidocaine was applied on laryngoscope blade and trachea.
62835119|NCT06004427|ACTIVE_COMPARATOR|control group|regular diet program
62253304|NCT03029741|EXPERIMENTAL|Bioavailability of AZD0284|"To assess the absolute bioavailability of a single oral dose of AZD0284 in healthy subjects.~To assess the pharmacokinetics (PK) of a single intravenous (IV) microdose of \[14C\]AZD0284 in healthy subjects."
62253305|NCT03341975|EXPERIMENTAL|Intervention|They will receive the same pamphlet as controls and the enhanced ED SexHealth intervention with the educator. Based on behaviors, CDS system recommendations (generated from screening survey responses only for intervention participants), and discussions, participants may be offered testing (for pregnancy, gonorrhea/chlamydia, and /or HIV), hormonal birth control, condoms, emergency contraception (for immediate or future use), treatment for previously diagnosed (yet untreated) infection with gonorrhea/chlamydia, and a scheduled appointment at Adolescent Clinic (for ongoing care, including repeat STI/HIV testing if needed). All services will be provided at point of care, costs will be covered by the study.
62253306|NCT03341975|NO_INTERVENTION|Control|They will receive a printed health pamphlet and a list of local resources with the phone number for Adolescent Clinic. Participants will then be referred back to their ED provider, who will provide their standard care.
62253307|NCT05476042|ACTIVE_COMPARATOR|Prescribe Erythropoieti|
62253308|NCT05476042|PLACEBO_COMPARATOR|Prescribe placebo|
62253309|NCT03926689|EXPERIMENTAL|Suaahara II Standard + SMS|Suaahara II standard multi sectoral nutrition interventions (home visits, radio program, etc.) Suaahara II monthly SMS campaign targeting all adult household members of households in the 1000-day period between conception and a child's second birthday
62253310|NCT03926689|ACTIVE_COMPARATOR|Suaahara II Standard|Suaahara II standard multi sectoral nutrition interventions (home visits, radio program, etc.)
62253311|NCT00998270|ACTIVE_COMPARATOR|Autologous arm|
62253312|NCT00998270|EXPERIMENTAL|Allogeneic arm|
62253313|NCT03073668|EXPERIMENTAL|Heart Failure Patients|After obtaining written informed consent, patients will undergo induction with general anesthesia as per clinical practice. The chest will be open but pericardium left intact. Cardiac hemodynamics will be measured using PA catheter already in place at rest, and then during conditions of increased cardiac preload, induced by passive leg elevation and saline bolus (300 ml administered over 1-2 minutes). The surgical team will perform anterior pericardiotomy. This will not be a complete pericardiectomy but rather a limited anterior incision to gain access to the heart for surgical exposure. The surgical team will then repeat hemodynamic assessments at rest and with acute volume loading (leg raise + saline) in exactly the same manner as with the pericardium intact.
62253314|NCT02831192|EXPERIMENTAL|MST（microtransplantation）|
62253315|NCT01194453|EXPERIMENTAL|Group A|
62253316|NCT01194453|ACTIVE_COMPARATOR|Group B|
62253317|NCT04941066|EXPERIMENTAL|Active neurofeedback|Receiving feedback signals from the rumination-related brain functional connectivity.
62253318|NCT04941066|SHAM_COMPARATOR|Sham neurofeedback|Receiving artificially generated feedback signals.
62253319|NCT03786562|PLACEBO_COMPARATOR|Placebo group|
62253320|NCT03786562|ACTIVE_COMPARATOR|Nalbuphine group|
62253321|NCT01400035||test group, control group|"Test group: Patients will be given cytidine diphosphate choline 0.4-0.5g, aspirin 75-100mg or Clopidogrel 75mg, intravenous infusion of Cavinton 30mg once a day.~Control group: Patients will be given cytidine diphosphate choline 0.4-0.5g, aspirin 75-100mg or Clopidogrel 75mg once a day."
62442446|NCT05361148||SAM (Severe Acute Malnutrition) Lusaka|"This group comprises children with or without prior MALN in early childhood. Some are from a study which identified 1195 children with MALN (mean age 16 months, 11.6% HIV-infected) in a house-to-house survey in a low-income area, Misisi, Lusaka in 2009. Some children are from a study of body composition and indicators of chronic diseases (HbA1c, lipids); 100 were hospitalised with MALN when \< 2 years and 76 are never-malnourished neighbourhood controls.~Sample numbers at previous follow-ups and expected:~* Age \< 2 y: 400 total, 200 WHZ\<-3, 200 well-nourished~* Age 9 y: 186 total, 110 previous MALN, 76 no MALN; currently 17 (9%) BMIZ \<-2~* Expected for SAMPA: 400 total"
62611710|NCT05543031|EXPERIMENTAL|Control group|"There are 9 (35.8%) female and 14 (64,2%) male preschool children with normal hearing in the control group.~Children ranging in age from 5 to 6 who also have age-appropriate language skills."
62052232|NCT02157480|EXPERIMENTAL|electrostimulation 3 days per week|20 minutes ambulatory bi-quadricipital electrostimulation sessions three times per week for 6 weeks
62052233|NCT02157480|EXPERIMENTAL|electrostimulation 5 days per week|20 minutes ambulatory bi-quadricipital electrostimulation sessions five times per week for 6 weeks
62611711|NCT06513156|NO_INTERVENTION|Treatment As Usual|Will receive treatment for infection and opioid use disorder per the usual care at each hospital
62835120|NCT06004427|EXPERIMENTAL|exercise group|resistance exercise program
62253322|NCT01210092||Macintosh #3 Laryngoscope|
62253323|NCT01210092||Glidescope|
62253324|NCT01210092||Ambu Pentax AWS|
62253325|NCT01210092||McGrath|
62253326|NCT01210092||Airtraq|
62253327|NCT01210092||Storz C-MAC|
62253328|NCT01898871|EXPERIMENTAL|Ready to Use Suplementary Food (RUSF)|A daily ration of 40 kcal/kg of body weight during 56 days
62253329|NCT01898871|ACTIVE_COMPARATOR|Corn Soya Blend (CSB+)|A daily ration of 40 kcal/kg of body weight during 56 days
62253330|NCT01421940|PLACEBO_COMPARATOR|Control|Individuals who take placebo after total mesorectal excision
62253331|NCT01421940|EXPERIMENTAL|Udenafil|Individuals who take udenafil after total mesorectal excision
62253332|NCT02630342|EXPERIMENTAL|Group 1: preparation materials only|This group will receive preparation materials for a clinical MRI scan. These include links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan. Preparation for this group will occur only at home.
62253333|NCT02630342|EXPERIMENTAL|Group 2: Materials with review|This group will receive in preparation for a clinical MRI scan links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan. Preparation for this group will occur at home and include a visit with research team to review preparation materials with the research team
62442447|NCT05361148||CICADA (Chronic Infections, Co-morbidities and Diabetes in Africa), Mwanza, Tanzania|"The CICADA cohort comprises HIV-infected and uninfected recruited since 2010. CICADA involved 3 annual visits for data on HbA1c, OGTT, insulin, anthropometry, body composition, and diabetes lifestyle risk factors. CICADA has the most detailed longitudinal diabetes data of the project cohorts, archived fasting samples, and are the oldest so have had longer to develop diabetes; therefore, this cohort will be used for the in-depth and longitudinal components (hypotheses 3 and 4).~Sample numbers at previous follow-ups and expected:~* 12 y prior: 447 total, 300 (67%) BMI \> 18.5 kg/m2, 74 (17%) BMI 17 to 18.5 kg/m2 73 (16%) BMI \<17 kg/m2~* 10 y prior: 704 total, 304 (43%) BMI 17 to 18.5 kg/m2, 400 (57%) BMI\<17 kg/m2~* 3 y prior: 1947 total, 1519 (78%) BMI \> 18.5 kg/m2, 275 (14%) BMI 17 to18.5 kg/m2, 152 (8%) BMI \<17 kg/m2~* Expected for SAMPA: 1200 total"
62052234|NCT02344446|EXPERIMENTAL|Skilled Therapy|Differential physical therapy treatment, based on assessment results, with follow-up visits for PT treatment 1 - 2 times per week until patient achieves at least 1 primary outcome. They will pragmatically design an individualized and progressive treatment plan, including manual therapy (manipulation and/or mobilization), neuromotor control strategies, and vestibular rehabilitation techniques, depending on the findings at assessment and patient response. Therapists can also tailor education regarding mental and physical rest according to specific parameters provided by the treating physician. Patients may also be prescribed a home exercise program and exercise education. The precise treatment strategies will be recorded.
62835121|NCT00427765|EXPERIMENTAL|Busulfan + Melphalan|Busulfan 32 mg/m\^2 intravenous (IV) for 1 Day then 130 mg/m\^2 IV for 4 Days; and Melphalan 70 mg/m\^2 IV for 2 Days
62835122|NCT01198977|ACTIVE_COMPARATOR|Brief telephone-based counseling|Telephone based counseling and instructional video
62835123|NCT01198977|PLACEBO_COMPARATOR|Education Counseling|Mailed Physical Activity information and instructional video only
62835124|NCT01716234|EXPERIMENTAL|POS 12 BID 2 to <7 Years|Participants aged 2 to \<7 years received posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
62835125|NCT01716234|EXPERIMENTAL|POS 12 BID 7 to <18 Years|Participants aged 7 to \<18 years received posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
62052235|NCT05208684|EXPERIMENTAL|Breast stimulation|A 30-minute stimulation with moderate intensity by an electric milk pump (Elvie Pump) will be performed.
62253334|NCT02630342|EXPERIMENTAL|Group 3: Mock MRI scanner|This group will receive the same materials as training group 1. In addition they will attend the mock scanner where the research team will utilise a mock MRI scanner to practice lying down in a scanner, staying still , wearing headphones and watching a movie/video on the mirror system.
62253335|NCT02630342|NO_INTERVENTION|Neuro-oncology retrospective controls|A retrospective control group of neuro-oncology patients from the 3 years prior to the study initiation. This group will be used to determine the age at which patients were able to complete a diagnostic MRI without GA
62253336|NCT02630342|EXPERIMENTAL|Neuro-oncology prospective|Child life specialist preparation will be provided to these patients. This preparation for Diagnostic MRI scanning in which utilise the Mock MRI scanner as preparation for the scan.
62253337|NCT05315050|EXPERIMENTAL|Educational session and Informational Pamphlet|
62442448|NCT05361148||NUSTART Lusaka|"We will trace and recruit 200 previously malnourished HIV-infected adults from the NUSTART Lusaka participants plus 100 non-HIV-infected neighbourhood controls to the SAMPA study. As for NUSTART Mwanza, there was a high mortality rate during the first 12 weeks of ART.~Sample numbers at previous follow-ups and expected:~* 10 y prior: 1111 total, 437 (39%) BMI 17 to 18.5 kg/m2, 674 (61%) BMI\<17 kg/m2~* Expected for SAMPA: 300 total"
62253338|NCT05315050|ACTIVE_COMPARATOR|Informational Pamphlet|
62253339|NCT04165226|ACTIVE_COMPARATOR|Low level light therapy (LLLT)|Low level light therapy using 808/915 nm infra red diode laser
62253340|NCT04165226|ACTIVE_COMPARATOR|Fractional CO2|Fractional carbon dioxide laser 10600 nm
62253341|NCT04165226|ACTIVE_COMPARATOR|Combined fractional CO2 and LLLT|Combined fractional CO2 laser and low level light therapy
62253342|NCT01154244||Drug naive type II DM|Newly diagnosed type II Diabetes Mellitus
62442449|NCT05361148||St-ATT (Starting Anti-TB Treatment) Cohort, Philippines|"Between Aug 2018 and Feb 2020, the St-ATT cohort recruited 900 adults within 5 days of starting a new 6 or 9 month anti-TB regimen in three provinces: Cebu, Negros Occidental and Metro Manila, encompassing urban, peri-urban and rural populations. 17% had HbA1c \>=7.0% (probable diabetes in TB) with an additional 30% with HbA1c 5.8%-7.0% ('prediabetes'/mild TB-induced hyperglycaemia). Post-treatment follow-up is ongoing. This cohort will be involved in in-depth analyses for hypothesis 3.~Sample numbers at previous follow-ups and expected:~* 1-2 y prior: 900 total, 495 BMI \>18.5 kg/m2, 189 (21%) BMI 17.0 -18.5 kg/m2, 216 (24%) BMI \<17 kg/m2~* Expected for SAMPA: 600 total"
62442450|NCT05361148||CLHNS (Cebu Longitudinal Health and Nutrition Survey), Philippines|"The cohort was recruited in 1983-84. Since the original follow-up to age 2 years, there have been 8 follow-up surveys including in 2019 when 1300, \~40% of the initial cohort, were available. Loss from the cohort over time is mostly from out-migration and those remaining are more rural and of lower socioeconomic status. In follow-up surveys, data collection included: anthropometry, diet (24-hr recall), health history, blood pressure and other chronic disease risk factors, school achievement, and, for older ages, reproductive history. This cohort represents our longest follow-up of MALN diagnosed by anthropometry resulting primarily from poor nutrition, not specific severe infections.~Sample numbers at previous follow-ups and expected:~* Birth: 28 LBW of the 144 with childhood MALN~* Age \< 2 y: of 420 total to be included, 144 (34%) WHZ\<-3~* Expected for SAMPA: 420 total"
62442451|NCT01995617|EXPERIMENTAL|Low Dose (Cohort 1)|
62835126|NCT01716234|EXPERIMENTAL|POS 18 BID 2 to <7 Years|Participants aged 2 to \<7 years received posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
62835127|NCT01716234|EXPERIMENTAL|POS 18 BID 7 to <18 Years|Participants aged 7 to \<18 years received posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
62835128|NCT01716234|EXPERIMENTAL|POS 18 TID 2 to <7 Years|Participants aged 2 to \<7 years received posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
62835129|NCT01716234|EXPERIMENTAL|POS 18 TID 7 to <18 Years|Participants aged 7 to \<18 years received posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
62835130|NCT01716234|EXPERIMENTAL|POS 12 TID 3 months to <2 Years|Participants aged 3 months to \<2 years received posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
62835131|NCT02387502|EXPERIMENTAL|Intubation with Macintosh laryngoscope|40 patients were intubated with Macintosh laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
62835132|NCT02387502|ACTIVE_COMPARATOR|Intubation with MacCoy laryngoscope|40 patients were intubated with MacCoy laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
62835133|NCT02387502|ACTIVE_COMPARATOR|Intubation with Airtraq laryngoscope|40 patients were intubated with Airtraq laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
62253343|NCT06010771|NO_INTERVENTION|Control Group|Routine aspiration will be applied to the control group. No action will be taken.
62253344|NCT06010771|EXPERIMENTAL|Experimental Group|During the aspiration process, the experimental group will listen to fairy tales and watch cartoons.
62253345|NCT01634035||diabetic hemodialysis|all patient diabetic and on hemodialysis were involved if they are on hemodialysis for more than 3 months
62835134|NCT04002102|EXPERIMENTAL|OLP treatment|Participants randomized to the treatment group will receive: 1) educational materials; 2) positive expectancy; 3) 2 placebo pills twice a day for 21 days.
62253346|NCT03086499||The study population|Patients with pectus excavatum having consulted at the Montpellier University Hospital and who have had corrective surgery.
62835135|NCT04002102|OTHER|Usual care|Participants randomized to the no treatment group will remain in standard care alone for 21 days and receive educational materials.
62253347|NCT04026347|EXPERIMENTAL|Vesair|Subjects are treated with Vesair Balloon at enrollment (day 0)
62253348|NCT04026347|SHAM_COMPARATOR|Sham|Subjects are treated with sham at enrollment (day 0) and treated with balloon (if desired) after six month visit.
62253349|NCT03664154|EXPERIMENTAL|Stress and Feeding (SAFE)|The SAFE intervention is grounded in a general theory of guided participation (GP) that posits learning will be facilitated by an emotionally regulated state of the mother. Efforts to help mothers manage stress will better position them to learn and attend to feeding their infants. GP links the two components: stress management (SM) and guided feeding (GF). SM provides skills to manage perceived stress and regulate emotion. GF provides education with skill building to help mothers become more sensitive and responsive to their infant. SAFE is delivered through a secure, password-protected responsive website with practice opportunities.
62253350|NCT01839396|ACTIVE_COMPARATOR|Medium continuous dose of stimulation|Subjects in this arm will receive stimulation settings at a medium continuous dose of Deep Brain stimulation that may have been effective in previous DBS patients.
62253351|NCT01839396|SHAM_COMPARATOR|Low intermittent dose of stimulation|Subjects in this arm will receive stimulation settings at a lower intermittent dose of Deep Brain stimulation which is less likely to be effective.
62253352|NCT04568278|EXPERIMENTAL|Intervention Group|a mobile application using the PRO-CTCAE along with usual care
62253353|NCT04568278|NO_INTERVENTION|Controlled Group|Usual care
62253354|NCT06208384|EXPERIMENTAL|Statin eye drop|Use of topical atorvastatin eye drop 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
62253355|NCT06208384|PLACEBO_COMPARATOR|Control|Use of topical eye drops as a placebo same as intervention group but without active ingredient of atorvastatin 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
62835136|NCT04002102|ACTIVE_COMPARATOR|Expectancy Group|Participants receive educational materials and positive expectancy orientation via Zoom or telephone
62835137|NCT04157413||Stunted Group|A comparative cross sectional study will compare stunted group and non-stunted group on amino acid intake, blood amino acid and intestinal permeability. Stunted group is defined as children who have LAZ \<-2 SD
62253356|NCT00773721|EXPERIMENTAL|1|Volunteers who are currently using CPAP treatment will trial a new mask system for up to five weeks
62253357|NCT01776762|EXPERIMENTAL|Individual nutritional therapy|Individual nutritional therapy provided by registered dietician by means of three Home-visits
62623584|NCT03472937|ACTIVE_COMPARATOR|Outpatient cervical ripening group|Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (intervention arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next day to be admitted to labor and delivery for induction of labor with oxytocin.
62835138|NCT04157413||Non-stunted Group|Non-stunted group will be those with LAZ \>= 0.5 SD matching by age and sex with stunted group. Other criteria will be similar. No Intervention will be given to the groups in this proposed protocol.
62835139|NCT04205877||Registry Group|All participants will have the same data collected at the same time points.
62835140|NCT06589089|EXPERIMENTAL|Patients treated with stem cell boost|If the patient continues to have unrelieved hematologic toxicity after CAR-T cell therapy, consider infusing a reserve of stem cells; If there is no significant recovery from myelosuppression, another stem cell infusion can be performed.
62835141|NCT00892476|EXPERIMENTAL|1|Infants receive supplemental calcium in their 24 cal/oz formula or fortified breast milk.
62052236|NCT06384586|PLACEBO_COMPARATOR|Placebo|Placebo 60 ml Shot, matched in volume, taste and colour and did not contain any active ingredients. 1 shot to be consumed per session
62052237|NCT06384586|EXPERIMENTAL|Functional Energy shot|60ml functional energy shot contained a proprietary blend of caffeine, ginseng, vitamins and taurine. 1 shot to be consumed per session
62253358|NCT01776762|NO_INTERVENTION|Standard Follow-home programme|Standard Follow-home programme without individual nutritional therapy
62253359|NCT03000179|EXPERIMENTAL|Avelumab Monotherapy|Participants receive avelumab by IV infusion following pretreatment with H1 blockers and acetaminophen once every 2 weeks.
62253360|NCT02794818||Participating Patients|Participating patients will receive a prescription for weekly CSA produce boxes with nutritional education
62253361|NCT02794818||Participating Providers|Participating providers will be surveyed at the end of the pilot to evaluate their perceived program efficacy, the benefit of the program to their patients, and elicit program feedback.
62253362|NCT05453032|EXPERIMENTAL|Patients with BPD assigned to the trial of 10 active tDCS sessions followed by psychotherapy|Patients diagnosed with Borderline Personality disorder and BPDSI score is \> or = 17 will be assigned for active tDCS session (NeuroConn, Germany) candidates will have 20-minute session per day for 10 weekdays in 2 weeks. Then they will attend short term psychotherapy session for 3 months.
62253363|NCT04169490|EXPERIMENTAL|FS2 Emulsion Moisturizer|The FS2 Emulsion Moisturizer Arm is comprised of three (3) topical treatments including: Placebo Cream Base Emulsion Moisturizer, FS2 Emulsion Moisturizer and Active Comparator Onion Skin Extract Gel (Mederma). The topical treatments are applied b.d. for 120 days.
62253364|NCT04169490|EXPERIMENTAL|Active Comparator + FS2 Emulsion Moisturizer|The Active Comparator + FS2 Emulsion Moisturizer Arm is comprised of two (2) topical treatments including: Active Comparator Silicone Gel (Kelo-Cote), and Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer. The topical treatments are applied b.d. for 120 days.
62442452|NCT01995617|EXPERIMENTAL|Mid Dose (Cohort 2)|
62835142|NCT00892476|ACTIVE_COMPARATOR|2|Infants will receive fortified breast milk or 24 cal/oz formula
62835143|NCT04601961|ACTIVE_COMPARATOR|SEVO Group|Patients in SEVO group will be anaesthetized by inhalational anaesthesia using sevoflurane.
62835144|NCT04601961|EXPERIMENTAL|TIVA group|The patients in TIVA group will be anaesthetized using total intravenous propofol.
62835145|NCT06473636|EXPERIMENTAL|mindfulness group|Received a four-week mindfulness training program.
62835146|NCT06473636|NO_INTERVENTION|control group|Received only one mindfulness lecture over four weeks. Following the completion of the study, the control group could also undergo the same mindfulness training program if they volunteered.
62835147|NCT02773810|EXPERIMENTAL|Integrated Family Planning Services|Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
62835148|NCT06244160|EXPERIMENTAL|Intervention|High flow oxygen therapy delivered via nasal cannalue
62835149|NCT06244160|NO_INTERVENTION|Control|Standard care with oxygen therapy as required.
62052238|NCT01094132|OTHER|Review by colposcopy + multispectral digital colposcopy|All patients belong under this arm, as all will be reviewed by both conventional colposcopy and by Multispectral Digital Colposcopy (MDC). The nature of these techniques are explained below.
62052239|NCT06524726||PNH patients not receiving anti-complement treatment|PNH patients of any age who are not receiving any anti-complement treatment
62442453|NCT01995617|EXPERIMENTAL|High Dose (Cohort 3)|
62442454|NCT03086720|EXPERIMENTAL|Sodium hypochlorite|Dentin pre-treatment with a experimental solution (sodium hupochlorite), after the dentin acid etching
62442455|NCT03086720|PLACEBO_COMPARATOR|Water|Application of water (placebo) after dentin acid etching
62442456|NCT05332210|EXPERIMENTAL|HBM9161 Drug Product (680mg)|"HBM9161 680mg: subcutaneous injection, 6 times per treatment cycle, once a week; the second cycle of treatment may start 4 weeks after the last dose of the previous treatment cycle; if the disease state is still stable 4 weeks after the last dose, the observation can be continued until the disease activity is aggravated (improvement of MG-ADL \< 3 points compared with the previous treatment cycle), and the next treatment cycle can start.~The dose may be reduced to 340 per investigator's discretion. Return to the dose of 680 mg is not permitted after a dose reduction is made."
62835150|NCT01850212||Male (≥ 50 years), TDF|Male (≥ 50 years of age) on regimens containing tenofovir disoproxil fumarate (TDF)
62835151|NCT01850212||Male (≥ 50 years of age), Non-TDF|Male (≥ 50 years of age) on non-TDF (tenofovir disoproxil fumarate) based nucleoside reverse transcriptase inhibitors (NRTIs)
62442457|NCT03713710|EXPERIMENTAL|Pap testing|Women assigned to this arm will be scheduled a Pap testing appointment at the local health department
62835152|NCT01850212||Female (Postmenopausal), TDF|Female (postmenopausal) on regimens containing tenofovir disoproxil fumarate (TDF)
62835153|NCT01850212||Female (Postmenopausal), Non-TDF|Female (postmenopausal) on non-TDF (tenofovir disoproxil fumarate) based NRTIs
62835154|NCT00925457||001|Current Domperidone Current domperidone at any dose regardless of proton pump inhibitor status
62835155|NCT00925457||002|Current proton pump inhibitor (PPI) Current PPI and not current dapoxetine
62835156|NCT00925457||003|No Intervention Neither current domperidone nor current PPI
62835157|NCT03081429||With stroke|
62835158|NCT03081429||Without stroke|
62835159|NCT06516029||Overall Asciminib Cohort|Adult patients diagnosed with Ph+ CML-CP, with or without the T3151 mutation, who initiated asciminib in any line of therapy.
62442458|NCT03713710|EXPERIMENTAL|Choice|Women assigned to this arm will be given a choice between scheduling an appointment for a Pap testing at the health department or engage in self-sampling for HPV testing at home
62442459|NCT00614055|ACTIVE_COMPARATOR|Insulin glargine|
62442460|NCT00614055|EXPERIMENTAL|SIAC 30 (B)|
62442461|NCT00614055|EXPERIMENTAL|SIAC 45 (B)|
62442462|NCT02853929|EXPERIMENTAL|dTpa Group|This group will consist of healthy male or female infants, aged 9 months at the time of enrollment, born to mothers who received a single dose of Boostrix during pregnancy and a dose of placebo immediately post-delivery. All enrolled subjects in this group who will come back for subsequent visit will receive a booster dose of Infanrix hexa co-administered with Prevenar 13 according to the routine national/local immunization or study procedure
62442463|NCT02853929|ACTIVE_COMPARATOR|Control Group|This group will consist of healthy male or female infants, aged 9 months at the time of enrollment, born to mothers who received a dose of placebo during pregnancy and single dose of Boostrix immediately post-delivery. All enrolled subjects in this group who will come back for subsequent visit will receive a booster dose of Infanrix hexa co-administered with Prevenar 13 according to the routine national/local immunization or study procedure
62442464|NCT05593406|EXPERIMENTAL|Vibration Group|The intervention-vibration group, in addition to the conventional physical therapy- NDT they received, were also included in mechanical vibration.
62623585|NCT03271593||All children admitted|All children admitted to hospital
62835160|NCT05623917|EXPERIMENTAL|Exercised group|the group will contain 20 females. the females will receive tele-supervised Diaphragmatic Respiratory Exercise ( applied at the homes of the females two times per the day, at the morning and at the evening, twenty minutes for every time, the sessions will be applied daily for 3 months in all females).
62835161|NCT05623917|NO_INTERVENTION|control group|he females in the this group will be waiting-list control females who will receive no training.
62835162|NCT04686669|EXPERIMENTAL|Subjects receiving treatment sequence ABC|Subjects will receive treatment sequence ABC on Days 1, 3 and 5 respectively; A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state, C= 3x50 milligrams FOR-6219 tablet given in fasted state.
62835163|NCT04686669|EXPERIMENTAL|Subjects receiving treatment sequence BCA|Subjects will receive treatment sequence BCA on Days 1, 3 and 5 respectively; B= 3x50 milligrams FOR-6219 tablet given in fed state, C= 3x50 milligrams FOR-6219 tablet given in fasted state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state.
62835164|NCT04686669|EXPERIMENTAL|Subjects receiving treatment sequence CAB|Subjects will receive treatment sequence CAB on Days 1, 3 and 5 respectively; C= 3x50 milligrams FOR-6219 tablet given in fasted state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state.
62611712|NCT06513156|EXPERIMENTAL|Integrated Infectious Diseases and Medication for Opioid Use Disorder Clinic (IC)|The Integrated ID/MOUD Clinic will provide facilitated linkage to a clinic providing medical treatment aimed at treating OUD, resolving the sentinel infection, treating existing ID complications of OUD (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and MOUD treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and MOUD providers. The dual goals of the IC intervention are to 1) to facilitate accessibility to ID and OUD care and 2) to ensure care coordination between outpatient ID and MOUD providers.
62611713|NCT06513156|EXPERIMENTAL|NavSTAR-CHOICE (NS)|The NavSTAR (NS) arm will consist of targeted support delivered by a Patient Navigation team (see Navigation Dyad, below) to enhance participants' linkage with outpatient OUD treatment and recommended medical care for infections and other presenting illnesses. The Navigation Dyad will work in concert with existing resources in the hospital system and broader community to ensure continuity of care (initial linkage and subsequent retention) during the 6-month period after hospital discharge when patients are at elevated risk of disengaging from care, inpatient readmission, and other adverse outcomes.
62611714|NCT03959904|ACTIVE_COMPARATOR|Small Stitch|Small stitch for wound closure
62611715|NCT03959904|ACTIVE_COMPARATOR|Large Stitch|Large Stitch for wound closure
62611716|NCT05194956|EXPERIMENTAL|Arm 1 - Alginate impressions followed by digital intraoral scan|The participant will have alginate impressions taken for orthodontic treatment records first. Followed by a digital intraoral scan a minimum of 4-6 weeks washout period. After each intervention, the participant will complete a modified visual analogue scale (VAS) questionnaire about their experience.
62623586|NCT02032615|ACTIVE_COMPARATOR|Education plus Gudness Nutritional Bar|Subjects will receive education about anemia and will consume Gudness Nutrition bars for 3 months
62835165|NCT04686669|EXPERIMENTAL|Subjects receiving treatment sequence ACB|Subjects will receive treatment sequence ACB on Days 1, 3 and 5 respectively; A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, C= 3x50 milligrams FOR-6219 tablet given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state.
62835166|NCT04686669|EXPERIMENTAL|Subjects receiving treatment sequence BAC|Subjects will receive treatment sequence BAC on Days 1, 3 and 5 respectively; B= 3x50 milligrams FOR-6219 tablet given in fed state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, C= 3x50 milligrams FOR-6219 tablet given in fasted state.
62835167|NCT04686669|EXPERIMENTAL|Subjects receiving treatment sequence CBA|Subjects will receive treatment sequence CBA on Days 1, 3 and 5 respectively; C= 3x50 milligrams FOR-6219 tablet given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state.
62835168|NCT02916368||with surgery|
62835169|NCT02916368||with chemotherapy or radiotherapy|
62253365|NCT04192851|EXPERIMENTAL|Tent Pole Grafting Technique|"* Bone graft \[NanoBone® granulate 0,6 mm (24% Silica / 76% Hydroxylapatite)\] is mixed with the patient blood and placed to cover the screws completely, the defect is overcorrected with particulate material in anticipation of future graft resorption.~* PRF membrane is prepared by:~Ten milliliters of whole venous blood will be collected in sterile glass test tubes without anticoagulant. Then the test tubes will be placed in a table centrifuge machine at 3000 revolutions per minute (rpm) for 10 minutes.After separation of PRF, the membrane is prepared compression device."
62253366|NCT03487809||NTUH|National Taiwan University Hospital, all participants receive Duasma (budesonide, 200mcg/puff)
62442465|NCT05593406|ACTIVE_COMPARATOR|Control Group|The Control group received only conventional physical therapy- NDT.
62442466|NCT01523795|EXPERIMENTAL|Motion-controlled video gaming|Participants played motion-controlled video games that involved at least throwing, hitting, or dancing motions using a Wii or Xbox 360 console for one hour
62442467|NCT01523795|ACTIVE_COMPARATOR|Traditional video gaming|Participants played traditional (handheld gamepad controller-based) video games using a Playstation 3 console for one hour
62442468|NCT01523795|ACTIVE_COMPARATOR|Television watching|Participants watched television via Netflix instant streaming for one hour
62442469|NCT03348709|EXPERIMENTAL|Isoosmolar|Iso-osmolar oral supplement (276 mOsm/kg)
62253367|NCT03487809||FJUH|Fu Jen University Hospital, all participants receive Duasma (budesonide, 200mcg/puff)
62442470|NCT03348709|ACTIVE_COMPARATOR|Hyperosmolar|Hyper-osmolar oral supplement (681 mOsm/kg)
62442471|NCT02531542|OTHER|READ echography|
62253368|NCT03487809||CGH|Cathay General Hospital, all participants receive Alvesco (Ciclesonide, 160mcg/puff)
62253369|NCT00535314|EXPERIMENTAL|RTA 402 Dose1|Dose1 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
62442472|NCT01684566|EXPERIMENTAL|Standard-Of-Care + episil(R)|Standard-Of-Care plus episil® administered as three consecutive pump-strokes for a total volume of 0.45 mL applied 3 times daily and additionally, as needed
62442473|NCT01684566|OTHER|Standard-Of-Care|Oral hygiene procedures
62442474|NCT01808209|EXPERIMENTAL|stenfilcon A|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
62442475|NCT01808209|ACTIVE_COMPARATOR|filcon II 3|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
62442476|NCT01178983|EXPERIMENTAL|telebiofeedback|
62442477|NCT01178983|ACTIVE_COMPARATOR|biofeedback|
62253370|NCT00535314|EXPERIMENTAL|RTA 402 Dose2|Dose2 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
62052240|NCT06524726||PNH patients receiving anti-complement treatment|PNH patients of any age who are receiving an approved anti-complement treatment
62253371|NCT01751399|EXPERIMENTAL|LY2605541-Normal Hepatic Function|Participants with normal hepatic function will receive a single subcutaneous (SC) dose of 0.075 milligrams per kilogram (mg/kg) LY2605541
62442478|NCT03811041|EXPERIMENTAL|PC articulated with MDA|Depressed parent encountered in PC for confirmation of depression with Hopkins Symptom Checklist-25 (HSCL25) scale. If confirmed, the adolescent will also be encountered by the GP for a screening test of depression (Adolescent Depression Rating Scale - ADRS). If negative, the patient will go out of the study. If positive, 2 others tests will be performed to study the intensity of the depression (Child depressionInventory - CDI) and the quality of life (Pediatric Quality of Life InventoryTM).Finally, the patient will be oriented to the MDA of Brest and will meet again the GP at 6 and 12 month to answers the same tests.
62442479|NCT03811041|ACTIVE_COMPARATOR|Routine cares|Depressed parent encountered in PC for confirmation of depression with Hopkins Symptom Checklist-25 (HSCL25) scale. If confirmed, the adolescent will also be encountered by the GP for a screening test of depression (Adolescent Depression Rating Scale - ADRS). If negative, the patient will go out of the study. If positive, 2 others tests will be performed to study the intensity of the depression (Child depressionInventory - CDI) and the quality of life (Pediatric Quality of Life InventoryTM). Finally, the patient will be oriented to the routine cares and will meet again the GP at 6 and 12 month to answers the same tests.
62052241|NCT01631890|ACTIVE_COMPARATOR|standard endotherapy|
62253372|NCT01751399|EXPERIMENTAL|LY2605541-Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541
62253373|NCT01751399|EXPERIMENTAL|LY2605541-Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541
62253374|NCT01751399|EXPERIMENTAL|LY2605541-Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541
62442480|NCT03811041|EXPERIMENTAL|Parental depression|Parental depression will be studied. Depressed adolescent encountered in MDA of Marseille for confirmation of depression with 3 tests : ADRS, CDI and PedsQL. If positive, the parent will come to the MDA for a screening test of depression (HSCL25). Parents and adolescent are seen only once.
62442481|NCT02062606||AIS|Surgical implantation of the K2M MESA Rail™ Deformity System in the treatment of Adolescent Idiopathic Scoliosis (AIS).
62442482|NCT05273385|EXPERIMENTAL|Nanodropper|Participants will receive the Nanodropper with instructions and attend clinic visits at baseline, 1, and 3 months. Participants will administer their eye drops using the Nanodropper.
62442483|NCT05273385|NO_INTERVENTION|Standard of Care Dropper|Participants will receive standard of care eye dropper with instructions and attend clinic visits at baseline, 1, and 3 months. Participants will administer their eye drops using the standard of care eye dropper.
62611717|NCT05194956|EXPERIMENTAL|Arm 2 - Digital intraoral scan followed by alginate impressions|The participant will have a digital intraoral taken for orthodontic treatment records first. Followed by alginate impressions a minimum of 4-6 weeks washout period. After each intervention, the participant will complete a modified visual analogue scale (VAS) questionnaire about their experience.
62611718|NCT00006305|ACTIVE_COMPARATOR|Revascularization and Insulin Providing (IP)|Prompt revascularization with intensive medical therapy and insulin providing glycemic control strategy
62611719|NCT00006305|ACTIVE_COMPARATOR|Revascularization and Insulin Sensitizing (IS)|Prompt revascularization with intensive medical therapy and insulin sensitizing glycemic control strategy
62611720|NCT00006305|ACTIVE_COMPARATOR|Medical Therapy and Insulin Providing (IP)|Intensive medical therapy with delayed revascularization if clinically indicated and insulin providing glycemic control strategy
62052242|NCT01631890|EXPERIMENTAL|Endoscopic Ultrasound assisted endoscopic glue injection|
62052243|NCT03375502|EXPERIMENTAL|MG1111(Varicella vaccine)|A single injection of 0.5ml MG1111 will be administered subcutaneously at Visit 1
62052244|NCT03375502|ACTIVE_COMPARATOR|Comparator(Varicella vaccine)|A single injection of 0.5ml comparator will be administered subcutaneously at Visit 1
62052245|NCT03476629|EXPERIMENTAL|Combined Training|Combined Training with 2 types of physical activity
62052246|NCT03476629|EXPERIMENTAL|Standard Training|Physical activity with aerobic exercise
62253375|NCT03837626|PLACEBO_COMPARATOR|Placebo|6 months of daily placebo
62253376|NCT03837626|EXPERIMENTAL|Amiloride|6 months of amiloride (max dose 5 mg) treatment
62253377|NCT03906383|EXPERIMENTAL|Remote Ischemic Conditioning|
62253378|NCT02034630|EXPERIMENTAL|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
62253379|NCT04095728|EXPERIMENTAL|Investigational Product|
62253380|NCT04095728|PLACEBO_COMPARATOR|Placebo|
62253381|NCT01054144|EXPERIMENTAL|Response Adapted Therapy|Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.
62253382|NCT04925167|EXPERIMENTAL|argatroban group|Patients received argatroban for anticoagulation during V-V ECMO.
62253383|NCT04925167|ACTIVE_COMPARATOR|UFH group|Patients received UFH for anticoagulation during V-V ECMO.
62253384|NCT02330822|EXPERIMENTAL|Hyaluronic Acid Group|In this Group, Hyaluronic acid will be injected following extraction.
62253385|NCT02330822|NO_INTERVENTION|Traditional Extraction Group|In this group, traditional extraction procedures will be followed.
62835170|NCT00003278|EXPERIMENTAL|radiation + dexamethasone|"Patients undergo whole-brain radiotherapy (WBRT) daily 5 days a week for 4.5 weeks. Beginning 30 days after WBRT is completed, patients receive high-dose dexamethasone IV on days 1-5 during course 1 and on day 1 only during all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients are followed at 1 month after radiotherapy, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter."
62835171|NCT00041561|PLACEBO_COMPARATOR|2|Nitrogen gas
62835172|NCT00041561|EXPERIMENTAL|1|Inhaled Nitric Oxide
62052247|NCT03476629|EXPERIMENTAL|Respiratory Muscle Training|Respiratory muscle performance
62052248|NCT03784040|EXPERIMENTAL|(Arm A) OTSGC-A24 + nivolumab|Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (\~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14 each 28 day cycle (q28d) for up to 24 months.
62442484|NCT04783363|EXPERIMENTAL|Arm A|"* Visit 1: with Snoezelen session before invasive care~* Visit 2: standard care (=without Snoezelen session) before invasive care"
62442485|NCT04783363|EXPERIMENTAL|Arm B|"* Visit 1: standard care (=without Snoezelen session) before invasive care~* Visit 2: with Snoezelen session before invasive care"
62442486|NCT01816698|ACTIVE_COMPARATOR|Taurine|Interventions Drug: Taurine granule Arms: Group 1
62442487|NCT01816698|PLACEBO_COMPARATOR|Placebo|Interventions Drug: Placebo Arms: Group 2
62442488|NCT01063478|EXPERIMENTAL|RAD001, Chemotherapy, Radiation|RAD001 + Chemotherapy and Radiation
62442489|NCT04877184|EXPERIMENTAL|Transcranial ultrasound stimulation and rehabilitation|The investigators expect to enroll 10 people in the experimental group.
62442490|NCT04877184|ACTIVE_COMPARATOR|Rehabilitation|The investigators expect to enroll 10 people in the control group.
62442491|NCT06169774|EXPERIMENTAL|Educational video|Participants will be asked to watch an education video addressing aseptic techniques to safely handle central catheters at home during parenteral nutrition infusions.
62442492|NCT06169774|NO_INTERVENTION|No educational video|Participants will be managed according to routine care.
62442493|NCT02646345||Pre Checklist|All surgical encounters before surgical checklist implementation
62442494|NCT02646345||Post Checklist|All surgical encounters after surgical checklist implementation
62442495|NCT06014450|EXPERIMENTAL|PCI arm|"72 stage IV NSCLC patients were randomly enrolled in the group. And all required to have a baseline negative MRI scan for central nervous system (CNS) disease.~For patients with positive TKI detection, TKI combined with concurrent radiotherapy DT60-70Gy for the primary tumor. Imaging reexamination 2 months after TKI treatment confirmed the efficacy of CR, PR, and SD; meanwhile, reexamination of head MR Examination confirmed no intracranial metastasis, and PCI was performed DT 30Gy/10f.~For patients with negative TKI detection, the treatment mode was platinum-based regimen chemotherapy combined with concurrent radiotherapy for DT60-70Gy for the primary tumor. Imaging reexamination after 2 cycles of chemotherapy confirmed the efficacy of CR, PR, and SD, and skull MR Examination confirmed that there was no intracranial metastasis. PCI DT: 30Gy/10f.Systematic imaging examinations in the first month following systemic treatment, every 3 months in 2 years, and every 6 months in 5 years."
62442496|NCT06014450|PLACEBO_COMPARATOR|observation arm|"72 stage IV NSCLC enrolled in the observation group. And all required to have a baseline negative magnetic resonance imaging (MRI) scan for central nervous system (CNS) disease. For patients with positive TKI detection, TKI combined with concurrent radiotherapy DT60-70Gy for the primary tumor.~For patients with negative TKI detection, the treatment mode was platinum-based regimen chemotherapy combined with concurrent radiotherapy for DT60-70Gy for the primary tumor. Imaging reexamination after 2 cycles of chemotherapy confirmed the efficacy of CR, PR, and SD, and skull MR Examination confirmed that there was no intracranial metastasis. then observation. Systematic imaging examinations in the first month following systemic treatment, every 3 months in 2 years, and every 6 months in 5 years."
62442497|NCT06173245|EXPERIMENTAL|Intravitreal injection of ranibizumab|These patients were received three intravitreal injection of ranibizumab with one month interval.
62442498|NCT02115256|ACTIVE_COMPARATOR|Intravenous Terbutaline|0.25 mL of Intravenous Terbutaline
62442499|NCT02115256|ACTIVE_COMPARATOR|Intravenous Nitroglycerine|IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
62835173|NCT02446574|EXPERIMENTAL|Arm A|"During the Phase I it will administered weekly paclitaxel(dose escalation) and cisplatin with concurrent radiation therapy~During the Phase II it will administered weekly paclitaxel(dose according to phase I) and cisplatin with concurrent radiation therapy"
62835174|NCT00721383|EXPERIMENTAL|Treatment|Physical activity and caregiver skill-building
62835175|NCT00721383|ACTIVE_COMPARATOR|Control|caregiver skill-building
62835176|NCT05336591||Medical doctor|
62052249|NCT03784040|EXPERIMENTAL|(Arm B) OTSGC-A24 + nivolumab + ipilimumab|Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (\~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14. Ipilimumab 1mg/kg (IV) will be administered q6w (i.e. C1D1, C2D15, C3D1 ...) of each 28 day cycle for up to 24 months.
62052250|NCT05405959|EXPERIMENTAL|Kinesiotaping (KT) with EDF technique|the patients were seated and asked to flex their neck laterally to the contralateral side and to rotate their head to the same side while the shoulder was adducted. I band was first fold in half and then divided into 5 lines without cutting the ends to form a web shape. Two pieces of web shaped 20-25 cm length KT were used. The end of the KT was applied to the acromion, and the spinal process of C7 vertebra without stretching, but the web on the muscle had %10-15 tension. The second web shaped band was applied using the same technique between acromion and thoracal vertebral insertion of the middle trapezius muscle. Kinesio tape was planned to stay on for five days; it was applied twice, with two days of rest between applications Trapezius stretching exercises were given to patients as home exercise program.
62442500|NCT01441271|ACTIVE_COMPARATOR|total abdominal colectomy|the standard of care for fulminant clostridium difficile colitis is a total abdominal colectomy
62052251|NCT05405959|SHAM_COMPARATOR|Sham Kinesiotaping|The sham group received improper KT application consisting two I strips (same material as the real application) applied with no tension on c7 spinal process as cross sign. For sham taping, the cervical spine of the participants was placed in a neutral position. Kinesio tape was planned to stay on for five days; it was applied twice, with two days of rest between applications Trapezius stretching exercises were given to patients as home exercise program
62611721|NCT00006305|ACTIVE_COMPARATOR|Medical Therapy and Insulin Sensitizing (IS)|Intensive medical therapy with delayed revascularization if clinically indicated and insulin sensitizing glycemic control strategy
62835177|NCT05336591||Nurses (Pediatric department and youth healthcare)|
62835178|NCT05336591||Other professionals in treatment (e.g. dieticians, physiotherapists)|
62835179|NCT05336591||Other (such as policy makers)|
62835180|NCT01052337|ACTIVE_COMPARATOR|propofol|
62835181|NCT01052337|ACTIVE_COMPARATOR|sevofluorane|
62052252|NCT03337646|OTHER|Lisdexamphetamine|All participants will receive Lisdexamfetamine Dimesylate (LDX) at an optimized dose based on protocol
62052253|NCT05809206|EXPERIMENTAL|Glutes maximus Strengthening group|Twenty patients received Strengthening exercises for Glutes maximus muscle and conventional physical therapy (corrective exercises and ultrasound).
62052254|NCT05809206|EXPERIMENTAL|Glutes Medius Strengthening group|Twenty patients received Strengthening exercises for Glutes medius muscle and conventional physical therapy (corrective Exercises and therapeutic ultrasound (US).
62442501|NCT01441271|EXPERIMENTAL|Ileal diversion and lavage|The tested intervention in this trial will be: intraoperative colonic lavage using a high volume polyethylene glycol/electrolyte solution, that will clear Clostridium difficile infection resulting in eradication of FCDC while preserving the colon.
62442502|NCT04473079|EXPERIMENTAL|Experimental group|These participants will receive the standard treatment for H. pylori eradication (proton-pump inhibitor and antibiotics) plus probiotic formulation (commercially-available as Lacidofil) for 12 weeks.
62611722|NCT06731192|EXPERIMENTAL|MSC Theatment|Conventional symptomatic supportive treatment and human umbilical cord mesenchymal stem cells treatment
62835182|NCT02775500||Apremilast-Exposed Cohort|Women who have been exposed to apremilast in pregnancy for an approved indication in the first trimester of pregnancy for any length of time from the date of conception.
62835183|NCT02775500||Diseased Comparison Cohort|Women with an approved disease who have not been exposed to apremilast at any time in pregnancy.
62835184|NCT02775500||Healthy Comparison Cohort|Healthy women who have no diagnosis of an approved indication or other chronic illness, have not taken apremilast in pregnancy, nor have they been exposed to any known human teratogen during pregnancy.
62835185|NCT02775500||Apremilast-Exposed Registry Group|Women who have been exposed to apremilast in pregnancy, for any length of time following the first day of the last menstrual period until the end of pregnancy who do not qualify for the prospective cohort study.
62835186|NCT02740101|EXPERIMENTAL|oxytocin nasal spray|subjects administrating oxytocin were divided into experimental group
62442503|NCT04473079|PLACEBO_COMPARATOR|Placebo group|These participants will receive the standard treatment for H. pylori eradication (proton-pump inhibitor and antibiotics) plus placebo for 12 weeks.
62442504|NCT01793610|ACTIVE_COMPARATOR|Comparator-dose (40 mg) MDMA and Psychotherapy|Participants receive an initial dose of comparator-dose MDMA (40 mg) during each of the two experimental sessions.
62442505|NCT01793610|EXPERIMENTAL|Active Dose 2 (100 mg) MDMA and Psychotherapy|Participants receive an initial dose of Active Dose 2 MDMA (100 mg) during each of the two experimental sessions.
62611723|NCT06731192|PLACEBO_COMPARATOR|Placebo Control|Conventional symptomatic supportive treatment and normal saline as a placebo control
62611724|NCT01325194|EXPERIMENTAL|CNS prophylaxis|
62611725|NCT02494401|ACTIVE_COMPARATOR|Internet-based self-management program|Internet-based self-management program Patients randomized to active treatment intervention will be assigned to the Internet program. The site will be accessed via secured website. The modules will be presented 1-2 per week and will be moderated by a researcher with expertise in moderating Discussion Boards.
62253386|NCT02968069|EXPERIMENTAL|Suspected gastric cancerous lesions|Magnifying endoscopy with NBI would be conducted for every patient included in our study
62442506|NCT01793610|EXPERIMENTAL|Active Dose 1 (125 mg) MDMA and Psychotherapy|Participants receive an initial dose of Active Dose 1 MDMA (125 mg) during each of two experimental sessions.
62611726|NCT02494401|OTHER|Education book group|Educational book group. Participants in the control group will receive a copy of The Scleroderma Book: A Guide for Patients and Families, by Dr. Maureen Mayes.
62253387|NCT05239611|NO_INTERVENTION|Usual care|Participants will receive usual standard of care
62253388|NCT05239611|ACTIVE_COMPARATOR|exercise coaching|Participants will receive weekly coaching intervention
62253389|NCT00947700|NO_INTERVENTION|Assessment & Monitoring|No Intervention. Parent-Child participants in assessment and monitoring visits but does not receive any study provided treatment.
62442507|NCT02226796|ACTIVE_COMPARATOR|Prime Condition|The primed (PRIME) condition is an intervention that will consist of presentation of a-tDCS for 20 minutes to the dorsolateral prefrontal cortex prior to 40 minutes of behavioral naming treatment, while the subject sits comfortably in a chair.
62442508|NCT02226796|ACTIVE_COMPARATOR|Non-Prime Condition/Control|The non-primed (NON-PRIME) condition, or sham controlled, is an intervention that will consist of presentation of sham tDCS to the dorsolateral prefrontal cortex for 20 minutes prior to 40 minutes of behavioral naming treatment, while the subject sits comfortably in a chair.
62442509|NCT02958657|EXPERIMENTAL|Exercise Training|Patients randomized to the training group will start the supervised regular training program 01 month after the myocardial infarction, and it will last for three months.
62442510|NCT02958657|NO_INTERVENTION|Control Group|Patients in the control group will receive general instructions regarding rehabilitation post-acute myocardial infarction and will be followed for four months after the myocardial infarction.
62442511|NCT01618266||Ozurdex® (dexamethasone intravitreal implant)|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
62442512|NCT01243996|EXPERIMENTAL|Infant treated with high dose ibuprofen|
62611727|NCT03217968|EXPERIMENTAL|Active|120 minutes of Cefaly® Abortive Program device stimulation as abortive treatment of an early stage migraine attack
62611728|NCT03777111|ACTIVE_COMPARATOR|Single Task Training Group|"Gait and balance exercises will be applied in single task training group.~* Semi-tandem, tandem stand with eyes open and close~* One leg stance with eyes open and close~* Gait exercises; walking forwards, backwards, sidewards, semi-tandem and tandem walking~* Reaching forward and sidewards with eyes open and close"
62611729|NCT03777111|EXPERIMENTAL|Dual Task Training Group|"The exercises given in the single task training group will be combined with the cognitive tasks.~* Semi-tandem, tandem stand with recall a sequence of numbers~* One leg stance with writing pre-defined letters or words with other foot~* Semi-tandem or tandem walking with saying previous number (one or two previous) from number that researcher has given before~* Walking sidewards with collecting numbers that researcher has given~* Walking backwards with counting forward by one (then two or three)~* Reaching forward with counting backward one (then two or three)~* Reaching sidewards with saying next number (one or two next) from number that researcher has given before"
62623587|NCT02032615|PLACEBO_COMPARATOR|Education with no nutrition bar|Subjects will receive education about anemia but will not receive nutrition bar
62835187|NCT02740101|PLACEBO_COMPARATOR|placebo nasal spray|subjects administrating placebo were divided into controlled group
62835188|NCT03008369|EXPERIMENTAL|Treatment (lenvatinib)|Patients receive lenvatinib PO once daily on days 1-28. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
62835189|NCT00675272|ACTIVE_COMPARATOR|1|hydrocortisone treatment 50mg iv x4
62253390|NCT00947700|EXPERIMENTAL|Assessment, Monitoring + Intervention|Parent-Child participants in assessment and monitoring visits but also the Promoting First Relationships PFR intervention (http://pfrprogram. Org). PFR is a 10 weekly 60-85 minute in-home visits by a masters level mental health provider trained in the PFR curriculum. The PFR curriculum focuses on increasing parenting sensitivity using attachment theory-informed, strength-based consultation strategies. The curriculum is fully manualized and fidelity was assessed according to the manual.
62253391|NCT02342496|PLACEBO_COMPARATOR|Placebo|Powder consisting of maltodextrine, treated to resemble the Active product in appearance and taste.
62253392|NCT02342496|ACTIVE_COMPARATOR|Active, only probiotics|Powder consisting of freezedried bacteria at 10 billions cfu/daily dose and maltodextrine, treated to resemble the Active product in appearance and taste.
62253393|NCT02342496|ACTIVE_COMPARATOR|Active, blend of berries and probiotics|Powder consisting of freezedried berries , probiotics at 10 billions cfu/daily dose and maltodextrine.
62253394|NCT03897907|EXPERIMENTAL|Psychologically Informed Education|This arm will provide an education intervention which will attempt to address maladaptive psychological behaviors in adolescents with knee pain
62253395|NCT03897907|PLACEBO_COMPARATOR|Control Education|This arm will provide education of basic knee anatomy and will not address maladaptive psychological behaviors.
62253396|NCT05052073||MD patients|"* patients with different forms of muscle dystrophy, for example~* facioscapulohumeral dystrophy~* dysferlinopathy~* caveolinopathy"
62253397|NCT05052073||Controls|- healthy age- and sex-matched controls (10 men, 10 women)
62253398|NCT03246139|EXPERIMENTAL|Action observation, imagery & execution|
62052255|NCT05809206|ACTIVE_COMPARATOR|Conventional treatment group|Twenty Patients received conventional therapy (corrective exercises and ultrasound).
62253399|NCT03246139|ACTIVE_COMPARATOR|Action observation|
62835190|NCT00675272|PLACEBO_COMPARATOR|2|Placebo iv every 6 hours
62253400|NCT03246139|ACTIVE_COMPARATOR|Control treatment|
62835191|NCT00636493|EXPERIMENTAL|Vein Occlusion Eye|Eye with retinal vein occlusion receiving fluocinolone acetonide sustained drug delivery device
62835192|NCT04968275|EXPERIMENTAL|CHAMPS and EIS|The Cannabis Harm-reducing App for Managing Practices Safely (CHAMPS) is a brief harm reduction e-intervention based on the principles of motivational interviewing and harm reduction approaches. This e-intervention will be completed by the participant using a smart phone. There will be a total of six individual sessions each lasting 15-20 min. There will be one booster session offered at 4 weeks post-intervention to review goal setting, evaluate motivation around changing cannabis use practices. This e-intervention will be administered adjunctively to psychosis early intervention services (EIS).
62835193|NCT04968275|NO_INTERVENTION|EIS alone|Early intervention services (EIS) for psychosis will be offered as per standard of care at participating clinical sites. Theses services vary but typically include pharmacotherapy and individual and/or group psychotherapy. Any visits and services offered in the EIS arm will be considered 'usual care' and administered either through in-person clinic visits, phone calls, or video calls. Relevant service information will be collected for study purposes.
62835194|NCT03584477|ACTIVE_COMPARATOR|Conventional rehabilitation|5 sessions / week of 1 hour of occupational therapy
62835195|NCT03584477|ACTIVE_COMPARATOR|Robotic rehabilitation with assistance|5 sessions / week of 1 hour of rehabilitation of the upper limb with 30 min of conventional rehabilitation and 30 min of robotic rehabilitation with assistance.
62835196|NCT03584477|ACTIVE_COMPARATOR|Non-assistance robotic rehabilitation|5 sessions / week of 1 hour of rehabilitation of the upper limb including 30 min of conventional rehabilitation and 30 min of robotic rehabilitation without assistance.
62835197|NCT00606606|EXPERIMENTAL|I - Intervention units|nursing home units, provided HIT CDS intervention
62835198|NCT00606606|NO_INTERVENTION|C - control units|nursing home units, not provided the HIT CDS intervention
62835199|NCT02196844|EXPERIMENTAL|Yoga Group|Couple-Based Hatha Yoga Program: 5-6 weeks of a yoga program, three sessions per week (up to 15 sessions) during radiation treatment. At fifth session, CD given for practicing yoga at home. 10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later. Saliva samples to measure the level of cortisol collected at baseline visit, at end of treatment, and 3 months after radiation therapy. 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
62052256|NCT00604526|EXPERIMENTAL|1|Questionnaires, Iridium 192 radioactive seeds
62253401|NCT00362414|EXPERIMENTAL|Dual Growth Factor|All patients received erythropoietin and beta-hCG. This was the only treatment arm in the study, i.e., all enrollees received active therapy.
62253402|NCT00829049|ACTIVE_COMPARATOR|Tazarotene Cream 0.1%|1 pea-size amount, QD x 16 weeks
62253403|NCT00829049|ACTIVE_COMPARATOR|Adapalene Gel 0.3%|1 pea-size amount, QD x 16 weeks
62253404|NCT01422148|OTHER|Amiodarone|oral amiodarone
62253405|NCT01422148|EXPERIMENTAL|minocycline|intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
62623588|NCT01228812||RA patients|Patients with Rheumatoid Arthritis
62253406|NCT01550250|EXPERIMENTAL|Immediate Night-time Compression|Women randomized to the immediate night-time compression system group will be measured for a custom-made night-time compression system. Women in this group will be instructed to wear their night-time compression system garment for a minimum of 5 nights per week over the 12-week intervention period. A gradual increase in nights worn and wear-time of the garment will occur over the first two weeks. From weeks 3 to 12 of the study, the participants will be asked to wear the garment for 8 hours per night, for a minimum of five nights per week.
62623589|NCT01228812||Healthy subjects|Healthy subjects matched for age and sex
62052257|NCT04272502|EXPERIMENTAL|Sequence A|CKD-828, D326, D337, CKD-F1, CKD-F2
62052258|NCT04272502|EXPERIMENTAL|Sequence B|CKD-828, D326, D337, CKD-F1, CKD-F2
62052259|NCT04272502|EXPERIMENTAL|Sequence C|CKD-828, D326, D337, CKD-F1, CKD-F2
62052260|NCT01353781|EXPERIMENTAL|AZD5363|Ascending doses of AZD5363 administered orally to patients to define the maximum tolerated dose (MTD)
62052261|NCT03724487|EXPERIMENTAL|Coachman|The first study condition, A COmmunity and Tech-Based ApproaCh for Hypertension Self-MANagement (COACHMAN) will be exposed to three Technology-based Interventions (TBI) accessible via smartphone and counseling from a local community nurse organization for hypertension self-management support.
62052262|NCT03724487|EXPERIMENTAL|Enhanced Usual Care|The second study condition, Enhanced Usual Care (EUC) will be exposed to routine and standard hypertension education materials and one session on self-monitoring blood pressure.
62052263|NCT05782049|OTHER|Group of case patients|"1. Patients with Rheumatoid Arthritis~2. Patients with Sjögren's Syndrome"
62052264|NCT05782049|OTHER|Group of control patients|Patients with Sicca, Asthenia, Polyalgia Syndrome (SAPS)
62052265|NCT05648162|EXPERIMENTAL|Electrical acupuncture+ tDCS + NDT-Bobath Rehabilitation|Electrical acupuncture, tDCS, and NDT-BOBATH rehabilitation were performed for 30 minutes per time, respectively. The number of intervention was held for about a month, five times a week(a total of 20 times).
62253407|NCT01550250|ACTIVE_COMPARATOR|Delayed Group: Standard Care|Women randomized to the delayed night-time compression system group will receive standard care for lymphedema maintenance. Each participant will be instructed to wear their day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week. Following the twelve-week delay period, women in this arm of the trial will be fitted for their respective night-time compression system garment and will follow the protocol outlined in the experimental arm of the trial.
62623590|NCT02616198|ACTIVE_COMPARATOR|EquiaFil G-coat|EquiaFil G-coat combination was applied on one randomly selected cavity to be restored
62835200|NCT02196844|EXPERIMENTAL|Wait-List Control Group|"10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule, at radiation treatment completion, and again 3 months later. Saliva samples to measure the level of cortisol collected at baseline visit, at end of treatment, and 3 months after radiation therapy. 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.~Participants given the option to take part in the couple-based Hatha Yoga program (off study) after they finish their last questionnaire packet."
62835201|NCT02196844|EXPERIMENTAL|Caregivers|"Yoga Group - Caregivers: 5-6 weeks of yoga during patient's radiation treatment. At fifth session, caregiver given CD for practicing yoga at home. During each week of patient's radiation, caregiver completes questionnaire about their feelings about yoga sessions. 10 questionnaires completed before patient's first radiation treatment, each week during radiation, 5 halfway through radiation, at radiation completion, and again 3 months later. Saliva samples collected at baseline visit, at end of treatment, and 3 months after patient's radiation therapy.~Waitlist-Control Group - Caregivers: 10 questionnaires completed before patient's first radiation treatment, each week during radiation, 5 halfway through radiation. at radiation completion, and again 3 months later. Saliva samples collected at baseline visit, at end of treatment, and 3 months after radiation therapy.~Caregivers given option to take part in yoga program after they finish their last questionnaire packet."
62253408|NCT06304077|EXPERIMENTAL|forest|virtual reality (VR) assisted gait therapy in a forest landscape
62253409|NCT06304077|EXPERIMENTAL|urban|virtual reality (VR) assisted gait therapy in a urban landscape
62253410|NCT06304077|EXPERIMENTAL|rural|virtual reality (VR) assisted gait therapy in a rural landscape
62253411|NCT06304077|NO_INTERVENTION|control|standard gait therapy
62611730|NCT01371929||ICU patients who become septic|Patients considered to be at risk of becoming septic based upon his/her clinical presentation during admittance or transfer to an ICU will be tested for the presence of plasma iNOS using our PliNOSa test on the day of ICU entry and their sepsis status will be followed for three days to determine if they develop sepsis, severe sepsis, or septic shock. Approximately, 50% of the enrolled patients are expected to develop sepsis, severe sepsis, or septic shock.
62835202|NCT06655428|EXPERIMENTAL|Endobronchial Thermal Liquid Ablation (ETLA) Treatment|Participants will undergo up to two ETLA procedures separated by a minimum three-month interval.
62835203|NCT03863769||Lumbar Spinal Stenosis|Questionnaire, chiropractic treatment, and posture and performance testing.
62835204|NCT00704236|EXPERIMENTAL|A|
62835205|NCT00704236|PLACEBO_COMPARATOR|B|
62835206|NCT02376153|EXPERIMENTAL|ABS deployed and active|Air Barrier System (ABS) will be deployed onto the surgical field and activated.
62835207|NCT02376153|SHAM_COMPARATOR|ABS deployed and NOT active|Air Barrier System (ABS) will be deployed onto the surgical field and NOT activated. This is a sham comparator to reduce the influence of the presence of the device and provide user blinding.
62835208|NCT00750087||1|Schizophrenia patients stabilized on Seroquel XR
62835209|NCT01441076|EXPERIMENTAL|Anakinra|Treatment with Anakinra 100mg subcutaneous daily with option to escalate dose up to 300mg subcutaneous daily
62835210|NCT05995106|EXPERIMENTAL|App Group|Patients assigned to the app group receive assistance from the research team to install the Heart4U application and familiarize themselves with its usage.
62835211|NCT05995106|NO_INTERVENTION|Usual Care Group|The app (n=290) and usual care groups (n-290) continue to receive active treatment as previously administered (guideline-based prenatal care).
62835212|NCT03399552|EXPERIMENTAL|Avelumab|The treatment will consist of one dose of avelumab every other week as well as a short course of SBRT after the first two doses of avelumab.
62835213|NCT04349397||Pediatric tonsillectomy patients|All patients enrolled into study prior to undergoing tonsillectomy or adenotonsillectomy
62835214|NCT06218966|EXPERIMENTAL|study group with INCAT|study group with patients receiving intracochlear steroid treatment with the intracochlear catheter INCAT prior to application of the cochlear implant electrode array
62835215|NCT06516978|EXPERIMENTAL|Pola-RCHP-X|From cycles 1 to 6, patients will receive Polatuzumab Vedotin 1.8 mg/kg, Rituximab 375 mg/m², Cyclophosphamide 750 mg/m², and Doxorubicin 50 mg/m² on day 1 of each cycle, and Prednisone 100 mg/day from days 1 to 5. From cycles 2 to 6, patients will receive either Orelabrutinib 150 mg/day (days 1-21), Venetoclax 800 mg (days 4-10 in cycle 2; days 1-10 in cycles 3-6), Chidamide 20 mg/day (days 1, 4, 8, 11), Penpulimab 200 mg/day (day 0), or Lenalidomide 25 mg/day (days 1-10). In cycles 7 to 8, patients will receive Rituximab 375 mg/m² on day 1 of each cycle.
62253412|NCT03862144|EXPERIMENTAL|Netupitant/Palonosetron & Dexamethasone|"* Netupitant/Palonosetron (NEPA) will be administered orally at the dose of 300 MG (milligrams) netupitant/0.5 palonosetron 1 hour before the start of any chemotherapy cycle.~* Dexamethasone 12 mg will be added on day 1 only of each cycle."
62253413|NCT01131520|EXPERIMENTAL|Computerized Brief Intervention|Computerized one-session brief intervention for drug use
62253414|NCT01131520|ACTIVE_COMPARATOR|Counselor delivered brief intervention|This is a brief intervention focused on drug use delivered by a behavioral health counselor and based on motivational interviewing
62253415|NCT06247631||Control|Easy airway: unassisted mask ventilation, ventilation without the need for an airway, achieving oxygen saturation above 90% during mask ventilation, and unassisted intubation with less than three attempts.
62253416|NCT06247631||Difficult airway|Difficult airway: assisted mask ventilation, need for airway during ventilation, oxygen saturation falling below 90% during mask ventilation, assisted intubation, intubation attempt three and above
62253417|NCT03184077|ACTIVE_COMPARATOR|Polyglactin 910|
62253418|NCT03184077|ACTIVE_COMPARATOR|poliglecaprone 25|
62253419|NCT05701098|EXPERIMENTAL|Break Wave™ Procedure|The subject will undergo the Break Wave procedure.
62253420|NCT03708549|EXPERIMENTAL|Berberine group|"Berberine 300mg（three times a day） plus Metformin simulant 250mg（three times a day）agent plus any atypical antipsychotic drug~Metformin simulant were matched to metformin in shape, smell and colour were sealed in identical bottles"
62835216|NCT06516978|ACTIVE_COMPARATOR|RCHOP-X|From cycles 1 to 6, patients will receive Rituximab 375 mg/m², Cyclophosphamide 750 mg/m², Doxorubicin 50 mg/m², and Vincristine 1.4 mg/m² on day 1 of each cycle, and Prednisone 100 mg/day from days 1 to 5. From cycles 2 to 6, patients will receive either Orelabrutinib 150 mg/day (days 1-21), Venetoclax 800 mg (days 4-10 in cycle 2; days 1-10 in cycles 3-6), Chidamide 20 mg/day (days 1, 4, 8, 11), Penpulimab 200 mg/day (day 0), or Lenalidomide 25 mg/day (days 1-10). In cycles 7 to 8, patients will receive Rituximab 375 mg/m² on day 1 of each cycle.
62835217|NCT06516978|ACTIVE_COMPARATOR|Pola-RCHP|From cycles 1 to 6, patients will receive Polatuzumab Vedotin at 1.8 mg/kg, Rituximab at 375 mg/m², Cyclophosphamide at 750 mg/m², and Doxorubicin at 50 mg/m² on day 1 of each cycle, and Prednisone at 100 mg/day from days 1 to 5. In cycles 7 to 8, patients will receive Rituximab at 375 mg/m² on day 1 of each cycle.
62835218|NCT02869464||Patients presenting with IA|These patients will undergo an abdominal ultrasound (Imaging - Ultrasound) to test for abdominal aortic aneurysm(s). RNA, DNA testing will be planned on banked samples
62052266|NCT05648162|ACTIVE_COMPARATOR|Acupuncture + sham tDCS + NDT-Bobath Rehabilitation|Acupuncture, tDCS, and NDT-BOBATH rehabilitation were performed for 30 minutes per time, respectively. The number of intervention was held for about a month, five times a week(a total of 20 times).
62052267|NCT04643925|EXPERIMENTAL|hCG priming|"Control cycle: A standard IVF/ICSI cycle in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and the GnRH antagonist (Fyremadel 0.25 mg) from stimulation day 5-6 followed by blastocyst culture and a freeze-all strategy.~Study cycle: hCG priming by Ovitrelle 260 IE once daily for 8 weeks followed by a standard IVF/ICSI cycle in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and the GnRH antagonist (Fyremadel 0.25 mg) from stimulation day 5-6 followed by a single blastocyst transfer at day 5."
62052268|NCT00699439|ACTIVE_COMPARATOR|A|If a patient is identified as having an asthma exacerbation by the Bayesian Network, the paper-based flow-chart will be printed out to place on the chart.
62052269|NCT00699439|NO_INTERVENTION|B|If a patient is identified as having an asthma exacerbation by the Bayesian Network, and assigned to the control group, no flow-chart will be printed out.
62052270|NCT03613675|EXPERIMENTAL|Video games|All participants will be asked to play 4 video games.
62052271|NCT00724581|EXPERIMENTAL|A|
62052272|NCT01280838|EXPERIMENTAL|Theory-based behavioral intervention|Participants in this arm will receive a single-session, theory-based intervention (Hombre Seguro) at baseline that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and Motivational Interviewing (MI) to increase clients' use of condoms with FSWs. The intervention lasts approximately 45 minutes.
62052273|NCT01280838|ACTIVE_COMPARATOR|Didactic attention-control condition|The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
62052274|NCT00695630|EXPERIMENTAL|1|Flumazenil 2mL
62052275|NCT00695630|PLACEBO_COMPARATOR|2|Saline, 2mL SM
62052276|NCT00742079|EXPERIMENTAL|1 D-cycloserine, placebo|Participants will receive D-cycloserine 1 hour before a cognitive behavioral therapy (CBT) session on Week 1, and they will receive placebo 1 hour before a CBT session on Week 2.
62052277|NCT00742079|EXPERIMENTAL|2 Placebo, D-cycloserine|Participants will receive placebo 1 hour before a CBT session on Week 1, and they will receive D-cycloserine 1 hour before a CBT session on Week 2.
62052278|NCT06298851|EXPERIMENTAL|Neural Mobilization Group (NMG)|Participants of NMG performed sciatic, femoral and peroneal nerve and lumbar region gliding. All glides include 4 sets of 10 repetitions, with each gliding cycle lasting 6 seconds, and a 1-minute rest between sets for both extremities.
62835219|NCT02869464||Patients presenting with AAA|These patients will undergo a non-contrast enhanced magnetic resonance angiogram (MRA) (Imaging - MRA) to test for intracranial aneurysm(s). RNA, DNA testing will be planned on banked samples
62052279|NCT06298851|EXPERIMENTAL|Dynamic Stretching Group (DSG)|"4 sets of 10 repetitions will be performed, each exercise cycle lasting 6 seconds, and a 1-minute rest period will be given between sets. All stretching exercises will be performed in two circuits.~Exercises:~Walking on toes Walk and keep the right knee on the ground Walk and do not touch the left knee to the ground Walking with the knee flexed to 90° and abducting and adducting the hip Walking with the knee fully extended and hip flexion leaning forward Jogging and 90° forward flexion of the right/left hip Jogging and right/left hip adduction"
62052280|NCT06298851|EXPERIMENTAL|Static Stretching Group (SSG)|"4 sets of 4 repetitions will be applied to the lumbar extensor, hamstring, quadriceps and gastrocnemius muscles of both extremities, each stretching lasting 15 seconds, and a 1-minute rest period will be left between sets.~Static Stretching Exercises:~Standing quadriceps stretch Modified hamstring stretching Gastrocnemius stretching Adductor stretching Lumbar stretching"
62052281|NCT02228070|EXPERIMENTAL|strabismus video goggles|
62052282|NCT00620750|EXPERIMENTAL|Extended release injectable naltrexone|
62052283|NCT03774901|EXPERIMENTAL|avelumab maintenance|Avelumab will be administered at a dose of 10 mg/kg every 2 weeks with appropriate supportive care
62835220|NCT02734459|EXPERIMENTAL|tobramycin and dexamethasone ophthalmic test ointment|The test drug (tobramycin is an aminoglycoside antibiotic and dexamethasone is a corticosteroid) will be administered in one eye before the cataract surgery.
62253421|NCT03708549|ACTIVE_COMPARATOR|Metformin group|"Metformin 250mg（three times a day） plus Berberine simulant 250mg（three times a day）agent plus any atypical antipsychotic drug~Berberine simulant were matched to Berberine in shape, smell and colour were sealed in identical bottles"
62253422|NCT02937194|EXPERIMENTAL|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) for the expectant mothers and their husbands together with oral health education materials on infant's tooth development and eruption, establishment of proper feeding, dietary and toothbrushing habits will be given before baby delivery. Reinforcement of OHI and demonstrations on how to clean the infant's oral cavities and perform toothbrushing will be delivered after the babies are born.
62442513|NCT02540148|EXPERIMENTAL|Active Treatment|Patients will be fully consented before the start of the study. In the treatment group, subjects will undergo a treatment session to the enrolled eyes for three days during Week 1, followed by a single treatment session during Weeks 2, 14 and 26 with the Nova Oculus device. A treatment session is 15 minutes of treatment on each closed eye lid for a total of 30 minutes. ETDRS visual acuity will be performed on all subjects at enrollment (prior to the first treatment), prior to each treatment session, and at four weeks from enrollment. The effect of treatments with the Nova Oculus device compared to sham treatment on the visual acuity of subjects with dry AMD will be determined.e.
62253423|NCT02937194|ACTIVE_COMPARATOR|Pamphlets distribution|Pamphlets for adults' and pregnant women's oral health care will be distributed when recruited and information on the babies' oral health care will be distributed before baby delivery.
62253424|NCT05337787|EXPERIMENTAL|Experimental|The students in the experimental group were trained using the flipped learning model.
62253425|NCT05337787|NO_INTERVENTION|Control|The students in the control group were trained using only a traditional education method.
62253426|NCT03268928|EXPERIMENTAL|Story Starters Intervention|"Children will receive the the Story Starters intervention for six months. Each child will be visited by a trained Story Starter volunteer twice a week while the child is in preschool. The sessions will last 20 minutes and in each session the Story Starter volunteer and child will read books and play with toys. The Story Starter volunteers will keep a record of the number of sessions each child attends.~Each child will receive one new book per month delivered to their home address by Dolly Parton's Imagination Library."
62253427|NCT03268928|OTHER|Wait-list Control|"Children in the wait-list control arm will continue to attend preschool as normal during the randomised controlled trial (RCT) and will receive the Story Starters intervention after the RCT has finished.~Each child will receive one new book per month delivered to their home address by Dolly Parton's Imagination Library."
62253428|NCT05051150|ACTIVE_COMPARATOR|epinephrine 0.03 mcg|
62253429|NCT05051150|ACTIVE_COMPARATOR|epinephrine 0.05 mcg|
62253430|NCT05051150|ACTIVE_COMPARATOR|epinephrine 0.07 mcg|
62442514|NCT02540148|SHAM_COMPARATOR|Non-active treatment|A second group of subjects will act as the control group. This group will undergo sham treatment to the enrolled eyes at the same intervals as the treatment group (Weeks 2, 14 and 26), but with a nonfunctional Nova Oculus device. A treatment session is 15 minutes of treatment on each closed eye lid for a total of 30 minutes. ETDRS visual acuity will be performed on all subjects at enrollment (prior to the first treatment), prior to each treatment session, and at four weeks from enrollment. The effect of treatments with the Nova Oculus device compared to sham treatment on the visual acuity of subjects with dry AMD will be determined.
62442515|NCT02971956|EXPERIMENTAL|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
62835221|NCT02734459|ACTIVE_COMPARATOR|TobraDex® ointment|The reference drug (tobramycin is an aminoglycoside antibiotic and dexamethasone is a corticosteroid) will be administered in another eye before the cataract surgery.
62835222|NCT02797613|EXPERIMENTAL|Restricted Reporting|"Microbiology laboratory will report Positive urine cultures may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call 777-xxxx (researcher mobile phone) for identification and susceptibility results"
62835223|NCT02797613|NO_INTERVENTION|Standard Reporting|Microbiology laboratory will report identification and susceptibility results
62835224|NCT05427188|EXPERIMENTAL|MIST-paradigm|HV assigned in the MIST paradigm will receive psychosocial stress
62835225|NCT05427188|SHAM_COMPARATOR|Sham-paradigm|HV assigned in the MIST paradigm will receive no psychosocial stress
62052284|NCT02267005|EXPERIMENTAL|Treatment|patients on this arm will be treated with creapure supplements
62052285|NCT02267005|PLACEBO_COMPARATOR|Placebo|patients on this arm will be given a placebo glucose tablet supplement
62052286|NCT05009108||Czech adult patients after a stroke|Czech adults patients after a stroke will be asked to fill in a informed agreement and as well to answer short questionnaire. Then they will be tested by the Purdue Pegboard Test in only one session. Video of their performance will be obtained as well.
62623591|NCT02616198|ACTIVE_COMPARATOR|EquiaFil Fuji Varnish|EquiaFil Fuji Varnish combination was applied on one randomly selected cavity to be restored
62253431|NCT00656240|EXPERIMENTAL|1|
62253432|NCT00656240|EXPERIMENTAL|2|
62253433|NCT04760951|EXPERIMENTAL|TOTUM-070|Experimental active diet supplement TOTUM-070 taken 2 times per day
62253434|NCT04760951|PLACEBO_COMPARATOR|Placebo|Placebo comparator taken 2 times per day
62835226|NCT04667221|EXPERIMENTAL|Anodal transcranial direct current stimulation|Patients will be bilaterally stimulated with anodal tDCS at the parietal cortex (Brodmann Area 7).
62835227|NCT04667221|EXPERIMENTAL|Cathodal transcranial direct current stimulation|Patients will be bilaterally stimulated with cathodal tDCS at the parietal cortex (Brodmann Area 7).
62835228|NCT04667221|SHAM_COMPARATOR|Sham transcranial direct current stimulation for anodal group|Patients will be bilaterally stimulated with sham tDCS at the parietal cortex (Brodmann Area 7). As a consequence of the crossover design, both experimental arms receive sham stimulation.
62835229|NCT04667221|SHAM_COMPARATOR|Sham transcranial direct current stimulation for cathodal group|Patients will be bilaterally stimulated with sham tDCS at the parietal cortex (Brodmann Area 7). As a consequence of the crossover design, both experimental arms receive sham stimulation.
62253435|NCT01892592|NO_INTERVENTION|Usual Care|No Interventions
62052287|NCT03741101|EXPERIMENTAL|single arm study|children treated with trametinib
62052288|NCT04793906|EXPERIMENTAL|Beef|
62611731|NCT01371929||ICU patients who do not become septic|Patients considered to be at risk of becoming septic based upon his/her clinical presentation during admittance or transfer to an ICU will be tested for the presence of plasma iNOS using our PliNOSa test on the day of ICU entry and their sepsis status will be followed for three days to determine if they develop sepsis, severe sepsis, or septic shock. Approximately, 50% of the enrolled patients are expected NOT to develop sepsis, severe sepsis, or septic shock.
62611732|NCT00231309|OTHER|single arm|
62611733|NCT05304494||Severe Breathlessness|Breathlessness requiring admission or supplementary oxygen
62611734|NCT05304494||Moderate Breathlessness|Breathlessness requiring medical intervention \< 24 hours without meeting the criteria for severe breathlessness
62052289|NCT04793906|EXPERIMENTAL|Plant-based alternative|
62052290|NCT01714804|EXPERIMENTAL|Prospective|Accell Evo3
62052291|NCT05840484||Cohort-1|Participants with localized very low- or low-risk prostate cancer meeting consensus criteria for active surveillance
62052292|NCT05840484||Cohort-2|Participants with NCCN intermediate-risk localized prostate cancer requesting active surveillance (per patient and clinician shared decision making);
62052293|NCT05840484||Cohort-3|"Participants with severe medical comorbidities (defined as CCI estimated 10-year survival \< 50% and agreed by treating clinician) and high- or very high-risk group localized prostate cancer.~Clinical trial investigators and staff will make every effort to integrate study visits with the subjects' clinic visits during participation."
62611735|NCT05304494||Mild Breathlessness|Breathlessness not requiring any medical intervention within 24 hours other than a dose change in the individuals pre-established pharmacological treatment plan
62611736|NCT05338866||Cohort 1. Cohort 2|"A total of 6 courses of oxaliplatin plus capecitabine chemotherapy and 2 courses of capecitabine single drug chemotherapy were performed. Concurrent chemoradiotherapy starts at the second cycle.~Cohort 1: For patients with low rectal cancer who refused surgery before the initial diagnosis and treatment, the first stage of radiotherapy used conventional linear accelerated radiotherapy, with doses of GTV 50Gy/25f and CTV 45Gy/25f for 5-6 weeks. Subsequently, the second stage of radiotherapy boost was continued with MR linear accelerator, and the dose was GTV 16\~20Gy/8\~10f for 2 weeks.~Cohort 2: For locally advanced low rectal cancer patients who did not achieve clinical complete remission 6-8 weeks after neoadjuvant radiochemotherapy and refused surgery, radiotherapy was given in the first stage at the doses of GTV 50Gy/25f and CTV 45Gy/25f for 5-6 weeks. In the second stage, MR linear accelerator was used for radiotherapy boosting, and the dose was GTV 30Gy/15f for 3 weeks."
62611737|NCT04365049||Nab-Paclitaxel+Gemcitabine+Camrelizumab+Radiotherapy|Chemotherapy consisted of eight 21-day cycles of nab-paclitaxel plus gemcitabine (nab-paclitaxel 125 mg/m² by intravenous infusion for approximately 30-45 mins, followed by gemcitabine 1000mg/m² intravenous infusion for approximately 30 mins on days 1 and 8). Anti-PD-1 antibody (camrelizumab, Hengrui Medicine Co., Ltd) 200 mg was administered intravenously for 30 mins every three weeks. During the chemotherapy-treated period, camrelizumab was administered on day 1 of each 21-day cycle before the infusion of chemotherapy. Radiotherapy started after two cycles of chemotherapy. A total radiation dose greater than 50 Gy without damaging organ function was the essential requirement.
62623592|NCT02616198|ACTIVE_COMPARATOR|Riva SC G-coat|River SC G-coat combination was applied on one randomly selected cavity to be restored
62835230|NCT06248996|ACTIVE_COMPARATOR|Conventionally fractioned (standard) group|This groups is treated with standard radiotherapy treatment: RT 2.0 Gy daily to final radiation dose 68.0 Gy or
62835231|NCT06248996|EXPERIMENTAL|HFX-RT group|Treated with Hyperfractionated radiotherapy (HFX-RT): Gy twice daily (10 fractions/week) with final dose 83.0 Gy
62052294|NCT05993845||Project population for total hip arthroplasty surgery recordings|We plan to record 60 total hip arthroplasty (THA) surgeries in the operating theatre performed by different surgeons of the hip team at Balgrist University Hospital or Kantonsspital Baden or Kantonsspital Winterthur, for data collection purposes.
62052295|NCT01690884|PLACEBO_COMPARATOR|Placebo|To determine if there is an increase in adenosine interstitial levels in the forearm.
62835232|NCT04452084|ACTIVE_COMPARATOR|Control|
62052296|NCT01690884|ACTIVE_COMPARATOR|Dipyridamole|To determine if there is an increase in adenosine interstitial levels in the forearm.
62052297|NCT01690884|EXPERIMENTAL|Ticagrelor|To determine if there is an increase in adenosine interstitial levels in the forearm.
62052298|NCT04979039||normal pregnancy|Adult pregnant women scheduled for cesarean section under spinal anesthesia
62052299|NCT03076268|EXPERIMENTAL|Treatment Group|The investigators will deliver the TMP Curriculum to 45 Treatment families. The TMP Curriculum is comprised of 1) 12 educational modules, 2) animations and videos of real parent-child interactions to teach parents about the science behind child brain development, and model strategies for improving parents' child-directed speech, 3) video modeling and collaborative goal setting, and 4) quantitative linguistic feedback from Language ENvironment Analysis (LENA) recordings. This curriculum is delivered in Spanish.
62052300|NCT03076268|NO_INTERVENTION|Control Group|The investigators will deliver a Nutrition Curriculum to 45Control families. The Nutrition Curriculum provides information about the importance of healthy nutrition for child development, strategies for healthy eating, and meal preparation.This curriculum is delivered in Spanish.
62052301|NCT05047874||short-term (3 days) high-dose (1000 mg) systemic methylprednisolone|retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom we administered short-term (3 days) high-dose (1000 mg) systemic methylprednisolone
62052302|NCT05047874||low-dose long-term (2x 40 mg) systemic methylprednisolone|retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom low-dose long-term (2x 40 mg) systemic methylprednisolone
62052303|NCT04536090|EXPERIMENTAL|Isoquercetin (IQC-950AN)|1000 mg Isoquercetin b.i.d. on day 1, then 500 mg Isoquercetin b.i.d. for 27 more days, plus standard of care (as defined below)
62052304|NCT04536090|NO_INTERVENTION|Standard of care|This arm will receive standard of care based on national guidelines. This may change as new information regarding best practice emerges.
62052305|NCT06304350|EXPERIMENTAL|Combination of pembrolizumab and platinum containing dual drugs|After 2 courses of treatment with pembrolizumab combined with platinum containing dual drugs (albumin paclitaxel+carboplatin), surgery was performed, and postoperative pembrolizumab immunomaintenance therapy continued
62052306|NCT06491771|ACTIVE_COMPARATOR|cryotherapy with tranexamic acid|precision cryotherapy via boosting mode combined with tranexamic acid
62052307|NCT06491771|PLACEBO_COMPARATOR|cryotherapy with normal saline|precision cryotherapy via boosting mode combined with normal saline
62253436|NCT01892592|NO_INTERVENTION|Medication enhancement|Pharmacist will optimize current Kaiser medication protocol for treatment of hypertension.
62611738|NCT04365049||Nab-Paclitaxel+Gemcitabine|Chemotherapy consisted of eight 21-day cycles of nab-paclitaxel plus gemcitabine (nab-paclitaxel 125 mg/m² by intravenous infusion for approximately 30-45 mins, followed by gemcitabine 1000mg/m² intravenous infusion for approximately 30 mins on days 1 and 8).
62052308|NCT01903421|ACTIVE_COMPARATOR|Spinal anesthesia group|Spinal anesthesia group will receive bupivacaine 10-15mg anesthesia according to the standard practice. Supplemental sedation with intravenous anesthetics (midazolam/propofol) will be optional.
62052309|NCT01903421|ACTIVE_COMPARATOR|General anesthesia group|Induction of anesthesia will be achieved with propofol 1.5-2mg/kg and fentanyl 1-3g/kg. Anesthesia will be maintained with inhalational anesthesia (isoflurane or sevoflurane) at the discretion of anesthesiologist in charge of the case. A mixture of Air/O2 will be used to maintain adequate oxygenation. Nitrous oxide will not be used.
62052310|NCT01637103|EXPERIMENTAL|Cognitive therapy of depression|
62052311|NCT01637103|EXPERIMENTAL|Bright light therapy|
62052312|NCT01637103|NO_INTERVENTION|Waiting list|
62052313|NCT01302431|EXPERIMENTAL|Nurse-Led Manualised Telephone support|Participants assigned to this arm of the study will receive 4 nurse-led telephone support calls over a three month time-frame
62611739|NCT03050047|EXPERIMENTAL|BCD-100 0.3 mg/kg|Patients who receive BCD-100 in a dose of 0.3 mg/kg
62052314|NCT01302431|NO_INTERVENTION|Usual care|Participants randomised to this arm of the study will receive their usual care which comprises caregivers calling nurse specialists when they needs advice and support
62835233|NCT04452084|EXPERIMENTAL|Experimental Procedure|
62253437|NCT01892592|EXPERIMENTAL|Diet and Lifestyle Arm|Patients will receive up to 16 wellness coaching sessions focusing on DASH doest and lifestyle changes - Behavioral Intervention
62835234|NCT03237455|EXPERIMENTAL|study group|Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
62835235|NCT03237455|ACTIVE_COMPARATOR|control group|Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
62835236|NCT02546271|EXPERIMENTAL|Treatment Group|GPS program - an 8-week, peer-led group counselling program using motivational interviewing techniques.
62835237|NCT01526577|EXPERIMENTAL|LC23-1306|experimental drug
62835238|NCT01526577|PLACEBO_COMPARATOR|placebo|LC23-1306 placebo
62835239|NCT01526577|ACTIVE_COMPARATOR|Ticagrelor|active comparator
62835240|NCT06275516|EXPERIMENTAL|VR+treadmill training group|Multi-sensory stimulation immersive VR+ treadmill training with suitable for training intensity. 20 minutes a day for 30 days, a total of 600 minutes (training frequency is adjusted according to the patient's own conditions).
62835241|NCT06275516|ACTIVE_COMPARATOR|treadmill training group|Only treadmill training similarly with suitable for training intensity in the control group. 20 minutes a day for 30 days, a total of 600 minutes (training frequency is adjusted according to the patient's own conditions).
62835242|NCT00404612|PLACEBO_COMPARATOR|Placebo|
62835243|NCT00404612|ACTIVE_COMPARATOR|LX211, 0.2 mg/kg|
62052315|NCT01856530|EXPERIMENTAL|Oxytocin|Liquid intranasal oxytocin, 24 IU, administered once
62052316|NCT01856530|PLACEBO_COMPARATOR|Placebo|Matched placebo nasal spray
62052317|NCT01479998|ACTIVE_COMPARATOR|Standard care and nicotine replacement therapy|standard care is 4 counseling sessions and nicotine replacement therapy
62052318|NCT01479998|EXPERIMENTAL|standard care plus NRT plus contingency management|standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
62052319|NCT06159010||Acute kidney injury|
62052320|NCT06159010||Patients with non-acute kidney injury|
62052321|NCT03775200|EXPERIMENTAL|Low dose|Low dose Psilocybin
62052322|NCT03775200|EXPERIMENTAL|Medium dose|Medium dose Psilocybin
62052323|NCT03775200|EXPERIMENTAL|High dose|High dose Psilocybin
62253438|NCT06210477||Low compliance|Low urinary tract symptoms with low bladder compliance
62253439|NCT04190979|EXPERIMENTAL|Single arm|TrackCath
62253440|NCT02941705|ACTIVE_COMPARATOR|RECIEVED CELLS|this arm will receive the CDCs /CAP 1002 solution
62253441|NCT02941705|PLACEBO_COMPARATOR|CONTROL ARM|this arm will receive a solution during randomization but will not receive the CDCs
62835244|NCT00404612|ACTIVE_COMPARATOR|LX211, 0.4 mg/kg|
62835245|NCT00404612|ACTIVE_COMPARATOR|LX211, 0.6 mg/kg|
62253442|NCT05149664|EXPERIMENTAL|VibratoSleeve TUS|Subjects will receive 30 TUS treatments, each one lasting 90 minutes on the calf of a leg with peripheral arterial disease.
62611740|NCT03050047|EXPERIMENTAL|BCD-100 1 mg/kg|Patients who receive BCD-100 in a dose of 1 mg/kg
62611741|NCT03050047|EXPERIMENTAL|BCD-100 3 mg/kg|Patients who receive BCD-100 in a dose of 3 mg/kg
62611742|NCT03050047|EXPERIMENTAL|BCD-100 10 mg/kg|Patients who receive BCD-100 in a dose of 10 mg/kg
62611743|NCT02106143|EXPERIMENTAL|RejuvenAir™ Radial Spray Cryotherapy|Subjects will receive Rejuvenair Radial SCT prior to lobectomy.
62611744|NCT00869557|EXPERIMENTAL|Stribild|
62611745|NCT00869557|ACTIVE_COMPARATOR|Atripla|
62835246|NCT01070017|EXPERIMENTAL|Intervention: DOT-HAART|Intervention group will receive community-based monthly adherence visits, standard care, and DOT-HAART.
62835247|NCT01070017|NO_INTERVENTION|No DOT-HAART|Control group receives community-based monthly adherence visits and standard care, but no DOT-HAART.
62052324|NCT01873430|ACTIVE_COMPARATOR|Melatonin: Melatonin cream 2,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied
62052325|NCT01873430|ACTIVE_COMPARATOR|Melatonin: Melatonin cream 0,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.
62052326|NCT01873430|ACTIVE_COMPARATOR|Melatonin: Melatonin cream 12,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.
62052327|NCT01873430|PLACEBO_COMPARATOR|placebo cream|One square on the back of each volunteers will be randomized to have placebo cream (vehicle) applied.
62052328|NCT01873430|NO_INTERVENTION|No treatment|One square on the back of each volunteers will be randomized to receive no treatment.
62052329|NCT05032001|EXPERIMENTAL|Metformin|Metformin 1.7-2.5mg per day during twelve weeks
62052330|NCT05032001|EXPERIMENTAL|Metformina + IDDP-4|Metformin 1.7-2.5mg per day plus Linagliptin 5mg per day or Sitagliptin 50-100mg per day
62052331|NCT05032001|EXPERIMENTAL|Metformina + ISGLT-2|Metformin 1.7-2.5mg per day plus Empaglifozin 10-25mg per day or Dapaglifozin 10mg per day
62442516|NCT03991832|EXPERIMENTAL|Cohort A: IDH mutated glioma|Olaparib, by mouth (orally), twice a day, every day. Durvalumab, by vein (intravenously), on Day 1 of every 28 day cycle.
62442517|NCT03991832|EXPERIMENTAL|Cohort B: IDH mutated cholangiocarcinoma|Olaparib, by mouth (orally), twice a day, every day. Durvalumab, by vein (intravenously), on Day 1 of every 28 day cycle.
62835248|NCT02853058|ACTIVE_COMPARATOR|normal PI|Uterine artery PI expresserd in MoM is \<95e percentile
62835249|NCT02853058|ACTIVE_COMPARATOR|pathological PI|Uterine artery PI expressed in Multiple of Mediane (MoM) is \>=95e percentile
62052332|NCT00295022|PLACEBO_COMPARATOR|Placebo (PBO)|Placebo was administered orally on Days 1 and 2.
62052333|NCT00295022|EXPERIMENTAL|Montelukast (MLKT)|10 mg of Montelukast (MLKT) was administered orally on Days 1 and 2.
62052334|NCT00295022|EXPERIMENTAL|Levocetirizine (LCTZ)|5 mg of Levocetirizine (LCTZ) was administered orally on Days 1 and 2.
62442518|NCT03317236|EXPERIMENTAL|Reference - Test|A new extended release formulation containing quetiapine 50 mg (T) followed by a branded formulation (R).
62442519|NCT03317236|EXPERIMENTAL|Test - Reference|A branded formulation (R) followed by a new extended release formulation containing quetiapine 50 mg (T).
62835250|NCT05486377|EXPERIMENTAL|Remimazolam|General anesthesia with remimazolam-remifentanil TIVA.
62052335|NCT01169714|EXPERIMENTAL|Dosing Healthy Adult|Ascending Doses in Healthy Adult Volunteers
62442520|NCT01215123||Bevacizumab|Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
62442521|NCT00004342||Adult Neutropenic Subject|Adult subjects with diagnosis of severe chronic neutropenia
62052336|NCT01169714|EXPERIMENTAL|Dosing Healthy Elderly|Dosing in Healthy Elderly volunteers
62052337|NCT01494844|OTHER|Device interface comfort assessment|Single group rates one noninvasive respiratory monitoring interface and then another.
62052338|NCT00686452||1|Swimmers without AHR
62052339|NCT00686452||2|Swimmers with asymptomatic AHR
62052340|NCT00686452||3|Swimmers with symptomatic AHR and use only of beta-2 adrenargic
62052341|NCT00686452||4|Swimmers with asthma and inhaled corticosteroids
62052342|NCT00686452||5|Healthy Subjects
62052343|NCT00686452||6|Healthy subjects with AHR
62052344|NCT00686452||7|Healthy subjects with symptomatic AHR (asthma) but without treatment
62052345|NCT06148220|EXPERIMENTAL|patients with renal cancer|Intravenous injection of 3.7 MBq \[0.1 mCi\]/kg of \[18F\]RCCB6 or \[68Ga\]Ga-NOTA-RCCB6 in a single dose
62052346|NCT06148220|EXPERIMENTAL|patients with lymphoma|Intravenous injection of 3.7 MBq \[0.1 mCi\]/kg of \[18F\]RCCB6 or \[68Ga\]Ga-NOTA-RCCB6 in a single dose
62835251|NCT05486377|NO_INTERVENTION|Desflurane|General anesthesia with maintaining with desflurane (induction:PPF, remifentanil CIV)
62835252|NCT02625857|EXPERIMENTAL|Dose Cohort 1A and 1B|JNJ-64041809 will be administered intravenously (IV) once every 21 days.
62052347|NCT04716699|EXPERIMENTAL|Health services research (lidocaine, surgery)|Patients receive bolus lidocaine IV per standard of care. After intubation, patients receive another infusion of lidocaine IV over 4 hours or until the end of surgery. Patients also undergo collection of blood and tumor samples at the start of surgery and hourly afterwards until a total of 4 samples are collected.
62052348|NCT01552564||STEMI patients|Consecutive patients presenting through the PPCI service
62253443|NCT00474110|EXPERIMENTAL|1|Ketamine and hydromorphone for patient-controlled relief in children's mucositis.
62253444|NCT01294904||renal transplant patients|Patients undergoing transplantation
62442522|NCT00004342||Minor Neutropenic Subject|Children under 18 years of age who are diagnosed with severe chronic neutropenia
62835253|NCT02625857|EXPERIMENTAL|Dose Cohort 2A and 2B|JNJ-64041809 will be administered intravenously (IV) once every 21 days.
62835254|NCT04045028|EXPERIMENTAL|Arm A: Tiragolumab R/R MM|Participants with relapsed or refractory (R/R) Multiple Myeloma (MM) will receive a single dose of 600 mg tiragolumab by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W).
62835255|NCT04045028|EXPERIMENTAL|Arm B: Tiragolumab R/R NHL|Participants with relapsed or refractory (R/R) non-Hodgkin Lymphoma (NHL) will receive a single dose of 600 mg tiragolumab by IV infusion Q3W.
62611746|NCT04471571|ACTIVE_COMPARATOR|Resin infiltration group|Enamel lesions for this group will be treated only by resin infiltration.
62052349|NCT04602130|EXPERIMENTAL|Massage|Massages were performed starting from the face, focused on the newborns forehead, and then around the eyes and cheeks with gentle touches. Then, newborns' chest area and the upper and lower extremities were massaged. Finally, newborns'were placed prone position and the back was massaged. Nurses recorded newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form.
62052350|NCT04602130|EXPERIMENTAL|Sponge Bathing|In the sponge bathing group, the newborns' eyes, faces (outward from the midline), around the ear and the back of the ear were wiped from the inside out with cotton wipes and dried. Then, the chest area and arms, abdomen and back, legs and feet, respectively, were wiped and dried. Finally, the genital area was cleaned, before diapering the newborn. Nurses recorded newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form
62253445|NCT01294904||dialysis patients|hemodialysis patients and peritoneal dialysis patients. Before and after a dialysis session
62253446|NCT01294904||patients with renal insufficiency|outpatient patients with chronic kidney disease stage 2, 3 and 4
62253447|NCT01294904||Chronic kidney disease|outpatient cohort. Those with mild renal insufficiency
62253448|NCT05712148|EXPERIMENTAL|Retinitis Pigmentosa patients|Suprachoroidal mesenchymal stem cell implanted Retinitis pigmentosa patients
62253449|NCT05954923|EXPERIMENTAL|Primary arm|This is a single-arm study. Each subject will participate in 6 experimental days in a randomized order. The interventions are equimolar bolus infusions of A) glutamine, B) arginine, C) alanine, D) leucine, E) proline and F) saline (placebo)
62611747|NCT04471571|EXPERIMENTAL|Microabrasion + resin infiltration group|Enamel lesions for this group will be treated first by microabrasion followed by resin infiltration.
62611748|NCT02503644|ACTIVE_COMPARATOR|IVA337 800mg|Patients receive twice daily 400mg IVA337.
62611749|NCT02503644|ACTIVE_COMPARATOR|IVA337 1200mg|Patients receive twice daily 600mg IVA337.
62611750|NCT02503644|PLACEBO_COMPARATOR|Placebo|Patients receive twice daily placebo.
62611751|NCT00636636|EXPERIMENTAL|G-ER|Gabapentin - Extended Release
62611752|NCT00636636|PLACEBO_COMPARATOR|Placebo|Sugar pill
62611753|NCT05234034||chronic low back pain (LBP)|persons with chronic low back pain (LBP) will be included in this arm.
62611754|NCT05234034||chronic neck pain (CNP)|persons with chronic neck pain (CNP) will be included in this arm.
62835256|NCT04045028|EXPERIMENTAL|Arm C: Tiragolumab + Daratumumab R/R MM|Participants with R/R MM will receive 600 mg tiragolumab Q3W + daratumumab by subcutaneous (SC) injection.
62835257|NCT04045028|EXPERIMENTAL|Arm D: Tiragolumab + Rituximab R/R NHL|Participants with R/R NHL will receive 600 mg tiragolumab Q3W + rituximab by IV infusion and SC injection (optional).
62835258|NCT04045028|EXPERIMENTAL|Arm E: Tiragolumab + Atezolizumab + Daratumumab R/R MM|Participants with R/R MM will receive 600 mg tiragolumab Q3W + atezolizumab by IV infusion Q3W + daratumumab by SC injection.
62835259|NCT04219384||Critical-illness related cardiac arrest (CIRCA)|Those experiencing a critical illness-related cardiac arrest in a participating adult, general ICU
62835260|NCT00194428|EXPERIMENTAL|1|Almond enriched diet
62835261|NCT00194428|ACTIVE_COMPARATOR|2|Low-fat diet
62835262|NCT06188767|EXPERIMENTAL|Testosterone|Participants are randomized to a single injection of 1000 mg testosterone undecanoate
62253450|NCT05985148|EXPERIMENTAL|Single-fraction stereotactic radiosurgery (SRS)|"Patients will be treated with single-fraction radiation therapy at three dose levels:~70 Gy, 80 Gy, and 90 Gy using image-guided SRS techniques."
62253451|NCT01953575|EXPERIMENTAL|Active Eosinophilic Esophagitis|Subjects with an eosinophil count greater than 15 eosinophil per high-powered field (Eos/HPF) and do not have trouble swallowing during the clinical endoscopy
62442523|NCT00004342||Parent of Minor Neutropenic Subjects|Parent of minor subjects (i.e., children under 18 years of age) who are diagnosed with severe chronic neutropenia
62611755|NCT05234034||chronic shoulder pain (CSP)|persons with chronic shoulder pain (CSP) will be included in this arm.
62611756|NCT05234034||osteoarthritis (OA)|persons with osteoarthritis (OA) will be included in this arm.
62611757|NCT05234034||fibromyalgia (FM)|persons with fibromyalgia (FM) will be included in this arm.
62611758|NCT05234034||chronic Temporomandibular Disorder (CTMD)|persons with chronic temporomandibular disorder (CTMD) will be included in this arm.
62611759|NCT05681637|EXPERIMENTAL|Hypoxia|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of volunteer hands throughout the experiment.
62835263|NCT06188767|PLACEBO_COMPARATOR|Placebo|Participants are randomized to a single placebo injection
62835264|NCT03266510|EXPERIMENTAL|Inspiratory muscle strength training|Using a handheld device, subjects were perform 30 breaths a day, six days a week. The device produces resistance that increases the effort of breathing in. The resistance to breathing will be strong.
62835265|NCT03266510|SHAM_COMPARATOR|Sham training|Using a handheld device, subjects were perform 30 breaths a day, six days a week. The device produces resistance that increases the effort of breathing in. The resistance to breathing will be weak.
62835266|NCT05681767|EXPERIMENTAL|Intervention group|Motivational multicomponent lifestyle intervention + treatment as usual
62052351|NCT04602130|EXPERIMENTAL|Tub bathing|In the tub bathing group, before being immersed in the tub, the newborns' faces and heads were cleaned outwards from the midline and dried. Then, the neck, chest, arms, back, legs and genital area were soaped, before the full body was rinsed and dried. Finally, umbilical cord care was performed, and the baby was diapered. Nurses recorded the newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form.
62835267|NCT05681767|OTHER|Control group|Treatment as usual
62835268|NCT05950074|EXPERIMENTAL|"It´s Up To You program"|"Participants will receive the prevention program It´s Up To You during the academic year in school hours."
62835269|NCT05950074|NO_INTERVENTION|Control|The control group will receive the usual teaching activities regarding substance use prevention.
62052352|NCT04602130|NO_INTERVENTION|Control|The newborns in the control group did not undergo any intervention other than standard clinical practices. All physiological measurements (pulse, respiration, oxygen saturation and body temperature) were performed by nurses and recorded on the Newborn Follow-up Form.
62835270|NCT01982097||Group 1|
62835271|NCT02229669|EXPERIMENTAL|Horizontal incisions|Coronally advanced flap was performed by using horizontal interdental incisions. An initial horizontal incision was made slightly coronal to the CEJ from the distal to the mesial papilla of the teeth with the recessions. A second incision, 1 to 2 mm apart and parallel to the first incision, was made apically. A sulcular incision was made to link the second incisions and the blade was inserted extending beyond the mucogingival junction, to create a uniform split-thickness flap. The tissue between the two incisions was partially removed to obtain a uniform receptor site that permitted primary closure. Approximation sutures to place the edge of the flap at the base of the remaining papilla were performed.
62835272|NCT02229669|EXPERIMENTAL|Oblique incisions|Coronally advanced flap was performed by using oblique incisions in interdental areas, according to the technique proposed by Zucchelli \& De Sanctis (2000). Oblique submarginal interdental incisions were performed and continued with the intrasulcular incisions at the recession defects, resulting in a envelop flap that was raised with a split-full-split approach in the coronal-apical direction. During coronal advancement, each surgical papilla was dislocated with respect to the de-epithelized anatomic papilla by the oblique incisions. Interrupted sutures were performed to stabilize single surgical papilla over the interdental connective tissue bed.
62835273|NCT02581410|EXPERIMENTAL|GSK1437173A Group|Subjects ≥ 65 years of age who received Zostavax vaccine ≥ 5 years earlier and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
62052353|NCT04435041||Remote assessment tools|Qualitative methods: semi-structured interviews for approx 40 front line clinical practitioners
62052354|NCT04435041||RECAP early warning score|Development of disease specific early warning score, building on earlier work through literature review and NEWS2 score
62052355|NCT04435041||Implementation/Scale up case studies|Study of implementation and scale up of remote-by-default at four different UK sites
62052356|NCT04435041||Infrastructure strengthening|Theory and data driven change effort involving policymakers, regulators, professional bodies, industry, patients and citizens with a view to overcoming interacting issues impacting success of digital projects.
62052357|NCT04699435|EXPERIMENTAL|Control|Patients with a BMI \<25 kg / m² requiring general anesthesia with a pre-oxygenation for 3 minutes
62052358|NCT04699435|EXPERIMENTAL|PreOx_3min|Patients with a BMI between 30 kg / m² and 40 kg / m² requiring general anesthesia randomized to the pre-oxygenation group for 3 minutes
62253452|NCT01953575|EXPERIMENTAL|Inactive Eosinophilic Esophagitis|Subjects with an eosinophil count less than 15 eosinophil per high-powered field (Eos/HPF) and do not have trouble swallowing during the clinical endoscopy
62253453|NCT01953575|PLACEBO_COMPARATOR|Control group|Subjects are those undergoing clinically indicated upper endoscopy for nonesophageal symptoms in whom a normal-appearing esophagus was found at the time of endoscopy
62253454|NCT04568395|EXPERIMENTAL|PLWH smoker|PLWH who smoke will undergo 3 interventions : acute TCIG use, acute ECIG use and acute sham control
62253455|NCT04067479|EXPERIMENTAL|Young|"21-30 year old men and women Inclusion/Exclusion Criteria~1. All subjects will be sedentary or recreationally active (sedentary: one day or less per week of aerobic or resistance exercise for at least a year or recreationally active: not training for competitive events).~2. Age: 21-30 years~3. Body mass index \<35 kg•m-2,~4. Chronic users of medications such as acetaminophen, ibuprofen, or prescription cyclooxygenase inhibitors will be excluded as these medications have been shown to alter tendon physiology.~5. Individuals with diabetes will be excluded. Diabetes is thought to change the structure of tendon.~6. Individuals with a history of tendon pain will be excluded, as chronic tendon pain is associated with changes in the structure of tendon.~7. Persons with allergies/sentivitiy to amino acids or ingedianet of Cystal Light will be excluded."
62442524|NCT03853577|ACTIVE_COMPARATOR|Psilocybin|
62052359|NCT04699435|EXPERIMENTAL|PreOx_6min|Patients with a BMI between 30 kg / m² and 40 kg / m² requiring general anesthesia randomized to the pre-oxygenation group for 6 minutes
62052360|NCT04658641|ACTIVE_COMPARATOR|Standard clinical pulse shape|Standard clinical pulse shape as used in clinical practice (cathodic stimulation).
62052361|NCT04658641|EXPERIMENTAL|Complex pulse shape|Complex pulse shape (i.e. biphasic pulse shape anode first, biphasic pulse shape cathode first, hyperpolarizing pre-pulse or depolarizing pre-pulse).
62052362|NCT04336735|EXPERIMENTAL|Immunization Tool Users|Users will trial a novel transplant-specific immunization tool (app)
62052363|NCT01431001|EXPERIMENTAL|Coil Configuration A|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
62052364|NCT01431001|EXPERIMENTAL|Coil Configuration B|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
62052365|NCT02395861|EXPERIMENTAL|Electrophysiologic analyses|
62052366|NCT00863655|EXPERIMENTAL|Everolimus + Exemestane|Everolimus 10 mg daily in combination with exemestane 25 mg daily
62052367|NCT00863655|ACTIVE_COMPARATOR|Placebo + Exemestane|Placebo of everolimus in combination with exemestane 25 mg daily
62052368|NCT05471037|ACTIVE_COMPARATOR|Long Biliopancreatic Limb LRYGB|25 morbidly obese patients undergoing gastric bypass surgery, participating in SLIM Trial.
62052369|NCT05471037|ACTIVE_COMPARATOR|Short Biliopancreatic Limb LRYGB|25 morbidly obese patients undergoing gastric bypass surgery, participating in SLIM Trial.
62442525|NCT03853577|PLACEBO_COMPARATOR|Placebo|
62442526|NCT00820456||Colorectal Cancer, Hepatic Metastasis|Eligible participants in Arm A enrolled in this imaging study will: be older than 18, have metastatic colorectal cancer with at least one hepatic lesion, and be treated with FOLFOX in combination with bevacizumab.
62442527|NCT00820456||Primary Tumor Undefined, Hepatic Metastasis|Eligible participants in Arm B enrolled in this imaging study will: be older than 18, must have prior histological documentation of any types of cancer with metastasis to the liver, and must be in stable treatment conditions prior to and between scans.
62442528|NCT03735784|EXPERIMENTAL|AWARE condition|AWARE is a four-session Motivational Interviewing (MI)-informed group risk reduction intervention that incorporates education, skills building and personalized feedback.
62835274|NCT02581410|ACTIVE_COMPARATOR|Control Group|Subjects ≥ 65 years of age who never received Zostavax vaccine and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
62052370|NCT05471037|NO_INTERVENTION|Control|15 normal weight control group without surgery.
62052371|NCT02831257|EXPERIMENTAL|AZD2014|"18 patients will be enrolled in this study in a single stage.~* AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.~* One cycle will consist of 28 days (1 cycle = 28 days)."
62052372|NCT05771779|EXPERIMENTAL|Arm A: Oral Cholera Vaccine (OCV) only|Based on randomization (n= 413) Potential participants will be vaccinated with OCV on Day 0 and Day 28. Two doses of MR vaccine will be given on day 56 and day 236. A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28, Day 56, Day 84 and Day 264 . All details will be recorded in the eCRF.
62052373|NCT05771779|EXPERIMENTAL|Arm B: Typhoid Conjugate Vaccine (TCV) only|Based on randomization (n= 314) Potential participants will be vaccinated with TCV on Day 0 and two doses of MR vaccine will be given on Day 56 and Day 236. A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28, Day 84 and Day 264 . All details will be recorded in the eCRF.
62253456|NCT04067479|EXPERIMENTAL|Older Adults|"Inclusion/Exclusion Criteria~1. All subjects will be sedentary or recreationally active (sedentary: one day or less per week of aerobic or resistance exercise for at least a year or recreationally active: not training for competitive events).~2. Age: 60-75 years~3. Body mass index \<35 kg•m-2~4. Chronic users of medications such as acetaminophen, ibuprofen, or prescription cyclooxygenase inhibitors will be excluded as these medications have been shown to alter tendon physiology.~5. Individuals with diabetes will be excluded. Diabetes is thought to change the structure of tendon.~6. Individuals with a history of tendon pain will be excluded, as chronic tendon pain is associated with changes in the structure of tendon.~7. Persons with allergies/sentivitiy to amino acids or ingedianet of Cystal Light will be excluded."
62253457|NCT00754351|EXPERIMENTAL|1|Bevacizumab-\>Docetaxel-\>Gemcitabine
62835275|NCT05677568||Prospective|"Prospective patients are identified prior to undergoing the Carillon procedure and are only enrolled after being successfully implanted with the Carillon device (prior to hospital discharge). Prospective patients will have applicable medical history and details of the Carillon implant procedure collected from medical records. After the patient is discharged, the patient's primary care specialist (cardiologist) and clinical investigation site staff will coordinate follow-up evaluations. Patients will be evaluated at one (1), six (6), twelve (12) months per standard of care and with annual contact for an additional four (4) years, for a total of five (5) years to assess long-term safety of the Carillon implant."
62835276|NCT05677568||Retrospective/Prospective|"Retrospective/Prospective patients are implanted with the Carillon device and are currently being followed-up per standard of care. These patients will have applicable data collected from their medical records, including medical history, data about the Carillon procedure and follow-up visit data done since receiving the Carillon implant. They will be evaluated prospectively per standard of care follow-up through five (5) years post-implant to assess long-term safety of the Carillon implant."
62052374|NCT05771779|EXPERIMENTAL|Arm C: Measles and Rubella (MR) only|Based on randomization (n= 250) Potential participants will be vaccinated with MR on Day 0 and Day 180. A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28 and Day 208 . All details will be recorded in the eCRF.
62253458|NCT02205411|EXPERIMENTAL|HeartAssist 5® VAD System|Implant of the HeartAssist 5® VAD System
62253459|NCT02205411|ACTIVE_COMPARATOR|Control VAD|
62253460|NCT05040893|EXPERIMENTAL|Outpatient Physiotherapy Intervention|POETIC will test a patient-oriented, outpatient physiotherapy intervention tailored to each patient based on their symptoms, functional limitations, and goals. The intervention consists of eight one-on-one, supervised sessions delivered over 8 to 10 weeks, approximately one week apart. Each session will be approximately one hour long.
62253461|NCT05080049|EXPERIMENTAL|erythropoietin|Erythropoietin alpha or theta 40,000 UI (1 ml) sc each week if Hb \<12 g/dL (for maximum 5 weeks)
62835277|NCT04035460|ACTIVE_COMPARATOR|Helmet oxygenation group|Patients randomized to helmet NIPPV will receive noninvasive oxygenation and ventilation via a latex free helmet
62835278|NCT04035460|ACTIVE_COMPARATOR|High Flow Nasal Oxygen|Oxygen will be passed through a heated humidifier and applied continuously through large-bore nasal prongs
62052375|NCT05771779|EXPERIMENTAL|Arm D: Co-administration of Measles and Rubella (MR) and Typhoid Conjugate Vaccine (TCV)|Based on randomization (n= 314) Potential participants will be vaccinated with TCV on Day 0 and two doses of MR vaccine will be given on Day 0 and Day 180 . A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28 and Day 208 . All details will be recorded in the eCRF.
62052376|NCT05771779|EXPERIMENTAL|Arm E: Co-administration of Measles and Rubella (MR) and Oral Cholera Vaccine (OCV)|Based on randomization (n= 413) Potential participants will be vaccinated with OCV on Day 0 and Day 28 . Two doses of MR vaccine will be given on Day 0 and Day 180 . A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28 , Day 56 and Day 208 . All details will be recorded in the eCRF.
62253462|NCT05080049|PLACEBO_COMPARATOR|Placebo|saline sc injection (1 ml) each weeks if Hb \<12 g/dL, for a maximum of 5 weeks,
62253463|NCT00130702|EXPERIMENTAL|Gefitinib (Iressa)|All patients will receive Gefitinib (Iressa) at a dose of 750 mg orally (three 250 mg tabs) each day.
62253464|NCT04906356||Study group|Single group observational study
62253465|NCT05060120||confirmed ovarian torsion|immediately before laparoscopy and 1 day post- operation and four weeks after laparoscopy a panel of serum biomarkers will be tested
62253466|NCT05060120||confirmed non ovarian torsion|immediately before laparoscopy
62253467|NCT05060120||control group|match control Compare healthy controls with patients with or without ovarian torsion as confirmed by laparoscopy
62253468|NCT03877536|EXPERIMENTAL|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|Genvoya® (Elvitegravir, corbiscistat, Emtricitabine and Tenofovir Alafenamide): once a day antiretroviral pill starting within 1 week of enrollment.
62253469|NCT04755348|EXPERIMENTAL|Product usage order ABFCED|Subjects will use each of the 6 products (ABFCED) during an familiarization period, followed by a 4 hour Test Session
62253470|NCT04755348|EXPERIMENTAL|Product usage order BCADFE|Subjects will use each of the 6 products (ABECD) during an familiarization period, followed by a 4 hour Test Session
62253471|NCT04755348|EXPERIMENTAL|Product usage order CDBEAF|Subjects will use each of the 6 products (CDBEAF) during an familiarization period, followed by a 4 hour Test Session
62253472|NCT04755348|EXPERIMENTAL|Product usage order DECFBA|Subjects will use each of the 6 products (DECFBA) during an familiarization period, followed by a 4 hour Test Session
62253473|NCT04755348|EXPERIMENTAL|Product usage order EFDACB|Subjects will use each of the 6 products (EFDACB) during an familiarization period, followed by a 4 hour Test Session
62835279|NCT02979496|OTHER|0 g pomace (control)|16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
62835280|NCT02979496|EXPERIMENTAL|90 g pomace|16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
62052377|NCT05771779|EXPERIMENTAL|Arm F: Co-administration of Typhoid Conjugate Vaccine (TCV) and Oral Cholera Vaccine (OCV)|Based on randomization (n= 413) Potential participants will be vaccinated with TCV on Day 0 . Two doses of OCV vaccine will be given on Day 0 and Day 28. Also two doses of MR vaccine will be given on Day 56 and Day 236. A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28 , Day 56 , Day 84 and Day 264 . All details will be recorded in the eCRF.
62052378|NCT02287584|PLACEBO_COMPARATOR|DSP-5423P Placebo|Percutaneous DSP-5423P Placebo was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
62052379|NCT02287584|EXPERIMENTAL|DSP-5423P 40mg|Percutaneous DSP-5423P 40mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
62052380|NCT02287584|EXPERIMENTAL|DSP-5423P 80mg|Percutaneous DSP-5423P 80mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
62052381|NCT02287584|EXPERIMENTAL|DSP-5423P Placebo-to-Flex|Percutaneous Subjects received DSP-5423P Placebo once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.
62052382|NCT02287584|EXPERIMENTAL|DSP-5423P Active-to-Flex|Percutaneous Subjects received DSP-5423P 40mg or 80mg once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.
62052383|NCT03164980|EXPERIMENTAL|Arm A|PLD followed by Trabectedin. Treatment is repeated every 3 weeks for 6 cycles or until disease progression.
62253474|NCT04755348|EXPERIMENTAL|Product usage order FAEBDC|Subjects will use each of the 6 products (FAEBDC) during an familiarization period, followed by a 4 hour Test Session
62442529|NCT03735784|NO_INTERVENTION|Standard Care condition|"Participants in the Standard Care condition have access to usual care at the drop-in center where the study is being conducted."
62442530|NCT05448716||Light Chain Cardiac Amyloidosis|Participants with light chain cardiac amyloidosis actively receiving chemotherapy or undergoing autologous bone marrow transplant
62442531|NCT01095757|OTHER|Plerixafor + Chemo and G-CSF|Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.
62442532|NCT02001779|EXPERIMENTAL|Biliary SEMS loaded with 125I seeds|A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
62253475|NCT05492734|EXPERIMENTAL|Treatment|Drug: EDG-5506
62253476|NCT03087188||Utilization of inhalator|Film sequences will be shown to patients using incorrect application technique in order to improve technique. Learning success will be assessed subsequently and at a follow-up visit after 2-8 weeks
62253477|NCT02246582|OTHER|Group A|Subjects underwent FST at 30 mins, 50 hrs and 146 hrs from Enlite 3 Sensors connected to GST3C, GST4C Transmitter, and GSR
62442533|NCT02001779|ACTIVE_COMPARATOR|Conventional biliary SEMS|A self-expandable metallic biliary stent is inserted in patients with inoperable malignant biliary obstruction.
62442534|NCT03065127|EXPERIMENTAL|Cognitive Training|"Participants will independently complete cognitive exercises on the Smartbrain Pro computer software. These exercises aim to train different aspects of executive function. The difficulty level of each exercise will increase relative to each participant's progress. Sessions will last for one hour, occurring twice weekly for a period of 4 weeks."
62835281|NCT02979496|EXPERIMENTAL|180 g pomace|16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
62835282|NCT02979496|OTHER|Flavored water (control)|16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
62835283|NCT00891904|EXPERIMENTAL|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once weekly in weeks 1-5
62835284|NCT01931566|PLACEBO_COMPARATOR|Low Risk Placebo|Pioglitazone placebo-matching tablets, orally, once daily to participants assigned to low risk group for developing MCI-AD for up to 5 years.
62835285|NCT01931566|PLACEBO_COMPARATOR|High Risk Placebo|Pioglitazone placebo-matching tablets, orally, once daily to participants assigned to high risk group for developing MCI-AD for up to 5 years.
62253478|NCT02246582|OTHER|Group B|Subjects underwent FST at 14 hrs, 62 hrs and 158 hrs from Enlite 3 Sensors connected to GST3C, GST4C Transmitter, and GSR
62253479|NCT05740085||Rheumatoid Arthritis Patients|Patients that are diagnosed with rheumatoid arthritis
62253480|NCT05510154|EXPERIMENTAL|Brief Advice|Brief Advice involves basic e-cigarette education and advice to switch.
62253481|NCT05510154|EXPERIMENTAL|Single Training|Single Training is the same as Brief Advice but includes one session of real-time training on how to puff on the e-cigarette.
62442535|NCT03065127|EXPERIMENTAL|Cognitive Behavioural Therapy|Participants will undergo one-on-one sessions of cognitive-behavioural therapy (CBT) working with a therapist to establish an individualized CBT plan which will focus on symptoms of anxiety. Participants will complete a total of eight one-hour sessions over 4 weeks.
62611760|NCT06020209|EXPERIMENTAL|STEMI patients|Patients with reperfused ST-segment Elevation Myocardial Infarction
62611761|NCT05016297|EXPERIMENTAL|baricitinib 4mg per day + HCQ 200mg twice a day|On the basis of the HCQ treatment before, patients in this group will be added on baricitinib 4mg once a day.
62835286|NCT01931566|EXPERIMENTAL|High Risk Pioglitazone|Pioglitazone 0.8 mg, sustained release (SR) tablets, orally, once daily to participants assigned to high risk group for developing MCI-AD for up to 5 years.
62052384|NCT03164980|EXPERIMENTAL|Arm B|"* Carboplatin/PLD~* Carboplatin/Gemcitabine~* Carboplatin/Paclitaxel Patients will be treated for 6 cycles or until PD, unacceptable toxicity or patient's wish to discontinue, whichever occurs first."
62052385|NCT04377932|EXPERIMENTAL|AGAR T cells|GPC3-CAR and the IL15 (AGAR T cells) will be administered to patients with GPC3-positive solid tumors.
62052386|NCT06518421||Healthy Controls|"Brain imaging, clinical data, and cognitive data will be prospectively collect and analyze in both healthy control and patients with trigeminal neuralgia groups. Prospective data collection for control group includes:~* MRI scan (1 timepoint)~* Neuropsychological assessments (1 timepoint)"
62052387|NCT06518421||Trigeminal Neuralgia|"Trigeminal Neuralgia is the most common chronic neuropathic facial pain disorder, characterized by the sudden onset of intermittent, intense, shock-like pain in distributions of the trigeminal nerve branches. TN has several unique features that distinguish it as an ideal model for the study of chronic pain: TN is largely unilateral; is severe in its nature; has stereotypical presentation among patients; and is not associated with other sensory deficits observed in other chronic pain disorders, such as numbness.~Brain imaging, clinical data, and cognitive data will be prospectively collect and analyze in both healthy control and patients with trigeminal neuralgia groups. Prospective data collection for TN group includes:~* MRI scan (2 timepoints; pre- and 6-month post-surgery)~* Neuropsychological assessments (2 timepoints; pre- and 6-month post-surgery)"
62052388|NCT00876538|EXPERIMENTAL|TRO19622|2 capsules of TRO19622 (330mg) once day with the noon meal
62253482|NCT05510154|EXPERIMENTAL|Training to Competency|Training to Competency is the same as Single Training but includes three real-time training sessions rather than one.
62253483|NCT01667081||Grazoprevir|Participants who previously received grazoprevir as study treatment on a prior study.
62253484|NCT03364582||Men-observed dietary pattern|Health Professionals Follow-up Study: a prospective cohort of male health professionals
62442536|NCT03065127|EXPERIMENTAL|Proprioceptive Training|Participants will complete one-on-one sessions a target matching proprioceptive training protocol using their upper and lower limbs. For the upper limb target-reaching task, participants will be seated in front of a surface marked with ten targets. They will first visualize a specified target, then blindfolded and asked to reach towards that target with the blindfold on. The blindfold will then be removed allowing participants to view their performance relative to the target. This task will be repeated for the remaining targets on both sides and for both upper and lower limbs. Participants will complete a total of eight one-hour sessions over 4 weeks.
62442537|NCT01831063|NO_INTERVENTION|1|This group received the traditional seizure teaching. This consisted of verbal instruction from health care professionals on acute seizure management and administration of the rescue medication.
62442538|NCT01831063|EXPERIMENTAL|2|This group received the traditional seizure teaching as well as the supplemental simulation based seizure management teaching. The simulation based seizure teaching consisted of numerous opportunities to manage a simulated seizure with instructor guidance and feedback. This session was deemed complete when caregivers verbalized confidence with seizure management.
62442539|NCT00988169|EXPERIMENTAL|oral erlotinib and pulsed doses of oral AT-101|This will be an open-label, single institution, phase II trial. The study will assess the efficacy of the combination of the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and the novel pan-Bcl-2 inhibitor, AT-101, in treatment-naïve advanced (Wet Stage IIIB and IV)NSCLC patients with EGFR activating mutations A planned pause of 21 days will be performed after enrollment of the 10th and 20th patient to assess for excessive toxicity.
62442540|NCT06325085|EXPERIMENTAL|Compensatory and restorative rehabilitation techniques|compensatory and restorative rehabilitation techniques in stroke patients
62442541|NCT06325085|ACTIVE_COMPARATOR|Traditional cognitive Rehabilitation training|Naming words Counting numbers backwards Spell the word backwards
62442542|NCT03381547|ACTIVE_COMPARATOR|A|Pegilodecakin: Dose level depending on weight will be 0.8 mg or 1.6 mg, dose formulation 4 mg/mL.
62442543|NCT03381547|ACTIVE_COMPARATOR|B|Pegilodecakin: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 4 mg/mL.
62442544|NCT03381547|ACTIVE_COMPARATOR|C|Pegilodecakin: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 2 mg/mL.
62052389|NCT00876538|PLACEBO_COMPARATOR|Control|2 capsules of placebo once day with the noon meal
62052390|NCT04534257|EXPERIMENTAL|Angioplasty with SELUTION Sirolimus DCB|Subjects with infra-inguinal occlusive lesions will be treated with SELUTION Sirolimus DCB
62052391|NCT05897476|EXPERIMENTAL|ultrasound arm|every patient will be examine with ultrasound
62052392|NCT03916432|EXPERIMENTAL|Interventional group|HELIOS biodegradable polymer sirolimus-eluting stents
62253485|NCT03364582||Women-observed dietary pattern|Nurses' Health Study: a prospective cohort of female registered nurses
62253486|NCT03199664|ACTIVE_COMPARATOR|Group A (NB-UVB)|Intervention: patients will be treated with Narrow band ultra violet rays alone for 6 months
62442545|NCT03827213|EXPERIMENTAL|Single shot Interscalene Nerve Block|This group will receive an interscalene nerve block. This will be administered as a single 20mL injection consisting of a mixture of 10mL of Exparel and 10mL of 0.5% bupivacaine hydrochloride.
62442546|NCT03827213|ACTIVE_COMPARATOR|Indwelling Interscalene Catheter|"This group will receive an indwelling interscalene catheter placed posterior to C5-C6 nerve roots (between the shoulders) and administered 15 mL of 0.5% ropivacaine plain for the block with no superficial cervical block. The On-Q pump will be set at a rate of 4 mL/hr."
62442547|NCT00753714|EXPERIMENTAL|A|Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.
62052393|NCT01507636|ACTIVE_COMPARATOR|Group 1|Occupational therapy using a special arm function training.
62052394|NCT01507636|ACTIVE_COMPARATOR|Group 2|Physical therapy using the Theraband for training of force.
62253487|NCT03199664|ACTIVE_COMPARATOR|Group B ( combined NB-UVB & Tacrolimus)|Intervention: patients will be treated with NB-UVB \& Tacrolimus 0.03 % ointment for 6 months
62253488|NCT01829971|EXPERIMENTAL|MRX34|Single agent MRX34
62835287|NCT00082225|EXPERIMENTAL|EBV specific T cells|"Patients receiving CTLs as therapy for relapsed Lymphoma or who are at high risk for relapse or patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.~A fixed dose of CD45 MAb (400ug/kg over 4 hours daily times 4 given over 2 daily IV infusions) will be used."
62052395|NCT06096701||Intervention|Intervention group will receive blood pressure (BP) cuffs. The BP cuff is connected in a Health Insurance Portability and Accountability Act-compliant fashion to the patient's medical record, allowing for documentation and communication with the nurse and the care team. Alerts are triggered if a patient has not checked her BP for 3 days or when readings fall outside a specific threshold (high or low BP alerts). Based on these alerts, the nurse follows up with these patients and reminds them to take a reading. The nurse will also notify participants with elevated BP values to repeat their BP and will contact the participants by phone to discuss symptoms and antihypertensive medications. Patients will be managed based on a clinical algorithm for initiation of antihypertensive medications without the need for an outpatient visit if considered appropriate by the clinical provider.
62052396|NCT06096701||Historical or Concurrent controls|Individuals who had hypertensive disorders during pregnancy but who did not receive the BP cuffs will serve as the control group.
62052397|NCT05440370|EXPERIMENTAL|MegaCarti® application after microfracture|The experimental group is applied with MegaCarti® after microfracture. Afterwards, they visit at 6 weeks, 12 weeks, 24 weeks, and 48 weeks to conduct examinations and assess Questionnaires. Long-term follow-up Study is performed to subject that completes 48-week visit, at every 6 months for 5 years.
62052398|NCT05440370|ACTIVE_COMPARATOR|Microfracture only|The control group undergoes microfracture and they visit at 6 weeks, 12 weeks, 24 weeks, and 48 weeks after surgery to conduct examinations and assess Questionnaires.
62052399|NCT01742364|EXPERIMENTAL|Bioject Intradermal (ID) Pen|Intradermal administration of BCG vaccine via the Bioject ID Pen.
62052400|NCT01742364|ACTIVE_COMPARATOR|Needle and syringe|Intradermal administration of BCG vaccine via needle and syringe.
62052401|NCT06239870|EXPERIMENTAL|neoadjuvant therapy|"1. Induction therapy stage: chemotherapy combined with immunotherapy for 2 cycles: Envafolimab: 200mg, subcutaneous injection, Q2W, 2 cycles; mFOLFOX6: Q2W, 2 cycles (concurrent administration of envollizumab on the first day of chemotherapy).~2. Concurrent chemoradiotherapy: long-term chemoradiotherapy combined with immunotherapy for 3 cycles: radiation therapy: 50Gy/25f, 2Gy every day, 5 days a week for 5 weeks; Capecitabine: 825mg/m2 orally (1650mg/m2/d) twice a day in the morning and evening, 5 days a week, simultaneous with radiation therapy, for a total of 25 days; Envafolimab: 200mg, subcutaneous injection, Q2W, 3 cycles (Envafolimab was administered on day 1, day 15, and day 29 of radiotherapy).~Iii. Consolidation treatment stage: chemotherapy combined with immunotherapy for 2 cycles: Envafolimab: 200mg, subcutaneous injection, Q2W, 2 cycles; mFOLFOX6: Q2W, 2 cycles. (Concurrent administration of envafolimab on the first day of chemotherapy)."
62052402|NCT01711762|EXPERIMENTAL|GDC-0973 Single Arm|
62052403|NCT01595893|EXPERIMENTAL|Vitamin D3|
62052404|NCT01595893|PLACEBO_COMPARATOR|Placebo|
62052405|NCT03776825||Perianal Crohn's Disease|Permacol Paste injection
62052406|NCT03171779||Usual practice|
62052407|NCT03171779||IPEM|Interprofessional Training in Early Identification and Multidimensional Evaluation (IPEM) of patients' palliative needs
62052408|NCT03171779||IPEM and PAS|Interprofessional Early Identification Training and Multidimensional Assessment (IPEM) of patients' palliative needs, and to the Early Care Planning (SAP)
62052409|NCT06229132|OTHER|LGBTQ-affirmative CBT treatment|LGBTQ-affirmative CBT includes client case conceptualizations to personalize treatment delivery and functional relevance. Modules raise awareness of the impact of sexual minority stress on mental, behavioral, and sexual health; instill cognitive flexibility toward minority stress cognitions; and reduce maladaptive avoidance tendencies rooted in minority stress. The treatment is guided by six principles: (1) normalizing mood and anxiety as a common response to LGBTQ-related stress; (2) challenging persistent, inflexible LGBTQ-related stress-induced cognitions; (3) encouraging assertive behavior and open self-expression in safe situations to effectively cope with the consequences of LGBTQ-related stress; (4) validating LGBTQ clients' unique strengths; (5) building authentic relationships as an essential resource for LGBTQ people's mental health; and (6) recognizing intersectional identities as a source of stress and resilience. The intervention consists of 16 sessions delivered on Zoom.
62052410|NCT04044222|EXPERIMENTAL|Treatment (Sintilimab, etoposide, ifosfamide, carboplatin)|Patients receive sintilimab IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Sintilimab in combination with ICE chemotherapy repeats every 21 days for 6 courses.
62442548|NCT00753714|PLACEBO_COMPARATOR|B|Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.
62442549|NCT04990622|EXPERIMENTAL|Dietary flavonoid group|"Participants will be encouraged to consume 2 x flavonoid-rich food items per day from the following list of flavonoid-rich foods across 2 weeks, above what they already consume each day, typically.~* Berry fruits (\~120g) e.g. blueberries, raspberries, strawberries, blackberries, blackcurrants, mixed berries~* 2 large squares of dark chocolate (at least 70% cocoa)~* 4-5 cups of tea (black or green) or coffee (normal or decaf varieties)~* 1 large glass of red wine\* (250ml)~* 1 portion of leafy green vegetables such as spinach or cabbage (\~70g)~* 1 glass (250ml) of fresh orange or grapefruit juice (not from concentrate)"
62835288|NCT02268175|EXPERIMENTAL|ARM 1|"Participants will be randomized in a 2:1 ratio to neoadjuvant treatment (ARM 1) or (ARM 2).~Participants will receive the assigned study treatment per cycle~* Enzalutamide- Once daily at prespecified dose, orally~* Abiraterone Acetate- Once daily at prespecified dose, orally~* Prednisone-Once daily at prespecified dose, orally~* Leuprolide Acetate-Intermuscular injection at prespecified dose and duration"
62835289|NCT02268175|EXPERIMENTAL|ARM 2|"Participants will be randomized in a 2:1 ratio to neoadjuvant treatment (ARM 1) or (ARM 2).~Participants will receive the assigned study treatment per cycle.~* Enzalutamide- once daily at prespecified dose, orally~* Leuprolide Acetate- Intermuscular injection at prespecified dose and duration"
62052411|NCT04044222|EXPERIMENTAL|Treatment (placebo, etoposide, ifosfamide, carboplatin)|Patients receive placebo IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Placebo in combination with ICE chemotherapy repeats every 21 days for 6 courses.
62052412|NCT01078480|EXPERIMENTAL|Arm sling treatment|Displaced midshaft fracture of the collar bone treated with an arm sling
62052413|NCT01078480|EXPERIMENTAL|Operation|Displaced midshaft fracture of the collar bone treated with operation using a pre contoured titanium plate and screws.
62052414|NCT01595568|EXPERIMENTAL|Learning to cope with your impulsivity|Cognitive-behavioural intervention targeting impulsive personality
62253489|NCT05111665|EXPERIMENTAL|Mindfulness-based Cognitive Therapy (MBCT)|Remitted depressed participants received eight-weekly, two-hour MBCT sessions (Segal et al., 2013). This program combines MBSR meditation practices (e.g., body scan, mindful stretching, mindfulness of breath/body/sounds/thoughts) with traditional CT techniques (e.g., psychoeducation about depression symptoms and automatic thoughts, exercises designed to demonstrate how the nature of one's thoughts change with one's mood, questioning of automatic thoughts and creating a relapse prevention plan). Finally, participants engaged in a daily meditation practice and homework exercises directed at integrating the application of awareness skills into daily life. Each MBCT group was led by a masters-level clinician who was an active MBCT/Mindfulness-Based Stress Reduction (MBSR) instructor.
62835290|NCT02556840|ACTIVE_COMPARATOR|Insulin therapy from the beginning of pregnancy|"Insulin therapy (Glargine/Lantus®, Détémir/Levemir® , Insulatard® , Umuline NPH® , Lispro/Humalog® , Asparte/Novorapid® or Actrapid ®) administered from the beginning of pregnancy according to maternal blood glucose (if fasting blood glucose \> 0.95g/l or post-prandial blood glucose \> 1.20g/l) as recommended by the national guidelines for gestational diabetes mellitus.~Insulin administered to patients either by subcutaneous injections or by pump."
62835291|NCT02556840|EXPERIMENTAL|Insulin therapy initiated according to fetal growth|"Insulin therapy (Glargine/Lantus®, Détémir/Levemir® , Insulatard® , Umuline NPH® , Lispro/Humalog® , Asparte/Novorapid® or Actrapid ®) initiated according to fetal growth evaluated by ultrasonography measurements. MODY2 women will not be treated with insulin until delivery, except when the fetal abdominal circumference exceeds ≥ the 75 percentile on one US or maternal fasting capillary blood glucose is ≥ 1,20 g/L or maternal post-prandial capillary blood glucose is ≥ 2,00 g/L.~Insulin administered to patients either by subcutaneous injections or by pump."
62253490|NCT05111665|ACTIVE_COMPARATOR|Relaxation Group Therapy (RGT)|The revised edition of the Changeways Relaxation Programme (Paterson, 1997) served as the active control condition to control for non-specific group factors including group participation, expectation of change or therapeutic contact and attention. The rationale was that relaxation can be used to better manage life stressors which precipitate depressive episodes. Participants received eight-weekly, two-hour relaxation training sessions. This group program combines psychoeducation regarding the effects of stress, diaphragmatic breathing, progressive muscle relaxation, passive relaxation and imagery. It also incorporates time for participants to discuss the events of the week to facilitate the supportive aspect of group participation. Finally, participants were asked to engage in daily exercises to practice the various relaxation strategies. Each RGT group was led by a doctoral-level therapist.
62442550|NCT04990622|NO_INTERVENTION|Control group|Participants will be given no instructions regarding adding food items to their diet. They will be encouraged to continue their diet as normal for 2 weeks.
62442551|NCT04773093|ACTIVE_COMPARATOR|Continous Intravenous Lidocaine Infusion|Patient will recieve Continous Intravenous Lidocaine Infusion
62835292|NCT02143388|EXPERIMENTAL|Concurrent chemoradiation + adjuvant chemotherapy|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
62835293|NCT02143388|ACTIVE_COMPARATOR|Concurrent chemoradiation|IMRT combine with cisplatin concurrent chemotherapy
62052415|NCT01595568|EXPERIMENTAL|Learning to cope with your sensation seeking|Cognitive behavioural intervention designed to help sensation seeking youth manage their need for stimulation and excitement.
62835294|NCT03460249|ACTIVE_COMPARATOR|BP table or chair, systolic or diastolic|record the BP obtained in each patient position
62835295|NCT03460249|ACTIVE_COMPARATOR|as above|as above
62835296|NCT00973635|NO_INTERVENTION|Traditional training|"Patients of subjects with no detailed curriculum for handoff skills during non-intervention months.~Learners provided a brief outline of how to perform discharge summaries (handout).~Learners given two core articles describing some of the communication issues regarding handoff safety.~Handoff teaching left to discretion of the subintern's team (typically the see one, do one, teach one method).~No feedback given to these subinterns on their performance of their handoff skills."
62052416|NCT01595568|EXPERIMENTAL|Learning to cope with your anxiety sensitivity|Cognitive behavioural intervention teaching anxiety sensitive youth to manager their sensitivity to threat and anxiety.
62052417|NCT01595568|EXPERIMENTAL|Learning to manage your negative thinking|Cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
62052418|NCT03340402|EXPERIMENTAL|Accelerated Partial Breast Irradiation|"Accelerated partial breast irradiation using proton beam scanning will consist of;~* 5 daily treatments using custom prone patient immobilization, contrast-enhanced CT planning, and daily image guidance~* Radiation therapy may be delivered with photons if proton treatments cannot be delivered~* Dose will be prescribed such that the gross tumor (GTV) receives the prescription dose per institutional policy and standard of care~* Daily target localization will also be confirmed using AlignRTTM"
62052419|NCT05321550||Fibromyalgia patients|Fibromyalgia patients diagnosed according to the 2010 ACR-criteria
62052420|NCT05321550||Neck pain patients|"* Patients with non-specific, idiopathic neck pain complaints~* Patients with neck pain complaints of traumatic origin type whiplash grade 1 (pain, stiffness or tenderness of the neck and no objective physical abnormalities) and grade 2 (neck complaints and musculoskeletal disorders such as reduced range of motion and tender pain points) according to the Quebec Task Force on Whiplash Associated Disorders"
62835297|NCT00973635|EXPERIMENTAL|Intervention|Group that receives educational intervention.
62835298|NCT05028543|PLACEBO_COMPARATOR|conventional TLH|women that will be subjected to conventional Total laparoscopic hysterectomy
62052421|NCT05321550||Low back pain patients|Patients with non-specific, idiopathic back pain complaints
62253491|NCT05111665|PLACEBO_COMPARATOR|Treatment as usual (TAU)|Participants randomized to the TAU group were instructed that participants would receive MBCT at the end of the follow-up period and to seek help from their family doctors or other sources as the normally would, should the participants encounter symptomatic deterioration or other difficulties over the course of the study. At the end of the follow-up phase, participants in the TAU and RGT group were offered the opportunity to receive MBCT.
62052422|NCT05321550||Healthy controls|Age, sex and BMI-matched healthy controls
62052423|NCT05988021|EXPERIMENTAL|Cohort 1: Sequence ABCD|"Participants assigned to sequence ABCD will receive the following treatments:~Period 1: Single dose of 30 mg CCX168 after a high-fat, high-calorie meal (Treatment A).~Period 2: After a washout period of ≥ 10 days, single dose of 30 mg CCX168 in the fasted state (Treatment B).~Period 3: After a washout period of ≥ 10 days, single dose of 3 mg CCX168 in the fasted state (Treatment C).~Period 4: 24 hours after the 3 mg CCX168 dose in Period 3, single dose of 100 mg CCX168 on Day 1, and then 100 mg CCX168 twice daily from Day 2 through Day 6. On Day 7, only a morning dose of 100 mg CCX168 (Treatment D)."
62052424|NCT05988021|EXPERIMENTAL|Cohort 2: Sequence BACD|"Participants assigned to sequence BACD will receive the following treatments:~Period 1: Single dose of 30 mg CCX168 in the fasted state (Treatment B).~Period 2: After a washout period of ≥ 10 days, single dose of 30 mg CCX168 after a high-fat, high-calorie meal (Treatment A).~Period 3: After a washout period of ≥ 10 days, single dose of 3 mg CCX168 in the fasted state (Treatment C).~Period 4: 24 hours after the 3 mg CCX168 dose in Period 3, single dose of 100 mg CCX168 on Day 1, and then 100 mg CCX168 twice daily from Day 2 through Day 6. On Day 7, only a morning dose of 100 mg CCX168 (Treatment D)."
62052425|NCT00801541||AMD|Patients with wet AMD in one eye and dry AMD in the other eye (study eye).
62253492|NCT00618410|ACTIVE_COMPARATOR|Carbon dioxide|nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge
62253493|NCT00618410|PLACEBO_COMPARATOR|Placebo|nasal placebo administered 30 minutes prior to nasal challenge
62253494|NCT02313298|EXPERIMENTAL|Stereotactic Body Radiotherapy|An extreme hypofractionated regimen of 36.25Gy in 5 fractions over 10-11 days
62253495|NCT03157505|ACTIVE_COMPARATOR|Purethal Birch immunotherapy|Purethat Birch intervention and symptomatic treatment for 24 months
62253496|NCT03157505|PLACEBO_COMPARATOR|placebo and symptomatic treatment|placebo intervention and symtomatic treatment during 24 months
62253497|NCT03493087|ACTIVE_COMPARATOR|Menakinon-7|Menakinon-7 360 µg tablet by mouth, every day for 6 weeks
62253498|NCT03493087|ACTIVE_COMPARATOR|Diet with vitamin K|Diet rich in vitamin K for 6 weeks
62253499|NCT00445224|EXPERIMENTAL|Hip Progressive Resistive Exercises|Exercises targeting hip musculature such as hip abduction and hip external rotation that was progressed by increased resistance following typical progressive resistive exercise approach.
62253500|NCT00445224|ACTIVE_COMPARATOR|Quad Progressive Resistive Exercises|Exercises targeting quadriceps musculature such as quadriceps isometric setting, terminal knee extensions, and straight leg raises that was progressed by increased resistance following typical progressive resistive exercise approach..
62253501|NCT05150600|EXPERIMENTAL|Group Inverse Ratio Ventilation (IRV)|The inspiratory to expiratory (I:E) ratio in this group will be 2:1 with the maximum inspiratory time (Ti) of 1.3 seconds
62253502|NCT05150600|NO_INTERVENTION|Group Conventional Ratio Ventilation (CRV)|The inspiratory to expiratory (I:E) ratio in this group will be 1:2 with the minimum inspiratory time (Ti) of 0.4 seconds
62442552|NCT04773093|PLACEBO_COMPARATOR|Placebo|Patient will recieve placebo (NaCl 0.9% infusion)
62442553|NCT04537676||DFU Participants|A cohort of 200 DFU patients who have been prescribed the Podimetrics System by their healthcare providers will be recruited upon providing informed consent. Potential participants will be asked to indicate their interest in participating in this patient empowerment study during their initial phone consultation for mat set-up with the Podimetrics care-management team. Participants will be followed for one year and answer a set of identical questionnaires at three time points: at baseline, at 6-month and at 12-month post enrollment.
62442554|NCT01405950|EXPERIMENTAL|Dose Level 1|
62253503|NCT02774447||Rectal cancer patients with ileostoma|"In association with anterior resection of rectal cancer these patients obtain loop-ileostoma in order to avoid complications. These are closed within a few months and according to previous studies the admission time is 3-5 days after operation. This study is a single-arm study. The arm include patients having had rectal cancer operation and who have obtained a loop-ileostoma and that meet the inclusion criteria.~The operation procedure is standardized; shortly described by dissecting the ileostoma from the abdominal wall and everting the stoma ledges, which will be sutured or stapled. The patients will be observed for 23 hours, and if there are no contraindications according to described criteria the patient can be discharged form the hospital, however all patients will be followed up."
62253504|NCT05608005|EXPERIMENTAL|Group 1|2 doses, 21 days apart, of Panblok H7 dose 1 + MF59
62253505|NCT05608005|EXPERIMENTAL|Group 2|2 doses, 21 days apart, of Panblok H7 dose 2 + MF59
62253506|NCT05608005|ACTIVE_COMPARATOR|Group 3|2 doses, 21 days apart, of Panblok H7 dose 3 unadjuvanted
62253507|NCT00110981|EXPERIMENTAL|Single-arm|
62253508|NCT01686009|EXPERIMENTAL|Intra-nasal ketamine|0.5 mg/kg ketamine intra-nasally; then 0.25 mg/kg repeat dose after 10 minutes if necessary
62253509|NCT06273670||Service providers|General practitioners, specialists, nurses, and social workers.
62253510|NCT06273670||Clients|All clients who were attending family planning centers in public health facilities at the study period will be included if they have had a postpartum LARC method (Copper IUD, Progestin-releasing IUS or Subdermal implant) or willing to use it in the first year after delivery.
62253511|NCT04353284|EXPERIMENTAL|Camostat mesylate|Camostat mesylate 200mg taken 7 days.
62253512|NCT04353284|PLACEBO_COMPARATOR|Placebo|Placebo taken for 7 days.
62253513|NCT04994197||Diagnosis group of patients with urothelial cancer|Patients with painless intermittent gross hematuria during outpatient/emergency/hospitalization diagnose as urothelial carcinoma in this study will be assigned to this group
62253514|NCT04994197||Diagnosis group of patients with benign urinary diseases|Patients with painless intermittent gross hematuria during outpatient/emergency/hospitalization diagnose as benign urinary diseases in this study will be assigned to this group
62253515|NCT04994197||Recurrence diagnosis group with urothelial cancer|Patients who were diagnosed with non-muscle invasive urothelial carcinoma and diagnosed as recurrent urothelial carcinoma in this study will be assigned to this group
62442555|NCT01405950|EXPERIMENTAL|Dose Level 2|
62835299|NCT05028543|EXPERIMENTAL|TLH with prior uterine artery clipping at its origin|women that will be subjected to TLH with prior uterine artery clipping at its origin
62442556|NCT01405950|EXPERIMENTAL|Dose Level 3|
62253516|NCT04994197||Recurrence diagnosis group with benign urinary diseases|Patients who were diagnosed with non-muscle invasive urothelial carcinoma and diagnosed as benign urinary diseases in this study will be assigned to this group
62253517|NCT03857204|EXPERIMENTAL|performing US scans for fetal weight assessment.|
62253518|NCT05082584|EXPERIMENTAL|Vadadustat|Cohort 1: participants with ≥12 years to \<17 years; Cohort 2: participants with ≥6 years to \<12 years; Cohort 3(a): participants with ≥2 years to \<6 years; and Cohort 3(b): participants with ≥4 months to \<2 years
62253519|NCT02518451|EXPERIMENTAL|(Test) Group I|Valsartan 160 mg film-coated caplets of PT Dexa Medica
62835300|NCT01256138||transplantation|
62253520|NCT02518451|ACTIVE_COMPARATOR|(Reference) Group II|Valsartan 160 mg film-coated caplets (Diovan® 160)
62442557|NCT01405950|EXPERIMENTAL|Dose Level 4|
62442558|NCT05692882|EXPERIMENTAL|Percutaneous transluminal angioplasty and stenting|All patients will be implanted with Drug-Eluting Stents (NOVA DES).
62442559|NCT02585674|EXPERIMENTAL|MyStar DoseCoach|MyStar DoseCoach - Device-supported treat-to-target regimen. Insulin glargine is administered subcutaneously on top of potential background therapy using oral anti-diabetic drug(s) or GLP1 RA injectable antihyperglycemic drug(s).
62442560|NCT02585674|ACTIVE_COMPARATOR|Routine Titration|Routine Titration - Routine titration defined by the Investigator. Insulin glargine is administered subcutaneously on top of potential background therapy using oral anti-diabetic drug(s) or GLP1 RA injectable antihyperglycemic drug(s).
62442561|NCT05788042|ACTIVE_COMPARATOR|Active transcranial Direct Current Stimulation (tDCS)|It will be given continuously for 30 minutes at 2 mA, twice daily (separated by \>=2 hours) over the first 4 weeks, and daily over the second 4 weeks of the 8 week acute treatment period (84 sessions total).
62442562|NCT05788042|SHAM_COMPARATOR|Sham transcranial Direct Current Stimulation (tDCS)|It will involve an initial ramping up to 0.5 mA and then a ramp down to 0 mA for the remainder of each treatment. The same number of sessions as active tDCS will be administered.
62623593|NCT02616198|ACTIVE_COMPARATOR|Riva SC Fuji Varnish|River SC Fuji Varnish combination was applied on one randomly selected cavity to be restored
62835301|NCT01256138||control|
62835302|NCT02395081|PLACEBO_COMPARATOR|600 IU|Women will receive prenatal vitamins containing 600 IU of Vitamin D.
62835303|NCT02395081|EXPERIMENTAL|2000 IU|Women will receive prenatal vitamins containing 2000 IU of Vitamin D.
62253521|NCT01492764||Active Group|This group will receive brief ablation at localized sources (Focal Impulse and Rotor Modulation, FIRM)
62253522|NCT01492764||Control Group|This group receives traditional ablation for this disorder
62253523|NCT03228303|ACTIVE_COMPARATOR|Chronic phase CML treated by nilotinib|Newly diagnosed
62253524|NCT03228303|ACTIVE_COMPARATOR|Chronic phase CML treated by imatinib|Newly diagnosed
62253525|NCT03625687|EXPERIMENTAL|Treatment with Direct Acting Antiviral for HCV|8 weeks of treatment with HCV Direct Acting Antiviral tablet (Mavyret or Epclusa)
62835304|NCT02395081|EXPERIMENTAL|4000 IU|Women will receive prenatal vitamins containing 4000 IU of Vitamin D.
62835305|NCT00493129|EXPERIMENTAL|Ontak|Ontak administered intravenously on Days 1-5 at the dose of 9 µg/kg/day, with a rest period from Days 6-21.
62611762|NCT05016297|ACTIVE_COMPARATOR|HCQ 200mg twice a day|Patients in this group will be given HCQ 200mg twice a day for 12 weeks. Patients who has no response to HCQ treatment alone at week 12 will be switched to baricitinib + HCQ group and added on baricitinib 4mg per day until the end of the study (week 24).
62253526|NCT04735822|EXPERIMENTAL|Part 1: Belumosudil Sequence ABFCED|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen A (delivered by Vehicle 1); Regimen B (delivered by Vehicle 2); Regimen F (delivered by Vehicle 6); Regimen C (delivered by Vehicle 3); Regimen E (delivered by Vehicle 5); Regimen D (delivered by Vehicle 4);
62253527|NCT04735822|EXPERIMENTAL|Part 1: Belumosudil Sequence BCADFE|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen B (delivered by Vehicle 2); Regimen C (delivered by Vehicle 3); Regimen A (delivered by Vehicle 1); Regimen D (delivered by Vehicle 4); Regimen F (delivered by Vehicle 6); Regimen E (delivered by Vehicle 5)
62253528|NCT04735822|EXPERIMENTAL|Part 1: Belumosudil Sequence CDBEAF|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen C (delivered by Vehicle 3); Regimen D (delivered by Vehicle 4); Regimen B (delivered by Vehicle 2); Regimen E (delivered by Vehicle 6); Regimen A (delivered by Vehicle 1); Regimen F (delivered by Vehicle 6)
62611763|NCT03011541|OTHER|Arm 1|BMSC provided retrobulbar, subtenon and intravenous for one or both eyes
62611764|NCT02839876|EXPERIMENTAL|Intravenous acetaminophen|Subjects receive 1000 mg acetaminophen IV immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an oral placebo.
62611765|NCT02839876|ACTIVE_COMPARATOR|Oral acetaminophen|Subjects receive 1000 mg acetaminophen PO immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an intravenous placebo.
62052426|NCT03917368|EXPERIMENTAL|Ultrasound scan of the internal jugular veins|Hospitalised adult patients, requiring a scheduled central venous catheterisation and measurement of the central venous pressure as part of their usual care, will undergo a non-invasive ultrasound scan of the internal jugular veins (both side of the neck) synchronized with an ECG trace, to assess the jugular venous pulse. This procedure will be performed once throughout the study.
62052427|NCT03581084|EXPERIMENTAL|N-acetylcysteine|"This study will look at the effects of a medication, called n-acetylcysteine or NAC, on lung function. NAC is already approved for use in people with chronic airway conditions, including asthma. However, it is not known who this medication works best in. We believe this medication will likely have the most benefit in people with asthma that have mucus in their airways or mucus plugging. Initial study procedures will include lung function measurements, a low dose CT scan, a blood draw, and a sputum induction. The CT lung imaging will identify asthmatics with mucus plugs."
62052428|NCT04126408|SHAM_COMPARATOR|Sham arm|gammaCore sham device which will not provide stimulation of the vagus nerve
62253529|NCT04735822|EXPERIMENTAL|Part 1: Belumosudil Sequence DECFBA|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen D (delivered by Vehicle 4); Regimen E (delivered by Vehicle 5); Regimen C (delivered by Vehicle 3); Regimen F (delivered by Vehicle 6); Regimen B (delivered by Vehicle 2); Regimen A (delivered by Vehicle 1)
62253530|NCT04735822|EXPERIMENTAL|Part 1: Belumosudil Sequence EFDACB|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen E (delivered by Vehicle 5); Regimen F (delivered by Vehicle 6); Regimen D (delivered by Vehicle 4); Regimen A (delivered by Vehicle 1); Regimen C (delivered by Vehicle 3); Regimen B (delivered by Vehicle 2)
62253531|NCT04735822|EXPERIMENTAL|Part 1: Belumosudil Sequence FAEBDC|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen F (delivered by Vehicle 6); Regimen A (delivered by Vehicle 1); Regimen E (delivered by Vehicle 5); Regimen B (delivered by Vehicle 2); Regimen D (delivered by Vehicle 4); Regimen C (delivered by Vehicle 3).
62253532|NCT04735822|EXPERIMENTAL|Part 2: Belumosudil Sequence GHI|Subjects receive 1 dose in the following sequence; Regimen G (belumosudil 200 mg tablet fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed)
62253533|NCT04735822|EXPERIMENTAL|Part 2: Belumosudil Sequence HIG|Subjects receive 1 dose in the following sequence: Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen G (belumosudil 200 mg tablet fed)
62253534|NCT04735822|EXPERIMENTAL|Part 2: Belumosudil Sequence IGH|Subjects receive 1 dose in the following sequence: Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen G (belumosudil 200 mg tablet fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted)
62253535|NCT04735822|EXPERIMENTAL|Part 2: Belumosudil Sequence IHG|Subjects receive 1 dose in the following sequence: Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen G (belumosudil 200 mg tablet fed)
62611766|NCT03453281|EXPERIMENTAL|Aflibercept Injection [Eylea]|Intravitreal injection of 2 mg in 0.05 ml Aflibercept. Frequency: once Duration: 10-15 minutes
62611767|NCT06528171|OTHER|Covid-long (CL+)|Assessment of musculoskeletal disorders, cognitive and neurocognitive assessments, Behavioral assessment, Work Difficulty Scale, Digital testing, brain MRI, Biological Analysis
62611768|NCT06528171|OTHER|Acute Covid (CL-)|Brain MRI, Biological Analysis
62611769|NCT03362580||Group A|Patients diagnosed with diabetes mellitus, type 1 or type 2, aged 15 years or older
62835306|NCT06411080|EXPERIMENTAL|Management with ultrasound information|An ultrasound report will be provided to the attending care team. The report will contain information related to abdominal and thoracic ultrasound exams with expert interpretation regarding anticipated risks of fluid administration.
62835307|NCT06411080|NO_INTERVENTION|Usual care|Usual care without information from Point-Of-Care ultrasound assessment of fluid tolerance.
62835308|NCT03388164|ACTIVE_COMPARATOR|Escitalopram + RT2CK17|10mg escitalopram + 5mg RT2CK17 will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the placebo comparator by a local compounding pharmacy in Tulsa, Oklahoma.
62835309|NCT03388164|PLACEBO_COMPARATOR|Escitalopram + Placebo|10mg escitalopram + 5mg placebo will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the active comparator by a local compounding pharmacy in Tulsa, Oklahoma.
62835310|NCT04198714|EXPERIMENTAL|Pudendal block|9cc of 0.25% Marcaine + 1cc of 40mg/mL triamcinolone. 5cc will be injected transvaginally in the area of the pudendal nerve on each side.
62611770|NCT03362580||Group B|Patients non-diagnosed with diabetes mellitus, aged 15 years or older
62611771|NCT03943927|EXPERIMENTAL|Pharmacogenetic-guided metoprolol management|
62611772|NCT00483704|EXPERIMENTAL|Telcagepant 140 mg|Telcagepant 140 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 140 mg or placebo.
62611773|NCT00483704|EXPERIMENTAL|Telcagepant 280 mg|Telcagepant 280 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 280 mg or placebo.
62835311|NCT04198714|PLACEBO_COMPARATOR|Placebo injection|10cc normal saline. 5cc will be injected transvaginally in the area of the pudendal nerve on each side.
62835312|NCT03906448|EXPERIMENTAL|Astrocytoma Patients|Patients newly diagnosed with Grade II and III astrocytoma.
62835313|NCT03906448|NO_INTERVENTION|Control Arm|Data collection from medical record only
62253536|NCT04735822|EXPERIMENTAL|Part 2: Belumosudil Sequence GIH|Subjects receive 1 dose in the following sequence: Regimen G (belumosudil 200 mg tablet fed); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted)
62611774|NCT00483704|PLACEBO_COMPARATOR|Control Group 1|Placebo, oral, tablet, across 3 migraine attacks (1st, 2nd, and 4th). Telcagepant 140 mg will be administered for the 3rd migraine attack. Participants will receive placebo for the optional second dose. For migraine attacks 2, 3, and 4, no study medication will be provided as an optional second dose.
62253537|NCT04735822|EXPERIMENTAL|Part 2: Belumosudil Sequence HGI|Subjects receive 1 dose in the following sequence: Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen G (belumosudil 200 mg tablet); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed);
62253538|NCT01235559|PLACEBO_COMPARATOR|Placebo|
62253539|NCT01235559|EXPERIMENTAL|bitopertin [RO4917838] 1|
62253540|NCT01235559|EXPERIMENTAL|bitopertin [RO4917838] 2|
62253541|NCT01961401|EXPERIMENTAL|High intensity exercise|High intensity, short duration exercise on bike
62253542|NCT01961401|EXPERIMENTAL|Moderate exercise|Moderate intensity exercise training on bike
62835314|NCT03881852|EXPERIMENTAL|AXS-12 (reboxetine)|
62835315|NCT03881852|PLACEBO_COMPARATOR|Placebo|
62442563|NCT05788042|ACTIVE_COMPARATOR|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS twice per day (separated by ≥ 2 hours) over the first 4 weeks. Two sessions per day (separated by ≥ 2 hours), given on 2 days each week for the following 4 weeks. The total number of rTMS sessions over the 8 week acute treatment period will be 56.
62442564|NCT05788042|SHAM_COMPARATOR|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS twice per day (separated by ≥ 2 hours) over the first 4 weeks. Two sessions per day (separated by ≥ 2 hours), given on 2 days each week for the following 4 weeks. The same number of sessions as active rTMS will be administered.
62835316|NCT04292899|EXPERIMENTAL|Part A: Remdesivir (RDV), 5 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
62052429|NCT04126408|ACTIVE_COMPARATOR|Treatment group|Active gammaCore device that supplies non-invasive stimulation of the cervical branch of the Vagus nerve
62052430|NCT05900856|EXPERIMENTAL|low caloric diet regimn|patients will follow low caloric diet regimn (1600: 2000 Kcal/ day), lipids approximately (20: 35%) of total caloric intake, protein approximately (10: 35%) of total caloric intake and high complexed carbohydrate intake approximately (45: 65%) of total caloric intake (with increased fiber-rich whole grain breads, cereals, fruits and vegetables), for eight weeks.
62052431|NCT05900856|EXPERIMENTAL|ultrasound cavitation for 30 minutes, twice per week for eight weeks and low caloric diet regimn|"ultrasound cavitation, Dae Yang, Mabel 6, frequency (50: 60) Hz, power consumption 150 W, power input AC (100: 230) V, hand probe diameter 8.0 cm, serial number DY73-15037, produced by DAEYANG MEDICAL company, made in Korea. the device will be applied for 30 minutes on the abdominal area, twice per week for eight weeks.~low caloric diet regimn patients will follow low caloric diet regimn (1600: 2000 Kcal/ day), lipids approximately (20: 35%) of total caloric intake, protein approximately (10: 35%) of total caloric intake and high complexed carbohydrate intake approximately (45: 65%) of total caloric intake (with increased fiber-rich whole grain breads, cereals, fruits and vegetables), for eight weeks."
62611775|NCT00483704|PLACEBO_COMPARATOR|Control Group 2|Placebo, oral, tablet, across 3 migraine attacks (1st, 2nd, and 3rd). Telcagepant 140 mg will be administered for the 4th migraine attack. Participants will receive placebo for the optional second dose. For migraine attacks 2, 3, and 4, no study medication will be provided as an optional second dose.
62835317|NCT04292899|EXPERIMENTAL|Part A: Remdesivir, 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
62835318|NCT04292899|EXPERIMENTAL|Part B: Remdesivir, 10 Days (Extension)|Part B (Extension) will enroll participants after enrollment to Part A is complete. Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2-10.
62052432|NCT04177680|EXPERIMENTAL|Omega-3 pentaenoic acid (MAT9001)|2g MAT9001 capsules twice daily with meals
62611776|NCT01276119|EXPERIMENTAL|Cohort A, CDP6038 0.001 mg/kg, iv|
62835319|NCT04292899|EXPERIMENTAL|Part B: Remdesivir 10 days (Mechanically Ventilated)|Participants on mechanical ventilation will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2-10
62835320|NCT05982418|EXPERIMENTAL|3D Printed Models|This cohort will consist of 54 prospective cases whereby patient-specific 3D printed models will be available to the surgeon during RARP for manipulation.
62052433|NCT04177680|ACTIVE_COMPARATOR|Icosapent ethyl (Vascepa)|2g Vascepa capsules twice daily with meals
62442565|NCT00186914|OTHER|1|
62835321|NCT05982418|EXPERIMENTAL|3D Virtual Models|This cohort will consist of 54 prospective cases whereby 3D virtual models will be available to the surgeon during RARP for manipulation using Innersight Labs platform.
62442566|NCT00887627|EXPERIMENTAL|1. Mild Renal Function Impaired Subjects|
62442567|NCT00887627|EXPERIMENTAL|2. Moderate Renal Function Impaired Subjects|
62611777|NCT01276119|EXPERIMENTAL|Cohort B, CDP6038 0.01 mg/kg, iv|
62052434|NCT04824079|EXPERIMENTAL|Keynatinib treatment group|All subjects shall be treated with Keynatinib twice a day (once every 12±3 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. Every 21 days is a treatment cycle .
62052435|NCT00141739|EXPERIMENTAL|GVHD prophylaxis|GVHD prophylaxis with etanercept
62442568|NCT00887627|EXPERIMENTAL|3. Subjects with Normal Renal Function|
62442569|NCT02535819|EXPERIMENTAL|Subluxation|Nucleus is hydrodissected until it lilts above the capsular bag, rotated to face the incision then tumbled and emulsification continues from the opposite equator outside in until complete
62835322|NCT00844961|EXPERIMENTAL|Internet CBT|10 weeks of internet delivered cognitive behaviour therapy
62253543|NCT01961401|NO_INTERVENTION|No exercise|No exercise, resting in the lab
62253544|NCT03823404|EXPERIMENTAL|COR388 80 mg twice daily (BID)|COR388 hydrochloric acid (HCl), 80 mg orally administered capsule, BID (twice daily) with water approximately 12 hours apart and no less than 6 hours apart
62442570|NCT02535819|OTHER|Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
62442571|NCT03331965|EXPERIMENTAL|Metoclopramide|A one-time dose of promotility agent (2 mL of Metoclopramide 5 MG/ML Injectable Solution in 8 mL saline IV) will be administered at the time of GJ placement. After administration of the pro-motility drug, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
62611778|NCT01276119|EXPERIMENTAL|Cohort C, CDP6038 0.03 mg/kg, iv|
62611779|NCT01276119|EXPERIMENTAL|Cohort D, CDP6038 0.1 mg/kg, iv|
62835323|NCT00844961|NO_INTERVENTION|Waiting list|Waiting list which is offered treatment after completion of post intervention assessments
62052436|NCT05848479|ACTIVE_COMPARATOR|control group|Abdominal bracing
62052437|NCT05848479|ACTIVE_COMPARATOR|study group|Abdominal bracing and clamshell exercise
62253545|NCT03823404|EXPERIMENTAL|COR388 40 mg BID|COR388 HCl, 40 mg orally administered capsule, BID with water approximately 12 hours apart and no less than 6 hours apart
62611780|NCT01276119|EXPERIMENTAL|Cohort E, CDP6038 0.3 mg/kg, iv|
62611781|NCT01276119|EXPERIMENTAL|Cohort G, CDP6038 1.0 mg/kg, iv|
62835324|NCT05119881|EXPERIMENTAL|MT+tDCS|The participants will receive mirror therapy combined with real transcranial direct current stimulation.
62835325|NCT05119881|ACTIVE_COMPARATOR|MT+sham tDCS|The participants will receive mirror therapy combined with sham transcranial direct current stimulation.
62835326|NCT05119881|ACTIVE_COMPARATOR|sham MT + tDCS|The participants will receive sham mirror therapy combined with real transcranial direct current stimulation.
62835327|NCT00965172|EXPERIMENTAL|Caphosol|Caphosol (calcium phosphate)
62611782|NCT01276119|EXPERIMENTAL|Cohort I, CDP6038 3.0 mg/kg, iv|
62052438|NCT03970239|EXPERIMENTAL|Parkinson's Disease patients|"All study participants undergo functional imaging of the serotoninergic system with Positron Emission Tomography (PET) using \[11 Carbon\]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile (\[11C\]-DASB) and \[18 Fluorine\]-altanserin (\[18F\]-altanserin). \[11C\] -DASB is a highly specific PET radiotracer which binds to the serotonin transporter (SERT).~\[18F\]-altanserin is a highly specific PET radiotracer which specifically binds to the serotonin 5-hydroxytryptamine receptor 2A (5-HT2A) receptor."
62052439|NCT03970239|EXPERIMENTAL|Imaging of healthy volunteers|"All healthy volunteers undergo functional imaging of the serotoninergic system with Positron Emission Tomography (PET) using \[18F\]-altanserin.~\[18F\]-altanserin is a highly specific PET radiotracer which specifically binds to the serotonin 5-hydroxytryptamine receptor 2A (5-HT2A) receptor."
62835328|NCT00965172|ACTIVE_COMPARATOR|Baking Soda|Control Group (standard of care)
62835329|NCT02175524||Case|Patients proved to be oral and esophageal cancer and had the habit of areca nut chewing.
62835330|NCT02175524||Control|Patients proved to be oral and esophageal cancer and did not have the habit of areca nut chewing.
62835331|NCT02578706|ACTIVE_COMPARATOR|Aspirin and placebo|At week 0, participants will be administered aspirin 81mg (one tablet) and placebo for clopidogrel 75 mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
62835332|NCT02578706|ACTIVE_COMPARATOR|Clopidogrel and placebo|At week 0, participants will be administered clopidogrel 75 mg (one tablet) and placebo for aspirin 81 mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
62052440|NCT00496899||1|Women in active labor
62611783|NCT01276119|EXPERIMENTAL|Cohort K, CDP6038 10.0 mg/kg, iv|
62611784|NCT01276119|PLACEBO_COMPARATOR|Cohort A, Placebo, iv|
62611785|NCT01276119|PLACEBO_COMPARATOR|Cohort B, C, D, E, G, I, K, Placebo, iv|
62611786|NCT01276119|EXPERIMENTAL|Cohort F, CDP6038 0.3 mg/kg, sc|
62835333|NCT02578706|PLACEBO_COMPARATOR|Placebos only|At week 0, participants will be administered placebo for aspirin 81 mg (one tablet) and placebo for clopidogrel 75mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
62835334|NCT04264936|EXPERIMENTAL|RC48-ADC and JS001|
62835335|NCT02410226|ACTIVE_COMPARATOR|Palpation|Double-space combined spinal-epidural anesthesia, Sham ultrasound procedure
62835336|NCT02410226|EXPERIMENTAL|Ultrasound|Double-space combined spinal-epidural anesthesia, Preprocedure spinal ultrasound
62052441|NCT04560166|EXPERIMENTAL|Naxitamab and GM-CSF in combination with irinotecan and temozolomide|"A treatment cycle is 21 days. The patients will receive irinotecan 50 mg/m2/day IV and temozolomide 100 mg/m2/day orally (both on Days 1-5) in combination with naxitamab 2.25 mg/kg/day IV (Days 2, 4, 8 and 10) (total 9 mg/kg per cycle), and GM-CSF 250 ug/m2/day sc, (Days 6-10).~Patients will receive up to 18 IT cycles after enrollment. Naxitamab and GM-CSF will be given for at least 8 cycles."
62835337|NCT06051149|ACTIVE_COMPARATOR|Epidural Catheter|procedure Will be performed under sterile precautions utilizing fluoroscopy, RK needle.patient will be placed prone with a pillow under the abdomen.The sacral area draped from the top of the iliac crest to the bottom of the buttocks.The sacral Corns and the sacral hiatus will be palpated,is in the gluteal fold opposite the affected side will be infiltrated with lidocaine16gauge RK needle will be passed through the described entry point advanced to a point below the S3foramen to prevent S3nerve root damage.Placement will be confirmed by lateral and anteroposterior fluoroscopic views and after aspiration is negative for blood and CSF10mL of iohexol will be injected under fluoroscopy.Once the needle placement is confirmed to be in the epidural space, a lumbar epidurogram will be carried out utilizing approximately2to5 mL of contrast. then the bevel of the needle should face the ventrolateral aspect of the caudal canal.
62835338|NCT06051149|ACTIVE_COMPARATOR|RACZ Catheter|same as procedure described above but using RACZ Catheter set
62835339|NCT06051149|ACTIVE_COMPARATOR|NAVI catheter|same as procedure described above but using NAVI Catheter set
62052442|NCT03974659|ACTIVE_COMPARATOR|Theta Burst Stimulation|"Intervention group: ten consecutive days bilateral cerebellar VIIa lobules Theta Burst Stimulation.~Intermittent Theta Burst Stimulation(Positive stimulation) is used in right cerebellar VIIa lobule.Each stimulus had three 50 Hz monopulses, which were repeated every 200 ms. Each stimulation continued for 2 seconds and rested for 8 seconds. The total intervention time was 200s (600 pulses) Continuous Theta Burst Stimulation(Negative stimulation) is used in left cerebellar VIIa lobule,three 50 Hz monopulses in each stimulus, each with an interval of 200 ms, and each intervention lasted 40s (600 pulses).~The stimulation intensity was 80% Rest Motor Threshold.According to the patients' condition, age and tolerance,the intensity should be adjusted."
62253546|NCT03823404|PLACEBO_COMPARATOR|Placebo BID|Placebo orally administered capsule, BID with water approximately 12 hours apart and no less than 6 hours apart
62611787|NCT01276119|EXPERIMENTAL|Cohort H, CDP6038 1.0 mg/kg, sc|
62611788|NCT01276119|EXPERIMENTAL|Cohort J, CDP6038 3.0 mg/kg, sc|
62611789|NCT01276119|PLACEBO_COMPARATOR|Cohort F, H, J, Placebo, sc|
62611790|NCT02719834||Acetaminophen, then placebo|Participants in this group will receive acetaminophen for the first four weeks, then placebo for the next four weeks.
62611791|NCT02719834||Placebo, then acetaminophen|Participants in this group will receive placebo for the first four weeks, then acetaminophen for the next four weeks.
62611792|NCT00195494|ACTIVE_COMPARATOR|1a|Etanercept + Methorexate for Period 1 (first 12 months) and Period 2 (Second 12 months)
62611793|NCT00195494|ACTIVE_COMPARATOR|1b|Etanercept + Methotrexate for Period 1 (First 12 months) and Etanercept alone for Period 2 (Second 12 months)
62611794|NCT00195494|ACTIVE_COMPARATOR|2a|Methotrexate alone in Period 1 (First 12 months) and etanercept + Methotrexate in Period 2 (Second 12 months)
62835340|NCT06272396|EXPERIMENTAL|Smart watch|ECG done with smart watch
62835341|NCT04057950|ACTIVE_COMPARATOR|treating shampoo|treating shampoo (1% Selenium Disulfide (SeS2)/1% salicylic acid-based shampoo) 1144628 D cosmetic product
62442572|NCT03331965|PLACEBO_COMPARATOR|Saline|A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement. After administration of the placebo, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
62835342|NCT04057950|PLACEBO_COMPARATOR|vehicle|1144781 cosmetic product
62835343|NCT05209971||macular thickness and visual acuity|optical coherence tomography
62835344|NCT03370978|EXPERIMENTAL|Text Messaging|Receives text messages to remind of upcoming follow-up appointment with primary care doctor. Also provides opportunity for subjects to text ED staff for follow-up care concerns or to reschedule primary care appointment.
62835345|NCT03370978|NO_INTERVENTION|Usual Care|Received usual care including follow-up phone calls if clinically indicated.
62835346|NCT04765891|EXPERIMENTAL|Positional Release Therapy|Participants were randomly assigned the positional release therapy treatment group. The participants underwent the treatment.
62835347|NCT04765891|EXPERIMENTAL|Therapeutic Massage|Participants were randomly assigned the therapeutic massage treatment group. The participants underwent the treatment.
62253547|NCT04213105|EXPERIMENTAL|QL1206|QL1206 injection (60mg) by subcutaneous injection once on the first day
62835348|NCT05950711|EXPERIMENTAL|Ketamine-MBCT Intervention|One Arm: Combination of MBCT with a single ketamine infusion
62835349|NCT02086253|EXPERIMENTAL|BQ-788|Effect of BQ-788 on the magnitude of sustained flow-mediated dilatation
62835350|NCT02086253|EXPERIMENTAL|BQ-123|Effect of BQ-123 on the magnitude of sustained flow-mediated dilatation
62835351|NCT02086253|EXPERIMENTAL|BQ-788 + BQ-123|Effect of BQ-788+BQ-123 on the magnitude of sustained flow-mediated dilatation
62835352|NCT06189053||Cohort 1: Post-vaccine Myocarditis (PVM)|Cohort 1 will include participants with a myocarditis event diagnosis or service date within 30 days on/after a SPIKEVAX vaccination and participants with at least 1 dose of SPIKEVAX in the 7 days prior to and including the index date.
62835353|NCT06189053||Cohort 2: All Other Myocarditis|Cohort 2 will include participants with no evidence of SPIKEVAX and no evidence of other vaccines targeting SARS CoV-2 within 30 days on/after a SPIKEVAX vaccination.
62835354|NCT04512157|EXPERIMENTAL|PATHS, Intervention preschools|These preschools implement PATHS for one school year
62835355|NCT04512157|NO_INTERVENTION|Waitlist control preschools|Preschool as usual, which does have some social emotional learning but not PATHS specifically
62835356|NCT00811915|EXPERIMENTAL|Sirolimus|"Group A : Sirolimus introduction and tacrolimus withdrawal~* Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14.~* Sirolimus daily dose according to CYP3A5 genotype CYP3A5\*1/\*1 or \*1/\*3: 4 mg/d CYPY3A5\*3/\*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml"
62835357|NCT00811915|ACTIVE_COMPARATOR|B|Tacrolimus (Advagraf) dose to obtain a trough level between 4 and 10 ng/ml
62835358|NCT04326803|EXPERIMENTAL|Vaccine group|Administration of 3 doses hepatitis B vaccine (recombinant hepatitis B vaccine, injectable suspension for intramuscular use) at month 0, 1 and 2.
62835359|NCT00694642|ACTIVE_COMPARATOR|selected CD133+cells|Transendocardial injection of selected CD133+cells
62835360|NCT00694642|NO_INTERVENTION|no injection|Boths groups were treated with G-CSF, underwent an apheresis and NOGA mapping
62835361|NCT04999540|EXPERIMENTAL|Tucidinostat + Fulvestrant|"Patients receive 30 mg Chidamide twice per week. Fulvestrant 500mg (2 syringes of Fulvestrant 250mg), Fulvestrant 500 mg i.m. every 28 (+/- 3) days plus an additional 500 mg on day 14 (+/-3) of first month only.~Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
62835362|NCT03950297|EXPERIMENTAL|609A group|Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation Level cohort 1. Dose 1 mg/kg, Q3W, IV. Subjects 3-6; Dose Escalation Level cohort 2. Dose 3 mg/kg, Q3W, IV. Subjects 3-6; Dose Escalation Level cohort 3. Dose 200mg, Q3W, IV. Subjects 3-6; Dose Escalation Level cohort 4. Dose 10 mg/kg, Q3W, IV. Subjects 3-6;
62835363|NCT01042106|EXPERIMENTAL|DSP-8658|DSP-8658 2.5, 10, 20, 40 mg once daily
62835364|NCT01042106|PLACEBO_COMPARATOR|Placebo|Placebo 2.5, 10, 20, and 40 mg doses once daily
62835365|NCT04803552|EXPERIMENTAL|Contactless sleep apnea screening vs respiratory polygraphy|
62835366|NCT00588016|EXPERIMENTAL|Itraconazole|Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
62835367|NCT01600716|EXPERIMENTAL|OnabotulinumtoxinA|OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for a second onabotulinumtoxinA 100 U injection.
62835368|NCT01600716|OTHER|Placebo (Normal Saline)|Placebo (normal saline) is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for an onabotulinumtoxinA injection.
62835369|NCT00279487|ACTIVE_COMPARATOR|Arm 1|Patients will receive 1200mg gabapentin 1-2 hours prior to surgery.
62835370|NCT00279487|PLACEBO_COMPARATOR|Arm 2|Patients will receive placebo 1-2 hours prior to surgery.
62835371|NCT05971485||Melatonin group|Preterm neonates will receive melatonin 30 minutes before the venous cannula insertion.
62835372|NCT05971485||Control group|Preterm neonates will undergo venous cannula insertion without giving melatonin before the procedure.
62835373|NCT04856800|EXPERIMENTAL|Whey|Whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients). 20 g of whey protein will be ingested 30 min. prior to breakfast from diagnosis of GDM (around week 28) and until delivery.
62835374|NCT04856800|PLACEBO_COMPARATOR|Placebo|The placebo will be ingested 30 min. prior to breakfast from diagnosis of GDM (around week 28) and until delivery.
62835375|NCT00831181|EXPERIMENTAL|Preoperative Chemoradiation|Preoperative Chemoradiation with oxaliplatin/5-FU followed by mesorectal excision and 5-FU / leucovorin (FOLFOX 6)
62835376|NCT03570710|PLACEBO_COMPARATOR|normal saline arm group|110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
62835377|NCT03570710|ACTIVE_COMPARATOR|intravenous tranexamic acid group|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
62835378|NCT03570710|ACTIVE_COMPARATOR|Topical tranexamic acid group|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
62611795|NCT00195494|ACTIVE_COMPARATOR|2b|Methotrexate alone in Period 1 (First 12 months) and Methotrexate alone in Period 2 (Second 12 months)
62835379|NCT01875796|EXPERIMENTAL|Cannabis & Anxiety Reduction Treatment|Cognitive-behavioral treatment program that integrates strategies to manage both cannabis use and anxiety with techniques to address motivation to change cannabis use.
62835380|NCT01875796|ACTIVE_COMPARATOR|Motivation/cognitive-behavioral therapy|Motivational Enhancement Therapy (MET) and cognitive-behavioral therapy (CBT) that includes techniques to address motivation to change cannabis use with strategies to manage use.
62835381|NCT03404700|EXPERIMENTAL|Group 1:Test breakfast A and B|"\*Please note: Part I of the study does not have separate groups. All subjects will undergo RFPM. The description of groups presented below is for part II of the study.~Subjects will have egg breakfast(test breakfast A) and egg breakfast with high saturated fat (test breakfast B) in any order."
62835382|NCT03404700|EXPERIMENTAL|Group 2:Test breakfast A and C|Subjects will have egg breakfast and (test breakfast A) and cereal breakfast (test breakfast C) in any order.
62835383|NCT03404700|EXPERIMENTAL|Group 3:Test breakfast A and D|Subjects will have egg breakfast (test breakfast A) and cereal breakfast (test breakfast C) in any order.
62835384|NCT03404700|EXPERIMENTAL|Group 4:Test breakfast B and C|Subjects will have egg breakfast with high saturated fat (test breakfast B) and cereal breakfast (test breakfast C) in any order.
62611796|NCT01207115|EXPERIMENTAL|ABT-652 high dose|ABT-652 capsules- twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm.
62611797|NCT01207115|EXPERIMENTAL|ABT-652 low dose|ABT-652 capsules - twice daily for 8 weeks. The dose ABT-652 will depend on the Arm
62611798|NCT01207115|ACTIVE_COMPARATOR|Naproxen|Naproxen capsules- twice daily for 8 weeks
62611799|NCT01207115|PLACEBO_COMPARATOR|Placebo|Placebo capsules- twice daily for 8 weeks
62835385|NCT03404700|EXPERIMENTAL|Group 5:Test breakfast B and D|Subjects will have egg breakfast with high saturated fat (test breakfast B) and cereal breakfast with high saturated fat (test breakfast D) in any order.
62253548|NCT04213105|ACTIVE_COMPARATOR|Prolia®|Prolia® injection (120mg) by subcutaneous injection once on the first day
62442573|NCT01497483|ACTIVE_COMPARATOR|Pravastatin alone|Subjects will be dosed with Pravastatin alone (40 mg)
62442574|NCT01497483|EXPERIMENTAL|Pravastatin and Cyclosporine|Subjects will be dosed with pravastatin and cyclosporine.
62611800|NCT01535586|ACTIVE_COMPARATOR|CPAP|participants will be treated with continuous positive airway pressure (CPAP) for 12 weeks
62611801|NCT01535586|ACTIVE_COMPARATOR|MAD|Participants will be treated with a mandibular advancing device for 12 weeks
62611802|NCT00098540|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62611803|NCT02440217||DCM-AGT|Subjects with both dilated cardiomyopathy (DCM) and abnormal glucose tolerance (AGT, either impaired glucose tolerance or type 2 diabetes).
62611804|NCT02440217||DCM-NGT|Subjects with dilated cardiomyopathy (DCM) and normal glucose tolerance (NGT).
62611805|NCT02440217||N-AGT|Subjects without dilated cardiomyopathy (N) with abnormal glucose tolerance (AGT, either impaired glucose tolerance or type 2 diabetes).
62611806|NCT04982978|ACTIVE_COMPARATOR|PMT Threat Appraisal|The PMT present group will include an 8-minute informational video that explains the current research and health risks associated with vaping, within the context of a threat appraisal focus (Perceived Vulnerability and Perceived Severity). During this video intervention, the severity and vulnerability of vaping among young adults, both in the short and long-term health effects will be presented. In addition, the video will explain the negative impact of vaping and focus the attention of the participants on the lack of research and information that currently exists on popular vaping products and the potentially devastating impact it can have on the health of young adult populations.
62611807|NCT04982978|SHAM_COMPARATOR|Nutrition and Lifestyle Control|"The PMT absent group will feature an 8-minute nutritional information video as an attention control strategy titled, Vaping Health Effects. During this video intervention, the general risks and benefits of nutrition and lifestyle will be presented. The focus of this video will be on how a balanced diet and proper lifestyle choices (i.e., adequate sleep, diet, etc.) can benefit the participants lives in the short-term and long-term."
62611808|NCT03174678|EXPERIMENTAL|Dexmedetomidine|Group administered 1µg/kg dexmedetomidine oral
62611809|NCT03174678|OTHER|Control|Apple juice
62611810|NCT02552498|EXPERIMENTAL|vertical|Strangulation is applied on the the buccal side of the attached gingiva, parallel to the long axis of tooth 12, at the distal third of the tooth.
62253549|NCT00887120|ACTIVE_COMPARATOR|1|Lopinavir/ritonavir standard dose + zidovudine and lamivudine
62442575|NCT03057587||NIRS Monitoring|A NIRS sensor will be placed on the forehead of the patient upon entry to the operating room and will remain on, as tolerated, for the duration of surgery
62442576|NCT04709900|ACTIVE_COMPARATOR|Intervention group|CT angiography, FFR-CT and dynamic CT stress myocardial perfusion guided treatment strategy
62442577|NCT04709900|NO_INTERVENTION|Standard care group|Evaluation and treatment strategy according to contemporary clinical practice
62253550|NCT00887120|ACTIVE_COMPARATOR|2|Lopinavir/ritonavir low dose (70% of standard dose) + zidovudine and lamivudine
62442578|NCT00003557|EXPERIMENTAL|Arm A|Dolastatin-10 (400 mcg/m2 IV every 3 weeks)
62253551|NCT00475722|ACTIVE_COMPARATOR|1 Healthy Eating|Healthy People 2010 Diet using an exchange list
62253552|NCT00475722|EXPERIMENTAL|2 Mediterranean|Mediterranean Diet using an exchange list
62253553|NCT02558114|OTHER|Group A|Patients will receive ribavirin during 12 weeks
62442579|NCT00310427|EXPERIMENTAL|LY686017|Subjects received 50 mg of the NK1 antagonist LY686017 orally on a daily basis.
62442580|NCT00310427|PLACEBO_COMPARATOR|Placebo|Subjects received placebo orally on a daily basis
62442581|NCT03362151|EXPERIMENTAL|Regular pasta|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of regular pasta. They will consume this meal on two separate occasions.
62442582|NCT03362151|EXPERIMENTAL|High protein pasta|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of high protein pasta. They will consume this meal on two separate occasions.
62442583|NCT03362151|EXPERIMENTAL|White rice|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of white rice. They will consume this meal on two separate occasions.
62442584|NCT02087059|EXPERIMENTAL|Ruxolitinib|Ruxolitinib was administered orally twice daily at the starting dose of 5 mg, 15 mg or 20 mg bid based on Baseline platelet counts. The dosage was subsequently adjusted for safety and efficacy so that each patient was titrated to their most appropriate dose.
62611811|NCT02552498|EXPERIMENTAL|horizontal|Strangulation is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the tooth 12, 2 mm far from the gingival margin.
62611812|NCT02552498|EXPERIMENTAL|papilla base|Strangulation is applied on the the buccal side of the attached gingiva, on the base of the mesial papilla of tooth 12, in straight line going from one side of papilla to the other.
62611813|NCT05865847||Lowest income groups|Deciles of equivalized net household income. The method compares the whole socioeconomic distribution.
62611814|NCT01580345|ACTIVE_COMPARATOR|Docosa-hexaenoic Acid (DHA)|
62611815|NCT01580345|PLACEBO_COMPARATOR|Placebo|Corn-Soy Oil
62611816|NCT02068859|EXPERIMENTAL|Diclofenac Cream 8%|Diclofenac Cream 8% applied 3-4 times daily for 6 weeks.
62052443|NCT03974659|SHAM_COMPARATOR|sham Theta Burst Stimulation|sham group: we flip coil to make fake stimulation, the stimulation will also make sounds, but no magnetic field effect, the stimulation mode is the same as the intervention group.
62611817|NCT02068859|ACTIVE_COMPARATOR|Control|Diclofenac Gel 1% applied 3-4 times daily fr 6 weeks
62442585|NCT02689895|OTHER|Intervention|Research assistants visit participants at home, and send SMS texts on scheduled days for 3 months to encourage adherence to ART. Pill charts, visit charts and text charts are completed. this is called modified directly administered anti-retroviral therapy (mDAART). In addition to the intervention, participants receive standard care at their usual clinic which comprises 3 monthly doctor reviews and adherence counseling at each review visit.
62442586|NCT02689895|NO_INTERVENTION|Control|Participants get usual care at their clinic, which comprises 3 monthly doctor review visits and adherence counseling at each visit.
62611818|NCT05659641|EXPERIMENTAL|Branch-type intraoperative stent system with double branch structure|"Learning curve case group~Experimental: Beijing PerMed branch-type intraoperative stent system with double branch structure."
62611819|NCT05659641|EXPERIMENTAL|Single Branch Structure Stent Graft System single group|Beijing PerMed single branch intraoperative stent system
62611820|NCT05659641|OTHER|CRONUS® Stent Graft System In Surgical Operation|Control group：CRONUS® Stent Graft
62611821|NCT02237560|EXPERIMENTAL|Cybercycle-Game|Combined aerobic \& cognitive exercise for 6 months, 3-5x/week.
62611822|NCT02237560|ACTIVE_COMPARATOR|Cybercyle-Tour|Aerobic exercise only for 6 months, 3-5x/week.
62611823|NCT02237560|ACTIVE_COMPARATOR|Game Only|Cognitive exercise only 6 months, 3-5x/week.
62611824|NCT02847026|ACTIVE_COMPARATOR|IPV at 14 and 22 weeks of age, Rotarix|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a full dose IPV booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
62611825|NCT02847026|ACTIVE_COMPARATOR|IPV at 14 and 22 weeks of age, RotaTeq|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a full dose IPV booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
62611826|NCT02847026|ACTIVE_COMPARATOR|IPV at 14 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
62611827|NCT02847026|ACTIVE_COMPARATOR|IPV at 14 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
62611828|NCT02847026|ACTIVE_COMPARATOR|IPV at 6 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of IPV at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
62611829|NCT02847026|ACTIVE_COMPARATOR|IPV at 6 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of IPV at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
62611830|NCT02847026|ACTIVE_COMPARATOR|fIPV at 6-14-22 weeks of age, Rotarix|Participants in this arm will receive fractional doses of IPV (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
62611831|NCT02847026|ACTIVE_COMPARATOR|fIPV at 6-14-22 weeks of age, RotaTeq|Participants in this arm will receive fractional doses of IPV (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
62611832|NCT02620085||Graves' disease|Patient had been diagnosed of Graves' disease and now under euthyroid status
62611833|NCT00769756||2|"Financial incentive~For the parents the financial incentive was 5 euros for every kilogram of weight-loss. For children the weight loss was calculated differently, taking into account the individual need of each child to lose weight. Children with a body mass index between the 90th and 97th age-adjusted BMI-percentile were asked to maintain their weight, and were paid in dependence on how well they managed to achieve this goal. Children with age-adjusted BMI-percentiles between 97 and 99, or above the 99th age-adjusted BMI-percentile received 5 euros per weight losses of respectively 500 g or 1 kg."
62442587|NCT00508378||Interview & Questionnaires|
62611834|NCT00769756||1|The telemedical equipment consisted of a weighing scale for each family, an accelerometer for each participant, and a Homebox for each family which received the data from the scale and the accelerometers via bluetooth and transfered them via a telephone link to a server in Munich.
62611835|NCT00769756||3|The basic diet for all participants was supported by a list giving the calorie contents of a large variety of food-stuffs. The dual diet group received a second list giving the glycemic index (GI) for a large variety of carbohy-drates. Emphasis was placed on a preference for low-GI carbohydrates but not on avoidance of carbohydrates as required by the Atkins diet.
62611836|NCT05940077|EXPERIMENTAL|Community-based exercise|
62611837|NCT00308750|EXPERIMENTAL|Enzastaurin/Pemetrexed/Carboplatin|
62611838|NCT00308750|EXPERIMENTAL|Pemetrexed/Carboplatin|
62611839|NCT00308750|ACTIVE_COMPARATOR|Docetaxel/Carboplatin|
62052444|NCT03026218|EXPERIMENTAL|Group and Glucose Mama|Enrolled subjects with have GlucoseMama application and group care.
62052445|NCT03026218|PLACEBO_COMPARATOR|Group and No Glucose Mama|Enrolled participants will be enrolled in group care but will not have access to GlucoseMama application.
62442588|NCT03103581|EXPERIMENTAL|BLI4700|BLI4700 Bowel Preparation (Investigational Regimen)
62442589|NCT03496792|EXPERIMENTAL|Tilt + external pressure|"Tilt + external pressure on legs performed in both BP elevated with standing and BP maintained with standing groups."
62611840|NCT00964015|ACTIVE_COMPARATOR|Starch group|Patients randomized to the Starch group will receive Voluven (6% Hydroxyethyl Starch 130/0.4) for their intravenous bolus and fluid resuscitation requirements.
62611841|NCT00964015|ACTIVE_COMPARATOR|Saline group|Patients randomized to the Saline group will receive 0.9% Normal Saline for their intravenous fluid bolus and resuscitation requirements
62611842|NCT01481272|EXPERIMENTAL|O-IVAC|Ofatumumab Etoposide Ifosfamide Mesna Cytarabine Methotrexate Leukovorin Granulocyte-Colony Stimulating Factor
62835386|NCT03404700|EXPERIMENTAL|Group 6:Test breakfast C and D|Subjects will have cereal breakfast (test breakfast C) and cereal breakfast with high saturated fat (test breakfast D) in any order
62052446|NCT03026218|EXPERIMENTAL|Traditional and glucoseMama|Enrolled subjects will have traditional care and glucoseMama
62835387|NCT02506244|EXPERIMENTAL|Immediate Monitoring|"Individuals randomized to immediate monitoring will receive the ZIO XT patch sensor and wear it for the first and last 2 week period of the 4 month monitoring period of time 0 to 4 months.~Note: Approximately 250 consenting participants will also be invited to participate in a sub-study to wear an additional monitoring device (Amiigo wristband) continuously over the 4 month monitoring period."
62442590|NCT03496792|PLACEBO_COMPARATOR|Tilt + no external pressure|"Tilt + no external pressure performed in both BP elevated with standing and BP maintained with standing groups."
62611843|NCT06730282|EXPERIMENTAL|Danggui Shaoyao San|Participants in this group will receive Danggui Shaoyao San, a traditional Chinese medicine (TCM) formula, for the treatment of primary dysmenorrhea. The medication will be administered starting 3 to 7 days before menstruation and continued until 3 days after menstruation for two consecutive menstrual cycles. Danggui Shaoyao San is intended to regulate blood flow, reduce inflammation, and alleviate uterine contractions associated with dysmenorrhea.
62052447|NCT03026218|NO_INTERVENTION|Traditional and no GlucoseMama|enrolled subjects will not have access to group care or GlucoseMama.
62052448|NCT05541562||PVT group|The diagnosis of LC was based on clinical, laboratory, and radiological analyses, and/or liver biopsies. PVT was diagnosed according to the consensus for management of PVT in LC (2020, Shanghai) \[1\]. The inclusion criteria were as follows: (I) age ≥18 years, (II) Doppler ultrasound was the first-choice imaging modality; however, enhanced computed tomography or magnetic resonance imaging could also be used for confirmation at the time of admission to our hospital, and (III) patients with PVT on imaging examination but with insufficient evidence for the diagnosis of cirrhosis, hepatic vein pressure gradient measurement, and liver biopsy. Patients with primary or secondary hepatic malignant tumors, other malignant tumors, hematologic diseases, Budd-Chiari syndrome, non-cirrhotic PVT, inflammatory diseases, and other severe diseases were excluded.
62052449|NCT05541562||Non-PVT group|(1) Patients with cirrhosis diagnosed in accordance with the 2019 Guidelines for the Diagnosis and Treatment of Cirrhosis;(2)Color ultrasound, CT, MRI, and other imaging studies confirmed the absence of portal vein thrombosis and the specific location of the thrombosis.
62052450|NCT04860947||MS patients|
62052451|NCT03051503|ACTIVE_COMPARATOR|The Transdermal Therapeutic System-Fentanyl (TTS-F) group|(TTS-F) group (n=30) 50ug/h patch, placed 12 hs preoperatively.
62052452|NCT03051503|PLACEBO_COMPARATOR|Intravenous patient-controlled analgesia (PCA) morphine|IV (PCA) morphine for pain in the postoperative period.
62052453|NCT02640248||Cuff ETT|
62052454|NCT05282043|EXPERIMENTAL|post COVID-19 group|In this group cases, who were infected with COVID-19 and had at least 12 weeks after diagnosis, will be allocated. Those should have no symptoms of COVID-19 such as fever, cough, ageusia, anosmia, diarrhea, arthralgia, myalgia, sore throat, headache, chest pain.
62052455|NCT05282043|ACTIVE_COMPARATOR|healthy control group|In this group cases, who were not infected with COVID-19 will be allocated.
62052456|NCT04857203||Group 1|Low levels of Vitamin D
62442591|NCT03496792|EXPERIMENTAL|Limb occlusion + negative pressure|"Limb occlusion + negative pressure performed in both BP elevated with standing and BP maintained with standing groups."
62611844|NCT06730282|EXPERIMENTAL|Cuscuta Chinensis|Participants in this group will receive Cuscuta Chinensis, a TCM formula commonly used to support kidney function and alleviate menstrual pain. The medication will be administered starting 3 to 7 days before menstruation and continued until 3 days after menstruation for two consecutive menstrual cycles. This group aims to evaluate the efficacy of Cuscuta Chinensis in managing dysmenorrhea symptoms.
62835388|NCT02506244|ACTIVE_COMPARATOR|Delayed Monitoring|"Individuals randomized to delayed monitoring will receive usual care for 4 months after which they will receive the ZIO XT patch sensor and wear it for the first and last 2 week period of study months 4 through 8.~Note: Approximately 250 consenting participants will also be invited to participate in a sub-study to wear an additional monitoring device (Amiigo wristband) daily for months 4 through 8."
62835389|NCT02189317|EXPERIMENTAL|Exparel|This arm will receive Exparel
62442592|NCT03496792|PLACEBO_COMPARATOR|Limb occlusion + no negative pressure|"Limb occlusion + no negative pressure performed in both BP elevated with standing and BP maintained with standing groups."
62835390|NCT02189317|NO_INTERVENTION|Control|
62835391|NCT03035357|EXPERIMENTAL|Daratumumab|Participants receive Daratumumab by vein over about 1 hour 1 time a week during Weeks 1-4.
62835392|NCT00693771|EXPERIMENTAL|1|
62253554|NCT02558114|OTHER|Group B|"Patients will receive:~* ribavirin during 12 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is undetectable at week 4 after treatment start (adjust to renal function)~* - ribavirin during 24 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is detectable at week 4 after treatment start (adjust to renal function)"
62253555|NCT00698724|ACTIVE_COMPARATOR|1|Group 1: Xibrom, Optive
62253556|NCT00698724|ACTIVE_COMPARATOR|2|Group 2: Xibrom, Pred Forte
62253557|NCT00790686|EXPERIMENTAL|1|Memokath 051
62253558|NCT00733954|ACTIVE_COMPARATOR|clobetasol propionate spray|clobetasol propionate spray 0.05%
62253559|NCT00733954|ACTIVE_COMPARATOR|clobetasol propionate ointment|clobetasol propionate ointment 0.05%
62253560|NCT02613884|EXPERIMENTAL|Treatment|All patients with a 25OHD level \<30 ng/dL will be given 250,000 IU D3 (cholecalciferol) orally at one point in time and during CF clinic.
62253561|NCT05247814||Patients admitted to interdisciplinary polypharmacy consultation service|Patients admitted to the Interdisciplinary Polypharmacy Consultation Service of the Department of Geriatric's University Outpatient Clinic in cooperation with the Institute of Clinical Pharmacology
62253562|NCT02525055|EXPERIMENTAL|Infectious titre 1|6 participants aged 18 to 45 were inoculated with 1mL containing 2.8 x 10\*3 TCID50 of virus
62253563|NCT02525055|EXPERIMENTAL|Infectious titre 2|6 participants aged 18 to 45 were inoculated with 1mL containing 2.5 x 10\*4 TCID50 of virus
62253564|NCT02525055|EXPERIMENTAL|Infectious titre 3|6 participants aged 18 to 45 were inoculated with 1mL containing 3.6 x 10\*5 TCID50 of virus
62835393|NCT04048356|EXPERIMENTAL|Chlorhexidine gluconate|Chlorhexidine gluconate 2% vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
62253565|NCT02525055|EXPERIMENTAL|Infectious titre 4|6 participants aged 18 to 45 were inoculated with 1mL containing 4.7 x 10\*6 TCID50 of virus
62253566|NCT02525055|EXPERIMENTAL|Infectious titre 5 (age 18 to 45 y)|6 participants aged 18 to 45 were inoculated with 1mL containing 3.5 x 10\*5 TCID50 of virus.
62253567|NCT02525055|EXPERIMENTAL|Infectious titre 5 (age 46 to 64 y)|16 participants aged 46 to 64 were inoculated with 1mL containing 3.5 x 10\*5 TCID50 of virus.
62835394|NCT04048356|ACTIVE_COMPARATOR|Povidone Iodine|Povidone iodine vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
62835395|NCT00439517|EXPERIMENTAL|1|UFOX + Cetuximab
62253568|NCT03968107||Women with a pregnancy of at least 31 weeks|All pregnant women with a pregnancy of at least 31 weeks and having to perform a fetal MRI to identify a cerebral, pulmonary or renal fetal malformation, or due to a diagnostic doubt on ultrasound on an abnormality of these structures, will be proposed inclusion in the study.
62442593|NCT01433536||cranial trauma and fracture|Individuals presenting a cranial trauma that are classified at equal to or less than 8 on the Glasgow scale, combined with a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
62835396|NCT00439517|ACTIVE_COMPARATOR|2|FOLFOX4 + Cetuximab
62835397|NCT05293223|EXPERIMENTAL|Group A|One dose Sputnik V + one dose Ad5-nCoV
62835398|NCT05293223|NO_INTERVENTION|Group B|Samples stored at the immunology lab of the Buenos Aires University Medical School, corresponding to individuals vaccinated with 2 doses of Sputnik V.
62835399|NCT02419001|EXPERIMENTAL|Period 1 - Treatment Sequence AB|"Treatment Sequence AB:~* Period 1: Ceftriaxone 1 g infused IV over 30 minutes~* \[Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg (1 x 75 mg capsule) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion\]"
62835400|NCT02419001|EXPERIMENTAL|Period 1 - Treatment Sequence AC|"* Period 1: Ceftriaxone 1 g infused IV over 30 minutes~* \[Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg (2 x 75 mg capsules) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion\]"
62253569|NCT05220397|NO_INTERVENTION|Initial Responders|Individuals who have received the Pfizer or Moderna vaccines and have high levels of spike antibodies in their blood, will receive standard of care immunosuppressive (IS) medications.
62253570|NCT05220397|EXPERIMENTAL|Segment I|Segment I: individuals who have a spike protein test result less than 250 U/mL at the screening visit. Subjects will be randomized to receive a change or maintain their current immunosuppression medication regimen and then receive the Janssen Ad26.CoV2.S vaccine.
62253571|NCT05220397|EXPERIMENTAL|Segment II|Segment II: individuals from Segment I who have a spike protein test result less than 250 U/mL 28 days after receiving the Janssen Ad26.CoV2.S vaccine in Segment I. Subjects will be randomized to receive a change or maintain their current immunosuppression medication regimen and then receive an additional Janssen Ad26.CoV2.S vaccine.
62253572|NCT04077541|EXPERIMENTAL|The experimental group|The trauma care bundles combined with the internet platform.
62253573|NCT04077541|NO_INTERVENTION|The control group|Only trauma care bundles.
62253574|NCT02451579|ACTIVE_COMPARATOR|Cetirizine Hydrochloride|Prophylactic use of cetirizine hydrochloride prior to and after Topical 5-aminolevulinic Acid Photodynamic Therapy
62253575|NCT02451579|PLACEBO_COMPARATOR|Placebo|Prophylactic use of placebo prior to and after Topical 5-aminolevulinic Acid Photodynamic Therapy
62253576|NCT01624987|EXPERIMENTAL|NET for Forensic Offender Rehabilitation|Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)
62253577|NCT02016820|EXPERIMENTAL|Omeprazole (suspension)|Open-label, with all subjects receiving omeprazole
62253578|NCT02016820|OTHER|Lifestyle Modification|Treated with lifestyle modification (upright feeding, smaller meals, elevation of the head of the bed, etc.)
62442594|NCT01433536||cranial trauma|Individuals presenting a cranial trauma that are classified at equal to or less than 8 on the Glasgow scale
62442595|NCT01433536||spinal trauma with fracture|Individuals presenting a spinal fracture that are classified with an ASIA score of A, B, or C, combined with a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
62442596|NCT01433536||spinal trauma|Individuals presenting a spinal fracture that are classified with an ASIA score of A, B, or C
62442597|NCT01433536||high velocity fracture, inferior limb|Individuals that present a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
62442598|NCT01433536||Control|Healthy individuals
62835401|NCT02419001|EXPERIMENTAL|Period 2 - Treatment Sequence AB|"Treatment Sequence AB:~* \[Period 1: Ceftriaxone 1 g infused IV over 30 minutes\]~* Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg (1 x 75 mg capsule) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion"
62835402|NCT02419001|EXPERIMENTAL|Period 2 - Treatment Sequence AC|"* \[Period 1: Ceftriaxone 1 g infused IV over 30 minutes\]~* Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg (2 x 75 mg capsules) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion"
62052457|NCT04857203||Group 2|High levels of Vitamin D
62052458|NCT00340457||Cases|African American patients with renal cancer from two geographic areas of the US
62253579|NCT05741281|EXPERIMENTAL|STUDY GROUP|Physical exercises will be carried out for patients in the study group . The physical exercise intervention phase will take three weeks for each patient (three sessions per week for three weeks - Nine sessions for each group). It will be applied for two groups each week for three weeks (one group / day - 3 sessions /week for each group - six days/ week for the two groups).
62253580|NCT05741281|ACTIVE_COMPARATOR|Control group|Those in the control group will be left to undergo the usual hospital routine
62052459|NCT00340457||Controls|African American participants without renal cancer from two geographic areas of the US
62052460|NCT05987306|EXPERIMENTAL|Intervention|a standard weight loss and internalized weight bias intervention with self-compassion exercises
62052461|NCT01473693||surgery-only group|This will be a prospective study to investigate chemotherapy related structural brain changes in individuals undergoing anatomic lung resection for non-small cell carcinoma with and without, induction systemic chemotherapy treatment.
62052462|NCT01473693||induction chemotherapy group|This will be a prospective study to investigate chemotherapy related structural brain changes in individuals undergoing anatomic lung resection for non-small cell carcinoma with and without induction systemic chemotherapy treatment.
62052463|NCT01497522|EXPERIMENTAL|Vildagliptin|In addition to their stable dose of metformin monotherapy, patients should take vildagliptin 50 mg twice daily.
62253581|NCT00560742|ACTIVE_COMPARATOR|Control|
62253582|NCT00560742|EXPERIMENTAL|Intramuscular|
62253583|NCT00560742|EXPERIMENTAL|Intracoronary|
62253584|NCT05891340|NO_INTERVENTION|Control|Preoperative exercise, alcohol and smoking cessation are recommended to patients.
62253585|NCT05891340|ACTIVE_COMPARATOR|Intervention|Respiratory muscle exercise (two times a day) and walking (5000steps/day) are recommended to the patients preoperatively.
62253586|NCT01671111|EXPERIMENTAL|SSP-004814AQ|
62253587|NCT01595126||Patients with Central Nervous System Tumors|
62253588|NCT04092296|EXPERIMENTAL|resin infiltration|resin infiltrant (Icon product, DMG, Hamburg,Germany)
62253589|NCT04092296|ACTIVE_COMPARATOR|remineralization|
62253590|NCT04526743||BS patients|Candidates to primary BS undergoing laparoscopic gastric bypass (LGBP) or laparoscopic sleeve gastrectomy (LSG) from September 2020 to September 2021. Patients will be evaluated prior to BS and at 4 months, 1, 3 and 5 years after BS.
62253591|NCT04526743||no BS patient|A control group of subjects with obesity not candidates to BS matched with the intervention group for age, sex and BMI prior to BS. Patients will be evaluated once.
62442599|NCT01938976|EXPERIMENTAL|Adolescent Asthma Action|Adolescent Asthma Action in Jordan (TAJ) Plus the added class smoke free pledge will be implemented in high schools in Jordan and will be compared to the TAJ alone for its efficacy in decreasing smoking rates, lowering CO1 levela and nicotine dependence.
62835403|NCT04444453|EXPERIMENTAL|Pedometer|Admitted patients who receive a pedometer to wear during their hospital stay to measure steps ambulated
62835404|NCT04444453|NO_INTERVENTION|Control|Patients admitted to hospital who do not receive a pedometer, but receive all other usual standard of care
62835405|NCT04799912|EXPERIMENTAL|Elective labor induction|Elective labor induction via oxytocin between 39 weeks of gestation and 0 day and 39 weeks of gestation and 4 days for women with favorable cervix. Those with an unfavorable cervix (Bishop score \< 6) will first undergo cervical ripening (method left to the discretion of the practitioner) in conjunction with or followed by oxytocin stimulation unless a contraindication arises. Except for elective induction of labor between 39 weeks of gestation and 0 day and 39 weeks of gestation and 4 days, the obstetrical management will not be modified compared to routine obstetrical management.
62835406|NCT04799912|NO_INTERVENTION|Expectant management|Standard follow-up visits until at least 41 weeks of gestation and 0 day without elective labor induction unless a medical indication is present. Antepartum fetal testing will be initiated no later than 41 weeks of gestation and 1 day according to policies at each center (according to the French guidelines). If still pregnant, women will undergo induction at 41 weeks of gestation and 6 days (according to the French guidelines)
62253592|NCT05424172|EXPERIMENTAL|Stage-I: Self Monitoring Exercise Using a Health App|Participants will be randomized into one of two groups: Group 1 (self monitoring using a non-interactive app), and Group 2 (self monitoring using an interactive app). Participants in both groups will be provided a customized exercise program to complete over the duration of the study. Within either app, participants will be able to view assigned exercises, log additional exercises completed, complete questionnaires as needed, and access additional resources. Participants will use their own smartphone to receive the health app. Participants will continue using their Stage-I app intervention for the entire duration of the study (weeks 1-24).
62253593|NCT05424172|EXPERIMENTAL|Stage-II: Strategy to Address Non-Adherence|After 12 weeks, the participants will be categorized as adherents or non-adherents based on their rates of adhering to the SCI exercise guidelines during Stage-I. Non-adherents (those who met the exercise guidelines \<50% of the weeks) will be randomized to receive an augmented intervention of motivational interviewing-based e-coaching (2x per month or 4x per month) in addition to their Stage-I assigned app for 12 weeks (weeks 13-24) to further increase rates of exercise. All non-adherents who will be assigned to the e-coaching interventions will be asked to complete at least daily EMA surveys. A coach who is trained in motivational interviewing will review the EMA data and work collaboratively with participants to identify barriers and facilitators and develop individualized strategies to improve exercise adherence. Adherents (those who met the exercise guidelines \>50% of the weeks) will continue with only their Stage-I assigned app intervention throughout Stage-II.
62253594|NCT01043276|EXPERIMENTAL|Treatment A|
62253595|NCT01043276|EXPERIMENTAL|Treatment B|
62253596|NCT01043276|EXPERIMENTAL|Treatment C|
62253597|NCT01043276|EXPERIMENTAL|Treatment D|
62442600|NCT01938976|EXPERIMENTAL|TAJ|TAJ Plus the class smoke free pledge will be implemented in high schools in Jordan and compared to TAJ alone
62442601|NCT00063128|EXPERIMENTAL|A|
62835407|NCT06088784|EXPERIMENTAL|Part 1a (Single Ascending Doses (SAD)): ATH-399A|Participants will receive single oral dose of ATH-399A capsule in up to 5 ascending dose levels (5mg, 10mg, 20mg, 40mg, 80mg).
62442602|NCT00063128|ACTIVE_COMPARATOR|B|
62442603|NCT01234779|EXPERIMENTAL|A|
62442604|NCT01234779|EXPERIMENTAL|B|
62835408|NCT06088784|PLACEBO_COMPARATOR|Part 1a (SAD): Placebo|Participants will receive single oral dose of placebo-matched to ATH-399A capsule.
62835409|NCT06088784|EXPERIMENTAL|Part 1b (High calorie): ATH-399A|Participants will receive single oral dose of ATH-399A capsule after high-calorie, high-fat breakfast and then will cross over to receive single oral dose of ATH-399A capsule after fasting.
62442605|NCT01234779|ACTIVE_COMPARATOR|C|
62442606|NCT01234779|PLACEBO_COMPARATOR|D|
62835410|NCT06088784|EXPERIMENTAL|Part 1b (Fasting): ATH-399A|Participants will receive single oral dose of ATH-399A capsule after fasting and then will cross over to receive single oral dose of ATH-399A capsule after high-calorie, high-fat breakfast.
62052464|NCT01497522|PLACEBO_COMPARATOR|Placebo|In addition to their stable dose of metformin monotherapy, patients should take vildagliptin matching placebo.
62253598|NCT01043276|EXPERIMENTAL|Treatment E|
62253599|NCT05620147|EXPERIMENTAL|Root canal instrumentation EdgeFile X7 to size #35/0.06|The mechanical preparation will be continued using EdgeFile X7 #35 .04 and #35 .06
62253600|NCT05620147|EXPERIMENTAL|Root canal instrumentation EdgeFile X7 to size #45/0.04|The mechanical preparation will be continued using EdgeFile X7 #35 .04, #40 .04 and #45 .04
62253601|NCT05620147|EXPERIMENTAL|Root canal instrumentation EdgeFile X7 to size #45/0.06|The mechanical preparation will be continued using EdgeFile X7 #35 .04, #40 .04, #45 .04 and #45 .06
62253602|NCT05620147|ACTIVE_COMPARATOR|Root canal instrumentation EdgeFile X7 to size #35/0.04|The mechanical preparation will be continued using EdgeFile X7 #35 .04
62253603|NCT01423851|EXPERIMENTAL|Intervention: Drug: NS-018|In Phase 1 part, subjects were treated with oral NS-018 at a dose of 75 - 400 mg once daily or 100 - 400 mg twice daily. In Phase 2 part, subjects were treated with oral NS-018 at a dose of 300 mg once daily.
62442607|NCT02003495|EXPERIMENTAL|MCV-ACYW135 Vaccine Group|"Participants at age 2 to 6 years of enrollment will receive 1 dose on Meningococcal ( A, C, Y and W 135) conjugate vaccine.~Participants at age 6 to 23 months of enrollment will receive 2 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 3 months apart.~Participants at age 3 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 1 month apart.~Participants at age 2 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 2 months apart."
62835411|NCT06088784|EXPERIMENTAL|Part 2 (Multiple Ascending doses (MAD)): ATH-399A|Participants will receive once daily (QD) dose of ATH-399A capsules from Day 1 to Day 12 in fasted state.
62253604|NCT00682448|ACTIVE_COMPARATOR|1|Olanzapine plus metformin: olanzapine plus metformin 500 mg titrated up to but no greater than 2,000 mg based upon fasting blood glucose during study visits over six months.
62253605|NCT00682448|PLACEBO_COMPARATOR|2|Olanzapine plus Drug: Placebo. Subjects will remain on olanzapine plus placebo for 6 months.
62052465|NCT03980925|EXPERIMENTAL|Nivolumab + platinum-doublet chemotherapy|"1. Induction Phase: Nivolumab 360 mg IV plus Carboplatin IV (AUC=5) plus Etoposide 10mg/m2/day on days 1-3D, all every 3 weeks up to 6 cycles followed by Nivolumab 480mg for 24 months or until PD, death or toxicity.~   Order of administration: Nivolumab, Carboplatin, Etoposide~2. Maintenance Phase Nivolumab 480 mg IV will be administered every 4 weeks (±3 days) for 2 years."
62052466|NCT02459366||control|establish the reliability of measurement of lumbopelvic asymmetry, mechanical and physical properties of thoracolumbar fascia, and the norm of different age
62253606|NCT01572675||Group Arcoxia®|Participants who were either previously treated with Arcoxia® or initiated on study treatment with Arcoxia®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use.
62442608|NCT02003495|ACTIVE_COMPARATOR|MPV-ACYW135 Vaccine Group|Participants at age 2 to 6 years of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
62442609|NCT02003495|ACTIVE_COMPARATOR|MPV-A Vaccine Group|Participants at age 6 to 23 months of enrollment will receive 2 doses on Group A Meningococcal Polysaccharide vaccine at 3 months apart.
62835412|NCT06088784|PLACEBO_COMPARATOR|Part 2 (MAD): Placebo|Participants will receive QD dose of placebo-matched to ATH-399A capsules from Day 1 to Day 12 in fasted state.
62835413|NCT06088784|EXPERIMENTAL|Additional Cohort (Ages 56-80 years old): ATH-399A|Participants will receive QD dose of ATH-399A capsules from Day 1 to Day 12 in fasted state following MAD dosing.
62835414|NCT06088784|PLACEBO_COMPARATOR|Additional Cohort: (Ages 56-80 years old) Placebo|Participants will receive QD dose of placebo-matched to ATH-399A capsules from Day 1 to Day 12 in fasted state following MAD dosing.
62835415|NCT03430102||LeftHeartCath|Patients scheduled for LV catheterization for direct measurement of LVEDP
62835416|NCT02472470|EXPERIMENTAL|Treatment|intermitten TBS (iTBS) rTMS applied to the left Dorsolateral Prefrontal Cortex (DLPFC) + continuous TBS (cTBS) rTMS applied to the right DLPFC. The order will be counterbalanced. Administration of this treatment takes roughly 10 minutes. This treatment will be applied daily, 5 days/week, for 2 weeks.
62835417|NCT04012957|EXPERIMENTAL|Darbepoetin Alfa Injection|Randomly assigned to receive Darbepoetin in a 1:1 ratio for 24 weeks.
62835418|NCT04012957|ACTIVE_COMPARATOR|Desidustat oral tablet|Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.
62835419|NCT00874094|ACTIVE_COMPARATOR|platelet rich fibrin matrix|Both nasolabial folds treated with 0-2 cc of autologous platelet rich fibrin matrix,sufficient to efface nasolabial fold
62835420|NCT00885170|EXPERIMENTAL|Odanacatib 50 mg|Odanacatib 50 mg tablets once weekly for 24 months. Vitamin D3 (dietary supplement), two 2800 IU tablets, taken once weekly for 24 months. Participants received calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
62835421|NCT00885170|PLACEBO_COMPARATOR|Placebo|Placebo to odanacatib 50 mg tablets once weekly for 24 months. Vitamin D3 (dietary supplement), two 2800 IU tablets, taken once weekly for 24 months. Participants received calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
62835422|NCT02290249|ACTIVE_COMPARATOR|normal airway|İntubation with glidescope or airtraq in normal airway
62835423|NCT02290249|ACTIVE_COMPARATOR|tongue edema|intubation with glidescope or airtraq in tongue edema simulation
62835424|NCT02290249|ACTIVE_COMPARATOR|face-to-face|intubation with glidescope or airtraq in face-to-face intubation
62835425|NCT01112839|ACTIVE_COMPARATOR|Less Intensive Group|Participants in this group would receive print materials on diet and exercise and two individual counseling sessions; one at the beginning of the study and another 6 months later.
62835426|NCT01112839|EXPERIMENTAL|Intensive Group|Participants in this group would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
62835427|NCT02763670|OTHER|Interventional|PRETICARD patient care management
62052467|NCT02459366||low back pain|compare the differences among asymptomatic subjects and patients with and without lumbopelvic asymmetry, and investigate whether lumbopelvic symmetry, core muscle contractility, proprioception and standing balance change after manipulating thoracolumbar fascia tissue by physical therapy
62835428|NCT02763670|OTHER|Control|"Heterogenous as usual patient care management."
62835429|NCT03752437|EXPERIMENTAL|Real Weight|Injection of 300 IU of heparin based on REAL weight. This injection will be controlled by an ACT (activated clotting time) one minute after the injection.
62442610|NCT02003495|ACTIVE_COMPARATOR|MCV-AC Vaccine Group|Participants at age 3 to 5 months of enrollment will receive 3 doses on Group A and C Meningococcal conjugate vaccine at 1 month apart.
62442611|NCT02003495|PLACEBO_COMPARATOR|Hib Vaccine Group|Participants at age 2 to 5 months of enrollment will receive 3 doses on Haemophilus Influenzae Type b Conjugate Vaccine at 2 months apart.
62835430|NCT03752437|EXPERIMENTAL|Ideal Weight|Injection of 300 IU of heparin based on IDEAL weight. This injection will be controlled by an ACT (activated clotting time) one minute after the injection.
62052468|NCT05403164||Periodontitis|Patients with periodontitis which is defined by interdental clinical attachment loss (CAL) ≥ 2 non-adjacent teeth, or Buccal or Oral CAL ≥ 3 mm with probing pocket depth (PPD) \> 3 mm is detectable at ≥2 teeth. All patients should be indicated for periodontal surgery.
62052469|NCT05403164||Healthy periodontium|Healthy periodontium is defined by absence of CAL, PPD ≤3 mm, bleeding on probing \<10%, and no evidence of radiological bone loss. Gingival samples are collected from subjects referred for gingivectomy for esthetic reasons such as crown lengthening, gummy smile or prior to teeth extraction for orthodontic treatment.
62052470|NCT05827952|NO_INTERVENTION|Groups/Cohorts|"The Self-learning group was designed to provide a description of the goals of the course and a reading of the Atomic Habits book. In the first session, the goals of the study were explained, the basic abilities of the caregiver and the case, the games, the relationship, the main problems that the caregiver wanted to change, the Parent Problem Checklist to help assess the caregiver's direction in identifying their own expectations, and the caregiver's perceived barriers and difficulties. The next 8 weeks of the course are based on the parents' self-study progress, and the study provides an online platform or a paper sheet to keep track of the self-study process and to contact the researcher at any time if there are any unexpected situations or problems. The record sheets were returned at the end of the 8-week period, and the self-study group received a face-to-face consultation at the end of the post-test."
62052471|NCT05827952|EXPERIMENTAL|Interventions|Hybrid group used Atomic Habits (20-minute audiobook format), a role structure and a game structure, online schedule reminders more than twice a week and individual counseling sessions (online and physical) for one to two total interventions. The online schedule reminders consisted of four major habits, each with four concepts, to adapt the online audiobook interventions to the caregivers' relationship-building habits with the children A total of 16 sessions are delivered. Parents simply receive the course through digital media and complete the online schedule reminder within the course progress, narrowing down the indicators of habit change and achieving behavioral change through multiple executions.
62052472|NCT02475785|EXPERIMENTAL|FFRD and mini plates group|"Upper will be bonded, levelled and aligned until reaching 0.019 x 0.025 ss archwires.~2 Y shaped mini plates will be inserted in the mandibular symphysis Insertion of the FFRD with Direct application over the mandibular mini plates"
62442612|NCT03183466|EXPERIMENTAL|Patients included in inclusion criteria|
62442613|NCT02224209|EXPERIMENTAL|Staged angioplasty|"Using Abbott EPD systems (Accunet/Emboshield), a balloon, stent~Method of stage-1 angioplasty~The stent can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield) if distal filter cannot be used, balloon angioplasty can be performed under proximal protection device; Use a balloon with diameter of 2mm × 2cm for stage-1 dilation until angiography shows residual stenosis \<70%.~Method of stage-2:~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield); Use an Abbott balloon (diameter of 4 \~ 6mm) for pre-dilation or post-dilation; After the placement of stent, the angioplasty is a success when residual stenosis is \<30%."
62442614|NCT02224209|ACTIVE_COMPARATOR|Routine single-stage CAS|"Using a balloon, stent~Routine stenting procedure:~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield); Use an Abbott balloon (diameter of 4 \~ 6mm) for pre-dilation or post-dilation; After the placement of stent, the angioplasty is a success when residual stenosis is \<30%."
62442615|NCT04579874|EXPERIMENTAL|LIVERFASt validation|blood draw for LIVERFASt
62442616|NCT05117008|EXPERIMENTAL|belantamab mafodotin|Belantamab mafodotin is an intravenous drug.
62442617|NCT04624191|EXPERIMENTAL|Intervention Group|Intervention group participants will be asked to measure their oxygen saturation on a daily basis.
62442618|NCT04624191|NO_INTERVENTION|Control Group|Usual Care
62623594|NCT05447455|ACTIVE_COMPARATOR|TAP block group|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
62835431|NCT04931706||N-Sleve patients|Patient that were selected for surgery
62835432|NCT05067725|NO_INTERVENTION|Control|Standard of practice
62835433|NCT05067725|EXPERIMENTAL|CarePath Intervention|Clinician decision support computer tool that consists of a best practice alert (BPA) embedded with a headache questionnaire, Medication Express Lane (for medication ordering), and Ask-a-doc button (for prompt virtual consultation with a neurologist)
62835434|NCT01632722|ACTIVE_COMPARATOR|ArmA|
62835435|NCT01632722|ACTIVE_COMPARATOR|ArmB|
62835436|NCT04168918|EXPERIMENTAL|Group Psychological Intervention|One topic will be discussed at each of the six sessions using some principles from cognitive behavioral therapy and psychoeducation.
62835437|NCT04168918|NO_INTERVENTION|Treatment-as-usual|Participants will receive their usual care which involves being seen by a mental health professional (psychologist, psychiatrist/resident in psychiatry, or mental health nurse).
62835438|NCT00684918|EXPERIMENTAL|Experimental|In the Pilot Schedule portion of the study 3 hour vs 24 hour infusion schedules of obatoclax.
62835439|NCT02551887|NO_INTERVENTION|Usual Care|Usual Care Only
62835440|NCT02551887|ACTIVE_COMPARATOR|Automated Reminder|Reminder
62835441|NCT02551887|EXPERIMENTAL|Automated Reminder Plus Script|Provider sees both reminder and script.
62052473|NCT02475785|ACTIVE_COMPARATOR|conventional FFRD|"Upper and lower arches will be bonded, levelled and aligned until reaching 0.019 x 0.025 ss archwires.~Insertion of FFRD with application over the lower archwire"
62052474|NCT02475785|NO_INTERVENTION|untreated control group|Patients will be observed for an average duration of 6-8 months
62052475|NCT05078151|OTHER|Metastatic prostate cancer|Patients will receive whole-body MRI with diffusion-weighted imaging at baseline and after 4 and 8 weeks of treatment.
62052476|NCT03083938|EXPERIMENTAL|Omental Roll-up|
62052477|NCT03083938|NO_INTERVENTION|No Omental Roll-up|
62052478|NCT01221948|EXPERIMENTAL|Deep Brain Stimulation|Rechargeable Deep Brain Stimulation System
62052479|NCT00006364|EXPERIMENTAL|Treatment (omacetaxine mepesuccinate)|"Remission induction therapy: Patients receive remission induction therapy comprising homoharringtonine IV continuously over 24 hours on day 1 and then subcutaneously (SC) twice daily on days 2-14 for course 1. Subsequent courses of remission induction therapy comprise homoharringtonine SC twice daily on days 1-14. Treatment continues monthly for at least 2 courses.~Maintenance therapy: Patients with complete hematologic remission receive maintenance therapy comprising homoharringtonine SC twice daily on days 1-7 monthly for 3 years in the absence of disease progression or unacceptable toxicity."
62052480|NCT05460923|EXPERIMENTAL|Swiss Ball Exercises|Swiss ball exercises along with baseline treatment trunk twists,
62835442|NCT02973750||Pre-Surgery Chemotherapy Patients|All participants. Patients receiving chemotherapy with carboplatin and paclitaxel before their debulking surgery, who may have more chemotherapy after surgery. Sampling procedures will include: Baseline Biopsy; Tissue Collection; Blood Draws.
62835443|NCT02567812||In-patient with PID|In-patient with PID who diagnosed at Kangbuk Samsung Hospital
62835444|NCT04459650|EXPERIMENTAL|Female Breast Cancer Pts|Participants include female breast cancer patients who either receive endocrine therapy and suffer from endocrine induced alopecia or suffer from post chemotherapy induced alopecia.
62052481|NCT05460923|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation|pelvic neuromuscular facilitation techniques including various PNF movement patterns along with the baseline treatment
62052482|NCT01857401||Observational study|Blood draw only, observational study
62052483|NCT05527067||α-synucleinopathy|Participants with clinical diagnosis of α-synucleinopathy.
62052484|NCT05527067||Healthy controls|Healthy controls
62052485|NCT02962479||TNF blocker-naïve ankylosing spondylitis patients|
62835445|NCT01954446|EXPERIMENTAL|ContiPress vs. 3M|ContiPress vs. 3M passive and during exercise
62835446|NCT01954446|EXPERIMENTAL|ContiPress vs. Mobil-O-Graph|ContiPress vs. Mobil-O-Graph passive, then oscillometric passive, then oscillometric for 24 hrs every 15 mins.
62835447|NCT05916079||breastfeeding success (Yes)|Mothers are to be contacted at 1 month to assess the main outcome: breastfeeding status (Yes vs No) classified as breastfeeding success (Yes) or breastfeeding failure (No).
62052486|NCT02962479||TNF blocker-exposed ankylosing spondylitis patients|
62052487|NCT02962479||TNF blocker-naïve nrSpA patients|
62052488|NCT02962479||TNF blocker-exposed nrSpA patients|
62052489|NCT02962479||Healthy Participants|
62253607|NCT01572675||Group Celebrex®|Participants who were either previously treated with Celebrex® or initiated on study treatment with Celebrex®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use.
62052490|NCT05688748|EXPERIMENTAL|Dengue monitoring system|The participants will be given access to download a dengue self-monitoring application and use the application at home to key in their symptoms, three times a day throughout their outpatient follow up for dengue.
62052491|NCT05688748|NO_INTERVENTION|Usual care|Patients will be managed as per usual outpatient care for dengue in the clinic.
62052492|NCT01551199|EXPERIMENTAL|Multiple Channel Exposure Therapy|MCET-V is a cognitive-behavioral treatment for persons with comorbid PTSD and panic attacks
62052493|NCT02142647|ACTIVE_COMPARATOR|meat group|Infants in this group will receive complementary foods with high protein content mainly from meat
62052494|NCT02142647|ACTIVE_COMPARATOR|dairy group|infants in this group will receive complementary foods mainly from dairy
62835448|NCT05916079||breastfeeding failure (No)|Mothers are to be contacted at 1 month to assess the main outcome: breastfeeding status (Yes vs No) classified as breastfeeding success (Yes) or breastfeeding failure (No).
62835449|NCT01206218|ACTIVE_COMPARATOR|Group A|FLOT Regimen
62835450|NCT01206218|EXPERIMENTAL|Group B|FLO Regimen or FLOT Regimen
62052495|NCT02826200|EXPERIMENTAL|Group 1 (SOC+OAT)|Patients with reduced leaflet motion or with prosthetic heart valve thrombosis receiving single antiplatelet therapy plus oral anticoagulant therapy.
62253608|NCT01925924|EXPERIMENTAL|Resin-modified glass ionomer cement|Resin-modified glass ionomer cement is used to attach the fixed orthodontic brackets (brace) to the teeth.
62253609|NCT01925924|ACTIVE_COMPARATOR|Composite resin|Composite resin is used to attach fixed orthodontic brackets (brace)to the teeth.
62253610|NCT00397033|EXPERIMENTAL|002|Paliperidone ER 12mg/day paliperidone er for 6 weeks
62253611|NCT00397033|EXPERIMENTAL|001|Paliperidone ER 6mg/day paliperidone er for 6 weeks
62611845|NCT06730282|EXPERIMENTAL|Danggui Shaoyao San + Cuscuta Chinensis|articipants in this group will receive a combination of Danggui Shaoyao San and Cuscuta Chinensis. The combined therapy will be administered starting 3 to 7 days before menstruation and continued until 3 days after menstruation for two consecutive menstrual cycles. This group aims to assess whether the combination therapy provides enhanced efficacy in reducing pain and other menstrual symptoms compared to single interventions.
62611846|NCT06730282|PLACEBO_COMPARATOR|Placebo|Participants in this group will receive a placebo that matches the study medications in appearance and packaging. The placebo will be administered starting 3 to 7 days before menstruation and continued until 3 days after menstruation for two consecutive menstrual cycles. This group serves as a control to evaluate the specific effects of the active interventions on primary dysmenorrhea.
62611847|NCT01018160||001|
62611848|NCT02445859|ACTIVE_COMPARATOR|Standard regimen|Cefuroxime 1.5grams pre-operatively Repeated every 4 hours
62611849|NCT02445859|EXPERIMENTAL|Interventional regimen|Cefuroxime continuous infusion targeting 64mg/l serum concentrations.
62052496|NCT02826200|ACTIVE_COMPARATOR|Group 2 (SOC)|Patients with reduced leaflet motion or with prosthetic heart valve thrombosis receiving standard of care therapy.
62253612|NCT00397033|PLACEBO_COMPARATOR|003|Placebo Placebo for 6 weeks
62052497|NCT05378243|EXPERIMENTAL|Robotic Gait Training|8 weeks of therapy with the robotic gait training device 4-5 times a week for 1 hour each session
62052498|NCT05378243|EXPERIMENTAL|Functional Clinical Therapy|8 weeks of therapy with a custom designed therapy program for the participant's needs 4-5 times a week for 1 hour each session
62253613|NCT00786747|EXPERIMENTAL|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
62253614|NCT00786747|ACTIVE_COMPARATOR|Non-tailored control computer program|This program provides non-tailored, generic information about colorectal cancer screening, in the user's preferred language (English or Spanish).
62253615|NCT00272064|OTHER|1|Telecare system
62253616|NCT00272064|OTHER|2|Self Monitoring Blood Glucose (SMBG)system.
62253617|NCT00535275|EXPERIMENTAL|A|
62253618|NCT00535275|ACTIVE_COMPARATOR|B|Docetaxel monotherapy
62253619|NCT02723695|EXPERIMENTAL|Patients|Surgery (cochlear implantation)
62253620|NCT02723695|ACTIVE_COMPARATOR|Controls|Asymptomatic subjects
62253621|NCT04553705|EXPERIMENTAL|Omega-3/thymoquinone supplementation|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA \& 200-300mg DHA) (3% thymoquinone) per day for one month.~In addition to the standard care"
62253622|NCT04553705|EXPERIMENTAL|Omega-3/thymoquinone / Indian Costus supplementation|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA \& 200-300mg DHA), (3% thymoquinone),(Indian Costus) per day for one month.~In addition to the standard care"
62253623|NCT04553705|EXPERIMENTAL|Omega-3/thymoquinone / Quinine pills|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA \& 200-300mg DHA), (3% thymoquinone),(1g Quinine) per day for one month.~In addition to the standard care"
62253624|NCT04553705|EXPERIMENTAL|Omega-3/thymoquinone / Anise seed capsule|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA \& 200-300mg DHA), (3% thymoquinone),(450mg anise seed) per day for one month.~In addition to the standard care"
62611850|NCT06112678|EXPERIMENTAL|Sequence 1|Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-348(6) - A single oral dose of 1 tablet under fasting condition Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 4: CKD-348(6) - A single oral dose of 1 tablet under fasting condition
62835451|NCT02643446||G1: IPV+OPV, 1 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months of age, that is one month after the first dose of IPV and just before the first dose of OPV.
62253625|NCT04553705|EXPERIMENTAL|Omega-3/thymoquinone / Deglycyrrhizinated Licorice|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA \& 200-300mg DHA), (3% thymoquinone),(Deglycyrrhizinated Licorice 800 mg ) per day for one month.~In addition to the standard care"
62611851|NCT06112678|EXPERIMENTAL|Sequence 2|Period 1: CKD-348(6) - A single oral dose of 1 tablet under fasting condition Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-348(6) - A single oral dose of 1 tablet under fasting condition Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
62611852|NCT03250585||Sickle Cell Patients with Acute Chest Syndrome|Sickle cell patients with active acute chest syndrome (ACS) from which samples of EBC and plasma will be collected during acute illness within 48 hours of admission with or diagnosis of ACS (Time point 1) in 3 sessions each 1 hour apart (Time point 1a, 1b, and 1c), and 2 weeks after discharge when have returned to steady-state (Time point 2). Time point 2 samples will serve as control (baseline) samples.
62835452|NCT02643446||G2: IPV+OPV, 1 m+7d followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the first dose of OPV.
62835453|NCT02643446||G3: IPV+OPV, 2 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 4 months of age, that is one month after the first dose of OPV and just before the second dose of OPV.
62052499|NCT03496662|EXPERIMENTAL|Part A - Experimental Dose Level 0|"* BMS-813160 300 mg twice per day~* Nivolumab 30-minute intravenous (IV) infusion at a flat dose of 480 mg on Day 1 of each 28-day cycle~* Gemcitabine 30-minute IV infusion 1000 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle~* Nab-paclitaxel 30-40-minute IV infusion 125 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle~* Post-treatment biopsy at the end of cycle 2~* Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cyclesore cycles"
62052500|NCT03496662|ACTIVE_COMPARATOR|Part A - Control (chemotherapy only)|"* Gemcitabine 30-minute IV infusion 1000 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle Nab-paclitaxel 30-40-minute IV infusion 125 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle~* Post treatment biopsy at the end of cycle 2~* Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles"
62052501|NCT03496662|EXPERIMENTAL|Part B - Dose expansion|"* BMS-813160 300 mg twice per day~* Nivolumab 30-minute IV infusion at a flat dose of 480 mg on Day 1 of each 28-day cycle~* Gemcitabine 30-minute IV infusion 1000 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle~* Nab-paclitaxel 30-40-minute IV infusion 125 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle~* Post-treatment biopsy at the end of cycle 2~* Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles"
62253626|NCT04553705|ACTIVE_COMPARATOR|Active Comparator: standard care|The standard protocol care for COVID-19 approved from ministry of health at Saudi arabia
62253627|NCT04556396|EXPERIMENTAL|Intervention arm|This arm will receive cone beam CT to perform an abdomen-pelvis CT scan immediately following initial percutaneous nephrolithotomy, before the patient emerges from general anesthesia, to allow the surgeon to determine whether additional work is needed or whether the procedure can be concluded without requiring further imaging or future interventions.
62253628|NCT04556396|NO_INTERVENTION|Retrospective arm|This arm will contain a retrospective cohort of patients who underwent surgery prior to the enrollment of the intervention arm. These patients received the standard of care, namely helical CT postoperative day one.
62835454|NCT02643446||G4: IPV+OPV, 3 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 5 months of age, that is one month after the second dose of OPV.
62052502|NCT01886911|ACTIVE_COMPARATOR|Control for Attention Intervention|Attentional Control Game is an active control group. We expect subjects in this group to play a control game for 2 weeks (plus or minus 7 days).
62052503|NCT01886911|EXPERIMENTAL|Prosocial Training Intervention Game|The prosocial intervention group, which we expect will be play the experimental prosocial training game for 2 weeks (plus or minus 7 days).
62052504|NCT01886911|EXPERIMENTAL|Attention Training Intervention Game|The attention intervention group, which we expect will be play the experimental attention training game for 2 weeks (plus or minus 7 days).
62052505|NCT01886911|ACTIVE_COMPARATOR|Control for Prosocial Intervention|This is an active control group. We expect subjects in this group to play a control game for 2 weeks (plus or minus 7 days).
62052506|NCT03766256|EXPERIMENTAL|Shared decision-making with pharmacists|Pharmacist-coordinated shared decision making about treatment for history of gestational diabetes mellitus (lifestyle change and/or metformin), using a decision tool
62052507|NCT04049318||24 weeks|Subjects who participated in the intervention who have data available at week 24
62052508|NCT04049318||48 weeks|Subjects who participated in the intervention who have data available at week 48
62052509|NCT01210833|ACTIVE_COMPARATOR|Healthy participants|Healthy participants aged from 18 to 60 with no history of hand injuries recruited by convenience sampling.
62052510|NCT01210833|EXPERIMENTAL|Hand Injured participants|Participants with hand injuries aged from 18 to 60 recruited from the outpatients attending the occupational therapy clinic.
62052511|NCT03829163|ACTIVE_COMPARATOR|Conventional Walker Group|
62052512|NCT03829163|EXPERIMENTAL|HAW Group|
62052513|NCT02295839|NO_INTERVENTION|Usual care|
62052514|NCT02295839|EXPERIMENTAL|Sleep Hygiene and Relaxation Education|
62835455|NCT02643446||G5: OPV, 3 m followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 5 months of age, that is one month after the third dose of OPV.
62835456|NCT02643446||G6: OPV, 1 m followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 3 months of age, that is one month after the first dose of OPV and just before the second dose of OPV.
62835457|NCT02643446||G7: OPV, 1 m+7d followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of OPV.
62835458|NCT02643446||G8: IPV+IPV, 1 m+7d followup|Using 2 dose IPV and 1 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of IPV.
62835459|NCT02643446||G9: IPV+IPV, 2 m followup|Using 2 doses of IPV and 1 doses of OPV at 2, 3,4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 4 months of age, that is one month after the second dose of IPV and just before the first dose of OPV.
62835460|NCT02643446||G10: IPV+OPV, 1 m and 3 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months of age, that is one month after the first dose of IPV and just before the first dose of OPV;the third sample at 5 months of age, that is one month after the second dose of OPV.
62835461|NCT02643446||G11: IPV+OPV, 1 m+7d and 2 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the first dose of OPV,the third sample at 4 months of age, that is one month after the first dose of OPV.
62052515|NCT00491985|EXPERIMENTAL|Study Group 1|Subjects aged 9 to 17 years
62052516|NCT00491985|EXPERIMENTAL|Study Group 2|Subjects aged 3 to 8 years
62052517|NCT00491985|EXPERIMENTAL|Study Group 3|Subjects aged 6 to 35 months
62611853|NCT02237040|EXPERIMENTAL|treatment group|Patients are treated with the mandibular manipulation technique termly and mouth opening training
62611854|NCT02331849|OTHER|Eosinophilic esophagitis|Patients with eosinophilic esophagitis after exclusion of GERD
62052518|NCT01938833|EXPERIMENTAL|Treatment (Romidepsin and Abraxane)|Patients receive abraxane IV over 30 minutes and romidepsin IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62052519|NCT05059379|ACTIVE_COMPARATOR|Breast/chest wall+undisseted axillary+IMN+medial SCL ( medial SCL radiation)|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and medial supraclavicular node. Treatment will be given by normfractionated or hypofractionated radiotherapy (50Gy/25Fx/5w or 42.5Gy/16Fx/3.5w). IMRT and VMAT technique are recommended.
62052520|NCT05059379|EXPERIMENTAL|Breast/chest wall+undisseted axillary+IMN+entie SCL (entire SCL radiation)|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular node. Treatment will be given by normfractionated or hypofractionated radiotherapy (50Gy/25Fx/5w or 42.5Gy/16Fx/3.5w). IMRT and VMAT technique are recommended.
62052521|NCT01184365|EXPERIMENTAL|EnMP-1|The goal of the EnMP-1 is to enable participants, through a behavioural, psycho-educational intervention, to better manage and understand their fatigue. This program is provided in four, two-hour sessions held weekly.
62052522|NCT01184365|ACTIVE_COMPARATOR|EnMP-2|The goal of the EnMP-2 is to control for group effects
62052523|NCT05847179|EXPERIMENTAL|Treatment Group|all subjects will receive Progerinin 2400mg (1200mg twice daily) after morning and evening meals for a year
62052524|NCT02617225||DHaAL Intervention|The group receives standard Ailment-free Life (DHaAL) DHaAL intervention
62052525|NCT02617225||DHaAL +CFSS Intervention|This group received the standard DHaAL intervention and additional support under another UNICEF program named Child Friendly School System (CFSS).
62611855|NCT02811575||Patients with diabetes|Patients with type 2 diabetes will have biopsy during coloscopy.
62611856|NCT02811575||Control|Patients without type 2 diabetes will have biopsy during coloscopy.
62611857|NCT02565706|ACTIVE_COMPARATOR|WIC Fresh Start Program|Participants in this arm receive the Fresh Start program.
62835462|NCT02643446||G12: IPV+IPV,1 m+7d and 2 m followup|Using 2 dose IPV and 1 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of IPV,the third sample at 4 months of age, that is one month after the second dose of IPV.
62052526|NCT02617225||Control|This group receive the standard / business-as-usual support from the Education Department, but does not receive DHaAL or CFSS Interventions.
62052527|NCT02614495|EXPERIMENTAL|Surufatinib|300mg once-daily
62052528|NCT05079022|EXPERIMENTAL|Furmonertinib|ctDNA-MRD positive participants received 3 years of furmonertinib once daily as adjuvant therapy after radical surgery until disease progression or unacceptable toxicity occurs.
62835463|NCT03812757||Supraclavicular fossa US scanning|Following insertion of at least 20 cm of the guidewire into the right subclavian vein, the probe is shifted to the right supraclavicular fossa to scan the right internal jugular vein in order to exclude malposition of the guidewire. The probe is then tilted in a caudal direction to obtain a view of the guidewire within the superior vena cava. Misplaced guidewires will be corrected under real-time ultrasound guidance.
62835464|NCT00445913|EXPERIMENTAL|control dendritic cells|autologous dendritic cells that are not treated
62835465|NCT00445913|EXPERIMENTAL|AS ODN dendrtitic cells|autologous dendritic cells treated ex vivo with the mixture of the antisense oligonucleotides
62052529|NCT02335190|EXPERIMENTAL|PSN block and RF ablation|Participants will first undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. On a separate visit, participants will then undergo ablation of the PSN at the lateral crest under ultrasound-guidance.
62052530|NCT04065100|EXPERIMENTAL|Study group|Maternal PCOS
62052531|NCT04065100|ACTIVE_COMPARATOR|Comaprator|Non-PCOS pregnant women
62052532|NCT02775955|EXPERIMENTAL|RX0041-002|Active
62052533|NCT03680625|ACTIVE_COMPARATOR|Passive Distraction|The child will watch a video on an iPad® during the pin removal procedure and/or removal of sutures.
62611858|NCT02565706|ACTIVE_COMPARATOR|Existing Online Health Education|Participants in this arm receive existing online WIC health education.
62611859|NCT02565706|EXPERIMENTAL|WIC Fresh Start Program (FMNP)|Participants in this arm receive the Fresh Start program and WIC Farmers' Market Nutrition Program (FMNP) vouchers redeemable at farmers' markets.
62611860|NCT02565706|ACTIVE_COMPARATOR|Existing Online Health Education (FMNP)|Participants in this arm receive existing online WIC health education and WIC Farmers' Market Nutrition Program (FMNP) vouchers redeemable at farmers' markets.
62611861|NCT01612507|EXPERIMENTAL|A|600 mg Ceftaroline fosamil 1 h infusion
62611862|NCT01612507|EXPERIMENTAL|B|Placebo 1 h infusion
62611863|NCT01612507|EXPERIMENTAL|C|600 mg Ceftaroline fosamil 2 h infusion
62611864|NCT01612507|EXPERIMENTAL|D|Placebo 2 h infusion
62611865|NCT01273155|ACTIVE_COMPARATOR|Normal Function-Belinostat 1000 mg/m(2)|Normal Liver Function was defined as bilirubin ≤Upper Limit of Normal (ULN) and aspartate aminotransferase (AST) ≤ ULN.
62835466|NCT06390748|EXPERIMENTAL|standard care plus esmolol|Patients in this group were administered Esmolol, a beta-1 selective adrenergic blocker, alongside the standard sepsis care protocols. The dosage of Esmolol was adjusted to maintain heart rate within predefined targets. Additionally, daily electrocardiogram (ECG) monitoring was conducted to assess changes in the QT interval, a critical measure given the potential cardiac effects of beta-blockers. This group aimed to explore not only the immunomodulatory effects of Esmolol but also its safety profile in terms of cardiac function in septic patients.
62835467|NCT06390748|NO_INTERVENTION|standard care|Patients in this cohort received the standard of care for sepsis without any additional intervention. This treatment included antibiotics, fluids, and other supportive therapies as dictated by current clinical guidelines for sepsis management.
62835468|NCT05106400|OTHER|ZTlido (Lidocaine Topical System) 1.8%|
62052534|NCT03680625|EXPERIMENTAL|Virtual Reality Distraction|The child will visualize and interact with the virtual environment using an Oculus Quest® head-mounted device throughout the pin removal procedure and/or removal of sutures.
62052535|NCT04617132||Online Mindfulness Group|Families with PPDA receiving evidence-based MBCT/MBSR intervention
62052536|NCT00089141|ACTIVE_COMPARATOR|Mycophenolate mofetil|Patients receive oral mycophenolate mofetil twice daily.
62052537|NCT00089141|PLACEBO_COMPARATOR|Placebo|Patients receive oral placebo twice daily
62052538|NCT02292017|EXPERIMENTAL|Embolization of intracranial aneurysm|Embolization with Target Coils
62052539|NCT03721120|EXPERIMENTAL|Liquid biopsy|Liquid biopsy will be performed at the first visit using InVisionFirst®. Treatment will be determined by (i) genomic characterization in plasma for patients with druggable alteration in first-line, (ii) after pathology results (including assessment of PD-L1 level of expression by immunohistochemistry) for patients with an informative molecular characterization on plasma and no druggable alteration in first-line and (iii) after pathology results and tissue molecular characterization for the remaining patients.
62835469|NCT05106400|OTHER|Salonpas (Lidocaine Patch 4%)|
62835470|NCT05106400|OTHER|Aspercreme (Lidocaine Patch 4%)|
62835471|NCT05106400|OTHER|IcyHot (Lidocaine 4% + Menthol 1% Patch)|
62835472|NCT04612504|EXPERIMENTAL|SynOV1.1 Injection|
62835473|NCT04671017|EXPERIMENTAL|Low Dose: VLA2001|
62835474|NCT04671017|EXPERIMENTAL|Medium Dose: VLA2001|
62835475|NCT04671017|EXPERIMENTAL|High Dose: VLA2001|
62835476|NCT04671017|EXPERIMENTAL|Booster: High Dose: VLA2001|
62052540|NCT03721120|NO_INTERVENTION|Cytological or histological sampling|During the first visit, cytological or histological sampling will be planned and treatment will be initiated according to European Society of Medical Oncology (ESMO) recommendations; in case of a tissue sample inadequate for genomic characterization, physicians may resort to liquid biopsy according to their usual practice and available technology.
62253629|NCT02535715|EXPERIMENTAL|ORAMED ORMD-0801 capsules- 2x8mg 1st; 3x8mg 2nd, 1x16mg 3rd|Two 8 mg ORAMED capsules containing insulin then 3X8mg ORAMED capsules containing insulin, second study then 1X16mg ORAMED capsules containing insulin, third study
62611866|NCT01273155|EXPERIMENTAL|Mild Dysfunction-Belinostat 750 mg/m(2)|Mild Liver Dysfunction was defined as bilirubin \>Upper Limit of Normal (ULN) but ≤1.5 x ULN and/or aspartate aminotransferase (AST) \> ULN.
62611867|NCT01273155|EXPERIMENTAL|Mild Dysfunction-Belinostat 1000 mg/m(2)|Mild Liver Dysfunction was defined as bilirubin \>Upper Limit of Normal (ULN) but ≤1.5 x ULN and/or aspartate aminotransferase (AST) \> ULN.
62611868|NCT01273155|EXPERIMENTAL|Moderate Dysfunction-Belinostat 500 mg/m(2)|Moderate Liver Dysfunction was defined as bilirubin \>1.5 to ≤ 3 x ULN and any aspartate aminotransferase (AST).
62611869|NCT01273155|EXPERIMENTAL|Moderate Dysfunction-Belinostat 750 mg/m(2)|Moderate Liver Dysfunction was defined as bilirubin \>1.5 to ≤ 3 x ULN and any aspartate aminotransferase (AST).
62611870|NCT01273155|EXPERIMENTAL|Severe Dysfunction-Belinostat 250 mg/m(2)|Severe Liver Dysfunction was defined as bilirubin \>3 but ≤ 10 x ULN and any aspartate aminotransferase (AST).
62835477|NCT03630315|EXPERIMENTAL|Cohort 1 (Low Dose)|Subjects will receive a low dose of OTX-TKI
62835478|NCT03630315|EXPERIMENTAL|Cohort 2 (Middle Dose)|Subjects will receive a middle dose of OTX-TKI.
62835479|NCT03630315|EXPERIMENTAL|Cohort 3 (High Dose)|Subjects will receive a high dose of OTX-TKI.
62835480|NCT03630315|EXPERIMENTAL|Cohort 3 (Anti-VEGF)|Subjects will receive OTX-TKI plus a single anti-VEGF injection
62835481|NCT03630315|EXPERIMENTAL|Cohort 4 (High Dose)|Subjects will receive a high dose of OTX-TKI.
62835482|NCT03630315|EXPERIMENTAL|Cohort 4 (Anti-VEGF)|Subjects will receive OTX-TKI plus a single anti-VEGF injection
62052541|NCT03446014||Control Group for Fitbit Sub-Study|Patient will be given Fitbit device, but will have no access to Fitbit website or interface. The coordinator will set up the patient's Fitbit on the office computer and will have access to the fitbit's associated username and password (this will be generated by the coordinator). The patient will be instructed to walk as much as they can each day, and to check the Fitbit wrist band periodically throughout the day to view their walking progress. At the end of the three month intervention, the patient will complete questionnaires and undergo a repeat 6 minute walk test.
62052542|NCT03446014||Intervention Group for Fitbit Sub-Study|Patient will be given the Fitbit device and instructed on how to use it. They will be given their username and password to the Fitbit device, and instructed on how to interact with other patients in the study as well as the coordinator on the Fitbit website. The coordinator will also show the patient how to install the application on a smart phone device and use the device via smartphone. The patient will then be instructed to walk as far as they can each day for a period of 12 weeks. Patients will check their steps daily and interact with other patients who participate in the study. Patients will return for a 3 month follow-up appointment where they will undergo a redo 6 minute walk test and questionnaires.
62052543|NCT03656601||Vaginal delivery|Women that had only vaginal delivery
62253630|NCT02535715|EXPERIMENTAL|ORAMED ORMD-0801 capsules- 3x8mg 1st, 1x16mg 2nd, 2x8mg 3rd|Three 8mg ORAMED capsules containing insulin then 1X16mg ORAMED capsules containing insulin, second study then 2X8mg ORAMED capsules containing insulin, third study
62611871|NCT01273155|EXPERIMENTAL|Severe Dysfunction-Belinostat 350 mg/m(2)|Severe Liver Dysfunction was defined as bilirubin \>3 but ≤ 10 x ULN and any aspartate aminotransferase (AST).
62611872|NCT03835065|ACTIVE_COMPARATOR|Long Arm Fiberglass Cast|Conscious sedation will be provided to patient while the reduction is performed by a cast trained orthopedic resident using standard techniques under fluoroscopic guidance. The arm will be held by an assistant or finger traps in the absence thereof. The arm will not be suspended until after the manipulation is performed. A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be extended to the shoulder joint if the patient is assigned to the long arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
62623595|NCT05447455|ACTIVE_COMPARATOR|LAWI group|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
62835483|NCT02874872|EXPERIMENTAL|OASIS Collaborative|The nursing homes in this arm will receive facilitated implementation of two tools aimed at minimizing unnecessary antibiotic use. Facilitated implementation includes coaching of the nursing home staff on use of the tools. In addition, nursing home management will be coached on how to monitor implementation fidelity, antibiotic utilization, and consequences to over- and under-utilization of antibiotics as feedback on the effectiveness of the intervention. Finally, nursing home management will receive coaching on how to develop and implement a sustain plan for the OASIS intervention.
62835484|NCT02874872|NO_INTERVENTION|Control|The nursing homes in this arm will continue care as usual, with no tools or facilitated implementation.
62835485|NCT06030024|EXPERIMENTAL|Active rTMS|Participants in this one and only arm in the current study received active repetitive transcranial magnetic stimulation.
62835486|NCT01501565|NO_INTERVENTION|Control|Standard analgesic therapy: iv Metamizol 2 g q8h
62052544|NCT03656601||Cesarean-section|Women that had only cesarean-section
62253631|NCT02535715|EXPERIMENTAL|ORAMED ORMD-0801 capsules-1x16mg 1st, 2x8mg 2nd, 3x8mg 3rd|One 16mg ORAMED capsule containing insulin then 2X8mg ORAMED capsule containing insulin, second study then 3X8mg ORAMED capsule containing insulin, third study
62253632|NCT05659784|EXPERIMENTAL|Telerehabilitation|
62611873|NCT03835065|EXPERIMENTAL|Short Arm Fiberglass Cast|Conscious sedation will be provided to patient while the reduction is performed by a cast trained orthopedic resident using standard techniques under fluoroscopic guidance. The arm will be held by an assistant or finger traps in the absence thereof. The arm will not be suspended until after the manipulation is performed. A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be complete at this point if the patient is assigned to the short arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
62253633|NCT00749476|EXPERIMENTAL|1|
62253634|NCT01655420||LASIK|Individuals aged 21 to 84 years planning to undergo refractive surgery using LASIK for myopia, hyperopia, or astigmatism
62442619|NCT04261257|EXPERIMENTAL|Cardiac scanner|"As part of the usual care of patients hospitalized for stroke, the following examinations are carried out: a serum pregnancy test for women of childbearing age, a trans-thoracic cardiac ultrasound, a transesophageal cardiac ultrasound according to the needs of your care, an echo-doppler of the supraaortic trunks, a CT angiography of the supraaortic trunks (CT scan of the cerebral arteries), a transcranial Doppler, a biological assessment, a 24-hour holter or long-term holter.~Within 24 hours after admission: The cerebral artery scan, (usual care), is carried out and is supplemented by the additional examination of this research corresponding to a cardiac scanner (not requiring additional injection of contrast medium).~The following examinations of usual care are carried out within 3 days of inclusion: a trans-thoracic cardiac ultrasound, and a transesophageal cardiac ultrasound according to the needs of patient's care."
62442620|NCT06463964||Group I|( Patients with worsening ADHF)
62442621|NCT06463964||Group II|(Patients with new (de novo ) ADHF)
62442622|NCT01273103|EXPERIMENTAL|Treatment|\[14C\]- GSK2248761 200 mg
62442623|NCT03349333|EXPERIMENTAL|pralatrexate|Vitamin B12 and folic acid will be taken concurrently with pralatrexate
62442624|NCT05186610||FDG PET/CT guided metabolic core needle biopsy group|2- Fluorodeoxyglucose (FDG) PET-positive lesions at initial presentation or at the end of treatment were considered for PET/CT guided biopsy after discussion with the hemato oncologist.
62442625|NCT03309800|EXPERIMENTAL|Experimental|HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
62052545|NCT03656601||Nulliparous|Women without delivery
62253635|NCT01372150|EXPERIMENTAL|DVS SR|
62253636|NCT01372150|OTHER|Fluoxetine|Active control for assay sensitivity
62442626|NCT03309800|PLACEBO_COMPARATOR|Placebo comparator|HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
62253637|NCT01372150|EXPERIMENTAL|Placebo|
62253638|NCT00943774||All subjects|All subject participants
62253639|NCT06226311||Children of IoMum pregnants cohort|IoMum participants without congenital malformations or gestational diabetes, with a singleton pregnancy with live birth, who provided contact and a T1 urine sample, will be invited to participate under signed informed consent.
62253640|NCT01943513|EXPERIMENTAL|BIIB023|Participants receive intravenous (IV) infusions of BIIB023
62253641|NCT01943513|PLACEBO_COMPARATOR|Placebo|Participants receive intravenous (IV) infusions of placebo
62253642|NCT01750320|EXPERIMENTAL|Koning Breast CT - guided Biopsy|
62253643|NCT05163184||Laparotomy|Patients undergoing laparotomy
62253644|NCT04937244|EXPERIMENTAL|Patients with new or recurrent malignant gliomas|
62253645|NCT05901493|EXPERIMENTAL|Blocked Evening Only Training|One hour training in the evening, followed by a one hour training 24 hours later
62253646|NCT05901493|EXPERIMENTAL|Distributed Evening Training|One hour training in the evening, followed by a two 30 min trainings 12 and 24 hours later
62253647|NCT05901493|EXPERIMENTAL|Blocked Evening-Morning Training|One hour training in the evening, followed by a one hour training 12 hours later
62253648|NCT05901493|EXPERIMENTAL|Blocked Morning Only Training|One hour training in the morning, followed by a one hour training 24 hours later
62442627|NCT04288596||Eligible for Registry|All consecutive patients who undergo any of the five ACHDi interventions (complex catheterization, ASD closure, PFO closure, CoA stenting, and PPVI) at the time of Registry launch, who have also consented to participate.
62442628|NCT03028272|ACTIVE_COMPARATOR|Fascia|Autologous donor substrate
62442629|NCT03028272|EXPERIMENTAL|Skye Barrier|Amniotic membrane allograft
62253649|NCT05901493|EXPERIMENTAL|Distributed Morning Training|One hour training in the morning, followed by a two 30 min trainings 12 and 24 hours later
62253650|NCT05901493|EXPERIMENTAL|Blocked Morning-Evening Training|One hour training in the morning, followed by a one hour training 12 hours later
62253651|NCT05161091|EXPERIMENTAL|Radio-induced oral mucositis / Medical Device|Patient with radio-induced oral mucositis at least grade 2 treated with experimental medical device
62253652|NCT05161091|PLACEBO_COMPARATOR|Radio-induced oral mucositis / Placebo comparator|Patient with radio-induced oral mucositis at least grade 2 treated with placebo
62253653|NCT05161091|EXPERIMENTAL|Chemo-induced oral mucositis / Medical Device|Patient with chemo-induced oral mucositis at least grade 2 treated with experimental medical device
62253654|NCT05161091|PLACEBO_COMPARATOR|Chemo-induced oral mucositis / placebo comparator|Patient with chemo-induced oral mucositis at least grade 2 treated with placebo
62253655|NCT00419146|EXPERIMENTAL|Ethyl EPA (active) and Vitamins E + C (active)|
62253656|NCT00419146|EXPERIMENTAL|Ethyl EPA (active) and Vitamins E+C (placebo)|
62253657|NCT00419146|EXPERIMENTAL|Ethyl EPA (placebo) and Vitamins E+C (active)|
62253658|NCT00419146|PLACEBO_COMPARATOR|Ethyl EPA (placebo) and Vitamins E+C (placebo)|
62253659|NCT02594969|ACTIVE_COMPARATOR|Healthy Group|These subjects do not have atopic dermatitis and are considered healthy. They will participate in the bleach bath and the moisturizer application.
62253660|NCT02594969|EXPERIMENTAL|Atopic Dermatitis Group|These subjects have atopic dermatitis and are considered healthy. They will participate in the bleach bath and the moisturizer application.
62253661|NCT01161355|EXPERIMENTAL|AZD9668|Tablets and intravenous (IV) dose
62253662|NCT01245387||Macugen|
62253663|NCT01345747|EXPERIMENTAL|laryngeal tube|laryngeal tube suction has suction port
62253664|NCT01345747|EXPERIMENTAL|endotracheal tube|
62253665|NCT01599299||Ultrasound, internal jugular vein|All patients who will need a central venous access (into the right jugular vein) preoperative are included.
62253666|NCT05799079|EXPERIMENTAL|Treatment (Venetoclax, DEC-C)|Patients receive venetoclax PO daily for 28 days in a 28-day cycle. Patients receive DEC-C PO daily on days 1-5 of a 28-day cycle. Patients undergo bone marrow biopsy and aspiration and blood sample collection throughout the study.
62442630|NCT04158856|EXPERIMENTAL|Experimental Arm|adjuvant Pyrotinib plus Trastuzumab
62253667|NCT04234672|EXPERIMENTAL|TAK-831 500 mg + [14C]TAK-831 50 μg + [14C]TAK-831 500 mg|TAK-831 500 mg, tablet, orally, once on Day 1, followed by \[14C\]TAK-831 50 micrograms (μg) \[approximately 1 microcurie (μCi)\], infusion, intravenously (IV), once on Day 1 of Treatment Period 1, followed by a washout period of 8 days, further followed by \[14C\]TAK-831 500 mg (approximately 100 μCi), suspension, orally, once under fasted state on Day 1 of Treatment Period 2.
62253668|NCT06151912|EXPERIMENTAL|Fibrin Glue Group|Sleeve gastrectomy will be performed on morbidly obese patients, starting 3 cm cranial to the pylorus, under the guidance of a 36 F bougie. Then, Fibrin Glue (TisseelTM-Baxter, USA) will be applied to the staple line.
62442631|NCT02419313|ACTIVE_COMPARATOR|Placebo, then Xeomin|Subjects randomized to receive the placebo ( saline) will receive an equivalent volume as the active study drug (1cc). The injections will be into -10 hand and forearm muscles. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. The subject will then cross over to an Active Intervention arm to receive incobotulinumtoxinA which will be injected in the same pattern as the saline.
62611874|NCT03994484|EXPERIMENTAL|HA121-28 tables|Participants will receive oral HA121-28 at a starting dose of 25 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
62253669|NCT06151912|ACTIVE_COMPARATOR|Suture Group|Sleeve gastrectomy will be performed on morbidly obese patients, starting 3 cm cranial to the pylorus, under the guidance of a 36 F bougie. Then, the stapler line will be sutured with continuous sutures with 3/0 prolene suture, with the stapler line inverted.
62253670|NCT05767554|EXPERIMENTAL|Brief modified behavioral activation|Participants randomized to the behavioral activation condition will meet with a graduate level clinician for one hour.
62611875|NCT01069237||OPTI-FREE Replenish|Multi-Purpose Solution for soft contact lenses
62835487|NCT01501565|EXPERIMENTAL|TAP|"Transverse abdominal plain (TAP) blockade with local anesthetic: Bupivacaine chlorhydrate 0.25% adjusted by weight and type of surgery. Maximum dose: 150 mg of bupivacaine.~Two approaches are done: 1)Posterior TAP: the needle insertion point is cephalad to the iliac crest, behind the midaxillary line. The needle is inserted under ultrasound guidance in plane. Local anesthetics is deposited between the internal oblique and transversus abdominis muscles, 2)Subcostal TAP: the needle is inserted ultrasound guided perpendicularly to abdominal wall, directed parallel to the costal margin but oblique to the sagittal plane. Local anesthestic is deposited between transversus abdominis and the rectus abdominis muscles."
62253671|NCT05767554|NO_INTERVENTION|Measurement-only control|Participants who are not randomized to the active condition will take part in a measurement-only control condition. They will participate in all portions of the study except for the in-person behavioral activation session. They will complete a baseline and fill out daily surveys.
62253672|NCT02475226||Patients with body and head trauma|type of the brain injury in patients with brain damage associated both general body and head trauma
62253673|NCT02475226||Patients with pure head trauma|type of the brain injury in patients with brain damage associated pure head trauma
62253674|NCT02475226||Patients with spontaneous hemorrhage|type of the brain injury in Patients with brain damage associated spontaneous hemorrhage
62253675|NCT00616915|OTHER|1|Wellbutrin SR switched to Wellbutrin XL
62253676|NCT05604495||Adult patients with bronchiectasis (unknown cause)|Diagnosis of bronchiectasis was performed using chest HRCT scans in suspected patients with coughing and expectoration, or long durations of hemoptysis. High-resolution images were obtained during full inspiration at 1-mm collimation and 10-mm intervals from the apex to the base of the lungs. The presence of bronchiectasis was confirmed based on the following criteria: 1) lack of tapering in the bronchi; 2) dilation of the bronchi where the internal diameter was larger than that of the adjacent pulmonary artery; or 3) visualization of the peripheral bronchi within 1 cm of the costal pleural surface or the adjacent mediastinal pleural surface.
62253677|NCT03067571|EXPERIMENTAL|Treatment (daratumumab)|Patients receive daratumumab IV over 3.25-6.5 hours on days 1, 8, 15 and 22 of cycles 1-2, on days 1 and 15 of cycles 3-6, and on day 1 of subsequent cycles. Cycles repeat every 28 days.
62442632|NCT02419313|ACTIVE_COMPARATOR|Xeomin, then Placebo|Subjects will all receive injections with incobotulinumtoxinA injections, 100unit/cc into 6-10 muscles of the forearm. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. These subjects will then cross over and receive placebo ( saline) in the same distribution as their second treatment.
62442633|NCT04275687|EXPERIMENTAL|thoracic irradiation|"For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions.~For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4\~7 daily fractions as a boost. Concurrent chemotherapy consists of weekly docetaxel and nedaplatin."
62611876|NCT01069237||Clear Care|Lens Care Solution for contact lenses
62835488|NCT03527459|ACTIVE_COMPARATOR|SPARC A|SPARC A is an existing clinical program which has a general focus on negative cognitions.
62253678|NCT06322836|OTHER|intervention arm|there is only one intervention arm
62253679|NCT04458662||Eumenorrheic women|"The project consisted on two sections carrying out at the same time: Iron physiology (Study I) and Muscle damage (Study II).~For the study I, the exercise protocol consisted on an interval running test. 5 min warm-up at 60% of the vVO2peak followed by 8 bouts of 3 min at 85% of the vVO2peak with 90 secs recovery at 30% of the vVO2peak between bouts. Finally, a 5 min cool down was performed at 30% of the vVO2peak.~The study II protocol was based on an eccentric-based resistance exercise protocol consisted on 10 sets of 10 reps of plate-loaded parallel back squats at 60% of their previously calculated 1RM with 2 mins recoveries between sets.~In both studies, eumenorrheic participants were evaluated at three specific moments of the menstrual cycle: Early-follicular phase (EFP), late-follicular phase (LFP) and mid-luteal phase (MLP);"
62253680|NCT04458662||Oral contraceptive users|"The project consisted on two sections carrying out at the same time: Iron physiology (Study I) and Muscle damage (Study II).~For the study I, the exercise protocol consisted on an interval running test. 5 min warm-up at 60% of the vVO2peak followed by 8 bouts of 3 min at 85% of the vVO2peak with 90 secs recovery at 30% of the vVO2peak between bouts. Finally, a 5 min cool down was performed at 30% of the vVO2peak.~The study II protocol was based on an eccentric-based resistance exercise protocol consisted on 10 sets of 10 reps of plate-loaded parallel back squats at 60% of their previously calculated 1RM with 2 mins recoveries between sets.~Oral contraceptive users performed the trial at two moments: Withdrawal phase (WP) and active pill phase (APP)."
62611877|NCT05390463||PERFoRM|Patients with surgically treated peri-articular fractures of the upper extremity (proximal humerus and distal radius fractures) undergoing treatment within the MDTU (Multi Disciplinary Trauma Unit) of the Zuyderland MC in Heerlen are included in this study.
62611878|NCT05105399|NO_INTERVENTION|Morphine|
62835489|NCT03527459|EXPERIMENTAL|SPARC B|SPARC B includes all aspects of the SPARC A clinical program, but targets negative cognitions of perceived burdensomeness in some sessions.
62835490|NCT02922647|EXPERIMENTAL|suprapubic catheterization|Intervention:suprapubic catheterization after rectal resection with low anastomosis. Evaluate the urinary tract infection rate on the four days postoperative.
62052546|NCT03533426|ACTIVE_COMPARATOR|Pump based patient controlled analgesia|"Analgesia is maintained using disposable silicon ballon pump Accufuser containing morphine 0.2 mg/ml, 8mg ondansetron plus and 180 mg ketorolac. The infusion rate is 5 ml / h and lockout interval of 15min. the hourly delivered morphine dose is 1-1.8 mg \& the pump is sufficient for about 60 hours according to patient response."
62611879|NCT05105399|ACTIVE_COMPARATOR|Continuous|
62253681|NCT04458662||Postmenopausal women|"he project consisted on two sections carrying out at the same time: Iron physiology (Study I) and Muscle damage (Study II).~For the study I, the exercise protocol consisted on an interval running test. 5 min warm-up at 60% of the vVO2peak followed by 8 bouts of 3 min at 85% of the vVO2peak with 90 secs recovery at 30% of the vVO2peak between bouts. Finally, a 5 min cool down was performed at 30% of the vVO2peak.~The study II protocol was based on an eccentric-based resistance exercise protocol consisted on 10 sets of 10 reps of plate-loaded parallel back squats at 60% of their previously calculated 1RM with 2 mins recoveries between sets.~Postmenopausal women were tested only once, since their hormonal status does not fluctuate."
62052547|NCT03533426|ACTIVE_COMPARATOR|serratus anterior plane catheter block|"Linear ultrasound transducer (superficial) 6-12 MHz is utilized to count the ribs up to 4th or 5 th rib in the mid-axillary line. Musculature of thoracic wall is identified sonographically,an echogenic needle 14-16 G, 100 mm is inserted in plane with the U/S probe towards the plane deep to the serratus anterior muscle. Under real - time U/S, single shot of 20ml contrast medium iohexol = omnipaque 150 mg I2 / ml is injected to check the plane and level (T3-T8/9) of SAPB.A reinforced radiopaque catheter is threaded through the needle and its final position underneath the plane of serratus anterior muscle is confirmed fluoroscopically. 20ml 0.25% levobupivacaine (Chirocaine).Analgesia is maintained using 0.125% levobupivacaine infusion at a rate of 7-12 ml/h according to patient response."
62052548|NCT05772975|EXPERIMENTAL|E-PRF|After the impacted mandibular third molar has been surgically removed E-PRF is placed in the dentoalveolar defect and the wound is primarily closed.
62052549|NCT05772975|EXPERIMENTAL|H-PRF|After the impacted mandibular third molar has been surgically removed H-PRF is placed in the dentoalveolar defect PRF made with horizontal centrifuge and the wound is primarily closed.
62052550|NCT05772975|NO_INTERVENTION|CONTROL|After the impacted mandibular third molar has been surgically removed, the wound is primarily closed.
62052551|NCT04984707|EXPERIMENTAL|Experimental Group -KX0826|KX0826 is tropically applied to the scalp of healthy male subjects with Androgenetic Alopecia with a single dose.The applied dosage cohorts are 3mg, 12mg, 48mg and 96mg.
62253682|NCT05484479|EXPERIMENTAL|Exercised group|For 6 months, MeTS elderly (25 elderly) with chronic periodontal disease will be trained using sixty-minute Baduanjin training/exercise (5 times weekly)
62253683|NCT05484479|NO_INTERVENTION|control group|For 6 months, MeTS elderly (25 elderly) with chronic periodontal disease will receive no training
62253684|NCT04498208|EXPERIMENTAL|Personalized prehabilitation|Patients will participate in a personalized health optimization program combining one-on-one coaching, tailored to each patient's physical, nutritional, well-being and cognitive status baseline. Prehabilitation will last from a minimum of 14 days to a maximum of 42 days before surgery
62442634|NCT02214927|EXPERIMENTAL|BI 11634 single rising dose|tablet
62442635|NCT02214927|EXPERIMENTAL|BI 11634 cross-over|sequence: 1. tablet 2. drinking solution
62611880|NCT05105399|ACTIVE_COMPARATOR|Single|
62052552|NCT04984707|PLACEBO_COMPARATOR|Control Group- Placebo|Placebo is tropically applied to the scalp of healthy male subjects with Androgenetic Alopecia with a single dose.
62052553|NCT05635578|EXPERIMENTAL|Experimental:|reiki will be aplicated
62052554|NCT05635578|NO_INTERVENTION|Control|Routine maintenance will be applied.
62052555|NCT02598986|PLACEBO_COMPARATOR|white pita bread|Pita bread made of white wheat flour
62052556|NCT02598986|NO_INTERVENTION|Whole grain pita bread|no macronutrient supplementation
62253685|NCT04498208|NO_INTERVENTION|Standard prehabilitation|Patients in the control group will be provided with standard instructions in a hard-copy form specific to prehabilitation before surgery associating physical, nutritional, stress-reduction and cognitive recommendations without any personalized coaching for at least 14 days prior to surgery.
62442636|NCT01393990|EXPERIMENTAL|LY2228820|"The study had 4 parts, dose-escalation (Part A), 2 dose-confirmation (Parts B and C), and a tumor-specific expansion for metastatic breast cancer (Part D).~Part A: Participants received escalating doses of 10, 20, 40, 65, 90, 120, 160, 200, 300, 420 and 560 milligrams (mg) of LY2228820 every 12 hours on Days 1 through 14 of a 28-day cycle.~Part B: Participants received 420 mg of LY2228820 every 12 hours Days 1 through 14 of a 28-day cycle. Participants received midazolam orally 2 days before the first dose and again after the morning dose of study drug on Day 8 during the first cycle of treatment.~Part C: Participants received 300 mg of LY2228820 every 12 hours Days 1 through 14 of a 28-day cycle.~Part D: Participants received 200 mg and 300 mg of LY2228820 in combination with tamoxifen."
62442637|NCT04669821|EXPERIMENTAL|HSK3486|
62442638|NCT04669821|ACTIVE_COMPARATOR|Propofol|
62442639|NCT03500770|EXPERIMENTAL|Transcranial Direct Current Stimulator|The Transcranial Direct Current Stimulator device (tDCS) is a safe technique which poses a non-significant risk to study subjects. This technique uses weak current which is applied by using two electrodes. In the literature, no undesirable or long-lasting side effects due to device have been reported, nor have any participants reportedly abandoned a study due to discomfort.
62442640|NCT01623661|OTHER|hypertonic saline|hypertonic saline 3.0% (7 ml/kg)
62442641|NCT04297683|EXPERIMENTAL|Regimen A - Zilucoplan|Participants are randomized to receive either active zilucoplan or matching placebo.
62442642|NCT04297683|EXPERIMENTAL|Regimen B - Verdiperstat|Participants are randomized to receive either active verdiperstat or matching placebo.
62611881|NCT04289090|EXPERIMENTAL|Group A|Group A will begin anesthesia maintenance with sevoflurane-only, then will be switched after 30 minutes to anesthesia with propofol-only.
62611882|NCT04289090|EXPERIMENTAL|Group B|Group B will begin anesthesia with propofol-only then will be switched to sevoflurane-only.
62611883|NCT04730115||Group 1. The treatment group (T)|The treatment group comprised of 30 cases treated with functional appliance for one year in puberty.
62611884|NCT04730115||Group 2. The control group (C)|The control group consists of 12 patients who had insufficient oral hygiene; didn't take any orthodontic treatment for one year.
62611885|NCT06365268||Patients|Mother-child whose care course for the child's congenital axial tumor included treatment at the AP-HP between 2010 and 2021. Fetus presenting a malignant or benign solid tumor of thoracic, abdominal or pelvic location and whose clinico-radiological or histological diagnosis is confirmed postnatally up to 1 year of life with the onset of symptoms in the first three months of life.
62253686|NCT03880032|EXPERIMENTAL|Cognitive Behavioral Therapy Intervention for Anxiety|Pregnant women experiencing anxiety randomized to the Happy Mother Healthy Baby (HMHB) intervention receive a CBT-based psychosocial intervention (with six core and up to six booster sessions). HMHB is a facility-based intervention delivered by non-specialist providers. It is aimed to raise psychosocial awareness and facilitate positive change inter personal wellbeing, social support, and bonding with their baby during pregnancy. It addresses with relapse prevention, planning for the baby's arrival, and in management of emotional challenges in the early postnatal period. Family member/s will be invited to attend 3 core sessions.
62253687|NCT03880032|NO_INTERVENTION|Enhanced Usual Care|Women randomized to the control group will receive enhanced usual care (EUC). The World Health Organization (WHO) recommends 8 antenatal visits for a positive pregnancy experience, the number of visits our EUC control group participants will receive (depending on their gestational week). Usual care will also be enhanced by hospital staff receiving additional training in mental health treatment and counseling. Reminder calls were given, provider visits were facilitated (shorter wait times), and transportation to assist participants in attending appointments and medically indicated ultrasounds were paid for (as in the intervention group).
62253688|NCT00844155|ACTIVE_COMPARATOR|A.Oseltamivir 75 mg dose|Patients will be randomized to two groups (group A) to receive oseltamivir at 75 mg, or (group B) to receive the drug at 150 mg in the fasting or fed state.
62253689|NCT00844155|ACTIVE_COMPARATOR|B. Oseltamivir 150mg|Patients will be randomized to groups (group A) to receive oseltamivir at 75 mg, or group B to receive the drug at 150 mg in the fasting or fed state.
62253690|NCT06181942||single-port urological surgeries with the SP single-port robot|who have received or plan to receive radical prostatectomy (RP), partial nephrectomy (PN), radical nephrectomy (RN), radical resection of the renal pelvic carcinoma (one position), pyeloplasty and other single-port urological surgeries with the SP single-port robot.
62253691|NCT02512809|EXPERIMENTAL|Isoflurane Arm|Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with isoflurane.
62253692|NCT02512809|EXPERIMENTAL|Dexmedetomidine/remifentanil Arm|Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with dexmedetomidine and remifentanil infusions..
62253693|NCT02512809|NO_INTERVENTION|MRI Control Arm|Otherwise healthy pediatric patients, aged 0-5 years, undergoing MRI with general anesthesia for evaluation of non-neurologic disease. Patients will receive a standardized general anesthetic with isoflurane.
62253694|NCT01391403|EXPERIMENTAL|Artemisinin, anti-toxoplasma|Artemisinin
62835491|NCT02922647|ACTIVE_COMPARATOR|transurethral catheterization|Intervention:transurethral catheterization after rectal resection with low anastomosis. Evaluate the urinary tract infection rate on the four days postoperative.
62835492|NCT05264922|ACTIVE_COMPARATOR|Fibrin Glue|Single 4 milliliter (mL) injection of 0.9% normal saline and fibrin glue solution
62835493|NCT05264922|EXPERIMENTAL|SVF cells and Fibrin Glue|Nucleated adipose-derived cells loaded in a fibrin glue scaffold
62052557|NCT02598986|EXPERIMENTAL|Restored white pita bread|macronutrient supplementation
62835494|NCT03146416|EXPERIMENTAL|Cohort 1|Evinacumab SC or placebo SC
62835495|NCT03146416|EXPERIMENTAL|Cohort 2|Low dose regimen: evinacumab IV or placebo IV
62052558|NCT02598986|EXPERIMENTAL|Fortified white pita bread|macronutrient supplementation 2
62052559|NCT03310073|EXPERIMENTAL|bOPV (bivalent OPV Bio Farma)|"bOPV one dose corresponds to 2 drops (0.1ml). The vaccine shall be given orally.~The subject received bOPV, Pentabio and IPV according to the study schedule."
62052560|NCT05852132|EXPERIMENTAL|PPV+PRP|PPV was performed for severe non-proliferative diabetic retinopathy with PRP.
62253695|NCT01391403|PLACEBO_COMPARATOR|Placebo|Placebo looks like the active drug, with the same dose.
62253696|NCT00747643|ACTIVE_COMPARATOR|Varenicline|For participants in the varenicline group, the medication doses followed the recommended dose schedule for the first 15 days of treatment: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day on days 8-15.
62253697|NCT00747643|PLACEBO_COMPARATOR|Placebo|Participants in this group received a placebo instead of medication. The placebo was taken once a day on days 1-3, twice a day on days 4-15.
62253698|NCT05097521||Veterans using practitioner delivered CIH therapies only|Veterans using practitioner-delivered (acupuncture, chiropractic care, massage) CIH therapies only
62442643|NCT04297683|EXPERIMENTAL|Regimen C - CNM-Au8|Participants are randomized to receive either active CNM-Au8 or matching placebo.
62835496|NCT03146416|EXPERIMENTAL|Cohort 3|High dose regimen: evinacumab IV or placebo IV
62835497|NCT03146416|EXPERIMENTAL|Cohort 4|Evinacumab or placebo SC every week (QW) x 8 doses
62835498|NCT03146416|EXPERIMENTAL|Cohort 5|Evinacumab or placebo SC x 1 dose
62835499|NCT04204889|EXPERIMENTAL|Oxaloacetate|3+3 dose escalating trial starting with 500mg twice daily orally and ending with 2500mg twice daily.
62835500|NCT05945342|ACTIVE_COMPARATOR|Simple Medication|Escitalopram alone treatment
62835501|NCT05945342|ACTIVE_COMPARATOR|Simple Psychotherapy|Simple interpersonal psychotherapy group
62835502|NCT05945342|EXPERIMENTAL|Medication combined with psychotherapy|Medication combined with interpersonal psychotherapy
62835503|NCT05945342|EXPERIMENTAL|Medication combined with physical therapy group|Medication combined with robotic navigational repetitive transcranial magnetic stimulation
62835504|NCT05945342|SHAM_COMPARATOR|Medication combined with sham physical therapy group|Medication combined with sham robotic navigational repetitive transcranial magnetic stimulation
62835505|NCT01291732|EXPERIMENTAL|BI 135585 XX|single dose of BI 135585
62835506|NCT01291732|PLACEBO_COMPARATOR|matching placebo|single dose of matching placebo
62253699|NCT05097521||Veterans using self-care CIH therapies only|Veterans using self-care (yoga, meditation, Tai Chi, Qi Gong) CIH therapies only
62253700|NCT05097521||Veterans using a combination of practitioner-delivered and self-care CIH therapies (dual-care)|Veterans using a combination of practitioner-delivered and self-care CIH therapies (dual-care)
62253701|NCT01678989||Patient group|Children with BD, (20 children) 12-18 year-old who agreed to participate in the study will be established.
62835507|NCT04664699|OTHER|Plethysmographic Variability Index group|32 patients who presented to emergency department HUSM diagnosed with severe traumatic brain injury who were randomly assigned to the PVI group
62835508|NCT04664699|OTHER|Standard monitoring group|32 patients who presented to emergency department HUSM diagnosed with severe traumatic brain injury who were randomly assigned to the standard monitoring group
62835509|NCT03478709||Volume expansion|
62835510|NCT03478709||norepinephrine|
62052561|NCT05852132|ACTIVE_COMPARATOR|Pars plana vitrectomy(PPV)|Vitrectomy was performed for severe non-proliferative diabetic retinopathy, but panretinal photocoagulation(PRP) was not performed
62835511|NCT03309735||1|Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
62052562|NCT05852132|PLACEBO_COMPARATOR|Panretinal photocoagulation(PRP)|Only PRP was used for severe non-proliferative diabetic retinopathy.
62253702|NCT01678989||Risk group|Twenty healthy children of 12-18 years old who have mothers and/or fathers who previously assessed by an adult psychiatrist and diagnosed as BD according to DSM-IV diagnostic criteria, and who agreed to participate in the study. The age and gender of the groups will be matched.
62253703|NCT01678989||Healthy control group|Twenty participants between the ages of 12-18 who agree to participate in the study and whose family members do not have BD. The age and the gender of the groups will be matched.
62052563|NCT05521425|EXPERIMENTAL|Intervention Group|"Training + Helping Hands provided for CAPD bag exchange procedures at home"
62442644|NCT04297683|EXPERIMENTAL|Regimen D - Pridopidine|Participants are randomized to receive either active Pridopidine or matching placebo.
62442645|NCT04297683|EXPERIMENTAL|Regimen E - SLS-005 Trehalose|Participants are randomized to receive either active SLS-005 Trehalose or matching placebo.
62835512|NCT03309735||2|Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
62835513|NCT03309735||3|Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
62835514|NCT04672278|EXPERIMENTAL|Group A|
62835515|NCT04672278|EXPERIMENTAL|Group B|
62835516|NCT00583076|EXPERIMENTAL|1|AST-120, 2grams, three times daily
62052564|NCT05521425|NO_INTERVENTION|Control Group|"Training alone (without Helping Hands provided to assist in bag exchange procedures)"
62052565|NCT06356194|EXPERIMENTAL|BEM/RZR vs BEM/RZR + BIK vs BIK|n=14
62052566|NCT06356194|EXPERIMENTAL|BIK vs BEM/RZR + BIK vs BEM/RZR|n=14
62052567|NCT04390984|EXPERIMENTAL|1|Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.
62253704|NCT05374382|EXPERIMENTAL|Strengthening|Participants received a 9-weeks strengthening-based prehabilitation program before ACL reconstruction, followed by a standardized post-operative rehabilitation program
62442646|NCT04297683|EXPERIMENTAL|Regimen F- ABBV-CLS-7262|Participants are randomized to receive either active ABBV-CLS-7262 or matching placebo.
62442647|NCT04297683|EXPERIMENTAL|Regimen G - DNL343|Participants are randomized to receive either active DNL343 or matching placebo.
62442648|NCT06544343|EXPERIMENTAL|Remote Monitoring|
62442649|NCT06544343|PLACEBO_COMPARATOR|On site only|
62442650|NCT04978454|EXPERIMENTAL|Cohort 1A|10\^4 TCID50of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5mL per nostril) (n=1) administered intranasally on Day 1. If 80% or more subjects in Cohort 1A meet the case definition for influenza, proceed to Cohort 1B. If fewer than 80% of subjects meet the case definition for influenza in Cohort 1A, the dose will escalate to include Cohort 2A. N = 13
62835517|NCT05727124|ACTIVE_COMPARATOR|Evaluation of Poul Gjessing spring for orthodontic maxillary canine retraction|20 Orthodontic patient treated by Poul Gjessing spring for canine retraction split mouth.
62835518|NCT05727124|ACTIVE_COMPARATOR|Evaluation of T loop for orthodontic maxillary canine retraction|20 Orthodontic patient treated by T loop for canine retraction split mouth
62052568|NCT06579170||Recreational water users|Recreational water users of any age and their pet dogs present at the beaches and waterfronts in this study during recruitment days.
62253705|NCT05374382|ACTIVE_COMPARATOR|Conventional|Participants received a 9-weeks conventional prehabilitation program (targeting pain knee mobility) before ACL reconstruction, followed by a standardized post-operative rehabilitation program
62442651|NCT04978454|EXPERIMENTAL|Cohort 1B|10\^4 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If 80% or more subjects in Cohort 1A and 1B meet the case definition for influenza, proceed to Cohort 1C. Cumulatively, if fewer than 80% of subjects in Cohorts 1A and 1B meet the case definition for influenza, the dose will escalate to include Cohort 2A. N = 13
62835519|NCT04000633|ACTIVE_COMPARATOR|lidocaine group|the patients of this group will recieve nebulization of 5 ml of 2% lidocaine prior to induction of general anesthesia
62253706|NCT05374382|NO_INTERVENTION|Control|No prehabilitation program Participants received only a standardized post-operative rehabilitation program
62253707|NCT04427150|EXPERIMENTAL|Auditory Training Group|12 hours of psychoacoustic training over 8 weeks
62835520|NCT04000633|PLACEBO_COMPARATOR|Placebo group|the patients of this group will recieve nebulization of 5 ml of normal saline prior to induction of general anesthesia
62835521|NCT01725516|EXPERIMENTAL|Myofascial release technique|
62835522|NCT00588107|EXPERIMENTAL|Web site access|Web intervention- and access to pharmacotherapy
62835523|NCT00588107|ACTIVE_COMPARATOR|print materials|Receives tailored print materials and access to pharmacotherapy (Materials condition)
62611886|NCT00465543|PLACEBO_COMPARATOR|II|Arm 2 receives 4 weeks of placebo mint tea (consumed twice a day) followed by 4 weeks of washout and then a further 4 weeks of treatment with study mint tea (consumed twice a day).
62611887|NCT00465543|PLACEBO_COMPARATOR|I|Arm 1 receives 4 weeks of treatment with mint tea high in rosmarinic acid, consumed twice a day. Treatment is followed by a 4 week wash-out phase. Subjects then enter a 4 week phase of placebo mint tea (low in rosmarinic acid), to be consumed twice a day.
62611888|NCT03402347|EXPERIMENTAL|Laser irradiation regimes|Non-ionising radiation intervention will be applied to skin explants
62611889|NCT00568334|EXPERIMENTAL|VARILRIX HSA-FREE GROUP|Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine produced without human serum albumin (HSA-Free), administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).
62611890|NCT00568334|EXPERIMENTAL|VARILRIX GROUP|Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine, administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).
62611891|NCT05079321|EXPERIMENTAL|Coated Scleral Lens|Participants wear a lens coated with Hydra-PEG.
62611892|NCT05079321|PLACEBO_COMPARATOR|Uncoated Scleral Lens|Participants wear an uncoated (control) lens.
62835524|NCT04970225|EXPERIMENTAL|Stable state|"45 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France:~* With severe cftr mutations~* With or without PA chronic infection~* Treated or not with Ivacaftor-Lumacaftor"
62253708|NCT04427150|ACTIVE_COMPARATOR|Other Training Group|12 hours of non-psychoacoustic training over 8 weeks
62253709|NCT04427150|NO_INTERVENTION|TD Group|
62253710|NCT06132165|ACTIVE_COMPARATOR|Kybella Injection|
62442652|NCT04978454|EXPERIMENTAL|Cohort 1C|10\^4 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and sham sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If 80% or more of the subjects in Cohorts 1A, 1B, and 1C combined meet the case definition for influenza then the optimal dose of 104 TCID50 will be selected. Cumulatively, if fewer than 80% of subjects in Cohorts 1A, 1B, and 1C meet the case definition for influenza the dose will escalate to include Cohort 2A. N = 13
62835525|NCT04970225|EXPERIMENTAL|Starting Ivacaftor-Tezacaftor-Elexacaftor|"40 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France:~* With at least one severe cftr mutation~* With or without PA chronic infection~* Initiating Ivacaftor-Tezacaftor-Elexacaftor"
62253711|NCT06132165|ACTIVE_COMPARATOR|Asclera Injection|
62253712|NCT06132165|ACTIVE_COMPARATOR|1064nm laser|
62253713|NCT06132165|ACTIVE_COMPARATOR|755nm laser|
62253714|NCT01978782|ACTIVE_COMPARATOR|raltegravir alone|raltegravir 400 mg BID for 5 days
62253715|NCT01978782|ACTIVE_COMPARATOR|citalopram alone|citalopram 10 mg QD for 3 days, followed by citalopram 20 mg QD for 13-14 days
62253716|NCT01978782|EXPERIMENTAL|raltegravir + citalopram|raltegravir 500 mg BID and citalopram 20 mg QD for 5 days
62253717|NCT03256955|OTHER|Tof Watch SX and Tof Cuff|Patients undergoing surgery with intubation and receiving a single intubation dose of rocuronium (0.6 mg/kg) under propofol anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
62253718|NCT04957550|EXPERIMENTAL|Treatment group A|SHR0302 tablets dose 1+ Placebo dose 2
62253719|NCT04957550|EXPERIMENTAL|Treatment group B|SHR0302 tablets dose 2+ Placebo dose 1
62442653|NCT04978454|EXPERIMENTAL|Cohort 2A|10\^5 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If 70% or more subjects in Cohort 2A meet the case definition for influenza, proceed to Cohort 1B. If fewer than 70% of subjects meet the case definition for influenza in Cohort 2A, the dose will escalate to include Cohort 3A. N = 13
62442654|NCT04978454|EXPERIMENTAL|Cohort 2B|10\^5 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1.If 70% or more subjects in Cohort 2A and 2B meet the case definition for influenza, proceed to Cohort 2C. Cumulatively, if fewer than 70% of subjects in Cohorts 2A and 2B meet the case definition for influenza, the dose will escalate to include Cohort 3A N = 13
62442655|NCT04978454|EXPERIMENTAL|Cohort 2C|10\^5 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If 70% or more of the subjects in Cohorts 2A, 2B, and 2C combined meet the case definition for influenza then the optimal dose of 10\^4 TCID50 will be selected. Cumulatively, if fewer than 70% of subjects in Cohorts 2A, 2B, and 2C meet the case definition for influenza the dose will escalate to include Cohort 3A. N = 13
62253720|NCT04957550|PLACEBO_COMPARATOR|Treatment group C|Placebo dose1 + placebo dose 2
62442656|NCT04978454|EXPERIMENTAL|Cohort 3A|10\^6 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=17) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If no safety threshold is met (halting conditions) proceed to Cohort 3B. N = 18
62611893|NCT05958108|NO_INTERVENTION|Control group|Primary care centers allocated to the Control Group will continue with healthcare as usual. They will receive the intervention at the end of the trial, once all post-intervention data has been collected (waitlist approach). Although audits will be conducted in this group, the centers in this group will not have access to the feedback reports or any other information with the results from the audits.
62623596|NCT03584230|EXPERIMENTAL|Positive Condition|"Students will be assigned to a group that receives positive nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs positive nonverbal behaviors to students in the same t-shirt color and negative nonverbal behaviors to students in another t-shirt color.~Intervention: Assigned to positive group"
62253721|NCT06049381||Patients receive LY007 CD20 CAR-T|
62253722|NCT06049381||Patients receive commerial CD19 CAR-T in China|
62253723|NCT00366821||1|Examine the outcomes following cardiac surgery in those newborns with genetic abnormalities.
62611894|NCT05958108|EXPERIMENTAL|SinergiAPS intervention group|"SinergiAPS is an assessment and monitoring tool designed to support primary healthcare centers to identify potential problems and areas for improvement related to patient safety based on information provided by their own patients. This intervention consists of three main elements:~1. Patient safety audit of healthcare centers: Patient safety is evaluated from the perspective of patients using the validated PREOS-PC questionnaire.~2. Feedback of results to healthcare centers: SinergiAPS automatically generates a report with the audit results. This feedback report is specific to each healthcare center and includes a comparison with other participating centers to facilitate benchmarking.~3. Design of action plans: The centers design patient safety improvement plans based on the problems identified in their center's result report. For this purpose, the SinergiAPS web tool provides resources, training materials, and recommendations on how to improve patient safety in primary care."
62253724|NCT00366821||2|Examine the outcomes following cardiac surgery in newborns without genetic abnormalities.
62253725|NCT06254742|EXPERIMENTAL|Treatment group A|first cycle: Auto-HHPG-19K Injection second cycle: HHPG-19K Injection
62835526|NCT04970225|EXPERIMENTAL|Exacerbation|15 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France and hospitalized for respiratory exacerbation
62835527|NCT02407600|ACTIVE_COMPARATOR|Fosparepitant administered in 1st cycle|Fosaprepitant (Emend) for Injection 150 mg is administered, one time, intravenously on day 1 only, as an infusion with a duration of 30 minutes. It will be initiated approximately 30 minutes prior to the subjects first chemotherapy cycle. An intravenous saline placebo will be administered on day 1 of the second chemotherapy cycle, in the same manor as EMEND for Injection.
62835528|NCT02407600|SHAM_COMPARATOR|Fosaprepitant administered in 2nd cycle|Subject will receive a saline Placebo intravenously on day 1 of their first chemotherapy cycle. For the subject's second chemotherapy cycle, EMEND for Injection 150 mg is administered, one time, intravenously on day 1, as an infusion with a duration of 30 minutes. It will be initiated approximately 30 minutes prior to the subjects second chemotherapy cycle.
62835529|NCT03174730|EXPERIMENTAL|Growth mindset|In addition to SmartQuit (the app), study participants will receive the content in the form on one growth mindset tip (sent in an email) per day starting on the first day of the study. Email exercises will be sent out every 3 days and there are a total of 8 emails.
62835530|NCT03174730|OTHER|Control|Participants will get SmartQuit, but not the growth mindset intervention.
62835531|NCT02094157|ACTIVE_COMPARATOR|Bridged regimen|Bridged regimen Warfarin therapy is stopped for 5 days before surgery and restarted in the evening of surgery at double the usual dose for two days. Bridging with low-molecular-weight heparin at therapeutic dose is given for 2½ days before surgery.
62835532|NCT02094157|EXPERIMENTAL|Tapered warfarin regimen|Tapered warfarin regimen Warfarin is given at half the usual maintenance dose for 3-6 days before surgery depending on the INR at the baseline visit. A double dose is given in the evening of surgery. No bridging with LMWH is used.
62835533|NCT06517420|NO_INTERVENTION|Control Group (No intervention group)|"Patients were asked Individual Information Form, Nightingale Symptom Assessment Scale, FACT-G Quality of Life Scale, WHO Mucositis Evaluation Form, Rhodes Nausea Vomiting Gagging Index, ASCO Diarrhea Assessment Scale and Constipation Assessment Scale (CAS) were filled in.~No treatment was performed on the patients in the control group, and the patients continued their chemotherapy treatment.~After 4 sessions, Nightingale Symptom Assessment Scale, FACT-G Quality of Life Scale, WHO Mucositis Evaluation Form, Rhodes Nausea Vomiting Gagging Index, ASCO Diarrhea Evaluation Scale and Constipation Assessment Scale (CAS) were filled in again."
62835534|NCT06517420|EXPERIMENTAL|Experimental group (intervention group)|"Patients were asked Individual Information Form, Nightingale Symptom Assessment Scale, FACT-G Quality of Life Scale , WHO Mucositis Evaluation Form, Rhodes Nausea Vomiting Gagging Index, ASCO Diarrhea Assessment Scale and Constipation Assessment Scale (CAS) were filled in.~He was informed to consume 250 ml of kefir twice a day, before and after meals, for 1 week after the chemotherapy session, and to gargle in the mouth while consuming kefir, hold it for a while, and then swallow.~At the end of each chemotherapy session and the 4th session, the Nightingale Symptom Assessment Scale, FACT-G Quality of Life Scale, WHO Mucositis Evaluation Form, Rhodes Nausea Vomiting Gagging Index, ASCO Diarrhea Assessment Scale and Constipation Assessment Scale (CAS) were applied by the practitioner. ."
62253726|NCT06254742|EXPERIMENTAL|Treatment group B|first cycle: HHPG-19K Injection second cycle: Auto-HHPG-19K Injection
62253727|NCT01782573|ACTIVE_COMPARATOR|Chlorhexidine gluconate ( CHG )|(i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
62253728|NCT01782573|ACTIVE_COMPARATOR|0.9% Sodium Chloride ( N/S )|(i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
62253729|NCT01891500|EXPERIMENTAL|Early inhaled nitric oxide|Patients randomized to receive iNO at OI 10-15.
62253730|NCT01891500|PLACEBO_COMPARATOR|Bioinert inhaled gas (nitrogen gas)|Patients randomized to bioinert inhaled gas at OI 10-15.
62611895|NCT02195596|EXPERIMENTAL|High intensity aerobic exercise+strength|"The program consist in a Continuous High aerobic exercise and moderate intensity intervals (ShoshanaB et al, 2012) combined with muscular strength exercises and joint mobility. Patients come three times a week for six months to the primary health center. A fitness expert nurse is responsible for monitoring the performance and adapt to the physical condition of the patient.Each exercise session consists of warming up time period, period of work and back to calm. Exercise intensity during the work period increases progressively as the program progresses. Aerobic exercise is performed on a cycle ergometer or treadmill.Muscle strength exercises and joint mobility are performed with dumbbells and ankle weights adapted to each patient."
62611896|NCT02195596|ACTIVE_COMPARATOR|Low intensity aerobic exercise+strength|The control group performed an exercise program similar to intervention but at low intensity that is below 35 or 40% of heart rate reserve (HRR).
62611897|NCT02184910||gastritis and pepsinogen|
62611898|NCT02572856|EXPERIMENTAL|CGM patients|Apply continuous glucose monitor, calibrate and make glucose measurements. Measurements are blinded to the care provider
62835535|NCT06589115|ACTIVE_COMPARATOR|Rehabilitation Protocol|Standard physical therapy will be performed according to the clinic standard with manual lymphatic drainage, cryotherapy, and 20 minutes of physical therapy two times a week for fourteen weeks following the initial post-operative visit.
62253731|NCT01891500|ACTIVE_COMPARATOR|Crossover iNO|Patients who deteriorate (OI \>20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
62611899|NCT06442202|EXPERIMENTAL|Allele A + Diet Intervention|Subjects with allele A carriers (AA/AT) FTO rs9939609 gene type, took a Balanced Nutritional Diet Intervention for 28 days. Besides, this group received nutritional education. Twelve (12) subjects were included in this group.
62611900|NCT06442202|EXPERIMENTAL|T Homozygote + Diet Intervention|Subjects with T homozygote FTO rs9939609 gene type, took a Balanced Nutritional Diet Intervention for 28 days. Besides, this group received nutritional education. Eight (8) subjects were included in this group.
62611901|NCT06442202|PLACEBO_COMPARATOR|Allele A Control|Subjects with allele A carriers (AA/AT) FTO rs9939609 gene type, control group, eat ad libitum. This group also received nutritional education. Ten (10) subjects were included in this group.
62611902|NCT06442202|PLACEBO_COMPARATOR|T Homozygote Control|Subjects with T Homogyzot FTO rs9939609 gene type, control group, eat ad libitum. This group also received nutritional education. Eight (8) subjects were included in this group.
62611903|NCT06731569|ACTIVE_COMPARATOR|Traditional rotary drill (Control Group)|Participants in this arm will undergo Maxillary Sinus Floor Augmentation (MSFA) using the traditional rotary drill. The procedure involves preparing the lateral window with a rose-head bur, ensuring precision and irrigation to minimize trauma. The traditional drill is widely used in clinical practice but requires significant skill to avoid complications like Schneiderian membrane perforation.
62835536|NCT06589115|EXPERIMENTAL|Rehabilitation Protocol and Blood Flow Restriction|In addition to the standard physical therapy, the blood flow restriction group will also begin standard physical therapy care supplemented with blood flow restriction therapy two times a week for 10 weeks after wound healing.
62835537|NCT01807624|EXPERIMENTAL|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
62835538|NCT03040336|EXPERIMENTAL|Prehabilitation|Standard of care + Prehabilitation
62835539|NCT03040336|NO_INTERVENTION|Standard of Care|Standard of Care
62835540|NCT06188143|NO_INTERVENTION|Control group|No medication before hysteroscopic procedure
62052569|NCT05095272|EXPERIMENTAL|Healthy malaria-naive US adults|A single dose of cryopreserved inoculum containing blood-stage P. vivax will be administered IV
62253732|NCT02512406||Patients with Tourette Syndrome|Questionnaires including the Sensory Profile or the Adult/Adolescent Sensory profile and Children's Yale-Brown Obsessive Compulsive Scale or Yale Global Tic Severity Scale will be administered. When time permits, the Children's Yale-Brown Obsessive Compulsive Scale or Yale-Brown Obsessive Compulsive Scale will also be administered. Demographic data will also be collected for each study patient.
62253733|NCT01811745|EXPERIMENTAL|Jaques-Dalcroze eurhythmics training|Once-weekly 60-min Jaques-Dalcroze eurhythmics class, for 12 months.
62835541|NCT06188143|EXPERIMENTAL|Ibuprofen-Paracetamol|Ibuprofen 40mg and Paracetamol 500mg per oral, single dose each, before hysteroscopic procedure 30minutes
62253734|NCT01811745|ACTIVE_COMPARATOR|Multicomponent exercise training|Once-weekly 60-min multicomponent exercise class supplemented by one 30-min home-based exercise session, for 12 months.
62253735|NCT04747834|ACTIVE_COMPARATOR|Cohort 1|Subjects with mild to moderate cataracts (Grade 1 to 2) scheduled to undergo mechanical non-phacoemulsification lens extraction using low-energy segment removal with a micro-interventional irrigation/aspiration port (MICOR-304) to evacuate the lens prior to intraocular lens insertion.
62253736|NCT04747834|ACTIVE_COMPARATOR|Cohort 2|Subjects with moderate to dense cataracts (Grade 2+ to 3+) scheduled to undergo mechanical non-phacoemulsification lens extraction using low-energy segment removal with a micro-interventional irrigation/aspiration port (MICOR-304) to evacuate the lens prior to intraocular lens insertion..
62253737|NCT05752695||ACL injured athletes|Athletes with defined ACL injury.
62253738|NCT04272840|NO_INTERVENTION|Standard Care|Participants will attend a 30-45 min workshop. Trainees will review Diabetes Canada Clinical Practice Guidelines Job Aids (Just the Basics, the Handy Portion Guide, and Basic Carbohydrate Counting) and teach data provision skills (how to complete a three day diet record).
62253739|NCT04272840|EXPERIMENTAL|Low Glycemic Index|Standard care + Glycemic Index. Participants will attend a 30-45 min workshop. Trainees will review Diabetes Canada Clinical Practice Guidelines Job Aids (Just the Basics, the Handy Portion Guide, and Basic Carbohydrate Counting) and teach data provision skills (how to complete a three day diet record). Diabetes Canada and Dietitian's Canada resources on glycemic index will also be reviewed: the Glycemic Index Food Guide, Flip Cards, and Recipes.
62253740|NCT03576599|ACTIVE_COMPARATOR|Zoledronic Acid Injectable Product|Patients randomized to treatment with Zoledronic Acid 5mg infusion, repeated after 3 months
62253741|NCT03576599|PLACEBO_COMPARATOR|Placebo|Patients randomized to Placebo infusion (saline), repeated after 3 months
62835542|NCT03324087||Adult patients with ITP|The investigators are undertaking a multi-center, prospective trail of 1000 adult ITP patients and use SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.
62835543|NCT05152394|EXPERIMENTAL|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
62253742|NCT02244320||functional BPH|patients with functional BPH who switched from phytotherapy to ALNA®
62253743|NCT03294226|EXPERIMENTAL|AuraGain|After anesthetic induction, AuraGain is inserted for airway management. Size of the device is selected according to the manufacturer's recommendation; size 1.5 for 5-10kg, size 2 for 10-20kg.
62442657|NCT04978454|EXPERIMENTAL|Cohort 3B|10\^6 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=17) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. N = 18
62835544|NCT01935206|PLACEBO_COMPARATOR|Placebo|The effect of naloxone (2 mg/kg) on secondary hyperalgesia 168 hours after a first-degree burn-injury is compared to the placebo effect.
62835545|NCT01935206|EXPERIMENTAL|Naloxone (2 mg/kg)|The effect of naloxone (2 mg/kg) on secondary hyperalgesia 168 hours after a first-degree burn-injury is compared to the placebo effect.
62835546|NCT02894684|EXPERIMENTAL|AZLI then Standard Care|Upon first exacerbation this arm will receive AZLI, on their second they will receive standard care
62835547|NCT02894684|ACTIVE_COMPARATOR|Standard Care then AZLI|Upon first exacerbation this arm will receive standard care, on the second exacerbation this arm will receive AZLI
62052570|NCT02522143|SHAM_COMPARATOR|Informational Sessions|Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
62253744|NCT03294226|ACTIVE_COMPARATOR|I-gel|After anesthetic induction, I-gel is inserted for airway management. Size of the device is selected according to the patient's weight; size 1.5 for 5-10kg, size 2 for 10-20kg.
62253745|NCT05875051|EXPERIMENTAL|Reduced-exertion high intensity training group|The REHIT part will consist of maximum cycling sprints of all-out exercise at 100% of the HRmax, increasing for up to 10 seconds, 15 seconds on week two and 20 seconds on week three.
62442658|NCT00861237|PLACEBO_COMPARATOR|Placebo globules group|Patients receive Placebo globules made out of sugar and looking similar to active drug sublingually before surgery.
62442659|NCT00861237|ACTIVE_COMPARATOR|Nux vomica group|Patients receive Nux vomica globules made out of sugar sublingually before surgery.
62835548|NCT02863120|ACTIVE_COMPARATOR|Liposomal bupivacaine|Periarticular infiltration of 20cc of liposomal bupivacaine with 10cc of normal saline and 30cc of bupivacaine HCl administered prior to cementation of knee implants
62835549|NCT02863120|ACTIVE_COMPARATOR|Adductor canal and tibial nerve block|Preoperative tibial nerve block with 15cc bupivacaine HCl and adductor canal block with 20cc adductor canal block. Postoperative continuous adductor canal block with 550cc ropivacaine at 8cc per hour
62835550|NCT01209416|ACTIVE_COMPARATOR|Ghrelin / Acipimox|Ghrelin infusion and tablet acipimox
62253746|NCT05875051|ACTIVE_COMPARATOR|Short moderate intensity training group|The SMIT part of the session will consist of 6 minutes of moderate intensity exercise at 60-70% HRmax.
62253747|NCT02013453|ACTIVE_COMPARATOR|Observational|Patients on the Observational arm are currently being treated with a proton pump inhibitor (PPIs) such as Omeprazole. They will receive standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
62835551|NCT01209416|ACTIVE_COMPARATOR|Ghrelin / placebo|Ghrelin infusion and placebo tablets
62052571|NCT02522143|EXPERIMENTAL|Condensed-DBT treatment intervention|Condensed-DBT treatment intervention includes all DBT components, tailored to students.
62052572|NCT02300857|ACTIVE_COMPARATOR|Low carbohydrate diet|
62052573|NCT02300857|ACTIVE_COMPARATOR|Moderate carbohydrate diet|
62052574|NCT02300857|ACTIVE_COMPARATOR|High carbohydrate diet|
62052575|NCT00490256|NO_INTERVENTION|Control|Arm 1 is the control arm. This arm will receive the standard cardiopulmonary bypass circuit.
62052576|NCT00490256|ACTIVE_COMPARATOR|Experimental|This arm is the modified selective perfusion arm. This arm will receive the modified cardiopulmonary circuit.
62052577|NCT01265602|EXPERIMENTAL|LAS41007|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
62052578|NCT01265602|ACTIVE_COMPARATOR|LASW1510|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
62052579|NCT01265602|PLACEBO_COMPARATOR|vehicle|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
62052580|NCT00831064|ACTIVE_COMPARATOR|1. 4L PEG only|4L PEG PO
62052581|NCT00831064|ACTIVE_COMPARATOR|2. 2L PEG plus bisacodyl|2L PEG PO + 4 tablets bisacodyl PO
62052582|NCT00831064|ACTIVE_COMPARATOR|3. NaP|90 cc NaP PO
62835552|NCT01209416|ACTIVE_COMPARATOR|Placebo / Acipimox|saline infusion and tablet Acipimox
62835553|NCT01209416|PLACEBO_COMPARATOR|Placebo / placebo|saline infusion and placebo tablets
62835554|NCT01249079||Schizophrenia Family|
62052583|NCT00831064|ACTIVE_COMPARATOR|4. PSMC plus Mg-citrate|PSMC plus 300 cc Mg-citrate PO
62052584|NCT01060553|EXPERIMENTAL|Arm 1|The treatment program consisted of 24 semi-individualized acupuncture treatments over 12 weeks. It combines front and back treatments to avoid point fatigue (tolerance due to frequent use). The front treat-ment uses 11 needles, bilateral at acupuncture points LR3, PC6, HT7, ST36, SP6, and one at Yintang; the back treatment uses 14 needles, bilateral at points GB20, and BL14, 15, 18, 20, 21, and 23. There are 15 other points from which the flexibly prescribed points could be chosen
62052585|NCT01060553|NO_INTERVENTION|wait list control|subjects were put on a wait list control. due to small numbers completing in both groups, the data from the wait list who completed acupuncture are combined with the experimental treatment group for analysis.
62052586|NCT03619590||Exposure Group|Pregnant women who were exposed to Twinrix within 28 days prior to conception or at any time during pregnancy. Reporting of exposed pregnancies is voluntary and prospective.
62442660|NCT00906347|ACTIVE_COMPARATOR|Oxytocin augmentation|Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
62442661|NCT00906347|ACTIVE_COMPARATOR|Misoprostol augmentation|Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
62835555|NCT06204640|EXPERIMENTAL|spironolactone|
62835556|NCT06204640|NO_INTERVENTION|standard of care|
62052587|NCT02159443||Study Participants|Those who meet eligibility criteria and consent to participate in the study.
62052588|NCT01412801|EXPERIMENTAL|HIVneg|HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of Group B streptococcus vaccine.
62052589|NCT01412801|EXPERIMENTAL|HIVposCD4HIGH|HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count \>350 cells/µL received one dose of Group B streptococcus vaccine.
62052590|NCT01412801|EXPERIMENTAL|HIVposCD4LOW|HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but \> 50 cells/µL received one dose of Group B streptococcus vaccine
62052591|NCT03043001|OTHER|add-on memantine therapy|add-on memantine treatment
62052592|NCT03500055|EXPERIMENTAL|Abdominal Closure Bundle|Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin.
62052593|NCT03500055|NO_INTERVENTION|Control|Normal operative procedure. The abdominal closure bundle will not be used.
62052594|NCT03495388||Major Inpatient Surgeries|Children ages 8-17.9 undergoing pectus excavatum or idiopathic scoliosis spinal fusion at Riley Hospital for Children, who have consented to participate in an observational clinical study as approved by the IU IRB, protocol #1707525204.
62052595|NCT00308256|EXPERIMENTAL|Nurse counseling|Phone calls performed by nurse 15 days after each monthly visit
62052596|NCT00308256|NO_INTERVENTION|Control|Normal monthly follow-up without phone calls
62835557|NCT06263413||Patients with pigmented lesions and suspected malignancy|Patients treated at IDEI hospitals and with pigments skin lesions, which are suspected malignancy. The practitioners will take a photo of the lesion and upload into the tool so as to confirm both the diagnosis and suspicion of malignancy
62611904|NCT06731569|EXPERIMENTAL|AI-powered drill (Intervention Group)|Participants in this arm will undergo MSFA using a newly designed AI-powered drill. This innovative drill automatically stops rotation upon detecting the Schneiderian membrane, reducing the risk of perforation. The intervention also includes the use of specialized hydraulic pressure to aid in membrane elevation and preparation of the lateral window for grafting. The AI drill aims to enhance precision, efficiency, and safety during the procedure.
62611905|NCT03092336|EXPERIMENTAL|Electrical Stimulation|"The training with electrostimulation will be performed with the following intensity:~Medium frequency current: 2.500Hz Modulation frequency: up to 50Hz Time on / off: 1: 2 Average session time 10 to 15 min Being applied in the same muscle groups that will be trained in the group that will perform strength training."
62611906|NCT03092336|EXPERIMENTAL|Strength training|There will be 10 exercises: upper limbs: Supine with dumbbells; High pulley pull; Alternating thread with dumbbells; Triceps dumbbell test; Lower limbs: knee extensor, squatting with body weight, plantar flexion, knee flexion and plantar dorsiflexion. The session time will be from 45 minutes to one hour 2 times weekly totaling at the end of the 12 weeks, 24 strength training sessions.
62611907|NCT04415021|EXPERIMENTAL|Diaphragmatic and İliopsoas Myofascial Release Techniques|Subjects in this arm will receive different myofascial release techniques aimed to relaxation the myofascial tension of the diaphragmatic and iliopsoas muscles.
62835558|NCT06263413||Patients diagnosed with acne|Patients treated at IDEI hospitals and diagnosed with acne. Practitioners will take a photo of patients' face and upload it into the tool so as to check the severity of acne and compare it with the gold standard
62835559|NCT06263413||Patients diagnosed with femenine androgenetic alopecia|Patients treated at IDEI hospitals and diagnosed with femenine androgenetic alopecia. Practitioners will take a photo of the top of the head and upload it into the tool so as to check the severity of alopecia and compare it with the gold standard
62835560|NCT04883827||RCC with clear cell component|
62835561|NCT04883827||Healthy Volunteer (no longer recruiting)|
62835562|NCT06198582|EXPERIMENTAL|Virtual Reality Intervention Group|Consisted of patients who received a virtual reality-based task-specific exercise programme in addition to the early passive mobilisation programme
62835563|NCT06198582|NO_INTERVENTION|Control Group|Consisted of patients who received the early passive mobilisation programme
62835564|NCT03387618|EXPERIMENTAL|Investigational Scan|new-generation digital PET/CT imaging technology
62611908|NCT04415021|SHAM_COMPARATOR|Sham Myofascial Release Techniques|Subjects in this arm will receive the same manual techniques of the diaphragmatic and iliopsoas myofascial release group, but without the myofascial stimulus.
62442662|NCT01834521|EXPERIMENTAL|Web-based screening and tailored support|A personalized website (username/password) will become available to patients assigned to the intervention arm for 12 subsequent weeks. Key features of the website are self-screening, tailored patient education and self-referral. Self-screening will be performed by an online version of the Dutch Distress thermometer (DT) and Problem List (PL). Patients will receive digital feedback on their DT score immediately after test completion together with information regarding problems reported on the PL, (self)help options and possibilities for referral to professional care. Contact information of one of the investigators will also be available to discuss questions, problems and/or referral needs. Patients may also request a telephone call.
62611909|NCT01968902|ACTIVE_COMPARATOR|incabotulinumtoxinA|intramuscular injection, 200 to 400 units, 1 injection visit only
62052597|NCT01239667|EXPERIMENTAL|Life style counseling|Individual oriented rehabilitation plan in collaboration with the patient followed by measuring health related quality of life and self care behavior
62442663|NCT01834521|NO_INTERVENTION|Standard care|Patients assigned to standard convalescent care will receive the usual follow-up care delivered by their treating oncologists. Patients will be referred to psychosocial or allied care by their oncologist and/or oncology nurse if certain physical and/or psychosocial problems require more in-depth professional care
62611910|NCT01968902|PLACEBO_COMPARATOR|Placebo|intramuscular injection, saline 200 - 400 units , 1 injection visit only
62835565|NCT05807620|EXPERIMENTAL|Eye Cream|"Eye Cream composed of botanical extracts, bioavailable peptides, THD Ascorbate and Caffeine.~Subjects to apply a dime size amount onto the under-eye area and crow's feet area while avoiding direct eye contact twice daily for the duration of the 12-week clinical study."
62835566|NCT00045617|EXPERIMENTAL|cisplatin and etoposide followed by vaccine|standard chemotherapy with cisplatin and etoposide followed by cisplans and etoposide with an anti-idiotype monoclonal antibody vaccine
62835567|NCT03557034|NO_INTERVENTION|Standard of Care Monitoring|Standard of Care
62835568|NCT03557034|EXPERIMENTAL|Kardia Monitoring|Kardia Mobile/Kardia Pro
62835569|NCT00628108|PLACEBO_COMPARATOR|Placebo|
62835570|NCT00628108|EXPERIMENTAL|Levocetirizine|
62835571|NCT03848832|EXPERIMENTAL|5 milligrams per kilogram per day (mg/kg/day) GWP42003-P|100 milligrams per milliliter (mg/mL) GWP42003-P oral solution. Taken twice daily (morning and evening).
62835572|NCT03848832|EXPERIMENTAL|15 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution. Taken twice daily (morning and evening).
62835573|NCT03848832|PLACEBO_COMPARATOR|Placebo|Placebo oral solution (0 mg/mL GWP42003-P) volume matched to 5 mg/kg/day or 15 mg/kg/day GWP42003-P. Taken twice daily (morning and evening).
62835574|NCT03333278|ACTIVE_COMPARATOR|Vitamins|intravenous: Ascorbic acid (Vitamin C: 1.5g every 6 hours) Thiamine (Vitamin B1: 200mg every 12 hours) Hydrocortisone (50mg every 6 hours)
62835575|NCT03333278|OTHER|Control|Hydrocortisone (50mg every 6 hours)
62052598|NCT01635608|ACTIVE_COMPARATOR|non-caloric water|500 mg paracetamol, 50 mg talinolol and 500 mg amoxicillin dissolved in 240 ml non-caloric water immediately before administration after overnight fasting
62253748|NCT02013453|ACTIVE_COMPARATOR|Standard Chemo + Placebo|Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI). They will be randomized to receive placebo along with standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
62253749|NCT02013453|EXPERIMENTAL|Standard Chemo + Omeprazole|Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI). They will be randomized to receive Omeprazole along with standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
62052599|NCT01635608|ACTIVE_COMPARATOR|caloric water|500 mg paracetamol, 50 mg talinolol and 500 mg amoxicillin dissolved in 240 ml caloric water immediately before oral administration after overnight fasting
62052600|NCT02010476||Normal insulin sensitivity|cognitively normal men without insulin resistance
62052601|NCT02010476||Insulin resistance|cognitively normal men with insulin resistance
62253750|NCT01622192|EXPERIMENTAL|Automated probe|
62253751|NCT03390543|EXPERIMENTAL|Device group (Group D)|Arm Description: Patients in this group are assigned to receive internal jugular vein catheterization guided by ultrasound and simple needle guide device.
62253752|NCT03390543|PLACEBO_COMPARATOR|sono only group (Group S)|Patients in this group are assigned to receive internal jugular vein catheterization guided by ultrasound without simple needle guide device.
62253753|NCT05746299|EXPERIMENTAL|Immediate Congruent|Participants will learn and be tested on two different semantic categories with the same structure that dictates the co-occurrence of different features.
62253754|NCT05746299|EXPERIMENTAL|Immediate Incongruent|Participants will learn and be tested on two different semantic categories with different structures that dictate the co-occurrence of different features.
62835576|NCT00783107|EXPERIMENTAL|Cyclosporine|
62835577|NCT00783107|PLACEBO_COMPARATOR|Placebo|Subjects will be randomly assigned to Cyclosporine or placebo, in a ratio of 2:1.
62253755|NCT05746299|EXPERIMENTAL|Awake Incongruent|Participants will learn two different semantic categories, neither of which has a Modular structure. After a 2.5-hour break, they will learn and be tested on a novel semantic category with a Modular structure.
62253756|NCT05746299|EXPERIMENTAL|Awake Congruent|Participants will learn two different semantic categories, one of which has a Modular structure. After a 2.5-hour break, they will learn and be tested on a novel semantic category with a Modular structure.
62253757|NCT05746299|EXPERIMENTAL|Sleep Incongruent|Participants will learn two different semantic categories, one of which has a Modular structure. After a 2-hour nap opportunity, during which TMR will be used to reactivate the non-Modular category, participants will take a 30-minute break. After the break, they will learn and be tested on a novel semantic category with a Modular structure.
62253758|NCT05746299|EXPERIMENTAL|Sleep Congruent (SWS)|Participants will learn two different semantic categories, one of which has a Modular structure. After a 2-hour nap opportunity, during which TMR will be used to reactivate the Modular category during slow wave sleep (SWS), participants will take a 30-minute break. After the break, they will learn and be tested on a novel semantic category with a Modular structure.
62253759|NCT05746299|EXPERIMENTAL|Sleep Congruent (REM)|Participants will learn two different semantic categories, one of which has a Modular structure. After a 2-hour nap opportunity, during which TMR will be used to reactivate the Modular category during rapid eye movement (REM) sleep, participants will take a 30-minute break. After the break, they will learn and be tested on a novel semantic category with a Modular structure.
62253760|NCT05015192|EXPERIMENTAL|NH102 3mg|NH102 3mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
62253761|NCT05015192|EXPERIMENTAL|NH102 9mg|NH102 9mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
62611911|NCT04663347|EXPERIMENTAL|Arm 1 - Epcoritamab + R-CHOP|In participants with previously untreated DLBCL.
62835578|NCT02823015||Study population|The study population consists of adult surgery patients, scheduled for breast cancer surgery at St-Luc University Hospital.
62835579|NCT02779101|EXPERIMENTAL|Single arm|pembrolizumab
62835580|NCT03495089|EXPERIMENTAL|patients with type 2 DM|"Patients with type 2 DM over 40 years of age, with or without symptoms of neuropathy, attended in Primary Care.~Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance- DEC quantification using the Sudoscan® device."
62052602|NCT03612648|EXPERIMENTAL|TRI-APBI|"* Brachytherapy TRI-APBI the PTV is prescribed 7.5 Gy x three fractions given over two to three days OR~* External beam TRI-APBI the PTV is prescribed 8.5 Gy x three fractions given over two to three days"
62052603|NCT01991366||Eptifibatide Pre PCI|Receive eptifibatide pre PCI
62052604|NCT01991366||Eptifibatide during PCI|Receive eptifibatide during PCI
62611912|NCT04663347|EXPERIMENTAL|Arm 2 - Epcoritamab + R2|In participants with R/R FL.
62052605|NCT01991366||No Eptifibatide|Receive no eptifibatide
62052606|NCT04044456|EXPERIMENTAL|GMT plus attention|GMT consists of 2-hour, 10 weekly sessions using an interactive Power Point presentations. Attention training consists of 2-hour computerized attention training using Attention Process Training III and Brain HQ.
62052607|NCT04044456|PLACEBO_COMPARATOR|BHW plus movies|Brain Health Workshop consists of 2-hour, 10 weekly sessions using Power Point presentations and national geographic movies (2-hour, 10 weekly sessions).
62052608|NCT04492358|EXPERIMENTAL|colchicine + prednisone|Prednisone should be administered for 3 consecutive days (60 mg/d) together with colchicine (at doses of 0.5 to 1.5 mg/d, adjusted for weight and renal function) for 3 days and maintained for 14 days in total (0.5 mg/d).
62253762|NCT05015192|EXPERIMENTAL|NH102 20mg|NH102 20mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
62253763|NCT05015192|EXPERIMENTAL|NH102 40mg|NH102 40mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
62253764|NCT05015192|EXPERIMENTAL|NH102 60mg|NH102 60mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
62253765|NCT05015192|EXPERIMENTAL|NH102 80mg|NH102 80mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
62253766|NCT01080248|EXPERIMENTAL|Arm 1 (gemcitabine & pazopanib)|"Gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle.~Pazopanib 800 mg PO daily of each 28 day cycle."
62052609|NCT04492358|ACTIVE_COMPARATOR|Standard treatment|The standard treatment used in each site will be administered to the patients assigned to the control group.
62253767|NCT04202770|EXPERIMENTAL|Treatment|Patients deemed potentially appropriate candidates for exosome and focused ultrasound therapy for either treatment refractory depression (trMDD), anxiety, or neurodegenerative dementia will be treated with exosomes derived from healthy, full-term Cesarean section amniotic fluid. Up to one hour of transcranial focused ultrasound will be administered immediately prior to exosome treatment in an attempt to facilitate enhanced deployment to the subgenual cingulate for trMDD, the amygdala for anxiety, or the hippocampus for dementia. Target location will be determined by the physician upon enrollment depending on the patient's specific syndrome. Patients will be given 15cc of unconcentrated solution allogenic exosomes (equivalent to 21 million stem cells, Kimera Corporation) intravenously in 200 ccs of normal saline dripped over thirty minutes to one hour.
62253768|NCT03999723|EXPERIMENTAL|Vitamin C|Oral vitamin C (ascorbic acid) will be given in a dose of 1000 mg daily (two capsules of 500 mg once daily) starting day 1 in the 1st azacitidine (AZA) cycle (D1/C1) and continuing until discontinuation of AZA or end of study, whichever occurs earlier.
62442664|NCT03555370|EXPERIMENTAL|Standard of Care Group|"Standard of Care:~The standard of care protocol consists of standardized in office and at home behavioral management to include sleep, hydration, nutrition, and stress management interventions. Participants will also be assigned physical activity that they will complete during their visits and at home. Physical activity for the standard of care group will include 15 minutes of flexibility/range of motion exercises, and 10 minutes of aerobic-based daily physical activity (e.g.,walking, stationary cycle)."
62052610|NCT04030858|EXPERIMENTAL|Treatment group|The treatment group will eat a nutrient-dense plant-based diet and attend weekly nutrition education sessions.
62611913|NCT04663347|EXPERIMENTAL|Arm 3 - Epcoritamab + BR|In participants with previously untreated FL.
62611914|NCT04663347|EXPERIMENTAL|Arm 4 - Epcoritamab + R-DHAX/C|In participants with R/R DLBCL eligible for ASCT.
62611915|NCT04663347|EXPERIMENTAL|Arm 5 - Epcoritamab + GemOx|In participants with R/R DLBCL ineligible ASCT.
62611916|NCT04663347|EXPERIMENTAL|Arm 6 - Epcoritamab + R2|In participants with previously untreated FL.
62611917|NCT04663347|EXPERIMENTAL|Arm 7 - Epcoritamab maintenance|In participants with FL who achieved a CR or PR after receiving SOC treatment in 1L or 2L.
62052611|NCT04030858|NO_INTERVENTION|Control group|
62052612|NCT03444233|EXPERIMENTAL|low f1 diet|low fructose diet week 1
62052613|NCT03444233|EXPERIMENTAL|fruit rich diet|fruit rich diet week 2
62052614|NCT03444233|EXPERIMENTAL|low f2 diet|low fructose diet week 3
62052615|NCT03444233|EXPERIMENTAL|HFCS rich diet|HFCS rich diet week 4
62052616|NCT03740308|ACTIVE_COMPARATOR|Locally Made Zirconia Crowns|One operator completes all the teeth preparing and restoring procedures. Local anesthesia is achieved using Lidocaine Hydrochloride 2% with Epinephrine 1:100,000. The teeth are then isolated using a rubber dam. After caries excavation, the teeth are prepared according to manufacturer instructions.
62052617|NCT03740308|EXPERIMENTAL|ZR Zirconia Crwons NuSmile ® Crowns|One operator completes all the teeth preparing and restoring procedures. Local anesthesia is achieved using Lidocaine Hydrochloride 2% with Epinephrine 1:100,000. The teeth are then isolated using a rubber dam. After caries excavation, the teeth are prepared according to manufacturer instructions. (Same as Arm 1 Description)
62052618|NCT02352597|ACTIVE_COMPARATOR|clomiphene citrate|only50 mg orally every 8 hours started from cycle day 3 for 5 days
62052619|NCT02352597|ACTIVE_COMPARATOR|estradiol valerate and CC|2mg estradiol valerate orally daily from cycle day 7 - 11 in addition to CC
62611918|NCT04663347|EXPERIMENTAL|Arm 8 - Epcoritamab + R mini-CHOP|In participants with previously untreated DLBCL who are ineligible to receive full-dose anthracycline.
62052620|NCT02352597|ACTIVE_COMPARATOR|Phytoestrogen and CC|20mg of cimifuga racemosaorally from day 1- 12) in addition to CC
62253769|NCT03999723|PLACEBO_COMPARATOR|Placebo|Placebo will be administered orally as two capsules once daily that look and taste identical to the capsules containing vitamin C. Treatment will start day 1 in the 1st azacitidine (AZA) cycle (D1/C1) and continuing until discontinuation of AZA or end of study, whichever occurs earlier. The content of the placebo capsules is glucose monohydrate, potato starch, gelatin, magnesium stearate and talc.
62442665|NCT03555370|EXPERIMENTAL|Vestibular Exercise Intervention Group|The vestibular group will complete the behavioral management activities described above, as well as prescribed in-office and at home vestibular exercises from each of four groups: 1) gaze stability training (i.e., integrated eye and head movements on fixed target), 2) visual motion training (i.e., integrated eye and head movements with busy visual background), 3) standing balance (i.e., standing in different stances), and 4) dynamic gait (i.e., walking with head turns). Participants will be prescribed to one of four levels of these four exercise groups based on presentation of symptoms/impairment as indicated on the VOMS. Progression through the four levels will be based on symptom tolerance and successful completion of all exercises at the current level.
62835581|NCT03495089|EXPERIMENTAL|prediabetes|"Patients with intermediate alterations of glucose metabolism defined as impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) determined by OGTT after 2-hour 75 g oral glucose administration.~Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance-DEC quantification using the Sudoscan® device."
62442666|NCT01775761|EXPERIMENTAL|Period 1: 960 mg tafamidis (Vyndaqel)|
62442667|NCT01775761|EXPERIMENTAL|Period 2: 400 mg moxifloxacin|400 mg moxifloxacin
62442668|NCT01775761|EXPERIMENTAL|Period 3: Placebo|
62835582|NCT03495089|EXPERIMENTAL|control group|Patients without glucose alterations (normal glucose tolerance). Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance-DEC quantification using the Sudoscan® device.
62835583|NCT04906902|EXPERIMENTAL|Acalabrutinib Dose Escalation|"Phase 1 Dose escalation will occur using a 3+3 dose escalation approach, evaluating three separate dose levels.~* Acalabrutinib 200mg 2x daily~* Acalabrutinib 300mg 2x daily~* Acalabrutinib 400mg 2x daily"
62835584|NCT04906902|EXPERIMENTAL|Acalabrutinib Dose Expansion|"Phase 2~Participants will receive Acalabrutinib at the pre-determined dosage established in Phase 1."
62835585|NCT02608684|EXPERIMENTAL|Cisplatin+Gemcitabine+Pembrolizumab|"2 cycles of 750mg gemcitabine and 30mg cisplatin chemotherapy (standard of care) followed by 4 cycles of gemcitabine and cisplatin combined with pembrolizumab in 21-day treatment cycles followed by single-agent pembrolizumab maintenance therapy for up to 2 years of treatment (6 cycles combination treatment + 28 cycles maintenance).~Gemcitabine 750 mg/m2 every 3 weeks (Q3W) x 6 cycles IV infusion~-Day 1 and Day 8 of each 3 week cycle Standard of care~Cisplatin 30 mg/m2 Q3W x 6 cycles IV infusion~-Day 1 and Day 8 of each 3 week cycle after gemcitabine Standard of care~Pembrolizumab 200 mg Q3W starting with cycle 3 IV infusion~-Day 1 of each 3 week cycle after gemcitabine and cisplatin Experimental"
62835586|NCT02869568||Patients with ovarian cancer diagnosis|
62052621|NCT04224324||T & A patients|pediatric patients undergoing tonsillectomy and adenoidectomy
62052622|NCT03933475|EXPERIMENTAL|Intendu Active Brain Trainer Telerehabilitation Games|Use of telerehabilitation Games within the home environment
62052623|NCT00834106|EXPERIMENTAL|qHPV|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6
62052624|NCT00834106|PLACEBO_COMPARATOR|Placebo|Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6
62052625|NCT05830994|ACTIVE_COMPARATOR|G-POEM procedure|Gastric peroral endoscopic myotomy
62442669|NCT02209779|EXPERIMENTAL|BIBR 796 BS, low dose|twice daily doses of 5 mg for 4 weeks
62442670|NCT02209779|EXPERIMENTAL|BIBR 796 BS, medium dose 1|twice daily doses of 10 mg for 4 weeks
62442671|NCT02209779|EXPERIMENTAL|BIBR 796 BS, medium dose 2|twice daily doses of 20 mg for 4 weeks
62442672|NCT02209779|EXPERIMENTAL|BIBR 796 BS, high dose|twice daily doses of 30 mg for 4 weeks
62442673|NCT02209779|ACTIVE_COMPARATOR|Placebo|
62442674|NCT02593981|ACTIVE_COMPARATOR|Fruit/Honey Drink|Fruit/Honey Drink (2 canisters) will be taken orally twice a day. Subjects will consume the drink on days 1 through 28.
62442675|NCT02593981|PLACEBO_COMPARATOR|Placebo|Placebo (2 canisters) will be taken orally twice a day. Subjects will consume the placebo drink on days 1 through 28.
62611919|NCT04663347|EXPERIMENTAL|Arm 9 - Epcoritamab + Lenalidomide|In participants with R/R FL who progressed within 24 months of initiation of first-line anti-CD20-containing immunochemotherapy.
62611920|NCT04663347|EXPERIMENTAL|Arm 10 - Epcoritamab + R-ICE|In participants with R/R DLBCL eligible for ASCT.
62835587|NCT03802292|ACTIVE_COMPARATOR|Single Ascending Dose YQ23|
62835588|NCT03802292|PLACEBO_COMPARATOR|Single Dose Placebo|
62835589|NCT05679869|ACTIVE_COMPARATOR|VR Simulated Outdoor Environment|Exposure to recorded outdoor environmental sounds
62052626|NCT05830994|PLACEBO_COMPARATOR|Sham procedure|sham endsocopy with biopsy
62253770|NCT00002970|EXPERIMENTAL|Arm I|"GROUP 1: Patients receive a 1 hour infusion of compound 506U78 daily for 5 days in the absence of neurologic toxicity. The course repeats every 21 days. If a first relapse T-cell ALL study of higher priority is not open, then the patient may continue to receive the drug every 21 days for a maximum of 2 years provided that the patient has achieved a second complete response.~GROUPS 2 and 4: Patients receive compound 506U78 every 21 days for a maximum of 2 years, in the absence of disease progression. After 3 courses a patient may be given CNS prophylaxis with triple intrathecal therapy (TIT), consisting of methotrexate, cytarabine and hydrocortisone after consultation with study coordinator. TIT should be given every 12 weeks.~GROUP 3: Patients receive compound 506U78 every 21 days for a maximum of 2 years, in the absence of disease progression. TIT will be given on day 1 of weeks 1-4, 6, 9 and every 6 weeks for 12 weeks, and then every 9 weeks thereafter. This stratum is open."
62253771|NCT02704546|EXPERIMENTAL|Methylphenidate|In experimental days taking MPH, subjects will take 20mg Ritalin® (Novartis AG) in two tablets of 10mg, by swallow 1 hour prior to performing the physical test.
62253772|NCT02704546|PLACEBO_COMPARATOR|Placebo|In experimental days with placebo subjects will be asked to ingest 2 capsules identical to Ritalin® capsules, by swallow 1 hour prior to performing the physical test.
62253773|NCT01614938|ACTIVE_COMPARATOR|cisplatin-radiotherapy (CRT)|The arm receiving docetaxel-cisplatin neoadjuvant chemotherapy followed by concurrent weekly cisplatin and radiotherapy
62052627|NCT04012684|EXPERIMENTAL|rTMS: left first|One-session rTMS is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session rTMS is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
62253774|NCT01614938|EXPERIMENTAL|cetuximab-radiotherapy (ERT)|The arm receiving docetaxel-cisplatin neoadjuvant chemotherapy followed by concurrent cetuximab and radiotherapy
62253775|NCT04026178|EXPERIMENTAL|Metreleptin|Subjects will receive prescribed dosage of metreleptin as indicated in the USPI Patients (males and females) ≤ 40 kg: 0.06mg/kg Male patients \> 40 kg: 2.5mg Female patients \> 40 kg: 5mg
62253776|NCT01012102|EXPERIMENTAL|Group 1|EMD 640744 30μg and Montanide® ISA 51 VG
62611921|NCT05998317|EXPERIMENTAL|At-night dexamethasone|Patients in the intervention group will receive intravenous 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
62611922|NCT05998317|ACTIVE_COMPARATOR|At-induction dexamethasone|Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
62835590|NCT05679869|EXPERIMENTAL|VR Simulated Outdoor Environment with Masking Sounds|Exposure to recorded outdoor environmental sounds augmented with masking sounds
62835591|NCT02064777|EXPERIMENTAL|Tacrolimus|
62835592|NCT06151457|OTHER|Standard group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62835593|NCT06151457|OTHER|Intensive group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62835594|NCT04783493|ACTIVE_COMPARATOR|ACTIVE|In the active group, non-invasive transcutaneous magnetic stimulation of the dorsal spine will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (chest level T2-T3). The stimulation intensity will represent 100% of the motor threshold, this determined by abdominal muscle contractions, found from single pulses, applied gradually every 10 seconds until the contractions appear. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hz repeated at 5 Hz. In total, 1200 pulses will be applied for 3 minutes and 58 seconds.
62253777|NCT01012102|EXPERIMENTAL|Group 2|EMD 640744 100μg and Montanide® ISA 51 VG
62253778|NCT01012102|EXPERIMENTAL|Group 3|EMD 640744 300μg and Montanide® ISA 51 VG
62253779|NCT04206748|EXPERIMENTAL|iGlucose Smart Meter|
62253780|NCT04206748|PLACEBO_COMPARATOR|Rx glucose meter|
62611923|NCT00970424|PLACEBO_COMPARATOR|1|placebo, oral tablet administered once daily on background of pioglitazone
62253781|NCT03625050|EXPERIMENTAL|Chuna + Usual care|
62253782|NCT03625050|ACTIVE_COMPARATOR|Usual care|
62253783|NCT00975169||TZDs User|
62835595|NCT04783493|PLACEBO_COMPARATOR|PLACEBO|In the placebo group, a coil will be allocated in the T2-T3 thoracic region, however this coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, far from its field of view, to provide idea from the sound stimulus that is being stimulated. To create a sensation of muscle contraction and impression of active stimulation, both the placebo and active groups will be subjected to the sensory effect of transcutaneous electrical neurostimulation (TENS).
62253784|NCT01987960|PLACEBO_COMPARATOR|Placebo|Placebo adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER)
62253785|NCT01987960|EXPERIMENTAL|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER). Brexpiprazole dosing was 1mg/day for one week, followed by 2mg/day for 3 weeks. Thereafter the dose was flexible and could be adjusted from 1 to 3 mg/day.
62253786|NCT02171962|EXPERIMENTAL|Zilver® PTX® VI|
62253787|NCT05533879|EXPERIMENTAL|Yoga group|Women with having received a minimum of 17 points from the kinesiophobia questionnaire, have chronic low back pain and aged between 25-65
62253788|NCT03010306|NO_INTERVENTION|Nutrition only|Monthly food baskets were provided to the nutrition only group. Food baskets included basic foods to sustain a family of three over one month's time, such as rice and evaporated milk. Food baskets were valued at approximately $28 US Dollars per basket.
62253789|NCT03010306|ACTIVE_COMPARATOR|Nutrition + CASITA|The CASITA intervention was given by a community health worker (CHW) and involves individual and group modalities. HOME-CASITA took place at the dyad's place of residence, and the GROUP-CASITA at a local community center. All CASITA participants received 12 weekly sessions over 3 months. Interventions retain core elements of the SPARK approach: coaching parents on child development stimulation and providing social support and encouragement. Each session is as follows: 1) Child observation \& knowledge sharing about child development; 2) Practice of reciprocal attention focusing and social interaction activities; 3) Parent encouragement on behavior and developmental interactions; and 4) Parent social support through referral assistance, reassurance, and validation of parent's concerns.
62611924|NCT00970424|EXPERIMENTAL|2|dutogliptin, oral tablet administered once daily on background of pioglitazone
62611925|NCT02149095|EXPERIMENTAL|TransCon PEG treprostinil|Dosing will begin at 0.116 mg/kg TransCon PEG treprostinil subcutaneous injection and the dose escalated in subsequent cohorts to MTD.
62611926|NCT02022475|ACTIVE_COMPARATOR|Cholecalciferol|100 000 units vitamin D3 single dose
62253790|NCT02663557||non-hypertension with lower BPV|patients meeting to flowing two criteria: 1. mean SBP\<140 mmHg; 2. Systolic blood pressure-coefficient variation (SBP-CV) \< Median SBP-CV
62253791|NCT02663557||non-hypertension with higher BPV|patients meeting to flowing two criteria: 1. mean SBP\< 140 mmHg; 2. SBP-CV \> Median SBP-CV
62253792|NCT02663557||hypertension with lower BPV|patients meeting to flowing two criteria: 1. mean SBP\> 140 mmHg; 2. SBP-CV \< Median SBP-CV
62253793|NCT02663557||hypertension with higher BPV|patients meeting to flowing two criteria: 1. mean SBP\> 140 mmHg; 2. SBP-CV \> Median SBP-CV
62611927|NCT02022475|PLACEBO_COMPARATOR|Placebo|similar appearance
62611928|NCT02003456|EXPERIMENTAL|Cardiac PET scan|To evaluate methods that could allow the use of two radiotracers(rubidium-82/18F-fluorodeoxyglucose(FDG)and rubidium-82, that are used in cardiac positron emission tomography(PET)imaging scans to be performed at one time instead of the current method which involves being imaged at separate times, several hours apart.
62611929|NCT05447910|EXPERIMENTAL|Treatment (letrozole)|Patients receive letrozole PO QD for 2-8 weeks prior to surgery in the absence of disease progression or unacceptable toxicity. Patients then undergo collection of blood and tissue samples.
62611930|NCT04526574|ACTIVE_COMPARATOR|Coadministration Group|Participants receive injections of pneumococcal vaccine (20vPnC) and influenza vaccine at the same visit, and then receive an injection of saline 1 month later.
62835596|NCT02895893|EXPERIMENTAL|Smartphone app condition|"Men who are at risk for HIV and already prescribed and taking Truvada will be asked to use an application on their smart phones called PrEP Smart."
62835597|NCT00406484|EXPERIMENTAL|1|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
62611931|NCT04526574|ACTIVE_COMPARATOR|Separate Administration Group|Participants receive injections of saline and influenza vaccine at the same visit, and then receive an injection of 20vPnC 1 month later.
62052628|NCT04012684|EXPERIMENTAL|rTMS: right first|"One-session rTMS is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session rTMS is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.~After at least two weeks, stimulations of the same parameters are given over left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well."
62052629|NCT04012684|SHAM_COMPARATOR|Sham: left first|One-session sham stimulation is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session sham stimulation is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
62052630|NCT04012684|SHAM_COMPARATOR|Sham: right first|One-session sham stimulation is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session sham stimulation is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
62052631|NCT05777148|EXPERIMENTAL|postdilution online hemodiafiltration|hemodialysis by using post dilution online HDF technique
62052632|NCT05777148|EXPERIMENTAL|super high-flux hemodialysis|hemodialysis by using super high-flux dialyzer
62052633|NCT01222169|EXPERIMENTAL|larynx assessment under stimulation|
62052634|NCT01222169|PLACEBO_COMPARATOR|Larynx assessment under stimulation|
62052635|NCT00929825|EXPERIMENTAL|Elastomers|Patients will use hyperboloid as mechanical salivary stimuli. Patients will chew hyperboloid 3 times a day
62052636|NCT00929825|EXPERIMENTAL|TENS|TENS is a eletric stimuli that will be use in the skin near to parotid glands. Patients will receive TENS treatment as eletric salivary stimuli. Patients will receive TENS stimuli once a day for 15 days
62052637|NCT00929825|EXPERIMENTAL|Elastomers+TENS|Patients will receive TENS plus hyperboloid as eletric and mechanical treatment for salivary stimuli
62253794|NCT05805384|EXPERIMENTAL|Cochlear Implant Users|Participants will complete up to 4 experiments evaluating the use of the Speech Enhancement using Dynamic thresholding Approach (SEDA) algorithm. Each testing session will take between 4-6 hours to complete. Testing sessions will continue until the completion of the experiments.
62253795|NCT00151970|ACTIVE_COMPARATOR|Methylphenidate Transdermal System|The duration of MTS patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
62253796|NCT00151970|PLACEBO_COMPARATOR|Placebo|The duration of placebo patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
62611932|NCT02371668|PLACEBO_COMPARATOR|Placebo|Placebo, 5% dextrose (D-glucose) water
62611933|NCT02371668|EXPERIMENTAL|CR6261|CR6261, Investigational monoclonal antibody against influenza A viruses
62052638|NCT00929825|NO_INTERVENTION|No therapy (control)|Patients will not receive intervention
62253797|NCT00151970|ACTIVE_COMPARATOR|Concerta|CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
62253798|NCT03174418||Cohort A|Patients with bifurcated coronary lesions treated by percutaneous coronary interventions.
62253799|NCT03174418||Cohort B|Patients with untreated bifurcated coronary lesions.
62253800|NCT03779308|EXPERIMENTAL|Intervention|The participants will receive whole body vibration therapy while standing with hand support on a vibration platform.
62253801|NCT03858842||PF-ILD and SSc-ILD patients|PF-ILD and SSc-ILD patients
62611934|NCT03684421||Long Antagonist Protocol|Clinical pregnancy rate and live birth rates of patients who followed Long Antagonist Protocol for COS
62611935|NCT03684421||Classical Antagonist Protocol|Clinical pregnancy rate and live birth rates of patients who followed Classical Antagonist Protocol for COS
62253802|NCT01693354|ACTIVE_COMPARATOR|HF dialysis|HF (high-flux) dialysis is standard hemodialysis treatment performed by using a high permeability dialyzer instead of a low permeability one.
62253803|NCT01693354|EXPERIMENTAL|Mid-dilution HDF|Mid-dilution is a newly developed hemodiafiltration therapy able to allow a simultaneous pre- and post-dilution infusion.
62253804|NCT00054704|EXPERIMENTAL|Riluzole|Riluzole was dispensed either once or twice a day as 50 mg tablets. Riluzole dosing began at 50 mg twice per day by mouth and was increased on a weekly basis by 50 mg, as tolerated, to achieve a dose of 200 mg/day. Dose escalations continued until at least a 50% reduction in depression (MADRS) scores, intolerable side effects, or study completion. Dose was raised on a weekly basis by 50 mg until the dose of 200 mg was achieved unless precluded by an adverse event. If significant side effects occurred, titration was slowed and doses were reduced under double-blind conditions. The maximum permitted dose of riluzole was 200 mg/day. Those subjects not tolerating a dosage of 50 mg/day were removed from the study.
62611936|NCT04935801|SHAM_COMPARATOR|LD Vehicle_GNP|Low dose (LD) comparator (2.5nmol) - gold nanoparticle (14.8ug) without peptides
62611937|NCT04935801|EXPERIMENTAL|LD PepGNP-Dengue|Low dose (LD) peptide vaccine (2.5nmol) - gold nanoparticle (14.8ug) plus peptides
62052639|NCT05063708|SHAM_COMPARATOR|Traditional dysphagia therapy plus sham Neuromuscular electrostimulation|"Traditional dysphagia therapy (TDT) involved orofacial, lingual, and laryngeal motor exercises and compensatory swallowing strategies included various modifications of head, neck, and body postures and adjustment of food/liquid temperature, viscosity, and volume. The choice of specific strategies was based on the FEES findings and the clinical swallowing examination. The rehabilitative treatment will be administered in the 8 centers taking part to the study. The electrodes in this sham group will be placed in the same positions as the active treatment, with a current between 3 and 5 mA (average of 3.5 mA) current unable to perform muscle contraction. Every MS patient will be received 16 sessions of TDT according to their degree of dysphagia, contemporary associated with Sham neuromuscular electrostimulation two 30-min treatment a day, separated by a rest period of at least 45 minutes for four consecutive days per week, within a period of 4 weeks"
62052640|NCT05063708|EXPERIMENTAL|traditional dysphagia therapy plus Neuromuscular electrostimulation|Every MS patient will be treated with traditional dysphagia therapy, associated with an active neuromuscular electrostimulation. The amplitude will be increased until the subject will feel a 'grabbing sensation' which corresponded to muscular contraction. This will be the amplitude used for the therapy. This process will be repeated for the second channel of the stimulator. The typical electrical stimulus is at 80 Hz and at 300 microsec, and it will be adapted to avoid annoying stimulus to the patients. During therapy, both channels will be active. Every MS patient will be received 16 sessions of traditional dysphagia therapy according to their degree of dysphagia, contemporary associated with neuromuscular electrostimulation , according to our previous experiences, two 30-min treatment a day, separated by a rest period of at least 45 minutes for four consecutive days per week, within a period of 4 weeks.
62052641|NCT06193265||Surgery under full endoscopy|A full endoscopic surgery will be performed on patienst with herniated disc
62052642|NCT06193265||Conventional microscopic surgery|A conventional microscopic surgery will be performed on patienst with herniated disc
62052643|NCT05867654|OTHER|Osteomyelitis Treated with Oral Antibiotics|"Patients that are receiving oral antibiotics for the treatment of their osteomyelitis.~Based on the indication, patients will receive one the following medications orally for 6-8weeks: Amoxicillin-clavulanate 875mg/125mg q12hrs, clindamycin 300mg q6hrs, Levofloxacin 750mg QID, Penicillin 500mg q6hrs"
62253805|NCT00054704|PLACEBO_COMPARATOR|Placebo|Placebo pills resembling 50 mg riluzole tables were dispensed either once or twice a day. Dosing began at 50 mg twice per day by mouth and was increased on a weekly basis by 50 mg, as tolerated, to achieve a dose of 200 mg/day. Dose escalations continued until at least a 50% reduction in depression (MADRS) scores, intolerable side effects, or study completion. Dose was raised on a weekly basis by 50 mg until the dose of 200 mg was achieved unless precluded by an adverse event. If significant side effects occurred, titration was slowed and doses were reduced under double-blind conditions. The maximum permitted dose of riluzole was 200 mg/day. Those subjects not tolerating a dosage of 50 mg/day were removed from the study.
62253806|NCT00785044||Group|No participants received any drug administration. No intervention conducted.
62253807|NCT00244270|EXPERIMENTAL|1|totally implantable vascular access device
62253808|NCT04209036||3D laparoscopy arm|patients submitted to total hysterectomy using a 3D laparoscopic camera
62253809|NCT04209036||2D laparoscopy arm|patients submitted to total hysterectomy using a 2D laparoscopic camera (standard laparoscopic camera)
62253810|NCT05815251||Sphereplast group|Patients with osteoporotic vertebral compression fractures identified as candidates for kyphoplasty treatment with porous trabecular titanium microspheres
62611938|NCT04935801|SHAM_COMPARATOR|HD vehicle-GNP|High dose (HD) comparator (7.5nmol) - gold nanoparticle (44.5ug) without peptides
62611939|NCT04935801|EXPERIMENTAL|HD PepGNP-Dengue|High dose (HD) peptide vaccine (7.5nmol) - gold nanoparticle (44.5ug) plus peptides
62611940|NCT00106639|EXPERIMENTAL|CP-690,550 15 mg BID|
62611941|NCT00106639|EXPERIMENTAL|CP-690,550 30 mg BID|
62611942|NCT00106639|ACTIVE_COMPARATOR|tacrolimus|
62611943|NCT04336852|EXPERIMENTAL|Arm 1|
62611944|NCT06731400|EXPERIMENTAL|EPA Suplementation|Six healthy individuals will be supplemented with fish oil for eight weeks, with blood samples collected before and after the intervention.
62611945|NCT01946698||Fertility patients|Women with endometriosis compared to women without endometriosis. Different samples will be collected (blood, follicular fluid, cells from the uterus)
62611946|NCT03717168|ACTIVE_COMPARATOR|Recombinant human growth hormone|Patients who received growth hormone immediately after tracheostomy.
62611947|NCT03717168|ACTIVE_COMPARATOR|Control|Patients who did not receive growth hormone and followed the conventional weaning trials
62253811|NCT00612170|EXPERIMENTAL|3|
62611948|NCT02286375|EXPERIMENTAL|Intervention group|Interventions include providing comprehensive assessment from Omaha system, giving information regarding the self-care management, assisting and coordinating self-regulating skills and abilities, and providing social support from health-social care team to community-dwelling older adults for three months
62611949|NCT02286375|PLACEBO_COMPARATOR|customary care group|Customary care includes receiving community services from the community center in the district, providing monthly social call by a reserch assistant for three months
62611950|NCT06497556|EXPERIMENTAL|Divarasib|Participants will receive divarasib orally, once daily (QD).
62611951|NCT06497556|ACTIVE_COMPARATOR|KRAS G12C inhibitor|Participants will receive Sotorasib orally QD or adagrasib orally twice a day (BID)
62253812|NCT00612170|SHAM_COMPARATOR|4|
62442676|NCT04435613|OTHER|protective mechanical ventilation|Ten patients with moderate to severe ARDS were subjected to a nearly ultra-protective ventilation strategy generating a reduction in minute ventilation (Tidal volume of 5 ml/kg of predicted body weight together with a 20% reduction in respiratory rate). In addition to end-inspiratory pause, prolongation was set to avoid hypercapnia. Protocol phases: Baseline conditions: Tidal volume of 7 ml/kg. I: Tidal volume of 6 ml/kg. II: Tidal volume of 5 ml/kg. III: Increase end-inspiratory pause until achieving an I:E ratio equal to 1. IV: Respiratory rate reduction until 20% of the basal condition keeping constant I:E ratio equal to 1
62253813|NCT00612170|EXPERIMENTAL|1|
62442677|NCT04648410||Members of European Society of Intensive Care|Members of European Society of Intensive Care will obtain an electronic survey considering their routine clinical practice regarding the administration of systemic corticosteroids among patients with COVID-19 ARDS
62253814|NCT00612170|EXPERIMENTAL|2|
62253815|NCT03662165|EXPERIMENTAL|Intervention|"The primary intervention consisted of a text message informing participants that HIV self-test kits were available at all North Star Alliance clinics in Kenya. The message was sent three times, one week apart, first in Kiswahili, then in English and then again in Kiswahili, and read: You can now self-test at home or in the clinic for HIV using a new test kit available from all North Star Alliance clinics in Kenya. Your health, our priority."
62611952|NCT00723463|EXPERIMENTAL|A|To determine if apparent diffusion coefficient values can differentiate tumors from normal tissues using a 3T MRI scan.
62253816|NCT03662165|EXPERIMENTAL|Enhanced Standard of Care|"Those randomized to the enhanced Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent three times, one week apart first in Kiswahili, then in English and then again in Kiswahili. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority."
62253817|NCT03662165|ACTIVE_COMPARATOR|Traditional Standard of Care|"Those randomized to the traditional SOC arm received the SOC message one time sent simultaneously in both Kiswahili and English. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority."
62442678|NCT03191721|EXPERIMENTAL|Test: Triclosan toothpaste|"To brush twice a day with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.~Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction."
62611953|NCT04153968|EXPERIMENTAL|Phase 1|Determination absorption and bioconversion kinetics of \[13C14\]β-cryptoxanthin and provide external validation for single-sample prediction methods.
62611954|NCT04153968|EXPERIMENTAL|Phase 2|Test the bioefficacy of provitamin A carotenoids (pVACs) in maize by comparing a high β-cryptoxanthin:β-carotene (βCX:βC) variety to a low βCX:βC variety in combination with external \[13C\]-labelled pVACs.
62611955|NCT04650126|EXPERIMENTAL|ATM001|Escalating dose levels of ATM001 administered as single dose in healthy subjects
62611956|NCT04650126|PLACEBO_COMPARATOR|ATM001 Placebo|Escalating dose levels of ATM001 Placebo administered as single dose in healthy subjects
62835598|NCT00406484|ACTIVE_COMPARATOR|2|Standard drug counseling
62835599|NCT03854097|EXPERIMENTAL|Active PAD group|-40mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
62835600|NCT03854097|EXPERIMENTAL|Placebo PAD group|-10mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
62835601|NCT03854097|EXPERIMENTAL|Healthy Volunteers|-40 mmHg of Intermittent Negative Pressure (INP) for 5 days
62835602|NCT04761328|EXPERIMENTAL|Cessation of treatment|If the patient is randomized to this arm, they will be asked to stop their immunotherapy
62835603|NCT01707199|EXPERIMENTAL|Artesunate + Sulphadoxine-pyrimethamine|"AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date."
62835604|NCT06472232|EXPERIMENTAL|Chloroprocaine group|Selection of local anesthetics for epidural labor analgesia with low concentration of chloroprocaine combined with sufentanil
62835605|NCT06472232|PLACEBO_COMPARATOR|Ropivacaine group|Selection of local anesthetics for epidural labor analgesia with low concentration of ropivacaine combined with sufentanil
62835606|NCT05324514|ACTIVE_COMPARATOR|Standard of Care|STSG grafting application.
62835607|NCT05324514|EXPERIMENTAL|High Density|MSTC high density application.
62835608|NCT05324514|EXPERIMENTAL|Low Density|MSTC low density application.
62835609|NCT04962308|EXPERIMENTAL|Experimental Group|200 subjects in group A1 will receive one dose of booster immunization 3 months after the completion of the second dose of primary immunization of the SARS-CoV-2 Inactivated vaccine.
62835610|NCT04962308|EXPERIMENTAL|Control Group|200 subjects in group A2 will receive one dose of booster immunization 5 months after the completion of the second dose of primary immunization of the SARS-CoV-2 Inactivated vaccine.
62253818|NCT05396079|EXPERIMENTAL|Tahini and bread|"After an overnight fast (10-12 h), participants will come tο the lab and, after a 10-min resting period in the supine position in a quiet room with temperature a constant 20-25 °C, assessment of blood pressure, pulse rate, hemodynamic parameters, and endothelial function will be performed.~Then, an intravenous cannula will be inserted into a forearm vein and a baseline blood sample will be collected (time 0) as well as urine sample will be also collected. Afterward, each patient will consume 2 slices of white bread with 50 g of tahini and collection of the blood and urine sample will be repeated 1,2, 3 and 4 h postprandially. Assessment of blood pressure, pulse rate, hemodynamic parameters, and endothelial function will be also repeated at the end of the trial. During the trial, patients will not be allowed to eat or drink anything apart from water."
62253819|NCT05396079|EXPERIMENTAL|Margarine, cheese and bread|"After an overnight fast (10-12 h), participants will come tο the lab and, after a 10-min resting period in the supine position in a quiet room with temperature a constant 20-25 °C, assessment of blood pressure, pulse rate, hemodynamic parameters, and endothelial function will be performed.~Then, an intravenous cannula will be inserted into a forearm vein and a baseline blood sample will be collected (time 0) as well as urine sample will be also collected. Afterward, each patient will consume 2 slices of white bread with 46 g of margarine and 38 g of lowfat cheese and collection of the blood and urine sample will be repeated 1,2, 3 and 4 h postprandially. Assessment of blood pressure, pulse rate, hemodynamic parameters, and endothelial function will be also repeated at the end of the trial. During the trial, patients will not be allowed to eat or drink anything apart from water."
62611957|NCT05383872|EXPERIMENTAL|Exablate BBBD|Using Exablate Model 4000 Type 2 for liquid biopsy in subjects with Glioblastoma
62611958|NCT02238756|EXPERIMENTAL|CV8102|
62611959|NCT02238756|ACTIVE_COMPARATOR|Rabipur|
62611960|NCT02238756|EXPERIMENTAL|CV8102 + Rabipur|
62611961|NCT06731751||Spontaneous Intracranial Haemorrhage Patients|Patients of any age with the presence of spontaneous intracranial haemorrhage (parenchymal, intraventricular and / or subarachnoid haemorrhage) on intracranial imaging (and absence of a history of trauma).
62835611|NCT04962308|EXPERIMENTAL|Safety group|1000 subjects in group B will be enrolled and receive 1 dose of booster immunization more than 3 months after the completion of the second dose of primary immunization of the SARS-CoV-2 Inactivated vaccine
62253820|NCT06226350|EXPERIMENTAL|F520 monotherapy|
62835612|NCT03036202||one group|All patients treated for cardiac arrest, meeting our inclusions criteria will be enrolled in the study. No interventions regarding the national guidelines will be jeopardized, as the plasma concentration following a single dose of epinephrine will be measured in all patient.
62442679|NCT03191721|PLACEBO_COMPARATOR|Control: Fluoride toothpaste|"To brush twice a day with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.~Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction."
62442680|NCT00417599|EXPERIMENTAL|Lifestyle intervention|Behavioral lifestyle intervention versus control group. The Behavioral intervention consists of behavioral lessons delivered over the internet.
62442681|NCT00417599|EXPERIMENTAL|control|The intervention for the waiting list control group was usual care.
62442682|NCT03978871|EXPERIMENTAL|Growth Mindset|Persuasive education about emotions, brain development, and teenagers' ability to learn how to manage emotions
62442683|NCT03978871|ACTIVE_COMPARATOR|Brain Education|Neutral education about functions of different parts of the brain
62442684|NCT06547528|EXPERIMENTAL|ONO-4685|
62442685|NCT00682721|ACTIVE_COMPARATOR|2|Valacyclovir 1 gm daily x number of days active in the study
62442686|NCT00682721|PLACEBO_COMPARATOR|1|
62442687|NCT04556669|EXPERIMENTAL|CD22（aPD-L1）CAR-T cells|
62442688|NCT05089994|EXPERIMENTAL|Group 1 (QLBA) will include 30 patients|will receive ultrasound-guided anterior approach quadratus lumborum block
62611962|NCT04102683|EXPERIMENTAL|Intervention Group|The experimental recreation program, which consisted of two sessions per week and lasted approximately 1 hour each session, lasted for 8 weeks between March 2019 and May 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions.
62611963|NCT04102683|NO_INTERVENTION|Control Group|
62611964|NCT02507024||Intervention|The online questionnaire includes questions about how ANCA-associated vasculitis effects patients quality of life.
62611965|NCT06730373|EXPERIMENTAL|Disitamab Vedotin+Sintilimab+S-1|
62611966|NCT06730373|ACTIVE_COMPARATOR|Trastuzumab+Chemotherapy（XELOX/FP/XP) ± Sintilimab|
62611967|NCT01764659||All enrolled patients|Contrast-enhanced 4D computed tomography
62835613|NCT02546206|EXPERIMENTAL|Probiotic Yoghurt|Probiotic yoghurt consumption
62835614|NCT02546206|PLACEBO_COMPARATOR|Natural Yoghurt|Natural yoghurt consumption
62835615|NCT02753504|EXPERIMENTAL|CKD-519 50mg|CKD-519 50mg or placebo
62835616|NCT02753504|EXPERIMENTAL|CKD-519 100mg|CKD-519 100mg or placebo
62835617|NCT02753504|EXPERIMENTAL|CKD-519 200mg|CKD-519 200mg or placebo
62835618|NCT06442319|EXPERIMENTAL|Platelet-rich Plasma|
62835619|NCT06442319|ACTIVE_COMPARATOR|Hyaluronic Acid|
62835620|NCT00369265|EXPERIMENTAL|Lansoprazole|Lansoprazole 30 mg Twice Daily
62835621|NCT00369265|PLACEBO_COMPARATOR|Sugar pill|placebo
62835622|NCT04442828||Primary mitral regurgitation|Patients with mitral regurgitation due to mitral valve disease
62835623|NCT04442828||Secondary mitral regurgitation|Patients with mitral regurgitation due to ventricular or atrial disease
62835624|NCT02028273||Control|Healthy control group. No history of substance abuse or dependence.
62835625|NCT02028273||Actively using patients|Participants actively using cocaine.
62835626|NCT02028273||Abstinent Patients|Participants who have been abstinent from cocaine use for 3-6 months.
62835627|NCT03075514|ACTIVE_COMPARATOR|Modified ketogenic diet (MKD)|MKD: 80% fat and 5% carbohydrate (% of total energy requirements per day).
62835628|NCT03075514|ACTIVE_COMPARATOR|Medium chain triglyceride (MCT) diet|MCT: 75% fat (30% of which is medium chain fatty acids taken as a supplement) and 5% carbohydrate (% of total energy requirements per day).
62835629|NCT05738642|EXPERIMENTAL|4F-PCC group|1. Basic and normative treatment in accordance with the European Guidelines for Major Bleeding 2019: effective hemostatic measures and target-oriented correction of coagulation function. 2. 4 F- PCC by intravenous infusion of cluster
62835630|NCT05738642|NO_INTERVENTION|non 4F-PCC group|1. Basic and normative treatment in accordance with the European Guidelines for Major Bleeding 2019: effective hemostatic measures and target-oriented correction of coagulation function.
62835631|NCT03323424|EXPERIMENTAL|Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)|Patients with metastatic breast, colorectal or head or neck cancers and corresponding with the inclusion criteria will receive a systemic treatment, according to the usual practice, but also a Stereotactic Body Radio-Therapy (SBRT).
62835632|NCT03323424|ACTIVE_COMPARATOR|Systemic treatment|Patients with metastatic breast, colorectal or head or neck cancers and corresponding with the inclusion criteria will receive a systemic treatment, according to the usual practice.
62835633|NCT04932486|EXPERIMENTAL|Transcutaneous electrical stimulation|Participants will be asked to use the stimulator for 6 weeks at home. The study objectives will be evaluated after 6 weeks post-activation of the device.
62835634|NCT03077841|EXPERIMENTAL|Arm I (hypofractionated partial breast irradiation)|Patients undergo hypofractionated partial breast irradiation daily for 5 days. Patients may then receive 3 additional boost fractions at the discretion of the doctor.
62835635|NCT03077841|ACTIVE_COMPARATOR|Arm II (hypofractionated partial breast irradiation)|Patients undergo standard breast irradiation daily for 15 days. Patients may then receive 5 additional boost fractions at the discretion of the doctor.
62835636|NCT04467372|EXPERIMENTAL|Tart cherry juice concentrate|tart cherry juice
62835637|NCT04467372|EXPERIMENTAL|Freeze dried tart cherry powder|tart cherry capsules
62835638|NCT04467372|EXPERIMENTAL|Juice placebo|kool-aid
62253821|NCT04173689|ACTIVE_COMPARATOR|Inspiratuar muscle training group|This group will be given inspiratory muscle training (IMT) at home for 15 minutes twice a day for 7 days a week with the resh Threshold IMT 'device. In the IMT group, the initial training intensity will be determined by measuring the maximal inspiratory muscle strength (MRP) with the intraoral pressure measuring device, 30% of the measured MRP value will be started at the first evaluation and the new training intensity will be determined by calculating 30% of the measured value by repeating the MRP measurement every week.
62835639|NCT04467372|EXPERIMENTAL|Capsule placebo|maltodextrin
62835640|NCT01170169|EXPERIMENTAL|Omeprazole|Omeprazole Delayed Release Capsules of Dr. Reddy's laboratories limited
62835641|NCT01170169|ACTIVE_COMPARATOR|Prilosec|Prilosec® 40 mg of Merck \& Co.Inc.
62442689|NCT05089994|EXPERIMENTAL|Group 2 (QLBI)will include 30 patients.|received ultrasound-guided intramuscular quadratus lumborum.
62442690|NCT02623790|EXPERIMENTAL|Test meal (butter)|Subjects will eat one test meal containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
62442691|NCT02623790|EXPERIMENTAL|Test meal (cheddar cheese)|Subjects will eat one test meal containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
62835642|NCT00074048|EXPERIMENTAL|1|BL22 immunotoxin
62835643|NCT03846206|EXPERIMENTAL|mediterranean diet|Patients do Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months
62835644|NCT03846206|NO_INTERVENTION|Usual diet|Patients do usual diet for three months
62835645|NCT00880919|ACTIVE_COMPARATOR|1|Seroquel XR 150mg oral tablets taken daily for 8 weeks.
62835646|NCT00880919|ACTIVE_COMPARATOR|2|Seroquel XR 300mg oral tablets taken daily for 8 weeks.
62835647|NCT00880919|PLACEBO_COMPARATOR|3|Equivalent number of placebo oral tablets taken daily for 8 weeks.
62835648|NCT00055913|EXPERIMENTAL|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 15 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62835649|NCT00055913|EXPERIMENTAL|Arm II|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62835650|NCT03895749|ACTIVE_COMPARATOR|Neo40 Daily|Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.
62253822|NCT04173689|ACTIVE_COMPARATOR|Exercise group|This group will perform upper extremity and trunk exercises combined with breathing exercises at home for 7 days, twice a day for 15 minutes. Patients in both groups will perform a single 15-minute session once a week at the hospital under the supervision of a physiotherapist.
62253823|NCT04188795|EXPERIMENTAL|Intervention|"Participants who met the criteria for inclusion in the study and volunteered to participate in the study were divided into experimental and control groups by block randomization method.~After obtaining written informed consent, the Patient Information Form, Mini Nutritional Assessment- Short Form, Confusion Assessment Method, Barthel Index and Visual Analog Scale were applied to patients. Nursing care was applied to hip fracture patients in the experimental group in accordance with the care protocol developed to prevent delirium. Delirium preventive care protocol was consist of; psychosocial care, monitoring of oxygen saturation, prevention of dehydration, nutritional support, normal elimination, pain control, sleep regulation, avoidance of bladder catheterization and early mobilization.~Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day."
62253824|NCT04188795|NO_INTERVENTION|Control Group|After obtaining written informed consent, the Patient Information Form, Mini Nutritional Assessment- Short Form, Confusion Assessment Method, Barthel Index and Visual Analog Scale were applied to patients. Routine nursing care was applied to hip fracture patients in the control group. Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day.
62253825|NCT00240981|EXPERIMENTAL|Treatment|
62442692|NCT02623790|EXPERIMENTAL|Test meal (cream cheese)|Subjects will eat one test meal containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
62442693|NCT01117961|NO_INTERVENTION|control|
62611968|NCT06545630|EXPERIMENTAL|Participant Group/Arm|"Tumor antigen-sensitized vaccine is administrated, 1-week interval, totally 2 times.~2-week later, Neo-antigen DC vaccine is administrated, 2-week interval, totally 5 times.~According to the conditions of patients, it will be used for five more times"
62052644|NCT05613790|EXPERIMENTAL|Active HD-tDCS|Participants in the active arm will receive 20 min of real High-Definition transcranial direct current stimulation. Additional ramp-up and ramp-down phases at the beginning and the end of stimulation will last for 30 s.
62611969|NCT02305446|EXPERIMENTAL|rMenB+OMV NZ|Subjects who received two doses of rMenB+OMV NZ according to a 0, 2-month schedule
62611970|NCT05133258||Chronic Suppurative Otitis Media group|Enrolled subjects with persistent otorrhea due to CSOM and prescribed with standard of care (prescription for antibiotic drops from a pharmacy of their choice with specific written instructions for self-administration).
62623597|NCT03584230|EXPERIMENTAL|Negative Condition|"Students will be assigned to a group that receives negative nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs negative nonverbal behaviors to students in the same t-shirt color and positive nonverbal behaviors to students in another t-shirt color.~Intervention: Assigned to negative group"
62052645|NCT05613790|EXPERIMENTAL|Sham HD-tDCS|During the sham session, the montage will be identical, however, the current amplitude will ramp up for 30 seconds, and for the remaining stimulation time, the current flow will terminate and will be kept to zero. Ramp-down phase at the end of stimulation will last for 30 s.
62052646|NCT05375474|EXPERIMENTAL|Oral anticoagulation therapy group|Vitamin-K antagonists (warfarin), therapeutic INR: 1.8-2.5
62052647|NCT05375474|ACTIVE_COMPARATOR|Single antiplatelet therapy group|Aspirin, 75-100mg
62052648|NCT02230956|EXPERIMENTAL|OnabotulinumtoxinA 400 U|OnabotulinumtoxinA 400 U injection into the intra-articular space of the study knee on Day 1.
62052649|NCT02230956|EXPERIMENTAL|OnabotulinumtoxinA 200 U|OnabotulinumtoxinA 200 U injection into the intra-articular space of the study knee on Day 1.
62052650|NCT02230956|PLACEBO_COMPARATOR|Placebo|Placebo (Normal Saline) injection into the intra-articular space of the study knee on Day 1.
62052651|NCT03852563|EXPERIMENTAL|Women_Hemiface BAY207543|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with BAY207543 is investigated.
62253826|NCT00240981|PLACEBO_COMPARATOR|Placebo|
62442694|NCT01117961|EXPERIMENTAL|Intervention|Lifestyle intervention delivered during pregnancy
62442695|NCT04084756|EXPERIMENTAL|Couples Crisis Response Plan|
62253827|NCT02700997|EXPERIMENTAL|Vascular clip|Application of a clip to dissolvable sutures.
62442696|NCT04084756|ACTIVE_COMPARATOR|Mental Health Education|
62442697|NCT03419195|EXPERIMENTAL|Type 2 diabetes|Men and women between the ages of 30-55 with well controlled type 2 diabetes (A1C \<9%).
62442698|NCT03419195|EXPERIMENTAL|Healthy overweight controls|Men and women between the ages of 30-55 with BMI 25-40 and limited immediate family history of type 2 diabetes.
62442699|NCT05358210|EXPERIMENTAL|Blueberry Consumption|Randomized participants will consume 1 cup of frozen blueberries, provided by the trial, daily for 12 weeks.
62442700|NCT05358210|ACTIVE_COMPARATOR|Dried Date Consumption|Randomized participants will consume 2-3 dried dates, provided by the trial, daily for 12 weeks.
62442701|NCT04559620|EXPERIMENTAL|Maternal voice|Mother's voice will be played for 1 week between week 2 and 3 of life
62442702|NCT04559620|NO_INTERVENTION|Control|NO intervention between week 2 and 3
62442703|NCT02212405|SHAM_COMPARATOR|rTMS Sham + PET|An advanced sham coil will be used that mimicks the sound and sensation of real repetitive Transcranial Magnetic Stimulation. The repetitive Transcranial Magnetic Stimulation sham intervention is followed by radiotracer and PET.
62835651|NCT03895749|PLACEBO_COMPARATOR|Placebo|Per Capsule: Beet Juice concentrate, Carmine, Croscarmellose Sodium, D-Mannitol, Magnesium Stearate, Orange flavour, Silicon dioxide, Stevia rebaudiana leaf, Xylitol.
62835652|NCT02397161|EXPERIMENTAL|AT-NMT|AT-NMT group - will receive a 12-week EEG biofeedback mental attention-neuromuscular training
62835653|NCT02397161|EXPERIMENTAL|NMT alone|NMT group - will receive a 12-week neuromuscular training
62835654|NCT02397161|EXPERIMENTAL|AT alone|AT group - will receive a 12-week EEG biofeedback mental attention training
62835655|NCT02397161|NO_INTERVENTION|Control|Control group - no intervention for 12 weeks
62835656|NCT00847210|EXPERIMENTAL|Dexlansoprazole MR 30 mg QD|
62835657|NCT00847210|EXPERIMENTAL|Dexlansoprazole MR 60 mg QD|
62052652|NCT03852563|ACTIVE_COMPARATOR|Women_Hemiface Vaseline|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with vaseline is investigated.
62052653|NCT02785640|EXPERIMENTAL|Prompt group|Following feedback on their baseline sitting behaviour and an education session on the health benefits of breaking prolonged sitting, the prompt group will receive hourly prompts on their PC to stand. The prompts will be delivered via Microsoft Outlook and will run for a period of 10 weeks. The messages will be short in length, varied and centre around the key message of breaking prolonged sitting by standing
62052654|NCT02785640|NO_INTERVENTION|Control group|The control group will receive the same education session as the prompt group, as well as feedback on their baseline sitting behaviour. However, the will not receive prompts on their PC.
62442704|NCT02212405|EXPERIMENTAL|rTMS 1Hz + PET|Deep repetitive Transcranial Magnetic Stimulation will be applied to the insula for 30 minutes. This will consist of 20 trains each comprising of 50 pulses at 1Hz. The inter-train interval is 15 seconds. The intervention is followed by radiotracer and PET.
62442705|NCT02212405|EXPERIMENTAL|rTMS 10Hz + PET.|Deep repetitive Transcranial Magnetic Stimulation will be applied to the insula for 30 minutes. This will consist of 34 trains each comprising of 30 pulses at 10Hz. The inter-train interval is 3 seconds. The intervention is followed by radiotracer and PET.
62442706|NCT05314569|PLACEBO_COMPARATOR|Control group(C)|anesthesia will be maintained using Isoflurane 1.2MAC keeping the bispectral index( BIS) between 40-60%.
62442707|NCT05314569|ACTIVE_COMPARATOR|Ketamine-dexmedetomidine group( KD)|After induction of anesthesia , dexmedetomidine will be given(1 ug /kg ) over 10 min, then ketamine(2 m/kg) . maintenance throughout the procedure, with the bispectral index between 40 and 60%. by infusing Dexmedetomidine( 0.5 μg/.kg /.h r)) ketamine,( 1 m/kg/hr),
62442708|NCT05314569|ACTIVE_COMPARATOR|. Fentanyl- midazolam group (FM)|After induction of anesthesia fentanyl( 3 μg/kg), midazolam( 100 ug /kg over 2 to 3 minutes) maintenance throughout the procedure, with the bispectral index between 40 and 60%. by infusing midazolam (1 ug /kg /min)-fentanyl( 2 μg/kg/h ).
62442709|NCT00979160|EXPERIMENTAL|Dasatinib|Patient will be treat at a starting dose of 20mg once daily, that can be escalated up to 100mg once daily.
62442710|NCT00674219|ACTIVE_COMPARATOR|OCD group|OCD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication.
62442711|NCT00674219|ACTIVE_COMPARATOR|GAD group|GAD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication.
62835658|NCT02042963||KNOW-KT|1000 Kidney transplant recipients in Korea
62835659|NCT05611320|EXPERIMENTAL|Awareness Campaign|Raise awareness among parents about how and why to use local produce in their kid's meals.
62835660|NCT05611320|EXPERIMENTAL|Online Shopping|Provide information about an online shopping platform where the parents can shop for local produce online, and have it delivered, to disrupt their current ingredient-selection habits.
62442712|NCT06546579|EXPERIMENTAL|Experimental group|All participants will be asked to perform self-sampling and irrespective of the result will receive current standard-of-care from their health care provider for their suspected scabies.
62835661|NCT01471288|ACTIVE_COMPARATOR|Group3|Normal controls
62835662|NCT01471288|PLACEBO_COMPARATOR|Group4|Normal controls
62835663|NCT01471288|ACTIVE_COMPARATOR|Group 1|Hypothyroid patients taking levothyroxin.
62835664|NCT01471288|PLACEBO_COMPARATOR|Group2|Hypothyroid patients taking levothyroxin
62442713|NCT06398470|OTHER|Radical prostatectomy|The patients will undergo radical prostatectomy with nerve sparing decisions based on the results of the NeuroSAFE technique
62623598|NCT03584230|NO_INTERVENTION|No Cues Condition|Students will be assigned to a group that receives no nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs positive nonverbal behaviors to students in a different t-shirt color and negative nonverbal behaviors to students in a different t-shirt color. Students wearing the same t-shirt color as the participant never interact with the teacher.
62623599|NCT05409716|EXPERIMENTAL|Compressive Elastic dressing|Patients who received compressive elastic dressing as a hemostasis technique after coronary angiography using radial approach.
62835665|NCT05695508|EXPERIMENTAL|Arm A Tec-DRd Induction and Tec-D Maintenance|Arm A participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab SC, lenalidomide and dexamethasone in 6 cycles of induction therapy, followed by teclistamab SC injection in combination with daratumumab SC in maximum 18 cycles of maintenance therapy.
62835666|NCT05695508|EXPERIMENTAL|Arm B Tec-DVRd Induction and Tec-D Maintenance|Arm B participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab SC, lenalidomide, dexamethasone and bortezomib in 6 cycles of induction therapy, followed by teclistamab SC injection in combination with daratumumab SC in maximum 18 cycles of maintenance therapy.
62052655|NCT01665703|EXPERIMENTAL|FDG PET/MR|Participents will undergo a gadolinium enhanced FDG PET/MR study.
62835667|NCT05695508|EXPERIMENTAL|Arm C Tec-D Maintenance|Arm C participants will receive maximum 18 cycles of teclistamab SC injection in combination with daratumumab SC and lenalidomide as maintenance therapy.
62052656|NCT02613819|EXPERIMENTAL|Stereotactic Ablative Body Radiotherapy|"Stereotactic Ablative Body Radiotherapy (SABR)~Treatment schedule 1: 26 Gray (Gy) in 1 fraction, for tumours of less than or equal to 4cm in size.~Treatment schedule 2: 42 Gray (Gy) in 3 fractions, for tumours of greater than 4cm in size"
62052657|NCT05323617|EXPERIMENTAL|Arm 1: Previously Untreated IST|Participants with SAA/vSAA that are previously untreated with IST.
62253828|NCT00797199||1-Treatment Group 1|Women receiving HRT treatment of Premarin.
62052658|NCT05323617|EXPERIMENTAL|Arm 2: Refractory IST|Participants with SAA/vSAA that are refractory to IST.
62052659|NCT05861128|EXPERIMENTAL|Jaktinib 100mg BID (twice daily)|
62052660|NCT01728519|EXPERIMENTAL|AllerT SC|AllerT subcutaneous injections
62253829|NCT00797199||2-Treatment Group 2|Women receiving combination HRT treatment of Premarin + Provera.
62253830|NCT00797199||3- Treatment Group 3|Women receiving combination HRT treatment of Premarin + Prometrium.
62253831|NCT00797199||4- Controls|Women not on HRT or healthy controls.
62253832|NCT06401824|EXPERIMENTAL|sacituzumab govitecan (SG) plus bevacizumab|SG 10mg/kg intravenous day 1 and day 8 of a 21-day cycle, + bevacizumab 15 mg/kg iv day 1 of a 21-day cycle till unacceptable toxicity or disease progression.
62253833|NCT02214602|EXPERIMENTAL|Study group(Epirubicin)|in this arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor
62253834|NCT02214602|NO_INTERVENTION|Control group|in this arm -control group- : patients will not receive immediate intravesical instillation of of epirubicin after compete transurethral resection of bladder tumor.
62253835|NCT05501938|EXPERIMENTAL|Cerclage|Perform physical exam indicated cerclage between 24w0d to 25w6d
62253836|NCT05501938|NO_INTERVENTION|Control|No intervention; routine monitoring in pregnancy for preterm delivery
62253837|NCT04035018|EXPERIMENTAL|pharmacopuncture therapy|The physicians will select one or more pharmacopuncture therapy for each participants. The physicians will also decide dosage and frequency of treatment according to the participant's status.
62442714|NCT04371614|ACTIVE_COMPARATOR|Prime Time Sister Circle Intervention|The women in this arm participate in a Prime Time Sister Circle (PTSC). The PTSC is a multi-faceted, facilitated, curriculum- and community-based, intensive, support group intervention with 25-30 mid-life African American women per group. PTSC addresses three key modifiable health risk factors for chronic disease: unmanaged stress, physical inactivity, and unhealthy nutritional choices. It also addresses additional risk factors that contribute to unhealthy lifestyles: lack of knowledge or misinformation about major illnesses-cardiovascular disease (CVD), hypertension, diabetes, cancer, stress and depression-and the failure of African American women to prioritize their health and take proactive steps to manage their health and health outcomes. PTSC gives African American women the information, motivation, tools, skills, and consultative support they need to improve and maintain their health.
62253838|NCT04035018|ACTIVE_COMPARATOR|physical therapy|The physicians will select one or more physical therapy for each participants. The physicians will also decide intensity and frequency of treatment according to the participant's status.
62253839|NCT03562572|EXPERIMENTAL|Ischemia driven revascularization|In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload, which may lead to deterioration of cardiac and renal function of the patient.
62442715|NCT04371614|NO_INTERVENTION|Usual Care|The women in the arm do not receive the intervention but provide data at baseline, 3 months, 9 months and 15 months.
62623600|NCT05409716|ACTIVE_COMPARATOR|wristband TR Band|Patients who received wristband TR Band as a hemostasis technique after coronary angiography using radial approach.
62835668|NCT05695508|EXPERIMENTAL|Arm A1 Tec-DRd Induction and Tec-D Maintenance|Arm A1 participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab SC, lenalidomide and dexamethasone in 6 cycles of induction therapy, followed by teclistamab SC injection in combination with daratumumab SC in maximum 18 cycles of maintenance therapy.
62835669|NCT05695508|EXPERIMENTAL|Arm C2 Tal-DR Maintenance|Arm C2 participants will receive maximum 18 cycles of talquetamab SC injection in combination with daratumumab SC and lenalidomide as maintenance therapy.
62835670|NCT05695508|EXPERIMENTAL|Arm D Tec-DRd Induction and Tec-Tal following induction|Arm D participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab SC, lenalidomide and dexamethasone in 6 cycles of induction therapy, followed by a combination of teclistamab and talquetamab SC injection in maximum 18 cycles of following induction therapy.
62052661|NCT01728519|PLACEBO_COMPARATOR|Placebo SC|placebo subcutaneous injections
62052662|NCT01728519|EXPERIMENTAL|AllerT ID|AllerT intra-dermal injections
62052663|NCT01728519|PLACEBO_COMPARATOR|Placebo ID|placebo intra-dermal injections
62052664|NCT03266770|OTHER|RELIEF stent placement|After meeting the inclusion criteria and being consented, patients will have the RELIEF stent inserted in the ureter during cystoscopy per standard of care for ureteral stent placement.
62052665|NCT04433364||Screening group|"a general population of women giving birth, called screening group included at routine antenatal visits, their partners, and children"
62052666|NCT04433364||COVID-19 group|"group of women testing positive for SARS-CoV-2 or falling ill with COVID-19, called COVID-19 group, their partners, and children"
62052667|NCT05749055|EXPERIMENTAL|ENX-102|Four weeks of 2 mg of ENX-102 in capsule form followed by 3 weeks of tapered dose plus 2 weeks of placebo in capsule form (before and/or after the ENX-102 treatment period), taken orally once daily in the evening for a 9-week total treatment period.
62052668|NCT05749055|PLACEBO_COMPARATOR|Placebo|Nine weeks of placebo in capsule form taken orally once daily in the evening for a 9-week total treatment period.
62052669|NCT03248258||Metastatic Breast Interview Participants - Shared Decision Making|Metastatic Breast Patient Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
62611971|NCT04938713|ACTIVE_COMPARATOR|AB group|"If A = Ketamine and B = Esketamine, each patient included in the study will be randomized in a sequence of administration of the two products. The AB sequence consists of patients starting with intravenous Ketamine 0,3 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 1) and continuing with intravenous Esketamine 0,15 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 2). Each patient will be monitored during the IV perfusion, and then, the next hour.~The patient will receive a total of two infusions of Ketamine and two infusions of Esketamine. Each patient will be his own witness because having received the two products without knowing which he started with. A wash-out period of one week will be observed between the two administration periods to avoid so-called carry-over effects according to which the administration of the first drug could influence the effect of the second drug administered."
62052670|NCT03248258||Early Stage Breast Interview Participants - Shared Decision Making|Early Stage Breast Patient Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
62052671|NCT03248258||Provider Focus Group -Shared Decision Making|Clinic Provider Participants will participate in a focus group on the topic of Shared Decision Making. This will be a one time, focus group interview with a trained moderator.
62052672|NCT03248258||Non-UAB Provider Shared Decision Making|Non-UAB Provider Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
62052673|NCT03248258||Early Stage de-escalation Interview Participants|Early Stage Breast Patient Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
62052674|NCT03248258||Patient Advocate de-escalation Interview Participants|Patient Advocate Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
62052675|NCT03248258||Physician de-escalation Interview Participants|Physician Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
62052676|NCT03248258||Early Stage Feedback Interview Participants|Early Stage Breast Patient Participants will be interviewed to provide feedback on a decision making tool (video). This will be a one time, one-on-one interview with a trained interviewer.
62052677|NCT01127646|EXPERIMENTAL|Atomoxetine|Participants received 25-80 milligrams (mg) of atomoxetine orally, once daily during the run-in period for up to 7 days. The run-in period was followed by the 4-week on/off period in which participants received 25-80 mg of atomoxetine orally, once daily for 4 weeks, except for the off-days, where participants received 1 or 2 oral once daily placebo doses per week, with 6 nonconsecutive, double-blinded placebo doses in total over the 4-week on/off period. The on/off period was followed by a run-out period in which participants received 25-80 mg of atomoxetine orally, once daily for 1-5 days.
62052678|NCT01127646|ACTIVE_COMPARATOR|Osmotic-release oral system methylphenidate|Participants received 18-54 mg of osmotic-release oral system (OROS) methylphenidate orally, once daily during the run-in period for up to 7 days. The run-in period was followed by the 4-week on/off period in which participants received 18-54 mg of OROS methylphenidate orally, once daily for 4 weeks, except for the off-days, where participants received 1 or 2 oral once daily placebo doses per week, with 6 nonconsecutive, double-blinded placebo doses in total over the 4-week on/off period. The on/off period was followed by a run-out period in which participants received 18-54 mg of OROS methylphenidate orally, once daily for 1-5 days.
62052679|NCT02366650||Lund ED|appr 100-200 patients at Lund ED
62052680|NCT02366650||Helsingborg ED|appr 100-200 patients at Helsingborg ED
62052681|NCT02366650||Vancouver ED|appr 100 patients at St Paul's hospital ED
62623601|NCT03077425|EXPERIMENTAL|Intervention|An RCT will enroll 360 mothers (total) of children 4-6 month olds from New York City (n=3) and New Jersey (n=2) pediatric practices. Half (180) will be assigned to the Community Health Worker intervention comprised of: a) home visits with mothers/families (n=6 visits over one year) and follow up telephone support; b) patient navigation to make/keep timely dental visits (2x by 18 months).
62052682|NCT02366650||Bern ED|appr 100 patients at Bern ED
62052683|NCT05024669|NO_INTERVENTION|Control Group|where no desensitizer application was done,
62052684|NCT05024669|EXPERIMENTAL|Group GL|applied with Gluma dentin desensitizer
62052685|NCT05024669|EXPERIMENTAL|Group SF|applied with Shieldforce desensitizer
62052686|NCT05024669|EXPERIMENTAL|Group TC|applied with Telio CS desensitizer
62052687|NCT02801539|EXPERIMENTAL|Respiratory muscle training (RMT)|Subjects in the experimental arm will be given an inspiratory and expiratory RMT device to use during Duke-based and home-based RMT therapy.
62052688|NCT02801539|SHAM_COMPARATOR|Sham-RMT|Subjects in control arm will be given an inspiratory and expiratory sham-device and will complete Duke-based and home-based sham-RMT therapy.
62835671|NCT05695508|EXPERIMENTAL|Arm E Tal-DRd Induction and Tec-D Maintenance|Arm E participants will receive talquetamab as subcutaneous (SC) injection in combination with daratumumab SC, lenalidomide and dexamethasone in 6 cycles of induction therapy, followed by teclistamab SC injection in combination with daratumumab SC in maximum 18 cycles of maintenance therapy.
62052689|NCT01779726|EXPERIMENTAL|CT scan before chest physician|CT scan before chest physician
62052690|NCT01779726|ACTIVE_COMPARATOR|Usual diagnostic workup|Usual diagnostic workup
62052691|NCT02255032|EXPERIMENTAL|4 mg CLS-TA|Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
62052692|NCT02255032|EXPERIMENTAL|0.8 mg CLS-TA|Single unilateral, suprachoroidal injection of 8 mg/mL (0.8 mg in 100 µL) of CLS-TA
62253840|NCT03562572|ACTIVE_COMPARATOR|Usual care group|In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
62253841|NCT01788033|ACTIVE_COMPARATOR|XOMA 052|0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
62253842|NCT01788033|PLACEBO_COMPARATOR|Placebo|0.3 mg/kg placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
62253843|NCT02709499|SHAM_COMPARATOR|0J LLLT|The intervention will be made with the machine off.
62442716|NCT02831062|NO_INTERVENTION|ad lib diet|Patients who have an episode of Stage 2/3 AKI and are followed in a focused post-AKI clinic. Patients will be asked to continue on their regular diet and the protein and caloric ingestion will be recorded at each visit.
62835672|NCT05695508|EXPERIMENTAL|Arm E1 Tal-DRd Induction and Tal-D Maintenance|Arm E1 participants will receive talquetamab as subcutaneous (SC) injection in combination with daratumumab SC, lenalidomide and dexamethasone in 6 cycles of induction therapy, followed by talquetamab SC injection in combination with daratumumab SC in maximum 18 cycles of maintenance therapy.
62835673|NCT05695508|EXPERIMENTAL|Arm F Tal-DVRd Induction and Tec-D Maintenance|Arm F participants will receive talquetamab as subcutaneous (SC) injection in combination with daratumumab SC, bortezomib, lenalidomide and dexamethasone in 6 cycles of induction therapy, followed by teclistamab SC injection in combination with daratumumab SC in maximum 18 cycles of maintenance therapy.
62835674|NCT05695508|EXPERIMENTAL|Arm F1 Tal-DVRd Induction and Tal-D Maintenance|Arm F1 participants will receive talquetamab as subcutaneous (SC) injection in combination with daratumumab SC, bortezomib, lenalidomide and dexamethasone in 6 cycles of induction therapy, followed by talquetamab SC injection in combination with daratumumab SC in maximum 18 cycles of maintenance therapy.
62835675|NCT05965544|ACTIVE_COMPARATOR|Group PreS|The block will be applied in the preoperative period
62835676|NCT05965544|ACTIVE_COMPARATOR|Group PostS|The block will be applied in the postoperative period
62052693|NCT05505630|EXPERIMENTAL|Saline first injection; ketamine second injection|Subjects in this arm will receive a single intravenous infusion of placebo at the first injection visit and a single intravenous infusion ketamine at the second injection visit.
62052694|NCT05505630|EXPERIMENTAL|Saline first injection; midazolam second injection|Subjects in this arm will receive a single intravenous infusion of placebo at the first injection visit and a single intravenous infusion midazolam at the second injection visit
62052695|NCT05505630|EXPERIMENTAL|Saline first injection; dexmedetomidine second injection|Subjects in this arm will receive a single intravenous infusion of placebo at the first injection visit and a single intravenous infusion dexmedetomidine at the second injection visit.
62052696|NCT05505630|EXPERIMENTAL|Ketamine first injection; Saline second injection|Subjects in this arm will receive a single intravenous infusion of ketamine at the first injection visit and a single intravenous infusion placebo at the second injection visit.
62052697|NCT05505630|EXPERIMENTAL|Ketamine first injection; midazolam second injection|Subjects in this arm will receive a single intravenous infusion of ketamine at the first injection visit and a single intravenous infusion midazolam at the second injection visit.
62052698|NCT05505630|EXPERIMENTAL|Ketamine first injection; dexmedetomidine second injection|Subjects in this arm will receive a single intravenous infusion of ketamine at the first injection visit and a single intravenous infusion dexmedetomidine at the second injection visit.
62052699|NCT05505630|EXPERIMENTAL|Midazolam first injection; Saline second injection|Subjects in this arm will receive a single intravenous infusion of midazolam at the first injection visit and a single intravenous infusion placebo at the second injection visit.
62253844|NCT02709499|EXPERIMENTAL|6J LLLT|The Laser radiation will be made with 4J by spot
62253845|NCT04615754|EXPERIMENTAL|3-OHB vs Saline|3-OHB will be infused for 2.5 hours in IPAH (n=5) and CETPH (n=5) patients- 6 in each group is recruited for taking drop-out into account
62253846|NCT04615754|EXPERIMENTAL|Saline vs 3-OHB|Saline will be infused for 2.5 hours in IPAH (n=5) and CETPH (n=5) patients- 6 in each group is recruited for taking drop-out into account
62253847|NCT01378858|EXPERIMENTAL|Varenicline treatment as usual (TAU)|Subjects in the TAU arm will self administer varenicline for 12 weeks.
62253848|NCT01378858|EXPERIMENTAL|Varenicline directly observed therapy|Subjects in the directly observed therapy (DOT) arm will receive varenicline directly administered by methadone clinic nurses 4-6 times per week at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.
62442717|NCT02831062|EXPERIMENTAL|Low Protein Diet + Ketosteril|Patients who have an episode of Stage 2/3 AKI and are followed in a focused post-AKI clinic. Patients in this arm will be prescribed a low protein diet (LPD) and +Ketosteril supplementation, containing 0.6 g protein/kg per day, phosphorus 5-10 mg/kg/day, Ketosteril 1 capsule per 5 kg body weight/day divided over three doses (max 8 capsules per dose). Protein and caloric ingestion will be recorded.
62835677|NCT03901872||Acute Iliofemoral DVT|Suitable patients would be invited to take part in this trial as part of standard of care.
62835678|NCT02641782|ACTIVE_COMPARATOR|Standard Arm|Standard IL-2 i.v. together with antibody ch14.18, GM-CSF and retinoic acid
62052700|NCT05505630|EXPERIMENTAL|Midazolam first injection; ketamine second injection|Subjects in this arm will receive a single intravenous infusion of midazolam at the first injection visit and a single intravenous infusion ketamine at the second injection visit.
62052701|NCT05505630|EXPERIMENTAL|Midazolam first injection; dexmedetomidine second injection|Subjects in this arm will receive a single intravenous infusion of midazolam at the first injection visit and a single intravenous infusion dexmedetomidine at the second injection visit.
62052702|NCT05505630|EXPERIMENTAL|Dexmedetomidine first injection; Saline second injection|Subjects in this arm will receive a single intravenous infusion of dexmedetomidine at the first injection visit and a single intravenous infusion placebo at the second injection visit.
62052703|NCT05505630|EXPERIMENTAL|Dexmedetomidine first injection; ketamine second injection|Subjects in this arm will receive a single intravenous infusion of dexmedetomidine at the first injection visit and a single intravenous infusion ketamine at the second injection visit.
62052704|NCT05505630|EXPERIMENTAL|Dexmedetomidine first injection; midazolam second injection|Subjects in this arm will receive a single intravenous infusion of dexmedetomidine at the first injection visit and a single intravenous infusion midazolam at the second injection visit.
62052705|NCT03638206|EXPERIMENTAL|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
62052706|NCT02932046||Standardized noon meal|"Patients with anorexia nervosa during in-patient treatment are rating hunger and satiety on a visual analogue scale before and after a standardized and supervised meal. The meal is treatment as usual in a specialized ward. A patient may participate several times, if readmitted."
62052707|NCT01928420|EXPERIMENTAL|NIC5-15|Subjects with Alzheimer's Disease Intervention: Drug: NIC5-15
62052708|NCT01928420|PLACEBO_COMPARATOR|Placebo|Subjects with Alzheimer's Disease Intervention: Drug: Placebo
62052709|NCT05700500|EXPERIMENTAL|shockwave therapy|The calcification will be located by ultrasound and the energy will be applied in the precise place. 3 sessions will be carried out as follows: 1, 2, 3 weeks This procedure will be carried out by a single experienced Physical and Rehabilitation medical doctor
62253849|NCT05151003||Patients admitted to University Hospital San Martino, Genova, Italy|Adult patients admitted to University Hospital San Martino, Genova, Italy
62052710|NCT05700500|EXPERIMENTAL|Ultrasound-Guided Barbotage|The calcification will be located by ultrasound. By injecting serum at high pressure, it is intended to wash away the calcification. A subacromial inyection will be associated with this procedure. A maximum of 3 Ultrasound-Guided Barbotage will be performed with an interval of 6 weeks between each puncture. This procedure will be performed by two experienced radiologists
62253850|NCT05376826|EXPERIMENTAL|Prefrail and Frail CLD Patients|Nurse- led Physical Therapy include Video based range of Motion Exercises for 10-20 min.
62253851|NCT05376826|NO_INTERVENTION|Control Group|Routine Interventions
62253852|NCT05281107|PLACEBO_COMPARATOR|Placebo, 500 mg calcium|Participants received 500 mg calcium in berry flavoured sachet powder daily for 16 weeks
62442718|NCT02655354|EXPERIMENTAL|Intervention|The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.
62442719|NCT02655354|NO_INTERVENTION|Usual Care|Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.
62442720|NCT04139174||adolescent group|"Panoramic radiographs of finished orthodontic cases will be collected after fulfilling the inclusion and exclusion criteria. Then the collected data will be divided into two groups according to age either adolescent (12-18 years old) or adult group (after 18 years old).~measurements will be done on the radiograph using digital software."
62835679|NCT02641782|EXPERIMENTAL|Experimental Arm|IL-2 s.c. together with antibody ch14.18, GM-CSF and retinoic acid
62835680|NCT06109636||Normal group|
62052711|NCT05700500|EXPERIMENTAL|us guided subacromial injections|An US guided subacromial injection (1 cc of corticostheroid ) and anesthetic (2 cc of mepivacaine) will be performed. The periodicity will be one infiltration every 8-10 weeks, being able to carry out a maximum of 3 per year.
62052712|NCT01738880|ACTIVE_COMPARATOR|group C|intraoperative fluid management based on CVP
62052713|NCT01738880|EXPERIMENTAL|group S|intraoperative fluid management based on SVV
62052714|NCT05414539|EXPERIMENTAL|Intervention group|"OptiCogs Online is a 6-week telehealth intervention consisting of cognitive, physical activity and educational components. Cognitive component of the intervention: Throughout the six-week intervention period, there will be three individualised one-to-one cognitive sessions (occurring on week one, week three and week five), delivered by an occupational therapist. Physical activity: The physical activity component will be delivered via telehealth by a physiotherapist.~* Aerobic: Progressions from Week 1-Week 6 will result in individual achieving 60 mins moderate intensity aerobic activity @ frequency of 3 times per week as tolerated.~* Muscular strengthening: Progressions from Week 1-Week 6 will result in the person post-stroke achieving 10 strengthening exercises x 10 reps x 3 sets @ frequency of 3 times per week as tolerated. Cognitive education: The cognitive education component is underpinned by the Bridges stroke self-management package and based on self-efficacy principles."
62052715|NCT02274857|ACTIVE_COMPARATOR|Standard PVI Ablation|Standard catheter ablation including pulmonary vein isolation (PVI) procedure for the treatment of persistent AF.
62253853|NCT05281107|ACTIVE_COMPARATOR|600 IU vitamin D + 500 mg calcium|Participants received 600 IU vitamin D with 500 mg calcium in berry flavoured sachet powder daily for 16 weeks
62253854|NCT05281107|ACTIVE_COMPARATOR|1200 IU vitamin D + 500 mg calcium|Participants received 1200 IU vitamin D with 500 mg calcium in berry flavoured sachet powder daily for 16 weeks
62835681|NCT05858723|EXPERIMENTAL|Allergic participants|
62835682|NCT05858723|EXPERIMENTAL|Healthy participants|
62835683|NCT00350415|EXPERIMENTAL|1|Asacol 2.4 g/day (400 mg tablet)
62835684|NCT00350415|ACTIVE_COMPARATOR|2|Asacol 4,8 g/day (800 mg tablet), oral, for 6 weeks
62052716|NCT02274857|EXPERIMENTAL|FIRM-guided Procedure and PVI|FIRM-guided procedure followed by standard catheter ablation including PVI.
62835685|NCT01318239|EXPERIMENTAL|Standard Chemotherapy with Avastin|
62835686|NCT01318239|ACTIVE_COMPARATOR|Standard Chemotherapy only|
62052717|NCT05324969|EXPERIMENTAL|MM-based MI group|Intervention group parents will receive 9 intervention sessions every other week by trained staff via 9 online sessions via Zoom or phone calls. Each intervention session will last 30-40 minutes. Intervention group parents will receive 3 text messages per week. No in-person contacts will be conducted without MSU department permission. All assessments will be delivered remotely with guided phone calls or zoom conference. The assessment of dyads' BMI, %BF, and WC will be obtained remotely from the parents using the scale and measuring tape delivered to their home.
62253855|NCT05281107|ACTIVE_COMPARATOR|4000 IU vitamin D + 500 mg calcium|Participants received 4000 IU vitamin D with 500 mg calcium in berry flavoured sachet powder daily for 16 weeks
62253856|NCT03658265|ACTIVE_COMPARATOR|7 days SIE plus 4 weeks PRE|Participants in this group will start shoulder isotonic exercise 7 days after surgery and begin progressive resistance exercise 4 weeks after surgery.
62442721|NCT04139174||adult group|"Panoramic radiographs of finished orthodontic cases will be collected after fulfilling the inclusion and exclusion criteria. Then the collected data will be divided into two groups according to age either adolescent (12-18 years old) or adult group (after 18 years old).~measurements will be done on the radiograph using digital software."
62611972|NCT04938713|OTHER|BA group|"If A = Ketamine and B = Esketamine, each patient included in the study will be randomized in a sequence of administration of the two products. The BA sequence consists of patients starting with intravenous Esketamine 0,15 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 1) and continuing with intravenous Ketamine 0,3 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 2). Each patient will be monitored during the IV perfusion, and then, the next hour.~The patient will receive a total of two infusions of Esketamine and then two infusions of Ketamine. Each patient will be his own witness because having received the two products without knowing which he started with. A wash-out period of one week will be observed between the two administration periods to avoid so-called carry-over effects according to which the administration of the first drug could influence the effect of the second drug administered."
62835687|NCT02263027|EXPERIMENTAL|Vaccine, then placebo|1 injection of trivalent inactivated influenza vaccine, 0.5mL/dose, as approved for use in Canada for season of enrolment followed by 1 injection of normal saline placebo, 0.5mL/dose, 28 days later
62835688|NCT02263027|EXPERIMENTAL|Placebo, then vaccine|1 injection of normal saline placebo, 0.5mL/dose followed by 1 injection of trivalent inactivated influenza vaccine, 0.5mL/dose, as approved for use in Canada for season of enrolment, 28 days later
62052718|NCT05324969|OTHER|Control group|Control group parents will receive a total of 9 emailed packets of educational materials (without information related to the mindfulness-based motivational interviewing \[MM-based-MI\]). The pre and post assessments will be collected the same way as the participants at intervention group.
62052719|NCT04468269|EXPERIMENTAL|balance training with sensory integration group|Conventional treatment: Static stretching exercises such as trunk rotation, flexion, and extension; hip flexors stretch, standing hamstring stretch; plantar flexors stretch, shoulder, elbow and wrist flexors and supinators stretch. Stretching will be applied for 30-sec hold with 30-sec rest. 3-5 times for each muscle group. For 40 min/day and 3 days/week for 6 weeks to improve balance and postural stability.
62253857|NCT03658265|EXPERIMENTAL|7 days SIE plus 3 weeks PRE|Participants in this group will start shoulder isotonic exercise 7 days after surgery and begin progressive resistance exercise 3 weeks after surgery.
62253858|NCT03658265|EXPERIMENTAL|3 days SIE plus 4 weeks PRE|Participants in this group will start shoulder isotonic exercise 3 days after surgery and begin progressive resistance exercise 4 weeks after surgery.
62442722|NCT05044442|NO_INTERVENTION|Control|Participants will continue with their habitual lifestyle but perform no exercise for 2 weeks
62442723|NCT05044442|ACTIVE_COMPARATOR|Moderate intensity continous training|Participants will complete moderate intensity continous training during a 2 week intervention period
62442724|NCT05044442|EXPERIMENTAL|high intensity interval training|Participants will complete high intensity interval training during a 2 week intervention period
62442725|NCT04058483|ACTIVE_COMPARATOR|HIP First|Participants randomized to perform the in-person hypnotizability test first. This will be followed within 1 week with the by-phone rHIP test performed by a second, randomly-assigned investigator.
62442726|NCT04058483|ACTIVE_COMPARATOR|rHIP First|Participants randomized to perform the by-phone hypnotizability test first. This will be followed within 1 week with the in-peron HIP test performed by a second, randomly-assigned investigator.
62442727|NCT01720628||Behçet's patients|Serum levels of angiogenin, bFGF, VEGF levels in Behçet's patients with ocular involvement group, without ocular involvement group and control group
62442728|NCT03642574|EXPERIMENTAL|PIMT methylation|Subjects will have blastocyst biopsy and whole genome DNA methylation sequencing done with 2 or 7 good-quality embryos on Day 5 to 7. Principle of freeze-all and single thawed blastocyst transfer will be applied. Only embryos with euploid chromosome will be transfered to the uterus. The outcome of all euploids transfers within 1 year will be followed up. During study, every subject will have at most one live birth.
62052720|NCT04468269|EXPERIMENTAL|balance training without sensory integration group|Conventional treatment: Static stretching exercises such as trunk rotation, flexion, and extension; hip flexors stretch, standing hamstring stretch; plantar flexors stretch, shoulder, elbow and wrist flexors and supinators stretch. Stretching will be applied for 30-sec hold with 30-sec rest. 3-5 times for each muscle group.For 40 min/day and 3 days/week for 6 weeks to improve balance and postural stability
62253859|NCT03658265|EXPERIMENTAL|3 days SIE plus 3 weeks PRE|Participants in this group will start shoulder isotonic exercise 3 days after surgery and begin progressive resistance exercise 3 weeks after surgery.
62253860|NCT04404322|EXPERIMENTAL|IPT A SCI|The IPT-A SCI follows the intervention protocol, which includes an intensive phase of 5 weekly 50-minute sessions and 3 follow up personal emails.
62253861|NCT04404322|ACTIVE_COMPARATOR|Treatment as usual|TAU patients receive an integrative combination of psychodynamic, supportive and cognitive behavioural therapy, usually lasting between 10-30 weeks.
62835689|NCT02536963||PVS Screening and reference examination|All enrolled participants will be screened with the Pediatric Vision Scanner (PVS screening) during a well-child visit to compare whether the results of the PVS match the results of the regular eye examination performed during the well-visit. They will then receive a reference examination performed by a fellowship-trained pediatric ophthalmologist. Results will be compared with PVS screening results.
62835690|NCT01378585|EXPERIMENTAL|Treatment 1|Test drug treatment: 3 x 490 mg DLBS1033 daily
62052721|NCT00822081|ACTIVE_COMPARATOR|1|brimonidine/timolol. Fixed-combination monotherapy.
62052722|NCT00822081|ACTIVE_COMPARATOR|2|dorzolamide/timolol. Fixed-combination monotherapy.
62052723|NCT00822081|ACTIVE_COMPARATOR|3|prostaglandin analogue+ brimonidine/timolol fixed combination.
62052724|NCT00822081|ACTIVE_COMPARATOR|4|prostaglandin analogue+dorzolamide/timolol fixed combination.
62052725|NCT05692505||Positive test subjects|Subjects having previous positive tests verified by certified laboratory
62052726|NCT05692505||Control subjects|Subjects having no previous positive tests verified by certified laboratory
62052727|NCT05318924|EXPERIMENTAL|Ghrelin infusion|To achieve approximately stable elevated ghrelin levels during the infusion procedure, the investigators will use a loading dose of 1 mcg/kg as well as an infusion rate of 0.051 mcg/kg/min in line with recent studies (Farokhnia, Grodin, Lee et al., 2017) and general recommendations (Garin, Burns, Kaul et al., 2013).
62052728|NCT05318924|PLACEBO_COMPARATOR|Placebo infusion|Saline
62052729|NCT05318924|NO_INTERVENTION|Patients with MDD|Patients with major depressive disorder will be enrolled for comparison to healthy participants on the reward task battery, but not randomized to the ghrelin vs. saline infusion.
62611973|NCT00830518|EXPERIMENTAL|Alisertib|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period, in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).
62835691|NCT01378585|PLACEBO_COMPARATOR|Treatment 2|Placebo treatment: 3 x 1 tablet daily
62835692|NCT03659669||Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with diagnosed CLL and eligible to venetoclax as per label.
62052730|NCT00529750|EXPERIMENTAL|Irbesartan Group|150 mg p.o. once a day, 30 minutes before breakfast during 12 weeks
62052731|NCT00529750|ACTIVE_COMPARATOR|Atenolol Group|50 mg p.o. once a day, 30 minutes before breakfast during 12 weeks.
62835693|NCT03066947|EXPERIMENTAL|SV-BR-1-GM Monotherapy|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites \~2 and \~4 days after SV-BR-1-GM inoculation
62835694|NCT00649207|EXPERIMENTAL|1|"This is an open label study; therefore, there are no numbered/labeled study arms.~This is a dose escalation study, ABT-888 dose will be escalated in conjunction with two schedules of whole brain radiation therapy (WBRT). Subjects may be treated WBRT for 3 weeks (15 days) or 2 weeks (10 days)."
62835695|NCT03562377|EXPERIMENTAL|Tralokinumab|"Week 0 to 16:~Tralokinumab will be given as subcutaneous injections.~Subjects will receive a tralokinumab loading dose at Day 0 followed by tralokinumab injection regimen A. The last administration will occur at Week 14."
62253862|NCT04404322|NO_INTERVENTION|wait list|WL patients are monitored by a trained clinician during their waiting period and complete the study questionnaire battery at the parallel time intervals.
62253863|NCT02867865|ACTIVE_COMPARATOR|Chemotherapy arm|"Post staging laparoscopy, all patients will receive chemotherapy using Injection Gemcitabine 1000 mg/m2 delivered day 1 and 8 every 3 weeks.~In addition, Injection Cisplatin 25 mg/m2 for and 4 cycles week 1 to week 11."
62253864|NCT02867865|EXPERIMENTAL|Chemoradiation arm|"Post staging laparoscopy in Experimental arm The radiation dose will be 50-55 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2). Radiotherapy will be for 5 weeks which will be followed by 2 cycles of chemotherapy with Injection Gemcitabine (Gemcite,Gemzar) 1000 mg/m2 delivered day 1 and 8 every 3 weeks and cisplatin (Cisplat, Cytoplatin) 25 mg/m2from week 7 to week 11.~During week 12-13 patients will undergo repeat PETCECT scan. If the scan shows partial or good response then patients will be evaluated for surgery. Surgery if possible will be done between weeks 13-15. In case of inoperable disease patients will receive further chemotherapy"
62835696|NCT03562377|PLACEBO_COMPARATOR|Placebo|"Placebo (dummy treatment) will be given as subcutaneous injections.~Subjects will receive a placebo loading dose at Day 0 followed by placebo injection regimen A. The last administration will occur at Week 14."
62835697|NCT00555698|EXPERIMENTAL|DBS|DBS
62835698|NCT03350672|EXPERIMENTAL|Cohort 1a|"Age 18 or older at the time of signed informed consent~* Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP~* Willing and able to independently provide written informed consent~* Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test"
62835699|NCT03350672|EXPERIMENTAL|Cohort 1b|"Age 18 or older at the time of signed informed consent~* Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP~* Willing and able to independently provide written informed consent~* Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test"
62835700|NCT03350672|ACTIVE_COMPARATOR|Cohort 2|"* Age 18 or older at the time of signed informed consent~* Willing and able to independently provide written informed consent~* Last viral load \< 20 copies/mL within the last four weeks of screening~* Must be on combination antiretroviral therapy that includes TAF/FTC for at least 6 months~* Undetectable viral load, as defined by \< 50 copies/ml, for at least 6 months"
62052732|NCT02583425|EXPERIMENTAL|DFN-11|DFN-11 Injection upon occurrence of migraine
62052733|NCT00992680|EXPERIMENTAL|Group A|Anastomotic Coupler System + standard of care per GOLD
62052734|NCT00992680|NO_INTERVENTION|Group B|Standard of care per GOLD alone
62052735|NCT04437433|EXPERIMENTAL|Atogepant 60 mg|Taken once daily
62052736|NCT03664479|EXPERIMENTAL|classical electrical stimulation protocol|"* apply 4 channel electrical stimulation device with protocol 1.~* It will simultaneously stimulate suprahyoid, thyrohyoid and sternothyroid m with 4 channel electrical stimulation device.~* during apply the device, we evaluate the manometry and videofluoroscopic swallowing study for evaluation of deglutition function."
62611974|NCT05559528||Public health system|Group with patients treated in the public health system in Brazil. They will be stratified according to whether or not CDK 4/6 inhibitors are used in therapy.
62611975|NCT05559528||Private health system|Group with patients treated in the private health system in Brazil. They will be stratified according to whether or not CDK 4/6 inhibitors are used in therapy.
62611976|NCT00553293|ACTIVE_COMPARATOR|A,1|rFSH + rLH arm
62835701|NCT02778789||Tocilizumab|Drug administration of Tocilizumab s.c. or i.v. depending on the preference of the patient and/or physician according to the label
62835702|NCT02778789||TNF-alpha Inhibitor|Drug administration s.c. or i.v. of the TNF-Alpha Inhibitor depending on the preference of the patient and/or physician according to the label
62835703|NCT04963439|EXPERIMENTAL|Treatment Sequence AB|Participants will receive single oral dose of macitentan formulated as final market image (FMI) in fasted conditions (test) (Treatment A) in treatment period 1 followed by a single oral dose of macitentan as the clinical service formulation (CSF) in fasted conditions (reference) (Treatment B) in treatment period 2 on Day 1. Study intervention intake in subsequent intervention periods in an individual participant will be separated by a washout period of at least 10 days.
62835704|NCT04963439|EXPERIMENTAL|Treatment Sequence BA|Participants will receive Treatment B in treatment period 1 followed by Treatment A in treatment period 2 on Day 1. Study intervention intake in subsequent intervention periods in an individual participant will be separated by a washout period of at least 10 days.
62052737|NCT03664479|EXPERIMENTAL|revised sequential activation protocol|"* apply 4 channel electrical stimulation device with protocol 2~* Is a revised sequential activation protocol, it sequentially stimulate bilateral suprahyoid m (channel 1), pharyngeal constrictors (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device.~* during apply the synchronized electrical stimulation device, we will evaluate the parameters same as group 1."
62253865|NCT01429818|EXPERIMENTAL|Glimepiride/metformin|
62253866|NCT01429818|ACTIVE_COMPARATOR|Metformin|
62253867|NCT01733979|EXPERIMENTAL|Heme-Iron Polypeptide|
62253868|NCT01733979|PLACEBO_COMPARATOR|Placebo|
62253869|NCT01733979|ACTIVE_COMPARATOR|Heme-Iron|
62835705|NCT02009904||Phenylketonuria (PKU); Healthy Controls|Children with PKU (5-18y); Age and Gender matched healthy subjects for comparison
62835706|NCT03666663|EXPERIMENTAL|Lidocaine|Participants will receive SPG blocks with lidocaine.
62835707|NCT03666663|EXPERIMENTAL|Bupivacaine|Participants will receive SPG blocks with bupivacaine
62835708|NCT03666663|EXPERIMENTAL|Ropivacaine|Participants will receive SPG blocks with ropivacaine
62835709|NCT03666663|PLACEBO_COMPARATOR|Placebo (saline)|Participants will receive SPG blocks with placebo (saline)
62253870|NCT01733979|ACTIVE_COMPARATOR|Organic Iron|
62253871|NCT02181816||Azilsartan/Amlodipine|Azilsartan/Amlodipine combination tablets (20 mg/2.5 mg or 20 mg/5 mg), orally, once daily for up to 12 months. Participants will receive interventions as part of routine medical care.
62442729|NCT02322879|EXPERIMENTAL|Acetaminophen first, then Acetaminophen + Propylene Glycol|"Subjects in this arm will receive 4 grams of solid acetaminophen formulation for two weeks, followed by a two week wash out period.~Then, subjects will receive 4 grams of solid acetaminophen formulation in addition to 70 mg/kg/day of liquid propylene glycol for two weeks.~The total study time is 6 weeks."
62611977|NCT00553293|PLACEBO_COMPARATOR|A,2|rFSH alone
62835710|NCT05295095|NO_INTERVENTION|control group|Classical extubation technique : ETT was removed with continuous endotracheal suction
62253872|NCT03215550||Carotid Endarterectomy|Patients who are scheduled to undergo carotid endarterectomy for symptomatic carotid artery stenosis (≥50% by NASCET criteria for men, ≥70% for women) who are above 40 years of age.
62611978|NCT05667207|EXPERIMENTAL|Point-of-care microscopy and dipstick guided management|GPs whose practice is allocated to the intervention will have their management guided by POCTs, namely phase-contrast microscopy and urinary dipsticks for all patients consenting for participation.
62835711|NCT05295095|EXPERIMENTAL|VSPEP|ETT was removed with APL valve set to 20cmH2O
62835712|NCT05295095|EXPERIMENTAL|VSAIPEP|ETT removed with ventilator parameters were set for PSV mode (inspiratory pressure of 10cmH2O and PEEP identical to that administered in the operating room
62835713|NCT03809104|EXPERIMENTAL|elderly with sarcopenia|Virtual reality-based rehabilitation programs
62052738|NCT06491836|ACTIVE_COMPARATOR|Arm 1: Patients who will follow food regimen without any food restriction.|
62052739|NCT06491836|EXPERIMENTAL|Arm 2: Patients who will follow food regimen based on oligoantigenic diet.|
62052740|NCT05166941|EXPERIMENTAL|Experimental group|It is a closed group in which the training program is implemented.
62052741|NCT05166941|NO_INTERVENTION|Control Group|No training program was applied to this group.
62835714|NCT06514014|NO_INTERVENTION|Donor Milk|
62835715|NCT06514014|ACTIVE_COMPARATOR|Preterm Infant Formula|
62835716|NCT06185543|ACTIVE_COMPARATOR|PrimeC|2 tablets of PrimeC administered twice daily (4 tablets a day), total daily dose of 1360 mg ciprofloxacin and 136 mg celecoxib orally.
62835717|NCT06185543|PLACEBO_COMPARATOR|Placebo|2 tablets of Placebo administered twice daily (4 tablets a day). Placebo tablets are matched in size, color and taste.
62835718|NCT05660577|EXPERIMENTAL|e Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens|
62835719|NCT06416384|EXPERIMENTAL|Hand Massage Group|The researcher applied a hand massage to the hand area of the patients in the experimental group on the side without fistula for five minutes, three times a week for four weeks.
62052742|NCT02521662|ACTIVE_COMPARATOR|Patch|21mg nicotine patch daily for 14 weeks (including a 2 week prequit period) plus behavioural support for six weeks post-quit
62442730|NCT02322879|EXPERIMENTAL|Acetaminophen + Propylene Glycol first, then Acetaminophen|"Subjects in this arm will receive 4 grams of solid acetaminophen formulation in addition to 70 mg/kg/day of liquid propylene glycol for two weeks, followed by a two week wash out period.~Then, subjects will receive 4 grams of solid acetaminophen formulation for two weeks.~The total study time is 6 weeks."
62442731|NCT05359432|EXPERIMENTAL|Empagliflozin|
62442732|NCT05359432|EXPERIMENTAL|Vildagliptin|
62442733|NCT05055271||Delphi panel|The Delphi panel will include 10 international experts in sleep and respiratory medicine. Two panelists will serve as co-chairs and eight panelists will serve as section leads for the major topic areas throughout the process. A series of planning sessions will be conducted with the co-chairs and section leads prior to implementation of the survey.
62442734|NCT01811446|EXPERIMENTAL|Obese|Subjects with BMI \> 30
62442735|NCT01811446|EXPERIMENTAL|COPD|Non-hospitalized COPD patients
62442736|NCT02780778|EXPERIMENTAL|Treatment group|Apatinib：500 mg，po，qd； Docetaxel：60mg/m²，vein input 1hour，every 3w
62835720|NCT06416384|OTHER|Control Group|Patients in the control group received routine nursing care in the clinic for four weeks.
62835721|NCT00719472|EXPERIMENTAL|Rituximab 375 mg/m^2|Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m\^2 administered by intravenous (IV) infusion on Day 1 of each cycle.
62442737|NCT03409185|EXPERIMENTAL|Alcon lens group|Alcon 1 piece SA60AT lens
62442738|NCT03409185|ACTIVE_COMPARATOR|AMO lens group|AMO 1 piece Sensar AABOO lens
62442739|NCT01108900||Patients with erectile dysfunction (ED)|100 ED patients in the study that were switched to sildenafil after a previous treatment with udenafil proved ineffective and/or was poorly tolerated
62835722|NCT01153529||Group 1|OEF/OIF Veterans
62835723|NCT01039740|EXPERIMENTAL|Responders|Reponders is a patients group who showed 50% or greater decrease in the HAM-D score at 6 weeks after treating with mirtazapine
62835724|NCT01039740|EXPERIMENTAL|Non-responders|Non-responders is a patients group who did not show 50% or greater decrease in the HAM-D score at 6 weeks after treating with mirtazapine
62052743|NCT02521662|ACTIVE_COMPARATOR|Patch and nicotine-free e-cigarette|21mg nicotine patch (daily) and nicotine-free e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit
62052744|NCT02521662|ACTIVE_COMPARATOR|Patch and nicotine e-cigarette|21mg nicotine patch (daily) and nicotine e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit
62442740|NCT05326022|EXPERIMENTAL|medical therapy group|formed of 20 patients to whom ordinary medical therapy as the pervious groups and placebo shame laser had been applied.
62611979|NCT05667207|NO_INTERVENTION|Usual care|Practices in the control arm will not have their management guided by POCTs. They will perform usual care. The treatment decision is usually based on symptoms and dip-stick test results (i.e., erythrocytes, leukocytes, nitrites).
62835725|NCT04588571|EXPERIMENTAL|Endovascular treatment|Patients (n=55) with recanalization of the femoral-popliteal arterial segment (TASC II, type D) above the knee with a biomimetic braided nitinol stent.
62052745|NCT03859258||Patient having Cesarean section|Transvaginal sonography for patients having ceserean section to assess uterine Niche development and parameters
62052746|NCT03859258||Patient delivered vaginally|Transvaginal sonography for patients having vaginal delivery to confirm absence of uterine Niche development
62052747|NCT03521726|OTHER|Intraluminal Amoxicillin eradication|20 Patients receive intraluminal Amoxicillin eradication of H. pylori.
62052748|NCT03521726|OTHER|Rabeprazole, Amoxicillin dual therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole and Amoxicillin) for 14 days.
62052749|NCT02521402|OTHER|Keloid Revision Surgery with Biovance|All enrolled patients will have Biovance applied during Keloid Revision Surgery
62052750|NCT01977014||Patient with LenusPro pump|
62052751|NCT00552084|EXPERIMENTAL|Fish Oil|4 grams fish oil daily for 24 weeks
62052752|NCT00552084|PLACEBO_COMPARATOR|Placebo|corn oil taken daily for 24 weeks
62052753|NCT03360708|EXPERIMENTAL|Treatment (vaccine therapy)|Patients receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 1, 3, and 5 of courses 2 and 3, and on day 1 of subsequent courses. Treatment with malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine repeats every 21 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
62052754|NCT01589172||Pediatric Brain Trauma Patients|
62052755|NCT03340480|EXPERIMENTAL|NVP-1402-1|NVP-1402 was administered once a day for 24 hours
62052756|NCT03340480|EXPERIMENTAL|NVP-1402-2|NVP-1402 was administered once a day for 24 hours
62052757|NCT03138096|EXPERIMENTAL|Group 1 - five Pb(PfCS@UIS4)-infected mosquitoes|(Group 1) will be exposed to bites of five Pb(PfCS@UIS4)-infected mosquitoes
62052758|NCT03138096|EXPERIMENTAL|Group 2 - 25 Pb(PfCS@UIS4)-infected mosquito bites|(group 2) will be exposed to 25 Pb(PfCS@UIS4)-infected mosquito bites
62052759|NCT03138096|EXPERIMENTAL|Group 3 - 75 Pb(PfCS@UIS4)-infected mosquito bites|(group 3) will be exposed to 75 Pb(PfCS@UIS4)-infected mosquito bites
62052760|NCT03138096|OTHER|Group 4 - Infectivity control group of Phase 1|Infectivity control group of Phase 1
62052761|NCT03138096|OTHER|Group 5 - Infectivity control group of Phase 2|Infectivity control group of Phase 2
62052762|NCT00664937|PLACEBO_COMPARATOR|I|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
62253873|NCT00395863|ACTIVE_COMPARATOR|MultiHance|0.5 M MultiHance at a single injection
62253874|NCT00395863|ACTIVE_COMPARATOR|Magnevist|0.5 M Magnevist at a single injection
62253875|NCT03357315|EXPERIMENTAL|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62835726|NCT04588571|ACTIVE_COMPARATOR|Open surgery|Patients (n=55) with femoropopliteal proximal bypass with a prolonged atherosclerotic lesion of the femoropopliteal arterial segment (TASC II, type D).
62611980|NCT00444860|EXPERIMENTAL|1|Zostavax
62835727|NCT02964143|EXPERIMENTAL|Experimental group|Patients from this group will be treated with a combination of platelet-rich plasma (PRP) and hyaluronic acid (HA) prepared with the Cellular Matrix / A-CP HA medical device
62052763|NCT00664937|PLACEBO_COMPARATOR|II|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
62052764|NCT00664937|PLACEBO_COMPARATOR|III|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
62835728|NCT02964143|ACTIVE_COMPARATOR|Control group 1|Patients from this group will be treated with a well-recognized hyaluronic acid named Ostenil® Plus
62052765|NCT02722512|EXPERIMENTAL|Newly Diagnosed High Grade Glioma (HGG)|Heat Shock Protein Peptide Complex-96 (HSPPC-96) therapy will be given between 0-28 days after the completion of radiation therapy (XRT) AND no more than 60 days from completion of XRT. Vaccine will be given once weekly for 4 weeks. The 4 weeks (28 days) of vaccine administration will be followed by an observation visit. In patients with sufficient vaccine (on both Arms A and B), a maintenance therapy will be instituted. It will be administered at the same dose the patient was enrolled at and given every 2 weeks until vaccine is exhausted or there is evidence of tumor progression. The first dose of maintenance vaccine should be administered 7 days after completion of the observation visit.
62052766|NCT02722512|EXPERIMENTAL|Recurrent HGG and Ependymoma|On Arm B, Heat Shock Protein Peptide Complex-96 (HSPPC-96) will be given as soon as possible after tumor resection post-operative recovery and sufficient time for vaccine preparation (typically 0-28 days post-operatively) AND no more than 60 days post-operatively. Vaccine will be given once weekly for 4 weeks. These 4 weeks (28 days) of vaccines will be followed by an observation visit. In patients with sufficient vaccine, a maintenance therapy will be given. It will be given at the same dose the patient was enrolled at and given every 2 weeks until vaccine is exhausted or there is evidence of tumor progression. The first dose of maintenance vaccine should be given 7 days after completion of the observation visit.
62052767|NCT01566175|EXPERIMENTAL|Neovasc coronary sinus reducer|open label: Neovasc coronary sinus reducer
62052768|NCT06414486|EXPERIMENTAL|Dietary supplement group|Participants received orally 1 tablet containing 200mg of Red Panax Ginseng for 4 weeks
62052769|NCT06414486|PLACEBO_COMPARATOR|Control group|Participants received orally 1 tablet similar to the test product, containing no active principle for 3 weeks
62052770|NCT00031486|EXPERIMENTAL|Valacyclovir|
62253876|NCT03357315|NO_INTERVENTION|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62442741|NCT05326022|EXPERIMENTAL|medical therapy and Microcurrent group|formed of 20 patients to whom the microcurrent therapy had been applied with ordinary medical therapy.
62052771|NCT00031486|PLACEBO_COMPARATOR|Placebo|
62052772|NCT00850889|ACTIVE_COMPARATOR|1|Juvederm Ultra Injectable Gel with Lidocaine
62052773|NCT00850889|ACTIVE_COMPARATOR|2|Restylane Injectable Gel
62052774|NCT03523312|EXPERIMENTAL|HFA-IMRT|Eligible patients will receive HFA-IMRT to a total dose of 67.5 Gy in 15 fractions or 75Gy in 25 fractions to areas of gross tumor with concurrent capecitabine. Cross-sectional imaging will be repeated 4-6 weeks after the end of CRT to assess for resectability.
62052775|NCT00733499|OTHER|LCS Complete Duofix|102 patients
62052776|NCT00733499|ACTIVE_COMPARATOR|LCS Complete Porocoat|104 patients
62442742|NCT05326022|EXPERIMENTAL|medical therapy and Low-Level Laser Therapy group|formed of 20 patients to whom the Low Level Laser Therapy had been applied with ordinary medical therapy.
62442743|NCT06395649|ACTIVE_COMPARATOR|Classical rTMS to M1x|The patients will receive repetitive transcranial magnetic stimulation (rTMS) to the primary cortex (M1) according to the classical treatment.
62835729|NCT02964143|ACTIVE_COMPARATOR|Control group 2|Patients from this group will be treated with PRP alone, prepared with RegenKit-BCT-1
62052777|NCT05758831|ACTIVE_COMPARATOR|Ocrelizumab|Day 0 (300mg), Day 15(300mg), and then 300 mg every 6 months (M6, M12, M18 and M24)
62835730|NCT00131248|OTHER|Anti-reflux Medications, then Placebo (group 1)|"3-day course of anti-reflux medications, followed by 7-day course placebo, followed by 4-day course anti-reflux medications.~All study medication administered via nipple or orogastric (OG) tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes."
62835731|NCT00131248|OTHER|Placebo, then Anti-reflux Medications|"3-day course placebo, followed by 7-day course anti-reflux medication, followed by 4-day course placebo.~All study medication administered via nipple or OG tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes."
62835732|NCT05056389|EXPERIMENTAL|NIPEX-OXA arm|20 patients treated with NIPEC-OXA after CRS and HIPEC.
62442744|NCT06395649|EXPERIMENTAL|High connectivity target|The patients will receive repetitive transcranial magnetic stimulation (rTMS) to target showing the largest connectivity during the TMS-EEG assessment one week before starting the treatment
62611981|NCT02423668||50% Partial adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. Second eye refinement in the intra-ocular lens power selection for the second eye was performed using a theoretical 50% partial adjustment of the PE1. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
62835733|NCT06425900|EXPERIMENTAL|Winlevi (Clascoterone ) cream 1%|
62835734|NCT01596010|EXPERIMENTAL|New formulation|
62835735|NCT01596010|ACTIVE_COMPARATOR|Old formulation|
62442745|NCT06395649|EXPERIMENTAL|Low connectivity target|The patients will receive repetitive transcranial magnetic stimulation (rTMS) to target showing the lowest connectivity during the TMS-EEG assessment one week before starting the treatment
62835736|NCT05021978|EXPERIMENTAL|Part A: Open-label 20 and 40 mg PRAX-944|Once daily, oral dosing with 7 days of 20 mg and 7 days of 40 mg
62835737|NCT05021978|EXPERIMENTAL|Part B: Open-label titration PRAX-944 (120 mg) followed by blinded PRAX-944|Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 28 days of 120 mg
62052778|NCT05758831|EXPERIMENTAL|Rituximab|Day 0 (1000mg), Day 15 (1000 mg), and then 500 mg every 6 months (M6, M12, M18 and M24)
62442746|NCT06395649|SHAM_COMPARATOR|Sham stimulation|Subjects experiencing significant pain reduction (according to the primary outcome) by the treatment will be asked if they would like to continue maintenance stimulation sessions. Participants accepted to join this part of the study will receive 1 stimulation session every 2 weeks for 4 weeks (total of 2 stimulation sessions). The participants will receive either active stimulation exactly as they received previously or sham stimulation with rTMS in a double-blind, randomized, placebo-controlled, two-group setup.
62835738|NCT05021978|ACTIVE_COMPARATOR|Part B: Open-label titration PRAX-944 (120 mg) followed by blinded placebo|Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 14 days of 120 mg, 14 days placebo
62835739|NCT01351181|EXPERIMENTAL|Exercise advice|Behavioural
62052779|NCT04371146|EXPERIMENTAL|Dopamine reuptake inhibitor|Participants in the dopamine reuptake inhibitor group will be asked to take one pill containing 35 mg methylphenidate 1.5 hours before performing the tasks.
62052780|NCT04371146|EXPERIMENTAL|Noradrenaline reuptake inhibitor|Participants in the noradrenaline reuptake inhibitor group will be asked to take one pill containing 8 mg reboxetine 1.5 hours before performing the tasks.
62442747|NCT03824522||All Study Participants|Participants who are newly prescribed with Adynovate and participants previously treated with Adynovate will be treated with ADYNOVATE for hemophilia A at the time of enrollment according to a regimen determined by the study site treating physician.
62611982|NCT02423668||No adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. The intra-ocular lens power selection for the second eye was performed irrespective of the first eye prediction error. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
62835740|NCT01351181|OTHER|Normal Care|Normal care
62835741|NCT01896219|ACTIVE_COMPARATOR|Gesture performed under control tomodensitometric (CT)|Conventional
62835742|NCT01896219|EXPERIMENTAL|Gesture performed under Navigation-assisted procedure (NAV)|Use of the IMACTIS-CT® Navigation System
62835743|NCT04042948|EXPERIMENTAL|Experimental Group|preventive use non-steroidal anti-inflammatory drugs to before the removal of drainage tube
62835744|NCT04042948|NO_INTERVENTION|Control Group|without any intervention when remove the drainage tube
62835745|NCT06462599||Cases|Patients with ischaemic stroke
62835746|NCT06462599||Control|Healthy individuals
62835747|NCT03780166|EXPERIMENTAL|Parsaclisib|
62835748|NCT00793897|EXPERIMENTAL|Sequential allocation of patients in two dosing schedules|
62052781|NCT04371146|PLACEBO_COMPARATOR|Placebo|Participants in the placebo group will be asked to take a placebo pill 1.5 hours before performing the tasks.
62052782|NCT02003079||Diagnosed with or without Chronic Rhinosinusitis|
62442748|NCT00793845|EXPERIMENTAL|High risk neuroblastoma|"1. Conventional chemotherapy (9 cycles)~2. Surgery conventional chemotherapy (after 6 cycles of chemotherapy)~3. Tandem HDCT/autoSCT~   * First HDCT (cyclophosphamide, etoposide, carboplatin)~  * Second HDCT (total body irradiation, thiotepa, melphalan)~4. Local radiotherapy~5. Retinoic acid, interleukin-2"
62835749|NCT01929746|EXPERIMENTAL|BIIB019, 75 mg|BIIB019 delivered via Subcutaneous Injection
62835750|NCT01929746|EXPERIMENTAL|BIIB019, 150 mg|BIIB019 delivered via Subcutaneous Injection
62835751|NCT03758040|EXPERIMENTAL|Slips on Turns|Slips administered during walking on a curved paths of radii 1.0, or 2.0 meters in early, middle or late stance to the inside or outside foot.
62835752|NCT03758040|EXPERIMENTAL|Slips on Slopes|Slips administered during walking on sloped ground of 5.0 or 10.0 degrees mediolaterally or anteroposteriorly, or flat ground, in early middle or late stance. For mediolateral slopes, slips will be administered to the uphill or downhill foot.
62835753|NCT01327482|EXPERIMENTAL|All|All patients were part of the intervention arm, as this was a pharmacokinetic study. All women took Raltegravir 400mg orally, twice daily for 3 weeks.
62835754|NCT01582269|EXPERIMENTAL|LY2157299 monohydrate plus lomustine|"300 mg/day LY2157299, given orally for 14 days, followed by 14 days of rest, equaling a 28-day cycle.~First lomustine dose will be given as 100 mg/m2 on day 7 cycle 1. Remaining doses are based on the investigator's discretion and will be given orally once every 6 weeks in capsules to equal 100 to 130 mg/m2."
62835755|NCT01582269|EXPERIMENTAL|LY2157299 monohydrate|300 mg/day LY2157299, given orally for 14 days, followed by 14 days of rest, equaling a 28-day cycle (unblinded)
62611983|NCT02423668||Full adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. Second eye refinement in the intra-ocular lens power selection for the second eye was performed using a theoretical 100% partial adjustment of the PE1. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
62611984|NCT04135066|OTHER|Refined grain breakfast|white bread (100g) + milk powder (25g)
62835756|NCT01582269|ACTIVE_COMPARATOR|lomustine plus placebo|"First lomustine dose will be given as 100 mg/m2 on day 7 cycle 1. Remaining doses are based on the investigator's discretion and will be given orally once every 6 weeks in capsules to equal 100 to 130 mg/m2.~LY2157299 monohydrate-matched placebo, given orally as tablets for 14 days, followed by 14 days of rest, equaling a 28-day cycle."
62052783|NCT04762693||Cough monitoring|All enrolled participants will be asked to install the acoustic surveillance software in their smartphones and use it to record night-time coughs for a minimum 30-day period.
62052784|NCT02474290|EXPERIMENTAL|Sorafenib group|Sorafenib will be used from day 30 to 180 post-transplantation.
62052785|NCT02474290|NO_INTERVENTION|non-Sorafenib group|
62052786|NCT04653402|EXPERIMENTAL|Study arm 1|Placing a closed suction drain after hydrocelectomy for primary vaginal hydrocele
62442749|NCT05645458|NO_INTERVENTION|Control group|Pre-tests will be applied to the caregiver before the patient is discharged, and the first data will be obtained by observing during PEG care. Then, traditional training on PEG care will be given to the patient's relatives. The tests applied after this training will be applied again. Tests and observation forms will be applied in the 1st month and 3rd month after discharge. By making home visit the participant, recording will be video-recorded so that his identity will not be seen while he is doing PEG care, and the recording will be transcribed to the observation form by 2 blinded people other than the researcher.
62052787|NCT04653402|ACTIVE_COMPARATOR|Study arm 2|Not placing a drain after hydrocelectomy in primary vaginal hydrocele
62442750|NCT05645458|EXPERIMENTAL|experimental group|In addition to maintaining the control group, the experimental group is monitored by installing the mobile application we have developed.
62442751|NCT01252433|EXPERIMENTAL|Entree energy density 100%|100% energy density
62442752|NCT01252433|EXPERIMENTAL|Entree energy density 85%|85% energy density
62442753|NCT01252433|EXPERIMENTAL|Entree energy density 75%|75% energy density
62611985|NCT04135066|OTHER|Whole grain breakfast|plain oats (70g) + milk powder (25g)
62611986|NCT05398705|EXPERIMENTAL|Low-dose cepharanthine + standardized medical treatment|Drug: cepharanthine (tablet) Day 1\~5: 20mg, Q8H X 5 days + standardized medical treatment
62611987|NCT05398705|EXPERIMENTAL|High-dose cepharanthine + standardized medical treatment|Drug: cepharanthine (tablet) Day 1\~5: 40mg, Q8H X 5 days + standardized medical treatment
62611988|NCT05398705|PLACEBO_COMPARATOR|placebo+standardized medical treatment|Drug: cepharanthine placebo (tablet) Day 1\~5: placebo + standardized medical treatment
62611989|NCT02773745|NO_INTERVENTION|Standard of Care|Participant will receive standard of care and a brochure on healthy eating.
62611990|NCT02773745|ACTIVE_COMPARATOR|Aquatic Prehabilitation Group|The prehabilitation group will undergo 6-8 weeks of individualized aquatic exercise in a heated pool (60 min/session, 3 times per week). Aquatic equipment maybe used to challenge balance and trunk stabilization.
62611991|NCT05765448|ACTIVE_COMPARATOR|Soy-based control meal|Bowl of soup noodles prepared with 10g soy protein isolate soup base and consumed with a pack of plain crackers (approximately 65g available carbohydrate in total).
62611992|NCT05765448|EXPERIMENTAL|Laver/nori macroalgae (Porphyra umbilicus) whole biomass-based treatment meal|Bowl of soup noodles prepared with 10g Laver/nori macroalgae (Porphyra umbilicus) whole biomass soup base and consumed with a pack of plain crackers (approximately 65g available carbohydrate in total).
62835757|NCT03818321|EXPERIMENTAL|Methenamine Hippurate with Cranberry|Subjects will be instructed to take Methenamine Hippurate 1 g tablet ( 1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.
62835758|NCT03818321|PLACEBO_COMPARATOR|Placebo with Cranberry|"Subjects will be instructed to take Placebo tablet (1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.~Cranberry capsules were incorporated into the standard practice of Cincinnati Urogynecology Associates, TriHealth Inc in mid-March 2016."
62052788|NCT05970822|EXPERIMENTAL|BC3402+azacitidine|Subjects will receive azacitidine and BC3402 in a treatment cycle.
62052789|NCT02357030|EXPERIMENTAL|Methyl-P plus GWI Nutrient Formula|Methylphenidate hydrochloride plus a GWI Nutrient Formula (K-PAX Synergy), both taken twice daily.
62052790|NCT00451165||colon|
62611993|NCT05765448|EXPERIMENTAL|Laver/nori macroalgae (Porphyra umbilicus) protein isolates-based treatment meal|Bowl of soup noodles prepared with 10g Laver/nori macroalgae (Porphyra umbilicus) protein isolates soup base and consumed with a pack of plain crackers (approximately 65g available carbohydrate in total).
62611994|NCT05765448|EXPERIMENTAL|Microalgae (Chlorella vulgaris) whole biomass-based treatment meal|Bowl of soup noodles prepared with 10g microalgae (Chlorella vulgaris) whole biomass soup base and consumed with a pack of plain crackers (approximately 65g available carbohydrate in total).
62442754|NCT01760122|EXPERIMENTAL|Ypeginterferon Alfa-2b|
62442755|NCT01760122|ACTIVE_COMPARATOR|Pegasys|
62442756|NCT04588428|EXPERIMENTAL|Part 1: INO-4700 Group A|Participants received one intradermal (ID) injection of 0.6 milligram (mg) of INO-4700 followed by electroporation (EP) using the CELLECTRA™ 2000 device on Day 0 and Week 4.
62611995|NCT05765448|EXPERIMENTAL|Microalgae (Chlorella vulgaris) protein isolates-based treatment meal|Bowl of soup noodles prepared with 10g microalgae (Chlorella vulgaris) protein isolates soup base and consumed with a pack of plain crackers (approximately 65g available carbohydrate in total).
62442757|NCT04588428|EXPERIMENTAL|Part 1: INO-4700 Group B|Participants received one ID injection of 1.0 mg of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
62442758|NCT04588428|EXPERIMENTAL|Part 1: INO-4700 Group C|Participants received one ID injection of 1.0 mg of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
62442759|NCT04588428|EXPERIMENTAL|Part 1: INO-4700 Group D|Participants received two ID injections (in an acceptable location on two different limbs) of 0.5 mg each of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
62442760|NCT04588428|EXPERIMENTAL|Part 1: INO-4700 Group E|Participants received two ID injections (in an acceptable location on two different limbs) of 1.0 mg each of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
62052791|NCT00451165||rectum|
62052792|NCT04251884|EXPERIMENTAL|Receiving the pudendal nerve block|
62442761|NCT04588428|PLACEBO_COMPARATOR|Part 1: Placebo Group F|Participants received one ID injection of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
62442762|NCT04588428|PLACEBO_COMPARATOR|Part 1: Placebo Group G|Participants received one ID injection of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
62442763|NCT04588428|PLACEBO_COMPARATOR|Part 1: Placebo Group H|Participants received two ID injections (in an acceptable location on two different limbs) of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
62442764|NCT04588428|PLACEBO_COMPARATOR|Part 1: Placebo Group I|Participants received two ID injections (in an acceptable location on two different limbs) of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
62611996|NCT02338466|PLACEBO_COMPARATOR|rt-PA|"Patients treated by thrombolysis with rt -PA within 4h30 of the onset of symptoms to a proximal middle cerebral artery occlusion visible on a MRI 1 are pre- included. A second MRI ( IRM2 ) is performed between 1 hour and 1.5 hours after administration of rt-PA in the usual way .~After the treatment by rt-PA, if there is no recanalization (TIMI score: 0,1, 2a), the patient is included. A patient included will be randomized either in the arm rt-PA treatment only or in the arm rt-PA + tenecteplase treatment. If he is included in the arm rt-PA only, he will not receive any other treatment for the study."
62611997|NCT02338466|ACTIVE_COMPARATOR|rt-PA + tenecteplase|"If patient is in the arm rt-PA + tenecteplase, he will receive tenecteplase (50UI/Kg) treatment. A third MRI will be performed at 24hour that will assess the recanalization status (TIMI), the final volume infarct and the hemorrhagic complications."
62611998|NCT02841956|EXPERIMENTAL|Electronic Screen + Education (Phase 1)|Electronic screening of participants and targeted education of providers according to standard EDAPT model.
62052793|NCT04251884|ACTIVE_COMPARATOR|Not receiving the pudendal nerve block|
62052794|NCT04421482|OTHER|Very Low Birth Weight Preterm Infants|Very Low Birth Weight Preterm Infants (birth weight less than 1,500g and less than 32 weeks gestation) admitted to NYU Winthrop NICU. (n=42)
62052795|NCT03738202|EXPERIMENTAL|Intervention|Multifaceted intervention package will be implemented at textile mills in the intervention arm.
62442765|NCT04588428|EXPERIMENTAL|Part 2: Parts 2A and 2B|Participants were planned to receive ID injection of INO-4700 based on optimal dose and regimen selection in Part 1 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4 or Week 8 and a booster dose at Week 48 (only for Part 2B participants were planned to receive a third dose).
62052796|NCT03738202|NO_INTERVENTION|Control|No intervention will be provided to mills in the control arm.
62052797|NCT06100419|EXPERIMENTAL|Block|This group consists of patients who underwent SPSIP block.
62442766|NCT01987284|EXPERIMENTAL|SER100|SER100 10 mg s.c. twice daily
62442767|NCT01987284|PLACEBO_COMPARATOR|Placebo|Placebo administered s.c. twice daily
62611999|NCT02841956|ACTIVE_COMPARATOR|Targeted Provider Education (Phase 1)|Targeted education of providers according to standard EDAPT model.
62612000|NCT02841956|EXPERIMENTAL|Community Mobile Engagement (Phase 2)|Clinical intake interviews take place via videoconference at a location in the community convenient for the participant.
62442768|NCT03781856|EXPERIMENTAL|La Vida Buena Program|Administered in a group setting over the course of 8 weeks in a community setting.
62612001|NCT02841956|ACTIVE_COMPARATOR|Clinic based Engagement (Phase 2)|Clinical intake interviews take place at the EDAPT clinic.
62612002|NCT00805519|ACTIVE_COMPARATOR|Glucosamine and chondroitin sulfate|in this group patients will receive Glucosamine and chondroitin sulfate oral dietary supplementation
62442769|NCT03781856|ACTIVE_COMPARATOR|Brief educational session|Administered one on one or in a group setting in a one-hour session at the clinic
62612003|NCT00805519|EXPERIMENTAL|P :glucosa, chondroitin, Prednis|in this group patients will receive glucosamine and chondroitin sulfate plus Prednisolone oral administration
62612004|NCT00805519|EXPERIMENTAL|Glucosa, Chondroitin, Chloroquine|in this group pateints will orally receive Glucosamine and Chondroitin sulfate plus Chloroquine.
62612005|NCT00805519|EXPERIMENTAL|Glucosa, Chondro, Prednis,Chloroq|in this group patients will receive Glucosamine and Chondroitin sulfate plus Prednisolone and Chloroquine
62612006|NCT05335915|EXPERIMENTAL|Original/Tobacco Flavored Pouch (low nicotine dose)|participants will use a tobacco flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
62442770|NCT03949556|EXPERIMENTAL|Intervention program - stress management program|This intervention program on stress management is developed to prevent suicidal ideation in medical students and residents.
62612007|NCT05335915|EXPERIMENTAL|Original/Tobacco Flavored Pouch (high nicotine dose)|participants will use a tobacco flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
62612008|NCT05335915|EXPERIMENTAL|Mint/Menthol Flavored Pouch (low nicotine dose)|participants will use a mint/menthol flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
62612009|NCT05335915|EXPERIMENTAL|Mint/Menthol Flavored Pouch (high nicotine dose)|participants will use a mint/menthol flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
62442771|NCT03949556|ACTIVE_COMPARATOR|Intervention program - health promotion program|This intervention program on health promotion is developed to prevent suicidal ideation in medical students and residents.
62612010|NCT05335915|EXPERIMENTAL|Fruit Flavored Pouch (low nicotine dose)|participants will use a fruit flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
62442772|NCT03949556|PLACEBO_COMPARATOR|Control condition - general information|Participants will receive weekly emails and SMSs, over the same periods of time, with general information about health except mental health, e.g. prevention of melanoma, dental care....
62612011|NCT05335915|EXPERIMENTAL|Fruit Flavored Pouch (high nicotine dose)|participants will use a fruit flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
62612012|NCT05335915|ACTIVE_COMPARATOR|Own brand cigarettes|participants will smoke participants' own brand of cigarettes under both controlled (experimenter-directed) and ad libitum use conditions
62052798|NCT05994209|NO_INTERVENTION|Control Group|Nationwide resource referral and intervention waitlist
62052799|NCT05994209|EXPERIMENTAL|Experimental Group A: Mobile App Intervention|quitSTART Mobile Application Adapted for Vaping Cessation Among Young Adults
62442773|NCT03286413|EXPERIMENTAL|microwave ablation|Microwave ablation（MWA）refers to all electromagnetic methods of inducing tumor destruction by using devices with frequencies greater than or equal to 900MHz. The rotation of dipole molecules accounts for most of the heat generated during MWA. Water molecules as dipoles attempt to continuously reorient at the same rate in microwave's oscillating electric field. As a result of microwave transmission, the water molecules flip back and forth billions of times a second. The vigorous movement of water molecules produce friction and heat, thus inducing cellular death via coagulation necrosis. The microwave unit (KY-2000, Kangyou Medical, Nanjing, China) is capable of producing 100 Watts of power at 2450 MHz.The needle antenna has a diameter of 1.6 mm (16G) and a length of 10 cm. The active tip length is 3mm and 5mm.
62442774|NCT03286413|ACTIVE_COMPARATOR|cryoablation|Clinically, cryosurgery is accomplished by placing a cryoprobe(up to 3.5 mm) through a stab incision into the tumor under ultrasound guidance.Liquid nitrogen is utilized under low operating pressure as cryogen which is controlled by the computer modulated cryogen regulator. The cryoprobe achieves rapid freezing by means of an active freeze zone at its distal tip.
62442775|NCT01011569||cage|patient who underwent stand alone cage insertion after discectomy
62612013|NCT05389826|EXPERIMENTAL|mHealth App group|Patients will be followed with the developed mobile web app,
62612014|NCT05389826|NO_INTERVENTION|Control|Patients will be treated according to the current clinical practice.
62612015|NCT02912455|ACTIVE_COMPARATOR|Study Drug (canagliflozin)|Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
62612016|NCT02912455|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
62835759|NCT02654769|ACTIVE_COMPARATOR|Active Comparator Picato®|Picato® (ingenol mebutate) gel, 0.05% (Leo Pharma Inc.) \[Reference Listed Drug (RLD)\]
62835760|NCT02654769|EXPERIMENTAL|Generic Ingenol Mebutate|Generic ingenol mebutate gel, 0.05% \[Test\]
62052800|NCT05994209|EXPERIMENTAL|Experimental Group B: Mobile App Intervention with Embedded Chatbot Feature|quitSTART Mobile Application Adapted for Vaping Cessation Among Young Adults Including Embedded Chatbot Feature
62052801|NCT03311282|EXPERIMENTAL|Feeding Bottle 0m+|10 infants aged 0-4 weeks (+/- 7 days): 0-4 m bottle. 0-4 months, 250 ml, 2 angled teats: newborn (also referred to as low flow) and infant (also referred to as medium flow), for infants aged 0-4 weeks (+/- 7 days) / over 9 weeks of participation.
62612017|NCT00269477|EXPERIMENTAL|Menactra® Vaccine Group 1|Participants had previously received a dose of Menactra® vaccine in Study MTA02,did not participate in Study MTA19 (NCT 00777790). They provided a pre-vaccination blood sample on Day 0, received one booster dose of Menactra® vaccine on Day 0 and provided 3 additional blood samples on Day 3, Day 7, and Day 28 post-vaccination.
62835761|NCT02654769|PLACEBO_COMPARATOR|Vehicle Foam|Vehicle gel of the test product
62052802|NCT03311282|EXPERIMENTAL|Feeding Bottle 4m+|10 infants aged 4 months (+/- 10 days): 4-6 m bottle. 4-6 months, 250 ml, non-angled teat), for infants aged 4 months (+/- 10 days) / over 9 weeks of participation.
62835762|NCT02610114|EXPERIMENTAL|Z-Score and computer algorithm|
62052803|NCT03311282|EXPERIMENTAL|Feeding Bottle 6m+|10 infants aged 6-10 months (+/- 10 days): 6m+ bottle. 6 months and over, 250 ml, longer teat) for infants aged form 6 to 10 months (+/- 10 days) / over 9 weeks of participation.
62052804|NCT03311282|NO_INTERVENTION|exclusively or prevalently breast-fed infants 0m+|10 infants aged 0-4 weeks (+/- 7 days)
62052805|NCT03311282|NO_INTERVENTION|exclusively or prevalently breast-fed infants 4m+|10 infants aged 4 months (+/- 10 days)
62052806|NCT03311282|NO_INTERVENTION|exclusively or prevalently breast-fed infants 6m+|10 infants aged 6-10 months (+/- 10 days) (at least 2 breastfeeding sessions per day)
62052807|NCT06090916|ACTIVE_COMPARATOR|ARM I (Standard of care)|Patients receive standard nutrition care and record dietary intake and physical activity using Myfitness Pal smartphone application on study.
62052808|NCT06090916|EXPERIMENTAL|ARM II (Dietary intervention)|Patients undergo malnutrition screening with a registered dietician at baseline and participate in 12 weekly nutrition support sessions and those at moderate to high risk for malnutrition receive a personalized diet prescription on study. Patients also record dietary intake and physical activity using Myfitness Pal smartphone application on study.
62052809|NCT00921063|EXPERIMENTAL|PD 0332334 250 mg|
62052810|NCT00921063|EXPERIMENTAL|PD 0332334 100 mg|
62052811|NCT00921063|PLACEBO_COMPARATOR|placebo|
62052812|NCT00921063|ACTIVE_COMPARATOR|Alprazolam extended release|
62442776|NCT01011569||plate|patient who underwent plate fixation and autologous ilia bone graft after discectomy
62442777|NCT00289627|EXPERIMENTAL|ipilimumab (MDX-010, BMS-734016)|
62442778|NCT02140684||eNO monitoring|Patients undergoing eNO monitoring at the index prescription date
62442779|NCT02140684||No eNO monitoring|
62442780|NCT02676219|EXPERIMENTAL|RS01|oral care product containing containing sodium monofluorophosphate and sodium fluoride
62442781|NCT02676219|PLACEBO_COMPARATOR|Water|Water
62442782|NCT03114956|EXPERIMENTAL|Group A|Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
62835763|NCT02610114|ACTIVE_COMPARATOR|Z-Score|
62835764|NCT03813927|EXPERIMENTAL|Vitamin D|supplementation with tablet 170 μg Vitamin D each day.
62835765|NCT03813927|PLACEBO_COMPARATOR|Placebo|Placebo, tablet with 20 μg Vitamin D each day.
62052813|NCT04123925|EXPERIMENTAL|Nivolumab|Patients will receive nivolumab at a flat dosage of 240 mg every two weeks on Day -28 and Day-14 (+/- one day) prior to planned surgery on Day 0 or up to +7 days
62052814|NCT05063214||Ultrasound assessment|Muscle ultrasound evaluation
62835766|NCT00692835|ACTIVE_COMPARATOR|A|Patients with mini Video Assisted Thyroidectomy (miVAT)
62442783|NCT03114956|EXPERIMENTAL|Group B|Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.
62442784|NCT03114956|EXPERIMENTAL|Group C|Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.
62835767|NCT00692835|ACTIVE_COMPARATOR|B|Immediate postoperative course of patients with classic Thyroidectomy (cTT)
62835768|NCT06120374||Adjuvant radioimmunotherapy|Participants underwent adjuvant radioimmunotherapy
62835769|NCT06120374||Adjuvant chemotherapy|Participants underwent radical total nephroureterectomy and adjuvant chemotherapy
62835770|NCT05403424||Group 1: Pregnant women with pelvic girdle pain|This group will consist of pregnant women diagnosed with pelvic girdle pain.
62253877|NCT06372548|EXPERIMENTAL|Find You! Cure My Animal Friends|Participants in the experimental group completed the game in this app. The goal of the game is to guide the amblyopic children to develop the habit of rehabilitation training, so that the amblyopic children will keep their interest in completing the exercises according to the time in the game. A story of an animal intern doctor is constructed, and the player will play the role of an animal doctor according to the guidance of the plot, wear the corresponding eye patches and complete the set visual training tasks in the game. The study aims to improve the overall treatment adherence by increasing the attractiveness of the visual training game to children, cultivating long-term training habits, and mitigating the negative effects of amblyopia treatment. The path to achieve this goal consists of the following components: (1) narrative content, (2) interactive forms combined with masking therapy, (3) incentives, and (4) visual design that is consistent with children's preferences.
62835771|NCT05403424||Group 2: Pregnant women without pelvic girdle pain|This group will consist of pregnant women who do not have pelvic girdle pain.
62835772|NCT05403424||Group 3: Non-pregnant women|This group will consist of non-pregnant women.
62052815|NCT04280653|EXPERIMENTAL|NDE L68 StableFit® punctal plug|Each study subject that qualifies at the baseline visit will receive an NDE L68 StableFit® punctal plug in the lower punctum in one of their eyes. All study plugs will remain in the study subject's lower punctum for a period of 28 + 4 days after insertion
62253878|NCT06372548|ACTIVE_COMPARATOR|DuoBao Vision Training System|Software Co.'s DuoBao Vision Training System. A number of visual function tests and ophthalmology strabismus amblyopia specialist examinatio. The data is transmitted to the data center and the expert intelligent system to develop a targeted personalized amblyopia training program. Control group participants completed the training components in this app.
62253879|NCT05132842||Observational (survey)|Patients complete a survey about knowledge and awareness of medical cannabis, perceived risks and benefits of cannabis, mode and frequency of use (if applicable), impact on cancer-related symptoms, patient provider discussions about cannabis, and demographic characteristics including health and digital literacy.
62835773|NCT01260116||1|Ziprasidone,Zeldox capsule
62835774|NCT05204004|EXPERIMENTAL|Sunrise|Participants under investigation for OSA will use both devices (Sunrise solution and overnight polygraphy) simultaneously for a single overnight sleep study. Participants randomised to the 'Sunrise' arm will receive their treatment decision based on the Sunrise solution.
62835775|NCT05204004|ACTIVE_COMPARATOR|Polygraphy|Participants under investigation for OSA will use both devices (Sunrise solution and overnight polygraphy) simultaneously for a single overnight sleep study. Participants randomised to the 'polygraphy' arm will receive their treatment decision based on the polygraphy.
62835776|NCT01577888|EXPERIMENTAL|Lithotripsy Treatment|Shockwave System Treatment -Lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic peripheral arteries.
62052816|NCT03672838|ACTIVE_COMPARATOR|Cohort 1|Patients with NF1
62052817|NCT03672838|ACTIVE_COMPARATOR|Cohort 2|Patients with NF2
62052818|NCT01065350|ACTIVE_COMPARATOR|Propofol|As part of the induction, patients will be given 2 milligrams of propofol per kilogram (mg/kg) of body weight. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL.
62835777|NCT03232697|OTHER|Healthy subjects|Subjects will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
62835778|NCT03232697|OTHER|Alzheimer patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
62052819|NCT01065350|EXPERIMENTAL|Ketofol|"As part of the induction, patients will be given 20 mL syringe of an admixture called ketofol, which combines ketamine and propofol in one syringe. The dose is weight-based such that ketamine will represent 0.75 mg/kg of the dose and propofol, 1.5 mg/kg of the dose."
62052820|NCT02676401|EXPERIMENTAL|MT-3995 Low|
62052821|NCT02676401|EXPERIMENTAL|MT-3995 Middle|
62052822|NCT02676401|EXPERIMENTAL|MT-3995 High|
62052823|NCT03014063||Hemodynamic responders|Those with a mean arterial pressure of at least 65mmHg and a decrease in catecholamine dose (in norepinephrine equivalents) from initiation of exogenous vasopressin therapy to the time of the sample collection used for analysis of plasma vasopressin concentration
62835779|NCT03232697|OTHER|Parkinson and Huntington patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
62835780|NCT03232697|OTHER|Diabetic patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
62835781|NCT01143246|EXPERIMENTAL|Terlipressin|Participants receive terlipressin intravenously as a bolus injection, followed by a saline flush. Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol.
62835782|NCT01143246|PLACEBO_COMPARATOR|Placebo|Participants receive matching placebo intravenously as a bolus injection, followed by a saline flush. Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol.
62253880|NCT02035085|EXPERIMENTAL|CS-1000|Breast cancer patients with RIF will undergo liposuction, the autologous SVF cell fraction will be isolated and labeled with CS-1000 in the operating room without entering cell culture, which will then be returned to the patient at the site of breast grafting.
62835783|NCT05546632||Critically ill patients|Patients included in this study will have blood sampling using EDTA tube and nex generation Cyto-Chex BCT tubes in order to compare compare the expression of mHLA-DR with these two types of tubes
62835784|NCT04378543|EXPERIMENTAL|ART252-L|local autologous bone graft will be treated ex vivo once with ART352-L prior to re-implantation into the site of spinal fusion
62835785|NCT03986086|EXPERIMENTAL|MPH966|Participants receive MPH966 at RP2D tablet orally twice daily from the start of conditioning chemotherapy through 45 days post transplant.
62835786|NCT03986086|PLACEBO_COMPARATOR|Placebo|Participants receive MPH placebo tablet matching MPH966 orally twice daily from the start of conditioning chemotherapy through 45 days post transplant.
62835787|NCT05897203|ACTIVE_COMPARATOR|Investigational Medicinal product A (IMP A) + Standard of Care (SoC)|Participants in this arm will receive the both the Investigational medicinal product (IMP A) and the standard of care
62835788|NCT05897203|ACTIVE_COMPARATOR|Investigational Medicinal product B (IMP B) + Standard of Care (SoC)|Participants in this arm will receive the both the Investigational medicinal product (IMP B) and the standard of care
62835789|NCT05897203|OTHER|Standard of care (SoC)|Participants in this arm will receive only the standard of care
62835790|NCT03291496||Preterm Neonates|Blood collection Preterm. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.
62835791|NCT03291496||Term Neonates|Blood collection Term. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.
62835792|NCT03291496||Healthy Adult|One-time whole blood draw of 1ml collection
62835793|NCT02773316|EXPERIMENTAL|MR902 50/0.5 mg|MR902 50/0.5 mg PR tablets, single dose oral
62835794|NCT02773316|EXPERIMENTAL|MR902 200/2 mg|MR902 200/2 mg PR tablets, single dose oral
62835795|NCT02773316|ACTIVE_COMPARATOR|IR morphine sulphate 10 mg/5mL solution|IR morphine sulphate 10 mg/5mL solution, single dose oral
62835796|NCT02484118|EXPERIMENTAL|Targeted blood flow rate 320 ml/min|Hemodialysis blood flow will be targeted at 320 ml/min during hemodialysis for two weeks
62442785|NCT03114956|EXPERIMENTAL|Group D|A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
62612018|NCT00269477|EXPERIMENTAL|Menactra® Vaccine Group 2|Participants had previously received a dose of Menactra® vaccine in Study MTA02,did not participate in Study MTA19 (NCT 00777790). They provided a pre-vaccination blood sample on Day 0, received one booster dose of Menactra® vaccine on Day 0 and provided 3 additional blood samples on Day 5, Day 14, and Day 28 post-vaccination
62835797|NCT02484118|EXPERIMENTAL|Targeted blood flow rate 380 ml/min|Hemodialysis blood flow will be targeted at 380 ml/min during hemodialysis for two weeks
62835798|NCT02528981|EXPERIMENTAL|Probiotic|L. rhamnosus GR-1 and L. reuteri RC-14 will be supplied to 100 randomized pregnant people in gelatin capsules containing 2.5 billion viable cells of each strain (CFU). These organisms have been previously shown to colonize the vagina after being taken orally (11) and displace the pathogens causing bacterial vaginosis (12) and vaginal yeast infections (13), and have been shown to be an effective treatment, or accessory to treatment of these conditions. (7- 9, 13)
62442786|NCT03849365|EXPERIMENTAL|TOOKAD VTP|TOOKAD is administered as part of focal VTP under general anaesthetic. TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
62835799|NCT02528981|PLACEBO_COMPARATOR|Placebo|Placebo capsules will be supplied to 100 randomized pregnant people in gelatin capsules that are identical to the probiotics that the experimental group will receive.
62835800|NCT00030914|EXPERIMENTAL|Arm I: venlafaxine|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive oral venlafaxine once daily for 6 weeks beginning on day 8. After week 7, patients with satisfactory efficacy may continue venlafaxine for up to 6 months. Patients with unsatisfactory efficacy may cross over to arm III.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
62835801|NCT00030914|EXPERIMENTAL|Arm II: medroxyprogesterone - long term|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive medroxyprogesterone intramuscularly (IM) on days 8, 22, and 36 for a total of 3 injections. After week 7, patients with unsatisfactory efficacy may cross over to arm I.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
62835802|NCT00030914|EXPERIMENTAL|Arm III: medroxyprogesterone - short term|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive medroxyprogesterone IM once on day 8. After week 7, patients with unsatisfactory efficacy may cross over to arm I.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
62835803|NCT02503137|EXPERIMENTAL|Experimental Arm 1|Topical SM04554 0.15% solution, once daily for approximately 90 days
62835804|NCT02503137|EXPERIMENTAL|Experimental Arm 2|Topical SM04554 0.25% solution, once daily for approximately 90 days
62835805|NCT02503137|PLACEBO_COMPARATOR|Vehicle|Topical vehicle solution, once daily for approximately 90 days
62052824|NCT03014063||Hemodynamic non-responders|Those without a mean arterial pressure of at least 65mmHg and/or a decrease in catecholamine dose (in norepinephrine equivalents) from initiation of exogenous vasopressin therapy to the time of the sample collection used for analysis of plasma vasopressin concentration
62442787|NCT04433481|EXPERIMENTAL|DABIGATRAN|150mg BD for 12 months
62835806|NCT04772274|EXPERIMENTAL|SB17|SB17 (proposed ustekinumab biosimilar)
62835807|NCT04772274|ACTIVE_COMPARATOR|EU Stelara|EU sourced Stelara (ustekinumab)
62052825|NCT02087982||Seniors|"The study will be based on a 6-months assessment period, with two consecutive monitoring visits on enrollment.~Patient follow-up after 3 months will be conducted by telephone and monitoring after 6 months will be carried out as part of a routine consultation.~Each subject will have a BGA (Brief Geriatric assesment)."
62052826|NCT03681574|EXPERIMENTAL|Placebo Group|The placebo group will receive placebo concentrate orally (0.3 mL/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
62253881|NCT04594382|ACTIVE_COMPARATOR|T30/60|Before extubation, opioid administration will be given by a single dose of opioids in case of measured PDR values of ≥12.
62253882|NCT04594382|ACTIVE_COMPARATOR|Non-T30/60|A standardized single dose of opioid will be given intravenously before extubation, regardless of the measured pupillometry PDR values.
62253883|NCT04594382|NO_INTERVENTION|Standard Care group|The amount of administered piritramid in the OR will be left to the discretion of the anesthesiologist attending the participant.
62253884|NCT01147744|EXPERIMENTAL|GSK2190915 10mg and placebo|GSK2190915 10mg (1 x 10mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
62442788|NCT04433481|PLACEBO_COMPARATOR|Placebo|Placebo
62442789|NCT01777685|OTHER|sulpiride 50 mg|
62835808|NCT04772274|ACTIVE_COMPARATOR|US Stelara|US sourced Stelara (ustekinumab)
62835809|NCT04295720|EXPERIMENTAL|Transcranial magnetic stimulation (TMS)|We propose to test the efficacy of rTMS for the treatment of PCCI. Efficacy measures will include baseline and post-rTMS neuropsychological testing, functional MRI and biometry data using body worn sensors.
62835810|NCT03141138|EXPERIMENTAL|Group 1: TDENV-PIV on Day 0|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
62835811|NCT03141138|EXPERIMENTAL|Group 1: TDENV-LAV F17 on Day 180|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
62253885|NCT01147744|EXPERIMENTAL|GSK2190915 30mg and placebo|GSK2190915 30mg (1 x 30mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
62052827|NCT03681574|EXPERIMENTAL|GABA 15mg/kg Group|The GABA 15mg/kg group will receive gabapentin syrup orally (15 mg/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
62835812|NCT03141138|EXPERIMENTAL|Group 2: TDENV-PIV on Day 0|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
62835813|NCT03141138|EXPERIMENTAL|Group 2:TDENV-LAV F17 on Day 90|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
62835814|NCT01258686|EXPERIMENTAL|silymarin, treatment|
62052828|NCT03681574|EXPERIMENTAL|GABA 30mg/kg Group|The GABA 30mg/kg group will receive gabapentin syrup orally (30 mg/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
62253886|NCT01147744|EXPERIMENTAL|GSK2190915 100mg QD and placebo|GSK2190915 100mg (1 x 100mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
62253887|NCT01147744|EXPERIMENTAL|GSK2190915 300mg QD and placebo|GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
62253888|NCT01147744|ACTIVE_COMPARATOR|Fluticasone propionate 100mcg and placebo|Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS and two placebo tablets in the morning and one placebo capsule in the evening
62253889|NCT01147744|ACTIVE_COMPARATOR|Montelukast 10mg and placebo|Montelukast 10mg (1 x 10mg capsule) once daily in the evening and two placebo tablets in the morning and inhaled placebo twice daily via ACCUHALER/DISKUS
62253890|NCT01147744|PLACEBO_COMPARATOR|Placebo Comparator|Two GSK2190915 placebo tablets once daily in the morning, montelukast placebo capsule once daily in the evening and fluticasone propionate placebo twice daily via ACCUHALER/DISKUS
62253891|NCT01559493||FFR; iFR|Interventional Cardiology, Pressure wire, fractional flow reserve, coronary flow measurement
62052829|NCT03125005|EXPERIMENTAL|Rainbow Universal Pulse Oximeter Sensor|All subjects will be enrolled in the test group and will receive Rainbow Universal Pulse Oximeter Sensor.
62253892|NCT05956730|EXPERIMENTAL|Group 1|The proposed protocol includes a part of aerobic training and a subsequent part of strengthening exercises for large muscle groups. The total duration of each session will be approximately 30 minutes. There are 2 weekly training sessions for 3 months.
62442790|NCT04712006|EXPERIMENTAL|Cohort 1: JNJ-64304500|Participants will receive single subcutaneous (SC) Dose 1 of JNJ-64304500 on Day 1.
62442791|NCT04712006|EXPERIMENTAL|Cohort 2: JNJ-64304500|Participants will receive single SC Dose 2 of JNJ-64304500 on Day 1.
62835815|NCT01258686|PLACEBO_COMPARATOR|placebo|
62835816|NCT06221306|EXPERIMENTAL|Narrow diameter implant placement (NDI) (3.3)|
62835817|NCT06221306|ACTIVE_COMPARATOR|Standard diameter implant (SDI) placement (4.1) with simultaneous bone augmentation.|
62612019|NCT00269477|ACTIVE_COMPARATOR|Meningococcal Vaccine-naive Group 3|Participants have never received Meningococcal vaccine and provided one blood sample pre-vaccination on Day 0, received a dose of Menactra® vaccine on Day 0, and provided 3 additional blood samples on Day 3, Day 7, and Day 28 post-vaccination.
62612020|NCT00269477|ACTIVE_COMPARATOR|Meningococcal Vaccine-naive Group 4|Participants have never received Meningococcal vaccine and provided one blood sample pre-vaccination on Day 0, received a dose of Menactra® vaccine on Day 0, and provided 3 additional blood samples on Day 5, Day 14, and Day 28 post-vaccination.
62612021|NCT05083052|PLACEBO_COMPARATOR|PLACEBO|Carbonato de cálcio: 40,0%, Glicerina: 20,0%, Lauril Sulfato de sódio: 1,2%, Carboximetilcelulose: 2,0%, Goma xantana: 1,0%, Metilparabeno (nipagim): 0,15%, EDTA: 0,5%, Sacarina: 0,1%, Flavorizante: 0,75%, Água deionizada q.s.p - 100mL.
62612022|NCT05083052|EXPERIMENTAL|PROPOLIS 10%|Carbonato de cálcio: 40,0%, Glicerina: 20,0%, Lauril Sulfato de sódio: 1,2%, Carboximetilcelulose: 2,0%, Goma xantana: 1,0%, Metilparabeno (nipagim): 0,15%, EDTA: 0,5%, Sacarina: 0,1%, Flavorizante: 0,75%, Própolis a 10%, Água deionizada q.s.p - 100mL.
62442792|NCT02135874|EXPERIMENTAL|Treatment (combination chemotherapy)|See Detailed Description.
62612023|NCT05083052|EXPERIMENTAL|PROPOLIS 15%|Carbonato de cálcio: 40,0%, Glicerina: 20,0%, Lauril Sulfato de sódio: 1,2%, Carboximetilcelulose: 2,0%, Goma xantana: 1,0%, Metilparabeno (nipagim): 0,15%, EDTA: 0,5%, Sacarina: 0,1%, Flavorizante: 0,75%, Própolis a 15%, Água deionizada q.s.p - 100mL.
62835818|NCT04330404|EXPERIMENTAL|Cognitive strategy training|The experimental group will receive the Cognitive strategy training (CST), which includes awareness enhancement, cognitive-related education, discussion of everyday cognitive difficulties, generation of cognitive strategies, cognitive strategy practice, and homework assignments.
62835819|NCT04330404|ACTIVE_COMPARATOR|group interactive game|The active control group will receive group interactive game, including table games and games using songs, balloons, newspapers and so on.
62442793|NCT02473510|EXPERIMENTAL|Trivalent Influenza Vaccine|A single dose of 10\^(7.0 +/- 0.5) fluorescent focus units (FFU) per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
62442794|NCT02473510|PLACEBO_COMPARATOR|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
62442795|NCT02588183|EXPERIMENTAL|ArticFont Advance ST|Patients undergoing PV isolation with the ArticFont Advance ST Cryoenergy Balloon Catheter
62442796|NCT02286518|EXPERIMENTAL|Cohort 1A: TAK-114 10 mg|Orally, once only.
62442797|NCT02286518|EXPERIMENTAL|Cohort 1B: TAK-114 10 mg|Orally, once
62442798|NCT02286518|EXPERIMENTAL|Cohort 2A: TAK-114 20 mg|Orally, once
62612024|NCT05918861|EXPERIMENTAL|Dalcetrapib|Dalcetrapib 600 mg (two 300 mg tablets) orally once daily
62612025|NCT05918861|PLACEBO_COMPARATOR|Placebo|Matching dalcetrapib placebo tablets (2 tablets) orally once per day
62612026|NCT03831269|ACTIVE_COMPARATOR|Azithromycin|The dose of azithromycin will be 10mg/kg/day oral suspension for 3 consecutive days for pediatric patients (\<12 years old) and 500mg/day in three consecutive days for adults. The cycle will be repeated every seven days (3 cycles/month) and will be repeated if required according to patient's response up to 6 cycles. Side effects of therapy will be recorded. This protocol is based on previous case reports.
62612027|NCT03831269|ACTIVE_COMPARATOR|Nb UVB|Patients recruited for nbUVB phototherapy will have an initial dose of 0.3J-0.5J according to Fitzpatrick's skin type. The dosage will be increased by 0.3J in every other treatment session. The sessions will be given 3 times weekly until improvement is noted or reaching 8 weeks at the EOS. We arrived at this initial dose based on our previous experience with Egyptian patients in Kasr Alainy phototherapy unit in Dermatology Department, Cairo University.
62612028|NCT02004327|EXPERIMENTAL|A Group|"1. 1st administration - DW1029M300mg PO Once~2. 2nd administration - DW1029M600mg PO Once~3. 3rd administration - DW1029M1200mg PO Once"
62835820|NCT03498937|EXPERIMENTAL|Group 1|Subjects suffering from Borderline Personality Disorder randomly assigned to start the trial by 10 active tDCS sessions, followed by 10 sham tDCS sessions
62835821|NCT03498937|EXPERIMENTAL|Group 2|Subjects suffering from Borderline Personality Disorder randomly assigned to start the trial by 10 sham tDCS sessions, followed by 10 active tDCS sessions
62442799|NCT02286518|EXPERIMENTAL|Cohort 2B: TAK-114 20 mg|Orally, once
62442800|NCT02286518|EXPERIMENTAL|Cohort 3A: TAK-114 50 mg|Orally, once
62442801|NCT02286518|EXPERIMENTAL|Cohort 3B: TAK-114 50 mg|Orally, once
62442802|NCT02286518|EXPERIMENTAL|Cohort 4a: TAK-114 20 mg|Period 1: Single-dose administration in a fasting state Period 2: Single-dose administration 30 minutes after breakfast
62442803|NCT02286518|EXPERIMENTAL|Cohort 4b: TAK-114 20 mg|Period 1: Single-dose administration 30 minutes after breakfast Period 2: Single-dose administration in a fasting state
62442804|NCT02286518|EXPERIMENTAL|Cohort 5A: TAK-114 20 mg|Orally, Twice daily, 10 days
62442805|NCT02286518|EXPERIMENTAL|Cohort 5B: TAK-114 20 mg|Orally, Twice daily, 10 days
62442806|NCT02286518|EXPERIMENTAL|Cohort 6A: TAK-114 50 mg|Orally, Twice daily, 10 days
62442807|NCT02286518|EXPERIMENTAL|Cohort 6B: TAK-114 50 mg|Orally, Twice daily, 10 days
62442808|NCT02286518|PLACEBO_COMPARATOR|Cohort 1A, 2A, 3A: TAK-114 placebo|Cohort 1A, 2A, 3A: Orally, once
62442809|NCT02286518|PLACEBO_COMPARATOR|Cohort 5A: TAK-114 placebo|Cohort 5A: Orally, Twice daily, 10 days
62612029|NCT02004327|EXPERIMENTAL|B Group|"1. 1st administration - DW1029M600mg PO Once~2. 2nd administration - DW1029M1200mg PO Once~3. 3rd administration - DW1029M300mg PO Once"
62612030|NCT02004327|EXPERIMENTAL|C Group|"1. 1st administration - DW1029M1200mg PO Once~2. 2nd administration - DW1029M300mg PO Once~3. 3rd administration - DW1029M600mg PO Once"
62052830|NCT05745142||metastatic Renal Cell Carcinoma patients|metastatic Renal Cell Carcinoma patients with clear cell histology.
62253893|NCT05956730|ACTIVE_COMPARATOR|Group 2|The proposed protocol includes a part of aerobic training and a subsequent part of strengthening exercises for large muscle groups. The total duration of each session will be approximately 30 minutes. There are 2 weekly training sessions for 3 months.
62442810|NCT02286518|PLACEBO_COMPARATOR|Cohort 6A: TAK-114 placebo|Cohort 6A: Orally, Twice daily, 10 days
62835822|NCT05429008|OTHER|HMPL-A83|Drug: HMPL-A83 The starting dose of HMPL-A83 is 0.3 mg/kg IV QW with escalating dose levels of 1, 3, 10, 20, and 30 mg/kg IV QW, in 28-day treatment cycles.
62442811|NCT06547853|EXPERIMENTAL|Combined exercise training|In the combined exercise training regimen, participants will perform two hospital-based sessions with 45 minutes of aerobic dance and resistance training. The intensity of the aerobic dance will be \~ 132-135 beats per minute, whereas the intensity of the resistance training will be measured by the subjective rate of perceived exertion. The resistance exercise training regimen was set in a circuit, and participants will perform six exercises per session targeting the large muscle groups. Each exercise will be executed in two sets per session.
62442812|NCT00708331|EXPERIMENTAL|1|
62442813|NCT03807323|EXPERIMENTAL|'Lifestyle counselling and exercise' .|The study is a single-arm study where all participants undergo the same intervention 'Lifestyle counselling and exercise' .
62442814|NCT01729416|EXPERIMENTAL|Water Exchange Colonoscopy|The intervention will be water exchange colonoscopy in patients who are randomized to have screening colonoscopy with water exchange colonoscopy.
62442815|NCT01729416|ACTIVE_COMPARATOR|Air colonoscopy|The intervention will be colonoscopy using the traditional air method in patients who are randomized to have screening colonoscopy with air colonoscopy.
62442816|NCT06543836|EXPERIMENTAL|PD-1 inhibitor+Tyrosine kinase inhibitor(TKI)|PD-1 inhibitor: Sintilimab 200mg, d1, TKI: Fruquintinib 5mg Qd, d1-14, Q3w. Efficacy assessment every 2 cycles.
62442817|NCT06543836|ACTIVE_COMPARATOR|Tyrosine kinase inhibitor(TKI)|"The treatment regimen consists of the following options:~Option 1: Fruquintinib 5mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months.~Option 2: Regorafenib 160mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months."
62442818|NCT02863250||Massively transfused patients|Patients (18+ years) who have had a critical bleeding event that necessitated a massive transfusion (defined as 5 or more units of red cells in any 4 hour period)
62612031|NCT02394405||valve surgery|valve plasty/replacement surgery
62612032|NCT02394405||off-pump CABG|off-pump CABG
62612033|NCT02394405||CPB-CABG|CABG with CardioPulmonal Bypass
62052831|NCT01837160||Healthy Volunteers|"10 patients with normal echocardiogram studies and no history of ischaemic heart disease.~Patients to recieve CT-PET with fluciclatide, cardiac MRI scan, CT-coronary angiogram and echocardiogram."
62052832|NCT01837160||Moderate Aortic Stenosis (n=10)|"Patients with moderate aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
62052833|NCT01837160||Mild Aortic Stenosis (n=10)|"Patients with mild aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
62253894|NCT03021499|EXPERIMENTAL|Voclosporin|oral, 23.7 mg twice daily (BID)
62253895|NCT03021499|PLACEBO_COMPARATOR|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules twice daily (BID)
62442819|NCT04887883||Males|10 young healthy biological males aged 18 - 30 y
62442820|NCT04887883||Females|10 young healthy biological females aged 18 - 30 y
62442821|NCT00606684|ACTIVE_COMPARATOR|GW642444|GW642444
62442822|NCT00606684|PLACEBO_COMPARATOR|placebo|
62612034|NCT04344535|ACTIVE_COMPARATOR|Convalescent Donor Plasma|
62612035|NCT04344535|PLACEBO_COMPARATOR|Standard Donor Plasma|
62612036|NCT04536961|EXPERIMENTAL|Part A: Reference Treatment|
62612037|NCT04536961|EXPERIMENTAL|Part A Prototype|
62835823|NCT00118417|EXPERIMENTAL|1|Participants in phase II will receive sertraline, or an equivalent medication, up to 100 mg plus a placebo pill. Participants in phase III will receive the same medication with cognitive behavioral therapy.
62612038|NCT04536961|EXPERIMENTAL|Part C Reference Treatment|
62835824|NCT00118417|EXPERIMENTAL|2|Participants in phase II will receive sertraline, or equivalent medication, up to 200 mg. Participants in phase III they will receive the same medication with flexible clonazepam augmentation.
62835825|NCT05279677|EXPERIMENTAL|FMT|Fecal microbiota transplantation plus Sintilimab and Fruquintinib
62052834|NCT01837160||Severe aortic Stenosis (n=10)|"Patients with severe aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
62052835|NCT01837160||Severe Aortic Stenosis for AVR (n=10)|"Patients with severe aortic stenosis proceeding to aortic valve replacement. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo a repeat CT-PET scan 3 months after the operation.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 months after the operation."
62253896|NCT03211221|ACTIVE_COMPARATOR|Active rTMS|Active stimulation parameters will be 1-Hz, 10 seconds per train, 10 pulses per train (3 seconds inter-train interval) for a total of 160 trains (1600 pulses/session) at 130% of resting motor threshold (MT) (using the lowest value of the dominant hemisphere), once a day, 5 day/week, for 3 weeks. The coil will be positioned over the pre-SMA, targeted using the International 10-20 EEG System. Pre-SMA is defined at 15% of the distance between inion and nasion anterior to Cz (vertex) on the sagittal midline. The coil will be placed with the handle along the sagittal midline, pointing towards the occiput to stimulate bilaterally and simultaneously the pre-SMA.
62442823|NCT01680185|ACTIVE_COMPARATOR|Sensor-augmented Insulin Pump|Continuous subcutaneous sensor-augmented insulin-pump therapy (SAPT) with an insulin pump from Medtronic (Paradigm® Velo) for a period of approximately 3 months post-transplantation.
62442824|NCT01680185|ACTIVE_COMPARATOR|Basal insulin|NPH insulin titration regimen, as specified in the IPT-NODAT study
62253897|NCT03211221|PLACEBO_COMPARATOR|Sham rTMS|Sham TMS will be administered by tilting the coil 90° off the scalp, with one wing of the coil touching the scalp. This sham-TMS approach produces a clicking sound that is very similar to an active TMS pulse and induces a voltage in the brain that is more than 75% lower than active TMS.
62442825|NCT01680185|ACTIVE_COMPARATOR|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation
62442826|NCT01626378|EXPERIMENTAL|TRx0237 200 mg/day group|
62442827|NCT01626378|PLACEBO_COMPARATOR|Placebo|
62442828|NCT03487796|EXPERIMENTAL|MySTYLE|MySTYLE is online, brief and encourages parent-adolescent communication about sex and HIV prevention. Participants (non-heterosexual Black adolescent males and parents/caregivers) will receive two texts per week (for eight weeks) with links to intervention content that includes video, games and graphics to improve knowledge, motivation and skills for HIV prevention. Topics include assertive communication, sexual safety, goal setting, and resilience.
62442829|NCT03487796|OTHER|Waitlist Control|Participants randomized to the waitlist control will be eligible to receive the eight-week MySTYLE intervention after the completion of the 4-month follow-up assessment. During their first four months of participation, waitlist control participants will not receive any intervention materials.
62442830|NCT04675177|ACTIVE_COMPARATOR|Polidocanol foam sclerotherapy|Patients submitted to polidocanol foam sclerotherapy
62442831|NCT04675177|ACTIVE_COMPARATOR|Doppler-guided hemorrhoidal artery ligation|Patients submitted to doppler-guided hemorrhoidal artery ligation
62442832|NCT00530400|EXPERIMENTAL|1|intravenous 1.5g cefuroxime
62442833|NCT00530400|PLACEBO_COMPARATOR|2|intravenous placebo
62612039|NCT04536961|EXPERIMENTAL|Part C: Prototype|
62612040|NCT04536961|EXPERIMENTAL|Part B: Treatment 1|
62835826|NCT04100252||Group 1 (Women with AFI<5 cm at the time of PPROM diagnosis)|Pregnant women who were diagnosed PPROM the gestational ages of 23+0 and 33+0 were examined ultrasonographically at the first admission. Women with AFI\<5 were enrolled in the Group 1.
62835827|NCT04100252||Group 2 (Women with AFI≥5 cm at the time of PPROM diagnosis)|Pregnant women who were diagnosed PPROM the gestational ages of 23+0 and 33+0 were examined ultrasonographically at the first admission. Women with AFI≥5 were enrolled in the Group 2.
62835828|NCT02426203||Pulmonary Endarterectomy patients|Patients undergoing pulmonary endarterectomy surgery at Papworth Hospital
62835829|NCT01916954|ACTIVE_COMPARATOR|3-day artemether-lumefantrine|Standard artemether-lumefantrine regimen (3-day treatment)
62835830|NCT01916954|EXPERIMENTAL|5-day artemether-lumefantrine|Artemether-lumefantrine extended regimen (5-day treatment)
62835831|NCT02156622||Depression Care Manager|All enrolled in AIM 3 received decision support from Depression Care Manager
62253898|NCT00359138|EXPERIMENTAL|Desloratadine 5 mg tablet + Levocetirizine placebo capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
62442834|NCT05266781||Open surgical repair|Aneurysmectomy and aortic reconstruction with a surgical graft
62442835|NCT05266781||Endovascular repair|Off-the-shelf or custom-made Fenestrated/Branched-Endovascular Aortic Repair - F/BEVAR
62442836|NCT02563483|EXPERIMENTAL|Yoga and compassion meditation program|"The duration of this group was 8 weeks. The program included sessions 3 times per week, with each session lasting 1 hour and 15 minutes. The volunteers performed yoga classes composed of asana (poses), pranayama (breathing exercise) and meditation."
62442837|NCT02563483|NO_INTERVENTION|control|this group was a non treatment group.
62612041|NCT04536961|EXPERIMENTAL|Part B: Treatment 2|
62612042|NCT04536961|EXPERIMENTAL|Part B: Treatment 3|
62612043|NCT04536961|EXPERIMENTAL|Part B: Treatment 4|
62612044|NCT04536961|EXPERIMENTAL|Part B: Treatment 5|
62612045|NCT03769194|ACTIVE_COMPARATOR|VLA15 low dose|VLA15 low dose with Alum.
62835832|NCT06383481|EXPERIMENTAL|Experimental group|"After the mobile application is introduced to the patients, T-CSUQ-SV will be applied first. Following the introduction and information of the mobile application, the Introductory Information Form, GKAÖ, BARÖ, VHI-10, SF-36 Quality of Life Scale will be filled out face to face with the patients 1 day before the surgery. The mobile application will be available to the patient. On the first day after the surgery, patients will fill out the GKAÖ, VHI-10, Postoperative Recovery Index, and SF-36 Quality of Life Scale. During each meeting with patients, reminders will be given for the use of the mobile application, and it will be recommended that they read the information in the education section of the mobile application. In the 1st week after the surgery, patients will fill out GKAÖ, BARÖ, VHI-10, and Postoperative Recovery Index. At the 4th and 12th weeks after the surgery, patients will fill out the GKAÖ, BARÖ, VHI-10, Postoperative Recovery Index, SF-36 Quality of Life Scale."
62612046|NCT03769194|ACTIVE_COMPARATOR|VLA15 medium dose|VLA15 medium dose with Alum.
62052836|NCT00840723||Current smokers|Current cigarette smokers with no other illness
62612047|NCT03769194|ACTIVE_COMPARATOR|VLA15 high dose|VLA15 high dose with Alum.
62052837|NCT00840723||Healthy controls|Healthy non smokers
62052838|NCT01757834|EXPERIMENTAL|SWUS Elastography|This is a noninvasive technique using focused ultrasonic beams (pushing beams.) Several pushing beams at increasing depths are transmitted to generate a quasi-plane shear wave frame that propagates throughout the imaging area. After generating the shear wave, an ultrafast imaging sequence is performed to acquire successive raw radiofrequency dots at a very high frame rate (up to 20,000 per second). A tissue elasticity assessment can be derived from shear wave propagation speed. A color-coded image is displayed; softer tissue in blue and stiffer tissue in red. Quantitative information is delivered by drawing regions of interest on the thyroid and surrounding tissues which is the Elasticity Index expressed in kilo-Pascal (kPa). Due to the lack of manual compression and known value of the strength of pushing beam, SWUS gives an objective number to stiffness within the nodule.
62052839|NCT04978714||Women with cystocele|All women with ≥ stage II cystocele who visited the urogynecological department of a medical center for cystocele repair
62052840|NCT03859882|EXPERIMENTAL|Caffeine|Caffeine 5 mg/kg/day in 2 administration (08:00 and 14:00) per day
62052841|NCT03859882|PLACEBO_COMPARATOR|placebo|in 2 administration (08:00 and 14:00) per day
62052842|NCT06206967|EXPERIMENTAL|Physical Activity Promotion Group|"The rehabilitation program has the purpose of motivating patients to be more physically active. The treatment protocol had a total duration of 12 weeks.~Three sessions are conducted during hospitalization for the education of patients and to start physical activity. A diary is provided to patients to record the activities that they perform during each week until completing the 12 weeks.~Additionally, phone calls are performed at 15 days, 1 and 2 months to motivate patients and answer any questions they may have."
62253899|NCT00359138|ACTIVE_COMPARATOR|Desloratadine placebo tablet + Levocetirizine 5 mg capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
62612048|NCT03769194|PLACEBO_COMPARATOR|Placebo|
62612049|NCT05464251||Subjects with spinal epidural abscess with a history of drug abuse|
62253900|NCT00359138|PLACEBO_COMPARATOR|Desloratadine placebo tablet + Levocetirizine placebo capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
62253901|NCT06094751|EXPERIMENTAL|ACT Guide for Insomnia|Participants will complete 2 modules of an online Acceptance and Commitment Therapy (ACT) Guide designed to focus on insomnia among college students. Module 1 will be available to participants at the start of week 1 and throughout the course of the study. Module 2 will become available at the start of week 3 and participants will have access throughout the study
62253902|NCT06094751|NO_INTERVENTION|Waitlist|Participants randomized into the waitlist condition will not have access to the ACT Guide for Insomnia until the conclusion of their time in the study (8 weeks after randomization).
62612050|NCT05464251||Subjects with spinal epidural abscess with no history of drug abuse|
62612051|NCT04557956|ACTIVE_COMPARATOR|Arm I (tazemetostat) phase II|Patients receive tazemetostat PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and MRI throughout the study. At the time of progression, patients may crossover to Arm II after completion of radiation therapy.
62612052|NCT04557956|EXPERIMENTAL|Arm II (tazemetostat, dabrafenib, trametinib) phase I/phase II|Patients receive tazemetostat orally PO BID, dabrafenib PO BID, and trametinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy, CT scan, MRI, and MUGA or ECHO throughout the study.
62052843|NCT06206967|ACTIVE_COMPARATOR|Control group|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
62052844|NCT00259064|EXPERIMENTAL|Gefitinib|ZD1839 + BSC (best supportive care)
62835833|NCT06383481|NO_INTERVENTION|Control Group|Control Group Patients in the control group will be provided with standard patient care and information. No application will be made. In summary, week 1 data collection forms will be filled out with the patients at the end of the first week. At the end of the 1st month, 1st month data collection forms will be filled out. At the end of the 3rd month, the study will be terminated by filling out the 3rd month data collection forms.
62052845|NCT00259064|PLACEBO_COMPARATOR|Placebo|Placebo + BSC (best supportive care)
62052846|NCT06142136|ACTIVE_COMPARATOR|Vitamin D3 sublingual sprayable microemulsion.|Total participants: 34 participants Duration: 30 days.
62052847|NCT06142136|ACTIVE_COMPARATOR|Vitamin D3 oil droplets.|Total participants: 33 participants Duration: 30 days.
62612053|NCT03433300|EXPERIMENTAL|Microprocessor Knee|Ottobock Kenevo/Ottobock C-Leg
62835834|NCT05592717||Yutiq group|Patients will receive YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye and will be followed for 36 months after treatment.
62835835|NCT05592717||traditional therapy group|Patients were treated with glucocorticoids alone or glucocorticoids combined with immunosuppressants and were followed for up to 36 months.
62052848|NCT06142136|ACTIVE_COMPARATOR|Vitamin D3 capsules.|Total participants: 32 participants Duration: 30 days.
62052849|NCT02856113|PLACEBO_COMPARATOR|Placebo|Alogliptin matching-placebo tablets, orally, once daily (QD) for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period.
62052850|NCT02856113|EXPERIMENTAL|Alogliptin 25 mg|Alogliptin 25 mg tablets, orally, QD for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period.
62612054|NCT03433300|ACTIVE_COMPARATOR|Nonmicroprocessor knee|Ottobock 3R60 for K3 participants, Ottobock 3R62 for K2 participants.
62052851|NCT00091247|EXPERIMENTAL|tetracycline|"Patients receive oral tetracycline twice daily. Treatment continues for 4 weeks in the absence of unacceptable toxicity.~Quality of life is assessed at baseline and then weekly for 8 weeks.~Patients are followed at weeks 4 and 8."
62052852|NCT00091247|PLACEBO_COMPARATOR|placebo|"Patients receive oral placebo twice daily. Treatment continues for 4 weeks in the absence of unacceptable toxicity.~Quality of life is assessed at baseline and then weekly for 8 weeks.~Patients are followed at weeks 4 and 8."
62612055|NCT05061485|EXPERIMENTAL|Sucrose|The participants will be served a test drink with 75g sucrose dissolved in water
62612056|NCT05061485|EXPERIMENTAL|Sucrose + protein|The participants will be served a test drink with 75g sucrose dissolved in water and \~ 100 kcal protein (whey protein)
62052853|NCT03569384|EXPERIMENTAL|"Intervention group tele-rehabilitation"|"Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist. Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system. Workout Sessions with a Virtual Physiotherapist Agent (VPA):~The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time."
62612057|NCT05061485|EXPERIMENTAL|Sucrose + fat|The participants will be served a test drink with 75g sucrose dissolved in water and \~ 100 kcal fat (cream)
62612058|NCT01971632|ACTIVE_COMPARATOR|Oxycodone/Naloxone|
62612059|NCT01971632|PLACEBO_COMPARATOR|Placebo oxycodone/naloxone|
62612060|NCT01688141|NO_INTERVENTION|Control|Usual care
62612061|NCT01688141|ACTIVE_COMPARATOR|Enhanced Management|Practices randomised to the intervention group will be offered an enhanced level of CKD disease management led by clinical nurse specialists based on an intervention previously piloted in high risk patients. Here, high risk patients identified will be invited to a CKD clinic for tailored management of bp and proteinuria and referral as needed.
62612062|NCT02028169||Participants Receiving Anti-TNF for PsA|Participants who are actively working (full-time or part-time) with rheumatologist-confirmed PsA for which the physician has initiated treatment with an anti-TNF.
62612063|NCT05687838|EXPERIMENTAL|Relaxing Music Group|"The patients in this group will listen to specially composed MusiCure® compositions, which contain melodies with soft rhythm (60-80 bpm), including harp, cello, strings, and nature sounds (such as rain, bird, forest sound). The patients scheduled to receive chemotherapy for the first time, will be allowed to listen to music for at least one hour during chemotherapy with over-ear headphones (Sennheiser HD280) and an MP3 player. Anxiety and satisfaction levels of the patients will be recorded before and after the music application."
62835836|NCT01021891|EXPERIMENTAL|Non-Diabetic Subj. w/o COPD|Single dose, 30 units
62835837|NCT01021891|EXPERIMENTAL|Non-Diabetic Subj. with COPD|Single dose, 30 units
62612064|NCT05687838|ACTIVE_COMPARATOR|Turkish Makam Music Group|"The patients in this group will listen to the Rast Makam, which was created as a result of research conducted by the Turkish Music Research and Promotion Group (TÜMATA) and provides individuals with comfort and inner peace. The patients scheduled to receive chemotherapy for the first time, will be allowed to listen to music for at least one hour during chemotherapy with over-ear headphones (Sennheiser HD280) and an MP3 player. Anxiety and satisfaction levels of the patients will be recorded before and after the music application."
62052854|NCT03569384|ACTIVE_COMPARATOR|Control|COPD patients in the control group will undergo the conventional standardized rehabilitation program as implemented at the Department of Respiratory Medicine and Allergy, Aarhus University Hospital. The program is an 8 weeks program consisting of 2 weekly group training sessions at the hospital with instruction by a physiotherapists and 6 hours of education about COPD and its treatment.
62052855|NCT03347916|PLACEBO_COMPARATOR|Control group|patients received strawberry juice 5 ml volume, one hour before induction.
62052856|NCT03347916|ACTIVE_COMPARATOR|Gabapentin group|patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
62052857|NCT05125575|EXPERIMENTAL|Treatment A|Test Product Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)
62052858|NCT05125575|ACTIVE_COMPARATOR|Treatment B|Reference Product Glucophage® XR 1000 mg Prolonged Release Tablets (Merck Serono Ltd, UK)
62052859|NCT02288754||Stage II or III curative surgery (closed to accrual)|Patients with stage II or III solid tumors undergoing curative intend surgery enrolled before surgery.
62052860|NCT02288754||Stage II or III neoadjuvant therapy cohort (closed to accrual)|Patients with stage II or III solid tumors undergoing neoadjuvant therapy followed by curative intend surgery enrolled before neoadjuvant therapy.
62052861|NCT02288754||Metastatic disease|Patients with advanced, recurrent and/or metastatic disease requiring systemic therapy with chemotherapy, targeted therapy, immunotherapy or a combination of any before initiation of any therapy or a new line of therapy following documentation of disease progression on prior therapy.
62052862|NCT03648112|ACTIVE_COMPARATOR|Intervention 1|"Intervention 1: Crude oat flakes (dietary supplement) 80 g of crude oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes."
62052863|NCT03648112|ACTIVE_COMPARATOR|Intervention 2|"Roasted oat flakes (dietary supplement) 80 g of roasted oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~These oat flakes were roasted at 150°C for 20 minutes.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes."
62052864|NCT03648112|ACTIVE_COMPARATOR|Intervention 3|"Crude barley flakes (dietary supplement) 80 g of crude oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes"
62612065|NCT05687838|NO_INTERVENTION|Control Group|The patients in this group will not receive any musical interventions and will receive standard treatment and care during chemotherapy.
62612066|NCT04026711|ACTIVE_COMPARATOR|MitoQ|MitoQ 40 mg per day for 12 weeks
62612067|NCT04026711|PLACEBO_COMPARATOR|Placebo|placebo daily for 12 weeks
62835838|NCT05586438|EXPERIMENTAL|blood draws|All patients enrolled will have PK blood samples obtained around a colistin dosing
62835839|NCT01562093|EXPERIMENTAL|local nasal steroids|
62835840|NCT01562093|PLACEBO_COMPARATOR|placebo|
62835841|NCT01129856|ACTIVE_COMPARATOR|Ocular Iontophoresis EGP-437, Low Dose|Ocular Iontophoresis with EGP-437 4.0 mA-min at 1.5 mA
62835842|NCT01129856|ACTIVE_COMPARATOR|Ocular Iontophoresis EGP-437, High Dose|Ocular Iontophoresis with EGP-437 6.5 mA-min at 2.5 mA
62253903|NCT04244630|OTHER|Antioxidants|Eligible patients will receive over-the-counter anti-oxidants, namely vitamin E, NAc cysteine, L-cystine, Nicotinamide and Taurursodiol at defined doses.
62612068|NCT05739305||Cancer|Death certificates of patients died by cancer or with cancer.
62612069|NCT05739305||Cardiovascular|Death certificates of patients died by cardiovascular conditions or complications.
62835843|NCT01129856|PLACEBO_COMPARATOR|Ocular Iontophoresis Placebo|Ocular Iontophoresis with Placebo 6.5 mA-min at 2.5 mA
62253904|NCT04515225||HIV-infected patients|All HIV-infected patients on active follow-up, whatever clinical and biological condition, on ARV treatment or not, and whatever ARV combination
62612070|NCT05739305||Tuberculosis|Death certificates of patients died by or with tuberculosis, including patients with HIV.
62612071|NCT05739305||Infants|Death certificates of pediatric patients with more than a month of birth, and less than 18 years old.
62835844|NCT01321099|EXPERIMENTAL|NaFeEDTA|
62835845|NCT01321099|EXPERIMENTAL|Phatase|
62835846|NCT01321099|EXPERIMENTAL|Vitamin C|
62835847|NCT06595719|EXPERIMENTAL|Probiotics with standard care|62 mild to moderate UC patients were supplemented with multi-strain probiotics consisting of 6 active strains from Bifidobacterium and Lactobacillus species for 12 weeks.
62835848|NCT06595719|PLACEBO_COMPARATOR|Placebo with standard care|62 mild to moderate UC patients were supplemented with placebo, containing no active bacteria strains for 12 weeks
62052865|NCT03648112|ACTIVE_COMPARATOR|Intervention 4|"Roasted barley flakes (dietary supplement) 80 g of roasted oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes."
62052866|NCT03648112|PLACEBO_COMPARATOR|control|"White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread."
62612072|NCT05739305||Congenital malformations|Death certificates of patients died by congenital malformations, independently of age.
62835849|NCT01408173|EXPERIMENTAL|NPC-11|"* Loading Dose (Day 1): Caffeine citrate 20 mg/kg body weight will be administered intravenously using a syringe infusion pump over 30 minutes.~* Maintenance Dose (Day 2～Day 10): After an interval 24 hours, caffeine citrate 5 mg/kg body weight will be administered intravenously (over 10 minutes) or orally if the patients will be able to receive oral administration once a day. The maintenance dose can be increased to a maximum 10 mg/kg caffeine citrate once a day if apnea persists."
62835850|NCT06367140|EXPERIMENTAL|constraint-induced movement therapy groups|The device utilized EMG sensors to collect signals from the leg muscles, which then controlled the cycling motion. This group underwent specific training sessions designed to enhance muscle activation on the affected side by inducing voluntary contractions through cycling, with the aim of improving muscle strength, balance, and activities of daily living. The sessions included a structured regimen of warm-up, active cycling with therapist-guided acceleration based on muscle activation, and cool-down periods, conducted under supervision for safety and effectiveness.
62052867|NCT02262286||Brain Injury|Brain Injury
62052868|NCT02262286||Control|Healthy, or Head Trauma, or Orthopedic Trauma, or Poly-Trauma
62253905|NCT05542550|ACTIVE_COMPARATOR|Voice Rest|48 hours of voice rest prescribed following injection
62253906|NCT05542550|EXPERIMENTAL|No voice rest|No voice rest required following injection
62442838|NCT01513668|EXPERIMENTAL|Acetaminophen extended release Gel tabs|Acetaminophen extended release Gel tabs 650 mg of OHM Laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
62442839|NCT01513668|ACTIVE_COMPARATOR|Tylenol® 650 mg|Tylenol® 650 mg of McNeil Consumer and Specialty Pharmaceuticals, Division of McNeil PPC, INC. Fort Washington, PA 19034 USA
62442840|NCT06098170|EXPERIMENTAL|Unguided use of the My SCI Toolkit program|
62612073|NCT05739305||Maternal|Death certificates of patients died by obstetrical conditions during pregnancy or delivery.
62052869|NCT05634044|EXPERIMENTAL|eNose device use|Participants will place the e-Nose device in their bathroom to record VOCs from the ambient air after they have a bowel movement. In addition to this, all participants will complete 2 blood draws 3 stool collections, and questionnaires over the course of 4 visits during a 3 week period.
62052870|NCT02656810|EXPERIMENTAL|Sequence A|Single subcutaneous injection of two teriparatide products (PF708 and Forteo)
62052871|NCT02656810|EXPERIMENTAL|Sequence B|Single subcutaneous injection of two teriparatide products (Forteo and PF708)
62052872|NCT05836948|EXPERIMENTAL|SHR-9839|three stages: dose escalation, dose expansion and efficacy expansion.
62052873|NCT03144895|OTHER|Arterial catheter|by anatomical placement alone
62052874|NCT03144895|OTHER|Placement|of an arterial catheter by ultrasound tracking
62052875|NCT03092284|ACTIVE_COMPARATOR|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Allogeneic adipose derived stromal cells
62052876|NCT03092284|PLACEBO_COMPARATOR|Placebo|Saline
62612074|NCT05739305||Contagious|Death certificates of patients died by contagious/infectious diseases.
62612075|NCT05823467|EXPERIMENTAL|Post operative Antibiotic|Patients in this arm will have a prescription for one week or post operative antibiotic ( 7-day course of TMP-SMX DS )
62052877|NCT05865743|EXPERIMENTAL|SDD treatment|Standard of care + SDD treatment
62052878|NCT05865743|NO_INTERVENTION|Standard of care|Standard of care
62253907|NCT04896047|EXPERIMENTAL|CKD patients|Patients with CKD, non-diabetic, without a history of renal transplantation, without digestive pathology, aged 18 to 70 and an estimate of the glomerular filtration rate (eGFR) \<60 ml / min / 1.73m2 according to the formula of CKD-EPI.
62253908|NCT04896047|ACTIVE_COMPARATOR|Haemodialysis patients|Patients on hemodialysis, for more than 3 months, with no history of kidney transplantation, without digestive pathology, aged 18 to 70 with a BMI between 18 and 30 kg / m2
62253909|NCT04896047|ACTIVE_COMPARATOR|Healthy volunteers|Healthy volunteers (controls) recruited from the population of living kidney donors
62442841|NCT06098170|EXPERIMENTAL|Coached My SCI Toolkit|
62442842|NCT06098170|NO_INTERVENTION|Wait-list control|Participants will not access the My SCI Toolkit program during the 8-week study period and will be asked to continue daily life, including management of pain, as usual.
62612076|NCT05823467|EXPERIMENTAL|Post operative Wound VAC|Patient will have a 7-day application of ciNPT dressing post operatively.
62835851|NCT06367140|SHAM_COMPARATOR|general cycling training groups|This group followed a similar session structure to the CIMCT group, including warm-up, cycling at a comfortable pace, and cool-down phases, but without the targeted muscle activation component.
62253910|NCT04341636|EXPERIMENTAL|vertical bitewing|All of the bitewing radiographs will be evaluated by two experienced restorative dentists for caries. All observers will be instructed on the definition of the rating scale before the examination sessions. The observers will be using the following a 5-point confidence scale as follows: 1=caries definitely absent; 2=caries probably absent; 3=equal chance of caries being present or absent; 4=caries probably present; 5=caries definitely present. If caries was detected a second 5-point confidence scale as follows: 1=caries mostly absent (\< 25%); 2=caries slightly presence( 25%-50%) ; 3=about half of the border are presence; 4=caries probably clear ( most boarders are presence); 5=caries definitely clear ( all borders are presence ).
62612077|NCT05823467|NO_INTERVENTION|No Intervention|Patient will be treated as standard of care which is no intervention.
62612078|NCT01839799|EXPERIMENTAL|Arm 1 - FOLFIRINOX|"FOLFIRINOX:~Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles over 8 weeks~Chemoradiation:~Radiation to begin no sooner than 28 days from last day of chemotherapy.~On Day 1(+ 2days to accommodate scheduling difficulties):~Infusional 5-FU (225 mg/m2 continuous infusion during radiation) and radiation therapy as defined.~FOLFIRINOX:~Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated"
62835852|NCT00801177|EXPERIMENTAL|IMC-11F8 (Every week)|Cycle of therapy administered intravenously, once a week for 6 weeks, for a total of six doses per cycle.
62835853|NCT00801177|EXPERIMENTAL|IMC-11F8 (Every other week)|Cycle of therapy administered intravenously, every other week for 6 weeks, for a total of three doses per cycle.
62835854|NCT02688777|EXPERIMENTAL|Immediate Backward Walking Training|Individuals will participate in 18 sessions of Backward Walking training immediately following baseline assessment.
62835855|NCT02688777|ACTIVE_COMPARATOR|Delayed Backward Walking Training|Individuals will participate in 18 sessions of Backward Walking training at 1-year post-strokeD
62835856|NCT02926885|ACTIVE_COMPARATOR|CONVENTIONAL LIVER RETRACTOR DEVICE|USE OF CONVENTIONAL LIVER RETRACTOR FOR THE LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
62835857|NCT02926885|EXPERIMENTAL|FLEXIBLE LIVER RETRACTOR DEVICE|USE OF THE FLEXIBLE LIVER RETRACTOR FOR THE LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
62835858|NCT01740648|EXPERIMENTAL|Treatment (trametinib, fluorouracil, radiation, surgery)|"Patients receive trametinib PO (by mouth) QD (daily) on days -14 through -10 and 1-38 and fluorouracil IV continuously 5 days a week from days 1-38. Patients also undergo radiation therapy 5 days a week on days 1-33. Patients then undergo surgery 6-10 weeks later.~Patients achieving negative surgical margins after complete resection of tumor receive postoperative chemotherapy comprising leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46 hours on days 1 and 15 OR oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46 hours on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
62442843|NCT03958279||primipara giving birth|"The investigators involve every primipara giving birth in a period of two years.~Exclusion criteria:~* a) Unwilling to participate~* b) Minors (under 18 years old)~* c) Foetus mortus or perinatal death of the newborn~* d) Admission of the newborn to the ICU~* e) Unfamiliar with slovak language~* f) Multiple pregnancy"
62442844|NCT06114056|EXPERIMENTAL|JWK007 injection|AAVrh74 was used as the vector for JWK007 injection. Because the Dystrophin gene is too large to be used for conventional rAAV loading (AAV packaging capacity \< 5.0kb), we independently designed a new micro-dystrophin (μDystrophin) for each functional domain of the gene. The protein includes structures essential for promoting neuronal nitric oxide synthase (nNOS) activity and membrane-binding domains.
62052879|NCT03785574|ACTIVE_COMPARATOR|A:chemotherapy immediately|Treated with chemotherapy immediately. First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO
62052880|NCT03785574|EXPERIMENTAL|B:follow up|"B1: follow up until hCG level met FIGO diagnostic criteria of GTN, then chemotherapy.~B2: follow up until hCG level declined to normal spontaneously."
62052881|NCT00973661|EXPERIMENTAL|Electronic tools|
62052882|NCT00973661|NO_INTERVENTION|Usual care|
62612079|NCT01839799|EXPERIMENTAL|Arm 2 - Gemcitabine / Abraxane|"Gemcitabine / Abraxane Gemcitabine 1000 mg/m2 Days 1, 8, 15 Abraxane 125 mg/m2 Days 1, 8, 15 Two cycles over 8 weeks~Chemoradiation:~Radiation to begin no sooner than 28 days from last day of chemotherapy. On Day 1 (+ 2days to accommodate scheduling difficulties) Infusional 5-FU (225 mg/m2 continuous infusion during radiation) and radiation therapy as defined.~Gemcitabine / Abraxane Gemcitabine 1000 mg/m2 Days 1, 8, 15 Abraxane 125 mg/m2 Days 1, 8, 15 Two cycles, if tolerated"
62612080|NCT00181649|EXPERIMENTAL|Recombinant human prolactin|
62835859|NCT01709084|EXPERIMENTAL|Group 1|Patients will receive fixed dose combination (FDC) tablet of tenofovir disoproxil fumarate/emtricitabine/rilpivirine with a meal, until Week 48.
62835860|NCT01709084|ACTIVE_COMPARATOR|Group 2|Patients will receive FDC tablet of tenofovir disoproxil fumarate/emtricitabine /efavirenz on an empty stomach at bedtime, until Week 48.
62835861|NCT04396639|EXPERIMENTAL|Treatment Arm|Fifty eligible male subjects will be enrolled in the treatment arm to receive Moroctocog alfa (AF-CC) until 24 exposure days (EDs) or a period of up to 8 weeks on treatment had occurred (whichever occurs first).
62835862|NCT04078425|EXPERIMENTAL|HF with preserved EF|50patients of heart failure with preserved ejection fration will receive anti.failure treatment(lanoxin,beta blocker,diuretics) for one month with follow up echocardiography before and after
62052883|NCT03187990|EXPERIMENTAL|PET/MRI before biopsy|Patients with suspected areas on mpMRI will undergo additional \[68Ga\]PSMA-11 PET/MRI scan with subsequent mpMRI and PET/MRI guided biopsy.
62442845|NCT03075033|ACTIVE_COMPARATOR|SOS gruop|Use of The Shikani Optical Stylet In Patients At Risk Of Secondary Cervical Spine Injury
62253911|NCT04341636|ACTIVE_COMPARATOR|horizontal bitewing|All of the bitewing radiographs will be evaluated by two experienced periodontist for bone loss measurements. The steel wire will be used to determine the magnification factor as explained by G Li et al. 8 The steel wire and cemento enamel junction (CEJ) - if not obscure by caries - will be used as reference points for bone loss measurements. Each tooth will be measured mesially and distally twice and all these measurements will be adjusted using the steel measurement.9 All the measurements will be conducted using IC measure INK software.
62442846|NCT03075033|ACTIVE_COMPARATOR|Awake Fiberoptic Intubation|Use of Awake Fiberoptic Intubation In Patients At Risk Of Secondary Cervical Spine Injury
62052884|NCT03187990|EXPERIMENTAL|PET/MRI after biopsy|Patients with unclear areas or a negative finding in the mpMRI for MRI guided biopsy but positive biopsy, which will undergo the additional \[68Ga\]PSMA-11 PET/MRI scan with \[68Ga\]PSMA.
62835863|NCT04078425|EXPERIMENTAL|HF with preserved EF recive eplernone|50 patients with heart failure with preserved ejection frationnwill receive traditional anti-failure treatment in addition to aldosterone antagonist (Eplernone) with follow up echocardiography and aldosterone level before and after
62835864|NCT05109468||Anal cancer patients|Non-metastatic squamous anus cancer with the presence of an HPV infection authenticated on the biopsy
62442847|NCT04654403|EXPERIMENTAL|Camrelizumab|Camrelizumab (200 mg every 2 weeks),Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years)
62442848|NCT04654403|ACTIVE_COMPARATOR|Camrelizumab plus chemotherapy|Camrelizumab plus chemotherapy(Camrelizumab 200 mg every 3 weeks,docetaxel 75mg/m2/d plus cisplatin 75 mg/m2/d on day 1 every 3 weeks),)Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years).
62442849|NCT02414880|ACTIVE_COMPARATOR|Sugammadex/ Normal liver|"Patients with American Society of Anesthesiologists physical status (ASA) class I with normal preoperative liver functions undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg."
62612081|NCT02563691|EXPERIMENTAL|Stereotactic radiotherapy|Stereotactic radiotherapy will be delivered to the prostate (if not previously treated) and to all metastatic tumours.
62835865|NCT05811663||DanFunD baseline|"Data from the DanFunD baseline cohort will be included. It comprises a total of 9,656 (33.7% of the invited participants) men and women aged 18-76 years born in Denmark and living in the Western part of greater Copenhagen.~Individuals with FSD are identified by means of self-reported questionnaires (n=9,656) and diagnostic research interviews (n=1,590).~Participants with FSD will be defined as follows:~FSD operationalised by the Bodily Distress Syndrome single- and multi-organ type will be defined with both self-reported questionnaires and diagnostic interviews.~Three functional somatic syndromes, i.e. irritable bowel, chronic widespread pain, and chronic fatigue will be defined with questionnaires.~Severe physical disease will be defined by means of self-report as having received at least one of the following five diagnoses: Cancer, stroke, myocardial infarction, other heart disease, and obstructive pulmonary disease."
62835866|NCT05614596|ACTIVE_COMPARATOR|CT guided for patient with chronic low back pain|CT guided treatment in patients with low back pain
62612082|NCT03186989|EXPERIMENTAL|IONIS-MAPTRx|IONIS MAPTRx (Study Drug)
62835867|NCT05614596|ACTIVE_COMPARATOR|Flouroscopic guided for patient wit chronic low back pain|Flouroscopic guided treatment in patients with low back pain
62253912|NCT01205828|EXPERIMENTAL|Temozolomide and ABT-888 in HCC patients|Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days ABT-888 40 mg BID PO Days 1-7 every 28 days
62253913|NCT04429165||ACL reconstruction|ACL reconstruction using an autologous hamstring tendon
62612083|NCT03186989|PLACEBO_COMPARATOR|Placebo|Artificial CSF
62612084|NCT03032172|EXPERIMENTAL|Risdiplam|Participants will receive multiple doses of risdiplam orally once daily for 24 months. After 24-month treatment, participants will be offered the opportunity to enter the open-label extension (OLE) phase for 3 years.
62835868|NCT01942837|EXPERIMENTAL|Enzalutamide|"Administration: 160 mg orally once daily with a 28-day cycle. Treatment will be continued until evidence of symptomatic or radiographic progression or the participant is taken off the study for another reason.~Dosing: 160 mg orally taken once daily as four 40 mg capsules."
62612085|NCT01294748|EXPERIMENTAL|MiStent DES|The MiStent SES is a sirolimus-eluting absorbable polymer stent for coronary artery revascularization.
62835869|NCT06278714|EXPERIMENTAL|Intervention group|The EG (experimental group) will perform the diaphragmatic fatigue protocol using a specific inspiratory endurance test, in which volunteers, one-on-one, and in a single session, will breathe against submaximal inspiratory loads equivalent to 60% of their MIP (Maximum Inspiratory Pressure) through a threshold valve device. The participants will follow a free pattern of breathing until they are unable to establish flow during at least 3 maximum inspiratory efforts.
62612086|NCT01294748|ACTIVE_COMPARATOR|Endeavor DES|The Endeavor DES is an everolimus-eluting durable polymer stent for coronary artery revascularization.
62253914|NCT04429165||control group|knee-healthy, age-matched subjects as a control group
62612087|NCT02778386|EXPERIMENTAL|Cohort 1|6 subjects, male \& female will receive one dose each of 200 mg of N-Methanocarbathymidine orally in capsules. Each subject will be evaluated for any clinical signs of any toxicity.
62253915|NCT05341479||Surgical treatment for early-stage OPC|Early-stage OPC patients treated with surgery according to proper indications (CSCO 2021 and NCCN 2021).
62253916|NCT05341479||RT treatment for early-stage OPC|Early-stage OPC patients treated with radiotherapy (RT) according to proper indications (CSCO 2021 and NCCN 2021).
62253917|NCT05341479||CRT treatment for advanced OPC|Advanced OPC patients treated with chemoradiotherapy (CRT) according to proper indications (CSCO 2021 and NCCN 2021).
62612088|NCT02778386|EXPERIMENTAL|Cohort 2|6 subjects, male \& female will receive one dose each of 400 mg of N-Methanocarbathymidine orally in capsules. Each subject will be evaluated for any clinical signs of any toxicity.
62612089|NCT02778386|EXPERIMENTAL|Cohort 3|8 subjects, males and females, 6 subjects will receive one dose each 800 mg of N-Methanocarbathymidine orally in capsules and 2 will receive a placebo capsule. Each subject will be evaluated for any clinical signs of any toxicity.
62612090|NCT02778386|EXPERIMENTAL|Cohort 4|8 subjects, males and females, 6 subjects will receive one dose each 1200 mg of N-Methanocarbathymidine orally in capsules and 2 will receive a placebo capsule. Each subject will be evaluated for any clinical signs of any toxicity.
62612091|NCT01618916|EXPERIMENTAL|1.0 milligrams per kilogram (mg/kg) LY3015014 Every 2 Weeks|1.0 mg/kg LY3015014 given subcutaneously (SC) once every 2 weeks for 29 days.
62835870|NCT06278714|NO_INTERVENTION|Control group|they will not receive any intervention. Just sit and wait the same amount of time that the intervention and the activation group needs to finish their protocol (around 10 minutes)
62835871|NCT06278714|ACTIVE_COMPARATOR|Activation group|The activation group will perform the protocol of 2 sets of 30 repetitions at 40% of their MIP, one-on-one, and in a single session, breathing against submaximal inspiratory loads using a threshold valve device. The participants will follow a free pattern of breathing until complete the protocol.
62835872|NCT00981110|ACTIVE_COMPARATOR|Mepore Self-adhesive absorbent dressing|Mepore Self-adhesive absorbent dressing
62835873|NCT00981110|EXPERIMENTAL|AQUAGEL Ag Hydrofiber Wound Dressing|AQUAGEL Ag Hydrofiber Wound Dressing
62253918|NCT05341479||Surgical treatment for advanced OPC|Advanced OPC patients treated with surgery according to proper indications (CSCO 2021 and NCCN 2021).
62253919|NCT05341479||Neoadjuvant treatment for advanced OPC|Advanced OPC patients treated with neoadjuvant treatment according to proper indications (CSCO 2021 and NCCN 2021).
62253920|NCT00290199|EXPERIMENTAL|Transcervical Foley Catheter|
62253921|NCT00290199|NO_INTERVENTION|No Foley|
62253922|NCT00097773|PLACEBO_COMPARATOR|Cycled TOBI & placebo|Tobramycin inhalation solution and oral placebo for six consecutive quarterly cycles
62835874|NCT01385293|EXPERIMENTAL|Study arm|BKM120 at 100mg orally daily
62052885|NCT03685838|ACTIVE_COMPARATOR|Compression|Patient will receive Class II above knee compression stockings, and will be asked to wear it for 1 week. This would involve wearing the stocking during daytime but patients will be allowed to take it off at night whilst in bed.
62253923|NCT00097773|ACTIVE_COMPARATOR|Cycled TOBI & oral ciprofloxacin|Tobramycin solution for inhalation and oral ciprofloxacin for six consecutive quarterly cycles.
62253924|NCT00097773|PLACEBO_COMPARATOR|Culture based TOBI & placebo|Tobramycin solution for inhalation and oral placebo administered only when quarterly respiratory cultures are found positive for Pa.
62253925|NCT00097773|ACTIVE_COMPARATOR|Culture based TOBI & oral cipro|Tobramycin solution for inhalation and oral ciprofloxacin administered only when quarterly respiratory cultures are found positive for Pa.
62253926|NCT06387654||Patients suffering from autoimmune, dysimmune or auto-inflammatory dermatological disease|Biological samples will be collected in the normal diagnosis and follow-up process
62253927|NCT02295371||Patients with an incident|Patients undergoing a safety incident while being treated with drugs
62612092|NCT01618916|EXPERIMENTAL|1.0 mg/kg LY3015014 Every 4 Weeks|1.0 mg/kg LY3015014 given SC once every 4 weeks for 29 days.
62612093|NCT01618916|EXPERIMENTAL|3.0 mg/kg LY3015014 Every 2 Weeks|3.0 mg/kg LY3015014 given SC once every 2 weeks for 29 days.
62612094|NCT01618916|EXPERIMENTAL|3.0 mg/kg LY3015014 Every 4 Weeks|3.0 mg/kg LY3015014 given SC once every 4 weeks for 29 days.
62253928|NCT04196075|EXPERIMENTAL|Andrographis Paniculata treatment|Single lot of Andrographis paniculata (AP) concentrated granules (Andrographis Herba) will be manufactured by Nong's Company Limited under GMP standard
62253929|NCT04598997||600 patients involved in the prospective study|These patients will be contacted by telephone follow-up, offered participation in the study and sent the information and non-opposition letter. In case of refusal, data will not be used.
62612095|NCT01618916|PLACEBO_COMPARATOR|Placebo Every 2 Weeks|Saline injection (to match LY3015014) given SC once every 2 weeks for 29 days.
62052886|NCT03685838|NO_INTERVENTION|No Compression|Patient will not receive any compression stockings.
62612096|NCT01618916|PLACEBO_COMPARATOR|Placebo Every 4 Weeks|Saline injection (to match LY3015014) given SC once every 4 weeks for 29 days.
62052887|NCT01720290|EXPERIMENTAL|Rep|
62052888|NCT01720290|ACTIVE_COMPARATOR|Met|
62052889|NCT01720290|ACTIVE_COMPARATOR|Rep + met|
62253930|NCT04598997||1000 patients involved in a non-human study|To train the algorithm to recognize images in the context of STEMI revascularization, 1000 normal coronary angiograms performed in a stable disease context will also be identified.
62253931|NCT01805167|OTHER|subjects with a cochlear implant|
62253932|NCT04982757|EXPERIMENTAL|Depression - DMPFC target to (for non-responders) LPFC target|Participants with treatment resistant depression will receive a 5-day course of rTMS delivered to the DMPFC. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (LPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant.
62052890|NCT00589355||1|postmenopausal women with glucose intolerance (either pre-diabetes or diet-controlled diabetes)
62253933|NCT04982757|ACTIVE_COMPARATOR|Depression - LPFC target to (for non-responders) DMPFC target|Participants with treatment resistant depression will receive a 5-day course of rTMS delivered to the LPFC. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (DMPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant.
62442850|NCT02414880|ACTIVE_COMPARATOR|Neostigmine / Normal liver|"Patients with American Society of Anesthesiologists physical status (ASA) class I with normal preoperative liver functions undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg."
62442851|NCT02414880|ACTIVE_COMPARATOR|Sugammadex / Liver cirrhosis|"Patients with liver cirrhosis, Child classification A with a Model for End-Stage Liver Disease (MELD) score \<10 undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg."
62052891|NCT00589355||2|postmenopausal women with normal glucose tolerance
62052892|NCT01746095|EXPERIMENTAL|Vancomycin hydrochloride inhalation powder|32 or 64 mg twice daily (BID)
62052893|NCT01746095|PLACEBO_COMPARATOR|Placebo inhalation powder|Matching placebo inhalation powder BID
62052894|NCT03042455|EXPERIMENTAL|Robot and rTMS|Robot-Assisted upper arm training and Repetitive Transcranial Magnetic Stimulation group(intervention group 1)
62052895|NCT03042455|EXPERIMENTAL|Robot|Robot-Assisted upper arm training group(intervention group2)
62052896|NCT03042455|ACTIVE_COMPARATOR|Conventional|Conventional training group(control group)
62052897|NCT00986076|EXPERIMENTAL|Enoxaparin infusion|"Congenital Cataract Surgery with IOL implantation~Intraocular infusion of Enoxaparin"
62052898|NCT00986076|PLACEBO_COMPARATOR|Balanced Salt Solution Infusion|Congenital Cataract Surgery with IOL implantation Intraocular infusion of Balanced Salt Solution
62442852|NCT02414880|ACTIVE_COMPARATOR|Neostigmine / Liver cirrhosis|"Patients with liver cirrhosis, Child classification A with a Model for End-Stage Liver Disease (MELD) score \<10 undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg."
62442853|NCT05702281|OTHER|ReLARC 3|"ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.~ReLARC® 3 is inserted through a hysteroscope (KARL STORZ HOPKINS® Wide Angle Straight Forward Telescope 6°, art. no. 26208AMA in combination with the irrigation pump Endomat® select)."
62612097|NCT01944826||Tako-Tsubo And Cancer Registry|
62612098|NCT01926197|ACTIVE_COMPARATOR|Modified FOLFIRINOX|Modified FOLFIRINOX (mFFX), a chemotherapeutic treatment regimen of 5FU, leucovorin, irinotecan, and oxaliplatin.
62612099|NCT01926197|EXPERIMENTAL|Modified FOLFIRINOX plus Stereotactic Body Radiotherapy|Modified FOLFIRINOX (mFFX), a chemotherapeutic treatment regimen of 5FU, leucovorin, irinotecan, and oxaliplatin, in combination with stereotactic body radiotherapy (SBRT)
62612100|NCT03197740|ACTIVE_COMPARATOR|aricept Tab 5mg|
62612101|NCT03197740|EXPERIMENTAL|donepezil patch 25cm2|
62052899|NCT03662932|EXPERIMENTAL|Early intensive mobilization|Progressed mobilization from postoperative day 0.
62612102|NCT03197740|ACTIVE_COMPARATOR|aricept Tab 10mg|
62612103|NCT03197740|EXPERIMENTAL|donepezil patch 50cm2|
62612104|NCT02685072|EXPERIMENTAL|TNP + Progesterone|Transdermal Nicotine Patch + Progesterone (200 mgs BID)
62052900|NCT04209816||ApoC-III LOF|Carriers of apo-CIII loss-of-function mutation
62052901|NCT04209816||ApoC-III GOF|Carriers of apo-CIII gain-of-function mutation
62052902|NCT04209816||TM6SF2-KK|Carriers of TM6SF2 E167K mutation
62052903|NCT04209816||PNLPLA3-MM|Carriers of PNLPLA3 I148M mutation
62052904|NCT04209816||Control|No ApoC-III, TM6SF2 E167K or PNLPLA3 I148M mutation
62052905|NCT04209816||ApoE variants|Carriers of E2/2, E3/3 or E4/4 mutation
62052906|NCT04209816||LIPG|LIPG gene LOF or GOF variant carriers
62052907|NCT04209816||ANGPTL3 or ANGPTL8|ANGPTL3 and ANGPTL8 gene LOF or GOF variant carriers
62612105|NCT02685072|PLACEBO_COMPARATOR|TNP + Placebo|Transdermal Nicotine Patch + Placebo (for Progesterone)
62612106|NCT02957604||Specific Evolocumab-Exposed Cohort|Women diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH), who were exposed to Evolocumab (Repatha) during pregnancy
62612107|NCT02957604||Comparison Group I|Women diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH) who were not exposed to Evolocumab during pregnancy
62612108|NCT02957604||Comparison Group II|A general comparison group of pregnant women who have not been diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH), and who were not exposed to Evolocumab during pregnancy.
62253934|NCT04982757|EXPERIMENTAL|OCD - DMPFC target to (for non-responders) LPFC target|Participants with OCD will receive a 5-day course of rTMS delivered to the DMPFC.Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (LPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant.
62253935|NCT04982757|ACTIVE_COMPARATOR|OCD - LPFC target to (for non-responders) DMPFC target|Participants with OCD will receive a 5-day course of rTMS delivered to the LPFC. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (DMPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant.
62253936|NCT03668600|EXPERIMENTAL|Rapastinel|Rapastinel 450 mg (prefilled syringe, weekly or biweekly or up to 4 weeks at the investigator's discretion intravenous IV administration)
62253937|NCT04514120|EXPERIMENTAL|Stable CRS|Patients diagnosed with Chronic Rhinosinusitis including those with or without nasal polyposis and/or with Allergic Fungal Rhinosinusitis and stable condition
62253938|NCT04514120|EXPERIMENTAL|Non-stable CRS|Patients diagnosed with Chronic Rhinosinusitis including those with or without nasal polyposis and with Allergic Fungal Rhinosinusitis who are experiencing an exacerbation
62253939|NCT06443164|EXPERIMENTAL|Pain Management Class|Pain Management Class Prior to Gender Affirming Surgery
62253940|NCT06443164|ACTIVE_COMPARATOR|SOC - No Class|SOC for Gender Affirming Surgery
62253941|NCT03314740|ACTIVE_COMPARATOR|Arm A|Intravenous administration of weekly Paclitaxel (dosage: 80 mg/mq) for a maximum of 6 cycles. Cycle is defined as 4 weeks.
62442854|NCT05702281|OTHER|ReLARC 10|"ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.~ReLARC® 10 is inserted through a hysteroscope (KARL STORZ HOPKINS® Wide Angle Straight Forward Telescope 6°, art. no. 26208AMA in combination with the irrigation pump Endomat® select)."
62442855|NCT05071547|EXPERIMENTAL|Internet-delivered acceptance and commitment therapy addition|The IACT addition supplies participants with weekly educational material and additional exercises in line with live IRPR, although enriched with multimedia. Participants will have access to their rehabilitation content via the web-site and can practice in their homes in-between live sessions of IRPR.
62253942|NCT03314740|EXPERIMENTAL|Arm B|"Oral administration of two experimental drugs:~* Cediranib 20 mg/day given 7 days per week~* Olaparib 600 mg / day (i.e. 300 mg twice a day) 7 days per week until progression, unacceptable toxicity, patient or physician decision to discontinue or death."
62442856|NCT05071547|ACTIVE_COMPARATOR|Interdisciplinary pain rehabilitation program|A 6-week long multimodal treatment including approximately 108 hours on site, focusing on return to work. Psychologists, physicians, physiotherapists (PT) and occupational therapists (OT) give synchronized treatments with a CBT/ACT approach.
62442857|NCT06432621|EXPERIMENTAL|Group S|patients who will receive sugammadex for recovery from rocuronium and its effect will be assessed by ultrasound and nerve stimulation.
62442858|NCT06432621|EXPERIMENTAL|Group N|patients who will receive neostigmine for recovery from rocuronium and its effect will be assessed by ultrasound and nerve stimulation.
62612109|NCT02957604||General Evolocumab-Exposed Case Series|Women who were exposed to Evolocumab (Repatha) but do not fulfill eligibility criteria for the Specific Evolocumab-Exposed Cohort
62612110|NCT04256213|EXPERIMENTAL|Nivolumab + Ipilimumab|
62612111|NCT06182384|EXPERIMENTAL|Sequence A|
62612112|NCT06182384|EXPERIMENTAL|Sequence B|
62612113|NCT01761305|EXPERIMENTAL|Brace|Hypercorrective night-time brace worn 8 hours per night. A prescription of general physical activity will be provided at a dose of 60 minutes per day. Instructions regarding physical activity will be delivered during a one hour session.
62612114|NCT01761305|EXPERIMENTAL|Scoliosis specific exercises.|Scoliosis specific exercises. The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. An additional session will be provided every 6 months for the entirety of the study. A prescription of general physical activity will be provided at a dose of 60 minutes per day.
62612115|NCT01761305|ACTIVE_COMPARATOR|Self-mediated physical activity.|A prescription of general physical activity will be provided at a dose of 60 minutes per day. Instructions will be delivered during a 1 hour session.
62612116|NCT00669019|EXPERIMENTAL|Saracatinib|Patients receive saracatinib 175 mg oral once daily in the absence of disease progression or unacceptable toxicity.
62612117|NCT06730737|EXPERIMENTAL|Video intervention group|"The intervention is an interactive preventive education video lasting approximately 10 minutes. The video is interactive because it asks the patients to answer simple questions about the content in the video to keep them engaged. For instance, if the participant indicates that they do not smoke, the video will skip the smoking cessation education and move directly to the other prevention domains."
62612118|NCT06730737|NO_INTERVENTION|Control|This arm consists of those randomized to receive no video
62835875|NCT06373952|EXPERIMENTAL|CINTAI|Participants randomized to the Jom-TestPlus group will have access to all Jom-TestPlus features, including: assessment center; online registration; risk calculator; HIVST kit order, management, and monitoring; automated reminders; real-time e-counseling (eHIVST, active referral services); chemsex-related harm reduction services (screening, chemsex e-counseling, PartyPack ordering), chat function (ability to chat with counselors and research staff); and knowledge center (multimedia library on information and resources on HIV testing, PrEP, treatment, risks, and chemsex). Participants will follow a defined pathway to accessing HIVST kit ordering, e-counseling, and subsequent O2O linkage to clinical services.
62835876|NCT06373952|ACTIVE_COMPARATOR|Control|being deactivated. The TAU group will have access to the assessment center (risk assessment, follow-up surveys), knowledge center (multimedia library on information and resources on HIV testing, PrEP, treatment, risks, and chemsex), and a voucher for no-cost community-based HIV testing (sent via secure, encrypted email or can be downloaded on the Jom-TestPlus).
62052908|NCT01007656|EXPERIMENTAL|GD Antrodia camphorata|"GD Antrodia Camphorata is the extract from mycelium of the fungus Antrodia Camphorata which is an endemic species in Taiwan. According to the literatures, mycelium of Antrodia camphorata is beneficial to health. Moreover, the study product GD Antrodia Camphorata has been approved by Department of Health, Taiwan as a health supplement (approval number A00124)."
62612119|NCT04849533|EXPERIMENTAL|Group D Bela/EVR|rATG induction/belatacept/everolimus/early steroid withdrawal rATG 1.5mg/kg IV X 4 doses over 10 days belatacept 10mg/kg IV X 1 on POD 1, POD 5, weeks 2, 4, 8, and 12 then 5mg/kg IV X 1 on week 16 and then every 4 weeks thereafter Steroid taper x 5 days (500mg IV, 250mg IV, 125mg IV, 80mg po, 60mg po) Everolimus started within 24hours at 2mg BID and dosed to level 3-8ng/ml
62052909|NCT00541918|ACTIVE_COMPARATOR|1|propofol
62052910|NCT00541918|EXPERIMENTAL|2|sevoflurane
62052911|NCT03107078|EXPERIMENTAL|Group Ia|"I:The increase of fat volume dominates .~a:The weekly protocol was as follows: 0.5 g glucocorticoids weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks."
62052912|NCT03107078|EXPERIMENTAL|Group Ib|"I:The increase of fat volume dominates. b:The qod protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months."
62253943|NCT03314740|EXPERIMENTAL|Arm C|"Oral administration of two experimental drugs:~* Cediranib 20 mg/day given 5 days per week~* Olaparib 600 mg / day (i.e. 300 mg twice a day) 7 days per week until progression, unacceptable toxicity, patient or physician decision to discontinue or death."
62253944|NCT03721510|ACTIVE_COMPARATOR|Group 1A|HIV-uninfected volunteers receiving one IV infusion
62253945|NCT03721510|ACTIVE_COMPARATOR|Group 1B|HIV-uninfected volunteers receiving one IV infusion
62442859|NCT04919083||Non-exposed cohort (protective factor)|Group of patients operated on during the year 2021 in San Juan de Dios Hospital for hip fracture and to which the new programme implementing functional recovery and therapeutic exercise will be applied with follow-up for one year. The implementation of a functional recovery plan and subsequent follow-up is considered a protective factor in relation to the loss of functionality.
62052913|NCT03107078|EXPERIMENTAL|Group IIa|"II:The increase of extraocular muscles volume dominates .~a:The weekly protocol was as follows: 0.5 g glucocorticoids weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks."
62052914|NCT03107078|EXPERIMENTAL|Group IIb|"II:The increase of extraocular muscles volume dominates . b:The qod protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months."
62253946|NCT03721510|ACTIVE_COMPARATOR|Group 2|HIV-infected volunteers on ART receiving three or six IV infusions
62253947|NCT03653130|EXPERIMENTAL|Intervention Program|Participants will receive an instrument (violin, viola, or cello). Intervention sessions will take place twice a week at the Domiciliary and once per week at the Domiciliary or at a community location (Richard L. Roudebush VA Medical Center or Regenstrief Institute). Each session will include: thirty minutes of group music instruction by an experienced music educator with skills in adult music education followed by thirty minutes of weekly adult ensemble experience.
62612120|NCT04849533|ACTIVE_COMPARATOR|Group E Bela/MMF|rATG induction/belatacept/mycophenolate/chronic steroidsrATG 1.5mg/kg IV X 4 doses over 10 days belatacept 10mg/kg IV X 1 on POD 1, POD 5, weeks 2, 4, 8, and 12 then 5mg/kg IV X 1 on week 16 and then every 4 weeks thereafter Steroid taper x 5 days (500mg IV, 250mg IV, 125mg IV, 80mg po, 60mg po) and then 5mg po daily thereafter MMF 1gm BID started pre-op and then continued throughout study
62612121|NCT00659776|ACTIVE_COMPARATOR|Inflammatory lesions|Subjects with dural, central nervous system (CNS) parenchymal based inflammatory, vascular or demyelinating lesions.
62052915|NCT03178786|EXPERIMENTAL|Parkinson's Disease|
62442860|NCT04919083||Exposed cohort (retrospective)|Complete cohort of patients operated on during the year 2020 in San Juan de Dios Hospital for hip fracture and to whom no specific functional recovery plan was applied.
62835877|NCT03559374||Pregnant women|Consenting women will provide samples to be tested with Vanadis NIPT system.
62835878|NCT05644158|ACTIVE_COMPARATOR|Exercise group|Patients with intermittent claudication will receive conservative treatment with monitored exercise training for a total of 12 weeks (home-based training, minimum of three times a week, documented by using a diary with documentation of the type, the intensity and the duration of the training as well as by using a physical activity monitoring system (Move 4, Karlsruhe, Germany).
62052916|NCT03178786|SHAM_COMPARATOR|Healthy Control Subjects|
62052917|NCT04384263|EXPERIMENTAL|Tai Chi group|"During the 12-week online Tai Chi intervention, participants in the Tai Chi group will attend live online Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 45 minutes/session for 12 weeks. The participants will also practice Tai Chi offline between sessions using instructional videos that will be shared with them at the end of each live online Tai Chi session.~Participants in the Tai Chi group will be instructed: 1) to maintain their regular level of physical activity outside of the live online Tai Chi exercise sessions and offline Tai Chi exercise, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed."
62052918|NCT04384263|NO_INTERVENTION|control|"Participants in the control group will perform only their regular habitual daily activities throughout the 12 weeks of intervention period.~Participants in the control group will be instructed: 1) to maintain their regular level of physical activity and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed."
62052919|NCT05797831|EXPERIMENTAL|Part 1 Arm 1|Navtemadlin administered orally at 180 mg, once daily (QD) on Days 1-7 in a 28-day treatment cycles.
62052920|NCT05797831|EXPERIMENTAL|Part 1 Arm 2|Navtemadlin administered orally at 240 mg, once daily (QD) on Days 1-7 in a 28-day treatment cycles.
62052921|NCT05797831|NO_INTERVENTION|Part 1 Arm 3|"Observational control (watch and wait) on a 28-day cycle."
62052922|NCT05797831|EXPERIMENTAL|Part 2 Arm A|Navtemadlin administered orally at 180 mg once daily (QD) on Days 1-7 in a 28-day treatment cycles.
62253948|NCT03653130|NO_INTERVENTION|Usual Care Control|Usual care at VA Domiciliary including participation in Domiciliary recreational therapy electives (if eligible).
62253949|NCT03653130|NO_INTERVENTION|Retrospective Chart Review|Retrospective chart reviews case-matched to intervention participants for age and biological sex factors.
62442861|NCT05924711||Case group|The case group will consist of 20 patients who will have implants diagnosed with peri-implantitis, according to the 2017 World Workshop Classification case definition.
62442862|NCT05924711||Control group|The control group will include 20 subjects who will have implants with peri-implant health according to the 2017 World Workshop Classification case definition.
62442863|NCT06163833|PLACEBO_COMPARATOR|1-control (placebo)|Administration: once (bolus), intravenous, 36mL
62052923|NCT05797831|EXPERIMENTAL|Part 2 Arm B|Navtemadlin administered orally at 240 mg once daily (QD) on Days 1-7 in a 28-day treatment cycles.
62052924|NCT05797831|PLACEBO_COMPARATOR|Part 2 Arm C|Placebo administered orally at 180 mg once daily (QD) on Days 1-7 in a 28-day administration cycle.
62052925|NCT05797831|PLACEBO_COMPARATOR|Part 2 Arm D|Placebo administered orally at 240 mg once daily (QD) on Days 1-7 in a 28-day administration cycle.
62052926|NCT00003006||Group 1|At the time of thoracotomy and pulmonary resection, patients have samples of bone marrow, primary tumor, and intrathoracic lymph nodes harvested. The presence of occult metastases in bone marrow and lymph nodes is assessed using immunohistochemistry or reverse transcriptase-polymerase chain reaction.
62052927|NCT05639179|EXPERIMENTAL|Assigned Interventions|Subjects who meet the enrollment conditions will receive intravenous infusion of UCAR-T Cells after lymphodepletion.
62052928|NCT04113954|EXPERIMENTAL|Leg 1 ACB + low dose SNB-PF|Right leg and 0.375% mepivacaine popliteal fossa-sciatic
62052929|NCT04113954|EXPERIMENTAL|Leg 1 ACB + high dose SNB-PF|Right leg and 1.5% mepivacaine popliteal fossa-sciatic
62253950|NCT06490796|EXPERIMENTAL|Expanded diaphragm exercise arm|participants will use Ohmbelt device during 360-degree expansive diaphragm exercise session.
62253951|NCT06490796|ACTIVE_COMPARATOR|Standard diaphragm exercise arm|participants will attend standard breathing exercise sessions.
62253952|NCT03967366||plasma melatonin 1|Quartile 1 of plasma melatonin
62442864|NCT06163833|EXPERIMENTAL|2-MSCs 80*10^6|Administration: once (bolus), intravenous, 36mL
62442865|NCT06163833|EXPERIMENTAL|3-MSCs 160*10^6|Administration: once (bolus), intravenous, 36mL
62442866|NCT04841278|EXPERIMENTAL|EUS/ERCP|Patients with liver graft dysfunction enrolled sequentially for proposed protocol: EUS with possible interventions and possible ERCP
62835879|NCT05644158|ACTIVE_COMPARATOR|Revascularization group|will receive revascularization of the underlying atherosclerosis lesion of the superficial femoral artery. Depending on the exact morphology of the lesion, patients with short superficial femoral artery lesions (\<25 cm) will be subdivided into group 2A with endovascular treatment and patients with long superficial femoral artery lesions (\>25 cm) will be subdivided into group 2B with open surgical treatment
62835880|NCT05644158|NO_INTERVENTION|Healthy control group|Patients undergoing surgery for symptomatic varicose veins with excluded PAD will serve as a control group.
62835881|NCT02399176|EXPERIMENTAL|Yoga of minimal intensity|Does Yoga: At least 4 times/week.
62442867|NCT02008721|ACTIVE_COMPARATOR|EGCG as putative neuroprotective agent|Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
62835882|NCT00694941|EXPERIMENTAL|E|ONO-2506PO in the presence of Riluzole
62835883|NCT06080841|EXPERIMENTAL|Group 1|1g of curcumin.
62835884|NCT06080841|EXPERIMENTAL|Group 2|1 g curcumin + 5 mg piperine.
62835885|NCT06080841|EXPERIMENTAL|Group 3|3 g of curcumin.
62835886|NCT06080841|EXPERIMENTAL|Group 4|3 g curcumin + 15 mg piperine.
62835887|NCT06080841|EXPERIMENTAL|Group 5|6 g of curcumin.
62835888|NCT06080841|EXPERIMENTAL|Group 6|6 g curcumin + 15 mg piperine.
62835889|NCT04195841|EXPERIMENTAL|Test group|Two horizontal incisions placed 1-2 mm away from the papilla of the teeth adjacent to the edentulous space following the mesial and distal contour of the teeth. These two horizontal incisions are then connected by an oblique incision from the disto-buccal to mesio lingual point angles.
62835890|NCT04195841|EXPERIMENTAL|Control group|Sulcular incisions placed in the proximal sides of the adjacent tooth facing the edentulous space in a bucco lingual direction extending between the proximal line angles Mid crestal incision performed in the attached mucosa of the edentulous area connecting the sulcular incisions of the adjacent teeth from the distal to mesial tooth
62835891|NCT03286517|EXPERIMENTAL|Tanner Stage I|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 9.5 µg/BW.
62052930|NCT04113954|EXPERIMENTAL|Leg 2 ACB + low dose SNB-PF|Left leg and 0.375% mepivacaine popliteal fossa-sciatic
62052931|NCT04113954|EXPERIMENTAL|Leg 2 ACB + high dose SNB-PF|Left leg and 1.5% mepivacaine popliteal fossa-sciatic
62442868|NCT02008721|PLACEBO_COMPARATOR|Placebo|Placebo
62835892|NCT03286517|EXPERIMENTAL|Tanner Stage II|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 11.50 µg/BW.
62835893|NCT03286517|EXPERIMENTAL|Tanner Stage III|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 12.67 µg/BW.
62835894|NCT03286517|EXPERIMENTAL|Tanner Stage IV|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 15.11 µg/BW.
62835895|NCT03286517|EXPERIMENTAL|Tanner stage V|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 20.5 µg/BW.
62835896|NCT03286517|EXPERIMENTAL|Adult Group|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 1 µg/kg.
62835897|NCT05952882|EXPERIMENTAL|LIME 3mg/1500mg|Metformin XR (extended-release) was initiated with a dose of 750 mg once per day for 2 week and increased to 1500 mg once per day for up to 12 weeks. Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), then titrated in increments of 0.6 mg once daily every 1 to 3 weeks to a final dose of 3.0 mg liraglutide SC daily for up to 12 weeks.
62835898|NCT05952882|ACTIVE_COMPARATOR|MET 1500mg|Metformin XR (extended-release) was initiated with a dose of 750 mg once per day for 2 week and increased to 1500 mg once per day for up to 12 weeks
62835899|NCT04502082|EXPERIMENTAL|ET140203 TCells|ET140203 T Cells
62835900|NCT04786717|EXPERIMENTAL|core muscle training|Training the endurance of the core muscle.
62835901|NCT04786717|EXPERIMENTAL|movement control training|Based from the initial test, the subjects will receive lumbar movement control exercise. They will perform each lumbar movement control exercise in different position.
62835902|NCT04786717|EXPERIMENTAL|combined imagery and movement control training|The intervention of this group is mostly same as the movement control training group. The different part is that the first 3 times of the movement will be practiced through image training, and the subjects will practice the real movement in the rest of 7 times.
62835903|NCT04148365||Paediatric Uveitis|Patients with Uveitis below the age of 18 years.
62052932|NCT04113954|EXPERIMENTAL|Leg 1 ACB only|Right leg and 1.5% mepivacaine ACB
62442869|NCT06544876|ACTIVE_COMPARATOR|healthy younger adult|
62835904|NCT00275509|EXPERIMENTAL|Thymoglobulin|Thymoglobulin was administered as 1.5 mg/kg prior to reperfusion followed by 6 post-operative doses on days 1 through 6.
62052933|NCT04113954|EXPERIMENTAL|Leg 2 ACB only|Left leg and 1.5% mepivacaine ACB
62253953|NCT03967366||plasma melatonin 2|Quartile 2 of plasma melatonin
62253954|NCT03967366||plasma melatonin 3|Quartile 3 of plasma melatonin
62253955|NCT03967366||plasma melatonin 4|Quartile 4 of plasma melatonin
62442870|NCT06544876|ACTIVE_COMPARATOR|Healthy older adult|
62442871|NCT06544876|EXPERIMENTAL|older adult with diabetic peripheral neuropathy|
62835905|NCT00275509|EXPERIMENTAL|Daclizumab|Daclizumab was administered as 2 mg/kg prior to reperfusion followed by 1 mg/kg every other week for 8 weeks post-operatively (4 post-operative doses).
62835906|NCT03382353|ACTIVE_COMPARATOR|No Treatment (NT)|Educational training
62835907|NCT03382353|EXPERIMENTAL|Partial Treatment (PT)|Nutritional supplementation \& Counselling on a brain-healthy diet
62835908|NCT03382353|EXPERIMENTAL|Full Treatment (FT)|Nutritional supplementation \& Counselling on a brain-healthy diet \& Physical exercise training \& Computerized cognitive training
62835909|NCT06601764|EXPERIMENTAL|Group A: Circuit training|Circuits Training Exercise Group
62052934|NCT04082884|EXPERIMENTAL|Very Low Carbohydrate Diet|Participants will follow a high protein very low carbohydrate diet (VLCD) for 2 weeks. This will be 11% of caloric intake from carbohydrates, 54% of calories from protein, and 35% of calories from fat. Immediately following this, participants will follow a high protein very low carbohydrate diet (VLCD) which will be 11% of caloric intake from carbohydrates, 23% of calories from protein, and 66% of calories from fat.
62052935|NCT02623855|ACTIVE_COMPARATOR|Park prescription|Park prescription, pedometry.
62253956|NCT02230254|EXPERIMENTAL|PROMUS POREMIER stent|Single-arm treatment group receiving interventional PROMUS PRIMIER study stent
62835910|NCT06601764|ACTIVE_COMPARATOR|Group B: Progressive Resistance Exercise Group|Progressive Resistance Exercise Group
62835911|NCT02978976|EXPERIMENTAL|betamethasone|will receive two doses of 12mg betamethasone, then the pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug (betamethasone), 24 hours after the last dose, and on the day of elective Cs.
62835912|NCT02978976|PLACEBO_COMPARATOR|Saline|will receive saline injection placebo, then the pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug ( placebo), 24 hours after the last dose, and on the day of elective Cs.
62835913|NCT01120964|EXPERIMENTAL|Intravenous L-Citrulline|IV bolus of 150 mg/kg L-citrulline at the initiation of bypass, followed by L-citrulline (200 μmol/L) addition to the filtration or hemoconcentration replacement fluid used during bypass. Plus L-citrulline (20 mg/kg) bolus 30 minutes after decannulation from bypass, immediately followed by 9 mg/kg/h continuous L-citrulline infusion for 48 hours.
62835914|NCT01120964|PLACEBO_COMPARATOR|Placebo of Intravenous L-Citrulline|Placebo administered according to the same schedule as L-citrulline
62835915|NCT01926457|EXPERIMENTAL|First Trimester Treatment of Prediabetes|"Patients randomized to first trimester treatment will receive the following intervention immediately initiated upon diagnosis of prediabetes at \<15 weeks 0 days gestation~* diabetes education~* blood glucose monitoring~* medications as needed per California Diabetes and Pregnancy established protocol~* growth ultrasounds~* antenatal testing"
62835916|NCT01926457|ACTIVE_COMPARATOR|Third Trimester Treatment of Prediabetes|"Patients randomized to third trimester treatment will receive the following intervention to be initiated at 28 weeks of gestation~* diabetes education~* blood glucose monitoring~* medications as needed per California Diabetes and Pregnancy established protocol~* growth ultrasounds~* antenatal testing"
62835917|NCT00473564|EXPERIMENTAL|TORS Candidates|Participants who consented to undergo transoral robotic-assisted surgery using the da Vinci® Robotic System
62835918|NCT00489593|EXPERIMENTAL|Olanzapine|Olanzapine 2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
62835919|NCT06591403|EXPERIMENTAL|the different body positions and fingers|
62835920|NCT00544297|EXPERIMENTAL|PEP005 gel administration|0.05% PEP005 Topical Gel administered for two consecutive days to a 25cm2 contiguous AK treatment area on the top of the hand
62835921|NCT05136014||General cohorte|patient with non-small cell lung cancer undergoing surgical resection in the thoracic surgery department of the Nancy CHRU
62052936|NCT02623855|EXPERIMENTAL|Park prescription and family outings|Park prescription, pedometry, case management and 3 weekly family outings.
62052937|NCT04343586|EXPERIMENTAL|Adult treatment arm|Adults enrolled in the study will receive treatment (blue light phototherapy) on one area of their body affected by psoriasis or Grover's disease. The treatment area (restricted by size of the device) will be compared to untreated areas affected by disease on the same patient.
62253957|NCT05903729|EXPERIMENTAL|neurodevelopmental therapy group|in this group patients wil be treated with task oriented activities using neurodevelopmental therapy principles. This group will receive therapy session for 1 hour 6 days a week and for 8 weeks. total sessions will be 48. this group will receive task oriented neurodevelopmental therapy for 30 mins and next 30 mins it will receive conventional treatment.
62835922|NCT04663282|EXPERIMENTAL|INS068|Intervention: Drug: INS068 injection
62835923|NCT04663282|ACTIVE_COMPARATOR|IDeg|Intervention: Drug: insulin Degludec
62835924|NCT04089995||Coats + and LCC syndrome|
62835925|NCT00646880|ACTIVE_COMPARATOR|Propiverine/tolterodine group|
62052938|NCT00845884|EXPERIMENTAL|AVDCF|Drug: Docetaxel, Cisplatin, Capecitabine, Bevacizumab
62052939|NCT01291784|EXPERIMENTAL|monoclonal antibody to TGF-beta|starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
62052940|NCT00827541||1|Patients hospitalized because of cIAI or cSSTI
62253958|NCT05903729|EXPERIMENTAL|conventional physiotherapy group|in this group patients will be treated with conventional physiotherpy treatment protocol. this group will receive therapy session for one hour, 6 times in a week for 8 weeks. total therapy sessions will be 48. this group will receive 30 mins conventional physiotherapy treatment and 30 mins task oriented neurodevelopmental therapy.
62253959|NCT02899689|ACTIVE_COMPARATOR|Foley Bulb Group|Patients will have a Foley catheter inserted into the internal cervical os.
62253960|NCT02899689|EXPERIMENTAL|Dilapan Group|Patients will have Dilapan sticks inserted into the internal cervical os.
62253961|NCT04316377|ACTIVE_COMPARATOR|Treatment|Chloroquine therapy in addition to standard of care
62835926|NCT00646880|ACTIVE_COMPARATOR|Tolerodine/propiverine group|
62835927|NCT05342714|EXPERIMENTAL|RIC group|Participants in the experimental group receive both RIC and standard clinical therapy. The RIC treatment is composed of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 180 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion (Patent No.CN200820123637.X, China).
62835928|NCT05342714|NO_INTERVENTION|Control group|Participants in the control group receive standard clinical therapy.
62835929|NCT06238258|EXPERIMENTAL|Training Arm|
62835930|NCT00043979|EXPERIMENTAL|Arm 1- Sibling Donors|Donors (n = 30) were matched first degree relatives who were eligible to donate peripheral blood stem cells.
62253962|NCT04316377|NO_INTERVENTION|No Treatment|Standard of care
62835931|NCT00043979|EXPERIMENTAL|Arm 2 - Recipients|Recipients (n=30) were enrolled to receive peripheral blood stem cells (PBSC) and receive either cyclosporine or tacrolimus and sirolimus for graft versus host disease (GVHD) prophylaxis.
62253963|NCT04096027|EXPERIMENTAL|Early administration|Cabergoline administered the day before egg collection.
62253964|NCT04096027|EXPERIMENTAL|Late administration|Cabergoline administered after egg collection.
62253965|NCT04750876|ACTIVE_COMPARATOR|Conventional support|
62442872|NCT05118321|OTHER|Refinement and Feasibility Trial|"It is intra - individual comparison study~Arm 1: participant wore the custom-made upper limb exosuit and hand exoskeleton to perform the series of tasks Arm 0: participant perform the same tasks without the custom-made upper limb exosuit and hand exoskeleton."
62612122|NCT00659776|ACTIVE_COMPARATOR|Vascular lesions|subjects will include those with vascular CNS lesions such as ischemic stroke, transient ischemic attack (TIA) with suspected carotid embolic origin, or vasculopathy involving the carotids, (including diagnosed carotid stenosis \>50%) the aorta, or the arteries of the extremities, or diagnosed thrombosis of the intraabdominal, pelvic or extremity veins.
62612123|NCT00659776|ACTIVE_COMPARATOR|Lymph nodes|Subjects with enlarged cervical lymph nodes in which inflammatory processes (reactive lymph nodes) is part of the differentials.
62612124|NCT04104594|EXPERIMENTAL|patients with chronic rhinosinusitis with nasal polyps|
62835932|NCT06214065|EXPERIMENTAL|ASD: excitatory, then inhibitory, then sham rTMS|Participants in this group will undergo fMRI pre- and post- rTMS. Each will receive an excitatory, inhibitory and sham rTMS to the right temporoparietal junction (TPJ) on mentalizing task-related (MTR) activity over 4 study visits.
62835933|NCT06214065|EXPERIMENTAL|Typically Developing (TD): excitatory, then inhibitory, then sham rTMS|Participants in this group will undergo fMRI pre- and post- rTMS. Each will receive an excitatory, inhibitory and sham rTMS to the right temporoparietal junction (TPJ) on mentalizing task-related (MTR) activity over 4 study visits.
62835934|NCT01955421|EXPERIMENTAL|Erlotinib100|Patients will be randomized to buy and receive erlotinib 100mg qd.
62835935|NCT01955421|EXPERIMENTAL|Gefitinib250|Patients will be randomized to buy and receive gefitinib 250mg qd.
62052941|NCT06107595|EXPERIMENTAL|Efficacy of conditioned open label placebo pill|"On postoperative day 0, participant will self-administer one OLP with all opioid analgesics (whether administered intravenously or orally). This pairing will be done from postoperative day 0 to postoperative day 17.~Starting on postoperative day 2, participants take 3 scheduled placebo doses (pills or inhalation) every day, at 3 convenient times. In parallel, the OLP pairing to standard and rescue doses of opioids will continue.~The patients are told to continue taking both scheduled standalone COLP and paired COLP (if needed) until postoperative day 17."
62253966|NCT04750876|EXPERIMENTAL|Specific care, including the intervention of a psychologist and a physical therapist.|
62253967|NCT02243254|PLACEBO_COMPARATOR|high dose remifentanil without ibuprofen|remifentanil target-controlled infusion effect-site concentration 4 ng/ml normal saline before surgical incision
62253968|NCT02243254|PLACEBO_COMPARATOR|low dose remifentanil without ibuprofen|remifentanil target-controlled infusion effect-site concentration 1 ng/ml normal saline before surgical incision
62253969|NCT02243254|ACTIVE_COMPARATOR|high dose remifentanil with ibuprofen|remifentanil target-controlled infusion effect-site concentration 4 ng/ml Intravenous ibuprofen 800 mg before surgical incision
62253970|NCT02243254|ACTIVE_COMPARATOR|low dose remifentanil with ibuprofen|remifentanil target-controlled infusion effect-site concentration 1 ng/ml Intravenous ibuprofen 800 mg before surgical incision
62253971|NCT05210283||Stage ll or lll|Patients with stage ll or lll colorectal cancer
62253972|NCT01094587|ACTIVE_COMPARATOR|Sutured closure|
62442873|NCT06229600||Group A|"Patients with an established diagnosis according to the DSM-5 classification (DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS - FIFTH EDITION, 2014) and possible drug therapy (24).~* Schizophrenia spectrum disorders and other psychotic disorders~* Bipolar disorder and related disorders~* Depressive disorders~* Anxiety disorders~* Obsessive-compulsive disorder and related disorders~* Disorders related to traumatic and stressful events~* Dissociative disorders~* Somatic symptoms and related disorders~* Nutrition and eating disorders~* Evacuation disorders~* Sleep-wake disorders~* Sexual dysfunctions~* Gender dysphoria~* Disruptive behaviour, impulse control and conduct disorder~* Substance-related and addiction disorders~* Personality disorders~* Paraphilia disorders~* Autism spectrum disorders~* ADHD"
62442874|NCT06229600||Group B|Patients on medication (psychotropic drugs) without a reported/reported specific psychiatric diagnosis in their clinical history.
62612125|NCT04104594|OTHER|Patients with an indication for septoplasty = control group|
62835936|NCT04593537||MDD group|Participants with current major depressive disorder (MDD)
62253973|NCT01094587|ACTIVE_COMPARATOR|Sutureless closure|
62835937|NCT04593537||Control group|Participants without a family and personal history of a mood disorder, schizophrenia or substance/alcohol abuse but other disorders often co-morbid with MDD are allowed such as anxiety disorders
62835938|NCT02036814|EXPERIMENTAL|Group A who underwent to an inter-relational strategy|Group A who underwent to a health educational orientation program (inter-relational strategy)
62835939|NCT02036814|EXPERIMENTAL|Group B who underwent group orientation by the nurse|
62835940|NCT05208099||Patients with Hidradenitis suppurativa|
62835941|NCT05208099||Controls (coming for abdominoplasty)|
62835942|NCT06141525|EXPERIMENTAL|RIC group|In the RIC group, patients will undergo RIC training in the 3 days before and 7 days after the CABG surgery.
62835943|NCT06141525|NO_INTERVENTION|Control group|In the control group, a blood pressure cuff, same as the cuff in the RIC group, will be placed on both upper arms of the patients but only pressurized to 60 mmHg. The rest of the procedures will be the same.
62835944|NCT01034332|EXPERIMENTAL|One-cycle induction chemotherapy|TP-HDFL, TP-CCRT, Esophagectomy
62835945|NCT01749215|EXPERIMENTAL|Topiramate|Topiramate capsules daily - up to 300 mg
62835946|NCT01749215|PLACEBO_COMPARATOR|Placebo|Placebo capsules daily - up to 300 mg
62253974|NCT01628445|ACTIVE_COMPARATOR|liraglutide|liraglutide 1.8 mg injected once daily
62253975|NCT01628445|PLACEBO_COMPARATOR|Placebo injection|
62835947|NCT00110448|ACTIVE_COMPARATOR|1|Aspirin use
62835948|NCT00110448|ACTIVE_COMPARATOR|2|No aspirin use
62835949|NCT06145620|EXPERIMENTAL|Therapeutic exercise, back care and pain neuroscience education group|
62835950|NCT06145620|ACTIVE_COMPARATOR|Standarized written exercise group|
62835951|NCT00658359|ACTIVE_COMPARATOR|Treatment Arm 1|Treatment Arm 1 will also receive standard of care medications
62835952|NCT00658359|EXPERIMENTAL|Treatment Arm 2|Treatment Arm 2 will also receive standard of care medications
62835953|NCT00658359|EXPERIMENTAL|Treatment Arm 3|Treatment Arm 3 will also receive standard of care medications
62052942|NCT06107595|EXPERIMENTAL|Efficacy of conditioned open label placebo odor|"1 drops of clove oil (i.e. eugenol) will be disposed on a cotton and inserted into a stick. The patients will be asked to actively smell them by sniffing using a stick of inhalation. On postoperative day 0, participant will self-administer one OLP with all opioid analgesics (whether administered intravenously or orally). This pairing will be done from postoperative day 0 to postoperative day 17.~On postoperative day 2, participants take 3 scheduled placebo doses (pills or inhalation) every day, at 3 convenient times. In parallel, the OLP pairing to standard and rescue doses of opioids will continue.~The patients are told to continue taking both scheduled standalone COLP and paired COLP (if needed) until postoperative day 17"
62052943|NCT06107595|ACTIVE_COMPARATOR|Standard of care|Usual postoperative pain management, relying mainly on opioids
62612126|NCT04482036|PLACEBO_COMPARATOR|Dementia Collaborative Care|"Patient and caregivers assigned to the three in-person assessments and no mobile application group will complete the following:~* The caregiver will be asked to complete three in-person assessments that involve answering survey questions and an interview.~* Some of the questions asked will be related to Behavioral and/or Psychological Symptoms the patient experiences.~* The caregiver will be asked to answer questions about the patient, the patient's experience with the research study and the caregiver's own experience with the research study.~* If the patient's symptoms or the caregiver's distress answers reach a high enough level, a member of the research study team and clinical team will contact the caregiver to ask more questions and check in on the patient and caregiver's safety.~* The research study team will also notify Dr. Bateman (the person responsible for the research)."
62612127|NCT04482036|ACTIVE_COMPARATOR|Dementia Collaborative Care Plus BrainCare Notes Application|"Patient and caregivers assigned to the three in-person assessments and mobile application group will complete the same tasks that Group 1 (control group) will complete with the addition of the following:~* The caregiver will be asked to monitor the patient and complete 5 to 10-minute long surveys (the neuropsychiatric inventory questionnaire) sent to the caregiver through the mobile application or in-person at each follow-up visit.~* The caregiver will be asked to monitor and complete these surveys at different times for a period of 6 months."
62612128|NCT02174575|ACTIVE_COMPARATOR|Sevoflurane|Patients are randomized into 2 groups (Desflurane group and Sevoflurane group) depending on the anesthetic agents administered during anesthesia.
62612129|NCT02174575|ACTIVE_COMPARATOR|Desflurane|Patients are randomized into 2 groups (Desflurane group and Sevoflurane group) depending on the anesthetic agents administered during anesthesia.
62612130|NCT01126008|EXPERIMENTAL|weekly docetaxel and cisplatin|
62612131|NCT05817500||ICU patients with > 48h mechanical ventilation and/or > 5 days stay in ICU|
62612132|NCT00677859|EXPERIMENTAL|Single dose Arm|There will be six cohorts of three patients each. Three escalating doses of MultiStem will be evaluated.
62612133|NCT00677859|EXPERIMENTAL|Repeat Dose Arm|There will be six cohorts of three patients each. Four dosing regimens will be evaluated,varying doses at three times weekly or five times weekly.
62052944|NCT06443502|EXPERIMENTAL|Vedolizumab|Vedolizumab, high dose in participants with body weight \>=30 kg, medium dose in participants with body weight \>15 to \<30 kg and low dose in participants with body weight 10 to 15 kg, infusion, intravenously at Day 1, Weeks 2 and 6 during induction period and every 8 weeks (Q8W) at Weeks 14, 22 and 30 during maintenance period along with ciprofloxacin, metronidazole, vancomycin, amoxicillin clavulanate or rifaximin concomitant antibiotics, orally from Day 1 to Week 2 during induction period (unless intolerant or contraindicated).
62052945|NCT05947214|EXPERIMENTAL|Myofascial Decompression Therapy|15 minute's moist heat will be given first. Patient was lied prone on couch with their upper torso unclothed, covered with massage oil than placed cup on skin and suction will created in cups by pump.
62253976|NCT01133899|EXPERIMENTAL|GAA-2|2.4 grams of guanidinoacetic acid
62612134|NCT03965455||conventional group|
62612135|NCT03965455||diode laser group|
62835954|NCT02551939|EXPERIMENTAL|fat graft|Autologous Fat Grafting
62835955|NCT02056587|EXPERIMENTAL|Everolimus|All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
62835956|NCT01162642|EXPERIMENTAL|Green Tea|4 cups daily of green tea for 6 weeks
62835957|NCT01162642|PLACEBO_COMPARATOR|No Green Tea|4 cups daily of placebo tea for 6 weeks
62253977|NCT01133899|EXPERIMENTAL|GAA-1|1.2 grams of guanidinoacetic acid
62253978|NCT01133899|EXPERIMENTAL|GAA-4|4.8 grams of guanidinoacetic acid
62253979|NCT01133899|PLACEBO_COMPARATOR|PLACEBO|cellulose
62253980|NCT00738153||A|
62253981|NCT00692484|EXPERIMENTAL|1|Chlorhexidine gluconate 2%
62253982|NCT00692484|ACTIVE_COMPARATOR|2|Povidone iodine scrub and paint
62442875|NCT06229600||Group C|Patients without a history/reported psychiatric disorder and without specific psychopharmacological therapy.
62442876|NCT06229600||Group D|Patients with a history of diagnosed neurocognitive disorder.
62442877|NCT06229600||Group E|"Patients in the practice without a history/report of psychiatric disorders and without specific psychopharmacological treatment on admission who are diagnosed during admission.~This is a subgroup of the C group."
62442878|NCT06229600||Group F|"Patients in the practice without a history/report of psychiatric disorders and without specific psychopharmacological therapy on admission who are diagnosed during admission for suspected psychiatric/neurocognitive pathology and are discharged with indications for further investigation at the territorial services.~This is a subgroup of the C group."
62442879|NCT05466890|EXPERIMENTAL|PL8177|PL8177 will be given orally and daily from baseline until end of study.
62442880|NCT05466890|PLACEBO_COMPARATOR|Placebo|Approximately 1/4 of randomized patients will receive matching placebo as means of comparison to active treatment PL8177.
62442881|NCT05420428|PLACEBO_COMPARATOR|endotracheal intubation|under general anesthesia, patients received tracheal intubation.
62052946|NCT05947214|EXPERIMENTAL|Positional Release technique|Positional Release technique (PRT) is apply after application of moist heat pack for 15 minute. The subjects received PRT will be in supine lying with the therapist sitting on the affected side, tender points were located along with the upper fibers of trapezius muscle. The subject's head was laterally flexed towards the side of tender point, then therapist grasps the subject's forearm and abducts shoulder to approximately 900 and adds slight flexion or extension to fine-tune.
62052947|NCT04386434|EXPERIMENTAL|Active for Life|The Active Life intervention includes structured walking, functional circuit training, stretching and behavior/educational components.
62052948|NCT03427684|EXPERIMENTAL|Hypo-fractionated radiotherapy|Hypo-fractionated neoadjuvant radiotherapy concurrent with S1 chemotherapy for local advanced gastric cancer
62253983|NCT00596947|EXPERIMENTAL|Prednisone Withdrawal|Participants randomized to the prednisone withdrawal group, received 4 medications to prevent rejection. Thymoglobulin (rabbit antithymocyte globulin) was given intravenously in the operating room at the time of transplant. Subsequent intravenous doses were administered to participants an inpatient or outpatient for a total of 3 to 5 doses. Participants also began taking Prograf (tacrolimus) and CellCept (mycophenolate mofetil)orally within 24 hours of transplant and continued indefinitely. The steroids were initially given in the operating room intravenously at time of transplant as Solu-medrol (methylprednisolone)and were then switched to daily oral prednisone doses. The participant's dose of prednisone was rapidly decreased until it was completely eliminated by day 6 post-transplant.
62442882|NCT05420428|EXPERIMENTAL|supraglottic airway device|under general anesthesia, patients received supraglottic airway device
62442883|NCT02960074|EXPERIMENTAL|Non-antibiotics Arm|The first 10 patients will not receive antibiotics prior to receiving the investigational agent, which consists of screened-donor inoculum of a biologically active human substance (FMT). We will give oral frozen FMT over 2 days.
62442884|NCT02960074|EXPERIMENTAL|Antibiotics Arm|An additional 5 patients will receive antibiotics prior to receiving the investigational agent, which consists of screened-donor inoculum of a biologically active human substance (FMT). We will give oral frozen FMT over 2 days.
62612136|NCT02865200|EXPERIMENTAL|Dry Needling Application|Dry needling was performed on active and/or latent TPs at Gluteus Medius, Quadratus Lumborum, Multifidus, Erector Spinae muscles of the subjects in the study groups without applying any local anesthetic substance. The needles were applied with a 90º angle for Multifidus, Quadratus Lumborum and Gluteus Medius muscles; while they were applied with a 45º angle for Erector Spinae muscles. Thin stainless steel needles of 0.25x0.40 mm and 0.30x0.60 mm were applied in infiltration form on the TP through many points in conformity with the injection technique. The needles were kept on the body for 20 minutes and at the 10th minute, the needle was rolled and re-stimulation was enabled. The treatment was applied twice a week, which is equal to 6 sessions in total.
62835958|NCT06398756|ACTIVE_COMPARATOR|conventional rehabilitation|17 cerebral palsy patients will be included in the conventional rehabilitation program.
62835959|NCT06398756|ACTIVE_COMPARATOR|conventional rehabilitation and aquatic therapy|17 cerebral palsy patients will be included in the conventional rehabilitation and aquatic therapy program.
62835960|NCT00664625|EXPERIMENTAL|1|"BMS-791325 (100 mg)~or~placebo match for (100 mg)"
62835961|NCT00664625|EXPERIMENTAL|2|"BMS-791325 (300 mg)~or~placebo match for (300 mg)"
62052949|NCT02753309|ACTIVE_COMPARATOR|Rapamycin 0.5mg|Subject will take Rapamycin (Sirolimus) 0.5mg once daily for approximately 28 days
62052950|NCT02753309|ACTIVE_COMPARATOR|Rapamycin 2.0mg|Subject will take Rapamycin (Sirolimus) 2.0mg once daily for approximately 28 days
62442885|NCT04666766|ACTIVE_COMPARATOR|Traumatic intracranial hemorrhage|Patients with traumatic intracranial hemorrhage diagnosed by Computerized Tomography of the head
62442886|NCT04666766|ACTIVE_COMPARATOR|Trauma without traumatic intracranial hemorrhage|Patients with trauma to the head but traumatic intracranial hemorrhage ruled out by Computerized tomography of the head
62442887|NCT04666766|ACTIVE_COMPARATOR|Healthy age-matched volunteers|Healthy age-matched volunteers with no previous trauma to the head within the past two weeks.
62442888|NCT05718388|OTHER|Control group (A)|They received a physiotherapy program
62442889|NCT05718388|EXPERIMENTAL|study Group (B)|They received the same program given to control group (A) in addition to isokinetic resistance training of the less affected upper limb for shoulder abductors in concentric mode at the angular velocity of 180 degree/ second
62835962|NCT00664625|EXPERIMENTAL|3|"BMS-791325 (900 mg)~or~placebo match for (900 mg)"
62835963|NCT00664625|EXPERIMENTAL|4|"BMS-791325 (potential dose between 10-800 mg)~or~placebo match for (10-800 mg)"
62835964|NCT02392624|EXPERIMENTAL|Omalizumab|Participants will receive open-label omalizumab treatment at 300 mg SC Q4W for 24 weeks. After 24 weeks open-label treatment, eligible participants will be randomized to receive omalizumab treatment at 300 mg SC Q4W for next 24 weeks (up to Week 48). Participants randomized to omalizumab may, at the discretion of the investigator, be transitioned from blinded study drug to open-label omalizumab at 300 mg SC Q4W if they experience clinically significant worsening in their CIU (as judged by the investigator). Participants who are transitioned to open-label omalizumab will continue to receive open-label omalizumab as study drug until Week 48.
62052951|NCT02753309|NO_INTERVENTION|Control|Subject will be apart of the control group and won't take the study drug being tested
62442890|NCT03974633|PLACEBO_COMPARATOR|Control|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, without administering any type of non-invasive analgesic
62442891|NCT03974633|EXPERIMENTAL|Vibration|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, while applicating a vibrating device on the skin below the injection site, before and during injection.
62442892|NCT03974633|EXPERIMENTAL|Cold|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, after applicating a bag of 50mL of frozen physiologic saline covered with a plastic glove on the injection site for 50 seconds
62835965|NCT02392624|PLACEBO_COMPARATOR|Placebo|Participants will receive open-label omalizumab treatment at 300 mg SC Q4W for 24 weeks. After 24 weeks open-label treatment, eligible participants will be randomized to receive placebo SC Q4W for next 24 weeks (up to Week 48). Participants randomized to placebo may, at the discretion of the investigator, be transitioned from blinded study drug to open-label omalizumab at 300 mg SC Q4W if they experience clinically significant worsening in their CIU (as judged by the investigator). Participants who are transitioned to open-label omalizumab will continue to receive open-label omalizumab as study drug until Week 48.
62612137|NCT02865200|EXPERIMENTAL|Classic Physiotherapy Program|"Hot-pack was applied for 20 minutes. Burst TENS was applied on the lumbar regions of the cases of the control group paravertebrally with 4-electrode reusable silicone rubber. The dimensions of electrode is 5x5cm. Pulse width was set for 100 µsn, pulse frequency was set for 2 Hz, cycle time is set for 0.5 seconds and the amplitude was increased until visible muscle contraction was reached. If the muscle contraction is lost during the session, the amplitude was increased again. The period of treatment was 6 sessions in total with 25 minutes of each.~Ultrasound was paravertebrally applied to the lower back regions of the subjects. The treatment was applied with 1 MHz frequency, 1.5 W/cm2 power, for 6 minutes a day, for 10 sessions in total with direct contact with the patient's skin."
62612138|NCT01879033|ACTIVE_COMPARATOR|Obese adolescents|Those with BMI more than or equal to 95th percentile. This group was further divided into two subgroups on the basis of Oral Glucose Tolerance Test (OGTT) into normal and impaired glucose tolerance groups. Reactive hyperemia peripheral artery tonometry (Rh-PAT)score and blood levels for glucose, insulin, lipids and adipocytokines will be measured in the study.
62052952|NCT04558190|EXPERIMENTAL|Lipid infusion + MitoQ|Subjects undergo a hyperinsulinemic isoglycemic clamp preceded by MitoQ administration and intravenous lipid infusion
62052953|NCT04558190|PLACEBO_COMPARATOR|Lipid infusion + placebo|Subjects undergo a hyperinsulinemic isoglycemic clamp preceded by placebo administration and intravenous lipid infusion
62052954|NCT04558190|NO_INTERVENTION|Control|Subjects undergo a hyperinsulinemic isoglycemic clamp
62612139|NCT01879033|PLACEBO_COMPARATOR|Lean adolescents|BMI between 5th-85th percentile.Reactive hyperemia peripheral artery tonometry (Rh-PAT)score and blood levels of glucose, insulin, lipids and adipocytokines will be measured in the study.
62612140|NCT01766232||Obstructed nasolacrimal drainage group|This group of patients is clinically identified as having epiphora due to an obstruction of the lacrimal drainage system.
62612141|NCT01766232||Ectropion group|This group of patients is clinically determined to have functional epiphora due to ectropion and a patent lacrimal drainage system.
62052955|NCT04558190|OTHER|Lipid infusion + beta2-agonist|Subjects undergo a hyperinsulinemic isoglycemic clamp with intravenous infusion of lipid and salbutamol
62052956|NCT01556126|EXPERIMENTAL|Amphilimus eluting stent (Cre8)|Sirolimus formulated coronary eluting stent
62052957|NCT01111123|ACTIVE_COMPARATOR|1|Lac-Hydrin lotion twice daily everyday + Ultravate ointment twice daily on weekends only
62442893|NCT03974633|EXPERIMENTAL|Anesthetic cream|subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, after applicating a uniform thickness of 2mm of the anesthetic cream EMLA covered with an adhesive transparent plastic dressing for 30 minutes
62442894|NCT04467008||One group of patients|
62835966|NCT05275283|NO_INTERVENTION|Control group|Applying tidal volume 7 ml/kg without PEEP
62835967|NCT05275283|EXPERIMENTAL|PEEP group|Applying tidal volume 7 ml/kg with 6 cmH2O of PEEP
62052958|NCT01111123|PLACEBO_COMPARATOR|2|Lac-Hydrin lotion twice daily everyday + placebo ointment twice daily on weekends only
62612142|NCT04956627|EXPERIMENTAL|BMS-986166|
62612143|NCT04956627|EXPERIMENTAL|BMS-986166 + Itraconazole|
62612144|NCT04956627|EXPERIMENTAL|BMS-986166 + Phenytoin|
62835968|NCT04379895|ACTIVE_COMPARATOR|Heated RF ablation|Patients with OA that will undergo heated RF of the genicular nerves
62835969|NCT04379895|ACTIVE_COMPARATOR|Pulsed RF ablation|Patients with OA that will undergo pulsed RF of the genicular nerves
62612145|NCT04956627|EXPERIMENTAL|BMS-986166 + Gemfibrozil|
62612146|NCT01210144|EXPERIMENTAL|Gonal-f® + Ovitrelle® + Long Agonist Protocol|
62612147|NCT01210144|EXPERIMENTAL|Gonal-f® + Ovitrelle® + Multi-dose Antagonist Protocol|
62835970|NCT00757302|EXPERIMENTAL|I|For the first 10 patients, only a pre-operative procedure will be performed.
62052959|NCT04508608||Ischemic cardiomyopathy group - 1 (ICM-1)|"Inclusion criteria:~1. History of myocardial infarction (MI) or revascularization (CABG or PCI);~2. \> 75% stenosis of left main or proximal left anterior descending artery (LAD) and/ or stenosis of \> 75% of ≥2 epicardial vessels (based on coronary angiography (CA) data);~3. LV ejection fraction (EF) \<40% and increase in LV volumes according to echocardiography (ECHO)~Exclusion criteria:~1. Presence of contraindications to the stress test with inotropic stimulation;~2. inflammatory myocardial diseases;~3. the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;~4. life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury)."
62442895|NCT06017414|EXPERIMENTAL|Growth Path Intervention|Participants for this arm are members of the 7 Cups platform (signed up as 'members', but not signed up as 'listeners') who will receive the Systemic Psychotherapy-informed growth path intervention.
62835971|NCT00757302|EXPERIMENTAL|II|The last 100 patients will receive the complete procedure.
62835972|NCT04184089|EXPERIMENTAL|Control group|High flow rate of 5 L/min and FiO2 of 40%
62052960|NCT04508608||Ischemic cardiomyopathy group - 2 (ICM-2)|"Inclusion criteria:~1. History of myocardial infarction (MI) or revascularization (CABG or PCI);~2. \> 75% stenosis of left main or proximal LAD and/ or stenosis of \> 75% of ≥2 epicardial vessels (based on coronary angiography (CA) data);~3. LV EF \<40% and increase in LV volumes according to echocardiography (ECHO)~Exclusion criteria:~1. Presence of contraindications to the stress test with inotropic stimulation;~2. inflammatory myocardial diseases;~3. the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;~4. life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury)."
62052961|NCT04508608||Control group for GBPS.|"Inclusion criteria:~1. Absence of obstructive coronary artery lesion;~2. Absence of history of MI and revascularization.~Exclusion criteria:~1. Presence of contraindications to the stress test with inotropic stimulation;~2. inflammatory myocardial diseases;~3. the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;~4. life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury)."
62052962|NCT04508608||Control group for CFR.|"1. Presence of obstructive coronary artery lesion;~2. Indications for coronary artery bypass grafting~Exclusion criteria:~1. Presence of contraindications to the adenosine stress test;~2. inflammatory myocardial diseases;~3. the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;~4. life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury)."
62253984|NCT00596947|ACTIVE_COMPARATOR|Prednisone Maintenance|Participants randomized to the prednisone maintenance group, received 4 medications to prevent rejection. Thymoglobulin (rabbit antithymocyte globulin) was initiated intravenously in the operating room at the time of transplant. Subsequent intravenous doses were administered an inpatient or outpatient for a total of 3 to 5 doses. Participants began taking Prograf (tacrolimus) and CellCept (mycophenolate mofetil)orally within 24 hours of transplant and continued on them indefinitely. The steroids were initially given intravenously in the operating room at time of transplant as Solu-medrol (methylprednisolone) and were then switched to daily oral prednisone tablets. Participants remained on all drugs according to their doctor's standard of care, and the prednisone was not be eliminated.
62835973|NCT04184089|EXPERIMENTAL|Group 15 liter|Nasal cannula at flow rate of 15 L/min and FiO2 of 40%
62835974|NCT04184089|EXPERIMENTAL|Group 60 liter|Nasal cannula at flow rate of 60 L/min and FiO2 of 40%
62835975|NCT01339143|ACTIVE_COMPARATOR|Pioglitazone|pioglitazone: 15mg, QD, PO, 16 weeks
62835976|NCT01339143|EXPERIMENTAL|vildagliptin|vildagliptin 50mg,BID,PO,16 weeks
62835977|NCT03652805|EXPERIMENTAL|IPL344|IPL344 will be administered Intravenously on a daily basis. The dose range of IPL344 is 1.7-3.2 mg/kg
62835978|NCT04400201|EXPERIMENTAL|Remimazolam Tosilate|
62835979|NCT04400201|ACTIVE_COMPARATOR|Propofol|
62835980|NCT05932823||Laminar Airflow|total hip arthroplasty performed in an operating room using laminar airflow ventilation system
62253985|NCT00906893|EXPERIMENTAL|1|
62835981|NCT05932823||Turbulent Airflow|total hip arthroplasty performed in an operating room using turbulent airflow ventilation system
62835982|NCT02633306|EXPERIMENTAL|Transcranial Magnetic Stimulation|transcranial magnetic stimulation
62835983|NCT01206725|OTHER|. Moderate Intensity Exercise Group|Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.
62835984|NCT01206725|OTHER|Aerobic interval training|Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min.
62835985|NCT01523106|ACTIVE_COMPARATOR|Carnitine|Patients will take 4grams of L-carnitine (2 grams twice daily) for 3 months
62835986|NCT01523106|PLACEBO_COMPARATOR|Placebo|Patients will take placebo for 3 months. Placebo is manufactured by the same company as the L-carnitine and will have a similar appearance.
62253986|NCT02148991||Irbesartan|Patients on irbesartan treatment
62253987|NCT06237543||Hypotension|Patients with a 30% decrease in SBP from baseline and a decrease in MAP below 65 mmHg in the first 10 minutes after anesthesia induction will be considered to have hypotension.
62253988|NCT06237543||none hypotension|Patients who do not have a 30% decrease from the baseline in SBP and a decrease in MAP below 65 mmHg in the first 10 minutes after anesthesia induction will be considered as not having hypotension.
62253989|NCT00766948||No Treatment|
62835987|NCT05940480|EXPERIMENTAL|TCM Daoyin intervention group|Participants randomized to TCM Daoyin intervention group receive health education plus a TCM Daoyin training program. The TCM Daoyin training program was a 16-week, instructor-led group training program.
62835988|NCT05940480|ACTIVE_COMPARATOR|Health education control group|Participants randomized to the health education control group only receive health education and no additional training program.
62835989|NCT02318706|PLACEBO_COMPARATOR|placebo|placebo group (14 weeks)
62835990|NCT02318706|EXPERIMENTAL|DS-5565 15mg|DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
62835991|NCT02318706|EXPERIMENTAL|DS-5565 20 mg group|DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
62835992|NCT02318706|EXPERIMENTAL|DS-5565 30 mg group|DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
62835993|NCT00892099|EXPERIMENTAL|High Dose Ergocalciferol|Receives 50,000 IU of ergocalciferol weekly
62835994|NCT00892099|EXPERIMENTAL|Low Dose Ergocalciferol|Receives 50,000 IU of ergocalciferol per month
62835995|NCT00892099|PLACEBO_COMPARATOR|Placebo|Receives no ergocalciferol
62253990|NCT04703673||Sinolpan® group|Sinolpan® group: patients suffering from rhinosinusitis and, where appropriate, from bronchitis; intake of Sinolpan® 100 mg or Sinolpan® forte 200 mg (cineol) according to the instructions for use; before and after treatment for rhinosinusitis and, where appropriate, from bronchitis, patients complete a questionnaire that contains the Rhinosinusitis Quality of Life questionnaire and Questions about the severity of bronchitis symptoms. The latter should only be answered by patients who suffer from bronchitis in addition to rhinosinusitis.
62835996|NCT00759941|EXPERIMENTAL|Xalatan + Azopt|Xalatan dosed once a day at 10 pm, with Azopt dosed three times a day at 8 AM, 2 PM, and 10:05 PM as an adjunctive therapy for 3 months.
62835997|NCT00759941|ACTIVE_COMPARATOR|Xalatan + Placebo|Xalatan dosed once a day at 10 pm, with placebo dosed three times a day at 8 AM, 2 PM, and 10:05 PM concomitantly for 3 months.
62835998|NCT04316013|ACTIVE_COMPARATOR|A|Sevoflurane + intravenous lidocaine
62442896|NCT06017414|NO_INTERVENTION|Waitlist followed by Growth Path Intervention|Participants for this arm are members of the 7 Cups platform (signed up as 'members', but not signed up as 'listeners'). The waitlist comparator condition has 7 Cups access and use as usual during the waitlist period. Participants will receive access to the Systemic Psychotherapy-informed growth path intervention after the waitlist condition of 7 weeks is completed.
62835999|NCT04316013|ACTIVE_COMPARATOR|B|Sevoflurane
62836000|NCT04316013|ACTIVE_COMPARATOR|C|Propofol TIVA + intravenous lidocaine
62836001|NCT04316013|ACTIVE_COMPARATOR|D|Propofol TIVA
62836002|NCT00927953|EXPERIMENTAL|MGAWN1|30 mg/kg single intravenous infusion of MGAWN1
62836003|NCT00927953|PLACEBO_COMPARATOR|Placebo - Normal Saline|single intravenous infusion of saline placebo
62836004|NCT02304367|EXPERIMENTAL|Burosumab|Participants received burosumab at a starting dose of 0.3 mg/kg administered subcutaneously (SC) every 4 weeks (Q4W). Doses may have been titrated up to a maximum of 2.0 mg/kg every 2 weeks (Q2W) in order to achieve fasting peak serum phosphorus levels within the target range of 2.5 to 4.0 mg/dL.
62836005|NCT06067360|EXPERIMENTAL|sleeve|Evaluation of IFIS sleeve performance
62836006|NCT02819804|EXPERIMENTAL|Treatment (dasatinib, nivolumab)|Patients receive dasatinib PO QD on days 1-28 and nivolumab IV over 30 minutes on days 8 and 22 of course 1 and on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62442897|NCT06017414|EXPERIMENTAL|Listener Training Intervention|Participants for this arm are listeners on the 7 Cups platform (signed up as 'listeners', but not signed up as 'members') who will receive the Systemic Psychotherapy-informed listener training intervention.
62253991|NCT04703673||Nasal spray group|Control group: patients with rhinosinusitis; Use of nasal decongestants according to the instructions for use. Before and after treatment for rhinosinusitis, patients complete a questionnaire that includes the Rhinosinusitis Quality of Life questionnaire.
62253992|NCT04489251||PH subjects|"* Pediatric subjects ages 2-17 years~* Subjects undergoing a clinically indicated cardiac catheterization.~* Subjects with proven or being evaluated for pulmonary hypertension in WHO classification group 1 or 3†~* Subjects will be categorized as PAH subjects if they meet the hemodynamic criteria: pulmonary artery pressure \>20mmHg, pulmonary vascular resistance index \>3 Woods units\*m2, and wedge pressures \<15mmHg."
62442898|NCT06017414|NO_INTERVENTION|Waitlist followed by Listener Training Intervention|Participants for this arm are listeners on the 7 Cups platform (signed up as 'listeners', but not signed up as 'members'). The waitlist comparator condition has 7 Cups access and use as usual during the waitlist period. Participants will receive access to the Systemic Psychotherapy-informed listener training intervention after the waitlist condition of 7 weeks is completed.
62442899|NCT00219856|EXPERIMENTAL|1|Anesthesic induction and maintenance with intravenous propofol.
62442900|NCT00219856|ACTIVE_COMPARATOR|2|Anesthesic induction with intravenous penthotal and maintenance with inhaled desflurane.
62836007|NCT02785523|EXPERIMENTAL|G. SPORE LIPIDS|"Form: Capsule Dosage and frequency: This group receives ganoderma spore lipids capsules 600mg TID in addition to the chemotherapy.~Duration: 6 chemotherapy cycles."
62836008|NCT02785523|PLACEBO_COMPARATOR|Placebo|"Form: Capsule Dosage and frequency: This group receives placebo capsules 600mg TID in addition to the chemotherapy.~Duration: 6 chemotherapy cycles."
62836009|NCT01790724|EXPERIMENTAL|Walking exercise|Participants will be instructed in safe walking exercise. They will participate in an eight week, tapered, on-site program. Participants will also attend group workshops where they will learn self-regulatory skills such as goal-setting, self-monitoring, barrier trouble-shooting, rewarding, and relapse prevention and recovery.
62836010|NCT01790724|ACTIVE_COMPARATOR|Metabolic health education|Participants will complete an eight-week online metabolic health education course. Topics will include glucose control, insulin, weight management, nutrition, physical activity, eye/kidney/foot health, stress reduction, and doctor-patient communication.
62836011|NCT01867671|EXPERIMENTAL|Peanut Oral Immune Therapy (OIT)|Peanut OIT for 134 weeks followed by peanut avoidance for 26 weeks.
62836012|NCT01867671|PLACEBO_COMPARATOR|Peanut Placebo|Peanut placebo for 134 weeks followed by peanut avoidance for 26 weeks. The placebo extract will be derived from oat flour source material.
62836013|NCT00599339||Neupro|Neupro at study onset
62836014|NCT00599339||Dopamine Agonist|Other Dopamine-Agonist at study onset
62836015|NCT00599339||L-Dopa|L-Dopa
62836016|NCT00599339||Neupro + L-Dopa|Neupro in combination with L-Dopa at study onset
62836017|NCT00599339||Dopamine Agonist + L-Dopa|Other Dopamine Agonist in combination with L-Dopa at study onset
62612148|NCT04150068|EXPERIMENTAL|Cohort 1A: Lenacapavir|"Participants with HIV-1 ribonucleic acid (RNA) ≥ 400 copies/mL and with a \<0.5 log10 HIV-1 RNA decline at Cohort Selection visit compared with screening visit will receive oral lenacapavir (LEN) 600 mg tablet on Days 1 and 2 and 300 mg tablet on Day 8, while continuing their failing regimen in blinded Functional Monotherapy Period (Baseline to Day 14); followed by unblinded Maintenance Period where participants will receive subcutaneous (SC) LEN 927 mg and will initiate an optimized background regimen (OBR) at Day 1 SC Visit (14 days after the first dose of oral LEN).~Participants will receive their subsequent SC LEN injection at Week 26 Visit (relative to Day 1 SC). Participants will be given an option to receive SC LEN injection at Weeks 52 and 156, while continuing their OBR, until product becomes accessible to participants through an access program or until Gilead elects to discontinue the study in the country."
62253993|NCT04489251||Control subjects|"* Pediatric subjects ages 2-17 years~* Subjects undergoing a clinically indicated cardiac catheterization.~* Subjects can be categorized as control subjects if they do not have PH on catheterization and do not meet any exclusion criteria."
62253994|NCT06125769|EXPERIMENTAL|Study population|"Candidates will be evaluated by the Multidisciplinary Group after routine radiological studies (CT, MRI, PET-MRI/CT).~Patients will receive 6 months of standard of care chemotherapy and undergo PET-MRI with FDG to exclude the presence of extrahepatic disease.~Following completion of therapy, patients will undergo radiological restaging. If the disease is resectable, the patient will be considered for curative-intent surgical resection; if not, the patients will be evaluated by the Center's Multidisciplinary Transplantation Group. Patients will continue chemotherapy until a compatible liver becomes available. If there are no further contraindications, exploratory laparotomy and surgical nodal staging of the tumor will be performed at the time of transplantation. If there are no signs of extrahepatic disease, transplantation will be conducted according to institutional protocols."
62253995|NCT02528370|EXPERIMENTAL|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
62253996|NCT02528370|NO_INTERVENTION|No telEPOC / Usual Care|"The control group follows the usual care protocol in our health system. That includes periodic control by their primary and respiratory specialist. They receive non-structured information/education about COPD and follow a programmed control agenda depending on the severity of the disease every 4-6 months.~Generally speaking the differences between the two cohorts were the educational structured program and the telemonitoring control."
62253997|NCT02879227|ACTIVE_COMPARATOR|Arm Cisplatin|Radiotherapy 50 Gy with cisplatin 75 mg/2 Day 1 and day 22 (2)
62253998|NCT02879227|EXPERIMENTAL|Arm Oxaliplatin|Radiotherapy 50Gy Oxaliplatin 85mg/m2 every 2 weeks, (6)
62253999|NCT00805272|EXPERIMENTAL|1|
62254000|NCT05568108||nerve transfer|masseteric nerve to central branch facial nerve. (Early fibrillation on EMG)
62254001|NCT05568108||nerve and free functioning muscle transfer|Masseteric nerve to free functioning muscle transfer. (Late no fibrillation on EMG)
62254002|NCT02524522|ACTIVE_COMPARATOR|INTELLiVENT-ASV mode|Active comparator: Discontinuation of mechanical ventilation in postoperative period will be provided using automatically driven mode - INTELLiVENT-ASV. In the INTELLiVENT-ASV mode target EtCO2 will be 30-35 mm Hg, target SpO2 - 94-98%, quick wean option - activated.
62442901|NCT02355548||Outpatient Treatment|All patients eligible for the study will have their PE treated in the outpatient setting.
62612149|NCT04150068|PLACEBO_COMPARATOR|Cohort 1B: Placebo to Lenacapavir|"Participants with HIV-1 RNA ≥ 400 copies/mL and with a \<0.5 log10 HIV-1 RNA decline at the Cohort Selection visit compared with screening visit will receive oral LEN placebo on Days 1, 2, and 8 while continuing their failing regimen in blinded Functional Monotherapy Period (Baseline to Day 14); followed by unblinded Maintenance Period where participants will receive oral LEN 600 mg on Days 15 and 16 and 300 mg on Day 22, and will initiate an OBR on Day 15. At Day 1 SC (14 days after the first dose of oral LEN), participants will receive SC LEN 927 mg while continuing OBR.~Participants will receive their subsequent SC LEN injection at Week 26 Visit (relative to Day 1 SC). Participants will be given an option to receive SC LEN injection at Weeks 52 and 156, while continuing their OBR, until the product becomes accessible to participants through an access program or until Gilead elects to discontinue study in the country."
62254003|NCT02524522|ACTIVE_COMPARATOR|SIMV mode|Active comparator: Discontinuation from mechanical ventilation in postoperative period will be provided using physician driven protocol. The synchronized intermittent mandatory ventilation (SIMV) mode settings will be as follows: PEEP 5 cm of water, FiO2 to achieve SpO2 \> 94 %. Inspiratory pressure will be adjusted to deliver a tidal volume (VT) of 8 mL/kg predicted body weight; pressure support will be 2 cm of water higher. Respiratory rate (RR) will be adjusted to provide EtCO2 of 30-35 mm Hg. Respiratory rate and inspiratory pressure will be decreased gradually every 30 minutes. After decrease of inspiratory pressure to 6 cm of water (8 cm of water in case of BMI \> 30 kg/m2) and respiratory rate to 6/min, the spontaneous breathing trial (SBT) will be started.
62612150|NCT04150068|EXPERIMENTAL|Cohort 2: Lenacapavir|"Participants with a ≥ 0.5 log10 copies/mL HIV-1 RNA decline at the Cohort Selection Visit compared with the screening visit or with HIV-1 RNA \< 400 copies/mL or if Cohort 1 is fully enrolled will receive oral LEN 600 mg tablet on Days 1 and 2 and 300 mg tablet on Day 8, and will initiate an OBR on Day 1 in Oral Lead-in Period (Baseline to Day 14); followed by Maintenance Period where participants will receive SC LEN 927 mg at Day 1 SC Visit (14 days after the first dose of oral LEN) while continuing their OBR.~Participants will receive their subsequent SC LEN injection at Week 26 Visit (relative to Day 1 SC). Participants will be given an option to receive SC LEN injection at Weeks 52 and 156, while continuing their OBR, until the product becomes accessible to participants through an access program or until Gilead elects to discontinue the study in the country."
62254004|NCT03932656||Females with borderline personality disorder|
62254005|NCT04972474|NO_INTERVENTION|RADAR-MDD Questionnaire App as Usual|The RADAR-MDD questionnaire app as usual asks participants to complete 3x active tasks per week, with one reminder notification at 9am on a day that a questionnaire is due. The notification reads 'Questionnaire Time. Won't usually take longer than 3 minutes'. The participant is not able to view any data progress, aside from through the Fitbit app, which was present in the original RADAR-MDD study.
62612151|NCT05721300|EXPERIMENTAL|experience group|"patients receive NAs（EntecavirorTenofovirorTenofovir alafenamide） combine with interferon treatments for 48weeks, and then continue NAs treatment"
62612152|NCT05721300|ACTIVE_COMPARATOR|control group|"patients receive NAs treatment（EntecavirorTenofovirorTenofovir alafenamide）"
62612153|NCT01285492|EXPERIMENTAL|QVA149|QVA149 110/50 μg once a day (o.d)
62612154|NCT01285492|ACTIVE_COMPARATOR|Tiotropium|tiotropium 18 μg o.d.
62612155|NCT04383340|EXPERIMENTAL|Mother-Infant Transaction Program|Four sessions were delivered to the mothers one-on-one based on a manualized protocol while the infants were still in the neonatal intensive care units. These coaching sessions included psychological care for the mother and topics on recognizing premature infant's characteristics, understanding and recognizing signs of infant stress and infant's engagement and disengagement cues, principles of graded stimulation, and how to optimize interactions and avoid over-stimulating the infant.
62612156|NCT04383340|ACTIVE_COMPARATOR|Treatment as usual|For this group, infants and mothers received standard hospital care following the initial baseline assessment; these mothers were invited to ask questions about recommended ways to take care of their infants, but no specific knowledge or skills targeted by the adapted MITP program were taught
62836018|NCT02902562|OTHER|Study Visit|You will have a Contrast Enhanced Ultrasound (CEUS) and contrast Magnetic Resonance Imaging (MRI) which will take about 2 hours.
62836019|NCT06365632|EXPERIMENTAL|Surgical intervention due to acute phlegmanous appendicitis using the drug antispike|"Placebo-controlled, single-blind clinical trial of the effectiveness, tolerability and safety of the drug Antispike, gel, 100 g in a bottle produced by Unitary Enterprise Unitehprom BGU, Republic of Belarus, in adult patients after surgery for acute phlegmonous appendicitis. An antegrade appendectomy is performed, after which the drug Antispike is used."
62836020|NCT06365632|SHAM_COMPARATOR|surgical intervention due to acute phlegmanous appendicitis|An antegrade appendectomy is performed without using Antispike.
62836021|NCT03823742|EXPERIMENTAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
62836022|NCT03823742|EXPERIMENTAL|Low FODMAP diet|Low FODMAP diet
62612157|NCT05639504||NEWS2 score of 2-4|Bio-sample collection
62612158|NCT05639504||NEWS2 score of 5-6|Bio-sample collection
62612159|NCT05639504||NEWS2 score of ≥7|Bio-sample collection
62612160|NCT03905538|EXPERIMENTAL|[18F]FLT-PET/CT Arm|The experimental \[18F\]FLT-PET/CT will be completed before initiation of chemotherapy and prior to the third cycle (or month) of chemotherapy. Laboratory analysis and correlative radiology, as directed per clinical care based on the primary diagnosis, are required within 30 days of the baseline \[18F\]FLT PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
62612161|NCT04621643|EXPERIMENTAL|digital cognitive behavioral therapy (dCBT-I)|
62612162|NCT04621643|ACTIVE_COMPARATOR|Patient education about sleep (PE)|
62612163|NCT05822583|EXPERIMENTAL|active treatment group|Active treatment group (IV abatacept infusion, 10 mg/kg up to 1750 mg) + baseline IM
62052963|NCT02498834|EXPERIMENTAL|Educational Video and Question Prompt List|Parents and adolescents in this group will watch a short educational video in English or Spanish on an iPad about the importance of encouraging adolescents to ask questions and to be involved during their pediatric asthma visits to improve their self-management skills. Also, the adolescents in this group will be handed a question prompt list to complete, which will be collected after the medical visit.
62052964|NCT02498834|NO_INTERVENTION|Control group|Standard of care will be used
62612164|NCT05822583|PLACEBO_COMPARATOR|Control group|Placebo group (IV infusion of normal saline) + baseline IM
62612165|NCT06184906|PLACEBO_COMPARATOR|CONTROLS|Participants in the control arm will undergo a traditional weaning process. This involves primarily the use of industrial baby foods, with a gradual introduction of fresh foods. Legumes will be introduced at around 7-8 months, and fresh fish will be incorporated into the diet after one year of age.
62836023|NCT05933850|EXPERIMENTAL|Strong Family Programme Intervention|There will be 3 weekly group sessions of the strong family programme with caregivers and children (8-12 families per group).
62836024|NCT05933850|ACTIVE_COMPARATOR|Waitlist control group|This group will be on the waiting list and receive SF programme training sessions once the study will be completed.
62836025|NCT02868632|EXPERIMENTAL|Cohort A: MEDI4736 + SBRT|MEDI4736 10 mg/kg IV every 2 weeks plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 10 Subjects
62836026|NCT02868632|EXPERIMENTAL|Cohort B:Tremelimumab + SBRT|Tremelimumab 10 mg/kg IV every 4 weeks plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 10 Subjects
62836027|NCT02868632|EXPERIMENTAL|Cohort C: MEDI4736 + Tremelimumab + SBRT|MEDI4736 + Tremelimumab (recommended phase 2 IV dose for combination) plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 16 Subjects
62836028|NCT05488535|EXPERIMENTAL|Non-significant risk study of a cochlear implant headpiece|This arm aims to evaluate a cochlear implant headpiece.
62836029|NCT01660724|EXPERIMENTAL|Ultrasound guided arterial puncture|Patients randomised to the this arm has arterial puncture performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
62836030|NCT01660724|ACTIVE_COMPARATOR|Conventional arterial puncture technique|Patients randomised to the active comparator arm has arterial puncture performed using the conventional technique
62836031|NCT00594841|ACTIVE_COMPARATOR|1|Conservative (nonoperative) management of the AC joint dislocation.
62836032|NCT00594841|EXPERIMENTAL|2|Operative fixation (i.e., ORIF) of the dislocation with a hook plate and screws.
62836033|NCT01083771|EXPERIMENTAL|Olive Oil|At least 3 tablespoons of olive oil each day
62052965|NCT04036461|EXPERIMENTAL|Arm 1 (CC-99712 monotherapy)|CC-99712 will be administered via intravenous (IV) infusion.
62836034|NCT03461614|EXPERIMENTAL|Exercise Group|In addition to the service routine rehabilitation program, in this group all participant receive as group training with instructor supervising 5-6 participants. The specific days of the week and time of day in which the participants trained remained constant throughout each training protocol. Training programs lasted 6 weeks and comprised 2 training sessions per week with a total of 12 training sessions. A 45-60 min training sessions per week with a 2 day gap between each session.
62836035|NCT03461614|OTHER|Control Group|In addition to the service routine rehabilitation program, participants in the Control group participated in leisure activities such as table tennis/basketball under service staff supervision for 45-60 minutes, 2 times a week, 6 weeks similar time period of Exercise group.
62052966|NCT04036461|EXPERIMENTAL|Arm 2 (CC-99712 and BMS-986405 combination)|CC-99712 will be administered via IV infusion. BMS-986405 will be administered orally.
62052967|NCT04022967|EXPERIMENTAL|Arm 1 : Dual maintenance therapy DTG+3TC|
62052968|NCT04022967|EXPERIMENTAL|Arm 2 : Dual maintenance therapy ATV/r+3TC|
62836036|NCT02041624||allergic rhino-conjunctivitis|Patient with proven allergic rhino-conjunctivitis due to grass pollen
62836037|NCT01026480||IPAA Patients|Patients who have had their IPAA procedures performed by Dr. Becker
62836038|NCT03229785|EXPERIMENTAL|Human Umbilical Cord Blood Plasma|Six intravenous infusions of human umbilical cord blood plasma (HUCBP) during a twelve month study period. The amount of HUCBP being infused on each occasion is 50 mL.
62836039|NCT02154698|ACTIVE_COMPARATOR|22-gauge Standard Needle|Participants will have each node sampled starting with the standard 22G needle on the first pass followed by the ProCore 22G needle on the second pass (for a total of 8 passes)
62836040|NCT02154698|ACTIVE_COMPARATOR|22-gauge ProCore Needle|Participants will have each node sampled starting with the ProCore 22G on the first pass followed by the standard 22G needle on the second pass (for a total of 8 passes)
62836041|NCT00735488||A|Thalassemia Minor carriers
62836042|NCT00735488||B|Sickle cell carriers
62836043|NCT04773535||healthy Volunteers|Adult (\>18y) healthy volunteers without previous injuries or pathologies of the hand and upper extremity
62836044|NCT06118398||Exposed group|Intravenous methylprednisolone (IVMP) plus Efgartigimod
62836045|NCT06118398||Control group|IVMP
62836046|NCT00722306|EXPERIMENTAL|A425|A425 Treated
62836047|NCT04259996||MODIFIED NATURAL CYCLE|"The term 'modified natural cycle' refers to a natural cycle in which ovulation is triggered by exogenous hCG administration in order to provide optimal timing scheduling embryo transfer. In contrast to the natural cycle, the applied hCG may lead to a different luteal phase profile. Luteal phase support is common clinical practice in those cycles.~On the day of embryo transfer (ET), eligible patients being transferred one or two good quality embryos on day 5 of development according to the Spanish ASEBIR classification will be informed about the nature of the study, read the informed consent (IC) form and decide if entering into the study. After signing the IC form, a blood test will be performed in a time frame between 1 and 2 hours before the ET.~The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer."
62836048|NCT04259996||STIMULATED CYCLE|"On the day of embryo transfer (ET), eligible patients being transferred one or two good quality embryos on day 5 of development according to the Spanish ASEBIR classification will be informed about the nature of the study, read the informed consent (IC) form and decide if entering into the study. After signing the IC form, a blood test will be performed in a time frame between 1 and 2 hours before the ET.~The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer."
62052969|NCT04022967|ACTIVE_COMPARATOR|Arm 3 : Reference triple therapy TDF+3TC+EFV or DTG+3TC+TDF|
62052970|NCT01048814||Ovarian, Peritoneal, Fallopian Cancer|Recurrent, Peristent or Refractory
62052971|NCT01891448|EXPERIMENTAL|WebCONSORT tool|This WebCONSORT tool allows authors to combine different extensions relevant to their trial and generate a list of items and a flowchart specific to their trial design and the type of intervention tested.
62052972|NCT01891448|OTHER|Modified WebCONSORT tool|This tool will include the flowchart part of the WEBCONSORT tool but not the main checklist or elements relating to CONSORT extensions.
62052973|NCT05711862|EXPERIMENTAL|1 week Placebo then 1 week SUVO|After 1 week of placebo treatment there will be 1 week of wash out period before start of study medication
62052974|NCT05711862|EXPERIMENTAL|1 week SUVO then 1 week Placebo|After 1 week of SUVO treatment there will be 1 week of wash out period before start of placebo
62052975|NCT05531279|EXPERIMENTAL|PEG-rhG-CSF group A|PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected,after monitoring ANC\>0.5×109/L,the drug was stopped,and then ANC\<0.5×109/L was temporarily supplemented with one dose of the same drug.
62836049|NCT05019911||Patients with COPD alone|In the cross-sectional part, the group of patients with COPD alone will be monitored by traditional sleep monitoring equipment (polysomnography) and millimeter wave radar equipment. In the cohort part, this group of patients will be continuously monitored by millimeter wave radar equipment for vital signs combined with pulse oxygen saturation, end expiratory CO2 and other indicators continuously monitored.
62052976|NCT05531279|EXPERIMENTAL|PEG-rhG-CSF group B|PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected,after monitoring ANC\>0.5×109/L,the drug was stopped,and then ANC\<0.5×109/L was temporarily supplemented with one dose of the same drug.
62052977|NCT05531279|EXPERIMENTAL|rhG-CSF group(short-acting )|rhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.After monitoring ANC\>0.5×109/L,the drug was stopped,and then ANC\<0.5×109/L was temporarily supplemented with one dose of the same drug.
62052978|NCT02940574|EXPERIMENTAL|Syntocinon (Oxytocin, product code RVG 03716)|Administration via nasal spray
62052979|NCT02940574|PLACEBO_COMPARATOR|Placebo (Physiological water(sodium chloride (NaCl) solution))|Administration via nasal spray
62052980|NCT02393287||Reproline|this is an observational trial ; there is no intervention
62052981|NCT03716375|EXPERIMENTAL|use of fibrinolytic agent|Chest tube drainage with intrapleural urokinase instillation 1000 IU/ml
62836050|NCT05019911||Patients with COPD combined with sleep apnea hypopnea syndrome|In the cross-sectional part, the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by traditional sleep monitoring equipment (polysomnography) and millimeter wave radar equipment. In the cohort part, this group of patients will be continuously monitored by millimeter wave radar equipment for vital signs combined with pulse oxygen saturation, end expiratory CO2 and other indicators continuously monitored.
62836051|NCT05741671||natural course|"To study the value of sonographic features including vascularity in the prediction of fibroids' volume change at follow-up during their (1) natural course or (2) long-term use of exogenous hormone exposure; after initiation of (3) SPRMs or GnRH-analogues treatment or (4) exogenous hormonal exposure; or after (5) embolization or (6) ablation therapy .~Primary outcome: Natural behaviour - 1 year"
62254006|NCT04972474|EXPERIMENTAL|RADAR-MDD Adapted Questionnaire App|"The following components are also present:~Notifications: The notification will alternate between the phrases 'Questionnaire Time. Symptom tracking might increase self-awareness of your emotions (Bakker \& Rickard, 2018)', 'Questionnaire Time. Symptom tracking is a technique often used in treatment to increase insight into your symptoms (Kramer et al., 2014)', and 'Questionnaire Time. Tracking your symptoms through a smartphone and Fitbit might help research to better understand health conditions'.~Progress visualisation: Participants will be able to view their questionnaire completion progress as a visualisation through the app, in the form of a graph.~Additional components: An additional text on the home screen of the active app will read 'You can contact your research team between 9am-5pm Mon-Fri if you have questions, onradar-engage@kcl.ac.uk'."
62254007|NCT01923142|EXPERIMENTAL|Outer-Root-Sheath Melanocytes Suspension|This arm includes all patients sides (left or right) treated with autologous outer-root-sheath melanocytes suspension followed by targeted UVB phototherapy
62254008|NCT01923142|PLACEBO_COMPARATOR|Placebo|This arm includes all patients sides (left or right) treated with placebo followed by targeted UVB phototherapy
62254009|NCT00290342|EXPERIMENTAL|Infanrix-IPV Group|Healthy male or female subjects between and including 8 to 12 weeks (56-90 days) of age at the time of the first vaccination, who were born after a gestation period of 36 to 42 weeks, received 3 doses of the GSK Biologicals' combined Infanrix™-IPV (DTPa-IPV) vaccine at 2, 4 and 6 months of age, intramuscularly into the antero-lateral thigh.
62254010|NCT00290342|ACTIVE_COMPARATOR|Infanrix + IMOVAX Polio Group|Healthy male or female subjects between and including 8 to 12 weeks (56-90 days) of age at the time of the first vaccination, who were born after a gestation period of 36 to 42 weeks, received 3 doses of the GSK Biologicals' Infanrix™ (DTPa) vaccine co-administered with Sanofi-Pasteur's IMOVAX Polio® (IPV) vaccine at 2, 4 and 6 months of age, intramuscularly into the antero-lateral sides of opposite thighs.
62254011|NCT04981470|EXPERIMENTAL|Investigational Device|Subjects implanted with the baroloop device
62254012|NCT03371979|EXPERIMENTAL|Pegzilarginase plus Pembrolizumab|Phase 1 \& 2
62254013|NCT05549700|EXPERIMENTAL|Common fibular nerve group|The subjects of this group will receive electric nerve stimulation on the sciatic nerve through a lateral approach to stimulate the behavior corresponding to the common fibular nerve
62254014|NCT05549700|EXPERIMENTAL|Tibial nerve group|The subjects of this group will receive electric nerve stimulation on the sciatic nerve through a lateral approach to stimulate the behavior corresponding to the tibial nerve
62254015|NCT01713621|EXPERIMENTAL|OZ439 100mg|Single dose of 100mg of OZ439 administered as an oral suspension
62254016|NCT01713621|EXPERIMENTAL|OZ439 500mg|Single dose of 500mg of OZ439 administered as an oral suspension
62254017|NCT02597569||Historical Control|Patient participants will be recruited from an inpatient rehabilitation stroke unit prior to introducing CO-OP KT training to the stroke team. Patient participants will receive Usual Care from their stroke team.
62254018|NCT02597569||CO-OP KT Exposure group|Patient participants will be recruited from an inpatient rehabilitation stroke unit after the stroke team has been exposed to CO-OP KT training. Patient participants will receive Usual Care, augmented by CO-OP KT, from their stroke team.
62254019|NCT01322750||With CTCs|Those individuals whom are identified with CTCs
62254020|NCT01322750||Without CTCs|Those individuals whom present and did not have CTCs
62254021|NCT05496179|ACTIVE_COMPARATOR|Prucalopride|Patients will receive prucalopride (2 mg) once daily for 7 days.
62612166|NCT06184906|EXPERIMENTAL|Treated|"Participants in the experimental arm will follow a Mediterranean Diet (MD) weaning schema. This approach includes exclusively fresh foods that are part of the traditional MD, modified to suit infants. Key elements of this diet include:~* Seasonal fruit and vegetables, such as broccoli and cauliflower, served as purees from the beginning of weaning.~* A variety of fresh blue fish (e.g., anchovies, mackerel, flag fish, cod, sole) introduced at 7 months, seasoned with garlic and cherry tomatoes.~* Use of spices and herbs like thyme, marjoram, rosemary, parsley, garlic, and onion to flavor meals.~* Exclusion of salt; meals are instead enhanced with 2 g of Parmesan cheese for taste.~* Avoidance of sweets."
62612167|NCT00766844|EXPERIMENTAL|Active|Spinal cord stimulation
62612168|NCT06730412||HPV-associated head and neck cancer patients treated with surgery|AJCC 8 Stage I-III HPV+ head and neck cancer patients treated with curative intent surgery
62612169|NCT04610450|EXPERIMENTAL|RCI-BE-10|Robot assisted cochlear implant surgery.
62836052|NCT05741671||during long-term use of exogenous hormone exposure|"To study the value of sonographic features including vascularity in the prediction of fibroids' volume change at follow-up during their (1) natural course or (2) long-term use of exogenous hormone exposure; after initiation of (3) SPRMs or GnRH-analogues treatment or (4) exogenous hormonal exposure; or after (5) embolization or (6) ablation therapy .~Primary outcome: Long-term exogenous hormonal exposure - 1 year"
62836053|NCT05741671||Selective progesterone receptor modulators treatment or GnRH-analogues treatment|"To study the value of sonographic features including vascularity in the prediction of fibroids' volume change at follow-up during their (1) natural course or (2) long-term use of exogenous hormone exposure; after initiation of (3) SPRMs or GnRH-analogues treatment or (4) exogenous hormonal exposure; or after (5) embolization or (6) ablation therapy .~Primary outcome: SPRMs or GnRH-analogues - 3 months"
62836054|NCT05741671||after initiation exogenous hormonal exposure|"To study the value of sonographic features including vascularity in the prediction of fibroids' volume change at follow-up during their (1) natural course or (2) long-term use of exogenous hormone exposure; after initiation of (3) SPRMs or GnRH-analogues treatment or (4) exogenous hormonal exposure; or after (5) embolization or (6) ablation therapy .~Primary outcome: Initiation of exogenous hormonal exposure - 1 year"
62052982|NCT03716375|NO_INTERVENTION|no use of any drug|Chest tube drainage
62052983|NCT04707625|OTHER|Aflibercept|All subjects will receive aflibercept every 4 weeks. Once vascular endothelial growth factor levels become normal and macular edema improves treatment windows will be extended up to every 12 weeks.
62052984|NCT00501189||1|Those getting Gardasil vaccination for low grade Pap abnormality.
62052985|NCT00501189||2|Historical group that did not get Gardasil.
62052986|NCT05780294|PLACEBO_COMPARATOR|Control group|"Chemotherapy:~5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle; Lobaplatin: 30mg/m2, used on the 1st and 28th day of each cycle; Q60d; Every 2 months for a treatment cycle, use 6 cycles, a total of 12 months.~Drug: Placebo After diagnosis of stage IV, recurrent or metastatic nasopharyngeal carcinoma (within 3 weeks before treatment), placebo tablets were started,) 2 tablets/dose 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, 3 tablets/dose 3 times daily during chemotherapy, and continued to be given orally 2 tablets/dose 3 times daily for 4 weeks after the end of chemotherapy. In case of grade III-IV myelosuppression during treatment, recombinant human granulocyte-stimulating factor injection (manufactured by Qilu Pharmaceutical Co., Ltd.) was given again at 2\~5ug/kg, subcutaneously once daily, and the clinical trial was terminated."
62052987|NCT05780294|ACTIVE_COMPARATOR|Experimental group|"Chemotherapy:~5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle; Lobaplatin: 30mg/m2, used on the 1st and 28th day of each cycle; Q60d; Every 2 months for a treatment cycle, use 6 cycles, a total of 12 months.~Drug: Leucogen After the diagnosis of stage IV, recurrent or metastatic nasopharyngeal carcinoma (within 3 weeks before treatment), oral leucogen tablets (manufactured by JIANGSU JIBEIER PHARMACEUTICAL CO.,LTD, 20 mg/tablet) were started and 40 mg/dose was used 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, and 60 mg/dose was used 3 times daily during chemotherapy, and 40 mg/dose was continued orally 3 times daily for 4 weeks after the end of chemotherapy. In case of grade III-IV myelosuppression during treatment, recombinant human granulocyte-stimulating factor injection (manufactured by Qilu Pharmaceutical Co., Ltd.) was given again at 2\~5ug/kg, subcutaneously once daily, and the clinical trial was terminated."
62052988|NCT00845338|EXPERIMENTAL|Arm 1|
62052989|NCT02742298|OTHER|QMUS|All patients will undergo serial quantitative muscle ultrasound.
62254022|NCT05496179|ACTIVE_COMPARATOR|Metoclopramide|Patients will receive metoclopramide (10 mg) three times daily for 7 days.
62254023|NCT02091778|EXPERIMENTAL|Fast Gelling Dressing|
62254024|NCT06396078|EXPERIMENTAL|Intervention group|"Participants randomized to the intervention group will receive the following regimen:~* Ceftriaxone 1 g IV q 24 hours x 7 days~* Clarithromycin 500 mg PO BID x 7 days~* Metronidazole 500 mg PO q 12 hours x 7 days"
62254025|NCT06396078|OTHER|Standard of care|"Participants randomized to the standard care group will receive the following regimen:~* Ampicillin 2 g IV q 6 hours x 48 hours followed by amoxicillin 250 mg q 8 hours for an additional 5 days~* Azithromycin 1 g PO x 1 dose OR erythromycin 250 mg IV q 6 hours x 48 hours followed by erythromycin 333 mg PO TID for an additional 5 days"
62254026|NCT01688596|NO_INTERVENTION|No Treatment|"The No Treatment group includes patients undergoing laparoscopic hysterectomy without local infiltration of bupivacaine."
62442902|NCT05728177|EXPERIMENTAL|STUDY GROUP|"Patients' medical charts in the outpatient clinic were reviewed to identify those who meet the inclusion criteria. Patients who meet the predetermined inclusion criteria were recruited in the study using simple randomization technique using computer-generated sequence technique to pick up these patients. After simple sampling and dividing patients into two groups of study and control. Patients from the study and control groups were interviewed individually by the researcher to apply the study tools~The program of intervention took four-weeks for each patient (total eight sessions- four outpatient sessions and four home-based sessions- two sessions per week- one outpatient and one home session/week). The outpatient sessions were done once per week during the patient visit to the outpatient clinic, as the patients visited the clinic 4 times/ month."
62442903|NCT05728177|ACTIVE_COMPARATOR|Control group|Patients in this control group will be left without any intervention to undergo the usual outpatient routine care.
62836055|NCT05741671||embolization therapy|"To study the value of sonographic features including vascularity in the prediction of fibroids' volume change at follow-up during their (1) natural course or (2) long-term use of exogenous hormone exposure; after initiation of (3) SPRMs or GnRH-analogues treatment or (4) exogenous hormonal exposure; or after (5) embolization or (6) ablation therapy .~Primary outcome: Embolization - 6 months"
62836056|NCT05741671||ablation therapy|"To study the value of sonographic features including vascularity in the prediction of fibroids' volume change at follow-up during their (1) natural course or (2) long-term use of exogenous hormone exposure; after initiation of (3) SPRMs or GnRH-analogues treatment or (4) exogenous hormonal exposure; or after (5) embolization or (6) ablation therapy .~Primary outcome: Ablation therapy - 6 months"
62836057|NCT04542239||Infants with GER|Infants (N=25) meeting inclusion/exclusion criteria
62836058|NCT04542239||Controls without GER|Infants (N=10) meeting inclusion/exclusion criteria, but no GER
62836059|NCT02233361|EXPERIMENTAL|Counseling|The intervention group will be informed in advance of a follow-up appointment six month after they have received their hearing aid. They will know that support will be given and time-use of the hearing aid will be checked out. Counseling on hearing aid use will be given.
62836060|NCT02233361|NO_INTERVENTION|Counselling|The control group will not receive any information of a follow-up appointment. However, they will receive a notice on this after six month.
62836061|NCT05853536||Standard of Care|As recommended by treatment guidelines.
62836062|NCT05853536||Cardiovascular Intervention|"Examples include:~* Cardiac surgery - Coronary artery bypass grafting (CABG), Repair and replacement of heart valve and other cardiovascular surgery including surgery on the thoracic aorta.~* On-pump / off-pump / minimally invasive bypass.~* Open / Transcatheter approach for valve replacement or repair.~* Open versus minimally invasive valve repair/ replacement.~* Procedural coronary revascularization Percutaneous Coronary Intervention.~* Closure of the left atrial appendage."
62836063|NCT00998296|EXPERIMENTAL|BIBW 2992 + BIBF 1120|This is a phase I dose escalation clinical trial and the data obtained shall determine the MTD for the combination of BIBW 2992/BIBF 1120 in 28-day of treatment.
62836064|NCT02831972|EXPERIMENTAL|Period 1|A single oral dose of AG-120 will be administered at Hour 0 followed by PK sampling for 504 hours (21 days).
62836065|NCT02831972|EXPERIMENTAL|Period 2|In Period 2, multiple oral doses of itraconazole will be administered once daily (QD) for 18 consecutive days (Days -4 to 14) with a single oral dose of AG-120 coadministered at Hour 0 on Day 1. PK sampling for AG-120 will be taken for 504 hours (21 days) following AG-120 dosing on Day 1. PK sampling will also be collected for itraconazole and its metabolite, hydroxy-itraconazole, from Day -2 up to Day 13.
62836066|NCT04775628|EXPERIMENTAL|inferior glide|Inferior glide of the right humerus till no motion is visual on the imaging
62052990|NCT02742298|OTHER|EIM|All patients will undergo serial electrical impedance myography measures.
62052991|NCT03017417|EXPERIMENTAL|Exercise Intervention arm|"exercise training intervention to include:~* DEXA scan will collect data on via a full body scan to determine post-cranial appendicular whole body LM, whole body fat free mass (FFM) and whole body FM.~* Muscle Strength assessment~* Physical function assessment~* Questionnaires and diet diaries"
62052992|NCT03017417|ACTIVE_COMPARATOR|standard of care arm|"* standard treatment~* exercise advice~* Questionnaires"
62052993|NCT04836702||Left ventricular function|"* Depressed LV function~  1. LV ejection fraction \< 50%~ 2. LV systolic function; defined as mild / mod / sev decreased~ 3. LV diastolic function; defined as mild (g1 ) / mod (g2) / sev ( g3) decreased~* Normal LV function"
62442904|NCT03749655|NO_INTERVENTION|PR+CBT|Standard care Pulmonary rehabilitation will be given alongside cognitive behavioural therapy
62442905|NCT03749655|EXPERIMENTAL|PR+CBT+PA Promotion.|Standard care Pulmonary rehabilitation will be given alongside cognitive behavioural therapy and physical activity promotion.
62836067|NCT02535806|EXPERIMENTAL|Treatment Arm|"Velcade will be given IV push on days 1,4,8 and 11 at a dose of 1.3 mg/m2/dose. At least 72 hours must have relapsed between doses.~IT Methotrexate (CNS Negative patients only) on days 1 and 8; age based dosing IT Methotrexate/Hydrocortisone/AraC (CNS positive patients only) on days 1, 8, 15 and 22; age based dosing.~Dexamethasone: Days 1-5 and 15-19; 10mg/m2/dose PO BID. Mitoxantrone: Days 1 and 2; 10mg/m2/dose Vincristine: days 1, 8, 15, and 22 at 1.5 mg/m2 (Maximum dose 2 mg) PEG-asparaginase: Days 3 and 17, 2500 IU/m2/dose"
62442906|NCT01548781|EXPERIMENTAL|Viscous Resistance & Abduction Loading|The intervention for the experimental group entails practicing reaching utilizing the robotic device, ACT3D, with the experimental element of horizontal viscosity in combination with abduction loading.
62836068|NCT00970996|EXPERIMENTAL|Biochemotherapy|Abraxane with Cisplatin, Temozolomide, interleukin-2 and interferon a2b
62052994|NCT04836702||Right ventricular function|"* Depressed RV function~  a. RV systolic function defined as mild / mod / sev decreased~* Normal RV function"
62052995|NCT04836702||Valvular lesions|"* Moderate or severe valvular lesions~  1. Aortic stenosis~ 2. Aortic regurgitation~ 3. Mitral stenosis~ 4. Mitral regurgitation~ 5. Tricuspid regurgitation~* Clinically normal valvular lesions~  1. No valvular lesion~ 2. Mild stenosis / regurgitation of above mentioned lesions"
62052996|NCT05435274|EXPERIMENTAL|HS-10376|"Phase 1a：Dose Escalation：Subjects with advanced NSCLC will be enrolled in dose escalation cohorts. Dose escalation of HS-10376 will be done to determine maximum tolerated dose.~Phase 1b：Dose Expansion：Depending on data obtained from the dose escalation part, dose expansion may proceed with multiple cohorts in subjects with advanced NSCLC having a EGFR/HER2 Exon 20 insertion mutation.~Phase 2：Subjects with locally advanced or metastatic EGFR Exon 20 insertion NSCLC will be enrolled in phase 2 part to evaluate the efficacy and sufficient safety of HS-10376 as monotherapy."
62052997|NCT02168530|PLACEBO_COMPARATOR|Placebo|
62052998|NCT02168530|EXPERIMENTAL|Vismodegib|
62052999|NCT04846088|EXPERIMENTAL|Product usage order ABICHDGEF|Subjects will use each of the 9 products (ABICHDGEF) during a familiarization period, followed by a 3 hour Test Session
62053000|NCT04846088|EXPERIMENTAL|Product usage order BCADIEHFG|Subjects will use each of the 9 products (BCADIEHFG) during a familiarization period, followed by a 3 hour Test Session
62053001|NCT04846088|EXPERIMENTAL|Product usage order CDBEAFIGH|Subjects will use each of the 9 products (CDBEAFIGH) during a familiarization period, followed by a 3 hour Test Session
62053002|NCT04846088|EXPERIMENTAL|Product usage order DECFBGAHI|Subjects will use each of the 9 products (DECFBGAHI) during a familiarization period, followed by a 3 hour Test Session
62053003|NCT04846088|EXPERIMENTAL|Product usage order EFDGCHBIA|Subjects will use each of the 9 products (EFDGCHBIA) during a familiarization period, followed by a 3 hour Test Session
62053004|NCT04846088|EXPERIMENTAL|Product usage order FGEHDICAB|Subjects will use each of the 9 products (FGEHDICAB) during a familiarization period, followed by a 3 hour Test Session
62254027|NCT01688596|ACTIVE_COMPARATOR|Bupivacaine|"The Bupivacaine Arm includes all patients who will receive bupivacaine injection on their trocar sites after the laparoscopic hysterectomy is completed. Bupivacaine (0.25%) will be injected through the closed incisions ensuring subcutaneous tissue, fascia, muscle and pre-peritoneal space of the trocar incision sites are infiltrated. All incisions 8 mm and greater are injected with 10 cc while all incisions 5 mm or less are infiltrated with 5 cc."
62254028|NCT06317818|EXPERIMENTAL|"MSCs group"|One local injection of MSCs (3\*10\^7 cells) after endoscopic dilatation of the stricture
62254029|NCT06317818|PLACEBO_COMPARATOR|"control group"|One local injection of the placebo (cell-free cell suspension solution devoid of cells) after endoscopic dilatation of the stricture
62254030|NCT03583983|OTHER|Personalized Health Recommendations|
62254031|NCT03583983|OTHER|No Health Recommendations|
62836069|NCT05747794|EXPERIMENTAL|open label lead-in (phase 2): eftilagimod alpha 30mg + paclitaxel|eftilagimod alpha 30mg s.c. + 80mg/m\^2 paclitaxel i.v. (same-day administration): The trial consists of a chemo-immunotherapy (chemo-IO) phase followed by an immunotherapy (IO)-phase. The chemo-IO phase consists of a planned 6 cycles of 4 weeks (28 days each) that may be longer or shorter depending on chemo tolerance. The IO-phase is planned to follow the chemo-IO phase. A maximum of 13 cycles (approx. 12 months) of treatment is planned.
62836070|NCT05747794|EXPERIMENTAL|open label lead-in (phase 2): eftilagimod alpha 90mg + paclitaxel|eftilagimod alpha 90mg s.c. + 80mg/m\^2 paclitaxel i.v. (same-day administration): The trial consists of a chemo-immunotherapy (chemo-IO) phase followed by an immunotherapy (IO)-phase. The chemo-IO phase consists of a planned 6 cycles of 4 weeks (28 days each) that may be longer or shorter depending on chemo tolerance. The IO-phase is planned to follow the chemo-IO phase. A maximum of 13 cycles (approx. 12 months) of treatment is planned.
62836071|NCT05747794|EXPERIMENTAL|Phase 3: eftilagimod alpha + paclitaxel|eftilagimod alpha s.c. (OBD) + 80mg/m\^2 paclitaxel i.v. (same-day administration): The trial consists of a chemo-immunotherapy (chemo-IO) phase followed by an immunotherapy (IO)-phase. The chemo-IO phase consists of a planned 6 cycles of 4 weeks (28 days each) that may be longer or shorter depending on chemo tolerance. The IO-phase is planned to follow the chemo-IO phase. A maximum of 13 cycles (approx. 12 months) of treatment is planned.
62836072|NCT05747794|PLACEBO_COMPARATOR|Phase 3: placebo + paclitaxel|placebo s.c. + 80mg/m\^2 paclitaxel i.v. (same-day administration): The trial consists of a chemo-immunotherapy (chemo-IO) phase followed by an immunotherapy (IO)-phase. The chemo-IO phase consists of a planned 6 cycles of 4 weeks (28 days each) that may be longer or shorter depending on chemo tolerance. The IO-phase is planned to follow the chemo-IO phase. A maximum of 13 cycles (approx. 12 months) of treatment is planned.
62836073|NCT03352037|OTHER|Single Arm|In this project, there is only one study group which comprises of patients with pancreatic cystic neoplasms who will undergo pancreatic PET/MRI.
62836074|NCT05652439||Fixed triple therapy BDP/FF/GB via DPI|COPD patients new users of fixed triple therapy BDP/FF/GB administered via DPI formulation according to local clinical practice
62836075|NCT05652439||Fixed triple therapy BDP/FF/GB via pMDI|COPD patients new users of fixed triple therapy BDP/FF/GB administered via pMDI formulation according to local clinical practice
62836076|NCT01140126|EXPERIMENTAL|Antibody (UB-421)|
62836077|NCT01164709|EXPERIMENTAL|bortezomib + nelfinavir|escalation 3 by 3 cohorts
62836078|NCT00541385|EXPERIMENTAL|PA group|"Oral pyronaridine/artesunate (PA, 60:20mg granules) once a day for 3 consecutive days (Days 0, 1, and 2).~Posology based on body weight ranges."
62053005|NCT04846088|EXPERIMENTAL|Product usage order GHFIEADBC|Subjects will use each of the 9 products (GHFIEADBC) during a familiarization period, followed by a 3 hour Test Session
62053006|NCT04846088|EXPERIMENTAL|Product usage order HIGAFBECD|Subjects will use each of the 9 products (HIGAFBECD) during a familiarization period, followed by a 3 hour Test Session
62053007|NCT04846088|EXPERIMENTAL|Product usage order IAHBGCFDE|Subjects will use each of the 9 products (IAHBGCFDE) during a familiarization period, followed by a 3 hour Test Session
62053008|NCT04846088|EXPERIMENTAL|Product usage order FEGDHCIBA|Subjects will use each of the 9 products (FEGDHCIBA) during a familiarization period, followed by a 3 hour Test Session
62254032|NCT05439486|ACTIVE_COMPARATOR|100% oxygen|ED patients in this group exposed to hyperbaric oxygen 100 % concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
62254033|NCT05439486|PLACEBO_COMPARATOR|ordinary room oxygen|ED patients in this group exposed to normal air oxygen concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
62254034|NCT01866384|OTHER|Normal Temperature|72 hours of Normal Temperature (36-37 degrees Celcius). Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
62612170|NCT01980498|EXPERIMENTAL|PecFent nasal spray|"Patients that have signed the ICF and met inclusion and exclusion criteria are randomly assigned 1:1 to receive one of the following IP-BTP treatments:~1. Fentanyl pectin nasal spray (FPNS)~2. Physician choice-Usual Care (PC-UC)"
62254035|NCT01866384|EXPERIMENTAL|Mild Induced Hypothermia|72 hours of mild induced hypothermia (32-34 degrees Celcius). Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
62254036|NCT05147272|EXPERIMENTAL|Phase 1 Dose Escalation|Multiple dose levels of RP-6306 and gemcitabine
62612171|NCT01980498|ACTIVE_COMPARATOR|Physician choice-Usual Care (PC-UC)|"Patients that have signed the ICF and met inclusion and exclusion criteria are randomly assigned 1:1 to receive one of the following IP-BTP treatments:~1. Fentanyl pectin nasal spray (FPNS)~2. Physician choice-Usual Care (PC-UC)"
62836079|NCT00541385|ACTIVE_COMPARATOR|AL group|"Oral artemether/lumefantrine (AL, 20:120mg crushed tablets) twice a day for 3 consecutive days (Days 0, 1, and 2).~Posology based on body weight ranges."
62442907|NCT01548781|ACTIVE_COMPARATOR|Abduction Loading|The intervention for the active comparison group entails practicing reaching utilizing the robotic device, ACT3D, with only abduction loading.
62612172|NCT00535392|EXPERIMENTAL|Levetiracetam|
62612173|NCT02816541|EXPERIMENTAL|Pelvis Retroverted|Pilates-based therapeutic exercises performed with a posterior pelvic tilt
62836080|NCT01792895|ACTIVE_COMPARATOR|Manipulation group|This Technique will be applied over four sessions, during two weeks
62836081|NCT01792895|ACTIVE_COMPARATOR|Mobilisation|This treatment will be applied on cervical spine during four sessions, over two weeks
62836082|NCT01792895|ACTIVE_COMPARATOR|Mobilization with movement|This Technique will be applied over four sessions, during two weeks
62836083|NCT04913077|OTHER|Removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)|FTRD (Ovesco company) in tumors up to 10 mm and predominantly intraluminal growth directly by sucking into the cap, at 10-20 mm and/or intramural/extramural growth by prior circumcision and lateral preparation, so that the lesions can be better pulled into the cap. The procedure depends on the endosonographic extent of the findings. The lesions are pulled into the cap with grippers and other instruments and, if necessary, with a snare and then resected with FTRD
62836084|NCT02941601|EXPERIMENTAL|Cohort 1: Necitumumab + Gemcitabine and Carboplatin|Predominately European sites. Gemcitabine administered intravenously (IV) and carboplatin IV plus necitumumab IV.
62836085|NCT02941601|EXPERIMENTAL|Cohort 2: Necitumumab + Gemcitabine and Carboplatin|Predominately United States sites. Gemcitabine administered IV and carboplatin IV plus necitumumab IV.
62442908|NCT05946083|ACTIVE_COMPARATOR|Binge Drinkers with Inulin Intervention|23 binge drinkers (\~50 % male and \~50 % female) will be given a daily dose of inulin.
62442909|NCT05946083|PLACEBO_COMPARATOR|Binge Drinkers with Maltodextrin Intervention|23 binge drinkers (\~50 % male and \~50 % female) will be given a daily dose of maltodextrin.
62442910|NCT05946083|NO_INTERVENTION|Non/Low-Drinkers|36 non/low-drinkers will not be given any dietary fiber.
62612174|NCT02816541|EXPERIMENTAL|Pelvis in Neutral Position|Pilates-based therapeutic exercises performed with a neutral position of the pelvis
62254037|NCT01753128|ACTIVE_COMPARATOR|imipramine|
62254038|NCT04521023|EXPERIMENTAL|A|
62254039|NCT04521023|ACTIVE_COMPARATOR|B|
62254040|NCT04350385|EXPERIMENTAL|Group 1|Agility Training
62254041|NCT04350385|ACTIVE_COMPARATOR|Group 2|.Conventional intervention
62442911|NCT03118739|EXPERIMENTAL|Verinurad 9 mg+Febuxostat 80 mg|Capsule administered orally, once daily for 24 weeks
62442912|NCT03118739|PLACEBO_COMPARATOR|Placebo|Capsule administered orally, once daily for 24 weeks
62442913|NCT01415921|EXPERIMENTAL|Pyridostigmine Bromide|Forced titration protocol 15-60 mg every 8 hours as tolerated
62442914|NCT01415921|PLACEBO_COMPARATOR|Placebo|Matching placebo forced titration 15-60 mg as tolerated
62442915|NCT00322556|EXPERIMENTAL|IgPro10|See Intervention Description
62612175|NCT02816541|ACTIVE_COMPARATOR|Control Group|Aerobic exercise performed on a treadmill
62612176|NCT01025648|EXPERIMENTAL|T1 - E004 90 mcg/actuation|T1 - E004 (epinephrine inhalation aerosol) 90 mcg/actuation - treatment by 2 actuations of E004 at 90 mcg/actuation
62612177|NCT01025648|EXPERIMENTAL|T2 - E004 125 mcg/actuation|E004 (epinephrine inhalation aerosol), 125 mcg, 2 actuations
62612178|NCT01025648|EXPERIMENTAL|T3 - 160 mcg/actuation|E004 (epinephrine inhalation aerosol), 160 mcg - E004 (epinephrine inhalation aerosol), 160 mcg/ actuation, 2 actuations
62836086|NCT04030910|EXPERIMENTAL|'LIFEView' intervention|"The 'LIFEView' session(s) involves the use of audiovisual software by Motitech AS (technology provided by and used with permission from Motitech AS). For its primary uses as Motiview, the audiovisual software was coupled to a mobile user-adapted cycle-trainer. Since a secondary benefit of the virtual cycle trip may include reminiscence which may in-turn facilitate conversation of past experiences, the audiovisual software is being adapted for use in reminiscence therapy for a palliative care population.~As there is an extensive library available to participants and 'LIFEView' sessions could potentially be longer than feasible for research personnel to conduct, each 'LIFEView' session will be limited to up to 3 videos per session or up to 1 hour of videos per session, whichever is a shorter duration. Additional post-study 'LIFEView' sessions can be provided upon request from participants."
62836087|NCT00560352|EXPERIMENTAL|Dasatinib + Bortezomib + Dexamethasone|Phase I dose escalation study
62836088|NCT05298956|SHAM_COMPARATOR|Sham|Participants will receive sham laser to the right forehead.
62836089|NCT05298956|ACTIVE_COMPARATOR|Transcranial infrared laser stimulation|Participants will receive transcranial infrared laser stimulation to the right forehead.
62836090|NCT05105204||Individuals need intra-arterial catheter at the radial artery for blood pressure monitoring|Individuals who requiring the use of intra-arterial catheter at the radial artery for continuous blood pressure monitoring for at least two hours as part of their planned care.
62836091|NCT01699438|EXPERIMENTAL|Mesalazine|
62836092|NCT01699438|PLACEBO_COMPARATOR|Placebo|
62836093|NCT01921309|EXPERIMENTAL|Trinity CoC Total Hip System|total hip replacement with a ceramic femoral head and ceramic acetabular cup liner
62836094|NCT01921309|ACTIVE_COMPARATOR|Trinity Ceramic-on-Poly THR|total hip replacement with a ceramic femoral head and polyethylene acetabular cup liner
62836095|NCT00929695|EXPERIMENTAL|Arm I (Low-dose)|Patients receive low-dose prednisone or methylprednisolone once or twice daily in the absence of disease progression or unacceptable toxicity.
62836096|NCT00929695|ACTIVE_COMPARATOR|Arm II (Standard-dose)|Patients receive standard-dose prednisone or methylprednisolone once or twice daily in the absence of disease progression or unacceptable toxicity.
62836097|NCT00460083|ACTIVE_COMPARATOR|Elidel(r)|
62836098|NCT00460083|EXPERIMENTAL|Epiceram(r)|
62836099|NCT02765516|ACTIVE_COMPARATOR|Plant sterols|
62836100|NCT02765516|PLACEBO_COMPARATOR|Placebo|
62836101|NCT00555516|ACTIVE_COMPARATOR|1|"1. The chemotherapy regimen of group 1 is restricted to AC or CAF during the first cycle~2. Group 1 will receive EW02 for 15 consecutive days during the second cycle~3. will receive EW02 at 700mg tid/day for 15 consecutive days during the third cycle."
62836102|NCT00555516|PLACEBO_COMPARATOR|2|"1. The chemotherapy regimen of group 2 is restricted to AC or CAF during the first cycle~2. Group 2 will receive 15 consecutive days of Placebo~3. Group 2 will receive EW02 at 700mg tid/day for 15 consecutive days during the third cycle"
62836103|NCT02327832|EXPERIMENTAL|Autologous BMSCs|Infusion of cultured autologous bone marrow derived mesenchymal stem cells
62836104|NCT02851472|EXPERIMENTAL|Inhaled Nitric Oxide|iNO will be given at 20 ppm, continuous, via inhalation before (1 hour), during (3 hours) and after (2 hours) elective blood transfusion and NIRS monitoring
62053009|NCT04846088|EXPERIMENTAL|Product usage order GFHEIDACB|Subjects will use each of the 9 products (GFHEIDACB) during a familiarization period, followed by a 3 hour Test Session
62254042|NCT05207995|EXPERIMENTAL|Patients with Type 1 Diabetes Mellitus receiving standard treatment and Tolerogenic Dendritic Cells|Group 1: Patients with Type 1 Diabetes Mellitus receiving standard treatment and Tolerogenic Dendritic Cells
62836105|NCT02851472|ACTIVE_COMPARATOR|Placebo|Placebo gas (nitrogen) will be given continuous, via inhalation at the same ppm, before (1 hour), during (3 hours) and after (2 hours) elective blood transfusion and NIRS monitoring
62836106|NCT05384652||subjects with NASH|
62836107|NCT05384652||subjects with simple steatosis|
62836108|NCT05384652||healthy subjects|
62836109|NCT01850654|OTHER|Probands|Participants with colorectal or endometrial cancer.
62836110|NCT01850654|OTHER|First-degree relatives of the participants with CRC|The first-degree relatives of the CRC probands (participants with colorectal cancer).
62836111|NCT01850654|OTHER|At-risk relatives|The relatives of the participants found to have Lynch syndrome.
62836112|NCT01635153|ACTIVE_COMPARATOR|Protein calorie supplement plus micronutrient|
62836113|NCT01635153|PLACEBO_COMPARATOR|Micronutrient alone|
62836114|NCT05744817|NO_INTERVENTION|Control|30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 5 days/week, for 6 weeks, then no exercise for 12 weeks
62836115|NCT05744817|EXPERIMENTAL|IMST 1 day/week|30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 5 days/week, for 6 weeks, then 30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 1 day/week, for 12 weeks.
62836116|NCT05744817|EXPERIMENTAL|IMST 3 days/week|30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 5 days/week, for 6 weeks, then 30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 3 days/week, for 12 weeks.
62836117|NCT05788159|EXPERIMENTAL|Lacosamide extended release tablets|Test preparation (T): Lacosamide extended release tablets Specification: 100mg/tablet Lot number: 22121301 Content: 100mg/tablet Expiration date: December 12, 2024 Storage conditions: Store at 20℃\~25℃, short-term can be at 15C\~30℃ Manufacturer: Overseas Pharmaceutical,Ltd.
62053010|NCT04846088|EXPERIMENTAL|Product usage order HGIFAEBDC|Subjects will use each of the 9 products (HGIFAEBDC) during a familiarization period, followed by a 3 hour Test Session
62053011|NCT04846088|EXPERIMENTAL|Product usage order IHAGBFCED|Subjects will use each of the 9 products (IHAGBFCED) during a familiarization period, followed by a 3 hour Test Session
62053012|NCT04846088|EXPERIMENTAL|Product usage order AIBHCGDFE|Subjects will use each of the 9 products (AIBHCGDFE) during a familiarization period, followed by a 3 hour Test Session
62053013|NCT04846088|EXPERIMENTAL|Product usage order BACIDHEGF|Subjects will use each of the 9 products (BACIDHEGF) during a familiarization period, followed by a 3 hour Test Session
62254043|NCT05207995|ACTIVE_COMPARATOR|Patients with Type 1 Diabetes Mellitus receiving standard treatment|Group 2: Patients with Type 1 Diabetes Mellitus receiving standard treatment
62254044|NCT04404998|EXPERIMENTAL|Lower Energy Density & Lower Satiation|Test meal with lower energy density and lower satiation information
62053014|NCT04846088|EXPERIMENTAL|Product usage order CBDAEIFHG|Subjects will use each of the 9 products (CBDAEIFHG) during a familiarization period, followed by a 3 hour Test Session
62254045|NCT04404998|EXPERIMENTAL|Lower Energy Density & Higher Satiation|Test meal with lower energy density and higher satiation information
62612179|NCT01025648|EXPERIMENTAL|T4 - 220 mcg/actuation|E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations
62612180|NCT01025648|ACTIVE_COMPARATOR|A - Active control|epinephrine inhalation aerosol, CFC propelled 220 mcg Epinephrine Inhalation Aerosol, CFC-MDI, 2 actuations
62612181|NCT01025648|PLACEBO_COMPARATOR|P, Placebo HFA|E004 placebo single treatment with 2 inhalations
62612182|NCT01832909|EXPERIMENTAL|Walnut Diet first, then Control Diet|Controlled diet with 1.5 oz/d of walnuts, followed by controlled diet without walnuts.
62442916|NCT03253978|EXPERIMENTAL|SABR to prostate / seminal vesicles with pelvic ENI|36.25Gy / 5 fractions to prostate and seminal vesicles with additional SABR (25Gy /5 fractions) delivered to the pelvic nodes.
62612183|NCT01832909|EXPERIMENTAL|Control Diet first, then Walnut Diet|Controlled diet without almonds first (control), then controlled diet with 1.5 oz/d of almonds.
62612184|NCT00507832|ACTIVE_COMPARATOR|I|"Interindividual design:~active and comparator (one side each) applied twice daily"
62612185|NCT00507832|ACTIVE_COMPARATOR|II Hydrocortisone|Hydrocortisone, twice daily
62612186|NCT00494221|ACTIVE_COMPARATOR|FOLFOX + Cediranib 20 mg|FOLFOX + Cediranib 20 mg
62836118|NCT05788159|ACTIVE_COMPARATOR|Lacosamide Tablets|Reference preparation (R): Lacosamide Tablets Specification: 50mg/tablet Lot No.: 7883201 Content: 50mg/tablet Expiration date: September 2026 Storage condition: not more than 30C in airtight storage Manufacturer: Aesica Pharmaceuticals GmbH
62254046|NCT04404998|EXPERIMENTAL|Higher Energy Density & Lower Satiation|Test meal with higher energy density and lower satiation information
62442917|NCT03253978|ACTIVE_COMPARATOR|SABR to prostate and seminal vesicles only|36.25Gy / 5 fractions to prostate and seminal vesicles.
62612187|NCT00494221|ACTIVE_COMPARATOR|FOLFOX + Cediranib 30 mg|FOLFOX + Cediranib 30 mg
62612188|NCT00494221|PLACEBO_COMPARATOR|FOLFOX + Placebo Cediranib|FOLFOX + Placebo Cediranib
62612189|NCT01366638|EXPERIMENTAL|Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks), followed by PR until Week 24 or Week 48. Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \<1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
62612190|NCT01366638|EXPERIMENTAL|Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \<1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
62612191|NCT01366638|EXPERIMENTAL|Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.
62612192|NCT03595267||Rural and Remote Indigenous Communities|Point-of-care screening for Chronic Kidney Disease, Diabetes, and Hypertension will be administered in rural and remote communities in Manitoba, British Columbia, Alberta, Saskatchewan, and Ontario.
62612193|NCT05506514|EXPERIMENTAL|Hot|1h per day of water immersion at 42ºC for 11 days
62612194|NCT05506514|SHAM_COMPARATOR|Temperate|30min per day of water immersion at 32ºC for 11 days
62612195|NCT05506514|EXPERIMENTAL|Cold|15min per day of water immersion at 15ºC for 11 days
62836119|NCT00624182|EXPERIMENTAL|Phase I study|
62836120|NCT04342533|EXPERIMENTAL|ThuFLEP|Patients who underwent thulium fiber enucleation of the prostate
62836121|NCT04342533|ACTIVE_COMPARATOR|HoLEP|Patients who underwent holmium laser enucleation of the prostate
62836122|NCT02757508|ACTIVE_COMPARATOR|Control|Vitamins/minerals-200 mg premix
62836123|NCT02757508|EXPERIMENTAL|Group 1|Vitamins/minerals + Milk Protein (8.75 g)-the milk protein is a skim milk powder with the sugar lactose.
62053015|NCT04846088|EXPERIMENTAL|Product usage order DCEBFAGIH|Subjects will use each of the 9 products (DCEBFAGIH) during a familiarization period, followed by a 3 hour Test Session
62053016|NCT04846088|EXPERIMENTAL|Product usage order EDFCGBHAI|Subjects will use each of the 9 products (EDFCGBHAI) during a familiarization period, followed by a 3 hour Test Session
62053017|NCT05306366|EXPERIMENTAL|[11C]-Lu AF90103|Participants will receive \[11C\]-Lu AF90103 via an intravenous bolus injection on Day 1.
62053018|NCT01818674|EXPERIMENTAL|Group A - Microclinic Behavioral Health Enhanced Program|Group A received the Microclinic Behavioral Health Full Program (structured social interactions + fully interactive classroom education curriculum; parallel clinical screenings)
62254047|NCT04404998|EXPERIMENTAL|Higher Energy Density & Higher Satiation|Test meal with higher energy density and higher satiation information
62254048|NCT03280875|EXPERIMENTAL|healthy volunteers|
62442918|NCT01886300||Cohort|
62442919|NCT02202018|EXPERIMENTAL|Active KT Intervention|CKD clinics receiving the active knowledge translation intervention.
62442920|NCT02202018|NO_INTERVENTION|Usual standard of care|Clinics will continue their standard of care education and approach to use of home dialysis.
62612196|NCT04627961|EXPERIMENTAL|Patient|Patients with EBER positive nasopharyngeal carcinoma with recurrent or metastatic disease
62612197|NCT06112795||Observational|Participants attend an interview or participate in a focus group on study.
62612198|NCT03246841|OTHER|Analysis of the gene panel|The laboratory will carry out the TUMOSPEC gene panel analysis at the same time as the BRCA1 and BRCA2 analysis and will return a negative (no mutation) or positive (presence of a mutation allowing enrolment of family members) result.
62612199|NCT06671938|EXPERIMENTAL|exidavnemab|exidavnemab (cohort 1 - dose 1; cohort 2 - dose 2)
62612200|NCT06671938|PLACEBO_COMPARATOR|Placebo|
62836124|NCT02757508|EXPERIMENTAL|Group 2|Vitamins/minerals + Milk/plant Protein (8.75g)-the milk protein is a skim milk protein powder and the plant protein is a rice protein concentrate and the sugar lactose.
62836125|NCT02757508|EXPERIMENTAL|Group 3|Vitamins/minerals + Milk Protein (4.38g)-the milk protein is a skim milk protein powder with the sugar lactose.
62836126|NCT01483261|EXPERIMENTAL|Trauma-Focused Cognitive Behavioral Therapy|
62836127|NCT01483261|NO_INTERVENTION|Waiting List Control|
62836128|NCT04955691|EXPERIMENTAL|low carbohydrate diet|In this crossover study, participants will be randomized to either a low or standard carbohydrate for 2 weeks. Participants in the low carbohydrate group will limit carbohydrate intake to 15% of total daily calories.
62836129|NCT04955691|ACTIVE_COMPARATOR|standard carbohydrate diet|In this crossover study, participants will be randomized to either a low or standard carbohydrate for 2 weeks. Participants in the standard carbohydrate group will follow an ad libitum diet with standard carbohydrate intake.
62254049|NCT04072289|EXPERIMENTAL|Low cylinder (treatment)|0.25D and 0.50D cylinder treatments will be measured and treated by the laser.
62254050|NCT04072289|NO_INTERVENTION|Low cylinder (no treatment)|0.25D and 0.50D cylinder treatments will be measured but not treated by the laser. No spherical equivalent will be used.
62442921|NCT06406647|ACTIVE_COMPARATOR|ketamine with bupicavaine|(bupivacaine+ ketamine): 40patients received 40 ml of bupivacaine 0.25%(in total 100mg)+1mg per Kg of ketamine)
62442922|NCT06406647|ACTIVE_COMPARATOR|bupicavacine (control group)|(Bupivacaine): 40patients received40 ml of bupivacaine 0.25%(in total 100 mg)+2 ml saline.
62836130|NCT02975375||Preoperative geriatric consult or assessment|Patients who have a geriatric assessment of consult billed in the 4 months before surgery
62836131|NCT02975375||No Preoperative geriatric consult or assessment|Patients who do not have a geriatric assessment of consult billed in the 4 months before surgery
62836132|NCT05097963|EXPERIMENTAL|Subjects undergoing EUS shear wave elastography|Subject who are eligible will undergo EUS for clinical indications. EUS shear wave measurements will be gathered and studied to determine diagnostic accuracy when compared to MR Elastography.
62053019|NCT01818674|EXPERIMENTAL|Group B - Microclinic Behavioral Health Basic Program|Group B received the Microclinic Behavioral Health Basic Program (no social structured interactions; basic classroom education; parallel clinical screenings)
62053020|NCT01818674|NO_INTERVENTION|Group C - Controls with Parallel Monitoring|Group C only received standard care, and only received parallel risk factor screening measurements; not participation in classroom or any social activities.
62053021|NCT00792896|EXPERIMENTAL|1|Family conference + education materials
62053022|NCT00792896|NO_INTERVENTION|2|education materials
62836133|NCT02955173|EXPERIMENTAL|Open surgery of rectal cancer|Patients undergoing rectal cancer resection in an open approach
62053023|NCT01148654||1- Preterm Labor 22.0-33.6 weeks gestational age|Pregnant women between 22.0 and 33.6 weeks gestational age presenting to the Hospital of the University of Pennsylvania (HUP) complaining of Preterm labor (PTL), preterm premature rupture of membranes (PPROM), or cervical insufficiency (CI).
62053024|NCT01148654||2- Preterm birth 34-36.6 weeks gestational age|Pregnant women delivering at the University of Pennsylvania between 34.0 and 36.6 weeks gestational age
62053025|NCT01691625|EXPERIMENTAL|concurrent chemoradiotherapy plus DC-CIK immunotherapy|patients will receive concurrent chemoradiotherapy plur DC-CIK immunotherapy
62053026|NCT01691625|ACTIVE_COMPARATOR|Concurrent chemoradiation only|patients will receive concurrent chemoradiotherapy only
62053027|NCT01174420|EXPERIMENTAL|ologen Collagen Matrix|
62053028|NCT01174420|ACTIVE_COMPARATOR|Mitomycin-C (MMC)|
62053029|NCT02862379|EXPERIMENTAL|Elderly patients that fall|Personalized rehabilitation program for elderly patients that fall for the first time. This intervention is a home-based program combining exercises, home modifications and education on fall risk factors.
62053030|NCT02280239|PLACEBO_COMPARATOR|Control Group|This group consists of stable but febrile ICU patients (temp \>38.3°C). Participants in this group will receive a one-time dose of placebo via the enteral route (via the gut), after which vital signs (including continuous measures of core temperature, heart rate, and blood pressure) will be monitored for 4 hours.
62053031|NCT02280239|EXPERIMENTAL|Acetaminophen Group|This group consists of stable but febrile ICU patients (temp \>38.3°C). Participants in this group will receive a one-time does of acetaminophen 650mg via the enteral route (via the gut), after which vital signs (including continuous measures of core temperature, heart rate, and blood pressure) will be monitored for 4 hours.
62836134|NCT02955173|EXPERIMENTAL|Laparoscopic surgery of rectal cancer|Patients undergoing rectal cancer resection in a laparoscopic approach
62836135|NCT02955173|EXPERIMENTAL|Open surgery of gastric cancer|Patients undergoing gastric cancer resection in an open approach
62836136|NCT02955173|EXPERIMENTAL|Laparoscopic surgery of gastric cancer|Patients undergoing gastric cancer resection in a laparoscopic approach
62836137|NCT01635504|EXPERIMENTAL|botulinum toxin A|
62836138|NCT02183649|EXPERIMENTAL|pentoxyverine citrate vs. placebo|All subjects were allocated to receive both verum and placebo in randomised order
62836139|NCT01267500|EXPERIMENTAL|Non-surgical therapy|patching or fusion exercises
62836140|NCT01560832||Laboratory (PCR)-confirmed C.difficile infection|patient who has experienced the passage of 3 or more unformed or loose stools \[diarrhea\] conforming to the shape of a container within a 24-hour period and has a positive laboratory test result confirmed by PCR.
62442923|NCT02924857|EXPERIMENTAL|Test Group (Chocolate Touch)|"* The diameter of the Chocolate Touch should correspond to the diameter of the vessel for treatment with a balloon to artery ratio of 1.1:1.~* The Chocolate Touch must be inflated to at least nominal pressure. Maintain balloon inflation for a minimum of 2 minutes. The balloon may be inflated as long as required to achieve optimal angioplasty outcome.~* If delivery is attempted and failed, a new Chocolate Touch should be used for subsequent attempts after pre-dilatation."
62612201|NCT00006341|EXPERIMENTAL|Implant|A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
62836141|NCT04295447|OTHER|Standard of care|"1. Observation only or~2. An optional adjuvant radiation of the prostate bed in case of positive surgical margin"
62836142|NCT04295447|EXPERIMENTAL|Apalutamide|30 cycles apalutamide 240 mg (4 x 60 mg) once daily on days 1-28 of a 28-day cycle in addition to standard of care
62836143|NCT03418714|EXPERIMENTAL|Salvinorin A administration|All volunteers will be assigned to the salvinorin A administration arm.
62836144|NCT04477096|OTHER|single arm for each part: two arms|"PART1:In the first period, HS-10234 will be administered at 25 mg QD for 7 days. In the second period, HS-10234 at 25 mg in combination with Emtricitabine at 200 mg will be administered QD for 7 days.~PART2:In the first period, Emtricitabine will be administered at 200 mg QD for 7 days. In the second period, HS-10234 at 25 mg in combination with Emtricitabine at 200 mg will be administered QD for 7 days."
62053032|NCT03953963|EXPERIMENTAL|Intra-Abdominal Mesenteric Fat Extraction Group|All enrolled patients will undergo the combined minimally invasive laparoscopic and mini-laparotomy procedure to selectively extract excess intra-abdominal fat from the mesentery.
62053033|NCT03168568|EXPERIMENTAL|Valsartan/Sacubitril|Valsartan-Sacubitril 50mg/100mg twice daily, titrated to 200mg twice daily p.o. Duration of product administration: 3 months
62442924|NCT02924857|ACTIVE_COMPARATOR|Control Group (Lutonix Drug Coated Balloon)|"* Never inflate the Lutonix® Drug Coated Balloon (DCB)prior to reaching the target lesion.~* The Lutonix® Catheter should be advanced to the target site as fast as possible (i.e. 30 seconds) and immediately inflated to appropriate pressure to ensure full wall apposition (balloon to artery ratio of \>1:1).~* If the deployment of the Lutonix® Catheter exceeds 3 minutes, the catheter requires placement with a new unit.~* Maintain balloon inflation for a minimum of 2 minutes (120 seconds). The balloon may be inflated as long as required by standard of care to achieve a good angioplasty outcome."
62442925|NCT04124861|EXPERIMENTAL|Drug free|"Arm A: Drug free Glucocorticoid（GC）is tapered and stopped in 8 weeks(GCs at a dose of ≤ 2.5 mg of prednisone or equivalent for treatment of adrenal insufficiency) .~Immunosuppressant is also tapered and discontinues in 8 weeks."
62442926|NCT04124861|EXPERIMENTAL|IS monotherapy|Arm B: Immunosuppressant only Glucocorticoid（GC）is tapered and stopped in 8 weeks. The same type and dosage of immunosuppressive agent before admission, including Mycophenolate mate(\<= 1g/d) or Leflunomide (\<=20mg/d) or Methotrexate (\<=15mg/w) or Azathioprine (\<=100mg/d)
62442927|NCT04124861|EXPERIMENTAL|GC combined with IS|Arm C: GC+Immunosuppressant Both Glucocorticoid(GC) (no more than 7.5mg/d) and immunosuppressant are kept as maintaining dose.
62442928|NCT04089683||Doctors|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
62442929|NCT04089683||Nurses|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
62442930|NCT04089683||OT Technicians|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
62442931|NCT04089683||House keeping staff and cleaners|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
62442932|NCT01853306|EXPERIMENTAL|Veliparib formulation A|veliparib formulation A
62442933|NCT01853306|EXPERIMENTAL|Veliparib formulation B|Veliparib formulation B
62442934|NCT01853306|EXPERIMENTAL|Veliparib formulation C|veliparib formulation C
62442935|NCT01547039||Carotid endarterectomy (CEA)|Patients undergoing carotid endarterectomy
62836145|NCT04187781|OTHER|external microphone old|
62053034|NCT03168568|ACTIVE_COMPARATOR|Valsartan|Valsartan 40mg/80mg twice daily, titrated to 160mg twice daily p.o Duration of product administration: 3 months
62442936|NCT01830920|PLACEBO_COMPARATOR|Placebo|An identical appearing placebo will be administered.
62442937|NCT01830920|EXPERIMENTAL|THR-184 Dose 1|THR-184 initial pre-surgery low dose followed by (3) post surgery doses at the low dose.
62442938|NCT01830920|EXPERIMENTAL|THR-184 Dose 2|THR-184 initial pre-surgery mid-dose followed by (3) post surgery doses at the low dose.
62442939|NCT01830920|EXPERIMENTAL|THR-184 Dose 3|THR-184 initial pre-surgery high dose followed by (3) post surgery doses at the low dose.
62442940|NCT01830920|EXPERIMENTAL|THR-184 Dose 4|THR-184 initial pre-surgery high dose followed by (3) post surgery doses \~80% of the pre-surgery dose.
62442941|NCT02233790|EXPERIMENTAL|Ticagrelor|
62442942|NCT02233790|ACTIVE_COMPARATOR|Clopidogrel|
62442943|NCT04289727||Group 1|Those with Type 1 Diabetes.
62836146|NCT04187781|OTHER|external microphone new|
62836147|NCT06069375|EXPERIMENTAL|3.0 g/m2/day QD sodium phenylbutyrate|Up to 8 subjects (4 - ages 10-15 years old and 4 - 16 years of age and older) will be randomized to take 3.0 g/m2/day in one daily dose
62836148|NCT06069375|EXPERIMENTAL|3.0 g/m2/day BID sodium phenylbutyrate|Up to 8 subjects (4 - ages 10-15 years old and 4 - 16 years of age and older) will be randomized to take 3.0 g/m2/day divided into two daily doses taken 12 hours apart
62836149|NCT06069375|EXPERIMENTAL|4.0 g/m2/day BID sodium phenylbutyrate|Up to 8 subjects (4 - ages 10-15 years old and 4 - 16 years of age and older) will be randomized to take 4.0 g/m2/day divided into two daily doses taken 12 hours apart
62836150|NCT02283827|EXPERIMENTAL|Group A BIA 2-093 + Phenytoin (PHT)|Day 1 to 2: Pre-treatment 1: 600 mg ESL Day 3 to 8: Treatment 1: 1200 mg ESL Day 9 to 10: Treatment 1 + Pre-treatment 2: 1200 mg ESL+ 100 mg PHT Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + 300 mg PHT
62612202|NCT00889187|EXPERIMENTAL|Phase 1 Cohort 1: Photon Rad (30 Gy/12 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~At dose level 1, a total dose of 30 Gy in 10 fractions (3 Gy/day) was prescribed to the 95% isodose and administered 5 days per week over 12 days.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
62836151|NCT02283827|EXPERIMENTAL|Group B BIA 2-093 + Phenytoin (PHT)|Day 1 to 2: Pre-treatment 2: 100 mg PHT Day 3 to 8: Treatment 2: 300 mg PHT Day 9 to 10: Treatment 2 + Pre-treatment 1: 300 mg PHT + 600 mg ESL Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + 300 mg PHT
62836152|NCT02592590|EXPERIMENTAL|Group A|
62442944|NCT04289727||Group 2|Those without Type 1 Diabetes.
62442945|NCT06417996|NO_INTERVENTION|Control Group|The control group will not be monitored with continuity of care.
62442946|NCT06417996|EXPERIMENTAL|Digital Group|At the time of hospital discharge, the control group will be discharged without receipt of home monitoring, and the intervention group will receive a home monitoring kit with (NIBP (non-invasive blood pressure) and SPO2 (pulse oximetry) with instructions on how to use these devices. Patients in the intervention groups will receive digital communication for four weeks and have their NIBP, HR (heart rate), SPO2 and pain scores evaluated twice a day for two weeks.
62442947|NCT03440203||no Diabetic neuropathy|
62442948|NCT03440203||Diabetic peripheral neuropathy|
62836153|NCT02592590|EXPERIMENTAL|Group B|
62836154|NCT02592590|EXPERIMENTAL|Group C|
62836155|NCT02592590|ACTIVE_COMPARATOR|Group D|
62836156|NCT01173367|ACTIVE_COMPARATOR|Aggressive Fever Treatment|
62836157|NCT01173367|ACTIVE_COMPARATOR|Permissive Fever Treatment|
62836158|NCT01838096|EXPERIMENTAL|THA|
62442949|NCT03440203||Diabetic peripheral neuropathic pain|
62442950|NCT06170814||external odak|Exercise will be done for approximately 40 minutes, 3 days a week for 6 weeks. Ramps, obstacle jumping, stairs and tracks will be built to improve walking and balance functions. During exercises, attention is directed to movement and an environmental stimulus in the external focus of attention.
62836159|NCT03181932|EXPERIMENTAL|Double-blind vancomycin inhalation powder|Vancomycin inhalation powder 30 mg is administered twice daily (BID) during the 24-week double-blind period (Period 1) by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
62836160|NCT03181932|PLACEBO_COMPARATOR|Double-blind placebo inhalation powder|Matching placebo is administered BID during the 24-week double-blind period (Period 1) by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
62053035|NCT06362980|EXPERIMENTAL|BPI-1178 plus Osimertinib treatment|Patients will undergo treatment with a combination of BPI-1178 capsules and osimertinib tablets. Patients will orally receive a single dose of BPI-1178 (200 or 300 mg) capsules and osimertinib tablets (80 mg). After a 7-day washout period, continuous dosing will commence on the 8th day. During the continuous dosing phase, BPI-1178 capsules and osimertinib tablets will be administered once daily, with a treatment cycle consisting of 28 days.
62442951|NCT06170814||internal focus|Exercise will be done for approximately 40 minutes, 3 days a week for 6 weeks. Ramps, obstacle jumping, stairs, and tracks will be built to improve walking and balance functions. In internal focus during exercises, attention is directed directly to body movements.
62442952|NCT05861609|ACTIVE_COMPARATOR|No pain medication tapering (usual care)|Usual care
62836161|NCT03181932|EXPERIMENTAL|Open-label vancomycin inhalation powder|In the 24-week Period 2, all participants receive AeroVanc 30 mg BID by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
62836162|NCT03387397||Lower Medications (LM) cohort|Patients will be assigned to the Lower Medications (LM) cohort group (N=85) if they received a drug regimen of less than five different medications/day during the study period.
62836163|NCT03387397||Higher Medications (HM) cohort|Patients will be assigned to the Higher Medications (HM) cohort group (N=85) if they received a drug regimen of more than 5 different chronic medications/day during the study period.
62442953|NCT05861609|ACTIVE_COMPARATOR|Standardized pain medication tapering|Standardized pain medication tapering
62442954|NCT05861609|ACTIVE_COMPARATOR|Personalized pain medication tapering|Personalized pain medication tapering
62836164|NCT05513781||Chronic stroke patients with knee hyperextension|
62836165|NCT06029829|EXPERIMENTAL|Immunomonotherapy plus Chemotherapy plus Anti-angiogenesis Therapy|Any first-line treatment that includes immunotherapy、 Chemotherapy and Anti-angiogenesis Therapy
62836166|NCT03770767|EXPERIMENTAL|Intervention with insulin Fiasp|Women randomized to insulin Fiasp
62836167|NCT03770767|ACTIVE_COMPARATOR|Control (insulin Novorapid)|Women randomized to insulin NovoRapid
62836168|NCT00256568||Primary Care Practices|One hundred and three prescribers, managers, nurses and office staff at seven primary care practices in Vermont
62836169|NCT00905866||Quality of life|All participants undergoing parathyroidectomy
62836170|NCT05682196|EXPERIMENTAL|Rituximab plus standard of care (RTX)|Rituximab i.v of two perfusions (375 mg/m²) administered in a 14 day-interval added to a standard of care treatment
62836171|NCT05682196|ACTIVE_COMPARATOR|Standard of care treatment (Control)|Standard of care treatment
62836172|NCT03004937|EXPERIMENTAL|Single-Arm, Non-Randomized, Stepped Wedge|All patients who meet the inclusion criteria will receive the same intervention.
62836173|NCT02027441||Home-based Testing|"At enrollment, consenting index participants will provide the study staff with locator information and a complete list of individuals currently living in his/her home who may be eligible for home-based HIV testing intervention (Household Composition form).~The study staff and index participant will schedule a date/time for the study staffto visit the index participant's home. Study staff will also provide the index participant with an information sheet to give to household members.~A study testing team comprised of trained counselors and interviewers will visit the index participant's home on the pre-determined date/time and offer home-based HIV testing to those household members who are present."
62442955|NCT05585463||Oncology pediatric patients treated with acupuncture|"Patients in the oncology area of the Sant Joan de Déu Hospital treated at the UOPI (Integrative Pediatric Oncology Unit) from September 2019 to September 2021 have received treatment with acupuncture and intracutaneous Seirin New Pyonex Press Tack®.~Patients in active treatment and survivors are included. Acupuncture treatment can be received in a hospitalization ward, an intensive care unit, a day hospital or an outpatient clinic."
62442956|NCT04843085||O1|the more aggressive subgroup of oligodendroglioma samples of 30 patients
62836174|NCT03366077|ACTIVE_COMPARATOR|Active|L reuteri
62836175|NCT03366077|PLACEBO_COMPARATOR|Placebo|Placebo
62836176|NCT03449290|EXPERIMENTAL|Kinesio taping group|Kinesio taping was applied on trunk muscles
62836177|NCT03449290|SHAM_COMPARATOR|Control group|Sham Kinesio taping was applied on trunk muscles
62836178|NCT01976091|EXPERIMENTAL|Cohort 1A: SRP-9004 Low Dose (Single Limb Perfusion)|Non-ambulant participants with LGMD2D will receive 1 low dose of SRP-9004 via ILI to a single limb on Day 0.
62836179|NCT01976091|EXPERIMENTAL|Cohort 1B Low Dose (Bilateral Limb Perfusion)|Participants with LGMD2D will receive 1 low dose of SRP-9004 via ILI to both limbs on Day 0.
62836180|NCT01976091|EXPERIMENTAL|Cohort 2 High Dose (Bilateral Limb Perfusion)|Participants with LGMD2D will receive 1 high dose of SRP-9004 via ILI to both limbs on Day 0.
62836181|NCT01981382||Incident cases|Persistent nonspecific low back pain
62836182|NCT01981382||Controls|Acute low back pain that resolves in \<6 months
62836183|NCT01755182|ACTIVE_COMPARATOR|Pharmacologic therapy|Patients in this arm receive systemic pharmacologic therapy alone
62836184|NCT01755182|EXPERIMENTAL|TAE and pharmacologic therapy|Patients in this arm receive systemic pharmacologic therapy and TAE
62836185|NCT01065987|EXPERIMENTAL|Tizanidine HCl 4 mg|Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited
62836186|NCT01065987|ACTIVE_COMPARATOR|Zanaflex|Zanaflex 4 mg Tablets
62836187|NCT02178345||Surgical patients|The patients will undergo DW-MRI and (if patient is eligible and agrees) DCE-MRI study prior to surgery. The maximum time interval allowed between the MRI study and surgery will be six months.
62836188|NCT02178345||surveillance management patients|The patients will undergo DW-MRI and (if patient is eligible and agrees) DCE-MRI study while being on active surveillance.These patients can also receive the same DW and DCE MRI as a followup a year after the first.
62442957|NCT04843085||O2|subgroup 2 of oligodendroglioma samples of 30 patients
62442958|NCT04843085||O3|subgroup 3 of oligodendroglioma samples of 30 patients
62442959|NCT04843085||IDH-mutant astrocytomas|patients with IDH-mutant astrocytomas, samples of 15 patients
62442960|NCT04843085||IDH-wildtype glioblastomas|patients with IDH-wildtype glioblastomas, samples of 15 patients
62442961|NCT06379074|EXPERIMENTAL|Subgroup B2: CBT-I derived intervention|CBT-I derived intervention: 6 weekly online sessions with psychoeducation on sleep adapted to pregnancy, introduction of CBT-I techniques, discussion of sleep diaries and of acquired skills.
62612203|NCT00889187|EXPERIMENTAL|Phase I Cohort 2: Photon Rad (25 Gy/11 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~At dose level 2, a total dose of 25 Gy in 5 fractions was prescribed to the 95% isodose and administered at 5 Gy per fraction over 11 days.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
62612204|NCT00889187|EXPERIMENTAL|Phase I Cohort 3: Photon Rad (25 Gy/5 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~At dose level 3, a total dose of 25 Gy in 5 fractions was prescribed to the 95% isodose and administered at 5 Gy per fraction over 5 days.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
62612205|NCT00889187|EXPERIMENTAL|All Phase I: Photon Rad+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~All Phase I participants received the radiation regimen according to the established dose escalation schedule.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
62612206|NCT00889187|EXPERIMENTAL|Phase II: Photon Rad (MTD)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~Phase II participants received the radiation regimen established in the Phase I study (MTD).~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
62612207|NCT05461937|EXPERIMENTAL|'Getting things done after stroke' - an online executive function intervention|
62612208|NCT05461937|ACTIVE_COMPARATOR|Stroke psychoeducation|
62612209|NCT02629432||Cosyconet COPD Cohort|MRI and CT of the lung will be performed in a multi-centre cohort of 625 COPD-patients from the main COSYCONET cohort.
62612210|NCT03061240|EXPERIMENTAL|Postoperative patients|We recruit postoperative patients who undergo open surgery and are not receiving local anesthesia. We install a smart pain assessment tool on patient's skin to capture different type of data.
62612211|NCT05717803|EXPERIMENTAL|Segmentectomy|Segmentectomy is performed for ground glass-dominant invasive lung cancer with size of 2-3cm.
62612212|NCT05999656|EXPERIMENTAL|human cord blood-derived mononuclear cells (HCB-MNCs)|About 1×10\^8 of HCB-MNCs were injected 3 times at a week interval for each participant.
62612213|NCT02253550|EXPERIMENTAL|Cirrhosis|Patients with confirmed presence of cirrhosis will received 12 weeks of treatment with Sofosbuvir and Simeprevir
62612214|NCT02253550|EXPERIMENTAL|Non-Cirrhotic|Patients with confirmed absence of cirrhosis will received 8 weeks of treatment with Sofosbuvir and Simeprevir
62612215|NCT01054391|EXPERIMENTAL|NEC Arm|Utilization of NEC (Neurovascular Embolization Cover) for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistulae
62442962|NCT06379074|PLACEBO_COMPARATOR|Subgroup B1: psychological placebo intervention|Psychoeducation placebo control intervention: 6 weekly online sessions composed of educational videos (ca. 20 minutes) on aspects related to pregnancy and sleep.
62442963|NCT06379074|NO_INTERVENTION|Group A: control group|A control group of healthy pregnant women with no insomnia complaints (ISI \< 8) will be followed parallel to the intervention and control group, from the first trimester of pregnancy to 6 months post-partum to assess changes in sleep and psychological indices in pregnancy.
62442964|NCT02837510|OTHER|Standard smoking cessation counseling|Participants will receive a standard treatment program consisting of smoking cessation counseling.
62442965|NCT00670475|ACTIVE_COMPARATOR|P (Pircoxicam Group)|in this arm 100 patients with osteoarthritis of knee will receive piroxicam gel in blinded 60 grams tubes,they will be instructed to use 1 gram of piroxicam gel (with inserted dispensing device) three times in a day on the affected knee.
62612216|NCT01287975|ACTIVE_COMPARATOR|Standard Occupational Therapy|Standard Occupational Therapy for Wrist and Hand Training
62612217|NCT01287975|EXPERIMENTAL|BCI Haptic Knob|BCI controlled robotic-assisted training for wrist and hand
62612218|NCT01287975|EXPERIMENTAL|Haptic Knob|Robotic-assisted training for wrist and hand
62612219|NCT04633902|EXPERIMENTAL|Olaparib + Pembrolizumab|This arm will enroll patients who has advanced melanoma with a genetic HR mutation/ alteration including mutation/ deletion in ARID1A/B, ARID2, ATM, ATR, BARD1, BRCA1/2, BAP1, BRIP1, CHEK2, FANCA, FANCD2, MRN11A, PALB2, RAD50, RAD51, RAD54B.
62612220|NCT04720950|EXPERIMENTAL|Morning exercise|1 hour of exercise completed between 0800-1000
62442966|NCT00670475|EXPERIMENTAL|O (olive oil group)|in this arm 100 patients with osteoarthritis of knee will receive virgin olive oil in blinded 60 grams tubes,they will be instructed to use 1 gram of olive oil (with inserted dispensing device) three times in a day on the affected knee.
62442967|NCT00290745|EXPERIMENTAL|tamoxifen or letrozole|tamoxifen or letrozole work in treating women with ductal carcinoma in situ
62442968|NCT04368585|EXPERIMENTAL|TBPM-PI-HBr Alone (Period 1)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally alone.
62442969|NCT04368585|EXPERIMENTAL|TBPM-PI-HBr and Antacid (Period 2)|20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension will be coadministered with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr at Hour 0 on Day 1.
62442970|NCT04368585|EXPERIMENTAL|TBPM-PI-HBr and Omeprazole (Period 3)|40 mg (1 x 40 mg capsule) omeprazole administered QD at Hour -2 on Days 1 through 5, with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr administered at Hour 0 on Day 5.
62442971|NCT00798889|EXPERIMENTAL|Sunitinib|
62612221|NCT04720950|EXPERIMENTAL|Evening exercise|1 hour of exercise completed between 1800-2000
62254051|NCT04041986|EXPERIMENTAL|Site-Finding|Each subject will receive anodal, cathodal, and sham stimulation to both the ipsilesional and contralesional hemispheres in a series of six sessions (one condition per session), each separated by at least two days. During anodal and cathodal tDCS sessions, subjects will receive stimulation for 20 minutes with a current of 2.0 mA using a 5x5 cm electrode. During sham tDCS, a 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. The participant will complete pre/post language testing at each session in order to determine if the subject is a tDCS responder and if so, which site produces the best transient language improvement in that individual. Subjects who do not respond to tDCS will not be invited to move forward to the treatment phase.
62254052|NCT04041986|ACTIVE_COMPARATOR|Real tDCS|Half of our tDCS responders will be randomized to a group receiving 10 sessions (divided in to two five-day periods) of real tDCS. During real tDCS sessions, subjects will receive stimulation for 20 minutes at a current of 2.0 mA with a 5x5 cm electrode at their optimal responder site previously determined.
62612222|NCT02862132|EXPERIMENTAL|Vedolizumab|IV Vedolizumab 177mg/m2 Body Surface Area (BSA), max. 300mg Induction regimen: 0,2,6 and then every 8 weeks
62612223|NCT04902729|ACTIVE_COMPARATOR|Oxytocin 1IU|Oxytocin 1IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby, followed by infusion 80 mU/min (40 IU in 1L given at a rate of 120 mL/h).
62612224|NCT04902729|ACTIVE_COMPARATOR|Carbetocin 80mcg|Carbetocin 80mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
62612225|NCT01040182||ischemic stroke patients|
62612226|NCT01040182||healthy subjects without cerebrovascular disease|
62612227|NCT01048086|EXPERIMENTAL|Retinoic Acid|
62442972|NCT01492582|EXPERIMENTAL|Prevention (vaccine therapy)|Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) or nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.
62442973|NCT04738747|EXPERIMENTAL|Study arm (receive a WHOOP device)|Participants randomized to the WHOOP group will be given WHOOP wrist and arm bands to wear 24/7 after an orientation on their use
62612228|NCT01048086|PLACEBO_COMPARATOR|Placebo|
62612229|NCT03611582|EXPERIMENTAL|Semaglutide|Participants will receive semaglutide 2.4 mg during 68-week treatment period in addition to intensive behavioural therapy.
62612230|NCT03611582|PLACEBO_COMPARATOR|Semaglutide placebo|Participants will receive semaglutide placebo during 68-week treatment period in addition to intensive behavioural therapy.
62442974|NCT04738747|NO_INTERVENTION|Control arm (no intervention)|The control group will not have any intervention
62442975|NCT04875156|OTHER|normal volunteers|normal volunteers between 18 and 40 years old, men and women. Measurement of the range of motion of the metacarpophalangeal joint with a goniometer and pinch strength of the thumb with a dynamometer
62442976|NCT00275535|ACTIVE_COMPARATOR|Tacrolimus|Calcineurin inhibitor arm, consisting of treatment with tacrolimus, mycophenolate mofetil, and prednisone.
62442977|NCT00275535|ACTIVE_COMPARATOR|Sirolimus|Calcineurin inhibitor-free arm, consisting of treatment with rapamycin, mycophenolate mofetil, and prednisone.
62612231|NCT04655534|EXPERIMENTAL|IMW Group|Patients who performed inspiratory muscle warm-up (IMW) before inspiratory muscle training (IMT)
62612232|NCT04655534|EXPERIMENTAL|Standart IMT Group|Patients who performed standard inspiratory muscle training (IMT) without inspiratory muscle warm-up (IMW) protocol
62612233|NCT06397924|ACTIVE_COMPARATOR|Chitin Fiber|Chitin Fiber
62442978|NCT02585882|EXPERIMENTAL|Communal preschool feeding with fluoridated salt|"According to the allocation concealment, subjects of the test group were preschool children at the Kindergarten Wattenscheid in Gambia, Brikama-Kabafita, West Coast Region, The Gambia."
62442979|NCT02585882|NO_INTERVENTION|Communal preschool feeding with no fluoridated salt|"Subjects of the control group were preschool children at the Kindergarten Bottrop in Gambia, Brikama, West Coast Region, The Gambia."
62612234|NCT06397924|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62612235|NCT06730269|EXPERIMENTAL|Face-to-Face Rehabilitation Group|Participants in this arm received a thoracic corrective exercise program in person, consisting of four exercises targeting back extensor muscles. The exercises were performed three times a week for six weeks under the supervision of a trained therapist.
62612236|NCT06730269|EXPERIMENTAL|Telerehabilitation Group|Participants in this arm followed the same thoracic corrective exercise program, but the sessions were delivered online through the Fiziu platform. Exercises were performed three times a week for six weeks with remote guidance and monitoring.
62612237|NCT04750200|NO_INTERVENTION|Control Arm|Patients randomized to the control arm will undergo institutional standard of care treatment (surgical drainage and/or medical management for the CSDH.
62612238|NCT04750200|EXPERIMENTAL|Interventional Arm|Patients randomized to the interventional arm will undergo institutional standard of care treatment (surgical drainage and/or medical management for the CSDH as per the standard of care in the institution. These patients will then undergo EMMA within 48 hours after finishing the surgical drainage. The embolic agent and use of general anesthesia vs conscious sedation will be left to operators' preference and the institutional protocol. All patients will be followed as per the institutional standard of the care. Any peri-procedural complications and change in clinical status will be recorded.
62612239|NCT06521112|NO_INTERVENTION|Control Group|"Individual daily oral care frequency will not be determined for each patient in the control group.~0.2% chlorhexidine for 2 minutes, once per shift as frequently as the clinic routinely applies (3 shifts in total: once between 08:00-16:00; 16:00-24:00; 24:00-08:00) standard oral care will be applied with the solution containing."
62612240|NCT06521112|EXPERIMENTAL|Intervention Group|"Morning shift every day for 10 days; An individual Intensive Care Oral Care Frequency Rating Scale will be applied to each patient daily.~According to the results of the Intensive Care Oral Care Frequency Evaluation Scale, individual oral care frequency will be planned for each patient daily and recorded in the patient follow-up form.~Then, oral care will be applied with a solution containing 0.2% chlorhexidine gluconate for 2 minutes, in line with the clinical protocol and at the planned frequency."
62612241|NCT04875689|EXPERIMENTAL|Group A (Experimental)|Patient receive laser therapy along with conventional therapy
62612242|NCT04875689|OTHER|Group B: Conventional treatment|patient will receive conventional therapy
62836189|NCT02607709|PLACEBO_COMPARATOR|Nephroureterektomy|scheduled to receive routine standard open or robot assisted nephroureterectomy without lymphadenectomy
62836190|NCT02607709|EXPERIMENTAL|Nephroureterektomy + Lymphadenectomy|scheduled to received mapped lymphadenectomy in conjugation with nephroureterectomy
62254053|NCT04041986|SHAM_COMPARATOR|Sham tDCS|Half of our tDCS responders will be randomized to a group receiving 10 sessions (divided in to two five-day periods) of sham tDCS. During sham tDCS, a 2.0 mA current will be delivered for approximately 30 seconds at the beginning of the sham condition before being extinguished over the course of seconds. Individuals randomized into the sham arm will be offered the option to crossover to real tDCS after their participation is complete.
62442980|NCT03198299|ACTIVE_COMPARATOR|study group: MEI BIN insoles|Study group: participants in the study group were prescribed with customized insoles (MEI BIN insoles) to keep the subtalar joint in neutral position, for 12 weeks.
62442981|NCT03198299|NO_INTERVENTION|control group: without MEI BIN insoles|Control group: participants in the control group were not prescribed with customized insoles (MEI BIN insoles) to keep the subtalar joint in neutral position, for 12 weeks.
62442982|NCT00202137|ACTIVE_COMPARATOR|1|home blood pressure monitoring with automatic blood pressure device
62442983|NCT00202137|ACTIVE_COMPARATOR|2|physician monitoring of blood pressure by 3 monthly office visits
62442984|NCT02764489|EXPERIMENTAL|Part 1:FEIBA 85±15 U/kg at Regular Volume Then 50% Reduced Volume at 2 U/kg/min Rate or Vice Versa|Participants who were eligible were randomized to receive: 3 infusions (infusions 1, 2 and 3) of factor eight inhibitor bypassing activity (FEIBA) 85 ± 15 U/kg, reconstituted in regular volume sterile water for injection (SWFI) followed by 3 infusions (infusions 4, 5 and 6) of FEIBA 85 ± 15 U/kg reconstituted in 50% reduced volume SWFI (Sequence A) or: 3 infusions (infusions 1, 2 and 3) of FEIBA 85 ± 15 U/kg, reconstituted in 50% reduced volume SWFI, followed by 3 infusions of FEIBA 85 ± 15 U/kg, reconstituted in regular volume SWFI (Sequence B). All infusions in Part 1 were given at the standard infusion rate of 2 U/kg/min.
62442985|NCT02764489|EXPERIMENTAL|Part 2:FEIBA 85±15U/kg 50% Reduced Volume at 4U/kg/min Rate Then at 10U/kg/min Rate|Participants who completed Part 1, received FEIBA 85 ± 15 U/kg, reconstituted in 50% reduced volume SWFI at an increased rate of 4 U/kg/min for infusions 7, 8, and 9, followed by FEIBA 85 ± 15 U/kg, reconstituted in 50% reduced volume SWFI at an increased rate of 10 U/kg/min for infusions 10, 11, and 12.
62442986|NCT00892697|EXPERIMENTAL|Arm|15 subjects will receive Telaprevir in combination with pegylated interferon alfa-2a and ribavirin
62442987|NCT06320379|EXPERIMENTAL|Zypan|
62442988|NCT06320379|PLACEBO_COMPARATOR|Placebo|
62442989|NCT05079685||Cases-Control|Women aged 18-39 years, with BMI \<30 and good ovarian reserve, undergoing study for primary sterility, subsidiary of conducting tubal patency studies to rule out pathology of the same and thus be able to perform Spousal or Donor IA.
62442990|NCT01082952||Asthmatic patients|
62442991|NCT01082952||Non asthmatic patients|
62442992|NCT03404661||Pancreas Cancer Subjects|Patients with pancreas cancer will receive Synthetic Human Secretin during an endoscopy procedure.
62442993|NCT03404661||Control Subjects|Controls will receive Synthetic Human Secretin during an endoscopy procedure. Controls are at an elevated risk of pancreas cancer, including pancreatic cystic neoplasms.
62442994|NCT03404661||Familial Pancreatic Cancer Subjects|Subjects who have a family history of pancreas cancer will receive Synthetic Human Secretin during an endoscopy procedure.
62442995|NCT04328948|EXPERIMENTAL|Chemoradiation therapy with elective nodal irradiation|Chemoradiotherapy consists of 5-FU (1,000 mg / m2, day1-4, day29-32), CDDP (75 mg /m2, day1, 29) and radiotherapy (50.4 Gy/28Fr)
62442996|NCT04328948|ACTIVE_COMPARATOR|Chemoradiation therapy with involved field irradiation|Chemoradiotherapy consists of 5-FU (700 mg /m2, day1-4, day29-32), CDDP (70 mg /m2, day1,29) and radiotherapy (60 Gy/30Fr)
62442997|NCT01195922|EXPERIMENTAL|Sirolimus|Subjects will be treated with sirolimus 21 days
62442998|NCT05507554|ACTIVE_COMPARATOR|Opioid Group|This group comprises of patients with ureter stones stones who undergo ureteroscopy procedure. They will be randomized to intravenous injection Tramadol 50 mg. They will also be discharged on Tramadol oral capsule 50 mg for postoperative pain after the ureteroscopy procedure with stent placement
62612243|NCT01084213|ACTIVE_COMPARATOR|IPTp with SP|Study women will receive at least two doses of SP during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
62612244|NCT01084213|EXPERIMENTAL|IST using RDTs|Scheduled intermittent screening using rapid diagnostic tests and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester.
62836191|NCT00951340|ACTIVE_COMPARATOR|CBT with listening therapy|Participants will receive CBT with listening therapy.
62836192|NCT00951340|EXPERIMENTAL|CBT with emotional processing and interpersonal therapy|Participants will receive CBT with emotional processing and interpersonal therapy.
62442999|NCT05507554|ACTIVE_COMPARATOR|Paracetamol (Acetaminophen) Group|This group comprises of patients with ureter stones stones who undergo ureteroscopy procedure. They will be randomized to intravenous injection Paracetamol 1 Gram. They will also be discharged on oral Tablet Paracetamol 1 Gram for postoperative pain after the ureteroscopy procedure with stent placement
62443000|NCT05507554|ACTIVE_COMPARATOR|Diclofenac Sodium Group|This group comprises of patients with ureter stones stones who undergo ureteroscopy procedure. They will be randomized to intra muscular injection Diclofenac Sodium 50 mg. They will also be discharged on oral Tablet Diclofenac Sodium 50 mg for postoperative pain after the ureteroscopy procedure with stent placement.
62836193|NCT04840823|EXPERIMENTAL|Enoxacin 200mg twice daily|Enoxacin 200mg twice daily (one dose in the morning and one dose in the evening) for 30 days, except day 1 and day 30 when only the morning dose will be taken. Participants will take 1 active 200mg enoxacin tablet and 2 placebo tablets per dose.
62836194|NCT04840823|EXPERIMENTAL|Enoxacin 400mg twice daily|Enoxacin 400mg twice daily (one dose in the morning and one dose in the evening) for 30 days, except day 1 and day 30 when only the morning dose will be taken. Participants will take 2 active 200mg enoxacin tablets and 1 placebo tablet per dose.
62836195|NCT04840823|EXPERIMENTAL|Enoxacin 600mg twice daily|Enoxacin 600mg twice daily (one dose in the morning and one dose in the evening) for 30 days, except day 1 and day 30 when only the morning dose will be taken. Participants will take 3 active 200mg enoxacin tablets per dose.
62612245|NCT04018807|OTHER|Resource Pamphlet|Participants will receive a pamphlet detailing mental health and social service providers at the local, state, and national level.
62612246|NCT04018807|EXPERIMENTAL|Remote Therapy|Participants will receive eight 30-minute remote therapy sessions over the course of twelve weeks.
62612247|NCT04650334|OTHER|Perinatal Collaborative Care|Experimental: Perinatal Collaborative Care in Can Tho, Vietnam This is an active treatment arm consisting of 3 health centers receiving training in collaborative care and enrollment of a total of 100 perinatal patients into collaborative care.
62612248|NCT05926752|ACTIVE_COMPARATOR|Photobiomodulation|The participant will be treated with intravaginal SoLá photobiomodulation therapy for a total of nine treatments (two treatments a week). Each treatment lasting 5 minutes.
62612249|NCT05926752|ACTIVE_COMPARATOR|Pelvic Floor Physical therapy|The participant will be treated with pelvic floor physical therapy once a week for 8 weeks. Physical therapy involves standard approach of manual therapy including trigger point release, soft tissue mobilization, stretching, biofeedback, breathing techniques, relaxation yoga, and therapeutic exercises.
62612250|NCT03660124|EXPERIMENTAL|Deep Brain Stimulation Treatment|
62612251|NCT02279199||Control|Normative data from standardized assessment
62612252|NCT02279199||Hemophilia|Persons aged 4-21 with any severity of hemophilia A or B
62612253|NCT01804153|EXPERIMENTAL|Autologous expanded stem cells|Adipose-derived expanded stem cells
62612254|NCT05849506||Touch-RSI|"The group consists of patients with a Touch® implant in one thumb and an RSI arthroplasty in the other thumb.~Intervention: Patient questionnaire and clinical examination to investigate differences between the thumb with a Touch® implant and the thumb with an RSI."
62612255|NCT02164032|PLACEBO_COMPARATOR|Insulin dilution buffer|"During a subsequent 4-week treatment phase subjects will be randomly assigned to receive intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia.~Ectopic lipid content and heart function will be assessed weekly by non-invasive 1H magnetic resonance spectroscopy."
62836196|NCT02102178|EXPERIMENTAL|Group 1 (Intensive occupational therapy)|"All patients received pharmacological treatment for pain in accordance with the World Health Organization (WHO)'s analgesic ladder and occupational therapy follow-up, with guidance regarding activities of daily living (ADLs).~They also carried out therapeutic activities such as embroidery onto gauze (tapestry), weaving a scarf on a nail frame and playing dominos."
62254054|NCT03016208||Misoprostol vaginal insert for max. 24hrs|69 patients matching the inclusion criteria and received MVI for labour induction for a maximum of 24 hours
62443001|NCT04894422||No face mask|Volunteers who did not wear a face mask
62443002|NCT04894422||Cotton face mask|Voluntarily wearing a cotton face mask for 4 hours, following the government's guidelines during the COVID-19 pandemic.
62443003|NCT04894422||Surgical face mask|Voluntarily wearing a surgical face mask for 4 hours, following the government's guidelines during the COVID-19 pandemic.
62443004|NCT03611114|EXPERIMENTAL|Blood orange juice|Subjects will be asked to consume blood orange juice (400 ml/day) for 2 weeks.
62443005|NCT03611114|PLACEBO_COMPARATOR|Control drink|Subjects will be asked to consume a control drink (400 ml/day) for 2 weeks.
62443006|NCT05979181||No extrauterine disease group|Women having placenta previa percreta with no extrauterine disease (FIGO grade 3a)
62443007|NCT05979181||Extrauterine disease group|Women having placenta previa percreta with extrauterine disease (FIGO grades 3b and 3c)
62443008|NCT04402515||Tiotropium plus Olodaterol treatment regimen|
62443009|NCT04402515||Inhaled corticosteroids-containing treatment regimen|
62443010|NCT02687256|EXPERIMENTAL|Protocol 1: Standard then Extended Set|Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then will repeat the cycle for a total of 4 weeks.
62443011|NCT02687256|EXPERIMENTAL|Protocol 1: Extended then Standard Set|Participants will wear the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.
62612256|NCT02164032|ACTIVE_COMPARATOR|Intranasal Insulin administration|"During a subsequent 4-week treatment phase subjects will be randomly assigned to receive intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia.~Ectopic lipid content and heart function will be assessed weekly by non-invasive 1H magnetic resonance spectroscopy."
62612257|NCT05762055|EXPERIMENTAL|Intervention Group|Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology will be implanted for participants in this group
62612258|NCT05762055|EXPERIMENTAL|Control Group|Participants in this arm will receive an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology.
62612259|NCT04621162|EXPERIMENTAL|Positive Expectations (initial)|
62612260|NCT04621162|EXPERIMENTAL|Negative Expectations (initial)|
62612261|NCT04621162|PLACEBO_COMPARATOR|Neutral Expectations (initial)|
62443012|NCT02687256|EXPERIMENTAL|Protocol 2 (Part 1): Sequence 1|Participants will wear the control (standard) infusion set for 1 week, then the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4).
62443013|NCT02687256|EXPERIMENTAL|Protocol 2 (Part 1): Sequence 2|Participants will wear the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4), then the control (standard) infusion set (week 5).
62443014|NCT02687256|EXPERIMENTAL|Protocol 2 (Part 1): Sequence 3|Participants will wear the Extended Wear infusion set with heparin at 80 IU (week 1), 120 IU (week 2), and 200 IU (week 3), then the control (standard) infusion set (week 4), then the Extended Wear infusion set with heparin at 40 IU (week 5).
62612262|NCT04621162|EXPERIMENTAL|Positive Expectations (during intervention)|
62836197|NCT02102178|ACTIVE_COMPARATOR|Group 2 (Regular occupation therapy)|All patients received pharmacological treatment for pain in according to WHO's analgesic ladder and only guidance regarding ADLs from the occupational therapist.
62836198|NCT01582893|EXPERIMENTAL|HCO1100-P14L|HCO1100 is connected in row with low flux dialyzer P14L
62836199|NCT01582893|ACTIVE_COMPARATOR|P210H|High flux Filter P210H
62836200|NCT04254380|EXPERIMENTAL|Experimental: Gan & Lee Insulin Lispro Injection|Gan \& Lee Insulin Lispro Injection for subcutaneous injection, 100 U/mL, in a disposable multidose pen injector with a pre-filled 3-mL type I glass cartridge. Subjects randomized to the Gan \& Lee Insulin Lispro Injection group will participate in the study for 26 weeks.
62443015|NCT02687256|EXPERIMENTAL|Protocol 2 (Part 1): Sequence 4|Participants will wear the Extended Wear infusion set with heparin at 120 IU (week 1), and 200 IU (week 2), then the control (standard) infusion set (week 3), then the Extended Wear infusion set with heparin at 40 IU (week 4), and 80 IU (week 5).
62443016|NCT02687256|EXPERIMENTAL|Protocol 2 (Part 1): Sequence 5|Participants will wear the Extended Wear infusion set with heparin at 200 IU (week 1), then the control (standard) infusion set (week 2), then the Extended Wear infusion set with heparin at 40 IU (week 3), 80 IU (week 4), and 80 IU (week 5).
62443017|NCT02687256|EXPERIMENTAL|Protocol 2 (Part 2): Standard then Extended Set|Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then will repeat the cycle for a total of 4 weeks.
62443018|NCT02687256|EXPERIMENTAL|Protocol 2 (Part 1): Extended then Standard Set|Participants will wear the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.
62443019|NCT00818714|EXPERIMENTAL|1|Dose escalation study to define the maximum tolerated boost dose of stereotactic body radiation therapy (SBRT) to the residual primary tumor after definitive therapy with concurrent chemotherapy and external beam radiation.
62443020|NCT03275701|OTHER|Triumeq|Single Arm, Open Label
62443021|NCT01691755|PLACEBO_COMPARATOR|Placebo|
62443022|NCT01691755|EXPERIMENTAL|aleglitazar|
62443023|NCT06207825||Test cohort|A set of test images and videos will be collected prospectively from other subjects, according to the eligibility criteria, followed by random allocation of computer-generated sequence.Two expert endoscopists (with more than 5 years of experience in colonoscopy and a total number of procedures more than 1,000) and two junior endoscopists (with less than 3 years of experience in colonoscopy and a total number of procedures less than 500), who are blinded to the final diagnostic result, will be invited to classify the test set images and videos according to the pre-defined subtypes. All endoscopists will assess the test set data independently in a real-time basis. On the other hand, the CADx system will scan the test set images and videos independently. The prediction of ulcer subtypes will be recorded. The formal diagnostic report after evaluation by independent pathologists and gastroenterologists will be regarded as the ground truth.
62443024|NCT05186961||caregivers|Person who provided primary care for children younger than 18 years with swallowing disorders.
62443025|NCT01077206|ACTIVE_COMPARATOR|Simvastatin 80mg|
62443026|NCT01077206|ACTIVE_COMPARATOR|Simvastatin 40mg|
62443027|NCT06481800|EXPERIMENTAL|Group (A):Progressive muscle relaxation (PMR)|patients receive progressive muscle relaxation (PMR) for 20 minutes after each dialysis session during the first 2 hours the dialysis treatment with routine medical care for dialysis patients
62443028|NCT06481800|EXPERIMENTAL|Group (B): Manual lymphatic drainage (MLD)|patients receive Manual lymphatic drainage (MLD) for 20 minutes within after each dialysis session during the first 2 hours the dialysis treatment with routine medical care for dialysis patients.
62443029|NCT06481800|ACTIVE_COMPARATOR|Group (C):control|patients receive routine medical care for dialysis patients. Routine medical care for RLS and sleep quality in hemodialysis Anemia management, electrolyte balance,Avoiding caffeine and alcohol, establishing a regular sleep schedule leg care,Medicines that increase dopamine in the brain, affecting calcium channels, Opioids , Gabapentin and Pregabali , Benzodiazepines
62443030|NCT01100684|EXPERIMENTAL|Treatment|0.5 mg asimadoline bid
62443031|NCT01100684|PLACEBO_COMPARATOR|Placebo|Placebo
62443032|NCT01629875|EXPERIMENTAL|DWP450|
62443033|NCT01629875|ACTIVE_COMPARATOR|Botox|
62443034|NCT06541470|OTHER|Arm A: Cutting needle biopsy|Patients with pleural disease underwent US-assisted cutting needle biopsy.
62443035|NCT06541470|OTHER|Arm B: Abrams needle biopsy|Patients with pleural disease underwent US-assisted Abrams needle biopsy.
62443036|NCT05936528|EXPERIMENTAL|Lactoferrin|Lactoferrin 100 mg sachets with a dose of 200 mg (2 sachets) orally twice daily (400 mg per day) In addition to standard of care
62443037|NCT05936528|NO_INTERVENTION|Placebo|Standard of care only no intervention by lactoferrin
62443038|NCT02549742|EXPERIMENTAL|Electrochemotherapy|25 patients treated with electrochemotherapy
62443039|NCT02791776|OTHER|Scoliosis|"self-administered questionnaire (SRS 30) to assess the state of health and disability of patients.~collection of patient's radiographic and clinical parameters"
62443040|NCT03508895|EXPERIMENTAL|Whole hemp seed protein|25 grams of hemp seed protein powder, twice a day
62443041|NCT03508895|EXPERIMENTAL|Whole hemp seed protein plus bioactive peptides|22.5 grams of hemp seed protein and 2.5 grams of hemp seed protein hydrolysate derived bioactive peptides, twice a day
62443042|NCT03508895|ACTIVE_COMPARATOR|Casein protein|25 grams of protein powder, twice a day
62612263|NCT04621162|EXPERIMENTAL|Negative Expectations (during intervention)|
62612264|NCT04621162|PLACEBO_COMPARATOR|Neutral Expectations (during intervention)|
62612265|NCT02209025|PLACEBO_COMPARATOR|Placebo drink|A drink with the same components as the theobromine drink except for the theobromine
62612266|NCT02209025|EXPERIMENTAL|Theobromine|500mg theobromine in a drink
62836201|NCT04254380|ACTIVE_COMPARATOR|Active Comparator: Humalog|EU-authorized Humalog KwikPen® - insulin lispro injection, solution for subcutaneous injection, 100 U/mL (pre-filled). Subjects randomized to the Humalog group will participate in the study for 26 weeks.
62612267|NCT06730607||Cases: patients with sudden cardiac death or sustained ventricular arrhythmias during the follow-up|"Inclusion criteria~Patients will only be recruited if they fulfill ALL the inclusion criteria:~1. Age \> 18 years.~2. Myocarditis diagnosis \> 6 months before the inclusion in the study.~3. Signed informed consent.~4. CMR performed \> 6 months after myocarditis diagnosis~Exclusion criteria~Patients will be excluded if they meet ANY of the following exclusion criteria:~* Age \< 18 years.~* Pregnancy.~* Other concomitant structural heart diseases (e.g. congenital, non-ischemic, etc.)~* Active myocarditis~* Myocarditis diagnosis \< 6 months~* Previously documented sustained ventricular arrhythmias.~* Impossibility or contraindications to undergo LGE-CMR.~* Concomitant investigation treatments.~* Medical, geographical and social factors that make study participation impractical, and inability to give written informed consent. Patient's refusal to participate in the study."
62836202|NCT01764880|EXPERIMENTAL|SST0001 (Roneparstat)|"SST0001 once daily for 5 or 10 days in a cycle of 28 days. Starting dose 25 mg, to be escalated in subsequent cohorts.~Duration of treatment depending on toxicities observed or until documentation of disease progression or other discontinuation criteria are met."
62836203|NCT04315740|SHAM_COMPARATOR|Clean Air|Just clean air - no exposure
62836204|NCT04315740|EXPERIMENTAL|Cooking|Four ovens were frying pork - one at a time. When the first oven finished, the next oven started and so forth for approx. 7 hours.
62836205|NCT04315740|EXPERIMENTAL|Candles|10 lit candles were placed at a table. Burning for approx. 7 hours with light ventilation.
62836206|NCT02465619||Severe acute hepatitis|Severe acute hepatitis without ascites.
62254055|NCT03016208||Misoprostol vaginal insert for max. 10hrs|69 patients matching the inclusion criteria and received MVI for labour induction for a maximum of 10 hours
62836207|NCT02465619||Non-cirrhotic|
62254056|NCT02355249|EXPERIMENTAL|A group (MIE)|Via minimally invasive thoracol-laparoscopic esophagectomy.
62254057|NCT02355249|ACTIVE_COMPARATOR|B group (OE)|Via traditional three incisions esophagectomy.
62254058|NCT02743351|EXPERIMENTAL|ProTmune|"Conditioning regimen consisting of one of the following five preparative regimens: fludarabine and busulfan (FluBu4); busulfan (Bu) and cyclophosphamide (Cy); Cy and \>or=12 Gy total body irradiation (TBI); TBI and etoposide; or fludarabine and melphalan (FluMel 140).~Subjects will receive mPB cells from an available 8/8 HLA-A, -B, -C, and -DRB1-matched unrelated peripheral blood cell donor that were programmed ex vivo with ProTmune."
62254059|NCT02743351|ACTIVE_COMPARATOR|Control Arm|"Conditioning regimen consisting of one of the following five preparative regimens: fludarabine and busulfan (FluBu4); busulfan (Bu) and cyclophosphamide (Cy); Cy and \>or=12 Gy total body irradiation (TBI); TBI and etoposide; or fludarabine and melphalan (FluMel 140).~Subjects will receive unmanipulated mPB cells from an available 8/8 HLA-A, -B, -C, and -DRB1-matched unrelated peripheral blood cell donor."
62254060|NCT00268437|EXPERIMENTAL|Pemetrexed/Carboplatin|Pemetrexed+Carboplatin+Radiation
62254061|NCT03840512|EXPERIMENTAL|Oral CBD 75 BID|
62254062|NCT03840512|EXPERIMENTAL|Oral CBD 150 BID|
62254063|NCT03840512|EXPERIMENTAL|Oral CBD 300 BID|
62836208|NCT02465619||Cirrhotic patients with ascites|
62836209|NCT02465619||decompensated cirrhosis|
62254064|NCT03434340|EXPERIMENTAL|Granisetron & Dexamethasone & Peppermint essential oil|Granisetron 1mg and Dexamethasone 4mg administer as intravenous injection once right after delivery of newborn followed by Peppermint essential oil 2 drops on nasal strip applied for 6 hours
62836210|NCT04836780|EXPERIMENTAL|Dexamethasone|Dexamethasone base 6 mg once daily for seven days
62836211|NCT04836780|ACTIVE_COMPARATOR|Standard of care|Standard care therapy
62836212|NCT02129127|EXPERIMENTAL|Drug Coated Chocolate|Paclitaxel Coated Chocolate Balloon Angioplasty
62836213|NCT05740501||Observational (biospecimen collection, chart review)|Patients undergo collection of blood samples and have medical records reviewed on study.
62836214|NCT02640287|EXPERIMENTAL|Waldenström macroglobulinemia|Patients with diagnosis of Waldenström macroglobulinemia
62836215|NCT02640287|EXPERIMENTAL|Others B-cell malignancies|Patients with diagnosis of Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma or Multiple Myeloma
62836216|NCT02640287|OTHER|Healthy subjects|Control healthy subjects without B-cell malignancy
62836217|NCT04941677||schizophrenia group|No intervention age between 20-65, diagnosed schizophrenia by DSM-5.
62836218|NCT03869047|ACTIVE_COMPARATOR|quadratus lumborum block(dexmedetomidine+bupivacaine)|patients will receive combined general anesthesia and Quadratuslumborum block( transincisional ie before wound closure)with 19 mL of bupivacaine 0.20%plus 1 mic/kg of dexmedetomidine ,total volume 20 ml.
62836219|NCT03869047|ACTIVE_COMPARATOR|quadratus lumborum block(bupivacaine)|patients will receive combined general anesthesia and quadratus lumborum block (transincisional) with 20 ml of bupivacaine 0.20%.
62612268|NCT06730607||Controls:patients without sudden cardiac death or sustained ventricular arrhythmias during follow-up|"Patients will only be recruited if they fulfill ALL the inclusion criteria:~1. Age \> 18 years.~2. Myocarditis diagnosis \> 6 months before the inclusion in the study.~3. Signed informed consent.~4. CMR performed \> 6 months after myocarditis diagnosis~Patients will be excluded if they meet ANY of the following exclusion criteria:~* Age \< 18 years.~* Pregnancy.~* Other concomitant structural heart diseases (e.g. congenital, non-ischemic, etc.)~* Active myocarditis~* Myocarditis diagnosis \< 6 months~* Previously documented sustained ventricular arrhythmias.~* Impossibility or contraindications to undergo LGE-CMR.~* Concomitant investigation treatments.~* Medical, geographical and social factors that make study participation impractical, and"
62836220|NCT04754048|EXPERIMENTAL|Traumatic wounds|Treatment with negative pressure wound therapy.
62254065|NCT03434340|ACTIVE_COMPARATOR|Granisetron & Dexamethasone|Granisetron 1mg and Dexamethasone 4mg administer as intravenous injection once right after delivery of newborn
62254066|NCT03292809|EXPERIMENTAL|CyclASol Ophthalmic Solution|Cylclosporine A solution in vehicle
62254067|NCT03292809|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution|Vehicle only
62254068|NCT03104894|EXPERIMENTAL|Study Group|The study group will receive meibomian glands massage and artificial drops PRN
62254069|NCT03104894|SHAM_COMPARATOR|Control Group|The control group will receive sham meibomian glands massage and artificial drops PRN.
62443043|NCT02168647|EXPERIMENTAL|Behavioral Lifestyle counseling|Intervention group participants will take part in behavioral lifestyle counseling provided by a Registered Dietitian Nutritionist from week 14 of gestation through childbirth.
62254070|NCT06512012|EXPERIMENTAL|Yoga and exercise group|"Before starting yoga, How are you feeling today? will be asked to child. The yoga session will be individualized according to how the child feels. The content of the yoga sessions will progress in the form of warm-up exercises - breathing work - yoga postures (asana) - meditation - and progressive muscle relaxation exercises. Yoga sessions will be scheduled for 30 minutes. Yoga sessions and progressive muscle relaxation exercises will be held online once a week for eight weeks, then every two weeks for four months."
62612269|NCT01001806|ACTIVE_COMPARATOR|Acuvail|Acuvail to be given preoperatively. One drop 2 times daily (BID), 1 day pre op and day of surgery 3 doses prior to surgery
62254071|NCT06512012|NO_INTERVENTION|control group|no yoga or excersize intervention.
62443044|NCT02168647|ACTIVE_COMPARATOR|Control|Participants in the control arm will receive no form of lifestyle intervention.
62443045|NCT05784571||Older Adults|Adults 60-80 years of age with body mass index \> 30kg/m2
62443046|NCT03465410|ACTIVE_COMPARATOR|GROUP I Standard adjustment|Standard dosage of Tacrolimus
62612270|NCT01001806|ACTIVE_COMPARATOR|Xibrom|Xibrom to be given 1 drop 2 times daily (BID) the day before surgery and 3 doses the day of surgery prior to surgery
62612271|NCT01001806|ACTIVE_COMPARATOR|Nevanac|One day before surgery 1 drop 2 times daily (BID), then 3 doses the day of surgery
62612272|NCT05960032|EXPERIMENTAL|Zavegepant|Participants receiving Zavegepant for the treatment phase of the study
62836221|NCT04754048|EXPERIMENTAL|Subacute wounds (e.g., dehisced wounds)|Treatment with negative pressure wound therapy.
62836222|NCT04754048|EXPERIMENTAL|Flaps and Grafts|Treatment with negative pressure wound therapy.
62836223|NCT01300663||post-surgery symptom experience|women with vulvar intraephitelial neoplasia or vulvar cancer
62836224|NCT02660372|EXPERIMENTAL|Imonogas|Imonogas 120 mg, 1 capsule three times daily for 8 weeks
62836225|NCT02660372|ACTIVE_COMPARATOR|Espumisan|Espumisan 40 mg, 2 capsules four times daily for 8 weeks
62836226|NCT06002724||0|
62254072|NCT02371226|EXPERIMENTAL|Cohort 1|1 mg/kg AGT-181 (fusion protein of anti-human insulin receptor monoclonal antibody and alpha-L-iduronidase; HIRMAb-IDUA) administered once weekly x 8 weeks
62254073|NCT02371226|EXPERIMENTAL|Cohort 2|3 mg/kg AGT-181 (HIRMAb-IDUA) administered once weekly x 8 weeks
62254074|NCT02371226|EXPERIMENTAL|Cohort 3|6-9 mg/kg AGT-181 (HIRMAb-IDUA) administered once weekly x 8 weeks
62254075|NCT03135470||Current practice group|All plenipotentiary ambulatory surgery patients, with informed consent, during the three month study period
62254076|NCT03135470||Standard operating protocol group|All plenipotentiary ambulatory surgery patients, with informed consent, during the three month study period after creating and informing standardized operating protocol
62254077|NCT03135470||Mobile phone app group|All plenipotentiary ambulatory surgery patients during the three month study period with informed consent to use mobile phone app in assesment of pain and pain medication
62254078|NCT02556502|EXPERIMENTAL|FDG PET positive or negative|
62254079|NCT00577109|EXPERIMENTAL|1|
62254080|NCT01419951|ACTIVE_COMPARATOR|Clinic Only Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
62254081|NCT01419951|ACTIVE_COMPARATOR|Pediatrician Counseling|A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
62443047|NCT03465410|EXPERIMENTAL|GROUP II Bayesian prediction adjustment|Bayesian prediction Tacrolimus dosage
62443048|NCT00936377|EXPERIMENTAL|Dexmedetomidine, low dose|Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
62443049|NCT00936377|EXPERIMENTAL|Dexmedetomidine, high dose|Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
62443050|NCT00936377|PLACEBO_COMPARATOR|Placebo|Normal saline
62443051|NCT02038634|ACTIVE_COMPARATOR|Unguided injections|Corticosteroid injection (betamethasone) without ultrasound guidance.
62836227|NCT02253862|EXPERIMENTAL|Sequential treatment|
62836228|NCT02342028||OSA|"The study group enrolled patients with OSA, fulfilling the following requirements~1. 20\~60 years ago, female or males~2. Agree participate the study and sign informed consent~3. Has not received any treatment for OSA~4. No obvious comorbidities (including autoimmune diseases)~5. No history of sarcoidosis and tuberculosis~6. No use of steroid and immunosuppressant"
62836229|NCT02342028||Control|"The control group enrolled age-, gender- and BMI-matched individuals without OSA, fulfilling the following requirements~1. 20\~60 years ago, female or males~2. Agree participate the study and sign informed consent~3. No obvious comorbidities (including autoimmune diseases)~4. No history of sarcoidosis and tuberculosis~5. No use of steroid and immunosuppressant"
62443052|NCT02038634|ACTIVE_COMPARATOR|Ultrasound-guided injections|Corticosteroid injections (betamethasone) under ultrasound guidance.
62443053|NCT02082613|EXPERIMENTAL|Lord´s procedure|Lord´s procedure for testicular hydrocele, under local anesthesia in a conventional operation room, under sterile conditions
62053036|NCT00089089|EXPERIMENTAL|Treatment (decitabine)|"Patients receive decitabine IV over 1 hour on days 1-5 or on days 1-5 and 8-12. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients receive escalating doses of decitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
62053037|NCT02880592|EXPERIMENTAL|Fresh amniotic membrane/standard of care|This group will receive the Affinity Allograft and standard of care.
62443054|NCT02082613|ACTIVE_COMPARATOR|Sclerotherapy|Sclerotherapy with 4 ml of polidocanol 30mg/ml after complete emptying of the hydrocele. With or without local anesthesia, not performed in an operation room.
62443055|NCT03926078|OTHER|Patients under 18 years of age|Group A consists of patients that receive a chest radiography in the current work-up of PE.
62612273|NCT06283667||Wegovy®|Patients with obesity treated with Wegovy® (semaglutide) once weekly under real-world clinical practice conditions in Japan.
62612274|NCT06729905|EXPERIMENTAL|Yerba mate|Consumption of three cups of a yerba mate tea per day
62612275|NCT06729905|OTHER|Control|Consuming water or an isotonic drink, free of polyphenols or caffeine.
62612276|NCT04212143||children with kidney disease|Kidney transplant recipients age 3 to 21 years
62053038|NCT02880592|ACTIVE_COMPARATOR|Standard of Care|This group will receive standard of care for diabetic foot ulcers that includes offloading of the diabetic foot ulcer, debridement, and infection management using the appropriate dressings.
62053039|NCT03438695|EXPERIMENTAL|Motorized Spiral Enteroscopy|Patients with indication for total enteroscopy. day1: anterograde motorized spiral enteroscopy, day 2: retrograde motorized spiral enteroscopy
62053040|NCT03817892|NO_INTERVENTION|Unguided 2 minutes (U2)|"The External Chest Compression are performed without guidance of the CPRmeter device (according to the current guidelines).~The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 2 minutes according to the current guidelines."
62053041|NCT03817892|EXPERIMENTAL|Unguided 4 minutes (U4)|"The External Chest Compression are performed without guidance of the CPRmeter device (according to the current guidelines).~The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 4 minutes. (Rhythm of a relay 4 minutes)"
62053042|NCT03817892|EXPERIMENTAL|Guided 2 minutes (G2)|The External Chest Compression are performed with guidance of the CPRmeter device. (Guidance of the External Chest Compression) The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 2 minutes according to the current guidelines.
62053043|NCT03817892|EXPERIMENTAL|Guided 4 minutes (G4)|The External Chest Compression are performed with guidance of the CPRmeter device. (Guidance of the External Chest Compression) The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 4 minutes. (Rhythm of a relay 4 minutes)
62053044|NCT03076476|ACTIVE_COMPARATOR|DES-std group|(DES: drug-eluting stent). Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.
62443056|NCT03926078|OTHER|Patients aged 18 years or older|Group B consists of patients that receive a CT scan in the current work-up of PE.
62443057|NCT04351295|EXPERIMENTAL|Faviprevir|Faviprevir
62443058|NCT04351295|ACTIVE_COMPARATOR|chloroquine|chloroquine
62612277|NCT04212143||healthy control|Healthy children age 3 to 21 years
62612278|NCT01804699||Proband|Probands - Participants diagnosed with ARVC according to the 2010 Task Force Criteria
62612279|NCT01804699||Family|First Degree Family member (blood related mother, father, sister, brother, child) of the proband
62612280|NCT05551689|ACTIVE_COMPARATOR|ADHD monitoring as usual|ADHD patient monitoring as usual based on psychostimulant prescription and follow up
62836230|NCT02461758|OTHER|Control Group|A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled. All healthy individuals will receive standard dose influenza vaccine SDIV.
62836231|NCT02461758|OTHER|Vedolizumab Group + standard dose influenza vaccine (SDIV)|A group of 20 patients who are currently on vedolizumab. All individuals in this group will receive SDIV
62836232|NCT02461758|OTHER|High dose influenza vaccine (HDIV)|"This arm will be a double blind randomized controlled trial of High dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy.~40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme."
62836233|NCT02461758|OTHER|Standard dose influenza vaccine (SDIV)|"This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy.~40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme."
62612281|NCT05551689|EXPERIMENTAL|FOCUS ADHD|ADHD patient monitoring as usual based on psychostimulant prescription and follow up plus the indication to use the FOCUS ADHD app as a treatment monitoring tool
62612282|NCT05551689|EXPERIMENTAL|FOCUS ADHD and the elegibility for discount concession on treatment purchase|ADHD patient monitoring as usual based on psychostimulant prescription and follow up plus the indication to use the FOCUS ADHD app as a treatment monitoring tool. In this arm patients are also eligible for a discount of at least 25% of the drug cost (after the first month of treatment) if they register and maintain at least 80% of their treatment adherence on the FOCUS ADHD app. The discount is granted after week 4 until the end of the follow up period.
62612283|NCT01565798|EXPERIMENTAL|Copper Surfaced Room|Patients sequentially randomized to this arm were admitted to an ICU room with copper surfaced objects.
62612284|NCT01565798|NO_INTERVENTION|Standard Surfaced Room|Patients sequentially randomized to this arm were admitted to an ICU room with standard surfaced objects
62254082|NCT01419951|EXPERIMENTAL|Clinic + Home Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
62254083|NCT00012220|ACTIVE_COMPARATOR|Gemcitabine|Standard treatment
62254084|NCT00012220|EXPERIMENTAL|Gemcitabine + cisplastin|Addition of cisplastin to gemcitabine
62254085|NCT00012220|EXPERIMENTAL|Gemcitabine + docetaxel|Addition of docetaxel to gemcitabine
62254086|NCT00012220|EXPERIMENTAL|Gemcitabine + Irinotecan|Addition of irinotecan to gemcitabine
62254087|NCT05132374|EXPERIMENTAL|Treatment Group|Those receiving standard practice early childhood mental health consultation but enhanced with the I-T CHILD as a framework for consultation
62254088|NCT05132374|NO_INTERVENTION|Waitlist-control group|Those who receive no intervention until the end of the evaluation period)
62612285|NCT00667797|EXPERIMENTAL|1|levalbuterol 1.25 mg
62053045|NCT03076476|EXPERIMENTAL|DES-slow group|"(DES: drug-eluting stent). Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.~After the interim analysis DES-slow to be compared with BVS."
62053046|NCT03076476|EXPERIMENTAL|BVS group|(Bioresorbable Vascular Scaffold) Introduced after the interim analysis (phase 2) for comparison with DES-slow.
62053047|NCT00521703|EXPERIMENTAL|1|group treated
62612286|NCT00667797|ACTIVE_COMPARATOR|2|Racemic albuterol 2.5 mg
62053048|NCT00521703|PLACEBO_COMPARATOR|2|control group
62053049|NCT02976142|EXPERIMENTAL|neoadjuvant chemoimmunotherapy|Patients with gastric cancer and verified free cancer cells who receive 1 course of intraperitoneal immunotherapy with interleykin-2 + 3 courses of systemic chemotherapy (Cisplatin + 5-FU). In case of downstaging (M1 -\> M0) surgical treatment will be performed.
62053050|NCT02976142|NO_INTERVENTION|neoadjuvant chemotherapy|Patients with gastric cancer and verified free cancer cells who receive 3 courses of systemic chemotherapy (Cisplatin + 5-FU). In case of downstaging (M1 -\> M0) surgical treatment will be performed.
62053051|NCT02740049|EXPERIMENTAL|Astma patients|Participant undergoes a bronchoscopy to isolate epithelial cells
62053052|NCT01444859|PLACEBO_COMPARATOR|Placebo capsule|40 subjects allocated to daily placebo capsule for 10 weeks
62053053|NCT01444859|EXPERIMENTAL|Trenev Trio®/Healthy Trinity®|80 subjects allocated to Trenev Trio®/Healthy Trinity® for 10 weeks
62053054|NCT01120249|EXPERIMENTAL|Arm I|Patients receive oral everolimus once daily on days 1-42. Treatment repeats every 6 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
62053055|NCT01120249|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo once daily on days 1-42. Treatment repeats every 6 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
62053056|NCT06329726||PD - undergone DBS|Patients with Parkinson's disease treated with DBS of the subthalamic nucleus
62053057|NCT06329726||PD - not undergone DBS|Patients with Parkinson's disease not treated with DBS
62254089|NCT02782520|ACTIVE_COMPARATOR|Ringer Lactate|Ringer Lactate group
62254090|NCT02782520|EXPERIMENTAL|Hypertonic saline|Hypertonic saline group
62254091|NCT05246020|EXPERIMENTAL|NHIPEC|Treatment: Four tubes will be placed via the laparoscopic ports and HIPEC will be given within 24 hours after laparoscopic evaluation.
62254092|NCT05246020|ACTIVE_COMPARATOR|Intravenous NACT|Drug:Three cycles of intravenous NACT will be given in this group. The regimen of intravenous NACT is docetaxel 60-75mg/m2 followed by carboplatin area under curve(AUC) 5 for a 21-day cycle.
62254093|NCT03048539||Transoral endoscopic thyroidectomy|Patient who fit with the eligible criteria and choose endoscopic thyroidectomy by himself.
62612287|NCT02135705||Lomitapide|Lomitapide as prescribed by Physician.
62612288|NCT02101749|ACTIVE_COMPARATOR|trivalent inactivated influenza (INTANZA)|Intradermal injection
62612289|NCT02101749|ACTIVE_COMPARATOR|trivalent inactivated influenza (VAXIGRIP)|Intramuscle injection
62254094|NCT03048539||Conventional thyroidectomy|Patient who fit with the eligible criteria and choose conventional thyroidectomy by himself.
62053058|NCT00766675|EXPERIMENTAL|Tramadol hydrochloride/acetaminophen|Tramadol hydrochloride/acetaminophen oral tablet will be administered as 37.5 /325 milligram respectively once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
62053059|NCT03257332||EDFI Cohort|Subjects should have received surgery for rectal cancer (low anterior resection).
62053060|NCT05897255|ACTIVE_COMPARATOR|Control Group|"In Control group, conventional method to reduce diastasis recti will be provided.~Commonly used exercises in the treatment of DRA including abdominal hollowing, curl-ups, sit-ups, pelvic bridging, SLR will be performed by the patients.~The conventional exercise program will be given 3days/week for 6 weeks and will include 2 sets of 5 reps of each exercise."
62053061|NCT05897255|EXPERIMENTAL|Experimental Group A|"In experimental group A, Kinesiotape along with core strengthening exercises will be provided.~The core strengthening exercise program will be given 45 minutes of session 3days/week for 6 weeks. Each exercise will have 5-10 repetitions with a period of rest in between to avoid fatigue and muscle spasm."
62053062|NCT05897255|EXPERIMENTAL|Experimental Group B|"In experimental group B, SEMG biofeedback assisted core strengthening exercises with kinesiotaping will be provided.~Surface EMG activity will be recorded from the left and right abdominal muscles while the exercises will be performed in different positions."
62836234|NCT06212726|EXPERIMENTAL|InjureFree Concussion Communication Tool|During the second phase of this trial, participants assigned to the experimental group (Buchholz and Gainesville High Schools) will receive the current standard of care for return to learn following SRRC with the addition of InjureFree, a wed-based injury tracking and communication tool. InjureFree will serve as a centralized area for concussion management team members to communicate and document participant progress with the return to learn program.
62836235|NCT06212726|NO_INTERVENTION|Control|During the second phase of this trial, participants assigned to the control group (Newberry, Santa Fe and Eastside High Schools) Will not receive any intervention other than the current standard of care for return to learn following SRRC currently in place.
62836236|NCT04609176|EXPERIMENTAL|Camrelizumab+Apatinib+SOX|Participants who have not received any previous therapy for their disease will receive Camrelizumab and Apatinib in combination with Oxaliplatin and S-1. Camrelizumab 200mg, day1; Apatinib 250mg qd p.o.;Oxaliplatin 130 mg/m2 day1; S-1 40-60 mg (calculated according to the body surface area) bid day1-14. 3 weeks for one cycle.
62053063|NCT01226901|EXPERIMENTAL|MK-4827 once daily|MK-4827
62053064|NCT05396989||First-onset of depressed patients|first attack
62053065|NCT05396989||Patients with recurrent depression|relapse
62254095|NCT01778439|EXPERIMENTAL|OMP-52M51|
62254096|NCT02166164|EXPERIMENTAL|Experiemental pain models|all study participants will be tested with the same experimental pain models: Brief thermal sensitization, Long thermal stimulation, and Heat-pain-detection threshold.
62254097|NCT01770470||Patients receiving chronic hemodialysis|Dialysis patients chewing chitosan-containing gum
62443059|NCT01380028|PLACEBO_COMPARATOR|placebo|The aim of this prospective multicenter randomized, double blind, is to evaluate in patients with chronic subdural hematoma, compared with placebo, the efficacy of postoperative corticosteroid treatment orally for approximately 2 months on the rate of clinical recurrence
62612290|NCT01315795|EXPERIMENTAL|Symptomatic polycystic liver disease (PCLD) patients|Symptomatic polycystic liver disease (PCLD) patients
62612291|NCT01745107|NO_INTERVENTION|surgery alone|No prophylactic postoperative radiation therapy,that is surgery alone is developed in this arm
62836237|NCT04609176|EXPERIMENTAL|Camrelizumab+Apatinib|Participants who have received at least one prior therapy for their advanced disease will receive Camrelizumab and Apatinib. Camrelizumab 200mg, day1; Apatinib 250mg qd p.o. 3 weeks for one cycle.
62254098|NCT06148987||Questionnaire group|"This study will be conducted in Turkey between January and August Ferbruary 2024, and it aims to investigate the Turkish translation, reliability, and validity of the AAE-A survey. All participants must meet the following inclusion criteria: (i) be 18 years old or older, (ii) use smart devices and tools, and (iii) provide written consent to participate. Participants with specific abnormalities such as cognitive or neurological disorders, upper extremity pain, functional limitations, or cognitive impairments will be excluded from the study to ensure the accuracy of the norms. It is estimated that a sample size of 270 individuals, with 10 individuals per item, will be needed for the sample size of this study."
62254099|NCT02982369|EXPERIMENTAL|Spinal Manipulation|"High-velocity and low-amplitude (HVLA) manipulation techniques to the cervical and thoracic region and pain education.~The subjects will receive the treatment twice a week, for four weeks, totaling eight sessions, with an average duration of 30 minutes."
62836238|NCT06286488|EXPERIMENTAL|Evaluation of immunogenicity and tolerance of quadrivalent influenza vaccine in obese adults|Scientific observations published during the 2009 influenza pandemic have highlighted the more severe course and complications of influenza in obese people. The effect of excessive body fat in humans on the immune response to influenza vaccination is not fully explained by the available studies. Study aim was the evaluation of immunological efficacy and tolerance of QIV in obese adult patients and the relationship between the degree of obesity and immunogenicity of quadrivalent QIV in obese adult patients. Free of charge influenza vaccination was done with a quadrivalent Sanofi Pasteur Vaxigrip Tetra vaccine at a dose of 0.5 ml according to WHO recommendations for 2017/2018 for the northern hemisphere.
62836239|NCT06286488|EXPERIMENTAL|Immunogenicity of QIV in pregnant women, including transplacental transport of antibodies|Many studies confirm the safety of vaccinations against influenza during pregnancy for pregnant women as well for children. Previous studies have assessed the immunological efficacy of a monovalent and trivalent vaccine, but studies assessing the immunological efficacy and tolerability of the tetravalent, inactivated influenza vaccine in pregnant women are missing.The aim of the study is to assess immunogenicity and tolerance of tetravalent, inactivated influenza vaccine in pregnant women, depending on the duration of vaccination (II or III trimester) by assessing the level of antibodies in neonatal umbilical cord blood (transplacental transfer). Free of charge influenza vaccination was done with a quadrivalent Sanofi Pasteur Vaxigrip Tetra vaccine at a dose of 0.5 ml according to WHO recommendations for 2021/2022, 2022/2023 for the northern hemisphere.
62836240|NCT00198822|EXPERIMENTAL|1|Weekly oral supplement with 7000 µg retinol equivalents from early pregnancy through 12 weeks following termination of pregnancy
62836241|NCT00198822|EXPERIMENTAL|2|Weekly oral supplement with 42 mg of beta-carotene from early pregnancy through 12 weeks following termination of pregnancy
62836242|NCT00198822|PLACEBO_COMPARATOR|3|Weekly oral supplement with placebo from early pregnancy through 12 weeks following termination of pregnancy
62836243|NCT03370432||Colorectal cancer cases|1038 participants diagnosed with colorectal cancer from the Diet, Cancer and Health cohort.
62836244|NCT03370432||Sub-cohort members|1857 persons randomly selected within the full cohort at time of entry into the Diet, Cancer and Health cohort. These participants serve as controls for the colorectal cancer cases.
62254100|NCT02982369|SHAM_COMPARATOR|Pain Education|"Pain education and a simulation of spinal manipulation (sham), involving manual contact over the cervical and thoracic region totaling 10 minutes.~The subjects will receive the treatment twice a week, for four weeks, totaling eight sessions, with an average duration of 30 minutes."
62254101|NCT05217121|ACTIVE_COMPARATOR|Group Q = QLB group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
62836245|NCT02806102||High-risk|"Acute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have at least one of the following risk factors:~* Age ≥ 65 years~* Diabetes mellitus requiring medication~* Documented history of a second prior presumed spontaneous MI (\>1 year ago)~* Documented history of angiographic evidence of multivessel coronary artery disease~* Chronic, non-end stage renal dysfunction"
62053066|NCT01984697|EXPERIMENTAL|Girls 9 to 14 Years V503 at Months 0 and 6|Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
62053067|NCT01984697|EXPERIMENTAL|Boys 9 to 14 Years V503 at Months 0 and 6|Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
62053068|NCT01984697|EXPERIMENTAL|Girls and Boys 9 to 14 Years V503 at Months 0 and 12|Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.
62053069|NCT01984697|EXPERIMENTAL|Girls 9 to 14 Years V503 at Months 0, 2, and 6|Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
62254102|NCT05217121|ACTIVE_COMPARATOR|Group M = mTLIP block group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
62254103|NCT02066311|EXPERIMENTAL|nelfinavir|Nelfinavir tablets will be taken by oral administration, 750mg (three 250 mg tablets) three times a day
62254104|NCT01650025|PLACEBO_COMPARATOR|VSL#3 placebo|The placebo comparator is administered in the same form and dose as the active ingredient. The patient will take 2 sachets a day for 4 months.
62254105|NCT01650025|ACTIVE_COMPARATOR|VSL#3 active probiotic|VSL#3 is a probiotic preparation containing 8 different strains of lactic acid bacteria and bifidobacteria. Each sachet contains 450 billion bacteria and the patient will be requested to take 2 sachets a day for 4 months
62254106|NCT05670769|EXPERIMENTAL|Experimental|"* All forms will be filled in by the pregnant women at the beginning of the study.~* The first interview will be face-to-face at the hospital.~* A calendar will be created about home visits and timings for home midwifery care and counseling by meeting the pregnant woman at the hospital and obtaining their contact information.~* Weekly home visits will be made to the pregnant women in the first month and training will be provided with the training booklet developed in line with the home midwifery care model based on the continuous midwifery care model during the home visits. Afterwards, two more home visits will be made to the pregnant women on a monthly basis and a total of 6 home visits will be made.~* Pregnant women will be in constant communication via mobile phone.~* After the sixth home visit, the Intention, Attitude and Behavior Scale in Gestational Diabetes and the Diabetes Self-Care Activities Questionnaire will be filled."
62254107|NCT05670769|NO_INTERVENTION|Control|"* All forms will be filled in by the pregnant women at the beginning of the study.~* Pregnant women in the control group will not be subjected to any application other than the routine pregnancy follow-up and examinations recommended in the hospital.~* Forms will be filled in parallel with the intervention group"
62254108|NCT02456597|ACTIVE_COMPARATOR|lidocainhydrochlorid|Lidocaine 20mg/ml, 15 ml injected perineural at the sciatic nerve
62254109|NCT02456597|PLACEBO_COMPARATOR|Isotonic saline|0.9% Saline Solution, 15ml injected perineural at the contralateral sciatic nerve
62254110|NCT04673227||Contact with active TB/ LTBI|After a close contact with bacteriologically confirmed TB suspicion for LTBI with an evidence of previous BCG vaccination status TB confirmed with TST (TST ≥ 5 mm or BCG unvaccinated or TST ≥ 15 mm for BCG vaccinated) 20 children and adolescents 20 adults
62612292|NCT01745107|EXPERIMENTAL|surgery plus radiation|Prophylactic postoperative radiation therapy is developed in this arm
62612293|NCT04170244||Atopic Dermatitis|"Intervention is whatever Rx the URMC dermatologist thinks is best suited to the subject as part of real-world disease management in her clinic.~1. Ages:13-65 yrs of age (inclusive), all genders, races and ethnicities~2. Additional 66+ yrs of age group, all genders, races and ethnicities"
62612294|NCT04170244||Healthy control|"No intervention~Ages:~1. 13-65 yrs of age (inclusive), all genders, races and ethnicities~2. Additional 66+ yrs of age group, all genders, races and ethnicities"
62836246|NCT02806102||Low-risk|Acute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have none of the pre-specified risk factors
62836247|NCT00105781|OTHER|Arm 1|
62836248|NCT05174403||SPG5 patients|Adult SPG5 patients with diagnostic confirmed by the identification of two mutations in the CYP7B1 gene
62836249|NCT00132704||A|The experiments in Group A will be conducted in order to determine if human tumor microvascular endothelium displays similar dose parameters as mouse tumor endothelium, and if the microvascular endothelium of tumors of different types behaves in a similar fashion in its response to IR.
62836250|NCT00132704||B|The experiments in Group B will be conducted in order to determine if tumor endothelium isolated to near homogeneity demonstrates dose parameters similar to those used in single dose radiotherapy of brain tumors.
62836251|NCT01904994|NO_INTERVENTION|Standard of Care|Participants will be managed per standard of care following prevailing Swaziland Ministry of Health guidelines.
62836252|NCT01904994|EXPERIMENTAL|Combined Intervention Strategy|Point-of-care (POC) CD4+ (cluster of differentiation 4) Count Accelerated ART initiation for ART eligible participants Basic care and prevention package Cellular Appointment Reminders and Follow-Up Financial Incentives
62836253|NCT02642016|EXPERIMENTAL|CDX-0158|
62836254|NCT03773276|EXPERIMENTAL|Norepinephrine boluses|Single arm study
62836255|NCT05133141||Echelon Contour|This prospective study will include the participants who plan to have an elective colorectal surgical procedure and collect clinical data in a post-market setting. Investigators will perform each procedure using the device in compliance with their standard surgical approach and the Echelon Contour instruction for use (IFU).
62836256|NCT00756613||465 VADT participants|The participants had previously participated in the VADT CSP #465 study
62836257|NCT02350140|EXPERIMENTAL|Text messaging from beginning|Half of the health facilities will be randomly allocated to receive the TextIT intervention during the first time period (six months), while the other half to continue with current standard care (first step)
62836258|NCT02350140|ACTIVE_COMPARATOR|Text messaging after 6 months of control|Half the facilities will receive standard of care for six months (first time period). After the first time period, the these facilities will then also receive the TextIT intervention (second step)
62836259|NCT02306317|ACTIVE_COMPARATOR|Control by nursing.|FiO2 adjusted manually by nursing staff. Intervention: Other. Standard procedure
62836260|NCT02306317|EXPERIMENTAL|Control by parents.|FiO2 adjusted manually by parents. Intervention. Other. Experimental procedure
62836261|NCT05647148|EXPERIMENTAL|intervention group|progressive relaxiation exercises Will do sixty minutes of progressive relaxation exercise for three consecutive days
62254111|NCT04673227||Active TB group|Active TB group with positive microbial culture and pathological chest radiography or chest CT 20 children and adolescents 20 adults
62836262|NCT05647148|NO_INTERVENTION|Control group:|no intervention
62836263|NCT01829906|EXPERIMENTAL|Outpatient group|Multidisciplinary outpatient programme including both individual and group-based therapy. During the first visit, every patient will have an individual consultation with the dietician, physiotherapist and psychiatric nurse. After this, the patients will be followed up in groups every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
62836264|NCT01829906|EXPERIMENTAL|Inpatient group|"Inpatient lifestyle programme offered at a rehabilitation center consisting of a continuous care weight loss program, with three intermittent stays (each with three-week duration) over a one year period."
62836265|NCT01886066|EXPERIMENTAL|Indocyanine Green|All patients on study will have ICG injection for SLN mapping
62836266|NCT01902095|EXPERIMENTAL|Tooth powder (test) arm|Experimental arm: tooth powder
62836267|NCT01902095|ACTIVE_COMPARATOR|Tooth Paste (control)|Tooth Paste
62612295|NCT04170244||Psoriasis|"Intervention is whatever Rx the URMC dermatologist thinks is best suited to the subject as part of real-world disease management in her clinic. Ages:13-65 yrs of age (inclusive), all genders, races and ethnicities."
62612296|NCT06598189|EXPERIMENTAL|Ear-Worn Group|"All consented patients admitted to the Epilepsy Monitoring Unit (EMU) who are on continuous EEG (cEEG) will wear the ear-worn seizure detection device (EarSD) and there will be no randomization.~The Ear-SD Device will be simultaneously worn by EMU patients on continuous video 21 electrode EEG (International 10-20 system) and single channel electrocardiogram (ECG). Daily skin assessment will be conducted and electrodes will be replaced as needed. At the end of the study, a self-reported short qualitative survey will be conducted to assess the overall experience of the enrolled subjects. The EarSD device and electrodes will be removed at the end of the study with the last skin examination."
62612297|NCT01782560|PLACEBO_COMPARATOR|Placebo|Two different placebo formulations will be created which will designed to be identical in appearance, taste, and consistency to the two study medications.
62053070|NCT01984697|ACTIVE_COMPARATOR|Young Women 16 to 26 Years V503 at Months 0, 2, and 6|Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
62053071|NCT03455452||Cohort 1: Nivolumab|Participants diagnosed with advanced renal cell carcinoma (RCC) and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of RCC
62612298|NCT01782560|ACTIVE_COMPARATOR|Omeprazole|Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. 2 mg/kg/day omeprazole.
62612299|NCT03877224|EXPERIMENTAL|Dapagliflozin|Green, diamond shaped, film coated tablets 10 mg administered orally, once daily
62612300|NCT03877224|PLACEBO_COMPARATOR|Placebo|Green, diamond shaped, film coated tablets placebo administered orally, once daily
62612301|NCT00232466|NO_INTERVENTION|2|conservative therapy (no intervention)
62612302|NCT00232466|ACTIVE_COMPARATOR|1|Vertebroplasty
62053072|NCT03455452||Cohort 2: Nivolumab + Ipilimumab|Participants diagnosed with advanced RCC and whose physician has decided to start a new systemic therapy with nivolumab + ipilimumab for the first time for the treatment of RCC
62053073|NCT00669786|ACTIVE_COMPARATOR|HMG|Human Menopausal Gonadotropin (HMG)
62053074|NCT00669786|ACTIVE_COMPARATOR|r-FSH|Recombinant Follicle Stimulating Hormone
62053075|NCT00980369||Chronic anal fissures|Group A: with vertical incision Group B: with parallel incision
62053076|NCT00980369||Parallel incision, vertical insicion|
62254112|NCT04673227||Contact with active TB/ negative|After a close contact with bacteriologically confirmed TB no evidence of TB in TST or IGRA test for 3 months 20 children and adolescents 20 adults
62612303|NCT05490823|EXPERIMENTAL|Eligible patients for app-based anemia screening|Device: A smartphone app for anemia screening This app can achieve automatic detection of anemia based on patient-sourced images of fingernails and conjunctivae.
62836268|NCT01853735||bowel injury, NPO|Patients with bowel injury who remain nil-per-os (fed nothing)
62836269|NCT01853735||bowel injury, EN|Patients with bowel injury who are fed by enteral nutrition (EN)
62254113|NCT02061670|EXPERIMENTAL|Ragweed-SPIRE 1|Ragweed-SPIRE regimen 1 given 2 weeks apart
62254114|NCT02061670|EXPERIMENTAL|Ragweed-SPIRE 2|Ragweed-SPIRE regimen 2 given 2 weeks apart
62836270|NCT01853735||no bowel injury, NPO|Patients without bowl injury who remain nil-per-os (fed nothing)
62836271|NCT01853735||no bowel injury, EN|Patient without bowl injury who are fed by enteral nutrition (EN)
62836272|NCT00681278||1|Hypertension patients with Type II Diabetes mellitus
62254115|NCT02061670|PLACEBO_COMPARATOR|Placebo|Placebo given 2 weeks apart
62254116|NCT05567575|EXPERIMENTAL|TechCare|"Participants in this arm will receive a mobile app based cognitive behavior therapy informed TechCare intervention for a period of 12 weeks."
62254117|NCT05567575|ACTIVE_COMPARATOR|Wait-List control group:|Participants in this arm will be offered the intervention once the intervention arm have completed their 3rd month outcome assessment.
62254118|NCT00086970|EXPERIMENTAL|Arm I (ifosfamide)|Patients receive high-dose ifosfamide IV continuously over 72 hours on days 1-3.
62612304|NCT05062720|EXPERIMENTAL|Local consolidative therapy (LCT) + systemic therapy|Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies
62612305|NCT05062720|ACTIVE_COMPARATOR|Systemic therapy alone|Appropriate second-line systemic therapy, as defined in the NCCN guidelines will be used during study treatment (https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf). The choice of specific regimen will be left to the discretion of the treating oncologist but cannot include other experimental or investigational treatment. Sample appropriate systemic therapies include FOLFOX or FOLFIRI with a biologic agent such as an anti-angiogenic antibody or anti-EGFR antibody.
62612306|NCT02689310|OTHER|Standard Care - Stage III Pressure Ulcers|Patients with a stage III pressure ulcer who are randomized into this arm will be given standard treatment (hydrogel, collegense, and silver alginate dressings).
62836273|NCT03891849|EXPERIMENTAL|octreotide (25 µg/hour) perfusion|octreotide (25 µg/hour) plus norepinephrine will be administered for patient with haemorrhagic shock after variceal bleeding during 2 to 5 days according recommendations and regular protocol in the medical unit
62836274|NCT03586154|OTHER|Group A|patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml
62836275|NCT03586154|ACTIVE_COMPARATOR|Group B|patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml plus posterior approach shoulder injection with PRP.
62836276|NCT00930046|ACTIVE_COMPARATOR|Ropivacaine group|Patients in this group will receive ropivacaine via the wound catheter for the first 48hrs after surgery
62836277|NCT00930046|PLACEBO_COMPARATOR|Normal Saline Group|Will receive an infusion of normal saline for 48hrs post-operatively via the wound catheter.
62836278|NCT06523920|EXPERIMENTAL|UWsolution|Flap preserved in UW solution and cold storage during the ischemia time
62836279|NCT06523920|SHAM_COMPARATOR|No perfusion|Flap without perfusion and cold storage
62612307|NCT02689310|EXPERIMENTAL|Honey Treatment - Stage III Pressure Ulcers|Patients with a stage III pressure ulcer who are randomized into this treatment arm will be given leptospermum scoparium honey dressings for treatment of their wound.
62836280|NCT01241201|PLACEBO_COMPARATOR|Placebo|placebo for probiotic treatment
62836281|NCT00988728|EXPERIMENTAL|SCH 900435|SCH 900435 (Org 25935): a Glycine Uptake Inhibitor
62053077|NCT04791072|EXPERIMENTAL|Telecoaching group|They will be given breathing exercise training and will be asked to do it every day for 8 weeks. In addition to breathing exercises, the use of incentive spirometry and aerobic exercise training will be provided. They will be asked to do breathing exercises, use of incentive spirometry and strengthening exercises for at least 20 minutes every day and 5 times a week. They will be called by phone once a week and encouraging speeches will be made.
62053078|NCT04791072|ACTIVE_COMPARATOR|Control Group|They will be given breathing exercise training and will be asked to do it every day. In addition to breathing exercises, the use of incentive spirometry and aerobic exercise training will be provided. They will be asked to do breathing exercises, use of incentive spirometry and strengthening exercises for at least 20 minutes every day and 5 times a week. There will be no interviews in the control group.
62053079|NCT00256503|EXPERIMENTAL|Insomnia|Insomnia subjects who receive 8 session cognitive behavioral therapy for insomnia.
62053080|NCT00256503|NO_INTERVENTION|Good Sleeper|Good sleeper controls who receive no intervention
62053081|NCT03469284|EXPERIMENTAL|Group 1 (lower dose methylene blue, standard of care)|Patients receive lower dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
62053082|NCT03469284|EXPERIMENTAL|Group 2 (medium dose methylene blue, standard of care)|Patients receive medium dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
62053083|NCT03469284|EXPERIMENTAL|Group 3 (higher dose methylene blue, standard of care)|Patients receive higher dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
62053084|NCT03469284|ACTIVE_COMPARATOR|Group 4 (standard of care)|Patients receive standard of care therapy.
62836282|NCT00988728|PLACEBO_COMPARATOR|Placebo|
62836283|NCT00988728|ACTIVE_COMPARATOR|Olanzapine|
62836284|NCT04615832|EXPERIMENTAL|Toffee Full Face Mask|Toffee Full Face Mask: Full face mask for PAP therapy applied in a home environment for 2 weeks.
62836285|NCT02870907|EXPERIMENTAL|Low risk group|No treatment
62053085|NCT02386384||Control|Normal fertile
62053086|NCT02386384||Implantation Failure|Failure to conceive
62053087|NCT02386384||Recurrent Pregnancy Loss|2 or more unexplained miscarriages
62053088|NCT03258216||peptic ulcer|patients who had upper GI symptoms and diagnosed as peptic ulcer by panendoscopy, followed tongue images by Automatic Tongue Diagnosis System
62053089|NCT03258216||healthy|patients who had no past history or systemic disease, diagnosed as UGI negative finding by panendoscopy, followed tongue images by Automatic Tongue Diagnosis System
62053090|NCT06579586||Children undergoing tonsillectomy ± adenoidectomy|It is aimed to understand whether high parental anxiety leads to increased pain in children undergoing tonsillectomy ± adenoidectomy surgery and whether it increases the development of complications.
62053091|NCT04646239||Participants in the CROWN CORONATION trial|The CROWN CORONATION trial will randomly allocate adult participants to a single intramuscular injection of MMR vaccine or Placebo (0.9% saline). All participants in this sub-study receive SARS-CoV-2 specific vaccine subsequent to the MMR or Placebo injection.
62053092|NCT01900600|PLACEBO_COMPARATOR|Placebo|Placebo
62254119|NCT00086970|EXPERIMENTAL|Arm II (O6-benzylguanine, ifosfamide)|Patients receive a bolus dose of O6-benzylguanine (BG) IV over 1 hour on day 1 followed by BG IV continuously and high-dose ifosfamide IV continuously over 72 hours on days 1-3.
62254120|NCT00942175|OTHER|Regimen A|Clopidogrel 75 mg QD
62836286|NCT02870907|EXPERIMENTAL|Intermediate risk sub group 1|2 cycles (4 courses): 2 courses of etoposide and Carboplatin from D1 to D5 and Vincristin at D22 and D26- Cyclophosphamide from D22 to D26.
62053093|NCT01900600|ACTIVE_COMPARATOR|Canakinumab 50 mg quarterly|Canakinumab 50 mg quarterly
62053094|NCT01900600|ACTIVE_COMPARATOR|Canakinumab 150 mg quarterly|Canakinumab 150 mg quarterly
62053095|NCT01900600|ACTIVE_COMPARATOR|Canakinumab 300 mg quarterly|Canakinumab 300 mg quarterly
62254121|NCT00942175|OTHER|Regimen B|Clopidogrel 75 mg QD and Lansoprazole 30 mg QD
62836287|NCT02870907|EXPERIMENTAL|Intermediate risk sub group 2|2 courses of Vincristin and Carboplatin
62836288|NCT02870907|EXPERIMENTAL|High risk group|"* Orbital irradiation~* 3 cycles of two different types of alternating chemotherapy courses (id 6 courses) :~  * Etoposide (100 mg/m²/d) and Carboplatin (160 mg/m²/d) with intrathecal Thiotepa injection.~ * Vincristin (1,5 mg/m²/d) - Cyclophosphamide (1000 mg/m²/d)~ * Cytapheresis for peripheral blood stem cells collection after the primary or the secondary courses of Vincristine- Cyclophosphamide.~* High dose chemotherapy :~  * Carboplatin (AUC : 7/d) - etoposide (250 mg/m²/d) - Thiotepa (300 mg/m²/d)~ * Peripheral bood stem cell transplantation."
62836289|NCT00713518|ACTIVE_COMPARATOR|Arm 1 ranibizumab|0.5 mg ranibizumab intravitreal injection given every 4 weeks from baseline to Week 12
62053096|NCT05438654|OTHER|Cohort of patients presenting to emergency department with abdominal right upper quadrant pain|This study is a single arm study analyzing a prospective population of patients presenting at the emergency department complaining of non-traumatic right upper quadrant abdominal pain. The analysis of the diagnostic approach will take place before and after the intervention on a same patient. The intervention is the use of Point of Care Ultrasound bedside.
62053097|NCT02660814|PLACEBO_COMPARATOR|Healthy periodontium without obesity|"GCF samples were taken at baseline~Intervention: Gingival crevicular fluid collection"
62254122|NCT00942175|OTHER|Regimen C|Clopidogrel 75 mg QD and Dexlansoprazole 60 mg QD
62254123|NCT00942175|OTHER|Regimen D|Clopidogrel 75 mg QD and Omeprazole 80 mg QD
62254124|NCT00942175|OTHER|Regimen E|Clopidogrel 75 mg QD and Esomeprazole 40 mg QD
62836290|NCT00713518|EXPERIMENTAL|Arm 2 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 3 mg PF-04523655 given by intravitreal injection every 2 weeks from Week 4 to Week 12
62836291|NCT00713518|EXPERIMENTAL|Arm 3 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 1 mg PF-04523655 given by intravitreal injection evey 4 weeks to Week 12
62836292|NCT00713518|EXPERIMENTAL|Arm 4 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 3 mg of PF-04523655 given by intravitreal injection every 4 weeks from Week 4 to Week 12
62836293|NCT00713518|EXPERIMENTAL|Arm 5 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 1 mg of PF-04523655 (30 minutes later) given in combination every 4 weeks from baseline to Week 12
62836294|NCT05854238|EXPERIMENTAL|TIRA-VoM|treated with transcatheter RF ablation system (TIRA catheter with its supplemental devices)
62836295|NCT02565108|EXPERIMENTAL|GWP42003-P 20 mg/kg/Day Dose|"Participants received GWP42003-P 20 milligrams \[mg\]/kilogram \[kg\]/day orally, twice daily immediately after their clobazam (CLB) dose. Participants titrated GWP42003-P to 20 mg/kg/day over 10 days and remained at this dose for the 21-day treatment period. Participants who then did not enter the open-label extension (OLE) or withdrew early had a 10-day taper (10% per day) period. Participants who transferred to the OLE (still blinded at that stage) tapered off their GWP42003-P treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P for the OLE.~All participants (in the GWP42003-P and Placebo treatment groups) were on a stable dose of CLB at Baseline, administered either once or twice daily as per the physician's preferred CLB dosing regimen for each participant, and continued taking CLB, as an Investigational Medicinal Product (IMP), for the duration of this study."
62836296|NCT02565108|PLACEBO_COMPARATOR|Placebo|"Participants received placebo (0 mg/milliliter \[mL\] GWP42003-P) orally, twice daily immediately after the participant's CLB dose. Participants titrated the placebo dose over 10 days, followed by a 21-day treatment period. Participants who then did not enter the OLE or withdrew early had a 10-day taper (10% per day) period. Participants who transferred to the OLE (still blinded at that stage) tapered off their placebo treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P for the OLE.~All participants (in the GWP42003-P and Placebo treatment groups) were on a stable dose of CLB at Baseline, administered either once or twice daily as per the physician's preferred CLB dosing regimen for each participant, and continued taking CLB, as an IMP, for the duration of this study."
62836297|NCT03490695|EXPERIMENTAL|Practice Facilitation Group A|After the first 12 months of usual care (No Practice Facilitation), group A will begin to receive the Practice Facilitation (PF) Strategy at the CHPS compounds in addition to Ghana's National Health insurance and the World Health Organization (WHO) CVD Risk Assessment package.
62836298|NCT03490695|EXPERIMENTAL|Practice Facilitation Group B|"Group B will receive Usual Care (no PF) between 12-24 months which includes Ghana's National Health Insurance, behavioral counseling and referral to care through the usual care system.~After 24 months into the trial, Group B will then receive Practice Facilitation strategy in addition to Ghana's National Health insurance and the World Health Organization (WHO) CVD Risk Assessment package for a duration of another 12 months, as this is a stepped wedge design.~During this 12 months period, practice facilitation will end in the Group A arm."
62836299|NCT03513939|EXPERIMENTAL|T1D Cell Pouch Recipients|Eligible Type 1 Diabetes Mellitus (T1D) subjects with hypoglycemia unawareness and a history of severe hypoglycemic episodes undergoing Sernova Cell Pouch intervention
62836300|NCT03543878|EXPERIMENTAL|Flicker for 8 Weeks|Participants will receive the Flicker exposure during the entire 8-week treatment period
62254125|NCT00169689|SHAM_COMPARATOR|rTMS|sham coil system versus verum rTMS stimulation
62254126|NCT01444248|EXPERIMENTAL|Amaryl MEX|
62053098|NCT02660814|ACTIVE_COMPARATOR|Chronic periodontitis without obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions)"
62254127|NCT01444248|ACTIVE_COMPARATOR|Amaryl M|
62254128|NCT01519596|EXPERIMENTAL|Arm I (physical activity)|Patients participate in an orientation session introducing the exercise program and protocol, reviewing fundamental principles, and demonstrating each activity. Patients also receive educational materials to facilitate orientation and adherence. Patients are offered 20-50 minute standard, intermediate, and/or low intensity physical activity sessions 5 days a week for 4 weeks. Patients also receive lifestyle-related counseling for 20-30 minutes once weekly.
62254129|NCT01519596|ACTIVE_COMPARATOR|Arm II (usual care)|Patients undergo usual care for 4 weeks.
62254130|NCT06385730|EXPERIMENTAL|neoadjuvant anti-PD-1|Drug: Immunotherapy Patients will receive the neoadjuvant immunotherapy with toripalimab followed by the esophagectomy.
62254131|NCT06385730|EXPERIMENTAL|neoadjuvant anti-PD-1 with LDRT|Drug: Immunotherapy Patients will receive the neoadjuvant low-dose radiotherapy plus immunotherapy with toripalimab followed by the esophagectomy.
62254132|NCT02307487|EXPERIMENTAL|Cohort A2|120 mg MMC in 90ml gel
62254133|NCT02307487|EXPERIMENTAL|Cohort B2|140 mg MMC in 90ml gel
62053099|NCT02660814|PLACEBO_COMPARATOR|Healthy periodontium with obesity|"GCF samples were taken at baseline~Intervention: Gingival crevicular fluid collection"
62254134|NCT02307487|EXPERIMENTAL|Cohort C2|160 mg MMC in 90ml gel
62254135|NCT02307487|EXPERIMENTAL|Cohort A|120 mg MMC in 60ml gel
62254136|NCT02307487|EXPERIMENTAL|Cohort B|140 mg MMC in 60ml gel
62254137|NCT02307487|EXPERIMENTAL|Cohort C|160 mg MMC in 60ml gel
62254138|NCT03278600|EXPERIMENTAL|site-specific therapy|standard treatments of sites of origin
62254139|NCT03278600|ACTIVE_COMPARATOR|standard empiric chemotherapy|standard empiric chemotherapy
62254140|NCT02218957|ACTIVE_COMPARATOR|Standard RYGB|Standard RYGB
62254141|NCT02218957|EXPERIMENTAL|Extended Pouch RYGB|Restrictive/extended pouch RYGB
62254142|NCT06226909|EXPERIMENTAL|Shear-wave elastography-guided|based on the shear-wave elastography, the area with the highest elasticity value will be the target area to perform pleural biopsy for at least 6 times
62254143|NCT06226909|ACTIVE_COMPARATOR|B-mode ultrasound-guided|based on the B-mode transthoracic ultrasound, the area with the maximal thickness will be the target area to perform pleural biopsy for at least 6 times
62254144|NCT03994328||Group 1|500 patients already receiving safinamide (50 or 100 mg/day) as add-on to L-dopa for no more than 2 months.
62612308|NCT02689310|OTHER|Standard Care - Stage IV Pressure Ulcers|Patients with a stage IV pressure ulcer who are randomized into this arm will be given standard treatment (hydrogel, collegense, and silver alginate dressings).
62836301|NCT03543878|ACTIVE_COMPARATOR|Flicker for 4 Weeks|Participants will receive the Flicker exposure during the second four weeks of the 8-week treatment period
62836302|NCT02740023|ACTIVE_COMPARATOR|Phonak Audéo V90-13|The Phonak Audéo V90-13 will be fitted to the participants individual hearing loss.
62836303|NCT02740023|EXPERIMENTAL|Successor of Phonak Audéo V90-13|The successor of Phonak Audéo V90-13 will be fitted to the participants individual hearing loss.
62836304|NCT04529018|EXPERIMENTAL|Healthy Volunteers|A group of 5 healthy volunteers will be tested with the PET radiotracer \[18F\]CETO to assess safety of tracer administration, and evaluate uptake by the normal adrenal glands.
62836305|NCT04529018|EXPERIMENTAL|Patients with primary aldosteronism|A group of 6 patients with Primary Aldosteronism (3 with unilateral and 3 with bilateral disease) will be tested with up to two administrations of the PET radiotracer \[18F\]CETO, to assess safety of tracer administration, evaluate the ability of \[18F\]CETO to distinguish between unilateral and bilateral cases of PA, and determine the effect of Dexamethasone in improving the quality of PET-CT images acquired following administration.
62836306|NCT02881606|ACTIVE_COMPARATOR|Naso-alveolar molding (NAM)|Active plates and nasal stents (Grayson method)
62836307|NCT02881606|ACTIVE_COMPARATOR|Computer aided design NAM (CAD/NAM)|Computer aided design active plates and nasal stents
62836308|NCT04287582||Level 1 DMD|According to Brooke Lower Extremity Functional Classification Level 1
62053100|NCT02660814|ACTIVE_COMPARATOR|Chronic periodontitis with obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions)"
62254145|NCT03994328||Group 2|500 patients receiving rasagiline 1 mg/day as add-on to L-dopa for no more than 2 months.
62254146|NCT03994328||Group 3|235 patients receiving other SoC drugs as add-on to L-dopa for no more than 2 months.
62254147|NCT04624464||Cohort 1: VRE negative at admission|"150 patients meeting the following inclusion criteria:~* ≥ 18 years~* Patients with malignant primary disease and current inpatient admission to a normal ward with expected inpatient stay of at least 15 days~* High risk of exposure to antibiotics during the stay~* Written informed consent of the patient after clarification has been given~Exclusion criteria:~* Already known current or documented past colonisation or infection by VRE~* Simultaneous participation in other studies is only an exclusion criterion if the other study explicitly excludes participation in observational studies or if the other study complicates the interpretation of the endpoints of AEGON (e.g. double-blind study on antibiotic use)."
62254148|NCT04624464||Cohort 2: VRE positive at admission|"A total 20 known VREf-positive patients meeting the following inclusion criteria:~* Intestinal VREf colonization already known at the time of admission (e.g. based on examinations during previous stays or in external facilities)~* Accommodation in a single room or alternatively multi-bed room with single occupancy on standard wards~* Expected stay of at least 7 days"
62836309|NCT04287582||Level 2-3 DMD|According to Brooke Lower Extremity Functional Classification Level 2 or 3
62836310|NCT04287582||Healthy Group|healthy children with similar demographic characteristics with children with DMD
62836311|NCT02832115|EXPERIMENTAL|Study|40 mg of topical lidocaine and 30 mg of topical nitroglycerine is applied to the wrist overlying radial pulse (centered approximately 1 inch proximal to the radial styloid process) at least 60 minutes before arterial puncture. Immediately prior to sterile preparation of access site, transdermal preparation will be removed in the cath lab.
62836312|NCT02832115|PLACEBO_COMPARATOR|Control|40 mg of topical lidocaine and placebo is applied to the wrist overlying radial pulse (centered approximately 1 inch proximal to the radial styloid process) at least 60 minutes before arterial puncture. Immediately prior to sterile preparation of access site, transdermal preparation will be removed in the cath lab.
62836313|NCT04605809|EXPERIMENTAL|combined motor and cognitive training|The combined motor and cognitive training group will undertake physical fitness training under sitting and standing, walking training while sequentially or simultaneously perform cognitive training.
62836314|NCT04605809|ACTIVE_COMPARATOR|motor training alone|The motor training alone group will train the same set of physical fitness training while sitting, standing, and walking as the combined motor and cognitive training group.
62612309|NCT02689310|EXPERIMENTAL|Honey Treatment - Stage IV Pressure Ulcers|Patients with a stage IV pressure ulcer who are randomized into this treatment arm will be given leptospermum scoparium honey dressings for treatment of their wound.
62612310|NCT01691703|EXPERIMENTAL|Videolaryngoscope and Bonfils|First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
62836315|NCT04605809|ACTIVE_COMPARATOR|cognitive training alone|The cognitive training alone group will train the same set of cognitive training while sitting as the combined motor and cognitive training group.
62836316|NCT04605809|NO_INTERVENTION|no intervention control group.|No intervention control group will maintain habit and daily activity.
62836317|NCT05437406|EXPERIMENTAL|PBT-AC|PBT-AC includes the elements of family based behavioral treatment for obesity, delivered exclusively to caregivers as the agents of change, via telehealth.
62836318|NCT05437406|ACTIVE_COMPARATOR|Health Education|This program provides information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress via telehealth.
62836319|NCT01519921|EXPERIMENTAL|PEG-IFN alfa-2a (Treatment naïve)|Eligible treatment naïve participants received peginterferon alfa-2a (PEGASYS) 180 micrograms (mcg) subcutaneously (SC) once weekly for 48 weeks, followed by 24 weeks of treatment-free follow-up.
62836320|NCT01519921|EXPERIMENTAL|PEG-IFN alfa-2a (YMDD mutant)|Eligible tyrosine-methionine-aspartate-aspartate (YMDD) mutant participants received PEGASYS 180 mcg SC once weekly for 48 weeks, followed by 24 weeks of treatment-free follow- up. Participants received lamivudine concomitantly for the initial 12 weeks.
62836321|NCT00654771||1|women undergoing evaluation for pre-eclampsia
62836322|NCT00264732|EXPERIMENTAL|1|
62836323|NCT00264732|EXPERIMENTAL|2|
62836324|NCT00264732|PLACEBO_COMPARATOR|3|
62836325|NCT05182749|PLACEBO_COMPARATOR|Placebo|Dose is 1mL of placebo given orally three times a day for 7 days (Phase 1) or 6 days (Phase 2a)
62836326|NCT05182749|EXPERIMENTAL|Bacteriophage|Dose is 1mL of bacteriophage preparation given orally three times a day for 7 days (Phase 1) or 6 days (Phase 2a)
62836327|NCT02791672||Same Day Discharge|Following a Latissimus Dorsi flap reconstruction patients will be offered discharge at 24 hours. Patients successfully discharged within 24 hours of their surgery will be included in the cohort group.
62053101|NCT05503589||student group|have taken the professional practice/internship lecture and be practicing in the hospital
62053102|NCT05503589||control group|who routinely work during the pandemic
62836328|NCT01637441|EXPERIMENTAL|laparoscopic sacropexy|under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
62612311|NCT02095405|ACTIVE_COMPARATOR|Caffeine arm|"SVT group: Caffeine tablets, 5 mg/kg.~AF group: Caffeinated substances and Dark Chocolate"
62836329|NCT01637441|EXPERIMENTAL|vaginal mesh|after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
62836330|NCT05380817|OTHER|BAWSI Group|By partnering with a community sports club (BAWSI), will the partnership recruitment model be effective in enrolling minority children.
62836331|NCT05380817|OTHER|YMCA of Silicon Valley Group|By partnering with a community organization (YMCA of Silicon Valley), will the partnership recruitment model be effective in enrolling minority children.
62836332|NCT01039519|EXPERIMENTAL|ganetespib 200 mg/m^2|Ganetespib (STA-9090) 200 mg/m\^2 intravenous infusion once weekly for 3 consecutive weeks followed by one week dose free interval (3 weeks on and 1 week off represent a treatment cycle). Treatment continues until disease progression or unacceptable toxicity.
62836333|NCT02434406|EXPERIMENTAL|Web-based intervention|Participants get access to the web-based intervention and are asked to work through the 8 modules of the intervention within eight weeks. The intervention program sends automated weekly email reminders about the current session. In addition, users are offered weekly optional 30-minute telephone support with a trained intervention coach.
62254149|NCT01969487|EXPERIMENTAL|Preoperative warm-up on simulator|Trainees perform standard practice tasks programmed into a robotic surgical simulator immediately before the surgery.
62254150|NCT01969487|NO_INTERVENTION|No preoperative warm-up|
62836334|NCT02434406|NO_INTERVENTION|Wait-list control|Participants get standard care and will be offered access to the web-based intervention at 8-weeks post-randomization.
62836335|NCT03461588|ACTIVE_COMPARATOR|Free-breathing|standard treatment
62836336|NCT03461588|EXPERIMENTAL|Deep inspiratory breath-holding|new technique
62254151|NCT05788744|EXPERIMENTAL|A: Experimental|Patients will receive surveillance with liver enzymes, CA 19-9, history, clinical evaluation of signs of recurrence (e.g. weight loss, abdominal pain or fatigue) in combination with analysis of plasma ctDNA (90 ml blood drawn per visit) every 3 months until disease progression or up to 36 months. If plasma ctDNA is positive the patient will have a CT scan (thorax and abdomen) and EUS every 3 months for 2 years and then every 6 months until disease recurrence or up to 36 months. If plasma ctDNA is negative the patient will have CT scan of thorax and abdomen and EUS every 6 months until disease recurrence or up to 36 months. Plasma eccDNA will be determined at the same time as ctDNA but a positive eccDNA result will not be informed to the patients.
62443060|NCT01380028|ACTIVE_COMPARATOR|oral corticosteroids|The aim of this prospective multicenter randomized, double blind, is to evaluate in patients with chronic subdural hematoma, compared with placebo, the efficacy of postoperative corticosteroid treatment orally for approximately 2 months on the rate of clinical recurrence
62612312|NCT02095405|PLACEBO_COMPARATOR|Placebo arm|"SVT group: Placebo~AF group: Decaffeinated substances and White Chocolate"
62612313|NCT06065228||UC|
62836337|NCT05811286|EXPERIMENTAL|Hysteroscopic morcellation 19 Fr. intrauterine BIGATTI Shaver for uterine intracavitary lesions|Single experimental arm of patients with a intracavitary lesion and elligible for hysteroscopic morcellation.
62836338|NCT03963258|ACTIVE_COMPARATOR|control group|Over a 3-week period, the subjects in the control group received 1 hour daily of conventional upper limb training 5 times a week,including compensatory techniques for activities of daily living, UE strength, therapist-guided techniques for facilitating normal UE movement patterns,and range of motion and traditional positioning
62836339|NCT03963258|EXPERIMENTAL|whole-body vibration group|Subjects in the whole-body vibration group received half an hour of daily conventional upper limb training, followed by whole-body vibration training for an additional half hour per day,5 days per week during a 3-week period
62836340|NCT00803569|EXPERIMENTAL|ALVAC(2)-NY-ESO-1(M)/TRICOM + GM-CSF|Patients received SC injections with ALVAC(2)-NY-ESO-1(M)/TRICOM (0.5 mL) on Day 1 and the GM-CSF sargramostim (100 μg) on Days 1 through 4 in continuous 28-day cycles for up to 6 cycles.
62836341|NCT06003894|ACTIVE_COMPARATOR|kegel group|Participants will only practice kegel exercises.
62836342|NCT06003894|EXPERIMENTAL|diaphragm group|In addition to kegel exercises, 360 degree expanded diaphragm breathing training will be given to the participants.
62836343|NCT04921072|EXPERIMENTAL|CG - Constant practice condition group|CG will be practicing only one specific pattern of step isometric contractions (SPSIC) scheme. It means that 90 trials in all training sessions will consist only of SPSIC 1.
62836344|NCT04921072|EXPERIMENTAL|VG - Variable practice condition group|VG will practice three SPSIC's (1-3). Each SPSIC will be practiced 30 times per session, which means that each session will consist of 90 SPSIC like CG.
62836345|NCT00843219||PET/CT Scan|
62053103|NCT06059976||Hypnosis|"Inclusion of patients undergoing major cardiac surgery who have received perioperative hypnosis sessions from January 2023.~After obtaining their consent to participate in this study"
62612314|NCT06065228||CD|
62836346|NCT04995952|EXPERIMENTAL|Gross motor training activity|Gross motor training activity It includes training of motor components of child grossly
62836347|NCT04995952|EXPERIMENTAL|Trunk targeted training|In this training group the particpiants were given the exercises that were focused the truck muscles
62836348|NCT04855526|EXPERIMENTAL|Occasional Users - High THC and High CBD Dose|People who smoke marijuana occasionally will be given a dose of high THC high CBD marijuana at the study visit
62836349|NCT04855526|EXPERIMENTAL|Occasional Users - High THC and No CBD Dose|People who smoke marijuana occasionally will be given a dose of high THC and no CBD marijuana at the study visit
62836350|NCT04855526|EXPERIMENTAL|Occasional Users - No THC and No CBD Dose|People who smoke marijuana occasionally will be given a dose of marijuana that contains no THC or CBD
62053104|NCT00989092|OTHER|Observational Group|Participants in the observation group were evaluated once every 2 weeks for the first 12 weeks (test period). No darbepoetin alfa was administered to the observation group during this period. Darbepoetin alfa could be initiated at a dose of 3.0 μg/kg once every 2 weeks beginning with the first visit after the test period at which the participants hemoglobin concentration was less than or equal to 11.0 g/dL. The dose of darbepoetin alfa could be increased to 5.0 μg/kg once every 2 weeks after 6 weeks of darbepoetin alfa treatment in participants with a hemoglobin change from baseline of less than 1.0 g/dL.
62053105|NCT00989092|ACTIVE_COMPARATOR|21 week treatment group|Participants in the treatment group received darbepoetin alfa subcutaneously (SC) at a dose of 3.0 μg/kg once every 2 weeks for 21 weeks. The dose of darbepoetin alfa could be increased at week 7 (to 5.0 μg/kg once every 2 weeks) or at week 13 (to 9.0 μg/kg once every 2 weeks) in participants with a hemoglobin change from baseline of less than 1.0 g/dL who dose escalated at week 7.
62053106|NCT03075384||open reduction and internal fixation|A classic method was used to treat unilateral complicated zygomatic fractures without the assistance of computer-assisted navigation system
62053107|NCT06018792||Pediatric sepsis|Study participants aged 3 months - 18 years who undergo collection of blood for conventional blood culture
62053108|NCT06018792||Late onset sepsis|Study participants aged up to 3 months who undergo culturing of blood for conventional blood culture Preterm infants aged \<32 weeks gestational age as a subgroup
62053109|NCT06018792||Early onset sepsis|Study participants aged up to 3 days who undergo culturing of blood for conventional blood culture
62053110|NCT06018792||Post antibiotic initiation cohort|participants for whom venipuncture is performed for follow up of inflammatory parameters \<36h after antibiotic initiation and blood draw for conventional culture or for whom a repeat intravenous catheterization is performed due to failing of a previous one \<36h after antibiotic initiation and blood draw for conventional culture
62053111|NCT06139757||Euploid embryo transfer group|Participants will wear the Oura Ring continuously for data collection starting in the month prior to their embryo transfer date. They will wear the Oura Ring throughout the preparation, embryo transfer, and post-transfer until either a negative pregnancy test or, if positive, until 8 weeks gestation. The study time for each participant will thus extend from either 5 weeks for negative pregnancy tests, to 10 weeks for normally continuing pregnancies.
62053112|NCT04569110||Pleural infection|Patients with clinically confirmed ongoing pleural infection.
62053113|NCT04569110||Negative control|Patients without pleural infection.
62053114|NCT05373355|EXPERIMENTAL|Cohort 1|TLL018 tablets 1piece,BID
62053115|NCT05373355|EXPERIMENTAL|Cohort 2|TLL018 tablets 3pieces, BID
62053116|NCT05373355|PLACEBO_COMPARATOR|Cohort 3|TLL018 placeboes 3pieces, BID
62053117|NCT04975269|ACTIVE_COMPARATOR|Acetazolamide|Acetazolamide (active)
62053118|NCT04975269|PLACEBO_COMPARATOR|Placebo|Placebo
62053119|NCT03760536||16-week Exercise Program|Interested patients will attend a group meeting where they will be screened and consented to the study. During weeks 1 and 2 patients will complete pre-intervention baseline assessments and blood draws followed by a 16-week supervised exercise program at Get REEL and HEAL facility. Study participants will complete progressive aerobic and resistance exercise training. Post-intervention weeks 1 and 2 participants will complete assessments, questionnaires and blood draws. Participants will be followed up at 6 and 12 months post intervention with physical assessments, questionnaires and blood draws. Annual follow-up will occur at year 2,3,4 and 5 post intervention with questionnaires only.
62053120|NCT00045708|EXPERIMENTAL|Group A [Anticonvulsants]|"Phase I: Dose Escalation - Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 patients experience dose-limiting toxicity.~Pharmacological Study Phase 1"
62053121|NCT00045708|EXPERIMENTAL|Group B [No Anticonvulsants]|"Phase I: Dose Escalation - Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 patients experience dose-limiting toxicity.~Pharmacological Study Phase 1"
62836351|NCT01817270|EXPERIMENTAL|Live Attenuated Varicella Vaccine|use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
62836352|NCT00712439|EXPERIMENTAL|1|
62836353|NCT00712439|PLACEBO_COMPARATOR|2|
62836354|NCT03310918|EXPERIMENTAL|Collaborative palliative and oncology care|"* 1st palliative care visit within 30 days of randomization in the outpatient or hospital~* In outpatient setting: once monthly palliative care visits (or video/ or phone)~* During hospital admissions: At least twice weekly palliative care visits"
62836355|NCT03310918|ACTIVE_COMPARATOR|Standard oncology care|"* Palliative care consults only upon request~* Standard oncology care"
62836356|NCT02393378|EXPERIMENTAL|Adalimumab 40 mg|Adalimumab 40 mg, subcutaneous (SC) injection at Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 as an add-on to weekly existing stable MTX and folic acid as per prescribed medication.
62836357|NCT02393378|ACTIVE_COMPARATOR|Namilumab 150 mg|Namilumab 150\*2 mg, SC injection at Week 0 followed by 150 mg, SC injections at Weeks 2, 6, 10, 14, 18, and 22 as an add-on to weekly existing stable MTX and folic acid as per prescribed medication.
62836358|NCT01391546|EXPERIMENTAL|ZOSTAVAX intramuscular (IM) route|Single dose of 0.65 mL via IM injection
62612315|NCT06509789|EXPERIMENTAL|Low intensity priming intermittent theta burst stimulation (iTBS)|Standard 600-pulse TBS will be applied using the MagPro X100 stimulator (MagVenture, Denmark) connected with a figure-of-eight coil (Cooling B-65). The resting motor threshold (RMT) of the motor cortex (M1) will be defined as the minimum intensity over the motor hotspot that could elicit an motor evoked potential (MEP) of no less than 50 μv over the first dorsal interosseous muscle in at least five out of 10 trials. Low intensity priming iTBS consists of a session of 55% RMT cTBS, followed by 70% RMT iTBS.
62836359|NCT01391546|ACTIVE_COMPARATOR|ZOSTAVAX subcutaneous (SC) route|Single dose of 0.65 mL via SC injection
62836360|NCT02677883|EXPERIMENTAL|Arm I: Manometry-guided thoracentesis|Intervention Group - Patients undergo fine needle- aspiration, called therapeutic thoracentesis, to drain fluid accumulated around the lung. Unlike Arm II, the intervention group will have their pleural pressure monitored during the procedure.
62053122|NCT00045708|EXPERIMENTAL|Group C [MTD-Phase 2)|"Maximum tolerated Dose (MTD-Phase 2) - subjects treated at dose determined by Group B~Drug: ixabepilone~Other Names:~BMS-247550 epothilone B lactam Ixempra Given IV"
62053123|NCT03123146|EXPERIMENTAL|Fb-Cognitive Behavioral Therapy|Functional Behavior-Based Cognitive Behavioral Therapy: Group activities, individual work in parent-child dyads, group parent training, and social skills exercises.
62053124|NCT03123146|NO_INTERVENTION|Treatment as Usual (TAU)|"Children assigned to this condition received usual care, meaning that they could continue with any services. This group acted as a control group whereby access to intervention was patient-directed."
62053125|NCT02833688|EXPERIMENTAL|dexmedetomidine|dexmedetomidine 2mg is diluted in 0.9% sodium chloride with the concentration of 4 ug ml-1 is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
62612316|NCT06509789|EXPERIMENTAL|Standard priming intermittent theta burst stimulation (iTBS)|Standard 600-pulse TBS will be applied using the MagPro X100 stimulator (MagVenture, Denmark) connected with a figure-of-eight coil (Cooling B-65). The resting motor threshold (RMT) of the motor cortex (M1) will be defined as the minimum intensity over the motor hotspot that could elicit an motor evoked potential (MEP) of no less than 50 μv over the first dorsal interosseous muscle in at least five out of 10 trials. Standard priming iTBS consists of a session of 70% RMT cTBS, followed by 70% RMT iTBS.
62836361|NCT02677883|ACTIVE_COMPARATOR|Arm II: Symptom-guided thoracentesis|Comparison Group - Patients undergo symptom-guided thoracentesis, the current standard-of-care is to drain fluid until 1) it is all gone or 2) a symptom occurs that indicates the lung may take longer to fully re-expand and drainage should be stopped.
62836362|NCT00919321|OTHER|PPV|
62053126|NCT02833688|PLACEBO_COMPARATOR|0.9% sodium chloride|0.9% sodium chloride is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
62836363|NCT06190704||CMD|Microvascular function was assessed using caIMR, and 460 coronary arteries were analyzed. CMD was identified with caIMR\>25U, in line with prior research.
62836364|NCT06190704||non-CMD|Microvascular function was assessed using caIMR, and 460 coronary arteries were analyzed. CMD was identified with caIMR≤25U, in line with prior research.
62836365|NCT05654818|EXPERIMENTAL|Vitamin D|
62836366|NCT05654818|PLACEBO_COMPARATOR|Control|
62836367|NCT01378871|EXPERIMENTAL|Antibody Therapy|Treatment with Imtox-25 intravenously over 4 hours every other day for 4 doses. Hospital admission is required during this treatment.
62836368|NCT03352609|EXPERIMENTAL|Active rTMS|5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
62053127|NCT00710606|EXPERIMENTAL|1- Obese Women /Nuvaring|Obese subjects (BMI 30-39.9)received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
62836369|NCT03352609|SHAM_COMPARATOR|Sham|5 session of sham rTMS delivered with Magpro (MagVenture) double blind rTMS system to mimic active intervention.
62053128|NCT00710606|ACTIVE_COMPARATOR|2- Normal Weight / Nuvaring|Normal weight subjects (BMI 19-24.9) received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
62053129|NCT00681304||1|Only one group of participants will be studies. There are no controls.
62053130|NCT04606277||Young Adult|
62053131|NCT01359670|EXPERIMENTAL|Tadalafil|
62053132|NCT01359670|EXPERIMENTAL|Sildenafil|
62053133|NCT01180543|ACTIVE_COMPARATOR|Active Comparator: Oplon Active Patch|
62836370|NCT04200599|EXPERIMENTAL|Early oxytocin Infusion|labour augmentation with oxytocin was started early following amniotomy.
62053134|NCT01180543|PLACEBO_COMPARATOR|Placebo Comparator: Placebo patch|
62053135|NCT01572025|EXPERIMENTAL|DHEA supplementation|
62612317|NCT06509789|ACTIVE_COMPARATOR|Nonpriming intermittent theta burst stimulation (iTBS)|Standard 600-pulse TBS will be applied using the MagPro X100 stimulator (MagVenture, Denmark) connected with a figure-of-eight coil (Cooling B-65). The resting motor threshold (RMT) of the motor cortex (M1) will be defined as the minimum intensity over the motor hotspot that could elicit an motor evoked potential (MEP) of no less than 50 μv over the first dorsal interosseous muscle in at least five out of 10 trials. Nonpriming iTBS consists of a session of 20% RMT cTBS (sham), followed by 70% RMT iTBS.
62836371|NCT04200599|ACTIVE_COMPARATOR|Late oxytocin infusion|oxytocin augmentation was delayed at two hours after amniotomny and this practice is currently being used as standard protocol in this hospital to manage women in labour.
62836372|NCT04623632|ACTIVE_COMPARATOR|Bupivacaine|the landmark is at the level of umbilicus 8 to 10 cms from midline bilaterally. A tiny nick is made in the skin with a 18G sharp needle to obliterate the cushion effect. Then an 18 G Tuohy needle will be insert perpendicular to skin directing the needle slightly towards the ipsilateral anterior superior iliac spine just before the closure of peritoneum. After feeling 2 pops of external and internal oblique aponeurosis the drug will be injected after aspiration. The injectate syringes will be prepared under aseptic technique; syringes contained bupivacaine 0.25% 40 ml. Once the plane is reached the surgeon places his hand inside the abdominal cavity at the level of needle insertion to reconfirm needle placement. A bleb is palpated by the surgeon as the injection continues. The back flow of drug after injection is one of the signs that drug has been deposited in the TAP plane
62053136|NCT01572025|PLACEBO_COMPARATOR|Control|
62053137|NCT06078579||Oral lichen planus patients|Assessment of salivary and serum leptin levels
62053138|NCT06078579||Healthy control group|Assessment of salivary and serum leptin levels
62053139|NCT03170011|EXPERIMENTAL|Intervention|The training protocol will be include 12 sessions completed over six weeks following a periodization training format. Each session will last approximately 40 minutes. At first, training will focus on high volume, low intensity, self-selected velocity with a progression to high intensity, low volume, self-selected velocity ending with a focus on power training (moderate intensity, moderate volume, high velocity movement) over the six weeks of training.
62053140|NCT05605210|EXPERIMENTAL|FN-NMES - 20 Hz|This group will receive a NMES-induced fatigue protocol, which will be applied to the femoral nerve (FN) using a stimulation frequency of 20 Hz. For this, the participant will be positioned on the isokinetic dynamometer (Biodex Medical System, Shirley - NY, USA) with the knee in 90° of flexion (0°=total extension). The participant will be instructed to remain relaxed and to not perform active muscle contraction.
62053141|NCT05605210|EXPERIMENTAL|FN-NMES - 100 Hz|This group will receive a NMES-induced fatigue protocol, which will be applied to the femoral nerve (FN) using a stimulation frequency of 100 Hz. For this, the participant will be positioned on the isokinetic dynamometer (Biodex Medical System, Shirley - NY, USA) with the knee in 90° of flexion (0°=total extension). The participant will be instructed to remain relaxed and to not perform active muscle contractions.
62612318|NCT06509789|SHAM_COMPARATOR|Sham stimulation|Standard 600-pulse TBS will be applied using the MagPro X100 stimulator (MagVenture, Denmark) connected with a figure-of-eight coil (Cooling B-65). The resting motor threshold (RMT) of the motor cortex (M1) will be defined as the minimum intensity over the motor hotspot that could elicit an motor evoked potential (MEP) of no less than 50 μv over the first dorsal interosseous muscle in at least five out of 10 trials. Sham stimulation consists of a session of 20% RMT cTBS (sham), followed by 20% RMT iTBS (sham).
62836373|NCT04623632|PLACEBO_COMPARATOR|Placebo|the landmark is at the level of umbilicus 8 to 10 cms from midline bilaterally. A tiny nick is made in the skin with a 18G sharp needle to obliterate the cushion effect. Then an 18 G Tuohy needle will be insert perpendicular to skin directing the needle slightly towards the ipsilateral anterior superior iliac spine just before the closure of peritoneum. After feeling 2 pops of external and internal oblique aponeurosis the drug will be injected after aspiration. The injectate syringes will be prepared under aseptic technique syringes contained either normal saline 40 ml. Once the plane is reached the surgeon places his hand inside the abdominal cavity at the level of needle insertion to reconfirm needle placement. A bleb is palpated by the surgeon as the injection continues. The back flow of drug after injection is one of the signs that drug has been deposited in the TAP plane
62836374|NCT05484895|EXPERIMENTAL|WeTest-WeLink intervention|"Participants will have access to WeTest-WeLink application on the WeChat platform, which provides multi-media contents on HIV-related health information, online self-assessments, linkage to providers, data reports, and personal stories, in addition to two-way communication with non-governmental organizations (NGOs), and free, additional HST."
62612319|NCT02262416|PLACEBO_COMPARATOR|controls|Normal saline of equivalent volume
62836375|NCT05484895|ACTIVE_COMPARATOR|Control|"Participants will receive contact information to local NGO to request basic information or receive emergency referrals; have access to standard WeChat group; and have free, additional HST."
62836376|NCT04468984|EXPERIMENTAL|Arm A: Navitoclax + Ruxolitinib|Participants will receive navitoclax tablets once daily and ruxolitinib tablets twice daily.
62836377|NCT04468984|ACTIVE_COMPARATOR|Arm B: Best Available Therapy (BAT)|Participants will receive one of the BAT options, per the investigator's discretion.
62443061|NCT04626427|EXPERIMENTAL|WavelinQ™ EndoAVF System|The WavelinQ™ EndoAVF System is indicated for the cutting and coagulation of blood vessel tissue in the peripheral vasculature for the creation of an AVF used for HD. The device is intended to be used in patients suffering from chronic kidney disease requiring HD by physicians trained and experienced in endovascular techniques. The WavelinQ™ EndoAVF System will be used for these intended purposes as part of this clinical investigation according to its instructions for use (IFU).
62612320|NCT02262416|ACTIVE_COMPARATOR|case|0.5mg Leuprolide acetate injection
62612321|NCT06206122|EXPERIMENTAL|The observation group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding"
62836378|NCT01046708|EXPERIMENTAL|micronized progesterone|
62836379|NCT01046708|NO_INTERVENTION|no utrogestan|
62836380|NCT02198378|ACTIVE_COMPARATOR|Morphine|Morphine group: administration of morphine will start with a 0.05 mg/kg bolus followed by reinjection of 2 mg every 5 minutes until effective analgesia is obtained, defined as NRS ≤ 3.
62836381|NCT02198378|EXPERIMENTAL|MEOPA and paracetamol|"The patient will be equipped with a facemask delivering MEOPA.The gas flow received by the patient is adapted to his/her ventilation.~During the same time, an intravenous injection of 1 g paracetamol will be administered."
62612322|NCT06206122|ACTIVE_COMPARATOR|The control group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines."
62836382|NCT04327804||Odd numbered birth year|The collection of patient samples will be different as defined by odd/even birth year. Patients born in an odd numbered year will first have their left nostril swabbed by the foam swab followed by their right nostril being swabbed by the two polyester swabs.
62836383|NCT04327804||Even numbered birth year|The collection of patient samples will be different as defined by odd/even birth year. Patients born in an even numbered year will first have their left nostril swabbed by the two polyester swabs followed by their right nostril being swabbed by a foam swab.
62053142|NCT05605210|EXPERIMENTAL|MP-NMES - 20 Hz|This arm will receive a NMES-induced fatigue protocol, which will be applied to the motor point (MP) of the rectus femoris muscle using a stimulation frequency of 20 Hz. For this, the participant will be positioned on the isokinetic dynamometer (Biodex Medical System, Shirley - NY, USA) with the knee at 90° of flexion (0°=total extension). The participant will be instructed to remain relaxed and to not perform active muscle contractions.
62254152|NCT05788744|NO_INTERVENTION|B: Control|Patients will receive surveillance until recurrence according to current Danish guidelines with liver enzymes, history and clinical evaluation every 3 months for two years and then every 6 months until 36 months. If an increase in liver enzymes is seen or clinical signs of recurrence (e.g. weight loss, abdominal pain or fatigue) patients will have a CT scan of thorax and abdomen. Blood samples (90 ml blood per visit) will be collected at the same time points as blood is drawn for liver enzymes (i.e. every 6 months until 36 months) for later analysis at the end of study of plasma ctDNA and eccDNA. These measurements will serve to enable post-trial comparison of oncological outcomes for the two arms.
62254153|NCT03665389|OTHER|Single Arm|Among patients who undergo TAVR at the kobe university hospital, those who are found to have moderate or severe stenosis on cCTA performed before surgery and judged to clinically require ischemia evaluation will be included in this study.
62443062|NCT04931420|EXPERIMENTAL|Arm A - Participants Who Receive Sequential Procedures|"If you are assigned to this arm, study doctors will sequentially remove and treat all visible cancer spots with surgery, radiation, ablation, or other procedures. These interventions might include surgical removal of the diseased part of your lung, liver, lymph nodes, and/or the lining of your belly. In addition, if surgery could not be done, we could treat these diseased spots with other modalities such as radiation and/or radiofrequency/microwave ablation.~If you're selected to be in this arm, the type of procedure you receive will vary based on your cancer and what the study doctor recommends for treatment."
62836384|NCT05211843|NO_INTERVENTION|No drink|Control; Participants will receive no drink
62836385|NCT05211843|EXPERIMENTAL|Drinking water|Intervention drink; Participants will receive 500 ml drinking water from the San Francisco tap (i.e. fluoridated tap water). 500 ml is the standard bottle size.
62254154|NCT05771064|EXPERIMENTAL|Gentle Moves|Three-month physical activity intervention.
62254155|NCT05771064|NO_INTERVENTION|Usual Care|Usual care provided by neuropsychologist.
62254156|NCT03936283|EXPERIMENTAL|Lifestyle Intervention|
62254157|NCT03936283|NO_INTERVENTION|Usual Care|
62254158|NCT04703036|EXPERIMENTAL|Active arm|The active supplements are glycine and N-acetylcysteine
62836386|NCT05211843|ACTIVE_COMPARATOR|Apple juice|Intervention drink; Participants will receive 200 ml box of apple juice. 200 ml is the standard serving usually available to this study population in the school setting
62836387|NCT01035125|NO_INTERVENTION|Waiting list|
62254159|NCT04703036|PLACEBO_COMPARATOR|Placebo arm|The placebo arm is alanine
62254160|NCT06011564|EXPERIMENTAL|Intervention|Reminder function
62612323|NCT03466749|EXPERIMENTAL|Intervention group|Paclitaxel Eluting Balloon Catheter treatment
62612324|NCT06535633|EXPERIMENTAL|Intervention arm: Exercise classes|The investigators have trained exercise trainers in Pain neuroscience and they will lead a set of classes, adapted to the needs of people with chronic pain. Focus groups with people with chronic pain detailed the important factors to consider in planning an exercise intervention, these being that the activity should be enjoyable, non-competitive and accessible to all levels of physical activity, and the venues should offer easy access with public transport. The investigators have identified three exercise types from the current LSP offerings that could meet the needs of people with chronic MSK pain, namely Tai Chi, Activator Pole walking and Aquarobics, which will run once a week for 8 weeks. The intervention group will also receive a paper-based education manual about physical activity and pain management education designed for people with chronic pain.
62836388|NCT01035125|EXPERIMENTAL|Self-management program|One week self-management program
62836389|NCT04562428|EXPERIMENTAL|XSLJZ|Xiang Sha Liu Jun Zi Decoction dry powder 7.5g/day tid
62836390|NCT04562428|PLACEBO_COMPARATOR|XSLJZ Placebo|10%Xiang Sha Liu Jun Zi Decoction dry powder 7.5g/day tid
62836391|NCT02196636|EXPERIMENTAL|Part 1: Single Ascending Dose (SAD)|Adaptive model per protocol
62254161|NCT06011564|NO_INTERVENTION|control|No reminder
62254162|NCT01978821|EXPERIMENTAL|stem cell|autologous bone marrow mononuclear cell transplantation
62254163|NCT00992420||GRAVITAS Study Arm A|"Tailored clopidogrel regimen - total first day dose 600-mg, then 150-mg every day for 6 months"
62254164|NCT00992420||GRAVITAS Study Arm B|"Standard clopidogrel regimen - a placebo loading dose (six placebo tablets) and then clopidogrel 75-mg and 1 placebo tablet every day for 6 months."
62254165|NCT00992420||GRAVITAS Study Arm C|Responders: A random sample of clopidogrel responders treated with a placebo loading dose (six placebo tablets) and then the standard clopidogrel regimen of 75-mg and 1 placebo tablet every day for 6 months.
62254166|NCT01719315||MDD with Hypersomnia|Participants with Major Depressive Disorder and co-morbid hypersomnia
62836392|NCT02196636|EXPERIMENTAL|Part 2: Food Effect (FE)|Fasted versus Fed
62254167|NCT01719315||MDD without hypersomnia|Participants with Major Depressive Disorder but without co-morbid hypersomnia
62254168|NCT01719315||BPAD with hypersomnia|Participants with Bipolar Affective Disorder and co-morbid hypersomnia
62836393|NCT01702649|EXPERIMENTAL|RPX2003 (Biapenem)|Single and multiple dose of RPX2003 (Biapenem).
62836394|NCT01702649|PLACEBO_COMPARATOR|Normal Saline|Single and multiple doses of normal saline.
62836395|NCT03403283||Diabetic|Diabetics with mild, moderate or severe non proliferative retinopathy and proliferative retinopathy
62836396|NCT03403283||Controls|Healthy Controls
62836397|NCT05903768|EXPERIMENTAL|Cyriax capsular stretching|Patient will be subjected to Hot Pack prior to treatment. Detailed intervention will include Active range of motion exercises,Home plan exercises.Anterior, Posterior and inferior capsular stretching.
62836398|NCT05903768|ACTIVE_COMPARATOR|Mobilization|Patient will be subjected to Hot Pack prior to treatment. Detailed intervention will include Active range of motion exercises,Home plan exercises and Maitland's Mobilization:
62836399|NCT04823247||Tildrakizumab|Patients diagnosed with moderate-to-severe plaque psoriasis who require systemic biologic therapy and qualify for treatment with an IL-23p19 inhibitor in real-world clinical practice, following the routine clinical practice on each patient country, will be observed for 24 months.
62836400|NCT01088724|EXPERIMENTAL|chemotherapy|
62836401|NCT04899986|EXPERIMENTAL|Trial Group|Patients from this group will use chlorhexidine Biorepair gel and toothpaste for home oral care.
62836402|NCT04899986|ACTIVE_COMPARATOR|Control Group|Patients from this group will not use chlorhexidine and Biorepair gels and toothpastes, but will perform home oral care with standard toothpastes.
62836403|NCT00425776|ACTIVE_COMPARATOR|Real acupuncture|
62836404|NCT00425776|SHAM_COMPARATOR|Sham acupuncture|
62836405|NCT00425776|NO_INTERVENTION|No intervention|
62836406|NCT02767414|EXPERIMENTAL|Respirio Flu Test and eLab Flu Test|"Upper respiratory tract samples from participants will be tested with:~Respirio Flu Test; eLab Flu Test; and Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)"
62254169|NCT01719315||BPAD without hypersomnia|Participants with Bipolar Affective Disorder without co-morbid hypersomnia
62254170|NCT01719315||Primary Hypersomnia|Patients with primary hypersomnia (idiopathic hypersomnia)
62254171|NCT01719315||Primary Insomnia|Patients with primary insomnia
62254172|NCT01719315||Narcolepsy|Subjects with narcolepsy
62254173|NCT01719315||Healthy Controls|healthy participants
62254174|NCT06001112|EXPERIMENTAL|acupuncture group|subjects will received cheek acupuncture for one time
62254175|NCT06001112|ACTIVE_COMPARATOR|etoricoxib|subjects will received etoricoxib 120mg for one time
62254176|NCT00703001|ACTIVE_COMPARATOR|1--Educational Intervention|Students in this arm will receive several in-class educational modules on basic oral health topics.
62254177|NCT00703001|ACTIVE_COMPARATOR|2--Referral intervention|Parents of student subjects will receive assistance in accessing oral health care for their child
62836407|NCT01166282|PLACEBO_COMPARATOR|Double-blind Placebo EOW|Placebo for adalimumab every other week (eow) for 12 weeks.
62836408|NCT01166282|EXPERIMENTAL|Double-blind Adalimumab EOW|Adalimumab (body surface area dosing 24 mg/m\^2 up to a maximum of 40 mg) every other week (eow) for 12 weeks.
62254178|NCT00754481|ACTIVE_COMPARATOR|1|
62836409|NCT01166282|EXPERIMENTAL|Open-label Adalimumab EOW|Adalimumab (body surface area dosing 24 mg/m\^2 up to a maximum of 40 mg) every other week (eow) for up to 192 weeks.
62836410|NCT01462370|EXPERIMENTAL|Etoricoxib+placebo ibuprofen then placebo etorcoxib+ibuprofen|Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.
62836411|NCT01462370|EXPERIMENTAL|Ibuprofen+placebo etoricoxib then etoricoxib+placebo ibuprofen|Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.
62836412|NCT00353483||Tissue, blood, and bone marrow (optional) collection|"* Undergo neoadjuvant systemic therapy~  * initial surgery for sentinel lymph node biopsy/portacath placement~ * definitive cancer surgery (if applicable)~ * when portacath is removed (1 year, if available)~ * if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis~* Undergo Adjuvant Systemic Therapy~  * initial surgery for a sentinel lymph node biopsy/portacath placement~ * when portacath is removed (1 year, if available)~ * If metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis.~* Undergone neoadjuvant systemic therapy~  * during definitive cancer surgery/portacath removal (if available)~ * if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis"
62254179|NCT00754481|EXPERIMENTAL|2|
62254180|NCT01034735|EXPERIMENTAL|Arm A|
62254181|NCT01034735|EXPERIMENTAL|Arm B|
62254182|NCT01034735|EXPERIMENTAL|Arm C|
62254183|NCT03714191||Improved outcomes|
62254184|NCT03714191||Regulatory reminder|
62254185|NCT03714191||Billing and documentation|
62254186|NCT03383497||Idiopathic Parkinson Disease|
62254187|NCT03383497||Other Parkinsonian syndromes|
62836413|NCT01023893||End-stage renal disease|
62836414|NCT02596932|OTHER|Tight control|"Intervention Standard Care:~Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level \> 100mg/dL or \< 60 mg/dL"
62254188|NCT05259722|EXPERIMENTAL|Delgocitinib cream 20 mg/g|Twice-daily topical application for up to 24 weeks
62254189|NCT05259722|ACTIVE_COMPARATOR|Alitretinoin capsules 30 mg per capsule|1 capsule per day for up to 24 weeks
62836415|NCT02596932|EXPERIMENTAL|Less tight control|"Intervention:~Less Tight glucose control protocol: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose \> 120 mg/dL or \< 60mg/dL"
62836416|NCT03365089|EXPERIMENTAL|Collateral vein ligation|Ligation of collateral veins under sonographic guidance
62612325|NCT06535633|NO_INTERVENTION|Control|"The control group comprises the same paper-based education manual about physical activity and pain management education designed for people with chronic pain and based on the Explain Pain principles. These participants will continue with usual care for their chronic pain. Based on PPI feedback suggesting the importance of equity for all who volunteer to take part, those in the control group will be offered the opportunity to participate in the intervention (group exercise classes) after they have completed their final follow up assessments."
62612326|NCT01990872|PLACEBO_COMPARATOR|Placebo in high calcium group|Placebo + habitual dietary calcium intake (\>1000 mg/d)
62612327|NCT01990872|ACTIVE_COMPARATOR|Vitamin D3 in low/moderate calcium group|Vitamin D3 (20 microgram/day) + habitual calcium intake \<700 mg/d
62612328|NCT01990872|PLACEBO_COMPARATOR|Placebo in low/moderate calcium group|Placebo + habitual calcium intake \<700 mg/d
62612329|NCT01990872|ACTIVE_COMPARATOR|Vitamin D3 in high calcium group|Vitamin D3 (20 microgram/day) + habitual calcium intake (\>1000 mg/d)
62612330|NCT06731725|EXPERIMENTAL|DayDrop®|Medical Device IIa class. DayDrop is a biocompatible ophthalmic solution indicated to relieve dryness and ocular irritation. DayDrop is composed of ectoine, carboxymethylcellulose, and sodium hyaluronate. The product is obtained by dissolving the components in a borate buffer (pH = 7.2-7.6) prepared with boric acid and sodium tetraborate. The manufacturing and packaging of the product are carried out under aseptic processing conditions following the UNE-EN ISO 13408:2015 standard, and the product is sterilized through sterilizing filtration. DayDrop is defined as a sterile product, buffered to a neutral pH, phosphate-free, preservative-free, and compatible with contact lenses according to ISO 11981.
62836417|NCT03365089|NO_INTERVENTION|Control|No collateral vein ligation.
62053143|NCT05605210|EXPERIMENTAL|MP-NMES - 100 Hz|This arm will receive a NMES-induced fatigue protocol, which will be applied to the motor point (MP) of the rectus femoris muscle using a stimulation frequency of 100 Hz. For this, the participant will be positioned on the isokinetic dynamometer (Biodex Medical System, Shirley - NY, USA) with the knee at 90° of flexion (0°=total extension). The participant will be instructed to remain relaxed and to not perform active muscle contractions.
62254190|NCT05111262|ACTIVE_COMPARATOR|As needed inhaled corticosteroid and long-acting beta-agonist|Symptom-driven ICS/LABA treatment strategy
62254191|NCT05111262|NO_INTERVENTION|Standard therapy: maintenance inhaled corticosteroid and as needed short-acting beta-agonist|Continue maintenance ICS and SABA therapy
62254192|NCT00737191|ACTIVE_COMPARATOR|Arm I|Patients receive oral opioid and oral placebo once daily for 4 weeks.
62254193|NCT00737191|EXPERIMENTAL|Arm II|Patients receive oral opioid and 2.5 mg oral olanzapine once daily for 4 weeks.
62254194|NCT00737191|EXPERIMENTAL|Arm III|Patients receive oral opioid and 5 mg oral olanzapine once daily for 4 weeks.
62443063|NCT04931420|OTHER|Arm B (Control) - Participants Who Receive Standard of Care Chemotherapy|Participants in this arm receive the current standard of care chemotherapy for their specific type of gastrointestinal cancer. This treatment may include the continuation of chemotherapy and a few procedures which may improve your quality of life.
62443064|NCT02861183|EXPERIMENTAL|OVT (Sodium Hyaluronate)|Sodium hyaluronate is supplied as a 2 mL unit dose in a 3 mL glass syringe.
62443065|NCT02861183|PLACEBO_COMPARATOR|Saline|0.9% sterile saline is supplied as a 2 mL unit dose in a 3 mL glass syringe.
62612331|NCT01053130|EXPERIMENTAL|weight loss surgery|laparoscopic sleeve gastrectomy
62612332|NCT01053130|ACTIVE_COMPARATOR|Lifestyle Intervention|Diet and exercise with or without pharmacotherapy
62836418|NCT01525069|EXPERIMENTAL|Arm A (HAI FUDR alone)|"* 14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~* This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~* The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
62254195|NCT05602038|ACTIVE_COMPARATOR|Group Q|QLB group will receive 30 ml 0.125% bupivacaine (Sunnypivacaine by Sunny Pharmaceuticals) for each side
62612333|NCT03953105||Resusci Baby|Resusci Baby used for the simulated emergency scenario
62612334|NCT03953105||Ambu® Junior|Ambu® Junior used for the simulated emergency scenario
62612335|NCT03782805|EXPERIMENTAL|treatment group|Group receiving a supplement of 10,000 IU of cholecalciferol (Euro-Pharm International, Canada) to be taken 3 times a week for a period of six months.
62254196|NCT05602038|ACTIVE_COMPARATOR|Group M|Intrathecal morphine 100mcg will be added to bupivacaine 0.5% 15mg and fentanyl 20 µg
62254197|NCT05602038|ACTIVE_COMPARATOR|Group QM|Intrathecal morphine 100mcg will be added to bupivacaine 0.5% 15mg and fentanyl 20 µg combined by QLB of 30 ml 0.125%bupivacain
62254198|NCT05602038|PLACEBO_COMPARATOR|Group C|Control group with intrathecal bupivacaine 0.5% 15mg and fentanyl 20 µg.
62254199|NCT01575106|EXPERIMENTAL|Arm 1|There is only one cohort in this study. All subjects receive the same intervention, the application of heat pain using TSA or CHEPS.
62836419|NCT01525069|EXPERIMENTAL|Arm B (HAI FUDR + gemcitabine)|"* Consists of Cohort B1, B2, and B3. Enrollment to specific cohorts will depend on the number of DLTs in each cohort. Each cohort has a different dose of FUDR and gemcitabine.~* Gemcitabine IV will be given on Days 1, 8, and 15 of each 28 day cycle in Cohort B1~* Gemcitabine IV will be given on Days 1 and 15 of each 28 day cycle in Cohort B2 \& B3~* 14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~* This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~* The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
62836420|NCT01525069|EXPERIMENTAL|Arm C (HAI FUDR + gemcitabine + oxaliplatin)|"* Consists of Cohort C1, C2, C3, and C4. Enrollment to specific cohorts will depend on the number of DLTs in each cohort. Each cohort has a different dose of FUDR, gemcitabine, and oxaliplatin.~* Gemcitabine IV will be given on Days 1 and 15 of each 28 day cycle.~* Oxaliplatin IV will be given on Days 1 and 15 of each 28 days cycle.~* 14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~* This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~* The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
62836421|NCT04773106|OTHER|Single-arm longterm Follow up ARGOS-SC Sensor Pressure system|The ARGOS-SC sensor was already implanted in a previous study as ARGOS-SC01.
62836422|NCT04569487|ACTIVE_COMPARATOR|Sarcopenic population|"Diagnosed sarcopenia following definition of the EWGSOP2:~* Muscle strength assessed by the handgrip test \<27 kg~* Skeletal muscle mass index (Appendicular lean muscle mass) assessed by DXA \<7.0 kg/m2"
62836423|NCT04569487|ACTIVE_COMPARATOR|Non sarcopenic population|"Non-sarcopenic population adapted from the EWGSOP2:~* Muscle strength assessed by the handgrip test ≥ 27 kg~* Skeletal muscle mass index (Appendicular lean muscle mass) assessed by DXA ≥ 7.0 kg/m2"
62836424|NCT02444078|EXPERIMENTAL|Exercise|Exercise sessions will be done in groups of three-to-eight persons; whilst being a group-based exercise program, participants will be guided and the exercises will be adapted in an individual basis, which may increase adherence and compliance rates.
62254200|NCT05184673|ACTIVE_COMPARATOR|hatha thermo-neutral|The hatha classes will hold each pose for 5 breaths in a room temperature (\~70 degrees Fahrenheit) space. Yoga sessions will be led by a 500hr Registered Yoga Teacher. This reduces the risk for injury due to the extensive training the yoga teacher will have received and the knowledge of cuing and sequencing for best practice. All study personnel will be vaccinated against SARS-CoV-2, reducing the risk of spreading SARS-CoV-2.
62254201|NCT05184673|ACTIVE_COMPARATOR|hatha hot|The hatha hot classes will hold each pose for 5 breaths in a room heated to 95 degrees Fahrenheit. Yoga sessions will be led by a 500hr Registered Yoga Teacher. This reduces the risk for injury due to the extensive training the yoga teacher will have received and the knowledge of cuing and sequencing for best practice. All study personnel will be vaccinated against SARS-CoV-2, reducing the risk of spreading SARS-CoV-2.
62254202|NCT05184673|ACTIVE_COMPARATOR|flow thermo-neutral|The flow hot classes will flow from each pose (one breath per movement) a room temperature (\~70 degrees Fahrenheit) space. Yoga sessions will be led by a 500hr Registered Yoga Teacher. This reduces the risk for injury due to the extensive training the yoga teacher will have received and the knowledge of cuing and sequencing for best practice. All study personnel will be vaccinated against SARS-CoV-2, reducing the risk of spreading SARS-CoV-2.
62443066|NCT05731154||thyroid eye disease group|"Patients who were diagnosed as thyroid eye disease. Periorbital images are taken by DSLR camera in the studio. Periorbital selfie images are taken by the patients with 6 smartphones including various camera modules.~CAS of TAO is evaluated by 3 ophthalmologists based on the periorbital digital images taken by DSLR camera and symptoms."
62443067|NCT03828461|EXPERIMENTAL|BITS + VR|Facilitated group therapy with behavioral practice; 16 weeks
62612336|NCT03782805|PLACEBO_COMPARATOR|Placebo group|Group receiving a placebo tablet (containing microcrystalline cellulose: 66.3%, starch: 33.2%, magnesium stearate: 0.5%, per serving) to be taken 3 times a week for a period of six months
62836425|NCT02444078|ACTIVE_COMPARATOR|Social activity|Participants in this group will participate in group-based activities such as music (percussion instruments), arts and board games; no intervention on physical activity will be provided to these participants.
62836426|NCT03570099||Prospective Naloxone cohort|The prospective cohort consists of study subjects receiving Naloxone nasal spray in the distribution program.
62836427|NCT03570099||Historical control cohort|Data from the historical control cohort will be collected from national registries years 2013-2017.
62836428|NCT04355039|EXPERIMENTAL|Pomalidomide, Dexamethasone & INCB053914 50 mg twice daily|INCB053914 will have a dose escalation in a 3 + 3 design.
62443068|NCT06528249|EXPERIMENTAL|Dose Escalation|Dose Escalation of Erythrocyte-αPD-1 conjugate monotherapy in patients with advanced malignancy
62612337|NCT03315611|ACTIVE_COMPARATOR|AD, sensitized, treated|Allergen challenge chamber and Treatment for 12 day with 'Eucerin AtopiControl Lotion' (for the body) and 'Eucerin AtopiControl facial cream' (for the face): 1,2 g twice daily.
62612338|NCT03315611|EXPERIMENTAL|AD, not sensitized, not treated|Allergen challenge chamber
62612339|NCT03315611|EXPERIMENTAL|AD, sensitized, not treated|Allergen challenge chamber
62612340|NCT04480333|EXPERIMENTAL|Drug: NA-831 - 0.10 mg/kg|3 Subjects will take inhaled formulation of NA-831 once a day for 5 days
62053144|NCT05605210|EXPERIMENTAL|FNMP-NMES - 20 Hz|This group will receive a NMES-induced fatigue protocol, which will be applied to the femoral nerve (FN) and to the motor point (MP) of the rectus femoris muscle using a stimulation frequency of 20 Hz. For this, the participant will be positioned on the isokinetic dynamometer (Biodex Medical System, Shirley - NY, USA) with the knee at 90° of flexion (0°=total extension). The participant will be instructed to remain relaxed and to not perform active muscle contractions.
62254203|NCT05184673|ACTIVE_COMPARATOR|flow hot|The flow hot classes will flow from each pose (one breath per movement) in a room heated to 95 degrees Fahrenheit. Yoga sessions will be led by a 500hr Registered Yoga Teacher. This reduces the risk for injury due to the extensive training the yoga teacher will have received and the knowledge of cuing and sequencing for best practice. All study personnel will be vaccinated against SARS-CoV-2, reducing the risk of spreading SARS-CoV-2.
62254204|NCT01830855|EXPERIMENTAL|rLP2086 lot 1|
62254205|NCT01830855|EXPERIMENTAL|rLP2086 lot 2|
62443069|NCT06528249|EXPERIMENTAL|Dose Expansion|Dose Expansion of Erythrocyte-αPD-1 conjugate monotherapy in patients with advanced malignancy
62612341|NCT04480333|PLACEBO_COMPARATOR|Comparable Placebo- 0.10 mg/kg|3 subjects will take inhaled formulation of placebo once a day for 5 days
62836429|NCT04355039|EXPERIMENTAL|Pomalidomide, Dexamethasone & INCB053914 65 mg twice daily|INCB053914 will have a dose escalation in a 3 + 3 design.
62836430|NCT04355039|EXPERIMENTAL|Pomalidomide, Dexamethasone & INCB053914 80 mg twice daily|INCB053914 will have a dose escalation in a 3 + 3 design.
62836431|NCT05796934|EXPERIMENTAL|Moments that Matter|The intervention group will receive the Moments that Matter (MTM) program, which will involve monthly peer group sessions and monthly home visits that are delivered by ECD promoters over an 18-month program duration, training of faith leaders, and the formation of ECD committees at the community-level.
62836432|NCT05796934|NO_INTERVENTION|Waitlist-Control|The control group will not immediately receive the MTM program but instead the standard of care services (e.g., those provided by community health volunteers which are primarily focused on maternal and child health and nutrition). After follow-up assessments are completed for the trial, then villages in the control group will receive the MTM program.
62836433|NCT06255431|ACTIVE_COMPARATOR|Cream Containing Spent Grain Wax Extract, Argan Oil, and Shea Butter (Ezerra Cream)|"Ezerra cream The creams are applied to the face twice daily (0,5 Finger Tip Unit/FTU), immediately after washing.~group A (intervention cream on the right side of the face and control cream on the left side of the face) and group B (intervention cream on the left side of the face and control cream on the right side of the face)."
62836434|NCT06255431|PLACEBO_COMPARATOR|Vehicle cream|Vehicle cream was prepared by the Pharmacy Department of Faculty of Medicine Universitas Indonesia and has similar consistency, color, and scent as the intervention cream. The creams are applied to the face twice daily (0,5 Finger Tip Unit/FTU), immediately after washing.
62836435|NCT02192489|EXPERIMENTAL|CC-220 0.3mg|CC-220 0.3 mg capsules by mouth (PO) daily for 12 weeks
62836436|NCT02192489|EXPERIMENTAL|CC-220 0.6mg|CC-220 0.6mg capsules by PO daily for 12 weeks
62254206|NCT01830855|EXPERIMENTAL|rLP2086 lot 3|
62443070|NCT06022133|EXPERIMENTAL|Dietary sodium restriction|DIetary sodium restriction
62443071|NCT06022133|NO_INTERVENTION|Usual diet|Usual diet
62443072|NCT01431755|OTHER|Restylane SubQ|
62612342|NCT04480333|EXPERIMENTAL|Drug: NA-831 - 0.20 mg/kg|6 Subjects will take inhaled formulation of NA-831 once a day for 5 days
62612343|NCT04480333|PLACEBO_COMPARATOR|Comparable Placebo- 0.20 mg/kg|3 subjects will take inhaled formulation of placebo once a day for 5 days
62612344|NCT04480333|EXPERIMENTAL|Drug: GS-5734 - 1.00 mg/kg|3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
62836437|NCT02192489|PLACEBO_COMPARATOR|Placebo|Identically matching placebo PO daily for 12 weeks
62836438|NCT02668978|EXPERIMENTAL|Hemopatch™|Hemopatch™ sealing hemostat
62254207|NCT01830855|ACTIVE_COMPARATOR|Control|Havrix (HAV) and Saline
62254208|NCT05678387||Healthy participants|Participants without chronic pain and depression
62254209|NCT05678387||Chronic Widespread Pain participants|Participants with Chronic Widespread Pain
62254210|NCT00966342|OTHER|Vaccine|Everyone gets licensed Influenza vaccine
62254211|NCT03023930|EXPERIMENTAL|Evidenced-based Practice Dissemination|Evaluating standard dissemination practice compared with implementation facilitation
62254212|NCT04792567|EXPERIMENTAL|Siponimod - continuous|Continuous treatment with siponimod (oral, daily, dose depending on CYP2C9 genotype: 2mg or 1 mg) during SARS-CoV-2 mRNA vaccination
62254213|NCT04792567|EXPERIMENTAL|Siponimod- interrupted|Siponimod (oral, daily, dose depending on CYP2C9 genotype: 2mg or 1 mg) with treatment interruption (for approx. 2-3 months) for the purpose of a SARS-CoV-2 mRNA vaccination
62836439|NCT02668978|ACTIVE_COMPARATOR|Control|Standard surgical technique
62836440|NCT03170596|EXPERIMENTAL|Tazarotene gel arm|The treatment protocol in this arm will consist of night time application of Tazarotene 0.1% gel during the entire study period. (3 months)
62443073|NCT01431755|OTHER|Restylane SubQ Lidocaine|
62443074|NCT06547723|EXPERIMENTAL|experimental group|Participants in the experimental group receive 20 sessions physiotherapy (in first-4-week, three sessions and next-4-week two sessions on a weekly basis) along with one MBSR session (total MBSR sessions are eight sessions), which also include regular MBSR homework.
62612345|NCT04480333|PLACEBO_COMPARATOR|Comparable Placebo- 1.00 mg.kg|3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
62612346|NCT04480333|EXPERIMENTAL|Drug: GS-5734 - 2.00 mg/kg|6 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
62836441|NCT03170596|ACTIVE_COMPARATOR|Microneedling arm|The treatment protocol in this arm will consist of four sessions of microneedling at monthly intervals. (0, 1, 2, 3 months)
62836442|NCT04355143|EXPERIMENTAL|Colchicine plus current care|Colchicine 0.6 mg po BID x 30 days plus current care per UCLA treating physicians
62836443|NCT04355143|ACTIVE_COMPARATOR|Current care alone|Current care per UCLA physicians alone (control arm)
62254214|NCT04792567|ACTIVE_COMPARATOR|Comparator|Baseline DMTs or no treatment during SARS-CoV-2 mRNA vaccination
62612347|NCT04480333|PLACEBO_COMPARATOR|Comparable Placebo - 2.00 mg/kg|3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
62836444|NCT00343460|ACTIVE_COMPARATOR|Arm I|Patients receive palonosetron hydrochloride IV, placebo subcutaneously (SC), and dexamethasone IV on day 1 of chemotherapy course 1. Patients in the high-risk (level 5) stratum also receive oral dexamethasone on days 2-4 of all treatment courses.
62836445|NCT00343460|EXPERIMENTAL|Arm II|Patients receive APF530 SC, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
62836446|NCT00343460|EXPERIMENTAL|Arm III|Patients receive APF530 SC at a higher dose, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC (at the same higher dose) and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
62836447|NCT05442476|EXPERIMENTAL|kinesiotaping|
62836448|NCT05442476|OTHER|Muscle Energy Technique|
62612348|NCT04480333|EXPERIMENTAL|Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|3 Subjects- will take inhaled formulation NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) once/day for 5 days
62836449|NCT00904137|ACTIVE_COMPARATOR|Cast|Above elbow fiberglass cast with a collar-and-cuff
62836450|NCT00904137|ACTIVE_COMPARATOR|Splint|Long arm posterior plaster splint with a collar-and-cuff
62836451|NCT00904137|ACTIVE_COMPARATOR|Tape|Elastoplast tape applied to keep the elbow in flexion, with a collar-and-cuff
62836452|NCT02844868|EXPERIMENTAL|Active tDCS|During the first 20 min of training program, patient will have active tCDS (2 mA )
62612349|NCT04480333|PLACEBO_COMPARATOR|Placebo- 0.10- mg/kg placebo+1.00 mg mg/kg|3 Subjects - inhaled formulation of placebo once/day for 5 days
62612350|NCT04480333|EXPERIMENTAL|Drugs: NA-831( 0.20 mg/kg) + GS-5734 (2.00 mg/kg)|6 Subjects- inhaled formulation of NA-831 (0.20 mg/kg) + GS-5734 (2.00 mg/kg) once/day for 5 days
62836453|NCT02844868|SHAM_COMPARATOR|sham tDCS|During the first 20 min of training program, patient will have sham tCDS
62836454|NCT04833218|ACTIVE_COMPARATOR|propranolol group|we will give propranolol 40 milligram tablet twice daily in orogastric or nasogastric tube
62836455|NCT04833218|ACTIVE_COMPARATOR|propranolol clonidine|we will give propranolol 20 milligram tablet twice daily and clonidine 150 microgram tablet twice daily in orogatric or nasogastric tube
62443075|NCT06547723|ACTIVE_COMPARATOR|control group|Participants in the control group receive 20 sessions physiotherapy (in first-4-week, three sessions and next-4-week two sessions on a weekly basis).
62612351|NCT04480333|PLACEBO_COMPARATOR|Placebo- 0.20 mg/kg + 2.00mg/kg|3 Subjects- inhaled formulation of placebo once/day for 5 days
62836456|NCT04833218|NO_INTERVENTION|control group|we will give conventional treatment, no propranolol nor clonidine
62836457|NCT06039111|EXPERIMENTAL|Sequential ICG and Technetium Detection|
62836458|NCT06117319|EXPERIMENTAL|Individual assistance|"5 sessions with individual assistance~The Virtual Reality (VR) activity will take the form of five (5) training sessions.~* Session 1: Basics of VR.~* Session 2: 1-multiplayer game mode.~* Session 3: Playing with a library. Browsing a library~* Session 4: 2-individual game mode.~* Session 5: Game practice.~For each session, in small groups of 3 people, it will be proposed to test games requiring only movements of the upper limbs of low to moderate intensity. Sitting will be mandatory for the tests in order to avoid falls."
62836459|NCT06117319|EXPERIMENTAL|Collective assistance|"4 sessions with collective assistance and 1 session with individual assistance (session 5)~The Virtual Reality (VR) activity will take the form of five (5) training sessions.~* Session 1: Basics of VR.~* Session 2: 1-multiplayer game mode.~* Session 3: Playing with a library. Browsing a library~* Session 4: 2-individual game mode.~* Session 5: Game practice.~For each session, in small groups of 3 people, it will be proposed to test games requiring only movements of the upper limbs of low to moderate intensity. Sitting will be mandatory for the tests in order to avoid falls."
62612352|NCT03058523||Non-Pregnant|30 non-pregnant women of childbearing age
62612353|NCT03058523||Pregnant|30 pregnant women
62612354|NCT02408952|EXPERIMENTAL|Primary Care Physician|If the adolescent is identified at risk for substance use, the screening and brief intervention referral to treatment delivered is by the primary care physician
62836460|NCT02377817|EXPERIMENTAL|PrenaBelt on First Sleep Test Night|Participants will be randomized to treatment order: sham PrenaBelt on first night, then PrenaBelt on second night, or vice versa. This will avoid the potential impact of changes to sleep across the two nights resulting from familiarization with the polysomnography equipment, which could bias the results.
62836461|NCT02377817|SHAM_COMPARATOR|Sham PrenaBelt on First Sleep Test Night|Participants will be randomized to treatment order: sham PrenaBelt on first night, then PrenaBelt on second night, or vice versa. This will avoid the potential impact of changes to sleep across the two nights resulting from familiarization with the polysomnography equipment, which could bias the results.
62053145|NCT05605210|EXPERIMENTAL|FNMP-NMES - 100 Hz|This group will receive a NMES-induced fatigue protocol, which will be applied to the femoral nerve (FN) and to the motor point (MP) of the rectus femoris muscle using a stimulation frequency of 100 Hz. For this, the participant will be positioned on the isokinetic dynamometer (Biodex Medical System, Shirley - NY, USA) with the knee at 90° of flexion (0°=total extension). The participant will be instructed to remain relaxed and to not perform active muscle contractions.
62053146|NCT01965938|ACTIVE_COMPARATOR|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
62053147|NCT01965938|OTHER|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
62254215|NCT03574857|ACTIVE_COMPARATOR|Metolazone|Metolazone 5 mg by mouth once daily for 2 days
62254216|NCT03574857|ACTIVE_COMPARATOR|Chlorothiazide|Chlorothiazide 500 mg IV once daily for 2 days
62254217|NCT02071212|ACTIVE_COMPARATOR|Clopidogrel|Loading dose 600 mg .Mainatinance dose 75 mg QD
62254218|NCT02071212|EXPERIMENTAL|Ticagrelor|Loading dose 180 mg . Maintenance 90 mg BID
62254219|NCT03624933|EXPERIMENTAL|28-Day Cannabis Abstinence|The study will assess the changes that occur after a 28-day abstinence period in patients with Major Depressive Disorder (MDD) and comorbid Cannabis Use Disorder (CUD). Patients will be instructed to initiate abstinence 12 hours prior to the baseline session and will come in for weekly visits involving a series of clinical, cognitive, and substance use assessments.
62254220|NCT00592267||1|
62254221|NCT03280654||Group 1:VAI levels <7,55|7,55 value was calculated as cut-off level for VAI by ROC analyse and area under curve was calculated as 0,487 Group 1 was defined as VAI levels \<7,55
62254222|NCT03280654||group 2:VAI levels >=7,55|7,55 value was calculated as cut-off level for VAI by ROC analyse and area under curve was calculated as 0,487 group 2 was defined as VAI levels \>=7,55
62612355|NCT02408952|EXPERIMENTAL|Behavioral Medicine Specialist|If the adolescent is identified at risk for substance use, the screening and brief intervention referral to treatment delivered by the behavioral medicine specialist
62612356|NCT02408952|NO_INTERVENTION|Usual Care|Care is administered as usual
62612357|NCT03107975|EXPERIMENTAL|Cell Therapy|intrathecal injection of human amniotic epithelial cells
62836462|NCT00296621|EXPERIMENTAL|1|
62254223|NCT05704764|NO_INTERVENTION|Minimally Enhanced TAU|Participants assigned to the minimally enhanced treatment-as-usual condition will receive an educational pamphlet about internalized stigma to read at their leisure and will be encouraged to continue in all their customary HIV- and substance use-related services.
62254224|NCT05704764|EXPERIMENTAL|ESS-HSU|Using the materials developed during study year one, up to nine approximately 60-90 minute sessions will be carried out with groups of 8-10 participants at a time randomized to receive ESS-HSU. Each by session will be administered by two facilitators and will be carried out over a virtual platform (e.g., Zoom, Teams). Any session hand-outs will be mailed and/or emailed to participants prior to each session and shared onscreen. Participants in the ESS-HSU condition may also receive study-provided tablet computers with data plans to facilitate their engagement in the intervention (as needed).
62254225|NCT03722342|EXPERIMENTAL|TTAC-0001 and pembrolizumab|TTAC-0001 and pembrolizumab combination therapy will be administered.
62254226|NCT03456648|EXPERIMENTAL|Part A : postdialysis low dose|Interdialytic kinetics of low dose (2.5 mg apixaban) post-dialysis
62254227|NCT03456648|EXPERIMENTAL|Part A: ipostdialysis high dose|Interdialytic kinetics of high dose (5 mg apixaban) post-dialysis
62254228|NCT03456648|EXPERIMENTAL|Part B : predialysis low dose|Intra- and interrdialytic kinetics of low (2.5 mg) apixaban pre-dialysis
62254229|NCT03456648|EXPERIMENTAL|Part B : predialysis high dose|Intra- and interrdialytic kinetics of high (5 mg) apixaban pre-dialysis
62254230|NCT04983173|EXPERIMENTAL|Experimental: Clomiphene Citrate (CC) + rFSH|Ovarian Stimulation with CC+rFSH
62836463|NCT00296621|PLACEBO_COMPARATOR|2|
62836464|NCT00691834|EXPERIMENTAL|1|Intracoronary delivery of unfractionated bone marrow mononuclear cells
62836465|NCT00691834|PLACEBO_COMPARATOR|2|Intracoronary delivery of placebo
62053148|NCT04653441|EXPERIMENTAL|Child-only Intervention|The children in this arm will receive only child intervention curriculum (peer group activities). The child intervention includes 20 hours of facilitator-guided programming delivered in 10 sessions in a peer-group setting and aims to increase resilience by developing a number of skills including positive thinking, emotional regulation, coping, and problem solving.
62053149|NCT04653441|EXPERIMENTAL|Child+Caregiver Intervention|The children in this arm will receive child intervention and their caregivers will receive the caregiver intervention, At the caregiver level, caregivers receive 10 hours of facilitator-guided programming delivered in five sessions that aims to increase positive parenting skills and build the capacity of the caregiver to engage in self-care and seek support.
62053150|NCT04653441|EXPERIMENTAL|Child+Caregiver+Community Intervention|The children in this arm will received child intervention; their family will receive caregiver intervention and community-based intervention. At the community level, trained community advocates (e.g., teachers, village nurses) conduct monthly home visits and organize a series of community-based activities over a period of two years to promote cohesion and strength within local communities and to increase community support for affected families.
62053151|NCT04653441|NO_INTERVENTION|Attention Control|Children and caregivers who do not receive any intervention activities
62053152|NCT02093767|ACTIVE_COMPARATOR|7.5g dose Synergy1|7.5 g/day dose of Synergy1 (oligofructose enriched inulin 1:1) for 9 weeks. The daily dose is dispersed in two sachets of 3.75 g each which are consumed at breakfast and dinner
62836466|NCT01436435|EXPERIMENTAL|Jetstream Atherectomy System|Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention including Atherectomy utilizing the Jetstream Atherectomy System with or without adjunctive therapy.
62836467|NCT04639258|EXPERIMENTAL|Medtronic Evolut™ PRO+ System|All study subjects will be treated with the Medtronic Evolut™ PRO+ TAVR System.
62836468|NCT06054074|EXPERIMENTAL|Low back pain|Participants with low back pain. They will perform the two induction procedures.
62053153|NCT02093767|ACTIVE_COMPARATOR|15g Synergy1|15 g/day dose of Synergy1 (oligofructose enriched inulin 1:1) for 9 weeks. The daily dose is dispersed in two sachets of 7.5 g each which are consumed at breakfast and dinner
62836469|NCT06239896|ACTIVE_COMPARATOR|Facilitated Group ACP Session|Participants in the group ACP visit arm will attend a one-time 90-minute facilitated group ACP session where they will review the movie version of the PREPARE program (about how to choose a medical decision maker and how to decide what matters most in life), including a new PSH-specific video and PREPARE easy-to-read ADs with the new PSH-specific content and cover letters.
62836470|NCT06239896|ACTIVE_COMPARATOR|Facilitated one-on-one ACP visits|Participants in the one-on-one ACP visit arm will attend a one-time 90-minute ACP session with a facilitator where they will review the movie version of the PREPARE program (about how to choose a medical decision maker and how to decide what matters most in life), including a new PSH-specific video and PREPARE easy-to-read ADs with the new PSH-specific content and cover letters.
62836471|NCT00357006|ACTIVE_COMPARATOR|1|100 mcg Estradiol
62836472|NCT00357006|ACTIVE_COMPARATOR|2|200 mcg Estradiol
62836473|NCT00357006|PLACEBO_COMPARATOR|3|adjunctive transdermal placebo
62836474|NCT00938704|ACTIVE_COMPARATOR|1|carboxymethylcellulose 0.5%, glycerin 0.9%
62836475|NCT00938704|ACTIVE_COMPARATOR|2|sodium hyaluronate 0.18%
62836476|NCT04057976|EXPERIMENTAL|Patients having pre-operative DTT prior to surgery|All patients in this study will undergo DTT as part of a pre-operative MRI.
62053154|NCT03301012|ACTIVE_COMPARATOR|Recovery Support as Usual Control|Participants in the control and experimental condition will have access to post treatment recovery support services as usual.
62254231|NCT04983173|ACTIVE_COMPARATOR|rFSH|Ovarian Stimulation with rFSH
62254232|NCT02130739||thoracic epidural anesthesia|thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy
62254233|NCT04492098||study group|women with spontaneous miscarriage
62254234|NCT04745039|EXPERIMENTAL|Endopatch System|Participants will be treated with Endopatch System
62254235|NCT02005991|EXPERIMENTAL|PF-05212377 70 mg|
62612358|NCT04683354|EXPERIMENTAL|Dose Escalation|There are 3 cohorts for the dose escalation study. Six subjects each cohort will receive oral administration of HL-085 capsules at three daily dose levels (12 mg, 18 mg and 24 mg). Three subjects of each cohort will receive TID and 3 subjects will receive BID dose regimen. Dose escalation can occur after 6 patients have completed 28 days of treatment and no or 1 DLT is identified.
62836477|NCT04606602|EXPERIMENTAL|30 mg|
62836478|NCT04606602|PLACEBO_COMPARATOR|Placebo|
62254236|NCT02005991|EXPERIMENTAL|PF-05212377 20 mg|
62836479|NCT04606602|EXPERIMENTAL|100 mg|
62836480|NCT04606602|EXPERIMENTAL|300 mg|
62836481|NCT04606602|EXPERIMENTAL|600 mg|
62836482|NCT04606602|EXPERIMENTAL|900 mg|
62836483|NCT04606602|EXPERIMENTAL|100 mg multi dose|
62836484|NCT04606602|EXPERIMENTAL|200 mg multi dose|
62836485|NCT04606602|EXPERIMENTAL|300 mg multi dose|
62836486|NCT04606602|EXPERIMENTAL|600 mg multi dose|
62836487|NCT04606602|PLACEBO_COMPARATOR|Placebo multi dose|
62836488|NCT01024413|EXPERIMENTAL|erlotinib|erlotinib 150 mg oral till disease progression
62836489|NCT01024413|ACTIVE_COMPARATOR|gefitinib|gefitinib 250mg oral till disease progression.
62612359|NCT04112095|EXPERIMENTAL|Use Phase Norgestrel 0.075 mg|Norgestrel 0.075 mg tablets to be taken orally, one tablet daily at the same time every day for up to 24 weeks
62612360|NCT01583205|EXPERIMENTAL|Coping Effectiveness Training|Coping Effectiveness Training -ALS (CET-ALS) is an eight session intervention derived from Coping Effectiveness Training (CET), a manualized intervention based on stress and coping theory. It is designed to strengthen coping skills and alleviate distress for either the patient or care partner following a diagnosis of ALS.
62612361|NCT05818319|OTHER|12 hours ETI pause|
62612362|NCT05818319|OTHER|36 hours ETI pause|
62053155|NCT03301012|EXPERIMENTAL|Smartphone Addiction Recovery Coach (SARC) - Assisted Relapse Prevention|Participants in the experimental condition will receive a smartphone, a calling/texting/data plan, and the SARC-YA mobile applications for the first 6 months post treatment discharge. Experimental participants will 1) complete a 2-3 minute recovery-focused ecological momentary assessment (EMA) at 5 random times a day, receive feedback on their current answers, and provided access to behavioral charting of their past answers over time; and 2) receive continuous access to a suite of self-initiated ecological momentary interventions (EMI) to support their recovery via tool box of coping tools, apps related to getting support, and apps related to maintaining a healthy lifestyle.
62612363|NCT05818319|OTHER|60 hours ETI pause|
62254237|NCT02005991|EXPERIMENTAL|PF-05212377 10 mg|
62254238|NCT05676684|EXPERIMENTAL|[Dapagliflozin] - [Dapagliflozin + Spironolactone]|"Drug will be administered according to sequence:~Dapagliflozin \[week 1-12\] - Dapagliflozin + Spironolactone \[week 13-25\]"
62612364|NCT02325245|EXPERIMENTAL|Metformin|Metformin tablet 500 mg three times a day for 16 weeks.
62612365|NCT02325245|PLACEBO_COMPARATOR|Placebo|Placebo tablet three times a day for 16 weeks.
62612366|NCT02090556||Cohort 1:|RA patients naive of Abatacept and any other biologic agents
62612367|NCT02090556||Cohort 2:|RA patients naive of Abatacept and who previously failed one or more biologic agents
62612368|NCT04060199|EXPERIMENTAL|Viltolarsen|Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.
62612369|NCT04060199|PLACEBO_COMPARATOR|Placebo|Patients amenable to exon 53 skipping will receive placebo intravenous (IV) infusions, weekly, for up to 48 weeks.
62612370|NCT04039321|ACTIVE_COMPARATOR|ESPB group|Before anaesthesia induction; bilateral ESP block will be performed under the guidance of USG. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. If patients' NRS score will ≥4/10, 100 mg IV tramadol will be performed.
62612371|NCT04039321|SHAM_COMPARATOR|Control group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. If patients' NRS score will ≥4/10, 100 mg IV tramadol will be performed.
62612372|NCT02974920|ACTIVE_COMPARATOR|Aspirin 100 mg|100 mg of aspirin daily for 180 days
62612373|NCT02974920|ACTIVE_COMPARATOR|Rivaroxaban 10 mg|10 mg of Rivaroxaban daily for 180 days
62612374|NCT04328610|EXPERIMENTAL|LYMPHA technique group|LVA at the time of Axillary Dissection
62612375|NCT04328610|NO_INTERVENTION|Non-LYMPHA technique group|No preventive surgical approach
62612376|NCT05180955|OTHER|Digital drainage system group|chest tube removal will be determined by air flow criteria as indicated by the digital drainage system data.
62612377|NCT05180955|OTHER|Digital drainage system + clamping trial group|In the control group removal will be determined by the same criteria of the digital drainage system but before removal, a chest tube clamping test will be performed.
62612378|NCT04788875|ACTIVE_COMPARATOR|Small Bite Technique Group|closure of laparotomy by small bites technique using PDS 2.0
62612379|NCT04788875|OTHER|Standardised Large Bites Technique Group|usual practice closure of laparotomy by standardised large bites technique using PDS 2.0
62612380|NCT03567161|EXPERIMENTAL|Cavitron ultrasonic surgical aspirator|"Patients.with periodontitis.~Inclusion criteria:~1. Having received a diagnosis of chronic periodontitis (Armitage 1999)~2. Being treated by full mouth debridement, and supportive periodontal treatment (SPT) in the last year (at least three sessions)~3. Having at least one residual pocket ≥ 5 mm with and intra bony component at least ≥ 2 mm~Exclusion criteria:~1. Smoking more than ten cigarettes per day~2. Pregnancy~3. Irregular compliance during SPT in the last year; and systemic conditions or therapies known to affect the healing potential of periodontal tissues (e.g., uncontrolled diabetes, oncological conditions, immunosuppressant drugs)."
62612381|NCT03090633|EXPERIMENTAL|Fetoscopy|All participants will undergo fetoscopic repair of fetal spina bifida.
62254239|NCT05676684|EXPERIMENTAL|[Dapagliflozin + Spironolactone] - [Dapagliflozin]|"Drug will be administered according to sequence:~Dapagliflozin + Spironolactone \[week 1-12\] - Dapagliflozin \[week 13-25\]"
62612382|NCT03464942|ACTIVE_COMPARATOR|Single Dose|SABR 20Gy given as a single dose (to 1 -4 metastases with at least 1 untreated metastasis) followed by atezolizumab (1200 mg) every 3 weeks for 24 months.
62612383|NCT03464942|ACTIVE_COMPARATOR|Fractionated Dose|SABR 24Gy given as 3 fractions (to 1 -4 metastases with at least 1 untreated metastasis) followed by atezolizumab (1200 mg) every 3 weeks for 24 months.
62612384|NCT01743534||Conservation of praxies and form plates|
62612385|NCT02669914|EXPERIMENTAL|Cohort A: Non-small cell lung cancer w/o corticosteroids|-MEDI4736 will be given to all patients \> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
62254240|NCT03932370||f-URS|
62254241|NCT03932370||mini-PCNL|
62254242|NCT01040351|EXPERIMENTAL|1: Hydrosalpinx needle aspiration|After the retrieval of oocytes an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely .
62254243|NCT01040351|NO_INTERVENTION|2. no aspiration|IVF-ET is done without prior aspiration of hydrosalpingeal fluid
62254244|NCT01966328|EXPERIMENTAL|36% Resolvine|Patients in this arm will be given one dose of 36% Resolvine intravitreal injection, with the possibility of a second dose at Day 30
62254245|NCT01966328|ACTIVE_COMPARATOR|9% Resolvine|Patients in this arm will be given one dose of 9% Resolvine intravitreal injection, with the possibility of a second dose at Day 30
62443076|NCT03644095|EXPERIMENTAL|Mucinex® SE 600 mg (extended-release)|Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet taken with 240 mL of water after an overnight fast
62443077|NCT03644095|ACTIVE_COMPARATOR|Vicks Cough Syrup 200 mg|Vicks Cough Syrup for Chesty Coughs 200 mg every 4 hours taken with 240 mL of water after an overnight fast
62443078|NCT00859469|EXPERIMENTAL|Oxaliplatin and Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 90 minutes, then Oxaliplatin 100 mg/m² IV infusion over 2 hours repeated for 14 days up to 6 cycles
62443079|NCT01842958|ACTIVE_COMPARATOR|4.1 mm implant diameter|Placement of a Straumann Bone Level Implants, 4.1 mm implant diameter, for single tooth replacement in the anterior and pre-molar region
62612386|NCT02669914|EXPERIMENTAL|Cohort B: Epithelial origin solid tumors w/o corticosteroids|-MEDI4736 will be given to all patients \> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
62612387|NCT02669914|EXPERIMENTAL|Cohort C: NSCLC or non-NSCLC w/corticosteroids|-MEDI4736 will be given to all patients \> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
62612388|NCT03723421|EXPERIMENTAL|Rapid Injection Group Without Aspiration|The tetanus vaccine was applied into the deltoid muscle of the left arm in the sitting position by rapid injection technique without aspiration.
62053156|NCT02721576|EXPERIMENTAL|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 \~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T\>40Gy/20f,week 1-\>5"
62053157|NCT03790761|EXPERIMENTAL|PREP 8.0 Curriculum|All participants enrolled in the program will be given the PREP 8.0 curriculum - there will be no comparison group.
62612389|NCT03723421|EXPERIMENTAL|Control|The tetanus vaccine was applied into the deltoid muscle of the left arm in the sitting position with the standard injection technique.
62612390|NCT02798354|EXPERIMENTAL|Reduce Elevated Blood Pressure Errors First|"Will provide baseline data on elevated blood pressure diagnosis and first intervene to reduce missed opportunities for elevated blood pressure diagnosis. Will then intervene to reduce missed opportunities for depression diagnosis and finally, intervene to reduce delayed diagnosis attributable to abnormal laboratory values.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
62053158|NCT02942602|EXPERIMENTAL|Atorvastatin 20 mg|lipid lowering treatment
62254246|NCT01015768|EXPERIMENTAL|Test eye|Uses ReNu Multiplus as multipurpose soaking solution
62443080|NCT01842958|EXPERIMENTAL|3.3 mm implant diameter|Placement of a Straumann Bone Level Implants, 3.3 mm implant diameter, for single tooth replacement in the anterior and pre-molar region
62612391|NCT02798354|EXPERIMENTAL|Reduce Depression Errors First|"Will provide baseline data on depression diagnosis and first intervene to reduce missed opportunities for depression diagnosis. Will then intervene to reduce delayed diagnosis attributable to abnormal laboratory values and finally, intervene to reduce missed opportunities for elevated blood pressure diagnosis.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
62612392|NCT02798354|EXPERIMENTAL|Reduce Lab Related Errors First|"Will provide baseline data on delayed diagnosis attributable to abnormal laboratory values and first intervene to reduce delayed diagnosis attributable to abnormal laboratory values. Will then intervene to reduce missed opportunities for elevated blood pressure diagnosis results and finally, to reduce missed opportunities for depression diagnosis.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
62612393|NCT06355843|EXPERIMENTAL|68Ga-FAPI PET/MRI scan|68Ga-PSMA PET/CT (PET/MR) before surgery or biopsy
62254247|NCT01015768|ACTIVE_COMPARATOR|Control|A new lens (PureVision) is soaked for 2 hours in non-preserved saline
62254248|NCT02509182|ACTIVE_COMPARATOR|100% FiO2|100% oxygen administered during pulmonary lobectomy surgery.
62254249|NCT02509182|EXPERIMENTAL|60% FiO2|60% oxygen administered during pulmonary lobectomy surgery.
62254250|NCT03827824|EXPERIMENTAL|Hysteroscopy & Virtual reality glasses|Hysteroscopy with use of virtual reality glasses
62254251|NCT03827824|ACTIVE_COMPARATOR|Hysteroscopy|Hysteroscopy without use of virtual reality glasses
62443081|NCT06026982|EXPERIMENTAL|Gut Health Surveys|Participants will take a pre-survey to evaluate their cravings. They will then be started on a regimen of probiotic and prebiotic with a pickle daily for 30 days to improve gut health. Then participants will take the same survey to evaluate if there has been any decrease in cravings.
62053159|NCT02942602|EXPERIMENTAL|Cholestyramine 8 g|lipid lowering treatment
62053160|NCT02942602|EXPERIMENTAL|Omega-3 (EPA+DHA) 2 g|lipid lowering treatment
62053161|NCT02942602|EXPERIMENTAL|Atorvastatin 5 mg + Ezetimibe 10 mg|lipid lowering treatment
62053162|NCT02942602|ACTIVE_COMPARATOR|Life style modification for management of dyslipidemia|
62836490|NCT05847816|EXPERIMENTAL|Experimental group: infrared vascular imaging|The patient's vital signs, skin color and skin turgor will be evaluated and recorded in the peripheral intravenous chemotherapy application registration form. After the tourniquet is attached, the stopwatch will be started and the catheter intervention process will be started when the vein visibility reaches the level where the nurse can insert the catheter. The stopwatch will be terminated at the stage of advancing the branule into the vein and fixing it with a plaster. If the catheterization application is successful or unsuccessful in the first attempt, it will be recorded. The pain and arm comfort levels in the form will be evaluated on a scale ranging from 0 to 10, with 0: none, 10: many, before and after the application (at the 5th, 30th, and 60th minutes).
62053163|NCT06259383|EXPERIMENTAL|Patients received oral ivermectin, adjunctive to conventional treatment|
62053164|NCT06259383|NO_INTERVENTION|Patients received conventional treatment|
62053165|NCT03781921||BN|Females with a current diagnosis of Bulimia Nervosa between 18 and 50 years old
62053166|NCT03781921||Controls|Females with no current or past diagnosis of any eating disorder; between 18 and 50 years old
62443082|NCT05175079|EXPERIMENTAL|Accupressure group|"acupressure band apply to P6 (nei guan) point which located three fingers below the skin wrinkles of the anterior wrist.~Acupressure band wear 3 times daily before breakfast, lunch and dinner for at least 10 minutes"
62612394|NCT01589679|OTHER|control/ standard of care|ALL SUBJECTS WILL RECEIVE SHOE INSERTS AND HOME STRETCHING REGIME. Control subjects will be treated with the Standard of Care during the first 12 weeks, but after the 12 weeks patients will be fit with MTP, which delivers a low-load, prolonged-duration stretch after completion of this study.
62612395|NCT01589679|EXPERIMENTAL|Dynasplint|ALL SUBJECTS WILL RECEIVE SHOE INSERTS AND HOME STRETCHING REGIME. Experimental subjects will be immediated treated with the Metatarsal Dynasplint, which delivers a low-load, prolonged-duration stretch for 60 minutes, three times per day.
62053167|NCT05672979|EXPERIMENTAL|Brolucizumab treated|"Intravitreal brolucizumab 6mg injection.~Initial treatment consists of a loading dose of three intravitreal injections of brolucizumab at monthly intervals. After 3 loading doses, patients are followed by monthly observation visits until the month 6 and bimonthly afterwards until disease-recurrence interval is determined (It can be monthly as per the investigator's judgement.). Following loading phase, the first treatment interval is determined by patients' disease recurrent interval, 1 month shorter than first recurrence interval (maximum first injection interval is 16 weeks). The injection interval is shortened if there is any fluid change or decreased visual acuity. If the criteria for treatment adjustment were not met and residual fluid was decreased from the previous visit, the injection interval is maintained. And the interval is extended if there was no fluid on OCT. The minimum and maximum injection intervals are 8 and 16 weeks, respectively."
62053168|NCT01385358|EXPERIMENTAL|Thoracoscopically Assisted Surgical Ablation|This arm will have an index thoracoscopically assisted surgical ablation.
62053169|NCT01385358|ACTIVE_COMPARATOR|Catheter Ablation|This is an active comparator arm where study subjects will undergo conventional catheter ablation.
62053170|NCT01075932|ACTIVE_COMPARATOR|1 g DHA-rich fish oil|1 g DHA-rich fish oil containing 450 mg DHA + 90 mg EPA plus 1 g olive oil
62053171|NCT01075932|ACTIVE_COMPARATOR|2 g DHA-rich fish oil|2 g DHA-rich fish oil containing 900 mg DHA + 180 mg EPA
62053172|NCT01075932|PLACEBO_COMPARATOR|Placebo|2 g olive oil
62053173|NCT05547243|EXPERIMENTAL|Low dose|Two doses were administered by intramuscular injection, 28 days apart
62053174|NCT05547243|EXPERIMENTAL|High dose|Two doses were administered by intramuscular injection, 28 days apart
62053175|NCT05547243|PLACEBO_COMPARATOR|Placebo|Two doses were administered by intramuscular injection, 28 days apart
62053176|NCT06065566|EXPERIMENTAL|Patients on bypass with cardiopulmonary bypass +gluta|Patients operated on bypass with cardiopulmonary bypass + glutamine
62053177|NCT06065566|PLACEBO_COMPARATOR|Patients on bypass + cardiopulmonary bypass + glutamine|Patients operated on bypass with cardiopulmonary bypass + glutamine
62443083|NCT05175079|PLACEBO_COMPARATOR|Control group|
62443084|NCT01753037|ACTIVE_COMPARATOR|DHEA Group|Oral administration of a capsule containing 130 mg of dehydroepiandrosterone (DHEA) for 5 days.
62254252|NCT01637220||case, control|Blood volume collected specifically for this study
62254253|NCT04881071|EXPERIMENTAL|Scarf|"Two hours after delivery, mothers will be informed of the benefits of the skin-to-skin method, and the towel with which mother and newborn are covered from the moment of delivery will be replaced by a NeoBulleⓇ scarf. This scarf, which can be used by the mother and/or her partner, is specific for practicing the skin-to-skin technique. It facilitates breastfeeding posture, keeps the newborn well covered and supported on the back. The NeoBulleⓇ scarf is not a baby carrier device that allows standing or walking without holding the baby with the arms. Nursing staff will ensure the proper understanding of scarf usage instructions by parents and provide them with written instructions. Mother and newborn will remain with the NeoBulleⓇ scarf placed in the delivery area until they are transferred to the hospitalization unit. Once in the hospitalization unit, mothers will have the option to continue contact with the baby using the scarf or dress the newborn."
62254254|NCT04881071|ACTIVE_COMPARATOR|Usual clinical practice|Two hours after delivery, mothers will be informed about the benefits of the skin-to-skin method, and the traditional practice in the study centers will be followed, whereby the newborn remains in contact with the mother, covered by a towel, from the moment of birth until both are transferred to the hospitalization unit. In the hospitalization unit, they will have the option to continue in this manner or dress the newborn.
62612396|NCT00528632||Cholesterolosis|I. Patients with gallbladder cholesterolosis and symptomatic cholelithiasis
62254255|NCT02431897|EXPERIMENTAL|Estrogen Cream|Conjugated Estrogens cream
62254256|NCT02431897|PLACEBO_COMPARATOR|Placebo Cream|Placebo cream
62254257|NCT03377842|ACTIVE_COMPARATOR|FOLFOX regimen|FOLFOX regime alone.
62254258|NCT03377842|EXPERIMENTAL|Apatinib and FOLFOX regimen|Apatinib combine with FOLFOX regimen.
62612397|NCT00528632||Cholelithiasis|II. Patients without gallbladder cholesterolosis and with symptomatic cholelithiasis
62612398|NCT00601822|EXPERIMENTAL|1|Group receiving cognitive behavioral therapy for anorexia nervosa (CBT-AN)
62612399|NCT00601822|EXPERIMENTAL|2|Group receiving cognitive behavioral therapy for anorexia nervosa, plus cognitive remediation therapy (CBT-AN+CRT)
62612400|NCT03982940|EXPERIMENTAL|BGP+ Stent Graft System|Application of BeGraft Peripheral Plus (BGP+) Stent Graft System as bridging stent in Branched Endovascular Repair (BEVAR) for complex aortic aneurysms
62612401|NCT06730555|EXPERIMENTAL|ACCESS Group|Participants in this group will receive the ACCESS intervention for up to 18 months
62612402|NCT06730555|ACTIVE_COMPARATOR|Control Group|Participants in this group will receive a link to the CDC Compendium of Evidence-Based Interventions for up to 18 months.
62612403|NCT04697212|EXPERIMENTAL|Healthcare team- + patient-directed intervention|Team education and patient tool
62612404|NCT04697212|ACTIVE_COMPARATOR|Healthcare team-directed intervention|Team education
62612405|NCT00033306|EXPERIMENTAL|BMS-247550|
62612406|NCT05525780|EXPERIMENTAL|GB-5001|GB-5001 Suspension for intramuscular (IM) injection at three doses
62612407|NCT05525780|PLACEBO_COMPARATOR|Placebo|Placebo Suspension for intramuscular (IM) injection, Volume to be matched with the active drug in the respective cohort
62612408|NCT05525780|ACTIVE_COMPARATOR|Oral cohort|Aricept® tablet
62254259|NCT03236220|EXPERIMENTAL|N-acetyl-L-cysteine group|Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine.
62254260|NCT03887533|EXPERIMENTAL|VTS-270 at 500 mg/kg|Participant received dose of 500 mg/kg of intravenous VTS-270 administered over 2 hours monthly for 12 months. Participant also received 900 mg intrathecal VTS-270 therapy monthly for 18 months.
62612409|NCT06356818|ACTIVE_COMPARATOR|Conventional physiotherapy program group|Physiotherapy and rehabilitation treatment program will be applied to the patients. In this program, a 30-40-minute exercise protocol including proprioceptive, balance and strengthening exercises will be applied.
62612410|NCT06356818|ACTIVE_COMPARATOR|Virtual reality (VR) program group|Virtual reality (VR) program will be applied in addition to the conventional physiotherapy program. In VR; the subjects will be asked to stand on the Wii fit balance board and will be able to physically and visually see and participate in the game. Nintendo Wii Fit Plus will last 30 minutes in total as warm-up exercise (5 minutes), workout (20 minutes) and cool-down exercise (5 minutes). Interactive video games will be used, including both strength and balance exercises. The exercises in the study include 5 muscle strengthening (e.g. forward lunge/ lunge, single leg extension, side leg raise, single leg bend, rowing) and 5 balance exercises (e.g. playing soccer, ski slalom, tightrope walk, snowboard slalom) among the programs built into the Nintendo Wii Fit Plus.
62612411|NCT06356818|ACTIVE_COMPARATOR|Motor imagery (MI) program group|In addition to VR and conventional physiotherapy programs motor imagery program will be given to the patients in this group. Using the explicit MI method, individuals will be explicitly instructed to perform imagery (2). The physiotherapist will ask the patient to imagine a real or fantasy place that is peaceful, happy and relaxing. Then, they will be asked to imagine that they are in this picture. Patients will be asked to imagine themselves doing physiotherapy exercises and feel the movements as vividly as possible. The content of the imagery program will last 20 minutes in total, with 5 minutes of relaxation and 15 minutes of imagery training.
62612412|NCT05580276||Study group|Adolescent with headache, 10-18 ages
62254261|NCT03887533|EXPERIMENTAL|VTS-270 at 1000 mg/kg|Participant received 1000 mg/kg of intravenous VTS-270 over 4 hours monthly for 12 months. Participant also received 900 mg intrathecal VTS-270 therapy monthly for 18 months.
62443085|NCT01753037|PLACEBO_COMPARATOR|Placebo Group|Oral administration of an identical capsule containing placebo for 5 days.
62443086|NCT03426930|ACTIVE_COMPARATOR|The reference treatment of dysmorphophobia used|
62443087|NCT03426930|EXPERIMENTAL|The reference treatment with the virtual reality|
62443088|NCT01159327|EXPERIMENTAL|Arm A|Sorafenib maintenance arm
62612413|NCT05580276||Control group|Adolescent without headache
62053178|NCT06065566|EXPERIMENTAL|patients without bypass + cardiopulmonary bypass +glutamine|Patients operated without bypass with cardiopulmonary bypass + glutamine
62053179|NCT06065566|PLACEBO_COMPARATOR|Patients without bypass + cardiopulmonary bypass +placebo|Patients operated without bypass with cardiopulmonary bypass + placebo
62053180|NCT04670692|EXPERIMENTAL|5G-MCE examination|There will be 20 volunteers assigned to the 5G-MCE system group. These patients will accept the magnetically controlled capsule examination in Yinchuan. After an overnight fasting and drinking 800-1000 mL water and simethicone for gastric dilatation and preparation, the subjects put on the data recorder with the help of the assistant in Yinchuan. Then, the assistant activated the capsule with the capsule locator. The patient is instructed to swallow the capsule with a small amount of water to effectively observe the esophagus and dentate line. After the capsule entering into the stomach, the examination will be performed through the 5G-MCE system by the endoscopist (W.Z.), with experience of more than 1000 cases of MCE operation, in Shanghai.
62053181|NCT04670692|ACTIVE_COMPARATOR|MCE examination|There will be 20 volunteers assigned to the MCE system group as comparator group. After an overnight fasting and drinking 800-1000 mL water and simethicone for gastric dilatation and preparation, the subjects put on the data recorder with the help of the endoscopist. Then, the endoscopist activated the capsule with the capsule locator. The patient is instructed to assume the left lateral decubitus position and to swallow the capsule with a small amount of water to effectively observe the esophagus and dentate line. Then, under the guidance of the endoscopist (W.Z.) face to face, subject continue the examination of stomach and duodenum.
62612414|NCT02393326|EXPERIMENTAL|Partial pulpotomy with biodentine|Biodentine is gently applied to the pulp stumps
62612415|NCT02393326|OTHER|Formocresol pulpotomy|A cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min.
62612416|NCT05631782|ACTIVE_COMPARATOR|Control group|losartan tablets were taken orally (J20180054; Hangzhou Merck Pharmaceutical Co., Ltd.; specification 50 mg) at a dose of 50 mg per day. Furosemide was injected intravenously (TCM approved by H41021056; Suicheng Pharmaceutical Co., Ltd.; specification 20 mg: 2mL) at a dose of 100 mg per day. Uremic clearance granule was mixed with water and taken (Z20073256; Kangchen Pharmaceutical (Khorgos) Co., Ltd.; Specification 5 g) at a dose of 5 g at 6:00,12:00 and 10 g at 22:00 every day. Treatment lasted for 10 - 14 days.
62053182|NCT03373526|ACTIVE_COMPARATOR|Aerobic Physical Training|Aerobic Training
62053183|NCT03373526|EXPERIMENTAL|Combined Physical Training|Inspiratory Muscle Training Aerobic Training
62053184|NCT03684122|EXPERIMENTAL|Injection of Umbilical cord derived MSCs|Allogenic Umbilical Cord derived stem cells injected intravenously to enrolled PD patients
62053185|NCT03684122|EXPERIMENTAL|Injection of MSCs differentiated into neural stem cells NSCs|Allogenic Umbilical Cord derived stem cells (MSCs) differentiated into neural stem cells (NSCs) injected intrathecaly and intravenously to enrolled PD patients.
62623602|NCT03077425|PLACEBO_COMPARATOR|Enhanced Usual Care (EUC)|"Community Health Workers (CHWs)- will deliver the EUC to all study participants at their 6 month well-child visit, which will occur just after their T0 Baseline Interview, just prior to randomization. EUC Components: 1) Pamphlet- CHWs will hand out and review deliver and review a pamphlet with basic ECC and Obesity prevention messages for parents of 6-18 month olds; and 2) Dental Referral List of dentists who will see 12 month olds, and who accept most insurance plans in the pediatric practices we are recruiting from.~Thus, the EUC will be delivered to n=180 families in the EUC Control and n=180 families in the Intervention group."
62053186|NCT02577055|ACTIVE_COMPARATOR|myomectomy|Women will be treated with surgical removal of all fibroids, either by laparoscopic or abdominal route
62053187|NCT02577055|EXPERIMENTAL|embolisation|Women will be treated with fertility sparing uterine arteries embolization (i..e. with ultra thin catheter, and particles' diameter \> 500µm)
62053188|NCT05147948|EXPERIMENTAL|Treatment|Internet delivered Acceptance and Commitment Therapy for PTSD and Chronic Pain, supported by a psychologist
62053189|NCT05147948|NO_INTERVENTION|Waitlist|Waitlist for 12 weeks.
62053190|NCT01361425|EXPERIMENTAL|methildopa|pregnant women with stable severe pre-eclampsia will use methildopa (1,5g/day)
62836491|NCT05847816|EXPERIMENTAL|Experimental group: isometric hand exercise|The patients to be included in this group will have applied isometric hand squeeze exercise, which lasted for twenty minutes a day, five days a week, before the PIVK procedure. On the fifth day, the patient's vital signs, skin color and skin turgor will be evaluated and recorded in the peripheral intravenous chemotherapy application registration form. Patients will be told how to use the stress ball 5 minutes before and during the PIVK procedure before the procedure. Patients will be taught to count from one to three and tighten and loosen the stress ball once, and they will be told to continue squeezing and loosening the stress ball in this way until the procedure is over. Focus their attention on the stress ball during the procedure.
62836492|NCT05847816|NO_INTERVENTION|Control group: no intervention|The patient's vital signs, skin color and skin turgor will be evaluated and recorded in the peripheral intravenous chemotherapy application registration form. After the tourniquet is attached, the stop watch will be started and the catheter intervention process will be started when the vein visibility reaches the level where the nurse can insert the catheter. If the PIVC application is successful or unsuccessful in the first attempt, it will be recorded. PIC success will be evaluated according to whether the branule is placed in the vein. The pain and arm comfort levels in the form will be evaluated on a scale ranging from 0 to 10, with 0: none, 10: many, before and after the application (at the 5th, 30th, and 60th minutes).
62053191|NCT01361425|PLACEBO_COMPARATOR|placebo|stable pregnant women with severe preeclampsia will use placebo
62053192|NCT02073825|EXPERIMENTAL|Web Brief Intervention (WBI)|4-session WBI
62053193|NCT02073825|NO_INTERVENTION|Delayed-WBI|4-session WBI after follow-up
62053194|NCT02454192|OTHER|CHAMPS Intervention|Tailored asthma education and counseling for children with moderate to severe asthma who have confirmed allergies to environmental triggers present in their homes provided through a combination of clinic and home visits
62053195|NCT02454192|NO_INTERVENTION|Usual Care|Usual asthma care and management
62053196|NCT02028026|EXPERIMENTAL|Vilazodone|10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
62053197|NCT02028026|ACTIVE_COMPARATOR|Citalopram|20 mg/day for 2 weeks and then 40 mg/day for 6 weeks.
62053198|NCT03160989|EXPERIMENTAL|Postmenopausal and hypertensive women|The intervention will consist of a single session and after ten weeks of combined physical exercises (aerobic and resisted). All volunteers will participate in the same procedure.
62053199|NCT05232864|EXPERIMENTAL|Secukinumab|Secukinumab 300 mg solution for subcutaneous (s.c.) injection in a 2mL Pre-Filled Syringe (PFS)
62053200|NCT04065503|EXPERIMENTAL|Healthy Adults|Healthy adults will be given probiotic strains to evaluate the detection and persistence of the strains in the participant's feces.
62053201|NCT04292782|ACTIVE_COMPARATOR|CAUDAL BLOCK|Sonosite machine (M-Turbo) equipped with a large bandwidth, a multifrequency linear probe (6-19 MHz) and needle of diameter and length respectively between 22G and 25G, 35mm and 40mm according to the child's size (Braun).The patient is positioned laterally with their hips flexed to 90°. The sacral hiatus is forming with the two posterior superior iliac spines an equilateral triangle. The puncture is performed between the two sacral cornuae. The sacrococcygeal ligament gives a perceptible 'pop' when crossed. After crossing the sacro-coccygeal ligament, the needle is redirected 30° to the skin surface, and then advanced a few millimeters into sacral canal. After verifying absence of spontaneous reflux of blood or cerebrospinal fluid, slowly injection of Ropivacaine 0.25% 1ml/ kg
62053202|NCT04292782|EXPERIMENTAL|anterior Quadratus lumborum block|Sonosite machine (M-Turbo) equipped with a large bandwidth, a multifrequency linear probe (6-19 MHz) and a 22G, 50-mm, insulated facet type needle (BBraun Stimuplex Ultra 360°). Patients were placed in the lateral position, a probe was placed transversely to the abdominal flank. The needle was inserted using an in-plane technique and was preceded further into the fascia between the QLM and PM. Following confirmation of the correct space with the administration of 0.5-1 ml local anesthetic, block was induced with 1 ml/kg, 0.25% Ropivacaine,
62836493|NCT02212782|EXPERIMENTAL|A Group|1st oral administration of Linagliptin 5mg and 2nd oral administration of DW1029M 1200mg and Linagliptin 5mg
62836494|NCT02212782|EXPERIMENTAL|B Group|1st oral administration of DW1029M 1200mg and Linagliptin 5mg and 2nd oral administration of Linagliptin 5mg
62836495|NCT04114318|EXPERIMENTAL|Cognitive-Cycling|Dual-task cognitive-cycling training; cognitive and cycling training simultaneously
62053203|NCT02324556||Laparoscopic total mesorectal excision|Patients operated with laparoscopic total mesorectal surgery for rectal cancer
62053204|NCT02324556||transanal total mesorectal excision|Patients operated with a combined transanal and laparosocopic total mesorectal surgery for rectal cancer
62836496|NCT04114318|ACTIVE_COMPARATOR|Cycling|Single-task cycling training; stationary bicycle exercise training
62836497|NCT04033016|EXPERIMENTAL|Facebook and motivational interviewing group|Women from this group were included in social media intervention and in two sessions of motivational interviewing.
62836498|NCT04033016|EXPERIMENTAL|Facebook only group|Women from this group were included in the social media intervention only.
62836499|NCT04033016|NO_INTERVENTION|control group|women from this group only received the information on the benefits of physical activity during pregnancy.
62836500|NCT03703427|EXPERIMENTAL|Capecitabine|
62836501|NCT03703427|EXPERIMENTAL|Vinorelbine|
62836502|NCT04560673|EXPERIMENTAL|Group I (neurofeedback training, duloxetine)|Patients receive neurofeedback training over 1 hour 3-5 times weekly for up to 5 weeks. Patients also receive duloxetine PO QD for 5 weeks in the absence of unacceptable toxicity.
62836503|NCT04560673|EXPERIMENTAL|Group II (neurofeedback training)|Patients receive neurofeedback training over 1 hour 3-5 times weekly for up to 5 weeks.
62836504|NCT04560673|EXPERIMENTAL|Group III (duloxetine)|Patients receive duloxetine PO QD for 5 weeks in the absence of unacceptable toxicity.
62053205|NCT06391710|EXPERIMENTAL|HRS9531|
62053206|NCT06391710|PLACEBO_COMPARATOR|Placebo|
62053207|NCT00691938|EXPERIMENTAL|Level 1|"LBH589 10 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m\^2 IV on days 1-5 in a 28 day cycle."
62053208|NCT00691938|EXPERIMENTAL|Level 2|"LBH589 15 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m\^2 IV on days 1-5 in a 28 day cycle."
62443089|NCT01159327|NO_INTERVENTION|Arm B|observation arm
62836505|NCT03555448|ACTIVE_COMPARATOR|Once daily regimen|Once daily medication regimen (Envarsus and azathioprine)
62836506|NCT03555448|ACTIVE_COMPARATOR|Twice daily regimen|Twice daily medication regimen (Tacrolimus and mycophenolic acid)
62053209|NCT00691938|EXPERIMENTAL|Level 3|"LBH589 20 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m\^2 IV on days 1-5 in a 28 day cycle."
62836507|NCT01919567||Normal team|"Subjects who have problem at third molar of impacted tooth need to receive a surgery with general anesthesia.~Subjects must:~Should have a blood exam (20ml) before the surgery.~Site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample around third molar during the surgery."
62836508|NCT01919567||Oral dysplasia|"Subjects who are diagnosed with dysplasia of oral cavity.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
62053210|NCT00691938|EXPERIMENTAL|Level 4|"LBH589 30 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m\^2 IV on days 1-5 in a 28 day cycle."
62053211|NCT00691938|EXPERIMENTAL|Level 5|"LBH589 40 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m\^2 IV on days 1-5 in a 28 day cycle."
62053212|NCT00691938|EXPERIMENTAL|Level 5B|"LBH589 40 mg/day three times a week on nonconsecutive days for the first 2 weeks in a 28 day cycle.~Decitabine 20 mg/m\^2 IV on days 1-5 in a 28 day cycle."
62053213|NCT00691938|EXPERIMENTAL|Phase II|"LBH589 will be given in the dose and in the schedule that was found to work in the Phase I portion which was Level 5B.~Decitabine 20 mg/m\^2 IV on days 1-5 in a 28 day cycle."
62053214|NCT02805426|EXPERIMENTAL|Tranexamic acid|1950 mg oral tranexamic acid + 800 mcg sublingual misoprostol
62053215|NCT02805426|PLACEBO_COMPARATOR|Placebo|oral placebo + 800 mcg sublingual misoprostol
62053216|NCT02123602|EXPERIMENTAL|Core stabilization|This arm will receive 3 weeks of core stabilization training followed by 3 weeks of lower extremity stretching and strengthening as appropriate to address impairments noted in the examination and to progress function.
62053217|NCT02123602|ACTIVE_COMPARATOR|Lower extremity training only|This arm with receive 6 weeks of impairment based stretching and strengthening to restore function.
62053218|NCT02623465|EXPERIMENTAL|Part A:Insulin Lispro Test|Individualized doses of insulin lispro test formulation administered by injection under the skin once in each of 3 periods
62053219|NCT02623465|ACTIVE_COMPARATOR|Part A:Insulin Lispro Reference|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
62053220|NCT02623465|EXPERIMENTAL|Part B:Insulin Lispro Test|Individualized doses of insulin lispro test formulation administered by injection under the skin with each meal for 14 days
62053221|NCT02623465|ACTIVE_COMPARATOR|Part B:Insulin Lispro Reference|Individualized doses of insulin lispro reference formulation administered by injection under the skin with each meal for 14 days
62053222|NCT03359070|EXPERIMENTAL|Group 1 - dapaconazole cream 2%|Topical application of dapaconazole cream 2%, twice a day (7 to 8 a.m. and 6 to 7 p.m.) for 14 days.
62443090|NCT00324415|EXPERIMENTAL|CMT with Radiation Therapy|"All patients will receive combined modality therapy (CMT) with 2 cycles of cisplatin and 5-FU chemotherapy, given concurrently with radiation therapy. CMT consists of:~* Cetuximab 400 mg/m2 IV Day -7 (1 week before the cycle 1, Day 1 cisplatin/5-FU and RT), then 250 mg/m2 IV Days 1, 8, 15, 22, 29, 36 and 43 (a minimum of 6 and a maximum of 8 doses of cetuximab will be administered, including the loading dose).~* Cisplatin 75 mg/m2 IV on Day 1 (cycle 1) and Day 29 (cycle 2)~* 5-FU 1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)"
62053223|NCT03359070|ACTIVE_COMPARATOR|Group 2 - miconazole cream 2%|Topical application of miconazole cream 2%, twice a day (7 to 8 a.m. and 6 to 7 p.m.) for 14 days.
62053224|NCT05994144|NO_INTERVENTION|CONTROL|The control group, traditional DOTS is the group who will be attending daily to their respective PR-1/PR-2 throughout intensive phase.
62053225|NCT05994144|ACTIVE_COMPARATOR|INTERVENTION ARM (VOT)|The intervention group, video observed therapy (VOT) is the group who will be teleconferencing daily with their respective PR-1/PR-2 TB team via WhatsApp throughout the intensive phase.
62053226|NCT02635802|EXPERIMENTAL|Remifentanil|injection form concentration 20μg/ml loading dose 1.0-2.0μg/kg intravenous injection slowly,time \>1min,then 5μg/kg·h pumping until the operation is finished.
62053227|NCT02635802|EXPERIMENTAL|Lidocaine|injection form concentration 10mg/ml loading dose 100-400mg local anesthesia
62053228|NCT02635802|EXPERIMENTAL|Remifentanil+Lidocaine|"injection form concentration 20μg/ml loading dose 1.0-2.0μg/kg intravenous injection slowly,time \>1min,then 5μg/kg·h pumping until the operation is finished~+ injection form concentration 10mg/ml loading dose 100-400mg local anesthesia"
62053229|NCT04176380|EXPERIMENTAL|Administration of RAPA-201 cells|
62053230|NCT05570643|EXPERIMENTAL|LPS group|Healthy male volunteers that will receive an intravenous administration of LPS (2ng/kg) twice.
62443091|NCT01274728||ST-elevated myocardial infarction|Those with a condition of chestpain (or equal complains) and ECG changes confirming STEMI.
62443092|NCT04984109|SHAM_COMPARATOR|Control group|Patients will receive preoperative US-guided will receive sham PENG with an injection of just 1mL saline.
62612417|NCT05631782|EXPERIMENTAL|Treatment group|Shenkang decoction prescription: 15 g of semen cuscutae, herba epimedii and pericarpium arecae. 20 g of Eucommia ulmoides Oliv., radix astragali, codonopsis pilosula, salvia miltiorrhiza, tuckahoe, atractylodes macrocephala, Chinese yam, honeysuckle, polyporus umbellatus and dandelion. 15 g of safflower. 12 g of processed Fuzi. 10 g of Radix phytolaccae and sage. Golden cherry son 20 g and puzzle kernel 15 g were added to patients with frequent proteinuria and nocturia took. Yellow cypress 15 g was added to patients with damp-heat in lower-Jiao. The decoction pieces were purchased from the Traditional Chinese Medicine and Pharmacy Department of the First People's Hospital of Zunyi City. They were decocted by computer automatic decocting machine (model) and divided into 150 mL / bag, taken orally, once in the morning, noon and evening, 3 times / day, 1 bag / time, one pair a day. Treatment lasted for 10 - 14 days.
62612418|NCT02424864|OTHER|4D PET-CT|Other intervention: 4D PET-CT
62612419|NCT00053508|EXPERIMENTAL|Group 1|ACAM1000
62612420|NCT00053508|EXPERIMENTAL|Group 2|ACAM1000
62443093|NCT04984109|EXPERIMENTAL|PENG Group|Patients will receive preoperative US-guided will receive real PENG with an injection of 20mL of bupivacaine 0.25%+ 0.2mg/mL dexamethasone.
62612421|NCT00053508|EXPERIMENTAL|Group 3|ACAM1000
62612422|NCT00053508|ACTIVE_COMPARATOR|Group 4|Dryvax
62612423|NCT01550107|ACTIVE_COMPARATOR|Allopurinol|Allopurinol 600mg tablets
62612424|NCT01550107|PLACEBO_COMPARATOR|Lactose tablets|Placebo Lactose tablets
62254262|NCT02887404|EXPERIMENTAL|Spine surgery analgesic pathway|"Before surgery the subject will be given one time oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).~During surgery the subject will receive an infusion of ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start before the incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).~After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed."
62443094|NCT01093456||chronic kidney disease|ESKD patients treated with peritoneal dialysis
62612425|NCT06371066|EXPERIMENTAL|Experimental group|video-based training group
62612426|NCT06371066|OTHER|Control group|traditional formal training group
62612427|NCT05622227|EXPERIMENTAL|68Ga-P16-093 and 18F-FDG scan|Within 1 week, each patient underwent 68Ga-P16-093 and 18F-FDG PET/CT scan after intravenous administration of 68Ga-P16-093 and 18F-FDG, respectively.
62612428|NCT05786638|ACTIVE_COMPARATOR|Sublingual immunotherapy|50 Bronchial asthma (BA) patients received Sublingual immunotherapy
62612429|NCT05786638|ACTIVE_COMPARATOR|Subcutaneous immunotherapy|50 BA patients received Subcutaneous immunotherapy
62612430|NCT03286231||Healthy volunteers|Healthy volunteers who will undergo contrast-enhanced CT imaging of the gluteal venous vasculature in the prone and jackknife positions
62612431|NCT02893423|ACTIVE_COMPARATOR|Group 1 - 0.5% Ropivacaine|Patients will receive 0.5% Ropivacaine for the TAP block Procedure: Ultrasound guided TAP BLOCK Drug: 0.5% ropivacaine 20ml of 0.5% ropivacaine is used to perform the TAP block Other Names: •Naropin
62612432|NCT02893423|ACTIVE_COMPARATOR|Group 2 - 0.25% Ropivacaine|Patients will receive 0.25% for the TAP block Procedure: ULTRASOUND GUIDED TAP BLOCK Drug: 0.25% ropivacaine 20ml of 0.25% ropivacaine is used to perform the TAP block Other Names: •Naropin
62612433|NCT02893423|NO_INTERVENTION|Group 3 - No Tap Block|Patients will not receive a TAP BLOCK
62612434|NCT02147067|EXPERIMENTAL|Ranolazine|Ranolazine 1,000 mg twice daily
62612435|NCT02147067|PLACEBO_COMPARATOR|Placebo|Placebo twice daily
62443095|NCT01093456||Healthy volunteers|healthy volunteers, aged 18 years and above
62443096|NCT01501695|EXPERIMENTAL|5LGr, granule and placebo tablet|"Drug:5LGr; Dosage form:Granule;Strength:5 gram/sack;Mimic Tablet:0 mg/tablet. Dosage: 5LGr Granule: 1 sack, t.i.d. for patients less than 12 yrs,whereas 1.5 sacks, t.i.d. for patients 13-18 yrs.~Mimic tablet:For patients 5-12 yrs: 0.5 tablet, b.i.d for first 2 weeks, then 1 tablet, bid for next 6 weeks; for patients 13-18 yrs: tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.~Duration: 8 weeks."
62612436|NCT02585388|ACTIVE_COMPARATOR|Vinorelbine|Vinorelbine (metronomic) alone 3 times per week ( mondays, wednesdays, Fridays or Thursdays, Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.
62612437|NCT02585388|EXPERIMENTAL|Vinorelbine+Anastrozole or Letrozole|"Vinorelbine metronomic 3 times per week (mondays, wednesdays, Fridays or Thursdays,Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.~And:~Letrozole 2,5 mg every day or Anastrozole 1 mg every day. Until progression of disease or toxicity"
62612438|NCT04866680|EXPERIMENTAL|Personalized Circulating DNA follow-up|FFPE tissue sample + blood sample (20ml)
62612439|NCT00561483||Observation|Patients admitted to the hospital with decompensated heart failure
62612440|NCT05055856|ACTIVE_COMPARATOR|Frailty or more|patients with the geriatric syndrome who will be recruited at the geriatric out patient clinic
62612441|NCT05055856|PLACEBO_COMPARATOR|healthy|healthy aged people defined as in the modified SENIEUR protocol who will be recruited by an extern call thanks UZ Brussel website of thanks to staff's knowledge
62612442|NCT03146975|NO_INTERVENTION|Healthy|
62612443|NCT03146975|EXPERIMENTAL|Periodontitis without diabetes|
62612444|NCT03146975|EXPERIMENTAL|Periodontitis compensated diabetes|
62612445|NCT03146975|EXPERIMENTAL|Periodontitis decompensated diabetes|
62612446|NCT03146975|NO_INTERVENTION|Compensated diabetes non periodontitis|
62612447|NCT03146975|NO_INTERVENTION|Decompensated diabetes non periodontitis|
62612448|NCT01366300|ACTIVE_COMPARATOR|Intravenous lidocaine infusion|Intravenous lidocaine infusion during total intravenous anesthesia with propofol administered by target controlled infusion
62612449|NCT01366300|PLACEBO_COMPARATOR|Intravenous 0.9% saline infusion|Intravenous 0.9% saline infusion during total intravenous anesthesia with propofol administered by target controlled infusion
62612450|NCT02919007|EXPERIMENTAL|Silk'n HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual. Measure includes the ability to operate the device correctly according to the user manual.
62612451|NCT01337323||New prescription for fluticasone furoate nasal spray|patients receiving their first prescription for fluticasone furoate nasal spray and who have active seasonal allergic rhinitis with a history of using another intranasal steriod (INS) and other concomitant allergic rhinitis medications to treat their seasonal allergy symptoms.
62612452|NCT02612688|EXPERIMENTAL|ACP Video Program|Facility asked to implement ACP Video Program
62612453|NCT02612688|NO_INTERVENTION|Usual ACP procedures|Facility follows usual ACP procedures
62612454|NCT01627782|PLACEBO_COMPARATOR|Placebo 3 times/week|
62612455|NCT01627782|EXPERIMENTAL|Ketamine 3 times/week|
62612456|NCT01627782|EXPERIMENTAL|Ketamine 2 times/week|
62612457|NCT01627782|PLACEBO_COMPARATOR|Placebo 2 times/week|
62612458|NCT04786665|EXPERIMENTAL|Strawberry powder|Participants consume 1 package of standard strawberry powder (26 g) daily for 8 weeks
62612459|NCT04786665|PLACEBO_COMPARATOR|Placebo group|Participants consume 1 package of placebo powder (26 g) daily for 8 weeks
62612460|NCT00543998||Optical Measurement transillumination|Optical Measurement of sinus
62836509|NCT01919567||Oral cancer|"Subjects who suffer from oral cancer.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
62836510|NCT01095614||12 women with oral contraception|
62612461|NCT06548594|EXPERIMENTAL|Four Weeks of Active Transcutaneous Auricular Neurostimulation|Participants will receive 4 weeks of at-home, self-administered active Transcutaneous Auricular Neurostimulation (tAN).
62612462|NCT04400071|EXPERIMENTAL|Active Music Engagement|See intervention description.
62612463|NCT04400071|ACTIVE_COMPARATOR|Audio Storybooks|See intervention description.
62612464|NCT00630201|EXPERIMENTAL|Probuphine|buprenorphine implant
62836511|NCT01095614||12 women without any contraception|
62836512|NCT05050877||coronary angiography|The investigators recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention.
62612465|NCT06730035|EXPERIMENTAL|Experimental analysis on tissues|The results obtained from the study should not be considered conclusive but rather as generators of research hypotheses for potential subsequent studies to be conducted on larger populations.
62612466|NCT04338191|EXPERIMENTAL|mFOLFOXIRI adjuvant chemotherapy|Patients will receive mFOLFOXIRI once every two weeks for 6 cycles as adjuvant chemotherapy
62612467|NCT04338191|ACTIVE_COMPARATOR|mFOLFOX6 adjuvant chemotherapy|Patients will receive mFOLFOX6 once every two weeks for 6 cycles as adjuvant chemotherapy
62612468|NCT05462925|EXPERIMENTAL|Functional electrical stimulation therapy|Participants will receive 30 sessions of upper limb functional electrical stimulation therapy. Sessions will be 1 hour in length and take place 3-5 times per week.
62612469|NCT03193749|EXPERIMENTAL|Amiodarone Hydrochloride|Oral treatment for at least 6 months
62612470|NCT03193749|PLACEBO_COMPARATOR|Placebo|Oral treatment for at least 6 months
62836513|NCT04226755|EXPERIMENTAL|Heart failure|After a run-in phase of 2 weeks, patients will add 3 g of sodium chloride to every meal, using a NaCl tablet of 1 g. They will continue the sodium tablet for 4 weeks with a study visit every 2 weeks. A skin biopsy will be performed before the start of the augmented salt intake and after 4 weeks.
62836514|NCT04226755|ACTIVE_COMPARATOR|Healthy volunteer|After a run-in phase of 2 weeks, volunteers will add 3 g of sodium chloride to every meal, using a NaCl tablet of 1 g. They will continue the sodium tablet for 4 weeks with a study visit every 2 weeks.A skin biopsy will be performed before the start of the augmented salt intake and after 4 weeks.
62612471|NCT00760812|EXPERIMENTAL|ESI--Individual PII First Condition|This group will first receive the Early Social Interaction (ESI) model individual parent-implemented intervention (PII) for 9 months, followed by the ESI model group information, education, and support (IES) intervention for 9 months.
62612472|NCT00760812|EXPERIMENTAL|ESI--Group IES First Condition|The group will first receive ESI group IES condition for 9 months, followed by ESI individual PII for 9 months.
62612473|NCT00791830|ACTIVE_COMPARATOR|Irbesartan|
62612474|NCT00791830|PLACEBO_COMPARATOR|Placebo|
62612475|NCT01762449||Patients who received cyclophosphamide|Patients who received cyclophosphamide on the Scleroderma Lung Study
62612476|NCT01762449||Patients who received placebo|Patients who received placebo on the Scleroderma Lung Study
62612477|NCT03822494|EXPERIMENTAL|Dose Escalated CyberKnife SBRT|
62612478|NCT04442438|EXPERIMENTAL|Intensive care unit 1|Receives of intervention consisting of monthly moral case deliberation (ethical decision-making) meetings, planned and set up by ICU professionals which have received the task of being more attentive to ethical situations during work.
62612479|NCT04442438|OTHER|Intensive care unit 2|First non-intervention, then flips to experimental arm type after six months.
62254263|NCT02887404|ACTIVE_COMPARATOR|Usual care|"Placebo- Before surgery the subject will be given one time placebo oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).~Placebo- During surgery the subject will receive a placebo infusion of - ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start at incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).~After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed."
62254264|NCT03399981||Tysabri (TOUCH Cohort)|Participants from the Tysabri TOUCH prescribing programme who have switched to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate).
62254265|NCT03399981||Tysabri (EU MS Cohort)|Participants from the EU MS registry who have switched to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate).
62254266|NCT00838292|ACTIVE_COMPARATOR|ART: food|ART + food supplementation + nutrition counseling
62612480|NCT04442438|OTHER|Intensive care unit 3|First non-intervention, then flips to experimental arm type after six months.
62612481|NCT04442438|OTHER|Intensive care unit 4|First non-intervention, then flips to experimental arm type after twelve months.
62254267|NCT00838292|ACTIVE_COMPARATOR|ART: no food|ART + nutrition counseling
62836515|NCT02694016|EXPERIMENTAL|Remote ischemic preconditioning|Patient will undergo normal isolated aortic valve replacement surgery with a biological prosthesis and a preoperative lower leg remote ischemic preconditioning(RIPC) phase.
62836516|NCT02694016|NO_INTERVENTION|Control group|Patient will undergo normal isolated aortic valve replacement surgery with a biological prosthesis
62836517|NCT00482053|EXPERIMENTAL|Auto-HCT followed by Allo-HCT for Poor-risk DLBCL|"Participants will have peripheral blood stem cells (PBSC, aka progenitor / stem cells) mobilized to peripheral blood with rituximab, chemotherapy (cyclophosphamide or etoposide), and filgrastim; undergo apheresis to collect (self/autologous PBSC), and receive carmustine, etoposide, and cyclophosphamide as conditioning for PBSC infusion as a hematopoietic cell transplant (auto-HCT).~Then participants will receive allogeneic HCT (allo-HCT) transplant conditioning \[total lymphoid irradiation (TLI) + anti-thymocyte globulin (ATG)\] followed by allogenic PBSC (allo-HCT) obtained from a human leukocyte antigen (HLA)-matched or single mismatch filgrastim-mobilized donor. Participant allo-HCT transplant is to occur within 150 days of auto-HCT. Post-allo-HCT treatment includes cyclosporine + mycophenolate mofetil (MMF).~Subject's participation ends if donor is not identified within 150 days. Pre-medication includes acetaminophen; diphenhydramine; hydrocortisone; \& methylprednisolone."
62053231|NCT05570643|PLACEBO_COMPARATOR|Placebo group|Healthy male volunteers that will receive an intravenous administration of placebo (NaCl 0.9%).
62254268|NCT00838292|ACTIVE_COMPARATOR|pre-ART: food|no ART (cotrimoxazole provided) + food supplementation + nutrition counseling
62053232|NCT02253355|EXPERIMENTAL|Deep Brain Stimulation|Stimulation is on
62053233|NCT02253355|SHAM_COMPARATOR|Placebo|Stimulation is off
62254269|NCT00838292|ACTIVE_COMPARATOR|pre-ART: no food|no ART (cotrimoxazole provided) + nutrition counseling
62254270|NCT01567657|ACTIVE_COMPARATOR|Pethidin plus midazolam|Initial dose of 25 mg Pethidin iv. plus 1-2 mg Midazolam iv. Additional Bolus of Midazolam (1 mg wise iv.) if needed, until a maximal dose of 7 mg Midazolam iv.
62612482|NCT04442438|OTHER|Intensive care unit 5|First non-intervention, then flips to experimental arm type after twelve months.
62612483|NCT04442438|OTHER|Intensive care unit 6|First non-intervention, then flips to experimental arm type after Eighteen months.
62612484|NCT04548388|EXPERIMENTAL|Bobath approach|Bobath approach
62612485|NCT04548388|EXPERIMENTAL|whole body vibration|whole body vibration
62836518|NCT03937570|EXPERIMENTAL|EO GROUP|Patients underwent LVAD echo-optimization; the optimal device speed is confirmed at the end of procedure.
62053234|NCT01677143|ACTIVE_COMPARATOR|bupivacaine|Injection of 5 ml bupivacaine, 5mg/ml in each port site.
62053235|NCT01677143|PLACEBO_COMPARATOR|Placebo|Injection of 5 ml saline in each port site.
62053236|NCT06454617||Experimental|Patients that require a TC scan.
62254271|NCT01567657|ACTIVE_COMPARATOR|Propofol|Initial dose of Propofol of 50-60 mg iv. for patients 50 years or younger. Initial dose of Propofol of 30-40 mg iv. for patients over 50 years. If needed additional Bolus of 20-30 mg Propofol iv. as usual until sedation is achieved.
62254272|NCT05279248|EXPERIMENTAL|Group A|Participants in this arm will be simultaneously administrated with one dose of HPV 16/18 bivalent vaccine and one dose of MMR vaccine. six month later, they are going to receive a second dose of HPV 16/18 bivalent vaccine.
62254273|NCT05279248|ACTIVE_COMPARATOR|Group B|Participants in this arm will be receieve HPV 16/18 bivalent vaccine according to 2-dose schedule (0,6 months) first. After finished HPV vaccination, they are going to receive MMR vaccine at the 7th month.
62612486|NCT06125340|EXPERIMENTAL|Short-course treatment|5 days of placebo (after participants already received 3-5 days of antibiotics)
62612487|NCT06125340|ACTIVE_COMPARATOR|Standard-duration treatment|5 days of amoxicillin (after participants already received 3-5 days of antibiotics)
62254274|NCT05279248|ACTIVE_COMPARATOR|Group C|Participants in this arm will be receieve MMR vaccine first. One month later, they are going to receieve HPV 16/18 bivalent vaccine according to 2-dose schedule (1,7 months)
62836519|NCT03937570|NO_INTERVENTION|CONTROL GROUP|Patients underwent LVAD echo-optimization, but the optimal device speed is not confirmed at the end of procedure.
62836520|NCT05043662||Urothelial carcinoma group|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. CTU and cytology will be performed according to the routine of clinical practice (N=80).
62254275|NCT02428543|EXPERIMENTAL|Ponatinib arm|dose-escalation Arm _ 15, 30, 45mg Ponatinib per day. Each cohort will consist of 3 evaluable patients
62254276|NCT05687747|EXPERIMENTAL|68Gallium-FAPI-46 PET/MRI|Patients receiving Ga68-FAPI-46 will be injected at a dose of 4mCi +/- 2mCi (0.05mCi/kg). Whole body PET scans will be acquired 45mins post injection from head to mid thighs
62836521|NCT05043662||Control group|Patients need to undergo CTU examination and being treated for benign diseases with ureteroscopy, but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UroCAD, CTU and cytology assay (N=30).
62836522|NCT02281916|EXPERIMENTAL|P28GST treatment|P28GST as a parasite enzyme
62254277|NCT00830245|EXPERIMENTAL|Erlotinib|Erlotinib 150mg/day (if no negative conversion --\> increment to 250mg/day)
62254278|NCT01518881|EXPERIMENTAL|TKM-100201|
62254279|NCT01518881|PLACEBO_COMPARATOR|Placebo|
62254280|NCT01524198|PLACEBO_COMPARATOR|Normal Saline|Subjects who are receiving normal saline (NS) in addition to Albuterol 2.5 mg if \< 20 kg or 5 mg if \>= 20 kg body weight and ipratropium bromide (IB) 250 mcg; 3 nebulizations back to back
62254281|NCT01524198|ACTIVE_COMPARATOR|Budesonide|Subjects with acute asthma exacerbation who receive Budesonide 500 mcg, in addition to Albuterol 2.5 mg if \< 20 kg body weight or 5 mg if \>= 20 kg body weight and Ipratropium Bromine (IB) 250 mcg; 3 nebulization doses back to back
62254282|NCT04588662||Uveal Melanoma|Diagnosis of uveal melanoma Ability to provide written informed consent for participation in the prospective registry OR an institutional waiver by the IRB/ethics committee for retrospective data collection without written informed consent
62254283|NCT05506176|EXPERIMENTAL|SIM-0417|orally administrated SIM0417+ ritonavir
62254284|NCT05506176|PLACEBO_COMPARATOR|Placebo|Placebo
62254285|NCT01973374|NO_INTERVENTION|Routine Care|
62836523|NCT01073111|ACTIVE_COMPARATOR|zotarolimus-eluting stents (ENDEAVOR®)|
62254286|NCT01973374|EXPERIMENTAL|Text Message Intervention|The text message intervention group receives usual prenatal and diabetic care in addition to two text messages per week throughout the pregnancy and a reminder text message prior to the postpartum visit. The text message intervention group also fills out a survey about the intervention after delivery.
62254287|NCT02441413|EXPERIMENTAL|HRCT scans|HRCT scan will be taken
62254288|NCT01214694|EXPERIMENTAL|Active Comparator: Internet Resources Comparison (IRC)|Participants will receive the Internet resource comparison group treatment
62254289|NCT01214694|EXPERIMENTAL|I-InTERACT|Participants will receive a 24 week, 27 session internet-based parenting skills program
62254290|NCT01214694|EXPERIMENTAL|I-InTERACT Express|Participants will receive an abbreviated 7 week, 14 session version of the I-InTERACT parenting skills program.
62836524|NCT01073111|ACTIVE_COMPARATOR|sirolimus-eluting stents (CYPHER SELECT® PLUS)|
62836525|NCT01073111|ACTIVE_COMPARATOR|everolimus-eluting stents (PROMUS®)|
62836526|NCT01856959|EXPERIMENTAL|nebulized magnesium sulfate|nebulized magnesium sulfate 150mg and consisted about 5 min,which used only once
62836527|NCT01856959|EXPERIMENTAL|nebulized magnesium sulfate & albuterol|nebulized magnesium sulfate 150mg \& albuterol 2.5mg and consisted about 5 min,which used only once
62836528|NCT01856959|ACTIVE_COMPARATOR|nebulized albuterol|nebulized albuterol 2.5mg and consisted about 5 min,which used only once
62836529|NCT06521333|EXPERIMENTAL|Resveratrol-Based gel|The Resveratrol-Based gel will be applied using a sterile plastic syringe, and the palatal wound will be immediately covered by an acrylic resin stent. Three days postoperatively, the patients will be recalled, the stent will be removed for evaluation and the Resveratrol gel will be reapplied.
62053237|NCT01669798|EXPERIMENTAL|BIBF 1120|BIBF 1120 will be administered at a daily oral dose of 200 mg BID until disease progression or adverse effects prohibit further therapy.
62053238|NCT02294578||Lung Cancer|Patients with biopsy proven lung cancer
62612488|NCT01669785|ACTIVE_COMPARATOR|Group C|"NUPRO Classic Prophy Paste~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains no Novamin or Fluoride..~Leave in contact for 60 seconds, rinse with water and expectorate."
62053239|NCT02294578||Controls|Patients with lung lesions suspicious for the presence of cancer and with cancer excluded after further diagnostic study
62053240|NCT06405399|EXPERIMENTAL|Guided observed|Students attended the simulated clinical experience as non-participant observers, but were supported by an observation rubric. Observation took place in situ, within the simulation laboratory itself, in an adjacent video-monitored room.
62053241|NCT06405399|NO_INTERVENTION|Control group: Participant|Students attended the simulated clinical experience directly as participants.
62053242|NCT01207570|EXPERIMENTAL|Endermotherapy|The subjects in the experimental group will receive a single session (5 minutes) of endermotherapy) applied to the gastrocnemius/soleus muscle group in the more affected side. The treatment will b e carried out by a qualified physiotherapist.
62053243|NCT01207570|ACTIVE_COMPARATOR|Passive stretching|The subjects in this group will receive a single session of passive stretching of the gastrocnemius/soleus muscle for 5 minutes.
62053244|NCT02422602|ACTIVE_COMPARATOR|Taking conventional charge|No further information is given to the patient during the first and only contact with the nurse of the coordinator center. A time will be dedicated by the IDE to answer questions of the patient.
62254291|NCT01651858|EXPERIMENTAL|Nurigra Chewable tablet|
62254292|NCT01651858|ACTIVE_COMPARATOR|Viagra|
62254293|NCT04183283|EXPERIMENTAL|LY3526318|LY3526318 administered orally in three of four study periods.
62254294|NCT04183283|PLACEBO_COMPARATOR|Placebo|Placebo administered orally in one of four study periods.
62254295|NCT04870411||Patients with auto-immune or autoinflammatory diseases|Patients with auto-immune or autoinflammatory diseases treated with immunosuppressants and/or biologics
62612489|NCT01669785|EXPERIMENTAL|Group A|"NUPRO Sensodyne Prophy Paste w/ Novamin~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains 15% Novamin. Does not contain Fluoride.~Leave in contact for 60 seconds, rinse with water and expectorate"
62612490|NCT01669785|EXPERIMENTAL|Group B|"NUPRO Sensodyne Prophy Paste w/ Novamin w/ Fluoride~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains 1.23% fluoride ion and 15% Novamin.~Leave in contact for 60 seconds, rinse with water and expectorate."
62836530|NCT06521333|ACTIVE_COMPARATOR|Hyaluronic acid gel 0.2%|0.2% hyaluronic acid gel (Gengigel®) The 0.2% Hyaluronic acid gel will be applied using a sterile plastic syringe, and the palatal wound will be covered by an acrylic resin stent. Three days postoperatively, the patients will be recalled, the stent will be removed for evaluation, and the Hyaluronic acid gel will be reapplied.
62836531|NCT06521333|PLACEBO_COMPARATOR|Acrylic resin stent only.|The palatal donor site covered with acrylic resin stent only.
62836532|NCT01397968|EXPERIMENTAL|YKP3089|
62836533|NCT01397968|PLACEBO_COMPARATOR|Placebo|
62836534|NCT04607018|ACTIVE_COMPARATOR|Chronic intake group|healthy subjects (control group) receive PMA-zeolite as powder. They take the product already before the study started (since 28 days before or even longer)
62836535|NCT04607018|ACTIVE_COMPARATOR|Naive intake group|healthy subjects (control group) receive PMA-zeolite as powder. They take the product only since the first day of the study
62836536|NCT01746901|PLACEBO_COMPARATOR|Treatment A|
62836537|NCT01746901|EXPERIMENTAL|Treatment B|
62836538|NCT01746901|EXPERIMENTAL|Treatment C|
62836539|NCT01746901|ACTIVE_COMPARATOR|Treatment D|
62836540|NCT01746901|EXPERIMENTAL|Treatment E|
62836541|NCT01746901|ACTIVE_COMPARATOR|Treatment F|
62836542|NCT01374984||Subjects treated with VIGIV.|"Subjects treated with VIGIV deployed from the US Strategic National Stockpile for any of the following conditions:~* Eczema vaccinatum.~* Progressive vaccinia.~* Severe generalized vaccinia.~* Vaccinia infections in individuals who have skin conditions.~* Aberrant infections induced by vaccinia virus (except in cases of isolated keratitis)."
62836543|NCT04287790||Health professionals after intervention|Health professionals (physicians, advanced practice providers, pharmacists, social workers, and nurses) who work on the designated general medicine services at Yale New Haven Hospital after implementation intervention (July 2020)
62836544|NCT04287790||Hospitalized patient before intervention|Patients discharged from the general medicine service at Yale New Haven Hospital York street campus following hospitalization for an alcohol related diagnosis 18 months before the start (January 1st 2020) of the implementation intervention
62836545|NCT04287790||Health professionals before intervention|Health professionals (physicians, advanced practice providers, pharmacists, social workers, and nurses) who work on the designated general medicine services at Yale New Haven Hospital after implementation intervention (December 2019)
62836546|NCT04287790||Hospitalized patient after intervention|Patients discharged from the general medicine service at Yale New Haven Hospital York street campus following hospitalization for an alcohol related diagnosis 12 months after the start (January 1st 2020) of the implementation intervention
62836547|NCT02445898|ACTIVE_COMPARATOR|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
62836548|NCT02445898|PLACEBO_COMPARATOR|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
62836549|NCT05612620||RPL|Samples from the vagina, fornix and cervical canal and rectum will be taken by introducing a flocked nylon swab to the vagina via a speculum and circular swabbing for 5-10 seconds before using any antiseptics.
62836550|NCT05612620||Healthy|Samples from the vagina, fornix and cervical canal and rectum will be taken by introducing a flocked nylon swab to the vagina via a speculum and circular swabbing for 5-10 seconds before using any antiseptics.
62836551|NCT03754998|EXPERIMENTAL|Intervention Group|The participating dyads in intervention communities were invited to consume veo soup/meal (HSM) three times a week and provided weekly supply of iodized salt (450 g) for the household usage as well as being engaged in dry season container gardening. The veo soup/meal is a local Ghanaian soup/meal mainly made of Hibiscus Sabdarifa leaves. It is a soup when prepared a bit watery and consumed with 'tou zaafi' (millet or corn based cooked paste). It is also a meal when prepared thick and eaten by itself. The Hibiscus Sabdariffa leaves meal (HSM) used in the present study was made of 18 kg Hibiscus Sabdariffa leaves, 8 kg groundnut, 1.1 kg dawadawa (fermented African locust beans), 3 kg dried fish plus 0.045 kg iodized salt, cooked with about 23 L (23 kg) water to yield 52.5 kg HSM. In each community, groups of ten women took turns to share the cooking activities, washing of bowls, and making water available for cooking. No treatment provided in our control communities.
62836552|NCT01298648||Humira|Participants who were prescribed Humira per approved prescribing information of Humira in Japan.
62836553|NCT04148846|ACTIVE_COMPARATOR|Clinical treatment - old protocol|In group I, patients will receive clinical treatment according to the institution's old protocol for post dural puncture headache.
62836554|NCT04148846|ACTIVE_COMPARATOR|Clinical treatment - new protocol|In group II, patients will receive clinical treatment, according to the new protocol of the institution.
62836555|NCT04148846|EXPERIMENTAL|Sphenopalatine block|In group III patients will receive clinical treatment, according to the new protocol of the institution, associated with sphenopalatine block.
62836556|NCT03143062||Cases|150 patients that suffered an in-hospital cardiac arrest in a hospital ward.
62836557|NCT03143062||Controls|300 patients that did not suffer an in-hospital cardiac arrest but was treated in a hospital ward.
62836558|NCT04922632|EXPERIMENTAL|Transcendental Medication (TM)|Transcendental Meditation (TM): a mind-body program that allows the participant to experience progressively quieter, less excited states of mental activity, with growing experience of restful alertness in mind and body.
62836559|NCT04922632|EXPERIMENTAL|Experience Resolution Methodology (ERM)|Experience Resolution Methodology (ERM): is a specific, protocolized coaching method that aims to maximize an individual's performance, professional development and well-being by recognizing and resolving subjective stress associated with specific situations, circumstances, events or experiences.
62836560|NCT04922632|EXPERIMENTAL|TM+ERM|Transcendental Meditation (TM) and Experience Resolution Methodology (ERM): an integrative method using both TM and ERM coaching with ERM with the aim of achieving an overall restful, alertness in mind and body and maximizing performance, professional development and well-being.
62836561|NCT04922632|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Treatment As Usual (TAU): is the existing Duke Health \& Well-being services, such as the availability of acupuncture, integrative health coaching, integrative nutrition and weight management, personal exercise training, massage therapy, yoga therapy, mindfulness-based stress reduction (MBSR), experiencing mindfulness, group fitness classes, gentle yoga, or chair yoga, as well as additional resources such as Personal Assistance Services (PAS).
62836562|NCT02733640|ACTIVE_COMPARATOR|Pantoprazole|Drug: Pantoprazole 40 mg once-daily
62254296|NCT04870411||Patients without auto-immune or autoinflammatory diseases|Patients without auto-immune or autoinflammatory diseases and not treated with immunosuppressants and/or biologics
62254297|NCT04725695|EXPERIMENTAL|Viscous lidocaine|Oral viscous lidocaine 20 mg/ml, 10 ml
62612491|NCT05844163||Intracranial aneurysm clipping group|Patients in Intracranial aneurysm clipping group receive neurosurgical clipping.
62612492|NCT05844163||Coil embolization or stent-assisted coil embolization group|Patients in coil embolization or stent-assisted coil embolization group receive coil embolization or stent-assisted coil embolization according to individualized condition.
62612493|NCT05844163||Flow diversion group.|Patients in flow diversion group receive flow diverters.
62612494|NCT06188104|EXPERIMENTAL|TCA plus acetic acid 1|No lesion group,
62254298|NCT04725695|PLACEBO_COMPARATOR|Placebo|Oral viscous solution without active drug, 10 ml
62254299|NCT02601677|EXPERIMENTAL|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
62254300|NCT02601677|ACTIVE_COMPARATOR|Standard Control|Fluoxetine
62254301|NCT01767675|EXPERIMENTAL|Secondary Cytoreductive Surgery with HIPEC|secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B). In some patients randomized to HIPEC at MSKCC only , peritoneal fluid and blood samples will be drawn before, during and after the HIPEC procedure.
62254302|NCT01767675|EXPERIMENTAL|Secondary Cytoreductive Surgery without HIPEC|secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B).
62254303|NCT06216379||Preterm|Children born before 37 gestational weeks
62254304|NCT06216379||Term|Children born after 37 weeks of gestation
62836563|NCT02733640|EXPERIMENTAL|Ranitidine|Drug: Ranitidine 150 mg twice-daily
62254305|NCT05774925|EXPERIMENTAL|Healthy Periodontium|Full-mouth clinical periodontal measurements recorded and saliva obtained.
62254306|NCT05774925|EXPERIMENTAL|Gingivitis|Full-mouth clinical periodontal measurements recorded and saliva obtained.
62254307|NCT05774925|EXPERIMENTAL|Periodontitis|Full-mouth clinical periodontal measurements recorded and saliva obtained.
62254308|NCT01936636||Cancer patients treated for BTcP|"All patients 18 years of age and older with breakthrough cancer pain (BTcP) who are registered in the Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program and receiving Abstral® under the direction of a TIRF REMS Access program-registered physician are eligible for the study.~Patients or their proxy with a witness must be able to sign written informed consent to participate in the study; and the patient may also use a proxy caregiver to assist in the completion of the study questionnaires."
62443097|NCT01501695|ACTIVE_COMPARATOR|tiapride tabletand mimic 5LGr granule|"Tiapride are 100 mg scored tablets. Mimic 5LGr granule are preparation that contain no active ingredient, and act as placebo.~Dosage: Tiaptride tablet: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.~Mimic 5LGr Granule:Strength:0 gram/sack.Dosage:1 sack for patients less than 12 yrs,while 1.5 sacks for patients 13-18 yrs.Frequency: T.i.d.~Duration: 8 weeks."
62612495|NCT06188104|NO_INTERVENTION|Acetic acid 1|No lesion group, Applying acetic acid which normally used during colposcopic examination at transformation zone during colposcopic examination
62612496|NCT06188104|EXPERIMENTAL|TCA plus acetic acid 2|Having lesion with normal pathologic examination
62254309|NCT05514990|EXPERIMENTAL|Cohort I (standard therapy)|Patients receive bortezomib SC) or IV and dexamethasone PO, IV, or IM on days 1, 8, and 15 of each cycle. Patients also receive pembrolizumab IV over 30 minutes on day 9 of each cycle. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
62836564|NCT05185869|EXPERIMENTAL|AG+SHR6390|Subjects will receive SHR6390 plus nab-paclitaxel and gemcitabine
62254310|NCT05514990|EXPERIMENTAL|Cohort II (standard therapy, pelareorep)|Patients receive bortezomib SC or IV and dexamethasone either PO, IV, or IM on days 1, 8, and 15 of each cycle. Patients also receive pelareorep IV over 60 minutes on days 1, 2, 8, 9, 15, and 16 and pembrolizumab IV over 30 minutes on day 9 of each cycle. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
62254311|NCT01979159|EXPERIMENTAL|Combined Aphasia-ApraxiaTreatment|Administration of Combined Aphasia and Apraxia of Speech Treatment )(CAAST) to 4 persons with aphasia and apraxia of speech in the context of single-subject designs
62443098|NCT01501695|PLACEBO_COMPARATOR|placebo, granule and tablet|"This arm includes mimic preparation of 5LGr granule and tiapride tablets , which doesn't contain active ingredients.~Dosage form: Mimic Granule:Strength:0 gram/sack Dosage:1 sack, t.i.d for patients less than 12 yrs,while 1.5 sacks, t.i.d for patients 13-18 yrs.~Mimic tablet:Strength:0 mg/tablet.For patients 5-12 yrs: 0.5 tablets b.i.d for first 2 weeks, then 1 tablet,b.i.d for next 6 weeks; for patients 13-18 yrs:1 tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.~Duration: 8 weeks."
62443099|NCT00071916||African American|Adult African American participants with compensated chronic hepatitis C who have not been previously been treated with interferon and/or ribavirin.
62836565|NCT01099462||Children with fever|
62836566|NCT00981448|EXPERIMENTAL|Zinc supplement|
62254312|NCT02689531||High-Risk (Adult =>18 years old)|"Treated with one or more of the following respiratory modalities for at least 12 continuous hours, either currently or within the prior 7 days:~* Invasive mechanical ventilation~* Noninvasive ventilation (BiPAP or CPAP for any indication other than obstructive sleep apnea)~* High-flow, supplemental oxygen therapy via nasal cannula. Only include systems that using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM.~* High flow supplemental oxygen therapy delivering at least 50% FiO2 via aerosol facemask or tracheostomy collar (mask). Only include systems using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM.~* Supplemental oxygen therapy delivered via either partial or non-rebreather face mask"
62254313|NCT02689531||Other-ICU/Standard Risk|Patients do not fulfill high-risk criteria, but, are receiving an antibiotic for treatment of lower respiratory tract infection or undifferentiated sepsis.
62254314|NCT02689531||High-Risk (Pediatric ≥120 days old and <18 years old)|"Currently treated with one or more of the following respiratory modalities for at least 24 hours:~* Invasive mechanical ventilation via endotracheal intubation~* New initiation of mechanical ventilation, BiPAP or CPAP via tracheostomy~* Noninvasive ventilation (BiPAP or CPAP for any indication other than obstructive sleep apnea)~* High-flow, supplemental oxygen therapy delivering at least 1.5LMP with 100% FiO2 via nasal cannula when delivered using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM~* High flow supplemental oxygen therapy delivering at least 50% FiO2 via aerosol facemask or tracheostomy collar (mask) when delivered using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM~* Supplemental oxygen therapy delivered via either partial or non-rebreather face mask"
62254315|NCT02689531||High-Risk (Pediatric <120 days old)|Currently treated with mechanical ventilation via endotracheal intubation for at least 5 days
62254316|NCT02660203|EXPERIMENTAL|forced expiration|2 daily sessions of forced expiration on ipsilateral decubitus from day 1 after surgery until chest tube removal
62254317|NCT02660203|NO_INTERVENTION|control|No session of forced expiration
62254318|NCT05692492|EXPERIMENTAL|ZSP1601 50mg BID|
62254319|NCT05692492|EXPERIMENTAL|ZSP1601 100 mg BID|
62254320|NCT05692492|PLACEBO_COMPARATOR|Placebo|
62254321|NCT02017353|EXPERIMENTAL|Curcuphyt|Intake of Curcuphyt capsules, 2 g per day during 2 weeks
62254322|NCT01508104|EXPERIMENTAL|BEZ235 and Everolimus|
62443100|NCT00071916||Caucasian|Caucasian participants with compensated chronic hepatitis C who have not been previously been treated with interferon and/or ribavirin.
62612497|NCT06188104|NO_INTERVENTION|Acetic acid 2|Having lesion with normal pathologic examination, Applying acetic acid which normally used during colposcopic examination at transformation zone and lesion during colposcopic examination
62612498|NCT06188104|EXPERIMENTAL|TCA plus acetic acid 3|Having lesion with low-grade abnomality on pathologic examination,
62836567|NCT01821118|EXPERIMENTAL|1|
62254323|NCT01434420|EXPERIMENTAL|Triple negative breast cancer|Triple negative breast cancer
62254324|NCT04943081|EXPERIMENTAL|Case group|Adult patients with age group ≥ 18 years old with renal stones candidate for PCNL with pre-operative estimated GFR less than 90 ml/min/1.7 m2 and ≥ 15 ml/min/1.7 m2.
62443101|NCT06544187||Participants|The first phase of the study will involve 56 participants who are potential candidates for oesophagectomy, gastrectomy or pancreaticoduodenectomy procedures following a confirmed cancer diagnosis. Participants who provide their consent will undergo Magnetic Resonance Spectroscopy (MRS) scans of their semitendinosus muscle in the thigh. Participants on this pathway also undergo Cardiopulmonary Exercise Test (CPET) tests, which is a standard procedure. No delay to their normal treatment pathway will be introduced from the addition of the MRS scan, and MR scans can be arranged within two weeks from referral
62612499|NCT06188104|NO_INTERVENTION|Acetic acid 3|Having lesion with low-grade abnomality on pathologic examination, Applying acetic acid which normally used during colposcopic examination at transformation zone and lesion during colposcopic examination
62836568|NCT01821118|PLACEBO_COMPARATOR|2|
62612500|NCT00336323|ACTIVE_COMPARATOR|1|Laser photocoagulation at baseline
62612501|NCT00336323|EXPERIMENTAL|2|1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks
62612502|NCT00336323|EXPERIMENTAL|3|2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks
62612503|NCT00336323|EXPERIMENTAL|4|1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
62612504|NCT00336323|EXPERIMENTAL|5|1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
62612505|NCT01493700|EXPERIMENTAL|control|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
62836569|NCT03651414||Control|Patients hospitalized ab initio in Internal Medicine or similar for at least one night
62836570|NCT03651414||Outlier|Patients spending at least one night in a ward different from Internal Medicine despite the presence of medical diseases, due to lack of available beds
62836571|NCT06020820|EXPERIMENTAL|Cervical Rehabilitation program (Intervention Group) Group A|Positional release technique on trapezius muscle, Suboccipital muscle release, Stretching of pectoralis muscle
62836572|NCT06020820|ACTIVE_COMPARATOR|(control group) Group B|neck and shoulder ROMS
62836573|NCT01765257|EXPERIMENTAL|rasagiline|Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France
62254325|NCT02009436|EXPERIMENTAL|Treatment (azacitidine)|Patients receive azacitidine via nebulizer over 20 minutes QD on days 1-5 and 15-19. Treatment repeats every 28 days for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients may continue treatment on a case-by-case basis at the discretion of principal investigator and Institutional Review Board.
62836574|NCT01765257|PLACEBO_COMPARATOR|placebo|Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France
62053245|NCT02422602|EXPERIMENTAL|Personalized information intervention|The intervention of personalized information will be made as appropriate to the patient's needs and will include: Personalized telephone information carried by a nurse trained in therapeutic education. A time will be dedicated by the IDE to answer questions of the patient. The delivery of paper documents, a list of recommended websites and phone remote monitoring will be performed by the nurse at J30 and J45 to check understanding of the information provided, the actual reading of the paper documents, or effective consultation of websites. A time will be dedicated by the IDE to answer questions at the remote monitoring of the patient to J30 and J45.
62053246|NCT04309916|EXPERIMENTAL|Tegoprazan 50mg|Tegoprazan 50mg tablet, once daily, oral administration
62053247|NCT04309916|ACTIVE_COMPARATOR|Esomeprazole 40mg|Esomeprazole 40mg tablet, once daily, oral administration
62053248|NCT04204369|EXPERIMENTAL|Teaching arm|This group received the teaching intervention and was evaluated before and after the intervention. Improvement was compared to their performance prior to the intervention.
62053249|NCT04663451||Toxic Nodule|Hyperthyroid patients with underlying toxic nodule
62053250|NCT04663451||Toxic multinodular goiter|Hyperthyroid patients with underlying toxic multinodular goiter
62612506|NCT01493700|ACTIVE_COMPARATOR|electrically heated circuit|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
62612507|NCT04030325|EXPERIMENTAL|Sequential Post Feedback Information Delivery|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment.
62836575|NCT06522100|EXPERIMENTAL|Experimental group|Randomization in experimental group in addition to conventional HF therapy for 6 months.
62836576|NCT06522100|PLACEBO_COMPARATOR|Control group|Randomization in control group in addition to conventional HF therapy for 6 months.
62836577|NCT04846738||brain damaged patients|"All major brain damaged patients (stroke or head trauma) admitted to reanimation will be included.~In the usual practice, they have a Transcranial Doppler and the measurement of the photomotor reflex by quantitative Pupillometry.~It is planned to collect the simultaneous values of the different parameters during 2,000 measurements.~The data will be collected retrospectively from 01/12/2020, and prospectively from 01/04/2021."
62836578|NCT00225732|ACTIVE_COMPARATOR|intravenous ibuprofen|
62836579|NCT00225732|PLACEBO_COMPARATOR|normal saline|
62053251|NCT04930692|EXPERIMENTAL|Preoperative SLNs mapping provided by CT-lymphography method|Sentinel lymph nodes will be mapped by contrast-enhanced CT lymphography in breast cancer patients. A mixture of 4 mL iopamidol and 2 mL of 1% lidocaine hydrochloride will be used as a contrast agent provided by periaoreolar injection. No later than 10 days after the CT lymphography patients will receive surgical treatment with sentinel lymph node biopsy using the ICG-fluorescence method.
62053252|NCT05029258||Locally advanced cervical cancer patients treated with standard of care chemoradiation|
62053253|NCT05129943|ACTIVE_COMPARATOR|active distraction group|local anesthesia with video game using VR device
62053254|NCT05129943|ACTIVE_COMPARATOR|passive distraction group|local anesthesia with cartoon video using VR device
62053255|NCT05224258|EXPERIMENTAL|MiniMed 780G System Utilizing Insulin Fiasp|Subjects with insulin-requiring type 1 diabetes age 7-80 using the MiniMed 780G system with Insulin Fiasp® for a period of three months.
62254326|NCT03962738|EXPERIMENTAL|50 milligram (mg) Lasmiditan|50 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
62053256|NCT05493592|NO_INTERVENTION|Standardized physical activity protocol (EXA control group)|Physical activity protocol for 24 weeks. Protocol of dietetics and food hygiene for 24 weeks.
62254327|NCT03962738|EXPERIMENTAL|100 mg Lasmiditan|100 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
62254328|NCT03962738|EXPERIMENTAL|200 mg Lasmiditan|200 mg Lasmiditan (two 100 mg tablets) plus one placebo tablet (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
62254329|NCT03962738|PLACEBO_COMPARATOR|Placebo|Placebo tablets (to match 50 mg, 100 mg, 200 mg Lasmiditan dose tablets) administered once orally to treat a single migraine attack.
62254330|NCT01018628|ACTIVE_COMPARATOR|Cohort 1 - Dose Level A (25 mg/day)|Cohort 1 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 25 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 25 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
62836580|NCT00993967|EXPERIMENTAL|Idebenone|1350 mg/day or 2250 mg/day for patients weighing ≤45 kg or \>45 kg, respectively.In case of poor tolerability, dose reduction to 450 mg/day or 900 mg/day, respectively, were allowed.
62836581|NCT03874988|EXPERIMENTAL|Portion-Controlled Meals|Participants will receive prepackaged food, delivered biweekly to their home over the course of 13 weeks, with costs covered by the grant. Depending on their calorie goals, participants will drink and eat a mix of shakes and entrees each day, plus up to five fruits and vegetables. HMR entrees and shakes are formulated to provide recommended levels of macronutrients, vitamins, sodium, fat, cholesterol and fiber and fortified to meet at least 100% of the recommended daily allowance for essential vitamins and minerals.
62836582|NCT03874988|EXPERIMENTAL|Enhanced Self-Monitoring|Participants will be encouraged to self-monitor 4 specific behaviors daily: 1) measuring their food; 2) measuring their physical activity; 3) recording their food, drink, and physical activity; and 4) monitoring their weight. To achieve this aim, participants will attend a single group-based educational session at baseline during which they will be provided the self-monitoring equipment (scale and Garmin vivofit) and receive training about how to use the Lilypad scale and smartphone food tracking app.
62254331|NCT01018628|ACTIVE_COMPARATOR|Cohort 2 - Dose Level B (75 mg/day)|Cohort 2 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 75 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 75 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
62623603|NCT05644678|ACTIVE_COMPARATOR|Conventional treatment|Patients will be treated using the fixed appliances to track the impacted canines after opening the appropriate distance
62053257|NCT05493592|EXPERIMENTAL|Standardized physical activity protocol associated with the consumption of Cajanus cajan (EXACAJAN)|The EXACAJAN protocol will be continued for 24 weeks. It will combine 3 times a week with 100 grams of pigeon peas in the diet. Protocol of dietetics and food hygiene for 24 weeks.
62053258|NCT02355067|EXPERIMENTAL|Social Media Format|Social Media Intervention for women with postpartum depression (PPD) symptoms
62053259|NCT02355067|ACTIVE_COMPARATOR|In-Person Format|Traditional In-Person Intervention for Women with postpartum depression (PPD)
62053260|NCT03835325|EXPERIMENTAL|Cogmax®|Research participants will receive 2 capsules of Cogmax® per day (after lunch) for 12 weeks.
62053261|NCT00367965|EXPERIMENTAL|1|eszopiclone 3 mg
62053262|NCT00367965|PLACEBO_COMPARATOR|2|placebo tablet
62053263|NCT04547725|EXPERIMENTAL|CRS-IP (Arm-A)|Stage IV gastric cancer with limited peritoneal carcinomatosis (peritoneal carcinomatosis index \[PCI\] ≤ 10)
62053264|NCT04547725|EXPERIMENTAL|CRS-IP (Arm-B)|Stage IV gastric cancer with positive peritoneal wash cytology (CY1/P0)
62254332|NCT01018628|ACTIVE_COMPARATOR|Cohort 3 - Dose Level C (250 mg/day)|Cohort 3 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 250 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 250 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
62254333|NCT01018628|ACTIVE_COMPARATOR|Cohort 4 - Dose Level D (500 mg/day)|Cohort 4 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 500 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 500 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
62254334|NCT01018628|ACTIVE_COMPARATOR|Cohort 5 - Dose Level E (1000 mg/day)|Cohort 5 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 1000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 1000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
62254335|NCT01018628|ACTIVE_COMPARATOR|Cohort 6 - Dose Level F (2000 mg/day)|Cohort 6 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 2000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 2000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
62254336|NCT01018628|ACTIVE_COMPARATOR|Cohort 7 - Dose Level G (3000 mg/day)|Cohort 7 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 3000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 3000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
62443102|NCT06544187||Healthy volunteers|25 healthy volunteers. Their role will be to help us understand the consistency in Intra-Myocellular Liquid (IMCL) composition using Magnetic Resonance Spectroscopy (MRS) techniques. These volunteers will be sourced from the UHNM Trust staff, in accordance with Trust Standard Operating Procedure (SOP): The Safe Scanning of Volunteers in Magnetic Resonance Imagine (MRI). Each volunteer will undergo two MRS scans initially. All three MRS scans will be performed in a single session, with the session lasting about 20 minutes. Additionally, each volunteer will return for a single repeat session of MRS acquisition using the same MRI system and protocol, scheduled at two weeks after the initial scans
62623604|NCT05644678|EXPERIMENTAL|Surgically-assisted treatment|Patients will be treated using fixed appliances assisted by minimally-invasive corticotomy (alveolar perforations and piezocision) to accelerate impacted canines' traction after opening the appropriate distance.
62254337|NCT01018628|ACTIVE_COMPARATOR|Cohort 8 - Dose Level H (500 mg/day in fed state)|Cohort 8 will be administered at approximately the same time every dosing day and 30 minutes following the start of consumption of a standardized high-fat meal. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The dose of SRT2379 administered to subjects in the fed state is planned to be 500 mg, however this may be modified upwards or downwards following evaluation of safety and pharmacokinetic data from earlier cohorts. The fed cohort will be the final cohort dosed in the study.
62254338|NCT00471705|EXPERIMENTAL|Miltefosine|Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
62254339|NCT00471705|ACTIVE_COMPARATOR|Glucantime®|Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
62254340|NCT00471705|EXPERIMENTAL|Thermotherapy|One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
62254341|NCT05449990|NO_INTERVENTION|CONTROL GROUP: survey and Standard Care (SC)|150 (75 patients and 75 family members)
62254342|NCT05449990|EXPERIMENTAL|EXPERIMENTAL GROUP: participation in patient-and-family-centered interdisciplinary rounds (PFCC-IR)|150 (75 patients and 75 family members)
62053265|NCT03203655|EXPERIMENTAL|Intervention Group|The intervention group will be enrolled in the CareMessage™ Adult Obesity texting program, which sends a text message 3 to 5 times a week, encouraging lifestyle modifications (diet and exercise education, and behavioral strategies) that can lead to healthy weight loss.
62254343|NCT03082105|EXPERIMENTAL|Winter snow|First test series breathing in dry snow in winter
62836583|NCT03874988|EXPERIMENTAL|GLB-SCI|The content and delivery format of the developed GLB SCI lifestyle intervention program is subject to change based on guidance of the SCI Consumer Group. Therefore, this section provides a general description of the GLB AIM (lifestyle intervention program adapted for impaired mobility). The content of the GLB AIM core meetings include a mix of in-person (4) and telephone (9) sessions. The initial meeting is conducted in person, with one in-person sessions delivered each month, and the intervening weeks delivered by telephone. To achieve weight loss, participants will be encouraged to follow daily calorie and fat gram goals to achieve a .5 to 1 pound weight loss over the 13 weeks. Participants will also be encouraged to gradually increase their physical activity to ultimately achieve 150 weekly minutes.
62836584|NCT03874988|EXPERIMENTAL|GLB-SCI+|The final multicomponent GLB SCI+ will include combining specific intervention strategies identified from the previous 3 interventions as effective and usable. If all 3 strategies yield evidence in support of being included, the combined intervention would encompass (1) providing prepackaged foods for a specified period of time to facilitate greater initial weight loss, (2) encouraging enhanced self-monitoring of food, physical activity, and weight using devices and apps along with social support, and (3) delivering the further adapted GLB SCI in a group-based format to teach skills helpful in making lifestyle changes.
62836585|NCT03168776|EXPERIMENTAL|BuMA Supreme Coronary Stent System|
62053266|NCT03203655|OTHER|Control Group|The control group will receive the control condition. They will hear an initial talk about weight loss but will not be enrolled in any program or intervention.
62053267|NCT02330432|EXPERIMENTAL|Mycobacterium w group|Patients in the experimental arm (Mw) in addition to standard care will receive single daily dose of 0.3 mL of Mw (heat-inactivated Mw \[0.5 × 10\^9\]; Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
62254344|NCT03082105|EXPERIMENTAL|Intermediate snow|Second test series breathing in dry/wet snow in intermediate season
62443103|NCT00328874|PLACEBO_COMPARATOR|Placebo|
62612508|NCT04030325|EXPERIMENTAL|Sequential Post Feedback Information Delivery +Text Messages|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment. Additionally, participants receive the Text Message Booster Component in the days before and during the high risk drinking event celebration(s).
62836586|NCT03168776|ACTIVE_COMPARATOR|Xience or Promus Everolimus Stent System|
62836587|NCT04475302|EXPERIMENTAL|Intervention arm|In the identified hotspots, BCG vaccine will be offered to all the elderly between 60 - 80 years of age. Those who get vaccinated will be followed for a period of 6-months.
62053268|NCT02330432|ACTIVE_COMPARATOR|Best standard care|Best standard care for sepsis
62053269|NCT05129267|ACTIVE_COMPARATOR|Group B|Scaling and Root Debridement + iPRF
62053270|NCT05129267|ACTIVE_COMPARATOR|Group C|Scaling and Root Debridement + iPRF +Vitamin C
62443104|NCT00328874|ACTIVE_COMPARATOR|Coenzyme Q10|
62443105|NCT02742090|EXPERIMENTAL|Umbralisib|Participants received 800 milligrams (mg) of umbralisib, orally, once daily until disease progression, unacceptable toxicity or the end of the study for 60.7 months.
62053271|NCT05129267|NO_INTERVENTION|Group A|Scaling and Root Debridement
62053272|NCT00948974|ACTIVE_COMPARATOR|cognitive therapy|cognitive therapy and exposure
62053273|NCT00948974|ACTIVE_COMPARATOR|acceptance and committment therapy|acceptance and commitment therapy and exposure
62254345|NCT03082105|EXPERIMENTAL|Spring snow|Third test series breathing in very wet snow in spring
62443106|NCT04935827||Patients initiating dialysis for end-stage kidney disease|"Patients whose start of dialysis is from 12/1/2007-11/30/2017. We use the following inclusion criteria:~* Adult (\>= 18 years old)~* Did not die or have a transplant prior to the 90th day of dialysis~* Valid medical evidence form~* Medicare Part A/B as primary payer in the 30 days prior to initiating dialysis~* Initiating dialysis in the USA"
62443107|NCT01340352||study group: previous preterm labor|
62612509|NCT04030325|EXPERIMENTAL|Simultaneous Post Feedback Information Delivery|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content.
62623605|NCT02927678||Diabetic patients with osteomyelitis|Patients with a clinical and radiological diagnosis of osteomyelitis were included in two diabetic centers
62053274|NCT04978155||Echo group|All the patients (n=90) who had an AVF creation with preoperative venous identification by the surgeon at CHU de TOULOUSE (echo group).
62053275|NCT04978155||Control|All the patients (n=93) who had a native AVF placed during the year 2019 without having received immediate preoperative ultrasound and therefore there was no alteration in the surgical project in relation to that planned at the time of the consultation
62053276|NCT00421434|EXPERIMENTAL|Nitazoxanide-Peginterferon|One oral nitazoxanide 500 mg tablet with food twice daily for 12 weeks followed by 36 weeks of one oral nitazoxanide 500 mg tablet plus weekly injections of 180 µg peginterferon alfa-2a.
62053277|NCT00421434|EXPERIMENTAL|Nitazoxanide-Peginterferon-Ribavirin|One oral nitazoxanide 500 mg tablet with food twice daily for 12 weeks followed by 36 weeks of one oral nitazoxanide 500 mg tablet plus weekly injections of 180 µg peginterferon alfa-2a plus oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses.
62053278|NCT00421434|ACTIVE_COMPARATOR|Peginterferon-Ribavirin|Weekly injections of 180 µg peginterferon alfa-2a plus oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
62053279|NCT03794622||Bone marrow concentration group|Consecutive patients receive intramedullary nail fixation with bone marrow concentration.
62053280|NCT03794622||Historical control group|Previous age- and gender-matched patients who receive intramedullary nail fixation only.
62053281|NCT01058304|EXPERIMENTAL|Group Physical Therapy for Knee OA|Group Physical Therapy for Knee OA
62053282|NCT01058304|ACTIVE_COMPARATOR|Individual Physical Therapy for Knee OA|Individual Physical Therapy for Knee OA
62254346|NCT05561361||SAAE group|Subjects received super selective adrenal artery embolization treatment
62254347|NCT05561361||Spironolactone group|Subjects received spironolactone treatment
62053283|NCT00551252|EXPERIMENTAL|I|
62053284|NCT02227875|EXPERIMENTAL|Mylan's insulin Glargine|receive Mylan's insulin Glargine
62053285|NCT02227875|ACTIVE_COMPARATOR|Lantus®|receive Lantus®
62053286|NCT01972633|ACTIVE_COMPARATOR|1470nm Laser|Patient with varicose vein treated with 1470nm Laser (Biolitec)
62053287|NCT01972633|ACTIVE_COMPARATOR|VNUS Closure Fast|Patient with varicose vein treated with VNUS Closure Fast (Radiofrequency System)
62053288|NCT01807364||Congenital adrenal hyperplasia|Patients \> 18 yrs with classical or non classical CAH diagnosed during childhood
62053289|NCT01807364||controls|control patients
62053290|NCT02749357|ACTIVE_COMPARATOR|Control|"Intervention: Control group, with 30 training sessions in robotic orthosis with duration of 30 minutes during 6 weeks.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen.The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
62254348|NCT04688151|EXPERIMENTAL|Dose level 1,Dose level 2|Dose level 1 Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO once every day Durvalumab 1500mg infusion once every 4 weeks Dose level 2 Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO twice every day Durvalumab 1500mg infusion once every 4 weeks
62254349|NCT01180478|OTHER|Narrow Band Imaging|Narrow Band Imaging (NBI)
62254350|NCT01180478|OTHER|White Light Trans Urethral Resection|White Light Trans Urethral Resection
62053291|NCT02749357|EXPERIMENTAL|Experimental|"Intervention: Experimental group, with 30 training sessions in robotic orthosis with duration of 60 minutes during 6 weeks.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen.The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
62053292|NCT02003352|EXPERIMENTAL|Functional Neurological Rehabilitation|Functional Neurological and physical/vestibular rehabilitation strategies
62053293|NCT00261495|ACTIVE_COMPARATOR|Oxycodone|
62254351|NCT03537144|ACTIVE_COMPARATOR|Indomethacin|Indomethacin as drug to treat PDA.
62254352|NCT03537144|EXPERIMENTAL|Acetaminophen|Acetaminophen as drug to treat PDA.
62254353|NCT02726087|EXPERIMENTAL|ministernotomy|"Minimally invasive aortic valve replacement with Partial J upper hemisternotomy through right 4th intercostal space, performed according to current standard of care practice."
62254354|NCT02726087|ACTIVE_COMPARATOR|full sternotomy|Full sternotomy AVR through a standard median sternotomy, performed according to current standard of care practice.
62254355|NCT01687075|EXPERIMENTAL|CR8|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
62254356|NCT04425720|ACTIVE_COMPARATOR|Standard Of Care|Patients without wearable monitoring technology undergoing routine standard of care at the hospital.
62443108|NCT01340352||control group:previous term delivery|
62443109|NCT04066881|EXPERIMENTAL|Group A|"278 participants will receive DNA-HIV-PT123 vaccine and AIDSVAX® B/E protein at weeks 0, 4, 24 and 48.~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm~1ml of AIDSVAX® B/E will be injected into the deltoid muscle of the right arm~1 tab of Truvada (0-26 weeks)"
62053294|NCT00261495|EXPERIMENTAL|OROS hydromorphone HCl|
62053295|NCT00808574|EXPERIMENTAL|Intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
62053296|NCT00808574|NO_INTERVENTION|Control|No risk assessment or presentation
62053297|NCT06434948|EXPERIMENTAL|Omega-3 Ethyl Esters 4 g|Patients will be given 4 grams of omega-3 ethyl esters orally before surgery and for 3 days postoperatively.
62053298|NCT06434948|EXPERIMENTAL|Omega-3 Ethyl Esters 2 g|Patients will be given 2 grams of omega-3 ethyl esters orally before surgery and for 3 days postoperatively.
62053299|NCT06434948|NO_INTERVENTION|Standard of Care|Patients will not receive any study drug.
62053300|NCT00325364|EXPERIMENTAL|1|
62053301|NCT00325364|ACTIVE_COMPARATOR|2|
62053302|NCT00404495|EXPERIMENTAL|Temozolomide + Irinotecan|
62053303|NCT03045848||Biofreedom drug-coated stent|Subject implanted Biofreedom DCS for coronary artery disease
62053304|NCT03279835||Absence of cognitive disorder|
62053305|NCT03279835||Asymptomatic cognitive disorder|
62053306|NCT03279835||Symptomatic cognitive impairment|
62053307|NCT03279835||HIV associated dementia|
62254357|NCT04425720|EXPERIMENTAL|Monitored|Patients who are diagnosed with COVID-19 and are undergoing self-quarantine will be closely monitored using a wearable device, and shared-clinical decisions will be made based on the monitored data and patient diary
62053308|NCT02094443|EXPERIMENTAL|Alisporivir 300 mg BID|Alisporivir (ALV) 300 mg twice daily (BID) with ribavirin for 12 or 24 weeks based on Week 2 response, with a safety follow-up of at least 4 weeks, during which patients did not receive any study medication
62053309|NCT02094443|EXPERIMENTAL|Alisporivir 400 mg BID|ALV 400 mg twice daily (BID) with ribavirin for 12 or 24 weeks based on Week 2 response, with a safety follow-up of at least 4 weeks, during which patients did not receive any study medication
62053310|NCT03684486|EXPERIMENTAL|rehabilitation by effort|8 sessions of rehabilitation by effort in sports medicine
62254358|NCT01129362||Group 1|Participants that only received Pentacel® vaccine.
62254359|NCT01129362||Group 2|Participants that only received a single brand of pertussis vaccine other than Pentacel® vaccine.
62254360|NCT01129362||Group 3|Participants that received more than one brand of Pertussis vaccine or one or more doses of an unknown brand.
62254361|NCT00587002|ACTIVE_COMPARATOR|1|Gender comparison
62254362|NCT00912847||JHC|AFP \> 20 ng/ml and USG positive
62254363|NCT00912847||Non JHC|patient without AFP \> 20 or USG negative
62254364|NCT00860184||50-79% stenosis|Subjects with 50-79% stenosis of the carotid artery Absence of prior ischemic neurological symptoms Age 18 or older
62443110|NCT04066881|EXPERIMENTAL|Group B|"278 participants will receive DNA-HIV-PT123 and CN54gp140+MPLA-L at weeks 0 and 4, then MVA and CN54gp140+MPLA-L at weeks 24 and 48~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm~1ml (1x108 pfu) of MVA will be injected into the deltoid muscle of the left upper arm~0.4mL containing a mixture of 100mcg CN54gp140 and 5mcg MPLA-L will be injected into the deltoid muscle of the right upper arm~1 tab of Truvada (0-26 weeks)"
62053311|NCT00003092|EXPERIMENTAL|Paclitaxel|"Patients receive a single dose of IV paclitaxel over 3 hours. Additional cycles of paclitaxel will be given at the discretion of the physician.~Patients are followed for second malignancies, disease progression, and survival."
62053312|NCT02571270|ACTIVE_COMPARATOR|Active lifestyle|Active lifestyle involves nutritional education, physical activity and active recreation.
62053313|NCT02571270|ACTIVE_COMPARATOR|Lifestyle counseling|Lifestyle counseling helps patients to have better self-care.
62053314|NCT02571270|ACTIVE_COMPARATOR|secondary prevention|Secondary prevention it is essential to prevent a new unfavorable event.
62053315|NCT02571270|ACTIVE_COMPARATOR|survival|The survival of patients with heart failure may increase with exercise training.
62053316|NCT00676182||Arm 1: Telerehabilitation|telerehabilitation
62053317|NCT06144424|EXPERIMENTAL|EP262 150 mg|
62053318|NCT06144424|PLACEBO_COMPARATOR|Placebo|
62053319|NCT02961530|EXPERIMENTAL|Group 1.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isokinetic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
62053320|NCT02961530|ACTIVE_COMPARATOR|Group 2.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isotonic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
62053321|NCT04193839||Paper Order Entry cohort|Patients admitted to the NICU during the pre-intervention phase, enrolled in the study after parental consent. The medications prescribed to the patients enrolled during the pre-intervention period will be handled with the paper order entry
62053322|NCT04193839||CPOE + BCMA cohort|Patients admitted to the NICU during the post-intervention phase, enrolled in the study after parental consent. The medications prescribed to the patients enrolled during the post-intervention period will be handled with the Computerized Provider Order Entry + Bar Code Medication Administration (BCMA)
62053323|NCT05584891||group 1|radical mastoidectomy
62053324|NCT05584891||group2|mastoid obliteration operation.
62053325|NCT04997707|ACTIVE_COMPARATOR|P group|75-100 µg/kg/min propofol
62053326|NCT04997707|ACTIVE_COMPARATOR|BA group|25ug/kg/min propofol and 0.2% below corrected-to-age- half MAC of sevoflurane
62053327|NCT04882774|NO_INTERVENTION|Fluid Management|Fluid management protocol only
62053328|NCT04882774|EXPERIMENTAL|Oral Treprostinil|Drug - oral treprostinil
62053329|NCT04418635|EXPERIMENTAL|Tamsulosin and Prosta-OK® Neo|Tamsulosin 0.2mg once daily and Prosta-OK® Neo 707mg 2 tablets twice daily for 85 days
62254365|NCT02751762||Prospective Longitudinal Cohort|Patients who have recently initiated long-term opioid therapy or initiated ER/LA opioid therapy
62254366|NCT02751762||Cross-sectional Cohort|Patients who have been treated with opioids (including at least one ER/LA opioid) for greater than one year
62254367|NCT02984579||All Subjects|"All strains in Phase 1 and all Sputum samples in Phase 2 were tested with Hain Genotype MTBDRplus V1, Hain Genotype MTBDRplus V2, and YD REBA MTB-MDR diagnostic tests.~Investigators and Operators were blinded to all other results for a sample upon data entry."
62254368|NCT03885791|EXPERIMENTAL|Vaginal cryotherapy - intervention|"The intervention group will be provided with one vaginal cryotherapy tube, filled with a mixture of isopropyl alcohol (2ml) and water (8ml) that has been kept in the freezer. This mixture results in a slushy consistency and prevents the solution from freezing solid thus decreases the risk of discomfort or injury due to the temperature of the tube. Patients will insert this tube into the vagina to a comfortable depth. A lubricant will be provided for comfort with tube insertion, if necessary. At the conclusion of the treatment, this tube will be washed thoroughly and given to the patient in a clean plastic baggie for use at home. They will be instructed to store these tubes in their home freezer."
62254369|NCT03885791|PLACEBO_COMPARATOR|Vaginal cryotherapy - control|The control group will be provided with an identical tube that is empty. An empty tube was chosen as the control because a tube with room-temperature liquid may still be perceived as cold. Patients will insert this tube into the vagina to a comfortable depth. A lubricant will be provided for comfort with tube insertion, if necessary. At the conclusion of the treatment, this tube will be washed thoroughly and given to the patient in a clean plastic baggie for use at home. They will be instructed to store these tubes in their home at room temperature.
62254370|NCT02852603||thoracic aortic aneurysm and dissection|Patients with thoracic aortic aneurysm and/or dissection are recruited in the study.
62254371|NCT05492695|ACTIVE_COMPARATOR|Galcanezumab + BMPT|"* 240 mg of galcanezumab will be administered once as a loading dose at Visit 2, followed by monthly doses of 120 mg at Visits 3 and 4.~* All participants will be required to continue BMPT. For consistency purposes visit 2/ randomization should be scheduled within +/- 3 days of subjects next Botox administration as part of BMPT."
62053330|NCT04418635|PLACEBO_COMPARATOR|Tamsulosin and Prosta-OK® Neo-matched placebo|Tamsulosin 0.2mg once daily and Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days
62254372|NCT05492695|PLACEBO_COMPARATOR|Placebo + BMPT|• Galcanezumab matching placebo will be administered at Visits 2, 3 and 4.
62254373|NCT02073175|EXPERIMENTAL|Postpartum with crying spells-Full dose|"Healthy women who are within the first 18 months postpartum and have crying spells but do not have major depression. The effect of the dietary supplement in reducing sadness in this group will be assessed.~Intervention: Full dose dietary supplement Motherwell"
62254374|NCT02073175|EXPERIMENTAL|Day-5 postpartum - Full dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.~Intervention: Full dose dietary supplement Motherwell"
62254375|NCT02073175|EXPERIMENTAL|Day-5 postpartum - Half dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the proposed dietary supplement consumption, is being done after delivery and during postpartum.~Intervention: Half dose dietary supplement Motherwell"
62254376|NCT02073175|EXPERIMENTAL|Day-5 postpartum - Quarter dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the proposed dietary supplement consumption, is being done after delivery and during postpartum.~Intervention: Quarter dose dietary supplement Motherwell"
62254377|NCT02073175|OTHER|Day-5 postpartum - Control|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving a control supplement consumption, is being done after delivery and during postpartum.~Intervention: Control protein to compare with Motherwell"
62254378|NCT05378997|EXPERIMENTAL|Dose group 1|0.15 mL of TCP-25 gel (0.86 mg/mL) or 0.15 mL placebo gel per wound applied as topical treatment on days 1, 2, 3, 5, and 8
62443111|NCT04066881|PLACEBO_COMPARATOR|Group C:|"278 participants will receive Sodium Chloride 0.9% (Normal Saline) placebo at weeks 0,4,24, and 48~The volume will be matched to the vaccine at 1ml for DNA, MVA and AIDSVAX® B/E, but 0.4ml for CN54gp140 in MPLA-L. Participants will be randomly divided in a 1:1 ratio to receive 1ml in each arm at the four timepoints or 1ml in the left arm and 0.4ml in the right arm at the four timepoints.~1 tab of Truvada (0-26 weeks)"
62443112|NCT04066881|ACTIVE_COMPARATOR|Group D|"278 participants will receive DNA-HIV-PT123 vaccine and AIDSVAX® B/E protein at weeks 0, 4, 24 and 48.~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm~1ml of AIDSVAX® B/E will be injected into the deltoid muscle of the right arm~1 tab of Descovy (0-26 weeks)"
62443113|NCT04066881|EXPERIMENTAL|Group E|"278 participants will receive DNA-HIV-PT123 and CN54gp140+MPLA-L at weeks 0 and 4, then MVA and CN54gp140+MPLA-L at weeks 24 and 48~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm~1ml (1x108 pfu) of MVA will be injected into the deltoid muscle of the left upper arm~0.4mL containing a mixture of 100mcg CN54gp140 and 5mcg MPLA-L will be injected into the deltoid muscle of the right upper arm~1 tab of Descovy (0-26 weeks)"
62623606|NCT00003522|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62053331|NCT01518855|EXPERIMENTAL|Arm 1|Adalat CR 20-40mg od + Diovan 40-80mg od
62053332|NCT01518855|ACTIVE_COMPARATOR|Arm 2|Norvasc 2.5-5mg od + Diovan 40-80mg od
62053333|NCT03831321|ACTIVE_COMPARATOR|Diclofenac group|The group who are 50 mg Diclofenac Sodium and lubricant gel administered one hour before cystoscopy and local
62254379|NCT05378997|EXPERIMENTAL|Dose group 2|0.15 mL of TCP-25 gel (2.9 mg/mL) or 0.15 mL placebo gel per wound applied as topical treatment on days 1, 2, 3, 5, and 8
62254380|NCT05378997|EXPERIMENTAL|Dose group 3|0.15 mL of TCP-25 gel (8.6 mg/mL) or 0.15 mL placebo gel per wound applied as topical treatment on days 1, 2, 3, 5, and 8
62254381|NCT01976520|EXPERIMENTAL|Oncoquest-CLL vaccine treatment|Patients receive Oncoquest-CLL vaccine subcutaneously on Day 1 and 15, and then monthly for 3 months in the absence of disease progression or unacceptable toxicity.
62254382|NCT01686776|ACTIVE_COMPARATOR|123 I-HSA + 125 I-HSA|Healthy Volunteers, N=16
62254383|NCT01686776|EXPERIMENTAL|123 I- HSA + 125 I-HSA|Patients, planned for elective Major Abdominal Surgery, N=16
62254384|NCT01686776|EXPERIMENTAL|123-I-HSA+125 I-HSA|Patients, with a acute pancreatitis or cholecystitis, N=16
62053334|NCT03831321|PLACEBO_COMPARATOR|Placebo|The group who are not administered 50 mg Diclofenac Sodium before cystoscopy and administered lubricant gel just before local cystoscopy
62053335|NCT00435279|EXPERIMENTAL|Eszopiclone|
62053336|NCT00435279|EXPERIMENTAL|Placebo|
62053337|NCT03358056|EXPERIMENTAL|Mindfulness-based Cognitive Therapy|
62254385|NCT01529177|EXPERIMENTAL|Metformin / clomid / hCG|"Metformin 1000 mg orally to be given daily for one week then twice daily for 2 weeks then 3 times daily for 6 months.~After 3 months from starting metformin the participant will receive 2 more medications in addition to metformin:~Clomid 50 mg orally per day and 5000 IU human chorionic gonadotrophin (hCG ) IM once per week for three months."
62254386|NCT01529177|EXPERIMENTAL|Clomid / hCG|Clomid 50 mg per day will be administered orally and human chorionic gonadotrophin ( choriomon ) 5000 IU will be administered IM once per week. Both medications will be given for 6 month.
62254387|NCT04002037|ACTIVE_COMPARATOR|Triamcinolone 40mg/mL|A corticosteroid injection of Triamcinolone 40mg/mL will be given to subjects to treat their symptoms of trigger finger.
62254388|NCT04002037|ACTIVE_COMPARATOR|Triamcinolone 10mg/mL|A corticosteroid injection of Triamcinolone 10mg/mL will be given to subjects to treat their symptoms of trigger finger.
62254389|NCT04002037|ACTIVE_COMPARATOR|Soluble dexamethasone 4mg/mL|A corticosteroid injection of Soluble Dexamethasone 4mg/mL will be given to subjects to treat their symptoms of trigger finger.
62254390|NCT05571228|EXPERIMENTAL|Internalized stigma group|BOOST is an 8 session group intervention, delivered over 4 weeks. The program uses evidence based therapeutic techniques and integrates cognitive behavioural therapy and peer support to reduce or prevent the internalization of stigma in early psychosis. Sessions 1-4 focus on dispelling stigmatizing myths about psychosis and evaluating the accuracy of group members or societies stigmatizing beliefs in order to normalize experiences associated with and reactions to the symptoms of psychosis. Sessions 5-8 teach behavioural approaches for self-empowerment through social skills training, development of assertiveness skills, and goal setting. Role-plays that are specific to young people with psychosis, which were co-developed with people with lived experience, provide opportunities to practice these skills in session. During role plays, participants monitor stigmatizing beliefs that may interfere with communication or pursuing goals.
62254391|NCT00917527|PLACEBO_COMPARATOR|Control|
62254392|NCT00917527|EXPERIMENTAL|Atorvastatin|
62254393|NCT02746133||Chronic kidney disease (pre-dialysis)|Observational study: Supplemented protein-restricted diet
62836588|NCT04475302|NO_INTERVENTION|Control arm|"1. in the hotspots, those who do not agree for vaccination, will be considered as controls. They will have an entry and exit interview at baseline and end of study period~2. in situations where we are unable to enrol the required number of controls from the vaccination hotspot zones, then hotspots in the neighbouring area / wards where BCG is not offered will be taken as control sites. Elderly between 60-80 years in those areas would be considered as control sites for the study. The elderly participants will be approached for an entry and exit interview, if they agree. If they do not agree for an exit interview at the end of 6-months, then the status of those in the control group would be collected either from the corporation records / other medical database."
62836589|NCT04485390||First responder group|Cardiac arrest victims in remote areas resuscitated by the first responders before the arrival of the EMS.
62836590|NCT04485390||EMS groups|Cardiac arrest victims in remote areas resuscitated by the EMS.
62443114|NCT04066881|PLACEBO_COMPARATOR|Group G|"278 participants will receive Sodium Chloride 0.9% (Normal Saline) placebo at weeks 0,4,24, and 48~The volume will be matched to the vaccine at 1ml for DNA, MVA and AIDSVAX® B/E, but 0.4ml for CN54gp140 in MPLA-L. Participants will be randomly divided in a 1:1 ratio to receive 1ml in each arm at the four timepoints or 1ml in the left arm and 0.4ml in the right arm at the four timepoints.~1 tab of Descovy (0-26 weeks)"
62443115|NCT06301555|NO_INTERVENTION|Blank Control|No intervention
62443116|NCT06301555|EXPERIMENTAL|RL Algorithm Intervention|
62443117|NCT06301555|ACTIVE_COMPARATOR|No Algorithm Active Control|
62053338|NCT03403322|OTHER|First test|All measures were evaluated
62443118|NCT01761526|EXPERIMENTAL|Rotigotine in Healthy Japanese|"* Rotigotine transdermal patch~* Single dose application of 2 mg / 24 hours Rotigotine in Healthy Japanese subjects~* Transdermal patch over 24 hours"
62443119|NCT01761526|EXPERIMENTAL|Rotigotine in Caucasian|"* Rotigotine transdermal patch~* Single-Dose application of 2 mg / 24 hours Rotigotine in healthy Caucasian subjects~* Transdermal patch over 24 hours"
62443120|NCT04633837|NO_INTERVENTION|Group 1 Control|Group 1 will undergo standard arthroscopic shoulder surgery without the ECM injection.
62053339|NCT03403322|OTHER|Second test|All measures were evaluated
62053340|NCT02605564|ACTIVE_COMPARATOR|study Group A|Gluten free diet
62053341|NCT02605564|PLACEBO_COMPARATOR|Study Group B|No intervention
62836591|NCT05862649|EXPERIMENTAL|PD patients|Men and women with idiopathic PD (Hoehn \& Yahr scale 1-2) aged 40-85 years
62836592|NCT02689037|EXPERIMENTAL|stenting+medical treatment|Patients in PTAS+MT group will receive Percutaneous transluminal angioplasty and stenting and medical treatment (aspirin 100mg daily and clopidogrel 75mg daily)
62836593|NCT02689037|ACTIVE_COMPARATOR|Aspirin plus clopidogrel|Patients in aspirin plus clopidogrel group will receive aspirin 100mg daily and clopidogrel 75mg daily for 90 days.
62836594|NCT02109497|OTHER|Caffeine Dosing|Single dose of caffeine 100 mg administered
62836595|NCT00557713|EXPERIMENTAL|A|"1. -Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)~2. -Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))~3. -Surgery (6-8 weeks after last bevacizumab dose)~4. -Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)"
62836596|NCT04972903||Group 1.HIV+/SAM+|Group 1. HIV-infected with SAM (WHZ\<-3SD or edematous malnutrition or MUAC \<115) (HIV+/SAM+)
62836597|NCT04972903||Group 2. HIV+/SAM-|Group 2. HIV-infected without SAM (none of the 3 criteria above) (HIV+/SAM-)
62836598|NCT04972903||Group 3. HIV-/SAM+|Group 3. HIV-negative with SAM (WHZ\<-3SD or edematous malnutrition or MUAC \<115) (HIV-/SAM+)
62053342|NCT02481284||Laser Doppler Perfusion Imaging|20 consequetive cases undergoing breast reconstruction with Deep inferior epigastric artery perforator flap who had evaluation of the microcirculation of the abdominal skin with laser Doppler perfusion imaging
62254394|NCT02032550|EXPERIMENTAL|Preference Based Decision Aid|The experimental arm of preference based decision aid intervention will complete a web-based conjoint analysis instrument for preference assessment.
62254395|NCT02032550|NO_INTERVENTION|Usual Care|Participants randomized into this group will have usual care from their doctors without any intervention
62254396|NCT05522179|EXPERIMENTAL|NutraHeal|NutraHeal™ is a nutritional supplement that contains 7.5 micrograms (300 IU) of Vitamin D3, 80 mg of Calcium as Calcium Hydroxymethylbutyrate Monohydrate, 7.5 mg of Zinc, 600 mg of Calcium Hydroxymethylbutyrate Monohydrate, and 45 mg of Bromelain.
62254397|NCT05522179|EXPERIMENTAL|NutraHeal Plus|NutraHeal Plus™ is a nutritional supplement that contains 80 mg of Calcium as Calcium Hydroxymethylbutyrate Monohydrate, 7.5 mg of Zinc, 600 mg of Calcium Hydroxymethylbutyrate Monohydrate, 45 mg of Bromelain, and 7.5 mg of reduced Nicotinamide Adenine Dinucleotide (NADH).
62443121|NCT04633837|ACTIVE_COMPARATOR|Group 2: ECM Injectable graft|Group 2 will undergo arthroscopic shoulder surgery and receive 2cc of the injectable extracellular matrix injection placed into the glenohumeral joint space via a transtendon approach at the end of the surgery
62623607|NCT04536675|EXPERIMENTAL|VI/UME|Anoro (Vilanterol 25mcg/Umeclinidium 62.5mcg) in Ellipta device Inhaled through mouth once daily
62836599|NCT04972903||Group 4. HIV-/SAM-|Group 4. HIV-negative without SAM (none of the 3 criteria above) (HIV-/SAM-)
62836600|NCT04446104|EXPERIMENTAL|Hydroxychloroquine|Participants will receive hydroxychloroquine tablet 400mg loading dose, followed by 200mg daily for 42 days
62836601|NCT04446104|EXPERIMENTAL|Ivermectin|Participants will receive ivermectin tablet 12mg single dose
62836602|NCT04446104|EXPERIMENTAL|Zinc/ Vitamin C|Participants will receive zinc tablet 80 mg/vitamin C 500mg daily for 42 days
62053343|NCT03362359|EXPERIMENTAL|Ga-68-PSMA-11|
62836603|NCT04446104|EXPERIMENTAL|Povidone-iodine throat spray|Participants will receive povidone-iodine throat spray (3 times daily) for 42 days
62836604|NCT04446104|ACTIVE_COMPARATOR|Vitamin C|Participants will receive vitamin C tablet 500mg daily for 42 days
62053344|NCT04896632|EXPERIMENTAL|INE963|Part A is a single ascending dose (SAD) study with 7 planned cohorts Part B is a multiple dose (MD) study with 2 planned cohort q24h x 3 day of either INE963 or placebo
62053345|NCT04896632|PLACEBO_COMPARATOR|Placebo group|Part A is a single ascending dose (SAD) study with 7 planned cohorts Part B is a multiple dose (MD) study with 2 planned cohort q24h x 3 day of either INE963 or placebo
62053346|NCT04031482||Ongoing or incipient targeted therapies|Ongoing or incipient targeted therapies with biologics and/or other targeted therapies (e.g. Janus kinase inhibitors)
62053347|NCT01875185|EXPERIMENTAL|Aspirin|The patients are given aspirin 81 mg orally for 7 days.
62254398|NCT05522179|NO_INTERVENTION|Standard of Care|Receive standard of care for 1 week prior to surgery and 3 weeks after foot surgery.
62254399|NCT03177616|NO_INTERVENTION|Usual Care|Subjects randomized to the usual care control group will continue using their usual medical care as prescribed by their physician. They are not to use any chiropractic treatment or begin new therapies.
62254400|NCT03177616|EXPERIMENTAL|Chiropractic Treatment + Usual Care|Patients will receive a course of 10 chiropractic treatments over a 14 week period. They are to also maintain their usual medical care as prescribed by their physician, but are not to begin any new therapies.
62254401|NCT02917681|EXPERIMENTAL|MSC injection|Patients will be followed for 3 months before bone marrow aspiration (BMA). Patients will receive 2 intrathecal MSC injections, 1 and 2 months after BMA. The patients will be followed for 6 months after the interventions.
62443122|NCT02244437|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen has been shown to prevent AMS from previous studies.
62254402|NCT05301868|EXPERIMENTAL|Multidomain intervention|The participants in the intervention arm will receive all five components of the intervention: (1) monitoring and management of metabolic and vascular risk factors; (2) cognitive training; (3) physical exercise; (4) nutritional guidance; and (5) motivational training via none-face-to-face tablet PC application (app).
62053348|NCT02551523|EXPERIMENTAL|Dolutegravir monotherapy|92 patients will be simplified to once daily dolutegravir monotherapy.
62254403|NCT05604820|EXPERIMENTAL|experimental|Progressive Muscle Relaxation Exercise
62612510|NCT04030325|EXPERIMENTAL|Simultaneous Post Feedback Information Delivery +Text Messages|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content. Additionally, participants receive the Text Message Booster Component in the days before and during the high risk drinking event celebration(s).
62612511|NCT04030325|NO_INTERVENTION|Assessment Only Control|Participants complete baseline survey, longitudinal follow up assessments, and pre- and post- event surveys.
62612512|NCT02525536|EXPERIMENTAL|Trebananib 3 mg/kg|Trebananib (AMG 386) 3 milligram/kilogram (mg/kg), 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
62623608|NCT04536675|PLACEBO_COMPARATOR|Control|Placebo (including lactose monohydrate) in Ellipta device Inhaled through mouth once daily
62836605|NCT03943654||Children living within study delivery area w/o danger signs|Families who call the healthline service about a sick child (no danger signs) and live within the mobile pharmacy delivery area will receive illness assessments and treatment recommendations over the phone. Immediately following calls a nurse will conduct household visits to complete in-person assessments of the children. Illness progression will be tracked with a 8-12 day follow up call. The phone and in-person assessments will be compared to evaluate safety and accuracy of the healthline.
62836606|NCT03943654||Children living outside study delivery area w/o danger signs|Families who call the healthline service about a sick child (no danger signs) and live outside the delivery area will receive illness assessments and treatment recommendations over the phone. Illness progression will be tracked with a 8-12 day follow up call.
62254404|NCT05604820|NO_INTERVENTION|no ıntervention|
62254405|NCT00771134|EXPERIMENTAL|Lu AA39959|
62836607|NCT03943654||Children who are identified as having danger signs|Families who call the healthline service about a sick child and who are identified as having a danger sign will be directed to the nearest medical facility. Illness progression will be tracked with a 8-12 day follow up call.
62836608|NCT01541696||Group B|subjects in this group will receive Micronutrient Supplements only.
62836609|NCT01541696||Group C|Subjects in this Group will receive Micronutrient Supplements plus Zinc.
62836610|NCT02754440|EXPERIMENTAL|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
62053349|NCT02551523|ACTIVE_COMPARATOR|Standard of care combination antiretroviral therapy|46 patients will go on with standard of care combination antiretroviral therapy consisting of either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor or a integrase inhibitor in combination with two nucleoside reverse transcriptase inhibitors.
62053350|NCT01713725|ACTIVE_COMPARATOR|Omalizumab 300 mg|"* Subcutaneous route~* 300 mg dose (independent from total IgE, weight or high)"
62053351|NCT01713725|PLACEBO_COMPARATOR|Placebo|"* Saline serum~* Subcutaneous route~* 0.6 ml saline serum with same volume as an active treatment"
62254406|NCT00771134|PLACEBO_COMPARATOR|Placebo|
62254407|NCT00771134|ACTIVE_COMPARATOR|Quetiapine|
62254408|NCT02403362|EXPERIMENTAL|EPO-018B 0.025 mg/kg|EPO-018B starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
62254409|NCT02403362|EXPERIMENTAL|EPO-018B 0.05 mg/kg|EPO-018B starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
62254410|NCT02403362|EXPERIMENTAL|EPO-018B 0.08 mg/kg|EPO-018B starting dose of 0.08 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
62254411|NCT04168073|EXPERIMENTAL|High sodium diet|
62254412|NCT04168073|EXPERIMENTAL|Low sodium diet|
62254413|NCT01015651|ACTIVE_COMPARATOR|remifentanil-2|In this group, patients are receiving a continuous i.v. infusion of remifentanil according to a target effect site concentration of 2 ng/ml.
62254414|NCT01015651|ACTIVE_COMPARATOR|remifentanil-4|In this group, patients are receiving a continuous i.v. infusion of remifentanil according to a target effect site concentration of 4 ng/ml.
62254415|NCT01868256|EXPERIMENTAL|Early discharge (< 72 h)|Patients randomized the early discharge group will be discharged from the hospital in \< 72 hours
62254416|NCT01868256|ACTIVE_COMPARATOR|Conventional discharge|Patients randomized to the conventional discharge group will be discharged according to the local hospital protocol and/or treating physician criterion
62254417|NCT02383095|EXPERIMENTAL|Art-therapy|16 Art-therapy sessions
62254418|NCT02383095|ACTIVE_COMPARATOR|Metacognitive therapy|16 Metacognitive therapy sessions
62254419|NCT04223895|EXPERIMENTAL|Group 1|Period 1: D012, D326, D337(3 tabs, once) / Period 2: CKD-386 F1(1 tab, once)/ Period 3: CKD-386 F2(1 tab, once)
62254420|NCT04223895|EXPERIMENTAL|Group 2|Period 1: D012, D326, D337(3 tabs, once) / Period 2: CKD-386 F2(1 tab, once)/ Period 3: CKD-386 F1(1 tab, once)
62254421|NCT04223895|EXPERIMENTAL|Group 3|Period 1: CKD-386 F1(1 tab, once) / Period 2: D012, D326, D337(3 tabs, once) Period 3: CKD-386 F2(1 tab, once)
62254422|NCT04223895|EXPERIMENTAL|Group 4|Period 1: CKD-386 F1(1 tab, once) / Period 2: CKD-386 F2(1 tab, once) / Period 3: D012, D326, D337(3 tabs, once)
62254423|NCT04223895|EXPERIMENTAL|Group 5|Period 1: CKD-386 F2(1 tab, once) / Period 2: D012, D326, D337(3 tabs, once)/ Period 3: CKD-386 F1(1 tab, once)
62254424|NCT04223895|EXPERIMENTAL|Group 6|Period 1: CKD-386 F2(1 tab, once) / Period 2: CKD-386 F1(1 tab, once) / Period 3: D012, D326, D337(3 tabs, once)
62254425|NCT01944683|EXPERIMENTAL|GGF2|"Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.~Each patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively."
62836611|NCT02754440|EXPERIMENTAL|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
62053352|NCT01330602|EXPERIMENTAL|Lifestyle counseling|"All participants randomised into the IMPRESS Intervention group will undergo tailored health profiling.This individual assessment will be carried out within the clinic setting.~The key elements of the IMPRESS intervention include:~* Promoting a healthy lifestyle~* Supporting lifestyle and risk modification~* Encouraging active self-management of risk and chronic disease~* Improving coordination of care~* Pharmacological therapy All the individuals in the intervention group will receive a comprehensive report on their risk status and ideal goals."
62836612|NCT02754440|EXPERIMENTAL|Triple Platelet Product|Healthy adult volunteer blood donors that qualify for a triple unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
62836613|NCT06127849|PLACEBO_COMPARATOR|Resistance Training + Placebo (Capsule) + Placebo (Sachet)|"A sachet of 20 gms of Placebo dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~One capsule of placebo to be taken 30 minutes after placebo sachet in the morning."
62836614|NCT06127849|ACTIVE_COMPARATOR|Resistance Training + Whey protein (40 gms) + Placebo (Capsule)|"A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~One capsule of Placebo to be taken 30 minutes after whey protein in the morning."
62053353|NCT01330602|NO_INTERVENTION|Usual care arm|"Usual Care Following the assessment of absolute cardiovascular risk, usual care participants will be provided a report outlining areas in which improvements could be made for the prevention of atherosclerotic burden.~No restrictions will be made in respect to usual care management. As such, the prescription of standard medications for primary prevention of atherosclerotic burden based on individual risk factors is anticipated in 20-30% of usual care participants.~At 18 months and three years those in the usual care arm will be invited to undergo repeat CIMT measurements, pathology, absolute risk score calculation and health-related questionnaires as part of the structured study follow-up"
62053354|NCT04550325|EXPERIMENTAL|Immune gamma globulin (IgG)|Single dose of 4g Immune gamma globulin (IgG) preparation Kamada Anti-SARS-CoV-2 given as an intravenous infusion
62053355|NCT01488916||Vitamin D deficiency|patients with serum vitamin D levels of the lower tertile
62053356|NCT01488916||Vitamin D inadequacy|patients with serum vitamin D levels of the middle tertile
62053357|NCT01488916||Reference group|patients with serum vitamin D levels of the upper tertile
62053358|NCT00571961|EXPERIMENTAL|1|HIV negative subjects currently enrolled in a long-term buprenorphine maintenance therapy program for at least 3 months who have been on stable dose of buprenorphine for at least 3 weeks will be admitted to the General Clinical Research Center (GCRC) for pharmacokinetic (PK) blood draws at intervals over a 24-hour period. Subjects will then receive Kaletra and buprenorphine coadministered for 14 days. Subjects will be admitted to the GCRC for a second PK sampling day.
62053359|NCT00628797|OTHER|A UVA1 B no UVA1|half body irradiation with random allocation right and left; after three months of treatment treatment of both sides
62053360|NCT00628797|EXPERIMENTAL|A UVA1|
62254426|NCT01944683|PLACEBO_COMPARATOR|Placebo|"Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.~Each patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively."
62612513|NCT02525536|EXPERIMENTAL|Trebananib 10 mg/kg|Trebananib (AMG 386) 10 mg/kg, 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
62836615|NCT06127849|ACTIVE_COMPARATOR|Resistance Training + Whey protein (40 gms) + EB-PA (500 mg)|"A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~One capsule of EB0-PA to be taken 30 minutes after whey protein in the morning."
62254427|NCT01543828|EXPERIMENTAL|indacaterol then placebo|In treatment 1: participants received indacaterol 75 µg one dose delivered via single-dose dry-powder inhaler (SDDPI) followed by treatment 2: placebo one dose via SDDPI between day 7 and 10. Albuterol was available for use as rescue medication.
62254428|NCT01543828|PLACEBO_COMPARATOR|placebo then indacaterol|In treatment 1, participants received placebo one dose delivered via SDDPI followed by treatment 2: indacaterol 75 µg one dose delivered via SDDPI between Day 7 and Day 10. Albuterol was available for use as rescue medication.
62254429|NCT02554903|EXPERIMENTAL|Macitentan 10 mg po|Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.
62443123|NCT02244437|EXPERIMENTAL|Acetaminophen|Acetaminophen has not been tested yet in AMS prevention.
62053361|NCT05655754|ACTIVE_COMPARATOR|Methohexital|"Initial dose: methohexital 1 mg/kg (≙ 80 mg methohexital in a subject with 80 kg). If sufficient hypnosis is not achieved with the initial dose further doses of 10 mg methohexital will be administered until sufficient depth of anesthesia according to defined criteria is achieved. Criteria for sufficient depth of anesthesia will be comprised by a) the abolition of the eye-lash reflex b) absence of motor reaction upon inflation of the tourniquet.~Maintenance dose: none (The drug combination is injected in order to initiate anesthesia) Route of administration: intravenous Duration: few seconds to initiate anesthesia. The procedure will be repeated for each ECT session."
62053362|NCT05655754|ACTIVE_COMPARATOR|Ketofol|"Esketamine and propofol will be prepared shortly before injection by the nurse anesthetist as follows: 4 ml esketamine 25mg/ml, 6ml NaCl (0,9%), 10ml propofol (10mg/ml). The stability of ketamine-propofol mixtures (undiluted, 50:50 ratio) in one syringe has been documented for up to 3 hours.~Initial dose: esketamine 0,5 mg/kg + propofol 0,5 mg/kg (≙ 40 mg esketamine + 40 mg propofol in a subject with 80 kg). If sufficient hypnosis is not achieved with the initial dose further doses of 5mg esketamine and 5 mg propofol will be administered until a sufficient depth of anesthesia is achieved.~Maintenance dose: none (The drug combination is injected in order to initiate anesthesia) Route of administration: intravenous Duration: few seconds to initiate anesthesia. The procedure will be repeated for each ECT session"
62053363|NCT01389193|EXPERIMENTAL|Ibudilast|
62254430|NCT02554903|PLACEBO_COMPARATOR|Placebo sugar pill|Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.
62254431|NCT04603885|EXPERIMENTAL|Aerobic exercise group|Aerobic exercise will be measured with a Polar United fitness watch. Heart rate during exercise will be measured using a Polar United fitness watch, which has been validated for monitoring moderate and high intensity physical activity.
62254432|NCT04603885|PLACEBO_COMPARATOR|Attention control group|The time-equivalent, stretching movements will serve as the placebo exercise condition in this proposed study. Previous research has shown that stretching could reduce attrition and patient dissatisfaction and better ensure allocation concealment. Following baseline measures, a student will demonstrate the use of a Polar United fitness watch and stretching movements via zoom from week 3 to week 5. Starting on week 3, participants will perform the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise.
62836616|NCT05004441|EXPERIMENTAL|First-line treatment|"First-line treatment: Fruquintinib Combined With mFOLFOX6/FOLFIRI for twelve cycles.~Maintenance treatment: Fruquintinib and Capecitabine"
62443124|NCT02545413|EXPERIMENTAL|Probiotic|Probiotic VSL#3 will be given at a dose of one capsule thrice daily for 8 weeks, amounting to a total of 337.5 billion CFU/day. Each capsule contains 112.5 billion viable lyophilized bacteria of four strains of Lactobacillus (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734), three strains of Bifidobacterium (B. longum DSM 24736, B. breve DSM 24732, B. infantis DSM 24737) and one strain of Streptococcus (S. thermophilus DSM 24731) and excipients.
62836617|NCT06491485|EXPERIMENTAL|Group M (Magnesium sulfate)|a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine with magnesium sulfate 50 mg/kg (maximum 2g) will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
62836618|NCT06491485|EXPERIMENTAL|Group B (Sodium bicarbonate)|a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine with 50 ml 4.2% sodium bicarbonate will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
62053364|NCT01389193|PLACEBO_COMPARATOR|Placebo|
62836619|NCT06491485|ACTIVE_COMPARATOR|Group C|a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
62053365|NCT00002864|ACTIVE_COMPARATOR|Octreotide|
62836620|NCT04122716|ACTIVE_COMPARATOR|Liraglutide + exercise|"Liraglutide: 3 mg/day sc. The GLP-1 RA, liraglutide (3.0 mg), or placebo, will be administrated once daily as subcutaneous injections in the abdomen or thigh. The starting dose is 0.6 mg with weekly increments of 0.6 mg until 3.0 mg is achieved. The titration procedure will be prolonged for participants who do not tolerate fast up-titration. Participants who do not tolerate the 3.0 mg dose may in special circumstances stay at lower dose (2.4 mg). However, the aim is to reach 3.0 mg for all study participants.~Exercise: 150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations."
62254433|NCT05772754|OTHER|Chronic heart failure partecipants|Patients in the Department of Cardiovascular Sciences with signs and symptoms of chronic heart failure, elevated natriuretic peptide levels, left atrial dilatation and/or left ventricular hypertrophy, ejection fraction greater than 50% on echocardiographic evaluation HFpEF
62254434|NCT05772754|OTHER|Chronic hert faiure and ejection fraction less than 40% at echocardiographic evaluation|Patients admitted to the Department of Cardiovascular Sciences with signs and symptoms of chronic heart failure\*, ejection fraction less than 40% at echocardiographic evaluation HFrEF
62254435|NCT05772754|OTHER|Partecipants with pulmonary hypertension|Patients admitted with advanced HFpEF with development of pulmonary hypertension PH-HFpEF
62254436|NCT05772754|OTHER|Partecipants with advanced HFrEF|Patients admitted with advanced HFrEF with development of pulmonary hypertension PH-HFrEF
62053366|NCT00002864|ACTIVE_COMPARATOR|Tamoxifen|
62443125|NCT02545413|PLACEBO_COMPARATOR|Placebo|Placebo capsules will be given at a dose of one capsule thrice daily for 8 weeks; Placebo capsules contain all excipients as present in capsules (without the 8 strains of bacteria as mentioned above).
62254437|NCT05772754|OTHER|Control Group|12 Controls (CTRL), recruited in the outpatient setting among subjects with cardiovascular disease, in the absence of heart failure
62836621|NCT04122716|OTHER|Liraglutide + non-exercise|"Liraglutide: 3 mg/day sc. The GLP-1 RA, liraglutide (3.0 mg), or placebo, will be administrated once daily as subcutaneous injections in the abdomen or thigh. The starting dose is 0.6 mg with weekly increments of 0.6 mg until 3.0 mg is achieved. The titration procedure will be prolonged for participants who do not tolerate fast up-titration. Participants who do not tolerate the 3.0 mg dose may in special circumstances stay at lower dose (2.4 mg). However, the aim is to reach 3.0 mg for all study participants.~Non-exercise: Participants should stay at same physical activity level (i.e. max. 2 h of vigorous endurance training/week) as when the participant was included in the study."
62836622|NCT04122716|OTHER|Placebo + exercise|"Placebo: 3mg/day sc.~Exercise: 150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations."
62254438|NCT05823415|EXPERIMENTAL|Laterally closed tunnel technique with CTG|
62254439|NCT05823415|ACTIVE_COMPARATOR|Coronally advanced flap with CTG|
62254440|NCT04533555|EXPERIMENTAL|Universal genetic testing|Detection of genetic risk using a broad panel of cancer risk genes.
62053367|NCT01650493||Group A|Clinpro 5000
62053368|NCT01650493||Group B|MI Paste Plus
62053369|NCT01650493||Group C|Toms of Maine
62053370|NCT01387555|EXPERIMENTAL|Arm A|Patients on Arm A will receive 1 e9 pfu (plaque forming units) total dose of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) on each of six (6) treatments over 18 weeks.
62053371|NCT01387555|OTHER|Arm B|Patients on the control arm (Arm B) will have best supportive care over 18 weeks.
62053372|NCT01991652||Wilms tumour|"Children diagnosed with a Wilms tumour receive SIOP PODC Wilms tumour treatment; preoperative chemotherapy, surgery and postoperative chemotherapy (= standard care).~One group of patients."
62053373|NCT02707692|OTHER|Pneumococcal, then Influenza, then Placebo vaccination|Participants first received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of saline (placebo).
62053374|NCT02707692|OTHER|Pneumococcal, then Placebo, then Influenza vaccination|Participants first received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of saline (placebo). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK).
62254441|NCT04533555|ACTIVE_COMPARATOR|Standard|We will refer a subset of patients who meet guideline criteria based on age, cancer type, and family history, for genetic counseling and testing.
62612514|NCT02525536|EXPERIMENTAL|Trebananib 30 mg/kg|Trebananib (AMG 386) 30 mg/kg, 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
62053375|NCT02707692|OTHER|Influenza, then Pneumococcal, then Placebo vaccination|Participants first received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of saline (placebo).
62254442|NCT01327820||Open aortic aneurysm repair|
62053376|NCT02707692|OTHER|Influenza, then Placebo, then Pneumococcal vaccination|Participants first received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of saline (placebo). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®).
62053377|NCT02707692|OTHER|Placebo, then Pneumococcal, then Influenza vaccination|Participants first received a 0.5 mL injection of saline (placebo). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK).
62254443|NCT01327820||Endovascular aortic aneurysm repair|
62254444|NCT01327820||Infra-inguinal lower limb revascularisation|
62254445|NCT00095875|EXPERIMENTAL|Arm I|Patients receive induction chemotherapy comprising docetaxel, cisplatin, and fluorouracil. Treatment repeats every 21 days for 3 courses. Patients achieving a pathologic complete response at the primary site and a clinical complete response in the neck then receive carboplatin once weekly and undergo concurrent radiotherapy once daily, 5 days a week, for 7 weeks. Patients with a partial response at the primary site (i.e., positive biopsy), stable disease, or radiographic evidence of persistent disease in the neck receive docetaxel once weekly for 4 weeks and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 6 weeks.
62254446|NCT00095875|EXPERIMENTAL|Arm II|Patients receive cisplatin IV on weeks 1 and 4 and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 6 weeks.
62254447|NCT04123236||Oral Health Impact Profile|To evaluate the Oral Health-related Quality of Life, Turkish version of Oral Health Impact Profile-14 was used. Responses were made on a scale 0 (never), 1(hardly ever), 2 (occasionally), 3 (fairly often),and 4 (very often).Oral Health-related Quality of Life impairment was characterized by the Oral Health Impact Profile-14 summary score (the sum of all 14 items, potential range 0-56). Higher Oral Health Impact Profile-14 scores mean worse Oral Health-related Quality of Life and vice versa.
62443126|NCT01288859|EXPERIMENTAL|encapsulated curcumin|
62443127|NCT01288859|EXPERIMENTAL|encapsulated curcumin + PQG|PQG means Piperine, Quercetin and Genistein
62443128|NCT01288859|ACTIVE_COMPARATOR|free cocoa polyphenol|
62443129|NCT01288859|PLACEBO_COMPARATOR|control|
62612515|NCT04847102|EXPERIMENTAL|Study group|
62612516|NCT04847102|PLACEBO_COMPARATOR|Control group|
62612517|NCT06020534||No-stenosis group|Patients who had no pre-existing aortoiliac stenosis before kidney transplantation.
62612518|NCT06020534||TASC A/B stenosis|Patients who had TASC A or B aortoiliac stenosis before kidney transplantation.
62053378|NCT02707692|OTHER|Placebo, then Influenza, then Pneumococcal vaccination|Participants first received a 0.5 mL injection of saline (placebo). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®).
62053379|NCT04513613||Subjects with a clinical indication for PVI|Subjects with a clinical indication for Peripheral Vascular Intervention (PVI).
62053380|NCT03761303|ACTIVE_COMPARATOR|active rTMS|Patients in the intervetion group (active rTMS stimulation) receive active 10 Hz rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
62053381|NCT03761303|SHAM_COMPARATOR|sham rTMS|Patients in the control group receive sham rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
62053382|NCT03019510|PLACEBO_COMPARATOR|no exercise|Subjects will be studied from 6 pm to 7 am following 48 hr of no exercise
62053383|NCT03019510|ACTIVE_COMPARATOR|morning exercise|Subjects will be studied from 6 pm to 7 am. Subjects will have exercised at 7 am on that day.
62053384|NCT03019510|ACTIVE_COMPARATOR|evening exercise|Subjects will be studied from 6 pm to 7 am. Subjects will exercise at 8 pm following dinner on the study day.
62053385|NCT01111838|EXPERIMENTAL|STA-9090|This is an open-label Phase 2 clinical study in patients with advanced colorectal cancer (CRC). Patients will be treated with 200mg/m2 of STA-9090 during a 1-hour intravenous infusion 1 time per week for three consecutive weeks followed by a 1 week dose-free interval. Patients tolerating STA-9090 will be permitted to continue treatment until disease progression.
62053386|NCT00605202|ACTIVE_COMPARATOR|Licorice|
62053387|NCT00605202|ACTIVE_COMPARATOR|Licorice and HCTZ|
62053388|NCT01218880|EXPERIMENTAL|M2ES-A|
62053389|NCT01218880|EXPERIMENTAL|M2ES-B|
62053390|NCT01218880|EXPERIMENTAL|M2ES-C|
62053391|NCT01218880|EXPERIMENTAL|M2ES-D|
62053392|NCT05215067|EXPERIMENTAL|AK104 plus Docetaxel|AK104 RP2D + Docetaxel 75mg/m\^2 every 3 weeks until progressive disease or unacceptable toxicity.
62053393|NCT02165332|PLACEBO_COMPARATOR|Part 1: Placebo|Saline solution, given as a minimum of a 2 hour infusion
62053394|NCT02165332|EXPERIMENTAL|Part 1: RO7033877|Single ascending dose
62053395|NCT02165332|EXPERIMENTAL|Part 2: RO7033877|Single-dose 4-way crossover
62053396|NCT04260230|EXPERIMENTAL|Lifetemp/Lifetouch sensors|Participants will be asked to wear the sensors for six weeks. Data will be collected from the devices but will only be reviewed retrospectively and will not be used to alter participants care in any way.
62053397|NCT02776332|ACTIVE_COMPARATOR|3 day group|Manual expression for 3 days after delivery Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery
62053398|NCT02776332|ACTIVE_COMPARATOR|7 day group|The 7 day group will manually express for 7 days after delivery. Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery follow up phone call at 5 days to encourage continued manual expression
62836623|NCT04122716|NO_INTERVENTION|Placebo + non-exercise|"Placebo: 3mg/day sc.~Non-exercise: Participants should stay at same physical activity level (i.e. max. 2 h of vigorous endurance training/week) as when the participant was included in the study."
62836624|NCT03452657|EXPERIMENTAL|Ranibizumab|Participants received 0.5mg intravitreal ranibizumab injection
62612519|NCT06020534||TASC C/D stenosis|Patients who had TASC C or D aortoiliac stenosis before kidney transplantation.
62836625|NCT03452657|SHAM_COMPARATOR|Sham-injection|No drug involved in the sham procedure; patient's eye is anesthetized and a syringe without needle gently pressed on the conjunctival surface to simulate the force of an actual injection
62836626|NCT05156034|EXPERIMENTAL|SRK-001- Dose 1|Participants will receive intravenous (IV) SRK-001 every 2 weeks (Q2W) for 4 doses.
62053399|NCT02390934|EXPERIMENTAL|Radium 223|Radium-223 (Xofigo®) will be supplied in vials as a ready-to-use solution for intravenous administration. The activity (administered radioactivity) will be 50 kBq/kg b.w., and multiple treatment activities up to 6 injections will be administered at intervals of 4 weeks.
62053400|NCT02347657|PLACEBO_COMPARATOR|Placebo|Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA tablet administered orally in the evening up to Week 24.
62053401|NCT02347657|EXPERIMENTAL|VX-661/IVA|VX-661 100 mg plus IVA 150 mg FDC tablet administered orally in the morning and IVA 150 mg tablet administered orally in the evening up to Week 24.
62053402|NCT03264651|EXPERIMENTAL|oral enobosarm and anastrozole|9 mg of oral enbosarm and 1 mg of anastrozole daily
62053403|NCT00169559|PLACEBO_COMPARATOR|Arm 1|Placebo
62053404|NCT00169559|ACTIVE_COMPARATOR|Arm 2|Fenofibrate
62053405|NCT05097846|EXPERIMENTAL|Group1: Vonoprazan Fumarate + amoxicillin + doxycycline|
62053406|NCT05097846|EXPERIMENTAL|Group2: Vonoprazan Fumarate + furazolidone + doxycycline|
62053407|NCT05097846|EXPERIMENTAL|Group3: esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline|
62053408|NCT05097846|EXPERIMENTAL|Group4: esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline|
62053409|NCT00736307|EXPERIMENTAL|1|Cultured limbal stem cells Transplantation
62053410|NCT03117595|ACTIVE_COMPARATOR|BF|Interventions: Intrathecal administration -Bupivacaine 2.5mg (0.5ml) + Fentanyl 25mcg (0.5ml) + 1ml sterile water in one shot Ephedrine 3-5mg in aliquots in the event of hypotension Promethazine 12.5 - 25mg in the event of vomiting or significant pruritus naloxone 2mcg/kg in the event of respiratory distress
62053411|NCT03117595|ACTIVE_COMPARATOR|BFM|Interventions: Intrathecal administration - Bupivacaine 2.5mg (0.5ml) + fentanyl 25mcg (0.5ml) + 0.25mg morphine (0.25ml) + 0.75ml sterile water in one shot ephedrine 3-5mg in aliquots for hypotension Promethazine 12.5 - 25mg for vomiting or significant pruritus Naloxone 2mcg/kg in the event of respiratory distress
62612520|NCT03027323|OTHER|AxoTrack System guided CVC insertion|AxoTrack System guided CVC
62612521|NCT03027323|NO_INTERVENTION|CVC insertion guided by landmark|Anatomical landmarks to guide CVC
62612522|NCT03973697|EXPERIMENTAL|Single dose of PMT|
62612523|NCT03973697|EXPERIMENTAL|Two doses of PMT|Administered within 24 hours
62836627|NCT05156034|EXPERIMENTAL|SRK-001- Dose 2|Participants will receive IV SRK-001 every 4 weeks (Q4W) for 2 doses.
62443130|NCT01288859|EXPERIMENTAL|encapsulated cocoa polyphenols|
62612524|NCT01920659|EXPERIMENTAL|High Intensity Training (HIT)|6 weeks of HIT, 3 times a week (3-5 1min on/off)
62612525|NCT01920659|EXPERIMENTAL|REHIT|6 weeks of HIT, 3 times a week (20sec)
62612526|NCT01920659|NO_INTERVENTION|control|control
62836628|NCT05156034|EXPERIMENTAL|SRK-001- Dose 3|Participants will receive IV SRK-001 Q2W for 4 doses.
62053412|NCT04077619|EXPERIMENTAL|Modern pain neuroscience approach|Behavioral: Modern pain neuroscience approach
62053413|NCT04077619|ACTIVE_COMPARATOR|Usual care evidence-based physiotherapy|Behavioral: Usual care evidence-based physiotherapy
62053414|NCT05838261||Children with cleft palate with velopharyngeal insufficiency undergoing surgical treatment|Children with combined or isolated cleft palate with velopharyngeal insufficiency undergoing surgical treatment with pharyngeal flap
62053415|NCT01942681|OTHER|Propiverine Hydrochloride Administration|Administration of Propiverine Hydrochloride for 12 weeks
62053416|NCT04209725|EXPERIMENTAL|CPX-351 and Quizartinib treatment|Participants with FLT3 mutation positive AML will be given CPX-351 followed by quizartinib in three phases: induction, consolidation, and maintenance.
62053417|NCT06427655|NO_INTERVENTION|intermittent suction|intermittent suction during intubation
62053418|NCT06427655|EXPERIMENTAL|SALAD|SALAD suction during intubation
62053419|NCT01171092|EXPERIMENTAL|bortezomib and G-CSF|
62053420|NCT00615732|EXPERIMENTAL|1|qigong
62053421|NCT00615732|ACTIVE_COMPARATOR|2|exercise therapy
62053422|NCT00615732|NO_INTERVENTION|3|
62053423|NCT01576822|ACTIVE_COMPARATOR|Low Dose|Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna). Participants will be able to schedule visits on any of 7 days per week. Maximum flexibility in hours of operation as well as flexibility in which days are attended will be utilized to increase likelihood of retention. Participants will be able to attend 9 consecutive sessions, should they wish.
62053424|NCT01576822|ACTIVE_COMPARATOR|High Dose|Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna). Participants will be able to schedule visits on any of 7 days per week. Maximum flexibility in hours of operation as well as flexibility in which days are attended will be utilized to increase likelihood of retention. A participant may attend visits for 15 consecutive days, should they wish.
62053425|NCT02384564|EXPERIMENTAL|Ambu King Vision Video Laryngoscope aBlade System|The trachea will be intubated using the Ambu King Vision Video Laryngoscope with the appropriate sized blade (size 1 or 2) based on manufacturer guidelines and clinical judgement.
62053426|NCT02384564|ACTIVE_COMPARATOR|Direct Laryngoscope|The trachea will be intubated via direct laryngoscopy using a traditional straight blade laryngoscope, with appropriately sized blade based on manufacturer guidelines and clinical judgement.
62053427|NCT02462525|EXPERIMENTAL|ABBV-838 dose escalation|Varying doses of ABBV-838
62053428|NCT02462525|EXPERIMENTAL|ABBV-838 plus pomalidomide/dexamethasone|ABBV-838 to be evaluated with pomalidomide/dexamethasone.
62053429|NCT01760421|EXPERIMENTAL|Hydroxychloroquine|Receive treatment with hydroxychloroquine
62053430|NCT01061333|EXPERIMENTAL|Placebo|Placebo
62053431|NCT01061333|EXPERIMENTAL|Montelukast|Montelukast
62053432|NCT01061333|EXPERIMENTAL|Nedocromil|Nedocromil
62053433|NCT01061333|EXPERIMENTAL|Mometasone|Mometasone
62443131|NCT01288859|ACTIVE_COMPARATOR|free curcumin|Subjects will consume bread added with free curcumin
62443132|NCT00654485|EXPERIMENTAL|1|Rosuvastatin
62443133|NCT00654485|ACTIVE_COMPARATOR|2|Atorvastatin
62443134|NCT06165120|ACTIVE_COMPARATOR|group A; Bracka's repair group|This group will undergo Bracka's repair using preputial graft in treatment of proximal hypospadias with marked ventral curvature
62443135|NCT06165120|ACTIVE_COMPARATOR|group B; STPIF repair group|This group will undergo STPIF repair using preputial flap in treatment of proximal hypospadias with marked ventral curvature
62443136|NCT02724007||All participants|
62612527|NCT00638209|ACTIVE_COMPARATOR|I|
62612528|NCT00638209|PLACEBO_COMPARATOR|P|
62836629|NCT05156034|PLACEBO_COMPARATOR|Placebo|Participants will receive IV placebo Q2W for 4 doses or Q4W for 2 doses.
62836630|NCT04540913|EXPERIMENTAL|RHA 3|"Injection of RHA 3 into into the vermillion body, vermillion border, and oral commissures of the lips (up to 3 ml with a max of 1.5 ml per lip), injected into the lip mucosa and/or mid to deep dermis as appropriate for lip augmentation.~Optional touch up treatment provided at 4 Weeks, optional retreatment at 36 or 52 Weeks."
62254448|NCT04123236||Helkimo's anamnestic dysfunction index|As a method based on patient feedback for the determination of the degree of temporomandibular disorders, anamnestic index was used. For this purpose eight questions were asked to the patients that includes answers as 'yes' or 'no'. (Table 2) The analyses of the questionnaire was done according to anamnestic scale as 0: no symptoms; I: mild symptoms (sensation of the jaw fatigue, jaw stiffness, and temporomandibular joint sounds as clicking or crepitus) and II:severe symptoms (included one or more of the following: Difficulty in the mouth opening, jaw locking, mandible dislocation and its painful movement and painful temporomandibular joint region and/or masticatory muscles)
62443137|NCT01855126|EXPERIMENTAL|Blue light|The study protocol consisted of two 8-week intervention/control periods in which each participant wore either the intervention (blue light) or control (red light) mask every night, with the order of presentation of the two conditions randomized by the study's biostatistician. A light mask housing two blue Light Emitting Diodes (LED) arrays delivered a train of blue or red light pulses of 2 second duration that were presented every 30 s for no longer than 2 hr, resulting in a maximum total of approximately 240 pulses per night. the blue light mask was worn nightly for 8 weeks. There will be a two week washout period between each intervention
62836631|NCT04540913|ACTIVE_COMPARATOR|Restylane- L|"Injection of Restylane- L into into the vermillion body, vermillion border, and oral commissures of the lips (up to 3 ml with a max of 1.5 ml per lip), injected into the lip mucosa and/or mid to deep dermis as appropriate for lip augmentation.~Optional touch up treatment provided at 4 Weeks."
62254449|NCT04123236||Visual analog scale (VAS) for facial pain:|Facial pain was measured by asking the patients if they had had any pain during last 12 months and made them mark the intensity of the pain on a visual analog scale which had the anchor points at the left (no pain) and right (worse pain) ends of a 10 cm horizontal line. The analyses of the facial pain was done as fallowing: if the patient marked no facial pain the Visual analog scale value was accepted as 0 and if the patient marked any level of facial pain Visual analog scale value was accepted as 1.
62254450|NCT04123236||Helkimo's clinical dysfunction index (DI):|Maximum opening of mandible, deviation during opening, dysfunction of temporomandibular joint, pain in the temporomandibular joint and pain in the masticatory muscles was evaluated
62254451|NCT05606081|EXPERIMENTAL|Use of risk prediction scores|The prediction model is being used to identify patients who are at highest risk for colorectal cancer based on their risk scores.
62254452|NCT03533972|EXPERIMENTAL|Test group|subjects will be provided with Ashwagandha capsules 500 mg twice daily, after meals with plain water for 1 month
62254453|NCT03533972|PLACEBO_COMPARATOR|Control group|subjects will be provided with placebo capsules.
62612529|NCT04609709|EXPERIMENTAL|thrust manipulation, electric dry needling and exercise|thrust manipulation, electric dry needling and exercise
62836632|NCT00345358|ACTIVE_COMPARATOR|Synflorix <6M Group|This group consisted of subjects up to 6 months of age at first vaccination who received 3 doses of Synflorix™ vaccine co-administered with Infanrix™ IPV/Hib at 3, 4 and 5 months of age and a booster dose of the same vaccines at 12-15 months of age. Vaccines were administrated intramuscularly in the right (Synflorix™) or the left (Infanrix™ IPV/Hib ) thigh or deltoid region (deltoid region only for children \>12 months of age if muscle size was adequate).
62053434|NCT03320616|EXPERIMENTAL|Sequence 1|4 single doses of EYP001a: Period 1 first dose morning fasted, second dose morning fed; Period 2 first dose evening fasted, second dose evening fed
62053435|NCT03320616|EXPERIMENTAL|Sequence 2|4 single doses of EYP001a: Period 1 first dose evening fasted, second dose evening fed; Period 2 first dose morning fasted, second dose morning fed
62053436|NCT03320616|EXPERIMENTAL|Sequence 3|4 single doses of EYP001a: Period 1 first dose morning fed, second dose morning fasted; Period 2 first dose evening fed, second dose evening fasted
62053437|NCT03320616|EXPERIMENTAL|Sequence 4|4 single doses of EYP001a: Period 1 first dose evening fed, second dose evening fasted; Period 2 first dose morning fed, second dose morning fasted
62612530|NCT04609709|ACTIVE_COMPARATOR|non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS|non-thrust mobilization, soft-tissue mobilization, exercise and TENS
62612531|NCT03146728||tetraplegia, paraplegia|motor complete spinal cord injured individuals with tetraplegia or paraplegia
62612532|NCT03146728||able-bodied|age height and weight matched able bodied
62836633|NCT00345358|EXPERIMENTAL|Synflorix 7-11M Group|This group consisted of subjects 7 to 11 months of age at first vaccination who received 2 doses of Synflorix™, one first dose at enrolment followed by a second dose one month later, and a booster dose at 12-15 months of age. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children \>12 months of age if muscle size was adequate).
62053438|NCT06265272||Cirrhosis|55 Patients with liver cirrhosis
62053439|NCT05961852|EXPERIMENTAL|Treatment arm|Cutting and drug-coated balloon angioplasty
62053440|NCT02659787|ACTIVE_COMPARATOR|Low dose buprenorphine|Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
62053441|NCT02659787|PLACEBO_COMPARATOR|Placebo|Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
62053442|NCT03138174||Diabetes|One group consisting of diabetic subjects
62053443|NCT05713201||Index PCI|Patients with an aneurysmatic right coronary artery undergoing index PCI in the acute setting.
62053444|NCT05713201||Staged PCI|Patients with an aneurysmatic right coronary artery undergoing staged PCI in the acute setting.
62053445|NCT05135416|ACTIVE_COMPARATOR|chewing gum Group|"Questions related to surgery and bowel function found in the Participant Information Form it will be filled in. The chewing gum group data will be followed up with the Follow-up Form- Chewing Gum Group . Women who make up the gum group, based on the time of arrival in the room 2. per hour, 4. and 6 o'clock. they'll chew gum an hour. Chewing gum based on knowledge of the literature its duration will be limited to 15 minutes, and a new gum will be introduced with each chewing. To all women the same brand will be given unsweetened chewing gum, which is easy to chew, does not contain sorbitol and xylitol. Sorbitol GIS problems in the case of ingestion of gums containing it, while gums containing xylitol are more in order not to ignore the decongestant risk of diarrhea when consumed, sugar-free chewing gum was preferred."
62053446|NCT05135416|ACTIVE_COMPARATOR|Control group|"Questions related to surgery and bowel function found in the Participant Information Form it will be filled in. The control group data were followed up with the Follow-up Form-Control Group will be. Of the women who made up the control group, it was not until the bowel sounds were first heard that bowel sounds will be listened to by the service nurse december 2 hours intervals. The patient has gas-stool by querying the output, it will be saved. Application of analgesics to pain levelsin the case of Visual Analog Scale (Visual Analog Scale -Vas) within 15 minutes it will be evaluated with. After the end of the researcher's 8-hour shift, the time of gas extraction and defecation is estimated since it cannot be done, women can set the time of gas extraction and defecation as time/date; they'll record it. Assessment of pain level, first 8. After the time of 16 and 24. in the hours will be made."
62053447|NCT02817035|EXPERIMENTAL|noninvasive mechanical ventilation|To investigate the change of the neural inspiratory time and expiratory delay noninvasive mechanical ventilation ,in comparison to spontaneous breathing
62053448|NCT02608398||overweight children at weight-loss camp|This is an observational study there is no intervention. The investigators will carry out metabolic profiling on a cohort of overweight or obese children who are attending a commercial weight loss camp for 2-5 weeks.
62254454|NCT05560373|EXPERIMENTAL|The operation group-The treatment group|after operational treatment: ①the best basic treatment ②i.m. huperzine A injection (0.2mg), qd, 8d.
62254455|NCT05560373|OTHER|The operation group-The control group|after operational treatment: ①the best basic treatment
62254456|NCT05560373|EXPERIMENTAL|The intervention group-The treatment group|after interventional treatment: ①the best basic treatment ②i.m. huperzine A injection (0.2mg), qd, 8d.
62443138|NCT01855126|PLACEBO_COMPARATOR|Red light|The study protocol consisted of two 8-week intervention/control periods in which each participant wore either the intervention (blue light) or control (red light) mask every night, with the order of presentation of the two conditions randomized by the study's biostatistician. A light mask housing two red Light Emitting Diodes (LED) arrays delivered a train of blue or red light pulses of 2 second duration that were presented every 30 s for no longer than 2 hr, resulting in a maximum total of approximately 240 pulses per night. the red light mask was worn nightly for 8 weeks, with a two week washout period between each intervention
62254457|NCT05560373|OTHER|The intervention group-The control group|after interventional treatment: ①the best basic treatment
62254458|NCT05895682|EXPERIMENTAL|Induced hypoxia|Volunteers were monitored using end-tidal carbon dioxide partial pressure and fraction of inspired oxygen. Each volunteer was placed in a semi-Fowler's position and connected to a breathing circuit to administer the nitrogen-air-carbon dioxide mixtures. A nose clip was applied to prevent breathing of room air. For frequent blood sampling, an arterial cannula was placed in the radial artery of each volunteer. Pulse oximeter probes were simultaneously attached to each volunteer's fingers. Each volunteer was exposed to various levels of induced hypoxia from 70\~100% of SaO2. Each plateau of oxygen saturation was maintained for at least 30 s until stabilization, after which 1 ml of arterial blood was drawn into a heparinized syringe. The study period consisted of two rounds of hypoxia, and the volunteers were maintained on room air between each round. SaO2 measurements using a CO-oximeter were used as a reference for the SpO2 accuracy.
62254459|NCT03078374|OTHER|Reduced Anticoagulation|Reduced anticoagulation
62443139|NCT01802346|EXPERIMENTAL|Arm I (low-calorie diet)|Patients eat a special low-calorie diet during 3 days prior to chemotherapy, during the 12 weeks of chemotherapy, and 2 days after chemotherapy. Patients are provided with all meals and all food to be consumed and maintain a diary of the food consumed and appropriate amounts.
62443140|NCT01802346|ACTIVE_COMPARATOR|Arm II (normal diet)|Patients eat a normal diet and receive dietary advice which may include consultation with a nutritionist. Patients maintain a diary of the food consumed and appropriate amounts.
62254460|NCT02763709||Cases|Children admitted in Pediatric ICU for more than 24 hours with Pediatric Risk of Mortality (PRISM) score III \> 20
62254461|NCT01380379|EXPERIMENTAL|Life skills and self-defense training|Women will participate in a therapeutic group which covers education, skills, and empowerment activities.
62254462|NCT01127659|ACTIVE_COMPARATOR|diabetes with HH-active|Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.
62443141|NCT03857113||PSMA-radioguided surgery|Tc-99m-PSMA combined with a gamma probe, guidance of the surgical resection of recurrent PC lymph node metastases
62254463|NCT01127659|NO_INTERVENTION|diabetes with normal testosterone|Eugonadal subjects with diabetes. They will not be treated
62053449|NCT04635579|EXPERIMENTAL|Anterior cruciate ligament reconstruction group|Single session blood flow restriction of lower limb to individuals who have undergone anterior ligament reconstruction surgery
62254464|NCT01127659|ACTIVE_COMPARATOR|obese with HH-active|Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.
62254465|NCT01127659|NO_INTERVENTION|obese with normal testosterone|Eugonadal non-diabetic obese subjects. They will not be treated
62254466|NCT01127659|PLACEBO_COMPARATOR|Diabetes with HH-placebo|Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to placebo.
62254467|NCT01127659|PLACEBO_COMPARATOR|Obese with HH-placebo|Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to placebo.
62254468|NCT00520728|EXPERIMENTAL|A|Experimental arm receives 12 week intervention along with standard care.
62254469|NCT03777540||Age; timing of gastric resection|Patients 80-85 years; Patients \> 85 years; Elective and urgent surgery.
62254470|NCT04060082||Persons Diagnosed|Individuals with a diagnosis of bvFTD.
62254471|NCT04060082||Persons At Risk|Individuals with a known genetic risk factor for bvFTD: people with genetic testing that identified a disease-causing change in a gene that is known to cause bvFTD, such as in C9ORF72, MAPT, GRN, VCP, TARDBP, CHMP2B, or another gene that has been identified as causing FTD in the family
62254472|NCT05417607|OTHER|A+ Treatment/Feasibility participants|Total participation is expected to require a maximum of 20 weeks (plus optional remote follow-up at 16 week). Diagnostic/screening visits occur between 1 and 6 weeks prior to baseline and start of coaching. ESDM-informed parent coaching (\~1 hour sessions) is delivered remotely (through telehealth) with a study clinician for 8 weeks and strategies are implemented within the child's typical daily routines by the caregiver. No medication is provided by the study team. Data is collected weekly and final assessment will be obtained at 16 weeks after baseline.
62612533|NCT02454634|EXPERIMENTAL|IDH1 peptide vaccine|The IDH1 peptide vaccine is a 20mer peptide encompassing the IDH1R132H-mutated region emulsified in Montanide®. It is injected subcutaneously and administered in combination with topical imiquimod. The vaccine is administered 8 times every 2 or 4 weeks.
62443142|NCT04531033|PLACEBO_COMPARATOR|Placebo|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
62443143|NCT04531033|EXPERIMENTAL|Low dose 10 billion CFU per day|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
62443144|NCT04531033|EXPERIMENTAL|High dose 15 billion CFU per day|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
62836634|NCT00345358|EXPERIMENTAL|Synflorix 12-23M Group|This group consisted of subjects 12 to 23 months inclusive at first vaccination who received 2 doses of Synflorix™, one first dose at enrolment followed by a second dose 2 months later. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children \>12 months of age if muscle size was adequate).
62053450|NCT04635579|ACTIVE_COMPARATOR|Control group|Single session blood flow restriction of lower limb to individuals who have no musculoskeletal injuries
62053451|NCT03559101|ACTIVE_COMPARATOR|Beverage 1 - Control|Distilled Water
62053452|NCT03559101|EXPERIMENTAL|Beverage 2|Medical Food 1 (8 amino acids, 60 mmol/L Na, 20 mmol/L K + citrate, Cl)
62053453|NCT03559101|EXPERIMENTAL|Beverage 3|Medical Food 2 (8 amino acids, 30 mmol/L Na, 10 mmol/L K + citrate, Cl)
62053454|NCT03559101|EXPERIMENTAL|Beverage 4|Pedialyte
62053455|NCT03559101|EXPERIMENTAL|Beverage 5|Gatorade
62053456|NCT00791843|EXPERIMENTAL|GHRH and placebo|Everyone will receive 12 weeks of GHRH and 12 weeks of Placebo
62053457|NCT02389257|EXPERIMENTAL|MINIMAG / MEG|Cerebral magnetic fields
62053458|NCT02389257|EXPERIMENTAL|MINIMAG / ECG|Cardiac magnetic fields
62053459|NCT02131870|ACTIVE_COMPARATOR|L plantarum DSM 9843|
62053460|NCT02131870|PLACEBO_COMPARATOR|Placebo|
62053461|NCT01722760||Term and preterm infants|Term and preterm infants
62053462|NCT06155708|EXPERIMENTAL|Ketone|- Ketone monoester supplement in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.45ml/kg body weight) ingested with water and vanilla-flavored stevia in a total volume of 100 ml.
62053463|NCT06155708|PLACEBO_COMPARATOR|Placebo|100 ml water combined with 10ml bitter flavor and vanilla-flavored stevia
62053464|NCT03471663|EXPERIMENTAL|D-0502|D-0502
62053465|NCT03471663|EXPERIMENTAL|D-0502 in combination with palbociclib|D-0502 in combination with palbociclib
62053466|NCT04577677|EXPERIMENTAL|optimization of control anesthetic condition|
62053467|NCT04577677|EXPERIMENTAL|understanding tDCS effect on motor learning|
62053468|NCT04577677|EXPERIMENTAL|understanding tDCS effects on cortical excitability|
62053469|NCT04577677|EXPERIMENTAL|optimizing peripheral nerve stimulation protocols|
62053470|NCT04577677|EXPERIMENTAL|Effect peripheral nerve stimulation on motor learning|
62053471|NCT04647032|EXPERIMENTAL|Theta Stimulation Group|This group will receive 6 Hz (theta) stimulation
62053472|NCT04647032|ACTIVE_COMPARATOR|Delta Stimulation Group|This group will receive 1 Hz (delta) stimulation
62053473|NCT05194306|EXPERIMENTAL|Perla® Cold Preservation solution|Perla® is a Cold Preservation Solution, with purpose to wash out, preserve during transport liver and kidney grafts in optimal conditions from the donor to the recipient.
62053474|NCT03720938|NO_INTERVENTION|Control Group|Physically inactive children who did not play AVGs.
62053475|NCT03720938|EXPERIMENTAL|Intervention Group|Physically inactive children who played alternately Nintendo Wii® active video games for 50-60 min, 3 days a week, 12 weeks, in laboratory environment.
62443145|NCT00564161||1|
62443146|NCT00564161||2|
62443147|NCT03013933|EXPERIMENTAL|Treatment (cyclosporine, verapamil, brentuximab vedotin)|Patients receive cyclosporine PO BID on days 1-5, verapamil hydrochloride PO QID on days 1-5, and brentuximab vedotin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62443148|NCT01616303|ACTIVE_COMPARATOR|carboplatin & paclitaxel|first-line chemotherapy for ovarian cancer
62443149|NCT01616303|EXPERIMENTAL|carboplatin & paclitaxel & oregovomab|first-line chemotherapy for ovarian cancer plus oregovomab
62254473|NCT05340361||In vivo|OCT examination is performed using a frequency-domain OCT system (C7 DragonflyTM OPTISTM Imaging Catheter, Abbott Vascular, Santa Clara, CA, USA) with a 5.4 or 7.5 cm total pullback length according to a non-occlusive technique. The procedure is performed via radial or femoral access with a ≥6 Fr guiding catheter. The OCT catheter is advanced over the 0.014-inch PCI wire and the implanted stent was crossed after administration of intracoronary nitrates of 200 µg. For blood clearing, contrast media was injected through the guiding catheter with an automated power injector. The standard infusion rate was 4 mL/s for 4 seconds with 250 PSI. Follow-up OCT image acquisition was achieved with the same method. After post-PCI OCT, we evaluate the factor regarding post-PCI optimization target by European Expert Consensus.
62254474|NCT02429726|EXPERIMENTAL|rAdp53|2 x 10\^12 viral particles of rAdp53 gene are given in 40 ml of saline by intra-cavity infusion at day of 7, 15 and 21
62254475|NCT02429726|ACTIVE_COMPARATOR|cisplatin|cisplatin 40 mg in 40 ml of saline are given by intra-cavity infusion at day of 7, 15 and 21
62254476|NCT02429726|EXPERIMENTAL|rAdp53 plus cisplatin|2 x 10\^12 viral particles of rAdp53 gene and cisplatin 40 mg in 40 ml of saline are given by intra-cavity infusion at day of 7, 15 and 21
62254477|NCT04252053|EXPERIMENTAL|Supervised Pilates-Based Core Stability Training Group|In order to detect the effects of pilates-based core stabilization training (PBCST) on isokinetic knee strength and postural sways, individuals with MS will receive pilates-based core stabilization training for 8 weeks and 2 days a week. One educational session will perform to teach basic principles of pilates based training. Individuals in this group will receive treatment at the clinic by physiotherapist supervision. All sessions will be individualized (not group training).
62053476|NCT01288274|ACTIVE_COMPARATOR|Injection by Health Extension Worker|Women who receive injectable contraceptive from clinic based health extension workers (HEWs) during the study period
62254478|NCT04252053|ACTIVE_COMPARATOR|Home exercise group|The home exercise group will perform the same PBCST exercises at home during the same period (8 weeks, 2 days a week) as the brochures prepared for them. Individuals in this group will receive one educational session which includes basic principles of pilates and one session which includes two-week exercise program. Participants will be invited to the clinic every two weeks to ensure the progression of the exercises and the exercise program will be updated.
62254479|NCT00845013||HIV Infection|HIV-infected individuals with the clinical diagnosis of pulmonary hypertension or HIV-infected individuals who have mildly elevated pulmonary arterial pressures
62254480|NCT01788384|ACTIVE_COMPARATOR|Acanya|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% gel (Valeant Pharmaceuticals, North America)
62254481|NCT01788384|EXPERIMENTAL|Clindamycin Phosphate / Benzoyl Peroxide|Clindamycin Phosphate / Benzoyl Peroxide Gel, 1.2%/2.5%
62443150|NCT00281619||Mycophenolic Acid (CellCept)|purpose of this study is to determine how fast children, who have had a recent kidney transplant, absorb, breakdown and eliminate mycophenolic acid (CellCept) following their prescribed dose
62053477|NCT01288274|ACTIVE_COMPARATOR|Injection by Community Health Worker|Women who receive injectable contraceptive through community based distributors from community based reproductive health agents (CBRHAs) during the study period
62053478|NCT04737902||VATS with ESPB|Study subjects underwent anaesthesia and VATS without a change in their routine care. At the end of the surgery, an erector spinae plane block was performed for acute pain control following our institutional protocol for perioperative care.
62053479|NCT02438943|ACTIVE_COMPARATOR|Audit and Physician intervention|The intervention will comprise the feedback of the results of the baseline audit, training in motivational interviewing for clinic staff, use of a physician reminder stamp in the patients' charts and distribution of patient education cards
62053480|NCT02438943|SHAM_COMPARATOR|Audit only|The intervention will comprise the feedback of the results of the baseline audit only
62053481|NCT02662062|EXPERIMENTAL|Pembrolizumab|Pembrolizumab to be administered via IV 200mg 3 weekly commenced concurrently with chemoradiotherapy, and continuing until 12 week cystoscopy.
62053482|NCT04393298|EXPERIMENTAL|Part A|Study participants assigned this arm will receive UCB6114 as monotherapy in escalating cohorts at pre-specified dose levels.
62053483|NCT04393298|EXPERIMENTAL|Part A1|Study participants will receive predefined doses of UCB6114 as monotherapy administered intravenously at pre-specified time points.
62053484|NCT04393298|EXPERIMENTAL|Part B|Study participants assigned to this arm will receive UCB6114 in escalating cohorts at pre-specified dose levels in combination with trifluridine/tipiracil (TFD/TPI).
62053485|NCT04393298|EXPERIMENTAL|Part C|Study participants assigned to this arm will receive UCB6114 in escalating cohorts at pre-specified dose levels in combination with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) regimen.
62053486|NCT05747963|EXPERIMENTAL|software-delivered CBT-I|Subjects in intervention group will receive a digital CBT-I for 6 weeks. The automated software incorporates all core elements of CBT-I, tailoring content based on each participant's reported baseline sleep function and sleep progress.
62254482|NCT01788384|PLACEBO_COMPARATOR|Vehicle Gel|Placebo (Vehicle Gel)of the test product (Watson Laboratories, Inc.)
62254483|NCT02108860|EXPERIMENTAL|Blinded abatacept|Participants will receive blinded abatacept 125 mg administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission by treatment month 6.
62612534|NCT06361615|ACTIVE_COMPARATOR|Simple-Task (multicomponent physical exercise)|Single-task (ST) training group developed an exercise program based on Functional Exercise Circuit (FEC) protocol
62612535|NCT06361615|EXPERIMENTAL|Dual-Task training (multicomponent physical exercise + cognitive tasks)|Dual-task (DT) training group performed motor (FEC) plus cognitive tasks
62612536|NCT04322786||ACEI user|Individuals with an ACEI prescription in the study population.
62612537|NCT04322786||Matched controls|Individuals without an ACEI prescription, and matched to the users by sex and 10-year age categories.
62053487|NCT05747963|ACTIVE_COMPARATOR|online PE|Subjects in control group will receive information about insomnia and sleep health education content.
62053488|NCT01944202|EXPERIMENTAL|Educational Intervention|"Physicians in the intervention arm receive the following multi-faceted educational intervention on transthoracic echocardiogram appropriateness: 1) a lecture at the beginning of the study period, which describes the Appropriate Use Criteria (AUC) for echocardiography and highlights common clinical scenarios for which outpatient TTEs are ordered, 2) an electronic pocket card via email that provides tips on appropriate ordering of TTEs, and 3) an individualized monthly feedback report that categorized TTEs ordered over the preceding month. The feedback reports contains the number of TTEs ordered during the month and how many are classified as appropriate, inappropriate, or uncertain based on the 2011 AUC."
62053489|NCT01944202|NO_INTERVENTION|Control group|Physicians in the control arm have their TTE orders tracked and classified, but do not receive any feedback on their ordering behavior.
62612538|NCT01333956|PLACEBO_COMPARATOR|Control|Patients will receive 0mg of pregabalin
62612539|NCT01333956|EXPERIMENTAL|50mg Arm|Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of post-operative day (POD)14 and one capsule at bedtime POD15, POD16.
62612540|NCT01333956|EXPERIMENTAL|100mg Arm|Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
62254484|NCT02108860|PLACEBO_COMPARATOR|blinded placebo|Participants will receive blinded placebo. Placebo will be administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission by treatment month 6.
62254485|NCT03620890|ACTIVE_COMPARATOR|Neutral Protamine Hagedorn (NPH)|NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
62254486|NCT03620890|ACTIVE_COMPARATOR|Detemir|Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)
62254487|NCT00069927|EXPERIMENTAL|Arm 1- Adderall- XR®|Adderall-XR® 1 10 mg/day for 3-12 weeks depending on subject's response
62254488|NCT00069927|EXPERIMENTAL|Arm II Concerta®|Concerta ® 18 mg/day for 3-12 weeks depending on subject's response
62254489|NCT05299775||HIV infected time|Group are divided by Infected time: 0-2W, 2W-12M, \>1Y
62053490|NCT02681614|EXPERIMENTAL|Uronav|"Participants will undergo a Uronav guided biopsy with Magnetic Resonance Imaging confirmation.~All biopsies will be completed in the outpatient setting in the ambulatory OR prior to routine prostate brachytherapy under general anesthesia."
62254490|NCT05299775||different constitutions|Group are divided by different constitutions:It includes 9 basic types of constitution, yang deficiency , yin deficiency , qi deficiency , phlegm dampness , damp-heat, blood stasis, special diathesis , qi depression , gentleness constitution .
62254491|NCT02718924||morbidly obese pregnant|Term pregnant women with BMI more than 40
62254492|NCT02718924||non obese pregnant|Term pregnant women with BMI less than 30
62254493|NCT06089148||contrast enhanced mammography, tomosynthesis and MRI|CEDM and tomosynthesis versus MRI
62254494|NCT02951286|EXPERIMENTAL|high pull headgear + OBA|A modified version of the Open Bite Appliance (OBA),introduced by Erverdi and Usumez, will be applied with high pull headgear for Orthoclassic ®1300 NE Alpha Drive, McMinnville, OR 97128 USA 866.752.0065.
62254495|NCT02951286|EXPERIMENTAL|OBA (control group)|A modified version of the Open Bite Appliance (OBA),introduced by Erverdi and Usumez, will be applied only.
62254496|NCT02925702||Radium-223|Radium-223 55 mBq/Kg every 4 weeks IV
62254497|NCT03979690|EXPERIMENTAL|Subjects Receiving Colonoscopy|Subjects receiving tandem colonoscopies using the NISInspire-C System followed by a Conventional Colonoscopy
62254498|NCT05899881|EXPERIMENTAL|Yoga intervention|10 week yoga intervention; one yoga session per week, 60 minutes in length
62254499|NCT05899881|NO_INTERVENTION|Control|Waitlist control asked not to make any lifestyle changes over the 10 week intervention period, and not engage in yoga
62254500|NCT04428463|ACTIVE_COMPARATOR|tympanoplasty using fascia and cartilage|tympanoplasty under general anesthesia using fascia and cartilage witch is the gold standard for treating tympanic membrane perforations.
62254501|NCT04428463|EXPERIMENTAL|Tachosil|repair of tympanic perforations under local anesthesia using Tachosil patch.
62254502|NCT04265716|ACTIVE_COMPARATOR|L. reuteri|Topical administration of ointment with L. reuteri DSM17938, rubbed into skin twice per day
62254503|NCT04265716|PLACEBO_COMPARATOR|Placebo|Rubbed into skin twice per day
62254504|NCT06295367|ACTIVE_COMPARATOR|ARM A (Enhanced usual care)|Patients receive PAF brochure describing financial navigation services.
62254505|NCT06295367|EXPERIMENTAL|ARM B (CostCOM)|Patients receive usual financial care per practice standard of care and CostCOM financial counseling sessions over 1 hour within 30 days after enrollment and at 3, 6 and 12 months.
62443151|NCT05768828||Migraine|Patients suffering from migraine based on ICHD-3 criteria
62612541|NCT01333956|EXPERIMENTAL|150mg Arm|Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
62836635|NCT00345358|EXPERIMENTAL|Synflorix >=24M Group|This group consisted of subjects aged between 24 months (inclusive) to 5 years (inclusive) at vaccination who received one dose of Synflorix™. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children \>12 months of age if muscle size was adequate).
62836636|NCT01735331||VEGF level|VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss.
62836637|NCT01735331||control group|Patients with Abnormal Uterine Bleeding
62836638|NCT02217358|EXPERIMENTAL|NBI endoscopy|150 patients with suspected lesion in larynx and hypopharynx on standard ENT white light endoscopy examination will undergo NBI endoscopy in order to compare the outcomes of these two examination methods
62836639|NCT04961957|ACTIVE_COMPARATOR|Waterproof padding|Waterproof, short leg walking cast for 3-7 weeks
62836640|NCT04961957|ACTIVE_COMPARATOR|Non-waterproof padding|Non-waterproof, short leg walking cast for 3-7 weeks
62836641|NCT02853617|EXPERIMENTAL|AV0328 - Cohort 1|Cohort 1 will receive 15 µg to be given as an IM injection
62836642|NCT02853617|EXPERIMENTAL|AV0328 - Cohort 2|Cohorts 2 will receive 30 µg to be given as an IM injection
62053491|NCT01870193|ACTIVE_COMPARATOR|Young controls|Young controls will be studied before and after receiving cysteine and glycine for 2 weeks
62612542|NCT05558800|ACTIVE_COMPARATOR|Xpeed|Implant with Xpeed surface
62836643|NCT02853617|EXPERIMENTAL|AV0328 - Cohort 3|Cohorts 3 will receive 75 µg to be given as an IM injection
62836644|NCT02853617|EXPERIMENTAL|AV0328 - Cohort 4|Cohorts 4 will receive 150 µg to be given as an IM injection
62836645|NCT02401789|EXPERIMENTAL|test - implant placement|The possibility of counteracting unfavourable ridge modelling after multiple tooth extractions by placing implants in the fresh extraction sites
62836646|NCT02401789|NO_INTERVENTION|control- natural healing|
62254506|NCT06295367|EXPERIMENTAL|Non-patient participants: (interview)|Non-patient participants complete surveys and participant in 1 on 1 in depth semi-structured interview over 20-30 minutes at 15-39 months after first patient enrollment.
62254507|NCT03416270|EXPERIMENTAL|Ertuglifozin Treatment Arm|Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) for 12 weeks
62612543|NCT05558800|ACTIVE_COMPARATOR|SLA surface|Implant with SLA surface
62612544|NCT05558800|PLACEBO_COMPARATOR|Machined|Implant with machined surface
62612545|NCT05558800|ACTIVE_COMPARATOR|XPEEDActive|Implant with plasma treatment reactivated XPEED implant surface
62053492|NCT01870193|ACTIVE_COMPARATOR|Elderly active|Elderly subjects in the active group will receive glycine plus cysteine (as n-acetylcysteine) for 4 months, and be studied at baseline, 2 weeks and 4 months
62053493|NCT01870193|PLACEBO_COMPARATOR|Elderly placebo|Elderly subjects in the placebo group will receive alanine for 4 months, and be studied at baseline, 2 weeks and 4 months
62612546|NCT05848323|EXPERIMENTAL|Relaxation Training|Didactic and experiential training in one or more relaxation techniques such as diaphragmatic breathing, progressive muscle relaxation, autogenic relaxation, and guided imagery to reduce autonomic nervous system arousal.
62612547|NCT05848323|EXPERIMENTAL|Behavioral Activation|Didactic material and practice focused on identification and reduction of avoidance behaviors (e.g., excessive rest) and increased engagement in valued and reinforcing activities (e.g., physical activity, social engagement).
62612548|NCT05848323|EXPERIMENTAL|Cognitive Therapy|Didactic material and practice focused on identifying, challenging, and modifying inaccurate and/or unhelpful patterns of thought about the self and the world (e.g., catastrophizing the meaning and consequences of fatigue) to change unwanted behavioral patterns (e.g., excessive rest).
62836647|NCT02585518||Obese|Children and adolescents with a BMI at or above the 85th percentile for age and sex
62836648|NCT02585518||Healthy control|Children and adolescents with a BMI below the 85th percentile for age and sex
62836649|NCT02532803|EXPERIMENTAL|Novel pelvic MRI scan assessment|All patients with rectal tumours of 20-50mm in size who consent to enter the trial will receive novel staging report for their pelvic MRI scan.
62836650|NCT01279148||Biopsy/Ablation - CONTROL GROUP|The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded by pushing the start button again.
62254508|NCT03416270|PLACEBO_COMPARATOR|Placebo Arm|Placebo Matching Ertugliflozin Tablet for 12 weeks
62254509|NCT01824511|EXPERIMENTAL|Smokers Cease Smoking|Participants are paid to quit smoking without using any medications.
62254510|NCT01966614|EXPERIMENTAL|PRX302|PRX302 injection
62254511|NCT01966614|PLACEBO_COMPARATOR|Placebo|Placebo (Vehicle-only injection)
62254512|NCT01093274|ACTIVE_COMPARATOR|Polyethylene glycol|Preparation with Polyethylene Glycol and bisacodyl
62254513|NCT01093274|EXPERIMENTAL|Picolax|Preparation with Sodium Picosulphate and Bisacodyl.
62254514|NCT04898920|PLACEBO_COMPARATOR|Control Group|The patients will receive 10 ml of normal saline as a placebo dexamethasone before surgery.
62254515|NCT04898920|EXPERIMENTAL|Dexamethasone Group|Those patients will receive 16 mg dexamethasone in 10 ml of normal saline before surgery.
62254516|NCT03850600|EXPERIMENTAL|Diet-CD|dietary intervention: 8-10 weeks of diet intervention
62254517|NCT03850600|NO_INTERVENTION|No-Diet-CD|Usual diet with no intervention
62254518|NCT03850600|NO_INTERVENTION|No-Diet-Control|Unaffected controls at the same gestational stage will follow usual diet and no intervention
62254519|NCT03134742||Control Group|Subjects will not have any additional scans only those that are standard of care. Their data will be used for comparison
62254520|NCT03134742||CT Scan only|Three CT Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment.
62254521|NCT03134742||DEXA Scans only|Three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment
62254522|NCT03134742||CT and DEXA Scans|Three CT Scans and three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment
62254523|NCT04358263|EXPERIMENTAL|rtCGM|Patients with use of the Guardian Connect Mobile system (real-time continuous glucose monitoring).
62254524|NCT04358263|EXPERIMENTAL|isCGM|Patients with use of the FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring).
62254525|NCT03754140|EXPERIMENTAL|Polidocanol Injection|Polidocanol (3%) 0.1ml intralesional injection per 10mm diameter lesion
62254526|NCT00527436|OTHER|Dietary Supplement|Fish oil pill
62254527|NCT00527436|PLACEBO_COMPARATOR|Placebo|Placebo matched corn oil pill
62254528|NCT03422562|ACTIVE_COMPARATOR|Probiotic|Florababy probiotic (0.5g per day) will be started at or after 72 hours of life and will be administered in 1ml sterile water prior to feed.
62053494|NCT06423040|NO_INTERVENTION|Control|
62053495|NCT06423040|EXPERIMENTAL|Experiment|
62053496|NCT03945838||Breast cancer related lymphedema|All patients were included in the complete decongestive therapy programme. This therapy includes patient education, skin care, exercises, manual lymphatic drainage (self), and compression bandage therapy.
62053497|NCT03888664|EXPERIMENTAL|FRDA patients treated with gIFN|1st 2 weeks: gIFN 100 ugr/three times a week From the 3rd week: gIFN 200 ugr three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks
62053498|NCT01122381|EXPERIMENTAL|Arm 1-ethosuximide|"ethosuximide blinded capsules of 250mg ESX; titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed 30mg/kg/d) vs maximum tolerability"
62053499|NCT01122381|PLACEBO_COMPARATOR|Arm 2-placebo comparator|"placebo same size blinded capsules as the 250mg ESX; similar titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed 30mg/kg/d) vs maximum tolerability"
62053500|NCT02681302|EXPERIMENTAL|All Participants|"* Ipilimumab 1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22~* Nivolumab 3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26"
62053501|NCT05545982|EXPERIMENTAL|Intubation with Miller approach|"Posttest group: Patient receive intubation with conventional video laryngoscope with Miller approach.~Pretest group: Patient receive intubation with conventional video laryngoscope with Macintosh approach."
62053502|NCT00810836|ACTIVE_COMPARATOR|1|BG00012 480 mg/day
62053503|NCT00810836|ACTIVE_COMPARATOR|2|BG00012 720 mg/day
62053504|NCT00810836|PLACEBO_COMPARATOR|3|
62053505|NCT05957926|EXPERIMENTAL|Hyaluronic acid + Hydroxyapatite|hyaluronic acid is used for bone regeneration and it has a good potential for osteogenesis and mineralization so it can have synergistic effect when used with hydroxyapatite for bone regeneration after cyst enucleation
62053506|NCT05957926|ACTIVE_COMPARATOR|Hydroxyapatite alone|Hydroxyapatite is inorganic component of bone tissue used as bone graft, scaffolds, filler and cement for repair and regeneration of bone defect , and it stimulates bone remodeling by generating surface active moieties or cell signaling process
62053507|NCT04309084|EXPERIMENTAL|Phase I|Up to three dosing cohorts of CYNK-001 given on Day 2 or Days 2, 7, 14 post ASCT. Once MTD has been determined, the Expansion cohort will commence.
62053508|NCT01622010|EXPERIMENTAL|Standard care with video enhancement|"Receive standard care of an invitation to attend an Allied Health Education Class. May be referred to physiotherapy from Heart Failure Clinic at Physician request per standard clinic protocol. In addition are provided a copy of Keeping the Beat with Physiotherapy: Heart Failure edition education DVD related to heart failure, exercise and self management."
62053509|NCT01622010|ACTIVE_COMPARATOR|Standard care|Receive standard care of an invitation to attend an Allied Health Education Class. May be referred to physiotherapy from Heart Failure Clinic at Physician request per standard clinic protocol.
62254529|NCT03422562|NO_INTERVENTION|Control|Standard of care arm
62254530|NCT05414981|ACTIVE_COMPARATOR|ABI-H3733|
62053510|NCT01083654|ACTIVE_COMPARATOR|Standard Treatment Counseling|Standard Treatment (ST) will consist of 12 weeks of open-label varenicline and smoking cessation counseling consisting of four sessions: one in-person pre-quit counseling session during Study Visit 2, counseling during a phone call on the day after the quit day, and two additional in-person counseling sessions at Study Visits 3 and 4 (one week and three weeks after the quit day, respectively).
62254531|NCT05414981|PLACEBO_COMPARATOR|Placebo|
62254532|NCT00003440|EXPERIMENTAL|Arm A (paclitaxel)|Patients receive paclitaxel intravenously (IV) over 3 hours every 3 weeks.
62254533|NCT00003440|ACTIVE_COMPARATOR|Arm B (paclitaxel)|Patients receive paclitaxel IV over 1 hour weekly.
62254534|NCT00003440|EXPERIMENTAL|Arm C (paclitaxel, trastuzumab)|Patients receive paclitaxel as in Arm I. Patients also receive trastuzumab IV weekly.
62254535|NCT00003440|ACTIVE_COMPARATOR|Arm D (paclitaxel, trastuzumab)|Patients receive paclitaxel as in Arm II and trastuzumab as in Arm III.
62254536|NCT00003440|EXPERIMENTAL|Am E (paclitaxel, trastuzumab)|Patients receive paclitaxel and trastuzumab as in Arm C.
62254537|NCT00003440|ACTIVE_COMPARATOR|Arm F (paclitaxel, trastuzumab)|Patients receive paclitaxel and trastuzumab as in Arm D.
62443152|NCT05768828||Controls|Patients free of headaches or not suffering from headaches with a frequency that exceeds 1x/year
62443153|NCT01768962|ACTIVE_COMPARATOR|Sequence A|2 weeks, 6 week washout, 2 weeks
62443154|NCT01768962|ACTIVE_COMPARATOR|Sequence B|2 weeks, 6 week washout, 2 weeks
62443155|NCT00711503|PLACEBO_COMPARATOR|2|The patients are instructed to administer placebo by subcutaneous injection
62443156|NCT00711503|EXPERIMENTAL|1|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) \[13\] at a dose of 100 mg once daily by subcutaneous injection
62443157|NCT05720533|EXPERIMENTAL|Disitamab Vedotin Combined With Sintilimab|Treatment regimen is Disitamab vedotin 2.5mg/kg and Sintilimab 200mg every 21 days, until disease progression or intolerable adverse reactions or death.
62443158|NCT05517850|ACTIVE_COMPARATOR|Therapist-guided|12 weeks of therapist-guided, exposure-based intervention via tha internet, with comprehensive material
62443159|NCT05517850|EXPERIMENTAL|Self-guided|12 weeks of self-guided, exposure-based intervention via the internet, with shortened and improved material
62443160|NCT01562795|EXPERIMENTAL|group 1|
62443161|NCT01562795|EXPERIMENTAL|group 2|
62443162|NCT01562795|EXPERIMENTAL|group 3|
62443163|NCT01562795|OTHER|group 4|
62254538|NCT03361150|EXPERIMENTAL|HIT|Preoperative nutrition, relaxation strategies + high intensity interval training (HIT). HIT alternates a series of high-intensity bouts with relief period. This will be a personalized, 3 times per week, 40-min exercise. Protein supplement will be prescribed if needed to achieve a daily intake of 1.5 g protein/kg.
62254539|NCT03361150|ACTIVE_COMPARATOR|MCT|Preoperative nutrition, relaxation strategies + high intensity interval training (MCT). MCT is continuous exercise with a constant intensity below anaerobic threshold. This will be a personalized, 3 times per week, 40-min exercise. Protein supplement will be prescribed if needed to achieve a daily intake of 1.5 g protein/kg.
62254540|NCT02988180|OTHER|intervention group|Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
62254541|NCT02988180|OTHER|control group|The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
62254542|NCT04186975||Low-risk pregnant women|Normal cohort: this cohort consists of pregnancies which are not at risk. Data are recorded during the normal checkup happening as part of the usual care pathway
62254543|NCT04186975||High-risk pregnant women|Risk cohort: this cohort consists of pregnancies at risk and which are regularly recorded for the purpose of fetal surveillance. Specifically, the investigators recruit pregnancies with intra uterine growth restricted fetuses for this study.
62443164|NCT01195571|NO_INTERVENTION|vaccine administration|Each subject will receive on of four chimera CMV vaccines
62443165|NCT05452577|EXPERIMENTAL|Chinese medicine group|"Participants received Suanzaoren Decoction and Huanglian Wendan Decoction orally twice daily for 4 weeks.~Subjects who had previously taken Western medicine hypnotics continued to take them, and those who did not take them did not add Western medicine hypnotics."
62836651|NCT01279148||Biopsy/Ablation - STUDY GROUP:|"The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. The physician will then be un-blinded and shown the PercuNav screen and will correct the desired approach path and another screen capture will be taken. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded. At the end of the procedure, and if clinically indicated, a verification CT computed tomography scan will be taken with the needle in place and, sent to the PercuNav. Radiation dosage, due to CT imaging, will also be recorded."
62836652|NCT04625504|EXPERIMENTAL|Mindfulness Based Intervention (MBI)|Patients Active Intervention group
62254544|NCT02559297|ACTIVE_COMPARATOR|Sevoflurane|In sevoflurane arm (n=20) at the beginning after successful intubation, 2 L/min nitric oxide (N2O), 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O.
62254545|NCT02559297|EXPERIMENTAL|Desflurane|In desflurane arm (n=20) at the beginning after successful intubation, 2 L/min N2O, 2 L/min O2, and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 MAC of desflurane in 50% O2 and 50% N2O.
62254546|NCT00277186|ACTIVE_COMPARATOR|Intervention|Patients entering new care continuum
62254547|NCT00277186|ACTIVE_COMPARATOR|Control|Patient enter existing conventional approach
62254548|NCT00665873|ACTIVE_COMPARATOR|A|Antibiotics
62254549|NCT00665873|ACTIVE_COMPARATOR|B|No Antibiotics
62254550|NCT02039804|EXPERIMENTAL|Hyaluronic acid|Injectable hyaluronic acid.
62254551|NCT02039804|ACTIVE_COMPARATOR|Corticosteroids|Injectable corticosteroids.
62254552|NCT06389981|EXPERIMENTAL|Peer led intervention|The peer-led program will be pilot tested enrolling 40 self-identified lung cancer screening eligible Black Veterans.
62254553|NCT06293248|NO_INTERVENTION|Control group|Patients in this group received routine care and no music application was performed.
62443166|NCT05452577|ACTIVE_COMPARATOR|Western medicine group|Participants received Estazolam 1mg tablet orally once daily for 4 weeks.
62443167|NCT03432000|EXPERIMENTAL|subjects with schizophrenia|Performances on temporal task Subjective alterations of time perception in patients with an adapted scale (EAWE) Global symptomatology with PANSS (positive and negative symptom scale)
62443168|NCT03432000|SHAM_COMPARATOR|healthy subjects|Evaluate the links (correlation) between perception of temporal sequencing and perception of causality using an adapted experimental paradigm (Michotte paradigm) and to compare performance between healthy subjects and controls Investigate the existence of a correlation between these alterations and the peculiarities of the subjective experience of time (EAWE scale) in the group of subjects with schizophrenia
62443169|NCT00208390|OTHER|Summit Tapered Hip System|A cementless, tapered femoral component for use in total hip replacement
62443170|NCT05522010|ACTIVE_COMPARATOR|Group (1) (ACDF)|All patients on this group will undergo Anterior Cervical Discectomy And Fusion
62443171|NCT05522010|ACTIVE_COMPARATOR|Group (2) (DCI)|All patients on this group will undergo Dynamic Cervical Implant
62443172|NCT01162590|EXPERIMENTAL|Rotarix Group|Subjects will receive Rotarix™.
62443173|NCT01162590|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive placebo.
62443174|NCT00614159||GI Endoscopy|
62836653|NCT04625504|NO_INTERVENTION|Wait-list Control (WL)|Patients Control receiving no treatment
62836654|NCT04625504|NO_INTERVENTION|Healthy Control (HC)|Healthy Control receiving no treatment
62836655|NCT02494323|EXPERIMENTAL|Functional Electrical Stimulation|Dual channel stimulation of the peroneal nerve to improve dropfoot
62612549|NCT03743402|EXPERIMENTAL|Pain self-management|"This intervention will have 4 components:~1. telephone-delivered evidence-based pain self-management training,~2. web-based video of successfully tapered patients with motivational interviewing debriefing,~3. a voluntary, self-paced opioid taper~4. opioid and non-opioid prescribing guidance for the patient's primary care provider."
62836656|NCT02346162|EXPERIMENTAL|Intervention|Weight management intervention
62836657|NCT02346162|OTHER|Usual Care Control|Usual Care for planning healthy pregnancy
62836658|NCT03356041|ACTIVE_COMPARATOR|Intervention Group|The intervention group will receive the three months' lifestyle modification program by a clinical pharmacist.
62836659|NCT03356041|NO_INTERVENTION|Usual care Group|The usual care group will be provided the standard medical services
62836660|NCT05361707|EXPERIMENTAL|Tasimelteon|Drug: Tasimelteon
62836661|NCT00214890|ACTIVE_COMPARATOR|Tenofovir|As part of this study visit, you participants will be assigned by chance to receive either TDF alone or ABC alone
62443175|NCT06527716|NO_INTERVENTION|Traditional media|A PDF link to the pressure injury prevention course will be placed on the Nursing Information System (NIS) login interface, allowing nurses to view or download it at their convenience. A digital learning platform is also provided for downloading the self-study course materials.
62836662|NCT00214890|ACTIVE_COMPARATOR|Abacavir|As part of this study visit, you participants will be assigned by chance to receive either TDF alone or ABC alone
62836663|NCT04764422|PLACEBO_COMPARATOR|Placebo|0.9% Normal Saline for injection
62836664|NCT04764422|ACTIVE_COMPARATOR|NDV-HXP-S 1 µg|35 subjects age 18-59 will receive NDV-HXP-S 1 µg study vacine administered 0.5 mL IM
62836665|NCT04764422|ACTIVE_COMPARATOR|NDV-HXP-S 3 µg|35 subjects age 18-59 will receive NDV-HXP-S 3 µg study vacine administered 0.5 mL IM
62443176|NCT06527716|EXPERIMENTAL|Digital multimedia combined with practical courses|Join LINE@, which provides multimedia teaching materials and clinical scenario-based learning on a digital platform. The course includes basic knowledge learning, quizzes, and unit reviews, accessible anytime and anywhere. The digital platform continuously prompts pressure injury-related care questions and key points to stimulate learning motivation, encouraging discussion and brainstorming in the platform's discussion area.
62836666|NCT04764422|ACTIVE_COMPARATOR|NDV-HXP-S 10 µg|35 subjects age 18-59 will receive NDV-HXP-S 10 µg study vacine administered 0.5 mL IM
62836667|NCT04764422|ACTIVE_COMPARATOR|NDV-HXP-S 1 µg + CpG1018 1.5 mg|35 subjects age 18-59 will receive NDV-HXP-S 1 µg + CpG1018 1.5 mg study vacine administered 0.5 mL IM
62836668|NCT04764422|ACTIVE_COMPARATOR|NDV-HXP-S 3 µg + CpG1018 1.5 mg|35 subjects age 18-59 will receive NDV-HXP-S 3 µg + CpG1018 1.5 mg study vacine administered 0.5 mL IM
62836669|NCT06410196|ACTIVE_COMPARATOR|Positive mood modulation|Use of happy/positive autobiographical memories which are vivid, emotionally pleasurable and not drug-related, as assessed by individual interview and ratings
62836670|NCT06410196|SHAM_COMPARATOR|Neutral mood modulation|Use of neutral/procedural autobiographical memories which are vivid, emotionally neutral and not drug-related, as assessed by individual interview and ratings
62836671|NCT05569278|EXPERIMENTAL|GEH200486 Cohort 1|Participants will receive 0.05 mmol/kg of GE200486 0.5 M injection
62836672|NCT05569278|EXPERIMENTAL|GEH200486 Cohort 2|Participants will receive 0.1 mmol/kg of GE200486 0.5 M injection
62836673|NCT05569278|EXPERIMENTAL|GEH200486 Cohort 3|Participants will receive 0.2 mmol/kg of GE200486 0.5 M injection
62836674|NCT05569278|EXPERIMENTAL|GEH200486 Cohort 4|Participants will receive 0.3 mmol/kg of GE200486 0.5 M injection
62254554|NCT06293248|EXPERIMENTAL|Experimental group|"The patient information form, vital signs registration form, and state-trait anxiety scale were administered to the patients in the music group while they were in the ward before being sent to the CAG laboratory. Afterward, Rast, Acemasiran, and Huseyni music from Classical Turkish Music modes were optionally offered to the patients, and before the CAG procedure (while the patient was waiting for the procedure in the CAG laboratory), the music preferred by the patients was played with headphones for 15-20 minutes in order not to disturb other patients. After CAG, 15 minutes after the patient arrived at the service, he listened to music for 15-20 minutes. Then, the vital signs registration form, state-trait anxiety scale, Perianesthesia Comfort Scale-PCS and Patient Satisfaction Survey on Nursing Care Quality (PSSNCQ) were applied."
62254555|NCT01771055|EXPERIMENTAL|Galactose|Galactose
62254556|NCT01771055|PLACEBO_COMPARATOR|Standard resuscitation|Standard surgical methods of controlling bleeding
62254557|NCT01520311|OTHER|SVG + eSVS Mesh vs Control SVG|Either the Circumflex Coronary Artery or the Right Coronary Artery will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
62254558|NCT02466867|EXPERIMENTAL|Naftin® Cream, 2% (younger pediatric cohort)|Subject aged 2 years to 5 years, 11 months with tinea corporis
62254559|NCT02466867|EXPERIMENTAL|Naftin® Cream, 2% (older pediatric cohort)|Subject aged 6 years to 11 years, 11 months with tinea corporis
62254560|NCT01523496|ACTIVE_COMPARATOR|HIV + Young Adults|All will be HIV+ and receiving randomized dose of vitamin D control dose (low dose) or supplementation dose (vitamin D medium dose or vitamin D high dose)
62254561|NCT01523496|ACTIVE_COMPARATOR|HIV - Controls|HIV negative controls will be receiving randomized Vitamin D doses: control vitamin D dose (low dose) or vitamin D supplementation dose (vitamin D medium dose or vitamin D high dose)
62254562|NCT00750698|EXPERIMENTAL|Erlotinib-responsive|"Participants self-administered entinostat in combination with continued erlotinib self-administration.~Erlotinib-responsive participants are those who progressed following either a complete or partial response to erlotinib or a period of stable disease lasting at least 3 months."
62254563|NCT00750698|EXPERIMENTAL|Erlotinib-nonresponsive|"Participants self-administered entinostat in combination with continued erlotinib self-administration.~Erlotinib-nonresponsive participants are those who either progressed immediately during treatment with erlotinib (after at least 1 full cycle of erlotinib treatment) or had an objective response or period of stable disease lasting less than 3 months."
62254564|NCT01056510|EXPERIMENTAL|A|
62254565|NCT01056510|EXPERIMENTAL|B|
62836675|NCT05524597|EXPERIMENTAL|Writing about Experiences|Participants will be asked to write about experiences with familiar individuals in their lives.
62254566|NCT04416555|PLACEBO_COMPARATOR|VR googles using exposure sham program|The study groups will receive VR googles and the sham program
62836676|NCT05524597|PLACEBO_COMPARATOR|Writing about Places|Participants will be asked to write about experiences with familiar places in their lives.
62836677|NCT02874989|EXPERIMENTAL|Dasatinib + Quercetin|
62836678|NCT02874989|PLACEBO_COMPARATOR|Placebo|
62836679|NCT06517693|EXPERIMENTAL|Cohort 1 Stratum Formula Fed (FF)|Single subcutaneous (SC) dose of PGT121.414.LS at birth, based on weight.
62836680|NCT06517693|EXPERIMENTAL|Cohort 1 Stratum Breastfed (BF)|Initial SC dose of PGT121.414.LS at birth, based on weight. Second SC dose of 100 mg PGT121.414.LS at Week 12, if still breastfeeding. Dosing at Week 12 is not based on weight.
62836681|NCT06517693|EXPERIMENTAL|Cohort 2 Stratum FF|Single SC doses of PGT121.414.LS and VRC07-523LS at birth, based on weight.
62053511|NCT01083654|EXPERIMENTAL|Culturally-Tailored Treatment|The Culturally-Tailored Treatment will consist of 12 weeks of open-label varenicline and culturally-tailored (for American Indians) smoking cessation counseling consisting of four sessions: one in-person pre-quit counseling session during Study Visit 2, counseling during a phone call on the day after the quit day, and two additional in-person counseling sessions at Study Visits 3 and 4 (one week and three weeks after the quit day, respectively).
62053512|NCT05100043||Cases|Patients having multiple recurrent and recalcitrant cutaneous and genital warts
62053513|NCT05100043||Controls|Healthy volunteers matched for age and sex
62053514|NCT04692792|PLACEBO_COMPARATOR|Placebo drink|
62053515|NCT04692792|EXPERIMENTAL|Dai Dai flower drink|
62053516|NCT06496217|EXPERIMENTAL|Single 900 µg dose of MBX 2109|A single, 900 µg dose of MBX 2109 will be administered subcutaneously in the abdomen
62053517|NCT00153998|ACTIVE_COMPARATOR|1|Cetuximab and FOLFIRI
62053518|NCT00153998|ACTIVE_COMPARATOR|2|Cetuximab and FOLFOX
62053519|NCT01067209||Diabetic/Obese Gastric bypass patients|Subjects with obesity including those with known diabetes or those with a high likelihood of diabetes who will undergo gastric bypass surgery.
62053520|NCT03917004|EXPERIMENTAL|hypotension group (group H )|particcipants in hypotension group are received controlled hypertension in the operation.
62053521|NCT03917004|NO_INTERVENTION|control group (group C )|participants in cotrol group are received no controlled hypertension in the operation
62254567|NCT04416555|ACTIVE_COMPARATOR|VR googles and the real VR program experience.|The study group will receive the VR googles and the real VR program experience.
62836682|NCT06517693|EXPERIMENTAL|Cohort 2 Stratum BF|Initial SC doses of PGT121.414.LS and VRC07-523LS at birth, based on weight. Second SC doses of 100 mg of PGT121.414.LS and 100 mg VRC07-523LS at Week 12, if still breastfeeding. Dosing at Week 12 is not based on weight.
62836683|NCT01623453||Low dose group|Group1. Low dose group
62254568|NCT03804736|ACTIVE_COMPARATOR|FMT-c|Patients in this arm received FMT-c (15 capsules every 12 h for 2 days)
62254569|NCT03804736|EXPERIMENTAL|FMT-c lactobacillus|Patients in this arm received FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
62612550|NCT03743402|ACTIVE_COMPARATOR|usual care|Patients randomized to usual care will continue to receive care as usual from their Kaiser primary care provider.
62836684|NCT01623453||High dose group|Group2. High dose group
62836685|NCT00478023|ACTIVE_COMPARATOR|Morphine|
62836686|NCT00478023|EXPERIMENTAL|Tapentadol 50 mg immediate release|
62836687|NCT00478023|EXPERIMENTAL|Tapentadol 75 mg immediate release|
62836688|NCT00478023|EXPERIMENTAL|Tapentadol 100 mg immediate release|
62836689|NCT00478023|PLACEBO_COMPARATOR|Matched placebo|
62836690|NCT00396253|EXPERIMENTAL|Tenecteplase|At each treatment, subjects had 2 mL (2 mg) of tenecteplase instilled into each lumen of their HD catheter. Subjects could receive up to three treatments with tenecteplase, the first two as part of the initial treatment course and one additional treatment as part of the retreatment (RT) course. The first treatment, followed by a 1-hour dwell time, was given to all subjects at Visit 1. At the end of hemodialysis at Visit 1, eligible subjects had a second treatment instilled for an extended dwell time until the start of Visit 2 (up to 72 hours).
62836691|NCT01054885|EXPERIMENTAL|Fluticasone Furoate Inhalation Powder|Inhaled Corticosteroid (ICS)
62836692|NCT01054885|EXPERIMENTAL|FF Inhalation Pwdr|Inhaled Corticosteroid (ICS)
62836693|NCT01054885|EXPERIMENTAL|Fluticasone Furoate/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
62836694|NCT01054885|EXPERIMENTAL|FF/GW642444 Inhalation Pwdr|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
62836695|NCT01054885|EXPERIMENTAL|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
62836696|NCT01054885|PLACEBO_COMPARATOR|Placebo|Placebo
62836697|NCT02784899|EXPERIMENTAL|iloprost group|iloprost inhalation group
62836698|NCT02784899|PLACEBO_COMPARATOR|control group|normal saline inhalation group
62836699|NCT03873792|OTHER|Allergy pregnant women|
62836700|NCT03873792|OTHER|Health pregnant women|
62836701|NCT04857320|EXPERIMENTAL|Main Experimental|Each subject will receive doses applied to the skin of 0.075 IUs / Kilogram Body Weight, 0.1 IUs/Kilogram Body Weight and 0.15 IUs /Kilogram Body Weight
62836702|NCT05914337|EXPERIMENTAL|Rheumatoid Arthritis Group|30 patients aged 18-60 years who met the 2010 American College of Rheumatology / European League Against Rheumatism Rheumatoid arthritis criteria were included in the study. A program consisting of strengthening and stretching exercises 2 days a week was applied to the study group for 8 weeks. One day a week, 30 minutes of mild moderate walking was requested. 30 healthy controls aged 18-60 years who included in the study. Of the cases at the beginning and at the end of the treatment; 5-10 cc peripheral blood samples were taken into one Ethylenediaminetetraacetic acid tube. Then Numeric Rating Scale (NRS) was used for pain, 28-joint Disease Activity Score (DAS28) was used to calculate disease activity, Health Assessment Questionnaire (HAQ) was used to assess general health and Short Form-36 (SF-36) was used to evaluate quality of life. In the samples taken, gene expressions of miRNA-146a, miRNA-155, miRNA-16, miRNA-145 were determined by real-time polymerase chain reaction method.
62836703|NCT02939443|OTHER|cross-sectional study|
62836704|NCT06316050|ACTIVE_COMPARATOR|humeral retroversion 0º|will be carried out with patients operated with reverse shoulder arthroplasty (at 0º and 30º of humeral retroversion) included consecutively in Terrassa Hospital
62836705|NCT06316050|NO_INTERVENTION|humeral retroversion 30º|will be carried out with patients operated with reverse shoulder arthroplasty (at 0º and 30º of humeral retroversion) included consecutively in Terrassa Hospital
62836706|NCT03487432|EXPERIMENTAL|OPN NC|Patients receiving a Super High-Pressure NC PTCA Balloon (OPN NC)
62836707|NCT03487432|EXPERIMENTAL|NSE Alpha|Patients receiving a Scoring PTCA Balloon (NSE Alpha)
62836708|NCT01405144|ACTIVE_COMPARATOR|5% 5-fluoruracil cream|30 patients will use 5% 5-fluoruracil cream, twice a day, during 3 weeks, in one randomized forearm
62836709|NCT01405144|ACTIVE_COMPARATOR|5% 5-fluoruracil peeling|The same 30 patients will be submitted to 4 applications of 5% 5-fluoruracil superficial peeling in the other forearm
62836710|NCT04496583|ACTIVE_COMPARATOR|Fluid Balance Depletive Strategy Group|Patients with fluid overload under a depletive strategy to attain a predetermined negative balance
62836711|NCT04496583|EXPERIMENTAL|Preload Responsiveness Depletive Strategy Group|Patients with fluid overload under a depletive strategy to attain a state of preload responsiveness
62836712|NCT06071689|ACTIVE_COMPARATOR|PEEK group|patients receive all-on-4 prostheses constructed from CAD/CAM milled PEEK framework.
62836713|NCT06071689|ACTIVE_COMPARATOR|Soft metal group|patients receive all-on-4 prostheses constructed from CAD/CAM milled soft metal framework.
62836714|NCT06071689|ACTIVE_COMPARATOR|selective laser melting group|patients receive all-on-4 prostheses constructed from 3D printed selective laser melting Co-Cr framework.
62836715|NCT06331143|EXPERIMENTAL|Mid-Transverse Process block (MTP) group|Patients will receive mid-transverse process to pleura (MTP) block after induction of anesthesia.
62836716|NCT06331143|EXPERIMENTAL|Intrathecal morphine (IM) group|Patients will receive intrathecal morphine in a dose of 12 μg/kg (max 1000 μg) immediately after induction of anesthesia.
62836717|NCT05836896|EXPERIMENTAL|MDC-CAR-BCMA001|MDC-CAR-BCMA001 will be administered intravenously in ascending dose levels. This trial will test a total of 4 dose levels in order to identify the MTD and/or recommended phase 2 dose for MDC-CAR-BCMA001.
62836718|NCT04904614|OTHER|single arm|Letermovir 480 mg daily for cmv prophylaxis
62836719|NCT05702606|ACTIVE_COMPARATOR|Control Group|3 rESWT sessions with a time interval of 1 week between each session.
62443177|NCT03243279||Surgical|No interventions. Patients undergoing cardiothoracic surgery will be assessed for baroreflex sensitivity and the outcomes of interest.
62254570|NCT00793260|ACTIVE_COMPARATOR|Usual Support Group|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
62254571|NCT00793260|EXPERIMENTAL|Enhanced Support Group|The Enhanced-Support Group intervention used more sophisticated predictive models, more extensive outreach to engage individuals, and provided tighter feedback loops to inform the care support process.
62254572|NCT04269148||Head and Neck Cancer patients|Turkish patients diagnosed with head and neck cancer
62254573|NCT06426251|EXPERIMENTAL|intervention group|This group of patient will receive photobiomodulation pads on the part of surgical site and the machine will emit near-infrared light.
62254574|NCT06426251|SHAM_COMPARATOR|control group|This group of patient will have photobiomodulation pads on the body surface as intervention group, but the machine will not emit near-infrared light.
62443178|NCT01653197|EXPERIMENTAL|Control|"On top of reminder, state: Here's a fun fact to cheer you on your way: and include a curiosity-inducing question and answer (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space? // A: Texas)"
62612551|NCT02086409|EXPERIMENTAL|Yogurt supplemented with vitamin D and calcium|20 participants take yogurt supplemented with vitamin D and calcium during 12 weeks
62612552|NCT02086409|ACTIVE_COMPARATOR|Yogurt not supplemented with vitamin D and calcium|20 participants take yogurt not supplemented with vitamin D and calcium during 12 weeks
62612553|NCT02456961|ACTIVE_COMPARATOR|Standard epithelium-off CXL|Removing the central 8-10mm of the epithelium and applying a riboflavin solution (0.1% riboflavin-5-phosphate and 20% dextran T-500) to the corneal surface 30 minutes before irradiation and at 5 minutes intervals during the course of a 30 minute exposure to 370 nm UVA with an irradiance of 3 mWcm-2 (UFalink, Russian Federation)
62836720|NCT05702606|EXPERIMENTAL|Experimental Group A|3 rESTW sessions with a time interval of 2 weeks between each session.
62254575|NCT00928889|EXPERIMENTAL|Nateglinide 120 mg|Nateglinide was taken orally 3 times daily, 10 minutes before meals for 4 weeks.
62254576|NCT00928889|ACTIVE_COMPARATOR|Acarbose 50 mg|Acarbose 50 mg was taken orally 3 times daily, with the first bite of food at meals for 4 weeks.
62254577|NCT02554747|EXPERIMENTAL|Navigated laser|Aflibercept, Navilas®
62254578|NCT02554747|ACTIVE_COMPARATOR|Conventional laser|Aflibercept, Pascal
62443179|NCT01653197|EXPERIMENTAL|Curiosity|"On top of reminder, state: Here's a fun fact to cheer you on your way. and include a curiosity-inducing question (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space?) Place the answer under a scratch-off patch (A: Texas)."
62443180|NCT01653197|EXPERIMENTAL|Curiosity linked to Action|"On top of reminder, state: Here's a fun fact to cheer you on your way. Reward yourself by scratching off the answer only after you've made your \[colonoscopy/mammogram/etc.\] appointment! and include a curiosity-inducing question (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space?) Place the answer under a scratch-off patch (A: Texas)"
62443181|NCT06224582|EXPERIMENTAL|Yinxingmihuan group|standardized medical treatment regimen plus Yinxingmihuan oral solution (oral, 10 ml once, 3 times a day)
62836721|NCT05702606|EXPERIMENTAL|Experimental Group B|3 rESTW sessions with a time interval of 4 weeks between each session.
62443182|NCT06224582|PLACEBO_COMPARATOR|Placebo group|standardized medical treatment regimen plus Placebo oral solution (oral, 10 ml once, 3 times a day)
62443183|NCT03875183|EXPERIMENTAL|INL1 50mg BID|INL1 50mg dose to be given twice daily using one 50mg capsule and two matching placebo capsules at each dose
62443184|NCT03875183|EXPERIMENTAL|INL1 150 mg BID|INL1 150mg dose to be given twice daily using three 50mg capsules at each dose
62254579|NCT04183816|EXPERIMENTAL|Total cold-water immersion group|"Participants allocated to the TCWI group completed a session of 15-minutes in cold water with a temperature of 12°C. Each Participant was totally immersed in a pool while his/her head and neck remained above water level. The water's temperature was continuously measured by a mercury-in-glass thermometer and maintained at the aforementioned temperature by continuously adding ice blocks.~With respect to depth of immersion, TCWI is more efficient than partial CWI since exposing a larger area of the body is needed for cardiovascular changes to occur (Murray and Cardinale, 2015; Stephens et al., 2016)."
62254580|NCT04183816|ACTIVE_COMPARATOR|Ice massage group|Participants in the IM group were seated. The investigator in charge of this intervention group applied Ice cubes massage in a clockwise circular motion on the thigh area (quadriceps) for 15 minutes.
62254581|NCT06473311|EXPERIMENTAL|whole body vibration|
62254582|NCT06473311|EXPERIMENTAL|virtual reality|
62053522|NCT04152265|OTHER|No Intervention: Current screening practice.|Patients will be asked to complete the Food Frequency Questionnaire (FFQ) and the questionnaire about The World Health Organization Quality Of Life (WHOQOL-BREF), also and will be collected the demographic and anthropometric data
62254583|NCT00161187|EXPERIMENTAL|Treatment|Biological/Vaccine: therapeutic allogeneic lymphocytes The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
62254584|NCT02341638|EXPERIMENTAL|Part A Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
62254585|NCT02341638|EXPERIMENTAL|Part A Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
62254586|NCT02341638|EXPERIMENTAL|Part A Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
62254587|NCT02341638|EXPERIMENTAL|Part A Panel 4: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
62254588|NCT02341638|EXPERIMENTAL|Part A Panel 5: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
62836722|NCT04595747|EXPERIMENTAL|Treatment (rogaratinib)|Patients receive rogaratinib PO BID on days 1-28 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy at baseline and progression and CT, MRI, and PET-CT every 8 weeks. Patients may also undergo blood sample collection on study.
62254589|NCT02341638|EXPERIMENTAL|Part A Panel 6: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
62254590|NCT02341638|EXPERIMENTAL|Part A Panel 7: BMS-986141|Single dose by mouth as specified
62254591|NCT02341638|EXPERIMENTAL|Part A Panel 8: BMS-986141|Single dose by mouth as specified
62254592|NCT02341638|EXPERIMENTAL|Part B Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
62612554|NCT02456961|EXPERIMENTAL|Transepithelial CXL via iontophoresis of riboflavin|"impregnation of the cornea with a riboflavin 0.1% hypotonic solution is performed by using an iontophoresis device (galvanizator; Potok-1, Russian Federation). The passive electrode (anode) was applied to the inferior part of the cervical vertebrae. The active electrode (cathode), a bath tube (glass or plastic - 10-12 ml) is applied to the open eye,then r the tube is taped to the skin of the orbital margins and filled with riboflavin 0.1%. The current intensity is initially 0.2 mA and then gradually increased to 1.0 mA at 0.2 mA for 1 minute at 10-second intervals increments to determine individual tolerance. The total time that the riboflavin administration is 10 minutes.~Standard surface UVA irradiation (370 nm, 3 mW/cm2) using UFalink device, (Russian Federation) is then applied at a 5-cm distance for 30 minutes with continuing hypotonic riboflavin drops every 2 minutes"
62254593|NCT02341638|EXPERIMENTAL|Part B Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
62612555|NCT05825651||Exposure group|Group with history of COVID-19 infections and vaccines, as well as health-related, behavioral, socioeconomic exposures.
62612556|NCT05825651||Non-exposure group|Group without history of COVID-19 infections and vaccines, as well as health-related, behavioral, socioeconomic exposures.
62836723|NCT04202107||Urban|"Men and women between 18 and 49 years of age living in the selected urban communities in Rwanda and who are familiar with the diet.~Participants in this study should be acquainted with cooking practices to be able to cite all the ingredients that are used in the preparation of the dishes/ meals"
62254594|NCT02341638|EXPERIMENTAL|Part B Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
62254595|NCT02341638|EXPERIMENTAL|Part C Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
62254596|NCT02341638|EXPERIMENTAL|Part C Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
62254597|NCT02341638|EXPERIMENTAL|Part C Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
62254598|NCT02341638|EXPERIMENTAL|Part D Panel 1: BMS-986141 and Aspirin|BMS-986141 and Aspirin by mouth as specified
62254599|NCT02341638|PLACEBO_COMPARATOR|Part D Panel 1: Placebo matching BMS-986141 and Aspirin|BMS-986141 placebo and Aspirin by mouth as specified
62254600|NCT02341638|EXPERIMENTAL|Part E Panel 1: BMS-986141 and Itraconazole|BMS-986141 and Itraconazole by mouth as specified
62254601|NCT02802748|EXPERIMENTAL|Metronomic Vinorelbine + Letrozole|"* Oral Vinorelbine: 50 mg (30 mg + 20 mg) three times a week, for 3 weeks~* Letrozole: 2.5mg daily, for 3 weeks"
62254602|NCT02802748|ACTIVE_COMPARATOR|Letrozole alone|Letrozole: 2.5mg daily, for 3 weeks
62254603|NCT02802748|ACTIVE_COMPARATOR|Metronomic Vinorelbine alone|Oral Vinorelbine: 50 mg (30 mg + 20 mg) three times a week, for 3 weeks
62254604|NCT01553136|PLACEBO_COMPARATOR|Sugar pill|
62254605|NCT01553136|ACTIVE_COMPARATOR|Varenicline|
62053523|NCT04152265|EXPERIMENTAL|Experimental: Sequential screening strategy|People aged between 50-65, will take part in the study. Patients, which will take in a screening colonoscopy, will be divided into two groups according to the result obtained. The first group, will be constitute the patients with a positive test result, while the second group (control) will be constitute the patients with the negative test result. In addition, from the Subjects the samples of blood and faeces will be collected.
62254606|NCT05103878|EXPERIMENTAL|BT051 100 mg|Participants will receive a single oral dose of 100mg BT051.
62254607|NCT05103878|EXPERIMENTAL|BT051 300 mg|Participants will receive a single oral dose of 300mg BT051.
62254608|NCT05103878|EXPERIMENTAL|BT051 700 mg|Participants will receive a single oral dose of 700mg BT051.
62254609|NCT05103878|EXPERIMENTAL|BT051 1500 mg|Participants will receive a single oral dose of 1500mg BT051.
62836724|NCT04202107||Rural|"Men and women between 18 and 49 years of age living in the selected urban communities in Rwanda and who are familiar with the diet.~Participants in this study should be acquainted with cooking practices to be able to cite all the ingredients that are used in the preparation of the dishes/ meals"
62836725|NCT04469335|EXPERIMENTAL|mobile neurofeedback|
62836726|NCT04469335|SHAM_COMPARATOR|sham control|
62836727|NCT04469335|EXPERIMENTAL|medication +mobile neurofeedback|
62836728|NCT04469335|SHAM_COMPARATOR|medication + sham control|
62053524|NCT01558310|ACTIVE_COMPARATOR|Group A|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52.The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
62836729|NCT04937218|EXPERIMENTAL|Egg demand creation campaign|Egg demand creation campaign using Above-the-line and Below-the-line methods for 14 months. Above-the-line interventions include television, radio, celebrity ambassadors and out-of-home advertising (e.g., billboards). Below-the-line interventions include interpersonal communication activation, trade promotions, point-of-sale materials, food demonstrations and giveaways and door-to-door activation.
62836730|NCT04937218|NO_INTERVENTION|Comparison|Comparison arm with no campaign
62836731|NCT04424719|OTHER|Patients with uveal melanoma|
62836732|NCT06514768|EXPERIMENTAL|JY231 injection for the treatment of B-cell acute lymphoblastic leukemia( B-ALL )|
62836733|NCT01003769|EXPERIMENTAL|Treatment (lenalidomide in combination with AT-101)|Patients receive lenalidomide PO QD on days 1-21. Beginning in course 2, patients also receive AT-101 PO BID on days 1-3. Treatment repeats every 28 days for up to 11 courses (49-56 days for course 12 or last course of treatment) in the absence of disease progression or unacceptable toxicity.
62836734|NCT02105181|OTHER|Fully covered metal stent (FCMS)|There is one arm in the study : the intervention consists on placing a device which is a fully covered metal stent in the biliary tract of all patients
62053525|NCT01558310|PLACEBO_COMPARATOR|Group B|Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
62053526|NCT03551275|EXPERIMENTAL|Cohort no. 1, BCD-132, 100 mg, IV|"Cohort no. 1, Group #1 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 100 mg.~Cohort no. 1, Group #2 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 50 mg and second dose of 50 mg IV after 14 days period after first infusion.~If there is no DLT within the first 14 days after infusion then Cohort no.2 is included."
62053527|NCT03551275|EXPERIMENTAL|Cohort no. 2, BCD-132, 250 mg, IV|"Cohort no. 2, Group #3 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 250 mg.~Cohort no. 2, Group #4 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 125 mg and second dose of 125 mg IV after 14 days period after first infusion.~If there is no DLT within the first 14 days after infusion then Cohort no.3 is included."
62053528|NCT03551275|EXPERIMENTAL|Cohort no. 3, BCD-132, 500 mg, IV|"Cohort no. 3, Group #5 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 500 mg.~Cohort no. 3, Group #6 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 250 mg and second dose of 250 mg IV after 14 days period after first infusion.~If there is no DLT within the first 14 days after infusion then Cohort no.4 is included."
62053529|NCT03551275|EXPERIMENTAL|Cohort no. 4, BCD-132, 1000 mg, IV|"Cohort no. 4, Group #7 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 1000 mg.~Cohort no. 4, Group #8 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 500 mg and second dose of 500 mg IV after 14 days period after first infusion."
62053530|NCT01383889|OTHER|Treading mill exercise|Pregnant women in this group will perform treadmill exercise during 20 minutes. The intensity of exercise will be maintained between 60% and 80% of maximum heart rate by Karvonen formula, in addition to the subjective perception of exertion on the modified Borg scale (moderate intensity).
62053531|NCT01383889|OTHER|Stationary bicycle exercise|Pregnant women in this group will perform exercise using a stationary bicycle. The intensity of exercise will be maintained between 60% and 80% of maximum heart rate by Karvonen formula, in addition to the subjective perception of exertion on the modified Borg scale (moderate intensity).
62053532|NCT00917163|EXPERIMENTAL|Supralimus(R) Sirolimus Eluting Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
62053533|NCT00917163|ACTIVE_COMPARATOR|Xience V™ Everolimus Eluting Stent|The XIENCE V™ Everolimus Eluting Coronary Stent System consisting of the MULTI-LINK VISION® Coronary Stent System coated with a formulation containing everolimus, the active ingredient, embedded in a non-erodible polymer., Drug Load: 100 µg/cm2
62053534|NCT02417103|ACTIVE_COMPARATOR|GLP-1 (Liraglutide)|Daily subcutaneous injection of Lirglutide over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg
62053535|NCT02417103|PLACEBO_COMPARATOR|Placebo Comparator|Daily subcutaneous injection of PL1/PR1 Placebo over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg
62254610|NCT05103878|EXPERIMENTAL|BT051 3500 mg|Participants will receive a single oral dose of 3500mg BT051.
62254611|NCT05103878|PLACEBO_COMPARATOR|Placebo|Participants will receive a single oral dose of Placebo matching BT051 dose.
62254612|NCT01677156||Receiving Corus CAD (ASGES)|Patients receiving Corus CAD (ASGES) to aid in the diagnosis of obstructive CAD
62254613|NCT04664361|EXPERIMENTAL|NMN 250|NMN tablet (250 mg)
62053536|NCT03975699||Patients in centre 1: Louis-Mourier Hospital|All SCD follow-up consultations were conducted jointly by a paediatrician and a clinical psychologist.
62254614|NCT04664361|EXPERIMENTAL|NMN 500|NMN tablet (500 mg)
62254615|NCT04664361|PLACEBO_COMPARATOR|Placebo|NMN-free placebo tablet.
62254616|NCT01864499|EXPERIMENTAL|Tumor Resection|
62254617|NCT01864499|ACTIVE_COMPARATOR|Biopsy Brain Tumor|
62254618|NCT04137120||Patients_Ocular disease|Adult patients treated for wet age-related macular degeneration (wAMD), or diabetic macular edema (DME), or macular edema secondary to central retinal vein occlusion (CRVO), or macular edema secondary to branch retinal vein occlusion (BRVO) or myopic choroidal neovascularization (mCNV) in routine clinical practice in Mexico (overall cohort)
62612557|NCT00458575|EXPERIMENTAL|CNTO 2476|Participants 1 to 4: advanced retinitis pigmentosa (RP) with light perception only (LP); Participant 5: combination visual acuity of LP in the treated eye and no better than hand motion (HM) in the fellow eye; and Participants 6 to 9: advanced RP with hand motion (HM) will receive different dose levels of CNTO 2476.
62254619|NCT03450291|EXPERIMENTAL|Recovered from anorexia nervosa|Those who have a past diagnosis of AN (defined by the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria) but are currently recovered, as shown by BMI over 18.5 throughout the last 12 months (self-report and current weight measured). Defined as either 'fully recovered'and: score must be within the 'normal range' of the Eating Disorders Examination Questionnaire (EDE-Q) global mean scores for young women, below 20 on the EAT-26 and below 16 on the Clinical Impairment Assessment for Eating Disorders (CIA); or partially recovered where one or more of these scores may be above the above-mentioned cutoffs.
62254620|NCT03450291|EXPERIMENTAL|High scoring on the EAT-26|Those who score above 20 on the EAT-26, but who do not declare a former diagnosis of an eating disorder (though they may meet criteria for a current diagnosis during the Structured Clinical Interview for the DSM-5).
62254621|NCT03450291|EXPERIMENTAL|Healthy controls|No history of or current diagnosis of any psychiatric disorder (especially eating disorders) which could impact study results.
62254622|NCT03913702|ACTIVE_COMPARATOR|Ketorolac|Assigned patients will receive a subacromial injection of ketorolac 60mg (2ml + 8ml lidocaine 1%)
62254623|NCT03913702|ACTIVE_COMPARATOR|Methylprednisolone|Assigned patients will receive a subacromial injection of methylprednisolone 80mg (1ml + 9ml lidocaine 1%)
62612558|NCT04776278|EXPERIMENTAL|Brief Alcohol Intervention (BAI) + Substance Free Activity Session (SFAS)|Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive the Substance-free activity session (SFAS), a 50-minute counseling session designed to increase the salience of the individual's goals, to highlight the connection between their current patterns of behavior (including drinking and substance-free activities) and the attainment of these goals, and to increase future orientation and engagement in enjoyable and goal-directed activities that are inconsistent with substance use (even if the participant has no desire to change their use).
62836735|NCT00543413|EXPERIMENTAL|1|Arm 1: Drug 250 mg
62836736|NCT00543413|EXPERIMENTAL|2|Arm 2: Drug 500 mg
62254624|NCT02386280|EXPERIMENTAL|Motivational Interviewing for Change of Parenting Styles|After measured parental style across the scale, the motivational interviewing will be applied in order to modify the parenting styles of risk for involvement with drug use and maintenance of protective factors. This approach will occur in 5 segments .
62254625|NCT02386280|SHAM_COMPARATOR|Psicoeducation|General information about drugs and ways of prevention
62836737|NCT00543413|ACTIVE_COMPARATOR|3|Arm 3: Active Comparator
62836738|NCT00543413|PLACEBO_COMPARATOR|4|Arm 4: Pbo Comparator
62254626|NCT02490475|EXPERIMENTAL|RhuMab 2C4 + Docetaxel 100 mg/m^2 (Level 3)|Docetaxel will be administered via intravenous (IV) infusion on Day 1 of each 3-week cycle at a dose of 100 mg/m\^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
62053537|NCT03975699||Patients in centre 2: Evry hospital|All SCD follow-up consultations were conducted by a paediatrician alone. The unit had close links with the local psycho-medical paediatric care centre when specialized referrals were necessary.
62053538|NCT03975699||Patients in centre 3: Clamart hospital|All SCD follow-up consultations were conducted by a paediatrician alone.
62053539|NCT04454398|EXPERIMENTAL|COVI-GUARD|COVI-GUARD (STI-1499) administered via a single IV push injection at a dose of 10 mg, 30 mg, 100 mg, or 200 mg, in addition to standard of care
62254627|NCT02490475|EXPERIMENTAL|RhuMab 2C4 + Docetaxel 60 mg/m^2 (Level 1)|Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 60 mg/m\^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
62254628|NCT02490475|EXPERIMENTAL|RhuMab 2C4 + Docetaxel 75 mg/m^2 (Level 2)|Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
62053540|NCT04454398|PLACEBO_COMPARATOR|Placebo|Placebo administered via a single IV push injection, in addition to standard of care
62254629|NCT05125055|EXPERIMENTAL|Neoadjuvant TTP|The participants will receive two cycles of intravenous Albumin paclitaxel (260mg/ m\^2), Cisplatin (75mg/ m\^2) and Toripalimab (anti-PD-1 inhibitor, 240 mg) on d1 and d22.
62254630|NCT05125055|ACTIVE_COMPARATOR|Neoadjuvant TPF|The participants will receive two cycles of intravenous Docetaxel (75 mg/m\^2) on d1 and d22, Cisplatin (75 mg/m\^2) on d1 and d22, and 5-Fluorouracil (750 mg/m\^2/day) for 5 days (d1-5 and d22-26), the interval is 16±1 days.
62254631|NCT06149390||Consoliation with ASCT|consolidation therapy with first-line ASCT in PTCL patients who achieved CR after first-line treatment.
62254632|NCT06149390||non-ASCT|consolidation therapy without first-line ASCT in PTCL patients who achieved CR after first-line treatment.
62836739|NCT04615377|EXPERIMENTAL|Kaia hip and knee pain app|Kaia software application: Kaia Knee and Hip pain app (version 2.37.0) The Kaia Knee and Hip pain app is an investigational device, which is intended as a digital aid for the self-management of osteoarthritis for use by adults (between 22 to 75 years old) without supervision by healthcare professionals in a home setting.
62836740|NCT04615377|ACTIVE_COMPARATOR|Treatment as usual|Participants will be encouraged to continue the treatment that they have been on without restriction
62836741|NCT02390193|EXPERIMENTAL|Hemodialysis|Chronic kidney disease patients undergoing hemodialysis will be recruited consecutively and screened for eligibility using a standardised protocol.
62836742|NCT03714672|EXPERIMENTAL|Tramadol/Diclofenac 50/50|Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
62053541|NCT04773795|EXPERIMENTAL|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
62254633|NCT04577729|EXPERIMENTAL|Allogenic FMT group|Allogenic FMT group: patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.
62836743|NCT03714672|EXPERIMENTAL|Tramadol/Diclofenac 25/25|Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
62836744|NCT03714672|ACTIVE_COMPARATOR|Tramadol 50|Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
62836745|NCT03714672|ACTIVE_COMPARATOR|Diclofenac 50|Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction
62836746|NCT01394003|EXPERIMENTAL|LY2584702|"Oral dose escalation starting at 25 milligrams (mg), daily for 28 day cycles in Part A; oral dose escalation starting at 50 mg, twice daily for 28 day cycles in Part B; oral dose with schedule determined by Parts A and B will be administered in Part C (dose confirmation).~Part A: Participants received 25 mg, 50 mg, 100 mg and 200 mg once daily (QD) and 300 mg twice daily (BID) of LY2584702 capsule, for a 28-day cycle during Part A of the study until the criteria for maximum tolerated dose (MTD) were met.~Part B: Participants received 50 mg, 75 mg and 100 mg LY2584702 orally as a capsule, twice daily (BID) for a 28-day cycle during Part B of the study until the criteria for maximum tolerated dose (MTD) were met."
62836747|NCT04913935||TMC OA|women who were diagnosed with TMC OA
62836748|NCT04913935||Control|healty volunteer women
62053542|NCT04654988|EXPERIMENTAL|Immunosuppression|Prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months and Azathioprine: 2 mg/kg daily for 12 months
62053543|NCT04654988|PLACEBO_COMPARATOR|Placebo|placebo matching prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months and placebo matching azathioprine: 2 mg/kg daily for 12 months
62053544|NCT05100264|EXPERIMENTAL|Vaginal washing 5% acetic acid|
62053545|NCT05100264|PLACEBO_COMPARATOR|Vaginal washing 0.9% N/S|
62053546|NCT02091479|EXPERIMENTAL|UFH Early group|anticoagulant (UFH or LMWH) reintroduction at 48h to 72h after hemorrhage
62254634|NCT04577729|PLACEBO_COMPARATOR|Autologous FMT group|Autologous FMT group: patients receiving their own stool in terms of sham FMT.
62443185|NCT03875183|EXPERIMENTAL|INL1 300 mg BID|INL1 300mg dose to be given twice daily using three 100mg capsules at each dose
62443186|NCT03875183|PLACEBO_COMPARATOR|Placebo|Placebo dose to be given twice daily using 3 placebo capsules at each dose
62443187|NCT06287697||Longitudinal study-Thailand|"Cohort 1: 60 children were started at 6-8 months old, and were followed-up at 9-11, 12-14 and 15-17 months old.~Cohort 2: 71 children were started at 12-14 months old, were followed-up 15-17, 18-21 and 21-24 months old."
62254635|NCT06189495|EXPERIMENTAL|GenSci048|1. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of Genakumab injection every 4 weeks according to their group.The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with Genakumab injection until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive Genakumab injection 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel
62443188|NCT06287697||Cross-sectional study-Pakistan|Children aged 6-8, 9-11, 12-14, 15-17, 18-20, 21-23 months, both sexes.
62443189|NCT06287697||Cross-sectional study-Philippines|Children aged 6-8, 9-11, 12-14, 15-17, 18-20, 21-23 months, both sexes.
62443190|NCT06287697||Cross-sectional study-Sri Lanka|Children aged 6-8, 9-11, 12-14, 15-17, 18-20, 21-23 months, both sexes.
62443191|NCT06287697||Cross-sectional study-Vietnam|Children aged 6-8, 9-11, 12-14, 15-17, 18-20, 21-23 months, both sexes.
62443192|NCT05713877|EXPERIMENTAL|Enteral melatonin 9 mg|Melatonin 9 mg from a 1 mg/mL oral suspension of melatonin in ORA-BLEND SF® (sugar-free flavoured suspending vehicle). Final volume in the oral syringe will be 9 mL.
62443193|NCT05713877|PLACEBO_COMPARATOR|Enteral placebo|ORA-BLEND SF® (sugar-free flavoured suspending vehicle). Final volume in the oral syringe will be 9 mL.
62443194|NCT03820154|ACTIVE_COMPARATOR|Skin Prick Test TAPE|"The Skin Prick Test Tape is an innovative sterile all-in drug carrying 8 allergens and 2 control solutions including prick needles in one Tape for easy use and standardization. Single use. Reading of wheal reactions after 15 minutes, facilitated by stripes with the allergen names."
62443195|NCT03820154|ACTIVE_COMPARATOR|Skin Prick Test|The conventional SPT is the world-wide standard in allergy Type 1 diagnosis for inhalant and food allergens. Drops of allergens are applied to the forearm and, with the help of a lancet, brought into the skin. Reading of wheal reactions after 15 minutes.
62443196|NCT02161952|EXPERIMENTAL|Pirfenidone|Pirfenidone 400 mg capsules, orally administered thrice daily to yield a daily dose of 1200 mg during two years.
62443197|NCT02161952|PLACEBO_COMPARATOR|Matched equivalent placebo|Matched equivalent placebo
62443198|NCT05653791||Filgotinib treated patients|
62443199|NCT06230471|EXPERIMENTAL|Pembrolizumab,Lenvatinib and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）|Drug：Pembrolizumab Pembrolizumab 200 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle. Drug: Lenvatinib Oral Product The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of \<60 kg, taken once daily. Drug: Chemotherapy GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks
62443200|NCT06230471|EXPERIMENTAL|Pembrolizumab and Lenvatinib|Drug：Pembrolizumab Pembrolizumab 200 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle. Drug: Lenvatinib Oral Product The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of \<60 kg, taken once daily.
62443201|NCT06230471|ACTIVE_COMPARATOR|Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）|Drug：Pembrolizumab Pembrolizumab 200 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle. Drug: GEMOX Chemotherapy GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks
62443202|NCT03776032|EXPERIMENTAL|Darbepoetin alfa|Participants received once a week darbepoetin alfa, administered by subcutaneous injection at a starting dose of 2.25 µg/kg for up to 12 weeks. The dose of darbepoetin alfa may have been adjusted based on hemoglobin levels to a maximum dose of 4.5 µg/kg /week.
62053547|NCT02091479|ACTIVE_COMPARATOR|UFH Late group|anticoagulant (UFH or LMWH) réintroduction 120h to 144h after hemorrhage
62053548|NCT04436666|EXPERIMENTAL|Ice Application|Music-funded, park, nature and seaside walks, submarine, museum, with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel display resolution, China) for 10 minutes to diabetic patients before blood glucose measurement and insulin injection The videos that the patient wants to watch will be watched from videos such as his trip Studies have indicated that these videos are relaxing environments, and motion videos should not be watched to reduce nausea and vomiting.
62053549|NCT04436666|EXPERIMENTAL|Virtual Reality|Before the blood glucose measurement and insulin injection, patients with diabetes will be given ice for 5 minutes. It is planned to apply ice cubes in liquid-proof ice bags.
62053550|NCT04436666|NO_INTERVENTION|control|No Intervention
62254636|NCT06189495|PLACEBO_COMPARATOR|GenSci048 placebo|".1. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of placebo every 4 weeks according to their group The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with placebo until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive placebo 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).~4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel)"
62254637|NCT02470468|EXPERIMENTAL|DCVAC add on to SOC|Combination therapy with DCVAC and Standard of Care (Carboplatin, Paclitaxel)
62443203|NCT03776032|PLACEBO_COMPARATOR|Placebo|Participants received once a week placebo, administered by subcutaneous injection for up to 12 weeks.
62836749|NCT05185661|EXPERIMENTAL|Intervention Group|"1. Two surveys: Demographic, lifestyle, hygiene-related (1) \& knowledge, attitude, and practice (2) regarding anemia at baseline and end line of study.~2. Investigations and physical examination will perform for CBC blood test except ESR, urine R/E, stool R/E, Height, weight for BMI, waist circumference, hip circumference, hip - waist ratio, and mid-upper arm circumference (MUAC) at baseline, mid-line, and end-line of study."
62836750|NCT05185661|NO_INTERVENTION|Control Group|"1. Two surveys: Demographic, lifestyle, hygiene-related (1) \& knowledge, attitude, and practice (2) regarding anemia at baseline and end line of study.~2. Investigations and physical examination will perform for CBC blood test except ESR, urine R/E, stool R/E, Height, weight for BMI, waist circumference, hip circumference, hip - waist ratio, and mid-upper arm circumference (MUAC) at baseline, mid-line, and end-line of study."
62836751|NCT04268381||Healthy (n=23)|
62836752|NCT04268381||Gingivitis (n=20)|
62836753|NCT04268381||Periodontitis (n=40)|
62836754|NCT00184301|EXPERIMENTAL|inpatient treatment|inpatient treatment during 1 year
62836755|NCT00184301|ACTIVE_COMPARATOR|outpatient treatment|intensive outpatient treatment consisting of two-weekly group sessions during 1 year
62836756|NCT04238897|EXPERIMENTAL|Ticon Aspherical Daily Disposable Soft Contact Lens|The subject will be requested to wear lens 8 hours a day, 5 days a week at least. The contact lens will be worn and replaced every day. All subjects will be followed for 1 year post device allocation with a brief clinical assessment at 1 day, 1 week, 1, 3, 6, 9, 12 months.
62836757|NCT04238897|PLACEBO_COMPARATOR|Ticon Daily Soft Contact Lens|The subject will be requested to wear lens 8 hours a day, 5 days a week at least. The contact lens will be worn and replaced every day. All subjects will be followed for 1 year post device allocation with a brief clinical assessment at 1 day, 1 week, 1, 3, 6, 9, 12 months.
62836758|NCT03742323|EXPERIMENTAL|Idelalisib|
62836759|NCT05676619|OTHER|Single cohort of healthy volunteers|Single cohort of healthy volunteers
62836760|NCT03637738|EXPERIMENTAL|RIOP-Intrabeam® system|"Surgery with Intrabeam®. A first visit will be scheduled at 2 months from surgery then at 6 months then every 6 months for 5 years, then every year after 5 years.~Additional EBRT may be performed +/- chemotherapy if the treatment received is insufficient."
62836761|NCT03637738|ACTIVE_COMPARATOR|conventional surgery +RTE|surgery, EBRT over 33 sessions then visit at 6 months then every 6 months 6 for 5 years, then every year after 5 years.
62836762|NCT02858362|EXPERIMENTAL|Cohort 1: SMT C1100 Formulation 1|Participants received 2.5 g SMT C1100 formulation 1 orally twice-daily for at least 48 weeks.
62836763|NCT02858362|EXPERIMENTAL|Cohort 2: SMT C1100 Formulation 2|Participants received 1 g SMT C1100 formulation 2 orally twice-daily for at least 48 weeks.
62836764|NCT02858362|EXPERIMENTAL|Cohort 3: SMT C1100 Formulation 1|Participants in this cohort had previously received SMT C1100, but were not eligible for Cohorts 1 or 2. Participants received 2.5 g SMT C1100 formulation 1 orally twice-daily for at least 48 weeks.
62836765|NCT05663632||group 1 heart failure patients|
62836766|NCT05663632||Group 2 controle|
62836767|NCT04055077|ACTIVE_COMPARATOR|ASA I/LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
62836768|NCT04055077|ACTIVE_COMPARATOR|ASA II/LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
62836769|NCT04055077|ACTIVE_COMPARATOR|ASA III/LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
62053551|NCT01245946|EXPERIMENTAL|Photodynamic therapy|
62836770|NCT04055077|EXPERIMENTAL|ASA I/HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
62836771|NCT04055077|EXPERIMENTAL|ASA II/HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
62836772|NCT04055077|EXPERIMENTAL|ASA III/HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
62836773|NCT03071419|EXPERIMENTAL|Nutrition and Parenting Intervention|Participants (n=30, father/child dyads in groups of 10) will receive an 8 session (2 hours/session) community-based intervention including nutrition and parent education with between-session technology enhancements.
62836774|NCT03071419|ACTIVE_COMPARATOR|Wait-list Control|Participants (n=30, father/child dyads in groups of 10) will serve as a wait-list control group and receive the same Nutrition and Parenting Intervention after completing pre and post assessments several weeks apart.
62836775|NCT05441748|EXPERIMENTAL|Intervention treatment|Intervention treatment will contain walnuts and be consumed everyday for 3 weeks.
62053552|NCT01245946|EXPERIMENTAL|Conventional therapy|
62836776|NCT05441748|EXPERIMENTAL|Intervention treatment oil|Intervention treatment will contain walnut oil in foods and be consumed everyday for 3 weeks.
62836777|NCT05441748|PLACEBO_COMPARATOR|Control treatment|Intervention treatment will contain corn oil in foods and be consumed everyday for 3 weeks.
62836778|NCT00890123|ACTIVE_COMPARATOR|Omegaven|Patients in this arm will receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperatively.
62836779|NCT00890123|NO_INTERVENTION|Without Omegaven|Patients will not receive IV Omega 3 fatty acids
62836780|NCT05422898|EXPERIMENTAL|Gist|Gist-based messages on COVID-19 vaccination and moderated group discussions in a private Facebook group
62053553|NCT05616364|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine is a sedative, analgesic, anxiolytic, sympatholytic, and opioid-sparing alpha 2 adrenergic agonist with good selectivity and specificity.It has been shown to lower the threshold for shivering. Dexmedetomidine does not affect the locus ceruleus of the spinal cord, and it does not cause respiratory depression. \[8\] In postoperative patients, dexmedetomidine lowers cortisol and norepinephrine levels, as well as blood glucose, interleukin (IL)-6, tumour necrosis factor-a, and C-reactive protein, and raises interleukin-10. Moreover, because Dexmedetomidine does not affect upper airway reflexes, it is an excellent option.It was believed that the sedative impact of intravenous injection on newborn infants was very minimal and could be disregarded due to the delayed sedative effects
62254638|NCT02470468|EXPERIMENTAL|DCVAC and immune enhancers add on to SOC|Combination therapy with DCVAC, immune enhancers (Interferon-α, Hydroxychloroquine) and Standard of Care (Carboplatin, Paclitaxel)
62836781|NCT05422898|PLACEBO_COMPARATOR|Information|Link to Facebook COVID-19 Information Center
62836782|NCT04381754||AVG/AVF Treated with Passeo-18 Lux|Patients with failing dialysis access, treated lesions located between the anastomosis to the axillary-subclavian vein junction.
62836783|NCT03859310||Normal|no glaucoma or retinal pathology or corneal conditions
62836784|NCT03859310||Glaucoma|diagnosis of glaucoma
62836785|NCT03859310||Retina|diagnosis of AMD, DR or other retinal pathology
62836786|NCT03859310||Cornea|wear contact lens or prior refractive surgery or having dry eye or KCN
62836787|NCT01842217|OTHER|Premenopausal women|healthy female subjects: premenopausal
62836788|NCT01842217|OTHER|Postmenopausal women|healthy female subjects: postmenopausal
62836789|NCT05120401||dry eye with presbyopia|dry eye with presbyopia , Intervention : glasses prescrubed
62254639|NCT02470468|OTHER|Standard of Care Chemotherapy|Standard of Care chemotherapy (Carboplatin, Paclitaxel)
62254640|NCT05201027|EXPERIMENTAL|trifocal intraocular lens|Implantation of new trifocal intraocular lens
62254641|NCT02453490|EXPERIMENTAL|Raltitrexed-based chemotherapy|Raltitrexed plus Oxaliplatin/Raltitrexed plus Irinotecan
62254642|NCT02453490|ACTIVE_COMPARATOR|5-fluorouracil-based chemotherapy|5-fluorouracil plus Oxaliplatin/5-fluorouracil plus Irinotecan
62254643|NCT06428084|ACTIVE_COMPARATOR|Ondansetron|19 participants in group O received 4 mg of ondansetron intravenously.
62254644|NCT06428084|ACTIVE_COMPARATOR|Haloperidol|19 participants in group H received 1 mg of Haloperidol intravenously.
62254645|NCT06399523|EXPERIMENTAL|VR therapy|
62254646|NCT06399523|PLACEBO_COMPARATOR|VR sham|
62254647|NCT03621332||Questionnaire adminstration|All patients who participate will complete questionnaires
62836790|NCT05120401||dry eye with presbyopia without glasses use|no glasses use
62836791|NCT01666028|EXPERIMENTAL|Closed Loop Glucose control|Subject's glucose level is controlled by the automated closed loop glucose control system
62836792|NCT01666028|ACTIVE_COMPARATOR|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
62836793|NCT05178004||Non-IgE-mediated CMPA|Infants with mild, moderate and severe non-IgE-mediated cow's milk protein allergy
62836794|NCT05178004||IgE-mediated CMPA|Infants with IgE-mediated CMPA
62836795|NCT05178004||Healthy|Healthy infants who have never shown signs of cow's milk protein allergy
62836796|NCT05178004||Non allergic gastrointestinal conditions|Infants with suspected cow's milk allergic at enrolment and ruled out following Oral Food Challenge
62836797|NCT04117516|ACTIVE_COMPARATOR|Open surgery|30 patients will be operated with an open carpal tunnel release.
62836798|NCT04117516|EXPERIMENTAL|Percutaneous surgery|30 patients will be operated with a percutaneous carpal tunnel release.
62836799|NCT02532881|EXPERIMENTAL|Treatment as ususal (TAU) + Video Access|Patients in this arm receive access to various videos on the study website as well as treatment as usual (written information provided by the clinic).
62836800|NCT02532881|PLACEBO_COMPARATOR|Treatment as usual (TAU)|Patients in this arm receive treatment as usual (written information provided by the clinic).
62254648|NCT06118151|EXPERIMENTAL|sentinel cohort 1|20 Participants in each age group will receive either Influenza hemagglutinin mRNA vaccine candidate dose 1 or dose 2 and half number of the participants in each age group also receiving the RIV4 control
62053554|NCT05616364|EXPERIMENTAL|Tramadol|Tramadol, a centrally acting analgesic with -opioid agonist properties and little action on kappa and delta receptors, has been proven to be beneficial in preventing post-spinal shivering. The method of action is thought to be through a modulatory influence on central monoaminergic pathways, which inhibits noradrenaline and serotonin neuronal absorption in the spinal cord while boosting hydroxyltryptamine production, resetting the body temperature regulatory center. \[3\] However, it has many side effects, including nausea, vomiting, and dizziness, which add to the patient's pain. \[5\] Hence research into novel solutions with adequate safety and effectiveness is strongly advised. In this sense, despite taking into account the gold standard for post spinal shivering control is pethidine. it is contraindicated in breastfeeding which is both legally and ethically challenging for women.
62254649|NCT06118151|EXPERIMENTAL|sentinel cohort 2|20 Participants in each age group will receive either Influenza hemagglutinin mRNA vaccine candidate dose 3 or dose 4 and half number of the participants in each age group also receiving the RIV4 control
62836801|NCT02436629|ACTIVE_COMPARATOR|Nitrate-rich concentrated beetroot juice|Dietary supplement: 800 mg of nitrate in 140 mL of concentrated beetroot juice (Beet-IT)
62836802|NCT02436629|PLACEBO_COMPARATOR|Nitrate-depleted conc. beetroot juice|Placebo: 140 mL of nitrate-depleted concentrated red beetroot juice
62254650|NCT06118151|EXPERIMENTAL|sentinel cohort 3|10 Participants in each age group will receive Influenza hemagglutinin mRNA vaccine candidate dose 5 with half of the participants in each age group also receiving the RIV4 control
62254651|NCT06118151|EXPERIMENTAL|main cohort 1|40 Participants in each age group will receive either Influenza hemagglutinin mRNA vaccine candidate dose 1 or dose 2 and half number of the participants in each age group also receiving the RIV4 control
62612559|NCT04776278|EXPERIMENTAL|Relaxation Training (RT) + Substance Free Activity Session (SFAS)|Participants will complete a relaxation training session that will include a clinician leading them through a diaphragmatic breathing exercise, a progressive muscle relaxation protocol, and then a brief breath-counting (mindfulness) exercise. A week later, the participant will receive the SFAS, a 50-minute counseling session designed to increase the salience of the individual's goals, to highlight the connection between their current patterns of behavior (including drinking and substance-free activities) and the attainment of these goals, and to increase future orientation and engagement in enjoyable and goal-directed activities that are inconsistent with substance use (even if the participant has no desire to change their use).
62836803|NCT05375760|OTHER|Arm A|600 mg AZD7442 following 300 mg AZD7442 every 3 months (5 doses totally)
62836804|NCT05375760|OTHER|Arm B|1200mg AZD7442 following 600 mg AZD7442 every 6 months (3 doses totally)
62836805|NCT00763880|EXPERIMENTAL|Lidocaine|Subjects randomly assigned to this arm will receive 2% lidocaine by injection into their fracture site in the form of a hematoma block.
62836806|NCT00763880|PLACEBO_COMPARATOR|Normal Saline|Subjects randomly assigned to this arm will receive normal saline by injection into their fracture site
62836807|NCT05737953||Mucinous tumour group|
62836808|NCT05737953||Non-mucinous tumour group|
62836809|NCT05194735|EXPERIMENTAL|TCR-T Cell Drug Product|"Phase I: Dose-escalation of TCR-T Cell Drug Product~Phase II: Single dose of TCR-T Cell Drug Product after MTD/RP2D determine in Phase I portion of the study"
62836810|NCT05194735|EXPERIMENTAL|TCR-T Cell Drug Product with Aldesleukin (IL-2)|"Phase I: Dose-escalation of TCR-T Cell Drug Product with Aldesleukin (IL-2)~Phase II: Single dose of TCR-T Cell Drug Product with Aldesleukin (IL-2) after MTD/RP2D determine in Phase I portion of the study"
62836811|NCT05876897||Diagnostic Ultrasound|
62836812|NCT06003049|ACTIVE_COMPARATOR|Treatment Arm|OnabotulinumtoxinA
62254652|NCT06118151|EXPERIMENTAL|main cohort 2|40 Participants in each age group will receive either Influenza hemagglutinin mRNA vaccine candidate dose 3 or dose 4 and half number of the participants in each age group also receiving the RIV4 control
62254653|NCT06118151|EXPERIMENTAL|main cohort 3|20 Participants in each age group will receive Influenza hemagglutinin mRNA vaccine candidate dose 5, and half number of the participants in each age group also receiving the RIV4 control
62836813|NCT06003049|PLACEBO_COMPARATOR|Placebo Arm|Normal saline
62254654|NCT06229106|ACTIVE_COMPARATOR|Symfony IOL|The Symfony IOL is a lens designed to provide high quality vision up tp 26 inches reducing the need for glasses after routine cataract surgery in patients with or without astigmatism.
62053555|NCT04000841|EXPERIMENTAL|Intervention|Intervention participants receive access to the Mindful You app for 12 weeks. They will use the app to listen to guided meditations and to receive notifications, messages, and reminders that they select and ones sent to all participants by the app.
62053556|NCT04000841|NO_INTERVENTION|Waitlist Control|Waitlist control participants will continue business as usual with regards to stress-management and reduction.
62053557|NCT03626779|OTHER|immediate placment and loading with prf|Immediat placment and loading with prf
62254655|NCT06229106|ACTIVE_COMPARATOR|Vivity IOL|The Vivity IOL is a lens that provides extended range of vision ranging from distance to near reducing the need for glasses after routine cataract surgery in patients with or without astigmatism.
62254656|NCT04689204|EXPERIMENTAL|Administration of CTA30X|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
62443204|NCT06545422|EXPERIMENTAL|Experimental group|"70 experimental group patients participated in the study; St. John's wort oil was applied to the coccyx area(width 10cm, length 10cm) of the patient included in the study at the same times every day for 21 days, starting from Day 0.~The first day of hospitalization is considered day 0 and skin moisture is measured. The skin is cleaned and dried. 4 or 5 drops of St. John's wort oil were dropped onto the area and applied with a cotton pad.The next day, skin moisture is measured then the skin is cleaned and dried and St. John's wort oil is applied again. This Process continues for 21 days and is recorded."
62443205|NCT06545422|OTHER|Control Group|"70 control group patients participated in the study; The skin protective barrier cream used in routine care of the coccyx region (width 10 cm, length 10 cm) of the patient included in the study was applied at the same hours every day for 21 days, starting from day 0.~The first day of hospitalization is considered day 0 and skin moisture is measured. The skin is cleaned and dried.Barrier cream is applied to the patient's coccyx area.The next day, at the same time, skin moisture is measured, then the skin is cleaned and dried, and barrier cream is applied again.Transactions are made and recorded every day for 21 days."
62443206|NCT03333525|EXPERIMENTAL|Insulin dose-CARB counting HPM group|HPM (high protein meal), contained 36 g protein,17 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
62443207|NCT03333525|EXPERIMENTAL|Insulin dose-CARB counting HPFM group|HPFM (high protein-high fat meal), contained 36 g protein,30 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
62443208|NCT03333525|EXPERIMENTAL|Insulin dose-CARB+FPU counting-HPFM|HPFM (high protein-high fat meal), contained 36 g protein,30 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting plus fat-protein counting (insulin-to-carbohydrate ratio-ICR and fat-protein unit-FPU).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
62443209|NCT03333525|ACTIVE_COMPARATOR|Insulin dose-CARB counting SM group|SM (standart meal), contained 24 g protein,17 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR and fat-protein unit-FPU).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
62053558|NCT03626779|NO_INTERVENTION|immediate implant placment and loading|Immediate implant placment and loading without prf
62053559|NCT03834103|OTHER|Arm 1: Self-rehabilitation arm|Self-rehabilitation arm
62053560|NCT03030443||Oral Sedation|"Patients in this group will receive a standard procedure first trimester abortion using oral sedation for pain management following the clinic's protocol.~Patients in both groups will be administered a Visual Analog Scale (VAS) assessing pain on an unmarked 100mm VAS scale with anchors at 0mm (left) being no pain and 100mm (right) being pain as bad as it could be before their procedure and immediately following procedure completion."
62254657|NCT04267770|EXPERIMENTAL|circadian insulin infusion rates|Initial variable basal rates aim to replicate circadian changes in insulin requirements and are derived from total basal insulin in adults over 24 years old, and from weight in adults aged 18 to 24 years.
62254658|NCT04267770|ACTIVE_COMPARATOR|flat rates|flat basal rate
62254659|NCT06323603||1. Textile industry workers|Workers from the textile industry, that manufactures non-wovens fibers
62254660|NCT06323603||2. Plastic Recycling Workers|Workers involved in recycling and waste management of plastic
62254661|NCT06323603||3. Controls|Control group that will match the characteristics of grup 1 and 2
62254662|NCT01274819|EXPERIMENTAL|Dynamic light|ICU patients exposed to dynamic light during ICU stay
62254663|NCT01274819|NO_INTERVENTION|Normal Light|control group is exposed to normal light during ICU stay
62443210|NCT02367053|EXPERIMENTAL|ZP4207|single dose of ZP4207 in ascending doses (s.c. and i.m.)
62443211|NCT02367053|ACTIVE_COMPARATOR|native glucagon|single fixed dose of glucagon
62053561|NCT03030443||Nitrous Oxide|"Patients in this group will receive a standard procedure first trimester abortion using titrated nitrous oxide for pain management following the clinic's protocol.~Patients in both groups will be administered a Visual Analog Scale (VAS) assessing pain on an unmarked 100mm VAS scale with anchors at 0mm (left) being no pain and 100mm (right) being pain as bad as it could be before their procedure and immediately following procedure completion."
62053562|NCT01870362|EXPERIMENTAL|Probiotic (Inersan) Arm|Inersan Lozenges (2 Lozenges bid). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
62053563|NCT01870362|PLACEBO_COMPARATOR|Placebo Arm|Placebo Lozenges (2 lozenges bid). Placebo lozenge contains only excipients (without probiotic).
62053564|NCT01981525|EXPERIMENTAL|Arm 1|Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose.
62612560|NCT04776278|ACTIVE_COMPARATOR|Education Control|This minimal contact control condition will include a brief (2-3 minute) discussion where the research assistant (RA) who completed the assessment session will describe the educational handout. This condition is meant to approximate a public health-level approach to providing referral information and some of the content included in the BAI+SFAS condition but without any of the personalized information or motivational interviewing. Participants will receive information on risks associated with alcohol/drug misuse, strategies for reducing alcohol problems, managing stress, and goal-setting. The handout will also include links to hotlines, websites, and apps related to these domains. This condition will not include booster contact
62053565|NCT03430193|EXPERIMENTAL|FIRM group|FIRM program consisted of total 10 days session including PT, in two times twenty-minute sessions per day and 4 times OT during admission initiated before transfer to rehabilitation ward. PT (Weight bearing exercise, strengthening exercise, gait training, aerobic exercise and functional training) progressed gradually based on individual functional level and OT of activities of daily life (ADL) training (transfer, sit to stand, bed mobility, dressing, self-care retraining and using adaptive equipment) was provided.
62053566|NCT03430193|ACTIVE_COMPARATOR|Conventional group|Conventional rehabilitation program consisted of total 10 days session of PT focused on simple standing and gait training, in one time twenty-minute sessions per day.
62053567|NCT03430193|NO_INTERVENTION|No-rehabilitation group|Discharged patients not transferred to rehabilitation unit after surgery for hip fracture.
62053568|NCT04960605|OTHER|Test group|Patients with Primary Sjögren Syndrom
62053569|NCT04960605|OTHER|Control group|Patients with Primary Sjögren Syndrom, matched to the test group
62254664|NCT04861675||Prospective follow up cohort study|Assessment of Changes in Oral Health-related Quality of Life , Oral Hygiene status and Body Growth in Egyptian Children with Special Health Care Needs following Dental Treatment under General Anaesthesia
62254665|NCT04092348||study group|children aged 2-17 years and diagnosed as new cases of acute lymphoblastic leukemia
62254666|NCT04092348||control group|healthy age- and sex-matched children without ahistory of any malignancies
62443212|NCT00783757|EXPERIMENTAL|Optical Imaging|Tomographic Optical Imaging Arm
62254667|NCT04171479||Manual|Subjects who underwent epicardial mapping and/or ablation using a manual technique will comprise this group.
62443213|NCT05220670|EXPERIMENTAL|HIIT Group|This group receives a training in which intervals of intense work and periods of active rest are combined using a cycle ergometer with an intensity of 85-95% of the maximum heart rate \[MHR\], followed by intervals of active rest of 3 minutes duration. at 50-70% MCF.
62443214|NCT05220670|EXPERIMENTAL|MICT Group|The participants will perform a training on the cycle ergometer with an intensity close to 70% FCM maintained for 40 minutes and will be controlled individually.
62254668|NCT04171479||Remote Magnetic Navigation|Subjects who underwent epicardial mapping and/or ablation using a remote magnetic technique (using Stereotaxis Niobe system) will comprise this group.
62254669|NCT00770770|EXPERIMENTAL|Fluocinolone Acetonide 0.2 µg/day|0.2 µg/day
62254670|NCT00770770|EXPERIMENTAL|Fluocinolone Acetonide 0.5 µg/day|0.5 µg/day
62254671|NCT00821938|ACTIVE_COMPARATOR|CRT-ICD|
62254672|NCT00821938|PLACEBO_COMPARATOR|DDD-ICD|
62254673|NCT03209206|EXPERIMENTAL|Docetaxel bladder instillation arm|After Surgery, intravesical chemotherapy with in 48 hrs (Docetaxel 75 mg diluted in 100 cc of normal saline)
62254674|NCT03209206|PLACEBO_COMPARATOR|Control arm|After Surgery, intravesical chemotherapy with in 48 hrs (Placebo, 100 cc of normal saline)
62836814|NCT03224819|EXPERIMENTAL|Dose Escalation|"The dose-escalation cohorts to estimate the MTD will use 2 schedules of emerfetamab administration: Schedule A (Day 1/Day 5 dosing in 14-day cycles) and Schedule B (once daily dosing for cycle 1 followed by twice weekly dosing in following cycles).~For Schedule A the starting dose for the first cohort will be 0.05 μg emerfetamab administered as short term IV infusions on day 1 and day 5. The doses administered for the following cohorts will be recommended by the Dose Level Review Team (DLRT).~For Schedule B the starting dose will be 72 μg emerfetamab administered as short-term IV infusions daily (QD) during the 14-day cycle 1 after the 72 μg target dose is found to be relatively safe and tolerable by the DLRT for Schedule A."
62254675|NCT01429584|ACTIVE_COMPARATOR|0.25% bupivacaine|interscalene nerve block with 0.25% bupivacaine
62254676|NCT01429584|ACTIVE_COMPARATOR|0.125% bupivacaine|interscalene nerve block with 0.125% bupivacaine
62254677|NCT03883191|EXPERIMENTAL|Mix probiotics powder|Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.
62836815|NCT03224819|EXPERIMENTAL|Expansion Phase|For each schedule, upon completion of the dose escalation cohorts, additional participants may be enrolled to receive emerfetamab at a dose at or below the MTD estimated in the dose escalation cohorts.
62836816|NCT05119361||before protocol implementation|"A control group reflecting usual practice about net ultrafiltration and deresuscitation strategy in patients with continuous renal replacement therapy in our Department.~All patients meeting eligibility criteria between 01/01/2020 and 31/12/2021 will be include."
62254678|NCT03883191|PLACEBO_COMPARATOR|Placebo powder|Taking 1 pack of placebo powder three times a day before meals for three months.
62254679|NCT04602806||Moderate to Severe TBI Subjects|Adult patients (age 18-65y inclusive) presenting to the Emergency Department (ED) with a history of acute TBI as per American Congress of Rehabilitation Medicine (ACRM) Criteria (i.e., patient has sustained a traumatically-induced physiological disruption of brain function).
62836817|NCT05119361||after protocol implementation|All patients treated by our deresuscitation protocol between 15/02/2020 and 15/08/2021 will be included.
62836818|NCT00811018|EXPERIMENTAL|Sitaxsentan|Sitaxsentan
62836819|NCT02177565|EXPERIMENTAL|carrier plus BMSCs|carrier plus in vitro expanded autologous BMSCs
62836820|NCT02177565|PLACEBO_COMPARATOR|carrier alone (control).|Carrier alone
62836821|NCT05542719||frequency of dyslipidemias|To describe the frequency of dyslipidemias in high-risk and very high-risk patients with atherosclerotic cardiovascular disease and analyze the impact of using an application to achieve dyslipidemia treatment goals at one-year follow-up.
62836822|NCT01803607|EXPERIMENTAL|Odanacatib 50 mg|Participants will receive odanacatib 50 mg once weekly for 24 months. Additionally, all participants will receive weekly supplementation with 5600 international units (IU) of Vitamin D3 and, if required, will be provided with an open-label daily calcium supplement of 500 mg (sourced locally as calcium carbonate or calcium citrate) to ensure a total daily intake (from both dietary and supplemental sources) of approximately 1200 mg of elemental calcium.
62254680|NCT01329445||DeNovo NT patient|Patients who have received or who are scheduled to receive a DeNovo NT graft for repair of 1-2 knee cartilage lesions.
62254681|NCT02106286|ACTIVE_COMPARATOR|Bisoprolol|Patients not betablocked at baseline receive an acute 72hr dose of beta blocker therapy before CPET
62254682|NCT02106286|NO_INTERVENTION|No Bisoprolol|No beta blocker given
62254683|NCT03945357|ACTIVE_COMPARATOR|Saline Irrigation|Normal saline is to be placed into the dissected retromuscular space AFTER placement and fixation of mesh. This should fill the cavity completely to the level of the skin. Irrigant is to be left to stand for a total of three minutes and then evacuated. Additional irrigation with saline PRIOR to the randomization is permitted at the surgeons' discretion for hemostasis with no requirement for duration. Additional saline irrigation of the subcutaneous space after fascia closure should be performed prior to skin closure.
62254684|NCT03945357|ACTIVE_COMPARATOR|Antibiotic Irrigation|Antibiotic solution is prepared consisting of 240 mg gentamicin and 600 mg clindamycin in 500 ml saline to ensure proper concentration. This solution should be placed into the dissected retromuscular space AFTER placement and fixation of mesh. This should fill the cavity completely to the level of the skin. Irrigant is to be left to stand for a total of three minutes and then evacuated. Additional irrigation with saline PRIOR to the randomization is permitted at the surgeons' discretion for hemostasis with no requirement for duration. Additional antibiotic irrigation of the subcutaneous space after fascia closure should be performed prior to skin closure. This second irrigation is not timed.
62612561|NCT03438058||With complement-activating anti-HLA DSAs|Patients with complement-activating anti-HLA DSAs either C1q, C3d, C4d and IgG subclass
62254685|NCT03725579|EXPERIMENTAL|mepivacaine hydrochloride|2% Mepivacaine hydrochloride with 1:100,000 epinephrine anaesthetic solution. Each patient received two inferior alveolar nerve block injections of the tested anesthetic solution by using a side loading aspirating syringe and 27-gauge long needle
62254686|NCT03725579|ACTIVE_COMPARATOR|articaine hydrochloride|4 % Articaine hydrochloride with 1:100,000 epinephrine anaesthetic solution. Each patient received two inferior alveolar nerve block injections of the tested anesthetic solution by using a side loading aspirating syringe and 27-gauge long needle
62254687|NCT05242731|ACTIVE_COMPARATOR|Study group|Studygroup: Working with MSmonitor and video calling. Complete research questionnaires every 3 months in the Case Report Form, Researchmanager.
62254688|NCT05242731|ACTIVE_COMPARATOR|Controlgroup|Became care as usual (CAU), not working with MSmonitor or video calling. Complete research questionnaires every 3 months in the Case Report Form, researchmanager.
62254689|NCT06043115||covid-19 survival cohort|consists of surviving patients
62836823|NCT01803607|PLACEBO_COMPARATOR|Placebo|Participants will receive dose-matched placebo to odanacatib once weekly for 24 months. Additionally, all participants will receive weekly supplementation with 5600 IU Vitamin D3 and, if required, will be provided with an open-label daily calcium supplement of 500 mg (sourced locally as calcium carbonate or calcium citrate) to ensure a total daily intake (from both dietary and supplemental sources) of approximately 1200 mg of elemental calcium.
62836824|NCT04458870|EXPERIMENTAL|Acceptance and Commitment Therapy|
62836825|NCT05928962|EXPERIMENTAL|PD-1 With Recombinant Human Adenovirus Type 5 Injection|"1. Recombinant Human Type 5 Adenovirus Injection:~   Drug specification: 5.0 x 1011vp/0.5ml/stem. Dosage: Dilute with equal volume of saline before injection. For injection of lesions with a longest diameter ≥10mm and ≤40mm, 2 injections of recombinant human type 5 adenovirus injection per tumour, 1ml in total; for injection of lesions with a longest diameter ≥40mm and ≤80mm, 4 injections of recombinant human type 5 adenovirus injection per tumour, 2ml in total.~2. PD1 monoclonal antibody (Tremelimumab):~Dosage: 3mg/kg."
62836826|NCT05985252|EXPERIMENTAL|Virtual ileostomy|Laparoscopic or robotic surgery with virtual ileostomy
62836827|NCT05985252|ACTIVE_COMPARATOR|Diverting ileostomy|Laparoscopic or robotic surgery with diverting ileostomy
62053570|NCT00967382|NO_INTERVENTION|Control|"Subjects randomized to control will receive identical obstetrical care and follow-up, but not antenatal dalteparin.~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
62053571|NCT00967382|ACTIVE_COMPARATOR|dalteparin sodium|"Subjects randomized to the treatment group will receive daily injections of dalteparin during the antenatal period. They will be taught how to self-administer sub-cutaneous injections of dalteparin 5000 IU once daily (o.d.) until gestational age 20, then twice daily (bid) until 37 weeks gestation or onset of labour.~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
62053572|NCT04960826||Crohn's disease patients|
62053573|NCT04960826||Non IBD patients|
62053574|NCT03013023|PLACEBO_COMPARATOR|Routine care|Control group
62254690|NCT06043115||covid-19 mortality cohort|consists of deceased patients
62254691|NCT03281668|EXPERIMENTAL|Intervention|Intervention consists of High Intensity Interval Training (HIIT) session which is af 3-5 minute warm up, followed by 10 repetitions of 1 minute bouts at individualized training intensity with 1 minute rest periods.
62254692|NCT02755207||Suspected ACS group|Patients admitted to the hospital with the diagnosis of ACS
62254693|NCT02755207||Blank control group|Patients admitted to the hospital without the diagnosis of ACS
62836828|NCT01119378|EXPERIMENTAL|Post Menopausal|post menopausal women between the ages 50-70 yrs.
62836829|NCT04342325|EXPERIMENTAL|ADR-001|Intravenous infusion of ADR-001 (Mesenchymal stem cell)
62836830|NCT03719859|EXPERIMENTAL|Physical Therapy (PT) Group|Subjects will attend formal physical therapy after surgery.
62612562|NCT03438058||Without complement-activating anti-HLA DSAs|Patients with anti-HLA DSAs but without the ability to activate the complement (either C1q, C3d, C4d and IgG subclass)
62836831|NCT03719859|ACTIVE_COMPARATOR|Home Therapy (HT) Group|Subjects will receive instruction from clinical staff regarding home therapy exercises after surgery.
62836832|NCT05474157||Study group|15 patients Patients followed in the Intensive Care Unit due to COVID-19 infection
62053575|NCT03013023|ACTIVE_COMPARATOR|Behavioral-support interventions (BS)|NNS, FT, positional support, and oral sucrose feeding will be provided while infants are undergoing painful procedures
62053576|NCT03013023|ACTIVE_COMPARATOR|Parent-infant transaction program (PITP)|The PITP will be a six-session, one-on-one teaching intervention beginning on day 22 after birth, with four sessions at bedside, and two home-visit sessions within the first month after discharge.
62053577|NCT03013023|ACTIVE_COMPARATOR|BS+PITP|Behavioral-support interventions + Parent-infant transaction program
62053578|NCT05632835|EXPERIMENTAL|3D printing guide plate group|3D-printed customized guide plate will be used to guide the puncture in endoscopic spinal surgeries.
62053579|NCT05632835|ACTIVE_COMPARATOR|Conventional guidance group|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
62053580|NCT00524914|EXPERIMENTAL|1|Apomorphine
62053581|NCT00524914|PLACEBO_COMPARATOR|2|Placebo
62254694|NCT00742248|ACTIVE_COMPARATOR|A|Formoterol pMDI
62254695|NCT00742248|ACTIVE_COMPARATOR|B|Formoterol dry powder
62254696|NCT00742248|PLACEBO_COMPARATOR|C|Placebo pMDI DPI
62612563|NCT03438058||Without DSAs and without complement-activating DSAs|Matching group of patients without DSAs and without complement-activating DSAs
62053582|NCT01670448|ACTIVE_COMPARATOR|PECBLOCK performed with bupivacaine|Active drug given through PECBLOCK in these patients.
62254697|NCT03350295|EXPERIMENTAL|GRP1 - Assess relative bioavailability(3-way cross-over)|"GROUP 1 (Treatments A, B, C) All 3 treatments in Group 1 consist of a dose of 120 mg nifurtimox (4 x 30 mg tablets). Participants received the 3 treatments in one of six treatment sequences under fed condition.~Treatment A, dose administration with fast in vitro dissolution characteristics Treatment B, dose administration with medium in vitro dissolution characteristics Treatment C, dose administration with slow in vitro dissolution characteristics"
62254698|NCT03350295|EXPERIMENTAL|GRP2 - Assess relative bioavailability (2-way cross-over)|"GROUP 2 (Treatments D and E) Participants received the 2 treatments in one of two treatment sequences under fed condition.~Treatment D, a single dose 30 mg nifurtimox dose with medium in vitro dissolution characteristics Treatment E, a single dose of 120 mg nifurtimox"
62254699|NCT00279019|EXPERIMENTAL|Subjects receiving treatment sequence 1|Eligible subjects will receive treatment sequence 1; GSK233705 20 micrograms, GSK233705 100 micrograms, tiotropium and placebo.
62254700|NCT00279019|EXPERIMENTAL|Subjects receiving treatment sequence 2|Eligible subjects will receive treatment sequence 2; GSK233705 20 micrograms, Placebo, GSK233705 50 micrograms and tiotropium.
62254701|NCT00279019|EXPERIMENTAL|Subjects receiving treatment sequence 3|Eligible subjects will receive treatment sequence 3; GSK233705 20 micrograms, tiotropium, Placebo and GSK233705 50 micrograms.
62254702|NCT00279019|EXPERIMENTAL|Subjects receiving treatment sequence 4|Eligible subjects will receive treatment sequence 4; GSK233705 20 micrograms, placebo, tiotropium and GSK233705 50 micrograms.
62254703|NCT00279019|EXPERIMENTAL|Subjects receiving treatment sequence 5|Eligible subjects will receive treatment sequence 5; Placebo, tiotropium, GSK233705 20 micrograms and GSK233705 50 micrograms.
62254704|NCT00279019|EXPERIMENTAL|Subjects receiving treatment sequence 6|Eligible subjects will receive treatment sequence 6; Placebo, GSK233705 20 micrograms, GSK233705 50 micrograms and tiotropium.
62254705|NCT00279019|EXPERIMENTAL|Subjects receiving treatment sequence 7|Eligible subjects will receive treatment sequence 7; tiotropium, GSK233705 20 micrograms, GSK233705 50 micrograms and Placebo.
62836833|NCT05474157||Control group|15 patients Patients who admitted to the 'Physical Medicine and Rehabilitation' clinic for other reasons during the pandemic period
62612564|NCT02787213||Women with preterm delivery|
62254706|NCT00279019|EXPERIMENTAL|Subjects receiving treatment sequence 8|Eligible subjects will receive treatment sequence 8; tiotropium, GSK233705 20 micrograms, Placebo and GSK233705 50 micrograms.
62254707|NCT00279019|EXPERIMENTAL|Subjects receiving treatment sequence 9|Eligible subjects will receive treatment sequence 9; GSK233705 20 micrograms, tiotropium, GSK233705 50 micrograms and Placebo.
62254708|NCT00279019|EXPERIMENTAL|Subjects receiving treatment sequence 10|Eligible subjects will receive treatment sequence 10; GSK233705 20 micrograms, GSK233705 100 micrograms, Placebo and tiotropium.
62053583|NCT01670448|PLACEBO_COMPARATOR|PECBLOCK performed with NaCl 0.9%|Placebo drug given through PECBLOCK in these patients
62053584|NCT04235907|ACTIVE_COMPARATOR|Traditional Physical Therapy|Patients will be given a prescription to see a physical therapist and a paper-based rehabilitation protocol. Patients will be allowed to receive physical therapy at a location of patients' choosing. This arm represents the current standard of care.
62254709|NCT00279019|EXPERIMENTAL|Subjects receiving treatment sequence 11|Eligible subjects will receive treatment sequence 11; Placebo, GSK233705 20 micrograms, tiotropium, and GSK233705 50 micrograms.
62254710|NCT00279019|EXPERIMENTAL|Subjects receiving treatment sequence 12|Eligible subjects will receive treatment sequence 12; Tiotropium, Placebo, GSK233705 20 micrograms and GSK233705 50 micrograms.
62254711|NCT00279019|EXPERIMENTAL|Subjects receiving treatment sequence 13|Eligible subjects will receive treatment sequence 13; Placebo, GSK233705 20 micrograms, GSK233705 50 micrograms and GSK233705 100 micrograms.
62254712|NCT00279019|EXPERIMENTAL|Subjects receiving treatment sequence 14|Eligible subjects will receive treatment sequence 14; GSK233705 20 micrograms, placebo, GSK233705 50 micrograms and GSK233705 100 micrograms.
62254713|NCT00279019|EXPERIMENTAL|Subjects receiving treatment sequence 15|Eligible subjects will receive treatment sequence 15; GSK233705 20 micrograms, GSK233705 100 micrograms, Placebo and GSK233705 50 micrograms.
62254714|NCT00279019|EXPERIMENTAL|Subjects receiving treatment sequence 16|Eligible subjects will receive treatment sequence 16; GSK233705 20 micrograms, GSK233705 100 micrograms, GSK233705 50 micrograms and Placebo.
62612565|NCT02787213||Women without preterm delivery|
62612566|NCT05429099|ACTIVE_COMPARATOR|Free-Hand Surgery (FHS)|In FHS, the site surgeon will proceed with the surgery as per their routine practice.
62836834|NCT04199988||Athletes with shoulder pain|Overhead athletes with shoulder pain
62836835|NCT04199988||Athletes without shoulder pain|Overhead athletes without shoulder pain
62836836|NCT02367833|EXPERIMENTAL|Combined Oral Contraceptives (COC)|Apri (or generic equivalent - Reclipsen) (30µg/d EE, 150 µg/d desogestrel) is a monophasic dosing regimen of 21 active and 7 placebo pills. On Day 1 of the Intervention, participants in the COC group will begin taking the COC pill. Each participant in this group will ingest active pills from the first pack each day for the first 21 days. Pills ingested on days 22 through 28 are placebo pills. A second pill pack will begin on day 29 and pills with active ingredients will be ingested from the second pack each day for days 29-49. On day 50, the participants will immediately begin a 3rd pill pack, if the post-study testing is still occurring, and will ingest a pill with active ingredients from the third pack for days 50-56 (or for as long as the post-study testing is occurring).
62836837|NCT02367833|EXPERIMENTAL|Transdermal Contraceptive (TDC)|Participants in the TDC group will apply a 20 cm2 patch (Xulane: 20µg/d EE,150µg/d norelgestromin) to the abdomen, upper arm or buttock. The patch will be changed once weekly on the same day each week for weeks 1-3 (days 1-21, removed on day 22) and weeks 5-8 (days 29-56). Week 4 (days 22-28) will be a patch-free week. As soon as the post-study testing is complete, subjects will remove the patch.
62836838|NCT02367833|EXPERIMENTAL|Contraceptive Vaginal Ring (CVR)|Participants in the CVR group (NuvaRing - 15µg/d EE/120µg/d etonogestrel) will insert a vaginal ring into the vagina on Day 1 of the intervention. The vaginal ring will be removed and discarded after 3 weeks of continuous use (days 1-21 of continuous use and removed on day 22). There will be one week (days 22-28) that will be ring-free. A new ring will be inserted for days 29-49. On day 50, the second ring will be removed, and a third ring will be immediately inserted into the vagina (if the post-study testing is still occurring). The third ring will remain in the vagina for the last week of the post-study period (days 50-56). As soon as the post-study testing is complete, subjects will remove the ring.
62836839|NCT02367833|NO_INTERVENTION|Control Group|The Control group will complete all procedures with the exception of contraceptive therapy.
62836840|NCT02892448|ACTIVE_COMPARATOR|Unilateral Hip Resurfacing|Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
62836841|NCT02892448|ACTIVE_COMPARATOR|Bilateral Hip Resurfacing|Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
62836842|NCT02892448|ACTIVE_COMPARATOR|Non-Metal on Metal Total Hip|Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
62836843|NCT02964091|OTHER|Harvoni|sofosbuvir/ledipasvir once daily for 12 weeks
62836844|NCT04186143|EXPERIMENTAL|Experimental-Study Group|In addition to the conservative treatment of the control group, closed cinetic chain exercises were applied for 12 weeks.
62254715|NCT04334707||Acute Kidney Injury Cohort|The focus will be on acute intrinsic non-glomerular disease, primarily on acute tubular necrosis (ATN). KPMP will also include a special population of patients at risk for AKI or with early AKI captured by an open (surgical) kidney biopsy performed at the time of clinically indicated laparotomy.
62254716|NCT04334707||Chronic Kidney Diseases Cohort|High priority populations include CKD in the setting of diabetes (diabetic kidney disease, DKD) and hypertension-associated CKD (H-CKD). A special population of people with long-standing type 1 diabetes (more than 25 years) who remain free of clinically-evident DKD will also be included.
62836845|NCT04186143|ACTIVE_COMPARATOR|Active Comparator|In addition to the conservative treatment of the control group, opened cinetic chain exercises were applied for 12 weeks.
62836846|NCT04186143|OTHER|Control Group|Conservative treatment was applied for 12 weeks.
62254717|NCT02484833|ACTIVE_COMPARATOR|FOLFIRI + Cetuximab until disease progression|FOLFIRI + Cetuximab until disease progression
62836847|NCT01686399|EXPERIMENTAL|The study has a single arm|The study has one arm The whole population of the campus will be exposed to the intervention. the effectiveness will be assessed using a random selection twice - before and after the intervention
62836848|NCT03292367||ldTRA|Patients who are planned to perform coronary angiography will be enrolled via left distal radial artery
62254718|NCT02484833|EXPERIMENTAL|FOLFIRI + Cetuximab followed by Cetuximab alone|FOLFIRI + Cetuximab for 8 cycles followed by Cetuximab alone until disease progression
62836849|NCT03186742|EXPERIMENTAL|Group A|The patients who had Eplerenone 50mg tab once a day added to their standard hypertensive treatment.
62836850|NCT03186742|NO_INTERVENTION|Group B|The patients who did not receive an additional drug to their standard hypertensive treatment.
62836851|NCT02289261|ACTIVE_COMPARATOR|Control|Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
62836852|NCT02289261|ACTIVE_COMPARATOR|Morphine plus dexmedetomidine|Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
62836853|NCT06523361|OTHER|introduction of the intervention phase before session 4 with occupational therapist|"The first group will be repeated three times. For each participant, the beginning of the intervention will be randomized. All participants will undergo a baseline phase, intervention phase, and follow-up phase. During the baseline phase, participants serve as controls. As the randomized beginning of the intervention varies across subjects, the length of the baseline phase also varies. The objective is to identify a change in the outcome measure when the intervention starts, despite the differing lengths of the baseline phases across participants."
62254719|NCT02193321|EXPERIMENTAL|Amniotic membrane patch placement|One amniotic membrane patch will be placed on the epicardial surface of the heart immediately following a CABG procedure prior to wound closure.
62254720|NCT02193321|NO_INTERVENTION|Control|Amniotic membrane patch will not be placed after CABG procedure prior to wound closure.
62443215|NCT05220670|NO_INTERVENTION|Control Group|The participants will receive advice on the general positive effects of the regular practice of physical activity, and will be given the guide of recommendations for the promotion of physical activity.
62053585|NCT04235907|ACTIVE_COMPARATOR|Telerehabilitation|Patients will be given access to a website containing instructions with pictures and videos for the exercises patients are to complete as part of patients' rehabilitation. Patients will not be given a prescription to physical therapy. Patients in this group will receive weekly calls from a physical therapist during weeks 6-12 post-operatively.
62443216|NCT01823445|EXPERIMENTAL|Xylitol disk|Daily use of 8 disks containing 0.5 grams xylitol each for two weeks. The disks adhere to gum tissue with a food grade adhesive backing and slowly dissolve. The disks are applied one on each side of the mouth in the morning after breakfast, again at midday, and four are applied, two on each side, at bedtime.
62836854|NCT06523361|OTHER|introduction of the intervention phase before session 5 with occupational therapist|"The second group will be repeated three times. For each participant, the beginning of the intervention will be randomized. All participants will undergo a baseline phase, intervention phase, and follow-up phase. During the baseline phase, participants serve as controls. As the randomized beginning of the intervention varies across subjects, the length of the baseline phase also varies. The objective is to identify a change in the outcome measure when the intervention starts, despite the differing lengths of the baseline phases across participants."
62836855|NCT06523361|OTHER|introduction of the intervention phase before session 6 with occupational therapist|"The third group will be repeated three times. For each participant, the beginning of the intervention will be randomized. All participants will undergo a baseline phase, intervention phase, and follow-up phase. During the baseline phase, participants serve as controls. As the randomized beginning of the intervention varies across subjects, the length of the baseline phase also varies. The objective is to identify a change in the outcome measure when the intervention starts, despite the differing lengths of the baseline phases across participants."
62836856|NCT06523361|OTHER|introduction of the intervention phase before session 7 with occupational therapist|"The fourth group will be repeated three times. For each participant, the beginning of the intervention will be randomized. All participants will undergo a baseline phase, intervention phase, and follow-up phase. During the baseline phase, participants serve as controls. As the randomized beginning of the intervention varies across subjects, the length of the baseline phase also varies. The objective is to identify a change in the outcome measure when the intervention starts, despite the differing lengths of the baseline phases across participants."
62053586|NCT04922151|EXPERIMENTAL|group I|601 1.25mg
62053587|NCT04922151|ACTIVE_COMPARATOR|group II|Ranibizuman 0.5 mg
62053588|NCT03717090||Patients with PJI|
62053589|NCT00908089|ACTIVE_COMPARATOR|Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab|Combination therapy with 3 DMARDs (starting with methotrexate 10-25 mg/week, sulphasalazine 1-2 g/day and hydroxychloroquine 35 mg/kg/week)+ Prednisolon 7.5 mg/day + infliximab 3 mg/kg at weeks 4, 6, 10, 18, 26
62053590|NCT00908089|PLACEBO_COMPARATOR|Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo|Combination therapy with 3 DMARDs (starting with methotrexate 10-25 mg/week, sulphasalazine 1-2 g/day and hydroxychloroquine 25 mg/kg/week)+ Prednisolon 7.5 mg/day + placebo at weeks 4, 6, 10, 18, 26
62836857|NCT04963868|EXPERIMENTAL|The novel strategy group|The stents were removed during the last necrosectomy when the endpoint of necrosectomy was achieved
62053591|NCT05725252|EXPERIMENTAL|NVP-2203|After fasting (except water) for at least 10 hours before dosing, oral administration of investigational product once daily on Period 1(or Period 2)
62053592|NCT05725252|ACTIVE_COMPARATOR|NVP-2203-R|After fasting (except water) for at least 10 hours before dosing, oral administration of investigational product once daily on Period 1(or Period 2)
62053593|NCT01080222|EXPERIMENTAL|Treatment Arm A|Treatment Arm A was discontinued as a result of patients meeting a pre-defined stopping rule related to viral breakthrough during the first four weeks of dosing.
62053594|NCT01080222|EXPERIMENTAL|Treatment Arm B|Treatment Arm B was discontinued as a result of patients meeting a pre-defined stopping rule relating to viral breakthrough.
62053595|NCT01080222|EXPERIMENTAL|Treatment Arm C|"* Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~* Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 12 weeks for a total treatment duration of 24 weeks.~* Enrollment for this arm is complete. No additional subjects will be recruited."
62053596|NCT01080222|EXPERIMENTAL|Treatment Arm D|"* Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~* Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 12 weeks for a total treatment duration of 24 weeks.~* Enrollment for this arm is complete. No additional subjects will be recruited."
62053597|NCT01080222|EXPERIMENTAL|Treatment Arm E|"* Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~* Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 24 weeks for a total treatment duration of 36 weeks."
62053598|NCT01080222|EXPERIMENTAL|Treatment Arm F|"* Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~* Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 24 weeks for a total treatment duration of 36 weeks."
62053599|NCT05009524|EXPERIMENTAL|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES (interactive Physical and Cognitive Exercise System) involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
62254721|NCT02209298||CoreValve Transcatheter Valve|Medtronic CoreValve SystemTM is designed to replace the native or surgical bioprosthetic aortic heart valve without open heart surgery and without concomitant surgical removal of the failing valve. The support frame is manufactured by Nitinol, which has multi-level, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from a single layer of porcine pericardium into a tri-leaflet configuration. The bioprosthesis is processed with alpha-amino oleic acid (AOA™), which is a compound derived from oleic acid, a naturally occurring long-chain fatty acid. AOA™ is an antimineralization treatment shown to reduce both early and late valvular calcification.
62254722|NCT00718445||MND|"* Patients seen in the MDA/ALS Center of Hope at Drexel University College of Medicine~* Patients seen in the Department of Neurology at Drexel University College of Medicine"
62254723|NCT01565915|EXPERIMENTAL|Perlane-L|Perlane-L treatment
62254724|NCT01565915|SHAM_COMPARATOR|Non-Treatment|Non-Treatment Arm
62443217|NCT01104857|EXPERIMENTAL|Diaphragm muscle biopsy|Patients admitted to the ICU meeting severe sepsis / septic shock criteria
62443218|NCT01104857|ACTIVE_COMPARATOR|Elective laparotomy|
62836858|NCT04963868|ACTIVE_COMPARATOR|The conventional strategy group|The stent was removed after the last necrosectomy when clinical symptoms were relieved and fluid was nearly completely resolved confirmed by CT image
62836859|NCT05848999|EXPERIMENTAL|Arm of UCLM802 Cell Injection (Anti-mesothelin CAR-T cells)|Anti-mesothelin CAR-T cells Injection Anti-mesothelin CAR-T cells are autologous genetically modified T cells. A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by Anti-mesothelin CAR-T cells injection.
62836860|NCT00787358|ACTIVE_COMPARATOR|ZT-031|
62053600|NCT05009524|ACTIVE_COMPARATOR|PACE (physical and cognitive exercise)|"PACE (Physical and Cognitive Exercise) involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
62053601|NCT06150781||Erenumab-aooe-exposed|Pregnant women with confirmed migraine who received erenumab-aooe before or during pregnancy will qualify to be included in the cohort. Dosing and treatment duration of erenumab-aooe as part of this observational study is at the discretion of the healthcare provider (HCP) in accordance with local clinical practice and local labeling.
62053602|NCT06150781||Erenumab-aooe-unexposed (Internal Comparator)|Pregnant women with clinically confirmed migraine who were not exposed to erenumab-aooe before or during pregnancy will be included in the internal comparator cohort.
62443219|NCT00171509|ACTIVE_COMPARATOR|BID cyclosporine|control group continuing with a BID administration of cyclosporine and C2 monitoring.
62836861|NCT00787358|PLACEBO_COMPARATOR|Placebo|
62836862|NCT05451901|EXPERIMENTAL|Immediate necrosectomy|Endoscopic necrosectomy will be conducted in the same session of EUS-guided drainage (or at least within 72 hours of randomization) and be repeated until clinical success.
62836863|NCT05451901|ACTIVE_COMPARATOR|Step-up approach|Step-up treatment will be conducted if a patient's condition does not improve after EUS-guided drainage. The step-up approach includes increasing the number of stents, adding another EUS-guided drainage, and performing percutaneous drainage after 72-96 hours of the initial drainage. Endoscopic necrosectomy is considered when clinical improvement is not observed even after two times of step-up treatment.
62836864|NCT04220541|EXPERIMENTAL|Motor learning based exercise group|
62836865|NCT04220541|EXPERIMENTAL|Symptomatic exercise group|
62836866|NCT05108012|EXPERIMENTAL|Test group|The investigators will inject the activated NK cells, 1-3 times with weekly interval into tumor cavity.
62836867|NCT04938154|EXPERIMENTAL|DBS On|
62836868|NCT04938154|SHAM_COMPARATOR|DBS Off|
62836869|NCT02284243|EXPERIMENTAL|DEX-IN 50mcg|DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
62836870|NCT02284243|PLACEBO_COMPARATOR|IN Placebo|IN Placebo every 6 hours for 48 hours.
62836871|NCT01239693|ACTIVE_COMPARATOR|IFA group|Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
62836872|NCT01239693|ACTIVE_COMPARATOR|MMN group|Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients' Children from 6 to 18 months of age: None
62836873|NCT01239693|EXPERIMENTAL|LNS group|Women during pregnancy: 1 sachet of LNS-P\&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P\&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
62836874|NCT01110902|EXPERIMENTAL|AGO178C 0.5 mg /day|
62836875|NCT01110902|EXPERIMENTAL|AGO178C 1 mg / day|
62836876|NCT01110902|PLACEBO_COMPARATOR|Placebo|
62836877|NCT03968562|ACTIVE_COMPARATOR|2% Doxycycline Cream in Generic Aquaphor|2% Doxycycline Cream in Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration. Will perform concurrent to Placebo Comparator
62443220|NCT00171509|EXPERIMENTAL|OAD cyclosporine|conversion to OAD administration of cyclosporine with the same daily dose as received prior to conversion
62443221|NCT00171509|EXPERIMENTAL|OAD cyclosporine reduced|OAD administration of cyclosporine with a daily dose adjusted to a reduced C2
62836878|NCT03968562|PLACEBO_COMPARATOR|Generic Aquaphor|Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration. Will perform concurrent to Active Comparator.
62836879|NCT01931293|EXPERIMENTAL|HLA-DR and DQ antigens|Isolation of patient's lymphocytes from 10 cc of blood to determine the HLA-DR and DQ antigens at the first visit.
62836880|NCT04109261||Palbociclib treatment|
62836881|NCT01586572|EXPERIMENTAL|mOPV1- Arm A|Arm A will be administered a second dose of mOPV1 seven days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at day 79.
62836882|NCT01586572|EXPERIMENTAL|mOPV1- Arm B|Arm B will be administered a second dose of mOPV1 fourteen days after after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 86 days.
62836883|NCT01586572|EXPERIMENTAL|mOPV1-Arm C|Arm C will receive the second dose of mOPV1 thirty days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 102 days.
62836884|NCT01586572|EXPERIMENTAL|Arm D- bOPV1,3|Arm D will be administered a second dose of bOPV1,3 thirty days after the 42 day bOPV1,3 index dose.Second dose of tOPV2 will be given at day 102.
62836885|NCT04543279|EXPERIMENTAL|Part A: Fostamatinib|The starting dose of fostamatinib is 100 mg twice daily (BID). After the first cycle, if no major dose related safety issue is observed and the platelet count is less than 50K/microL, then the fostamatinib dose will be increased to 150 mg BID for the next 2 cycles; otherwise the dose may be continued at 100 mg BID.
62836886|NCT04543279|EXPERIMENTAL|Part B: Fostamatinib + Ruxolitinib|"After 3 cycles of fostamatinib monotherapy, all patients with a sustained platelet count ≥ 50K/microL, will continue on the current fostamatinib dose plus ruxolitinib at the recommended dose per standard prescribing guidelines for an additional 9 cycles.~Patients who do not reach platelet count of at least 50K/microL but who achieve clinical benefit per the treating provider may continue on single agent fostamatinib for up to 12 total treatment cycles. If these patients achieve a sustained platelet count of ≥ 50K/microL at any point prior to Cycle 10 Day 1, then they may be eligible to enroll in Part B of the study and continue treatment with fostamatinib and ruxolitinib for the remainder of the study."
62254725|NCT01607424|EXPERIMENTAL|RECOS: 42 hours CR, 14 week-treatment.|RECOS(Cognitive Remediation for Schizophrenia) exercises were designed by SBT Company and adapted by Vianin et al (2007) for specific use in schizophrenia. It includes computer based and paper and pencil exercises that target 5 main cognitive functions. RECOS modules focus on the relevant cognitive domains, which have been recommended by the MATRICS consensus. Each exercise has 10 difficulty levels. Allocation of the training modules in RECOS was determined according to the standard scores obtained in the comprehensive neuropsychological assessment. Each patient participated in the module corresponding to his/her most altered cognitive area.
62254726|NCT01607424|ACTIVE_COMPARATOR|CRT: 42 hours CR, 14 week-treatment|CRT (Cognitive Remediation Therapy) exercises are the ones used by Wykes et al (1999). The CRT method consists of 3 modules: flexibility, memory (A and B) and planning (A and B). Each module involves a series of paper and pencil exercises with parallel forms providing with gradual difficulty.
62443222|NCT02429154|ACTIVE_COMPARATOR|Normocapnia|The Child will be ventilated in order to achieve an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa). Measurements will be performed after steady state condition. Then the ventilation will be reduced to allow ETCO2 to reach 6.5 kPa before repeating the measurements. Finally, the child will be again ventilated to obtain a normocapnia condition.
62443223|NCT02429154|OTHER|Mild Hypercapnia|The Child will be ventilated in order to achieve a ETCO2 of 6.5 kPa. Measurements will be performed after steady state condition. Then the ventilation will be increased to allow ETCO2 to reach 5.5 kPa before repeating the measurements. Finally, the child will be again ventilated to obtain a mild hypercapnic condition
62254727|NCT06000995||Pulmonologists|pulmonologists actively performing fiberoptic bronchoscopy
62254728|NCT00263744|EXPERIMENTAL|1|MEDI517
62254729|NCT00263744|ACTIVE_COMPARATOR|2|Aluminum hydroxide
62254730|NCT05560542|OTHER|Dexamethasone group (D)|Patients will receive intrathecal hyperbaric bupivacaine 0.5% in a dose of 12.5 mg (2.5 ml) mixed with morphine in a dose of 200 µg (0.5 ml was withdrawn from a syringe containing 4 mg morphine sulfate diluted in 10 ml normal saline) \[Total volume 4 ml\], followed by intrathecal dexamethasone 4 mg (1ml).
62443224|NCT04611269||Adult, patients with COVID-19 admitted to the ICU requiring mechanical ventilation|"This is a prospective cohort study including patients \>18 years RT-PCR positive for SARS Cov-2 admitted to the ICU that require mechanical ventilation. Epidemiological data, comorbidities, previous signs of symptoms of COVID-19. On admission, severity of disease scores, laboratory management data, blood gases and acid-base chemistry,respiratory and mechanical ventilation management,and complications (Development of ARDS, septic shock, acute kidney injury, thromboembolic events, infections and septic shock, will be recorded. If patients die, causes of death will be recorded.Treatments administered by attending physicians will be registered.~Dates of hospital and ICU admission, of death and/or discharge will be recorded.~No intervention will be administered. Follow-up will continue until death or ICU/hospital discharge"
62443225|NCT03446560|ACTIVE_COMPARATOR|CPAP, conventional follow up|Follow up of patients after initiation of treatment according to clinical routine at the study site.
62443226|NCT03446560|ACTIVE_COMPARATOR|CPAP, telemedicine based follow up|Follow up of patients after initiation of treatment according to a telemedicine based routine.
62443227|NCT04396470|EXPERIMENTAL|tVNS treatment|
62254731|NCT05560542|OTHER|Atropine group (A)|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg (2.5 ml 0.5%) mixed with morphine 200 µg (0.5 ml) and atropine100 µg (0.5 ml was withdrawn from a syringe containing 2 mg atropine sulfate diluted in 10 ml normal saline) \[Total volume 3.5 ml\].
62443228|NCT04396470|SHAM_COMPARATOR|tVNS sham treatment|
62836887|NCT06517589|EXPERIMENTAL|Process-based Cognitive Behavioral Therapy|In PBT (20 sessions), treatment is initiated by a collaborative interpretation of the dynamic network model using smartphone-based Ecological Momentary Assessment collected during the baseline. Based on the outcome of the dynamic network model, interventions are selected on the basis of empirical evidence for mechanisms of change matching to the central node of the individual patient, besides feedback loops and self-loops, as the key process maintaining the maladaptive pattern. Interventions are conceptualized in the evolutionary framework as variation, selection and retention of an adaptive mode of the central node related to the specific context of the problem. The change of this variable is monitored using daily judgements on the basis of EMA. Further treatment planning focuses on additional targets to establish the adaptive modes of the dimensions as defined in the positive network model. Concomitant medication is allowed and will be controlled in statistical analyses.
62254732|NCT05560542|OTHER|Dexamethasone and Atropine group (DA)|Patients will receive intrathecal hyperbaric bupivacaine in a dose of 12.5 mg (2.5 ml) mixed with morphine 200 µg (0.5 ml) and atropine 100 µg (0.5 ml), followed by intrathecal injection of dexamethasone 4 mg (1 ml) \[Total volume 4.5 ml\] .
62443229|NCT02022501|EXPERIMENTAL|Low Dose DE-120|Single 20 µL intravitreal injection of Low Dose DE-120 injectable solution
62443230|NCT02022501|EXPERIMENTAL|Medium Dose DE-120|Single 20 µL intravitreal injection of Medium Dose DE-120 injectable solution
62443231|NCT02022501|EXPERIMENTAL|High Dose DE-120|Single 20 µL intravitreal injection of High Dose DE-120 injectable solution
62443232|NCT00902135||Group 1|
62443233|NCT00902135||Group 2|
62836888|NCT06517589|ACTIVE_COMPARATOR|Traditional Cognitive Behavioral Therapy|In r-CBT (20 sessions) a naturalistic setting is retained for treatment decisions. Treatment planning follows traditional theories about the effects of the interventions on factors maintaining the disorder, e.g. avoidance and exposure in anxiety disorder or reduced reinforcement of activities and behavioral activation in depression. Interventions are selected on the basis of common treatment manuals related to diagnoses, e.g. CBT for depression. Individual data from the behavioral analysis are used to taylor the techniques to the problem behaviors or dysfunctional thoughts of patients. Treatment process focuses mainly on the implementation of the manualized interventions adapted to the individual patient as recommended in the National guidelines for treatment of depression and anxiety disorders. Concomitant medication is allowed and will be controlled in statistical analyses.
62836889|NCT02030652|EXPERIMENTAL|SNIPPV Group|Synchronized nasal intermittent positive pressure using NAVA ( Intermittent nasal positive pressure positive ventilation.)
62836890|NCT02030652|ACTIVE_COMPARATOR|CPAP Group|Nasal CPAP group without intermittent ventilation.
62836891|NCT02084407|ACTIVE_COMPARATOR|DM1 subject with cardiopathy|Clinical examination, Skin biopsy, Blood and urine sampling
62836892|NCT02084407|ACTIVE_COMPARATOR|DM1 subject without cardiopathy|Clinical examination, Skin biopsy, Blood and urine sampling
62836893|NCT02084407|ACTIVE_COMPARATOR|Not DM1subject|Clinical examination, Skin biopsy, Blood and urine sampling
62836894|NCT03916913|EXPERIMENTAL|Local therapy|Consolidation local radiotherapy
62836895|NCT01265537|EXPERIMENTAL|Low target tacrolimus (Advagraf)|"This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and low-target Advagraf."
62836896|NCT01265537|ACTIVE_COMPARATOR|Standard target tacrolimus (Advagraf)|"This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and standard target Advagraf."
62836897|NCT01526733|SHAM_COMPARATOR|Insulin (Aspart or Lispro)-Sham|"In Phase I or Phase II of the study, participants received 0.15 units per kilogram (U/kg) insulin (either insulin aspart or insulin lispro) as a continuous subcutaneous insulin infusion (CSII) for 16 days, with sham injections administered prior to outpatient euglycemic clamps on Days 1 and 4 and prior to outpatient meal test procedures on Days 7, 10, 13, and 16.~Each Phase was separated by a washout period of 5 to 21 days."
62836898|NCT01526733|EXPERIMENTAL|Insulin (Aspart or Lispro)-rHuPH20|"In Phase I or Phase II of the study, participants received 0.15 U/kg insulin (either insulin aspart or insulin lispro) as a CSII for 16 days. Prior to outpatient euglycemic clamps on Days 1 and 4 and prior to outpatient meal test procedures on Days 7, 10, 13, and 16, participants received a 1 mL (150 U) injection of recombinant human hyaluronidase (rHuPH20).~Each Phase was separated by a washout period of 5 to 21 days."
62836899|NCT04289974||Palbociclib+fulvestrant|"100 cases of patients with ER+, HER2- breast cancer, experienced resistance after first line endocrinotherapy, will be assigned participants into treatment regimen, including palbociclib combined with fulvestrant.~FFPE blocks/sections or fresh tumor tissues/biopsies will be obtained from the hospitals on the points before administration and since resistance appearance. The tissue will be sequenced by a pan-cancer DNA panel (500+ genes) and whole transcriptome sequencing (WTS).~5-10 ml peripheral blood will be collected from each patient on the points before administration, 1 month after treatment, every subsequent visit and resistance appearance. The liquid biopsy will be sequenced by a pan-cancer ctDNA panel (300+ genes).~The genomic characteristics of patients received resistance will be analyzed. The relevant pathway mechanisms will be identified."
62836900|NCT03074240|ACTIVE_COMPARATOR|TAPB Group|Compare the instance in the TAPB group of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia when undergoing TAPB to anesthetize the abdominal wall.
62836901|NCT03074240|ACTIVE_COMPARATOR|RSB Group|Compare the instance in the RSB group of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia when undergoing RSB to anesthetize the abdominal wall.
62836902|NCT04767919|ACTIVE_COMPARATOR|Standard Percutaneous Nephrolithotomy (sPCNL)|The first arm will consist of a Standard of Care standard percutaneous nephrolithotomy (sPCNL)- performed using a 30 Fr access sheath following balloon dilation.
62836903|NCT04767919|ACTIVE_COMPARATOR|Minimally Invasive Percutaneous Nephrolithotomy (MIP)|The second arm will consist of a Standard of Care mini percutaneous nephrolithotomy (mPCNL)- performed using an 18 Fr access sheath following either balloon dilation or dilation using a single step metal dilator.
62836904|NCT02788552|ACTIVE_COMPARATOR|Acute Symptomatic WKS- 300mg|Thiamine Hydrochloride 300mg daily (i.e. 100mg 3 times/day) for 5 days
62836905|NCT02788552|ACTIVE_COMPARATOR|Acute Symptomatic WKS - 900mg|Thiamine Hydrochloride 900mg daily (i.e. 300mg 3 times/day) for 5 days
62836906|NCT02788552|ACTIVE_COMPARATOR|Acute Symptomatic WKS - 1500mg|Thiamine Hydrochloride 1500mg daily (i.e. 500mg 3 times/day) for 5 days.
62612567|NCT05429099|EXPERIMENTAL|Virtual Surgical Planning (VSP)|The trial research engineer (RE), located at Vancouver General Hospital (VGH), will segment the CT data to create a 3D model for surgical planning. During the teleconference between site surgeon (SS) and RE, the RE will load the CT data and the segmented 3D model into the virtual planning environment. With the RE navigating the software, which was created in-house at VGH and used in a previous case series, the SS will determine the extent of disease and define the resection planes. After the cutting planes are created, the RE will use the software to create the reconstruction plan with either the patient-specific fibula or scapula. Once the surgeon is satisfied with the plan, the teleconference will end and the RE will create and 3D print the surgical guides for the mandible, for the fibula or scapula, as well as the 3D computed reconstruction.
62612568|NCT05698784||"Group a inappropriate"|"In the inappropriate , we placed prescriptions with no indication, 123I-FP-CIT SPECT"
62612569|NCT05698784||"Group b uncertain"|"In the uncertain, we did not have sufficient data to determine with certainty whether this was an inappropriate or relevant indication."
62612570|NCT05698784||"Group c relevant"|"In the relevant , the prescriptions concerned the differential diagnosis between neurodegenerative parkinsonism and secondary parkinsonian syndromes"
62836907|NCT02788552|ACTIVE_COMPARATOR|High-risk subclinical WKS- 100mg|Thiamine Hydrochloride 100mg once daily for 3 days.
62836908|NCT02788552|ACTIVE_COMPARATOR|High-risk subclinical WKS- 300mg|Thiamine Hydrochloride 300mg (i.e. 100mg 3 time/day) for 3 days
62836909|NCT02788552|ACTIVE_COMPARATOR|High-risk subclinical WKS - 900mg|Thiamine Hydrochloride 900mg daily (i.e. 300mg 3 times/day) for 3 days.
62836910|NCT01252498||Radiotherapy|Patients receiving radiotherapy or chemoradiotherapy for head and neck cancer
62836911|NCT01815697|EXPERIMENTAL|Enhanced External Counterpulsation|Men with benign prostatic hyperplasia receive 35- 36 hours Enhanced External Counterpulsation treatment
62836912|NCT01815697|NO_INTERVENTION|Control|Men with benign prostatic hyperplasia without Enhanced External Counterpulsation treatment as control
62836913|NCT03460236||PRP|Symptomatic early knee osteoarthritis subjects who have elected to receive PRP treatment.
62836914|NCT06379815|EXPERIMENTAL|Sodium Lactate|Participants will received 0.45 g/kg of sodium lactate (SO179, Spectrum Chemical MFG Group) mixed with water. This will be mixed at a ratio of 30 mL per g of lactate. Lemon juice is added to the mixture at a specific ratio to balance the pH of the solution. Crystal light will also be added to avoid any taste differences between beverages.
62836915|NCT06379815|PLACEBO_COMPARATOR|Sodium Chloride|Participants will receive a equimolar amount of sodium chloride (S9888, MilliporeSigma) mixed with water. The amount of water, lemon juice, and crystal light will be matched to that of the sodium lactate condition.
62836916|NCT00741182|EXPERIMENTAL|Femur PTH(1-34)|24 participants with trochanteric fractures will be assigned to Forsteo (PTH(1-34)) treatment
62836917|NCT00741182|NO_INTERVENTION|Femur Control|"24 participants with trochanteric fractures will be assigned to no treatment"
62836918|NCT00741182|EXPERIMENTAL|Humerus PTH(1-34)|24 participants with collum chirurgicum fracture will be assigned to Forsteo (PTH(1-34)) treatment
62836919|NCT00741182|NO_INTERVENTION|Humerus Control|"24 participants with collum chirurgicum fracture will be assigned to no treatment."
62836920|NCT01715324|EXPERIMENTAL|Growth Hormon|The participants randomized in the control group will be prescribed a regular antagonist IVF cycle with dose appropriate stimulation medication and will receive 2.5 mg of Adjuvant Growth Hormon (Saizen) daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering.
62254733|NCT03651453|ACTIVE_COMPARATOR|Standard Care|Participants will receive standard information about harm reduction as available at the drug treatment centers.
62836921|NCT01715324|NO_INTERVENTION|Control|The participants randomized in the control group will be prescribed a regular antagonist IVF cycle with dose appropriate stimulation medication without Adjuvant Growth Hormon (Saizen).
62836922|NCT02841904|OTHER|CLE|CLE assessed by the pathologist
62836923|NCT02841904|ACTIVE_COMPARATOR|Biopsy|Histology assessed by the pathologist
62836924|NCT06393699|EXPERIMENTAL|incremental|application of increments of packable composite in non carious cervical lesions
62836925|NCT06393699|EXPERIMENTAL|bulk fill heated|application of heated composite as bulk in the lesions without incrementation after heating with caps warmer
62836926|NCT06393699|EXPERIMENTAL|incremental heated|application of composite in increments after being heated by caps warmer
62836927|NCT06393699|EXPERIMENTAL|flowable|application of flowable composite in non carious cervical lesions
62254734|NCT03651453|EXPERIMENTAL|Decision aid|Participants in this arm will receive the adapted decision aid for PrEP.
62836928|NCT03788252|ACTIVE_COMPARATOR|Renamezin|oral treatment duration: three times a day, 7 capsules (2g) once, for 48 weeks
62836929|NCT03788252|NO_INTERVENTION|Non-Renamezin|no use of Renamezin
62836930|NCT05288803||Control cohort|The investigators will collect outcomes for 100 Veterans treated with usual care rehabilitation after total knee arthroplasty. Data will be collected at all participating clinical locations. Data collection for these Veterans will precede data collection for the intervention cohort.
62836931|NCT05288803||Intervention cohort|The investigators will implement the clinical decision support tool in all participating clinic locations. We will collect outcomes for 100 Veterans treated in rehabilitation with use of the clinical decision support tool. Data collection for these Veterans will occur after data collection is complete for the Control cohort.
62836932|NCT05724888|EXPERIMENTAL|Intervention_Winnipeg|The intervention arm will take place in a 12 week intervention (3 sessions per week) which will use a peer mentoring network based on the circle of courage to encourage adolescents with T2D to achieve the WHO recommended target of 300 minutes of moderate to vigorous PA weekly.
62053603|NCT06150781||Women Without Migraine (External Comparator)|Pregnant woman without migraine will be included in this cohort as external comparator. The Metropolitan Atlanta Congenital Defects Program (MACDP) birth defects classification system will be used to characterize major and minor congenital malformations for this study.
62053604|NCT01949870|OTHER|Selumetinib|25mg/day, 50mg/day and 75mg/day
62836933|NCT05724888|NO_INTERVENTION|Control_Winnipeg|The control group will receive standard recommendations for increasing daily PA from the Canadian Society of Exercise Physiology and the American Heart Association.
62836934|NCT05724888|EXPERIMENTAL|Intervention_STP|The intervention arm will take place in a 12 week intervention (3 sessions per week) which will use a peer mentoring network based on the circle of courage to encourage adolescents with T2D to achieve the WHO recommended target of 300 minutes of moderate to vigorous PA weekly.
62836935|NCT05724888|NO_INTERVENTION|Control_STP|The control group will receive standard recommendations for increasing daily PA from the Canadian Society of Exercise Physiology and the American Heart Association.
62836936|NCT01630876|SHAM_COMPARATOR|Vitrectomy only group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only.
62836937|NCT01630876|EXPERIMENTAL|Combined therapy group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection.
62836938|NCT05779540|ACTIVE_COMPARATOR|Intervention|Active Device
62836939|NCT05779540|SHAM_COMPARATOR|Control|Sham Device
62836940|NCT04730232|EXPERIMENTAL|Tislelizumab and Nab-Paclitaxel|Tislelizumab 200mg IV on day 1 in combination with nab-paclitaxel 200mg IV on day 2 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.
62836941|NCT03327207||Study group|Children who receive Growth hormone treatment. Non Interventional
62836942|NCT03327207||Control group|Healthy children . Non Interventional
62053605|NCT01807806|EXPERIMENTAL|Role-playing game|All eligible participants were invited to play the role playing game
62053606|NCT03223532|ACTIVE_COMPARATOR|PrePex Day 7 FRP|"Standard PrePex procedure, 1 week after device placement foreskin and device are removed.~\*Subjects must be adequately vaccinated, or willing to be vaccinated, against Tetanus based on appropriate national guidance for male circumcision"
62053607|NCT03223532|EXPERIMENTAL|PrePex Day 0 FRP|On the day of device placement the foreskin is removed, the device is removed 1 week later.
62053608|NCT03645902||Acute stroke patients|MRI examinations will be performed on a 3 T GE MR750 W scanner. Two readers, an experienced neuroradiologist (8 years of experience in neuroradiology) and a junior radiologist (3 years of experience in general radiology) will independently analyze eSWAN and TOF images in random order, looking for arterial occlusions. Analysis will be based on a 2-point-scale: arterial occlusion, based on a local signal loss, or acceptable permeability.
62053609|NCT02427789|NO_INTERVENTION|Control|In this group patients will not have physical exercises
62053610|NCT02427789|ACTIVE_COMPARATOR|Physical Exercise|In this group patients will make physical exercise
62053611|NCT00908401|ACTIVE_COMPARATOR|sucrose|This group will receive oral sucrose for procedural pain
62254735|NCT01666509|EXPERIMENTAL|Rossoseq™|Gel, topically applied twice daily
62443234|NCT00902135||Group 3|
62443235|NCT01033383|PLACEBO_COMPARATOR|3 placebo capsules|3 placebo capsules qd
62836943|NCT03750123||Kawasaki Disease (KD)|Children 5 years after Kawasaki Disease
62836944|NCT03750123||Healthy controls (HC)|Age- and sexmatched healthy siblings of children after Kawasaki Disease
62836945|NCT00840112|EXPERIMENTAL|LCHAD/TFP with peripheral neuropathy|Subjects diagnosed with LCHAD or TFP and with documented peripheral neuropathy
62836946|NCT04913038||case group|children over 2 years of age and prepubescent ventilated and sedated in pediatric intensive care.
62053612|NCT00908401|EXPERIMENTAL|breastmilk|this group will receive breastmilk as analgesic product to avoid procedural pain
62254736|NCT01666509|PLACEBO_COMPARATOR|Vehicle|Gel, topically applied twice
62443236|NCT01033383|EXPERIMENTAL|1 cranberry capsule & 2 placebo capsules|1 active cranberry capsule and 2 placebo capsules qd
62443237|NCT01033383|EXPERIMENTAL|2 cranberry capsules & 1 placebo capsule|2 active cranberry capsules and 1 placebo capsules qd
62836947|NCT02052518|EXPERIMENTAL|Enhanced NFN Home Program|Education and Skill set training with materials to implement the behaviors recommended. Using a motivational interviewing framework, intervention participants will receive dietary and activity counseling, develop a Family Wellness Plan and will be linked to community resources.
62836948|NCT02052518|PLACEBO_COMPARATOR|Nurturing Family Network Home Visitation|Mothers will receive the standard of care from the Nurturing Families Network Home Visitation program
62836949|NCT03153943|EXPERIMENTAL|Workbook support group|Printed educational workbook and pedometer.
62254737|NCT02276781||PAD Participants|PAD participants from among consecutive patients with PAD identified from Chicago area non-invasive vascular laboratories
62836950|NCT03153943|EXPERIMENTAL|HIP Mobile e-Monitoring support group|Remote monitoring via smart shoe insoles and a coaching with enabling educational electronic program accessed through a tablet.
62254738|NCT01274715|EXPERIMENTAL|Behavioral Health Coaching arm|This is a single-arm, pilot study of a health behavior coaching intervention to consist of 12 sessions of coaching over a 3 month period. There is no control arm for this pilot study.
62443238|NCT01033383|EXPERIMENTAL|3 cranberry capsules|3 active cranberry capsules qd
62836951|NCT00589394|OTHER|pneumococcal vaccination (Pneumovax)|"Intervention:~Patients receive one dose of the Pneumovax vaccine. The 23 pneumococcal serotypes are measured before and after vaccination in order to measure response in a healthy population."
62836952|NCT01662570|ACTIVE_COMPARATOR|Beverage Choice Lifestyle Modification|The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake.
62836953|NCT01662570|OTHER|Nutrition Education (NE)|This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included.
62836954|NCT02783807|EXPERIMENTAL|Eyenez Retinal Camera v200|Retinal images from Eyenez Retinal Camera v200 of healthy and diseased subjects
62836955|NCT02783807|ACTIVE_COMPARATOR|Volk Pictor Ret 1|Retinal images from Volk Pictor Ret 1 of healthy and diseased subjects
62836956|NCT02633202|EXPERIMENTAL|RT group|intensity modulated-radiotherapy (IMRT) alone: Patients receive intensity modulated-radiotherapy (IMRT) alone
62836957|NCT02633202|ACTIVE_COMPARATOR|CCRT group|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles
62053613|NCT01153139|EXPERIMENTAL|bilateral theta burst stimulation to the DLPFC|intermittent TBS (iTBS) to the left DLPFC continuous TBS (cTBS) to the right DLPFC
62612571|NCT06376305|OTHER|EndoBarrier in diabetes with obstructive sleep apnoea|The arm will consist of patients diabetes or prediabetes who also have moderate obstructive sleep apnoea requiring continuous positive pressure ventilation
62254739|NCT04417764|EXPERIMENTAL|TACE combined PD-1 knockout T cell treatment|
62443239|NCT05736081|EXPERIMENTAL|Intravitreal dexamethasone implant|All patients were included here and received one intravitreal dexamethasone implant 0.7mg
62612572|NCT04748952||Adult with horizontal bone defect|"30 implants will be placed in osteotomy sites prepared by osseodensification for patients with horizontal bone deficiency based on radiographic findings (CBCT).~Alveolar ridge width will be measured intraoperatively before and after osteotomy site preparation to assess the amount of ridge expansion. Implant stability will be measured immediately after implant installation and 16 weeks later."
62836958|NCT03829202|EXPERIMENTAL|A-B-A Group|Daily use of own mechanical knee for 4 weeks (A), followed by RheoKnee microprocessor prosthetic knee for 4 weeks (B), and concluding with own mechanical knee for 4 weeks (A).
62836959|NCT03829202|EXPERIMENTAL|B-A-B Group|Daily use of RheoKnee microprocessor prosthetic knee for 4 weeks (B), followed by own mechanical knee for 4 weeks (A), and concluding with RheoKnee microprocessor prosthetic knee for 4 weeks (B).
62836960|NCT05372172||Cognitively unimpaired|A consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
62053614|NCT01153139|PLACEBO_COMPARATOR|Sham stimulation|Sham stimulation with a 45° tilted coil
62053615|NCT03811184||MemScreen|Each participants will undergo MemScreen : a screening tool on smartphone for detecting mild cognitive impairment.
62254740|NCT03782402|EXPERIMENTAL|Cannabinoids (THC and CBD)|THC and CBD
62254741|NCT03782402|PLACEBO_COMPARATOR|Placebo Cannabinoids|placebo cannabinoids
62254742|NCT06155500||OTQ923|Patients were administered OTQ923 while enrolled on the treatment protocol (CADPT03A12101). Enrolled patients on this study will not be administered any study treatment.
62443240|NCT00891293|EXPERIMENTAL|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
62443241|NCT01573520|NO_INTERVENTION|usual care|
62254743|NCT03194386|NO_INTERVENTION|Control|usual care
62254744|NCT03194386|ACTIVE_COMPARATOR|Reassurance|15 minutes psychologist visit
62443242|NCT01573520|ACTIVE_COMPARATOR|adherence intervention arm|Monitoring drug adherence to guide treatment
62443243|NCT05079737||Subjects with Fitzpatrick Skin Type I-III|Subjects 21 years of age or older with Fitzpatrick Skin Type I-III will be enrolled and analyzed by age.
62612573|NCT03414905||Aspira Catheter & Drainage System|"* Participants will have standard of care ultrasound and placement of the Aspira Catheter and Drainage System on Day 1~* The removal of the Aspira Catheter and Drainage System will be dependent upon future ultrasound assessment and fluid output"
62612574|NCT05892549||COVID|
62612575|NCT05892549||Other respiratory diseases|
62612576|NCT05892549||Healthy|
62612577|NCT06438575|OTHER|Usual Care|Vaginitis diagnosis and treatment will be based on usual provider evaluation and treatment during the office visit
62612578|NCT06438575|OTHER|Same Day Results|the Xpert® Xpress MVP test will be run in real time as a point of care test at the time of the office visit and the results will be made available to the provider in approximately one hour. Providers will be asked to use the MVP test result for diagnosis and treatment of the participant.
62612579|NCT02952872|EXPERIMENTAL|Arm 1|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, no animated narrator, and no motivational content.
62612580|NCT02952872|EXPERIMENTAL|Arm 2|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, no animated narrator, and motivational content.
62612581|NCT02952872|EXPERIMENTAL|Arm 3|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, the presence of an animated narrator, and no motivational content.
62612582|NCT02952872|EXPERIMENTAL|Arm 4|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, the presence of an animated narrator, and motivational content.
62612583|NCT02952872|EXPERIMENTAL|Arm 5|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, no animated narrator, and no motivational content.
62612584|NCT02952872|EXPERIMENTAL|Arm 6|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, no animated narrator, and the presence of motivational content.
62836961|NCT05372172||Mild cognitive impairment|A consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
62836962|NCT05372172||Alzheimer's disease|A consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
62443244|NCT05079737||Subjects with Fitzpatrick Skin Type IV-VII|Subjects 21 years of age or older with Fitzpatrick Skin Type IV-VII will be enrolled and analyzed by age.
62836963|NCT01696539|EXPERIMENTAL|Walking Intervention|Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
62836964|NCT01696539|ACTIVE_COMPARATOR|Standard of Care|Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
62836965|NCT00332176|EXPERIMENTAL|1|
62836966|NCT00332176|EXPERIMENTAL|2|
62836967|NCT00332176|ACTIVE_COMPARATOR|3|
62836968|NCT02178150|ACTIVE_COMPARATOR|Magnesium Oxide|magnesium tablets, 250 milligram magnesium, 8 weeks, every day 1 tablet
62443245|NCT00793052|EXPERIMENTAL|A|
62443246|NCT03561259|EXPERIMENTAL|131I-MIBG|131I-MIBG
62443247|NCT03561259|EXPERIMENTAL|131I-MIBG + Vorinostat|131I-MIBG + Vorinostat
62443248|NCT00545558|EXPERIMENTAL|1|Participants will receive ART consisting of efavirenz and the co-formulation of emtricitabine and tenofovir disoproxil fumarate. If participants are unable to tolerate the treatment, a different regimen will be prescribed.
62836969|NCT02178150|PLACEBO_COMPARATOR|Placebo|Placebo tablets, the same in color, odor and appearance with magnesium tablets, 8 weeks, one tablet every day
62836970|NCT05036733|EXPERIMENTAL|Dupilumab|
62836971|NCT01459497|ACTIVE_COMPARATOR|Radiation Therapy|Arm A:Image-Guided Radiation Therapy (IGRT), 60 Gy in 15 fractions in 3 weeks
62836972|NCT01459497|ACTIVE_COMPARATOR|Conventional Radiation|Arm B: Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
62836973|NCT01235078||Intraosseous vascular access|subjects with urgent vascular access needs in whom intraosseous vascular access has been attempted and/or established.
62836974|NCT01907035|EXPERIMENTAL|Cognitive-behavioral intervention|Cognitive-behavioral intervention: Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with practitioner plus routine therapy in the field of primary care in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
62836975|NCT01907035|ACTIVE_COMPARATOR|Usual care|Family practice attention without the psychologist support
62836976|NCT04430816|ACTIVE_COMPARATOR|modified chevrel technique|22 participant with large midline incisional hernia underwent repair by double mesh modification of chevrel's technique
62836977|NCT04430816|ACTIVE_COMPARATOR|ON LAY mesh hernioplasty|21 participant with large midline incisional hernia underwent repair by online mesh hernioplasty
62053616|NCT03995784|EXPERIMENTAL|Intravenous Dose|Coagulation Factor IX variant, 50 IU/kg by intravenous route
62443249|NCT01214603|EXPERIMENTAL|LY2090314|"Cohort 1: 40 milligrams (mg) LY2090314 administered on Days 1, 8, and 15 of a 28-day cycle for at least two (2) 28-day cycles. Participants experiencing clinical benefit may continue treatment until after the discontinuation criteria are met.~Due to a protocol amendment on September 2010, the study added 2 additional treatment schedules/cohorts. Cohort 2: 40 mg dose given on Days 1, 5, and 9 of a 21-day cycle. Cohort 3: 40 mg dose given on Days 1, 5, 9, and 12 of a 21-day cycle. Participants experiencing clinical benefit may continue treatment until after the discontinuation criteria are met."
62443250|NCT02056275|EXPERIMENTAL|ONS + dietary counseling|ONS/day + dietary counseling
62443251|NCT02056275|ACTIVE_COMPARATOR|Dietary counseling|Dietary counseling
62053617|NCT03995784|EXPERIMENTAL|Subcutaneous Dosing|Coagulation Factor IX variant, 100 IU/kg by subcutaneous route
62053618|NCT04372628|ACTIVE_COMPARATOR|Group 1 - Lopinavir/Ritonavir|Lopinavir/Ritonavir 400 mg/100 mg orally twice daily for twenty-eight doses (Days 1-14)
62053619|NCT04372628|PLACEBO_COMPARATOR|Control Group|Placebo unmatched orally twice daily for 14 days
62053620|NCT03040284|EXPERIMENTAL|aneurysmal subarachnoid hemorrhage|
62836978|NCT06522022|EXPERIMENTAL|Culturally Responsive SBIRT for OB|Participants randomized to Culturally Responsive SBIRT for OB will participate in the intervention visit (20-30 minutes) while waiting for their OB visit (or after the visit if time does not allow) and then engage in their prenatal care visit as usual. If any safety concerns emerge during the visit, the lay provider will contact the clinical staff on the study
62836979|NCT06522022|EXPERIMENTAL|Brief Screening for PTSD|Participants randomized to Brief Screening For PTSD, screening will be conducted as part of regular clinic activities during the initial prenatal care visit. Specifically, clinic staff (nurse, PA) or study staff will ask the questions in the PC-PTSD-5 along with the standard procedure to administer the Edinburgh Postnatal Depression Scale (EPDS), and the provider will review the results with the patient during the prenatal care visit and provide referral resources regardless of screen outcome. Positive PTSD screens (PC-PTSD-5 ≥ 3) will be referred to the hospital's integrated care team following the same model as positive EPDS screens.
62836980|NCT00892346|EXPERIMENTAL|Single ASCT with Thalidomide maintenance|"Single ASCT followed by Thalidomide maintenance:~1. patients recieved 4-6 cycles of standard VAD chemotherapy or Thalidomide/dexamethasone as induction therapy~2. CTX+G-SCF mobilization to collecetd PBSC~3. Patiens recieved Mel 200 as conditioning followed by Thalidomide 100mg maintenance"
62836981|NCT03708614|OTHER|Controlled energy intake with elevated protein intake|Dietary intervention - Participants will be counseled to elevate protein and control energy intake for ten consecutive weeks.
62053621|NCT01984580|EXPERIMENTAL|Zinc|
62254745|NCT03194386|EXPERIMENTAL|R-TEP EMDR|Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing (R-TEP EMDR) At the end of cares, before ED discharge, a trained psychologist will conduct a single R-TEP EMDR session. Each session may last about 60 minutes
62254746|NCT03028051||chronic pain patients|Finnish speaking, adult chronic pain patients, aged 18 - 75 years, referred to pain clinic
62254747|NCT03853811|EXPERIMENTAL|Mitchell Shoe + AFO|Group will receive standard Mitchell shoes along with the custom orthotic insert.
62612585|NCT02952872|EXPERIMENTAL|Arm 7|7. Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, an animated narrator guiding the intervention, and no motivational content.
62836982|NCT04032093|EXPERIMENTAL|RSV dose with aluminum hydroxide|RSV vaccine with aluminum hydroxide
62836983|NCT04032093|EXPERIMENTAL|RSV dose without aluminum hydroxide|RSV vaccine without aluminum hydroxide
62836984|NCT04032093|EXPERIMENTAL|Higher RSV dose with aluminum hydroxide|Higher dose level RSV vaccine with aluminum hydroxide
62836985|NCT04032093|EXPERIMENTAL|Higher RSV dose without aluminum hydroxide|Higher dose level RSV vaccine without aluminum hydroxide
62836986|NCT04032093|PLACEBO_COMPARATOR|Placebo dose|Normal saline solution for injection (0.9% sodium chloride injection)
62836987|NCT05076162||Group 1|Serum 25(OH)D levels \<12 ng/ml
62836988|NCT05076162||Group 2|Serum 25(OH)D levels ≥12 ng/ml
62836989|NCT01751620|EXPERIMENTAL|Project ACCEPT|Participants randomized to the intervention (Project ACCEPT) arm.
62254748|NCT03853811|NO_INTERVENTION|Standard Mitchell Shoe (Control - Standard Treatment)|Group will receive standard treatment which includes bracing with standard Mitchell shoes (no custom orthotic). Patients would receive this treatment regardless of study participation.
62254749|NCT05058755|EXPERIMENTAL|TALE regimen|tislelizumab plus azacytidine and lenalidomide
62836990|NCT01751620|ACTIVE_COMPARATOR|HEALTH|Participants randomized to the comparison (HEALTH) arm.
62836991|NCT01017198|EXPERIMENTAL|BIIB021 and Food|The food phase will assess the effect of a high fat meal on the pharmacokinetics of BIIB021.
62836992|NCT01017198|EXPERIMENTAL|BIIB021 and Antacid|Antacid phase will assess the effect of an antacid on the pharmacokinetics of BIIB021.
62053622|NCT01984580|PLACEBO_COMPARATOR|sodium|
62053623|NCT03782311||2 groups: OHSE-high and OHSE-low|"OHSE-high: Group with ≥ 50 OHSE scores received motivation and oral hygiene instructions .~OHSE-low: Group with \< 30 OHSE scores received motivation and oral hygiene instructions ."
62254750|NCT05058755|EXPERIMENTAL|TEPA regimen|tislelizumab plus etoposide and pegaspargase
62254751|NCT05546164||Hemiparetic group|This group will contains 60 children with hemiparesis
62254752|NCT05546164||Normal group|This group will contains 60 children with normal children
62443252|NCT01692171|EXPERIMENTAL|Teste|Enoxalow (Heparin, Low-Molecular-Weight) - Blau Farmacêutica S/A.
62836993|NCT00903188|ACTIVE_COMPARATOR|Cyclosporine|Simulect + cyclosporine + Myfortic + steroid stop at 3 months
62836994|NCT00903188|ACTIVE_COMPARATOR|Everolimus|Simulect + cyclosporine (decrease dose in one week at month 3 and replace by Everolimus (Certican)) + Myfortic + steroid maintenance
62836995|NCT03831750|EXPERIMENTAL|Stress Reduction Intervention|Participants will receive the standard of care for IBD and training and access to an online stress reduction intervention.
62836996|NCT03831750|NO_INTERVENTION|Control|Participants will receive the standard of care for IBD.
62053624|NCT06500494||Retrospective Cohort|Patients who initiated an oral vinorelbine treatment for advanced breast cancer over the 2011-2020 targeted enrollment period
62053625|NCT06500494||Prospective Cohort|Patients initiating an oral vinorelbine treatment for advanced breast cancer at or after inclusion in the study and eligible for prospective collection of QoL data and PPQ and WPAI questionnaires
62053626|NCT05873374|EXPERIMENTAL|50 μg Baiya SARS-CoV-2 Vax 2|0.5 mL of Baiya SARS-CoV-2 Vax 2 Vaccine as a booster dose via IM injection on Day 1 for adult participants (18 - 64 years old)
62053627|NCT05873374|PLACEBO_COMPARATOR|Placebo|0.5 mL of placebo via IM injection on Day 1 for adult participants (18 - 64 years old)
62612586|NCT02952872|EXPERIMENTAL|Arm 8|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and the presence of motivational content.
62612587|NCT02952872|EXPERIMENTAL|Arm 9|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, no animated narrator, and no motivational content.
62612588|NCT02952872|EXPERIMENTAL|Arm 10|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, no animated narrator, and the presence of motivational content.
62836997|NCT05447884|EXPERIMENTAL|Group A - Participants without neurological disorders|Individuals without any neurological disorders will be recruited (Group A). Usually, participants from this group are able to walk normally on different terrains and at multiple typical walking speeds.
62836998|NCT05447884|EXPERIMENTAL|Group B - Participants with paretic stroke|Individuals with paretic stroke will be recruited (Group S). Usually, participants from this group have limited hip joint motion of range, weakened hip joint flexion or extension, or both flexion and extension functionalities, but they can also walk independently.
62836999|NCT02359097|EXPERIMENTAL|Diagnostic (DSC/DCE-CBV, SS-CBV mapping)|Patients receive 2 doses (2nd dose optional) of gadoteridol IV and undergo MRI including DSC or DCE-CBV mapping over approximately 45-60 minutes on day 1. Within 3 days, patients receive 3 doses of ferumoxytol non-stoichiometric magnetite IV and undergo MRI including DSC and SS-CBV mapping after each dose over approximately 90 minutes. Patients undergo MRI without contrast 24 hours after ferumoxytol non-stoichiometric magnetite over approximately 30 minutes. This 3 day series of imaging repeats at different stages of disease and may be performed up to 5 times: prior to surgery, prior to chemoradiation therapy, 4-6 weeks post-chemoradiation therapy, at time of progression on gadolinium MRI per RANO criteria, and again at time of progression (if the previous time of progression showed pseudoprogression).
62837000|NCT02173899|EXPERIMENTAL|varicella-1|The second varicella vaccine and 1 year of the interval time between 2 doses
62837001|NCT02173899|EXPERIMENTAL|varicella-3|The second varicella vaccine and 3 years of the interval time between 2 doses
62837002|NCT02173899|EXPERIMENTAL|varicella-5|The second varicella vaccine and 5 years of the interval time between 2 doses
62837003|NCT00976404|ACTIVE_COMPARATOR|Maraviroc + raltegravir intensification|ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)
62053628|NCT03681210||Patients implanted with HVAD System|Patients intended to be implanted with a HVAD for use as destination therapy are eligible for enrollment into the DT PAS and must be consented for the study prior to the HVAD implant.
62053629|NCT00779779||Rotarix Group|Subjects received 2 oral doses of Rotarix vaccine at an interval of at least 4 weeks between doses. The first dose was given from the age of 6 weeks and vaccination with both doses was to be completed by 24 weeks of age.
62053630|NCT02440347|EXPERIMENTAL|Computer controlled anesthetic delivery by Anaeject|Patients received single dose of 0.6 ml of 4% articaine with epinephrine (1:100.000) by computer controlled anesthetic delivery system (C-CLADS) for AMSA nerve block
62443253|NCT01692171|ACTIVE_COMPARATOR|Comparador|Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis
62443254|NCT02405611|ACTIVE_COMPARATOR|active control|mothers and children are in active control group and only receive the questionnaires
62443255|NCT02405611|EXPERIMENTAL|mother and student|an intervention group in which mothers and children receive the intervention and questionnaires
62443256|NCT02405611|EXPERIMENTAL|children|only the children receive the intervention and mothers and children receive the questionnaires
62443257|NCT06364020||Adult patients seen in specialized periodontology consultation at Rothschild Hospital|The population that will be studied will be patients received in the first specialized clinical periodontology consultation aged between 18 and 60 years.
62443258|NCT04585555||Accuryn Monitoring System|Observational only (no intervention). Patients undergoing cardiovascular surgical intervention(s) monitored with the Accuryn Monitoring System (per standard of care) during their hospital stay.
62443259|NCT04476082||Initial Diagnosis|Patients with initial diagnosis of a malignant condition of the gastrointestinal tract planned to receive cytostatic treatment.
62443260|NCT04476082||Ongoing Cytostatic Treatment|Patients with a malignant condition of the gastrointestinal tract already receiving cytostatic treatment.
62443261|NCT06245616|EXPERIMENTAL|Pomace olive oil group|The arm receives a breakfast with pomace olive oil as main fat source.
62443262|NCT06245616|ACTIVE_COMPARATOR|High-oleic sunflower oil group|The arm receives a breakfast with high-oleic sunflower oil as main fat source.
62443263|NCT00447603|ACTIVE_COMPARATOR|Losartan 50 mg|Losartan 50 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg once daily for 4 weeks
62443264|NCT00447603|ACTIVE_COMPARATOR|Losartan 100 mg|Losartan 100 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 100 mg/hydrochlorothiazide (HCTZ) 12.5 mg once daily for 4 weeks
62443265|NCT00447603|EXPERIMENTAL|Losartan 50 mg/HCTZ 12.5 mg|Losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 50 mg once daily for 4 weeks
62443266|NCT00447603|EXPERIMENTAL|Losartan 100 mg/HCTZ 12.5 mg|Losartan 100 mg/hydrochlorothiazide (HCTZ) 12.5 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 100 mg once daily for 4 weeks
62443267|NCT03237559||eligible couples|Eligible couples refers to methods that are adopted by eligible couples for having physically and psychologically healthy conception and pregnancy
62443268|NCT01141283|EXPERIMENTAL|BTDS|Buprenorphine transdermal patch
62443269|NCT00209209|ACTIVE_COMPARATOR|1|"1. randomisation: R-CHOP~2. randomisation: IFN maintenance"
62443270|NCT00209209|EXPERIMENTAL|2|"1. randomisation: R-FC~2. randomisation: Rituximab maintnenance"
62443271|NCT04875234||Legally Blind Dry AMD Patients|Legally Blind Dry AMD Patients with either unilateral or bilateral blindness
62053631|NCT02440347|ACTIVE_COMPARATOR|Conventional anesthetic delivery by carpule syringe|Patients received single dose of 0.6 ml of 4% articaine with epinephrine (1:100.000) by conventional anesthetic delivery for AMSA nerve block
62837004|NCT00976404|EXPERIMENTAL|Maraviroc + raltegravir intens. plus DNA + HIV-rAd5 vaccine|ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)
62443272|NCT06240962|OTHER|Strength Training|They will receive the strength training only will follow a protocol (6 weeks, 3 sessions/week) that feature training modifications to help control injury-related symptoms.
62837005|NCT04273035|ACTIVE_COMPARATOR|Midazolam Group|"* Midazolam(Buccolam 5mg/ml)~* 0.5mg/kg oral, max 12mg~* one time~* given 30 min prior to going to holding"
62837006|NCT04273035|ACTIVE_COMPARATOR|IPAD group|"* No premedication~* IPAD when arriving at the holding~* any games, movies, clips, puzzles"
62837007|NCT03262844|PLACEBO_COMPARATOR|Conservative treatment|Conservative physiotherapy, intermittent catheterization, or drug treatment for bladder or bowel dysfunction
62837008|NCT03262844|EXPERIMENTAL|Capsule surgery|Nerve root axial decompression surgery (Capsule surgery)
62837009|NCT02143999||Cohort|
62837010|NCT04446884|EXPERIMENTAL|mesenchymal stem cells|Patients with Stress urinary incontinence receiving standard treatment plus adipose-derived mesenchymal stem cells
62837011|NCT04446884|ACTIVE_COMPARATOR|control|Patients with Stress urinary incontinence receiving standard treatment
62053632|NCT01654601|EXPERIMENTAL|A Group|"1.1st Administration - DWCZP tablet 100mg Mutiple dose~2.2nd Administration - Clozaril tablet 100mg Mutiple dose"
62053633|NCT01654601|EXPERIMENTAL|B Group|"1.1st Administration - Clozaril tablet 100mg Mutiple dose~2.2nd Administration - DWCZP tablet 100mg Mutiple dose"
62053634|NCT02264184|EXPERIMENTAL|Tamsulosin + Paroxetine|"Tamsulosin: q.d on day 1~Paroxetine: higher dose q.d. on days -7 to 2 q.d., lower dose on days -10 to -8 and 3 to 5"
62053635|NCT02264184|ACTIVE_COMPARATOR|Tamsulosin|Tamsulosin: q.d on day 1
62053636|NCT04224064|EXPERIMENTAL|Healthy subjects cohort|A single blood sample will be made in healthy subjects.
62837012|NCT04711226|EXPERIMENTAL|AT-1501 Single Arm|
62443273|NCT06240962|OTHER|Mindfulness Exercise|They will receive the mindfulness-exercise group will receive an 6-week mindfulness intervention in addition to the strength training protocol.
62612589|NCT02952872|EXPERIMENTAL|Arm 11|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, an animated narrator to guide the intervention, and no motivational content.
62053637|NCT04224064|EXPERIMENTAL|Liposarcoma patients cohort|Blood samples will be collected at different times: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.
62053638|NCT05732441|NO_INTERVENTION|Conventional treatment group|Routine treatment protocol are used base on clinical guidelines
62443274|NCT06546111|PLACEBO_COMPARATOR|Group 1 (placebo group)|Patients will receive standard triple therapy (Omeprazole 20 mg cap PO BID + Clarithromycin 500 mg tab PO BID + Amoxicillin 1000 mg PO BID) and placebo tab PO BID for 14 days
62443275|NCT06546111|EXPERIMENTAL|Group 2 (intervention group)|Patients will receive standard triple therapy (Omeprazole 20 mg cap PO BID + Clarithromycin 500 mg tab PO BID + Amoxicillin 1000 mg PO BID) and Diosmin/Hesperidin (Daflon®) 500mg tab PO BID for 14 days.
62837013|NCT04294680|EXPERIMENTAL|Opiate Sparing|Cryotherapy one hour daily four times per day for two weeks postoperative Acetaminophen 1000 milligrams every six hours by mouth for fourteen days postoperative Gabapentin 100 milligrams three times per day by mouth for thirty days postoperative Celecoxib 100 milligrams two times per day by mouth for thirty days postoperative Esomeproazole 20 milligrams daily by mouth for thirty days postoperative Ondansetron 4 milligrams every eight hours by mouth as needed for nausea and/or vomiting for fourteen days postoperative Oxycodone 5 milligrams every six hours by mouth as needed for uncontrolled pain for fourteen days postoperative
62837014|NCT04294680|NO_INTERVENTION|Opiate Based|Oxycodone 5 to 10 milligrams every four to six hours by mouth as needed for pain for fourteen days postoperative Acetaminophen 1000 milligrams every six hours by mouth for fourteen days postoperative Gabapentin 100 milligrams three times per day by mouth for thirty days postoperative Celecoxib 100 milligrams two times per day by mouth for thirty days postoperative Esomeprazole 20 milligrams daily by mouth for thirty days postoperative Ondansetron 4 milligrams every eight hours by mouth as needed for nausea and/or vomiting for fourteen days postoperative
62837015|NCT05147259|EXPERIMENTAL|Cohort one: Low dose|Subjects will be randomized to a treatment sequence consisting of two treatment periods: received two formulation HR011408 injections successively
62837016|NCT05147259|EXPERIMENTAL|Cohort two: Medium dose|Subjects will be randomized to a treatment sequence consisting of two treatment periods: received two formulation HR011408 injections successively
62837017|NCT05147259|EXPERIMENTAL|Cohort three: high dose|Subjects will be randomized to a treatment sequence consisting of two treatment periods: received two formulation HR011408 injections successively
62837018|NCT00699114|PLACEBO_COMPARATOR|Placebo|Single dose placebo capsule
62837019|NCT00699114|ACTIVE_COMPARATOR|Ibuprofen 400 mg|Single dose ibuprofen 400 mg capsule
62837020|NCT00699114|ACTIVE_COMPARATOR|Ibuprofen 600 mg|Single dose ibuprofen 600 mg capsule
62837021|NCT00699114|ACTIVE_COMPARATOR|Ibuprofen 800 mg|Single dose ibuprofen 800 mg capsule
62837022|NCT00699114|ACTIVE_COMPARATOR|Paracetamol 500 mg|Paracetamol 500 mg (acetaminophen) capsule
62837023|NCT00699114|ACTIVE_COMPARATOR|Paracetamol 1000 mg|Single dose paracetamol 1000 mg (acetaminophen) capsule
62837024|NCT00699114|ACTIVE_COMPARATOR|Paracetamol 1000 mg + codeine 60 mg|Single dose paracetamol (acetaminophen) 1000 mg + codeine 60 mg capsule
62837025|NCT01601548|EXPERIMENTAL|Intervention Arm|Subjects are randomized to the Mindfulness Based Cancer Recovery (MBSR) intervention. Participants are presented with mindfulness medication techniques and share their experiences related to these meditation practices. There is a home practice component with an expectation of regular home meditation practice of 45 minutes per day. A full day silent retreat will occur in the second half of the course, providing an opportunity for class participants to gain experience with mindfulness techniques.
62837026|NCT01601548|NO_INTERVENTION|Control Arm|No intervention is administered. Health-related quality of life questionnaires will be completed.
62837027|NCT03042819|EXPERIMENTAL|Selinexor plus Doxorubicin|"Selinexor will be given by mouth (orally) once a week:~Dose Level -1 = 40 mg Dose Level 1 (Starting Dose) = 60 mg Dose Level 2 = 80 mg~Doxorubicin will be given by vein (intravenously) at a dose of 75 mg/m2 once every 3 weeks."
62837028|NCT00737672|EXPERIMENTAL|VIABAHN Treatment Group|Use of GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Comparator Arm
62612590|NCT02952872|EXPERIMENTAL|Arm 12|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, an animated narrator to guide the intervention, and the presence of motivational content.
62612591|NCT02952872|EXPERIMENTAL|Arm 13|13. Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, no animated narrator, and no motivational content.
62837029|NCT00737672|ACTIVE_COMPARATOR|PTA Treatment Group|Percutaneous Transluminal Angioplasty (PTA) in arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Experimental Arm
62837030|NCT06025968|EXPERIMENTAL|i-CBT|Cognitive behavioral therapy for insomnia with adjustment for MS.
62837031|NCT06025968|ACTIVE_COMPARATOR|Applied relaxation|Applied relaxation with adjustments for MS.
62612592|NCT02952872|EXPERIMENTAL|Arm 14|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, no animated narrator, and the presence of motivational content.
62612593|NCT02952872|EXPERIMENTAL|Arm 15|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and no motivational content.
62612594|NCT02952872|EXPERIMENTAL|Arm 16|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and the presence of motivational content.
62612595|NCT06730932|EXPERIMENTAL|JS004 combine with Toripalimab|
62612596|NCT05865158|EXPERIMENTAL|Institionalized group|Group of institutionalized people with chronic cardiovascular diseases.
62837032|NCT05653869|EXPERIMENTAL|APS03118 Dose Escalation|APS03118 administered orally
62837033|NCT04778137|EXPERIMENTAL|CMAB007|75mg×2
62837034|NCT04778137|ACTIVE_COMPARATOR|Xolair|150mg
62837035|NCT01434199|EXPERIMENTAL|UPD guided group|Both the colonoscopist and assistant will be viewing the imager screen during the whole procedure.
62837036|NCT01434199|NO_INTERVENTION|non-UPD guided group|Conventional colonoscopy would be done without image guidance.
62612597|NCT05865158|EXPERIMENTAL|Community-dwelling group|Group of community-dwelling people with chronic cardiovascular diseases.
62053639|NCT05732441|EXPERIMENTAL|Conventional treatment group combined with Huange capsule|Based on the clinical guidelines, the routine treatment was used in addition to Huange Capsule.
62053640|NCT02977559|EXPERIMENTAL|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable for ventilation
62837037|NCT03378271|EXPERIMENTAL|FGM/CGM|"each patient will have a CGM and a FGM, subcutaneous glucose sensors, the data will be compared to the time-matched reference blood glucose measurements.~Each ambulatory patient will sample capillary blood with the HemoCue meter and measure the concentration of glucose minimum 3 times per day for 14 days. The concentration of finger-stick capillary blood glucose will be measured using the self-monitoring blood glucose (SMBG) hemocue meter in their daily living. The subjects will record SMBG, in a written diary. Subjects will dose insulin according to their routine methods throughout the 14 day study"
62837038|NCT01843816||healthy subjects|18-65 aged healthy subjects who have no disorder that may disturb posture or erect position (inflammatory diseases, kyphosis, scoliosis, joint deformities)
62837039|NCT00559819|ACTIVE_COMPARATOR|Alcohol|Alcohol
62837040|NCT00559819|PLACEBO_COMPARATOR|Placebo|Orange juice
62837041|NCT03854279|EXPERIMENTAL|Bizact|Tonsillectomy will be done With the Bizact device
62837042|NCT03854279|ACTIVE_COMPARATOR|Electro-scissor|Tonsillectomy will be done With electro-scissors
62837043|NCT06215261|EXPERIMENTAL|Methylone|
62837044|NCT06215261|PLACEBO_COMPARATOR|Placebo|
62837045|NCT01128283||Sepsis|Patients with severe sepsis
62837046|NCT01128283||Non-infected|ICU patients without evidence of infection
62837047|NCT03710161|EXPERIMENTAL|4000 IU Vitamin D|4000 IU Vitamin D taken daily for six months
62053641|NCT02977559|EXPERIMENTAL|Laryngeal Mask Airway AuraGain|Laryngeal Mask Airway AuraGain for oxygenation and ventilation
62053642|NCT00053495|EXPERIMENTAL|Group 1: ACAM2000 Dose 1|Participants will receive a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units (PFU)/mL on Day 0.
62053643|NCT00053495|EXPERIMENTAL|Group 2: ACAM2000 Dose 2|Participants will receive a single dose of ACAM2000 smallpox vaccine, 2.0x10-8th plaque-forming units/mL on Day 0.
62053644|NCT00053495|EXPERIMENTAL|Group 3: ACAM2000 Dose 3|Participants will receive a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0
62053645|NCT00053495|EXPERIMENTAL|Group 4: ACAM2000 Dose 4|Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0
62053646|NCT00053495|ACTIVE_COMPARATOR|Group 5: Dryvax® Vaccine|Participants will receive a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0
62053647|NCT00982930|EXPERIMENTAL|Tobramycin Inhalation Powder (TIP)|Participants received 112 mg (four 28 mg capsules) of TIP administered by the T-326 Inhaler, twice a day (b.i.d.), given in a cycle of 28 days on treatment followed by 28 days off treatment (one cycle = 56 days) for up to 3 cycles.
62053648|NCT03179644|EXPERIMENTAL|Bi-pulmonary transplantation|Adult patient admitted in the Respiratory Distress and Severe Infections Intensive Care Unit in the postoperative period following a double lung transplant after written informed consent.
62612598|NCT05672589|EXPERIMENTAL|Relaxed rotational thromboelastometry|Relaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients bleed.
62612599|NCT05672589|ACTIVE_COMPARATOR|Standard coagulation tests|Standard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed
62837048|NCT03710161|ACTIVE_COMPARATOR|800 IU Vitamin D|800 IU Vitamin D taken daily for six months
62837049|NCT06400043|EXPERIMENTAL|Treadmill walking|Participants will be asked to walk at different gait velocities for 1 minute. The treadmill speed will be increased incrementally at 0.1m/s intervals until just before running. The comfortable walking speed will be determined.
62837050|NCT04242524|EXPERIMENTAL|Circadian Clock Alignment - High BMI|Subjects will come to the Sleep Lab three nights before their bariatric surgery procedure for an intervention that will align their central circadian clock. The intervention includes eating meals and snacks at fixed times and having lights off at a specific time at night and lights on at a specific time in the morning.
62837051|NCT04242524|ACTIVE_COMPARATOR|Circadian Clock Control - High BMI|Subjects will not come to the Sleep Lab and will live normally at home with no changes to their meal, sleep or wake times.
62612600|NCT02373007|OTHER|Classic Scopinaro Surgery|Patients will get the Bariatric surgery using the Classic Scopinaro Techniques
62837052|NCT04242524|ACTIVE_COMPARATOR|Circadian Clock Control - Low BMI|Subjects will not come to the Sleep Lab and will live normally at home with no changes to their meal, sleep or wake times.
62837053|NCT06071806|OTHER|surgery/Topical application of fluorouracil|The entire cyst lining radically enucleated with peripheral ostectomy was carried out for all bony walls to remove the microscopic satellite cyst, a sterile radiopaque quarter-inch ribbon gauze coated with 5-FU cream was packed into the surgical wound. Closure of the wound was then done in the usual manner using 3/0 vicryl leaving approximately1 cm of a small distal end of the gauze exposed to allow for easy removal after 24 hours postoperatively
62837054|NCT01077076|EXPERIMENTAL|Zegerid OTC Capsules|20 mg omeprazole and 1100 mg sodium bicarbonate
62053649|NCT02685722|EXPERIMENTAL|UC-MSCs Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.treatment period and follow-up period.In accordance with chronic wound criteria for the patient,By producing the principle of random number,Were randomly divided into UC-MSCs Gel group or Gel group,The researchers according to the situation of wound healing time and decided to use the secondary treatment,to observe the clinical efficacy and safety.
62443276|NCT05416658|EXPERIMENTAL|The Antipsychotic Medication Decision Aid (APM-DA) intervention clinics|Three pairs of comparable clinics (out of 22 clinics where OnTrackNY operates) based on the same region of the state and similar numbers of patients with similar demographic composition. One of each paired clinic is assigned to the intervention group by a blinded Co-I who will generate binary random variables.
62612601|NCT02373007|OTHER|Modified Scopinaro Surgery|Patients will get Bariatric surgery using the Modified Scopinaro Techniques
62837055|NCT01077076|ACTIVE_COMPARATOR|Prilosec OTC™ tablets containing 20 mg-equivalent omeprazole|20.6 mg omeprazole-magnesium complex.
62837056|NCT01077076|PLACEBO_COMPARATOR|Placebo|Inert substance
62837057|NCT05641259|EXPERIMENTAL|Dose Escalation|"LP-108: Cycle 0: ramp-up from Day 1, Cycle 1+: at escalating dose levels in participants with AML, MDS or CMML.~Azacitidine: beginning on Day 1 through Day 7 of each Cycle (expect for Cycle 0).~Strong/moderate CYP3A inhibitor and inducer are prohibited. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
62254753|NCT03184233|OTHER|Cerebral aneurysm surgery with RVP|Subjects receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere (contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels will be determinated preoperatively, peroperative and at 6, 12 and 24 hours postoperative by blood sample. Maximum cTnl level and cTnl level 24 hours will be compared. Brain oxygenation (Sct O₂) by near-infrared spectroscopy will be monitored. During surgery subjects allocated in this study arm will undergo RVP.
62254754|NCT03184233|ACTIVE_COMPARATOR|Craniotomy without RVP|"Subjects receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere (contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels will be determinated preoperatively, peroperative and at 6, 12 and 24 hours postoperative by blood sample. Maximum cTnl level and cTnl level 24 hours will be compared. Brain oxygenation (Sct O₂) by near-infrared spectroscopy will be monitored.~No rapid ventricular pacing is applied perioperatively."
62254755|NCT06476210|EXPERIMENTAL|BDL interventionv group|
62254756|NCT01997762|PLACEBO_COMPARATOR|Placebo|Corn starch capsules, 1 capsule twice a day for 3 months
62612602|NCT03946371||Extubation Success|Patients who do not require re-intubation, upto 48 hours after a planned extubation in the adult intensive care unit.
62612603|NCT03946371||Extubation failure|Patients who required re-intubation within 48 hours after a planned extubation in adult intensive care unit.
62837058|NCT05641259|EXPERIMENTAL|Safety Expansion|"LP-108: Cycle 0: ramp-up from Day 1, Cycle 1+: Participants with AML, MDS or CMML will be treated with LP-108 to enable selection of the recommended Phase 2 dose (RP2D).~Azacitidine: beginning on Day 1 through Day 7 of each Cycle (expect for Cycle 0).~Strong/moderate CYP3A inhibitor and inducer are prohibited. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
62837059|NCT05641259|EXPERIMENTAL|Efficacy Expansion [AML]|"LP-108: Cycle 0: ramp-up from Day 1, Cycle 1+: at RP2D level in participants with AML .~Azacitidine: beginning on Day 1 through Day 7 of each Cycle (expect for Cycle 0).~After the completion of Part 1, the Part 2 dose expansion phase will begin. Strong/moderate CYP3A inhibitor and inducer are prohibited. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
62837060|NCT05641259|EXPERIMENTAL|Efficacy Expansion [MDS&CMML]|"LP-108: Cycle 0: ramp-up, Cycle 1+: at RP2D level in participants with MDS or CMML.~Azacitidine: beginning on Day 1 through Day 7 of each Cycle (expect for Cycle 0).~Strong/moderate CYP3A inhibitor and inducer are prohibited. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
62254757|NCT01997762|EXPERIMENTAL|Resveratrol|Resveratrol capsules, 250 mg twice a day for 3 months
62254758|NCT04290663|ACTIVE_COMPARATOR|RAI group|
62254759|NCT04290663|EXPERIMENTAL|GUIDED FOLLOW-UP group|
62254760|NCT04845321|EXPERIMENTAL|VNRX-9945|Oral dosing
62254761|NCT04845321|PLACEBO_COMPARATOR|Placebo|Oral dosing
62443277|NCT05416658|NO_INTERVENTION|Treatment As Usual (TAU) clinics|The other clinic of each of the three pairs will be assigned to TAU.
62443278|NCT05729633|EXPERIMENTAL|Robot mediated Impairment-oriented training(RMIT)|Participant receives 20 hours of robot mediated impairment-oriented training applied via the Optimo Regen
62443279|NCT05729633|EXPERIMENTAL|Robot mediated impairment-orientyed and task-specific training (RMIT+RMTT)|Participant receives a total of 20 hours of robotic therapy. 10 hours will be in the form of RMIT and 10 hours in the form of RMTT
62443280|NCT03788681|ACTIVE_COMPARATOR|"oral estradiol  estradiol valerate"|"this group will include ( 85 ) poor responder women undergoing a trial of IVF/ICSI .This group will receive oral estradiol  estradiol valerate  (Cyclo-Progynova® , 2mg , Bayer Schering Pharma Ag , Germany ) from within 24 hours ovum pickup of the cycle."
62254762|NCT06245876||Cases Cohort|Subjects age 50-80 years old, with smoking history of at least 20 pack years with either (a) a high suspicion for lung cancer, who are planned to undergo biopsy or surgery to establish a definitive diagnosis after enrollment; or (b) confirmed primary lung cancer diagnosis, treatment naïve subjects.
62837061|NCT01524055|OTHER|Air|Air as insufflation gas during single-balloon enteroscopy.
62837062|NCT01524055|OTHER|CO2|CO2 as insufflation gas during single-balloon enteroscopy.
62837063|NCT05552937|EXPERIMENTAL|Tafasitamab and Lenalidomide|Tafasitamab and lenalidomide will be coadministered for up to 12 cycles (28 days per cycle).followed by tafasitamab monotherapy (in participants with stable disease or better) until treatment withdrawal criteria are met.
62837064|NCT01671319|EXPERIMENTAL|dose dense TC + pegfilgrastim|Docetaxel + Cyclophosphamide chemotherapy given every 2 weeks x 4 cycles plus pegfilgrastim given 24-48 hours post day 1 of each cycle
62837065|NCT03931369|EXPERIMENTAL|Tolvaptan test|15 MG pill administered tolvatan once, one day
62837066|NCT02949791|ACTIVE_COMPARATOR|Low Intra abdominal pressure HIPEC|Cytoreductive surgery and HIPEC with low intra-abdominal pressure
62837067|NCT02949791|EXPERIMENTAL|High Intra abdominal pressure HIPEC|Cytoreductive surgery and HIPEC with high intra-abdominal pressure
62053650|NCT02685722|EXPERIMENTAL|Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.treatment period and follow-up period.In accordance with chronic wound criteria for the patient,By producing the principle of random number,Were randomly divided into UC-MSCs Gel group or Gel group,The researchers according to the situation of wound healing time and decided to use the secondary treatment,to observe the clinical efficacy and safety.
62837068|NCT05539898|OTHER|ICD|ICD implanted
62254763|NCT06245876||USPSTF At Risk - Control Cohort|Healthy subjects aged 50-80 years old with smoking history of at least 20 pack years.
62837069|NCT01859624|EXPERIMENTAL|Albuterol|This study includes the off-label administration of oral albuterol (4 mg pill) and tracking the effect of motor function at two additional visits, 6 and 12 weeks following the initiation of the study drug. The initial dose of albuterol will be a 4 mg daily for the first 6 weeks. If the 4 mg is well tolerated, the dose will be increased to 8 mg at the 6 week visit.
62837070|NCT05064137|EXPERIMENTAL|Curodont Repair® ( monomeric self - assembling peptide P11-4 )|Self assembling peptide P11-4 as Curodont Repair® can remineralize WSLs in a deeper manner than fluoride by guided enamel regeneration by forming a three-dimensional matrix within the subsurface body of an initial carious lesion to which calcium and phosphate ions found in natural saliva can bind and build de novo hydroxyapatite crystals.
62837071|NCT05064137|EXPERIMENTAL|Clinpro white varnish® ( Tricalcium Phosphate Fluoride Varnish, 5% F- )|Tri-calcium phosphate can be hydrolyzed rapidly to form calcium hydroxyapatite (HAp). The processes of hydrolysis and formation of HAp are accelerated by the presence of NaF ions as in case of Clinpro white varnish®. Moreover, the HAp formed by such hydrolysis tends to have a greater uptake of fluoride than conventional HAp.
62837072|NCT05064137|ACTIVE_COMPARATOR|Voco-profluorid® fluoride varnish (5% sodium fluoride)|Fluoride varnish is the gold standard for treating WSLs.
62837073|NCT03755349|EXPERIMENTAL|Intervention group|Both burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes of the intervention side are covered by burr-hole covers.
62837074|NCT03755349|ACTIVE_COMPARATOR|Control group|None of the burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes on the control side are left uncovered.
62053651|NCT02082925|EXPERIMENTAL|COPD patient|
62254764|NCT06245876||Healthy Control Cohort|Healthy subjects aged 20-80 years old which are non-smokers or with smoking history of less than 20 pack years.
62053652|NCT01395108|PLACEBO_COMPARATOR|Placebo|Placebo
62053653|NCT01395108|ACTIVE_COMPARATOR|Nemonoxacin 125mg|Nemonoxacin 125mg
62053654|NCT01395108|ACTIVE_COMPARATOR|Nemonoxacin 250mg|Nemonoxacin 250mg
62053655|NCT01395108|ACTIVE_COMPARATOR|Nemonoxacin 500mg|Nemonoxacin 500mg
62053656|NCT01395108|ACTIVE_COMPARATOR|Nemonoxacin 750mg|Nemonoxacin 750mg
62053657|NCT01395108|ACTIVE_COMPARATOR|Nemonoxacin 1000mg|Nemonoxacin 1000mg
62053658|NCT03652779|EXPERIMENTAL|Tecarfarin 10mg|
62053659|NCT03652779|EXPERIMENTAL|Tecarfarin 20mg|
62053660|NCT03652779|EXPERIMENTAL|Tecarfarin 30mg|
62053661|NCT03652779|EXPERIMENTAL|Tecarfarin 40mg|
62837075|NCT06023017|EXPERIMENTAL|Prone Position Training group (PPT group)|All patients were admitted to our hospital at least 3 days before surgery. Patients in the intervention group (PPT group) received the prone position training daily in the hospital, three times a day, and about 1 hours every times, for at least 3 days before surgery. On the day of admission to the hospital, the patients in the PPT group were instructed to perform prone position training by nurses who were previously trained by prone position training.
62837076|NCT06023017|PLACEBO_COMPARATOR|Control group (C group)|Patients in the control group (C group) received standard perioperative care without any prone position training.
62612604|NCT01900860|ACTIVE_COMPARATOR|vitamin D 10,000 IU|Subjects in this arm receive 10,000 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
62053662|NCT02179502|EXPERIMENTAL|GLPG1690 single dose|Single oral dose of GLPG1690 suspension or solid formulation - ascending doses
62053663|NCT02179502|PLACEBO_COMPARATOR|Placebo single dose|Single oral dose of placebo suspension or solid formulation
62053664|NCT02179502|EXPERIMENTAL|GLPG1690 multiple doses|Multiple oral doses of GLPG1690 suspension - ascending doses
62837077|NCT05366062|EXPERIMENTAL|Treatment Arm|This is a Treatment Protocol for patients with severe and immediately life-threatening GBM that had surgical resection and first line treatment with radiation therapy and temozolamide per current standard of care. Patients will be treated with recurring 28-day cycles of ERC1671, GM-CSF, Cyclophosphomide, Bevacizumab, and Pembrolizumab until progression of disease and at the discretion of the treating physician.
62053665|NCT02179502|PLACEBO_COMPARATOR|Placebo multiple doses|Multiple oral doses of placebo suspension
62053666|NCT01682213|EXPERIMENTAL|dabrafenib|This is a single institution phase II trial assessing the efficacy of adjuvant dabrafenib (GSK2118436) in patients with surgically resected AJCC stage IIIC melanoma characterized by a BRAFV600E/K mutation.
62053667|NCT01356680|ACTIVE_COMPARATOR|Arm A|2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy IF-RT irrespective of FDG-PET results after chemotherapy
62254765|NCT04643990||LDT Combined with TDF for Treatment|The patients take one tablet of LDTand one tablet of TDF every night and continue to 12 months.
62254766|NCT04643990||Only TAF treatment.|The patients take one tablet of TAF every night and continue to 12 months.
62254767|NCT06410365|EXPERIMENTAL|intrathecal dexmedetomidine+ bupivacaine|intrathecal bupivacaine 0.75%(1.2ml+plus 5 μg Dex (diluted in N/S up to the volume of 1 ml intrathecally once
62837078|NCT00598910|EXPERIMENTAL|A|
62254768|NCT06410365|EXPERIMENTAL|intravenous dexmedetomidine+ bupivacane|intravenous dexmedetomidine 1mcg/kg in normal saline + intrathecal .75% bupivacaine (1.2ml)
62254769|NCT01150175|EXPERIMENTAL|Autologous bone marrow cells|
62254770|NCT01150175|PLACEBO_COMPARATOR|Plasma|
62612605|NCT01900860|ACTIVE_COMPARATOR|Vitamin D 4000 IU|Subjects in this arm receive 4,000 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
62612606|NCT01900860|ACTIVE_COMPARATOR|Vitamin D 400 IU|Subjects in this arm receive 400 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
62612607|NCT06346171|EXPERIMENTAL|Virtual Reality Integrative Psychotherapy|This group will undergo the same virtual reality exposure software during the colonoscopy procedure, but the psychotherapist will implement the integrative psychotherapy framework during the procedure.
62837079|NCT00598910|PLACEBO_COMPARATOR|B|
62053668|NCT01356680|EXPERIMENTAL|Arm B|2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy IN-RT if FDG-PET is positive after chemotherapy; 2 cycles BEACOPPescalated plus 2 cycles ABVD and treatment stop if FDG-PET is negative after chemotherapy
62053669|NCT06397599|ACTIVE_COMPARATOR|denture adhesive|use denture adhesive
62053670|NCT06397599|ACTIVE_COMPARATOR|non adhesive|conventional denture without denture adhesive
62053671|NCT00812279|EXPERIMENTAL|1. SMAR|Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times.
62053672|NCT00812279|ACTIVE_COMPARATOR|2 Conventional cigarette (CC)|Subjects will be allowed to smoke without any limit on consumption during the designated smoking times.
62254771|NCT00113074|EXPERIMENTAL|1|Weight management and blood pressure control intervention
62254772|NCT00113074|ACTIVE_COMPARATOR|3|Self-help materials targeting lifestyle modification
62254773|NCT00113074|EXPERIMENTAL|2|Weight management intervention
62837080|NCT06169059|EXPERIMENTAL|Treatment(Experimental): JLP-2004|Group I(Peroid I-comparator, Peroid II-JLP-2004), Group II(Period I-JLP-2004, Period II-Comparator)
62053673|NCT00812279|ACTIVE_COMPARATOR|3. smoking cessation (SC)|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
62053674|NCT03595930||Subjects who received ARNUITY|This PMS will be conducted with subjects who were administered ARNUITY in accordance with the approved label.
62053675|NCT06004414|EXPERIMENTAL|SilverCloud|Adolescents who screen positive for significant mental health symptoms and who are enrolled in their school-based health center (SBHC) randomized to receive SilverCloud.
62053676|NCT06004414|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Adolescents who screen positive for significant mental health symptoms and who are enrolled in their school-based health center (SBHC) randomized to receive psychotherapy.
62053677|NCT04426643|EXPERIMENTAL|mesenchymal stem cells|Patients with Urinary incontinence receiving standard treatment plus adipose-derived mesenchymal stem cells
62053678|NCT04426643|ACTIVE_COMPARATOR|control|Patients with Urinary incontinence receiving standard treatment
62053679|NCT03513406|ACTIVE_COMPARATOR|Sugammadex|Muscle relaxant reversal will be attained with sugammadex 2 mg/kgm IV.
62254774|NCT00262522|EXPERIMENTAL|LPV/r 800/200 mg QD Tablet|
62254775|NCT00262522|EXPERIMENTAL|LPV/r 800/200 mg QD SGC (Through Week 8)|
62254776|NCT00262522|ACTIVE_COMPARATOR|LPV/r 400/100 mg BID Tablet|
62254777|NCT00262522|ACTIVE_COMPARATOR|LPV/r 400/100 mg BID SGC (Through Week 8)|
62254778|NCT04312035|EXPERIMENTAL|End-range mobilization|End-range mobilization performed in end-position of the knee joint
62254779|NCT04312035|EXPERIMENTAL|Non end-range mobilization|Non end-range mobilization performed in loose-packed position of the knee joint
62837081|NCT06169059|ACTIVE_COMPARATOR|Control(Active Comparator): JC-013|Group I(Peroid I-comparator, Peroid II-JLP-2004), Group II(Period I-JLP-2004, Period II-Comparator)
62612608|NCT06346171|SHAM_COMPARATOR|Virtual Reality Distraction|This group will be exposed to the virtual reality environment as a distraction, but although receiving support in exploring the virtual world, no psychotherapy techniques will implemented.
62612609|NCT06346171|NO_INTERVENTION|Control group|This group will undergo treatment as usual according to state-of-the-art guidelines for non-sedated colonoscopy.
62612610|NCT03443258|EXPERIMENTAL|Intervention Group (IG)|Patients receive needs assessment tool integrated in nursing consultation in accordance with requirements by Danish Health and Medicine Board follow-up program for HNC patients. The consultation consists of 6 steps 1. Welcoming patient; 2. Introducing patient to assessment tool; 3. Discuss symptoms and concerns patient wishes to discuss; 4. Follow up on patients symptoms, concerns and emotional reactions/problems; 5. Accompany/support patient during appointment with surgeon and in cooperation with patient and surgeon ensure that problems arising from the tool needing medical attention are focused on; 6. Continue the consultation after appointment with surgeon; refer patient to multi-disciplinary team members when needed
62612611|NCT03443258|NO_INTERVENTION|Control Group (CG)|CG will receive standard care according to the Danish Health and Medicine Board's follow-up program for HNC patients. At present this is done by a staff nurse interviewing the patient, who is a member of the rehabilitation team who perform nursing consultations. The interview takes place after the appointment with the surgeon. The nurse refers the patient to physical rehabilitation if needed
62612612|NCT01260961|ACTIVE_COMPARATOR|Docosa Hexanoic Acid|
62612613|NCT01260961|PLACEBO_COMPARATOR|Placebo|
62612614|NCT05426109|EXPERIMENTAL|Peanut snacks|Participants will be provided and consume an extra 500 kcal/day of peanut-containing snacks for 10 weeks.
62612615|NCT05426109|ACTIVE_COMPARATOR|No peanut-containing snacks|Participants will be provided and consume an extra 500 kcal/day of snacks without peanuts or peanut-containing foods for 10 weeks.
62612616|NCT02768922|EXPERIMENTAL|Aphasia telerehabilitation|Speech and language therapy is given by telemedicine to improve expressive language function. The therapy will include knowledge based tasks of aphasia rehabilitation including training of language forms and overall functional communication. A special emphasis will be put on naming training. The telerehabilitation will be given in a addition to standard face-to-face aphasia rehabilitation
62612617|NCT02768922|ACTIVE_COMPARATOR|Control|Control Group receives standard face-to-face aphasia rehabilitation
62612618|NCT01335854|NO_INTERVENTION|Usual Care|Usual care for 3 months. This consists of a phone call after one week of treatment, and clinic appointments at the sleep center following one month and three months of CPAP treatment.
62612619|NCT01335854|EXPERIMENTAL|Web-Access to CPAP Data|Usual care and web-based access to CPAP adherence data for 3 months. Participants in this group will be asked to review their CPAP use daily in the first week of treatment and as desired over the next 3 months by accessing a password protected website.
62612620|NCT01335854|EXPERIMENTAL|Web-Access to CPAP Data & Incentive|Usual care and web-based access to CPAP data for 3 months with financial incentives. Participants in this group will be asked to review their CPAP use daily in the first week of treatment and as desired over the next 3 months by accessing a password protected website. Financial incentive terminated after 1 week.
62612621|NCT04436705|EXPERIMENTAL|Progressive Muscle Relaxation (PMR) technique|Participants in intervention group continued Progressive Muscle Relaxation (PMR) technique daily for 20 minutes for a total of four weeks addition to usual care. The usual care consists of pharmacological interventions to manage Cancer-related pain.
62612622|NCT04436705|NO_INTERVENTION|control|control group received only usual care for their pain during the study period. The usual care consists of pharmacological interventions to manage Cancer-related pain.
62612623|NCT06158009|EXPERIMENTAL|Norepinephrine group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62612624|NCT06158009|EXPERIMENTAL|Phenylephrine group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62612625|NCT04819412|EXPERIMENTAL|ROTAVAC 5C -F1|ROTAVAC 5C formulation BBIL-R2014-1
62612626|NCT04819412|EXPERIMENTAL|ROTAVAC 5C -F2|ROTAVAC5C formulation BBIL-R2014-2
62612627|NCT04819412|ACTIVE_COMPARATOR|ROTAVAC®|ROTAVAC® with 5 minutes prior administration of 2.5 ml of buffer
62053680|NCT03513406|ACTIVE_COMPARATOR|Neostigmine|Muscle relaxant reversal will be attained with neostigmine 50 mcg/kgm plus glycopyrrolate10 mcg/kgm IV.
62053681|NCT06099457|EXPERIMENTAL|Treatment|Sibtime web-based intervention.
62053682|NCT06099457|NO_INTERVENTION|Control|Business as usual.
62053683|NCT02415179|EXPERIMENTAL|Inhaled Mometasone/formoterol|Inhaled Mometasone/Formoterol (100/5 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
62612628|NCT06597968||Image going through AI tool|these are the images going through the AI tool
62612629|NCT06597968||image not going through AI tool|these are the images not going through the AI tool
62612630|NCT06197308|EXPERIMENTAL|PCS patients|
62612631|NCT03750409|ACTIVE_COMPARATOR|Helmet Active Device|Patients will be randomized 2:1 ratio to receive either the helmet active device or the helmet sham matched device. EACH device will be delivered with a highly visible tag with either an 'A' or 'B' respective to the study group the patient was randomized to.
62612632|NCT03750409|SHAM_COMPARATOR|Helmet Sham|Patients will be randomized 2:1 ratio to receive either the helmet active device or the helmet sham matched device. EACH device will be delivered with a highly visible tag with either an 'A' or 'B' respective to the study group the patient was randomized to.
62612633|NCT00814541|EXPERIMENTAL|1|Relapsed patients, previously treated with VAD or VAD like regimen (VAMP, C-VAMP and Z-Dex are examples of VAD like therapy) and who have had autologous transplants at least 1 year previously.Patients may proceed directly to PAD therapy or have had a maximum of one other line of therapy before PAD.
62612634|NCT00814541|EXPERIMENTAL|2|Relapsed patients, previously treated with VAD or VAD-like regimen who have not had autologous transplantation and achieved at least PR (Appendix A). Patients may proceed directly to PAD therapy or have had a maximum of two other lines of therapy before PAD.
62612635|NCT00814541|EXPERIMENTAL|3|Patients refractory (MR, NC or PD) to VAD or VAD-like therapy. Patients should proceed directly to PAD therapy. Patients with NC or PD may proceed to PAD after a minimum of two cycles of VAD or VAD-like therapy or a minimum of 4 cycles, if MR.
62254780|NCT04312035|PLACEBO_COMPARATOR|Control|Sham technique performed in loose-packed position of the knee joint
62254781|NCT04187300|EXPERIMENTAL|DV3396|Semaglutide administered with the DV3396 pen-injector (Formulation D)
62443281|NCT03788681|PLACEBO_COMPARATOR|placebo|this group will include ( 85 ) poor responder women undergoing a trial of IVF/ICSI . This group will receive oral placebo (tablets) from within 24 hours ovum pickup of the cycle
62443282|NCT01464827|EXPERIMENTAL|Group A|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 8 weeks.
62837082|NCT00359320|EXPERIMENTAL|Mucosa-to-jejunal mucosa technique of pancreaticojejunosto|Determine whether a duct mucosa-to-jejunal mucosa technique of pancreaticojejunostomy will improve the pancreatic fistula rate
62837083|NCT04055623|EXPERIMENTAL|Intravenous infusion of Treg cells + Interleukin-2 injections|For the first six months: T-regulatory cells taken from a participant will be increased in numbers outside the body in a lab and then returned back to the same participant through intravenous (IV) infusions once per month. The participant will also take Interleukin-2 (IL2) injections three times per week.
62837084|NCT04055623|PLACEBO_COMPARATOR|Intravenous infusion w/Placebo + matching placebo injections|For the first six months: Participants will receive matching placebo or inactive intravenous (IV) infusions once per month. The participant will also take a matching inactive placebo injection three times per week.
62837085|NCT04055623|EXPERIMENTAL|2nd 6-months Open Label: Treg Infusions + IL-2 injections|For second six months: All participants will receive their own expanded/increased in numbers Treg cells by monthly infusion plus 3 times per week subcutaneous injections of IL-2.
62837086|NCT02820493|OTHER|single arm study|Vedolizumab 300 mg iv at week 0, week 2 and week 6, than every 8 weeks.
62837087|NCT00472030|EXPERIMENTAL|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
62837088|NCT00472030|ACTIVE_COMPARATOR|Prednisone|The control arm of the study will receive standard prednisone therapy to a maximum dose of 0.5 mg/kg/day.
62837089|NCT01950130|EXPERIMENTAL|IABP group|Preoperative IABP insertion
62837090|NCT01950130|NO_INTERVENTION|Control group|Preoperative conservative treatment
62254782|NCT04187300|EXPERIMENTAL|PDS290|Semaglutide administered with the PDS290 pen-injector (Formulation B)
62254783|NCT05088642|EXPERIMENTAL|Mild hepatic impairment (Child-Pugh Class A)|
62837091|NCT06361108|EXPERIMENTAL|Cohort M1 (10active, 2 placebo)|296 mg/administration
62837092|NCT06361108|EXPERIMENTAL|Cohort M2 (10 active, 2 placebo)|414 mg/administration
62837093|NCT05825378|EXPERIMENTAL|group dexamethasone|Dexamethasone 8mg+0.375% ropivacaine
62053684|NCT02415179|ACTIVE_COMPARATOR|Inhaled Fluticasone/Salmeterol|Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
62254784|NCT05088642|EXPERIMENTAL|Moderate hepatic impairment (Child-Pugh Class B)|
62254785|NCT05088642|EXPERIMENTAL|Normal hepatic function|
62254786|NCT06108713|EXPERIMENTAL|Addition of juggling|Group taking part in juggling exercise protocol in a crossover regimen.
62254787|NCT06108713|NO_INTERVENTION|Without addition of juggling|Group not taking part in juggling exercise protocol in a crossover regimen.
62837094|NCT05825378|SHAM_COMPARATOR|group control|0.375% ropivacaine
62837095|NCT01734018||Cohort|
62837096|NCT03419286||EGFR MUTATED|patient with lung cancer with EGFR mutation before transformation into small cell lung cancer
62837097|NCT03419286||EGFR NON MUTATED|patient with lung cancer without driver oncogenic before transformation into small cell lung cancer
62254788|NCT02201121|EXPERIMENTAL|phenylephrine group, dopamine group, ephedrine group|"phenylephrine group: use the phenylephrine to increase the SAP from low to high level.~dopamine group: use the dopamine to increase the SAP from low to high level. ephedrine group:use the ephedrine to increase the SAP from low to high level."
62254789|NCT06455917|EXPERIMENTAL|Tumor-infiltrating lymphocyte product (TIL) transfer|Tumor-specific T cells are expanded from excised tumor samples and stimulated in cell culture with interleukin-2 (IL-2). The resulting autologous TILs are then re-infused to the patient after a non-myeloablative lymphodepleting chemotherapy with cyclophosphamide and fludarabine. Activation of TILs in the patient is then supported by IL-2 administration. The transplant product will be produced in the Good Manufacturing Practice (GMP) facility of the University Hospital in Basel.
62837098|NCT00645346|EXPERIMENTAL|1|Subjects will receive either 5, 10 or 20 mcg of the vaccine
62837099|NCT00645346|PLACEBO_COMPARATOR|2|Subjects will receive placebo control
62837100|NCT05843396|ACTIVE_COMPARATOR|Neonatal Massage Received|
62837101|NCT05843396|NO_INTERVENTION|No Massage Received|
62837102|NCT03000660|EXPERIMENTAL|Venetoclax and Dexamethasone|Venetoclax will be given at one of four escalating doses (100 mg/day, 200 mg/day, 400 mg/day, or 800 mg/day) by mouth on each day of the cycle. Dexamethasone will be given at 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
62254790|NCT02107495||CHF-confirmed subjects|Subjects 21 years of age or greater with clinically confirmed heart failure or have presented to the clinical site with signs, symptoms and/or risk factors suggestive of heart failure.
62254791|NCT02107495||Subjects with potentially co-morbidities|non-CHF subjects 21 years or greater, with potentially confounding comorbidities such as diabetes, renal insufficiency, hypertension and chronic obstructive pulmonary disease (COPD).
62254792|NCT02107495||Apparently healthy subjects|Apparently healthy subjects (meeting inclusion criteria) greater than 45 years of age, with no prior history of myocardial infarction (MI), acute coronary syndrome (ACS) congestive heart failure (CHF) or any other cardiac-related disease.
62443283|NCT01464827|EXPERIMENTAL|Group B|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
62837103|NCT03292796|OTHER|Stop prostaglandin eye drops post op|Stop prostaglandin eye drops post operatively. Prostaglandins either stopped or continued after cataract surgery. Latanoprost Travaprost Bimatoprost Tafluprost
62837104|NCT03292796|OTHER|Continue prostaglandin eye drops post op|Continue prostaglandin eye drops post operatively Prostaglandins either stopped or continued after cataract surgery. Latanoprost Travaprost Bimatoprost Tafluprost
62612636|NCT03017976||Competitive swimmers|Regular and naïf competitive swimmers will be followed for a mean period of 90 days. A battery of measurements and biological samples will be collected at the baseline evaluation and 90 days after, in order to evaluate long-term changes in respiratory health biomarkers. Measurements will also be performed before and after a single regular training session in order to assess acute effects in respiratory health biomarkers.
62612637|NCT03017976||Recreational swimmers and swimming pool staff|Swimming pool physicochemical and microbiological characteristics and the association between each parameter measured as an indicator of water and air quality, contamination of surfaces will be evaluated and the association with recreational users, swimming teachers and pool attendants health parameters will be studied.
62254793|NCT03761511|ACTIVE_COMPARATOR|Treatment arm|Nicotinamide 4 g (capsules) or highest tolerated dose with a minimum of 2 g/d per os once daily
62612638|NCT03797989|EXPERIMENTAL|Phase A: Group 1|Each volunteer will receive one vial of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
62612639|NCT03797989|EXPERIMENTAL|Phase A: Group 2|Each volunteer will receive a fifth of a vial (1:5 dilution) of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
62612640|NCT03797989|EXPERIMENTAL|Phase A: Group 3|Each volunteer will receive one twentieth of a vial (1:20 dilution) of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
62612641|NCT03797989|EXPERIMENTAL|Phase B: Group 4|The six volunteers from Groups 1, 2 and 3 in will undergo secondary challenge using the optimal inoculum, as determined in Phase A of the study. They will constitute 'Group 4' in Phase B. This will occur approximately eight months (and up to nine months) later after their primary challenge.
62443284|NCT01464827|EXPERIMENTAL|Group C|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
62612642|NCT03797989|EXPERIMENTAL|Phase B: Group 6|Three new malaria naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls to Group 4.
62612643|NCT03797989|EXPERIMENTAL|Phase C: Group 5|The six volunteers from Group 4 in Phase B will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 5 in Phase C. This will occur approximately sixteen months (and up to twenty months) later after their secondary challenge.
62612644|NCT03797989|EXPERIMENTAL|Phase C: Group 7|The three volunteers from Group 6 who underwent primary challenge in Phase B undergo secondary challenge, again using the optimal inoculum as determined in Phase A, and will now form Group 7 in Phase C. This will occur approximately six months (and up to nine months) later after their primary challenge.
62612645|NCT03797989|EXPERIMENTAL|Phase C: Group 9|Four to eight new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 5 and 7.
62837105|NCT05216354|EXPERIMENTAL|Cohort 1 (healthy subjects)|8 subject with normal renal function will be administered 5mg (1 x 5 mg capsule) fruquintinib
62837106|NCT05216354|EXPERIMENTAL|Cohort 2 (severe renal impairment)|8 subjects with severe renal impairment will be administered 2 mg (2 x 1 mg capsules) fruquintinib
62837107|NCT05216354|EXPERIMENTAL|Cohort 3 (moderate renal impairment)|8 subjects with moderate renal impairment will be administered 5 mg (a x 5 mg capsule) fruquintinib
62837108|NCT00476853|ACTIVE_COMPARATOR|1|NVP 400 mg
62053685|NCT03620630|NO_INTERVENTION|Usual Care|Patients allocated to usual care will continue with their current NHS management in line with national and local guidelines.
62254794|NCT03761511|PLACEBO_COMPARATOR|Placebo arm|Matching Placebo (capsules) once daily
62254795|NCT03075813|EXPERIMENTAL|Intervention Cluster|"Surgical surveillance data submitted to the DICON Surgical Database will undergo immediate analysis by optimized SPC methods. If a signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is required.~Optimized SPC methods include the application of two SPC charts. The investigator determined that when either chart identifies a signal, the study will have approximately 90% sensitivity and 65% specificity to identify important increases in rates of SSI."
62443285|NCT01464827|EXPERIMENTAL|Group D|Treatment-naïve participants received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
62443286|NCT01464827|EXPERIMENTAL|Group E|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.
62443287|NCT01464827|EXPERIMENTAL|Group F|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
62443288|NCT01464827|EXPERIMENTAL|Group G|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
62443289|NCT01464827|EXPERIMENTAL|Group H|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
62443290|NCT01464827|EXPERIMENTAL|Group I|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
62837109|NCT00476853|ACTIVE_COMPARATOR|2|NVP 600 mg
62837110|NCT00357903|OTHER|1|
62837111|NCT06174415|EXPERIMENTAL|Experimental group|The experimental group consisted of the patients themselves. Compare data before and after treatment
62837112|NCT02058303|EXPERIMENTAL|Exparel forearm block|Under ultrasound guidance, 3-5 milliliters (mL) Exparel will be injected around the 3 nerves of the forearm prior to surgery. 20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
62053686|NCT03620630|ACTIVE_COMPARATOR|myCOPD|Patients allocated to the myCOPD arm will receive access to a web based application called myCOPD
62053687|NCT02097979|EXPERIMENTAL|Glaucoma Educational Intervention|
62254796|NCT03075813|NO_INTERVENTION|Control Cluster|Local personnel in clusters randomized to traditional surveillance and feedback will receive bar graph reports and data interpretation per routine DICON surveillance. These reports will be provided every 6 months.
62254797|NCT03896542|EXPERIMENTAL|Commercial video game|the group commercial video game received 30 minutes of conventional therapy plus 30 minutes of rehab training using Xbox Kinect-based games.
62254798|NCT03896542|EXPERIMENTAL|Rehabilitation video game|the group rehabilitation video game received 30 minutes of conventional therapy plus 30 minutes of rehab games.
62254799|NCT03896542|NO_INTERVENTION|The control group|The control group received 30 minutes of conventional therapy
62254800|NCT02139254||Low risk|Pregnant women with a low risk for metabolic diseases
62254801|NCT02139254||High risk|Pregnant women with a high risk for metabolic diseases
62254802|NCT01149889|EXPERIMENTAL|active stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
62837113|NCT02058303|ACTIVE_COMPARATOR|Bupivacaine supraclavicular block|Under ultrasound guidance, 20-30 mL 0.5% Bupivacaine will be used for the supraclavicular block.
62837114|NCT05868616||Group 1 - Implantation|Patients admitted for CRT implantation according to current ESC/AHA guidelines
62837115|NCT05868616||Group 2 - 6 months control|Patients admitted for 6 months routine checkups of their CRT devices
62837116|NCT00397865|EXPERIMENTAL|A|
62837117|NCT00825487|EXPERIMENTAL|ARQ 621 treatment|
62837118|NCT05710484||Inferior alveolar nerve block anesthesia cohort|This group will consist of participants who are undergoing procedures that require mandibular anesthesia as routine part of care. Participants in this group will have voice recordings taken before and after the administration of anesthesia. The aim is to assess any changes in voice characteristics attributable to the effect of the anesthesia.
62837119|NCT05459896|EXPERIMENTAL|Experimental Group|Participants in the experimental group will be triaged to receive different types of interventions at Level 2, namely physical activity training, mindfulness coping strategies and energy conservation techniques, based on participants' screening and outcome assessment results at Level 1. These interventions will be taught in the 8-week regular supervision phase and self-practice during the 16-week self-help phase. The features in the Health Apps for Post-Pandemic Years (HAPPY) will be introduced to the participants in the first two sessions. In the other six sessions participants will be provided guidance in practicing the assigned intervention. Participants will self-practice the assigned intervention at home during 16-week self-help phase. At Level 3 Self-management, participants will be encouraged to work through a total of six thematic modules which aim to enhance participants' favourable appraisals of the current stress factors, to reduce stress levels and improve coping.
62837120|NCT05459896|NO_INTERVENTION|Waitlist Control Group|Participants in the waitlist control group will receive materials on the promotion of physical and psychological health during the waiting period. Participants will then receive the same 24-week intervention as the experimental group in Week 25 after completing the baseline assessment.
62053688|NCT02097979|NO_INTERVENTION|Delayed Intervention|
62053689|NCT04241458|EXPERIMENTAL|BI 706321|
62053690|NCT04241458|PLACEBO_COMPARATOR|Placebo|
62053691|NCT03344224||normal blood lipid/protein group|
62053692|NCT03344224||abnormal blood lipid/protein group|
62053693|NCT01705743|ACTIVE_COMPARATOR|Group 1 Sevoflurane+Nitrous oxide|
62254803|NCT00288249|EXPERIMENTAL|Arm 2|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 \[30-minute infusion\] in Arm 3 and 22 mg/m2 \[3-hour infusion\] in Arm 4)
62254804|NCT00288249|EXPERIMENTAL|Arm 3|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 \[30-minute infusion\] in Arm 3 and 22 mg/m2 \[3-hour infusion\] in Arm 4)
62254805|NCT00288249|EXPERIMENTAL|Arm 4|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 \[30-minute infusion\] in Arm 3 and 22 mg/m2 \[3-hour infusion\] in Arm 4)
62254806|NCT00288249|EXPERIMENTAL|Arm 1|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 \[30-minute infusion\] in Arm 3 and 22 mg/m2 \[3-hour infusion\] in Arm 4)
62254807|NCT02423551|NO_INTERVENTION|Control|Usual diet
62053694|NCT01705743|ACTIVE_COMPARATOR|Group 2 Sevoflurane|
62053695|NCT01344668|OTHER|Standard Diabetes Education|Standard Diabetes Education
62053696|NCT01344668|OTHER|Enhanced Diabetes Education|Enhanced Diabetes Education
62053697|NCT00454571|EXPERIMENTAL|Pazopanib|Patients receive pazopanib hydrochloride PO QD on days 1-28 after treatment with leuprolide acetate and goserelin acetate. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62053698|NCT00454571|ACTIVE_COMPARATOR|Observation|Patients undergo observation after treatment with leuprolide acetate and goserelin acetate.
62254808|NCT02423551|EXPERIMENTAL|MRE|MRE consumption
62254809|NCT05357690|EXPERIMENTAL|Stellate ganglion block with local anesthetic|Subjects will receive a single injection of bupivacaine in a stellate ganglion block
62612646|NCT03797989|EXPERIMENTAL|Phase D: Group 8|The three volunteers from Group 7 in Phase C will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 8 in Phase D. This will occur approximately five months (and up to ten months) after their secondary challenge.
62612647|NCT03797989|EXPERIMENTAL|Phase D: Group 10|The four to eight volunteers from Group 9 in Phase C will undergo secondary challenge, using the optimal inoculum as determined in Phase A, and form Group 10 in Phase D. This will occur approximately six months (and up to nine months) later after their primary challenge.
62612648|NCT03797989|EXPERIMENTAL|Phase D: Group 12|Four to eight new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 8 and 10.
62612649|NCT03797989|EXPERIMENTAL|Phase E: Group 11|The four to eight volunteers from Group 10 in Phase D will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 11 in Phase E. This will occur approximately five months (and up to ten months) after their secondary challenge.
62612650|NCT03797989|EXPERIMENTAL|Phase E: Group 13|The four to eight volunteers from Group 12 in Phase D will undergo secondary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 13 in Phase E. This will occur approximately five months (and up to ten months) after their secondary challenge.
62612651|NCT03797989|EXPERIMENTAL|Phase E: Group 15|Two new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 11 and 13.
62612652|NCT03797989|EXPERIMENTAL|Phase F: Group 14|The four to eight volunteers from Group 13 in Phase E will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 14 in Phase F. This will occur approximately five months (and up to ten months) after their secondary challenge.
62612653|NCT03797989|EXPERIMENTAL|Phase F: Group 16|Two new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Group 14.
62254810|NCT05357690|SHAM_COMPARATOR|Stellate ganglion block with saline placebo|Subjects will receive a single injection of saline in a stellate ganglion block
62254811|NCT05287945|EXPERIMENTAL|Orellanine|Orellanine administered intravenously
62254812|NCT02572674|OTHER|experimental arm|Experimental follow up : Neuropsychological assessment at 6 month and genetic samples
62254813|NCT02687542|PLACEBO_COMPARATOR|Placebo|Placebo
62254814|NCT02687542|EXPERIMENTAL|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose level (1 mg QD)
62254815|NCT02687542|EXPERIMENTAL|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
62254816|NCT02687542|EXPERIMENTAL|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751 higher middle dose 2 (7 mg QD)
62254817|NCT02687542|EXPERIMENTAL|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
62254818|NCT00225979|EXPERIMENTAL|SMS995|
62254819|NCT05231499||healthy volunteers|
62443291|NCT01464827|EXPERIMENTAL|Group J|Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
62443292|NCT01464827|EXPERIMENTAL|Group K|Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
62443293|NCT01464827|EXPERIMENTAL|Group L|Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
62612654|NCT04931719|ACTIVE_COMPARATOR|the PRP+Artz group|The patients in the PRP+Artz group received one intraarticular Artz injection (2.5 ml) followed consecutively by one intraarticular injection of PRP (3ml).
62612655|NCT04931719|EXPERIMENTAL|the PRP+HYAJOINT Plus group|The patients in the PRP+HYAJOINT Plus group received one intraarticular HYAJOINT Plus injection (3ml) followed by one intraarticular injection of PRP (3ml).
62612656|NCT02795936|ACTIVE_COMPARATOR|Institutional based rehabilitation|Conduct cardiac rehabilitation exercise protocol within the hospital
62612657|NCT02795936|ACTIVE_COMPARATOR|Home based rehabilitation|Conduct cardiac rehabilitation exercise protocol at home
62612658|NCT02795936|PLACEBO_COMPARATOR|Observational arm|No prescribed exercises, followed up monthly
62612659|NCT01553994||HPV vaccinated, non-vaccinated|Individuals born between 1989 and 1996. HPV-vaccinated will be compared to non-vaccinated in regards to condyloma status post vaccination.
62254820|NCT05231499||immunocompromised subjects|
62254821|NCT05060263|EXPERIMENTAL|Cohort 1|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
62254822|NCT05060263|EXPERIMENTAL|Cohort 2|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
62254823|NCT05060263|EXPERIMENTAL|Cohort 3|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
62254824|NCT05060263|EXPERIMENTAL|Cohort 4|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
62254825|NCT05060263|EXPERIMENTAL|Cohort 5|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
62254826|NCT05060263|EXPERIMENTAL|Cohort 6|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
62612660|NCT00041041|EXPERIMENTAL|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62837121|NCT04006132|EXPERIMENTAL|Ponto 3 SuperPower sound processor|All patients will be fitted with two bone-anchored sound processors (Ponto 3 SuperPower), unilaterally and bilaterally.
62837122|NCT05887388|EXPERIMENTAL|Intervention|Connect-Home Plus will be delivered in the skilled nursing facility and via telephone after discharge.
62837123|NCT02566369|EXPERIMENTAL|CD5789 (trifarotene) 50μg/g Cream|CD5789 (trifarotene) 50μg/g Cream
62837124|NCT02566369|PLACEBO_COMPARATOR|Placebo Cream|Placebo cream
62837125|NCT00967837|EXPERIMENTAL|Diabetes with non healing wounds|To determine and monitor progress of diabetic patients with non healing wounds that have failed conventional 60 day treatment respond to pulsatile intravenous insulin therapy in improving and completing healing in non healing wounds
62837126|NCT02716480|EXPERIMENTAL|Mobility Coaching|"45 patients undergoing bariatric surgery received a monthly mobility coaching session of 20 to 30 min by phone during 6 months."
62837127|NCT02716480|EXPERIMENTAL|Diet Coaching|"45 patients undergoing bariatric surgery received a monthly diet coaching session of 20 to 30 min by phone during 6 months."
62837128|NCT02565368|EXPERIMENTAL|RT group|R: Reference drug(Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg) 1T T: Test drug(CKD-395 0.5/1000mg) 1T
62837129|NCT02565368|EXPERIMENTAL|TR group|T: Test drug(CKD-395 0.5/1000mg) 1T R: Reference drug(Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg) 1T
62837130|NCT02001259|ACTIVE_COMPARATOR|Epidural lidocaine|epidural lidocaine: 3 mL of 1% lidocaine with adrenaline and 3 mL of 1% lidocaine without adrenaline into epidural catheter at 48 hr after surgery
62837131|NCT02001259|EXPERIMENTAL|epidural triamsinolone|epidural triamsinolone: 40 mg of triamsinolone (1 mL), 2.5 mL of 1% lidocaine with adrenaline and 2.5 mL of 1% lidocaine without adrenaline into epidural catheter at 48 hr after surgery
62837132|NCT06284135|EXPERIMENTAL|Michl-stitch|
62837133|NCT06284135|NO_INTERVENTION|control|
62837134|NCT04767529|EXPERIMENTAL|EFX 28 mg|
62837135|NCT04767529|EXPERIMENTAL|EFX 50 mg|
62837136|NCT04767529|PLACEBO_COMPARATOR|Placebo|
62612661|NCT04222842|EXPERIMENTAL|CM082 Tablet|Code Name: CM082 Tablet Other Name: X-82 Dosage and Administration: 25mg BID/50mg QD/50mg BID, P.O., two-week on/two-week off in four-week cycles until disease progression or unacceptable toxicity
62612662|NCT03529344|ACTIVE_COMPARATOR|Blue whiting protein hydrolysate|Dietary Supplement: Blue whiting protein hydrolysate 6g protein per day for 6wk
62837137|NCT06097715|ACTIVE_COMPARATOR|patient group|patients which previosly diagnosed with chronic liver diseases or presented with manifestations of chronic liver diseases
62837138|NCT06097715|ACTIVE_COMPARATOR|control group|children in the same age and sex of the patient group and presented to Sohag Universty Hospital due to any complaint rather than hepatic and gastrointestinal disease.
62837139|NCT01001819||1|Chronic Rhinosinusitis w/o nasal polyps
62837140|NCT01001819||2|No sinus disease
62837141|NCT00946387|EXPERIMENTAL|1|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
62837142|NCT00946387|ACTIVE_COMPARATOR|2|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
62837143|NCT03651297|EXPERIMENTAL|Younger Adults|First group will include 20 young adults with no history of falls or fear of falling. They will complete both interventions: Balance Training with Fall-Arrest Harness and Balance Training with Adjustable Harness.
62837144|NCT03651297|EXPERIMENTAL|Older adults|Second group will include 20 older adults with a self-reported history of falls or fear of falling. They will complete both interventions: Balance Training with Fall-Arrest Harness and Balance Training with Adjustable Harness.
62837145|NCT02106858||Group 1|Patients treated by Physician with Stivarga under approved local prescriptions
62837146|NCT06147388||CIN 2, CIN 3|Bioptically verified CIN 2 or CIN 3 lesion
62837147|NCT05504785|ACTIVE_COMPARATOR|Control Group|Twenty type 2 diabetic patients in the Control Group will be managed according to standard-of-care methods at TJUH using finger-stick blood glucose measurements in an attempt to maintain the patient's blood glucose levels in the desired target range (80 to 180 mg/dL). Three blinded CGM will be used to record the patient's glucose trend data (for 20 days maximum) for future download to a computer and analysis.
62053699|NCT04040309|EXPERIMENTAL|Plasma rich in growth factors group|Group of patients who will receive 1 ml of PRGF 2nd fractions injections into their trigger points in the masseter muscle.
62053700|NCT04040309|ACTIVE_COMPARATOR|Lidocaine group|Group of patients who will receive 1 ml 2% Lidocaine injections into the myofascial trigger point in the masseter muscle.
62254827|NCT05060263|EXPERIMENTAL|Cohort 7|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
62612663|NCT03529344|PLACEBO_COMPARATOR|Placebo Comparator: Control|Control group will receive non-caloric juice without protein supplementation
62837148|NCT05504785|ACTIVE_COMPARATOR|Investigational Group|Forty type 2 diabetic patients in the Investigational Group will be managed by the orthopedic floor nurses using the real-time DexCom G6 CGM trend data to determine the appropriate therapy to maintain the patient's glucose levels in the desired target range (80 to 180 mg/dL). In addition, three blinded CGM will be used to record the patient's glucose trend data (for 20 days maximum) for future download to a computer and analysis.
62837149|NCT01093157|ACTIVE_COMPARATOR|ACTH (HP Acthar gel) 40 units|
62254828|NCT04993040|EXPERIMENTAL|Oraxol|Subjects will receive Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.
62254829|NCT04791839|EXPERIMENTAL|Cohort A: Zimberelimab + Domvanalimab + Etrumadenant|"* Patients will be treated on 21-day cycles with 360 mg zimberelimab intravenously on Day 1, 15 mg/kg domvanalimab intravenously on Day 1, and 150 mg etrumadenant orally daily on Days 1 to 21.~* Cohort A participants are those that have PD-L1 1-49%"
62837150|NCT01093157|ACTIVE_COMPARATOR|ACTH (HP Acthar gel) 80 units|
62837151|NCT02745119|EXPERIMENTAL|Lampalizumab Every 4 Weeks|Participants who received either lampalizumab or sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit will receive open-label lampalizumab as 10 milligrams (mg) via ITV injection, administered every 4 weeks.
62837152|NCT02745119|EXPERIMENTAL|Lampalizumab Every 6 Weeks|Participants who received either lampalizumab or sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit will receive open-label lampalizumab as 10 mg via ITV injection, administered every 6 weeks.
62837153|NCT01216189||Preoperative radiotherapy|Women with rectal cancer treated with preoperative radiotherapy (RT) and surgery.
62837154|NCT01216189||No preoperative radiotherapy|Women with rectal cancer treated with surgery alone (no RT).
62837155|NCT05908019|EXPERIMENTAL|Web-based health care program|We aim to develop a PAH web-based health care program, and to evaluate the effects of this program on ameliorating social support, self-care ability and active tolerance, and improving symptom distress, anxiety, depression and quality of life in patients with PAH.
62837156|NCT05908019|NO_INTERVENTION|Usual care|usual care
62837157|NCT03077412|EXPERIMENTAL|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
62837158|NCT03077412|EXPERIMENTAL|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg for 24 weeks
62254830|NCT04791839|EXPERIMENTAL|Cohort B: Zimberelimab + Domvanalimab + Etrumadenant|"* Patients will be treated on 21-day cycles with 360 mg zimberelimab intravenously on Day 1, 15 mg/kg domvanalimab intravenously on Day 1, and 150 mg etrumadenant orally daily on Days 1 to 21.~* Cohort B participants are those that have PD-L1 ≥ 50%."
62837159|NCT03077412|EXPERIMENTAL|Placebo|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
62837160|NCT05098431|EXPERIMENTAL|Experimental Arm|Receive Quadriceps MEPs during procedure
62053701|NCT03118921|EXPERIMENTAL|Virtual reality|The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software
62443294|NCT01464827|EXPERIMENTAL|Group M|Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
62443295|NCT01464827|EXPERIMENTAL|Group N|Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
62612664|NCT03329105|EXPERIMENTAL|Sea Salt Mouth Rinse|
62612665|NCT03329105|ACTIVE_COMPARATOR|Standardized Oral Health Practices|
62837161|NCT06410092|EXPERIMENTAL|Arm 1 Part 1 Dose Escalation|Escalating doses of FTL001 depending on cohort at enrollment
62837162|NCT06410092|EXPERIMENTAL|Arm 1 Part 2 Dose Expansion|Two dose groups of FTL001 depending on data of Arm 1 Part 1
62837163|NCT02639221|EXPERIMENTAL|PXT002331|
62443296|NCT01504113||Study 1 goup|Patients who are planned to receive targeted agents
62837164|NCT02639221|PLACEBO_COMPARATOR|Placebo|
62837165|NCT02396121|EXPERIMENTAL|Interventional|Administration of 1 bottle of an oral nutritional supplement, Renutryl® Booster (600 kcal), during 28 days.
62837166|NCT04207788|EXPERIMENTAL|Intervention|HIP-REP programme offers elderly with hip fracture add on activity-focused interventions.
62837167|NCT04207788|ACTIVE_COMPARATOR|Usual care|The elderly with hip fracture in the control group will receive usual care.
62837168|NCT05969652|EXPERIMENTAL|Heavy slow resistance group (HSR group)|"The investigators are planning a 6-week rehabilitation program, 2 days a week. The same physiotherapy and home exercise program will be applied to both groups. The physiotherapy and home exercise program will include patient education, stretching, range of motion and posture exercises. Resistance training will consist of different exercise principles but the same types of exercises. Resistance training: Dumball will be used as exercise equipment. Exercise intensity determined using the Numerical Pain Rating Scale (NPRS).~Individual loading will be made according to the amount of weight. The maximum amount of pain producing pain less than 4 on the Numerical Pain Assessment Scale will be determined as exercise intensity. It will include 3 different exercises: 1) Full can. 2) External rotation in side lying. 3) Internal rotation in side lying."
62837169|NCT05969652|ACTIVE_COMPARATOR|Eccentric exercise training group (EE group)|"The investigators are planning a 6-week rehabilitation program, 2 days a week. The same physiotherapy and home exercise program will be applied to both groups. The physiotherapy and home exercise program will include patient education, stretching, range of motion and posture exercises. Resistance training will consist of different exercise principles but the same types of exercises. Resistance training: Dumball will be used as exercise equipment. Exercise intensity determined using the Numerical Pain Rating Scale (NPRS).~Individual loading will be made according to the amount of weight. The maximum amount of pain producing pain less than 4 on the Numerical Pain Assessment Scale will be determined as exercise intensity. It will include 3 different exercises: 1) Full can. 2) External rotation in side lying. 3) Internal rotation in side lying."
62837170|NCT00905801|OTHER|Arm A CT Perfusion|"Arm A Procedure~On the first required study visit, subject will undergo one SOC CT scan followed by the research component:~* CTP imaging: Single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from clinical scan~* Subject will stand up and walk around, and then lay back down~* CT Perfusion imaging: Second single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from their clinical scan~Procedures will be repeated at optional second study visit \~6-8 weeks later."
62837171|NCT00905801|OTHER|Arm B CT Perfusion|"Arm B Procedure~On the first required study visit, subject will undergo one SOC CT scan followed by the research component:~- CT Perfusion imaging: Single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from clinical scan~Procedures will be repeated at optional second study visit \~6-8 weeks later."
62837172|NCT01605955||Fingertip Pulse Oximeter|SPO2 measurement range: 70%-99%
62837173|NCT01605955||CO-oximeter|SaO2 measurement range: 70%-99%
62612666|NCT04490018|EXPERIMENTAL|Group 1: MenACYW Conjugate Vaccine + 9vHPV + Tdap-IPV Vaccines (Sequential Administration)|Participants received 0.5-milliliter (mL) intramuscular injection of MenACYW Conjugate vaccine on Day 01 and 0.5-mL intramuscular injection of 9vHPV + Tdap-IPV vaccines (sequentially after MenACYW vaccine) at Day 31.
62837174|NCT05914974||Control Group|Chemotherapy without immunotherapy
62837175|NCT05914974||Experimental Group|Chemotherapy in combination with immunotherapy
62837176|NCT02281513|OTHER|ANTLER Pilot Cohort|Pilot study participants will be provided the smartphone application, fitbit activity monitor, and coaching sessions.
62837177|NCT01232023|EXPERIMENTAL|100mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
62443297|NCT01504113||Study 2 case group|Patients who have received targeted therapy
62053702|NCT06243185|EXPERIMENTAL|Dalpiciclib+letrozole|Drug: Dalpiciclib 150mg qd, d1-21, q4w Letrozole 2.5mg qd, q4w
62254831|NCT04310085|EXPERIMENTAL|PfSPZ-DVI challenge and artemether lumefantrine|"16 healthy, malaria-naïve males and females, aged 18-55 years, were enrolled in 2 cohorts (8 participants/cohort; a participant may be enrolled in one cohort only). There were two target levels of parasitaemia previously achieved in healthy participants in malaria VIS at other study sites, i.e., 5000 parasites/mL blood in Cohort 1 and 10000 parasites/mL blood in Cohort 2. (Based on observed levels of parasitaemia in Cohort 1, the target threshold for treatment in Cohort 2 was maintained at 5,000 p/mL).~qPCR was performed, malaria clinical score assessed twice daily and participants were administered registered antimalarial therapy, i.e., Riamet®, when the following criteria were met:~1. Cohort 1: ≥5000 parasites/mL blood or earlier if a participant has a malaria clinical score \>6 or at Investigator's discretion.~2. Cohort 2: ≥10000 parasites/mL blood or earlier if a participant has a malaria clinical score \>6 or at Investigator's discretion."
62254832|NCT00038727|ACTIVE_COMPARATOR|1 Original Lifestyle|randomized to unmasked Intensive Lifestyle during the DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle plus DPPOS Boost Lifestyle sessions in DPPOS Phase 1 and 2
62254833|NCT00038727|ACTIVE_COMPARATOR|2 Original Metformin|randomized to the masked metformin treatment group during DPP and continued open label in DPPOS. Participants were also offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2.
62254834|NCT00038727|PLACEBO_COMPARATOR|3 Original Placebo|randomized to masked placebo during DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2
62837178|NCT01232023|EXPERIMENTAL|200mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
62254835|NCT03345823|EXPERIMENTAL|Substudy 1: Cohort 1 Upadacitinib Dose A|This is a maintenance group which includes participants who achieved clinical response to upadacitinib in studies M14-431 and M14-433 and will receive upadacitinib dose A for 52 weeks.
62254836|NCT03345823|EXPERIMENTAL|Substudy 1: Cohort 1 Upadacitinib Dose B|This is a maintenance group which includes participants who achieved clinical response to upadacitinib in studies M14-431 and M14-433 and will receive upadacitinib dose B for 52 weeks.
62254837|NCT03345823|EXPERIMENTAL|Substudy 1: Cohort 1 Placebo|This is a maintenance group which includes participants who achieved clinical response to upadacitinib in studies M14-431 and M14-433 and will receive placebo for 52 weeks.
62254838|NCT03345823|EXPERIMENTAL|Substudy 1: Cohort 2 Placebo|This is a maintenance group which includes participants who received double-blind placebo in studies M14-431 and M14-433 and achieved clinical response will continue to receive blinded placebo for 52 Weeks.
62254839|NCT03345823|EXPERIMENTAL|Substudy 1: Cohort 3 Upadacitinib Dose B|This is a maintenance group which includes participants who achieved clinical response to upadacitinib from the extended treatment period of studies M14-431 and M14-433 and will receive upadacitinib Dose B for 52 Weeks.
62254840|NCT03345823|EXPERIMENTAL|Substudy 2: Cohort 4 Upadacitinib Dose B|This is a long-term extension group which includes participants who achieved clinical response in the open-label extended treatment period of study M14-431 and will receive upadacitinib dose B for 240 weeks.
62443298|NCT01504113||study 2 control group|Psoriasis patients without target therapy
62837179|NCT01232023|EXPERIMENTAL|400mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
62837180|NCT01232023|EXPERIMENTAL|800mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
62837181|NCT00516360|EXPERIMENTAL|1|Chlorhexidien as the antibacterial agent used to cleanse the hub of neonatal central lines
62053703|NCT06350929||Research procedures|Patients with heart failure
62053704|NCT05965830||Study cohort|The study population consists of clinically stable infants or pediatric patients up to 12 months of age admitted to the PICU.
62053705|NCT04158414|EXPERIMENTAL|Different types of cancer Patients|Lymphoma,Nasopharyngeal Cancer; Esophageal Cancer, Cervical cancer; Hepatobiliary and pancreatic cancer; Sarcoma; Prostate Cancer
62053706|NCT05882110|EXPERIMENTAL|Patients with a body surface wound of 30% TBSA or more and requiring at least 2 weeks to repair|
62837182|NCT00516360|ACTIVE_COMPARATOR|2|Isopropyl alcohol as the antibacterial agent used to cleanse the hub of neonatal central lines
62837183|NCT06125717|ACTIVE_COMPARATOR|15 μg of the H1 influenza antigen|
62837184|NCT06125717|ACTIVE_COMPARATOR|7.5 μg of the H1 influenza antigen|
62837185|NCT06125717|PLACEBO_COMPARATOR|Placebo (no antigen)|
62837186|NCT01369537||adults > 65 yrs undergoing noncardiac surgery|
62837187|NCT06383533|EXPERIMENTAL|Experimental: Disitamab Vedotin Plus Cadonilimab|Disitamab Vedotin: 2.0mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Cardonilimab: 6mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle.
62837188|NCT04161157|EXPERIMENTAL|Pathways|Pathways is designed to help patients identify and pursue values-based goals and address potential goal obstacles, including lung cancer stigma.
62837189|NCT00487656|EXPERIMENTAL|ART-123|6 mg/ml ampule solution for injection
62053707|NCT03773458|OTHER|Eligible patients for AI test.|Device: An artificial system for the screening of scoliosis
62053708|NCT01333735||Patients with chemotherapy group|Patients with breast or colon cancer must beginning a chemotherapy (colon group was ended)
62053709|NCT01333735||Patients without chemotherapy group|patient with breast or colon cancer should not receive chemotherapy (colon group was ended)
62053710|NCT02710448|EXPERIMENTAL|Metformin|Metformin in patients with renal failure
62254841|NCT03345823|EXPERIMENTAL|Substudy 2: Cohort 5 Upadacitinib Dose A|This is a long-term extension group which includes participants who complete Substudy 1 and will receive upadacitinib dose A for 240 weeks.
62254842|NCT03345823|EXPERIMENTAL|Substudy 2: Cohort 5 Upadacitinib Dose B|This is a long-term extension group which includes participants who complete Substudy 1 and will receive upadacitinib dose B for 240 weeks.
62254843|NCT03345823|EXPERIMENTAL|Substudy 2: Cohort 5 Placebo|This is a long-term extension group which includes participants who complete Substudy 1 and will receive placebo for 240 weeks.
62254844|NCT04519411|EXPERIMENTAL|Intubated pediatric patients with COVID-19 respiratory failure|
62837190|NCT00487656|PLACEBO_COMPARATOR|Placebo|6 mg/mlampule of solution for injection
62837191|NCT01370382||Time interval|"Patients are divided according to the interval between the onset of chest pain symptoms and presentation at the hospital in an early(\<4 hours) and late(\> = 4 hours) group."
62254845|NCT04335942|OTHER|AFNOR 3.6 alerts|"Alert called AFNOR 3.6 in connection with the dispersion index described by Drummond et al 1985 and validated by Sprigle et al 2003. This alert corresponds to the quantification of the percentage of weight on the slick distributed over a small area (55% on one to three zones totalling 30cm2),"
62254846|NCT04335942|OTHER|AFNOR 3.6 alerts and Guidelines|"AFNOR 3.6 alerts and Guidelines alerts. By alertes Guidelines we mean the clinical recommendations of the Spinal Cord medicine association, i.e. weight relief every 15 to 30 minutes (Bergstrom et al., 1992; Nixon, 1985; Ho and Bogie, 2007) over a period of 1 minute 51 (Coggrave and Rose 2003) for spinal cord injuries. For patients who do not push up, a tilt of at least 25° of seat and 120° of backrest or a minimum of 45° in one block (Dicianno et al. 2009)."
62837192|NCT00622440|ACTIVE_COMPARATOR|1|
62837193|NCT00622440|PLACEBO_COMPARATOR|2|
62837194|NCT04795687||Ischemic stroke patients|
62837195|NCT04795687||Control|
62837196|NCT01554241|EXPERIMENTAL|vitamin D3 800 IU/day|recommended daily dosage of 800 IU/day D3
62837197|NCT01554241|EXPERIMENTAL|2000 IU/day D3|D3 2000 IU/day
62837198|NCT01554241|EXPERIMENTAL|vitamin D3 4000 IU/day|D3 4000 IU/day
62837199|NCT01554241|EXPERIMENTAL|50,000 IU/week D3|D3 50,000 IU weekly
62837200|NCT02963285||0 to 6 months|
62837201|NCT02963285||7 months to less than 1 year|
62837202|NCT02963285||1 to less than 2 years|
62837203|NCT02963285||2 to less than 6 years|
62837204|NCT02963285||6 to 12 years|
62837205|NCT02961829|NO_INTERVENTION|Antiretroviral Treated (ART) Group|Five patients will receive no further intervention this group (control group)
62837206|NCT02961829|EXPERIMENTAL|ART Intensification Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks
62837207|NCT02961829|EXPERIMENTAL|ART Intensification + Nicotinamide Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks.
62837208|NCT02961829|EXPERIMENTAL|ART Intensification + Auranofin Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks and the gold salt auranofin for 24 weeks.
62837209|NCT02961829|EXPERIMENTAL|ART Intensification + DC vaccine Group|Five patients will receive antiretroviral intensification with dolutegravir and for 48 weeks, and dendritic cell vaccine.
62053711|NCT05003102|EXPERIMENTAL|Dexmedetomidine cycling then Standard Pediatric Intensive Care Unit (PICU) sedation protocol|One the first night, participants receive a dexmedetomidine bolus of 0.5 mcg/kg which is then titrated at an increased drip rate of 0.3 mcg/kg/hr until a.) a targeted Richmond Agitation-Sedation Scale (RASS) state that is one level deeper than what was targeted during the day is achieved or b.) infusion is at max drip rate (dexmedetomidine 2 mcg/kg/hr). On the second night, participants receive the standard PICU Sedation Protocol of fentanyl infusion at 1 mcg/kg/hr and dexmedetomidine infusion at 0.3 mcg/kg/hr with no modifications made until goal RASS reached or at max infusion drips achieved (fentanyl 5 mcg/kg/hr and dexmedetomidine 2 mcg/kg/hr).
62837210|NCT02961829|EXPERIMENTAL|Multi Interventional Group|Five patients will receive antiretroviral intensification with dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks, and gold salt for 24 weeks and dendritic cell vaccine.
62254847|NCT05111444|OTHER|Camrelizumab+Pyrotinib + Chemotherapy|Camrelizumab (200 mg) will be administered intravenously \[IV\] on day 1 of each 3-week cycle. Pyrotinib (320 mg) will be administered orally once daily \[QD\] on every 21 days. Chemotherapy will either be XELOX, SOX or TS.
62254848|NCT00977236|EXPERIMENTAL|Orthokeratology lenses|Children wearing orthokeratology at night for partial correction and spectacles at daytime for residual refractive error will be study group
62837211|NCT04691076|EXPERIMENTAL|Propofol/Esketamine sedation|Propofol target-controlled infusion is performed first,when the infusion concentration reaches 1.5μg/ml,esketamine 0.15mg/kg is injected intravenously;then the dose is adjusted according to the depth of anesthesia and the modified observer's assessment of alert /sedation scale, and propofol target-controlled infusion for every increase of 5μg/ml in concentration, the corresponding increase of esketamine is 0.05mg/kg; the total dose of esketamine used in surgery shall not exceed 0.5mg/kg.
62254849|NCT00977236|OTHER|Single-vision spectacle lenses|Children wearing single-vision spectacles in the daytime for correcting the refractive error will serve as control group
62254850|NCT01565044|EXPERIMENTAL|" AUTO  Group"|
62254851|NCT01565044|SHAM_COMPARATOR|" CONTROL  Group"|
62254852|NCT02114164|ACTIVE_COMPARATOR|AirSeal System|This group receives the AirSeal System for intraoperative insufflation.
62254853|NCT02114164|ACTIVE_COMPARATOR|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
62254854|NCT03351751|PLACEBO_COMPARATOR|Placebo|Subjects receiving placebo
62254855|NCT03351751|EXPERIMENTAL|PF-06372865|Subjects receiving PF-06372865
62254856|NCT02285920|ACTIVE_COMPARATOR|Spironolactone 12.5 mg|Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
62254857|NCT02285920|ACTIVE_COMPARATOR|Spironolactone 25 mg|Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
62254858|NCT02285920|ACTIVE_COMPARATOR|Spironolactone 50 mg|Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
62254859|NCT02285920|PLACEBO_COMPARATOR|Placebo|Participants will be treated with placebo for 36 weeks.
62254860|NCT02825355||Patients with cervical cancer|All patients receive sentinel node mapping as the conventional treatment.
62254861|NCT02825355||Patients with endometrial cancer|All patients receive sentinel node mapping as the conventional treatment.
62254862|NCT06065293||Mothers involved in a local non-profit|
62254863|NCT02665052|EXPERIMENTAL|Home-Based BATRAC|Home-based BATRAC training will consist of 45 minutes of high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
62254864|NCT02665052|EXPERIMENTAL|Lab-based BATRAC plus TTT|Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and rest periods followed by 15 minutes of therapist guided transition to task training (TTT).
62612667|NCT04490018|ACTIVE_COMPARATOR|Group 2: Nimenrix® + 9vHPV + Tdap-IPV Vaccines (Sequential Administration)|Participants received 0.5-mL intramuscular injection of Nimenrix® vaccine on Day 01 and 0.5-mL intramuscular injection of 9vHPV + Tdap-IPV vaccines (sequentially after Nimenrix® vaccine) at Day 31.
62254865|NCT02665052|PLACEBO_COMPARATOR|Delayed Entry Usual Care|Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions. They will also receive weekly phone calls to record general activity level. After serving as a control, this group will be entered into their randomized active intervention group of either lab-based BATRAC + TTT training, or Lab-based Robot+ TTT.
62443299|NCT04050397|EXPERIMENTAL|Supervised exercise arm|Informational initiation lecture and supervised exercise twice a week for 12 weeks followed by 12 weeks of non-supervised exercise.
62053712|NCT05003102|ACTIVE_COMPARATOR|Standard Pediatric Intensive Care Unit (PICU) sedation protocol then Dexmedetomidine cycling|On the first night, participants will receive the standard PICU Sedation Protocol of fentanyl infusion at 1 mcg/kg/hr and dexmedetomidine infusion at 0.3 mcg/kg/hr with no modifications made until goal RASS reached or at max infusion drips achieved (fentanyl 5 mcg/kg/hr and dexmedetomidine 2 mcg/kg/hr). On the second night, participants receive a dexmedetomidine bolus of 0.5 mcg/kg which is then titrated at an increased drip rate of 0.3 mcg/kg/hr until a.) a targeted Richmond Agitation-Sedation Scale (RASS) state that is one level deeper than what was targeted during the day is achieved or b.) infusion is at max drip rate (dexmedetomidine 2 mcg/kg/hr).
62053713|NCT05081869|EXPERIMENTAL|Online Yoga Based Exercise Program|A 50-minute online exercise program consisting of 5 categories will be created. The program will last 8 weeks, twice a week. In the first category, 20-30 seconds of stretching was applied to iliopsoas, hamstring, adductor, tensor fascia lata, piriformis, quadratus lumborum, quadriceps femoris and gastrocnemius muscles. In the second category, stabilization and pelvic mobilization exercises will be applied to the core muscles. Each exercise will be performed in 3 sets of 10 repetitions. In the third category, strengthening exercises will be done for the gluteal muscles, abdominal muscles, erector spine, quadriceps femoris and latissimus dorsi. Each exercise will be performed as 10 repetitions and 3 sets. In the fourth category, 3 sets and 10 repetitions of kegel exercises will be done. minute diaphragmatic breathing will be applied.
62053714|NCT05081869|SHAM_COMPARATOR|Education Program|The informative training was given to both group members individually and online. In the training program; The female reproductive system organs, the structure of the pelvis, the location and functions of the pelvic floor muscles, the definition and physiology of menstruation, the types and risk factors of dysmenorrhea, the definition and symptoms of primary dysmenorrhea, treatment methods for coping with pain in primary dysmenorrhea were mentioned.
62053715|NCT02461095|ACTIVE_COMPARATOR|Impairment based approach|The intervention will address the patients impairments found during evaluation. Treatment will based on the Physical therapist evaluation and will be individualized to each patient.
62053716|NCT02461095|EXPERIMENTAL|PFPS algorithm|The Patellofemoral Syndrome algorithm is designed to determine what deficits a patient may have and addressing these sequentially. This subgrouping first assesses a patient fear avoidance beliefs, flexibility, body mechanics, and then strength and functional ability. The reason for sequential treatment is that there is evidence that without adequate flexibility a patient will be unable to perform exercises with proper body mechanics, and without proper mechanics strengthening and functional activity can cause increased stress on the patellofemoral joint. Progression through each specific subgroup is based on objective goals. Once the patient has met these goals they are progressed to the next treatment subgroup until discharge.
62053717|NCT02347644|EXPERIMENTAL|Brief Motivational Interview|Given a brief motivational interview encouraging reduced use of alcohol and drugs.
62053718|NCT02347644|NO_INTERVENTION|Youth Control Group|Given a brochure with all available organizations in the community for help with alcohol and drug problems.
62053719|NCT04545996|ACTIVE_COMPARATOR|Cervical Rang of Motion Exercises.|Cervical exercises for mechanical neck pain.
62053720|NCT04545996|EXPERIMENTAL|Cervical Exercises.|Cervical exercises for the management of mechanical neck pain.
62254866|NCT05114395|EXPERIMENTAL|Telerehabilitation Group|"The intervention group includes a hybrid program of face-to-face sessions and video sessions. In the first consultation, a face-to-face one, patients will be instructed with behavioral and lifestyle measures and it will be prescribed a 12-week exercise program, including exercises to be performed three times a day and two weekly exercise sessions - three face-to-face sessions (2 initial and one at 8 weeks) and video sessions of 30 minutes, divided into 3 phases with gradual addition of exercises of increasing difficulty in terms of duration, number of repetitions and positions.~In the middle of the treatment (at 6 weeks) a medical teleconsultation is performed for reassessment. In the end of the 12-week program there will also be a face-to-face consultation."
62053721|NCT05701514|NO_INTERVENTION|Conservative arm|Children assigned to this treatment arm will be conservatively managed, and will continue to be followed until the age of 5 years (end of study inclusion).
62053722|NCT05701514|ACTIVE_COMPARATOR|Surgical arm|Children assigned to this treatment arm will undergo elective surgical resection at the age of 6-9 months, and will continue to be followed until the age of 5 years (end of study inclusion).
62053723|NCT01875380|EXPERIMENTAL|Regorafenib|Regorafenib will be administered orally at the initial dosage of 160 mg per day for 3 weeks,followed by one week of rest, according to the 3/1 regimen.
62053724|NCT02958592||study group|patients with liver tumor intend to perform hepatectomy
62053725|NCT03637244|EXPERIMENTAL|Experimental Condition|Patients assigned to the experimental condition (LDQ + DS and HDQ + DS) will be asked to use the bookmarked link to the decision-aid within the first 7-14 days (and thereafter as needed) during the study period. The routine care group will be asked to use a bookmarked link to frequently asked questions on tenofovir + emtricitabine for PrEP. All groups will be compared on decision-quality at 14-days, self-reported PrEP initiation at 30-days, and PrEP adherence at 60-days post enrollment.
62053726|NCT04247659|EXPERIMENTAL|Experimental group|In the experimental group, sodium aescinate is added on the basis of conventional treatment(such as anti-platelet and improve circulation).The treatment course of sodium aescinate is 10 days,20mg/day.
62053727|NCT04247659|NO_INTERVENTION|Control group|The control group will receive conventional treatment(anti-platelet and improve circulation) without sodium aescinate.
62053728|NCT02459262|ACTIVE_COMPARATOR|GBS-NN Vaccine|GBS-NN vaccine administered either adsorbed to Alhydrogel® or alone.
62053729|NCT02459262|PLACEBO_COMPARATOR|Sterile dilution buffer with Alhydrogel|The placebo will contain either Alhydrogel® or buffer alone.
62254867|NCT05114395|ACTIVE_COMPARATOR|Face-to-Face Group|The control group develops the entire program in face-to-face consultations and exercise sessions.
62254868|NCT02453373|EXPERIMENTAL|ThermoSuit Cooling Induction|Induction of therapeutic hypothermia (32-34 degrees C) using the LRS ThermoSuit System. Prior to initiating hypothermia, Magnesium Sulfate will be administered intravenously to control shivering and tPA administered intravenously (if indicated). Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort. Neurothrombectomy will be performed if indicated.
62254869|NCT02453373|NO_INTERVENTION|Historical Control|Historical patients treated for ischemic stroke using conventional medical treatments, but without induced hypothermia.
62053730|NCT03066401||obese patients with dysmetabolic hyperferritinemia|"PATIENTS: obese patients with dysmetabolic hyperferritinemia undergoing a therapeutic bleeding.~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver."
62254870|NCT04912284||General population|Questionnaire administered to adult population
62254871|NCT04912284||Health care workers|Questionnaire administered to adult health care workers
62254872|NCT01866579||ethambutol optic neuropathy|
62254873|NCT04756700|EXPERIMENTAL|Healthy Participants|Healthy participants matched with PwMS will have their cognitive and motor functions assessed using the DigiCog (BCCAMS app) tablet once in clinic and Konectom smartphone-based application for 2 days in clinic and at least 15 days at home.
62254874|NCT04756700|EXPERIMENTAL|PwMS: Participants with MS|Participants with MS will have their cognitive and motor functions assessed using the DigiCog (BCCAMS app) tablet once in clinic and Konectom smartphone-based application for 2 days in clinic and at least 15 days at home.
62612668|NCT04490018|EXPERIMENTAL|Group 3: MenACYW Conjugate Vaccine + 9vHPV + Tdap-IPV Vaccines (Concomitant Administration)|Participants received 0.5-mL intramuscular injection of MenACYW Conjugate vaccine concomitantly with 9vHPV + Tdap-IPV vaccines on Day 01.
62612669|NCT01624402|EXPERIMENTAL|Ecosystem Focused Therapy (EFT)|Ecosystem Focused Therapy (EFT) follows a structured personalization approach based on the model of adaptive functioning, in which behavior is a function of the person's competence and the demands of the environment.
62612670|NCT01624402|ACTIVE_COMPARATOR|Education on Stroke and Depression (ESD)|Education on Stroke and Depression (ESD) is home-delivered and imparts education about depression, stroke, and the role of available treatments.
62612671|NCT02062775|ACTIVE_COMPARATOR|Self-Fixating Hernia Mesh|Self-fixating polyester mesh will be used for laparoscopic inguinal hernia repair.
62837212|NCT04691076|ACTIVE_COMPARATOR|Propofol/Fentanyl sedation|Propofol target-controlled infusion is performed first.When the infusion concentration reaches 1.5μg/ml, fentanyl 0.6μg/kg is injected intravenously; then the dose is adjusted according to the depth of anesthesia and the modified observer's assessment of alert /sedation scale, and propofol target-controlled infusion for every increase of 5μg/ml in concentration,the corresponding increase of fentanyl is 0.2ug/kg; the total dose of fentanyl used in surgery shall not exceed 1.2ug/kg.
62837213|NCT00355966|ACTIVE_COMPARATOR|A|In group A, immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
62837214|NCT00355966|ACTIVE_COMPARATOR|B|In Group B immediate induction of labour will be done by application of vaginal PGE2 gel 0.5 gm at an interval of 6 hours , a maximum of 2 doses.
62837215|NCT03501108|NO_INTERVENTION|Control|Patients in the control arm receive usual pharmaceutical care in hospital i.e. daily medication review by the attending physicians and ward-assigned pharmacist.
62053731|NCT04909580|EXPERIMENTAL|decision coaching|Decision coaching with a patient decision aid guided by the Ottawa Decision Support Framework
62837216|NCT03501108|EXPERIMENTAL|Intervention|Patients in the intervention arm receive usual pharmaceutical care as per the control group plus application of STOPPFrail deprescribing criteria advice points on their medication list at a single time point i.e. within 24 hours of randomization. The bespoke STOPPFrail advice report is presented to the patient's attending physician who then adjusts the patient's prescriptions according to the STOPPFrail advice points. The attending physician can implement as few or as many STOPPFrail advice points as he/she sees appropriate.
62053732|NCT02597426||Patient|Nasopharyngeal carcinoma (NPC) patients who are disease free more than four years after definitive management with radiotherapy +/- chemotherapy who were treated with Intensity-Modulated Radiotherapy (IMRT), study will involve Collection of demographic data, endocrine assessment (Pituitary and Thyroid), Patient reported outcomes (Quality of Life Questionnaire), neurocognitive assessment (Behavioral rating scale) and audiology assessment (Assessment of hearing)
62053733|NCT02597426||Caregiver/Family member|Caregivers for patients who consent to participate. Study will involve Frontal Systems Behavior Scale- FrSBe (behavioral rating scale)
62837217|NCT04816552|EXPERIMENTAL|CHoBI7 mHealth program Arm|The first arm will receive the CHoBI7 mHealth program and a general message on oral rehydration solution (ORS) (CHoBI7 mHealth program Arm) .
62837218|NCT04816552|ACTIVE_COMPARATOR|Standard Recommendation Arm|The second arm will serve as a Control Arm and only receive a general message on oral rehydration solution (ORS).
62254875|NCT01552291|ACTIVE_COMPARATOR|Glutamin|
62254876|NCT01552291|PLACEBO_COMPARATOR|Placebo|
62254877|NCT04641455|EXPERIMENTAL|A mucolytic solution|mucolytic solution - 100 ml of water + 600 mg of N-acetylcysteine (3 tablets of 200 mg ACC long), 320 mg of simethicone (8 ml of Espumisan sir. 40 mg / ml)administered 20-30 minutes prior to upper endoscopy
62254878|NCT04641455|ACTIVE_COMPARATOR|B mucolytic solution|mucolytic solution-100 ml water + 400 mg N-acetylcysteine (2 tablets 200 mg ACC long), 20 mg simethicone (0.5 ml Espumisan sir. 40 mg / ml) administered 20-30 minutes prior to upper endoscopy
62254879|NCT04641455|PLACEBO_COMPARATOR|C Water|100 ml of water 20-30 minutes prior to upper endoscopy
62837219|NCT04257929|ACTIVE_COMPARATOR|Double-Blind Treatment Phase Lower Dose Pitolisant|"Pediatric patients (6 to less than 12 years of age):~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 8.9 mg pitolisant administered once daily in the morning.~Adolescent patients (12 to less than 18 years of age):~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 13.35 mg pitolisant administered once daily in the morning.~Adult patients (18 to 65 years of age):~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning."
62254880|NCT04641455|NO_INTERVENTION|D No intervention|Upper endoscopy without neither mucolytic solution nor water prior to upper endoscopy.
62053734|NCT04088721|EXPERIMENTAL|AD17002 20μg|Intranasal weekly dosing of AD17002 for three times
62053735|NCT04088721|EXPERIMENTAL|AD17002 40μg|Intranasal weekly dosing of AD17002 for three times
62254881|NCT04832958|EXPERIMENTAL|Radioguided surgery|"* 68Ga-PSMA PET/MRI acquisition~* 99mTc-PSMA-I\&S intravenous injection the day before surgery~* 99mTc-PSMA-I\&S SPECT/CT imaging~* 99mTc-PSMA-RGS to detect an increased count rate at the level of the nodal stations~* Robot-assisted ePLND followed by RP~* 99mTc-PSMA-RGS to detect an increased count rate in the prostatic fossa after removal of the primary tumor~* Histopathological examination~* Monitoring of adverse events and perioperative outcomes after surgery"
62254882|NCT00113230|EXPERIMENTAL|Avastin|Capecitabine, Avastin (RHUMAB VEGF/Bevacizumab) And Radiotherapy
62053736|NCT04088721|EXPERIMENTAL|AD17002 60μg|Intranasal weekly dosing of AD17002 for three times
62053737|NCT04088721|PLACEBO_COMPARATOR|Placebo|Intranasal weekly dosing (placebo) for three times
62254883|NCT05742997|ACTIVE_COMPARATOR|PartoSure|Use of PartoSure to determine the risk of preterm birth
62254884|NCT05742997|ACTIVE_COMPARATOR|Fetal Fibronectine (fFn)|Use of fFn to determine the risk of preterm birth
62254885|NCT05833048|EXPERIMENTAL|Rectus Sheath Block|
62443300|NCT04050397|ACTIVE_COMPARATOR|Non-supervised exercise arm|Informational initiation lecture and only non-supervised exercise
62443301|NCT01516359||patients with cardiac surgery|
62443302|NCT00131989|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-14 or 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR may be considered for retreatment with sorafenib for up to an additional 6 courses upon disease recurrence provided the duration of CR is longer than 1 month.
62443303|NCT04548895||LTCF residents and involved health practitioners|"The intervention will take place in nursing homes, assisted living facilities and long-term care facilities (LTCF) in the United States (henceforth collectively referred to as LTCF).~Staff who work in the participating LTCF ≥ 20 hours/week and who have direct contact with the residents are also eligible to participate and to employ the biometric monitoring equipment in their private residences."
62443304|NCT03273985|EXPERIMENTAL|Dry needling|
62254886|NCT05833048|NO_INTERVENTION|No block|
62254887|NCT00753831|EXPERIMENTAL|1|Aurosling
62254888|NCT02640833|EXPERIMENTAL|Duvelisib+Venetoclax|
62254889|NCT01376778|ACTIVE_COMPARATOR|CMV hyperimmune globulin - Cytogam®|Infusion of Cytogam®, Cytomegalovirus Immune Globulin Intravenous (Human) (CMV-IGIV)
62254890|NCT01376778|PLACEBO_COMPARATOR|Placebo|IV 5% albumin diluted 1 to 9 with 5% Dextrose in water (D5W)
62254891|NCT06319313|EXPERIMENTAL|JMT101+ docetaxel|
62254892|NCT06319313|EXPERIMENTAL|JMT101+HB1801|
62254893|NCT06319313|EXPERIMENTAL|HB1801|
62254894|NCT02545621||ARDS Group (acute respiratory distress syndrome)|The purpose of this monocentric observational prospective pathophysiology study is to compare alveolar monocyte/macrophage activation profiles between patients with or without ARDS
62254895|NCT02545621||control group|The purpose of this monocentric observational prospective pathophysiology study is to compare alveolar monocyte/macrophage activation profiles between patients with or without ARDS
62254896|NCT03598816|EXPERIMENTAL|Arm 1: Durvalumab + Tremelimumab + Neoantigen DNA Vaccine|"* All patients will receive durvalumab intravenous (IV) at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses~* All patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles~* The first vaccination will take place two weeks after confirmed disease progression on targeted therapy. This will be Day 1 of the first 28-day cycle of treatment with durvalumab and tremelimumab~* The schedule of vaccination is Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, and Cycle 5 Day 1 (for a total of 6 doses)"
62254897|NCT03598816|EXPERIMENTAL|Arm 2: Durvalumab + Tremelimumab|"* All patients will receive durvalumab IV at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses~* All patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles."
62443305|NCT03273985|EXPERIMENTAL|Ischemic compression|
62443306|NCT04968171||People with newly diagnosed diabetes mellitus type 1|"People with newly diagnosed diabetes mellitus type 1 admitted to the Department of Internal Medicine and Diabetology.~Treated with intensive insulin therapy. Measurement of VO2max between 3 and 12 month after diagnosis. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years."
62612672|NCT02062775|PLACEBO_COMPARATOR|Non-Fixating Hernia Mesh|Non-fixating polyester mesh will be used for laparoscopic hernia repair.
62254898|NCT04858750|OTHER|Cook D-J stent group|"Patients randomized to this group received Cook (Limerick, Ireland, USI-626-R) D-J stent.~Note: USI is an unexpandable acronym."
62254899|NCT04858750|OTHER|KYB anti-reflux D-J stent group|Patients randomized to this group received KYB (Shenzhen, China, 3201162) anti-reflux D-J stent.
62254900|NCT04858750|OTHER|Urovision trigonal D-J stent group|"Patients randomized to this group received Urovision (Bad Aibling, Germany, ST-230726) trigonal D-J stent.~Note: ST is an unexpandable acronym. Aibling is a German region name."
62254901|NCT03883594|EXPERIMENTAL|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
62612673|NCT04825496|EXPERIMENTAL|ssCART-19 Cells|"Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to ssCART-19 cells infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
62612674|NCT02265757|EXPERIMENTAL|No Cognitive Rehabilitation|Will receive a 10 day intervention program (over 2 weeks) consisting of Computer Brain Fitness Training, Support Group, Wellness Education and Physical Exercise.
62254902|NCT01582022|EXPERIMENTAL|local anesthetic|local anesthetic agent
62612675|NCT02265757|EXPERIMENTAL|No Computer Brain Fitness Training|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Support Group, Wellness Education and Physical Exercise
62612676|NCT02265757|EXPERIMENTAL|No Support Group|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Wellness Education and Physical Exercise
62053738|NCT04184323|ACTIVE_COMPARATOR|EX-527|The drug will be administered daily for 5 days beginning with the start of progesterone therapy and ended 24 hours before embryo transfer
62254903|NCT01582022|PLACEBO_COMPARATOR|normal saline|comparator
62254904|NCT01460199|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62254905|NCT01460199|EXPERIMENTAL|CTP-499|
62254906|NCT02760979|ACTIVE_COMPARATOR|Denosumab|Patients treated with Denosumab
62254907|NCT02760979|PLACEBO_COMPARATOR|Placebo|Patients treated with placebo
62254908|NCT04492462|EXPERIMENTAL|Formal Physical Therapy|
62254909|NCT04492462|EXPERIMENTAL|Self-directed Physical Therapy|
62254910|NCT01786096|EXPERIMENTAL|SGN-CD19A|SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
62612677|NCT02265757|EXPERIMENTAL|No Wellness Education|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Support Group, and Physical Exercise
62612678|NCT02265757|EXPERIMENTAL|No Physical Exercise|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Support Group, and Wellness Education
62612679|NCT06434363|EXPERIMENTAL|Safety Lead-In|
62612680|NCT06434363|EXPERIMENTAL|Dose Escalation|
62612681|NCT06434363|EXPERIMENTAL|Dose Expansion|
62612682|NCT05844085|SHAM_COMPARATOR|Non-polar lipids|A food product containing 15 g plant-based non-polar lipids. The fat is consumed blended with a carbohydrate source containing 50 g available carbohydrates.
62612683|NCT05844085|PLACEBO_COMPARATOR|No Lipids|Reference product. A carbohydrate source containing 50 g available carbohydrates.
62254911|NCT05856916|EXPERIMENTAL|Creatine Supplementation|Participants randomized to receive creatine. Study participants will be asked to track their daily administration on a log provided by the study team.
62254912|NCT05856916|PLACEBO_COMPARATOR|Placebo|Participants randomized to receive placebo. Study participants will be asked to track their daily administration on a log provided by the study team.
62254913|NCT03388242||Normal control people|These people are age-matched with the patients with MCI. No intervention is applied.
62612684|NCT05844085|EXPERIMENTAL|Polar Lipids low|A food product containing 15 g plant-based lipids, of which 50% is polar lipids and 50% is non-polar lipids.The fat is consumed blended with a carbohydrate source containing 50 g available carbohydrates.
62837220|NCT04257929|ACTIVE_COMPARATOR|Double-Blind Treatment Phase Higher Dose Pitolisant|"Pediatric patients (6 to less than 12 years of age):~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning.~Adolescent patients (12 to less than 18 years of age):~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 26.7 mg pitolisant administered once daily in the morning.~Adult patients (18 to 65 years of age):~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 35.6 mg pitolisant administered once daily in the morning."
62837221|NCT04257929|PLACEBO_COMPARATOR|Double-Blind Treatment Phase Placebo|"Pediatric patients (6 to less than 12 years of age):~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets~Adolescent patients (12 to less than 18 years of age):~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets~Adult patients (18 to 65 years of age):~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets"
62053739|NCT04184323|PLACEBO_COMPARATOR|Placebo|The placebo will be administered daily for 5 days beginning with the start of progesterone therapy and ended 24 hours before embryo transfer
62254914|NCT03388242||Patients with MCI|These patients have met the criteria for diagnosing MCI. No intervention is applied.
62254915|NCT03388242||Patients with AD|These patients are diagnosed with AD. No intervention is applied.
62254916|NCT03210389|EXPERIMENTAL|lobaplatin+5-FU|Patients enrolled in this trial would get 4-6 cycles of lobaplatin + 5-FU chemotherapy.
62254917|NCT05837442|EXPERIMENTAL|Osteopathic Manual Therapy Group (OMTG)|The total duration of all techniques applied is 30 minutes. The techniques used in the extremities were applied to both extremities.
62254918|NCT05837442|NO_INTERVENTION|Control Group (CG)|No intervention was made to the patients in the control group.
62254919|NCT03666312||Cohort A|The study will include patients from the two main Italian liver transplantation centers (Ospedale Le Molinette, Torino and Azienda Ospedaliera Pisana, Pisa), allowing to enroll 220 patients in the first 18 months of the proposed study. More in details, all \>18-years-old patients listed for and undergoing liver transplantation will be included in the study after signing an informed consent. Each patient will then be prospectively followed one year.
62254920|NCT03666312||Cohort B|A second cohort of 55 patients will then be enrolled in the following 6 months as internal validation sample, and will be analogously monitored until the end of the 3-years-long study.
62443307|NCT02200133|EXPERIMENTAL|Individualized Survivorship Care Plan (SCP)|"* Participant information sheet and instructions on how to use the SCP~* Patient version of individualized SCP that includes but is not limited to: (1) a treatment summary that consists of disease characteristics and treatment details (including HCT), and (2) recommendations for preventive care and screening for late complications based on patient treatment exposures (age, type of transplant, use of TBI, corticosteroid exposure as part of HCT, and history of GVHD)~* Newest Vital Sign nutrition label to measure health literacy and its instructions~* Participants may receive other materials their transplant center routinely provides to patients for follow-up care (e.g., discharge summary or clinic note)"
62612685|NCT05844085|EXPERIMENTAL|Polar Lipids high|A food product containing 15 g plant-based lipids, of which 100 % is polar lipids. The fat is consumed blended with a carbohydrate source containing 50 g available carbohydrates.
62612686|NCT00381329|ACTIVE_COMPARATOR|1|Motivational Interviewing (MI)
62612687|NCT00381329|ACTIVE_COMPARATOR|2|Structured Brief Advice (SBA)
62612688|NCT03712267|EXPERIMENTAL|Electronic Media Enhanced|Research assistants will collect information on participants' electronic messaging behavior and content and provide that for use to participants' clinicians.
62612689|NCT03712267|PLACEBO_COMPARATOR|Treatment As Usual|Participants will not have their electronic messaging reviewed prior to their typically scheduled clinical appointments.
62612690|NCT01118572|EXPERIMENTAL|YM177 group|
62254921|NCT01152684||HIV-Positive Latinos living in San Diego or Tijuana|This is an exploratory study of Latinos living with HIV in the San Diego-Tijuana US-Mexico border region.
62254922|NCT02999867|EXPERIMENTAL|M1 triticale and mung bean|M1: triticale and mung bean as a processed food is assigned to patients at a dose of 50-100 g/d for 30-day dietary intervention.
62837222|NCT04257929|OTHER|Open-Label Pitolisant|"Age-based dosing (prior to implementation of amendment 6) with maximum once daily doses of 17.8 mg for pediatric patients (6 to \<12 years), 26.7 mg for adolescent patients (12 to \<18 years), or 35.6 mg for adult patients (18 to 65 years).~Weight-based dosing (after implementation of amendment 6) with maximum once daily doses of 17.8 mg for patients ≤40 kg, 35.6 mg for patients \>40 to ≤80 kg, and 44.5 mg for patients \>80 kg."
62837223|NCT01563809|ACTIVE_COMPARATOR|Low androgens FSH+LH|Patients with androgens below threshold receiving FSH+LH for ovarian stimulation
62837224|NCT01563809|ACTIVE_COMPARATOR|High androgens FSH+LH|Patients with androgens above threshold receiving FSH+LH for ovarian stimulation
62053740|NCT05008952|ACTIVE_COMPARATOR|Control group|The control group for this study will consist of individuals with normal BMI (18.5 - 24.9 kg/m2), body fat percent \< 25% (male) or \< 35% (female), and up to 1 other risk factor among the following: blood pressure \> 130/85 mmHg, fasting glucose \>100 mg/dL, fasting triglycerides \>150 mg/dL, and HDL \< 40 (male) or \< 50 (female).
62053741|NCT05008952|EXPERIMENTAL|Normal-weight obesity|Individuals with normal-weight obesity will be defined as having normal BMI (18.5 - 24.9 kg/m2), body fat percent \> 25% (male) or \> 35% (female).
62053742|NCT05008952|ACTIVE_COMPARATOR|Metabolic Syndrome|Metabolic syndrome will be defined using the international Diabetes Federation criteria of an obese BMI ( \> 30 kg/m2) and 2 or more of the following risk factors: blood pressure \> 130/85 mmHg, fasting glucose \>100 mg/dL, fasting triglycerides \>150 mg/dL, and HDL \< 40 (male) or \< 50 (female).
62053743|NCT02546830|EXPERIMENTAL|FreeO2 v2.2 active|Automatic Oxygen Administration
62053744|NCT02546830|ACTIVE_COMPARATOR|FreeO2 v2.2 with manual oxygenation|Manual Oxygen Administration
62053745|NCT02914132|OTHER|Seraph 100 Filter|Renal replacement patient with bacteremia.
62053746|NCT04159974|EXPERIMENTAL|Durvalumab|Treatment arm A will receive durvalumab IV in a dosage of 1500mg every four weeks for 12 months as mono therapy.
62254923|NCT02999867|EXPERIMENTAL|M2 adzuki bean|M2: adzuki bean as a processed food is assigned to patients at a dose of 50-100 g/d for 30-day dietary intervention.
62254924|NCT03041350|EXPERIMENTAL|Smartphone video-assisted ALS & Conventional CPR|"In study period, using this video medical control, high-quality CPR, cardiac arrest rhythm confirmation, defibrillation, proper drug administration instructions, advanced airway insertion, etc. are performed. The medical director then decides on patient transfer if the asystole and pulseless electrical activity findings are persistent even after more than 20-minutes of ALS.~The conventional CPR is Basic life support only in the automatic external defibrillator (AED) mode 5-10 minutes at the scene, are not allowed to stop resuscitation at the scene unless there is a return of spontaneous circulation (ROSC) or pre-hospital cardiac arrest patient has already been transported to a hospital."
62254925|NCT01048749|ACTIVE_COMPARATOR|aquatic vertical supsension|Spinal height measurement using a stadiometer following aquatic vertical suspension
62443308|NCT02200133|NO_INTERVENTION|Usual care (no SCP)|"* Materials that their transplant center routinely provides to patients for follow-up care~* Newest Vital Sign nutrition label to measure health literacy and its instructions~* Participants randomized to the usual care arm who complete the 6 month study assessments will receive their individualized SCP upon completion of the patient's participation. Participants who withdraw from the study or who do not complete the 6 month assessment will not receive the individualized SCP."
62443309|NCT05057195|EXPERIMENTAL|Interstitial radiation therapy|Duration: 11 days
62443310|NCT05057195|ACTIVE_COMPARATOR|Postoperative external beam therapy, on the bed of the removed tumor|Duration: 4 weeks
62443311|NCT04604639||Out-of-hospital cardiac arrest|Patients suffering an out-of-hospital cardiac arrest to who the ambulance service was requested to attend.
62443312|NCT00819728|EXPERIMENTAL|Taxotere/Irinotecan|
62443313|NCT03753997|NO_INTERVENTION|Conventional therapy|Patiens´s will come to the clinic for regular contact with a diabetes nurse.
62443314|NCT03753997|EXPERIMENTAL|Treatment by a Psychologist|Patients will meet with a diabetes educated psychologist over 9 months and will come to the clinic for regular contact with a diabetes nurse
62443315|NCT06527352|OTHER|classical shaped mask airway|
62443316|NCT06527352|OTHER|tulip shaped mask airway|
62443317|NCT03316859|EXPERIMENTAL|Naloxegol|naloxegol 25 mg pill
62053747|NCT04159974|EXPERIMENTAL|Durvalumab + Tremelimumab|Treatment arm B receives durvalumab in a dosage of 1500mg every 4 weeks (-3/+7 days) for 12 months post-surgery. In addition these patients receive tremelimumab IV in a fixed dose of 75mg for the first four months on day 1; 29; 57; 85 (-3/+7).
62053748|NCT02022579|EXPERIMENTAL|DCE-MRI and DWI|Single arm study, diagnosis defined as BIRADS 3, 4, or 5 lesion(s) based on DCE-MRI only with DWI collected in tandem as standard practice.
62254926|NCT01048749|ACTIVE_COMPARATOR|land-based supine flexion condition|Spine height will be measured with a stadiometer following completion of the supine land-based flexion position.
62254927|NCT01357655|ACTIVE_COMPARATOR|Arm 1: Dasatinib|
62254928|NCT01357655|EXPERIMENTAL|Arm2: Dasatinib + BMS-833923|Dasatinib for 1 year followed by dasatinib plus BMS-833923 for 2 years followed by dasatinib alone for approximately 2 years; depending on response
62254929|NCT00530283||A|Patients with Squamous cell cancer of neck nodes, unknown primary
62443318|NCT03316859|PLACEBO_COMPARATOR|Placebo|placebo pill
62837225|NCT01563809|NO_INTERVENTION|High androgens FSH alone|
62837226|NCT01563809|NO_INTERVENTION|Low androgens, FSH alone|
62837227|NCT00516516|EXPERIMENTAL|I|Oral L-Carnitine, 1g PO twice daily
62837228|NCT00516516|PLACEBO_COMPARATOR|II|Placebo, similar in appearance to experimental drug, given orally twice daily.
62053749|NCT05177445|EXPERIMENTAL|Intervention group with phototherapy|Patients that present loss of smell 4 weeks after their coronavirus-19 infection and that have had a real-time polymerase chain reaction (reverse transcriptase polymerase chain reaction ) positive for coronavirus-19 will receive the phototherapy intervention. It consists of the introduction of the nasal probe of the phototherapy device in the nasal cavity of the patient. A mixture of ultraviolet light A, ultraviolet light B and red light will be applied between 2 and 3 minutes. The patient will receive a maximum of 10 interventions. Furthermore both oral corticosteroids (prednisone 40mg) and olfactory training will be applied, in the intervals of daily for 10 days and daily for the duration of the study respectively.
62254930|NCT02712151|ACTIVE_COMPARATOR|Abdominal Wall Block with Ropivacaine 0.2%|Patients will receive bilateral transversus abdominis plane and rectus sheath blocks via ultrasound guidance. A total of 1.0ml/kg distributed between the four blocks (0.4+0.4+0.1+0.1) of 0.2% Ropivacaine (max 50ml) will be injected, as a one time single shot injection, into the fours sites. Surgical infiltration of the four port sites will receive 0.4ml/kg of sterile saline.
62443319|NCT05642026|EXPERIMENTAL|continuous intercostal nerve block (CINB)|patients admitted to the adult trauma service with rib fractures who are receiving CINB
62837229|NCT06214234|OTHER|Early band ligation|Patients with liver cirrhosis present with variceal bleeding underwent band ligation within 12 hours of presentation
62837230|NCT06214234|OTHER|Delayed band ligation|Patients with liver cirrhosis present with variceal bleeding underwent band ligation within more than 12 hours of presentation
62837231|NCT02035267|PLACEBO_COMPARATOR|Placebo - Grade 1|Participants received placebo administered in 0.2 mL subcutaneous (SC) injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With CR SMFRS Grade 1 (mild).
62837232|NCT02035267|EXPERIMENTAL|ATX-101 deoxycholic acid injection - Grade 1|Participants received deoxycholic acid 2 mg/cm\^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With Clinician-Reported Submental Fat Rating Scale (CR SMFRS) Grade 1 (mild).
62443320|NCT05642026|ACTIVE_COMPARATOR|standard medical care|patients admitted to the adult trauma service with rib fractures who are receiving standard medical care
62443321|NCT01856985|EXPERIMENTAL|Misoprostol at clinic|"Eligible women will receive 200 mg mifepristone to be administered at home or at the clinic and will receive either 800 µg misoprostol buccally (study 1) or 800 µg misoprostol sublingually (study 2) to self administer at home.~Participants will be asked to return to the hospital 14 days later for a follow-up visit."
62837233|NCT02035267|PLACEBO_COMPARATOR|Placebo - Grade 4|Participants received placebo administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With CR SMFRS Grade 4 (extreme).
62053750|NCT05177445|ACTIVE_COMPARATOR|Intervention group (corticosteroids + OT) without Phototherapy|Patients that present loss of smell 4 weeks after their coronavirus-19 infection and that have had a real-time polymerase chain reaction (reverse transcriptase polymerase chain reaction )and both oral corticosteroids (prednisone 40mg) and olfactory training will be applied, in the intervals of daily for 10 days and daily for the duration of the study respectively.
62254931|NCT02712151|ACTIVE_COMPARATOR|Surgical Infiltration with Ropivacaine 0.5%|Patients will receive surgical infiltration of local anesthetic into the 4 laparoscopic port sites. A total of 0.4 ml/kg (0.1+0.1+0.1+0.1) of 0.5% Ropivacaine, divided between the four port sites (max 20 ml), will be used. A total of 1ml/kg, divided between the TAP (0.4ml/kg on each side) and RS (0.1ml/kg on each side), of sterile saline will be used for the nerve blocks.
62254932|NCT03333642|EXPERIMENTAL|Duodenal Ileal interposition|Duodenal Ileal Interposition with Sleeve Gastrectomy.
62254933|NCT02171845||Foetus|
62254934|NCT02216721||Non primary aldosteronism|Non primary aldosteronism patients undergoing usual anti hypertensive treatment
62254935|NCT02216721||Primary Aldosteronism|Patients with confirmed primary aldosteronism undergoing treatment
62254936|NCT02982590|ACTIVE_COMPARATOR|warfarin sodium|warfarin daily, dosage according to INR monitor. Aim INR 2-3
62254937|NCT02982590|EXPERIMENTAL|apixaban|Apixaban 5 MG Oral Tablet \[ELIQUIS\] will be given for randomly selected patients for 3 months.
62254938|NCT05987059|EXPERIMENTAL|Standard Structured Follow-Up|Mailed informational flyer(s) on prioritized cardiovascular risks
62254939|NCT05987059|EXPERIMENTAL|Enhanced Structured Follow-Up|text or phone message(s) focused on the same prioritized risks + mailed informational flyer(s). These will be in addition to the SBIRT intervention delivered by Healthy Start and other similar community organization staff that all participants will receive.
62254940|NCT05171348|EXPERIMENTAL|CM326 55mg Q2W|55mg for 6 doses, SC, Q2W
62254941|NCT05171348|EXPERIMENTAL|CM326 110mg Q2W|110mg for 6 doses, SC, Q2W
62254942|NCT05171348|EXPERIMENTAL|CM326 220mg Q2W|220mg for 6 doses, SC, Q2W
62254943|NCT05171348|EXPERIMENTAL|CM326 220mg Q4W|220mg for 3 doses, SC, Q4W
62254944|NCT05171348|PLACEBO_COMPARATOR|Placebo|Placebo
62612691|NCT01118572|ACTIVE_COMPARATOR|etodolac group|
62612692|NCT01118572|PLACEBO_COMPARATOR|placebo group|
62612693|NCT02696434|ACTIVE_COMPARATOR|PBO NTX + BUP|Placebo naltrexone + buprenorphine
62612694|NCT02696434|EXPERIMENTAL|NTX + BUP|Naltrexone + buprenorphine
62612695|NCT06731556|EXPERIMENTAL|Intranasal Paracetamol|Participants in this arm received intranasal paracetamol (1.25 mg/mL) for postoperative pain control. Pain levels were assessed using the Modified CHEOPS scale and the Wong-Baker VAS for children aged 4-8 years, and the standard VAS for children aged 9-15 years. Assessments were performed at 15, 30, 60, 120 minutes, and 2, 4, 6, and 12 hours post-surgery.
62612696|NCT06731556|EXPERIMENTAL|Intranasal Diclofenac Sodium|Participants in this arm received intranasal diclofenac sodium (0.0625 mg/mL) for postoperative pain control. Pain levels were assessed using the Modified CHEOPS scale and the Wong-Baker VAS for children aged 4-8 years, and the standard VAS for children aged 9-15 years. Assessments were performed at 15, 30, 60, 120 minutes, and 2, 4, 6, and 12 hours post-surgery.
62612697|NCT06731556|EXPERIMENTAL|Intranasal Ibuprofen|Participants in this arm received intranasal ibuprofen (0.375 mg/mL) for postoperative pain control. Pain levels were assessed using the Modified CHEOPS scale and the Wong-Baker VAS for children aged 4-8 years, and the standard VAS for children aged 9-15 years. Assessments were performed at 15, 30, 60, 120 minutes, and 2, 4, 6, and 12 hours post-surgery.
62612698|NCT06731556|ACTIVE_COMPARATOR|Intravenous Paracetamol|Participants in this arm received intravenous paracetamol (20 mg/kg/day, twice daily) for postoperative pain control. Pain levels were assessed using the Modified CHEOPS scale and the Wong-Baker VAS for children aged 4-8 years, and the standard VAS for children aged 9-15 years. Assessments were performed at 15, 30, 60, 120 minutes, and 2, 4, 6, and 12 hours post-surgery.
62612699|NCT06162377|EXPERIMENTAL|Methylnaltrexone|Participants will be given 14 pre-filled syringes of methylnaltrexone. Participants will be instructed how to take the drug as an injection under the skin of your abdominal area.
62612700|NCT04174937|EXPERIMENTAL|Potentiator of antibiotics (PA)|Potenciator of antibiotics (PA) , albumin complex of tetraiodid was given per os, single and multiple doses for the different periods (but not exceeding 14 days)
62612701|NCT04174937|PLACEBO_COMPARATOR|Patients taking placebo PA|Placebo without any active pharmaceutical ingredients was given per os dosed for the patients in same periods of time as per experimental group, single and multiple doses for the different periods (but not exceeding 14 days)
62612702|NCT02203162|EXPERIMENTAL|cough reflex sensitivity|electronic cigarette exposure
62612703|NCT04049006|EXPERIMENTAL|complex-treatment benefiting group|Participants in the intervention group will receive the complex treatment and the usual clinical practice.
62837234|NCT02035267|EXPERIMENTAL|ATX-101 deoxycholic acid injection - Grade 4|Participants received deoxycholic acid 2 mg/cm\^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants with CR SMFRS Grade 4 (extreme).
62053751|NCT05960825|EXPERIMENTAL|Group MOPs|Group MOPs : will include 9 patients who willreceive MOPs with maxillary canine retraction that will be performed on intervention sides according to a standardized protocol.
62053752|NCT05960825|NO_INTERVENTION|Group IMOPS|other side in group which is control group
62612704|NCT04049006|NO_INTERVENTION|complex-treatment no benefiting group|Participants in the control group will receive the care from the usual clinical practice
62612705|NCT03131934|EXPERIMENTAL|Autologous EBV-CTL transduced with SFG-CNA12/SFG-CNA8|"All patients will receive the autologous EBV CTL retrovirally transduced with with (a) a calcineurin mutant (CNA12) that confers resistance to tacrolimus and (b) a control calcineurin mutant (CNA8). For each patient two ATIMPs will be generated:~* Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12~* Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8~An equal dose (10x7/m2) of CNA12+ EBV CTL and CNA8+ EBV CTL will be administered intravenously on day 0.~While awaiting ATIMP generation, patients may receive a single dose of Rituximab and other immunosuppressants (e.g. MMF) will be reduced, but tacrolimus will be maintained at therapeutic levels."
62837235|NCT00426413||1|Obese AA subjects with DKA or severe hyperglycemia
62254945|NCT00528580|EXPERIMENTAL|1|Simvastatin 80 mg once daily PO (or via NG or G-tube)
62443322|NCT04741360|EXPERIMENTAL|Modified Story Memory Technique|
62443323|NCT04741360|OTHER|Control|
62443324|NCT04354194|EXPERIMENTAL|Conventional Physiotherapy Group|This group will receive 15 sessions of conventional physiotherapy programme 5 times per week.
62443325|NCT04354194|EXPERIMENTAL|Osteopathic Manipulative Treatment Group|This group will receive 9 sessions of Osteopathic Manipulative Treatment programme 3 times per week.
62443326|NCT04634409|PLACEBO_COMPARATOR|Placebo (Pbo)|"Treatment 1: Pbo administered intravenously (IV).~Treatment 8: Pbo For 700 mg Bamlanivimab (BAM) + 500 mg VIR-7831 (Amendment (C-e)) administered IV.~Treatment 11: Pbo For 175 mg Bebtelovimab (BEB) \& 700 mg BAM +1400 mg Etesevimab ( ETE) +175 mg BEB (Low Risk Participants) administered IV.~Pooled Placebo (Addendum 4, IV) administered IV.~Pooled Placebo (Addendum 4, SC) administered SC."
62443327|NCT04634409|EXPERIMENTAL|BAM + ETE|"Treatment 2: 175 mg BAM +350 mg ETE administered IV.~Treatment 3: 700 mg BAM +1400 mg ETE administered IV.~Treatment 4: 2800 mg BAM +2800 mg ETE administered IV.~Treatment 6: 350 mg BAM +700 mg ETE administered IV.~Unintentional Dosing: 700 mg BAM +700 mg ETE administered IV.~700 mg BAM + 1400 mg ETE 30-min (Addendum (2)) administered IV.~700 mg BAM + 1400 mg ETE 15-min (Addendum (2)) administered IV."
62837236|NCT00426413||2|obese nondiabetic subjects, age 19-65.
62837237|NCT00426413||3|Any subjects with recurrent DKA. Recurrent DKA is defined as more than one admission to Grady Memorial Hospital.
62837238|NCT00986856|EXPERIMENTAL|Fucidin® cream|
62837239|NCT00986856|PLACEBO_COMPARATOR|Fucidin® cream vehicle|
62053753|NCT05960825|EXPERIMENTAL|Group i-PRF|group i-PRF: will include 9 patients receive i-PRF that will be performed on intervention sides according to a standardized protocol
62254946|NCT00528580|PLACEBO_COMPARATOR|2|Identical-appearing placebo PO (or via NG or G-tube)
62254947|NCT05486520|ACTIVE_COMPARATOR|BREAST MRI IMAGES FROM HEALTHY VOLUNTEERS|"All participants will be recruited prior to their scheduled diagnostic imaging or diagnostic procedures.~The expected time to complete the study is a maximum of 1.5 hours with approximately 30-60 minutes of scan time, depending on the specific MRI software being tested."
62254948|NCT05486520|EXPERIMENTAL|BREAST MRI IMAGES FROM PERSONS WITH KNOWN BREAST PATHOLOGIES BENIGN AND MALIGNANT|"All participants will be recruited prior to their scheduled diagnostic imaging or diagnostic procedures.~The expected time to complete the study is a maximum of 1.5 hours with approximately 30-60 minutes of scan time, depending on the specific MRI software being tested."
62837240|NCT04041414|EXPERIMENTAL|Intervention schools|Schools will be assigned to either intervention or control schools. Students in intervention schools will receive the intervention in semester 1.
62837241|NCT04041414|ACTIVE_COMPARATOR|Control schools|Students in control schools will receive no intervention
62053754|NCT05960825|NO_INTERVENTION|group i-PRF2|other side in group which is control group
62254949|NCT01395875||COPD patients with moderate exacerbations|COPD patients with COPD-related using ICD-9 codes physician office/outpatient visit with a dispensing for oral corticosteroid (OCS) or antibiotic (ABX) within 5 days of the visit (Phy+Rx)
62254950|NCT04752176||Tinnitus group|At least 20 patients suffering from tinnitus will be enrolled in the study.
62254951|NCT04752176||Hyperacusis group|At least 20 patients suffering from hyperacusis will be enrolled in the study.
62254952|NCT05784636|EXPERIMENTAL|Non-invasive BiPAP ventilation treatment group|Patients were first treated with HFNC on the basis of conventional treatment. The initial parameters were temperature: 31-37 °C, flow rate: 30-40 L/min, maintaining SpO2\>92%, adjusting oxygen concentration according to blood oxygen saturation, and treatment duration was 24 h. After 24 h, patients were treated with non-invasive ventilator-assisted ventilation BiPAP mode until discharge
62254953|NCT05784636|EXPERIMENTAL|HFNC treatment group|On the basis of conventional treatment, patients were first administered a noninvasive ventilator with the following initial parameters. BiPAP mode with an initial inspiratory pressure (IPAP) of 8-15 cmH2O and an initial expiratory pressure (EPAP) of 4-8 cmH2O. These parameters were adjusted according to the patient's specific conditions. After 24 hours of treatment, patients received HFNC until discharge.
62254954|NCT01208584||Chronic posttraumatic paraplegia|Paraplegic patients (Thoracic level of lesion Th1-Th12), ASIA A, spinal cord injury (SCI) 12-24 months
62254955|NCT01208584||Acute posttraumatic paraplegia|Paraplegic patients (Thoracic level of lesion Th1-Th12), ASIA A,SCI 2-6 months,
62254956|NCT01208584||Myelomeningocele patients|Myelomeningocele patients (congenital paraplegia, thoracic level of lesion Th1-Th12) ASIA A
62254957|NCT01208584||Volunteers|Volunteers without any neurological deficits
62254958|NCT05888090|EXPERIMENTAL|Intervention Group 1|
62254959|NCT05888090|EXPERIMENTAL|Intervention Group 2|
62612706|NCT04929860|ACTIVE_COMPARATOR|handwashing|This arm receives a scalable social marketing campaign using innovative behaviour change approaches to improve handwashing. The intervention is delivered by a commercial social marketing business unrelated to the investigating organisations
62837242|NCT06515600|EXPERIMENTAL|Study group|Group (A) (study group) will include 30 patients who practiced flow trigger sensitivity adjustment on mechanical ventilation for 1 week twice daily in addition to their plan of treatment.
62837243|NCT06515600|ACTIVE_COMPARATOR|Controlled group|Group (B) (controlled group) will include 30 patients who received their routine plan of weaning of mechanical ventilator (controlled mode then spontaneous mode and finally spontaneous breathing trial).
62837244|NCT04298242|EXPERIMENTAL|MRgFUS Treatment|The pancreatic tumor will be ablated with magnetic resonance guided focused ultrasound (MRgFUS).
62254960|NCT05888090|EXPERIMENTAL|Intervention Group 3|
62254961|NCT02771509|ACTIVE_COMPARATOR|ANG-3777|Study drug will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.
62254962|NCT02771509|PLACEBO_COMPARATOR|Normal Saline|The placebo will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.
62443328|NCT04634409|EXPERIMENTAL|BAM|"Treatment 5: 700 mg BAM administered IV.~700 mg BAM 15-min (Addendum (2)) administered IV."
62837245|NCT00417417|EXPERIMENTAL|Rilonacept|Rilonacept 320 mg subcutaneous at each treatment visit
62837246|NCT00417417|SHAM_COMPARATOR|Placebo|Normal saline subcutaneously at each treatment visit.
62053755|NCT01230255|EXPERIMENTAL|Percutaneous catheter decompression|Ultrasound guided percutaneous catheter drainage of free intra-peritoneal fluid or blood
62254963|NCT01226459|EXPERIMENTAL|Minoxidil Foam|5% Minoxidil Topical Foam
62254964|NCT01226459|PLACEBO_COMPARATOR|Vehicle Foam|Vehicle Topical Foam
62254965|NCT04497129|EXPERIMENTAL|ROMTech PortableConnect|Rehabilitation Using the ROMTech PortableConnect Device
62053756|NCT01230255|ACTIVE_COMPARATOR|Open abdominal decompression|Surgical treatment of elevated intra-abdominal pressure through traditional open abdominal decompression
62053757|NCT03785067|EXPERIMENTAL|Triple Pill (Active Treatment)|"Main Study: Fixed low-dose combination BP-lowering pill (Triple Pill) telmisartan 20mg + amlodipine 2.5mg + indapamide 1.25mg~Sub-Study: single-arm"
62254966|NCT04497129|ACTIVE_COMPARATOR|Traditional Rehabilitation & Continuous Passive Motion Device|Combination of OPPT and HHPT in conjunction with CPM device usage
62443329|NCT04634409|EXPERIMENTAL|BAM + VIR-7831|Treatment 7: 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e)) administered IV.
62612707|NCT04929860|NO_INTERVENTION|control|
62254967|NCT00025220|EXPERIMENTAL|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62254968|NCT01886339||Healthy population|
62254969|NCT01490450|PLACEBO_COMPARATOR|PBO: Placebo matching BMS-945429|
62254970|NCT01490450|EXPERIMENTAL|BMS-945429 (25mg)|
62254971|NCT01490450|EXPERIMENTAL|BMS-945429 (100mg)|
62254972|NCT01490450|EXPERIMENTAL|BMS-945429 (200mg)|
62254973|NCT01830751|EXPERIMENTAL|Limit trunk flexion upon rising|Immediately upon rising particpants perform the Restrained Sitting Treatment intervention for one hour.
62254974|NCT01830751|SHAM_COMPARATOR|Limit trunk flexion before going to bed|Immediately prior to going to bed, particpants perform the Restrained Sitting Treatment intervention for one hour.
62254975|NCT02665169|EXPERIMENTAL|Exercise intervention group|Supervised exercise intervention of 12 months. One Taiji and one gym training per week for first six months followed by 6 months free independent use of municipal facilities, including gym, swimming hall and weight room. Written and oral health counselling provided.
62254976|NCT02665169|ACTIVE_COMPARATOR|Control group|Control group, without any induced exercise intervention. Written and oral health counselling provided.
62254977|NCT01837030|OTHER|Oral Iron|
62254978|NCT01837030|OTHER|Oral Iron and Capsule Endoscopy|
62254979|NCT05338177|EXPERIMENTAL|Immunosuppression reduction|Participants stop mycophenolate or azathioprine for two weeks peri-vaccination. Treatment is stopped on week before vaccination and only restarted one week after vaccination
62612708|NCT05621967|EXPERIMENTAL|Silent Breathing / Tonation Breathing Techniques (TBT)|"Twice a week during the patient's 8 weeks of pulmonary rehabilitation:~1. For first 4 weeks, twice a week - 20 min of silent quiet breathing while sitting.~2. Next 4 weeks, twice a week - 20 min of TBT guided by a facilitator virtually"
62612709|NCT05621967|EXPERIMENTAL|Silent Breathing / Music Driven Vocal Exercises (MDVE)|"Twice a week during the patient's 8 weeks of pulmonary rehabilitation:~1. For first 4 weeks, twice a week - 20 min of silent quiet breathing while sitting.~2. Next 4 weeks, twice a week - 20 min of MDVE guided by a facilitator in-person"
62254980|NCT05338177|ACTIVE_COMPARATOR|No immunosuppression reduction|no alterations to immunosuppression
62612710|NCT05621967|EXPERIMENTAL|Tonation Breathing Techniques (TBT) / Silent Breathing|"Twice a week during the patient's 8 weeks of pulmonary rehabilitation:~1. For first 4 weeks, twice a week - 20 min of TBT guided by a facilitator virtually~2. Next 4 weeks, twice a week - 20 min of silent quiet breathing while sitting."
62612711|NCT05621967|EXPERIMENTAL|Music Driven Vocal Exercises (MDVE) / Silent Breathing|"Twice a week during the patient's 8 weeks of pulmonary rehabilitation:~1. For first 4 weeks, twice a week - 20 min of MDVE guided by a facilitator in-person~2. Next 4 weeks, twice a week - 20 min of silent quiet breathing while sitting."
62612712|NCT02485418|EXPERIMENTAL|Propofol infusion|"All subjects will be treated with an intravenous propofol infusion at the following escalating rate schedule:~20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes"
62612713|NCT05835427|EXPERIMENTAL|Fibromyalgia individual|Cervical Extensor Stretch, cervical flexor stretch, cervical lateral flexion stretch, thoracic stretch, pectoral stretch, lumbar extensor stretch, posterior capsule stretch, knee flexor stretch, gastro-soleus stretch, quadriceps stretch, cat-camel exercise, shoulder circles, neck flip- tilting the neck to the right and left, relaxation of the abdominal and back muscles, posterior pelvic tilt.
62254981|NCT03163589|EXPERIMENTAL|study group|Within 4 to 6 hours after birth all cases with moderate to severe hypoxic ischemic encephalopathy will be enrolled in therapeutic hypothermia using total body cooling and temperature and Receive erythropoietin (1000 U/kg intravenously) on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
62254982|NCT03163589|PLACEBO_COMPARATOR|control group|Within 4 to 6 hours after birth cases with moderate to severe hypoxic ischemic encephalopathy enrolled in therapeutic hypothermia using total body cooling and temperature and Receive normal saline on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
62254983|NCT04411420|ACTIVE_COMPARATOR|Integrated Care Pathway|The integrated care pathway provides both on-site physical therapy services and centrally-delivered services via telephone or video from study providers at the Durham VA.
62254984|NCT04411420|ACTIVE_COMPARATOR|Coordinated Care Management Pathway|The care management pathway involves a referral of patients from a physician to a pain navigator on site at the local VA who is knowledgeable in current recommended treatment guidelines for low back pain.
62254985|NCT05102851||Patient with acute coronary syndrome|All patients with the acute coronary syndrome were included in the study. Pre-diabetic patient. Non-diabetic patient(Controlled)
62254986|NCT00383084|EXPERIMENTAL|1|Group 1 participants will take part in 30 minutes total of self-selected lifestyle physical activity throughout the day, 5 to 7 days per week. Twice a month, they will attend group sessions designed to help participants develop and maintain a more physically active lifestyle. Goal setting, self-monitoring, and pain management will be discussed at these sessions.
62254987|NCT00383084|ACTIVE_COMPARATOR|2|Group 2 participants will attend monthly fibromyalgia educational sessions, which will focus on understanding the symptoms of FM, learning to manage pain and fatigue, and developing self-help strategies.
62254988|NCT01713842|EXPERIMENTAL|TCZ|Tocilizumab at week 0, week 4 and week 8 8mg/kg at each perfusion
62254989|NCT05517395|EXPERIMENTAL|health nutrition education|The participants in intervention group will receive health nutrition education based on a health belief model including nutrition health education (booklet), and telephone call support.
62254990|NCT05517395|ACTIVE_COMPARATOR|usual care|Control group will only receive usual care. Usual care is routine measurement of children including height, length, weight, head circumference, monitoring children's activities, and monitoring the immunization status of children.
62837247|NCT00670748|EXPERIMENTAL|#1 Anti-NY-ESO-1 TCR PBL+HD IL-2 Mel/RCC|Patients with melanoma or renal cell cancer (RCC) will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin.
62837248|NCT00670748|EXPERIMENTAL|#2 Anti-NY-ESO-1 TCR PBL+HD IL-2 OtherCa|Patients with cancers other than melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by anti-NY ESO-1 TCR PBL and high dose (HD) aldesleukin
62837249|NCT00670748|EXPERIMENTAL|#3ESO1 TCR PBL+ALVAC ESO1+HD IL2 Mel/RCC|Patients with melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by replication-defective recombinant canarypox virus (ALVAC) NY-ESO-1 vaccine, anti-NY ESO-1 TCR PBL and high dose aldesleukin
62837250|NCT00670748|EXPERIMENTAL|#4ESO1 TCR PBL+ALVAC ESO1+HD IL2 OtherCa|Patients with cancers other than melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by ALVAC NY-ESO-1 vaccine, anti-NY ESO-1 TCR PBL and high dose aldesleukin
62837251|NCT02324192|OTHER|Normal ultrasonography|Patients with normal ultrasonography findings
62837252|NCT02324192|OTHER|Inflammatory ultrasonography|Patients with inflammatory ultrasonography findings
62837253|NCT02022124|EXPERIMENTAL|microcrystalline cellulose (open-label inert substance)|3-week course of non-deceptive placebo using placebo pills plus the usual regime that the patients had been prescribed at the time of intake.
62837254|NCT02022124|NO_INTERVENTION|Usual care treatment|This arm will entail a 3-week course of the stable treatment the patient is following at time of intake.
62837255|NCT03566134|PLACEBO_COMPARATOR|Placebo|DA-8010 placebo + Solifenacin succinate placebo
62837256|NCT03566134|EXPERIMENTAL|DA-8010 2.5mg|DA-8010 2.5mg + Solifenacin succinate placebo
62053758|NCT03785067|PLACEBO_COMPARATOR|Placebo|"Main Study: Matched placebo, received via blinded study capsules~Sub-Study: single-arm"
62053759|NCT02129101|EXPERIMENTAL|Treatment (azacitidine, sonidegib, decitabine)|"Patients receive azacitidine SC or IV on days 1-7, sonidegib PO QD on days 1-28 or 1-7\* or decitabine IV on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: Sonidegib PO QD is given on days 1-7 if in combination with azacitidine or on days 1-28 is given if in combination with decitabine."
62053760|NCT03659422|OTHER|Intervention Arm|Modified Paleolithic diet and vitamin/ supplement program was part of previous approaches to managing ALS related symptoms over an 18 month period. This is a safety study. We will be assessing if patients can implement the proposed modified Paleolithic diet (Wahls Elimination), if lean muscle mass is maintained on the study diet, and what changes occur in the ALS functional symptoms and quality of life.
62254991|NCT05526690|ACTIVE_COMPARATOR|Treatment A: Immediate-release metformin|"Treatment A: single 1000 mg dose of immediate-release metformin~Subjects will be randomly assigned to 1 of 2 sequences: AB or BA.~* Treatment A: a single 1000 mg dose of immediate-release metformin; and~* Treatment B: a single 1000 mg dose of immediate-release metformin coadministered with a 10 mg dose of CIN-107.~All study medication will be administered at 8:00 AM (±2 hours). There will be a minimum 10-day washout between administration of study drug in each treatment period."
62254992|NCT05526690|EXPERIMENTAL|Treatment B: Immediate-release metformin coadministered with a CIN-107|"Treatment B: a single 1000 mg dose of immediate-release metformin coadministered with a 10 mg dose of CIN-107~Subjects will be randomly assigned to 1 of 2 sequences: AB or BA.~* Treatment A: a single 1000 mg dose of immediate-release metformin; and~* Treatment B: a single 1000 mg dose of immediate-release metformin coadministered with a 10 mg dose of CIN-107.~All study medication will be administered at 8:00 AM (±2 hours). For Treatment B, the dose of CIN-107 will be administered 2 hours prior to the dose of metformin.~There will be a minimum 10-day washout between administration of study drug in each treatment period."
62254993|NCT05349851||Renal failure patiens|Patients with advanced renal failure
62837257|NCT03566134|EXPERIMENTAL|DA-8010 5mg|DA-8010 5mg + Solifenacin succinate placebo
62837258|NCT03566134|ACTIVE_COMPARATOR|Solifenacin 5mg|DA-8010 placebo + Solifenacin succinate 5mg
62837259|NCT00985361|EXPERIMENTAL|Vitamin D 2000 international units daily|
62837260|NCT00985361|ACTIVE_COMPARATOR|Vitamin C 500mg daily|
62837261|NCT04291898|ACTIVE_COMPARATOR|Device: ASO|Participants implanted with the AMPLATZER™ Septal Occluder (ASO)
62837262|NCT04291898|ACTIVE_COMPARATOR|Device: FSO|Participants implanted with the Occlutech Figulla Flex II® (FSO).
62837263|NCT04291898|ACTIVE_COMPARATOR|Device: GSO/GAO|Participants implanted with the GORE® CARDIOFORM ASD Occluder (GSO/GAO)
62837264|NCT04103749|EXPERIMENTAL|Exalt DScope 02|Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
62053761|NCT00041782|EXPERIMENTAL|Dalteparin|
62053762|NCT00815867|EXPERIMENTAL|A|Patient will receive Epoetin Beta
62053763|NCT00815867|NO_INTERVENTION|B|
62053764|NCT03502863|EXPERIMENTAL|Digital refraction|Web-based application for obtaining the refractive error and visual acuity of each eye, using a computer and a smart phone
62053765|NCT03502863|ACTIVE_COMPARATOR|Manual Refraction|Manual manifest refraction is performed by an eyesore specialist using a phoropter.
62254994|NCT03218098|EXPERIMENTAL|Smaller Incision|UVATS access for lobectomy with small skin access 4 cm
62612714|NCT05835427|EXPERIMENTAL|Healthy volunteers|Cervical Extensor Stretch, cervical flexor stretch, cervical lateral flexion stretch, thoracic stretch, pectoral stretch, lumbar extensor stretch, posterior capsule stretch, knee flexor stretch, gastro-soleus stretch, quadriceps stretch, cat-camel exercise, shoulder circles, neck flip- tilting the neck to the right and left, relaxation of the abdominal and back muscles, posterior pelvic tilt.
62612715|NCT00426660|EXPERIMENTAL|1|
62254995|NCT03218098|ACTIVE_COMPARATOR|Traditional Incision|UVATS access for lobectomy with longer skin access 8 cm
62254996|NCT01072305|EXPERIMENTAL|Intermittent pneumatic compression (IPC)|IPC from induction of general anesthesia to completion of skin closure.
62254997|NCT01072305|PLACEBO_COMPARATOR|control|IPC - placebo from induction of general anesthesia to closure of the skin
62837265|NCT01907711|SHAM_COMPARATOR|Sham Acupuncture.|That through the center of the guide tube is inserted blunt rod, producing the sensation of a prick in each of the eight points that are not acupuncture points. No intervention is a completely inert as it involves some type of peripheral stimulus, but the technique is closer to a placebo and offers interesting option from a methodologic al point of view showing and ability to mimic real acupuncture The points are not used acupuncture points but are fictional points. The patient should remáis lying prone during the 20 minutes of the session, so the placebo technique remains hidden. Every five minutes the acupuncturist will repeat the action in the corresponding eigh points.
62837266|NCT01907711|ACTIVE_COMPARATOR|True acupuncture|The AV is an energy balance treatment with the aim of restoring health and well-being of the patient. Since each patient may have moré than three diagnoses of Traditional Chinese Medicine, will undertake a Major effort of synthesis of acupuncture points for treatment in a session, use the AV 8 - 12 needles, are held in place for 20 minutes with bidirectional rotation of the sleeve needle for one minute every five minutes (a total of four rotations for session). And in the AS 8 tube rod guides with blunt tip for 20 minutes. The same time be devoted to the patients in each treatment group similar, the time requested for the period of pre and post-treatment will be identical in all cases.
62612716|NCT01555918|EXPERIMENTAL|Isavuconazole single oral dose - Part 1|
62837267|NCT04785703||oral lichen planus group|patients with chronic bollus erosive lichen planus
62837268|NCT02170103|EXPERIMENTAL|Ultrasound and microbubbles|Patients who provide emergent consent will be randomized to either conventional therapy for a heart attack, or conventional therapy and ultrasound with microbubbles. The ultrasound will be applied both before and after emergent heart catheterization, in order to break up the blood clots that are not only in the artery supplying the heart muscle, but also in the small branches (capillaries) that are fed by this artery.
62837269|NCT02170103|OTHER|Standard of care|Emergent PCI/antithrombotic/antiplatelet therapy with Echocardiogram to assess Left Ventricular Ejection Fraction (LVEF) and Aspirin, Plavix, or Direct Thrombin Inhibitor.
62837270|NCT05724095|SHAM_COMPARATOR|control|
62254998|NCT00739011|EXPERIMENTAL|1|
62443330|NCT04634409|EXPERIMENTAL|BEB|"Treatment 9: 175 mg BEB (Amendment (f), Low Risk Participants) administered IV.~Treatment 12: 175 mg BEB (Amendment (f), High Risk Participants) administered IV.~70 mg BEB 140 mg/Min (Addendum 4, IV) administered IV.~175 mg BEB 140 mg/Min (Addendum 4, IV) administered IV.~175 mg BEB 350 mg/Min (Addendum 4, IV) administered IV.~1750 mg BEB 350 mg/Min (Addendum 4, IV) administered IV.~280 mg BEB (Addendum 4, SC) administered SC.~560 mg BEB (Addendum 4, SC) administered SC."
62837271|NCT05724095|EXPERIMENTAL|low frequency stimulation|
62254999|NCT02536313|EXPERIMENTAL|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
62255000|NCT02536313|EXPERIMENTAL|SOF/VEL/VOX + RBV|SOF/VEL/VOX + RBV for 12 weeks
62612717|NCT01555918|EXPERIMENTAL|Isavuconazole single intravenous (IV) dose - Part 1|
62612718|NCT01555918|EXPERIMENTAL|Isavuconazole multiple oral doses - Part 2|
62837272|NCT05724095|EXPERIMENTAL|high frequency stimulation|
62837273|NCT04922385|EXPERIMENTAL|CBT|Individual 4-week CBT protocol
62837274|NCT02037399|EXPERIMENTAL|intravenous dexamethasone|To receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD
62837275|NCT02037399|PLACEBO_COMPARATOR|intravenous normal saline|To receive normal saline as placebo intravenous immediately after ESD
62837276|NCT03604406|EXPERIMENTAL|Varicella Zoster Vaccine (Zostavax)|Live zoster vaccine injection will be administered as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
62053766|NCT05094531|EXPERIMENTAL|Intervention group|"Participants of this experimental group will have to attend the prevention program which is organised in eight 2-hour workshops, one every other week.~Groups of 10-12 participants will be established prior to the first session of the program and will remain the same throughout the program."
62255001|NCT03761875|OTHER|CHB patients|a blood sample is done during a follow-up visit
62255002|NCT03761875|OTHER|Control group|a blood sample
62255003|NCT02535884|EXPERIMENTAL|Stimulation group|Patients in the stimulation group will be stimulated immediately after implantation of the Stimulator (ACTIVA® PC neurostimulator (Model 37601))
62255004|NCT02535884|SHAM_COMPARATOR|Non-stimulation group|Patients in the non-stimulation group will not be stimulated for the first three months after implantation of the Stimulator (ACTIVA® PC neurostimulator (Model 37601))
62612719|NCT01555918|EXPERIMENTAL|Isavuconazole multiple intravenous (IV) doses -Part 2|
62612720|NCT01739764|EXPERIMENTAL|Vemurafenib 480mg BID|Participants received oral vemurafenib at 480 mg BID, depending on the last dose in the antecedent protocol until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator, death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the sponsor to terminate the study, whichever occurs first.
62255005|NCT02375152|EXPERIMENTAL|Surgical Intervention|
62255006|NCT00006151|EXPERIMENTAL|Accu Drops (AD&C)|The experimental group (N=30) will be prescribed active Accu Drops (AD\&C) plus behavioral therapy.
62837277|NCT03604406|PLACEBO_COMPARATOR|Placebo Injection (Zostavax Comparator)|Saline injection will be administered as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
62255007|NCT00006151|PLACEBO_COMPARATOR|Placebo|The control condition (N=30) will be prescribed placebo Accu Drops (PD\&C) plus behavioral therapy.
62837278|NCT03604406|EXPERIMENTAL|Varicella Zoster Vaccine (Shingrix)|Non-live zoster vaccine injection will be administered twice, 8 weeks apart, as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
62837279|NCT03604406|PLACEBO_COMPARATOR|Placebo Injection (Shingrix Comparator)|Saline injection will be administered twice, 8 weeks apart, as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
62255008|NCT04207450|PLACEBO_COMPARATOR|Placebo Group|Placebo Gel + Placebo Solution (Distilled Water)
62255009|NCT04207450|EXPERIMENTAL|Placebo Gel + Glutaraldehyde (GPG)|Placebo Gel + 5% Glutaraldehyde Aqueous Solution
62255010|NCT04207450|EXPERIMENTAL|Phosphoric Acid + Glutaraldehyde (GAG)|37% Phosphoric Acid + Glutaraldehyde Aqueous Solution (GAG)
62255011|NCT03215420|EXPERIMENTAL|Certain or probable Meniere's disease|
62255012|NCT06243042||Enuretic|Children complaining of monosymptomatic enuresis
62255013|NCT06243042||Non-enuretic|Healthy non enuretic children
62255014|NCT02171611|EXPERIMENTAL|Dabigatran etexilate pellets|
62255015|NCT02171611|EXPERIMENTAL|Dabigatran etexilate powder|
62255016|NCT02171611|ACTIVE_COMPARATOR|Dabigatran etexilate capsule|
62255017|NCT01252212|EXPERIMENTAL|Receiving SMS alerts|The patients randomized to this arm will have a SMS message sent to them regarding medication adherence for antiretroviral medications, anti-hypertensive medications, anti-depressants, hyperglycemic controlling medications and hypercholesterolemia controlling medications as well as life style supportive suggestions.
62255018|NCT01252212|ACTIVE_COMPARATOR|No SMS messages|The patients randomized to this arm will have a SMS message sent to them regarding healthy life style supportive suggestions.
62255019|NCT01621230|ACTIVE_COMPARATOR|Epidural fentanyl|A continuous epidural infusion of fentanyl 10 mcg/cc at a basal infusion rate of 10 ml/hr with a patient-controlled epidural analgesia (PCEA) demand dose of 5 mL/hr for pain. Meperidine 25 mg intravenously every 1 hour for breakthrough pain as needed.
62255020|NCT01621230|PLACEBO_COMPARATOR|Epidural bupivacaine plus fentanyl|A continuous epidural infusion of bupivacaine plus fentanyl during the second stage (i.e. 10 cm dilation) of labor. Epidural infusion are 10 ml/hr basal infusion plus 5 ml/hr demand dose via patient-controlled epidural analgesia (PCEA). Meperidine 25 mg intravenously every 1 hour for breakthrough pain as needed .
62837280|NCT02911168|ACTIVE_COMPARATOR|Proximal Intercostal Block|See Intervention Section
62255021|NCT03853720|EXPERIMENTAL|Intervention arm|combined and simultaneous balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices
62255022|NCT01398020|ACTIVE_COMPARATOR|Standard bowel prep|Subject will receive standard bowel prep prior to colonoscopy.
62255023|NCT01398020|EXPERIMENTAL|2L Bi-Peglyte|Subjects will be asked to take 2L Bi-Peglyte + 15mg bisacodyl for bowel prep the day before colonoscopy.
62255024|NCT05043571|EXPERIMENTAL|Single arm|Single arm Phase I Clinical Trial
62255025|NCT03988530|ACTIVE_COMPARATOR|DPI-386 Nasal Gel|DPI-386 Nasal Gel (0.2 mg / 0.12 g)
62255026|NCT03988530|PLACEBO_COMPARATOR|Placebo Nasal Gel|placebo nasal gel (0.12 g)
62255027|NCT01250340|EXPERIMENTAL|Aspirin|100 mg/day for 30 days
62255028|NCT01250340|PLACEBO_COMPARATOR|Placebo|1 cp /day for 30 days
62255029|NCT01053299|ACTIVE_COMPARATOR|No treatment|Every child, without exception, born in the peroid 1.2.1998 - 31.12.2006, still alive, will be called for to take a Xray of their hips aimed at comparing the ultrasound-values taken newborn.
62255030|NCT01353196||stenosis|carotid stenosis
62255031|NCT01353196||no stenosis|no stenosis
62837281|NCT02911168|ACTIVE_COMPARATOR|Paravertebral Block|See Intervention Section
62837282|NCT03678519||Exposed workers|Flour mills workers exposed to health hazards
62837283|NCT00891943|OTHER|Structured lifestyle support|Intervention group-structured lifestyle support.
62837284|NCT00891943|NO_INTERVENTION|Usual care for weight management|"This is the control group, and they will receive usual care for weight management at their GP practice."
62837285|NCT05659186|EXPERIMENTAL|Treatment Cohort|Tislelizumab administration on day 1, and Anlotinib continuous administration from days 1 to 14， every three weeks Radiotherapy
62837286|NCT00996333|EXPERIMENTAL|Gemzar, Taxotere, Xeloda|"Gemcitabine, Docetaxel, Capecitabine:~Gemzar intravenously on Day 4 and 11 Taxotere intravenously on Day 4 and 11 Xeloda tablet taken orally every day for 14 days"
62837287|NCT01103752||Surgery|This group (n=220) consist of patients undergoing hip or knee replacement in a fast-track setup and they are tested 3 times for postoperative cognitive dysfunction.
62837288|NCT01523093|ACTIVE_COMPARATOR|Zofran ODT|Zofran ODT (Ondansetron) orally disintegrating tablets 8mg Manufactured By Cardinal Health, Blagrove, Swindon, Wiltshire, UK SN58RU
62053767|NCT05094531|NO_INTERVENTION|No-intervention group|Participants of the no-intervention group will not have to attend the prevention program.
62837289|NCT01523093|EXPERIMENTAL|Ondansetron Orally Disintegrating Tablets|Ondansetron 8 mg Orally Disintegrating Tablets Manufactured By OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc, USA)
62053768|NCT00640627|EXPERIMENTAL|A|
62053769|NCT00640627|PLACEBO_COMPARATOR|B|
62053770|NCT00514683|EXPERIMENTAL|dose 1|low dose BIBF1120 once daily
62053771|NCT00514683|EXPERIMENTAL|dose 2|low dose BIBF 1120 twice daily
62053772|NCT00514683|EXPERIMENTAL|dose 3|intermediate dose BIBF 1120 twice daily
62053773|NCT00514683|EXPERIMENTAL|dose 4|high dose BIBF 1120 twice daily
62053774|NCT00514683|PLACEBO_COMPARATOR|placebo|placebo
62053775|NCT04424862|EXPERIMENTAL|Multitarget Therapy|The combined therapy with prednisone, ciclosporin and mycophenolate mofetil.
62053776|NCT04424862|ACTIVE_COMPARATOR|Control|Ponticelli Regimen
62053777|NCT01666808|EXPERIMENTAL|FACBC PET scan|A trial group in which anti-3-\[18F\]FACBC PET-CT is used to guide radiotherapy decisions and radiotherapy treatment volumes.
62053778|NCT01666808|ACTIVE_COMPARATOR|Conventional-Only Imaging|A control group whose treatment decisions will be made based on conventional imaging - bone scan and abdominopelvic CT and/or MR scan.
62053779|NCT06041984|EXPERIMENTAL|Glycopyrrolate|Participants will receive intravenous glycopyrrolate 0.2 mg while receiving anesthetic.
62837290|NCT01647347|EXPERIMENTAL|test treatment|"Test treatment:~* 1 min mouthwash with 10% PVP-iodine~* 1 min subgingival rinsing with 10% PVP-iodine~* 1 min ultrasonic debridement with 10% PVP-iodine as cooling liquid~* blood sampling from the V.mediana cupidi"
62837291|NCT01647347|PLACEBO_COMPARATOR|Control group|"Control:~* 1 min mouthwash with water~* 1 min subgingival rinsing with water~* 1 min ultrasonic debridement with water as cooling liquid~* blood sampling from the V.mediana cupidi"
62837292|NCT03651401||rotator cuff related shoulder pain|Participants were assessed for SME, pain (rest, activity, night, measurement), and upper extremity function (FIT-HaNSA).
62837293|NCT03651401||age gender matched healthy controls|Participants were assessed for SME, and upper extremity function (FIT-HaNSA).
62053780|NCT06041984|PLACEBO_COMPARATOR|Placebo|Participants will receive intravenous 1ml saline while receiving anesthetic.
62053781|NCT04863625|EXPERIMENTAL|Experimental group|748 students from two secondary schools for the intervention group will be selected and participated in a peer led education process on substance use (smoking, drinking and chewing) prevention based on the Theory of Planned Behavior (TPB).
62053782|NCT04863625|NO_INTERVENTION|Control group|748 students from two secondary schools for the control group will selected and receive t their school's regular curriculum.
62837294|NCT01926561||Hypotensive bradycardic event|The participants are assigned to hypotensive bradycardic event (HBE) group when they experience signs or symptoms associated with syncope, hypotension, or bradycardia, which are treated with vasopressors or inotropics following sitting position after interscalene brachial plexus block is done. Otherwise, they are assigned to non-HBE group.
62837295|NCT00553878|PLACEBO_COMPARATOR|dutasteride|
62837296|NCT03762993|EXPERIMENTAL|Healthy Adults|Participants will complete vocal rest and controlled phonation
62837297|NCT03762993|EXPERIMENTAL|Healthy Adults reporting Vocal Fatigue|Participants will complete vocal rest and controlled phonation
62837298|NCT04178603|EXPERIMENTAL|Acute Exercise Trial|Lean control subjects and insulin resistant subjects perform an acute bout of one-legged knee-extensor exercise. Glucose metabolism is investigated before exercise (basal), during exercise and for 120 min of recovery.
62053783|NCT01636999|EXPERIMENTAL|Butorphanol|The main study arm will be examining how well a 50% Nitrous Oxide/50% Oxygen gas mixture is in reducing labor pains in term labor patients with less than 5 cm cervical dilation, compared to 2mg of Butorphanol (a common synthetic opiod used for labor pains in this setting).
62053784|NCT02891720|ACTIVE_COMPARATOR|ARM A: Proteus Sensor System (PSS) First|ARM A will receive Proteus Sensor System (PSS) first. At 12-week intervals participants will crossover to the next condition.
62053785|NCT02891720|NO_INTERVENTION|ARM B: SOC First|ARM B will 12 weeks of FTC/TDS standard of care (SOC) first. At 12-week intervals participants will crossover to the next condition.
62053786|NCT05461703|EXPERIMENTAL|Planet Nutrition Program (PNP) implemented by nutrition and physical activity advanced students|"The PNP consists of:~Nutrition education sessions: Nutrition advanced students of the University of Sonora will provide 1 face-to-face group class of one hour per week. The PNP handbook will be used to bring the different topics and dynamics to reinforce learning. The program will be focused on establishing some health-related goals.~Physical activity sessions: Three classes of 1 hour per week will be implemented by physical activity advanced students of the University of Sonora, independent of the school's curricular physical activity classes. A physical activity handbook designed by the study team will be used. Children will work on developing different skills.~Parents participation: They will receive one printed brochure with nutrition topics weekly. Also, they will be asked for their Facebook user (to create a private group) or the email to upload the information of the brochure and other didactic materials. Nutrition students will be in charge of providing the information."
62053787|NCT05461703|EXPERIMENTAL|Planet Nutrition (PNP) implemented by school teachers|"The PNP consists of:~Nutrition education sessions: Fourth grade school teachers will provide 1 face-to-face group class of one hour per week. The PNP handbook will be used to bring the different topics and dynamics to reinforce learning. The program will be focused on establishing some health-related goals.~Physical activity sessions: Three classes of 1 hour per week will be implemented by physical activity advanced students of the University of Sonora, independent of the school's curricular physical activity classes. A physical activity handbook designed by the study team will be used. Children will work on developing different skills.~Parents participation: They will receive one printed brochure with nutrition topics weekly. Also, they will be asked for their Facebook user (to create a private group) or the email and upload the information of the brochure and other didactic materials. School teachers will be in charge of providing the information."
62053788|NCT05461703|NO_INTERVENTION|Control Group|Scholars of this group will continue with their normal school nutrition and physical activity classes. At the end of the study they will have access to the program materials through a web page.
62612721|NCT01739764|EXPERIMENTAL|Vemurafenib 720mg BID|Participants received oral vemurafenib at 720 mg BID, depending on the last dose in the antecedent protocol until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator, death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the sponsor to terminate the study, whichever occurs first.
62612722|NCT01739764|EXPERIMENTAL|Vemurafenib 960mg BID|Participants received oral vemurafenib at 960 mg BID, depending on the last dose in the antecedent protocol until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator, death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the sponsor to terminate the study, whichever occurs first.
62612723|NCT04220099||schizophrenia patients needed ECT treatment|Whether patients need ECT treatment are assessed by clinicians according to American Psychiatric Association(APA) guidelines.
62612724|NCT05307718||The basic cohort|The subjects with the newly indicated indication for use: NOAC; platelet aggregation inhibitors from the P2Y12 receptor antagonist group; and HMG-CoA reductase inhibitors (statins
62837299|NCT04178603|EXPERIMENTAL|Insulin Sensitivity post Exercise|Lean control subjects and insulin resistant subjects perform an acute bout of one-legged knee-extensor exercise and insulin action is investigated 4 hours after cessation of exercise. Insulin action is investigated by a 120 min euglycemic-hyperinsulinemic euglycemic clamp.
62612725|NCT05307718||Cases|"Cases will be subjects who have observed ADRs during follow-up: bleeding that meets the criteria of major or non-major, clinically relevant bleeding (for anticoagulants and platelet aggregation inhibitors); muscle or liver lesions (for statins); any other serious ADR."
62612726|NCT05307718||Controls|Controls will be subjects in whom no ADRs were observed during the study
62612727|NCT03818555|OTHER|Sebacia Microparticles Treatment|
62612728|NCT04936113|EXPERIMENTAL|FB-401|FB-401 applied topically
62053789|NCT04606784|EXPERIMENTAL|Ampion|Ampion
62053790|NCT04606784|OTHER|Standard of Care|Standard of Care
62053791|NCT00908492|ACTIVE_COMPARATOR|Education Control|
62612729|NCT00987597|EXPERIMENTAL|cognitive behavioural approach|specific technique of cigarette exposure and nicotinic treatment adjustment
62612730|NCT00987597|ACTIVE_COMPARATOR|usual approach|recommendations and nicotinic substitutes
62612731|NCT05432219|EXPERIMENTAL|Endoscopic Transoral Retropterygoid Nasopharyngectomy|a novel endoscopic approach to resect nasopharyngeal carcinoma
62612732|NCT03157726|ACTIVE_COMPARATOR|TUKEP(enucleation of prostate)|"Patients accept TUKEP (transurethral plasmakinetic enucleation of prostate). The TUKEP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running, the beak of resectoscope was used to enucleation of prostate and the bipolar loop was used to cutting and coagulation, There are many manufacturers of Bipolar TURP systems. Any bipolar plasmakinetic system approved by the CFDA (Chinese food and drug administration) may be used for the study.~The bipolar plasmakinetic system was set at 160 W for cutting and 100 W for coagulation."
62612733|NCT03157726|ACTIVE_COMPARATOR|TURP(resection of prostate)|"Patients accept TURP (transurethral resection of prostate). The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system approved by the CFDA (Chinese food and drug administration) may be used for the study.~The bipolar plasmakinetic system was set at 160 W for cutting and 100 W for coagulation."
62612734|NCT01081405|EXPERIMENTAL|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
62837300|NCT06518408||study group|Patients enrolled who switch to receive Cabotegravir long acting plus Rilpivirine long acting intramuscular injection every 2 months
62837301|NCT01167413||FIbromyalgia Patients|Patients diagnosed as suffering from Fibromyalgia according to the ACR criteria
62053792|NCT00908492|EXPERIMENTAL|Environmental Skill Building|
62053793|NCT00995501|ACTIVE_COMPARATOR|Intensive Glucose Control, Dexamethasone, light anesthesia|"* Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~* Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~* Light anesthesia target BIS of 55"
62612735|NCT05509010||Retrospective|4000 patients who were clinically evaluated by CTCA from 1 Jan 2007 to 31 Oct 2017.
62612736|NCT05509010||Prospective|4000 patients who are clinically evaluated by CTCA.
62612737|NCT04792372|OTHER|Periodontitis patients|Single-group receiving periodontal treatment. The data will be evaluated according to the healing potential of individuals in the group and also site-specifically.
62612738|NCT04172922|EXPERIMENTAL|Open label, topical sirolimus arm|Single arm, open label study of1% sirolimus ointment applied to affected area twice daily for the first four weeks followed by once daily for 5 months.
62612739|NCT03856333|OTHER|traditional treatment|30 minutes of conventional TENS, 20 minutes of hotpack, 8 minutes of therapeutic ultrasound and isotonic, isometric, stretching and relaxation exercises 2 weeks, 5 days in a week.
62612740|NCT06442449|EXPERIMENTAL|Trial group 1|vaccination with sIPV+MMR
62837302|NCT02982980|EXPERIMENTAL|Physiotherapy Guidance Mastectomy|Patients who underwent radical breast surgery, received pre and postoperative assessment and orientation.
62837303|NCT02982980|EXPERIMENTAL|Phys Muscle strengthening Mastectomy|Patients who underwent radical breast surgery, in addition to receiving guidance, had, weekly, physical therapy sessions with the goal to increase muscle strength in the upper limbs, between one and three months after surgery.
62255032|NCT01640652|EXPERIMENTAL|Low dose vaccine arm|To investigate safety, tolerability and immunogenicity of 25 µg of the serogroup B meningococcal protein vaccine MenPF-1 in healthy adults aged 18 to 50 years of age when given three doses of vaccine with 8 weeks interval.
62612741|NCT06442449|EXPERIMENTAL|Trial group 2|vaccination with sIPV+HepA-I
62837304|NCT02982980|EXPERIMENTAL|Physiotherapy Guidance Quadrantectomy|Patients who underwent partial breast surgery, received pre and postoperative assessment and orientation.
62255033|NCT01640652|EXPERIMENTAL|High dose vaccine arm|To investigate safety, tolerability and immunogenicity of 50 µg of the serogroup B meningococcal protein vaccine MenPF-1 in healthy adults aged 18 to 50 years of age when given three doses of vaccine with 8 weeks interval.
62443331|NCT04634409|EXPERIMENTAL|BAM+ ETE + BEB|"Treatment 10: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), Low Risk Participants) administered IV.~Treatment 13: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), High Risk Participants) administered IV.~Treatment 14: 700 mg BAM + 1400 mg ETE + 175 mg BEB(Amendment (g), High Risk, Updated Centers for Disease Control and Prevention (CDC) Criteria) administered IV.~175/700/1400 mg BAM + ETE + BEB 350 mg/Min (Addendum 4, IV) administered IV."
62612742|NCT06442449|ACTIVE_COMPARATOR|Control group 1|vaccination with sIPV
62837305|NCT02982980|EXPERIMENTAL|Phys Muscle strengthening Quadrantectomy|Patients who underwent partial breast surgery, in addition to receiving guidance, had, weekly, physical therapy sessions with the goal to increase muscle strength in the upper limbs, between one and three months after surgery.
62255034|NCT02332395||Emergency caesarean section|patients whose underwent emergency caesarean section operation
62255035|NCT02332395||Elective caesarean section|patients whose underwent elective caesarean section operation
62255036|NCT05911659||Non smokers- non diabetic patients|
62837306|NCT05779189|EXPERIMENTAL|Intervention|Participants will receive conventional health education and game-based virtual reality (game) in person.
62255037|NCT05911659||smokers non diabetic patients|
62255038|NCT05911659||non smokers diabetic patients|
62255039|NCT05911659||smokers diabetic patients|
62837307|NCT05779189|ACTIVE_COMPARATOR|Control|Participants will receive conventional health education and 4 video of balance exercise.
62255040|NCT04623203||children with migraine|Children that were diagnosed at the neurology clinic with migraine at the years 2007-2010. A follow up visit at 2020 of their current headache condition.
62255041|NCT04623203||children with TTH|children that were diagnosed at the neurology clinic with TTH at the years 2007-2010. A follow up visit at 2020 of their current headache condition.
62612743|NCT06442449|ACTIVE_COMPARATOR|Control group 2|vaccination with MMR
62612744|NCT06442449|ACTIVE_COMPARATOR|Control group 3|vaccination with HepA-I
62612745|NCT06593652|ACTIVE_COMPARATOR|Teen Intervene - Adolescent Only|Only the youth will participate in the brief intervention, Teen Intervene. The youth will participate in manual-standardized Teen Intervene sessions.
62837308|NCT05396183||3D-PCT group|Participant will receive three-dimensional printing co-planar template (3D-PCT) assisted CT-guided head and neck neoplasm biopsy and prospective accuracy and safety data will record.
62837309|NCT05127863|EXPERIMENTAL|2 to 5 ASD or TDL patients|2 to 5 ASD or TDL patients, 8 to 14 years old, with no intellectual disability.
62612746|NCT06593652|EXPERIMENTAL|Teen Intervene - Caregiver Involvement|The youth will participate in two Teen Intervene sessions. Additionally, the caregiver(s) will participate in a single, caregiver-only Teen Intervene session.
62255042|NCT01480999||Laparotomy (open surgery)|
62053794|NCT00995501|ACTIVE_COMPARATOR|Intensive Glucose Control, Dexamethasone, Deep anesthesia|"* Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~* Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~* Deep anesthesia target BIS of 35"
62053795|NCT00995501|ACTIVE_COMPARATOR|Intensive Glucose Control, placebo, Light anesthesia|"* Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~* Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~* Light anesthesia target BIS of 55"
62053796|NCT00995501|ACTIVE_COMPARATOR|Conventional Glucose Control, Dexamethasone, Light anesthesia|"* Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~* Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~* Light anesthesia target BIS of 55"
62255043|NCT01480999||Laparoscopic surgery|
62255044|NCT01480999||Robotic assisted surgery|
62837310|NCT05556811|ACTIVE_COMPARATOR|LSA-1|Light Scheduling Algorithm-1 (LSA-1): High circadian effective irradiances + Blue Enriched Light episodes
62255045|NCT03975621|EXPERIMENTAL|Immediate Intervention|The immediate intervention group will receive the intervention at the time of consent (baseline) and will be enrolled in the intervention for a total of 6 months. Patients will receive the tablet, a pedometer and an exercise band. Patients will use Nurse AMIE while receiving weekly phone calls from a patient navigator. After 90 days of the intervention observation will take place for 90 days, the patient will be asked to continue using Nurse AMIE without a patient navigator's presence.
62255046|NCT03975621|EXPERIMENTAL|Delayed Intervention|The delayed intervention group will receive the intervention 3 months after consent (6 months of intervention with 3 months delay total of 9 months); the patient will then follow the same pattern as listed above. The only difference is we will ask the delayed intervention group to wear a FitBit device for 1 week following consent in order to gain baseline data as to their activity/movement.
62255047|NCT03286686|EXPERIMENTAL|Experience 1|
62255048|NCT03286686|EXPERIMENTAL|Experience 2|
62255049|NCT03286686|EXPERIMENTAL|Experience 3|
62255050|NCT03286686|EXPERIMENTAL|Experience 4|
62612747|NCT06593652|EXPERIMENTAL|Teen Intervene - Online Caregiver Support Tool|Only the youth will participate in the brief intervention, Teen Intervene. The youth will participate in two Teen Intervene sessions. Caregiver(s) will be provided with an online tool (Family Checkup Online) that addresses parenting strategies to support their youth.
62837311|NCT05556811|ACTIVE_COMPARATOR|LSA-2|Light Scheduling Algorithm-2 (LSA-2): High circadian effective irradiances without Blue Enriched Light episodes.
62837312|NCT05556811|ACTIVE_COMPARATOR|LSA-3|Light Scheduling Algorithm-3 (LSA-3): Irradiance levels comparable to conventional hospital lighting (control group).
62837313|NCT03530124|OTHER|Vaccinated|In the study arm, infants will receive PCV13, DTaP, HBV, IPV, and Hib vaccines within 12 hours of randomization. Infants will be monitored from time of vaccination to 48 hours post-vaccination for the occurrence of apnea, bradycardia and desaturation.
62837314|NCT03530124|NO_INTERVENTION|Unvaccinated|In the study arm, infants will not receive PCV13, DTaP, HBV, IPV, and Hib vaccines during the study. Infants will be monitored from randomization to 48 hours post-randomization for the occurrence of apnea, bradycardia and desaturation.
62837315|NCT03120897|EXPERIMENTAL|Test group|The subjects will be enrolled into the test group and will receive RAM sensor.
62837316|NCT00738933|ACTIVE_COMPARATOR|A|A group of patients consuming 2 grams plant stanols 4-8 weeks before the operation
62837317|NCT00738933|ACTIVE_COMPARATOR|E|A group of patients consuming daily 2 grams plant sterols 4-8 weeks before the operation.
62837318|NCT00738933|PLACEBO_COMPARATOR|C|
62837319|NCT04029285|OTHER|Traditional Gym Based exercise - Control|Twice weekly sessions of TGB exercise for six weeks.
62837320|NCT04029285|EXPERIMENTAL|Exergaming|Twice weekly sessions of exergames for six weeks.
62255051|NCT03286686|EXPERIMENTAL|Experience 5|
62255052|NCT03286686|EXPERIMENTAL|Experience 6|
62255053|NCT04933604||LPN group|39 patients with high complexity renal tumors who underwent laparoscopic partial nephrectomy
62255054|NCT04933604||LRN group|39 patients with high complexity renal tumors who underwent laparoscopic radical nephrectomy
62255055|NCT02524821|ACTIVE_COMPARATOR|drugs only, fasted|1 x 850 mg metformin tablet, under fasting conditions.
62255056|NCT02524821|EXPERIMENTAL|Gelesis100 plus drugs, fasted|3 x 0.75 g Gelesis100 capsules, followed 30 minutes later by the administration of 1 x 850 mg metformin tablet, under fasting conditions.
62255057|NCT02524821|ACTIVE_COMPARATOR|drugs only, fed|1 x 850 mg metformin tablet, followed by the ingestion of a high-fat, high-caloric meal.
62443332|NCT04775784||Adult neurosurgical patients|Adult, both sex, neurosurgical patients candidate for intracranial surgery, able to sign informed consent.
62837321|NCT01718405|EXPERIMENTAL|Exercise Group|Each individual subject will give a blood sample for genetic analysis and undertake an exercise session and a rest session as a control. Cognitive function will be tested before and after each session.
62837322|NCT04596384|EXPERIMENTAL|Group I (telemonitoring program, actigraph, TapCloud)|Before surgery, patients complete a functional and nutritional assessment. The home environment of patients will also be assessed. Based on findings, patients undergo personalized prehabilitation. Patients also wear an actigraph throughout the study to measure and record daily steps taken and sedentary time. Patients use the TapCloud app on a smart device (phone, tablet) or home computer to collect, track, and report their symptoms. Based on patient input in the TapCloud app, a real-time alert is sent to an RN when predetermined thresholds are met. RNs then contact the patient via the TapCloud app and further phone calls if necessary. Patients, caregivers and surgeons may also participate in a focus group in-person, via telephone, or videoconferencing.
62255058|NCT02524821|ACTIVE_COMPARATOR|Gelesis100 plus drugs, fed|3 x 0.75 g Gelesis100 capsules, followed by the ingestion of a high-fat, high-caloric meal, followed by the administration of 1 x 850 mg metformin tablet (fed conditions).
62255059|NCT00820950|EXPERIMENTAL|Cohort A: INCB018424 Ruxolitinib 0.5%|INCB018424 Ruxolitinib 0.5% vs vehicle applied once daily for 28 days
62255060|NCT00820950|EXPERIMENTAL|Cohort B: INCB018424 Ruxolitinib 1.0%|INCB018424 Ruxolitinib 1.0% vs vehicle applied once daily for 28 days
62255061|NCT00820950|EXPERIMENTAL|Cohort C: INCB018424 Ruxolitinib 1.5%|INCB018424 Ruxolitinib 1.5% vs vehicle applied twice for 28 days
62255062|NCT00820950|EXPERIMENTAL|Cohort D: 18424 Ruxolitinib vs Dovonex® calcipotriene|INCB018424 up to 1.5% versus Dovonex® calcipotriene 0.005% cream applied BID for 28 days
62255063|NCT00820950|EXPERIMENTAL|Cohort E: 18424 Ruxolitinib vs Diprolene® AF betamethasone diproprionate|INCB018424 up to 1.5% versus Diprolene ® AF betamethasone dipropionate 0.05% cream applied twice a day for 28 days
62255064|NCT03600142|NO_INTERVENTION|Standard of Care (SoC)|Participants randomized to the control condition will receive the standard HIV counseling protocol in the clinic, which is administered by clinic nurses. According to the Tanzania PMTCT guidelines, HIV pre-test counseling should provide education about HIV and prepare a woman (and her partner, if present) for HIV testing. For anyone who tests positive for HIV, counseling should help the woman/couple to accept an HIV test result and discuss implications for treatment.
62255065|NCT03600142|EXPERIMENTAL|SoC + stigma counseling (Maisha)|Participants randomized to the intervention condition will receive the SoC counseling plus Maisha, a brief, scalable, theory-based counseling intervention that addresses HIV stigma at entry into antenatal care. Maisha involves a video delivered to all women prior to HIV testing, and, if a woman tests positive for HIV, two counseling sessions. If a male partner is present with the women, he may also be enrolled and participate in the first two counseling sessions together with the woman.
62255066|NCT01568775|EXPERIMENTAL|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
62255067|NCT04637607|EXPERIMENTAL|Ear-Acupressure Group|The subjects will receive true auricular acupoints stimulation with the attachment of Vaccaria seeds during the first round of play. After finishing the first round, the subjects will receive sham auricular acupoints stimulation.
62255068|NCT04637607|SHAM_COMPARATOR|Sham-Acupressure Group|The subjects will receive sham auricular acupoints stimulation with the attachment of Vaccaria seeds during the first round of play. After finishing the first round, the subjects will receive true auricular acupoints stimulation. (Crossover)
62255069|NCT00940979|NO_INTERVENTION|No use of integuseal|
62255070|NCT00940979|EXPERIMENTAL|Use of Integuseal|Application of a layer of Integuseal (Cyanoacrylate) from a ready to use applicator preoperative before incision Polymerisation immobilise the bacteria that survived the conventional skin preparation This way there will be les contamination of the wound.
62255071|NCT03585218|EXPERIMENTAL|Experimental Group|The Experimental Group participants will be submitted to the inhalation of the hedonic aroma during the chemotherapeutic treatment, this being the intervention of the study.The control group is not subject to intervention.
62837323|NCT04596384|ACTIVE_COMPARATOR|Group II (surgeon-only perioperative care program)|Patients and their families meet with the surgeon at least once before surgery. After surgery, patients are managed daily during post-operative care. Patients may receive a referral for functional and nutritional prehabilitation at the discretion of the surgeon/surgical team. Patients and their families receive instructions to follow the standard procedures for reporting problems between clinic visits, including contacting their surgical team if symptoms become severe and physical function worsens; and the use of the hospital call line to report problems. Patients, caregivers and surgeons may receive the opportunity to participate in focus group in-person, via telephone, or videoconferencing.
62255072|NCT03585218|NO_INTERVENTION|Control Group|The control group is not subject to intervention.
62053797|NCT00995501|ACTIVE_COMPARATOR|Intensive Glucose Control, Placebo, Deep anesthesia|"* Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~* Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~* Deep anesthesia target BIS of 35"
62837324|NCT01422343||1|
62255073|NCT06295341||cases - children with familial short stature|- 35 children, aged between 6 and 14 years, of both sexes, with familial short stature (height \< 3rd centile according to the Italian reference standards) and their caregivers of reference. Children with familial short stature will be characterized by: short stature in other members of the family group, not necessarily the parents, harmonious appearance, without particular clinical signs and normal pubertal development, parallel growth curve below the 3rd centile, bone age corresponding to chronological age. Children and teenagers with obesity (BMI \> 97th centile) will be excluded
62255074|NCT06295341||cases - children with normal height|35 children, aged between 6 and 14 years, of both sexes, with normal height (height \> 25th centile) and weight.
62255075|NCT06295341||cases - children with growth hormone deficiency|"10 children, aged between 6 and 14 years, of both sexes, affected by isolated GH deficiency according to the criteria established by AIFA note 39 for this pathology (short stature: ≤ -3 SD or ≤ -2 SD and growth velocity/year ≤ -1.0 SD for age and sex evaluated at least 6 months apart and peak GH at two different pharmacological stimulus tests \< 8 ng/ml). The exclusion criterion from the present study (and from treatment with rhGH) will be the presence of organic pathologies at the hypothalamic-pituitary level (assessed by performing brain MRI).~Children with GH deficiency are evaluated in baseline conditions and after 6 months of therapy with recombinant DNA GH (at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day)."
62255076|NCT03764891||Uphold|Patients who underwent Uphold procedure
62255077|NCT03764891||Perigee|Patients who underwent Perigee procedure
62255078|NCT03648008|ACTIVE_COMPARATOR|Group M|Drug: Morphine Background: No Bolus infusion: 0.015 mg\*kg-1
62255079|NCT03648008|EXPERIMENTAL|Group NBH|Drug: Hydromorphone Background: No Bolus infusion: 0.002 mg\*kg-1
62255080|NCT03648008|EXPERIMENTAL|Group BH|Drug: Hydromorphone Background: 0.002 mg\*kg-1\*h-1 Bolus infusion: 0.002 mg\*kg-1
62255081|NCT04206020|PLACEBO_COMPARATOR|Placebo Comparator: SkQ1 Vehicle|Vehicle for SkQ1 Ophthalmic Solution
62255082|NCT04206020|ACTIVE_COMPARATOR|SkQ1|SkQ1 Ophthalmic Solution
62255083|NCT00642395|EXPERIMENTAL|1|bortézomib
62255084|NCT05470920|EXPERIMENTAL|Electronic decision aid arm|Receive decision aid followed by an appointment with their oncologist.
62255085|NCT05470920|ACTIVE_COMPARATOR|Genetic counselor Arm|Receive pretest counseling with a genetic counselor.
62255086|NCT05018039|EXPERIMENTAL|Collaborative care model|"Collaborative care involves three professionals: a physical health care provider (physiotherapist or occupational therapist), a mental health care provider (psychologist or psychiatrist) and a case manager. The case manager will work closely with the patient to identify the mental health support necessary. This may involve appointments with a psychologist or psychiatrist as part of their musculoskeletal treatment.~The case manager will define a treatment plan and organise appointments with the patients and monitor their progress using validated questionnaires, adjusting their mental or physical care support when required. This professional will also monitor patients' attendance and support managing their appointments and routinely update the clinical team on patient progress, and relaying information back to the clinical team. This model of care will work in parallel to the regular musculoskeletal appointments with the physiotherapist and/or occupational therapist (usual care)."
62255087|NCT05018039|NO_INTERVENTION|Usal Care|"Current usual care within musculoskeletal outpatients involves an initial patient assessment by a physiotherapist or occupational therapist (or both) to determine the needs and goals of the patient in relation to their musculoskeletal condition. Clinicians also help to inform, educate, and empower patients to self-manage their rehabilitation where possible.~Following this initial assessment, patients are provided with a plan of their therapy treatment. The therapist(s) progress patients exercise, as appropriate. Therapy is most often a 1:1 session but can also include group classes. Physical therapy involves exercise and education, while occupational therapy focuses on practical strategies to perform daily tasks.~If the therapists feel that patients require additional support for their mental health problems, they can request this support via the General Practitioner or the hospital mental health services."
62255088|NCT03331861|EXPERIMENTAL|Metformin|Metformin for 6 months
62255089|NCT03331861|PLACEBO_COMPARATOR|Placebo|Matched placebo for 6 months
62255090|NCT03609138||Study Cohort|
62837325|NCT02861885||Lesion SSL|Patient cohort referred by colonoscopy screening indication, digestive syndrome or monitoring, with ascendant colon macroscopic SSL suspicion throughout white light during colonoscopy
62837326|NCT03008057|ACTIVE_COMPARATOR|vitamin D supplementation|patients with type 2 diabetes receive 1 tablet (4000 IU ) vitamin D supplementation, one time a day, for 3 months.
62837327|NCT03008057|PLACEBO_COMPARATOR|vitamin D placebo|patients with type 2 diabetes receive one tablet of vitamin D placebo for 3 months
62837328|NCT02572102|EXPERIMENTAL|Energy Drink|Two 16 ounce containers of an Energy Drink
62837329|NCT02572102|ACTIVE_COMPARATOR|Panax Ginseng|800 mg of Panax Ginseng in 70 mL of cherry syrup, 20 mL of lime juice, 410 mL of carbonated water
62837330|NCT02572102|PLACEBO_COMPARATOR|Placebo|70 mL of cherry syrup, 20 mL of lime juice, 410 mL of carbonated water
62837331|NCT03895840|EXPERIMENTAL|Intra-articular Zilretta injection|32 mg Zilretta in a 5ml diluent for each knee, per manufacturer guidelines
62255091|NCT05395611||Lung cancer|"Patients with primary non small cell lung cancer listed for tumor resection. EBP, plasma and lung tumor tissue will be collected for protein profiling.~Collection of EBP will be done at 2 time points before and after surgery. Collection of plasma will be done at 2 time points before and after surgery. Collection of lung/tumor tissue will be done at the time of surgery"
62255092|NCT05395611||Control|Patients without lung cancer matched according to age and smoking history (control cohort) Collection of EBP will be done at one time point. Collection of plasma will be done at one time point.
62837332|NCT04731545|ACTIVE_COMPARATOR|thin buccal bone|
62837333|NCT04731545|ACTIVE_COMPARATOR|thick buccal bone|
62837334|NCT02910531|EXPERIMENTAL|ALA supplement|"Clinical data including medical history, plain KUB x-ray and renal ultrasound, routine blood work and 24-hour urine collections for all subjects will be collected as part of normal clinical care at routine clinical visit every 4 months.~Subjects in this study arm will be taking one supplement tablet containing 1200 mg of alpha lipoic acid orally once daily for three years.~At the end of the three years of study drug treatment, all subjects will undergo a low dose non-contrast CT scan to look for a silent change in stone size."
62053798|NCT00995501|ACTIVE_COMPARATOR|Conventional Glucose Control, Dexamethasone, Deep anesthesia|"* Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~* Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~* Deep anesthesia target BIS of 35"
62053799|NCT00995501|ACTIVE_COMPARATOR|Conventional Glucose Control, Placebo, Light anesthesia|"* Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~* Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~* Light anesthesia target BIS of 55"
62053800|NCT00995501|PLACEBO_COMPARATOR|Conventional Glucose Control, Placebo, Deep anesthesia|"* Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~* Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~* Deep anesthesia target BIS of 35"
62053801|NCT03671174|EXPERIMENTAL|Prednisone + hydroxychloroquine + anticoagulation|Oral low-dose prednisone PLUS Oral hydroxychloroquine PLUS Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
62612748|NCT04373642|EXPERIMENTAL|Pembrolizumab + QUADSHOT Radiotherapy|"Combination Treatment~* Pembrolizumab by IV once on day 1 of 21 day cycle, begin 7 days before the first round of QUAD SHOT radiotherapy.~* QUAD SHOT radiotherapy twice a day for two days, begin 7 days after the first dose of pembrolizumab; repeat every 28 days for up to 3 rounds.~Maintenance Treatment~* Pembrolizumab by IV once on day 1 of 21 day cycle~* On day 21, if the medical oncologist feels that the patient may safely continue treatment, patient will receive a new 21 days cycle of treatment with pebrolizumab."
62837335|NCT02910531|PLACEBO_COMPARATOR|Placebo|"Clinical data including medical history, plain KUB x-ray and renal ultrasound, routine blood work and 24-hour urine collections for all subjects will be collected as part of normal clinical care at routine clinical visit every 4 months.~Subjects in this study arm will be taking one placebo tablet containing 10 mg of sucrose orally once daily for three years.~At the end of the three years of study drug treatment, all subjects will undergo a low dose non-contrast CT scan to look for a silent change in stone size."
62053802|NCT03671174|EXPERIMENTAL|Hydroxychloroquine + anticoagulation|Oral hydroxychloroquine PLUS Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
62053803|NCT03671174|ACTIVE_COMPARATOR|Anticoagulation|Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
62053804|NCT05421455|OTHER|Biologic group|treat paticipants with up to 2 biologics
62053805|NCT05421455|OTHER|Surgery group|treat paticipants with surgery
62255093|NCT04823572|ACTIVE_COMPARATOR|A-PRF Advanced Platelet-Rich Fibrin|Comparing healing effect of an autologous product with open flap debridement.
62255094|NCT04823572|ACTIVE_COMPARATOR|OFD Open Flap Debridement|Comparing healing effect of an autologous product with open flap debridement.
62837336|NCT01020240|NO_INTERVENTION|Avaliation|This group will have 15 women in puerperium and will be realize an interview to avalide the cesarean discomforts in immediate puerperium. These dates will be use for elaborate the orientations guide.
62837337|NCT01020240|NO_INTERVENTION|Orientation|In this group will be realize an interview to avalide the cesarean discomforts in immediate puerperium or in the first post operatory and in the second post operatory wil be realize a new interview.
62837338|NCT01020240|EXPERIMENTAL|Guide|in This group wiil be realize an interview to avalide the cesarean discomforts in immediate puerperium or in the first post operatory, will be realize the orientations and the guide will be give, and in the second post operatory will be realize a new interview.
62837339|NCT01147510|ACTIVE_COMPARATOR|Monotherapy of medium dose ICS|
62053806|NCT04959890||Subjects Previously Treated with Strimvelis (or GSK2696273) Gene Therapy|It is expected that this study will include approximately 70 eligible samples from approximately 15 subjects previously treated with gamma retroviral gene therapy (gRV-GT).
62053807|NCT01375270|EXPERIMENTAL|Glucotoxicity Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest, isocaloric meal feeding, and experimental elevation of blood glucose."
62255095|NCT04298775|ACTIVE_COMPARATOR|spinal anesthesia with morphine|This patients received subarachnoid anesthesia with 20 mg of Hyperbaric Bupivacaine + 200 mcg of Morphine
62255096|NCT04298775|ACTIVE_COMPARATOR|spinal anesthesia without morphine + peripheral nerve block|This patients received subarachnoid anesthesia with 20 mg of Hyperbaric Bupivacaine and peripheral nerve block with 0.2 to 0.375% Ropivacaine, in a volume of 20 to 30 mL.
62612749|NCT03057964|EXPERIMENTAL|PDL (Pulsed Dye Laser) and Fractional Photothermolysis|
62612750|NCT03057964|NO_INTERVENTION|Control|
62837340|NCT01147510|EXPERIMENTAL|Combination of low ICS and montelukast|
62612751|NCT02093403|EXPERIMENTAL|Treatment (decitabine and selinexor)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10 and selinexor PO on days 11, 13, 18, 20, 25 and 27. Treatment repeats every 31 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive decitabine IV over 1 hour on days 1-5 and selinexor PO on days 6, 8, 13, 15, 20 and 22. Courses repeat every 31 days in the absence of disease progression or unacceptable toxicity."
62837341|NCT01931319|EXPERIMENTAL|Intravenous Baclofen|Three single doses were evaluated using three cohorts (N=12 per cohort). Subjects received single doses of baclofen: 7.5, 11.5 or 15mg 10-minute intravenous infusion administered over 10 minutes by an infusion pump and 10, 15, or 20mg taken orally with a 48-hour washout phase between oral and intravenous arms of the study. Initially, 3 subjects received study drug at a given dose, after assessing the safety and tolerance of baclofen the additional 9 subjects received study drug.
62443333|NCT02136732|EXPERIMENTAL|Active self-management intervention|Participants will receive home visits and phone calls from a registered nurse and social worker. The registered nurse and social worker will provide participants one on one coaching, education, support and referrals to community resources to help them manage their chronic conditions.
62443334|NCT02136732|ACTIVE_COMPARATOR|Attention control phone calls|Participants will receive an initial visit and then a phone call every other month from a social services aide who can provide information about community resources that might be helpful.
62837342|NCT02769585|EXPERIMENTAL|Self-hypnosis|Subjects underwent two group sessions one week apart with a certified hypnotherapist to teach them the process of self-hypnosis for the purpose of attaining weight loss. Subjects were asked to perform self-hypnosis once or twice a day for the duration of the one year trial.
62837343|NCT02769585|ACTIVE_COMPARATOR|CDE training|Subjects underwent two group sessions one week apart with a certified diabetes educator to teach them re: diet and nutrition specifically as regards to a diabetic striving to lose weight. Subjects were asked to remain compliant with dietary restrictions for the duration of the one year trial.
62837344|NCT01082068|EXPERIMENTAL|Arm 1|XL147 (SAR245408) + letrozole
62837345|NCT01082068|EXPERIMENTAL|Arm 2|XL765 + letrozole
62837346|NCT03328091|ACTIVE_COMPARATOR|Traditional pre-test genetic counseling|"* In-person consultation with licensed genetic counselor at the Center for Cancer Genetics and Prevention before genetic testing~* Participant is given a pamphlet introducing prostate cancer genes, genetic testing~* Participant is sent electronic family history tool~* Participant is given the Genetic Testing Information for Decision Making packet. After the genetic counseling session, patient is asked if they would like to proceed with genetic testing."
62837347|NCT03328091|EXPERIMENTAL|Pre-test video education|"* Participant is given a pamphlet that describes the basics of prostate cancer genes, genetic testing~* Participant is sent electronic family history tool~* Participant is approached in clinic by research staff at a pre-planned time~* The patient is given the Genetic Testing Information for Decision Making packet~* The pre-test video education is a short video. Information will be provided about the basics of genetics and mutations, the potential benefits, risks, and limitations of genetic testing, and the possible results the participant may receive"
62837348|NCT01096355|EXPERIMENTAL|Group A|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3 and 8-10.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
62837349|NCT01096355|EXPERIMENTAL|Group B|"Patients receive oral RO4929097 once daily on days 1-7.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
62837350|NCT01096355|EXPERIMENTAL|Group C|"Patients receive oral RO4929097 once daily on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
62612752|NCT05456633||Capri Cervical 3D Static|Subjects who have undergone or will undergo VBR in the cervical spine (C2 to T1 in the USA, C3 to C7 outside of the USA) to replace diseased or damaged vertebral bodies due to tumor, trauma (i.e., fracture), or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spine cord and neural tissues in cervical degenerative disorders
62612753|NCT05456633||Capri Cervical 3D Expendable|Subjects who have undergone or will undergo VBR in the cervical spine (C2 to T1 in the USA, C3 to C7 outside of the USA) to replace diseased or damaged vertebral bodies due to tumor, trauma (i.e., fracture), or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spine cord and neural tissues in cervical degenerative disorders
62612754|NCT05456633||Capri Thoracolumbar Expandable|Subjects who have undergone or will undergo VBR in the thoracolumbar spine (T1 to L5) with Capri Thoracolumbar Expandable to replace collapsed, damaged, or unstable vertebral bodies due to tumor or trauma (i.e., fracture)
62612755|NCT02468713|EXPERIMENTAL|Group 1|Combiflex® lipid peri as a reference product (Period 1) -\> Winuf® peri as a test product (Period 2)
62837351|NCT01096355|EXPERIMENTAL|Group D|"Patients receive oral RO4929097 once daily on days 1, 8, and 15.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
62255097|NCT04860271|ACTIVE_COMPARATOR|Filiform Needle|Respondent are health workers that is having mild to moderate anxiety symptoms, with Hamilton Anxiety Scale less than 25. This arm will receive 6 acupuncture treatment within 2 weeks, and will be taken outcome measurements 4 times, that is before the first treatment, after the third treatment, after the sixth treatment and at 2 weeks after the sixth treatment.
62255098|NCT04860271|ACTIVE_COMPARATOR|Press Needle|Respondent are health workers that is having mild to moderate anxiety symptoms, with Hamilton Anxiety Scale less than 25. This arm will receive 3 acupuncture treatment within 2 weeks, and will be taken outcome measurements 4 times, that is before the first needle placement, after replacing the first sets of needles, after removing the third sets of needles and at 2 weeks after removing the third sets of needle.
62255099|NCT02251379|EXPERIMENTAL|ECS + Medication Group|"The Environmental Control Strategy (Home Environmental Intervention) plus inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)"
62255100|NCT02251379|ACTIVE_COMPARATOR|Medication Group Alone|inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)
62255101|NCT02213575|OTHER|Minocycline|Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.
62612756|NCT02468713|EXPERIMENTAL|Group 2|Winuf® peri as a test product (Period 1) -\> Combiflex® lipid peri as a reference product (Period 2)
62837352|NCT01096355|EXPERIMENTAL|Group E|"Patients receive oral RO4929097 once daily on days 1, 4, 8, 11, 15, and 18.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
62837353|NCT01096355|EXPERIMENTAL|Group F|"Patients receive oral RO4929097 once daily days 1-5, 8-12, and 15-19.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
62837354|NCT04298671|EXPERIMENTAL|Yoga-Pilates Group|The 30-minute web-based video exercise program will combine the best yoga-Pilates exercises focused on the pelvic floor, based on prior research and expert opinion, in collaboration with yoga-Pilates instructors that participants will complete 4 times per week for 8 weeks.
62837355|NCT01308177|PLACEBO_COMPARATOR|PPI+placebo|
62053808|NCT01375270|NO_INTERVENTION|Control Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest and isocaloric meal feeding."
62255102|NCT05602662|EXPERIMENTAL|Music therapy during mechanical ventilation in the iCU.|Headphones with music.
62612757|NCT04283474|EXPERIMENTAL|XG005-03|XG005-03 in 3 dose levels
62612758|NCT04283474|PLACEBO_COMPARATOR|Placebo|Placebo in all cohort
62612759|NCT04081831||New-users of Low-dose aspirin (exposed group)|New-users of low-dose aspirin is defined as patients who did not receive any prescriptions of low-dose aspirin one year prior to the index date.
62612760|NCT04081831||Users of Paracetamol (non-exposed group)|Users of Paracetamol is defined as patients who receive first prescription of paracetamol during the study period. Since the patients receiving low-dose aspirin are potentially less healthy compared to non-users of aspirin, patients receiving paracetamol as the control group can minimise healthy user bias.
62255103|NCT05602662|SHAM_COMPARATOR|Comparator|Headphones only.
62255104|NCT05043714|EXPERIMENTAL|Intravenous|"Phase 1a Part A: One cycle (28 days) of NG-641 on Days 1, 3 and 5 and nivolumab on Day 15, followed by nivolumab every 4 weeks.~Phase 1a Part B: NG-641 on Days 1, 3 and 5 and one nivolumab on Day 15 in each of up to eight 28-day cycles."
62255105|NCT01612468|EXPERIMENTAL|Liraglutide|
62255106|NCT01612468|PLACEBO_COMPARATOR|Placebo|
62255107|NCT05458973||Frontline cohort|
62255108|NCT05458973||recurrent cohort|
62255109|NCT02593162|EXPERIMENTAL|Group 1|12 weeks of Faldaprevir plus low dose TD-6450 plus Ribavirin
62255110|NCT02593162|EXPERIMENTAL|Group 2|12 weeks of Faldaprevir plus high dose TD-6450 plus Ribavirin
62255111|NCT05864742|EXPERIMENTAL|Standard-Risk Cohort|Patients without the high-risk mutations (no 9p21.1-24.3 loss, no SMARCA2 or SMARCA4 mut/del) will be treated with ibrutinib, rituximab and venetoclax.
62612761|NCT02735096|EXPERIMENTAL|Vestibular Patients for EquiCue Testing|Subjects with vestibular deficiency will try the intraoral electronic balance aid to see whether there is improvement in balance.
62837356|NCT01308177|ACTIVE_COMPARATOR|PPI+ES|
62255112|NCT05864742|EXPERIMENTAL|High-Risk Cohort|Patients with the high-risk mutations (9p21.1-24.3 loss, SMARCA2 and/or SMARCA4 mut/del) will be treated with ibrutinib, rituximab, venetoclax and navitoclax.
62443335|NCT02231710|EXPERIMENTAL|BPX-501 and Rimiducid|Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by Rimiducid infusion on day 7
62612762|NCT04772521|EXPERIMENTAL|Intervention|Personalized chat-based support and nicotine replacement therapy sampling (NRT-S) for continued smokers at 6 months for intervention group
62053809|NCT01375270|EXPERIMENTAL|Lipotoxicity Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest, isocaloric meal feeding, and experimental elevation of blood free fatty acids."
62053810|NCT05682092|ACTIVE_COMPARATOR|WonderLab Collagen Tripeptide Drink|"25ml/bottle, containing the following ingredients per 25ml serving:~* Collagen 6000 mg~* Vitamins C 250 mg~* Hyaluronic acid 50 mg~* Nicotinamide 0.45 mg"
62255113|NCT03207711|ACTIVE_COMPARATOR|Diet Education|All participants will receive instruction in the carbohydrate-restricted diet (CR).The study diet has approximately 10% of kcal coming from carbohydrate, typically 50 grams/day or fewer, not including fiber. Participants will be encouraged to eat a normal amount of protein, typically about 80-100 grams/day (about 20-25% of calories), and the rest of their calories from fat. Foods that are encouraged include green leafy and other non-starchy vegetables, nuts, seeds, oils (especially olive oil), fish, poultry, tofu, and avocados. Other foods consistent with the diet include berries (in modest amounts), meats, eggs, and cheese. Key foods to minimize include any sugar-sweetened foods or beverages, bread, pasta, potatoes, highly processed packaged foods, and other starchy foods.
62255114|NCT03207711|EXPERIMENTAL|Diet Education + Mindfulness|In addition to the carbohydrate-restricted diet described above, the Ed+MBI group will receive mindfulness training consisting of two integrated components: 1) use of a mindful eating app at home to learn and practice mindfulness skills for food-cravings and eating, and 2) in-person group-based meetings to discuss and troubleshoot how the mindfulness practices are working. Key mindfulness content includes helping people improve their relationship with food and control food cravings and using mindful eating approaches including paying attention, noticing habit loops, understanding brain science and food/sugar addiction, disrupting emotional and stress eating, cultivating acceptance and curiosity, lovingkindness, detaching from thoughts, using healthy restraint, and maintaining motivation.
62255115|NCT03029715|OTHER|Intravenous anaesthesia|Propofol Dexmedetomidine Remifentanil
62255116|NCT03029715|OTHER|Inhalation anaesthesia|Desflurane Remifentanil
62255117|NCT01129830|OTHER|Dehydroepiandrosterone|infertile women with low anti mullerian hormone levels
62443336|NCT00405977|PLACEBO_COMPARATOR|Physiologic saline|
62443337|NCT00405977|ACTIVE_COMPARATOR|Magnesium sulphate|
62443338|NCT04098081|EXPERIMENTAL|galeterone|galeterone orally once daily
62443339|NCT04098081|EXPERIMENTAL|galeterone+gemcitabine|daily dose galeterone and weekly dose of gemcitabine
62443340|NCT01806974|OTHER|patient with parodontitis|Patient with rheumatoid arthritis and pparodontitis.
62443341|NCT01806974|OTHER|Patient without parodontitis|Patient with rheumatoid arthritis but periodontally healthy
62443342|NCT04025385|NO_INTERVENTION|Control Group|Patients will participate in regular training units
62443343|NCT04025385|ACTIVE_COMPARATOR|HIIT Group|Patients will participate in high intensity interval training
62443344|NCT03741491||Birkebeiner with AF|Persons already included in the Birkebeiner Aging Study (BIAS) (completed the Birkebeiner cross-country ski race in 2009/10 born 1945 and earlier) and BAF-study (completed the Birkebeiner cross-country ski race in 1999 and was born in 1960 and earlier) with AF.
62443345|NCT03741491||Birkebeiner without AF|Persons already included in the Birkebeiner Aging Study (BIAS) (completed the Birkebeiner cross-country ski race in 2009/10 born 1945 and earlier) and BAF-study (completed the Birkebeiner cross-country ski race in 1999 and was born in 1960 and earlier) without AF
62443346|NCT03741491||Control with AF|Persons included in HELMILO 2009 (Health and Environment Study in Oslo 2009), born 1960 and earlier with AF
62443347|NCT03741491||Control without AF|Persons included in HELMILO 2009 (Health and Environment Study in Oslo 2009), born 1960 and earlier without AF
62443348|NCT01319097|OTHER|Sorbion Sachet S|Subject will evaluate Sorbion Sachet S dressing for 4 weeks.
62443349|NCT04049552|EXPERIMENTAL|RAPA intervention|Rapamycin ointment will be applied to one keloid on the subject
62443350|NCT04049552|PLACEBO_COMPARATOR|Placebo|Placebo will be applied as a control on one keloid on the subject
62443351|NCT06091800||control group (periodontally healthy)|no attachment loss, probing pocket depth ≤ 3 mm, minimal bleeding on probing ≤ 10%, and no radiographic bone loss
62612763|NCT04772521|PLACEBO_COMPARATOR|Control|Regular text-based support and nicotine replacement therapy sampling (NRT-S) for continued smokers at 6 months for control group
62255118|NCT05001984|ACTIVE_COMPARATOR|Intervention group|In addition to high-intensity statin and antiplatelet treatment, patients will receive treatment of alirocumab 75mg subcutaneously every 2 weeks for a total of 26 weeks
62255119|NCT05001984|NO_INTERVENTION|Control group|Patient will have high-intensity statin and antiplatelet treatment.
62837357|NCT02484885|OTHER|Healthy Volunteers|Healthy volunteers will undergo pulmonary function tests, hyperpolarized Xenon MRI at each visit.
62053811|NCT05682092|PLACEBO_COMPARATOR|Ordinary Drink|"25ml/bottle, containing the following ingredients per 25ml serving:~* Peach juice 8 mg~* Erythritol 10 mg"
62255120|NCT02060942||Coronary artery bypass grafting|Post Anaesthetic Care Unit (PACU) patients treated with coronary artery bypass grafting (CABG) are highly eligible for this study. These are patients with an indication for fast track treatment (PACU) post-cardiac surgery with a good left ventricular ejection fraction without significant co-morbidity. The final decision for PACU-classification is taken by the responsible anaesthesiologist and intensivist in close collaboration with the cardiothoracic surgeon performing the operation, as well as the cardiologist.
62255121|NCT03588182|EXPERIMENTAL|Group VR|Virtual reality (VR) experience VR visualization of a 3-dimensional relaxing nature scene with the accompanying audio. The patient will be offered a selection of scenes from which to choose, played continuously on a Samsung Gear VRTM(San Jose, CA) headset and headphones. The goal is for the patient to use the intervention for the entire duration of the external cephalic version procedure (ECV), which typically lasts 15 - 30 minutes.The patient will also receive verbal reassurance and coaching as needed. The obstetrician will communicate as usual with the patient.
62837358|NCT05938400|EXPERIMENTAL|One step polyvinylsiloxane impression technique|All impressions in this group will be recorded in a single stage, mixing light-bodied PVS material and putty PVS material simultaneously and recording of impression of prepared tooth
62837359|NCT05938400|ACTIVE_COMPARATOR|Two step polyvinylsiloxane impression technique|All impressions in this group will be made in two stages, recording putty PVS impression first and then reloading it with light-bodied PVS material to record final impression.
62837360|NCT04411667|EXPERIMENTAL|Group A (study drug+SOC)|Standard of care plus IVIG (Octagam) 0.5g/kg IVPB actual body weight daily x 3 days, with premedication methylprednisolone 40 mg IV push x 1 30-50 minutes before each IVIG infusion. Initial infusion rate of IVIG (Octagam) will be of 0.6 mL/kg/hour, increasing to a maximum rate of 100ml/hr, if tolerated.
62837361|NCT04411667|NO_INTERVENTION|Group B (SOC)|Standard of Care
62837362|NCT05240391|ACTIVE_COMPARATOR|Arm receiving 20% Human Albumin|20% Human albumin given intravenously over 4 hours
62837363|NCT05240391|EXPERIMENTAL|Arm receiving Midodrine|Tablet Midodrine 2.5 mg - 3 tablets thrice daily orally starting just before paracentesis
62837364|NCT02559999|OTHER|EEG responses|The study compares electroencephalographical responses (EEG) to painful stimuli tonic to those evoked by non-painful stimuli and with or without virtual reality
62837365|NCT00790842|EXPERIMENTAL|Group A - CrCl 30-60 mL/min|Creatinine clearance 30 - 60 mL/min, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
62837366|NCT00790842|EXPERIMENTAL|Group B, CrCl < 30 mL/min|Creatinine clearance \< 30 mL/min, not on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
62837367|NCT00790842|EXPERIMENTAL|Group C, CrCl < 30 mL/min, on dialysis|Creatinine clearance \< 30 mL/min and on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
62837368|NCT05234697||Morning group|Surgery performed during 08:00 to 12:00
62837369|NCT05234697||Afternoon group|Surgery performed during 14:00 to 18:00
62053812|NCT02026830||Diabetic foot infection|Patients with DM (Diabetes Mellitus) presenting with a diabetic foot infection will be enrolled in the current trial to determine the causative microorganisms and their antibiotic sensitivity patterns in diabetic patients with a foot infection in Turkey.
62443352|NCT06091800||periodontitis group|interdental clinical attachment level ≥ 5 mm, probing pocket depth ≥ 6 mm, radiographic bone loss extending to the middle or apical thirds of the root, mid-crest defect, and a history of ≤4 teeth loss of periodontal origin
62837370|NCT05945537|EXPERIMENTAL|A (INI-822)|Participants will receive INI-822 orally once daily.
62837371|NCT05945537|PLACEBO_COMPARATOR|B (Placebo)|Participants will receive placebo orally once daily.
62837372|NCT02352389||Influenza|"Children and young adults identified as having influenza infections by the St. Jude Children's Research Hospital diagnostic microbiology will be approached to participate in the study. Biological samples will be collected on Day 0 within 72 hours of the diagnosis of influenza, and at 7, 14, 21, and 28 days later.~Interventions: Symptom checklist, Blood sample, Nasal swab, Oropharyngeal swab, Stool sample."
62837373|NCT02000869||wait-listed kidney transplant candidates|
62837374|NCT03193593|PLACEBO_COMPARATOR|Placebo Injections|"Intervention: Drug: Placebo~Single Saline Injection into the Pectoralis Muscle"
62837375|NCT03193593|ACTIVE_COMPARATOR|EB-001 Dose 1|"Intervention: Drug: EB-001~1st Dose in escalation paradigm. Single Injection of active drug into the pectoralis muscle"
62837376|NCT03193593|ACTIVE_COMPARATOR|EB-001 Dose 2 (1.6X)|"Intervention: Drug: EB-001~2nd Dose in escalation paradigm, 1.6X Dose 1. Single Injection of active drug into the pectoralis muscle"
62837377|NCT03193593|ACTIVE_COMPARATOR|EB-001 Dose 3 (3.3X)|"Intervention: Drug: EB-001~3rd Dose in escalation paradigm, 3.3X Dose 1. Single Injection of active drug into the pectoralis muscle"
62837378|NCT03193593|ACTIVE_COMPARATOR|EB-001 Dose 4 (6.7X)|"Intervention: Drug: EB-001~4th Dose in escalation paradigm, 6.7X Dose 1. Single Injection of active drug into the pectoralis muscle"
62837379|NCT03193593|ACTIVE_COMPARATOR|EB-001 Dose 5 (10X)|"Intervention: Drug: EB-001~5th Dose in escalation paradigm, 10X Dose 1. Single Injection of active drug into the pectoralis muscle"
62053813|NCT00658567|EXPERIMENTAL|2|pimavanserin tartrate (ACP-103) 20 mg, tablet, once daily by mouth, 6 weeks
62612764|NCT06084624|EXPERIMENTAL|Rebamipide mouthwash|Rebamipide mouthwash will be administered four times daily for one week or till healing
62837380|NCT03193593|ACTIVE_COMPARATOR|EB-001 Dose 6 (13.3X)|"Intervention: Drug: EB-001~6th Dose in escalation paradigm, 13.3X Dose 1. Single Injection of active drug into the pectoralis muscle"
62837381|NCT00419588||1-Healthy Infants|"Group 1: We have recruited 50 healthy infants born \>37 weeks gestation, and between 2 and 36 months of age. Infants were excluded for any of the following reasons.~1. Congenital cardio-respiratory disease~2. Hospitalization for respiratory illness~3. Treatment with asthma medications for more than one time~4. Small for gestational age at birth~5. More than one respiratory illness~6. More than one episode of wheezing"
62837382|NCT00419588||3-Premature Infants|"Group 3: We will recruit 115 infants born prematurely, 23-35 weeks gestation. Subjects will be evaluated at the corrected age between 2 and 24 months. The subjects will have no oxygen requirements, and be clinically stable outpatients when evaluated. Infants will be excluded for any of the following reasons.~1. Congenital cardio-respiratory disease~2. Severe developmental delay"
62255122|NCT03588182|NO_INTERVENTION|Group No VR|No intervention will be provided for the control group, who will receive usual management at CUMC, which involves provision of no analgesia or sedation for the procedure, which typically lasts 15 - 30 minutes. Verbal reassurance and coaching is routinely provided by caregivers, including encouraging deep breathing, particularly during painful manipulation of the abdomen, for the duration of the procedure. The obstetrician will communicate as usual with the patient - for example advising that he/she is about to begin the procedure and giving updates as to the degree of success.
62612765|NCT06084624|ACTIVE_COMPARATOR|Betamethasone mouthwash|Betamethasone mouthwash of will be administered four times daily for one week or till healing
62612766|NCT02828137||Low NLR group|Neutrophil-to-Lymphocyte (NLR) Ratio \< 1.78
62612767|NCT02828137||Intermediate NLR group|1.78 \< Neutrophil-to-Lymphocyte (NLR) Ratio \< 3.90
62612768|NCT02828137||High NLR group|Neutrophil-to-Lymphocyte (NLR) Ratio \> 3.90
62612769|NCT01475032|EXPERIMENTAL|CHF 1535|CHF 1535 (BDP/FF) for 12 weeks
62612770|NCT01475032|ACTIVE_COMPARATOR|BDP|BDP for 12 weeks
62612771|NCT01475032|ACTIVE_COMPARATOR|BDP+FF|free combo BDP+FF for 12 weeks
62612772|NCT06001541|EXPERIMENTAL|Web-SUCCEED+Enhanced Usual Care|web-SUCCEED, usual care, psychoeducational materials and resources for caregivers.
62612773|NCT06001541|ACTIVE_COMPARATOR|Enhanced Usual Care|Usual care, enhanced by psychoeducational materials and resources for caregivers.
62612774|NCT03063099|EXPERIMENTAL|ReNu™ Injection|ReNu™ is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
62612775|NCT01389258|EXPERIMENTAL|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
62612776|NCT02074800|EXPERIMENTAL|Part 1|Participants will receive either 1.4 or 2.8 mg/kg of either Sp2/0-derived CNTO 328 or CHO-derived CNTO 328 or placebo.
62612777|NCT02074800|EXPERIMENTAL|Part 2|Participants will receive 1.4 mg/kg of either Sp2/0-derived or CHO-derived CNTO 328.
62612778|NCT04448639||STEMI|Patients with ST-elevation myocardial Infarction (STEMI) (TS) who undergo urgent coronary angiography within 12 hours of symptom onset.
62612779|NCT04448639||TS|Patients with Takotsubo Syndrome (TS) who undergo urgent coronary angiography within 12 hours ofsymptom onset.
62612780|NCT05155930|EXPERIMENTAL|IFS|Internal Family Systems (IFS)
62612781|NCT06338618|EXPERIMENTAL|liver treatment protocol|The liver treatment protocol consists of performing twelve visceral manual techniques in an approximate time of 30 minutes twice a week for 4 weeks.
62612782|NCT06338618|NO_INTERVENTION|placebo comparator|This group will not receive any type of treatment
62837383|NCT00419588||2-Healthy Infants CT|"Group 2: The investigators recruited 50 infants born at \> 37 weeks gestation and they were evaluated between 2 and 36 months of age when scheduled for high resolution computed tomography (HRCT) imaging for non-respiratory medical problems. Subjects were enrolled and HRCT of the chest were obtained. Infants were excluded for the following reasons:~1. Congenital cardio-respiratory disease~2. Hospitalization for respiratory illness~3. Treatment with asthma medications"
62612783|NCT05464121|EXPERIMENTAL|Blended intervention for AjD.|Blended intervention for AjD. Main components: psychoeducation, techniques for regulating emotions, exposure, problem-solving techniques, Mindfulness, acceptance and elaboration of the stressful event, positive psychology strategies and relapse prevention.
62612784|NCT01464853|EXPERIMENTAL|Specialized Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
62612785|NCT01464853|ACTIVE_COMPARATOR|Standard Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
62612786|NCT02971800|EXPERIMENTAL|sodium fluorescein|"Once hysterectomy completed, a 10 % solution of sodium fluorescein at a 0,25 ml dose (25 mg) is injected before performing diagnostic cystoscopy for all patient.~Name: Fluorescite Injection 10%, contains sodium fluorescein (equivalent to fluorescein 10% w/v) Dosage : 25 mg Frequency: only once"
62612787|NCT05288933|ACTIVE_COMPARATOR|Group (A) conventional physical therapy|20 participants will receive conventional physical therapy.TENS, the frequency of the current is 100 Hz and the duty cycle is 250 microseconds, three times per week for 4 weeks. Ultrasound waves, frequency 1 MHz with intensity 1 W/cm2, a pulsed mode for 5 minutes, three times per week for 4 weeks, passive stretching, and isometric exercises three times per week for 4 weeks.
62612788|NCT05288933|EXPERIMENTAL|Group (B )IASTM and conventional physical therapy|20 participants will receive Instrument-Assisted Soft Tissue Mobilization (IASTM) and conventional physical therapy, the M2T blade will be used to find the exact areas of restriction in the upper trapezius. Then the M2T blade will be used, at an angle of 45 and using treatment planes 1, 2, and 3, to apply slow strokes along with the muscle, without causing any discomfort or pain, from the muscle origin to its insertion (sweeping technique), for approximately 3 min. This procedure will be repeated twice a week for four weeks
62612789|NCT05288933|EXPERIMENTAL|Group (C) HPPT US and conventional physical therapy|20 participants will receive High Power Pain Threshold Ultrasound (HPPT US) and conventional physical therapy. For the HPPT US, ultrasound waves will be applied to trigger points of the upper trapezius in continuous mode, and the power of ultrasound will first increase to the threshold pain level at intensity (1.5-2 W/cm) according to the patient for 4-5 seconds with the probe placed directly on the trigger point and held motionlessly and then reduced to one-half of that intensity for15 seconds with the probe placed directly on the trigger point and move in a circular motion and repeat this three times. This procedure will be repeated twice a week for two weeks
62612790|NCT04106271|EXPERIMENTAL|Experimental group|dyadic pain management program will be accessible by the intervention group
62612791|NCT04106271|NO_INTERVENTION|Control group|No intervention for the control group, only one-page simple material related to pain will be provided.
62612792|NCT01469975|EXPERIMENTAL|Arm A: Dose level 1|1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y
62612793|NCT01469975|EXPERIMENTAL|Arm B: Dose level 2|1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y
62612794|NCT01469975|EXPERIMENTAL|Arm C: Dose level 3|3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y
62612795|NCT04456166||Patient who received carbohydrate loading|Patients with diabetes mellitus type 2 who are planned to receive a carbohydrate beverage (400 ml (12.8% carbohydrates, 50 kcal/100 ml; Nucare NONPO Ⓡ , Daesang Wellife, Korea) before the operation and up to 2 hours before the induction of anesthesia outside this clinical study setting
62612796|NCT03116009|ACTIVE_COMPARATOR|Screening for diabetes with 1-hour GCT and HbA1|Participants in this group will do 1-hour GCT before 20 weeks of gestation. Those with positive test will undergo 3-hours OGTT. Diabetes will be diagnosed if they have two or more abnormal values out of the 4 values and they will be treated accordingly based on the institutional protocol. They will also have HbA1C done.
62612797|NCT03116009|EXPERIMENTAL|Early screening with only HbA1C|Participants in this group will only have HbA1C done before 20 weeks but will do the standard diabetes screening at 24 - 28 weeks. Those who have abnormal values will also be treated based on the institutional protocol.
62612798|NCT03468452||Early extubation|The endotracheal tube is removed in the operation room, and no suction support is required after surgery.
62612799|NCT03468452||late extubation|"Take the tracheal tube back to the ward for respiratory support or removal of air.~The catheter is inserted again within 48h."
62612800|NCT02536781|PLACEBO_COMPARATOR|Placebol|Placebo
62612801|NCT02536781|ACTIVE_COMPARATOR|Anthocynin|Anthocyanin
62612802|NCT06730984|EXPERIMENTAL|Endoscopy-Assisted Tracheal Intubation|Tracheal Intubation Under Endoscopic Guidance
62612803|NCT06730984|ACTIVE_COMPARATOR|Traditional Tracheal Intubation|Tracheal Intubation Under Video Laryngoscopy
62612804|NCT05392088||Miocardial injury|Patients hospitalized at Policlinico Universitario A. Gemelli IRCSS since March 1, 2021, with a diagnosis of SARS-CoV-2 infection (≥1 positive nasopharyngeal swab) and at least one value of high-sensitivity cardiac troponin I (hs-cTnI) \>99th percentile upper reference limit measured during the index hospitalization.
62612805|NCT05392088||No Miocardial injury|Patients hospitalized at Policlinico Universitario A. Gemelli IRCSS since March 1, 2021, with a diagnosis of SARS-CoV-2 infection (≥1 positive nasopharyngeal swab) and value of high-sensitivity cardiac troponin I (hs-cTnI) \<99th percentile upper reference limit.
62612806|NCT02041052|ACTIVE_COMPARATOR|Conventional Whipple procedure|Conventional Whipple procedure
62053814|NCT00658567|PLACEBO_COMPARATOR|Placebo|Placebo tablet, once daily by mouth, 6 weeks
62053815|NCT00658567|EXPERIMENTAL|1|pimavanserin tartrate (ACP-103) 10 mg, tablet, once daily by mouth, 6 weeks
62612807|NCT02041052|EXPERIMENTAL|Subtotal gastrectomy added to whipple procedure.|Subtotal gastrectomy added to Whipple procedure.
62612808|NCT00645645||holoprosencephaly (HPE)|individuals with overt or subtle clinical findings consistent with the HPE spectrum are eligible to participate
62612809|NCT01903993|ACTIVE_COMPARATOR|Docetaxel|Participants received docetaxel 75 milligram per meter square (mg/m\^2) administered intravenously on Day 1 of each 21 day cycle until disease progression or unacceptable toxicity or death.
62612810|NCT01903993|EXPERIMENTAL|Atezolizumab|Participants were administered atezolizumab intravenously on Day 1 of each 21 day cycle at a fixed dose of 1200 mg. Atezolizumab treatment were to continued as long as participants were experiencing clinical benefit as assessed by the investigator.
62612811|NCT05859763|EXPERIMENTAL|Patients diagnosed with pulmonary fibrosis|Patients of Pulmonary Fibrosis SPECT/CT imaging: The patients were subcutaneously injected with 99mTc-HFAPI and underwent SPECT/CT imaging.
62612812|NCT05892159|EXPERIMENTAL|HRV biofeedback|An HRV biofeedback tool will be employed in which individuals will breathe at their resonance frequency to optimize HRV and autonomic nervous system signatures.
62612813|NCT04715217|EXPERIMENTAL|Low Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 0.5×10\^6 CAR+T cells/kg.
62612814|NCT04715217|EXPERIMENTAL|Middle Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of middle dose group will be intravenously infuse with 2.0×10\^6 CAR+Tcells/kg.
62612815|NCT04715217|EXPERIMENTAL|High Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of high dose group will be intravenously infuse with 5.0×10\^6 CAR+Tcells/kg.
62612816|NCT04715217|EXPERIMENTAL|Amplification Dose Group|CD19-CD22 CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 0.5-5.0×10\^6 CAR+Tcells/kg.
62612817|NCT05376293|ACTIVE_COMPARATOR|Behavioral internet program|Participants randomized to the Internet program will receive a 12-week behavioral Internet program designed to increase physical activity to recommended levels.
62612818|NCT05376293|SHAM_COMPARATOR|Informational newsletter condition|Participants randomized to the newsletter condition will receive 6 newsletters, delivered every other week during the 3-month program.
62837384|NCT02713464|ACTIVE_COMPARATOR|maternal education|Phase IIa: Pregnant women attending antenatal clinics or postpartum in clinics or hospital who receive programmed maternal education about risks and care of newborn jaundice.
62837385|NCT02713464|NO_INTERVENTION|Historic control|Phase I: (before-after design) Baseline prevalence of acute bilirubin encephalopathy before maternal education instituted.
62443353|NCT05943925||Healthy control group|"The criteria for the recruitment will be:~Inclusion criteria: more than 60 years. Exclusion criteria: Significant neurology disease diagnosed, infectious treatment with antibiotics in the previous 6 months prior to providing the stool sample, corticosteroid use, immunosuppressors or immunostimulants treatment, illnesses of the gastrointestinal (GI) tract, large doses of commercial probiotics consumed (greater than or equal to 108 colony forming units (cfu) per organisms per day).~This control group were recruited from relatives of the patients enrolled or general population and interviewed at the hospital (relatives, University or their homes).~Neuropsychological, functional and neuropsychiatric assessment and stool sample."
62612819|NCT01025466|ACTIVE_COMPARATOR|rivastigmine patch monotherapy|
62837386|NCT02713464|NO_INTERVENTION|No intervention|Phase IIb: Opportunistic controls - infants of mothers who failed to receive education about risks and care of newborn jaundice.
62837387|NCT02064257|EXPERIMENTAL|Intervention group|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention. The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
62837388|NCT02064257|NO_INTERVENTION|Assessment-only group|The assessment-only group will participate in all pre- and post-intervention assessments, but will not receive the Listening Project Protocol.
62837389|NCT05220072|EXPERIMENTAL|Carbon-14 BIA 28-6156|Healthy volunteers receive a single dose of Carbon-14 BIA 28-6156
62837390|NCT04685044|OTHER|Healthy Volunteers|BrainPET insert
62837391|NCT06415136||SeaSpine Shoreline|All enrolled patients will receive the SeaSpine Shoreline device.
62837392|NCT05552989||Key stakeholders of the local disaster relief community|
62837393|NCT01303367||antipsychotic agents|
62837394|NCT01303367||non-antipsychotic agents|
62053816|NCT01343602|EXPERIMENTAL|mod. Constraint-Induced Movement Therapy|CIMT at home is applied in the patients' home over the course of four weeks including (i.e. 20 consecutive days) 2 hours of daily training together with an instructed non-professional coach (e.g. family member) applying shaping techniques.
62053817|NCT01343602|OTHER|Therapy as usual|Patients in this arm will receive usual care dose-matched to the intervention group (250-300 minutes).
62053818|NCT03046615||EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that is commonly used for recording.
62612820|NCT01025466|ACTIVE_COMPARATOR|Combination therapy with memantine|
62612821|NCT00094523|EXPERIMENTAL|Treatment Arm A|Subjects switched their baseline PI for fosamprenavir (± ritonavir) while maintaining their baseline regimen of two nucleoside or nucleotide reverse transcriptase inhibitors for 48 weeks.
62837395|NCT02145377|EXPERIMENTAL|PXVX0200 10E8 then placebo|PXVX0200 10E8 on day 0; Placebo on day 14
62837396|NCT02145377|EXPERIMENTAL|Placebo, then PXVX0200 10E8|Placebo on day 0; PXVX0200 10E8 on day 14
62837397|NCT02145377|EXPERIMENTAL|PXVX0200 10E9 then Placebo|PXVX0200 10E9 on day 0; Placebo on day 14
62837398|NCT02145377|EXPERIMENTAL|Placebo then PXVX0200 10E9|Placebo on day 0; PXVX0200 10E9 on day 14
62837399|NCT02145377|ACTIVE_COMPARATOR|Shanchol|Two doses of Shanchol, on day 0 and day 14
62837400|NCT03710577|EXPERIMENTAL|Yoga|40 minutes of Vinyasa yoga
62837401|NCT03710577|PLACEBO_COMPARATOR|Quiet Rest|40 minutes of quiet rest
62837402|NCT04254172||Single cohort|There is no randomization or stratification in this study. All subjects will complete the same study assessments.
62837403|NCT05510596|OTHER|Patients with CAR-T Cell treatment|Single arm All patient will undergo an MRI with contrast injection, a blood withdrawal and a neurological consultation with neuropsychological tests
62837404|NCT01287741|ACTIVE_COMPARATOR|Rituximab+Chemotherapy|Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.
62837405|NCT01287741|EXPERIMENTAL|Obinutuzumab+Chemotherapy|Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.
62837406|NCT02538978|EXPERIMENTAL|Device Arm|Device arm subjects will receive an intra-operative point of care aspiration, preparation and intramuscular injection of autologous bone marrow concentrate (aBMC) into the afflicted lower index limb.
62837407|NCT02538978|PLACEBO_COMPARATOR|Placebo Arm|Placebo arm subjects will undergo an intra-operative point of care aspiration and preparation of bone marrow via the investigational device exactly as the Treatment Arm. However, instead of receiving the dosing with the aBMC device output, they will receive an intramuscular injection of diluted autologous peripheral blood into the afflicted lower index limb.
62837408|NCT03913507|EXPERIMENTAL|one group : patients with suspicion of cystic fibrosis|
62837409|NCT00636298|EXPERIMENTAL|A|Single arm treatment with combination of cetuximab and bevacizumab
62837410|NCT03613519|PLACEBO_COMPARATOR|Patient education (sleep hygiene)|A web-based program that presents ways to improve behaviors and environments that can affect sleep.
62053819|NCT03046615||Standard Needles|The current solution to monitor eye movement during surgery is to place standard needles in the muscles surrounding the eye.
62837411|NCT03613519|ACTIVE_COMPARATOR|SHUTi (Sleep Healthy Using the Internet)|SHUTi is web-based cognitive-behavioral therapy instrument for insomnia (CBT-I)
62837412|NCT03613519|ACTIVE_COMPARATOR|modified SHUTi (SHUTi modified for Black women)|The CBT-I instrument tailored for Black women.
62837413|NCT00513916|EXPERIMENTAL|Arm I|"Participants partake in a high soy diet consisting of 2 daily soy servings (approximately 50mg isoflavones).~The choice of soy foods will include ½ cup of tofu, ¾ cup of soy milk, or ¼ cup of soy nuts. Replacement of currently consumed foods with soy foods will be encouraged."
62837414|NCT00513916|ACTIVE_COMPARATOR|Arm II|Participants will be asked to keep their soy intake below 3 servings per week. The participants will also receive general nutrition counseling.
62837415|NCT03641586|EXPERIMENTAL|Stage I|Approximately 25-35 Chinese subjects with local advanced or metastatic malignant solid tumor will be enrolled in the dose escalation stage of BGB-283 until maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) determination
62053820|NCT05016583|EXPERIMENTAL|Paula Method|
62053821|NCT03022201|EXPERIMENTAL|DA-9701|In this arm, the study participants will receive DA-9701 30mg + placebo domperidone tablet tid ac for 4 weeks.
62053822|NCT03022201|ACTIVE_COMPARATOR|Domperidone|(This study is a randomized, double-blinded, non-inferiority trial. Thus it is designed to have no placebo arm.) In this arm, the study participants will receive domperidone 10mg + placebo DA-9701 tablet tid ac +for 4 weeks.
62837416|NCT03641586|EXPERIMENTAL|Stage II|Approximately 15-30 melanoma subjects will be enrolled in dose expansion stage of BGB-283
62837417|NCT03641586|EXPERIMENTAL|Stage III|20 subjects will be enrolled for food effect stage of BGB-283
62837418|NCT02622282|EXPERIMENTAL|Experimental Group|Participants will receive text messages and telephone calls during the length of their participation. Participants will receive a handout with information on PAD and physical activity.
62255123|NCT03886311|EXPERIMENTAL|Talimogene laherparepvec, Nivolumab and Trabectedin|"This is an open label phase 2 study using known doses of TALIMOGENE LAHERPAREPVEC injected intratumorally, and NIVOLUMAB AND TRABECTEDIN given intravenously.~A total of 40 previously untreated and treated patients will receive TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks, NIVOLUMAB 240 mg IV over 30 min q 2 weeks and TALIMOGENE LAHERPAREPVEC intratumorally q 2 weeks according to tumor size (see Schematic of Study Design and Imlygic product information; www.accessdata.fda.gov). Patients in this study may continue treatment until significant disease progression (see below for criteria for discontinuation of therapy) or unacceptable toxicity occurs up to one year of therapy."
62255124|NCT02577744|ACTIVE_COMPARATOR|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
62443354|NCT05943925||Alzheimer Disease (AD)|"The criteria for the recruitment will be:~Inclusion criteria: Alzheimer Disease (AD) diagnosed by the neurology service; more than 60 years.~Exclusion criteria: Comorbidity with other significant neurology disease, infectious treatment with antibiotics in the previous 6 months prior to providing the stool sample, corticosteroid use, immunosuppressors or immunostimulants treatment, illnesses of the GI tract, large doses of commercial probiotics consumed (greater than or equal to 108 colony forming units (cfu) per organisms per day).~Neuropsychological, functional and neuropsychiatric assessment and stool sample."
62837419|NCT02622282|ACTIVE_COMPARATOR|Control Group|Participants will receive a handout with information on PAD and physical activity.
62612822|NCT00094523|EXPERIMENTAL|Treatment Arm B|Subjects continued baseline regimen for first 24 weeks with the option of switching their initial PI for fosamprenavir (± ritonavir) while maintaining their baseline nucleoside or nucleotide reverse transcriptase inhibitor regimen for another 24 weeks
62612823|NCT03278405|EXPERIMENTAL|Intervention Arm|Treatment with avelumab
62837420|NCT02297594|EXPERIMENTAL|AK0529|Generic name: AK0529 Dosage Form: capsule
62837421|NCT02297594|PLACEBO_COMPARATOR|Placebo|Sugar placebo
62837422|NCT04129008|EXPERIMENTAL|Indobufen|
62837423|NCT04129008|ACTIVE_COMPARATOR|Aspirin|
62837424|NCT03983811|EXPERIMENTAL|Chemotherapy+Icotinib|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity
62837425|NCT03983811|PLACEBO_COMPARATOR|Chemotherapy+Placebo|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated placebo (D8-15) every 3 weeks, and continued placebo for 2 years or until the occurrence of disease relapse, metastasis or unacceptable toxicity
62053823|NCT01330433|NO_INTERVENTION|No CoSeal Surgical Spray|A patient randomized to the No CoSeal Surgical Spray group will not have CoSeal Surgical Spray applied at the end of their first staged procedure.
62255125|NCT02577744|ACTIVE_COMPARATOR|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
62837426|NCT05251324||Participants With Hot Flushes (at least 3 per day)|"At Visit 1, participants will complete informed consent, questionnaires regarding medical history, physical activity levels, stress and anxiety, menopause symptoms and a hot flush behavior scale. Visit one will be completed remotely using a HIPAA-compliant online platform or over the phone.~At Visit 2, baseline measurements will be recorded for two hours and spontaneous hot flushes will be detected. Participants will then have a temperature-controlled, water-circulating heating pad at a consistent temperature of 107˚F placed on their torso for 30 min, followed by five min of recovery. This will be followed by a blood draw to measure sex hormones. At either Visit 2 or a separate visit, participants will have a dual energy x-ray absorptiometry scan for a body composition assessment. For participants taking prescribed MHT, a standard protocol for enrollment and they may complete up to six study visits."
62255126|NCT06433830|EXPERIMENTAL|Hetrombopag|patients receive oral hetrombopag at an initial dose of 7.5 mg QD
62255127|NCT03422432|EXPERIMENTAL|Group 1|Patients are identified pre-operatively on radiological imaging. Prophylactic HIPEC will be delivered intra-operatively, immediately after the resection of the primary tumour, and only if the patient is deemed well enough to receive the HIPEC.
62255128|NCT03422432|EXPERIMENTAL|Group 2|Patients are identified post-operative based on histological findings. They will be counselled to receive prophylactic HIPEC only. If peritoneal nodules are found during surgery, these patients will be excluded from the study.
62255129|NCT00880659|EXPERIMENTAL|1|Promotion of handwashing with soap and maintenance of a fully stocked handwashing station.
62255130|NCT00880659|NO_INTERVENTION|2|Practice of routine handwashing among the household members
62255131|NCT04609228||Blood-transfusion non-acceptors|Blood-transfusion non-acceptors
62255132|NCT04609228||Blood-transfusion acceptors|Blood-transfusion acceptors
62612824|NCT04165616||Individuals with stroke|
62612825|NCT06330220|EXPERIMENTAL|Aflibercept loading|Administration of 2㎎ intravitreal aflibercept three times monthly after diagnosis
62255133|NCT05131984||Multiple Sclerosis patients on Ocrelizumab at Brigham and Women's Hospital|All MS patients at the Brigham MS Center who have been diagnosed with relapsing remitting multiple sclerosis (RRMS) or primary progressive multiple sclerosis (PPMS), ages 18 or older, on Ocrelizumab for at least one year and have received at least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg), who have been followed at these institutions for clinical care and brain and/or spinal cord MRI, and who have received Ocrelizumab infusions at these institutions for the duration of the study period.
62837427|NCT05251324||Participants Without Hot Flushes|"At Visit 1, participants will complete informed consent, questionnaires regarding medical history, physical activity levels, stress and anxiety, menopause symptoms and a hot flush behavior scale. Visit one will be completed remotely using a HIPAA-compliant online platform or over the phone.~At Visit 2, baseline measurements will be recorded for two hours and spontaneous hot flushes will be detected. Participants will then have a temperature-controlled, water-circulating heating pad at a consistent temperature of 107˚F placed on their torso for 30 min, followed by five min of recovery. This will be followed by a blood draw to measure sex hormones. At either Visit 2 or a separate visit, participants will have a dual energy x-ray absorptiometry scan for a body composition assessment. For participants taking prescribed MHT, a standard protocol for enrollment and they may complete up to six study visits."
62053824|NCT01330433|EXPERIMENTAL|CoSeal Spray Group|CoSeal Spray will be applied at the end of the first staged procedure in patients randomized to the experimental group.
62053825|NCT01573806|ACTIVE_COMPARATOR|Exenatide|Subjects dosed with exenatide in Phase 2
62053826|NCT01573806|PLACEBO_COMPARATOR|Exenatide vehicle|Subjects dosed with exenatide vehicle in Phase 2
62053827|NCT03882879|EXPERIMENTAL|Arm 1|Participants in Arm 1 will begin participation in 6 months of karate classes immediately after the pre-intervention study visits.
62837428|NCT02581241|EXPERIMENTAL|drug-induced long QT syndrome|"20 adults aged above 18 years which were hospitalized in Tel Aviv medical center between January 2013 and June 2015 due to drug-induced long QT syndrome and the associated torsades de pointes, have no exclusion criteria and provide informed consent to participate in the study.~Interventions. Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
62837429|NCT02581241|ACTIVE_COMPARATOR|control|"20 adults aged above 18 years which were hospitalized in Tel Aviv medical center between January 2013 and June 2015 and were treated with specific drugs (antibiotics) that potentially prolong the QT interval but they do not have drug-induced long QT syndrome, have no exclusion criteria and provide informed consent to participate in the study.~Interventions. Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
62837430|NCT06344221|ACTIVE_COMPARATOR|Young Healthy Controls|The 3 groups, made up of participants with different pathologies and ages, will receive the same intervention (clinical motor and sensory tests and optional TMS). We are studying the difference in results between these groups.
62837431|NCT06344221|ACTIVE_COMPARATOR|Healthy controls matched in age and sex with stroke patients|The 3 groups, made up of participants with different pathologies and ages, will receive the same intervention (clinical motor and sensory tests and optional TMS). We are studying the difference in results between these groups.
62837432|NCT06344221|EXPERIMENTAL|Chronic stroke patients|The 3 groups, made up of participants with different pathologies and ages, will receive the same intervention (clinical motor and sensory tests and optional TMS). We are studying the difference in results between these groups.
62053828|NCT03882879|EXPERIMENTAL|Arm 2|Participants in Arm 2 will continue their usual exercise routine for six months followed by karate classes for six months
62837433|NCT04179669|EXPERIMENTAL|IBI306|Participants received IBI306 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
62837434|NCT04179669|EXPERIMENTAL|placebo|Participants received Placebo 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
62053829|NCT03243422|ACTIVE_COMPARATOR|Successful aging health education intervention|Individual sessions on healthy aging topics
62053830|NCT03243422|ACTIVE_COMPARATOR|Hearing intervention|Best practices hearing rehabilitative treatment
62255134|NCT05131984||Multiple Sclerosis patients on Ocrelizumab at Boston Medical Center|All MS patients at the Boston Medical Center MS Clinic who have been diagnosed with RRMS or PPMS, ages 18 or older, on Ocrelizumab for at least one year and have received at least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg), who have been followed at these institutions for clinical care and brain and/or spinal cord MRI, and who have received Ocrelizumab infusions at these institutions for the duration of the study period.
62837435|NCT00179192|NO_INTERVENTION|1|control group
62837436|NCT00179192|ACTIVE_COMPARATOR|2|angioplasty intervention
62255135|NCT04638972||Tactile Sense Method|In clinical practice, tactile sense and conventional radiography have been the methods of choice for determination of working length for a long time. However, these two methods have some limitations in determining working length. While the accuracy rate in tactile sense changes with experience, radiographic examination in children is usually hard due to poor cooperation or the unsuitable sensor size for child's small mouth \[7\]. Also, these techniques may yield inaccurate information especially in cases with root resorption
62612826|NCT00862459|EXPERIMENTAL|Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.03 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg body weight (BW) of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
62053831|NCT05562479||Non exposed to Sars Cov 2 egg donors|Evaluate the results within oocyte retrieval, oocyte fertilisation and blastocyst formation.
62255136|NCT04638972||Radiographic Method (digital periapical radiography)|In clinical practice, tactile sense and conventional radiography have been the methods of choice for determination of working length for a long time. However, these two methods have some limitations in determining working length. While the accuracy rate in tactile sense changes with experience, radiographic examination in children is usually hard due to poor cooperation or the unsuitable sensor size for child's small mouth \[7\]. Also, these techniques may yield inaccurate information especially in cases with root resorption
62612827|NCT00862459|EXPERIMENTAL|Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.1 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
62612828|NCT00862459|EXPERIMENTAL|Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.3 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
62612829|NCT00396383|EXPERIMENTAL|Participants with Multiple Myeloma (MM)|Participants with MM who were eligible for autologous peripheral blood stem cell transplantation.
62612830|NCT00577005|EXPERIMENTAL|1|Levetiracetam tablets
62612831|NCT00577005|PLACEBO_COMPARATOR|2|matching placebo
62612832|NCT03472313|EXPERIMENTAL|Experimental: [18F]MNI-958|To assess the safety and tolerability and to determine the radiation dosimetry of \[18F\]MNI-958.
62612833|NCT00401401|EXPERIMENTAL|Zalutumumab 4 mg/kg|Zalutumumab 8 weekly infusions
62612834|NCT00401401|EXPERIMENTAL|Zalutumumab 8 mg/kg|Zalutumumab 8 weekly infusions
62053832|NCT05562479||Exposed to Sars Cov 2 Infection|Evaluate the results within oocyte retrieval, oocyte fertilisation and blastocyst formation, after being exposed to the infection.
62255137|NCT04638972||Ipex® EAL|Electronic apex locaters (EALs), which are based on electrical principles instead of visual determinants, have been used more frequently in primary teeth.
62612835|NCT00401401|EXPERIMENTAL|Zalutumumab 12 mg/kg|Zalutumumab 8 weekly infusions
62612836|NCT00401401|EXPERIMENTAL|Zalutumumab 16 mg/kg|Zalutumumab 8 weekly infusions
62612837|NCT01918072||Stepped wedge participants|"Designated Women's Health Providers with one or more episodes of care for women patients during each period of the intervention.~Designated Women's Health Provider: Primary care provider who are proficient in women's health, and should have a minimum of 10% of their patient panels being comprised by women."
62612838|NCT01918072||Electronic consultation survey participants|"Designated Women's Health Providers who completed surveys about use of electronic consultations.~Designated Women's Health Provider: Primary care provider who are proficient in women's health, and should have a minimum of 10% of their patient panels being comprised by women."
62612839|NCT01918072||Quality assessment participants|Primary care providers delivering women's health care for one or more of the following conditions: abnormal uterine bleeding; menopausal symptoms; urinary incontinence.
62612840|NCT02696928|OTHER|Artemeter-Lumefantrine (combination therapy)|"33 patients~(standard of care)"
62612841|NCT02696928|ACTIVE_COMPARATOR|Artemeter-Lumefantrine and Primaquine (combination therapy)|33 patients
62837437|NCT00179192|ACTIVE_COMPARATOR|3|surgery intervention
62837438|NCT02198768||Ankle Fracture|Patients with isolated ankle fractures.
62255138|NCT04638972||Propex® pixi EAL|Electronic apex locaters (EALs), which are based on electrical principles instead of visual determinants, have been used more frequently in primary teeth.
62837439|NCT02198768||Ankle Fracture-Dislocation|Patients with ankle fracture-dislocations.
62837440|NCT00328107|EXPERIMENTAL|Low Dose|Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2004/05 formulation containing 45μg of each hemagglutinin derived from A/Wyoming/3/03(H3N2) and 15μg from A/New Caledonia/20/99(H1N1) and B/Jiangsu/10/03
62053833|NCT05562479||Exposed to Sars Cov 2 Vaccines|Evaluate the results within oocyte retrieval, oocyte fertilisation and blastocyst formation, after being exposed to vaccination.
62053834|NCT00969397|EXPERIMENTAL|Topical Antiangiogenic|Topical Antiangiogenic Agents
62612842|NCT02696928|EXPERIMENTAL|Artemeter-Lumefantrine and MB (combination therapy)|33 patients
62612843|NCT06259786||Nocturnal Bruxism|The Quality of Life (The Pediatric Quality of Life Inventory - PedsQL), Postural Changes (New York Posture Analysis - NYPA), Cervical Proprioception (CROM Device), Mandibular Movement Capacity (Maximum Mouth Opening - The Caliper and Excursions- The Linear Rule) will be evaluated.
62612844|NCT06259786||Healthy Group|The Quality of Life (The Pediatric Quality of Life Inventory - PedsQL), Postural Changes (New York Posture Analysis - NYPA), Cervical Proprioception (CROM Device), Mandibular Movement Capacity (Maximum Mouth Opening - The Caliper and Excursions- The Linear Ruler) will be evaluated.
62612845|NCT02787083|EXPERIMENTAL|Mirabegron|These patients will receive mirabegron 50mg tablets daily for 12 weeks.
62612846|NCT02787083|PLACEBO_COMPARATOR|Placebo|These patients will receive placebo tablets daily for 12 weeks.
62612847|NCT01375634|PLACEBO_COMPARATOR|Placebo|Normal saline
62612848|NCT01375634|EXPERIMENTAL|Midazolam|Midazolam
62612849|NCT02273908||Pregabalin|Patients will be treated for 8 weeks with pregabalin in primary care: no intervention
62053835|NCT00969397|EXPERIMENTAL|Pulsed Dye Laser|Pulsed Dye Laser
62053836|NCT01407159||Thoracic Stentgraft plus E-XL|male and female patients with complicated type B aortic dissection involving the infra-diaphragmatic aorta treated with any thoracic stentgraft extended by the E-XL aortic stent
62053837|NCT01407159||Control group|"historical control group fulfilling the following criteria:~* Age +/- 3 years~* Sex matched~* Same follow-up period"
62612850|NCT02273908||Usual care|Patients will be treated for 8 weeks with other analgesics in usual care: no intervention
62612851|NCT02083653|EXPERIMENTAL|Arm A: Sym004 (12 mg/kg)|Sym004 will be administered as an intravenous infusion at a dose of 12 milligrams per kilogram (mg/kg) weekly until unacceptable toxicity, disease progression, or consent withdrawal.
62837441|NCT00328107|EXPERIMENTAL|Full Dose|Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2004/05 formulation containing 45μg of each hemagglutinin derived from A/Wyoming/3/03(H3N2), A/New Caledonia/20/99(H1N1) and B/Jiangsu/10/03
62837442|NCT00328107|PLACEBO_COMPARATOR|Placebo|0.9% Sodium Chloride
62053838|NCT04470245|ACTIVE_COMPARATOR|Healthy volunteers|
62053839|NCT04470245|ACTIVE_COMPARATOR|Patients undergoing surgery|We will include adults (over 18 years of age) undergoing surgical decompression of the ulnar nerve at the elbow for cubital tunnel syndrome.
62837443|NCT02289157|EXPERIMENTAL|Negative Pressure Wound Therapy|After standard cesarean section completed patients will have Prevena negative pressure wound therapy system placed.
62053840|NCT01313143|EXPERIMENTAL|AOP200704, infusion|
62053841|NCT01313143|ACTIVE_COMPARATOR|Esmolol, infusion|
62053842|NCT03988166|OTHER|Chronic Total Occlusion Percutaneous Coronary Intervention|CTO percutaneous coronary intervention (PCI) in which at least one Teleflex guidewire and at least one Turnpike catheter are used.
62053843|NCT01370525|EXPERIMENTAL|Esomeprazole 20 mg|
62053844|NCT01370525|PLACEBO_COMPARATOR|Placebo|
62053845|NCT00679328|EXPERIMENTAL|1|Surgical implantation of OP-1
62612852|NCT02083653|EXPERIMENTAL|Arm B: Sym004 (9/6 mg/kg)|Sym004 will be administered as an intravenous infusion at a loading dose of 9 mg/kg followed by 6 mg/kg weekly until unacceptable toxicity, disease progression, or consent withdrawal.
62837444|NCT02289157|NO_INTERVENTION|Standard dressing|After standard cesarean section completed patients will have standard dressing placed.
62837445|NCT02991976|ACTIVE_COMPARATOR|35% O2|Patient receiving 35% O2 during carotid endarterectomy, Intervention - oxygen concentration
62053846|NCT00679328|ACTIVE_COMPARATOR|2|Surgical implantation of bone graft material
62612853|NCT02083653|ACTIVE_COMPARATOR|Arm C: Investigator's Choice|Best supportive care (BSC) or Fluorouracil (5-FU) or Capecitabine will be given as per Investigator's discretion.
62612854|NCT03998137||Autograft|Standard Rigid Fixation plus autograft
62053847|NCT01069354|EXPERIMENTAL|Radiesse® Mixed with Lidocaine|Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
62053848|NCT01069354|ACTIVE_COMPARATOR|Radiesse® without Lidocaine|Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
62053849|NCT04636372|EXPERIMENTAL|Intense pulsed light therapy group|
62053850|NCT04636372|EXPERIMENTAL|Hot compress massage group|
62053851|NCT04636372|EXPERIMENTAL|Intense pulsed light therapy and hot compress massage group|
62053852|NCT03333798|EXPERIMENTAL|Cognitive-Behavioral Intervention|Cognitive-Behavioral Intervention with community worker support.
62612855|NCT03998137||AUGMENT® Injectable|Standard rigid fixation plus AUGMENT® Injectable Bone Graft
62612856|NCT06731231|NO_INTERVENTION|Control|Renal Transplantation patients who are DM pre-study / PTDM who don't take SGLT2i
62612857|NCT06731231|ACTIVE_COMPARATOR|Intervention|Renal Transplantation patients who are DM pre-study / PTDM who take SGLT2i
62612858|NCT06601465|EXPERIMENTAL|Vericiguat|A starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of HF standard of care. Uptitrated gradually every 2 weeks to 5 mg daily and then to the target dose of 10 mg daily.
62612859|NCT06601465|NO_INTERVENTION|Standard of Care|Conventional management of heart failure and mild-to-moderate cognitive impairment.
62837446|NCT02991976|ACTIVE_COMPARATOR|100% O2|Patient receiving 100% O2 during carotid endarterectomy, Intervention - oxygen concentration
62837447|NCT01181349||P07535 study participants with a TOF ratio <0.9|Participants enrolled in the P07535 study who are included in the primary outcome measurement, which is defined as the incidence of postoperative residual neuromuscular blockade, who had a TOF ratio \<0.9 at PACU arrival.
62053853|NCT03333798|ACTIVE_COMPARATOR|Standard psychosocial care|Standard psychosocial care delivered by health services.
62053854|NCT00252538||Group 1|Research participants are: 1) male or female, 2) age 18 or older, 3) chronically infected with the hepatitis C virus, 4) candidates for interferon therapy, 4) not on antidepressant treatment , and 5) not currently abusing any substances such as alcohol or intravenous drugs, or having abused in the past 6 months
62053855|NCT06040190|PLACEBO_COMPARATOR|topical placebo tablet|magnesium silicate placebo tablet three times a day for 21 days
62053856|NCT06040190|NO_INTERVENTION|control|artificial saliva
62053857|NCT06040190|EXPERIMENTAL|topical clonazepam tablet|2.0 mg Clonazepam tablet three times a day for 21 days
62053858|NCT06040190|EXPERIMENTAL|oral alpha-lipoic acid capsule|300 mg alpha-lipoic acid capsule twice a day for 60 days
62612860|NCT02398370|EXPERIMENTAL|Injection of PMD-MSCs into the penis|Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based patient reported treatment satisfaction.
62837448|NCT01181349||P07535 study participants with a TOF ratio ≥0.9|Participants enrolled in the P07535 study who are included in the primary outcome measurement, which is defined as the incidence of postoperative residual neuromuscular blockade, who had a TOF ratio ≥0.9 at PACU arrival.
62837449|NCT05740540|EXPERIMENTAL|Implantation, controller development, and evaluation|This phase includes installing the device and setting the individual up for home use, creating advanced controllers for walking and evaluating the effect of the device over several months.
62837450|NCT06395337|EXPERIMENTAL|Intraoperative multi-modality imaging|Patients receive a single intravenous dose of \[111In\]In-DOTA-ANTI-CEA antibody. At day 4 or 5 after antibody injection a SPECT/CT scan will be acquired. At day 6 or 7 standard of care cytoreductive surgery will be performed. This will be extended with the use of dual-modality imaging.
62837451|NCT03976219|EXPERIMENTAL|Evoked potentials of ECAPs and SSEPs|Patients implanted with a spinal cord stimulator. In this arm, we are measuring the evoked potentials of electric compound action potentials (ECAPs) and somatosensory evoked potentials (SSEPs).
62837452|NCT05254704||Group - assessment of reproductibility of TEX-Q-F|"This groupe will fill in the questionnaire twice :~* at first before the anesthesia consultation~* then, 7 days after the consultation (without further information) This group will be composed of 100 subjects.~We will then assess the influence of their answers on their recovery by collecting their answer of QoR-15 (quality of recovery) and EVAN-G (satisfaction) at 24 hours after the surgery."
62837453|NCT05254704||Group - assessment of the responsiveness of the questionnaire after information|"This group will also fill in the questionnaire twice :~* at first before the anesthesia consultation~* then, 7 days after the consultation and AFTER a phone interview (about 15 minutes) with an experienced practitioner to provide appropriate information concerning the anesthesia and the postoperative rehabilitation process.~This group will also be composed of 100 subjects.~We will then assess the influence of their answers on their recovery by collecting their answer of QoR-15 (quality of recovery) and EVAN-G (satisfaction) at 24 hours after the surgery."
62053859|NCT06040190|EXPERIMENTAL|topical phytotherapic capsaicin gel|0.025 mg capsaicin gel 4 times a day for 14 days
62612861|NCT00546741|EXPERIMENTAL|1|
62612862|NCT00546741|ACTIVE_COMPARATOR|2|
62612863|NCT00546741|ACTIVE_COMPARATOR|3|
62612864|NCT04484844|EXPERIMENTAL|Shield Force Plus Varnish|Shield force plus (SFP), Self-reinforcing (SR) monomer technology supplied in the form of one component self-etching light-cured dental adhesive, which is characterized by an SR monomer component that penetrates the tooth substrate. Multi-point interactions with apatite calcium and three-dimensional cross-linking occur reactions.it forms a thin even, hard coating on the tooth surface that gives the tooth substrate a superior binding power.
62837454|NCT02865577||Adult asthma|"Adult asthma subjects with airflow limitation (FEV1% predicted \< 80%) will be recruited for this study.~Participants will undergo following study assessments:~1. Clinical History~2. Health status and disease control questionnaires~3. Focused physical examination~4. Electrocardiogram (ECG)~5. Blood test~6. Spirometry~7. Echocardiogram~8. Cardiac magnetic resonance (CMR) imaging~9. CMR survey"
62837455|NCT02865577||Adult COPD|"Adult COPD subjects with airflow limitation (FEV1% predicted \< 80%) will be recruited for this study.~Participants will undergo following study assessments:~1. Clinical History~2. Health status and disease control questionnaires~3. Focused physical examination~4. Electrocardiogram (ECG)~5. Blood test~6. Spirometry~7. Echocardiogram~8. Cardiac magnetic resonance (CMR) imaging~9. CMR survey"
62837456|NCT02865577||Healthy participants|"Healthy participants with no past history of cardiovascular or respiratory disease.~Participants will undergo following study assessments:~1. Clinical History~2. Focused physical examination~3. Electrocardiogram (ECG)~4. Blood test~5. Spirometry~6. Echocardiogram~7. Cardiac magnetic resonance (CMR) imaging~8. CMR survey"
62837457|NCT00753649|EXPERIMENTAL|Aboriginal infants group|
62837458|NCT00753649|ACTIVE_COMPARATOR|Other Non-Aboriginal infants|
62837459|NCT05684393|EXPERIMENTAL|Anatomy based fitting|
62837460|NCT05684393|ACTIVE_COMPARATOR|Standard fitting|
62837461|NCT01342016|EXPERIMENTAL|tacrolimus group|tacrolimus capsule + leflunomide placebo
62837462|NCT01342016|ACTIVE_COMPARATOR|leflunomide group|tacrolimus placebo + leflunomide tablet
62837463|NCT03330301||Exposed|"1. Individuals born between June1983 and May1985 were exposed to the mandatory vitamin D margarine fortification during fetal life.~2. Cases: individuals defined as having one of the aforementioned diseases of interest from the registers"
62837464|NCT03330301||Non-exposed|"1. Individuals born between September1986 and August 1988 were not exposed to the mandatory vitamin D margarine fortification during fetal life.~2. Controls: cohort of matched disease-free individuals"
62837465|NCT04312724|ACTIVE_COMPARATOR|Clinical need|Participants enrolled that require a new socket.
62837466|NCT04312724|EXPERIMENTAL|No clincal need|Participants enrolled that do not require a new socket
62837467|NCT04119531||Patients with insomnia|In the preoperative room patients will be asked to participate to the study and will be asked to answer the 4-item Jenkins-Sleep Questionaire.If they accept to participate, written informed consent will be taken from the patients. According to their answers to the questionaire , patients will be divided into two groups :those with or without insomnia.
62837468|NCT04119531||Patients without insomnia|In the preoperative room patients will be asked to participate to the study and will be asked to answer the 4-item Jenkins-Sleep Questionaire.If they accept to participate, written informed consent will be taken from the patients. According to their answers to the questionaire , patients will be divided into two groups :those with or without insomnia.
62837469|NCT02224001|EXPERIMENTAL|Asian rhinoplasty, septal cartilage|"A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts~The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result."
62837470|NCT03515330|NO_INTERVENTION|Standard of Care|Participants in the control arm will be instructed to take their immunosuppressant medications as prescribed and attend required follow-up as is standard of care, and will not receive the mHealth application.
62837471|NCT03515330|EXPERIMENTAL|mHealth Intervention|Participants in the intervention arm will receive the mHealth app either while they are an inpatient post-transplant, or at their first post-transplant clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the application and explain its functioning. Participants will then use the application to aid in immunosuppressant medication adherence post-transplant.
62837472|NCT06172309|EXPERIMENTAL|NTQ1062|NTQ1062 Tablets will be administered orally QD in a 28-day cycle (21 days on treatment followed by 7 days off treatment) in sequential cohorts.
62837473|NCT05915910||GSD1b G339C Homozygous (n=3)|
62053860|NCT06040190|EXPERIMENTAL|local photobiomodulation|Photobiomodulation with wavelength of 810 nm, power of 0.6 W, power density of 1.2 W/cm², beam area of 0.5 cm², and energy of 6 J.
62053861|NCT00941798|EXPERIMENTAL|QMF149 Twisthaler® 500/400|QMF149 Twisthaler® (indacaterol maleate 500 µg/mometasone furoate 400 µg), once daily (QD)
62837474|NCT05915910||GSD1b L348FS Homozygous (n=3)|
62837475|NCT05915910||GSD1b G339C/ L348FS Heterozygous (n=3)|
62837476|NCT05915910||GSD1b Parents (n=6)|
62837477|NCT01165216|EXPERIMENTAL|Dose Level 1: Ipilimumab, 3 mg/kg + Paclitaxel + Carboplatin|Participants received ipilimumab, 3 mg/kg, administered as a single dose intravenously (IV) over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m\^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, area under the curve (AUC)=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
62837478|NCT01165216|EXPERIMENTAL|Dose Level 2: Ipilimumab, 10 mg/kg + Paclitaxel + Carboplatin|Participants received ipilimumab, 10 mg/kg, administered as a single dose IV over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m\^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, AUC=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
62837479|NCT02268357|EXPERIMENTAL|Propranolol|capsules PROPRANOLOL (study medication); 80 mg 1 hour preoperative; 40 mg directly postoperative
62053862|NCT00941798|ACTIVE_COMPARATOR|Mometasone Twisthaler®|Mometasone Twisthaler®, 400 µg QD
62837480|NCT02268357|PLACEBO_COMPARATOR|Placebo|capsules MICROCRYSTALLINE CELLULOSE (study medication); 80 mg 1 hour preoperative; 40 mg directly postoperative
62837481|NCT04129463|ACTIVE_COMPARATOR|SST with Iris incarceration|infants that underwent SST with iris incarceration procedure
62255139|NCT00003702|EXPERIMENTAL|Arm I (methotrexate)|Patients receive methotrexate intramuscularly once weekly in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.
62255140|NCT00003702|EXPERIMENTAL|Arm II (dactinomycin)|Patients receive dactinomycin IV over 15 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.
62255141|NCT00003895|EXPERIMENTAL|gp100:209-217(210M) + HPV 16 E7:12-20 (every 2 weeks)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 2 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory biomarker analysis.
62612865|NCT04484844|ACTIVE_COMPARATOR|Sodium Fluoride varnish|Topical application of varnish fluoride (sodium fluoride NaF) effect on exposed dentine as a desensitizing agent, the varnish fluoride process is caused by the reaction between NaF and calcium ions resulting in calcium fluoride crystals being deposited on the openings of the dentinal tubules that decrease pain.
62612866|NCT04081116|EXPERIMENTAL|MI-E testing symmetric settings|Symmetric settings is one of 3 different settings that will be tested on the same day but in randomized order.
62837482|NCT04129463|ACTIVE_COMPARATOR|Conventional trabeculotomy|infants that underwent Conventional trabeculotomy
62837483|NCT04665167|ACTIVE_COMPARATOR|Body image exposure|Guided non-judgmental exposure, 40 minutes total
62837484|NCT04665167|ACTIVE_COMPARATOR|Self-compassion|8 Short self-compassion meditations, 40 minutes total
62837485|NCT05086107|EXPERIMENTAL|Group 1|subjects with mild renal impairment (eGFR: 60 to 89 mL/min)
62837486|NCT05086107|EXPERIMENTAL|Group 2|subjects with moderate renal impairment (eGFRr: 30 to 59 mL/min)
62837487|NCT05086107|EXPERIMENTAL|Group 3|subjects with severe renal impairment (eGFR: 15-29 mL/min)
62837488|NCT05086107|EXPERIMENTAL|Group 4|subjects with normal renal function (eGFR: ≥ 90 mL/min)
62837489|NCT05086107|EXPERIMENTAL|Group 5|subjects with end stage renal disease (ESRD) eGFR: \<15 mL/min requiring dialysis (with BV100 dosing and PK during the dialysis-free interval)
62837490|NCT05086107|EXPERIMENTAL|Group 6|subjects with ESRD (eGFRr: \<15 mL/min) requiring dialysis (with BV100 dosing and PK on the day of dialysis)
62837491|NCT01463644|ACTIVE_COMPARATOR|mepolizumab|
62837492|NCT01463644|PLACEBO_COMPARATOR|placebo|
62837493|NCT02305719||Epidural anesthesia|Patients receiving thoracic epidural anesthesia for thoracoscopic surgery. Standard regimen with 8-20 ml Ropivacaine 0,5% in the epidural catheter. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered.
62837494|NCT02305719||Serratus-anterior-plane-Block|"Patients receiving (ultrasound-guided) Serratus-anterior-plane-Block for thoracoscopic surgery.~Standard regimen up to 20 ml Ropivacaine 0,5%, were installed. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered."
62837495|NCT02305719||Local infiltration|Patients receiving local infiltration with up to 20 ml Ropivacaine 0,5% for thoracoscopic surgery (at the site of thoracoscopy)
62837496|NCT04653077|EXPERIMENTAL|stem cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
62837497|NCT01467960||Group I|Healthy Subjects aged 20-40
62837498|NCT01467960||Group II|Healthy Subjects aged 40-65
62837499|NCT01467960||Group III|Healthy Subjects aged more than 65
62837500|NCT01467960||Group A|Patients at Stage I, H\&Y classification
62837501|NCT01467960||Group B|Patients at Stage II, H\&Y classification
62837502|NCT01467960||Group C|Patients at Stage more than III, H\&Y classification
62837503|NCT00560001|EXPERIMENTAL|A|Those subjects that receive an MD.2 Medication Dispenser
62837504|NCT00560001|NO_INTERVENTION|B|Control subjects that do not receive an MD.2 Medication Dispenser, but continue to take their medications utilizing standard care, such as pill boxes, etc.
62837505|NCT02812342|EXPERIMENTAL|Tofacitinib ointment|Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
62837506|NCT01793324||GER|All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel® or Seroquel® XR seen by general practitioners and psychiatrists in Germany based upon patient encounters recorded in IMS Disease Analyzer during the calendar period 13 February 2012 - 31 August 2012
62053863|NCT01537302|EXPERIMENTAL|Ocelot System|CTO crossing in femoropopliteal arteries using the Ocelot System
62837507|NCT01793324||UK|All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel® or Seroquel® XR seen by general practitioners in the United Kingdom based upon patient encounters recorded in IMS Disease Analyzer during the calendar period from 11 January 2012 - 31 July 2012
62837508|NCT03937934|EXPERIMENTAL|Subjects with long term health condition|Subjects that have been identified as having food insecurity based on a two question screening tool, and also has one of more of the following chronic diseases Hypertension, Heart disease, Stroke/TIA, DM 2, Cancer/history of cancer, obesity or osteoarthritis will receive weekly nutrition educaiton
62837509|NCT00972062|PLACEBO_COMPARATOR|Placebo cream|Cream base used in compounding medications into cream media
62837510|NCT00972062|EXPERIMENTAL|Herbal Cream|Herbal cream (Bach's Rescue Remedy Cream) applied to skin site reactions from MS medications
62053864|NCT05508503||CRC group|patients with colorectal cancer
62053865|NCT05508503||Control group|patients without colorectal cancer
62612867|NCT04081116|EXPERIMENTAL|MI-E testing assymetric settings|Asymmetric settings is one of 3 different settings that will be tested on the same day but in randomized order.
62612868|NCT04081116|SHAM_COMPARATOR|Settings in use|Settings in use is one of 3 different settings that will be tested on the same day but in randomized order
62612869|NCT02102100|EXPERIMENTAL|Menthol-Preferring Smokers|Each subject in this arm received a random sequence of 3 different inhaled menthol conditions across 3 test sessions (a single menthol condition for each test session). In each test session, a random order of one saline, and 2 nicotine (0.25 mg and 0.5 mg /70 kg) infusions were given one hour apart, concurrent with the randomized menthol inhalation condition for that test session.
62612870|NCT02102100|EXPERIMENTAL|Non-Menthol Preferring Smokers|Each subject in this arm received a random sequence of 3 different inhaled menthol conditions across 3 test sessions (a single menthol condition for each test session). In each test session, a random order of one saline, and 2 nicotine (0.25 mg and 0.5 mg /70 kg) infusions were given one hour apart, concurrent with the randomized menthol inhalation condition for that test session.
62837511|NCT06347120|ACTIVE_COMPARATOR|Control group (NGT+ group)|Patients treated with standard NOM (NGT, intravenous administration of fluids, nill per os, analgesic, antiemetic treatment, and clinical and biochemical monitoring for 72h)
62837512|NCT06347120|EXPERIMENTAL|Experimental group (NGT- group)|Patients treated with NOM without NGT insertion (intravenous administration of fluids, nill per os, analgesic, antiemetic treatment, and clinical and biochemical monitoring for 72h)
62837513|NCT00776074|EXPERIMENTAL|Leuprorelin (GF)|
62837514|NCT00776074|EXPERIMENTAL|Leuprorelin (GC)|
62837515|NCT06324513|EXPERIMENTAL|Med-CDED|The Mediterranean Crohn's Disease Exclusion Diet (Med-CDED) is the exclusion diet (CDED) adapted to the Mediterranean diet pattern. The Med-CDED consists of 2 phases in dietary therapy and a maintenance phase: the first phase lasting 8 weeks, the second phase lasting 16 weeks, and the maintenance phase, which for the purposes of the study will last 28 weeks.
62837516|NCT06324513|ACTIVE_COMPARATOR|CDED|The original Crohn's disease exclusion diet, used as a comparator, is widely employed among first-line treatments in clinical practice for inducing remission in pediatric patients with Crohn's disease
62837517|NCT00256997|EXPERIMENTAL|Risperidone long-acting injection (LAI)|Risperidone LAI 25 milligram (mg), 37.5 mg or 50 mg intramuscular (injection of a substance into a muscle) injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following the dose increase. Duration of treatment will be 24 months.
62837518|NCT00256997|ACTIVE_COMPARATOR|Oral atypical Antipsychotic|Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
62837519|NCT04642690||Group 1-NSE|Patients found to have grossly normal squamous epithelium during endoscopy
62837520|NCT04642690||Group 2-EEG|Patients found to have grossly apparent erosive esophagitis \>1cm with Los Angeles Classification A-D
62837521|NCT04642690||Group 3-NDBE Short|Patients with non-dysplastic Barrett's Esophagus (NDBE) \> 1cm (Short Segment)
62837522|NCT04642690||Group 4-NDBE Long|Patients with non-dysplastic Barrett's Esophagus (NDBE) \> 1cm (Long Segment)
62053866|NCT01870388|EXPERIMENTAL|Baricitinib (Healthy)|Group 1: 4 milligrams (mg) baricitinib administered once, orally, to participants with normal hepatic function.
62053867|NCT01870388|EXPERIMENTAL|Baricitinib (Moderate)|Group 2: 4 mg baricitinib administered once, orally, to participants with moderate hepatic impairment.
62053868|NCT01870388|EXPERIMENTAL|Baricitinib (Mild)|Group 3: 4 mg baricitinib administered once, orally, to participants with mild hepatic impairment. Enrollment is contingent on data from Groups 1 and 2.
62053869|NCT00337272|PLACEBO_COMPARATOR|1 (Placebo)|Patients will take placebo 30 minutes before bedtime days 1-28 of treatment period.
62612871|NCT02278692|ACTIVE_COMPARATOR|Vitamin K|Vitamin K1 (phytonadione) 10 mg orally three times a week after dialysis for 12 weeks
62612872|NCT02278692|PLACEBO_COMPARATOR|Placebo|Identical appearing placebo orally three times a week after dialysis for 12 weeks
62837523|NCT04642690||Group 5|Barrett's Esophagus (BE) with high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC)
62837524|NCT04642690||Group 6-Esophagectomy|Patients undergoing resection of esophageal cancer
62837525|NCT04642690||Group -7 Pilot and Feasibility|Patients undergoing EGD with NSE, NDBE, BE-HGD, or EAC for feasibility of analytical techniques
62837526|NCT04490876||Retinal Detachment with PVR|Proliferative vitreoretinopathy (PVR), a major complication of rhegmatogenous retinal detachment (RRD), is an abnormal process whereby proliferative, contractile cellular membranes form in the vitreous and on both sides of the retina, resulting in tractional retinal detachment with fixed retinal folds. Patients with RD complicated by PVR will be included, and the proposed intervention will be performed.
62837527|NCT01647217|EXPERIMENTAL|Terpinen-4-ol Treatment Arm|8 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (3 / 5 patients) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
62837528|NCT01647217|PLACEBO_COMPARATOR|Placepo Pads Contol Arm|9 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (5 / 4 patients) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
62837529|NCT02886455|EXPERIMENTAL|Cohort 4|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin at two different time points (4 and 24 hours).~There are two visits:~Visit 1:~Two adhesive strips (standard adhesive strip and new adhesive strip)contaminated with the subjects own output are applied on the peristomal skin and allowed to sit for 4 hours before being removed~Visit 2: Two adhesive strips (standard adhesive strip and new adhesive strip)contaminated with the subjects own output are applied on the peristomal skin and allowed to sit for 24 hours before being removed"
62837530|NCT05039892|EXPERIMENTAL|All eligible subjects|
62837531|NCT02106390|EXPERIMENTAL|rMenB+ACWY|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
62837532|NCT02106390|ACTIVE_COMPARATOR|rMENB|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
62443355|NCT05943925||Mild Cognitive Impairment (MCI)- amnesic|"The criteria for the recruitment will be:~Inclusion criteria: Mild Cognitive Impairment (MCI) amnesic, diagnosed by the neurology service; more than 60 years.~Exclusion criteria: Comorbidity with other significant neurology disease, infectious treatment with antibiotics in the previous 6 months prior to providing the stool sample, corticosteroid use, immunosuppressors or immunostimulants treatment, illnesses of the gastrointestinal (GI) tract, large doses of commercial probiotics consumed (greater than or equal to 108 colony forming units (cfu) per organisms per day).~Neuropsychological, functional and neuropsychiatric assessment and stool sample."
62053870|NCT00337272|ACTIVE_COMPARATOR|2 (Ramelteon)|Patients will take 8 mgs of ramelteon 30 minutes before bedtime days 1-28 of treatment period.
62612873|NCT04981600|ACTIVE_COMPARATOR|Laser Group|Grade II-III hemorrhoids present a special challenge to surgeons since aggressive surgery exposes the patient to several per- and postoperative complications. Therefore new techniques have been developed and one of the most popular contemporary technique is laser hemorrhoidectomy. By this technique a laser probe is inserted above the dentate line and advanced to the apex of the cushion and several shots are delivered while pulling out the probe gradually. The idea is to compromise the vascular flow of corpus cavernosum recti, hence shrinking the hemorrhoidal cushion.
62837533|NCT02106390|ACTIVE_COMPARATOR|MenACWY|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
62837534|NCT03599739||Follow-On Cohort|We will survey 823 nursing facilities who participated in the aTIV Influenza Vaccination and Morbitiy and Mortality in U.S. Nursing Homes study in 2016-2017. We anticipate a 70% response rate from this sample for participation.
62837535|NCT03599739||Parallel Cohort|We will survey an additional 1000 facilities (i.e., facilities not participating in the original 2016-2017 study, but meeting the same entry criteria, except prior use of high dose vaccine will be allowed) in order to capture a cohort that used a wide range of self-selected vaccine choices. We anticipate a 50% response rate from this sample.
62837536|NCT00829504|EXPERIMENTAL|1|
62837537|NCT00829504|ACTIVE_COMPARATOR|2|
62255142|NCT00003895|EXPERIMENTAL|gp100:209-217(210M) + HPV 16 E7:12-20 (every 3 weeks)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 3 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory biomarker analysis.
62255143|NCT06082388|ACTIVE_COMPARATOR|Atropine|Patients in whom during electrophysiological study atropine will be used. I.v. bolus of 0.01 mg/kg b.w. will be administered to reach the increase of heart rate of 25% or up to 130/min. If necessary, dose will be increased every 5 minutes until mention above parameters are achieved. Maximum dose will be 0.4 mg/kg b.w.
62612874|NCT04981600|ACTIVE_COMPARATOR|RF (Radiofrequency) Group|Another recent and similar method is radiofrequency coagulation which depends on transmitting radiofrequency waves to tissue. This transmission results in conversion of radiofrequency waves into heat and causes coagulation necrosis in corpus cavernosum recti. The necrosis leads to fibrosis of the surrounding vessels and consequently cushion shrinkage is achieved.
62837538|NCT01999257|NO_INTERVENTION|In-person counselling|Similar to standard of care, wherein Ashkenazi Jewish individuals seeking carrier genetic screening meet a genetic counsellor for an in-person education and counselling session.
62837539|NCT01999257|ACTIVE_COMPARATOR|Online pre-test genetic education tool|Use of a web-based pre-test education program, wherein the information from a typical genetic counselling session for carrier screening in Ashkenazi Jewish individuals is presented.
62837540|NCT01840982|EXPERIMENTAL|Giant embryonic brown rice|
62255144|NCT06082388|ACTIVE_COMPARATOR|Isoprenaline|Patients in whom during electrophysiological study isoprenaline will be used. Continuous i.v. infusion of 0.01 mcg/kg b.w./min will be administered to reach the increase of heart rate of 25% or up to 130/min. If necessary, dose will be doubled every 5 minutes until mention above parameters are achieved. Maximum dose will be 20 mcg/min.
62837541|NCT01840982|EXPERIMENTAL|Giant embryonic rice|
62255145|NCT00175877|EXPERIMENTAL|Certolizumab Pegol|All patients received Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) every two weeks, given as two 1 ml injections of CZP for at least six months and then 200 mg of CZP sc every two weeks, given as one 1 ml injection.
62255146|NCT02549430|EXPERIMENTAL|Arm A|Palbociclib monoterapy
62255147|NCT02549430|EXPERIMENTAL|Arm B|Palbociclib + HT (Anastrozole, Letrozole, Exemestane, Fulvestrant)
62837542|NCT01840982|ACTIVE_COMPARATOR|White rice|
62255148|NCT00906568||Sensitized vs non-sensitized|CF with and without SAD defined by MEF25 \<50%
62612875|NCT02527915|EXPERIMENTAL|Mental Health eConsults|Primary care clinics that will receive the eConsults intervention at the start of the study.
62837543|NCT01840982|ACTIVE_COMPARATOR|Glucose solution|
62837544|NCT02424877|EXPERIMENTAL|SandRA|cell phone monitoring
62837545|NCT02424877|NO_INTERVENTION|Control|conventional monitoring
62837546|NCT00604773||delirious patients|minimal one positive CAM-ICU score during ICU admission
62837547|NCT00604773||non-delirious patients|without any positive CAM-ICU scores during ICU admission
62255149|NCT04091490|EXPERIMENTAL|Patients with relapsed/refractory Hodgkin's lymphoma|A clinical study of safety and efficacy of treatment with Nivolumab and DHAP in patients with relapsed/refractory Hodgkin's lymphoma
62255150|NCT02680132|EXPERIMENTAL|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
62255151|NCT02680132|ACTIVE_COMPARATOR|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
62255152|NCT02489643|EXPERIMENTAL|Receiving training|Patients will be visited and receive information about the prescribed topical treatment according to the normal course and procedure of an outpatient visit at our institution. At the end of the visit, they will also receive practical instructions on dosages and application modalities of the topical therapy.
62837548|NCT01559857|ACTIVE_COMPARATOR|Pioglitazone|50% of participants will be allocated to 12 weeks of treatment with 30 mg/day of Pioglitazone.
62837549|NCT01559857|PLACEBO_COMPARATOR|Sugar pill|50% of participants will be randomized to 12 weeks of treatment with placebo pill.
62837550|NCT02772367||Breast Cancer Patients|In study participants undergoing breast reconstruction surgery prior to breast radiation therapy, we will obtain skin tissue at the time of reconstruction surgery from the surgical specimen.
62837551|NCT00217607|EXPERIMENTAL|Paclitaxel|"Paclitaxel 80 mg/m² Day 1, Day 8 and Day 15. No treatment on Day 22.~1 cycle = 28 days.~Treatment duration: 6 cycles (=6 months)"
62837552|NCT05498714|ACTIVE_COMPARATOR|the control group|The dosing regimen of high-risk patients will be PEG combined with lactulose.
62053871|NCT06129864|EXPERIMENTAL|Study Arm|Participants in this arm will receive volrustomig.
62053872|NCT06129864|NO_INTERVENTION|Observation Arm|Patients in this arm will undergo observation.
62255153|NCT02489643|NO_INTERVENTION|No-receiving training|
62255154|NCT00651417|ACTIVE_COMPARATOR|1|Organic Germanium tablets 5 times a day
62255155|NCT00651417|PLACEBO_COMPARATOR|2|Placebo tablets 3 -5 times per day
62255156|NCT00847145|EXPERIMENTAL|12B12M (1a)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age,respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
62255157|NCT00847145|EXPERIMENTAL|12B13M (1b)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.
62255158|NCT00847145|EXPERIMENTAL|12M13B15B (2a)|Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.
62612876|NCT02527915|ACTIVE_COMPARATOR|Usual care|"Primary care clinics that will deliver care as usual for nine months, and will receive the eConsults intervention nine months subsequent to the eConsults intervention clinics."
62612877|NCT03124355|EXPERIMENTAL|Placebo pill with vagal/sham stimulation|Patients will receive a single oral dose of placebo sugar pill, and 1.5-2 hours later they will have two tilt table tests: one with vagal stimulation and one with sham vagal stimulation
62837553|NCT05498714|EXPERIMENTAL|CSP+lactulose group|The dosing regimen of high-risk patients will be CSP combined with lactulose.
62837554|NCT02718144|EXPERIMENTAL|estetrol|3 + 3 design with inter-patient dose escalation
62837555|NCT01678404|EXPERIMENTAL|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
62837556|NCT03089281|OTHER|SmartDelay™ algorithm|Subjects programmed with AV Delay and pacing chamber determined by SmartDelay
62837557|NCT03089281|OTHER|Fixed AV Delay with BiV pacing|Subjects programmed with a Fixed AV Delay of 120ms with BiV pacing
62837558|NCT02272439||Unexplained (male)|Men of couples with a diagnosis of Unexplained infertility (n=15)
62837559|NCT02272439||Unexplained (female)|Women of couples with a diagnosis of Unexplained infertility (n=15)
62837560|NCT02272439||male factor (male)|Men of couples with a diagnosis of male factor infertility (n=15)
62837561|NCT02272439||male factor (female/control)|Women of couples with a diagnosis of male factor infertility (n=15)
62837562|NCT02272439||PCOS (female)|Women of couples with a diagnosis of Polycystic Ovarian Syndrome-related infertility (n=15)
62837563|NCT02272439||PCOS (male/control)|Men of couples with a diagnosis of Polycystic Ovarian Syndrome-related infertility (n=15)
62837564|NCT02272439||healthy volunteer (male/control)|Men with a history of no reproductive dysfunction and proven fertility (n=15)
62837565|NCT02272439||healthy volunteer (female/control)|Women with a history of no reproductive dysfunction and proven fertility (n=15)
62837566|NCT00365833||Recipients of Kidney Transplant|Patients Transplanted with Live or Deceased Donor's Kidney. Standard of Care treatment pre- and post-transplant.
62837567|NCT00517244||A|Primary anxiety disorder
62837568|NCT00517244||B|Primary obsessive compulsive disorder
62837569|NCT00517244||C|Healthy children with no previous history of an anxiety disorder
62837570|NCT02217202|EXPERIMENTAL|ConvaTec Ag|Use of ConvaTec Ag sugical cover dressing post-operatively until wound has healed.
62837571|NCT03317184|EXPERIMENTAL|Periumbilical incisions|
62837572|NCT03317184|EXPERIMENTAL|Pfannenstiel incision|
62837573|NCT03677557|OTHER|Cutaquig Intervention|Participants with primary or secondary immunodeficiency disease who are currently on subcutaneous immunoglobulin treatment but have developed adverse events including allergic reaction and are willing to change the treatment product to 16.5% Cutaquig.
62837574|NCT02645669|EXPERIMENTAL|Study site|Scaling and Root planing (SRP) was followed by placement of S boulardii-FOS mixture
62837575|NCT02645669|PLACEBO_COMPARATOR|Control site|Only Scaling and Root planing (SRP) was performed
62837576|NCT02185482|EXPERIMENTAL|Physician Supported Care|The intervention is an individualized, stepped-care depression treatment program provided by a depression clinical specialist primary care physician.
62837577|NCT02185482|OTHER|Usual care|Usual care patients will be advised to consult with their primary care physician regarding depression. Primary care physicians prescribe antidepressant medication and can refer patients to the Mental Health Services.
62612878|NCT03124355|EXPERIMENTAL|Pyridostigmine with vagal/sham stimulation|Patients will receive a single oral dose of pyridostigmine pill 30 mg, and 1.5-2 hours later they will have two tilt table tests: one with vagal stimulation and one with sham vagal stimulation
62837578|NCT03522896|PLACEBO_COMPARATOR|control meal|glucose, fructose, sucrose, malic acid and citric acid in water
62837579|NCT03522896|EXPERIMENTAL|test meal 1|orange juice with added hesperidin (low dose)
62837580|NCT03522896|EXPERIMENTAL|test meal 2|orange juice with added hesperidin (high dose)
62837581|NCT03522896|EXPERIMENTAL|test meal 3|diluted orange juice with added hesperidin
62053873|NCT03113292|EXPERIMENTAL|Pilates Method|Mat Pilates Program, 2x/week, for 6 weeks, supervised by a Physiotherapist. Sessions will last forty five min, with 4 individuals per session. On average, 10 to 15 exercises will be performed per session, with repetitions ranging from 10 to 20 times, according subject's limitations. If necessary, the exercises will be adapted individually for the three levels of difficulty: basic, intermediate and advanced. Progress will be dependent on the absence of postural compensations when performing the repetitions of the exercises.
62612879|NCT03124355|EXPERIMENTAL|Galantamine with vagal/sham stimulation|Patients will receive a single oral dose of galantamine pill 8 mg, and 1.5-2 hours later they will have two tilt table tests:one with vagal stimulation and one with sham vagal stimulation
62612880|NCT00076258|EXPERIMENTAL|SSRI+ LD|A low dose aerobic exercise (LD) augmentation intervention to SSRI
62837582|NCT01241227||Chronic liver disease|All patients with chronic liver disease followed using FibroScan and non-invasive markers
62837583|NCT00585767||1|Patients with two kidneys
62837584|NCT00585767||2|Patients with solitary kidney
62837585|NCT05846854|EXPERIMENTAL|Alagille syndrome|Patients with complex cardiac conditions requiring cardiothoracic surgery who also have a history of Alagille syndrome.
62837586|NCT05846854|EXPERIMENTAL|No history of Alagille syndrome|Patients with complex cardiac conditions requiring cardiothoracic surgery who do not have a diagnosis of Alagille syndrome.
62837587|NCT03946475|OTHER|Intervention group|4 schools in 4 subdistrict which are divided into north and south Malang District. North area (Lawang and Singosari) and South area (Kepanjen and Gondanglegi).
62837588|NCT03946475|NO_INTERVENTION|Control group|4 schools in 4 subdistrict which are divided into north (Sumberpucung), south (Lawang and Singosari), and east (Tumpang) Malang District.
62837589|NCT04630496|EXPERIMENTAL|PRE-OPERATIVE EXERCISE TRACKING|"Participant baseline information will be collected from their electronic medical records.~After enrollment, participants will be provided a mobile device (Fitbit) to wear for tracking steps for 1 week prior to their scheduled surgery.~Participants will keep a log of daily steps for the 1 week they are wearing the device and receive one progress check-in call during the week.~The device and log will be turned in either on a pre-surgery clinic visit or on the day of surgery whichever comes first."
62837590|NCT05805917|EXPERIMENTAL|25 subjects treated with Neoviderm Skin Emulsion|
62837591|NCT05805917|ACTIVE_COMPARATOR|25 patients treated with Connettivina 0.2% Cream|
62837592|NCT01965574|EXPERIMENTAL|Single arm|
62837593|NCT02495519|EXPERIMENTAL|imatinib|Imatinib 400 mg/day until disease progression
62837594|NCT03423784|EXPERIMENTAL|HA BPX V3.3|A HMWHA gel available in a formulation specificaly designed for use in infants
62837595|NCT03423784|ACTIVE_COMPARATOR|Dentinox-Gel N|Gold standard for teething symptoms
62837596|NCT02395471|EXPERIMENTAL|Patient wth Barrett's|Subjects presenting for routine endoscopic BE surveillance examinations
62837597|NCT02395471|EXPERIMENTAL|Patients with GERD|Subjects with gastroesophageal reflux disease (GERD) symptoms undergoing upper endoscopy for screening for BE
62255159|NCT00847145|EXPERIMENTAL|12M12B14B (2b)|Previously in the parent study subjects ahd received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.
62255160|NCT00847145|EXPERIMENTAL|12B12M (3a)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ at 2, 4 and 6 months of age respectively. These subjects had received one booster (fourth) dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
62255161|NCT00847145|EXPERIMENTAL|12B13M (3b)|Previously in the present study subjects had received three doses of rMenB+OMV NZ at 12 months of age respectively. These subjects one booster (fourth) dose of rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.
62255162|NCT00847145|EXPERIMENTAL|12B12M_C (4a)|Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age respectively. These subjects had received one single dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
62255163|NCT00847145|EXPERIMENTAL|12B13M_C (4b)|Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age. These subjects received one single dose o rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.
62255164|NCT01196520||BL Cases|Children from East Africa diagnosed with BL
62443356|NCT05943925||Parkinson Disease Dementia (PDD)|"The criteria for the recruitment will be:~Inclusion criteria: Parkinson Disease Dementia (PDD) diagnosed by the neurology service; more than 60 years.~Exclusion criteria: Comorbidity with other significant neurology disease, infectious treatment with antibiotics in the previous 6 months prior to providing the stool sample, corticosteroid use, immunosuppressors or immunostimulants treatment, illnesses of the gastrointestinal (GI) tract, large doses of commercial probiotics consumed (greater than or equal to 108 colony forming units (cfu) per organisms per day).~Neuropsychological, functional and neuropsychiatric assessment and stool sample."
62612881|NCT00076258|EXPERIMENTAL|SSRI+ PHD|A public health dose of aerobic exercise (PHD) augmentation intervention to SSRI
62612882|NCT03930784||Participants|Divided for analysis as having suffered post-operative complications or not
62612883|NCT03213418|EXPERIMENTAL|Contingency management|
62255165|NCT01196520||HCII Controls|Matched controls from the local health clinics
62255166|NCT01196520||Population Controls|Matched controls from the geographic region
62255167|NCT04932850|EXPERIMENTAL|Active|"3 active cohorts are involved into study: Cohort 1 (48 mg), Cohort 2 (100 mg) and Cohort 3 (400 mg).~Each cohort is composed of two groups. The subjects enrolled in the first group of each cohort (groups 1, 3 and 5 for Cohorts 1, 2 and 3, respectively) will be sentinel subjects and will be treated one at the time at 48 h intervals in order to evaluate possible treatment-related adverse events."
62255168|NCT04932850|PLACEBO_COMPARATOR|Placebo|Placebo will be administered to 2 subjects for each cohort.
62255169|NCT03670043|ACTIVE_COMPARATOR|Metformin ER|The subjects developing GI-related symptoms with metformin will be randomized to Metformin Extended Release (ER)
62255170|NCT03670043|EXPERIMENTAL|Psyllium|The subjects developing GI-related symptoms with metformin will be randomized to Psyllium
62255171|NCT00777621|ACTIVE_COMPARATOR|Calorie restriction|
62612884|NCT02115061|ACTIVE_COMPARATOR|Cyanoacrylate|"This group owned fourteen patients who met all the inclusion criteria. These will be treated with cyanoacrylate.~Treatment: cyanoacrylate"
62612885|NCT02115061|SHAM_COMPARATOR|Coil + cyanocrylate|"This group had fourteen patients who met all inclusion criteria. These will be treated with coil + cyanoacrylate.~Treatment: coil + cyanoacrylate"
62612886|NCT04785560|ACTIVE_COMPARATOR|Shunt setting 4 (=110 mm H20)|Patients randomised to have the Certas Plus valve initial shunt setting post-operatively set to 4 (110 mm H20), our standard setting.
62255172|NCT00777621|ACTIVE_COMPARATOR|Exercise|
62612887|NCT04785560|ACTIVE_COMPARATOR|Shunt setting 8 (=400 mm H20)|Patients randomised to have the Certas Plus valve initial shunt setting post-operatively set to 8 (400 mm H20 a k a virtual off), in practice a closed non-functional shunt.
62255173|NCT00777621|EXPERIMENTAL|Calorie restriction and exercise|
62612888|NCT02254057|EXPERIMENTAL|BIBT 986 BS - single rising dose|
62612889|NCT02254057|PLACEBO_COMPARATOR|Placebo|
62612890|NCT02709681||SCD patients|Patients followed in 32 Italian Centers.
62612891|NCT05769920|EXPERIMENTAL|TTHX1114 Dose Level 1|TTHX1114(NM141) Ophthalmic Solution (DL1): 1 drop (gtt) to the Study Eye (SE) twice daily for a total of 7 days
62255174|NCT04046081|OTHER|Dichloroacetate|Open label study
62255175|NCT05755295|EXPERIMENTAL|horse therapy|
62255176|NCT02047253|EXPERIMENTAL|Carfilzomib|Carfilzomib is administered twice-weekly on consecutive days (days 1, 2, 8, 9, 15, 16) as a 30-minute intravenous infusion for 3 weeks every 4 weeks (1 cycle) with dexamethasone given as pre-medication. The dose of carfilzomib is 20 mg/m2 on days 1 and 2 of cycle 1 and is then escalated in succeeding weeks and cycles to 56 mg/m2 if no dose limiting toxicities occur. Acyclovir is given orally at 400 mg twice daily during therapy but may be discontinued at some point. Therapy will continue until side effects become unacceptable, the disease progresses, or the doctor withdraws the patient.
62255177|NCT04666779||No access|Group not accessing chiropractic care
62255178|NCT04666779||Access to care|Group with access to care in a 6 months period. Differences in the degree of access, measured in ranges of numbers of visits, will be used as independent variable within this group.
62255179|NCT03901105|EXPERIMENTAL|Flortaucipir PET Scan|No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) will be read by independent, blinded readers.
62255180|NCT02774512|EXPERIMENTAL|Nilotinib|A specific colonoscopy is performed in order to take biopsy for biological studies to determine the ZAK-0 expression status. Then the patient receives nilotinib orally at the dose of 800 mg/day (400 mg twice a day) for 7 days. The patient is scheduled for surgery the morning after the last take of the nilotinib (12 hours). When the colectomy is performed, the surgeon collects different tumoral samples which are immediately delivered to the laboratory.
62255181|NCT05752877|EXPERIMENTAL|Interventional Group|
62255182|NCT04349982||No cardiovascular risk|If no patients with no cardiovascular risk can be included in the study, we will divide the cohorts into different categories (e.g. low, medium and high cardiovascular risk).
62255183|NCT04349982||low cardiovascular risk|
62255184|NCT04349982||high cardiovascular risk|
62255185|NCT03526770|ACTIVE_COMPARATOR|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test carbonated drink."
62837598|NCT05542030|EXPERIMENTAL|Endoscopic mucosal resection + CAD-Eye™|"This group constitutes patients with lesions suggestive of high-grade dysplasia or early invasive cancer approached with endoscopic mucosal resection, subjected to colonoscopy + CAD-Eye™ system evaluation for the detection of remaining malignant tissue.~For this group, the investigators used as a complement tool an AI system (CAD-Eye™) for the detection of remaining lesions immediately after EMR and in a three-month follow-up."
62837599|NCT05542030|ACTIVE_COMPARATOR|Endoscopic mucosal resection without CAD Eye|"This group constitutes patients with lesions suggestive of high-grade dysplasia or early invasive cancer approached with endoscopic mucosal resection and subjected to colonoscopy. The detection of remaining lesions immediately after EMR is based on the visual impression of the expert.~For this group, the investigators used as a complement tool an AI system (CAD-Eye™) only for the evaluation of the post-procedure scar to detect remaining lesions in the three-month follow-up."
62837600|NCT00983658|EXPERIMENTAL|huMAb OX40L|
62837601|NCT00983658|PLACEBO_COMPARATOR|Placebo|
62255186|NCT03526770|EXPERIMENTAL|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention"
62612892|NCT05769920|EXPERIMENTAL|TTHX1114 Dose Level 2|TTHX1114(NM141) Ophthalmic Solution (DL2): 1 drop (gtt) to the Study Eye (SE) twice daily for a total of 7 days
62612893|NCT05769920|EXPERIMENTAL|TTHX1114 Dose Level 3|TTHX1114(NM141) Ophthalmic Solution (DL3): 1 drop (gtt) to the Study Eye (SE) twice daily for a total of 7 days
62837602|NCT05465577|EXPERIMENTAL|Financial Navigation- Patients Only|Patients only participated in financial navigation program.
62837603|NCT05465577|EXPERIMENTAL|Financial Navigation- Patient and Caregiver|Patients and their caregivers participated as a dyad in financial navigation program.
62837604|NCT02369796|EXPERIMENTAL|TAK-448 3 µg once weekly|TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
62837605|NCT02369796|EXPERIMENTAL|TAK-448 1 µg once weekly|TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
62837606|NCT02369796|EXPERIMENTAL|TAK-448 0.3 µg once weekly|TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
62837607|NCT02369796|EXPERIMENTAL|TAK-448 0.3 µg twice weekly|TAK-448 0.3 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.
62837608|NCT02369796|EXPERIMENTAL|TAK-448 0.1 µg twice weekly|TAK-448 0.1 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.
62837609|NCT00802945|EXPERIMENTAL|NKTR-102 q14d|NKTR-102
62837610|NCT00802945|EXPERIMENTAL|NKTR-102 q21d|NKTR-102
62837611|NCT00604487|ACTIVE_COMPARATOR|1|Insertion of the Atad double balloon ripener device (100 ml NS in each balloon).
62837612|NCT00604487|ACTIVE_COMPARATOR|2|Insertion of the double balloon instillation device (100 ml NS in each balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
62837613|NCT00604487|ACTIVE_COMPARATOR|3|Insertion of the folly catheter (40 ml NS in the balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
62837614|NCT04506138|EXPERIMENTAL|Camrelizumab plus Chemotherapy|
62053874|NCT03113292|ACTIVE_COMPARATOR|Home Exercise Prescription|Composed by two familiarization sessions, supervised by a Physiotherapist. The protocol include postural reeducation exercises, stretching and muscle strengthening, stabilization and mobilization of the spine. Subsequently, participants will receive an educational booklet containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. Also, it will include a booklet with the prescription of therapeutic home exercises to be performed during the next 6 weeks. It will be recommended that the participants perform the exercises 2x/week. Participants will also be contacted weekly by email and/or telephone, for remote supervision and for checking the prescribed exercises.
62255187|NCT03526770|EXPERIMENTAL|Group 3: 0.2% chlorhexidine|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
62255188|NCT03526770|EXPERIMENTAL|Group 4: fluoridated tooth paste|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the tooth paste as an intervention."
62612894|NCT05769920|EXPERIMENTAL|TTHX1114 Dose Level 4|TTHX1114(NM141) Ophthalmic Solution (DL4): 1 drop (gtt) to the Study Eye (SE) twice daily for a total of 7 days
62612895|NCT02532452|EXPERIMENTAL|Viral Specific VST Infusion|3rd party VST infusion
62612896|NCT03648554|EXPERIMENTAL|dulaglutide (TRULICITY®) 1.5 mg|dulaglutide (TRULICITY®) subcutaneous administration, one weekly injection, in a dose of 1.5 mg of dulaglutide for 52 weeks in combinaison with reinforced dietary monitoring as same as control group.
62612897|NCT03648554|SHAM_COMPARATOR|reinforced dietary monitoring|reinforced dietary monitoring with frequent dietary consultations, based on American Heart Association (AHA) recommendations
62612898|NCT06404944|EXPERIMENTAL|Slope Implant|The patients received implants with a sloped platform edge.
62837615|NCT02287766||Control|Men and women ages 21-85 lacking any medical diagnosis (as defined in the protocol) of one or more of the following cancer, coronary artery disease or heart attack, renal failure or dialysis, hepatitis, Multiple Sclerosis, or any autoimmune disorder.
62837616|NCT02287766||Metabolic Syndrome Diagnosis Group|Men and women ages 21-85 with at least of at least three of the following (as defined in the protocol) : Elevated waist circumference, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, elevated fasting glucose.
62837617|NCT01442103|EXPERIMENTAL|Device, dressing|Normlgel Ag is an opaque, amorphous hydrogel containing a high water content, water soluble polymer chains and an antimicrobial silver compound.
62837618|NCT00087867|EXPERIMENTAL|001|SCIO-469 two 30-mg capsules three times daily
62837619|NCT00087867|OTHER|002|SCIO-469 and bortezomib In addition to SCIO-469 patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1 4 8 and 11 of a 21-day cycle followed by a 10-day rest period
62837620|NCT06514560||Non-allometric dosing|"40 patients who will not use allometric dosing will be included~miltefosine will be given based on weight: 30-45 kg: 100mg miltefosine per day \>45 kg: 150mg miltefosine per day"
62612899|NCT06404944|ACTIVE_COMPARATOR|Implant and guided bone regeneration|The patients received implants and guided bone regeneration
62837621|NCT06514560||allometric dosing (weight below 30 kg)|"40 patients who weigh less than 30kg and therefore get allometric dosing will be recruited.~Dosing is given based on weight, height, and sex, according to Dorlo et al 2012"
62837622|NCT01010646|EXPERIMENTAL|GP1N IFN alfa-2bXL 27 MUI + Ribavirin|IFN alfa-2bXL 27 MUI, powder and solvent for solution injection
62837623|NCT01010646|EXPERIMENTAL|GP2N IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI, powder and solvent for solution injection
62837624|NCT01010646|ACTIVE_COMPARATOR|GP3N IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg,administered once a week for 12 weeks by subcutaneous injections
62837625|NCT05585450|EXPERIMENTAL|Electroacupuncture (EA) group|"Participants in the EA group will receive treatment at bilateral Bladder Meridian (BL) 32 \[Ciliao\], BL33 \[Zhongliao\], BL35 \[Huiyang\], and Spleen Meridian (SP) 6 \[Sanyinjiao\].~BL32, in the second posterior sacral foramen; BL33, in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; SP6, posterior to the medial border of the tibia, 3 cun (≈60mm) superior to the prominence of the medial malleolus.~The treatment will last 30 minutes for each session, 3 sessions per week (ideally every other day) for a succession of 8 weeks."
62053875|NCT04701463|EXPERIMENTAL|L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate supplement|
62053876|NCT04701463|PLACEBO_COMPARATOR|Placebo|
62053877|NCT03895554||Normal volunteers|Normal, healthy volunteers with undergo cardiac PET stress testing.
62837626|NCT05585450|SHAM_COMPARATOR|Sham Electroacupuncture (SA) group|"Participants in the SA group will receive treatment at bilateral sham BL32, BL33, BL35, and SP6.~Sham BL32, in the area of 2 cun (≈40mm) horizontally outside BL32; Sham BL33, in the area of 2 cun (≈40mm) horizontally outside BL33; Sham BL35, 2 cun (≈40mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons.~The treatment will last 30 minutes for each session, 3 sessions per week (ideally every other day) for a succession of 8 weeks."
62837627|NCT06226493|EXPERIMENTAL|TaVNS intervention|Before starting applying taVNS, patients will be assessed using the FMA-U and the mRS for motor recovery as well as the MOCA for cognitive recovery. Resting state EEG will be recorded with eyes open during 15 minutes using our 64 electrodes cap (actiCHamp Plus; brainproducts.com), just after the behavioral assessment is performed. On the same day, patients will receive taVNS for 45 minutes, during therapy. The stimulation parameters, will be as follows: 250ms square pulses at 20 Hz. The electrical stimulation will given for 45 minutes a day for 10 working days (5 days a week for 2 weeks). The amplitude will be 1.7mA but may be reduced to 1.0mA if the patient is unable to tolerate due to discomfort or pain. After the last taVNS session is applied, outcome measures will be administered again by the research team. A follow-up at 6 months after the end of the last session will be conducted over the phone using the adapted version of the mRS and the MOCA.
62837628|NCT02873351|EXPERIMENTAL|carbidopa-levodopa 25-100 mg|Treatment with carbidopa-levodopa 25-100 mg tablets dosed once daily at bedtime for 45 +/- 5 days followed by carbidopa-levodopa 25-100 mg tablets dosed 3 times daily for 45 +/- 5 days.
62837629|NCT02873351|PLACEBO_COMPARATOR|Placebo for carbidopa-levodopa 25-100 mg|Treatment with placebo for carbidopa-levodopa 25-100 mg in identical tablets dosed once daily at bedtime for 45 +/- 5 days followed by placebo for carbidopa-levodopa 25-100 mg tablets dosed 3 times daily for 45 +/- 5 days.
62837630|NCT04336878|EXPERIMENTAL|Healthy Habits in Pregnancy and Beyond intervention|Intervention delivered in early pregnancy during an existing antenatal appointment. 1:1 intervention session (15-20 minutes) with the intervention facilitator (clinician/researcher). Participants provided with a self-guided leaflet for weight management focusing on making 10 simple diet and activity behaviours habitual, including advice on food choice \& purchasing, portion size, eating behaviour \& keeping active. The tips promote habit formation, nutrition awareness, avoidance of behavioural relapse, and reiterate guidance for pregnant women. Participants provided with a record-keeping logbook and access to an 'app' to self-monitor their weight and behaviours against the 10 target behaviours, during pregnancy and up to 6 weeks postpartum.
62255189|NCT03526770|EXPERIMENTAL|Group 5: Polyol containing gum|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
62255190|NCT03526770|EXPERIMENTAL|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention"
62255191|NCT00729482|EXPERIMENTAL|1|Treatment Arm (RAD001)
62255192|NCT01037660|EXPERIMENTAL|Metformin|Metformin
62255193|NCT00376090|EXPERIMENTAL|Group I Vaccine|
62255194|NCT00376090|PLACEBO_COMPARATOR|Group I Placebo|
62255195|NCT00376090|EXPERIMENTAL|Group II Vaccine|
62255196|NCT00376090|PLACEBO_COMPARATOR|Group II Placebo|
62837631|NCT04336878|NO_INTERVENTION|Control group|The control group will receive 'usual' antenatal care which does not involve routinely delivered specific or standardised dietary advice.
62837632|NCT01512238||Pharmaceutical care|
62255197|NCT00376090|EXPERIMENTAL|Group III Vaccine|
62255198|NCT00376090|PLACEBO_COMPARATOR|Group III Placebo|
62255199|NCT00376090|EXPERIMENTAL|Group IV Vaccine|
62837633|NCT01512238||Control|
62837634|NCT00663091|EXPERIMENTAL|Bacteriophages|
62255200|NCT00376090|PLACEBO_COMPARATOR|Group IV Placebo|
62255201|NCT04856930|EXPERIMENTAL|ANB019 Biological Humanized Monoclonal Antibody Low Dose|
62255202|NCT04856930|EXPERIMENTAL|ANB019 Biological Humanized Monoclonal Antibody High Dose|
62255203|NCT04856930|PLACEBO_COMPARATOR|Placebo Solution|
62255204|NCT02197338|EXPERIMENTAL|Short Wire, Small Tome|Short wire system, small sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
62255205|NCT02197338|ACTIVE_COMPARATOR|Short Wire, Standard Tome|Short wire system, standard sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
62255206|NCT02197338|ACTIVE_COMPARATOR|Long Wire, Small Tome|Long wire system, small sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
62255207|NCT02197338|ACTIVE_COMPARATOR|Long Wire, Standard Tome|Long wire system, standard sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
62255208|NCT00636675|EXPERIMENTAL|Fall QI|Falls QI includes quality improvement training about falls to be implement by indigenous nursing home staff with support of study personnel.
62255209|NCT00636675|EXPERIMENTAL|Connect & Falls QI|Connect is delivered, followed by Falls. Behavioral intervention to improve staff interaction for better care planning and execution. Connect will be delivered, followed by the Falls quality improvement intervention.
62255210|NCT01166100|EXPERIMENTAL|Fluoxetine Hydrochloride|Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited
62255211|NCT01166100|ACTIVE_COMPARATOR|Prozac ® weekly TM|Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company
62255212|NCT00542464|PLACEBO_COMPARATOR|Cohort 1|1.0 mg/kg Imprime PGG administered daily over 1 hr for 7 consecutive days
62053878|NCT01048892|EXPERIMENTAL|Treatment (NTX-010)|
62053879|NCT06037460|EXPERIMENTAL|Gradual discontinuation of TCZ|
62837635|NCT03498404|EXPERIMENTAL|Photodynamic Therapy and SRP|"Procedure/Surgery: Photodynamic Therapy After a surgical access, the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). Teeth with furcation lesion will increase over 60 seconds into the lesion. Before the application, the supragingival plaque will be removed.~Treatment with TFDa in the Test Group maintained the protocol of applications in the periods of 2, 7 and 14 days post-surgical intervention."
62053880|NCT06037460|ACTIVE_COMPARATOR|Immediate discontinuation of TCZ|
62053881|NCT01701414|SHAM_COMPARATOR|Standard Care (SC)|The SC group will receive a sham injection of normal saline in order to blind both the participants and the treating physicians. A 7.5-MHz linear transducer will be placed on the side of the affected hip 1cm below the inguinal ligament. 1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice.
62053882|NCT01701414|EXPERIMENTAL|Femoral Nerve Block (FNB)|"Participants randomized to the second group, FNB group, will receive an Ultrasound (US) guided femoral nerve block using a Sonosite TitanTM (Sonosite, Inc., Bothell, WA) with a 7.5-MHz linear array transducer. Using this technique, 25ml of 0.5% bupivacaine will be injected along the nerve sheath. The femoral, obturator, and lateral cutaneous nerve are anesthetized with this technique (thus the name 3-in-1 femoral block is often used), providing maximum analgesia to the hip."
62053883|NCT02313987||A-Usual care- Standard care for NOCAD|"Subjects with non obstructive CAD (20-70% luminal diameter stenosis) and normal Endothelial function as defined by EndoScore.~These subjects will receive the standard care usually provided in each facility for patients with NOCAD"
62837636|NCT03498404|SHAM_COMPARATOR|SRP and Sham Photodynamic Therapy|Procedure/Surgery: Sham Photodynamic Therapy After a surgical access, the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. Before the application, the supragingival plaque will be removed.
62053884|NCT02313987||B1-Usual Care-Standard care for NOCAD|"Subjects with non obstructive CAD (20-70% luminal diameter stenosis ) and abnormal Endothelial function as defined by EndoScore.~These subjects will receive the standard care usually provided in each facility for patients with NOCAD. (Same care as Group A)"
62053885|NCT02313987||B2- Endothelial function guid care|"Subjects with non obstructive CAD and abnormal Endothelial function as defined by EndoScore.~These subjects will receive the an Endothelial Function-guided Therapy."
62053886|NCT06225102|EXPERIMENTAL|experimental group|"The intervention group was first given training on the definition of kegel exercises, diagnostic criteria, treatment, benefits and how to do kegel exercises on the Zoom platform.~A second meeting was held for the participants of the initiative group who could not attend this training.~At the same time, a message was sent to the WhatsApp application group where the intervention group was located three times a day by the researchers to remind them to do kegel exercises in the morning, noon and evening."
62053887|NCT06225102|NO_INTERVENTION|control group|No intervention was made in the control group
62053888|NCT05727722|EXPERIMENTAL|Micro-encapsulated Hepatocyte Intraperitoneal Transplantation Cohort 1|Participants will each be administered the dosage of 0.15×10\^9 for one time, with 60 days follow-up after the cell infusion.
62612900|NCT03271671|ACTIVE_COMPARATOR|PSV|Pressure support ventilation
62612901|NCT03271671|EXPERIMENTAL|NAVA|Neurally adjusted ventilator assist
62837637|NCT05611190|OTHER|Usual Care|Participants randomized to usual care will be evaluated according to institutional standard practice. The investigators will review clinical data and results of the diagnostic tests to recommend a treatment strategy, according to the institution's standard practice.
62837638|NCT05611190|EXPERIMENTAL|CT-FFR|Participants randomized to a CT-FFR strategy will be assigned to non-invasive CT-FFR evaluation. The investigators will review the results CT-FFR, and will recommend a further ICA test if CT-FFR≤0.8. The investigators will review the results of all available diagnostic tests, including CT-FFR and ICA, and will recommend a treatment strategy accordingly.
62837639|NCT04147780||Primary vulvar cancer, tumor ≥ 4cm|"Patients with primary squamous cell vulvar cancer, unifocal tumor ≥ 4cm:~Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy"
62837640|NCT04147780||Primary vulvar cancer, multifocal tumor|"Patients with primary squamous cell vulvar cancer, multifocal tumor:~Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy"
62612902|NCT00422292|EXPERIMENTAL|Menactra® at 9 and 12 Months|Participants will received Menactra® vaccination at 9 and 12 months of age.
62612903|NCT00422292|EXPERIMENTAL|Menactra® at 9 Months and Menactra® + MMRV at 12 Months|Participants will receive Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV) vaccine at 12 months of age
62053889|NCT05727722|EXPERIMENTAL|Micro-encapsulated Hepatocyte Intraperitoneal Transplantation Cohort 2|Participants will each be administered the dosage of 0.5×10\^9 for one time, with 60 days follow-up after the cell infusion.
62053890|NCT05727722|EXPERIMENTAL|Micro-encapsulated Hepatocyte Intraperitoneal Transplantation Cohort 3|Participants will each be administered the dosage of 1.5×10\^9 for one time, with 60 days follow-up after the cell infusion.
62053891|NCT05727722|EXPERIMENTAL|Micro-encapsulated Hepatocyte Intraperitoneal Transplantation Cohort 4|Participants will each be administered the dosage of 4.5×10\^9 for one time, with 60 days follow-up after the cell infusion.
62053892|NCT01078155||Participants with Active Rheumatoid Arthritis (RA)|Participants (women and men) with active early and long-standing RA according to American College of Rheumatology revised criteria from 1987 were prescribed adalimumab in the usual manner in accordance with the terms of the local market authorization with regards to dose, population and indication as well as local guidelines. The decision to prescribe or not to prescribe an anti-TNF was taken prior to a participant's enrollment in the study.
62837641|NCT04147780||Local recurrence after vulvar cancer, no earlier treatment|"Patients with a local recurrence of a primary squamous cell vulvar cancer, earlier without treatment of the groins or solely sentinel node biopsy:~Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy"
62837642|NCT04147780||Local recurrence after vulvar cancer, earlier treatment|"Patients with a local recurrence of a primary squamous cell vulvar cancer, earlier treatment of the groins by lymphadenectomy and / or (chemo-)radiation:~Sentinel node biopsy if detectable, otherwise no groin treatment"
62443357|NCT05943925||Lewy bodies dementia (LBD)|"The criteria for the recruitment will be:~Inclusion criteria: Lewy Body Dementia (LBD) diagnosed by the neurology service; more than 60 years.~Exclusion criteria: Comorbidity with other significant neurology disease, infectious treatment with antibiotics in the previous 6 months prior to providing the stool sample, corticosteroid use, immunosuppressors or immunostimulants treatment, illnesses of the gastrointestinal (GI) tract, large doses of commercial probiotics consumed (greater than or equal to 108 colony forming units (cfu) per organisms per day).~Neuropsychological, functional and neuropsychiatric assessment and stool sample."
62837643|NCT02949284|EXPERIMENTAL|Arm I (androgen receptor ARN-509, radical prostatectomy)|Patients receive androgen receptor antagonist ARN-509 PO daily for 3 months. Patients then undergo radical prostatectomy.
62837644|NCT02949284|ACTIVE_COMPARATOR|Arm II (ARN-509, abiraterone acetate, GnRH, prednisone, RP)|Patients receive GnRH agonist SC on day 1, androgen receptor antagonist ARN-509 PO daily PO for 4 times, abiraterone acetate PO daily for 4 times, and prednisone PO daily for 3 months. Patients then undergo radical prostatectomy.
62837645|NCT02949284|ACTIVE_COMPARATOR|Arm III (radical prostatectomy)|Patients undergo radical prostatectomy.
62837646|NCT02684825|EXPERIMENTAL|Continuous plus standard cardiac monitoring|Continuous cardiac monitoring by Reveal LINQTM- LNQ11 Internal Loop Recorder (ILR) plus standard cardiac monitoring
62443358|NCT05943925||Frontotemporal Dementia (FTD)-behavioral variant|"The criteria for the recruitment will be:~Inclusion criteria: Frontotemporal Dementia (FTD)-behavioral variant diagnosed by the neurology service; more than 60 years.~Exclusion criteria: Comorbidity with other significant neurology disease, infectious treatment with antibiotics in the previous 6 months prior to providing the stool sample, corticosteroid use, immunosuppressors or immunostimulants treatment, illnesses of the gastrointestinal (GI) tract, large doses of commercial probiotics consumed (greater than or equal to 108 colony forming units (cfu) per organisms per day).~Neuropsychological, functional and neuropsychiatric assessment and stool sample."
62443359|NCT05943925||Alzheimer disease (AD)-control|"Inclusion criteria: Alzheimer Disease (AD) diagnosed by the neurology service; more than 65 years. Exclusion criteria: Comorbidity with other significant neurology disease, infectious treatment with antibiotics in the previous 6 months prior to providing the stool sample, corticosteroid use, immunosuppressors or immunostimulants treatment, illnesses of the gastrointestinal (GI) tract, large doses of commercial probiotics consumed (greater than or equal to 108 colony forming units (cfu) per organisms per day).~Neuropsychological, functional and neuropsychiatric assessment and stool sample at basal, 12 weeks and 24 weeks."
62443360|NCT05943925||Alzheimer disease (AD)-probiotic|"Inclusion criteria: Alzheimer Disease (AD) diagnosed by the neurology service; more than 65 years. Exclusion criteria: Comorbidity with other significant neurology disease, infectious treatment with antibiotics in the previous 6 months prior to providing the stool sample, corticosteroid use, immunosuppressors or immunostimulants treatment, illnesses of the gastrointestinal (GI) tract, large doses of commercial probiotics consumed (greater than or equal to 108 colony forming units (cfu) per organisms per day).~Neuropsychological, functional and neuropsychiatric assessment and stool sample at basal, 12 weeks and 24 weeks."
62443361|NCT05892757|EXPERIMENTAL|Atogepant|Participants will receive single dose of atogepant on Day 1.
62443362|NCT05892757|ACTIVE_COMPARATOR|Ubrogepant|Participants will receive single dose of ubrogepant on Day 1.
62443363|NCT01533857|EXPERIMENTAL|Black tea|black tea
62837647|NCT02684825|NO_INTERVENTION|Standard cardiac monitoring|Routine cardiac monitoring with follow-up at the same frequency, but with no Implantable Loop Recorder
62837648|NCT04601649|EXPERIMENTAL|Intervention|Participants will take part in the PrEP Talk intervention sessions.
62053893|NCT04285658||Ureteroscopy|
62443364|NCT01533857|PLACEBO_COMPARATOR|placebo|
62837649|NCT04601649|NO_INTERVENTION|Control|Participants will receive standard care.
62053894|NCT04285658||Percutaneous Nephrolithotomy|
62053895|NCT04285658||Shock Wave Lithotripsy|
62255213|NCT00542464|PLACEBO_COMPARATOR|Cohort 2|2.0 mg/kg Imprime PGG administered daily over 1 hr for 7 consecutive days
62837650|NCT03549767|EXPERIMENTAL|Springfusor|Women in this group will have their loading dose (4 gm of 50% Magnesium sulphate in 10 ml syringe administered over 20 minutes) and maintenance therapy (4 gm of 50% Magnesium sulphate in 10 ml syringe administered over 4 hours through an IV infusion administered using a Springfusor pump.. The 4 gm maintenance dose will be repeated every 4 hours for 24 hours.
62053896|NCT04109014|OTHER|FASTLANE II Group|Participants will participate in the FASTLANE II Intervention. Counseling sessions will focus on: 1) depressive symptoms, 2) methamphetamine use, and 3) sexual risk behaviors. Three sessions will be devoted to each topic area. Trained staff will use a client-centered approach and develop a goal for each area alongside the participant. Counseling sessions will remain confidential and will not be audio recorded.
62612904|NCT00422292|EXPERIMENTAL|Menactra® at 9 Months and Menactra® + PCV at 12 Months|Participants will receive Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age
62612905|NCT00422292|ACTIVE_COMPARATOR|MMRV + PCV at 12 Months|Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age
62612906|NCT04812405|OTHER|Teeth|Occlusal examination
62837651|NCT03549767|ACTIVE_COMPARATOR|Standard of care|The control group will have Magnesium sulphate administered using the Pritchard regimen, which involves administration of loading dose of 4 gm of 20% Magnesium sulphate IV over 15-20 minutes, immediately followed by 10 gm of 50% Magnesium sulphate IM (5gm on each buttock). The maintenance dose of 5 gm of 50% Magnesium sulphate IM every 4 hourly in alternate buttocks continued for 24 hours
62837652|NCT03725891|ACTIVE_COMPARATOR|Aspirin 162 mg|Aspirin 81mg tow tablet once a day from recruitment until 37 weeks or labor whichever comes first
62837653|NCT03725891|ACTIVE_COMPARATOR|Aspirin 81 mg plus placebo|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first plus placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
62837654|NCT03811704|EXPERIMENTAL|Experimental group|Hepatectomy procedures were performed under Laparoscopic surgical navigation system and Indocyanine Green guidance.
62837655|NCT01290770||obese men|obese men with chest pain like angina
62837656|NCT02840461|EXPERIMENTAL|Ivermectin Cream, 1%|test product, manufactured by Actavis Laboratories UT, Inc.
62837657|NCT02840461|ACTIVE_COMPARATOR|SoolantraTM (ivermectin) Cream, 1%|reference product, manufactured by Galderma Laboratories, L.P.
62053897|NCT04176939|EXPERIMENTAL|HZ/su Group|"Eligible adult participants with renal transplant taking daily chronic immunosuppressive therapy who had a complete 2-dose Herpes Zoster (HZ/su) vaccination course in the primary ZOSTER-041 (NCT02058589) study.~47 of these participants further received 1 or 2 additional doses of HZ/su vaccine in the revaccination phase of the current ZOSTER-073 (NCT04176939) study, first dose at Month 24 and second dose at Month 25."
62053898|NCT01906671|EXPERIMENTAL|Puri-Nethol|Tablet formulation of 6-mercaptopurine
62053899|NCT01906671|EXPERIMENTAL|Xaluprine|Oral liquid formulation of 6-mercaptopurine
62053900|NCT02626832|EXPERIMENTAL|Healthy Control|This group is represented by healthy controls
62053901|NCT02626832|EXPERIMENTAL|Depression|This experimental group is represented by subjects with depression
62053902|NCT02626832|EXPERIMENTAL|Schizophrenia|This experimental group is represented by subjects with schizophrenia
62443365|NCT00672828|ACTIVE_COMPARATOR|Non-tailored CRC screening brochure|Participants undergo a baseline interview via telephone and receive a non-tailored CRC screening brochure in the clinic prior to visit with healthcare provider. Participants then undergo telephone interviews at 1 week, 6 months, and 15 months.
62612907|NCT03295175||Congenital Megaprepuce|Congenital Megaprepuce Hematoxylin-eosin and smooth muscle actin markers
62837658|NCT02840461|PLACEBO_COMPARATOR|Placebo/Vehicle cream|Placebo, manufactured by Actavis Laboratories UT, Inc.
62837659|NCT02079961|EXPERIMENTAL|Micronutrient-fortified yoghurt|"Micronutrient-fortified yoghurt + BCC~All eligible children within the intervention arm will receive one fortified yoghurt per day, every day of the week, if the household satisfied to the contract of reliability in milk supply during the previous week, during the one year duration of the intervention."
62612908|NCT03295175||Hypospadias|Hypospadias Hematoxylin-eosin and smooth muscle actin markers
62612909|NCT03295175||Control|Circumcision for non-medical reasons. Hematoxylin-eosin and smooth muscle actin markers
62612910|NCT03307122|ACTIVE_COMPARATOR|Routine Infant Formula 1|Routine infant formula with probiotic
62612911|NCT03307122|ACTIVE_COMPARATOR|Routine Infant Formula 2|Routine infant formula with probiotic and prebiotic
62837660|NCT02079961|ACTIVE_COMPARATOR|Control|"BCC~Children will not receive fortified yoghurt during the duration of the intervention"
62837661|NCT03384862|EXPERIMENTAL|Nutritional Intervention Arm|5 μg vitamin B12 plus 400 μg folic acid
62837662|NCT03384862|PLACEBO_COMPARATOR|Control Arm|Placebo
62837663|NCT03949803|EXPERIMENTAL|Morning Chocolate|Test the if Chocolate Timing in the morning changes the metabolism
62837664|NCT03949803|EXPERIMENTAL|Evening Chocolate|Test the if Chocolate Timing before bedtime changes the metabolism
62837665|NCT03949803|EXPERIMENTAL|No Chocolate (Control)|Test the if no Chocolate Timing may affect the metabolism
62837666|NCT05433519||Pregnant Women|Pregnant women with gestational age established at less than 14 weeks of gestation
62837667|NCT04085289|EXPERIMENTAL|Galcanezumab|Participants received single subcutaneous (SC) doses of 120 milligram (mg) or 240 mg Galcanezumab.
62837668|NCT04085289|PLACEBO_COMPARATOR|Placebo|Participants received a single SC dose of Placebo.
62612912|NCT03669484|EXPERIMENTAL|Remimazolam|"The induction of anesthesia: intravenous infusion of 6 mg/kg/h until registration of loss of consciousness.~Maintenance of anesthesia: Remimazolam intravenous infusion initiated at a dose of 1 mg/kg/h; the dose level was adjusted accordingly based on a systemic patient monitoring until the end of operation to 2 mg/kg/h maximum; In case of loss of consciousness was not registered in 2.5 minutes of continuous intravenous infusion: drug administration was terminated. If loss of consciousness was not registered during 30 seconds, other sedative drugs were used for induction and maintenance of anesthesia.~In case of signs of awakening (fluctuation of blood pressure/heart rate, lacrimation, sweating, etc.) were observed: intravenous bolus infusion (maximum level of 12 mg/kg/h for 1 minute). If signs of awakening remained remimazolam administration was discontinued and other sedatives were used."
62837669|NCT03370900|NO_INTERVENTION|Learning and Assessment at 12 months|Study participants will complete an 80 case learning set followed by a 20-case post test. The study intervention in this group is a 20-case test at 12 months.
62837670|NCT03370900|EXPERIMENTAL|Testing Every Two Months|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests without any feedback at 2, 4, 6, 8, 10, 12 months.
62053903|NCT02626832|EXPERIMENTAL|Prodromal subjects|This experimental group is represented by subjects with prodromal symptoms for schizophrenia
62612913|NCT03669484|ACTIVE_COMPARATOR|Propofol|"The induction of anesthesia: intravenous infusion of 1.5-2.5 mg/kg for about 1 minute.~Maintenance of anesthesia: intravenous infusion for a total dose of 4-12 mg/kg/h; the dose level was adjusted accordingly based on a systemic patient monitoring until the end of operation.~In case of loss of consciousness was not registered other sedative drugs were used for induction and maintenance of anesthesia.~In case of signs of awakening (fluctuation of blood pressure/heart rate, lacrimation, sweating, etc.) were observed and propofol dose adjustment had not resulted in the desired effect and signs of awakening were saved: the use of propofol was discontinued and other sedatives were used."
62053904|NCT01591382|ACTIVE_COMPARATOR|Ketamine|Participants received postoperative hydromorphone patient-controlled analgesia (PCA) and continuous ketamine (0.2 mg/kg/hour). Ketamine is being compared to the use of placebo, in addition to intravenous opioids, for postop pain control in opioid dependent patients who undergo major surgery.
62053905|NCT01591382|PLACEBO_COMPARATOR|Placebo|Participants received postoperative hydromorphone PCA and continuous ketamine-matching placebo (infusion of saline).
62443366|NCT00672828|EXPERIMENTAL|Interactive computer intervention|Participants undergo a baseline interview via telephone and complete an interactive computer intervention in the clinic prior to visit with healthcare provider. Participants then undergo telephone interviews at 1 week, 6 months, and 15 months.
62443367|NCT00522288|EXPERIMENTAL|Contact Lens|Soft contact lenses
62443368|NCT00522288|ACTIVE_COMPARATOR|Spectacle|Spectacles
62443369|NCT01371513||PSA level|more than 2.5ng/ml
62837671|NCT03370900|EXPERIMENTAL|Low Bolus Feedback|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests at 2, 4, 6, 8, 10, 12 months. At 6 months, the 20-case post-test will be delivered with feedback.
62837672|NCT03370900|EXPERIMENTAL|High Bolus Feedback|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests at 2, 4, 6, 8, 10, 12 months. At 4, 8, and 12 months, the 20-case post-test will be delivered with feedback.
62053906|NCT01030445||Elevated Mean Arterial Blood Pressure|Mean arterial pressure greater than 1 standard deviation above the mean based on age
62053907|NCT01030445||Decrease Mean Arterial Blood Pressure|Mean arterial pressure greater than 1 standard deviation below the mean based on age
62053908|NCT01030445||Normal Mean Arterial Blood Pressure|Mean arterial pressure within the standard deviation of the mean based on age
62255214|NCT00542464|PLACEBO_COMPARATOR|Cohort 3|4.0 mg/kg Imprime PGG administered daily over 2 hr for 7 consecutive days
62612914|NCT06233877|EXPERIMENTAL|G-GLIP plus Mitomycin C|G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin every 2 weeks plus Mitomycin C every 4 weeks
62612915|NCT06731374|EXPERIMENTAL|PCV-15 Vaccination|One dose (0.5 ml) of PCV-15 is to be given Intramuscularly (IM) into the deltoid region of the arm at day 0.
62612916|NCT06731374|PLACEBO_COMPARATOR|Placebo|0.9% saline is to be given Intramuscularly (IM) into the deltoid region of the arm at day 0.
62612917|NCT01242501|EXPERIMENTAL|60 Min. Risk Reduction Counseling|Single 60 min Social Cognitive Theory-based counseling session delivered in STI clinic setting in Cape Town South Africa. Includes educational, motivational, and sexual risk reduction skills components delivered in a single face-to-face counseling session.
62612918|NCT01242501|ACTIVE_COMPARATOR|20-min single session education|Single brief HIV/STI education only session for men and women receiving sexually transmitted infection clinic services in South Africa. Includes only brief educational information on sexual risks for HIV infection in a single face-to-face counseling session.
62612919|NCT04148859|EXPERIMENTAL|pregnant women|women who have to undergo amnioreduction due to TTTS
62612920|NCT03588013|EXPERIMENTAL|Moderate/severe malnourishment|Pakistani children from age 0 to 6 months with weight for height Z score (WHZ) \< -2 at the time of enrollment. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth. Those participants who remain WHZ \< -2 despite interventions are eligible for medical evaluation for more advanced workup of malnutrition, including UGI endoscopy and biopsy.
62612921|NCT03588013|ACTIVE_COMPARATOR|Well nourished children|Pakistani children from age 0 to 6 months who would be growing normally, with WHZ \> 0, to serve as controls. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth.
62612922|NCT03588013|NO_INTERVENTION|US children with celiac disease|Comparative group for the Pakistani WHZ \<-2 children who undergo UGI endoscopy and biopsy. Environmental Enteropathy and celiac disease have some shared features therefore we plan to enroll children under the age of 6 years with newly diagnosed celiac disease per endoscopy at CCHMC to assess the extent to which gene signatures and associated biologic pathways for children with celiac disease or environmental enteropathy overlap or differ.
62612923|NCT03588013|NO_INTERVENTION|US children with Crohn's disease|Comparative group for the Pakistani WHZ \<-2 children who undergo UGI endoscopy and biopsy. As some differentially expressed ileal gene signatures for Crohn's disease bear remarkable similarities to individual gene expression patterns previously reported for EE, children under the age of 10 years with newly diagnosed Crohn's disease per endoscopy at CCHMC will be enrolled to study these similarities and any differences
62612924|NCT03588013|NO_INTERVENTION|Healthy age-matched US children|Comparative group for the Pakistani WHZ \<-2 children who undergo UGI endoscopy and biopsy. Number of upper gastrointestinal endoscopies performed in children less than 2 years old are limited in Pakistan, therefore US age-matched controls will be used; healthy children \< 3 years old will be enrolled, who will undergo endoscopy at CCHMC as part of a diagnostic workup for digestive symptoms, but whose biopsies and diagnoses are not supportive of eosinophilic esophagitis, celiac disease, or inflammatory bowel disease, and who were not treated with antibiotics ≤ 4 weeks prior to endoscopy.
62837673|NCT02503761|ACTIVE_COMPARATOR|Infusion arm|Infants will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection. Each dose will be infused over four hours.
62053909|NCT04581525|EXPERIMENTAL|tDCS of DLPFC|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to the left dorsolateral prefrontal cortex (DLPFC). Subjects will undergo stimulation once a day for 10 consecutive weekdays.
62443370|NCT00031421||1|16 received ganciclovir at 8 mg/kg/day in the previous study.
62053910|NCT04581525|EXPERIMENTAL|tDCS of M1|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to the left primary motor cortex (M1). Subjects will undergo stimulation once a day for 10 consecutive weekdays.
62443371|NCT00031421||2|31 received ganciclovir at 12 mg/kg/day in the previous study.
62053911|NCT04581525|SHAM_COMPARATOR|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation. Subjects will undergo stimulation once a day for 10 consecutive weekdays.
62053912|NCT05015816|EXPERIMENTAL|Group A: Time series|Individuals at high risk of developing melanoma will be invited to attend for sequential TBP imaging, full body skin examination by a Dermatologist and completion of a case report form (CRF) every three months for two years. At the end of the study participants will also be invited to complete a feasibility questionnaire
62443372|NCT05725590|EXPERIMENTAL|external pancreatic duct stent|
62443373|NCT05725590|EXPERIMENTAL|internal pancreatic duct stent|
62443374|NCT01377363||Not treatment|Locally recurrent breast carcinoma or metastatic
62443375|NCT02478060|EXPERIMENTAL|Cohort 1|Birch-SPIRE or placebo, 2 weeks apart
62443376|NCT02478060|EXPERIMENTAL|Cohort 2|Birch-SPIRE or placebo, 2 weeks apart
62443377|NCT02478060|EXPERIMENTAL|Cohort 3|Birch-SPIRE or placebo, 2 weeks apart
62443378|NCT02478060|EXPERIMENTAL|Cohort 4|Birch-SPIRE or placebo, 2 weeks apart
62443379|NCT02478060|EXPERIMENTAL|Cohort 5|Birch-SPIRE or placebo, 2 weeks apart
62443380|NCT01472588|EXPERIMENTAL|Community Health Coach|DPP behavioral lifestyle intervention delivered by Community Health Coach (CHWs)
62443381|NCT01472588|EXPERIMENTAL|Public Health Coach|DPP behavioral lifestyle intervention delivered by health professionals (PHCs)
62443382|NCT01472588|OTHER|Self Help|Booklet, Aim for a Healthy Weight (DHHS, NIH-NHLBI) provided.
62612925|NCT02084914|EXPERIMENTAL|Group A|Endometrial scraching of uterine cavity by pipelle .
62612926|NCT02084914|ACTIVE_COMPARATOR|Group B|Uterine sound intoduced into uterine cavity without scratch .
62612927|NCT04565821|EXPERIMENTAL|Feasibility of trans-nasal IPD probe|The purpose of this study is to examine the feasibility of using a trans-nasal IPD probe as a measurement tool for gut permeability
62612928|NCT03081091|ACTIVE_COMPARATOR|Intervention group (A) Acupuncture|The treatments performed will be personalized and the treatment criteria will be based on the use of the Yuan and Luo points. In clinical practice, the Yuan (source) points and the Luo (connecting) points can be used jointly, linking the two associated meridians (external-internal) in such a way that, after assessing the state of a meridian's path, its Yuan point will be combined with the Luo point of its coupled meridian and vice versa; all this depending on the condition of the muscle fibres and on the path that wants to be treated for these.
62837674|NCT02503761|ACTIVE_COMPARATOR|Bolus group|Infants will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection. Each dose will be infused over thirty minutes.
62053913|NCT05015816|NO_INTERVENTION|Group B: Baseline cohort|All patients who undergo standard care and are selected for total body photography (TBP) imaging will be invited to consent to this group. Any individuals who have had previous TBP imaging will also be eligible to enter Group B of this study. A baseline CRF will be completed and a participant feasibility questionnaire. There will be no additional images taken for the purposes of the study and no additional clinic visits in relation to this part of the study. However, individuals who consent to Group B will also agree to share any future TBP images taken in the department over the next two years so that any sequential images can also be included in the analysis
62612929|NCT03081091|SHAM_COMPARATOR|Control group (C) Sham Acupuncture:|"The course of action with the patient from the group that will use sham acupuncture will be the same as in the group that receives real treatment: patient in supine position, cleaning of the treated area, use of eye mask during the treatments and selection of points following the previously described Yuan and Luo points' criteria, based on traditional Chinese medicine.~The difference of sham acupuncture will lie on the way of performing the acupuncture technique. It will follow the validated technique of sham acupuncture with the Park device, without needle penetration in the patient's body."
62053914|NCT05369715|EXPERIMENTAL|Morning|60 minutes cycling on cycle ergometer in the morning (11:30). Steady-state test at an intensity of 65% of participant's heart rate reserve.
62443383|NCT02140164|EXPERIMENTAL|Minocycline|Oral administration of minocycline
62612930|NCT04842799|EXPERIMENTAL|Digital delivery of genetic pre-test information|Half of participants will be provided with genetic pre-test information via the BRCA-DIRECT digital platform.
62837675|NCT05173753|ACTIVE_COMPARATOR|Novel self-adhesive composite restoration (Surefil one)|
62837676|NCT05173753|ACTIVE_COMPARATOR|conventional composite resin restoration(VOCO Grandio)|
62837677|NCT02945488|EXPERIMENTAL|Exercise and dietary plan|Combination cardiovascular and resistance training and Mediterranean dietary plan
62053915|NCT05369715|EXPERIMENTAL|Evening|60 minutes cycling on cycle ergometer in the evening (18:30). Steady-state test at an intensity of 65% of participant's heart rate reserve.
62053916|NCT00314925|EXPERIMENTAL|1|
62443384|NCT01602614||Group 1|≤ 27 weeks 6 days gestational age at birth and ≤ 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
62443385|NCT01602614||Group 2|≤ 27 weeks 6 days gestational age at birth and \> 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
62837678|NCT02945488|EXPERIMENTAL|Exercise and no dietary plan|Combination cardiovascular and resistance training and participants regular diet (control diet)
62837679|NCT02945488|EXPERIMENTAL|Stretching and dietary plan|Flexibility training (control exercise) and Mediterranean dietary plan
62837680|NCT02945488|ACTIVE_COMPARATOR|Stretching and no dietary plan|Flexibility training (control exercise) and participants regular diet (control diet)
62837681|NCT01834911|EXPERIMENTAL|Tetrabenazine withdrawal|Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently taking the medication.
62837682|NCT04563143|OTHER|Novel stimulation|All subjects will undergo periods of stimulation using novel stimulation patterns
62837683|NCT05394155|EXPERIMENTAL|Leucine intake|For this study, each participant will be randomly assigned to receive up to 7 intake levels of leucine, ranging from 10 to 75 mg/kg/d.
62837684|NCT04306341|EXPERIMENTAL|Experimental|Neurofeedback in conjunction with Dialectical Behavior Therapy
62837685|NCT04306341|NO_INTERVENTION|Control|Dialectical Behavior Therapy (treatment as usual)
62837686|NCT04530084|EXPERIMENTAL|Diagnosed with open angle glaucoma|
62053917|NCT03468959||Mother-child pairs|Families were recruited from lists of children receiving autism services obtained via the California Department of Developmental Services (DDS), from other studies at the Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, or by self-referrals. The inclusion criteria were: a) mother or father had a biological child with ASD, and the mother was b) at least 18 years old; c) pregnant or planning a pregnancy, and biologically able to become pregnant; d) living within 2 hours of the MIND Institute; e) sufficiently fluent in English.
62053918|NCT06398483|ACTIVE_COMPARATOR|Group A|Group A : acute bony mallet finger managed by micro plate fixation
62053919|NCT06398483|ACTIVE_COMPARATOR|Group B|Group B : Acute bony mallet finger managed by blocking k.wire fixation
62053920|NCT01132625|EXPERIMENTAL|AUY922|
62255215|NCT01979536|EXPERIMENTAL|Arm BV (brentuximab vedotin, combination chemotherapy)|"COURSE A (CYCLES 1, 3, AND 5): Patients receive brentuximab vedotin IV over 30 minutes on day 1, dexamethasone PO BID or IV on days 1-5, ifosfamide IV over 60 minutes on days 1-5, methotrexate IV over 3 hours on day 1, cytarabine IV over 1-30 minutes every 12 hours for 4 doses on days 4 and 5, and etoposide IV over 2 hours on days 4 and 5.~COURSE B (CYCLES 2, 4, AND 6): Patients receive brentuximab vedotin, dexamethasone, and methotrexate as in Arm BV, Course A. Patients also receive cyclophosphamide IV over 15-30 minutes on days 1-5 and doxorubicin hydrochloride IV over 1-15 minutes on days 4 and 5."
62255216|NCT01979536|EXPERIMENTAL|Arm CZ (crizotinib, combination chemotherapy)|"COURSE A (CYCLES 1, 3, AND 5): Patients receive crizotinib PO BID on days 1-21 and dexamethasone, ifosfamide, methotrexate, cytarabine, and etoposide as in Arm BV, Course A.~COURSE B (CYCLES 2, 4, AND 6): Patients receive crizotinib PO BID as in Arm CZ, Course A and dexamethasone, cyclophosphamide, methotrexate, and doxorubicin hydrochloride as in Arm BV, Course B."
62443386|NCT01602614||Group 3|≥ 28 weeks 0 days gestational age at birth and ≤ 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
62837687|NCT03326336|OTHER|Cohort|3 dose escalation cohorts (low, medium and high dose) with 3 subjects per cohort followed by an extension cohort at the highest-well tolerated dose with 3 to 9 subjects.
62443387|NCT01602614||Group 4|≥ 28 weeks 0 days gestational age at birth and \> 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
62443388|NCT05336279|EXPERIMENTAL|Treatment group TR|T - R
62443389|NCT05336279|EXPERIMENTAL|Treatment group RT|R -T
62443390|NCT00288171|EXPERIMENTAL|Allopurinal|Hypertensive renal transplant recipients with elevated uric acid will the treated with allopurinol and placebo in an randomized cross over fashion. Subjects will serve as their own controls.
62053921|NCT03949790|ACTIVE_COMPARATOR|Intercostal block with ESPB|Performed ESPB in VATs with intercostal nerve block
62837688|NCT02955849|EXPERIMENTAL|SLT laser group|"1. selective laser trabeculoplasty for 360 degrees the study eye.~2. Patients having 1 or 2 quadrants of angle with trabecular meshwork not visible will undergo Laser peripheral iridotomy prior to selective laser trabeculoplasty to maximize the amount of angle visible;~3. Cataract surgery will be offered if indicated and completed within 3 months of selective laser trabeculoplasty , if accepted by the patient.~4. Patients will be re-examined every 4 months and selective laser trabeculoplasty performed again according to the above protocol if intraocular pressure exceeds the target (25% reduction from the original intraocular pressure or \< 21 mmHg, whichever is lower)."
62837689|NCT02955849|NO_INTERVENTION|Standard care group|"* Trabeculectomy as usually performed by the operative surgeon in one eye (study eye).~* Both Mitomycin and releasable sutures are permitted if indicated in the opinion of the surgeon and s/he can perform and/or has access.~* Simultaneous cataract surgery is permitted if indicated in the opinion of the operating surgeon.~* Patients will be re-examined every 4 months， and Timolol 0.5% added bid if intraocular pressure exceeds the target (25% reduction from the original intraocular pressure or \< 21 mmHg, whichever is lower)"
62837690|NCT02955849|NO_INTERVENTION|Drug treatment group|Patients not accepting the offered treatment for the study eye within 3 months will receive topical Timolol 0.5% bid at the usual price, with the prescription to be refilled per usual practice at the hospital (usually monthly).
62837691|NCT02586740||Pulmonary artery rehabilitation|Patients with pulmonary artery stenosis or small pulmonary arteries following surgical repair for tetralogy of Fallot with pulmonary atresia and major aortopulmonary collaterals undergoing cardiac catheterization.
62837692|NCT02675634|EXPERIMENTAL|Test A, Test B, Subjects own product|The subjects first test Coloplast Test A, followed by Coloplast Test B and finally Subjects own product
62053922|NCT03949790|ACTIVE_COMPARATOR|Intercostal block without ESPB|Not Performed ESPB in VATs with intercostal nerve block
62053923|NCT03871088|ACTIVE_COMPARATOR|Eicosapentaenoic acid (EPA)|Eicosapentaenoic acid (EPA) is an omega-3 fatty acid. In physiological literature, it is given the name 20:5(n-3).
62053924|NCT03871088|EXPERIMENTAL|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA) is an omega-3 fatty acid. In physiological literature, it is given the name 22:6(n-3).
62053925|NCT03871088|ACTIVE_COMPARATOR|EPA/DHA combination|EPA/DHA means the combination of omega-3 fatty acids Eicosapentaenoic and Docosahexaenoic acids.
62053926|NCT00331344|EXPERIMENTAL|Treatment (combination chemotherapy)|Patients receive mitoxantrone hydrochloride IV over 30 minutes and ixabepilone IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
62053927|NCT02754102|EXPERIMENTAL|Sunscreen Spray-Liquid|All subjects are patched with the same product
62053928|NCT00991341|ACTIVE_COMPARATOR|Shorter-storage red blood cell units|Red blood cell units stored \<= 10 days
62255217|NCT06348485||NPC received Curative radiotherapy|
62255218|NCT02430142||Vasoocclusive testing in sepsis|Septic patients defined according to the Surviving Sepsis Campaign (SSC)
62443391|NCT00288171|PLACEBO_COMPARATOR|Placebo|
62443392|NCT01451905|ACTIVE_COMPARATOR|Psoriasis|
62443393|NCT01451905|PLACEBO_COMPARATOR|Placebo|
62443394|NCT01729702|OTHER|single group - consecutive patients|
62443395|NCT01839084|EXPERIMENTAL|Xenon|Gaseous anesthetic, dosage: 60% (v/v) in 40% oxygen, continuous application during surgery
62837693|NCT02675634|EXPERIMENTAL|Test A, Subjects own product, Test B|The subjects first test Coloplast Test A, followed by Subjects own product, and finally Coloplast Test B
62837694|NCT02675634|EXPERIMENTAL|Test B, Test A, Subjects own product|The subjects first test Coloplast Test B, followed by Coloplast Test A and finally Subjects own product
62837695|NCT02675634|EXPERIMENTAL|Test B, Subjects own product, Test A|The subjects first test Coloplast Test B, followed by Subjects own product, and finally Coloplast Test A
62053929|NCT00991341|ACTIVE_COMPARATOR|Longer-storage red blood cell units|Red blood cell units stored \>= 21 days
62053930|NCT03467932|ACTIVE_COMPARATOR|Cohort A: ORMD-0801 once daily - QHS|Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
62053931|NCT03467932|ACTIVE_COMPARATOR|Cohort A: ORMD-0801 twice daily - BID|Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
62255219|NCT02430142||Vasoocclusive testing in severe sepsis|Severe septic patients defined according to the Surviving Sepsis Campaign (SSC)
62255220|NCT02430142||Vasoocclusive testing in sepsic shock|Septic shock patients defined according to the Surviving Sepsis Campaign (SSC)
62255221|NCT05038462|ACTIVE_COMPARATOR|Maternal supplementation with Lactoferrin and DHA|The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily
62255222|NCT05038462|PLACEBO_COMPARATOR|Placebo|Product with the same physical appearance and taste as the main intervention but without therapeutic effect
62443396|NCT01839084|ACTIVE_COMPARATOR|Isoflurane|Inhalative anesthetic, dosage: 1.2% (v/v) in 40% oxygen/medical air , continuous application during surgery
62053932|NCT03467932|ACTIVE_COMPARATOR|Cohort A: ORMD-0801 three times daily - TID|ORMD-0801 three times daily - TID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.
62053933|NCT03467932|PLACEBO_COMPARATOR|Cohort A: Matched Placebo Oral Capsule|Placebo matched to one of the three active comparator arms. (either QHS, BID, or TID)
62053934|NCT03467932|PLACEBO_COMPARATOR|Cohort A: Excipient-Matched Placebo three times daily-TID|"Excipient matched placebo in a non-randomized single-blind fashion, TID, dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.~This is an exploratory arm, per FDA. The results of this arm are not included in the primary analysis."
62443397|NCT04767269|EXPERIMENTAL|cuminum cyminum mouthwash|cuminum cyminum mouthwash in chronic gingivitis patients
62443398|NCT04767269|ACTIVE_COMPARATOR|herbal mouthwash|herbal mouthwash in chronic gingivitis patients
62443399|NCT01409356|EXPERIMENTAL|Diet+Exercise|Program of weight loss through diet+exercise (=intervention)
62443400|NCT05684926|EXPERIMENTAL|Experimental Group|The intervention group is a group of asthmatic children aged 6-11 years, determined by randomization. Yoga asana includes pranayama and concentration. It will be held 3 days a week for 12 weeks.
62443401|NCT05684926|NO_INTERVENTION|Control Group|The control group is a group of asthmatic children aged 6-11 years, determined by randomization method. He will be put on the waiting list and after the second evaluation, yoga exercises will be done for 8 weeks.
62612931|NCT04842799|NO_INTERVENTION|Genetic counselling telephone appointment to discuss genetic pre-test information|Half of participants will be provided with genetic pre-test information via the normal standard pathway - a telephone consultation with a Genetic Counsellor.
62053935|NCT03467932|ACTIVE_COMPARATOR|Cohort B:ORMD-0801, 8 mg once daily - QHS:|ORMD-0801 8 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
62053936|NCT03467932|ACTIVE_COMPARATOR|Cohort B: ORMD-0801 8 mg twice daily - BID|ORMD-0801 8 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
62255223|NCT04086004|EXPERIMENTAL|Group I Experimental Motor Imagery|Motor imagery practice
62255224|NCT04086004|EXPERIMENTAL|Group II Dual Task Training|Dual-task balance training
62255225|NCT06011343|PLACEBO_COMPARATOR|Placebo and Sbv|Eleven CL patients will receive meglumine antimoniate by EV route at 20mg/kg/day, for 20 days.
62255226|NCT06011343|EXPERIMENTAL|Tofacitinib and Sbv|Eleven CL patients will receive oral tofatinib (10mg daily for 30 days) associated to meglumine antimoniate by EV route at 20mg/kg/day, for 20 days.
62255227|NCT00825279|ACTIVE_COMPARATOR|1-BMS|Bare Metal Stent (Euca STS Flex)
62255228|NCT00825279|EXPERIMENTAL|2-DES|Drug Eluting Stent (Euca STS Flex DE), Paclitaxel Eluting stent with biodegradable polymer
62255229|NCT05310643|EXPERIMENTAL|Treatment phase|"Induction therapy:~* nivolumab 240 mg~* ipilimumab 1 mg/kg~every 3 weeks for 4 dosing cycles (4 infusions of nivolumab and ipilimumab).~Maintenance therapy:~- nivolumab 480 mg~every 4 weeks (21 infusions)."
62612932|NCT04842799|EXPERIMENTAL|Digital delivery of BRCA-gene testing results|97.5% of participant's with a negative (normal) result will receive their BRCA-gene testing result via the BRCA-DIRECT digital platform.
62612933|NCT04842799|NO_INTERVENTION|Genetic counselling telephone appointment to discuss BRCA-gene testing results|2.5% of participants with a negative (normal) result and those with positive results will receive their BRCA-gene testing result via the normal standard pathway - a telephone consultation with a Genetic Counsellor.
62255230|NCT03198520|OTHER|Polymer Removable Partial Denture|Evaluate the change in patient Oral Health-related Quality of Life while wearing the Solvay Dental 360™ polymer Removable Partial Denture (RPD)
62612934|NCT02791646|EXPERIMENTAL|PCST-Full|PCST-full will consist of a 5-session intervention delivered to participants at the medical center by their therapist.
62255231|NCT04973982|ACTIVE_COMPARATOR|ENVARSUS|ENVARSUS used as per licence
62837696|NCT02675634|EXPERIMENTAL|Subjects own product, Test A, Test B|The subjects first test Subjects own product, followed by Test A, and finally Coloplast Test B
62837697|NCT02675634|EXPERIMENTAL|Subjects own product, Test B, Test A|The subjects first test Subjects own product, followed by Test B, and finally Coloplast Test A
62255232|NCT04973982|ACTIVE_COMPARATOR|ADOPORT|ADOPTION used as per licence
62612935|NCT02791646|EXPERIMENTAL|PCST-Brief|Pain coping skills training brief (PCST-Brief) will consist of a 60 minute, in-person session followed by 4-weeks of daily text messaging
62612936|NCT01665677|EXPERIMENTAL|Atorvastatin calcium (Lipitor)|"Atorvastatin will be administered at a dose of 40 mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning.~Patients will receive atorvastatin until +180 days or until the patient develops grade II-IV acute GVHD, extensive chronic GVHD, or any grade 3-4 toxicity related to atorvastatin."
62837698|NCT00721968|ACTIVE_COMPARATOR|1|Treatment Group (Group 1): Glaukos Trabecular Micro-Bypass Stent Model GTS400; implantation in conjunction with cataract surgery
62837699|NCT00721968|PLACEBO_COMPARATOR|2|Control Group (Group 2): Cataract surgery only
62837700|NCT02039141|EXPERIMENTAL|Every Little Step Counts Intervention|Exercise classes (3/week) Lifestyle sessions (1/week)
62837701|NCT02039141|NO_INTERVENTION|Delayed ELSC Intervention Group|Control group (delayed intervention group)
62053937|NCT03467932|ACTIVE_COMPARATOR|Cohort B: ORMD-0801 16 mg once daily - QHS:|ORMD-0801 16 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
62053938|NCT03467932|ACTIVE_COMPARATOR|Cohort B: ORMD-0801 16 mg twice daily - BID|ORMD-0801 16 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
62612937|NCT01665677|EXPERIMENTAL|Unrelated Donor|"Atorvastatin will be administered at a dose of 40 mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning.~Patients will receive atorvastatin until +180 days or until the patient develops grade II-IV acute GVHD, extensive chronic GVHD, or any grade 3-4 toxicity related to atorvastatin."
62837702|NCT01543048||Women with CIN3 treated by conization|
62837703|NCT03657082|EXPERIMENTAL|Arm A|In this arm, patients will receive the experimental condition first, then the sham condition
62837704|NCT03657082|EXPERIMENTAL|Arm B|In this arm, patients will receive the sham condition first, then the experimental condition
62255233|NCT04329351|EXPERIMENTAL|Guided bone regeneration Group|After extraction, Guided bone regeneration was conducted using the PTFE-d membrane (CytoplastTM Ti-250 Titanium-Reinforced, Anterior Narrow 12 mm x 24 mm, Osteogenics, Lubbock, TX, USA) was customized with scissors and adjusted over the socket, exceeding three millimeters from its margins. Then, the membrane was inserted subperiostally under the buccal and palatal flaps with the help of the Molt detacher. Minimal flap reflection was performed to stabilize the membrane, which was maintained intentionally exposed to the oral environment. Before suturing, the passive stability of the membrane over the alveolus was confirmed, as well as the absence of folds or wrinkles in the membrane. The flaps were then be approached in the pre-extraction position and sutured with crossed sutures, aiming to increase the stability of the membrane, with PTFE 4-0 thread (Cytoplast PTFE, CS0618PREM, Osteogenics, Lubbock, TX, USA).
62837705|NCT02462135|EXPERIMENTAL|Virtual interactive memory training|Training sessions of the VIMT group are divided into initial training and booster training. Each training session is 45 minutes/day, 3 sessions/week, for 12 weeks for both initial training and booster training (36 sessions each).
62612938|NCT04485494||Professional Rugby Athletes|These are the cohort of players that consent to the study and have a preseason baseline blood sample taken. If the participant from this cohort then receives a concussion they are assessed by the World Rugby's Head Injury Assessment (HIA) and then enter into the return to play (RTP) protocol which means they cannot play a competitive game for 6 days.
62612939|NCT02095015||Analysis population|All subjects enrolled in the study who meet the eligibility criteria
62612940|NCT01156051|EXPERIMENTAL|Guanfacine Extended-Release Tablets|Guanfacine Extended-Release Tablets 1mg, 2mg, 3mg, and 4mg
62612941|NCT01156051|PLACEBO_COMPARATOR|Placebo comparator|Placebo control
62612942|NCT02503371||Women under IVF stimulation at the begining and end|Coagulation parameters will be measured for all parturients at the beginning and conclusion of an IVF simulation cycle with the use of thromboelastogram
62837706|NCT02462135|ACTIVE_COMPARATOR|Passive information activities|The training of active control group is the same as VIMT group (45 min/day, 3 days/week, for 12 weeks, for a total of 36 sessions). The active control group receives only the initial training.
62255234|NCT04329351|PLACEBO_COMPARATOR|Non-Guided bone regeneration group|After extraction, no further treatment (No addition of Guided bone regeneration) was performed. The flaps were then repositioned and sutured with 5.0 nylon thread (Ethicon, Jonhson's Jonhson, São José dos Campos).
62612943|NCT06516874|EXPERIMENTAL|Trauma-Focused Cognitive Behavioral Therapy for complex presentation (TF-CBT-CP)|The TF-CBT-CP includes: a) conducting clinical assessment sessions; b) providing psychoeducation on PTSD and CPTSD; c) facilitating the development of coping strategies to manage distressing experiences; d) implementing behavioral activation techniques to reintegrate into daily activities; e) fostering the acquisition of emotional regulation strategies and interpersonal relationship skills; f) utilizing in-vivo (live) and imaginal exposure methods to confront the traumatic memory; g) cognitive work to cope with distorted thoughts, and h) relapse prevention.
62612944|NCT06516874|OTHER|CONTROL GROUP|The usual treatment (TAU) includes staying on a waiting list, access to pharmacological treatment, and/or non-specialized PTSD psychotherapy sessions. CMHCS professionals will provide this treatment.
62612945|NCT04241393|EXPERIMENTAL|Tavapadon|
62612946|NCT06605118|EXPERIMENTAL|Azithromycin prophylaxis and standard of care preoperative antibiotics|500mg of intravenous azithromycin administered up to 1 hour prior to cesarean incision (or as soon as feasible after incision) and infused over one hour per FDA infusion recommendations for azithromycin. Additionally patients will received standard of care preoperative antibiotics (excluding azithromycin) prior to incision.
62612947|NCT06605118|PLACEBO_COMPARATOR|Placebo and standard of care preoperative antibiotics|Normal saline administered up to 1 hour prior to cesarean incision (or as soon as feasible after incision) and infused over one hour in addition to standard of care preoperative antibiotics (excluding azithromycin) prior to incision.
62612948|NCT01726621|OTHER|Insulin dependent diabetics|Subjects currently using an insulin pump transferred to use the Medtronic MiniMed 620G and 640G insulin pumps and Guardian Link transmitter
62612949|NCT05422768||Warrior Renew|Warrior Renew is a program for military sexual trauma (MST).
62612950|NCT05422768||Warrior Renew + EAL|Warrior Renew and EAL are combined into one program for military sexual trauma (MST).
62612951|NCT01135875||GBM Patients|GBM Patients with a histologically confirmed or suspected diagnosis of glioblastoma multiforme.
62612952|NCT01135875||Normal Controls|Normal Controls will be adult volunteers who identify themselves as not having been diagnosed with a glioblastoma multiforme.
62612953|NCT03904368|ACTIVE_COMPARATOR|Myomectomy group|women with intramural myoma not reaching endometrial cavity will undergo open myomectomy followed by ovarian stimulation for in vitro fertilization 6 months after the operation
62612954|NCT03904368|ACTIVE_COMPARATOR|Conservative group|women with intramural myoma not reaching endometrial cavity will undergo ovarian stimulation for in vitro fertilization
62612955|NCT01030471|EXPERIMENTAL|Lifestyle counseling|
62612956|NCT01030471|NO_INTERVENTION|Wait list control group|
62612957|NCT03001479|NO_INTERVENTION|Standard: Liquid HMF and liquid protein|This is our standard breast milk fortification in our NICU. One packet (5 mL) of Similac Human Milk Fortifier Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. After infants reach full feedings (160 ml/kg/d), 3 ml/kg of Similac Liquid Protein Fortifier is added (0.5 g/kg protein). This is increased to 6 ml/kg (1 g/kg protein) the next day.
62837707|NCT03335670|EXPERIMENTAL|[68Ga]Pentixafor PET scan|4 mCi (range 3-5 mCi) of \[68Ga\]Pentixafor is administered intravenously over 1 minute using an infusion pump. PET imaging is performed from time of infusion for about 90 minutes. Approximately 12 blood samples (\~ 1 tsp) will be taken for pharmacokinetic analysis.
62837708|NCT00201110|EXPERIMENTAL|1|Intensive Intervention: CVD Risk Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
62837709|NCT00201110|ACTIVE_COMPARATOR|2|Brief Intervention: CVD Risk Education (1 session) + Brief Health Problem-Solving Training (1 session)
62837710|NCT01852409|EXPERIMENTAL|bevacizumab|The study evaluate 4 dose level of bevacizumab:2.5mg /kg;5 mg /kg;7.5mg /kg; 1.25mg /kg;
62837711|NCT05153096|EXPERIMENTAL|Experimental: solid tumors|"Dose-escalation stage: Patients will receive NBL-015 once every two or three weeks, starting at a dose of 1 mg/kg.~Cohort-expansion stage: Patients will receive NBL-015 at selected dose as per the results of dose-escalation stage."
62837712|NCT03516968|EXPERIMENTAL|Monthly bolus arm|
62837713|NCT03516968|ACTIVE_COMPARATOR|Daily arm|
62053939|NCT03467932|PLACEBO_COMPARATOR|Cohort B - Matched Placebo Oral Capsule|Cohort B - Matched Placebo Oral Capsule: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
62053940|NCT00846105|EXPERIMENTAL|Rapid PCR screen|Rapid PCR screen test for detection of MRSA carriers upon hospital admission
62053941|NCT00846105|ACTIVE_COMPARATOR|Conventional culture|Conventional culture screen for detection of MRSA carriers upon hospital admission
62837714|NCT03516968|OTHER|Control group|Group of obese patients without vitamin D deficiency
62255235|NCT00725881|EXPERIMENTAL|1|.25 mg/kg TSC
62255236|NCT00725881|EXPERIMENTAL|2|.5 mg/kg TSC
62255237|NCT00725881|EXPERIMENTAL|3|.75 mg/kg TSC
62612958|NCT03001479|EXPERIMENTAL|Intervention: HMF Hydrolyzed Protein Concentrated Liquid|One packet (5 mL) of Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. Feedings then continue to be advanced to full volume (160 ml/kg/d).
62612959|NCT05083806|EXPERIMENTAL|Pompe disease|Actual condition
62612960|NCT05083806|ACTIVE_COMPARATOR|Muscular dystrophy|Different known condition
62612961|NCT05083806|ACTIVE_COMPARATOR|Healthy volunteer|Healthy control
62612962|NCT04296851|EXPERIMENTAL|niclosamide|650mg daily
62837715|NCT01497223|EXPERIMENTAL|MGCD290 and Fluconazole|Oral Administration of MGCD290 and Fluconazole
62837716|NCT01497223|NO_INTERVENTION|Fluconazole|This is an Active Comparator: Oral Administration of Fluconazole with Placebo
62612963|NCT04296851|PLACEBO_COMPARATOR|placebo|identical- appearing placebo
62612964|NCT01239082|OTHER|Arm 1|Colonoscopy (one time screening)
62612965|NCT01239082|OTHER|Arm 2|FIT (annually)
62255238|NCT00725881|EXPERIMENTAL|4|1.0 mg/kg TSC
62255239|NCT00725881|EXPERIMENTAL|5|1.25 mg/kg TSC
62255240|NCT00725881|EXPERIMENTAL|6|1.5 mg/kg TSC
62255241|NCT00725881|EXPERIMENTAL|7|1.75 mg/kg TSC
62255242|NCT00725881|EXPERIMENTAL|8|2.0 mg/kg TSC
62443402|NCT04290078|EXPERIMENTAL|Kaia Back Pain Study Intervention|"The study intervention consists of training sessions conducted daily by the participant via Kaia back pain program. This content combines several approaches that may be effective when used together such as physical exercises, relaxation practices and learning modules. Additionally, there is availability of an electronic motion coach on a set of exercises.~Users also receive behavioural health coaching provided by Kaia's coaching staff based on a coaching curriculum."
62443403|NCT04290078|ACTIVE_COMPARATOR|Control Group|Participants in the control arm will be provided with online links to educational materials about home exercises and pain management and asked to continue their usual care. On-line resources will include links to Web MD, the National Library of Medicine (Medline), and OnHealth.
62443404|NCT01193621|ACTIVE_COMPARATOR|haloperidol|"0.5, 1, 3 mg of haloperidol will be administered orally every 24 hours for 7 days to 4 healthy subjects in each dose level (a total of 12 subjects).~Dose groups are as follows; D2-receptor occupancy study Group Single Oral Dose No. of subjects~1. 0.5 mg 4~2. 1 mg 4~3. 5 mg 4"
62443405|NCT02078063|EXPERIMENTAL|Mepivacaine|10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter
62443406|NCT02078063|PLACEBO_COMPARATOR|NaCL|10 ml NaCl 9mg/ml instilled into the uterus through a hydrosonography catheter
62443407|NCT01449058|EXPERIMENTAL|BYL719 + MEK162|BYL719 plus MEK162. Dose escalation with a starting dose for the first cohort of 200mg QD BYL719 and 30mg BID MEK162
62612966|NCT01353573|ACTIVE_COMPARATOR|Fixed Gantry Radiosurgery|Single fraction radiosurgery will be prescribed using a Fixed Gantry Linear Accelerator
62612967|NCT01353573|EXPERIMENTAL|Robotic Radiosurgery|Single fraction radiosurgery will be prescribed using a robotic linear accelerator
62612968|NCT01375582|EXPERIMENTAL|Drop Administration|
62612969|NCT02702141|EXPERIMENTAL|SGN-CD19B|
62837717|NCT03236636|EXPERIMENTAL|Icaritin|Icaritin:600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
62255243|NCT00725881|PLACEBO_COMPARATOR|9|5.0 mL 0.9% normal saline
62443408|NCT02598102|EXPERIMENTAL|Diclofenac sodium|Oral diclofenac 75 mg one hour prior to stent removal
62443409|NCT02598102|PLACEBO_COMPARATOR|Placebo|Placebo one hour prior to stent removal
62612970|NCT05095311|EXPERIMENTAL|Experimental group|This subset of 12 individuals will complete all experimental study visits, and will ingest either 1) a placebo pill and placebo inhaler contents or 2) a cetirizine HCl pill (10 mg) and placebo inhaler contents in a randomized order and double-blind fashion.
62612971|NCT05095311|NO_INTERVENTION|Selection pool|Twenty-four total individuals will be recruited for the initial portion of the study, and the aforementioned 12 (6 men, 6 women) will be a subset of the initial 24. The other 12 participants will not take part in further study.
62612972|NCT01108692|EXPERIMENTAL|Active|Patients will be followed by telecardiology.
62612973|NCT01108692|ACTIVE_COMPARATOR|Control|Patients will be followed in the conventional manner. They will be equipped with telecardiology but data will not be used for patient surveillance.
62612974|NCT05838911|ACTIVE_COMPARATOR|Control Group|The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks.
62612975|NCT05838911|EXPERIMENTAL|Study Group|The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation (NMES) of gluteus max., quadriceps, and calf muscles performed for 30 min /day for five days a week for three consecutive weeks.
62612976|NCT03900221||Pregnant women with multiple sclerosis or related neurological|Children born to women with multiple sclerosis or related neurological syndromes.
62612977|NCT01160094||Patients|ErbB2+ metastatic breast cancer patients
62612978|NCT05677815||patients with COVID-19 infection underwent surgery in 2023|Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional
62837718|NCT03236636|ACTIVE_COMPARATOR|HUACHANSU PIAN|HUANCHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
62255244|NCT02742064||MDD-Single Episode|1. Subjects who have experienced 1 episode of major depressive disorder (MDD) in their lifetime.
62255245|NCT02742064||MDD-Recurrent|1. Subjects who have experienced 2 or more episodes of depressive disorder (MDD) in their lifetime.
62255246|NCT02742064||Bipolar Disorder|1. Subjects who have been diagnosed with bipolar disorder in their lifetime.
62255247|NCT06038240|EXPERIMENTAL|Savoring Meditation|A 4-session meditation intervention in which participants are trained to generate positive emotional states and focus their awareness on those states throughout the meditation.
62255248|NCT06038240|OTHER|Pain Self-Management and Education|Education Control
62255249|NCT00937261|EXPERIMENTAL|Risperdal|Risperdal 2-8mg per day
62255250|NCT00937261|EXPERIMENTAL|Invega|Invega 6-12mg per day
62255251|NCT00185952|ACTIVE_COMPARATOR|Nifedipine|Maintenance tocolysis with nifedipine.
62255252|NCT00185952|PLACEBO_COMPARATOR|Placebo|Maintenance tocolysis with placebo tablets.
62255253|NCT05140512|EXPERIMENTAL|LY01005 3.6 mg|Intramuscular injections of LY01005 3.6 mg every 28 days for a maximum of 3 consecutive doses.
62255254|NCT05140512|ACTIVE_COMPARATOR|ZOLADEX® 3.6 mg|Subcutaneous injections of ZOLADEX® 3.6 mg every 28 days for a maximum of 3 consecutive doses.
62255255|NCT03387436|NO_INTERVENTION|1.) Treatment as usual (TAU)|Patients assigned to this arm will receive palliative treatment as usual.
62255256|NCT03387436|SHAM_COMPARATOR|2.) Sham-Intervention|Patients assigned to this arm will receive an sham intervention with unspecific supportive therapy (i.e. listening, empathy etc., but no specific intervention rationale) and palliative treatment as usual.
62255257|NCT03387436|EXPERIMENTAL|3.) Study-Intervention|Patients assigned to this arm will receive the study-intervention and palliative treatment as usual.
62255258|NCT01661855|ACTIVE_COMPARATOR|Riluzole|
62255259|NCT01661855|PLACEBO_COMPARATOR|Placebo|
62255260|NCT05691998||Patients|the previous prosthesis experience
62255261|NCT03688399|EXPERIMENTAL|IOL Implantation experimental|hydrophobic, trifocal intraocular lens POD L GF with light distribution far \> intermediate \> near
62255262|NCT03688399|ACTIVE_COMPARATOR|IOL Implantation Comparator|hydrophobic, trifocal intraocular lens POD F GF with light distribution far \> near \> intermediate
62255263|NCT06087250||Fluid responsive|"A 15% increase in cardiac output following a fluid challenge ( 6ml/kg crystalloid solution infusion in 30 min).~Carotid corrected flow time measured before and after fluid challenge by ultrasound."
62255264|NCT06087250||Fluid non-responsive|"Failure of 15% increase in cardiac output following a fluid challenge ( 6ml/kg crystalloid solution infusion in 30 min).~Carotid corrected flow time measured before and after fluid challenge by ultrasound."
62443410|NCT05904015|EXPERIMENTAL|Hypofractionated radiotherapy group|"Envafolimab: 300mg SC d1,Q3W,2 cycles Cisplatin/carboplatin: Cisplatin: 75 mg/m2 IV d1,Q3W ,2 cycles or Carboplatin:AUC=5/6 IV d1,Q3W,2cycles Etoposide: 100mg/m2 IV d1,Q3W ,2 cycles Radiotherapy: Provide a prescription dose of 45Gy at a 95% PTV dose, with a single split dose of 3Gy, once a day, 5 times a week, for a total of 15 times.~Envafolimab maintenance: 300mg,SC, d1. Q3W, up to 2 years or until PD or intolerable."
62255265|NCT00625495|EXPERIMENTAL|1|IV Nexium
62255266|NCT00625495|EXPERIMENTAL|2|Oral Nexium
62255267|NCT04350528||Chlorpromazine|
62255268|NCT04350528||Pentobarbital|
62255269|NCT01640509|EXPERIMENTAL|synchrotron radiation|treated by synchrotron radiation
62443411|NCT05904015|EXPERIMENTAL|Conventional Radiotherapy|Envafolimab: 300mg SC d1,Q3W,2 cycles Cisplatin/carboplatin:Cisplatin:75 mg/m2 IV d1,Q3W ,2 cycles or Carboplatin:AUC=5/6 IV d1,Q3W,2cycles Etoposide: 100mg/m2 IV d1,Q3W ,2 cycles Radiotherapy: Provide a prescription dose of 60Gy at a 95% PTV dose, with a single split dose of 2Gy, once per day, 5 times per week, for a total of 30 times Envafolimab maintenance: 300mg,SC, d1. Q3W, up to 2 years or until PD or intolerable.
62443412|NCT00996866|PLACEBO_COMPARATOR|Placebo|Half of subjects will be randomized to the placebo group.
62443413|NCT00996866|ACTIVE_COMPARATOR|Vitamin D3|This is the study group that receives Vitamin D supplementation.
62443414|NCT00217854|OTHER|Open label inhaled fluticasone|Patients are treated with open label high dose fluticasone for 30 days then discontinued. Comparisons are pre- and post- treatment single arm.
62255270|NCT05860842|EXPERIMENTAL|exercise training|6-month supervised exercise training program
62255271|NCT06466031|EXPERIMENTAL|Resection and radiotherapy according to the MRI & PET fusion|Tumor resection and radiotherapy will be planned based on the fusion of MRI and PET.
62443415|NCT00901368|EXPERIMENTAL|1|CHF1535 (beclometasone dipropionate plus formoterol, 400/24 µg daily)
62443416|NCT00901368|ACTIVE_COMPARATOR|2|Seretide® Diskus® (fluticasone plus salmeterol, 500/100 µg /daily)
62443417|NCT02248532|ACTIVE_COMPARATOR|Group A|Repetitive stem cell administration
62255272|NCT06466031|EXPERIMENTAL|Radiotherapy according to the MRI & PET fusion|Tumor resection will be planned based on the MRI. Radiotherapy will be planned according to the fusion of MRI \& PET.
62255273|NCT06466031|SHAM_COMPARATOR|Resection and radiotherapy according to the MRI|Tumor resection and radiotherapy will be planned based on the MRI.
62255274|NCT03663426|ACTIVE_COMPARATOR|control group opioid anesthesia|standard anesthesia using opioids
62255275|NCT03663426|EXPERIMENTAL|study group opioid free anesthesia|opioid free anesthesia and high dose glucocorticoids
62053942|NCT05254548|EXPERIMENTAL|ACT-539313 with or without a standard combination (probe substrate)|Treatment arm has 4 in-house treatment periods. In Treatment Period 1, participants will receive a single oral dose of the standardized combination (probe substrate: containing flurbiprofen \[50 mg\], midazolam \[2 mg\] and omeprazole 20 \[mg\]) on Day 1. Participants will be discharged from the study site on Day 2 and will be re-admitted on Day 7. In Treatment Period 2 (morning of Day 8) a first oral dose of 100 mg ACT-539313 will be administered. One hour later a single oral dose of the probe substrate will be administered. In the evening of Day 8, a second oral dose of 100 mg ACT-539313 will be administered. During Treatment Period 3 (morning of Day 9, ending on the evening of Day 14) oral doses of 100 mg ACT-539313 will be administered in the morning and evening. In Treatment Period 4 (Day 15), a single oral dose of 100 mg ACT-539313 together with the probe substrate will be administered. The participants will receive the last dose of ACT-539313 in the evening of Day 15.
62053943|NCT03329898|EXPERIMENTAL|dried biological amnion graft|dried biological amnion graft patients, who are with IUA, treated by uterine application of dried biological amnion graft + disposable balloon uterine stent + hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
62053944|NCT03329898|SHAM_COMPARATOR|disposable balloon uterine stent only|disposable balloon uterine stent patients, who are with IUA, treated by uterine application of disposable balloon uterine stent only + hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
62053945|NCT01606527|EXPERIMENTAL|Ibuprofen|Ibuprofen 600mg taken three times daily for four days.
62053946|NCT01606527|PLACEBO_COMPARATOR|placebo|Avicel placebo capsules three times daily for four days
62053947|NCT01463956|EXPERIMENTAL|Boceprevir, Pegylated interferon and Ribavirin|"* Lead-in phase (4 week): Pegylated interferon + Ribavirin~* Triple therapy regimen for 44 weeks :Boceprevir + Pegylated interferon + Ribavirin~* Pegylated interferon + Ribavirin therapy until transplantation (less or equal to 24 weeks)"
62053948|NCT01635257||suspected pulmonary embolism patients|patients with clinical suspicion of PE and with a simplified Well's score\>4 (PE likely) or with a D-dimer value ≥500ng/ml presenting to the emergency departments of Careggi University Hospital (Firenze), of San Luigi Gonzaga University Hospital (Torino) of Ospedale Pierantoni-Morgagni (Forlì)
62053949|NCT06525844|ACTIVE_COMPARATOR|regenerative endodontic therapy with blood clot|In the procedures of regenerative endodontics therapy, K-files were intentionally used to violate the periapical tissues via overinstrumentation up to 2-3mm past the apical foramen to induce bleeding. The adequate blood need to be full with canal space and below the CEJ, then wait for 10-15min to coagulate.
62053950|NCT06525844|EXPERIMENTAL|regenerative endodontic therapy with I-PRF|In the procedures of regenerative endodontics therapy, K-files were intentionally used to violate the periapical tissues via overinstrumentation up to 2-3mm past the apical foramen to induce bleeding. Only the apex 1/3 of the root canal need to be filled with blood. PRF was injected into the root canal to a level below the CEJ, then wait for 10-15min to coagulate.
62053951|NCT00661739|EXPERIMENTAL|Singular Arm|Bendamustine treatment
62053952|NCT04934579|EXPERIMENTAL|R2-MTX|Experimental arm will be treated with R2-MTX regimen(Lenalidomide plus Rituximab and Methotrexate) for 6 cycles as initiate induction.If the patients achieved complete remission（CR）or partial remission（PR）with additional whole-brain radiotherapy（WBRT）, they processed to R2 maintenance(Lenalidomide plus Rituximab) for 4 cycles.
62053953|NCT01489943|EXPERIMENTAL|All subjects receiving treatment|During the treatment subjects will receive Midazolam 3 mg on Day 1, Pioglitazone 15 mg on Day 2, Omeprazole 40 mg on Day 3, Rosuvastatin 10 mg on Day 4, GSK1605786 500 mg twice daily (BID) from Day 5 to 10, GSK1605786 500 mg BID + Midazolam 3 mg on Day 11, GSK1605786 500 mg BID + Pioglitazone 15 mg on Day 12, GSK1605786 500 mg BID + Omeprazole 40 mg on Day 12, GSK1605786 500 mg BID + Rosuvastatin 10 mg on Day 14 as single sequence.
62053954|NCT05028426||Traditional method of care|Patients managed according to the traditional care protocol without an enhanced recovery program
62053955|NCT05028426||Some elements of a fast-track program|operative and postoperative techniques were modified according to a fast-track program
62053956|NCT05028426||Full enhanced recovery program|Patients were managed in an enhanced recovery program (elements of the previous fast-track program were modified and preoperative education was added)
62053957|NCT04859634||Zhongshan Ophthalmic Center|The participant only needs to take an ultra-widefield fundus image as usual.
62255276|NCT01670539|EXPERIMENTAL|Telemonitor|"In addition to routine care, the HomMed Telemonitor wireless telemonitoring system (intervention)will be used in the patient's home for 14 days to alert the clinical research nurse to changes in patients conditions in order to contact them to teach self-management. The Honeywell HomMed Genesis™ DM Remote Patient Care Monitor will be used to measure temperature, pulse, oxygen level,weight and blood pressure. The telemonitor will also ask for a YES or NO response to questions on symptoms such as difficulty breathing. Research nurses review the data daily and call the participant for 2 weeks, and continue to monitor outcomes for 2 months."
62443418|NCT02248532|ACTIVE_COMPARATOR|Group B|Single stem cell administration
62612979|NCT05677815||patients without COVID-19 infection underwent surgery in 2023|Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional
62612980|NCT00911586|EXPERIMENTAL|Testosterone Undecanoate|Oral testosterone undecanoate, 200 mg testosterone (T) as TU, twice daily for 28 days.
62053958|NCT04859634||Shenzhen Ophthalmic Center|The participant only needs to take an ultra-widefield fundus image as usual.
62053959|NCT04859634||Beijin Tongren Hospital|The participant only needs to take an ultra-widefield fundus image as usual.
62612981|NCT00520767|EXPERIMENTAL|Melphalan, Dexamethasone, Bortezomib,|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22; Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23; Melphalan 9 mg/m2/day days 1-4
62612982|NCT01245153|EXPERIMENTAL|Rectal Balloon Training|Subjects in combined RBT and PFMT group are taught Foley catheter insertion technique. The catheter is inserted into the rectum until the lower end of the balloon is 1 cm inside from the anus. Then the balloon is blown with clean water. Subjects will contract pelvic floor muscle in standing position by contracting the pelvic floor muscle, hold and count 1 to 5, then relax and count 1 to 5. Subjects are instructed to do the exercise 15 times/set, 3 sets/day, every day for 6 weeks.
62612983|NCT01245153|ACTIVE_COMPARATOR|Control group|Patients receive Pelvic floor muscle training without inserting any kinds of equipment.
62612984|NCT01638403|EXPERIMENTAL|BF2.649|BF2.649 (pitolisant) is a novel, highly potent, selective, orally active histamine H3 receptor antagonist/inverse agonist (Ki of 0.3 nM) at the human receptor.
62837719|NCT01012440|EXPERIMENTAL|Beast cancer subjects|Subject will have assessment of neoadjuvant chemotherapy treatment response by both MRI and PEM to compare methods
62837720|NCT02181088|EXPERIMENTAL|Group 1 (ChAd63 RH5 low dose)|1 dose of ChAd63 RH5 5 x 10\^9 vp intramuscularly
62837721|NCT02181088|EXPERIMENTAL|Group 2A (ChAd63 RH5 full dose)|1 dose of ChAd63 RH5 at 5 x 10\^10 vp intramuscularly
62837722|NCT02181088|EXPERIMENTAL|Group 2B (ChAd63 RH5 full dose and MVA RH5 low dose)|1 dose of ChAd63 RH5 at 5 x 10\^10 vp intramuscularly and 1 dose MVA RH5 at 1 x 10\^8 pfu 8 weeks later intramuscularly
62837723|NCT02181088|EXPERIMENTAL|Group 2C (ChAd63 RH5 full dose and MVA RH5 full dose)|1 dose of ChAd63 RH5 at 5 x 10\^10 vp intramuscularly and 1 dose MVA RH5 at 2 x 10\^8 pfu 8 weeks later intramuscularly
62837724|NCT00633113|ACTIVE_COMPARATOR|1|- Medial Parapatellar Arthrotomy (MPPA) technique
62443419|NCT06286553|EXPERIMENTAL|Trunk Exercise and Inspiratory Muscle Training Group (IMT+TEG)|The Trunk Exercise and Inspiratory Muscle Training Group (IMT+TEG) will follow a comprehensive, 12-week therapeutic exercise program that involves progressive strengthening exercises specifically targeting the trunk and pelvic floor muscles, functional retraining exercises, and additional exercises focusing on strengthening the inspiratory muscles (Inspiratory Muscle Training - IMT).
62612985|NCT01638403|ACTIVE_COMPARATOR|Vigil|"Therapeutic indications Narcolepsy with and without cataplexy. Moderate to severe obstructive sleep apnoea syndrome with excessive daytime sleepiness despite adequate CPAP therapy.~Moderate to severe chronic shift work sleep disorder with excessive sleepiness in patients who work rotating night shifts, if other sleep hygiene measures did not lead to a satisfactory improvement."
62837725|NCT00633113|ACTIVE_COMPARATOR|2|- Subvastus (SV) technique
62612986|NCT01638403|PLACEBO_COMPARATOR|Placebo|
62612987|NCT06731179||Long COVID diagnosis|Long COVID diagnosis
62612988|NCT06731179||ME/CFS symptoms|ME/CFS symptoms
62612989|NCT06731179||PTLDS symptoms|PTLDS symptoms
62612990|NCT06731179||Healthy Individuals|Healthy Individuals
62612991|NCT06730711||NPSCI|NPSCI was defined as a score of MMSE≥26.
62612992|NCT06730711||PSCI|The prime outcome PSCI was defined as the cognitive impairment occurred after stroke and was still present three months after stroke and cognitive impairment was defined as a score of MMSE\<26.
62612993|NCT05032729|PLACEBO_COMPARATOR|Placebo beverage|"* Flavor~* Non-nutritive sweetener~* Color added to match whey appearance"
62612994|NCT05032729|EXPERIMENTAL|Higher tryptophan beverage|"* 2.7g high Glycemic Index Carbohydrate~* 40g whey~* 0.855g tryptophan~* 660mg theanine~* 53mcg 5'AMP~* Non-nutritive sweetener~* Flavor"
62612995|NCT05032729|EXPERIMENTAL|Lower tryptophan beverage|"* 2.7g high Glycemic Index Carbohydrate~* 30g whey~* 0.641g tryptophan~* 660mg theanine~* 53mcg 5'AMP~* Non-nutritive sweetener~* Flavor"
62837726|NCT02379091|PLACEBO_COMPARATOR|Placebo|Namilumab placebo-matching, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
62837727|NCT02379091|EXPERIMENTAL|Namilumab 20 mg/mL|Namilumab 20 mg/mL, subcutaneous (SC) injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
62837728|NCT02379091|EXPERIMENTAL|Namilumab 80 mg/mL|Namilumab 80 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
62837729|NCT02379091|EXPERIMENTAL|Namilumab 150 mg/mL|Namilumab 150 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant was discontinued from the study. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
62837730|NCT03636516|ACTIVE_COMPARATOR|jj stent yes|
62837731|NCT03636516|ACTIVE_COMPARATOR|jj stent no|
62837732|NCT04145518|ACTIVE_COMPARATOR|Naproxen/Placebo Crossover|"Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill. Randomization with a block size only known by the statistician, will be programmed to be allocated out of REDcap.~Our clinical research pharmacy will provide naproxen and an identical looking placebo in containers with codes only known to the statistician to provide a double-blinded experimental design.~On a subsequent episode of menstrual pain (1-2 months later), participants will receive the opposite treatment and undergo the exact same assessments."
62837733|NCT04145518|PLACEBO_COMPARATOR|Placebo/Naproxen Crossover|Participants will receive placebo first in this arm.
62837734|NCT04561765|EXPERIMENTAL|iCanCope|In this group, individuals will receive the iCanCope-NF program. The intervention will be delivered on a restricted password-protected mobile application. Participants will be encouraged to log onto the pain diary app (via automated alerts) once per day over the 8-week period to complete pain diary entries and develop and track their goals related to their pain, physical, social activities, sleep, as well as work through content based on their goals.
62837735|NCT04561765|EXPERIMENTAL|iCanCop+Contingency Management|In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers. Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application. Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
62837736|NCT04561765|NO_INTERVENTION|Control Group|The control group is designed to assess for potential effects on outcomes of time, attention, during the study. In addition to usual care, participants will be required to complete baseline and follow-up assessments similar to that of the intervention groups. They will be given that patient education, through preapproved flyers and information found from national websites regarding pain management, but no self-management strategies or opportunities for social support. They will not have access to the mobile application during the course of experiment; however, the control group will be offered the full iCanCope-NF program following the trial (T2) for a period of 2 months after the study is over.
62837737|NCT02302339|EXPERIMENTAL|Glembatumumab vedotin|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle.
62053960|NCT04859634||Xudong Ophthalmic Center|The participant only needs to take an ultra-widefield fundus image as usual.
62053961|NCT04859634||IKang Physical Examination Center|The participant only needs to take an ultra-widefield fundus image as usual.
62053962|NCT04859634||Yangxi General Hospital People's Hospital|The participant only needs to take an ultra-widefield fundus image as usual.
62053963|NCT04859634||Guangdong Provincial People's Hospital|The participant only needs to take an ultra-widefield fundus image as usual.
62053964|NCT06526221|EXPERIMENTAL|Urine isoniazid testing (intervention arm)|This is the only study group/arm in this study. Participants in this study arm will receive urine isoniazid testing using the IsoScreen test in the TB clinic at monthly clinical and medication refill visits at month 1, 2, 3, 4, and 5 (5 times total). The will also undergo urine isoniazid testing using the IsoScreen test at home visits after months 1, 3, and 5 of treatment (3 times total).
62053965|NCT04812366|ACTIVE_COMPARATOR|Group 1a|LHRHa plus apalutamide.
62053966|NCT04812366|ACTIVE_COMPARATOR|Group 1b|LHRHa plus apalutamide plus abiraterone acetate plus prednisone.
62255277|NCT01670539|NO_INTERVENTION|Routine care for patients with lungCa|Traditional physician ordered post-hospital care for patients with lung CA in rural WV requires patients to make an outpatient office/ clinic visit two to three weeks after discharge;a few patients receive homecare service referrals. No attempt to change care - just monitor what is used and collect study data at Discharge, 2 weeks, one month and two months.
62738853|NCT06027814|EXPERIMENTAL|PN+mHealth|The intervention is patient navigation and mHealth in addition to treatment-as-usual. The intervention consists of a patient navigator (PN) with the mHealth adherence application facilitating telehealth visits, two-way chats, video-DOT, and delivery of financial incentives via smartphone for adherence and linkage to outpatient treatment within 30 days. Participants will be asked to upload medication adherence videos once a day over the 30 days post discharge from the hospital. Patients will be instructed to continue to take their medication as prescribed in any circumstance where they are unable to upload the video for any reason.
62255278|NCT03094351|EXPERIMENTAL|Robot assisted esophagectomy|Robot-assisted esophagectomy with gastric conduit formation.
62255279|NCT03094351|ACTIVE_COMPARATOR|Thoracoscopic esophagectomy|Conventional thoracoscopic esophagectomy with gastric conduit formation.
62255280|NCT05421312|OTHER|cefazolin|The cefazolin antimicrobial prophylaxis (2000mg single dose intravenously 15-60 minutes before incision) is part of standard of care.
62255281|NCT05421312|OTHER|Clindamycin|The clindamycin (600mg three times daily orally) PJI therapy is part of standard care.
62255282|NCT01436084|EXPERIMENTAL|SB1518|400 mg orally a day for 28 day cycle.
62255283|NCT01825291||sleep apnea|
62255284|NCT06345430|EXPERIMENTAL|Exopulse Molli Suit Interventipn|"After initial evaluations, patients received a single session for 1 hour. Exopulse Mollii Suit will be applied. The stimulation level of the electrodes will be determined by the automatically by the system in accordance with the level of pain they indicate for their parts, individually tailored to the person.~will be created. Patients will wear the Exopulse Mollii Suit, which is suitable for their body size, Hacettepe University Physics They will dress in the room reserved for them at the Faculty of Treatment and Rehabilitation."
62255285|NCT00754793|ACTIVE_COMPARATOR|1|escitalopram 10mg - 30mg daily
62255286|NCT00754793|PLACEBO_COMPARATOR|2|
62255287|NCT06446245|EXPERIMENTAL|Doxycycline + standard anti-tuberculous treatment + corticosteroid therapy|Doxycycline 100 mg twice daily with once daily anti-tuberculous treatment comprising of at least three agents, including rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 15 - 20 mg/kg, ± pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day, or aminoglycosides or quinolones according to managing physicians' discretion. Adjunctive corticosteroids to be dosed at 0.4mg/kg/day of dexamethasone or equivalent for week 1, then 0.3mg/kg/day for week 2, 0.2mg/kg/day for week 3, 0.1mg/kg/day for week 4, then tapered to stop over the next 4 weeks. Other forms of corticosteroids are also acceptable e.g. hydrocortisone, methylprednisolone at the equivalent dosage. Where needed, the drugs will be adjusted according to renal function. These will be given daily for 8 weeks. Subsequently doxycycline will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician.
62255288|NCT06446245|PLACEBO_COMPARATOR|Placebo + standard anti-tuberculous treatment + corticosteroid therapy|Placebo twice daily with once daily anti-tuberculous treatment comprising of at least three agents, including rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 15-20 mg/kg, ± pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day, or aminoglycosides or quinolones according to managing physicians' discretion. Adjunctive corticosteroids to be dosed at 0.4mg/kg/day of dexamethasone or equivalent for week 1, then 0.3mg/kg/day for week 2, 0.2mg/kg/day for week 3, 0.1mg/kg/day for week 4, then tapered to stop over the next 4 weeks. Other forms of corticosteroids are also acceptable e.g. hydrocortisone, methylprednisolone at the equivalent dosage. Where needed, the drugs will be adjusted according to renal function. These will be given daily for 8 weeks. Subsequently placebo will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician.
62255289|NCT04687332|EXPERIMENTAL|plasma exchange|patients were treated with plasma exchange
62255290|NCT04687332|EXPERIMENTAL|immunadsorption|patients were treated with immunadsorption
62255291|NCT02369107|EXPERIMENTAL|Verum acupuncture and medicine|Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
62738854|NCT01904396|EXPERIMENTAL|CarnitineDeficient|Patients identified with primary and secondary carnitine deficiency in the cardiomyopathy population will be prescribed with carnitine supplements to assess cardiac muscle function and status.
62738855|NCT06659003||Pilot Implementation|"In order to understand feasibility and acceptability of the pilot implementation, we had key informants complete structured assessments - the majority of these key informants were Partner Services Staff Members (DIS or DIS Managers) from Chicago who reported on their experiences of the initial installation and pilot activities and the feasibility and acceptability of Network Canvas. Key informants also included directors of STD/HIV Prevention Programs, Informational Technology Staff responsible for deploying and maintaining the technical systems which support or are connected to Partner Services, and local Chicago Public Health Surveillance Staff Members.~To evaluate our secondary outcome (Preliminary Efficacy), we worked with Howard Brown and CDPH to obtain anonymized program-level administrative metrics. As data received by our team was completely stripped of identifiers, this work was considered 'exempt' human subjects research."
62738856|NCT02709460|EXPERIMENTAL|Lateral occlusion|Women included in this arm is randomized to lateral occlusion of the uterine artery
62738857|NCT02709460|ACTIVE_COMPARATOR|cervical occlusion|Women included in this arm is randomized to occlusion of the uterine artery at cervical entry
62612996|NCT04851418||Possible NSTE-ACS|All patients with a suspicion of non-ST-elevation acute coronary syndrome (NSTE-ACS) in the pre-hospital phase are eligible for inclusion. In all included patients, the POC cTn will be performed and the HEART-score will be calculated in the pre-hospital phase. Simultaneously, a venous blood sample will be drawn from the venous access site for later hs-cTn testing. Outcomes of both the POC cTn or the pre-hospital HEART-score will be blinded for the physicians at the emergency department (ED) and will not affect current treatment strategy. All patients with suspected NSTE-ACS will undergo hs-cTn testing and the HEART-score will also be calculated at the ED (T1, standard of care). Here, an additional venous blood sample will be drawn next to routine blood testing testing (T1).
62612997|NCT00676416||1|Propofol general anesthesia for asthmatic patients
62612998|NCT00676416||2|Propofol general anesthesia for non-asthmatic patients
62053967|NCT04812366|ACTIVE_COMPARATOR|Group 2a|LHRHa plus abiraterone acetate plus prednisone.
62053968|NCT04812366|ACTIVE_COMPARATOR|Group 2b|LHRHa plus abiraterone acetate plus prednisone plus docetaxel.
62053969|NCT04812366|ACTIVE_COMPARATOR|Group 3|LHRHa plus abiraterone acetate plus prednisone plus niraparib
62053970|NCT04812366|ACTIVE_COMPARATOR|Group 4|LHRHa plus apalutamide plus atezolizumab
62053971|NCT00379522|ACTIVE_COMPARATOR|Vasopressin|Vasopressin, 10 I.U./4 ml, Solution for Injection
62053972|NCT00379522|PLACEBO_COMPARATOR|Saline|Saline placebo 4 ml, Solution for Injection
62053973|NCT05225064|NO_INTERVENTION|Control|No vaccine or mask promotion, but access to vaccines increased to match access in intervention villages
62053974|NCT05225064|EXPERIMENTAL|Village-level vaccine clinics with monetary, non-monetary, or no incentive|Village-level vaccine clinics with monetary, non-monetary, or no incentive. Villages are cross-randomized to grocery coupon, food ration, no incentive, or grocery coupon to both community member and community health worker after the community member has received a vaccination.
62053975|NCT05225064|EXPERIMENTAL|Household-level vaccination with monetary or no incentive|Household-level vaccination with monetary incentive or no incentive. Villages are cross-randomized to grocery coupon or no incentive upon receiving vaccination
62255292|NCT02369107|SHAM_COMPARATOR|Sham acupuncture and medicine|Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
62612999|NCT00028522|EXPERIMENTAL|Treatment (chemotherapy)|"SCHEDULE A: Patients receive R(+)XK469 IV over 30 minutes on days 1, 3, and 5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R(+)XK469 until the recommended phase II dose or MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued and treated at the recommended phase II dose (for a maximum of 20 patients treated at that dose).~SCHEDULE B: Once the recommended phase II dose is determined on schedule A, additional patients are accrued and receive escalating doses of R(+)XK469 IV over 30-60 minutes on day 1, beginning at a reduced dose. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Dose escalation continues as in Schedule A."
62613000|NCT05219097||Cell Based Assay (CBA)|Use AChR/MuSK Ab CBA Kit (Tianjin New Terrain Biological Technology Co., Ltd, China) to detect AChR and MuSK Ab of myasthenia gravis
62255293|NCT02639572|EXPERIMENTAL|Siloss® bone graft|Based on the sequence, in the test site,Siloss® was placed.
62738858|NCT03206918|EXPERIMENTAL|Zanubrutinib|
62738859|NCT04848519|EXPERIMENTAL|Treatment (propranolol hydrochloride, immune checkpoint inhibitor)|The specific ICI that the subject would receive will be dependent on the clinical need and associated FDA approval.
62738860|NCT04848519|OTHER|Treatment (immune checkpoint inhibitor)|The specific ICI that the subject would receive will be dependent on the clinical need and associated FDA approval.
62738861|NCT04876404||Parkinson's Disease|Individuals with early stage Parkinson's Disease (diagnosed within the last 5 years)
62738862|NCT04876404||Healthy Controls|Healthy control individuals with no neurological or mood disorders.
62738863|NCT05511376|ACTIVE_COMPARATOR|DIET|Personal nutrition programs were prepared according to ideal body weight, with protein intake as 30% of total daily calories or 1-1.2 g/kg.
62613001|NCT05219097||RIPA Assay|Use AChR and MuSK Ab radioimmunoassay kit (RSR Limited, UK) to detect AChR and MuSK Ab of myasthenia gravis
62613002|NCT05219097||ELISA Assay|Use AChR Ab ELISA Kit (RSR Limited, UK) and MuSK ELISA kit (IBL Limited, Germany) to detect AChR and MuSK Ab of myasthenia gravis
62837738|NCT02302339|EXPERIMENTAL|Glembatumumab vedotin and varlilumab|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. Varlilumab administered as an intravenous infusion on Day 1 of cycles 1, 2, 4, 6, 8 and 10.
62837739|NCT02302339|EXPERIMENTAL|Glembatumumab vedotin and PD-1 targeted checkpoint inhibitor|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. Nivolumab OR pembrolizumab administered according to institutional standard of care.
62837740|NCT02302339|EXPERIMENTAL|Glembatumumab vedotin and CDX-301|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. CDX-301 is injected once a day for five days before cycles 1 and 2.
62837741|NCT05419778||Group A (Osteogen plug®)|The surgical procedure will be conducted following standard procedures for tooth exodontia and ridge preservation. The selected individual sites will be subjected to the standard of care extraction protocol and then randomized to receive treatment with a type I bovine Achilles tendon collagen with bioactive resorbable calcium apatite crystals (CCAC)(Osteogen) ridge augmentation procedures. Intra-oral photographs will be made at the same optic focal distance using a ruler which will be used to evaluate areas where the membrane is still exposed and not epithelized. At 4-6 weeks and again at 20 weeks postoperatively, each study subject will return for implant placement in the ridge preservation area.
62837742|NCT05419778||Group B ( MInerOss® )|The surgical procedure will be conducted following standard procedures for tooth exodontia and ridge preservation. The selected individual sites will be subjected to the standard of care extraction protocol and then randomized to a cortico-cancellous bone chips mix with polytetrafluoroethylene (dPTFE)(Cytoplast) barrier membrane ridge augmentation procedures. Intra-oral photographs will be made at the same optic focal distance using a ruler which will be used to evaluate areas where the membrane is still exposed and not epithelized. At 4-6 weeks and again at 20 weeks postoperatively, each study subject will return for implant placement in the ridge preservation area.
62837743|NCT03060096|EXPERIMENTAL|Moderate Anxiety/depression: Low Intensity Stepped care|participants with moderate symptoms (PHQ-9-14; GAD-7: 10-14) will be randomized to either low-intensity stepped care or enhanced usual care. Stepped care consist of a self-guided cognitive behavioral therapy (CBT) workbook to reduce anxiety and depressive symptoms and biweekly (every two weeks) check-in calls from research staff to assess changes in symptom severity/immediate need for psychiatric treatment and provide minimal support.
62053976|NCT05225064|EXPERIMENTAL|Village-level vaccination without incentive, plus mask promotion|Individuals are encourage to attend village-level vaccine clinics but not given any incentive. Mask distribution and reinforcement activities are conducted in villages at a similar time as vaccine promotion.
62053977|NCT05225064|EXPERIMENTAL|Village-level vaccination without incentive|Individuals are encourage to attend village-level vaccine clinics but not given any incentive.
62443420|NCT06286553|ACTIVE_COMPARATOR|Trunk Exercise Group (TEG)|The Trunk Exercise Group (TEG) will partake in a comprehensive 12-week therapeutic exercise program that involves progressive strengthening exercises specifically targeting the trunk and pelvic floor muscles, alongside functional retraining exercises.
62443421|NCT06286553|ACTIVE_COMPARATOR|Control group (CG)|The control group (CG) will receive general management information for DRA, and written instructions for engaging the deeper abdominals and pelvic floor muscles, accompanied by an educational exercise session. Participants will be encouraged to perform these contractions regularly, without guidance or supervision.
62443422|NCT03361514|ACTIVE_COMPARATOR|Supported Protocolized Discontinuation|Supported Protocolized Discontinuation (SPD) Patients will receive guidance of their GP and can have supportive meetings with the mental health assistant.
62443423|NCT03361514|EXPERIMENTAL|SPD + Mindfulness (MBCT)|In addition to the SPD (as mentioned above) patients are offered Mindfulness Based Cognitive Therapy (MBCT)
62443424|NCT04779619||Non-clinical Control|people who score below clinical cut off on measures of anxiety and depression (scoring \<10 on PHQ-9 and \<8 on GAD-7) and emotionally unstable personality traits (BSL-23) and are not currently using mental health services
62613003|NCT00371709|EXPERIMENTAL|Arm 1|
62613004|NCT00371709|OTHER|Arm 2|Historical Comparator: control data derived from the TAXUS IV and TAXUS V studies
62613005|NCT03782532|EXPERIMENTAL|Dupilumab|For patients without oral corticosteroids (OCS) maintenance therapy, dose 1 of dupilumab administered once in 2 weeks (q2w) with loading dose of dupilumab, two times dose 1; for patients on OCS maintenance therapy, the dose will be dupilumab dose 2 q2w with loading dose 2 times dose 2
62613006|NCT03782532|PLACEBO_COMPARATOR|Placebo for dupilumab|For patients without OCS maintenance therapy, the patients will take placebo matching to dupilumab dose 1 q2w with loading dose; for patients on OCS maintenance therapy, the patients will take placebo matching to dupilumab dose 2 q2w with loading dose
62613007|NCT03763058|OTHER|Music intervention|The music intervention is administered via a smartphone- (and computer-) based application called Music Care.
62613008|NCT01014481|EXPERIMENTAL|start antiretroviral treatment|the optimal timing to initiate antiretroviral therapy in HIV-infected patients who are receiving tuberculosis treatment between at 4 weeks and at 12 weeks after tuberculosis treatment
62613009|NCT01997970|EXPERIMENTAL|Treadmill workstation|Will receive a health talk with recommendations about diet and physical activity habits and will also receive a treadmill workstation at regular office site for 12 months.
62613010|NCT01997970|EXPERIMENTAL|Control group|Will receive a health talk with recommendations about diet and physical activity habits. Will continue to work with conventional office work at their regular desk.
62255294|NCT02639572|PLACEBO_COMPARATOR|Hydroxyapatitie Bone graf|Based on the sequence, the control site which was treated by Hydroxyapatite graft only.
62443425|NCT04779619||Clinical Group A|people who are accessing treatment through IAPT services and score above clinical cut off on measures of anxiety and/or depression (\>9 on PHQ-9 and/or \>7 on GAD-7) but below clinical cut off on a measure of emotionally unstable personality traits (BSL-23)
62443426|NCT04779619||Clinical Group B|people who are accessing treatment through IAPT services and score above clinical cut off on (BSL-23) a measure of emotionally unstable personality traits (irrespective of their scores on the PHQ-9 and GAD-7)
62443427|NCT04120168||DMD and Pompe Disease Cohort|The aim of this study gropu was to determine the frequency of Duchenne muscular dystrophin in boys and adolescents with unexplained transaminase elevation for at least 3 months and in late onset Pompe disease in girls and boys and to determine the demographic and clinical characteristics of these patients.
62443428|NCT02180061|EXPERIMENTAL|Advanced Cutaneous Melanoma|Participants with advanced cutaneous melanoma received pembrolizumab, 2 mg/kg, intravenously (IV) over 30 minutes on Day 1 of each 3-week dosing cycle (Q3W).
62443429|NCT02180061|EXPERIMENTAL|Advanced Mucosal Melanoma|Participants with advanced mucosal melanoma received pembrolizumab, 2 mg/kg, IV over 30 minutes on Day 1 Q3W.
62443430|NCT05781659|EXPERIMENTAL|Ultrasound elastography guided pleural biopsy group|
62443431|NCT05781659|EXPERIMENTAL|Traditional ultrasound-guided pleural biopsy group|
62443432|NCT04448171|ACTIVE_COMPARATOR|Activated TENS Unit with standard pain control measures|Activated TENS Unit with standard pain control measures during Office Based Cystoscopic Intra-detrusor Onabotulinumtoxin A Injection
62443433|NCT04448171|PLACEBO_COMPARATOR|Sham TENS Unit with standard pain control measures|Sham TENS Unit with standard pain control measures during Office Based Cystoscopic Intra-detrusor Onabotulinumtoxin A Injection
62443434|NCT05642156|ACTIVE_COMPARATOR|Sequential HD - Conventional HD|In sequence A patients will be treated with sequential HD first, for a total of 8 session and then switched to a conventional HD schedule for another 8 sessions.
62443435|NCT05642156|ACTIVE_COMPARATOR|Conventional HD - Sequential HD|In sequence A patients will be treated with conventional HD first, for a total of 8 session and then switched to a sequential HD schedule for another 8 sessions.
62443436|NCT04939974|ACTIVE_COMPARATOR|probiotic|The probiotic preparation selected for this study will contain use three species of probiotic bacterias namely Lactobacillus rhamnosus - ATCC 21052, Lactobacillus plantarum - ATCC 8014 and Bifidobacterium longum subsp. Infantis-ATCC 15707 at the dose of one billion (10 9 ) CFU/g of product (Total 3x10 9 CFU/g).
62443437|NCT04939974|PLACEBO_COMPARATOR|placebo|Placebo packet same in colour, smell and constituent to that of placebo one packet daily for 24 weeks
62443438|NCT03385746|EXPERIMENTAL|polyamide|metal reinforced polyamide denture base material
62443439|NCT03385746|ACTIVE_COMPARATOR|heat cured acrylic resin|conventional heat cured acrylic resin denture base
62443440|NCT05615623|EXPERIMENTAL|Blood Brain Barrier Disruption (BBBD)|Exablate MR Guided Focused Ultrasound for Blood Brain Barrier Disruption with Doxorubicin for treating pediatric patients with DIPG
62613011|NCT02464865|EXPERIMENTAL|Thiamine 1|presence of severe symptoms and signs of thiamine deficiency: heart failure, convulsion, coma, loss of ankle and knee jerks with muscular wasting and paralysis (typically symmetrical foot- and wrist-drop)
62255295|NCT04918745|OTHER|ABC|"A = Baseline stimulation, no modulation~B = Baseline stimulation, modulation stimulation~C = Reduced baseline stimulation, modulation stimulation"
62613012|NCT02464865|OTHER|Non-thiamine|no symptoms and signs of thiamine deficiency
62613013|NCT02464865|EXPERIMENTAL|Thiamine 2|presence of mild symptoms and signs of thiamine deficiency; peripheral neuropathy alone (paraesthesia of hands and feet)
62613014|NCT01052623|EXPERIMENTAL|Growth hormone-testing (GH/IGF-1-testing)|"Patients (girls over 8 years and boys over 10 years) are primed with estradiol 1 mg orally for 2 days, to help avoid false results of growth hormone (GH) levels in blood samples. Then provocation testing is done, with two tests back to back. It determines blood levels of GH and the body's response to testing with drugs called arginine and clonidine. Patients are admitted to the pediatric inpatient unit and will have an intravenous (IV) line placed in the arm. Arginine is given by IV over 30 minutes, and blood samples are taken as indicated.~The next day, the clonidine test is performed according to current guidelines. Then the IGF-1 generation test is done to see if the patient has the ability to generate IGF-1 in response to injections of GH for 5 consecutive days."
62613015|NCT05080361||Reports of adverse events associated with the use of BRAF +/- MEK inhibitors|"Reports of adverse event (individual case safety reports) from Vigibase, the World Health Organization pharmacovigilance database related to the use of BRAF +/- MEK inhibitors from inception (1986) until March, 1, 2021 will be extracted.~Cases concurrently reporting on immune checkpoint inhibitor therapies will be excluded."
62613016|NCT04544163|EXPERIMENTAL|Magnesium sulphate- Fentanyl|30 mg per kg MgSo4 infusion in 100 ml saline over 10 minutes
62613017|NCT04544163|EXPERIMENTAL|Fentanyl 4 mic|4 mic per kg fentanyl i.v
62613018|NCT04544163|ACTIVE_COMPARATOR|Fentanyl|2 mic per kg fentanyl i.v
62613019|NCT04544163|EXPERIMENTAL|Lidocaine- Fentanyl|Lidocaine 1.5 mg/kg
62613020|NCT04441749||nCLE Analysis|Needle based confocal laser endomicroscopy (nCLE) employs a small fiber which can be passed through a biopsy needle to enable real time microscopic imaging of cells. With resolution of 3.5 microns it is possible to identify key features consistent with malignancy and pulmonary fibrosis
62837744|NCT03060096|EXPERIMENTAL|Severe Anxiety/depression: High Intensity Stepped Care|Participants with severe symptoms (PHQ-9: 15-27; GAD-7: 15-21) will be randomized to high intensity stepped care (consist of a CBT workbook with accompanying psychotherapy by a Master's-level therapist delivered by telephone) or EUC. EUC consist of information about referrals/resources locally and nationally.
62837745|NCT03060096|ACTIVE_COMPARATOR|Enhanced Usual Care Control (EUC)|"Participants randomized to EUC will receive information about local referrals/resources (support groups, mental health providers, etc.). They will also be provided Facing Forward: Life after Cancer Treatment, a book developed by the NCI to assist with transition from active treatment to survivorship. Participants will receive information on self-help workbooks for anxiety \& depressive symptoms. EUC control will receive a copy of the CBT workbook on completion of the study."
62837746|NCT06096961|EXPERIMENTAL|Mothers using baby scent|Mothers in the experimental group will be given baby clothes that their babies will wear for 12 hours and will be asked to smell these clothes during the milking process. The work will continue for four days. Saliva cortisol test and mother-infant attachment scale will be applied on the first day and the last day.
62837747|NCT06096961|NO_INTERVENTION|Mothers who do not use baby scent|Mothers in the control group will express milk without any intervention. The works will continue for 4 days. Saliva cortisol test and mother-baby attachment scale will be applied on the first day and the last day.
62837748|NCT04799093||Cannabis users|
62837749|NCT04799093||Normals|
62837750|NCT06152393||Control patients|Controls were patients diagnosed with TPHA/TPPA serology ≥80 and neurological symptoms requiring a lumbar puncture.
62837751|NCT06152393||NS1 patients|NS1 includes: 1) neurological symptoms suggestive of central nervous system (CNS) involvement or acute ophthalmological or acute auditory signs consistent with neurosyhilis (NS), or syphilis with treatment serological failure (\< fourfold decrease in the antibody titer of RPR/VDRL 12 months after treatment), and 2) a TPHA/TPPA serology ≥ 80 and a CSF-TPHA/TPPA test ≥ 320, and 3) either CSF-WBC \> 5 cells/mm3, and/or CSF-protein \> 0,45g/l in the absence of other known causes of these abnormalities, and/or a reactive CSF-VDRL/RPR test, and 4) no differential diagnosis.
62837752|NCT06152393||NS2 patients|NS2 includes:1) acute ocular symptoms (recent and sudden decrease in visual acuity) and/or acute otologic dysfunctions (sudden hearing loss, acute tinnitus or vertigo) without other known diagnosis for these clinical abnormalities, 2) and a TPHA/TPPA serology ≥ 80, 3) and a response to NS treatment assessed by ophthalmologic or hearing tests and at least a fourfold reduction of RPR/VDRL titer in blood after 12 months following treatment.
62837753|NCT05486806||participants|all participants in this study must have a diagnosis of a neurodegenerative movement disorder
62837754|NCT01628666|EXPERIMENTAL|Conventional|Preoperative Antibiotics: Cefazolin preoperative, vancomycin in penicillin allergic patients.
62837755|NCT01628666|EXPERIMENTAL|Incremental|Preoperative antibiotics (Cefazolin and Vancomycin) Bacitracin pocket wash and 2 days of oral Cefalexin post operative.
62255296|NCT04918745|OTHER|ACB|"A = Baseline stimulation, no modulation~C = Reduced baseline stimulation, modulation stimulation~B = Baseline stimulation, modulation stimulation"
62443441|NCT02716883|NO_INTERVENTION|Non AMT|"Freshly prepared fortified eye drops (cefazolin 50 mg/mL and amikacin 14 mg/mL) were applied as starting treatment. In the first 3 days, eye drops are applied round the clock followed by drops every 2 h during waking hours until results of laboratory investigation were available.~After preparation of the culture results, the antimicrobial treatment was narrowed according to bacterial sensitivity. Also topical betamethasone 0.1% four times a day on a tapering weekly dosage until 3-4 weeks is used for all patients. If the patient underwent any tectonic procedure during the treatment such as keratoplasty, cyanoacrylate glue are documented"
62613021|NCT03518411|EXPERIMENTAL|Medical Students|Cognitive Behavioral Therapy Protocol
62613022|NCT06509919||Patients with elevated PSA test results (4-10ng/ml)|
62613023|NCT01134861|ACTIVE_COMPARATOR|Arm 1: Sequential ChemoRT|Vinblastine 6 mg/m2 i.v. bolus weekly first 5 weeks Cisplatin 100 mg/m2 i.v. over 30-60 minutes, days 1 \& 29 RT: 63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 50
62053978|NCT01321554|EXPERIMENTAL|Lenvatinib (Randomization Phase)|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
62053979|NCT01321554|PLACEBO_COMPARATOR|Placebo (Randomization Phase)|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
62255297|NCT04918745|OTHER|BAC|"B = Baseline stimulation, modulation stimulation~A = Baseline stimulation, no modulation~C = Reduced baseline stimulation, modulation stimulation"
62255298|NCT04918745|OTHER|BCA|"B = Baseline stimulation, modulation stimulation~C = Reduced baseline stimulation, modulation stimulation~A = Baseline stimulation, no modulation"
62255299|NCT04918745|OTHER|CAB|"C = Reduced baseline stimulation, modulation stimulation~A = Baseline stimulation, no modulation~B = Baseline stimulation, modulation stimulation"
62613024|NCT01134861|EXPERIMENTAL|Arm 2: Concurrent STD RT|Vinblastine 5 mg/m2 i.v. bolus weekly first 5 weeks Cisplatin 100 mg/m2 i.v. over 30-60 minutes, days 1 \& 29 RT: 63 GY/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1
62613025|NCT01134861|EXPERIMENTAL|Arm 3: Concurrent HFX RT|Oral VP-16 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40 (76 mg/day if BSA \< 1.7m2) Cisplatin 50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36 RT: 69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1
62613026|NCT03541707|ACTIVE_COMPARATOR|Active Therapy|
62613027|NCT03541707|SHAM_COMPARATOR|"As if Stimulation"|
62613028|NCT02787057|EXPERIMENTAL|Control group|IP vancomycin 1g every 5 days combined with IP ceftazidime 1g QD. The duration of treatment was based on internatinal society of peritoneal dialysis (ISPD) guideline recommendations.
62613029|NCT02787057|ACTIVE_COMPARATOR|study group|IP vancomycin 1g every 5 days combined with oral moxifloxacin 400mg QD. The duration of treatment was based on ISPD guideline recommendations.
62613030|NCT06058611|EXPERIMENTAL|Intervention group 1 (GI1)|Intervention group 1 (IG1) will carry out personalised and adapted computerised cognitive stimulation (CE) through the stimulus platform; 30 minutes/day, 5 days/week, 8 weeks; 40 sessions. The following will be worked on: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.
62613031|NCT06058611|EXPERIMENTAL|Intervention group 2 (GI2)|"Intervention group 2 (IG2) will perform between 2 and 5 cognitively stimulating leisure activities for 8 weeks. These leisure activities will be selected from the adapted version of the Karp et al. 2006 questionnaire (Karp et al., 2006) taking into account the three components of leisure activities (mental, physical and social). The questionnaire contains 29 activities.~In addition to indicating which cognitively stimulating leisure activities they perform on a weekly basis, participants in IG2 will indicate their daily frequency (\< 30 min, 30min-1 hour, 1-2 hours, \> 2 hours), commenting on whether they have carried them out individually or in a group. It will also be taken into account whether these activities were previously carried out according to their stage of life."
62613032|NCT06058611|NO_INTERVENTION|Control Group (CG)|The control group (CG) will not receive any intervention during the study period.
62613033|NCT01835028||Classical Low-Flow, Low-Gradient AS|"Observational study in patients with Classical Low-Flow, Low-Gradient Aortic Stenosis and Low LV Ejection Fraction undergoing surgical aortic valve replacement, transcatheter aortic valve replacement, or conservative management:~I- Baseline visit: Medical history, physical / functional evaluation, blood biomarkers, resting echocardiography, stress echocardiography, aortic valve calcium scoring by computed tomography, myocardial fibrosis by magnetic resonance imaging II- Follow-up: clinical outcomes, physical / functional evaluation, echocardiography, blood biomarkers"
62837756|NCT02282514|EXPERIMENTAL|Hematopoietic Stem Cell Transplantation|The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused intravenously before each dose of rATG. Autologous hematopoietic stem cells will be infused intravenously on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.
62837757|NCT02460419|EXPERIMENTAL|maintenance capecitabine|maintenance capecitabine plus best supportive care(BSC)
62837758|NCT02460419|OTHER|best supportive care|Best supportive care and following-up every 6-8 weeks
62837759|NCT06450483|EXPERIMENTAL|Auricular vagus stimulation in Group 1|Frequency: 25 Hz applied on the tragus of the ear, pulse length: 250 μs. A total of 4 sessions (2 sessions for 2 weeks). The sessions will be consistent with every participant where they were given their sessions on the same days every week.
62837760|NCT06450483|EXPERIMENTAL|Auricular vagus stimulation in Group 2|Frequency: 10 Hz on the tragus of the ear, pulse length: 250 μs.A total of 4 sessions (2 sessions for 2 weeks). The sessions will be consistent with every participant where they will be given their sessions on the same days every week.
62837761|NCT01550224|ACTIVE_COMPARATOR|Participant Group 1 (methylated MGMT promoter)|Participants with methylated O6-methylguanine DNA methyltransferase (MGMT) promoter, ie, expected to have no expression of MGMT protein, will be assigned into Group 1, and will receive vorinostat 500 mg orally 3 times daily for 3 days, followed by conventional doses of temozolomide (200 mg/m2 for 7 days).
62837762|NCT01550224|ACTIVE_COMPARATOR|Participant Group 2 (non-methylated MGMT promoter)|Participants with non-methylated O6-methylguanine DNA methyltransferase (MGMT) promoter, ie, expected to have expression MGMT protein, will be assigned to into Group 2, and will initially receive daily, low doses (protracted dose schedule) of temozolomide (100 mg/m2) for 14 days in an attempt to inactivate MGMT activity. Following the protracted dose schedule, participants will receive vorinostat 500 mg orally 3 times daily for 3 days, followed by conventional doses of temozolomide (200 mg/m2 for 7 days).
62837763|NCT02869880|ACTIVE_COMPARATOR|Standard Pre-consent Discussion|Standard pre-consent discussion for a clinical trial.
62255300|NCT04918745|OTHER|CBA|"C = Reduced baseline stimulation, modulation stimulation~B = Baseline stimulation, modulation stimulation~A = Baseline stimulation, no modulation"
62255301|NCT03277742|ACTIVE_COMPARATOR|Control|This arm will receive the standard of care for patients with TB and DM2
62255302|NCT03277742|EXPERIMENTAL|Intervention|This arm will receive the community intervention
62613034|NCT01835028||Paradoxical Low-Flow, Low-Gradient AS|"Observational study in patients with Paradoxical Low-Flow, Low-Gradient Aortic Stenosis and Preserved LV Ejection Fraction undergoing surgical aortic valve replacement, transcatheter aortic valve replacement, or conservative management:~I- Baseline visit: Medical history, physical / functional evaluation, blood biomarkers, resting echocardiography, stress echocardiography, aortic valve calcium scoring by computed tomography, myocardial fibrosis by magnetic resonance imaging II- Follow-up: clinical outcomes, physical / functional evaluation, echocardiography, blood biomarkers"
62613035|NCT02661061|EXPERIMENTAL|Ketamine|Trial Interventions: participants will receive four two-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
62613036|NCT02661061|ACTIVE_COMPARATOR|Midazolam|Trial Interventions: participants will receive four two-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
62837764|NCT02869880|EXPERIMENTAL|Enhanced Pre-consent Discussion|The enhanced pre-consent discussion intervention is a tool that includes both textual and graphical information regarding the trial and an interactive component designed to initiate and facilitate conversations between all parties in the decision-parent, patient, healthcare provider and research staff.
62837765|NCT02739061|ACTIVE_COMPARATOR|cognitive behavioral group therapy|cognitive behavioral group therapy
62837766|NCT02739061|ACTIVE_COMPARATOR|drug therapy|drug therapy
62255303|NCT02512133|EXPERIMENTAL|MIGS Hydrus Ivantis|opening the anterior chamber (2mm.) injecting visco-material, injecting the Hydrus stent in the Schlemm's canal under gonioscopic control
62613037|NCT05887024|OTHER|controlled|thirty patients will receive conventional physical therapy program (TENS, electric heating packs, and McKenzie back exercises).
62613038|NCT05887024|ACTIVE_COMPARATOR|shock wave therapy|thirty patients will receive radial extracorporeal shock wave therapy and conventional physical therapy program (TENS, electric heating packs, and McKenzie back exercises).
62613039|NCT03331731|EXPERIMENTAL|Single arm|Single Arm
62837767|NCT02739061|ACTIVE_COMPARATOR|The combination therapy|cognitive behavioral group therapy and drug therapy
62837768|NCT06214273|ACTIVE_COMPARATOR|Ibuprofen oral gel and miconazole oral gel|One group will receive conventional oral therapy composed of topical ibuprofen oral gel as an anti-inflammatory and analgesic and topical miconazole as an anti-fungal oral gel.
62837769|NCT06214273|EXPERIMENTAL|low-level diode laser diode laser|The second group will receive a diode laser with a wave length range of 800-980 nm and power less than 500 ml.
62837770|NCT06214273|EXPERIMENTAL|Chamomile|The third group will receive chamomile 3% mucoadhesive gel.
62837771|NCT03805282|EXPERIMENTAL|Female 18 to 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
62613040|NCT01724684|OTHER|Telehealth program|Telehealth program service
62613041|NCT01724684|OTHER|Usual care|Usual care service
62837772|NCT03805282|ACTIVE_COMPARATOR|Male 18 to 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
62837773|NCT03805282|ACTIVE_COMPARATOR|Male > 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
62837774|NCT03805282|ACTIVE_COMPARATOR|Female > 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
62837775|NCT05176405|EXPERIMENTAL|Elissa's EE Song|Participants will have to click on the watch button to start the YouTube video as it is without manipulation. Right after exposure, the first and second arms will be asked if they have seen either of the presented materials before.
62255304|NCT02512133|EXPERIMENTAL|SLT|Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
62255305|NCT04972240|ACTIVE_COMPARATOR|Customized PEEK abutment/ crown on a Ti base.|
62255306|NCT04972240|NO_INTERVENTION|Prefabricated titanium abutment, supporting ceramometal separate crown.|
62613042|NCT06319560|EXPERIMENTAL|Hydroxychloroquine group|Oral hydroxychloroquine 200mg daily will be prescribed to women in this group from recruitment (14-20 weeks) till delivery
62613043|NCT06319560|NO_INTERVENTION|Standard treatment group|Women will receive standard treatment for diabetes such as metformin and insulin.
62837776|NCT05176405|ACTIVE_COMPARATOR|Standard of Care|Participants will be assigned to read general infographic messages adopted from the Saudi Ministry of Health (MOH) in the breast cancer early screening context in Arabic/English. Right after exposure, the first and second arms will be asked if they have seen either of the presented materials before.
62837777|NCT05176405|NO_INTERVENTION|Control Group|The third arm of this trial is the control group who will not be exposed to any preventative messages.
62837778|NCT04961411||published cases of patients with gallstone ileus|We will observe clinical signs, diagnostic procedures and therapeutic procedures and options
62613044|NCT01643278|EXPERIMENTAL|Treatment (dasatinib and ipilimumab)|Patients receive dasatinib PO QD for 7 days. Patients then receive dasatinib PO QD and ipilimumab IV once on weeks 1, 4, 7 and 10. Beginning on week 24, patients then receive dasatinib PO QD and ipilimumab IV once every 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62837779|NCT00904592|EXPERIMENTAL|Qi ming granula|"Study group(combined therapy with Intervention of TCM): Basic therapy ＆ treating both on deficiency and stasis of blood.~1. Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management, exercise and education.~2. Qi ming granula, Usage: 4.5g，po，tid."
62053980|NCT01321554|EXPERIMENTAL|Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)|Participants will receive lenvatinib 24 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
62053981|NCT01321554|EXPERIMENTAL|Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)|Participants will receive lenvatinib 20 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
62613045|NCT06252467|ACTIVE_COMPARATOR|Active Comparator|"Device: Active Photobiomodulation Therapy Phototherapy treatment (Photobiomodulation therapy or placebo) was performed using a Photobiomodulation therapy device (Vectra Genisys Systems, Chattanooga Group, Dallas, TX, USA). The cluster probe consisted of five low-level laser therapy diodes (850 nm) and 28 light emitting diodes therapy (670 nm, 880 nm, and 950 nm). Photobiomodulation therapy was applied in nine sites of each quadriceps femoris muscle~. A dosage of 15 J per site led to a total energy of 135 J per thigh, effectively increasing cycling performance in a previous study. We chose to apply Photobiomodulation therapy specifically to the quadriceps femoris because this muscle group is of utmost significance in generating torque and propelling the pedaling cycle. Its pivotal role in cycling performance made this muscle a prime target for the Photobiomodulation therapy intervention in our study."
62738864|NCT05511376|ACTIVE_COMPARATOR|EXERCISE|"A pre-exercise breathing exercise study was planned.~Exercise:~It was planned to apply the Moderate Resistant Exercise Protocol (3 days a week for 60 minutes) and as aerobic exercise, walking 5 days a week (150 minutes / week) as 30 minutes / day."
62053982|NCT04318184|EXPERIMENTAL|Exercise|Submaximal aerobic exercise protocol
62053983|NCT06491472|EXPERIMENTAL|Ivonescimab(AK112/SMT112)+SBRT+gemcitabine+nab-paclitaxel|"Ivonescimab(AK112/SMT112) (20mg/kg,Q3W) +gemcitabine(1000 mg/m²,IV, d1/8, Q3W)+nab-paclitaxel(25mg/m2, IV, d1/8, Q3W)~+SBRT(5Gy \*5 F)"
62053984|NCT05741957|EXPERIMENTAL|Once-a-week Exercise|Once-a-week vigorous-intensity exercise for 4 months.
62053985|NCT05741957|EXPERIMENTAL|Thrice-a-week Exercise|Thrice-a-week vigorous-intensity exercise for 4 months.
62053986|NCT05741957|OTHER|Usual Care Control|Bi-weekly health education for 4 months.
62053987|NCT01291914|EXPERIMENTAL|FX005|
62053988|NCT01291914|PLACEBO_COMPARATOR|Placebo 1 (Carrier)|
62053989|NCT01291914|PLACEBO_COMPARATOR|Placebo 2 (Diluent)|
62738865|NCT05511376|ACTIVE_COMPARATOR|AURICULAR VAGUS NERVE STIMULATION|"The Vagustim device was applied in Biphasic, Frequency 10 Hz, Modulation mode, with a pulse width of 300 μs, for 30 minutes /3 days/week by keeping the current intensity constant where the participants felt comfortable.~It will be applied as bilateral VSS from the tragus and turbinate parts of the ear."
62738866|NCT03781973|NO_INTERVENTION|Pre-intervention|"Those whose last pediatric visit was in the year before the intervention (2018).~Medical record data abstracted from patient charts at the time of the final pediatric visit."
62738867|NCT03781973|OTHER|Early Intervention|"Those whose last pediatric visit was in the year immediately after the start of the intervention (2019).~The intervention will begin on Jan 1, 2019 and includes the following :~1. Data Platform: Medical record data abstracted from patient charts at the time of the final pediatric visit. .~2. Quality performance feedback reports: We will generate centre-level performance reports. Centres will be able to compare their performance to that of all other centres and to achievable benchmarks.~3. Patient transition experience surveys at the final pediatric visit and 12 months later.~4. Diabetes teams may direct patients and families to online transition resources."
62837780|NCT00904592|PLACEBO_COMPARATOR|placebo comparator|"Control group: Basic therapy ＆ placebo~1. Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~2. placebo,Usage: 4.5g，po，tid"
62053990|NCT05161299||Control (normal practice)|Patients that underwent surgery (across all specialities), performed by a surgeon in an operating theatre, AND had a positive SARS-CoV-2 PCR swab or rapid antigen test (if PCR swab is not available) within 7 days before or 30 days after surgery. Patients can be included regardless of whether a specific variant is suspected or unknown
62053991|NCT01426971|EXPERIMENTAL|Ibuprofen+caffeine|2 capsules
62053992|NCT01426971|ACTIVE_COMPARATOR|Ibuprofen|2 capsules
62053993|NCT06196450|EXPERIMENTAL|Intervention arm|Vivomixx also known as VSL#3, Powder (in sachets), weight 4.4g, 450 X 10\^9 cfu of probiotic bacteria per sachet, dose 1 sachet daily for 56 days
62053994|NCT06196450|PLACEBO_COMPARATOR|Placebo arm|Microcrystalline maltose, Powder (in sachets), weight 4.4g, dose 1 sachet daily for 56 days
62255307|NCT05472467|EXPERIMENTAL|Immunotherapy combined with Stereotactic Body Radiation Therapy|"1. Camrelizumab： 200mg IV Q3W~2. Chemotherapy：Squamous carcinoma: docetaxel 60 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6 d1, 21 days for one cycle, up to 4 cycles.~   Non-squamous carcinoma: pemetrexed 500 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6, d1,21 days for one cycle, up to 4 cycles.~3. Stereotactic Body Radiation Therapy(SBRT) for Oligometastatic the total dose 35Gy/5f(7.0Gy/f,5f per week)。"
62443442|NCT02716883|ACTIVE_COMPARATOR|AMT|"This group (case group) received above mentioned routine antibiotic therapy followed by double-layer amniotic membrane transplantation 2-5 days after the start of medications and the second group (control group) only received routine antibacterial therapy.~The AM was trimmed in two layers to fit the corneal ulcer and was placed with its epithelium (basement membrane) side up, secured with 10/0 nylon sutures, supported by a therapeutic contact lens. If the patient underwent any tectonic procedure during the treatment such as keratoplasty, cyanoacrylate glue are documented."
62443443|NCT01815021|EXPERIMENTAL|amorphous calcium carbonate|50, 100 and 200 mg elemental calcium tablets, according to the doctor's decision
62837781|NCT04948359||Group I (The patients intubated with cuffed ETT of ID number 4.5)|Groups are classified according to endotracheal tube ID numbers. In this group we aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 4.5 size internal diameter (ID) endotracheal cuff tube.
62255308|NCT06360250|EXPERIMENTAL|Experimental group|Each dose (1.0 ml) contained 1.25 mg of fully human anti-tetanus toxin monoclonal antibody A82 and 1.25 mg of fully human anti-tetanus toxin monoclonal antibody B86,2.5 mg (1.0 ml) / vial
62255309|NCT06360250|ACTIVE_COMPARATOR|Positive control group|Tetanus with human immunoglobulin
62255310|NCT06360250|PLACEBO_COMPARATOR|Placebo group|There were no active ingredients, and other ingredients were the same
62255311|NCT02821923|NO_INTERVENTION|Control|no treatment
62255312|NCT02821923|ACTIVE_COMPARATOR|E967-Xylitol|24g xylitol/d
62443444|NCT01815021|ACTIVE_COMPARATOR|crystalline calcium supplements|Tablets, according to the doctor's decision
62443445|NCT00565981|EXPERIMENTAL|Overall study|The FLUSALEM protocol combines 4 cycles of oral fludarabine phosphate (40mg/m² d1-3; q 29d) and an intensive dose schedule of alemtuzumab (30mg sc.3 times weekly for 16 weeks) in an outpatient setting
62053995|NCT06184711|EXPERIMENTAL|Transcranial Magnetic Stimulation combined with the McNeill Dysphagia Therapy Programme|The McNeill Dysphagia Therapy programme (MDTP) combined with Transcranial Magnetic Stimulation (TMS) will be applied to the first experimental group.
62255313|NCT02821923|ACTIVE_COMPARATOR|E968-Erythritol|36g erythritol/d
62255314|NCT01554644|ACTIVE_COMPARATOR|Prontosan Solution and Gel|ProntosanTM Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and ProntosanTM Wound Gel (PHMB 0.1%, Betaine 0.1%)
62255315|NCT01554644|PLACEBO_COMPARATOR|Saline Solution and Inert Gel|
62613046|NCT06252467|PLACEBO_COMPARATOR|Placebo Comparator|Device: Placebo Photobiomodulation The placebo treatment was performed in exactly the same manner as the Photobiomodulation therapy treatment, but with the device switched off, and the cluster was held stationary in contact with the skin at a 90° angle, with light pressure on the skin. The total application time of Photobiomodulation therapy or placebo was \~5 min for both limbs (9 points per thigh = 18 points × 16 s per point) before each time-to-exhaustion test.
62613047|NCT06400004|ACTIVE_COMPARATOR|Bolus administration|Bolus administration of 2 mL undiluted Lumason®
62255316|NCT01417338||Pulmonary hypertension group|Patients who were firstly diagnosed as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
62613048|NCT06400004|EXPERIMENTAL|Continuous infusion|Continuous infusion of 8 mL of diluted Lumason®
62613049|NCT03394625|EXPERIMENTAL|immediate implant placement using socket shield technique|Socket shield technique is a recent technique which is by sectioning the root and extraction of palatal part and leaving buccal part of the root with its attachment of periodontal ligament and vascularization still intact then placing implant in palatal socket.
62255317|NCT03163251|EXPERIMENTAL|READ-SG Cohort|Each post-graduate year (PGY) will receive the intervention of a monthly peer-facilitated small group sessions (READ-SG Sessions) based on topics that are common to residency training and based on themes regarding humanism in medicine.
62443446|NCT06036758||Persons with Stage 2 to Stage 3 AKI|Persons with Stage 2 to Stage 3 AKI who are in the ICU.
62255318|NCT05897723|EXPERIMENTAL|Treatment Group|All enrolled subjects will undergo breast reduction or breast mastectomy in which scar assessment will be made after pre-surgical treatment in a split-body design, involving a single treatment of RF application to one side of the surgical area(s) within 24 hours prior to the procedure. The subject will act as their own control, where one surgical area will be treated, and the other will not be and will act as the control. Tissue samples will be biopsied from RF treated skin, as well as non-treated skin, at follow up visits. The samples will be used for histological evaluation to assess tissue structure and regeneration following surgery.
62255319|NCT03715894||Patients with aortic stenosis|Patients receiving Edwards SAPIEN 3 aortic transcatheter valve Implantation, who are with a high risk for PPI
62255320|NCT02779959|EXPERIMENTAL|Buccal Prochlorperazine|Experimental arm of two buccally absorbable prochlorperazine tablets (6 mg) plus 2 cc IV saline
62443447|NCT02539030|ACTIVE_COMPARATOR|microfracture|simple microfracture for cartilage defect of knee
62443448|NCT02539030|EXPERIMENTAL|modified microfracture using collagen|modified microfracture using collagen (CartiFill) for cartilage defect of knee
62443449|NCT01396044|EXPERIMENTAL|Electronic checklist|Electronic checklist
62443450|NCT01396044|EXPERIMENTAL|Verbal prompting|Verbal prompting with written checklist
62443451|NCT01021995|EXPERIMENTAL|echinacea|
62443452|NCT01021995|PLACEBO_COMPARATOR|placebo|
62443453|NCT05017233|EXPERIMENTAL|Experimental group, all volunteer will be scanned.|All participation accept Spectral CT scanning; No group;
62053996|NCT06184711|SHAM_COMPARATOR|Sham Transcranial Magnetic Stimulation combined with the McNeill Dysphagia Therapy programme|The McNeill Dysphagia Therapy programme (MDTP) combined with sham Transcranial Magnetic Stimulation (TMS) will be applied to the sham comparator group.
62053997|NCT06184711|EXPERIMENTAL|Transcranial Magnetic Stimülation|Only Transcranial Magnetic Stimulation (TMS) will be applied to the second experimental group.
62255321|NCT02779959|ACTIVE_COMPARATOR|Intravenous Prochlorperazine|Accepted Standard of care receiving 10 mg (2 cc) of intravenous prochlorperazine plus two saccharin absorbable placebo tablets.
62255322|NCT01490814|ACTIVE_COMPARATOR|Cryoballoon ablation|
62255323|NCT01490814|ACTIVE_COMPARATOR|Radiofrequency ablation|
62443454|NCT05635825||Healthy Asian|Healthy Asian, non-vegetarian that is aged between 21 to 99, literate and numerate.
62443455|NCT05877820|EXPERIMENTAL|Tislelizumab+Lenvatinib combination therapy|Participants receive tislelizumab 200 mg intravenously every 3 weeks PLUS lenvatinib 20mg orally once daily.
62443456|NCT00106028|PLACEBO_COMPARATOR|Placebo Daily|placebo tablet, once a day for one year then for two years open label risedronate
62443457|NCT00106028|EXPERIMENTAL|Risedronate Daily|risedronate tablet, once a day for one year then for two years open label risedronate once a day
62443458|NCT05477979||Cohort 1: advanced NSCLC patients receiving first-line ICIs (STRESS-LUNG-1 study)|For stage IIIB-IV patients with NSCLC who have received immune checkpoint inhibitors as first-line therapy.
62443459|NCT05477979||Cohort 2: limited-stage and extensive-stage SCLC patients receiving ICIs (STRESS-LUNG-2 study)|For limited-stage and extensive-stage SCLC patients who have received immune checkpoint inhibitors
62443460|NCT05477979||Cohort 3: NSCLC patients receive neoadjuvant therapy of ICIs（STRESS-LUNG-3 study）|For stage IB-IIIB patients with non-small cell lung cancer who have received neoadjuvant therapy of immune checkpoint inhibitors.
62443461|NCT05477979||Cohort 4: NSCLC patients receive radical resection (STRESS-LUNG-4 study))|For early-stage patients with non-small cell lung cancer who have received radical resection.
62443462|NCT04829695|EXPERIMENTAL|Artesunate-amodiaquine (Arm A)|Artesunate-amodiaquine is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
62443463|NCT04829695|ACTIVE_COMPARATOR|Artemether-lumefantrine (Arm B)|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
62443464|NCT04431986||NuAge participants|All Individuals of the NuAge study who agreed to be part of the NuAge Database for future research purposes
62443465|NCT00969332|EXPERIMENTAL|Omegaven|0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
62443466|NCT05763433||ambulatory upper limb bone surgery carried out under axillary PNB|Patients will receive a slow intravenous injection of 0.1mg/kg max 10 mg intravenous dexamethasone in a 2cc syringe (5 mg/cc dexamethasone) after PNB is performed, prior to tourniquet placement and the start of surgery.
62613050|NCT03394625|ACTIVE_COMPARATOR|immediate implant placement using xenograft material|placing xenograft material in gap between implant and buccal bone
62255324|NCT06299657|EXPERIMENTAL|IMPROVE|In this arm, participants will receive the IMPROVE intervention, a clinician-delivered protocol targeting anxiety and uncertainty.
62837782|NCT04948359||Group II (The patients intubated with cuffed ETT of ID number 5.0)|Groups are classified according to endotracheal tube ID numbers. In this group we aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.0 size internal diameter (ID) endotracheal cuff tube.
62255325|NCT06299657|ACTIVE_COMPARATOR|PHET|In this arm, participants will receive a clinician-delivered protocol with a digital component, called PHET. PHET focuses on healthy living more broadly and does not include information about anxiety or uncertainty.
62255326|NCT01458912|EXPERIMENTAL|BI 54903 HD q.d.|Patients receive 2 puffs BI 54903 HD q.d. via Respimat inhaler (p.m.) combined with 2 puffs placebo (a.m.)
62255327|NCT01458912|PLACEBO_COMPARATOR|Placebo|Patients receive 2 puffs Placebo b.i.d. via Respimat inhaler
62255328|NCT01458912|EXPERIMENTAL|BI 54903 MD b.i.d.|Patients receive 2 puffs BI 54903 MD b.i.d.via Respimat inhaler
62255329|NCT00714675|EXPERIMENTAL|1|Citrulline
62255330|NCT00714675|ACTIVE_COMPARATOR|2|Amino acids
62255331|NCT05092542|NO_INTERVENTION|Random Sample of Latinx Immigrants|random sample comparison group of Latinx immigrants who are NOT randomly assigned to a treatment condition
62837783|NCT04948359||Group III (The patients intubated with cuffed ETT of ID number 5.5)|Groups are classified according to endotracheal tube ID numbers. In this group we aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.5 size internal diameter (ID) endotracheal cuff tube.
62255332|NCT05092542|EXPERIMENTAL|Refugee & Immigrant Well-being Project (RIWP) Intervention|6-month mental health intervention that pairs university students with newcomers to engage in mutual learning, resource mobilization, and social change efforts
62255333|NCT05092542|NO_INTERVENTION|Treatment-as-usual Waitlist Control Group|participants recruited from community-based organizations receive usual services from community-based organizations and may participate in RIWP intervention in Year 3
62255334|NCT05244291|EXPERIMENTAL|Intervention Group 1|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times in 1 weeks.
62255335|NCT05244291|EXPERIMENTAL|Intervention Group 2|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
62255336|NCT05244291|NO_INTERVENTION|Control Group|The therapeutic touch will not be applied to the control group infants. However, the routine follow-up and behavior of the weekly baby will be evaluated to ensure that parents are blind.
62255337|NCT02354222|EXPERIMENTAL|Teneligliptin + Canagliflozin|Patients receive Teneligliptin for 24 weeks in combination with Canagliflozin.
62255338|NCT02354222|PLACEBO_COMPARATOR|Placebo + Canagliflozin|Patients receive placebo for 24 weeks in combination with Canagliflozin.
62443467|NCT03058510||Stable CAD Patients|Stable CAD patients with calcified bifurcation lesion
62443468|NCT03588390|EXPERIMENTAL|Dose Group 1|Participants were orally administered single dose of BI 1323495 dose group 1 or matching placebo film-coated tablet with 240 mL of water after an overnight fast of at least 10 h.
62255339|NCT04100681|ACTIVE_COMPARATOR|Active FlowOx™|The application of pulsating negative pressure will be up to 120 minutes long per day. The pulsating negative pressure used will be approximately 40 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.
62255340|NCT04100681|SHAM_COMPARATOR|Sham FlowOx™ (Placebo)|The application of a mild pulsating negative pressure will be up to 120 minutes long. The pulsating negative pressure used will be approximately 10 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.
62255341|NCT02724384|EXPERIMENTAL|Group 1|Plasma treatment using Plasma delivery system A 3 treatments/week for 2 weeks, then monthly
62255342|NCT02724384|EXPERIMENTAL|Group 2|Plasma treatment using Plasma delivery system A 2 treatments/week for 2 weeks, then monthly
62443469|NCT03588390|EXPERIMENTAL|Dose Group 2|Participants were orally administered single dose of BI 1323495 dose group 2 or matching placebo film-coated tablet with 240 mL of water after an overnight fast of at least 10 h.
62837784|NCT00060840|ACTIVE_COMPARATOR|Inhaled Nitric Oxide|Inhaled Nitric Oxide (iNO) at 40 parts per million (ppm)
62837785|NCT00060840|PLACEBO_COMPARATOR|Nitrogen|Nitrogen (N2) administered at 40 ppm.
62053998|NCT01115257|OTHER|group 1|90 eyes of 90 patients, with severe PDR, some with tractional retinal detachment (TRD) not involving the macula were included in the study and treated with vitrectomy
62613051|NCT06046209|EXPERIMENTAL|Control Lens, then Test Lens|Participants wore the Control Lens for 90 minutes, then the Test Lens for 90 minutes.
62613052|NCT06046209|EXPERIMENTAL|Test Lens, then Control Lens|Participants wore the Test Lens for 90 minutes, then the Control Lens for 90 minutes.
62613053|NCT04373564|EXPERIMENTAL|Linear GBCAs|Adult participants, who were scheduled for repeated enhanced magnetic resonance imaging (MRI), receive a linear gadoliniumbased contrast agent (GBCA, i.e. Eovist/ Primovist, MultiHance or Omniscan) prior to MRI. Each participant will receive the same GBCA throughout the study.
62053999|NCT01115257|OTHER|panretinalphotocoagulation (group 2)|90 eyes of 90 patients, with severe PDR, some with tractional retinal detachment (TRD) not involving the macula were included in the study and treated with panretinalphotocoagulation
62255343|NCT02724384|EXPERIMENTAL|Group 3|Plasma treatment using Plasma delivery system B 3 treatments/week for 2 weeks, then monthly
62255344|NCT03062592|NO_INTERVENTION|Screening/Baseline|A standard OGTT with no supplementation/intervention
62255345|NCT03062592|EXPERIMENTAL|Non-hydrolyzed pine nut oil|Standard OGTT supplemented with 3 g of non-hydrolyzed pine nut oil
62255346|NCT03062592|EXPERIMENTAL|hydrolyzed pine nut oil|Standard OGTT supplemented with 3 g of hydrolyzed pine nut oil
62255347|NCT01537198||Pediatric Participants at High Risk of RSV|Pediatric participants at high risk of respiratory syncytial virus (RSV) in need of the prevention of serious lower respiratory tract disease caused by RSV were prescribed Synagis prophylaxis in usual practice according to the approved Korean product label. The decision to prescribe or not to prescribe Synagis was taken prior to a participant's enrollment in the study.
62255348|NCT04524702|EXPERIMENTAL|Treatment (paricalcitol, hydroxychloroquine, chemotherapy)|Beginning day -14, patients receive paricalcitol IV three times weekly and hydroxychloroquine PO BID. Patients also receive gemcitabine IV over 30 minutes and nab-paclitaxel IV over 30 minutes on days 1, 8, 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62255349|NCT01529099|EXPERIMENTAL|Sigma HP Partial Knee|Partial knee replacement
62255350|NCT02317211|PLACEBO_COMPARATOR|control|placebo 320 mg daily for twelve weeks
62255351|NCT02317211|EXPERIMENTAL|anthocyanins treatment|anthocyanin supplement 320mg daily for twelve weeks
62255352|NCT02472041|EXPERIMENTAL|Reanimator Group|Reanimator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®), which was connected in a circuit extending along the Muller Resuscitator equipment applied continuously for four series 10 of the patient breaths active and with an interval of two minutes between them in Fowler 45 position
62613054|NCT04373564|EXPERIMENTAL|Macrocyclic GBCAs|Adult participants, who were scheduled for repeated enhanced magnetic resonance imaging (MRI), receive a macrocyclic gadolinium-based contrast agent (GBCA, i.e. Gadavist/ Gadovist, Dotarem, Magnescope or ProHance) prior to MRI. Each participant will receive the same GBCA throughout the study.
62613055|NCT04373564|OTHER|No GBCA (Control arm)|Adult participants who were never exposed to any gadolinium-based contrast agent and matching the population characteristics of the two GBCA arms. They will not receive any gadolinium-based contrast agent over the study course, but may undergo clinically indicated imaging (e.g. unenhanced magnetic resonance imaging (MRI), unenhanced or enhanced computed tomography, ultrasound and/or X-ray).
62054000|NCT05797103|EXPERIMENTAL|electrolyzed water spray group|Participants with bacteria E-coli and an attenuated human flu virus on their hands will receive one treatment with the novel electrolyzed water and complete the questionnaire.
62054001|NCT05797103|EXPERIMENTAL|untreated tap water group|Participants with bacteria E-coli and an attenuated human flu virus on their hands will receive one treatment with the untreated tap water and complete the questionnaire.
62613056|NCT06176469||Population-level and representative cohort|
62613057|NCT01417858|ACTIVE_COMPARATOR|brimonidine 0.2%|
62613058|NCT01417858|ACTIVE_COMPARATOR|brimonidine 0.1%|
62613059|NCT02942043|EXPERIMENTAL|Group A (low dose group)|Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
62054002|NCT03320018|EXPERIMENTAL|Hydrogen/Minocycline|"Hydrogen will be infused into aqueous solution (normal saline or water) at as high a concentration as possible (saturation = 1.6 ppm), and administered intravenously or orally respectively, TID for 3 days.~Similarly, Minocycline will be administered either i.v. or p.o. once daily for 5 days."
62054003|NCT03320018|PLACEBO_COMPARATOR|Placebo Hydrogen/Placebo Minocycline|Normal saline will be substituted for both Hydrogen and Minocycline for intravenous administration. Water will be substituted for hydrogen when administered p.o., and placebo capsules will be substituted for minocycline.
62054004|NCT00223626|EXPERIMENTAL|Topiramate|
62054005|NCT00223626|PLACEBO_COMPARATOR|Placebo|
62613060|NCT02942043|EXPERIMENTAL|Group B (medium dose group)|Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
62054006|NCT04136886|ACTIVE_COMPARATOR|IMRT and concurrent cisplatin|IMRT and concurrent cisplatin to treat T3/T4 locally recurrent NPC patients. Cisplatin 100mg/M2 is to give D1,D22 of IMRT for 2 cycles. IMRT is to give GTV 60Gy in 27 fraction
62837786|NCT01695304|EXPERIMENTAL|Intervention Arm|Households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water.
62837787|NCT01695304|NO_INTERVENTION|Control Arm|Households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
62255353|NCT02472041|EXPERIMENTAL|Control Group|Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment (Table 1). Guidelines to the active, progressive and early mobilization.
62255354|NCT04154670|EXPERIMENTAL|Normal kidney function|MGTA-145 single dose
62255355|NCT04154670|EXPERIMENTAL|Mild decrease in GFR|MGTA-145 single dose
62837788|NCT00865566|EXPERIMENTAL|1|Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
62837789|NCT00865566|PLACEBO_COMPARATOR|2|Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
62837790|NCT03162549||Inflammatory Bowel Disease|Pts presenting to enrolling sites across the US are invited to enroll if eligible
62837791|NCT04139213|ACTIVE_COMPARATOR|Usual care|usual medication assisted treatment for maintenance care of opioid use disorder
62837792|NCT04139213|EXPERIMENTAL|Pharmacy MAT|pharmacy-based medication assisted treatment for maintenance care of opioid use disorder
62837793|NCT02944487|EXPERIMENTAL|Single ascending doses of lucerastat|Subjects were enrolled sequentially in 4 groups and received a single oral dose of lucerastat from 100 mg to 1000 mg in the morning of Day 1
62837794|NCT02944487|EXPERIMENTAL|B.i.d. Dose Group|Subjects received two doses of lucerastat (2 x 1 g) 12 hours apart on Day 1
62837795|NCT02944487|PLACEBO_COMPARATOR|Placebo for singe ascending doses|These subjects received matching placebo administered orally in the morning of Day 1
62837796|NCT02944487|PLACEBO_COMPARATOR|Placebo for b.i.d.Group|These subjects received matching placebo administered orally in the morning and in the evening of Day 1
62054007|NCT04136886|EXPERIMENTAL|IMRT alone|IMRT alone to treat T3/T4 locally recurrent NPC patients. IMRT is to give 60Gy in 27 fraction
62255356|NCT04154670|EXPERIMENTAL|Moderate decrease in GFR|MGTA-145 single dose
62255357|NCT00382720|EXPERIMENTAL|TE (Taxotere and Eloxatin)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin). Each chemotherapy cycle was repeated every 21 days.~Participants received either the optimal or non-optimal dose for Taxotere and Eloxatin. Participants who received the optimal dose for Taxotere and Eloxatin were analyzed in this study."
62443470|NCT03588390|EXPERIMENTAL|Dose Group 3|Participants were orally administered single dose of BI 1323495 dose group 3 or matching placebo film-coated tablet with 240 mL of water after an overnight fast of at least 10 h.
62443471|NCT03588390|EXPERIMENTAL|Dose Group 4|Participants were orally administered single dose of BI 1323495 dose group 4 or matching placebo film-coated tablet with 240 mL of water after an overnight fast of at least 10 h.
62443472|NCT03588390|EXPERIMENTAL|Dose Group 5|Participants were orally administered single dose of BI 1323495 dose group 5 or matching placebo film-coated tablet with 240 mL of water after an overnight fast of at least 10 h.
62443473|NCT03588390|EXPERIMENTAL|Dose Group 6|Participants were orally administered single dose of BI 1323495 dose group 6 or matching placebo film-coated tablet with 240 mL of water after an overnight fast of at least 10 h.
62443474|NCT03588390|EXPERIMENTAL|Dose Group 7|Participants were orally administered single dose of BI 1323495 dose group 7 or matching placebo film-coated tablet with 240 mL of water after an overnight fast of at least 10 h.
62443475|NCT03588390|EXPERIMENTAL|Dose Group 8|Participants were orally administered single dose of BI 1323495 dose group 8 or matching placebo film-coated tablet with 240 mL of water after an overnight fast of at least 10 h.
62443476|NCT02566135|ACTIVE_COMPARATOR|Group-I|Tracheal intubation using I-gel and ventilating bougie insertion. In Group-I, following general anaesthesia I-gel is to be inserted, through it ventilating bougie is to be inserted then I-gel is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
62443477|NCT02566135|ACTIVE_COMPARATOR|Group-C|Tracheal intubation using C-LMA and ventilating bougie insertion. In Group-C, following general anaesthesia C-LMA is to be inserted, through it ventilating bougie is to be inserted then C-LMA is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
62443478|NCT01896297|OTHER|dabigatran etexilate|75mg BID by oral
62443479|NCT01666886|EXPERIMENTAL|Mandibular Advancement Device (MAD)|Mandibular advancement during therapy with a mandibular advancement device (MAD) in 90% of maximal protrusion
62443480|NCT06321081|EXPERIMENTAL|ICE treatment group|any RAS wild type mCRC patients who had got benefits from cetuximab or irinotecan will be treated with ICE regimen (Irinotecan 150mg/m2,Q2W, cetuximab 500mg/m2, Q2W, envafolimab 200mg, Q2w)
62443481|NCT02517190|OTHER|Stress response measurements|
62443482|NCT00918970||SNA group|This group will have a real-time analysis of autonomic nervous system activity during its intensive care hospitalisation
62443483|NCT00918970||Clinical group|This group will have a conventional clinical analysis during its intensive care hospitalisation
62054008|NCT06492980|EXPERIMENTAL|Triple-branched stent graft group|The device in this clinical trial implanted covered stents in the aortic arch, three branches, and descending thoracic aorta, replacing surgical anastomosis with interventional treatment.
62054009|NCT06492980|ACTIVE_COMPARATOR|Aortic arch replacement with frozen elephant trunk|This surgical method is ascending aorta + arch replacement + elephant trunk stent , that is, artificial blood vessels are used to replace the ascending aorta and aortic arch, arch anastomosis or three-branch blood vessel anastomosis is performed in the aortic arch, and a covered stent is placed in the descending thoracic aorta (Frozen Elephant Trunk Technique).
62613061|NCT02942043|EXPERIMENTAL|Group C (high dose group)|Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
62613062|NCT05981014|EXPERIMENTAL|Phase I and phase II: Chemotherapy + LNL treatment|Participants in both phase I and phase II portions receive two cycles of doxorubicin or epirubicin, plus cyclophosphamide (AC or EC), followed by neoadjuvant LNL treatment, which consists of non-myeloablative lymphocyte depleting regimen of chemotherapy with cyclophosphamide and fludarabine, followed by infusion of LNL and interleukin-2. After LNL treatment, participants receive four-cycles of nab-paclitaxel as neoadjuvant therapy prior to definitive surgery. The choice of doxorubicin or epirubicin should be the same as the prior neoadjuvant chemotherapy.
62613063|NCT05981014|ACTIVE_COMPARATOR|Phase II: Chemotherapy|The single-arm phase I study did not have this arm. Participants in phase II portion receive two cycles of doxorubicin or epirubicin, plus cyclophosphamide (AC or EC), followed by four-cycles of nab-paclitaxel as neoadjuvant therapy prior to definitive surgery. The choice of doxorubicin or epirubicin should be the same as the prior neoadjuvant chemotherapy.
62613064|NCT01065909||Diabetes type 2|
62613065|NCT01065909||Chronic Pain|
62613066|NCT01065909||Atrial Fibrillation|
62613067|NCT02045732|EXPERIMENTAL|Cohort 1|
62613068|NCT02045732|EXPERIMENTAL|PF-06342674 1.5 mg/kg|
62613069|NCT02045732|EXPERIMENTAL|PF-06342674 6.0 mg/kg (q2 Weeks)|
62613070|NCT02045732|EXPERIMENTAL|PF-06342674 6.0 mg/kg (q1 Week)|
62613071|NCT06209281|EXPERIMENTAL|Experimental group 1|1 drop each time, once every night at bedtime
62613072|NCT06209281|EXPERIMENTAL|Experimental group 2|1 drop each time, once every night at bedtime
62613073|NCT06209281|EXPERIMENTAL|control group|1 drop each time, once every night at bedtime
62837797|NCT05991297|ACTIVE_COMPARATOR|Classical physical therapy and rehabilitation program|Classical rehabilitation program (stretching, strenght, balance and coordination exercise) for fifty minutes.
62837798|NCT05991297|EXPERIMENTAL|Deep sensory asisted therapy and rehabilitation program|Deep sensory asisted rehabilitation program (stretching, strenght, balance and coordination and deep sensory exercises) for fifty minutes.
62837799|NCT06250348||ARDS patients|ARDS patients admitted in ICU ;intubated and mechanically ventilated for less than 24 hours
62837800|NCT06250348||Control group|Healthy subjects without pulmonary nor inflammatory pathology, who underwent a benign surgical procedure (thyroid or parathyroid surgery) requiring general anesthesia with intubation and mechanical ventilation.
62837801|NCT01641185|EXPERIMENTAL|protons|irradiation 20 x 3,3 GyE protons
62837802|NCT01641185|EXPERIMENTAL|carbon ions|irradiation 20 x 3,3 GyE carbon ions
62443484|NCT05653713|EXPERIMENTAL|CSL324|Intravenous (IV) dose of CSL324
62837803|NCT03088956||bvFTD|Participants with behavioral variant frontotemporal dementia (bvFTD) (n=37)
62837804|NCT03088956||Healthy|Healthy Participants (n=10)
62837805|NCT01424072|NO_INTERVENTION|Control Group|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
62837806|NCT01424072|EXPERIMENTAL|Auriculotherapy by needles|The investigators used 3 points, Shenmen, Kidney, and Brain Stem with semi-permanent needles of 1.8 mm, 1 time per week for 8 sessions.
62443485|NCT05653713|PLACEBO_COMPARATOR|Placebo|IV dose of 0.9% saline
62443486|NCT01686178|EXPERIMENTAL|Anti-smoking social marketing campaign|"In prior research, a high risk subpopulation of young adults was identified in San Diego, CA: the hipster subculture. We developed a yearlong pilot social branding intervention to decrease smoking among this group, using social events and social leaders to promote a strong nonsmoking lifestyle. The intervention rationale is based on utilizing industry market research tools to define the target audience and directly countering tobacco industry lifestyle marketing strategies. We now propose to extend this intervention to three other cities (tailoring the intervention to a high-risk subpopulation of young adults in each city) and evaluate it in a multicenter quasi-experimental controlled trial."
62443487|NCT01686178|NO_INTERVENTION|Control|Survey research data will be collected in control cities with the same schedule as data collection in the cities where the intervention is taking place.
62613074|NCT01714856|EXPERIMENTAL|Test Product|Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fed conditions
62837807|NCT01424072|EXPERIMENTAL|Auriculotherapy by seeds|The investigators used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.
62837808|NCT05716282||NMB estimation group|All patients undergoing surgery with a single dose of 0.6 mg/kg rocuronium and quantitative neuromuscular transmission monitoring by TOFScan at the adductor pollicis.
62837809|NCT01174719|ACTIVE_COMPARATOR|Hydroxyethylstarch|
62837810|NCT01174719|ACTIVE_COMPARATOR|Humanalbumin|
62613075|NCT01714856|EXPERIMENTAL|Reference Product|Single oral dose of REQUIP XL Tablets 2mg under fed conditions
62613076|NCT01420042|PLACEBO_COMPARATOR|Placebo (lemon flavoured cordial)|NNZ-2566 reconstituted in Lemon flavoured cordial and Water for Injection. 6/8 subjects in each cohort (3 cohorts in total) to receive NNZ-2566 experimental treatment.
62613077|NCT01420042|EXPERIMENTAL|NNZ-2566|
62837811|NCT01174719|ACTIVE_COMPARATOR|Ringer lactate|
62837812|NCT04674761|EXPERIMENTAL|Odevixibat (A4250)|Capsules for oral administration once daily for 24 weeks.
62837813|NCT04674761|PLACEBO_COMPARATOR|Placebo|Capsules for oral administration (to match active) once daily for 24 weeks.
62837814|NCT01441232|EXPERIMENTAL|Treatment A|
62837815|NCT01441232|EXPERIMENTAL|Treatment C|
62837816|NCT01441232|ACTIVE_COMPARATOR|Treatment B|
62837817|NCT02640534|EXPERIMENTAL|Enzalutamide + Metformin|Enzalutamide 160 mg od + metformin 850 mg bid until disease progression
62613078|NCT03236116|EXPERIMENTAL|Almond Group|Participants will consumed almonds every day for 6 months, but will not be allowed to consume any other nuts or nut products.
62613079|NCT03236116|EXPERIMENTAL|Control Group|Participants will continue with their normal eating routine for 6 months, but will not be allowed to consume any nuts or nut products.
62613080|NCT00571025|EXPERIMENTAL|1|AD risk assessment based on family history and APOE genotype
62613081|NCT00571025|ACTIVE_COMPARATOR|2|AD risk assessment based on family history alone
62613082|NCT01657656|EXPERIMENTAL|Vitamin D group|Vitamin D supplement by Tishcon
62837818|NCT02640534|ACTIVE_COMPARATOR|Enzalutamide|Enzalutamide 160 mg od until disease progression
62837819|NCT04347876||Group A|COVID-19 positive with positive tuberculin test
62613083|NCT01657656|PLACEBO_COMPARATOR|Control group|Identically appearing capsules
62054010|NCT03390387|EXPERIMENTAL|Dexa intermittent|Induction therapy with intermittent Dexamethasone administration (1-15 days - 6 mg/m2, 15-22 day - pause, 22-29 days - 6 mg/m2).
62613084|NCT02005900|EXPERIMENTAL|DHA|Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART
62613085|NCT02005900|PLACEBO_COMPARATOR|PLACEBO|
62613086|NCT04150705|EXPERIMENTAL|FDG PET/MRI|-Patients will undergo FDG-PET/MRI in lieu of the standard pelvic MRI at up to 6 time-points at which it would normally be performed in their care for the period of time extending 30-36 months from the time of enrollment (depending on enrollment point). In the surveillance period, when patients typically undergo pelvic MRI every 3 months, the FDG-PET/MRI will be done in lieu of the standard pelvic MRI on an approximately every-other-scan basis. In other words, the FDG-PET/MRI will occur roughly once every 6 months.
62613087|NCT00586898|EXPERIMENTAL|1|
62837820|NCT04347876||Group B|COVID-19 positive with negative tuberculin test
62837821|NCT04749992||Non-Dreamers|Experimental Group
62837822|NCT04749992||Dreamers|Comparison Group
62837823|NCT02224807|ACTIVE_COMPARATOR|Progressive Resistance Training (PRT) and a healthy diet|PRT will be done with resistance bands; participants will receive instruction on three resistance band exercises (triceps, biceps, and shoulder overhead) from an American College of Sports Medicine (ACSM) certified exercise specialist. Participants also will receive dietary counseling from a registered dietitian on correcting nutrient deficiencies that are detected during analysis of their 2-day dietary recalls.
62054011|NCT03390387|ACTIVE_COMPARATOR|Dexa constant|Induction therapy with continuous Dexamethasone administration (6 mg/m2 1-29 days).
62613088|NCT04184635|EXPERIMENTAL|Experimental ECMO + IABP Arm|"VA-ECMO will be instituted percutaneously under echo guidance via the femoral route as soon as possible.~An IABP will be systematically inserted in the contralateral femoral artery (unless technically not possible)."
62613089|NCT04184635|NO_INTERVENTION|Control Conventional Treatment Arm|Standard management of cardiogenic shock due to myocardial infarction according to the current ESC guidelines. It is not recommended to use IABP support and no other TCS device (e.g., ECMO, Impella, Thoratec PHP, TandemHeart) will be permitted in the control group.
62613090|NCT01709773|EXPERIMENTAL|Focal treatment arm|
62613091|NCT06730399||Cryotherapy group|Postoperative treatment using computed-assisted-cryotherapy in the first week postoperative in addition to usual care
62613092|NCT06730399||Control group|Postoperative treatment according to usual care
62613093|NCT05914389|EXPERIMENTAL|Standard chemotherapy control cohort|Patients with locally advanced colon cancer who met the inclusion criteria received two cycles of Capecitabine and Oxaliplatin （Capox） regimen chemotherapy and were evaluated by enhanced CT. Patients with more than 20% regression of maximum diameter of colon tumor in enhanced CT image will be randomly assigned to the Standard chemotherapy control cohort and continued with two more cycles of Capox chemotherapy. Then, these patients will receive curative surgery for colon cancer.
62054012|NCT03390387|ACTIVE_COMPARATOR|Dexa|Therapy with Dexamethasone (6 mg/m2) as basic glucocorticoid preparation.
62054013|NCT03390387|EXPERIMENTAL|Medrol|Therapy with Methylprednisolone (60 mg/m2) as basic glucocorticoid preparation.
62054014|NCT03390387|EXPERIMENTAL|IDA|Induction and consolidation therapy with Idarubicin
62054015|NCT03390387|ACTIVE_COMPARATOR|DNR|Induction and consolidation therapy with Daunorubicin
62054016|NCT03390387|EXPERIMENTAL|Protocol Ib+|Two-phase induction therapy (additional second phase of induction - protocol Ib)
62054017|NCT03390387|ACTIVE_COMPARATOR|Protocol Ib-|Standard induction therapy (without second phase)
62613094|NCT05914389|EXPERIMENTAL|Enhancement regimen of combined Anti-PD-L1 monoclonal antibody|Patients with locally advanced colon cancer who met the inclusion criteria received two cycles of Capecitabine and Oxaliplatin （Capox） regimen chemotherapy and were evaluated by enhanced CT. Patients with more than 20% regression of maximum diameter of colon tumor in enhanced CT image will be randomly assigned to the Enhancement regimen of combined Anti-PD-L1 monoclonal antibody and continued with two more cycles of Capox chemotherapy along with the reduced dosage of Anti-PD-L1 monoclonal antibody. Then, these patients will receive curative surgery for colon cancer.
62613095|NCT05914389|EXPERIMENTAL|Enhancement regimen of combined lactobacillus and Anti-PD-L1 monoclonal antibody|Patients with locally advanced colon cancer who met the inclusion criteria received two cycles of Capecitabine and Oxaliplatin （Capox） regimen chemotherapy and were evaluated by enhanced CT. Patients with more than 20% regression of maximum diameter of colon tumor in enhanced CT image will be randomly assigned to the Enhancement regimen of combined lactobacillus and Anti-PD-L1 monoclonal antibody and continued with two more cycles of Capox chemotherapy along with the reduced dosage of Anti-PD-L1 monoclonal antibody and Clostridium butyricum. Then, these patients will receive curative surgery for colon cancer.
62613096|NCT04960397|EXPERIMENTAL|Cohort 1|A cohort of influenza non-naïve 45 healthy children, 9-17 years old, will receive a single dose of 10\^9 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=30) or placebo (N=15) at Day 1. N=45.
62613097|NCT04960397|EXPERIMENTAL|Cohort 2|A cohort of influenza non-naïve 45 healthy children, 2-8 years old, will receive a single dose of 10\^8 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=30) or placebo (N=15) at Day 1 intranasally. N= 45
62054018|NCT03390387|ACTIVE_COMPARATOR|Bortezomib-|Consolidation therapy without Bortezomib
62054019|NCT03390387|EXPERIMENTAL|Bortezomib+|Consolidation therapy with Bortezomib 1.3 mg/m2 N12 (N4 in each reinduction)
62054020|NCT03407690||PIN2 study participants|All those giving swabs for the study
62054021|NCT05775055|EXPERIMENTAL|Commercially Available Oral Rehydration Solution A|A commercially available oral rehydration solution (\~2.8% carbohydrate, \~45 mmol/L sodium, \~20 mmol/L potassium, 34 mmol/L chloride)
62613098|NCT04960397|EXPERIMENTAL|Cohort 3|Once, there is sufficient evidence of safety and tolerability in Cohorts 1 and 2,and enrollment has completed of all 45 in each of these cohorts. Cohort 3 will begin enrollment. A cohort of influenza non-naïve 25 healthy children, 2-8 years old, will receive a single dose of 10\^9 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=15) or placebo (N=10) at Day 1. N=25.
62613099|NCT04960397|EXPERIMENTAL|Cohort 4|Once, there is sufficient evidence of safety and tolerability in Cohort 3 and enrollment has been completed for this cohort, and fifth cohorts (Cohorts 4 and 5) will begin enrollment. A cohort of influenza non-naïve 25 healthy children, 2-8 years old, will receive two doses of the 10\^9 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=15) or two doses of placebo (N=10) at Day 1 and Day 29. N=25
62054022|NCT05775055|EXPERIMENTAL|Commercially Available Oral Rehydration Solution B|A commercially available oral rehydration solution (\~0.1% carbohydrate, \~2% amino acids (protein), \~67 mmol/L sodium, \~20 mmol/L potassium, 30 mmol/L chloride)
62054023|NCT05775055|EXPERIMENTAL|Commercially Available Oral Rehydration Solution C|A commercially available oral rehydration solution (\~2.2% carbohydrate, \~45 mmol/L sodium, \~20 mmol/L potassium)
62255358|NCT00382720|EXPERIMENTAL|TEF (Taxotere, Eloxatin and 5-FU)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and 5-FU (5-Fluorouracil). Each chemotherapy cycle was repeated every 14 days.~Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and 5-FU. Participants who received the optimal dose for Taxotere, Eloxatin and 5-FU were analyzed in this study."
62613100|NCT04168840||Patient undergoing general anesthesia with intubation|Patient undergoing general anesthesia with intubation We will explore clinical airway parameters and external ultrasound parameters of the airway
62837824|NCT02224807|EXPERIMENTAL|PRT and a healthy diet, plus weight loss|This arm will receive all components of the active comparator arm, plus counseling to achieve a weight loss of 1.5-2 pounds/week. Participants will be trained on how to achieve this caloric deficit through both dietary restriction and increased physical activity. Weight loss will be promoted via a healthy, nutritionally adequate diet consistent with American Cancer Society guidelines. Protein levels will be based on 0.8 g/kg body weight. The distribution of food groups will be customized for preferences. An exercise program will be tailored taking into account kcal expenditure for various activities at a specific body weight; expenditures of 200-400 kcal/day will serve as a goal. Aerobic training of large muscles (legs) will be emphasized to achieve a greater kcal deficit; ramping of intensity and volume over time will be pursued as per the ACSM guidelines. Participants will train once weekly while supervised by an exercise physiologist and daily at home.
62613101|NCT05111509|EXPERIMENTAL|[203Pb]VMT-α-NET SPECT/CT|injection of \[203Pb\]VMT-α-NET with serialized imaging and dosimetry measurements
62613102|NCT02290145|EXPERIMENTAL|TPF group|TPF induction chemotherapy followed with surgery and post-operative radiotherapy docetaxel 75mg/m2 cisplatin 75 mg/m2 5-Fu 750 mg/m2/day
62054024|NCT04815044||Women from the PED-t study|Women who participated in the PED-t study in 2016-2018 who report previous (or in future time) pregnancy.
62613103|NCT02290145|OTHER|surgery group|surgery with post-operative radiotherapy
62613104|NCT00002575|EXPERIMENTAL|Conventional surgery|"Patients undergo open laparotomy and colectomy. A standard incision is made through the abdominal wall and the abdominal cavity is explored. A right or left colectomy or a sigmoid resection is performed.~Patients may be entered on adjuvant chemotherapy trials after surgery provided the subsequent trial does not include radiotherapy and allows entry of patients from both arms.~Quality of life is assessed at baseline and on days 2 and 14 after surgery, at 2 months, and then at 18 months. (closed as of 4/30/99)~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 3 years."
62613105|NCT00002575|EXPERIMENTAL|Laparoscopic-assisted colectomy|"Patients undergo a laparoscopic-assisted colectomy. A small infraumbilical incision is made through the abdominal skin and the abdominal cavity is insufflated with CO2 to allow access and visualization. The abdominal cavity is explored. If advanced local disease is identified, a celiotomy and colectomy are performed. Otherwise, a right or left colectomy or sigmoid resection is performed using laparoscopic-assisted techniques.~Patients may be entered on adjuvant chemotherapy trials after surgery provided the subsequent trial does not include radiotherapy and allows entry of patients from both arms.~Quality of life is assessed at baseline and on days 2 and 14 after surgery, at 2 months, and then at 18 months. (closed as of 4/30/99)~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 3 years."
62054025|NCT03245138|EXPERIMENTAL|endoscopic third ventriculostomy|endoscopic third ventriculostomy for the treatment of iNPH
62054026|NCT03245138|ACTIVE_COMPARATOR|ventricular peritoneal shunt|Insertion of a ventriculo-peritoneal Shunt for the treatment of iNPH
62054027|NCT00118898|EXPERIMENTAL|EFV, FTC/TDF, and placebo ABC/3TC|Participants will receive EFV, FTC/TDF, and placebo for ABC/3TC for at least 96 weeks
62054028|NCT00118898|EXPERIMENTAL|EFV, ABC/3TC and placebo FTC/TDF|Participants will receive EFV, ABC/3TC, and placebo for FTC/TDF for at least 96 weeks
62054029|NCT00118898|EXPERIMENTAL|RTV-boosted ATV, FTC/TDF, and placebo ABC/3TC|Participants will receive RTV-boosted ATV, FTC/TDF, and placebo for ABC/3TC for at least 96 weeks
62054030|NCT00118898|EXPERIMENTAL|RTV-boosted ATV, ABC/3TC, and placebo FTC/TDF|Participants will receive RTV-boosted ATV, ABC/3TC, and placebo for FTC/TDF for at least 96 weeks
62054031|NCT02654990|EXPERIMENTAL|Arm A - 20 mg Panobinostat TIW|20 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and per oral dexamethasone
62054032|NCT02654990|EXPERIMENTAL|Arm B - 20 mg Panobinostat BIW|20 mg panobinostat BIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and per oral dexamethasone
62054033|NCT02654990|EXPERIMENTAL|Arm C - 10 mg Panobinostat TIW|10 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and per oral dexamethasone
62054034|NCT00914277|EXPERIMENTAL|Sequence 1|"Period 1: placebo~Period 2: sildenafil~Period 3: SAR407899 dose level 2~Period 4: SAR407899 dose level 1"
62837825|NCT04944004|EXPERIMENTAL|Experimental CBCT Group|Participants of CBCT group will attend individual computer-based cognitive training sessions. Researcher will give instruction in the use of the computerized training programs and assists participants during their training sessions.
62613106|NCT03555942|ACTIVE_COMPARATOR|Early follicular phase protocol|On day 2 or 3 of the menstrual cycle, following baseline blood sampling, a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.
62613107|NCT03555942|EXPERIMENTAL|Luteal phase protocol|Following baseline blood sampling on cycle day 2 of 3 of the menstrual cycle, patients will be followed up with blood and ultrasound from cycle day 10 onwards till the detection of serum LH peak. LH peak will be defined as an increase in serum LH above 20IU/LH. Five (5) days after the LH peak a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.
62837826|NCT04944004|ACTIVE_COMPARATOR|Training As Usual (TAU) Group|Participants of TAU group will attend usual training sessions offered by the training centres with similar intensity and frequency as the CBCT training.
62837827|NCT04981483|EXPERIMENTAL|Any age and parity with placenta accreta spectrum|After removal of the placenta, grasping the cervix from the both lips and one from each side of the cervical canal at the level of the internal os, each uterine angle and grasped the remaining lower uterine segment and Nelaton catheter was inserted inside the cervical canal to avoid closing the cervix with sutures of the uterine incision.Closing the uterine incision;taking suture at the lateral angle of the cervix and suturing it to the lower edge of the uterine angle, then another continuous suture was attached to the upper edge of the uterine incision angle\[outside in-in out then out in-in out\] and the same technique was repeated on the other side (cervico-isthmic sutures). controlling bleeding from the inner surface of the remaining lower uterine segment was done by 2-3 interrupted sutures between the lower uterine segment and the anterior cervical lip. closing of the uterine incision in continuous non-locking manner
62837828|NCT06256796|NO_INTERVENTION|moderate group controlled patients|
62837829|NCT06256796|EXPERIMENTAL|moderate group study patients|
62255359|NCT00382720|EXPERIMENTAL|TEX (Taxotere, Eloxatin and Xeloda)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and capecitabine (Xeloda). Each chemotherapy cycle was repeated every 21 days.~Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and Xeloda. Participants who received the optimal dose for Taxotere, Eloxatin and Xeloda were analyzed in this study."
62255360|NCT02467283||Patients with Chronic Periodontitis|"All subjects were free of systemic diseases and to be included, individuals had to be older than 18 years of age.~Chronic periodontitis was diagnosed according to American Academy of Periodontology 1999 Consensus Report."
62255361|NCT02467283||Control Patients|"Control subjects had no radiographic evidence of bone loss or any sign of past and present periodontitis.~All subjects were free of systemic diseases and to be included, individuals had to be older than 18 years of age."
62255362|NCT03406247|EXPERIMENTAL|Nivolumab|Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months
62255363|NCT03406247|EXPERIMENTAL|Nivolumab + Ipilimumab|"Patients in cohorts 2 and 2bis will be administered~* nivolumab 240 mg every 2 weeks during 6 months~* ipilimumab 1mg/kg IV every 6 weeks during 6 months"
62255364|NCT00123292|EXPERIMENTAL|1|
62255365|NCT00123292|EXPERIMENTAL|2|
62255366|NCT00123292|EXPERIMENTAL|3|
62255367|NCT00123292|EXPERIMENTAL|4a|
62255368|NCT00123292|EXPERIMENTAL|4b|
62255369|NCT03868540|EXPERIMENTAL|BI 1291583|
62255370|NCT03868540|PLACEBO_COMPARATOR|Placebo|
62255371|NCT00257166|EXPERIMENTAL|Ziprasidone oral capsules|
62255372|NCT00257166|PLACEBO_COMPARATOR|Placebo|
62255373|NCT00424749|EXPERIMENTAL|Rituximab|375 mg/m\^2/week for 4 weeks
62255374|NCT04552275|OTHER|HALT Cohort|Patients who develop HALT
62255375|NCT04552275|OTHER|Control Group|Patients who do not develop HALT
62255376|NCT04957342|ACTIVE_COMPARATOR|Sutures|Patients assigned to Sutures group will not have the allograft placed on the donor site. One current clinical standard of practice is to place sutures on donor site. Patients assigned to Sutures group will have sutures placed on donor site.
62255377|NCT04957342|EXPERIMENTAL|Allograft and Sutures|Patients assigned to Allograft and Sutures will have allograft placed and secured with sutures on the donor site.
62255378|NCT04424160|EXPERIMENTAL|Endometrial PRP|Patients in whom endometrial PRP was performed
62255379|NCT05327920||Participants Receiving Upadacitinib|Participants receiving upadacitinib for Rheumatoid Arthritis
62837830|NCT06256796|NO_INTERVENTION|sever controlled group|
62837831|NCT06256796|EXPERIMENTAL|sever study group|
62837832|NCT00048074|EXPERIMENTAL|1|oral placebo daily and IV ibandronate 2 mg q 2 mo
62255380|NCT01141114|EXPERIMENTAL|Use of a Patient Navigator|
62054035|NCT00914277|EXPERIMENTAL|Sequence 2|"Period 1: sildenafil~Period 2: SAR407899 dose level 1~Period 3: placebo~Period 4: SAR407899 dose level 2"
62054036|NCT00914277|EXPERIMENTAL|Sequence 3|"Period 1: SAR407899 dose level 1~Period 2: SAR407899 dose level 2~Period 3: sildenafil~Period 4: placebo"
62255381|NCT01141114|OTHER|Usual Care|No Intervention - usual care
62255382|NCT01898572||Newly diagnosed T2DM|Newly diagnosed T2DM with no CVD. Standard care.
62255383|NCT01898572||Control individuals|Control individuals matched by age, gender, dyslipidemia, hypertension and smoking habit. Standard care.
62255384|NCT03344419|EXPERIMENTAL|CI-581a+MET+MBRP|Administration of CI-581a at 0.71 mg/kg during weeks 1 and 5 combined with a 12-week course in MET and MBRP
62837833|NCT00048074|EXPERIMENTAL|2|oral ibandronate 2.5 mg daily and IV placebo q 2 mo and q 3 mo
62837834|NCT00048074|EXPERIMENTAL|3|oral placebo daily and IV ibandronate 3 mg q 3 mo
62837835|NCT01688349|EXPERIMENTAL|Cushing group|AT biopsy during partial nephrectomy
62054037|NCT00914277|EXPERIMENTAL|Sequence 4|"Period 1: SAR407899 dose level 2~Period 2: placebo~Period 3: SAR407899 dose level 1~Period 4: sildenafil"
62054038|NCT01896401|EXPERIMENTAL|InSeal's Vascular Closure Device|Use of the experimental VCD to close the access site of the artery
62054039|NCT01568268|EXPERIMENTAL|Palonsetron|
62054040|NCT01568268|PLACEBO_COMPARATOR|Placebo|
62255385|NCT03344419|ACTIVE_COMPARATOR|CI-581b+MET+MBRP|Administration of CI-581b at 0.025 mg/kg during weeks 1 and 5 combined with a 12-week course in MET and MBRP
62255386|NCT01205230|EXPERIMENTAL|Pazonib+ketoconazole|Administration of oral pazopanib 400mg (2 200-mg tablets) once-daily each morning for at least 7 consecutive doses during Period 1. Then administration of oral ketoconazole 400 mg (2 - 200 mg tablets) followed immediately by pazopanib 400 mg (2 -200 mg tablets) once-daily each morning for a total of 5 consecutive doses during Period 2.
62054041|NCT02346019|EXPERIMENTAL|Surgical: Medial thighplasty|Perform a standard medial thighplasty with our without additional thigh liposuction on up to three obese transfemoral amputee subjects. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
62054042|NCT00152464|EXPERIMENTAL|Levocetirizine (LCTZ)|0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.
62255387|NCT01205230|EXPERIMENTAL|Pazonib+esomeprazole|Subjects will receive orally administered pazopanib 800mg (4 - 200mg tablets) once-daily each morning for at least 7 consecutive doses in Period 1. In the evening on the last day of Period 1, subjects will take their initial dose of esomeprazole 40 mg (1 - 40 mg capsule) approximately 3 hours after the evening meal. Subjects will continue to receive pazopanib (each morning) and esomeprazole each evening once-daily for a total of 5 consecutive doses.
62255388|NCT05780255||COVID-19 positive patients|Patients with a PCR-confirmed COVID-19 infection, with ARDS and supported by VV-ECMO
62255389|NCT05764382|EXPERIMENTAL|T'ai Chi and Qigong Rehabilitation|
62837836|NCT01688349|OTHER|Controls1|normal weight metabolic healthy patients having partial nephrectomy with small AT Biopsy.
62837837|NCT01688349|OTHER|Controls2|obese individuals already included and having biopsies of VAT and SCAT stocked.
62255390|NCT05764382|ACTIVE_COMPARATOR|Usual care|
62255391|NCT01186796|EXPERIMENTAL|Fulvestrant|
62837838|NCT01070485|EXPERIMENTAL|Radium-223 dichloride (Xofigo, BAY 88-8223)|Patients were to receive 4 intravenous administrations of Radium-223 at a dose of 50 kBq/kg body weight (b.w) at intervals of 4 weeks. Radium-223 was given as add-on therapy to existing bisphosphonate therapy.
62837839|NCT01342211|PLACEBO_COMPARATOR|Treatment A|
62054043|NCT00152464|PLACEBO_COMPARATOR|Placebo (PBO)|Placebo was administered as oral drops twice daily.
62054044|NCT05182645|EXPERIMENTAL|lifestyle-modification|Once a week for 10 weeks with a circumference of 60 hours with mindfulness-based stress reduction and further process of the Mind / body medicine.
62255392|NCT01798368|EXPERIMENTAL|PBASE system 2.0|
62255393|NCT01306799||Barrett's Esophagus, Erosive Esophagitis, GERD|
62255394|NCT05160155|ACTIVE_COMPARATOR|Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area. The block will be terminated.
62255395|NCT05160155|ACTIVE_COMPARATOR|Intercostal Block|The USG probe will be placed at the level of the posterior axillary line and the broken ribs. The ribs, external intercostal muscle, and internal intercostal muscle structures will be imaged. 3 ml of 0.25% bupivacaine will be injected into the subcostal area. This 3 ml 0.25% bupivacaine injection will be administered for each broken rib. The block will be terminated.
62443488|NCT03338465|ACTIVE_COMPARATOR|Group A|3 weekly sessions of focused extracorporeal shockwave treatment (2.000 impulses at 0.20 millijoules/mm2 per session)
62054045|NCT05182645|ACTIVE_COMPARATOR|waiting control group|A unique education unit within the scope of 3 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training. After the follow-up measurement opportunity to participate in the program.
62054046|NCT03079310|EXPERIMENTAL|Spinal cord stimulation|Boston Scientific SCS system
62054047|NCT06491849||Orthodontic Mini Implant Group|Participants with at least one orthodontic mini implant placed for anchorage during orthodontic treatment. The study will evaluate the peri-implant conditions, including gingival and mucosal inflammation, implant stability, and other related factors.
62054048|NCT03152084|EXPERIMENTAL|Arm 1|T2DM subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
62054049|NCT03152084|EXPERIMENTAL|Arm 2|T2DM subjects with an eGFR (CKD-EPI) between \>90 and ≤130 mL/min/1.73m2 for patients aged 59 or younger, between \>85 and ≤130 mL/min/1.73m2 for patients aged 60 to 69, and between \>75 and ≤130 mL/min/1.73m2 for patients aged 70 or older at the Screening Visit.
62054050|NCT03152084|EXPERIMENTAL|Arm 3|Non-diabetic subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
62054051|NCT04372836|NO_INTERVENTION|Control arm|During laparoscopic enucleation of unilateral endometrial cyst, no intervention is added to subjects allocated to control arm.
62054052|NCT04372836|EXPERIMENTAL|Study arm (with vasopressin injection)|During laparoscopic enucleation of unilateral endometrial cyst, diluted vasopressin is injected into the interface between endometrioma and ovarian parenchyma of patients allocated to study arm.
62837840|NCT01342211|EXPERIMENTAL|Treatment B|
62837841|NCT01342211|EXPERIMENTAL|Treatment C|
62837842|NCT01342211|EXPERIMENTAL|Treatment D|
62837843|NCT01342211|EXPERIMENTAL|Treatment E|
62837844|NCT02309242|NO_INTERVENTION|Neuropsychological assessment, MRI|This is a cross-sectional mono-center study examining survivors who were exposed to chemotherapy for bone or soft tissue sarcomas in childhood. Survivors of bone or soft tissue sarcomas will be examined with neuropsychological tests, questionnaires and advanced MR imaging (Neuropsychological assessment, MRI). Results will be compared to a healthy control group matched for age and sex.
62837845|NCT04791332|EXPERIMENTAL|Single Dose Cohort: Cohort 1 and 2|Participants will receive a single oral dose of JNJ-67953964 or a matching placebo on Day 1.
62837846|NCT04791332|EXPERIMENTAL|Multiple Dose Cohort: Cohort 3|Participants will receive multiple oral dose of JNJ-67953964 once daily or a matching placebo up to Day 14.
62837847|NCT02321709|EXPERIMENTAL|SAR113244 cohort 1|Two administrations of dosage 1 SAR113244 or placebo subcutaneous dose (Q4 weeks)
62837848|NCT02321709|EXPERIMENTAL|SAR113244 cohort 2|Two administrations of dosage 2 SAR113244 or placebo subcutaneous dose (Q4 weeks)
62054053|NCT04911309|ACTIVE_COMPARATOR|Group 1: 12 weeks functional exercise training followed by standard therapy|"12 weeks functional exercise training twice per week, each session lasting 60 min, additionally to standard therapy. Training sessions will be performed in a group-setting consisting of minimum 4 and maximum 8 participants and coached by experienced sport scientists with the supervision of a medical doctor. The exercises will be individually pants and constantly recorded in order to allow a progression over the course of the 12 week-period. The motor tasks and exercises will be tailored to individual capacity by experienced and trained sport scientists and coaches, therefore insuring the participants' safety and a continuous and progressive monitoring of training load.~After 12 weeks the groups will switch the intervention method. Group 1 will therefore reassume their standard therapy for 12 weeks."
62054054|NCT04911309|ACTIVE_COMPARATOR|Group 2: 12 weeks standard therapy / treatment followed by 12 weeks functional exercise training|"12 weeks standard therapy / treatment; the standard therapy group receives no additional exercise sessions. After 12 weeks the groups will switch the intervention method. Group 1 will therefore reassume their standard therapy for 12 weeks.~After 12 weeks the groups will switch the intervention method. Group 2 will perform the same intervention which Group 1 received over the first course of 12 weeks."
62054055|NCT00489710|EXPERIMENTAL|Talabostat|Talabostat 600 mcg orally, daily x 14 days (21 day cycle); 2 cycles
62054056|NCT02221401|EXPERIMENTAL|Treatment A (FDC)|
62837849|NCT02321709|EXPERIMENTAL|SAR113244 cohort 3|Two administrations of dosage 3 SAR113244 or placebo subcutaneous dose (Q4 weeks)
62837850|NCT05378750|EXPERIMENTAL|Intervention group|"Bio-impedance spectroscopy.~Treatment algorithm for diuretic therapy."
62837851|NCT05378750|NO_INTERVENTION|Control group|No intervention.
62837852|NCT05341141|EXPERIMENTAL|ddEC-ddT and cryotherapy combined with compression|Cryotherapy will be applied using a frozen glove and sock for 15 minutes before, during and 15 minutes after each albumin-paclitaxel infusion. Compression therapy will be applied using a surgical glove for 30 minutes before, during and 30 minutes after each albumin-paclitaxel infusion.
62837853|NCT05341141|OTHER|ddEC-ddT|ddEC-ddT will be administered without cryotherapy combined with compression.
62255396|NCT04383379|EXPERIMENTAL|Intervention group|6 NICUs in the intervention group . The participating units of the intervention group determine the improvement items (one or more) in each quarter from the list of best practices of breast feeding quality improvement of Jiangsu Province, and report the improvement plan to the supervision unit, and recommend the application of PDSA (plan-do-study-act) for the implementation of quality improvement loop. Report the implementation of quality improvement to the supervision unit on a quarterly basis.
62255397|NCT04383379|NO_INTERVENTION|control group|Continue current practices
62837854|NCT05513794|EXPERIMENTAL|Patient group|Patient with parkinson disease
62054057|NCT02221401|ACTIVE_COMPARATOR|Treatment B (single agents)|
62837855|NCT05513794|EXPERIMENTAL|Healthy volunteer group|Healthy volunteer
62837856|NCT01786577||Surgery|80 patients will undergo total knee replacement surgery; two Magnetic Resonance Imaging scans; cognitive assessment testing.
62837857|NCT01786577||Non-Surgery|80 non-surgery participants will be included as part of the control group; two Magnetic Resonance Imaging scans; cognitive assessment testing.
62837858|NCT02018718|OTHER|Marathoners|
62837859|NCT02282098|EXPERIMENTAL|Active Colchicine|The intervention group will receive colchicine 0.6 mg twice daily orally for 3 months
62837860|NCT02282098|PLACEBO_COMPARATOR|Placebo Colchicine|The control group will receive colchicine placebo 0.6mg twice daily orally for 3 months.
62837861|NCT00346697|EXPERIMENTAL|LOVAZA|4 g/d of omega-3 fatty acid esters, plus dietary counseling
62837862|NCT00346697|PLACEBO_COMPARATOR|Placebo|Corn oil placebo, plus dietary counselling
62837863|NCT04454918|EXPERIMENTAL|TAK-906 50 mg + [14C]-TAK-906 100 mcg + [14C]-TAK-906 50 mg|TAK-906 50 mg, capsule, orally, once on Day 1, followed by \[14C\]-TAK-906 100 micrograms (μg) \[approximately 1 microcurie (μCi)\], IV infusion, once on Day 1 of Treatment Period 1, followed by a Washout Period of 7 days, further followed by \[14C\]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
62837864|NCT03727256|ACTIVE_COMPARATOR|Group 1 patients|Patients have grade 2 or 3 knee osteoarthritis ultrasound therapy
62837865|NCT03727256|ACTIVE_COMPARATOR|Group 2 patients|Patients have grade 2 or 3 knee osteoarthritis neuromuscular electrical stimulation application
62837866|NCT05576454|EXPERIMENTAL|BAT2606 Injection|PFS, Strength: 100 mg/1 mL, 100 mg, Subcutaneous injection.
62837867|NCT05576454|ACTIVE_COMPARATOR|Mepolizumab Injection (EU-licensed Nucala®)|PFS, Strength: 100 mg/1 mL, 100 mg, Subcutaneous injection.
62837868|NCT05576454|ACTIVE_COMPARATOR|Mepolizumab Injection (US-licensed Nucala®)|PFS, Strength: 100 mg/1 mL, 100 mg, Subcutaneous injection.
62837869|NCT05151276|EXPERIMENTAL|Intervention Group|individuals with odd sequence numbers were assigned to the intervention group (n=46)
62837870|NCT05151276|NO_INTERVENTION|Control Group|those with even numbers to the control group (n=47).
62837871|NCT05793268|EXPERIMENTAL|Finite Therapy|Discontinuation of nucleos(t)ide analog (Nuc) therapy
62054058|NCT05818150|EXPERIMENTAL|Genicular artery embolization with Embosphere Microspheres|"Device: Embosphere Microspheres~Embolic Agent: Embosphere Microspheres"
62613108|NCT03129295|EXPERIMENTAL|MPC-SHRC|oral tablet four times a day for 3 days
62255398|NCT06284551||Control Group|Healthy youths and adults aged 15-24 years old.
62255399|NCT06284551||Experimental Group|Youths and adults aged 15-24 years old with diagnosis of major depressive disorder, anxiety disorder, post traumatic stress disorder, or Adjustment disorder according to DSM-V.
62613109|NCT03129295|PLACEBO_COMPARATOR|Placebo|oral tablet four times a day for 3 days
62613110|NCT06217744|EXPERIMENTAL|Automated Intervention|The intervention will last for 3 months, with two psychoeducational modules delivered per month.
62613111|NCT06217744|EXPERIMENTAL|Blended Intervention|The intervention will last for 3 months, with two psychoeducational modules delivered per month. In addition, regular synchronous or asynchronous psychoeducational sessions conducted by a licensed psychologist will be held with the participants.
62613112|NCT06217744|NO_INTERVENTION|Waitlist|This group will undergo the evaluations on the same schedule like the active groups. No intervention will be done.
62613113|NCT01587417|EXPERIMENTAL|BI 187004 CL|1 single dose per subject as oral solution
62613114|NCT01587417|PLACEBO_COMPARATOR|Placebo to BI 187004 CL|1 single dose per subject as oral solution
62613115|NCT01708720|EXPERIMENTAL|Sabin-IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, and 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose
62255400|NCT01762215|EXPERIMENTAL|PLM|Upon consenting to the study, participants will be asked to register an account on PatientsLikeMe; no personal identifiers will be required. As part of registration patients create a user name and password for the website and share their email with PatientsLikeMe. Participants will be asked to provide a set of demographic variables and to complete a survey assessing elements of self-management, disease knowledge, social support, and quality of life. Paticipants will then use the PatientsLikeMe website for 6 weeks as much as they wish. After 6 weeks the participants are asked to complete a second survey.
62255401|NCT05842369|EXPERIMENTAL|ADVOS|Application of the ADVOS device for
62255402|NCT05842369|ACTIVE_COMPARATOR|CVVHD|Application of CVVHD
62255403|NCT04193020||steroid only group (SG)|
62255404|NCT04193020||combined (steroid and adjuvant drug) group (CG)|
62255405|NCT04193020||bilogic therapy group (BTG)|
62255406|NCT01353040|EXPERIMENTAL|AVI-6003|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
62613116|NCT01708720|EXPERIMENTAL|Adjuvanted Sabin-IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, and 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose, adjuvanted with 0.5 mg aluminium hydroxide
62613117|NCT01708720|ACTIVE_COMPARATOR|IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose
62613118|NCT04478500|ACTIVE_COMPARATOR|Minocycline Group|Subjects will be randomized to receive Minocycline 100mg twice daily
62613119|NCT04478500|PLACEBO_COMPARATOR|Placebo Group|Subjects will be randomized to receive placebo.
62837872|NCT05793268|ACTIVE_COMPARATOR|Continuous Therapy|Continuation of oral Nuc monotherapy using entecavir (0.5mg/tab, once per day), tenofovir disoproxil fumarate (300mg/tab, once per day), or tenofovir alafenamide (25mg/tab, once per day) for 3 years
62255407|NCT01353040|PLACEBO_COMPARATOR|Placebo|Normal saline
62255408|NCT05280028||Tibolone|Tibolone 2.5 mg per day
62255409|NCT05280028||Indivina|Estradiol valerate (E2V) 1mg \& medroxyprogesterone acetate 2.5 mg (MPA) per day
62255410|NCT00670436|ACTIVE_COMPARATOR|A 1|paclitaxel eluting PTCA balloon (SeQuent please) after bare-metal stenting of a chronic total occlusion in a native coronary artery
62255411|NCT00670436|ACTIVE_COMPARATOR|A2|historical population of patients with a chronic total occlusion in a native coronary artery treated with the paclitaxel eluting Taxus stent (Boston Scientific)
62255412|NCT02479100|OTHER|Undergo a CESM|Patients will undergo an experimental Contrast Enhanced Spectral Mammogram (CESM) in addition to standard diagnostic procedures
62255413|NCT02479100|NO_INTERVENTION|Follow Standard care|Patient will follow standard care pathway.
62255414|NCT02146508|EXPERIMENTAL|Endoscopic treatment|Participants undergo upper GI endoscopy with endoscopic mucosal resection (EMR) and/or radiofrequency ablation (RFA) of esophageal squamous dysplasia (ESD). After initial therapy participants undergo repeat endoscopy every 3 months for a year, with re-biopsy and re-treatment of residual ESD as appropriate.
62054059|NCT05818150|ACTIVE_COMPARATOR|Corticosteroid Injection of the knee|Drug: Corticosteroid injection
62255415|NCT02585219||High-grade Glioma Patients|"Patients with suspicion of newly diagnosed high-grade glioma eligible for standard therapy (surgical resection followed by chemoradiotherapy).~Patients with a second brain tumor, brain surgery earlier or prior radiotherapy to the brain are excluded. Patients with only a biopsy be excluded.~The group will consist of 10 patients. This number may be adjusted for patients who are found to have a different diagnosis after histological examination or fall out. For a pilot feasibility study our experience that a number of 10 patients is sufficient for PET examination."
62613120|NCT05057117|ACTIVE_COMPARATOR|Botulinum toxin A|One treatment with standard dosage (50-100 units) of botulinum toxin A in one axilla
62613121|NCT05057117|ACTIVE_COMPARATOR|Microwave thermolysis|One standard treatment (energy level 5) with microwave thermolysis in one axilla
62613122|NCT00851864|EXPERIMENTAL|A|Women requiring therapeutic anticoagulation, singleton pregnancy,\<30weeks
62613123|NCT01074151||Pregnant patients exposed to Cymbalta|Pregnant patients exposed to Cymbalta (duloxetine) at any time during pregnancy, beginning on or after the first day of the last menstrual period
62613124|NCT04937907|EXPERIMENTAL|Hydroxychloroquine Cohort|Patients in the cohort will receive Hydroxychloroquine(HCQ) throughout the study.Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day for 6 months. During treatment with HCQ, patients also received enalapril(5-10mg qd).
62613125|NCT04937907|SHAM_COMPARATOR|Comparator Cohort|During treatment with HCQ, Patients randomized to Comparator Cohort only received enalapril(5-10mg qd).
62613126|NCT05971472|ACTIVE_COMPARATOR|Arthroscopic Repair|Arthroscopic Repair for medial meniscus posterior root tears
62613127|NCT05971472|ACTIVE_COMPARATOR|High tibial osteotomy|Open wedge High tibial osteotomy for medial meniscus posterior root tears
62613128|NCT02810171|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|
62613129|NCT02810171|OTHER|Relaxation Therapy|
62613130|NCT02810171|NO_INTERVENTION|No Intervention: Healthy youth only|Healthy control participants, matched to gender and age with anxiety patients, will be enrolled. These healthy participants will be scanned with fMRI before and after \~16 weeks, but without any intervention (i.e., no therapy).
62837873|NCT02406508|EXPERIMENTAL|Hepatic Delivery System Treatment followed by Sorafenib|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System.~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 3 cycles of treatment.~After the Melphalan/HDS treatment patients will be treated with sorafenib according to the package prescribing information."
62837874|NCT00649038|EXPERIMENTAL|1|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
62837875|NCT00649038|ACTIVE_COMPARATOR|2|Lotensin HCT® Tablets 20 mg/25 mg
62837876|NCT00888732|EXPERIMENTAL|Insulin therapy|Insulin Aspart, Biphasic Insulin Aspart 70 and 50 \& Fast-acting Human Insulin
62837877|NCT02131506|EXPERIMENTAL|Lapatinib, Caelyx|"* Lapatinib is given at escalating doses orally and continuously on days 1-21.~* Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1."
62837878|NCT02844309|EXPERIMENTAL|Thalidomide|thalidomide 50-150mg per night
62837879|NCT04289064||Fundus image quality assessment|Device: an artificial intelligence system for quality assessment of fundus images. These patients are enrolled in primary healthcare units or the AI clinic at Zhongshan Ophthalmic Center.
62837880|NCT03941288|ACTIVE_COMPARATOR|Pharmacodynamics and clinical effects of cannabidiol|"Cannabidiol will be administered orally twice daily in equally divided doses starting at 2.5mg/kg per day and increasing by 2.5 to 5.0mg/kg every other day until the target dose of 20mg/kg is reached.~Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days."
62837881|NCT03941288|PLACEBO_COMPARATOR|pharmacodynamics and clinical effects of placebo|"Placebo will be administered orally twice daily in equally divided doses starting at 2.5mg/kg per day and increasing by 2.5 to 5.0mg/kg every other day until the target dose of 20mg/kg is reached.~Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days."
62837882|NCT05374512|EXPERIMENTAL|Dato-DXd|Arm 1: Dato-DXd
62837883|NCT05374512|ACTIVE_COMPARATOR|Investigator's Choice of Chemotherapy (ICC)|"Arm 2:~If no prior taxane, or prior taxane in the (neo)adjuvant setting and DFI \> 12 months, paclitaxel or nab-paclitaxel~If prior taxane and DFI ≤ 12 months: capecitabine, carboplatin, or eribulin."
62837884|NCT05593978|EXPERIMENTAL|Culinary Medicine|Those in this group will receive culinary medicine, which includes cooking videos and educational videos to help educate on ways to increase protein intake through lean ground beef.
62837885|NCT05593978|OTHER|Control|This group will only receive recipes containing lean ground beef to help increase protein intake.
62837886|NCT04982263||Mild cases|Patients with confirmed COVID-19 and with mild disease
62837887|NCT04982263||Severe cases|Patients with confirmed COVID-19 and with severe disease
62837888|NCT03798353|EXPERIMENTAL|Experimental group|"The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.~In addition, the matrix-cell (PeriCord) construct will be placed on the ischemic area of the non-candidate revascularization area and will be fixed using surgical glue.~PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix ."
62837889|NCT03798353|ACTIVE_COMPARATOR|Control group|The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed.
62837890|NCT03254758|EXPERIMENTAL|Mesenchymal stem cell|"Phase 1 Dose escalation : low Mid High Single administalation of ADR-001~Phase 2 The recommended dose of ADR-001"
62837891|NCT03083834|EXPERIMENTAL|healthy subjects|low-dose cosyntropin stimulation test
62837892|NCT03083834|EXPERIMENTAL|hypoadrenal mitotane treated patients|low-dose cosyntropin stimulation test
62837893|NCT03083834|EXPERIMENTAL|hypoadrenal no-mitotane treated patients|low-dose cosyntropin stimulation test
62837894|NCT01004991|EXPERIMENTAL|All patients|subjects will receive azacytidine dose dependent on dose-escalation schedule at time of enrollment - all will receive standard dose RCHOP
62837895|NCT03154411|EXPERIMENTAL|ABY-029|ABY-029 will be administered prior to surgery and tissue will be examined ex vivo to determine binding with EGFR positive tumor tissue.
62837896|NCT01175577|ACTIVE_COMPARATOR|Supplement 1|
62255416|NCT03378804|EXPERIMENTAL|PIEB-PCEA|"Programmed intermittent epidural bolus (PIEB) application of ropivacaine 0.2% with patient-controlled epidural analgesia:~The background rate is set at 6ml per hour. The patient-controlled bolus function is programmed with 4ml at a lock-out interval of 30min."
62837897|NCT01175577|ACTIVE_COMPARATOR|Supplement 2|
62837898|NCT01175577|ACTIVE_COMPARATOR|Food-based Intervention|
62837899|NCT01175577|PLACEBO_COMPARATOR|Placebo|
62837900|NCT04127006||Vision Cohort 1|Participants with the better eye Screening Visit visual acuity ETDRS letter score of 54 or more \[approximate Snellen equivalent 20/80 or better\] and visual field diameter 10 degrees or more in every meridian of the central field
62837901|NCT04127006||Vision Cohort 2|Participants with the better eye Screening Visit visual acuity ETDRS letter score of 19-53 \[approximate Snellen equivalent 20/100 - 20/400\] or (visual acuity ETDRS letter score of 54 or more \[approximate Snellen equivalent 20/80 or better\] and visual field diameter less than 10 degrees in any meridian of the central field)
62837902|NCT04127006||Vision Cohort 3|Participants with the better eye Screening Visit visual acuity ETDRS letter score of 18 or less \[approximate Snellen equivalent 20/500 or worse\]
62837903|NCT00909298|EXPERIMENTAL|1|TTP889 300 mg
62837904|NCT00909298|PLACEBO_COMPARATOR|2|TTP889 Placebo
62837905|NCT02357368|EXPERIMENTAL|Depot medroxyprogesterone acetate (DMPA)|DMPA will be administered every 12 weeks at 150 mg by intramuscular (IM) injection at week 3 of study enrollment and repeated at week 15.
62837906|NCT02357368|EXPERIMENTAL|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant will be placed at study week 3.
62443489|NCT03338465|ACTIVE_COMPARATOR|Group B|3 weekly sessions of focused extracorporeal shockwave treatment (2.000 impulses at 0.01 millijoules/mm2 per session)
62613131|NCT04239443|EXPERIMENTAL|SHR1210 and Apatinib|"NSCLC participants will be given intravenous administration of SHR-1210 (200mg/2w) and oral of Apatinib (250mg/d) , soft tissue sarcoma will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (500mg/d), and uterine cancer will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (250mg/d).~The duration of treatment will till the disease progression, death, or unacceptable toxicity show up."
62613132|NCT03477643||Refractory Multiple Myeloma|Patients with relapsed and refractory multiple myeloma who have received treatment with pomalidomide, cyclophosphamide, and dexamethasone following the GEM-PETHEMA clinical practice guidelines between 01/01/2015 to 01/04/2018
62613133|NCT03341117|ACTIVE_COMPARATOR|Acetylsalicylic acid|The patients were randomly assigned to received Acetylsalicylic acid 300 mg once daily for 90 days
62613134|NCT03341117|PLACEBO_COMPARATOR|calcined magnesia|"The patients were randomly assigned to received placebo (calcinaned magnesia),~1 capsule 300 mg before each meal for a period of 90 days."
62613135|NCT05167916|EXPERIMENTAL|T1 Bladder cancer patients|
62837907|NCT02357368|EXPERIMENTAL|Levonorgestrel intrauterine device (Lng-IUD)|A standard Mirena IUD will be placed at study week 3.
62837908|NCT02357368|EXPERIMENTAL|ParaGard® T 380A Intrauterine Copper Contraceptive|A standard ParaGuard IUD will be placed at study week 3.
62837909|NCT02038933|EXPERIMENTAL|Nivolumab (3 mg/kg)|Nivolumab 3 mg/kg solution intravenously every 2 weeks until progression or unacceptable toxicity
62837910|NCT03441815|EXPERIMENTAL|XC8 2 mg|Cohort 1: 6 subjects were randomized in a 2:1 ratio to be treated either with 2 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
62837911|NCT03441815|EXPERIMENTAL|XC8 10 mg|Cohort 2: 6 subjects were randomized in a 2:1 ratio to be treated either with 10 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
62837912|NCT03441815|EXPERIMENTAL|XC8 50 mg|Cohort 3: 6 subjects were randomized in a 2:1 ratio to be treated either with 50 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
62837913|NCT03441815|EXPERIMENTAL|XC8 200 mg|Cohort 4: 10 subjects were randomized in a 4:1 ratio to be treated either with 200 mg XC8 (8 subjects) or placebo (2 subjects, see placebo arm).
62837914|NCT03441815|PLACEBO_COMPARATOR|Placebo|Placebo comparator arm consists of 8 subjects (2 subjects in each cohort).
62837915|NCT03753828||patients de novo colonized by fungi|Patients in Cystic Fibrosis de novo colonized by fungi during their follow-up
62837916|NCT00331097|ACTIVE_COMPARATOR|A|Standard chemotherapy with CMF
62054060|NCT03040713|EXPERIMENTAL|FTD Subjects|Subjects diagnosed by dementia specialist with a clinical Frontotemporal Dementia (FTD) syndrome and expected tau or tar DNA binding protein (TDP)-43 pathology receiving a flortaucipir PET scan
62054061|NCT01077544|EXPERIMENTAL|Group 1|1 year to \< 10 years pediatric patients with newly diagnosed CP-Ph+ CML, or CP or AP-Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or relapsed/refractory Ph+ ALL (acute lymphoblastic leukemia) treated at the proposed dose of 230 mg/m2 bid.
62255417|NCT03378804|ACTIVE_COMPARATOR|CEI-PCEA|"Continous epidural analgesia with patient-controlled analgesia using ropivacaine 0.2%:~The background rate is set at 6 ml / h continuously. The patient-controlled bolus function is programmed in with 4ml at a lock-out interval of 30min."
62255418|NCT05341362|NO_INTERVENTION|Blank Group|In this group, the anesthesia management is conducted according to the anesthetists' experience, based on the regular monitor.
62255419|NCT05341362|EXPERIMENTAL|LiDCOrapid Group|In this group, the anesthesia management is conducted based on both the regular monitor and the hemodynamic figures on the LiDCOrapid.
62255420|NCT01729975||18-28 years old Non-pathologic|
62255421|NCT01729975||29-80 years old Non-Pathologic|
62255422|NCT01729975||29-80 years old pathologic corneal disease|
62255423|NCT05739565|EXPERIMENTAL|Acti-Pair program|"* Motivational support by the peer (a patient with the same pathology who meets the WHO recommendations for physical activity), who will provide motivational follow-up~* The implementation of a personalized and realistic physical activity project for the patient via the physical activity support systems (sport health centers)~* Support from health professionals (GP) via the prescription of physical activity and from adapted physical activity (APA) professionals"
62255424|NCT05739565|NO_INTERVENTION|Usual care|The control group will be made up of patients followed up for prostate cancer and benefiting from usual care which consists of giving advice and recommendations for physical activity in consultation, aiming to make patients more active in their daily lives (=usual practice, physical activity to be carried out independently, at home).
62255425|NCT05381142|EXPERIMENTAL|Elinzanetant (BAY3427080)|Healthy female participants who meet all of the inclusion criteria and do not meet any of the exclusion criteria will be randomized to treatment with elinzanetant.
62255426|NCT05381142|PLACEBO_COMPARATOR|Placebo|Healthy female participants who meet all of the inclusion criteria and do not meet any of the exclusion criteria will be randomized and assigned to treatment with placebo.
62255427|NCT03099642|EXPERIMENTAL|Ultrasound assisted lumbar puncture|The intervention of interest will be the ultrasound-assisted lumbar puncture (UALP). To do this, the treating physician will perform a bedside ultrasound of the spine to identify and mark the level of the conus medullaris and preferred puncture site prior to LP
62255428|NCT03099642|NO_INTERVENTION|Standard lumbar puncture|The control group will have a standard landmark-based lumbar puncture
62613136|NCT05360914|EXPERIMENTAL|Hospital at Home (HaH) treatment|The patients in this arm will receive the intervention.
62613137|NCT05360914|ACTIVE_COMPARATOR|Standard hospital admission|The patients in this arm are the control group and will receive the standard hospital treatment.
62837917|NCT00331097|EXPERIMENTAL|B|Weekly docetaxel
62837918|NCT02357771|PLACEBO_COMPARATOR|Placebo Arm|Placebo Lozenges (4 Lozenges per day; 2 lozenges in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
62837919|NCT02357771|EXPERIMENTAL|Probiotic Arm|Lactobacillus brevis CD2 Lozenges (4 Lozenges per day; 2 lozenges in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
62837920|NCT00298558|ACTIVE_COMPARATOR|Memory Training|Memory training focused on verbal episodic memory. Participants were taught mnemonic strategies for remembering lists and sequences of items, text material, and main ideas and details of stories and other text-based information.
62255429|NCT00699465|ACTIVE_COMPARATOR|1|Early enoxaparin
62837921|NCT00298558|ACTIVE_COMPARATOR|Reasoning Training|Reasoning training focused on the ability to solve problems that follow a serial pattern. Participants were taught strategies to identify the pattern or sequence required to solve a problem.
62837922|NCT00298558|ACTIVE_COMPARATOR|Speed of Processing Training|Speed of processing training focused on visual search and the ability to identify and locate visual information quickly in a divided attention format. Participants practiced increasingly complex speeded tasks on a computer.
62837923|NCT00298558|PLACEBO_COMPARATOR|Control|This group did not complete any cognitive training interventions
62837924|NCT03611153|EXPERIMENTAL|AZD4831 Oral myeloperoxidase inhibitor|Patient may take 30 mg of oral myeloperoxidase inhibitor following baseline right heart catheterization.
62837925|NCT03611153|PLACEBO_COMPARATOR|Placebo|Patient may take 30 mg of placebo oral capsule following baseline right heart catheterization.
62837926|NCT01301027|ACTIVE_COMPARATOR|Pioglitazone|15 mg/day pioglitazone for 2 weeks, then 30 mg/day for remaining 24 weeks
62255430|NCT00699465|PLACEBO_COMPARATOR|2|Late enoxaparin
62255431|NCT05442151|OTHER|FAPI-PET/CT group|
62255432|NCT00304200|EXPERIMENTAL|Single arm, Open Label|Single arm, Open Label Temodar and Sutent
62255433|NCT02863731|EXPERIMENTAL|Alternating postures: first day|Alternating body postures on the first day of measurement. Sitting body posture on the second day of measurement.
62255434|NCT02863731|EXPERIMENTAL|Alternating postures: second day|Alternating body postures on the second day of measurement. Sitting body posture on the first day of measurement.
62255435|NCT02863731|NO_INTERVENTION|Control group|Sitting body posture on both days of measurement.
62255436|NCT04328246|EXPERIMENTAL|IES Device + Standard of Care|Intermittent electrical stimulation system. Charged pulses will be administered to bilateral gluteus maximus through surface electrodes. Stimulation occurs at 30 Hz for 10s every 10 minutes. The intervention is administered 24/7 and added to the standard of care management. Standard of care is defined as turning the patient every two hours.
62255437|NCT04328246|ACTIVE_COMPARATOR|Standard of Care|Standard of care treatment for pressure injuries is turning the patient every two hours.
62255438|NCT00603460|ACTIVE_COMPARATOR|A|
62255439|NCT00603460|ACTIVE_COMPARATOR|B|
62255440|NCT04378816|EXPERIMENTAL|QPL intervention group|Using shared decision making support tool(Question Prompt List) for intervention
62255441|NCT04378816|NO_INTERVENTION|Usual care group|No intervention, just continue using usual care
62255442|NCT03768180||Patient with infective endocarditis|All patients diagnosed with infective endocarditis after TAVR
62255443|NCT05710120||Before Period (January 2022 to October 2022)|All AIDS Healthcare Foundation Healthcare Centers will be contributing to the before phase of this study. In the before phase, alerts identifying patients who are eligible to be screened for hepatitis C infection will NOT be disseminated to healthcare providers and clinic staff. Routine clinical care will be administered without knowledge of the intervention.
62255444|NCT05710120||After Period (January 2023 to October 2023)|All AIDS Healthcare Foundation Healthcare Centers will be contributing to the after phase of this study. In the after phase, alerts identifying patients who are are eligible to be screened for hepatitis C infection will be disseminated to healthcare providers and clinic staff.
62255445|NCT02819635|PLACEBO_COMPARATOR|SS1: Placebo|During the 8-week induction phase in Substudy 1, participants received placebo for upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks.
62255446|NCT02819635|EXPERIMENTAL|SS1: Upadacitinib 7.5 mg|During the 8-week induction phase in Substudy 1, participants received 7.5 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks.
62837927|NCT01301027|PLACEBO_COMPARATOR|Placebo|1 placebo pill a day matching the pioglitazone treatment for 26 weeks
62255447|NCT02819635|EXPERIMENTAL|SS1: Upadacitinib 15 mg|During the 8-week induction phase in Substudy 1, participants received 15 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks.
62255448|NCT02819635|EXPERIMENTAL|SS1: Upadacitinib 30 mg|During the 8-week induction phase in Substudy 1, participants received 30 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Additional participants were enrolled during the Substudy 1 analysis period and received 30 mg upadacitinib film-coated tablets once daily by mouth (QD) for 4 weeks.
62255449|NCT02819635|EXPERIMENTAL|SS1: Upadacitinib 45 mg|During the 8-week induction phase in Substudy 1, participants received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Additional participants were enrolled during the Substudy 1 analysis period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 4 weeks.
62255450|NCT02819635|EXPERIMENTAL|SS2: Placebo/Upadacitinib 45 mg|During the Substudy 2 Part 1 induction period, participants received placebo for upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Participants who did not achieve clinical response at Week 8 of Part 1 were enrolled in an open-label extended treatment period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for an additional 8 weeks.
62255451|NCT02819635|EXPERIMENTAL|SS2: Upadacitinib 45 mg/Upadacitinib 45 mg|During the Substudy 2 Part 1 induction period, participants received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Participants who did not achieve clinical response at Week 8 of Part 1 were enrolled in an open-label expended treatment period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for an additional 8 weeks.
62837928|NCT05736068|EXPERIMENTAL|Non-surgical|No reduction. Application of a cast.
62837929|NCT05736068|ACTIVE_COMPARATOR|Surgical|Closed reduction under general anesthesia with or without additional pin fixation of surgeons' choice followed by cast immobilization.
62837930|NCT04075032|EXPERIMENTAL|Pomegranate extract-1|Consumption of 2 daily capsules (900 mg pomegranate extract, PE) for 4 weeks
62837931|NCT04075032|PLACEBO_COMPARATOR|Placebo-1|Consumption of 2 daily capsules (900 mg microcrystalline cellulose, PLA) for 4 weeks
62837932|NCT04075032|PLACEBO_COMPARATOR|Placebo-2|Consumption of 2 daily capsules (900 mg microcrystalline cellulose, PLA) for 4 weeks. This arm is the previous PE-1 after crossover and one month of wash-out
62613138|NCT01250171|EXPERIMENTAL|Secukinumab 10 mg/kg|Patients received a single dose of secukinumab 10 mg/kg infused intravenously over a 2 hour period.
62613139|NCT01250171|EXPERIMENTAL|Canakinumab 10 mg/kg|Patients received a single dose of canakinumab 10 mg/kg infused intravenously over a 2 hour period.
62613140|NCT01250171|PLACEBO_COMPARATOR|Placebo|Patients received a single placebo infusion intravenously over a 2 hour period.
62613141|NCT04111861|EXPERIMENTAL|Intevention|To see if singing can be used as a detractive method from patients experiencing ongoing pain.
62613142|NCT02024737||Moderate-Severe COPD|"Patients with moderate to severe COPD, as defined by GOLD 2-3 (The GOLD classifications are the main method doctors use to describe the severity of COPD.~GOLD is short for the Global Initiative for Chronic Obstructive Lung Disease, a collaboration between the National Institutes of Health and the World Health Organization)"
62613143|NCT01608516|EXPERIMENTAL|68Ga-NODAGA-RGD radiotracer|All patients will undergo a 68Ga-NODAGA-RGD PET/CT, a 18F-FDG PET/CT, a MRI and a US.
62613144|NCT05278494|EXPERIMENTAL|Dextromethorphan|
62613145|NCT05278494|PLACEBO_COMPARATOR|Placebo|
62613146|NCT05691166|EXPERIMENTAL|Progressive resistance training|Twice weekly high-intensity progressive resistance training for 12 months
62613147|NCT05691166|ACTIVE_COMPARATOR|Control|Referred to general practitioner
62613148|NCT00628927||METH and/or cocaine dependent group|The METH and/or cocaine dependent group were also enrolled in CTN0031 (NCT00573183) and seeking treatment. This group will be analyzed based on whether or not they completed treatment as defined by the study.
62613149|NCT00628927||Non METH and/or cocaine dependent group|The Non METH and/or cocaine dependent group participants are normal controls recruited from the community.
62613150|NCT03252197|EXPERIMENTAL|New device group|participants who are tested performance for ultrasound guided cannulation using device
62613151|NCT03252197|ACTIVE_COMPARATOR|Conventional group|participants who are tested performance for ultrasound guided cannulation using conventional method
62613152|NCT03597139|EXPERIMENTAL|Voclosporin ophthalmic solution (VOS)|0.2% VOS, Twice Daily (BID), both eyes for 28 days
62255452|NCT02819635|EXPERIMENTAL|SS3: M14-675 clinical responders|Participants in Study M14-675 (NCT03653026) who achieved clinical response defined by Adapted Mayo Score at Week 8 or Week 16 in that study and did not meet any study discontinuation criteria were eligible to enroll into Substudy 3. Participants were re-randomized and treated with a blinded treatment assignment (15 mg upadacitinib film-coated tablets once daily by mouth \[QD\], or 30 mg upadacitinib film-coated tablets QD, or placebo for upadacitinib film-coated tablets QD) for up to 52 weeks.
62613153|NCT03597139|ACTIVE_COMPARATOR|Comparator|0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days
62613154|NCT06731842|OTHER|TAU PET and MRI investigation|
62837933|NCT04075032|EXPERIMENTAL|Pomegranate extract-2|Consumption of 2 daily capsules (900 mg pomegranate extract, PE) for 4 weeks. This arm is the previous PLA-1 after crossover and one month of wash-out.
62837934|NCT05408442||Prone|ARDS patients during mechanical ventilation in prone position
62255453|NCT05838079||New-borns (CBHS-I)|New-borns, within the first 30 days of birth.
62255454|NCT05838079||Children (CBH and CBHS-I)|Children, 3-13 years of age. The children from the original inclusion in CBH, and those included in CBHS-I.
62255455|NCT05838079||Family members|Children and adults, age 1-99 years of age. Some subprojects will invite the family members of the participating child for family examinations.
62613155|NCT01446250|EXPERIMENTAL|Alisporivir|At the time of partial clinical hold, participants randomized to original treatment arms A and B (Alisporivir triple therapy arms with Peginterferon alfa-2a and Ribavirin) discontinued alisporivir treatment immediately while continuing their treatments with the other two therapies. These participants were combined into the same arm because they received the same dose of alisporivir 400 mg twice per day (BID) for the same duration. Amendment 1 offered them the opportunity to continue in the study receiving boceprevir triple therapy.
62613156|NCT01446250|ACTIVE_COMPARATOR|Boceprevir|Participants randomized to boceprevir triple therapy with Peginterferon alfa-2a and Ribavirin (the original treatment arm C).
62613157|NCT05471336|EXPERIMENTAL|Enteral Feeding during Therapeutic Hypothermia and Rewarming|Trophic feeds of expressed breast milk or donor breast milk at a volume of between 10-15 mL/kg/day will be ordered and administered to the patient via orogastric or nasogastric tube. Trophic feeds will be continued at the same volume for the duration of the hypothermia treatment (72 hours) and the rewarming period (8-12 hours). Once the patient is fully rewarmed, feeds will be advanced as appropriate according to the clinical judgment of the primary medical team as is the current standard of care.
62613158|NCT03970200|ACTIVE_COMPARATOR|No investigational product|Participants who receive the antibiotics usually prescribed for C diff infection.
62255456|NCT00364520||Shanghai Workers|Shanghai Workers
62613159|NCT03970200|EXPERIMENTAL|Upper gastrointestinal Fecal Microbiota Transplantation|Participants who receive the antibiotics usually prescribed for C diff infection, along with PMT that is given by mouth in capsules or through a tube that goes into your stomach/intestines if you already have one (upper delivery). You will not be assigned to this group if you cannot take any medications either by mouth or through a tube safely, as determined by your doctor
62613160|NCT03970200|EXPERIMENTAL|Lower gastrointestinal Fecal Microbiota Transplantation|Participants who receive the antibiotics usually prescribed for C diff infection, along with PMT that is given through the rectum by an enema (lower delivery).
62837935|NCT02351856|EXPERIMENTAL|ARRY-371797|
62837936|NCT01377103|PLACEBO_COMPARATOR|Placebo|Placebo Gel
62837937|NCT01377103|ACTIVE_COMPARATOR|Testosterone Supplementation|Testosterone Gel
62837938|NCT00584636|EXPERIMENTAL|Pulmicort Respules|using pulmicort respules
62837939|NCT03952975|OTHER|follicular phase group|The menstrual dates of patients were normalized to a 28-day cycle with the following formula: adjusted day of the menstrual cycle = (14 X day of the cycle at the time of surgery) / (cycle length of the patient - 14). In light of this formula patients were classified into the follicular phase group (defined as \<15 adjusted days, group A).
62837940|NCT03952975|OTHER|luteal phase group|The menstrual dates of patients were normalized to a 28-day cycle with the following formula: adjusted day of the menstrual cycle = (14 X day of the cycle at the time of surgery) / (cycle length of the patient - 14) \[14\]. In light of this formula, patients were classified into the luteal phase group (defined as ≥15 adjusted days, group B).
62837941|NCT01885741|EXPERIMENTAL|IPBS|
62255457|NCT03974776|EXPERIMENTAL|PF-06946860|Single subcutaneous administration of PF-06946860
62255458|NCT03974776|PLACEBO_COMPARATOR|Placebo|Single subcutaneous administration of placebo
62255459|NCT01651104|EXPERIMENTAL|Adjuvanted Trivalent Influenza Virus Vaccine|
62255460|NCT01121523|EXPERIMENTAL|Cue-directed tactile stimulation|
62255461|NCT01121523|ACTIVE_COMPARATOR|Control group|
62255462|NCT02280395|EXPERIMENTAL|RUT058-60|
62255463|NCT02280395|PLACEBO_COMPARATOR|Sterile Saline for Irrigation|
62613161|NCT03906851|EXPERIMENTAL|Activity and diet|"Multi-component, holistic model with a) physical activity, b) nutrition, and c) psychosocial work.~A: physical activity will be provided as a pedagogical tool in subjects Mathematics, Norwegian and English B: Focus on school meals and menus in school cafeteria C: Psychosocial work with focus on the associations between physical activity, nutrition and psychosocial health. Collaboration between schools and school health services"
62613162|NCT03906851|NO_INTERVENTION|Control|Schools are required to perform teaching activities, school meals and school cafeteria menus as usual
62255464|NCT03069352|EXPERIMENTAL|Venetoclax + Low Dose Cytarabine (LDAC)|Venetoclax 600 mg orally every day (QD) plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.
62255465|NCT03069352|PLACEBO_COMPARATOR|Placebo + LDAC|Matching placebo to venetoclax orally QD plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.
62255466|NCT01792349|EXPERIMENTAL|STARFISH intervention|STARFISH is a smartphone-based programme designed as a behavioural intervention to encourage the user to become more physically active
62255467|NCT01792349|NO_INTERVENTION|Control group|A smartphone application will record levels of physical activity, but subjects will not have access to daily step count or to the STARFISH application.
62255468|NCT03199040|EXPERIMENTAL|Neoantigen DNA vaccine + Durvalumab|"* The first neoantigen DNA vaccine injection will take place following the completion of standard of care therapy. The day of the first vaccine injection will be referred to as Day 1~* The schedule of vaccination is Day 1, Day 29 ± 7, Day 57 ± 7, Day 85 ± 7, Day 113 ± 7, and Day 141 ± 7 with at least 21 days between injection days~* For patients who are randomized to the neoantigen DNA vaccine plus durvalumab arm, the neoantigen-specific T cell response will be assessed prior to Day 85. If a neoantigen-specific T cell response is present, durvalumab will be started on Day 85, and will be administered Q4W at a dose of 1500 mg over the course of 60 minutes. If a neoantigen-specific T cell response is not present, these patients will be replaced but may continue to receive the neoantigen DNA vaccine on study. They will not be transferred to the vaccine-only arm."
62613163|NCT01282333|EXPERIMENTAL|Treatment (veliparib, gemcitabine hydrochloride, cisplatin)|Patients receive veliparib orally every 12 hours on days 1-12, gemcitabine hydrochloride IV over 30 minutes on days 3 and 10, and cisplatin IV over 60-120 minutes on day 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with suspected or known germline BRCA mutations may continue to receive single-agent veliparib continuously in the absence of disease progression or unacceptable toxicity. Patients may undergo blood, tumor tissue, and hair follicle sample collection periodically for pharmacokinetic and correlative studies.
62613164|NCT04499105|EXPERIMENTAL|Mesenchymal Stem Cell|Mesenchymal Stem cell + Nacl 0.9%
62613165|NCT04422314||Cohort 1|Lyme disease testing cohort
62613166|NCT04422314||Cohort 2|Endemic, asymptomatic controls
62837942|NCT05271877||Pregnant women|Pregnant women, regardless of the gestational age.
62837943|NCT04980703|EXPERIMENTAL|Grain moxibustion|Grain moxibustion +standard care
62837944|NCT04980703|SHAM_COMPARATOR|Sham grain moxibustion|Sham grain moxibustion +standard care
62837945|NCT04980703|OTHER|Wait-list control|Standard care
62837946|NCT06492746|EXPERIMENTAL|Cardiopulmonary bypass patients receiving blood pressure and oximetry monitoring|
62837947|NCT04843007||NanoAlvand Pemetrexed|500 mg/m\^2 pemetrexed, intravenous (IV) infusion
62837948|NCT00852852|EXPERIMENTAL|Intervention|Patient participants in the intervention arm can access educational information about self-care strategies, track and share reports of their symptoms and quality of life issues over time, and receive coaching on how to discuss these issues with their care team.
62054062|NCT01077544|EXPERIMENTAL|Group 2|\>= 10 years to \<18 years pediatric patients with newly diagnosed CP-Ph+ CML, or CP or AP-Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or relapsed/refractory Ph+ ALL (acute lymphoblastic leukemia) treated at the proposed dose of 230 mg/m2 bid.
62054063|NCT01154569|ACTIVE_COMPARATOR|Post Roux-en-Y gastric bypass|Post-bypass receiving a single dose of azithromycin
62054064|NCT01154569|ACTIVE_COMPARATOR|Controls|BMI and sex matched. Have not undergone surgery
62255469|NCT03199040|EXPERIMENTAL|Neoantigen DNA vaccine|"* The first neoantigen DNA vaccine injection will take place following the completion of standard of care therapy. The day of the first vaccine injection will be referred to as Day 1~* The schedule of vaccination is Day 1, Day 29 ± 7, Day 57 ± 7, Day 85 ± 7, Day 113 ± 7, and Day 141 ± 7 with at least 21 days between injection days"
62255470|NCT03083704|EXPERIMENTAL|Cohort 1|
62255471|NCT03083704|EXPERIMENTAL|Cohort 2|
62255472|NCT03083704|EXPERIMENTAL|Cohort 3|
62255473|NCT03083704|EXPERIMENTAL|Cohort 4|
62255474|NCT03083704|EXPERIMENTAL|Cohort 5|
62255475|NCT03083704|EXPERIMENTAL|Cohort 6|
62255476|NCT03083704|EXPERIMENTAL|Cohort 7|
62255477|NCT03083704|EXPERIMENTAL|Cohort 8|
62255478|NCT03083704|EXPERIMENTAL|Cohort 9|
62255479|NCT03083704|EXPERIMENTAL|Cohort 10|
62255480|NCT03083704|EXPERIMENTAL|Cohort 11|
62255481|NCT00501007||Non-psychiatric smokers|Smokers not meeting criteria for Schizophrenia or Schizoaffective Disorder
62255482|NCT00501007||Smokers with Schizophrenia|Smokers meeting criteria for schizophrenia or schizoaffective disorder
62613167|NCT04422314||Cohort 3|Non-endemic, asymptomatic controls
62837949|NCT00852852|NO_INTERVENTION|Control|Participants in the control arm access the ESRA-C from home or clinic to self-assess only.
62837950|NCT01072643|EXPERIMENTAL|Dexmedetomidine|To study safety of DEX with regard to effect on PVR; There will be 3 study groups (n=8 per group). The groups will be based on DEX doses as follows- Group 1 - Bolus 1 mcg/kg followed by infusion 0.7 mcg/kg/hr Group 2 - Bolus 1.5 mcg/kg followed by infusion 1.05 mcg/kg/hr Group 3 - Bolus 2 mcg/kg followed by infusion 1.4 mcg/kg/hr
62837951|NCT02099955|NO_INTERVENTION|Screening Study|To determine the prevalence and severity of vitamin D deficiency and glucose tolerance in persons with chronic SCI.
62837952|NCT02099955|EXPERIMENTAL|Pulmonary Arm|"Vitamin D3 Supplementation and Pulmonary Function:~1. To determine the relationship between levels of vitamin D and overall pulmonary function, as measured by PFTs (spirometry and body plethysmography).~2. To determine effects of vitamin D supplementations on overall pulmonary function and selected biomarkers of inflammation (FeNO, pH, 8- isoprostane levels)."
62255483|NCT04602169|ACTIVE_COMPARATOR|PVI only group|Patients allocated to this group will receive PV re-isolation alone
62255484|NCT04602169|ACTIVE_COMPARATOR|PVI + SVC group|Patients allocated to this group will receive PV re-isolation with SVC isolation.
62255485|NCT04066036||Study Population|The study will enroll a total of 1,000 ART-experienced participants from the study sites in Uganda and South Africa who are being transitioned to TLD from non-nucleoside reverse transcriptase-based antiretroviral therapy.
62443490|NCT01861327|EXPERIMENTAL|lower limb angioplasty with CO2|lower limb angioplasty made with carbon dioxide as contrast media
62443491|NCT01861327|ACTIVE_COMPARATOR|lower limb angioplasty with Iodine|lower limb angioplasty made with Iodine as contrast media
62443492|NCT01861327|EXPERIMENTAL|aorto-iliac angioplasty with CO2|aorto-iliac angioplasty made with carbon dioxide as contrast media
62443493|NCT01861327|ACTIVE_COMPARATOR|aorto-iliac angioplasty with Iodine|aorto-iliac angioplasty made with Iodine as contrast media
62443494|NCT01861327|EXPERIMENTAL|endovascular AAA correction with CO2|endovascular abdominal aortic aneurysm (AAA) correction made with carbon dioxide as contrast media
62443495|NCT01861327|ACTIVE_COMPARATOR|endovascular AAA correction with Iodine|endovascular abdominal aortic aneurysm (AAA) correction made with Iodine as contrast media
62443496|NCT00132509|EXPERIMENTAL|DFIL|
62837953|NCT02099955|EXPERIMENTAL|Endocrine Arm|"Vitamin D3 Supplementation and Endocrine Function:~To determine the effect of vitamin D replacement therapy on carbohydrate metabolism and insulin resistance in persons with vitamin D deficiency (\<20ng/ml) and IGT, mild DM (e.g. fasting serum glucose \<140 mg/dL) and/or IR."
62837954|NCT02999672|EXPERIMENTAL|Cohort 1 (UBC)|First six participants with locally advanced (unresectable and not treatable with curative intent) or metastatic UBC will initially receive Regimen A (trastuzumab emtansine at a dose of 2.4 mg/kg qw). An iDMC will assess the safety among the first six participants and decide whether dose will be switched to Regimen B (trastuzumab emtansine at a dose of 3.6 mg/kg q3w).
62255486|NCT02645760|ACTIVE_COMPARATOR|Core stabilization exercise|7-weeks of core stabilization exercise
62255487|NCT02645760|ACTIVE_COMPARATOR|conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
62255488|NCT00843518|EXPERIMENTAL|LY451395|3 milligram (mg) LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate
62255489|NCT00843518|PLACEBO_COMPARATOR|Placebo|Placebo orally twice daily for 12 weeks
62255490|NCT04240015||Periodontitis|Periodontitis group consisted of patients diagnosed with periodontitis
62443497|NCT00132509|ACTIVE_COMPARATOR|NINDS|
62443498|NCT06304870|PLACEBO_COMPARATOR|Rehabilitation therapy+Placebo Glossopharyngeal Nerve Block|The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy and placebo nerve block.
62443499|NCT06304870|EXPERIMENTAL|Rehabilitation therapy+Glossopharyngeal Nerve Block|The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. Based on this, the patients in the experimental group are provided with Stellate Ganglion Block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day.
62443500|NCT03271528|EXPERIMENTAL|Lacosamide|Lacosamide titration was done to a target dose of 300mg. Participants took 100 mg of lacosamide once on day 1, 100 mg twice per day from day 2 through day 6 (200 mg daily total), on day 7 the lacosamide dose was increased to 150 mg twice daily (300 mg daily total), and on day 8 the participant took one dose of 150 mg.
62443501|NCT03271528|PLACEBO_COMPARATOR|Placebo oral capsule|Participants took a placebo oral capsule once on day 1, twice per day from day 2 to day 7, and once on day 8.
62443502|NCT01188733|EXPERIMENTAL|Sandostatin LAR 10mg|Sandostatin LAR ( long-acting octreotide) administered every 28 days in a dose of 10mg
62255491|NCT04240015||Patients without periodontitis|Patients without periodontitis group constituted patients without periodontitis
62443503|NCT01188733|EXPERIMENTAL|Sandostatin LAR 30mg|Comparison of drug doses
62443504|NCT01188733|PLACEBO_COMPARATOR|Saline|Saline control
62443505|NCT05785455|ACTIVE_COMPARATOR|Usual care|"Subjects will receive a health education program during 5 group sessions of 60 minutes, taught by physical therapists without training in pain neuroscience education.~All patients will receive 5 sessions, regardless of the group they belong to. Group education sessions will be in groups (of 5-6 patients), respecting the safety distance. Group sessions will be held in person, in small groups, at the health center, on a weekly basis. Both groups will receive online monitoring of the exercise program. An image with more information about the intervention and control is attached in Annex 2."
62443506|NCT05785455|EXPERIMENTAL|COGMO Intervention|Each subject will receive. a first individual session to assess their beliefs about pain and coping strategies, combining motivational interviewing and pain neuroscience education techniques, followed by 4 group sessions of 60 minutes, focused on the neurophysiology of pain and self-efficacy techniques in pain control, emphasizing . in two-way communication and followed by cognition targeted exercise therapy. These sessions will be taught by physiotherapists with specific training in motivational interviewing, pain neuroscience education and cognition targeted exercise
62443507|NCT02617108|EXPERIMENTAL|Foley balloon|Foley balloon following TCRS: a Foley balloon with 4 ml of normal saline solution will be placed into the uterine cavity at the end of the operation for five days.
62443508|NCT02617108|NO_INTERVENTION|control groups|control groups: women will not receive any therapy of the treatment (comparison group).
62054065|NCT01819246|ACTIVE_COMPARATOR|Pheresis Treatment Arm|
62054066|NCT01819246|SHAM_COMPARATOR|Control Arm|
62054067|NCT02080884||CLL patients on Mabthera (rituximab)|
62255492|NCT04529681|EXPERIMENTAL|Intervention Group|Intervention group will be equipped with Stroke Riskometer Apps and informational leaflets. In the beginning of the study, investigators will guide the participants to download and install the Stroke Riskometer Apps and how to use the application to measure, monitor and self-manage the stroke risk. Participants will be followed up until six weeks with four points of data collection; baseline, second week, fourth week and sixth week.
62255493|NCT04529681|OTHER|Control Group|Control group will be given the informational leaflets consist of stroke-related leaflet, CVDs-related leaflet and the healthy eating behaviors. Participants will be followed up until six weeks with four points of data collection; baseline, second week, fourth week and sixth week.
62613168|NCT04422314||Cohort 4|Potential cross-reactive disease states
62613169|NCT04422314||Cohort 5|Lyme disease testing cohort
62613170|NCT02411318|EXPERIMENTAL|Cardiovascular Exercise|Participants will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes. For example, a 30 year old will have a target heart rate zone of 95-162 beats per minute. A baseline blood sample will be acquired before the participant begins exercising. In the following 30 minutes, participants will ride the exercise bike, and their heart rate and general status will be assessed continuously. Specifically, heart rate will be monitored using a chest strap heart rate monitor. Two additional lancet punctures will be performed after the exercise to measure the changes in neutrophil function: one immediately following the 30 minute exercise period and one 30 minutes after the exercise has been completed.
62613171|NCT02411318|EXPERIMENTAL|Caffeine Consumption|Participants will be exposed to a moderate dose of caffeine (200 mg capsule in one sitting) from a common commercial product. After consent and screening, a baseline blood sample will be acquired using the lancet puncture procedure. The participant will then be instructed to swallow a 200 mg caffeine capsule. Two additional lancet punctures will be performed after the caffeine ingestion: one after 30 minutes post-ingestion and another one after 60 minutes.
62837955|NCT02999672|EXPERIMENTAL|Cohort 2 (Pancreatic cancer/cholangiocarcinoma)|First six participants with metastatic pancreatic cancer/cholangiocarcinoma will receive Regimen A (trastuzumab emtansine at a dose of 2.4 mg/kg qw). An iDMC will assess the safety among the first six participants and decide whether dose will be switched to Regimen B (trastuzumab emtansine at a dose of 3.6 mg/kg q3w).
62255494|NCT06076837|EXPERIMENTAL|Dose Escalation - Botensilimab + balstilimab + triplet chemotherapy + chloroquine + celecoxib|Botensilimab 50 mg IV D1 of each cycle; Balstilimab 240 mg IV on D 1, 15, and 29 of each cycle; Triplet chemo (nab-paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2 +cisplatin 25 mg/m2 IV infusion on D 1, 8, 22, and 29 of each cycle; Chloroquine phosphate (Aralen) 500 mg po (300 mg equivalent chloroquine base) on D 1, 8, 15, 22, 29, and 36 of each cycle; Celecoxib 200 mg po twice daily (BID) on D 1 through 5 of each cycle Famotidine 20 mg po BID on D 1 through 5 of each cycle Aspirin 81 mg po every day (QD) thrombotic event prevention
62255495|NCT06076837|EXPERIMENTAL|Expansion Cohort - Botensilimab + balstilimab i+ triplet chemotherapy + chloroquine + celecoxib|Botensilimab (MTD TBD) D1 of each cycle; Balstilimab 240 mg IV on D 1, 15, and 29 of each cycle; Triplet chemo (nab-paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2 +cisplatin 25 mg/m2 IV infusion on D 1, 8, 22, and 29 of each cycle; Chloroquine phosphate (Aralen) 500 mg po (300 mg equivalent chloroquine base) on D 1, 8, 15, 22, 29, and 36 of each cycle; Celecoxib 200 mg po twice daily (BID) on D 1 through 5 of each cycle Famotidine 20 mg po BID on D 1 through 5 of each cycle Aspirin 81 mg po every day (QD) thrombotic event prevention
62255496|NCT06240221||Saber-C|All enrolled patients will receive the Elevation Spine Saber-C System according to surgeon standard of care.
62443509|NCT02617108|EXPERIMENTAL|postoperative estrogen therapy groups|Subjects received postoperative hormone therapy as per the protocol in use in our center for Asherman Syndrome. Immediately after the operation, the subjects were started on a 3- month course of cyclical hormonal therapy, consisting of orally administrated oestradiol valerate 2-4mg/day for 21 days, orally administrated medroxyprogesterone acetate 8mg /day from day 12 to 21 of the oestradiol valerate therapy. The second treatment cycle started one week after the completion of the first cycle, and the third treatment cycle started one week after the second cycle.
62443510|NCT02302573|EXPERIMENTAL|placenta accreta|contast-enhanced ultrasound with sonovue
62443511|NCT05923164||Breast Cancer Patients|Patients who had undergone breast cancer surgery, aged between 18-75 years-old
62443512|NCT06154382||group 1: eltroxin administration|patients witn low T4 level who recieved eltroxin in ICU
62837956|NCT00912795|EXPERIMENTAL|SMS Turkey|6-week smoking cessation program delivered via daily text messages
62837957|NCT00912795|NO_INTERVENTION|Brochure control|7-page brochure that provided general information and tips on how to quit smoking
62837958|NCT00997308|EXPERIMENTAL|AZD1446 Low|Low dose of AZD1446
62837959|NCT00997308|EXPERIMENTAL|AZD1446 High|High dose of AZD1446
62837960|NCT00997308|PLACEBO_COMPARATOR|Placebo|
62443513|NCT06154382||group 2: no eltroxin administration|patients witn low T4 level who did not recieve eltroxin in ICU
62443514|NCT05781698|ACTIVE_COMPARATOR|Control Group|The control group ( Mesalamine group, n =35 ) will receive 1 g mesalamine three times daily for 6 months
62443515|NCT05781698|ACTIVE_COMPARATOR|Fenofibrate group|Patients will receive 1 g mesalamine three times daily plus Fenofibrate (160 mg/day) for 6 months
62837961|NCT05654532|EXPERIMENTAL|AC699 Dose Escalation|Participants will receive an assigned dose of AC699 monotherapy during dose escalation. One cycle is defined as 28 days.
62837962|NCT03553303|EXPERIMENTAL|Intervention|Increasing doses of Sacubitril/Valsartan
62837963|NCT03705143|PLACEBO_COMPARATOR|Treatment as Usual|Participants will receive no additional intervention besides the services they are currently receiving at the MMT clinic.
62613172|NCT02411318|EXPERIMENTAL|Ethanol Ingestion|Participants will be weighed and their required alcohol dose determined according to the equation used by the Madison Police Department during alcohol training workshops: 1 mL of 80 proof (40%) alcohol per pound of body weight. Participants will be permitted to consume the drink at their own pace, although no slower than one drink per hour. Breath Alcohol Concentration (BAC) will be tested 20 minutes after drinking has ceased in order to clear mouth alcohol that may affect the BAC reading. Participants at 0.05 BAC and above will have blood drawn via lancet puncture. In addition to the lancet puncture done once the alcohol level is reached, an additional lancet puncture will be performed 1 hour later.
62255497|NCT05857527|EXPERIMENTAL|Soterix taVNS stimulation using EMG sensors|We will trial use of a new taVNS unit that uses automated EMG sensors to trigger stimulation and an optional Bluetooth manual trigger. This experimental device will be used to during CIMT rehabilitation treatment to pair stimulation with active movement.
62255498|NCT05418673|EXPERIMENTAL|BIIB122 225 mg|Participants will receive 225 mg of BIIB122 tablets, orally, once daily (QD) for up to 180 weeks.
62443516|NCT05921903|EXPERIMENTAL|RSV_IC_1 group|Immunocompromised (IC) patients receiving 1 dose of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1).
62443517|NCT05921903|EXPERIMENTAL|RSV_IC_2 group|Immunocompromised (IC) patients receiving 2 doses of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1) and Visit 3 (Visit 1 + 30-60 days).
62443518|NCT05921903|ACTIVE_COMPARATOR|RSV_HA group|Healthy participants receiving 1 dose of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1).
62443519|NCT04820842|EXPERIMENTAL|Active Drug Extension Period: TAK-994 30 mg|TAK-994 30 mg, twice daily (BID) tablets, orally, from Day 1 (Day 57 of previous study) to Day 56 in the Active Drug Extension Period.
62443520|NCT04820842|EXPERIMENTAL|Active Drug Extension Period: TAK-994 90 mg|TAK-994 90 mg, BID, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56 in the Active Drug Extension Period.
62443521|NCT04820842|EXPERIMENTAL|Active Drug Extension Period: TAK-994 180 mg|TAK-994 180 mg, BID, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56 in the Active Drug Extension Period.
62443522|NCT04820842|EXPERIMENTAL|Double-blind Randomized Withdrawal Period: TAK-994 30 mg|Following the Active Drug Extension Period, participants randomized to active treatment 30 mg, BID, meeting eligibility specification and continued to receive same dose (TAK-994, 30 mg, BID, tablets, orally) from Day 57 to Day 84 in the Double-blind Randomized Withdrawal Period.
62443523|NCT04820842|EXPERIMENTAL|Double-blind Randomized Withdrawal Period: TAK-994 90 mg|Following the Active Drug Extension Period, participants randomized to active treatment 90 mg, BID, meeting eligibility specification and continued to receive same dose (TAK-994, 90 mg, BID, tablets, orally) from Day 57 to Day 84 in the Double-blind Randomized Withdrawal Period.
62443524|NCT04820842|EXPERIMENTAL|Double-blind Randomized Withdrawal Period: TAK-994 180 mg|Following the Active Drug Extension Period, participants randomized to active treatment 180 mg, BID, meeting eligibility specification and continued to receive same dose (TAK-994, 180 mg, BID, tablets, orally) from Day 57 to Day 84 in the Double-blind Randomized Withdrawal Period.
62443525|NCT04820842|PLACEBO_COMPARATOR|Double-blind Randomized Withdrawal Period: Placebo|Following the Active Drug Extension Period participants meeting eligibility specification and received placebo-matching tablets for 4 weeks (from Day 57 to Day 84) in the Double-blind Randomized Withdrawal Period.
62443526|NCT01890707|ACTIVE_COMPARATOR|Deep Sedation|Deep sedation
62443527|NCT01890707|OTHER|General Anesthesia|Administration of general anesthesia. Propofol given IV, succinylcholine and rocuronium given IV and Sevoflurane via the endotracheal tube.
62255499|NCT05418673|PLACEBO_COMPARATOR|BIIB122-Matching Placebo|Participants will receive BIIB122-matching placebo tablets, orally, QD for up to 180 weeks.
62255500|NCT04474665|OTHER|Implant placement accuracy|Blueprint planning software will be used to plan reverse shoulder replacement surgery. Accuracy of the placement compared to the plan will be assessed post-surgery.
62443528|NCT05363124|EXPERIMENTAL|PEWS calculation|PEWS calculation by parents using AI-based smartphone app PEWS calculation by nurse using conventional procedure
62443529|NCT03317197|PLACEBO_COMPARATOR|Control Group|"* Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only~* Control group receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~  * Syringe No. 1 : Saline solution~ * Syringe No. 2 : Saline solution"
62443530|NCT03317197|ACTIVE_COMPARATOR|Experimental Group 1|"* Using Vasopressin \[20 IU/CPR cycle\] injection until the 5th cycle~* Experimental Group 1 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~  * Syringe No. 1 : Vasopressin~ * Syringe No. 2 : Saline solution"
62443531|NCT03317197|ACTIVE_COMPARATOR|Experimental Group 2|"* Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)~* Experimental Group 2 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~  * Syringe No. 1 : Saline solution~ * Syringe No. 2 : Steroid"
62443532|NCT03317197|EXPERIMENTAL|Experimental Group 3|"* Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)~* Experimental Group 3 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~  * Syringe No. 1 : Vasopressin~ * Syringe No. 2 : Steroid"
62443533|NCT02506790|EXPERIMENTAL|Toremifene and metformin|Toremifene 60 mg daily with metformin 850 mg BID
62443534|NCT02506790|EXPERIMENTAL|Toremifene and melatonin|Toremifene 60 mg daily with melatonin 3 mg before sleep daily
62255501|NCT05144750|EXPERIMENTAL|Fruit and Vegetable Prescription Program Cohort|All participants received the program intervention.
62255502|NCT02791984|EXPERIMENTAL|Fluid challenge with 250 ml of Ringer Lactate|
62837964|NCT03705143|EXPERIMENTAL|Chinese translated LETS ACT|In addition to services participants are currently receiving at the MMT clinic, individuals will attend six group-based one-hour behavioral activation treatment sessions.
62255503|NCT03747211|EXPERIMENTAL|Aerobic exercise intervention|Aerobic exercise by high intensity interval training, 3 times per week for 12 weeks
62443535|NCT02506790|ACTIVE_COMPARATOR|Toremifene|Toremifene 60 mg daily
62443536|NCT06194097|EXPERIMENTAL|Adenoidectomy|
62054068|NCT02448940|EXPERIMENTAL|Species of Lactobacillus|2 capsule/day of Lactofem Containing Species of Lactobacillus
62054069|NCT02448940|PLACEBO_COMPARATOR|lactose|2 capsule/day Containing lactose
62054070|NCT00262795|EXPERIMENTAL|F|Fludarabine
62054071|NCT00262795|ACTIVE_COMPARATOR|CLB|Chlorambucil
62054072|NCT02859402|EXPERIMENTAL|Experimental Arm|Conditioning chemotherapy: Fludarabine and Busulfan followed by Allogeneic stem cell transplantation
62054073|NCT02445313||Control|Normal, healthy participants
62054074|NCT02445313||AMD|Age-related Macular Degeneration participants
62054075|NCT06318325||gymnasts|gymnasts ages 9-16 years. All participants are of competitive level, each participating in at least four competitions per year
62054076|NCT04325438|EXPERIMENTAL|Pharmaceutical Care|Groups with usual care by health professionals and additional health interventions provided by pharmacists. Number of intervention groups in each cluster is different, depending on the starting time of the intervention.
62054077|NCT04325438|NO_INTERVENTION|Non-Pharmaceutical Care|Groups with usual care from health providers other than pharmacists. Number of intervention groups in each cluster is different, depending on the starting time of the intervention.
62054078|NCT04304352|EXPERIMENTAL|Metronomic VEX|Metronomic VEX (Oral Cyclophosphamide 50 mg daily continuous, Oral Capecitabine 500 mg, thrice daily continuous, Oral Vinorelbine 40 mg day 1,3 and 5 every week
62255504|NCT03747211|NO_INTERVENTION|Control group|No intervention for 12 weeks
62255505|NCT01845012|EXPERIMENTAL|Daily hemodialysis at low dialysate flow|
62255506|NCT01186575|EXPERIMENTAL|Text Message|Context-sensitive text messages are sent to men after undergoing circumcision
62255507|NCT01186575|NO_INTERVENTION|Usual Care|Usual care after adult male circumcision (no text messages)
62255508|NCT00918801||Type 1 Diabetes Mellitus|Adolescents ages 13-18 with T1DM
62443537|NCT06194097|EXPERIMENTAL|Endoscopic Sinus surgery and Adenoidectomy|
62443538|NCT01169090|EXPERIMENTAL|SK-0403 100 mg QD|
62443539|NCT01169090|EXPERIMENTAL|SK-0403 200 mg QD|
62443540|NCT01169090|EXPERIMENTAL|SK-0403 400 mg QD|
62443541|NCT01169090|EXPERIMENTAL|SK-0403 200 mg BID|
62443542|NCT01169090|SHAM_COMPARATOR|Placebo|
62443543|NCT01169090|ACTIVE_COMPARATOR|Sitagliptin 100 mg QD|
62255509|NCT00918801||Non Controls|Healthy adolescents ages 13-18 without T1DM
62255510|NCT05539768|EXPERIMENTAL|HS-IT101 monotherapy|1x10\^9-6x10\^10 in vitro expanded autologous TIL (HS-IT101) will be infused i.v. to patients with advanced solid tumor after lymphodepletion treatment with fludarabine and cyclophosphamide, and then followed by the administration of a regimen of IL-2.
62443544|NCT02171936||chronic pain|
62443545|NCT05964647|ACTIVE_COMPARATOR|LSD + ketanserin|
62443546|NCT05964647|ACTIVE_COMPARATOR|LSD+ olanzapine|
62443547|NCT05964647|ACTIVE_COMPARATOR|LSD+ lorazepam|
62443548|NCT05964647|ACTIVE_COMPARATOR|LSD + placebo|
62443549|NCT05964647|PLACEBO_COMPARATOR|Placebo + placebo|
62443550|NCT00729235|EXPERIMENTAL|1|"Slow VT zone programmed as a Monitoring zone (Monitoring arm)"
62443551|NCT00729235|EXPERIMENTAL|2|Slow VT zone programmed with ATP therapies (therapy arm).
62837965|NCT01947140|EXPERIMENTAL|Phase I: Schedule A|Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 8 of each 21 day cycle
62837966|NCT01947140|EXPERIMENTAL|Phase I: Schedule B|Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 15 of each 28 day cycle
62613173|NCT02411318|EXPERIMENTAL|Glucose Ingestion|After a baseline blood sample is acquired, participants will consume 100 grams of glucose within 5 minutes. Two additional lancet punctures will be performed after the glucose ingestion, one at 30 minutes post-ingestion, and one at 60 minutes post-ingestion.
62613174|NCT02411318|EXPERIMENTAL|Glucose and Caffeine Ingestion|After a baseline blood sample is acquired, participants will swallow 200mg of caffeine in capsule form and consume 100 grams of glucose within 5 minutes. Two additional lancet punctures will be performed after the caffeine and glucose ingestion, one at 30 minutes post-ingestion, and one at 60 minutes post-ingestion.
62613175|NCT01935128|EXPERIMENTAL|Arm 1 Everolimus/Reduced dose tacrolimus|In this arm, the myfortic® will be weaned off quickly and everolimus (Zortress®) initiated to achieve a target level of 3-8 ng/ml with a mean of 6 ng/ml. Once achieving a therapeutic dose of everolimus (Zortress®) the tacrolimus (Prograf® or Hecoria®) dose will be reduced a target level of 3-5 ng/ml.
62613176|NCT01511003|EXPERIMENTAL|Tacrolimus group|oral
62613177|NCT05636358|EXPERIMENTAL|Home-based hypnotherapy|"The intervention includes existing home-based hypnotherapy self-exercises in MP3 format for a period of three months.~The intervention group of children with FAP or IBS in primary care receives the home-based hypnotherapy self exercises in addition to care as usual by their GP according to the guideline commissioned by the Dutch Society of GPs."
62613178|NCT05636358|NO_INTERVENTION|Control|The control group of children with FAP or IBS in primary care will receive only care as usual by their GP. After the end of the study, the control group will also receive access to the home-based hypnotherapy exercises, if desired.
62613179|NCT02867202|EXPERIMENTAL|Intrauterine balloon|The heart-shaped intrauterine balloon is designed to fit into the cavity of the uterus,and removed on the 7th day after surgery. And hysteroscopy was taken out again after two or three months to re-evaluate the uterine adhesions.
62255511|NCT00542295|EXPERIMENTAL|A|
62613180|NCT02867202|EXPERIMENTAL|intrauterine device Plus Foley Catheter|Intrauterine Contraceptive Device Plus Foley Catheter are inserted into the uterine after hysteroscopic adhesiolysis. Foley Catheter is removed after three days while intrauterine device is removed at the second hysteroscopy. Uterine adhesions are judged again at the second hysteroscopy.
62613181|NCT00819572|EXPERIMENTAL|1|DLX105 low dose
62613182|NCT00819572|EXPERIMENTAL|2|DLX105 high dose
62613183|NCT00819572|PLACEBO_COMPARATOR|3|
62613184|NCT06195475||exposure to tidal volumes greater than 8 ml/kg of predicted body weight|exposure to tidal volumes greater than 8 ml/kg of predicted body weight during the initial 48 hours of pressure support mode mechanical ventilation
62613185|NCT06195475||tidal volume equal to or less than 8 ml/kg of predicted body weight|individuals who maintain a tidal volume equal to or less than 8 ml/kg of predicted body weight
62613186|NCT01216046|EXPERIMENTAL|Treatment Arm|Subjects randomized to study drug will take VX-809 for 14 days followed by a 14 day washout. Next subjects will take VX-770 for 14 days followed by a 14 day washout. Lastly, subjects will take both VX-809 and VX-770 for 14 days.
62613187|NCT01216046|PLACEBO_COMPARATOR|Placebo Arm|Subjects randomized to placebo will take VX-809 placebo for 14 days followed by a 14 day washout. Next subjects will take VX-770 placebo for 14 days followed by a 14 day washout. Lastly, subjects will take both VX-809 and VX-770 placebo for 14 days.
62255512|NCT00542295|PLACEBO_COMPARATOR|B|
62255513|NCT03012087|EXPERIMENTAL|Intervention Group|MyHealthyChoices
62255514|NCT03012087|PLACEBO_COMPARATOR|Control Group|Health Risk Assessment
62255515|NCT05362422|EXPERIMENTAL|PAS|
62255516|NCT05362422|SHAM_COMPARATOR|SHAM|
62255517|NCT05802654|EXPERIMENTAL|Participants receiving SBRT|The participants enrolled will receive single fraction of ultra-high dose SBRT(30Gy/1F).
62255518|NCT05342662|EXPERIMENTAL|Blue light-blocking glasses|Participants will wear blue light-blocking glasses to evaluate whether sleep behaviors improve.
62255519|NCT05342662|PLACEBO_COMPARATOR|Glasses with clear lenses|Participants will wear glasses with clear lenses to serve as the control condition.
62255520|NCT05638542||Control group|Patients who are not diagnosed with colorectal adenoma or colorectal cancer
62255521|NCT05638542||Colorectal adenoma group|Patients who are diagnosed with colorectal adenoma
62255522|NCT05638542||Colorectal cancer group|Patients who are diagnosed with colorectal cancer
62255523|NCT03854929|ACTIVE_COMPARATOR|Ciprofloxacin|Each sachet CIPROFLOXACIN of 3g powder contains: 250mg Ciprofloxacin HCl, dissolved in water, dosed to 15mg/kg body weight /twice daily (apart 12 hours)/ 3 days.
62255524|NCT03854929|EXPERIMENTAL|Azithromycin|Each sachet AZICINE of 1.5 g powder contains: 250mg of Azithromycin dihydrate, dissolved in warm water, dosed to 10mg/kg body weight /daily/ 3 days
62837967|NCT01947140|EXPERIMENTAL|Phase II|Subjects will receive Pralatrexate 25 mg/m2 and Romidepsin 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle
62255525|NCT01312038|EXPERIMENTAL|simethicone|125 mg tablet
62255526|NCT01312038|PLACEBO_COMPARATOR|placebo|chewable calcium tablet
62443552|NCT04023331|EXPERIMENTAL|67Cu-SARTATE|"64Cu-SARTATE - patients will receive a bolus injection of 64Cu-SARTATE during screening, and following each 67Cu-SARTATE Therapy Cycle at a rate of 2.0 MBq/kg.~67Cu-SARTATE - In the dose escalation phase, patients will receive a single administration of 67Cu-SARTATE as an IV infusion (dose will be determined based on cohort allocation). In the expansion phase, patients will receive at least 2 administrations of 67Cu-SARTATE a the MTD level as a slow IV infusion.~Participants in either phase of the study that demonstrate therapeutic benefit following treatment with 67Cu-SARTATE at any dose may be offered additional Therapy Cycles (each participant may receive a maximum of 4 Therapy Cycles in total)."
62443553|NCT04744844|EXPERIMENTAL|DNA-amplification selection|In the experimental arm, all blastocysts will undergo routine morphological assessment, with the 3 top-scoring blastocysts undergoing blastocoel fluid biopsy (BF-biopsy) and whole-genomic amplification. A single blastocyst with no DNA amplification will be selected for transfer in a frozen embryo transfer cycle.
62443554|NCT04744844|ACTIVE_COMPARATOR|Morfological-score selection|In the active comparator arm, all blastocysts will undergo routine morphological assessment. The (single) top-scoring blastocyst will be selected for transfer in a frozen embryo transfer cycle.
62837968|NCT04539795|PLACEBO_COMPARATOR|Placebo oral tablet|placebo
62837969|NCT04539795|ACTIVE_COMPARATOR|Alvelestat oral tablet - dose 1|MPH966
62255527|NCT05038020|EXPERIMENTAL|AKST4290|Subjects will receive AKST4290, 400mg twice daily, for 24 weeks
62255528|NCT05038020|PLACEBO_COMPARATOR|Placebo|Subjects will receive matching Placebo, twice daily, for 24 weeks
62255529|NCT05288218|EXPERIMENTAL|Leak-free bronchoscope adapter|"The mechanical ventilation circuit used in patients with respiratory failure is considered a closed-loop circuit between the patient and the ventilator. This allows air to flow from the ventilator to the patient and back to the circuit without escaping to the ambient environment. To perform bronchoscopy, a standard adapter is spliced into the ventilator circuit, which allows the bronchoscope to enter the ventilation circuit granting access to the patient's airways. This study will compare the efficacy of the standard commercially available adapter to the newly developed leak-free adapter. The intervention is considered the leak-free bronchoscope adapter."
62255530|NCT05288218|ACTIVE_COMPARATOR|Standard bronchoscope adapter|The mechanical ventilation circuit used in patients with respiratory failure is considered a closed-loop circuit between the patient and the ventilator. This allows air to flow from the ventilator to the patient and back to the circuit without escaping to the ambient environment. To perform bronchoscopy, a standard adapter is spliced into the ventilator circuit, which allows the bronchoscope to enter the ventilation circuit granting access to the patient's airways. This study will compare the efficacy of the standard commercially available adapter to the newly developed leak-free adapter. This arm utilizes the standard adapter.
62255531|NCT02462668|PLACEBO_COMPARATOR|Control|"Preoxygenation with Bag-mask ventilation before fibreoptic bronchoscopy assisted intubation.~Intervention: Bag-mask ventilation."
62443555|NCT03957733|EXPERIMENTAL|Experimental arm|Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX (capecitabine and oxaliplatin) and surgery. Consolidation chemotherapy will start 2-4 weeks after the end of CRT. Surgery will be performed 2-4 weeks after the last chemotherapy cycle. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (4 cycles of modified FOLFOX6 or 3 cycles of XELOX).
62837970|NCT04539795|ACTIVE_COMPARATOR|Alvelestat oral tablet - dose 2|MPH966
62837971|NCT04539795|ACTIVE_COMPARATOR|Alvelestat oral tablet - dose 3|MPH966
62837972|NCT03630445|EXPERIMENTAL|Isomaltooligosaccharides (IMOs)|"Isomaltooligosaccharides (IMOs) incorporated into a yogurt test meal.~IMOs are a mixture of short-chain carbohydrates with a purported slow digestion property."
62837973|NCT03630445|EXPERIMENTAL|Xtend® sucromalt|"Xtend® sucromalt incorporated into a yogurt test meal.~Sucromalt is derived from a combination of sucrose (cane or beet sugar) and maltose (corn sugar), yet it has been found to be slowly digested."
62837974|NCT03630445|EXPERIMENTAL|Combination of IMOs and Xtend® sucromalt|Combination of IMOs and Xtend® sucromalt incorporated into a yogurt test meal.
62837975|NCT03630445|EXPERIMENTAL|Raw corn starch|"Raw corn starch incorporated into a yogurt test meal.~Raw corn starch is uncooked starch from corn. Because it is not cooked, it has a slow digestion property."
62054079|NCT02331602|ACTIVE_COMPARATOR|rivaroxaban|Patients are assigned to receive rivaroxaban 15mg once daily for 12 months according to a computer-generated randomization sequence at the central registration center. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
62054080|NCT02331602|ACTIVE_COMPARATOR|dabigatran|Patients are assigned to receive dabigatran 150mg twice daily for 12 months according to a computer-generated randomization sequence at the central registration center. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
62255532|NCT02462668|EXPERIMENTAL|NIPPV|"The NIPPV group preoxygenation with noninvasive positive pressure ventilation(NIPPV), And then receives fibreoptic bronchoscopy intubation through a face mask (there is a small hole allow to insert the tracheal tube through the mask into trachea) during NIPPV.~Intervention: noninvasive positive pressure ventilation(NIPPV)"
62255533|NCT01218464|EXPERIMENTAL|Conventional plus MSC treatment|Participants will receive conventional treatment plus a dose of MSC from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit
62837976|NCT03630445|EXPERIMENTAL|Maltodextrin|"Maltodextrin incorporated into a yogurt test meal.~Maltodextrin is a type of starchy carbohydrate (polysaccharide) composed of units of D-glucose (simple sugars). The maltodextrin used for this study had a fast digestion property."
62837977|NCT04814004|EXPERIMENTAL|hCD19.IL15.CAR-iNKT cells|Dose escalation follows the accelerated titration and the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
62837978|NCT00942227|ACTIVE_COMPARATOR|Extension oriented treatment approach|Extension exercises. Subjects are instructed in a progression of extension oriented movements for the lumbar spine. Manual therapy may be added to further increase extension movement and/or reduction of symptoms.
62837979|NCT00942227|EXPERIMENTAL|Mechanical traction plus extension-oriented treatment|Mechanical lumbar traction will be utilized in addition to extension oriented exercises. Subjects are also instructed in a progression of extension oriented movements for the lumbar spine. Manual therapy may be added to increase extension movement and/or reduce radicular symptoms.
62837980|NCT03400839||Patients with ILD|"Patients with a medical diagnosis of interstitial lung disease.~Patients will be submitted to the assessment of:~* Daily physical activity levels;~* 6-minute walk test;~* Cardiopulmonary exercise testing;~* Muscle Function;~* Lung Function;~* Body composition;~* HRQoL - SGRQ-I;~* HRQoL - SF36;~* Anxiety and depression;~* Symptoms - mMRC~* Symptoms - UCSD/SOBQ;~* Sleep quality;~* Sleepiness;~* Inflammatory markers and oxidative stress.~* Functional performance tests"
62837981|NCT03400839||Control Group|"Age-matched peers without lung diseases.~Participants will be submitted to the assessment of:~* Daily physical activity levels;~* 6-minute walk test;~* Cardiopulmonary exercise testing;~* Muscle Function;~* Lung Function;~* Body composition;~* HRQoL - SF36;~* Anxiety and depression;~* Sleep quality;~* Sleepiness;~* Inflammatory markers and oxidative stress.~* Functional performance tests"
62837982|NCT06212336|EXPERIMENTAL|Favipiravir 1600|Oral favipiravir: 2400 mg BID D1; 1600 mg BID D2-D10
62054081|NCT02341508|EXPERIMENTAL|Lpathomab|0.5 mg/kg Lpathomab, 1.0 mg/kg Lpathomab, 3.0 mg/kg Lpathomab, 10 mg/kg Lpathomab, 20 mg/kg Lpathomab,
62054082|NCT02341508|PLACEBO_COMPARATOR|Placebo|Saline solution for intravenous infusion
62054083|NCT03953339|ACTIVE_COMPARATOR|no release|no release of the suprascapular nerve during arthroscopic repair of a rotator cuff tendon repair
62054084|NCT03953339|EXPERIMENTAL|release|arthroscopic release of the suprascapular nerve according to the established, standard technique during arthroscopic repair of a rotator cuff tendon repair
62054085|NCT02803125|ACTIVE_COMPARATOR|Developed psychosocial intervention|The active intervention in this study that will be compared to support group control
62054086|NCT02803125|PLACEBO_COMPARATOR|Support group control|This is the comparison group
62054087|NCT02475603|EXPERIMENTAL|tourniquet|Total knee arthroplasty will be performed with tourniquet
62054088|NCT02475603|EXPERIMENTAL|non-tourniquet|Total knee arthroplasty will be performed without tourniquet
62054089|NCT02945332|EXPERIMENTAL|Required supervised walking|Device: Fitbit Flexes
62054090|NCT02945332|ACTIVE_COMPARATOR|Non-required supervised walking|Device: Fitbit Flexes
62054091|NCT02708225|EXPERIMENTAL|interventional - with a medical clown|will perform pulmonary function test without the presence of a clown and an hour later will re-do the test with a medical clown present
62054092|NCT02708225|NO_INTERVENTION|non interventional|will perform pulmonary function test without the presence of a clown and an hour later will re-do the test without a medical clown present
62054093|NCT04423822||Firefighter|Firefighter with high cardiovascular risk
62054094|NCT02138266||Non-Pathologic Adults age 18-28 yrs|Non-Pathologic Adults age 18-28 yrs
62054095|NCT02138266||Non-Pathologic Adults age 29-80 yrs|Non-Pathologic Adults age 29-80 yrs
62054096|NCT02138266||Pathologic Adults age 29-80 yrs|Pathologic Adults age 29-80 yrs
62054097|NCT06168292|EXPERIMENTAL|Experimental|The clinical study will be conducted in the following order. Of patients with extrahepatic cholangiocarcinoma requiring biliary drainage, those who meet the inclusion criteria and consent to the study will be enrolled in the study and hospitalized to undergo endoscopic biliary drainage. The histologic or cytologic examination will be performed at the time of the first biliary drainage, and the extent of the cholangiocarcinoma lesion will be assessed during the procedure. After the diagnosis of extrahepatic cholangiocarcinoma, ID-RFA will be performed, and a biliary stent will be inserted for biliary drainage. Radiotherapy will be performed within 1 month of ID-RFA.
62054098|NCT01493505|PLACEBO_COMPARATOR|Placebo|Placebo Paclitaxel Carboplatin
62837983|NCT06212336|ACTIVE_COMPARATOR|Ribavirin|Intravenous ribavirin (Irrua regimen - 100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day) then 25 mg/kg single dose days 2-7, 12.5 mg/kg single dose days 8-10).
62054099|NCT01493505|ACTIVE_COMPARATOR|AMG 386|AMG 386 Paclitaxel Carboplatin
62837984|NCT06212336|EXPERIMENTAL|Favipiravir 1200 + ribavirin|Oral favipiravir: 2400 mg BID D1; 1200 mg BID D2-D10 Intravenous ribavirin (Irrua regimen - 100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day) then 25 mg/kg single dose days 2-7, 12.5 mg/kg single dose days 8-10).
62837985|NCT06212336|EXPERIMENTAL|Ribavirin + dexamethasone|IV ribavirin, Irrua regimen IV or oral dexamethasone 6mg/day (For the first 48 hours, dexamethasone will be given intravenously (i. Afterwards, a switch to oral dexamethasone (same dosage) is permitted at the discretion of the study physician.)
62837986|NCT04805398|EXPERIMENTAL|CM310|CM310 300mg is given subcutaneously (SC) every two weeks for 16-week treatment
62054100|NCT02512523|EXPERIMENTAL|Teneligliptin|Film-coated tablet for oral administration Dosage: 20mg/tablet Frequency and duration: 1 tablet/day for 4 weeks
62054101|NCT02512523|ACTIVE_COMPARATOR|Sitagliptin|Film-coated tablet for oral administration Dosage: 100mg/tablet Frequency and duration: 1 tablet/day for 4 weeks
62054102|NCT04595721|NO_INTERVENTION|Standard of care|Participants will receive standard injection procedures
62054103|NCT04595721|ACTIVE_COMPARATOR|Visual distraction|Participants engage in visual distraction during the injection procedures
62054104|NCT04595721|ACTIVE_COMPARATOR|Physical distraction|Participants engage in physical distraction during the injection procedures
62054105|NCT01298505|EXPERIMENTAL|PF-03654764 2.5mg plus fexofenadine 60mg|
62054106|NCT01298505|EXPERIMENTAL|PF-03654764 5mg plus fexofenadine 60mg|
62054107|NCT01298505|PLACEBO_COMPARATOR|placebo|
62054108|NCT03943966|EXPERIMENTAL|Myocardial Infarction|
62255534|NCT01218464|EXPERIMENTAL|Conventional plus pacebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit
62837987|NCT04805398|PLACEBO_COMPARATOR|Placebo|Placebo is given subcutaneously (SC) every two weeks for 16-week treatment.
62837988|NCT05635253|OTHER|GROUP GSEM|In-office whitening treatment with 35% Hydrogen Peroxide
62837989|NCT05635253|EXPERIMENTAL|GROUP GP|In-office whitening treatment with 35% Hydrogen Peroxide + Polishing of whitened teeth
62837990|NCT00953056|EXPERIMENTAL|Cohort I - RotaTeq™, Adults|Adults randomized to receive a single dose of RotaTeq™.
62837991|NCT00953056|PLACEBO_COMPARATOR|Cohort I - Placebo, Adults|Adults randomized to receive a single dose of matching placebo to RotaTeq™.
62837992|NCT00953056|EXPERIMENTAL|Cohort II - RotaTeq™, Children|Children randomized to receive a single dose of RotaTeq™.
62837993|NCT00953056|PLACEBO_COMPARATOR|Cohort II - Placebo, Children|Children randomized to receive a single dose of matching placebo to RotaTeq™.
62837994|NCT00953056|EXPERIMENTAL|Cohort III - RotaTeq™, Infants|Infants randomized to receive 3 doses of RotaTeq™.
62837995|NCT00953056|PLACEBO_COMPARATOR|Cohort III - Placebo, Infants|Infants randomized to receive 3 doses of matching placebo to RotaTeq™.
62613188|NCT05339412|EXPERIMENTAL|Technology Based Training Tool Only|The technology-based training tool will train facilitators to deliver the behavioral health intervention PHAT Life, which is an innovative HIV/STI, substance use, and mental health intervention for juvenile offenders. The training tool reviews each of PHAT Life's 8 sessions. The curriculum targets broad psychosocial factors implicated in HIV/STI-risk behavior, including promoting positive attitudes toward HIV/STI prevention, self-efficacy to reduce risk, and less substance misuse and sexual risk taking. Content emphasizes the importance of emotion regulation skills to manage strong feelings, uses goal setting and training in positive thought processes to plan ahead, encourages recognition of personal responsibility in future outcomes, and helps youth identify strategies and behaviors to accomplish short- and long-term goals.
62613189|NCT05339412|EXPERIMENTAL|Technology Based Training Tool plus Live Supervision|Participants randomized to this condition will receive (in addition to the training tool described above) access to live supervision delivered remotely via commercially available video conferencing software (Zoom). Facilitators-in-training will complete two mock roleplays of curriculum activities, which can be conducted live via Zoom with PHAT Life trainers (either Dr. Floyd or Dr. Snow-Hill) or can be recorded and submitted via the app. Trainers will review for fidelity and provide feedback. During the supervision sessions, participants will have the opportunity to clarify content, ask questions, roleplay group sessions to practice difficult parts of the group sessions, and review feedback on role plays.
62613190|NCT05836675|EXPERIMENTAL|Experimental Intradialytic exercise|Aerobic, resistance and Kegel exercises
62255535|NCT01027819|ACTIVE_COMPARATOR|Mobile bearing|Mobile bearing type between polyethylene insert and tibial component MB type will be randomly used in total knee arthroplasty
62613191|NCT03710369|SHAM_COMPARATOR|Normoxia|Exercise in room air (normoxia). Sildenafil
62613192|NCT03710369|ACTIVE_COMPARATOR|Hypoxia|Exercise in hypoxic air (reduced O2 concentration) that simulates 2500m elevation for 30-40 minutes with Sildenafil. Placebo
62613193|NCT05917808|EXPERIMENTAL|Study arm|Only study arm in the study. Participants consume a ready-to-eat wholegrain porridge on two consecutive evenings and repeat OGTT
62613194|NCT04375501||COVID-19 positive|All patients admitted with fractured neck of femur during specified time period testing POSITIVE for COVID-19
62613195|NCT04375501||COVID-19 negative|All patients admitted with fractured neck of femur during specified time period testing NEGATIVE for COVID-19
62837996|NCT05064592||Patients|Medical records of minor patients hospitalized between 2015 and 2020 in PICU and having been under sedation and prolonged invasive mechanical ventilation (\> 72h).
62837997|NCT00515762|EXPERIMENTAL|1: scalp cooling|scalp cooling
62613196|NCT05917067||Children (<18 years) that will undergo total thyroidectomy for any indication|
62613197|NCT03905356|EXPERIMENTAL|Exercise|"The exercise intervention will utilize the Moving Through Cancer: A Guide to Exercise for Cancer Survivors framework. A certified cancer exercise physiologist will work through this guide at radiation therapy visits, with at least 1 visit per week, per the study schema. The cancer exercise physiologist will teach participants proper: warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. The cancer exercise physiologist will tailor the instruction to convey special considerations for exercise based on treatment and cancer type. The patient will perform supervised exercise in the Exercise Medicine Unit under the guidance of the cancer exercise specialist. The exercise done will be educational in nature (i.e. learning about proper walking form, proper intensity for a warmup/cool down, proper techniques for resistance exercises)."
62613198|NCT05807438|ACTIVE_COMPARATOR|Foam Roller group|Myofascial release with foam roller, hamstring and gastrocnemius muscle groups were trained with foam roller for 30 seconds with 2 repetitions
62613199|NCT05807438|ACTIVE_COMPARATOR|Manual myofascial release group(Hands on)|We used the following treatment protocol for all patients in the MFR group. The techniques were performed by a physiotherapist with experience in MFR.
62613200|NCT06351852|EXPERIMENTAL|Primary|6 subjects will receive 2 medications transdermally.
62613201|NCT00715845|EXPERIMENTAL|2|
62613202|NCT04728555|EXPERIMENTAL|Game before RT start|Intervention of a digital game five days before start of RadioTherapy
62837998|NCT01411046||RA treated with prednisolone|Patients with RA treated with prednisolone, minimum 5 mg/day for minimum 6 months. Patients are grouped according to haplotype of 4 SNPs of the glucocorticoid recepror gene. Patients with or without these polymorphisms were invited to a Synacthen® test, but patients with a mixed hetero- and homozygote genotype were not. Adrenal function is evaluated with a Synacthen test.
62255536|NCT01027819|ACTIVE_COMPARATOR|Fixed bearing|Fixed bearing type between polyethylene insert and tibial component FB type will be randomly used in total knee arthroplasty
62613203|NCT04728555|EXPERIMENTAL|Game after RT start|Intervention of a digital game three days after start of RadioTherapy
62613204|NCT05011097|EXPERIMENTAL|Y150|Subjects who meet the enrollment criteria will enter the core treatment period and receive a cycle of treatment with Y150 (once weekly for 4 weeks) via intravenous infusion. And eligible subjects who complete the core treatment period will receive a cycle of extended treatment (once weekly for 4 weeks) until disease progression or toxicity intolerance.
62613205|NCT05584800|EXPERIMENTAL|Dose Escalation|
62613206|NCT05584800|EXPERIMENTAL|Dose Expansion|Tumor type: colorectal cancer，pancreatic cancer
62837999|NCT06516016||800 presymptomatic participants|"* Visit interview~* Neurological evaluation (NeuroPrems Scale and Self-administered REDCap questionnaires)~* Psychological evaluation (Motivation, life trajectories and experiencies and semi-structured interview)~* Cognition and behavior evaluation (Neuropsychological battery and Self-administered REDCap QR)~* Imaging (MRI 3T and PET DPA-714)~* Neurophysiology (Eye movement recording, Magnetoencephalography, Body posture and gait recording, voice and language recording)~* Skin aging (Skin quantitative elasticity assessment)~* Sleep (Videopolysomnography)~* Biosampling (Blood draw, lumbar puncture, saliva sampling, skin biopsy, nasal brush and tear fluid collection)"
62054109|NCT03943966|ACTIVE_COMPARATOR|Stable coronary disease with intracoronary stent insertion|
62054110|NCT03943966|ACTIVE_COMPARATOR|Deep vein thrombosis and Pulmonary embolus|
62255537|NCT01684072|EXPERIMENTAL|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
62613207|NCT06240988|EXPERIMENTAL|Modified Constraint Induced Movement Therapy|Group that will be provided with Modified Constraint Induced Movement Therapy. A protocol of 10 minutes of MCIMT therapy will be given including constraints.
62838000|NCT06516016||200 healthy volunteers|"* Visit interview~* Neurological evaluation (NeuroPrems Scale and Self-administered REDCap questionnaires)~* Psychological evaluation (Motivation, life trajectories and experiencies and semi-structured interview)~* Cognition and behavior evaluation (Neuropsychological battery and Self-administered REDCap QR)~* Imaging (MRI 3T and PET DPA-714)~* Neurophysiology (Eye movement recording, Magnetoencephalography, Body posture and gait recording, voice and language recording)~* Skin aging (Skin quantitative elasticity assessment)~* Sleep (Videopolysomnography)~* Biosampling (Blood draw, lumbar puncture, saliva sampling, skin biopsy, nasal brush and tear fluid collection)"
62838001|NCT01537705|EXPERIMENTAL|Neuron012703|Amino acid formulation for the dietary management of symptoms related to periphal neuropathy.
62838002|NCT02124785|EXPERIMENTAL|HAV Group|Subjects who were previously vaccinated with Havrix in primary studies.
62838003|NCT05322382|EXPERIMENTAL|Single|Subjects undergo an interventional procedure and non-invasive measurements of SpO2.
62838004|NCT00659789|EXPERIMENTAL|Vacc-4x|Vacc-4x reconstituted in sterile water (0.1 mL) at a dose of 1.2mg per intradermal administration. Participants are given a total of 6 immunizations over 18 weeks (weeks 1, 2, 3, 4, 16, 18). Recombinant human granulocyte macrophage colony stimulating factor (rhuGM-CSF) Leukine (0.06mg in 0.1 mL) administered intradermally is used as a local adjuvant.
62838005|NCT00659789|PLACEBO_COMPARATOR|Placebo|Placebo injections consisting of sterile water (0.1 mL) in place of Vacc-4x. Placebo injections consisting of sterile water (0.1 mL) in place of Leukine.
62838006|NCT04093102||cases|cases with obsrtuctive sleep apnea
62838007|NCT04093102||control|cases without obstructive sleep apnea.
62838008|NCT06147791|EXPERIMENTAL|Group with drainage|
62838009|NCT06147791|NO_INTERVENTION|Group without drainage|
62838010|NCT04376866|EXPERIMENTAL|Toripalimab+CCRT|"Toripalimab 240mg, and Cisplatin 100mg/m2 (every three weeks),D1,D22,D43 of intensity modulated radiotherapy (IMRT), followed by Toripalimab 240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy.~IMRT: total dose 60-66Gy, 1.8-2.0Gy/f"
62838011|NCT04376866|NO_INTERVENTION|CCRT alone|"Cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy (IMRT).~IMRT: total dose 60-66Gy, 1.8-2.0Gy/f"
62838012|NCT04001322|EXPERIMENTAL|14 Intervention LGAs|Various target beneficiaries will receive broadcast, targeted and individualized SMS messages on immunization.
62838013|NCT04001322|OTHER|7 Control LGAs|This arm will not receive any SMS messages on immunization
62838014|NCT01886053|ACTIVE_COMPARATOR|Ertapenem|
62838015|NCT01886053|EXPERIMENTAL|Faropenem（low-dose group)|
62838016|NCT01886053|EXPERIMENTAL|Faropenem（high dose group）|
62838017|NCT00997646||Patients in hospitalist-run ward|Patients was admitted from ER to a hospitalist-run ward.
62838018|NCT00997646||Patients in conventional ward|Patients was admitted from ER to a non hospitalist-run ward.
62838019|NCT03586466|EXPERIMENTAL|BupreCare|The BupreCare system is an integrated medication management and patient monitoring system, consisting of a smart medication-tracking dispenser and online platform. The dispensing component is a portable smart dispenser and secure pill cartridges that is programmed with an individualized treatment plan for each patient. This arm will be assigned a MedicaSafe device that will have their buprenorphine/naloxone securely stored. Treatment reports of their dispensation history will be collated and available to the treatment team.
62838020|NCT03586466|ACTIVE_COMPARATOR|Treatment as Usual|This arm represents an active comparator for the experimental group. Subjects in this group will undergo TAU, with no changes to the way that they receive their medication. They will have pill counts bi-weekly to examine adherence.
62054111|NCT03943966|ACTIVE_COMPARATOR|Surgical and Transcatheter Aortic valve replacement|
62054112|NCT03943966|ACTIVE_COMPARATOR|Transient ischaemic attack and stroke|
62838021|NCT03586466|ACTIVE_COMPARATOR|Treatment as Usual with MEMS|This arm represents a second active comparator for the experimental group. Subjects in this group will receive their medication in a MEMS pill bottle, but otherwise will undergo TAU.
62838022|NCT05676177|EXPERIMENTAL|Main study arm|"All consenting participants will be invited to the radiology department during the medical screening rounds or at a different day (at their convenience). They will be scanned on both MRI and CT using dedicated protocols. Both scans will be conducted at the same day within a time-frame of 6 hours of each other. No follow up visit will be required.~MRI would be performed on a 3 Tesla magnet using a dedicated short protocol consisting of axial and coronal T2-weighted scans for anatomic assessment, and a dual-echo scan to assess for liver fat. The scan time would be less than 10 minutes.~CT scans will be performed using a single CT device. Ultra-low dose dual energy CT (ULD-DECT) scanning protocol parameters liver fat measurement (estimated scan time - less than 2 minutes)."
62838023|NCT02206633||Elderly, assisted living residents|Hydration Monitor ultrasound measurements
62054113|NCT06130046||OLT|Observation of MR-proADM levels at protocol timepoints to predict main (DGF and AR) and secondary (surgical complications, infections, others) complications after liver transplantation at our Institution.
62054114|NCT06130046||KT|Observation of MR-proADM levels at protocol timepoints to predict main (DGF and AR) and secondary (surgical complications, urological complications, infections, others) complications after kidney transplantation at our Institution.
62054115|NCT04186780|EXPERIMENTAL|Intervention group|Intervention group: patients with borderline cholesterol consumed two cereal bars with Shiitake per day for 66 days.
62054116|NCT04186780|PLACEBO_COMPARATOR|Placebo group|Patients with borderline cholesterol consumed two placebo cereal bars for 66 days.
62255538|NCT01684072|ACTIVE_COMPARATOR|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
62613208|NCT06240988|EXPERIMENTAL|Motor Imagery Technique|Group that will be provided with Motor Imagery Technique by grasping an object and placing it into a container, or in imagining to perform the same action.
62613209|NCT02656563|EXPERIMENTAL|Radium 223 Arm|Radium 223 Dichloride (Xofigo®)
62613210|NCT02656563|NO_INTERVENTION|Non Treatment Arm|Control Arm
62613211|NCT06730152|EXPERIMENTAL|WeChat Information-Motivation-Behavioral Skills Model Intervention Group|The intervention group would undergo a six-week intervention program. Researchers promoted a public WeChat account to the intervention group, and participants received the intervention by following the account. They automatically received pushed articles or videos, providing them with relevant knowledge about overcoming smartphone addiction. Furthermore, they would be motivated to quit their addiction through real-life cases of smartphone addiction etc., in addition to some practical skills of overcoming.
62613212|NCT06730152|NO_INTERVENTION|Control group|without any intervention, maintain normal life and study state
62613213|NCT02295787|EXPERIMENTAL|Ketamine|Intranasal Ketamine 50mg administered six times over three weeks.
62613214|NCT02295787|PLACEBO_COMPARATOR|Placebo|Intranasal saline solution administered six times over three weeks.
62613215|NCT00636961|EXPERIMENTAL|Sequence 1: Indacaterol 300μg followed by Placebo|In period I, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. In period II, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. For each treatment period and for each patient, the doses were to be administered between 7am and 12am. A period of at least 4 days but no more than 21 days separated each treatment period. Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
62613216|NCT00636961|EXPERIMENTAL|Sequence 2 : Placebo followed by Indacaterol 300μg|In period I, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. In period II, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. For each treatment period and for each patient, the doses were to be administered between 7am and 12am. A period of at least 4 days but no more than 21 days separated each treatment period. Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
62613217|NCT01666210|ACTIVE_COMPARATOR|Dexamethasone Punctum Plug|Sustained and tapered release of dexamethasone from hydrogel punctum plug following insertion over 30 days
62255539|NCT02988570|EXPERIMENTAL|children born very preterm|A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
62613218|NCT01666210|PLACEBO_COMPARATOR|Placebo Vehicle Punctum Plug|Placebo punctum plug insertion
62255540|NCT06265857|ACTIVE_COMPARATOR|The control group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy.~Besides, the control group was given enteral nutritional support with nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation."
62613219|NCT05869877|NO_INTERVENTION|Control|Proficient RN who works in IV Therapy Department - PIVC inserted without using ultrasound; non-bordered transparent dressing; 1-1.25 inch catheter; microbore extension set with neutral needleless connector; transpore tape. Standard of care
62613220|NCT05869877|EXPERIMENTAL|Bundled|Proficient RN who works in IV Therapy Department - 6 cm catheter inserted with or without ultrasound; chlorhexidine embedded transparent bordered dressing; transpore tape; microbore extension set with antireflux needleless connector
62613221|NCT04023305|EXPERIMENTAL|Nonfocal ARDS|ARDS patient with nonfocal lung imaging phenotype
62613222|NCT04023305|EXPERIMENTAL|Focal ARDS|ARDS patient with focal lung imaging phenotype
62613223|NCT03760458|EXPERIMENTAL|Weight Band #1 (6 to less than 10 kg at study entry)|Children weighing 6 to less than 10 kg at study entry. These children received 3 dispersible tablets of ABC/DTG/3TC daily while weighing 6-\<10 kg; as their weight increased, they received higher doses consistent with their new weight band.
62255541|NCT06265857|EXPERIMENTAL|The observation group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy.~Besides, the observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the relevant guidelines."
62255542|NCT02439996|EXPERIMENTAL|IVIG(1g/kg,once)|The KD children will be randomly assigned to three groups. The patients in group C will receive IVIG 1g/kg once.
62255543|NCT02439996|EXPERIMENTAL|IVIG(1g/kg,twice)|The KD children will be randomly assigned to three groups. The patients in group B will receive IVIG 1g/kg for 2 days continuousl.
62613224|NCT03760458|EXPERIMENTAL|Weight Band #2 (10 to less than 14 kg at study entry)|Children weighing 10 to less than 14 kg at study entry. These children received 4 dispersible tablets of ABC/DTG/3TC daily while weighing 10-\<14 kg; as their weight increased, they received higher doses consistent with their new weight band.
62613225|NCT03760458|EXPERIMENTAL|Weight Band #3 (14 to less than 20 kg at study entry)|Children weighing 14 to less than 20 kg at study entry. These children received 5 dispersible tablets of ABC/DTG/3TC daily while weighing 14-\<20 kg; as their weight increased, they received higher doses consistent with their new weight band.
62613226|NCT03760458|EXPERIMENTAL|Weight Band #4 (20 to less than 25 kg at study entry)|Children weighing 20 to less than 25 kg at study entry. These children received 6 dispersible tablets of ABC/DTG/3TC daily while weighing 20-\<25 kg; as their weight increased, they received higher doses consistent with their new weight band.
62443556|NCT03957733|NO_INTERVENTION|Standard arm|Long course CRT will be followed by surgery 10-12 weeks after the end of CRT. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (8 cycles of modified FOLFOX6 or 6 cycles of XELOX).
62443557|NCT03475797|EXPERIMENTAL|Occipital Nerve Stimulation (ONS)|Occipital nerve stimulation with percutaneous or surgical lead plus optimal medical management
62443558|NCT03475797|ACTIVE_COMPARATOR|Optimal Medical Management (OMM)|Optimal Medical Management according to what is done in routine clinical practice
62443559|NCT06152913|EXPERIMENTAL|HANDS-ON treatment with random baselines|Participants are randomly allocated to one of four baseline periods (2.5 weeks, 3 weeks, 3.5 weeks, or 4 weeks). Participants then receive the HANDS-ON treatment. This treatment consists of three phases across nine weeks. After the treatment, there is a follow-up period of 4 weeks.
62838024|NCT04067817|EXPERIMENTAL|norepinephrine|Blood pressure is generally maintained at value not less than 80% of baseline during intraoperative period. If the blood pressure is within normal range and SVV is less than 9, patient will be given a continuous infusion of crystalloid solution. However, when blood pressure drops and SVV is greater than 13, a bolus of 200mL colloid will then be quickly administered. If the blood pressure doesn't recover back to normal range within 5 minutes after bolus, norepinephrine will be given through the central venous catheter. If SVV is between 9 and 13, a bolus of crystalloid at 8mL/kg/h will be administered
62838025|NCT04067817|EXPERIMENTAL|phenylephrine|Blood pressure is generally maintained at value not less than 80% of baseline during intraoperative period. If the blood pressure is within normal range and SVV is less than 9, patient will be given a continuous infusion of crystalloid solution. However, when blood pressure drops and SVV is greater than 13, a bolus of 200mL colloid will then be quickly administered. If the blood pressure doesn't recover back to normal range within 5 minutes after bolus, phenylephrine will be given through the central venous catheter. If SVV is between 9 and 13, a bolus of crystalloid at 8mL/kg/h will be administered.
62838026|NCT05482100||Patients monitored with OmniGraf Testing|Subjects will have OmniGraf™ testing at study enrollment and thereafter every 3 months or at the same time as standard routine labs (minimum two per year). In addition, subjects will have OmniGraf™ testing at any time there is a workup for clinical events and referral to advanced care (transplant center, biopsy, etc)
62838027|NCT00689858|EXPERIMENTAL|1|Period 1: Cilostazol, Ginkgo biloba Period 2:Cilostazol, placebo
62054117|NCT04945148|EXPERIMENTAL|Metformin|Patients who have been selected with an OXPHOS+ status, will start standard radiotherapy (RT, 60Gy/6 weeks), concomitant TMZ chemotherapy (75mg/m²/day), and metformin by 7 weeks after surgery and adjuvant TMZ + metformin will follow onwards until the 12th cycle of TMZ. Patients still in remission after this time-point will continue metformin alone until progression.
62443560|NCT01014390|EXPERIMENTAL|WallFlex Biliary RX FC Stent System|The WallFlex Biliary RX Fully Covered Stent System is being evaluated for treatment of benign biliary strictures.
62443561|NCT05555459|EXPERIMENTAL|CompressOn group|125 participant patients undergoing bone fixation surgical operation specified in the study description. All bone fixation surgeries are performed using Inion CompressOn screws.
62443562|NCT05287659|EXPERIMENTAL|VLCKD group|patients followed a structured VLCKD protocol (800Kcal/die)
62443563|NCT05287659|ACTIVE_COMPARATOR|VLCKD and Physical Training group|patients followed a structured VLCKD protocol (800Kcal/die) combined with interval training (IT), two times a week
62443564|NCT05287659|ACTIVE_COMPARATOR|LCD and Leucine supplementation group|patients followed a LCD regimen (1000 kcal/day) with supplementation of 18 g whey proteins which 4.1 g of leucine
62443565|NCT02402868|EXPERIMENTAL|Intranasal ketamine and saline|Intranasal ketamine (each single dose, 8 mg/kg prepared in 0.9% NS in 3 mL syringe and atomizer, to a maximum of 6.4 mL) PLUS IV 0.9% NS 0.02 mL/kg
62443566|NCT02402868|ACTIVE_COMPARATOR|Intravenous ketamine and saline|Intravenous ketamine (single dose, 1 mg/kg, to a maximum 100 mg) PLUS intranasal 0.9% NS 0.08 mL/kg divided to both nares
62613227|NCT03760458|EXPERIMENTAL|Weight Band #5 (25 kg or greater at study entry)|Children weighing 25 kg or greater at study entry. These children received 1 immediate release tablet of ABC/DTG/3TC daily.
62054118|NCT00269802|EXPERIMENTAL|001|OROS methylphenidate HCl
62054119|NCT00269802|ACTIVE_COMPARATOR|002|Ritalin
62838028|NCT00689858|ACTIVE_COMPARATOR|2|Period 1: Cilostazol, placebo Period 2: Cilostazol, Ginkgo biloba
62838029|NCT04602780||CI users|
62255544|NCT02439996|ACTIVE_COMPARATOR|IVIG(2g/kg.once)|The KD children will be randomly assigned to three groups. The patients in group A will receive IVIG 2g/kg once.
62443567|NCT01508273|EXPERIMENTAL|Exercise Intervention Program Group|At baseline study visit, participant shown how to complete the physical exercises performed while on study. Pedometer received to track physical activity. Resistance training bands given to use as part of the home-based exercise program. At the baseline study visit, directions received on how to use the study website. Access given to website that will allow tracking of exercise behavior and help set goals. Access given to an internet-based curriculum that will help teach about goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Participant asked to visit website every week. Participant records activity and the number of steps taken every day on the website. Survey completed monthly about attitudes and beliefs about physical activity.
62443568|NCT01508273|OTHER|Sedentary Behavior and Dietary Intervention Group|Access given to internet-based curriculum to help teach about goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Participants read information about improving the quality of their diet and cutting back on sedentary behavior. Participants record on the website how much television watched and how many fruits and vegetables eaten every day. Survey completed monthly about attitudes and beliefs about sedentary behavior and dietary intake.
62255545|NCT03941678|EXPERIMENTAL|Creatine|0.3 g/kg/d creatine for 7 days; 0.1 g/kg/d creatine for 63 days
62255546|NCT03941678|PLACEBO_COMPARATOR|Placebo|0.3 g/kg/d placebo for 7 days; 0.1 g/kg/d placebo for 63 days
62255547|NCT05931796|ACTIVE_COMPARATOR|Group A|NON-ERAS pathway All patients received best of care practice, with standardization of preoperative and postoperative care
62255548|NCT05931796|ACTIVE_COMPARATOR|Group B|ERAS pathway ERAS consist of approximately 15 elements (or components) that include preoperative, intraoperative, and postoperative interventions .
62255549|NCT05376215|ACTIVE_COMPARATOR|Fitting method A first, then fitting method B|"Participants will be fit with a set of hearing devices that are programmed to fitting method A first. This fitting method will use specific programming parameters and software to determine the most appropriate fitting algorithm.~Following a home trial with fitting method A, participants will then be fit with a set of hearing devices that are programmed to fitting method B. This fitting method will use a different set of programming parameters and software to determine the most appropriate algorithm."
62838030|NCT03822845|EXPERIMENTAL|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET/CT scan
62838031|NCT01483521|EXPERIMENTAL|Waitlist families|"Experimental arm consisted of randomized waitlist families who received home visitation where mothers were taught to play with their children in a developmentally appropriate manner and also engaged in a co-construction task.~Control arm families did not get any active intervention. Parents from both arm types completed pre and post questionnaires to measure child's externalizing behaviors and parenting stress.~Parents from experimental group were encouraged to keep a diary of their play record."
62255550|NCT05376215|EXPERIMENTAL|Fitting method B first, then fitting method A|"Participants will be fit with a set of hearing aids that are programmed using fitting method B. This fitting method will use a different set of programming parameters and software to determine the most appropriate algorithm.~Following a home trial with fitting method B, participants will then be fit with a set of hearing devices that are programmed to fitting method A. This fitting method will use specific programming parameters and software to determine the most appropriate fitting algorithm."
62255551|NCT04106882|EXPERIMENTAL|Arm 1: Metabolic Manipulation via Diet fMRI|All subjects are tested three times, each in a different diet-induced metabolic state: glycolytic (glucose burning), fasting (8 hours no food), and ketotic (fat burning). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink up to 75g glucose. Data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
62443569|NCT01508273|EXPERIMENTAL|Chair-based Study Group|Patients participate in chair-based exercise study. Participants receive chair-based exercise DVD. Chair-based exercise program participation for a total of 8 weeks. Participants receive self-report assessments about quality of life and asked to participate in physical assessments of their balance and coordination.
62838032|NCT01578369|EXPERIMENTAL|Exercise group|Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
62838033|NCT01578369|NO_INTERVENTION|Control|Usual care
62838034|NCT06289907|ACTIVE_COMPARATOR|Active group|Dietary supplement containing a proprietary botanical blend with NK3R antagonistic activity
62838035|NCT06289907|PLACEBO_COMPARATOR|Placebo group|"Placebo capsule containing:~* Microcrystalline cellulose~* Silicon dioxide micronized~* Magnesium stearate"
62838036|NCT04371159|EXPERIMENTAL|Velieve U.S.|Each participant will test their urine sample using the Velieve U.S. device
62838037|NCT04382352|EXPERIMENTAL|Humanized Anti-HER2 Monoclonal Antibody Compound for Injection|Registration number: CTR20181455 Indications: HER2-positive recurrent or metastatic breast cancer Experimental popular topic: Phase Ia clinical study of recombinant anti-HER2 humanized monoclonal antibody composition
62838038|NCT02884713|EXPERIMENTAL|Levofloxacin and Doxycycline and Esomeprazole|The rescue treatment was given for ten days consisting of levofloxacin 500 mg once daily, doxycycline 100 mg twice daily, and esomeprazole 20 mg twice daily
62255552|NCT04106882|EXPERIMENTAL|Arm 2: Metabolic Manipulation via Ketone Supplement fMRI|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink either of two fuel sources. In the ketotic (ketone burning) session they will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones. Data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
62255553|NCT04106882|EXPERIMENTAL|Arm 3: Metabolic Manipulation via Ketone Supplement MR/PET|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). For both sessions, the investigators will intravenously administer the FDG radioisotope continuously throughout the scan. Thus, PET will map glucose uptake across the brain, while MRS is simultaneously used to measure production of the neurotransmitters glutamine and GABA. While having their brains scanned with MR/PET, subjects are initially tested at rest, and then perform a task. Subjects will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones.
62613228|NCT02742714|EXPERIMENTAL|PillCam SBC|The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
62255554|NCT05018247|ACTIVE_COMPARATOR|Urgent revascularization with Optimal Medical Therapy|Revascularization will be performed via either Percutaneous Coronary Intervention or Coronary Artery Bypass Graft, and the selection of the specific procedure will be at the discretion of the patient and their physician(s). Patients will be followed for one year after randomization. Follow-up visits will occur at Baseline, Day 105, and Day 365. At each visit, a rest-stress PET assessment will be performed, and adverse events related to study procedures and cardiac disease will be captured.
62255555|NCT05018247|OTHER|Optimal Medical Treatment with delayed revascularization|OMT without revascularization for a minimum of approximately 105 days if clinically stable. At their first follow-up visit (Day 105±20), patients will be offered the option of continued medical treatment or elective revascularization consistent with informed patient preference and clinical judgement. Patients, in consultation with their physicians, may elect to undergo revascularization at any time thereafter and will be followed for one year after randomization. Follow-up visits will occur at Baseline, Day 105, and Day 365. At each visit, a rest-stress PET assessment will be performed, and adverse events related to study procedures and cardiac disease will be captured.
62255556|NCT02685423|EXPERIMENTAL|Visual Deprivation - 10 days|10 days of visual deprivation followed by vision training
62613229|NCT02156973|NO_INTERVENTION|Group One Usual care|Patients attending for CT coronary angiography all receive an information leaflet with their appointment letter, and a brief verbal description of the scan by the radiographer immediately before it is undertaken, as standard care. All patients attending will be offered the opportunity to complete a short questionnaire (until all patients are recruited - anticipated to be 4 weeks). The Speilberger State-Trait Anxiety Index has been abbreviated and validated for use in outpatient settings to gauge levels of pre-procedural anxiety. This will be undertaken on arrival and repeated immediately before the scan, to see if patients feel better prepared after the standard interaction with staff.
62613230|NCT02156973|EXPERIMENTAL|Group Two Video information|The patient video will be introduced to Group Two once Group One has been completed. In addition to the information sheet these patients (again, for four weeks or until recruitment is complete) will be sent an internet hyperlink to its presence on YouTube (video-sharing website) and the Hospital website with their appointment letter. Patients who do not have internet access will be offered the opportunity to see the video in the preparation room while waiting for their scan. Questionnaires will be administered as before, again done twice to examine any late impact of the information on patient anxiety, and the patient will undergo their test.
62613231|NCT01451164|EXPERIMENTAL|High dose|
62613232|NCT01451164|EXPERIMENTAL|Mid dose|
62613233|NCT01451164|EXPERIMENTAL|Low dose|
62613234|NCT01451164|PLACEBO_COMPARATOR|Placebo|
62613235|NCT06510920|EXPERIMENTAL|Obese children aerobic exercise intervention group|Aerobic exercise intervention on children obesity in the experimental group, the form of aerobic exercise for football and volleyball training, strength control in moderate intensity, time 1 hour, twice a week.
62255557|NCT02685423|ACTIVE_COMPARATOR|Vision Training Only|Vision training without visual deprivation
62255558|NCT02679014|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo capsules (2 capsules) twice daily for 28 days.
62255559|NCT02679014|EXPERIMENTAL|RO5459072|Participants will receive RO5459072 100 milligrams (mg) capsules (2\*50 mg capsules) twice daily for 28 days.
62255560|NCT01797497|EXPERIMENTAL|Care plan and coaching group|In the intervention group, parents complete a referral care plan with their children's physicians and receive a brief coaching session about how to exchange information with specialists. Outcome data are collected from parents before and after the specialist visit.
62613236|NCT06510920|NO_INTERVENTION|Obese children of control group|Control group in obese children will be conducted in normal school physical education, in addition to no other exercise intervention.
62054120|NCT00269802|PLACEBO_COMPARATOR|003|Placebo
62443570|NCT04558216|EXPERIMENTAL|Vonoprazan single doses / rifampin single doses|Participants will be administered a single oral dose of 20 mg of vonoprazan oral tablets on Day 1 and Day 17. Participants will also be administered single daily doses of 600 mg rifampin oral capsules on Days 3 through 18.
62443571|NCT00636831|PLACEBO_COMPARATOR|cont|
62443572|NCT00636831|ACTIVE_COMPARATOR|intervention|
62443573|NCT04951128|EXPERIMENTAL|Tranexamic acid arm|Eyelid(s) that received tranexamic acid in the local anesthetic
62443574|NCT04951128|ACTIVE_COMPARATOR|Control|Eyelid(s) that receive local anesthetic without tranexamic acid
62443575|NCT00734864|OTHER|1|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs).
62443576|NCT00734864|OTHER|2|Subjects NOT taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs).
62443577|NCT01965561|EXPERIMENTAL|CRoC|Use of Combat Ready Clamp (CRoC)
62054121|NCT06200337|OTHER|Group A|In the first session, acupuncture was applied at BL65, the second at TB3, and the third at SP3. Each session was seperated 24 hours interval.
62255561|NCT01797497|NO_INTERVENTION|Preintervention group|In the preintervention group, no care plan is used and no coaching takes place. Outcome data are collected from parents before and after the specialist visit.
62255562|NCT01465100|EXPERIMENTAL|Hepatocyte Transplantation|See Below.
62255563|NCT04858763||2020 Cohort|This is the 2020 MS cohort who experienced a clinician confirmed relapse during April - June 2020, during the first wave of the COVID-19 pandemic.
62255564|NCT04858763||2019 Cohort|2019 MS cohort who experienced a clinician confirmed relapse during April - June 2019.
62255565|NCT03440099|OTHER|Training|All participants will participate in the 16-week resistance exercise training program.
62255566|NCT01534247|EXPERIMENTAL|CAZAVI|CAZ-AVI (2000 mg ceftazidime/500 mg avibactam)
62255567|NCT01534247|ACTIVE_COMPARATOR|Metronidazole|Metronidazole (500 mg)
62255568|NCT01534247|ACTIVE_COMPARATOR|CAZAVI+metronidazole|CAZ-AVI (2000mg ceftazidime/500 mg avibactam) + metronidazole (500 mg)
62255569|NCT00096785|ACTIVE_COMPARATOR|A1|
62255570|NCT00096785|ACTIVE_COMPARATOR|A2|
62255571|NCT01826799||adult ICU patients|All adult patients without hearing disabilities and admitted to the ICU more than 48 hours ago, with a Richmond Agitation-Sedation Scale (RASS) of -2 or higher and the capability to understand Dutch are eligible.
62255572|NCT01434589|NO_INTERVENTION|Wait list control|
62255573|NCT01434589|EXPERIMENTAL|STICA Intervention|
62255574|NCT00923403|PLACEBO_COMPARATOR|Placebo Comparator|control dairy milk
62255575|NCT00923403|EXPERIMENTAL|experimental|plant sterol enriched soymilk
62443578|NCT01965561|EXPERIMENTAL|AAJT|Use of Abdominal Aortic and Junctional Tourniquet
62054122|NCT06200337|OTHER|Group B|In the first session, acupuncture will be applied at SP3, the second at BL65, and the third at TB3. Each session was seperated 24 hours interval.
62255576|NCT05837156|ACTIVE_COMPARATOR|group cyclophenol|Calculated by body weight (kg), the initial dose of continuous infusion of cyclopophenol is 0.8 mg/kg/h. During the infusion, the researchers adjusted the rate according to the reaction of the subjects, and the adjustment range was 0.4 mg/kg/h-2.4 mg/kg/h.
62255577|NCT05837156|ACTIVE_COMPARATOR|group heptaflurane|The anesthetic sevoflurane is inhaled for anesthesia maintenance. The initial concentration of sevoflurane is 1.5-2.0%, which can be adjusted to the expected effect according to the subject's reaction.
62255578|NCT05837156|EXPERIMENTAL|group heptaflurane combined cyclophenol|Inhaled anesthetic sevoflurane combined with a small dose of cyclopophenol for anesthesia maintenance. The initial concentration of sevoflurane is 0.5%, and the initial dose of cyclopophenol is 0.4 mg/kg/h.After that, sevoflurane or cyclopophenol (with an adjustment range of 0.2 mg/kg/h-1.2 mg/kg/h) can be adjusted to the expected effect according to the subject's reaction.
62255579|NCT05242055||Integrated group|Patients in the integrated group should be the patients getting integrated diagnosis and treatment during following up period. Integrated diagnosis and treatment includes control of hypertension, hyperglycemia, hyperlipidemia, anemia, CKD-MBD, and malnutrition by regular follow-up according to the guidelines of Kidney Disease- Improving Global Outcomes and of Chinese Medical Association in 2021.
62255580|NCT05242055||Unintegrated group|Patients in the unintegrated group are those who do not follow the contents of guidelines in some items of the integrated diagnosis and treatment during follow-up.
62255581|NCT03417908|ACTIVE_COMPARATOR|COPD - PNF|COPD - PNF
62255582|NCT03417908|SHAM_COMPARATOR|COPD - sham|COPD - sham
62255583|NCT03417908|ACTIVE_COMPARATOR|Individuals Without COPD - PNF|Individuals Without COPD - PNF
62255584|NCT03417908|SHAM_COMPARATOR|Individuals Without COPD - sham|Individuals Without COPD - sham
62255585|NCT04881825|EXPERIMENTAL|once-weekly glepaglutide|All participants will receive 10 mg of glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.)
62443579|NCT01965561|EXPERIMENTAL|JETT|Junctional Emergency Treatment Tool
62443580|NCT01965561|EXPERIMENTAL|SJT|SAM Junctional Tourniquet
62443581|NCT05503849|EXPERIMENTAL|Proactive management during pregnancy|A combination of dietary, physical activity and lifestyle modification.
62443582|NCT05503849|NO_INTERVENTION|Standard Care|No additional intervention beyond standard care procedure.
62443583|NCT05635045|EXPERIMENTAL|Cohort 1|"Subjects with grade 1 Tc99-PYP scans who have clinical features suggestive of ATTR-CM or have grade 1 Tc99-PYP scans but endomyocardial biopsy evidence of TTR cardiac amyloidosis will be administered single dose evuzamitide \<1mCi.~1. Heart failure with a preserved ejection fraction (EF\>40%)~2. Grade 1 Tc99-PYP scan performed for clinical suspicion of ATTR-CM~3. No evidence of monoclonal proteins by assessment of serum kappa and lambda free light chain ratio and immunofixation of serum and urine.~4. Left ventricular septal OR inferolateral wall thickness ≥12 mm"
62613237|NCT03580499|EXPERIMENTAL|Supportive Care (vitamin B6)|Participants receive vitamin B6 PO daily for 12 weeks.
62613238|NCT02801526|EXPERIMENTAL|Candesartan and Amlodipine|Candesartan 16mg and Amlodipine 5mg, PO, 1days or 22days
62054123|NCT06200337|OTHER|Group C|In the first session, acupuncture will be applied at TB3, the second at SP3, and the third at BL65. Each session was seperated 24 hours interval.
62443584|NCT05635045|EXPERIMENTAL|Cohort 2|"Subjects with TTR variant such as Phe64Leu, late onset Val30Met, etc.) that are associated with cardiac amyloidosis but have PYP scans not diagnostic of ATTR-CM will be administered single dose evuzamitide \<1mCi.~1. Tc99-PYP scan performed for clinical suspicion of ATTR-CM that is not diagnostic of ATTR-CM~2. No evidence of monoclonal proteins by assessment of serum kappa and lambda free light chain ratio and immunofixation of serum and urine.~3. Left ventricular septal OR inferolateral wall thickness ≥12 mm with echocardiographic features of ATTR-CM (low tissue doppler velocities, preserved apical strain, elevated E/E') or CMR features of an infiltrative cardiomyopathy (increased wall thickness with delayed enhancement or difficulty nulling of the myocardium)"
62613239|NCT02801526|EXPERIMENTAL|CKD-330|CKD-330 16/5mg - A, PO, 1days or 22days
62613240|NCT05099172|EXPERIMENTAL|Dose escalation|Doses of BAY2927088 will be increased in a stepwise fashion up to the MTD or MAD.
62613241|NCT05099172|EXPERIMENTAL|Backfill|Dose Escalation and Backfill run concurrently
62613242|NCT05099172|EXPERIMENTAL|Dose expansion|Eight independent groups (group A, B1, B2, C, D, E, F, G) are planned. Dose Expansion may start at a dose level that has been evaluated in Escalation/Backfill in at least 9 participants and considered safe or at any other dose levels that are below the highest dose level that is considered safe.
62613243|NCT05099172|EXPERIMENTAL|Extension part|Initiation of the Extension part will depend on the benefit-risk profile observed during Dose Expansion. Additionally, enrollment may be prematurely terminated based on emerging data at the discretion of the Sponsor.
62255586|NCT04090710|ACTIVE_COMPARATOR|Standard of Care I/N alone|induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
62255587|NCT04090710|EXPERIMENTAL|Standard of Care I/N plus primary disease SBRT|induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for one cycle, followed by SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks. Approximately one week following completion of SBRT, patients will start cycle 2 of immunotherapy as per standard of care. The total time elapsed between the start of cycle 1 and 2 of I/N should be no more than 6 weeks. After completion of up to four cycles of I/N, patients will proceed to standard of care maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
62255588|NCT03533647||entire cohort (observational)|none (observational study)
62255589|NCT03081442|ACTIVE_COMPARATOR|Misoprostol group|Sixty women received 600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion.
62255590|NCT03081442|PLACEBO_COMPARATOR|placebo group|Sixty women received the placebo vaginally six hours before IUD insertion. Placebo is the same in size, color and shape to misoprostol.
62255591|NCT03105167|EXPERIMENTAL|CBT-TLIF group|Patients who are randomised to the CBT-TLIF group will have cortical bone trajectory screws instead of pedicle screws During the opreation. After preventive use of antibliotics,A small skin incision was made at the fused segment, an entry point for insertion of the CBT screws was drilled in the junction of the center of the superior articular process and 1 mm inferior to the inferior border of the transverse process according to Matsukawa et al.A straight probe was used to create a trajectory for the CBT screws from the entry point to the opposite corner of the pedicle and vertebral body under anteroposterior fluoroscopic guidance.nilateral facetectomy is performed to gain access to the intervertebral disc.Afterwards, interbody fusion was performed.Device: CBT screws.
62613244|NCT03339336|EXPERIMENTAL|BIIB074 350 mg|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 350 mg tablets orally BID Double-Blind Treatment Period.
62613245|NCT03339336|EXPERIMENTAL|BIIB074 200 mg|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 200 mg tablets orally BID Double-Blind Treatment Period.
62613246|NCT03339336|PLACEBO_COMPARATOR|Placebo|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 placebo-matching tablets orally BID Double-Blind Treatment Period.
62838039|NCT03419559|EXPERIMENTAL|LN-145 in combination with durvalumab|After nonmyeloablative (NMA) lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
62613247|NCT02398513|EXPERIMENTAL|Regorafenib (Stivarga, BAY73-4506)|Patients enrolled in the study will start treatment with Regorafenib160 mg (given by four 40 mg tablets of Regorafenib) on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, Regorafenib 160 mg QD will be administered for 21 days, followed by 7 days off treatment. Treatment with Regorafenib will continue until the patient either progresses or meets one of the criteria for withdrawal prespecified in the study protocol.
62613248|NCT05571423|ACTIVE_COMPARATOR|Medical Play Intervention|This group of participants will be engaged in medical play before the dental exam visit.
62613249|NCT05571423|PLACEBO_COMPARATOR|Routine Play Intervention|This group of participants be engaged in routine play (coloring exercise) before the dental exam visit.
62613250|NCT02890849|EXPERIMENTAL|a prospective, open, self-controlled phase I clinical study|The project is planned to explore the consistency analysis of PD-L1 expression level detected in cancer tissues and pExo.We have designed to detected the expression levels of PD-L1 mRNA and protein in cancer tissue and detected the expression levels of PD-L1 mRNA in pExo.by using variance analysis of repeated measures design information.
62443585|NCT05635045|EXPERIMENTAL|Cohort 3|"Subjects with ATTR-CM from either ATTRwt or Val122Ile variant who have biopsy proven evidence of extra-cardiac TTR amyloidosis or clinical suspicion of extracardiac disease, including but not limited to peripheral neuropathy, carpal tunnel syndrome, spinal stenosis will be administered single dose evuzamitide \<1mCi..~1. ATTR-CM defined by the following~   1. Amyloid deposits in cardiac or non-cardiac tissue confirmed by Congo Red (or equivalent) staining OR technetium scintigraphy with 99m Tc-pyrophosphate with Grade 2 or 3 cardiac uptake in the absence of abnormal light chains ratio,~  2. End-diastolic interventricular septum thickness of \> 12 mm on previous echocardiogram~2. TTR genotype shown to be either Val122Ile or wild type."
62613251|NCT01053338|EXPERIMENTAL|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets of Dr. Reddy's
62613252|NCT01053338|ACTIVE_COMPARATOR|Advil|Advil PM 200 mg/38 mg Tablets of Wyeth
62613253|NCT04739332|EXPERIMENTAL|NBO intervention for at-risk mothers|NBO intervention for at- risk mothers. 3 NBO sessions added to the routine follow-up delivered once per week during the first month postpartum. The intervention is delivered by a nurse certified in the NBO system.
62613254|NCT04739332|NO_INTERVENTION|Treatment as usual|Participants receive 3 routine follow-up by the local health visitor/midwife during the first month
62613255|NCT04647994||Covid-19 HC patients|Pregnant women hospitalized with symptoms and diagnosis of SARS-CoV-2 at HC-FMUSP.
62613256|NCT04647994||Delivery patients|Asymptomatic pregnant women that tested SARS-CoV-2 serology (positive or negative serology) at the delivery time at Universitarian Hospital HU-USP and HC-FMUSP.
62838040|NCT02591966||Biomarker group|"1. The patients who receive neoadjuvant systemic treatments:~2. The patients who have distant metastatic sites at first and recur from surgery:~3. The patients who are going to receive first-line chemotherapy:"
62838041|NCT04558294|EXPERIMENTAL|100 μg LSD + Ketanserin placebo|
62838042|NCT04558294|EXPERIMENTAL|100 μg LSD + Ketanserin (40mg)|
62613257|NCT04647994||Prenatal patients|Pregnant women that performs prenatal care in Universitarian Hospital HU-USP or HC-FMUSP with diagnosis of SARS-CoV-2.
62613258|NCT04647994||Negative serology patients|Pregnant women that performs prenatal care with symptoms and tested serology/swab negative for SARS-CoV-2.
62255592|NCT03105167|EXPERIMENTAL|PS-TLIF group|Patients who are randomised to the PS-TLIF group will have pedicle screws During the opreation. A posterior midline incision, about 6 cm, was performed at the level of interest level under fluoroscopic guidance. Pedicle screws were inserted into the vertebral body by using freehand, and the inferior and superior articular processes and part pf the lamina were removed by using an osteotome. To expose the lateral border of the ipsilateral nerve root, the ligamentum flavum was removed. Afterwards, interbody fusion was performed.Device:traditional pedicle screws.
62613259|NCT00935064|ACTIVE_COMPARATOR|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
62613260|NCT00935064|PLACEBO_COMPARATOR|Placebo|
62613261|NCT01725360|EXPERIMENTAL|montelukast|A leukotriene receptor antagonist (LTRA, montelukast) is added to a basic treatment of inhaled corticosteroids (ICS) + long-acting betamimetics (LABA) in well-controlled patients with asthma.
62613262|NCT00089635|EXPERIMENTAL|Panitumumab|Panitumumab was administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks until participants developed progressive disease, were unable to tolerate investigational product, or discontinued for other reasons.
62838043|NCT04539132|EXPERIMENTAL|Intervention Group|"The intervention group will participate in the 6-month interdisciplinary comprehensive rehabilitation program. The ABI Wellness (ABIW) program aimed at this population would be 7 hours a week (2 days per week will be scheduled for the intervention group), consisting of around 4 hours of cognitive training (through specified drills, cognitive exercises focused on executive functioning), 1 hour of physical exercise, 1 hour of mindfulness sessions (meditation) and scheduled break times."
62838044|NCT04539132|NO_INTERVENTION|Control Group|"The non-intervention group or control group will have all the same pre-tests administered as the intervention group, however, will not participate in the cognitive program. The control group will be required to complete the assessment periods only, however, keep a record of their daily activities in a log format which is presented in the materials included herein. No other intervention or programming will be provided."
62838045|NCT04235621||FSGS/TR-MCD|Patients with FSGS/TR-MCD
62838046|NCT04235621||Diabetic Nephropathy (DN)|Patients with DN
62838047|NCT03032978|EXPERIMENTAL|Calcium silicate|intervention
62613263|NCT03139864|EXPERIMENTAL|type 1 diabetes|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
62838048|NCT03032978|ACTIVE_COMPARATOR|Calcium Hydroxide|Comparator
62613264|NCT03139864|ACTIVE_COMPARATOR|without type 1 diabetes|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
62613265|NCT05888181|EXPERIMENTAL|Intervention group A (weekly RAID)|Access to the study app with weekly prompts to complete the patient-reported questionnaire Rheumatoid Arthritis Impact of Disease (RAID)
62613266|NCT05888181|EXPERIMENTAL|Intervention group B (monthly RAID)|Access to the study app with monthly prompts to complete the patient-reported questionnaire Rheumatoid Arthritis Impact of Disease (RAID)
62255593|NCT02265770|EXPERIMENTAL|Stratum 1 arm A|Conformal radiotherapy followed by 16 weeks of VEC + CDDP.
62613267|NCT05888181|NO_INTERVENTION|Control group (usual care)|No access to the study app, follow-up according to usual care standards. This includes informal screening for general wellbeing during outpatient clinic visits, with referral to specific allied health professionals for additional education or non-pharmacological support if needed. The scores derived from study-related questionnaires can be used as a guide for these discussions. As part of standard care, participants in both the control group and the intervention groups will also receive a standardised educational leaflet about RA.
62838049|NCT04766840|EXPERIMENTAL|IM73 CAR-T|"Drug: IM73 CAR-T Cells~* Fludarabine~* Cyclophosphamide"
62443586|NCT05436821|EXPERIMENTAL|Vagus nerve stimulation|"Auricular Vagus Nerve Stimulation (AVNS) was applied to the experimental group. AVNS application was applied to both ears simultaneously for 20 minutes, with waveform biphasic asymmetric, pulse duration 300 microseconds and frequency 25 hertz. AVNS application was made with Vagustim brand device.~The acute effect of the application was evaluated in both groups by isometric quadriceps strength measurement, heart rate variability measurement, grip strength measurement and modified star balance test measurement performed before and after the single session AVNS."
62838050|NCT06001073||Coronary artery disease group|Diagnosis of coronary artery disease by clinical guidelines.
62838051|NCT06001073||Arrhythmia group|Diagnosis of arrhythmia by clinical guidelines. by clinical guidelines.
62443587|NCT05436821|SHAM_COMPARATOR|Control group|"Sham Auricular Vagus Nerve Stimulation (AVNS) was applied to the experimental group. AVNS application was applied to both ears simultaneously for 20 minutes, with no pulse. AVNS application was made with Vagustim brand device.~Before and after sham AVNS isometric quadriceps strength measurement, heart rate variability measurement, grip strength measurement and modified star balance test measurement performed."
62255594|NCT02265770|ACTIVE_COMPARATOR|Stratum 1 arm B|Conformal radiotherapy.
62443588|NCT01748890|EXPERIMENTAL|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
62838052|NCT06001073||Heart valve disease group|Diagnosis of heart valve disease by clinical guidelines.
62838053|NCT06001073||aortic dissection group|Diagnosis of aortic dissection by clinical guidelines.
62838054|NCT06001073||Cardiac masses group|Diagnosis of cardiac messes by clinical guidelines.
62613268|NCT01699308|EXPERIMENTAL|Genotropin|10 persons with TBI and GHD will receive daily rhGH injections titrated to bring their GH levels into the normal range for one year. Treatment is initiated using Genotropin (rhGH) at an initial daily dose of 200mcg/day subcutaneously with a titration schedule calling for an increase in daily dosage by 200 mcg every two months until the target daily dose, 600 mcg/day, is achieved. The 10 GHD subjects will be assessed at baseline with EEG, fMRI and DTI and neuropsychological measures, again at 6 months, and a third time at 12 months.
62443589|NCT03887689|EXPERIMENTAL|Modified prolonged exposure|Participants will receive three sessions of modified prolonged exposure therapy.
62443590|NCT02729155|EXPERIMENTAL|RIPre + RIPost|Intervention: RIPre 200 mmHg + RIPost 200 mmHg
62443591|NCT02729155|EXPERIMENTAL|RIPre + Sham|Intervention: RIPre 200 mmHg + Sham 10 mmHg
62613269|NCT01699308|NO_INTERVENTION|Control|5 demographically-matched TBI with normal GH subjects will be assessed at baseline (with EEG, fMRI and DTI, and neuropsychological measures) and at 12 months.
62838055|NCT06001073||Myocarditis group|Diagnosis of myocarditis by clinical guidelines.
62838056|NCT06001073||Hypertension group|Diagnosis of hypertension by clinical guidelines.
62838057|NCT06001073||Cardiomyopathy group|Diagnosis of cardiomyopathy by clinical guidelines.
62838058|NCT06001073||Structural heart disease group|Diagnosis of structural heart disease by clinical guidelines.
62838059|NCT06001073||Ischemic cerebrovascular disease group|Diagnosis of ischemic cerebrovascular disease by clinical guidelines.
62838060|NCT06001073||Hemorrhagic cerebrovascular disease group|Diagnosis of hemorrhagic cerebrovascular disease by clinical guidelines.
62838061|NCT06001073||Intracranial space occupying lesion group|Diagnosis of intracranial space occupying by clinical guidelines.
62838062|NCT00569959|OTHER|Fasting|
62838063|NCT00569959|OTHER|Non-fasting|
62838064|NCT06282978|EXPERIMENTAL|Elranatamab|Elranatamab will be administered by subcutaneous (SC) injection
62838065|NCT02350296|EXPERIMENTAL|Test - Reference (KSL 40 mg - OKi® 80 mg)|In this arm, a single dose of the test product (1 tablet; 40 mg KLS) was orally administered, under fasting conditions, in the first study period (day 1, 08:00±1h), and, after a wash-out period of at least 4 days, a single dose of the reference product OKi® 80 mg (half a sachet, 40 mg KLS) was orally administered, under fasting conditions, in the second study period (day 1, Visit 5, 08:00 ±1h).
62255595|NCT02265770|EXPERIMENTAL|Stratum 2 arm A|VEC + HD-MTX followed by conformal radiotherapy +/- boost
62255596|NCT02265770|ACTIVE_COMPARATOR|Stratum 2 arm B|VEC followed by conformal radiotherapy +/- boost
62255597|NCT02265770|EXPERIMENTAL|Stratum 3 arm A|Chemotherapy + Valproate.
62255598|NCT02265770|ACTIVE_COMPARATOR|Stratum 3 arm B|Chemotherapy
62255599|NCT05888727|EXPERIMENTAL|Exercise Training Intervention|
62255600|NCT05888727|ACTIVE_COMPARATOR|Wellness Control|
62255601|NCT01541189|EXPERIMENTAL|valsartan|After 1-week screening period, all of the eligible patients receive valsartan 80mg/day for 2 weeks, then the dosage will be titrated to 160mg/day for further 8 weeks therapy for all of the subjects.
62443592|NCT02729155|EXPERIMENTAL|Sham + RIPost|Intervention: Sham 10 mmHg + RIPost 200 mmHg
62443593|NCT02729155|SHAM_COMPARATOR|Sham + Sham|Intervention: Sham 10 mmHg + Sham 10 mmHg
62613270|NCT06295497|OTHER|Artificial intelligence-based programme (Lung-SIGHT)|Artificial intelligence (AI) algorithms have been demonstrated to function well and complement radiologists as second or concurrent readers in pulmonary nodule detection. AI Lung nodule detection and quantification solution are now widely used in the hospitals in the United Kingdom and at least eight other European countries. The sensitivity of nodule detection by radiologists increased from 72% to 80% with the aid of the AI programme. A clinical trial in Taiwan showed that using AI programme alone achieved an overall sensitivity of 95.6% in nodule detection, and superior performance in detecting nodule sized 4-5 mm comparing to radiologists. Overall, application of AI in CT analysis and lung nodule detection may significantly reduce the cost and workload of radiologist.
62613271|NCT06239571|EXPERIMENTAL|Dyadic Resiliency Intervention|All participants will receive the intervention, a brief dyadic resiliency intervention
62613272|NCT01669200|PLACEBO_COMPARATOR|Placebo Oil|Differential changes will be compared in the test group versus the control group at one month and six months with respect to BHB and insulin levels, and at six months with respect to cognitive scores.
62613273|NCT01669200|EXPERIMENTAL|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group versus the control group at one month and six months with respect to BHB and insulin levels, and at six months with respect to cognitive scores.
62054124|NCT05332457|ACTIVE_COMPARATOR|Arm A|"Phase I : Participants will undergo first CPET (Day 0) at trough concentration of BB. After 7-day regular usage of BB, the second CPET(Day 7) will be performed at peak concentration of BB. Participants will enter the second phase if the results of CPET fulfill the pre-determined conditions as follows: (1) Chronotropic index \< 0.8 at peak level of BB, (2) Resting HR \< 110 bpm at trough level of BB, (3) Absent of unstable arrhythmia or unstable hemodynamics during CPET at trough level.~Phase II: BB dosage will be reduced. Daily blood pressure, heart rate and adverse event will be recorded. If participants remained clinically stable, the third CPET(Day 21) will be performed 14 days after the reduction of dosage. If participants' resting heart rate exceed 110 bpm, the dosage will be adjusted to the original level."
62054125|NCT05332457|ACTIVE_COMPARATOR|Arm B|"Phase I : Participants will undergo first CPET(Day 0) at peak concentration of BB. After 7-day regular usage of BB, the second CPET(Day 7) will be performed at trough concentration of BB. Participants will enter the second phase if the results of CPET fulfill the pre-determined conditions as follows: (1) Chronotropic index \< 0.8 at peak level of BB, (2) Resting HR \< 110 bpm at trough level of BB, (3) Absent of unstable arrhythmia or unstable hemodynamics during CPET at trough level.~Phase II: BB dosage will be reduced. Daily blood pressure, heart rate and adverse event will be recorded. If participants remained clinically stable, the third CPET(Day 21) will be performed 14 days after the reduction of dosage. If participants' resting heart rate exceed 110 bpm, the dosage will be adjusted to the original level."
62613274|NCT04424771||Health workers|They include doctors, nurses, techinicians, biologists and other non technical inhospital workers
62613275|NCT02254122|EXPERIMENTAL|BEA 2180 BR|
62613276|NCT02254122|PLACEBO_COMPARATOR|Placebo|
62613277|NCT04257253|EXPERIMENTAL|Targeted exercise program|Targeted motor control and isolated lumbar extensor strengthening exercises. Supervised 12-week program, 2 times a week.
62613278|NCT04257253|ACTIVE_COMPARATOR|General exercise program|General exercise program including upper body and lower body strengthening and flexibility exercises. Supervised 12-week program, 2 times a week.
62613279|NCT00969514||Robotic cystectomy|Patients undergoing robotic laparoscopic cystectomy at Beaumont Hospital-RO
62613280|NCT04108663|SHAM_COMPARATOR|Sham|Sham tDCS (ramp up and ramp down of electrical current before as well as after task performance to elicit physical sensations similar to verum tDCS)
62613281|NCT04108663|ACTIVE_COMPARATOR|L1A|"Active tDCS~* laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)~* intensity: of 1 mA~* polarity: anodal"
62613282|NCT04108663|ACTIVE_COMPARATOR|R1A|"Active tDCS~* laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)~* intensity: of 1 mA~* polarity: anodal"
62613283|NCT04108663|ACTIVE_COMPARATOR|L2A|"Active tDCS~* laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)~* intensity: of 2 mA~* polarity: anodal"
62613284|NCT04108663|ACTIVE_COMPARATOR|R2A|"Active tDCS~* laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)~* intensity: of 2 mA~* polarity: anodal"
62613285|NCT04108663|ACTIVE_COMPARATOR|L1C|"Active tDCS~* laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)~* intensity: of 1 mA~* polarity: cathodal"
62054126|NCT01016301|ACTIVE_COMPARATOR|Pharmacist service,|The pharmacist service consists of medication review, drug treatment discussion with the patient, and a medication report.
62613286|NCT04108663|ACTIVE_COMPARATOR|R1C|"Active tDCS~* laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)~* intensity: of 1 mA~* polarity: cathodal"
62613287|NCT04108663|ACTIVE_COMPARATOR|L2C|"Active tDCS~* laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)~* intensity: of 2 mA~* polarity: cathodal"
62613288|NCT04108663|ACTIVE_COMPARATOR|R2C|"Active tDCS~* laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)~* intensity: of 2 mA~* polarity: cathodal"
62613289|NCT03438188|EXPERIMENTAL|Smoker Group|The smokers group will be scanned on 2 occasions: (1) after a 4 day monitored practice quit attempt (biochemically verified), and (2) after 4 days of smoking as usual (order counterbalanced).
62613290|NCT03438188|NO_INTERVENTION|Non-Smoking Comparison Group|Healthy non-smokers will complete one period (comparable to abstinence arm) of the study to serve as a baseline comparison group.
62613291|NCT01790516|EXPERIMENTAL|Cisplatin|Cisplatin
62613292|NCT01790516|EXPERIMENTAL|Cetuximab|cetuximab
62613293|NCT00495859|ACTIVE_COMPARATOR|1|Study group will receive formula enriched with arginine, ω-3 fatty acids, and nucleotides once daily
62613294|NCT00495859|ACTIVE_COMPARATOR|2|controls receive an isocaloric isonitrogenous non-specific nutritional support
62613295|NCT01065363|EXPERIMENTAL|Lifestyle conseling|
62613296|NCT03807401|ACTIVE_COMPARATOR|Classical prismatic adaptation|Classical prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
62054127|NCT01016301|NO_INTERVENTION|Control|Usual care
62613297|NCT03807401|EXPERIMENTAL|Virtual prismatic adaptation|virtual prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
62255602|NCT05427409|ACTIVE_COMPARATOR|Beta-alanine supplementation|Beta-alanine (4.8 grams) pills (Crown Nutrition, Haro, Spain) in four doses each day during a 4-week supplementation period.
62255603|NCT05427409|PLACEBO_COMPARATOR|Placebo supplementation|Placebo (4.8 grams) pills (Crown Nutrition, Haro, Spain) contain fructose (300mg) and excipients (1200 mg) such as cellulose, calcium phosphate, silicon dioxide and magnesium stearate in four doses each day during a 4-week supplementation period.
62613298|NCT03807401|EXPERIMENTAL|Imaged prismatic adaptation|Imaged prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
62255604|NCT03789461|EXPERIMENTAL|Fecal Microbiota Transplantation|FMT infusion
62255605|NCT01656148|EXPERIMENTAL|Fampridine-SR|Initially all participants receive Fampridine-SR 10 mg BID in an open label enrichment phase lasting four weeks. Those 40% responding the most by SSST will go onto phase two. 50% of these will receive 10 mg Fampridine-SR BID for four weeks.
62613299|NCT05731336||NR group (Non-retreatment/rechallenge group)|participants who receive immunotherapy or targeted drugs or other chemotherapy beyond treated with oxaliplatin and irinotecan
62255606|NCT01656148|PLACEBO_COMPARATOR|Placebo|In the intervention phase 50% will receive placebo BID
62613300|NCT05731336||RT group (Retreatment group)|participants retreated oxaliplatin or irinotecan who were treated with oxaliplatin and irinotecan and progressed after 3 months of oxaliplatin or irinotecan discontinuation.
62613301|NCT05731336||RC group (Rechallenge group)|participants rechallenging oxaliplatin or irinotecan who were treated with oxaliplatin and irinotecan and progressed within 3 months of oxaliplatin or irinotecan discontinuation.
62838066|NCT02350296|EXPERIMENTAL|Reference - Test (OKi® 80 mg - KSL 40 mg)|In this arm, a single dose of the reference product OKi® 80 mg (half a sachet, 40 mg KLS) was orally administered, under fasting conditions, in the first study period (day 1, Visit 3, 08:00 ±1h) and, after a wash-out period of at least 4 days, a single dose of the test product (1 tablet; 40 mg KLS) was orally administered, under fasting conditions, in the second study period (day 1, Visit 5, 08:00±1h).
62838067|NCT01470326||Bazedoxifene Tablets|Subjects taking Bazedoxifene Tablets
62838068|NCT04782583||CAS|
62838069|NCT04782583||TEMOIN|
62838070|NCT04258800|EXPERIMENTAL|With music|Colonoscopy performed with music
62838071|NCT04258800|NO_INTERVENTION|Without music|Colonoscopy performed without music
62838072|NCT04563949||PLA-|PLA- initially and repeat testing 1-2 years later
62255607|NCT06462300|EXPERIMENTAL|Meaning-centered intervention condition|The group of participants receiving the meaning-centered intervention
62255608|NCT06462300|NO_INTERVENTION|Waitlist control condition|The group of participants not receiving an intervention
62255609|NCT05182463|EXPERIMENTAL|Sequential Combination Group|Oral nucleos(t)ide analogues (NAs) (Entecavir(ETV), Tenofovir disoproxil fumarate tablets(TDF) or Tenofovir Alafenamide Fumarate(TAF)) is used for 12-24 weeks, followed by combination therapy with peginterferon α-2b. The Maximum course is 96 weeks. Follow-up period is 144 weeks.
62443594|NCT01743365|EXPERIMENTAL|Cisplatin-5FU-Afatinib|"Cisplatin 75mg/m2 iv administered on Day 1, 5FU 750mg/m2 at 24-hour iv infusion on Days 1-4, Afatinib (BIBW-2992) 40mg per os on Days 3-5, 8-12, 15-19 of each cycle. Administration of Afatinib will start on Day 3 of each cycle with an administration interval on each weekend (Weekday on, Weekend off) for 21 days. The administration of the combination Cisplatin-5FU-Afatinib will be continued until disease progression, appearance of significant toxicity, completion of 6 cycles, or withdrawal of consent. At completion of 6 cycles of the combination, in the absence of disease progression, the administration of Afatinib as maintenance monotherapy will be continued until disease progression, appearance of significant toxicity, or withdrawal of consent at the weekday on-weekend off schedule."
62443595|NCT03908255|PLACEBO_COMPARATOR|Control Group|The control group will receive current standard of care (locoregional therapy of the liver, serial bloodwork and imaging, serial assessments in clinic), consume a maltodextrin placebo supplement beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months.
62443596|NCT03908255|EXPERIMENTAL|Intervention Group|In the intervention group, patients will receive current standard of care (locoregional therapy of the liver, serial bloodwork and imaging, serial assessments in clinic) and consume BCAA supplements beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months.
62443597|NCT01566799|EXPERIMENTAL|Metformin|Patients will be receive 12 weeks of paclitaxel followed by 4 cycles of FAC combined with 500 mg/day of metformin p.o.
62443598|NCT03265899|EXPERIMENTAL|Oxytocin|40 IU Oxytocin, intranasal application 30 min prior to the experiment
62838073|NCT04563949||PLA+|Not eligible for the study
62838074|NCT03941470||unexplained recurrent pregnancy loss|peripheral blood sample examined by flowcytometry
62838075|NCT03941470||control fertile multipara|peripheral blood sample examined by flowcytometry
62255610|NCT05182463|EXPERIMENTAL|Initial Combination Group|NAs combined with peginterferon are used for 12-24 weeks, followed by peginterferon α-2b. The Maximum course is 96 weeks. Follow-up period is 144 weeks.
62613302|NCT01004718|EXPERIMENTAL|Fludeoxyglucose F18 (FDG) PET/CT scans|Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration.
62613303|NCT01593254|ACTIVE_COMPARATOR|Arm 1: Imatinib (≥400 mg)|Imatinib ≥400 mg tablets by mouth once daily (QD) or twice daily (BID) up to 60 months
62443599|NCT03265899|PLACEBO_COMPARATOR|Placebo|sodium chloride solution, intranasal application 30 min prior to the experiment
62613304|NCT01593254|ACTIVE_COMPARATOR|Arm 2: Dasatinib (100 mg)|Dasatinib 100 mg tablet by mouth QD up to 60 months
62613305|NCT05843240|ACTIVE_COMPARATOR|rTMS|Patients are treated with repetitive transcranial magnetic stimulation (rTMS).
62613306|NCT05843240|PLACEBO_COMPARATOR|sham-rTMS|Patients are treated with sham repetitive transcranial magnetic stimulation (sham-rTMS).
62838076|NCT04777175||KRAS mutation|patients carry with KRAS mutation
62838077|NCT04777175||ALK fusion|patients carry with ALK fusion
62838078|NCT04777175||ERBB2 mutation|patients carry with ERBB2 mutation
62838079|NCT04777175||MET skipping/amplication|patients carry with MET skipping/amplication
62054128|NCT01077830||Ezetimibe/Simvastatin 10/40 mg|Participants who received Ezetimibe/Simvastatin 10/40 mg in the base study
62255611|NCT05182463|EXPERIMENTAL|Whole-course Combination Group|NAs combined with peginterferon are used for a maximum course of 96 weeks. Follow-up period is 144 weeks.
62255612|NCT05182463|EXPERIMENTAL|Peginterferon Monotherapy Group|Peginterferon is used for a maximum course of 96 weeks. Follow-up period is 144 weeks.
62255613|NCT05182463|EXPERIMENTAL|NAs Monotherapy Group|NAs is used for a maximum course of 96 weeks. Follow-up period is 144 weeks.
62255614|NCT02013947|OTHER|Moderate altitude group|2 weeks of exercise at 1900 meters sea level
62255615|NCT02013947|OTHER|low altitude group|2 weeks of exercise at 400 meters sea level
62443600|NCT04658875|EXPERIMENTAL|Spirulina maxima supplementation and exercise group|Supplementation with Spirulina maxima (4.5 g/d) with a systematic physical exercise program during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
62838080|NCT04777175||RET fusion|patients carry with RET fusion
62838081|NCT04777175||BRAF mutation|patients carry with BRAF mutation
62838082|NCT03739125|EXPERIMENTAL|CKD-501 0.5mg|CKD-501 0.5mg
62838083|NCT03739125|PLACEBO_COMPARATOR|Placebo|Placebo
62838084|NCT03193502|EXPERIMENTAL|Portal Vein thrombosis|rivaroxaban
62838085|NCT06119139|ACTIVE_COMPARATOR|1.8 ml 4% articaine buccal infiltration.|
62838086|NCT06119139|EXPERIMENTAL|3.6 ml 4% articaine buccal infiltration|
62054129|NCT01077830||Placebo|Participants who received placebo in the base study
62054130|NCT04721379|EXPERIMENTAL|Heartfulness Meditation Group|Participants will be guided through relaxation and meditation session with a Heartfulness trainer with EEG and EKG recording. After finishing the session, they fill out meditation depth questionnaire.
62054131|NCT04721379|ACTIVE_COMPARATOR|Control Group with Self Meditation|Participants will be self-guided through relaxation and meditation session without a trainer with EEG and EKG recording. After finishing the session, they fill out meditation depth questionnaire.
62054132|NCT00929084|OTHER|Survivor Stories Arm|Women in the Survivor Stories intervention arm will be given the Survivor Stories Tablet to take home for two weeks at three different time points over a two year period.
62054133|NCT00929084|OTHER|Control Arm|Women in the Control Arm will receive standard care.
62255616|NCT06292091|ACTIVE_COMPARATOR|Captopril|Single dose of captopril 12.5 mg
62255617|NCT06292091|EXPERIMENTAL|Sodium bicarbonate+captopril|Single dose of captopril 12.5 mg during multiple doses of sodium bicarbonate 1 g every 4-6 hours
62255618|NCT06292091|EXPERIMENTAL|Torsemide+captopril|Single dose of captopril 12.5 mg during multiple doses of torsemide 20 mg every 6-12 hours
62255619|NCT04159142|EXPERIMENTAL|Nab-paclitaxel + Carboplatin|Nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles； Maintenance therapy: Capecitabine 1000 mg/m\^2 bid, d1-14; every 21 days, until disease progression or intolerable toxicity;
62255620|NCT04159142|EXPERIMENTAL|Nab-paclitaxel + Capecitabine|Nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and capecitabine given IV at 1000 mg/m\^2 bid, d1-14 every 21 days x 6 cycles； Maintenance therapy: Capecitabine 1000 mg/m\^2 bid, d1-14; every 21 days, until disease progression or intolerable toxicity;
62255621|NCT05784779|EXPERIMENTAL|GH509|
62255622|NCT05784779|PLACEBO_COMPARATOR|Placebo|
62255623|NCT03033173||CTS group|
62255624|NCT03033173||Healthy subjects|
62255625|NCT01379469|ACTIVE_COMPARATOR|Drug-Carbamazepine (Tegretol XR)|One arm receives Drug-Carbamazepine (Tegretol XR).All subjects have severe liver disease due to alpha-1-antitrypsin deficiency.
62255626|NCT01379469|PLACEBO_COMPARATOR|Drug-Carbamazepine (Tegretol XR) Placebo|One arm receives Carbamazepine (Tegretol-XR) placebo.All subjects have severe liver disease due to alpha-1-antitrypsin deficiency.
62255627|NCT05340894|ACTIVE_COMPARATOR|Mckenzie group|"* adolescents will receive 4 weeks Mckenzie exercise program~* Follow-up:pre-test (Baseline), 2 weeks post-test and 4 weeks post-test."
62255628|NCT05340894|ACTIVE_COMPARATOR|William's group|"* adolescents will receive 4 weeks William's exercise program~* Follow-up:pre-test (Baseline), 2 weeks post-test and 4 weeks post-test."
62255629|NCT04452474|EXPERIMENTAL|Olokizumab 64 mg|Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy
62255630|NCT04452474|PLACEBO_COMPARATOR|Placebo|Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Placebo on Day 1, in addition to standard therapy
62613307|NCT00221039|EXPERIMENTAL|DRUG+ECP|UVVADEX +ECP will be administered to patients with CTCL.Duration of Treatment: The study will consist of 2 treatment periods, a 6-month initial period and a 6-month follow-up period where photopheresis therapy may continue.
62613308|NCT03583905|EXPERIMENTAL|Experimental Group 1|Patients assigned to this group are treated with CKD-330, D086
62613309|NCT03583905|PLACEBO_COMPARATOR|Placebo Group 1|Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the D086)
62054134|NCT03445065|EXPERIMENTAL|Cohort 1, Enabled - Eversense XL CGM System|Cohort 1 included patients with clinically confirmed diagnosis of Type 1 or Type 2 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and had an HbA1c \>8%. All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Enabled group were trained and allowed to use the Eversense XL system for continuous glucose monitoring (CGM). They were not allowed to use another CGM or FGM system.
62255631|NCT02177396|EXPERIMENTAL|Telmisartan|
62255632|NCT02177396|ACTIVE_COMPARATOR|Valsartan|
62255633|NCT04667377|EXPERIMENTAL|0.6 mg BI 456906|
62255634|NCT04667377|PLACEBO_COMPARATOR|Placebo group|
62613310|NCT03583905|PLACEBO_COMPARATOR|Placebo Group 2|Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the CKD-330)
62613311|NCT06365450|EXPERIMENTAL|Educational Single-group|1 educational session on cervical cancer and one educational session on breast cancer
62613312|NCT06182618||low-carbohydrate diet|20-30% carbohydrates, 40-45%fat, and 30-40%protein
62613313|NCT06182618||balanced diet|50-65% carbohydrate, 20-30% fat and 10-20% protein
62613314|NCT06182618||pharmacotherapy|semaglutide (1mg per week) or/and metformin (o.5g three times a day)
62255635|NCT04667377|EXPERIMENTAL|2.4 mg BI456906|
62255636|NCT04667377|EXPERIMENTAL|3.6 mg BI 456906|
62255637|NCT04667377|EXPERIMENTAL|4.8 mg BI 456906|
62255638|NCT04305275|EXPERIMENTAL|SAGE-324 60 mg|Participants received SAGE-324, 60 milligrams (mg), oral tablets, once daily (QD), in the morning for 28 days.
62613315|NCT02769936|PLACEBO_COMPARATOR|Healthy Adult - Placebo|Single dose placebo pill in healthy adults
62613316|NCT02769936|EXPERIMENTAL|Healthy Adult - D-cycloserine|Single 100 mg dose D-cycloserine pill in healthy adults
62255639|NCT04305275|PLACEBO_COMPARATOR|SAGE-324 Matched Placebo|Participants received SAGE-324 matched placebo, oral tablets, QD, in the morning for 28 days.
62255640|NCT00699270||Biomet Humeral Stems|Biomet Humeral Stems: Comprehensive®, BioModular®, and Bi-Angular® Shoulder Systems
62255641|NCT06323564||Parkinson Disease (PD)|"The trial will be divided into two periods T0 (first evaluation at the time of admission to hospital) and T1 (15 days after T0, during rehabilitation period in hospital for patients with Parkinson's disease).~First, as soon as patients are admitted to acute care,neuropsychological tests and self-report questionnaires will be administered.~Subsequently, at both T0 and T1, standardized emotional images from the International Affective Picture System (IAPS) will be administered. For the entire duration of the test, peripheral physiological parameters such as ECG, BVP, GSR, EOG, RSP and facial EMG (corrugator and zygomaticus) will also be detected, as objective measures of emotional arousal (T0-T1)."
62613317|NCT02769936|PLACEBO_COMPARATOR|Schizophrenia - Placebo|Single dose placebo pill in schizophrenia patients
62613318|NCT02769936|EXPERIMENTAL|Schizophrenia - D-cycloserine|Single 100 mg dose D-cycloserine pill in schizophrenia patients
62613319|NCT01621971|EXPERIMENTAL|milrinone inhalation|inhaled milirinone and IV placebo (0.9% normal saline 0.05 ml/kg) are administered in Group IH.
62613320|NCT01621971|ACTIVE_COMPARATOR|intravenous milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an IV bolus of milrinone (50 μg/kg) are administered in Group IV
62613321|NCT04736641||Patients group|Individuals with hip disease and chronic pain on hip
62613322|NCT01912352|EXPERIMENTAL|Methylphenidate|Participants were treated with methylphenidate (ranging from to 63mg) for 8 weeks. Doses of methylphenidate were titrated depending on symptoms and adverse eff ects at the 2nd and 4th weeks of treatment.
62054135|NCT03445065|ACTIVE_COMPARATOR|Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)|Cohort 1 included patients with clinically confirmed diagnosis of Type 1 or Type 2 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and had an HbA1c \>8%. All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Control group were to continue using their usual glucose monitoring system (self-monitoring of blood glucose \[SMBG\] or flash glucose monitoring \[FGM\]), and the implanted Eversense XL CGM System remained in blinded mode.
62054136|NCT03445065|EXPERIMENTAL|Cohort 2, Enabled - Eversense XL CGM System|Cohort 2 included patients with Type 1 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and spending \>1.5 hours per day with a sensor mean glucose of \<70 mg/dL for at least 28 days (time in hypoglycemia). All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Enabled group were trained and allowed to use the Eversense XL system for continuous glucose monitoring (CGM). They were not allowed to use another CGM or FGM system.
62255642|NCT06323564||Anorexia Nervosa (AN)|"The trial will be divided into two periods T0 (first evaluation at the time of admission to hospital) and T1 (4 weeks after T0, during rehabilitation period in hospital.~First, as soon as patients are admitted to acute care, neuropsychological tests and self-report questionnaires will be administered.~Subsequently, at both T0 and T1, standardized emotional images from the International Affective Picture System (IAPS) will be administered. For the entire duration of the test, peripheral physiological parameters such as ECG, BVP, GSR, EOG, RSP and facial EMG (corrugator and zygomaticus) will also be detected, as objective measures of emotional arousal (T0-T1). Furthermore, the analysis of bio-humoral parameters (interleukin 6, cortisol, serotonin, catecholamines and endorphins) will be also performed through morning venous blood sampling at T0, at half of the rehabilitation process and at T1."
62255643|NCT04452045|EXPERIMENTAL|SweetDreams|Access to a mobile and computer accessible adaptation of existing evidence based sleep interventions.
62443601|NCT04658875|EXPERIMENTAL|Spirulina maxima supplementation|Supplementation with Spirulina maxima (4.5 g/d) without exercise program during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
62443602|NCT04658875|EXPERIMENTAL|Exercise group|Systematic physical exercise program during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
62443603|NCT04658875|ACTIVE_COMPARATOR|Control group|No systematic physical exercise program and No supplementation during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
62613323|NCT05691959|PLACEBO_COMPARATOR|Normal Saline|Normal saline 50 ml intravenous piggyback once over 10 minutes
62613324|NCT05691959|EXPERIMENTAL|Calcium chloride|x grams in 50 ml ivpb once over 10 minutes
62613325|NCT03303391|NO_INTERVENTION|Standard Care|This arm of subjects will have all aspects of fluid management and dialysis management managed by the his/her individual nephrologist
62054137|NCT03445065|ACTIVE_COMPARATOR|Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)|Cohort 2 included patients with Type 1 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and spending \>1.5 hours per day with a sensor mean glucose of \<70 mg/dL for at least 28 days (time in hypoglycemia). All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Control group were to continue using their usual glucose monitoring system (self-monitoring of blood glucose \[SMBG\] or flash glucose monitoring \[FGM\]), and the implanted Eversense XL CGM System remained in blinded mode.
62054138|NCT01738750|EXPERIMENTAL|Cost Information Included|Group of patients that will receive cost information for both the laparoscopic and open surgical procedures prior to choice of procedure.
62054139|NCT01738750|NO_INTERVENTION|No Cost Information Included|Group of patients that will not receive cost information for the laparoscopic and open surgical procedures prior to choice of procedure.
62255644|NCT04452045|NO_INTERVENTION|Waitlist Control|Wait list condition with future access to a mobile and computer accessible adaptation of existing evidence based sleep interventions.
62255645|NCT04704830|EXPERIMENTAL|Standard Regime - Group 1-1|R21/Matrix-M at primary series and first booster, control vaccine at second and third booster, n = 400, 5-36 months olds
62255646|NCT04704830|EXPERIMENTAL|Standard Regime - Group 1-2|R21/Matrix-M at primary series, first booster and second booster, control vaccine at third booster, n = 400, 5-36 months olds
62255647|NCT04704830|EXPERIMENTAL|Standard Regime - Group 1-3|R21/Matrix-M at primary series and first booster, control vaccine at second booster and R21/Matrix-M at third booster, n = 400, 5-36 months olds
62838087|NCT03729700|EXPERIMENTAL|Almond supplementation|The almond dose will be provided as 20% of total energy (20% E) in the diet. This dose was selected based on a previous randomized trial examining lipid parameters in response to 0, 10%, and 20% E as dietary almonds and a recent meta-analysis of intervention trials.
62443604|NCT00279942|ACTIVE_COMPARATOR|Soy|A shake that contained 20 g of soy protein and 160 mg of soy isoflavone.
62838088|NCT03729700|NO_INTERVENTION|Control snack|The control snack will be a typical western diet snack. The calorie-matched control snack will be commercially available individually wrapped food products.
62838089|NCT04071288||laparoscopic burch colposuspension|who underwent total laparoscopic hysterectomy for benign causes and had simultaneous incontinence; patients undergoing laparoscopic burch colposuspension
62838090|NCT04071288||mid urethral sling operations|who underwent total laparoscopic hysterectomy for benign causes and had simultaneous incontinence; patients undergoing mid-urethral sling operations
62838091|NCT03644004||Women with medical history of gestational diabetes|Patients followed at the hospital of Vienne for gestational diabetes in 2016.
62054140|NCT03967769|NO_INTERVENTION|Standard Practice|Infants will have high Flow nasal cannulae placed into the nares before induction. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
62255648|NCT04704830|EXPERIMENTAL|Standard Regime - Group 1-4|R21/Matrix-M at primary series, first booster, second booster and third booster, n = 400, 5-36 months olds
62255649|NCT04704830|PLACEBO_COMPARATOR|Standard Regime - Group 2|Control vaccine at primary series, first booster, second booster and third booster, n=800, 5-36 month olds
62255650|NCT04704830|EXPERIMENTAL|Seasonal Regime - Group 3-1|R21/Matrix-M at primary series and first booster, control vaccine at second and third booster, n = 400, 5-36 months olds
62255651|NCT04704830|EXPERIMENTAL|Seasonal Regime - Group 3-2|R21/Matrix-M at primary series, first booster and second booster, control vaccine at third booster, n = 400, 5-36 months olds
62255652|NCT04704830|EXPERIMENTAL|Seasonal Regime - Group 3-3|R21/Matrix-M at primary series and first booster, control vaccine at second booster and R21/Matrix-M at third booster, n = 400, 5-36 months olds
62255653|NCT04704830|EXPERIMENTAL|Seasonal Regime - Group 3-4|R21/Matrix-M at primary series, first booster, second booster and third booster, n = 400, 5-36 months olds
62255654|NCT04704830|PLACEBO_COMPARATOR|Seasonal Regime - Group 4|Control vaccine at primary series, first booster, second booster and third booster, n=800, 5-36 month olds
62443605|NCT00279942|PLACEBO_COMPARATOR|Placebo|A shake that contained 20 g of milk-based protein (casein) and no isoflavone.
62443606|NCT06354985|ACTIVE_COMPARATOR|Group A: Placebo Drug + Exercise Program One|Group A: Placebo Drug + Exercise Program One for 8 weeks.
62443607|NCT06354985|PLACEBO_COMPARATOR|Group B: Placebo Drug + Exercise Program Two|Group B: Placebo Drug + Exercise Program Two for 8 weeks.
62443608|NCT06354985|ACTIVE_COMPARATOR|Group C: Modafinil 200 mg/day + Exercise Program One|Group C: Modafinil 200 mg/day + Exercise Program One for 8 weeks.
62443609|NCT06354985|ACTIVE_COMPARATOR|Group D: Modafinil 200 mg/day + Exercise Program Two|Group D: Modafinil 200 mg/day + Exercise Program Two for 8 weeks.
62255655|NCT03926975|EXPERIMENTAL|Experimental: Scleral Lens|One eye will be randomly selected to wear a scleral lens for a 6-hour testing period.
62255656|NCT03926975|ACTIVE_COMPARATOR|Control: no lens|The contralateral eye will not wear a lens.
62255657|NCT05442099|EXPERIMENTAL|Iso-principle music playlist|Participants listen to the iso-principle music playlist for 30 minutes.
62255658|NCT05442099|SHAM_COMPARATOR|Generic calm music playlist|Participants listen to the generic music playlist for 30 minutes.
62255659|NCT02330575|ACTIVE_COMPARATOR|Standard Care|Participants in this group will receive standard education on the importance of physical activity in the recovery from cancer and how to become more active. Participants assigned to this group will have the option to participate in the exercise program after the 16-week follow-up assessment.
62255660|NCT02330575|EXPERIMENTAL|Supervised Community-based Exercise|Participants in this group will take part in an 8-week supervised exercise program at the YMCA. Following the 8-week intervention, participants will have the option to continue for an additional 8-weeks at the YMCA (fee for service) or follow an 8-week self-directed program.
62255661|NCT00359021|EXPERIMENTAL|001|TMC125 200 mg twice daily until commercially available
62255662|NCT04327765|EXPERIMENTAL|Cohort 1|Single orally-inhaled dose
62255663|NCT04327765|EXPERIMENTAL|Cohort 2|Single orally-inhaled dose
62255664|NCT04327765|EXPERIMENTAL|Cohort 3|Single orally-inhaled dose
62255665|NCT02942914|EXPERIMENTAL|LY3209590|LY3209590 administered subcutaneously (SC).
62255666|NCT02942914|PLACEBO_COMPARATOR|Placebo|Placebo (sterile saline) administered SC.
62255667|NCT02942914|ACTIVE_COMPARATOR|Insulin Glargine (Lantus)|Insulin Glargine administered SC.
62255668|NCT03690076||Control|patients with normal weight (23 \< BMI \< 27) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis
62613326|NCT03303391|EXPERIMENTAL|IBPS Group|This group will have ultrafiltration prescriptions dictated by a pre-specified protocol that is based on monthly assessment of intradialytic blood pressure slopes obtained over a two week period.
62255669|NCT03690076||Endocarditis|patients with normal weight (23 \< BMI \< 27) carriers of endocarditis with surgery indication
62255670|NCT03690076||Obese|obese patients (BMI \> 30 with waist to hip ratio \> or = 1 in men and 0.85 in women) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis
62255671|NCT02398708||Chronic Graft-Versus-Host Disease|This group will have questionnaires, clinical data, a blood sample and a stool sample collected to be compared with the other group.
62255672|NCT02398708||No Chronic Graft-Versus-Host Disease|This group will have questionnaires, clinical data, a blood sample and a stool sample collected to be compared with the other group.
62255673|NCT03924752|EXPERIMENTAL|Healthy individuals using powered exoskeleton|This study will be conducted on a sample population of able-bodied subjects (single arm). Each subject will test with each condition of the exoskeleton (repeated measures).
62255674|NCT04699019||Active Runners|All participants will be required to run unshod for a combination of four prescribed speeds (walking and up to 9 mph) and three different foot strike patterns (rearfoot, midfoot, and forefoot) on level ground.
62255675|NCT04439604||patient undergoing surgery under general anaesthesia|
62613327|NCT01910220|PLACEBO_COMPARATOR|Group 1|placebo
62255676|NCT04579562||COVID-19 positive AKI|
62255677|NCT04579562||COVID-19 positive no AKI|
62255678|NCT04579562||COVID negative AKI|
62443610|NCT02010723|ACTIVE_COMPARATOR|surgery|crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia
62613328|NCT01910220|EXPERIMENTAL|Group 2|REGN1033 (SAR391786)
62255679|NCT03974087|ACTIVE_COMPARATOR|MCI patients with real transcranial direct current stimulation|Patients will receive 2mA stimulation in 10 consecutive sessions.
62255680|NCT03974087|SHAM_COMPARATOR|MCI patients with sham transcranial direct current stimulation|Patients will receive sham stimulation in 10 consecutive sessions.
62255681|NCT03310450||Group 140kms cycling|"Participants of Tour de Borobudur 2017 140 km cycling touring and willing to participate in the study.~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
62255682|NCT03310450||Group 100kms cycling|"Participants of Tour de Borobudur 2017 100 km cycling touring and willing to participate in the study.~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
62255683|NCT03310450||Group 240kms cycling|"Participants of North Coast 2017 240 km cycling touring and willing to participate in the study.~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
62255684|NCT02075242|ACTIVE_COMPARATOR|tacrolimus|Control group: Tacrolimus + Corticosteroid (dual oral therapy)
62255685|NCT02075242|EXPERIMENTAL|Mycophenolate Mofetil|Tacrolimus + Mycophenolate Mofetil+Corticosteroid (triple oral therapy)
62255686|NCT02015442|EXPERIMENTAL|High sucrose diet|High sucrose diet for 7 days
62255687|NCT02015442|EXPERIMENTAL|Low sucrose diet|Low sucrose diet for 7 days
62255688|NCT00820911|ACTIVE_COMPARATOR|cyclosporine (reduced exposure) / everolimus|
62255689|NCT00820911|EXPERIMENTAL|AEB071 300 mg b.i.d. / everolimus|
62255690|NCT00820911|EXPERIMENTAL|AEB071 200 mg b.i.d. / everolimus|
62613329|NCT01910220|PLACEBO_COMPARATOR|Group 3|placebo + exercise regimen
62054141|NCT03967769|EXPERIMENTAL|Low Flow oxygenation|Infants will have conventional nasal cannulae into the nares prior to induction of anesthesia. They will be removed from the nares at the end of the study when the airway has been secured. There will be 0,2L/kg/min of oxygen flowing through the cannulae in this group during the study.
62054142|NCT03967769|EXPERIMENTAL|High Flow Oxygenation|Infants will have conventional nasal cannulae into the nares prior to induction of anesthesia. They will be removed from the nares at the end of the study when the airway has been secured. There will be 1L/kg/min of oxygen flowing through the cannulae in this group during the study.
62255691|NCT01892163|ACTIVE_COMPARATOR|Ozurdex PRN dosing|Ozurdex PRN dosing versus Ozurdex fixed dosing
62255692|NCT01892163|EXPERIMENTAL|Ozurdex fixed dosing|
62255693|NCT04662658|OTHER|Visit 1 UVA|"Visit 1 will last approximately 4 hours, and will include consenting, collection of data, questionnaires, and procedures as follows:~1. Informed consent~2. Demographic data~3. Smoking history~4. Medical history review~5. Medication review~6. Limited physical exam~7. 6-minute walk test~8. St. George's Respiratory Questionnaire (SGRQ)~9. Baseline dyspnea index (BDI)~10. Chronic respiratory questionnaire (CRQ)~11. PFTs including:~    1. Pre-bronchodilator spirometry/ post bronchodilator spirometry.~   2. Body plethysmography (static lung volumes)~   3. Carbon monoxide diffusion capacity (DLCO)~12. Collection of peripheral blood (20mL), exhaled breath condensate (EBC), and urine~13. Hyperpolarized xenon-129 MRI (HXeMRI) if all eligibility criteria are met"
62255694|NCT04662658|OTHER|Visit 2 Duke University|"Visit 2 will last about 3 hours, and will occur within 2-12 weeks of Visit 1. The purpose of this study visit is to obtain a measure of basic test-retest variability on 6 e-cigarette users and 6 control subjects. Participants will be selected based on age and sex matching needs at the time of enrollment.~During Visit 2, changes in health since Visit 1 will be assessed. In addition, the following will be done in accordance with the parent protocol:~1. The standard MR compatibility screening form will be completed.~2. Spirometry will be performed before and after MR imaging.~3. A limited physical exam~4. Female subjects who could be pregnant will take a urine pregnancy test prior to imaging.~5. Xenon MRI will be performed~In addition to the above, the following will be completed:~* Carbon monoxide diffusion capacity (DLCO)~* Peripheral blood (20mL) and urine"
62613330|NCT01910220|EXPERIMENTAL|Group 4|REGN1033 (SAR391786) + exercise regimen
62613331|NCT04991038|EXPERIMENTAL|DAISe Thrombectomy Device|Mechanical Thrombectomy with DAISe
62613332|NCT04991038|ACTIVE_COMPARATOR|Stent Retriever|Mechanical Thrombectomy with TREVO or Solitaire Device
62613333|NCT03008772||PCI with Commercially available DES|Patients who have undergone PCI and received a commercially available drug eluting stent
62838092|NCT04249986|ACTIVE_COMPARATOR|The Borg Rating of Perceived Exertion between 17 and 19 lb BPW|Participants will be randomized to both 17 and 19 pounds for the first hike and the alternate condition for the second hike. A random number generator will create 1 block that includes 10 participants in each block to ensure comparable numbers to subjects starting at different base backpack weight. Participants assignments will then be included in a sealed manila envelopes.
62255695|NCT05149222|OTHER|Digital Acceptance and Commitment Therapy (ACT) Arm|Pragmatic
62443611|NCT02010723|EXPERIMENTAL|sclerotherapy|foam sclerotherapy with aethoxysclerol foam
62613334|NCT03008772||Stent Types|the stent types for angina classification at follow up
62838093|NCT04249986|ACTIVE_COMPARATOR|The Borg Rating of Perceived Exertion between 19 and 17 lb BPW|Participants will be randomized to both 19 or 17 pounds for the first hike and the alternate condition for the second hike. A random number generator will create 1 block that includes 10 participants in each block to ensure comparable numbers to subjects starting at different base backpack weight. Participants assignments will then be included in a sealed manila envelopes.
62443612|NCT03517852|EXPERIMENTAL|Arm 1|Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with peritoneal carcinomatosis during standard course of treatment (cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, or CRS-HIPEC).
62443613|NCT01289509|EXPERIMENTAL|Experimental 1|Drug: E5501
62443614|NCT01289509|EXPERIMENTAL|Experimental 2|Drug: E5501
62443615|NCT00859625|EXPERIMENTAL|1|Nurse participation during colonoscope withdrawal
62443616|NCT00859625|NO_INTERVENTION|2|usual colonoscopy practice
62443617|NCT00938652|ACTIVE_COMPARATOR|Arm G/C|gemcitabine/carboplatin on Days 1 and 8 of 21-day cycle(s)
62054143|NCT00674622|EXPERIMENTAL|Group 1-Prolotherapy|Deep injection with 15% dextrose in lidocaine
62054144|NCT00674622|PLACEBO_COMPARATOR|Group 2-Deep Saline/Lidocaine|Deep injection with saline/lidocaine
62054145|NCT00674622|PLACEBO_COMPARATOR|Group 3-Superficial Saline/lidocaine|Superficial injection with saline/lidocaine
62443618|NCT00938652|EXPERIMENTAL|Arm G/C/I|gemcitabine/carboplatin on Days 1 and 8, plus iniparib on Days 1, 4, 8, and 11 of 21-day cycle(s)
62443619|NCT02472678|OTHER|Standard care|The control group will receive standard care.
62443620|NCT02472678|EXPERIMENTAL|Experimental group|In addition to standard care, the experimental group will be given access to the web-based tailored information and support system (with a username/password)
62443621|NCT02714686|EXPERIMENTAL|Radio Mass Media Family Planning Campaign|Clusters receive a three-year mass media campaign on family planning in an attempt to reduce cognitive barriers to contraception
62443622|NCT02714686|NO_INTERVENTION|Control group|
62443623|NCT03724110||Pre-Telestroke|Retrospective collection of defined metrics for all TIA patients admitted to the participating ASRH 2 years prior to implementation of an inpatient telestroke service.
62443624|NCT03724110||Post-Telestroke|Prospective collection of defined metrics for all TIA patients admitted to the participating ASRH after implementation of an inpatient telestroke service.
62443625|NCT04096391|ACTIVE_COMPARATOR|Intrathecal Drug Delivery System|Subjects randomized to the Intrathecal Drug Delivery System group will be implanted with the Prometra System under sterile technique in accordance with the Instructions for Use. The pump will be filled at the time of implantation with the prescribed medication.
62443626|NCT04096391|ACTIVE_COMPARATOR|Conventional Medical Management|Subjects randomized to the Conventional Medical Management group will continue with the standard of care procedures.
62443627|NCT06376032|EXPERIMENTAL|Group 1|Participants receive immediate 12-week access to EndeavorOTC.
62054146|NCT05104528|OTHER|Non-invasive cardiometry|"OSYPKA Medical ICONTM Noninvasive CardiometerTM Model C3 A technique for the non-invasive determination of SV, CO, cardiac index, stroke index and HR along with other hemodynamic parameters such as preload (Thoracic Fluid Index), afterload and others.~The changes of impedance over time are integrated in a complex algorithm that allows to measure CO and the other above-mentioned parameters."
62255696|NCT01496729|ACTIVE_COMPARATOR|Transversus abdominis plane (TAP) block with ropivacaine|A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure
62838094|NCT02194478|OTHER|8 Week Meditation|Allina Health employees undergoing 8 week meditation intervention
62838095|NCT05377255|OTHER|Arm 1 Interventional Therapy|Subjects will first receive 4 doses of 4 mg each (total: 16 mg) of naloxone through the AP003 device (Arm 1) before the washout period.
62838096|NCT05377255|OTHER|Arm 2 Reference Therapy|Subjects will first receive 2 doses of 4 mg each (total: 8 mg) of the naloxone through the NARCAN Nasal Spray device (reference therapy, Arm 2) before the washout period.
62838097|NCT01092546|EXPERIMENTAL|Arm 1|
62838098|NCT05103046|EXPERIMENTAL|Dose Finding as Monotherapy - Part 1|UCT-03-008 Dose Finding
62838099|NCT05103046|EXPERIMENTAL|Expansion as Monotherapy - Part 2|UCT-03-008 RP2D Expansion
62838100|NCT05345899|OTHER|chronic rheumatism|Population of patients followed for chronic inflammatory rheumatism in remission or lupus in low activity, with chronic residual pain
62838101|NCT05579613|EXPERIMENTAL|Interactive virtual reality device group|"Group A will receive the same as group B and will receiveVR training by Xbox Kinect 360 (15 min per session 3 times per week) for 4 weeks. C"
62838102|NCT05579613|EXPERIMENTAL|chin tuck exercise for posture correction (traditional treatment ) group|Group B will receive traditional treatment (chin tuck exercise for posture correction); 3 min each day for 4 weeks, three sets of 10 repetitions (each repetition was held for 5 sec) will be performed.
62838103|NCT02461641|OTHER|Standard of Care|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe.
62613335|NCT04792307|OTHER|Neuromuscular electrical stimulation (NMES) to one leg|"* NMES left leg, no high protein ice cream supplementation~* NMES right leg, no high protein ice cream supplementation"
62255697|NCT01496729|SHAM_COMPARATOR|Sham TAP block with normal saline|A sham TAP block with normal saline will be performed at the end of the surgical procedure.
62255698|NCT05040802||Pertussis Case Group|"Infants between 2 days to less than 2 months of age for whom a case of pertussis was reported (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case and/or clinically compatible illness) and who met case inclusion criteria.~This post-hoc analysis was limited to infants born of mothers vaccinated with Adacel or who did not receive any tetanus, diphtheria, and acellular pertussis (Tdap) vaccine."
62838104|NCT02461641|EXPERIMENTAL|NuShield|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe. In addition, wounds will be treated with a dehydrated amnion-chorion membrane, NuShield, for up to 4 weeks.
62838105|NCT02461641|EXPERIMENTAL|Affinity|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe. In addition, wounds will be treated with a fresh hypothermically stored amniotic membrane, Affinity, for up to 4 weeks.
62255699|NCT05040802||Control Group|"Infants born at the same hospital as the case-infant who were less than 2 months old on the case-infant's cough onset date, and who met control inclusion criteria.~This post-hoc analysis was limited to infants born of mothers vaccinated with Adacel or who did not receive any Tdap vaccine."
62443628|NCT06376032|EXPERIMENTAL|Group 2|Participants receive 12-week access to EndeavorOTC 6-weeks after Group 1.
62613336|NCT04792307|OTHER|High protein ice cream supplementation|"* NMES left leg, high protein ice cream supplementation~* NMES right leg, high protein ice cream supplementation"
62838106|NCT00824577||250~300 patients|heart rate variability, heart function and Kt/V
62838107|NCT02230033|EXPERIMENTAL|Treatment A|Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1.
62838108|NCT02230033|EXPERIMENTAL|Treatment B|Itraconazole 200 mg (2 capsules of 100 mg) will be administered once daily orally from Day 1 until Day 32, along with single oral dose of JNJ-56021927 240 mg capsule on Day 4.
62838109|NCT02230033|EXPERIMENTAL|Treatment C|Gemfibrozil 600 mg oral tablet will be administered twice daily from Day 1 until Day 32, along with single oral dose of JNJ-56021927 240 mg capsule on Day 4.
62054147|NCT01970605||Patients with PAOD or aneurysms|"Patients~* in Fontaine class \> IIa,~* in need of aneurysm repair,~* with defined cardiovascular risk factors or~* graft infections.~Surgical reconstruction with defined Silver Graft vascular prosthesis."
62054148|NCT02525614|ACTIVE_COMPARATOR|Triathlon Standard Keel|Triathlon Cruciate Retaining knee (CR) with a tibial keel of standard length randomised against Triathlon Cruciate Retaining knee (CR) with a tibial part with a short keel, both system will be used with cemented fixation. The short tibial keel is thought to facilitate the surgery due to easier access and better positioning possibilities. This study is aimed to evaluate if the short tibial keel will have equal fixation and migration properties as the standard keel.
62054149|NCT02525614|ACTIVE_COMPARATOR|Triathlon Short Keel|Triathlon Cruciate Retaining knee (CR) with a tibial keel of standard length randomised against Triathlon Cruciate Retaining knee (CR) with a tibial part with a short keel, both system will be used with cemented fixation. The short tibial keel is thought to facilitate the surgery due to easier access and better positioning possibilities. This study is aimed to evaluate if the short tibial keel will have equal fixation and migration properties as the standard keel.
62054150|NCT05673629|EXPERIMENTAL|The treatment group-Utidelone in combination with AC|"Utidelone Injection at 30 mg/m2/d administered on days 1-5 of each cycle. Doxorubicin Injection at 50mg/m2 and Cyclophosphamide Injection at 500 mg/m2 administered once daily on day 1 of each cycle.~One treatment cycle has 21 days, and there are 6 cycles in total."
62054151|NCT05673629|ACTIVE_COMPARATOR|The control group-Docetaxel in combination with AC|"Docetaxel Injection at 75 mg/m2, Doxorubicin Injection at 50 mg/m2, and Cyclophosphamide Injection at 500mg/m2, administered on day 1 of each cycle.~One cycle has 21 days, and there are 6 cycles in total."
62054152|NCT02591550||patients with normal cough sensitivity|
62054153|NCT02591550||patients with high cough sensitivity|
62054154|NCT02591550||healty controls|
62054155|NCT00571701|ACTIVE_COMPARATOR|celecoxib first, then placebo|Patients randomized to start celecoxib 6 months after enrollment. Then cross over to placebo after 1 year. Celecoxib dosing will be given orally 400mg once a day for adults, 200 mg once a day for pediatric patients between 12-25kg, 100mg once a day for pediatric patients \< 12kg
62054156|NCT00571701|PLACEBO_COMPARATOR|Placebo first, then celecoxib|Patients randomized to start placebo 6 months after enrollment. One placebo capsule will be taken orally once a day. Placebo will match appearance of active celecoxib capsules. Cross over to 12 months of treatment with celecoxib after 1 year.
62054157|NCT05439954||Case group|（a）patients fulfilling the Diagnostic Criteria of the Diagnostic and Statistical Manual of Mental Disorders 5th Edition（DSM-V); (b)age:14 and under 14 years old; (c)first clinic visit, never-treated; (d)without injury to head and other diseases of the nervous system.
62054158|NCT05439954||Control Group|（a）healthy subject of same ages;(b)without injury to head and diseases of the nervous system; (c)without family history of mental disorders; (d)without other somatic illness.
62054159|NCT06064864|EXPERIMENTAL|Non-response to SC infliximab at week 30 and switched to infliximab IV 10 mg/kg every 8 weeks|"Patients with moderately to severely active Crohn's disease will be given IV (intravenous) infliximab 5 mg/kg at week 0 and 2. Then, they will be treated with SC (subcutaneous) infliximab every 2 weeks from week 6. At week 30. patients will be allocated to one of 3 arms according to their response to SC infliximab.~\[Arm 1\] Non-responders at week 30: Switched to infliximab IV 10 mg/kg every 8 weeks"
62054160|NCT06064864|EXPERIMENTAL|Response to SC infliximab at week 30 and then, switched to infliximab IV 5 mg/kg every 8 weeks|"Patients with moderately to severely active Crohn's disease will be given IV (intravenous) infliximab 5 mg/kg at week 0 and 2. Then, they will be treated with SC (subcutaneous) infliximab every 2 weeks from week 6. At week 30. patients will be allocated to one of 3 arms according to their response to SC infliximab.~\[Arm 2\] Response to SC infliximab at week 30 and then, randomly allocated to infliximab IV 5 mg/kg every 8 weeks"
62443629|NCT02004847|EXPERIMENTAL|High Intensity (HI) vs control|PSO-CT02 device: Light wavelength 453nm, high intensity, compared to contralateral untreated control plaque on the same patient.
62443630|NCT02004847|EXPERIMENTAL|Low Intensity (LI) vs control|PSO-CT02 device: Light wavelength 453nm, low intensity, compared to contralateral untreated control plaque on the same patient.
62054161|NCT06064864|ACTIVE_COMPARATOR|Response to SC infliximab at week 30 and then, continued infliximab SC 120 mg every 2 weeks|"Patients with moderately to severely active Crohn's disease will be given IV (intravenous) infliximab 5 mg/kg at week 0 and 2. Then, they will be treated with SC (subcutaneous) infliximab every 2 weeks from week 6. At week 30. patients will be allocated to one of 3 arms according to their response to SC infliximab.~\[Arm 3\] Response to SC infliximab at week 30 and then, randomly allocated to infliximab SC 120 mg every 2 weeks"
62054162|NCT04509895|EXPERIMENTAL|lateral extensile approach in calcaneal fractures fixation|Lateral extensile approach is the standard approach for intra-articular calcaneal fractures .
62054163|NCT04509895|EXPERIMENTAL|minimally invasive sinus tarsi approach in calc.fixation|Sinus tarsi approach become one of the most frequently applied minimally invasive approaches.
62054164|NCT03256825|OTHER|Rapid diagnostics|patients admitted to medical and surgical wards with urinary tract infections at Ålesund Hospital, Moere and Romsdal, Norway. Here, rapid diagnostics alone will be implemented.
62054165|NCT03256825|OTHER|Rapid diagnostics and RADS|patients admitted to medical and surgical wards with urinary tract infections at Molde Hospital, Moere and Romsdal, Norway. Here, rapid diagnostics will be implemented in conjunction with Real-time antimicrobial stewardship decision support : rapid diagnostics and RADS.
62054166|NCT00783380|EXPERIMENTAL|Virosomal influenza vaccine|
62054167|NCT00783380|ACTIVE_COMPARATOR|Subunit influenza vaccine|
62054168|NCT04957862|ACTIVE_COMPARATOR|robotic assisted evacuation|In the intervention arm, patients will receive stereotactic robotic assisted HICH evacuation according to the protocol under general anesthesia.
62255700|NCT01440270|EXPERIMENTAL|Neo-adjuvant Erbitux-based chemotherapy|Neo-adjuvant Erbitux-based chemotherapy before surgery: Erbitux, Docetaxel, Cisplatin.
62255701|NCT01043341|ACTIVE_COMPARATOR|behavioral|the women received a folder about HPV infection and vaccines and answered a questionaire about sexual behavior, HPV infection and vaccines.
62443631|NCT05291845|EXPERIMENTAL|Candida antigen group|25 patients will be treated with Candida antigen. All patients will be directly injected with Candida antigen into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
62838110|NCT04442802|EXPERIMENTAL|Long time balloon inflation|During the endovascular intervention the angioplasty balloon will be inflated for 6 minutes to treat the occlusive-stenotic femoropopliteal arterial lesion
62838111|NCT04442802|ACTIVE_COMPARATOR|Short time balloon inflation|During the endovascular intervention the angioplasty balloon will be inflated for 3 minutes to treat the occlusive-stenotic femoropopliteal arterial lesion
62838112|NCT02760953|EXPERIMENTAL|TUR with Cryoablation|Patients received TUR to treat bladder cancer and immediate cryoablation was applied on the tumor bed in order to eliminate possible residual tumor. Two or three cycles of freeze could be give to fully cover the lesion. One cycle last three to five minutes base on our previous animal experiments.
62838113|NCT02760953|ACTIVE_COMPARATOR|TUR with instant instillation|Patients received TUR to treat bladder cancer and pirarubicin instillation was given within 24 hours after TUR. This is in accord with the current guideline.
62838114|NCT01897688|EXPERIMENTAL|Islet Cell Transplant|All qualified subjects will be put on United Network for Organ Sharing (UNOS) Islet Transplant wait list for potential islet cell transplant.
62838115|NCT05379998|EXPERIMENTAL|Group A(neural mobilization)|sciatic nerve mobilization(sliding technique)
62838116|NCT05379998|EXPERIMENTAL|Group B(PNF hold relax)|PNF hold relax technique of Hamstring muscle
62838117|NCT00327600|EXPERIMENTAL|imexon + DTIC|
62838118|NCT01683357||Multiple Bilobar CLM|Patients selected for hepatectomy because carrier of multiple (\> or = to 4), bilobar CLM
62443632|NCT05291845|EXPERIMENTAL|Bivalent HPV vaccine|25 patients will be treated with the Bivalent HPV vaccine. All patients will be directly injected with the vaccine into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
62443633|NCT05291845|EXPERIMENTAL|both agents group|25 patients will be treated with Both agents at the same session. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
62838119|NCT04818372|EXPERIMENTAL|Dose escalation|"Subjects enrolled in this arm will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.~Dose escalation will be carried out according to a modified 3+3 dose-escalation design. Accelerated dose titration design will be used for the first 4 dose levels (0.006mg/kg, 0.06mg/kg, 0.3mg/kg and 1.0mg/kg) and then traditional 3+3 dose escalation design will be used for the following levels (2.0mg/kg, 4.0mg/kg, 8.0mg/kg, 16mg/kg and 24mg/kg)."
62838120|NCT04818372|EXPERIMENTAL|Dose expansion _Cohort 1|This cohort will comprise subjects with RRMM. Subjects will receive the CM313 in combination with dexamethasone.
62838121|NCT04818372|EXPERIMENTAL|Dose expansion _Cohort 2|This cohort will comprise subjects with RRMM and NDMM. Subjects will receive the CM313 in combination with Rd regimen.
62838122|NCT02804113|EXPERIMENTAL|Supera Peripheral Stent System|
62838123|NCT06339372|OTHER|Group A (standard feeding)|Patients received only standard feeding with caloric distribution (45%-50% carbohydrates,20-35% from fats and 10-35% from protein)
62255702|NCT01043341|NO_INTERVENTION|no intervention|the women answered a questionaire about sexual behavior, HPV infection and vaccines
62838124|NCT06339372|EXPERIMENTAL|Group B (immunonutrition mixture)|Patients received perioperative supplementation with omega 3 and dipeptiven (immunonutrition mixture) plus standard feeding.
62838125|NCT00515619|EXPERIMENTAL|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing
62613337|NCT06533267|EXPERIMENTAL|Surgery plus close follow-up|"Surgery:~Endoscopic Nasopharyngectomy: Radical resection of the primary lesion using nasal endoscopy."
62255703|NCT03127839|ACTIVE_COMPARATOR|Eccentric Strengthening Exercise|Patients will be asked to complete at least 6 outpatient PT sessions over a 4-week period. This will include an individualized impairment-focused approach, utilizing eccentric strengthening exercises of the rotator cuff to address any impairments or reinforce any standard of care manual treatment. Patients will also be given a home exercise program with instructions so that they can perform the eccentric strengthening exercises daily at home.
62255704|NCT03127839|ACTIVE_COMPARATOR|Traditional Strengthening Exercise|Patients will be asked to complete at least 6 outpatient PT sessions over a 4-week period. This will include an individualized impairment-focused approach, utilizing traditional rotator cuff strengthening exercises to address any impairments or reinforce any standard of care manual treatment. Patients will also be given a home exercise program with instructions so that they can perform the traditional rotator cuff strengthening exercises daily at home.
62255705|NCT03127839|ACTIVE_COMPARATOR|Eccentric Exercise + pain education|"In addition to the treatment provided in the Eccentric Exercise Arm patients will receive additional self-management training education focused on neuroscience of pain principles.~This will include e a 5-minute video called Understanding pain in less than 5 minutes, and what to do about it!, or aka explain pain video. The patients will also receive an interactive education booklet and review session with their PT, a series of weekly e-mails that reinforce key components of the booklet and video; and reinforcing messages when in the clinic doing their exercises."
62255706|NCT03127839|ACTIVE_COMPARATOR|Traditional Exercise + pain education|"In addition to the treatment provided in the Traditional Exercise Arm patients will receive additional self-management training education focused on neuroscience of pain principles.~This will include e a 5-minute video called Understanding pain in less than 5 minutes, and what to do about it!, or aka explain pain video. The patients will also receive an interactive education booklet and review session with their PT, a series of weekly e-mails that reinforce key components of the booklet and video; and reinforcing messages when in the clinic doing their exercises."
62255707|NCT04134182|EXPERIMENTAL|Nivolumab + Ipilimumab|Patients will receive a combination of ipilimumab, followed by nivolumab for 16 weeks.
62838126|NCT02910882|EXPERIMENTAL|Single Arm|"Cohort I (PEGPH20 Dose Escalation + Gemcitabine and Concurrent Radiotherapy), First 3 Patients:~An abbreviated sequential dose escalation schema for the first 3 patients (each subsequent patient will be accrued only after no dose limiting toxicities are found in the first 2 weeks of concurrent therapy for the previous patient).~Intravenous (IV) PEGPH20, per dose escalation guidelines for first 3 patients; Intravenous (IV) Gemcitabine (Standard Regimen); Radiotherapy (Standard Regimen);~Cohort II (PEGPH20 + Gemcitabine and Concurrent Radiotherapy), Patients 4 - 10:~IV PEGPH20, per dosing level determined in dose escalation (Cohort I); IV Gemcitabine (Standard Regimen); Radiotherapy (Standard Regimen);"
62838127|NCT01726439||CHB patients who are naive to NUC treatment|CHB patients who are naive to NUC at enrollment and be treated at hospitals at tier 2 cities in China
62838128|NCT05569083||Patients with Subjective Cognitive Decline|Patients complaining about cognitive decline with normal functioning on the activities of daily living and unsatisfied criteria for MCI or dementia at baseline.
62838129|NCT05569083||Patients with Mild Cognitive Impairment|Patients diagnosed with MCI
62838130|NCT05569083||Healthy controls|
62838131|NCT00714870|OTHER|1|intervention: this group will attend the nutrition and exercise program control group: this group will not attend the nutrition and exercise program
62255708|NCT01638572||neuroblastoma patients|
62443634|NCT03801629|EXPERIMENTAL|High Morphine Dose|Subjects in this experimental arm will receive a single intramuscular morphine dose (non-dominant deltoid muscle; 0.07 mg/kg).
62443635|NCT03801629|EXPERIMENTAL|Low Morphine Dose|Subjects in this experimental arm will receive a single intramuscular morphine dose (non-dominant deltoid muscle; 0.04 mg/kg).
62443636|NCT00860314|ACTIVE_COMPARATOR|AP Position|Cardioversion with antero-posterior electrode position
62838132|NCT02620748|EXPERIMENTAL|Tranexamic Acid|This arm will receive an injection of Tranexamic Acid
62838133|NCT02620748|PLACEBO_COMPARATOR|Saline|This arm will receive an injection of Saline Solution
62838134|NCT02202941|EXPERIMENTAL|Procalcitonin guided treatment|Patients who will be randomized to this arm will receive antibiotics therapy based on procalcitonin-guided algorithm.
62838135|NCT02202941|ACTIVE_COMPARATOR|Conventional treatment|Patients who will be randomized to this arm will receive antibiotic therapy based on conventional practice.
62838136|NCT01259414|EXPERIMENTAL|group1|Chemoembolization with solvent with specific gravity less than lipiodol
62838137|NCT01259414|EXPERIMENTAL|group2|Chemoembolization with Solvent with specific gravity equivalent to lipiodol
62443637|NCT00860314|ACTIVE_COMPARATOR|AL Position|Cardioversion with antero-lateral electrode position
62443638|NCT04895618|EXPERIMENTAL|Erchonia GVL|520 nanometers (nm) and 405 nm dual-diode laser application
62443639|NCT05885230|ACTIVE_COMPARATOR|PIFB group|patients will receive bilateral ultrasound-guided pecto-intercostal fascial block using 20 ml of bupivacaine 0.25% for each side.
62443640|NCT05885230|ACTIVE_COMPARATOR|LIDOCAINE group|1.5 mg/kg lidocaine will be administered after induction of anesthesia, then 2mg/kg/h lidocaine will be administered with continuous intravenous infusion until the end of the surgery.
62255709|NCT02329080|EXPERIMENTAL|MATRIX - R-ICE - Conditioning and ASCT|"MATRIX (courses 1,2,3): Rituximab 375 mg/m2 d0/Methotrexate 3.5 g/m2 d1/Cytarabine 2 g/m2 d2 \& d3/Thiotepa 30 mg/m2 d4/Liposomial Cytarabine 50 mg\* d5~R-ICE (courses 4,5,6):Rituximab 375 mg/m2 d1/Etoposide 100 mg/m2 d1,d2, d3/Ifosfamide 5 g/m2 d2/Carboplatin 5 AUC d2/Liposomial Cytarabine 50 mg\* d4~\*If liposomal cytarabine is not available, standard intrathecal chemotherapy with methotrexate 10 mg + cytarabine 40 mg + hydrocortisone 50 mg can be administered. Oral steroids are suggested for 2-3 days after intrathecal liposomial cytarabine delivery to prevent chemical or aseptic meningitis/ arachnoiditis.~Conditioning and ASCT: BCNU (carmustine)\*\* 400 mg/m2 d-6/Thiotepa 5 mg/kg d-5 \& d-4 ASCT: 5 x 106 CD34+cells/kg d0~\*\*In case of BCNU unavailability, the recommended conditioning regimen (Phase IV) is: Thiotepa 5 mg/kg d-6 \& d-5/Busulfan 3.2 mg/kg d-4,d -3,d-2/Clonazepam 2 mg/d d-4,d -3,d-2 ASCT: 5 x 106 CD34+cells/kg d0"
62255710|NCT06489600|EXPERIMENTAL|No Rays, Thanks Mineral sunscreen|Wash your face with standard facewash and apply a pea size amount on the face in the morning.
62054169|NCT04957862|NO_INTERVENTION|Concomitant care|All enrolled HICH patients in this study will receive standard medical treatment in the first 3-4 weeks according to the ASA/AHA guideline . Continued medical treatment is applied to patients in the control arm. Both arms will receive identical rehabilitation therapy three times per week for 180 days at one facility. Rehabilitation therapy includes identical physical therapy, occupational therapy, speech therapy, functional training, acupuncture and massage.
62054170|NCT05767684|EXPERIMENTAL|Arm 1: DCs monotherapy|DCs injection on day 1, 8, 15, 29, 85, 141, 197, 253 and 309.
62255711|NCT02801656|EXPERIMENTAL|Fecal Microbiota Transplantation|Oral, encapsulated fecal microbiota transplantation
62255712|NCT02801656|ACTIVE_COMPARATOR|Vancomycin|125 mg po qid x 10 days
62255713|NCT02164175||HeRO Graft|End stage renal disease patients who receive HeRO Graft implant for dialysis access
62255714|NCT02075489|EXPERIMENTAL|Acupressure|This group of patients will serve as the experimental group and receive acupressure treatment in addition to routine clinical care. Acupressure will be provided 40 mins/day, 2 days/week for 6 weeks (total of 12 sessions).
62255715|NCT02075489|ACTIVE_COMPARATOR|Reiki|This group of participants will serve as control group and receive Reiki treatment in addition to routine clinical care. Reiki will be provided 40 mins/day, 2 days/week for 6 weeks (total of 12 sessions).
62054171|NCT05767684|EXPERIMENTAL|Arm 2: DCs with booster of anti-VEGF/anti-PD-1.|DCs injection on day 1, 8, 15, 29, 85, 141, 197, 253 and 309 plus lenvatinib 10mg QD on day 43-77 and nivolumab 3mg/kg on day 43, 57 and 71.
62054172|NCT05105802|EXPERIMENTAL|Mindfulness Intervention|MBI training will consist of a 4-week custom-made program that include, setting intentions and check-in with mood, audio-recorded lectures, guided meditations such as body scans, and writing events journal. Each standardized course will be unlocked as the child progresses through the program. Users will be encouraged to participate in the app-based activities for a total of 10-15 minutes every day, with a minimum of 4 days in a week, over a period of 4 weeks.
62255716|NCT03908320|EXPERIMENTAL|Menstrual Cycle Timing|
62255717|NCT03908320|ACTIVE_COMPARATOR|Menstrual Cycle Monitoring|
62443641|NCT02840656||healthy adult subject|oropharyngeal and rectal swabbing to collect Gram-negative bacilli
62838138|NCT00337480|NO_INTERVENTION|conventional|This arm is the conventional way of taking care of patients after an acute coronary syndrome
62255718|NCT03750578|EXPERIMENTAL|Virtual Reality Group|Patients in this group will be offered virtual reality distraction through the use of OR in addition to standard of care.
62255719|NCT03750578|NO_INTERVENTION|Standard of care group|Patients in this group will receive standard care, including the proposition to use topical anesthetic cream prior to venipuncture attempt, usual distraction and positioning proposed by the treating nurse.
62255720|NCT02681679|EXPERIMENTAL|0.1% bromfenac ophthalmic solution|Patients received 0.1% bromfenac ophthalmic solution twice a day for 3 days before surgery.
62443642|NCT06486363|ACTIVE_COMPARATOR|Aspirin combined with clopidogrel|Participants in this group shall take Aspirin (100 mg/day) + clopidogrel (75 mg/day) for at least 5 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment
62443643|NCT06486363|EXPERIMENTAL|Aspirin combined with half-dose ticagrelor|Participants in this group shall take Aspirin (100 mg/day) + half dose of ticagrelor (45 mg, 12 hours/time), at least for 3 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment.
62838139|NCT00337480|ACTIVE_COMPARATOR|structured|This arm is an active way to monitor and educate patients after their acute coronary syndrome, with the intervention of health members in a House of Education
62838140|NCT02932241|EXPERIMENTAL|Computerized DBT skills training|The Computerized Dialectical Behavior Therapy Skills Training (cDBT) intervention includes 4 mindfulness, 6 emotion regulations, 2 distress tolerance, and 4 addiction skills. cDBT will retain the essence of DBT skills by being didactically focused, having a predetermined agenda driven by skills to be taught, emphasizing modeling through video vignettes, incorporating in session practice of skills whenever feasible, reviewing homework at beginning of sessions before teaching new skills, and assigning practice between sessions.
62838141|NCT02932241|NO_INTERVENTION|Waitlist|A waitlist (WL) control condition was chosen considering the pilot nature of the study, feasibility, and the overall goal of assessing treatment's promise. Participants will be assessed for drinking and suicidal urges in the same manner as in the cDBT condition. After 8 weeks, subjects will be able to enroll in the intervention.
62838142|NCT05335226|EXPERIMENTAL|Haplo-HSCT group|58 patients will be involved in this group
62838143|NCT05335226|EXPERIMENTAL|Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation group|58 patients will be involved in this group
62838144|NCT05717543|EXPERIMENTAL|Patient with corneal pathology, crystalline pathology, or pigmentary glaucoma|"Patient with corneal pathology, crystalline pathology, or pigmentary glaucoma will be included.~Imaging by retroillumination will be realized. In case of bilateral disease, both eyes will be photographed"
62838145|NCT06384014|ACTIVE_COMPARATOR|Retrograde canal filling technique|Apical resection application after retrograde root canal filling
62838146|NCT06384014|ACTIVE_COMPARATOR|Orthograde canal filling technique|Apical resection application after orthograde root canal filling
62255721|NCT02681679|PLACEBO_COMPARATOR|control physiological normal saline|Patients received control physiological normal saline twice a day for 3 days before surgery.
62255722|NCT06317675|EXPERIMENTAL|Osteopathic manipulative treatment (OMT)|Participants will receive four OMTs at week 1, 2, 4 and 8. Joint mobilization techniques for ribs, cervical and dorsal spine, as well as visceral treatment, soft-tissue release on diaphragm and abdominal wall will be used.
62443644|NCT00781755|EXPERIMENTAL|1|VAR-MI: This group will receive 1mg/day varenicline (titrated from .5mg/day) and two sessions of a motivational interviewing platform CBT treatment over the course of two weeks.
62838147|NCT00996853||Total vaccinated cohort|The Total vaccinated cohort will include all subjects with at least one vaccine administration documented.
62838148|NCT00203099|ACTIVE_COMPARATOR|Glatiramer Acetate, N-Acetylcysteine|
62838149|NCT01541241||copper IUD used|"Group I: includes 50 cases using CIUD and complaining of menorrhagia or menometrorrhagia.~Group II: includes 50 cases using CIUD and not complaining of abnormal uterine bleeding."
62838150|NCT06116370|ACTIVE_COMPARATOR|BPH patients treated with Rezum procedure|Patients aged 50-80 years with prostate volumes of 50-120 ml, sexually active, and have severe LUTS treated with Rezum procedure
62613338|NCT06533267|ACTIVE_COMPARATOR|Intensity modulated radiotherapy|"Radiotherapy:~Intensity-modulated Radiotherapy:~GTVnx: 69.96Gy/33Fr/2.12Gy CTV1: 59.4Gy/33Fr/1.8Gy CTV2: 54.12Gy/33Fr/1.64Gy"
62613339|NCT00006220|EXPERIMENTAL|Phase I|Starting dose of arsenic trioxide of 0.15 mg/kg/day
62613340|NCT00006220|EXPERIMENTAL|Phase II|MTD of arsenic trioxide
62838151|NCT06116370|ACTIVE_COMPARATOR|BPH patients treated with B-TURP procedure|Patients aged 50-80 years with prostate volumes of 50-120 ml, sexually active, and have severe LUTS treated with Rezum procedure
62838152|NCT04188561|ACTIVE_COMPARATOR|Intraarticular injection Group|Patients included in the study had been received 2 ml hyaluronic acid with concentration of 22mg/ml . Platelet rich plasma is arranged by withdrawing 10 ml of patient's personal venous blood, anticoagulant is added, and centrifuged by duo-spin method, at the rate of 3500 rpm for five minutes then injected twice with 2 weeks interval
62613341|NCT00006220|EXPERIMENTAL|Treatment Failure|Arsenic trioxide and tretinoin
62255723|NCT06317675|ACTIVE_COMPARATOR|OMT + breathing exercises.|This group will receive OMTs and five breathing exercises to perform daily at home. A recorded video of the exercises will be provided to participants in this group.
62613342|NCT01803776|EXPERIMENTAL|lifestyle counseling|Physical activity and dietary counseling
62255724|NCT06317675|NO_INTERVENTION|Control|Usual care group (PPI or reflux suppressant)
62255725|NCT01589276||Emergency hernia repairs|
62255726|NCT01589276||Elective hernia repairs|
62255727|NCT02219282|ACTIVE_COMPARATOR|Group Dentulous|Laryngeal Mask Unique insertion
62255728|NCT02219282|EXPERIMENTAL|Group Edentulous|Laryngeal Mask Unique insertion
62443645|NCT00781755|PLACEBO_COMPARATOR|2|PLA-MI: VAR-MI: This group will receive a daily placebo pill and two sessions of a motivational interviewing platform CBT treatment over the course of two weeks.
62613343|NCT01803776|NO_INTERVENTION|Control|No active intervention
62255729|NCT02426476|EXPERIMENTAL|active HRVB training|Heart rate variability biofeedback training
62255730|NCT02426476|SHAM_COMPARATOR|sham HRVB training|passive relaxation
62443646|NCT06544525|EXPERIMENTAL|chronic low back pain|Age 18-64 years with low back pain duration greater than 3 months.
62443647|NCT02447536|ACTIVE_COMPARATOR|BCG-DENMARK|"Infants randomised to receive BCG-DENMARK at dismissal from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine BCG-Denmark 1331 (Statens Serum Institute) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.~NOTE: By 1st of July 2016, infants in this arm has received BCG-Japan due to a worldwide shortage of BCG-Denmark because of a halt in production of this vaccine at the Statens Serum Institut in Copenhagen."
62838153|NCT04188561|ACTIVE_COMPARATOR|Radiofrequency Group|Radiofrequency Generator is a four electrode pain management for interventional pain management procedures. Patients had been placed in the supine position and their knee will be supported by a small pillow placed beneath the popliteal fossa. Fluoroscopic images of knee joint had been obtained. Possible locations of genicular nerves had been determined on the lateral, medial aspects of the lower end of the femoral bone and on the medial aspect of the tibia, under fluoroscopic guidance.
62838154|NCT02918214||echocardiography|Each patient will be hemodynamically assessed using echocardiography: Day1 defines the first echocardiography performed within the first 12 hours (ideally within the first 6 h) following the diagnosis of septic shock, Day2 and Day3 define the examination performed 24 to 36 h and 48 to 72 h later (guidance of treatment during the acute phase), Day end defines the examination performed after vasopressors cessation (end of hemodynamic failure). In addition, echocardiography will be performed on ICU discharge and on Day28 or on hospital discharge (whatever occurs first) to document potential reversibility of LV diastolic dysfunction. Transthoracic echocardiography will always first be performed and transesophageal echocardiography will be limited to ventilated patients without adequate surface echocardiographic image quality, under sedation and during the initial phase of septic shock (D1 to D3), according to the standards of care of participating centers.
62054173|NCT05105802|ACTIVE_COMPARATOR|Cognitive Sham Application + Usual Care|Usual care recommends that the patient refrain from physical and cognitive activities for 24-48 hours after injury. After the rest period, it is recommended that low to moderate levels of physical and cognitive activity be gradually started 24-48 hours after injury. The activities should be performed at a level that does not result in recurrence or exacerbation of symptoms. Children must refrain from any activities that increase the risk of re-injury (drills with body contact or that risk falls) until fully asymptomatic and cleared by their primary care or other medical provider. We consider this arm as active as participants will be assigned to a cognitive sham app (cognitive math game) delivered via the same app (same main interface as the mindfulness intervention). However, they will not take part in the MBI program for the first 4 weeks. On a daily basis, participants will be asked questions about their stress and emotions and about their symptoms.
62838155|NCT06654531|ACTIVE_COMPARATOR|group 1 (I.V group )|Patients in the I.V group (n = 25) received intrathecal hyperbaric bupivacaine 15 mg together with NSS 0.5 ml, followed by an I.V bolus dose of dexmedetomidine 0.5 μg/kg over 10 min and then an I.V infusion of a maintenance dose of 0.5 μg/kg/h (200 μg dexmedetomidine in 2 ml added to 48 ml NSS yielded dexmedetomidine 4 μg /ml) for the entire period of surgery.
62838156|NCT06654531|ACTIVE_COMPARATOR|group 2 (intrathecal group)|25 patients received intrathecal 15 mg hyperbaric bupivacaine (Marcaine 0.5%; Astra Zeneca, UK) together with 5 μg Dexmedetomidine (Precedex; Abbott; Chicago, IL, USA, 100 μg/ml diluted with normal saline solution (NSS) to 10 μg/ml), followed by an NSS I.V bolus and an I.V infusion of maintenance volume equivalent to that of the I.V group throughout the entire period of the surgery.
62838157|NCT02362282|ACTIVE_COMPARATOR|Gait plus cognitive training|Rehabilitation of walking/gait, combined with rehabilitation of cognitive function
62838158|NCT02362282|ACTIVE_COMPARATOR|Gait plus arm training|Rehabilitation of walking/gait, combined with rehabilitation of arm function
62838159|NCT00588835|EXPERIMENTAL|A|Aprepitant 125mg oral on day 1 and 80mg on day 2 and 3 during CE treatment.
62838160|NCT00588835|ACTIVE_COMPARATOR|B|CE cycle with standard anti-emetic regimen.
62838161|NCT00998361|EXPERIMENTAL|Stem Cell Transplant|All the patient who are affected by refractory or resistant or relapsed Soft tissue sarcoma o Ewing sarcoma who find an HLA compatible allogeneic donor and are submitted to Stem cell transplantation
62054174|NCT01159743||Efavirenz|HIV-infected patients on initial antiretroviral therapy for at least two years with efavirenz (Sustiva®; EFV) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
62054175|NCT01159743||Lopinavir / Ritonavir|HIV-infected patients on initial antiretroviral therapy for at least two years with lopinavir/ritonavir (Kaletra®; LPV/r) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
62613344|NCT00928655|EXPERIMENTAL|acetazolamide|combination of acetazolamide and nocturnal continuous positive airway pressure ventilation
62613345|NCT00928655|PLACEBO_COMPARATOR|placebo capsules|combination of placebo and nocturnal continuous positive airway pressure ventilation
62255731|NCT05301920|EXPERIMENTAL|Experimental Group|N=20 60Hz pulse electrical stimulation The clinical trial device performs a personal electrical stimulation around the trigeminal nerves for 4weeks (6 times/week), 20 minutes each time.
62255732|NCT00053950|EXPERIMENTAL|Cohort I|Groups of 3-6 patients receive escalating doses of PZA at a fixed infusion time until the MTD is determined. In both cohorts the MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients receive G-CSF IV or subcutaneously beginning on day 4 and continuing until blood counts recover. Patients also undergo reinfusion of stem cells over 15-30 minutes on day 4 as needed per protocol.
62255733|NCT00053950|EXPERIMENTAL|Cohort II|Groups of 3-6 patients receive PZA at the dose/hour established in cohort I at escalating infusion times until another MTD is determined. In both cohorts the MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients receive G-CSF IV or subcutaneously beginning on day 4 and continuing until blood counts recover. Patients also undergo reinfusion of stem cells over 15-30 minutes on day 4 as needed per protocol.
62443648|NCT02447536|ACTIVE_COMPARATOR|BCG-RUSSIA|Infants randomised to receive BCG-RUSSIA at dismissal from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-Russia-I (Serum Institute of India) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.
62838162|NCT03018652|EXPERIMENTAL|Intervention group|IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks) n=8
62838163|NCT03018652|PLACEBO_COMPARATOR|Control group|Normal saline (0.9% NaCl) 5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks) n=8
62838164|NCT00770172|EXPERIMENTAL|Arm I|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily for 6 days beginning 1 week after the start of chemotherapy (days 7-12). If chemotherapy begins on day 8, patients receive G-CSF SC on days 9-14.
62838165|NCT00770172|EXPERIMENTAL|Arm II|Patients receive G-CSF SC every 2 days on days 10-20 for up to 6 injections.
62838166|NCT02606513|EXPERIMENTAL|Comparison of CTU vs MRU|CTU is the primary test of choice for the evaluation of the UUT. The performance of MRU will be compared to that of CTU in the same patient population
62443649|NCT00927121|ACTIVE_COMPARATOR|Group 1 : G_1|G_1: stimulation for 4 - 6 hours a day, 4 tones per sequence
62443650|NCT00927121|ACTIVE_COMPARATOR|Group 2 :G_2|G_2: stimulation for 4 - 6 hours a day with 12-tone sequences
62443651|NCT00927121|ACTIVE_COMPARATOR|Group3 : G_3|G_3: stimulation for 4 - 6 hours a day, 4 tones per sequence with a signal controlled by EEG measurement
62443652|NCT00927121|ACTIVE_COMPARATOR|Group 4 : G_4|G_4: stimulation for 1 hour a day, 4 tones per sequence
62443653|NCT00927121|PLACEBO_COMPARATOR|Group5 : G_5|G_5: stimulation with placebo-tone
62613346|NCT03545646|EXPERIMENTAL|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic System
62443654|NCT00545233|EXPERIMENTAL|PEG-INF alpha-2a + ribavirin+ pioglitazone|Participants received pioglitazone in a 16 week run-in period (30 mg per day orally for 8 weeks followed by 45 mg per day orally for 8 weeks). Participants then received piogliatzone 45 mg daily orally plus 18 μg of Peginterferon Alfa-2a (PEG-INF alpha-2a) subcutaneous (sc) once a week plus ribavirin (1000 - 1600 mg/day orally as a split dose in the morning and the evening based on the participant's body weight) for 48 weeks in the anti-HCV treatment phase. Participants received 45 mg of pioglitazone per day orally in the 24 week follow-up period.
62613347|NCT06460610|EXPERIMENTAL|Blow Bottle technique|Blow Bottle Technique will be performed to emphasizing deep diaphragmatic breathing and controlled exhalation. Blow Bottle sessions for up to 20 minutes per day for 3 days in a week .Total 12 sessions in 4 weeks.
62613348|NCT06460610|ACTIVE_COMPARATOR|(Acapella along with Diaphragmatic Breathing)|Acapella will be performed to Improves clearance of secretion to facilitates opening of airway in patients with lung disease to mobilize secretions and improve lung function. Daily session for 20 minutes per day for 3 days in a week. Total 12 sessions in 4 weeks
62838167|NCT00885534|EXPERIMENTAL|Chemotherapy|This is a single institution phase II trial in stage III or IV melanoma patients with measurable disease but no prior cytotoxic chemotherapy and not thought to be curable by surgery.Before starting the chemotherapy, you may need to have a fresh biopsy of your tumor. If you have already had a tumor biopsy that we can use, you may not need another biopsy. Your study doctor will review with you the biopsies you have had. We will try to obtain biopsy material that already exists but if we cannot, you will need another biopsy.
62838168|NCT03995602|EXPERIMENTAL|Dragon fruit first then placebo|2 weeks of dragon fruit juice intake or placebo with crossover to the other
62838169|NCT03995602|EXPERIMENTAL|Placebo first then dragon fruit|2 weeks of dragon fruit juice intake or placebo with crossover to the other
62054176|NCT05762991||Helicobacter pylori infection and premalignant gastric lesion|Application of artificial intelligence to analyze the correlation between endoscopic images and urea breath test results/histopathological results.
62054177|NCT05180266|EXPERIMENTAL|Therapeutic Touch Group|In order to examine the effects of therapeutic touch on menopausal symptoms, sleep and quality of life, women will be given therapeutic touch for 15 minutes, once a week for four weeks.Therapeutic touchis a form of descriptive treatment that lasts approximately 15-20 minutes, in which hands are used on or near the body to correct abnormalities in the person's energy field and to achieve healing, and the energy in the universe is transferred from the practitioner's hands to the applied individual.
62054178|NCT05180266|EXPERIMENTAL|Music Listening Group|The women were asked to listen to the relaxation music included in the relaxation exercises CD prepared by the Turkish Psychological Association every day for four weeks in a comfortable environment at home for 30 minutes before bedtime.
62054179|NCT05180266|OTHER|Control Group|No action will be taken on the control group for four weeks.
62054180|NCT00169000|EXPERIMENTAL|Capecitabine and Docetaxel|Escalating doses of capecitabine days 1-14 with a fixed dose of docetaxel on Day 8 of a 21 day cycle
62054181|NCT03402516|EXPERIMENTAL|18.5Fr resector|Used of a 18.5Fr bipolar resector for hysteroscopic myomectomy. Cervical dilatation would be performed until Hegar bougie number 7 and then a classic hysteroscopic resection will be performed with a 18.5Fr bipolar resector.
62054182|NCT03402516|ACTIVE_COMPARATOR|26Fr resector|Used of a 26Fr bipolar resector for hysteroscopic myomectomy. Cervical dilatation would be performed until Hegar bougie number 10 and then a classic hysteroscopic resection will be performed with a 24Fr bipolar resector.
62613349|NCT00422422|EXPERIMENTAL|Brivaracetam|
62613350|NCT02565199|EXPERIMENTAL|Single motor training only|For a pilot experiment, healthy, right-handed subjects will complete one testing session. During the testing session, subjects will complete motor training. The results of this experiment will determine the motor training protocol used in the main experiment.
62613351|NCT02565199|EXPERIMENTAL|Repetitive TMS during motor training|Healthy, right-handed subjects will complete five testing sessions. During each testing session, subjects will complete motor training while receiving one of five repetitive transcranial magnetic stimulation (rTMS) protocols. Subjects will receive a different rTMS protocol at each testing session. By the end of the study, each subject will have received all rTMS protocols.
62054183|NCT00895700|EXPERIMENTAL|Web-based behavioral intervention|
62054184|NCT00895700|NO_INTERVENTION|Usual care|
62054185|NCT02350712|EXPERIMENTAL|All Participants - Period 1|All participants receive patritumab with cetuximab plus platinum-based therapy (cisplatin or carboplatin) in Period 1 - Initial phase of the trial.
62443655|NCT00545233|ACTIVE_COMPARATOR|PEG-INF alpha-2a + ribavirin|Participants received 18 μg of Peginterferon Alfa-2a (PEG-INF alpha-2a) subcutaneous (sc) once a week plus ribavirin (1000 - 1600 mg/day orally as a split dose in the morning and the evening based on the participant's body weight) for 48 weeks in the anti-HCV treatment phase followed by a treatment free 24 week follow-up period.
62443656|NCT02588573|ACTIVE_COMPARATOR|Etafilcon A (control)|Subjects in each of the habitual wearing groups will be randomized to wear either the test or control lens in either the left or right eye.
62838170|NCT04798404||Exercise Intervention in 20 collective sessions|104 elders recruited among the community (mean age: 82.1 ± 5.7, 72 women and 32 men), diagnosed in initial consultation with mobility disability risk (sedentary or/and pre-frail/frail or/and sarcopenia at least probable) who participated in 20 collective sessions twice a week and two hours per week, and have been seen for reassessment in final consultation.
62054186|NCT02350712|EXPERIMENTAL|All Participants - Period 2|Participants deriving clinical benefit enter Period 2 - Extension phase, during which they continue to receive patritumab with cetuximab, but not platinum-based therapy.
62838171|NCT02849899|ACTIVE_COMPARATOR|Vildagliptin|Group 1 will be treated with Vildagliptin 50 or 100 mg/day for 2 months, then 25 or 50 mg/d for 1 month depending on their creatinine assay.
62054187|NCT01068808||Nonallergic rhinitis|Nonallergic rhinitis (negative skin prick test)
62443657|NCT02588573|ACTIVE_COMPARATOR|Somofilcon A (test)|Subjects in each of the habitual wearing groups will be randomized to wear either the test or control lens in either the left or right eye.
62838172|NCT02849899|PLACEBO_COMPARATOR|Placebo|Group 2 will be treated with placebo according to the same dosage.
62838173|NCT01237197|EXPERIMENTAL|Exenatide, then Open-Label Exenatide|Exenatide 5 micrograms (mcg): administered with injection twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study (5 months)
62838174|NCT01237197|PLACEBO_COMPARATOR|Placebo, then Open Label Exenatide|Placebo injection twice a day for three months; Exenatide open label 5mcg twice a day for one month and up-titrated to 10mcg twice a day for remaining two months of study.
62838175|NCT00995800|ACTIVE_COMPARATOR|Fluticasone propionate / Formoterol fumarate|
62838176|NCT00995800|PLACEBO_COMPARATOR|Fluticasone propionate / Formoterol fumarate placebo|
62054188|NCT02049723||Patients with GERD|The knowledge level on GERD among Korean patients with gastroesophageal disease was evaluated by the method of multicenter survey
62443658|NCT02616692||HCC patients / Cohort 1|Patient preferences associated with oral anti-cancer therapy (Sorafenib), repeated TACE, and HAIC and their perceptions regarding the respective treatment characteristics
62443659|NCT04485988||No-beta blocker|
62443660|NCT04485988||beta blocker|
62054189|NCT05160324|ACTIVE_COMPARATOR|Axillary dissection (standard treatment)|"Axillary dissection in women with sentinel lymph node metastases.~(removal of at least 10 lymph nodes recommended)"
62054190|NCT05160324|EXPERIMENTAL|Preservation of axillary lymph nodes|Omission of Axillary dissection in women with sentinel lymph node metastases.
62054191|NCT02281448|OTHER|Treatment sequence A|oral once daily dose of 1200 mg of BIA 2-093 plus single-dose of a contraceptive for 15 days followed by washout and 3 days of oral single-dose contraceptive
62443661|NCT05764889|EXPERIMENTAL|Experimental group|Patients in the experimental group were wrapped with the Flexible Sleeve Penis Protection Device post-operatively.
62443662|NCT05764889|OTHER|Control group|Patients in the control group were wrapped with traditional gauze after operation.
62838177|NCT00706238|EXPERIMENTAL|GSK1203486A Group|"Patients received 4 cycles of MAGE-A3 product as follows:~* Cycle 1: 6 doses, each given at a 2-week interval,~* Cycle 2: 6 doses, each given at a 3-week interval~* Cycle 3: 4 doses, each given at a 6-week interval~* Cycle 4: 4 doses, each given at a 3-month interval followed by 4 doses, each given at a 6-month interval.~The MAGE-A3 product was administered intramuscularly in the deltoid or lateral regions of the thighs, alternately on the right and left sides."
62838178|NCT04423302|EXPERIMENTAL|TOTUM-63 3 intakes per day|Experimental active diet supplement TOTUM-63 taken 3 times per day (blinded arm)
62838179|NCT04423302|PLACEBO_COMPARATOR|Placebo 3 intakes per day|Placebo comparator taken 3 times per day (blinded arm)
62838180|NCT04423302|EXPERIMENTAL|TOTUM-63 2 intakes per day|Experimental active diet supplement TOTUM-63 taken 2 times per day (open arm)
62838181|NCT04226196|EXPERIMENTAL|Axis 0|IOL Implantation at the 0 +/- 10 degrees axis
62838182|NCT04226196|EXPERIMENTAL|Axis 45|IOL Implantation at the 45 +/- 10 degrees axis
62838183|NCT04226196|EXPERIMENTAL|Axis 90|IOL Implantation at the 90 +/- 10 degrees axis
62838184|NCT04226196|EXPERIMENTAL|Axis 135|IOL Implantation at the 135 +/- 10 degrees axis
62838185|NCT03193099|OTHER|Premanifest HTT mutation carriers|
62838186|NCT03193099|OTHER|non HTT mutation carriers|
62443663|NCT02539563|ACTIVE_COMPARATOR|peanut ball|the peanut shaped birthing ball after labor analgesia will be utilized
62838187|NCT06165393|EXPERIMENTAL|Slow-release CHO-AA|Alginate encapsulated Carbohydrates and Amino Acids
62838188|NCT06165393|EXPERIMENTAL|Slow-release CHO|Alginate encapsulated Carbohydrates
62838189|NCT06165393|ACTIVE_COMPARATOR|CHO|Carbohydrates only
62838190|NCT05360680|EXPERIMENTAL|CUE-102 (1mg/kg) Dose Escalation|CUE-102 (1 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
62838191|NCT05360680|EXPERIMENTAL|CUE-102 (2 mg/kg) Dose Escalation|CUE-102 (2 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
62838192|NCT05360680|EXPERIMENTAL|CUE-102 (4 mg/kg) Dose Escalation|CUE-102 (4 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
62838193|NCT05360680|EXPERIMENTAL|CUE-102 (8 mg/kg) Dose Escalation|CUE-102 (8 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
62838194|NCT05360680|EXPERIMENTAL|CUE-102 Dose Expansion at Determined RP2D|Dose expansion of CUE-102 at determined RP2D Monotherapy IV infusion every 3 weeks for up to 2 years
62838195|NCT01470261||ADHD medicated|Children aged 5-17 years with clinical diagnosis of ADHD and not previously treated with methylphenidate who have an agreement with their physician to begin treatment with methylphenidate.
62838196|NCT01470261||ADHD unmedicated controls|Children aged between 5-17 years with clinical diagnosis and not previously treated with methylphenidate who have an agreement with their physician NOT to treat with methylphenidate
62443664|NCT02539563|NO_INTERVENTION|no peanut ball|the peanut shaped birthing ball will not be utilized during labor
62838197|NCT01470261||Non-ADHD controls|Any child, including siblings of a child in either the ADHD-medicated or ADHD-unmedicated control group, who is 5-17 years old. These children must have a low rating (\<1.5) on the clinician-rated Swanson Nolan and Pelham IV Rating scale (SNAP IV) and not be medicated with with either dexamfetamine or atomoxetine.
62838198|NCT03422094|EXPERIMENTAL|Cohort A: NeoVax+Nivolumab (start at time of progression)|"* NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~* Nivolumab 480 mg i.v. given on Day 1 of each cycle beginning at time of progression"
62838199|NCT03422094|EXPERIMENTAL|Cohort B: NeoVax+Nivolumab (start with Cycle 2)|"* NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~* Nivolumab 480 mg i.v. given on Day 1 of each cycle beginning with Cycle 2 (start of boosting phase)"
62838200|NCT03422094|EXPERIMENTAL|Cohort C: NeoVax + Nivolumab (start with Cycle 1)|"* NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~* Nivolumab 480 mg i.v. given on Day 1 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)"
62838201|NCT03422094|EXPERIMENTAL|Cohort D: NeoVax+Ipilimumab+Nivolumab (start with Cycle 3)|"* NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~* Ipilimumab 1 mg/kg i.v. given on Days 1 and 22 of Cycle 1 (priming phase)~* Nivolumab 480 mg i.v. given on Day 1 of Cycle 3 and then on Day 1 of each subsequent cycle"
62838202|NCT03422094|EXPERIMENTAL|Cohort E: NeoVax+Ipilimumab+Nivolumab (day 1&15 each cycle)|"* NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~* Ipilimumab 1 mg/kg i.v. given every 6 weeks beginning on Day 1 of Cycle 1 (C1D1, C2D15, C4D1, C5D15, C7D1, C8D15 ...)~* Nivolumab 3 mg/kg i.v. given on Days 1 and 15 of each cycle (q2w) beginning on Day 1 of Cycle 1"
62838203|NCT03703180||MS|representative cohort of relapsing-remitting MS (n=50) and progressive MS patients (n=50) over the typical age range of 18-65. During two years of follow-up the integrity and function of the visual system will be observed annually with optical coherence tomography, high and low contrast visual acuity and a vision related quality of life questionnaire.
62443665|NCT03085446|EXPERIMENTAL|PDM nutritional intervention|
62443666|NCT03085446|EXPERIMENTAL|control|General information on nutrition and health
62443667|NCT04297852|ACTIVE_COMPARATOR|Vegan drink|Treatment group
62443668|NCT04297852|PLACEBO_COMPARATOR|Control|Placebo group
62443669|NCT04383704|EXPERIMENTAL|calorie-restricted modified MIND diet|This arm received instruction in modifying the content of their diet to meet MIND pattern guidelines.
62443670|NCT04383704|ACTIVE_COMPARATOR|calorie-restricted standard control diet|They instructed to calorie-restricted diet alone.
62443671|NCT04973956|ACTIVE_COMPARATOR|Relaxation group|This group will perform the APMR
62443672|NCT04973956|ACTIVE_COMPARATOR|Control group|This group will perform the control intervention
62443673|NCT01928446|EXPERIMENTAL|Lithium|Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
62443674|NCT01928446|PLACEBO_COMPARATOR|Placebo|Placebo tablets will be given to the subjects for the duration of follow-up (1 year). Dose adjustments will mimic the intervention arm of the study
62443675|NCT01225328|EXPERIMENTAL|Intervention|Telephone-delivered Behavioral Activation/Problem Solving (BA/PS) intervention
62443676|NCT05954715|EXPERIMENTAL|IPC (Ischaemic Preconditioning)|IPC will be administered to the upper limb using cuff inflation pressures of 200 mmHg or 60mm Hg above the systolic BP (whichever is higher). Four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation will be applied.
62613352|NCT00722163|EXPERIMENTAL|1|behavioural
62838204|NCT03703180||Controls|Age and Gender matched healthy controls (n=100) will undergo the same assessments as the MS cohort to build up a representative normative dataset.
62838205|NCT04522544|EXPERIMENTAL|SIRT (Arm A)|Y-90 SIRT + Tremelimumab + Durvalumab
62054192|NCT02281448|OTHER|Treatment sequence B|oral single-dose of a contraceptive for 3 days after pre-treatment with an oral once daily dose of 1200 mg of BIA 2-093 plus single-dose of a contraceptive for 15 days
62054193|NCT05284825|EXPERIMENTAL|12 Gy in 6 daily fractions|
62054194|NCT00539279|EXPERIMENTAL|Prolonged Exposure Therapy (PE)|Prolonged Exposure Therapy (PE)
62054195|NCT00539279|ACTIVE_COMPARATOR|Relaxation Training (RT)|Relaxation Training (RT)
62054196|NCT05140330|EXPERIMENTAL|Intervention|7 ALAPAGE sessions over 2 months and 1 evaluation session at 3 months
62054197|NCT05140330|OTHER|Control|3 evaluation sessions over 2 months and 1 session at 3 months
62443677|NCT05954715|SHAM_COMPARATOR|Sham|The Sham intervention will be administered with a BP cuff over the upper arm being inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles will comprise of four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation.
62443678|NCT02801058|NO_INTERVENTION|Control|Simple observation
62443679|NCT02801058|SHAM_COMPARATOR|Shame|Light touch manipulative simulation
62838206|NCT04522544|EXPERIMENTAL|TACE (Arm B)|DEB-TACE + Tremelimumab + Durvalumab
62838207|NCT06170294|EXPERIMENTAL|TCR-MAGE-A4 T-Cells|The subjects enrolled will be sequentially assigned to the corresponding dose level.
62443680|NCT02801058|EXPERIMENTAL|Treatment|Osteopathic manipulative techniques on the abdominal diaphragm
62443681|NCT05349903|EXPERIMENTAL|Rice flour|Rapidly digestible control
62443682|NCT05349903|EXPERIMENTAL|Alternanoligosaccharide 15|
62443683|NCT05349903|EXPERIMENTAL|Waxy potato starch|
62838208|NCT03349034|EXPERIMENTAL|Test Group|Local Ropivicaine Infusion
62838209|NCT03349034|PLACEBO_COMPARATOR|Control Group|Local Saline Infusion
62838210|NCT02203968|PLACEBO_COMPARATOR|Normal saline|Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
62443684|NCT05349903|EXPERIMENTAL|Combination of waxy potato starch and epigallocatechin gallate (EGCG)|
62443685|NCT05349903|EXPERIMENTAL|Combination of chickpea flour and epigallocatechin gallate (EGCG)|
62613353|NCT00722163|ACTIVE_COMPARATOR|2|befriending
62443686|NCT05349903|EXPERIMENTAL|Inulin|
62443687|NCT03465891|EXPERIMENTAL|atezolizumab|All patients will receive open-label atezolizumab 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).
62443688|NCT03465891|EXPERIMENTAL|atezolizumab plus low-dose, local radiotherapy|All patients will receive open-label atezolizumab 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year). 4Gy will be administered in 2 fractions to a single nodal site amenable to radiation as identified by the radiation oncologist on day 2 and day 3 of Cycle 1 (over the two days following to the first dose of atezolizumab ).
62613354|NCT00722163|NO_INTERVENTION|3|TAU
62838211|NCT02203968|ACTIVE_COMPARATOR|Fibrinogen concentrate|Fibrinogen concentrate (RiaSTAP™) is a freeze-dried lyophilised plasma product presented in powdered form. The powder is reconstituted with water for intravenous injection at a concentration of 20 mg fibrinogen per ml. The concentrate is formulated with human albumin, L-arginine, sodium citrate and sodium chloride. RiaSTAP™ is supplied as a purified lyophilisate in a 1g dosage form and is reconstituted in 50 ml of sterile water. The final volume of RiaSTAP™ to be infused in this study will therefore be 300 ml.
62838212|NCT01335672||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
62838213|NCT02248246|OTHER|Colectomy with Harmonic ACE®+7 Shears|Laparoscopic colectomy with Harmonic ACE®+7 Shears for dissection and vessel transection
62255734|NCT05897021|EXPERIMENTAL|Expressive Writing on Minority Stressors|The EWMS protocol will consist of 3 sessions delivered by a therapist (either in-person or remotely via telehealth platform) to sexual minority Veterans. The intervention will begin with an overview of the intervention, brief psychoeducation about expressive writing, and a review of the potential benefits of expressive writing. The initial session will also consist of psychoeducation on sexual minority stressors and common reactions to these stressors (i.e., universal stress reactions and minority-identity specific reactions) and how this relates to psychological outcomes, such as depression and anxiety, and high-risk behaviors, such as substance use and suicidal ideation. The initial session will be 60 minutes (introduction, psychoeducation, and first writing exercise) and the following two sessions (feedback, writing exercises, and check-ins) will take approximately 40 minutes.
62255735|NCT05897021|PLACEBO_COMPARATOR|Neutral Writing|To be comparable to EWMS, the control intervention will also be a 3-session individual intervention involving engaging in a writing exercise per session. For the control writing exercises, participants will be asked to write for 30 minutes about their daily activities since waking up that day based on Pennebaker's standard writing paradigm (Pennebaker \& Beall, 1987). Individuals in the control condition will also be given information about the purpose of the writing exercises to be comparable to the psychoeducation information provided in EWMS. Similar to EWMS, the clinician will check in with the participant about the writing session, such as asking how the session went and how it felt to do the writing, following the 30 minutes of writing.
62255736|NCT06159387|EXPERIMENTAL|Cannabis extract|Thirty patients will receive cannabis extract (total daily dose) 384 mg of CBD and 11.4 mg of THC divided into one intake in the morning (1 mL of oily solution - 192 mg of CBD and 5.7 mg of THC) and one intake in the evening ( 1 mL of oily solution - 192 mg of CBD and 5.7 mg of THC) during breakfast and dinner and psychotherapy.
62255737|NCT06159387|PLACEBO_COMPARATOR|Placebo|The other 30 subjects will receive placebo (same volumes of oily solution without active ingredient) and psychotherapy. Titration will be done with an initial dose of 1 mL taken at night and increased over 2 days to 1 mL morning and night. Patients using placebo will make similar increments to maintain the blind nature of the study.
62255738|NCT05584982|EXPERIMENTAL|AtbFinder-1|persons with cystic fibrosis to whom AtbFinder was used to formulate an individualized antibiotic regimen
62255739|NCT01660555||Patiënts scheduled for colonoscopy|Ill prepared colon during index colonoscopy or sigmoidoscopy: Boston scale \<3
62255740|NCT06296238||Enhanced Nutrition Package (ENP) health center + Enhanced Infection Management Package (EIMP)|ENP: Health centers were strengthened to provide WHO/FMOH-recommended nutrition interventions in pregnancy. Pregnant women received a supply of adequately iodized salt for household use and iron-folate tablets from enrollment to birth. Women with undernutrition (MUAC \<23 cm), also received a daily balanced energy protein supplement. EIMP: Pregnant women were screened at enrollment for bacteriuria with urine culture and antimicrobial susceptibility testing and presumptive deworming with mebendazole 500mg. Some women also received screening for chlamydia and gonorrhea and symptomatic women were tested for bacterial vaginosis and trichomonas. For women with chlamydia or gonorrhea, the participant was treated per FMOH guidelines with recommended antibiotics. STI/RTI screening was eventually discontinued due to supply shortage and the low prevalence of STI. At ANC follow-up visits, infected women were treated with antibiotics and persistent infection was retreated.
62255741|NCT06296238||ENP health center, routine care infection management participant|ENP: The health centers were strengthened to provide WHO/FMOH-recommended nutrition interventions in pregnancy. Pregnant women received a supply of adequately iodized salt for household use and iron-folate tablets from enrollment to birth. Women with undernutrition (MUAC \<23 cm), also received a daily balanced energy protein supplement. Standard infection care: Maternal genitourinary tract infections is managed as per standard FMOH health center guidelines that utilize a syndromic management approach.
62255742|NCT06296238||Routine nutrition care health center, EIMP participant|"Routine nutrition care: Maternal nutrition was managed as per standard FMOH health center guidelines.~EIMP: Pregnant women were screened at enrollment for bacteriuria with urine culture and antimicrobial susceptibility testing and presumptive deworming with mebendazole 500mg. Some women also received screening for chlamydia and gonorrhea and symptomatic women were tested for bacterial vaginosis and trichomonas. For women with chlamydia or gonorrhea, the participant (and partner) was treated per FMOH guidelines with recommended antibiotics. STI/RTI screening was eventually discontinued due to supply shortage and the low prevalence of STI. At ANC follow-up visits, infected women were treated with antibiotics and persistent infection was retreated."
62054198|NCT03645967|OTHER|ReadyCleanse for IUC|ReadyCleanse Cloths will be used for the standard of care for indwelling urinary catheter care and maintenance. The old standard of care will no longer be used.
62255743|NCT06296238||Routine of care nutrition and infection management|Pregnant women received routine strengthened antenatal care services at the health center per FMOH guidelines. Maternal genitourinary tract infections were managed as per standard FMOH health center guidelines that utilize a syndromic management approach.
62255744|NCT04483674|EXPERIMENTAL|Biktarvy|Patients will receive one pill with 50mg bictegravir/200mg emtricitabine /25mg tenofovir alafenamide orally once a day, for 48 weeks
62255745|NCT04312685|ACTIVE_COMPARATOR|Prometra Programmable Pump|Pain scores and drug doses will be prospectively collected for valve-gated Prometra® Programmable Pump system(Flowonix Medical)' at (refills 1-3) and will be compared to 3 months retrospectively collected pain scores (VAS, ODI and Global Pain Scale Assessments) and drug doses prior to peristaltic pump explant.
62255746|NCT04312685|NO_INTERVENTION|Retrospective records for peristaltic pump|Prior pain scores and drug doses from the patients who need a new valve gated pump will be recorded and used for comparison after it is changed.
62255747|NCT01392677|EXPERIMENTAL|Dapagliflozin 10 mg tablet|
62443689|NCT05429203|ACTIVE_COMPARATOR|Duodenoscope with single-use distal cover|Patients will undergo ERCP using a duodenoscope with a single-use distal cover
62255748|NCT01392677|PLACEBO_COMPARATOR|matching placebo tablet|
62255749|NCT04114292|EXPERIMENTAL|TUDCA|1.75-2 grams daily in divided dosing
62443690|NCT05429203|ACTIVE_COMPARATOR|Conventional Duodenoscope|Patients will undergo ERCP using a conventional duodenoscope
62443691|NCT02347930||Confirmed acute kidney injury|Confirmed acute kidney injury
62443692|NCT02463617|OTHER|PD patients|
62054199|NCT02073461|EXPERIMENTAL|CD1579 2.5%|Benzoyl Peroxide 2.5%
62054200|NCT02073461|EXPERIMENTAL|CD1579 5%|Benzoyl Peroxide 5%
62054201|NCT02073461|PLACEBO_COMPARATOR|Vehicle|Vehicle
62054202|NCT04293263|EXPERIMENTAL|MCI patients hospitalised in the research departments|each of the elderly in the study group will listen to personalized music twice a week for an hour each time together with a musical partner. Joint listening is performed with 2 pairs of headphones that connect via a splitter to the partner's cell phone. A listening session will take place in a period of 30 minutes and not more than 60 minutes.
62255750|NCT02069470|EXPERIMENTAL|Continuing Medical Education|Continuing Medical Education
62255751|NCT02069470|NO_INTERVENTION|Usual care|Usual care
62255752|NCT06064942|EXPERIMENTAL|MFNT Intervention (Treatment Group)|Parents of children with ADHD who are randomized in Treatment Group will first take part in a pre-tested 4-session MFNT intervention programme. The parents will participate in lectures, group discussions, video demonstrations, and in-group exercises offered in these four mentored sessions, while their children will attend the second and fourth sessions.
62255753|NCT06064942|EXPERIMENTAL|MFNT Intervention (Wait Listing Control Group)|Families of children with ADHD who are randomized in Wait Listing Control Group receive services as usual by the school social personnel during the intervention period. The 4-session MFNT intervention program will be delivered to them after the intervention period.
62255754|NCT05337579|ACTIVE_COMPARATOR|Supplemental Rest Breaks|
62255755|NCT05337579|ACTIVE_COMPARATOR|Exercise Breaks|
62255756|NCT05337579|EXPERIMENTAL|Supplemental Rest and Exercise Breaks|
62255757|NCT04053647||Hypoparathyroid patients|Patients with persistent hypoparathyroidism after total thyroidectomy, defined as serum PTH inferior to 15 pg/mL 6 months after surgery and the need of vitamin-calcic supplementation.
62255758|NCT04053647||Control patients, without hypoparathyroidism|
62255759|NCT04311697|EXPERIMENTAL|Aviptadil IV in escalating doses + standard of care|Patients will be administered Aviptadil IV in escalating doses of 50 pmol, 100 pmol, 150 pmol/kg/hr
62255760|NCT04311697|EXPERIMENTAL|Placebo + standard of care|Patients will first be treated with placebo infusion + maximal intensive care
62613355|NCT06505928|EXPERIMENTAL|Hepalatide 2.1mg|hepalatide 2.1mg/d, s.c. for 48 weeks
62255761|NCT04927286|EXPERIMENTAL|Mentoring+Mindfulness|
62255762|NCT04927286|ACTIVE_COMPARATOR|Mentoring as usual|
62255763|NCT01530425||Phase 1 assessments|Regency Wheelchairs and APDK 12-inch wide wheelchairs
62613356|NCT06505928|EXPERIMENTAL|Hepalatide 4.2mg|hepalatide 4.2mg/d, s.c. for 48 weeks
62613357|NCT06505928|NO_INTERVENTION|delayed treatment groups|delayed treatment for 48 weeks
62613358|NCT02362152||Ingenol mebutate|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
62255764|NCT01530425||Phase 2 assessments|Hope Haven and APDK 14-16 inch wide wheelchairs
62255765|NCT01530425||Phase 3 assessments|Motivation and Whirlwind wheelchairs
62613359|NCT02362152||5-fluorouracil|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
62613360|NCT02362152||Imiquimod|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
62255766|NCT02142738|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles.
62255767|NCT02142738|ACTIVE_COMPARATOR|Paclitaxel+Carboplatin|Participants receive paclitaxel 200 mg/m\^2 and carboplatin Area Under the Curve (AUC) 5 or 6, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m\^2 every three weeks (Q3W) maintenance for participants with non-squamous histologies for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
62613361|NCT02362152||Diclofenac|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
62054203|NCT04293263|ACTIVE_COMPARATOR|MCI patients hospitalized in the research departments|each of the elderly in the control group will Listen to random music twice a week for about 40 minutes each time, on personal headphones.
62255768|NCT02142738|ACTIVE_COMPARATOR|Pemetrexed+Carboplatin|Participants receive pemetrexed 500 mg/m\^2 and carboplatin AUC 5 or 6, IV infusion on Day 1 of each 21-day cycle for 4-6 cycles; participants with non-squamous histologies may then receive pemetrexed 500 mg/m\^2 on Day 1 of each 21-day cycle as maintenance therapy for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
62255769|NCT02142738|ACTIVE_COMPARATOR|Pemetrexed+Cisplatin|Participants receive pemetrexed 500 mg/m\^2 and cisplatin 75 mg/m\^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m\^2 Q3W maintenance for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
62255770|NCT02142738|ACTIVE_COMPARATOR|Gemcitabine+Carboplatin|Participants receive gemcitabine 1250 mg/m\^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and carboplatin AUC 5 or 6, administered as IV infusion on Day 1 of a 21-day cycle, for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
62255771|NCT02142738|ACTIVE_COMPARATOR|Gemcitabine+Cisplatin|Participants receive gemcitabine 1250 mg/m\^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and cisplatin 75 mg/m\^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
62255772|NCT02787187|ACTIVE_COMPARATOR|Standard resection|Pancreaticoduodenectomy (child's digestive reconstruction); Standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
62255773|NCT02787187|EXPERIMENTAL|Extended resection|Pancreaticoduodenectomy (child's digestive reconstruction)extended lymphadenectomy No8p 12a 12p 14c 14d 16
62255774|NCT02499861|EXPERIMENTAL|Decitabine and Genistein|continuous 24 hours Intravenous decitabine followed by oral genistein for 20 days.
62255775|NCT00130195|EXPERIMENTAL|A|
62255776|NCT01105676|EXPERIMENTAL|single group single arm study|Open no masking is used. All involved know the identity of the intervention assignment
62255777|NCT02058030|OTHER|3cm head elevation|Insertion of ProSeal laryngeal mask airway
62255778|NCT02058030|ACTIVE_COMPARATOR|6cm head elevation|Insertion of ProSeal laryngeal mask airway
62613362|NCT05935423|EXPERIMENTAL|UC-MSC|Patients assigned in UC-MSC intervention group will get Umbilical Cord Mesenchymal Stem Cell transplantation
62613363|NCT05935423|NO_INTERVENTION|Control|Patient assigned in control group doesn't get Umbilical Cord Mesenchymal Stem Cell transplantation. However, they will be fully treated based on European Society of Cardiology (ESC) guidelines
62613364|NCT06084247|EXPERIMENTAL|KARL STORZ Curved Scope|
62054204|NCT04059757|EXPERIMENTAL|Fecal Microbiota Transplantation (FMT)|"One dose of FMT equal to 30 capsules will be administered on day 1 of a 28 day cycle. Steroids and routine GVHD prophylaxis medications and antibiotics may be administered concurrently with FMT therapy.~Participants will be followed for 28 days following completion of the FMT dose or protocol defined outcome.~aGVHD will be treated as per standard of care."
62054205|NCT02644590|EXPERIMENTAL|Melatonin treatment|Adolescents with Type 1 Diabetes will undergo baseline 24 hour ambulatory blood pressure monitoring, followed by treatment with Melatonin for 3 weeks, using a single tablet at bed time, and repeat of the 24-hour blood pressure test following treatment period.
62255779|NCT02135211|EXPERIMENTAL|Lifestyle counseling|This is a single arm, quasi-experimental, pre- and post- test study design to test the feasibility and acceptability of a multiple risk factor, lifestyle intervention in patients receiving surgical treatment for lung cancer or those suspected of having lung cancer.
62255780|NCT02282150|OTHER|Conventional vs modified hydrocortisone;|5 weeks of conventional hydrocortisone followed by 16 weeks of modified-release hydrocortisone (Plenadren)
62255781|NCT06174844||Sample 1|Data collected from 1st January to 30th June of 2024
62255782|NCT06174844||Sample 2|Data collected from 1st January to 30th June of 2025
62255783|NCT03691129|EXPERIMENTAL|Yoga participant groups|Yoga participant groups will practice elderly yoga for four months. We will collect their blood before and after their participation in the elderly yoga program. There will be two subgroups which are Advanced group and Beginner group.
62255784|NCT03691129|NO_INTERVENTION|Non-Yoga participant groups|Non-Yoga participant groups will not practice yoga for four months and will be used as the control. We will collect their blood before and after the elderly yoga program. There will be two subgroups which are Elderly group and Young group.
62255785|NCT02075359||Preschoolers|Preschoolers, ages 3 to 5
62255786|NCT05818553|EXPERIMENTAL|Part A: Randomized, Double-Blind 0.5mg/kg/day PRAX-562 or PRAX-562/Placebo|Eligible participants from each cohort will be randomized in a 1:1 ratio to either 0.5 milligrams/kilograms/day (mg/kg/day) PRAX-562 for 16 weeks (PRAX-562 arm) or 0.5 mg/kg/day PRAX-562 for 12 weeks and matching placebo for 4 weeks (PRAX-562/placebo arm) administered orally or via gastrostomy tube (G-tube).
62255787|NCT05818553|EXPERIMENTAL|Part B: Open-Label Extension Treatment 0.5mg/kg/day PRAX-562|Eligible participants will receive 0.5mg/kg/day administered orally or via G-tube for 48 weeks.
62255788|NCT03514342||Interscalene brachial plexus block|Ultrasound-guided interscalene brachial plexus block with 25 ml to 30 ml of 0.75% ropivacaine
62613365|NCT06084247|ACTIVE_COMPARATOR|Conventional scopes|
62613366|NCT03203174|EXPERIMENTAL|Split-hand Microneedle Botulinum Toxin A|One palm with microneedle pretreatment prior to application of topical botulinum toxin A
62613367|NCT03203174|SHAM_COMPARATOR|Split-hand Sham Microneedle Botulinum Toxin A|Contralateral palm with sham microneedle pretreatment prior to application of topical botulinum toxin A
62738868|NCT03781973|OTHER|Post-Intervention|"Those whose last pediatric visit was in the second year after the intervention (2020).~The intervention includes the following :~1. Data Platform: Medical record data abstracted from patient charts at the time of the final pediatric visit. .~2. Quality performance feedback reports: We will generate centre-level performance reports. Centres will be able to compare their performance to that of all other centres and to achievable benchmarks.~3. Patient transition experience surveys at the final pediatric visit and 12 months later.~4. Diabetes teams may direct patients and families to online transition resources."
62738869|NCT04488354|EXPERIMENTAL|CLBR001 treated patients|Patients who have been administered with CLBR001
62738870|NCT01734785|ACTIVE_COMPARATOR|Linagliptin|5 mg once daily
62054206|NCT03381261|EXPERIMENTAL|Botulinum toxin type A injection arm|All patients will be injected with Botulinum toxin on one side of the back of the head.
62054207|NCT02503267||patients with congenital heart disease|patients with congenital heart disease
62054208|NCT04849130|ACTIVE_COMPARATOR|Static reconstruction technique according to Schöttle|Static reconstruction technique according to Schöttle
62255789|NCT04093843|EXPERIMENTAL|TMS|Open label single arm study to determine safety and effectiveness of TMS for post stroke depression
62255790|NCT04515914||Decitabine therapy|The patients are treated with decitabine at least 1 cycles
62255791|NCT04515914||non-Decitabine therapy|The Patients are diagnosed as MDS and do not be treated with decitabine therapy
62255792|NCT03251742|ACTIVE_COMPARATOR|Fontan patient population|
62255793|NCT03251742|SHAM_COMPARATOR|Healthy volunteers|
62255794|NCT03300895|EXPERIMENTAL|High-intensity interval training|
62255795|NCT03300895|ACTIVE_COMPARATOR|Moderate-intensity continuous exercise|
62255796|NCT01118273|EXPERIMENTAL|Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|
62738871|NCT01734785|EXPERIMENTAL|Empagliflozin + Linagliptin low dose|1 tablet once daily
62738872|NCT01734785|EXPERIMENTAL|Empagliflozin + Linagliptin high dose|1 tablet once daily
62738873|NCT05436522|EXPERIMENTAL|Remimazolam TIVA|Induction: Remimazolam, sufentanil, cisatracurium. Maintenance: Remimazolam, remifentanil, cisatracurium.
62738874|NCT05436522|ACTIVE_COMPARATOR|Propofol TIVA|Induction: Propofol, sufentanil, cisatracurium. Maintenance: Propofol, remifentanil, cisatracurium.
62738875|NCT06137430||Diabetic patients with chronic heart failure|
62738876|NCT06137430||Non_diabetic patients with chronic heart failure|
62738877|NCT05330936|ACTIVE_COMPARATOR|Group A|Steroid combination ointment in the treatment of chronic Plaque Psoriasis
62738878|NCT05330936|ACTIVE_COMPARATOR|Group B|Cyanocobalamin in Avocado Oil cream in the treatment of chronic Plaque
62738879|NCT04817839|EXPERIMENTAL|3-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 3-weeks post operation.
62054209|NCT04849130|ACTIVE_COMPARATOR|Dynamic reconstruction technique according to Becher|Dynamic reconstruction technique according to Becher
62738880|NCT04817839|EXPERIMENTAL|6-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 6-weeks post operation.
62054210|NCT06023875|EXPERIMENTAL|Experimental group|Patients with locally advanced operable head and neck squamous cell carcinoma
62255797|NCT01118273|ACTIVE_COMPARATOR|Naproxen Sodium 440 mg (BAYH6689)|
62255798|NCT01118273|EXPERIMENTAL|Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|
62255799|NCT01118273|ACTIVE_COMPARATOR|Naproxen Sodium 220 mg (BAYH6689)|
62255800|NCT01118273|ACTIVE_COMPARATOR|DPH 50mg|
62255801|NCT01118273|ACTIVE_COMPARATOR|Ibuprofen 400 mg / Diphenhydramine citrate 76 mg|
62255802|NCT03349775|ACTIVE_COMPARATOR|Metformin|Metformin: 500mg twice daily for 1 week, followed by 1g twice daily for a total of 3 months.
62255803|NCT03349775|PLACEBO_COMPARATOR|Placebo|Placebo: 500 mgh twice daily for 1 week, followed by 1g twice daily for a total of 3 months.
62255804|NCT05533138|ACTIVE_COMPARATOR|Assessment form allocated by chance & guided ICBT for antenatal depression|Patients are randomized to assessment modality (telephone, video or face-to-face visit) of a perinatal psychiatric semi-structured assessment \& and are randomised to treatment with internet-CBT for antenatal depression without extra-support (10 weeks)
62255805|NCT05533138|ACTIVE_COMPARATOR|Assessment form allocated by choice & guided ICBT for antenatal depression|Patients choose assessment modality (telephone, video or face-to-face visit) of a perinatal psychiatric semi-structured assessment \& are randomised to treatment with internet-CBT for antenatal depression without extra-support (10 weeks)
62255806|NCT05533138|EXPERIMENTAL|Assessment form allocated by chance & guided ICBT for antenatal depression with extra support|Patients are randomized to assessment modality (telephone, video or face-to-face visit) of a perinatal psychiatric semi-structured assessment \& and are randomised to treatment with internet-CBT for antenatal depression with extra-support
62738881|NCT00191945|EXPERIMENTAL|Atomoxetine|atomoxetine: 0.5 mg/kg/day every day (QD),by mouth (PO) for 2 weeks, 1.2 - 1.4 mg/kg/day QD, PO for 10 weeks, then 1.2 - 1.4 mg/kg/day QD, PO for up to 1 year
62054211|NCT05224375|EXPERIMENTAL|Treatment|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure system.
62054212|NCT01487980|ACTIVE_COMPARATOR|Early cord clamping|Within 30 seconds after birth.
62054213|NCT01487980|EXPERIMENTAL|Delayed cord clamping|Between 2 and 3 minutes after birth
62054214|NCT04150991|EXPERIMENTAL|Fiber intervention|The investigator's targeted supplemental fiber mixture (35 g total) will be composed of 6g of fiber from oligofructose + 10g from resistant maltodextrin + 12g from acacia gum + 4g from whole foods + 3g from RS2; and will be split into three meals each day.
62054215|NCT04150991|PLACEBO_COMPARATOR|Placebo treatment|Maltodextrin will be used as a placebo control, as it is digested in the small intestine and thus does not exert local effects in the colon.
62054216|NCT05032365|EXPERIMENTAL|Close-loop FiO2 Controller|Two hours period where the fraction of inspired oxygen (FiO2) delivered will be automatically titrated based on SpO2 values obtained from the patient.
62054217|NCT05032365|ACTIVE_COMPARATOR|Conventional|Two hours period where the FiO2 delivered will be conventionally adjusted by the healthcare personnel based on SpO2 values obtained from the patient.
62054218|NCT04322604|PLACEBO_COMPARATOR|Placebo|Placebo
62054219|NCT04322604|EXPERIMENTAL|3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002): a first dose of 1 mg/kg followed by 5 monthly doses of 3 mg/kg.
62255807|NCT05533138|EXPERIMENTAL|Assessment form allocated by choice & guided ICBT for antenatal depression with extra support|Patients choose assessment modality (telephone, video or face-to-face visit) of a perinatal psychiatric semi-structured assessment \& are randomised to treatment with internet-CBT for antenatal depression with extra-support (10 weeks)
62255808|NCT00871845|NO_INTERVENTION|LEAN (non obese, naive)|Patients naive to hepatitis C therapy with body mass index (BMI) \<25
62738882|NCT00191945|PLACEBO_COMPARATOR|Placebo|placebo every day (QD), by mouth (PO) for 12 weeks,then possibility to switch to atomoxetine at 0.5 mg/kg/day QD, PO for 1 week, then to 1.2 - 1.4 mg/kg/day QD, PO for up to 1 year (open-label extension)
62738883|NCT05114707|EXPERIMENTAL|camrelizumab group|
62738884|NCT02940899|ACTIVE_COMPARATOR|Intervention: Syracuse University Fir Families Program (SUFFP)|SUFFP is a randomized control trial comparing two groups of families of children with autism spectrum disorders. 20 families participated in the intervention program
62738885|NCT02940899|ACTIVE_COMPARATOR|Control: Syracuse University Fir Families Program (SUFFP)|20 families served as a wait-list control group. The control group will fill out the same pre and post measures as the intervention families (membership in the control vs. intervention group will be selected semi-randomly such that the average age of each of the two groups is equal), which will allow us to tease apart the effects of development vs. those related to the intervention.
62738886|NCT01472354|NO_INTERVENTION|Standard of care referral to specialist|Subjects are referred for education, counseling and evaluation for HCV treatment to a specialty health care provider
62054220|NCT00426608|EXPERIMENTAL|Session 1|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 gram per kilogram (g/kg) and Dose 2 of AEBCD sequence. In AEBCD sequence A is placebo, E Alprazolam, B GSK6561679 10 milligram (mg), C GSK6561679 50 mg and D GSK6561679 400 mg. Wash-out period will be of 7 days.
62255809|NCT00871845|OTHER|OVERWEIGHT (obese, naive, control)|Patients naive to hepatitis C therapy with BMI ≥ 25, received Dietary and Lifestyle modification educational sessions (one-time 15 minute weight loss instruction and pamphlet and enrolled into weight management program with 5 weekly one-hour nutrition and physical exercise education sessions after initial evaluation followed by monthly follow up.)
62255810|NCT00454259|EXPERIMENTAL|1|0,5 µg/kg
62255811|NCT00454259|EXPERIMENTAL|2|0,05 µg/kg
62255812|NCT00454259|EXPERIMENTAL|3|0,005 µg/kg
62255813|NCT00454259|PLACEBO_COMPARATOR|4|NaCl 0,9 %
62255814|NCT05653622|EXPERIMENTAL|SIB-DOPA|
62255815|NCT04037748|EXPERIMENTAL|First Puran T4®, then Eutirox®|Participants received single oral dose of Puran T4® 600 micrograms (mcg) (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 1 followed by single oral dose of Eutirox® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 2 under fasting conditions. A wash-out period of 70 days was maintained between the Treatment Periods 1 and 2.
62255816|NCT04037748|EXPERIMENTAL|First Eutirox®, then Puran T4®|Participants received single oral dose of Eutirox® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 1 followed by single oral dose of Puran T4® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 2 under fasting conditions. A wash-out period of 70 days was maintained between the Treatment Periods 1 and 2.
62255817|NCT02691754|EXPERIMENTAL|free paracetamol|the General Practitioners can prescribe paracetamol for free (covered by NHS). Patients can receive monthly dose at the local hospital
62255818|NCT02691754|NO_INTERVENTION|standard drug prescription|"Paracetamol is not included in the list of drugs than can be prescribed in charge of National Health System by General Practitioners.~The General Practitioners can prescribe other drugs or recommend paracetamol payed by the patient (out of pocket) at the chemistry."
62255819|NCT01912742|EXPERIMENTAL|Rapid weight loss group|The rapid weight loss group will follow a commercial very-low calorie diet (VLCD) during 4 weeks. The participants allocated to this group will follow a 550 (women) - 660 (men) kcal/day diet. The VLCD products provide 110kcal/pack and include a variety of milkshakes, smoothies and soups. In addition to VLCD products, calorie-free drinks and some low-starch vegetables (maximum 2 cups/day) will be allowed. Drinking at least 2.5 liters of non-caloric liquids will be recommended.
62255820|NCT01912742|EXPERIMENTAL|Slow weight loss group|The slow weight loss group will be prescribed an individualized low calorie diet (LCD) (1200-1500kcal/day), during 8 weeks, using meal replacements (such as smoothies, soups and cereal bars) and conventional foods. The macronutrient composition will be matched with that of the VLCD.
62738887|NCT01472354|EXPERIMENTAL|LEAP-C Group Intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with HCV treatment to decrease decisional conflict, increase HCV knowledge, improve communication
62738888|NCT02159898|EXPERIMENTAL|EndoMAXX Endoluminal Valve Technology (EVT)|EndoMAXX Endoluminal Valve Technology (EVT) Fully Covered Esophageal Stent with Valve
62054221|NCT00426608|EXPERIMENTAL|Session 2|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of BACED sequence. In BACED sequence B is GSK6561679 10 mg, A placebo, C GSK6561679 50 mg, E Alprazolam, and D GSK6561679 400 mg. Wash-out period will be of 7 days.
62255821|NCT02671357||ERAMIP with EEN|Minimally invasive pancreaticoduodenectomy (MIPD) with stented pancreatic-gastrostomy \& Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES). All patients are submitted to an ERAS trajectory with EEN
62255822|NCT06331442|EXPERIMENTAL|Photodynamic therapy group|Group of participants (n=10) allocated to this group will receive photodynamic therapy which consists of toluidine blue based dye (155 mg/mL) and 660 nm diode laser. Participants will be subjected to this treatment right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
62255823|NCT06331442|ACTIVE_COMPARATOR|Tricalcium phosphate varnish with 5% NaF group|Group of participants (n=10) allocated to this group will receive tricalcium varnish with 5% NaF which will be applied according to the manufacturer's recommendations. Participants will be subjected to this treatment right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
62255824|NCT06331442|ACTIVE_COMPARATOR|Chlorhexidine varnish group|Group of participants (n=10) allocated to this group will receive chlorhexidine varnish which will be applied according to the manufacturer's recommendations. Participants will be subjected to this treatment right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
62255825|NCT06331442|NO_INTERVENTION|Negative control group|Group of participants (n=10) allocated to this group will not receive an intervention.
62255826|NCT03561103|EXPERIMENTAL|RCT: Intervention|Participants in the RCT intervention arm will receive client-centered representative payee services in addition to the standard of care.
62738889|NCT02159898|ACTIVE_COMPARATOR|EndoMAXX|EndoMAXX Fully Covered Esophageal Stent
62738890|NCT00586040|EXPERIMENTAL|1|superficial closure with PTB
62738891|NCT00586040|ACTIVE_COMPARATOR|2|superficial sutures
62255827|NCT03561103|NO_INTERVENTION|RCT: Control|Participants in the RCT control group will receive the standard of care.
62255828|NCT03561103|EXPERIMENTAL|Choice Intervention|Participants in the Choice intervention arm will receive client-centered representative payee services in addition to the standard of care. They will not be randomly assigned.
62255829|NCT03561103|NO_INTERVENTION|Choice Control|Participants in the RCT control group will receive the standard of care. They will not be randomly assigned.
62255830|NCT04869345|EXPERIMENTAL|LARKSPUR intervention|Lessons in Affect Regulation to Keep Stress and Pain UndeR control
62255831|NCT04869345|NO_INTERVENTION|Attention Control Condition|Daily emotion reporting/no intervention
62255832|NCT00927654|EXPERIMENTAL|Iloprost|
62255833|NCT00927654|PLACEBO_COMPARATOR|Isotonic Sodium Chloride solution 0.9 %|
62255834|NCT06118983|EXPERIMENTAL|I-TRANSFER-HF|This is a 1-year long intervention period when I-TRANSFER-HF is in operation.
62613368|NCT02907775|ACTIVE_COMPARATOR|Transcutaneous Electric Nerve Stimulus|Researcher 1 who is blind to patients' allocation group will perform the baseline assessments. The researcher 2 will determine the maximum tolerable level of stimulation. The researcher 2 will demonstrate to the participant how to apply the stimulation and will instruct the participant. The participant will revive the first intervention in the Royal Hallamshire Hospital under supervision of researcher 2. The researcher 2 will then issue the participants in Group-2 (SBS) with Shefstim and six multichannel electrodes. They will instruct each participant to change the electrode once every 3 days. On the 15th day the researcher 2 will visit them at home and issue further 6 multichannel electrodes and collect back the previous set. At the end of week 4, the patient will come to Hospital.
62255835|NCT06118983|NO_INTERVENTION|Standard of Care (usual care)|This is a baseline period of usual care (UC) with no intervention.
62255836|NCT05071079|EXPERIMENTAL|Challenge with whole dose blood-stage inoculum (neat)|Whole dose: one whole vial, containing approximately 0.5 mL of red blood cells, will be reconstituted in 0.9% saline, to a total volume of 5 mL
62255837|NCT05071079|EXPERIMENTAL|Challenge with 1:5 dilution blood-stage inoculum|1:5 dilution: one fifth of a vial (containing approximately 0.1 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.
62255838|NCT05071079|EXPERIMENTAL|Challenge with 1:10 dilution blood-stage inoculum|1:10 dilution: one tenth of a vial (containing approximately 0.05 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.
62255839|NCT05071079|EXPERIMENTAL|Challenge with 1:20 dilution blood-stage inoculum|1:20 dilution: one twenties of a vial (containing approximately 0.025 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.
62255840|NCT02680925|PLACEBO_COMPARATOR|Conventional ventilation group|Mechanical ventilation is maintained with tidal volume (TV) of 10 ml/kg without PEEP during two-lung ventilation and TV of 8 ml/kg without PEEP during one-lung ventilation. Alveolar recruitment is performed 3 times; after intubation, before one-lung ventilation and after lung resection.
62738892|NCT02356523||Delirium patients|Patients positive to Confusion Assessment Method (CAM) assessment ad admission and during hospital stay
62738893|NCT02356523||control group|Patients negative to Confusion Assessment Method (CAM) assessment ad admission and during hospital stay
62054222|NCT00426608|EXPERIMENTAL|Session 3|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of CBEAD sequence. In CBEAD sequence C is GSK6561679 50 mg, B GSK6561679 10 mg, E Alprazolam, A placebo, and D GSK6561679 400 mg. Wash-out period will be of 7 days.
62255841|NCT02680925|ACTIVE_COMPARATOR|Lung protective ventilation group|Mechanical ventilation is maintained with tidal volume (TV) of 6 ml/kg with PEEP 6 cmH2O during two-lung ventilation and TV of 4 ml/kg PEEP 6 cmH2O during one-lung ventilation. Alveolar recruitment is performed 3 times; after intubation, before one-lung ventilation and after lung resection.
62255842|NCT03039400|EXPERIMENTAL|Web-based physio group|Those in the web-based physio group will have an individual exercise program set up by a treating physiotherapist on webbasedphysio.com after an initial face-to-face assessment. They will be encouraged to undertake their exercise program at least twice per week and diarize their work. Participants will receive a weekly phone call from their treating physiotherapist for the first two weeks. The treating physiotherapist will review the exercise diary of each participant every two weeks, and remotely alter the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.
62738894|NCT00395070|EXPERIMENTAL|Treatment Arm|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
62738895|NCT00395070|ACTIVE_COMPARATOR|Control Arm|DTIC 1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR TMZ 150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
62738896|NCT06661291|EXPERIMENTAL|Pip Care Intervention Group|Subjects randomized to the Pip Care Intervention group will receive access to the Pip Care digital health platform 1-week prior to their scheduled elective, inpatient surgery and retain access to the digital health platform for 30-days following surgery.
62738897|NCT06661291|ACTIVE_COMPARATOR|Standard of Care Group|Subjects randomized to the standard of care group will receive routine standard of care for their planned elective, inpatient surgery.
62054223|NCT00426608|EXPERIMENTAL|Session 4|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of ECABD sequence. In ECABD sequence E is Alprazolam, C is GSK6561679 50 mg, A placebo, B GSK6561679 10 mg and D GSK6561679 400 mg. Wash-out period will be of 7 days.
62255843|NCT03039400|ACTIVE_COMPARATOR|Standard care group|Those in the standard care group will have their exercise program explained to them at an initial face-to-face assessment with a treating physiotherapist as per usual care. They will receive a written, home-based exercise program. Participants in the usual care group will also be encouraged to undertake their exercise program at least twice per week, and will be asked to keep an exercise diary, in paper format. Participants in the usual care group will also receive a weekly phone call from the physiotherapist for the first two weeks to check on progress.
62255844|NCT03562130|EXPERIMENTAL|Revestive|Revestive® (teduglutide)is administered in children sub cutaneous injection at 0.05 mg/kg body weight once daily
62054224|NCT00426608|EXPERIMENTAL|Session 5|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of GSK561679 400 mg and alprazopam placebo. Wash-out period will be of 7 days.
62054225|NCT01456299|PLACEBO_COMPARATOR|Control|The control group, which received an infusion of normal saline.
62054226|NCT01456299|ACTIVE_COMPARATOR|Remifentanil 1|"Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml."
62613369|NCT02907775|ACTIVE_COMPARATOR|Sensory Barrage Stimulation|Researcher 1 who is blind to patients' allocation group will perform the baseline assessments. The researcher 2 will determine the maximum tolerable level of stimulation. The researcher 2 will demonstrate to the participant how to apply the stimulation and will instruct the participant. The participant will revive the first intervention in the Royal Hallamshire Hospital under supervision of researcher 2. The researcher 2 will then issue the participants in Group-2 (SBS) with Shefstim and six multichannel electrodes. They will instruct each participant to change the electrode once every 3 days. On the 15th day the researcher 2 will visit them at home and issue further 6 multichannel electrodes and collect back the previous set. At the end of week 4, the patient will come to Hospital.
62613370|NCT03623295||Cohort study population|For the main cohort study, we will include 500 patients with moderate or mild hemophilia A and 500 patients with moderate or mild hemophilia B.
62613371|NCT03623295||Sub study population|A subset of 200 patients of the cohort study population will be investigated in more detail by longitudinal data collection.
62613372|NCT05229952|EXPERIMENTAL|Constant infusion of 13C2-oxalate|Subjects who have passed screening, will consume a low-oxalate, normal calcium controlled diet for 5 days total. On Days 3 and 4, subjects will collect two 24-hour urines. On Day 5, they will receive a carbon 13 oxalate infusion which will occur at a constant rate for 6 hours, in the fasted state, following a priming dose. Hourly urine and twice hourly blood samples will be collected during the 6 hours. Meals will be resumed at the end of the infusion and timed urine collections will take place at home until the next day. A DXA scan will be performed to assess body composition at another date.
62054227|NCT01456299|ACTIVE_COMPARATOR|Remifentanil 2|"Remifentanil 2: The R2 group, which received a target effect-site remifentanil concentration of 2 ng/ml."
62054228|NCT04177225||Patients with normal diastolic function|Patients undergoing scheduled surgical procedures requiring general anesthesia and invasive arterial pressure and advanced cardiac function monitoring. A trans thoracic ultrasound examination of cardiac function will be performed before induction of general anesthesia . In the operating room, the anesthesia care team will place all of the standard intra-operative monitors and then induce general anesthesia. After induction, the ultrasound examination will be repeated and the planned additional intra-operative monitors will be placed. The arterial catheter will be attached to a FloTrac/EV1000 monitor that will be used to guide fluid management during the procedure. The sensitivity and specificity of SVV to predict the response of cardiac output to intravenous fluid administration will be assessed in this patient group distinguished by their normal left ventricular diastolic function.
62255845|NCT00868348|PLACEBO_COMPARATOR|Saline|
62255846|NCT00868348|ACTIVE_COMPARATOR|Ketorolac|
62255847|NCT06242379|EXPERIMENTAL|Bone marrow-mesenchymal stem cell-derived small extracellular vesicles|Single intravitreal injection of Good Manufacturing Practice (GMP) compliant bone marrow (BM)-mesenchymal stem cell (MSC)-derived small extracellular vesicles (sEVs) (50 μg) for single eye
62255848|NCT03375398|EXPERIMENTAL|3 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice consumed with 3 tablets Sugardown™
62255849|NCT03375398|PLACEBO_COMPARATOR|Rice only|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice
62255850|NCT03375398|EXPERIMENTAL|6 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice consumed with 6 tablets Sugardown™
62613373|NCT03462992||FIT-positive individuals|Patients being positive to an FIT test performed in the context of the Flemish (Northern Belgium) colorectal cancer screening campaign. These patients are male and female between 56 and 74 years old.
62613374|NCT01397240|EXPERIMENTAL|Albis|Drug: Albis Tab 2 tab, twice a day
62613375|NCT01397240|PLACEBO_COMPARATOR|Placebo|Placebo 2 tab, twice a day
62255851|NCT01030159||001|
62255852|NCT02623127|EXPERIMENTAL|Sunitinib|Sunitinib will be administered orally at a dose of 50 mg once daily in 3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment.
62255853|NCT01922817|ACTIVE_COMPARATOR|Saxagliptin|5mg once daily in addition to insulin therapy
62255854|NCT01922817|PLACEBO_COMPARATOR|Placebo|Crossover Placebo once daily
62255855|NCT01469182|EXPERIMENTAL|SCH 39641 12 Amb a 1-U|12 Units short ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) extract in an AIT, sublingual, once daily.
62255856|NCT01469182|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet, sublingual, once daily.
62255857|NCT04860570||Open Appendectomy (OA) + Double-ring wound-edge protector (2RWEP)|Intervention group: Patients with diagnosis of acute appendicitis treated by open appendectomy using a double-ring wound-edge protector.
62255858|NCT04860570||Laparoscopic Appendectomy (LA)|Control group: Patients with diagnosis of acute appendicitis treated by laparoscopic appendectomy.
62838214|NCT06472843||Interval|Participants in the interval condition will begin with a gradual one minute warm up effort with a ramp in the resistance gradually increasing from 0 watts to 60% of their peak power output (Wpeak) over 1 minute. They will then perform five sets of high intensity intervals with rest between these efforts. The intervals will be at 100% Wpeak for 15 seconds followed by 60% Wpeak for 45 seconds. During the work intervals participants will be encouraged to apply the highest cadence they can produce for the 15 second interval and resume a freely chosen cadence in the rest periods. After five interval repetitions (5 minutes) they will gradually warm-down from 60% Wpeak to 0 watts over 1 minute.
62838215|NCT06472843||Steady State|Participants in the steady state condition will begin the intervention with a gradual one minute warm up effort with a ramp in the resistance gradually increasing from 0 watts to 70% of their Wpeak over 1 minute. They will then continue at this resistance level at a freely chosen cadence for 5 minutes, after which they will gradually warm-down to 0 watts over 1 minute.
62838216|NCT02132429|EXPERIMENTAL|AMG 333|Subjects will receive a single oral dose of AMG 333 daily for 14 days.
62838217|NCT02132429|PLACEBO_COMPARATOR|Placebo|Subjects will receive a single oral dose of placebo daily for 14 days.
62838218|NCT05224999|EXPERIMENTAL|nivolumab|
62838219|NCT00055757|EXPERIMENTAL|Treatment (tipifarnib, gemcitabine, cisplatin)|"Patients receive oral tipifarnib twice daily on days 1-14, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients with at least stable disease may continue to receive oral tipifarnib alone twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
62838220|NCT03080896|ACTIVE_COMPARATOR|control group videolaryngoscope/preformed stylet|The control group will intubate using the video-laryngoscope / pre formed stylet. Will convert to using video-laryngoscope and fiber-optic bronchoscope (aScope III) if failure to intubate occurs
62838221|NCT03080896|EXPERIMENTAL|Interventional Group videolaryngoscope/fibeoptic bronch|The interventional group will Intubate using the video-laryngoscope and the fiber-optic bronchoscope (aScope III)
62838222|NCT03108469|ACTIVE_COMPARATOR|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.
62838223|NCT03108469|PLACEBO_COMPARATOR|Placebo|Those randomized to placebo will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.
62054229|NCT04177225||Patients with abnormal diastolic function|Patients undergoing scheduled surgical procedures requiring general anesthesia and invasive arterial pressure and advanced cardiac function monitoring. A trans thoracic ultrasound examination of cardiac function will be performed before induction of general anesthesia . In the operating room, the anesthesia care team will place all of the standard intra-operative monitors and then induce general anesthesia. After induction, the ultrasound examination will be repeated and the planned additional intra-operative monitors will be placed. The arterial catheter will be attached to a FloTrac/EV1000 monitor that will be used to guide fluid management during the procedure. The sensitivity and specificity of SVV to predict the response of cardiac output to intravenous fluid administration will be assessed in this patient group distinguished by their abnormal left ventricular diastolic function.
62255859|NCT05273034|EXPERIMENTAL|1-h sepsis bundle|
62255860|NCT05273034|NO_INTERVENTION|Current practice|
62255861|NCT04743921|EXPERIMENTAL|Reparel Sleeve Group|Patients receiving reparel knee sleeve for treatment of knee osteoarthritis.
62255862|NCT04400370||Pediatric patients undergoing lung resection|
62255863|NCT03509142|EXPERIMENTAL|IBS implantation|Implantation of IBS in patients with coronary artery lesions. All the subjects will be assigned to cohort 1 (n=30) and cohort 2 (n=15).
62613376|NCT03338244|ACTIVE_COMPARATOR|Azithro|Communities will receive four rounds of biannual mass azithromycin.
62613377|NCT03338244|PLACEBO_COMPARATOR|Placebo|Communities will receive four rounds of biannual mass placebo.
62613378|NCT00099632|EXPERIMENTAL|7-day 3TC/ZDV|SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.
62838224|NCT05651061|EXPERIMENTAL|Dose cohorts|Dose cohorts were designed to evaluate the safety, immunogenicity and PK/PD.
62838225|NCT00714727|OTHER|1|
62838226|NCT00500513|EXPERIMENTAL|Implanted Markers + CT + RT|
62838227|NCT02334462|EXPERIMENTAL|Group 1- Mali|Arm A1 (N=5) to receive 16 micrograms Pfs25M on D0, D28 Arm A2 (N=50) to receive 47 micrograms Pfs25M and Normal Saline on D0, D28, D168, D530
62838228|NCT02334462|EXPERIMENTAL|Group 1-U.S|Arm 1a (N=5) to receive 16 micrograms Pfs25M on D0, D28. Arm 1b (N=5) to receive 47 micrograms Pfs25M on D0, D28.
62054230|NCT03945864|EXPERIMENTAL|antimicrobial synthetic bone graft|This group will have parenteral antibiotics and antimicrobial (silver ions) synthetic bone graft
62054231|NCT03945864|ACTIVE_COMPARATOR|parenteral antibiotics with pure synthetic bone graft|This group will have parenteral antibiotics and pure synthetic bone graft
62838229|NCT02334462|EXPERIMENTAL|Group 2- Mali|Arm B1 (N=5) to receive 15 micrograms Pfs230D1M on D0, D28 Pfs230D1M-EPA/Alhydrogel Arm B2 (N=50) to receive 40 micrograms Pfs230D1M and Normal Saline on D0, D28, D168, D530
62838230|NCT02334462|EXPERIMENTAL|Group 2-U.S|Arm 2a (N=5) to receive 5 micrograms Pfs230D1M on D0, D28.Arm 2b (N=5) to receive 15 micrograms Pgs230D1M on D0, D28. Arm 2c (N=5) to receive 40 micrograms Pfs230D1M on D0, D28.
62838231|NCT02334462|EXPERIMENTAL|Group 3- Mali|Arm C1 (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28Arm C2 (N=50) to receive 47 micrograms Pfs25M and 40 microgramsPfs230D1M on D0, D28, D168, D530
62838232|NCT02334462|EXPERIMENTAL|Group 3- U.S.|Arm 3a (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28. Arm 3b (N=5) to receive 47 micrograms Pfs25M and 40 micrograms Pfs230D1M on D0, D28.
62613379|NCT00099632|EXPERIMENTAL|21-day 3TC/ZDV|SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.
62613380|NCT00099632|EXPERIMENTAL|7-day FTC/TDF|SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.
62613381|NCT00099632|EXPERIMENTAL|21-day FTC/TDF|SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.
62613382|NCT00099632|EXPERIMENTAL|7-day LPV/r|SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.
62613383|NCT00099632|EXPERIMENTAL|21-day LPV/r|SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r
62838233|NCT02334462|ACTIVE_COMPARATOR|Group 4- Mali|Arm D1 (N=5) to receive TWINRIX on D0, D28Arm D2 (N=5) to receive TWINRIX and NormalSaline on D0, D28Arm D3 (N=50) to receive TWINRIX and NormalSaline on D0, D28, D168; to receive Menactra andNormal Saline on D530
62838234|NCT02295618|EXPERIMENTAL|ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
62613384|NCT04760223|EXPERIMENTAL|Video intervention 1|We presented a 100-second video to study participants to reduce stigma towards depression (a boy presenter). The protagonist discussed his own depression and how getting help assist him.
62613385|NCT04760223|EXPERIMENTAL|Video intervention 2|We presented a 100-second video to study participants to reduce stigma towards depression (a girl presenter). The protagonist discussed his own depression and how getting help assist her.
62838235|NCT02295618|EXPERIMENTAL|ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
62838236|NCT02421835|PLACEBO_COMPARATOR|Placebo control|2 capsules of 350 mg maltodextrin to be consumed daily for 12 weeks
62613386|NCT04760223|PLACEBO_COMPARATOR|control video 1|A 100-second video presenting a boy without depression
62613387|NCT04760223|PLACEBO_COMPARATOR|control video 2|A 100-second video presenting a girl without depression
62613388|NCT01488396|EXPERIMENTAL|0.05%cyclosporin eye drop|
62613389|NCT03385616|EXPERIMENTAL|Treatment with GATS|Gala Airway Treatment System (GATS)
62613390|NCT04255966||Plasmafit® Revision Structan®|Plasmafit® Revision Structan® Hip Endoprosthesis Cup
62838237|NCT02421835|ACTIVE_COMPARATOR|Olive leaf extract|2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily for 12 weeks
62443693|NCT04466150|ACTIVE_COMPARATOR|Ocrelizumab treated|Participants age 18-50 with a first clinical presentation of MS or high-risk CIS diagnosed within 90 days of screening will be treated with ocrelizumab (300 mg IV x 2 doses given 2 weeks apart) at disease origin and with maintenance ocrelizumab 600 mg every 6 months through 30 months with a final study visit at 3 years
62443694|NCT04466150|NO_INTERVENTION|Observational study cohort|Subjects enrolled into an observational study matched for the same disease duration and who are either untreated or treated with alternate MS disease modifying therapies will serve as a parallel reference group
62613391|NCT06396013|EXPERIMENTAL|experimental group|The experimental group received topical Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment, twice a day for 12 weeks
62613392|NCT06396013|PLACEBO_COMPARATOR|control group|The control group received topical placebo twice a day for 12 weeks
62838238|NCT02421835|PLACEBO_COMPARATOR|Physical activity|2 capsules of 350 mg maltodextrin to be consumed daily combined with gradually increase physical activity levels over 12 weeks
62838239|NCT02421835|ACTIVE_COMPARATOR|Physical activity and olive leaf extract|2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily combined with gradually increase physical activity levels over 12 weeks
62838240|NCT04573582|EXPERIMENTAL|Enasidenib (CC-90007) tablet|Participants will receive one 100 mg enasidenib (CC-90007) tablet the morning of Day 1 which will be administered in the fasted state.
62054232|NCT01360541|EXPERIMENTAL|Radiofrequency ablation|Endoscopic radiofrequency ablation of BE
62613393|NCT05501067|ACTIVE_COMPARATOR|tai chi group|patients will receive tai chi exercise program
62613394|NCT05501067|ACTIVE_COMPARATOR|control group|no intervention
62054233|NCT01360541|ACTIVE_COMPARATOR|Surveillance|Endoscopic surveillance and PPI treatment
62255864|NCT01471015|ACTIVE_COMPARATOR|High dose Darbepoetin alfa|10 mcg/kg/dose Darbe x2 doses, with the first dose within 12 hours of delivery and the second dose at 7 days
62255865|NCT01471015|ACTIVE_COMPARATOR|Low dose Darbepoetin alfa|2 mcg/kg/dose Darbe x2, with the first dose given within 12 hours of delivery and the second dose given at 7 days old.
62255866|NCT01471015|PLACEBO_COMPARATOR|Placebo|Placebo given x2 doses, with the first given within 12 hours of delivery and the second given at 7 days old
62443695|NCT04580056||Incision Group|Women following IVF treatment with donor oocytes who underwent during hysteroscopy fundus endometrial scratching by incision, before embryo transfer.
62443696|NCT04580056||No incision Group|Women following IVF treatment with donor oocytes who underwent office hysteroscopy without fundus endometrial scratching by incision, before embryo transfer.
62443697|NCT04137263|EXPERIMENTAL|Treatment|Subjects will receive dose formulation for treatment of melasma
62443698|NCT03276975|ACTIVE_COMPARATOR|Patching of CSF Leaks with Autologous Blood and Fibrin|CT fluoroscopy-guided blood and fibrin glue patching targeted to the site of CSF leak.
62613395|NCT05266924|EXPERIMENTAL|Test group|Foligraf 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen Follicle Stimulating Hormone (Human Recombinant) manufactured by Bharat Serums and Vaccines Ltd
62613396|NCT05266924|ACTIVE_COMPARATOR|Reference group|Gonal-f Recombinant Human Follicle Stimulating Hormone
62613397|NCT06192498|EXPERIMENTAL|Virtual Reality Glasses Group|Virtual Reality(VR) Glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses before starting the application and it continued until the end of the Blood Draw procedure.
62613398|NCT06192498|EXPERIMENTAL|Kaleidoscope Group|Kaleidoscope were introduced to the children pre-procedure. The children were made to watch Kaleidoscope before starting the application and it continued until the end of the Blood Draw procedure.
62613399|NCT06192498|EXPERIMENTAL|Distraction Cards Group|Distraction Cards were introduced to the children pre-procedure. The children were made to apply Distraction Cards before starting the application and it continued until the end of the Blood Draw procedure.
62613400|NCT06192498|NO_INTERVENTION|Control Group|In this group, children received routine blood draw procedure.
62838241|NCT01469611|EXPERIMENTAL|JX-594|Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.
62838242|NCT05368246|EXPERIMENTAL|Interventional arm|Electrical stimulation to the dorsal genital nerve.
62838243|NCT05571332|EXPERIMENTAL|Avatrombopag+CsA+ p-ATG|Patients received p-ATG for 5 consecutive days (day 1-5), at a dose of 20 mg/kg/day. CSA is started at 3 mg/kg orally in two doses. Concentrations maintained at 200-250 ng/ml to achieve maximum efficacy and then tapered by 25 mg every 3 months; Avatrombopag: 40 mg orally once daily for a total of 12 weeks. A total of 39 patients were expected to be included.
62838244|NCT05434416|NO_INTERVENTION|No Interventions|Given access to all interventions at the end of the 5 weeks of the trial.
62838245|NCT05434416|EXPERIMENTAL|Short-term interventions|Participants have access only to short-term interventions. Given access to all interventions at the end of the 5 weeks of the trial.
62838246|NCT05434416|EXPERIMENTAL|Short-term and long-term interventions|Short-term and long-term interventions Participants have access to short-term and all long-term interventions.
62255867|NCT00674583|EXPERIMENTAL|Nimenrix Group|Healthy male or female subjects between, and including 2 and 10 years of age, intramuscularly received 1 dose of Nimenrix™ vaccine into the non-dominant deltoid region, at Day 0.
62255868|NCT00674583|ACTIVE_COMPARATOR|Menjugate Group|Healthy male or female subjects between, and including 2 and 10 years of age, intramuscularly received 1 dose of Menjugate® vaccine into the non-dominant thigh region, at Day 0.
62255869|NCT00995475|EXPERIMENTAL|Inhaled corticosteroid, Then placebo|FP 250μg per actuation pMDI one puff twice daily (total daily dose 500μg) for two weeks then FP 250μg per actuation pMDI four puffs twice daily (total daily dose 2000μg) for two weeks. After a washout period of 2 weeks, they then received FP matched placebo pMDI one puff twice daily for two weeks then FP four puffs twice daily for two weeks.
62613401|NCT04521114|EXPERIMENTAL|Leronlimab 700 mg|Leronlimab 700 mg SC weekly injection
62613402|NCT04521114|EXPERIMENTAL|Leronlimab 350 mg|Leronlimab 350 mg SC weekly injection
62613403|NCT04521114|PLACEBO_COMPARATOR|Placebo|Placebo SC weekly injection
62613404|NCT03174691|EXPERIMENTAL|Hormonal levels|Collect blood samples Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
62613405|NCT01260584|EXPERIMENTAL|Prasugrel|Prasugrel 10 mg film-coated tablet daily dose × 10 days. To maintain blinding, placebo film-coated tablets matching clopidogrel in appearance will be given daily × 10 days to subjects in the prasugrel treatment group. In addition, aspirin 81 mg to 325 mg daily will be taken.
62838247|NCT05434416|EXPERIMENTAL|Long-term intervention: Meditations|Participants have access to short-term interventions. Participants have access to one long-term intervention: Meditations. Given access to all interventions at the end of the 5 weeks of the trial.
62838248|NCT05434416|EXPERIMENTAL|Long-term intervention: Mindfulness|Participants have access to short-term interventions. Participants have access to one long-term intervention: Mindfulness. Given access to all interventions at the end of the 5 weeks of the trial.
62255870|NCT00995475|PLACEBO_COMPARATOR|Placebo control, Then inhaled corticosteroid|FP matched placebo pMDI one puff twice daily for two weeks then FP four puffs twice daily for two weeks. After a washout period of 2 weeks, they then received FP 250μg per actuation pMDI one puff twice daily (total daily dose 500μg) for two weeks then FP 250μg per actuation pMDI four puffs twice daily (total daily dose 2000μg) for two weeks.
62443699|NCT03276975|PLACEBO_COMPARATOR|Simulated Patching Procedure|Instead of injection of blood and fibrin glue patching material through the needles, an equivalent volume of preservative free sterile Elliots B solution will be injected.
62443700|NCT02919475|EXPERIMENTAL|JTE-051 Dose 1|One dose of study drug by mouth daily for 12 weeks
62613406|NCT01260584|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 75 mg film-coated tablet daily dose x 10 days To maintain blinding, placebo film-coated tablets matching prasugrel in appearance will be given daily × 10 days to subjects in the clopidogrel treatment group. In addition, aspirin 81 mg to 325 mg daily will be taken.
62613407|NCT05577234|EXPERIMENTAL|Animal-assisted intervention|The dog accompanied by the zootherapist will participate in the care of the sessions. During these sessions, the dog will be brought into the child's presence in the waiting room until the end of the dental consultation.
62613408|NCT05577234|OTHER|Standard care|The treatment sessions will only involve the use of conventional behavioural strategies.
62613409|NCT04504149|EXPERIMENTAL|PRIMED|Shared decision making session
62613410|NCT04504149|NO_INTERVENTION|Usual Care|The investigators will characterize usual care using chart review and administrative data to identify medications (prescribed, filled), number of mental health sessions received, types of providers seen, and the content of treatment sessions as captured in chart notes.
62613411|NCT05646966|ACTIVE_COMPARATOR|healthy subjects|healthy subjects
62613412|NCT05646966|NO_INTERVENTION|stroke patients|first time stroke patients
62255871|NCT05376475||Virtual setup cohort|Participants in this cohort will use a night vision camera and level III home sleep apnea test. If the participant has a bed partner who consents to be in the study, the bed partner will also use a level III home sleep apnea test and be recorded by the night vision camera.
62255872|NCT05376475||In-person setup cohort|Participants in this cohort will use a night vision camera, a level III home sleep apnea test, a maternal-fetal transabdominal electrocardiographic heart rate monitor, and a pressure sensing mat. If the participant has a bed partner who consents to be in the study, the bed partner will also use a level III home sleep apnea test and be recorded by the night vision camera (maternal-fetal transabdominal electrocardiographic heart rate monitor and a pressure sensing mat will not be used by the bed partner).
62255873|NCT03880487|EXPERIMENTAL|KP-1199|
62255874|NCT03880487|PLACEBO_COMPARATOR|Placebo oral capsules|
62255875|NCT03880487|ACTIVE_COMPARATOR|Oxycodone oral capsules|
62255876|NCT00006469|OTHER|Single arm study|Concurrent Paclitaxel, Carboplatin, and External-Beam Radiation Followed by Surgical Resection in Locally Advanced Non-Small-Cell Lung Cancer
62255877|NCT04778982||dose-escalation Phase|KN026 20 mg/kg + palbociclib125 mg/day+Fulvestrant 500 mg (Patients with HR+/HER2-positive MBC )
62255878|NCT04778982||parallel-group expansion Phase|KN026 20 mg/kg + palbociclib +Fulvestrant 500 mg(Patients with HR+/HER2-positive MBC )
62255879|NCT02319187|ACTIVE_COMPARATOR|Arm A|S1
62255880|NCT02319187|EXPERIMENTAL|Arm B|S1 and irinotecan
62255881|NCT05896488||Cystic fibrosis|No intervention - only assessments
62255882|NCT05896488||Healthy Control|No intervention- only assessments
62255883|NCT03697720|EXPERIMENTAL|Primary Dysmenorrhea|We will look at the effects of naproxen 500mg use on pain starting just before and during menses.
62255884|NCT01710384|EXPERIMENTAL|betamethasoneb, 34-36 weeks, preterm labor|betamethasone 12 mg 2 injections will be given 24-hours apart.
62255885|NCT01710384|NO_INTERVENTION|preterm labor, 34-37 weeks|betamethasone 12 mg 2 injections will be given 24-hours apart.
62255886|NCT00808236|EXPERIMENTAL|RhinoChill|Intra-arrest cooling with the RhinoChill during advanced cardiac life support
62255887|NCT00808236|OTHER|Control|Advanced cardiac life support, only
62255888|NCT03735927|NO_INTERVENTION|Control phase|no intervention, i.e. care as usual
62255889|NCT03735927|EXPERIMENTAL|Intervention phase|experimental intervention: spot monitoring device (excl. sham), i.e. use of DeltaScan
62255890|NCT04267419||healthy Control|MDA and NO in saliva
62255891|NCT04267419||keratosis|MDA and NO in saliva
62255892|NCT04267419||leukoplakia|MDA and NO in saliva
62255893|NCT04267419||Oral lichen Planus|MDA and NO in saliva
62255894|NCT04267419||oral Squamous cell carcinoma|MDA and NO in saliva
62613413|NCT00047229|EXPERIMENTAL|G3139 in combination with Doxorubicin|
62613414|NCT01790152||Ancillary-Correlative (laboratory biomarker analysis)|Patients complete a diagnostic symptom checklist, undergo a physical exam, echocardiogram, collection of serum for biomarker testing, and a 6 minute walk test, and complete quality of life, family history, physical activity, and smoking questionnaires.
62255895|NCT00427349|EXPERIMENTAL|AMG 706+Octreotide|"Patients receive oral AMG 706 and octreotide acetate intramuscularly (IM) once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the morning. AMG 706 was taken daily without breaks in treatment.~One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles."
62838249|NCT05434416|EXPERIMENTAL|Long-term intervention: My beliefs|Participants have access to short-term interventions. Participants have access to one long-term intervention: My beliefs. Given access to all interventions at the end of the 5 weeks of the trial.
62054234|NCT06524063|EXPERIMENTAL|Survivin-loaded dendritic cell injection|Patients will undergo a combined treatment of radiotherapy and temozolomide (TMZ) for a duration of 6 weeks, with concurrent chemotherapy. After completing this phase, there will be a 4-week interval (28 days) before entering multiple cycles of adjuvant TMZ chemotherapy. Each cycle will last 28 days, involving daily oral administration of temozolomide at a dose of 150-200mg/m2 for 5 consecutive days, followed by a 23-day drug-free period. This entire cycle will be repeated every 28 days. Nine days after completing the standard 6-week concurrent chemoradiotherapy, targeted Survivin DC cell injections will be administered. The injections will be given on days 0, 14, and 28. The administration will involve both intradermal (ID) and intravenous (IV) routes.
62443701|NCT02919475|EXPERIMENTAL|JTE-051 Dose 2|One dose of study drug by mouth daily for 12 weeks
62443702|NCT02919475|EXPERIMENTAL|JTE-051 Dose 3|One dose of study drug by mouth daily for 12 weeks
62255896|NCT02667275|EXPERIMENTAL|A-101 Solution|A-101 Solution 40% administered once
62255897|NCT02667275|PLACEBO_COMPARATOR|Vehicle Solution|Vehicle Solution administered once
62255898|NCT06463691|EXPERIMENTAL|Treatment arm|Sonrotoclax, orally, 320 mg once daily following ramp-up. Zanubrutinib, orally, 320 mg total daily dose. CD20mab, which is recommended Rituximab, 375mg/m2, from C1 to C12
62255899|NCT04591730||Type I maternity|Fathers who experienced a first childbirth in a type I maternity in Lorraine.
62255900|NCT04591730||Type II maternity|Fathers who experienced a first childbirth in a type II maternity in Lorraine.
62255901|NCT04591730||Type III maternity|Fathers who experienced a first childbirth in a type III maternity in Lorraine.
62255902|NCT05855057||Flank suspended supine position percutaneous nephrolithotomy|This group included 41 patients in flank suspended supine position percutaneous nephrolithotomy.
62255903|NCT05855057||Supine percutaneous nephrolithotomy group|This group included 41 patients in supine percutaneous nephrolithotomy.
62443703|NCT02919475|EXPERIMENTAL|JTE-051 Dose 4|One dose of study drug by mouth daily for 12 weeks
62443704|NCT02919475|EXPERIMENTAL|Placebo|One dose of study drug by mouth daily for 12 weeks
62443705|NCT05043532|ACTIVE_COMPARATOR|Two passes performed during EUS-FNB of pancreatic adenocarcinoma|Once the pancreatic mass is identified on endoscopic ultrasound examination, total of two passes will be performed during find needle biopsy and placed in 10% formalin for processing for molecular profiling.
62443706|NCT05043532|ACTIVE_COMPARATOR|Three passes performed during EUS-FNB of pancreatic adenocarcinoma|Once the pancreatic mass is identified on endoscopic ultrasound examination, total of three passes will be performed during find needle biopsy and placed in 10% formalin for processing for molecular profiling.
62443707|NCT02289209|EXPERIMENTAL|Reirradiation + MK-3475|Reirradiation 1.2 Gy BID for 5 days a week for 5 weeks with MK-3475 (Keytruda, pembrolizumab) 200mg intravenous every 3 weeks until 3 months post completion of reirradiation.
62443708|NCT01712412|EXPERIMENTAL|IW-9179|Oral IW-9179 taken daily for two weeks
62443709|NCT01712412|PLACEBO_COMPARATOR|Placebo|Oral placebo taken daily for two weeks
62443710|NCT06081725|EXPERIMENTAL|Playful interactions first session in a face-to-face format|Playful interactions operationalized by dramatic improvisation techniques based on verbal and non-verbal elements in a face-to-face format. This arm will take part in the playful interactions in a face-to-face format in the first session and in the active control in the second session
62443711|NCT06081725|ACTIVE_COMPARATOR|An active control condition first session in a face-to-face format|An active control condition that involves introductory conversation and movement exercises in a face-to-face format. This arm will take part in the active control in a face-to-face format in the first session and in the playful interaction in the second session
62838250|NCT05434416|EXPERIMENTAL|Long-term intervention: Success Diary|Participants have access to short-term interventions. Participants have access to one long-term intervention: Success Diary. Given access to all interventions at the end of the 5 weeks of the trial.
62255904|NCT05855057||Prone percutaneous nephrolithotomy group|This group included 41 patients in prone percutaneous nephrolithotomy.
62255905|NCT01824992|NO_INTERVENTION|Observation|subject only got observation
62255906|NCT01824992|EXPERIMENTAL|Drug|subject were treated with Yallaferon®， the recombinant human interferon α-2b gel
62443712|NCT06081725|EXPERIMENTAL|Playful interactions first session in an online format.|Playful interactions are operationalized by dramatic improvisation techniques based on verbal and non-verbal elements in an online format. This arm will take part in the playful interactions in an online format in the first session and the online active control in the second session
62613415|NCT06105541|EXPERIMENTAL|2 Weeks Sham tAN followed by 2 Weeks Active tAN|Participants will be randomized to receive 2 weeks of at-home, self-administered sham Transcutaneous Auricular Neurostimulation (tAN), followed by 2 weeks of at-home, self-administered active Transcutaneous Auricular Neurostimulation (tAN).
62054235|NCT05168579|EXPERIMENTAL|Deliberate practice|Trainees will be paired with a coach, and will meet, once per week for thirty minutes, over a three week period. During the training session, coach-trainee dyads will play a puzzle video game, and will discuss contextual cues that should inform triage decisions. At the completion of the three weeks, trainees will complete a semi-structured, debriefing interview and a virtual simulation to assess triage performance.
62054236|NCT05168579|NO_INTERVENTION|Control|Participants in the control group will complete a virtual simulation.
62054237|NCT04956328|EXPERIMENTAL|OCA Tablets 5-10 mg|OCA 5 mg once daily in combination with UDCA for 24 weeks and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
62054238|NCT04956328|PLACEBO_COMPARATOR|Placebo|Placebo once daily in combination with UDCA for 48 weeks.
62054239|NCT00872040||Nuliparous women and their husbands|Women in their first pregnancy with their husbands
62054240|NCT02865070||2 infants (ages 1-6mo) non-NICU setting|
62054241|NCT02865070||10 babies (full term, ages 37-42 weeks)|
62054242|NCT02865070||5 babies (premature, ages 34-37 weeks)|
62054243|NCT02865070||5 babies (premature, ages 31-34 weeks)|
62255907|NCT03317470|ACTIVE_COMPARATOR|Phase I:|"* In Phase 1 of the study (first five months), the investigators will enroll new patients when they call them to remind them of their first colposcopy appointment. If patients consent, the investigators also will assess their basic needs during the call. Those who screen positive for at least one unmet basic need, will be referred to the 2-1-1 helpline at their clinic visit (or this information will be sent to them if they miss their clinic visit).~* All women enrolled in our study will be asked to complete our basic needs survey and take a follow-up survey at the time of their first colposcopy visit.~* For patients in phase 1, the follow-up survey will only assess acceptability of the basic needs survey (five questions)"
62255908|NCT03317470|EXPERIMENTAL|Phase 2:|"-In Phase 2 of the study (second five months), new colposcopy patients will be approached and consented in a similar fashion as in Phase 1 and asked to complete the basic needs survey. However, this time, patients who screen positive with at least one unmet basic need will be offered assistance by a life navigator (a trained case manager) who will contact the patients by phone within 2 business days of completing the survey.~The life navigator will connect patients with community resources in each area to help with their unmet basic needs.~* All women enrolled in our study will be asked to complete our basic needs survey and take a follow-up survey at the time of their first colposcopy visit.~* Patients enrolled in phase 2 will be asked the same five questions in addition to seven more assessing perceived effectiveness of the life navigator"
62443713|NCT06081725|ACTIVE_COMPARATOR|An active control condition first session in an online format|An active control condition that involves introductory conversation and movement exercises in an online format. This arm will take part in the active control in an online format in the first session and in the online playful interaction in the second session.
62443714|NCT05431153|EXPERIMENTAL|PF-07104091 Sequence 1|Participants randomized to Sequence 1 will receive Treatments A, B, C, and D in Periods 1 through 4, respectively in the form of tablets by mouth.
62443715|NCT05431153|EXPERIMENTAL|PF-07104091 Sequence 2|Participants randomized to Sequence 2 will receive Treatments B, C, A, and D in Periods 1 through 4, respectively in the form of tablets by mouth.
62443716|NCT05431153|EXPERIMENTAL|PF-07104091 Sequence 3|Participants randomized to Sequence 3 will receive Treatments C, A, B, and D in Periods 1 through 4, respectively in the form of tablets by mouth.
62443717|NCT05431153|EXPERIMENTAL|PF-07104091 Sequence 4|Participants randomized to Sequence 4 will receive Treatments A, B, C, and E in Periods 1 through 4, respectively in the form of tablets by mouth.
62443718|NCT05431153|EXPERIMENTAL|PF-07104091 Sequence 5|Participants randomized to Sequence 5 will receive Treatments B, C, A, and E in Periods 1 through 4, respectively in the form of tablets by mouth.
62443719|NCT05431153|EXPERIMENTAL|PF-07104091 Sequence 6|Participants randomized to Sequence 6 will receive Treatments C, A, B, and E in Periods 1 through 4, respectively in the form of tablets by mouth.
62443720|NCT05586971|EXPERIMENTAL|Tigulixostat 100mg|Tigulixostat 100mg, Once a day (QD) for up to 12 months
62838251|NCT05434416|EXPERIMENTAL|Long-term intervention: Gratitude Journal|Participants have access to short-term interventions. Participants have access to one long-term intervention: Gratitude Journal. Given access to all interventions at the end of the 5 weeks of the trial.
62838252|NCT05434416|EXPERIMENTAL|Long-term intervention: Planner|Participants have access to short-term interventions. Participants have access to one long-term intervention: Planner. Given access to all interventions at the end of the 5 weeks of the trial.
62443721|NCT05586971|EXPERIMENTAL|Tigulixostat 200mg|Tigulixostat 200mg, Once a day (QD) for up to 12 months
62443722|NCT05586971|EXPERIMENTAL|Tigulixostat 300mg|Tigulixostat 300mg (100mg + 200mg), Once a day (QD) for up to 12 months
62443723|NCT05586971|ACTIVE_COMPARATOR|Titrated allopurinol (100-800mg)|Allopurinol 100-800mg, three times a day (TID) for up to 12 months. The allopurinol dose will be increased in 100 mg increments up to 800mg.
62054244|NCT02865070||5 babies (premature, ages 28-31 weeks)|
62054245|NCT02865070||5 babies (premature, ages 25-28 weeks)|
62054246|NCT02865070||5 babies (premature, ages 23-25 weeks)|
62054247|NCT02865070||30 babies (any gestational age under 6 months)|
62613416|NCT06105541|EXPERIMENTAL|Four Weeks of Active Transcutaneous Auricular Neurostimulation|Participants will be randomized to receive 2 weeks of at-home, self-administered active Transcutaneous Auricular Neurostimulation (tAN), followed by 2 additional weeks of at-home, self-administered active Transcutaneous Auricular Neurostimulation (tAN)
62838253|NCT05434416|EXPERIMENTAL|Long-term intervention: Journey to Sobriety|Participants have access to short-term interventions. Participants have access to one long-term intervention: Journey to Sobriety. Given access to all interventions at the end of the 5 weeks of the trial.
62838254|NCT05434416|EXPERIMENTAL|Long-term intervention: Mood Journal|Participants have access to short-term interventions. Participants have access to one long-term intervention: Mood Journal. Given access to all interventions at the end of the 5 weeks of the trial.
62838255|NCT05434416|EXPERIMENTAL|Long-term intervention: Dream Diary|Participants have access to short-term interventions. Participants have access to one long-term intervention: Dream Diary. Given access to all interventions at the end of the 5 weeks of the trial.
62838256|NCT05434416|EXPERIMENTAL|Long-term intervention: Thinking traps|Participants have access to short-term interventions. Participants have access to one long-term intervention: Thinking traps. Given access to all interventions at the end of the 5 weeks of the trial.
62054248|NCT02865070||25 neonates (ages 24-29 weeks for sub-study)|
62054249|NCT05384028|EXPERIMENTAL|Experimental|Patients in the experimental group will receive full-course case management from a multidisciplinary team from admission to 6 months after discharge
62255909|NCT00415857|EXPERIMENTAL|PR1 + Imatinib|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses. Continue receiving imatinib by mouth at the same dose received during the last 6 months. GM-CSF 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
62613417|NCT04291365|OTHER|Normal weight|
62613418|NCT04291365|OTHER|Obesity Class 1|
62613419|NCT04291365|OTHER|Obesity Class 2|
62054250|NCT05384028|ACTIVE_COMPARATOR|Control|Patients in the control group will receive routine inpatient care and post-discharge follow-up management
62054251|NCT03078816|EXPERIMENTAL|DBS active|"All participants will be enrolled in DBS placement and active stimulation. The following components will be used:~* Activa PC Primary Cell Neurostimulator - (Model 37601)~* Activa RC Rechargeable Neurostimulator - (Model 37612)~* Activa SC Single Cell Neurostimulator (Models 37602 and 37603)~* DBS Lead - (Model 3387)~* DBS Extension - (Models 37085/6)~* Patient Programmer - (Model 37642)~* Test Stimulator - (Model 3625)~* N'Vision Clinician Programmer - (Model 8840)~* N'Vision Software Application Card - (Model 8870)"
62054252|NCT04333420|EXPERIMENTAL|Phase II: IFX-1 + BSC|Phase II study part: IFX-1: 800mg intravenously administered, BSC: Best supportive care
62613420|NCT04291365|OTHER|Obesity Class 3|
62613421|NCT02623608|EXPERIMENTAL|High fat meal|Subjects eat a high fat breakfast (reference breakfast) at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h.
62054253|NCT04333420|OTHER|Phase II: BSC|Phase II study part: BSC: Best supportive care
62054254|NCT04333420|EXPERIMENTAL|Phase III: IFX-1 + SOC|Phase III study part: IFX-1: 800mg intravenously administered, SOC: Standard of care
62054255|NCT04333420|PLACEBO_COMPARATOR|Phase III: Placebo + SOC|Phase III study part: Placebo: placebo infusion intravenously administered, SOC: Standard of care
62838257|NCT03345784|EXPERIMENTAL|Treatment (radiation therapy, adavosertib, cisplatin)|Patients undergo external beam radiation therapy on days 1-5 and receive adavosertib PO on days 1, 3, and 5 or QD on days 1-5 and cisplatin IV over 1 hour on day 1 or 3. Cycles repeat each week for up to 5 weeks in the absence of disease progression of unacceptable toxicity.
62838258|NCT01271985|ACTIVE_COMPARATOR|PolyPill|PolyPill once daily and Minimal Care
62838259|NCT01271985|ACTIVE_COMPARATOR|Minimal care|Minimal care.
62838260|NCT01271985|NO_INTERVENTION|Usual care|Basic primary health care provided by the local physicians and Community Health Workers consistent with the current Iranian Health Care System guidelines.
62838261|NCT02763501|ACTIVE_COMPARATOR|RCT|"patients operated with laparoscopic gastric bypass surgery within a register based RCT from May 1st 2010 until Nov 14th 2011.~1:1 randomization to closure of mesenteric defects by running, non-absorbable sutures"
62443724|NCT05586971|PLACEBO_COMPARATOR|Placebo|Placebo, three times a day (TID) for up to 6 months.
62443725|NCT01625377|ACTIVE_COMPARATOR|Tacrolimus|From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids. From randomization to month 6 : tacrolimus (C0 6-10 ng/ml) + mycophenolic acid 1440 mg/d ± oral corticosteroids
62838262|NCT02763501|ACTIVE_COMPARATOR|non-RCT|"patients operated with laparoscopic gastric bypass surgery outside of the RCT from May 1st 2010 until Nov 14th 2011.~Intervention of mesenteric defects according to local tradition or choice of surgeon (non-randomized)"
62054256|NCT01222195|EXPERIMENTAL|Lenalidomide + Darbepoetin alfa|Lenalidomide 10 mg/day orally days 1-21 and Darbepoetin alfa 200 mcg subcutaneously every 2 weeks of 28 day cycle
62054257|NCT02930473|EXPERIMENTAL|Psychotherapeutic Intervention(s) for Anxiety|"People diagnosed with Anxiety (according to ICNP/NANDA standardized nursing language) will be treated using Nursing Interventions Classification (NIC) psychotherapeutic intervention(s) for anxiety (plus psychopharmaceuticals)."
62054258|NCT02930473|ACTIVE_COMPARATOR|Treatment-as-Usual for Anxiety|"People diagnosed with Anxiety (according to ICNP/NANDA standardized nursing language) will receive treatment as usual for anxiety (psychopharmaceuticals)."
62255910|NCT00415857|EXPERIMENTAL|PR1 + Imatinib + Interferon|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses. Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination. GM-CSF 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
62255911|NCT04810182||Glioblastoma Patients treated with Regorafenib|Patients with a confirmed diagnosis of Glioblastoma for whom a decision to treat with regorafenib has been made (by the treating physician).
62255912|NCT05753267|ACTIVE_COMPARATOR|Control Group|Mesalamine group will receive 1 g mesalamine three times daily for 6 months
62443726|NCT01625377|EXPERIMENTAL|Everolimus (RAD001)|"From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids.~From randomization to month 6 : everolimus (recommended starting dose of 2 mg/day, then adjusted to achieve the target 6 ≤ C0 ≤ 10 ng/mL, until W24) + mycophenolic acid 1440 mg/d ± oral corticosteroids. The dose of tacrolimus was reduced by 50% twice: at the introduction of everolimus and at week 8 post-transplantation. Tacrolimus had to be finally discontinued in week 12 post-transplantation (by week 16 at the latest)."
62838263|NCT02724618|EXPERIMENTAL|Curcumin plus RT|120mg/day nanocurcumin during RT course
62838264|NCT02724618|PLACEBO_COMPARATOR|Placebo plus RT|120mg/day placebo of nanocurcumin during RT course
62255913|NCT05753267|ACTIVE_COMPARATOR|Fenofibrate group|Fenofibrate group will receive 1 g mesalamine three times daily plus Fenofibrate (160 mg/day) for 6 months
62838265|NCT06009848|EXPERIMENTAL|Cadonilimab (AK104) combined with Nab -Paclitaxel|Cadonilimab (10 mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+Nab-Paclitaxel(200 mg/m2, Q3W, 6cycles), every 3 weeks (21 days) is a treatment cycle
62255914|NCT05803200||HyQvia|Pregnant female participants who have insurance coverage with full prescriptions benefits exposed to HyQvia during the period from 90 days before the last menstrual period (LMP) through 30 days after delivery will be observed retrospectively from 1 January 2014 to 31 December 2020 (up to 7 years).
62255915|NCT05094791||Telescoping Lag Screw|Intertrochanteric fractures treated with Arthrex Hip Nail with Telescoping Screw
62255916|NCT05094791||Standard lag Screw|Intertrochanteric fractures treated with Zimmer Natural Nail Cephalomedullary Nail
62255917|NCT05094791||Standard lag screw with addition of worm screw|Intertrochanteric fractures treated with Smith and Nephew TRIGEN INTERTAN
62255918|NCT05261763|ACTIVE_COMPARATOR|Group A|Group A will receive trigger point dry needling in quadricep muscles
62255919|NCT05261763|SHAM_COMPARATOR|Group B|Group B will get Sham needling in quadriceps muscles
62054259|NCT03841045||ulcerative colitis patient|people that have UC diagnosis can participate in the study. the disease can be at any level and the patients can handle any medications.
62255920|NCT05166629|OTHER|Usual Care|Usual care in the POWER Kids weight management program includes a nutrition assessment and education by a registered dietician nutritionist (RD). This includes taking a detailed dietary history, and providing individualized counseling, motivational interviewing, and nutrition education handouts/ web-based resources.
62255921|NCT05166629|EXPERIMENTAL|Eatable Alphabet|The intervention group will receive usual care, as described above, plus a set of Eatable Alphabet cards, which will be utilized during the visit for counseling and education, and given to the family to take home and use as they wish.
62255922|NCT02953639|PLACEBO_COMPARATOR|Placebo|Participants received matching Placebo to Basmisanil orally twice daily for 24 weeks.
62443727|NCT01790620|EXPERIMENTAL|CVVHD-ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVHD with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVHD. No citrate anticoagulation will be used.
62054260|NCT03841045||CD patient|people that have CD diagnosis can participate in the study. the disease can be at any label and the patients can handle any medications.
62054261|NCT03841045||Health people|control group. no IBD patients can be included. patients with other diseases can be included.
62255923|NCT02953639|EXPERIMENTAL|Basmisanil 80mg BID|Participants received Basmisanil 80 mg orally twice daily (BID) for 24 weeks.
62443728|NCT01790620|ACTIVE_COMPARATOR|CVVH-ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVH with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVH. No citrate anticoagulation will be used.
62255924|NCT02953639|EXPERIMENTAL|Basmisanil 240mg BID|Participants received Basmisanil 240 mg orally twice daily (BID) for 24 weeks.
62443729|NCT04925206|EXPERIMENTAL|ET-01|
62443730|NCT02509000|ACTIVE_COMPARATOR|Active-mode|Air purifier in active-mode
62613422|NCT02623608|EXPERIMENTAL|High fat meal + Active Ingredient 1|"Subjects eat the same high fat breakfast with the active ingredient 1 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
62613423|NCT02623608|EXPERIMENTAL|High fat meal + Active Ingredient 2|"Subjects eat the same high fat breakfast with the active ingredient 2 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
62838266|NCT03473509|EXPERIMENTAL|Chronic Kidney Disease (CKD) Registry|The CKD registry provided primary care practice teams with point-of-care data about patient-specific CKD status, recent ambulatory clinic blood pressure (BP) readings, status of Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) prescription, and quantification of albuminuria (UACR). It also provided data about diabetes care, immunization status, and data pertinent to age appropriate cancer screening, to align with usual care. Point-of-care decision support reminded primary care providers (PCPs) about guideline concordant care for individuals with CKD. Quarterly feedback to practice teams and individual PCPs identified patients with CKD and BP \>140/90 mmHg, those not prescribed an ACEi/ARB, and those with albuminuria.
62054262|NCT04068350||Single arm|The evaluation at 3 months of the postoperative pain will be carried out without the information collected in preoperative and immediate postoperative.
62255925|NCT00528021|ACTIVE_COMPARATOR|1|Subjects are treated either once (day1) or twice (day 1 and 7) with either placebo or 2.5% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair.
62255926|NCT00528021|ACTIVE_COMPARATOR|2|Subjects are treated either once (day1) or twice (day 1 and 7) with either placebo or 10% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair.
62255927|NCT00528021|ACTIVE_COMPARATOR|3|Subjects are treated either once (day1) or twice (day 1 and 7) with either placebo or 12.5% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair.
62255928|NCT00528021|PLACEBO_COMPARATOR|4|
62054263|NCT00213655||Daily instillation of BCG for 3 weeks then every 6 months|Effect of daily instillation of BCG (27 mg) for 3 weeks then one instillation of BCG (27 mg) every 6 months for 36 months on bladder tumor recurrence
62054264|NCT00213655||Daily instillation of BCG for 2 weeks then every 3 months|Effect of daily instillation of BCG (27 mg) for 2 weeks then one instillation of BCG (27 mg) every 3 months for 36 months on bladder tumor recurrence
62054265|NCT03839654|EXPERIMENTAL|continuous positive airway pressure|The CPAP treatment group received both baseline medicine and CPAP treatment for 7 days preoperatively.
62054266|NCT03839654|NO_INTERVENTION|non-continuous positive airway pressure|The non-CPAP treatment group received baseline medicine treatment without CPAP treatment.
62054267|NCT01843998|EXPERIMENTAL|Sirolimus 0.1% ointment|Sirolimus 0.1% ointment
62054268|NCT03404492|OTHER|Patients with pulmonary hypertension|
62255929|NCT01961349|PLACEBO_COMPARATOR|Group 1|Group 1 (placebo group) is treated by Anaesthesiologist
62255930|NCT01961349|ACTIVE_COMPARATOR|Group 2|Group 2 (ICI35,868 without EES0000645/A) is treated by Anaesthesiologist
62255931|NCT01961349|ACTIVE_COMPARATOR|Group 3|Group 3 (ICI35,868 with EES0000645/A) is treated by Endoscopist
62255932|NCT05584670|EXPERIMENTAL|SAR445877 Escalation Phase (Part 1)|SAR445877 monotherapy will be administered intravenously in patients with solid tumors over a 14-day cycle.
62443731|NCT02509000|SHAM_COMPARATOR|Sham-mode|Air purifier in sham-mode
62613424|NCT02623608|EXPERIMENTAL|High fat meal + Active Ingredient 3|"Subjects eat the same high fat breakfast with the active ingredient 3 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
62255933|NCT05584670|EXPERIMENTAL|SAR445877 Expansion/Optimization Phase: Cohort A1 (Part 2A)|SAR445877 monotherapy will be administered intravenously (IV) in patients with non-small cell lung cancer (NSCLC).
62838267|NCT03473509|NO_INTERVENTION|Usual Care Registry|Usual care consisted of an electronic registry that was in use before trial implementation. It provided practice teams with point-of-care data about diabetes care, age-appropriate cancer screening and immunizations, but no CKD-related data. Medical assistants were encouraged to use the usual care registry to identify patients who were due for cancer screening or immunizations. Quarterly feedback was not provided for practice teams randomized to receive usual care.
62838268|NCT01771289|EXPERIMENTAL|chemoradiation|
62255934|NCT05584670|EXPERIMENTAL|SAR445877 Expansion/Optimization Phase: Cohort A2 (Part 2A)|SAR445877 monotherapy will be administered intravenously in patients with non-small cell lung cancer (NSCLC).
62255935|NCT05584670|EXPERIMENTAL|SAR445877 Expansion/Optimization Phase: Cohort B (Part 2A)|SAR445877 monotherapy will be administered IV in patients with hepatocellular carcinoma (HCC).
62255936|NCT05584670|EXPERIMENTAL|SAR445877 Expansion/Optimization Phase: Cohort C1 (Part 2A)|SAR445877 monotherapy will be administered IV in patients with gastric cancer/gastro esophageal junction adenocarcinoma (GC/GEJ).
62255937|NCT05584670|EXPERIMENTAL|SAR445877 Expansion/Optimization Phase: Cohort C2 (Part 2A)|SAR445877 monotherapy will be administered IV in patients with gastric cancer/gastro esophageal junction adenocarcinoma (GC/GEJ).
62255938|NCT05584670|EXPERIMENTAL|SAR445877 Expansion/Optimization Phase: Cohort D (Part 2A)|SAR445877 monotherapy will be administered IV in patients with immune infiltrated tumor type.
62255939|NCT05584670|EXPERIMENTAL|SAR445877 Expansion/Optimization Phase: Cohort E1 (Part 2A)|SAR445877 monotherapy will be administered IV in patients with colorectal cancer (CRC).
62255940|NCT05584670|EXPERIMENTAL|SAR445877 Expansion/Optimization Phase: Cohort E2 (Part 2A)|SAR445877 monotherapy will be administered IV in patients with colorectal cancer (CRC).
62443732|NCT03443869|EXPERIMENTAL|Letermovir|LET 480mg (or 240 mg when administered concomitantly with cyclosporin A) tablet orally; placebo to VGCV tablet orally once daily; and 400 mg capsule of acyclovir (ACV) orally every 12 hours for 28 weeks
62443733|NCT03443869|ACTIVE_COMPARATOR|Valganciclovir|900 mg VGCV tablet orally, once daily; placebo to LET tablet orally once daily; and placebo to ACV orally every 12 hours for 28 weeks
62613425|NCT02623608|EXPERIMENTAL|High fat meal + Active Ingredient 4|"Subjects eat the same high fat breakfast with the active ingredient 4 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
62838269|NCT00658125|EXPERIMENTAL|Experimental|
62838270|NCT02182752|ACTIVE_COMPARATOR|Ropivacaine - Tramadol|
62838271|NCT02182752|ACTIVE_COMPARATOR|Ropivacaine|
62838272|NCT01117363|EXPERIMENTAL|Rye porrige breakfast|
62838273|NCT01117363|ACTIVE_COMPARATOR|Refined wheat reference bread breakfast|
62838274|NCT00642083|EXPERIMENTAL|1|viabahn stent-graft
62838275|NCT01584440|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo during Stage 1 and Stage 2 of the study.
62838276|NCT01584440|EXPERIMENTAL|AVP-923|Participants will receive AVP-923-20 and AVP-923-30 in a sequential manner during Stage 1 and Stage 2 of the study.
62838277|NCT01584440|EXPERIMENTAL|Placebo then AVP-923|Participants will receive placebo in Stage 1 followed by AVP-923 in Stage 2.
62838278|NCT00000258|ACTIVE_COMPARATOR|Informed group|Group inhaled placebo and varying doses of nitrous oxide in pairs then chose which they wanted for a third inhalation.
62838279|NCT00000258|ACTIVE_COMPARATOR|Non-informed Group|Group and technician were blinded as to which gas they were inhaling in pairs with third inhalation subject's choice.
62838280|NCT01774396|OTHER|group 2|The intervention will be the injection of Emervel® Volume Lidocaine alone in the dorsa of one hand and Emervel® Deep Lidocaine alone in the dorsa of the contralateral hand.
62054269|NCT04236258|ACTIVE_COMPARATOR|Nifedipine|This arm will be postpartum women with high blood pressure who need an antihypertensive and have been assigned to start nifedipine extended release 30 mg daily as their starting antihypertensive.
62613426|NCT01425606||blood test|to measure levels of sodium, albumin and acid - base status in venous blood
62838281|NCT01774396|EXPERIMENTAL|group 1|EThe intervention will be the injection of mervel® Volume Lidocaine plus Emervel® Touch in the dorsa of one hand and Emervel® Deep Lidocaine plus Emervel® Touch in the dorsa of the contralateral hand
62838282|NCT01982656|EXPERIMENTAL|Massage technique|In addition to standard medical care and pharmacologic interventions, massage technique for 20 minutes for 5 to 14 days while in the ICU will be provided to help alleviate pain and anxiety in the patient.
62838283|NCT01982656|PLACEBO_COMPARATOR|No intervention|Patients with an aneurysmal subarachnoid hemorrhage will receive standard medical care to include pharmacologic interventions prescribed by the primary physician and nonpharmacologic interventions provided by the bedside RN such as ice or heat to address their pain and anxiety needs.
62838284|NCT05000255|EXPERIMENTAL|Intervention 1: According to DGP|For the first group, a psychological intervention for psychoeducational measures and psychosocial support, was designed according to the recommendations of the DGP - Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V. for the rehabilitation of post-COVID-19 patients (DGP, 2020). The interventions start approximately two days after data collection at T0. The second measurement time point (T1) is scheduled at the time of patient discharge after the interventions have been implemented. Only patients who scored 8 or higher on the Hospital Anxiety and Depression Scale (HADS) at admission will participate in the interventions. This psychological intervention will be applied to both groups of patients (non-Covid/Covid patients)
62838285|NCT05000255|ACTIVE_COMPARATOR|"Intervention 2: According to Cacioppo E.A.S.E."|The second intervention was designed after Cacioppo's intervention EASE, for processing loneliness. This psychological intervention will be applied to both groups of patients (non-Covid/Covid patients), too. The interventions start approximately two days after data collection at T0. The second measurement time point (T1) is scheduled at the time of patient discharge after the interventions have been implemented. Only patients who scored 8 or higher on the Hospital Anxiety and Depression Scale (HADS) at admission will participate in the interventions.
62838286|NCT05000255|NO_INTERVENTION|Care as Usual; Standard psychological Support|The patients receive standard care from the psychologists, as is usual in this unit. No intervention is carried out.
62054270|NCT04236258|ACTIVE_COMPARATOR|Enalapril|This arm will be postpartum women with high blood pressure who need an antihypertensive and have been assigned to start enalapril 10 mg daily as their starting antihypertensive.
62054271|NCT01747590|EXPERIMENTAL|Zolpidem, Alprazolam, Caffeine, and Placebo|The 4 medications are given in a counterbalanced design.
62838287|NCT02970162|EXPERIMENTAL|amifampridine phosphate|amifampridine phosphate 10 mg (amifampridine equivalent) by mouth, 30 to 80 mg total daily dose, 3 to 4 times per day for 4 days
62054272|NCT06349148|EXPERIMENTAL|immunonutrition|enteral immunonutrition
62054273|NCT06349148|ACTIVE_COMPARATOR|standard nutrition|standard oral enteral nutrition
62054274|NCT05795530||Cochlear implant recipients|57 consecutive cochlear implant recipients
62443734|NCT04034030|EXPERIMENTAL|Treatment Group|This study will be conducted over one year in 10 focal CSWS patients ranging in age from 3 to 21 years. The patients will be recruited from the large patient population that is served by the Children's Mercy Comprehensive Epilepsy Monitoring Unit (EMU) in Overland Park, Kansas. Subjects will be identified from these EMU patient population. Those meeting inclusion criteria will be approached for possible enrollment. Inclusion criteria will be defined by patients that were diagnosed with focal CSWS in accordance with the ILAE classification with SWI \>85% during NREM sleep on their previous or most recent EEG. Patients and their parents/guardians will provide assent/consent for participation in the study after being briefed on the nature of the study, by reading and signing assent and assent/consent forms, respectively
62443735|NCT06404697|EXPERIMENTAL|High-risk|High-risk patients will undergo boost irradiation to the SCV with a cumulative dose of ≥60 Gy.
62443736|NCT04109027|EXPERIMENTAL|BrainStrong-GSR|Goal-directed State Regulation Training (GSR)
62443737|NCT04109027|ACTIVE_COMPARATOR|BrainStrong-OPT|Optimization of Brain Functioning (OPT)
62443738|NCT03811197|EXPERIMENTAL|individual MNT|Dietary counseling via face to face meeting
62838288|NCT02970162|PLACEBO_COMPARATOR|placebo (for amifampridine phosphate)|placebo by mouth 3 to 4 times per day for 4 days
62838289|NCT01421719|EXPERIMENTAL|botulinum toxin treatment|botulinum toxin treatment Injection of Botox into urinary bladder for neurogenic symptoms.
62838290|NCT01492335|EXPERIMENTAL|Cognitive Report|Primary care physicians in the Cognitive Report group receive the results of their patients cognitive testing together with clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations.
62838291|NCT01492335|EXPERIMENTAL|Treatment As Usual|Physicians in the Treatment As Usual Group do not receive the results of their patients cognitive assessment, they do not receive treatment recommendations, nor are they told of the patients diagnosis (Normal, Mild Cognitive Impairment, Dementia)
62054275|NCT03075059|EXPERIMENTAL|Intervention|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
62255941|NCT05584670|EXPERIMENTAL|SAR445877 Expansion/Optimization Phase: Cohort E3 (Part 2B)|SAR445877 will be administered IV in combination with cetuximab in patients with colorectal cancer (CRC).
62255942|NCT01304095|ACTIVE_COMPARATOR|Ranolazine|Ranolazine in addition to standard of care medical therapy
62255943|NCT01304095|NO_INTERVENTION|Standard of Care|
62255944|NCT00299962|EXPERIMENTAL|Dose level 4|
62443739|NCT03811197|EXPERIMENTAL|Individual MNT and T|Dietary counseling via face to face meeting and Telemedicine
62443740|NCT03811197|EXPERIMENTAL|Individual MNT and HS|Dietary counseling via face to face meeting and Hypnotic Suggestions
62838292|NCT06437041|EXPERIMENTAL|Treatment|Patients will receive three enemas of ornidazole 0.5g+50ml saline through the TET tube, followed by WMT once daily for a duration of 3 days.
62838293|NCT06437041|PLACEBO_COMPARATOR|Control|Patients will receive three enemas of a placebo of equal volume through the TET tube, followed by WMT once daily for a duration of 3 days.
62838294|NCT04359316|EXPERIMENTAL|Azithromycin|
62613427|NCT05967923|EXPERIMENTAL|Group (a)|Patients in this group will receive shock wave therapy once a week for four weeks in addition to routine physical therapy program.
62255945|NCT00299962|EXPERIMENTAL|Dose level 5|
62443741|NCT05055791|EXPERIMENTAL|Arm 1|Cohort 1-3 dose level 1-3 in subjects with relapsed or refractory haematological malignancies including AML/ALL/CMML/CLL.
62838295|NCT04359316|ACTIVE_COMPARATOR|Hydroxychloroquine|
62838296|NCT02902861|ACTIVE_COMPARATOR|methotrexate|Once weekly (every 7 days) s.c. administration of 17.5 mg MTX. If PASI50 is not reached after 8 weeks (week 8) or PASI75 is not reached after 24 weeks, the dosing will be increased to 22.5 mg MTX/week. If patients were already dosed with 22.5 mg MTX/week in week 24 and PASI50 is not reached, patients will be excluded from treatment. Primary endpoint after 16 weeks.
62443742|NCT05055791|EXPERIMENTAL|Arm 2|Cohort 1-3 dose level 1-3 in subjects with relapsed or refractory haematological malignancies including AML/ALL/CMML/CLL.
62613428|NCT05967923|EXPERIMENTAL|Group (b)|Patients in this group will receive low level lazer therapy three times per week for four weeks in addition to routine physical therapy program.
62443743|NCT02984839||Intra-abdominal surgery group|"The study population will include patients presenting for elective or non-elective intra-abdominal surgery requiring general anesthesia with neuromuscular blockade at OhioHealth Doctors Hospital.~Quantitative TOF will be recorded by Stimpod NMS450 in PACU."
62613429|NCT05967923|EXPERIMENTAL|Group (c)|Patients in this group will receive only routine physical therapy program.
62443744|NCT02984839||Non-intra-abdominal surgery group|"The study population will include patients presenting for elective or non-elective non intra-abdominal surgery requiring general anesthesia with neuromuscular blockade at OhioHealth Doctors Hospital.~Quantitative TOF will be recorded by Stimpod NMS450 in PACU."
62443745|NCT02272348|EXPERIMENTAL|Education to functional insulin therapy immediately|Immediately after inclusion, patients will follow a functional insulin therapy training course during 2.5 days.
62613430|NCT02800941||Oral anticoagulant treatment|Patients with pulmonary hypertension are treated with oral anticoagulants according to the usual practice. Patients have follow-up at 3, 6 and 12 months.
62613431|NCT00827658|ACTIVE_COMPARATOR|Hypothenar Palm block|Hypothenar Palmar block group. Local anesthetic is placed at this location in this study group. The same local composition (Intervention) is used for both study groups. The trial is a comparison of location not the Intervention.
62613432|NCT00827658|ACTIVE_COMPARATOR|Volar Wrist Block|Volar Wrist block group. Local anesthetic is placed at this location in this study group. The same local composition (Intervention) is used for both study groups. The trial is a comparison of location not the Intervention.
62613433|NCT01163006|EXPERIMENTAL|polydextrose|
62613434|NCT01163006|EXPERIMENTAL|soluble glucofibre|
62613435|NCT01163006|PLACEBO_COMPARATOR|isocaloric dietary control|
62613436|NCT01163006|PLACEBO_COMPARATOR|full caloric control|
62613437|NCT01981148||Healthy patients|Healthy patients
62838297|NCT02902861|PLACEBO_COMPARATOR|Placebo (NaCl-Solution)|Once weekly (every 7 days) s.c. administration of 0.35 mL placebo If PASI50 is not reached after 8 weeks (week 8), the dosing will be increased to 0.45 mL placebo/week. Primary endpoint after 16 weeks. After 16 weeks patients will receive 17.5 mg MTX / week. If PASI50 is not reached after 8 weeks of MTX treatment (week 24), uptitration to 22.5 mg MTX/ 0.45 mL Plac / week will be done. Patients, who will reach PASI75 under placebo treatment after 16 weeks, will be dosed neither with placebo nor with MTX until relapse. After relapse the patients will be dosed with a starting dose of 17.5 mg MTX / week.
62838298|NCT02912689|EXPERIMENTAL|Neurally adjusted ventilator assist|Neurally adjusted ventilator assist (NAVA) during NIV for exacerbation of COPD.
62838299|NCT02912689|ACTIVE_COMPARATOR|Pressure support ventilation|Pressure support ventilation (PSV) during NIV for exacerbation of COPD.
62838300|NCT03554564|EXPERIMENTAL|VOICE/Fitbit|VOICE enrollment with Fitbit walking activity tracking. During the VOICE phase, participants will use the digital health platform that integrates PAD-specific educational content, surveys, and Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase).
62838301|NCT03554564|OTHER|Daily self-reported exercise adherence|Usual care prescribed by physician (walking exercise instructions). During the Usual Care control phase, participants will conduct walking exercise based on instructions received in clinic. Walking exercise will be tracked and self-reported by participants, using a written calendar log. Participants will not have access to the VOICE platform, or use of Fitbit technology during this phase.
62838302|NCT02145013||Portal hypertension|Hepatectomy
62838303|NCT02145013||No portal hypertension|Hepatectomy
62838304|NCT04847336||Women|Women of any age who gave births in hospitals from WHO European Region, from 1 march 2020
62443746|NCT02272348|OTHER|No education to functional insulin therapy immediately|After inclusion in the study, patients go on usual diabetes management. At the end of study, they will receive education to functional insulin therapy.
62443747|NCT02139683|EXPERIMENTAL|HIFU treatment|HIFU treatment in patient diagnosed with fibroadenoma
62255946|NCT00299962|EXPERIMENTAL|Dose Level 1|on Days 1 and 15
62255947|NCT00299962|EXPERIMENTAL|Dose Level 2|On Days 1 and 15
62255948|NCT00299962|EXPERIMENTAL|Dose Level 3|On Days 1 and 15
62255949|NCT05801328|EXPERIMENTAL|Occlusal ending of wires|The wires will be bent occlusally for the interventional side
62255950|NCT05801328|NO_INTERVENTION|Apical ending of wires|The wires will be bent apically for the control side.
62255951|NCT01752751||Cancer Patients Age 65 or above|Cancer patients age 65 years or above with a diagnosis of head and neck cancer or lung cancer with radiotherapy or chemoradiotherapy planned as part of curative standard treatment.
62443748|NCT05079854|ACTIVE_COMPARATOR|INTRACAMERAL MOXIFLOXACIN|After the surgery, the antibiotic is intracameral administered, Moxifloxacin 0.5% 0.1mL.
62443749|NCT05079854|ACTIVE_COMPARATOR|TOPICAL MOXIFLOXACIN|After the surgery, the antibiotic is topical administered, Moxifloxacin 0.5% 0.1mL.
62443750|NCT03509298|EXPERIMENTAL|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
62443751|NCT03509298|ACTIVE_COMPARATOR|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length\<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
62443752|NCT03509298|NO_INTERVENTION|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62054276|NCT03075059|NO_INTERVENTION|Control|Patients randomized to the control group will not receive the preoperative phone call or written materials and will only receive SOC Child Life services on the day of surgery.
62838305|NCT04847336||Health workers|Health workers directly involved in assistance at childbirth (pregnancy, childbirth and peripartum) at hospital level in WHO European Region, from 1 march 2020
62054277|NCT00844857|EXPERIMENTAL|Olanzapine/Fluoxetine Combination|
62613438|NCT01981148||Patients with various retinal diseases|Various retinal diseases (vascular, hereditary, degenerative)
62838306|NCT02453711|EXPERIMENTAL|Sema 0.05 mg|Dose 0.05 mg
62838307|NCT02453711|EXPERIMENTAL|Sema 0.1 mg|Dose 0.05 or 0.1 mg with dose escalation every fourth week
62255952|NCT04755075|EXPERIMENTAL|Cohort 1|Subjects with Normal Hepatic Function: All patients to receive study drug (Surufatinib 250mg) on Day 1
62054278|NCT00844857|PLACEBO_COMPARATOR|Placebo|
62255953|NCT04755075|EXPERIMENTAL|Cohort 2|Subjects with Moderate Hepatic Impairment: All patients to receive study drug (Surufatnib 250mg) on Day 1
62054279|NCT03991117|EXPERIMENTAL|80 %1RM, Regular Tempo|Participants performed three sets of unilateral knee extension with a load that was 80 % of their one-repetition maximum (1RM) at a tempo of three seconds per repetition.
62054280|NCT03991117|EXPERIMENTAL|80 %1RM, Slow Tempo|Participants performed three sets of unilateral knee extension with a load that was 80 % of their one-repetition maximum (1RM) at a tempo of seven seconds per repetition.
62054281|NCT03991117|EXPERIMENTAL|30 %1RM, Regular Tempo|Participants performed three sets of unilateral knee extension with a load that was 30 % of their one-repetition maximum (1RM) at a tempo of three seconds per repetition.
62054282|NCT03991117|EXPERIMENTAL|30 %1RM, Slow Tempo|Participants performed three sets of unilateral knee extension with a load that was 30 % of their one-repetition maximum (1RM) at a tempo of seven seconds per repetition.
62054283|NCT05383664|EXPERIMENTAL|Clinical Screening|Subjects will be screened for systemic blood markers responsive to 3-4 subsequent UV exposure over the course of 4-5 laboratory visits over the course of one week.
62054284|NCT01320332|EXPERIMENTAL|ASP3291 low dose|
62443753|NCT02100865|EXPERIMENTAL|Solar powered oxygen|Solar panels used to drive an oxygen concentrator to deliver at stream of oxygen at approximately 90% FiO2 and a rate of 1-5L/min.
62443754|NCT02100865|ACTIVE_COMPARATOR|Oxygen from cylinders|Conventional oxygen delivery from compressed gas cylinders
62054285|NCT01320332|EXPERIMENTAL|ASP3291 high dose|
62054286|NCT01320332|PLACEBO_COMPARATOR|Placebo|
62054287|NCT02100774||healthy male adults|no added micronutrient, tomato puree, lutein supplement, vitamin E supplement, vitamin D supplement
62054288|NCT05826925|EXPERIMENTAL|Decision aid|Participants will use the decision aid in the postpartum period
62054289|NCT05826925|NO_INTERVENTION|Usual care|Participants will receive standard postpartum care
62054290|NCT00790452|ACTIVE_COMPARATOR|Group 1 (Aspirin)|Aspirin 325 mg/day orally
62255954|NCT04755075|EXPERIMENTAL|Cohort 3 (if enrolled)|Subjects with Mild Hepatic Impairment: All patients to receive study drug (Surufatnib 250mg) on Day 1
62443755|NCT06015373|EXPERIMENTAL|Patients with CSPH receiving carvedilol twice daily and supress the night dose of carvedilol|In this experimental study, 34 patients with CSPH receiving carvedilol twice daily were asked to supress the night dose of carvedilol, in order to have a dose interval of approximately 24 hours. Spleen stiffness measurement (SSM) by transient elastography (TE) was performed and compared with SSM prior or under treatment. Same procedure was applied to liver stiffness measurement (LSM).
62613439|NCT05805605|EXPERIMENTAL|Cy/Flu/TBI + Post transplant CY|
62613440|NCT04426669|EXPERIMENTAL|CISH CRISPR TIL / Phase I Arm|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +escalating doses of CISH inactivated TIL + high-dose aldesleukin
62255955|NCT04967079|EXPERIMENTAL|Trametinib + Anlotinib|Anlotinib given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) plus trametinib 2 milligrams (mg) given orally, once daily.
62255956|NCT06453811|EXPERIMENTAL|Experimental Group|Couples assigned to the experimental group will be included in a three-week program, attending a self-efficacy theory-based childbirth preparation program in groups of 4-5 couples, scheduled according to their availability. At the end of the sessions, brochures reflecting the educational content will be given to the couples to read at home. These couples will also receive routine care provided at the hospital, which includes standard antenatal follow-up and information about pregnancy and childbirth during physician visits. After the completion of the training, couples will receive weekly phone calls until their estimated due date to reinforce the educational content.
62838308|NCT02453711|EXPERIMENTAL|Sema 0.2 mg|Dose 0.05, 0.1 or 0.2 mg with dose escalation every fourth week
62838309|NCT02453711|EXPERIMENTAL|Sema 0.3 mg|Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every fourth week
62838310|NCT02453711|EXPERIMENTAL|Sema 0.4 mg|Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every fourth week
62838311|NCT02453711|EXPERIMENTAL|Sema 0.3 mg (fast dose escalation)|Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every second week
62443756|NCT05432271|ACTIVE_COMPARATOR|Control|Calorie labels shown on front of product packaging
62443757|NCT05432271|EXPERIMENTAL|Green labels|"Green label added to front of product packaging for healthy products; no additional labels shown for less healthy products"
62838312|NCT02453711|EXPERIMENTAL|Sema 0.4 mg (fast dose escalation)|Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every second week
62255957|NCT06453811|NO_INTERVENTION|Control Group|No additional intervention will be provided to couples in the control group, and they will receive the routine care provided at the hospital. This routine care includes standard antenatal follow-ups, during which pregnant women and their spouses receive information about pregnancy and childbirth only during physician examinations.
62255958|NCT01329679|EXPERIMENTAL|Energy Drink|Energy drink, 2 oz twice daily for 7 days
62443758|NCT05432271|EXPERIMENTAL|Traffic light labels|Red/yellow/green labels added to front of product packaging for less healthy/moderately healthy/healthy products, respectively
62054291|NCT00790452|PLACEBO_COMPARATOR|Group 2 (Placebo)|Tablet/day orally
62054292|NCT04462666|EXPERIMENTAL|HZG intervention|During the 5-day treatment period, participants in the Experimental group will receive 10 sacks of experimental granules. They will be instructed to take two sacks per day, one in the morning and one in the evening, in approximately 30 minutes after the meal.. The placebo etoricoxib will also be taken daily in the morning for 5 days.
62054293|NCT04462666|ACTIVE_COMPARATOR|Etoricoxib intervention|During the 5-day treatment period, participants in the Etoricoxib group will receive 5 Etoricoxib capsules. They will be instructed to take one capsule per day in the morning, at approximately 30 minutes after the meal. The placebo HZKL will also be taken daily in the morning for 5 days.
62443759|NCT05432271|EXPERIMENTAL|Physical activity calorie equivalent labels|Labels added to front of product packaging that display products' calorie content in terms of physical activity required to burn those calories
62054294|NCT04462666|PLACEBO_COMPARATOR|Placebo intervention|During the 5-day treatment period, participants in the Placebo group will receive 10 sacks of placebo HZG. They will be instructed to take two sacks per day, one sack in the morning and one in the evening, at approximately 30 minutes after the meal. And the placebo etoricoxib also be taken daily in the morning for 5 days.
62054295|NCT02015494|EXPERIMENTAL|4 mcg VAX2012Q|4 mcg VAX2012Q
62838313|NCT02453711|ACTIVE_COMPARATOR|Lira 3.0 mg|Dose 0.6, 1.2, 1.8, 2.4, 3.0 mg with dose escalation every week
62838314|NCT02453711|PLACEBO_COMPARATOR|Placebo Sema 0.05 mg|Placebo arm matching active arm Sema 0.05 mg
62054296|NCT02015494|EXPERIMENTAL|8 mcg VAX2012Q|8 mcg VAX2012Q
62054297|NCT02015494|EXPERIMENTAL|14 mcg VAX2012Q|14 mcg VAX2012Q
62443760|NCT05432271|EXPERIMENTAL|"High in nutrient warning labels"|Labels added to front of product packaging that signal when the product exceeds thresholds for sugar, sodium, saturated fat, or calorie content
62443761|NCT02668302|EXPERIMENTAL|Treatment|Bilateral in-office placement of a steroid-eluting sinus implant following ethmoidectomy in addition to post-op standard of care, including debridement, irrigation, and topical steroids
62443762|NCT02668302|ACTIVE_COMPARATOR|Control|Post-op standard of care, including debridement, irrigation, and topical steroids
62443763|NCT05333250|EXPERIMENTAL|Modafinil|One 200mg modafinil capsule once daily for one week
62443764|NCT05333250|PLACEBO_COMPARATOR|Placebo|One placebo capsule once daily for one week
62443765|NCT02678910|EXPERIMENTAL|Ovarian Cryopreservation|Removal of the ovary for cryopreservation is an investigational procedure. 100% of the tissue will be used for the participant's future use.
62443766|NCT03955692|ACTIVE_COMPARATOR|Active tDCS|Cathodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the anode will be placed over the right supraorbital (Fp2), using rectangular saline-soaked sponge pads 35 cm2. The current intensity of 1.5 mA will be used for 15 mins for a session.
62613441|NCT04426669|EXPERIMENTAL|CISH CRISPR TIL / Phase II Arm|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of CISH inactivated TIL
62838315|NCT02453711|PLACEBO_COMPARATOR|Placebo Sema 0.1 mg|Placebo arm matching active arm Sema 0.1 mg
62838316|NCT02453711|PLACEBO_COMPARATOR|Placebo Sema 0.2 mg|Placebo arm matching active arm Sema 0.2 mg
62838317|NCT02453711|PLACEBO_COMPARATOR|Placebo Sema 0.3 mg|Placebo arm matching active arm Sema 0.3 mg
62838318|NCT02453711|PLACEBO_COMPARATOR|Placebo Sema 0.4 mg|Placebo arm matching active arm Sema 0.4 mg
62838319|NCT02453711|PLACEBO_COMPARATOR|Placebo Sema 0.3 mg (fast dose escalation)|Placebo arm matching active arm Sema 0.3 mg (fast dose escalation)
62838320|NCT02453711|PLACEBO_COMPARATOR|Placebo Sema 0.4 mg (fast dose escalation)|Placebo arm matching active arm Sema 0.4 mg (fast dose escalation)
62054298|NCT02015494|EXPERIMENTAL|18 mcg VAX2012Q|18 mcg VAX2012Q
62054299|NCT02015494|EXPERIMENTAL|12 mcg VAX2012Q|12 mcg VAX2012Q
62054300|NCT02015494|EXPERIMENTAL|8 mcg VAX2012Q repeated|8 mcg VAX2012Q
62255959|NCT01329679|PLACEBO_COMPARATOR|Placebo|Water, lime juice and cherry flavoring, 2 oz twice daily for 7 days
62255960|NCT05788887|PLACEBO_COMPARATOR|Control|The meal contained 100g of white wheat bread and 80g of Italian Parmesan PDO cheese.
62255961|NCT05788887|OTHER|Intervention|The meal contained 100g of white wheat bread and 80g of Authentic Ladotyri Mytilinis PDO cheese.
62255962|NCT01086020|ACTIVE_COMPARATOR|atorvastatin|patients will be treated with atorvastatin 10mg/d after randomization, and continued for two years
62255963|NCT01086020|EXPERIMENTAL|atorvastatin and ezetimibe|patients will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d after randomization, and continued for two years
62255964|NCT04536428|EXPERIMENTAL|ClearEndoclip|This arm is a group in whom ClearEndoclip would be used for the treatment of bleeding.
62255965|NCT04536428|ACTIVE_COMPARATOR|EZ clip|This arm is a group in whom EZ clip would be used for the treatment of bleeding.
62054301|NCT02015494|EXPERIMENTAL|12 mcg VAX2012Q repeated|12 mcg VAX2012Q
62054302|NCT06526364||MS patients|MS patients, recruited from the SMSC, are annually (optional 6-monthly) assessed and additionally, perform digital measurements with the Healios+Me app continuously after baseline up to 5 years as an optional follow-up study extension.
62054303|NCT03790995||High risk prostate cancer|"Patients with initial cT2c-3-4, cN +, Gleason score (GS) more than 7 or PSA \> 20ng/mL were labelled as high-risk prostate cancer.~Both groups received robot assisted laparoscopic prostatectomy. Matching across age (continuous), year of surgery (2009+2010, 2011, 2012, 2013, 2014, 2015+2016), nerve sparing (bilateral, unilateral or no nerve sparing) and centre size (continuous). 1:1 coarsened exact matching. Continuous variables are temporarily coarsened as followed: age (\<55, 55-\<65, 65-\<75, 75+) and centre size (\<50, 50-\<100, 100+ cases/year)."
62255966|NCT03451786|EXPERIMENTAL|Treatment group|
62613442|NCT00461110|EXPERIMENTAL|1|Active
62838321|NCT02453711|PLACEBO_COMPARATOR|Placebo Lira 3.0 mg|Placebo arm matching active arm Lira 3.0 mg
62838322|NCT05666310|ACTIVE_COMPARATOR|Zoledronic Acid|
62838323|NCT05666310|ACTIVE_COMPARATOR|Denosumab|
62255967|NCT03169764|EXPERIMENTAL|Nant HNSCC Vaccine|avelumab, bevacizumab, capecitabine, cetuximab, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab-paclitaxel, nivolumab, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
62613443|NCT00461110|EXPERIMENTAL|2|Active
62613444|NCT05827406||Group 1: item set 1|A group of patients with psychiatric problems, consecutively recruited from 5 specific sites in Stockholm, are asked to participate in the study. If they agree to participate, they will respond to a group of item sets (item set 1) that measure relevant psychopathological dimensions. Two hundred patients are asked to participate. We assume 50 % participation to receive 100 responses.
62838324|NCT06522139|EXPERIMENTAL|Sperimental|Implantation of Episealer Talus Implant
62838325|NCT05510232|EXPERIMENTAL|A treatment group that will watch a non-VR video via an iPad|"Demographic appropriate screening for inclusion ( including age and available past medical history)~Patient consent (before randomization),~iPad administration (description below),~cast sawing,~physical examination (before and after procedure),~pulse oximetry application (HR measured 3 minutes pre-procedure and throughout entire procedure),~NRS VAS pain administration (3 minutes pre-procedure and immediately post-procedure) in patients over 8 years(Will mark on scale),~VAS Faces pain administration (3 minutes pre-procedure and immediately post-procedure) in patients under 8 years (Will point to face),~NRS VAS anxiety administration (3 minutes pre-procedure and immediately post-procedure)(Will mark on scale),~VAS Faces anxiety scale administration in patients under 8 years(Will point to face),~Patient/parent satisfaction administration (post-procedure)."
62255968|NCT03146000|EXPERIMENTAL|lidocaine-prilocaine|women will receive 5 mg lidocaine-prilocaine cream topically on the episiotomy line
62255969|NCT03146000|ACTIVE_COMPARATOR|meloxicam|women will receive one 15 mg meloxicam rectal suppository
62255970|NCT02715375|EXPERIMENTAL|Device: CREON2000A|Children with mild to moderate asthma maintains allergy medicines have an experimental ultra violet device installed in their homes.
62255971|NCT02715375|SHAM_COMPARATOR|Device: Sham Comparator|Children with mild to moderate asthma maintains allergy medicines have a sham device using a shielded blue light sham lamp that otherwise resembles the experimental device installed in their homes.
62255972|NCT02330887|EXPERIMENTAL|Intervention Cohort|We will use a cohort of 60 women from intervention village clusters for the group antenatal care intervention.
62255973|NCT02330887|ACTIVE_COMPARATOR|Control Cohort|We will use a cohort of 60 women from control village clusters as an active comparison.
62255974|NCT04200053|EXPERIMENTAL|Reflexology massage|Reflexology massage
62255975|NCT04200053|EXPERIMENTAL|Reflexology massage and passive music|Reflexology massage and passive music
62255976|NCT04200053|NO_INTERVENTION|Control|Control
62443767|NCT03955692|SHAM_COMPARATOR|Sham tDCS|Cathodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the anode will be placed over the right supraorbital (Fp2), using rectangular saline-soaked sponge pads 35 cm2. The current intensity of 1.5 mA will flow continuously only 120 seconds. The electrode will be attached until the end of stimulation even the current flows only at the beginning.
62443768|NCT02410148|ACTIVE_COMPARATOR|Papilledema|non-invasive aICP measurement in patientes with papilledema
62443769|NCT02410148|ACTIVE_COMPARATOR|open angle glaucoma|non-invasive aICP measurement in patients with glaucoma
62443770|NCT04707274||Patients group|Individuals with greater trochanteric pain syndrome and gluteal tendinopathy
62443771|NCT03246698|EXPERIMENTAL|Isolytic stretching group|The participants in this group will receive isolytic stretching in modified cross body position. Additionally they will receive standard physiotherapy.
62443772|NCT03246698|EXPERIMENTAL|Static stretching group|"The participants in this group will receive static stretching in modified cross body position.~Additionally they will receive standard physiotherapy."
62255977|NCT03791242|ACTIVE_COMPARATOR|Group 1|33 morbidly obese patients with severe OSAS and suitable for gastric bypass surgery, who underwent 4 weeks of CPAC treatment (these patients will not be required to change their eating habits) according to the standard
62255978|NCT03791242|ACTIVE_COMPARATOR|Group 2|33 morbidly obese patients with severe OSAS and BS candidates who underwent CPAC + KMED treatment for 4 weeks
62255979|NCT03589599|EXPERIMENTAL|Flavored tobacco|All participants will be completing a lab visit where they smoke flavored waterpipe tobacco ad lib for up to 45 min.
62255980|NCT03589599|EXPERIMENTAL|Non-flavored tobacco|All participants will be completing a lab visit where they smoke non-flavored waterpipe tobacco ad lib for up to 45 min.
62255981|NCT01463670|EXPERIMENTAL|lenalidomide|The proposed study is designed as a Phase II, multi-center trial of lenalidomide intensification in patients with asymptomatic POD while on low dose lenalidomide maintenance after HDM/ASCT or on continuous/maintenance therapy after initial treatment.
62255982|NCT06097442||Participants with Long-COVID Using Apollo|Participants with long-COVID symptoms who have consented to be part of this study will use an Apollo device according to a suggested schedule pre-set within their Apollo app, which participants can alter as they see fit.
62443773|NCT03246698|ACTIVE_COMPARATOR|Control group|The participants in this group will receive only standard physiotherapy.
62443774|NCT04812509|EXPERIMENTAL|MW032|MW032 injection(120mg) was administered subcutaneously once every 4 weeks for a maximum of 13 consecutive doses throughout the trial, according to the investigator's assessment.
62443775|NCT04812509|ACTIVE_COMPARATOR|Xgeva®|Xgeva® injection(120mg) was administered subcutaneously every 4 weeks for a maximum of 13 cumulative doses throughout the trial,according to the investigator's assessment.
62443776|NCT00654706|EXPERIMENTAL|Sertindole|
62443777|NCT00654706|ACTIVE_COMPARATOR|Quetiapine|
62443778|NCT03741608|ACTIVE_COMPARATOR|Education, BP cuff & training|High blood pressure management education. Home blood pressure measurement
62443779|NCT03741608|ACTIVE_COMPARATOR|Education only|High blood pressure management education
62443780|NCT00467584|ACTIVE_COMPARATOR|High Dose Aspirin|High Dose Aspirin; 1300 milligrams of aspirin per day, taken by mouth as two tablets, twice per day for 8 weeks
62443781|NCT00467584|ACTIVE_COMPARATOR|Low Dose Aspirin|Low Dose Aspirin; 162 milligrams of aspirin per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
62443782|NCT00467584|PLACEBO_COMPARATOR|Placebo|Placebo tablets, matching the active aspirin tablets in appearance, taken by mouth twice per day for 8 weeks
62443783|NCT01960816|EXPERIMENTAL|InFlux System|Intervention: Procedure: thermal coagulation of tissue in the nasal airway
62255983|NCT04170803|EXPERIMENTAL|True Dry Needling|"Active duty DoD beneficiaries, with shoulder pain will be recruited from Army Medical Department Center and School (AMEDDC\&S) and the Brooke Army Medical Center (BAMC) Outpatient Physical Therapy Clinic who meet inclusion and exclusion criteria. The TDN treatment will consist of a trained investigator inserting a needle through the participant's skin, into the infraspinatus muscle using FDA approved (FDA regulation # 880.5580) disposable 0.25 x 40 mm stainless steel Seirin J-type needles (Seirin, Japan). Each shoulder will undergo this treatment. Each needle insertion will last approximately 2-3 seconds using the sparrow pecking (in and out) technique to the depth of the scapula at 3 locations in the infraspinatus muscle on the affected (painful) side. When detectable, the needle insertion will specifically target palpably painful and/or taut bands of tissue. Immediately after use, all needles will be disposed of in approved sharps containers."
62255984|NCT04170803|SHAM_COMPARATOR|Sham Dry Needling|The sham dry-needling procedure will mimic the dry needling procedures by placing a blunted instrument in a needling guide tube against the skin. The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in previous studies performed at AMEDDC\&S and have found it to be indistinguishable from real dry needling by the great majority of participants..
62255985|NCT02663453|EXPERIMENTAL|study group|multicomponent lipid emulsion composed of 30% soybean oil, 30% MCTs, 25% olive oil and 15% fish oil (SMOF lipid) was administered at a dose of 1gm/kg/day within 24 hours after birth; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.The macronutrients and micronutrients were provided using the same products in both groups.
62255986|NCT02663453|ACTIVE_COMPARATOR|control group|pure soybean oil lipid emulsion(intralipid) was administered at a dose of 1gm/kg/day within 24 hours after birth; lipid dosage was increased by an increment of 0.5gm/kg/day until the maximal dose of 3.5gm/kg/day was reached.The macronutrients and micronutrients were provided using the same products in both groups.
62443784|NCT03538756|EXPERIMENTAL|Baseline Group A--Walkasins On Then Off|"Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a one-hour rest period, they will be retested with Walkasins turned off.~After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits"
62443785|NCT03538756|EXPERIMENTAL|Baseline Group B--Walkasins Off Then On|"Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a one-hour rest period, they will be retested with Walkasins turned on.~After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits."
62443786|NCT03538756|EXPERIMENTAL|Single Arm Long-Term Follow-up|"During the baseline visit, participants were randomized to two groups that applied to the first visit only. After the baseline visit, community-dwelling participants received Walkasins to wear over the next 52 weeks. They returned for follow-up visits at weeks 2, 6, 10, 26, and 52, during which they repeated the functional measures while wearing their Walkasins and responded to the questionnaires. Between weeks 10 and 26 and 26 and 52, they were contacted periodically to remind them of study requirements and to collect follow-up information regarding health changes, adverse events, pain scores, device usage, and device functioning.~Note: Due to COVID-19 disruptions, some participants were not able to return for all in-person follow-up visits. They completed the patient-reported outcome measures via telephone visits."
62443787|NCT05112328|EXPERIMENTAL|Intervention|Exocrine Pacancreatic enzyme(Norzyme Capsule 40000 capsules) after meals 3 times a day
62443788|NCT05112328|PLACEBO_COMPARATOR|Control|Placebo after meals 3 times a day
62255987|NCT05289570|EXPERIMENTAL|Voxelotor Arm|500 mg of Voxelotor two times a day (for a total daily dose of 1000 mg per day) for 5 days. This dose may increase to a total maximum daily dose of 1500 mg (500 mg three times a day), if subject tolerates the initial dose as determined by study doctor.
62255988|NCT03098849|EXPERIMENTAL|Buteyko Training|Breathing exercises according to the Buteyko Breathing Technique
62255989|NCT03098849|NO_INTERVENTION|Control Group|Standard care as usual
62255990|NCT06078423|EXPERIMENTAL|Investigational Vaccine - 5-dose program|Freeze-dried human rabies vaccine (MRC-5 cells), 1.0 ml after reconstitution, with a titer of not less than 5.24 IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
62255991|NCT06078423|EXPERIMENTAL|Investigational Vaccine - 4-dose program|Freeze-dried human rabies vaccine (MRC-5 cells), 1.0 ml after reconstitution, with a titer of not less than 5.24 IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
62255992|NCT06078423|ACTIVE_COMPARATOR|Control vaccine - 5-dose program|Freeze-dried human rabies vaccine (MRC-5 cells), 1.0 ml after reconstitution, with a titer of not less than 4.57 IU, ,Chengdu Kanghua Biological Products Co., Ltd
62255993|NCT06078423|ACTIVE_COMPARATOR|Control vaccine - 4-dose program|Freeze-dried human rabies vaccine (MRC-5 cells), 1.0 ml after reconstitution, with a titer of not less than 4.57 IU, ,Chengdu Kanghua Biological Products Co., Ltd
62255994|NCT03566355|EXPERIMENTAL|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
62255995|NCT02277015|EXPERIMENTAL|ETI without chest compressions|Endotracheal intubation during pediatric resuscitation without chest compressions.
62255996|NCT02277015|EXPERIMENTAL|ETI with chest compressions|Endotracheal intubation during pediatric resuscitation with chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control).
62255997|NCT01971021|ACTIVE_COMPARATOR|PICC-line|PICC line insertion.
62255998|NCT01971021|ACTIVE_COMPARATOR|PORT|Subcutaneous venous port insertion
62443789|NCT02874495||Healthy volunteers|22 persons.
62443790|NCT02874495||Patients with Crohn's disease|22 patients.
62054304|NCT03790995||Low - intermediate risk prostate cancer|"Initial PSA levels less or equal than 20 ng/mL with GS of 7 or less and cT1-2a-2b, 2 were labelled as low and intermediate risk prostate cancer and served as a control group.~Both groups received robot assisted laparoscopic prostatectomy. Matching across age (continuous), year of surgery (2009+2010, 2011, 2012, 2013, 2014, 2015+2016), nerve sparing (bilateral, unilateral or no nerve sparing) and centre size (continuous). 1:1 coarsened exact matching. Continuous variables are temporarily coarsened as followed: age (\<55, 55-\<65, 65-\<75, 75+) and centre size (\<50, 50-\<100, 100+ cases/year)."
62443791|NCT06529263|EXPERIMENTAL|Massage group|is the newborn massage group.The experimental group was massaged twice a day for 15 minutes 30 minutes after feeding and routine care for 4 days.
62054305|NCT01443221|ACTIVE_COMPARATOR|Free combination|Free combination of Mitiglinide 10mg and Metformin 500mg
62054306|NCT01443221|EXPERIMENTAL|Fixed-dose combination|Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
62054307|NCT05855369|ACTIVE_COMPARATOR|Combination Trigeminal Nerve Stimulation (TNS) and active Smell Training (ST)|30 minutes of once/day TNS and twice/day ST conducted 5 days/week for 12 weeks and a total of 60 stimulation and 120 smell training sessions
62443792|NCT06529263|NO_INTERVENTION|Control group|is the group without intervention
62443793|NCT02265848|ACTIVE_COMPARATOR|Treatment group A|Subjects assigned to treatment group A will begin the 7 week study with high frequency stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the low frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
62443794|NCT02265848|ACTIVE_COMPARATOR|Treatment group B|Subjects assigned to treatment group B will begin the 7 week study with low frequency stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the high frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
62838326|NCT05510232|EXPERIMENTAL|A treatment group that will have headset on and will watch a non-VR video|"Demographic appropriate screening for inclusion ( including age and available past medical history)~Patient consent (before randomization),~Video administration via headset(description below),~Cast sawing,~Physical examination (before and after procedure),~Pulse oximetry application (HR measured 3 minutes pre-procedure and throughout entire procedure),~NRS VAS pain administration (3 minutes pre-procedure and immediately post-procedure) in patients over 8 years(Will mark on scale),~VAS Faces pain administration (3 minutes pre-procedure and immediately post-procedure)in patients under 8 years(Will point to face),~NRS VAS anxiety administration (3 minutes pre-procedure and immediately post-procedure)(Will mark on scale),~VAS Faces anxiety administration (3 minutes pre-procedure and immediately post-procedure) in patients under 8 years (Will point to face),~Patient/parent satisfaction administration (post-procedure)."
62838327|NCT05510232|EXPERIMENTAL|A treatment group that will be immersed in the VR game (Bear Blast) via the headset.|"Demographic appropriate screening for inclusion ( including age and available past medical history)~Patient consent (before randomization)~VR assembly and administration (description below)~Cast sawing,~physical examination (before and after procedure) ,~pulse oximetry application (HR measured 3 minutes pre-procedure and throughout entire procedure),~NRS VAS pain administration (3 minutes pre-procedure and immediately post-procedure) in patients over 8,-(Will mark on scale)~VAS Faces pain administration (3 minutes pre-procedure and immediately post-procedure) in patients under 8 years(Will point to face),~NRS VAS anxiety administration (3 minutes pre-procedure and immediately post-procedure)(Will mark on scale),~VAS Faces anxiety scale administration (3 minutes pre-procedure and immediately post-procedure) in patients under 8 years(Will point to face),~Patient/parent satisfaction administration (post-procedure)."
62838328|NCT04441918|EXPERIMENTAL|Test group|
62838329|NCT04441918|EXPERIMENTAL|Control group|
62838330|NCT05756959|EXPERIMENTAL|PBM therapy + SVS|Low lever red light therapy with single vision spectacles
62838331|NCT05756959|EXPERIMENTAL|Peripheral defocus spectacles|a spectacles with special design with peripheral myopic defocus to control myopia progression
62838332|NCT05756959|EXPERIMENTAL|PBM +Peripheral defocus spectacles|Low lever red light therapy with a spectacles with special design with peripheral myopic defocus to control myopia progression
62054308|NCT05855369|ACTIVE_COMPARATOR|Active Smell Training (ST)|5 minutes of daily ST conducted twice/day, 5 days/week for 12 weeks and a total of 120 training session
62054309|NCT05855369|PLACEBO_COMPARATOR|Placebo Smell Training (PBO)|5 minutes of daily PBO conducted twice/day, 5 days/week for 12 weeks and a total of 120 training sessions
62255999|NCT04300699|OTHER|Ovarian cancer patients over 70 years receiving chemotherapy|Patients with ovarian cancer receiving chemotherapy as either first line treatment (i.e. newly diagnosed advanced stage III/IV cancer) or at first relapse. Patients to receive a Geriatric Assessment including interventions for functional or other identified deficits and appropriate specialist algorithm-determined interventions.
62256000|NCT05539729|EXPERIMENTAL|Vancomycin|125mg antibiotic taken 4 times daily by mouth
62256001|NCT05539729|PLACEBO_COMPARATOR|Placebo|Matching placebo taken 4 times daily by mouth
62443795|NCT06243354|EXPERIMENTAL|Test product-HYP-2090PTSA|
62256002|NCT02681328||Afirma GEC|single molecular test GEC of collected tissue
62613445|NCT05827406||Group 2: reduced item set 1|We analyze data from group 1 and optimize item set 1 for the best measurement with the least number of items. Then, we recruit 200 new patients from the five sites in Stockholm with psychiatric issues for the psychometric validation of the reduced item set. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment. If the reduced item set 1 fails to validate, we may need to change it and recruit additional groups to optimize it.
62613446|NCT05827406||Group 3: item set 2|A group of patients with psychiatric problems, consecutively recruited from 5 specific sites in Stockholm, are asked to participate in the study. If they agree to participate, they will respond to a group of item sets (item set 2) that measure relevant psychopathological dimensions. Two hundred patients are asked to participate. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment.
62613447|NCT05827406||Group 4: reduced item set 2|We analyze data from group 3 and optimize item set 2 for the best measurement with the least number of items. Then, we recruit 200 new patients from the five sites in Stockholm with psychiatric issues for the psychometric validation of the reduced item set. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment. If the reduced item set 2 fails to validate, we may need to change it and recruit additional groups to optimize it
62256003|NCT02681328||ThyroSeq v.2|single molecular test ThyroSeq v.2 of collected tissue
62256004|NCT02681328||Afirma GSC|single molecular test GSC of collected tissue
62613448|NCT05827406||Group 5: item set 3|A group of patients with psychiatric problems, consecutively recruited from 5 specific sites in Stockholm, are asked to participate in the study. If they agree to participate, they will respond to a group of item sets (item set 3) that measure relevant psychopathological dimensions. Two hundred patients are asked to participate. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment.
62256005|NCT02681328||ThyroSeq v.3|single molecular test ThyroSeq v.3 of collected tissue
62256006|NCT04530773|EXPERIMENTAL|GROUP1|
62256007|NCT04530773|EXPERIMENTAL|GROUP2|
62256008|NCT04530773|EXPERIMENTAL|GROUP3|
62256009|NCT04530773|EXPERIMENTAL|GROUP4|
62256010|NCT04530773|EXPERIMENTAL|GROUP5|
62256011|NCT04686747||Esophageal Cancer|
62256012|NCT04686747||Gastric Cancer|
62256013|NCT04686747||Pancreatic Cancer|
62256014|NCT04686747||Colorectal Cancer|
62256015|NCT02839057||Surgical treatment|Patients ≥70 years with C2 fracture coded in patient registry (ICD-10: S12.1) treated with surgical fracture stabilisation
62256016|NCT02839057||Non-surgical treatment|Patients ≥70 years with C2 fracture coded in patient registry (ICD-10: S12.1) treated non-surgically
62256017|NCT04956003|NO_INTERVENTION|Control Group|No intervention, but assessment of cardiometabolic health and cognition
62256018|NCT04956003|EXPERIMENTAL|Intervention Group|Implementing a daily 45-minute physical activity session as an integral part of learning.
62256019|NCT05687331||Patients with hemarthrosis|10 patients that sustained a knee trauma and have hemarthrosis during knee arthrocentesis (red color of the synovial fluid)
62256020|NCT05687331||Patients without hemarthrosis|10 patients that sustained a knee trauma and do not have hemarthrosis during knee arthrocentesis (yellow color of the synovial fluid)
62443796|NCT01801696|EXPERIMENTAL|Parent massage tx group|Children in this group receive the parent-delivered massage intervention right after randomization.
62838333|NCT05756959|PLACEBO_COMPARATOR|Control|single vision spectacles only as the control
62443797|NCT01801696|EXPERIMENTAL|Parent massage wait-list control group|Children in this group receive the parent-delivered massage intervention 5 months after randomization.
62443798|NCT02779816|EXPERIMENTAL|Intervention (pen device)|Subjects will use the pen device when using their commercially available insulin pens
62443799|NCT02779816|NO_INTERVENTION|Control|Subjects will use the commercially available insulin pens only (no adaptive pen device).
62443800|NCT06252779|EXPERIMENTAL|Plasma stimulation therapy group|
62443801|NCT06252779|PLACEBO_COMPARATOR|False stimulation treatment group|
62838334|NCT05808829|EXPERIMENTAL|Experimental: Progressive Muscle Relaxation Exercise|Participants performed muscle relaxation exercises at least 4 times a week for 6 weeks. Once a week, the researcher exercised with the participants in online groups to control the research and to check whether the participants were doing the exercise correctly.
62838335|NCT05808829|NO_INTERVENTION|No Intervention: Control Group|The participants continued their daily life.
62838336|NCT05302726|ACTIVE_COMPARATOR|Oral estrogen|oral estrogen (2 mg/24 hours)
62838337|NCT05302726|ACTIVE_COMPARATOR|Transdermal estrogen|Transdermal estrogen (100ug/24 hours)
62838338|NCT05302726|NO_INTERVENTION|No treatment|Estrogen pause
62443802|NCT01309919|ACTIVE_COMPARATOR|IUD Arm|Subjects who receive an IUD within 48 hours of delivery (vaginal or cesarean birth)
62443803|NCT01309919|OTHER|Diary Arm|Subjects who will not have an IUD placed postpartum; they may use another form of contraception, or no form at all
62443804|NCT02505100|EXPERIMENTAL|Touching relaxant|session of massage
62443805|NCT02505100|EXPERIMENTAL|Hypnoses|session of hypnoses
62443806|NCT02505100|NO_INTERVENTION|Standared care|standard care
62613449|NCT05827406||Group 6: reduced item set 3|We analyze data from group 5 and optimize item set 3 for the best measurement with the least number of items. Then, we recruit 200 new patients from the five sites in Stockholm with psychiatric issues for the psychometric validation of the reduced item set. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment. If the reduced item set 3 fails to validate, we may need to change it and recruit additional groups to optimize it
62838339|NCT03507569|EXPERIMENTAL|RO7017773|The first two participants of the first cohort are anticipated to receive a single dose of RO7017773 orally. The doses to be tested in the subsequent cohorts of participants will be determined by review of PET scan, PK, and safety results from the previous dose level.
62838340|NCT01234389|OTHER|H. pylori positive patients|
62838341|NCT01234389|OTHER|H. pylori negative patients|
62838342|NCT03229980|ACTIVE_COMPARATOR|Group L|Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg The content of cardioplegic solution will be (K+, 10mmol/L) lidocaine 50 mg/L, magnesium sulphate 1 gm/L,dextrose 25% 25 mL/L and sodium bicarbonate 8.4% 25 mL/L during cardiac surgery. Cardioplegic infusion duration will be infused over 300s.
62838343|NCT03229980|ACTIVE_COMPARATOR|Group S|Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg The content of cardioplegic solution will be (K+, 30mmol/L) lidocaine 150 mg/L, magnesium sulphate 3 gm/L, dextrose 25% 25 mL/L and sodium bicarbonate 8.4% 25 mL/L during cardiac surgery.
62838344|NCT04517175||Myelodysplastic syndrome (MDS) patients|MDS patients will be divided according to prognostic parameters in sub-cohorts.
62838345|NCT04517175||Acute myeloid Leukemia (AML) patients|AML patients will be divided according to prognostic parameters in sub-cohorts.
62838346|NCT04517175||Myelodysplastic syndrome/neoplasm (MDS/MPN) patients|MDS/MPN patients will be divided according to prognostic parameters in sub-cohorts.
62838347|NCT00512915|ACTIVE_COMPARATOR|1699T (Optisense)|Implantation of the Optisense Lead 1699T, programming of the shortest possible postventricular atrial blanking period (PVAB)
62838348|NCT00512915|ACTIVE_COMPARATOR|Standard lead|Implantation of a standard bipolar atrial pacing lead. Optimization of the postventricular atrial blanking period (PVAB) after implantation.
62838349|NCT00455182|PLACEBO_COMPARATOR|1|Standard medical care
62838350|NCT00455182|EXPERIMENTAL|2|Acupuncture
62838351|NCT00455182|SHAM_COMPARATOR|3|Sham acupuncture
62838352|NCT03139591|ACTIVE_COMPARATOR|lidocaine inhalation|Lidocaine inhalation group: 1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection
62838353|NCT03139591|ACTIVE_COMPARATOR|intravenous dexamethasone|Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone
62838354|NCT00254384|EXPERIMENTAL|Treatment (docetaxel, cisplatin, erlotinib hydrochloride)|Patients receive docetaxel IV over 1 hour followed by cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning within 90 days following definitive surgical resection, patients receive erlotinib hydrochloride PO daily for up to 1 year.
62838355|NCT05637580||combined well responder|Both primary tumor and nodal response achieve major pathological response (MPR).
62838356|NCT05637580||poor responder|Primary tumor or/and nodal response can not achieve MPR.
62838357|NCT02644421|EXPERIMENTAL|VVZ-149|"The following doses will be administered intravenously:~* Loading Dose: 1.8 mg/kg VVZ-149 over 0.5 hours~* Maintenance infusion: 1.3 mg/kg/hr VVZ-149 over 7.5 hours"
62838358|NCT02644421|ACTIVE_COMPARATOR|Lidocaine|"The following doses will be administered intravenously:~* Lidocaine 4mg/kg LBM over 0.5 hours~* Normal saline over 7.5 hours"
62838359|NCT02644421|PLACEBO_COMPARATOR|Placebo|Normal saline administered intravenously over 8 hours
62838360|NCT04040387|EXPERIMENTAL|Treatment Arm|Intervention with NightWare Therapeutic System
62838361|NCT04040387|SHAM_COMPARATOR|Sham Arm|NightWare system set to not provide any interventions
62838362|NCT02449148|EXPERIMENTAL|Intermittent Calorie Restriction|2 days per week fasting with 25 % energy intake and 5 days per week at 100% energy intake
62838363|NCT02449148|EXPERIMENTAL|Continuous Calorie Restriction|daily energy intake of 80 %
62838364|NCT02449148|NO_INTERVENTION|Healthy Nutrition|general advice on healthy nutrition
62838365|NCT01771224|EXPERIMENTAL|palmitoleic acid|Palmitoleic acid: 720 mg/day for 56 days
62838366|NCT01771224|PLACEBO_COMPARATOR|Sugar pill|Sugar pill: 720 mg/day for 56 days
62838367|NCT04313062|EXPERIMENTAL|Intervention|"The intervention group will receive the PM ACTIVAS' intervention model. This intervention will be done by a member of the technical staff (previously trained) at the patient's home (house call). In the house call, the trainee will perform a multidimensional assessment of the patient's falling risks factor (internal and external), deliver a  Falling Prevention Kit  and lastly establish together (with the patient and their family) a plan to change the hazards in their home. The patients will receive a telephone follow-up by the same technical staff member until the final house call, which will be 12 months after the recruiting. Finally, 12 months after recruitment, they will receive a last house call where the trainee will assess with the patient and the family the plan, ask for the  Falls and Events Calendar  given at recruitment (where the older person and/or their family registered every trip or fall during the 12-month period), and conduct the final survey."
62838368|NCT04313062|NO_INTERVENTION|Standard care|"The control group will receive the standard care from the community health center. They will not receive a telephone follow-up. They will receive a house call 12 months after recruitment by a trainee, who will conduct the final survey and ask for the  Falls and Events Calendar  given at recruitment (where the older person and/or their family registered every trip or fall during the 12-month period). Lastly, they will receive an abbreviated intervention for falling prevention and be given the  Falling Prevention Kit ."
62838369|NCT02356861|ACTIVE_COMPARATOR|Real, Active LED Treatment Series|These participants will first receive a series of 12, sham LED treatments, At 1 week post completion of the Sham LED treatment series, participants in this group receive a series of 12 real LED treatments from the helmet housing LEDs that deliver photons of light in the infrared range.
62838370|NCT02356861|SHAM_COMPARATOR|Sham LED Treatment Series|These participants will first receive an initial series of 12 sham LED treatments from the helmet containing the sham LEDs.
62838371|NCT02506413|OTHER|MNCH Intervention Package|"The division assigned to this arm received a comprehensive Maternal and Newborn Health (MNH) intervention package using the 'MamaToto Process'. Key intervention activities included:~1. engaging district leaders in district health system strengthening;~2. strengthening health facility-based MNH services; and~3. establishing a Maternal, Newborn, and Child Health focused lay Community Health Worker program."
62054310|NCT04414579|NO_INTERVENTION|No Intervention: Conventional Insulin Aspart (NovoLog®)|In the aspart group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Aspart is put into their pump and delivered to their body through a small tube placed under your skin. In this NovoLog®-only treatment group, the subject will take aspart with each meal while your pump also gives you a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
62838372|NCT05738304|EXPERIMENTAL|External Ureteral Catheter group|After RIRS, an external ureteral catheter will be placed for one day.
62256021|NCT04858451|EXPERIMENTAL|All participants|"In Part 1a, up to 48 patients will be administered single ascending doses of RESP301 (1-6ml; 8 patients per dose cohort). Provided that individual stopping criteria are not met in ≥3 participants, and there are no serious adverse events that are at least possibly related to RESP301, the next dose cohort can be enrolled. Patients can be enrolled into more than one dose cohort provided they did not meet individual stopping criteria.~In Part 1b, 8 participants will receive RESP301 at MTD determined in Part 1a, with short-acting bronchodilator administered 10min prior to RESP301.~In Part 2, a minimum of 150 patients will be enrolled. This may include patients who took part in Part 1. At least the first 50 patients will receive a test dose of RESP301 before enrolment into the dormant phase. Patients who experience flare-up symptoms while in the dormant phase, may proceed to the treatment phase where they will self-administer RESP301 at home for 7 days."
62838373|NCT05738304|ACTIVE_COMPARATOR|Double J group|After RIRS, a double J internal ureteral stent will be placed for 2 weeks.
62838374|NCT02549872||Dementia|Patients with a recorded diagnosis of dementia in primary or secondary care
62838375|NCT02549872||Non-dementia|Patients without a recorded diagnosis of dementia in primary or secondary care
62838376|NCT00248040|EXPERIMENTAL|reparixin group - continuous infusion|"Continuous iv infusion into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.~A dose of 2.772 mg/kg/h was administered for12 hours."
62838377|NCT00248040|EXPERIMENTAL|reparixin group - intermittent infusion|"Intermittent iv infusion into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.~A dose of 2.244 mg/kg was administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were administered over a total period of 22.5 hours."
62256022|NCT05839275|EXPERIMENTAL|Treatment Arm|"There will be 52 patients with high-risk localized extremity and truncal soft tissue sarcoma recruited.~In safety lead-in phase (phase Ib): using 3+3 design, patients will receive 6 cycles of Surufatinib in three different dosages and Sintilimab. And radiotherapy will begin in week 4.~In extended phase (phase II): Surufatinib in RP2D, Sintilimab and radiotherapy will be applied as before."
62613450|NCT05827406||Group 7: item set 4|A group of patients with psychiatric problems, consecutively recruited from 5 specific sites in Stockholm, are asked to participate in the study. If they agree to participate, they will respond to a group of item sets (item set 4) that measure relevant psychopathological dimensions. Two hundred patients are asked to participate. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment.
62838378|NCT00248040|PLACEBO_COMPARATOR|placebo infusion|Continuous/intermittent iv infusion of a volume/schedule matched saline into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.
62838379|NCT04784572|OTHER|First injection delay and second injection delay|"During the first injection, the patient will make 3 scales: END, EVAF and insight and there will be an assessment of induration, redness and swelling done with nurses.~During the second injection, the patient will perform the END and EVAF scale and then follow up with a maintenance"
62838380|NCT05268913||Women with BRCA1/2 genes|
62838381|NCT05268913||Women with breast cancer|
62838382|NCT05268913||Women with obesity|
62838383|NCT01941186|EXPERIMENTAL|Patient Decision Aid|After positive screen for a developmental concern the intervention group will receive the Patient Decision Aid (PDA), as well as, a text message reminder to follow up with Early Intervention.
62838384|NCT01941186|NO_INTERVENTION|Routine Care|After screening positive for a potential development delay those in the control arm will receive routine care, in this case, a handout explaining Early Intervention services.
62838385|NCT00380367|EXPERIMENTAL|Quadrivalent HPV VLP Vaccine (Types 6, 11, 16, 18)|Participants who enroll receive a total of 3 intramuscular injections of Quadrivalent HPV VLP vaccine (types 6, 11, 16, 18) given on Day 1, Month 2 and Month 6.
62838386|NCT05235269|OTHER|Single arm|I-124 AT-01
62838387|NCT06383728|EXPERIMENTAL|Osimertinib|Patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma will receive Osimertinib ( 80mg/d, ≥9 weeks).
62838388|NCT01465360||Study patients|Patients newly referred to a Reference Memory Center with a complaint of memory impairment for AD diagnostic workup.
62256023|NCT03025230|EXPERIMENTAL|Experimental group|Dry needling technique and the application of a rectangular, biphasic, asymmetric analgesic electric current by selecting a frequency of 2 Hz with a pulse width 40 μs, with an intensity located at the tolerance threshold and for a time of 20 minutes.
62256024|NCT03025230|ACTIVE_COMPARATOR|Control group|Dry technique in PG.The needle will be moved in-and-out into different directions to encounter sensitive spots in PG region.
62256025|NCT00721370|EXPERIMENTAL|1|Patients imaged using ICG:HSA and NIR imaging system
62838389|NCT01939418|EXPERIMENTAL|RAD001|gemcitabine 800mg/m2, D1 and D8 iv. every 3 weeks. cisplatin 30mg/m2, D1 and D8 iv. every 3 weeks. RAD001 5mg QD. po.
62838390|NCT06416124||Elite and Olympic Mexican track and field athletes|All 74 athletes competing in track and field events during the XXIV Central American and Caribbean Athletics Championship will be considered
62838391|NCT05876000|EXPERIMENTAL|Corheart 6 LVAS|The Corheart 6 Left Ventricular Assist System (Corheart 6 LVAS) to be used on patients with advanced left ventricular heart failure.
62054311|NCT04414579|ACTIVE_COMPARATOR|Faster Insulin Aspart (Fiasp®)|In the Fiasp group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Fiasp is put into their pump and delivered to their body through a small tube placed under their skin. In this Fiasp treatment group, the subject will take fiasp with each meal while their pump also gives them a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
62054312|NCT02537639||Control group|Control group. Standard teaching in transesophageal echocardiography.
62256026|NCT02285777|EXPERIMENTAL|MenABCWY Group|Subjects who received 2 doses of MenABCWY vaccine in the parent study and a 3rd dose of MenABCWY vaccine in the current study.
62256027|NCT02285777|ACTIVE_COMPARATOR|MenACWY Group|Subjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study and 1 dose of placebo in the current study.
62256028|NCT02385149|EXPERIMENTAL|whole grain wheat|98g whole grain wheat per day for 12 weeks
62256029|NCT02385149|EXPERIMENTAL|refined wheat|coloured refined wheat control intervention
62256030|NCT01806350|EXPERIMENTAL|Arm I (PFMT)|Patients receive a handout describing behavioral management tips for urinary incontinence, including information and suggestions about optimal volume fluid intake, constipation management, measures to reduce urgency by spreading fluid intake, and avoiding caffeine and other bladder irritants that have proved effective in other intervention trials. Patients undergo PFMT over 20-30 minutes teaching them to contract the pelvic floor muscles correctly and receive feedback to avoid the contraction of abdominal, gluteal or adductor muscles. Patients are asked to perform 3 sets of 10 pelvic muscle contractions with a goal of holding the contraction for 5 seconds daily for 12 weeks and also receive a reminder phone call to address concerns and review the instructions at 4 weeks.
62256031|NCT01806350|ACTIVE_COMPARATOR|Arm II (usual care)|Patients receive usual care for urinary incontinence, with an option to join the training program after completion of study.
62256032|NCT01225731|EXPERIMENTAL|Part 1: Tildrakizumab 5 mg|Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4
62256033|NCT01225731|EXPERIMENTAL|Part 1: Tildrakizumab 25 mg|Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4
62256034|NCT01225731|EXPERIMENTAL|Part 1: Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4
62256035|NCT01225731|EXPERIMENTAL|Part 1: Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4
62256036|NCT01225731|PLACEBO_COMPARATOR|Part 1: Placebo|Participants receive placebo, SC, at Weeks 0 and 4
62256037|NCT01225731|EXPERIMENTAL|Part 2: Tildrakizumab 5 mg|Participants receive tildrakizumab 5 mg, SC, every 12 weeks for up to 36 weeks
62256038|NCT01225731|EXPERIMENTAL|Part 2: Tildrakizumab 25 mg|Participants receive tildrakizumab 25 mg, SC, every 12 weeks for up to 36 weeks
62256039|NCT01225731|EXPERIMENTAL|Part 2: Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg, SC, every 12 weeks for up to 36 weeks
62838392|NCT04495920|EXPERIMENTAL|Test product|
62256040|NCT01225731|EXPERIMENTAL|Part 2: Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg, SC, every 12 weeks for up to 36 weeks
62256041|NCT01225731|NO_INTERVENTION|Part 3: Tildrakizumab 5 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
62838393|NCT02542319|EXPERIMENTAL|Magnesium|Oral Magnesium Hydroxide (Mablet 360 mg) twice daily for 12 months.
62838394|NCT02542319|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets twice daily for 12 months.
62838395|NCT04632836||NIV participant (non invasive-ventilation participant)|"From patient:~* demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~* equipment data (type, indication, parameters, observance, usage data),~* medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)~* responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)~From partner:~* demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~* responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
62054313|NCT02537639||Intervention group|Intervention group. Additional teaching with a transesophageal echocardiography simulator.
62054314|NCT04807465|OTHER|G-Premio universal adhesive used in smoker participants|Participants who smoke at least 10 cigarettes per day
62054315|NCT04807465|OTHER|G-Premio universal adhesive used in non-smoker participants|participants who non-smoke have never smoked before
62054316|NCT00779389|EXPERIMENTAL|Arm A|Erlotinib 150 mg
62054317|NCT00779389|EXPERIMENTAL|Arm B|Dasatinib + placebo
62054318|NCT00779389|EXPERIMENTAL|Arm C|Erlotinib (150 mg) plus Dasatinib (100 mg) for 14-21 days.
62054319|NCT00779389|PLACEBO_COMPARATOR|Arm D|Placebo for 14-21 days
62256042|NCT01225731|NO_INTERVENTION|Part 3: Tildrakizumab 25 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
62256043|NCT01225731|NO_INTERVENTION|Part 3: Tildrakizumab 100 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
62256044|NCT01225731|NO_INTERVENTION|Part 3: Tildrakizumab 200 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
62613451|NCT05827406||Group 8: reduced item set 4|We analyze data from group 7 and optimize item set 4 for the best measurement with the least number of items. Then, we recruit 200 new patients from the five sites in Stockholm with psychiatric issues for the psychometric validation of the reduced item set. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment. If the reduced item set 4 fails to validate, we may need to change it and recruit additional groups to optimize it.
62613452|NCT05827406||Group 9: item set 5|A group of patients with psychiatric problems, consecutively recruited from 5 specific sites in Stockholm, are asked to participate in the study. If they agree to participate, they will respond to a group of item sets (item set 5) that measure relevant psychopathological dimensions. Two hundred patients are asked to participate. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment.
62256045|NCT01225731|NO_INTERVENTION|Part 3: Placebo Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
62613453|NCT05827406||Group 10: reduced item set 5|We analyze data from group 9 and optimize item set 5 for the best measurement with the least number of items. Then, we recruit 200 new patients from the five sites in Stockholm with psychiatric issues for the psychometric validation of the reduced item set. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment. If the reduced item set 5 fails to validate, we may need to change it and recruit additional groups to optimize it.
62256046|NCT00784381||1|
62256047|NCT00784381||2|These units use the same electronic prescribing system, but had no counselling software
62613454|NCT05827406||Group 11: item set 6|A group of patients with psychiatric problems, consecutively recruited from 5 specific sites in Stockholm, are asked to participate in the study. If they agree to participate, they will respond to a group of item sets (item set 6) that measure relevant psychopathological dimensions. Two hundred patients are asked to participate. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment.
62613455|NCT05827406||Group 12: reduced item set 6|We analyze data from group 11 and optimize item set 6 for the best measurement with the least number of items. Then, we recruit 200 new patients from the five sites in Stockholm with psychiatric issues for the psychometric validation of the reduced item set. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment. If the reduced item set 6 fails to validate, we may need to change it and recruit additional groups to optimize it.
62613456|NCT05827406||Group 13: combined item sets|In this group, we aim to combine the optimized item sets in item sets 1-6. We recruit 1000 new patients from the five sites in Stockholm with psychiatric issues for the psychometric validation of the combined item set. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment.
62613457|NCT05827406||Group 14: reduced combined item sets|We analyze data from group 13 and optimize the combined item set for the best measurement with the least number of items and the least number of dimensions. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment. If the reduced combined item set fails to validate, we may need to change it and recruit additional groups to optimize it.
62613458|NCT05086666|EXPERIMENTAL|Urothelial Carcinoma with FGFR2/3 Gene Alterations|Evaluate the Efficacy of AZD4547 in Urothelial Carcinoma Patients with FGFR2/3 Gene Alterations
62613459|NCT00607542|ACTIVE_COMPARATOR|1|starting dose of baclofen 2.5 mg PO TID with dose escalation as tolerated
62613460|NCT04050579|OTHER|OPIE in thin inverventricular septum|The Principal Investigator use the OPIE probe to measure the anterior basilar septal thickness. Myectomy will be performed and OPIE will be repeated.
62613461|NCT03218228|PLACEBO_COMPARATOR|implants in healthy individuals|immediate placement of dental implants in individuals with healthy periodontium. the device is dental implants, radiographs, william's periodontal probe
62613462|NCT03218228|EXPERIMENTAL|implants in periodontitis patients|immediate implantation in patients suffering from aggressive periodontitis. the device is the dental implants, radiographs, william's periodontal probe
62613463|NCT00395642|EXPERIMENTAL|HM with weight and BP remote monitoring|Device based Home Monitoring and weight and blood pressure remote monitoring
62256048|NCT01981915|EXPERIMENTAL|Lung Insufflation Volume|Measurement of the lung volume after hyperinsufflation with positive pressure by IPPB or LIAM
62256049|NCT01981915|EXPERIMENTAL|Peak Cough Flow|Measurement of the peak cough flow after hyperinsufflation with positive pressure by IPPB or LIAM
62256050|NCT05369104|EXPERIMENTAL|Bacteriophages arm|1 mL (PP1493 or PP1815) or 2 mL (PP1493 and PP1815) of suspension of bacteriophages diluted in solution of NaCl 0,9% at the end of DAIR procedure.
62613464|NCT00347321|EXPERIMENTAL|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
62613465|NCT03621891||healthy individuals|Orally and systemically healthy individuals who has no hypo-functional teeth, hyper-occlusion or occlusal trauma
62613466|NCT03621891||periodontitis patients|Systemically healthy individuals who has chronic periodontitis but no hypo-functional teeth, hyper-occlusion or occlusal trauma
62256051|NCT05369104|PLACEBO_COMPARATOR|Control Arm|One local administration of NaCl 0,9% solution is administered at the end of the DAIR procedure.
62256052|NCT02668874|OTHER|Isolite System|The Isolite technique utilizes a flexible plastic dental adapter to separate the cheek and tongue prior to sealant placement.
62256053|NCT02668874|OTHER|Cotton Roll technique|A cotton roll is placed between the cheek and tongue prior to sealant placement.
62256054|NCT04368572|EXPERIMENTAL|lumbar puncture under hypnosis|Hypnosis is the only act added by protocol to patients receiving a lumbar puncture as part of the etiological assessment of cognitive disorders
62256055|NCT04368572|ACTIVE_COMPARATOR|lumbar puncture without hypnosis|Lumbar puncture is performed by a physician assisted by a nurse or a psychologist who reassure the patient during the installation and the procedure.
62256056|NCT02595671|ACTIVE_COMPARATOR|Waiting Group|Patients will not receive a treatment during the actual intervention. This group will receive the digital super coach as an incentive at the end of the trial.
62838396|NCT04632836||CPAP participant (continuous positive airway pressure participant)|"From patient:~* demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~* equipment data (type, indication, parameters, observance, usage data),~* medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)~* responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)~From partner:~* demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~* responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
62838397|NCT04632836||LTOT participant (long term oxygen therapy participant)|"From patient:~* demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~* equipment data (type, indication, parameters, observance, usage data),~* medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)~* responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)~From partner:~* demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~* responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
62838398|NCT02510508|EXPERIMENTAL|Group CRAFT|"All CSO's who are allocated to CRAFT group condition will be offered seven sessions of a CRAFT Group format. Each group will meet for 90 minutes weekly and will be completed within 2 months. The group content is based on the CRAFT techniques described by a training manual written by Roozen, Smith and Meyers (2015). Furthermore the CSOs in this condition will also receive a Dutch version of the CRAFT self-help book (Self Directed CRAFT Delivery), Get your loved one sober: Alternatives to nagging, pleading and threatening (Meyers \& Wolfe, 2012). Groups will engage in a combination of didactic teaching, role-play of new communication styles and discuss their experiences utilizing CRAFT skills."
62838399|NCT02510508|ACTIVE_COMPARATOR|Self-Directed CRAFT Delivery|"CSO's allocated to the Self- Directed CRAFT Delivery will receive the Dutch version of the CRAFT self-help book, Get your loved one sober: Alternatives to nagging, pleading and threatening (Meyers \& Wolfe, 2012). The book helps CSO's how to utilize the CRAFT model in their daily lives. It includes guidelines for responding to IP behavior, improving positive communication skills, improving the CSO's own well-being and explains how to engage the IP into treatment."
62838400|NCT02510508|NO_INTERVENTION|Non-intervention|Participants assigned to the non-intervention condition will be placed on a Group CRAFT waiting list.
62838401|NCT03593746|EXPERIMENTAL|HIIT and LED therapy|Light-Emitting Diode (LED) therapy followed by physical training with high intensity interval training (HIIT)
62838402|NCT03593746|SHAM_COMPARATOR|High intensity interval training (HIIT)|Light-Emitting Diode (LED) therapy simulation followed by physical training with high intensity interval training (HIIT)
62838403|NCT03593746|EXPERIMENTAL|Combined training and LED therapy|Light-Emitting Diode (LED) therapy followed by physical training with combined training
62838404|NCT03593746|SHAM_COMPARATOR|Combined training|Light-Emitting Diode (LED) therapy simulation followed by physical training with combined training.
62838405|NCT04666220||Renal cell carcinoma (RCC)|"For all series, clinical and epidemiological features will be recorded, all available histological slides will be reviewed and, on the primary tumor slides, histological characteristics will be re-assessed.~Whenever multiple samples of tumors would be present, those having the tumor-surrounding tissue interface will be selected and stained with CD34 antibody.~VETC will be evaluated independently by, at least, two pathologists, blinded to clinical data. VETC will be recorded as positive or negative, being VETC defined as CD34 unequivocal immunoreactivity of a continuous lining of endothelial cells around tumor clusters. VETC will be considered alternative to the common capillary pattern, consisting in small circular or linear blood vessels."
62256057|NCT02595671|ACTIVE_COMPARATOR|Conventional face to face PA & dietitian|Participants will receive both dietary and physical activity advice. The advice is provided my medical trained staff (eg. dieticia, physiotherapist) according to a standardised protocol. The number of consultations are respectively three and four for diet and physcial activity.
62256058|NCT02595671|ACTIVE_COMPARATOR|Digital Super Coach|Only receive coaching via digital super coach.
62256059|NCT02595671|ACTIVE_COMPARATOR|Digital Super Coach + minimal coaching|Receive digital super coach and only have a few appointments with a physical activity coach and a dietitian.
62256060|NCT05382247|ACTIVE_COMPARATOR|pediatric patients with neuromuscular diseases|
62256061|NCT05382247|ACTIVE_COMPARATOR|children not suffering from neuromuscular diseases|
62256062|NCT05735730|OTHER|Epidemiologic study|This is an epidemiologic study. No arms are considered.
62256063|NCT04519359|EXPERIMENTAL|Stop Arm|Stop NAs therapy
62256064|NCT04519359|NO_INTERVENTION|Continue Arm|Continue NAs therapy
62838406|NCT04666220||Adrenal carcinoma|see (RCC)
62838407|NCT01685502||Group 1|Patients treated with Glucobay OD under practical manner
62838408|NCT04863469|EXPERIMENTAL|B-POC high load Intervention|aerobic exercise \[heartrate range (HRR) 70-75% of max HR, on treadmill\] and a computerized high-load task for 45 minutes, 3 times per week, for 6 weeks
62256065|NCT02604316|EXPERIMENTAL|Arabinoxylan|10 days of weight loss diet calculated as 100% RMR + 15g Arabinoxylan (Medium Chain Naxus, BioActor b.v., Netherlands) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40% carbohydrate
62256066|NCT02604316|NO_INTERVENTION|Control- Non Arabinoxylan|10 days of weight loss diet calculated 100% RMR using a heterogeneous natural fibre for food ingredients, 30% protein, 30% fat, 40% CHO.
62256067|NCT02604316|EXPERIMENTAL|Beta-Glucan|10 days of weight loss diet calculated as 100% RMR AND 6g Beta-Glucan (Viscofibre, Naturex SA, France) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40%
62256068|NCT02604316|NO_INTERVENTION|Control Non Beta glucan|10 days of weight loss diet calculated 100% RMR using a heterogeneous natural fibre for food ingredients, 30% protein, 30% fat, 40% CHO.
62054320|NCT02513069|EXPERIMENTAL|Mobile Contingency Management (mCM)|"The mCM arm represents a proactive tele-health intervention that combines guideline based cognitive-behavioral smoking cessation telephone counseling, a tele-medicine clinic for access to nicotine replacement therapy (NRT), and intensive behavioral therapy administered via a smart phone (with carbon monoxide monitor) based application. NRT may include nicotine patches (21 mg, 14 mg, and or 7 mg) used daily for six weeks from the smoking quit date. Dosage will depend on participants' reported smoking patterns and carbon monoxide readings. NRT may also include a rescue method, i.e., either nicotine gum or nicotine lozenge. The participants' preferred NRT rescue method will be prescribed and used as needed to reduce smoking craving for six weeks from the smoking quit date."
62613467|NCT03621891||healthy-occlusal trauma|Orally and systemically healthy individuals who has occlusal trauma caused by bruxism
62613468|NCT03621891||periodontitis-occlusal trauma|Systemically healthy individuals who has both chronic periodontitis and occlusal trauma caused by bruxism
62613469|NCT06294444|EXPERIMENTAL|Constraint induced Movement Therapy|Group of 15 members will be given constraint induced movement therapy for 6 weeks.
62613470|NCT06294444|EXPERIMENTAL|Mirror therapy group|Group of 15 members will be given modified constraint induced movement therapy with mirror theray for 6 weeks.
62613471|NCT04318132|EXPERIMENTAL|NIDEK Mirante Comparison - Normal|Subjects without any current ocular pathology other than cataract in either eye
62613472|NCT04318132|EXPERIMENTAL|NIDEK Mirante Comparison - Retina|Subjects diagnosed with retinal pathology
62838409|NCT04863469|SHAM_COMPARATOR|B-POC low load intervention|aerobic exercise \[heartrate range (HRR) 70-75% of max HR, on treadmill\] and a computerized low-load task for 45 minutes, 3 times per week, for 6 weeks
62054321|NCT02513069|ACTIVE_COMPARATOR|Tele-Health for Smoking Ccessation|"TELE-HEALTH FOR SMOKING CESSATION is a proactive tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same guideline based cognitive-behavioral smoking cessation telephone counseling, and tele-medicine clinic for access to NRT as in the mCM intervention. NRT may include nicotine patches (21 mg, 14 mg, and or 7 mg) used daily for six weeks from the smoking quit date. Dosage will depend on participants' reported smoking patterns and carbon monoxide readings. NRT may also include a rescue method, i.e., either nicotine gum or nicotine lozenge. The participants' preferred NRT rescue method will be prescribed and used as needed to reduce smoking craving for six weeks from the smoking quit date."
62613473|NCT04318132|EXPERIMENTAL|NIDEK Mirante Comparison - Glaucoma|Subjects who have been diagnosed with glaucoma
62613474|NCT04318132|EXPERIMENTAL|NIDEK Mirante Comparison - Corneal disease|Subjects with corneal pathologies
62613475|NCT04693156|ACTIVE_COMPARATOR|oblique subcostal tap block|ultrasound-guided right oblique subcostal TAP block with an anesthetic solution of %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl (sodium chloride) 10ml and ultrasound-guided posterior TAP block with %0.9 NaCl 30ml
62613476|NCT04693156|ACTIVE_COMPARATOR|posterior tap block|ultrasound-guided right oblique subcostal TAP block with %0.9 NaCl 30ml and ultrasound-guided posterior TAP block with an anesthetic solution of %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml
62613477|NCT04693156|ACTIVE_COMPARATOR|dual tap block|ultrasound-guided right oblique subcostal TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml and ultrasound-guided posterior TAP block with an anesthetic solution of %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml
62838410|NCT03830307|EXPERIMENTAL|Intervention Group|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
62613478|NCT02001272|EXPERIMENTAL|A:Paclitaxel + Carboplatin every 3 weeks|Patients randomized to the arm A receive 6 courses the following regimen: Paclitaxel 175 mg/m²/3 hours, I.V. and carboplatin AUC 5, I.V. every 3 weeks (1 cycle = 21 days).
62613479|NCT02001272|EXPERIMENTAL|B:Carboplatin monotherapy every 3 weeks|Patients randomized to the arm B receive 6 courses the following regimen: Carboplatin monotherapy AUC 5 or 6 every 3 weeks (1 cycle = 21 days).
62838411|NCT01850758|ACTIVE_COMPARATOR|Regenexx SD|Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged ligament.
62838412|NCT01850758|ACTIVE_COMPARATOR|Exercise Therapy|Subjects will be instructed in a set of appropriate knee strengthening exercises and given an instructional hand-out to take home.
62838413|NCT05808543|EXPERIMENTAL|Both EARS training package (BEARS) and Usual Care|BEARS is a compilation of virtual reality games designed specifically for young people with bilateral cochlear implants. The hardware is either: A Head Mounted Display Device or an iPad with headphones.
62838414|NCT05808543|ACTIVE_COMPARATOR|Usual Care|Usual care describes the routine rehabilitation received by participants via their implant centre.
62838415|NCT01450332|EXPERIMENTAL|study|
62838416|NCT02196662|EXPERIMENTAL|Treatment A|IBD98-M: mesalamine-sodium hyaluronate 200mg-28.75mg X2
62838417|NCT02196662|EXPERIMENTAL|Treatment B|IBD98-M without HA: Mesalamine 200mg X2
62838418|NCT02196662|EXPERIMENTAL|Treatment C|Delzicol 200 mg X2
62838419|NCT02668562|EXPERIMENTAL|Early CABG|Patients to undergo early CABG
62443807|NCT03931083||Portable magnification device (Gynocular™)|The Gynocular™ examination will be performed following the steps involved in colposcopy as described in the IARC colposcopy manual. These steps include: visualization of the vagina, vulva and cervix following insertion of a speculum, magnified assessment after application of normal saline, examination of cervical vessel patterns using the red-free mode (or green filter), application of 5% acetic acid for 1 minute and finally assessment following application with Lugol's iodine. The findings of the live examination will be documented using the parameters of the Swede score. Each parameter is scored between zero and two. Treatment will be based on the results found at histopathology, unless the woman is also VIA positive in which case, after biopsy she will undergo routine treatment as per local guidelines. The results will be used to determine the optimal threshold for treatment in WLHIV.
62838420|NCT02668562|ACTIVE_COMPARATOR|Delayed CABG|Patients to undergo delayed CABG
62443808|NCT03931083||Testing for high risk HPV (HRHPV)|To reduce the number of examinations undergone by the study participant during the same day, HRHPV testing will be carried out at the time of the first gynecological examination by the VIA nurse (see next arm). Using specific single-use cervical cytobrush provided by GeneXpert, a specimen will be collected immediately prior to VIA examination. Cervical cytobrush specimens will be placed into ThinPrep PreservCyt (Cepheid, Sunnyvale, CA) immediately after collection. The HR-HPV testing of cervical specimens will be conducted by a GeneXpert™ machine (Cepheid, Sunnyvale, CA), which will be placed at the health facility and will be operated by a trained nurse in accordance with the manufacturer's instructions. Additionally, as part of the baseline clinical characteristics of the study participant, the study participant will undergo an STI test at the same time. The sample will be collected and tested using the same GeneXpertTM platform.
62443809|NCT03931083||Visual inspection with acetic acid (VIA)|VIA, which is standard of care for cervical cancer screening in Zambia, will be carried out using the methodology described by IARC. This is summarized as follows: visualization of the vagina, vulva and cervix following insertion of a speculum; assessment with the naked eye after application of normal saline; and further assessment after application of 5% acetic acid for 1 minute. This will be recorded as normal or abnormal by the assessor.
62613480|NCT02001272|EXPERIMENTAL|C:Weekly Paclitaxel and Carboplatin|Patients randomized to the arm C receive 6 courses the following regimen: weekly paclitaxel 60 mg/m²/1 hour and weekly carboplatin AUC 2 (d1, d8, d15 ; d1=d29) (1 cycle = 28 days).
62613481|NCT00473824|EXPERIMENTAL|Civacir Treated|Hepatitis C Immune Globulin Intravenous (Human) 5% \[Civacir\], 18 infusions total, per schedule, of Civacir 300 or 400 mg/kg of body weight, with standard post-transplant site specific routine immunosuppressant therapy .
62613482|NCT00473824|NO_INTERVENTION|Observational Control|Observation on standard post-transplant site specific routine immunosuppressant therapy without infusions of Hepatitis C Immune Globulin Intravenous (Human) 5% \[Civacir\].
62838421|NCT00943618|ACTIVE_COMPARATOR|Group 1|Varenicline and Bupropion
62838422|NCT00943618|PLACEBO_COMPARATOR|Group 2|Varenicline and Placebo
62838423|NCT00943618|PLACEBO_COMPARATOR|Group 3|Placebo that looks like varenicline and a placebo that looks like bupropion.
62838424|NCT05479357|ACTIVE_COMPARATOR|Oxytocin|the control group will be given 10 iu intravenously.
62838425|NCT05479357|ACTIVE_COMPARATOR|Carbetocin|the treatment group will be given 100 microgram intravenously.
62838426|NCT06271746|ACTIVE_COMPARATOR|Treatment with active FibroNova device|Treatment of Fibromyalgia pain and symptoms with active FibroNova device. Participants will treat with an active device twice a day.
62838427|NCT06271746|PLACEBO_COMPARATOR|Treatment with Sham FibroNova device|Treatment of Fibromyalgia pain and symptoms with Sham FibroNova device. Participants will treat with a sham device twice a day.
62256069|NCT05376813|EXPERIMENTAL|Experimental arm|All participants are healthy volunteers
62256070|NCT03852862|EXPERIMENTAL|Serratus plane block with paravertebral block|Association of Serratus plane block and paravertebral block for anesthesia
62613483|NCT02972333|EXPERIMENTAL|AZD9291 80mg oral each day±RT|AZD9291(80mg, QD, p.o.) was provided to patients with confirmed EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI and concurrent with brain metastasis. Radiation therapy will be implemented according to investigator's clinical practice(A 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.).
62613484|NCT03761823||Healthy subjects|Healthy subjects
62054322|NCT00559208||Children's Aid Societies|Comparing differential response (Wraparound) with usual care
62054323|NCT03281122|EXPERIMENTAL|Arm A|Specified dose on specified days
62054324|NCT03281122|PLACEBO_COMPARATOR|Arm B|Specified dose on specified days
62054325|NCT04340310||Home respiratory poligraphy|Group A: Children between 4 and 14 years-old with initial OSA suspicion there will be allocated to Home Respiratory Polygraphy (HRP)
62613485|NCT03761823||Patients|Patients extubated after \> 5 days of mechanical ventilation.
62054326|NCT04340310||Polysomnography|Group B: Children between 4 and 14 years-old with initial OSA suspicion and concommitant diseases and false negative suspicion from HRP there will allocated to Hospital Nocturnal Polysomnography
62054327|NCT02560870|ACTIVE_COMPARATOR|Aloe Vera mouthwash|mouthwash (Aleo Vera)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
62613486|NCT03402230|EXPERIMENTAL|Arm I (Avmacol lower dose, Avmacol higher dose)|Participants receive lower dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days. After 10-14 days, participants receive higher dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days.
62613487|NCT03402230|EXPERIMENTAL|Arm II (Avmacol higher dose, Avmacol lower dose)|Participants receive higher dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days. After 10-14 days, participants receive lower dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days.
62613488|NCT05303233|EXPERIMENTAL|TIBIAL group|All patients allocated to the TIBIAL group will receive an adductor canal block with 20ml of ropivacaine 0.75% and a selective tibial nerve block with 5 ml of ropivacaine 0.75% prior to surgery,
62613489|NCT05303233|ACTIVE_COMPARATOR|IPACK group|All patients allocated to the IPACK group will receive an adductor canal block with 20ml of ropivacaine 0.75% and an IPACK with 20ml of ropivacaine 0.2% prior to surgery.
62613490|NCT02590757|ACTIVE_COMPARATOR|NIV-NAVA|Noninvasive ventilation in this group is practiced with NIV-NAVA
62054328|NCT02560870|ACTIVE_COMPARATOR|Chlorhexidine mouthwash|mouthwash (Chlorhexidine )10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
62054329|NCT03414801|ACTIVE_COMPARATOR|Cohort 1|Cat Allergic Subjects
62054330|NCT03414801|ACTIVE_COMPARATOR|Cohort 2|Non-Allergic Subjects will
62054331|NCT03372330||Sepsis with PAD|"Patients admitted to the intensive care unit with the diagnosis of sepsis (quick SOFA score \>=2) and with ankle-brachial index \< 0.9 or vascular Duplex confirmed peripheral artery disease.~\* Standard care for sepsis and PAD"
62054332|NCT03372330||Sepsis without PAD|"Patients admitted to the intensive care unit with the diagnosis of sepsis (quick SOFA score \>=2) and with ankle-brachial index \>= 0.9 or vascular Duplex found no evidence of peripheral artery disease.~\* Standard care for sepsis"
62613491|NCT02590757|ACTIVE_COMPARATOR|N-CPAP|Patients in this group will receive nasal continuous positive airway pressure as routinely in neonatal intensive care unit.
62054333|NCT05861362|EXPERIMENTAL|FAST|5:2 intermittent fasting group
62054334|NCT00947661|EXPERIMENTAL|SPARC0912|Test drug
62054335|NCT00947661|EXPERIMENTAL|Reference0912|Reference drug
62054336|NCT03504098||Lung cancer patients tumor|Using to analysis metabolomic markers, one carbon folate nutrition levels in lung cancer patients.
62256071|NCT03852862|ACTIVE_COMPARATOR|paravertebral block alone|Paravertebral block for anesthesia
62256072|NCT02792270|EXPERIMENTAL|Caloric Restriction Diet|"Patients will meet with the Registered Dietitian to discuss calorie, protein, and fluid needs.The dietitian will calculate calorie needs.~* Calorie needs will be reduced by 30%.~* Protein needs will be estimated based on 0.8g/kg BW and then reduced by 70%.~* Dietitian will educate participants on electrolytes and fluid intake based on the reduced food intake."
62256073|NCT02792270|NO_INTERVENTION|Normal Diet|Participant will follow a normal diet.
62256074|NCT01427998|ACTIVE_COMPARATOR|olive leaf extract|Olive leaf polyphenol concentrate (OLPC) extraction OLPC was prepared from olive leaves as follows (Zaslave et al, 2005) : The leaves were randomly picked from the Barnea cultivar in the Jezreel Valley region of Israel and immediately freeze-dried on dry ice. After the leaves were thoroughly rinsed with sterile distilled water to remove dust, insecticides, and contaminating material, the leaves were ground and successively Soxhlet extracted with hexane for 3 h and 80% aqueous ethanol for 6 h. The alcoholic extract was concentrated under reduced pressure at 25 °C, and reconstituted with 30% ethanol in water.
62613492|NCT02498509|EXPERIMENTAL|Treatment|CKD-342
62613493|NCT02498509|ACTIVE_COMPARATOR|Control 1|Mometasone furoate
62054337|NCT03504098||Lung cancer patients blood|Using to analysis folate, B12, homocysteine levels in plasma and RBC. Using to analysis cDNA gene test in buffy coat.
62054338|NCT03504098||Lung cancer patients|Supply nutrition counseling
62054339|NCT03848702|EXPERIMENTAL|Healthy volunteers|All volunteers wore the DRFB
62613494|NCT02498509|ACTIVE_COMPARATOR|Control 2|Levocabastine HCL
62613495|NCT05863793|EXPERIMENTAL|Manual Acupuncture Group|Treatment will be performed by licensed acupuncturists who have at least 5 years of experience in acupuncture. All the acupuncturists will be trained how to locate acupoints, puncture, and manipulate needles before trials.
62613496|NCT05863793|SHAM_COMPARATOR|Sham Acupuncture|The procedure and duration of treatment in the sham acupuncture group will be identical in the MA group except the needles are blunt tip and there will be no skin penetration and needle manipulation for De qi.
62613497|NCT06263517|EXPERIMENTAL|Arm 1|Intra articular clodronate 2 mg/2 ml once a week for 4 weeks (total clodronate dose = 8 mg)
62613498|NCT06263517|EXPERIMENTAL|Arm 2|Intra articular clodronate 5 mg/2 ml once a week for 4 weeks (total clodronate dose = 20 mg).
62256075|NCT01427998|PLACEBO_COMPARATOR|placebo|matched placebo
62256076|NCT04298736|EXPERIMENTAL|Bariatric Surgery|Obese patients, BMI from 30 to 45, with or without type 2 diabetes, submitted to either laparoscopic Roux-en-Y Gastric Bypass or laparoscopic Sleeve Gastrectomy
62613499|NCT06263517|EXPERIMENTAL|Arm 3|Intra articular clodronate 10 mg/2 ml once a week for 4 weeks (total clodronate dose = 40 mg)
62613500|NCT06263517|PLACEBO_COMPARATOR|Arm 4|Placebo 2 ml once a week for 4 weeks (total clodronate dose = 0 mg).
62054340|NCT03848702|EXPERIMENTAL|Patients with DRF|All patients wore the DRFB
62054341|NCT02007642||No study treatment|
62054342|NCT01855854|EXPERIMENTAL|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or unacceptable toxicity.
62054343|NCT00209807|EXPERIMENTAL|1|subjects with MDD randomized to Escitalopram
62054344|NCT00209807|ACTIVE_COMPARATOR|2|MDD patients receiving reboxetine
62256077|NCT04298736|ACTIVE_COMPARATOR|Lifestyle Modification|Obese patients, BMI from 30 to 45, with or without type 2 diabetes, submitted to guided diet and physical activity.
62256078|NCT05092178|EXPERIMENTAL|Calorie restricted diet and exercise intervention|"The CR diet and exercise group received a balanced diet with an energy consists carbohydrates 45-65%; fat 20-35%; and protein 10- 35% and a deficit of 600 kcal/day from their daily energy requirement.~The exercise intervention included aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for ≥2 d/week for 6 months."
62256079|NCT05092178|ACTIVE_COMPARATOR|exercise group|In exercise alone group, participants then underwent their usual habitual dietary diet and the above exercise intervention during the program.
62054345|NCT00209807|OTHER|3|Healthy volonteers
62054346|NCT05582304|EXPERIMENTAL|TEST/CONTROL/Photopic CSF|Eligible subjects who are habitual wearers of silicone hydrogel contact lenses will be randomized to the photopic condition and randomized contralaterally to the TEST/CONTROL lenses.
62256080|NCT05095220||Observational Cohort|
62256081|NCT02043821|OTHER|Placebo|Placebo 1250mg/m2 tablet by mouth every 12 hours for 14 days
62054347|NCT05582304|EXPERIMENTAL|TEST/CONTROL/Mesopic CSF|Eligible subjects who are habitual wearers of silicone hydrogel contact lenses will be randomized to the mesopic condition and randomized contralaterally to the TEST/CONTROL lenses.
62256082|NCT02043821|EXPERIMENTAL|Capecitabine|Capecitabine 1250mg/m2 tablet by mouth every 12 hours for 14 days
62738898|NCT06351774|EXPERIMENTAL|PT|Participants will receive physiotherapy per clinical practice guideline recommendations for 8 weeks (Phase 1). At week 10, participants will complete the Oswestry Disability Index (ODI) to determine their response to treatment. Individuals who report a favorable response to PT, defined by a threshold of improvement of at least 30% in their ODI, will continue with their PT for an additional 8 weeks. Individuals who do not favorably respond to PT will receive the Healthy Minds Innovation (HMI) app for an additional 8 weeks (Phase 2).
62738899|NCT06351774|EXPERIMENTAL|PT+HMI|Participants will receive physiotherapy per clinical practice guideline recommendations for 8 weeks, in addition to the Healthy Minds Innovation app (Phase 1). At week 10, participants will complete the Oswestry Disability Index (ODI) to determine their response to treatment. Individuals who report a favorable response to PT+HMI, defined by a threshold of improvement of at least 30% in their ODI, will continue with their PT+HMI for an additional 8 weeks. Individuals who do not favorably respond to PT+HMI will receive an in-person teacher-guided tai chi session and tai chi videos for guided self-practice for an additional 8 weeks (Phase 2).
62613501|NCT02440854||Patients with non-small cell lung cancer (NSCLC) treated with afatinib|Patients with advanced/metastatic non-small cell lung cancer (NSCLC) in Greece treated with afatinib. Patients were treated as per the routine medical practice in terms of visit frequency, types of assessments performed and with adherence to the local prescribing requirements for afatinib. Patients were observed in the context of the study until the end of study participation, defined as a maximum of 48 months after afatinib treatment initiation or until disease progression, death, withdrawal of consent, unacceptable toxicity, study completion or physician's decision whichever occurred earlier.
62613502|NCT05445700|ACTIVE_COMPARATOR|Non-frail|FRAIL scale= 0
62613503|NCT05445700|ACTIVE_COMPARATOR|Pre_frail|FRAIL scale= 1-2
62613504|NCT05445700|ACTIVE_COMPARATOR|Frail|FRAIL scale \>2
62256083|NCT00362349|EXPERIMENTAL|1|IVIg
62256084|NCT05488600||Team Sports|30 elite athletes between the ages of 20-30 who are interested in team sports
62256085|NCT05488600||Individual Sports|30 elite athletes between the ages of 20-30 who are interested in individual sports
62256086|NCT05488600||Control Group|30 healthy individuals between the ages of 20-30 who are not interested in sports
62256087|NCT05787873|EXPERIMENTAL|Sequence A|"Period 1: SIPS-2209-1 - A single oral dose of 1 tablet under fasting condition~Period 2: SIPS-2209-2, SIPS-2209-3 - A single oral dose of 2 tablets under fasting condition"
62256088|NCT05787873|EXPERIMENTAL|Sequence B|"Period 1: SIPS-2209-2, SIPS-2209-3 - A single oral dose of 2 tablets under fasting condition~Period 2: SIPS-2209-1 - A single oral dose of 1 tablet under fasting condition"
62613505|NCT04854083|EXPERIMENTAL|Semaglutide|The intervention study for the patients with T2DM begins with a low-calorie diet (LCD) phase run-in for 13 weeks. During re-introduction of food, the participants will be assigned to semaglutide 1.34mg/ml treatment for 44 weeks (dose escalation in total 8 weeks, maintenance period for 36 weeks).
62613506|NCT04854083|PLACEBO_COMPARATOR|Placebo|The intervention study for the patients with T2DM begins with a low-calorie diet (LCD) phase run-in for 13 weeks. During re-introduction of food, the participants will be assigned to placebo treatment for 44 weeks (dose escalation in total 8 weeks, maintenance period for 36 weeks).
62613507|NCT06266520|EXPERIMENTAL|Group 1 (MNK therapy to release the superficial fascia)|The patient, positioned supine and wearing shorts for full lower limb exposure, undergoes layered palpation by the practitioner at the procedure points, identifying tender nodules and swelling in superficial fascia and muscles, followed by disinfection with an iodophor cotton swab. The practitioner, donning sterile latex gloves, holds the micro-needle-knife between the thumb and index finger of the right hand, inserting it parallel to the body's longitudinal axis, while the left thumb presses and holds the cord-like nodules for parallel incisions, with a maximum insertion depth of 5mm, performing lifting and cutting motions. Depending on the nodule size, 1-3 incisions are made. Post-procedure, any bruising or tissue fluid is expelled by massaging from distal to proximal around the incision. The area is then compressed with dry sterile gauze until bleeding ceases. Treatments are administered every other day, totaling six sessions.
62738900|NCT03073317|EXPERIMENTAL|INTERVENTION|Clinical protocol using FullPIERS and sFlit/PLGF ratio (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)
62738901|NCT03073317|NO_INTERVENTION|CONTROL|Usual clinic control
62738902|NCT04839068||First is retrospective part|: by obtaining the data from the patients records in a period between January 1st 2019 to December 31st 2019, and from May 1st 2020 to December (excluding women conceived before April 1st 2020)
62738903|NCT04839068||Second is prospective part|the same data will be obtained from the patient records in the same way in a period from the January 1st 2021 to the December 31st to assess the pregnancy outcomes in pregnant women who conceived after occurrence of Covid 19 pandemic in Egypt.
62738904|NCT05906680||Ulcerative Colitis (UC)|Patients with ulcerative colitis undergoing endoscopy and biopsies-collection according to the standard of care. First diagnosis for UC, treatment naive patients (≥18 and \<40 years), with no previously documented gastrointestinal infections. Furthermore, clinical and endoscopic evaluation (Mayo score≥2).
62738905|NCT05906680||Crohn's Disease (CD)|Patients with Crohn's disease undergoing endoscopy and biopsies-collection according to the standard of care. First diagnosis for CD, treatment naive patients (≥18 and \<40 years), with no previously documented gastrointestinal infections. Furthermore, clinical and endoscopic evaluation (Harvey-Bradshaw score≥5 and overall Simplified Endoscopic Score (SES-CD)\> 2).
62738906|NCT05906680||No UC and CD|Subjects undergoing endoscopy and biopsies-collection according to the standard of care (≥18 and \<40 years) (for example patients in screening for colorectal cancer disease). Subjects not affected by UC or CD according to the previously reported clinical and endoscopic evaluation criteria.
62738907|NCT04829786|EXPERIMENTAL|Japanese group|The subjects will receive in Period 1 either the low-dose or high-dose first, and in Period 2 they will receive the alternate dose. There is a washout period between periods.
62738908|NCT04829786|EXPERIMENTAL|non-Asian group|The subjects will receive in Period 1 either the low-dose or high-dose first, and in Period 2 they will receive the alternate dose. There is a washout period between periods.
62738909|NCT01023685|EXPERIMENTAL|CAD106|
62738910|NCT05536414|EXPERIMENTAL|Centanafadine + Placebo|
62738911|NCT05536414|EXPERIMENTAL|Centanafadine + Escitalopram|
62738912|NCT05536414|ACTIVE_COMPARATOR|Escitalopram + Placebo|
62054348|NCT05582304|EXPERIMENTAL|CONTROL/TEST/Photopic CSF|Eligible subjects who are habitual wearers of silicone hydrogel contact lenses will be randomized to the photopic condition and randomized contralaterally to the CONTROL/TEST lenses.
62054349|NCT05582304|EXPERIMENTAL|CONTROL/TEST/Mesopic CSF|Eligible subjects who are habitual wearers of silicone hydrogel contact lenses will be randomized to the mesopic condition and randomized contralaterally to the CONTROL/TEST lenses.
62256089|NCT02997527|EXPERIMENTAL|Intraluminal impedance testing|"During the participant's clinical endoscopy the 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope.~* The catheter (tiny tube) will be placed through the endoscope in your esophagus 1 cm above where your stomach and esophagus meet for 5 seconds.~* At 2 cm above where your stomach and esophagus meet the catheter will be placed for 5 seconds~* And at 3 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds.~* At 4 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds.~* At 5 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds."
62256090|NCT04518215|EXPERIMENTAL|ESPB group|Erector Spinae Plain Block
62256091|NCT04518215|ACTIVE_COMPARATOR|IV Analgesia group|Intra-Venous Analgesia
62256092|NCT04267536||Participants treated with upadacitinib monotherapy|Participants will receive upadacitinib for 12 months as prescribed by the physician
62054350|NCT02605226|EXPERIMENTAL|Arm I|"Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.~Patients receive cryoablation therapy."
62054351|NCT02605226|EXPERIMENTAL|Arm II|Patients receive androgen ablation as in arm I. Patients receive external beam radiation therapy.
62054352|NCT02158884|OTHER|IDEO brace|IDEO brace
62054353|NCT03793725|EXPERIMENTAL|SHR-1210 + Apatinib|Drug: SHR-1210 SHR-1210 was administered 200mg iv every 2 weeks Drug: Apatinib Apatinib was administered 500mg oral daily during the first 2 weeks and then 250 mg qd
62256093|NCT04267536||Participants treated with upadacitinib in combination with MTX|Participants will receive upadacitinib in combination with MTX as prescribed by the physician for 12 months
62613508|NCT06266520|ACTIVE_COMPARATOR|Group 2 (acupuncture)|Group 2 receives acupuncture treatment, employing needles produced by Suzhou Medical Supplies Factory Co., Ltd., with specifications of 0.30mm\*40mm and conforming to standard GB2024-1994. Patients, positioned prone or laterally with exposed lower limbs below the knee, are disinfected with an iodophor cotton swab. Acupuncture points selected include GB34, GB39, BL60, BL40, ST41, KI9, and KI6. The practitioner applies pressure to the points with the left hand and swiftly inserts the needle with the right, using a 0.30mm\*40mm disposable sterile acupuncture needle, penetrating the skin about 0.5-0.8 inches. After achieving deqi, the needle is twisted and thrust several times, left in place for 30 minutes. Upon removal, the needle site is compressed with a dry cotton swab until bleeding stops. Treatments occur every other day, totaling six sessions
62054354|NCT01398670|EXPERIMENTAL|Lispro arm|Lispro and Lispro Mix 75/25 /Lispro Mix 50/50
62613509|NCT06249321|EXPERIMENTAL|mFOLFIRINOX plus radiotherapy|Patients with advanced pancreatic adenocarcinoma will receive the modified FOLFIRINOX regimen (oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy.
62256094|NCT03173131|EXPERIMENTAL|Opioid counseling group|Counseling provided to patients prior to surgery regarding opioid usage, side effect, long term effect and risks of opioids.
62256095|NCT03173131|NO_INTERVENTION|No Counseling|No preoperative counseling will be provided to this group. Standard medication information will be provided only.
62054355|NCT01398670|ACTIVE_COMPARATOR|Humalog® arm|Humalog® and Humalog® Mix75/25 / Humalog® Mix50/50
62054356|NCT02486601|EXPERIMENTAL|nab-paclitaxel + FOLFOX|nab-paclitaxel + FOLFOX nab-paclitaxel: 150 mg/m2 D1 every 2 weeks Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks 5-FU infusion: 2400mg/m2 48h infusion every 2 weeks 6 pre-operative cycles 6 post-operative cycles (optional)
62613510|NCT00700154|EXPERIMENTAL|Insulin infusion (aspart)|
62054357|NCT05667467|EXPERIMENTAL|CONTROL GROUP|
62256096|NCT00827606|EXPERIMENTAL|Atorvastatin|All subjects will be treated with atorvastatin
62256097|NCT05039450|EXPERIMENTAL|EFX 28 mg (Main Study)|
62256098|NCT05039450|EXPERIMENTAL|EFX 50 mg (Main Study)|
62256099|NCT05039450|PLACEBO_COMPARATOR|Placebo (Main Study)|
62738913|NCT05536414|PLACEBO_COMPARATOR|Placebo + Placebo|
62738914|NCT04370587|EXPERIMENTAL|Phase 1|T3011 single agent dose escalation in participants with solid tumors
62738915|NCT04370587|EXPERIMENTAL|Phase 2a Part 1 Arm A|RP2D T3011 single agent in participants with melanoma
62738916|NCT04370587|EXPERIMENTAL|Phase 2a Part 1 Arm B|RP2D T3011 single agent in participants with other solid tumors
62738917|NCT04370587|EXPERIMENTAL|Phase 2a Part 2 Arm C|RP2D T3011 + pembrolizumab in participants with NSCLC
62738918|NCT04370587|EXPERIMENTAL|Rollover Arm|RP2D T3011 + pembrolizumab in participants who have progressed on T3011 single agent
62054358|NCT05667467|EXPERIMENTAL|NURSE GROUP|
62054359|NCT05667467|EXPERIMENTAL|STUDY GROUP|
62054360|NCT00001981||Patients with acromegaly|Patients with acromegaly
62256100|NCT05039450|EXPERIMENTAL|EFX 50 mg (Cohort D)|
62256101|NCT05039450|PLACEBO_COMPARATOR|Placebo (Cohort D)|
62256102|NCT00050648|ACTIVE_COMPARATOR|cyclosporine|oral medication 2mg/kg/day orally from Day 0 until Day 90
62738919|NCT05270941|ACTIVE_COMPARATOR|Control Groups|"Control groups. This clinical trial was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+T-PRF) or control (CAF+SCTG) groups after initially evaluating the clinical parameters and randomized by coin flip method.~Intervention: Procedure: Control groups"
62738920|NCT05270941|EXPERIMENTAL|Test Group|"Test groups. This clinical trial was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+T-PRF) or control (CAF+SCTG) groups after initially evaluating the clinical parameters and randomized by coin flip method.~Intervention: Procedure: Control groups Intervention: Procedure: test groups"
62738921|NCT01049204|ACTIVE_COMPARATOR|Group 1|Nadir CD4 count \>200 cells/µl blood and randomised to Maraviroc 150mg BD
62738922|NCT01049204|PLACEBO_COMPARATOR|Group 2|Nadir CD4 count \>200 cells/µl blood and randomised to placebo twice daily for 24 weeks
62613511|NCT00700154|NO_INTERVENTION|Standard care|Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.
62613512|NCT05817214|EXPERIMENTAL|Treatment arm|This trial has a single treatment arm. All participants will receive small treatment including cadonilimab, anlotinib and granulocyte-macrophage colony-stimulating factor in this arm
62613513|NCT02301039|EXPERIMENTAL|Soft tissue sarcoma|Patients with the following types of soft tissue sarcoma: leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH, MPNST and synovial sarcoma). Pembrolizumab will be administered at 200 mg intravenously every 3 weeks
62613514|NCT02301039|EXPERIMENTAL|Bone sarcoma|Patients with the following types of bone sarcoma: Ewing sarcoma, osteosarcoma, and chondrosarcoma \[de-differentiated or mesenchymal\]. Pembrolizumab will be administered at 200 mg intravenously every 3 weeks
62613515|NCT02301039|EXPERIMENTAL|Expansion|Patients with the following types of soft tissue sarcoma: poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma. Pembrolizumab was administered at 200 mg intravenously every 3 weeks
62613516|NCT05571215|EXPERIMENTAL|Combined tDCS and PNE|This is a single-arm pilot study used to evaluate the treatment effects of combining pain neuroscience education (PNE) and transcranial direct current stimulation (tDCS). All participants will receive the same Intervention, which includes five sessions of tDCS to the left dorsolateral prefrontal cortex (DLPFC) plus PNE over two weeks.
62613517|NCT03111615|EXPERIMENTAL|Aromatase Inhibitor group|Female patients of 50 and above y.o. shall initiate hormone therapy (Letrozol 2.5 mg or Anastrazol 1 mg) immediately after the diagnosis until surgery.
62256103|NCT00050648|ACTIVE_COMPARATOR|anti-TAC|1mg/kg/dose medication every other week on the odd week (week 1-13)
62256104|NCT00050648|EXPERIMENTAL|Cyclosporine and anti-TAC|DaclizumabTM at 1mg/kg plus low dose cyclosporine (2 mg/kg/day)
62613518|NCT03111615|NO_INTERVENTION|Control group|Female patients of 50 and above y.o. that follow standard protocol (no pre-surgery (Letrozol 2.5 mg or Anastrazol 1 mg))
62613519|NCT03111615|OTHER|Aromatase Inhibitor Active surveillance|Female patients of 50 and above y.o. that refuse surgery and therefor follow standard protocol (only Letrozol 2.5mg or Anastrazol 1 mg) until disease progression, death or will of surgery In this subgroup we are going to include, under HT, female patients with CDis,that refuse the standard treatment with surgery plus eventual rt and/or ht
62738923|NCT01049204|ACTIVE_COMPARATOR|Group 3|Nadir CD4 count ≤200 cells/µl blood and randomised to Maraviroc 150mg BD
62738924|NCT01049204|PLACEBO_COMPARATOR|Group 4|Nadir CD4 count ≤200 cells/µl blood and randomised to placebo twice daily for 24 weeks
62738925|NCT05330494|EXPERIMENTAL|S1|TEAS treatment initiated at 30 minutes before induction and lasted for 30min,TEAS treatment(disperse-dense waves; frequency, 2/100 Hz)on acupoints Hegu(LI4) , Neiguan(PC6) and Zusanli（ST 36）of both sides, and the present intensity(8～12 mA) was the maximum current that could be tolerated.Then, the TEAS treatment was administered twice a day (once in the morning and once in the afternoon) on the first and second postoperative day, which lasted for 30 minutes each time.
62738926|NCT05330494|EXPERIMENTAL|S2|TEAS treatment initiated immediately after induction and stopped at the end of surgery,TEAS treatment(disperse-dense waves; frequency, 2/100 Hz)on acupoints Hegu(LI4) , Neiguan(PC6) and Zusanli（ST 36）of both sides, and the present intensity(8～12 mA) was the maximum current that could be tolerated.Then, the TEAS treatment was administered twice a day (once in the morning and once in the afternoon) on the first and second postoperative day, which lasted for 30 minutes each time.
62738927|NCT05330494|EXPERIMENTAL|S3|TEAS treatment initiated immediately after extubating and lasted for 30 minutes,TEAS treatment(disperse-dense waves; frequency, 2/100 Hz)on acupoints Hegu(LI4) , Neiguan(PC6) and Zusanli（ST 36）of both sides, and the present intensity(8～12 mA) was the maximum current that could be tolerated.Then, the TEAS treatment was administered twice a day (once in the morning and once in the afternoon) on the first and second postoperative day, which lasted for 30 minutes each time.
62738928|NCT05330494|SHAM_COMPARATOR|control|the control group was given all manipulations without electrical stimulation, electrodes were placed on the same acupoints, but no current was given
62738929|NCT04919031|EXPERIMENTAL|study|Inspiratory muscle trainer plus diaphragmatic release and traditional medications
62738930|NCT04919031|ACTIVE_COMPARATOR|control|inspiratory muscle trainer plus traditional medications
62738931|NCT06662318|ACTIVE_COMPARATOR|Group L|
62738932|NCT06662318|ACTIVE_COMPARATOR|Group D|
62738933|NCT06662318|ACTIVE_COMPARATOR|Group F|
62738934|NCT05661864|EXPERIMENTAL|Multi-Tiered Systems of Support for Teacher Training Evaluation|Participants will be randomized to a target practice group. The group will receive the multi-tiered systems of support (online instruction, self-monitoring, self-management) for the target practice. They will not receive instruction on the non-target practice until after study data collection concludes.
62613520|NCT03111615|OTHER|Aromatase Inhibitor Active surveillance + aas|emale patients of 50 and above y.o. that refuse surgery and therefor follow standard protocol (only Letrozol 2.5mg or Anastrazol 1 mg plus acetilsalicilic acid) until disease progression, death or will of surgery In this subgroup we are going to include, under HT, female patients with CDis,that refuse the standard treatment with surgery plus eventual rt and/or ht
62613521|NCT01575041|ACTIVE_COMPARATOR|Sodium|For 4 weeks subjects will consume 3 grams of sodium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet
62613522|NCT01575041|ACTIVE_COMPARATOR|Potassium|For 4 weeks subjects will consume 3 grams of potassium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet.
62613523|NCT01575041|PLACEBO_COMPARATOR|Placebo|For 4 weeks subjects will consume placebo capsules (content: cellulose) on top of a low-sodium low-potassium diet
62613524|NCT01785758|EXPERIMENTAL|Renal Group|Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade
62613525|NCT01785758|ACTIVE_COMPARATOR|Control group|Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade
62054361|NCT02780232|EXPERIMENTAL|Internet-based program|"Adolescents in the intervention will receive a tailored online program during 3 months.~Adolescents interact with the program via a monitoring e-mail that they receive every two weeks (Monitoring) and a website which allows them to access a number of links."
62613526|NCT05223088|EXPERIMENTAL|Tislelizumab combined with apatinib and oxaliplatin plus S1|Neoadjuvant immunotherapy, PD-1, plus apatinib and oxaliplatin plus S1 will be applied to patients with Borrmann IV、large Borrmann III type and Bulky N positive advanced gastric cancer before surgery.
62613527|NCT01438931|PLACEBO_COMPARATOR|Placebo group|Loading infusion of Placebo over 10 minutes followed by maintenance infusion of Placebo
62613528|NCT01438931|ACTIVE_COMPARATOR|DA-9501 0.5 mcg/kg group|Loading infusion of Dexmedetomidine 3.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr
62613529|NCT01438931|ACTIVE_COMPARATOR|DA-9501 1.0 mcg/kg group|Loading infusion of Dexmedetomidine 6.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr
62613530|NCT04632056||Beovu|Brolucizumab (Genetical Recombination) 6 mg (0.05 mL) was administered by intravitreal injection every 4 weeks for the first three doses(loading phase). In the following maintenance phase, Brolucizumab was basically administered every 12 weeks. The interval between treatments was adjusted as appropriate according to the symptoms. The interval between two doses was not to be shorter than 8 weeks
62613531|NCT03919344|OTHER|Central SAS cases|Patients with central apnea
62613532|NCT03919344|OTHER|Obstructive SAS controls|Patients with moderate to severe obstructive apnea (apnea-hypopnoea index ≥ 15 / h)
62613533|NCT03919344|OTHER|Snorers controls|Snorers controls : Patients with snoring, with or without mild obstructive apneas (index of apnea-hypopneas \<15 / h)
62613534|NCT02977728||Mild Traumatic Brain Injury|The investigators will include patients who have been diagnosed with a mild traumatic brain injury (Glasgow Coma Scale 13 and above). The patients will be aged between 18 and 55 years old and admitted to the Hospital Visp in the 24 hours preceding the testing.
62613535|NCT02977728||Orthopaedic Injury|The investigators will include patients who have been diagnosed with a traumatic orthopedic injury to one of their limbs. The patients will be aged between 18 and 55 years old and admitted to the Hospital Visp in the 24 hours preceding the testing.
62613536|NCT00567697|ACTIVE_COMPARATOR|A|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection
62613537|NCT00567697|SHAM_COMPARATOR|B|
62613538|NCT03986229|ACTIVE_COMPARATOR|With compression garments|"Evaluation of the variation in the travel speed of the center of pressure with compression garments and the standing static balance."
62613539|NCT03986229|ACTIVE_COMPARATOR|Without compression garments|"Evaluation of the variation in the travel speed of the center of pressure with compression garments and the standing static balance."
62613540|NCT00978393|EXPERIMENTAL|A|
62613541|NCT00978393|EXPERIMENTAL|B|
62613542|NCT00978393|EXPERIMENTAL|C|
62613543|NCT00978393|EXPERIMENTAL|D|
62613544|NCT00978393|EXPERIMENTAL|E|
62613545|NCT00978393|EXPERIMENTAL|F|
62613546|NCT04993599|EXPERIMENTAL|Pediatric patients|\<Intervention\> The participants(Pediatric patients) mainly interact with the social robot which is controlled by the researcher behind the scene
62613547|NCT04993599|EXPERIMENTAL|Carers|\<Intervention\> The participants(Carers) interact with the social robot and watch how their child interact with the robot which is controlled by the researcher behind the scene
62613548|NCT01955109|EXPERIMENTAL|Viaskin Peanut 250 mcg|
62738935|NCT05661864|NO_INTERVENTION|Control|Participants will not receive intervention on the non-target practice until after study data collection concludes. This practice will serve as the comparison for the group who received intervention on the practice.
62738936|NCT03133819|OTHER|Q-Sense_QST (TSA II)|"QST measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.~Using the method of limits, a threshold will determine as the average of four successive stimuli for cold and warmth sensation and two for heat pain."
62738937|NCT03146559|EXPERIMENTAL|EMG and TENS|"Wireless Bluetooth EMG (Myo) bracelet will be placed on the healthy forearm. A voluntary dorsi flexion of the healthy wrist produces data that will be transmitted to a PC and will be used to activate (via Arduino controller) a Transcutaneous Electric Nerve Stimulator (TENS), placed on the paretic forearm, that will stimulate wrist dorsi flexors.~5 days per week, for 3 weeks, 15 minutes per day."
62738938|NCT03146559|ACTIVE_COMPARATOR|TENS only|"Custom-built software \& hardware: PC + Arduino controller and Transcutaneous Electric Nerve Stimulator (TENS) device, will be used to stimulate wrist dorsi flexors of the paretic forearm.~5 days per week, for 3 weeks, 15 minutes per day."
62054362|NCT02780232|NO_INTERVENTION|Treatment as usual|-Waiting list control group.
62613549|NCT05811078|EXPERIMENTAL|Enterprise Group|"The contents of the research were created according to the Roy Adaptation model. Each session lasted an average of 2 hours.~Peer interactive group support sessions were administered to the adolescents in the intervention group, one week apart. There were 7 sessions in total. The sitting arrangement of the training room is designed to allow children to interact with each other . The sessions lasted an average of 90 minutes as two 45-minute sessions. Between sessions, breaks that lasted for about 15 minutes were given and refreshments prepared for individuals with Type 1 diabetes were served during the breaks. During the break, the adolescents were given the opportunity to interact with each other by chatting. Fun exercise and kitchen workshop activities were also organized as interaction sessions in the initiative group."
62613550|NCT05811078|NO_INTERVENTION|Control Group|"Adolescents and their families were informed in the diabetes education room in the pediatric endocrine service of the hospital where the study was conducted, and their written consent was obtained. Within the scope of the pre-test, Diabetes Adolescent Diagnosis Form, Diabetes Information Evaluation Form, Diabetes Management Self-Efficacy Scale in Adolescents with Type 1 Diabetes and Child's Attitude towards Own Disease Scale were applied. Then, individual diabetes education was given by the diabetes education nurse as a hospital routine. Three months after the training, the adolescents were called by phone to the hospital for control, HbA1c follow-up was taken and post-test applications were made."
62613551|NCT00179894|EXPERIMENTAL|1 Physician training|Physician participants will receive training in guidelines and medication monitoring
62613552|NCT00179894|NO_INTERVENTION|2|Physician participants will provide usual care and no special intervention
62613553|NCT02006056|EXPERIMENTAL|Secondary prophylaxis|Patients already experiencing mild nausea/vomiting within 24 hours before radiotherapy. Intervention is 8mg of ondansetron (Ondissolve) on the day of radiation treatment at least 1 hour prior to treatment and repeated approx. 608 hours later in the day (bid). For patients who are treated with 20Gy/5 fractions, or 30Gy/10 fractions, they will take ondansetron twice (bid) on each day of treatment, at least 1 hour prior to treatment, and also on weekends or holidays in between treatment.
62613554|NCT02006056|EXPERIMENTAL|Primary prophylaxis|Patients experiencing no nausea and vomiting 24 hours before commencement of radiotherapy. Intervention is 8mg of ondansetron (Ondissolve) on the day of radiation treatment at least 1 hour prior to treatment and repeated approx. 608 hours later in the day (bid). For patients who are treated with 20Gy/5 fractions, or 30Gy/10 fractions, they will take ondansetron twice (bid) on each day of treatment, at least 1 hour prior to treatment, and also on weekends or holidays in between treatment.
62613555|NCT05941442|EXPERIMENTAL|Darigabat|Participants will receive darigabat, up to a maximum dose of 12.5 mg, orally, BID, for two weeks in the Titration Period and thereafter, 25 mg, orally, BID for 12 weeks in the Maintenance Treatment Period.
62613556|NCT05941442|PLACEBO_COMPARATOR|Placebo|Participants will receive darigabat matching placebo, orally, BID for 2 weeks during the Titration period and thereafter for 12 weeks during the Maintenance Treatment Period.
62613557|NCT02250950|EXPERIMENTAL|MI and SDT Exercise Group|Intervention Condition: Participated in 12 weekly meetings led by MI- and SDT-trained exercise instructor.
62613558|NCT02250950|SHAM_COMPARATOR|Non-MI and SDT Exercise Group|Control Condition: Participated in 12 weekly meetings led by an exercise instructor who was not trained in MI and SDT.
62613559|NCT02245919|EXPERIMENTAL|Back on Track intervention|A biopsychosocial primary care intervention based on multidisciplinary pain rehabilitation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
62613560|NCT01454414|EXPERIMENTAL|Permethrin Impregnated Uniforms|Uniforms (including pants, shorts, shirts, socks, and hats) treated with long-lasting permethrin.
62613561|NCT01454414|NO_INTERVENTION|Placebo|Uniforms sent to Insect Shield, washed and refolded (no permethrin applied).
62613562|NCT00550264|EXPERIMENTAL|1|
62613563|NCT00550264|NO_INTERVENTION|2|
62838428|NCT05107726|EXPERIMENTAL|TRE Group|In the TRE group, study staff will instruct the family unit on limiting the eating window to 10-12 hours per day, during which they can eat ad libitum. Notably, in the TRE group, participants (children and adults) will be instructed to brush their teeth with a WIFI-enabled toothbrush in the morning and specifically within ½ hour after their evening meal. This will serve as a cue to stop evening eating, and information from the WIFI-enabled toothbrush will be accessed by study staff to approximate the eating window. The adult from each family unit will receive a daily REDCap-administered email to indicate the timing of the first meal of the day and the last meal of the day for the parent and child, which will also serve as an estimate of the eating window.
62838429|NCT05107726|NO_INTERVENTION|Standard of Care Group|The standard of care control group will receive dietary instruction that is based on a 1200-1500 calorie diet, as is typical of family-based interventions. Calorie counting will not be encouraged. However, families will be encouraged to follow appropriate portion sizes; increase vegetable, fruit and lean protein consumption; as well as decrease consumption of energy-dense but low-quality items (e.g., sugar sweetened beverages). Families in this group will also receive a WIFI-enabled toothbrush and daily REDCap surveys but will not be instructed on when to brush teeth or to shorten their eating window
62838430|NCT01672671|EXPERIMENTAL|Neoadjuvant platinum-based chemotherapy|Doxorubicin, Paclitaxel, Cisplatin
62838431|NCT01551511|EXPERIMENTAL|delta-9-tetrahydrocannabinol (namisol)|
62838432|NCT01551511|PLACEBO_COMPARATOR|Placebo|
62838433|NCT05885399|EXPERIMENTAL|penpulimab|Penpulimab will be administered intravenously at a dose of 200 mg every 3 weeks. Treatment continued until the patient exhibited radiographic or clinical disease progression or unacceptable adverse events.
62838434|NCT02780752|ACTIVE_COMPARATOR|Oral hymecromone 400mg po three times per day|Participants will be administered oral hymecromone 400mg po three times per day (1200 mg)
62054363|NCT03951038|ACTIVE_COMPARATOR|PCIA group|Participants in this group will receive PCIA post-operatively (tramadol 800 mg and flurbiprofen axetil 100mg with saline added up to a volume of 80ml in total ) and the equal volume of 0.9% normal saline will be conducted by ultrasound and receive a single injection between the longissimus and iliocostalis muscles both sides of the spine. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
62613564|NCT03292471|EXPERIMENTAL|Inhibitory only|Inhibitory 1Hz rTMS will be applied continuously for 1200 pulses (20 minutes) 5 days per week across 2 weeks (10 sessions total).
62613565|NCT03292471|EXPERIMENTAL|Excitatory primed|The inhibitory sequence described above will be preceded for each session by priming stimulation which will consist of intermittent 6-Hz rTMS applied in 5 second trains with 25 second intervals between trains for a total 600 pulses (10 minutes).
62613566|NCT02433899|EXPERIMENTAL|Test - Microsurgical semilunar flap|"Semilunar coronally repositioned flap performed under magnification with a surgical microscope.~SLI was carried out following the outline of the gingival margin with a microsurgical blade under (8x) magnification. An ISI was performed mid-facially. Then, a split-thickness dissection was performed from the initial incision coronally until connecting to the ISI. The mid-facial tissue was completely released, positioned coronally to the CEJ and held in place against the tooth. A cyanoacrilate adhesive (CAA) was applied over the post-surgical gingival margin and tooth enamel to stabilize the flap."
62613567|NCT02433899|ACTIVE_COMPARATOR|Control - Conventional Semilunar flap|Semilunar coronally repositioned flap performed without magnification. A semilunar incision (SLI) was carried out with a 15c surgical blade. An ISI was performed mid-facially. Then, a split-thickness dissection was performed from the initial incision coronally until connecting to the ISI. The mid-facial tissue was completely released, positioned coronally to the CEJ and held in place against the tooth. A cyanoacrilate adhesive (CAA) was applied over the post-surgical gingival margin and tooth enamel to stabilize the flap.
62838435|NCT02780752|ACTIVE_COMPARATOR|Oral hymecromone 800 mg po three times per day (2400 mg)|Participants will be be administered oral hymecromone 800 mg po three times per day (2400 mg)
62838436|NCT02780752|ACTIVE_COMPARATOR|Oral hymecromone 1200 mg three times per day (3600 mg)|Participants will be administered oral hymecromone 1200 mg three times per day (3600 mg)
62838437|NCT02447302|EXPERIMENTAL|Etrasimod Low Dose|Oral, low dose, daily for 12 Weeks
62838438|NCT02447302|EXPERIMENTAL|Etrasimod High Dose|Oral, high dose, daily for 12 weeks
62838439|NCT02447302|PLACEBO_COMPARATOR|Placebo|Oral, placebo, daily for 12 weeks.
62613568|NCT04451668|EXPERIMENTAL|FT218|once nightly sodium oxybate extended release oral solution (FT218)
62838440|NCT01240824|EXPERIMENTAL|BCG + aminophylline|Bacillus Calmette-Guerin (BCG) plus one of three escalating doses of aminophylline administered intravesically.
62838441|NCT04168606||Cases with placental abruption|"Cases of placental abruption included in our study will be clinically defined and will not be only diagnosed by histological examination.~All cases will be reviewed by an experienced obstetrician in order to confirm the diagnosis."
62838442|NCT02042274|EXPERIMENTAL|Fish oil supplement|Fish oil supplements providing up to 3g per day of EPA and DHA
62838443|NCT04749004|EXPERIMENTAL|Intervention Group|"Tracking of steps by means of a fitness tracker~For the economic experiments on time and risk preferences monetary rewards are used with the amount depending on the decisions of the participants.~Participants collect points for transmitting informations about the amount of steps taken on the basis of which they get a small reward (e.g., a skiing ticket)~Setting-up of a commitment contract on the individual's goal of monthly steps taken~Provision of financial incentives upon achievement of one's goal of steps taken~Provision of nudges (reminders)"
62054364|NCT03951038|EXPERIMENTAL|Lateral TLIPB group|Participants in this group will be conducted by ultrasound and receive a single injection between the longissimus and iliocostalis muscles both sides of the spine, and combined with PCIA post-operatively. The regimen of the Lateral TLIPB is 0.2% 20 ml ropivacaine respectively and the regimen of PCIA is same with PCIA group.
62613569|NCT03252366|ACTIVE_COMPARATOR|GELFOAM (ABSORBABLE GELATIN)|"Sterile Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic.~it act as a space maintainer and alternative to bone filler for new bone formation in the maxillary sinus. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids its effect appears to be more physical than the result of altering the blood clotting mechanism. When placed in soft tissues, GELFOAM is usually absorbed completely within four to six weeks, without inducing excessive scar tissue"
62613570|NCT03252366|ACTIVE_COMPARATOR|XENOGRAFT (TUTOGEN)|xenografts as a sinus bone replacement graft ,The osteoconductive properties of xenografts in human sinus grafting have been well documented. They are due to both their chemical composition and their macro and micro morphology.The efficacy of xenografts as a sinus bone replacement graft may be due to combination of factors. Foremost would be the osteoconductive capacity of xenografts. In addition, they supply minerals that are necessary for bone formation, their density provides stability to the graft and the implants placed in them, and this density persists long term due to the fact that these grafts do not completely resorb.
62838444|NCT04749004|NO_INTERVENTION|Control Group|"Tracking of steps by means of a fitness tracker~For the economic experiments on time and risk preferences monetary rewards are used with the amount depending on the decisions of the participants.~Participants collect points for transmitting informations about the amount of steps taken on the basis of which they get a small reward (e.g., a skiing ticket)~To keep incentives constant the control group will also receive the flat payment of €10 to disentangle the effects between the contract and financial incentives."
62838445|NCT06305832|EXPERIMENTAL|Rezvilutamide +ADT+ SRT|Rezvilutamide along with ADT for 6 cycles (28 days for each cycle) in combination with salvage radiation therapy (SRT) according to standard of care
62054365|NCT04092725|EXPERIMENTAL|Treatment A|Single oral 150-mg dose of DAB on Day 1 AM.
62256105|NCT04232228||Participants with Crohn's Disease (CD)|Adult participants with moderate to severe CD who agree to be part of the study and who fit the inclusion/exclusion criteria and use Care4Today inflammatory bowel disease (C4T IBD) alongside standard of care (SOC) at participating centers will be observed. Data available per clinical practice and via the C4T IBD application will be collected within this study. Participants will also be asked to complete questionnaires that are sent directly to the patients, which are not completed as part of clinical practice or via the application. Relevant data will be collected by prospectively following participants from the index date for 12 months, and also by retrospectively collecting data for the 6-month period prior to the index date from participant's medical records. Index is the activation date of C4T IBD application in participant's smartphone.
62256106|NCT03725124||Patients|Women with inflammatory bowel disease (IBD.
62054366|NCT04092725|EXPERIMENTAL|Treatment B|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.
62256107|NCT03725124||Partners|Partners of women with IBD.
62256108|NCT03725124||Healthcare Professionals|Healthcare professionals working with women with IBD.
62256109|NCT06497348|EXPERIMENTAL|experimental group|"The experimental group will receive mobilization treatment and exercises, while the control group will receive only exercises. Weekly one-hour sessions will be held, from Monday to Friday, with two times available for each patient. Changes in pain, mobility and functionality will be recorded in an Excel document to monitor progress.~To the experimental group, treated by physiotherapists who know the pathology, Maitland mobilization techniques will be applied, focused on passive neural and joint mobilizations. Flexion-extension, abduction-adduction, and external and internal rotation movements will be performed."
62256110|NCT06497348|ACTIVE_COMPARATOR|control group|The control group, treated by physiotherapists who will blindly evaluate the patients, will only be prescribed exercises, the same as the experimental group.
62256111|NCT04251910|ACTIVE_COMPARATOR|Cohort 1- 30 Micrograms|Cohort 1 consists of 10 patients out of whom 8 patients receive 30 Micrograms film and the remaining 2 patients receive a placebo
62054367|NCT05752799|ACTIVE_COMPARATOR|Opioid Based Anaesthesia|"This arm will receive:~* 2 mcg/kg fentanyl in 10 ml volume~* 0.2 mL/kg/h remifentanil infusion~* 0.1 mg/kg morphine"
62054368|NCT05752799|ACTIVE_COMPARATOR|Opioid Free Anaesthesia|"This arm will receive~* 40 mg/kg magnesium sulfate in 100 ml N/S infusion~* 0.4 mcg/kg dexmedetomidine, max total dose 50mcg in 50 ml N/S infusion~* 0.3 mg/kg ketamine in 10 ml volume~* 0.2 ml/kg of the Multimix regimen in 100 ml N/S infusion as a bolus (The Multimix regimen consists of 50mcg dexmedetomidine, 500 mg lidocaine and 50mg ketamine).~* 0.2 ml/kg/h of the Multimix regimen in 100 ml N/S infusion as a continuous infusion"
62256112|NCT04251910|ACTIVE_COMPARATOR|Cohort 2- 60 Micrograms|"Cohort 2 consists of 10 patients out of whom 8 patients receive 60 Micrograms film and the remaining 2 patients receive a placebo.~Additional 20 subjects receive 60 Micrograms or placebo."
62256113|NCT04251910|ACTIVE_COMPARATOR|Cohort 3- 90 Micrograms|Cohort 3 consists of 10 patients out of whom 8 patients receive 90 Micrograms film and the remaining 2 patients receive a placebo
62256114|NCT04251910|ACTIVE_COMPARATOR|Part B Cohort|Part B cohort consists 46 subjects receiving 40 Micrograms or placebo
62838446|NCT06305832|OTHER|ADT+ SRT|ADT for 6 cycles (28 days for each cycle) in combination with salvage radiation therapy (SRT) according to standard of care
62838447|NCT05283941|EXPERIMENTAL|Pistachio Group|The pistachio group will receive pistachio nuts in 2-ounce packs. This group will consume one pack every day over the course of the 12-week study.
62256115|NCT05575479||Idiopathic Parkinson's Patients|Patients with idiopathic parkinson's disease
62256116|NCT04040075|OTHER|Open label|Open label Biktarvy to establish suppression of HIV 1 with 184 V/I Resistance Mutation
62256117|NCT01271192|ACTIVE_COMPARATOR|Surgical resection and adjuvant therapy|Patients receive surgical resection and undergo FOLFIRI for 12 cycles, from 2-4 weeks after operation. Patients undergo radiotherapy once daily 5 days a week for 5-6 weeks, from 8-12 weeks after operation
62256118|NCT01271192|EXPERIMENTAL|Neoadjuvant followed by operation|Patients receive neoadjuvant chemoradiotherapy (mFOLFIRI for 5 cycles and undergo radiotherapy as in arm I from the second cycle of FOLFIRI), surgery and FOLFORI for 7 cycles from 2-4 weeks after operation.
62256119|NCT03104699|EXPERIMENTAL|Monotherapy|Dose of 3 mg/kg IV every 2 weeks for up to 24 months.
62613571|NCT01899105|EXPERIMENTAL|Part A|A single dose of 2 fixed-dose combination tablets of 200mg lumacaftor/125mg ivacaftor (total of 400mg lumacaftor/250mg ivacaftor) in the fed state and fasted state with a 14 day washout period in between each dosing occasion
62613572|NCT01899105|EXPERIMENTAL|Part B|A single dose of 3 fixed-dose combination tablets of 200mg lumacaftor/83mg ivacaftor (total of 600mg lumacaftor and 250mg ivacaftor) in the fed with a 14 day washout period in between dosing occasions
62613573|NCT05869656|EXPERIMENTAL|Alert recommending oral fluid restriction|The alert will suggest to the treating clinician to fluid restrict the patient to 1L of oral fluid per day
62613574|NCT05869656|ACTIVE_COMPARATOR|Alert recommending no oral fluid restriction|The alert will suggest to the treating clinician to continue without any oral fluid restriction
62613575|NCT01399489|EXPERIMENTAL|Exercise training|Individuals randomized to this arm get 48 sessions of personal training in a state of the art fitness facility
62613576|NCT01399489|NO_INTERVENTION|Control|Individuals in the control arm are expected to continue to live normally, following their doctor's advice but not engage in any formal exercise training.
62613577|NCT01055080|PLACEBO_COMPARATOR|Cow's milk formula|
62613578|NCT01055080|ACTIVE_COMPARATOR|Bovine insulin-free whey based formula|
62613579|NCT01055080|ACTIVE_COMPARATOR|Whey-based hydrolysed formula|
62613580|NCT01296594|ACTIVE_COMPARATOR|Usual Care|
62613581|NCT01296594|EXPERIMENTAL|usual care with cell phone monitoring and CM|In the CM condition, patients will carry a cell phone and record and send in time- and date-stamped self videos of medication ingestion.
62256120|NCT06489730||Highlanders living above 2500 m|Highlanders permanently living above 2500 m in the Aksay area in Kyrgyzstan
62256121|NCT06489730||Low altitude control|Healthy lowlanders living below 1000 m.
62613582|NCT05166850|EXPERIMENTAL|Preventive-Intervention-for-Cholera-for-7-Days (PICHA7) Mobile Health (mHealth) Program|Preventive-Intervention-for-Cholera-for-7-Days (PICHA7) mHealth program promoting handwashing with soap and water treatment for diarrhea patient households
62613583|NCT05166850|ACTIVE_COMPARATOR|Standard Arm|Standard recommendation in the Democratic Republic of the Congo for diarrhea patients upon discharge from health facilities
62613584|NCT03602794|ACTIVE_COMPARATOR|PECs Block|"Total local anaesthetic dose: 30ml ropivacaine 0.5%~•Pecs block will be performed by anaesthetist using ultrasound guidance in plane approach: 10ml ropivacaine 0.5% will be delivered at the plane between pectoralis major and pectoralis minor, another 20ml ropivacaine 0.5% will be delivered in the plane between the pectoralis minor and serratus anterior muscles at the level of the third and fourth ribs"
62613585|NCT03602794|PLACEBO_COMPARATOR|Local Infiltration|LIA will be performed by surgeon during the operation. The upper skin flap will be raised in the standard manner for mastectomy. The lateral border of the major pectoralis muscle will then be visualised. A volume of 10 ml ropivacaine 0.5% will be delivered between the inter-fascial planes of the pectoral muscles. The lower skin flap will then be raised in the standard manner for mastectomy and the breast is raised off the pectoralis muscle exposing the serratus anterior muscle. A volume of 20 ml ropivacaine 0.5% will be delivered between the muscle planes of the serratus anterior and pectoralis minor muscles.
62613586|NCT01256970||Polycystic Ovary Syndrome.|Polycystic ovary syndrome was diagnosed according to the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria: PCOM, chronic anovulation and hyperandrogenism.
62613587|NCT01256970||Normal Control|Normal control women were women who did not present with any of three PCOS criteria.
62613588|NCT05908500|OTHER|Standard CPR Training|Standard CPR training via American Heart Association or American Red Cross provided for 30 minutes during a high school class
62613589|NCT05908500|ACTIVE_COMPARATOR|CPR Game|Novel CPR game experience CPR training is provided for 30 minutes during a high school class.
62613590|NCT00509353|EXPERIMENTAL|Single Group|
62613591|NCT04554342|EXPERIMENTAL|healthy participants starting with candy V01|healthy participants testing a candy in 5 different variations by (unstimulated and stimulated) salivary flow rate (before and after comparison)
62613592|NCT04554342|EXPERIMENTAL|healthy participants starting with candy V02|
62613593|NCT04554342|EXPERIMENTAL|healthy participants starting with candy V03|
62443810|NCT03931083||Histopathological examination of tissue biopsies|All acetowhite lesions will be biopsied. When no lesion is seen, one biopsy is taken from each quadrant at the squamocolumnar junction. Biopsies will be sent and examined in a South African based lab. All histological slides will also be verified independently by an IARC trained pathologist at the end of the study. Histological endpoints are defined by the CIN classification system: CIN 1 affects only the lower third of the epithelium (mild dysplasia), CIN 2 involves two thirds of the epithelium and CIN 3 involves the full thickness (severe dysplasia and carcinoma in situ). These findings can be dichotomized by the Lower Anogenital Squamous Terminology into low-grade squamous intraepithelial lesions (LSIL) and high-grade squamous intraepithelial lesions (HSIL). All patients with CIN grade 2 that stained diffusely positive for p16 are considered as HSIL, all patients with CIN 3 are considered as HSIL. Expression of p16 will be visually assessed by immunohistochemistry.
62613594|NCT04554342|EXPERIMENTAL|healthy participants starting with candy V04|
62613595|NCT04554342|EXPERIMENTAL|healthy participants starting with candy V05|
62613596|NCT02733575|OTHER|Compassion Focused Therapy|Intervention
62613597|NCT03439462|EXPERIMENTAL|nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin)|Single arm, open-label, multi-institutional study to identify the RP2D and determine the efficacy and safety profile of nab-sirolimus administered as first-line therapy in combination with mFOLFOX6 and bevacizumab in patients with metastatic CRC.
62613598|NCT00926640|EXPERIMENTAL|1|Belinostat dose escalation
62613599|NCT00926640|EXPERIMENTAL|2|Belinostat UGT1A1 wild type/\*28 variant
62613600|NCT00926640|EXPERIMENTAL|3|Belinostat UGT1A1\*60 or 2/3/4 variant
62613601|NCT05958069|EXPERIMENTAL|minocycline|Treatment with minocycline combined with antiepileptic drugs: After enrollment, 100mg/day (50mg specification) of minocycline hydrochloride was administered for 12 consecutive weeks;
62738939|NCT05175430|ACTIVE_COMPARATOR|Pretreatment with paroxetine|Pretreatment with paroxetine (10 mg daily for 1 week followed by 20 mg daily for 5 weeks, per os), followed by administration of LSD (0.1 mg, per os) on the study day
62738940|NCT05175430|PLACEBO_COMPARATOR|Pretreatment with placebo|Pretreatment with placebo for 6 weeks (mannitol, per os), followed by administration of LSD (0.1 mg, per os) on the study day
62613602|NCT05768009|EXPERIMENTAL|Interscalene brachial plexus block (ISB)|• Group A will include 21 patients who will undergo the procedure under general anesthesia and ultrasound guided Interscalene brachial plexus block using 10 ml bupivacaine 0.25%.the interscalene block will be performed when the patient is in a supine position, with his/her head slightly elevated and turned away from the side to be blocked. The linear ultrasound probe (frequency 10-15 MHz) will be used with the depth setting of 2-4 cm. The probe will be initially placed near the midline of clavicle at the level of cricoid cartilage and scanned laterally to identify the carotid artery and internal jugular vein underneath the sternocleidomastoid muscle. By moving the probe laterally, the anterior scalene muscle will be identified below the lateral edge of the sternocleidomastoid. A groove containing the hypoechoic nerve structures will usually be identified. 10 mL of 0.25 bupivacaine will be injected into scalene groove around the nerve roots.
62256122|NCT03388359|EXPERIMENTAL|Allergic asthma|Bronchial asthma and sensitization to D. pteronyssinus allergen Interventions: Bronchial challenge with allergen (Dermatophagoides pteronyssinus, Dosimeter ProvoX (Ganshorns)); Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation (eosinophils, fibrobralst, airway smooth muscle cells); Inhibition of Wnt and Smad signaling pathways; Extracellular matrix turnover and deposition assessment.
62256123|NCT03388359|ACTIVE_COMPARATOR|Healthy subjects|"Healthy subjects without allergic and other chronic respiratory diseases (control group).~Interventions: Bronchial challenge with allergen (Dermatophagoides pteronyssinus, Dosimeter ProvoX (Ganshorns)); Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation (eosinophils, fibrobralst, airway smooth muscle cells); Inhibition of Wnt and Smad signaling pathways; Extracellular matrix turnover and deposition assessment."
62738941|NCT02977429|ACTIVE_COMPARATOR|standard group|"The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.than collect the data of ScvO2 and Pcv-aCO2:~ScvO2≥70%，and furthermore, Pcv-aCO2 is divided into ≤6mmHg and \>6mmHg"
62738942|NCT02977429|SHAM_COMPARATOR|control group|"The patients with ScvO2 \<70% will receive the standardized fluid therapy for 6 hours.than collect the data of ScvO2 and Pcv-aCO2:~ScvO2\<70%，and furthermore, Pcv-aCO2 is divided into ≤6mmHg and \>6mmHg"
62054369|NCT06259422|OTHER|Iohexol in addition to 125I-iothalamate and 131I-hippuran|In this clinical trial, patients receiving 125I-iothalamate and 131I-hippuran during routine clinical care, will also receive iohexol. This allows us to determine the mGFR using both methods in the same patient, and compare both methods in terms of accuracy and precision.
62054370|NCT04961008|EXPERIMENTAL|Bottle-PEP|Bottle-PEP
62054371|NCT04961008|ACTIVE_COMPARATOR|Routine physiotherapy|v
62054372|NCT02543255|EXPERIMENTAL|Abiraterone acetate + prednisone + leuprolide + cabazitaxel|Participants randomized to this arm will receive abiraterone acetate (1000 mg/day), prednisone (5 mg twice daily), leuprolide (22.5 mg every 3 months), and cabazitaxel (20 mg/m2, with 6 mg pegfilgrastim administered 24 h following cabazitaxel) prior to radical prostatectomy.
62256124|NCT03271398||Adult victims of sexual assault|
62256125|NCT03271398||Children who have been exposed to domestic abuse|
62256126|NCT03271398||Women with perinatal emotional complications|
62054373|NCT02543255|ACTIVE_COMPARATOR|Abiraterone acetate + prednisone + leuprolide|Participants randomized to this arm will receive abiraterone acetate (1000 mg/day) , prednisone (5 mg twice daily), and leuprolide (22.5 mg every 3 months) prior to radical prostatectomy.
62054374|NCT02037438|ACTIVE_COMPARATOR|CONV Arm|Conventional (CONV) care for the diagnosis and treatment of sleep disorders
62054375|NCT02037438|EXPERIMENTAL|PCCM ARM|Patient-Centered Outcomes and Coordinated Care Management (PCCM) for the diagnosis and treatment of sleep disorders
62054376|NCT01851174|EXPERIMENTAL|Gemcitabine and nab-Paclitaxel|"Gemcitabine (1,000 mg/m\^2) administered intravenously on days 1 and 15, every 28 days~nab-Paclitaxel (125 mg/m\^2) administered intravenously on days 1 and 15, every 28 days"
62256127|NCT03271398||Teens with behavior problems and histories of abuse|
62256128|NCT03271398||Veterans with military-related trauma|
62256129|NCT03271398||Survivors of intimate partner violence|
62256130|NCT03385603|EXPERIMENTAL|Fear-based Dilator Progression group|Participants in this group will complete a home dilator program using levels of pain-related fear to progress through the program.
62256131|NCT03385603|ACTIVE_COMPARATOR|Standard Dilator Progression Group|Participants in this group will complete a standard home program based on dilator manufacturer instructions for use.
62256132|NCT00143663|EXPERIMENTAL|Lapaquistat Acetate 100 mg QD|
62256133|NCT00143663|PLACEBO_COMPARATOR|Placebo QD|
62256134|NCT02203825|EXPERIMENTAL|CM-CS1 T-cell infusion|"The treatment will consist of a single infusion of CM-CS1 cells.~The following dose levels will be evaluated:~Cohort 1: 1x 10\^6 CM-CS1 T-cells Cohort 2: 3x 10\^6 CM-CS1 T-cells Cohort 3: 1x 10\^7 CM-CS1 T-cells Cohort 4: 3x 10\^7 CM-CS1 T-cells"
62256135|NCT05743738|OTHER|Presence of thrombosis|Doppler ultrasound D8, D15, D30, D45, D60 and D90
62256136|NCT05743738|NO_INTERVENTION|Absence of thrombosis|
62256137|NCT04948775|EXPERIMENTAL|Intervention Group|Cervical Stabilization Exercise Group
62256138|NCT04948775|NO_INTERVENTION|Control Group|Control Group
62256139|NCT06111833||Case (MODY)|"1. Age at diagnosis of diabetes ≤ 25 years old; and~2. BMI ≤ 25kg/m2; and~3. At least one parent suffers from type 2 diabetes"
62256140|NCT06111833||Family|Direct blood relatives/brothers and sisters of the Case group, who have contacted the research team through the subjects and are willing to participate in this study after giving full informed consent.
62256141|NCT06111833||Control|"1. Age at diagnosis of diabetes ≤ 40 years old, and without typical MODY characteristics~2. At least one parent suffers from type 2 diabetes"
62256142|NCT04663789|EXPERIMENTAL|Staple line plus reinforcement|In this experimental group, a lock stitch will be placed after transecting the pancreas with stapler.
62256143|NCT04663789|OTHER|staple line with no reinforcement|In this control group, no additional reinforcement is used after transecting the pancreas with stapler.
62256144|NCT01785459|ACTIVE_COMPARATOR|standard care|intravenous Prochlorperazine
62256145|NCT01785459|EXPERIMENTAL|treatment|0.5% bupivacaine
62256146|NCT02905929|EXPERIMENTAL|Sitting Less group|The 'reduce sitting' intervention group will receive three in-person health coaching sessions followed by five counseling phone calls. Participants will wear a thigh worn inclinometer for the first 3 weeks of the intervention, and at the mid-point of the intervention. At each in-person health coaching session participants will receive feedback from the ActivPAL showing periods throughout the day where participants have been sitting. In addition to the three initial in-person counseling sessions using the ActivPAL feedback, participants will receive phone calls from the health educator biweekly to help overcome barriers, to work on self-monitoring and planning skills, and to prepare relapse prevention. Tools to help prompt standing, including a standing desk, will also be provided.
62256147|NCT02905929|ACTIVE_COMPARATOR|Attention Control|Participants in the attention control condition will receive a healthy aging educational intervention developed and tested by the investigators in previous studies. This group will receive one in-person coaching session followed by seven phone coaching sessions.
62738943|NCT06235593|EXPERIMENTAL|Intervention Group|The intervention will be a combination of interviews and face-to-face follow-ups, with teleconsultations, based on other observational and experimental studies. The intervention program includes monitoring for 9 months
62256148|NCT06165848||General anesthesia|After preoxygenation, anesthesia induction was performed with 2 mg/kg IV propofol and 1 mcg/kg IV fentanyl in the general anesthesia group. Anesthesia was maintained with a mixture of 0.3-0.5 mcg/kg/min remifentanil, 2% sevoflurane, 50% air, 50% oxygen. The Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HAM-A), and the Beck Scale for Suicide Ideation (BSSI) were administered preoperatively and on postoperative day one by a psychiatrist.
62256149|NCT06165848||Sedation anesthesia|In the sedation group, 1 mcg/kg IV fentanyl and 1 mg/kg IV ketamine were administered at induction, and 30-50 mg IV propofol was added if necessary to maintain anesthesia. The Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HAM-A), and the Beck Scale for Suicide Ideation (BSSI) were administered preoperatively and on postoperative day one by a psychiatrist.
62256150|NCT04508400|EXPERIMENTAL|a single dose of fosaprepitant|Participants received a single dose of fosaprepitant (age-based adjustment) administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron (weight based) IV with dexamethasone (weight based) iv/po prior to chemotherapy and up to 72 hours after chemotherapy.
62256151|NCT04508400|PLACEBO_COMPARATOR|a single dose of matched placebo|Participants received a single dose of matched placebo for fosaprepitant administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron (weight based) IV with dexamethasone (weight based) iv/po prior to chemotherapy and up to 72 hours after chemotherapy.
62738944|NCT05245110|EXPERIMENTAL|experimental group|received a tele-exercise training program
62738945|NCT05245110|NO_INTERVENTION|control group|usual care only
62738946|NCT06301776|EXPERIMENTAL|Experimental group|3 Months DAPT+9 months ticagrelor monotherapy after Bridge(MicroPort NeuroTech, Shanghai, China) implantation
62738947|NCT06301776|ACTIVE_COMPARATOR|Control group|6 Months DAPT+6 months ticagrelor monotherapy after Bridge(MicroPort NeuroTech, Shanghai, China) implantation
62738948|NCT03040518|EXPERIMENTAL|Narrative SMS|"Participants will receive narrative SMS for 12 months.~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
62738949|NCT03040518|EXPERIMENTAL|Narrative SMS and Endowment Incentive|"Participants will receive narrative SMS for 12 months. In addition, they will receive an endowment incentive for verified weight loss.~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
62738950|NCT03040518|NO_INTERVENTION|Waiting List Control Group|"Participants will be on a waiting list for 12 months to receive the narrative SMS which will commence after 12 month outcome data has been collected. There will be no interim measurements or contacts by the research team. Men are therefore free to choose whether to try to lose weight during the 12 months.~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
62613603|NCT05768009|EXPERIMENTAL|pericapsular nerve block and superficial cervical plexus blocks|"• Group B will include 21 patients who will undergo the procedure under general anesthesia and combined pericapsular nerve block and superficial cervical plexus blocks (using 10 and 5 ml bupivacaine 0.25% respectively).~the patient's arm will be placed in external rotation and abducted at 45 degrees. The linear ultrasound probe will be placed longitudinally between the coracoid process and the humeral head. After identification of the humeral head, the subscapularis tendon and the deltoid muscle over it, a 50-mm sonovisible needle will be inserted using the in plane technique. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and 10 ml of 0.25% bupivacaine will be injected."
62838448|NCT05283941|NO_INTERVENTION|Control (Usual Diet) Group|The control group will not receive pistachio nuts. They will be asked to make no changes and continue to eat their regular diet.
62613604|NCT00467402|EXPERIMENTAL|1|
62613605|NCT00467402|EXPERIMENTAL|2|
62256152|NCT03755895|EXPERIMENTAL|experimental|patients to benefit from brachytherapy detachment under KALINOX and formal hypnosis
62256153|NCT03755895|ACTIVE_COMPARATOR|active comparator|patients to benefit from brachytherapy detachment under KALINOX
62256154|NCT01075412|EXPERIMENTAL|Group 2|Receives fourth \[F18\]Fluorothymidine (FLT) PET scan after 20 fractions of radiation therapy.
62613606|NCT00467402|PLACEBO_COMPARATOR|3|
62838449|NCT02728687|EXPERIMENTAL|Mannitol and menthol cream|Mannitol and menthol cream (Water, Mannitol, Propylene glycol, Isopropyl palmitate. Caprylic capric triglyceride, Ceteareth 20, Cetearyl alcohol, Glyceryl stearate, Polyethylene glycol 100 Stearate, Dimethicone, Octyldodecanol, Menthol, Lecithin, Ethylhexyl glycerin, Phenoxyethanol) applied as needed, up to 4 times daily for one month, to the feet of a person suffering from painful diabetic peripheral neuropathy. During the other month, the menthol cream will be applied to the participant's feet. Whether the mannitol and menthol cream will be given in the first or the second month will be chosen at random. At the end of the 2 months, if the participant chooses this cream, they will be given 3 months' supply of the cream to apply as needed to both feet.
62838450|NCT02728687|ACTIVE_COMPARATOR|Menthol cream|Cream containing menthol (Water, Propylene glycol, Isopropyl palmitate. Caprylic capric triglyceride, Ceteareth 20, Cetearyl alcohol, Glyceryl stearate, Polyethylene glycol 100 Stearate, Dimethicone, Octyldodecanol, Menthol, Lecithin, Ethylhexyl glycerin, Phenoxyethanol) applied as needed, up to 4 times daily for one month, to the feet of a person suffering from painful diabetic peripheral neuropathy. During the other month, the mannitol and menthol cream will applied to the participant's feet. Whether the menthol cream will be given in the first or the second month will be chosen at random. At the end of the 2 months, if the participant chooses this cream, they will be given 3 months' supply of the cream to apply as needed to both feet.
62256155|NCT01075412|EXPERIMENTAL|Group 1|Receives fourth \[F18\]Fluorothymidine (FLT) PET scan after 15 fractions of radiation therapy.
62838451|NCT00809718|OTHER|raltegravir and rifapentine|Concomitant administration of raltegravir and rifapentine in healthy volunteers
62838452|NCT02298010||Adjuvant chemotherapy group|Research subjects who were enrolled in CLASSIC trial and underwent adjuvant chemotherapy.
62838453|NCT02298010||Only surgery group|Research subjects who were enrolled in CLASSIC trial and did not undergo adjuvant chemotherapy
62838454|NCT00299169|EXPERIMENTAL|1|N of 1 trials of statin therapy
62838455|NCT00299169|OTHER|2|usual care
62838456|NCT03239106|EXPERIMENTAL|open label|All participants will receive Apremilast 30 mg BID.
62838457|NCT04084691|EXPERIMENTAL|Single Arm|Every patient will undergo every combination of physical exercise/meal type (3x3 combinations), one following the other. Each combination is replicated three times.
62054377|NCT01301391|EXPERIMENTAL|Milciclib|Milciclib Maleate capsules
62613607|NCT01491269|EXPERIMENTAL|Internet delivered CBT|Internet delivered cognitive behavioral intervention, 8 weeks treatment.
62838458|NCT00880243|EXPERIMENTAL|EMA+GM-CSF|"* Daunorubicine (CérubidineR) : 80 mg/m2/jour IV over 30 min from day 1 to day 3,~* AraC (AracytineR) : 500 mg/m2/jour IV from day 1 to day 3,~* Mitoxantrone (NovantroneR) : 12 mg/m2/jour IV over 30 min from day 8 to 9~* AraC (AracytineR) : 500 mg/m2/12h IV over 3 hours from day 8 to day10.~* GM-CSF (LeucomaxR): 5 µg/kg/jour IV over 6 hours from day 1 to day 10."
62838459|NCT00880243|ACTIVE_COMPARATOR|EMA without GM-CSF|"* Daunorubicine (CérubidineR) : 80 mg/m2/jour IV over 30 min from day 1 to day 3,~* AraC (AracytineR) : 500 mg/m2/jour IV from day 1 to day 3,~* Mitoxantrone (NovantroneR) : 12 mg/m2/jour IV over 30 min from day 8 to 9~* AraC (AracytineR) : 500 mg/m2/12h IV over 3 hours from day 8 to day10."
62838460|NCT00880243|EXPERIMENTAL|HD AraC+ GM-CSF|"* AraC (Aracytine) : 3 g/m2/12h IV (3 hours) on days 1, 3 , 5~* GM-CSF :5 µg/kg/d IV (6 hours) from day1 to day 5"
62838461|NCT00880243|ACTIVE_COMPARATOR|HD-AraC without GM-CSF|- AraC (Aracytine) : 3 g/m2/12h IV (3 hours) on days 1, 3 , 5
62838462|NCT02564003||Oxycodone|Oxycodone 0,1 mg/kg iv
62054378|NCT05606016|EXPERIMENTAL|Facilitated Self-Sampling Intervention (FSSI)|Participants in the FSSI arm will receive education on COVID-19 testing and be provided with rapid antigen tests. Participants will also receive pre and post surveys.
62256156|NCT01585272|EXPERIMENTAL|Rivastigmine|Eligible patients, who are under rivastigmine capsule 3 mg b.i.d. treatment for 4 weeks before Visit 2, will be recruited, followed by treatment switch from oral capsule to transdermal patch for 48 weeks maintenance treatment.
62256157|NCT03262454|EXPERIMENTAL|Interventions|Atezolizumab
62256158|NCT01948336|PLACEBO_COMPARATOR|Control|The patients in group C (control) (n=30) were bolused with 1 mg kg-1 ketamine (Ketalar®, Eczacibasi, Luleburgaz, Turkey) (IV) and 1 mg kg-1 propofol (Propofol 1% Fresenius, Fresenius Kabi Deutschland, Bad Homburg, Germany) (IV) followed by 1 mg kg-1 hour-1 ketamine (IV) and 50 µg kg-1 min-1 propofol (IV) infusion. Additionally a loading dose of 1 ml kg-1 D5 0.3% NaCl IV given over 10 minutes, followed by 0.5 ml kg-1 hour-1 IV D5 0.3% NaCl infusion were administered.
62256159|NCT01948336|ACTIVE_COMPARATOR|Dexmedetomidine|The patients in group D (dexmedetomidine) (n=30) were bolused with 1mg kg-1 ketamine (IV), 1mg kg-1 propofol (IV) followed by 1 mg kg-1 hour-1 ketamine (IV) and 50 µg kg-1 min-1 propofol (IV) infusion. Additionally a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.
62443811|NCT03454633|EXPERIMENTAL|Mild hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass at temperature 28.1 - 34 degrees Celsius
62443812|NCT03454633|ACTIVE_COMPARATOR|Moderate hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass at temperature 20.1 - 28 degrees Celsius
62443813|NCT00875719|ACTIVE_COMPARATOR|continuous v intermittent Oxygen therapy|intermittent oxygen compared to constant flow oxygen as regards walking distance
62443814|NCT04110028|EXPERIMENTAL|Nicotinamide riboside 250 mg|One capsule of 250 mg each morning for three months
62443815|NCT04110028|EXPERIMENTAL|Nicotinamide riboside 500 mg|One capsule of 250 mg each morning and afternoon for three months
62838463|NCT00026169|EXPERIMENTAL|Treatment (imatinib mesylate)|"Patients receive oral imatinib mesylate once or twice daily on days 1 and 4-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients in each stratum receive escalating doses of imatinib mesylate until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
62256160|NCT04998838|EXPERIMENTAL|Tenofovir Disoproxil Fumerate|Pregnant women (\&gt;=20 weeks of gestation) will be treated with TDF if clinically eligible; newborns will receive birth dose vaccine (and HBIG if eligible). Non-eligible women will be treated according to normal practices; newborns will still receive birth dose vaccine.
62256161|NCT03226145|ACTIVE_COMPARATOR|Patients|"80 Patients : 40 FC 40 IBS-C~Will have MRI Motility and High Resolution Manometry~Then will have:~Bisacodyl 10mg once daily for 10 days, and matched placebo hyoscine butylbromide Buscopan 20mg three times daily for 10 days, and matched placebo~Both agents will have their matched placebo dispensed alongside the active product of the other agent.~All agents to be used in this study as tools for their known mechanisms of action, rather than to assess their effects."
62256162|NCT03226145|ACTIVE_COMPARATOR|Healthy Volunteers|40 HVs Will have MRI Motility and High Resolution Manometry No other interventions
62256163|NCT04973475|EXPERIMENTAL|Experimental: Indocyanine Green Tracer|Indocyanine Green Tracer will be used in laparoscopic distal gastrectomy with lymph node dissection for gastric adenocarcinoma.
62443816|NCT04110028|EXPERIMENTAL|Nicotinamide riboside 1000 mg|Two capsules of 250 mg each morning and afternoon for three months
62838464|NCT04151303||Cerclage 1|Time to delivery after cerclage removal Between 36-36.6 weeks' gestation - group 1
62838465|NCT04151303||Cerclage 2|Time to delivery after cerclage removal Between 37-37.6 weeks' gestation - group 2
62838466|NCT04151303||Cerclage 3|Between 38-38.6 weeks' gestation - group 3
62838467|NCT04151303||Cerclage 4|Time to delivery after cerclage removal Beyond 39 weeks' gestation - group 4
62256164|NCT01164774|EXPERIMENTAL|Ramipril|Ramipril 10 mg capsules of Dr. Reddy's Laboratories Limited
62443817|NCT04110028|EXPERIMENTAL|Nicotinamide riboside 2000 mg|Four capsules of 250 mg each morning and afternoon for three months
62443818|NCT04110028|PLACEBO_COMPARATOR|Placebo for 250 mg nicotinamide riboside|One capsule each morning for three months
62443819|NCT04110028|PLACEBO_COMPARATOR|Placebo for 500 mg nicotinamide riboside|One capsule each morning and afternoon for three months
62443820|NCT04110028|PLACEBO_COMPARATOR|Placebo for 1000 mg nicotinamide riboside|Two capsules each morning and afternoon for three months
62054379|NCT05606016|EXPERIMENTAL|Testing Navigation Intervention (TNI).|Participants in the TNI arm will receive COVID-19 testing education and be navigated to PCR testing sites. Participants will also receive pre and post surveys.
62443821|NCT04110028|PLACEBO_COMPARATOR|Placebo for 2000 mg nicotinamide riboside|Four capsules each morning and afternoon for three months
62443822|NCT03449628|EXPERIMENTAL|L. casei DG®|"Interventions: Lactobacillus paracasei CNCMI1572 (At least 24 billion live cells per capsule)~1 capsule, b.i.d. for 12 weeks"
62443823|NCT03449628|PLACEBO_COMPARATOR|Placebo|"Interventions : capsules for oral use, indistinguishable from active product.~1 capsule, b.i.d. for 12 weeks"
62443824|NCT02153736|NO_INTERVENTION|Usual Care Group|This group of subjects will receive usual care provided in the medial system and community.
62256165|NCT01164774|ACTIVE_COMPARATOR|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
62256166|NCT03714321|EXPERIMENTAL|Mechanical insufflation-exsufflation arm|MIE will be given as prescribed by physician responsible at the intermediate care unit, typically every 4 hours. MIE will be administered with standard settings of insufflation 20 cm H2O and exsufflation 20 cm H2O, with possible individual changes from 10/-10 H2O up to 40/-40 H2O, and oxygen flow up to 15 l/min. The standard settings will be set to five cycles of 2 seconds insufflation, 3 seconds exsufflation with a three second pause between each cycle. Every treatment session consists of five rounds of five cycles, in all 25 insufflation/exsufflation, with time between each cycle of 30 seconds, meant used for suction.
62054380|NCT05606016|ACTIVE_COMPARATOR|Control|Participants in the Control Group arm will receive a CDC-designed COVID-19 testing brochures, and pre and post surveys only.
62838468|NCT02731105|ACTIVE_COMPARATOR|Arm 1|Acnatac® Gel on left face and Epiduo® Gel on right face once daily for three weeks
62838469|NCT02731105|ACTIVE_COMPARATOR|Arm 2|Epiduo® Gel on left face and Acnatac® Gel on right face once daily for three weeks
62256167|NCT03714321|NO_INTERVENTION|CPAP arm|CPAP will be given as prescribed by the physician responsible at the intermediate care unit, typically every 4 hours. CPAP will be administered with standard settings of H2O and an oxygen flow of 15L/min.
62838470|NCT02645019||Cuffed ETT|Airway secured using a cuffed endotracheal tube.
62838471|NCT02645019||LMA 2|Airway secured using a size 2 laryngeal mask airway.
62838472|NCT02645019||LMA 2.5|Airway secured using a size 2.5 laryngeal mask airway.
62054381|NCT04949958|EXPERIMENTAL|Experimental: Exercise Based Manual (Supervised)|Supervised Exercises with exercise based Manual (exercise \& Educational Component) for 3 days / week for 16 weeks. Each session will comprise of 60 minutes of different type of exercises including warm up and rest interval
62054382|NCT04949958|EXPERIMENTAL|Experimental: Exercise Based Manual (Home Based)|Experimental: Exercise Based Manual (Home Based) Home Based- Exercise Manual (Exercise \& Educational Component) for 16 weeks. Subject will be asked to maintain a regular exercise.
62256168|NCT03385811||Medical Professionals|no intervention, only questionnaire survey
62443825|NCT02153736|EXPERIMENTAL|SPEEDI Intervention|This group will receive and parent and physical therapy provided intervention to increase the infants opportunities for play which will enhance development.
62443826|NCT03072836|EXPERIMENTAL|CD alone|
62443827|NCT03072836|EXPERIMENTAL|SPA alone|
62443828|NCT03072836|EXPERIMENTAL|CD + SPA|
62443829|NCT03742674||Cohort patients post stroke|
62443830|NCT04232397|EXPERIMENTAL|therapy|therapy with 1 arm. Anlotinib 8mg qd po。
62443831|NCT01280981|EXPERIMENTAL|Tranexamic acid|Two 650 mg tablets orally 3 times per day with liquids for up to 5 days (not to exceed 3 doses in 1 day or 15 doses during the menstrual period).
62443832|NCT01082107|OTHER|Solar disinfection of drinking water|
62443833|NCT03490682|ACTIVE_COMPARATOR|Non-pregnant control|adult females aged less than 40 years, not currently pregnant, without significant medical history (American Society of Anesthesiologists ASA 1), fasting for at least 6 hours for solids and 1 hour for clear fluids.
62613608|NCT01491269|NO_INTERVENTION|No intervention|Waitlist
62613609|NCT05593237|EXPERIMENTAL|High Frequency rTMS|High frequency 10 Hz stimulation of motor cortex (M1)
62838473|NCT02645019||LMA 3|Airway secured using a size 3 laryngeal mask airway.
62838474|NCT02645019||LMA 4|Airway secured using a size 4 laryngeal mask airway.
62838475|NCT06161389|EXPERIMENTAL|Partially inflated mask|Participants will be invited to administer positive pressure ventilation by using a partially inflated mask in a neonatal manikin
62838476|NCT06161389|ACTIVE_COMPARATOR|Fully inflated mask|Participants will be invited to administer positive pressure ventilation by using a fully inflated mask in a neonatal manikin
62838477|NCT06142929||Primary Dupuytren disease|50 patients with primary Dupuytren disease that are selected for surgery and will undergo the resection of Dupuytren tissue with the microfasciectomy technique
62838478|NCT06142929||Recurrence Dupuytren disease|30 patients with recurrence Dupuytren disease that are selected for surgery and will undergo the resection of Dupuytren tissue with the microfasciectomy technique
62838479|NCT01193504|ACTIVE_COMPARATOR|Pred Forte|Patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Pred Forte BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
62838480|NCT01193504|ACTIVE_COMPARATOR|Lotemax|patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Lotemax BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
62838481|NCT01185080|EXPERIMENTAL|1. AZD8848|20 μg AZD8848 three times weekly
62838482|NCT01185080|PLACEBO_COMPARATOR|2. Placebo|Placebo three times weekly
62838483|NCT01185080|EXPERIMENTAL|3. AZD8848 and placebo|60 μg AZD8848 once weekly and placebo twice weekly
62838484|NCT03806764|NO_INTERVENTION|Retrospective study|Medical records of 250 allo-HSCT recipients will be evaluated retrospectively to determine the incidence and clinical outcomes of CMV viremia post HSCT, including both the direct (CMV disease) and indirect (such as invasive fungal infection, other viral infections, bacterial infection) effects on clinical outcomes.
62256169|NCT04001075|EXPERIMENTAL|TJ107|Patients enrolled in dose escalation part will be given 2 doses (28 days/dose) during the main-treatment period
62256170|NCT03880175|EXPERIMENTAL|FCC DEB and Anti-stigma|
62256171|NCT03880175|EXPERIMENTAL|FCC DEB and HIV info|
62256172|NCT03880175|EXPERIMENTAL|FCC DEB and ART info|
62256173|NCT03880175|EXPERIMENTAL|FCC DEB and HIV-ART info|
62256174|NCT03880175|EXPERIMENTAL|FCC DEB and high coupon value|
62256175|NCT03880175|EXPERIMENTAL|FCC DEB and no info|
62443834|NCT03490682|ACTIVE_COMPARATOR|Pregnant control|adult females aged less than 40 years, pregnant in the third trimester (gestation greater than 32 weeks on the day of the study) according to dates and the calculation of term established at the start of the pregnancy by an obstetrician, without significant medical history (American Society of Anesthesiologists ASA 1), fasting for at least 6 hours for solids and I hour for clear fluids.
62443835|NCT03490682|EXPERIMENTAL|Analgesia|adult females aged less than 40 years, without significant medical history (American Society of Anesthesiologists ASA 1), in labour in the delivery suite, with a working epidural, having consumed solid food more than 6 hours before inclusion in the study and clear fluids more than 1 hour before inclusion in the study, and allowed to ingest solids during labour (cervical dilatation strictly less than 8cm) conforming to local protocols.
62443836|NCT03490682|EXPERIMENTAL|Parturient|adult females aged less than 35 years, without significant medical history (American Society of Anesthesiologists ASA 1), in labour in the delivery suite, without any epidural analgesia, having consumed solid food more than 6 hours before inclusion in the study and clear fluids more than 1 hour before inclusion in the study, and allowed to ingest solids during labour (cervical dilatation strictly less than 8cm) conforming to local protocols.
62443837|NCT02904421||Group 1|the placebo group
62443838|NCT02904421||Group 2|the low-dose treatment group with 600mg calcium + 400IU Vit-D3/day
62443839|NCT02904421||Group 3|the high-dose treatment group with 600mg calcium + 800IU Vit-D3/day
62443840|NCT03090984|ACTIVE_COMPARATOR|PMMA (BKU)|"Patients included in the study will undergo 3 hemodialysis treatments. During the PMMA Arm, patient will be dialyzed using a BKU 1.6 (Toray) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.~During each study treatment, blood samples will be taken at specified time points (T0, T5, T15, T30, T90, T240) to assess overall coagulation activation (TAT, PF1+2, d-dimers), contact phase activation (kallikrein, fXIa, fXIIa), and activation of the extrinsic coagulation pathway (TF)."
62613610|NCT05593237|ACTIVE_COMPARATOR|Low Frequency rTMS|Low frequency 1 Hz stimulation of motor cortex (M1)
62613611|NCT01272375|EXPERIMENTAL|Treatment A PF-04764793|PF-04764793 using inhaler A
62054383|NCT04949958|PLACEBO_COMPARATOR|Placebo Comparator: Control|Age matched Control Group followed for 16 weeks with General Advise to active
62256176|NCT03880175|EXPERIMENTAL|FCC non-DEB and Anti-stigma|
62256177|NCT03880175|EXPERIMENTAL|FCC non-DEB and HIV info|
62256178|NCT03880175|EXPERIMENTAL|FCC non-DEB and ART info|
62256179|NCT03880175|EXPERIMENTAL|FCC non-DEB and HIV-ART info|
62256180|NCT03880175|EXPERIMENTAL|FCC non-DEB and high coupon value|
62256181|NCT03880175|EXPERIMENTAL|FCC non-DEB and no info|
62256182|NCT03880175|EXPERIMENTAL|FCC control and Anti-stigma|
62256183|NCT03880175|EXPERIMENTAL|FCC control and HIV info|
62256184|NCT03880175|EXPERIMENTAL|FCC control and ART info|
62256185|NCT03880175|EXPERIMENTAL|FCC control and HIV-ART info|
62256186|NCT03880175|EXPERIMENTAL|FCC control and High coupon value|
62256187|NCT03880175|NO_INTERVENTION|FCC control and no info|
62256188|NCT04896554|ACTIVE_COMPARATOR|quit smoking|patients who have quit smoking
62256189|NCT04896554|ACTIVE_COMPARATOR|not quit smoking|patients who have not quit smoking
62838485|NCT03806764|OTHER|Prospective study|"120 recipients of allo-HSCT will be recruited into the prospective part of the study. Participants will be reviewed pre-transplant, 6, 12, 24 and 52 weeks following HSCT during routine clinical visits. clinical assessment will be made such as CMV viremia, transplant related complications and current medications.~Participants who are at high risk of CMV will have study blood sampling taken to assess immune functions"
62838486|NCT03669341|EXPERIMENTAL|Deep Inspiration Breath Hold (DIBH)|DIBH extended by prior hyperventilation while breathing 100% O2
62256190|NCT02278562|ACTIVE_COMPARATOR|anakinra|100 mg of Anakinra in syringes administered subcutaneously 3 times a week for 3 months and lactose (placebo) in capsules administered orally 1 capsule per day for 3 months
62256191|NCT02278562|ACTIVE_COMPARATOR|actos|Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and 30 mg of Actos in capsules administered orally 1 capsule per day for 3 months
62443841|NCT03090984|ACTIVE_COMPARATOR|PS (Phylter)|Patients included in the study will undergo 3 hemodialysis treatments. During the PS Arm, patient will be dialyzed using a Phylter 1.7 (Bellco) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
62443842|NCT03090984|ACTIVE_COMPARATOR|AN69ST (Evodial)|Patients included in the study will undergo 3 hemodialysis treatments. During the AN69ST Arm, patient will be dialyzed using a Evodial 1.6 (Gambro) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
62443843|NCT05608564|EXPERIMENTAL|Local antibiotic group|A combination of Piperacillin and Tazobactam in gel form is applied using a syringe and a flexible blunt needle into the periodontal pockets 24 hours after the non-surgical periodontal therapy. After administration, the dry field should be maintained for 5 minutes and the patient should not rinse the oral cavity for 15 minutes.
62838487|NCT03669341|ACTIVE_COMPARATOR|High Frequency Percussive Ventilation (HFPV)|passive Ventilation by a jet ventilator
62838488|NCT00529867|ACTIVE_COMPARATOR|A|
62838489|NCT00529867|ACTIVE_COMPARATOR|B|
62838490|NCT06041607|EXPERIMENTAL|Shared meditation|"Shared meditation: mixed groups of patients, carers and third parties"
62838491|NCT06041607|ACTIVE_COMPARATOR|"Meditation patients"|groups of patients only
62838492|NCT00067730|EXPERIMENTAL|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
62256192|NCT02278562|PLACEBO_COMPARATOR|placebo 1 and 2|Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and lactose (placebo) in capsules administered orally 1 capsule per day for 3 months
62256193|NCT01228370|EXPERIMENTAL|Silodosin|Silodosin 8mg once a day for 12 weeks
62838493|NCT05438303|EXPERIMENTAL|Arm A (midazolam and omeprazole)|Participants will receive single oral doses of midazolam and omeprazole together (Day 1 of Treatment Periods 1 and 3) and repeated doses of AZD9833 (Days 1 to 5 of Treatment Period 2 and Day 1 of Treatment Period 3)
62256194|NCT04674514|EXPERIMENTAL|Arm A (Single agent)|Dose escalation APG-2575 at 3 dose levels 3+3 design.
62613612|NCT01272375|EXPERIMENTAL|Treatment B PF-04764793|PF-04764793 using inhaler A
62838494|NCT05438303|EXPERIMENTAL|Arm B (Dabigatran etexilate)|Participants will receive single oral doses of dabigatran etexilate (Day 1 of Treatment Periods 1 and 2) and single oral dose of AZD9833 (Day 1 of Treatment Period 2)
62838495|NCT05438303|EXPERIMENTAL|Arm C (Celecoxib)|Participants will receive single oral doses of celecoxib (Day 1 of Treatment Periods 1 and 3) and repeated oral doses of AZD9833 (Days 1 to 5 of Treatment Period 2 and Day 1 of Treatment Period 3)
62838496|NCT02141828|EXPERIMENTAL|EPZ-5676|EPZ-5676 Dose escalation and expansion cohorts
62838497|NCT04106752|ACTIVE_COMPARATOR|meal followed by caffeine|A standardized meal consisting of 2 slices of toast bread, organic peanut butter and jam was given to the participant. One and a half hours later, the participant ingested a caffeinated drink (3 mg per kg body weight of caffeine powder dissolved in water). After 30 mins, resting EE was measured using FM for 15 min while seated on the comfortable seat, and then for 5 min while seated on a cycle ergometer. Participants were then asked to pedal at 60 revolutions per minute (rpm) for 5 min per load at 20 watts (W), 35W, 50W, 65W, 80 W respectively. During cycling, EE was being measured using the FM, HR was monitored and rating of perceived exertion (RPE) was recorded in the last minute of every load cycle.
62838498|NCT04106752|ACTIVE_COMPARATOR|Caffeine followed by meal|Caffeine was given to the participant. After 1.5 hours the standardized meal was given followed by the same protocol mentioned above.
62838499|NCT04106752|ACTIVE_COMPARATOR|caffeine only|Caffeine will be given to the participant. 2 hours later the same protocol mentioned above will be applied
62838500|NCT04106752|ACTIVE_COMPARATOR|Meal only|A standardized meal will be given to the participant. 2 hours later the same protocol mentioned above will be applied.
62256195|NCT04674514|EXPERIMENTAL|Arm B (combo)|Dose escalation APG-2575 at 3 dose levels in combination with Rd, 3+3 design.
62256196|NCT04256460|EXPERIMENTAL|Intervention arm|Behavior intervention including health education on diet, exercises and self management support through peer support, and also receive regular care and follow up in community health centers
62256197|NCT04256460|NO_INTERVENTION|Control arm|Receiving regular care and follow up in Community health centers
62838501|NCT04106752|ACTIVE_COMPARATOR|meal plus caffeine|A standardized meal + a caffeinated drink (3 mg/kg of body weight of caffeine powder dissolved in water) will be given to the participant. 2 hours later resting EE is measured using a facemask (FM) for 10 min while seated on a cycle ergometer . The participant will be asked to pedal at 60 revolutions per minute (rpm) for 5 min per load at 20 watts (W), 35W, 50W, 65W, 80 W respectively.
62256198|NCT02154360|EXPERIMENTAL|Aprepitant|"Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days.~* 6 participants will be receiving an antiretroviral regimen containing atazanavir/ritonavir (300/100 mg) daily plus two other antiretrovirals.~* 6 participants will be receiving an antiretroviral regimen containing darunavir/ritonavir (800/100 mg) daily plus two other antiretrovirals."
62256199|NCT04443543|EXPERIMENTAL|Arm 1|"Arm 1 includes patients with MSS/pMMR. In this arm, patients receive consolidation chemotherapy after neoadjuvant chemoradiation (nCRT). The chemotherapy regimens either XELIRI or FOLFIRINOX, and the cycles of chemotherapy depend on patient tumor responses. For patients who reach cCR will enter the W\&W cohort and omit radical surgery, while those without cCR will receive radical surgery."
62054384|NCT04859725|EXPERIMENTAL|Hyperspectral Imaging with Snapscan camera|"Included patients will undergo a resection of the low grade glioma as standard-of-care. Hyperspectral imaging data will be acquired by the SnapScan HSI camera mounted on the (standard) surgical microscope.~As such, the surgical procedure does not deviate from the common, standard-of-care surgical procedures, apart from the acquisition of intraoperative scanning images using the SnapScan HSI camera on the microscope. The objective of this all is to get an initial high quality in vivo dataset to start exploring the potential of the technology."
62054385|NCT03582774|ACTIVE_COMPARATOR|Arm I (standard of care)|Participants receive standard of care SRT.
62256200|NCT04443543|EXPERIMENTAL|Arm 2|"Arm 2 includes patients with MSI-H/dMMR status. In this arm, patients receive consolidation immunotherapy of 3 cycles of tislelizumab after nCRT. For patients who reach cCR will enter the W\&W cohort and omit radical surgery, while those without cCR will receive radical surgery."
62256201|NCT04417179|EXPERIMENTAL|TAP block group|"the TAP block will be given by a high frequency linear ultrasound transducer of Siemens acuson x300 3-5MHz ultrasound .~a blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be used under direct ultrasound visualization, . After confirming the correct placement of the needle and the negative aspiration probe anaesthetic substance will be injected along the subcostal line in the transversus abdominis plane 20 ml 0.25% bupivacaine(10) , and the dissection of the plane was observed. The block will be performed bilaterally."
62256202|NCT04417179|EXPERIMENTAL|ESP group|the Erector Spinae block will be given by a high-frequency linear ultrasound transducer of Siemens acuson x300 3-5MHz ultrasound .A blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be used under strict aseptic precautions until the tip is deep to erector spinae muscle, The block will be performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally
62256203|NCT01871220|ACTIVE_COMPARATOR|Divergent Abutment|Divergent Transition Profile
62256204|NCT01871220|EXPERIMENTAL|Concave Abutment|Concave Transition Profile
62256205|NCT05304104|EXPERIMENTAL|Telehealth Cognitive Behavioral Therapy (teleCBT)|About one-half of participants will be randomly assigned to Telehealth Cognitive Behavioral Therapy (teleCBT), a virtual Cognitive Behavioral Therapy (CBT) for binge eating disorders delivered via an Office of Information and Technology (OI\&T)-approved video platform, by a master's-level research clinician. TeleCBT will be administered in 8 to 10 hourly individual sessions over a three-month treatment period.
62443844|NCT05608564|ACTIVE_COMPARATOR|Systemic antibotic group|Amoxicillin (500mg, 3 times a day, 7 days) and Metronidazole (400mg, 3 times a day, 7 days) per os at the beginning of non-surgical treatment.
62613613|NCT01272375|EXPERIMENTAL|Treatment C PF-04764793|PF-04764793 using inhaler A
62613614|NCT01272375|EXPERIMENTAL|Treatment D PF-04764793|PF-04764793 using inhaler A
62613615|NCT01272375|EXPERIMENTAL|Treatment E PF-04764793|PF-04764793 using inhaler B
62613616|NCT01272375|EXPERIMENTAL|Treatment F PF-04764793|PF-04764793 using inhaler B
62613617|NCT01272375|EXPERIMENTAL|Treatment G PF-04764793|PF-04764793 using inhaler B
62613618|NCT02357615|EXPERIMENTAL|nifedipine CR tablets (Xin Ran)|Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 8-week treatment period.
62838502|NCT05606432|EXPERIMENTAL|Group 1|Instructor-led, one-on-one M2M exercise group
62838503|NCT05606432|ACTIVE_COMPARATOR|Group 2|Self-guided control with pre-recorded standard exercise videos
62838504|NCT03135964|ACTIVE_COMPARATOR|foam|PU foam dressing from KCI
62838505|NCT03135964|ACTIVE_COMPARATOR|gauze|Polyhexamethylene biguamide (PHMB) impregnated gauze (Kerlix AMD, Covidien)
62838506|NCT02345993|ACTIVE_COMPARATOR|Extra fine Formoterol/Beclomethasone|"Group receiving the drug additional to standard treatment standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline, 0, 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40 minutes"
62613619|NCT02357615|ACTIVE_COMPARATOR|nifedipine CR tablets (Adalat)|Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 8-week treatment period.
62613620|NCT03737266|EXPERIMENTAL|Sonographically assisted breast surgery|Sonography assisted breast surgery
62838507|NCT02345993|PLACEBO_COMPARATOR|Placebo|"Group receiving placebo additional to standard treatment consisting in:~Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ Placebo, 3 puffs administered via aerochamber at baseline (0), 20, 40 minutes"
62443845|NCT06358352|NO_INTERVENTION|control group|Immediate implant placement with leaving the gap distance empty
62054386|NCT03582774|EXPERIMENTAL|Arm II (68Ga-PSMA-11 PET/CT)|Participants receive 68Ga-PSMA-11 IV and 50-100 minutes later undergo whole-body (skull base to mid-thighs) PET/CT. Participants then undergo SRT per the discretion of the treating radiation oncologist.
62256206|NCT05304104|ACTIVE_COMPARATOR|Self-Help Cognitive Behavioral Therapy (shCBT)|About one-half of participants will be randomly assigned to Self-Help Cognitive Behavioral Therapy (shCBT), a Self-Help CBT for binge eating disorders initiated by a research assistant via telephone and then continued by the participant at home. These materials are the same exact ones provided to participants in TeleCBT (i.e., treatments are matched for materials), and will be mailed to participants. They will be instructed to work independently through one chapter per week for the following 12 weeks (i.e., treatment length is matched to TeleCBT).
62256207|NCT02116777|EXPERIMENTAL|Treatment (talazoparib, temozolomide): Phase 1|(Part A): Patients receive talazoparib PO QD or BID on days 1-6 and temozolomide PO QD on days 2-6. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62256208|NCT02116777|EXPERIMENTAL|Treatment (talazoparib, temozolomide): Phase 2|(Part B): Relapse/Refractory EWS or PNET Patients receive MTD from Phase 1 portion of study. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62838508|NCT00135343|EXPERIMENTAL|A|
62838509|NCT00135343|EXPERIMENTAL|B|
62838510|NCT03057483||Elderly|People over 60 years of age. seasonal influenza vaccine
62838511|NCT03057483||Health care workers|People working in health care services seasonal influenza vaccine
62838512|NCT03057483||Pregnant women|Pregnant women seasonal influenza vaccine
62054387|NCT02513108|ACTIVE_COMPARATOR|same day discharge|patients discharged same day after uncomplicated PCI
62256209|NCT02281032|OTHER|interRAI Palliative Care|"15 experimental nursing homes:~* Caregivers of 15 participating nursing homes receive a training about the interRAI PC and the BelRAI webapplication~* Caregivers of 15 experimental nursing homes fill out the interRAI PC multidisciplinary every three months during one year for all nursing home residents with palliative care needs. Based on the results (Client Assessment Protocols and Scales) of the interRAI PC instrument, care plans are being evaluated, adapted and designed."
62256210|NCT02281032|NO_INTERVENTION|No interRAI Palliative Care|"15 control nursing homes:~- Caregivers of control nursing homes do not receive the intervention and provide care as usual"
62256211|NCT05407233|ACTIVE_COMPARATOR|Group 1|Doesn´t reuse the syringe for insulin application
62256212|NCT05407233|EXPERIMENTAL|Group 2|Uses the syringe five times to insulin application
62256213|NCT04097613|EXPERIMENTAL|Betadine Treatment|Study subjects will use betadine saline sinus rinse for period of 6 weeks.
62443846|NCT06358352|EXPERIMENTAL|PRF group|Immediate implant placement then placement of PRF around the implant in the gap distance
62443847|NCT06358352|EXPERIMENTAL|lutein group|Immediate implant placement then placement of lutein around the implant in the gap distance
62054388|NCT02513108|NO_INTERVENTION|standard care|standard care where patients are discharged the day after procedure after adequate observation
62054389|NCT05765279|EXPERIMENTAL|Treatment Group 1|
62054390|NCT05765279|EXPERIMENTAL|Treatment Group 2|
62443848|NCT02809092|EXPERIMENTAL|NK Cells + Chemotherapy Starting|"Starting on Day -7, G-CSF daily by vein until post nadir of absolute neutrophil counts (ANC) are equal or over 1000. Day -6 to Day -2 Fludarabine administrated by vein at 30 mg/m\^2. Four hours later Cytarabine administrated by vein at 2 g/m\^2. Natural killer (NK) cell infusion Days 0 to 14 for 6 doses total. The first group of participants receive lowest dose level. Each new group receives a higher dose than the group before it, if no intolerable side effects were seen. This will continue for up to 6 dose levels or until the highest tolerable dose of NK cells is found. One (1) to 10 participants will be treated in each dose level.~NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema."
62443849|NCT02117193|PLACEBO_COMPARATOR|Alcohol intake|1 g/kg of etanol combined. Beer without alcohol in the same volume will be used to placebo condition.
62443850|NCT02117193|ACTIVE_COMPARATOR|sleep deprivation|one night of sleep deprivation will be compared to 8h of normal sleep.
62054391|NCT05765279|PLACEBO_COMPARATOR|Control Group 3|
62054392|NCT05765279|PLACEBO_COMPARATOR|Control Group 4|
62054393|NCT01806584|ACTIVE_COMPARATOR|SRM003|
62054394|NCT01806584|OTHER|Participating Site's standard practice|
62838513|NCT03057483||Post partum women|Women who have given birth \< 45 days seasonal influenza vaccine
62838514|NCT03057483||Children|Children from 6 months to 5 years of age seasonal influenza vaccine
62838515|NCT01388335|EXPERIMENTAL|warfarin + enzastaurin|"On Day 1 of Period 1, a single 5-milligram (mg) oral dose of warfarin will be given, followed by at least a 7-day washout.~Period 2: 500 mg enzastaurin administered orally once daily for at least 19 consecutive days and 5 mg warfarin administered as a single oral dose on Day 15.~Safety Extension: Participants are allowed to continue receiving enzastaurin alone until disease progression or other discontinuation criteria are met."
62838516|NCT01516021|EXPERIMENTAL|high fat yoghurt intake|500 ml of a high fat yoghurt
62838517|NCT01516021|EXPERIMENTAL|low fat yoghurt intake|
62838518|NCT05812872|ACTIVE_COMPARATOR|Alveolar ridge preservationwith tooth graft|tooth graft
62838519|NCT05812872|ACTIVE_COMPARATOR|Alveolar ridge preservation with allograft|Allograft
62838520|NCT05812872|ACTIVE_COMPARATOR|Alveolar ridge preservation with alloplast|Beta Tri-Calcium phosphate
62838521|NCT02910791||atopic dermatitis|up to 40 subjects with atopic dermatitis will be enrolled into study.
62838522|NCT02910791||psoriasis|up to 20 subjects with psoriasis will be enrolled into study.
62838523|NCT02910791||people without skin conditions|Up to 40 subjects without skin conditions will be enrolled into study.
62054395|NCT06469749|EXPERIMENTAL|12-week peer-led intervention group on Instagram|Participants in the intervention group will receive 12-week peer-led intervention interactive modules on Instagram.
62054396|NCT06469749|NO_INTERVENTION|Control group|Participants in the control group will not engage in any intervention activities.
62443851|NCT06364800|EXPERIMENTAL|γδ T cells+ PD-1 monoclonal antibody+ targeted drugs|Patients will receive 4 cycles of ex-vivo expanded allogeneic γδ T cells treatments, at three-weeks' intervals. Ex-vivo expanded γδ T cells are transfused to patients in a typical 3+3 dose-escalation design (Dose escalation, 1×10\^8/kg, 2×10\^8/kg,4×10\^8/kg).
62443852|NCT06364800|ACTIVE_COMPARATOR|PD-1 monoclonal antibody+ targeted drugs|PD-1 monoclonal antibody+ targeted drugs
62838524|NCT02758184|EXPERIMENTAL|ROTEM Group|Patients who are randomized to receive ROTEM
62443853|NCT00838877|EXPERIMENTAL|1|
62838525|NCT02758184|OTHER|Control Group|Patients who are randomized not to receive ROTEM
62838526|NCT05821062||Group 1a|CAD patients with depression on standard ASA+CLP therapy.
62838527|NCT05821062||Group 1b|CAD Patients without depression on standard ASA+CLP therapy.
62838528|NCT05821062||Group 2a|CAD patients with depression on standard ASA+TCG/PSG therapy.
62054397|NCT03065296|EXPERIMENTAL|Musculoskeletal (MSK) Exercise Prescription|"* Phase I: Residents will be surveyed as to their knowledge and confidence in both diagnosing specific musculoskeletal (MSK) issues and prescribing the correct home rehabilitation regimen.~* In between phase 1 and phase 2 there will be a series of didactic lectures to educate resident on home exercise prescription and get them familiarized with the handouts.~* Phase II: Residents will be surveyed again in May 2017 with the same multiple choice questions and Likert style confidence scales from phase 1~The survey will consist of multiple choice and short essay questions, focused on the most common musculoskeletal (MSK) injuries seen in the primary care setting."
62054398|NCT03041779|ACTIVE_COMPARATOR|Paracetamol|Paracetamol 500Mg Suppository
62054399|NCT03041779|ACTIVE_COMPARATOR|Voltaren|Diclofenac Sodium 50Mg Suppository
62054400|NCT00639730|EXPERIMENTAL|A|This is open-label - all patients are placed on the diet. There is no control or placebo arm.
62054401|NCT00420199|ACTIVE_COMPARATOR|Abatacept + Methotrexate (Double-blind period)|
62256214|NCT03221491|EXPERIMENTAL|No Background Infusion Group(Group B0)|Patients in Group B0 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 0ml/h.
62443854|NCT01346410|EXPERIMENTAL|A|Stereotactic Radiation to Pancreas
62443855|NCT02320357|EXPERIMENTAL|Clopidogrel|
62838529|NCT05821062||Group 2b|CAD patients without depression on standard ASA+TCG/PSG therapy.
62838530|NCT05821062||Group 3a|CAD patients with depression on standard ASA treatment alone at least 1 month after TCG/PSG cessation.
62838531|NCT05821062||Group 3b|CAD patients without depression on standard ASA treatment alone at least 1 month after TCG/PSG cessation.
62838532|NCT05821062||Group 1c|Subjects with depression without CAD (DS) are enrolled are enrolled as a comparison group.
62054402|NCT00420199|PLACEBO_COMPARATOR|Placebo + Methotrexate (Double-blind period)|
62054403|NCT06128733|EXPERIMENTAL|Group 1: MenPenta Formulation 1|Participants (ACWY naive and primed adults or adolescents) will receive injections of the pentavalent meningococcal ABCYW vaccine and placebo
62054404|NCT06128733|EXPERIMENTAL|Group 2: MenPenta Formulation 2|Participants (ACWY naive and primed adults or adolescents) will receive injections of the pentavalent meningococcal ABCYW vaccine and placebo
62054405|NCT06128733|ACTIVE_COMPARATOR|Group 3: Bexsero® + Menveo®|Participants (ACWY naive and primed adults or adolescents) will receive injections of Bexsero® + Menveo® vaccine
62054406|NCT06128733|ACTIVE_COMPARATOR|Group 4: Trumenba® + Menveo®|Participants (ACWY naive and primed adults or adolescents) will receive injections of Trumenba® + Menveo® vaccine
62443856|NCT05786807|EXPERIMENTAL|Tegoprazan 50mg|single group
62443857|NCT05488184|EXPERIMENTAL|Dietary Supplement|Five different flavours of Oral Nutritional Supplement (ONS) prototypes were tested: tropical, pineapple, brownie, ham, tomato
62443858|NCT05112809|EXPERIMENTAL|Normal hearing subjects|Subjects with normal hearing will have a standard hearing test utilizing the cochlear stimulation system.
62838533|NCT05821062||Group 1d|Healthy control subjects (HC), subjects without depression and without CAD are enrolled as a comparison group.
62838534|NCT01297829|ACTIVE_COMPARATOR|IV Caldolor|
62838535|NCT01297829|PLACEBO_COMPARATOR|Placebo|
62838536|NCT01776216|EXPERIMENTAL|Dairy diet|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy into their everyday diet.
62256215|NCT03221491|EXPERIMENTAL|Low Background Infusion Group(Group B1)|Patients in Group B1 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 1ml/h.
62838537|NCT01776216|PLACEBO_COMPARATOR|Control diet|During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products into their everyday diet.
62838538|NCT02245217|EXPERIMENTAL|PET/CT Imaging arm|
62838539|NCT00357552|EXPERIMENTAL|LPV/r monotherapy|Participants will receive lopinavir/ritonavir twice daily for up to 104 weeks. Upon confirmation of virologic failure, emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) once a day will be added to their regimen.
62838540|NCT05442788|EXPERIMENTAL|HB0017 150mg|10 subjects is randomly assigned to receive HB0017 150mg or matching placebo at a ratio of 4:1.
62838541|NCT05442788|EXPERIMENTAL|HB0017 300mg|10 subjects is randomly assigned to receive HB0017 300mg or matching placebo at a ratio of 4:1.
62838542|NCT05442788|EXPERIMENTAL|HB0017 450mg|10 subjects is randomly assigned to receive HB0017 450mg or matching placebo at a ratio of 4:1.
62838543|NCT00457457|ACTIVE_COMPARATOR|Comparator|Tamsulosin 0.4 mg prolonged release
62838544|NCT00457457|EXPERIMENTAL|Treatment Arm|There are 5 possible UK-369,003 arms as follows: UK-369,003 MR (10mg, 25mg, 50mg \& 100mg), UK-369,003 IR (40mg),
62838545|NCT00214201|NO_INTERVENTION|1|Standard of Care CNI immunosuppression
62838546|NCT00214201|EXPERIMENTAL|2|Calcineurin inhibitor withdrawal
62838547|NCT01421732||Suspected dengue fever|Children aged 1-15 presenting at participating hospitals with symptoms of dengue fever
62838548|NCT04295278||Systemic inflammatory response syndrome|Systemic inflammatory response syndrome in patients in the pediatric intensive care unit.
62838549|NCT03494998||Children and young people|Aged 0-16 years
62838550|NCT02983552|EXPERIMENTAL|Binocular Computer Game Treatment|Binocular computer game treatment is defined as playing a Dig Rush application on an iPad® 1 hour per day, 5 days per week for 8 weeks in addition to continued spectacle correction (if required)
62838551|NCT02983552|ACTIVE_COMPARATOR|Continued Spectacle Correction|Continued spectacle correction is defined as wearing appropriate spectacle correction (if required) for all waking hours, 7 days per week for 8 weeks.
62838552|NCT02431923||EVD Close Contacts|At least one of the following:-Household contact of survivor at time of or since EVD event-Sexual contact with survivor since EVD event-Other selected contacts
62838553|NCT02431923||EVD Survivors|Subject listed on the Ministry of Health registry for Ebola survivors
62256216|NCT03221491|EXPERIMENTAL|High Background Infusion Group(Group B2)|Patients in Group B2 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 2ml/h.
62256217|NCT00823628|ACTIVE_COMPARATOR|iopromide|
62256218|NCT00823628|EXPERIMENTAL|iodixanol|
62256219|NCT03778528||Down syndrome|Individuals with Down syndrome undergoing cataract surgery.
62256220|NCT03778528||Control|Age-matched controls undergoing cataract surgery.
62443859|NCT05112809|EXPERIMENTAL|Bilateral hearing impaired|Subjects with bilateral hearing impairment will have a standard hearing test utilizing the cochlear stimulation system.
62443860|NCT05112809|EXPERIMENTAL|Asymmetrical hearing-impaired|Subjects with asymmetrical hearing-impairment will have a standard hearing test utilizing the cochlear stimulation system.
62443861|NCT06545968|EXPERIMENTAL|Intervention arm|These are the participants who will be randomised to receive the intervention at the start of the study.
62443862|NCT06545968|NO_INTERVENTION|Wait list control arm|These are participants who will not receive the intervention initially, but will move to the intervention arm after 6 months of follow-up
62443863|NCT02479828|ACTIVE_COMPARATOR|Fascia iliaca compartment block (FICB)|Under ultrasound guidance performing fascia iliaca compartment block, in which 40 ml ropivacaine 0,5% are injected under the fascia iliaca.
62838554|NCT02431923||Non Contact Controls|Selected Controls
62838555|NCT04371458|EXPERIMENTAL|Intraoperative providone-iodine lavage|Intraoperative providone-iodine lavage during resection
62838556|NCT04256083||AFE (amniotic fluid embolism)|Women for whom the diagnosis of amniotic fluid embolism was retained according to the UKOSS criteria.
62838557|NCT04256083||Control 1|Women admitted for prophylactic elective cesarean section.
62838558|NCT04256083||Control 2|Women with acute collapse in the peripartum period (with systolic blood pressure \<80 mmHg twice and for\> 5 minutes or acute peri-partum shock, for which the diagnosis of amniotic embolism has been ruled out).
62838559|NCT03171571|EXPERIMENTAL|Coaching procedure|Volunteers will received Updated National Dietary Guidelines about food and physical activity with a one year follow-up, plus connected coaching.
62838560|NCT02196948|EXPERIMENTAL|Electrolysis Percutaneous Therapeutic (EPTE)|Electrolysis Percutaneous Therapeutic (EPTE) consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon, to initiate a local inflammatory process allowing phagocytosis and repair of the affected tissue. The technique is pain-free since the electrical intensity is adapted to each patient. In addition, patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 4 weeks.
62256221|NCT00683163|ACTIVE_COMPARATOR|A: 6 months both + 18 months oral only|Group A will receive 6 months of monthly oral ibandronate 150 mg, plus daily PTH 1-84, 1.4 mg; followed by 18 months of ibandronate only. Placebo injections will be given months 13-15. Calcium + Vitamin D supplements, plus multivitamins are provided.
62838561|NCT02196948|EXPERIMENTAL|Eccentric exercise|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 4 weeks.
62838562|NCT03182569|EXPERIMENTAL|flexible catheter|The flexible Subcutaneous catheter for insulin administration
62838563|NCT03182569|ACTIVE_COMPARATOR|hourly rigid needle puncture|Hourly rigid needle puncture for Subcutaneous insulin administration
62838564|NCT04652037|EXPERIMENTAL|Acrysof IQ Vivity Toric Extended Vision Intraocular Lens Implantation|
62838565|NCT00641667|EXPERIMENTAL|Fentanyl|
62256222|NCT00683163|ACTIVE_COMPARATOR|B: (3 months injection + 9 months oral) x 2 years|Group B will receive 3 months of daily PTH 1-84, 1.4 mg; followed by 9 months of monthly oral ibandronate, 150 mg in year 1. In year 2, the group will receive another 3 months of daily PTH 1-84; followed by 9 months of monthly ibandronate. Placebo monthly pills will be given months 1-3 and months 13-15, and placebo injections will be given months 4-6. Calcium + Vitamin D supplements, plus multivitamins are provided.
62443864|NCT02479828|PLACEBO_COMPARATOR|Placebo (not FICB)|Half of the patients will not receive FICB
62838566|NCT05902806|EXPERIMENTAL|Comparison of current tube feed to intervention feed with upgraded composition|Subjects will use their own current practice tube feed for 1 week (baseline period) and will switch to the intervention tube feed with an upgraded composition with a comparable energy density and fiber content as their current tube for 2 weeks (intervention period). Since four different products will be evaluated (product A-D), there will be 4 study groups
62838567|NCT04724993|EXPERIMENTAL|Online Aerobic Dance Exercises|In this group, aerobic dance exercises will be applied online under the supervision of a physiotherapist. And participants will record their physical activities on the Physical Activity Tracking Chart.
62838568|NCT04724993|EXPERIMENTAL|Physical Activity Counseling|In this group, participants will be informed online about physical activity and exercise. And they will record their physical activities on the Physical Activity Tracking Chart too.
62838569|NCT03037177||CHL like GZL|Classical Hodgkin Lymphoma like Grey Zone Lymphoma (morphology of CHL and phenotype of PMBCL)
62054407|NCT06128733|ACTIVE_COMPARATOR|Group 5: MenQuadfi®|Participants (ACWY naive and primed adults or adolescents) will receive injections of MenQuadfi® vaccine and placebo
62054408|NCT06128733|EXPERIMENTAL|Group 6: Sanofi MenB|Participants (ACWY naive and primed adults or adolescents) will receive injections of SP MenB vaccine and placebo
62054409|NCT06128733|ACTIVE_COMPARATOR|Group 7: PENBRAYA|Participants (ACWY naive and primed adults or adolescents) will receive injections of PENBRAYA vaccine and placebo
62256223|NCT00278642|EXPERIMENTAL|stem cell transplantation|
62256224|NCT04221763|EXPERIMENTAL|Heart failure and abnormal cardiac conduction|Subjects will have an attempt at His-bundle pacing, left bundle pacing and biventricular pacing. Pacing at the His bundle and the left bundle will be attempted using a Medtronic SelectSecure™, Model 3830 lead. Delivery of the lead utilizes a deflectable sheath, the Medtronic SelectSite™, Model C304. Biventricular pacing will utilise a left ventricular lead placed in the coronary sinus using any of the 5 manufactures of CS leads Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical or in participants receiving permanent conduction system pacing left ventricular pacing will be achieved using a Cordis ATW™ wire placed in the coronary sinus.
62256225|NCT01942603||Observation|
62256226|NCT01942603||Complete Lymfnode Dissection|
62256227|NCT01819649|EXPERIMENTAL|Selenium enriched-yeast tablet; SelenoPRECISE 100 mcg/d|
62443865|NCT01713712|NO_INTERVENTION|Routine Obstetric Care|
62838570|NCT03037177||PMBCL like GZL|Primary Mediastinal B Cell Lymphoma like Grey Zone Lymphoma(morphology of PMBCL and phenotype of CHL)
62838571|NCT03037177||Composite|with a morphology of CHL on the one side and of PMBCL on the other side of the same diagnosis biopsy
62838572|NCT05196295|EXPERIMENTAL|Hydrogen capsules|Participants will be allocated by doctors and receive either 1 (n=5), 3 (n=5) or 6 (n=5) capsules every day for one month.
62838573|NCT04587427||Radium-223|Subjects who received the treatment of radium-223 during the before or after label change study periods.
62443866|NCT01713712|EXPERIMENTAL|Nutritional Counseling|Patients will receive an initial 90 minute nutritional consult followed by 60 minute follow up consults every 2 weeks to monitor weight gain and nutritional status.
62443867|NCT00969839|EXPERIMENTAL|Intramedullary Fixation System|Humeral fractures to be treated with the Intramedullary Fixation System
62838574|NCT02641288|EXPERIMENTAL|Ropivacaine irrigation|Using a standard irrigation device, 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
62443868|NCT00976547||Tinnitus patients|Group of 48 tinnitus patients
62443869|NCT03731481|EXPERIMENTAL|CHIP - Urban|Participants randomized by urban location of residence to receive CHIP Lifestyle Medicine program intervention.
62838575|NCT02641288|PLACEBO_COMPARATOR|Normal saline irrigation|Using a standard irrigation device, 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
62054410|NCT02524041|EXPERIMENTAL|secondary hyperparathyroidism|Blood specimen and HR-pQCT for measure bone quality and quantity
62256228|NCT01819649|EXPERIMENTAL|Selenium enriched-yeast tablet; SelenoPRECISE 200 mcg/d|
62256229|NCT01819649|EXPERIMENTAL|Selenium enriched-yeast tablet; SelenoPRECISE 300 mcg/d|
62256230|NCT01819649|PLACEBO_COMPARATOR|Yeast tablet|
62256231|NCT01508481||Diabetes high risk group|
62256232|NCT01699477|OTHER|Trancranial MRg Focused Ultrasound for Neuropatic Pain|
62613621|NCT03737266|ACTIVE_COMPARATOR|Conventional breast surgery|Conventional breast surgery
62256233|NCT03945526|ACTIVE_COMPARATOR|Astaxanthin|Astaxanthin supplementation will be given at 2 x 8mg for 7 days.
62256234|NCT03945526|PLACEBO_COMPARATOR|Control|A placebo will be given, which takes the form of a drug with the exact same shape and color as astaxanthin supplementation
62613622|NCT03346304|EXPERIMENTAL|PDT treatment (Intervention Arm)|Patients randomised to the PDT treatment (Intervention Arm) will have two courses of PDT treatment in total (for each lung treated). Follow-up is the same as for Control Arm patients: an AFB at 6, 12, 24, and at 36 months post-randomisation; with further AFB visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
62613623|NCT03346304|NO_INTERVENTION|Surveillance (Control Arm)|Patients randomised to the surveillance (Control Arm) will have: an AFB at 6, 12, 24, and at 36 months post-randomisation; with further AFB visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
62613624|NCT00743678|EXPERIMENTAL|NEO|NEO : Neoadjuvant therapy with FOLFOX6 plus cetuximab
62613625|NCT04131491|OTHER|Patients with Mild Cognitive Impairment (MCI) due to AD|Neuropsychological investigation, lumbar puncture, long term-EEG monitoring and/or MEG-EEG, magnetic resonance imaging (MRI), blood sample with deep genetic profiling and Apolipoprotein E (APOE) determination.
62613626|NCT04131491|OTHER|Healthy volunteers|Neuropsychological investigation, lumbar puncture, long term-EEG monitoring and/or MEG-EEG, MRI, blood sample with deep genetic profiling and APOE determination.
62613627|NCT02287259|EXPERIMENTAL|Olanzapine|PO start with 2.5mg daily once for 7days, since then flexible dose.
62613628|NCT02287259|ACTIVE_COMPARATOR|Lithium|PO start with 400mg daily twice for 7days, since then flexible dose.
62613629|NCT04177888|EXPERIMENTAL|Experimental group|Experimental group with 45 participants, received hot pack, which was a single-use pack filled with magnesium sulfate and water, squeezed between the hands to activate the warming effect, applied to the lower back area for 30 minutes followed by 10 minutes rest then again applied for 30 minutes. This procedure was repeated till delivery.
62613630|NCT04177888|NO_INTERVENTION|Control group|Control group with 46 participants received the hospital routine care that included Entonox inhalation as optional labor pain management.
62613631|NCT01524068|EXPERIMENTAL|Arm A - Standard Steroid Treatment|
62613632|NCT01524068|EXPERIMENTAL|Arm B - Experimental Treatment|
62613633|NCT00360802|ACTIVE_COMPARATOR|CBT|Cognitive Behavioral Treatment
62613634|NCT00360802|ACTIVE_COMPARATOR|MBSR|Mindfulness Based Stress Reduction
62613635|NCT05328284||PASCAL|patients treated with PASCAL leaflet repair system in the treatment of TR in a commercial use setting
62613636|NCT05680376||Recurrent Pregnancy loss|patients with a diagnosis of recurrent miscarriage
62613637|NCT05680376||Healthy Controls|healthy women at same age and similar demographics
62613638|NCT03845101|EXPERIMENTAL|CBT in virtuo|Receives CBT in group format with Virtual Reality Exposure Therapy
62256235|NCT02354066|EXPERIMENTAL|Hallux valgus Surgery|Measurement of the Brake Response Time by Pat. undergoing hallux valgus surgery (first metatarsal osteotomy, Chevron, SCARF, Austin, etc.)
62256236|NCT02354066|EXPERIMENTAL|Hallux valgus and forefoot surgery|Measurement of the Brake Response Time by Pat. undergoing hallux valgus surgery (first metatarsal osteotomy; Chevron, Austin, SCARF, etc.) and additional forefoot surgery (PIP arthrodesis, second/third/etc. metatarsal osteotomy, etc.; Peg-in-Hole, WEIL-Osteotomy, etc.)
62443870|NCT03731481|EXPERIMENTAL|CHIP - Rural|Participants randomized by rural location of residence to receive CHIP Lifestyle Medicine program intervention.
62613639|NCT03845101|ACTIVE_COMPARATOR|CBT in vivo|Active comparator, receives CBT in group format. Treatment as usual.
62613640|NCT05547776|EXPERIMENTAL|Arms and Interventions|"Mindfulness App Use~Participants will have the opportunity to use the mindfulness app for four weeks."
62613641|NCT02240303||Chronic Pain Group|Participants that experience chronic pain will have the following procedures performed: A sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin; Pressure sense will be produced by a device that will be pressed against the skin for several seconds; Pinprick pressure will be applied to determine if the pain can be rated; a Physical Performance test will be performed; and an magnetic resonance imaging (MRI) will be done. In addition, blood sample, blood pressure, heart rate, and skin temperature will be taken during the procedures.
62738951|NCT06662045||Iron-Deficient Group|This group consists of children diagnosed with iron-deficiency anemia.
62738952|NCT06662045||Control Group (Non-Anemic)|This group consists of children without iron-deficiency anemia.
62838576|NCT03038880|EXPERIMENTAL|6 mg Faricimab Q12W|6 mg faricimab was given by intravitreal (IVT) injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by 6 mg faricimab IVT injection once every 12 weeks (Q12W) from Week 24 up to Week 48 (injections at Weeks 24, 36, and 48; 3 injections).
62256237|NCT02354066|EXPERIMENTAL|Control Run|Measurement of the Brake Response Time by Healthy Participants; control run; brake response time measurement with normal shoe and both foot orthoses
62256238|NCT00677651||1|Five caucasian women
62256239|NCT00677651||2|Five caucasian men
62256240|NCT03669432|EXPERIMENTAL|Intensity Modulated radiotherapy|"In this Arm, after surgery, patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the PTV of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System."
62443871|NCT03731481|EXPERIMENTAL|FPD2- Urban|Participants randomized by urban location of residence to receive FPD2 Lifestyle Medicine program intervention.
62443872|NCT03731481|EXPERIMENTAL|FPD2 - Rural|Participants randomized by rural location of residence to receive FPD2 Lifestyle Medicine program intervention.
62256241|NCT03669432|OTHER|Surgery alone|In this Arm, after surgery patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. Patient under surgery arm will receive no further treatment after surgery and radio-iodine therapy and will be kept on a routine follow up
62613642|NCT02240303||No Chronic Pain Group|Participants that do not experience chronic pain will have the following procedures performed: A sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin; Pressure sense will be produced by a device that will be pressed against the skin for several seconds; Pinprick pressure will be applied to determine if the pain can be rated; a Physical Performance test will be performed; and an magnetic resonance imaging (MRI) will be done. In addition, blood sample, blood pressure, heart rate, and skin temperature will be taken during the procedures.
62613643|NCT03014622|EXPERIMENTAL|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
62256242|NCT02596477|EXPERIMENTAL|Vepoloxamer - Low dose|Vepoloxamer injection administered intravenously 225 mg/kg over 3 hours
62256243|NCT02596477|EXPERIMENTAL|Vepoloxamer - High dose|Vepoloxamer injection administered intravenously 450 mg/kg over 3 hours
62256244|NCT02596477|PLACEBO_COMPARATOR|5% dextrose in water (D5W)|D5W administered intravenously over 3 hours
62256245|NCT02014389||Healthy subjects|Healthy subjects will be used as control group
62256246|NCT02014389||Patients|Patients with Glaucoma , Patients with retinal dystrophy
62256247|NCT04229433|EXPERIMENTAL|SHR2285|Participants received one of 3 dose levels of SHR2285 administered as multiple oral doses.
62256248|NCT04229433|EXPERIMENTAL|Placebo|Participants received one of 3 dose levels of placebo administered as multiple oral doses.
62256249|NCT04286087|EXPERIMENTAL|Investigational Arm|
62256250|NCT04286087|ACTIVE_COMPARATOR|Control Group|
62256251|NCT06210698||Recurrent Angioedema|Broad definition: Angioedema due to urticaria (histaminergic/mast-cell) or non-urticarial (non-histaminergic) etiology Narrow definition: non-urticarial angioedema - distinguishing between C1-Inhibitor deficiency/dysfunction, and Angioedema with normal levels of C1-Inhibitor.
62256252|NCT06210698||Healthy Subjects|Broad definition: No medical history of angioedema of any kind, including urticaria (histaminergic) or drug-induced angioedema (e.g. ACE-Inhibitor angioedema)
62256253|NCT04485143||experimental group|Non-invasive Wearable Device
62256254|NCT01944293|EXPERIMENTAL|Ketamine|0.5 mg/kg, I.V. (in the vein)
62256255|NCT01944293|ACTIVE_COMPARATOR|Midazolam|0.02 mg/kg, I.V. (in the vein)
62256256|NCT05915689|EXPERIMENTAL|Myofascial arm pull technique|subjects in this group will be treated with myofascial arm pull technique
62256257|NCT05915689|EXPERIMENTAL|Post Isomeric relaxation technique|subjects in this group will be treated with post isometric relaxation technique
62256258|NCT05636592||Standard programme group|Standard programme group, immunotherapy alone
62613644|NCT03014622|PLACEBO_COMPARATOR|Placebo|Biological/Vaccine: Placebos Intramuscular injection
62613645|NCT05427747|EXPERIMENTAL|cefotaxime|ceotaxime 2g iv /8hr
62256259|NCT05636592||controlled programme group|controlled programme group, statin combined with immunotherapy
62256260|NCT04436536|EXPERIMENTAL|training with random speed changes|Walking training on treadmill with random speed changes, that is, random sequence of several different walking speeds
62256261|NCT04436536|ACTIVE_COMPARATOR|training with blocked speed changes|Walking training on treadmill with blocked speed changes, that is a steady progression of faster walking speed.
62256262|NCT02858908|EXPERIMENTAL|Cohort 1 - Tideglusib|1000 mg tideglusib, orally, once daily
62256263|NCT02858908|EXPERIMENTAL|Cohort 2 - Tideglusib|400 mg tideglusib, orally, once daily
62256264|NCT03536975|OTHER|Platform|"Group with access to the web platform CAREGIVERSPRO-MMD"
62256265|NCT03536975|NO_INTERVENTION|Control|Group without any access to the web platform
62256266|NCT03880942|ACTIVE_COMPARATOR|Informative Story Book|Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.
62256267|NCT03880942|PLACEBO_COMPARATOR|Non Informative Story Book|Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
62256268|NCT05679336|EXPERIMENTAL|Rituximab, Cyclophosphamide, and Corticosteroids group|The experimental treatment group: 40 participants will receive combined immunosuppressive therapy with Rituximab, Cyclophosphamide, and Corticosteroids.
62256269|NCT06427928|ACTIVE_COMPARATOR|Explains the perioperative process with pictures|
62256270|NCT06427928|OTHER|The perioperative process is only explained|
62256271|NCT00595322|EXPERIMENTAL|1|bevacizumab and radiation (IMRT)
62256272|NCT04035447|EXPERIMENTAL|Behavioral Symptom Management for Young Adult Cancer Survivors|The intervention provides systematic training in cognitive and behavioral coping skills (e.g., activity-rest cycling, cognitive defusion, relaxation training) delivered over the course of 8 sessions (12 therapy hours). By employing these strategies, participants learn to adjust their behaviors and emotions as well as interact differently with their thoughts in the service of better managing symptoms.
62613646|NCT05427747|EXPERIMENTAL|meropenem|meropenem 1g iv /8hr
62613647|NCT03709121|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%)|
62613648|NCT03709121|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.5%)|
62054411|NCT04189354|EXPERIMENTAL|Active t-DCS|Use of the t-DCS machine with the following stimulation parameters: current intensity of 2mA, electrode size of 25 cm2, duration of stimulation 20 minutes (excluding the fade-in and fade-out periods of 15 seconds).
62054412|NCT04189354|SHAM_COMPARATOR|Sham t-DCS|"The condition of use in sham mode follows the same procedure as the active t-DCS except that the active stimulation lasts only 30 seconds at 3mA (60 seconds of active stimulation taking into account the periods of fade in and fade out).~The stimulator remains switched on during the procedure but does not deliver current. The devices are fully automatic and deliver an active or sham current according to a randomized stimulation code whose meaning is unknown by the operator, in order to respect the triple blind."
62054413|NCT00533104|EXPERIMENTAL|BM-MNC|Patients are implanted with bone marrow - mononuclear cells
62054414|NCT00533104|EXPERIMENTAL|PB-MNC|Patients are implanted with peripheral blood - mononuclear cells
62054415|NCT02979639|EXPERIMENTAL|GSK1437173A Group|Subjects ≥ 50 years of age who will receive two doses of the GSK1437173A vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
62054416|NCT03221725|EXPERIMENTAL|sacrospinosus fixation group|The group which sacrospinous fixation was performed
62054417|NCT01624948|EXPERIMENTAL|Everolimus+Tacrolimus/Prednisone|This arm (group 1) will undergo mycophenolic acid (MPA) discontinuation with the addition of Zortress (everolimus) to their current regimen of tacrolimus and prednisone; All patients in group 1 will receive Zortress (everolimus) at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
62054418|NCT01624948|ACTIVE_COMPARATOR|Standard of care: 50% reduction of MPA|This arm (group 2) patients will continue with tacrolimus (target trough level of 6-10 ng/mL), prednisone, and undergo a 50% reduction of the MPA dose, which is the standard immunosuppression treatment for renal transplant recipients with evidence of BKV infection. At months 1, 2, and 3 post-randomization urine and plasma BKV levels will be re-checked. Renal allograft biopsies will be done for cause as clinically indicated.
62054419|NCT03921125||Responders|
62054420|NCT03921125||Non responders|
62054421|NCT03261284|EXPERIMENTAL|DIAMOND group|D-dimer and anti-Xa are mornitored. If D-dimer levels continue to rise (\>1.5 times previous result ), increase the dose of heparin to reach the upper limit of the treatment target; If the D-dimer levels is stable (\<1.5 times previous result ) or is decreasing, the anticoagulation dose is maintained at current level (no active bleeding) or decreased (active bleeding).
62256273|NCT04035447|ACTIVE_COMPARATOR|Waitlist Control|Waitlist control participants will receive the intervention and receive systematic training in cognitive and behavioral coping skills approximately 6 months into their participation in the study.
62256274|NCT02889406|EXPERIMENTAL|Motivational intervention|"Following the motivational interviewing schema, structured in 2 phases of treatment (motivational and intervention) and organised in 11 visits (one each month). The first and last visits will be performed in consultations of endocrinology unit from referral hospitals; the other visits will be held in paediatric primary care setting. Visits will be scheduled monthly and each one will last between 15 and 20 minutes.~In addition to individualized visits, three group workshops focused in nutrition education for families will be organized. Each workshop will last 45 minutes and will target parents/mothers and obese children, separately."
62054422|NCT03261284|ACTIVE_COMPARATOR|Control group|Heparin dose adjusted according to anti-Xa activity or activated partial thromboplastin time (aPTT). The target range is aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels (0.3 U/ml to 0.7 U/ml) for unfractionated heparin.
62054423|NCT01737346|EXPERIMENTAL|lomustine and procarbazine|1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
62054424|NCT04093674|EXPERIMENTAL|Clinical evaluation|Clinical periodontal parameters
62054425|NCT04093674|EXPERIMENTAL|Laser Doppler Flowmetry|Laser Doppler Flowmetry evaluation
62054426|NCT04093674|EXPERIMENTAL|Patient centered outcomes|Pain and discomfort/ Esthetics
62054427|NCT04111757|EXPERIMENTAL|Technolas TENEO 317 Model 2|One or both eyes of participants will undergo LASIK surgery with the Technolas® TENEO 317 Model 2 (version 1.28 US software) Excimer Laser on Day 0.
62054428|NCT00264420|EXPERIMENTAL|1|zoledronic acid plus radiation therapy
62054429|NCT04295954|EXPERIMENTAL|Yoga Intervention|"This group will receive the Yoga Intervention for dysmenorrhea that will consist of 3 yoga sessions a week of 30 minutes each, for 12 weeks. The first 4 weeks 1 of the sessions will be face to face and the other 2 home sessions guided by a vieo and a brochure, and tutored from the virtual platform by the yoga teacher and researchers. This space will also serve for participants to share experiences.~After the first 4 weeks, participants will continue with the virtually tutored home yoga program, consisting of 3 weekly sessions of 30 minutes until completing the 12 weeks. They will be protected in all cases by the teacher and researchers.~All intervention group participants will be invited to participate in online focus groups during week 12 to explore their experiences and satisfaction with the progress of the study and to implement adaptations, if necessary.~They will be evaluated before the start of the yoga program per month, 3 months, 6 months and a year after the intervention."
62256275|NCT02889406|NO_INTERVENTION|Control group|Children who are assigned to the control group will follow the usual treatment performed in paediatrics, what is following the Clinical Practice Guideline on the prevention and treatment of child and adolescent obesity. Monthly visits will be conducted in which weight, height and waist circumference will be measured and compliance with the initial advice will be reviewed.
62613649|NCT03709121|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution|
62054430|NCT04295954|NO_INTERVENTION|Control group without intervention|Participants in the comparison group without intervention will not receive yoga intervention, will follow their conventional treatment and their usual daily activities. They will be told not to do yoga. They will be evaluated in advance, per a month, 3 months, 6 months and a year after the intervention.
62054431|NCT04602884|EXPERIMENTAL|COVID-19 Positive patients|subjects who were found COVID-19 Positive according to swab test.
62256276|NCT03126695|EXPERIMENTAL|Treatment Sequence 1 (ADBC)|"Subjects were randomized to treatment sequence ADBC:~On Day 1, following an overnight fast of at least 10 hours, each subject will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
62256277|NCT03126695|EXPERIMENTAL|Treatment Sequence 2 (BACD)|"Subjects were randomized to treatment sequence BACD:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
62838577|NCT03038880|EXPERIMENTAL|6 mg Faricimab Q16W|6 mg faricimab was administered by IVT injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by no doses up to Week 24 when a protocol-defined assessment of disease activity was performed. Participants with disease activity at Week 24 initiated 6 mg faricimab IVT Q12W dosing, and participants without disease activity at Week 24 initiated 6 mg faricimab IVT once every 16 weeks (Q16W) dosing for the remainder of the study.
62256278|NCT03126695|EXPERIMENTAL|Treatment Sequence 3 (CBDA)|"Subjects were randomized to treatment sequence CBDA:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
62054432|NCT04602884|OTHER|Healthy subjects|subjects who were found COVID-19 Negative according to swab test.
62256279|NCT03126695|ACTIVE_COMPARATOR|Treatment Sequence 4 (DCAB)|"Subjects were randomized to treatment sequence DCAB:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
62256280|NCT03622463|EXPERIMENTAL|Antroquinonol 100 mg PO QD|Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol,once a day.
62256281|NCT03622463|EXPERIMENTAL|Antroquinonol 50 mg PO QD|Antroquinonol (Hocena) 50mg/capsule. 1 capsules antroquinonol and 1 capsule placebo, once a day.
62443873|NCT03329118|EXPERIMENTAL|SHR3824 1Omg,Simavastatin 40mg|two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
62443874|NCT05238493|EXPERIMENTAL|"Subcutaneous (SQ) Dose A"|Single dose of VEL-101 by SQ injection
62443875|NCT05238493|EXPERIMENTAL|"Intravenous (IV) Dose A"|Single dose of VEL-101 by IV infusion
62443876|NCT05238493|EXPERIMENTAL|"SQ Dose B"|Single dose of VEL-101 by SQ injection
62443877|NCT05238493|EXPERIMENTAL|"SQ Dose C"|Single dose of VEL-101 by SQ injection
62443878|NCT05238493|EXPERIMENTAL|"IV Dose C"|Single dose of VEL-101 by IV infusion
62443879|NCT05238493|EXPERIMENTAL|"SQ Dose D"|Single dose of VEL-101 by SQ injection
62443880|NCT05238493|EXPERIMENTAL|"SQ Dose E"|Single dose of VEL-101 by SQ injection
62443881|NCT05238493|PLACEBO_COMPARATOR|SQ or IV Placebo|Single dose of Placebo by SQ injection or IV infusion
62443882|NCT00784212|EXPERIMENTAL|Cohort 1|
62443883|NCT00784212|EXPERIMENTAL|Cohort II|
62838578|NCT03038880|ACTIVE_COMPARATOR|0.5 mg Ranibizumab Q4W|0.5 mg of ranibizumab was administered by IVT injection once every 4 weeks (Q4W) for 48 weeks (13 injections).
62443884|NCT00784212|EXPERIMENTAL|Cohort III|
62838579|NCT02809001|EXPERIMENTAL|Experimental: Fat grafting|Autologous fat graft transplantation subdermally to expanded skin.
62443885|NCT01960751|OTHER|neurocognitive tests|neurocognitive tests battery (MMSE, SDS, SF-36, HAD, BPRS, RAVLT, FACT-Cog, MoCA)
62443886|NCT03427957|EXPERIMENTAL|New hysteroscopic grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the new grasper with knurled terminal end and cutting jaws.
62838580|NCT02809001|NO_INTERVENTION|Control|Expansion was discontinued until the early signs of complication disappeared.
62838581|NCT03187392|ACTIVE_COMPARATOR|lidocaine injection|
62838582|NCT03187392|EXPERIMENTAL|lidocaine-prilocaine cream|
62838583|NCT01536886|PLACEBO_COMPARATOR|LEO 90100 vehicle|Aerosol foam with no active ingredient
62054433|NCT01600664|EXPERIMENTAL|interactive computer game|"Participants will be using the interactive computer game- My Diabetic Friend, installed on Intel-powered convertible classmate PC."
62054434|NCT01600664|ACTIVE_COMPARATOR|Convertible PC|Participants will be using the convertible classmate PC without the interactive computer game
62054435|NCT01820949||Control cohort|Standard care before implementation (pre-implementation)
62054436|NCT01820949||PBM cohort|After implementation of PBM program (post-implementation)
62256282|NCT03622463|PLACEBO_COMPARATOR|Placebo|Placebo capsule, 2 capsules placebo, once a day
62443887|NCT03427957|ACTIVE_COMPARATOR|Classic spoon grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the classic spoon grasper.
62443888|NCT03427957|ACTIVE_COMPARATOR|Classic alligator grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the classic alligator grasper.
62443889|NCT05368142|EXPERIMENTAL|N-CWS treatment group|Patients with N-CWS treatment
62443890|NCT05368142|PLACEBO_COMPARATOR|Control group（ treatment with Silver Ion-releasin)|Patients with Silver Ion-releasin
62443891|NCT01697007|EXPERIMENTAL|2 injections of DNA administered by Zetajet|This arm will receive 600 micrograms of HIVIS DNA given as 2 injections using the Zetajet device each injection will comprise of 0.1 ml at a concentration of 3mg/ml
62838584|NCT01536886|ACTIVE_COMPARATOR|Betamethasone plus calcipotriol|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) ointment
62613650|NCT03442699|EXPERIMENTAL|Cognitive Behavioral Therapy|Participants will receive up to 10 daily sessions of cognitive behavioral therapy (depending on length of stay), for about an hour each day. During this time the therapist will work to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.
62613651|NCT06285136|EXPERIMENTAL|Venetoclax in combination with Decitabine (+-sorafenib)|Venetoclax in combination with decitabine (+-sorafenib) Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time \>2h) Sorafenib 800mg/d, d8-14 (only for FLT3/ITD mutation positive patients)
62443892|NCT01697007|EXPERIMENTAL|2 injections DNA by Zetajet and electroporation|This arm will receive 600 micrograms of HIVIS DNA given as 2 injections using the Zetajet device each injection will comprise of 0.1 ml at a concentration of 3mg/ml followed by electroporation using the Derma Vax device.
62443893|NCT01697007|EXPERIMENTAL|1 injection DNA by Zetajet and electroporation|This arm will receive 600 micrograms of HIVIS DNA given in 1 injection using the Zetajet device the injection will comprise of 0.1 ml at a concentration of 6mg/ml followed by electroporation using the Derma Vax device.
62613652|NCT03737630|EXPERIMENTAL|GExp|This group will perform the inspiratory muscle training with moderate load
62613653|NCT03737630|ACTIVE_COMPARATOR|GCon|This group will initiate inspiratory muscle training with low load
62613654|NCT01092637||Cooled|Child was allocated standard intensive care plus moderate whole body hypothermia treatment within 6 hours of birth
62613655|NCT01092637||Non-cooled|Child was allocated standard intensive care only within 6 hours of birth
62613656|NCT05956522|EXPERIMENTAL|Test/reference|Subjects first receive a single-dose of 25 mg/5 mg test Empagliflozin And Linagliptin tablet (T, produced by Qilu Pharmaceutical (Hainan) Co., Ltd ) in the first treatment period and to receive the reference (R, Boehringer Ingelheim International GmbH \& Co. KG )in the second treatment period.
62838585|NCT01536886|EXPERIMENTAL|LEO 90100|LEO 90100 aerosol foam: calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)
62838586|NCT01536886|PLACEBO_COMPARATOR|Ointment vehicle|Ointment with no active ingredients
62054437|NCT02127086|EXPERIMENTAL|Intervention Group|The study design is a non-randomized quasi-experimental cohort design with two cohorts who will be sequentially studied. In phase 1, patients will comprise the usual care group (UCG), or control cohort, defined as receiving pain assessment and management practices that nurses are currently performing on the study units. In phase 2 the PAIN Algorithm coupled with analgesic order sets will be introduced to nurses and physicians on all participating units as the intervention. Patients enrolled in this phase will be considered the intervention group (IG), also called the experimental cohort. Nurses will be enrolled from the participating inpatient units to provide data on the clinical utility of the PAIN Algorithm.
62838587|NCT03619720|EXPERIMENTAL|Participants|
62838588|NCT02360878||Non-diabetic subjects|Obese (BMI \> 30 kg/m2) with normal glucose tolerance implanted with the EndoBarrier Gastrointestinal liner
62443894|NCT02688608|EXPERIMENTAL|Pembrolizumab|200 milligrams of Pembrolizumab will be given intravenously every 3 weeks.
62443895|NCT06041581|EXPERIMENTAL|SHADES Intervention|The SHADES intervention is a 6-month, modernized, collaborative care intervention in which a multidisciplinary team delivers established insomnia treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that harnesses technology to maximize access to and convenience of effective treatments and to minimize personnel, training, and space requirements. Our Intervention Team consists of an insomnia clinical specialist, a clinical behavioral sleep medicine and CBT-I delivery expert, a sleep research/medicine expert, and the patients' primary care providers. Treatments to be delivered are CBT-I in different modalities - internet, phone, and face-to-face - all of which are empirically supported.
62838589|NCT02360878||T2DM subjects|Obese (BMI \> 30 kg/m2) with type 2 diabetes implanted with the EndoBarrier Gastrointestinal liner
62838590|NCT00272311|ACTIVE_COMPARATOR|1|81 mg Aspirin
62838591|NCT00272311|ACTIVE_COMPARATOR|2|162 mg Aspirin
62838592|NCT00272311|ACTIVE_COMPARATOR|3|325 mg Aspirin
62838593|NCT00272311|ACTIVE_COMPARATOR|4|650 mg Aspirin
62838594|NCT00272311|ACTIVE_COMPARATOR|5|1300 mg Aspirin
62838595|NCT03028519|EXPERIMENTAL|Treatment|Vitamin D levels will be measured at the time of routine blood work. If Vitamin D levels are found to be low, patients will take 50,000 IU of vitamin D3 weekly daily as maintenance therapy. There is no prospective control arm.
62838596|NCT05765578||Moderna-Only Vaccine/Booster Series (MMMM Group)|Individuals who previously received Moderna COVID-19 vaccines in both primary series and first booster and a bivalent booster against Omicron BA.4/5 as the second booster dose (Moderna mRNA1273.222).
62054438|NCT02127086|NO_INTERVENTION|Usual Care Group|The study design is a non-randomized quasi-experimental cohort design with two cohorts who will be sequentially studied. In phase 1, patients will comprise the usual care group (UCG), or control cohort, defined as receiving pain assessment and management practices that nurses are currently performing on the study units. In phase 2 the PAIN Algorithm coupled with analgesic order sets will be introduced to nurses and physicians on all participating units as the intervention. Patients enrolled in this phase will be considered the intervention group (IG), also called the experimental cohort. Nurses will be enrolled from the participating inpatient units to provide data on the clinical utility of the PAIN Algorithm
62054439|NCT01873170||Combined Oral Contraceptive pills|Levonorgestrel/ethinyl estradiol 0.15mg/30mcg daily oral tabs x21 then 7 inert tabs
62613657|NCT05956522|EXPERIMENTAL|Reference/test|Subjects first receive a single-dose of 25 mg/5 mg reference Empagliflozin And Linagliptin tablet (R, Boehringer Ingelheim International GmbH \& Co. KG) in the first treatment period and to receive test tablet (T, produced by Qilu Pharmaceutical (Hainan) Co., Ltd) in the second treatment period.
62613658|NCT00204477|ACTIVE_COMPARATOR|Soy milk|Subjects will consume two soy milk drinks from the content of 2 sachets (40 g isoflavone-free soy protein and 600 mg calcium) in place of a small meal, five days per week. Each sachet will contain 20 g soy protein and 300 mg calcium. Content of sachets will be mixed with \~1.6 liter of water for ingestion.
62613659|NCT00204477|PLACEBO_COMPARATOR|Cow's milk|Subjects will consume two cow's milk drinks from the content of 2 sachets (40 g cow's milk protein, casein, and 600 mg calcium) in place of a small meal, five days per week. Each sachet will contain 20 g cow's milk protein and 300 mg calcium. Content of sachets will be mixed with \~1.6 liter of water for ingestion. Casein is free of ovarian hormones.
62054440|NCT01873170||depot medroxyprogesterone acetate|150mg DMPA intramuscular injection once every 3 months
62054441|NCT01873170||Levonorgestrel-intrauterine device|52mg levonorgestrel intrauterine device
62613660|NCT01553435|PLACEBO_COMPARATOR|Dextromethorphan, opioid analgisia, efficacy|
62613661|NCT01553435|PLACEBO_COMPARATOR|Placebo,opioid analgesia, efficacy|
62838597|NCT05765578||Pfizer-Only Vaccine/Booster Series (PPPP Group)|Individuals who previously received Pfizer COVID-19 vaccines in both primary series and first booster and a bivalent booster against Omicron BA.4/5 as the second booster dose (Pfizer-BNT 162b2 bivalent booster).
62838598|NCT05765578||Moderna mRNA COVID-19 updated vaccine (XBB.1.5): Comparison Group|Individuals who received Moderna 2023 updated COVID-19 vaccine (XBB.1.5).
62838599|NCT05765578||Pfizer-BioNTech COVID-19 updated vaccine (XBB.1.5): Reference Group|Individuals who received Pfizer 2023 updated COVID-19 vaccine (XBB.1.5).
62838600|NCT04408976||Software practices|Patients with urinary tract infection in practices using the clinical decision support software
62054442|NCT01873170||Copper intrauterine device|Copper T380A intrauterine device
62054443|NCT01873170||Etonogestrel contraceptive implant|68mg etonogestrel subdermal implant
62054444|NCT01873170||Control|Low risk of pregnancy due to sterilization, heterosexual abstinence, or consistent condom use
62443896|NCT06041581|ACTIVE_COMPARATOR|Active Control|Active Control (AC) consists of sleep education and hygiene (study staff), symptom monitoring (study staff), and usual primary care for insomnia (clinical staff).
62443897|NCT02806349|PLACEBO_COMPARATOR|Control|3g/d Cornstarch and 14g/d wheat bran control
62443898|NCT02806349|EXPERIMENTAL|K-GB&AG|3g/d American Ginseng and 7g/d Konjac-glucomannan fiber blend
62613662|NCT00795769|EXPERIMENTAL|Ondansetron therapy|Patients receive ondansetron IV once 30-60 minutes before undergoing autologous peripheral blood stem cell transplantation.
62838601|NCT04408976||Control practices|Patients with urinary tract infection in practices not using the clinical decision support software
62838602|NCT06067152|ACTIVE_COMPARATOR|T0= Enrollment|mechanical ventilation will be set according to the standard of care criteria
62838603|NCT06067152|ACTIVE_COMPARATOR|T1= guided MV at the end of SRM trial|EIT guided mechanical ventilation will be set
62443899|NCT00617435|EXPERIMENTAL|V|
62443900|NCT00617435|EXPERIMENTAL|N|
62443901|NCT00617435|EXPERIMENTAL|J|
62054445|NCT04939545|EXPERIMENTAL|Experimental Intervention Ropivacain|Ropivacain Fresenius 0.2% is a solution for infusion/ injection and will be continuously administered with an elastomer pump through the surgically placed intercostal catheter (ICC) between parietal pleura and fascia endo-thoracica at the level of surgical incision for a maximum of 72 hours at an initial standard flow rate setting of 6 ml/h using 2 mg/ml ropivacaine. In case pain exceeds 7 on NRS later than 2 hours after skin closure the flow rate will be adjusted on 8 ml/h. Furthermore, Ropivacain Fresenius 0.2% will be provided in a 20 ml glass vial for flushing the infusion line and subpleural administration.
62256283|NCT05097703|EXPERIMENTAL|Sleep Resource Intervention|"Half the participants in the study will be allocated to the intervention group. The resource will be sent to participants in this group, along with information about the research study and instructions for completing outcome measures. This will be followed up by a telephone call to ensure participants understand what is required of them and to answer any questions. All carers will be asked to complete questionnaires at baseline, immediately post intervention and at one-month post intervention; as well as sleep diaries for their child for the duration of the intervention period. Carers in the intervention group will also be asked to complete a diary of resource use as well as a feedback survey on their experience of using the resource.~Carers in the intervention group will be asked that they use the resource with their child at bedtime for a minimum of three-days a week over a one-month period."
62613663|NCT05804461|EXPERIMENTAL|Face-to-face intervention|A three-session face-to-face intervention using Motivational Interviewing with a facilitator; to increase Pre-Exposure Prophylaxis (PrEP) uptake. Pre-post-post evaluations after each session will be administered. Participation will last 150 days from the start to the last follow-up.
62613664|NCT05804461|EXPERIMENTAL|Online intervention|A three-session online intervention using Motivational Interviewing with a facilitator; to increase Pre-Exposure Prophylaxis (PrEP) uptake. Pre-post-post evaluations after each session will be administered. Participation will last 150 days from the start to the last follow-up.
62613665|NCT05804461|NO_INTERVENTION|Control|No intervention. Pre-post evaluations will be administered.
62838604|NCT06067152|ACTIVE_COMPARATOR|T2= 24 hours with EIT guided MV|evaluation of mechanical ventilation after 24h EIT-guided ventilation
62838605|NCT03847896|EXPERIMENTAL|BDA MDI (PT027) 160/180 μg|Budesonide/Albuterol sulfate BDA MDI (PT027) high dose
62838606|NCT03847896|EXPERIMENTAL|BDA MDI (PT027) 80/180 μg|Budesonide/Albuterol sulfate BDA MDI (PT027) low dose
62838607|NCT03847896|ACTIVE_COMPARATOR|BD MDI (PT008) 160 µg|Budesonide BD MDI (PT008)
62838608|NCT03847896|ACTIVE_COMPARATOR|AS MDI (PT007) 180 µg|Albuterol sulfate AS MDI (PT007)
62443902|NCT04559685|EXPERIMENTAL|Arm A Energy Dose-escalation|In Arm A, the dose-escalation cohort, there will be 3 cohorts of ascending MRgFUS power/energy dose combinations with a fixed SONALA-001 dose and fixed surgical time. Arm A will determine the power/energy dose combination for Arm B.
62443903|NCT04559685|EXPERIMENTAL|Arm B Time-escalation|In Arm B, the time-escalation cohort, the SONALA-001 and power/energy dose combination will be fixed. Participants will be enrolled into two time cohorts (2 days and 6 days post-SDT).
62443904|NCT04559685|EXPERIMENTAL|Arm C ALA Dose-escalation|In Arm C, the MRgFUS power/energy dose will be fixed based on Arm A MTD/OBD, with the SONALA-001 dose escalation.
62443905|NCT04559685|EXPERIMENTAL|Arm D MRgFUS alone|In Arm D, MRgFUS treatment alone will be given at the optimal energy determined from previous Arms.
62443906|NCT04559685|EXPERIMENTAL|Arm E Optimal energy and ALA dose|In Arm E patients will receive treatment at the optimal energy and ALA dose determined form prior Arms.
62443907|NCT03833388|EXPERIMENTAL|TOP1630 Ophthalmic Solution|
62443908|NCT03833388|PLACEBO_COMPARATOR|Placebo to TOP1630 Ophthalmic Solution|
62443909|NCT00577759|EXPERIMENTAL|Active Intervention|Direct referral to community organizations, with support for practices to do so. These include the North Carolina Tobacco Quitline, public health department dietitians, and the YMCA.
62838609|NCT03847896|PLACEBO_COMPARATOR|Placebo MDI|Placebo MDI
62443910|NCT00577759|EXPERIMENTAL|Passive Intervention|Provision of information about community organizations to patients as above.
62443911|NCT00577759|PLACEBO_COMPARATOR|Usual Care|Usual care
62838610|NCT01589042||Above the Knee|Patients treated with the Chocolate balloon for a lesion located above the knee
62838611|NCT01589042||Below the Knee|Patients treated with the Chocolate balloon for a lesion located below the knee
62838612|NCT04163952|EXPERIMENTAL|Treatment (talimogene laherparepvec, panitumumab)|Patients receive talimogene laherparepvec IM on day 1. Patients then receive talimogene laherparepvec IM and panitumumab IV over 30-90 minutes on day 22. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive up to 3 additional cycles of treatment per physician discretion.
62838613|NCT05497999|EXPERIMENTAL|Treatment Group|With Black and White Subgroups
62838614|NCT05497999|ACTIVE_COMPARATOR|Control Group|With Black and White Subgroups
62838615|NCT06519708|ACTIVE_COMPARATOR|Erector Spinae Plane Block|Patients will receive an ultrasound-guided erector spinae plane block with the injection of 30 ml bupivacaine 0.25% after induction of general anesthesia.
62256284|NCT05097703|NO_INTERVENTION|Control|Participants randomised to the wait-list control group will be asked to complete pre, post and follow-up measures, as well as keep a sleep diary for the duration of the intervention period. They will then be sent the resource after the final outcome measures have been collected to use as they wish.
62256285|NCT06474949|ACTIVE_COMPARATOR|Bupivacaine|Bupivacaine
62256286|NCT06474949|PLACEBO_COMPARATOR|Saline|Saline
62256287|NCT04276389|ACTIVE_COMPARATOR|OCT-guided arm|
62256288|NCT04276389|PLACEBO_COMPARATOR|Angiography-guided arm|
62256289|NCT03556436|EXPERIMENTAL|Group 1|YH25448 240mg single dose in korean
62256290|NCT03556436|EXPERIMENTAL|Group 2|YH25448 240mg single dose in caucasian
62256291|NCT01750931|OTHER|Meloxicam GSK 15mg|A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fed condition
62256292|NCT01750931|OTHER|Mobic 15mg|A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fed condition
62256293|NCT00904800|EXPERIMENTAL|1|Low dose
62256294|NCT00904800|EXPERIMENTAL|2|Middle dose
62256295|NCT00904800|EXPERIMENTAL|3|High dose
62256296|NCT00904800|PLACEBO_COMPARATOR|4|placebo
62256297|NCT02895880||usual care|first 25 participants will receive usual care (i.e. no risk communication tool)
62256298|NCT02895880||risk communication tool|next 25 participants, clinicians will use the risk communication tool in their discussion about statins and cardiovascular risk reduction
62256299|NCT04796051|EXPERIMENTAL|Neck orthosis - posterior cervical weight|The posterior cervical weight orthosis is made of a well-padded adjustable Velcro attached to the end with a two-kilogram weight attached with two durable straps. The device is firmly anchored around the curvature of the jaw and attached with Velcro to the apex of the skull. Neck orthosis group will use a cervical orthosis (with the posterior cervical neck weight) for 10 minutes / 3 times a day, for a total of 30 minutes a day
62256300|NCT04796051|ACTIVE_COMPARATOR|Deep cervical flexors exercise|Deep cervical flexors exercise group will do 15 repetitions x 3 sets of deep neck flexor exercises every day of the week.
62256301|NCT02245438|EXPERIMENTAL|TPV/RTV low dose|
62613666|NCT00803309|ACTIVE_COMPARATOR|A|PegIntron® 1.5 µg/kg once weekly (QW) subcutaneous (sc) plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 24 weeks beyond standard treatment with 24 weeks follow-up
62613667|NCT00803309|ACTIVE_COMPARATOR|B|PegIntron® 1.5 µg/kg QW sc plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 12 weeks beyond standard treatment with 24 weeks follow-up
62613668|NCT03229967||Exploration Cohort|Up to 150 VLBW (very low birthweight) infants enrolled from the Regional One Health NICU (neonatal intensive care unit). Weekly stool samples will be obtained. After 36 weeks infants diagnosed with BPD per NIH guidelines, will be matched with infants without BPD. Stool samples from these infants will be sent for 16s rRNA (ribosomal ribonucleic acid) sequencing after conclusion of initial enrollment period. ITS (internal transcribed spacer) DNA may also be used to characterize fungal communities.
62838616|NCT06519708|EXPERIMENTAL|External Oblique Intercostal Plane Block|Patients will receive an ultrasound-guided external oblique intercostal plan block Intraoperative with the injection of 30 ml bupivacaine 0.25% after induction of general anesthesia.
62838617|NCT01481818|EXPERIMENTAL|radioprotector|
62838618|NCT01288261|EXPERIMENTAL|Treatment|Paclitaxel, bavituximab, laboratory biomarker analysis and pharmacological study
62838619|NCT02986295||BioMimeTM Stent|No intervention / Ischemic heart disease with percutaneous coronary intervention with BioMimeTM Stent
62838620|NCT02986295||Ultimaster® Stent|No intervention / Ischemic heart disease with percutaneous coronary intervention with Ultimaster® stent
62256302|NCT02245438|EXPERIMENTAL|TPV/RTV high dose|
62256303|NCT05075525|EXPERIMENTAL|High Intensity Laser Therapy Group|Patients underwent High Intensity Laser Therapy (HILT) and exercise for 10 sessions
62256304|NCT05075525|EXPERIMENTAL|Ultrasound and Transcutaneous Electrical Nerve Stimulation Group|Patients will be treated by transcutaneous electrical nerve stimulation(TENS), ultrasound (US) and exercise for 10 sessions
62256305|NCT05075525|EXPERIMENTAL|Ultrasound and Interferential Current Stimulation Group|Patients will be treated with ultrasound (US) ,interferential current stimulation and exercise for 10 sessions
62256306|NCT02652338|ACTIVE_COMPARATOR|MNC-01|potassium, magnesium, and vitamins (MNC-01)
62256307|NCT02652338|PLACEBO_COMPARATOR|Placebo|cellulose, microcrystalline \[NF\], HPMC E15,
62256308|NCT02289430|EXPERIMENTAL|Crestor+Ezetrol|rosuvastatin+ezetimibe
62256309|NCT02289430|ACTIVE_COMPARATOR|Ezetrol|ezetimibe
62256310|NCT02289430|ACTIVE_COMPARATOR|Crestor|rosuvastatin
62256311|NCT01314963|EXPERIMENTAL|Intraoperative handheld Gamma Camera (pIHGC)|The prototype intraoperative handheld gamma camera (pIHGC)
62256312|NCT01314963|ACTIVE_COMPARATOR|Gamma probes (GP)|Standard of care intraoperative gamma probes (GP) currently in use.
62256313|NCT06502613||Melatonin phase delay|Salivary melatonin testing shows Melatonin phase delay
62256314|NCT06502613||Melatonin phase nromal, controls|Salivary melatonin testing shows normal, control group
62256315|NCT02877693|EXPERIMENTAL|Thoracic MRI Scan with 1.5 Tesla MRI|Subjects will be enrolled at least 60 days post successful St. Jude Medical™ MR Conditional ICD System implant. Enrolled subjects will undergo an elective 1.5T MRI scan within 30 days post enrollment. Post MRI visit all subjects will be followed up at 1-Month post MRI visit.
62443912|NCT00963183|EXPERIMENTAL|A|Drug: AZD5423
62256316|NCT02877693|EXPERIMENTAL|Thoracic MRI Scan with 3 Tesla MRI|Subjects will be enrolled at least 60 days post successful St. Jude Medical™ MR Conditional ICD System implant. Enrolled subjects will undergo an elective 3T MRI scan within 30 days post enrollment. Post MRI visit all subjects will be followed up at 1-Month post MRI visit.
62838621|NCT03106311|ACTIVE_COMPARATOR|Rupture of membranes group|Pregnant women with definite rupture of membranes will undergo speculum examination. Vaginal washing will be done. The washing fluid will be taken for quantitative and qualitative assessment of beta subunit of human chorionic gonadotropin.
62256317|NCT05513937|ACTIVE_COMPARATOR|Nebivolol|Single dose Phase (4 weeks): patients will be treated with Nebivolol 5mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Nebivolol 5mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Nebivolol 5mg/Amlodipine 5mg will continue with the same therapy.
62256318|NCT05513937|ACTIVE_COMPARATOR|Amlodipine|Single dose Phase (4 weeks): patients will be treated with Amlodipine 5 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Nebivolol 5 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Nebivolol 5mg/Amlodipine 5mg will continue with the same therapy.
62256319|NCT00546767|EXPERIMENTAL|Mail and Live Phone|
62256320|NCT00546767|EXPERIMENTAL|IVR|
62256321|NCT00546767|EXPERIMENTAL|Computer Kiosk|
62256322|NCT00546767|ACTIVE_COMPARATOR|Traditional|
62256323|NCT05171491||Indeterminate Lung Nodule|Subjects that present with indeterminate lung nodules at time of biopsy. No intervention outside of standard of care.
62443913|NCT00963183|PLACEBO_COMPARATOR|B|Drug: Placebo
62443914|NCT05295771|EXPERIMENTAL|Test arm|Geistlich Fibro-Gide ®.
62443915|NCT05295771|ACTIVE_COMPARATOR|Control|Autogenous Connective Tissue Graft.
62838622|NCT03106311|ACTIVE_COMPARATOR|Intact membranes group|Pregnant women with intact membranes will undergo speculum examination. Vaginal washing will be done. The washing fluid will be taken for quantitative and qualitative assessment of beta subunit of human chorionic gonadotropin.
62838623|NCT02231905|EXPERIMENTAL|BI-Sifrol®|Tablets were administrated after switching from prior treatment of dopamine agonist (talipexole), treatment period consisted of an ascending period and a maintenance period, total duration was 4 to 12 weeks.
62838624|NCT03715049|OTHER|Fraxel Laser Treatment|Using the energy and density settings within the FDA approved limits (5-40mJ at 30-100% density) that were narrowed down by the pre-clinical portion of the study, and analysis of abdominal and facial tissue treated in Objective 1, up to thirty (30) subjects will be recruited and treated one (1) time in the perioral region of the upper lip and followed for 6 months (study design below). The acute effects of the laser application will be determined by subjective analysis using the wrinkle severity scores.
62256324|NCT00829075|EXPERIMENTAL|I|only r-FSH TREATMENT
62256325|NCT00829075|EXPERIMENTAL|II|only HP-hMG TREATMENT
62443916|NCT01477437|EXPERIMENTAL|Intervention (experimental) Group|
62443917|NCT01477437|NO_INTERVENTION|Control group|
62443918|NCT01033344|PLACEBO_COMPARATOR|Placebo|Solution resembling active solution but without peptides
62256326|NCT00829075|EXPERIMENTAL|III|r-FSH plus HP-hMG TREATMENT
62256327|NCT05992870|EXPERIMENTAL|Neoadjuvant radiotherapy group|Radiotherapy followed by skin-sparing mastectomy and immediate implant-based reconstruction in HBCH
62256328|NCT04770389|PLACEBO_COMPARATOR|Placebo|placebo obicetrapib + placebo ezetimibe; once daily
62256329|NCT04770389|EXPERIMENTAL|Combination therapy|5 mg obicetrapib + 10 mg ezetimibe; once daily
62256330|NCT04770389|EXPERIMENTAL|Obicetrapib monotherapy|5 mg obicetrapib + placebo ezetimibe; once daily
62256331|NCT04770389|EXPERIMENTAL|Ezetimibe monotherapy|placebo obicetrapib + 10 mg ezetimibe; once daily
62256332|NCT01301950|ACTIVE_COMPARATOR|TruMatch® Personalized Solutions|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using TruMatch® Personalized Solutions (Custom Patient Instrumentation)
62256333|NCT01301950|ACTIVE_COMPARATOR|Conventional Total Knee Replacement|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments
62256334|NCT04173676|EXPERIMENTAL|use of indocyanine green|submucosal injection of ICG is by gastroscopy on the superior and inferior edge of the esophageal tumor,Dose of 0.5mg
62256335|NCT01391286|EXPERIMENTAL|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
62256336|NCT01391286|PLACEBO_COMPARATOR|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
62256337|NCT01171222||veteran soccer players from Saarland County, Germany|
62443919|NCT01033344|EXPERIMENTAL|Group 1|Cat-PAD dose group 1
62443920|NCT01033344|EXPERIMENTAL|Group 2|Cat-PAD Dose group 2
62443921|NCT06482593|ACTIVE_COMPARATOR|Groupe 1: ZOE-based sealant|ZOE-based sealant (GROSS-MAN, PROQUIDENT, COL)
62443922|NCT06482593|ACTIVE_COMPARATOR|Groupe 2: AH-Plus Epoxy Resin Sealer|Epoxy resin-based sealant (AH Plus, Dentsply DeTrey, Konstanz, Germany)
62443923|NCT06482593|EXPERIMENTAL|Groupe 3: Bio-C Sealer|Bioceramic sealer (Bio-C Sealer, ANGELUS, BRA)
62443924|NCT05240339||PD participants with minor phenomena|
62443925|NCT04727697|ACTIVE_COMPARATOR|Standard of Care, preoperative teaching group|The participants in this group will receive the preoperative teaching and handouts as is the current standard of care.
62443926|NCT04727697|EXPERIMENTAL|Augmented Reality perioperative experiences group|The participants in this group will receive the preoperative teaching and handouts as is the current standard of care in addition to receiving the augmented reality (AR) perioperative experience.
62838625|NCT01315639|OTHER|biomarkers, MRI and CSF|"Longitudinal multicenter study including 1300 subjects with amnestic impairment (MCI, n=650 and AD, n=650) derived from the main French national Memory Resources and Research Centers.~Participants will undergo at baseline and every 6 months a neurological examination, a neuropsychological assessment (and an oculomotor examination for those included from Broca Hospital).~Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
62838626|NCT04230278|EXPERIMENTAL|START-Play Intervention|Sitting Together And Reaching to Play is an intervention designed to work on motor-based problem-solving. Thus the activities keep thinking skills at the forefront while also working on advancing motor skills. When initially developed to work with children who were emerging sitters the motor tasks focused on sitting and reaching resulting in the name.
62838627|NCT04230278|ACTIVE_COMPARATOR|Movement, Orientation, Repetition, and Exercise (MORE-PT) - Usual Care Physical Therapy|This intervention was based on the observations of usual care from a previous study. Key principles included the use of Movement, Orientation, Repetition, and Exercise thus the intervention name was changed to MORE-PT before enrollment started. This reduced bias as the therapists and families were not informed this was usual care which could have biased them.
62838628|NCT03734380|EXPERIMENTAL|Laboratory-based gait retraining (LGR)|Subjects will attend 6 weekly sessions of stair ascent and descent exercise over six consecutive weeks. In each session, they walk at a self-selected speed on the instrumented staircase. The training time will be progressively increased from 15 to 30 minutes over the six sessions. The auditory feedback will be gradually removed in the last three sessions.
62838629|NCT03734380|EXPERIMENTAL|Sensor-based gait retraining (SGR)|Subjects will receive training similar to LGR, except the KAM measurement is based solely on inputs from IMUs embedded in the shoes. The training schedule, duration, and intensity will be identical to those of the LGR group.
62838630|NCT03734380|EXPERIMENTAL|Walking exercise control (Ctrl)|Subjects will attend 6 weekly sessions of stair ascent and descent exercise over six consecutive weeks. In each session, they will walk on the same instrumented staircase at a self-selected pace without any guidance on gait modification. The training period and training time per session will be identical to the other two groups.
62054446|NCT04939545|PLACEBO_COMPARATOR|Control Intervention Placebo|Placebo (NaCl 0.9% B. Braun) is an isotonic solution for infusion and will be continuously administered with an elastomer pump through the surgically placed intercostal catheter (ICC) between parietal pleura and fascia endo-thoracica at the level of surgical incision for a maximum of 72 hours at an initial standard flow rate setting of 6 ml/h using NaCl 0.9%. In case pain exceeds 7 on NRS later than 2 hours after skin closure the flow rate will be adjusted on 8 ml/h. Furthermore, NaCl 0.9% will be provided in a 20 ml glass vial for flushing the infusion line and for subpleural administration, which will be prepared by the hospital pharmacy.
62054447|NCT06525818|EXPERIMENTAL|Intervention group|All participants in the intervention group will be invited to weekly virtual group therapy mealtime sessions with the Speech-Language Pathologist and other participants in the intervention group. Additionally, families will engage in virtual therapy sessions at least biweekly focused on individualized goals informed by the expertise of the study team and published expert programs. Individualized programs will include virtual sessions with the occupational therapist, speech therapist, or combined therapies. The team will consult with the registered dietitian and Developmental and Behavioral Pediatrician as needed.
62256338|NCT03418129|EXPERIMENTAL|Mobile App Mindfulness|Participants engage in the use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
62256339|NCT03418129|EXPERIMENTAL|Mobile App Neurofeedback|Participants engage in use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
62256340|NCT03418129|EXPERIMENTAL|Mobile App Relaxation|Participants engage in use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
62256341|NCT01210807|EXPERIMENTAL|Multifocal Intraocular Lens|ZMB00 multifocal intraocular lens
62613669|NCT03229967||Validation Cohort|Up to 10 VLBW infants enrolled from the Le Bonheur Children's Hospital NICU. Weekly stool samples will be obtained. After 36 weeks infants diagnosed with BPD per NIH guidelines willl be matched with infants without BPD. Stool samples from these infants will be sent for 16s rRNA sequencing after conclusion of initial enrollment period.
62838631|NCT02492763|EXPERIMENTAL|MK-8521 300 μg|Participants receive double-blind MK-8521 300 μg daily (QD), subcutaneously, over 12 weeks.
62838632|NCT02492763|EXPERIMENTAL|MK-8521 180 μg|Participants receive double-blind MK-8521 180 μg QD, subcutaneously, over 12 weeks.
62838633|NCT02492763|PLACEBO_COMPARATOR|Placebo|Participants receive matching double-blind placebo, QD over 12 weeks.
62838634|NCT02492763|ACTIVE_COMPARATOR|Liraglutide 1.8 mg|Participants receive open-label 1.8 mg of liraglutide, QD, subcutaneously, over 12 weeks.
62838635|NCT05349071|EXPERIMENTAL|methylprednisolone group|a single preoperative dose of 500 mg of methylprednisolone diluted in 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
62443927|NCT01805427||patients treated with efavirenz|HIV-infected on stable HAART regimen with efavirenz
62613670|NCT03229967||Well Baby Cohort|40 Well Baby Infants have been enrolled and may be used for secondary analysis of microbial community composition of the meconium.
62838636|NCT05349071|ACTIVE_COMPARATOR|physiological saline group|a single preoperative dose of 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
62838637|NCT02256709|EXPERIMENTAL|single rising dose BIBP 5371 CL|
62838638|NCT02256709|EXPERIMENTAL|BIBP 5371 CL tablet high dose|to be compared with same daily dose level from single rising dose arm
62256342|NCT01210807|ACTIVE_COMPARATOR|Monofocal Intraocular Lens|ZCB00 monofocal intraocular lens
62443928|NCT01805427||patients treated with atazanavir|HIV-infected patients on stable HAART regimen with atazanavir
62838639|NCT02256709|EXPERIMENTAL|BIBP 5371 CL tablet low dose|to be compared with same daily dose level from single rising dose arm
62256343|NCT02884063||NGS reading for Media Free DNA|Ability to read the DNA product available in embryo culture media using NGS to have valuable diagnostic image for genetic composition of embryo before implantation.
62256344|NCT02884063||NGS reading for blastomer DNA|DNA extracted from Blastomere used for aneuploidy screening.
62443929|NCT01805427||patients treated with darunavir|HIV-infected patients on stable HAART regimen with darunavir
62054448|NCT06525818|OTHER|Control group|All participants in the control group will be invited to a weekly virtual group therapy mealtime session with other enrolled control group participants and a speech therapist who is not involved with the intervention. During this informal session, families will have the opportunity to meet other children with feeding tubes and their parents. The investigators will assess level of engagement (frequency of participation) and parental experience at interval assessments. Therapies research participants are already receiving or who begin to receive during the study period (early intervention community therapies, center-based therapies) will not be stopped during this intervention. Data will be collected on the frequency of these standard of care therapies. The assessments used for the control group will be the same assessments as the intervention group and will include the Speech Therapy Assessment; Occupational Therapy Assessment; and Pediatric Eating Assessment Toll.
62054449|NCT06448338|EXPERIMENTAL|MyDiaMate|2/3 of participants will be randomized into this arm. They will receive access to MyDiaMate for 6 months.
62054450|NCT06448338|NO_INTERVENTION|Care as Usual|1/3 of participants will be randomized into this arm. They will continue their care as usual for 3 months. After 3 months, they receive access to MyDiaMate if desired.
62054451|NCT05484388|EXPERIMENTAL|SN2|new absorbing hygiene product with absorption level Normal.
62054452|NCT05484388|EXPERIMENTAL|SP3|new absorbing hygiene product with absorption level Plus.
62256345|NCT05167682||Prehabilitation|25 patients scheduled for tumor-esophagectomy (Ivor-Lewis) who are capable and have given consent to participate in a smartphone-based prehabilitation program.
62256346|NCT05167682||Historical Cohort|Patients ≥ 65 years of age who have undergone tumor-related esophagectomy at the University Hospital of Cologne between 05/2016 and 04/2020, who have not participated in any form of prehabilitation procedures
62256347|NCT00809666|NO_INTERVENTION|Mercury|All subsequent blood pressure recording done using mercury sphygmomanometry
62613671|NCT01245816|EXPERIMENTAL|Eflornithine plus Sulindac|Eflornithine 500 mg and Sulindac 150 mg
62256348|NCT03370120|EXPERIMENTAL|Padsevonil|"Padsevonil will be administered in an open-label manner. The individual starting dose of each subject will be the one at the end of the parent study.~Once subjects enter EP0093 further individual dose adjustments are allowed after 1 week to the extent possible with the combination of tablet strengths available."
62256349|NCT02153528|ACTIVE_COMPARATOR|Standard TB treatment|Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
62613672|NCT01245816|ACTIVE_COMPARATOR|Elfornithine plus Placebo|Eflornithine 500 mg and Placebo
62256350|NCT02153528|EXPERIMENTAL|double rimfampicin|2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
62256351|NCT02447055|EXPERIMENTAL|Arm 1 (Flu/Mel/PT-Cy & Tac/MMF for certain cases)|"* Fludarabine 30 mg/m\^2 intravenously (IV) on Days -5, -4, -3, and -2~* Melphalan 140 mg/m\^2 IV on Day -2~* Tocilizumab 8 mg/m\^2 (capped at 800 mg) IV on Day -1~* Stem cell infusion on Day 0~* Cyclophosphamide 50 mg/kg IV on Days +3 and +4~* Tacrolimus 1 mg/day IV on Day +5 (for unrelated \& haploidentical cases)~* Mycophenolate mofetil 15 mg/kg orally three times per day on Day +5 (for unrelated \& haploidentical cases)~* Filgrastim 10 ug/kg/day subcutaneously until neutrophil recovery starting on Day +5"
62256352|NCT06264882|EXPERIMENTAL|Degarelix plus transdermal placebo|At baseline \& 10 weeks: 80-mg subcutaneous injection of degarelix acetate plus Placebo transdermal patch (applied twice per week)
62256353|NCT06264882|EXPERIMENTAL|Degarelix plus transdermal estradiol|At baseline \& 10 weeks: 80-mg subcutaneous injection of degarelix acetate plus 0.075mg estradiol transdermal patch (applied twice per week)
62256354|NCT05087355||Influenza|
62256355|NCT05087355||Covid 19|
62256356|NCT05087355||Control group|hospitalisation due to other disease (not influenza or Covid 19)
62443930|NCT01806233|EXPERIMENTAL|Acupuncture|acupuncture
62443931|NCT01806233|EXPERIMENTAL|Rehabilitation|rehabilitation exercise
62443932|NCT04255459|OTHER|Moist Snuff users|Subjects for whom moist snuff is their usual brand of tobacco product.
62613673|NCT01245816|ACTIVE_COMPARATOR|Sulindac plus Placebo|Sulindac 150 mg and Placebo
62613674|NCT05847296||Sarcopenia group|
62613675|NCT05847296||Non sarcopenic group|
62613676|NCT05172791|NO_INTERVENTION|Usual care|Clinical teams will decide on antibiotic duration for patients with possible pneumonia without external prompting
62838640|NCT02256709|PLACEBO_COMPARATOR|Placebo drinking solution|
62838641|NCT02256709|EXPERIMENTAL|BIBP 5371 CL drinking solution|
62838642|NCT02256709|EXPERIMENTAL|BIBP 5371 CL tablet high dose with food|
62838643|NCT02256709|EXPERIMENTAL|BIBP 5371 CL tablet low dose with food|
62838644|NCT02256709|PLACEBO_COMPARATOR|Placebo tablet|
62838645|NCT03638037||Study|69 women, delivered preterm babies (less than 37weeks).
62838646|NCT03638037||Control|69 women, delivered at term (38-42 weeks) of full tem babies.
62838647|NCT04585126|NO_INTERVENTION|General anesthesia without intermediate cervical block|General anesthesia performed by the anesthesiologist
62256357|NCT01664988|EXPERIMENTAL|muscular relaxation|muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
62838648|NCT04585126|ACTIVE_COMPARATOR|General anesthesia with intermediate cervical block|General anesthesia performed by the anesthesiologist associated with an echoguided intermediate cervical block (bilateral in total thyroidectomy, unilateral in partial thyroidectomy) : 10 to 30cc of ropivacaine (2 to 3,75 %)
62838649|NCT04422158|EXPERIMENTAL|Nuun Single strength|3 Nuun electrolyte tablets will be dissolved in 1.4 liters of water. Subjects will drink one liter of the prepared solution over 30 min (250 mL every 7.5 min)
62838650|NCT04422158|EXPERIMENTAL|Nuun Double strength|6 Nuun electrolyte tablets will be dissolved in 1.4 liters of water. Subjects will drink one liter of the prepared solution over 30 min (250 mL every 7.5 min)
62256358|NCT01664988|EXPERIMENTAL|breath control|include deep diaphragmatic breathing and decrease breath rate to 6-10/min
62256359|NCT01664988|OTHER|control|received routine care of clinic or health center and control their blood pressure weekly and use drugs if necessary
62256360|NCT06340048|EXPERIMENTAL|HiCM-188 Low dose therapy|Intramyocardial injection of HiCM-188 (50 million) during CABG surgery.
62256361|NCT06340048|EXPERIMENTAL|HiCM-188 Medium dose therapy|Intramyocardial injection of HiCM-188 (150 million) during CABG surgery. Interventions
62256362|NCT06340048|EXPERIMENTAL|HiCM-188 High dose therapy|Intramyocardial injection of HiCM-188 (450 million) during CABG surgery. Interventions
62443933|NCT04255459|OTHER|Camel Snus users|Subjects for whom Camel Snus is their usual brand of tobacco product.
62443934|NCT04255459|OTHER|Dual users of Camel Snus and cigarette|Subjects who use both Camel Snus and cigarettes as their usual brands of tobacco products.
62613677|NCT05172791|EXPERIMENTAL|Electronic alert|An electronic alert will be displayed within the electronic medical record of eligible patients that notes that the patient's respiratory rate and oxygenation are within the normal range and will advise stopping antibiotics prescribed for possible pneumonia
62613678|NCT05172791|EXPERIMENTAL|Pharmacist|Pharmacists will contact the treating teams of eligible patients to note that the patient's respiratory rate and oxygenation are within the normal range and will advise stopping antibiotics prescribed for possible pneumonia.
62838651|NCT04422158|PLACEBO_COMPARATOR|Control|Subjects will drink one liter of water over 30 min (250 mL every 7.5 min)
62838652|NCT00705952|EXPERIMENTAL|1|
62838653|NCT01173237|ACTIVE_COMPARATOR|Tracheal intubation|Endotracheal tube is a airway device used for ventilation or surfactant administration, in preterm babies with SDR surfactant deficiency.
62838654|NCT01173237|EXPERIMENTAL|Proseal laryngeal mask airway|Laryngeal mask airway is a airway device used for ventilation with self-inflating bag or flow-inflating bag. In this study it will be used for surfactant administration, in preterm babies with SDR surfactant deficiency.
62838655|NCT00902096||Prenatal factors|Prenatal factors to predict cord blood IgE
62256363|NCT01232543|EXPERIMENTAL|Product 0405|Topical Active Investigational Product 0405
62256364|NCT04405687||Severe head and face deformity|
62256365|NCT05403320|EXPERIMENTAL|AnapnoGuard group|Patients intubated with AnapnoGuard endotracheal tube (polyvinylchloride tube with ellipsoidal shape, thin wall polyurethane cuff with dual suction lines and an extra venting line) which is connected to AnapnoGuard 100 System
62256366|NCT05403320|ACTIVE_COMPARATOR|Control group|Patients intubated with TaperGuard Evac endotracheal tube (polyvinylchloride conic cuff with additional lumen for subglottic secretion suctioning)
62256367|NCT03597230|EXPERIMENTAL|patients operated on for pancreatic resection|All consecutive patients operated on for pancreatic resection
62256368|NCT02883023|EXPERIMENTAL|Electrosclerotherapy|One region of interest in the capillary malformation (approximately 1.5x1.5cm)will be treated with electrosclerotherapy
62256369|NCT02883023|ACTIVE_COMPARATOR|Intralesional bleomycin injections|One region of interest in the capillary malformation will be treated with intralesional bleomycin injections without electroporation
62443935|NCT04255459|OTHER|Dual users of moist snuff and cigarettes|Subjects who use both moist snuff and cigarettes as their usual brands of tobacco products.
62443936|NCT04255459|OTHER|Cigarette smokers|Subjects for whom cigarettes is their usual brand of tobacco product.
62443937|NCT04255459|OTHER|Non-tobacco users|Subjects who do not use tobacco products.
62443938|NCT00174499|EXPERIMENTAL|1|2 mg nicotine gum
62443939|NCT00174499|EXPERIMENTAL|2|4 mg nicotine gum
62443940|NCT05200702|EXPERIMENTAL|Knee-hip Powered Soft Exoskeleton|Patients and healthy subjects will use a Knee-hip Powered Soft Exoskeleton to perform different standardised tasks
62443941|NCT05200702|NO_INTERVENTION|No assistance device|Patients and healthy subjects will perform different standardised tasks without Knee-hip Powered Soft Exoskeleton
62613679|NCT05649943|OTHER|APA + ADT + RP/RT|Apalutamide 240 mg, four 60 mg tablets as an oral single daily dose, according to clinical practice, plus Androgen Deprivation Therapy (ADT) plus clinician-driven choice local treatment with Radiotherapy or Radical Prostatectomy, six months after starting treatment with apalutamide
62838656|NCT05267522|EXPERIMENTAL|Egg Diet|Egg diet, contains 2 eggs per day and limits saturated fat to 6% of energy intake. Cholesterol intake is 600mg/day. Protein and carbohydrate levels will be maintained at 20% and 40% of energy intake, respectively. This diet will be followed for 5 weeks.
62838657|NCT05267522|ACTIVE_COMPARATOR|Egg-free Diet|Egg-free diet, limits cholesterol to 300 mg/day (no eggs) with saturated fat intake at 12% of energy intake. Protein and carbohydrate levels will be maintained at 25% and 40% of energy intake, respectively. This diet will be followed for 5 weeks.
62838658|NCT05267522|ACTIVE_COMPARATOR|Control Diet|Comparator diet based on the average Australian diet, limited to 1 egg per week, with saturated fat intake at 12% of energy intake. Cholesterol intake is 600 mg/day. Protein and carbohydrate levels will be maintained at 25% and 40% of energy intake, respectively. This diet will be followed for 5 weeks.
62256370|NCT02883023|NO_INTERVENTION|No treatment|One region of interest in the capillary malformation (approximately 1.5x1.5cm)will not be treated.
62256371|NCT03327012|EXPERIMENTAL|Treatment of Panlongqi Tablet|Patients were treated with Panlongqi Tablet.
62256372|NCT03327012|PLACEBO_COMPARATOR|Treatment of Panlongqi Placebo|Patients were treated with Panlongqi Placebo Tablet.
62256373|NCT00063141|EXPERIMENTAL|Arm A|
62256374|NCT00063141|ACTIVE_COMPARATOR|Arm B|
62256375|NCT05319184|EXPERIMENTAL|Myofascial Release Group|The application will be made with the patient in the prone position. By applying a few grams of constant force to the lumbar paravertebral muscles bilaterally with the hand of the physiotherapist in the direction of restriction for 3-5 minutes, the fascia will be stretched and allow the tissue to relax on its own. Thus, it is aimed to decrease the tone and stiffness of the paravertebral muscles.
62256376|NCT05319184|EXPERIMENTAL|Kinesiology Taping Group|During the application, the participants will be positioned standing and facing backwards due to the ease of application. While taping the lumbar region, the kinesiology tape cut as a long strip (I tape) will be applied paravertebrally to the right and left sides of the spine. Rounded corners will be created to prevent premature loosening and unwanted bends in the belt. The patient will be asked to perform maximum trunk flexion and 2 I-shaped pieces will be taped with 10-15% tension from the lumbar region to the thoracic region. The tape will remain on the patient's skin for 30 minutes.
62256377|NCT05319184|NO_INTERVENTION|Control Group|No intervention.
62256378|NCT02861768|EXPERIMENTAL|diagnosis of M.tuberculosis infection|
62256379|NCT03778411||cACLD|200 people with compensated advanced chronic liver disease who have not undergone liver transplant
62613680|NCT05649943|OTHER|APA + ADT|Apalutamide 240 mg, four 60 mg tablets as an oral single daily dose, according to clinical practice, plus Androgen Deprivation Therapy (ADT)
62256380|NCT03778411||cACLD-post transplant|100 people with compensated advanced chronic liver disease who have previously undergone liver transplant
62256381|NCT01671540|EXPERIMENTAL|Intrapulmonary percussive ventilation|IPV is applied for 1 week (once a day) during the physical therapy treatment of the patient
62256382|NCT01671540|ACTIVE_COMPARATOR|standard airwy claerance regime|The standard treatment consists out of existing drainage techniques to remove secretion out of the lungs by means of breathing control exercises
62443942|NCT05434208|EXPERIMENTAL|A RESEARCH ARM: active telephonic follow-up by specialist nurse|"Early Palliative Care cancer patients will be randomized to active telephonic follow-up program by specialist nurses until end-of-treatment (28 days)~* Scheduled phone-calls each 7 days from T0 + unscheduled phone-calls (as needed)~  * Questionnaire: ESAS and IPOS;~ * Weight;~ * Medication intake;~ * ECOG-PS~* Scheduled phone-calls at End of Treatment (28 days from T0):~  * Questionnaire: ESAS and IPOS~ * Questionnaire: FAMCARE-2 for CGs"
62738953|NCT01703091|EXPERIMENTAL|Ramucirumab plus Docetaxel|Ramucirumab 10 milligram per kilogram (mg/kg) on Day 1 of every 21 day cycle, administered as an intravenous (IV) infusion over approximately 60 minutes. Docetaxel 60 milligram per square meter (mg/m2) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
62256383|NCT01543152|EXPERIMENTAL|Cohort 1 - IV cyclophosphamide 200 mg|
62256384|NCT01543152|EXPERIMENTAL|Cohort 2 - IV cyclophosphamide 0.5 g/m2|
62256385|NCT01543152|EXPERIMENTAL|Cohort 3 - IV cyclophosphamide 1.0 g/m2|
62256386|NCT01543152|EXPERIMENTAL|Cohort 4 - IV cyclophosphamide 2.0 g/m2|
62256387|NCT01543152|EXPERIMENTAL|Cohort 5 - IV cyclophosphamide 1.5 g/m2|
62256388|NCT06360991|EXPERIMENTAL|treatment-resistant obsessive-compulsive disorder (TR-OCD).|Patients will undergo bilateral DBS lead implantation.
62256389|NCT01704586|ACTIVE_COMPARATOR|Radioiodine|Standard procedures using only I-131. All patients in this arm will have assigned I-131 ablation, followed by periodic I-131 diagnostic re-evaluations after 4-6 months as needed.
62256390|NCT01704586|ACTIVE_COMPARATOR|I-124|I-124 PET/CT guided concept following ATA guideline recommendations after total thyroidectomy. Uptake outside of thyroid bed constitutes I-131 therapy for remnant ablation and metastasis therapy based on I-124 dosimetry. Remnant mass and/or metastasis mass will be estimated by a diagnostic CT scan simultaneously while doing PET at the optimum time point 2-3 days after administration of I-124. If there is no uptake outside of thyroid bed, no ablation will follow in stage I disease according to AJCC with the possibility of lymph node involvement but no distant metastasis and no microscopical residual disease (Patient age \<45y: any T, any N, M0; Patient age 45y or older: T1, N0, M0). Periodic follow-up may include I-124 PET/CT when indicated to determine whether or not another I-131 therapy has to follow. Thyroglobuline increase also constitutes I-124 PET/CT imaging.
62256391|NCT01223170|EXPERIMENTAL|Enhanced Internet-based intervention|Behavioral: Tailored content Behavioral: Generic Internet-based information Behavioral: Discussion forum Behavioral: Behavioral monitoring
62256392|NCT01223170|PLACEBO_COMPARATOR|Control|Behavioral: Generic Internet-based information Behavioral: Discussion forum
62256393|NCT02495155|ACTIVE_COMPARATOR|Fatigue|Participants who have received treatment for early stage breast cancer and who experience fatigue, rated at least a 4 on a scale of 0-10 during the previous week, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
62443943|NCT05434208|NO_INTERVENTION|B CONTROL GROUP: face-to-face visit at end of treatment|"Early Palliative Care cancer patients will be randomized to face-to-face visit at end of treatment (28 days)~* Unscheduled phone-calls, on patients initiative:~  * Questionnaire: ESAS and IPOS;~ * Weight;~ * Medication intake;~ * ECOG-PS~* Face-to-face visit at End of Treatment (28 days from T0):~  * Questionnaire: ESAS and IPOS~ * Questionnaire: FAMCARE-2 for CGs"
62738954|NCT01703091|PLACEBO_COMPARATOR|Placebo plus Docetaxel|Placebo (administered at a volume equivalent to a dose of milligram per kilogram (mg/kg)) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes. Docetaxel 60 mg/m2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
62838659|NCT00670306|EXPERIMENTAL|Cetrorelix 78 mg|Drug: Cetrorelix 52 mg week 0, and 26 mg week 2, intra muscular-2 doses in 2 weeks and follow up to week 26.
62256394|NCT02495155|ACTIVE_COMPARATOR|Treatment-related Pain|Participants who have received treatment for early stage breast cancer and who experience pain, rated at least a 4 on a scale of 0-10 during the previous week, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
62256395|NCT02495155|ACTIVE_COMPARATOR|Insomnia|Participants who have received treatment for early stage breast cancer and who experience insomnia, assessed as difficulty sleeping over the last week, yes or no, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
62256396|NCT00653614|EXPERIMENTAL|Arm 1|E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for 24 days and DRSP (ZK 30595) dose 1 (SHT04984F) for one day and placebo for three days in a 28 day cycle
62256397|NCT00653614|EXPERIMENTAL|Arm 2|E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for 24 days and DRSP (ZK 30595) dose 1 (SHT04984F) for two days and placebo for two days in a 28 day cycle
62256398|NCT00653614|EXPERIMENTAL|Arm 3|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for days 9-16, E2/DRSP (BAY 86-4891) dose 3 (80458755) for days 17-24, and placebo for days 25-28 in a 28 day cycle
62256399|NCT00653614|EXPERIMENTAL|Arm 4|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for days 9-16, E2/DRSP (BAY 86-4891) dose 3 (80458755) for days 17-24, placebo for 3 days, and DRSP (ZK 30595) dose 1 (SHT04984F) for one day in a 28 day cycle
62256400|NCT00653614|EXPERIMENTAL|Arm 5|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 4 (80458720) for days 9-16, E2/DRSP (BAY 86-4891) dose 5 (80458712) for days 17-24, and placebo for 4 days in a 28 day cycle
62256401|NCT00653614|EXPERIMENTAL|Arm 6|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 4 (80458720) for days 9-16, E2/DRSP (BAY 86-4891)dose 5 (80458712) for days 17-24, placebo for 3 days, and DRSP (ZK 30595) dose 2 (80458690) for one day in a 28 day cycle
62443944|NCT05715255|EXPERIMENTAL|Adaptive Intervention|The adaptive intervention sequence is assumed to affect psychological distress (depression and anxiety) severity of other symptoms and irAEs, as tested in Aim 1. Both the Automated Telephone Symptom Management (ATSM) system and the Telephone Interpersonal Counseling (TIP-C) interventions help participants to identify and understand troublesome symptoms, with suggestions to effectively self-manage these symptoms. The proposed interventions are expected to alleviate burdensome symptoms through several key mediating variables, as tested in Aim 2.
62613681|NCT00463840|EXPERIMENTAL|Oxaliplatin+ 5FU+ radiation (RT) /surgery /FOLFOX 6|"Concurrent chemoradiation before surgery and FOLFOX6 regimen after surgery~Radiation (RT) 180cGy daily x 5 days/week x 5 weeks, then additional 540 cGy in 3 fractions over a half week to pancreatic portal;~Combined with :~5FU 200 mg/m\^2 daily by continuous intravenous infusion (CIV) x 5 weeks and weekly Oxaliplatin 60 mg/m\^2, IV for 5 weeks (in Phase I, 30, 40, 50, and 60 mg/m\^2 Oxaliplatin were tested).~Observation for 2 weeks to assess dose-limiting toxicity (DLT)/Response. Surgery if deemed resectable.~Then modified FOLFOX 6 for 6 cycles (2 weeks/cycle):~Day 1 hour 0: Oxaliplatin 85 mg/m\^2 intravenously (IV) + Leucovorin 350 mg IV over 2 hours; hour 2: 5FU 400 mg/m\^2 IV bolus followed by 2400 mg/m\^2 IV over 46 hours."
62613682|NCT02804867||Depression|
62838660|NCT04258267|EXPERIMENTAL|Early mobilization|Patients will be allowed to use their shoulder earlier. The immobilization period is shorter.
62838661|NCT04258267|EXPERIMENTAL|Delayed mobilization|The immobilization period is longer.
62838662|NCT03682770|EXPERIMENTAL|dupilumab + AR101|Participant randomization of a ratio of 2 active dupilumab arms
62838663|NCT03682770|EXPERIMENTAL|placebo matching dupilumab + AR101|Participant randomization of a ratio of 1 placebo arm
62838664|NCT01413204|EXPERIMENTAL|TA-7284 Low|
62613683|NCT02804867||Bipolar disorder|
62838665|NCT01413204|EXPERIMENTAL|TA-7284 High|
62838666|NCT01413204|PLACEBO_COMPARATOR|Placebo|
62838667|NCT01981018|EXPERIMENTAL|Imagery-focused Cognitive Therapy|"10 sessions of imagery-focused Cognitive Therapy delivered approximately weekly by two co-therapists, divided in 4 assessment, 4 treatment and 4 consolidation sessions; additional 2 blip management sessions during therapy and 3 blip management and booster session during follow up can be delivered if necessary."
62054453|NCT05484388|OTHER|TENA Proskin Pants Normal|Reference product currently used by the participant (control for SN2).
62256402|NCT03803072|EXPERIMENTAL|Time restricted eating (TRE)|prolonging the duration of fasting between the last evening meal and the first meal of the next day
62256403|NCT03803072|NO_INTERVENTION|control|Standard care. Will receive a booklet about physical activity recommendations and healthy eating in pregnancy
62256404|NCT04697238|EXPERIMENTAL|High load (11 % of body weight vests)|Subjects in this arm will carry heavy weight (11 percent of body weight) vests for 5 weeks.
62256405|NCT04697238|PLACEBO_COMPARATOR|Low load (1 % of body weight vests)|Subjects in this arm will carry heavy weight (1 percent of body weight) vests for 5 weeks.
62256406|NCT06256315|EXPERIMENTAL|Group A:Hyper-ERAS(Length of Postoperative Hospital Stay<48h)|Patients treated with the Hyper-ERAS rehabilitation protocol and discharged within 48 hours were in group A.
62256407|NCT06256315|EXPERIMENTAL|Group B:Hyper-ERAS(LOPS>48h)|Patients treated with the ERAS rehabilitation protocol and discharged in more than 48 hours were in group B.
62256408|NCT06256315|NO_INTERVENTION|Group C:Control group|Patients eligible but not treated with the Hyper-ERAS rehabilitation protocol during the same period were in group C.
62256409|NCT02921074|EXPERIMENTAL|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 24 treatment sessions, up to 7 sessions per week, 36 minutes per session.
62613684|NCT02804867||Control|
62838668|NCT03846908|EXPERIMENTAL|MCT|subjects start with MCT fat load
62838669|NCT03846908|EXPERIMENTAL|SFA|subjects start with SFA fat load
62838670|NCT03846908|EXPERIMENTAL|MUFA|subjects start with MUFA fat load
62838671|NCT02052388|EXPERIMENTAL|Low Single Dose Brilacidin|0.6mg/kg Brilacidin IV (single dose)
62838672|NCT02052388|EXPERIMENTAL|High Single Dose Brilacidin|0.8mg/kg Brilacidin IV (single dose)
62054454|NCT05484388|OTHER|TENA Pants Original Plus|Reference product currently used by the participant (control for SP3).
62256410|NCT02921074|ACTIVE_COMPARATOR|Active Comparator|Commercially available computerized training requiring a total maximum of 24 treatment sessions, up to 7 sessions per week, 36 minutes per session.
62256411|NCT00331695|EXPERIMENTAL|1|17 alpha-hydroxyprogesterones caproate
62256412|NCT04702802|EXPERIMENTAL|Arm 1; PRO-149|Viscoelastic substance PRO-149 (sodium hyaluronate 3%) in pre-filled syringe to be applied in the ocular anterior chamber during phacoemulsification surgery in an amount sufficient to form the desired intraocular space and allow the technical maneuvers required for the procedure.
62443945|NCT05715255|ACTIVE_COMPARATOR|Active Control|Survivors in the active control will receive weekly AVR assessments of PROCTCAE symptoms, and summary of these assessments will be sent securely to HCPs. Survivors will not receive the Handbook and will not be prompted by the AVR to contact HCPs unless the symptoms are severe. An active control comparator was purposively selected to enable a more rigorous testing of intervention effectiveness in Aims 1 and 2. Also, the study team will be better able to address the question about which channel of communication (automated versus survivor initiated) results in better outcomes.
62443946|NCT01206361||fixed dose prostaglandin combination|
62613685|NCT01715142|EXPERIMENTAL|Gemcitabine+Abraxane|Chemotherapy combining gemcitabine and Abraxane during 4 weeks (1 cycle) before surgery (cohort 1: resectable patients) and during at least 8 weeks (2 cycles or more in case of response of stable disease) (cohort 2: locally advanced and metastatic patients)
62838673|NCT02052388|EXPERIMENTAL|3-Day Regimen Brilacidin|0.6mg/kg Brilacidin IV on Day 1, followed by 0.3mg/kg Brilacidin IV on Days 2 \& 3
62613686|NCT00438256|EXPERIMENTAL|Group 1|10 Radiation Sessions over 2 weeks
62838674|NCT02052388|ACTIVE_COMPARATOR|Standard dosing regimen Daptomycin|4mg/kg Daptomycin IV daily for 7 Days
62838675|NCT01698580|ACTIVE_COMPARATOR|usual care|The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
62256413|NCT04702802|ACTIVE_COMPARATOR|Arm 2; Healon® EndoCoat|Viscoelastic substance Healon® EndoCoat (sodium hyaluronate 3%) in pre-filled syringe to be applied in the ocular anterior chamber during phacoemulsification surgery in an amount sufficient to form the desired intraocular space and allow the technical maneuvers required for the procedure.
62256414|NCT01010698|EXPERIMENTAL|cimetidine (or acyclovir) capsule 1|formulation 1
62256415|NCT01010698|EXPERIMENTAL|cimetidine (or acyclovir) capsule 2|formulation 2
62256416|NCT01010698|EXPERIMENTAL|cimetidine (or acyclovir) capsule 3|formulation 3
62256417|NCT01010698|ACTIVE_COMPARATOR|cimetidine (or acyclovir) reference|reference product
62613687|NCT00438256|EXPERIMENTAL|Group 2|5 Radiation sessions: 3 in week 1 and 2 in week 2
62613688|NCT00438256|EXPERIMENTAL|Group 3|5 Radiation sessions: 4 in week 1 and 1 in week 2
62613689|NCT00438256|EXPERIMENTAL|Group 4|5 Radiation Sessions in one week
62613690|NCT02009371|EXPERIMENTAL|Light therapy|In this group, participants will be exposed to the LED treatment device (light box) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
62838676|NCT01698580|EXPERIMENTAL|Multifactorial Falls Prevention Program|12 week intervention for 10 to 12 participants with sessions once a week, lasting for 2 hours, consisting of: On-site exercises (progressive body balance exercise program),Home-based exercise program, Educational and Behavioural sessions and management of modifiable risk factors.
62838677|NCT00510822|PLACEBO_COMPARATOR|Placebo|Placebo + Sertraline
62838678|NCT00510822|EXPERIMENTAL|Cimicoxib|Sertraline + Cimicoxib
62838679|NCT02653599|EXPERIMENTAL|TTP273 300 mg daily (150 mg BID)|Two 75 mg tablets of TTP273 administered orally twice daily for 12 weeks
62838680|NCT02653599|EXPERIMENTAL|TTP273 150 mg daily|Two 75mg tablets of TTP273 administered orally once daily and two placebo tablets administered orally once daily for 12 weeks
62838681|NCT02653599|PLACEBO_COMPARATOR|Placebo|Two matching placebo tablets administered orally twice daily for 12 weeks
62838682|NCT01432730|EXPERIMENTAL|Gefapixant 600 mg>Placebo|Gefapixant, 600 mg, twice daily (BID), taken orally for 2 weeks followed by a 2-week washout period and then placebo to gefapixant, BID, taken orally for 2 weeks.
62256418|NCT01439542|EXPERIMENTAL|Radiotherapy|
62256419|NCT05905120|EXPERIMENTAL|Toludivenlafaxine hydrochloride sustained-release tablets|80 mg/tablet, 2 tablets each time, once a day, for 4 days
62256420|NCT05498350|EXPERIMENTAL|Early Trigger|
62256421|NCT05498350|EXPERIMENTAL|Delayed trigger|
62256422|NCT04974554|EXPERIMENTAL|FIT Families|1. FIT Families is a 6 month comprehensive multicomponent family-based behavioral intervention delivered by Community Health Workers (CHWs). FIT Families integrates home-based service delivery, Motivational Interviewing (MI; intrinsic motivation), Cognitive Behavior Skills Treatment (CBST; skills acquisition), supervised physical activity (PA), and Contingency Management (CM; extrinsic motivation). Sessions occur twice weekly for the first three months, and weekly for the second three months.
62838683|NCT01432730|EXPERIMENTAL|Placebo>Gefapixant 600 mg|Placebo to gefapixant BID, taken orally for 2 weeks followed by a 2-week washout period and then gefapixant, 600 mg, BID, taken orally for 2 weeks.
62256423|NCT04974554|ACTIVE_COMPARATOR|Home-Based Family Support|2. Home-based Family Support (HBFS). Adolescents and their primary caregiver randomly assigned to HBFS will receive 6 months of weekly, home-based, client-centered, non-directive supportive family counseling.
62613691|NCT02009371|PLACEBO_COMPARATOR|Control group|In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
62054455|NCT05771701|EXPERIMENTAL|Lateral epicondylitis patients|Patients that are diagnosed with lateral epicondylitis.
62054456|NCT00114608|EXPERIMENTAL|1|Electrical foot stimulation
62256424|NCT02198625|NO_INTERVENTION|FiO2 80%,Nonprotective Lung Ventilation|
62256425|NCT02198625|EXPERIMENTAL|FiO2 30%,Nonprotective Lung Ventilation|FiO2 30%,Nonprotective Lung Ventilation
62613692|NCT05022628|EXPERIMENTAL|Therapy arm|donafenib
62054457|NCT03965156|ACTIVE_COMPARATOR|Erector Spinae Plane Block|Bilateral Ultrasound Guided Erector Spinae Plane Block
62054458|NCT03965156|ACTIVE_COMPARATOR|transversus abdominis plane block|Ultrasound guided transversus abdominis plane block
62054459|NCT05127525|EXPERIMENTAL|Test Drug|IRX-101 drops instilled prior to intravitreal injection
62256426|NCT02198625|EXPERIMENTAL|FiO2 80%,protective Lung Ventilation|FiO2 80% and protective Lung Ventilation
62256427|NCT02198625|EXPERIMENTAL|FiO2 30%,protective Lung Ventilation|FiO2 30% and protective Lung Ventilation
62256428|NCT03181230||Adolescents|Adolescents and young adults with Turner syndrome will undergo studies of cardiometabolism, fitness, quality of life questionnaires, and a brief interview.
62256429|NCT03181230||Parents|One parent of a participant will complete parent-report quality of life questionnaires and a brief interview.
62256430|NCT05836142|EXPERIMENTAL|Experimental: progressive pressure release|Bilateral progressive pressure release in latent trigger points of the Flexor digitorum Brevis Muscle
62256431|NCT05026281|EXPERIMENTAL|Group 1|at H0 and H0+30min = blood sample taken
62256432|NCT05947994|EXPERIMENTAL|Optimal medical therapy failure|Symptomatic ischemic stroke patients were treated with Credo® Stent
62256433|NCT03839173|NO_INTERVENTION|Retrospective Chart Review|Retrospective Chart Review for historical controls. Historic controls fed cow's milk fortifier
62613693|NCT04660773|ACTIVE_COMPARATOR|NB UVB phototherapy|(20 patients) will receive NB UVB phototherapy 3 sessions per week for 2 months.
62613694|NCT04660773|ACTIVE_COMPARATOR|pregabalin|20 patients) will receive pregabalin oral therapy (50mg after each dialysis session) for 2 months.
62054460|NCT05127525|ACTIVE_COMPARATOR|Control|Povidone-Iodine/Betadine drops instilled prior to intravitreal injection
62054461|NCT04955834|EXPERIMENTAL|Insulin degludec injection|Insulin degludec injection subcutaneous administration once daily for 26 weeks in combination with Oral antidiabetic drugs (OADs) used before.
62256434|NCT03839173|EXPERIMENTAL|Prospective|"All neonates with birth weights ranging from 750-1500 grams and gestational ages 23-33 weeks admitted to the NICU at Augusta University within 24 hours of life will be eligible for screening within 72 hours of admission and upon parent's or legal guardian's consent.~Infants will be fed a human milk fortifier made with donor human milk. Data will be compared with historic control data."
62613695|NCT01262248||patients with colorectal polyps|
62838684|NCT03236376|EXPERIMENTAL|sensorimotor therapy|sensorimotor therapy will consist of 30minutes of sensory discrimination training and 30 minutes of sensorimotor training per session. The sensory discrimination training is based on on the SENSe training of Carey et all. The sensorimotor training is the same individually tailored motor therapy as described below, but with integration of sensory discrimination training aspects.
62838685|NCT03236376|ACTIVE_COMPARATOR|motor therapy|The motor therapy consists of 30 minutes of cognitive and attention-based table top games and 30 minutes of motor training per session. The cognitive-attention-based therapy consists of table top games such as chess, rush hour, or other smart games. Individually tailored motor therapy consists of a unilateral motor exercise program for the upper limb, while seated at a table, under supervision of a therapist to match the therapy and intensity provided in the other sensorimotor therapy group. This 30 minutes of motor arm training is based on a set of standardized exercises which comprise task-related practice for gross movements and dexterity including different grips and selective finger movements, and training in daily life activities, however without any attention to sensory discrimination training.
62443947|NCT02277457|EXPERIMENTAL|EGFR Mutation|Patients with an identified EGFR mutation will receive PET (Positron Emission Tomography) - Adaptive RT (Radiation Therapy) plus concurrent Erlotinib followed by 1 year total of Erlotinib Treatment.
62054462|NCT04955834|ACTIVE_COMPARATOR|Tresiba®|Insulin degludec injection（Tresiba®）subcutaneous administration once daily for 26 weeks in combination with Oral antidiabetic drugs (OADs) used before.
62054463|NCT04885933||COPD exacerbation|
62838686|NCT05304533|EXPERIMENTAL|Arm 1: MYK-224|
62838687|NCT05304533|EXPERIMENTAL|Arm 2: MYK-224 + Itraconazole|
62838688|NCT05304533|EXPERIMENTAL|Arm 3: MYK-224 + Verapamil|
62838689|NCT03417154|EXPERIMENTAL|Arm 1: Nivolumab every 2 weeks and Cyclophosphamide daily|
62838690|NCT03417154|EXPERIMENTAL|Arm 2: Nivolumab every 2 weeks and Cyclophosphamide every 7 days|
62838691|NCT04765319||Vets|Veterans receiving care from the PTSD Clinical Team at the Salt Lake City VAMC. All participants are adults with a diagnosis of PTSD. This study plans on reviewing data collected as part of standard clinical practices. The study will have no impact on the treatment provided to the patient.
62054464|NCT03379194|EXPERIMENTAL|'Antibiotic stewardship program'|Physicians receive quarterly over 24 months, first in January 2018 postal mail a feedback on their antibiotic prescriptions and updated antibiotic resistance information from the community. With the first letter, educational material, evidence-based guidelines for conditions leading to most outpatient prescriptions in primary care and leaflets for on using antibiotics wisely are provided. Additional material is made available on a study website that can be accessed by each physician in the intervention group by an unique access code.
62256435|NCT05377268|EXPERIMENTAL|LH Protocol|Patients will be randomized and data interpreters will be blinded to two, randomized, alternating 14-day protocols where the patients will be advised by the nurse educator verbally and by written instruction to inject insulin in sites of subclinical lipohypertrophy.
62256436|NCT05377268|ACTIVE_COMPARATOR|Normal Protocol|"Patients will be randomized and data interpreters will be blinded to two, randomized, alternating 14-day protocols where the patients will be advised by the nurse educator verbally and by written instruction to inject insulin in sites of normal subcutaneous tissue.~Outcomes measured will consist of mean glucose, glucose standard deviation around the mean value, percentage of time with glucose below 3 mmol/liter, and percentage of time spent with glicose above 10 mmol/liter. The device will be calibrated and placed by a trained research nurse. There will be a member of the rsearch team available 24 hours per day to answer subject questions."
62838692|NCT00936923|ACTIVE_COMPARATOR|furosemide1|Patients will take furosemide 60mg per day for 1 years and undergo a study assessment at 3, 6, 12, 18, 24 months .
62054465|NCT03379194|NO_INTERVENTION|Control|No intervention
62443948|NCT02277457|EXPERIMENTAL|ALK Rearrangement|Patients with an identified EGFR mutation will receive PET (Positron Emission Tomography) - Adaptive RT (Radiation Therapy) plus concurrent Crizotinib followed by 1 year total ofCrizotinib Treatment.
62443949|NCT03291977|EXPERIMENTAL|Fluorescein sodique FAURE|Fluorescein (Fluorescéine sodique FAURE) will be given intravenously during the induction of the anesthesia
62443950|NCT03291977|ACTIVE_COMPARATOR|White-light surgery|"In the control arm, the surgery will be performed under classical conditions (so-called  white-light  surgery)."
62443951|NCT02934295|EXPERIMENTAL|Pregnant women|
62443952|NCT02956642|EXPERIMENTAL|Blood Glucose Monitoring System|Participants in this arm will receive the Livongo Health System to manage diabetes. 150 participants will participate in this arm.
62443953|NCT02956642|ACTIVE_COMPARATOR|Standard Blood Glucose Monitoring|Participants in this arm will receive the iHealth Glucose Meter to take blood glucose measurements that will then be compared to participants from the Livongo Health System arm. 150 participants will participate in this arm.
62613696|NCT03756818|EXPERIMENTAL|Treatment (mivavotinib and paclitaxel)|Patients receive mivavotinib PO QD and paclitaxel IV over approximately 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62054466|NCT04537468|OTHER|Skin sample collection|Skin sample collection for gene expression analyses.
62054467|NCT00656279|EXPERIMENTAL|1|Intensive dietary phosphorus education
62613697|NCT05583045|EXPERIMENTAL|Olive Leaf Tea (OLT)|Daily intake, for 12 weeks, of olive leaf tea + lifestyle behavior change program.
62613698|NCT05583045|PLACEBO_COMPARATOR|Placebo tea (CON)|Daily intake, for 12 weeks, of placebo tea + lifestyle behavior change program
62613699|NCT02343380|EXPERIMENTAL|morning-first|calorimetric exam after a standard meal
62613700|NCT02343380|EXPERIMENTAL|evening-first|calorimetric exam after a standard meal
62054468|NCT00656279|NO_INTERVENTION|2|Standard dietary education consists of the dietitian assessing laboratory values and dietary intake and providing dietary education for abnormal values using handouts developed for specific nutrients.
62256437|NCT05307484|EXPERIMENTAL|Serious game group|Participants in the intervention group installed a mobile application, 'Sam's Mozzie Adventure'. This is a locally designed serious game which was co-created between SingHealth Polyclinics and AI Innovation Labs (AI2 Labs) Private Limited, specifically for this study. The principal investigator reviewed existing publicly available information on dengue prevention, including those on the National Environmental Agency (NEA) 'Stop Dengue' website, and provided the relevant content and pedagogical knowledge to the team of app developers from AI2 Labs. After creating the syllabus, the developers deployed their technological knowledge to integrate the dengue prevention information into the serious game. The participants were instructed to complete playing this serious game within 2 weeks.
62256438|NCT05307484|ACTIVE_COMPARATOR|Dengue prevention website group|The control group accessed the NEA 'Stop Dengue' website which contained dengue prevention information in the forms of online articles, posters and video. The participants were instructed to complete reading the online resources within 2 weeks.
62256439|NCT00018655|EXPERIMENTAL|Arm 1|Twelve Step Facilitation
62613701|NCT05821465||HeartWatch vs. Event Recorder|All patient-tagged (symptomatic) events recorded by the HeartWatch, and reference devices (Event Recorder) and all non-normal clinically significant rhythm auto-triggered and recorded events will be adjudicated and classified using literature-based definitions.
62838693|NCT00936923|ACTIVE_COMPARATOR|furosemide 2|Patients will take 120mg furosemide per day for 1 years and undergo a study assessment at 3, 6, 12, 18, 24 months .
62838694|NCT00936923|NO_INTERVENTION|control|Patients in control group will not take furosemide
62838695|NCT03714958|EXPERIMENTAL|combination HDM201 - Trametinib|"* HDM201: Therapeutic class HDM2 inhibitor, given Per Os every D1 and D8 over a 28 day cycle. Four dose-levels possible in dose escalation part: 40 mg, 80mg, 100 mg, 120mg.~* Trametinib: Therapeutic class Protein kinase inhibitor of MEK1 and MEK2 activation and kinase activity. Administrated daily, countinous dosing , twodose-level possible in dose escalation: 1.5 mg and 2mg"
62838696|NCT01472718|ACTIVE_COMPARATOR|standard primary coronary intervention|
62613702|NCT05821465||HeartWatch vs. Holter|All patient-tagged (symptomatic) events recorded by the HeartWatch, and reference devices (Holter) and all non-normal clinically significant rhythm auto-triggered and recorded events will be adjudicated and classified using literature-based definitions.
62613703|NCT01022216|ACTIVE_COMPARATOR|V.A.C.® Therapy|Vacuum Assisted Closure device that utilizes controlled negative pressure
62613704|NCT01022216|EXPERIMENTAL|Procellera™ Wound Dressing with V.A.C.® Therapy|Procellera wound dressing used as a primary contact layer on the wound bed, used in conjunction with NPWT
62256440|NCT00018655|EXPERIMENTAL|Arm 2|Integrated Cognitive Behavioral Treatment
62613705|NCT02703818|EXPERIMENTAL|Senza|Spinal Cord Stimulation for UEP
62613706|NCT03851978|EXPERIMENTAL|Pharmacist Vaccine Education|
62613707|NCT01158014|EXPERIMENTAL|Fibrin Glue, surgery|Conjunctival autograft will be glued using fibrin glue to pterygia bed after removal
62838697|NCT01472718|EXPERIMENTAL|coronary thrombectomy|
62838698|NCT04416841|EXPERIMENTAL|Tai Chi Chuan Group|In addition to conventional medical treatment, participants will receive 3 sessions of 1-hour Tai Chi Chuan training per week for 24 weeks and standard diabetic care education.
62838699|NCT04416841|ACTIVE_COMPARATOR|Fitness Walking Group|In addition to conventional medical treatment, participants will receive 3 sessions of 1-hour fitness walking training per week for 24 weeks and standard diabetic care education
62838700|NCT04416841|OTHER|Control group|In addition to conventional medical treatment, participants will receive standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
62838701|NCT01273519||RA, PsA, AS|Participants with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) prescribed Humira (adalimumab) in the usual manner and in accordance with the terms of the local marketing authorization with regards to dose, population and indication.
62838702|NCT05131737|EXPERIMENTAL|Constant work-rate at altitude 2500 m above sea level (high altitude)|Cycling at high altitude
62256441|NCT03454802|ACTIVE_COMPARATOR|Normal subjects|Normal subjects 'Passive Leg Raising'
62256442|NCT03454802|ACTIVE_COMPARATOR|ICU patients|ICU patients 'Passive Leg Raising'
62838703|NCT05131737|ACTIVE_COMPARATOR|Constant work-rate at altitude 470 m above sea level (low altitude)|Cycling at low altitude
62256443|NCT03454802|ACTIVE_COMPARATOR|Cardiac Outpatients|Cardiac Outpatients 'Passive Leg Raising'
62256444|NCT02783443||General anesthesia|Adult patients ASA 2-3 undergoing elective total knee replacement surgery under general anaesthesia.
62256445|NCT02783443||Regional anesthesia|Adult patients ASA 2-3 undergoing elective total knee replacement surgery under regional anaesthesia.
62256446|NCT04526236|PLACEBO_COMPARATOR|Methadone 0|Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered the placebo drug.
62443954|NCT05333419|EXPERIMENTAL|Single Dose 100ng/day PA5346 Latanoprost FA SR Ocular Implant|After washout, eligible subjects will be dosed with a single 100ng/day PA5346 Latanoprost FA SR Ocular Implant at study Day 0.
62838704|NCT02598583|EXPERIMENTAL|Cohort 1|"Participants were administered ALXN1210 900 mg.~In the Extension period participants continued at the same dose and frequency as the Primary Evaluation Period."
62838705|NCT02598583|EXPERIMENTAL|Cohort 2|"Participants were administered ALXN1210 1800 mg.~In the Extension period participants continued at the same dose and frequency as the Primary Evaluation Period."
62838706|NCT04618107|EXPERIMENTAL|Wide awake surgery|Wide awake local anaesthesia was used as mode of aneasthesia for tendon repair surgery. Functional outcome of in terms of active range of motion was calculated via Strickland method and American Society for the surgery of the hand criteria at sixth week of surgery using goniometer
62256447|NCT04526236|EXPERIMENTAL|Methadone 1|Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.05 mg/kg.
62256448|NCT04526236|EXPERIMENTAL|Methadone 2|Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.1 mg/kg.
62256449|NCT04526236|EXPERIMENTAL|Methadone 3|Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.2 mg/kg.
62256450|NCT06400173||Individuals (>45 years) with mild cognitive impairment and hearing loss|All tests will be administered.
62256451|NCT06400173||Individuals (>45 years) with dementia (Alzheimer, vascular or mixed) and hearing loss|All tests will be administered.
62256452|NCT06400173||Individuals (>45 years) with age-normal cognition and hearing loss|All tests will be administered.
62443955|NCT02780700|EXPERIMENTAL|Nintedanib|
62838707|NCT04618107|ACTIVE_COMPARATOR|General anaesthesia|Tendon repair surgeries were performed under general anaesthesia. Functional outcome of in terms of active range of motion was calculated via Strickland method and American Society for the surgery of the hand criteria at sixth week of surgery using goniometer
62054469|NCT02706314||Critically ill patients with CIP|Critically ill patients with a Sequential Organ Failure Assessment (SOFA)-Score \>7 with CIP
62613708|NCT01158014|ACTIVE_COMPARATOR|Control|Conjunctival autograft will be sutured using 10/0 vicryl sutures to pterygia bed after removal
62054470|NCT02706314||Critically ill patients without CIP|Critically ill patients with a Sequential Organ Failure Assessment (SOFA)-Score \>7 without CIP
62613709|NCT02578940|EXPERIMENTAL|Single arm|Single intravenous administration of 18F-Fluciclovine for PET Scan
62613710|NCT06511115|EXPERIMENTAL|New Technologies Group|Participants assigned to the experimental group will engage in an exercise program using technologies, including the Nintendo Wii, over a 12-week period, with a frequency of 3 sessions per week, each lasting 45 minutes.
62838708|NCT02217826|EXPERIMENTAL|DG3173|
62838709|NCT02217826|PLACEBO_COMPARATOR|Saline|
62054471|NCT02706314||Healthy volunteers|Healthy volunteers with neither critical illness nor CIP
62054472|NCT01406522|PLACEBO_COMPARATOR|Oral placebo|Inactive treatment
62054473|NCT01406522|EXPERIMENTAL|Oral tacrine|Oral tacrine
62054474|NCT03292848|EXPERIMENTAL|10 to <13 Years of Age|Two doses will be administered with a washout period of 14 days between the first dose of 1.5 mg the second dose of 3 mg.
62054475|NCT03292848|EXPERIMENTAL|6 to <10 Years of Age|Two doses will be administered with a washout period of 14 days between the first dose of 0.75 mg and the second dose of 1.5 mg.
62054476|NCT02839343|EXPERIMENTAL|mFOLFIRINOX + surgery + FOLFOX|Patients receive 8 cycles of mFOLFIRINOX. One cycle is 14 days. mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU. Patients undergo surgery and receive 4 cycles of FOLFOX 4-12 weeks after surgery. FOLFOX consists of oxaliplatin, leucovorin and 5-FU.
62256453|NCT01999569|NO_INTERVENTION|Control|Control cycle. No intervention.
62256454|NCT01999569|EXPERIMENTAL|Letrozole|5mg daily
62256455|NCT04717518||Lower Anchor Survey|Patients will likely rate their pain lower.
62256456|NCT04717518||Higher Anchor Survey|Patients will likely rate their pain higher.
62256457|NCT00988143|EXPERIMENTAL|Study Group 1|Participants will receive the 2009-2010 Trivalent Influenza Vaccine (TIV) (Pediatric dose have no preservatives)
62256458|NCT00988143|ACTIVE_COMPARATOR|Study Group 2|Participants will receive the 2008-2009 Trivalent Influenza Vaccine (TIV)
62256459|NCT00988143|ACTIVE_COMPARATOR|Study Group 3|Participants will receive the Quadrivalent Influenza Vaccine (QIV)
62256460|NCT01496131|ACTIVE_COMPARATOR|Standard therapy|Radiation therapy in combination with androgen deprivation therapy (ADT).
62256461|NCT01496131|EXPERIMENTAL|Standard therapy plus tecemotide (L-BLP25)|Standard therapy (radiation therapy in combination with ADT) plus tecemotide (L-BLP25).
62256462|NCT06414525|ACTIVE_COMPARATOR|Abdominal massage|The technique involves stroking and kneading the abdomen in a consistent pattern.
62256463|NCT06414525|ACTIVE_COMPARATOR|visceral manipulation|The technique involves visceral connective tissue manipulation.
62443956|NCT02780700|EXPERIMENTAL|Nintedanib plus capecitabine|
62443957|NCT04995978|EXPERIMENTAL|Pioglitazone|
62443958|NCT04995978|PLACEBO_COMPARATOR|placebo|
62443959|NCT03107013|EXPERIMENTAL|[14C]-BTD-001|
62443960|NCT03273244||Device monitoring|NeuroSense monitoring and ANI monitoring
62443961|NCT00631865|EXPERIMENTAL|cell transplantation group|Epidermal Cell transplantation in patients with vitiligo
62443962|NCT02587702|EXPERIMENTAL|Improved Infant Formula Group|Containing β-Palmitate Content
62443963|NCT02587702|PLACEBO_COMPARATOR|General Infant Formula Group|Excluding β-Palmitate Content
62256464|NCT06414525|ACTIVE_COMPARATOR|control|instructions on daily, dietary, toilet, and physical activity habits
62256465|NCT02362620||Docetaxel|Docetaxel 75mg/m2 IV every 3 weeks
62613711|NCT06511115|NO_INTERVENTION|Control Group|This group will not undergo the physical exercise intervention but will receive general recommendations for comprehensive health care. These include information about the benefits of physical exercise and tips for managing physical and mental health. The control group (CG) will undergo all the proposed physical and mental tests at the beginning of the study and again after 12 weeks. Additionally, during the study period, they will be monitored for changes in physical activity levels, as well as nutritional changes, sleep habits, and stress levels.
62838710|NCT02217826|ACTIVE_COMPARATOR|Octreotide|
62838711|NCT04259099||QUALITY OF LIFE QUESTIONNAIRES|The group is anticipated to consist of 150 female and male with osteoporosis, osteopenia or normal bone mineral density.
62838712|NCT05014087|EXPERIMENTAL|Arm A: Digoxin|In the digoxin arm, the intervention to be administered will be intravenous digoxin dosed by weight and by renal function using an adaption of the established FDA nomogram. Participants randomized to digoxin will receive an intravenous digoxin loading dose administered in 3 doses over 24 hours starting on Day 1. Digoxin levels will be monitored daily throughout the participant's hospital stay, to a maximum of 28 days. Digoxin will be discontinued at the time discharge if before 28 days.
62838713|NCT05014087|NO_INTERVENTION|Arm B: No Digoxin|In the no digoxin arm, no study drug or placebo will be administered.
62838714|NCT06139367|EXPERIMENTAL|TQB3454 tablets under fast condition|TQB3454 tablets 600mg, take one dose orally under fast condition.
62838715|NCT06139367|EXPERIMENTAL|TQB3454 tablets under fed condition|TQB3454 tablets 600mg, take one dose orally under fed condition.
62838716|NCT06132867|EXPERIMENTAL|Treatment A followed by Treatment B|Participants will receive 90 mg oral solution of brigatinib in a fasted state on Day 1 of Period 1 (Treatment A) followed by a washout period of at least 14 days and will receive 90 mg tablet of brigatinib in a fasted state on Day 1 of Period 2 (Treatment B).
62054477|NCT02839343|EXPERIMENTAL|mFOLFIRINOX + radiation + surgery + FOLFOX|Patients receive 7 cycles of mFOLFIRINOX. One cycle is 14 days. mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU. Patients receive radiation therapy then undergo surgery and receive 4 cycles of FOLFOX 4-12 weeks after surgery. FOLFOX consists of oxaliplatin, leucovorin and 5-FU.
62054478|NCT02187913|EXPERIMENTAL|Resistant starch|The test snack bar consumed has the resistant starch
62054479|NCT02187913|EXPERIMENTAL|Control|The control bar uses maltodextrin rather than the resistant starch.
62054480|NCT04440839|EXPERIMENTAL|Intervention|Telemedicine specialty consultation for patients
62256466|NCT02362620||Cabazitaxel|Cabazitaxel 20-25mg/m2 IV every 3 weeks
62256467|NCT04474795|EXPERIMENTAL|Staff - Educational training|Nurses, community health workers, and others involved in maternal healthcare
62256468|NCT02302352|ACTIVE_COMPARATOR|Probiotic|Oral probiotic 1g, once/day, containing: Lactobacillus paracasei, 10x9 CFU; Lactobacillus rhamnosus,10x9 CFU; Lactobacillus acidophillus, 10x9 CFU; Bifidobacterium lactis 10x9 CFU per sachet
62256469|NCT02302352|PLACEBO_COMPARATOR|Placebo|Maltodextrin 1g per sachet, once/day
62256470|NCT03719690|EXPERIMENTAL|AIM-HN|Tipifarnib, Oral Tablet. Dose Level 1 orally, bid on days 1-7 and 15-21 of 28-day treatment cycles
62256471|NCT03719690|NO_INTERVENTION|SEQ-HN|HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first line outcome data and additional follow up.
62256472|NCT04512053|EXPERIMENTAL|TAS-303|
62838717|NCT06132867|EXPERIMENTAL|Treatment B followed by Treatment A|Participants will receive 90 mg tablet of brigatinib in a fasted state on Day 1 of Period 1 (Treatment B) followed by a washout period of at least 14 days and will receive 90 mg oral solution of brigatinib in a fasted state on Day 1 of Period 2 (Treatment A).
62838718|NCT00598676|EXPERIMENTAL|BPRES|biodegradable polymer rapamycin-eluting stent
62838719|NCT00598676|ACTIVE_COMPARATOR|PPRES|permanent polymer rapamycin-eluting stent
62838720|NCT00598676|ACTIVE_COMPARATOR|PPEES|permanent polymer everolimus-eluting stent
62838721|NCT00606593|EXPERIMENTAL|ABECD|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
62838722|NCT00606593|EXPERIMENTAL|BCADE|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
62256473|NCT04512053|PLACEBO_COMPARATOR|Placebo|
62256474|NCT06006234||residents of elderly care institutions|residents of elderly care institutions
62256475|NCT00530985|EXPERIMENTAL|1|Benefits Counseling
62256476|NCT00530985|ACTIVE_COMPARATOR|2|VA Orientation
62054481|NCT04440839|NO_INTERVENTION|Standard Care|Standard in person referral to a specialist
62256477|NCT03434171|ACTIVE_COMPARATOR|Aerobic excercise|women who practiced treadmill exercise program for 30 minutes at 60% to 70% of maximum heart rate. The treatment sessions will be repeated 3 times per week for 12 weeks
62256478|NCT03434171|ACTIVE_COMPARATOR|Dietary modfications|women who received diet modification contains soy products (phytoestrogen) such as soy milk and soy beans every day for 12 weeks only
62256479|NCT04532476|EXPERIMENTAL|Laser treated side|Group of 22 participants whose mucose around right maxillary permanent molar was treated with laser.
62443964|NCT02587702|ACTIVE_COMPARATOR|Human Milk Group|Containing β-Palmitate Content Naturely in Human Milk
62443965|NCT01981486|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62256480|NCT04532476|PLACEBO_COMPARATOR|Placebo side|Placebo side was LEFT side.It was treated the same way as right with the difference that the laser was switched off, but with the maintained sound signal, implying laser was working, so participants were blinded to the allocation of the group, only the operator knew whether the side is laser treated or placebo.
62256481|NCT04660513||Morbid obesity|BMI 32.5 kg/m2 and above
62256482|NCT04660513||Non-obese healthy controls|BMI below 25 kg/m2
62256483|NCT06367075|EXPERIMENTAL|cadonilimab (AK104) with adriamycin|Run-In Period（C1）: cadonilimab10mg/kg, d1 ,q3w; Treatment period（C2\~C7）: adriamycin 25mg/m2, d1-d3，q3w; cadonilimab 10mg/kg, d1, q3w; Maintenance period（C8\~）: cadonilimab 10mg/kg, d1, q3w
62256484|NCT01122732||US Group|Interscalene catheter will be placed with US guidance without any nerve stimulation guidance.
62443966|NCT01981486|EXPERIMENTAL|PF-05180999|Modified-release tablets of PF-05180999
62613712|NCT03944993|EXPERIMENTAL|Pulsed Electromagnetic Field Therapy (Dominant leg)|Active Pulsed Electromagnetic Field therapy; exposed once weekly for 10 minutes on dominant leg.
62613713|NCT03944993|EXPERIMENTAL|Pulsed Electromagnetic Field Therapy (Non-dominant leg)|Active Pulsed Electromagnetic Field therapy; exposed once weekly for 10 minutes on non-dominant leg.
62613714|NCT03944993|SHAM_COMPARATOR|Sham Therapy (Control)|Inactive Pulsed Electromagnetic Field therapy; exposed once weekly for 10 minutes.
62613715|NCT01187264|ACTIVE_COMPARATOR|methotrexate 10 mg|oral methotrexate 10 mg once weekly
62613716|NCT01187264|ACTIVE_COMPARATOR|methotrexate 25mg|oral methotrexate 25 mg once weekly
62054482|NCT04876040|EXPERIMENTAL|PCI+Impella plus SSO2|Patients who present with STEMI-CS will undergo treatment with Impella, followed by PCI. Subjects are then immediately treated post-procedure with an infusion of SSO2 Therapy for a duration of 60 minutes.
62054483|NCT04876040|ACTIVE_COMPARATOR|PCI+Impella|Patients who present with STEMI-CS will undergo treatment with Impella, followed by PCI. Subjects are then immediately treated with Standard of Care.
62256485|NCT01122732||NS Group|Catheter will be placed using nerve stimulation guidance
62256486|NCT01884259|ACTIVE_COMPARATOR|A|"Patients receive 3 cycles (cycle duration 21 days) of docetaxel (75mg/m²), cisplatin (75mg/m²) and 5-fluorouracil (750mg/m²) followed by Cetuximab (weekly, starting with 400mg/m² then continuing with 250 mg/m²) with radiotherapy (concomitant boost for 6 weeks).~Active comparator is 5-fluorouracil for first three cycles."
62054484|NCT04504331|EXPERIMENTAL|Cohort 1: Infigratinib (100mg) + Tamoxifen|In study part 1 (dose exploration), participants will receive up to infigratinib 100 mg. 100 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + 20 mg/day tamoxifen
62054485|NCT04504331|EXPERIMENTAL|Cohort 2: Infigratinib (125mg) + Tamoxifen|In study part 1 (dose exploration), participants will receive up to infigratinib 125 mg. 125 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + 20 mg/ day tamoxifen
62443967|NCT01595009|EXPERIMENTAL|Everolimus (RAD001)|Participants received Everolimus 10 mg orally once daily until documented tumor progression, unacceptable toxicity or any other reason.
62256487|NCT01884259|EXPERIMENTAL|B|"All patients receive 3 cycles (cycle duration 21 days) of docetaxel (75mg/m²), cisplatin (75mg/m²) Cetuximab (weekly, starting with 400mg/m² and continuing with 250 mg/m²), followed by Cetuximab (weekly 250 mg/m²) with radiotherapy (concomitant boost for 6 weeks).~Experimental: cetuximab for the first three cycles."
62256488|NCT00005798|OTHER|CTC Conditioning Regimen|Cyclophosphamide Thiotepa Carboplatin
62256489|NCT02422888|EXPERIMENTAL|Ticagrelor|Ticagrelor 90 mg twice a day, tablet Duration: 1 year after PCI
62256490|NCT02422888|ACTIVE_COMPARATOR|Prasugrel|Prasugrel 10 mg once a day, tablet Duration: 1 year after PCI
62443968|NCT00418483|EXPERIMENTAL|Plasmin (Human) 25 mg|Plasmin (Human) 25 mg
62443969|NCT00418483|EXPERIMENTAL|Plasmin (Human) 50 mg|Plasmin (Human ) 50 mg
62443970|NCT00418483|EXPERIMENTAL|Plasmin (Human) 75 mg|Plasmin (Human) 75 mg
62443971|NCT00418483|EXPERIMENTAL|Plasmin (Human) 100 mg|Plasmin (Human) 100 mg
62443972|NCT00418483|EXPERIMENTAL|Plasmin (Human) 125 mg|Plasmin (Human) 125 mg
62443973|NCT00418483|EXPERIMENTAL|Plasmin (Human) 150 mg|Plasmin (Human) 150 mg
62443974|NCT00418483|EXPERIMENTAL|Plasmin (Human) 175 mg|Plasmin (Human) 175 mg
62613717|NCT03646487|EXPERIMENTAL|Probiotic LP299v|Women will receive 1 LP299v (10x10 colony forming units) in capsule form and 1 standard prenatal supplement in tablet form daily beginning at 15 weeks gestation through delivery.
62613718|NCT03646487|PLACEBO_COMPARATOR|Placebo|Women will receive 1 placebo in capsule form and 1 standard prenatal supplement in table form daily beginning at 15 weeks gestation through delivery.
62613719|NCT05606770|OTHER|Structured exercise|Participants assigned to Structured Exercise will be provided with twice weekly strengthening exercise classes, delivered through the digital platform. The exercise classes will follow a circuit class style, in order to target a moderate-vigorous exercise intensity, in keeping with recent guidelines on secondary stroke prevention. Classes will include a full body warm up followed by a circuit of eight strengthening exercises completed for between one and three sets of 12 repetitions. Participants will be encouraged to exercise to fatigue on the 12th repetition of each set. This will be repeated for increasing sets and adding resistance through the use of resistance bands. During each session, participants will be reminded to reach their targeted weekly step count goals. The structured exercise component is informed by international clinical guidelines (Kleindorfer et al 2021 and Billinger et al 2021).
62739013|NCT03308968|PLACEBO_COMPARATOR|Placebo|Double-blind (DB) period: Participants with CM or EM will receive 3 injections of placebo 1.5 milliliters (mL) SC on Day 0 and single injection of placebo 1.5 mL SC on Days 28 and 56. Open-label (OL) period: Participants with CM or EM will receive fremanezumab (TEV-48125) 225 milligrams (mg) SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
62256491|NCT02971631|PLACEBO_COMPARATOR|Placebo|Infusion of 1% human albumin in normal saline.
62256492|NCT02971631|EXPERIMENTAL|Exendin|Infusion of Exendin 9-39 in 1% human albumin in normal saline
62256493|NCT02241369|EXPERIMENTAL|Cohort I|3 mg of INO-3106 (D0); 6 mg of INO-3106 (Wk3); 6 mg of INO-3106 + 1 mg of INO-9012 (Wk6); 6 mg of INO-3106 + 1 mg of INO-9012 (Wk9);
62256494|NCT02241369|EXPERIMENTAL|Cohort II|6 mg of INO-3106 in combination with 1 mg of INO-9012, or at the MTD determined above at D0, Wk3, Wk6, Wk9
62256495|NCT06044207||Patients with perioperative neurocognitive dysfunction|
62256496|NCT06044207||Patients without perioperative neurocognitive dysfunction|
62739014|NCT03308968|EXPERIMENTAL|Fremanezumab Quarterly|DB period: Participants with CM or EM will receive fremanezumab 675 mg SC (3 injections of fremanezumab 225 mg/1.5 mL) on Day 0 followed by monthly SC administration of placebo 1.5 mL for 2 months (on Days 28 and 56). OL period: Participants with CM or EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
62256497|NCT02910947|EXPERIMENTAL|quadratus lumborum|
62256498|NCT02910947|EXPERIMENTAL|TAP(Transversus abdominis plane)|
62256499|NCT01534312|EXPERIMENTAL|CGMP protein|Casein glycomacropeptide 30 gram/day, unchanged prophylactic 5ASA dose
62256500|NCT01534312|ACTIVE_COMPARATOR|Standard oral 5ASA maximal dose|Increase from prophylactic dose 5ASA (mesalazine) to maximal oral dose, i.e. 4800 grams of mesalazine (Asacol/Mezavant)
62443975|NCT05489185|PLACEBO_COMPARATOR|Extracapsular fracture with intravenous contraindication (control).|Physiological saline
62739015|NCT03308968|EXPERIMENTAL|Fremanezumab Monthly|DB period: Participants with CM will receive fremanezumab 675 mg SC (3 injections of fremanezumab 225 mg/1.5 mL) on Day 0 followed by monthly SC administration of fremanezumab 225 mg (1 injection of fremanezumab 225 mg/1.5 mL) for 2 months (on Days 28 and 56). Participants with EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL) on Day 0 followed by monthly SC administration of fremanezumab 225 mg (1 injection of fremanezumab 225 mg/1.5 mL) for 2 months (on Days 28 and 56). OL period: Participants with CM or EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
62256501|NCT06024395|EXPERIMENTAL|Dental FearLess App|Dental FearLess app is an e-health intervention that includes psychoeducation about anxiety; affective, cognitive, and behavioral strategies for coping at the dentist.
62256502|NCT06024395|NO_INTERVENTION|Treatment as Usual|
62256503|NCT03331055|EXPERIMENTAL|percutaneous stimulation|PENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
62256504|NCT03331055|EXPERIMENTAL|trancutaneous stimulation|TENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
62256505|NCT03331055|NO_INTERVENTION|Control|Conventional analgesic medication is offered.
62256506|NCT02963116|EXPERIMENTAL|Treatment A|10 mg rosuvastatin tablet alone (fasting state)
62256507|NCT02963116|EXPERIMENTAL|Treatment B|10 mg rosuvastatin tablet + 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)
62256508|NCT02963116|EXPERIMENTAL|Treatment C|200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)
62256509|NCT02963116|EXPERIMENTAL|Treatment D|200 mg of AZD5718 oral suspension 50 mg/mL (fasting state)
62256510|NCT02963116|EXPERIMENTAL|Treatment E|200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fed state)
62256511|NCT00399789|ACTIVE_COMPARATOR|Perifosine 150 mg qd|A daily dose of 150 mg to be given in one dose at bedtime. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 200 mg to be given in one dose at bedtime.
62443976|NCT05489185|EXPERIMENTAL|Extracapsular fracture with intravenous contraindication (experimental).|Amchafibrin
62739016|NCT06464731|EXPERIMENTAL|Experimental Group|The operator will choose the optimal endovascular treatment strategy and device based on the patient's condition and clinical experience. This may include, but is not limited to, stent retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, etc. The endovascular treatment plan and relevant time points will be accurately recorded. The patient will receive the best medical treatment according to current local clinical research standards during and after the procedure.
62739017|NCT06464731|NO_INTERVENTION|Control Group|Patients will receive the best medical treatment according to local clinical research standards, including antiplatelet agents, anticoagulants, thrombolysis, etc., excluding any endovascular treatment. In the event of disease progression defined as neurological deterioration leading to an increase in NIHSS ≥4 points and excluding non-stroke factors within 24 hours, remedial endovascular treatment may be taken, including but not limited to stent retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, etc.
62739018|NCT06463431|EXPERIMENTAL|Cognitive Processing Therapy|"The intervention will consist of 14 90-minute weekly virtual sessions of CPT with a study therapist.~Session 1: Discuss sexual history/goals regarding PTSD and STBBI risk reduction, including reducing CAS, using medications to treat HIV/bacterial STBBIs, \& providing education about the benefits of using PrEP Session 2: Review the cognitive model for CPT and the index trauma Sessions 3-7: Address problematic appraisals of the index trauma, maladaptive thoughts, and the experience and expression of natural emotions. Teach cognitive intervention skills to facilitate cognitive \& emotional change Sessions 8-12: Discuss/challenge beliefs regarding safety, trust, power/control, esteem, \& intimacy Session 13: Identify how participant's changed beliefs may affect sexual decision making, CAS, and substance use in sexual situations Session 14: Discuss relapse prevention/goals for progress regarding PTSD, substance use, \& STBBI risk reduction"
62739019|NCT03530254|OTHER|PGT-A without ERA|Patients with PGT-A indication and ET in a Hormone Replacement Therapy (HRT cycle) according to the usual clinical practice (day 5 of progesterone supplementation: P+5/120h).
62739020|NCT03530254|OTHER|PGT-A and test ERA|"Patients with PGT-A indication and pET in HRT cycle following the ERA test indication (when the WOI is confirmed as Receptive)."
62739021|NCT06128889|EXPERIMENTAL|STRONG program|
62739022|NCT02767869|EXPERIMENTAL|Banaba|Banaba capsules, 500mg, two times per day before meals during 90 days
62054486|NCT04504331|EXPERIMENTAL|Cohort 3: Infigratinib (75mg) + Tamoxifen|In study part 1 (dose exploration), participants will receive up to infigratinib 75 mg. 75 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + 20 mg/day tamoxifen
62054487|NCT01968525|EXPERIMENTAL|Group A|the hemoglobin is \>12g/L in patients from group A.
62838723|NCT00606593|EXPERIMENTAL|CDBEA|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
62739023|NCT02767869|PLACEBO_COMPARATOR|Placebo|Calcined magnesia capsules, 500mg, two times per day before meals during 90 days
62054488|NCT01968525|EXPERIMENTAL|Group B|Hb 9-12g/L
62054489|NCT01968525|EXPERIMENTAL|Group C|Hb\<9g/L
62054490|NCT04424784|NO_INTERVENTION|20% O2|In the control group, oocyte pickup will be performed in atmospheric oxygen environment (20% oxygen, 89% nitrogen, 6% carbon dioxide).
62256512|NCT00399789|ACTIVE_COMPARATOR|Perifosine 900 mg per week|A weekly dose of 900 mg to be divided into three doses of 300 mg each. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 1,200 mg divided into four doses of 300 mg.
62256513|NCT00399789|ACTIVE_COMPARATOR|Perifosine 50 mg tid|A daily dose of 150 mg to be divided into three doses of 50 mg each. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 200 mg divided into four doses of 50 mg.
62256514|NCT05122884|EXPERIMENTAL|Milrinone group|The pharmacist prepares milrinone 20 mg with normal saline solution (NSS) 100 ml then starts dose 0.5 mg/kg/min for up to 12 hours. The doctor performs Echocardiogram before start Milrinone, during infusion, and after 12 hours from stop Milrinone. Other medications or interventions were used or not used depending on own doctor.
62443977|NCT05489185|PLACEBO_COMPARATOR|Extracapsular fracture without intravenous contraindication (control).|Physiological saline
62443978|NCT05489185|EXPERIMENTAL|Extracapsular fracture without intravenous contraindication (experimental).|Amchafibrin
62443979|NCT05489185|PLACEBO_COMPARATOR|Intracapsular fracture with intravenous contraindication (control).|Physiological saline
62443980|NCT05489185|EXPERIMENTAL|Intracapsular fracture with intravenous contraindication (experimental).|Amchafibrin
62443981|NCT05489185|ACTIVE_COMPARATOR|Intracapsular fracture without intravenous contraindication (control).|Physiological saline
62054491|NCT04424784|EXPERIMENTAL|5% O2|In the experimental group, oocyte pickup will be performed in a low oxygen tension environment (5% oxygen, 89% nitrogen, 6% carbon dioxide). If time lapse embryo culture system is used, fertilization check and embryo grading will also be conducted under the low oxygen tension environment.
62256515|NCT05122884|PLACEBO_COMPARATOR|Placebo group|The pharmacist uses 100 ml of NSS, packed out in the same format, dose, and administration of the drug were exactly the same as in the milrinone group. The doctor performs Echocardiogram same time as the milrinone group
62256516|NCT06029075|EXPERIMENTAL|"tACS Sham, tACS 10Hz, tACS 20Hz experimental order"|"1. tACS Sham is a temporary non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for up to 30 second, it is not designed to entrain neuronal activity into any external regulatory frequency patterns.~2. tACS 10Hz is a 10Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp or 20 or 40 minutes to entrain neuronal activity into 10Hz frequency patterns.~3. tACS 20Hz is a 20Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for 20 or 40 minutes to entrain neuronal activity into 20Hz frequency patterns."
62256517|NCT06029075|EXPERIMENTAL|"HD-tACS 20Hz, HD-tACS 10Hz, HD-tACS Sham experimental order"|"1. tACS 20Hz is a 20Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for 20 or 40 minutes to entrain neuronal activity into 20Hz frequency patterns.~2. tACS 10Hz is a 10Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp or 20 or 40 minutes to entrain neuronal activity into 10Hz frequency patterns.~3. tACS Sham is a temporary non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for up to 30 second, it is not designed to entrain neuronal activity into any external regulatory frequency patterns."
62054492|NCT03727243||Septic/septic shock patients|Patients with underlying confirmed or probable cause of infection leading to sepsis or septic shock will form the active group of interest.
62054493|NCT03727243||Non-septic/sterile inflammation patients|Patient with severe trauma, severe burns and patients admitted to ICU after major surgery or pancreatitis. Active comparator group.
62054494|NCT03727243||Healthy control patients|Active comparator group.
62739024|NCT05689671|EXPERIMENTAL|Pemetrexed-free Immunochemotherapy (Arm A)|Atezolizumab 1200 mg q3w, carboplatin AUC 5-6 q3w, nab-paclitaxel 100 mg/m2 qw (administered for 4 cycles with subsequent maintenance with atezolizumab monotherapy 1200 mg q3w until loss of clinical benefit or occurrence of unacceptable toxicity)
62739025|NCT05689671|ACTIVE_COMPARATOR|Pemetrexed-based Immunochemotherapy (Arm B)|Pembrolizumab 200 mg q3w, cisplatin 75 mg/m2 q3w OR carboplatin AUC 5-6 (each) q3w, pemetrexed 500 mg/m2 q3w (administered for 4 cycles with subsequent maintenance with pembrolizumab 200 mg AND pemetrexed 500 mg/m2 (each) q3w until loss of clinical benefit or occurrence of unacceptable toxicity)
62054495|NCT00824980|EXPERIMENTAL|IP10.C8 Gel|
62054496|NCT00824980|PLACEBO_COMPARATOR|Placebo Gel|
62443982|NCT05489185|EXPERIMENTAL|Intracapsular fracture without intravenous contraindication (experimental).|Amchafibrin
62443983|NCT02459704|EXPERIMENTAL|SCPF + EMD (TEST)|Semilunar coronally positioned flap with Enamel matrix derivative (Emdogain)
62443984|NCT02459704|ACTIVE_COMPARATOR|SCPF (CONTROL)|Semilunar coronally positioned flap alone
62739026|NCT03087877|OTHER|CGM Users|Prospective, non-randomized, single-arm. Continuous Glucose Monitoring. Acetaminophen challenge is the intervention.
62739027|NCT00729495|ACTIVE_COMPARATOR|1|marketed celecoxib
62739028|NCT00729495|EXPERIMENTAL|2|overencapsulated celecoxib
62739029|NCT05891015|EXPERIMENTAL|MIED+TAU group|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
62256518|NCT06029075|EXPERIMENTAL|"HD-tACS 10Hz, HD-tACS 20Hz, HD-tACS Sham experimental order"|"1. tACS 10Hz is a 10Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp or 20 or 40 minutes to entrain neuronal activity into 10Hz frequency patterns.~2. tACS 20Hz is a 20Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for 20 or 40 minutes to entrain neuronal activity into 20Hz frequency patterns.~3. tACS Sham is a temporary non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for up to 30 second, it is not designed to entrain neuronal activity into any external regulatory frequency patterns."
62256519|NCT02768090|EXPERIMENTAL|Skin Patch|Sweat will be collected from inflammatory and neoplastic skin lesions with an FDA approved diagnostic skin patch for analysis with mass spectrometry
62443985|NCT01617733|EXPERIMENTAL|Pasireotide|4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
62443986|NCT00977002|EXPERIMENTAL|PPNIV|Patient randomized to this group will be ventilated with Positive Pressure Noninvasive Ventilation post extubation
62443987|NCT00977002|ACTIVE_COMPARATOR|O2I|Patient randomized to this group will be submitted to traditional oxygen therapy post extubation
62443988|NCT04371250||Youth|Assessed group
62443989|NCT04144296|OTHER|Study Arm|All patient will be included in this arm
62443990|NCT02687009|EXPERIMENTAL|Niclosamide|
62443991|NCT05638152||before|routine care
62443992|NCT05638152||after|routine care + natural imagery in the PACU + access to music + access to aromatherapy + use of hypnoidal communication techniques by PACU nurses
62443993|NCT04947579|EXPERIMENTAL|Administration of CC-99677 150 mg QD PO|49 participants will be randomized to CC-99677 150 mg in biologic naive main study
62443994|NCT04947579|EXPERIMENTAL|Administration of CC-99677 60mg QD PO|49 participants will be randomized to CC-99677 60 mg in biologic naive main study
62443995|NCT04947579|PLACEBO_COMPARATOR|Administration of Placebo QD PO|49 participants will be randomized to placebo in biologic naive main study
62739030|NCT05891015|NO_INTERVENTION|the TAU-only group|treatment as usual (TAU) group consisted of all medicinal and psychological treatments received between baseline and follow-up (about five months). Medicinal treatments included receiving Lorazepam, Olanzapine, Paroxetine Hydrochloride, Sertraline, etc. Psychological treatments included receiving cognitive behavior therapy or psychodynamic therap
62739031|NCT02216968|EXPERIMENTAL|AA - Increase vegetable intake|"60 African-American (AA) preschool children will participate in the Intervention Group. 60 AA children will belong to the Control Group.~6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
62256520|NCT02441049|EXPERIMENTAL|Home-based promotora intervention|Study participants and their families received the home-based promotora family intervention
62443996|NCT04947579|EXPERIMENTAL|Administration of CC-99677 150 mg QD PO.|20 participants will be randomized to CC-99677 150 mg in biologic-failure substudy
62443997|NCT04947579|EXPERIMENTAL|Administration of CC-99677 60mg QD PO.|20 participants will be randomized to CC-99677 60 mg in biologic-failure substudy
62443998|NCT04947579|PLACEBO_COMPARATOR|Placebo additional dose cohort|10 participants will be randomized to placebo in biologic-failure substudy
62443999|NCT04254523|EXPERIMENTAL|Programmed intermittent epidural bolus (PIEB)|Programmed intermittent epidural boluses of bupivacaine 0,1% are administered every hour.
62444000|NCT04254523|EXPERIMENTAL|Continuous epidural infusion (CEI)|A continuous epidural infusion of bupivacaine 0,1% is administered at a prescribed rate in milliliters per hour.
62444001|NCT03947606|EXPERIMENTAL|Basic social support + communication + Ottawa guide|3 in-person/telephone weekly sessions on providing decision social support, tips for good communication, and decision support tools
62444002|NCT03947606|EXPERIMENTAL|Basic social support + communication|2 in-person/telephone weekly sessions on providing decision social support and tips for good communication
62444003|NCT03947606|EXPERIMENTAL|Basic social support + Ottawa guide|2 in-person/telephone weekly sessions on providing decision social support and decision support tools
62444004|NCT03947606|EXPERIMENTAL|Basic social support only|1 in-person/telephone weekly session on providing decision social support
62444005|NCT03947606|EXPERIMENTAL|Advanced social support + communication + Ottawa guide|5 in-person/telephone weekly sessions on providing decision social support, tips for good communication, and decision support tools
62444006|NCT03947606|EXPERIMENTAL|Advanced social support + communication|4 in-person/telephone weekly sessions on providing decision social support and tips for good communication
62444007|NCT03947606|EXPERIMENTAL|Advanced social support + Ottawa guide|4 in-person/telephone weekly sessions on providing decision social support and decision support tools
62444008|NCT03947606|EXPERIMENTAL|Advanced social support only|3 in-person/telephone weekly sessions on providing decision social support
62444009|NCT02495610|OTHER|Gait analysis and MRI|"* Gait analysis: Intervention: Treadmill with pressure sensors (FDM-THM-M-System (Force distribution method-treadmill); 'Zebris' medical GmbH), study-specific, but routine procedures.~* MRI: Intervention: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage."
62444010|NCT02342444|ACTIVE_COMPARATOR|Enoxaparin Sodium Injection 30 mg BID|Subjects are randomized to receive 30 mg twice daily of enoxaparin.
62444011|NCT02342444|ACTIVE_COMPARATOR|Enoxaparin Sodium Injection 40 mg QD|Subjects are randomized to receive 40 mg once daily of enoxaparin.
62444012|NCT06012058|EXPERIMENTAL|Retinal nerve fiber layer optical texture analysis (ROTA)|The RNFL is imaged with OCT for ROTA.
62613720|NCT05606770|OTHER|Lifestyle Physical Activity|The Lifestyle PA component was developed using the Behaviour Change Wheel (BCW) Guide to Designing Interventions and is underpinned by the COM-B model of behavior change (Michie et al., 2014). This posits that people need capability(C), opportunity(O), and motivation(M) to perform a behavior(B). The aim of the Lifestyle PA component is to increase the capability, opportunity, and motivation of participants to reach their daily step count goals. To achieve this the 3 stages of the BCW intervention design process were followed. The first stage, understanding the behaviour, is done through a review of the literature and primary qualitative research(Cardy et al., 2022). This stage identifies the change objectives of the intervention. Stage 2 requires the selection of intervention functions and the policies that would support them. The final stage is defining the content of the intervention using behaviour change techniques (BCTs) and selecting their mode of delivery.
62613721|NCT05929248|EXPERIMENTAL|Treatment group|conventional treatment plus Telitacicept 160 mg sc per week
62613722|NCT05929248|PLACEBO_COMPARATOR|Control group|Placebo plus conventional treatment
62613723|NCT05772507|EXPERIMENTAL|medical device under investigation|URGO AWC_008 or URGO AWC_022 dressing. These 2 dressings are similar and only the adhesive constitutes a difference. The choice of study dressing will be left to the discretion of the investigator during the treatment of the patient, depending on the nature of the wound and the condition of the peri-wound skin.
62613724|NCT03715387|EXPERIMENTAL|Tacrolimus Treatment|Tacrolimus Topical 0.1% Topical Ointment
62613725|NCT03715387|PLACEBO_COMPARATOR|Control|Patients will be self matched controls with one cheek receiving the study ointment and the other receiving a control ointment (polysporin ointment).
62838724|NCT00606593|EXPERIMENTAL|DECAB|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
62838725|NCT00606593|EXPERIMENTAL|EADBC|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
62838726|NCT00606593|EXPERIMENTAL|DCEBA|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
62613726|NCT03721211|EXPERIMENTAL|[11C]Martinostat|"* Subjects will be administered \[11C\]Martinostat, which is synthesized on site at the MGH Martinos Imaging Center~* All subjects will undergo an MR-PET scan of the thorax, including the breasts, to determine tumor uptake~* All subjects will be scanned using \[11C\]Martinostat during an imaging session on a Siemens Biograph mMR integrated MR-PET scanner~* PET imaging will begin concomitant with radiotracer administration"
62054497|NCT01542957|EXPERIMENTAL|Cognitive Behavioral + Dilemma Therapy|Combines Group Cognitive Behavioral Therapy with a Individual Dilemma-Focused Intervention
62838727|NCT00606593|EXPERIMENTAL|EDACB|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
62838728|NCT00606593|EXPERIMENTAL|AEBDC|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
62838729|NCT00606593|EXPERIMENTAL|BACED|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
62838730|NCT00606593|EXPERIMENTAL|CBDAE|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
62838731|NCT05411315|EXPERIMENTAL|Restricted-use of arterial catheters|
62838732|NCT05411315|ACTIVE_COMPARATOR|Standard-use of arterial catheters|
62838733|NCT02695563|NO_INTERVENTION|controls|The patients will be not treated with vaginal lactoferrin
62838734|NCT02695563|ACTIVE_COMPARATOR|Lactoferrin|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 4 hours prior to mid-trimester genetic amniocentesis.
62838735|NCT02026531|EXPERIMENTAL|3-Helium inhalation gas|This is a pilot study. The aim is to recruit 20 patients who will all receive the product under investigation.
62838736|NCT05062499|ACTIVE_COMPARATOR|Active TENS|electrical stimulation
62838737|NCT05062499|SHAM_COMPARATOR|Sham TENS|no stimulation
62838738|NCT03527732|PLACEBO_COMPARATOR|Arm A: albendazole|400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of placebo at day 0 administered orally
62838739|NCT03527732|EXPERIMENTAL|Arm B: albendazole and ivermectin|400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of ivermectin (Stromectol®) at day 0 administered orally
62838740|NCT01298986|ACTIVE_COMPARATOR|Pulmonary Vein Isolation|Patients who have paroxysmal or persistent atrial fibrillation but whose left atrium is \< /= 5.0
62256521|NCT02441049|NO_INTERVENTION|Delayed treatment control|Study participants received intervention materials after the final study evaluation measures were taken, 10 months post-baseline.
62838741|NCT01298986|EXPERIMENTAL|Hybrid procedure for patients with a left atrium < /= 5.0 cm|A combined procedure where the cardiac surgeon will place the ablation lesions on top of the heart and the electrophysiologist will place the lesions inside the heart. 3D mapping with be used to guide the procedure. The left atrial appendage will be surgically managed.
62256522|NCT03683277|EXPERIMENTAL|Ixazomib/Pomalidomide/Dexamethasone|"Single arm treatment organized in 2 separate phases~Induction phase : association of Ixazomib, Pomalidomide \& Dexamethasone (IPD) 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged \<75 years or Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years~Maintenance phase : association of Ixazomib and Pomalidomide (IP) 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21"
62054498|NCT01542957|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Combined Group and Individual Cognitive Behavioral Therapy
62054499|NCT03831243|ACTIVE_COMPARATOR|Single fraction of 8 Gy|The current standard treatment will be prescribed, i.e. a 3D-conformal radiotherapy of a single fraction dose of 8.0 Gy to the metastasis with a planning target volume (PTV) margin for set-up and positioning uncertainties of 1 cm. This can be performed at any linear accelerator.
62613727|NCT02334098|EXPERIMENTAL|Omega-3 supplemented drink|A 200 ml. drink product with 1.1 grams of omega-3 from Smartfish (Smartfish: Forsiden in Norway).
62613728|NCT02334098|PLACEBO_COMPARATOR|Placebo Drink|exactly the same fruit drink contained in the same packaging, but will contain no omega-3.
62613729|NCT02334098|NO_INTERVENTION|treatment-as-usual controls|No drinks are taken.
62838742|NCT01298986|ACTIVE_COMPARATOR|Cox Maze Procedure|All lesions of the Cox Maze procedure will be completed as originally described by Dr. James Cox using crypthermia. Patients will be randomized if there left atrium is \>5.0 cm but \< 6.1 cm and are experiencing paroxysmal or persistent atrial fibrillation
62838743|NCT01298986|EXPERIMENTAL|Hybrid Procedure|A collaborative approach between electrophysiologist and surgeons for patients with a left atrium \<5.0 cm and \< 6.1 cm where the surgeon will epicardially place the ablation lesions and the electrophysiologist will place the lesion lines endocardially. 3D mapping will be used and the left atrial appendage will be surgically managed.
62838744|NCT02658396|EXPERIMENTAL|GO-203-2C|"* Patients who fulfill eligibility criteria will be entered into the trial to receive Bortezomib and GO-203-2C.~* After the screening procedures confirm participation in the research study:~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have multiple myeloma, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.~* Bortezomib~* GO-203-2C"
62838745|NCT06021704|EXPERIMENTAL|Home Health Aides with Enhanced Curriculum Training|The enhanced curriculum of 108 hours of home health aide (HHA) training will constitute the Experimental arm. This arm consists of the 100 hours of the standard curriculum plus an 8-hour enhanced curriculum that includes additional didactic content and a skills practicum on dementia and recognizing and responding to dementia-related behaviors. As with the standard curriculum, the enhanced curriculum will be delivered by the training entity, CCHERS (Center for Community Health Education, Research and Service, Inc.). The enhanced component is delivered over an additional 2 instructional days (10% increase in instructional days from the standard curriculum).
62613730|NCT05197205|EXPERIMENTAL|sickle cell children group|A nasopharyngeal swab is taken during the consultation, with bacteriological analysis.
62256523|NCT00077363|EXPERIMENTAL|Treatment (tipifarnib, capecitabine)|Patients receive oral tipifarnib twice daily and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 4 additional courses beyond documentation of CR.
62256524|NCT03640598|OTHER|Ilioinguinal/iliohypogastric nerve blocks|The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks
62256525|NCT03640598|OTHER|Erector spinae nerve block|The patient will receive ultrasound-guided erector spinae nerve block
62256526|NCT02330978|EXPERIMENTAL|MSC transplantion|One group of glaucomatous patients will receive 10(6) autologous bone marrow-derived mesenchymal stem cells transplantation into their worst eyes, through an unique intravitreal injections, under anesthesia.
62444013|NCT06012058|ACTIVE_COMPARATOR|Optic disc photography|The optic disc is imaged with color fundus camera.
62444014|NCT01115218||Glaucoma patients|
62613731|NCT05197205|NO_INTERVENTION|control children group|healthy children control group (ACTIV network)
62613732|NCT04538287|ACTIVE_COMPARATOR|AtaCor StealthTrac Lead Model AC-1010|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1010. This was the first model evaluated in the study.
62613733|NCT04538287|ACTIVE_COMPARATOR|AtaCor StealthTrac Lead Model AC-1020|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1020. This was the second model evaluated in the study.
62613734|NCT04538287|ACTIVE_COMPARATOR|AtaCor StealthTrac Lead Model AC-1021|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1021. This was the third model evaluated in the study.
62838746|NCT06021704|NO_INTERVENTION|Home Health Aides with Standard Curriculum Training|"The standard curriculum of 100 hours of home health aide (HHA) training will constitute the No Intervention arm. This 100-hour training is the standard curriculum that has been used by the training entity, CCHERS (Center for Community Health Education, Research and Service, Inc.), for many years to qualify HHAs to receive certificates from the Massachusetts Home Care Aide Council. The standard curriculum includes 75 hours of basic instruction (ABC's for Direct Care Workers) and 25 hours of additional content on mental health and dementia topics. The standard curriculum is delivered over approximately on month, or 20 instructional days."
62838747|NCT00590265|EXPERIMENTAL|1|
62838748|NCT00590265|PLACEBO_COMPARATOR|2|
62838749|NCT03782506|EXPERIMENTAL|Interactive Music Therapy|Ten 45-minute individual interactive music therapy sessions.
62838750|NCT03782506|ACTIVE_COMPARATOR|Verbal-based Support|Ten 45-minute individual verbal support sessions.
62838751|NCT04616989|EXPERIMENTAL|Psycho-education intervention arm|Participants will receive psycho-education materials
62838752|NCT04616989|ACTIVE_COMPARATOR|Comparator arm|Participants will receive COVID-19 leaflets
62838753|NCT00619710|EXPERIMENTAL|1|Meropenem
62838754|NCT00619710|ACTIVE_COMPARATOR|2|Imipenem-cilastatin
62838755|NCT01615536|EXPERIMENTAL|Canine fossa trephine group (CFT)|
62838756|NCT01615536|ACTIVE_COMPARATOR|Non Canine fossa trephine group (NonCFT)|
62838757|NCT01210404|EXPERIMENTAL|1.0|
62838758|NCT04493788||PCOS group|
62838759|NCT04493788||Control group|
62838760|NCT03622476|EXPERIMENTAL|PK research|Interventional studies were performed in the 1-7 year old subgroup, and the children received a comprehensive assessment and PK test every 3 months. After the 72-hour washout period, 50 IU/kg of concentrated FVIII was administered in a single dose, and blood was taken within half an hour before the infusion and 1 h, 9 h, 24 h, and 48 h after the infusion, and the samples were centrifuged. If the assessment considers that the treatment is inadequate, then the valley concentration target is upgraded.
62838761|NCT03761368|EXPERIMENTAL|RIPC group|The RIPC group underwent Remote Ischemic Preconditioning.
62838762|NCT03761368|SHAM_COMPARATOR|Control group|Patients from control group had sham Remote Ischemic Preconditioning.
62838763|NCT05844007|EXPERIMENTAL|High School Students: Remote Delivery|Remote delivery of trauma-informed yoga session for high school students
62256527|NCT01033825|EXPERIMENTAL|Ciclesonide HFA Nasal Aerosol 320 mcg|Ciclesonide HFA Nasal Aerosol 320 mcg once daily
62838764|NCT05844007|EXPERIMENTAL|High School Students: Face-to-Face Delivery|Face-to-face delivery of trauma-informed yoga session for high school students
62838765|NCT05844007|EXPERIMENTAL|Teachers: Remote Delivery|Remote delivery of trauma-informed yoga session for teachers
62838766|NCT00487461|PLACEBO_COMPARATOR|Control Group|Placebo tablet
62838767|NCT00487461|EXPERIMENTAL|Study Group #1|Simvastatin 40 mg
62444015|NCT03907826|EXPERIMENTAL|PD-1 antibody plus chemoradiotherapy|Patients randomized to this arm will receive three cycles of PD-1 antibody (JS001, 240mg every three weeks) combined with GP chemotherapy, then receive IMRT and PD-1 antibody maintenance for eight cycles.
62838768|NCT00487461|EXPERIMENTAL|Study Group #2|Simvastatin 80 mg
62838769|NCT05824104|EXPERIMENTAL|Patients|The intermittent hypoxia protocol refers to four cycles of 5 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 7 days.
62838770|NCT05109143|ACTIVE_COMPARATOR|Group B|Standard Medical Treatment
62838771|NCT05109143|EXPERIMENTAL|Group A|Will be administered 100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia with Standard Medical Treatment
62838772|NCT03174600||Stroke patients|Stroke patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months
62838773|NCT05766696|EXPERIMENTAL|Atraumatic Restorative Treatment (ART)|GIC restorations placed using ART in a class room.
62054500|NCT03831243|EXPERIMENTAL|Single fraction of 20 Gy|Within the framework of stereotactic body radiotherapy, a single fraction dose of 20.0 Gy will be delivered to the metastasis using a PTV margin of 3-5 mm based on high-precision image-guided radiotherapy (IGRT). Therefore, only linear accelerators with the European Organization for Radiotherapy \& Oncology advisory committee on radiation oncology practice (ESTRO-ACROP) specifications for SBRT can be accepted. A risk-adapted approach will be applied, aiming for the highest possible dose no less than 16 Gy, while respecting the tolerances of critical organs at risk (e.g. spinal cord, cauda equina, brainstem etc.).
62256528|NCT01033825|EXPERIMENTAL|Ciclesonide HFA Nasal Aerosol 160 mcg|Ciclesonide HFA Nasal Aerosol 160 mcg once daily
62256529|NCT01033825|PLACEBO_COMPARATOR|HFA Nasal Aerosol placebo|HFA Nasal Aerosol Placebo once daily
62256530|NCT01033825|EXPERIMENTAL|Ciclesonide Aqueous Nasal Spray 200 mcg|Ciclesonide Aqueous Nasal Spray 200 mcg once daily
62838774|NCT05766696|ACTIVE_COMPARATOR|Conventional Cavity Preparation|GIC restorations placed using conventional cavity preparation in a mobile clinic.
62838775|NCT04445896||Study Participants|Patients with a diagnosis of a life-limiting illness who have previosuly had a discussion with a healthcare professional about the care they would want at the end of life
62838776|NCT00560170|EXPERIMENTAL|high dose statin|40mg of Simvastatin (n=20)
62838777|NCT00560170|ACTIVE_COMPARATOR|combination arm|10mg/10mg of Ezetimibe/Simvastatin (n=20)
62838778|NCT01663103|EXPERIMENTAL|Rilonacept|12 weeks of treatment with rilonacept
62838779|NCT01663103|PLACEBO_COMPARATOR|Placebo|Twelve weeks of treatment with placebo
62838780|NCT00575731|EXPERIMENTAL|Fine-Tuning|2-month intervention (8 lifestyle counseling classes)
62838781|NCT00575731|ACTIVE_COMPARATOR|Record-Keeping|2-month intervention (8 lifestyle counseling classes)
62838782|NCT06091683|EXPERIMENTAL|Adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC)|Preliminary laparoscopic exploration of the abdominal cavity and adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin and concurrent intravenous infusion of 5-fluorouracil and folinic acid.
62838783|NCT01167504||Saliva Sample Collection|Saliva collection
62838784|NCT04512612|ACTIVE_COMPARATOR|Dye based Chromoendoscopy|The patients enrolled in this group will undergo pan-colonic chromoendoscopy evaluation.
62256531|NCT01033825|PLACEBO_COMPARATOR|AQ Nasal Spray Placebo|AQ Nasal Spray Placebo once daily
62256532|NCT01033825|ACTIVE_COMPARATOR|Placebo HFA plus Dexamethasone 6 mcg|Placebo HFA plus Dexamethasone 6 mg once daily
62256533|NCT01033825|ACTIVE_COMPARATOR|Placebo AQ plus Dexamethasone 6 mg|Placebo AQ plus Dexamethasone 6 mg once daily
62256534|NCT02618655||Fever，none definite diagnosis|Those who have fever，but the doctor can not make definite diagnoses with the diagnostic methods available.
62256535|NCT05429788|EXPERIMENTAL|Low dose RLS103|3 mg CBD inhaled dry powder
62256536|NCT05429788|EXPERIMENTAL|High dose RLS103|6 mg CBD inhaled dry powder
62256537|NCT05429788|EXPERIMENTAL|placebo|placebo inhaled dry powder
62256538|NCT01059110|EXPERIMENTAL|Salicylate ointment|Salicylate ointment under occlusion (pomade M.O Cochon®)
62256539|NCT01059110|EXPERIMENTAL|Imiquimod|Imiquimod : Aldara®
62444016|NCT03907826|ACTIVE_COMPARATOR|Chemoradiotherapy|Patients randomized to this arm will receive three cycles of GP chemotherapy, then receive IMRT alone.
62444017|NCT01338844|EXPERIMENTAL|D-Chiro-inositol|Patients will receive 1.2g/day of D-chiro-inositol
62444018|NCT01338844|ACTIVE_COMPARATOR|Myo-inositol|Patients will receive 4g/day of myo-inositol
62444019|NCT04279639||qigong practice|Patients in this arm participated in qigong as part of their treatment at the Pain Management Unit
62444020|NCT04279639||control|Patients attend the pain management unit but do not undertake qigong practice.
62444021|NCT03982849|ACTIVE_COMPARATOR|Hydroquinone group|Hydroquinone 4% cream Cream applied once daily at night on affected areas for 3 months.
62444022|NCT03982849|EXPERIMENTAL|Silymarin group|Silymarin 0.7% cream Cream applied twice daily on affecectec areas for 3 months.
62613735|NCT04538287|ACTIVE_COMPARATOR|AtaCor StealthTrac Lead Model AC-1012|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1012. This is the fourth model currently being evaluated in the study.
62613736|NCT01140828|ACTIVE_COMPARATOR|Rabeprazole|Rabeprazole
62256540|NCT01059110|EXPERIMENTAL|5-fluoro-uracil|5-fluoro-uracil cream : Efudix®
62256541|NCT01059110|EXPERIMENTAL|Cryotherapy|liquid nitrogen : Cryotherapy
62256542|NCT01330342||HIV patients without lymphoma|HIV-infected subjects on cART without a diagnosis of lymphoma
62256543|NCT01330342||HIV patients with lymphoma|HIV seropositive individuals with lymphoma
62256544|NCT03939845|ACTIVE_COMPARATOR|TACE|
62444023|NCT04209920|ACTIVE_COMPARATOR|PMMA crown Group|Hypomineralized first permanent molars in patients with molar incisor hypomineralization.
62444024|NCT04209920|ACTIVE_COMPARATOR|Cast metal coping Group|Hypomineralized first permanent molars in patients with molar incisor hypomineralization.
62444025|NCT00467818|ACTIVE_COMPARATOR|Omega 3 fatty Acids, drug|Omega 3 Fatty acids will be dispensed to subjects in the active experimental group of the study.
62444026|NCT00467818|PLACEBO_COMPARATOR|Placebo|The placebo will be dispensed to subjects in the control group
62444027|NCT03120156|ACTIVE_COMPARATOR|No insoles|Control group of people with poor postural control that won't use insoles
62444028|NCT03120156|ACTIVE_COMPARATOR|Normal insoles|Control group of people with poor postural control that will get normal standard insoles.
62444029|NCT03120156|ACTIVE_COMPARATOR|Sensomotoric insoles|Control group of people with poor postural control that will get normal standard insoles.
62444030|NCT00330421|EXPERIMENTAL|Group I (sarcomas of extremity, closed accrual as of 5/30/07)|Patients receive oral sorafenib twice daily on days 1-14. Patients undergo surgical resection of the tumor on approximately day 15. Once patients recover from surgery (and radiotherapy if indicated), patients who demonstrate a clinically and pathologically significant response (≥ 25% reduction in tumor size or ≥ 25% necrosis in the surgical specimen) may continue sorafenib as above for a maximum of 6 months in the absence of disease progression or unacceptable toxicity and at the discretion of the principal investigator. Biopsy tissue and blood samples are examined for biomarkers and interstitial fluid pressure (IFP) is measured at baseline and immediately before surgery.
62444031|NCT00330421|EXPERIMENTAL|Group II (metastatic or inoperable sarcomas)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for 2 courses. Patients with responding or stable disease may continue sorafenib in the absence of disease progression or unacceptable toxicity. Biopsy tissue and blood samples are examined for biomarkers and IFP is measured at baseline and on days 28 and 56.
62256545|NCT03939845|EXPERIMENTAL|TACE+RT|
62256546|NCT02366559|ACTIVE_COMPARATOR|electrocautery|Blocks of subjects' lesions will be randomized 1:1 to receive electrocautery or 532 nm Nd:YAG laser. Prior to treatment with either electrocautery or 532nm Q-switched Nd:YAG laser, a topical EMLA cream will be applied to the lesions for at least 60 minutes under occlusion at the area of treatment.
62256547|NCT02366559|ACTIVE_COMPARATOR|532 nm Nd:YAG laser|Blocks of subjects' lesions will be randomized 1:1 to receive electrocautery or 532 nm Nd:YAG laser. Prior to treatment with either electrocautery or 532nm Q-switched Nd:YAG laser, a topical EMLA cream will be applied to the lesions for at least 60 minutes under occlusion at the area of treatment.
62256548|NCT00802204|ACTIVE_COMPARATOR|Lean controls|Lean complete baseline outcome measures only
62256549|NCT00802204|EXPERIMENTAL|Obese|Obese completing baseline and post-VLCD outcome measures
62256550|NCT01396174|ACTIVE_COMPARATOR|Standard Online Support Group|
62256551|NCT01396174|EXPERIMENTAL|Prosocial Online Support Group|
62256552|NCT04146740|EXPERIMENTAL|Structured Exercise Group|"Structured Exercise Group will receive medical and dietary interventions like insulin plus structured aerobic exercise regime of moderate intensity by using stationary cycle (3-5 MET) 10 min, brisk walk 10 min The combination of Stabilization exercise (10 repetitions) and PFM training ( 20 repetitions set).~Relaxation therapy including Mitchells physiological relaxation technique (10 repeatitions) alongwith deep breathing exercises.~Life style modification with postural guidance and back care would also be followed.~Exercise dosage would be twice a week for 05 weeks while exercise duration will be 45 to 50 min session under Physio supervision and home plan of 10 min exercise daily. Total 150 min per week. Data will be recorded at baseline then after treatment of 5 weeks."
62444032|NCT04984291|EXPERIMENTAL|Zimmer Biomet Total Shoulder Arthroplasty System|Patients who are having primary or revision total shoulder arthroplasty who will receive a Zimmer Biomet Total Shoulder Arthroplasty System.
62613737|NCT01140828|PLACEBO_COMPARATOR|Rabeprazole Placebo|Rabeprazole Placebo
62256553|NCT04146740|ACTIVE_COMPARATOR|Control Group|Control Group will receive no structured exercise regime only the group will be receiving medical and dietary interventions like insulin in addition of the postural education and back care from Physical Therapist due to ethical concerns and their outcomes will be observed at the baseline and then after 05 weeks.
62613738|NCT03372642||Subtalar endorthesis|Patients who underwent subtalar endorthesis for flexible pediatric flatfoot
62613739|NCT01652625|EXPERIMENTAL|Yunnan Baiyao toothpaste|The toothpaste containing 6.5 milligrams of Yunnan Baiyao was used twice daily as part of the patient's routine oral hygiene for 5 days.
62256554|NCT00654914|EXPERIMENTAL|Arm 1|
62256555|NCT01023867|EXPERIMENTAL|Alzheimer's disease group|Patients with Alzheimer's disease treated donepezil
62256556|NCT01023867|EXPERIMENTAL|Mixed Dementia group|Patients with Mixed Dementia treated donepezil
62256557|NCT03889275|EXPERIMENTAL|Cohort 1A: MEDI5395 Dose Level 1 + Sequential Durvalumab|Participants will receive IV infusions of MEDI5395 Dose Level 1 on Days 1, 4, 8, 10, 12, and 15 followed by durvalumab every 4 weeks (Q4W) starting from 14 days after the last dose of MEDI5395 for maximum of 2 years or until disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity; whichever occurs first.
62256558|NCT03889275|EXPERIMENTAL|Cohort 2A: MEDI5395 Dose Level 2 + Sequential Durvalumab|Participants will receive IV infusions of MEDI5395 Dose Level 2 on Days 1, 4, 8, 10, 12, and 15 followed by durvalumab Q4W starting from 14 days after the last dose of MEDI5395 for maximum of 2 years or until disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity; whichever occurs first.
62256559|NCT03889275|EXPERIMENTAL|Cohort 3A: MEDI5395 Dose Level 3 + Sequential Durvalumab|Participants will receive IV infusions of MEDI5395 Dose Level 3 on Days 1, 4, 8, 10, 12, and 15 followed by durvalumab Q4W starting from 14 days after the last dose of MEDI5395 for maximum of 2 years or until disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity; whichever occurs first.
62256560|NCT03889275|EXPERIMENTAL|Cohort 3A Backfill: MEDI5395 Dose Level 3 + Sequential Durvalumab|Participants will receive IV infusions of MEDI5395 Dose Level 2 on Day 1 and Dose Level 3 on Days 4, 8, 10, 12, and 15 followed by durvalumab Q4W starting from 14 days after the last dose of MEDI5395 for maximum of 2 years or until disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity; whichever occurs first.
62838785|NCT04512612|ACTIVE_COMPARATOR|High Definition White Light Endoscopy|The patients enrolled in this group will undergo high definition white light endoscopy based evaluation
62054501|NCT04709172|EXPERIMENTAL|Cefditoren pivoxil 400mg|Cefditoren pivoxil 400mg bid for 7 days
62256561|NCT03889275|EXPERIMENTAL|Cohort 4A: MEDI5395 Dose Level 4 + Sequential Durvalumab|Participants will receive IV infusions of MEDI5395 Dose Level 2 on Day 1 and Dose Level 4 on Days 4, 8, 10, 12, and 15 followed by durvalumab Q4W starting from 14 days after the last dose of MEDI5395 for maximum of 2 years or until disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity; whichever occurs first.
62444033|NCT02408666|OTHER|Interview|"Interview of epilepsy patients and their family about their experience with epilepsy, EEG registrations and daily life.~Interview of EEG-technologists and neurologists about their experience with EEG registrations and expections when thinking of a ideal EEG-cap."
62444034|NCT05551377|EXPERIMENTAL|Intervention group|At T0, in-clinic inclusion, we will record basic characteristics and several questionnaires, we will also perform a short tilt-table-test and standing blood pressure (BP) test. Intake is followed by one week of horizontal sleeping for baseline home-based BP measurements. Participants in the intervention group will then sleep in a head-up tilt position for two weeks each in angles 6°, 12° and 18°. At the second and final in-clinic meeting, at T1, measurements done at T0 will be repeated, complemented with an assessment of barriers and facilitators of HUTS. During HUTS daily BP measurements will be done, and data will be collected on orthostatic tolerance, nighttime urine production, subjective comfort of HUTS, falls.
62444035|NCT05551377|OTHER|Delayed intervention group|Follows the same structure as the intervention group, but starts with a HUTS placebo angle of 1° for two weeks, followed by two intervention angles of 6° and 12° for two weeks each. The 1°-angle serves as the control intervention.
62444036|NCT05736965|EXPERIMENTAL|SAV arm|Untreated acute myeloid leukemia who are ineligible for intensive chemotherapy or who refuse to receive intensive chemotherapy will receive selinexor in combination with azacitidine and venetoclax, 28 days per cycle, patients can receive transplants at any time once they achieved complete remission and other patients will continue to receive SAV regimen until disease progression or unacceptable toxic effects.
62444037|NCT06383559|EXPERIMENTAL|Experimental arm|XELOX regimen combined with Sintilimab and Lenvatinib
62444038|NCT01838902|OTHER|Eurartesim (control)|All participants will receive a complete course of DHA-PPQ (Eurartesim)
62444039|NCT01838902|EXPERIMENTAL|Primaquine 0.75mg base/kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.75mg/kg body weight
62444040|NCT01838902|EXPERIMENTAL|Primaquine 0.4mg base /kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.4mg base/kg Body weight
62444041|NCT01838902|EXPERIMENTAL|Primaquine 0.2mg base/kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.2mg base/kg body weight
62444042|NCT00928252|EXPERIMENTAL|Received 18F-fluorocholine PET/CT|IV fluorine-18 labeled methylcholine before PET/CT
62444043|NCT04292106|PLACEBO_COMPARATOR|Placebo|
62444044|NCT04292106|EXPERIMENTAL|Red Spinach Extract (RSE)|
62444045|NCT03454971|EXPERIMENTAL|MinOS arm|Patients are followed according to MinOS protocol:
62613740|NCT01652625|ACTIVE_COMPARATOR|placebo toothpaste|One gram of placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
62613741|NCT01631838|EXPERIMENTAL|Tocotrienol-rich fraction 400mg|
62054502|NCT02573922|EXPERIMENTAL|Oxycodone-naloxone|Oxycodone-naloxone prolonged release tablet twice a day
62054503|NCT02573922|ACTIVE_COMPARATOR|Oxycodone|Oxycodone prolonged release tablet twice a day
62613742|NCT01631838|EXPERIMENTAL|Placebo|
62838786|NCT06519474|EXPERIMENTAL|Upper chest compression|The Theraband will be wrapped around the subject's upper chest with upper edge of the Theraband aligned to the 3rd intercostal space and fastened on the upper rib cage for the upper chest compression arm.
62256562|NCT03889275|EXPERIMENTAL|Cohort 1B: MEDI5395 Dose Level 1 + Concurrent Durvalumab|Participants will receive IV infusions of MEDI5395 Dose Level 1 on Days 1, 4, 8, 10, 12, and 15 and durvalumab Q4W, starting from the same day as third dose of MEDI5395, for maximum of 2 years or until disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity; whichever occurs first.
62054504|NCT03265106|EXPERIMENTAL|BinD19|BinD19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity. Minimum/ maximum dose: 1x10\^6/kg / 1x10\^7/kg administered to childhood patients with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma.
62054505|NCT02158117|EXPERIMENTAL|nasal naloxone|8 and 16 mg/ml, comparator 1 mg/ml. Three daily occasions with at least 3 days washout between treatment (min 8 days).
62054506|NCT01331057||1:Sri Lankais|Children aged of four to six years old, in the nursery school and if their first language is unique : tamil.
62054507|NCT01331057||2: Algerian|Children aged of four to six years old, in the nursery school and if their first language is unique : arabic.
62054508|NCT01331057||3: Mali|Children aged of four to six years old, in the nursery school and if their first language is unique : SONINKE.
62054509|NCT01119898|EXPERIMENTAL|PENNSAID Gel|Diclofenac sodium 2.0% w/w
62054510|NCT01119898|PLACEBO_COMPARATOR|Vehicle|The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
62054511|NCT05788302|EXPERIMENTAL|Prolonged Exposure therapy for posttraumatic stress disorder|15 participants who meet study inclusion/exclusion criteria will be individually administered a full course of PE during 10, 60 minute-sessions, with independent multimodal assessment batteries administered at pre-treatment, mid-treatment (post session 5), post-treatment, and a 1-month follow-up.
62256563|NCT03889275|EXPERIMENTAL|Cohort 2B: MEDI5395 Dose Level 2 + Concurrent Durvalumab|Participants will receive IV infusions of MEDI5395 Dose Level 2 on Days 1, 4, 8, 10, 12, and 15 and durvalumab Q4W, starting from the same day as third dose of MEDI5395, for maximum of 2 years or until disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity; whichever occurs first.
62444046|NCT03158142|EXPERIMENTAL|Atropine group|One drop of Atropine Sulfate 1% Oph Soln will be administered either in the morning or at night in each eye. Study measurements will be taken approximately after 1, 12, 24 and 96 hours after drop instillation. After a 2 week wash out period with no eye drops, another drop of 1% atropine sulfate ophthalmic eye drops will be administered either in the morning or night (the visit that was not taken before) and study measurements will be scheduled approximately after 1, 12 24 and 96 hours after drop instillation
62444047|NCT02043366|PLACEBO_COMPARATOR|Normal Saline|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
62444048|NCT02043366|ACTIVE_COMPARATOR|Butorphanol|Butorphanol is intravenously administrated at a dose of 20μg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
62444049|NCT02043366|ACTIVE_COMPARATOR|Flurbiprofen axetilⅠ|Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
62054512|NCT04453423|OTHER|First-line Treatment|
62054513|NCT04453423|EXPERIMENTAL|Maintenance Treatment A|
62054514|NCT04453423|EXPERIMENTAL|Maintenance Treatment B|
62838787|NCT06519474|EXPERIMENTAL|Lower chest compression|The Theraband will be wrapped around the subject's lower rib cage by placing the central horizontal part of the Theraband at the xiphoid process of the sternum for the lower chest compression arm.
62838788|NCT02124317|EXPERIMENTAL|nanoparticle albumin-bound paclitaxel, S-1|nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycle: 6 cycles.
62838789|NCT02282605|EXPERIMENTAL|XF-73 2.0 mg/g nasal gel|0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris, twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.6mg XF-73 per naris/1.2mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
62054515|NCT04453423|EXPERIMENTAL|Maintenance Treatment C|
62838790|NCT02282605|EXPERIMENTAL|XF-73 0.5 mg/g nasal gel|0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.15mg XF-73 per naris/0.3mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
62838791|NCT02282605|PLACEBO_COMPARATOR|Placebo nasal gel|0.3mL nasal gel will be applied to each naris twice daily for two days. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
62838792|NCT02570048||Experimental: Mutebutton intervention|This one armed trail will recruit participants who have been diagnosed with Tinnitus for a minimum of 6 months. Participants will use the Mutebutton device in their own home for 30 minutes every day for 12 weeks. The intervention requires sitting in a quiet space with the earphones on and the tongue tip placed on their tongue.
62838793|NCT02044640||Appendectomy|Patients undergoing a laporascopic appendectomy
62838794|NCT06440681|ACTIVE_COMPARATOR|Lifestyle Modification Group (LMP)|"They are the people who will follow the lifestyle modification program, which is:~Dietary counseling and monitoring: reduce fat intake (30% of total energy and saturated fat 10% of total energy) and increase fiber intake (15 g/1000 kcal) in the diet Physical activity: moderate exercise (150 minutes/week)"
62054516|NCT06256289|EXPERIMENTAL|canagliflozin plus metformin group|canagliflozin 100 mg once daily plus metformin 1000 mg twice daily
62054517|NCT06256289|ACTIVE_COMPARATOR|metformin group|metformin 1000 mg twice daily
62054518|NCT01355601|EXPERIMENTAL|Group 1 - Control A|Nutritional beverage containing varying types and levels of carbohydrates
62256564|NCT03889275|EXPERIMENTAL|Cohort 3B: MEDI5395 Dose Level 3 + Concurrent Durvalumab|Participants will receive IV infusions of MEDI5395 Dose Level 3 on Days 1, 4, 8, 10, 12, and 15 and durvalumab Q4W, starting from the same day as third dose of MEDI5395, for maximum of 2 years or until disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity; whichever occurs first.
62054519|NCT01355601|EXPERIMENTAL|Group 2 - Experimental A|Nutritional Beverage with varying types and levels of carbohydrates
62613743|NCT03985189|EXPERIMENTAL|ME-401|ME-401 administered orally
62613744|NCT00727987|EXPERIMENTAL|CNTO 148 50 mg + methotrexate|
62613745|NCT00727987|EXPERIMENTAL|CNTO 148 100 mg + methotrexate|
62838795|NCT06440681|PLACEBO_COMPARATOR|Control group (CG)|They are people who will not follow the lifestyle modification program or they did not know about this program
62054520|NCT00567021||1|patients with GERD or NSAID-related ulcers
62256565|NCT03283124|ACTIVE_COMPARATOR|self-cut mesh procedure|This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10\*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.
62256566|NCT03283124|ACTIVE_COMPARATOR|mesh-kit procedure|This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.
62256567|NCT02594423|ACTIVE_COMPARATOR|Fine needle Diathermy|Fine needle Diathermy(FND) will be applied under topical anaesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels.
62256568|NCT02594423|ACTIVE_COMPARATOR|Fine Needle Diathermy and Bevacizumab|Fine needle Diathermy(FND) will be applied under topical anaesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels. Patients will receive subconjunctival injections of bevacizumab in the conjunctiva near the limbus in the quadrant(s) affected (total volume of between 0.2 ml-0.3 ml of the 2.5 mg/0.1 ml solution). The subconjunctival injections will be administered after FND in the same treated quadrants.
62256569|NCT02047682|EXPERIMENTAL|Biopsychosocial|Biopsychosocial intervention with Individually tailored physical exercises and stress management
62054521|NCT02710292|OTHER|DT1, then TE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.
62054522|NCT02710292|OTHER|TE, then DT1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.
62256570|NCT02047682|ACTIVE_COMPARATOR|Reference|"Reference group receiving usual care in terms of standard workplace ergonomics and physical exercises"
62256571|NCT01838616|EXPERIMENTAL|Tapentadol Prolonged Release (PR)|
62256572|NCT01838616|ACTIVE_COMPARATOR|Oxycodone/Naloxone Prolonged Release|
62256573|NCT05458765|ACTIVE_COMPARATOR|F/TAF|daily oral tablet
62256574|NCT05458765|ACTIVE_COMPARATOR|F/TDF|daily oral tablet
62256575|NCT04942795||Mechanical thrombectomy|Patients who underwent mechanical thrombectomy for large vessel occlusion of the anterior circulation
62256576|NCT03085524||Surgical Bypass|Subjects in the BEST-CLI trial assigned to surgical revascularization.
62613746|NCT00727987|PLACEBO_COMPARATOR|Placebo + methotrexate|
62613747|NCT02634983|EXPERIMENTAL|QVA149 110/50 mcg then Matching placebo|Single daily dose of 110/50 μg QVA149 for 8-10 days.
62613748|NCT02634983|PLACEBO_COMPARATOR|Matching placebo then QVA149 110/50 mcg|Single daily dose of matching placebo for 8-10 days.
62613749|NCT02962206|ACTIVE_COMPARATOR|Standard of care|Patients will undergo standard closed fracture reduction. The sedation type, reduction method, and immobilization method will be at the discretion of the treating physician. Point-of-care ultrasound will not be used.
62838796|NCT03714880|EXPERIMENTAL|Mifepristone|Participants ingest mifepristone 200 mg oral medication once 18-24 hours prior to dilator placement
62054523|NCT00736489|EXPERIMENTAL|crossover dose 1|AZD3199 120 microgram
62256577|NCT03085524||Endovascular|Subjects in the BEST-CLI trial assigned to endovascular revascularization.
62613750|NCT02962206|EXPERIMENTAL|Experimental Group|Patients will undergo standard closed fracture reduction with the addition of point-of-care ultrasound use to assess post-reduction dorsal angulation. The sedation type, reduction method, and immobilization method will be at the discretion of the treating physician.
62613751|NCT02771925|EXPERIMENTAL|gabapentin|Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2g/day divided in two doses for 24 weeks All patient will receive standard of care treatment
62838797|NCT03714880|PLACEBO_COMPARATOR|Placebo|Participants ingest placebo oral medication once 18-24 hours prior to dilator placement
62838798|NCT04995224||Study 1A|Prospective cohort study with 150 newly diagnosed patients with inflammatory bowel disease
62613752|NCT02771925|PLACEBO_COMPARATOR|Placebo|Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2g/day divided in two doses for 24 weeks All patient will receive standard of care treatment
62256578|NCT05627414|EXPERIMENTAL|Disitamab Vedotin Combined With Sintilimab and S-1|30 HER2 overexpression unresectable gastric cancer patients will enrolle and treate with Disitamab Vedotin, Sintilimab and S-1. During the study period, imaging examinations were conducted every 6-12 weeks to evaluate the tumor and whether it reached the operable standard. The scheme and duration of postoperative adjuvant treatment were determined by the investigator according to the patient's conditions (Sintilimab was recommended to be maintained for 1 year, and other drugs were increased or decreased according to the patient's conditions).
62838799|NCT04995224||Study 1B|Prospective cohort study with 450 newly diagnosed patients with IBD
62256579|NCT02384902|EXPERIMENTAL|low GI|low GI: participants were asked to consume low GI foods (GI\<55) in abundant, medium GI in moderate and high GI (GI\>70) rarely.
62256580|NCT02384902|EXPERIMENTAL|low GL|low GL: participants were asked to consume low GI foods and the amount of carbohydrate was controlled.
62256581|NCT02384902|EXPERIMENTAL|conventional diet|conventional diet: all carbohydrate were treated as the same.
62256582|NCT05511974|OTHER|obstructive sleep apnea patients|Group I : consist of sixty-three patients having OSA. Group II : consist of sixty-three non-OSA patients.
62613753|NCT03718195|OTHER|Pediatric formula|"Each child will receive a new formula for a period of seven days. The new formula is a nutritionally complete standard enteral tube feed, with ingredients derived from real food. The formula is a food for special medical purposes for use under medical supervision.~The dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube"
62054524|NCT00736489|EXPERIMENTAL|crossover dose 2|AZD3199 480 microgram
62054525|NCT00736489|EXPERIMENTAL|crossover dose 3|AZD3199 1920 microgram
62054526|NCT00736489|PLACEBO_COMPARATOR|crossover dose 4|Placebo
62054527|NCT00736489|ACTIVE_COMPARATOR|crossover dose 5|Formoterol 9 microgram
62054528|NCT00736489|ACTIVE_COMPARATOR|crossover dose 6|Formoterol 36 microgram
62256583|NCT00319150|NO_INTERVENTION|Standard of Care|Epo dose to remain constant throughout study
62838800|NCT04995224||Study 2|Cross-sectional study with 10,000 patients in IBD Boost study
62054529|NCT05781425||Multiple Myeloma patients|Treatment naïve multiple myeloma patients. There is no intervention.
62054530|NCT05601401|EXPERIMENTAL|Study arm|Patients receive RC48-ADC.
62256584|NCT00319150|ACTIVE_COMPARATOR|Dosage Decrease Arm|Arm 2 is to have an decrease of erythropoietin at regular intervals.
62256585|NCT06261073|ACTIVE_COMPARATOR|Patients with non-segmental vitiligo|30vitiligo patients their age above 18 years attending dermatology outpatient clinics of Sohag University hospital.
62256586|NCT06261073|ACTIVE_COMPARATOR|healthy volunteers.|.A group of age and sex- matched healthy participants will be included as a control group.
62613754|NCT00957905|EXPERIMENTAL|Part A (alvocidib and oxaliplatin)|Patients receive alvocidib IV over 1 hour and oxaliplatin IV over 2 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
62613755|NCT00957905|EXPERIMENTAL|Part B (alvocidib and FOLFOX)|Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours followed by fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
62613756|NCT02444039||Any Willing and Able Person for Ocular Imaging|Any Willing and Able Person for Ocular Imaging
62613757|NCT02425202|ACTIVE_COMPARATOR|Ketamine infusion|Ketamine infusion at 0.1 mg/kg/hr up to maximum of 10 mg/hr
62613758|NCT02425202|PLACEBO_COMPARATOR|Saline infusion|Saline infusion
62613759|NCT01621828|OTHER|video|video showing a patient's pathway into the operating room.
62054531|NCT05100225|EXPERIMENTAL|PTP-001 200 mg|A single intra-articular injection in the target knee of PTP-001 200 mg.
62054532|NCT05100225|EXPERIMENTAL|PTP-001 100 mg|A single intra-articular injection in the target knee of PTP-001 100 mg.
62054533|NCT05100225|PLACEBO_COMPARATOR|Placebo/saline|A single intra-articular injection in the target knee of 4mL of placebo control - physiological saline (0.9% sodium chloride injection, USP).
62054534|NCT02026856||Se-OI> 200|patients who received form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was higher than 200
62444050|NCT02043366|ACTIVE_COMPARATOR|Flurbiprofen axetilⅡ|Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before the skin closure and intraoperative pain management was with remifentanil
62613760|NCT01621828|OTHER|leaflet|a written leaflet, about the operating room experience and environment.
62838801|NCT04995224||Study 3|Cross-sectional study with 15,000 patients in IBD BioResource
62838802|NCT02876549|EXPERIMENTAL|G6PD Normal|
62838803|NCT02876549|EXPERIMENTAL|G6PD Deficient|
62838804|NCT06520774|EXPERIMENTAL|Concave Supra-arch Branched Stent-Graft System|Endovascular treatment of patients with Aortic Arch Diseases using Concave Supra-arch Branched Stent-Graft System
62838805|NCT02567578|EXPERIMENTAL|YH12852 0.1 mg|twice daily for 4 weeks
62256587|NCT05704894|EXPERIMENTAL|Intervention group|"Administration of Erythropoietin 150UI/Kg/week divided into 3 doses, IV, for a period of 12 weeks, in patients with hemoglobin between \<12g/dL.~Every week (1 to 12), the study medication will be administered 3 times, according to the proposed treatment, for those allocated in the intervention group. All assessments, procedures and notes must be recorded in a source document and in a CRF."
62256588|NCT05704894|NO_INTERVENTION|Control Group|For the control group, the procedures will be performed according to the institution's standard treatment (Vitamin B12 and folic acid). The use of Iron, Vitamin B12 and folic acid will be allowed both in the intervention arm and in the control arm. Doses should be prescribed at the physician's discretion.
62256589|NCT05919654|EXPERIMENTAL|Treatment|Myocare
62256590|NCT05919654|ACTIVE_COMPARATOR|Control|Clearview
62256591|NCT03944226|EXPERIMENTAL|Beetroot|16 patients confirmed with a diagnosis of invasive ductal carcinoma who will undergo wide local excision surgery or mastectomy. All patients in the single arm will undergo a 5 day intervention drinking concentrated beetroot juice and 2 magnetic resonance imaging scan sessions pre and post intervention. MRI scan sessions will be composed of research scans including diffusion and lipid profiling MR imaging methods and MR spectroscopy (MRS) methods.
62256592|NCT01825057|ACTIVE_COMPARATOR|See One|"Providers in See One only receive MI workshop training, giving them an opportunity to see the MI intervention and learn how to conduct it. The trainer encourages them to screen their patients for substance misuse and apply MI as indicated."
62256593|NCT01825057|EXPERIMENTAL|Do One|Following workshop training, MI-trained CL clinicians directly supervise providers' live bedside provision of MI to patients twice before beginning the trial and once midstream. In addition, providers have the option to request additional live supervision from CL clinicians during the trial, consistent with the apprenticeship model.
62256594|NCT01825057|EXPERIMENTAL|Order One|"Following the workshop, providers either administer MI themselves or order a MI for delivery by one of the MI-trained CL clinicians. Only providers in Order One can specifically request MI through a separate CL order in the electronic health record. The physicians or PAs directly place MI orders. Nurses contact physicians or PAs to place the MI order. The CL clinicians are trained in MI via a clinical trials training approach: 1) a 2-day skill-building workshop; 2) three post-workshop supervised practice cases based on review of audio recorded sessions; and 3) follow-up monthly group supervision to maintain and monitor the CL clinicians' MI practice. CL clinicians also learned supervisory practices to provide live supervision to providers in Do One."
62444051|NCT02043366|ACTIVE_COMPARATOR|Butorphanol-Flurbiprofen axetil|A dose of 10μg/ kg butorphanol and a dose of 0.5mg/ kg flurbiprofen axetil are intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
62444052|NCT02043366|SHAM_COMPARATOR|Sufentanil|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with sufentanil
62444053|NCT01323881|EXPERIMENTAL|intermittent theta burst stimulation|
62256595|NCT05230589||Patients with type 2 diabetes|once-daily oral semaglutide in a real-world adult population with type 2 diabetes
62256596|NCT03849417||Late-life Depression|Patients aged over 60 years old with severe depression
62256597|NCT03849417||Late-life Depression (ECT)|Patients aged over 60 years old with severe depression who are referred for treatment with electroconvulsive therapy
62256598|NCT03849417||Healthy Controls|Healthy volunteers over 60 years old who will form a comparison group
62444054|NCT01323881|PLACEBO_COMPARATOR|sham stimulation|
62444055|NCT06171698|EXPERIMENTAL|Research Prototype Monitor|
62444056|NCT02833415|EXPERIMENTAL|Empagliflozin|Empagliflozin 10 mg by mouth daily for 3 months.
62444057|NCT02833415|PLACEBO_COMPARATOR|Placebo|Placebo one tablet daily for 3 months
62444058|NCT06038357|EXPERIMENTAL|CBITS|Cognitive Behavioral Intervention for Trauma in Schools (CBITS)
62444059|NCT06038357|ACTIVE_COMPARATOR|Treatment as usual (TAU+)|Enhanced Treatment as Usual means regular care in child welfare program and mental health care. They also receive feedback on their assessments and a treatment recommendation.
62444060|NCT00720122|EXPERIMENTAL|Anorexia Nervosa Females|
62613761|NCT03409120|EXPERIMENTAL|Dystonia Severity Assessment|We will measure the effects of DBS on dystonia by assessing changes in the Burke-Fahn-Marsden Dystonia Rating Scale at 2, 4, 6, and 12 months after surgery to implant the Boston Scientific Vercise PC IPG with directional DBS lead versus preoperative baseline.
62613762|NCT02914431|EXPERIMENTAL|3D Printing Personalized Titanium Plate|After the LeFort I osteotomy, the intraoperative repositioning and fixation of the maxilla is accomplished using 3D printing personalized titanium plates.
62838806|NCT02567578|EXPERIMENTAL|YH12852 0.25 mg|twice daily for 4 weeks
62838807|NCT02567578|EXPERIMENTAL|YH12852 0.5 mg|twice daily for 4 weeks
62613763|NCT02914431|NO_INTERVENTION|CAD/CAM Surgical Splint|After the LeFort I osteotomy, the intraoperative repositioning of the maxilla is accomplished using CAD/CAM surgical splints and the fixation of the maxilla is accomplished using commercialization titanium plates.
62838808|NCT02567578|PLACEBO_COMPARATOR|Placebo|twice daily for 4 weeks
62838809|NCT05755321||BMI<25 and T2DM|10 Subjects with Body Mass Index (BMI) \<25 with Type 2 Diabetes Mellitus (T2DM) of both sex.
62838810|NCT05755321||BMI<25 without T2DM|10 Subjects with Body Mass Index (BMI) \<25 without Type 2 Diabetes Mellitus (T2DM) of both sex.
62838811|NCT05755321||BMI>30 and T2DM|10 Subjects with Body Mass Index (BMI) \>30 with Type 2 Diabetes Mellitus (T2DM) of both sex.
62838812|NCT05755321||BMI>30 without T2DM|10 Subjects with Body Mass Index (BMI) \>30 without Type 2 Diabetes Mellitus (T2DM) of both sex.
62838813|NCT02259088|EXPERIMENTAL|Ranibizumab (RFB002)|3 initial intravitreal injections to the study eye at Day 1, Month 1 and Month 2, followed by as-needed intravitreal injections of ranibizumab 0.5 mg guided by VA stabilization, plus sham laser
62838814|NCT02259088|ACTIVE_COMPARATOR|Laser|Laser photocoagulation applied to the study eye at Day 1, followed by active laser photocoagulation at intervals no shorter than 3 months apart, plus sham injections
62256599|NCT02486978|PLACEBO_COMPARATOR|Control (no supplement)|Reference will be white bread to give 50 g available carbohydrates with placebo capsule
62838815|NCT04518358|EXPERIMENTAL|Evaluation of Expert Guiding Technology|
62054535|NCT02026856||Se-OI <200|patients who received form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was lower than 200
62054536|NCT02026856||Placebo-OI> 200|patients who received continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was higher than 200
62256600|NCT02486978|EXPERIMENTAL|Dose 1|Test will comprise white bread to give 50 g available carbohydrates and one capsule of pomegranate/olive and one capsule placebo
62256601|NCT02486978|EXPERIMENTAL|Dose 2|Test will comprise white bread to give 50 g available carbohydrates and 2 capsules of pomegranate/olive.
62256602|NCT05891925|EXPERIMENTAL|older_adults_CRC|Over 30 healthy community-dwelling older adults belonging to a Community Rehabilitation Center (CRC) at Concepcion, Chile.
62256603|NCT03700281|NO_INTERVENTION|Control|No intervention
62256604|NCT03700281|EXPERIMENTAL|Messaging|Group will be sent flu vaccine promotion messages via text, email and U.S. Mail
62256605|NCT03700281|EXPERIMENTAL|Messaging plus incentive|Group will be sent flu vaccine promotion messages via text, email and U.S. Mail, and will be eligible to receive a gift card as incentive for receiving flu vaccine
62256606|NCT05459454|EXPERIMENTAL|Digital intervention group|"Participants will be instructed to download the Sidekick Health app and receive a code to access the 14-week digital intervention in addition to standard of care, as is defined for the control arm.~Beyond this, all patients in the interventional arm will also receive standard of care as defined for the control arm."
62256607|NCT05459454|NO_INTERVENTION|Standard of Care|The control arm will receive standard of care treatment. Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.
62256608|NCT01186120|EXPERIMENTAL|Biolimus A9-eluting stent|NOBORI stent
62256609|NCT01186120|ACTIVE_COMPARATOR|Everolimus-eluting stent|PROMUS ELEMENTE stent
62256610|NCT03675035|EXPERIMENTAL|Endomina|Reduction trough sutures of the gastro-jejunal anastomosis
62256611|NCT01628757||neoadjuvant chemotherapy|
62256612|NCT02605187|ACTIVE_COMPARATOR|No choice|No choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
62256613|NCT02605187|EXPERIMENTAL|Choice: low protocol|Choice given low dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
62256614|NCT02605187|EXPERIMENTAL|Choice: medium protocol|Choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
62256615|NCT02605187|EXPERIMENTAL|Choice: high protocol|Choice given high dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h gabapentin po one time dose
62444061|NCT05322564|NO_INTERVENTION|Standard of care cohort|Eligible wrist and ankle fracture patients booked for open reduction and internal fixation through our emergency day surgery program will be recruited and consented via telephone prior to their surgery date. The study participants will receive a post-operative prescription at the discretion of their attending surgeon, fellow or resident, with no intervention from the researchers involved in this study. On post-operative day three and post-operative day ten, these patients will be contacted by phone by the research team and asked to respond verbally to a questionnaire. Measures including quantity of opiates consumed, pain intensity and satisfaction with pain treatment will be recorded.
62256616|NCT02056197|PLACEBO_COMPARATOR|Placebo|Shortwave 30 minutes.
62256617|NCT02056197|ACTIVE_COMPARATOR|Stable|Stable surface exercises
62256618|NCT02056197|EXPERIMENTAL|Unstable|Unstable surface exercises
62256619|NCT02700412|EXPERIMENTAL|Epidiolex 100 milligram/milliliter (mg/mL) oral solution|"Participants will receive a CBD starting dose of 5 mg/kg/day in twice daily dosing and titrate by 5 mg/kg/2 weeks up to 25 mg/kg/day. Additional increases in dosing, by 5 mg/kg/day up to a maximum of 50 mg/kg/day, may be instituted at the discretion of the treating Principle Investigator (PI).~If a subject experiences a clinically significant or dose limiting adverse event (AE) or severe adverse event (SAE) attributable to CBD, the investigator will determine if a dose reduction or taper is necessary (decreases will occur in 5 mg/kg/2 week increments or at a rate felt appropriate by the treating PI)."
62256620|NCT00071942|EXPERIMENTAL|Treatment (vaccine therapy)|Patients receive vaccination comprising recombinant vaccinia-MUC-1 and recombinant vaccinia-TRICOM vaccine intradermally on days 1 and 29 (for a total of 2 doses) in the absence of disease progression or unacceptable toxicity.
62838816|NCT02189733|EXPERIMENTAL|Caplacizumab - Treatment A|Single s.c. dose of reconstituted lyophilized solution of caplacizumab followed by single s.c. dose of liquid formulation of caplacizumab
62838817|NCT02189733|EXPERIMENTAL|Caplacizumab - Treatment B|Single s.c. dose of liquid formulation of caplacizumab followed by single s.c. dose of reconstituted lyophilized solution of caplacizumab
62054537|NCT02026856||Placebo-OI <200|patients who who received continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was lower than 200
62613764|NCT06730828|NO_INTERVENTION|Group 1: 20 subjects in the control group, which is the standard of care (i.e., no CardiaMend-Amioda|Subjects in treatment Group 1 (control) will receive no CardiaMend-Amiodarone patches.
62838818|NCT02117661|EXPERIMENTAL|L-carnitine capsules|2000 mg daily (2x 500 mg capsules twice a day - BID) for six months
62054538|NCT03034343|EXPERIMENTAL|TAU+mindfulness applied face to face|4 sessions of 90 minutes/session Mindfulness based intervention applied in groups of 10-12 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is one month.
62256621|NCT05796908|EXPERIMENTAL|Aptis PRUJ Prothesis|Investigational Aptis PRUJ Prothesis treatment
62256622|NCT02691208|EXPERIMENTAL|Group I Kinesiotherapy|women with pain treated with a predefinided exercises protocol of 30 minutes.
62256623|NCT02691208|EXPERIMENTAL|Group II Acupuncture|women with pain treated with a predefinided exercises protocol of 30 minutes followed by 30 minutes of acupuncture, used in predefined points
62256624|NCT00215995|EXPERIMENTAL|Cisplatin, Irinotecan and ZD1839|As outlined in Detailed Description.
62256625|NCT01382797|PLACEBO_COMPARATOR|Placebo|Capsules for oral administration
62613765|NCT06730828|EXPERIMENTAL|Group 2: 20 subjects receiving CardiaMend-Amiodarone infused with 70 mg of amiodarone|"Subjects in Group 2 (70 mg) will receive three patches each as follows:~* One patch (5x6 cm) will be placed on top of the right atrium;~* One patch (3x5 cm) will be placed within the transverse sinus near the dome of the left atrium; and~* One patch (3x5 cm) will be placed within the oblique sinus on the posterior/inferior aspect of left atrium"
62256626|NCT01382797|EXPERIMENTAL|ALKS 37|Capsules for oral administration
62256627|NCT03271814|EXPERIMENTAL|LPS-Patient|Schizophrenia patients who are randomized to receive LPS injection.
62838819|NCT02117661|PLACEBO_COMPARATOR|Cellulose capsules|2x capsules twice a day - BID (4 total per day) for six months
62838820|NCT03524118|EXPERIMENTAL|Panel A: Pre-term clesrovimab Dose 1|Pre-term infants will receive clesrovimab Dose 1 via intramuscular (IM) injection and will be followed for up to 365 days.
62838821|NCT03524118|EXPERIMENTAL|Panel B: Pre-term clesrovimab Dose 2|Pre-term infants will receive clesrovimab Dose 2 via IM injection and will be followed for up to 365 days.
62838822|NCT03524118|EXPERIMENTAL|Panel C: Pre-term clesrovimab Dose 3|Pre-term infants will receive clesrovimab Dose 3 via IM injection and will be followed for up to 365 days.
62838823|NCT03524118|EXPERIMENTAL|Panel D1: Pre-term clesrovimab Dose 4|Pre-term infants enrolled prior to AM4 will receive clesrovimab Dose 4 via IM injection and will be followed for up to 365 days.
62054539|NCT03034343|EXPERIMENTAL|TAU + Mindfulness ICTs intervention|4 sessions of 60 minutes/session Mindfulness based intervention applied by ICTs (Internet-based program). The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the online program is two months.
62054540|NCT03034343|NO_INTERVENTION|Usual medical treatment (TAU)|In this group the general practitioner will apply the usual treatment (medication) but there will be no psychological treatment.
62054541|NCT03654781|ACTIVE_COMPARATOR|Triple therapy|Conventional triple antibiotic treatment would be applied to all patients (consisted of a 10-day course of Lansoprazole (a proton pump inhibitor) combined with amoxicillin ( 2 × 1 g daily) and clarithromycin (2 × 500 mg daily).
62054542|NCT03654781|EXPERIMENTAL|Combined treatment|"Periodontal treatment would be administered in addition to triple therapy consisted of a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).~Periodontal treatment consisted of supra and sub gingival scaling and root planing, oral hygiene instruction"
62054543|NCT02487498|EXPERIMENTAL|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
62054544|NCT02487498|EXPERIMENTAL|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
62838824|NCT03524118|EXPERIMENTAL|Panel D2: Pre-term clesrovimab Dose 4|Pre-term infants enrolled after AM4 will receive clesrovimab Dose 4 via IM injection and will be followed for up to 545 days.
62838825|NCT03524118|EXPERIMENTAL|Panel E1: Full-term clesrovimab Dose 4|Full-term infants enrolled prior to AM4 will receive clesrovimab Dose 4 via IM injection and will be followed for up to 365 days.
62838826|NCT03524118|EXPERIMENTAL|Panel E2: Full-term clesrovimab Dose 4|Full-term infants enrolled after AM4 will receive clesrovimab Dose 4 via IM injection and will be followed for up to 545 days.
62838827|NCT03524118|PLACEBO_COMPARATOR|Placebo|Pre-term infants will receive placebo via IM injection.
62838828|NCT02577718|EXPERIMENTAL|Nitroglycerin-Citrate-Ethanol (NiCE)|Antimicrobial Nitroglycerin-Citrate-Ethanol catheter lock solution was administered for 2 hours then flushed
62054545|NCT03895164|PLACEBO_COMPARATOR|Standard NE|Control Group will receive standard nutrition education package from primary health care.
62256628|NCT03271814|ACTIVE_COMPARATOR|LPS-Healthy|Healthy controls who are randomized to receive LPS injection.
62256629|NCT03271814|PLACEBO_COMPARATOR|Placebo-Patient|Schizophrenia patients who are randomized to receive placebo injection.
62256630|NCT02799407|NO_INTERVENTION|Traditional Long Form Consent|Participants will receive the traditional long-form consent form.
62256631|NCT02799407|EXPERIMENTAL|ResearchKit Consent|Participants will receive the Apple ResearchKit consent form.
62256632|NCT02427451|EXPERIMENTAL|Treatment (obinutuzumab, ibrutinib, Bcl-2 inhibitor GDC-0199)|Patients receive obinutuzumab IV on day 1 (days 1, 2, 8, and 15 for course 1 only) every 28 days for up to 8 courses. Beginning in course 2, patients receive ibrutinib PO QD on days 1-28. Beginning in course 3, patients receive Bcl-2 inhibitor GDC-0199 PO QD on days 1-28. Treatment repeats every 28 days for up to 14 courses in the absence of disease progression or unacceptable toxicity.
62256633|NCT03364244||Sildenafil|Pediatric patients receiving Revatio
62838829|NCT05727852||Experimental: patients with chronic respiratory diseases|"Included patients, aged ≥ 18 years, with chronic respiratory diseases: COPD, bronchial asthma, cystic fibrosis, lymphangioleiomyomatosis, hypersensitivity pneumonitis and other interstitial lung diseases.~Intervention: breath analysis using the Compact PTR-MS proton mass spectrometer by Ionicon (Austria); electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark; assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of electrocardiogram (ECG), phonocardiogram (PCG) and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs.~Interventions:~Diagnostic Test: Breath analysis using the Compact PTR-MS proton mass spectrometer; Diagnostic Test: Portable cardiac monitor CardioQvark; Diagnostic Test: Assessment of arterial stiffness using the VaSera VS-1500N."
62256634|NCT05069883|EXPERIMENTAL|Oral Steroid|In this group oral steroids were given after Direct vision internal urethrotomy
62256635|NCT05069883|PLACEBO_COMPARATOR|No Oral Steroids|In this group no oral steroids were given after Direct vision internal urethrotomy
62838830|NCT05727852||Active Comparator: Control|"Included subjects, aged ≥ 18 years.~Intervention: breath analysis using the Compact PTR-MS proton mass spectrometer by Ionicon (Austria); electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark; assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of ECG, phonocardiogram (PCG) and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs.~Interventions:~Diagnostic Test: Breath analysis using the Compact PTR-MS proton mass spectrometer; Diagnostic Test: Portable cardiac monitor CardioQvark; Diagnostic Test: Assessment of arterial stiffness using the VaSera VS-1500N."
62838831|NCT02114073|EXPERIMENTAL|Cyclosporine|In the first postoperative day following a standard, fornix-based trabeculectomy, ophthalmic emulsion of Cyclosporine A, 2%, every 4 hours for the first postoperative week and every 6 hours for the next 3 weeks will be prescribed for the patients.
62838832|NCT02114073|ACTIVE_COMPARATOR|Betamethasone|In the first postoperative day following a standard, fornix-based trabeculectomy, betamethasone eye drop, every 4 hours for the first postoperative week and every 6 hours for the next 3 weeks will be prescribed for the patients.
62838833|NCT05726708|EXPERIMENTAL|E-Learning|E-Learning coaching. 11 modules on line. 5 debriefing on visio conference with a professional (1/month)
62838834|NCT05726708|ACTIVE_COMPARATOR|Paediatric Autism Communication Therapy (PACT)|Parents will have 12 coaching sessions with a therapist, following the PACT model. Between each session, the parent will be asked to practice the strategies at home and to film themselves doing an activity with their child (10-minute film).
62054546|NCT03895164|EXPERIMENTAL|Enhanced NE|Intervention Group will receive standard nutrition education package from primary health care enhanced with local specific food-based complementary feeding recommendation
62054547|NCT06277479||AlloHSCT Rigshospitalet|All patients treated at Department of Hematology, Rigshospitalet
62054548|NCT06277479||AlloHSCT Skejby|All patients treated at Department of Hematology, Skejby
62054549|NCT03507621||Propofol Group|1- Propofol Group: Propofol group will use 1 mg / kg propofol for the patient.Preoperative blood will be taken from the patients and cortisol, acth, glucagon, aldosterone, adrenalin, noradrenalin, PGE2, CRH will be studied. During the operation, the patient's systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, oxygen saturation will be followed. Analgesia will be provided according to the body movements of the patient and VAS measurement will be performed. Remifentanyl will be used as a anelgesic 0.5 mcg/ kg during operation. The patient's pain will be assessed by the VAS (Visuel Analogue Scale) scoring system and during the first hour postoperatively after the patient's consciousness is complete .
62054550|NCT03507621||Sevoflurane Group|1- Sevofluran Group: sevoflurane was administered at one minimum alveolar concentration (MAC) to end-tidal concentrations of 3% to 5%.Preoperative blood will be taken from the patients and cortisol, acth, glucagon, aldosterone, adrenalin, noradrenalin, PGE2, CRH will be studied. During the operation, the patient's systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, oxygen saturation will be followed. Analgesia will be provided according to the body movements of the patient and VAS measurement will be performed. Remifentanyl will be used as a anelgesic 0.5 mcg/ kg during operation. The patient's pain will be assessed by the VAS (Visuel Analogue Scale) scoring system and during the first hour postoperatively after the patient's consciousness is complete.
62054551|NCT06484569|ACTIVE_COMPARATOR|control|They will receive ergonomics training
62054552|NCT06484569|EXPERIMENTAL|exercise|Ergonomics training, exercise training and cranio sacral therapy will be applied
62054553|NCT01493687|EXPERIMENTAL|CD5024|CD5024 1% Cream
62256636|NCT03358199||Study group|PCOS women with AMH level (≥ 7 ng/ml) who underwent LOD in the preceding 3 months prior to IVF/ICSI
62838835|NCT05726708|NO_INTERVENTION|Control|No parental coaching
62838836|NCT02149043||Ulcerative Colitis patients|30 patients with active ulcerative colitis will be put throe thermography and colonoscopy. Their stool will be tested for fecal calprotectin and their blood for CRP and other laboratory measures.
62054554|NCT01493687|PLACEBO_COMPARATOR|CD5024 Vehicle|CD5024 Vehicle Cream
62256637|NCT03358199||Control group|PCOS women with AMH level (≥ 7 ng/ml) who did not undergo LOD in the preceding 3 months prior to IVF/ICSI
62256638|NCT03173859|EXPERIMENTAL|Rotational|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 for 3 cycles, followed by apalutamide 240mg qD orally for 3 cycles. The duration of each cycle is 28 days
62256639|NCT03173859|ACTIVE_COMPARATOR|Sequential|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 until disease progression, followed by apalutamide 240mg qD orally until second disease progression.
62256640|NCT01795885|EXPERIMENTAL|16 and Pregnant|"Participants in this arm will be asked to watch an approximately 45-minute commercial-free episode of the show 16 and Pregnant once a week for 4 weeks."
62256641|NCT01371019||Women with preterm delivery|
62256642|NCT01371019||Women without preterm delivery|
62256643|NCT01365039|EXPERIMENTAL|Test lens|Test contact lens will be worn on a daily disposable wear basis.
62054555|NCT02877030|EXPERIMENTAL|Test control group|Start the sensorimotor exercises protocol with video game immediately after the first evaluation
62256644|NCT01365039|ACTIVE_COMPARATOR|SofLens lens|The currently marketed Bausch + Lomb SofLens daily disposable contact lens. Worn on a daily disposable wear basis.
62838837|NCT02149043||Healthy volunteers|30 healthy individuals matching sex and BMI to those of ulcerative colitis patients will be put throe thermography and have their stool tested for fecal calprotectin and their blood for CRP.
62838838|NCT02447523||Patients with metabolic syndrome|Patients fulfilling criteria to establish the diagnosis of metabolic syndrome
62838839|NCT02447523||Patients without metabolic syndrome|Patients not fulfilling criteria of the metabolic syndrome
62838840|NCT02694289|OTHER|Metformin|Continue Metformin while admitted to hospital
62838841|NCT02694289|OTHER|Subcutaneous (sliding scale) Insulin|Discontinue Metformin upon admission and be placed on sliding scale subcutaneous insulin treatment while admitted to hospital
62838842|NCT01419288|ACTIVE_COMPARATOR|No Body weight support|
62838843|NCT01419288|EXPERIMENTAL|Body weight support|
62838844|NCT01678235|EXPERIMENTAL|GLU_ASP|"Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.~First day: insulin glulisine~Second day: insulin aspart"
62838845|NCT01678235|EXPERIMENTAL|ASP_GLU|"Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.~First day: insulin aspart~Second day: insulin glulisine"
62838846|NCT00196313|EXPERIMENTAL|1 levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablet|
62838847|NCT00196313|PLACEBO_COMPARATOR|2|
62838848|NCT02292589|EXPERIMENTAL|Frontal Stimulation|Left dorsolateral prefrontal cortex stimulation
62838849|NCT02292589|EXPERIMENTAL|Temporal Stimulation|Left temporal cortex stimulation
62838850|NCT02292589|EXPERIMENTAL|Sham Stimulation|Sham stimulation
62613766|NCT06730828|EXPERIMENTAL|Group 3: 20 subjects receiving CardiaMend-Amiodarone infused with 150 mg of amiodarone.|"Subjects in Group 3 (150 mg) will receive three patches each as follows:~* One patch (5x6 cm) will be placed on top of the right atrium;~* One patch (3x5 cm) will be placed within the transverse sinus near the dome of the left atrium; and~* One patch (3x5 cm) will be placed within the oblique sinus on the posterior/inferior aspect of left atrium"
62838851|NCT01898559|EXPERIMENTAL|Black & Mild little cigars|"Participants switch from smoking their own brand of cigarettes to only smoking Black \& Mild little cigars.~Other: Switch to smoking only little cigars"
62838852|NCT01898559|EXPERIMENTAL|King Edward little cigars|"Participants switch from smoking their own brand of cigarettes to only smoking King Edward little cigars.~Other: Switch to smoking only little cigars"
62838853|NCT06045702||Group control|Adult patients with no genetic pathology other than male infertility of any type leading to an inability to procreate without medical assistance, and requiring surgery to recover spermatozoa for possible in vitro fertilization.
62838854|NCT06045702||CFTR-associated pathology|Major patients with cystic fibrosis or male infertility due to agenesis of the vas deferens. These patients will be included in the study because they have the prospect of procreation by in vitro fertilisation requiring surgery to recover spermatozoa.
62054556|NCT02877030|ACTIVE_COMPARATOR|Control test group|Start of sensorimotor exercises with video game protocol after ten weeks
62054557|NCT02877030|NO_INTERVENTION|comparison group|No intervention
62054558|NCT05488275|ACTIVE_COMPARATOR|MPFL static|Medial Patellofemoral Ligament reconstruction with hamstring graft - static procedure
62054559|NCT05488275|ACTIVE_COMPARATOR|Campbell|Medial Patellofemoral Ligament reconstruction using non-anatomic reconstruction (quadriceps femoris plasty - Campbell method)
62613767|NCT06730828|EXPERIMENTAL|Group 4: 20 subjects receiving CardiaMend-Amiodarone infused with 300 mg of amiodarone.|"Subjects in Group 4 (300 mg) will receive three patches each as follows:~* One patch (5x6 cm) will be placed on top of the right atrium;~* One patch (3x5 cm) will be placed within the transverse sinus near the dome of the left atrium; and~* One patch (3x5 cm) will be placed within the oblique sinus on the posterior/inferior aspect of left atrium"
62838855|NCT03532204|EXPERIMENTAL|Chemotherapy + SBRT|"Patients will received 2 courses of chemotherapy before SBRT if no hepatic or extra-hepatic progression identified.~All liver metastases will be irradiated. 4 doses prescription are allowed (according to the center, and the technique uded and the dosimetric constraints): 3x15 Gy, 4 x 15 Gy, 5 x10 Gy or 5 x 8 Gy.~The remaining courses of chemotherapy 2 to 3 weeks after completion of SBRT will be administered"
62838856|NCT03532204|ACTIVE_COMPARATOR|Chemotherapy|Patients will receive chemotherapy as initially scheduled
62838857|NCT04300166|ACTIVE_COMPARATOR|Telemedicine & Humidification Intervention|"In the telemedicine intervention arm, a telemetry device is instructed and attached to the CPAP. Patients are instructed to use CPAP every night. Data of the CPAP are downloaded to the internet once daily. On week days, a nurse/sleep technologist is checking the downloaded data three times per week. The contacts will be due to:~1. CPAP usage \<4h/ night for 3 consecutive night~2. the median leakage was above 0.4 L/sec on 3 consecutive nights The nurse/sleep technologist informs the patient of the problem observed, asks for explanations and gives advice on possibilities to solve the problem. The common problems and the respective solutions (Dry mouth/throat, nasal congestion, skin irritation, conjunctivitis, headache, loss of benefits) will be discussed. The patient is encouraged to use CPAP every night. In the case of adherence \>4h/night and acceptable leakage, a congratulatory message is sent to the patient via sms or e-mail."
62838858|NCT04300166|NO_INTERVENTION|Control without Telemedicine & humidification|In the control arm, no wireless telemedicine and humidifier will be used with CPAP but data stored in the CPAP machine are collected at the follow-up visit after 1 month
62838859|NCT06001957||Proband|Patient with extremely giant coronary artery ectasia (CAE) and positive family history
62838860|NCT02340364|EXPERIMENTAL|Education + PN Arm|208 patients randomized to self-care education+ Patient navigator-delivered self-care plan.
62838861|NCT02340364|ACTIVE_COMPARATOR|Educational Control Arm|- 208 patients randomized to self-care education alone.
62054560|NCT05488275|ACTIVE_COMPARATOR|MPFL dynamic|Medial Patellofemoral Ligament reconstruction with hamstring graft - dynamic procedure
62054561|NCT01674309|OTHER|single arm study/ non randomized trial|FOLFORINOX
62054562|NCT03738839|EXPERIMENTAL|Direct Bonding|On the individual teeth Conventional bracket placement Use conventional composite
62838862|NCT02842489|EXPERIMENTAL|left lateral tilt-down position|patients will be positioned on left lateral tilt-down position during colonoscopy until sigmoid-descending junction were examined, and then patients will be positioned on the left lateral horizontal position during colonoscopy
62838863|NCT02842489|ACTIVE_COMPARATOR|left lateral horizontal body position|patients will be positioned on the left lateral horizontal position during colonoscopy insertion
62838864|NCT02354053|ACTIVE_COMPARATOR|Current ART|Current ART + adherence support
62838865|NCT02354053|EXPERIMENTAL|Triumeq|Triumeq + adherence support
62838866|NCT01587924|EXPERIMENTAL|0.5 mg GSK1278863|once daily
62838867|NCT01587924|EXPERIMENTAL|2 mg GSK1278863|once daily
62054563|NCT03738839|EXPERIMENTAL|Indirect bonding|On the dental stone models Indirect bracket placement Use flowable composite Use transfer trays
62054564|NCT03738839|ACTIVE_COMPARATOR|Quantitative Light-Induced Fluorescence|Use special device and software Determination of the number and effect of caries
62054565|NCT01059643|EXPERIMENTAL|LY2523355|
62054566|NCT04034108|EXPERIMENTAL|Experiment group|All the patients were classified as AIS-A at the time of admission to the clinical center. The MRI was performed in all cases prior to and after the surgery. Surgeries were performed between 12 hours to 30 days after trauma. At 15 days after surgery, with protection of a tailored chest-waist cast made of polyurethane 8 foam for thoracic/lumbar injuries or a neck support for cervical injuries, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers.
62838868|NCT01587924|EXPERIMENTAL|5 mg GSK1278863|once daily
62838869|NCT01587924|ACTIVE_COMPARATOR|rhEPO|as required
62838870|NCT03590821|EXPERIMENTAL|Aspirin 81 mg/Placebo|Participants will receive aspirin in Phase 1 followed by matched placebo in Phase 2, or vice versa, over 14 days. The order will be randomized and aspirin/placebo will be double-blinded.
62838871|NCT03590821|EXPERIMENTAL|Celecoxib 200mg capsule|Participants will receive celecoxib in Phase 1 and Phase 2 over 7 days. This is open, meaning participant and investigator will recognize celecoxib capsules.
62838872|NCT05605886|PLACEBO_COMPARATOR|first group: (Control group)|"1. EMG will be performed for masseter \& temporalis muscles at the diagnosis appointment.~2. Patients will recieve a daily placebo tablet in the morning after breakfast for 4 days prior to injections.~3. Patients will receive a one-time treatment of 50 units of BoNT-A, the dose will be injected into the bilateral masseter muscles (16.7 units each masseter) and 1/3 into the bilateral temporalis (8.3 units each temporalis).~4. Follow up will be performed using EMG for the masseter and temporalis muscles 4 months after the BoNT-A injection."
62838873|NCT05605886|ACTIVE_COMPARATOR|second group. (intervention group)|"1. EMG will be performed for masseter \& temporalis muscles at the diagnosis appointment.~2. Patients will receive a daily zinc supplement tablets of 50 mg in the morning after breakfast for 4 days prior to injections.~3. Patients will receive a one-time treatment of 50 units of BoNT-A, the dose will be injected into the bilateral masseter muscles (16.7 units each masseter) and 1/3 into the bilateral temporalis (8.3 units each temporalis).~4. Follow up will be performed using EMG for the masseter and temporalis muscles 4 months after the BoNT-A injection."
62838874|NCT05842096|ACTIVE_COMPARATOR|Polycystic ovary syndrome (PCOS)|Women meeting the Rotterdam-ESHRE-ASRM criteria for a diagnosis of PCOS
62838875|NCT05842096|ACTIVE_COMPARATOR|Hypothalamic-Pituitary-Ovarian Axis Dysfunction (HPOD)|Women meeting the WHO criteria for a diagnosis of HPOD
62054567|NCT06303076|EXPERIMENTAL|Tizanidine Group|Participants will be asked to ingest Tinazidine, orally at home immediately before going to bed to sleep. Initially, the patients will be asked to ingest 2 mg HS, and it will be titrated up by 2 mg every 4 days, as per response and tolerability, up to a maximum dose of 0.1 mg/kg/HS.
62054568|NCT06303076|ACTIVE_COMPARATOR|Zolpidem Group|Participants will be asked to ingest Zolpidem 10 mg HS, orally at home before bedtime.
62256645|NCT00545298|NO_INTERVENTION|A - Standard of Care (control)|Standard of care - dressings and sustained compression only
62613768|NCT03705845|PLACEBO_COMPARATOR|Control|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
62838876|NCT05291312|OTHER|endoscopic assisted coblation|
62838877|NCT05291312|OTHER|conventional curettage|
62838878|NCT03807856|ACTIVE_COMPARATOR|Dabigatran Etexilate Mesylate|Dabigatran 150mg BID for 3 days
62838879|NCT03807856|ACTIVE_COMPARATOR|Standard of Care|Standard treatment for acute pancreatitis
62838880|NCT04727307|EXPERIMENTAL|Neoadjuvant Atezolizumab before radiofrequency ablation then adjuvant Atezolizumab + Bevacizumab|Neoadjuvant atezolizumab and adjuvant atezolizumab + bevacizumab in combination with percutaneous radiofrequency ablation
62838881|NCT04727307|ACTIVE_COMPARATOR|Percutaneous radiofrequency ablation|Percutaneous radiofrequency ablation, standard treatment
62613769|NCT03705845|ACTIVE_COMPARATOR|Intervention|One 430 mg tocotrienol softgel daily for 24 weeks. Each tocotrienol softgel (DeltaGold® Tocotrienol 70%) contains 430 mg tocotrienol (90% δ-tocotrienol+10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
62838882|NCT02905890|EXPERIMENTAL|Norethisterone enanthate plus condoms|200 mg Norethisterone enanthate intramuscularly every eight weeks at enrolment, 2 and 4 months. Counseling and condoms will be provided at enrolment, 1, 2, 3 and 4 months.
62838883|NCT02905890|ACTIVE_COMPARATOR|Condoms only|Counseling and condoms will be provided at enrolment, 1, 2, 3 and 4 months.
62444062|NCT05322564|EXPERIMENTAL|Standardized prescription cohort|Using the data collected from the standard of care cohort, a standardized pain prescription will be created. The average quantity of opiates consumed by the standard of care participants will be used to guide the quantity of opiates to be prescribed on the standardized prescription. In this arm, all eligible patients will be contacted and recruited by telephone prior to their surgery. These patients will be flagged on the day of surgery and given the standardized prescription post-operatively. They will then be asked to respond to the same questionnaires as the standard of care cohort via telephone on post-op day three and post-op day ten.
62613770|NCT03887117|ACTIVE_COMPARATOR|IQOS-1|"IQOS + Exercise Training Program~Subjects randomized to IQOS use will switch to IQOS use and participate in an exercise training program."
62838884|NCT05237076|EXPERIMENTAL|Diabetes Type 2|Patients with DM Type 2 using Oral Diabetes Medications only.
62838885|NCT05237076|ACTIVE_COMPARATOR|Healthy controls|Healthy controls without comorbidities.
62838886|NCT03983356|EXPERIMENTAL|Group of GPs receiving training|GPs, psychologists and social workers in the intervention regions will receive a training program.
62838887|NCT03983356|NO_INTERVENTION|Group of GPs receiving no attention|GPs, psychologists and social workers in the control regions will not receive information about the intervention.
62838888|NCT01052701|ACTIVE_COMPARATOR|Ribavirin plus Abacavir|Ribavirin plus Abacavir Administration intervention
62838889|NCT01052701|ACTIVE_COMPARATOR|Ribavirin alone|Ribavirin alone administration
62838890|NCT01168986|ACTIVE_COMPARATOR|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
62838891|NCT01168986|ACTIVE_COMPARATOR|Exercise|Participants perform an exercise to strengthen the deep neck flexors
62838892|NCT01168986|NO_INTERVENTION|No intervention|Participants receive/perform no intervention
62838893|NCT02461277|ACTIVE_COMPARATOR|Fast-track protocol|Before surgery, patients are informed about the surgical procedure, anesthesia and rehabilitation protocol. The surgery occurs in accordance with the principles of the Fast-track: minimal invasive surgery, epidural anesthetic management, avoiding the need opioid in postoperatory analgesia and use of an standardized postoperatory management protocol to an early oral intake and early mobilization.
62838894|NCT02461277|NO_INTERVENTION|Conventional care|Usual care routine postoperative
62838895|NCT04782479||in the air|the position of the practitioner's hand holding the tube was placed in the air while the assistant pulling back the stylet.
62838896|NCT04782479||on the cheek of a manikin|the position of the practitioner's hand holding the tube was placed on the cheek of a manikin while the assistant pulling back the stylet.
62838897|NCT06385626|EXPERIMENTAL|sucrose + raspberry leaf tea|Volunteers will be asked to consume 50 g of sucrose with 10 g of raspberry leaf tea dissolved in 300 mL of warm water.
62838898|NCT06385626|EXPERIMENTAL|glucose + raspberry leaf tea|Volunteers will be asked to consume 50 g of glucose with10 g of raspberry leaf tea dissolved in 300 mL of warm water.
62838899|NCT06385626|ACTIVE_COMPARATOR|sucrose|Volunteers will be asked to consume 50 g of sucrose without 10 g of raspberry leaf tea
62054569|NCT01758835|ACTIVE_COMPARATOR|Splint 3 weeks|Removable ankle brace/splint
62054570|NCT01758835|ACTIVE_COMPARATOR|Cast 3 weeks|Below-the-knee cast (glass fiber)
62256646|NCT00545298|EXPERIMENTAL|B Same treatment for 6 weeks|200ppm NO gas 8hrs/day 6 weeks NO gas in nitrogen is delivered constantly to a patch over the wound
62256647|NCT00545298|EXPERIMENTAL|C - modified treatment, 5 wks lower dose|200 ppm No gas 8 hrs/day 1 wk, 20ppm 8hrs/day 5 weeks Gas is NO in nitrogen delivered constantly for 8 hours to a patch over the wound
62256648|NCT02371239|EXPERIMENTAL|Sitting regime|The subjects will follow the sitting regime during four days. Each day: 14 hours sitting, 1 hour walking and 1 hour standing for daily care and 8 hours sleeping or lying.
62256649|NCT02371239|EXPERIMENTAL|Sit Less regime|Subjects will follow the sit less regime during four days. Each day will consist of 3 hours walking, 4 hours standing, 9 hours sitting and 8 hours sleeping or lying. The additional 2 hours of walking and 3 hours of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of \> 1 hour. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.
62838900|NCT06385626|ACTIVE_COMPARATOR|glucose|Volunteers will be asked to consume 50 g of glucose without 10 g of raspberry leaf tea
62054571|NCT01758835|ACTIVE_COMPARATOR|Cast 6 weeks|Below-the-knee cast (glass fiber)
62054572|NCT04452292|ACTIVE_COMPARATOR|No TP53/Rb1 Co-Mutation|HG-LCNEC tumor lacking the TP53/Rb1 co-mutation (non-small cell-like).
62054573|NCT04452292|EXPERIMENTAL|TP53/Rb1 Co-Mutation Present|HG-LCNEC tumor with the TP53/Rb1 co-mutation.
62613771|NCT03887117|ACTIVE_COMPARATOR|IQOS-2|"IQOS without Exercise Training Program~Subjects randomized to IQOS use will switch to IQOS use, but will not participate in an exercise training program."
62613772|NCT03887117|ACTIVE_COMPARATOR|Cigarette Smoking|"Cigarette Smoking + Exercise Training Program~Subjects randomized to continued cigarette smoking and participation in an exercise training program."
62613773|NCT03887117|ACTIVE_COMPARATOR|Smoking Abstinence|"Smoking Abstinence + Exercise Training Program~Subjects randomized to smoking abstinence and participation in an exercise training program."
62613774|NCT00871364|EXPERIMENTAL|A|VENLAFAXINE TABLETS 50 mg, single dose
62613775|NCT00871364|ACTIVE_COMPARATOR|B|Effexor® (venlafaxine HCl) Tablets equivalent to 50 mg venlafaxine, single dose
62613776|NCT02097459|EXPERIMENTAL|Failed group|Patients who have recurrence of menstruation after changing endocrine therapy to anastrozole and then go back to the original SERMs therapy.
62613777|NCT02097459|EXPERIMENTAL|Succeeded group|Patients who have no recurrence of menstruation after changing endocrine therapy and then go on with anastrozole therapy.
62613778|NCT02097459|ACTIVE_COMPARATOR|No chang group|Patients who don't change the endocrine therapy and go on with the original tamoxifen or toremifene therapy.
62838901|NCT03248206|ACTIVE_COMPARATOR|PNF exercise program group|The PNF home-program exercise group: perform grade 1\&2 two times a day, at least 3 times per week, for 3 sets of 12 repetitions to increase neuromuscular and musculoskeletal endurance. (Grade 1: The participants performs the diagonal- spiral pattern that will enhance the strength or movement of a targeted muscle or muscle group.; Grade 2:The participants performs PNF exercise with elastic bands . )
62838902|NCT03248206|EXPERIMENTAL|PNF in conjunction with tendon gliding exercise group|Patients in PNF in conjunction with TGE group will perform PNF grade 1\&2 as well as tendon gliding exercise two times a day, at least 3 times per week, for 3 sets of 10 repetitions. Training duration for both the two groups is twelve weeks.
62838903|NCT01708902|EXPERIMENTAL|linagliptin2.5mg / metformin500mg BID|patient to receive a tablet containing linagliptin 2.5mg and metformin 500mg BID
62613779|NCT02249013|EXPERIMENTAL|HIPEC|Neoadjuvant Chemotherapy (NACT) followed by Cytoreductive Surgery (CRS) under a Fast-track recovery strategy plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and thus, Adjuvant Chemotherapy
62613780|NCT02477709|EXPERIMENTAL|Gefapixant|Gefapixant oral tablets (150 mg) administered as a single dose
62613781|NCT02238938|EXPERIMENTAL|en-bloc resection|En- bloc resection is done after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily. Since the aim of this method is the total resection basally and laterally, only one session is intended.
62613782|NCT02238938|ACTIVE_COMPARATOR|piecemeal resection|"Piecemeal resection will be done by snare following marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps. High resolution endoscopes are mandatory.~After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done. This second session can be done by sigmoidoscopy."
62613783|NCT02940873|EXPERIMENTAL|HARPdoc courses|Hypoglycaemia Awareness Restoration Programme for adults with type 1 diabetes and problematic hypoglycaemia persisting despite optimised self-care (HARPdoc) - a combination of structured education around hypoglycaemia recognition, avoidance and treatment combined with hypoglycaemia-focussed cognitive behavioural therapy, delivered by diabetes educators, supported by a clinical psychologist, to small groups of eligible adults.
62838904|NCT01708902|EXPERIMENTAL|linagliptin2.5mg / metformin1000mg BID|patient to receive a tablet containing linagliptin 2.5mg and metformin 1000mg BID
62838905|NCT01708902|ACTIVE_COMPARATOR|metformin 500mg BID|patient to receive a tablet containing metformin 500mg BID
62838906|NCT01708902|ACTIVE_COMPARATOR|metformin 1000mg BID|patient to receive a tablet containing metformin 1000mg BID
62838907|NCT01708902|ACTIVE_COMPARATOR|linagliptin 5 mg QD|patient to receive a tablet containing linagliptin 5mg once daily
62838908|NCT05853991|EXPERIMENTAL|Therapeutic touch|The intervention will be based on 2 phases: 1) assessment to identify areas following the NAME procedure, 2) treatment to improve the function of the area identified
62256650|NCT02371239|EXPERIMENTAL|Exercise regime|Subjects will follow the exercise regime during four days. Each day will consist of 13 hours and 15 minutes sitting, ± 45 minutes supervised cycling on an ergometer, 1 hour walking and 1 hour standing for daily care and 8 hours sleeping or lying.
62256651|NCT01699945||Verbal Autopsies|The study involves filling of verbal autopsies for still births and deaths in women of reproductive age group.
62256652|NCT03022695|EXPERIMENTAL|Treatment with high-intensity focused ultrasound|
62256653|NCT03078075|EXPERIMENTAL|Active Medication Combination (AMC)|injectable extended release naltrexone plus once daily oral extended-release bupropion tablets
62256654|NCT03078075|PLACEBO_COMPARATOR|Matched Placebo (PLB)|injectable matching placebo plus once-daily oral placebo tablets
62613784|NCT02940873|ACTIVE_COMPARATOR|BGAT courses|Blood Glucose Awareness Training is an existing psycho-educational program which coaches adults with type 1 diabetes better to predict and recognise extremes of plasma glucose - hyper- and hypo-glycaemia. It has been shown to reduce severe hypoglycaemia rates.
62613785|NCT03057067|EXPERIMENTAL|pelvic vein embolization|female patients referred for assessment of chronic pelvic pain at the gynecological outpatient clinic or the Multidisciplinary Pain Clinic at St. Olavs Hospital, Trondheim, Norway
62613786|NCT00870506|NO_INTERVENTION|2|No intervention (control)
62613787|NCT00870506|EXPERIMENTAL|1|5-minute video on donation and transplantation
62613788|NCT04183465|ACTIVE_COMPARATOR|Health Education|All patients randomized to health education during the inclusion visit are managed according to current guidelines and as follows. Quality of life, functional capacity and home physical activity are assessed by proper tools.
62613789|NCT04183465|EXPERIMENTAL|Multi-domain lifestyle intervention|All patients randomized to experimental arm will receive diet counselling, aggressive control of CV risk factors, smoke cessation program and exercise training. The physical activity (PA) intervention will start the program with a supervised PA session immediately after the inclusion visit. Quality of life, functional capacity and daily activities will be assessed by proper tools. The program provides 6 supervised PA sessions (30, 60, 90, 180, 270 and 360 days after hospital discharge \[T0\]). At the end of each supervised session, calisthenics exercises derived from Otago Exercise Program are prescribed.
62613790|NCT03173365|EXPERIMENTAL|Brimonidine Tartrate|The respective palm to be treated with Brimonidine will be randomly assessed and will be matched for handedness to include equal numbers of dominant and non-dominant treated palms.
62613791|NCT00758134|EXPERIMENTAL|A|Trastuzumab 6 mg/Kg
62613792|NCT00592592|EXPERIMENTAL|Proton Beam Radiation|Proton Beam Radiation
62613793|NCT03412006|EXPERIMENTAL|Fulacimstat (BAY1142524)|Patients have to have a clinical diagnosis of diabetic kidney disease and have to be treated with standard of care for this condition
62613794|NCT03412006|PLACEBO_COMPARATOR|Placebo|Patients have to have a clinical diagnosis of diabetic kidney disease and have to be treated with standard of care for this condition
62613795|NCT01063231|EXPERIMENTAL|1|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
62613796|NCT04277767||mild cognitive impairment (MCI)|observational
62613797|NCT04277767||Patients with mild to moderate AD|observational
62613798|NCT04277767||Normal controls|observational
62613799|NCT04214405|EXPERIMENTAL|union of fractures|proper union of zygomatic fractures
62613800|NCT05524038|ACTIVE_COMPARATOR|(QL) group|In (QL) group, (lateral Approach) :patient receive this block with 20 mg bupivacaine hydrochloride plus 4mg dexamethasone
62613801|NCT05524038|ACTIVE_COMPARATOR|(ESB) group|In (ESB) group, Erector Spinae Plane Block: patient receive this block with 20 mg bupivacaine hydrochloride plus 4mg dexamethasone
62613802|NCT04687566|EXPERIMENTAL|dextromethorphan|Dextromethorphan, 60 mg per day, once daily, for 12 weeks
62613803|NCT04687566|EXPERIMENTAL|memantine|Memantine, 5 mg per day, once daily, for 12 weeks
62613804|NCT04687566|EXPERIMENTAL|dextromethorphan and memantine|Dextromethorphan (60mg per day) and memantine (5 mg per day) combination, once daily, for 12 weeks
62613805|NCT04687566|PLACEBO_COMPARATOR|placebo|placebo, once daily, for 12 weeks
62256655|NCT04804514|EXPERIMENTAL|KH001|The study consists of sequential dosing cohorts, 8 subjects per cohort will be administered KH001 or placebo.
62256656|NCT04804514|PLACEBO_COMPARATOR|Placebo|The study consists of sequential dosing cohorts, 8 subjects per cohort will be administered KH001 or placebo.
62256657|NCT00097747|PLACEBO_COMPARATOR|Placebo|Single injection administered intravenously
62256658|NCT00097747|EXPERIMENTAL|Peginesatide 0.025 mg/kg|Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.
62256659|NCT00097747|EXPERIMENTAL|Peginesatide 0.05 mg/kg|Single peginesatide dose of 0.05 mg/kg administered intravenously.
62256660|NCT00097747|EXPERIMENTAL|Peginesatide 0.10 mg/kg|Single peginesatide dose of 0.10 mg/kg administered intravenously.
62256661|NCT02870049|EXPERIMENTAL|Inreach strategy|This consists of a community health worker-delivered in clinic education regrading CRC screening with a fecal immunochemical test (FIT) kit, and telephone reminders.
62256662|NCT02870049|EXPERIMENTAL|Outreach strategy|This consists of mailed invitations to complete screening with an enclosed fecal immunochemical test (FIT) kit and telephone reminders.
62256663|NCT02870049|EXPERIMENTAL|Both Inreach and Outreach strategies|This is a combination of the above two strategies: Inreach and Outreach combined.
62256664|NCT02870049|ACTIVE_COMPARATOR|Usual care|Usual care in the clinic using the fecal immunochemical test (FIT) kit.
62256665|NCT00554359|EXPERIMENTAL|I5NP drug|
62256666|NCT00554359|PLACEBO_COMPARATOR|Placebo|
62256667|NCT04142775||intracranial hemorrhage (ICH)|ARDS patients treated with ECMO developing ICH
62256668|NCT04142775||no intracranial hemorrhage|ARDS patients treated with ECMO not developing ICH
62613806|NCT01290198|PLACEBO_COMPARATOR|Vehicle without ANESDERM (lidocaine, prilocaine)|
62613807|NCT01290198|ACTIVE_COMPARATOR|Vehicle with ANESDERM (lidocaine, prilocaine)|
62613808|NCT01290198|ACTIVE_COMPARATOR|Fluconazole without ANESDERM (lidocaine, prilocaine)|
62613809|NCT01290198|ACTIVE_COMPARATOR|Fluconazole with ANESDERM (lidocaine, prilocaine)|
62613810|NCT04716504||Minimally invasive surgery for a benign or malignant pulmonary lesion.|"The patients will be divided in three categories depending on the Body Mass Index:~* Category 1: 18,5 kg/m2 \< BMI \< 24,9 kg/m2 -Category 2: 25 kg/m2 \< BMI \< 29,9 kg/m2 /~* Category 3: 30,0 kg/m2 \< BMI \< 34,9 kg/m2"
62613811|NCT04268628||Participants with mCRPC|Participants with metastatic castration resistant prostate cancer (mCRPC) will be evaluated for genetic polymorphism and pharmacodynamic parameters from serum and plasma samples collected during the Abira-DES study (NCT02217566). Serum and plasma samples were collected after use of diethylstilbestrol (DES) and subsequent abiraterone acetate therapy. Peripheral blood samples were collected prior to initiation of abiraterone acetate therapy, after 12 weeks of therapy, and at the time of disease progression (evaluated by prostate specific antigen \[PSA\] response).
62613812|NCT03739580|EXPERIMENTAL|drug-coating balloon|drug-coating balloon (Orchid) intervention
62613813|NCT03739580|ACTIVE_COMPARATOR|stent deployment|metal bare stent intervention
62613814|NCT05310526|EXPERIMENTAL|Intervention Group|"1. Distribution of the Brazilian cardioprotective diet manual to primary health care~2. Training to prescribe the cardioprotective Brazilian diet. the training consists of 5 face-to-face modules lasting 4 hours each, in addition to a virtual module and group exercises.~3. Audit feedback"
62613815|NCT05310526|NO_INTERVENTION|Control Group|Distribution of the Brazilian cardioprotective diet manual to primary health care professionals
62613816|NCT02550704|EXPERIMENTAL|Irritable Bowel Syndrome with diarrhea|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability. Intestinal permeability is not routinely performed and is assessed in colonic biopsies (occludin, claudin and ZO-1 by western blot, qPCR and immunofluorescence)
62613817|NCT00815425||African Americans with RA|1063 participants with RA
62613818|NCT00815425||African-Americans without RA|550 participants without RA
62054574|NCT04916600|EXPERIMENTAL|NET active|Active, non-invasive, alternating current transcutaneous stimulation through electrodes placed transcranially on the mastoid regions. Treatment is self-administered, with participant control of device output level and duration according to perceived benefit. Minimum treatment duration is one-hour, with self-administered extension not to exceed 7 days.
62256669|NCT05404399|EXPERIMENTAL|Free From Pain Exercise Book|"Participants in Group 1 will be asked to engage in the 3 sets of exercises within the exercise book for the following 12 weeks. They will be advised to engage in the exercises at least five times a week. The ideal plan would be as follows:~Monday - Otago exercises. Tuesday - Neck and Back exercises. Wednesday - Otago exercises. Thursday - Reading the weekly reading material. Friday - Neck and Back exercises. Saturday - Otago exercises. Sunday - Rest day.~Furthermore, it will be recommended that participants in Group 1 read one motivation/reason chapter and one metaphor each week for 12 weeks, to ensure that they absorb the information fully and do not overbear themselves with information.~Participants in Group 1 will also be asked to fill in the exercise diary, found at the back of the exercise book, each time they exercise as part of the Free From Pain programme."
62613819|NCT03960424|EXPERIMENTAL|Diabetes Telemonitoring (DTM)|"Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for Type 2 Diabetes (T2D), uses smart devices to share information between patients, caregivers, and clinicians. DTM includes:1) weekly real time virtual visit between patient and clinician 2) vital signs monitoring/interpretation 3) diabetes management 4) patient interactive educational videos and teach back quizzes, reinforcing self-management strategies 5) a caregiver app with supportive capability."
62613820|NCT03960424|ACTIVE_COMPARATOR|Comprehensive Outpatient Management (COM)|"Comprehensive Outpatient Management (COM) is the most realistic evidence-based comparator, in that it is the most frequently recommended and used option for US T2D patients. COM, like DTM, is consistent with the 2018 American Diabetes Association (ADA) Standards which include, but are not limited to, past medical and family history, social history, medications, screening, physical examination, laboratory evaluation, etc.Patients are instructed to monitor blood glucose (within physician recommendations), and have routine or well visits every 3 months. Patients can set appointments with a T2D educator. COM patients will receive monthly calls from the study Registered Nurse (RN) to collect data."
62613821|NCT00771979|EXPERIMENTAL|1|
62613822|NCT02236078|EXPERIMENTAL|High dose isoniazid|INH 900 mg daily to be administered orally for 6 days (600 mg for patients weighing \<45 kg)
62613823|NCT00951106|EXPERIMENTAL|Pyrimethamine/sulfdoxine (Fansidar)|Pyrimethamine/sulfdoxine (Fansidar)
62256670|NCT05404399|ACTIVE_COMPARATOR|Usual Care (physiotherapy)|"Those in Group 2 (control group) will not be provided with the Free From Pain Exercise Book, and will instead be referred to physiotherapy as part of standard / usual care. They will be asked to report when their physiotherapy commenced."
62444063|NCT02461368|EXPERIMENTAL|anterior approach|Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
62444064|NCT02461368|ACTIVE_COMPARATOR|posterior approach|Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
62613824|NCT05619770|EXPERIMENTAL|101-PGC-005 (Intervention arm)|Bolus Injection containing 30mg of 101-PGC-005 will administered intravenously once daily for 3 consecutive days
62613825|NCT05277272||Patients with clinically suspected or confirmed Hemophagocytic Lymphohistiocytosis|Multi-institutional cohort registry of patients with clinically suspected or confirmed Hemophagocytic Lymphohistiocytosis
62256671|NCT01119742|EXPERIMENTAL|Butenafine Hydrochloride 1% A|1
62838909|NCT05853991|ACTIVE_COMPARATOR|Affective touch|Participants will receive an affective touch intervention following the standardised procedure for affective touch
62613826|NCT02348554|EXPERIMENTAL|Controlled conditions|Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 1h30 They wore 3 research sensors that estimated energy expenditure: Fitmate, Armband and Actiheart. They also wore smartphones (in front pant pockets) that collected accelerometry data.
62613827|NCT02348554|EXPERIMENTAL|Free-living conditions|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimated energy expenditure: Armband and Actiheart. They also wore smartphones (in front pant pockets) that collected accelerometry data.
62613828|NCT02895139|EXPERIMENTAL|Additive Manufactured Orthotic Device|Device will be produced via additive manufacture to the specification of a Health and Care Professions Council (HCPC) registered orthotist based on a digital foot scan.
62838910|NCT05853991|PLACEBO_COMPARATOR|Static touch|Participants will receive a static touch intervention following the standardised procedure for static touch
62838911|NCT03475836|PLACEBO_COMPARATOR|Placebo|Vegetable oil
62838912|NCT03475836|ACTIVE_COMPARATOR|High-dose mint essential oil|100 μL Mentha piperita essential oil (in vegetable oil)
62613829|NCT02895139|OTHER|Moulded Orthotic Device|Historic control collected using same protocol. Intervention was a moulded orthotic device produced from an impression box of the foot shape.
62256672|NCT01119742|EXPERIMENTAL|Butenafine Hydrochloride 1% B|2
62613830|NCT02895139|OTHER|Milled Orthotic Device|Historic control collected using same protocol. Device will be produced via Computer Aided Design/Computer Aided Manufacture (CAD/CAM) milling to the specification of a HCPC registered orthotist based on a digital foot scan.
62613831|NCT04930653|EXPERIMENTAL|Treatment (ECP, mogamulizumab)|Patients receive mogamulizumab IV over 60 minutes on days 1, 8, 15, 22, of cycle 1 and days 1 and 15 of subsequent cycles. Beginning in cycle 2, patients also undergo ECP over 3 hours on days 8, 9, 22,and 23. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving CR)/PR after 6 cycles receive up to 6 additional cycles of treatment in the absence of disease progression or unacceptable toxicity.
62613832|NCT05369494|EXPERIMENTAL|Experimental Product|Infant formula product consumed ad libitum as instructed for approximately 28 days; Powder formula mixed to 20 kcal/fl. oz.
62256673|NCT01119742|ACTIVE_COMPARATOR|Butenafine Hydrochloride 1%|3
62256674|NCT01119742|PLACEBO_COMPARATOR|Vehicle A|4
62613833|NCT06088368|ACTIVE_COMPARATOR|in-plane needle guidance|Ultrasound -guided lumbar plexus block
62613834|NCT06088368|ACTIVE_COMPARATOR|out-of-plane needle guidance|Ultrasound -guided lumbar plexus block
62838913|NCT03475836|ACTIVE_COMPARATOR|Low-dose mint essential oil|50 μL Mentha piperita essential oil (in vegetable oil)
62838914|NCT00872443||FOP|Patients who already have an occlusion of POF secondary to a cryptogenic CVA and younger than 55 years old and without characterized thromboembolic events.
62256675|NCT01119742|PLACEBO_COMPARATOR|Vehicle B|5
62256676|NCT01200550||1|
62256677|NCT02834221|EXPERIMENTAL|Real-time ultrasound-guided puncture|Cannulate each femoral veins with two wires with real-time ultrasound-guided method.
62256678|NCT02834221|OTHER|Anatomical landmark guided puncture|Cannulate each femoral veins with two wires with the anatomical landmark guided method.
62256679|NCT02220842|EXPERIMENTAL|Arm 1 Cohort A (Safety Evaluation):Atezolizumab + Obinutuzumab|Relapsed/refractory FL and DLBCL participants will receive obinutuzumab alone on Days 1, 8, and 15 of Cycle 1 (Cycle length = 21 days), followed by atezolizumab and obinutuzumab on Day 1 of Cycles 2-8, and then atezolizumab alone on Day 1 of Cycle 9 and every cycle thereafter until unacceptable toxicities or disease progression.
62256680|NCT02220842|EXPERIMENTAL|Arm 1 Cohort B (Expansion): Atezolizumab + Obinutuzumab|Relapsed/refractory FL participants will receive atezolizumab and obinutuzumab as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
62838915|NCT00602472|EXPERIMENTAL|linagliptin 5 mg|linagliptin 5 mg once daily
62838916|NCT00602472|PLACEBO_COMPARATOR|placebo|placebo matching linagliptin 5 mg tablets
62838917|NCT01482052|EXPERIMENTAL|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
62838918|NCT01482052|ACTIVE_COMPARATOR|US Licensed Vaccine|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
62613835|NCT01892878|OTHER|Single Arm Study|All patients will receive treatment
62256681|NCT02220842|EXPERIMENTAL|Arm 1 Cohort C (Expansion): Atezolizumab + Obinutuzumab|Relapsed/refractory DLBCL participants will receive atezolizumab and obinutuzumab as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
62838919|NCT02210039|EXPERIMENTAL|SECM Probe Imaging|SECM probe will be guided to a pre-determined length in the esophagus and spiral imaging will be performed using the SECM Imaging System.
62444065|NCT05618119|ACTIVE_COMPARATOR|Male|5 male participants will undergo a \[18F\]MC225 PET scan
62444066|NCT05618119|ACTIVE_COMPARATOR|Female|5 female participants will undergo a \[18F\]MC225 PET scan
62444067|NCT00054483|EXPERIMENTAL|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62613836|NCT03216655|EXPERIMENTAL|traditional group|phone call
62613837|NCT03216655|EXPERIMENTAL|new device group|wechat group
62613838|NCT06118450||high caIMR|caIMR≥25
62613839|NCT06118450||low caIMR|caIMR\<25
62613840|NCT05640388||RV3278A arm : Treated group|This group will receive the RV3278A - ET0943 product
62613841|NCT05640388||RV4632A arm : Control group|This group will receive the RV4632A - RY1845 product
62613842|NCT05982808|EXPERIMENTAL|Novel CLIF correction|ASD patients with novel CLIF correction
62256682|NCT02220842|EXPERIMENTAL|Arm 2 Cohort D (Safety Evaluation):Atezolizumab + Tazemetostat|Relapsed/refractory DLBCL participants will receive atezolizumab (on Day 1) and tazemetostat (on Days 1-21) of each 21-day cycle until unacceptable toxicities or disease progression.
62444068|NCT00135395|ACTIVE_COMPARATOR|A|
62444069|NCT00135395|ACTIVE_COMPARATOR|B|
62444070|NCT01073306|EXPERIMENTAL|Dengue Virus Subtype 2 Vaccine|Participants will receive a single dose of investigational vaccine for dengue virus subtype 2.
62444071|NCT01073306|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo vaccine.
62444072|NCT00387998|EXPERIMENTAL|Risk primer|"Booklet written by investigators know your chances"
62444073|NCT00387998|ACTIVE_COMPARATOR|Control booklet|AHRQ staying healthy booklet
62444074|NCT02330120|EXPERIMENTAL|propofol|Propofol infusion 0.5-2 mg/kg/h for sedation in mechanically ventilated patients
62444075|NCT02330120|ACTIVE_COMPARATOR|dexmedetomidine|dexmedetomidine infusion 0.2-0.7 mcg/kg/h for sedation in mechanically ventilated patients
62613843|NCT05982808|ACTIVE_COMPARATOR|conventional correction strategy|ASD patients with conventional correction strategy
62613844|NCT00821015|EXPERIMENTAL|Experimental|All study subjects will undergo cryoablation. This is a non-randomized trial.
62613845|NCT01028495|EXPERIMENTAL|gemcitabine and RX-0201|"Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.~RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off."
62613846|NCT05162755|EXPERIMENTAL|Dose escalation 1a: S95029|
62613847|NCT05162755|EXPERIMENTAL|Dose escalation 1b: S95029 and Sym021|
62613848|NCT05162755|EXPERIMENTAL|Dose expansion 2a: S095029 and Sym021 and anti-HER2 therapy|
62613849|NCT05162755|EXPERIMENTAL|Dose expansion 2b: S095029 and Sym021 and futuximab/modotuximab|
62613850|NCT00856843|ACTIVE_COMPARATOR|Polyethylene glycol 3350 based bowel preparation|Polyethylene glycol 3350 based bowel preparation
62613851|NCT00856843|EXPERIMENTAL|BLI800|BLI800
62613852|NCT05816759|EXPERIMENTAL|Sequence A|Period 1: CKD-383 (A single oral dose of 1 tablet under fed condition) Period 2: CKD-501, D744, D150 (A single oral dose of 3 tablets under fed condition)
62613853|NCT05816759|EXPERIMENTAL|Sequence B|Period 1: CKD-501, D744, D150 (A single oral dose of 3 tablets under fed condition) Period 2: CKD-383 (A single oral dose of 1 tablet under fed condition)
62613854|NCT02325921||Renal tumor.|Patients \>18 years of age with histopathologically confirmed renal tumor diagnosis.
62613855|NCT04965636|EXPERIMENTAL|Participants receiving mepolizumab|
62613856|NCT02342977|PLACEBO_COMPARATOR|Placebo|Patient will randomly receive a placebo
62613857|NCT02342977|EXPERIMENTAL|Experimental|Patients will randomly receive experimental drug (lacosamide).
62613858|NCT00610233|ACTIVE_COMPARATOR|A|Urodynamic investigation with deep brain stimulation ON
62613859|NCT00610233|EXPERIMENTAL|B|Urodynamics with deep brain stimulation OFF
62838920|NCT00888940|EXPERIMENTAL|ecallantide|
62838921|NCT00888940|ACTIVE_COMPARATOR|Cyklokapron(R)|
62838922|NCT06216509|OTHER|cirrhosis|patients with cirrhosis undergoing TIPS placement
62256683|NCT02220842|EXPERIMENTAL|Arm 2 Cohort E (Expansion): Atezolizumab + Tazemetostat|Relapsed/refractory DLBCL participants will receive atezolizumab and tazemetostat as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
62054575|NCT04916600|SHAM_COMPARATOR|NET sham|Sham, non-invasive, stimulation through electrodes placed transcranially on the mastoid regions. Treatment is self-administered, with participant control of device output level and duration according to perceived benefit. Minimum treatment duration is one-hour, with self-administered extension not to exceed 7 days.
62256684|NCT03397004|ACTIVE_COMPARATOR|doxycycline Hyclate|subjects will be treated with a 6-month course of doxycycline oral capsule at a dose of 100mg twice daily
62256685|NCT03397004|PLACEBO_COMPARATOR|Placebo|subjects will be given a placebo oral capsule twice daily for 6-months
62256686|NCT05961995|EXPERIMENTAL|HFN Meditation|Subjects will complete guided meditation sessions 3 x a week for six weeks delivered in the app via video, as well as pre- and post-meditation psychological state assessments.
62256687|NCT06124625|ACTIVE_COMPARATOR|Rehabilitation maintenance program|
62256688|NCT06124625|PLACEBO_COMPARATOR|No Rehabilitation maintenance program|
62256689|NCT02437864|NO_INTERVENTION|Baseline Group|Airway management (intubation) undertaken immediately after anesthetic induction, without simultaneous supplemental oxygen via nasal cannula.
62256690|NCT02437864|EXPERIMENTAL|With-Cannula Group|Airway management (intubation) undertaken immediately after anesthetic induction, with simultaneous supplemental oxygen via nasal cannula.
62256691|NCT00710879|EXPERIMENTAL|Multipurpose Solution|Multi-purpose solution administered to adapted FDA group I soft contact lens wearers and FDA group IV soft contact lens wearers.
62256692|NCT02769663||OSA|Patients with newly diagnosed obstructive sleep apnea and no medical comorbidity affecting cognition.
62256693|NCT02769663||healthy controls|Participants with no sleep disorder or other medical comorbidity affecting cognition.
62256694|NCT04051879||AN-R|Participants that meet Diagnostic And Statistical Manual Of Mental Disorders (DSM-V) criteria for Anorexia Nervosa restricting subtype.
62613860|NCT05805007|EXPERIMENTAL|Dose escalation|"Three cohorts of 3 patients each. All the patients enrolled in the study will receive a single subretinal injection in one eye.~Cohort 1: Subretinal administration of a single low dose ZVS203e at Day 0. Cohort 2: Subretinal administration of a single medium dose ZVS203e at Day 0. Cohort 3: Subretinal administration of a single high dose ZVS203e at Day 0."
62838923|NCT06216509|OTHER|porto sinusoidal vascular disorder and portal vein thrombosis|patients with porto sinusoidal vascular disorder and portal vein thrombosis either in the context of cirrhosis or non cirrhotic portal vein thrombosis
62838924|NCT00792220|EXPERIMENTAL|MSU|
62838925|NCT00792220|ACTIVE_COMPARATOR|OCCM|
62054576|NCT02032160|EXPERIMENTAL|Engerix B|Engerix B IM injection - 20ug At 0, 1 and 6 months
62256695|NCT04051879||AN-BP|Participants that meet DSM-V criteria for Anorexia Nervosa binging/purging subtype.
62256696|NCT04051879||Healthy Controls|Participants that do not meet DSM-V criteria for any disorder.
62256697|NCT05315960||Qualitative study|Consenting participants will complete a form asking about basic characteristics including age, sex, ethnicity, marital status etc. People living in long-term care and family carers will participate in an individual interview and professional staff will participate in an individual interview or focus group (between 5 and 10 participants) depending on their preference. The interview or focus group is expected to last 30-60 minutes. Sessions will be conducted in-person or online (using MS Teams), depending on preference and COVID-19-related restrictions. All sessions will be audio-recorded and transcribed.
62256698|NCT05315960||Cross-sectional study|"Procedures:~Consent will be obtained from residents, for those who have mental capacity to give informed consent, or from a nearest relative or caregiver as consultee, for those who lack capacity. Once consent is obtained, the LTC resident will be asked to complete a form asking about their characteristics and a questionnaire about their social connections which is expected to take approximately 15 minutes. The proxy will be asked to complete a sociodemographic form about themselves along with a number of questionnaires regarding the LTC resident's dementia severity, neuropsychiatric symptoms, activities of daily living and quality of life for comparison. Data collection for the proxy is expected to take approximately 30-60 minutes. Anticipated sample size 150 between Canada and the UK."
62256699|NCT03719703||Case 1|Children conceived by frozen embryo transfer
62256700|NCT03719703||Case 2|Children conceived by fresh embryo transfer
62256701|NCT03719703||Control|Naturally conceived children
62256702|NCT03871322|ACTIVE_COMPARATOR|Vitamin D group|vitamin D supplementation - time to fracture healing
62256703|NCT03871322|ACTIVE_COMPARATOR|Vitamin D and K2 group|Vitamin D and K 2 supplementation - time of fracture healing
62256704|NCT03871322|PLACEBO_COMPARATOR|Placebo group|Placebo - time to fracture healing
62256705|NCT05402475|EXPERIMENTAL|Experimental|Online cognitive behavioural therapy with the added components of mindfulness meditation
62256706|NCT05402475|ACTIVE_COMPARATOR|Active comparator|Online cognitive behavioural therapy alone
62256707|NCT02667665||Alzheimer's Disease Dementia|
62613861|NCT06444711|NO_INTERVENTION|Standard care|The participant will complete a questionnaire (EQ-5D-5L) at both baseline and six months. Their baseline information will be collected from their electronic health records. They will be advised to see their GP as part of their routine care. At six months they will attend a visit where their clinical observations will be recorded.
62838926|NCT02796183|OTHER|Diabetic macular edema|Bevacizumab (Altuzan) was injected subconjunctival space of the patients.
62838927|NCT00515268|EXPERIMENTAL|Subjects receiving GSK256066|Eligible subjects will be randomized to receive GSK256066 with inhaled doses of 25 micrograms or 87.5 micrograms once daily for 7 days, administered via an ACCUHALER.
62838928|NCT00515268|PLACEBO_COMPARATOR|Subjects receiving placebo|Eligible subjects will be randomized to receive placebo for 7 days, administered via an ACCUHALER.
62838929|NCT00693901|EXPERIMENTAL|1|Parks will be assigned to the community-based participatory research condition.
62838930|NCT00693901|ACTIVE_COMPARATOR|2|Parks will be assigned to the director-only condition.
62054577|NCT02032160|EXPERIMENTAL|Fendrix|Fendrix IM injection - 20ug At 0, 1 and 6 months
62838931|NCT00693901|NO_INTERVENTION|3|Parks will be assigned to the control condition and will receive no intervention.
62623609|NCT05100303|EXPERIMENTAL|Mitoxantrone Hydrochloride liposome and cytarabine|"Chemotherapy will be given in 28-day cycles, and total treatment period is 2 cycles.~Dose escalation phase:~Patients will receive 24 mg/m\^2, 30 mg/m\^2 or 36mg/m\^2 of mitoxantrone hydrochloride liposome daily by intravenous (IV) injections on the first day and 1.5 g/m\^2 of cytarabine twice daily by IV for 3 days (day 1, day3 and day5).~Dose expansion phase:~Patients with newly diagnosed AML will receive mitoxantrone hydrochloride liposome daily by IV on the first day, 100\~200 mg/m\^2 of cytarabine by IV for 7 days (day 1\~7). Patients with R/R AML will receive mitoxantrone hydrochloride liposome daily by IV on the first day, 1.5 g/m\^2 of cytarabine twice daily by IV for 3 days (day 1, day3 and day5). The dose size of mitoxantrone hydrochloride liposome will be determined by the investigator and the sponsor based on the results of the previous study."
62838932|NCT04070872|EXPERIMENTAL|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
62838933|NCT04070872|EXPERIMENTAL|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
62838934|NCT04251403|EXPERIMENTAL|Mucosal Irrigation|Following routine endoscopic evaluation, investigators will utilize the ERBEJET 2 device (ERBE USA Inc), which is commercially available for the treatment of mucosal lesions, to sample cells from the mucosal surface of the stomach. The aspirate will be collected for cytologic/pathologic assessment.
62838935|NCT02633020|EXPERIMENTAL|AMG 714|Participants were administered 8 mg/kg AMG 714 via intravenous infusion on day 0, day 7 and every 2 weeks thereafter through week 10.
62256708|NCT02667665||non-Dementia|
62444076|NCT05493696|EXPERIMENTAL|Group 1 (ALG+TPTP)|Patients received Antigravity treadmill training + Traditional physical therapy program
62256709|NCT01141036|ACTIVE_COMPARATOR|propofol|propofol
62054578|NCT00785317|EXPERIMENTAL|Angemin|1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP
62054579|NCT00785317|ACTIVE_COMPARATOR|Activelle|1 mg of oral E2 in continuous combination with 0.5 mg of NETA
62256710|NCT01141036|ACTIVE_COMPARATOR|Midazolam|Midazolam
62256711|NCT03317041|EXPERIMENTAL|Tecar treatment group|The capacitive-resistive electric transfer (Tecar) therapy treatment group will receive 45 minutes of Tecar therapy treatment.
62444077|NCT05493696|ACTIVE_COMPARATOR|Group 2 (TPTP)|Patients received a Traditional physical therapy program
62256712|NCT03317041|NO_INTERVENTION|Control group|Participants will test passively in a sitting position for 30-min period
62256713|NCT00866450|ACTIVE_COMPARATOR|Western style diet|high-fat, low-calcium diet
62256714|NCT00866450|ACTIVE_COMPARATOR|Prudent diet|low-fat, calcium-sufficient diet
62256715|NCT05774730||Emphysema quantitative analysis softwarebased on chest image AI technology|
62256716|NCT05774730||artificial analysis|
62256717|NCT05774730||imported Chartis detection system|
62256718|NCT03996876|ACTIVE_COMPARATOR|Threat ABM Training|Attention Bias Modification Training with threatening words
62256719|NCT03996876|PLACEBO_COMPARATOR|Neutral Attention Training|Non-active version of ABM Training
62256720|NCT03366688|ACTIVE_COMPARATOR|IBI306|Subcutaneous or intravenous injection of a single dose of IBI306, dose level according to ascending dose design
62256721|NCT03366688|PLACEBO_COMPARATOR|placebo|Subcutaneous or intravenous injection of a single dose of placebo, dose level according to ascending dose design
62256722|NCT04244526||Group1|Group 1:pregnant women with cystitis
62256723|NCT04244526||Group2|Group 2: pregnant women with Pyelonephritis
62256724|NCT04244526||Group3|Group 3: pregnant women with asymptomatic bacteriuria
62256725|NCT04811404|EXPERIMENTAL|Ethyl eicosapentaenoic acid|Ethyl eicosapentaenoic acid will be given at 1G by mouth twice per day
62444078|NCT03247283|EXPERIMENTAL|Single Oral Dose of BMS-986205|
62444079|NCT04248374|NO_INTERVENTION|Fatty Acid Taste|Fatty acid taste without sour adaptation
62444080|NCT04248374|EXPERIMENTAL|Fatty Acid Taste after sour adaptation|Fatty Acid Taste after sour adaptation
62444081|NCT01041781|EXPERIMENTAL|Arm I|Patients receive gemcitabine hydrochloride\* IV on days 1 and 8 OR pemetrexed disodium\* IV on day 1. Patients also receive carboplatin IV on day 1 and oral celecoxib twice daily on days 1-21.
62838936|NCT02633020|PLACEBO_COMPARATOR|Placebo|Participants were administered placebo via intravenous infusion on day 0, day 7 and every 2 weeks thereafter through week 10.
62838937|NCT03233581|EXPERIMENTAL|Fitbit + Facebook + Health Coaching|Participants will use the Fitbit device and join the Facebook group. They will also receive brief weekly health coaching from a research staff. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide them with support.
62613862|NCT06444711|ACTIVE_COMPARATOR|Optimisation arm|Participants in the intervention arm will attend a baseline visit and two further research appointments at three months and six months from time of randomisation, For baseline assessment, the research cardiology doctor will review the participant's GP records with relation to previous cardiovascular disease, hypertension, dyslipidaemia, chronic kidney disease, diabetes, BMI, COPD and smoking history. They will conduct observations and blood tests that are recommended in NICE guidance if the results are not already available. They will carry out an ambulatory lung test (to screen for risk of pulmonary diseases). They will recommend changes to treatment if the treatment the patient is currently on does not adhere to guidelines. The research team will provide a letter and verbal communication with the participant's GP of the recommendations. For the second visit at three months after randomisation, the research team doctor will conduct the same review as undertaken at the first visit.
62613863|NCT04151966||Cardioversion Group|Subjects scheduled to undergo direct current cardioversion (DCCV) as part of the clinical plan of care
62838938|NCT03233581|ACTIVE_COMPARATOR|Usual care control with Fitbit only|Participants will be loaned a Fitbit device only. They will not join the Facebook group nor receive health coaching. They will not select an adult family member or friend to receive a Fitbit device to provide them with support.
62838939|NCT03061396|EXPERIMENTAL|Electroacupuncture Single point|Single point PC6 means there is only one acupoint to be chosen: Neiguan(PC6)
62613864|NCT00699712|EXPERIMENTAL|A|Open-label regimen of doses 1 and 2 of CDNP
62838940|NCT03061396|EXPERIMENTAL|Electroacupuncture Matching points|There are three acupoints to be chosen:Bilateral Neiguan(PC6)and Zhongwan(CV12)
62054580|NCT02262546|EXPERIMENTAL|Pramipexole|
62054581|NCT02262546|ACTIVE_COMPARATOR|Moxifloxacin|
62054582|NCT02262546|PLACEBO_COMPARATOR|Pramipexole Placebo|
62054583|NCT02262546|PLACEBO_COMPARATOR|Moxifloxacin Placebo|
62054584|NCT03002064|EXPERIMENTAL|DP group|Docetaxel plus cisplatin. Docetaxel: 60mg per square metre on day 1 and Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
62054585|NCT03002064|ACTIVE_COMPARATOR|PF group|Cisplatin plus 5-fluorouracil. Cisplatin: 60mg per square metre on day 1 and 5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles.
62256726|NCT01612182||ESBL(+) Klebsiella pneumonia|All the patient who's the culture result showed ESBL(+) Klebsiella pneumonia in any site during hospitalization
62256727|NCT01612182||ESBL(-) Klebsiella pneumonia|All the patient who's the culture result showed ESBL(-) Klebsiella pneumonia in any site during hospitalization
62256728|NCT02433197|EXPERIMENTAL|Aerobic program|Individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants.
62613865|NCT00699712|EXPERIMENTAL|B|Open-label regimen of doses 2 and 3 of CDNP
62613866|NCT00699712|EXPERIMENTAL|C|Open-label regimen of doses 3 and 4 of CDNP
62613867|NCT01349127|ACTIVE_COMPARATOR|20µg Vitamin D3|Arm will receive per day one gelatin capsule containing 20µg (800IU) of vitamin D3 (Cholecalciferol).
62613868|NCT01349127|ACTIVE_COMPARATOR|20µg Vitamin D3 + 500 mg Calcium|Arm will receive per day one gelatin capsule containing 20µg (800IU) of vitamin D3 (Cholecalciferol) and one tablet of calcium carbonate containing 500mg of calcium.
62613869|NCT01349127|PLACEBO_COMPARATOR|Placebo|Arm will receive one gelatin capsule containing 0µg (0IU) of vitamin D3 (Cholecalciferol).
62838941|NCT04420104|EXPERIMENTAL|esp block group|
62838942|NCT04420104|ACTIVE_COMPARATOR|control group|
62838943|NCT04695808|EXPERIMENTAL|intervention group|Yoga practice will be done two days a week for 10 weeks.
62838944|NCT04695808|NO_INTERVENTION|control group|no intervention
62838945|NCT03792906|EXPERIMENTAL|Norepinephrine 6 mcg|Mothers in this group will receive a bolus of Norepinephrine 6 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
62838946|NCT03792906|ACTIVE_COMPARATOR|Norepinephrine 10 mcg|Mothers in this group will receive a bolus of Norepinephrine 10 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion.
62838947|NCT00655200||A|
62054586|NCT04469881|EXPERIMENTAL|Virtual Reality|Wear VR glasses and watch movies during surgery
62054587|NCT06341621|EXPERIMENTAL|endocrine drug plus 3-year abemaciclib without chemo|aromatase inhibitors with or without GnRHa plus 3-year lower dose (100mg bid) abemaciclib without chemotherapy.
62054588|NCT06341621|ACTIVE_COMPARATOR|treatment of physician's choice|treatment of physician's choice, including whether to receive chemotherapy, the chemotherapy regimen and the endocrine therapy regimen.
62256729|NCT02433197|NO_INTERVENTION|Control group|They will be instructed to continue their current activities and not to increase objectively levels of physical activity performed during the 8-week intervention.
62256730|NCT05357443|ACTIVE_COMPARATOR|Gastric Bypass with Transection of Vagal Nerves|
62256731|NCT05357443|PLACEBO_COMPARATOR|Gastric Bypass Without Transection of Vagal Nerves|
62256732|NCT00449683|EXPERIMENTAL|terazosin|open-label treatment group
62256733|NCT03159091|EXPERIMENTAL|Rengalin|Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).
62613870|NCT01196936|EXPERIMENTAL|Arm I (tamoxifen citrate)|Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
62613871|NCT01196936|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
62613872|NCT06731257|NO_INTERVENTION|Standard of care|For the standard group and study participants the clinical records will be reviewed to check if any primary or secondary endpoints were met. They will be contacted at 30 days for a telephone consultation after the index event (time from when patient was admitted), and they will be asked to fill in a patient satisfaction questionnaire
62613873|NCT06731257|OTHER|study group|Patients who are randomised to the study group will receive a blood pressure monitor and instructions on how to use the device and transfer data to the study team. The study nurses will contact the patient every day for 3 days following their discharge and perform an virtual ward round assessment by telephone (see table). This will determine whether the patient continues to be monitored via the virtual ward, or whether they need to be referred to the clinical team. They will be issued with an emergency contact number out of hours (coronary care unit LGI) and the nursing hub will operate from 8am to 5pm 7 days a week. They will be referred to the community cardiac rehabilitation service whilst on the pathway.
62613874|NCT05131932|EXPERIMENTAL|Inlet patch|Patients found to have an inlet patch on upper endoscopy
62613875|NCT05131932|NO_INTERVENTION|Controls|Patients without an inlet patch on upper endoscopy
62613876|NCT02666638|ACTIVE_COMPARATOR|Control Volunteers|MRI on up to a 7T scanner without contrast.
62054589|NCT03532308|EXPERIMENTAL|Intervention|Daily Fermented Soy (two 12.5g packets/day) (\~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
62256734|NCT03159091|PLACEBO_COMPARATOR|Placebo|Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).
62256735|NCT00105716|OTHER|Arm 1|
62613877|NCT02666638|EXPERIMENTAL|Clinical Patients|MRI on up to a 7T scanner without contrast.+ 10 minutes of research development imaging added onto their clinical MRI scans.
62613878|NCT05698537||People living with epilepsy (PwE)|Study participants with epilepsy
62613879|NCT05698537||Control subjects|Study participants without epilepsy
62256736|NCT04778436|EXPERIMENTAL|T7082|After inclusion, the patients will consume an association of 4 food supplements including Nutrof Total.
62444082|NCT01041781|ACTIVE_COMPARATOR|Arm II|Patients receive gemcitabine hydrochloride\* OR pemetrexed disodium\* and carboplatin as in arm I. Patients also receive oral placebo twice daily on days 1-21.
62613880|NCT05433272|EXPERIMENTAL|Trial group of participants have received two doses of CoronaVac®|400 participants have received two doses of CoronaVac® at least 3 months prior to this study ,including 150 participants aged 3-17 years old,125 participants aged 18-59 years old and 125 participants aged 60 years and above,will receive one booster dose of trivalent COVID-19 vaccine.
62444083|NCT03214718|EXPERIMENTAL|CML patients treated with imatinib 400 mg/day|Measurement of the level of myeloid derived suppressor cells (MDSCs) by flowctytometry for each newly diagnosed chronic phase chronic myeloid leukemia (CML) patients treated with imatinib 400 mg/day before starting treatment and every 3 months till one year and correlate between it and level of BCR-ABL gene level and the sokal score of the patients and deep molecular response of the patients after one year .
62444084|NCT03214718|ACTIVE_COMPARATOR|CML patients treated with nilotinib 600 mg/day|Measurement of the level of myeloid derived suppressor cells (MDSCs) for each newly diagnosed chronic phase chronic myeloid leukemia ( CML) patients treated with nilotinib 600 mg/day before starting treatment and every 3 months till one year and correlate between it and level of BCR-ABL gene, the sokal score and deep molecular response of the patients after one year .
62444085|NCT04835103|OTHER|Set a case management model for somatoform patients|Somatoform patients receiving case management, single group assignment, open label
62444086|NCT04835103|OTHER|Time-limited psychotherapy for somatoform patients|Somatoform patients receiving psychotherapy (based on cognitive-behavioral therapy and biofeedback therapy) vs treatment as usual, open label, non-randomized
62623610|NCT06137066|PLACEBO_COMPARATOR|Placebo|Placebo supplement consisting of microcrystalline cellulose with 5mg magnesium stearate and 5mg silicon dioxide.
62256737|NCT02950090|EXPERIMENTAL|MobilWise|MobilWise will use data transmitted from an affordable accelerometer-based personal monitor (Fitbit Flex) via Fitabase to: allow a remote coach to view and collect physical activity data generated by the personal monitor, and use that data to formulate and provide tailored behavioral support, using motivational interviewing. The coach has a phone conversation weekly x 12 using motivational interviewing with participants to set goals and encourage activity. Coaches mention patient use of treatment elements (accountability) and will be positively reinforcing for adherent participants, or will include positive statements for those who are not adherent (supportive).Participants are also encouraged to use all the features of Fitbit (social networking, challenges, email reminders).
62623611|NCT06137066|EXPERIMENTAL|200mg GCE +200mg ALA|200mg green coffee extract +200mg alpha-lipoic acid
62613881|NCT05433272|ACTIVE_COMPARATOR|Control group of participants have received two doses of CoronaVac®|400 participants have received two doses of CoronaVac® at least 3 months prior to this study ,including 150 participants aged 3-17 years old,125 participants aged 18-59 years old and 125 participants aged 60 years and above,will receive one booster dose of CoronaVac®.
62623612|NCT06137066|EXPERIMENTAL|200mg GCE +400mg ALA|200mg green coffee extract +200mg alpha-lipoic acid
62623613|NCT06137066|EXPERIMENTAL|200mg GCE +200mg DHB|200mg green coffee extract + 200mg dihydroberberine
62256738|NCT02950090|ACTIVE_COMPARATOR|Fitbit Only|will use data transmitted from an affordable accelerometer-based personal monitor (Fitbit Flex) to monitor their own progress and physical activity level without coaching support. Participants are again encouraged to use all the features of Fitbit (social networking, challenges, email reminders) to achieve activity levels.
62256739|NCT02950090|NO_INTERVENTION|Waitlist Control|Participants in the waitlist arm have exposure to the usual wellness supports provided by the company: Motiva is the internal corporate wellness program that is under the direction of the Chief Medical Officer. Initiated in 2000, Motiva is staffed by two full- time health professionals and two full-time healthy lifestyle professionals. Motiva provides wellness programming year round on a BCBSIL intranet web page plus an individual page called myMotiva, where self- assessment of health risks, including weight and physical activity behavior, is encouraged. Participating in myMotiva allows individuals to earn up to $200 per year in an incentive program called Wellness Rewards
62256740|NCT04511832|EXPERIMENTAL|Acupuncture to NSAIDs|
62256741|NCT04511832|EXPERIMENTAL|NSAIDs to Acupuncture|
62256742|NCT04511832|EXPERIMENTAL|Combined both acupuncture and NSAIDs|
62256743|NCT04790136|EXPERIMENTAL|GLA-015|GLA-015 (Glatt Pharmaceutical Services GmbH \& Co. KG, Germany); 5.051 g granules containing 1500 mg cannabidiol to be dispersed in water; oral multiple dose administration twice daily over 7 consecutive days after a light meal
62444087|NCT01413399|ACTIVE_COMPARATOR|Intra-Arrest Therapeutic Hypothermia|
62444088|NCT01413399|ACTIVE_COMPARATOR|Post-Arrest Therapeutic Hypothermia|
62444089|NCT04935775|EXPERIMENTAL|Untrained Touch Provided|
62444090|NCT04935775|NO_INTERVENTION|Standard of Care|
62444091|NCT04347447|EXPERIMENTAL|normal protein diet|The normal protein diet (Control) will contain the RDA for protein of (0.8 g/kg/d), with the protein provided from a variety of animal and plant-based sources, including lean beef (one 3-oz portion per week), chicken, eggs, dairy, beans, grains, nuts, seeds.
62444092|NCT04347447|EXPERIMENTAL|a beef protein-rich diet|High protein diet predominantly provided from lean beef (one 3-oz portion per day; total beef intake 24 oz/week). The energy content of the additional protein foods will be isocalorically offset by substitution for low-protein foods.
62444093|NCT04347447|EXPERIMENTAL|a protein-rich diet non-red meat|High-protein group from a variety of animal and plant-based sources (excluding additional red meats).
62444094|NCT00968383|ACTIVE_COMPARATOR|Optimal medical therapy|Conventional medical management, including aspirin, clopidogrel, statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) and/or aldosterone antagonist and risk factor modification
62444095|NCT00968383|EXPERIMENTAL|PCI with optimal medical therapy|Conventional medical management, including aspirin, clopidogrel, statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) and/or aldosterone antagonist and risk factor modification plus percutaneous coronary intervention and coronary stenting
62444096|NCT05909267|EXPERIMENTAL|L-dopa/Carbidopa followed by placebo|Participants will receive first L-dopa/Carbidopa (100/25 mg), and then placebo.
62444097|NCT05909267|EXPERIMENTAL|Placebo followed by L-dopa/Carbidopa|Participants will receive first placebo, and then L-dopa/Carbidopa (100/25 mg).
62444098|NCT01584609|EXPERIMENTAL|Penumbra System with Separator 3D|
62444099|NCT01584609|ACTIVE_COMPARATOR|Penumbra System alone|
62444100|NCT01182818||Observation|all adult patients (18 - 60 years of age) with an acute cerebrovascular event of any etiology
62444101|NCT04473508|EXPERIMENTAL|Treated|active treatment (Local anaesthetic): Local administration of ropivacaine 30 mL (5mg/mL)
62444102|NCT04473508|PLACEBO_COMPARATOR|Control|Local administration of Placebo ( Saline Solution)
62444103|NCT02029209|EXPERIMENTAL|Anlotinib|Anlotinib QD orally and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62444104|NCT02029209|PLACEBO_COMPARATOR|Placebo Capsule|Placebo capsule QD orally and it should be continued until disease progression or patients withdrawal of consent
62444105|NCT05477329|EXPERIMENTAL|Myopia control design spectacle lens|Test lenses
62444106|NCT05477329|OTHER|Single Vision design spectacle lens|Control lenses
62838948|NCT03585738|EXPERIMENTAL|Inositol + Folic acid|Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid before spontaneous conception until delivery.
62054590|NCT03532308|PLACEBO_COMPARATOR|Placebo|Daily (matched dose) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
62256744|NCT04790136|ACTIVE_COMPARATOR|"DAC C-052 Cannabidiol / NRF 22.10 Oily cannabidiol solution 100 mg/ml"|"DAC C-052 Cannabidiol / NRF 22.10 Ölige Cannabidiol-Lösung 100 mg/ml (Oily cannabidiol solution 100 mg/ml) (Glatt Pharmaceutical Services GmbH \& Co. KG, Germany; according to DAC/NRF specifications); 15 ml solution containing 1500 mg cannabidiol; oral multiple dose administration twice daily over 7 consecutive days after a light meal"
62256745|NCT00316355|ACTIVE_COMPARATOR|Traditional CBT|Cognitive-behavioral therapy (CBT) that incorporates exposure with ritual prevention (EX/RP)
62256746|NCT00316355|EXPERIMENTAL|Stepped-Care CBT|Stepped-care CBT
62256747|NCT02403336|EXPERIMENTAL|Behavioral group intervention|Professionals: 3 training sessions for updating the knowledge and learning skills. Patients: Health education workshop.
62256748|NCT02403336|ACTIVE_COMPARATOR|Usual clinical practice|Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
62256749|NCT04966520|EXPERIMENTAL|Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS) or sham|"Patients will participate in the prospective longitudinal research protocol over a period of 1.5 months.~Treatment will include 8 visits of either accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS) or iTBS sham stimulation. Patients will be informed that iTBS sham stimulations will be part of the protocol (but will be blind to when treatment/sham will be administered)."
62256750|NCT04341220|EXPERIMENTAL|Anodal tDCS + Exercise|Anodal tDCS applied over primary motor cortex (M1) - Dose: 1mA, 20 minutes + ( concomitantly) protocol of specific exercises for balance
62444107|NCT01394458|EXPERIMENTAL|30 % ethanol/ 4 % sodium citrate group|For patients randomized to the 30% ethanol /4 % sodium citrate group, the lock solution will be provided in pre-filled syringes for single use only. After each dialysis session, the locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. Any remaining 30% ethanol/4% sodium citrate solution in each syringe will be discarded. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.
62054591|NCT02395133|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW) from Week 1 (Day 1) to Week 36.
62838949|NCT03585738|PLACEBO_COMPARATOR|Folic acid|Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid before spontaneous conception until delivery.
62054592|NCT02395133|EXPERIMENTAL|Dupilumab 300 mg Q8W|Subcutaneous injection of Dupilumab 300 milligram (mg) alternatively with placebo (matched to Dupilumab) was administered once every eight week (Q8W) from Week 1 to Week 36.
62054593|NCT02395133|EXPERIMENTAL|Dupilumab 300 mg Q4W|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every four week (Q4W) from Week 1 to Week 36.
62613882|NCT05433272|EXPERIMENTAL|Trial group of participants have received three doses of CoronaVac®|300 participants have received three doses of CoronaVac® at least 3 months prior to this study ,including 150 participants aged 18-59 years old and 150 participants aged 60 years and above,will receive one booster dose of trivalent COVID-19 vaccine.
62613883|NCT05433272|ACTIVE_COMPARATOR|Control group of participants have received three doses of CoronaVac®|300 participants have received three doses of CoronaVac® at least 3 months prior to this study ,including 150 participants aged 18-59 years old and 150 participants aged 60 years and above,will receive one booster dose of CoronaVac®.
62838950|NCT04433988|PLACEBO_COMPARATOR|Control group|100 patients will receive standard treatment plus placebo
62054594|NCT02395133|EXPERIMENTAL|Dupilumab 300 mg Q2W/QW|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every week (QW) or twice a week (Q2W) from Week 1 to Week 36.
62054595|NCT02238925|EXPERIMENTAL|CPX-351|"Single Arm Study (Patients may receive up to 2 Inductions and 4 Consolidations):~Induction 1: CPX-351 will be given intravenously at 100units/m2 on days 1, 3, and 5 over a 90 minute infusion.~Induction 2: CPX-351 will be given intravenously at 100units/m2 on days 1 and 3 over a 90 minute infusion.~Consolidations 1-4: CPX-351 will be given intravenously at 65units/m2 on days 1 and 3 over a 90 minute infusion."
62054596|NCT01299519|EXPERIMENTAL|Weight Loss|Half of the subjects in the weight loss arm will lose 5% of their weight through a low-calorie diet, and half will also lose 10% and 15% body weight.
62256751|NCT04341220|SHAM_COMPARATOR|Sham tDCS + Exercise|Sham tDCS applied over primary motor cortex (M1) - Dose: 1mA, 30 seconds ON, + (concomitantly) protocol of specific exercises for balance
62623614|NCT04388124|PLACEBO_COMPARATOR|Placebo|Patient will receive placebo for 56 days: 2 capsules of 62.5 mg per day for 27 days +/-1 day, 2 capsules of 125 mg per day for 27 days +/-1 day.
62838951|NCT04433988|EXPERIMENTAL|Pentoxifylline group|100 patients will receive standard treatment plus pentoxifylline 1200 mg/day
62838952|NCT00126334|ACTIVE_COMPARATOR|1|Liberal transfusion threshold
62838953|NCT00126334|EXPERIMENTAL|2|Conservative transfusion threshold
62838954|NCT01145976|ACTIVE_COMPARATOR|CY-ATG(Arm1)|"Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2"
62838955|NCT01145976|EXPERIMENTAL|Flu-ATG(Arm2)|Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
62256752|NCT04700527|ACTIVE_COMPARATOR|Short Chain Fatty Acid (SCFA)|4-6 grams of powder mixed with food and taken everyday starting 1 week prior-1 week post Radiation Therapy.
62256753|NCT04700527|PLACEBO_COMPARATOR|Placebo (Tapioca)|5 grams taken everyday starting 1 week prior-1 week post Radiation Therapy.
62444108|NCT01394458|EXPERIMENTAL|Heparin 1000 U/ml|For patients randomized to the heparin group, the heparin will be provided in 10 ml glass vials. Two, 3 ml syringes will be used to draw up the required volume of heparin to fill each lumen. A separate syringe will be used to fill each catheter lumen. The necessary volume should match the lumen volume with no overfill. The locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.
62444109|NCT02028000|ACTIVE_COMPARATOR|INSORB staples skin closure|Women undergoing cesarean section delivery will have skin closure with INSORB staples.
62613884|NCT04617964||IUGR|sample of 40 pregnant women affected by intrauterine growth restriction (IUGR) Two referees will perform four successive measurements of the diameter of the right portal vein (RPV) during the same ultrasound examination at the third trimester. Each operator will qualify the appearance of the right portal vein as normal or collapsed using an evaluation grid, and will independently performe a series of two measurements using the same method.
62613885|NCT04617964||NORMAL|Ssample of 40 healthy pregnant women Two referees will perform four successive measurements of the diameter of the right portal vein (RPV) during the same ultrasound examination at the third trimester. Each operator will qualify the appearance of the right portal vein as normal or collapsed using an evaluation grid, and will independently performe a series of two measurements using the same method.
62054597|NCT01299519|ACTIVE_COMPARATOR|Weight Maintenance|Subjects in the weight maintenance arm will maintain a steady body weight (plus or minus 2% of initial body weight) for six months.
62054598|NCT02296190|EXPERIMENTAL|Etripamil|1 dose of Etripamil via 4 intranasal applications at time 0 (140 mg, 105 mg, 70 mg, or 35 mg)
62256754|NCT02947672|ACTIVE_COMPARATOR|Intravenous dexamethasone|50 patients will receive intravenous dexamethasone
62444110|NCT02028000|ACTIVE_COMPARATOR|Monocryl skin closure|Women undergoing cesarean section delivery will have skin closure with Monocryl.
62444111|NCT02028000|ACTIVE_COMPARATOR|Vicryl skin closure|Women undergoing cesarean section delivery will have Vicryl skin closure
62444112|NCT03306576|EXPERIMENTAL|ELS Extra composite|Commercially available composite resin restorative that will be used for direct restoration as per manufacturer's instructions
62444113|NCT03306576|ACTIVE_COMPARATOR|ELS composite|Commercially available composite resin restorative that will be used for direct restoration as per manufacturer's instructions
62444114|NCT03213756|EXPERIMENTAL|Preoperative isometric exercise (PIE) group|In the PIE group, the patients will perform daily preoperative exercise protocol based on isometric exercises using hand grip and elastic bands. They will perform this protocol for at least six and ideally eight weeks before surgery.
62613886|NCT01815775|EXPERIMENTAL|Normal pressure hydrocephalus|Hydrocephalus patients planned for shunting surgery. They will undergo clinical and imaging examinations at day 1, 3 months and 1 year after their surgery.
62054599|NCT02296190|PLACEBO_COMPARATOR|Placebo|1 dose of placebo via 4 intranasal applications at time 0
62054600|NCT01472874|EXPERIMENTAL|Once a day Trientine|Patients receive once a day trientine
62256755|NCT02947672|ACTIVE_COMPARATOR|Intra peritoneal dexamethasone|50 patients will receive intraperitoneal dexamethasone
62444115|NCT03213756|NO_INTERVENTION|Control group|Control group patients will follow the usual surgical waiting list protocol (Estimated 1,5-2 months).
62054601|NCT03019354|EXPERIMENTAL|high-flow nasal oxygen|high-flow nasal oxygen was used during intravenous general anesthesia
62256756|NCT01417598|EXPERIMENTAL|Gait and balance group training|The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
62256757|NCT01417598|EXPERIMENTAL|Gait and balance trainig + nordic walking|(only for Osteoporosis group)
62256758|NCT01417598|NO_INTERVENTION|Control group|
62613887|NCT04685928|EXPERIMENTAL|MRI arm|MRI prostate with contrast, followed by MRI-guided biopsy under local anaesthesia only if MRI show suspicious lesion. Men with non-suspicious MRI will not receive a biopsy.
62613888|NCT04685928|ACTIVE_COMPARATOR|TP-arm Systematic biopsy|24-core Systematic transperineal prostate biopsy under local anaesthesia
62256759|NCT01766128|ACTIVE_COMPARATOR|Zonisamide|The patients in this arm are treated with zonisamide 50mg/d
62256760|NCT01766128|PLACEBO_COMPARATOR|Placebo|The patients in this arm are treated with placebo
62256761|NCT04712721|EXPERIMENTAL|Glioblastoma Multiforme|All eligible participants will receive recommended dose of \[68Ga\]-FF58 of 3 Megabecquerel (MBq)/Kg (+/- 10%) \[but not more than 250 and not less than 150 MBq\].
62256762|NCT04712721|EXPERIMENTAL|Brain Metastasis from Breast Cancer|All eligible participants will receive recommended dose of \[68Ga\]-FF58 of 3 Megabecquerel (MBq)/Kg (+/- 10%) \[but not more than 250 and not less than 150 MBq\].
62444116|NCT06042283|EXPERIMENTAL|Intervention Group|Participants in this group will have Metacognitive Training-Silver program. Metacognitive Training-Silver program is an eight-module training that focuses on common cognitive problems and dysfunctional attitudes, beliefs and prejudices in solving problems seen in depression. The purpose of the sessions is to convey information about false beliefs and cognitive distortions, and to help sick individuals think critically, convey their thoughts, and acquire new problem-solving strategies through exercises.
62613889|NCT01239524|OTHER|DE-group|surgical denervation by excising 1 cm of proximal thoracodorsal nerve
62613890|NCT01239524|OTHER|IN group|thoracodorsal nerve is saved intact
62613891|NCT05628857|EXPERIMENTAL|Cohort 1|gastric cancer patients
62613892|NCT05628857|EXPERIMENTAL|cohort 2|colorectal cancer patients
62054602|NCT03019354|ACTIVE_COMPARATOR|Oxygen mask|oxygen mask was used during intravenous general anesthesia
62256763|NCT04712721|EXPERIMENTAL|Gastroesophageal adenocarcinoma|All eligible participants will receive recommended dose of \[68Ga\]FF58 of 3 Megabecquerel (MBq)/Kg (+/-10%) \[but not more than 250 and not less than 150 MBq\]
62256764|NCT04712721|EXPERIMENTAL|Pancreatic ductal adenocarcinoma|All eligible participants will receive recommended dose of \[68Ga\]FF58 of 3 Megabecquerel (MBq)/Kg (+/-10%) \[but not more than 250 and not less than 150 MBq\]
62054603|NCT03241979||laryngeal microsurgery|
62256765|NCT04935892|EXPERIMENTAL|Slippers|Patients wear slippers any time they are out of bed with a goal of avoiding any contact between socks/feet and the floor
62256766|NCT04935892|NO_INTERVENTION|Control|Patients receive standard care with no intervention
62613893|NCT05628857|EXPERIMENTAL|cohort 3|liver cancer patients
62054604|NCT03848598||Responders|Patients suffering from patellar tendinopathy who have complete pain resolution after performing isometric exercises.
62613894|NCT05628857|EXPERIMENTAL|cohort 4|other digestive system malignancies, including esophageal cancer, pancreatic cancer, gallbladder cancer, etc.
62613895|NCT06504524||Elranatamab|Patient cohort treated with elranatamab, coming form clinical trial Magnetis MM-3 trial
62613896|NCT06504524||Standard-of-care|Patients treated with the standard-of-care therapies according to G-BA's definition will come from real-world data sources
62613897|NCT00516802|EXPERIMENTAL|1|DTIC + KU-0059436
62054605|NCT03848598||Non-responders|Patients suffering from patellar tendinopathy who do not have complete pain resolution after performing isometric exercises.
62256767|NCT03118700|NO_INTERVENTION|Non-exercise Control|Subjects will come to the laboratory for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow. During this time, subjects will remain seated with their body posture maintained constant
62256768|NCT03118700|EXPERIMENTAL|Aerobic Interval Exercise|Subjects will be equipped with a heart rate (HR) monitor and perform an interval exercise bout on a cycle ergometer. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax. After the exercise, subjects will remain seated in the lab for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow.
62256769|NCT03118700|EXPERIMENTAL|Continuous Exercise|Subjects will be equipped with a heart rate (HR) monitor and perform an interval exercise bout on a cycle ergometer. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will perform a 30-minute exercise bout at a HR that elicits 75%-80% of their measured HRmax. Work rate will be adjusted, if needed, to keep HR within this value. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax. After the exercise, subjects will remain seated in the lab for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow.
62256770|NCT02021084|PLACEBO_COMPARATOR|placebo, response, adverse effect|children (5-17 years old) with FMF that are currently followed in the pediatric rheumatology clinic at Mayer children hospital Israel Haifa that are being treated with colchicine and suffering from either gastrointestinal adverse effect or partial response to colchicine.in the first 3 month patients will be followed with no interventions and will be required to record all there FMF episodes and their GIT adverse effect, in the second period the patients will be randomly divided into two groups patients that will received placebo arm one and patients that will receive probiotics arm two.
62256771|NCT02021084|ACTIVE_COMPARATOR|probiotic, response, adverse effect|children (5-17 years old) with FMF that are currently followed in the pediatric rheumatology clinic at Mayer children hospital Israel Haifa that are being treated with colchicine and suffering from either gastrointestinal adverse effect or partial response to colchicine.in the first 3 month patients will be followed with no interventions and will be required to record all there FMF episodes and their GIT adverse effect, in the second period the patients will be randomly divided into two groups patients that will received placebo arm one and patients that will receive probiotics arm two.
62256772|NCT05543577||Pharmacists|community, hospital and clinical pharmacists
62613898|NCT05960149|EXPERIMENTAL|Group using Indocyanine Green|Performing nerve-sparing robot-assisted laparoscopic radical prostatectomy by IV injecting of Indocyanine Green
62613899|NCT05960149|EXPERIMENTAL|The Indocyanine Green -unused group|Nerve-sparing robot-assisted laparoscopic radical prostatectomy without the use of Indocyanine Green
62613900|NCT06281158|EXPERIMENTAL|14C-DNL343|
62613901|NCT02772809|OTHER|Stroke survivors with low and moderate motor deficits|Subjects with low and moderate motor deficits will 1) complete exercises with 2 commercial (joystick and wheel) and the Theradrive haptic robot after pre assessment 2) then experience 12 therapy sessions on the Theradrive haptic robot with Adaptive Feedback. 3) Assessments pre and post therapy.
62613902|NCT01618461|NO_INTERVENTION|Text instructions|Medication instructions displayed in text format
62613903|NCT01618461|EXPERIMENTAL|Drug indication icons|Icons illustrate the purpose of each medication
62613904|NCT01618461|EXPERIMENTAL|Structured instructions|Graphical format shows what time(s) of day each medication should be taken
62613905|NCT01618461|EXPERIMENTAL|Icons + Structured instructions|Icons illustrate the purpose of each medication, and a graphical format shows what time(s) of day each medication should be taken
62613906|NCT04990271|EXPERIMENTAL|Conbercept intravitreal Injection|
62613907|NCT03193034|EXPERIMENTAL|ATTUNE Cementless RP TKA|Subjects will receive a cementless, rotating platform total knee arthroplasty.
62613908|NCT01230216|ACTIVE_COMPARATOR|intensive blood pressure control|systolic blood pressure less than 120 mmHg
62613909|NCT01230216|ACTIVE_COMPARATOR|standard blood pressure control|systolic blood pressure less than 140 mmHg
62054606|NCT03262740|EXPERIMENTAL|BMS-986195 and Oral Contraceptive|Oral administration of contraceptive, then progress to combination
62256773|NCT05543577||Medical interns|Medical interns of both sexes
62613910|NCT02152124||Controlled on LA-SMSA|Patients with controlled acromegaly on long-acting somatostatin analogs
62613911|NCT02152124||Controlled on LA-SMSA and pegvisomant|Patients with controlled acromegaly on long-acting somatostatin analogs and pegvisomant
62613912|NCT02152124||Controlled after surgery|Controlled acromegaly patients without need for medical therapy after surgery
62613913|NCT02152124||Healhy controls|Healthy volunteers
62613914|NCT02152124||Uncontrolled on LA-SMSA|Patients with uncontrolled acromegaly (i.e. with serum IGF-1 levels above age-specific thresholds and/or symptoms due to active acromegaly (e.g. excessive sweating, arthralgia)) on LA-SMSA monotherapy in maximal dosage
62054607|NCT04839263|ACTIVE_COMPARATOR|"FAST TRACK protocol"|"FAST TRACK protocol Preoperative evaluation and information~Patient general health state optimization proposal prior to hospitalization:~Preoperative strategy:~* Hospitalization on surgery day~* No prolonged fasting~Perioperative strategy:~* Pain control based on limited systemic opioid therapy use~* Anti-nausea prophylaxis~* Anaesthesia via IV propofol / remifentanyl~* Bladder catheter removal postoperative~Postoperative strategy:~* Pain control using balanced analgesia~* Gum chewing~* Early oral refeeding and rapid mobilization~* Venflon removal 6 hours post-op"
62256774|NCT03680911|EXPERIMENTAL|NAC Group|NAC group will be administered orally as a 4 gram loading dose, followed by 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
62256775|NCT03680911|PLACEBO_COMPARATOR|Placebo Group|Placebo group will be administered orally as a 4 gram loading dose, followed by 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
62256776|NCT05790382|EXPERIMENTAL|NM-101|Ascending doses of NM-101. IV infusion over 2 hours
62256777|NCT05790382|PLACEBO_COMPARATOR|Placebo|IV infusion over 2 hours
62256778|NCT06490341|EXPERIMENTAL|GP Combined with Nimotuzumab and Sintilimab|GP regimen(gemcitabine plus cisplatin) in combination with nimotuzumab and sintilimab
62256779|NCT01001468|EXPERIMENTAL|VB-201 20 mg|
62256780|NCT01001468|EXPERIMENTAL|VB-201 80 mg|
62256781|NCT01001468|PLACEBO_COMPARATOR|Placebo|Single daily dose of oral placebo
62256782|NCT03137589|NO_INTERVENTION|Control|Patients of this group are routinely treated without telemedical support.
62256783|NCT03137589|ACTIVE_COMPARATOR|Telemedical support|Patients of this group are routinely treated with telemedical support.
62444117|NCT06042283|NO_INTERVENTION|Control group|All participants in the control group will continue the treatment process determined in the routine. In this process, the patient participates in counseling and/or psychotherapy, ECT (electroconvulsive therapy) sessions, and psychopharmacological drugs. The control group will not participate in the Metacognitive Training-Silver program, an interview consisting of one session is planned considering for the placebo effect. At the end of the study, the Metacognitive Training-Silver program will be carried out with the voluntary participants in the control group, taking into account the ethics.
62444118|NCT04464694|EXPERIMENTAL|Ranibizumab|Single intravitreal injection of ranibizumab (0.5 mg) 3\~7 days before vitrectomy
62444119|NCT04464694|SHAM_COMPARATOR|Sham injection|Sham injection 3\~7 days before vitrectomy
62444120|NCT02629874|ACTIVE_COMPARATOR|EA-230 (30mg/kg)|Subjects will receive EA-230, 30 mg/kg
62444121|NCT02629874|ACTIVE_COMPARATOR|EA-230 (90mg/kg)|Subjects will receive EA-230, 90 mg/kg
62444122|NCT02629874|ACTIVE_COMPARATOR|EA-230 (180mg/kg)|Subjects will receive EA-230, 180 mg/kg
62444123|NCT02629874|PLACEBO_COMPARATOR|Placebo|subjects receive placebo
62256784|NCT00714428||Group 1: Item Development|Individuals with TBI to provide input to relevant questions for quality of life measure in TBI
62256785|NCT00714428||Group 2: Item Development|Clinicians who treat those with deployment related TBI to obtain their feedback on relevant questions pertaining to quality of life measures in TBI.
62444124|NCT04774575|NO_INTERVENTION|routine group|Patients will follow a standard clinical follow-up based on kidney allograft function (serum creatinine, estimated glomerular filtration rate (eGFR), proteinuria) and a surveillance allograft biopsies performed at 3 and 12 months after transplantation (M3 and M12). Visits with biopsies for clinical indication are left to the appreciation of the investigator
62444125|NCT04774575|EXPERIMENTAL|biomarker guided follow-up|"Patients will follow a biomarker-guided strategy based on specific non-invasive biomarkers as defined in EUTRAIN-1 study on the basis of its detection and prediction capacities for rejection at M3 to decide whether a biopsy is performed. At M12 a routine biopsy is performed.~Visits with biopsies for clinical indication are left to the appreciation of the investigator"
62444126|NCT04634110|EXPERIMENTAL|Patients with ALK+ NSCLC and brain metastases|Including patients with brain metastases from ALK (anaplastic lymphoma kinase) positive NSCLC (non-small cell lung cancer), who are either neurologically asymptomatic or who have only mild neurologic symptoms (RTOG \[Radiation therapy Oncology Group\] acute neurologic morbidity score 0-2) from their brain metastases, who are TKI (tyrosine kinase inhibitor) naïve or who have had prior exposure to crizotinib, but who are naïve to brigatinib and other ALK TKIs including alectinib, lorlatinib, and ceritinib.
62444127|NCT06057285|NO_INTERVENTION|AR technologies to develop a first aid cart learning system|The control group received traditional teaching.
62054608|NCT04839263|NO_INTERVENTION|"Conventional setting protocol"|"Conventional setting protocol~Preoperative strategy:~* Hospitalization on surgery day~* Fasting as of midnight prior to the day of surgery~Perioperative strategy:~- Balanced anaesthesia via halogens gases~Postoperative strategy:~* Same day refeeding and mobilization minimum 6 hours post operation~* Bladder catheter and Venflon removal on day 1"
62256786|NCT00714428||Group 3: Instrument Development|Individuals with deployment TBI who will complete the Beta version of the TBI QOL measure.
62256787|NCT04641767||BIOTRABIS>18 - Pathologic patients|Group that includes adult patients under study. Those with mild TBI will be recruited. In order to determine the severity of the mild TBI, the doctor uses a scale called the Glasgow GCS scale and mild TBI is understood as those with GCS: 14-15.
62256788|NCT04641767||BIOTRABIS>18 - Control patients|Group that includes adult control patients. Those with very mild TBI will be recruited (GCS: 15) without symptoms
62256789|NCT04641767||BIOTRABIS<18 - Pathologic patients|Group of paediatric patients under study. This will recruit those who come to the emergency department with mild TBI (GCS 14-15) or moderate (GCS 9-13).
62256790|NCT04641767||BIOTRABIS<18 - Control patients|Group that includes paediatric control patients. Those with very mild TBI will be recruited (GCS: 15) without symptoms
62256791|NCT04296214||A|Azacitidine 50 mg/m2 for 10 days each 28 days
62256792|NCT04296214||B|Azacitidine 75 mg/m2 for 7 days each 28 days
62256793|NCT04578860|ACTIVE_COMPARATOR|Treatment as usual|Usual treatment of sleep disorders consist of adequate sleep hygiene entails the behaviors, practices, rituals, and habits.
62256794|NCT04578860|EXPERIMENTAL|Music Intervention|Using the app Music Care
62256795|NCT04578860|PLACEBO_COMPARATOR|White Noise|Using an app producing white noise (like rain, storm, fan, wind...)
62256796|NCT02227732|OTHER|New Indwelling Pleural Catheter|
62613915|NCT00596999||1|all subjects will be treated with UCB and HPDSC
62613916|NCT02303834|NO_INTERVENTION|Control|The control group will not be fitted with CPAP.
62613917|NCT02303834|EXPERIMENTAL|CPAP group|The group will wear a CPAP device throughout the night. The mask fits comfortably over the nose and delivers a steady stream of air under slight pressure (auto-set).
62054609|NCT02733809|EXPERIMENTAL|Sorafenib|Group under the treatment ( sorafenib ) Maximum dose of 400 mg BID If subjects devolves adverse events, dose can be reduced.
62054610|NCT01079559|ACTIVE_COMPARATOR|Simplex™ P|All patients will receive preoperative antibiotics administered within the hour prior to surgery. All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
62054611|NCT01079559|EXPERIMENTAL|Simplex™ P with Tobramycin|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
62256797|NCT01886573|EXPERIMENTAL|Treatment (azacitidine, entinostat)|Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Patients undergo surgery between days 11-20 (this period can be extended 10 more days if adverse events from therapy impose a surgical risk).
62256798|NCT04227366|EXPERIMENTAL|Group 1|BCD-089
62444128|NCT06057285|EXPERIMENTAL|An ACLs cart training course was developed using augmented reality (AR) technologies|The developed first aid cart learning system was applied to ACLs drills in a regular ACLs training program, and an AR group used this learning system to assist in their learning. The AR group scanned the dedicated AR marker using a mobile device
62444129|NCT02637076|EXPERIMENTAL|narcolepsy with cataplexy|patients given single dose of Xyrem
62444130|NCT02637076|EXPERIMENTAL|healthy controls|healthy controls given a single dose of Xyrem
62613918|NCT01326000|EXPERIMENTAL|KRAS WT A|
62054612|NCT03105284|ACTIVE_COMPARATOR|Liposuction of fat|The intervention examined is the extraction method by liposuction.
62256799|NCT04227366|PLACEBO_COMPARATOR|Group 2|Placebo
62444131|NCT06035783||Observational cohort|Patients undergoing PCI of a severely calcified coronary lesion in need of OA to enable proper stent placement
62444132|NCT05489484|EXPERIMENTAL|MD-Shoulder Medical Device|MD-Shoulder Medical Device type I collagen based
62444133|NCT01236170||Group 1|Veterans with spinal cord injury or amputated limbs who use a wheelchair as their primary source of mobility
62444134|NCT02680795|EXPERIMENTAL|Wild Type UGT1A1|Cohort A: Open for Enrollment Wild Type UGT1A1, Belinostat IV
62444135|NCT02680795|EXPERIMENTAL|Heterozygous UGT1A1*28|Cohort B: Closed For Enrollment Heterozygous UGT1A1, Belinostat IV
62444136|NCT02680795|EXPERIMENTAL|Homozygous UGT1A1*28|Cohort C: Open For Enrollment Homozygous UGT1A1, Belinostat IV
62444137|NCT03804320|OTHER|Patients with small renal masses|Active surveillance
62613919|NCT01326000|ACTIVE_COMPARATOR|KRAS WT B|
62054613|NCT03105284|NO_INTERVENTION|Excision of fat|Control group
62444138|NCT00993616|EXPERIMENTAL|Treatment|Patients receive belinostat IV over 30 minutes on days 1-5 and carboplatin IV over 30-60 minutes on day 3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who are clinically responding or who, in the opinion of their physician, would continue to benefit from treatment may continue treatment beyond 6 courses.
62444139|NCT00672620|EXPERIMENTAL|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
62613920|NCT01326000|EXPERIMENTAL|KRAS mutant A|
62613921|NCT01326000|ACTIVE_COMPARATOR|KRAS mutant B|
62613922|NCT03171740|ACTIVE_COMPARATOR|Dexmedetomidine|Children will receive 1mcg/kg intranasal dexmedetomidine and oral saline, 30 minutes before going to operation theater.
62613923|NCT03171740|ACTIVE_COMPARATOR|Midazolam oral solution|Children will receive 0,5mg/kg oral midazolam and intranasal saline, 30 minutes before going to operation theater.
62054614|NCT01597830|EXPERIMENTAL|active shoe|
62054615|NCT01597830|SHAM_COMPARATOR|Control|
62054616|NCT01693692|EXPERIMENTAL|TD-9855 Group 1|Group 1 to be dosed with TD-9855
62054617|NCT01693692|EXPERIMENTAL|TD-9855 Group 2|Group 2 to be dosed with TD-9855
62054618|NCT01693692|PLACEBO_COMPARATOR|Placebo|Group to be dosed with Placebo
62256800|NCT01124903|EXPERIMENTAL|Dehydration|Multiple measures of hydration status were made when subjects were normally hydrated (euhydrated) and when dehydrated. The diagnostic usefulness of the measures was determined.
62256801|NCT02121600|OTHER|Docetaxel|Patients who will be receiving Docetaxel as cancer treatment will be assigned to Arm 1. All patients in this cohort will have a \[F-18\]-FCH PET scan with full body MRI scan
62256802|NCT02121600|OTHER|Abiraterone|Patients who will be receiving Abiraterone as cancer treatment will be assigned to Arm 2. All patients in this cohort will have a \[F-18\]-FCH PET scan with full body MRI scan.
62256803|NCT05352997||Group 1: on-target beta-lactams serum concentration|Patients with on-target beta-lactams serum concentration during 1st dosing
62444140|NCT00672620|EXPERIMENTAL|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
62613924|NCT06730724||Carpal tunnel syndrome|Patients with carpal tunnel syndrome
62613925|NCT06730724||Control group|Healthy controls without carpal tunnel syndrome
62613926|NCT02094950|EXPERIMENTAL|Lung Cancer Patient with Dyspnea|
62613927|NCT04634032||Hernia|Patients planned to undergo routine indirect inguinal hernia repair procedure
62838956|NCT02094924|EXPERIMENTAL|Sequence 1|Participants in this arm will receive treatment A in period 1 and treatment B in period 2. Subjects will receive a single reference FDC tablet of 16mg candesartan cilexetil/12.5mg HCTZ as Treatment A administered orally with 240mL of water and a single 16mg candesartan cilexetil/12.5mg HCTZ FDC tablet (GSK587323) as Treatment B.
62838957|NCT02094924|EXPERIMENTAL|Sequence 2|Participants in this arm will receive treatment B in period 1 and treatment A in period 2. Subjects will receive a single reference FDC tablet of 16mg candesartan cilexetil/12.5mg HCTZ as Treatment A administered orally with 240mL of water and a single 16mg candesartan cilexetil/12.5mg HCTZ FDC tablet (GSK587323) as Treatment B.
62838958|NCT05002296|ACTIVE_COMPARATOR|traditional physical therapy program|
62838959|NCT05002296|EXPERIMENTAL|rotatory upper cervical manipulation to both sides|
62838960|NCT03298035|ACTIVE_COMPARATOR|NCPAP as mode for apnea prevention|With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.
62838961|NCT03298035|EXPERIMENTAL|NIPPV as rescue mode for apnea prevention|With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
62444141|NCT00672620|ACTIVE_COMPARATOR|Duloxetine 60 mg|Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsules, orally, once daily for 1 week after the treatment period.
62444142|NCT00672620|PLACEBO_COMPARATOR|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
62444143|NCT03880279|EXPERIMENTAL|TAC01-CD19|TAC01-CD19, Autologous TAC (T cell antigen coupler) T cells, single infusion, multiple dosage levels.
62613928|NCT04634032||Control|Patients planned to undergo routine circumcision procedure
62838962|NCT01847326|EXPERIMENTAL|Treatment (induction therapy and AFHX or AXX)|See Detailed Description
62838963|NCT03137199|EXPERIMENTAL|Group receiving 20 million hMSCs|3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion
62838964|NCT03137199|EXPERIMENTAL|Group receiving 100 million hMSCs|3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion
62613929|NCT03726736|EXPERIMENTAL|Anlotinib combined Docetaxel|patients treated with anlotinib and Docetaxel (21 days for 1 cycle) until PD (progressive disease)
62613930|NCT03726736|ACTIVE_COMPARATOR|Docetaxel|patients treated with Docetaxel (21 days for 1 cycle) until PD (progressive disease)
62613931|NCT04481165||Adolescents with anorexia nervosa|Adolescents from 12 to 25 year old, cared for anorexia nervosa at the Maison de Solenn (Cochin hospital, Paris, France) et for whom antidepressive agents have been prescribed
62613932|NCT04283526|EXPERIMENTAL|NIS793 + MBG453|treatment with NIS793 + MBG453
62613933|NCT04283526|EXPERIMENTAL|NIS793 + MBG453 + Spartalizumab|Treatment with NIS793 + MBG453 + Spartalizumab
62613934|NCT04283526|EXPERIMENTAL|NIS793 + MBG453 + Decitabine|treatment with NIS793 + MBG453 + Decitabine
62613935|NCT04283526|EXPERIMENTAL|NIS793|treatment with NIS793
62613936|NCT04283526|EXPERIMENTAL|MBG453|treatment with MBG453
62613937|NCT01601002|EXPERIMENTAL|Mirtazapine|Mirtazapine in dosage of 7.5 mg to 45 mg/day
62613938|NCT04118556|EXPERIMENTAL|Decidua Stroma Cells (DSC)|"Placenta derived decidua stroma cells (DSC). In the first phase I part, two different dose levels will be used, 1x10\^6/kg and 3x10\^6/kg. Two doses, one week apart, will be given. The decision to proceed to the next dose level will depend on results observed at the previous dose level.~The dose in the randomized part will be based on the findings in the phase I part. In the Phase II study all patients will receive 2 doses, one week apart. Depending on response, up to 6 doses in total may be given. Additional doses (beyond the first 2 doses) may be given one week apart until response."
62613939|NCT04118556|ACTIVE_COMPARATOR|Best Available Treatment (BAT)|The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
62613940|NCT03333408|ACTIVE_COMPARATOR|Group A (Antibiotic)|Group A will receive postoperative oral antibiotics for 10 - 14 days (Clindamycin or Augmentin) upon discharge.
62613941|NCT03333408|NO_INTERVENTION|Group B (no Antibiotic)|Group B will not be given postoperative oral antibiotics upon discharge.
62613942|NCT03752060|EXPERIMENTAL|Resistance Training Group|These participants will participate in a progressive resistance training program three times per week on non-consecutive days for 16 weeks. During each session, participants will perform the following exercises: supine bench press, lat pulldown, lateral raise, seated row, leg press, leg extension, leg curl, biceps curl, and triceps extension. The exercises will be completed such that upper body and lower body exercises are alternated throughout each session. During the Weeks 1-4 of training, the subjects will complete two sets of 15 repetitions for each exercise at approximately 50% of their one-repetition maximum (1RM). During Weeks 5-8 of training, the subjects will complete three sets of 12 repetitions at approximately 60% 1RM. During Weeks 9-12, the subjects will complete four sets of 12 repetitions at approximately 60% 1RM. During Weeks 13-16 of training, the subjects will complete 4 sets of 10 repetitions at approximately 70% 1RM.
62623615|NCT04388124|EXPERIMENTAL|Bosentan|Patient will receive Bosentan for 56 days: 2 capsules of 62.5 mg per day for 27 days +/-1 day, 2 capsules of 125 mg per day for 27 days +/-1 day.
62444144|NCT04811261|EXPERIMENTAL|3+3 dose escalation|The first 3 subjects' patients will be administered 50 x 10\^6 ULSCs reconstituted in PBS with 1% human serum albumin in a volume of 250 ml, and monitored for adverse events or toxicities, immediately following dosing, and again at 30 days.
62444145|NCT02151097||High risk prostate cancer|Men ≥18 years of age diagnosed with high risk prostate cancer, defined as clinical stage ≥T2c, or Prostate Specific Antigen (PSA)\>20 ng/ml, or Gleason Score 8-10, scheduled to have radical prostatectomy.
62444146|NCT04106375|EXPERIMENTAL|Intervention Group|Women with a history of depression and no other mental health disorders undergoing Mindfulness Based Cognitive Therapy.
62444147|NCT04106375|NO_INTERVENTION|Control|Healthy women with no prior history of depression or other mental health disorders as a control group for time-repetition effects on brain activity and task performance
62444148|NCT00385541|ACTIVE_COMPARATOR|A|Patients receive morphine 1mg/dose PCA for postsurgical pain; max 10 mg/hr; lockout 6 minutes.
62444149|NCT00385541|ACTIVE_COMPARATOR|B|Patients receive hydromorphone 0.2mg/dose PCA for postsurgical pain; max 10mg/hr; lockout 6 minutes.
62444150|NCT03248856|OTHER|Group 1|Group 1 will receive triamcinolone acetonide 10mg 20 to 24hours before sampling.
62444151|NCT03248856|OTHER|Group 2|Group 2 will receive triamcinolone acetonide 40mg 20 to 24hours before sampling.
62444152|NCT03248856|OTHER|Group 3|Group 3 will receive triamcinolone acetonide 10mg 1 to 2 hours before sampling.
62444153|NCT03248856|OTHER|Group 4|Group 3 will receive triamcinolone acetonide 40mg 1 to 2 hours before sampling.
62444154|NCT01765985|EXPERIMENTAL|Intercurrent PSORIAMED|5 minutes twice a day for 12 weeks
62838965|NCT00684541|EXPERIMENTAL|Interpretation Modification Program|The IMP procedure was identical to the word-sentence association paradigm (WSAP; Beard \& Amir, 2009) except participants received feedback about their responses. Participants received positive feedback when they endorsed benign interpretations or rejected threat interpretations of the ambiguous sentences on 100% of trials and negative feedback when they endorsed threat interpretations or rejected benign interpretations on 100% of trials. This feedback manipulation was intended to reinforce a benign interpretation bias and extinguish the threat interpretation bias. Participants completed two blocks of 110 training trials in each session. Participants who completed Set A during the WSAP assessment saw Set B during the IMP and vice versa. Each IMP session lasted approximately 20 min.
62054619|NCT04536311|EXPERIMENTAL|Paravertebral block in surgical stabilization of rib fractures under awake or appropriate sedation|patients receive internal fixation for multiple rib fractures using paravertebral nerve block anesthesia in awareness status and keep spontaneous breath
62054620|NCT02878928|EXPERIMENTAL|IDgenetix Neuropsychiatric Test Panel Intervention|Medical providers for IDgenetix Neuropsychiatric Test Panel-guided group will make treatment recommendations based on test results. Patient outcomes will be measured throughout the duration of the study.
62054621|NCT02878928|NO_INTERVENTION|Control Group|Medical providers for the Control Group will not receive IDgenetix Neuropsychiatric Test Panel results and will make treatment recommendations as usual. Patient outcomes will be measured throughout the duration of the study.
62054622|NCT05145725||Idiopathic scoliosis in adolescents requiring surgery|
62054623|NCT01257880||Control (absence of PFO)|Persons who have migraine aura and no evidence of PFO, based on transcranial Doppler evaluation.
62054624|NCT01257880||Large PFO|Persons who have migraine aura and large PFO, as assessed by transcranial Doppler evaluation.
62838966|NCT00684541|PLACEBO_COMPARATOR|Interpretation Control Condition|The ICC was identical to the IMP, except that participants received positive feedback when they endorsed threat interpretations on half (50%) of the trials and negative feedback when they endorsed threat interpretations for the remaining half (50%) of trials. This frequency was the same for benign interpretations. Thus, the control group was reinforced equally for making threat and benign interpretations. The ICC was not intended to change interpretation significantly in either direction.
62838967|NCT02457143|EXPERIMENTAL|Letter|Patients will receive a reminder letter signed by their family physician which indicates which cancer screening tests they are overdue for and encourages them to book an appointment for screening.
62054625|NCT01893385|EXPERIMENTAL|vitamin D|The entire project will collect new information on the merits of the use of vitamin D in aging. A better knowledge of mechanisms involved and the impact of aging on them is a necessary prerequisite the definition of a new strategy using this drug in the elderly particularly fragile in order to improve its autonomy. This definition seems a sociological interest obvious economic knowing the current aging population and its impact future of our health system
62054626|NCT01893385|OTHER|INTANZA 15|The entire project will collect new information on the merits of the use of vitamin D in aging. A better knowledge of mechanisms involved and the impact of aging on them is a necessary prerequisite the definition of a new strategy using this drug in the elderly particularly fragile in order to improve its autonomy. This definition seems a sociological interest obvious economic knowing the current aging population and its impact future of our health system
62054627|NCT01727063|EXPERIMENTAL|Cell Therapy|Intramyocardial injection of autologous bone marrow-derived cells
62054628|NCT01727063|NO_INTERVENTION|Placebo|Saline injection
62054629|NCT01834508|OTHER|Treatment group|
62256804|NCT05352997||Group 2: off-target beta-lactams serum concentration|Patients with off-target beta-lactams serum concentrations during 1st dosing
62054630|NCT01686880|EXPERIMENTAL|Preoperative aTARE|The patients in this arm will receive Sirsphere trans-arterial radioembolization before surgery
62256805|NCT05352997||Group 3: off-target beta-lactams plasma concentration:|Patients with high beta-lactams plasma concentrations during 1st dosing
62256806|NCT05060653|EXPERIMENTAL|SBRT followed by surgical stabilization within 48 hours|SBRT and surgical stabilization will be performed within a 24 to 48-hour time window instead of today's standard of care of two weeks between surgical stabilization and conventional radiotherapy.
62256807|NCT03650920|EXPERIMENTAL|Recipient of HCV positive liver graft|A single center, open-label, pilot study examining 10 adult HCV negative liver transplant subjects who receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after liver transplantation, unless extenuating clinical circumstances arise (such as fibrosing cholestatic HCV, which would prompt earlier treatment, or non-hepatic comorbidities which would prompt delay in treatment).
62256808|NCT00456105|ACTIVE_COMPARATOR|1|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician, post operatively until hospital discharge and post discharge in the community.
62838968|NCT02457143|EXPERIMENTAL|Phone call|Patients will receive a phone call from a member of the practice staff. The call will inform them about which cancer screening tests they are overdue for and will encourage them to book an appointment for screening.
62838969|NCT04341870|EXPERIMENTAL|Sarilumab + Azithromycin + Hydroxychloroquine|Sarilumab combined with Azithromycin and Hydroxychloroquine
62838970|NCT04341870|ACTIVE_COMPARATOR|Sarilumab|Sarilumab only
62838971|NCT05303311|ACTIVE_COMPARATOR|Bupivacaine group|Patients will be anesthetized by spinal anesthesia by intrathecal injection of 3 ml hyperbaric bupivacaine 0.5% alone.
62256809|NCT00456105|EXPERIMENTAL|2|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team post operatively until hospital discharge and post discharge in the community. The Diabetes Action team will consist of a nurse coordinator who is a Certified Diabetes Educator (CDE) and a team of physicians specialized in the management of diabetes.
62256810|NCT00456105|PLACEBO_COMPARATOR|3|Subjects without diabetes will have their blood glucose levels monitored while in the hospital.
62256811|NCT01593293|ACTIVE_COMPARATOR|PemCarbo|Pemetrexed/Carboplatin arm
62054631|NCT02223039|EXPERIMENTAL|AbGn-168H Low Dose|Subject to receive low dose of AbGn-168H intravenously
62256812|NCT01593293|ACTIVE_COMPARATOR|Pem only|Pemetrexed arm
62444155|NCT01765985|ACTIVE_COMPARATOR|PLACEBO|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
62054632|NCT02223039|EXPERIMENTAL|AbGn-168H High Dose|Subject to receive high dose of AbGn-168H intravenously
62054633|NCT02223039|PLACEBO_COMPARATOR|Placebo|Subject to receive placebo intravenously
62054634|NCT05081492|EXPERIMENTAL|Treatment (CF33-hNIS-antiPDL1)|Patients receive CF33-hNIS-antiPDL1 IT on days 1 and 15. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
62054635|NCT00586599|OTHER|Control|Subjects who have no inflammatory disease who will be age/gender matched controls for the 2 other arms.
62054636|NCT00586599|OTHER|IBD and infliximab|Subjects who have IBD and will be receiving infliximab for the first time.
62444156|NCT00326079|ACTIVE_COMPARATOR|1|
62444157|NCT00326079|ACTIVE_COMPARATOR|2|
62444158|NCT03522948|EXPERIMENTAL|Open pilot|The intervention is a brief, in-person motivational intervention followed by 4 weeks of text messaging to reduce heavy episodic drinking and sexual risk behavior (unprotected anal intercourse) among men-who-have-sex-with-men.
62444159|NCT06484556|EXPERIMENTAL|NW-301V|NW-301V monotherapy in patients with Solid Tumors with KRAS G12V mutation
62444160|NCT06484556|EXPERIMENTAL|NW-301D|NW-301D monotherapy in patients with Solid Tumors with KRAS G12D mutation
62054637|NCT00586599|OTHER|Newly Diagnosed IBD|Subjects who are newly diagnosed with IBD and given corticosteroid therapy.
62054638|NCT00432874|EXPERIMENTAL|1|"Anterior stromal hydration (Wong method)"
62054639|NCT00432874|ACTIVE_COMPARATOR|2|Traditional lateral wound hydration
62054640|NCT04111068|EXPERIMENTAL|Active then Sham|Participants in this arm will be exposed to active stimulation during session 1 and sham/placebo stimulation during session 2
62054641|NCT04111068|EXPERIMENTAL|Sham then Active|Participants in this arm will be exposed to sham/placebo stimulation during session 1 and active stimulation during session 2
62444161|NCT02516566|EXPERIMENTAL|PEEP group|Mechanical ventilation with PEEP 8 cmH2O
62444162|NCT02516566|NO_INTERVENTION|No PEEP group|Mechanical ventilation with no PEEP
62444163|NCT05312645|EXPERIMENTAL|Diclofenac Gel|Nursing staff will apply 2 grams of diclofenac 1% gel topically to the posterior cervical region of the subject four times daily for 14 days. A questionnaire consisting of a Numeric Assessment Scale (NAS) and Headache Impact Test (HIT-6) will be administered at baseline (day 1), day 7, and at the study conclusion (day 14). A complete metabolic panel will obtained on day 0 and on day 14.
62444164|NCT05312645|PLACEBO_COMPARATOR|Control|Nursing staff will apply a petroleum gel based compound topically to the posterior cervical region of the subject four times daily for 14 days. A questionnaire consisting of a Numeric Assessment Scale (NAS) and Headache Impact Test (HIT-6) will be administered at baseline (day 1), day 7, and at the study conclusion (day 14). A complete metabolic panel will obtained on day 0 and on day 14.
62444165|NCT04916925|EXPERIMENTAL|pcos resistant to cc plus vit d|100 patients who are PCOS and resist CC will receive Vitamin D 10000 IU orally plus 150mg clomid orally for 3 months number and size of growing follicles will be monitored
62054642|NCT06363825|EXPERIMENTAL|Single arm|TAE+HAIC combined with camrelizumab and apatinib
62054643|NCT04447430|EXPERIMENTAL|bright light group|treat patients with bright light (10000 lux)
62054644|NCT04447430|PLACEBO_COMPARATOR|dim red light group|treat patients with dim red light (100 lux)
62054645|NCT01916005|EXPERIMENTAL|endocarditis|
62054646|NCT03610763|ACTIVE_COMPARATOR|Transplantation/Replantation Patients|Can plateaued hand function in hand transplantation patients/hand replantation patients in the chronic stage of recovery be facilitated by use of bi-hemispheric transcranial direct current stimulation (tDCS) combined with modified Constraint Induced Movement Therapy (CIMT)?
62256813|NCT03606993|EXPERIMENTAL|Lucky Iron Fish™ (LIF)|For Mother-infant dyads enrolled into the LIF arm, mother receives a cooking supplement: one \~ 200g iron ingot.
62256814|NCT03606993|NO_INTERVENTION|Enhanced standard of care (eSOC)|For mother-infant dyads in the eSOC arm, families are not provided iron supplementation (consistent with standard of care) but have additional visits and laboratory monitoring beyond well-child care (enhanced).
62256815|NCT05755841||1|Outpatient management of preterm prelabor rupture of membranes
62256816|NCT05755841||2|Inpatient management of preterm prelabor rupture of membranes
62256817|NCT03700320|ACTIVE_COMPARATOR|Oral SOC Migraine Preventive Medication|Oral standard of care (SOC) medication recognized as safe and effective for the prevention of migraine, based on investigator's judgement in consultation with the participant.
62256818|NCT03700320|EXPERIMENTAL|Atogepant 60 mg|Atogepant 60 mg tablet taken orally, once daily for 52 weeks.
62256819|NCT05952440||RA in remission who performed synovial biopsy before treatment change|
62444166|NCT01730677|EXPERIMENTAL|Lapatinib+Vinorelbine|lapatinib 1000mg, once daily vinorelbine 20mg/m2, D1 and D8, every 3 weeks
62444167|NCT01730677|NO_INTERVENTION|Vinorelbine|vinorelbine 30mg/m2, D1 and D8, every 3 weeks
62444168|NCT00838474|OTHER|music therapy|Each infant was randomized to receive music therapy or no music over 2 consecutive days
62256820|NCT05952440||RA in remission eligible to synovial biopsy before treatment change|
62256821|NCT05952440||Subjects asymptomatic for joint inflammation without ACPA/RF positivity|
62256822|NCT03213964|EXPERIMENTAL|Arm 1|"FATE-NK100 is a donor-derived NK cell product comprising ex vivo activated effector cells with enhanced anti-tumor activity.~FATE-NK100 is administered to determine the maximum tolerated doze/maximum feasible dose (MTD/MFD).~Interleukin-2 (IL-2) remains the only FDA approved drug that is capable of promoting NK cells activation and survival.~Lymphodepletion with Cyclophosphamide and Fludarabine."
62256823|NCT05445401|EXPERIMENTAL|Pre-rehabilitation group|Triple pre-rehabilitation interventions of exercise, nutrition and psychology during the neoadjuvant period
62444169|NCT05279014|ACTIVE_COMPARATOR|Exercise in a fed-state|12-weeks of exercise training, 50-minutes, 3 days per week performed 1.5-3 hours after a high-carbohydrate meal (1 g/kg body mass).
62838972|NCT05303311|ACTIVE_COMPARATOR|pethidine plus dexamethasone group|Patients will be anesthetized by spinal anesthesia by intrathecal injection of 1mg/kg preservative-free pethidine plus 4mg dexamethasone diluted to a volume of 3 ml with 0.9% sodium chloride
62838973|NCT04319588|EXPERIMENTAL|Parasternal Group|"The parasternal group of patients will receive the pre-operative parasternal block (20 ml of 0.5% Ropivacaine per side) in association with infiltration with local anesthetic of access to thoracic drainage (drainage infiltration with 20 ml of 0.25% Ropivacaine) at the end of the intervention combined to General Anesthesia."
62256824|NCT05445401|PLACEBO_COMPARATOR|Conventional group|Conventional group
62444170|NCT05279014|EXPERIMENTAL|Exercise in a fasted-state|12-weeks of exercise training, 50-minutes, 3 days per week performed after at least an 8-hour fast. A high-carbohydrate meal (1 g/kg body mass) will be consumed after exercise.
62444171|NCT01557595|EXPERIMENTAL|Adults with ADHD|"Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. Subjects will 19 years or older and have ADHD"
62444172|NCT04243174|OTHER|SMS Messages|Patients with type 2 diabetes will be recruited and will start receiving short SMS messages about physical activity, encouraging them to be more active and help them to build a healthy life style routine.
62444173|NCT01958281|EXPERIMENTAL|SOF 200 mg + RBV 200 mg (Cohort 1)|Participants with genotype 1 or 3 HCV infection will receive SOF 200 mg (2 × 100 mg tablets) plus RBV once daily for 24 weeks.
62444174|NCT01958281|EXPERIMENTAL|SOF 400 mg + RBV 200 mg (Cohort 2)|Participants with genotype 1 or 3 HCV infection will receive SOF 400 mg (4 × 100 mg tablets or 1 × 400 mg tablet) plus RBV once daily for 24 weeks.
62444175|NCT01958281|EXPERIMENTAL|LDV/SOF (Cohort 3)|Participants with genotype 1 or 4 HCV infection will receive LDV/SOF once daily for 12 weeks.
62444176|NCT00736320|ACTIVE_COMPARATOR|A|2 cycles ABVD followed by 20 Gy IF-RT irrespective of FDG-PET results after chemotherapy
62444177|NCT00736320|EXPERIMENTAL|B|2 cycles ABVD followed by 20 Gy IF-RT if FDG-PET is positive after chemotherapy; 2 cycles ABVD and treatment stop if FDG-PET is negative after chemotherapy
62623616|NCT04171362|EXPERIMENTAL|Migraine group|The study included patients diagnosed by migraine according to International Headache Community criteria with18-65 years of age followed by routine controls and who were volunteered
62838974|NCT04319588|ACTIVE_COMPARATOR|Case control group|"The case control group will only receive drainage infiltration with local anesthetic and standard intraoperative management with opioids."
62838975|NCT05346419|EXPERIMENTAL|Postmenopausal Osteopenia-osteoporosis patients|All participants were treated for 6 months with risedronate 35 mg and vitamin D 2800 IU once a week, with additional daily vitamin D supplementation of 4000 IU.
62256825|NCT03946137|EXPERIMENTAL|Sample|"30 patients of both sexes aged between 0 and 6 years with chronic neurological involvement with respiratory complications.~Individual sessions of chest therapy every fifteen days for three months, in total 6 respiratory physiotherapy sessions of 30 minutes each were performed. And the postural hygiene workshops were given to the parents, this educational intervention was carried out at the beginning of the study, at 3 months and at 6 months from the beginning. Each intervention lasted 4 hours with theoretical and practical part."
62256826|NCT03856853|EXPERIMENTAL|treatment group|pirfenidone group
62444178|NCT05152342|EXPERIMENTAL|Staff intervention|Half day virtual training for staff focusing on stigma reduction strategies.
62444179|NCT05152342|EXPERIMENTAL|Client intervention|Three session virtual therapy group for clients focusing on behavioral strategies to cope with stigma.
62444180|NCT02519283|ACTIVE_COMPARATOR|Standard of Care|In keeping with the strategy-based pragmatic nature of the trial, the discharge procedures will largely be kept as they are in common practice. Investigators will standardize usual care for ED discharge to include HF medication reconciliation as well as encourage 7-day follow-up.
62444181|NCT02519283|ACTIVE_COMPARATOR|GUIDED-HF|GWTG:HF has been successfully implemented across multiple inpatient populations and health systems over the last decade and has been shown to improve HF disparities.
62444182|NCT05043233||Patients with Graves' disease|Graves' disease was diagnosed based on clinical symptoms and laboratory findings. The clinical symptoms included heat intolerance, fatigue, increased appetite, increased sweating, weight loss, muscle weakness, tremors, and diffusely enlarged thyroid glands. The laboratory results included increased serum concentrations of free thyroxine (FT4) and/ or free triiodothyronine (FT3), decreased basal thyroid-stimulating hormone (TSH) level, and TRAb positivity. All participants in this study would be treated with anti-thyroid drugs(MMI: methimazole) according to the 2016 ATA guildline.
62256827|NCT03856853|PLACEBO_COMPARATOR|placebo group|placebo group
62256828|NCT04308070|EXPERIMENTAL|Catheter without Hemostatic Agent Following Aquablation|AQUABEAM System followed by catheter without hemostatic agent
62623617|NCT04171362|ACTIVE_COMPARATOR|Control group|The study included patients diagnosed by migraine according to International Headache Community criteria with 8-65 years of age followed by routine controls and were volunteered
62623618|NCT05951036|EXPERIMENTAL|LL-BFRt|30% of repetition maximum and 70% of arterial occlusion pressure
62623619|NCT05951036|SHAM_COMPARATOR|Sham LL-BFRt|30% of repetition maximum and 10% of arterial occlusion pressure
62256829|NCT04308070|EXPERIMENTAL|Catheter with Hemostatic Agent Following Aquablation|AQUABEAM System followed by catheter with hemostatic agent
62613943|NCT03752060|ACTIVE_COMPARATOR|Aerobic Training Group|Women randomized to the AT group will engage in aerobic exercise training that complies with ACSM recommendations10. Specifically, women will complete walking or stationary cycling sessions 5 times per week for 16 weeks. Heart rate data from the pre-intervention VO2peak tests (described below) will be used to estimate each participant's target training heart rate. Like the RT regimen, the AT intervention will be progressive in nature. During the first half of the intervention period, duration will increase by 5 minutes every 2 weeks, from 30 min to 45 min. In the second phase of the intervention, duration will remain constant at 45 min, but intensity will increase from 50% to 65% of heart rate reserve (HRR). Exercise sessions will take place on a treadmill and/or cycle ergometer.
62613944|NCT03752060|NO_INTERVENTION|Control Group|The control group will complete all baseline and post-testing, but will not complete any training for the 16 weeks between the baseline and post-testing sessions. These participants will also be instructed to maintain their current dietary and physical activity habits (see Lifestyle Controls section). All participants in the control group will also be provided an opportunity to come to the laboratory for two weeks after they have completed the study to receive instruction regarding resistance and/or aerobic training exercise prescription, and to complete supervised resistance and/or aerobic exercise training.
62613945|NCT04483284|EXPERIMENTAL|TACE combined with Camrelizumab|Camrelizumab（200mg q3w ivgtt）combined with TACE,the interval between TACE treatment and Carilizumab is not less than 7 days.
62256830|NCT05462964|NO_INTERVENTION|Control Group|Newborns in this group were started to camera recording 2 minutes before the procedure and routine OGT placement was performed. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the recording was stopped.After OGT insertion, a light touch was provided if necessary to ensure routine comfort of the baby for ethical reasons.
62256831|NCT05462964|EXPERIMENTAL|İntervention Group 1|Only a pacifier was given to the newborn.
62613946|NCT06143787|PLACEBO_COMPARATOR|Treatment (T1)|Standard hemostatic measures + Placebo matching with Tranexamic Acid Oral Solution 5%
62613947|NCT06143787|EXPERIMENTAL|Treatment (T2)|Standard hemostatic measures + Tranexamic Acid Oral Solution 5%
62256832|NCT05462964|EXPERIMENTAL|İntervention Group 2|The newborn was given a pacifier sweetened with 25% dextrose.
62256833|NCT05988450|EXPERIMENTAL|SQ-Kyrin TMVr System|Transcatheter edge-to-edge mitral valve repair using SQ-Kyrin TMVr System.
62444183|NCT03291457||Glucocorticoids + Tocilizumab|Participants with RA who are receiving glucocorticoid treatment will be observed for up to 52 weeks after starting tocilizumab.
62444184|NCT01862809||cases|smokers
62444185|NCT01862809||controls|non-smokers
62444186|NCT00580853|EXPERIMENTAL|varenicline|varenicline 2mg/day
62444187|NCT00580853|EXPERIMENTAL|Bupropion|Bupropion 300mg/day
62444188|NCT00580853|PLACEBO_COMPARATOR|Placebo|Placebo Control
62613948|NCT03623659|ACTIVE_COMPARATOR|AH group|Subjects whose vitrified/warmed blastocysts will be subjected to the treatment of laser assisted hatching
62613949|NCT03623659|NO_INTERVENTION|Control group|Subjects whose vitrified/warmed blastocysts will be subjected to the same procedures except for the treatment of laser assisted hatching
62613950|NCT00554541||Normal Body-Mass|BMI Index: 18.5-24.9 Ankle Brachial Index Venous physiologic study
62613951|NCT00554541||Obese Body-Mass|BMI Index: 30.0-39.9 Ankle Brachial Index Venous physiologic study
62613952|NCT00554541||Morbidly Obese Body-Mass|BMI Index: ≥ 40 Ankle Brachial Index Venous physiologic study
62613953|NCT06449508|NO_INTERVENTION|control|no intervention
62054647|NCT03610763|ACTIVE_COMPARATOR|Nerve Injury Patients active|Can plateaued hand function in peripheral nervous system injuries in the chronic stage of recovery be facilitated by use of bi-hemispheric transcranial direct current stimulation (tDCS) combined with modified Constraint Induced Movement Therapy (CIMT)?
62444189|NCT01144884|OTHER|Single arm trial|"Education:To standardize, treatment education will consist of counsel to stay active. Details will be given to subjects verbally \& reinforced in the home booklet.~Posture:Facilitation of proper posture has been show to increase recruitment of the lumbar multifidus \& deep neck flexors. Instruction will be given verbally \& in writing.~Stretching:Stretching exercises will be targeted to address these common impairments. Patients will be introduced to proper stretching procedures. Each stretch will be held for 30s \& repeated two times,each side as applicable. The following stretches will be performed:~Upper trap Anterior/medial Scalene Suboccipital Pectoralis~Muscular Performance: Muscle performance will be trained incorporating components of strength, endurance and motor control. Each of the exercises listed below are outlined based on progressions.~Isometric Cervical Extension Craniocervical flexion Seated Row Seated T Palms Up Seated Side Arm Raises"
62444190|NCT01555502||low complications|Patients who had VATS lung resection for NSCLC, and have no or low grade (grade 1 and 2) post operative complications based on the Clavien classification system.
62444191|NCT01555502||High complications|Patients who had VATS lung resection for NSCLC, and have no or high grade (grade 3 and 4) post operative complications based on the Clavien classification system.
62444192|NCT05544747|EXPERIMENTAL|Action Observation Therapy|The patients in the action observation therapy group will be required to observe the upper limb movements or functional actions in video clips. (i.e., the observation phase) and to execute what they had observed to the best of their ability (i.e., the execution phase). Three common categories of movements and tasks will be elected in the action observation therapy protocol based on the related literature
62256834|NCT03231046|EXPERIMENTAL|CBCT-US Fusion Arm|Clear Guide SCENERGY, CBCT-US
62256835|NCT03231046|ACTIVE_COMPARATOR|EM Fusion or No Fusion Arm|
62256836|NCT04185753||Obese adolescents with CI|Obese adolescents with chronotropic incompetence
62256837|NCT04185753||Control group|Obese adolescents without chronotropic incompetence
62256838|NCT02566291||Supreme Group|Measuring Success rate and Insertion Time
62256839|NCT02566291||Gain Group|Measuring Success rate and Insertion Time
62613954|NCT06449508|ACTIVE_COMPARATOR|probiotics|will receive 5 drops of probiotic supplement containing Bacillus clausil spores (Enterogermania amp 2 billion/5 mL) once daily plus phototherapy till discharge.
62054648|NCT03610763|NO_INTERVENTION|Actigraphy Testing|We will acquire a set of actigraphy data from a group of hand transplant/replant patients and unilateral, adult amputees in order to evaluate typical patterns of limb use prior to hand transplantation and to investigate prosthesis utilization.
62444193|NCT05544747|ACTIVE_COMPARATOR|Mirror Therapy|During the mirror therapy, the patients will be seated in front of a mirror box placed at their mid-sagittal plane. The affected arm of the participants will be placed inside the mirror box and the unaffected arm in front of the mirror. The patient will be instructed to watch the mirror reflection of the movement performed by his/her unaffected hand carefully and to imagine that the movement was performed by the affected hand.
62613955|NCT04148898|EXPERIMENTAL|osimertinb group|Osimertinib 80 mg oral daily
62613956|NCT04148898|EXPERIMENTAL|osimertinb combined with bevacizumab group|"Osimertinib 80 mg oral daily;~.bevacizumab 7.5 mg/kg intravenous every 3 weeks"
62054649|NCT02236065|EXPERIMENTAL|UCB + G-CSF|UCB + G-CSF
62054650|NCT01690130|EXPERIMENTAL|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual.The brain stimulation techniques could theoretically improve the efficacy of smoking cessation. Treatment was standardized at 100% magnetic field intensity relative to the participant's resting MT, at 10 pulses per second (10 Hz) for 5 seconds, with an intertrain interval of 10 seconds. Treatment session lasted for 15 minutes with 3000 pulses.
62613957|NCT02180607||Healthy Controls|Response to social feedback, monetary incentive delay, and go/no-go tasks
62613958|NCT02180607||MDD patients|Response to social feedback, monetary incentive delay, and go/no-go tasks
62613959|NCT02647489|EXPERIMENTAL|1A - 20 µg PAMVAC + Alhydrogel|The study participant will get 20 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
62613960|NCT02647489|EXPERIMENTAL|2A - 20 µg PAMVAC + GLA-SE|The study participant will get 20 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
62613961|NCT02647489|EXPERIMENTAL|3A - 20 µg PAMVAC + GLA-LSQ|The study participant will get 20 µg of PAMVAC adjuvanted with GLA-LSQ administrated three times with each time 28 days interval (day 0-28-56)
62054651|NCT01690130|SHAM_COMPARATOR|Sham Transcranial Magnetic Stimulation|Sham-TMS procedures: After rMT determination and DLPFC cortex localization, participants were fitted with two electrodes on the scalp just below the hairline. Electrodes were connected to an Epix VT® Transcutaneous Electrical Nerve Stimulation Device (Empi; St. Paul, MN, USA)
62613962|NCT02647489|EXPERIMENTAL|4A - 50 µg PAMVAC + Alhydrogel|The study participant will get 50 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
62054652|NCT05448898|EXPERIMENTAL|Traditional Chinese Medicine with olfactory training|"Traditional Chinese Medicine therapy:~Oral Traditional Chinese Medicine CU Xiu Tang once a day for at least 3 months~Olfactory training:~repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months"
62613963|NCT02647489|EXPERIMENTAL|5A - 50 µg PAMVAC + GLA-SE|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
62613964|NCT02647489|EXPERIMENTAL|6A - 50 µg PAMVAC + GLA-LSQ|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-LSQ administrated three times with each time 28 days interval (day 0-28-56)
62613965|NCT02647489|EXPERIMENTAL|1B - 50 µg PAMVAC + Alhydrogel|The study participant will get 50 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
62613966|NCT02647489|EXPERIMENTAL|2B - 50 µg PAMVAC + GLA-SE|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
62613967|NCT02647489|EXPERIMENTAL|3B - 100 µg PAMVAC + Alhydrogel|The study participant will get 100 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
62613968|NCT02647489|EXPERIMENTAL|4B - 100 µg PAMVAC + GLA-SE|The study participant will get 100 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
62054653|NCT05448898|EXPERIMENTAL|Olfactory training|repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
62054654|NCT02569710|EXPERIMENTAL|Cohorts 1 and 2 (Without Cirrhosis) : AL-335+ODV+SMV|Treatment-naïve non-cirrhotic Hepatitis C virus (HCV)-infected participants will receive AL-335 and Odalasvir (ODV) with Simeprevir (SMV) for 8 weeks.
62054655|NCT02569710|EXPERIMENTAL|Cohort 1b (Without Cirrhosis) : AL-335+ODV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV for 8 weeks.
62054656|NCT02569710|EXPERIMENTAL|Cohort 3 (Without Cirrhosis) : AL-335+ODV+SMV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV with SMV for 6 weeks.
62256840|NCT06466304|EXPERIMENTAL|study group|children patients with BTM accounted 20 children will receive two session per day of training by threshold inspiratory muscle trainer ( for six day per week for 12 weeks). the session will contain six sets of inspiratory muscle training and the one set will contain five respiratory cycles
62613969|NCT02647489|PLACEBO_COMPARATOR|5B - Placebo|The study participant will get Placebo (physiological saline solution) administrated three times with each time 28 days interval (day 0-28-56)
62613970|NCT03885999|EXPERIMENTAL|Fecobionics studies|
62613971|NCT02998359|ACTIVE_COMPARATOR|Hemiarthroplasty|A cemented polished double taper stem hemiarthroplasty inserted via an anterior-lateral surgical approach (Zimmer incorporated, UK).
62613972|NCT02998359|ACTIVE_COMPARATOR|Total hip replacment|A cemented polished double taper stem arthroplasty inserted via an anterior-lateral surgical approach with a cemented acetabular cup (Zimmer incorporated, UK).
62613973|NCT06230952||axial spondyloarthritis patients|patients diagnosed with axial spondyloarthritis
62613974|NCT02860390|NO_INTERVENTION|Adolescent - Control|Usual care arm of subjects aged 13-19 years old
62623620|NCT05951036|ACTIVE_COMPARATOR|HL-Et|70% of repetition maximum
62613975|NCT02860390|EXPERIMENTAL|Adolescent - SMS|Subjects aged 13-19 years and receiving Denver Health Asthma Management Program (text messaging intervention)
62444194|NCT01704664|ACTIVE_COMPARATOR|I - Nutritional therapy only during the postoperative period.|Postoperative nutritional therapy administered in group I will not include immunomodulating factors. Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb), starts 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will be increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition will be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
62444195|NCT01704664|ACTIVE_COMPARATOR|II - parenteral glutamine in postoperative time|The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
62444196|NCT01704664|ACTIVE_COMPARATOR|III - perioperative oral immunonutrition|Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they will be administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will be increased gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
62444197|NCT01704664|ACTIVE_COMPARATOR|IV - Perioperative parenteral immunonutrition|Nutritional therapy of group IV will be based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids will be administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will be started at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition will be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
62444198|NCT01292200|EXPERIMENTAL|watch DVD and small group discussion|Participants will watch the video in a group and discuss the video.
62444199|NCT01292200|PLACEBO_COMPARATOR|watch video only|watch a 22 minutes long video at home by herself.
62444200|NCT00981253|EXPERIMENTAL|SMT-enhanced Cardiac Rehabilitation|Standard exercise-based cardiac rehabilitation with weekly stress management training for 12 weeks.
62444201|NCT00981253|ACTIVE_COMPARATOR|Standard Cardiac Rehabilitation|Standard cardiac rehabilitation consisting of supervised exercise for 12 weeks.
62444202|NCT04087668|OTHER|Monitored Anesthesia Care|Patients in this arm will undergo an ERCP using monitored anesthesia care (MAC) with propofol based deep sedation.
62444203|NCT04087668|OTHER|General Anesthesia|Patients in this arm will receive standard general anesthesia with neuromuscular blockade.
62444204|NCT04087668|OTHER|General Anesthesia Without Neuromuscular Blockade|Patients in this arm will receive nasotracheal intubation without neuromuscular blockade.
62444205|NCT03862599|SHAM_COMPARATOR|Standard care + sham ESWT|Cialis and Vacuum pump + sham Extra-corporeal shockwave therapy (ESWT)
62444206|NCT03862599|ACTIVE_COMPARATOR|Standard care + active ESWT|Cialis and Vacuum pump + active Extra-corporeal shockwave therapy (ESWT)
62444207|NCT02661126|EXPERIMENTAL|Moderate RI Participants|Participants with an estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73m\^2 to \<60 mL/min/1.73m\^2 take 2 MK-3682B FDC tablets on Day 1 after fasting for 10 hours.
62444208|NCT02661126|EXPERIMENTAL|Severe RI Participants|Participants with an eGFR of ≥15 mL/min/1.73m\^2 to \<30 mL/min/1.73m\^2 take 2 MK-3682B FDC tablets on Day 1 after fasting for 10 hours.
62444209|NCT02661126|EXPERIMENTAL|Healthy Participants|Healthy participants (creatinine clearance \[CLcr\] ≥80 mL/min) take 2 MK-362B FDC tablets on Day 1 after fasting for 10 hours. Healthy participants are matched to RI participants based on mean age, body mass index (BMI) and gender.
62444210|NCT00794261|EXPERIMENTAL|Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
62444211|NCT00794261|ACTIVE_COMPARATOR|Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN \> 0.5 G/L)
62444212|NCT04902274|EXPERIMENTAL|Transcranial Direct Current Stimulation plus Physical Therapy|Participants in the experimental group will receive the current standard of care in ankle inversion sprain rehabilitation plus a 20-minute application of tDCS during each treatment session via the Halo Sport (Halo Neuroscience, San Francisco, CA) headset. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes.
62613976|NCT02860390|EXPERIMENTAL|Adolescent - SMS plus support person|Subjects aged 13-19 years, Denver Health Asthma Management Program (text messaging intervention) sent to subjects and subjects' chosen Person of Support.
62613977|NCT02860390|NO_INTERVENTION|Adult - Control|Usual care arm of subjects aged 20-40 years old.
62613978|NCT02860390|EXPERIMENTAL|Adult - SMS|Subjects aged 20-40 years and receiving Denver Health Asthma Management Program (text messaging intervention).
62613979|NCT05507502|ACTIVE_COMPARATOR|In-patient vaccination arm|Participants in this arm will receive the influenza vaccination during their heart failure hospitalization.
62054657|NCT02569710|EXPERIMENTAL|Cohort 4 (Without Cirrhosis) : AL-335+ODV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV up to 8 or 12 weeks.
62613980|NCT05507502|ACTIVE_COMPARATOR|In-clinic vaccination arm|Participants in this arm will receive the influenza vaccination during their follow up visit in the heart failure clinic 30 days post-discharge.
62613981|NCT02941354|EXPERIMENTAL|Turoctocog alfa|
62256841|NCT06466304|NO_INTERVENTION|control group|children patients with BTM accounted 20 children will receive no trianiing and will serve as control children group
62838976|NCT03172416|OTHER|Oxaliplatin|"3+3 dose escalation of oxaliplatin~This is a single arm phase I trial in a 3 + 3 dose escalation and cohort expansion design evaluating the safety and tolerability of PIPAC using oxaliplatin.~The pre-planned dose levels of oxaliplatin are 45mg/m2 (Cohort 1), 60mg/m2 (Cohort 2), 90mg/m2 (Cohort 3),120mg/m2 (Cohort 4) and 150mg/m2 (Cohort 5) administered as PIPAC. Successive cohorts of patients (3 participants/cohort) will be enrolled and started on a fixed dose of oxaliplatin. The protocol specifies oxaliplatin 45mg/m2 once every 6 weeks for Cohort 1. Dose escalation continues until dose-limiting toxicities (DLT) are observed in one-third of participants. If no DLT occurs, the next cohort will be enrolled at the next planned dose level. If 1 DLT occurs in a cohort, another 3 patients will be treated with the same dose level.~Oxaliplatin every 6 weeks with IV nivolumab every 2 weeks~PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks"
62838977|NCT03281200||Anatomical main group:|
62838978|NCT03281200||Therapeutic subgroup|
62838979|NCT03281200||Pharmacological subgroup|
62838980|NCT03281200||Chemical subgroup|
62256842|NCT04326712||Group 1|Unilateral transtibial amputees using conventinional manufactured socket
62256843|NCT04326712||Group 2|Unilateral transtibial amputees using 3D manufactured socket
62256844|NCT00552175|EXPERIMENTAL|Duloxetine 60|duloxetine 60 milligram (mg) taken orally every day
62256845|NCT00552175|EXPERIMENTAL|Duloxetine 40|Duloxetine 40 mg taken orally every day
62256846|NCT00552175|PLACEBO_COMPARATOR|Placebo|placebo comparator taken orally every day
62613982|NCT04093557|ACTIVE_COMPARATOR|Orton Score Cohort - High|"Patients will be scored using the Orton Score, a novel clinical prediction tool to determine which patients are at risk for poor bowel preps and may benefit from an extended prep. If they score highly, they will receive an extended GoLytely bowel prep."
62613983|NCT04093557|PLACEBO_COMPARATOR|Prospective Orton Score Cohort - Low|"Patients will be scored using the Orton Score, a novel clinical prediction tool to determine which patients are at risk for poor bowel preps and may benefit from an extended prep. If they do not score highly, they will receive a standard GoLytely (or Suprep) bowel prep."
62613984|NCT04093557|OTHER|Retrospective Cohort (before Orton Score)|
62838981|NCT03281200||Chemical substance|
62838982|NCT03521440|EXPERIMENTAL|Psychomotor Massage|Participants will be randomly allocated to individual sessions, and will receive two 30-minute individual sessions per week, for 8 weeks.
62838983|NCT03521440|EXPERIMENTAL|Progressive Muscle Relaxation|Participants will participate in 30-minute group sessions, twice a week, for 8 weeks.
62838984|NCT03521440|NO_INTERVENTION|Waiting List|Participants will maintain their daily routines through the experimental intervention period. After finishing all periods of data collection, participants will be invited to participate in one of the interventions previously offered to the experimental groups.
62256847|NCT02506595|EXPERIMENTAL|ERRT-M for Nightmares|Exposure, Relaxation, and Rescripting Therapy Military version (ERRT-M) -
62256848|NCT02506595|NO_INTERVENTION|Waitlist control|Participants randomized to the Waitlist control condition will be contacted once weekly for 5 weeks to monitored status and then invited to participant in treatment.
62838985|NCT06246461|EXPERIMENTAL|the control group: a total daily dose of 2,500 mg/m2|The control group was treated with capecitabine at a conventional dose: 1,250 mg/m2 orally twice daily (once in the morning and once in the evening; equivalent to a total daily dose of 2,500 mg/m2). Treatment was given for 2 weeks, followed by a 1 week of discontinuation, with each cycle lasting 3 weeks, and there were a total of 4 cycles. Administration: Swallow the tablet whole with water 30 min after breakfast and dinner every day.
62256849|NCT03359291|EXPERIMENTAL|Sequence AB|Subjects participate in two study periods: During the first period (treatment A), they receive a single oral dose of rosuvastatin on Day 1. During the second period (treatment B), they receive a single oral loading dose of macitentan on Day 5 and oral doses of macitentan from Day 6 to Day 16 (i.e., 11 doses). Subjects receive a single oral dose of 10 mg rosuvastatin concomitantly with macitentan in the morning of Day 10.
62256850|NCT03739905|EXPERIMENTAL|Blood Brain Barrier (BBB) Disruption|The ExAblate Model 4000 Type 2.0 System
62613985|NCT02481115||Critically Ill Children|Children in the Pediatric Critical Care Unit regardless of admitting diagnosis aged at least 6 months of age up to 5 years of age.
62613986|NCT02802644|EXPERIMENTAL|DPP-4 Inhibitor|Any dose of Sitagliptin for 6 months with any other oral anti-diabetic medication
62613987|NCT02802644|ACTIVE_COMPARATOR|Non DPP-4 Inhibitor|Oral anti-diabetic medication except DPP-4 inhibitor
62838986|NCT06246461|ACTIVE_COMPARATOR|the medium-dose group: a total daily dose of 2,000 mg/m2|The medium-dose group was treated with medium-dose capecitabine: 1,000 mg/m2 orally twice daily (once in the morning and once in the evening; equivalent to a total daily dose of 2,000 mg/m2). Treatment was given for 2 weeks, followed by a 1 week of discontinuation, with each cycle lasting 3 weeks, and there were a total of 4 cycles. Administration: Swallow the tablet whole with water 30 min after breakfast and dinner every day.
62613988|NCT05297500||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
62613989|NCT00466206|EXPERIMENTAL|3MP - Treatment Arm|Magnetic Mini-Mover Procedure using the Magnimplant and Magnatract
62613990|NCT04255407|EXPERIMENTAL|I-ONE® group|"I-ONE® therapy will be initiated in the 15 days preceding the ACL reconstruction surgery and in the first 60 days following the surgery.~Paracetamol 1000 mg will be supplied to both groups, to be taken for pain control as per normal clinical practice."
62613991|NCT04255407|PLACEBO_COMPARATOR|Control group|Patients will not be treated with I-ONE®. Pain will be treated with common NSAID and Paracetamol.
62613992|NCT00858468|EXPERIMENTAL|Group 1|Participants aged 6 to 12 Weeks at enrollment
62256851|NCT01994382|EXPERIMENTAL|Phase 1 Cerdulatinib|During Phase 1, participants will receive oral cerdulatinib on Day 1 and then starting on Day 4 at doses of 15 mg up to 100 mg QD or oral cerdulatinib at doses of 15 mg up to 45 mg BID in 28-day cycles (except Cohort 1 will have a 21-day cycle starting on Day 1) for up to 10 cycles.
62054658|NCT02569710|EXPERIMENTAL|Cohort 5 (Without Cirrhosis) : AL-335+ODV + SMV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV with SMV up to 8 or 12 weeks.
62054659|NCT02569710|EXPERIMENTAL|Cohorts 6, 7, 8 and 12 (With Cirrhosis) : AL-335+ODV+SMV|Treatment naïve or treatment experienced HCV-infected participants with compensated cirrhosis will receive AL-335 and ODV with SMV for 8 weeks.
62054660|NCT02569710|EXPERIMENTAL|Cohorts 9, 10 and 11 (With Cirrhosis) : AL-335+ODV+SMV|Treatment naïve or treatment experienced HCV-infected participants with compensated cirrhosis will receive AL-335 and ODV with SMV for 12 weeks.
62054661|NCT02569710|EXPERIMENTAL|Cohorts 12 to 15: AL-335+ODV With/without SMV|Based on safety, pharmacokinetic (PK), and viral load data, the treatment duration (4 to 12 weeks) and dose levels (AL-335: 400-1,200 milligram \[mg\], ODV: 25-50 mg with/without SMV: 75-150 mg) may be changed for ongoing and future cohorts (up to 15) after obtaining agreement from the Sponsor and the Principal Investigator.
62054662|NCT01768832|EXPERIMENTAL|Treadmill|Individuals assigned to the Treadmill group will complete two one hour treadmill training sessions per week for 12 weeks.
62054663|NCT01768832|EXPERIMENTAL|Tango|Individuals assigned to the Tango group will complete two one hour dance classes twice per week for 12 weeks.
62054664|NCT01768832|ACTIVE_COMPARATOR|Stretching|Individuals assigned to Stretching will complete two one hour stretching classes per week for 12 weeks.
62054665|NCT03403426|EXPERIMENTAL|Wingman Crossing Catheter|Use of the device to support CTO crossing
62054666|NCT05213195|EXPERIMENTAL|NKG2D CAR-NK|NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer Will be intra-peritoneal infusion in Stage 1 and combined with intra-venous infusion in Stage 2. While in Stage 3, the investigators will expand to other cancer type at certain situation
62256852|NCT01994382|EXPERIMENTAL|Phase 2a Cerdulatinib|During Phase 2a, participants in cohorts based on cancer type will receive oral cerdulatinib at starting doses of 35, 30, or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib can be reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.
62613993|NCT00858468|EXPERIMENTAL|Group 2|Participants aged 24 to 36 Weeks at enrollment
62613994|NCT03366961|OTHER|Conversion surgery|Palliative chemotherapy followed by radical gastrectomy
62613995|NCT02414802|EXPERIMENTAL|Combined thrombectomy device|A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis. Ten million U of urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy. Anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) at discharge
62613996|NCT02414802|OTHER|Catheter-directed thrombolysis|Participants will undergo catheter-directed thrombolysis alone. A total of 100,000 units urokinase will be pulse-spray injected through the catheter once every 4-6 h. Anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) at discharge
62613997|NCT01589809|EXPERIMENTAL|Nicotinamide|Comparison is made within-subjects to different doses and no treatment
62613998|NCT01072981|EXPERIMENTAL|HyperAcute-Pancreas Immunotherapy + Standard of Care|\*Adjuvant Standard of Care Treatment (SOC) consisting of gemcitabine with or without 5FU chemoradiation + HyperAcute Immunotherapy
62613999|NCT01072981|ACTIVE_COMPARATOR|Standard of Care alone|\*Adjuvant Standard of Care Treatment (SOC) consisting of gemcitabine with or without 5FU chemoradiation Alone
62054667|NCT02607982|EXPERIMENTAL|Concurrent Chemoradiotherapy Arm|Radiotherapy was delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks. Concurrent paclitaxel (135mg/m², d1) and oxaliplatin (125mg/ m², d1) were administered on Days 1 and Day 29 of radiotherapy.
62054668|NCT06327464|OTHER|Ketone supplement condition first|
62054669|NCT06327464|OTHER|Ketone supplement condition second|
62054670|NCT06143696|EXPERIMENTAL|the experimental group|Qingxin Zishen decoction, oral administration, 1 dose a day, 2 times a day. For 28 days of medication, every 28 days. Observation time for 3 courses.
62054671|NCT06143696|ACTIVE_COMPARATOR|the control group|Femoston, oral, 1 each time, once a day. For 28 days of medication, every 28 days. Observation time for 3 courses.
62054672|NCT01678131|EXPERIMENTAL|Vaniprevir 600 mg|Participants received 600 mg vaniprevir only on days 1-7, and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
62256853|NCT01994382|EXPERIMENTAL|Phase 2a Cerdulatinib plus Rituximab|During Phase 2a, participants in this cohort will receive oral cerdulatinib at their applicable dose and an IV injection of rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.
62256854|NCT01490099|EXPERIMENTAL|Treatment period 1|
62614000|NCT01399476|EXPERIMENTAL|Endoscopic Myotomy|
62054673|NCT01678131|EXPERIMENTAL|Vaniprevir 600 mg + Peg-IFN + RBV|Participants received 600 mg vaniprevir on Days 1-7; Peg-IFN alpha-2b once a week, RBV daily from Day 1 up to Day 21; and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
62054674|NCT01678131|EXPERIMENTAL|Vaniprevir 300 mg + Peg-IFN + RBV|Participants received 300 mg vaniprevir from Days 1-7; Peg-IFN alpha-2b once a week, RBV daily from Day 1 up to Day 21; and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
62054675|NCT06254898|ACTIVE_COMPARATOR|Child life standard of care|Child life standard of care
62054676|NCT06254898|EXPERIMENTAL|Child life standard of care + incentives provided with conditional agreement.|Child life standard of care + incentives provided with conditional agreement.
62256855|NCT01490099|ACTIVE_COMPARATOR|Treatment period 2|
62256856|NCT04777136|EXPERIMENTAL|Geriatric home visit|Home-visit where a comprehensive geriatric assessment will be performed
62256857|NCT04777136|ACTIVE_COMPARATOR|Standard care|No follow-up.
62614001|NCT01620333|EXPERIMENTAL|Treatment period 1|
62614002|NCT01620333|EXPERIMENTAL|Treatment period 2|
62614003|NCT01626404||Patients enrolled|All patients enrolled in the study
62614004|NCT04275102|EXPERIMENTAL|Three times weekly symptom screening|Three times weekly symptom reporting by guardians and children using the SPARK platform for 8 weeks
62614005|NCT03129113|EXPERIMENTAL|maraviroc (Arm A)|maraviroc dosed BID p/o (dose adjusted depending on background combination antiretroviral therapy).
62054677|NCT06254898|EXPERIMENTAL|Child life standard of care + incentive provided unconditionally.|Child life standard of care + incentive provided unconditionally.
62054678|NCT04078737|EXPERIMENTAL|Ticagrelor plus Aspirin Group|Ticagrelor of loading dosing of 180mg followed by 90mg bid for 3 months plus aspirin of loading dose of 75-300mg followed by 75mg daily for 21 days
62256858|NCT06443918|EXPERIMENTAL|Intervention|The intervention aims to improve child and family mental health and functioning through psychoeducation and family-based activities delivered via a smartphone app. This intervention also includes a just-in-time adaptive intervention (JITAI) for coaching family interactions in real-time. Caregivers will wear smartwatches and carry smartphones for 8 weeks. Children will wear smartwatches. A variety of types of data will be collected from the phones and watches, such as heart rate, activity levels, and sleep. We will also collect daily surveys, daily audio recordings, a 15-minute survey every 2 weeks about their experiences using the app, and check-in calls every 2 weeks.
62256859|NCT06443918|NO_INTERVENTION|Control group|Caregivers will wear smartwatches and carry smartphones for 8 weeks. Children will wear smartwatches. Participants will complete placebo psychoeducational modules matched in length and reading level to the intervention content. A variety of types of data will be collected from the phones and watches, such as heart rate, activity levels, and sleep. We will also collect daily surveys, daily audio recordings, a 15-minute survey every 2 weeks about their experiences using the app, and check-in calls every 2 weeks.
62444213|NCT04902274|SHAM_COMPARATOR|Sham Transcranial Direct Current Stimulation plus Physical Therapy|Participants in the sham control group will receive the current standard of care in ankle inversion sprain rehabilitation plus a 20-minute sham tDCS treatment, where the patient is wearing the tDCS headset, but stimulation is only applied for 30 seconds of the 20-minute period. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes.
62444214|NCT05074186|EXPERIMENTAL|neurological thrombectomy device|Revascularization device is an investigational device.
62444215|NCT03404076||GIST patients under TKI treatment|GIST patients under TKI treatment are subjected to Dual Energy CT
62444216|NCT03563950|EXPERIMENTAL|Rifampin + BMS-986224|Oral administration
62444217|NCT04179591|EXPERIMENTAL|Exercise|Exercises will be performed three times per week for six weeks.
62444218|NCT04179591|EXPERIMENTAL|Insole|Customized arch support insoles will be worn for six weeks.
62444219|NCT04179591|EXPERIMENTAL|Exercise plus Insole|Exercises will be performed three times per week, and customized arch support will be worn for six weeks.
62444220|NCT00264810|ACTIVE_COMPARATOR|Treatment Group (stimulation ON)|Group of subjects that have undergone RNS® System implantation that are randomized to receive RNS® System responsive stimulation (i.e. responsive stimulation enabled or turned ON) during the Blinded Evaluation Period. Stimulation is enabled during the Stimulation Optimization Period (second month post-implant) and may continue throughout the subject's participation in the study.
62444221|NCT00264810|SHAM_COMPARATOR|Sham Group (stimulation OFF)|Group of subjects that have undergone RNS® System implantation that are randomized to receive sham-stimulation (i.e. responsive stimulation disabled or turned OFF) during the Blinded Evaluation Period. Stimulation is enabled after transition into the Open Label Period (sixth month post-implant) and may continue for the remainder of the subject's participation in the study.
62444222|NCT03553784|EXPERIMENTAL|Intervention Group|Group delivered Low Intensity Cognitive Behavioural Therapy (CBT).
62444223|NCT03553784|NO_INTERVENTION|Control Group|No intervention.
62444224|NCT01501799|EXPERIMENTAL|Adapalene 0.1% and benzoyl peroxide 2.5% topical gel|
62444225|NCT01501799|ACTIVE_COMPARATOR|EPIDUO™ (adapalene 0.1% and benzoyl peroxide 2.5%) Gel|
62444226|NCT01501799|PLACEBO_COMPARATOR|Vehicle Gel|
62444227|NCT06544993|ACTIVE_COMPARATOR|right side of face|meso-Botox injection
62444228|NCT06544993|ACTIVE_COMPARATOR|left side of face|microneedling combined with Botulinum toxin-A
62444229|NCT05911230|OTHER|ADW-MRI imaging|Patients with a histopathologically proven glioblastoma or brain metastasis who have suspected tumor progression on standard MRI after standard first line therapy and who are candidates for surgical resection and undergoing the ADW-MRI preoperatively.
62444230|NCT00673985|ACTIVE_COMPARATOR|1|"PTA Only: Active Comparator~Percutaneous transluminal angioplasty (PTA) alone"
62444231|NCT00673985|EXPERIMENTAL|2|"Test Arm: Experimental~The main objective of this study is to assess the safety and effectiveness of the Edwards Lifesciences LifeStent nitinol self expandable stent device and its delivery system in the treatment of occlusive superficial femoral artery (SFA) disease."
62614006|NCT03129113|EXPERIMENTAL|metformin (Arm B)|metformin 500mg BID p/o.
62614007|NCT03129113|EXPERIMENTAL|maraviroc + metformin (Arm C)|maraviroc dosed BID p/o (dose adjusted depending on background combination antiretroviral therapy) PLUS metformin 500mg BID p/o.
62614008|NCT03129113|NO_INTERVENTION|no adjunctive therapy (Arm D)|no adjunctive therapy
62614009|NCT02716506||Symptomatic POP|POP surgery in year 2015
62614010|NCT05565352||Major Depressive Disorder|Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Major Depressive Disorder (MDD), as determined by a psychiatrist.
62614011|NCT05565352||Obsessive Compulsive Disorder|Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Obsessive Compulsive Disorder (OCD) as determined by a psychiatrist.
62614012|NCT05565352||Post traumatic Stress Disorder|Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Post-Traumatic Stress Disorder (PTSD) as determined by a psychiatrist.
62614013|NCT05565352||Somatoform Disorder|Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Somatoform Disorder as determined by a psychiatrist.
62614014|NCT05565352||Anxiety Disorder|Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Anxiety Disorder as determined by a psychiatrist.
62614015|NCT05565352||Dissociative Disorder|Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Dissociative Disorder as determined by a psychiatrist.
62614016|NCT05565352||Bipolar Disorder|Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Bipolar Disorder as determined by a psychiatrist.
62838987|NCT06246461|ACTIVE_COMPARATOR|the low-dose group: a total daily dose of 1,500 mg/m2|The low-dose group was treated with low-dose capecitabine: 750 mg/m2 orally twice daily (once in the morning and once in the evening; equivalent to a total daily dose of 1,500 mg/m2). Treatment was given for 3 weeks per cycle, with each cycle lasting 3 weeks, and there were a total of 4 cycles. Administration: Swallow the tablet whole with water 30 min after breakfast and dinner every day.
62838988|NCT04823013|EXPERIMENTAL|high power pain threshold ultrasound which the dose was kept constant group (HPPT-US 1)|Participants in HPPT-US 1 group received one session of HPPT-US treatment which the dose was kept constant. The technique delivers sound waves directly to the myofascial trigger points and results in immediate pain relief.
62838989|NCT04823013|EXPERIMENTAL|high power pain threshold ultrasound which the dose reduced to one half group (HPPT-US 2)|Participants in HPPT-US 2 group received one session of HPPT-US treatment which the dose reduced to one half. The technique delivers sound waves directly to the myofascial trigger points and results in immediate pain relief.
62054679|NCT04078737|ACTIVE_COMPARATOR|Clopidogrel plus Aspirin Group|Clopidogrel of loading dosing of 300mg followed by 75mg daily for 3 months plus aspirin loading dose of 75-300mg followed by 75mg daily for 21 days
62054680|NCT03489590|EXPERIMENTAL|19F MRI with PFP|PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. Before and after the MRI is complete, participants will perform spirometry maneuvers in a room outside of the magnet.
62054681|NCT03996057|EXPERIMENTAL|Methenamine augmentation|2g methenamine hippurate twice daily for 90 days added to a baseline regimen of low dose vaginal estrogen (two to three times per week) and d-mannose (1000 mg twice daily)
62054682|NCT03996057|ACTIVE_COMPARATOR|No methenamine augmentation|Baseline regimen of low dose vaginal estrogen (two to three times per week) and d-mannose (1000 mg twice daily)
62054683|NCT00985725|EXPERIMENTAL|Active|SPD489
62054684|NCT00985725|PLACEBO_COMPARATOR|Placebo|Placebo
62054685|NCT01530672|EXPERIMENTAL|ANC clients|
62838990|NCT04823013|EXPERIMENTAL|ischemic compression group|Participants in IC group received one session of ischemic compression therapy. Ischemic compression is a therapy technique used in manual therapy, where blockage of blood in an area of the body is deliberately made, so that a resurgence of local blood flow will occur upon release.
62054686|NCT02020122|ACTIVE_COMPARATOR|Duloxetine|DUL 60mg x once a day x 2 days. This arm will also take 2 non-active placebo x once a day x 2 days
62054687|NCT02020122|ACTIVE_COMPARATOR|Pregabalin|PGB 150mg x twice a day x 2 days
62054688|NCT02020122|PLACEBO_COMPARATOR|Placebo|Non active placebo x twice a day x 2 days
62054689|NCT02310555|ACTIVE_COMPARATOR|Gastric bypass|classic Gastric bypass
62054690|NCT02310555|ACTIVE_COMPARATOR|Modified gastric bypass.|Modified gastric bypass. Resection body and fundus gastric
62054691|NCT02310555|ACTIVE_COMPARATOR|Slevee Gastrectomy|Slevee Gastrectomy
62054692|NCT05485792|EXPERIMENTAL|18F-FAPI PET/CT|Each subject undergone both 18F-FDG and 68Ga-FAPI PET/CT scans within 2 week
62054693|NCT04842578|EXPERIMENTAL|group of thin cross- section of CT|Anatomic Segmentectomy with the Guidance of Thin Cross- Section of CT
62054694|NCT04842578|ACTIVE_COMPARATOR|group of thin 3D simulation|Anatomic Segmentectomy with the Guidance of 3D simulation
62054695|NCT00084370|EXPERIMENTAL|Group 1|Group I: Patients receive oral celecoxib twice daily for 3 months and then undergo prophylactic oophorectomy.
62614017|NCT02179476|EXPERIMENTAL|Glyder|Glyder Facet Restoration Device
62614018|NCT05988333|EXPERIMENTAL|Psychoeducational Family Intervention|The experimental intervention will be administered individually to each recruited family. Sessions will take place three times a month for a period ranging from 4 to 6 months (about 18 sessions in total). The number of sessions, as well as the frequency, may vary depending on the patient's clinical situation. Sessions will have an average duration of 60-90 minutes.
62054696|NCT00084370|EXPERIMENTAL|Group II|Group II: Patients undergo immediate prophylactic oophorectomy.
62054697|NCT02706860|EXPERIMENTAL|"80 mg atorvastatin for 2 days regimen"|80 mg atorvastatin/ day for 2 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
62054698|NCT02706860|EXPERIMENTAL|"40 mg atorvastatin for 5-9 days preoperative regime"|40 mg atorvastatin/ day for 5-9 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
62054699|NCT02706860|EXPERIMENTAL|"80 mg atorvastatin for 5-9 days preoperative regime"|80 mg atorvastatin/ day for 5-9 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
62054700|NCT03455322|ACTIVE_COMPARATOR|norepinephrine|norepinephrine continuous intravenous infusion in a dose of 0.05-0.3ug/Kg/min. average7-10 days to keep mean arterial pressure ≥ 80-100mmHg \& continued either until HRS reversal or for maximum 10 days.
62256860|NCT05548348|EXPERIMENTAL|Furmonertinib treatment|Furmonertinib will be administered orally at a dose of 160 mg per time, Q.D.
62838991|NCT01099332|ACTIVE_COMPARATOR|Gastro-retentive zinc cysteine tablet|Once daily administration by mouth of a gastro-retentive, sustained-release preparation of zinc cysteine with excipients, all G.R.A.S., with adequate water.
62838992|NCT01099332|PLACEBO_COMPARATOR|Identical appearance of placebo with active comparator|Once daily administration of placebo of identical physical appearance to that of active comparator with similar amount of water.
62838993|NCT02415413|EXPERIMENTAL|Carlizomib lenalidomide and low dose dexamethasone|"Induction treatment: patients included in the trial will receive an induction treatment for approximately 6 months (6 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)). After the third cycle of KRd, all patients will be mobilized with colony stimulating factor (G-CSF) alone to collect peripheral blood stem cell for the ASCT.~High dose therapy followed by autologous stem cell transplantation: patients will receive melphalan 200 mg/m2 via intravenous followed by autologous stem cell transplantation (HDT-ASCT).~Consolidation treatment: approximately 3 months after the autologous stem cell transplantation, patients will receive consolidation treatment for 2 months (2 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)).~Maintenance treatment: subsequently they will start a maintenance treatment that will be administered for approximately 24 months (24 cycles of lenalidomide and low dose dexamethasone"
62838994|NCT00110747|EXPERIMENTAL|S-Caine Peel|
62838995|NCT00110747|PLACEBO_COMPARATOR|Placebo Peel|
62838996|NCT02198118|NO_INTERVENTION|Control Group|Control group (CG) subjected only to evaluations and to no exercises.
62838997|NCT02198118|EXPERIMENTAL|Study Group|Study group (SG) instructed to perform domiciliary exercises for the upper limbs
62054701|NCT03455322|ACTIVE_COMPARATOR|midodrine & octreotide|midodrine 5mg three times/day orally \& can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous \& if needed increased to 200ug/6hS.C. for 7-10 days
62054702|NCT01241149|ACTIVE_COMPARATOR|Normal pH, abnormal Impedance|After 24hr pH-metry and impedance, those patients with normal pH (i.e. DeMeester score \<14.7) but with abnormal impedance scores will be offered anti-reflux surgery
62444232|NCT02405910|EXPERIMENTAL|A - Nab-paclitaxel 100mg + Gemcitabine 1250mg|Nab-paclitaxel 100 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on days 1, 8 and 15 of a 21 day cycle. On days 1 and 8 of each cycle, nab-paclitaxel administration will be followed by the administration of gemcitabine 1250 mg/m2 as a 30 minute infusion (maximum 40 minutes).
62444233|NCT02405910|EXPERIMENTAL|B - Nab-paclitaxel 125mg + Gemcitabine 1000mg|Nab-paclitaxel 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on days 1, 8 and 15 of a 28 day cycle. Each nab-paclitaxel administration will be followed by the administration of gemcitabine 1000 mg/m2 as a 30 minute infusion (maximum 40 minutes) on days 1, 8 and 15. Treatments will be repeated until progression or intolerance.
62444234|NCT06158061|ACTIVE_COMPARATOR|patient group|Patients with acne vulgaris ≥ 18 years old, both male and female patients will be included.
62444235|NCT06158061|ACTIVE_COMPARATOR|control group|healthy controls without acne vulgaris or other dermatological diseases like psoriasis, vitiligo, DLE
62444236|NCT03463356|EXPERIMENTAL|Shame Intervention|Participants will complete a two shame intervention sessions approximately one week apart.
62444237|NCT04336956||hospitalized children with Covid19|- Children \< 18 years old Patients under 18 years old, admitted in French pediatric wards with a confirmed COVID-19 infection on Nasal and pharyngeal swab specimens or blood samples tested positive for 2019-nCoV nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay; or on typical chest CT signs
62838998|NCT01967576|EXPERIMENTAL|1/Arm 1-Axitinib|Axitinib 5 mg twice a day on a 28-day cycle
62838999|NCT04986267||ACL Rupture|Female, aged 18-40 years of age with an acute ACL rupture of the knee that occurred within the last 3 months, who presented to a sports or orthopaedic clinic
62839000|NCT04174326|EXPERIMENTAL|Intervention group|A weekly 2 hour CBT for chronic pain group intervention for a duration of 6 weeks
62839001|NCT04174326|NO_INTERVENTION|Delayed intervention group|A waiting list for CBT for chronic pain group intervention.
62839002|NCT04531930||Surgery Group|Colorectal surgery
62839003|NCT04531930||Enhanced Colonoscopy Group|Enhanced colonoscopic treatment and surveillance
62839004|NCT04531930||Self Choice Group|The patients choose the interventional methods, even do nothing.
62839005|NCT05155267||Chronic Kidney disease participants (CKD)_HD|CKD submitted to hemodialysis (HD)
62054703|NCT01241149|PLACEBO_COMPARATOR|Abnormal pH|After 24hr pH-metry and impedance, those with abnormal pH scores (i.e. DeMeester score \>14.7)will be offered anti-reflux surgery
62054704|NCT02914925|EXPERIMENTAL|ArmeoSpring/CIT|Group will receive ArmeoSpring and CIT therapy
62054705|NCT01928966|ACTIVE_COMPARATOR|Group I - Pumpkin Seeds|First four weeks of study: consume perceived normal diet; Second four weeks of study: receive 1.5 ounces of pumpkin seeds per day for consumption; Third four weeks of the study: consume their perceived normal diet.
62054706|NCT01928966|ACTIVE_COMPARATOR|Group II - Pumpkin Seeds|First four weeks of study: consume perceived normal diet; Second four week period: consume perceived normal diet; Third four week period: receive 1.5 ounces of pumpkin seeds per day for consumption.
62614019|NCT05988333|ACTIVE_COMPARATOR|Informative intervention|The informative intervention consists of five sessions, administered every 7-10 days.
62614020|NCT04339309|ACTIVE_COMPARATOR|Kiel Center|Non-surgical periodontal treatment with interdental hygiene devices in periodontitis patients.
62839006|NCT05155267||Chronic Kidney disease participants (CKD)_PD|CKD non-submitted to hemodialysis (pre-dialysis:PD)
62839007|NCT05155267||Controls|Healthy participants
62839008|NCT06103786|EXPERIMENTAL|1. Repeated Sprint 2. Interval Sprint 3.Long-Pass Tracking Drill 4. Chase-The-Rabbit Tracking Drill|"1. Make repeated sprints on the ice for a certain distance to measure its speed.~2. On the ice, perform 15 seconds of intermittent acceleration on the ice, with 30 seconds between each slide.~3. On the ice, make a long pass before taking a shot, then turn to track back.~4. On the ice, skate down the ice, 2 on 1, with a puck to pass and shoot."
62054707|NCT06575569|EXPERIMENTAL|high-intensity interval training (HIIT) group|intensive interval training under the care of specialists for 12 weeks, 30-40 minutes per week, including starting 5-minute warm-up and last 5-minute cooling-off period, during exercise including 4 intervals, 85-95% of maximum heart rate (HR) reserve for 4 minutes, followed by 50-70% of maximum HR reserve for 3 minutes, so cycling 4 times.
62614021|NCT04339309|ACTIVE_COMPARATOR|Cairo Center|Non-surgical periodontal treatment without interdental hygiene devices in periodontitis patients.
62839009|NCT06103786|EXPERIMENTAL|1. Varied Pace Skating 2.Driblling and Shooting Drill 3. Passing and Catching training 4. 2-on-1|"1. On the ice, a 1-minute accelerated skate and skating at an even pace for 2 minutes~2. On the ice, dribbling the ball and shooting at the goal~3. On the ice, they stood facing each other at a distance of 20 meters and practiced passing and catching.~4. On the ice, practice 2-on-1 offensive tactics and complete shots on goal."
62054708|NCT06575569|ACTIVE_COMPARATOR|Moderate-intensity continuous training (MCT) group|patients exercise prescription for 12 weeks, 30-40 minutes, including 5 minutes of warm-up and cooling-off period of the last 5 minutes, during exercise intensity is 70-75% maximum heart rate reserve. The warm-up and cooling-off periods can be performed by stretching, flexibility exercises (i. e., neck, shoulders, upper back, hips, and ankles), and medium to low intensity (50-70% heart rate reserve).
62054709|NCT06069583|EXPERIMENTAL|Support integrated in usual care|PWT1D participants will have access to Support as part of their regular care (their HCPs will use Support in their care). PWT1D participants in ARM 1 are followed in one of the 4 participating clinics either in-person or remotely or hybrid.
62054710|NCT06069583|ACTIVE_COMPARATOR|Support through independent access|PWT1D participants will have access to Support, independently from their regular care (they may initiate discussion about the platform with their diabetes care team who might register themselves on the platform, but will not prompt to any specific section on the platform and will not receive any training about the platform). PWT1D participants in ARM 2 can be followed in any other clinics in Canada.
62054711|NCT06429605|NO_INTERVENTION|Control|Only our clinic's standard preoperative and postoperative care were used (Güngördük K, Selimoğlu B, Gülseren V, Yasar E, Comba C, Özdemir İA. Effect of abdominal hot pack application on gastrointestinal motility recovery after comprehensive gynecologic staging surgery. Int J Gynaecol Obstet. 2024 Mar;164(3):1108-1116)
62054712|NCT06429605|EXPERIMENTAL|Duloxetine|In addition to our standard clinical protocol, study patients were administered 60 mg oral duloxetine 2 hours before surgery and 24 hours after surgery
62054713|NCT00286793|EXPERIMENTAL|SIngle Arm Study of AT-101 in combination with Docetaxel|
62054714|NCT03356730|EXPERIMENTAL|Arm vitamin D|Vitamin D 5.000 IU a day for 2 months (10 drops after lunch)
62256861|NCT03862352||Coronary artery perforation (iatrogenic)|Any coronary artery perforation defined according to the Ellis criteria.
62256862|NCT02713542|EXPERIMENTAL|Autologous Conditioned Plasma (ACP)|3 Intra-articular (IA) injections at 1 week intervals
62256863|NCT02713542|PLACEBO_COMPARATOR|Normal Saline (NS)|3 NS Intra-articular (IA) injections at 1 week intervals
62256864|NCT02657161|ACTIVE_COMPARATOR|Group A|"Comparator vaccine RABIPUR®~Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14"
62256865|NCT02657161|EXPERIMENTAL|Group B|"PIKA Rabies vaccine~Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14"
62054715|NCT03356730|PLACEBO_COMPARATOR|Arm placebo|Placebo for 2 months (10 drops after lunch)
62054716|NCT00387894|EXPERIMENTAL|erlotinib hydrochloride (Tarceva)|During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
62256866|NCT02657161|EXPERIMENTAL|Group C|"PIKA Rabies vaccine with an accelerated regimen~Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose)"
62054717|NCT05035368|EXPERIMENTAL|Ladarixin - placebo|"In this arm the treatment sequence is ladarixin 400 mg twice-a-day, followed by placebo, as adjunctive therapy to insulin in overweight, IR, T1D patients.~IMP will be administered for 24 weeks in each treatment period with a 21-day washout between the two periods. (Ladarixin 24 weeks, washout 21 days, Placebo 24 weeks)."
62256867|NCT02365220|ACTIVE_COMPARATOR|No expectancy (control)|No expectancy instruction with regard to the efficacy of the daily smartphone-based training
62614022|NCT03402672|EXPERIMENTAL|AWAITS|Participants who meet criteria will receive the AWAITS self-administered, e-health application intervention.
62614023|NCT00085098|EXPERIMENTAL|Regimen A (radiotherapy only)|Within 52 days of surgery, patients will undergo standard-dose radiation therapy 5 days a week for approximately 5-6 weeks.
62839010|NCT00505349|NO_INTERVENTION|No Intervention Arm|Phase I in this study will involve the evaluation of blood-derived neurotrophic factors in healthy, younger adults (18-30.) Individuals in this group will not undergo computerized, cognitive training.
62256868|NCT02365220|EXPERIMENTAL|Prospective expectancy|"Prospective expectancy instruction (Training will have an effect on...) with regard to the efficacy of the daily smartphone-based training"
62256869|NCT02365220|EXPERIMENTAL|Retrospective expectancy|"Retrospective expectancy instruction (Training already had an effect on...) with regard to the efficacy of the daily smartphone-based training"
62256870|NCT02365220|EXPERIMENTAL|Prospective and retrospective expectancy|"Prospective (Training will have an effect on...) and retrospective (Training already had an effect on...) expectancy instruction with regard to the efficacy of the daily smartphone-based training"
62623621|NCT04137809|EXPERIMENTAL|Robot Group|1-arm study where eligible volunteers will undergo robotic testing for safety, comfort, and fit.
62839011|NCT00505349|EXPERIMENTAL|Cognitive Training|Phase II of this study will involve an evaluation of the pre- and post- cognitive training levels of blood-derived neurotrophic factors in healthy, mature adults. Participants randomized to this arm will receive SAAGE-based computerized cognitive training.
62839012|NCT01418690||Non-invasive near infra-red device (NIRS)|
62054718|NCT05035368|EXPERIMENTAL|Placebo - Ladarixin|"In this arm the treatment sequence is placebo followed by ladarixin 400 mg twice-a-day, as adjunctive therapy to insulin in overweight, IR, T1D patients.~IMP will be administered for 24 weeks in each treatment period with a 21-day washout between the two periods. (Placebo 24 weeks, washout 21 days, Ladarixin 24 weeks)."
62054719|NCT01555788|EXPERIMENTAL|Type 1 diabetic population|The only one arm (type 1 diabetic patients treated by basal-bolus insulin and external pumps) of this study will test an artificial pancreas system that uses the intraperitoneal route to deliver insulin (through DiaPort).
62839013|NCT01254422|EXPERIMENTAL|CYD Dengue vaccine group|Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months.
62054720|NCT00341302||Cohort 1|HIV Infected Pregnant Women
62839014|NCT01254422|PLACEBO_COMPARATOR|Placebo Group|Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months.
62839015|NCT02281383|EXPERIMENTAL|Bacillus Calmette-Guérin (BCG)|Patients will be treated with an induction course (6 intravesical instillations) of BCG followed by a second induction course (6 intravesical instillations), with a recovery period between the 2 treatment courses.
62054721|NCT00341302||Pediatric Cohort 2|HIV exposed , uninfected children born to HIV infected women
62054722|NCT00341302||Pediatric Cohort 3|HIV exposed, uninfected children 6 months to 5 years of age
62054723|NCT02368106||Radiation Therapy|Participants receiving one of the 11 listed therapy modalities.
62054724|NCT05794802|EXPERIMENTAL|BHB supplement condition|
62444238|NCT05159310|OTHER|Cast|Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast. A research assistant will facilitate the randomisation process so that the RC and the treating physician remain blinded to treatment allocation.
62054725|NCT05794802|PLACEBO_COMPARATOR|Placebo solution condition|
62444239|NCT05159310|OTHER|Splint|Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast. A research assistant will facilitate the randomisation process so that the RC and the treating physician remain blinded to treatment allocation.
62839016|NCT04651062|EXPERIMENTAL|endocuff|all patients having performed a screeningscolonoscopy and being randomized to colonoscopy with the use of endocuff
62839017|NCT04651062|ACTIVE_COMPARATOR|no cuff|all patients participating in a screeningscolonoscopy being randomized to colonoscopy without the use of endocuff
62839018|NCT01391078|EXPERIMENTAL|Sensimed Triggerfish|
62054726|NCT06203886|EXPERIMENTAL|Test Intervention arm|LumbaCure robotic device
62054727|NCT03054038|EXPERIMENTAL|Experimental|Patients receive afatinib PO QD on days 1-28 and necitumumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62054728|NCT05939921|EXPERIMENTAL|Treatment|T2DM patients will be provided with metformin in a specified dose
62054729|NCT01166516|OTHER|Treatment with HUD IBV Valve System|Treatment with HUD IBV Valve System in Post-Approval Study
62054730|NCT05399225||Platelets to lymphocytes ratio and procalcitonin|Platelets to lymphocytes ratio in patients with sepsis
62054731|NCT05399225||Procalcitonin group|Procalcitonin in patient with sepsis
62839019|NCT01391078|ACTIVE_COMPARATOR|Goldmann Applanation Tonometry/Perkins Tonometry|
62256871|NCT04646785|EXPERIMENTAL|Mindfulness-based cognitive therapy (MBCT) added to treatment as usual|Patients in the MBCT arm will in addition to their treatment as usual be invited to participate in MBCT.
62256872|NCT04646785|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Patients in this arm will receive treatment as usual.
62256873|NCT00859599|ACTIVE_COMPARATOR|1|"At the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A \& B, E \& F, X \& Y) the randomised patient shall receive.~Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed."
62839020|NCT01574092|EXPERIMENTAL|Irinotecan plus Cisplatin combination|This is a open-label study with only one treatment experimental arm. The patients will be treated, in a weekly basis, with 30 mg/m2 of cisplatino plus 65 mg/m2 of irinotecán (one cycle), until a total of 16 cycles.
62054732|NCT02447289|EXPERIMENTAL|Experimental|Intranasal administration of ketamine (4.0 mg/kg, max. 100 mg) and midazolam (0.2 mg/kg, max. 5 mg)
62839021|NCT00005080|EXPERIMENTAL|Nelarabine|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive up to 8 courses of therapy.
62256874|NCT00859599|PLACEBO_COMPARATOR|2|"At the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A \& B, E \& F, X \& Y) the randomised patient shall receive.~Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed."
62256875|NCT01967355|EXPERIMENTAL|Lipid apheresis|Lipid apheresis: lipid removing therapy,frequency and duration depending on the symptoms of mother and fetus.
62839022|NCT03332706||SG|Study Group is the group where the patients during observation suffer from spontaneous abortion or missed abortion,
62839023|NCT03332706||CG|Control Group is where the patients carry the normal live fetal for at least 8 weeks
62839024|NCT04646044|EXPERIMENTAL|Bempegaldesleukin IV + Standard of Care|
62839025|NCT04646044|PLACEBO_COMPARATOR|Placebo + Standard of Care|
62839026|NCT01134055|EXPERIMENTAL|investigational arm 1|5 mg/mL pazopanib eye drops TID with allowance for as-needed ranibizumab injection
62444240|NCT01165996|EXPERIMENTAL|Arm I: decitabine|INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts \&lt; 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
62444241|NCT01658475||periodontitis|those with periodontitis and those without periodontitis
62839027|NCT01134055|EXPERIMENTAL|investigational arm 2|5 mg/mL pazopanib eye drops QID with allowance for as-needed ranibizumab injection
62839028|NCT01134055|EXPERIMENTAL|investigational arm 3|10 mg/mL pazopanib eye drops BID with allowance for as-needed ranibizumab injection
62839029|NCT01134055|EXPERIMENTAL|investigational arm 4|10 mg/mL pazopanib eye drops TID with allowance for as-needed ranibizumab injection
62839030|NCT01134055|EXPERIMENTAL|investigational arm 5|10 mg/mL pazopanib eye drops QID with allowance for as-needed ranibizumab injection
62839031|NCT01134055|PLACEBO_COMPARATOR|placebo control arm|Placebo eye drops QID with allowance for as-needed ranibizumab injection
62054733|NCT02447289|ACTIVE_COMPARATOR|Comparator|Oral administration of ketamine (4.0 mg/kg, max. 100 mg) and midazolam (0.5 mg/kg, max. 20 mg)
62054734|NCT02447289|ACTIVE_COMPARATOR|Control|Oral administration of midazolam (1.0 mg/kg, max. 20 mg)
62054735|NCT00615264|EXPERIMENTAL|DiaPep277|DiaPep277 1.0 mg + 40 mg Mannitol in 0.5 mL lipid emulsion.
62054736|NCT00615264|PLACEBO_COMPARATOR|Placebo|Mannitol 40 mg in 0.5 mL lipid emulsion.
62054737|NCT03221855|ACTIVE_COMPARATOR|Domperidone|Domperidone 10mg every 8 hours for 7 days.
62054738|NCT03221855|PLACEBO_COMPARATOR|Placebo|Placebo 10mg every 8 hours for 7 days.
62054739|NCT04626739|EXPERIMENTAL|volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with Relapsed Refractory (R/R) non-Hodgkin lymphoma
62256876|NCT04512443||1|42 women (treated with Daflon 1000 mg (study group))
62256877|NCT04512443||2|41 women (placebo (control group))
62256878|NCT04140656|ACTIVE_COMPARATOR|Plantar sensitive exercise group|Plantar sensitive exercises:
62256879|NCT04140656|ACTIVE_COMPARATOR|Textured insole group|Textured insole group
62256880|NCT02325115||students (STUD)|The STUD population was a convenient sample of 75 first year students (51 females and 24 males); with 45 from a School of Business Management and 30 from a medical university.
62839032|NCT01134055|ACTIVE_COMPARATOR|active open-label control arm|Ranibizumab intravitreal injection every 4 weeks
62839033|NCT00768456|ACTIVE_COMPARATOR|1|Local infiltration with Ropivacaine
62839034|NCT00768456|PLACEBO_COMPARATOR|2|Local infiltration with Placebo (NaCl)
62839035|NCT00828204|EXPERIMENTAL|Avonex Single-Use Autoinjector|"Participants received open label weekly treatment with Avonex 30 mcg intramuscular (IM) injections, provided in Avonex prefilled syringes.~In the Main Study, injection #1: administration of Avonex prefilled syringe via manual IM injection on Day 1. Injections #2, #3, and #4: administration of Avonex prefilled syringe using the single-use autoinjector on Days 8, 15, and 22, respectively. In the Extension Study, participants were to continue treatment with the Avonex single-use autoinjector for up to an additional 12 weeks."
62839036|NCT05510349|EXPERIMENTAL|All the patients|Sonographic measure of placental elasticity and viscosity
62839037|NCT04028219||Transgender patients|Gender dysphoric patients undergoing hormone treatment
62839038|NCT00614731|EXPERIMENTAL|ID immunizations (100 mcg)|Participants will receive a total of two 100 mcg intradermal (ID) KLH carrier-protein immunizations with 1 mg/ml KLH per immunization. Immunizations will be given 21 days apart at Visits 5 and 6.
62839039|NCT00614731|EXPERIMENTAL|Scarification by 3 jabs|Participants will receive two scarification immunizations by 3 jabs containing 20 mg/ml of KLH carrier-protein. The immunizations will occur 21 days apart at Visits 5 and 6.
62839040|NCT00614731|EXPERIMENTAL|ID immunizations (250 mcg)|Enrollment will begin after the safety data for Groups 1A and 2A have been reviewed. Participants in this group will receive two 250 mcg ID KLH vaccinations containing 10 mg/ml of KLH carrier-protein. Immunizations will occur 21 days apart at Visits 5 and 6.
62839041|NCT00614731|EXPERIMENTAL|Scarification by 15 jabs|Enrollment will begin after the safety data from groups 1A and 2A has been examined. Participants in this group will receive a total of two scarification immunizations by 5 needles used to administer 15 jabs, each containing, 20 mg/ml of KLH carrier-protein. Immunizations will occur 21 days apart at Visits 5 and 6.
62839042|NCT01209013|EXPERIMENTAL|Medlight PDT Balloon|
62839043|NCT03584958||Ab interno goniotomy surgery|Gonioscopy-assisted transluminal trabeculotomy (GATT) surgery to decrease intraocular pressure.
62054740|NCT05398302|EXPERIMENTAL|Diagnostic (image-guided biopsy)|Patients undergo an image-guided biopsy at baseline and 2-4 weeks after cycle 2 of 177Lu-PSMA-617 therapy.
62839044|NCT03584958||Gelatin stent surgery|Subconjunctival stent (Xen) surgery to decrease intraocular pressure.
62839045|NCT03584958||Suprachoroid stent and cataract surgery|Suprachoroidal stent (Cypass) to decrease intraocular pressure in combination with cataract surgery.
62839046|NCT03584958||Trabeculectomy surgery|Glaucoma filtering surgery to decrease intraocular pressure.
62054741|NCT03466424||Group 1|preoperative short-course radiotherapy(5×6Gy) followed by 4×mFOLFOX6 chemotherapy
62054742|NCT03466424||Group 2|preoperative short-course radiotherapy(5×7Gy) followed by 4×mFOLFOX6 chemotherapy
62054743|NCT03466424||Group 3|preoperative short-course radiotherapy(5×8Gy) followed by 4×mFOLFOX6 chemotherapy
62054744|NCT01376323|EXPERIMENTAL|GSK256073 1mg bid|GSK256073 1mg capsule taken orally twice a day
62054745|NCT01376323|EXPERIMENTAL|GSK256073 2mg qd|GSK256073 2 x 1mg capsule taken orally once a day
62054746|NCT01376323|EXPERIMENTAL|GSK256073 5mg bid|GSK256073 5mg capsule taken orally twice a day
62839047|NCT03584958||Cataract surgery|Cataract surgery with no glaucoma procedure.
62054747|NCT01376323|EXPERIMENTAL|GSK256073 10mg qd|GSK256073 2 x 5mg capsule taken orally once a day
62054748|NCT01376323|EXPERIMENTAL|GSK256073 10mg bid|GSK256073 10mg capsule taken orally twice a day
62839048|NCT00356304|EXPERIMENTAL|1|Participants will receive motivational interviewing in addition to their antidepressant therapy
62839049|NCT00356304|ACTIVE_COMPARATOR|2|Participants will receive treatment as usual
62839050|NCT02698553|EXPERIMENTAL|Bupropion XL once daily|Healthy subjects will receive Bupropion XL 150milligram (mg) once daily for 5 days (Day 1 to Day 5) and then Bupropion XL 300 mg once daily from Day 6 to Day 14.
62839051|NCT01333930|EXPERIMENTAL|Test product (Active O2)|
62839052|NCT01333930|PLACEBO_COMPARATOR|Placebo (Adelholzener Mineralwasser)|
62054749|NCT01376323|EXPERIMENTAL|GSK256073 20mg qd|GSK256073 2x 10mg capsule taken orally once a day
62054750|NCT01376323|EXPERIMENTAL|GSK256073 25mg bid|GSK256073 25mg capsule taken orally twice a day
62054751|NCT01376323|EXPERIMENTAL|GSK256073 50mg qd|GSK256073 2x 25mg capsule taken orally once a day
62054752|NCT01376323|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules taken orally either once a day or twice a day
62054753|NCT01376323|ACTIVE_COMPARATOR|Sitagliptin 100mg qd|Commercially available Sitagliptin 100mg capsules taken once a day
62054754|NCT01915576|EXPERIMENTAL|BAY1125976 [once daily, dose-esc.]|Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
62614024|NCT00085098|EXPERIMENTAL|Regimen B (chemotherapy plus radiotherapy)|"Courses 1 and 2: Patients receive carboplatin IV over 1 hour on days 1 and 2 and etoposide IV over 2 hours on days 1-3. Treatment repeats every 21 days for 2 courses.~Within 3 weeks of completing chemotherapy, patients with CR undergo low-dose radiation therapy 5 days a week for 5 weeks. Patients with MRD, a PR, or SD receive chemotherapy courses 3 and 4 as outlined below.~Courses 3 and 4: Patients receive cisplatin IV over 6 hours on day 1, cyclophosphamide IV over 1 hour on days 2 and 3, and filgrastim (G-CSF), subcutaneous (SC) or IV beginning on day 4 and continuing until blood counts recover.~Treatment repeats every 21 days for 2 courses. Patients achieving a CR or MRD proceed to reduced-dose radiotherapy. Patients with a PR, SD, or progressive disease (PD) are restaged and may undergo standard radiation therapy as in regimen A. Reduced-dose radiation therapy: Within 6 weeks of starting course 4, patients undergo lower-dose radiation therapy once daily on days 1-5 for 5 weeks"
62614025|NCT01142765|EXPERIMENTAL|Group 1|1 dose of AdCh63 MSP1 and 1 dose MVA MSP1 followed by sporozoite challenge
62614026|NCT01142765|EXPERIMENTAL|Group 2|1 dose of AdCh63 AMA1 and 1 dose MVA AMA1 followed by sporozoite challenge
62614027|NCT01142765|EXPERIMENTAL|Group 3|1 dose of AdCh63 AMA1 and 1 dose AdCh63 MSP1 co-administered into separate arms followed by 1 dose of MVA AMA1 and 1 dose MVA MSP1 co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge
62614028|NCT01142765|EXPERIMENTAL|Group 4|1 dose of AdCh63 MSP1 and 1 dose AdCh63 ME-TRAP co-administered into separate arms followed by 1 dose of MVA MSP1 and 1 dose MVA ME-TRAP co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge
62256881|NCT02325115||working adults (WORK)|The WORK population was also a convenient sample of 113 (63 females and 256 males) working adults including 217 soldiers from Paris Fire Brigade, 93 nurses and 9 individuals from a research laboratory.
62256882|NCT02325115||remitted schizophrenia (PRS)|The PRS population was comprised of 121 remitted schizophrenia patients (39 females and 82 males) who were all clients of the rehabilitation centre for psychotic disorders (Le Vinatier hospital),
62839053|NCT03598686|NO_INTERVENTION|HOSENG Control|"Standard of care during a door-to-door HIV testing campaign:~1. For present household members: blood-based HIV testing~2. For absent household members or household members who refuse testing: They are encouraged to get tested by the Village Health Worker (VHW) or the nearby health facility"
62256883|NCT04828070||Registry participant|Prospective collection of clinical information, completion of anxiety/depression, microaggressions, and quality of life questionnaires
62256884|NCT02306109|ACTIVE_COMPARATOR|Standard motor rehabilitation treatment|
62256885|NCT02306109|EXPERIMENTAL|Intensive motor rehabilitation treatment|
62256886|NCT00066768|EXPERIMENTAL|Arm I|Patients receive low-dose suramin IV over 30 minutes and docetaxel IV over 1 hour on day 1.
62614029|NCT01142765|OTHER|Group 5|Non-vaccinated controls for sporozoite challenge
62614030|NCT04904783|ACTIVE_COMPARATOR|Study arm|10 patients of confirmed diagnosis of moderate COVID-19 who fulfil the inclusion criteria and give written informed consent would be in study arm. All patients, belong to both study and control groups would receive the same treatment (oxygen support, steroids, anticoagulant therapy, remdesivir and other supportive therapy) as per the Institute guidelines for management of moderate COVID-19 disease. Only low dose radiotherapy would be added to patients in the study arm.
62614031|NCT04904783|NO_INTERVENTION|Control Arm|10 patients of confirmed diagnosis of moderate COVID-19 who fulfil the inclusion criteria and have not given written informed consent would be in study arm. These patients would receive the same treatment (oxygen support, steroids, anticoagulant therapy, remdesivir and other supportive therapy) as per the Institute guidelines for management of moderate COVID-19 disease except low dose radiotherapy.
62614032|NCT04554758|EXPERIMENTAL|Sleeve gastrectomy|200 obesity patients who undergo laparoscopic sleeve gastrectomy
62256887|NCT00066768|EXPERIMENTAL|Arm II|Patients receive low-dose suramin IV over 30 minutes and gemcitabine IV over 30 minutes on days 1 and 8.
62256888|NCT06448702|ACTIVE_COMPARATOR|wet wrap therapy (WWT)|"WWT with mometasone propionate ointment: paraffin soft white 1: 10: once daily (45 minutes ± 15 minutes) x 3 times ±1 time (day 1, day 3, day 5 or any 3 days over 7days, subject to patient self-assessment).~For those who do not achieve EASI50 (50% reduction of baseline EASI) or EASI\<10 on Day 7, they will be asked to enroll to another arm (EECP arm), and have a follow-up visit on Day 14 and 4 weeks post last treatment."
62256889|NCT06448702|ACTIVE_COMPARATOR|EECP therapy|"EECP therapy once daily x 3 times ±1: Day 1, Day 3, Day 5 (or any 3 days over 7 days).~For those who do not achieve EASI50 or EASI total score \< 10 on day 7,(or BSA\>5%) they will be asked to continue for one more cycle (i.e. 3 more EECP sessions over the next 7 days), and will be followed up on Day 14 and at week 4 post-treatment."
62614033|NCT04554758|EXPERIMENTAL|Roux-en-Y gastric bypass|200 obesity patients who undergo laparoscopic Roux-en-Y gastric bypass
62614034|NCT03943823|ACTIVE_COMPARATOR|Estrogen vaginal cream|
62614035|NCT03943823|ACTIVE_COMPARATOR|Trimo-San vaginal gel|
62614036|NCT03920423|NO_INTERVENTION|shallow depth|Radial arterial deth is shallow than the cutoff point that relative to results.
62614037|NCT03920423|EXPERIMENTAL|improved depth|Radial arterial deth is shallow than the cutoff point that relative to results, and increased by injection of saline to more than deep cutoff point.
62614038|NCT02911259|EXPERIMENTAL|Group 1|Post-operative suction is set to -2 cmH2O.
62614039|NCT02911259|ACTIVE_COMPARATOR|Group 2|Post-operative suction is set to -10 cmH2O (standard treatment).
62839054|NCT03598686|EXPERIMENTAL|HOSENG Intervention|"HOSENG Intervention during a door-to-door HIV testing campaign:~1. For present household members: blood-based HIV testing~   a) If any absent person in the household: One of the present household members is tested and trained using the oral HIVST (OraQuick©)~2. For absent household members or household members who refuse testing: One oral HIVST (OraQuick©) is left behind and has to be brought back to the VHW after usage. Otherwise it will be collected by the VHW after two weeks."
62839055|NCT01956838|EXPERIMENTAL|Umami|intraduodenal infusion of umami
62256890|NCT05005806|ACTIVE_COMPARATOR|Omega 3 soft gel|participants in this group (1)omega 3 fatty acid soft gel 1000 mg will be given to participants twice daily for two months.
62256891|NCT05005806|PLACEBO_COMPARATOR|placebo|placebo group ,placebo soft gel designed same as omega 3 contain Vitamin A 1000 mg twice daily for two months
62256892|NCT03565575|EXPERIMENTAL|Interactive tablet-based quiz|Individuals participate in an interactive tablet-based risk perception and PrEP counselling information session.
62256893|NCT03565575|NO_INTERVENTION|Control arm|No intervention will be administered to the control arm
62614040|NCT00002525|EXPERIMENTAL|Perioperative 5-FU|"Within 24 hours of the colon resection, patients receive perioperative fluorouracil intravenously (IV) over 24 hours for 7 days.~After surgery (beginning 21-35 days post-surgery), 5-FU was given at a dose of 425 mg/m\^2 IV push on days 1-5, and leucovorin calcium was given at a dose of 20mg/m\^2 IV push on days 1-5"
62614041|NCT00002525|ACTIVE_COMPARATOR|No perioperative 5-FU|"Patients receive no perioperative fluorouracil.~After surgery (beginning 21-35 days post-surgery), 5-FU was given at a dose of 425 mg/m\^2 IV push on days 1-5, and leucovorin calcium was given at a dose of 20mg/m\^2 IV push on days 1-5"
62614042|NCT03489902|EXPERIMENTAL|Transobturator arm|Transobturator Paravaginal Repair
62614043|NCT03489902|EXPERIMENTAL|Transvaginal arm|traditional transvaginal Paravaginal Repair
62614044|NCT01225289|ACTIVE_COMPARATOR|with Multiple Sclerosis/ vitamin A|Patients with MS confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A
62256894|NCT00861250|EXPERIMENTAL|Vel/Dex|
62256895|NCT00974675|EXPERIMENTAL|CAT-354 1 mg/kg|CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
62256896|NCT00974675|EXPERIMENTAL|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
62256897|NCT00974675|EXPERIMENTAL|CAT-354 10mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
62256898|NCT00974675|PLACEBO_COMPARATOR|Placebo|Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.
62256899|NCT00619970|ACTIVE_COMPARATOR|Healthy Control|Healthy controls
62614045|NCT01225289|PLACEBO_COMPARATOR|with Multiple Sclerosis/ placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo per day
62614046|NCT05743998||Hemodialysis patients|They will fill 2 questionnaires and ill do some functional tests.
62614047|NCT05743998||Peritoneal dialysis patients|They will fill 2 questionnaires and ill do some functional tests.
62614048|NCT00001756||Healthy Volunteers|Healthy Volunteers
62614049|NCT00001756||Patients|Patients have mast cell hyperplasia compatible with a diagnosis of systemic mastocytosis (applicable to systemic mastocytosis patients only) or other allergic, hematologic, orimmunologic condition.
62614050|NCT06025994|NO_INTERVENTION|STANDARD OF CARE|Patients randomized to the control group will be managed according to current guidelines
62614051|NCT06025994|EXPERIMENTAL|MULTI-DOMAIN LIFESTILE INTERVENTION|"Patients will receive five different kinds of intervention:~i) strict management of CV and metabolic risk factors, ii) tailoring of medical therapy on the basis of the invasive assessment of CMD and coronary vasomotion, iii) dietary counselling, iv) exercise training v) psychological counselling"
62614052|NCT02717442|EXPERIMENTAL|OTO-104|12 mg dexamethasone
62614053|NCT02717442|PLACEBO_COMPARATOR|Placebo|
62614054|NCT01308632|EXPERIMENTAL|Temozolamide, irinotecan|"Phase I trial:~TMZ will be administered in a fixed schedule as follows:~TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.~100 mg/m2 in a morning single dose on days 8 and 22~CPT-11 starting dose:~100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)~One cycle = 28 days~CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 ."
62614055|NCT05241275|EXPERIMENTAL|Progressive Pulmonary Fibrosis|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Progressive Pulmonary Fibrosis patients receiving approved treatments.
62614056|NCT03208608||Normal hearing older adults|Older adults with normal hearing or age-related hearing loss
62614057|NCT04555499||Suspected stroke|Patients with suspected stroke who are evaluated by paramedics
62839056|NCT01956838|EXPERIMENTAL|sweet|intraduodenal infusion of sweet tastant
62839057|NCT01956838|EXPERIMENTAL|bitter|intraduodenal infusion of bitter tastant
62839058|NCT01956838|EXPERIMENTAL|combination|intraduodenal infusion of a combination of tastants (umami, bitter and sweet)
62256900|NCT00619970|ACTIVE_COMPARATOR|Children receiving Rifaximin|2/3 Patients with CAP
62256901|NCT00619970|PLACEBO_COMPARATOR|Children receiving Placebo|1/3 patients with CAP
62839059|NCT01956838|PLACEBO_COMPARATOR|placebo|intraduodenal infusion of placebo (tap water)
62839060|NCT05017272|ACTIVE_COMPARATOR|Opioid Addiction Recovery Support (OARS)|Data collected post-implementation of OARS in conjunction with medication for opioid use disorder (MOUD) at study sites.
62839061|NCT05017272|NO_INTERVENTION|Treatment as Usual|Data collected at baseline before OARS in conjunction with MOUD is implemented at study sites.
62839062|NCT03903588||Normal|Eyes judged as age-appropriate normal as determined by an Investigator and that meet applicable inclusion/exclusion criteria.
62839063|NCT03903588||Glaucoma|Eyes that have been diagnoses with Glaucoma
62839064|NCT03903588||Retinal Disease|Eyes that have been diagnoses with a Retinal Disease
62256902|NCT00997451|EXPERIMENTAL|Behavioral Self-Management|Cognitive-behavioral self-management
62256903|NCT00997451|ACTIVE_COMPARATOR|Symptom Monitoring|
62839065|NCT02365337||vitamin D levels < 20ng/ ml|Vitamin D levels \< 20ng/ ml
62256904|NCT00997451|NO_INTERVENTION|Standard Medical Care|
62256905|NCT05192356|EXPERIMENTAL|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348(3) - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348(3) - A single oral dose of 1 tablet under fasting condition"
62256906|NCT05192356|EXPERIMENTAL|Sequence 2|"Period 1: CKD-348(3) - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348(3) - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
62256907|NCT03817554|EXPERIMENTAL|Treatment group|Peritoneal dialysis patients diagnosed with restless legs syndrome will receive pramipexole.
62256908|NCT03817554|PLACEBO_COMPARATOR|Control group|Peritoneal dialysis patients diagnosed with restless legs syndrome will receive placebo.
62444242|NCT04556110|EXPERIMENTAL|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
62614058|NCT01868165||Cohort of older adults taking antihypertensives|Adults aged 80 and over treated with antihypertensive drugs
62614059|NCT01403259|EXPERIMENTAL|S-1 plus oxaliplatin|S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks for 6 cycles
62614060|NCT02094248|EXPERIMENTAL|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000U/ml, s.c injection
62839066|NCT02365337||vitamin D levels>20ng/ ml|Vitamin D levels \>20ng/ ml
62839067|NCT06048978|EXPERIMENTAL|Native Starch, then Processed Starch|Participants will first receive the Commercial Native Starch in a fasting state in one clinical visit. After a washout of \>24 hours, the participants will then receive the Extrusion Processed Starch in a fasting state in one clinical visit.
62256909|NCT02403570||Multiple Sclerosis|Brain MRI using advanced MR techniques
62256910|NCT01242267|EXPERIMENTAL|Phase 1|Phase 1 including Thalidomide Dose Levels of 600, 800, 1000 mg. Three patients will be entered at each dose level sequentially with a maximum of six patients enrolled at the highest dose level that defines dose-limiting toxicity. The starting dose will be 600mg/d x 5 days (dose level 1) given on days -5 to -1 before transplantation. Doses will be escalated in sequential order as listed below through cohorts of patients.
62614061|NCT02094248|PLACEBO_COMPARATOR|control|Normal saline，1ml/day, s.c injection
62839068|NCT06048978|EXPERIMENTAL|Processed Starch, then Native Starch|Participants will first receive the Extrusion Processed Starch in a fasting state in one clinical visit. After a washout of \>24 hours, the participants then will receive the Commercial Native Starch in a fasting state in one clinical visit.
62839069|NCT00888719|EXPERIMENTAL|CWP-0403 50mg|
62839070|NCT00888719|EXPERIMENTAL|CWP-0403 100mg|
62256911|NCT01242267|EXPERIMENTAL|Phase 2|Phase 2 Thalidomide Dose Level of 1000 mg. The maximum dose to be tested is 1000mg. When the MTD is defined, an additional 40 patients will be enrolled at this level. The first 3 patients of this cohort of 40 patients will be assessed for DLT (2 of 6 patients experiencing DLT at this dose will require dose-de-escalation as described above, and the phase II portion of the study re-initiated at the newly defined MTD).
62256912|NCT06541067|EXPERIMENTAL|Posaconazole|
62614062|NCT01683877|EXPERIMENTAL|FloSeal group|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
62614063|NCT01683877|ACTIVE_COMPARATOR|Electrocautery group|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
62839071|NCT00888719|PLACEBO_COMPARATOR|placebo|
62839072|NCT06093841|EXPERIMENTAL|Relmacabtagene Autoleucel|Experimental: Relmacabtagene Autoleucel Participants will receive cyclophosphamide250 mg/m\^2/day intravenously (IV) and fludarabine 25 mg/m\^2/day IV conditioning chemotherapy for 3 days followed by Relmacabtagene Autoleucel administered as a single IV infusion at a target dose of 1 x 10\^8 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells on Day1.
62256913|NCT05798676||mothers with pre-pregnancy normal weight and their infants|mothers with pre-pregnancy normal weight according to World Health Organization will provide blood and milk samples
62256914|NCT05798676||mothers with pre-pregnancy overweight or obesity and their infants|mothers with pre-pregnancy overweight or obesity according to World Health Organization will provide blood and milk samples
62256915|NCT03173729||Phase 1 Cohort 1|CRC (n = 150)
62256916|NCT03173729||Phase 1 Cohort 2|Precancerous polyps (n = 150)
62839073|NCT03616028|EXPERIMENTAL|Non-valvular AF adults|Left atrial appendage closure (LAAC) with the CLAAS device will be performed according to the device Instructions for Use, based on TEE, ICE and angiographic guidance, femoral venous access and inter-atrial septum crossing.
62839074|NCT02141204|EXPERIMENTAL|HRV Liq Group|Subjects aged 6 to 10 weeks at the time of first vaccination, who received two oral doses of Liquid Human Rotavirus Vaccine (HRV) according to a two-dose schedule, at Day 1 and Month 1.
62256917|NCT03173729||Phase 1 Cohort 3|Normal controls (n = 150)
62256918|NCT03173729||Phase 2 Field Test|75 patients who are high risk for CRC as described in the eligibility
62256919|NCT03173729||Phase 2 Validation Study Cohort 1|Family history of CRC (n = 330)
62256920|NCT03173729||Phase 2 Validation Study Cohort 2|LGI bleeding (n = 240)
62256921|NCT03173729||Phase 2 Validation Study Cohort 3|Patients with history of CRC (n = 75)
62256922|NCT01395199|PLACEBO_COMPARATOR|Starch pill|Placebo
62256923|NCT01395199|EXPERIMENTAL|Amlodipine|Amlodipine 5mg QD
62256924|NCT02285998|EXPERIMENTAL|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
62256925|NCT02285998|ACTIVE_COMPARATOR|Inactivated Influenza Vaccine|Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
62256926|NCT04897477|EXPERIMENTAL|combination of Azacytidine, Bendamustine and Piamprizumab|combination of Azacytidine, Bendamustine and Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma, every 28 days
62256927|NCT00645814|PLACEBO_COMPARATOR|A|
62256928|NCT00645814|ACTIVE_COMPARATOR|B|
62256929|NCT00645814|ACTIVE_COMPARATOR|C|
62614064|NCT01117415||Gall Bladder Surgery|Who have symptomatic cholelithiasis and wish to undergo laparoscopic cholecystectomy for treatment.
62614065|NCT06215794|EXPERIMENTAL|the experimental group|The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. Based on this, the patients in the experimental group are provided with Stellate Ganglion Block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day.
62614066|NCT06215794|ACTIVE_COMPARATOR|the control group|The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy.
62614067|NCT04966078|ACTIVE_COMPARATOR|liposuction|group A will be treated with liposuction
62614068|NCT04966078|ACTIVE_COMPARATOR|periareolar surgical excision|Group B will be treated with periareolar surgical excision
62614069|NCT04886362|EXPERIMENTAL|Intervention Group|Ivermectin 600 mcg/kg every 12 hours for 5 days.
62614070|NCT04886362|PLACEBO_COMPARATOR|Control Group|Same volume like ivermectin
62839075|NCT02141204|ACTIVE_COMPARATOR|HRV Lyo Group|Subjects aged 6 to 10 weeks at the time of first vaccination who received two oral doses of Lyophilized Human Rotavirus Vaccine (HRV) according to a two-dose schedule, at Day 1 and Month 1.
62839076|NCT04976543|EXPERIMENTAL|NWS group|nadroparin calcium injection subcutaneously every 12 hours for 1 month and switched to warfarin orally for 5 months
62256930|NCT02603367|EXPERIMENTAL|Supportive care (COMFORT communication intervention)|"Participants receive the printed communication tool A Communication Guide for Caregivers, a guide developed from the COMFORT communication curriculum, a national training program for palliative care communication. After a 1 week period to review the material, participants undergo communication coaching with a research nurse by phone over approximately 1 hour."
62256931|NCT02408705|ACTIVE_COMPARATOR|Liraglutide|3-month treatment of liraglutide
62256932|NCT02408705|PLACEBO_COMPARATOR|Placebo|3-month treatment of placebo
62256933|NCT02349399||Drug Utilisation / Cohort 1|New users of CPA/EE in 2011/2012 and in 2014
62256934|NCT01673711||Basic Science (deuterated phenanthrene tetraol)|Patients receive deuterated phenanthrene tetraol PO and collect urine for 6 hours after dosing.
62839077|NCT04976543|NO_INTERVENTION|control group|no anticoagulation therapy
62054755|NCT01915576|EXPERIMENTAL|BAY1125976 [twice daily, dose-esc.]|Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
62054756|NCT01915576|EXPERIMENTAL|BAY1125976 [MTD]|Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
62256935|NCT06039462|OTHER|Children undergoing surgery|
62256936|NCT02867176|OTHER|Corneal collagen CXL epi-off|For the epithelium-off procedure, the corneal epithelium is removed with a 10-minute soak time with isotonic riboflavin 0.1% solution and 4 minutes of exposure with 30 mw/cm2 ultraviolet-A irradiation.
62256937|NCT02867176|OTHER|Corneal collagen CXL epi-on|For the epithelium-on procedure, riboflavin is applied for a total soak of 4 minutes; the cornea is then completely rinsed with additional riboflavin for a total of 6 minutes. The ultraviolet-A irradiation is performed for 2 minutes and 40 seconds at 45mw/cm2.
62054757|NCT01659814||Individuals with Major Depressive Disorder|
62054758|NCT01659814||Healthy Control Individuals|
62054759|NCT00971750||Ultrasound Study Group|Patients with no history of gallbladder surgery who are undergoing elective laparoscopic roux-en-Y gastric bypass that have consented to undergo a preoperative transabdominal ultrasound in addition to routine preoperative assessment for surgery.
62054760|NCT02043028|EXPERIMENTAL|Group 1|"Participants compress the chest of a manikin with kneeling posture using a kneeling stool for chest compression posture during 5 minutes~2 weeks later, They perform the chest compression with standing posture using a step stool during 5 minutes"
62444243|NCT04556110|ACTIVE_COMPARATOR|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
62444244|NCT02931812||Cirrhotic subjects|15 cirrhotic patients in end-stage in waiting a graft
62444245|NCT02931812||Chronic kidney disease subjects|15 chronic kidney disease patients in end-stage in waiting a graft
62444246|NCT02931812||Healthy subjects|30 healthy subjects to compare
62054761|NCT02043028|EXPERIMENTAL|Group 2|"Participants compress the chest of a manikin with a standing posture using a step stool for chest compression posture during 5 minutes~2 weeks later, They perform the chest compression with a kneeling posture using a kneeling stool stool and bed height adjustment during 5 minutes"
62054762|NCT03060655|PLACEBO_COMPARATOR|PLGA-Mg material|The fixation of fragments of study group was accomplished with PLGA-Mg material.
62444247|NCT06482463|EXPERIMENTAL|Ventriculostomy-related nosocomial meningitis|Finally, two neurosurgical reanimators will retrospectively diagnose nosocomial meningitis, or the absence of meningitis, according to the information from the patient's medical records.
62444248|NCT06482463|OTHER|Absence of nosocomial meningitis|Finally, two neurosurgical reanimators will retrospectively diagnose nosocomial meningitis, or the absence of meningitis, according to the information from the patient's medical records.
62444249|NCT01903486|OTHER|Prednisone|Prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
62444250|NCT04884958||Index patient|Adults with confirmed clinical infection caused by Staphylococcus aureus, including skin and soft tissue infection or infection of a normally sterile site. These cases will be identified following admission to Anuradhapura General Hospital.
62444251|NCT04884958||Household contacts|This cohort are resident in the same household as the index patient (maximum of four).
62444252|NCT01809054|ACTIVE_COMPARATOR|Arixtra Arm|Arixtra (2.5 mg SQ/QD) subcutaneous injection daily for 2 weeks followed by aspirin 325 mg for 5 weeks
62444253|NCT01809054|ACTIVE_COMPARATOR|Pneumatic compression stockings arm|Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel) for 2 weeks with concomitant Aspirin 325 mg daily for 5 weeks.
62444254|NCT02915679|OTHER|Study participant|"All the participants performed blood sample for genetic purpose, psychiatric assessment and pain investigation:~* 81 depressed patients admitted after a recent suicidal act (\<8 days)~* 81 depressed subjects with a past history of suicidal act (\>1month)~* 80 depressed subjects without any personal history of suicidal behaviour"
62444255|NCT04593290|EXPERIMENTAL|Mild Cognitive Impairment (MCI)|MCI is defined as an early stage of cognitive decline that lies between normal age-matched cognitive function and the onset of very mild forms of dementia, and is associated with a slight but noticeable decline in abilities such as memory and thinking skills. Listening effort testing (with pupillometry) and cognitive testing will be administered for this group - and after a 6-week period of hearing aid use, these measures will be re-tested.
62839078|NCT05757544|EXPERIMENTAL|Dose optimization phase (open label): IV Ganaxolone bolus (variable) followed by infusion (variable)|
62839079|NCT05757544|EXPERIMENTAL|Double-blind phase: IV Ganaxolone + SOC|
62839080|NCT05757544|PLACEBO_COMPARATOR|Double-blind phase: IV Placebo + SOC|
62839081|NCT01744106|EXPERIMENTAL|pseudoephedrine hydrochloride 30 mg tablets|Test product
62839082|NCT01744106|PLACEBO_COMPARATOR|placebo tablets|Placebo
62839083|NCT00175396|ACTIVE_COMPARATOR|1|
62839084|NCT00175396|EXPERIMENTAL|2|
62054763|NCT03060655|PLACEBO_COMPARATOR|titanium alloy|The fixation of fragments of control group was accomplished with titanium alloy material.
62054764|NCT00212498||TB diagnosis|
62054765|NCT03038906||Cohort|Patients enrolling in NHLBI PETAL Network ROSE study of cisatracurium for moderate/severe ARDS at participating centers
62256938|NCT05609474||Users (adolescents or young adults)|1430 users (adolescents and young adults) with addiction problems and consulting CJC for the first time
62256939|NCT05609474||Caregivers|715 caregivers
62614071|NCT04631107|OTHER|Sequence ABC|AD109 Dose 1- 75 mg (A), then AD109 Dose 2- 37.5 mg (B), then Placebo (C).
62256940|NCT05609474||Consultations Jeunes Consommateurs CJCs|"Initial survey (month 0) of participating CJCs: assessment of the structural characteristics of the CJCs (type of CJC (hospital, association), urban/rural area, number of users, number of consultations per month, type of workers...)~- Telephone interview at the 6th and 12th month: assessment of variables related to the user's pathway (referral to a specialized medical or social service...)"
62256941|NCT00589420|EXPERIMENTAL|Phase II|All patients received sorafenib 200 mg bid daily and docetaxel 75 mg/m2 every 3 weeks
62256942|NCT01362361|EXPERIMENTAL|Arm A|mFOLFOX6 + BIBF 1120
62444256|NCT04593290|ACTIVE_COMPARATOR|Cognitively Healthy|This group is 40-85 years old and has no significant neurological or psychiatric disease. Listening effort testing (with pupillometry) and cognitive testing will be administered for this group - and after a 6-week period of hearing aid use, these measures will be re-tested.
62614072|NCT04631107|OTHER|Sequence ACB|AD109 Dose 1- 75 mg (A), then Placebo (C) then AD109 Dose 2- 37.5 mg (B)
62614073|NCT04631107|OTHER|Sequence BAC|AD109 Dose 2- 37.5 mg (B), then AD109 Dose 1- 75 mg (A), then Placebo (C)
62614074|NCT04631107|OTHER|Sequence BCA|AD109 Dose 2- 37.5 mg (B), then Placebo (C), then AD109 Dose 1- 75 mg (A)
62614075|NCT04631107|OTHER|Sequence CAB|Placebo (C), then AD109 Dose 1- 75 mg (A), then AD109 Dose 2- 37.5 mg (B)
62614076|NCT04631107|OTHER|Sequence CBA|Placebo (C), then AD109 Dose 2- 37.5 mg (B), then AD109 Dose 1- 75 mg (A)
62614077|NCT04562220|EXPERIMENTAL|Vibration Group|Routine conventional physical therapy will be applied to patients in the vibration group in 4 weeks and 45 minutes sessions. In addition, right after the sessions, 3 days a week, 30 Hz. frequency vibration will be applied. A vibration session will be as follows; 6 sets of vibrations will be applied, including 1 set of 1 minute vibration and 2 minutes of rest.
62614078|NCT04562220|ACTIVE_COMPARATOR|Control Group|Routine conventional physical therapy will be applied to the control group in 4 weeks and 60 minute sessions.
62614079|NCT04565483|EXPERIMENTAL|BENRALIZUMAB|Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.
62614080|NCT05765825|EXPERIMENTAL|LDRT concurrent cisplatin/carboplatin + etoposide + serplulimab|Participants will receive the following treatment regimens: The induction period consists of 4 cycles of 21 days each. Low-dose radiotherapy(LDRT) at 15Gy/5f will be performed concurrently from Day 1 to Day 5 (D1-D5) of Cycle 1. An efficacy assessment will be performed at the end of Cycle 2. For patients with primary lung lesions (intrathoracic lesions) evaluated as small PR (tumor shrinkage \< 80%)/SD/PD, ldrt at 15Gy/5f will be performed in addition to serplulimab with chemotherapy in Cycle 3. For subjects evaluated as PD/SD/PR with extrathoracic residual metastases, ldrt at 15Gy/5f will be performed in addition to serplulimab with chemotherapy in Cycle 4. After the induction period, the subjects will continue to receive maintenance treatment with serplulimab.
62614081|NCT01259674|EXPERIMENTAL|AboMeg-B-09 syrup|Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
62614082|NCT01259674|PLACEBO_COMPARATOR|Placebo|Placebo syrup
62256943|NCT01362361|PLACEBO_COMPARATOR|Arm B|mFOLFOX6+placebo
62256944|NCT02558673|EXPERIMENTAL|Egg|Study meals were administered in commonly consumed serving sizes (3 hard-boiled eggs) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
62256945|NCT02558673|EXPERIMENTAL|Beef|Study meals were administered in commonly consumed serving sizes (6 oz beef \[Philly-Gourmet Beef Patties\]) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
62256946|NCT02558673|EXPERIMENTAL|Fish|Study meals were administered in commonly consumed serving sizes (6 oz fish \[cod fillet\]) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
62256947|NCT02558673|ACTIVE_COMPARATOR|Fruit|Study meals were administered in commonly consumed serving sizes (2 single-serve packages of Mott's natural applesauce) and provided comparable amounts of control (or active comparator). Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period. For the fruit control, 50 mg deuterium-labeled methyl-d9-TMAO (d9-TMAO; Cambridge Isotopes) was added to one cup of water for oral consumption to enable the tracing of the metabolic fate of TMAO, and to assess its bioavailability and clearance.
62614083|NCT01532206|EXPERIMENTAL|Remote ischemic preconditioning|Remote ischemic preconditioning performed with Blood pressure cuff insufflation
62256948|NCT00507949|EXPERIMENTAL|1|Megestrol acetate: sachets of granulated 160 mg. Dose: 160 mg/b.i.d. Duration 8 weeks
62256949|NCT00507949|PLACEBO_COMPARATOR|2|The placebo is the excipient of the experimental drug.
62614084|NCT01532206|NO_INTERVENTION|Standard of care|Standard of care
62839085|NCT04349332|ACTIVE_COMPARATOR|Helmet non invasive ventilation (NIV)|Patients randomized to the intervention group will be extubated to helmet NIV.
62839086|NCT04349332|NO_INTERVENTION|Control invasive mechanical ventilation|Patients randomized to the control group will continue invasive mechanical ventilation. Once weaning criteria are met, patients will undergo a spontaneous breathing trial for 30 minutes. If the spontaneous breathing trial is successful, then the patient will be extubated.
62839087|NCT01730482|EXPERIMENTAL|[14C] AT1001 Arm|Each subject will receive a single oral dose of 150 mg of \[14C\] AT1001 as an aqueous solution containing 1 μCi AT1001 on Study Day 1.
62256950|NCT04086082|EXPERIMENTAL|Markerless Image Guidance Arm|Single arm trial using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging
62256951|NCT04750759|ACTIVE_COMPARATOR|Niclosamide + Camostat|Patients will receive the combination of niclosamide chewing tablets (2000 mg, once daily) and camostat tablets (600 mg, 4-times daily) over a period of 7 days.
62256952|NCT04750759|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo orally over a period of 7 days.
62256953|NCT03741114|ACTIVE_COMPARATOR|Foley's Catheter plus TA|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus 1 gm tranexamic acid in 100ml saline intravenous just before skin incision
62256954|NCT03741114|ACTIVE_COMPARATOR|Foley's Catheter plus placebo to TA|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus single injection of 100 ml intravenous saline before skin incision
62256955|NCT03295877|EXPERIMENTAL|RO7171009: SAD|Patients will receive a single dose of RO7171009, in multiple escalating cohorts.
62256956|NCT03295877|EXPERIMENTAL|RO7171009: MD|Patients will receive RO7171009 at maximum tolerated dose (MTD), identified during the SAD stage for three doses.
62256957|NCT04170439|OTHER|clomiphene plus metformin plus N acetyle cysteine|Women who will receive clomiphene citrate plus metformin plus n acetyle cysteine
62444257|NCT06008405|EXPERIMENTAL|TQB2928 Injection + Azacitidine for injection|"Dose escalation:~Intravenous infusion of TQB2928 Injection once a week, combined with azacitidine for injection (75 mg/m2, d1-7/q4w), 4 weeks (28 days) as a treatment cycle.~Dose expansion:~The maximum tolerated dose (MTD) or optimal biological dose (OBD) or recommended phase II dose (RP2D) determined in the dose-escalation phase is combined with azacitidine for injection for extended studies to further observe the safety and efficacy."
62444258|NCT01460927|OTHER|TriActive+ RF|Healthy male or female subjects 30-60 years of age, having at least two facial sub-areas (left peri-orbital, right peri-orbital or peri-oral) with visible lines/wrinkles and elastosis, which correlate to a score of 2-6 on the Fitzpatrick Classification of Wrinkling and Degree of Elastosis.
62444259|NCT03650400|EXPERIMENTAL|Cohort A Fevipiprant 75 mg|QAW039 75 mg Chewable tablet
62444260|NCT03650400|EXPERIMENTAL|Cohort B Feviprant 375 mg|QAW039 375 mg Chewable tablet
62444261|NCT06239922||Group 1|Older adults
62444262|NCT06239922||Group 2|Younger adults
62839088|NCT02321176|EXPERIMENTAL|pharmacokinetics,trans-resveratrol|tissues from the eyes of the surgery of patients who received 1 Longevinex containing 100 mg of trans resveratrol active ingredient brand capsule for three days
62256958|NCT04170439|OTHER|clomiphene plus metformin plus chromium|Women who will receive clomiphene plus metformin plus chromium
62256959|NCT04170439|OTHER|clomiphen citrate plus metformin|Women who will receive clomiphene plus metformin
62256960|NCT02458521|EXPERIMENTAL|Transcranial Magnetic Stimulation|TMS sessions will consist of both 10Hz left pre-frontal stimulation for 3,500 pulses followed by 1Hz right pre-frontal stimulation for 1,500 pulses per session, for a total stimulation time of approximately one hour per session.
62256961|NCT02458521|SHAM_COMPARATOR|Sham Transcranial Magnetic Stimulation|Sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7.
62444263|NCT03189797|EXPERIMENTAL|study group|"After defining the individual patient's likelihood risk status and the diagnosis for each lesion, ICCMS presents a management element to build a comprehensive patient care plan as follow:~In the study group they were given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) following the instructions in addition to fluoride mouth rinse. For the clinical approach motivational engagement was done by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year. and application of fluoride varnish every 6 months and dietary intake interventions."
62444264|NCT03189797|NO_INTERVENTION|control group|In the Control group participants assigned to the control condition will be advised to maintain their existing lifestyles. For ethical reasons, if the program shows its effectiveness, it will be made available to all groups at the end of the study.
62444265|NCT02477761|NO_INTERVENTION|Water preload|"During the Water preload study, each subject consume 500 ml of water 30 minutes before a 75 g glucose ingestion"
62444266|NCT02477761|EXPERIMENTAL|Nutrient preload|"During the Nutrient preload study, each subject consume a small mixed meal 30 minutes before a 75 g glucose ingestion. The meal is composed by 50 g of parmesan cheese, one small size boiled egg and 300 ml of water (250 kcal, 23 g protein, 17 g fat and 2 g of carbohydrate)."
62444267|NCT03951428||All Participants|
62444268|NCT04224090||Congenita coronary abnormalities (CAA)|"All the coronary arteries were differing from the definition of normal: when do not arise from the appropriate sinus of Valsalva (right or left) and not present a proper course and termination."
62444269|NCT01454700|EXPERIMENTAL|CSII plus CGM|Patients who has never been treated with insulin pump are randomized to 12 months with insulin pump therapy plus continuous glucose monitoring.
62839089|NCT01995188|EXPERIMENTAL|Dose Escalation Cohort: DNIB0600A+Carboplatin|DNIB0600A at an initial dose of 1.2 milligrams per kilogram (mg/kg) will be administered via intravenous (IV) infusion further following a dose-escalation until DLT under consultation of the investigator in combination with Carboplatin fixed dose of area under the curve (AUC)=6 mg/milliliter(mL)\*minute (min) administered by IV infusion on Day 1 of a 21-day cycle.
62839090|NCT01995188|EXPERIMENTAL|NSCLC Dose Expansion Cohort: DNIB0600A+Carboplatin|Recommended phase 2 dose (RP2D) of DNIB0600A administered via IV infusion in combination with Carboplatin, AUC=6 mg/mL\*min administered via IV infusion on Day 1 of each 21-day cycle in participants with NSCLC until disease progression or death, whichever occurs first.
62054766|NCT01956422|EXPERIMENTAL|Continuous Positive Airway Pressure(CPAP)|In the first 24 hours after laparoscopic prostatectomy patients undergo 3 CPAP cycles (PEEP 7.5, FIO2 40% delivered with Helmet)lasting 2 hours.
62839091|NCT01995188|EXPERIMENTAL|PSOC Dose Expansion Cohort: DNIB0600A+Carboplatin|RP2D of DNIB0600A administered via IV infusion in combination with AUC=6 mg/mL\*min administered via IV infusion on Day 1 of each 21-day cycle in participants with PSOC until disease progression or death, whichever occurs first.
62054767|NCT01956422|ACTIVE_COMPARATOR|Venturi Mask FiO2 40%|In the first 24 hours after laparoscopic prostatectomy patients breathe Oxygen 40% delivered with Venturi Mask
62054768|NCT03321825|EXPERIMENTAL|Belotero® Volume Lidocaine|Subdermal injection
62054769|NCT03321825|NO_INTERVENTION|No treatment|
62054770|NCT02202746|EXPERIMENTAL|Cohort A: Lucitanib (CO-3810) 10 mg daily|10 mg of lucitanib daily in patients with FGFR1-amplified or 11q-amplified metastatic breast cancer.
62054771|NCT02202746|EXPERIMENTAL|Cohort B: Lucitanib (CO-3810) 15 mg daily|15 mg of lucitanib daily in patients with FGFR1-amplified and 11q-amplified metastatic breast cancer.
62054772|NCT02202746|EXPERIMENTAL|Cohort C: Lucitanib (CO-3810) 10 mg daily|10 mg of lucitanib daily in patients with FGFR1 non-amplified and 11q non-amplified metastatic breast cancer.
62256962|NCT01512836|EXPERIMENTAL|Case Management|The patients who are randomized to the intervention group will be assigned to case management. The case manager is expected to integrate care from a health maintenance and promotion perspective, where the overall goal is the promote and support the patients self care (see intervention description).
62256963|NCT01512836|NO_INTERVENTION|Usual Care|Patients randomized to the usual care group will receive conventional health and social services. Patients in this group will not receive support from a case manager.
62256964|NCT05957250|EXPERIMENTAL|[68Ga]Ga-FAPI-46 PET/CT|Depending on study fase: injection(s) with \[68Ga\]Ga-FAPI-46 for one or two \[68Ga\]Ga-FAPI-46 PET/CT scan(s)
62256965|NCT01328951|EXPERIMENTAL|Early Erlotinib|Participants will receive blinded erlotinib as 150 mg PO once daily in the maintenance setting until disease progression, death, or unacceptable toxicity. Those who demonstrate disease progression may be unblinded to receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. Participants may be observed during a final SFU period after discontinuation from study treatment.
62444270|NCT01454700|ACTIVE_COMPARATOR|Multiple daily insulin injections|randomized to 12 months standard/usual insulin regimen (multiple daily injections). (stays on insulin pen).
62839092|NCT01995188|EXPERIMENTAL|PSOC Dose Expansion Cohort: DNIB0600A+Carboplatin+Bevacizumab|RP2D of DNIB0600A administered via IV infusion in combination with Carboplatin, AUC=6 mg/mL\*min and Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle in participants with PSOC until disease progression or death, whichever occurs first.
62444271|NCT04817592||Age1(20-25)|The groups are divided as per age
62444272|NCT04817592||Age2(25-30)|
62444273|NCT04817592||Age3(30-35)|
62444274|NCT04817592||Age4(35-40)|
62444275|NCT04817592||Age5(40-45)|
62054773|NCT06624748|EXPERIMENTAL|emotional and physical support to the pregnant woman provided by attendant|Following the information, the attendant will provide emotional and physical support to the pregnant woman (such as massage, supporting the pregnant woman while moving, giving the pregnant woman a warm shower), and all interventions made by the companion and their duration will be recorded by the researcher in the 'Birth Process Support Form'. When the cervical dilatation is 8 cm, the Birth Comfort Scale will be applied to the pregnant woman, and two hours after the birth, the Birth Satisfaction Scale and the Postpartum Comfort Scale will be applied. Information about the birth process will be recorded in the Birth Information Form. In addition, semi-structured questions in the 'Companion Interview Form' will be asked to the companions selected for qualitative interviews and voice recording will be recorded.
62256966|NCT01328951|PLACEBO_COMPARATOR|Late Erlotinib|Participants will receive blinded placebo tablets PO once daily in the maintenance setting until disease progression, death, or unacceptable toxicity. Those who demonstrate disease progression may be unblinded to receive second-line erlotinib as 150 mg PO once daily until disease progression, death, or unacceptable toxicity. Participants may be observed during a final SFU period after discontinuation from study treatment.
62256967|NCT01841502|ACTIVE_COMPARATOR|paroxetine alone|paroxetine 20 mg tablet once daily oral
62256968|NCT01841502|EXPERIMENTAL|paroxetine + telaprevir|paroxetine 20 mg tablet once daily + telaprevir 1125 mg (3 tablets 375mg) twice daily oral
62256969|NCT02324855|NO_INTERVENTION|Usual care|Subjects will receive the usual medical care in accordance with Spanish non cystic fibrosis bronchiectasis guidelines. In addition they will receive educational sessions about their disease and their pharmacology treatment.
62256970|NCT02324855|EXPERIMENTAL|Chest physiotherapy plus usual care|Subjects will introduce chest physiotherapy as part of their daily treatment
62256971|NCT02781142|EXPERIMENTAL|Motor imagery training|Persons with multiple sclerosis
62256972|NCT02781142|NO_INTERVENTION|Control group|Persons with multiple sclerosis
62256973|NCT02781142|NO_INTERVENTION|Healthy controls|Healthy participants
62839093|NCT04421027|EXPERIMENTAL|Baricitinib + Standard of Care (SOC)|4 milligrams (mg) of baricitinib (given as two 2 mg tablets) administered orally every day (QD) with standard of care.
62256974|NCT01561950|EXPERIMENTAL|Factor VII|
62444276|NCT03971942|EXPERIMENTAL|Neutral ABMT|8-session-ABMT during a two-week period and 4-session-booster-ABMT during a two-week period
62444277|NCT03971942|EXPERIMENTAL|Positive ABMT|8-session-ABMT during a two-week period and 4-session-booster-ABMT during a two-week period
62444278|NCT05719714|EXPERIMENTAL|Intervention group|Thirty individuals will be randomized to dapagliflozin 10mg to be taken daily for six months.
62444279|NCT05719714|NO_INTERVENTION|Standard of Care group|Thirty individuals will be randomized to standard of care treatment.
62444280|NCT02266836|EXPERIMENTAL|MyndMove|The MyndMove system is a neuromodulation device that delivers short electrical pulses to stimulate muscle contractions and enhance motor recovery following Stroke or Spinal Cord Injury. MyndMove delivers therapeutic stimulation sequences called protocols, which are coded therapeutic algorithms which assist muscle movement allowing the brain and central nervous system to be retrained restoring voluntary reaching and grasping functions lost following neurological injury. The MyndMove system comprises the hardware device, stimulation electrodes and cables, hand and foot switches, and integrated software.
62839094|NCT04421027|PLACEBO_COMPARATOR|Placebo + SOC|Placebo (given as two placebo tablets) administered orally QD with standard of care.
62839095|NCT05530564|EXPERIMENTAL|Low-pressure pneumoperitoneum|Participants undergone laparoscopic cholecystectomy by creation of a low-pressure pneumoperitoneum, set at 8-10 mm Hg
62839096|NCT05530564|ACTIVE_COMPARATOR|Standard-pressure pneumoperitoneum|Participants undergone laparoscopic cholecystectomy by creation of a standard-pressure pneumoperitoneum, set at 12-14 mm Hg
62256975|NCT01561950|PLACEBO_COMPARATOR|Placebo|
62839097|NCT01032252|NO_INTERVENTION|observational|Control group: followed by monthly falls calenders and four testing periods
62839098|NCT01032252|EXPERIMENTAL|Exercise group|16 week intervention, and followed by monthly fall calenders as well as 4 testing periods
62839099|NCT03967444|OTHER|Restylane Kysse|Hyaluronic acid
62839100|NCT03967444|OTHER|Restylane Kysse with other HA|Hyaluronic acid
62256976|NCT02459327|EXPERIMENTAL|VIP/FCU|VIP (Video Interaction Project) will be offered to all families assigned to the treatment group. FCU (Family Check Up) will be offered to families identified as high risk within the treatment group. Both treatments are parenting interventions.
62256977|NCT02459327|NO_INTERVENTION|Control|
62256978|NCT01258244||Audiovisual feedback on CPR|EMS technicians will receive audiovisual feedback from the ZOLL device on depth, frequency, and interruptions to cardiac compressions
62256979|NCT02114320|EXPERIMENTAL|EUS-BD-1|EUS-BD-1 inserts a partially covered self-expanding metallic (hybrid) stent with a dedicated introducer for EUS-BD
62256980|NCT02114320|EXPERIMENTAL|EUS-BD-2|EUS-BD-2 inserts a fully covered self-expanding metallic stent
62256981|NCT02670070|ACTIVE_COMPARATOR|Coadministration of G+R|Coadministration of gemigliptin 50mg and rosuvastatin 20mg
62256982|NCT02670070|EXPERIMENTAL|Combination G/R|Combination of gemigliptin 50mg / rosuvastatin 20mg
62444281|NCT03690479|ACTIVE_COMPARATOR|Ball Tip Probe|One half (upper or lower jaw) of the mouth will be probed using the new trial tip (ball-end probe, 0.6mm diameter).
62444282|NCT03690479|ACTIVE_COMPARATOR|Florida Probe Straight Tip Probe|One half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip (straight-end probe, 0.45mm diameter).
62256983|NCT05929716|EXPERIMENTAL|magrolimab, rituximab, and radiation, CAR T leukapheresis|"Participants may receive radiation therapy at any time during the study.~Participants will be given Magrolimab by vein once weekly for 4 doses by vein on an outpatient basis over about 180 minutes starting on Day 1 of Cycle 1.~Participants will be given Rituximab by vein once weekly for 4 doses over about 3-4 hours starting on Day 1 of Cycle 1. You will be given rituximab about 30 minutes (no more than 90 minutes) after magrolimab therapy finishes.~Participants will receive 1 dose of magrolimab and rituximab by vein one week before your CAR T leukapheresis and then 3 weekly doses of each drug starting 1 day after leukapheresis that will complete 1 week before lymphodepleting chemotherapy for CAR T"
62256984|NCT02639611|ACTIVE_COMPARATOR|Immediate Post Operative Acupuncture Treatment|
62256985|NCT02639611|ACTIVE_COMPARATOR|Acupuncture Treatment After 6 Weeks of Recovery|
62444283|NCT04249089|ACTIVE_COMPARATOR|Relaxation Group|
62444284|NCT04249089|NO_INTERVENTION|Control group|
62444285|NCT00774358|EXPERIMENTAL|Interleukin-2|We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
62444286|NCT05566665||ECMO requiring ARDS patients|"The study population for the Aim 1 study will comprise adult patients admitted to the participating ICUs suffering from ARDS (as defined by the Berlin criteria) and treated with ECMO.~The study population for the Aim 2 study will comprise the subgroup of patients as per Aim 1, whose clinical course is complicated by VAP necessitating antibiotic treatment with ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol."
62256986|NCT04363528|OTHER|Doppler Echo|patients will have a Doppler Echo when they enter ICU (within 48 hours) and a second Doppler Echo 7 days later
62256987|NCT02839408|PLACEBO_COMPARATOR|Periodontal treatment, talc powder tab|Periodontal treatment (scaling and root planning) and one tablet containing talc powder per day during 3 months
62256988|NCT02839408|EXPERIMENTAL|Periodontal treatment, Probitic|Periodontal treatment (scaling and root planning) and one sachet containing Lactobacillus rhamnosus SP1 per day during 3 months.
62256989|NCT02839408|EXPERIMENTAL|Periodontal treatment, Antibiotic|Periodontal treatment (scaling and root planning) and one tablet containing 500mg Azithromycin
62256990|NCT05327413||Group 1|
62256991|NCT02865018|EXPERIMENTAL|cetirizine|10mg oral each day
62256992|NCT02571127|EXPERIMENTAL|Only treatment|two weekly applications (monday and thursday or tuesday and friday) for 12 weeks
62256993|NCT04647474||Radical Prostatectomy|Participants undergoing any curative surgical treatment option for prostate cancer irregardless of approach (open, laparoscopic or robotic)
62256994|NCT04647474||Active Surveillance|Participants undergoing active surveillance as the management option for prostate cancer as defined by regular surveillance attendance at the primary treating site.
62444287|NCT05566665||Antibiotic treated ECMO requiring ARDS patients.|The study population for the Aim 2 study will comprise the subgroup of patients as per Aim 1, whose clinical course is complicated by VAP necessitating antibiotic treatment with ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol.
62444288|NCT04457869|EXPERIMENTAL|Single arm|
62444289|NCT03350048||Training Set|"First 500 participants recruited for the Training Set:~* Blood collection for optimization and validation (vs ELISA) of TransDot point-of-care test at LUMC and later for lab-based TransDot at local site laboratory~* Blood, sputum, saliva and urine collection for secondary objectives and repository"
62444290|NCT03350048||Test Set|"Subsequent 300 participants to be used for the Test Set:~* Fingerprick TransDot point-of-care test performed at field site after symptom screen and clinical evaluation and before CXR~* Blood, sputum, saliva and urine collection for secondary objectives and repository"
62839101|NCT00749853|EXPERIMENTAL|1|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
62054774|NCT06624748|NO_INTERVENTION|Standard of care|Women who are informed about the purpose and practices of the research and who agree to participate in the study voluntarily will not be deviated from routine practices in the hospital. Women who are followed and delivered by the same midwife will be included in the study to ensure that there is no difference between the groups in terms of episiotomy application and birth techniques. When the cervical dilatation is 8 cm, the Birth Comfort Scale will be applied to the pregnant woman, and two hours after the birth, the Birth Satisfaction Scale and the Postpartum Comfort Scale will be applied. Information about the birth process will be recorded in the Birth Information Form.
62054775|NCT00674570|EXPERIMENTAL|Arm 1: Hydrocortisone|Hydrocortisone
62054776|NCT00674570|EXPERIMENTAL|Arm 2: D-Cycloserine|D-Cycloserine
62054777|NCT00674570|PLACEBO_COMPARATOR|Arm 3: Placebo|Placebo
62054778|NCT02782390|EXPERIMENTAL|Hall Technique|single placement of stainless dental crowns on atypical cavities
62054779|NCT02782390|ACTIVE_COMPARATOR|Composite Resin|single placement of composite resin on atypical cavities
62256995|NCT04647474||Hormone Monotherapy|Participants undergoing medical hormone therapy (Antiandrogens and Gonadotropin-releasing hormone (GnRH) agonists or antagonists) or surgical castration (e.g. orchidectomy) options as the primary treatment for prostate cancer.
62256996|NCT04647474||Radical Radiotherapy|Participants undergoing primary radiotherapy treatment for prostate cancer irregardless of delivery methods (e.g. External beam radiation therapy or brachytherapy).
62256997|NCT05401084|ACTIVE_COMPARATOR|Carbohydrate|Counseling, education, and implementation of low carbohydrate diet.
62256998|NCT05401084|ACTIVE_COMPARATOR|Low gluten|Counseling, education, and implementation of low gluten diet.
62256999|NCT05401084|NO_INTERVENTION|Standard|No change/intervention in diet. Continuation of standard diet.
62257000|NCT01846728|EXPERIMENTAL|Estrogen suppression|Estrogen production will be suppressed using Lupron, a drug that blocks normal production of ovarian hormones
62257001|NCT02836028|EXPERIMENTAL|talazoparib|Cohorts 1A (PARP inhibitor naïve), 2A (PARP inhibitor sensitive), and 3A (PARP inhibitor refractory)
62257002|NCT02836028|ACTIVE_COMPARATOR|talazoparib + temozolomide|Cohorts 1B (PARP inhibitor naïve), 2B (PARP inhibitor sensitive), and 3B (PARP inhibitor refractory)
62257003|NCT00836043||Group 1|
62257004|NCT01887236|ACTIVE_COMPARATOR|Step Physical Activity|A physical activity program that is based on the Step Apparatus Training Program
62054780|NCT03015506|ACTIVE_COMPARATOR|White Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber).
62054781|NCT03015506|EXPERIMENTAL|Pea Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) pea flour.
62054782|NCT03015506|EXPERIMENTAL|Green Lentil Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) green lentil flour.
62054783|NCT03015506|EXPERIMENTAL|Red Lentil Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) red lentil flour.
62257005|NCT01887236|ACTIVE_COMPARATOR|Stability Ball|A physical activity program that is based on the Stability Ball
62257006|NCT05664542|EXPERIMENTAL|ESPB group|this group will receive ESPB using ropivacaine and dexmedetomidine
62257007|NCT05664542|NO_INTERVENTION|Control group|this group will not receive any block
62257008|NCT01877187|OTHER|Lipiodol|Lipiodol, 10cc per TACE.
62257009|NCT00612950|EXPERIMENTAL|GLP-1|
62257010|NCT00612950|EXPERIMENTAL|GIP|
62257011|NCT00612950|PLACEBO_COMPARATOR|saline|
62257012|NCT00337909|EXPERIMENTAL|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
62257013|NCT00337909|ACTIVE_COMPARATOR|Active Control|Educational DVDs
62257014|NCT00337909|NO_INTERVENTION|No Contact Control|
62257015|NCT01809951||Isomil Advance with LCP|4 spoonful of Isomil Advance with LCP in 240 mL of water, 4 times a day
62257016|NCT02513849|EXPERIMENTAL|Tamoxifen treatment|Patients will be administered tamoxifen, 80mg/ day orally for 4 days as a loading dose, followed by 20mg/ day thereafter until gastroscopy and biopsy 4 weeks later.
62257017|NCT01436136|ACTIVE_COMPARATOR|Intervention group|Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
62623622|NCT03187184|EXPERIMENTAL|OneOme RightMed® Test|OneOme RightMed® currently tests for 22 genes that impact over 340 drugs used in multiple fields of medicine, including oncology. The drugs tested for by OneOme RightMed® were generated from practice guidelines and the FDA's guidelines for genotyping, and drugs with published, clinical evidence supporting genotyping. Testing is done using a prepackaged OneOme RightMed® kit to collect a buccal swab. OneOme RightMed® PGx test uses a DNA Genotek ORAcollect OC-100 buccal swab kit to extract DNA, which is then analyzed through polymerase chain reaction (PCR).
62257018|NCT01436136|ACTIVE_COMPARATOR|Usual care (control) group|Within the context of an open, cohort study, GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.
62257019|NCT00548015|ACTIVE_COMPARATOR|State of the Art strategy|education, reminders, performance feedback,
62257020|NCT00548015|EXPERIMENTAL|extended strategy|state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
62257021|NCT06341530|EXPERIMENTAL|Treatment group|Anlotinib combined with penpulimab
62257022|NCT00993642|EXPERIMENTAL|All Participants|
62257023|NCT05015075|EXPERIMENTAL|CR group|participants who have exercise-based cardiac rehabilitation program after PM.
62257024|NCT05015075|PLACEBO_COMPARATOR|non-CR group|participants who have only routine regular follow-up after PM instead of CR program
62257025|NCT00625209|PLACEBO_COMPARATOR|1|placebo of hydrocortisone, placebo of fludrocortisone and placebo of activated protein C
62257026|NCT00625209|ACTIVE_COMPARATOR|2|Hydrocortisone plus fludrocortisone and a placebo of activated protein C
62257027|NCT00625209|ACTIVE_COMPARATOR|3|placebo of hydrocortisone, placebo of fludrocortisone and activated protein C
62257028|NCT00625209|ACTIVE_COMPARATOR|4|hydrocortisone plus fludrocortisone plus activated protein C
62257029|NCT05949619|EXPERIMENTAL|Study treatment|Participants receive BL-M02D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62257030|NCT05929898|EXPERIMENTAL|Intentional Versus Cue-Evoked Midbrain Activation|Participants meeting study inclusion will be scheduled for two sessions: one baseline behavioral visit and an fMRI session to assess the ability to self-stimulate VTA activation. Session one will include a battery of cognitive assessments and a demonstration of the reward-based learning task in session two. The experimental imaging task session will be done within one week of session one. Participants will been randomly split into two group: group one will complete a reward-based learning task before the VTA activation task and group two will complete reward task after VTA activation. During the VTA activation task, participants will be instructed to achieve a heightened state of motivation using personally relevant thoughts and imagery.
62257031|NCT05929898|EXPERIMENTAL|Intentional Midbrain Activation Effects on Effort-Based Decision Making|Participants will be randomly assigned to an MRI group or a behavioral control group. All participants will complete an effort-based learning task and a series of questionnaires in session one. Session two may include an MRI based on group assignment. Participants in the MRI group will complete the VTA activation task. Following, they will complete the effort task and questionnaires a second time. The behavioral control group will complete a second session consisting of the effort task and questionnaires.
62257032|NCT05929898|EXPERIMENTAL|Intentional Midbrain Activation Effects on Motivated Memory|Participants will take part in four sessions: visit 1-baseline + memory encoding, visit 2-memory retrieval, visit 3-memory encoding, visit 4-memory retrieval). Encoding and retrieval of the memoranda will occur 24 hours apart. Study visits will take place no more than 7 days apart. One group of participants will complete all sessions at the Center for Cognitive Neuroscience. The remainder of participants will complete the encoding sessions in the MRI machine, .
62257033|NCT02100436|EXPERIMENTAL|Cohort 3-8 years old|up to 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
62257034|NCT02100436|EXPERIMENTAL|Cohort 6-35 months old|up to 100 subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart. up to 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
62257035|NCT02100436|EXPERIMENTAL|Cohort 9-17 years old|up tp 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
62257036|NCT04278963|EXPERIMENTAL|Yin Hu Qing Wen Decoction Group|Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen Decoction (Granula) for 10 days.
62257037|NCT04278963|PLACEBO_COMPARATOR|Yinhu Qingwen Decoction low-dose group|Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen Decoction (Granula) for 10 days.
62444291|NCT01894984||Risperidone|Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor \[SSRI\]) will be maintained and will cease at Week 3.
62444292|NCT01894984||Oral atypical anti-psychotic|Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
62444293|NCT03788265|EXPERIMENTAL|injection|
62444294|NCT01939600|EXPERIMENTAL|All subjects|All subjects will undergo all 4 treatments, starch-free breakfast, Hi-Maize 260, Hylon VII and Amioca in randomized order
62257038|NCT04278963|ACTIVE_COMPARATOR|Integrated Chinese and Western Medicine group|Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into 3 times(once with 200ml). The Chinese medicine decoction will be given 200ml per time, three times a day for 10 days.
62257039|NCT05217485|EXPERIMENTAL|Infection and reverted atrial fibrillation|Patients who have developed first-diagnosed atrial fibrillaiton in the context of sepsis or infection
62257040|NCT05335499|EXPERIMENTAL|TAS5315 Dose 1|
62444295|NCT05287139||Hospital Beneficência Portuguesa de SP - BP1|Patients from private institutions.
62444296|NCT05287139||Hospital Pérola Byington - HPB2|Patients from public institutions.
62444297|NCT01153061|EXPERIMENTAL|Fistula closure with occluder|Patients with benign tracheoesophageal fistulas will be submitted to the correction with the occluder.
62623623|NCT02975531|EXPERIMENTAL|Simulator's construction|To build the simulator was selected a volunteer (VF) as a model. This volunteer had no complaints of pain or trauma to the cervical region. This region was used to collect the displacement of the skin and cytometry neck.
62614085|NCT03503734||Integrated headache care|"The treatment can be realized on an inpatient, outpatient and/or day care basis, according to the severity level of illness and comorbidities.~The inpatient treatment takes place at the Department of Internal and Integrative Medicine. The stay is slated for 14 days.~Day care can follow the inpatient stay or can be applied as sole therapy. As part of the standard care provided at the Department for Internal and Integrative Medicine, it occurs at a semi-residential clinic for 6 hours once a week over a total of 10 weeks.~The outpatient treatment is delivered in the Department's outpatient ward. It consists of acupuncture, cupping, hydrotherapy and massages as well as nutritional counseling. The patients can additionally be offered one-to-one mind-body-medicine interventions."
62614086|NCT01065714|EXPERIMENTAL|Hydrogel vehicle|Parallel designed study. Split body treatment
62614087|NCT01065714|ACTIVE_COMPARATOR|Eucerin Lotion|Parallel study design. Split body study.
62614088|NCT01010009|EXPERIMENTAL|Resveratrol 250mg|
62614089|NCT01010009|EXPERIMENTAL|Resveratrol 500mg|
62614090|NCT01010009|PLACEBO_COMPARATOR|Placebo|
62614091|NCT05170334|EXPERIMENTAL|Binimetinib + Belinostat|Participants will receive binimetinib by mouth two times a day, every day during each cycle. Each cycle will last for 21 days. Participants will receive belinostat by intravenous infusion on days 1 through 5 of each cycle.
62614092|NCT05145608|ACTIVE_COMPARATOR|Test- Lamotrigine ER Tablets USP 50mg|Single dose of Test- Lamotrigine ER Tablets USP 50mg will be administered
62614093|NCT05145608|ACTIVE_COMPARATOR|Reference- Lamictal® XRTM ER tablet 50mg|Single dose of Reference- Lamictal® XRTM (Lamotrigine) ER tablet 50mg will be administered
62054784|NCT03015506|EXPERIMENTAL|Chickpea Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) chickpea flour.
62054785|NCT03375281|EXPERIMENTAL|No touch group|RFA for small HCC would be done by using no touch technique
62054786|NCT01906684|EXPERIMENTAL|Acthar Gel|Acthar Gel is supplied as 5 mL multi-dose vial (63004-8710-1) containing 80 USP Units per mL. H.P. Acthar Gel (repository corticotropin injection). Acthar Gel will be administered as a subcutaneous daily dose of 80 units for up to 2 weeks.
62614094|NCT02474355|EXPERIMENTAL|AZD9291|Single arm of AZD9291, starting dose of 80mg
62614095|NCT06730594|EXPERIMENTAL|VL-BK-02 (25 billion CFU/Capsule)|One capsule per day to be consumed orally before breakfast Duration: 84 days (12 weeks)
62839102|NCT00749853|ACTIVE_COMPARATOR|2|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
62839103|NCT00520806|PLACEBO_COMPARATOR|Placebo|48 hour iv infusion of placebo
62839104|NCT00520806|EXPERIMENTAL|Relaxin|48 hour iv infusion of relaxin at 30 ug/kg/day
62257041|NCT05335499|EXPERIMENTAL|TAS5315 Dose 2|
62054787|NCT00817557|ACTIVE_COMPARATOR|Loteprednol|Loteprednol BID
62054788|NCT00817557|PLACEBO_COMPARATOR|Rewetter|Rewetter BID
62054789|NCT04748081||Surgery cohort|Patients who underwent hepatectomy (ICD-9-CM procedure code: 50.2, 50.22, 50.3 and 50.4) between 2000 and 2012 were identified as the surgery cohort.
62054790|NCT04748081||Control cohort|Patients without any record of hepatectomy between 2000 and 2012 were defined as the control cohort.
62257042|NCT05335499|EXPERIMENTAL|TAS5315 Dose 3|
62257043|NCT05335499|EXPERIMENTAL|AS5315 Dose 4|
62257044|NCT05335499|EXPERIMENTAL|TAS5315 Dose 5|
62614096|NCT06730594|PLACEBO_COMPARATOR|Placebo (Microcrystalline Cellulose - 375 mg/capsule)|One capsule per day to be consumed orally before breakfast Duration: 84 days (12 weeks)
62614097|NCT05458440|OTHER|Covid-19 Convalescent donors|The protocol will be explained during hospitalisation for each donor infected by SARS-CoV-2. If they agree, they will be included before they leave hospital. Few weeks later, if they have no exclusion criteria, they will consult in the hemapheresis department of the Nancy University hospital. After medical exams, a whole blood bag and blood samples will be taken with the aim to establish a bank of cryopreserved human leucocytes as a raw material for the generation of a T-Lymphocyte immunotherapy.
62614098|NCT05067894|EXPERIMENTAL|Adult - Vaccine candidate|50 µg dose, adult group (18-59 years)
62614099|NCT05067894|ACTIVE_COMPARATOR|Adult - Control|SARS-CoV-2 inactivated vaccine, adult group (18-59 years)
62614100|NCT05067894|EXPERIMENTAL|Elderly - Vaccine candidate|50 µg dose, elderly group (\> 60 years)
62614101|NCT05067894|ACTIVE_COMPARATOR|Elderly - Control|SARS-CoV-2 inactivated vaccine, elderly group (\> 60 years)
62614102|NCT01022164|OTHER|fibrin glue|
62614103|NCT05636982|EXPERIMENTAL|Telecare-based intervention program|This group of participants will receive a 3-month telecare-based intervention program which includes three main components: 1) online nurse case management supported by a health-social partnership team, 2) individual-specific video messages covering caregiving skills via WhatsApp, and 3) online information center and discussion forum via a password-protected, newly-developed caregiver website.
62614104|NCT05636982|NO_INTERVENTION|Control|The control group will receive conventional community services. The caregiver will attend five educational sessions that covers caregiving skills in the community centers on a fixed schedule.
62614105|NCT05345756|EXPERIMENTAL|Intraoral Protraction Technique|using intraoral appliance composed of modified lingual arch and miniscrews for indirect anchorage for maxillary protraction after Alt-RAMEC protocol using hybrid expander
62614106|NCT05345756|ACTIVE_COMPARATOR|Extraoral Protraction Technique|using facemask for maxillary protraction after ALT-RAMEC protocol
62614107|NCT01301885||Endometriosis|Women (19-48 years of age) with surgically confirmed endometriosis.
62614108|NCT01301885||Healthy women|Healthy women (32-48 years of age), symptom free, existence of endometriosis ruled out during laparoscopy for tubal ligation
62054791|NCT04247282|EXPERIMENTAL|Arm A, Cohort 1 Bintrafusp Alfa (M7824) (Days 1, 15)|M7824 (Days 1, 15)
62257045|NCT05335499|PLACEBO_COMPARATOR|Placebo|
62257046|NCT00657813|EXPERIMENTAL|Access [123I]MNI-330 and SPECT Imaging|
62257047|NCT06125912|EXPERIMENTAL|Test Arm|All participants will use both the test product and the active control. Participants will use the creams in the evening, applying the TBT Cream to the right side of the face, and the positive control on the left side of the face.
62257048|NCT03836495|EXPERIMENTAL|White bread unfortified (WB)|bread with no lysine no phosphorus
62257049|NCT03836495|EXPERIMENTAL|White bread fortified with lysine (WB-L)|Bread with lysine
62257050|NCT03836495|EXPERIMENTAL|White bread fortified with phosphorus (WB-P)|bread with phosphorus
62257051|NCT03836495|EXPERIMENTAL|White bread fortified with lysine and phosphorus (WB-LP)|Bread with phosphorus and lysine
62614109|NCT00369161|ACTIVE_COMPARATOR|Very low dose tacrolimus|The first dose of everolimus was to be administered not later than 24 hours after transplantation with a starting dose of 1.5 mg bis in diem/twice a day (b.i.d.) thereafter adjusted to maintain the trough blood levels between 3 and 8 ng/ml. Tacrolimus was to be initiated within 24 hours after reperfusion of the graft with a starting dose of 0.1 mg/kg/day thereafter adjusted to maintain the trough blood levels between 4 and 7 ng/ml. Up to months three all patients received the same treatment and after three months patients in this arm received tacrolimus to reach a trough blood level between 1.5 and 3 ng/ml. All patients received two doses of 20 mg basiliximab, administered as an intravenous bolus injection. The first dose was given on the day of transplantation, with the second dose being administered on the fourth day post-transplant. Intravenous (i.v.) prednisone (or equivalent) was given pre- or intra-operatively according to center practice.
62623624|NCT02975531|EXPERIMENTAL|Model Features|Thirty-nine volunteers (GT) were selected men and women aged over 18 years without history of trauma in the cervical region in order to determine the characteristics of the model: skin elasticity and cirtometry neck.
62257052|NCT06547658|EXPERIMENTAL|Mouth closed|Closing the mouth by applying pressure to the mentum until the teeth were in occlusion, without altering the head position. Performed during flow-limited breathing.
62257053|NCT06547658|NO_INTERVENTION|Mouth relaxed|Mouth in the natural relaxed position during sleep.
62257054|NCT04774731|EXPERIMENTAL|Whole Body Vibration|
62257055|NCT04774731|NO_INTERVENTION|Control|
62444298|NCT04467697|EXPERIMENTAL|SOV2012-F1-treated|Patients treated with SOV2012-F1, starting daily dose in MRS-TU-2019EXT is 400 mg - (200 mg with morning meal and 200 mg with evening meal). Dosing is titrated up to a maximum of 800 mg SOV2012-F1 per day (400 mg in the morning and 400 mg in the evening) or titrated down to a minimum of 100 mg SOV2012-F1 per day (100 mg in the morning) based on plasma T after 14 and 42 days of treatment, intermediate dose levels include total daily doses of 600 mg, 400 mg and 200 mg.
62444299|NCT04906603|EXPERIMENTAL|TBS Headache|
62839105|NCT03227120|EXPERIMENTAL|Prehabilitation Exercise|Receives Prehabilitation exercise program for three times a week for eight weeks of direct outpatient exercise instruction.
62054792|NCT04247282|EXPERIMENTAL|Arm B, Cohort 1 M7824 + TriAd Vaccine (ETBX-011, ETBX-051 & ETBX-061) (Day 1)|M7824 + TriAd vaccine (ETBX-011, ETBX-051 and ETBX-061) (Days 1)
62054793|NCT04247282|EXPERIMENTAL|Arm C, Cohort 1 M7824 + TriAd Vaccine (Day 1) + N-803 (Day 1)|M7824 + TriAd vaccine (Day 1) + N-803 (Day 1)
62054794|NCT03607357|EXPERIMENTAL|HFNO group/Group A|The patients should receive the treatment of high flow nasal oxygen immediately after extubation.
62257056|NCT04871269|EXPERIMENTAL|Drug: Dronabinol before the trauma film paradigm|
62257057|NCT04871269|EXPERIMENTAL|Drug: Dronabinol after the trauma film paradigm|
62257058|NCT04871269|PLACEBO_COMPARATOR|Placebo before and after the trauma film paradigm|
62257059|NCT04144374|EXPERIMENTAL|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 5 doses of omadacycline once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
62257060|NCT04144374|ACTIVE_COMPARATOR|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 doses of omadacycline once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
62257061|NCT04658901|EXPERIMENTAL|test group|use endovenous radiofrequency closure catheter (ERA-C70,ERA-C30) and endovenous radiofrequency closure generator (ERA-G5) made by Acotec Scientific Co.,Ltd.
62257062|NCT04658901|ACTIVE_COMPARATOR|control group|use the ClosureRFG™ and ClosureFast™ made by Medtronic Inc.
62257063|NCT01213420|EXPERIMENTAL|Aloë Vera FORMULA F-BC-096|
62257064|NCT01213420|ACTIVE_COMPARATOR|Aloë Vera FORMULA F-BC-096 with modified preservative|
62444300|NCT04463433|EXPERIMENTAL|Parent-child Relationship Intervention|The intervention involves five 2h weekly group sessions in which exercises in mindfulness are practiced and associated ABCDE theory is taught to improve emotional regulation and parent-child communication under COVID-2019.
62054795|NCT03607357|PLACEBO_COMPARATOR|NIV group/Group B|The patients should receive the treatment of non-invasive Ventilation immediately after extubation.
62054796|NCT05026125|ACTIVE_COMPARATOR|Group control|3 μg/kg (Ideal Body Weight) of Remifentanil
62257065|NCT01213420|ACTIVE_COMPARATOR|Eucerin Calming cream|
62257066|NCT01213420|ACTIVE_COMPARATOR|Nivea Cream|
62054797|NCT05026125|EXPERIMENTAL|Group Active|3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil
62614110|NCT00369161|ACTIVE_COMPARATOR|Low dose tacrolimus|The first dose of everolimus was to be administered not later than 24 hours after transplantation with a starting dose of 1.5 mg bis in diem/twice a day (b.i.d.) thereafter adjusted to maintain the trough blood levels between 3 and 8 ng/ml. Tacrolimus was to be initiated within 24 hours after reperfusion of the graft with a starting dose of 0.1 mg/kg/day thereafter adjusted to maintain the trough blood levels between 4 and 7 ng/ml. Up to months three all patients received the same treatment and after three months patients in this arm received tacrolimus to reach a trough blood level between 4 and 7 ng/ml. All patients received two doses of 20 mg basiliximab, administered as an intravenous bolus injection. The first dose was given on the day of transplantation, with the second dose being administered on the fourth day post-transplant. Intravenous (i.v.) prednisone (or equivalent) was given pre- or intra-operatively according to center practice.
62614111|NCT06355856|EXPERIMENTAL|DNN.22.17.036|Apply 1 ml to the bald area of the scalp, twice a day for 180 days.
62614112|NCT06355856|ACTIVE_COMPARATOR|10573048700|Apply 1 ml to the bald area of the scalp, twice a day for 180 days.
62614113|NCT02626650|ACTIVE_COMPARATOR|Check symptoms one has experienced|This is the baseline condition. When asked to indicate concussion symptoms (or most other kinds of symptoms for medical conditions), people usually place a check mark next to each symptom they have experienced.
62614114|NCT02626650|EXPERIMENTAL|Check symptoms one has not experienced|Participants place a check mark next to each symptom they have NOT experienced in the most recent sports season.
62614115|NCT02626650|EXPERIMENTAL|Uncheck symptoms one has experienced|To begin, all symptoms will be automatically checked. Participants are told to remove a check mark from each symptom they have experienced in the most recent sports season.
62054798|NCT02101086|EXPERIMENTAL|Autologous Cord Blood Transfusion|Autologous cord blood transfusion 10 mL per kg for anemia
62054799|NCT02101086|ACTIVE_COMPARATOR|Allogeneic blood transfusion|Allogeneic blood transfusion 10 mL per kg for anemia
62054800|NCT03260582|NO_INTERVENTION|Control arm (n=50)|Patients randomized to the control arm will receive usual cardiac rehabilitation care post-myocardial infarction.
62054801|NCT03260582|EXPERIMENTAL|Intervention arm: LifePod arm (n=100)|In addition to usual cardiac rehabilitation care, patients randomized to the LifePod arm will receive access to the LifePod® support software for six months.
62054802|NCT02308579||Multiple Sclerosis|Patients diagnosed with Multiple Sclerosis (MS), identified in the CTEVD trial
62054803|NCT02308579||Clinically Isolated Syndrome|Patients diagnosed with Clinically Isolated Syndrome (CIS), identified in the CTEVD trial.
62444301|NCT04463433|EXPERIMENTAL|Couple Relationship Intervention|The intervention involves four 2h weekly group sessions in which express feelings and wants clearly are practiced and associated Satir communication model is taught to improve couple conflict resolution and communication under COVID-2019.
62444302|NCT01609660|NO_INTERVENTION|Control group|No intervention at all
62444303|NCT01609660|EXPERIMENTAL|Study group|Use of Saccharomyces boulardii, 100mg for at least seven days before surgery
62614116|NCT02626650|EXPERIMENTAL|Uncheck symptoms one has not experienced.|To begin, all symptoms will be automatically checked. Participants are told to remove a check mark from each symptom they have NOT experienced in the most recent sports season.
62054804|NCT02308579||Other Neurological Disorders|Patients diagnosed with Other Neurological Disorders (OND), identified in the CTEVD trial. ONDs fall into one of four categories: Neurodegenerative, Vascular, Autoimmune, and Neuromuscular; and the following disorders: Acute Disseminated Encephalomyelitis (ADEM); Antiphospholipid Antibody (syndrome; APLA); Atypical, short-lasting neurodegenerative disease; Autoimmune disease not otherwise specified (NOS); Cerebellum Syndrome; Charcot-Marie Tooth Disease; Chiari Malformation; Chronic Fatigue Syndrome; Central Nervous System Vasculitis; Demyelinating Disease; Epilepsy; Headaches; Idiopathic Chronic Neuropathy; Migraines; Mitochondrial Disease; Myelopathy; Neurofibromatosis; Neuropathy; Optic Neuritis; Parasthesia related to Transient Ischemic Attacks (TIA); Parkinson's Disease; Restless legs syndrome; Seizures; Spinal Cerebellum Disease; Spinal Disc Degeneration; Syringomyelia; and Vertigo
62054805|NCT02308579||Healthy Controls|Individuals who are healthy (i.e., free from neurological conditions; HC) , identified in the CTEVD trial.
62054806|NCT01342458|EXPERIMENTAL|Intervention Group|Daily use of the intervention Flexible footwear (Moleca®) for 6 months, for at least 42 hours/week (approximately 6 hours/day, 7 days/week). The Moleca® shoe (Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a low-cost women's double canvas, flexible, flat, walking shoe without heels, with a 5-mm anti-slip rubber sole and a 3-mm flat insole of ethylene vinyl acetate that provides only protection but no correction. The mean weight of the shoe is 0.172±0.019 kg (range 0.091 to 0.182 kg), depending on size. This minimalist footwear is commonly worn by the elderly of all social classes and its average cost is US$ 6.25.
62444304|NCT03522922|ACTIVE_COMPARATOR|Dermaroller arm|Patients received a series of six treatments by dermaroller at 4 weeks interval and no topical anti scar treatment in between sessions.
62444305|NCT03522922|ACTIVE_COMPARATOR|Dermaroller + topical Vit. C arm|Patients received a series of six treatments by dermaroller at 4 weeks interval with the same maneuver and instructions as first group and each session was followed by immediate application of topical vitamin C serum plus once daily application in between sessions.
62614117|NCT05470855|EXPERIMENTAL|Experimental Group in Protective effect study|22500 subjects including 7500 subjects aged 1-3 years with no history of varicella vaccination,7500 subjects aged 4-6 years with a history of 1 dose of varicella vaccine,7500 subjects aged 7-12 years with a history of 1 dose of varicella vaccine will receive one dose of varicella vaccine.
62614118|NCT05470855|NO_INTERVENTION|Control Group in Protective effect study|22500 subjects including 7500 subjects aged 1-3 years with no history of varicella vaccination,7500 subjects aged 4-6 years with a history of 1 dose of varicella vaccine,7500 subjects aged 7-12 years with a history of 1 dose of varicella vaccine.
62614119|NCT05470855|EXPERIMENTAL|Safety group|30000 subjects from study 1 will be enrolled to conduct safety observation study,all adverse events of all subjects will be collected.
62614120|NCT05470855|EXPERIMENTAL|Etiological study group|Herpes fluid collected from varicella cases in study 1 will be used to conduct etiological study on the pathogenic strains of varicella cases.
62614121|NCT00895570|EXPERIMENTAL|Modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
62257067|NCT06178445|EXPERIMENTAL|SOC treatment with gemcitabine/cisplatin in combination with trastuzumab and pembrolizumab|"* Gemcitabine: 1000 mg/m2 on day 1 and day 8 of each 21-days cycle (Q3W)~* Cisplatin: 25 mg/m2 on day 1 and day 8 of each 21-days cycle~* Trastuzumab: initial dose 8 mg/kg, then 6 mg/kg on day 1 of each 21-days cycle~* Pembrolizumab: 200 mg on day 1 of each 21-days cycle"
62054807|NCT01342458|NO_INTERVENTION|Control Group|During the intervention period, patients from the Control Group (CG) were instructed not to wear Flexible footwear (Moleca®) or other similar minimalist footwear. During everyday activities, the CG group was only permitted to wear a standard, neutral tennis shoe. At the end of the intervention period, all CG participants also received one pair of Moleca® shoes at no cost.
62257068|NCT04472520|EXPERIMENTAL|Subject getting an ECG|Subjects getting an ECG will have AliveCore tracings obtained in 3 configurations; between right hand and left hand, between left hand and left lower leg (thigh, calf, and foot) and between right hand and left lower leg (thigh, calf, and foot).These configurations will be obtained with the participant lying in bed and in a sitting position.
62257069|NCT04672564|EXPERIMENTAL|Carrimycin|Patients will receive oral dose of 400 mg carrimycin once-daily and SOC for 14 days.
62257070|NCT04672564|PLACEBO_COMPARATOR|Placebo|Patients will receive oral dose of Placebo once-daily and SOC for 14 days.
62257071|NCT00332254|EXPERIMENTAL|1|Intra-articular IL-1Ra
62257072|NCT00332254|PLACEBO_COMPARATOR|2|Intra-articular saline
62257073|NCT00464321|EXPERIMENTAL|Cohort A|Dose Group
62257074|NCT00464321|EXPERIMENTAL|Cohort B|Dose Group
62257075|NCT00464321|EXPERIMENTAL|Cohort C|Dose Group
62257076|NCT00464321|EXPERIMENTAL|Cohort D|Dose Group
62257077|NCT02701452|EXPERIMENTAL|COAGO|All patients undergoing antagonist protocol and at high risk of OHSS (estradiol level ≥ 3000 pg/mL and/or more than 20 follicles ≥ 11mm on the day of triggering) were triggered by GnRH agonist.
62257078|NCT03399136|EXPERIMENTAL|Moderate-intensity aerobic exercise|In the moderate-intensity aerobic exercise group, participants performed a self-paced 1-mile walk (3-5 METs) on an indoor track in the same exercise center as the high-intensity exercise group. Initial sessions lasted 20-30 minutes and were increased weekly to 45 minutes in parallel to the duration of the high-intensity exercise group.
62257079|NCT03399136|EXPERIMENTAL|High-intensity aerobic exercise|In the high-intensity aerobic exercise group, exercise training was performed on a motorized treadmill with occasional substitution with the elliptical machine as needed for joint pain. Target heart rate was based on the baseline treadmill test and was calculated as percentage of the heart rate reserve (HRR=maximal HR-resting HR). Initially, participants trained for 20-30 minutes at 50-60% of HRR. Duration and intensity was increased by 10% weekly so that within 5-7 weeks the aerobic exercise sessions lasted 30-45 minutes at 70-85% of HRR and at the end of the 16 weeks lasted 40-45 minutes at 75-90% of HRR.
62614122|NCT00895570|PLACEBO_COMPARATOR|Placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
62257080|NCT03800784|EXPERIMENTAL|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
62257081|NCT04653610||HIV-infected individuals|
62257082|NCT04653610||HIV-seronegative healthy volunteers|
62257083|NCT05688878|EXPERIMENTAL|Experimental group|An exploratory-descriptive qualitative study will be conducted . This study will be conducted with 10 stroke patients receiving threshold electrical stimulation therapy. Threshold electrical stimulation will be applied for 4 weeks, 3 days a week, for one hour. At the end of the 4th week, semi-structured focus group interviews will be held with the patients. . In the semi-structured focus group interviews, the same questions will be asked to all participants and the verbal answers to these questions will be recorded with voice recorders. Compared to taking notes by hand; It will be preferable to record the conversation with a voice recorder because it has advantages such as recording all the interviews and allowing the interviewer to focus on the interview. Thematic analysis method will be used in the evaluation of the data.
62257084|NCT04563273|EXPERIMENTAL|Healthy people aged 18-45|Healthy people aged 18-45 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
62257085|NCT04563273|EXPERIMENTAL|Healthy people aged 46-65|Healthy people aged 46-65 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
62257086|NCT04563273|EXPERIMENTAL|Healthy people aged 11-17.|Healthy people aged 11-17 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
62444306|NCT03522922|ACTIVE_COMPARATOR|Topical Vit. C arm|Patients received once daily topical vitamin C serum capsule at night for six months. With monthly evaluation.
62614123|NCT01085084|PLACEBO_COMPARATOR|Placebo|Participants will receive 2 capsules of placebo matched to laquinimod orally once daily for 12 weeks.
62614124|NCT01085084|EXPERIMENTAL|Laquinimod 0.5 mg|Participants will receive 1 capsule of laquinimod 0.5 mg and 1 capsule of placebo matched to laquinimod orally once daily for 12 weeks.
62614125|NCT01085084|EXPERIMENTAL|Laquinimod 1 mg|Participants will receive 2 capsules of laquinimod 0.5 mg orally once daily for 12 weeks.
62614126|NCT04224220|ACTIVE_COMPARATOR|Adult Medical Care Coordination|This group will receive adult medical care coordination following discharge from a recent hospitalization.
62054808|NCT05261893|EXPERIMENTAL|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|"In this we will use myofascial stretching Elongation Longitudinaux Avec Decoaption Osteo Articulaire for knee osteoarthritis. Each patient perform half kneeling posture with homolateral foot and knee in alignment with hip while knee flex to 90° and retrovulsion of the pelvis. Chin tucked in and head towards ceiling. Patient elbow and wrist in extension and arms in external rotation. In this homolateral arm directed anteriorly and pushing arm away from body and contralateral arm directed superiorly and tibia externally rotated.~This position maintained for 1 minute with 15 secs rest. This group will receive 40 mins of session."
62614127|NCT04224220|ACTIVE_COMPARATOR|Remote Patient Monitoring|This group will receive remote patient monitoring following discharge from a recent hospitalization.
62614128|NCT04224220|NO_INTERVENTION|Usual Care|The usual care group will not receive additional supportive care following discharge from a recent hospitalization beyond what is typically offered through their primary care team.
62054809|NCT05261893|EXPERIMENTAL|Post Facilitation Stretching|"This group will receive post facilitation stretching technique. In this all the major muscles of the lower limb (quadriceps, hamstrings ,upper and lower calf muscles) are stretched .And the physiotherapist instruct the patient how to perform stretch . When we target a muscle and perform stretch patient feels sensation of stretch .~The stretch was hold on to 60 secs and repeated 3 times on each muscle group on each leg."
62054810|NCT00085202|EXPERIMENTAL|Stratum 1 (high-risk group)|"Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks. Six weeks after the completion of radiotherapy, patients receive high-dose chemotherapy followed by autologous stem cell transplantation (SCT) and filgrastim (G-CSF) with post-transplantation vincristine. High-dose chemotherapy and autologous SCT repeat every 4 weeks for 3 additional courses in the absence of unacceptable toxicity.~Interventions: vincristine, cisplatin, cyclophosphamide, autologous hematopoietic stem cell transplantation, filgrastim, radiation therapy"
62054811|NCT00085202|EXPERIMENTAL|Stratum 2 (average-risk group)|"Patients undergo craniospinal radiotherapy as in stratum 1, but at a lower dose. Patients receive high-dose chemotherapy, autologous SCT, G-CSF, and post-transplantation vincristine as in stratum 1.~Interventions: vincristine, cisplatin, cyclophosphamide, autologous hematopoietic stem cell transplantation, filgrastim, radiation therapy"
62257087|NCT04563273|EXPERIMENTAL|Healthy people aged 6-10|Healthy people aged 6-10 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
62257088|NCT00867789|EXPERIMENTAL|Trimethoprim-sulfamethaxazole|Incision and drainage of the abscess and treatment with oral TMP-SMX (100 patients)
62257089|NCT00867789|PLACEBO_COMPARATOR|Sugar pill|Incision and drainage of the abscess and treatment with oral placebo (100 patients)
62257090|NCT04931784|ACTIVE_COMPARATOR|Nitrate Group|with administration of intra-coronary nitrate before percutaneous coronary intervention
62054812|NCT00855010|EXPERIMENTAL|pioglitazone|pioglitazone tablet 45 mg once daily
62054813|NCT00855010|PLACEBO_COMPARATOR|placebo pill|placebo pill once daily (look-alike pill which contains no active ingredients)
62054814|NCT03039439||Ancillary-Correlative (laboratory biomarker analysis)|Previously collected tumor tissue and blood samples are analyzed via immunohistochemical profiling for identifying potential genes showing molecular aberrations as other types of cancer.
62257091|NCT04931784|PLACEBO_COMPARATOR|Control Group|without administration of intra-coronary nitrate before percutaneous coronary intervention
62444307|NCT00186927|EXPERIMENTAL|Participants|"Participants will be studied in three cohorts:~* Healthy seropositive children 3 years up to 6 years~* Healthy seropositive toddlers 12 months up to 24 months~* Healthy seronegative toddlers 12 months up to 24 months.~Each cohort will receive Sendai virus vaccine."
62614129|NCT06169956||Participants receiving neoadjuvant nivolumab in combination with platinum-based chemotherapy|
62614130|NCT01689233|EXPERIMENTAL|TRx0237 200 mg/day|
62054815|NCT03948984|EXPERIMENTAL|Therapeutic Music Session|
62054816|NCT06254534|PLACEBO_COMPARATOR|Control|In the control group, only unlabeled saline prepared in 50 ml will be administered intravenously for 10 minutes before general anesthesia induction after standard monitoring on the operating room table.
62054817|NCT06254534|EXPERIMENTAL|Lidocaine|lidocaine (1.5 mg/kg) within unlabeled saline prepared in 50 ml will be administered intravenously for 10 minutes before general anesthesia induction after standard monitoring on the operating room table.
62054818|NCT06254534|EXPERIMENTAL|magnesium|magnesium (20 mg/kg) within unlabeled saline prepared in 50 ml will be administered intravenously for 10 minutes before general anesthesia induction after standard monitoring on the operating room table.
62054819|NCT06254534|EXPERIMENTAL|dexmedetomidine|Dexmedetomidine (1 mcg/kg) within unlabeled saline prepared in 50 ml will be administered intravenously for 10 minutes before general anesthesia induction after standard monitoring on the operating room table.
62257092|NCT02079857|EXPERIMENTAL|Standard|Fixed protocol
62257093|NCT02079857|EXPERIMENTAL|Individualized|Individualized protocol
62257094|NCT02079857|SHAM_COMPARATOR|Control|Sham acupuncture/Placebo moxa
62257095|NCT02036242|EXPERIMENTAL|Sole local anesthetic|Epidural analgesia will be given with sole local anesthetic (0.125% ropivacaine) intermittently
62257096|NCT02036242|ACTIVE_COMPARATOR|Opioid plus local anesthetic|Epidural analgesia will be given with opioid (sufentanil) combined with local anesthetic (0.125% ropivacaine) intermittently
62257097|NCT04521829|EXPERIMENTAL|VR-enhanced treadmill walking|Participants will be tested during 2 sessions of VR-enhanced treadmill walking.
62444308|NCT05029583|EXPERIMENTAL|routine screening group|consists of 4 clusters randomized into Group 1 (includes different clinic sites from Group 2)
62614131|NCT01689233|PLACEBO_COMPARATOR|Placebo|
62614132|NCT02859688||SRS patient|
62614133|NCT02859688||father SRS patient|
62614134|NCT02859688||control patient|
62054820|NCT06254534|EXPERIMENTAL|Esmolol|Esmolol (1 mcq/kg) within unlabeled saline prepared in 50 ml will be administered intravenously for 10 minutes before general anesthesia induction after standard monitoring on the operating room table.
62257098|NCT03079206|EXPERIMENTAL|Hazelnut allergy|patients with positive case history of hazelnut allergy and a positive skin testing are undergoing a food challenge and blood sampling for basophile activation testing
62444309|NCT05029583|ACTIVE_COMPARATOR|physician-driven screening group|consists of 4 clusters randomized into Group 2 (includes different clinic sites from Group 1)
62614135|NCT00201617||1|normal hearing sensitivity
62054821|NCT04983108||ACLF|ACLF
62054822|NCT01194895|EXPERIMENTAL|protective ventilation|
62257099|NCT00906802|EXPERIMENTAL|R-Y reconstruction|the reconstruction was performed by R-Y anastomosis
62257100|NCT00906802|NO_INTERVENTION|conventional reconstruction|the anastomosis was performed by B-II
62444310|NCT04676594||Diagnosis of Pulmonary Fibrosis on Chest CT|Retrospective chart review of patients with a diagnosis of pulmonary fibrosis on chest CT.
62444311|NCT03133442|NO_INTERVENTION|Baseline Nights|No vestibular stimulation is applied. However, the sound of the moving bed will be played back to the participant at the right sound intensity level.
62444312|NCT03133442|EXPERIMENTAL|Movement Nights|Vestibular stimulation, in the form of gentle rocking movements, is provided using the Somnomat V4 rocking bed. Stimulation is provided for the entire 7 hours of the night from lights off to lights on. The stimulation frequency is in the range of 0.1-0.3 Hz, with an amplitude in the range of 0.05 to 0.1m
62614136|NCT00201617||2|Unilateral deafness who are implanted with a Bone Anchored Hearing Aid
62614137|NCT02513602||TEST group (kidney transplanted)|"Kidney transplanted patients, passed through dialysis phase presenting a mandibular edentulism. It will be scheduled one or two dental implants to be inserted in mandible.~This group will be subjected to a dental implant insertion procedure."
62614138|NCT02513602||CONTROL group (healthy patients)|Healthy patients, with an inserted mandibular implant, retrospectively enrolled with a preoperative cbct scan.
62054823|NCT01194895|ACTIVE_COMPARATOR|conventional ventilation|
62054824|NCT05956704|EXPERIMENTAL|Experimental Group|
62054825|NCT05956704|ACTIVE_COMPARATOR|Control group|
62054826|NCT05956704|NO_INTERVENTION|Blank control group|
62257101|NCT05797987||FES negative in MBC|Patients who did not present with any ER-positive lesions were characterized as with negative ER expression in the metastatic stage
62257102|NCT03938779|EXPERIMENTAL|Pelvic Floor Muscle Training (PFMT)|Experimental group will perform for 4 months a PFMT
62257103|NCT03938779|EXPERIMENTAL|Pad test|The experimental and control group will perform the pad test twice. At the beginning of the evaluation and 4 months after the PFMT. The modified pad test, has the durability of a workout (2h30min)
62257104|NCT03938779|NO_INTERVENTION|Kings Health Questionnaire|Kings Health Questionnaire to assess the impact of urinary incontinence on quality of life of women. Both groups will complete the questionnaire.
62257105|NCT03938779|NO_INTERVENTION|perineometer|Both groups will perform perineometry at baseline and 4 months after
62444313|NCT05716139|ACTIVE_COMPARATOR|Natural Cycle|In this,hCG trigger and Luteal Phase Support is monitored for the natural frozen embryo cycle procedure of IVF.
62444314|NCT05716139|OTHER|Artificial Cycle|In this, endometrial preparation and Luteal Phase Support is monitored for the artificial frozen embryo cycle procedure of IVF.
62444315|NCT04748211|EXPERIMENTAL|Infraclavicular Block|Group I received USG and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
62444316|NCT04748211|EXPERIMENTAL|Interscalen Block|Group II received USG and neurostimulator guided interscalen block. 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
62444317|NCT04509973|EXPERIMENTAL|Dexamethasone 12 mg|Intravenous bolus injection of dexamethasone 12 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 12 mg at sites, where dexamethasone is not available.
62444318|NCT04509973|ACTIVE_COMPARATOR|Dexamethasone 6 mg|Intravenous bolus injection of dexamethasone 6 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 6 mg at sites, where dexamethasone is not available.
62444319|NCT04003870|EXPERIMENTAL|Runner|Subject will undergo an assessment wearingeither the CASO or the HL. Sequence of CASO of HL will be randomly allocated.
62444320|NCT03867851|EXPERIMENTAL|IBsolvMIR|Study drug IBsolvMIR administered intravenously at 18 mg/kg on day of transplantation and 3 mg/kg on post-operative days 1, 3, 6.
62444321|NCT03867851|ACTIVE_COMPARATOR|Heparin|Heparin treatment according to clinical praxis.
62444322|NCT04195997|EXPERIMENTAL|bivalurudin|Bivalirudin will be given as a bolus of 0.75 mg/kg once transseptal puncture is successully performed with no pericardial effusion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
62614139|NCT05000853||Patients with iron deficiency|
62614140|NCT05000853||Patients without iron deficiency|
62614141|NCT03901508|EXPERIMENTAL|Anodal tDCS|Subjects will receive 20min anodal tDCS
62614142|NCT03901508|SHAM_COMPARATOR|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
62257106|NCT03598647|ACTIVE_COMPARATOR|Physical activity information - for non-exercisers only|Non-exercisers randomized to this condition will receive basic information about physical activity. This includes the national physical activity guidelines,clarification of 'moderate-intensity', exercise safety, and the progression of physical activity within the weight loss program.
62444323|NCT04195997|ACTIVE_COMPARATOR|heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
62614143|NCT01977716||Incident peritoneal dialysis patients|Patients with chronic kidney disease incident to peritoneal dialysis treatment
62614144|NCT05837793||frail|The mFi categorizes patients with a score of 0.27 or higher as frail and those with a score below that as the non-frail group.
62614145|NCT05837793||and non-frail|The mFi categorizes patients with a score of 0.27 or higher as frail and those with a score below that as the non-frail group.
62614146|NCT04221022|ACTIVE_COMPARATOR|Light physical activity (Group 1)|Female collegiate students were assessed by using Academic stress scale questionnaire, Cohen Perceived stress Scale and rapid assessment of physical activity (RAPA) to determine physical activity level and academic stress. They were assigned into Light Physical activity. Each subject in first group completed 6 weeks of exercise sessions which aimed to cope up academic stress among female collegiate students. Each subject was evaluated for changes in symptoms in each week.
62614147|NCT04221022|ACTIVE_COMPARATOR|Moderate physical activity (Group 2)|Female collegiate students were assessed by using Academic stress scale questionnaire, Cohen Perceived stress Scale and rapid assessment of physical activity (RAPA) to determine physical activity level and academic stress. They were assigned into moderate Physical activity. Each subject in first group completed 6 weeks of exercise sessions which aimed to cope up academic stress among female collegiate students. Each subject was evaluated for changes in symptoms in each week.
62614148|NCT04221022|ACTIVE_COMPARATOR|Vigorous physical activity (Group 3)|Female collegiate students were assessed by using Academic stress scale questionnaire, Cohen Perceived stress Scale and rapid assessment of physical activity (RAPA) to determine physical activity level and academic stress. They were assigned into vigorous Physical activity. Each subject in first group completed 6 weeks of exercise sessions which aimed to cope up academic stress among female collegiate students. Each subject was evaluated for changes in symptoms in each week.
62054827|NCT04075825|EXPERIMENTAL|Darvadstrocel|Participants who received a single dose of darvadstrocel, 120 million cells, intralesionally or darvadstrocel matching placebo previously in the ADMIRE-CD II study will be observed for efficacy and safety. No drug administration in this study.
62054828|NCT05850039||Study group|Patients with permanent or persistent AFib, undergoing surgical ablation, isolated or concomitant to valve surgery
62054829|NCT05850039||Mitral surgery control group|Patients undergoing isolated or concomitant mitral valve surgery
62614149|NCT00448812|EXPERIMENTAL|Alair Treatment|Subjects from PREDECESSOR STUDY (NCT00214526) treated with conventional therapy with ICS+LABA (inhaled corticosteroid + long-acting beta-agonist) plus Bronchial Thermoplasty with the Alair System.
62614150|NCT00448812|NO_INTERVENTION|Control|Control group subjects from PREDECESSOR STUDY (NCT00214526).
62614151|NCT03216603|EXPERIMENTAL|Health literacy intervention group|Health literacy intervention group will receive self-management help using a motivating interviewing technique delivered by nurses trained on motivating interviewing technique and COPD.
62614152|NCT03216603|NO_INTERVENTION|Usual care group|Usual care group will receive usual follow up
62054830|NCT05850039||Autoptic control group|Autopsy samples in subjects without arrhythmia
62054831|NCT01946022|ACTIVE_COMPARATOR|GnRH Agonist|GnRH long agonist protocol of invitro fertilization
62054832|NCT01946022|ACTIVE_COMPARATOR|GnRH Antagonist|GnRH fixed antagonist protocol of in vitro fertilization
62054833|NCT01422525||Trabeculectomy RNFL thickness OCT|
62054834|NCT01546259|NO_INTERVENTION|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
62257107|NCT03598647|EXPERIMENTAL|Affect and physical activity - for non-exercisers only|Non-exercisers randomized to this condition will receive the same basic information about physical activity as described above, but they will also receive a brief intervention focused on affective responses to exercise.
62257108|NCT03598647|NO_INTERVENTION|Exercisers|Engaging in \>=150 min/week of moderate-intensity exercise over the past 6 months and a most recent typical week
62444324|NCT06543264|EXPERIMENTAL|the study group|Cryotherapy (apparatus)
62444325|NCT06543264|NO_INTERVENTION|the control group|not received cryotherapy
62257109|NCT03598647|NO_INTERVENTION|Non-exercisers|Engaging in \<30 min/week of moderate-intensity exercise over the past 6 months and a most recent typical week
62444326|NCT05564949|EXPERIMENTAL|Classic Ketogenic Diet|Patients will adhere to a classic ketogenic diet for a period of 3 months with a possible extension depending on their compliance on the diet.
62257110|NCT05843006||STEMI + PCI|18 subjects referred for coronary angiography/PCI due to ST-segment elevation myocardial infarction (STEMI)
62444327|NCT04081337|PLACEBO_COMPARATOR|Placebo|Participants received placebo once weekly (QW) by Subcutaneous (SC) injection.
62444328|NCT04081337|EXPERIMENTAL|15 Milligram (mg) Tirzepatide|Participants received 15 mg of tirzepatide QW by SC injection.
62444329|NCT06530745|EXPERIMENTAL|PRP receiving group|Patients receiving platelet-rich plasma injections into temporomandibular joints.
62444330|NCT06530745|ACTIVE_COMPARATOR|HA receiving group|Patients receiving hyaluronic acid injections into temporomandibular joints.
62614153|NCT06137209|ACTIVE_COMPARATOR|Study Group A: Blis Q24 Serum at 1e7 cfu/ dose (Active)|Group A: Probiotic Micrococcus luteus Q24 serum (dose: 1e7 colony forming units per application)
62614154|NCT06137209|ACTIVE_COMPARATOR|Study Group B: Blis Q24 Serum at 1e6 cfu/ dose (Active)|Group B: Probiotic Micrococcus luteus Q24 serum (dose: 1e6 colony forming units per application)
62614155|NCT05213026||Apexification|"Apexification treatment was applied by a single operator (GK) in Istanbul University Faculty of Dentistry, Department of Pedodontics,~* Having no systemic or periodontal problems,~* Asymptomatic or diagnosed with apical periodontitis with fistula tract,~* Not having external/internal resorption, fracture, more than one root/canal,~* Root canal filling is sufficient for the MTA,~* Root canal filling and coronal restorations were completed in Istanbul University Faculty of Dentistry Department of Pedodontics,~* Cases with periapical radiographs taken before the procedure and at least one year after the procedure was included."
62614156|NCT05213026||Regenerative|"Apexification treatment was applied by a single operator (GK) in Istanbul University Faculty of Dentistry, Department of Pedodontics,~* Having no systemic or periodontal problems,~* Asymptomatic or diagnosed with apical periodontitis with fistula tract,~* Not having external/internal resorption, fracture, more than one root/canal,~* Root canal filling and coronal restorations were completed in Istanbul University Faculty of Dentistry Department of Pedodontics,~* Cases with periapical radiographs taken before the procedure and at least one year after the procedure was included."
62614157|NCT04441385|EXPERIMENTAL|Test arm|100 subjects will be randomly assigned to this arm. Patients in the test group will receive 300 mg of maraviroc BID for 14 days (added to standard care).
62614158|NCT04441385|OTHER|Control arm|100 subjects will be randomized in this arm and will be treated according to the standard care. The Ministry of Health has issued detailed guidelines for the management of COVID-19. Local Institutional Guidelines and Protocols for supportive management will also be implemented.
62614159|NCT04080089||Case group|Children over the age of 6 who came to the outpatient clinic of our hospital received the informed consent of the parents, and then included in the case group, conducted a self-made sleep questionnaire, established a file, and monitored the sleep on the Mofeh Time Sleep Apnea Monitor. The results were uploaded to the cloud system for analysis. 50 children with OSAHS were screened. Voluntary participation in the study; ability to complete all tests as well as magnetic resonance studies. Exclusion criteria: 1 mental retardation, generalized developmental disorders, severe physical and endocrine diseases, neurological diseases and other mental disorders; 2 visual and auditory diseases affecting the processing of cognitive information. 3 Psychiatric drugs were used in January.
62614160|NCT04080089||Control group|Children in the same age group of children with health checkups were screened for sleep and questionnaires without sleep. After receiving parental informed consent, 30 children were included in the control group. Exclusion criteria: 1 mental retardation, generalized developmental disorder, learning disabilities, conduct Disorders, severe physical and endocrine diseases, neurological diseases and other mental illnesses. 2 There are visual and auditory diseases that affect the processing of cognitive information.
62614161|NCT00956605|EXPERIMENTAL|EEG biofeedback intervention|
62614162|NCT00956605|ACTIVE_COMPARATOR|Non EEG biofeedback computerized attention training|
62614163|NCT00956605|NO_INTERVENTION|waitlist control|
62614164|NCT02922075|PLACEBO_COMPARATOR|CTL|No soft tissue graft was used. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
62614165|NCT02922075|EXPERIMENTAL|CM|Patient received a collagen matrix graft. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
62614166|NCT02922075|EXPERIMENTAL|CTG|Patient received a connective tissue graft. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
62614167|NCT04699825|ACTIVE_COMPARATOR|study group|new-born infants born from preeclampsia mother
62614168|NCT04699825|OTHER|control group|new-born infants born from mothers with normal pregnancy matched with the same gestational age, sex and race
62614169|NCT06516185|EXPERIMENTAL|Direct-printed aligner|The experimental group will be treated with the aligner system fabricated by direct printing. The current protocols described in the literature and by the manufacturer for the fabrication of the printed orthodontic devices will be followed.
62614170|NCT06516185|ACTIVE_COMPARATOR|Thermoformed aligner|The control group will be treated with the thermoformed or gold standard aligner system. The established protocols for treatment with thermoformed clear aligners will be followed.
62614171|NCT02724410|ACTIVE_COMPARATOR|home intravenous ertapenem and PICC|Placement of peripheral inserted central catheter (PICC) and completion of ten day antibiotic treatment with home (IV) ertapenem (Drug Class:carbapenem antibiotic) (15 mg/kg IV every twelve hours not to exceed 1 gm/day for ages \<13; age 13 or greater, then 1 gm daily)
62614172|NCT02724410|EXPERIMENTAL|home oral amoxicillin-clavulanate|Completion of ten day antibiotic treatment with home oral amoxicillin-clavulanate(Drug Class:beta lactam antibiotic)(15mg/kg every eight hours or 22.5mg/kg extended release tablets every twelve hours).
62614173|NCT05420493|EXPERIMENTAL|Intravenous of CAR-T|Infusion of CAR-T cells by dose of 3-10 x105 cells/kg
62614174|NCT02525302|EXPERIMENTAL|Cohort 1: HT-100 tablet, Dose 1|HT-100 multiple dose administration (dose 1).
62614175|NCT02525302|EXPERIMENTAL|Cohort 1: HT-100 tablet, Dose 2|HT-100 multiple dose administration (dose 1).
62257111|NCT05843006||Diagnostic coronary angiography without a resulting intervention (PCI)|6 subjects undergoing a diagnostic coronary angiography without a resulting intervention (PCI)
62444331|NCT00004843|EXPERIMENTAL|Parathyroidectomy|
62444332|NCT00004843|ACTIVE_COMPARATOR|Observation|
62444333|NCT04836156|EXPERIMENTAL|Neoadjuvant therapy base on PTC drug screening for triple negative early breast cancer|Patients with triple negative subtype will receive neoadjuvant chemotherapy based on PTC drug screening.
62444334|NCT04836156|EXPERIMENTAL|Neoadjuvant therapy base on PTC drug screening for luminal like early breast cancer|Patients with luminal like subtype will receive neoadjuvant chemotherapy based on PTC drug screening.
62444335|NCT00948402|EXPERIMENTAL|metformin|
62614176|NCT02525302|EXPERIMENTAL|Cohort 1: HT-100 tablet, Dose 3|HT-100 multiple dose administration (dose 1).
62614177|NCT02525302|EXPERIMENTAL|Cohort 1: HT-100 tablet, Dose 4|HT-100 multiple dose administration (dose 1).
62054835|NCT01546259|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
62257112|NCT05656768|EXPERIMENTAL|Constant Routine Protocol|Participants complete a 30-hour constant routine protocol to directly examine markers of endogenous circadian rhythms. In a constant routine protocol, participants remain in a dimly lit room (\<10 lux), in a semi-recumbent posture, remain awake, and consume iso-caloric snacks. Saliva samples are collected and core body temperature and blood pressure are measured.
62257113|NCT02389023|OTHER|standard gauze dressing|a standard post-operative dressing consisting of dry gauze and tape will be placed over the surgical site
62614178|NCT02525302|EXPERIMENTAL|Cohort 1: HT-100 tablet, Dose 5|HT-100 multiple dose administration (dose 1).
62257114|NCT02389023|OTHER|Prevena Incision Management System|the Prevena™ Incision Management System (PIMS) or ActiVAC® with the PrevenaTM Dressings (Peel and Place™ or Customizable™) will be placed over the surgical site. The Prevena dressing is not considered experimental and has FDA approval for coverage of at risk closed-surgical incisions. The dressing is already in clinical use for vascular surgery bypass operations at the University of Vermont Medical Center.
62257115|NCT03558984|EXPERIMENTAL|D-PLEX + SOC|For subjects randomized to the investigational treatment arm, D-PLEX treatment will be applied at the end of the index surgery just before closing the chest, as an adjunct to the SOC prophylactic antibiotic treatment.
62614179|NCT02441751||bleeding|intraoperative blood loss \> 500 ml
62614180|NCT02441751||no bleeding|intraoperative blood loss \< 500 ml
62614181|NCT00997022|EXPERIMENTAL|Sorafenib|Daily sorafenib taken orally
62614182|NCT02079298|ACTIVE_COMPARATOR|1|Premature newborn infants with Gestational Age 23+0 to 26+6 weeks who are treated only with fluconazole.
62614183|NCT02079298|ACTIVE_COMPARATOR|2|Premature newborn infants with Gestational Age 23+0 to 26+6 weeks who are treated with both fluconazole and Ibuprofen.
62614184|NCT02079298|ACTIVE_COMPARATOR|3|Premature newborn infants with Gestational Age 27+0 to 36+6 who are treated only with ibuprofen.
62614185|NCT02079298|PLACEBO_COMPARATOR|4|Premature newborn infants with Gestational Age 27+0 to 36+6 and fullterm infants who are not treated either with fluconazole or ibuprofen.
62614186|NCT01856504||CCTA Patient|"1. Consenting adult patients ≥18 years of age;~2. Suspected but without known prior history of CAD~3. Not actively taking heart rate lowering agents at least 48 hours prior to study (e.g., AV nodal blockers such as beta blockers, calcium channel blockers or digoxin)~4. Glomerular filtration rate \>60 ml/min~5. CCTA and ICA within 1 week of each other with no interscan event (e.g., myocardial infarction or coronary revascularization)"
62614187|NCT02185807|ACTIVE_COMPARATOR|video-assisted group|The video assistance patients watch a video in Cantonese or Mandarin explaining the surgery procedure and its risks, benefits and alternatives before discussion with their physicians, and receive face- to face discussion with their physicians as well.
62614188|NCT02185807|PLACEBO_COMPARATOR|control group|The control patients receive verbal information and discussion from their physicians.
62257116|NCT03558984|OTHER|Standard of Care|For subjects randomized to the control arm, the surgical treatment will be as per the SOC.
62614189|NCT03706001|EXPERIMENTAL|Experimental Arm|Participants will receive psychotherapy for once a week.
62614190|NCT03706001|NO_INTERVENTION|Control Arm|Participants will not receive any treatment for depression.
62614191|NCT03474094|EXPERIMENTAL|pre-operative radiotherapy and atezolizumab|Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery
62614192|NCT03474094|EXPERIMENTAL|pre-operative atezolizumab and post-operative radiotherapy|2 cycles of atezolizumab followed by surgery then post-operative radiotherapy
62444336|NCT00948402|ACTIVE_COMPARATOR|oral contraceptive|
62614193|NCT03474094|ACTIVE_COMPARATOR|pre-operative radiotherapy and post-operative atezolizumab|Pre-operative radiotherapy then surgery followed by 2 cycles of atezolizumab
62614194|NCT06365593||Patients with hATTR-PN|50 adult patients with hATTR-PN
62444337|NCT03342703||Patients with Liver Fibrosis Measurement|Group1: Patients will undergo an Ultrasound to correlate fibrosis measurements obtained using standard-of-care MRI.
62614195|NCT06365593||Patients with CIAP|50 adult patients with CIAP
62839106|NCT03227120|NO_INTERVENTION|Control|Receives the usual standard of care which is a one time Strength and Flexibility written home exercise program provided during total joint education pre-surgery class.
62839107|NCT01421615|PLACEBO_COMPARATOR|lotion|lotion:the patients in control group receive washing medicine and are followed up to the 4rd～7th days of postpartum.
62839108|NCT01421615|EXPERIMENTAL|lactobacilli capsule|
62839109|NCT01421615|EXPERIMENTAL|lactobacilli capsules|
62054836|NCT01756664|PLACEBO_COMPARATOR|Control|Vaseline has been used on the first day after laser treatment
62054837|NCT01756664|ACTIVE_COMPARATOR|Sunscreen|Sunscreen has been used on the first day after laser treatment
62054838|NCT02849275|PLACEBO_COMPARATOR|Lactose free 1% milk|Diet will be recorded with a 7-day diet record and participants will include an isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.
62444338|NCT03342703||Patients with Liver Steatosis Measurement|Group 2: Patients will undergo an Ultrasound to correlate steatosis measurements obtained using standard-of-care MRI.
62444339|NCT01890083|ACTIVE_COMPARATOR|Health Education|Participants will three attend heath education sessions per week for 26 weeks.
62444340|NCT01890083|EXPERIMENTAL|Exercise|Participants will engage in a public health dose of moderate-to-vigorous aerobic exercise for 26 weeks.
62444341|NCT03654209|EXPERIMENTAL|Argon Plasma Coagulation|Following polyp removal using standard of care methods, Argon Plasma Coagulation (APC) will be applied to the perimeter of the resection site before any clips are added.
62444342|NCT03654209|EXPERIMENTAL|Snare Tip Soft Coagulation|Following polyp removal using standard of care methods, Snare Tip Soft Coagulation (STSC) will be applied to the perimeter of the resection site before any clips are added.
62444343|NCT03654209|NO_INTERVENTION|No treatment|Following polyp removal using standard of care methods, neither APC nor STSC will be applied to the perimeter of the resection site. Clips may be added at the discretion of the PI.
62614196|NCT05020366|EXPERIMENTAL|Pro-PEAR|This group will receive the optimized Pro-PEAR intervention (in addition to usual care).
62614197|NCT05020366|ACTIVE_COMPARATOR|Enhanced Usual Care|This group will serve as the control group and only receive a report of their child's performance and adherence to World Health Organization recommendations based on baseline data.
62054839|NCT02849275|EXPERIMENTAL|Probiotic treatment|Diet will be recorded with a 7-day diet record and participants will include an isocaloric fermented milk (probiotic), consumed once daily, over 4-5 weeks.
62614198|NCT00224406|EXPERIMENTAL|Repertaxin|Both repertaxin and placebo were aqueous solutions packaged into identical clear glass Type I ampoule single dose units. Each ampoule contained 10 mL of either repertaxin or placebo.The dosing solution for infusion was prepared aseptically at the designated Pharmacy within each center and dispensed as 12.65 mg/mL solution in appropriate size infusion bags. An initial 'loading dose' of Repertaxin of 4.488 mg/kg body weight/hour was administered over 30 minutes followed by a maintenance dose of 2.772 mg/kg body weight/hour lasting 47.5 hours.The loading and maintenance doses were administered using the same dosing solution (Repertaxin 12.65 mg/ml), but with the pump rate altered to provide an infusion rate of approximately 0.35 mUkg/hour and 0.22 ml/kg/hour, respectively.
62839110|NCT02625909|EXPERIMENTAL|Drug: SOF/VEL for 6 weeks|Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the short treatment duration arm (A) for 6 weeks.
62054840|NCT01208948|ACTIVE_COMPARATOR|Alpha lipoic acid 600 mg|
62054841|NCT01208948|PLACEBO_COMPARATOR|placebo pill|
62444344|NCT03215173|EXPERIMENTAL|Fit After Baby Group|Fit After Baby mobile health lifestyle intervention to increase postpartum weight loss, increase postpartum physical activity, and improve postpartum diet.
62054842|NCT01953614|SHAM_COMPARATOR|Placebo group|Ten people. Participants will receive what appears to be a chiropractic adjustment but which actually is not. This is the sham adjustment. Participants will also fill out Achenbach questionnaire. There will be a follow up in 7 days.
62054843|NCT01953614|ACTIVE_COMPARATOR|Chiropractic adjustment|Ten people. Group will be getting chiropractic adjustments. Participants will be filling out Achenbach questionnaire. There will be a follow up in 7 days.
62054844|NCT01953614|NO_INTERVENTION|Control group|Ten people. This group will simply have their EEG recorded at baseline and after 7 days. There will be an Achenbach questionnaire like the two other groups.
62054845|NCT04894526|EXPERIMENTAL|Alternating energy intake schedule|To alternate between caloric overconsumption and caloric underconsumption from day-to-day
62054846|NCT04894526|ACTIVE_COMPARATOR|Regular energy intake schedule|To consume the usual energy intake on a daily basis
62444345|NCT03215173|ACTIVE_COMPARATOR|Text4Baby Control Group|Receive text messages from the free Text4Baby program.
62444346|NCT05347992||Standard of Care|Cohort(1) of the study will collect longitudinal blood samples from participants who are on the standard of care treatment for Systemic lupus erythematosus (SLE) based on Cohort specific inclusion criteria
62444347|NCT05347992||Biologics|Cohort(2) of the study will collect longitudinal blood samples from participants who are on biologics treatment for Systemic lupus erythematosus (SLE) based on Cohort specific inclusion criteria
62444348|NCT04064229|EXPERIMENTAL|Infiltrated Tissue|The ivWatch Model 400 sensors monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
62444349|NCT05900661|EXPERIMENTAL|myo-inositol|will recive Inofolic (myo-inositol 600µgm + folic acid 0.2 mg) 2 capsules at the morning and 2 capsules at the evening on empty stomach for 12 weeks
62444350|NCT05900661|EXPERIMENTAL|Somatropin|Somatropin (4 IU for 1month), SEDICO ,6th of october .Egypt. 1 s.c injection every 3 days for at least 1 month.
62444351|NCT05900661|EXPERIMENTAL|Dehydroepiandrosterone|DHEA 50 mg twice per day for 12 weeks in the last group , NATROL UK.Ltd.
62054847|NCT03464279|EXPERIMENTAL|Intervention Site|"The intervention Site (Urgent Care Center at LAC+USC Medical Center) will receive a three part intervention consisting of (1) Email Choosing Wisely® guidelines and presented journal club to all 16 urgent care clinicians, (2) leveraging EHR performance data to provide individual clinicians with case-specific audit-feedback (both via emails and in-person while precepting nurse practitioners) on low-value antibiotic prescribing, and (3) using a behavioral nudge, urgent care clinicians will sign a large poster committing to avoid prescribing low-value antibiotics for uncomplicated URIs displayed in the clinic."
62257117|NCT00254501|ACTIVE_COMPARATOR|Usual Care plus out-of-pocket cost waiver|Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.
62614199|NCT00224406|PLACEBO_COMPARATOR|Placebo|Both repertaxin and placebo were aqueous solutions packaged into identical clear glass Type I ampoule single dose units. The dosing solution for infusion was prepared aseptically at the designated Pharmacy within each center and dispensed as 12.65 mg/mL solution in appropriate size infusion bags. ampoule contained 10 mL of either repertaxin or placebo. An initial 'loading dose' of 9 mg/ml sodium chloride (NaCl) solution was administered over 30 minutes, followed by a maintenance dose lasting 47.5 hours.
62614200|NCT03367897||Bleeding ulcer/erosions|Patients with hematemesis and/or melena, anemia or positiv FOBT that during gastroscopy are diagnosed with ulcer and/or erosions of the ventricle and/or duodenum. Gastroscopy must be performed within 72 hours of the findings above.
62614201|NCT03367897||Peptic ulcer without bleeding|Control group for H. pylori will be patients with peptic ulcer without bleeding. These patients are systematically registered at SØ from August 2013 through the ongoing European registration study - HpEuReg study. SØ participate in this study, together with 9 other Norwegian hospitals, which is approved by REK.
62614202|NCT01929954|EXPERIMENTAL|Gintuit|Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The test treatment GINTUIT will be inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. An additional single layer of GINTUIT will cover the entire surface of the extraction socket at approx. 2-3 mm beyond the margins of the wound and fixed with non-resorbable sutures. The lower layer of this additional layer should be in contact with the previously applied GINTUIT.
62614203|NCT01929954|ACTIVE_COMPARATOR|Bio-Gide|Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The control treatment will be a collagen membrane (ie, Bio-Gide, applied per the Package Insert) inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. Crossed suspensory type sutures should also be placed over Bio-Gide, depending on the degree of stabilization needed. In all subjects, care should be taken in suturing to avoid advancement of the buccal gingival flap.
62614204|NCT03027076||Men with UCPPS|Genitourinary Specimen Collection for microbiome evaluation
62614205|NCT03027076||Asymptomatic Men|Genitourinary Specimen Collection for microbiome evaluation
62614206|NCT03027076||Women with UCPPS|Collect midstream urine samples
62839111|NCT02625909|EXPERIMENTAL|Drug: SOF/VEL for 12 weeks|Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the standard treatment duration arm (B) for 12 weeks.
62257118|NCT00254501|EXPERIMENTAL|EMPOWER|Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.
62257119|NCT05281133|EXPERIMENTAL|The group using virtual reality glasses|The video chosen by the children in the experimental group was started 1-2 minutes before the splint with virtual reality glasses and watched for an average of 7 minutes.
62257120|NCT05281133|NO_INTERVENTION|The group not using virtual reality glasses|In the control group, during the splint a video was not watched.
62614207|NCT03027076||Asymptomatic Women|Collect midstream urine samples
62257121|NCT00013208|OTHER|Arm 1|
62257122|NCT02023775||Patients implanted with Medtronic Melody valve|All patients that received a valve implantation were included in the registry.
62257123|NCT03568591|EXPERIMENTAL|Intervention Group (Treatment)|A treatment group cohort who have self-referred for the psychosensory therapy intervention (Havening Techniques).
62614208|NCT01995864|EXPERIMENTAL|CTI-TS|CTI-TS is a time-limited, 9-month long intervention, provided at the critical time when a person is first offered services at a mental health clinic, or, at the similarly critical time when a person first seeks to reconnect with a mental health clinic after a long lapse.
62257124|NCT03568591|NO_INTERVENTION|Control Group (Waiting List)|Self-referral waiting list cohort (usual care).
62614209|NCT01995864|NO_INTERVENTION|Usual Care|The Usual Care group will receive mental health services as provided by the local mental health services clinic.
62614210|NCT05867693|EXPERIMENTAL|IBS patients assigned to palmithoylethanolamide/polydatin treatment|Eligible patients (patients with symptoms meeting Rome IV criteria for diagnosis of IBS) will be randomly assigned to either co-micronised form palmithoylethanolamide/polydatin 200 mg/20 mg
62614211|NCT05867693|PLACEBO_COMPARATOR|IBS patients assigned to placebo treatment|Eligible patients (patients with symptoms meeting Rome IV criteria for diagnosis of IBS) will be randomly assigned to Placebo
62839112|NCT05190497|EXPERIMENTAL|intervention group|inspiratory muscle training in addition to routine chest physiotherapy in the form of (deep breathing, coughing, and early ambulation)
62839113|NCT05190497|NO_INTERVENTION|control|The Control group received only routine chest physiotherapy
62839114|NCT05305404|ACTIVE_COMPARATOR|Guanfacine|single dose of dexamethasone (1.5mg) administered orally
62839115|NCT05305404|PLACEBO_COMPARATOR|Placebo|single dose of placebo administered orally
62257125|NCT01626898|EXPERIMENTAL|HOLA en Grupos|The Spanish language HOLA en Grupos intervention consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants.
62614212|NCT00576004|ACTIVE_COMPARATOR|group A|Pelvic organ prolapse repair plus concomitant Burch Colposuspension
62054848|NCT03464279|ACTIVE_COMPARATOR|Control Site|The control site (Urgent Care Center at Olive View-Medical Center) will receive broader health system efforts to reduce antibiotic prescribing consisting of Center for Disease Control prescription pads for non-antibiotic treatments (e.g., decongestants) that offer patients alternatives to antibiotics.
62054849|NCT02385994|EXPERIMENTAL|enLighten Laser Treatment|Melasma, Cohort I or Lentigines, Cohort II will be treated with dual-pulse duration, dual-wavelength 532nm KTP/1064nm Nd:YAG laser.
62444352|NCT05717881|EXPERIMENTAL|Propolis|"Propolis supplements were packaged in marine capsules and consisted of poplar propolis powder (propolis concentrate, carob powder, magnesium stearate and silicon dioxide), concentrated to 30% total polyphenols.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
62614213|NCT00576004|ACTIVE_COMPARATOR|group B|Pelvic organ prolapse without Burch colposuspension
62614214|NCT01361867|OTHER|Robot-induced perturbations|The subject walks on a treadmill with his/her legs strapped to a robotic system (Lokomat by Hocoma AG) that generates mechanical perturbations aimed to modify the subject's walking pattern.
62614215|NCT01487213|NO_INTERVENTION|Controls|Routine follow-up at the clinic 2-3 weeks after the treatment
62614216|NCT01487213|OTHER|Home self test|Intervention
62614217|NCT02289105|EXPERIMENTAL|Mandatory active choice|The mandatory active choice group will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
62614218|NCT02289105|NO_INTERVENTION|Control|Participants in the control group will be presented an AD form only and will be encouraged to complete, and submit the form without having to declare the choice of completing or declining the AD.
62614219|NCT03257969|EXPERIMENTAL|The DROP program|
62614220|NCT03257969|OTHER|Standard of care|
62614221|NCT02552888|EXPERIMENTAL|treatment|Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg by mouth once per day.
62614222|NCT02552888|PLACEBO_COMPARATOR|Placebos|identical placebos.
62614223|NCT05462275|EXPERIMENTAL|Test group|There is only one group to evaluate this observational study.
62614224|NCT03994406|EXPERIMENTAL|CLM2 Topical Gel|CLM2 topical gel to be applied dermally to forehead twice daily, in the morning and at bedtime.
62614225|NCT03994406|PLACEBO_COMPARATOR|Placebo Topical Gel|Placebo topical gel to be applied dermally to forehead twice daily, in the morning and at bedtime.
62614226|NCT01777737|EXPERIMENTAL|Cotrimoxazole|Sulfamethoxazole 400 mg. + trimethoprim 80 mg. weight-adjusted
62054850|NCT02385994|NO_INTERVENTION|Control|Melasma subjects randomized to non-treatment will receive no treatments.
62054851|NCT06221423||Fru plus TAS-102|mCRC patients receiveing Fruquintinib combined with TAS-102 in third- or late- line
62257126|NCT01626898|ACTIVE_COMPARATOR|General health intervention|The Spanish language comparison condition consists of four 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
62257127|NCT02937012|EXPERIMENTAL|Bezafibrate & Ursodeoxycholic acid|Bezafibrate 200 mg capsule every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 12 months
62614227|NCT01777737|PLACEBO_COMPARATOR|Placebo|Identical capsules to cotrimoxazole
62614228|NCT05658952|ACTIVE_COMPARATOR|Angiography-guided PCI|Patients will receive PCI according to the interpretation of angiography findings by the Interventional Cardiologist.
62614229|NCT05658952|EXPERIMENTAL|Microcatheter-derived FFR|Patients will receive PCI according to the plan derived from the interpretation of the FFR pullback obtained with microcatheter FFR performed by the Interventional Cardiologist before and after PCI.
62054852|NCT04786379|EXPERIMENTAL|Patients with confirmed septic arthritis of the native knee|
62054853|NCT03705195|NO_INTERVENTION|No Intervention|All participants in study will complete two matched clamp studies (OGTT + IGII). The first matched clamp without any intervention the second matched clamp with low dose gliclazide
62054854|NCT03705195|EXPERIMENTAL|Low Dose Gliclazide|"The first 8 participants will complete the dose-ranging phase of LOGIC study. Low dose gliclazide is being used a physiological stimulus. In the dose-ranging phase, 4 participants will receive 10mg gliclazide, the remaining 4 will receive 20mg gliclazide. The allocation to 10mg or 20mg will be randomised and unblinded. The study will analyse after the first 8 participants to assess which dose produces the greatest augmentation of insulin secretion when acting synergistically with the incretin effect.~The further 12 participants will complete the study with the identified best dose."
62054855|NCT01860469|ACTIVE_COMPARATOR|plain mesh|standard practice of using plain mesh (non vancomycin-soaked) for open hernia repair
62257128|NCT02937012|PLACEBO_COMPARATOR|Placebo & Ursodeoxycholic acid|Placebo capsule (for bezafibrate 200 mg capsule) every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 12 months
62257129|NCT05003947|EXPERIMENTAL|Treatment Group|Single intravenous infusion of 100 million cells
62257130|NCT04059172|ACTIVE_COMPARATOR|Ibuprofen|one 200 mg tablet of ibuprofen and 2 placebo tablets
62257131|NCT04059172|EXPERIMENTAL|Ibuprofen and acetaminophen|one 200 mg table of ibuprofen and two 325 mg tablets of acetaminophen
62257132|NCT04059172|PLACEBO_COMPARATOR|Placebo|3 tablets of tableting compounds with no active ingredients
62257133|NCT05105464|EXPERIMENTAL|Dose Escalation Cohort|Six dose levels will be tested. The dose-limiting toxicity (DLT) will be assessed from the first administration of SYHA1815 to the end of the first cycle (28 days).
62257134|NCT05105464|EXPERIMENTAL|cohort Expansion Cohort|Once the expected effective dose is determined, four expansion cohorts will be started to further evaluate the safety, clinical activity and PK profile of SYHA1815.
62257135|NCT04041089|EXPERIMENTAL|Recognition of objects|Patients will do the therapy in the following order: object location, object manipulation and object recognition
62839116|NCT02752282|SHAM_COMPARATOR|Control Video|Participants in this study arm will be assigned to watch a short educational video about new pap screening guidelines for women. Intervention: Cancer Screening Guidelines.
62054856|NCT01860469|EXPERIMENTAL|vancomycin-soaked mesh|use of vancomycin-soaked mesh for open hernia repair
62257136|NCT04041089|EXPERIMENTAL|Location of objects|Patients will do the therapy in the following order: object recognition, object location, and object manipulation
62257137|NCT04041089|EXPERIMENTAL|Manipulation of objects|Patients will do the therapy in the following order: object manipulation, object recognition and object location
62257138|NCT05530720||Online survey with 3.000 participants using mobile website technology|
62257139|NCT00627887|EXPERIMENTAL|ECT+pharmacotherapy|Unilateral brief pulse ECT weekly for 6 weeks thereafter every 2 weeks; Venlafaxine target dose 300mg/day; Lithium target dose 0,5-0,8 mmol/L.
62257140|NCT00627887|ACTIVE_COMPARATOR|pharmacotherapy|Venlafaxine target dose 300mg/day; Lithium 0,5-0,8 mmol/L.
62257141|NCT00147056|EXPERIMENTAL|ExAblate transcranial system|MR Guided Focused Ultrasound
62614230|NCT05658952|EXPERIMENTAL|Angiography-derived FFR|Patients will receive PCI according to the plan derived from the interpretation of the FFR pullback obtained with angiography-derived FFR performed by the Interventional Cardiologist before PCI. The angiography-derived FFR can be repeated after PCI to check the results and eventually apply correcting maneuvers.
62054857|NCT00462280|EXPERIMENTAL|Two matched nevi group - Lovastatin|Patients with two matched nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
62054858|NCT00462280|PLACEBO_COMPARATOR|Two Matched Nevi Group - Placebo|Patients with two matched nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
62054859|NCT00462280|EXPERIMENTAL|One large nevi group - Lovastatin|Patients who have one large nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
62614231|NCT02927002|ACTIVE_COMPARATOR|Noninvasive brain stimulation: active|In active condition, subject will receive stimulation during all the 30-minute stimulation period
62614232|NCT02927002|SHAM_COMPARATOR|Noninvasive brain: sham|In sham condition, subject will receive stimulation only at the beginning and at the end of 30-minute stimulation period.
62257142|NCT03527134|EXPERIMENTAL|Amantadine treatment|To determine whether amantadine is effective in reducing the occurrence of postoperative cognitive dysfunction.
62257143|NCT03527134|NO_INTERVENTION|No-treatment|Patients will not receive any treatment.
62257144|NCT03890783||Patients after surgery of oropharyngeal cancers|Patients after surgery of oropharyngeal cancers with soft palate with free flap reconstruction and adjuvant radiotherapy
62444353|NCT05717881|PLACEBO_COMPARATOR|Placebo|"Placebo powder capsules (maltodextrin, fatty acids, magnesium salts and silicon dioxide) are presented in the same packaging to have an identical appearance and taste. Patients in the propolis group were dosed with propolis to reach 6 mg total polyphenols/kg body weight, based on the results of a previous preclinical study in mice.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
62444354|NCT04488640||Thyroid fine needle aspiration biopsy group|A group of 760 people who had a thyroid nodule and who had a thyroid fine needle aspiration biopsy for diagnosis.
62444355|NCT04488640||Thyroid core needle aspiration biopsy group|A patient group with 760 people who had a thyroid nodule and who had a thyroid fine needle aspiration biopsy for diagnosis and who underwent a core needle biopsy again. A total thyroidectomy was performed in 88 of these patients. Surgical pathology results, core needle results and TIRADS scores were compared.
62444356|NCT02203747||Pseudophakic implanted with toric IOL|Subjects bilaterally implanted with toric IOL
62839117|NCT02752282|ACTIVE_COMPARATOR|Intervention Video|Participants in this group will be assigned to watch a short educational video providing anticipatory counseling on their LNG-IUS' side effects and expected changes in bleeding. Intervention: Anticipatory Counseling
62839118|NCT05415917|EXPERIMENTAL|Group 1- Gemcitabine and Capecitabine Treatment|"Day 1, Day 8, Day 15 • Gemcitabine infused through a vein over 120 minutes~Day 1 - Day 21~• Capecitabine tablets will be taken two times a day; once in the morning and once in the evening. The tablets should not be crushed or split and should be taken with a full glass of water (8 ounces/240 milliliters) within 30 minutes after a meal."
62444357|NCT02203747||Pseudophakic implanted with non-toric IOL|Subjects bilaterally implanted with non-toric IOL
62444358|NCT03491358|ACTIVE_COMPARATOR|Wright jet nebulizer|Will employ the Wright jet nebulizer for use in an allergen challenge triad
62444359|NCT03491358|EXPERIMENTAL|Solo vibrating mesh nebulizer|Will employ the Aerogen Solo vibrating mesh device for use in an allergen challenge triad
62839119|NCT05415917|NO_INTERVENTION|Group 2 - Observational|Usual therapy used to treat this type of cancer, chemotherapy plus radiation therapy. If cancer returns during observation, there will be offered standard of care therapy. Follow-up visits will be every three months.
62839120|NCT01387997|EXPERIMENTAL|1|
62839121|NCT04059380||Patients with Hypoparathyroidism|Patients with Post-Surgical or Autoimmune Chronic Hypoparathyroidism requiring daily calcium and calcitriol therapy
62839122|NCT04059380||Healthy Controls|Age-, sex- and BMI- matched patients referring to our center for diagnostic procedures not affected by hypoparathyroidism
62257145|NCT04756505|EXPERIMENTAL|Treatment (bintrafusp alfa, NHS-IL12, radiation therapy)|Patients receive bintrafusp alfa IV over 1 hour on days 1 and 14 and immunocytokine NHS-IL12 SC on day 14. Beginning on day 14 of cycle 1, patients undergo radiation therapy QD for up to 4 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62257146|NCT05426512||Primary Hyperparthyroidism|
62257147|NCT05426512||Postmenopausal women|
62257148|NCT02583906|OTHER|cpap treatment|patients randomized to the 'no cpap' arm will not be treated by CPAP
62257149|NCT02583906|NO_INTERVENTION|no cpap|patients randomized to the 'cpap' arm will be treated by CPAP
62257150|NCT02688491|EXPERIMENTAL|A (Intervention group,sunitinib)|Beginning 4-12 weeks following radical nephrectomy, patients receive sunitinib malate PO QD for 4 weeks
62257151|NCT02688491|NO_INTERVENTION|B(observation group)|Patients with radical nephrectomy are observed without intervention
62444360|NCT06160999|EXPERIMENTAL|Religious Conference|Clusters will have religious conference.
62444361|NCT06160999|NO_INTERVENTION|Religious Conference control|Clusters will have not religious conference. Clusters' background characteristics matched to the Conference arm.
62614233|NCT02194764|EXPERIMENTAL|Expirimental Formulation|Participants will be administered a single encapsulated dose of the test formulation (Model Naltrexone 50mg containing 2-butanol). Breath samples will be taken over 90 minutes (-5, 0, 5, 10, 20, 40, 60, 90). Subjects will then be randomly crossed over to the four interventions (Formulation 1, Formulation 2, Formulation 3, Formulation-free positive control) three formulations from the first part of the study and a control administration (a capsule-in-capsule design).
62614234|NCT02515084|EXPERIMENTAL|18F-FDG-PET and dw-MRI|At the inclusion, both all patients, a 18F-FDG-PET/CT and a dw-MRI will be performed
62614235|NCT06408597|ACTIVE_COMPARATOR|Control group|Standard Fluid Therapy group
62614236|NCT06408597|EXPERIMENTAL|Nitroglycerin group|Nitroglycerin Infusion group
62614237|NCT06408597|EXPERIMENTAL|Mannitol group|Mannitol Infusion group
62614238|NCT04294251|EXPERIMENTAL|DWP450|
62614239|NCT04294251|PLACEBO_COMPARATOR|Placebo|
62614240|NCT05087121|EXPERIMENTAL|Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F) [Treatment Group]|The Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F) is a 6-week training course that focuses on mitigating poor sleep quality and promoting the adoption of behaviors conducive to quality sleep. This course includes modules on developing habits conducive to better sleep, adapting variable bedroom environments, and establishing techniques to reduce worry and frustration around falling asleep while recognizing and working through barriers unique to the career of firefighting.
62839123|NCT03304158|EXPERIMENTAL|FCHV visit-diabetes|
62839124|NCT03304158|NO_INTERVENTION|FCHV no visit-diabetes|
62839125|NCT03488017|EXPERIMENTAL|Placebo Ocular Coil (left eye)|Left eye
62839126|NCT03488017|EXPERIMENTAL|Placebo Ocular Coil (right eye)|Right eye
62839127|NCT05505617||Lung diffusing capacity measurements|Participants will be randomly allocated to perform single-breath lung diffusing capacity measurements on both devises during a single study visit.
62839128|NCT05971082||Recall study|Recruited individuals aged 20-60 at index imaging date invited for follow-up with liver elastography and fat prosentage measurement
62444362|NCT06160999|EXPERIMENTAL|Vaccine-in-a-van|"Clusters will have deployment of a mobile vaccine clinic (vaccine-in-a-van)."
62444363|NCT06160999|NO_INTERVENTION|Vaccine-in-a-van control|"Clusters will not have a deployment of a mobile vaccine clinic (vaccine-in-a-van). Clusters' background characteristics matched to the Van arm."
62444364|NCT05293028|EXPERIMENTAL|Drug:F527|F527 is dose-escalated sequentially by accelerated titration and i3+3 design.
62444365|NCT01439100|ACTIVE_COMPARATOR|OXN PR|Oxycodone/Naloxone Prolonged Release tablets
62444366|NCT01439100|PLACEBO_COMPARATOR|Dummy tablet|Placebo
62444367|NCT05303922|EXPERIMENTAL|DECT and MRI|Patients will be scanned with both DECT and MRI.
62444368|NCT04551885|EXPERIMENTAL|FT516 in combination with avelumab|
62444369|NCT04735419||Cases|Cases are defined as infants who develop invasive GBS disease (iGBS disease= isolation of GBS from a normally sterile site, i.e. blood or CSF) in the first 90 days of life.
62444370|NCT04735419||Controls|Controls are defined as infants who are exposed to the same serotype of GBS at birth as the case - but who do not develop iGBS disease in the first 90 days of life.
62444371|NCT04527471|ACTIVE_COMPARATOR|Ensifentrine + Standard of Care|30 subjects randomized to receive blinded, inhaled ensifentrine in addition to standard of care treatment for COVID-19 infection
62444372|NCT04527471|PLACEBO_COMPARATOR|Placebo + Standard of Care|15 subjects randomized to receive blinded, inhaled placebo in addition to standard of care treatment for COVID-19 infection
62839129|NCT02743104|ACTIVE_COMPARATOR|Ketamine for procedural sedation|"All patients will be sedated according to a written protocol which includes intravenous administration of midazolam and atropine. In addition, local anesthesia will be performed using lidocaine 1% sprayed once just above the vocal cords, and again at the level of the carina. Lidocaine doses are limited to a maximum total dose of 5mg/kg.~This study group will be exposed to ketamine as the main drug for sedation, as an initial bolus of 1-2 mg/kg initially and then titrated by additional doses of 1mg/kg per dose."
62444373|NCT04679870|EXPERIMENTAL|GB2064|GB2064 will be administered orally as 4 x 250 mg tablets twice a day.
62444374|NCT00717756|EXPERIMENTAL|Lenalidomide|
62444375|NCT04701697|ACTIVE_COMPARATOR|active comparator：HumanAlbumin|Participants received HumanAlbumin 10g/d
62444376|NCT04701697|EXPERIMENTAL|Experimental:Recombinant Human Albumin Injection 10g|Participants received Recombinant Human Albumin Injection 10g/d
62444377|NCT04701697|EXPERIMENTAL|Experimental:Recombinant Human Albumin Injection 20g|Participants received Recombinant Human Albumin Injection 20g/d
62839130|NCT02743104|ACTIVE_COMPARATOR|Propofol for procedural sedation|"All patients will be sedated according to a written protocol which includes intravenous administration of midazolam and atropine. In addition, local anesthesia will be performed using lidocaine 1% sprayed once just above the vocal cords, and again at the level of the carina. Lidocaine doses are limited to a maximum total dose of 5mg/kg.~This study group will be exposed to propofol as the main drug for sedation, as an initial bolus of 1-2 mg/kg initially and then titrated by additional doses of 1mg/kg per dose."
62839131|NCT05791604|EXPERIMENTAL|Probiotics group|Take probiotics during the study
62839132|NCT05791604|EXPERIMENTAL|Probiotics and prebiotics group|Take probiotics and prebiotics during the study
62839133|NCT05791604|NO_INTERVENTION|Control group|Take placebo food during the study
62054860|NCT00462280|PLACEBO_COMPARATOR|One Large Nevi Group - Placebo|Patients who have one large nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
62257152|NCT04158076|EXPERIMENTAL|Co-administered of AD-2071 and AD-2073|"48 subjects will be assigned and the subjects will be administered AD-2071(Ezetimibe/Rosuvastatin) and AD-2073(Telmisartan/Amlodipine) for 8 weeks."
62839134|NCT03970317|EXPERIMENTAL|Broad Band Light|Broad Band Light (BBL) motion treatment
62839135|NCT04437134||On-line exercise and education|Exercise (12 sessions) and education (2-3 sessions) delivered on-line. Patients attend both the exercise and educational sessions by logging on to virtual rooms using links sent out by e-mail. The sessions are led and supervised by GLA:D certified physiotherapists.
62839136|NCT04437134||On-site exercise and education|Exercise (12 sessions) and education (2-3 sessions) delivered on-site. Patients attend both the exercise and educational sessions at physiotherapy clinics in Denmark. The sessions are led and supervised by GLA:D certified physiotherapists.
62839137|NCT01376804|EXPERIMENTAL|Valganciclovir|Participants received a once daily oral dose (solution or tablets) of valganciclovir starting within 10 days of kidney transplant for up to 200 days post-transplant. Dose (in milligrams) was calculated using the algorithm \[7 \* Body Surface Area \* Creatinine Clearance\].
62839138|NCT02055118|EXPERIMENTAL|idursulfase-IT|10 mg administered via IT using IDDD (intrathecal drug delivery device) once a month for 52 weeks.
62839139|NCT02055118|OTHER|Nontreatment control|Patients will receive weekly standard of care treatment with IV Elaprase only.
62839140|NCT01081106|OTHER|Low-Level Laser Therapy|
62839141|NCT05083286|ACTIVE_COMPARATOR|OLD (4 U per 0.1 mL)|The total BOTOX dose will be 20U divided into 5 injections. Each injection will receive a total of 0.5 mL.
62839142|NCT05083286|ACTIVE_COMPARATOR|COLD (4 U per 0.02 mL group)|The total BOTOX dose will be 20U divided into 5 injections. Each injection will receive a total of 0.1 mL.
62839143|NCT02433366||Patients|
62839144|NCT02433366||Physicians|
62054861|NCT01303081|ACTIVE_COMPARATOR|Usual Care|Participants will be offered free smoking cessation programs, and be provided web-based education regarding the health and economic benefits of smoking cessation. Participants will also have the opportunity to submit weekly reports on their smoking habits. They will be informed that they will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days and 3 months (among those eligible).
62444378|NCT04701697|EXPERIMENTAL|Experimental:Recombinant Human Albumin Injection 30g|Participants received Recombinant Human Albumin Injection 30g/d
62614241|NCT05087121|NO_INTERVENTION|No Intervention Control Group|Non-Intervention Control Group (NIC) will not receive training during the course of the study, but will be offered the opportunity to receive training after the study ends.
62839145|NCT02454842|EXPERIMENTAL|TH-4000 (Tarloxotinib)|TH-4000 (Tarloxotinib), 150 mg/m2 will be administered by IV infusion on Days 1, 8, 15, and 22 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity
62839146|NCT06328335|EXPERIMENTAL|Comprehensive rehabilitation training+Rise-bed Training|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
62839147|NCT06328335|ACTIVE_COMPARATOR|Comprehensive rehabilitation training|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
62839148|NCT04282330|OTHER|CEST imaging performed|CEST imaging will be performed (15 min): Axial 3D volume acquisition at 3.5 mm isotropic voxel size, 20-30 offset frequencies, plus Axial 3D T1w and T2w map at same resolution for use in CEST quantification. A routine stroke MRI protocol will also be performed (10 min): Axial T2w; Axial DWI and ADC (apparent diffusion coefficient) using accelerated multi-band sequence; Axial T2w\* or SWI (susceptibility weighted imaging); and dynamic susceptibility contrast-enhanced (DSC) perfusion imaging following contrast agent administration (5 min, provided Radiology Department protocols allow DSC (e.g. no renal impairment)).
62054862|NCT01303081|EXPERIMENTAL|Individual Rewards|Same as USUAL CARE arm, plus financial incentive as follows: if participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators.
62054863|NCT01303081|EXPERIMENTAL|Fixed Deposits|Same as USUAL CARE arm, plus financial incentive as follows: participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
62257153|NCT04158076|ACTIVE_COMPARATOR|Co-administered of AD-2071 and AD-2072|"48 subjects will be assigned and the subjects will be administered AD-2071(Ezetimibe/Rosuvastatin) and AD-2072(Telmisartan) for 8 weeks."
62257154|NCT04158076|ACTIVE_COMPARATOR|AD-2073|"48 subjects will be assigned and the subjects will be administered AD-2073(Telmisartan/Amlodipine) for 8 weeks."
62839149|NCT04791163|EXPERIMENTAL|Sub-ischial socket|Start using the sub-ischial socket for four weeks and be tested with this socket.
62257155|NCT03581266|EXPERIMENTAL|Rye|A breakfast consisting of whole slices of wholemeal rye bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
62257156|NCT03581266|EXPERIMENTAL|Wheat|A breakfast consisting of whole slices of refined wheat bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
62257157|NCT00219284|EXPERIMENTAL|Immediate switch|Patients were switched the day after randomization from combined carbidopa/levodopa to combined carbidopa/levodopa/entacapone. Patients received the same doses of carbidopa (12.5, 25.0, or 37.5 mg) and levodopa (50, 100, or 150 mg) they were receiving prior to the switch, combined with 200 mg of entacapone. The frequency of doses per day prior to the switch remained the same after the switch.
62257158|NCT00219284|ACTIVE_COMPARATOR|Delayed switch|Patients were switched 4 weeks after randomization from combined carbidopa/levodopa to combined carbidopa/levodopa/entacapone. Patients received the same doses of carbidopa (12.5, 25.0, or 37.5 mg) and levodopa (50, 100, or 150 mg) they were receiving prior to the switch, combined with 200 mg of entacapone. The frequency of doses per day prior to the switch remained the same after the switch.
62257159|NCT02201420|EXPERIMENTAL|Tc 99m tilmanocept|Subjects who are enrolled and will receive 50 micrograms tilmanocept radiolabeled with 2 millicuries of Tc 99m and undergo serial SPECT or SPECT/CT imaging.
62257160|NCT02705924|EXPERIMENTAL|Psychoeducational intervention|group participating to the first psychoeducational intervention: it consists in a week-end session in a SPA center including several conferences about HBOC familial risk, cancer prevention, prophylactic possibilities (surgery), recommendations about nutrition and physical activity a risk modulators, assisted medical procreation and embryo selection, social support...). Besides conferences, Moreno role games and group sharing are organized under the supervision of a psychotherapist.
62257161|NCT02705924|OTHER|Waiting list|delayed intervention: group participating to the second psychoeducational intervention (6 months later). Intervention is same as in the intervention arm but it is delayed. Because questionnaires are completed before this second intervention in both arms and allocation to arms are randomized, it represents an adequate control group.
62257162|NCT04544475|EXPERIMENTAL|Investigational|
62257163|NCT04544475|ACTIVE_COMPARATOR|Standard of Care|
62614242|NCT05203198|NO_INTERVENTION|1. No adolescent modules + no parent modules|No adolescent nor parent modules will be offered to the participant.
62614243|NCT05203198|EXPERIMENTAL|2. Adolescent behavioral activation modules only|Adolescent behavioral activation modules only
62839150|NCT04791163|ACTIVE_COMPARATOR|Ischial containment socket|Start using the ischial containment socket for four weeks and be tested with this socket.
62839151|NCT05247047|EXPERIMENTAL|Device|Clusters in this arm will start using the device and use it for 6 weeks.
62257164|NCT01648790|EXPERIMENTAL|5 mg Prasugrel (ODT1)|5 mg Prasugrel as orally disintegrating tablet without Magnasweet® (ODT1) formulation administered once in the fasted state.
62257165|NCT01648790|EXPERIMENTAL|5 mg Prasugrel (ODT2)|5 mg Prasugrel as orally disintegrating tablet containing Magnasweet® (ODT2) formulation administered once in the fasted state.
62257166|NCT01648790|EXPERIMENTAL|5 mg Prasugrel (ODT2)-Suspension|5 mg Prasugrel as ODT2 formulation dispersed in water administered once, in the fasted state.
62257167|NCT01648790|EXPERIMENTAL|5 mg Prasugrel (ODT2)-Fed|5 mg Prasugrel as ODT2 formulation administered once, following a standardized breakfast.
62257168|NCT01648790|EXPERIMENTAL|2 mg Prasugrel (ODT2)|2 mg Prasugrel as ODT2 formulation administered once in the fasted state.
62444379|NCT01123486|EXPERIMENTAL|hydromorphone|open label single arm pharmacokinetic-pharmacodynamic study
62614244|NCT05203198|EXPERIMENTAL|3. Adolescent cognitive-behavioral therapy modules only|Adolescent cognitive-behavioral therapy modules only
62614245|NCT05203198|EXPERIMENTAL|4. Adolescent interpersonal therapy modules only|Adolescent interpersonal therapy modules only
62614246|NCT05203198|EXPERIMENTAL|5. Adolescent behavioral activation modules + cognitive-behavioral therapy modules|Adolescent behavioral activation modules Adolescent cognitive-behavioral therapy modules
62614247|NCT05203198|EXPERIMENTAL|6. Adolescent behavioral activation modules + interpersonal therapy modules|Adolescent behavioral activation modules Adolescent interpersonal therapy modules
62614248|NCT05203198|EXPERIMENTAL|7. Adolescent cognitive-behavioral therapy modules + interpersonal therapy modules|Adolescent cognitive-behavioral therapy modules Adolescent interpersonal therapy modules
62614249|NCT05203198|EXPERIMENTAL|8. Full Adolescent program only|Adolescent behavioral activation modules Adolescent cognitive-behavioral therapy modules Adolescent interpersonal therapy modules
62614250|NCT05203198|EXPERIMENTAL|9. Parent program modules only|Parent program modules
62257169|NCT01674075||Healthy adult volunteers|Healthy adult volunteers will be administered a J-Tip to the dorsum of his/her hand.
62257170|NCT00761306|EXPERIMENTAL|Vortioxetine|
62444380|NCT00532597|EXPERIMENTAL|O|
62444381|NCT00532597|ACTIVE_COMPARATOR|L|
62444382|NCT01638702|ACTIVE_COMPARATOR|Right sided PICC placement|Insertion of PICC on the right arm
62444383|NCT01638702|PLACEBO_COMPARATOR|Left sided arm placement|Insertion of PICC on the left arm
62614251|NCT05203198|EXPERIMENTAL|10. Adolescent behavioral activation modules + parent program modules|Adolescent behavioral activation modules Parent program modules
62614252|NCT05203198|EXPERIMENTAL|11. Adolescent cognitive-behavioral therapy modules + parent program modules|Adolescent cognitive-behavioral therapy modules Parent program modules
62614253|NCT05203198|EXPERIMENTAL|12. Adolescent interpersonal therapy modules + parent program modules|Adolescent interpersonal therapy modules Parent Program
62614254|NCT05203198|EXPERIMENTAL|13. Adolescent behavioral activation + cognitive-behavioral therapy + parent program modules|Adolescent behavioral activation modules Adolescent cognitive-behavioral therapy modules Parent program modules
62839152|NCT05247047|NO_INTERVENTION|Control|Clusters in this arm will not receive the device it will continue with usual care with no changes.
62839153|NCT05825573|ACTIVE_COMPARATOR|Reference treatment|
62839154|NCT05825573|EXPERIMENTAL|Direct Oral Anticoagulant|
62839155|NCT01642589|EXPERIMENTAL|Menactra® Group|Participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)
62839156|NCT01642589|ACTIVE_COMPARATOR|Tdap - Adacel® Group|Participants will receive Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap - Adacel®)
62054864|NCT01303081|EXPERIMENTAL|Chosen Deposits|Same as USUAL CARE, plus financial incentive as follows: participants will choose their deposit amount (XX = chosen deposit); this same amount will be returned upon success (that is, quit smoking by the target quit date, and having this confirmed by cotinine or anabasine tests). If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. The default deposit will be set to a certain monetary amount for consistency with other arms, and participants can increase or decrease this amount until they reach the amount they want to deposit.
62054865|NCT01303081|EXPERIMENTAL|Competitive Deposits (Pari-Mutuel)|"Same as USUAL CARE, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, and the payout for quitting on this arm will be Y x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
62054866|NCT04378192|ACTIVE_COMPARATOR|Face mask ventilation|Use of face mask ventilation technique after induction of anaesthesia and administration pf muscle relaxant till the insertion of the endotracheal tube in a morbidly obese patient undergoing sleeve gastrectomy
62257171|NCT04026698|EXPERIMENTAL|Resident and Family Engagement Intervention.|The intervention has three components: leadership coaching for managers, administrators/ directors of care in long-term care settings; a one-day in-person training session for staff and managers; and resident and family led huddles (brief, 15 minute meetings) with staff.
62257172|NCT02258789|EXPERIMENTAL|intervention - control|15 hours ( 3 times a week in 5 weeks) intense visio spatial scanning training Virtual Reality-method
62614255|NCT05203198|EXPERIMENTAL|14. Adolescent behavioral activation + interpersonal therapy + parent program modules|Adolescent behavioral activation modules Adolescent interpersonal therapy modules Parent program modules
62257173|NCT02359630|ACTIVE_COMPARATOR|EasyTube|Use of EasyTube during general anesthesia
62257174|NCT02359630|EXPERIMENTAL|Endotracheal tube|Use of endotrachel tube during general anesthesia
62257175|NCT03235830|ACTIVE_COMPARATOR|Enhanced Standard of Care (ESoC)|Subjects received a condensed version of the American Academy of Pediatrics Bright Futures content at their scheduled well-child visits though 6 months of age. The enhanced standard of care (ESoC) materials were added, by members of the research team, to registration packets and were given to caregivers by clinic staff, who were all trained to give the ESoC. For any patients who did not receive ESoC materials at their visit, an age-appropriate ESoC was mailed to the caregiver.
62444384|NCT03692676||Subjects with Asthma|Asthmatic patients prescribed Inhaled corticosteroids/Long-acting beta agonists (ICS/LABA FDC) before index date, initiated with Spiriva Respimat, or received a higher dose of ICS/LABA FDC, initiated LTRA , or switched to a new ICS/LABA FDC fom the previous ICS/LABA FDC
62839157|NCT03933085|EXPERIMENTAL|MCI Group|A within-subject, multiple baseline design, with each subject serving as their own control,4 will be implemented to get the maximum number of participants trained in the use of the MSS during the proposed funding period. This 2-year study will involve four phases: a 4-month translation and cultural adaptation development phase, a 12-month recruitment and treatment implementation phase, a 6-month post data collection only phase, and a 2-month data analysis and result writing phase. Data analyses will be conducted using the Statistical Package for the Social Sciences (SPSS) program.
62839158|NCT06073561|EXPERIMENTAL|Underwater mucosectomy|"Every colonoscopy should be performed with a high definition colonoscope, such as Olympus series Q185 or Q190 with virtual chromoendoscopy by NBI (Olympus Inc., Tokyo, Japan) or Fujifilm EC-760R-V/L or EC-760Z-V/L with virtual chromoendoscopy by LBI (Fujifilm Group, Japan).~A study investigator or a senior endoscopy fellow under their direct supervision should perform all procedures.~The U-EMR procedure should include the following steps: CO2 should be completely removed, and the bowel lumen filled with normal saline using a water jet pump (OFP-2, Olympus Medical System or similar) until the lesion is totally immersed in water. The lesion and 2-3 mm of normal surrounding mucosa should be resected using electrocauterization (VIO 200D Endocut Q Effect 3; ERBE Electromedizin, Tübingen, Germany)."
62257176|NCT03235830|EXPERIMENTAL|Enhanced Standard of Care (ESoC) + Text|Subjects assigned to the text messaging intervention group received four educational messages per week until their child was 6 months of age in addition to the ESoC documents. The text messages directly reflected Bright Futures and ESoC content, addressing infant development, safety, care, and the most common causes of nonurgent visits in the first year. Bright Futures content was adapted both for language and length to accommodate character limits and the patient population.
62444385|NCT05207215|ACTIVE_COMPARATOR|Group A: Video Conferencing|Video conferencing is a 2-way interactive session that is enabled using telecommunication networks and the internet. The investigators will be working with 3rd party provider to create the video conferencing platform. Subjects can login to do SAFE exercises while physiotherapists monitor remotely. Subjects will complete two sessions per week (1hour for each session) for 12 weeks.
62614256|NCT05203198|EXPERIMENTAL|15. Adolescent cognitive-behavioral therapy + interpersonal therapy + parent program modules|Adolescent cognitive-behavioral therapy modules Adolescent interpersonal therapy modules Parent program modules
62614257|NCT05203198|ACTIVE_COMPARATOR|16. All adolescent + parent program modules|Adolescent behavioral activation modules Adolescent cognitive-behavioral therapy modules Adolescent interpersonal therapy modules Parent program modules
62614258|NCT04733222|EXPERIMENTAL|Perturbation training|"Participants randomized to the treadmill perturbation training will initially perform three sessions performed within a week followed by a booster-session after six months."
62614259|NCT04733222|ACTIVE_COMPARATOR|Treadmill walking|"Participants randomized to the walking group will undergo three initial sessions within a week and a booster-session after six months."
62614260|NCT01819844|EXPERIMENTAL|Closed-loop blood glucose control|Type 1 diabetes, Type 2 diabetes, total daily dose (TDD) of insulin that is \> 1 u/kg or \> 2 u/kg.
62614261|NCT05487053|EXPERIMENTAL|Single-shot adductor canal block|
62054867|NCT04378192|ACTIVE_COMPARATOR|Laryngeal mask ventilation|Use of laryngeal mask airway LMA for ventilation after induction of anaesthesia and administration pf muscle relaxant till the insertion of the endotracheal tube in a morbidly obese patient undergoing sleeve gastrectomy
62614262|NCT05487053|ACTIVE_COMPARATOR|Continuous femoral nerve block|
62614263|NCT03899207|EXPERIMENTAL|training +acupressure|In the training+acupressure group, 10 women were excluded from the study since they could not participate in acupressure application at different times, 2 women were excluded since they had menstrual irregularities and 4 women were excluded since they could not be contacted.
62614264|NCT03899207|EXPERIMENTAL|training|In the training group, 4 women were excluded since they did not participate in the reminder training, 1 woman was excluded since she had menstrual irregularities, 3 women were excluded since they wanted to withdraw from the study and 3 women were excluded from the study since they could not be contacted.
62614265|NCT03899207|NO_INTERVENTION|control|In the control group, 4 women were excluded from the study since they could not be reached and 5 women were excluded since they did not agree to participate in the posttest.
62614266|NCT01002560||Malignant melanoma tumour tissue|
62054868|NCT03293225||add H2RA|Add antihistamines to standard drug therapy
62054869|NCT03293225||change ns-H1RA|Change to ns-H1RA in standard medication
62054870|NCT03293225||ns-H1RA(3-4 tabs)|Standard treatment with ns-H1RA 4X dose
62054871|NCT03293225||ns-H1RA(3-4kinds)|Use of NS 4 kinds for standard treatment
62054872|NCT03348072||Jehovah's witnesses|Jehovah's witnesses having undergone cardiac surgery between 1991 till 2012. Blood perfusions refused.
62614267|NCT01002560||Benign pigmented lesions & other skin cancers|Normal skin, benign melanocytic tumours, and skin cancers from lineages other than melanocytic, to be used as negative controls
62614268|NCT01243294|ACTIVE_COMPARATOR|SenSura|"CE marked and launched (The letters CE do not represent any specific words, though may have initially stood for Communauté Européenne (European Community) or Conformité Européenne (European Conformity). By affixing the CE marking to a product, the manufacturer declares that it meets EU safety and health and environmental requirements."
62614269|NCT01243294|ACTIVE_COMPARATOR|New ostomy appliance (SS)|SS = New ostomy appliance. Due to company confidentiality the product is just called SS and this is not short for any other names.
62614270|NCT01466517|ACTIVE_COMPARATOR|Reference Drug|
62614271|NCT01466517|ACTIVE_COMPARATOR|Test Drug|
62614272|NCT04505618|OTHER|Controls|Subjects in this group do not have any ocular pathology and are also not hypertensive. Some subjects in this arm will undergo retinal vascular reactivity assessments.
62839159|NCT01811966|SHAM_COMPARATOR|Control|preoperative none substitution of i.v. fluids.
62054873|NCT03348072||Control|Paired control group, twice as big as the experimental group. Pairing criteria: age, sex, type of surgery performed. The control group must accept blood transfusions.
62839160|NCT01811966|ACTIVE_COMPARATOR|Volume|preoperative substitution of a defined amount of i.v. fluids (8 ml/kg RingerAcetate solution for 15 min prior to introduction of anesthesia).
62054874|NCT02276170||Aminophylline per standard of care|
62054875|NCT01382329|EXPERIMENTAL|Treatment group I / Intramuscular|85 subjects to receive 2 intramuscular vaccinations at Dose A on Days 1 and 22
62054876|NCT01382329|EXPERIMENTAL|Treatment group II / Intramuscular|85 subjects to receive 2 intramuscular vaccinations at Dose B on Days 1 and 22
62614273|NCT04505618|OTHER|Diabetics with and without Diabetic Retinopathy Only|Subjects in this group only have diabetes with or without diabetic retinopathy. Some subjects in this arm will undergo retinal vascular reactivity assessments.
62614274|NCT04505618|OTHER|Hypertension Only|Subjects in this group only have hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.
62614275|NCT04505618|OTHER|Diabetics w/ or w/o Diabetic Retinopathy & Hypertension|Subjects in this group have diabetes with or without diabetic retinopathy and hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.
62614276|NCT05846113|EXPERIMENTAL|Renacare patients|"Male or female patients, age 18 years or older at the time of signing the informed consent form (ICF). If over the age of 65, patient must have a family history of CKD or clinical suspicion of genetic disorder.~Diagnosis of kidney disease"
62614277|NCT03000530|EXPERIMENTAL|Part A: SAGE-217|Participants received SAGE-217, 30 milligrams (mg), oral solution, once daily for 14 days, as tolerated.
62614278|NCT03000530|PLACEBO_COMPARATOR|Part B: Placebo|Eligible participants received matching placebo capsules once daily for 14 days.
62614279|NCT03000530|EXPERIMENTAL|Part B: SAGE-217|Eligible participants received SAGE-217, 30 mg, oral capsules, once daily for 14 days.
62054877|NCT01382329|EXPERIMENTAL|Treatment group III / Subcutaneous|85 subjects to receive 2 subcutaneous vaccinations at Dose A on Days 1 and 22
62054878|NCT01382329|EXPERIMENTAL|Treatment group IV / Subcutaneous|85 subjects to receive 2 subcutaneous vaccinations at Dose B on Days 1 and 22
62257177|NCT04417634|EXPERIMENTAL|RFR: resting full-cycle ratio|RFR will be used to drive PCI
62614280|NCT00938587|EXPERIMENTAL|PF-04171327 10 mg|
62839161|NCT01177397|EXPERIMENTAL|CC-223|All patients will receive CC-223, but serial patient groups will receive different dose levels in Phase 1. The number of groups will be determined by the number of dose levels required to establish dose-limiting toxicity.
62257178|NCT04417634|ACTIVE_COMPARATOR|FFR: fractional flow reserve|FFR will be used to drive PCI
62614281|NCT00938587|EXPERIMENTAL|PF-04171327 25 mg|
62614282|NCT00938587|ACTIVE_COMPARATOR|Prednisone|
62839162|NCT04780997|EXPERIMENTAL|Virtual Realty|Microsoft Xbox Kinect® was used for virtual reality exercises
62257179|NCT01312454|EXPERIMENTAL|AL-59412C Concentration 1|AL-59412C injectable solution, single intravitreal injection
62257180|NCT01312454|EXPERIMENTAL|AL-59412C Concentration 2|AL-59412C injectable solution, single intravitreal injection
62444386|NCT05207215|ACTIVE_COMPARATOR|Group B: Gamification|Gamification refers to exercise-driven gaming, where games are developed with specifications/parameters that incorporate exercise movements. Currently, the investigators have an ongoing pilot study on game-assisted rehabilitation at SGH Physiotherapy Outpatient clinic and the exercise games are developed by an external company. The investigators will engage an external company to develop exercise games based on the exercises used in SAFE programme. Each game will have different difficulty levels to provide progressive training for subjects
62839163|NCT05452343|EXPERIMENTAL|CM310|600 mg (first dosing) + 300 mg (subsequent dosing), once every two weeks
62444387|NCT05207215|ACTIVE_COMPARATOR|Group C: Self Guided|Subjects in the self-guided exercise programme will be instructed to do SAFE exercises at least twice a week for an hour each by themselves.
62444388|NCT05207215|PLACEBO_COMPARATOR|Group D: Self Guided|Subjects in the self-guided exercise programme will be instructed to do SAFE exercises at least twice a week for an hour each by themselves.
62839164|NCT05452343|PLACEBO_COMPARATOR|Placebo|once every two weeks
62257181|NCT01312454|ACTIVE_COMPARATOR|Travoprost|Travoprost injectable solution, single intravitreal injection
62257182|NCT01312454|PLACEBO_COMPARATOR|Vehicle|AL-59412C Vehicle, single intravitreal injection
62257183|NCT00480181|EXPERIMENTAL|Active|
62257184|NCT00480181|PLACEBO_COMPARATOR|placebo|
62257185|NCT03679533|ACTIVE_COMPARATOR|Active Cranberry Study Food|
62257186|NCT03679533|PLACEBO_COMPARATOR|Placebo Study Food|
62257187|NCT05162027|ACTIVE_COMPARATOR|Erenumab-aooe|"Erenumab-aooe 70 mg/ml. Subcutaneous injection. Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.~Other Name: Aimovig®"
62257188|NCT05162027|PLACEBO_COMPARATOR|Placebo|"Placebo. Subcutaneous injection.Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.~Other name: Placebo"
62257189|NCT03216096|EXPERIMENTAL|3% DE-089 ophthalmic solution|
62614283|NCT00938587|PLACEBO_COMPARATOR|Placebo|
62614284|NCT03482895||Patient: Blood sampling & Feces sampling|"Blood samplings at different times after a meal test: 0, 15, 30, 60, 90 and 120 minutes.~Feces sampling: collection during 24 hours"
62614285|NCT05612464||Primary dystonia group (genetic or idiopathic)|
62257190|NCT04501627||Participants with RE|Participants diagnosed with RE who have received 20 milligram (mg) of vonoprazan in routine clinical practice, will be observed prospectively. Data will be collected from participants' medical records, self-reported questionnaires and recorded information on symptom via diaries.
62257191|NCT04489745|EXPERIMENTAL|SBRT and ADT|Patients undergo SBRT to a dose of 40 Gy in 5 fractions to prostate, and optional 25 Gy in 5 fractions to SVs and Pelvic LNs, with 9 months of Androgen Deprivation Therapy
62839165|NCT03487705|OTHER|child essential tremor|electromyogram with accelerometer
62054879|NCT03013088|EXPERIMENTAL|CTO Crossing|With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
62054880|NCT06187740|EXPERIMENTAL|Starting Dose, Arm 1|For ES-SCLC patients who completed first-line four-cycle chemo-immunotherapy, and was evaluated to have any response to treatment. Thoracic radiotherapy is administered to treat residual thoracic lesions during immunotherapy maintenance phase. Thoracic radiotherapy should begin within 42 days after the end of the last chemotherapy at an initial dose of 30 Gy in 10 fractions (3 patients).
62054881|NCT06187740|EXPERIMENTAL|Dose escalation 1, Arm 2|"Dose escalation will start after acceptable safety was observed, first at: 35 Gy/10 Fx (3 patients). Radiotherapy was administered between two immunotherapy doses (3 weeks interval) to avoid thoracic radiotherapy on the same day with immunotherapy.~Immunotherapy was maintained until disease progression or the investigator 's judgment there was no further benefit from immunotherapy, patient died, intolerable toxicity developed. Toxicities were assessed periodically during the study. Local radiotherapy is permitted for symptomatic brain/bone metastases."
62054882|NCT06187740|EXPERIMENTAL|Dose escalation 2, Arm 3|"Dose escalation will continue after acceptable safety was observed in the previous dose gourp, at: 40 Gy/10 Fx (22 patients). Radiotherapy was administered between two immunotherapy doses (3 weeks interval) to avoid thoracic radiotherapy on the same day with immunotherapy.~Immunotherapy was maintained until disease progression or the investigator 's judgment there was no further benefit from immunotherapy, patient died, intolerable toxicity developed. Toxicities were assessed periodically during the study. Local radiotherapy is permitted for symptomatic brain/bone metastases."
62054883|NCT06373484|EXPERIMENTAL|Multi-Component Child and Parent Cognitive Behavioral Therapy|Parents and their children aged 6-12 with DBD who meet inclusion criteria.
62054884|NCT02847299|EXPERIMENTAL|Astral ventilator|instrumental increase of cough peak flow with air stacking
62257192|NCT04245514|EXPERIMENTAL|Durvalumab with 3 RT cohorts|Patients will be allocated in a 1:1:1 ratio to the three radiotherapy regimens (Arm A: 20 x 2 Gy weekdaily, Arm B: 5 x 5 Gy weekdaily, and Arm C: 3 x 8 Gy q2d) using the minimization method with a random component (80% allocation probability) to reduce predictability of allocation according to the following stratification factor: T classification (T1-2 vs T3-4).
62257193|NCT04493021|EXPERIMENTAL|Treatment with Dermal Cooling System|Dermal Cooling System will be used in all eligible subjects.
62257194|NCT00956397|ACTIVE_COMPARATOR|Control Participants|
62257195|NCT00956397|ACTIVE_COMPARATOR|FD Participants|
62257196|NCT00956397|PLACEBO_COMPARATOR|FD (Placebo) Participants|
62257197|NCT04735445|ACTIVE_COMPARATOR|Conventional screening|Standard screening in the participating centers, adjusted to the recommendations of the European AIDS Society (EACS).
62257198|NCT04735445|EXPERIMENTAL|Enhanced screening|Expanded screening for early detection of lung, liver, anal, cervical, breast, prostate, colorectal and skin cancer.
62839166|NCT06428292|ACTIVE_COMPARATOR|combined treadmill with virtual reality|Combining a virtual reality device with a treadmill and using it in a virtual environment, allowing the person to walk in different virtual environments
62257199|NCT01832220||PiZZ not on therapy|Individuals with the PiZZ genotype not on augmentation therapy.
62257200|NCT01832220||PiZZ on therapy|Individuals with the PiZZ genotype on augmentation therapy.
62839167|NCT06428292|ACTIVE_COMPARATOR|stationary bike combined with virtual reality|Combining a virtual reality device with a stationary bike and using it in a virtual environment, allowing the person to walk in different virtual environments
62839168|NCT01649817||Cohort|
62839169|NCT02877589||solid tumor|Patients receiving chemotherapy for solid tumors in Ambulatory Medicine Unit of the Reims University Hospital (France) between May 14, 2012 and July 31, 2013.
62839170|NCT04129996|EXPERIMENTAL|camrelizumab in combination with nab-paclitaxel and famitinib|
62839171|NCT01963078|PLACEBO_COMPARATOR|PTSD placebo Day 1, Oxytocin Day 2|Participants PTSD will self-administer matching placebo (containing all ingredients except OT) at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
62054885|NCT02847299|EXPERIMENTAL|Astral ventilator - mode kiné|instrumental increase of cough peak flow with hyperinsufflation
62257201|NCT01832220||PiMZ not on therapy|Individuals with the PiMZ genotype not on augmentation therapy.
62257202|NCT01832220||PiMM with COPD|Individuals with the PiMM genotype and COPD.
62257203|NCT02124278|EXPERIMENTAL|PUL-042 Inhalation Solution|Fixed dose combination of Pam2CSK4 acetate (Pam2) and ODN M362 (ODN) administered as an inhalation solution. Single dose administration by nebulization. Starting dose will be 2.9 micrograms Pam2: 4.25 micrograms ODN. Up to 7 doubling doses may be tested.
62257204|NCT02124278|PLACEBO_COMPARATOR|Sterile water for injection|Sterile water for injection administered by nebulization
62257205|NCT05795686|OTHER|"Patients of program AVanCer"|"Patients included in program AVanCer"
62257206|NCT03491007|NO_INTERVENTION|Placebo|Subjects will receive a one-time oral dose of PBO prior to initial brain imaging followed by sustained administration of PBO for 6 weeks.
62257207|NCT03491007|PLACEBO_COMPARATOR|DHEA|Subjects will receive a one-time oral dose of DHEA prior to initial brain imaging followed by sustained administration of DHEA for 6 weeks.
62257208|NCT04566770|EXPERIMENTAL|MID A|20 participants(18-49), Ad5-nCoV , two doses, Intramuscular administration
62614286|NCT05612464||Dystonic cerebral palsy group|
62257209|NCT04566770|PLACEBO_COMPARATOR|MID B|10 participants(18-49), Ad5-nCoV-placebo , two doses, Intramuscular administration
62257210|NCT04566770|EXPERIMENTAL|MIN A|100 participants(6-17), Ad5-nCoV , two doses, Intramuscular administration
62614287|NCT05612464||Control group|
62257211|NCT04566770|PLACEBO_COMPARATOR|MIN B|50 participants(6-17), Ad5-nCoV-placebo , two doses, Intramuscular administration
62614288|NCT06534827|NO_INTERVENTION|Services as Usual|Outpatient mental health services as usual
62054886|NCT00895622|NO_INTERVENTION|Low Risk|No treatment given.
62257212|NCT04566770|EXPERIMENTAL|OLD A|100 participants(56 years of age and above), Ad5-nCoV , two doses(Low dose), Intramuscular administration
62257213|NCT04566770|EXPERIMENTAL|OLD B|100 participants(56 years of age and above), Ad5-nCoV , two doses(Middle dose), Intramuscular administration
62257214|NCT04566770|PLACEBO_COMPARATOR|OLD C|50 participants(56 years of age and above), Ad5-nCoV-placebo , two doses, Intramuscular administration
62257215|NCT04566770|EXPERIMENTAL|EBOV A|34 participants, Ad5-nCoV , two doses, Intramuscular administration
62257216|NCT04566770|PLACEBO_COMPARATOR|EBOV B|17 participants, Ad5-nCoV , two doses, Intramuscular administration
62257217|NCT01816061|EXPERIMENTAL|Experimental - COMPASS|Goal-setting sessions
62257218|NCT01816061|ACTIVE_COMPARATOR|Control - COMPASS|Informative phone calls
62257219|NCT01475175|EXPERIMENTAL|CRT pacing at rest and during exercise|Rest and sub-maximal exercise
62257220|NCT01143727|ACTIVE_COMPARATOR|A|Santyl
62614289|NCT06534827|EXPERIMENTAL|GLM + Services as Usual|The Great Life Mentoring program (GLM) provides volunteer-based mentoring for school-age youth from low-resource families who are receiving outpatient mental health care. Each youth is paired with a mentor with whom they spend time in the community on a weekly basis for at least one year. Mentors are required to complete a 20-hour intensive training prior to being paired with a youth. Mentors also receive monthly in-person supervision from GLM staff for the first year of their meetings, which continues on an as-needed basis thereafter. Training and supervision are geared toward the unique opportunities and challenges that can occur when mentoring a youth with mental health needs. The goal is for the mentor to become an integral part of the child's mental health treatment, but the mentoring relationship is also sustained after treatment ends.
62614290|NCT03241433|ACTIVE_COMPARATOR|High intensity interval training|Exercise training will be conducted 3 times per week using cycle ergometers at commercial fitness facilities for 12 weeks 2 minute warmup/3 minute cooldown- at 50W Intensity- 3 X 20-second sprint interval cycling -as fast as possible at 90-95% peak power low intensity- 2 X 2 minute cycling at slow pace 50W
62614291|NCT03241433|ACTIVE_COMPARATOR|Moderate intensity continuous training|Exercise training will be conducted 3 times per week using cycle ergometers at commercial fitness facilities for 12 weeks 2 minute warmup/3 minute cooldown- at 50W Intensity- 45 minutes of continuous cycling at 45-60% peak power
62054887|NCT00895622|EXPERIMENTAL|Intermediate Risk|54 Gy radiotherapy
62054888|NCT00895622|EXPERIMENTAL|High Risk|60 Gy radiotherapy
62054889|NCT01424930|EXPERIMENTAL|Abiraterone+prednisone (low-fat meal)|Participants will receive abiraterone acetate at a starting dose of 1,000 milligram (mg) once daily for 7 days post 30-minutes of a standardized low-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
62054890|NCT01424930|EXPERIMENTAL|Abiraterone+prednisone (high-fat meal)|Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
62054891|NCT03675932|EXPERIMENTAL|Cycling Intervention|Single-arm trial. All participants will receive the same intervention of Rapid Cadence Cycling on a Solo-Rider Spin Bicycle
62054892|NCT03600584|EXPERIMENTAL|One-layer duct-to-mucosa Group|Modified one-layer duct-to-mucosa pancreaticojejunostomy is used after pancreaticoduodenectomy.
62257221|NCT01143727|ACTIVE_COMPARATOR|B|Tegaderm Hydrogel
62614292|NCT03241433|ACTIVE_COMPARATOR|No exercise|No excercise training will be done
62839172|NCT01963078|EXPERIMENTAL|PTSD Oxytocin Day 1, Placebo Day 2|Participants with PTSD will self-administer 24 IUs of OT nasal spray at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
62054893|NCT03600584|ACTIVE_COMPARATOR|Invagination Group|Invagination pancreaticojejunostomy is used after pancreaticoduodenectomy.
62257222|NCT01599520|EXPERIMENTAL|Spanish-Language Self-Administered Training + Usual Care|Participants randomized to this arm will receive Spanish-Language Self-Administered Training + Usual Care.
62257223|NCT01599520|ACTIVE_COMPARATOR|Usual Care Only|"Patients will be given the Spanish-language version of Chemotherapy and You: Support for People with Cancer (La quimioterapia y usted: Apoyo para las personas con cancer) published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health."
62257224|NCT02999542|EXPERIMENTAL|Music|Children will receive music via headphones
62257225|NCT02999542|EXPERIMENTAL|No music|Children will listen to silence via headphones
62257226|NCT04224675|OTHER|Ate|
62257227|NCT04224675|OTHER|Cap|
62257228|NCT06189807|OTHER|Control Group -|
62257229|NCT06189807|EXPERIMENTAL|Intervention Group - Decision aid|
62257230|NCT00933179|EXPERIMENTAL|Arm 1|
62257231|NCT00933179|ACTIVE_COMPARATOR|Arm 2|
62257232|NCT03279614|EXPERIMENTAL|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
62614293|NCT05404633|EXPERIMENTAL|Intradialytic exercise (patients)|Participants in this group will use the tested device to perform a 30-minute session of aerobic training (cycling during hemodialysis) at 3-4/10 on the Borg scale of perceived exertion.
62614294|NCT05404633|EXPERIMENTAL|Acute care exercise (patients)|Participants in this group will use the tested device to perform 2 x 10-minute of aerobic training (cycling in the hospital) interspersed with a 5-minute break. Exercise intensity will be of 2/10 on the Borg scale of perceived exertion (around 3 +/- 2 watts at 20 rpm).
62054894|NCT01837004|EXPERIMENTAL|CORTEX|The CORTEX group will attend 10, 2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task \& cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
62444389|NCT01259427|EXPERIMENTAL|Arm 1: Ending Self Stigma|Ending Self Stigma (ESS): Ending Self Stigma (ESS) is a 9-session small-group (4-8 persons) course designed to help individuals with serious mental Illness (SMI) develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
62614295|NCT05321472||group for training the algorithm|This group of images is used for training the algorithm of the artificial intelligence
62614296|NCT05321472||group for testing the algorithm|This group of images is used for testing the algorithm of the artificial intelligence
62614297|NCT01603394|EXPERIMENTAL|Pregabalin (300-600 mg/day; 150 mg/day starting dose)|
62614298|NCT05514743|ACTIVE_COMPARATOR|Heart rate|"Heart rate monitors can assess a person's heart rate and reveal whether it is high or low. Heart rate Trusted Source is a clinical indicator of overall cardiac health, and it can also help a person determine their performance during a workout."
62614299|NCT05514743|ACTIVE_COMPARATOR|Blood pressure|It will be carried out before and after interventions to determine the patients functional capacity (in the 7th.day \&in the 21st.day.) It will be used as a training tool as well as an assessment tool.
62614300|NCT01134289|ACTIVE_COMPARATOR|lumbar sympathetic block|Unilateral lumbar sympathetic blockade using chirocaine
62614301|NCT01134289|NO_INTERVENTION|contralateral side|
62614302|NCT01713894|OTHER|Decision Aid|In this arm of the study, parents will be counseled using a decision aid.
62614303|NCT01713894|OTHER|Standard|In this arm of the study, parents will be counseled using current standard methods.
62614304|NCT01540084|ACTIVE_COMPARATOR|conventional group|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered. To maintain conscious level of patient at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary.
62614305|NCT01540084|EXPERIMENTAL|cocktail group|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered. To maintain conscious level of patient at moderate or deep level, 1% propofol at the rate of 1 mg/kg/hr was administered. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
62614306|NCT01476306|PLACEBO_COMPARATOR|In-patient care|
62614307|NCT01476306|EXPERIMENTAL|Telemedicine care|
62054895|NCT02573025|EXPERIMENTAL|Test Followed by Reference|Participants will receive PEG-IFN alfa-2a BA-free formulation (Test) in Period 1, followed by PEG-IFN alfa-2a market formulation (Reference) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
62444390|NCT01259427|ACTIVE_COMPARATOR|Arm 2: Health and Wellness Group|Health and Wellness Group: The Health and Wellness group is a 9-session small-group (4-8 persons) course designed for individuals with serious mental illness (SMI). Each session focuses on discussion of specific health and wellness related issues and education on ways to better manage health related concerns (e.g., physical activity/exercise, nutrition, managing fatigue/sleep, tobacco and other substance use, etc).
62444391|NCT01314742|EXPERIMENTAL|Biotene OralBalance® gel Arm|Biotene OralBalance® gel contains antibacterial active ingredients: lactoperoxidase, lysozyme and lactoferrin. These enzymes occur naturally in the human milk and colostrum and have mimicking properties of the human saliva activity in vivo.
62614308|NCT05206786|EXPERIMENTAL|Control group. Conventional preventive work out|
62614309|NCT05206786|EXPERIMENTAL|Intervention group. Gluteus maximus strengthening specific program|
62614310|NCT01860118||Parkinson's Disease|1) the presence of bradykinesia and either rest tremor or rigidity; 2) asymmetric onset; 3) progressive motor symptoms 4) age at onset 21-99 years.
62614311|NCT01860118||Healthy Control|Healthy controls between ages of 21-99 years and a lack of PD in first-degree blood relatives
62614312|NCT05194852|ACTIVE_COMPARATOR|group 1|Group I received ultrasound-guided hydrodilatation with corticosteroid, saline, and local anesthetic via posterior intra-articular approach
62614313|NCT05194852|EXPERIMENTAL|group 2|group II received the same ultrasound-guided hydrodilatation via anterior rotator interval approach
62614314|NCT01170819|ACTIVE_COMPARATOR|Dinoprostone Vaginal Insert|
62614315|NCT01170819|EXPERIMENTAL|Double Balloon Catheter|
62614316|NCT06465069|EXPERIMENTAL|LY4052031 (Dose-escalation, Cohort A1)|Escalating doses of LY4052031 administered intravenously (IV).
62614317|NCT06465069|EXPERIMENTAL|LY4052031 (Dose-optimization, Cohort A2)|Comparing 2 or more doses (evaluated during dose escalation) of LY4052031 administered IV.
62257233|NCT00806195|EXPERIMENTAL|MenACWY-CRM197 + Routine Vaccines (Non-Detailed)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR: 12 months.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Non-Detailed - infants who only provided SAEs (Serious Adverse Events) and medically attended AEs (Adverse Events)."
62614318|NCT06465069|EXPERIMENTAL|LY4052031 (Dose-expansion, Cohort B1, B2, C1)|LY4052031 administered IV.
62839173|NCT01963078|PLACEBO_COMPARATOR|Resilient Placebo Day 1, Oxytocin Day 2|Resilient controls will self-administer matching placebo spray at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
62839174|NCT01963078|EXPERIMENTAL|Resilient Oxytocin Day 1, Placebo Day 2|Resilient controls will self-administer 24 IUs of OT nasal spray at 10:30 a.m.on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
62257234|NCT00806195|ACTIVE_COMPARATOR|Routine Vaccines (Non-Detailed)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6 months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR: 12 months.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Non-Detailed - subjects who only provided SAEs and medically attended AEs."
62257235|NCT00806195|EXPERIMENTAL|MenACWY-CRM197 + Routine Vaccines (Detailed)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs."
62444392|NCT01314742|PLACEBO_COMPARATOR|Sterile Water Arm|Sterile Water moisten cotton tipped applicator
62444393|NCT04999332|EXPERIMENTAL|Perioperative chemotherapy with LOTS|"LOTS as one cycle:~Leucovorin (30 mg) twice daily per oral, day 1 to 7; Oxaliplatin (85 mg per square meter) intravenously, day 1; Docetaxel (40 mg per square meter) intravenously, day 1; S-1 (35 mg per square meter) twice daily per oral, day 1 to 7~Pre-operative part:~Four cycles of LOTS every two weeks~Operative part:~Curative gastrectomy or gastroesophagectomy plus D2 lymphadenectomy~Post-operative part:~Four cycles of LOTS every two weeks"
62444394|NCT02663089|EXPERIMENTAL|[14C]-GSK961081 IV+GSK961081 inhalation; [14C]-GSK961081 oral|On Day 1 of Treatment Period 1, after an overnight fast of at least 8 hours, each subject will receive \[14C\] GSK961081 4 micrograms (mcg) by IV infusion over 1 hour. Within 5 minutes after the start of infusion, subjects will take 1200 mcg non-radiolabelled GSK961081 by inhalation. After Treatment Period 1, there will be a washout of at least 2 weeks. On Day 1 of Treatment Period 2, after an overnight fast of at least 8 hours, each subject will take 200 mcg \[14C\]-GSK961081 as an oral solution.
62444395|NCT01713309|ACTIVE_COMPARATOR|Filgrastim|Filgrastim 300 microgr/day subcutaneously for 7 days
62444396|NCT01713309|PLACEBO_COMPARATOR|NaCl 0.9%|Corresponding placebo once daily, subcutaneously for 7 days
62444397|NCT03013179||Black/African American Women and their 3-5 year old children|
62444398|NCT02165579||Age > 21, diabetes, osteomyelitis|1 Cohort, standard care, observational patients are: Diagnosis of diabetes mellitus Age ≥ 21 years Infectious Disease Society of America stage 3 infection
62444399|NCT01411267|EXPERIMENTAL|ALL AC220 @ 25mg/m2/day (Dose Level 1)|The starting dose is Dose Level 1 at 25 mg/m2/day. Dose escalation will proceed from level 1 to 2 to 3, and so on, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age.
62444400|NCT01411267|EXPERIMENTAL|AML AC220 @ 25mg/m2/day (Dose Level 1)|The starting dose is Dose Level 1 at 25 mg/m2/day. Dose escalation will proceed from level 1 to 2 to 3, and so on, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age.
62054896|NCT02573025|EXPERIMENTAL|Reference Followed by Test|Participants will receive PEG-IFN alfa-2a market formulation (Reference) in Period 1, followed by PEG-IFN alfa-2a BA-free formulation (Test) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
62054897|NCT04060602|EXPERIMENTAL|Personalized Feedback and Education|This arm is provided personalized feedback concerning their cannabis use in addition to educational materials about risky cannabis use.
62054898|NCT04060602|ACTIVE_COMPARATOR|Education|This arm is provided educational materials about risky cannabis use.
62054899|NCT06443619|ACTIVE_COMPARATOR|Group I|will receive unilateral USG-deep SAPB ; 15 ml 0.5 % isobaric bupivacaine with addition of 15ml glucose 10% to (30 ml total volume).
62054900|NCT06443619|ACTIVE_COMPARATOR|Group Π|will receive unilateral USG-deep SAPB; 15ml 0.5% isobaric bupivacaine to be diluted with 15ml isotonic saline0.9% (30 ml total volume).
62054901|NCT00508261|EXPERIMENTAL|Group A|Meningococcal vaccine GSK134612 co-administered with Infanrix hexa™
62054902|NCT00508261|EXPERIMENTAL|Group B|Meningococcal vaccine GSK134612 followed one month later by Infanrix hexa™
62054903|NCT00508261|ACTIVE_COMPARATOR|Group C|Infanrix hexa™ followed one month later by Meningococcal vaccine GSK134612
62054904|NCT00508261|ACTIVE_COMPARATOR|Group D|Meningitec™ vaccination
62054905|NCT05807581|NO_INTERVENTION|Biomarkers|
62257236|NCT00806195|ACTIVE_COMPARATOR|Routine Vaccines (Detailed)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6 months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, and Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs."
62444401|NCT01411267|EXPERIMENTAL|ALL AC220 @ 40mg/m2/day (Dose Level 2)|Dose escalation will proceed from level 1 to level 2 for AC220 at 40mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age.
62614319|NCT01922154|EXPERIMENTAL|intravitreal ranibizumab|Ranibizumab was injected into vitreous cavity in the study eye once (0.5 mg/0.05 ml) at least 1 week before performing trabeculectomy with mitomycin C.
62614320|NCT03539185|ACTIVE_COMPARATOR|Airtraq|Awake tracheal intubation using airtraq videolaryngoscope.
62614321|NCT03539185|ACTIVE_COMPARATOR|Fiberoptic|Awake nasotracheal tracheal intubation using flexible fiberoptic bronchoscope.
62054906|NCT05807581|ACTIVE_COMPARATOR|physical activity|
62054907|NCT05807581|NO_INTERVENTION|sedentary|
62054908|NCT05807581|ACTIVE_COMPARATOR|iTBS active|
62054909|NCT05807581|SHAM_COMPARATOR|iTBS sham|
62054910|NCT00732186|EXPERIMENTAL|Group 1 and Group 2|
62054911|NCT02411838|NO_INTERVENTION|Control group|Steroid treatment (10 total days), which is a standard therapy for significant MS relapses.
62054912|NCT02411838|EXPERIMENTAL|Calorie restriction|"The intervention in this group will be to undergo a regimen of calorie restriction through fasting every other day (named alternate day fasting).~Specifically this group will undergo alternate day fasting plus the same steroid regimen as the control group (CR GROUP).~During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of IVMP) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point."
62054913|NCT04104451|EXPERIMENTAL|Dose 1|
62054914|NCT04104451|EXPERIMENTAL|Dose 2|
62054915|NCT04104451|EXPERIMENTAL|Dose 3|
62054916|NCT00641823||1|
62054917|NCT00641823||2|
62054918|NCT00641823||3|
62054919|NCT05863130|EXPERIMENTAL|BI 764198 (C-14) (approach 1)|
62054920|NCT05863130|EXPERIMENTAL|BI 764198 (C-14) (approach 2)|
62054921|NCT01933022|OTHER|Single Arm: Eligard|Single Arm
62054922|NCT03877458|EXPERIMENTAL|L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088|Taking 1 mix probiotics capsule at bed time everyday for three months.
62614322|NCT02687295|PLACEBO_COMPARATOR|Control group|Control group subjects received the same diet restriction intervention as treatment group. However, their food products did not contain any active component.
62614323|NCT02687295|ACTIVE_COMPARATOR|Thylakoid group|Thylakoid group subjects received the same diet restriction intervention as the control group. However, their food products did contain an active component in the form of thylakoid powder.
62614324|NCT03882957|ACTIVE_COMPARATOR|Video|videos of media tasks being completed
62614325|NCT03882957|EXPERIMENTAL|media multi-task|media tasks
62614326|NCT03882957|EXPERIMENTAL|sustained attention task|a cognitive task that trains sustained attention
62614327|NCT01966302|EXPERIMENTAL|Beraprost open label|Compassionate use access to open label BPS-314d-MR
62054923|NCT03877458|EXPERIMENTAL|L. reuteri GL-104|Taking 1 probiotic capsule at bed time everyday for three months.
62054924|NCT03877458|PLACEBO_COMPARATOR|Placebo group|Taking 1 Placebo capsule at bed time everyday for three months.
62257237|NCT00806195|EXPERIMENTAL|MenACWY-CRM197 + Routine Vaccines (All)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~All (Detailed and Non-Detailed subjects): Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs; Non-Detailed - subjects who only provided SAEs and medically attended AEs."
62257238|NCT00806195|ACTIVE_COMPARATOR|Routine Vaccines (All)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, and Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~All (Detailed and Non-Detailed subjects): Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs; Non-Detailed - subjects who only provided SAEs and medically attended AEs."
62257239|NCT04644939|EXPERIMENTAL|Interventional group|Patients will receive bowel preparation instructions in a conventional way in addition to a telephone call for education purposes one day prior to procedure
62257240|NCT04644939|PLACEBO_COMPARATOR|Conventional group|Patients will receive bowel preparation instructions in a conventional way
62054925|NCT04765735|EXPERIMENTAL|Open-loop (OL) testing, then Closed-loop (CL) testing|Subjects receive Open-loop testing, then Closed-loop testing (Spinal Cord Stimulation - SCS Therapy)
62054926|NCT04765735|EXPERIMENTAL|Closed-loop testing, then Open-loop testing|Subjects receive Closed-loop testing, then Open-loop testing (Spinal Cord Stimulation - SCS Therapy)
62054927|NCT01741376|PLACEBO_COMPARATOR|Placebo + Placebo|Two placebos are given for 84 days.
62054928|NCT01741376|ACTIVE_COMPARATOR|Progesterone + Placebo|Progesterone (200 mg twice daily) and a placebo are given
62054929|NCT05884463|EXPERIMENTAL|Experimental|Patients underwent both 18F-FDG PET/CT and 18F-FDG PET/CT scan
62054930|NCT05403190|EXPERIMENTAL|Study arm|Patients with prostate cancer
62614328|NCT05535400|EXPERIMENTAL|The Physical-Psychological Integrative (PPI) intervention group|The PPI intervention will include eight weekly online group sessions (with each session lasts for 60-90 minutes). At the beginning of each online group meeting, the intervention provider will use motivational interviewing techniques to promote participants' adherence to the physical activity program, followed by on-line group psychological intervention
62614329|NCT05535400|ACTIVE_COMPARATOR|The brief online didactic education control group|Participants in the control group will receive a short video call (approximately 20 minutes each week for eight weeks) from the trained research assistant, i.e., RA 2 to provide general physical and psychological suggestions (e.g., encouragement of performing physical activities, and communication skills with family members/friends, and engagement in the community life). This is to control the contact effects of the PPI intervention.
62054931|NCT00775814|EXPERIMENTAL|Candesartan + Hydrochlorothiazide QD|
62054932|NCT00775814|ACTIVE_COMPARATOR|Hydrochlorothiazide QD|
62054933|NCT06569875|EXPERIMENTAL|Internet-based cognitive behavioural therapy program|Participants will have access to an internet-based cognitive behavioral therapy program called iCARE for eight weeks.
62054934|NCT06569875|NO_INTERVENTION|Treatment as usual|Participants in the control group will receive treatment as usual in their municipality.
62614330|NCT04497974|ACTIVE_COMPARATOR|Regular dietary sweetness exposure - Control|Regular dietary sweetness exposure (RSE) - The RSE group consumes a diet with 25 - 30 % energy from sweet tasting foods, for 6 months.
62054935|NCT00962247|EXPERIMENTAL|Sedentary; usual, 25% reduced, 50% reduced|The initial 3 weeks of the study, children were asked to maintain their usual targeted sedentary behaviors (TV, video game, computer use) measured by a television reduction device (TV Allowance). The following 3 weeks children were asked to reduce their targeted sedentary behaviors (TV, video game, computer use) by 25% from the usual sedentary condition using a television reduction device (TV Allowance). The final 3 weeks of the study, children were asked to reduce their targeted sedentary behaviors (TV, video game, computer use) by 50% from the usual sedentary condition using a television reduction device (TV Allowance)
62054936|NCT05801575|EXPERIMENTAL|Chinese Herbal Medicine (CHM) teabag, Cluster 1|Intervention Cluster 1 is the first intervention arm designed to examine the efficacy and safety of CHM teabag in decreasing stroke risk by machine-learning-based retinal image analysis in elderly population. It will receive 16 weeks of the intervention.
62054937|NCT05801575|EXPERIMENTAL|CHM teabag, Cluster 2|Intervention Cluster 2 is the second intervention arm designed to examine the efficacy and safety of CHM teabag in decreasing stroke risk by machine-learning-based retinal image analysis in elderly population. It will receive 12 weeks of the intervention.
62839175|NCT00183482|EXPERIMENTAL|Family Group Cognitive Behavioral|The intervention is a family group cognitive behavioral program for families of parents with a history of depression to teach parenting skills to parents and coping skills to children.
62054938|NCT05801575|EXPERIMENTAL|CHM teabag, Cluster 3|Intervention Cluster 3 is the third intervention arm designed to examine the efficacy and safety of CHM teabag in decreasing stroke risk by machine-learning-based retinal image analysis in elderly population. It will receive 8 weeks of the intervention.
62054939|NCT05801575|EXPERIMENTAL|CHM teabag, Cluster 4|Intervention Cluster 4 is the fourth intervention arm designed to examine the efficacy and safety of CHM teabag in decreasing stroke risk by machine-learning-based retinal image analysis in elderly population. It will receive 4 weeks of the intervention.
62839176|NCT00183482|ACTIVE_COMPARATOR|Written Information|The comparison arm involves providing written information about depression and stress to parents with a history of depression and their children.
62839177|NCT05078840||Patients with DLBCL limited stages and without risk factors|Patients with DLBCL in limited stages and without risk factors that will receive standard chemoimmunotherapy and their treatment will be adapted according to PET response after 3 cycles.
62839178|NCT02447003|EXPERIMENTAL|Cohort A: Pembrolizumab|Participants in Cohort A previously received at least one prior systemic treatment for metastatic breast cancer. Participants will be administered pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to \~ 2 years).
62054940|NCT05850468|ACTIVE_COMPARATOR|traditinal balanced anesthesia|fentanyl infusion after general anesthesia and erector spinea block
62054941|NCT05850468|EXPERIMENTAL|opioid free anesthesia|lidocaine and dextometidine infusion after general anesthesia and erector spinea block
62614331|NCT04497974|EXPERIMENTAL|Low dietary sweetness exposure - Experimental|Low dietary sweetness exposure (LSE) - The LSE group consumes a diet with 10 - 15 % energy from sweet tasting foods, for 6 months.
62054942|NCT00167830|EXPERIMENTAL|Lifestyle Intervention|Dietary modification and exercise.
62054943|NCT05476835|EXPERIMENTAL|experimental group (group A) - control group (groupB)|The experimental group (group A) performed respiratory exercises (in form of diaphragmatic breathing, pursed lip breathing exercise and incentive spirometer), rehab exercise program and walking exercise.
62054944|NCT05476835|NO_INTERVENTION|control group (group B)|The control group (group B) did not receive any physical therapy program
62054945|NCT06446505|EXPERIMENTAL|Early Decision Aid|Participants will receive the Decision Aid at baseline.
62054946|NCT06446505|ACTIVE_COMPARATOR|Delayed Decision Aid|Participants will receive the Decision Aid at the end of the deep brain stimulation surgery evaluation process.
62257241|NCT04272671|EXPERIMENTAL|Educational Intervention Arm|The intervention arm will receive educational material that enhances the standard of care for deprescribing opioids and BZDs.
62257242|NCT04272671|NO_INTERVENTION|Ususal Care (Control Arm)|Control group will receive standard of care
62257243|NCT01616420|NO_INTERVENTION|Delayed aPS|
62614332|NCT04497974|EXPERIMENTAL|High dietary sweetness exposure - Experimental|High dietary sweetness exposure (HSE) - The HSE group consumes a diet with 40 - 45 % energy from sweet tasting foods, for 6 months.
62257244|NCT01616420|EXPERIMENTAL|Immediate aPS|
62257245|NCT02381405|ACTIVE_COMPARATOR|A|Enterade beverage
62614333|NCT00307853|ACTIVE_COMPARATOR|1|TraumeelS
62614334|NCT00307853|PLACEBO_COMPARATOR|Placebo|
62614335|NCT01233752||Group A|Homozygous patients,using PCA administration with morphine chlorhydrate for postoperative analgesia, for the more frequent allele of the polymorphism A118G of OPRM1 gene
62614336|NCT01233752||Group B|Both homozygous and heterozygous patients,using PCA administration with morphine chlorhydrate for postoperative analgesia, for the less frequent allele of the polymorphism A118G of OPRM1 gene
62257246|NCT02381405|NO_INTERVENTION|B|Standard of care
62257247|NCT01349868|EXPERIMENTAL|PT005 MDI (Dose 1)|PT005 MDI (Dose 1)
62257248|NCT01349868|EXPERIMENTAL|PT005 MDI (Dose 2)|PT005 MDI (Dose 2)
62614337|NCT01603407|EXPERIMENTAL|Daily prednisone|daily prednisone (0.75 mg/kg/day)
62839179|NCT02447003|EXPERIMENTAL|Cohort B: Pembrolizumab|Participants in Cohort B previously received no prior systemic treatment for metastatic breast cancer AND had a programmed cell death-ligand 1 (PD-L1) positive tumor expression. Participants will be administered pembrolizumab 200 mg IV on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to \~ 2 years).
62614338|NCT01603407|EXPERIMENTAL|Intermittent prednisone|intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off)
62614339|NCT01603407|EXPERIMENTAL|Daily deflazacort|daily deflazacort (0.9 mg/kg/day
62614340|NCT05230745|EXPERIMENTAL|ContraBand implants|Percutaneous implantation of the ContraBand devices by right heart catheterization
62614341|NCT01080170||Anastrazole|Newly diagnosed, non-metastatic, hormone-receptor positive breast cancer patients, who have undergone lumpectomy, have been advised to not require chemotherapy, but will need to undergo radiation therapy and will be initiating therapy with anastrazole.
62614342|NCT01080170||Control group - 2|Healthy controls.
62839180|NCT05868122|EXPERIMENTAL|Acetaminophen/Naproxen Sodium Fixed Combination|Participants will receive oral doses of two Acetaminophen/Naproxen Sodium Fixed Combination tablets taken with water. Multiple doses will be administered over a 48-hour period.
62839181|NCT05868122|PLACEBO_COMPARATOR|Placebo|Participants will receive oral doses of two placebo tablets taken with water. Multiple doses will be administered over a 48-hour period.
62839182|NCT06193668|ACTIVE_COMPARATOR|High-fat overnutrition|Lipid overnutrition: 40% higher lipid consumption per day than required over three weeks.
62839183|NCT06193668|ACTIVE_COMPARATOR|Normocaloric macronutrient-balanced nutrition|Normocaloric, macronutrient-balanced nutrition per day over three weeks
62839184|NCT05653076|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose
62839185|NCT05653076|EXPERIMENTAL|Hibiscus sabdariffa extract|520 mg of Hibiscus sabdariffa extract
62839186|NCT03216226|EXPERIMENTAL|dasiglucagon (ZP4207)|Repeated single fixed doses (s.c.injection) of dasiglucagon
62839187|NCT03216226|EXPERIMENTAL|GlucaGen|Repeated single fixed doses (s.c.injection) of GlucaGen
62839188|NCT04841083|EXPERIMENTAL|Allay lamp (narrow band green light)|Subjects who purchased the Allay Lamp are asked to document the effects of spending time in the narrow band of green light it emits, on their headache or any of its associated symptoms.
62839189|NCT04296838|EXPERIMENTAL|refractory UME patients treated with Conbercept|patients in this arm should meet the inclusion criteria and the definition of refractory UME
62839190|NCT00967421|EXPERIMENTAL|BAC 0.5|BAC level 0.5 g/dL (drink + placebo pill)
62839191|NCT00967421|EXPERIMENTAL|BAC 1.0|BAC level 1.0 g/dL (drink + placebo pill)
62054947|NCT06212648|EXPERIMENTAL|SPC1001 High|SPC1001 High (Candesartan/Amlodipine/Indapamide)
62054948|NCT06212648|EXPERIMENTAL|SPC1001 Mid1|SPC1001 Mid1 (Candesartan/Amlodipine/Indapamide)
62054949|NCT06212648|EXPERIMENTAL|SPC1001 Mid2|SPC1001 Mid1 (Candesartan/Amlodipine/Indapamide)
62054950|NCT06212648|EXPERIMENTAL|SPC1001 Low|SPC1001 Low (Candesartan/Amlodipine/Indapamide)
62054951|NCT06212648|ACTIVE_COMPARATOR|SPC3001|SPC3001 (Candesartan 8mg)
62614343|NCT01031017|PLACEBO_COMPARATOR|placebo|group taking placebo
62614344|NCT01031017|ACTIVE_COMPARATOR|study group|group taking progesterone
62614345|NCT02867891||Chemotherapy alone|The specific interventions to the subjects of the study are assigned by the individual transplant center
62614346|NCT02867891||Chemotherapy/DLI|The specific interventions to the subjects of the study are assigned by the individual transplant center
62614347|NCT02867891||Sorafenib alone|The specific interventions to the subjects of the study are assigned by the individual transplant center
62614348|NCT02867891||Sorafenib/DLI|The specific interventions to the subjects of the study are assigned by the individual transplant center
62614349|NCT02949141|EXPERIMENTAL|Ultrasound|All patients will initially get an ultrasound (interpreted by emergency department physician) followed by chest x-ray (read by independent radiologist) and computed tomography (read by radiologist)
62614350|NCT05947435|EXPERIMENTAL|Tranexamic acid IV|Group A received an IV infusion of 10 mg/kg tranexamic acid for 20 minutes just before the surgical incision.
62614351|NCT05947435|EXPERIMENTAL|Tranexamic acid irrigation|10 mg/kg tranexamic acid was placed in the first irrigation solution
62839192|NCT00967421|PLACEBO_COMPARATOR|placebo|BAC level 0,0 g/dL (placebo drink+ placebo pill)
62839193|NCT00399906|ACTIVE_COMPARATOR|A1|10 mg
62839194|NCT00399906|ACTIVE_COMPARATOR|A2|30 mg
62839195|NCT00399906|ACTIVE_COMPARATOR|A3|100 mg
62839196|NCT00399906|PLACEBO_COMPARATOR|P1|10 or 100 mg
62054952|NCT06212648|ACTIVE_COMPARATOR|SPC4001|SPC4001 (Amlodipine 5mg)
62054953|NCT06212648|ACTIVE_COMPARATOR|SPC4002|SPC4002 (Amlodipine 10mg)
62054954|NCT06212648|PLACEBO_COMPARATOR|Placebo|SPC1001(High, Mid1, Mid2, Low) placebo, SPC3001 placebo, SPC4001 placebo, SPC4002 placebo
62054955|NCT01580839|EXPERIMENTAL|intravenous tissue plasminogen activator|
62054956|NCT01580839|PLACEBO_COMPARATOR|Placebo|
62257249|NCT01349868|EXPERIMENTAL|PT005 MDI (Dose 3)|PT005 MDI (Dose 3)
62257250|NCT01349868|PLACEBO_COMPARATOR|Placebo MDI|Placebo MDI
62614352|NCT05947435|NO_INTERVENTION|Control|The control group did not receive tranexamic acid in either way
62614353|NCT05724199|EXPERIMENTAL|Rocatinlimab Dose 1 + TCS/TCI|Rocatinlimab Dose 1 every 4 weeks (Q4W) for 24 weeks + TCS/TCI + loading dose at Week 2.
62614354|NCT05724199|EXPERIMENTAL|Rocatinlimab Dose 2 + TCS/TCI|Rocatinlimab Dose 2 Q4W for 24 weeks + TCS/TCI + loading dose at Week 2.
62614355|NCT05724199|PLACEBO_COMPARATOR|Placebo + TCS/TCI|Placebo Q4W for 24 weeks + TCS/TCI + loading dose at Week 2.
62614356|NCT00893139|EXPERIMENTAL|AL-38583 0.05%|AL-38583 ophthalmic solution 0.05%, 1 drop per eye, 3 times a day, for 35 days
62614357|NCT00893139|EXPERIMENTAL|AL-38583 0.10%|AL-38583 ophthalmic solution 0.10%, 1 drop per eye, 3 times a day, for 35 days
62614358|NCT00893139|PLACEBO_COMPARATOR|AL-38583 vehicle|Inactive ingredients used as a placebo comparator, 1 drop per eye, 3 times a day, for 35 days
62614359|NCT02309190||transpulmonary pressures|Esophageal balloon to measure transpulmonary pressures. PEEP adjustment as per transpulmonary pressures.
62614360|NCT06306768|OTHER|Remote Therapeutic Monitoring|Participants will receive 1 year of remote therapeutic monitoring via a connected health app and personal activity tracker to monitor their physical activity and exercise behaviors.
62614361|NCT05979974|EXPERIMENTAL|physiotherapy and high-PEMF|The patient undergoes physiotherapy and high-PEMF therapy twice a week, for a duration of three weeks.
62614362|NCT05979974|SHAM_COMPARATOR|physiotherapy and sham high-PEMF|The patient undergoes physiotherapy and sham high-PEMF therapy twice a week, for a duration of three weeks.
62614363|NCT06131216|EXPERIMENTAL|SHR-2022 Injection|
62839197|NCT03317015|EXPERIMENTAL|Group A - Nasacort®|Nasacort® will be sprayed twice in each nostril once every morning
62839198|NCT03317015|ACTIVE_COMPARATOR|Group B - Flixonase®|Flixonase® will be sprayed twice in each nostril once every morning
62839199|NCT04422483||Service Model Level Case Studies|Realist Interviews. MONTHS 9-30 (N=6-8 sites, 12 people per site, 96 interviewees)
62839200|NCT04422483||Individual/family level interviews|Child Interviews. MONTHS 9-30 (N=6-8 sites, 6 people per site, max. 48 interviewees)
62054957|NCT04059692|EXPERIMENTAL|Cervical manipulation intervention|"To perform the evaluation and detect the cervical vertebral level with mobility restriction, with the patient in supine position, a cervical examination is carried out to determine the mobility restriction, both in flexo-extension, as in inclination and rotation. To check the level of restriction, the post-anterior sliding test is performed.~The manipulation is performed following the criteria of thrust manipulations. A maximum of 3 manipulations are applied in total per subject, one for each level (high level C1-C2, medium level C3-C6, and low level C7), if necessary."
62257251|NCT01349868|ACTIVE_COMPARATOR|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 12 μg
62839201|NCT04422483||Individual child/family Level Case Studies:|MONTHS 10-30 (N=6-8 sites, 78 people per model (x4), 312 participants, 156 per NU/SCFT depending on distribution of sites)
62257252|NCT01349868|ACTIVE_COMPARATOR|Formoterol Fumarate 24 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 24 μg
62257253|NCT01454375|NO_INTERVENTION|Control Arm|No change in current practice
62257254|NCT01454375|EXPERIMENTAL|Referral fo QuitNow Services|Behavioural - referral to QuitNow Services, smoking cessation counseling telephone line supported by the Ministry of Healthy Living and Sport
62257255|NCT04222673|EXPERIMENTAL|Peer Specialist|The intervention will last 3-months, a time frame that overlaps with the typical duration of a VA suicide high risk flag. Meetings will be 30-45 minutes and occur primarily in the community, home, or by telephone. Session content will be rooted in Peer Specialists (PSs) offering nonjudgmental empathic support, active listening, and constructive disclosure and role modeling. A primary focus will be helping patients with flags to identify and strengthen connections with informal supports and participation in activities in their community that will enable them to feel more worthwhile as individuals and hopeful about their future.
62614364|NCT02905643||Study subjects|Patients who have or might have a brain tumor which may be a glioblastoma.
62614365|NCT01350375|PLACEBO_COMPARATOR|Saline|
62839202|NCT04422483||Focus groups:|MONTHS 9-30 (N=6-8 sites, 6-8 focus groups of up to 8 parents) N= 64
62839203|NCT06223984|ACTIVE_COMPARATOR|the group receiving standard treatment|In the group receiving standard treatment, hydroxychloroquine (400 mg/day for 5 days), low moleculer weight heparin, acetylsalicylic acid, favipiravir (3200 mg on day 1, 1200 mg on days 2-5).
62839204|NCT06223984|ACTIVE_COMPARATOR|the group receiving IVIG and pulse steroid|In the IVIG and pulse steroid group, patients received pulse steroid (250 mg/day methylprednisolone for 5 days) and intravenous immunoglobulin (400 mg/kg/day for 5 days) in addition to standard treatment. The IVIG preparations given to the patients were in 100 ml volume and 10% concentration, and the commercial name was Nanogam.
62839205|NCT02512029|EXPERIMENTAL|TBI Subjects|Subjects with history of recent subacute Traumatic Brain Injury (TBI) will receive a single IV injection, 370 megabecquerel (MBq) \[10 millicurie (mCi)\] of 18F-AV-1451 2 to 6 weeks following injury. They will return for a follow-up injection approximately 6 months following injury.
62839206|NCT02512029|EXPERIMENTAL|Control|Cognitively healthy volunteer subjects will receive a single IV injection, 370 megabecquerel (MBq) \[10 millicurie (mCi)\] of 18F-AV-1451.
62839207|NCT02271672|EXPERIMENTAL|XP1000 RF group|Subjects in the XP1000 RF group will be treated with the XP1000 RF device.
62839208|NCT02271672|SHAM_COMPARATOR|Sham group|Subjects in the Sham group will be treated with the sham XP1000 RF device.
62839209|NCT03823209|EXPERIMENTAL|Social Network Approach|"Participants will receive brief HIV counseling at baseline visit.~Leaders of social networks will be determined using data from participants. These leaders will then be invited to attend a 5-session small-group training that will teach them how to communicate the benefits of PrEP to their social network members.~All social network members will be asked about intervention exposure at 6- and 15-month followups."
62839210|NCT03823209|ACTIVE_COMPARATOR|Comparison|Participants will receive brief HIV counseling at baseline visit.
62839211|NCT04737304|EXPERIMENTAL|Dose Regimen Low Dose|Low Dose Strength
62839212|NCT04737304|EXPERIMENTAL|Dose Regimen High Dose|High Dose Strength
62839213|NCT04737304|PLACEBO_COMPARATOR|Placebo|Placebo
62839214|NCT05812911|ACTIVE_COMPARATOR|Standard oxygen therapy|Patients will receive standard oxygen. First attempt device in usual care.
62614366|NCT01350375|ACTIVE_COMPARATOR|Botox|
62614367|NCT05697302|EXPERIMENTAL|Relactation|
62614368|NCT05697302|ACTIVE_COMPARATOR|Control|
62614369|NCT04582565|ACTIVE_COMPARATOR|Control group|Control group will have standard of care, consisting of verbal and written information on lymphoedema prevention and standard access to breast care nurse.
62257256|NCT02516787|OTHER|EEG and NIRS measurements|
62257257|NCT01847482|EXPERIMENTAL|Therapeutic Hypothermia|
62257258|NCT05085639|EXPERIMENTAL|GLS-5310 1.2 mg (Group 1)|GLS-5310 1.2 mg (ID + Gene-Derm) at Day 0 and Week 8
62257259|NCT05085639|EXPERIMENTAL|GLS-5310 2.4 mg (Group 2)|GLS-5310 1.2 mg (ID + Gene-Derm) + 1.2 mg (IN) at Day 0 and Week 8
62257260|NCT05085639|EXPERIMENTAL|GLS-5310 1.2 mg (Group 3)|GLS-5310 1.2 mg ID at Day 0 and Week 8
62257261|NCT05085639|PLACEBO_COMPARATOR|Placebo (Group 4)|Placebo (ID + Gene-Derm) at Day 0 and Week 8
62257262|NCT04643028|OTHER|Home exercise|The exercise program will include active normal joint movements in the cervical region, postural exercises, strengthening exercises for the scapular retractor muscles, and stretching exercises for the pectoral muscles, levator scapula and upper part of the trapezius and breathing/relaxation exercises.
62614370|NCT04582565|EXPERIMENTAL|Combination product|Decongestive lymphatic therapy (DLT). DLT group will involve manual lymphatic drainage with a trained manual lymphatic drainage therapist.
62614371|NCT04015778|EXPERIMENTAL|Nivolumab Mono|In arm A, 24 participants will be enrolled into this arm according to PD-L1 expressing level (≥50%).Arm A consists of 3 cycles of neoadjuvant nivolumab (240mg every 2 weeks), and adjuvant nivolumab (240mg IV, over 30 min, every 2 weeks) up to 12 months
62839215|NCT05812911|EXPERIMENTAL|High-Flow nasal cannula therapy (HFNO)|Patient will receive HFNO using a humidification system or via the high-flow interface of the ICU ventilator.
62839216|NCT05812911|EXPERIMENTAL|Noninvasive ventilation therapy (NIV)|Between NIV sessions, patients will receive HFNO with the same modalities than the HFNO group.
62054958|NCT04059692|PLACEBO_COMPARATOR|Placebo intervention|This group will receive 15 minutes of sham techniques in a supine position over the stretcher. First, a series of short-time and no pressure contact with physiotherapist´s hands is performed in several points of head and shoulders for 10 minutes. Subsequently, light touch is applied on standardized anatomic areas, for 2 minutes each time.
62614372|NCT04015778|EXPERIMENTAL|Nivolumab Plus Chemo|In arm B, up to 12 participants will be enrolled into each subgroup according to PD-L1 expressing level (\<1% and 1%-49%).arm B consists of 3 cycles of neoadjuvant nivolumab (360mg every 3 weeks) with nab-paclitaxel and carboplatin(nab-paclitaxel 135 mg/m2, d1, 8 and carboplatin AUC 5, d1 every three weeks ), and adjuvant nivolumab (240mg IV, over 30 min, every 2 weeks) up to 12 months
62839217|NCT06418256||Patients|Adult patients cared in one of the APHP hospital (Necker-Enfants Malades Hospital, Saint-Antoine Hospital, Pitié Salpêtrière Hospital and Beaujon Hospital) for whom a splenic intervention (spleno-pancreectomy, or a total or partial splenectomy) is planned as part of their treatment.
62839218|NCT01223781|EXPERIMENTAL|Feedforward stimulation|Prior to any gait condition likely to invoke freez, auditory stimulation is presented
62839219|NCT01223781|EXPERIMENTAL|Feedback stimulation|Once a device identifies freezing, a auditory stimulation is triggered
62839220|NCT02559024|EXPERIMENTAL|21 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 21 days prior to surgery
62839221|NCT02559024|EXPERIMENTAL|14 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 14 days prior to surgery
62839222|NCT02559024|EXPERIMENTAL|7 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 7 days prior to surgery
62839223|NCT05777356||Omivorous|Healthy volunteers without dietary restrictions
62839224|NCT05777356||Vegetarians|Healthy volunteers who do not consume meat products
62839225|NCT05777356||Vegans|Healthy volunteers who do not consume any animal product
62839226|NCT05597488|EXPERIMENTAL|EUS guided portal pressure gradient measurement|At index OGD, the presence and severity of OV, GV and portal hypertensive gastropathy would be recorded. After endoscopic treatment of varices, recruited patients would undergo 1st measurement of EUS-PPG within 10-14 days after index OGD. The patients would then be enrolled into a variceal surveillance program and be started on B-blockers if not already prescribed. The patients would then be scheduled for another follow-up OGD at 3 months with measurement of the 2nd EUS-PPG. Finally, a third follow-up OGD and EUS-PPG would be performed in 1-year after 1st EUS-PPG. Endoscopic findings attributed to chronic cirrhosis would be assessed in the 3 months and 1 year OGD and the presence and severity of OV, GV and portal hypertensive gastropathy would be recorded.
62839227|NCT03793699||case group : realized a suicide attempt|adults having realized a suicide attempt and without histories of suicide attempt.
62839228|NCT03793699||control group : only suicidal ideas|adults having suicidal ideas without suicidal acting out and without histories of suicide attempt.
62839229|NCT00938067|EXPERIMENTAL|Staying Connected: Care Management|The intervention combines case management, psychopharmacological and culturally appropriate and individually tailored trauma support activities with evidence-based treatments.A key feature is the provision of a continuous healing relationship by a care management treatment team.The care manager, informed by the Native healer interviews, will provide a culturally appropriate and ongoing helping relationship to each intervention patient in the weeks and months post-injury and will remain in close contact with the trauma survivor subject for 6 months.Together, the care manager and trauma survivor subject will work on a plan to readjust to daily activities. The care management team will also coordinate psychopharmacological interventions for PTSD and related co-morbidities with primary care and or other community providers.
62839230|NCT01209689|EXPERIMENTAL|Tocilizumab 4 mg/kg|Patients received tocilizumab 4 mg/kg intravenously every 4 weeks for 24 weeks.
62839231|NCT01209689|EXPERIMENTAL|Tocilizumab 8 mg/kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks for 24 weeks.
62839232|NCT01209689|PLACEBO_COMPARATOR|Placebo|Patients received placebo to tocilizumab intravenously every 4 weeks for 24 weeks.
62839233|NCT03990727||Retinitis pigmentosa|Any type of retina dystrophy with pigment / retinitis pigmentosa
62839234|NCT03990727||Usher Syndrome|Retina dystrophy or retinitis pigmentosa associated with audition problems
62839235|NCT03990727||Cone>rod syndromes|Retina dystrophy diagnosed or started in central vision.
62839236|NCT03990727||Retinitis pigmentosa sx|Retinitis pigmentosa with any type of other features
62839237|NCT06320262|ACTIVE_COMPARATOR|Intervention group|They will receive wet cupping therapy (WCT) every month for 3 consecutive months in addition to a home-based graded exercise program.
62839238|NCT06320262|NO_INTERVENTION|Control group|they will receive a home-based graded exercise program, which is comprised of both aerobic and stretching exercises. The patients will be instructed to do the protocols with a gradual increase in both intensity and frequency.
62839239|NCT06521931|EXPERIMENTAL|PN20 group|thrombopoietin receptor agonist
62839240|NCT00971815|ACTIVE_COMPARATOR|escitalopram|A pill containing Escitalopram
62839241|NCT00971815|PLACEBO_COMPARATOR|placebo|a placebo pill
62839242|NCT04613037|EXPERIMENTAL|Treatment arm|Fecal Microbial Transplantation in adults with Atopic Dermatitis
62839243|NCT05221957|EXPERIMENTAL|Iron(III)isomaltoside 1000|Anemic patients receiving treatment with iron(III)isomaltoside
62839244|NCT05221957|NO_INTERVENTION|Historical comparison|Anemic patients without receiving treatment prior to surgery. Historical comparison.
62054959|NCT03073564|NO_INTERVENTION|Incremental cardiopulmonary test|Incremental cardiopulmonary test for upper limbs will be performed only to identify patients who exhibit dynamic hyperinflation during upper limb exercise.
62054960|NCT03073564|EXPERIMENTAL|Endurance test|The endurance test for upper limbs will be performed in two conditions: In the first the patients perform the test in usual breathing, without the use of EPAP. In the second the test will be performed using the EPAP mask.
62839245|NCT05221957|NO_INTERVENTION|Concurrent comparison|Non-anemic patients not receiving treatment with iron(III)isomaltoside prior to surgery
62839246|NCT00408200|OTHER|AAD:YES|Subjects receive membrane-active anti-arrhythmic medication after ablation. See intervention list below.
62839247|NCT00408200|OTHER|AAD:NO|Subjects do not receive membrane-active anti-arrhythmic medications after ablation.
62839248|NCT05601895||sorafenib group|FLT3- acute leukemia patients who receive sorafenib maintenance therapy after allo-HSCT. Sorafenib will be used from day 30 to 180 post-transplantation. The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
62839249|NCT05601895||non-sorafenib group|FLT3- acute leukemia patients who do not receive sorafenib maintenance therapy after allo-HSCT.
62839250|NCT00711191|EXPERIMENTAL|single arm|
62839251|NCT04217304|EXPERIMENTAL|Sonothrombolysis|Diagnostic myocardial contrast echocardiography with ultrasound contrast agent 5% Definity® plus Sonothrombolysis
62839252|NCT04217304|NO_INTERVENTION|Standard of Care|Diagnostic myocardial contrast echocardiography with ultrasound contrast agent 5% Definity®
62839253|NCT05022732|PLACEBO_COMPARATOR|Control formula|Excipients and gum arabic in tablet
62839254|NCT05022732|ACTIVE_COMPARATOR|Experimental formula|Polyglucosamine L112 (750 mg of chitosan for tablet formulated with ascorbic acid and tartaric acids in the relative proportions of 91-6-3% with the addition of formulating excipients)
62839255|NCT00946283|EXPERIMENTAL|Lactobacillus GG|Open label trial of Culturelle (Lactobacillus GG) administered to patients after engraftment, post allogeneic stem cell transplantation.
62839256|NCT04923282|ACTIVE_COMPARATOR|Group 1: single 1-hour IV infusion of 0.8 mg/kg recAP or placebo|single 1-hour IV infusion of 0.8 mg/kg recAP or placebo
62839257|NCT04923282|ACTIVE_COMPARATOR|Group 2: single 1-hour IV infusion of 1.6 mg/kg recAP or placebo|single 1-hour IV infusion of 1.6 mg/kg recAP or placebo
62839258|NCT04923282|ACTIVE_COMPARATOR|Group 3: single 1-hour IV infusion of 3.2 mg/kg recAP or placebo|single 1-hour IV infusion of 3.2 mg/kg recAP or placebo
62839259|NCT04923282|ACTIVE_COMPARATOR|Group 4: 1-hour infusions of 1.6 mg/kg recAP or placebo on Days 1, 2 and 3|1-hour infusions of 1.6 mg/kg recAP or placebo on Days 1, 2 and 3
62839260|NCT01443052||post-stroke patients|Stroke patients who had only one cerebrovascular accident, at least one year before inclusion and Able to walk without using assisting devices or ambulatory aids
62839261|NCT01443052||healthy subjects|Aged 65 to 80 years
62257263|NCT04643028|OTHER|Mulligan mobilization|Mulligan mobilization will be applied to this group in addition to the exercises in the home exercise group. In painless directions, each session will be applied in 3 sets, a set of 10 repetitions. Sixty seconds of rest will be given between sets.
62257264|NCT04643028|OTHER|Cervical stabilization|In addition to the exercises in the home exercise group, this group will be given cervical stabilization training that focuses on the deep neck muscles.
62444402|NCT01411267|EXPERIMENTAL|ALL AC220 @ 60mg/m2/day (Dose Level 3)|Dose escalation will proceed from level 2 to 3 for AC220 at 60mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. If toxicity at Dose Level 3 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
62444403|NCT01411267|EXPERIMENTAL|ALL AC220 @ 90mg/m2/day (Dose Level 4)|If the study dose of 60 mg/m2/day at Dose Level 3 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 4 at 90 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. If toxicity at Dose Level 4 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
62444404|NCT01411267|EXPERIMENTAL|ALL AC220 @ 130 mg/m2/day (Dose Level 5)|If the study dose of 90 mg/m2/day at Dose Level 4 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 5 at 130 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. Dose Level 5 is the highest dose for this study.
62839262|NCT01443052||fallers|Reported 2 or more falls within 6 months prior to the beginning of the study and Able to walk without using assisting devices or ambulatory aids
62839263|NCT03369262|EXPERIMENTAL|Active|"OBE022 plus atosiban:~OBE022 will be given orally from Day 1 to Day 7. OBE022 treatment will be initiated ideally simultaneously or at a maximum within 24 h after atosiban start.~* Loading dose: 1 000 mg on Day 1.~* Maintenance dose on Day 1: 500 mg in the evening if loading dose was administered in the morning. If loading dose was administered in the afternoon, then the next dose will take place on the morning of Day 2.~* Maintenance dose from Day 2 to Day 7: 500 mg twice a day (only morning dose on Day 7)~Atosiban will be administered over 48h as per label."
62257265|NCT02785016||Stress Urinary Incontinence|Females with stress urinary incontinence, who undergo a tension free surgical sling procedure.
62257266|NCT04277520|ACTIVE_COMPARATOR|Continous rotation|instrumentation was done in continuous rotation motion
62257267|NCT04277520|ACTIVE_COMPARATOR|Reciprocation|instrumentation was done in reciprocation motion
62257268|NCT04277520|ACTIVE_COMPARATOR|Adaptive motion|instrumentation was done in adaptive motion
62614373|NCT00492232|EXPERIMENTAL|Ramelteon 8 mg QD and current Zolpidem therapy|Zolpidem therapy will be reduced by dose, frequency, or both for up to 10 weeks.
62839264|NCT03369262|ACTIVE_COMPARATOR|Placebo|"OBE022 matching placebo plus atosiban:~OBE022 matching placebo administration will follow the same regimen as the active group.~Atosiban will be administered over 48h as per label."
62257269|NCT04020601|ACTIVE_COMPARATOR|PRE-GA|10 mL of 1% ropivacaine injection before the start of surgery and 10 ml of 5% dextrose injection at the end of surgery through the interscalene catheter
62257270|NCT04020601|SHAM_COMPARATOR|POST-GA|10 ml of 5% dextrose injection before the start of surgery and 1% ropivacaine injection at the end of surgery through the interscalene catheter
62839265|NCT05669911|EXPERIMENTAL|Teal Health Self-Collection Device Group|This group will use the Teal Health Self-Collection Device to evaluate the instructions for use, usability, and satisfaction with the self-collection device. Participants will also undergo a Pap smear performed by a clinician. Self-collected and clinician-collected research samples will undergo HPV testing and cytological analysis using tests that are FDA-approved for use for HPV and Pap cytology.
62839266|NCT06072664|EXPERIMENTAL|Caloric Compensation|The researchers will enroll 120 children from the long-term observational study, NCT06039878.
62839267|NCT02797938|EXPERIMENTAL|Taper guard tube|Taper guard tube was intubated in 26 patients
62839268|NCT02797938|ACTIVE_COMPARATOR|Cylindrical tube|Cylindrical tube was intubated in 26 patients
62839269|NCT03501719||Triple ART|Patients who remain in triple ART during the follow-up.
62839270|NCT03501719||Dual ART|Patients switched to dual ART during the follow-up.
62839271|NCT03501719||Monotherapy|Patients switched to monotherapy during the follow-up.
62839272|NCT04667130|EXPERIMENTAL|Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis|Providing information about the possibilities of physiotherapy, Computer Kinesiology, psychotherapy, Motor progam activating therapy, aerobic exercise
62839273|NCT00030732|ACTIVE_COMPARATOR|Gemcitabine + Capecitabine|Gemcitabine + Capecitabine
62839274|NCT00030732|ACTIVE_COMPARATOR|Gemcitabine alone|Gemcitabine alone
62839275|NCT03638765|EXPERIMENTAL|Experimental Treatment|Intratumoral injection of activated, autologous dendritic cells (DCVax-Direct) in brain metastases from lung cancer or breast cancer
62614374|NCT00492232|PLACEBO_COMPARATOR|Placebo QD and current Zolpidem therapy|Zolpidem therapy will be reduced by dose, frequency, or both for up to 10 weeks.
62614375|NCT01303133||Adults with Down Syndrome ages 30+ (PiB-/-)|We will be recruiting healthy adults with Down syndrome ages 30 and over. Participants cannot have a diagnosis of dementia.
62614376|NCT01303133||Adults with Down Syndrome ages 30+ (PiB-/+)|
62614377|NCT01303133||Adults with Down Syndrome ages 30+ (PiB+/+)|
62614378|NCT01255384||Non Diabetic-Controls|Pregnant women with uncomplicated pregnancy will be followed, their offsprings will be evaluated and followed for 5 years
62614379|NCT01255384||Diabetic Pregnancy|Pregnant women followed in the high risk clinic because of diabetes will be followed and their offspring's will be evaluated and followed for 5 years
62614380|NCT02897167||PAFIP patients (1)|"Individuals included in the First Episode Psychosis Clinical Program (PAFIP) between June 2011 and February 2016.~Retrospective study of frozen samples: samples at baseline and 3 months will be analyzed."
62614381|NCT02897167||PAFIP patients (2)|"Individuals included in the First Episode Psychosis Clinical Program (PAFIP) between September 2016 and September 2017.~Prospective study of fresh samples: samples at baseline and 3 months will be analyzed."
62614382|NCT02897167||Controls|Healthy subjects without psychotic disorder.
62614383|NCT04883684|EXPERIMENTAL|Patients(Care givers)|"1. 400 patients(caregivers) are enrolled and use the personal health wallet service (Personal Health Records service).~2. They fill out questionnaire to evaluate the service~3. Some of them are invited for an in-depth interview."
62614384|NCT06668103|EXPERIMENTAL|ABSK043 in combination with Firmonertinib|"This is an open-label phase 2 study with an escalation part and an expansion part.~* Escalation part: Previously treated patients with EGFR Mutated NSCLC will be enrolled.~  * Dose escalation cohort: up to 12 patients;~ * Dose confirmation cohort: at least 3 patients, and up to 12 patients.~* Expansion part:~  * Dose expansion cohort: up to 30 treatment-naïve patients with EGFR Mutated NSCLC are expected to be enrolled."
62614385|NCT03073356|EXPERIMENTAL|Control - Healthy test subjects|Age matched subjects without symptoms of heart failure or ischemic heart disease N=10
62614386|NCT03073356|EXPERIMENTAL|HFrEF - Heart failure patients investigated by PET|Patients with heart failure (HFrEF) N=12
62839276|NCT01312103|EXPERIMENTAL|Internet Based Safety Decision Aid|
62839277|NCT01312103|ACTIVE_COMPARATOR|Control Website|
62839278|NCT06442878|OTHER|Control and Experimental Group|The same group, will do the intervention will attend the belly dance program. The control group will maintain the usually daily activities, not attending any exercise program for a month and a half, and than will be a experimental group with 2 sessions / week of 60 minutes on alternated days.
62839279|NCT04129567|EXPERIMENTAL|Humidified oxygen|Delivering humidified oxygen at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
62614387|NCT03073356|EXPERIMENTAL|HFrEF - Right heart catheterization|Patients with heart failure (HFrEF) N=12
62614388|NCT03073356|EXPERIMENTAL|HFrEF - Right heart catheterization study 2|Dose finding study (increasing dosage of 3-OHB)
62614389|NCT03383094|ACTIVE_COMPARATOR|Control-radiotherapy/cisplatin|Intensity-modulated radiation therapy to 70 Gy in 33-35 fractions over 6.5 weeks plus concurrent cisplatin 100 mg/m2 every 3 weeks for 3 cycles (7 weeks)
62614390|NCT03383094|EXPERIMENTAL|Experimental-Radiotherapy/pembrolizumab|Intensity-modulated radiation therapy to 70 Gy in 33-35 fractions over 6.5 weeks plus concurrent and adjuvant pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles
62614391|NCT01438385||Interventional Endoscopy|Any group that went Interventional Endoscopy procedures.
62614392|NCT03304275|EXPERIMENTAL|Emergency Department vaccination group|Pertussis (Tdap) vaccine offered/administered in the Emergency Department
62614393|NCT03304275|EXPERIMENTAL|Public Health referral group|Public Health referral for Pertussis (Tdap) vaccine administration offered
62839280|NCT04129567|EXPERIMENTAL|Dry air|Delivering dry air at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
62839281|NCT04129567|PLACEBO_COMPARATOR|Humidified air|Delivering humidified air at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
62839282|NCT04129567|ACTIVE_COMPARATOR|Dry oxygen|Delivering dry oxygen at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
62839283|NCT02738385|EXPERIMENTAL|High Intensity Interval Training|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 300 kcal until the end of training.
62839284|NCT02738385|ACTIVE_COMPARATOR|Moderate Intensity Interval Training|Walking on a treadmill at 60-80% peak heart rate until expenditure of 300 kcal until the end of training.
62054961|NCT03073564|EXPERIMENTAL|Functional test|The functional test for upper limbs will be performed from protocol already published for the 6-min pegboard and ring test (6PBRT). In this stage the patients will perform the 6PBRT in usual breathing and as the use of the EPAP mask.
62614394|NCT01260272|ACTIVE_COMPARATOR|Alternative Snack Group|This group will receive 100 calorie alternative snack packs to consume three times a day with meals. Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables
62614395|NCT01260272|EXPERIMENTAL|Raisin Group|This group will receive raisins to consume three times a day with meals
62839285|NCT03860259|PLACEBO_COMPARATOR|Auriculotherapy without nitrogen gas|Auriculotherapy will be performed by certified research staff using a cryopuncture device in the post-anesthesia recovery room with an empty cryopuncture with no nitrogen gas. The patient will receive an interscalene nerve block, standard of care treatment for surgery, post-operative pain management, and physical therapy.
62839286|NCT03860259|ACTIVE_COMPARATOR|Auriculotherapy with nitrogen gas|Auriculotherapy will be performed by certified research staff using a cryopuncture device in the post-anesthesia recovery room with nitrogen gas. The patient will receive an interscalene nerve block, standard of care treatment for surgery, post-operative pain management, and physical therapy.
62614396|NCT00579332|PLACEBO_COMPARATOR|1|one a day placebo
62614397|NCT00579332|EXPERIMENTAL|2|Brassica intake
62054962|NCT05836870|EXPERIMENTAL|Group A-Enhanced Usual Care|Participants will be given general recommendations to increase physical activity and improve nutrition before surgery.
62614398|NCT00579332|EXPERIMENTAL|3|indole-3-carbinol supplement
62054963|NCT05836870|EXPERIMENTAL|Group B-Tele-supervised resistance exercises|Participants will take part in a monitored exercise program. The study team will provide more instructions and information about the program
62257271|NCT01981655|EXPERIMENTAL|0.5M Sodium lactate|A bolus of 0.5M Sodium lactate of 3 ml per kg body weight (BW) is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
62614399|NCT02215109||BRVO, Retinal vessel diameter|The retinal vessel diameter was measured Branch Retinal Vein Occlusion patients after intravitreal bevacizumab injection.
62839287|NCT03176706||Lebanese pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in the Lebanon.
62257272|NCT01981655|ACTIVE_COMPARATOR|Hartmann's solution|Hartmann's solution of 3 ml per kg BW is administered in 15 minutes. There is NO continuous infusion infused thereafter; i.e. in total 3 ml per kg over 24 hours
62839288|NCT03176706||Thai pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Thailand.
62257273|NCT01188200|EXPERIMENTAL|Nutritional Formula #M979|nutritional formula
62257274|NCT01188200|ACTIVE_COMPARATOR|Regular standard meal|standard meal
62257275|NCT04262687|EXPERIMENTAL|Immunotherapy + chemotherapy|Xelox bevacizumab plus pembrolizumab every 3 weeks up until disease progression, unacceptable toxicity, refusal by the patient, withdrawal of consent, pregnancy or decision by the investigator.
62054964|NCT03562065|EXPERIMENTAL|mesenchymal stem cells|"Phase I-II, Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:~* 1.10\^6 CSM / kg~* 2.10\^6 CSM / kg~* 4.10\^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion"
62054965|NCT02203708|ACTIVE_COMPARATOR|BPD prevention|Supportive Program for Mother with BPD (SuPMother-B) : BPD mothers participate to prevention program in groups or/and house calls.
62054966|NCT02203708|NO_INTERVENTION|Usual care of BPD mothers|BPD mothers don't participate to Supportive Program (SuPMother-B).
62257276|NCT01793142||Viviant treatment group|Viviant treatment group
62839289|NCT03176706||South African pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in South Africa.
62054967|NCT03888339|ACTIVE_COMPARATOR|Control group - Commercially available high abutments|Commercially available 2.5mm high abutments
62257277|NCT03497481||Neopterin Dosage|Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis
62257278|NCT00591097||pediatric|
62257279|NCT06451445|EXPERIMENTAL|IRE Treatment Arm|All patients enrolled in this trial will receive IRE treatment with the NanoKnife System.
62614400|NCT05233579|EXPERIMENTAL|Sulforaphane 1 Tablet|Participants are taking 1 tablet per day. All participants will start with 1 tablet and continue with 1 tablet for 2 weeks before increasing dose.
62614401|NCT05233579|EXPERIMENTAL|Sulforaphane 2 Tablets|Participants will increase dosage to 2 tablets per day after 2 weeks from the start of study participation. Participants will continue to take 2 tablets for 2 addiitonal weeks before increasing dose. If participants experience adverse side effects, participants will decrease dosage to 1 tablet.
62614402|NCT05233579|EXPERIMENTAL|Sulforaphane 3 Tablets|Participants will increase dosage to 3 tablets per day at 4 weeks from the start of study participation. Participants will continue to take 3 tablets for 2 addiitonal weeks before increasing dose. If participants experience adverse side effects, participants will decrease dosage to 2 tablets.
62054968|NCT03888339|EXPERIMENTAL|Test group - Modified shape abutments|Modified shape 2.5mm high abutments (imitating the shape of 0.5mm short abutments)
62054969|NCT03123848|EXPERIMENTAL|Darunavir/Cobicistat FDC (Prezcobix)|Participants will receive one darunavir/cobicistat fixed-dose combination (FDC) tablet, containing 800 milligram (mg) of darunavir (DRV) and 150 mg of cobicistat (COBI) in the morning on Day 1.
62054970|NCT00429663|OTHER|IM Nails|Reamed, Interlocking Intramedullary Nail - Randomized treatment
62054971|NCT00429663|OTHER|Plate Fixation|Locking Periarticular Plate - Randomized Treatment
62614403|NCT05233579|EXPERIMENTAL|Sulforaphane 4 Tablets|Participants will increase dosage to 4 tablets per day at 6 weeks from the start of study participation. Participants will continue to take 4 tablets for 2 addiitonal weeks before increasing dose. If participants experience adverse side effects, participants will decrease dosage to 3 tablets.
62839290|NCT03176706||New Zealand pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in New Zealand.
62839291|NCT03176706||Swedish Pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Sweden.
62054972|NCT00021814|PLACEBO_COMPARATOR|Placebo|Doxazosin and Finasteride placebos
62257280|NCT02414399|EXPERIMENTAL|Azithromycin|Azithromycin 10mg/kg for one day, then 5mg/kg for four days, a total of five days of experimental treatment.
62054973|NCT00021814|EXPERIMENTAL|Doxazosin|Doxazosin and Finasteride placebo
62054974|NCT00021814|EXPERIMENTAL|Finasteride|Doxazosin placebo and Finasteride
62257281|NCT02414399|PLACEBO_COMPARATOR|Placebo|5 days of taste/appearance/bottle-matched placebo
62257282|NCT00146315|ACTIVE_COMPARATOR|Control|Secondary prevention program for coronary heart disease
62839292|NCT03176706||Peruvian pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Peru.
62054975|NCT00021814|EXPERIMENTAL|Combination|Doxazosin and Finasteride
62054976|NCT04149925||AEON Endostapler|Stapling performed by AEON Endostapler
62054977|NCT04149925||Echelon Flex Powered Stapler|Stapling performed by Echelon Flex Powered Stapler
62054978|NCT01133158|EXPERIMENTAL|R-BMD|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone Induction: 6 Rituximab, Bendamustine, Mitoxantrone, Dexamethasone cycles Maintenance: Rituximab every 3 months for 2 years
62054979|NCT00263328|ACTIVE_COMPARATOR|Treatment group 1|Standard of care
62054980|NCT00263328|EXPERIMENTAL|Treatment group 2|Treatment group 2 also receives mycophenolate mofetil
62054981|NCT00263328|EXPERIMENTAL|Treatment group 3|Treatment group 3 does not receive mycophenolate mofetil
62257283|NCT00146315|EXPERIMENTAL|Supervised exercise|
62257284|NCT01989403||Lumbar disc herniation patients|LBP with sciatica, with a numeral rating scale (NRS) leg pain intensity of 5 or higher and onset within 1 year; (2) LDH confirmed by MRI
62839293|NCT03176706||Russian pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Russia.
62839294|NCT01707732|ACTIVE_COMPARATOR|Enoxaparin 40mg/ day|Enoxaparin administrated at the following dose : 40mg/ day
62839295|NCT01707732|EXPERIMENTAL|Enoxaparin 60 mg/day|Enoxaparin administrated at the following dose : 60 mg/day
62054982|NCT02768610|EXPERIMENTAL|dexmedetomidine|0.5 mcg/kg dexmedetomidine is administered before endotracheal intubation for 10 minutes
62257285|NCT04206605|PLACEBO_COMPARATOR|Placebo|Participants received placebo-matching lanadelumab subcutaneous (SC) injection once every 2 weeks (q2w) for up to 7 months.
62839296|NCT01157403|EXPERIMENTAL|mesenchymal stem cells|To study the safety and efficacy of autologous transplantation of bone marrow mesenchymal stem cells in treatment of newly diagnosed patients with T1DM.
62839297|NCT00882557|EXPERIMENTAL|A|9 mg/kg of daptomycin administered during the last 30 minutes of a hemodialysis session.
62839298|NCT00882557|EXPERIMENTAL|B|Post dialysis dosing
62839299|NCT01637129|ACTIVE_COMPARATOR|Magnetic Stimulation|Active Magnetic Stimulation with repetitive transcranial magnetic stimulation
62839300|NCT01637129|PLACEBO_COMPARATOR|No Intervention|Sham Magnetic Stimulation
62839301|NCT03172988|EXPERIMENTAL|Dexamethasone and flurbiprofen axetil|Dexamethasone 10 mg is administered before anesthesia induction. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
62839302|NCT03172988|EXPERIMENTAL|Dexamethasone and lipid microsphere|Dexamethasone 10 mg is administered before anesthesia induction. Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
62839303|NCT03172988|EXPERIMENTAL|Normal saline and flurbiprofen axetil|Normal saline 2 ml is administered before anesthesia induction. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
62839304|NCT03172988|PLACEBO_COMPARATOR|Normal saline and lipid microsphere|Normal saline 2 ml is administered before anesthesia induction. Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
62839305|NCT02354430|ACTIVE_COMPARATOR|Water-exercise|
62054983|NCT02768610|PLACEBO_COMPARATOR|Normal Saline|
62839306|NCT02354430|NO_INTERVENTION|Control group|
62839307|NCT01281800|ACTIVE_COMPARATOR|Cisplatin with pemetrexed|
62839308|NCT01281800|EXPERIMENTAL|Cisplatin with gemcitabine in long infusion|
62839309|NCT01137838||Patients with RA and new to abatacept|
62839310|NCT01137838||Patients with RA and new to infliximab|
62054984|NCT02561286|EXPERIMENTAL|HIV risk reduction|BRO HIV Risk Reduction Intervention
62054985|NCT02561286|ACTIVE_COMPARATOR|Health promotion control|Health Promotion Intervention
62054986|NCT02994914|EXPERIMENTAL|Score of the Onco Geriatric Evaluation between 200 et 160|According to the score obtained with the onco geriatric evaluation, patients with a score between 200 and 160 will receive a normo fractionated radiotherapy (66 Grays in 33 fractions). This scheme of radiotherapy is already used in the clinical practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
62054987|NCT02994914|EXPERIMENTAL|Score of the Onco Geriatric Evaluation between 159 et 120|According to the score obtained with the onco geriatric evaluation, patients with a score between 159 and 120 will receive an hypo fractionated radiotherapy (42,56 Grays in 16 fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
62257286|NCT04206605|EXPERIMENTAL|Lanadelumab 300mg|Participants received 300 mg of lanadelumab solution in a prefilled syringe (PFS) as SC injection once (q2w) for up to 6 months.
62257287|NCT00836628|EXPERIMENTAL|experimental|
62839311|NCT01137838||Patients with RA and new to etanercept|
62839312|NCT01137838||Patients with RA and new to adalimumab|
62839313|NCT01823952||Males|Adult 18-65
62839314|NCT02560558|EXPERIMENTAL|Belatacept 8-weekly|Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.
62839315|NCT02560558|ACTIVE_COMPARATOR|Belatacept 4-weekly|Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.
62839316|NCT01009216|EXPERIMENTAL|ABT-384|
62839317|NCT00804908|PLACEBO_COMPARATOR|Placebo for ABT-888 BID + TMZ QD|Placebo for ABT-888 twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
62839318|NCT00804908|ACTIVE_COMPARATOR|ABT-888 20 mg BID + TMZ QD|ABT-888 20 mg twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
62839319|NCT00804908|ACTIVE_COMPARATOR|ABT-888 40 mg BID + TMZ QD|ABT-888 40 mg twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
62614404|NCT05233579|EXPERIMENTAL|Sulforaphane 5 Tablets|Participants will increase dosage to 5 tablets per day at 8 weeks from the start of study participation. Participants will continue to take 5 tablets for 2 addiitonal weeks before increasing dose. If participants experience adverse side effects, participants will decrease dosage to 4 tablets.
62614405|NCT05233579|EXPERIMENTAL|Sulforaphane|Participants will increase dosage to 6 tablets per day at 10 weeks from the start of study participation. Participants will continue to take 6 tablets for 2 addiitonal weeks before increasing dose. If participants experience adverse side effects, participants will decrease dosage to 5 tablets.
62614406|NCT03181243|EXPERIMENTAL|MadaJet|Jet injector (Madajet medical Urology) preloaded as manufacturer's instruction
62614407|NCT03181243|EXPERIMENTAL|Needle injection|01 sterile 10-mL syringe with small gauge needle (25 ga), solution for sterile preparation, 10 - 15 mL Lidocaine 2%
62054988|NCT02994914|EXPERIMENTAL|Score of the Onco Geriatric Evaluation inferior to 119|According to the score obtained with the onco geriatric evaluation, patients with a score inferior to 119 will receive a large hypo fractionated radiotherapy (30 Grays in 5 weekly fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
62257288|NCT02878538|ACTIVE_COMPARATOR|deferiprone|Deferiprone will be administered three times a day (25mg/kg). Total dose per day will depend on participants' body weight for one, three month block.
62444405|NCT01411267|EXPERIMENTAL|AML AC220 @ 40mg/m2/day (Dose Level 2)|Dose escalation will proceed from level 1 to level 2 for AC220 at 40mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age.
62444406|NCT01411267|EXPERIMENTAL|AML AC220 @ 60mg/m2/day (Dose Level 3)|Dose escalation will proceed from level 2 to 3 for AC220 at 60mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. If toxicity at Dose Level 3 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
62614408|NCT00462176||1|All women (n=45) who had undergone CO2 laser laparoscopic radical excision of deep infiltrating endometriosis with active involvement of the colorectal surgeon performing a bowel resection were selected retrospectively from the list of all patients (n=more than 400) operated at the Leuven University Fertility Centre (LUFc) between September 2004 and July 2006.
62614409|NCT03299725|EXPERIMENTAL|Treatment arm|
62839320|NCT06208280|EXPERIMENTAL|Assigned Interventions|
62839321|NCT05171556||RV4942A arm|RV4942A study product is applied twice a day (morning and evening) on the face, neck and eye contour during the whole study.
62839322|NCT04276948|EXPERIMENTAL|Active1|312 mg dose of active
62839323|NCT04276948|EXPERIMENTAL|Active2|812 mg dose of active
62054989|NCT00823784|EXPERIMENTAL|1THD group|Series of 135 patients with 3rd degree Hemorrhoids treated by THD device under spinal anaesthesia
62054990|NCT00823784|ACTIVE_COMPARATOR|2 stapler group|135 patients with 3rd degree hemorrhoids will be treated by staple hemorrhoidopexy
62257289|NCT02878538|PLACEBO_COMPARATOR|Placebo Phase|Placebo tablets with inactive substance will be used. Total number of placebo tablets will be equivalent to the active tablets administered depending on participants' body weight for two, three month blocks.
62444407|NCT01411267|EXPERIMENTAL|AML AC220 @ 90mg/m2/day (Dose Level 4)|If the study dose of 60 mg/m2/day at Dose Level 3 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 4 at 90 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. If toxicity at Dose Level 4 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
62623625|NCT02975531|EXPERIMENTAL|Parameterization technique|Five physiotherapists (GP) with at least 5 years of experience in the technique were selected to perform the technique on the simulator and complete a questionnaire in order to evaluate the texture and skin elasticity, the curvature and size of the cervical spine format. They scored these items from the Likert scale. After evaluation they used the simulator to generate a standard guide training.
62839324|NCT04276948|PLACEBO_COMPARATOR|Placebo|placebo
62839325|NCT05401097|EXPERIMENTAL|Arm A (IDHi+Aza followed by Ven+aza)|For IDH1 mutated AML patients randomized to first-line therapy with IDHi+aza, patients will receive Ivosidenib 500mg po orally daily on Days 1-28 of each 28 day cycle. For IDH2 mutated AML patients randomized to first-line therapy with IDHi+aza, patients will receive Enasidenib 100mg po orally daily on Days 1-28 of each 28 day cycle. Azacitidine will be given to both groups intravenously or subcutaneously at 75mg/m2 daily on days 1-7 or 1-5/8-9 of each 28 day cycle. Subsequent cycles after CR/CRi/CRh/MLFS achievement may be adjusted in timing and dosing.
62839326|NCT05401097|EXPERIMENTAL|Arm B (Ven+aza followed by IDHi+aza)|For both IDH1 and IDH2 mutated AML patient randomized to first-line therapy with Ven+aza, patients will receive venetoclax dosing with the ramp-up and dosing per the FDA-label (based off of concurrent drug interactions). Azacitidine will be given intravenously at 75mg/m2 daily on days 1-7 of each 28-day cycle. Subsequent cycles after CR/CRi/CRh/MLFS achievement may be adjusted in timing and dosing.
62054991|NCT01242748|EXPERIMENTAL|Degarelix 240 mg/480 mg|
62054992|NCT01242748|ACTIVE_COMPARATOR|Goserelin acetate|
62257290|NCT04501770|EXPERIMENTAL|M802|Subjects who meet the enrollment criteria will enter the core treatment period and receive a cycle of treatment with M802 (once weekly for 4 weeks) via intravenous infusion. And eligible subjects who complete the core treatment period will receive a cycle of extended treatment (once weekly for 4 weeks) until disease progression or toxicity intolerance.
62257291|NCT00501371|ACTIVE_COMPARATOR|MCS|Group A: MCS 30 mg/day for 12 weeks
62444408|NCT01411267|EXPERIMENTAL|AML AC220 @ 130mg/m2/day (Dose Level 5)|If the study dose of 90 mg/m2/day at Dose Level 4 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 5 at 130 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. Dose Level 5 is the highest dose for this study.
62444409|NCT01797471|EXPERIMENTAL|LEAD RT|"* Lattice Extreme Ablative Dose (LEAD) Radiation Therapy (RT) on Day 1 at dose of 18 Gy followed by;~* Conventionally fractionated radiation therapy beginning on day 2 at 2 Gy per fraction for 30 fractions for a total dose of 60 Gy;~* Conventional Platinum Chemotherapy Doublet at discretion of treating physician beginning on day 2."
62444410|NCT01664689|ACTIVE_COMPARATOR|DiscoVisc|microcoaxial phacoemulsification performed with discovisc
62839327|NCT00526071|EXPERIMENTAL|Migalastat|Migalastat was administered orally, 150 mg QOD, 250 mg QD for 3 days, 4 days off per week for 2 months, or 500 mg QD for 3 days, 4 days off per week for up to 10 months, depending on the approval date of the protocol amendments at each site. Participants received migalastat for up to 56 months.
62839328|NCT01130480|EXPERIMENTAL|A|
62839329|NCT06432218|EXPERIMENTAL|the conventional education plus video education group|Watch video as well as receive conventional guidance.
62257292|NCT00501371|PLACEBO_COMPARATOR|Placebo|Placebo, 2 capsules per day
62614410|NCT02012959|EXPERIMENTAL|Tolvaptan Early Withdrawal|"All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment.~At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 millimoles/liter \[mmol/L\]) were randomized to either the Early or Late Withdrawal Group. Non-responders could continue treatment with tolvaptan for an additional 2 days.~Discontinued tolvaptan treatment immediately after randomization.~All participants were observed up to 14 days post randomization."
62623626|NCT02975531|EXPERIMENTAL|Simulator training|Twenty-six volunteers (GE) were selected, men and women, aged over 18 years without prior knowledge of the technique for simulator training.
62257293|NCT01017003|EXPERIMENTAL|1|0.6mg colchicine tablet
62444411|NCT01664689|ACTIVE_COMPARATOR|Healon 5|microcoaxial phacoemulsification using healon 5
62444412|NCT01664689|ACTIVE_COMPARATOR|Celoftal|microcoaxial phacoemulsification using celoftal
62839330|NCT06432218|ACTIVE_COMPARATOR|the conventional education group|Receive conventional guidance.
62839331|NCT03553693|EXPERIMENTAL|Intervention Clinics|RAPID-VL study intervention testing and counseling package, which includes near point-of-care viral load (VL) testing at local testing hubs, structured VL counseling, forms to track VL ordering and testing, with feedback and performance evaluations at regular intervals.
62839332|NCT03553693|NO_INTERVENTION|Control Clinics|Standard of care VL testing and counseling procedures consistent with country guidelines.
62054993|NCT02920697|EXPERIMENTAL|B-cell Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)|
62257294|NCT01017003|EXPERIMENTAL|2|colchicine 0.6mg q12 hours for 10 days
62444413|NCT03414866||Acute thoracic aortic syndrome|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
62623627|NCT02975531|EXPERIMENTAL|Training Evaluation|A physical therapist (VE) was selected to evaluate the volunteers (GE) before and after training in the simulator.
62839333|NCT02824653|EXPERIMENTAL|Mesenchymal Stem Cells|The experimental arm is comprised of GVHD patients receiving allogenic bone marrow mesenchymal stem cells
62054994|NCT02920697|EXPERIMENTAL|Chronic Lymphocytic Leukaemia (CLL)|
62054995|NCT01590290|ACTIVE_COMPARATOR|pay for performance|
62054996|NCT01590290|NO_INTERVENTION|no pay for performance|
62054997|NCT00304512|EXPERIMENTAL|Migalastat Low Dose 50 mg|Migalastat 50 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
62054998|NCT00304512|EXPERIMENTAL|Migalastat Middle Dose 150 mg|Migalastat 150 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
62257295|NCT00929877|EXPERIMENTAL|Ketoprofen lysinate 12.5 mg|
62257296|NCT00929877|EXPERIMENTAL|Ketoprofen lysinate 6.25 mg|
62257297|NCT00929877|PLACEBO_COMPARATOR|Matching placebo|
62257298|NCT03291223||GOS Participants|GOS is a disease specific registry open to all Gaucher patients irrespective of treatment status or type of treatment
62444414|NCT03414866||Subacute/chronic dissection of the aorta|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
62839334|NCT04876469|ACTIVE_COMPARATOR|Radiocontrast media group|"Pulsed radiofrequency (PRF) treatment will be applied to the dorsal root ganglion (DRG) by fluoroscopy-guidance at the level of nerve root compression due to disc herniation (L5 level) in both groups.~In patients in the Radiocontrast media group, contrast material will be given before the application, and primarily the localization of the DRG will be determined. After this stage, the needle will be directed towards the detected localization. Finally, the localization of the dorsal root ganglion will be confirmed by sensory and motor stimuli."
62839335|NCT04876469|ACTIVE_COMPARATOR|Non-radiocontrast media group|"Pulsed radiofrequency (PRF) treatment will be applied to the dorsal root ganglion (DRG) by fluoroscopy-guidance at the level of nerve root compression due to disc herniation (L5 level).~In patients in the Non-radiocontrast media group, the localization of the dorsal root ganglion will be determined just by sensory and motor stimuli."
62839336|NCT05256199|EXPERIMENTAL|high-intensity group|The high intensity group receives a personalized, supervised intervention consisting of group meetings and individual sessions.
62839337|NCT05256199|NO_INTERVENTION|low-intensity group|The low-intensity arm receives online access to general lifestyle-related health information.
62839338|NCT04510961|ACTIVE_COMPARATOR|Paraffin baths therapy (PBT) :group A|Patients in treatment group will receive paraffin wax baths for five days per week for 12 weeks.
62839339|NCT04510961|NO_INTERVENTION|Control group (B)|receive routine skin care program ; lifestyle change, emollients and moisturizers
62839340|NCT01723319|EXPERIMENTAL|1|deep TMS treatment
62839341|NCT01723319|SHAM_COMPARATOR|2|inactive treatment
62839342|NCT01833247||Epilepsy inpatients|Patients with epilepsy recorded in an inpatient video-EEG monitoring unit after a seizure.
62839343|NCT02324348|PLACEBO_COMPARATOR|Immediate coronary stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, stent implantation is done on the initial procedure in immediate coronary stenting group
62054999|NCT00304512|EXPERIMENTAL|Migalastat High Dose 250 mg|Migalastat 250 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
62257299|NCT02428855|EXPERIMENTAL|Dasatinib|"Patients with advanced intrahepatic cholangiocarcinoma who have either IDH1 or IDH2 mutations and have received at least one prior platinum containing regimen~* Dasatinib, oral, daily, predetermined dosage per cycle~* Radiologic Response Assessment every 2 cycles"
62257300|NCT00871182|EXPERIMENTAL|PT001 18 mcg|Inhaled PT001 18 mcg
62257301|NCT00871182|EXPERIMENTAL|PT001 36 mcg|Inhaled PT001 36 mcg
62257302|NCT00871182|EXPERIMENTAL|PT001 72 mcg|Inhaled PT001 72 mcg
62257303|NCT00871182|EXPERIMENTAL|PT001 144 mcg|Inhaled PT001 144 mcg
62257304|NCT00871182|PLACEBO_COMPARATOR|Inhaled Placebo|Inhaled Placebo
62257305|NCT00871182|ACTIVE_COMPARATOR|Tiotropium Handihaler|Tiotropium 18 mcg administered via Handihaler
62257306|NCT03963414|EXPERIMENTAL|Cohort 1|Durvalumab 1500 mg via IV infusion every 3 weeks, starting on Week 7, for up to a maximum of 2 doses/cycles followed by durvalumab maintenance monotherapy 1500 mg via IV infusion every 4 weeks, starting 4 weeks after Cycle 4.
62257307|NCT03963414|EXPERIMENTAL|Cohort 2|Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion every 3 weeks, starting on Week 7, for up to a maximum of 2 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion every 4 weeks, starting 4 weeks after the last infusion of the combination.
62257308|NCT01908270|EXPERIMENTAL|Yoga|Yoga intervention 12 weeks, weekly 90-minute intervention Yoga postures, breathing, relaxation, and meditation
62257309|NCT01908270|OTHER|Usual care|Patients continue usual care by their practitioner
62257310|NCT01498055||CIK therapy group|
62444415|NCT03414866||Aortic aneurysm|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
62444416|NCT03854084|EXPERIMENTAL|Intervention group|The cranial osteopathic techniques
62444417|NCT03854084|SHAM_COMPARATOR|control group|Control group
62444418|NCT03577236|EXPERIMENTAL|Zenflow Spring System|Receives treatment with the investigational device
62839344|NCT02324348|ACTIVE_COMPARATOR|Deferred coronary stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, only TIMI Ⅲ flow achievement is done on the initial procedure and stent implantation is deferred after 5-7 days admission in the deferred coronary stenting group.
62839345|NCT05034939|ACTIVE_COMPARATOR|FLEX Vessel Prep System followed with PTA (TEST arm)|FLEX Vessel Prep System is used to create circumferential, continuous micro-incisions along the length of the stenosis by performing a retrograde pullback through the lesion. Following FLEX, standard balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding instructions for use. Once advanced to the lesion, the balloon should be inflated according to the site's standard of care.
62839346|NCT05034939|ACTIVE_COMPARATOR|PTA only (CONTROL arm)|Standard Balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding instructions for use. Once advanced to the lesion, the balloon should be inflated according to the site's standard of care.
62839347|NCT06292208|EXPERIMENTAL|IBD0333|
62055000|NCT02756754|EXPERIMENTAL|Radiofrequency ablation|"Radiofrequency ablation (RFA) is a minimally invasive technique for eliminating both primary tumors and metastases.~The needles that will be used are monopolar RFA, the LeVeen™ Needle Electrode Family with a generator RF 3000 by Boston Scientific. The radiofrequency system will be used as the RFA generator device standard cycle of ablation will be applied in the patient. During RFA, blood pressure, pulse and oxygen saturation will be continuously monitored."
62055001|NCT05042089||pathological tumor stage 1-2 (pT1-2)|Stage pT1 and pT2 according to pathology results of patients who underwent partial or radical nephrectomy.
62257311|NCT01498055||control group|
62257312|NCT00632658||Patients with cGVHD|Pediatric Patients with cGVHD will be asked to participate in an interview with their Physician. The interview will ask the pediatric patients questions about their cGVHD. The interview will be audio-recorded.
62257313|NCT05937178||Recommend to initiate treatment in 2022 Chinese Guideline, but not in 2019 Chinese Guideline|Untreated population who does not be recommended to initiate treatment in 2022 Chinese Guideline, but not in 2019 Chinese Guideline. The initate treatment is to receive a first-line nucleos(t)ide analogue, i.e., entecavir, tenofovir disoproxil, or tenofovir alafenamide, tenofovir amibufenamide
62257314|NCT05937178||Recommend to initiate treatment in 2019 and 2022 Chinese Guideline, but not in AASLD/EASL guidelines|Untreated population will receive a first-line nucleos(t)ide analogue , i.e., entecavir, tenofovir disoproxil, or tenofovir alafenamide, tenofovir amibufenamide, and the population should meet the conditions that are recommended to initiate treatment in 2019 and 2022 Chinese guideline, but not in AASLD/EASL guidelines
62257315|NCT05937178||Treatment experienced and with partial response|Treatment experienced population who has received a first-line nucleos(t)ide analogue(NA) as monotherapy at least 48 weeks, i.e., entecavir, tenofovir disoproxil, or tenofovir alafenamide, tenofovir amibufenamide, and has partial response to NA. They will continue the original therpay or plans to change the therapy (e.g. switch another first-line NA, add-on another first-line NA, switch another first-line NA and add-on peginterferon alpha)
62257316|NCT06354114|EXPERIMENTAL|SYHX2011|Subjects will be administrated with SYHX2011 once every 3 weeks.
62257317|NCT00881127|EXPERIMENTAL|1|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)
62257318|NCT00881127|ACTIVE_COMPARATOR|2|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
62257319|NCT06240000|OTHER|Radiofrequency ablation|
62257320|NCT06240000|NO_INTERVENTION|conventional physical therapy|
62257321|NCT02830776|EXPERIMENTAL|Treatment group|This is a single-arm open label proof of concept pilot study evaluating use of Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping).
62839348|NCT03163303|EXPERIMENTAL|Tobacco Status Project (TSP) + Alcohol Intervention|Tobacco and alcohol intervention on Facebook and 14-day nicotine patch
62257322|NCT04101565|EXPERIMENTAL|Text4Father|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of baby's age.
62257323|NCT04101565|NO_INTERVENTION|Usual care|Usual care that is consistent with typical maternity care in involving expectant fathers.
62257324|NCT05262699|EXPERIMENTAL|Stimulation|During motor training participants in the stimulation arm receive vibro-tactile feedback applied to their fingers when touching an object as measured by force-sensing resistors mounted to the fingertips.
62257325|NCT05262699|PLACEBO_COMPARATOR|Control|The control group receives the same motor training with the same derives (force-sensing resistors, vibro-tactile stimulators) mounted to the hands but receives no stimulation.
62257326|NCT00336219|ACTIVE_COMPARATOR|1|Pantoprazole 40 mg
62257327|NCT05141370|EXPERIMENTAL|hand-held femtosecond laser|Anterior capsulorhexis will be performed with a hand-held femtosecond laser named CATSYS.
62257328|NCT06538948||Adult Females planned for RYGB surgery|Adult females leaving with obesity with BMI between 35 and 50 kg/m2 and scheduled for Roux-en-Y Gastric Bypass Surgery
62839349|NCT03163303|EXPERIMENTAL|Tobacco Status Project Intervention|Tobacco intervention on Facebook and 14-day nicotine patch
62839350|NCT03622788|EXPERIMENTAL|Treatment (chemotherapy, PBSCT, cytokine-treated veto cells)|"CONDITIONING REGIMEN: Patients receive ATG IV over 4 hours on days -9 to -7, and fludarabine IV over 1 hour on days -6 to -3, then undergo TBI on day -1.~TRANSPLANT: Patients undergo PBSCT IV over 30-60 minutes on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days +3 and +4 and cytokine-treated veto cells IV over 30-60 minutes on day +7."
62839351|NCT04555616|PLACEBO_COMPARATOR|Control Group|Alzheimer's disease patients and caregivers.
62839352|NCT04555616|EXPERIMENTAL|Standard Environmental Design|Alzheimer's disease patients and caregivers.
62055002|NCT05042089||pathological tumor stage ≥pT3a|Stage ≥pT3a according to pathology results of patients who underwent partial or radical nephrectomy.
62055003|NCT06151535|EXPERIMENTAL|ELAPR002f Injectable Gel|Participants will receive 3 treatment sessions 1 month apart of ELAPR002f injectable gel and will be followed for 4 months.
62055004|NCT02933801|EXPERIMENTAL|Arm A: ODM-201|600mg ODM-201 BID (twice daily) and Best Supportive Care until progression
62257329|NCT06538948||Adult Females planned for SG surgery|Adult females leaving with obesity with BMI between 35 and 50 kg/m2 and scheduled for Sleeve Gastrectomy Surgery
62839353|NCT04555616|EXPERIMENTAL|Individualized Environmental Design Protocol|Alzheimer's disease patients and caregivers.
62839354|NCT01684293|EXPERIMENTAL|Cognitive Rehabilitation|Occupational therapy-based cognitive rehabilitation
62839355|NCT01684293|PLACEBO_COMPARATOR|Psychoeducation/games|Psychoeducation/games
62839356|NCT03702153|EXPERIMENTAL|Infected abdominal wall group|A cohort of 40 patients carrying an active chronic mesh infection (mesh sinus, exposed mesh or mesh related enteric fistulas) resulting from a previous hernia repair, with or without an associated recurrent ventral hernia, and submitted to abdominal wall reconstruction with synthetic mesh.
62257330|NCT06538948||Adult Females with Obesity|Adult females leaving with obesity with BMI between 30 and 50 kg/m2 but not scheduled for any procedures of bariatric surgery
62614411|NCT02012959|EXPERIMENTAL|Tolvaptan Late Withdrawal|"All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment.~At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 mmol/L) were randomized to either the Early or Late Withdrawal Group in Treatment Phase B. Non-responders could continue treatment with tolvaptan for an additional 2 days.~Continued treatment for 2 additional days.~All participants were observed up to 14 days post randomization."
62257331|NCT06538948||Adult Females with Normal-Weight|Adult females with normal weight with BMI between 18.5 and 24.9 kg/m2
62257332|NCT06538948||Adult Males planned for RYGB surgery|Adult males leaving with obesity with BMI between 35 and 50 kg/m2 and scheduled for Roux-en-Y Gastric Bypass Surgery
62257333|NCT06538948||Adult Males with Obesity|Adult males leaving with obesity with BMI between 30 and 50 kg/m2 but not scheduled for any procedures of bariatric surgery
62055005|NCT02933801|PLACEBO_COMPARATOR|Arm B: Placebo|Placebo BID (twice daily) and Best Supportive Care until progression
62257334|NCT06538948||Adult Males with Normal-Weight|Adult males with normal weight with BMI between 18.5 and 24.9 kg/m2
62257335|NCT06538948||Adult Females and Males 5 years after RYGB surgery|Adult Females and Males who underwent RYGB surgery 5 years before study recruitment and study measurements
62257336|NCT06156683||Kesimpta-exposed|exposure to Kesimpta during the risk period
62839357|NCT03702153|ACTIVE_COMPARATOR|Clean control group|A cohort of 40 patients with ventral hernias, and submitted to clean ventral hernia repair with synthetic mesh.
62257337|NCT06156683||MSDMD-exposed|exposure to at least one Multiple sclerosis disease modifying drug (MSDMD) (other than Kesimpta) during the risk period
62257338|NCT06156683||MSDMD-unexposed|no exposure to Kesimpta or any other Multiple sclerosis disease modifying drug (MSDMD) during the risk period
62614412|NCT02968680|EXPERIMENTAL|Diagnostic (sonazoid, ultrasound imaging, SLNB)|Patients receive sonazoid ID and undergo ultrasound imaging. Patients also undergo standard of care SLNB.
62839358|NCT01579929|EXPERIMENTAL|LDE225, Etoposide and Cisplatin|This is a single institution phase I trial of LDE225 combined with etoposide and cisplatin in patients with untreated, newly diagnosed extensive stage small cell lung cancer (ES-SCLC). LDE225 is an oral drug, which will be taken daily by patients. Patient self-reporting via STAR will be used in an evaluation of the extent to which patient-reported toxicity influences dose finding in phase I clinical trials. Specifically, STAR reports will be presented to clinicians in real-time at clinic visits, \& clinicians will have an opportunity to either agree or modify the patient self-assessments \& use this information in their grading \& attribution of toxicities.
62839359|NCT02136069|EXPERIMENTAL|Etrolizumab + Placebo (IV)|Participants will receive ertolizumab (SC) Q4W until Week 52 along with placebo matched to infliximab as IV infusion until Week 46.
62257339|NCT06061315|EXPERIMENTAL|Collagen peptide group|This group will consume 1 serving of Collagen peptides, which is produced and marketed ® by GELITA AG, Germany under the brand name BODYBALANC each day.
62257340|NCT06061315|PLACEBO_COMPARATOR|Placebo group|This group will consume 1 serving of silicon dioxide (Sipernat 350, Evonik, Germany) each day. The product is absorbed in negligible amounts by the intestine and does therefore induce minor metabolic effects.
62257341|NCT03863600||Midwife-led continuity of care|Women receiving midwife-led model of care though the continuum of pregnancy, birth and postnatal period, and who registered at the governmental clinic in a rural village.
62257342|NCT03863600||Regular care|Women receiving regular maternal care through the continuum of pregnancy, birth and postnatal period, and who registered at the governmental clinic in a rural village.
62257343|NCT02592551|EXPERIMENTAL|MEDI4736|8 patients will receive an infusion of MEDI4736 (15 mg/kg intravenously, once), one to six weeks prior to surgical resection.
62257344|NCT02592551|ACTIVE_COMPARATOR|MEDI4736 + Tremelimumab|8 patients will receive an infusion of MEDI4736 (1500 mg intravenously, once) + tremelimumab (75mg intravenously, once), one to six weeks prior to surgical resection.
62257345|NCT02592551|PLACEBO_COMPARATOR|Untreated arm (control)|4 patients will not receive MEDI4736 or Tremelimumab.
62257346|NCT04996173|PLACEBO_COMPARATOR|Control|Bronchoscopic Balloon Dilation with Radial Cuts
62614413|NCT01846468|EXPERIMENTAL|Stage 1 : LHW090, Healthy Volunteers|Healthy Volunteers will receive single dose of LHW090 on Day 1.
62614414|NCT01846468|EXPERIMENTAL|Stage 2: LHW090, Healthy Volunteer|Healthy Volunteers across 7 single ascending dose cohorts will be administered LHW090 or matching placebo day 1
62614415|NCT01846468|EXPERIMENTAL|Stage 3: LHW090, Healthy Volunteer|Healthy Volunteers across 6 multiple ascending dose cohorts will be administered LHW090 or matching placebo for 14 days.
62614416|NCT01846468|EXPERIMENTAL|Stage 4: LHW090, Patients|Subjects with Chronic Renal Insufficiency across 3 cohorts will be administered a single dose of LHW090 in Day 1.
62614417|NCT05636072|EXPERIMENTAL|Treatment Immediately|Participants will engage in well-being tools immediately for 1-week.
62839360|NCT02136069|ACTIVE_COMPARATOR|Infliximab + Placebo (Injection)|Participants will receive IV infusion of infliximab at Weeks 0,2, and 6, then every 8 weeks until Week 46 partnered with placebo matched to etrolizumab by SC injection Q4W until Week 52.
62839361|NCT03008434|EXPERIMENTAL|Yoga Group|Yoga twice a week for 8 weeks focusing on balance and pain.
62839362|NCT01308437|EXPERIMENTAL|Wosulin (N or 70/30 with R)|Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
62839363|NCT01308437|ACTIVE_COMPARATOR|Novolin® (N or 70/30 with R)|Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
62839364|NCT04945928|EXPERIMENTAL|Surgery after conversion therapy|Participants with locally advanced or advanced NSCLC who received first-line treatment have been evaluated as resectable after multidisciplinary discussion involving the department of thoracic surgery, respiratory medicine, radiology and oncology.
62055006|NCT04665648|EXPERIMENTAL|Treatment arm|Patients who received intravenous nicorandil before and after reperfusion with primary percutaneous coronary intervention
62055007|NCT04665648|PLACEBO_COMPARATOR|Placebo arm|Patients who received intravenous placebo before and after reperfusion with primary primary percutaneous coronary intervention
62055008|NCT00958763|EXPERIMENTAL|Motivational Interviewing, Single - MIS|
62055009|NCT00958763|EXPERIMENTAL|Motivational Interviewing, Group - MIG|
62257347|NCT04996173|ACTIVE_COMPARATOR|Intervention|Bronchoscopic Balloon Dilation with Radial Cuts \& truFreeze Spray Cryotherapy
62257348|NCT03793465|EXPERIMENTAL|Tart Cherry Concentrate|Single arm, open-label design. Commercial Montmorency tart cherry juice concentrate. Servings (1 ounce or 2 tablespoon/serving) per day for three days
62257349|NCT04327687|EXPERIMENTAL|remote ischemic conditioning|remote ischemic conditioning is a physical strategy performed by an electric auto-control device with cuffs placed on bilateral arms: five cycles of 5-min inflation and 5-min deflation one or two times per day. The duration of the treatment is six months.
62257350|NCT04327687|ACTIVE_COMPARATOR|conventional therapy|conventional therapy
62257351|NCT06072521|ACTIVE_COMPARATOR|Lactoferrin bovine once a day|15 patients will be subjected to take 100mg of lactoferrin bovine in the form of sachets twice per day for 15 days.
62257352|NCT06072521|ACTIVE_COMPARATOR|Lactoferrin bovine twice a day|15 patients will be subjected to take 100mg of lactoferrin bovine in the form of sachets once per day for 15 days.
62257353|NCT06072521|NO_INTERVENTION|Control group|15 patients will be subjected to take only the standard treatment regimen that is applied at the National hepatology and tropical medicine research institute in Egypt.
62257354|NCT01641328|ACTIVE_COMPARATOR|Waitlist Control / Home-based training|This group will serve as a waitlist control group while the active group is performing training. Following assessment at the end of the active group period, this group will begin home-based training and will be assessed at the end of that 10 week period.
62257355|NCT01641328|EXPERIMENTAL|Cognitive Activation Group|This group will attend the 3/week group intervention meetings over 10 weeks.
62257356|NCT01298752|EXPERIMENTAL|Mapracorat|Mapracorat ophthalmic suspension
62257357|NCT01298752|PLACEBO_COMPARATOR|Vehicle|Vehicle of mapracorat ophthalmic suspension
62257358|NCT00362934|EXPERIMENTAL|1|
62444419|NCT06318650|EXPERIMENTAL|Allogenic Demineralized Dentin Matrix|Following atraumatic tooth extraction, curettes will be used to remove granulation tissues, and the socket will be irrigated with sterile normal saline.Then the socket will be filled with Allogeneic Dentin Matrix (that has been prepared before) to the crestal level of then bone followed by placement of a collagen membrane to cover the socket. Suturing technique will be a criss-cross horizontal mattress to ensure that most of the grafting material is covered.
62444420|NCT06318650|ACTIVE_COMPARATOR|Demineralized Freeze-Dried Bone Allograft|Following atraumatic tooth extraction, curettes will be used to remove granulation tissues, and the socket will be irrigated with sterile normal saline.Then the socket will be filled with Demineralized freeze-dried bone allograft (DFDBA) to the crestal level of then bone followed by placement of a collagen membrane to cover the socket. Suturing technique will be a criss-cross horizontal mattress to ensure that most of the grafting material is covered.
62444421|NCT04299854||Vaginal Dinoprostone|Induction of labor by 10mg of vaginal dinoprostone
62444422|NCT04299854||Single Balloon Foley Catheter|Induction of labor by single balloon Foley catheter
62444423|NCT06546644|EXPERIMENTAL|Intervention group|The children in the intervention group will receive a school-based structured health intervention to prevent obesity in children aged 5-12 years. A pre-tested validated structured school-based intervention is developed for children in the intervention group. The intervention included behavior change regarding dietary patterns and physical activity. Education will be provided to children in lectures, PowerPoint, smart handouts, and videos. The parents will also be involved in this educational stream through seminars and parent schools specially organized events.
62839365|NCT03247946|ACTIVE_COMPARATOR|Intervention group|intervention: upright head position
62257359|NCT00362934|ACTIVE_COMPARATOR|2|
62839366|NCT03247946|NO_INTERVENTION|Control group|no feeding position instructions
62839367|NCT02376699|EXPERIMENTAL|IV Monotherapy in Solid Tumors|SEA-CD40 administered IV
62839368|NCT02376699|EXPERIMENTAL|IV Monotherapy in Lymphomas|SEA-CD40 administered IV
62839369|NCT02376699|EXPERIMENTAL|Combination Therapy in Solid Tumors|SEA-CD40 (administered IV) + pembrolizumab
62839370|NCT02376699|EXPERIMENTAL|SC Monotherapy in Solid Tumors|SEA-CD40 administered SC
62055010|NCT00958763|OTHER|Usual Care Group - UCG|
62055011|NCT02010632|EXPERIMENTAL|Generic clopidogrel product|Apolets® 75 mg tablet
62055012|NCT02010632|ACTIVE_COMPARATOR|Original clopidogrel product|Plavix® 75mg tablet
62055013|NCT01865916|ACTIVE_COMPARATOR|2 Liters Bi-Peglyte|Subjects will be asked to take split dose of 2 Liters PEG + 15mg bisacodyl for bowel preparation the day before colonoscopy.
62055014|NCT01865916|EXPERIMENTAL|2 Liters Moviprep|Subject will be asked to take split dose of 2 Liters PEG + ascorbic acid for bowel preparation the day before colonoscopy
62257360|NCT00870220|EXPERIMENTAL|GH alone, Low dose E2 patch, Very Low-dose E2 patch|"Group 1: Growth hormone alone, no E2. Group 2: Growth Hormone plus Estradiol patch dose A(14 mcg/d x 10 d) x 6 months then Estradiol patch dose B(25 mcg/d x 10 d) x 6 months.~Group 3: Growth Hormone plus Estradiol patch dose B(25 mcg/d x 10 d) x 6 months then Estradiol patch dose C(25 mcg/d x 3 w) x 6 months."
62257361|NCT01378234|EXPERIMENTAL|EDPP Intervention|Receive EDPP transitional care intervention from social worker upon hospital discharge
62257362|NCT01378234|NO_INTERVENTION|Usual Care|Receive usual care upon hospital discharge
62257363|NCT01722175|EXPERIMENTAL|Arm I (ALPPS)|Patients undergo Associating Liver Partition with Portal Vein Ligation (ALPPS) step 1 surgery on day 0 and step 2 surgery 7-14 days later, based on patient's liver size.
62257364|NCT01722175|ACTIVE_COMPARATOR|Arm II (PVO)|Patients undergo portal vein occlusion (PVO) step 1 on day 0 and step 2 surgery 6-8 weeks later, based on patient's liver size.
62257365|NCT05863104|EXPERIMENTAL|Glycopyrronium Bromide (GPB) Cream|Formulation containing Glycopyrronium Bromide (GPB) for topical application
62257366|NCT00554567|EXPERIMENTAL|Intervention Arm|Fully Decentralized HIV Testing and Care Services
62257367|NCT02712476|ACTIVE_COMPARATOR|Mannitol,furosemide|Mannitol 0.5mg/kg and furosemide 0.5mg/kg IV is compared with mannitol 1mg/kg and furosemide 0.5mg/kg
62257368|NCT02712476|PLACEBO_COMPARATOR|Mannitol, placebo|Mannitol 0.5mg/kg and placebo is compared with mannitol+forosemide
62257369|NCT00199836|EXPERIMENTAL|Patients with Cancer Expressing NY-ESO-1 or LAGE-1 Antigen.|NY-ESO-1b peptide, 100 μg mixed with 1 mg CpG 7909 and 0.5mL of Montanide® ISA-51 was administered to patients with cancer expressing NY-ESO-1 or LAGE-1 antigen. The injections were given subcutaneously beginning on week 1 and repeated every three weeks for 4 injections total. There was a 3 week follow-up period after the last injection. In the absence of toxicity and progressive disease (PD), a second cycle was offered to patients who received 4 vaccinations.
62257370|NCT04202679|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to dupilumab 600 milligrams (mg) (loading dose), subcutaneously (SC) on Day 1 followed by placebo matched to dupilumab 300 mg once every 2 weeks (q2w) for 24 weeks added to background therapy of topical corticosteroids/topical calcineurin inhibitors (TCS/TCI) at stable dose.
62257371|NCT04202679|EXPERIMENTAL|Dupilumab 300 mg Q2W|Participants received dupilumab at a loading dose of 600 mg, SC on Day 1 followed by dupilumab 300 mg q2w for 24 weeks added to background therapy of TCS/TCI at stable dose.
62257372|NCT05376358|ACTIVE_COMPARATOR|Usual Care|Participants in this arm will receive no intervention and access treatment as usual per their mental health services provider. A mobile application (AWARE) which is not interactive and is only for purposes of data collection will be downloaded on the adolescents' smartphone.
62257373|NCT05376358|EXPERIMENTAL|MoodRing|Adolescent participants in this arm will download two mobile applications - a data collection non-interactive app to collect passive sensing data (AWARE) and the MoodRing (MR) mobile application with which they can visualize their data about their mood, sleep, activity, enter their own mood score, and access psychoeducational resources including links to a research-based website, SOVA. Their parents will download a parent MoodRing application which provides them with parenting resources and articles and a weekly report of their adolescents' mood as predicted by passive sensing. Clinical providers will receive access to a web portal where they can view their adolescent patients' data who are enrolled in the study.
62257374|NCT02569814|OTHER|Group 1|Subjects of Group 1 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 1 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 15th day.
62257375|NCT02569814|OTHER|Group 2|Subjects of Group 2 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 2 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 15th day.
62257376|NCT05280184|EXPERIMENTAL|Coin2Dose|BEI intervention that also combines automated text message reminders to dose for insulin; will test Contingent and Non-Contingent BEI
62257377|NCT05280184|NO_INTERVENTION|Standard Care Control|Standard care control group; will not receive automated text message reminders to dose for insulin nor BEI for daily BOLUS scores
62257378|NCT01187966|PLACEBO_COMPARATOR|Placebo|Drug: Placebo
62257379|NCT01187966|EXPERIMENTAL|High Dose (100mg/day)|
62257380|NCT01187966|EXPERIMENTAL|Low dose (50mg/day)|
62444424|NCT06546644|NO_INTERVENTION|Control|The children in the control group will receive no intervention.
62444425|NCT06467422|EXPERIMENTAL|Theta Stimulation(6Hz, generated with electrodes of 2kHz and 2.005kHz)|Session1#T1(10min)+DTI(15min) Session2#rsfMRI(8min)+rsfMRI-Theta tTIs(8min)+rsfMRI(8min)+TASK fMRI-Theta TI(20min)
62444426|NCT06467422|SHAM_COMPARATOR|High Frequency Stimulation(generated with two electrodes of 2kHz)|Session1#T1(10min)+DTI(15min) Session2#rsfMRI(8min)+rsfMRI-HF tTIs(8min)+rsfMRI(8min)+TASK fMRI-HF TI(20min)
62444427|NCT03082391|ACTIVE_COMPARATOR|Heavy weight Mesh|Intervention: Patients will undergo ventral hernia repair with implantation of a heavy weight mesh.
62444428|NCT03082391|ACTIVE_COMPARATOR|Medium weight Mesh|Intervention: Patients will undergo ventral hernia repair with implantation of a medium weight mesh.
62839371|NCT02376699|EXPERIMENTAL|SC Monotherapy in Lymphomas|SEA-CD40 administered SC
62839372|NCT02376699|EXPERIMENTAL|Combination Therapy in Pancreatic Cancer|SEA-CD40 (administered IV) + pembrolizumab + gemcitabine + nab-paclitaxel
62839373|NCT01804127|EXPERIMENTAL|R-CHOP|rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
62055015|NCT00685945|EXPERIMENTAL|Control (bradykinin infusion)|Bradykinin (Clinalfa AG, Läufelfingen, Switzerland)
62444429|NCT02691897|EXPERIMENTAL|Melatonin|Melatonin 3mg once daily at bedtime
62444430|NCT02691897|PLACEBO_COMPARATOR|Placebo|Placebo 1 tablet once daily at bedtime
62614418|NCT05636072|NO_INTERVENTION|Waitlist Control|Participants will wait 1 week to begin the well-being tools.
62614419|NCT02854605|EXPERIMENTAL|GS-9674 30 mg|GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
62839374|NCT02792530|OTHER|arm 1|Unuric hemodialytic patients who accumulate above 2.5 (4%) in intradialytic intervals before the nutritional intervention.
62839375|NCT01038843|EXPERIMENTAL|VA106483 1mg|
62839376|NCT01038843|EXPERIMENTAL|VA106483 2mg|
62839377|NCT01038843|EXPERIMENTAL|VA106483 4mg|
62257381|NCT04459052|OTHER|Oral and IV N acetyl Cysteine Cohort|Administration of Intravenous (IV) and Oral N-acetyl Cysteine (NAC) Intervention: IV NAC infusion: Dose: 50mg in 200ml of Dextrose 5% in Water (D5W), frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 500 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered). Oral NAC will be taken for approximately 6 ±3 months.
62257382|NCT04459052|OTHER|Waitlist Control Cohort|Standard of Care Treatment for approximately 6 ±3 months.
62257383|NCT03039231|EXPERIMENTAL|Freespira Breathing System (FBS)|The Freespira Breathing System (FBS) developed by Palo Alto Health Sciences, Inc, is a portable home device used for breathing biofeedback in adults with panic disorder (PD). FBS has received FDA clearance for the treatment of PD adults and is currently commercially available with more than 150 therapist providing the treatment nationally. FBS has not yet been tested for efficacy in an adult post traumatic stress disorder (PTSD) population. It has been suggested that there is overlap in the presence and persistence of symptoms between PD and PTSD patients. The primary goal of this study is to determine whether the FBS will produce similar benefit (both in quality and magnitude) in the defined population of patients with PTSD.
62257384|NCT02853448|EXPERIMENTAL|Novel Device|Every Subject will be assigned to the same arm. This arm calls for blood to be drawn using an original blood drawing apparatus as well as using the novel blood drawing apparatus.
62257385|NCT03610724|EXPERIMENTAL|Tisagenlecleucel|Participants were infused once with CAR-positive viable T cells
62257386|NCT01269762|EXPERIMENTAL|LipoCol Forte|Subject will receive single dose of one, two and four 600 milligram (mg) red yeast rice capsules (LipoCol Forte)and multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days.
62257387|NCT04968977||UPLM-ISR|
62444431|NCT02755480|EXPERIMENTAL|ultralow dose research|"An Ultralow Dose Thoracic Computed Tomography scan will be added to the standard of care Low dose CT scan.~The image quality of the ultralow dose CT will be compared to the Low dose thoracic Computed Tomography."
62257388|NCT02462356|ACTIVE_COMPARATOR|Conventional VATS|Via conventional VATS lobectomy and systematic lymph node dissection for lung cancer
62257389|NCT02462356|EXPERIMENTAL|Uniportal VATS|Via uniportal VATS lobectomy and systematic lymph node dissection for lung cancer
62257390|NCT06083441||Acute Brain Injury (ABI)|Patients that have suffered an ABI resulting in Coma (Glasgow Coma Scale (GCS) \< 9) will undergo SeeMe and CRS-R assessment once a day until hospital discharge
62257391|NCT06083441||Control|Healthy subjects will undergo SeeMe and CRS-R assessment once.
62257392|NCT03590730||Valvular heart disease|Patients with left ventricular dysfunction due to valvular heart disease who received ICD implantation for primary prevention of sudden cardiac death.
62257393|NCT00318214|EXPERIMENTAL|1|
62444432|NCT03378622|EXPERIMENTAL|Anchor|Anchor used for mesh attachment
62839378|NCT01038843|PLACEBO_COMPARATOR|Sugar pill|
62257394|NCT00318214|PLACEBO_COMPARATOR|2|
62257395|NCT01047371||Patients with Osteoarthrosis|All consecutive patients scheduled for total hip or knee arthroplasty
62257396|NCT04523636|ACTIVE_COMPARATOR|Custom Splint|Custom Splint- Thermoplastic device fabricated by occupational therapist
62257397|NCT04523636|ACTIVE_COMPARATOR|Prefabricated Splint|Prefabricated Splint- Commercially available from Restorative Care of America, Inc (RCAI)
62444433|NCT03378622|ACTIVE_COMPARATOR|Suture|Suture used for mesh attachment
62444434|NCT02784925|OTHER|fatty liver subjects|Ultrasound (US) B mode image is an alternative method to measure tissue structure and has proven to be an accurate technique to measure subcutaneous fat thickness.
62055016|NCT00685945|EXPERIMENTAL|L-NMMA + bradykinin|N-monomethyl-L-arginine (L-NMMA, NO synthase inhibitor; Bachem, Torrance, CA)
62257398|NCT04060420|EXPERIMENTAL|Comprehensive sexual and reproductive health services|In clusters randomised to the Yathu Yathu intervention, the comprehensive, community-based and peer-led intervention is being delivered. In addition to delivery of sexual and reproductive health services through community-based hubs, the intervention includes the Yathu Yathu prevention points cards, with which adolescents and young people can accrue points for accessing services at the Yathu Yathu hub and local health facility, and redeem rewards using these points.
62257399|NCT04060420|NO_INTERVENTION|Standard of care|In the comparison arm, adolescents and young people will have access to sexual and reproductive health services at the local health facility. They will also have a Yathu Yathu prevention points card, with which they can accrue points for accessing sexual and reproductive health services at the local health facility and redeem rewards using these points.
62257400|NCT01605279|EXPERIMENTAL|Dobutamine|Patients with low SVCF in the first 12 hours of life will be randomised to receive dobutamine or placebo.
62257401|NCT01605279|PLACEBO_COMPARATOR|Placebo|Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo.
62257402|NCT04030728||Group 1: Standardized coaching arm|Patients in this group receive a continuous standardized MOATT based patient education and coaching and optional eMBSR (electronic Mindfulness-Based Stress Reduction) within the first 24 weeks of Abemaciclib treatment.
62257403|NCT04030728||Group 2: Coaching according to local practice|Patients in this group receive a patient management according local routine.
62257404|NCT02384668|ACTIVE_COMPARATOR|Cholecalciferol|Cholecalciferol 70 mcg per day Other name: Vitamin D3.
62839379|NCT04334967|EXPERIMENTAL|Treatment Arm|Patients in the treatment arm will receive 200 mg oral hydroxychloroquine. Day 1: 400 mg doses twice (800 mg total). Days 2-5: 200 mg dose twice (400 mg total daily).
62257405|NCT02384668|PLACEBO_COMPARATOR|Placebo|"Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.~The placebo regimen is identical to the vitamin D3 regimen."
62257406|NCT04550104|ACTIVE_COMPARATOR|Radiotherapy only|
62839380|NCT04334967|ACTIVE_COMPARATOR|Control Arm|Patients in the control arm will receive 500 mg oral Vitamin C. Day 1: 1000 mg dose twice (2000 mg total) Days 2-5: 500 mg dose twice (1000 mg total daily).
62839381|NCT05053646|EXPERIMENTAL|Marrow venting arm|Meniscal suture associated with marrow venting procedure
62055017|NCT00685945|EXPERIMENTAL|Isosorbide + L-NMMA + bradykinin|Isosorbide (NO donor)
62257407|NCT04550104|EXPERIMENTAL|Olaparib + radiotherapy|
62257408|NCT04550104|EXPERIMENTAL|AZD1390 + radiotherapy|
62257409|NCT04550104|EXPERIMENTAL|Ceralasertib (AZD6738) + radiotherapy + Consolidation durvalumab|This study arm will include up to 12 months of consolidation durvalumab for eligible participants following the completion of radiotherapy +/- DDRi.
62257410|NCT04550104|EXPERIMENTAL|AZD5305 + radiotherapy + Consolidation durvalumab|This study arm will include up to 12 months of consolidation durvalumab for eligible participants following the completion of radiotherapy +/- DDRi.
62257411|NCT04550104|ACTIVE_COMPARATOR|RT + consolidation durvalumab|
62257412|NCT04550104|EXPERIMENTAL|Arm D - did not proceed|Arm D - did not proceed
62257413|NCT00715026|OTHER|Trilogy AB Acetabular Hip Implant System|Post Approval Study of Device.
62257414|NCT04822649|OTHER|Heart failure with preserved ejection fraction|Adenosine stress echocardiography, body composition, and cardiopulmonary exercise test will be done in all of the enrolled patients. Left ventricular end-diastolic pressure will be assessed during coronary angiography.
62257415|NCT04214379|OTHER|severe congenital ptosis|Patients with severe congenital ptosis with poor levator muscle function
62257416|NCT00839384|EXPERIMENTAL|Implant Advisa IPG|Advisa IPG implant
62257417|NCT03172832|ACTIVE_COMPARATOR|Percutaneous Transhepatic Drainage|Subjects randomized to this arm will undergo PTBD as the first drainage intervention.
62444435|NCT01147120|ACTIVE_COMPARATOR|Progressive Muscle Relaxation|
62444436|NCT01147120|ACTIVE_COMPARATOR|Clinical Massage Therapy|
62444437|NCT04487210|EXPERIMENTAL|Phase 1a (Low Dose)|15 subjects will be enrolled to receive Low-dose S-protein with adjuvant MVC-COV1901.
62839382|NCT05053646|ACTIVE_COMPARATOR|Control arm|Meniscal suture alone, without marrow venting procedure
62839383|NCT05752357||single arm, observational arm|Patients who received surgery will routinely followed up by pre-op CTC, post-op CTC until 6 months after surgery.
62839384|NCT03074838|EXPERIMENTAL|Transarterial aortic valve implantation|Patients that are treated by trans arterial valve implantation (TAVI)
62839385|NCT03074838|ACTIVE_COMPARATOR|Surgical aortic valve replacement|Patients that are treated by surgical aortic valve replacement (SAVR)
62055018|NCT00685945|EXPERIMENTAL|Sildenafil + L-NMMA + bradykinin|Sildenafil (phosphodiesterase type 5 (PDE5) inhibitor
62055019|NCT03048344|EXPERIMENTAL|Part 1|Subjects will receive oral ORH-2014 at a planned starting dose of 5 mg once daily (QD) in the fasted state. If escalation criteria are met, the administered dose will increase by 5 mg increments to a maximum of 50 mg QD. The starting daily dose is approximately half the typical IV dose (0.15 milligram per kilogram \[mg/kg\]) extrapolated to a 70-kg person.
62055020|NCT03048344|EXPERIMENTAL|Part 2|Subjects will receive a daily oral dose of ORH-2014 at the recommended dose identified in Part 1. ORH-2014 will be administered in the fasted state.
62055021|NCT05782543|NO_INTERVENTION|Hypothermic machine perfusion|
62055022|NCT05782543|ACTIVE_COMPARATOR|Normothermic machine perfusion|
62055023|NCT04963205|EXPERIMENTAL|Adjustable bed backrest|Sleeping in elevated body position (\>30 degrees from supine position) for 4 weeks is a requirement for the intervention group. Patients can define their own most comfortable position during the night.
62055024|NCT04963205|ACTIVE_COMPARATOR|Usual bed|"Sleeping in a standard bed and flat (\<30 degrees from supine position) position for 4 weeks. Patients can define their own most comfortable position during the night."
62839386|NCT01529567|ACTIVE_COMPARATOR|CBT without exposure|
62614420|NCT02854605|EXPERIMENTAL|GS-9674 100 mg|GS-9674 100 mg + placebo to match GS-9674 30 mg for 24 weeks
62614421|NCT02854605|PLACEBO_COMPARATOR|Placebo|Placebo to match GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
62614422|NCT05097599|OTHER|Lorbrena® (lorlatinib)|
62614423|NCT05097599|OTHER|Braftovi® (encorafenib) + Mektovi® (binimetinib)|
62614424|NCT05097599|OTHER|Talzenna® (talazoparib)|
62614425|NCT05097599|OTHER|Trodelvy® (sacituzumab govitecan-hziy)|
62257418|NCT03172832|ACTIVE_COMPARATOR|Endoscopic Retrograde Cholangiography|Subjects randomized to this arm will undergo ERC as the first drainage intervention.
62257419|NCT02409849|NO_INTERVENTION|control group|
62257420|NCT02409849|EXPERIMENTAL|Octreotide LAR treatment|The patients with unresectable or metastatic GEP or esophageal NEC who got CR/PR/SD after chemotherapy with IP or EP regimen qualified with the inclusion criteria are enrolled. All the patients enrolled in our study will be randomly assigned to receive octreotide LAR (group A) as maintenance treatment or follow up (group B) to disease progression.
62614426|NCT05097599|OTHER|Inlyta® (axitinib)|
62614427|NCT03104452||Pregnant Smokers|Participants are pregnant women who smoked in the six months prior to their pregnancy.
62614428|NCT04845945||PCV15 only|Draw blood for ELISA and OPA, then administer PCV15
62614429|NCT04845945||PPS23 only|Draw blood for ELISA and OPA, then administer PPS23
62839387|NCT01529567|EXPERIMENTAL|CBT with exposure|
62257421|NCT02992340|EXPERIMENTAL|Phase 1B|Varlitinib (starting dose at 200 mg BID) Cisplatin Gemcitabine
62257422|NCT02970604|EXPERIMENTAL|Aspirin|Non-enteric coated Aspirin 75mg once daily for 7 days
62257423|NCT02970604|NO_INTERVENTION|No treatment|No treatment for 7 days
62257424|NCT06156436||Paediatric Patients|
62614430|NCT04845945||PCV15 and PPS23|Draw blood for Administer PPS23 then draw blood again ELISA and OPA, then administer PCV15
62614431|NCT01040715|EXPERIMENTAL|TNFa Kinoid dose 1|
62614432|NCT01040715|EXPERIMENTAL|TNFa Kinoid dose 2|
62614433|NCT01040715|EXPERIMENTAL|TNFa Kinoid dose 3|
62614434|NCT00750256|EXPERIMENTAL|Cohorts|This study will be a single-blind, randomized, placebo-controlled, dose-rising, single dose, parallel group study with 6 proposed Cohorts from 2mg to 450mg.
62614435|NCT03581617||Infertile women|Inclusion criteria for the study group will be as follows: 21-38 years old, primary infertility (no live birth), regular menstrual cycle (24-35 days), body mass index (BMI) ≤ 25, FSH \<10 mUI/mL, E2 \< 50 pg/ml on day 2-3 of the menstrual cycle. They will be recruited at admission for tubal patency assessment.
62614436|NCT03581617||Fertile women|Inclusion criteria for control group will be as follows: 21-35 years old, almost one live birth, regular menstrual cycle (24-35 days), BMI ≤ 25, FSH \<10 mUI/mL, E2 \< 50 pg/mL on day 2-3 of the menstrual cycle. Women with endometritis, endometriosis, tubal factor, ovulatory dysfunction, anatomical uterine pathologies will be excluded.
62614437|NCT06497504|EXPERIMENTAL|Participants receiving Bepirovirsen|Participants will receive bepirovirsen.
62839388|NCT00991016|EXPERIMENTAL|PF-04805712|
62257425|NCT01652742|EXPERIMENTAL|BI 135585 XX|one single dose
62257426|NCT01651351|EXPERIMENTAL|Cohort 1|"Day 1:~* GLASSIA at 0.04 mL/kg/min~* Placebo at 0.2 mL/kg/min~Day 15:~* GLASSIA at 0.2 mL/kg/min~* Placebo at 0.04 mL/kg/min"
62257427|NCT01651351|EXPERIMENTAL|Cohort 2|"Day 1:~* GLASSIA at 0.2 mL/kg/min~* Placebo at 0.04 mL/kg/min~Day 15:~* GLASSIA at 0.04 mL/kg/min~* Placebo at 0.2 mL/kg/min"
62257428|NCT04912245|OTHER|Telehealth visit|Patients with either MCI or unrecognized dementia and their care partners (if available) will be approached to participate in a telehealth Advance Care Planning (ACP) visit with a member of the patient's primary care team via either telephone or video. Patients without willing or available care partners are still eligible to participate in the study.
62257429|NCT05151081||Enuresis, Non-Enuresis|Patients were divided into two gruops according to whether having NE or not during childhood
62257430|NCT01450449|EXPERIMENTAL|Arm 1 - Short Course Radiotherapy|Short Course
62614438|NCT06497504|PLACEBO_COMPARATOR|Participants receiving Placebo|Participants will receive placebo.
62614439|NCT02109406|EXPERIMENTAL|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
62614440|NCT02109406|EXPERIMENTAL|AZD 2115 Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
62614441|NCT02109406|PLACEBO_COMPARATOR|Placebo MDI|Placebo MDI administered as two inhalations BID
62614442|NCT05175521|PLACEBO_COMPARATOR|Eucalyptus Oil Scent|Eucalyptus oil diluted in mineral oil 1:20
62614443|NCT05175521|ACTIVE_COMPARATOR|Isopropyl Alcohol Vapors|Isopropyl Alcohol 70%
62614444|NCT03919591|OTHER|Open Label Pilot|Open Label Pilot Study. All subjects will receive the viral challenge inoculum.
62614445|NCT03951545|ACTIVE_COMPARATOR|Mechanical group|Group of patients whose tibial sections will be performed using extramedullary mechanical sighting
62614446|NCT03951545|EXPERIMENTAL|Gyroscopic group|Group whose tibial sections will be performed using gyroscopic and accelerometric navigation (I-Assist) will be randomized
62839389|NCT02047032|EXPERIMENTAL|acupuncture|BL33 and BL35 of both sides are used. Every session will last for 30 minuets and will be given every other day. There are 36 sessions for each participant in all (3 session per week, 12 weeks).
62257431|NCT01450449|ACTIVE_COMPARATOR|Arm 2 - Standard Course Radiotherapy|Standard Course
62444438|NCT04487210|EXPERIMENTAL|Phase 1b (Medium Dose)|15 subjects will be enrolled to receive Medium-dose S-protein with adjuvant MVC-COV1901.
62257432|NCT04822051|EXPERIMENTAL|Psychoeducation Group|"Uncertainty Management Psychoeducation Program was given."
62257433|NCT04822051|NO_INTERVENTION|Control Group|No attempt was made by the researcher during the study. Only data collection was carried out.
62257434|NCT04885803|EXPERIMENTAL|Nano Liquid D3|Arm receiving Nano Liquid Vitamin D3
62257435|NCT04885803|ACTIVE_COMPARATOR|Softgel D3|Group receiving Softgel Vitamin D3
62257436|NCT04885803|PLACEBO_COMPARATOR|Placebo Control|Liquid mixture, identical in process, taste, smell, and appearance to Nano Liquid D3, but containing no active ingredient (no Vitamin D3)
62444439|NCT04487210|EXPERIMENTAL|Phase 1c (High Dose)|15 subjects will be enrolled to receive High-dose S-protein with adjuvant MVC-COV1901.
62444440|NCT02729688|ACTIVE_COMPARATOR|ordinary elastic bandage|Bandaging was applied by spiral methods. Three ordinary elastic bandages were applied with 50 % stretching and 50% overlapping from foot to just below knee level.
62444441|NCT02729688|ACTIVE_COMPARATOR|customized pressure guide bandage|Bandaging was applied by spiral methods. Three customized pressure guide elastic bandage were applied by stretching until the elliptical shape marker in the bandage turned into circular shape with 50% overlapping from foot to just below knee level.
62444442|NCT04777630||Patients with low vision who experience Charles Bonnet hallucinations|No intervention, observation of neuroimaging and questionnaires
62444443|NCT04777630||Patients with low vision who do not experience Charles Bonnet hallucinations|No intervention, observation of neuroimaging and questionnaires
62444444|NCT00331630|EXPERIMENTAL|Treatment arm|30 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62839390|NCT02047032|ACTIVE_COMPARATOR|Solifenacin plus PFMT|Both PFMT and solifenacin will be given for 36 weeks. Solifenacin will be taken 5mg once daily, before or after meal. PFMT includes intensive exercises conducted in hospital and home exercises. Intensive exercises will be done once every week for the first 12 weeks and once every four weeks for the 13th to 36th week. Home exercises will be done three times daily for 36 weeks.
62257437|NCT03147781|NO_INTERVENTION|Standard care|Participants in this group only receive standard post-cesarean care of the study hospital. It includes mobility restraint, foley retention, IV fluid infusion, oral intake instructions, oral pain medications routine, and breastfeeding practice.
62257438|NCT03147781|SHAM_COMPARATOR|Sham AT with Medulla Junci|Participants in this group receive auricular tape with Medulla Junci in addition to standard post-cesarean care during the early 96 postpartum hours.
62444445|NCT00007878|EXPERIMENTAL|Treatment (bortezomib, fluorouracil, leucovorin calcium)|Patients receive bortezomib IV on days 1 and 4 and fluorouracil IV and leucovorin calcium IV on day 1 weekly for 2 weeks. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
62839391|NCT04887129|EXPERIMENTAL|Students and staff at Mary Cariola Center|All students enrolled at the Mary Cariola Center in Rochester, NY. All staff working at the Mary Cariola Center in Rochester, NY.
62839392|NCT02248519|ACTIVE_COMPARATOR|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
62839393|NCT02248519|EXPERIMENTAL|Laparoscopic Gastrectomy|Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy.
62839394|NCT02817464|EXPERIMENTAL|TV-46046 - 1|
62839395|NCT02817464|EXPERIMENTAL|TV-46046 - 2|
62257439|NCT03147781|EXPERIMENTAL|True AT with magnetic pellets|Participants in this group receive auricular tape with magnetic pellets in addition to standard post-cesarean care during the early 96 postpartum hours.
62257440|NCT01840579|EXPERIMENTAL|Pembrolizumab 2 mg/kg|In Part A, participants receive intravenous (IV) Pembrolizumab 2 mg/kg on Day 1 of Cycle 1 (28 days), Cycle 2 and any additional cycles (14 days).
62257441|NCT01840579|EXPERIMENTAL|Pembrolizumab 10 mg/kg|In Part A, participants receive IV Pembrolizumab 10 mg/kg on Day 1 of Cycle 1 (28 days), Cycle 2 and any additional cycles (14 days).
62257442|NCT01840579|EXPERIMENTAL|Pembrolizumab+Cisplatin/Pemetrexed|In Part B, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m\^2 + IV Pemetrexed 500 mg/m\^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pemetrexed in combination with IV pembrolizumab is permitted per standard of care, followed by IV pembrolizumab 200 mg every 3 weeks.
62444446|NCT06052371||Neonates|Newborn babies who are 28 days old or less with a corrected gestational age of at least 34 weeks and a weight of at least 1700g or more at the time of participation. They will be recruited from hospital neonatal units or wards.
62444447|NCT02133339|EXPERIMENTAL|TRN-157|
62444448|NCT02133339|PLACEBO_COMPARATOR|Placebo|
62614447|NCT03502694|EXPERIMENTAL|Regimen A (Low-Dose Lumicitabine)|Participants will receive a single 750 milligram (mg) loading dose (LD) (Dose 1) of lumicitabine and matching placebo followed by nine 250 mg tablets as maintenance doses (MDs) (Doses 2 to 10) of lumicitabine and matching placebo administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
62614448|NCT03502694|EXPERIMENTAL|Regimen B (High-Dose Lumicitabine)|Participants will receive a single 1000 mg LD (Dose 1) of lumicitabine followed by nine 500 mg tablets as MDs (Doses 2 to 10) of lumicitabine and matching placebo tablet, administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
62614449|NCT03502694|PLACEBO_COMPARATOR|Regimen C (Placebo)|Participants will receive a placebo LD (Dose 1) followed by nine MDs (Doses 2 to 10) of matching placebo, administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
62614450|NCT02690597|OTHER|Patient|"State-trait anxiety inventory Y-A form (STAI Y-A form)~Anxiety visual analog scale evaluation(A-AVS)."
62614451|NCT00675870|EXPERIMENTAL|1|
62614452|NCT06730659|EXPERIMENTAL|CHT101 infusion|CHT 101 will be dosing by IV.
62614453|NCT02570750||Group 1: smokers patients group|smokers (more than 10 cigarettes per day)
62614454|NCT02570750||Group 2 : non-smokers patients group|Smoking status will be classified as current and never/former. Former smokers will be defined as those who had stopped smoking at least 1 year before being interviewed for this study
62614455|NCT02278965|EXPERIMENTAL|Main Arm|Open Label- Metformin and Omega-3 fatty acids for 12 months post baseline data collection.
62614456|NCT04361214|EXPERIMENTAL|Leflunomide|"Leflunomide 300 mg once daily administered for three days followed by 30 mg once daily administered for two days or until fevers abate (maximum ten days of treatment allowed).~If patients report symptoms attributed to the medication, the dose will be administered at 50 mg once daily for the loading dose followed by 20 mg once daily."
62839396|NCT04299789||Probable Civilian|This cohort represents those in which the Military Service Identification Tool has determined are a civilian and have not served in the Armed Forces.
62839397|NCT04299789||Probable Veteran|This cohort represents those in which the Military Service Identification Tool has determined are a military veteran and have served in the Armed Forces.
62839398|NCT02389153|EXPERIMENTAL|collaborative care, CHD|Participants start with the collaborative care intervention at baseline directly after inclusion.
62257443|NCT01840579|EXPERIMENTAL|Pembrolizumab+Carboplatin/Pemetrexed|In Part B, participants receive IV Pembrolizumab 200 mg + IV Carboplatin Area Under The Curve (AUC) 5 mg/mL/minute + IV Pemetrexed 500 mg/m\^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pemetrexed in combination with IV pembrolizumab is permitted per standard of care, followed by IV pembrolizumab 200 mg every 3 weeks.
62839399|NCT02389153|ACTIVE_COMPARATOR|collaborative care CHD - waitlist|Participants start with the intervention 6 months after baseline, in the meantime they receive tau.
62839400|NCT00623142|NO_INTERVENTION|A|Patients in this arm were not treated with HBO prior to CABG
62444449|NCT00608205|ACTIVE_COMPARATOR|Arm A: Radiation with concurrent Cisplatin|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
62444450|NCT00608205|EXPERIMENTAL|Arm B: Radiation with concurrent 5-FU and Cisplatin|Patients undergo radiotherapy as in arm I and receive fluorouracil IV and cisplatin IV continuously on days 1-4 and 22-25 of radiotherapy.
62444451|NCT02721797||Skin|Patients with EDS diagnosis having surgery, have debrided skin retained for this research
62614457|NCT05690763|EXPERIMENTAL|XP-endo Finisher|use of XP-endo Finisher
62614458|NCT05690763|EXPERIMENTAL|EndoActivator|use of EndoActivator
62614459|NCT06424509||High admission|The quartile of participants using the highest degree of long (\>5 days) and/or compulsory psychiatric inpatient care.
62614460|NCT06424509||Low admission|The quartile of participants using the lowest degree of long (\>5 days) and/or compulsory psychiatric inpatient care.
62614461|NCT00839787|EXPERIMENTAL|Morphine|Morphine Sulfate: If weight is \<50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given.
62614462|NCT00839787|PLACEBO_COMPARATOR|Placebo|Normal saline
62614463|NCT04909372|NO_INTERVENTION|No labelling|Food products without any label in the virtual supermarket.
62614464|NCT04909372|EXPERIMENTAL|Environmental labelling|Food products with an environmental label in the virtual supermarket.
62614465|NCT03528564|EXPERIMENTAL|Epoetin alfa|Preoperative treatment of anemia with iron sucrose (Venofer) plus Epoetin Alfa (Eprex)
62614466|NCT03528564|PLACEBO_COMPARATOR|Intravenous Iron|Preoperative treatment of anemia with iron sucrose (Venofer) plus placebo (saline)
62839401|NCT00623142|EXPERIMENTAL|B|Patients in this arm were treated with HBO prior to CABG
62839402|NCT05029778|EXPERIMENTAL|Experimental L-arginine 3 g and L-citruline 2 g|Drug: L-arginine 3g and L-citruline 2g, Food supplement, PO , for 24 h, until birth
62257444|NCT01840579|EXPERIMENTAL|Pembrolizumab+Carboplatin/Paclitaxel|In Part C, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 6 mg/mL/minute + IV Paclitaxel 200 mg/m\^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
62444452|NCT02721797||Tendon|Patients with EDS diagnosis having surgery, have debrided tendon retained for this research
62444453|NCT02721797||Uterine tissue|Patients with EDS diagnosis having surgery, have debrided uterine tissue retained for this research
62839403|NCT05029778|EXPERIMENTAL|placebo|Placebo 3g ( starch ) PO for 24 h. until birth
62257445|NCT01840579|EXPERIMENTAL|Pembrolizumab+Carboplatin/Nab-paclitaxel|In Part C, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 6 mg/mL/minute on Day 1 of each 21-day cycle + IV Nab-paclitaxel 100 mg/m\^2 on Days 1, 8, and 15 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
62614467|NCT02364154||Control group-Blood sampling|-subjects with a normal colonoscopy
62839404|NCT05619172|EXPERIMENTAL|Nanrilkefusp alfa and cetuximab|Participants will be first treated with 9 µg/kg of nanrilkefusp alfa and then proceed to be treated with either 12 µg/kg or 6 µg/kg of nanrilkefusp alfa in combination with cetuximab (depending on the safety evaluation of the first safety cohort). Nanrilkefusp alfa treatment will be administered on day 1 (from cycle 2 onwards, ±1 day), day 2 (±1 day), day 8 (±1 day), and day 9 (±1 day) of each 21-day cycle. Cetuximab treatment will be administered on day 1 (from cycle 2 onwards, ±1 day), day 8 (±1 day), and day 15 (±1 day) of each 21-day cycle; on day 1 and day 8, cetuximab infusion will start within 30 minutes after nanrilkefusp alfa administration.
62839405|NCT06012552|EXPERIMENTAL|Stady group|The study group will receive oral tianeptine in a dose of 3x 12.5 mg per day (patients younger than 70) or 2x 12.5 mg per day (patients older than 70) for 16 weeks. In addition, the subjects will participate in group psychotherapy and neurological rehabilitation.
62839406|NCT06012552|PLACEBO_COMPARATOR|Control group|The control group will receive oral placebo in a dose of 3x 12.5 mg per day (patients younger than 70) or 2x 12.5 mg per day (patients older than 70) for 16 weeks. In addition, the subjects will participate in group psychotherapy and neurological rehabilitation.
62839407|NCT03543917|EXPERIMENTAL|New Medication Combination|Intervention: Combination Product: Perfusion with New Combination Medication Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours
62839408|NCT04607538||Patellar dislocation, but no trochlear dysplasia|This group consist of patients in age from 15-20 years old in the Faroe Islands, who experience patellar dislocation, but do not have femoral trochlear dysplasia measured on MRI or X-ray
62839409|NCT04607538||Patiens with patellar dislocation and trochlear dysplasia|This group consists of patients in the age from 15-20 years old in the Faroe Islands, who have experience one or more patellar dislocations and have femoral trochlear dysplasia measured on MRI or X-ray
62839410|NCT04607538||Patients with other knee injury|This group consists of patients in the age from 15-20 years old in the Faroe Islands, who have had an ACL-rupture or an meniscus injury.
62839411|NCT04619771|EXPERIMENTAL|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. We will deliver 5 CBT-I sessions over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
62839412|NCT02193503|EXPERIMENTAL|treatment|MVX-1-loaded capsules and injection of irradiated autologous tumor cells
62839413|NCT02111304|ACTIVE_COMPARATOR|Part A (Adults)|In Part A, approximately 170 adult patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 500 mg or placebo TID for up to 3 days
62614468|NCT02364154||Study group-Blood sampling|- subjects with colorectal cancer after colonoscopy
62614469|NCT05412966|EXPERIMENTAL|PEAR-002B / reSET-O|Digital Therapeutic
62257446|NCT01840579|EXPERIMENTAL|Pembrolizumab+Ipilimumab|In Part D, participants receive IV Pembrolizumab 200 mg on Day 1 of each 21-day cycle + IV Ipilimumab 1 mg/kg on Day 1 of every other 21-day cycle (every 42 days) for a maximum of 18 cycles of Ipilimumab (35 doses of Pembrolizumab).
62614470|NCT02281240||With hemostatic complications|The hemostatic and antithrombotic (thrombopoietin, interleukin-11, heparin) measures during HSCT.
62614471|NCT05587413|EXPERIMENTAL|treatment group|
62257447|NCT01840579|EXPERIMENTAL|Pembrolizumab+Cisplatin/Etoposide|In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m\^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
62444454|NCT02721797||Vaginal tissue|Patients with EDS diagnosis having surgery, have debrided vaginal tissues retained for this research
62444455|NCT02721797||Ligaments|Patients with EDS diagnosis having surgery, have debrided ligaments retained for this research
62444456|NCT02232074|EXPERIMENTAL|Patient navigation enhanced with legal support|In addition to receiving standard navigation, patients will be connected with a Patient Navigator who is partnered with a lawyer from Medical-Legal Partnership to provide personalized assistance with regard to social-legal barriers.
62444457|NCT02232074|NO_INTERVENTION|Standard patient navigation|These patients will receive standard patient navigation which will work to ensure that services are coordinated amongst medical personnel, while also addressing patients' needs.
62444458|NCT00376571|EXPERIMENTAL|Stenting of main vessel and side branch|Percutaneous coronary intervention
62444459|NCT00376571|EXPERIMENTAL|No side branch treatment|Percutaneous coronary intervention
62444460|NCT02337933|EXPERIMENTAL|Ursolic acid|Ursolic acid capsules, 150 mg, once a day before breakfast during 12 weeks
62444461|NCT02337933|PLACEBO_COMPARATOR|Placebo|Calcined magnesia capsules, 150 mg, once a day before breakfast during 12 weeks
62444462|NCT04177069||Visucomplex Plus monotherapy|Patients with early dry AMD will be treated with Visucomplex Plus monotherapy.
62444463|NCT04177069||anti-VEGF drug plus Visucomplex Plus|Dry or wet AMD patients under treatment with a stable dose of an anti-VEGF drug, Visucomplex Plus will be added-on, upon physician decision.
62055025|NCT01742156||Presence of coronary disease|All patients with or without coronary disease who are followed in coronary clinics or wards
62055026|NCT01742156||coronary disease|Is coronary disease associated with tortuosity of vessels Patients seen in cardiology clinics
62257448|NCT01840579|EXPERIMENTAL|Pembrolizumab+Carboplatin/Etoposide|In Part E, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 5 mg/mL/minute on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
62257449|NCT01840579|EXPERIMENTAL|Pembrolizumab+Cisplatin/Etoposide+G-CSF|In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m\^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles + lasting granulocyte colony-stimulating factor (G-CSF) (pegfilgrastim) 3.6 mg on Day 4 of Cycle 1. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
62257450|NCT02775084|EXPERIMENTAL|Healthy Fish Oil|8 grams fish oil
62257451|NCT02775084|PLACEBO_COMPARATOR|Olive Oil|8 grams olive oil
62257452|NCT02751593|EXPERIMENTAL|dexamethasone|dexamethasone 40mg/d for 4 days
62257453|NCT01414881|EXPERIMENTAL|mipomersen|mipomersen 200mg subcutaneously (SC) once weekly
62257454|NCT01414881|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously (SC) once weekly
62257455|NCT04116996|EXPERIMENTAL|Adults with Parkinson's disease and severe insomnia|1 arm study
62257456|NCT01610895|ACTIVE_COMPARATOR|Split-dose PEG Based Lavage (2L + 2L) + Low-fiber Diet|Patients randomized to this arm will have a split-dose Polyethylene Glycol Based lavage (2L + 2L), have a low-fibre diet 4 days prior to Colonoscopy and the day before Colonoscopy, have a low-fibre breakfast, a low-fibre lunch by 2PM and then drink only clear fluids until after the procedure is completed.
62614472|NCT05587413|NO_INTERVENTION|control group|
62614473|NCT00581425|EXPERIMENTAL|Treated|
62257457|NCT01610895|PLACEBO_COMPARATOR|Split-dose PEG Based Lavage (2L + 2L) + Clear fluid diet|Patients randomized to this arm will have a split-dose Polyethylene Glycol Based lavage (2L + 2L), have a low-fibre diet 4 days prior to Colonoscopy and the day before Colonoscopy, have a low-fibre breakfast and then drink only clear fluids until after the procedure is completed.
62257458|NCT04798937|EXPERIMENTAL|Intervention group|Youth in this group received usual care, consisting of medical consultations, in combination with a health education program based on motivational interviewing provided by a nurse
62257459|NCT04798937|NO_INTERVENTION|Control group|Youth in this group received usual care only consisting of medical consultations
62257460|NCT04341441|ACTIVE_COMPARATOR|Study Drug - Daily Dose|The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.
62257461|NCT04341441|ACTIVE_COMPARATOR|Study Drug - Weekly Dose|The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria.
62257462|NCT04341441|ACTIVE_COMPARATOR|Placebo|All treatment groups will receive placebo pills to have the patients take 2 pills a day. The randomized placebo arm will receive placebo pills made to resemble the daily dosing of HCQ. Similarly, the once a week treatment arm will receive placebo pills for the days not on HCQ medication.
62614474|NCT01547052|EXPERIMENTAL|DBT for children|Dialectical Behavior Therapy adapted for children
62614475|NCT01547052|ACTIVE_COMPARATOR|Enhanced Supportive-Educational Therapy|Enhanced Treatment-As-Usual, including supportive-educational model, cognitive-behavioral skills and parent management training
62623628|NCT06461689||patient treated as part of mCPRC|All patients treated with 177Lu-PSMA had post-therapy 68Ga-PSMA PET and 177Lu-PSMA-617 SPECT/CT.
62839414|NCT02111304|ACTIVE_COMPARATOR|Part B (Pediatric)|"Following completion of Part A, the data and safety monitoring board (DSMB) will review the unblinded data to assess safety and efficacy and conduct a futility analysis prior to proceeding to Part B.~Following the DSMB recommendation of dose and dosing schedule for pediatric patients, Part B will be initiated. Approximately 156 pediatric patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 or placebo at the recommended dose and dosing regimen."
62839415|NCT01399372|ACTIVE_COMPARATOR|Chemotherapy|Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 3-5 weeks later by two 28-day cycles of cytarabine.
62055027|NCT02887430|EXPERIMENTAL|intervention|Participants will be received 8 sessions of foot reflexology therapy, 30 minutes each (2 sessions per week of 4 weeks) and low back pain standard care
62055028|NCT02887430|NO_INTERVENTION|control|participants will be received standard care in general practice
62055029|NCT05526586|EXPERIMENTAL|Zero Alcohol Gum Prototype|Participants assigned to this group will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 milliliters (mL) of the Zero Alcohol Gum Prototype Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
62257463|NCT04341441|ACTIVE_COMPARATOR|Non-Randomized Active Comparator|A non-randomized comparator group will be enrolled in the study comprising of healthcare workers and first responders who are chronically on oral hydroxychloroquine as part of their standard of care for their autoimmune disease(s). This will be an open enrollment group and will provide information of chronic weight-based daily therapy of HCQ effectiveness as a prophylactic/preventive strategy.
62257464|NCT03574675|EXPERIMENTAL|Order Sham/Hypoxia|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
62055030|NCT05526586|EXPERIMENTAL|Alcohol Gum Prototype|Participants assigned to this group will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Alcohol Gum Prototype Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
62257465|NCT03574675|EXPERIMENTAL|Order Hypoxia/Sham|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
62257466|NCT02332499|ACTIVE_COMPARATOR|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62257467|NCT02332499|PLACEBO_COMPARATOR|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62257468|NCT01427465|EXPERIMENTAL|Consult|Consult
62257469|NCT01427465|EXPERIMENTAL|Newsletter|Newsletter
62839416|NCT01399372|EXPERIMENTAL|Chemotherapy + Low-Dose WBRT|Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 2-5 weeks later by 3 weeks of low-dose whole-brain radiotherapy (WBRT), followed 3-5 weeks later by two 28-day cycles of cytarabine.
62839417|NCT03192553|EXPERIMENTAL|Double Gloving Procedure|Participants will doff PPE using a double gloving procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
62839418|NCT03192553|EXPERIMENTAL|Intensified Hand Hygiene Procedure|Participants will doff PPE using an intensified hand hygiene procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
62839419|NCT03192553|EXPERIMENTAL|One-Step Procedure|Participants will doff PPE using a one-step procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
62839420|NCT03192553|OTHER|CDC Procedure (Control)|Participants will doff PPE following the CDC procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
62839421|NCT03688594|EXPERIMENTAL|couple : man and pregnant women|
62839422|NCT05198440|EXPERIMENTAL|Neuromodulation of vection|
62839423|NCT04282603|EXPERIMENTAL|Experimental Meal Replacement|Participants randomized to this arm will consume 5 servings/day of experimental meal replacement in conjunction of 400 kcal of solid food for 12 weeks during the weight loss portion of the trial. This will be followed by the consumption of 1 serving/day of experimental meal replacement for 12 weeks during the weight maintenance portion of the trial.
62839424|NCT04282603|ACTIVE_COMPARATOR|Bariatrics Advantage Meal Replacement|Participants randomized to this arm will consume 5 servings/day of Bariatrics Advantage meal replacement in conjunction of 400 kcal of solid food for 12 weeks during the weight loss portion of the trial. This will be followed by the consumption of 1 serving/day of Bariatrics Advantage meal replacement for 12 weeks during the weight maintenance portion of the trial.
62257470|NCT01427465|EXPERIMENTAL|Parent Letter|Parent Letter
62257471|NCT01427465|ACTIVE_COMPARATOR|Control|Control
62257472|NCT04080947|PLACEBO_COMPARATOR|Control group|26 patients will receive placebo (Control group)
62257473|NCT04080947|EXPERIMENTAL|Montelukast group|26 patients will receive montelukast 10 mg/ day
62257474|NCT04292808|OTHER|Penthrox|Low Dose Methoxyflurane
62257475|NCT00006047|EXPERIMENTAL|Combination Therapy|Combination Therapy with Oral 9-Nitrocamptothecin \& Oral Etoposide. Patients receive oral nitrocamptothecin on days 1-3 and oral etoposide on days 4-5 each week. Treatment continues in the absence of disease progression or unacceptable toxicity.
62257476|NCT05945186|EXPERIMENTAL|Single Arm|Baseline blood flow (hemodynamic) measurements will be obtained via ultrasound for all enrolled subjects. Following baseline measurements, compression will be applied and blood flow (hemodynamic) measurements will be repeated via ultrasound.
62257477|NCT01850485||normothermia, 36 degrees|microcirculation after cardiac arrest by SDF and NIRS, in patients treated with 36 degrees, difference is temperature, in this group 36
62257478|NCT01850485||33 degrees, therapeutic hypothermia|microcirculation after cardiac arrest by SDF and NIRS, in patients treated with 33 degrees, difference is temperature, in this group 33
62257479|NCT04670497|ACTIVE_COMPARATOR|ultrasound guided lumbar plexus block|patients were recieved lumbar plexus block ultrasound guided by shamrock technique using 0.5% bupavacaine in a dose 0.3ml/kg
62257480|NCT04670497|ACTIVE_COMPARATOR|ultrasound guided Fascia iliaca block|patients were received fascia iliaca block ultrasound guided using 0.5% bupoavacaine in a dose 0.3ml\\kg
62623629|NCT04642482|EXPERIMENTAL|Synbiotic|"A fine powder to be taken orally consists of~Viable cell 1,0 x 10\^9 Colony Forming Unit of :~* Lactobacillus plantarum 8,55 mg~* Streptococcus thermophilus 8,55 mg~* Bifidobacterium bifidum 2,55 mg~* Fructooligosaccharide 480 mg~* Additional components : isomalt, xylitol"
62839425|NCT03900091||Cases with clinical meningitis|Patients aged 0-12 years with suspected CNS infection, at the pediatric clinics at Mbarara Regional Referral Hospital or Holy Innocents Children's Hospital, Mbarara, Uganda.
62839426|NCT03900091||Control subjects|Patients aged 0-12 years, visiting the outpatient pediatric clinics at Mbarara Regional Referral Hospital or Holy Innocents Children's Hospital, Mbarara, Uganda, with fever clinically considered non-severe.
62839427|NCT02207452|OTHER|Salbutamol + Ipratropium|Treatment period 1: Salbutamol 5mg nebulised, single Dose. Treatment period 2: Ipratropium 500mcg nebulised, single dose.
62839428|NCT02207452|OTHER|Ipratropium + Salbutamol|Treatment period 1: Ipratropium 500mcg nebulised, single dose. Treatment period 2: Salbutamol 5mg nebulised, single Dose.
62839429|NCT01673737|EXPERIMENTAL|Part A Monotherapy|Dose escalation of daily or twice daily SAR260301 within a 28-day cycle, followed by an expansion phase at the maximal tolerated dose
62444464|NCT03077997|EXPERIMENTAL|Space from Diabetes|Participants will be assigned the 'Space from Diabetes' intervention in a supported mode for 8 weeks. Participants are assigned a clinical supporter, who will be a psychological well-being practitioner in an NHS Mental Health Service. As the participant works through the programme content, the supporter will provide them with a review of their progress and interactions with the platform 6 times over the 8 week supported period.
62257481|NCT03382158||Type I PPB|Type I PPB is an early manifestation of this malignant disease, cured in some cases by surgery. Surgical guidelines are presented. It is unknown whether adjuvant chemotherapy improves cure rates for individuals with Type I PPB. If the treating physicians select adjuvant chemotherapy treatment, chemotherapy options include a 22-week regimen: 4 courses of vincristine, actinomycin D and cyclophosphamide (VAC) followed by 3 courses of vincristine and actinomycin D (VA). Therapy decisions are the responsibility of the treating institution.
62257482|NCT03382158||Types II and III PPB|Types II and III PPB are aggressive sarcomas. Surgery and chemotherapy are necessary in all cases. Surgical guidelines are presented. Many children with Types II or III PPB receive a single-arm multi-agent chemotherapy neo-adjuvant/adjuvant regimen of IVADo (ifosfamide, vincristine, actinomycin, doxorubicin) for 36 weeks. Second and possible 3rd look surgery may be considered for local control. Radiation therapy may be considered. Specific therapy decisions are the responsibility of the treating institution.
62257483|NCT03382158||Type Ir PPB|Type Ir (regressed) PPB is a unique, purely cystic tumor which lacks a primitive cell component. The International PPB/DICER1 Registry will enroll and follow participants with Type Ir PPB, regardless of age.
62257484|NCT03382158||DICER1 Gene or Cond Assoc with DICER1|PPB and the associated conditions found in PPB families suggest a familial tendency to formation of tumors. The International PPB/DICER1 Registry for PPB, DICER1 and Associated Conditions study will enroll and follow participants who have the DICER1 gene mutations or conditions associated with PPB or DICER1.
62257485|NCT03096951|EXPERIMENTAL|Prehabilitation group|Preoperative and postoperative telerehabilitation
62257486|NCT03096951|ACTIVE_COMPARATOR|Rehabilitation group|Postoperative telerehabilitation
62839430|NCT01673737|EXPERIMENTAL|Part B Combination|Dose escalation of twice-daily SAR260301 within a 28-day cycle and in combination with 720 or 960 mg twice daily of Vemurafenib, followed by an expansion phase at the maximal tolerated dose of SAR260301 in combination
62444465|NCT06451809||Patients with MDD|Patients who are prescribed a course of 30 rTMS sessions to treat an episode of MDD at one of the nine participating centres
62257487|NCT04689581|EXPERIMENTAL|Bi-level erector spinae plane block|Bi-level ultrasound (US)-guided Erector spinae plane block (ESP) with 30 ml 0.25% bupivacaine at the T2 andT4 vertebral level will performe preoperatively to all patients in the ESP group.
62444466|NCT04740021|EXPERIMENTAL|Experimental: LP002+EP|Participants recieve LP002 10 mg/kg intravenous (IV) on day 1 PLUS carboplatin titrated to an area under the plasma drug concentration-time curve \[AUC\] 5 IV on day 1 PLUS etoposide 100 mg/m\^2 IV on days 1, 2 and 3 of each 21-day cycle
62444467|NCT05583383|EXPERIMENTAL|Cohort 1|camrelizumab was administered intravenously at a fixed dose of 200 mg, on the first day, once every 3 weeks, with a cycle of 3 weeks. Infusion for 30 min each time (no less than 20 min and no more than 60min); SOX: Oxaliplatin: 130 mg/m2, administered intravenously, on the first day, once every three weeks, and every three weeks is a cycle; S-1: according to BSA (\< \<1.25 40 mg；; 1.25-1.5 50 mg； \> \>1.5 60 mg), oral administration, d1-d14 twice a day, 3 weeks as a cycle; Trazumab was administered intravenously, with an initial loading dose of 8 mg/kg and a subsequent dose of 6 mg/kg, with a cycle of 3 weeks
62444468|NCT05583383|ACTIVE_COMPARATOR|Cohort 2|camrelizumab was administered intravenously at a fixed dose of 200 mg, on the first day, once every 3 weeks, with a cycle of 3 weeks. Infusion for 30 min each time (no less than 20 min and no more than 60min); SOX: Oxaliplatin: 130 mg/m2, administered intravenously, on the first day, once every three weeks, and every three weeks is a cycle; S-1: according to BSA (\< \<1.25 40 mg；; 1.25-1.5 50 mg； \> \>1.5 60 mg), oral administration, d1-d14 twice a day, 3 weeks as a cycle;
62444469|NCT05571709|ACTIVE_COMPARATOR|Aged individuals who perform exercise training|Aged individuals will perform an acute bout of resistance trainig (30 minutes). This training is focused on the lower limbs.
62839431|NCT05556044|OTHER|Empagliflozin 10 MG|
62257488|NCT04689581|EXPERIMENTAL|Modified pectoral nerve block|Ultrasound (US)-guided modified pectoral nerve block (PECs) with 30 ml 0.25% bupivacaine will performe preoperatively to all patients in the PECs group.
62444470|NCT05571709|SHAM_COMPARATOR|Aged individuals who stay sedentary|Aged individuals will remain seated for 30 minutes.
62623630|NCT04642482|ACTIVE_COMPARATOR|Placebo|A powder of 5 gram maltodextrin is given as active comparator, taken orally.
62623631|NCT04839666||Propofol|
62839432|NCT02192411|ACTIVE_COMPARATOR|Standard Lidocaine|50mL 1% lidocaine in 450mL normal saline
62257489|NCT06031649||Group A|30 mother underwent cesarean section
62839433|NCT02192411|EXPERIMENTAL|1/4 dose lidocaine|12.5mL 1% lidocaine in 487.5mL normal saline
62839434|NCT01908062|ACTIVE_COMPARATOR|Treatment as Usual|The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy. HIV-infected patients with alcohol use disorders are typically referred for residential, outpatient, and self-help groups.
62839435|NCT01908062|EXPERIMENTAL|Extended Release Naltrexone|Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
62839436|NCT04989335|EXPERIMENTAL|Bisantrene combined with Fludarabine and Clofarabine|"Bisantrene 250 mg at final concentration of 0.5 mg/mL will be administrated by intravenous (IV) infusion, delivered by a controlled-rate programmable pump via a central line over 2 hours.~Fludarabine (generic) and Clofarabine (generic) are commercially available as injection for intravenous infusion.~The treatment regimen will comprise daily IV infusion of Fludarabine (Flu), Clofarabine (Clo) and Bisantrene (Xan) administered via central venous line and controlled-rate infusion pump with a 1-hour break between each agent infusion, amounting to a total of 6 hours for each daily FluCloXan treatment in the following sequence:~* First, infusion over 60 minutes of Fludarabine (Flu) at 10 mg/m2~* Followed by infusion of Clofarabine (Clo) at 30 mg/m2 over 60 minutes~* Followed by infusion of Bisantrene (Xan) at 250 mg/m2 over 2 hours."
62257490|NCT06031649||Group B|30 healthy females who were in the control group
62257491|NCT00907348|EXPERIMENTAL|Cohorts 1 - 2 - 3 - 4|Chemiotherapy
62257492|NCT00577642|OTHER|Single arm|Single arm biomarker study after a single dose of zoledronic acid
62257493|NCT01199588|EXPERIMENTAL|Nexagon® High Dose|Weekly applications of Nexagon® high dose in addition to compression dressings.
62257494|NCT01199588|PLACEBO_COMPARATOR|Nexagon® Vehicle|Weekly applications of Nexagon® Vehicle in addition to compression dressings.
62257495|NCT01199588|NO_INTERVENTION|No Investigational Product|Weekly application of compression dressings.
62257496|NCT01199588|EXPERIMENTAL|Nexagon® Low Dose|Weekly applications of Nexagon® low dose in addition to compression dressings.
62257497|NCT06017570|EXPERIMENTAL|Low-risk Group|Participants with DMFT score: 0 or 1.
62257498|NCT06017570|EXPERIMENTAL|Modarate-risk Group|Participants with DMFT score: 2, 3, 4 or 5.
62257499|NCT06017570|EXPERIMENTAL|High-risk Group|Participants with DMFT score above 5.
62257500|NCT00767052|EXPERIMENTAL|Active|AZD1236 tablet
62257501|NCT00767052|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62839437|NCT03557060||Subjects receiving NUCALA|Subjects with a diagnosis of EPGA, for which NUCALA is indicated will be included.
62839438|NCT05684211|ACTIVE_COMPARATOR|Ametumumab (QW) + anti-PD-1 monoclonal antibody+ FOLFIRI|Ametumumab 450 mg/m2 (QW) + anti-PD-1 monoclonal antibody (in the case of toripalimab 3 mg/kg, Q2W) + FOLFIRI;
62839439|NCT05684211|ACTIVE_COMPARATOR|Ametumumab(Q2W) + anti-PD-1 monoclonal antibody + FOLFIRI;|Ametumumab 450 mg/m2 (Q2W) + anti-PD-1 monoclonal antibody (in the case of toripalimab 3 mg/kg, Q2W) + FOLFIRI;
62839440|NCT05684211|ACTIVE_COMPARATOR|Ametumumab (Q2W) + FOLFIRI;|Ametumumab 450 mg/m2 (Q2W) + FOLFIRI
62839441|NCT05684211|ACTIVE_COMPARATOR|Cetuximab + FOLFIRI;|Cetuximab 500 mg/m2 (Q2W) + FOLFIRI
62839442|NCT03743636|ACTIVE_COMPARATOR|Nicotinamide riboside + resveratrol|Participants randomized to the NR + resveratrol arm of the study will receive 1,000 mg of NR and 125 mg of resveratrol daily for six months.
62839443|NCT03743636|ACTIVE_COMPARATOR|Nicotinamide riboside + placebo|Participants randomized to the NR + placebo arm of the study will receive 1,000 mg of NR and a placebo daily for six months.
62839444|NCT03743636|PLACEBO_COMPARATOR|Placebo + placebo|Participants randomized to the placebo + placebo arm of study will receive placebo pills.
62257502|NCT00767052|OTHER|Relative bioavailability|AZD1236 Oral suspension
62257503|NCT00767052|OTHER|Relative bioavailability tablet|AZD1236 tablet
62257504|NCT04638348|EXPERIMENTAL|New Biofeedback|Women allocated to the new biofeedback group will be instructed to attach the biofeedback device to their underpants and then perform pelvic floor muscle training.
62257505|NCT04638348|ACTIVE_COMPARATOR|Conventional Biofeedback|Women allocated to the conventional biofeedback group will undergo pelvic floor muscle training with the conventional biofeedback probe inserted in the vagina
62257506|NCT04638348|ACTIVE_COMPARATOR|Control group|The control group will perform pelvic floor muscle training without any biofeedback device.
62839445|NCT01877395|EXPERIMENTAL|Purified Vero Rabies Vaccine Group|Participants will receive the Purified Vero Rabies Vaccine (VRVg)
62839446|NCT01877395|EXPERIMENTAL|Imovax® Rabies Vaccine Group|Participants will receive the Imovax® Rabies vaccine
62839447|NCT01680471|EXPERIMENTAL|Midazolam 0.03mg/kg|This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.
62839448|NCT01680471|EXPERIMENTAL|Midazolam 0.05mg/kg|This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.
62839449|NCT01680471|PLACEBO_COMPARATOR|Placebo|This group will be injected intravenous normal saline five minutes before the end of surgery.
62614476|NCT02190409|EXPERIMENTAL|Test, Control|Test: Minimum two tapered implants (Ankylosis, Dentsply Friadent) were placed to each patient. After surgical preparation of implant sockets, PRF that was prepared preoperatively was placed randomly to one of the sockets (PRF+). Acellular plasma portion of PRF was used to wet the implant placed into the PRF-coated socket Control: Other socket was selected as a control group (No Platelet Rich Fibrin used): In the control group no extra intervention used and the conventional procedure was done. Thus the readings of the experimental arm compared with this control.
62614477|NCT02379507|EXPERIMENTAL|DEC033 Study Product|Apply twice a day
62614478|NCT05132790|EXPERIMENTAL|TNBC|
62614479|NCT05132790|EXPERIMENTAL|HER2-/HR+BC|
62614480|NCT03954717||Participants in the Shepherd CAN DO Program|People with MS enrolled into the Shepherd CAN DO Program.
62839450|NCT05666167|EXPERIMENTAL|Exercise Initiation and Maintenance with Text Messaging and Booster Sessions|Participants receive 3 months of group telehealth exercise initiation plus text messaging followed by 6 months of text messaging plus monthly group telehealth exercise booster sessions.
62257507|NCT03335163|EXPERIMENTAL|ENG Implant Users|Healthy women using an ENG implant for at least 12 months and no greater than 36 months will be administered a 6 week titration schedule of topiramate to a max dose of 200mg bid by the final week.
62444471|NCT02419482|EXPERIMENTAL|4x4 minutes interval training|4x4 minutes high intensity interval training with 4 minute intervals
62614481|NCT03954717||Control Group-Shepherd (CG-S)|People with MS who are current patients of the MS Institute at the Shepherd Center.
62614482|NCT03954717||Control Group-iConquerMS (CG-iCMS)|iConquerMS members
62614483|NCT03954717||Support partners of CAN DO|Support partners of the participants in the Shepherd CAN DO Program group
62839451|NCT05666167|ACTIVE_COMPARATOR|Exercise Initiation and Maintenance with Text Messaging alone|Participants receive 3 months of group telehealth exercise initiation plus text messaging followed by 6 months of text messaging alone.
62839452|NCT03458819||Control|Patients on neither active Vitamin D or a statin
62839453|NCT03458819||Vit D|Patients on active Vitamin D but not a statin
62839454|NCT03458819||Statin|Patients on a statin but not active Vitamin D
62614484|NCT03954717||CG-S support partners|Support partners of the people with MS in the CG-S group.
62614485|NCT03954717||CG-iCMS|Support partners of the people with MS in the CG-iCMS group
62614486|NCT01516645|EXPERIMENTAL|KHK2898|
62614487|NCT03693001|EXPERIMENTAL|IC/FM Patients|All patients had been diagnosed with fibromyalgia and were suffering from IC by standard criteria.
62614488|NCT05255237|EXPERIMENTAL|Jaktinib|Patients will administer the study product twice per day for 24 weeks, for the safty assessment.
62614489|NCT05998460|EXPERIMENTAL|GGE with CGM|Participants randomized to the Glucose-Guided Intervention will be trained to align their mealtimes with a personalized glucose threshold monitored using continuous glucose monitoring (CGM) and the GGE study app.
62839455|NCT03458819||D + Statin|Patients on both active Vitamin D and a statin
62614490|NCT05998460|ACTIVE_COMPARATOR|CGM only|Participants randomized to the control arm will only wear a CGM.
62614491|NCT02958332|EXPERIMENTAL|video game program|Participants will play video games during 30 min , all along 5 sessions.
62614492|NCT01678599|OTHER|Benznidazol|This is a single arm, open label study; therefore, all subjects enrolled will receive benznidazol.
62614493|NCT01897571|EXPERIMENTAL|Phase 1|Patients in the Phase 1 portion of the study.
62614494|NCT01897571|EXPERIMENTAL|Phase 2 Group 1: Tazemetostat in R/R FL with Mutant EZH2|Patients with R/R FL with mutant EZH2 treated with tazemetostat as a single agent in Phase 2 of the study.
62444472|NCT02419482|EXPERIMENTAL|10x1 minute interval training|10x1 minute high intensity interval training with 1 minute intervals
62444473|NCT02419482|NO_INTERVENTION|control|Physical activity recommended
62444474|NCT04104958||Group 1|"Group 1 (n=50): women (age 20-40year) with PCOS who are diagnosed according to the criteria of the Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2003), which require two of the following 3 manifestations:~1. oligo- or anovulation,~2. clinical and/or biochemical signs of hyperandrogenism (\> 2.08 nmol/l),~3. polycystic ovaries on ultrasound examination (the presence of ≥12 follicles measuring 2-9 mm in diameter and/or ovarian volume \> 10 cm)"
62444475|NCT04104958||Group 2|Group 2 (n=50): women (age 20-40 year) with male factor infertility.
62614495|NCT01897571|EXPERIMENTAL|Phase 2 Group 2: Tazemetostat in R/R FL with Wild-Type EZH2|Patients with R/R FL with wild-type EZH2 treated with tazemetostat as a single agent in Phase 2 of the study.
62839456|NCT01189409|EXPERIMENTAL|PEG then Senna|PEG in stepped bowel protocol
62839457|NCT01189409|EXPERIMENTAL|Senna then PEG|Stepped bowel protocol with Senna then PEG
62839458|NCT05766046|EXPERIMENTAL|Standard arm|Volunteers with a negative baseline LDCT will repeat LDCT after the first screening with an annual interval (according to guidelines)
62839459|NCT05766046|EXPERIMENTAL|Risk-based arm|Volunteers with a negative baseline LDCT will repeat LDCT after the first screening with an interval of two years.
62839460|NCT03214848|NO_INTERVENTION|Standart of Care|Standard of care at the clinic is to discuss the abortion procedure without specific contraceptive counseling given prior to the day of abortion procedure.
62839461|NCT03214848|EXPERIMENTAL|Contraceptive education prior to abortion|Addition (to the standard or care) of a brief phone contraceptive education with optional financial counseling referral prior to abortion visit.
62839462|NCT02790190|EXPERIMENTAL|Individualized Adaptive radiotherapy|GTV dose per fraction will be 2.2-2.4 y per fraction for 20 fractions and PTV dose per fraction will be 2.0 Gy per fraction.Perform PET/CT before radiotherapy and at 36 Gy for treatment response assessment and adaptive plan.Adaptive plan treated at 2.2-3.8 Gy per fraction for GTV and 2.0 Gy for PTV in the final 10 fractions.
62257508|NCT04957576|SHAM_COMPARATOR|Asynchronous Stimulation|The right and the left disown hands will be stimulated with a tactile stimulation (paintbrush) in an asynchronous way, i.e. with a time-delay between one hand-touch and the other
62839463|NCT02790190|NO_INTERVENTION|Conventional radiotherapy|2 Gy per fraction for all patient,perform PET/CT before radiotherapy and at 40 Gy for treatment response assessment .Continue treatment to a total dose of 60 Gy.
62839464|NCT04315064|EXPERIMENTAL|Treatment with MTX110|
62257509|NCT04957576|EXPERIMENTAL|Synchronous Stimulation|The right and the left disown hands will be stimulated with a tactile stimulation (paintbrush) in synchronously, i.e. without a time-delay between one hand-touch and the other
62257510|NCT01193439||Patients with high risk|
62257511|NCT01193439||Patients in normal conditions|
62257512|NCT01858532|ACTIVE_COMPARATOR|Atrasentan|0.75 mg atrasentan once daily by mouth for up to 52 months
62839465|NCT03088735|EXPERIMENTAL|Blastocyst-stage embryo transfer strategy|
62839466|NCT03088735|ACTIVE_COMPARATOR|Cleavage-stage embryo transfer strategy|
62839467|NCT03644511||Patients with HCC|Treated with Nexavar and/or Stivarga as ≥ 2nd-line systemic treatment
62839468|NCT04178785|ACTIVE_COMPARATOR|REMIFENATIL|Prospective, single-center single blind randomized controlled trial. Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio. A blocked randomization scheme will be created using a computer-generated list of random numbers.
62257513|NCT01858532|PLACEBO_COMPARATOR|Placebo|Placebo once daily by mouth for up to 52 months
62257514|NCT01027611|EXPERIMENTAL|proparacaine HCL 0.5%|
62257515|NCT01027611|EXPERIMENTAL|proparacaine + lidocaine|
62257516|NCT01027611|EXPERIMENTAL|lidocaine gel|
62257517|NCT01483742|EXPERIMENTAL|Combination without RO5024048|Ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and ribavirin in treatment-naïve patients
62444476|NCT04570566|EXPERIMENTAL|titanium mish|horizontal alveolar ridge augmentation with non-resorbable titanium mish .evaluation after 4 months
62444477|NCT04570566|EXPERIMENTAL|pericardium membrane|horizontal alveolar ridge augmentation with resorbable pericardium membrane then .evaluation after 4 month.
62444478|NCT01123785|PLACEBO_COMPARATOR|Control|Matched vehicle-control
62444479|NCT01123785|EXPERIMENTAL|INO-8875|Adenosine agonist eye drop
62839469|NCT04178785|NO_INTERVENTION|FENTANYL|Prospective, single-center single blind randomized controlled trial. Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio. A blocked randomization scheme will be created using a computer-generated list of random numbers.
62839470|NCT03917953|EXPERIMENTAL|Arm I|Patients receive transcutaneous electrical acupoint stimulation therapy twice weekly for 4 weeks.
62839471|NCT03917953|SHAM_COMPARATOR|Arm II|Patients receive sham transcutaneous electrical acupoint stimulation therapy twice weekly for 4 weeks.
62257518|NCT01483742|EXPERIMENTAL|Combination with RO5024048|RO5024048 added to the combination treatment (ritonavir-boosted danoprevir in combination with Pegasys \[peginterferon alfa-2a\] and ribavirin) in prior null responder patients
62257519|NCT04127253|EXPERIMENTAL|transcranial direct current plus Brain training tools|20 minutes of transcranial direct current stimulation along with the application of motor imagery and action observation
62257520|NCT04127253|PLACEBO_COMPARATOR|Placebo transcranial direct current plus Brain training tools|A placebo intervention of direct transcranial stimulation being active during 15 seconds and then it will be turned off the rest of the time until 20 minutes. This group will also carry out the training of action observation and motor imagery.
62257521|NCT04127253|SHAM_COMPARATOR|Brain training tools in isolation|This group will act as a control, they will only carry out the training of action observation and motor imagery.
62257522|NCT02475070|ACTIVE_COMPARATOR|Vildagliptin first|Treatment with vildagliptin 50mg twice daily for two weeks followed by four weeks washout and then treatment with dapagliflozin 10mg once daily for two weeks
62257523|NCT02475070|ACTIVE_COMPARATOR|Dapagliflozin first|Treatment with dapagliflozin 10 mg once daily for two weeks followed by four weeks washout and then treatment with vildagliptin 50 mg twice daily for two weeks
62257524|NCT01505790|EXPERIMENTAL|CLOPIDOGREL GROUP|
62257525|NCT01505790|ACTIVE_COMPARATOR|PRASUGREL GROUP|
62444480|NCT04602104|EXPERIMENTAL|Phase 1: hMSC-Exos low dose|hMSC-Exos low-dose group
62444481|NCT04602104|EXPERIMENTAL|Phase 1: hMSC-Exos medium dose|hMSC-Exos medium-dose group
62444482|NCT04602104|EXPERIMENTAL|Phase 1: hMSC-Exos high dose|hMSC-Exos high-dose group
62444483|NCT04602104|EXPERIMENTAL|Phase 2: hMSC-Exos dosage 1|basic treatment+hMSC-Exos (a quarter of MTD/day)
62444484|NCT04602104|EXPERIMENTAL|Phase 2: hMSC-Exos dosage 2|basic treatment+hMSC-Exos (MTD/day)
62444485|NCT04602104|PLACEBO_COMPARATOR|Phase 2: control group|basic treatment+normal saline
62839472|NCT04048772|EXPERIMENTAL|Intervention|Standard of care in vitro fertilization patients randomized to the psychoeducational group intervention.
62839473|NCT04048772|OTHER|Control|Standard of care in vitro fertilization patients at our institution.
62839474|NCT01993797||Bronchiolitis|children presented with signs suggestive of bronchiolitis
62839475|NCT04087850|EXPERIMENTAL|Making Socially Accepting Inclusive Classrooms (MOSAIC)|
62839476|NCT04087850|NO_INTERVENTION|Typical Practice Control|
62257526|NCT03497585||Activity Pacing Framework|Adult patients attending rehabilitation programmes underpinned by the activity pacing framework.
62444486|NCT04381585|EXPERIMENTAL|Distraction osteogenesis using mini distractor|"A mini distractor will be used to move bone. Distraction osteogenesis originally developed for the severe craniofacial malformations has been adapted to correct vertical defects of the oral bone to improve bone volume for dental procedures.~However, the design of the distractor~1. has not evolved to adapt to a much smaller surgical site such as bone ridge in the oral cavity which necessitates a smaller screw.~2. are bulky, cumbersome to place, and cause significant discomfort to the patient.~3. has an extraoral component jutting out of the mouth to which a key (blue object) is attached to turn the screw to move bone fragments. Our Solution and the Innovation is to remove the extra-oral component by reducing the size and permitting an atraumatic placement of the screw under the gingiva (gum) thereby lessening irritation for the patient."
62444487|NCT04675983|EXPERIMENTAL|Sintilimab + Ramucirumab|Ramucirumab on days 1 and 8 in combination with Sintilimab on day 1 of each 21-day cycle until disease progression, intolerable toxicity or other criteria for treatment discontinuation
62444488|NCT04675983|ACTIVE_COMPARATOR|Cisplatin+ 5-fluorouracil/Oxaliplatin+capecitabine|Cisplatin on day 1 in combination with 5-fluorouracil, continuous pumping for 24 hours a day on days 1 to 5 of each 21-day cycle. (FP regimen) or Oxaliplatin on day 1 in combination with capecitabine on days 1 to 14 of each 21-day cycle. (XELOX regimen)
62614496|NCT01897571|EXPERIMENTAL|Phase 2 Group 3: Tazemetostat in R/R DLBCL|Patients with R/R DLBCL treated with tazemetostat as a single agent or tazemetostat in combination with prednisolone in Phase 2 of the study.
62614497|NCT05981404|EXPERIMENTAL|Low calorie and low carbohydrate meals with β-glucan.|On day 1, a low-calorie breakfast will be consumed at the metabolic investigation laboratory at New Lister Building (NLB) of Glasgow Royal Infirmary but low carbohydrate lunch and low-calorie dinner at home. On day 2, breakfast and lunch will be consumed at the laboratory and, prior to the breakfast, 1000mg of paracetamol will be taken, blood samples, breath hydrogen tests, appetite questionnaires will be obtained for 7 hours after the completion of breakfast. 3g β-glucan will be consumed with each meal on both days.
62614498|NCT05981404|EXPERIMENTAL|Low calorie and low carbohydrate meals with placebo.|On day 1, a low-calorie breakfast will be consumed at the metabolic investigation laboratory at New Lister Building (NLB) of Glasgow Royal Infirmary but low carbohydrate lunch and low-calorie dinner at home. On day 2, breakfast and lunch will be consumed at the laboratory and, prior to the breakfast, 1000mg of paracetamol will be taken, blood samples, breath hydrogen tests, appetite questionnaires will be obtained for 7 hours after the completion of breakfast. 3g cellulose will be consumed with each meal on both days.
62614499|NCT01429974||volunteers|
62614500|NCT04491526|EXPERIMENTAL|Tamsulosin Arm|p.o.
62614501|NCT04491526|PLACEBO_COMPARATOR|Placebo Arm|p.o.
62055031|NCT05526586|EXPERIMENTAL|Listerine Cool Mint Antiseptic Mouthwash|Participants assigned to this group will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Listerine Cool Mint Mouth rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
62257527|NCT01655342||formocresol|
62257528|NCT01102075|EXPERIMENTAL|Electroacupuncture|The Electroacupuncture therapy protocol included a total of 12 acupuncture points at the CV12,CV6, bilateral ST25, SP15, SP14,LI4, LI11, ST36, ST44. All acupuncture points were prepared with 70% alcohol pads, and disposable stainless steel needles were used. Abdominal acupuncture points were inserted horizontally 6\~6.5cm in depth and the others were inserted vertically 2\~2.5cm in depth until patient can feel De-Qi. All acupuncture points were stimulated electrically with a frequency of 24 Hz an intensity of 0.27-1.3mA(tolerable strength) with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks by practitioner who had had 6 years of acupuncture training and 3 more years of clinical experience.
62257529|NCT01102075|SHAM_COMPARATOR|Sham electroacupuncture procedure|The Sham electroacupuncture therapy protocol(Non-acupoint, No electrical stimulation)included the same number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment, but superficially at non acupuncture points 15 mm to the lateral of each acupuncture point was treated. The points were not stimulated electrically, but the sound of the pulse generator was heard by the participants. (Lee SH, LeeBC 2009) Those receiving EA or SEA therapy were treated on alternate days to prevent crosstalk among groups, which could have compromised the blinded study design.
62257530|NCT01102075|NO_INTERVENTION|Waiting list|No treatment was done for waiting group, but could receive same treatments as Electroacupuncture group after the end of trial.
62257531|NCT00803699|PLACEBO_COMPARATOR|Placebo|Capsule contains no selenium
62257532|NCT00803699|ACTIVE_COMPARATOR|Selenium as L-selenomethionine|50, 100, or 200 micrograms of selenium
62257533|NCT00496730|EXPERIMENTAL|Vytorin®|simvastatin (+) ezetimibe 10/20 mg (Vytorin®) ; tablet, once daily, 8 Weeks
62257534|NCT00496730|ACTIVE_COMPARATOR|atorvastatin|atorvastatin 10 mg; tablet, once daily, 8 Weeks
62257535|NCT03382977|EXPERIMENTAL|Part A Dose Level 1|VBI-1901 low dose (0.4 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
62614502|NCT03071679|EXPERIMENTAL|Omiganan|
62614503|NCT03071679|EXPERIMENTAL|Imiquimod|
62055032|NCT05526586|ACTIVE_COMPARATOR|Negative Control: 5 percent (%) Hydroalcohol|Participants assigned to this group will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the 5% Hydroalcohol Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
62055033|NCT04886479|EXPERIMENTAL|Daily Disposable Silicone Hydrogel Contact Lens Wearers|Participants wore Test Lens for 3 hours
62257536|NCT03382977|EXPERIMENTAL|Part A Dose Level 2|VBI-1901 intermediate dose (2 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
62257537|NCT03382977|EXPERIMENTAL|Part A Dose Level 3|VBI-1901 high dose (10 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
62614504|NCT03071679|EXPERIMENTAL|Omiganan 1% and Imiquimod|
62614505|NCT03071679|EXPERIMENTAL|Omiganan 2.5% and Imiquimod|
62614506|NCT03071679|PLACEBO_COMPARATOR|Placebo|Vehicle
62614507|NCT01137461|OTHER|abdominal ultrasound|traditional technique
62614508|NCT01137461|OTHER|transvaginal ultrasound|new technique
62614509|NCT05258799|EXPERIMENTAL|lderly Patients With Acute Myeloid Leukemia|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count \> 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
62614510|NCT05775926|EXPERIMENTAL|Experimental|Experimental Group: Nurses who met the criteria for participating in the study were informed about the study and their consent was obtained. Data collection forms were collected by the researcher at the end of the working hours. Training groups were formed on the days and times determined according to the interviews with the clinics where the research was conducted. In each hospital, training groups were formed outside the working hours of the nurses. The training was given to the nurses in the intervention group in an environment suitable for training in two days and 4 modules using interactive teaching methods. After the training, a month was waited for the nurses in the intervention group to experience care. One month after the training was given, data collection forms were distributed to the nurses in the intervention group and asked to fill in according to their self-reports.
62614511|NCT05775926|NO_INTERVENTION|Control|Control Group: Nurses who met the criteria for participating in the study were informed about the study and their consent was obtained. Data collection forms were collected by the researcher at the end of the working hours. No training was given to the control group. However, after the post-test application was made to the control group, the same training was given to the experimental group. One month later, data collection forms were distributed to the nurses in the control group and they were asked to fill in according to their self-reports. Data collection forms were collected by the researcher at the end of the working hours. Filling in the data takes about 15 minutes.
62614512|NCT02699476|ACTIVE_COMPARATOR|Individual + Computer A|Daily activities involve playing one hour of computer games (e.g., hangman, boggle, word scramble, chess; computer cognitive training A (CCA)), and two (2) 90 minute individual training sessions interacting one-on-one with a trainer in a variety of cognitive tasks including attention, memory, and comprehension of information.
62614513|NCT02699476|EXPERIMENTAL|Individual + Computer B|Daily activities involve playing an alternative set of computer games (computer cognitive training B (CCB)), and two (2) 90 minute individual training sessions interacting one-on-one with a trainer in a variety of cognitive tasks including attention, memory, and comprehension of information.
62614514|NCT02699476|ACTIVE_COMPARATOR|Group + Computer B|Daily activities involve group and individual cognitive therapy discussions on health, nutrition, and other topics and computer cognitive training B (CCB).
62614515|NCT00627809|EXPERIMENTAL|1|Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given
62055034|NCT04886479|EXPERIMENTAL|Daily Disposable Hydrogel Contact Lens Wearers|Participants wore Test Lens for 3 hours
62257538|NCT03382977|EXPERIMENTAL|Part B GM-CSF Adjuvant|VBI-1901 10 μg HCMV pp65 formulated with GM-CSF (200 μg) in 0.2 to 0.4 mL volume, given in two to four equal ID injections.
62257539|NCT03382977|EXPERIMENTAL|Part B AS01B Adjuvant|VBI-1901 10 μg HCMV pp65 formulated with AS01B (50 μg of QS-21 and 50 μg of MPL per dose) in 1.0 mL volume, given in one IM injection
62257540|NCT03382977|EXPERIMENTAL|Part C VBI-1901 with GM-CSF Adjuvant|VBI-1901 10 μg HCMV pp65 formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal ID injections.
62257541|NCT03382977|ACTIVE_COMPARATOR|Part C Standard of Care Treatment|Single-agent standard-of-care (SOC) treatment with either carmustine intravenously at a dose of 150 mg/m² or lomustine orally at a dose of 110 mg/m² (up to a maximum dose of 200 mg).
62055035|NCT04886479|ACTIVE_COMPARATOR|Non-lens Wearers|Participants did not receive Test Lens
62055036|NCT00687570|OTHER|B|Nutritional drinks 7 days before surgery instead of traditional Bowel preparation with Laxabon®
62257542|NCT00639691|EXPERIMENTAL|1|
62444489|NCT05521763|EXPERIMENTAL|Intervention package with the availability of vaccine supply only|"1. The investigators will work with the supplier to make that vaccine available at the hospital premises. Then a vaccination booth will be set up at the hospital premises and will administer the vaccine at the MRP.~2. All HCWs will be notified about only vaccine availability information by the hospital director and respective heads.~3. A list of all staff working in the study hospitals will be prepared, and they will be provided with an influenza vaccination record card with a unique identification number. The study staff will ensure receipt of vaccination cards for all participants.~4. A short message (SMS) will be delivered over the mobile phone number to all participants, e.g. vaccination program duration, venue, time, vaccine price, to cascade vaccination information to participants.~5. Posters with only vaccine delivery information (i.e. vaccination duration, vaccination venue, vaccine price) will be displayed at key hospital locations."
62257543|NCT01710995|ACTIVE_COMPARATOR|Zegerid 20mg capsule|Zegerid 20mg capsule (20mg omeprazole and 1100mg sodium carbonate
62257544|NCT01710995|ACTIVE_COMPARATOR|Zegerid 20mg powder for oral suspension|Zegerid 20mg powder for oral suspension (20mg omeprazole and 1680mg sodium bicarbonate)
62257545|NCT01710995|ACTIVE_COMPARATOR|Losec 20mg capsule|Losec 20mg capsule (20mg omeprazole)
62614516|NCT00627809|ACTIVE_COMPARATOR|2|Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed
62614517|NCT00871013|EXPERIMENTAL|MEL-VTD-PACE|Melphalan, Velcade, Thalidomide, Dexamethasone, CisPlatin, Adriamycin, Cyclophosphamide, Etoposide
62055037|NCT00687570|OTHER|A|Traditional bowel preparation with Laxabon®
62055038|NCT02163590|EXPERIMENTAL|2Hz mobilisation|A bilateral postero-anterior mobilisation applied to the fourth thoracic vertebra, at a 2Hz frequency.
62055039|NCT02163590|EXPERIMENTAL|0,5Hz mobilisation|A bilateral postero-anterior mobilisation applied to the fourth thoracic vertebra, at a 0,5Hz frequency.
62055040|NCT02163590|PLACEBO_COMPARATOR|Placebo|A simulation technique, that mimic the other groups, in this case only manual contact will be applied, without any oscillation.
62055041|NCT01381419|EXPERIMENTAL|Part A, Cohort 1|In Cohort 1, four subjects (two on active and two on placebo for first dose, and then three on active and one on placebo for subsequent doses) will be included. Subjects will be dosed at least 30 minutes apart over the dosing day and only doses administered where the predicted plasma concentration will remain below those corresponding to the MABEL.
62055042|NCT01381419|EXPERIMENTAL|Part A, cohort 2|In Cohort 2, 10 subjects will be included (8 active : 2 placebo). Dosing will start once the previous cohort (Cohort 1) has completed the Treatment Phase. For Cohort 2 and any subsequent cohorts, dosing will take place on two different days when a new dose is administered such that no more than one subject receives the agreed ascending dose on the first dosing day. Doses may be split in up to three divided doses given 2 to 3 hours apart. Dosing for the first four sessions in each cohort will be staggered over 2 days. On the first day of each dosing session, only one subject will receive the highest dose for that dosing session and at least one subject each will receive placebo. The remaining subjects in the cohort will be dosed on the second day according to the randomisation plan.
62055043|NCT01381419|EXPERIMENTAL|Part B|Part B of the study will consist of a Screening Visit (up to 30 days before the dosing session), three PET scans (where possible, all three scans may be performed in one visit when subject is admitted overnight) and a Follow-up Visit. Each subject will receive an oral dose of study drug. The dose may be split in up to three divided doses given 2 to 3 hours apart.
62055044|NCT03285048|EXPERIMENTAL|Cognitive Remediation Therapy|Cognitive Remediation Training is comprised of 8 weeks of active cognitive training using Brain HQ auditory and visual training tasks. Training is twice per week for up to 2 hours. Also included is a Bridging Group at each training session. The Bridging group provides information about cognitive training and compensatory strategies to generalize the benefits of training to daily life.
62257546|NCT04266184|EXPERIMENTAL|Kinesio tape (KT)|Abdominal and symphisis pubis supported lumbopelvic KT will be applied. This group will also receive the same educational program with the control group.
62257547|NCT04266184|ACTIVE_COMPARATOR|Pelvic belt (PB)|A narrow and flexible adjustable pelvic belt will be used in high position (just under the spina iliaca anterior superior). This group will also receive the same educational program with the control group.
62257548|NCT04266184|OTHER|Control group|This group will receive a 1-hour educational program composed of neuroscience education and ergonomic training.
62257549|NCT01323725|EXPERIMENTAL|Team-based financial incentives|Team-based financial incentives
62257550|NCT01239095|EXPERIMENTAL|Green Tea and Milk Thistle Supplements|Patients will receive green tea extract and milk thistle extract supplements for one week prior to surgery and for 30 days after surgery.
62614518|NCT03341494|EXPERIMENTAL|Gefitinib 250mg qd thalidomide 200mg qn|
62055045|NCT02789475|EXPERIMENTAL|amplodipine group|Amlodipine for 8 days and Amlodipine+Rosuvastatin for 5 days
62055046|NCT02789475|EXPERIMENTAL|rosuvastatin group|Rosuvastatin for 5 days and Amlodipine+Rosuvastatin for 8 days
62614519|NCT03341494|ACTIVE_COMPARATOR|Gefitinib 250mg qd|
62614520|NCT06403618||active surveillance|wait-and-see strategy
62614521|NCT06403618||immediate treatment|surgical treatment per clinical practice
62614522|NCT01551706|ACTIVE_COMPARATOR|ENI Patented Whole Grape Extract|ENI Patented Whole Grape Extract (350 mg) per day
62614523|NCT01551706|PLACEBO_COMPARATOR|Exicipient pill|
62614524|NCT03699813||scoliosis bleeding management based on aPTT/PT|"Bleeding and coagulopathy during surgery managed by clinical approach and aPTT/PT tests.~Blood loss, consumption of fresh frozen plasma (FFP), red blood cell units consumption and time to aPTT/PT tests result will be analysed."
62614525|NCT03699813||scoliosis bleeding management based on ROTEM|Bleeding and coagulopathy during surgery managed by ROTEM. Blood loss, consumption of fresh frozen plasma (FFP), red blood cell units consumption and time to aPTT/PT tests result will be analysed.
62614526|NCT06182436|EXPERIMENTAL|Virtual Reality Distraction|The child will play with the VR device for five minutes prior to the subcutaneous injection.
62614527|NCT06182436|ACTIVE_COMPARATOR|Standard Treatment|Standard care consisting of injecting dupilumab subcutaneously without any distractive measure, with the child having full knowledge of the intervention
62055047|NCT01746043|EXPERIMENTAL|Armodafinil + Placebo|Armodafinil 150 mg by mouth once a day for 6 weeks. Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
62257551|NCT05233020|EXPERIMENTAL|Robotic|Fifteen patients undergo rVHR operation.
62257552|NCT05233020|EXPERIMENTAL|hybrid|Fifteen patients undergo hybrid operation.
62257553|NCT04754360||Atrial fibrillation|Adult patients with atrial fibrillation
62257554|NCT04640272|EXPERIMENTAL|RBM-007 injectable solution|intravitreal injection
62257555|NCT05267275|EXPERIMENTAL|extended resection with splenic flexure mobilization|
62614528|NCT04939454|EXPERIMENTAL|sarcopenic COPD patient|
62614529|NCT04939454|OTHER|non-sarcopenic COPD patient|
62614530|NCT05649813||CRSwNP|Participants with CRSwNP in the Gulf region
62614531|NCT02657070|EXPERIMENTAL|Experimental Group|Virtual reality based therapy with augmented visuomotor feedback.
62614532|NCT02657070|ACTIVE_COMPARATOR|Control Group|Virtual reality based therapy without augmentation.
62614533|NCT05881122|EXPERIMENTAL|Mad Dog Dietary Consultation Intervention group|The intervention group received recipes for an anti-inflammatory diet and the 2-part consultation. The consultation consisted of a home-visit that included cooking and accessible kitchen equipment demonstrations, and an accompanied trip to the grocery store.
62614534|NCT05881122|NO_INTERVENTION|Control group|The controls received the recipes only.
62614535|NCT02394015||Trabectedin+ PLD|Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC.
62614536|NCT06249828|EXPERIMENTAL|MegaCarti^® application after Microfracture Surgery|The study group is applied with MegaCarti\^® after microfracture. Afterwards, they visit at 12 weeks, 24 weeks, and 48 weeks to conduct examinations and assess Questionnaires.
62614537|NCT06249828|ACTIVE_COMPARATOR|Microfracture Surgery without Medical Devices|The control group undergoes microfracture and they visit at 12 weeks, 24 weeks, and 48 weeks after surgery to conduct examinations and assess Questionnaires.
62257556|NCT01695395||Intellectual disabled adults without a mental disorder|
62055048|NCT01746043|EXPERIMENTAL|Minocycline + Placebo|Minocycline 100 mg by mouth 2 times a day for 6 weeks. Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
62055049|NCT01746043|EXPERIMENTAL|Armodafinil + Minocycline|Armodafinil 150 mg by mouth once a day for 6 weeks. Minocycline 100 mg by mouth 2 times a day for 6 weeks.Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
62055050|NCT01746043|PLACEBO_COMPARATOR|Placebos|Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
62444490|NCT05521763|EXPERIMENTAL|Intervention package with vaccinationation awareness only|"1. The hospital director and respective heads will notify all HCWs about participating in the vaccination awareness program facilitated by the study team.~2. The investigators will arrange separate seminars for each group of HCWs in the hospital to sensitize participants about the significance of receiving the influenza vaccine and the risk and benefits of influenza vaccination.~3. Posters containing messages on the importance of influenza vaccination will be displayed at key hospital locations, e.g., the main entrance of the hospital, nursing station, vaccine delivery point/place, doctors' room, nurses' room, intern doctors' room, common room canteen etc."
62257557|NCT01695395||Intellectual disabled adults with a mental disorder|
62257558|NCT01483781|EXPERIMENTAL|Canagliflozin|
62614538|NCT01516294|EXPERIMENTAL|Iray plus Lucentis|open label arm in which all subjects recieve a single 16 gy dose of radiation plus an injection of Lucentis.
62614539|NCT01211132|ACTIVE_COMPARATOR|Cap arm|
62614540|NCT01211132|ACTIVE_COMPARATOR|Standard arm|
62614541|NCT01273662|EXPERIMENTAL|Axitinib|
62257559|NCT01483781|PLACEBO_COMPARATOR|Placebo|
62257560|NCT01388660|EXPERIMENTAL|Cloas|A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin
62614542|NCT01722032|EXPERIMENTAL|Treatment|"The intervention centers' menus were modified to include more fresh fruit, fresh vegetables, low-fat (1%) or skim milk, water, less juice, and less simple carbohydrate snacks. The centers were also encouraged to incorporate fresh fruits and vegetables as often as possible for snack and meal time.~Physical Activity. Physical activity was promoted for at least 60 minutes per day. TV viewing, watching movies and playing computer games were logged and limited to 30 minutes or less per day. Schools adopted Best-Practice Policies."
62614543|NCT01722032|NO_INTERVENTION|Control|Those schools randomized to the control arm received a safety curriculum and some child care center locations received an attention control consisting of three visits from the University of Miami Safety Van which provided parents and teachers with home, car and child seat safety information. The control group received all the same pre-post measures as the intervention arms. They also received the same incentives as the intervention arms to foster involvement and ensure retention/reduce loss to follow up.
62257561|NCT01388660|ACTIVE_COMPARATOR|Plavix/Astrix|Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin)
62257562|NCT05613764|EXPERIMENTAL|"Control condition with waiting for you message"|This control condition will use the text message that the investigators found to be the best performing in their last mega-study of vaccine text messages to recommend a COVID vaccination.
62257563|NCT05613764|EXPERIMENTAL|Message from local pharmacy team|This condition will use a text message from the participant's local pharmacist recommending a COVID vaccination.
62257564|NCT01330134|EXPERIMENTAL|lidocaine onto skin prior to lidocaine subcutaneous injection|1-2ml of 1% lidocaine dripped onto the surface of the skin immediately prior to subcutaneous injection of 1% lidocaine.
62257565|NCT01330134|ACTIVE_COMPARATOR|lidocaine subcutaneous injection alone|1% lidocaine subcutaneous injection alone by standard approach
62055051|NCT05067569|EXPERIMENTAL|Digital brief behavioural therapy for insomnia|Participants randomised to the digital brief behavioural therapy for insomnia (SleepFix app) will be provided an unique access code to download the app. The intervention uses sleep retraining therapy to reduce excess time spent in bed and retrain sleep by matching time in bed (minimum of five and a half hours) to total sleep time. All participants in the intervention arm will also be provided a sleep-tracking wearable device (Fitbit) which will synchronised bed times (going to bed and rising) and are synchronised with the SleepFix app. Participants wil complete a daily sleep diary, rate sleep quality and mood. The intervention is provided for 6 weeks.
62614544|NCT05279118|EXPERIMENTAL|Ketogenic diet arm|Children who have consented to the study and have been randomised to ketogenic diet arm will get ketogenic diet under supervision while starting with rapid hiking of lipid to carbohydrate ratio and primary response will be assessed at 6 weeks. Ketogenic diet ratio will be hiked quickly upto a maximum of 4:!. The duration of ketogenic diet can be extended beyond the period of study based on response and parental choice. A minimum period of 6 weeks of diet therapy will be undertaken baring any undue adverse effects when the primary outcome will be assessed
62614545|NCT05279118|ACTIVE_COMPARATOR|ACTH arm|ACTH is the current standard therapy for children with west syndrome. Those who have been randomised to this arm will be started on high dose ACTH for 2 weeks followed by gradual tapering over remaining 4 weeks and primary response documented at 6 weeks of therapy. The high dose ACTh is 150U/m2 or 6U/kg dose administered IM daily for two weeks. After this the doses will be tapered gradually and ACTH will be stopped by 4 weeks for a total treatment duration of strictly 6 weeks.
62614546|NCT06264037||Patients with stroke|Patients with stroke during the hospital neurorehabilitation
62839477|NCT05071248|ACTIVE_COMPARATOR|patients with robot-assisted early mobilization|All patients will receive a physical examination at various time points to assess physical functionality and muscle strength, as well as a sonographic examination of leg muscles, diaphragm, and lungs. These examinations should be performed on day -1 (preoperatively), on postoperative days 1,2,3, then once a week if the patient remains in the ICU, on day 28, on the day of discharge from the ICU, and on a follow-up examination approximately 3 months after discharge from the ICU.The follow-up examination should only take place if the patients present themselves at the hospital anyway due to medically indicated follow-up examinations (not study-related). Alternatively, patients can be asked about their condition by telephone.
62839478|NCT05071248|NO_INTERVENTION|patients with conventional early mobilization (historic group)|All patients fulfill the same criteria like the intervention group and receive conventional early mobilization.
62257566|NCT00912028|ACTIVE_COMPARATOR|senofilcon A|contact lens
62257567|NCT00912028|ACTIVE_COMPARATOR|lotrafilcon B|contact lens
62614547|NCT06264037||People with Parkinson's disease|patients with Parkinson's disease the hospital neurorehabilitation
62614548|NCT06264037||Patients with multiple sclerosis|Patients with multiple sclerosis during the hospital neurorehabilitation
62614549|NCT06264037||Patients post operative oncological neuro surgery|Patients after oncological neurosurgical operation during the hospital neurorehabilitation
62614550|NCT05891106||AONDA Therapeutic|Lotrafilcon A contact lenses worn therapeutically as a bandage lens as instructed by the eye care professional
62614551|NCT03859180|EXPERIMENTAL|Focused breathing intervention group|Participants randomized to this group will be taught how to perform focused breathing for the self-management of anxiety and asked to practice for 4 minutes each day during a six week period. They may practice focused breathing in addition to the twice daily practices if they experience anxiety. They will be asked to document in a diary each time they practice focused breathing.
62839479|NCT03881215|EXPERIMENTAL|Platelet Rich Plasma|PRP
62839480|NCT03881215|ACTIVE_COMPARATOR|intra-uterine balloon|
62839481|NCT03899922||Uveitis induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of uveitis of patient treated by a drug, with a chronology compatible with the drug toxicity
62839482|NCT02403648|EXPERIMENTAL|BIOD-961, 1 mg IM|Intramuscular delivery of BIOD-961.
62839483|NCT02403648|ACTIVE_COMPARATOR|Lilly Glucagon, 1 mg IM|Intramuscular delivery of Lilly glucagon.
62839484|NCT02403648|ACTIVE_COMPARATOR|Novo Glucagon, 1 mg IM|Intramuscular delivery of Novo glucagon.
62839485|NCT02403648|EXPERIMENTAL|BIOD-961, 1 mg SC|Subcutaneous delivery of BIOD-961,
62839486|NCT02403648|ACTIVE_COMPARATOR|Lilly Glucagon, 1 mg SC|Subcutaneous delivery of Lilly glucagon.
62839487|NCT02403648|ACTIVE_COMPARATOR|Novo Glucagon, 1 mg SC|Subcutaneous delivery of Novo glucagon.
62257568|NCT00912028|ACTIVE_COMPARATOR|balafilcon A|contact lens
62257569|NCT00912028|ACTIVE_COMPARATOR|methafilcon A|contact lens
62257570|NCT00912028|ACTIVE_COMPARATOR|vifilcon A|contact lens
62257571|NCT05068466|EXPERIMENTAL|INCB054707 (Dose A)|Participants will be administered single-dose INCB054707 on Day 1 followed by once daily dose of INCB054707 on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours
62257572|NCT05068466|EXPERIMENTAL|INCB054707 (Dose B)|Participants will be administered a single-dose INCB054707 on Day 1 followed by once daily dose of INCB54707 on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours.
62614552|NCT03859180|NO_INTERVENTION|Control group|The participants randomized to this group with not be required to perform any additional behaviors for the six week period of the study. After completing post-tests they will be taught how to perform focused breathing for the self-management of anxiety.
62614553|NCT00253370|EXPERIMENTAL|BAY 43-9006, docetaxel, cisplatin|Patients receive oral BAY 43-9006 400mg twice daily on days 1-21. Patients also receive docetaxel IV, 75 mg/m2 over 1 hour and cisplatin IV, 75 mg/m2 over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62614554|NCT05262166|NO_INTERVENTION|Epidural Fentanyl group:|Epidural Fentanyl group: using an epidural catheter technique with epidural catheter set, and at L1-2 insertion level directed up to cover up to T6 sensory level, 5ml of bupivacaine 0.5%plus 50 micrograms fentanyl in a total volume of 40 ml added saline 0.9% (epidural injection of bolus of total Volume of 15 ml of 0.0625%bupivacaine with 1.25Mcg/ml fentanyl) then for next G anaesthesia hours to run in a 3-5 ml/h epidural infusion rate.
62614555|NCT05262166|EXPERIMENTAL|Intrathecal dexmedetomidine group:|Intrathecal dexmedetomidine plus heavy bupivacaine then general A
62614556|NCT03184129|EXPERIMENTAL|trial group|Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd., Wuhan, China (newly developed).
62839488|NCT06330558||group A|laparoscopic right adrenalectomy
62055052|NCT05067569|ACTIVE_COMPARATOR|Sleep Health Education wait-list control|"Participants randomised to the control group will gain access to the first Sleep Health Education module immediately following completion of baseline questionnaires. There are three modules provided bi-weekly with information about sleep health and broad details about managing sleep disturbances. Participants will receive a link to this information as each module is made available.~Upon completion of the study (week 26), the control group will receive free access to the SleepFix mobile application."
62055053|NCT06185010|EXPERIMENTAL|One Resistance Training Set (Single Session)|The participants will perform one resistance training session with one set.
62055054|NCT06185010|EXPERIMENTAL|Three Resistance Training Sets (Single Session)|The participants will perform one resistance training session with three sets.
62055055|NCT06185010|EXPERIMENTAL|One Resistance Training Set (8 Weeks)|The participants will perform eight weeks of resistance training (two sessions per week, separated by 72 hours of rest) with one set.
62055056|NCT06185010|EXPERIMENTAL|Three Resistance Training Sets (8 Weeks)|The participants will perform eight weeks of resistance training (two sessions per week, separated by 72 hours of rest) with three sets.
62055057|NCT06185010|EXPERIMENTAL|Control (8 Weeks)|The participants will not perform any form of physical exercise during the intervention period of eight weeks.
62055058|NCT02160314|PLACEBO_COMPARATOR|pad|absorbent pad control
62257573|NCT05068466|PLACEBO_COMPARATOR|Placebo (Dose A)|Participants will be administered single-dose placebo on Day 1 followed by once daily dose of placebo on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours
62257574|NCT05068466|PLACEBO_COMPARATOR|Placebo (Dose B)|Participants will be administered single-dose placebo on Day 1 followed by once daily dose of placebo on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours
62257575|NCT04898075|EXPERIMENTAL|Remote Contingency Management (CM) for nicotine abstinence|Participants will be paid increasing amounts of payment for each negative saliva cotinine test.
62257576|NCT04898075|PLACEBO_COMPARATOR|Control|Participants will be paid for providing saliva nicotine test, regardless of whether the test is positive or negative.
62257577|NCT01247636|EXPERIMENTAL|Home-exercise|
62257578|NCT03819348||TSM of HIV-negative Host|Eligible patients were HIV-infected adults who had talaromycosis that was confirmed by either microscopy or culture.
62444491|NCT05521763|EXPERIMENTAL|Intervention package with a combination of vaccine availability and awareness|"1. The investigators will work with the study hospital authority, Influenza vaccine manufacturer, and supplier company to set up a vaccination booth at the hospital premises to administer the vaccine at the market-rated price (MRP) by hospital nurses.~2. The hospital director and respective department heads will notify all HCWs to receive the offered influenza vaccine.~3. A list of all staff working in the study hospitals will be prepared, and they will be provided with an influenza vaccination record card with a unique identification number.~4. The investigators will arrange separate seminars for each group of HCWs in the hospital to sensitize participants about the significance of receiving the influenza vaccine and the risk and benefits of influenza vaccination.~5. A short message (SMS) will be delivered over the mobile phone number to all participants.~6. Posters with key messages will be displayed at key hospital locations,"
62444492|NCT05521763|NO_INTERVENTION|No intervention|In the control facility, we will not intervene in the existing knowledge and practice about influenza vaccination of the HCWs.
62614557|NCT03184129|EXPERIMENTAL|control group|Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
62614558|NCT00692497|ACTIVE_COMPARATOR|1|The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
62839489|NCT06330558||Group B|laparoscopic left adrenalectomy
62839490|NCT03468140|EXPERIMENTAL|Current end stage liver disease patients|Eculizumab
62839491|NCT03468140|OTHER|Historical controls|The Ochsner database will be used to obtain 5 historical matches for each study participant. Matching criteria for each patient will include: 1) gender; 2) (MELD) Score ± 5; 3) age ± 5 years; 4) body mass index (BMI) ± 5 kg/m2; 5) donor macrosteatosis ± 5%; and 6) CIT± 3 hours.
62839492|NCT02067481|EXPERIMENTAL|Single-arm weight loss intervention|This single-arm pre-post study, that involved one-hourly weekly diet sessions delivered by a dietician and 75-minute bi-weekly Physical Activity (AP) sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment.
62614559|NCT00692497|NO_INTERVENTION|2|Patients in the control group are randomised to use the regular patient pathway prior to day case outpatient surgery. All these patients are referred to the surgical outpatient clinic. At the outpatient clinic patients are examined by a surgeon and indications for surgery is decided by the surgeon. If indicated, patients are then referred to outpatient surgery and the surgical procedure is performed several weeks after the examination.
62614560|NCT01403506|ACTIVE_COMPARATOR|N-Acetyl Cysteine|N-Acetyl Cysteine: receive N-Acetyl Cysteine in addition to standard treatment
62614561|NCT01403506|NO_INTERVENTION|standard treatment|This group is without N-Acetyl Cysteine : just receives standard treatment
62614562|NCT04829630|OTHER|subjects who received three vs. four ID PEP at least two, five or 10 years earlier|"* 30 subjects who received three ID PEP at least two years earlier in Cambodia~* 30 subjects who received three ID PEP at least five years earlier in Cambodia~* 30 subjects who received three ID PEP at least 10 years earlier in Cambodia~* 30 subjects who received four ID PEP at least two years earlier in Madagascar~* 30 subjects who received four ID PEP at least five years earlier in Madagascar~* 30 subjects who received four ID PEP at least 10 years earlier in Madagascar"
62614563|NCT05720117|EXPERIMENTAL|PYX-201 Dose Escalation|Participants will receive escalating doses of PYX-201 to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of PYX-201. Intra-participant dose escalation may be considered for participants who have adequately tolerated therapy.
62614564|NCT06476431|ACTIVE_COMPARATOR|experimental Group 1|The experimental group 1 performs a dual cognitive task on a treadmill.
62614565|NCT06476431|ACTIVE_COMPARATOR|experimental Group 2|The experimental group 2 performs a non-dual task on a treadmill.
62614566|NCT02026804||Prenatal mental disorders|
62614567|NCT02290379|EXPERIMENTAL|TNX-201 35 mg|Drug: TNX-201 35 mg
62839493|NCT02979548|EXPERIMENTAL|Group A : Aprepitant (Add on therapy)|Aprepitant group will receive aprepitant capsules 1 h prior to chemotherapy on days 1-3 in addition to 5HT3 RA (Ondansetron). The dose of aprepitant will be given based on weight groups Weight 15-40 kg : Aprepitant 80 mg on days 1-3 Weight \> 41kg: Aprepitant 125 mg on day 1 followed by 80 mg on days 2-3 Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
62839494|NCT02979548|ACTIVE_COMPARATOR|Group B : 5HT3 RA (Ondansetron)|"On the day of chemotherapy, ondansetron will be administered to all patients as per our institutional practice in a dose of 0.15 mg/kg as an intravenous bolus 30 minutes before chemotherapy followed by every 8 hourly for 8 days.~Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day."
62055059|NCT02160314|EXPERIMENTAL|pessary|disposable, single-use pessary
62055060|NCT02417584|EXPERIMENTAL|positive airway pressure (PAP)|Treatment with positive airway pressure (PAP)
62257579|NCT05235945|EXPERIMENTAL|Online exercise intervention|A four-week preoperative physical activity intervention, involving a combination of supervised and unsupervised (live or pre-recorded), online exercise sessions. These sessions will be designed to meet the National physical activity guidelines (2020) of at least 150 minutes of low-moderate or 75 minutes of vigorous physical activity per week (or a combination of the two). The intervention will involve moderate intensity activities that aim to increase or maintain muscle strength (resistance training) as well as short bouts of vigorous aerobic exercise, using major muscle groups in the lower and upper body.
62839495|NCT04440904||Characteristic of aortic length and body surface mark|The diameters and lengths of blood vessels and the distances on the body surface were measured by three-dimensional reconstruction using related Software on CT Workstation
62614568|NCT02290379|EXPERIMENTAL|TNX-201 70 mg|Drug: TNX-201 70 mg
62614569|NCT02290379|EXPERIMENTAL|TNX-201 140 mg|Drug: TNX-201 140 mg
62055061|NCT02036645|EXPERIMENTAL|MEDI1814 IV|Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.
62055062|NCT02036645|PLACEBO_COMPARATOR|IV Placebo|Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.
62055063|NCT02036645|EXPERIMENTAL|MEDI1814 Sub Cutaneous Injection|2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort
62257580|NCT05235945|NO_INTERVENTION|Control|Usual care
62257581|NCT01933633|EXPERIMENTAL|Exercise|Regular exercise training for 10 weeks prior to assisted fertilisation
62257582|NCT01933633|NO_INTERVENTION|Control|Standard care
62257583|NCT03886753||Ease|Subjects using Ease as standard treatment. Registry and PK sampling
62614570|NCT02290379|ACTIVE_COMPARATOR|Racemic isometheptene 70 mg|Comparator: Racemic Isometheptene 70 mg
62614571|NCT02290379|PLACEBO_COMPARATOR|Placebo|Drug: Placebo
62614572|NCT02820181|EXPERIMENTAL|novel tracheostomy bi-ties|those with the novel tracheostomy bi-ties
62614573|NCT02820181|ACTIVE_COMPARATOR|traditional tracheostomy tie|those with traditional tracheostomy tie
62614574|NCT01734590|EXPERIMENTAL|Carbohydrate based food mix 1|Slowly digestible carbohydrate
62614575|NCT01734590|EXPERIMENTAL|Carbohydrate based food mix 2|Slowly digestible carbohydrate
62614576|NCT01734590|ACTIVE_COMPARATOR|Control carbohydrate based food|Rapidly digestible carbohydrate
62614577|NCT02447575|OTHER|MDI use Evaluation|"All subjects took 2 or more puffs of the placebo metered dose inhaler (MDI), attaching the Cognita electronic flowmeter to show measurements during the MDI use.~The inhaler technique is also evaluated by study staff prior to an education demonstration."
62614578|NCT00815334|EXPERIMENTAL|Patients with decreased bladder compliance|Patients who have decreased bladder compliance
62839496|NCT01107158||Group 1|Control group: these patients have mechanical dystocia; cholesterol metabolism factors are a priori not involved.
62614579|NCT00815334|ACTIVE_COMPARATOR|Patients with normal bladder compliance|Patients who have normal bladder compliance
62614580|NCT00575510|EXPERIMENTAL|Intervention|Culturally targeted behavioral and normative beliefs + knowledge/skills + salience + environmental constraints/barriers counseling
62257584|NCT03886753||Dream|Subjects using Dream as standard treatment. Registry and PK sampling
62257585|NCT03886753||Soothe|Subjects using Soothe as standard treatment. Registry and PK sampling
62257586|NCT03886753||Shine|Those subjects using Shine as standard treatment. Registry and PK sampling
62257587|NCT06166420|EXPERIMENTAL|home-based|A team made up of a Community Health Worker (CHW) and a nurse will do door-to-door sensitization and propose to eligible women to undergo HPV self-sampling test at home. Samples collected will be taken by the nurse to the hospital for HPV testing . Participants will receive a phone call: disclosure of the HPV test's result will be by phone call for HPV-negative participants; HPV-positive participants will be invited to the hospital for disclosure of their results. At the hospital, HP-positive participants will undergo visual assessment of their cervix and treatment if needed.
62614581|NCT00575510|ACTIVE_COMPARATOR|Active Control|nontargeted behavioral and normative beliefs + knowledge/skills + salience + environmental constraints/barriers counseling
62614582|NCT00575510|NO_INTERVENTION|Standard Care Only|Clinical standard of care at time of study
62614583|NCT04402359||Group A|Patients of Group A received meropenem one gram slowly IV infusion every 8 hours for 14 days and gentamicin 7 milligram (mg)/ Kilogram body weight per day slowly IV infusion once daily only for one week after ventilator for 2 weeks
62614584|NCT04402359||Group B|received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution). The solution for injection should be administered over 120 minutes.after ventilator for 2 weeks
62614585|NCT01037036|EXPERIMENTAL|Latanoprost Punctal Plug Delivery System followed by Xalatan|Subjects will have the Latanoprost Punctal Plug Delivery System placed for 4 week or until loss of efficacy. After removal of the Latanoprost Punctal Plug Delivery system, subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
62614586|NCT04519762|SHAM_COMPARATOR|Control group|Management of sepsis/ septic shock via fluids, antibiotics, vasopressors and inotropes.
62614587|NCT04519762|ACTIVE_COMPARATOR|Study group|Management of sepsis/ septic shock in addition to management of hypophosphatemia.
62614588|NCT04358315||Observational (smell or puff e-liquids)|All panel participants smell and user panelists puff flavored e-liquids and answer questions about the products.
62614589|NCT00182533|EXPERIMENTAL|1|Sertraline
62614590|NCT00182533|PLACEBO_COMPARATOR|2|Placebo
62614591|NCT04707365|EXPERIMENTAL|digestive cancers|Colorectal and pancreatobiliary cancers
62614592|NCT04271540|EXPERIMENTAL|Subjects treated with Tildrakizumab|Informed consent will be obtained from study participants willing to participate in MiNIMA. Study participants will then undergo the baseline rest/stress cardiac PET scan along with echocardiography. The final PET scan and echocardiogram will occur at 6 months after the intervention.
62257588|NCT06166420|ACTIVE_COMPARATOR|hospital-based|Community Health Worker (CHW) will do door-to-door sensitization and invite eligible women to attend cervical cancer screening at District Hospital Dschang. At the hospital they will do HPV self-sampling test. HPV-negative women will be advised to repeat the test after 5 years while HPV positive women will undergo visual assessment of the cervix with acetic acid and lugol (VIA/VILI) and treatment if needed.
62614593|NCT03888183|PLACEBO_COMPARATOR|salt solution without 0.15% HA|
62257589|NCT00349167|EXPERIMENTAL|PR-104|PR104 was administered as a 1-hr IV infusion every 21 days at doses ranging from 135 to 1400 mg/m2
62257590|NCT02847455|EXPERIMENTAL|5 mg ilaprazole|
62257591|NCT02847455|EXPERIMENTAL|10 mg ilaprazole|
62614594|NCT03888183|ACTIVE_COMPARATOR|preservative-free 0.15% HA|
62257592|NCT02847455|ACTIVE_COMPARATOR|10mg Rabeprazole|
62257593|NCT06490276|EXPERIMENTAL|Gait training with biofeedback group|The intervention is a 60-minute session and 3 sessions/week, totaling 4 weeks.
62257594|NCT06490276|ACTIVE_COMPARATOR|Gait training without biofeedback group|The intervention is a 60-minute session and 3 sessions/week, totaling 4 weeks.
62614595|NCT06729944|EXPERIMENTAL|Patients undergoing biliary tract resection|Patients undergoing biliary tract resection, as part of the normal care pathway, will be enrolled
62614596|NCT03004547||Chronic hemodialysis patients|Patients on standard in-centre 3 times a week hemodialysis
62614597|NCT03004547||Peritoneal dialysis patients|Patients on peritoneal dialysis
62614598|NCT03004547||Adult and paediatric patients with CKD stage 1-5|Patients with chronic kidney disease stage 1-5 (not dialysis dependent)
62614599|NCT03004547||Healthy adult and paediatric controls|Subjects without kidney disease
62614600|NCT03004547||Heart failure patients with and without renal dysfunction|Heart failure patients (atrial fibrillation etc ...) with and without renal dysfunction
62839497|NCT01107158||Group 2|These patients have uterine dystocia
62839498|NCT03615443||Treatment-naive metastatic non-squamous NSCLC|
62839499|NCT01681719|EXPERIMENTAL|WBV and resistance|used both interventions
62839500|NCT01681719|EXPERIMENTAL|WBV & resistance sham|used the vibrating platform and sham for resistance training
62257595|NCT02456844|EXPERIMENTAL|Group 1|Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142
62839501|NCT01681719|EXPERIMENTAL|Resistance & sham WBV|used resistance exercises and sham for vibrating platform
62839502|NCT05862168|EXPERIMENTAL|Treatment|
62614601|NCT06079632|EXPERIMENTAL|Single subject experiment|Each participant will first receive one-hour, one-on-one parent-child interaction strategy coaching every week via Telehealth until the parent's parent-child interaction skills and the child's social communication abilities reach a stable or upward trend, and the parent's sensory processing strategy utilization ability and the child's daily life participation scores that are continuously collected shows a stable or downward trend. After which, the one-hour, one-on-one sensory processing strategy coaching (C1) will be provided every week via Telehealth until the parent's sensory processing strategy utilization ability and the child's activity participation level reaches a stable trend.
62614602|NCT06079632|EXPERIMENTAL|RCT, Treatment group|Participant receive 12 weeks of sensory processing strategy coaching and parent-child interaction strategy coaching intervention.
62614603|NCT06079632|ACTIVE_COMPARATOR|RCT, Active Comparator|Participant will be provided with weekly self-learning materials and group discussion session for 12 weeks.
62257596|NCT02456844|EXPERIMENTAL|Group 2|Methotrexate,Leucovorin and BMS-986142
62257597|NCT03118232|ACTIVE_COMPARATOR|Decolonization|Nursing homes assigned to this arm will perform decolonization using topical antiseptic products.
62614604|NCT04793373|EXPERIMENTAL|EpiFaith® group|Study subject will have the epidural placement with an EpiFaith® syringe.
62614605|NCT04793373|ACTIVE_COMPARATOR|Conventional group|Study subject will have the epidural placement with a conventional glass syringe.
62614606|NCT02453256|PLACEBO_COMPARATOR|Double-Blind Placebo|Participants will receive double-blind matching placebo from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
62257598|NCT03118232|NO_INTERVENTION|Routine Bathing|Routine bathing per facility protocol.
62257599|NCT04501068||Ambu AuraGain|Ambu® AuraGainTM Patients undergoing anesthesia in which airway management includes a Ambu® AuraGainTM supraglottic airway and fulfill the inclusion criteria of the study.
62257600|NCT02614365|EXPERIMENTAL|Aerobic Exercise|6-month 3-time/week aerobic exercise, and a 12-month passive follow-up.
62257601|NCT02614365|ACTIVE_COMPARATOR|Stretch Exercise|6-month 3-time/week stretch exercise, and a 12-month passive follow-up.
62055064|NCT02036645|PLACEBO_COMPARATOR|Subcutaneous Placebo|2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort
62257602|NCT02753322|EXPERIMENTAL|Dual-task training group|"Subjects in this group will have 30 minutes of dual-task training with simultaneously performing balance and walking exercise and attention demanding tasks, and 30 minutes of stretching exercises.~The training program will last for 8 weeks with frequency of 2 sessions a week."
62257603|NCT02753322|ACTIVE_COMPARATOR|Single-task training group|"Subjects in this group will have single-task training with 30 minutes of balance and walking exercise and 30 minutes of attention demanding task performed separately.~The training program will last for 8 weeks with frequency of 2 sessions a week."
62614607|NCT02453256|EXPERIMENTAL|Double-Blind Tocilizumab|Participants will receive double-blind tocilizumab from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
62614608|NCT04769739|ACTIVE_COMPARATOR|CO2 insufflation|Colonoscopy will be performed in the traditional fashion, with minimal insufflation required to aid insertion. Cleaning in the CO2 group will be performed entirely during withdrawal.
62614609|NCT04769739|ACTIVE_COMPARATOR|WE with water|Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual decal debris, predominantly during insertion.
62614610|NCT04769739|EXPERIMENTAL|WE with 50% saline|Residual air in the colon will be removed, 50% salline (1:1 mixture of saline and water) will be infused to guide insertion through an airless lumen. Infused saline will be removed by suction, along with residual decal debris, predominantly during insertion.
62839503|NCT00882817|ACTIVE_COMPARATOR|1|Pulmonary Rehabilitation
62839504|NCT00882817|NO_INTERVENTION|2|
62839505|NCT03855059|PLACEBO_COMPARATOR|Placebos|Depending on the randomization, this group will receive a saline solution either in the IV catheter or the saline solution will be given perineural with the Mepivicaine nerve block solution.
62839506|NCT03855059|ACTIVE_COMPARATOR|Dexamethasone Sodium Phosphate|Depending on the randomization, this group will receive dexamethasone 0.1 - 0.15 mg/kg, either in the IV catheter or the dexamethasone, 0.1 - 0.15 mg/kg will be given perineural with the Mepivicaine nerve block solution.
62839507|NCT01573052|ACTIVE_COMPARATOR|Chlordiazepoxide|Chlordiazepoxide 25mg capsule or matching placebo capsule
62839508|NCT01573052|EXPERIMENTAL|Gabapentin|Gabapentin 300mg capsule or matching placebo capsule
62839509|NCT02219425|OTHER|endometrial biopsy|
62839510|NCT00296413||1|Valproate monotherapy
62839511|NCT00296413||2|Valproate monotherapy with combined oral contraceptive
62839512|NCT00296413||3|Lamotrigine monotherapy
62839513|NCT00296413||4|Lamotrigine monotherapy with combined oral contraceptive
62839514|NCT03135496||Surgery with CEC|
62839515|NCT03135496||Without CEC|
62839516|NCT03805152|ACTIVE_COMPARATOR|Neuronox(R) intramuscular injection|Neu-botulinum Toxin Type A (Neuronox(R) - botulinum toxin type A product by medyceles company , Korea) 50 units Intramuscular injection in the affected neck muscle that cause cervical dystonia every 12 weeks for 24 weeks ( 2 times , 12 week interval)
62839517|NCT03805152|ACTIVE_COMPARATOR|Dysport (R) intramuscular injection|Abo-botulinum Toxin Type A (Dysport (R) - botulinum toxin type A product by IPEN company, France ) 250 unit Intramuscular Injection in the affected neck muscle that cause cervical dystonia every 12 weeks for 24 weeks (2 times , 12 week interval)
62839518|NCT02458326|EXPERIMENTAL|Aerobic Training|The experimental group will follow the protocol: performing heating for 5 minutes at low speed on a treadmill; after heating, the speed is increased gradually until the patient reaches the proper heart rate for aerobic training obtained during cardiopulmonary exercise testing, maintaining the same for 20 minutes to perform the aerobic workout; completed, the velocity will be decreased to regain speed heating maintained for 5 minutes and finishing training. It is envisaged that in practice using the FC to ensure proper aerobic exercise for 20-60 minutes at a frequency of 3-5 times per week are effective in increasing the functional capacity of individuals with low fitness
62257604|NCT02753322|ACTIVE_COMPARATOR|Limbs exercise group|"Subjects in this group will have stretching and strengthening exercise for 60 minutes.~The training program will last for 8 weeks with frequency of 2 sessions a week."
62614611|NCT04769739|EXPERIMENTAL|WE with 25% saline|Residual air in the colon will be removed, 25% saline (1:3 mixture of saline and water) will be infused to guide insertion through an airless lumen. Infused saline will be removed by suction, along with residual decal debris, predominantly during insertion.
62614612|NCT05731752|EXPERIMENTAL|HX009|Study treatment: HX009 administered every 2 weeks (14 \[±3\] days) via intravenous infusion.
62614613|NCT03602625||Preterm group|All the live-born infants with gestational age less than 37weeks and more than 20weeks born in the cooperative hospital every day or every two or three days.
62444493|NCT02682290|OTHER|rheological measurement of sputum|"patients with COPD and patient with cystic fibrosis will perform a spontaneous expectoration.~Then all participants will have an induced expectoration with hypertonic salin solution."
62444494|NCT01987622|EXPERIMENTAL|Acupuncture|A series of acupuncture sessions within six weeks from the baseline
62614614|NCT03602625||Term group|The one next-live-born infants with gestational age at 37weeks or more than 37weeks.
62614615|NCT01814215|EXPERIMENTAL|Healthy Lifestyles Group|The Experimental Arm will receive the Keys to Healthy Family Child Care Homes intervention to be delivered over 9 months in 3 modules (3 months/module). The intervention group will be asked to participate in 3 workshops on 3 content areas. Participants will be asked to meet with a coach 3 times in-person, as well 3-9 times by phone/email, over the course of the 9-months. Three content areas are designed to help providers:(1) modify their own weight-related behaviors so they can role model healthy behaviors for children in their care (Healthy You module), (2) create environments that support children's physical activity and healthy dietary intakes (Healthy Home module), and (3) adopt sound business practices that will help them sustain the changes introduced (Healthy Business module).
62614616|NCT01814215|PLACEBO_COMPARATOR|Healthy Business Group|The Control Arm will receive the Healthy Business Education and Coaching program to be delivered over 9 months in 3 modules (3 months/module). The control group will be asked to participate in 3 workshops and a similar number of coaching contacts about their business practices. The focus on business topics is relevant, but not directly related to physical activity or nutrition.
62614617|NCT04265300|NO_INTERVENTION|Control|No intervention provided
62614618|NCT04265300|EXPERIMENTAL|Creative Roots|The intervention group will receive Creative Roots beverages and be instructed to have at least one drink (251mL) available at each meal (i.e. breakfast, lunch, and dinner) and drink as much as they would like throughout the day (i.e. ad libitum) of either Creative Roots or any other beverage they would normally consume. Subjects will be asked the keep their empty Creative Roots bottles to return them to the lab. Subjects will be instructed to refrigerate the beverages for better taste, and to refrigerate the beverages after opening.
62614619|NCT06141421||RWS study for SP CR Surgeries da Vinci SP Surgical System(SP1098)|
62614620|NCT05387694|EXPERIMENTAL|Knee prosthesis group|
62614621|NCT04510389|PLACEBO_COMPARATOR|Placebo|volunteers will receive 28 sachets containing 30g of maltodextrin to be consumed daily for 4 weeks. After that they will return to the 4-week visit and assessment when they will receive 28 sachets for the next 28 days when will return for the final vist and assessment.
62614622|NCT04510389|EXPERIMENTAL|Whey|volunteers will receive 28 sachets containing 30g of whey protein to be consumed daily for 4 weeks. After that they will return to the 4-week visit and assessment when they will receive 28 sachets for the next 28 days when will return for the final vist and assessment.
62614623|NCT03374657|EXPERIMENTAL|CPK Dose 1 (lowest dose)|CPK850, one subretinal injection to the study eye
62614624|NCT03374657|EXPERIMENTAL|CPK Dose 2 (next lowest dose)|CPK850, one subretinal injection to the study eye
62614625|NCT03374657|EXPERIMENTAL|CPK Dose 3 (third lowest dose)|CPK850, one subretinal injection to the study eye
62614626|NCT03374657|EXPERIMENTAL|CPK Dose 4 (highest dose)|CPK850, one subretinal injection to the study eye
62839519|NCT02458326|OTHER|Control Training|In the control group, these women will be guided to perform 10 minutes of heating on the treadmill with a low speed that does not cause patient effort (monitored by the Borg scale and FC close to the basement).
62839520|NCT00294970||PTSD|Patients with diagnosis of PTSD
62444495|NCT01987622|ACTIVE_COMPARATOR|Usual care|An intervention consisting of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed.
62444496|NCT02353065|ACTIVE_COMPARATOR|Control|Assessment of adequacy of reduction by bedside x-ray during period of intravenous regional anaesthesia (Biers block)
62444497|NCT02353065|EXPERIMENTAL|Ultrasound|Assessment of adequacy of reduction by bedside ultrasound performed by the treating clinician during period of intravenous regional anaesthesia (Biers block)
62444498|NCT03615794||Pregnant women with Mood Disorders|Pregnant women with a history or current diagnosis of Major Depressive Disorder or Bipolar Disorder
62839521|NCT00294970||OCD|Patients with diagnosis of OCD
62839522|NCT00294970||PTSD/OCD|Patients with diagnosis of comorbid PTSD and OCD
62055065|NCT00777907|ACTIVE_COMPARATOR|Coil embolization|Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed. Stents are not allowed in this arm.
62444499|NCT03615794||Healthy controls|Pregnant women without a history or current diagnosis of a mood disorder.
62444500|NCT01674478|EXPERIMENTAL|Microlipid with fish oil group|This group will be given early enteral lipid supplementation with Microlipid and fish oil.
62444501|NCT01674478|ACTIVE_COMPARATOR|Microlipid group|This group will be given early enteral lipid supplementation only with Microlipid.
62444502|NCT05720871|EXPERIMENTAL|Active rTMS + capsaicin 150μM|Each session (5 consecutive days) of active treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying focal (alpha D70 coil) rTMS (Magstim Rapid2, UK) over the pharyngeal M1 hotspot of the unaffected hemisphere.
62444503|NCT05720871|OTHER|sham rTMS + placebo|The same protocol will be applied, swallowing 10mL of placebo (potassium sorbate) but with the coil tilted 90º from the tangent of the skull, as a standard method for sham rTMS application.
62614627|NCT06393010|EXPERIMENTAL|exercise|Participants in the research will undergo a three-week online rehabilitation program, three times a week, lasting 40-45 minutes each session. The program includes posture, stretching, joint range of motion, strengthening exercises, pain education, and discussions. Conducted via Zoom, only the practitioner will be present during sessions. Non-attendance for two consecutive sessions or failure to provide feedback will result in exclusion. Exercises cover various body areas and types, including posture correction, range of motion, stretching, isometric neck and shoulder exercises, stick exercises, and strengthening exercises.
62444504|NCT05720871|EXPERIMENTAL|active tDCS + capsaicin 150μM|Active treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying 30min of 2.0mA tDCS (DC-Stimulator Plus, NeuroConn, Germany) with the anode placed over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5cm lateral / 1cm anterior to the vertex) and the cathode over the opposite supraorbital region.
62614628|NCT06393010|EXPERIMENTAL|plasebo|They won't exercise. They will only be evaluated at the beginning and after 2 months.
62614629|NCT00183833|EXPERIMENTAL|A|Xeloda plus gleevec
62614630|NCT00184093|EXPERIMENTAL|Gemcitabine weekly x 6 wks with concurrent external radiation|Gemcitabine 350 mg/m2 IV weekly x 6 weeks with concurrent external radiation
62614631|NCT04165096|EXPERIMENTAL|Boserolimab + Pembrolizumab|On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS boserolimab IV for a maximum of 35 cycles (approximately 2 years). All participants are premedicated 1.5 hours (±30 minutes) before infusion of boserolimab with 50 mg oral (PO) diphenhydramine (or equivalent dose of antihistamine) and 500-1000 mg of acetaminophen PO (or equivalent dose of analgesic).
62839523|NCT02682043|EXPERIMENTAL|Toy car|The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.
62055066|NCT00777907|EXPERIMENTAL|Pipeline|Placement of 1 or more Pipeline Embolization Device(s)(PED) into the parent artery at the target aneurysm.
62055067|NCT00420992|EXPERIMENTAL|ALO-01|Up to 80 mg twice a day (bid)
62055068|NCT00420992|PLACEBO_COMPARATOR|Placebo|Twice a day (bid)
62444505|NCT05720871|OTHER|sham tDCS + placebo|The same protocol will be applied, swallowing 10mL of placebo (potassium sorbate) but tDCS current is ramped up over 30s in order to simulate the active tDCS and then turned off for 30min23. Setup characteristics otherwise invariable.
62444506|NCT05912686|ACTIVE_COMPARATOR|high-dose arm|The test group will undergo high-dose atorvastatin treatment (80mg/day) for the first 3 days after the mechanical embolectomy, transitioning to a standard dose (20mg/day) of atorvastatin thereafter.
62839524|NCT03097809||Epilepsy Subjects|Subjects will be recruited from the epilepsy-monitoring unit. These subjects would have been already assessed by the Epilepsy Center at the Cleveland Clinic for surgical treatment of medically refractory epilepsy and would have already had SEEG electrodes placed in cortical and limbic areas for clinical diagnostic purposes.
62839525|NCT02622178|EXPERIMENTAL|Healthy Subjects|42 Healthy subjects with intraocular pressure less than 22 millimeters of mercury (mmHg), normal appearing optic discs and retinal nerve fiber layer, normal optical coherence technology (RNFL thickness) and normal visual field results in both eyes. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
62055069|NCT03571958|NO_INTERVENTION|Traditional OHI (Control)|"Advice giving method of OHI known as tell-show-do to inform, demonstrate, and expect patient compliance."
62055070|NCT03571958|EXPERIMENTAL|BMI (Test)|A derivative of motivational interviewing (MI), which is a patient-centered, collaborative counseling approach to strengthen an individual's intrinsic motivation towards a positive behavior change. BMI is intended for healthcare providers with limited time (5-10 minutes) to support a positive behavior change.
62055071|NCT06214286|EXPERIMENTAL|Shockwave|One group received shock wave therapy with the conventional physical therapy program including kinesio taping
62055072|NCT06214286|ACTIVE_COMPARATOR|conventional|conventional physical therapy program including kinesio taping without shock wave therapy
62055073|NCT05312567|EXPERIMENTAL|Active Treatment (FP-101)|White to off-white extended-release, round tablets containing FP-101.
62055074|NCT05312567|PLACEBO_COMPARATOR|Matching placebo|White to off-white round tablets without the active ingredient but otherwise matching in size and appearance.
62055075|NCT03591367|OTHER|Hematuria due to suspicious superficial bladder tumor|MicroRNAs-155 (miRNAs-155) and Human telomerase reverse transcriptase (hTERT)
62055076|NCT05244603|EXPERIMENTAL|Normal Hearing|Listeners with normal hearing
62055077|NCT05244603|EXPERIMENTAL|Hearing Impaired|Listeners with hearing loss
62055078|NCT02465671||Patients group|All patients with acute spontaneous basal ganglia hemorrhage admitted to the Jinhua People's Hospital within the first 24 h from stroke during the same period were enrolled.
62055079|NCT01160874|EXPERIMENTAL|TDA/H|
62055080|NCT01160874|OTHER|Sleep apnea patient|
62055081|NCT01160874|OTHER|Healthy volunteer|
62055082|NCT04436263|EXPERIMENTAL|Supplement|Ethanol-water extract of winery by-products
62055083|NCT04436263|PLACEBO_COMPARATOR|Placebo|Maltodextrin-based placebo
62444507|NCT05912686|OTHER|standard-dose arm|a standard dose (20mg/day) of atorvastatin after the mechanical embolectomy
62257605|NCT04922840|EXPERIMENTAL|High-intensity exercise (HIIT)|"Usual care; CVD risk assessment, lifestyle advice (heart-healthy diet, regular exercise, weight management and non-smoking) and relevant medication.~The 12-week intervention is carried out as individual or group sessions with maximal 4 patients, supervised by physiotherapists in primary health care. The HIIT group complete two weekly HIIT sessions and a third weekly session with exercise at moderate intensity. Exercise is tailored to each individual to provide the same relative exercise stress and to ensure progression. Target exercise intensity is tracked by a heart rate monitor.~Individual exercise session are recorded in a training diary. Succeeding the intervention, a questionnaire will be distributed to patients in the HIIT group. Semi-structured interviews will target physiotherapists supervising HIIT and 5-7 patients in the HIIT group."
62257606|NCT04922840|NO_INTERVENTION|Usual care|Control group participants receive the same treatment as usual care; CVD risk assessment including lifestyle advice (heart-healthy diet, regular exercise, weight management and non-smoking) and relevant medication. Control group participants are invited to a physiotherapist-led theoretical and practical HIIT session following study completion.
62257607|NCT06014892|EXPERIMENTAL|Intervention|"The intervention group will receive:~1. A Snoo smart sleep bassinet~2. A Willow wearable breast pump~3. Access to Maven Clinic for 24/7 on-demand perinatal care~4. A faculty mentor in their own department"
62614632|NCT04165096|EXPERIMENTAL|Pembrolizumab + MK-4830|On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-4830 IV for a maximum of 35 cycles (approximately 2 years).
62614633|NCT04165096|EXPERIMENTAL|Pembrolizumab + MK-0482|On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-0482 IV for a maximum of 35 cycles (approximately 2 years).
62614634|NCT03530319|ACTIVE_COMPARATOR|Azithromycin|Azithromycin (10mg/kg/day) is given to children with mycoplasma pneumonia for 3 days.
62614635|NCT03530319|EXPERIMENTAL|Doxycycline|Doxycycline (2-4mg/kg/day) is given to children with mycoplasma pneumonia for 5-10 days.
62614636|NCT04516863|ACTIVE_COMPARATOR|Patients with depression|"* Major depression according to DSM-V and ICD-10 (ICD F32.1, F32.2, F32.3, F33.1, F33.2, F33.3)~* Hamilton Depression Rating Scale \> 17"
62614637|NCT04516863|ACTIVE_COMPARATOR|Healthy controls|- Mental health
62614638|NCT00662428|EXPERIMENTAL|Intervention|
62839526|NCT02622178|EXPERIMENTAL|Glaucoma Suspects|45 Glaucoma suspects with glaucomatous appearance optic discs and/or thin retinal nerve fiber layer in at least one eye, normal optical coherence technology (RNFL thickness) and normal visual field results in both eyes. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
62055084|NCT04506255|EXPERIMENTAL|Silicone tape|Adult subjects will act as their own control and will be randomized to have silicone tape applied to one half of their abdominoplasty incision. Patients will apply silicone tape on a daily basis, with each piece lasting 24 hours. Tape may be removed for showers and replied after drying. Total length of treatment will be two and a half months.
62257608|NCT06014892|NO_INTERVENTION|Control|"The control arm will receive:~Current standard in the residency training program."
62257609|NCT01875783|EXPERIMENTAL|OCT imaging|All study participants will undergo optical coherence tomography imaging and will be referred to a retina specialist for further standard care evaluation and management if they are identified as having diabetic macular edema or the scan quality is not sufficient to evaluate macular status.
62444508|NCT01833949|ACTIVE_COMPARATOR|ULOD arm (N=49)|"Unilateral laparoscopic drilling~In the ULOD group, we treated the right ovary.The thermal dose of 60 J applied per one cubic centimeter of ovarian volume was calculated from the mean total energy applied on a 10 cm3 ovary (627 J) from three earlier ULOD reports. Ovarian volume had been measured by ultrasound at baseline to determine the total thermal dose to apply on the right ovary. The number of punctures (Np) was also calculated for each patient according to the following formula:~Np = 627 J / 30 W / 4 s Therefore, patients in the ULOD group differed in the number of punctures and energy received by the right ovary, depending on its volume."
62614639|NCT00662428|ACTIVE_COMPARATOR|Control|
62614640|NCT02864316|EXPERIMENTAL|Radiation-Induced Metastatic Sarcoma|a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
62614641|NCT02864316|EXPERIMENTAL|Radiation-Induced Non-Sarcoma Metastatic Solid Tumors|a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
62614642|NCT02410213|EXPERIMENTAL|Ferric Carboxymaltose (FCM)|FCM at 7.5 mg/kg or 15 mg/kg to a maximum single dose of 750 mg iron, whichever is smaller
62614643|NCT03526055|ACTIVE_COMPARATOR|<500 µS Pulse Width|Intervention includes spinal cord stimulation will be programmed to \<500 µS pulse width and patient will undergo an Algovita Spinal Cord Stimulation System trial procedures. Following the trial procedure, the subject's EPG will be set to the appropriate pulse width, based on the arm assigned, and then programmed to achieve optimal pain relief.
62055085|NCT04506255|NO_INTERVENTION|No dressing|Control treatment using the current standard of care at our institution to the other half, which is no dressing after the initial two week post-op period, will be used on the other half of the incision for comparison. Each individual patient will act as their own control.
62055086|NCT01957917|EXPERIMENTAL|NAC + Food Assistance|Arm 1 participants will receive NAC (nutritional assessment and counseling), plus a food ration once a month for 6 months if they continue their regular HIV care.
62055087|NCT01957917|EXPERIMENTAL|NAC + Cash Transfer|Arm 2 participants will receive NAC (nutritional assessment and counseling), plus a cash transfer equivalent in value to the food transfer once a month for 6 months if they continue their regular HIV care.
62614644|NCT03526055|EXPERIMENTAL|>1000 µS Pulse Width|Intervention includes spinal cord stimulation will be programmed to \>1000 µS pulse width and patient will undergo an Algovita Spinal Cord Stimulation System trial procedures. Following the trial procedure, the subject's EPG will be set to the appropriate pulse width, based on the arm assigned, and then programmed to achieve optimal pain relief.
62614645|NCT00980655|EXPERIMENTAL|1|
62055088|NCT01957917|ACTIVE_COMPARATOR|NAC Only|Arm 3 participants will receive NAC (nutrition assessment and counseling) only, which is the standard of care at the selected health facilities.
62614646|NCT04938414||subarachnoid hemorrhage|Patients with subarachnoid hemorrhage
62055089|NCT06096480||MMA group|adolescent spinal fusion patients who received intravenous multimodal analgesic strategy alone
62055090|NCT06096480||MMA-ESP-G group|adolescent spinal fusion patients who received a multimodal analgesic strategy in combination with a preoperative ESP block and oral gabapentin
62055091|NCT02584725|ACTIVE_COMPARATOR|5 mg/kg/dose tranexamic acid|5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
62055092|NCT02584725|ACTIVE_COMPARATOR|10 mg/kg/dose tranexamic acid|10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
62055093|NCT02584725|ACTIVE_COMPARATOR|15 mg/kg/dose tranexamic acid|15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
62055094|NCT03484455|EXPERIMENTAL|Hypothermic Machine Perfusion|Hypothermic Machine Perfusion with Organ Recovery Systems LLT system
62055095|NCT03484455|ACTIVE_COMPARATOR|Static Cold Storage|Standard of Care - Static Cold Storage
62614647|NCT04938414||Control|patients with non-neurological diseases
62614648|NCT03922841||Subjects with pleural disease|"The subject must meet all of the following inclusion criteria to participate in this study.~1. Evidence of pleural disease on chest radiograph or bedside ultrasound or Computed Tomography regardless of underlying aetiology~2. No age or gender restrictions~3. Ability to provide informed consent"
62614649|NCT05569993|ACTIVE_COMPARATOR|Glutamine group|30 patients will recieve .3 mg/kg of glutamine for first 7 days in ICU
62614650|NCT05569993|PLACEBO_COMPARATOR|Placcebo group|30 patients will recieve placcebo for first 7 days in ICU
62614651|NCT00783328|EXPERIMENTAL|1|Open label single arm trial
62055096|NCT02719379|EXPERIMENTAL|Asthmatics|19-20 year old asthmatics who agree to participate in study will have serum collected for analysis. PPSV23 vaccine \[Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)\] will be offered per the ACIP/CDC guidelines. Those who agree to receive the vaccine will have a second draw for serum 4-6 weeks post vaccination for immunization response. They will also be follow up after 1 year to assess for asthma control and outcomes. This arm will additionally allow for comparison of asthma outcomes and vaccine response
62055097|NCT02719379|ACTIVE_COMPARATOR|Non-asthmatics|19-20 year old non-asthmatic smokers who agree to participate in study will have serum collected for analysis. PPSV23 vaccine \[Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)\] will be offered per the ACIP/CDC guidelines. Those who agree to receive the vaccine will have a second draw for serum 4-6 weeks post vaccination for immunization response. This arm will allow for comparison of vaccine response between asthmatics and non-asthmatics (smokers)
62055098|NCT02719379|OTHER|Asthmatics - Serum Stored|Once the accrual for the experimental arm is met, 19-20 year old asthmatics who wish to participate in study will have serum collected for analysis. PPSV23 vaccine \[Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)\] will be offered per the ACIP/CDC guidelines. This arm will allow for study of baseline vaccine titers to pneumococcus in asthmatics at same time increase the vaccine uptake in the community.
62614652|NCT04043208|EXPERIMENTAL|Biofeedback|
62614653|NCT04043208|PLACEBO_COMPARATOR|Placebo|
62614654|NCT05186259|ACTIVE_COMPARATOR|Patients with chronic tinnitus|Patients with chronic subjective tinnitus (\> 3 months)
62614655|NCT05186259|ACTIVE_COMPARATOR|Patients with chronic idiopathic neck pain|Patients with chronic idiopathic neck pain (\> 3 months)
62614656|NCT05186259|ACTIVE_COMPARATOR|Patients with chronic tinnitus and chronic musculoskeletal pain|Patients with chronic tinnitus and chronic musculoskeletal pain (\> 3 months)
62614657|NCT05186259|ACTIVE_COMPARATOR|Healthy controls|Healthy controls without tinnitus or pain complaints
62614658|NCT04604964||Patients undergoing recto-sigmoid resection plus anastomosis|Patients undergoing recto-sigmoid resection and concurrent anastomosis during debulking surgery (primary or interval debunking surgery) for advanced epithelial ovarian cancer.
62614659|NCT05469022|EXPERIMENTAL|Neoadjuvant Lazertinib|Lazertinib as neoadjuvant treatment is administrated for 9 weeks before surgery. After surgical intervention the treatment is administrated upto 3 years to the patients with over stage 2 tumor. Treatment is discontinued in case of unacceptable toxicity or disease progression.
62055099|NCT02804087|EXPERIMENTAL|MobiusHD Implantation|
62055100|NCT02804087|SHAM_COMPARATOR|Sham Implantation|Sham
62614660|NCT04528329|EXPERIMENTAL|Early CS|early use of dexamethasone as early as the laboratory confirmation of inflammation.
62614661|NCT04528329|ACTIVE_COMPARATOR|Late CS|Dexamethasone is to be used lately upon the deterioration of cases
62257610|NCT04688775|EXPERIMENTAL|Sequence 1: Eptinezumab Then Placebo|Eptinezumab in the Placebo-controlled Period, followed by administration of placebo in the Active Treatment Period
62257611|NCT04688775|EXPERIMENTAL|Sequence 2: Placebo Then Eptinezumab|Placebo in the Placebo-controlled Period, followed by administration of eptinezumab in the Active Treatment Period
62257612|NCT02537886||Evaluation Group|Researchers will conduct a focus group to evaluate VIC after it has been developed and used by patients. Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC. We will use this information to enhance the generalizability of the VIC approach.
62257613|NCT01257815|EXPERIMENTAL|Ranibizumab 0.5mg|
62257614|NCT01987687|ACTIVE_COMPARATOR|Rest|Breakfast followed by a rest period prior to OGTT.
62257615|NCT01987687|EXPERIMENTAL|Exercise-immediate|Breakfast followed by exercise and an immediate OGTT
62257616|NCT01987687|EXPERIMENTAL|Exercise-delay|Breakfast followed by exercise and a delayed (1 h) OGTT.
62257617|NCT00833053|EXPERIMENTAL|IFX q 6 weeks|
62257618|NCT00833053|EXPERIMENTAL|IFX + MTX|
62257619|NCT04309942|EXPERIMENTAL|Guided Clinical Pharmacy Consultation group|Patients following either Revlimid - Velcade - Dexamethasone or Revlimid - Dexamethasone protocols with the benefit of a Guided Clinical Pharmacy Consultation before beginning oral anticancer treatment for multiple myeloma.
62257620|NCT04309942|NO_INTERVENTION|Standard group|Patients following either Revlimid - Velcade - Dexamethazone or Revlimid - Dexamethazone protocols but without the benefit of a Guided Clinical Pharmacy Consultation before beginning oral anticancer treatment for multiple myeloma.
62614662|NCT05535322||GLP-1RA|All GLP-1RA users: all T2D adults treated with GLP-1RA or initiating a GLP-1RA during the study period
62614663|NCT05535322||SGLT2i|SGLT2 inhibitors users with no GLP-1RA prescription: all T2D adults treated with SGLT2i or initiating treatment with SGLT2i during the study period and who were not treated with a GLP-1RA
62614664|NCT05535322||Insulin|Insulin users with no GLP-1RA and/or SGLT2i prescriptions: all T2D adults treated with insulin or initiating insulin treatment during the study period and who were not treated with GLP-1RA/SGLT2i
62055101|NCT01802684|EXPERIMENTAL|OPTIMOX-aflibercept|"Induction therapy (sequence #1)~* Regimen : aflibercept + modified FOLFOX7~* Duration : 6 cycles (3 months) Maintenance after induction (sequence #2) First phase (sequence #2A)~* Regimen : aflibercept + fluoropyrimidine (simplifed LV5FU2 or capecitabine)~* Duration : 6 cycles (3 months) Second phase (sequence #2B)~* Regimen : aflibercept +/- fluoropyrimidine (simplifed LV5FU2 or capecitabine) according to eligibility criteria for chemotherapy-free interval)~* Duration : until PD or limiting toxicity Reintroduction (sequence #3)~* Regimen : aflibercept + modified FOLFOX7~* Duration : 6 cycles (3 months) Maintenance after reintroduction (sequence #4)~* Regimen : aflibercept + fluoropyrimidine~* Duration : until PD or limiting toxicity"
62055102|NCT02115867|ACTIVE_COMPARATOR|Probiotic|"Probiotic arm Liquid broth~1 mL/kg every morning for 90 days"
62055103|NCT02115867|PLACEBO_COMPARATOR|Placebo|"Placebo arm Liquid broth~1 mL/kg each morning for 90 days"
62055104|NCT04936854|ACTIVE_COMPARATOR|Sirolimus|Patients with active thyroid eye disease will receive 2 mg Sirolimus (two 1 mg tablets) on the first day, followed by 0,5 mg Sirolimus (half 1 mg tablet) per day for 12 weeks.
62055105|NCT04936854|ACTIVE_COMPARATOR|Corticosteroids|Patients with active thyroid eye disease will receive 500 mg Methylprednisolone intravenously once a week for 6 weeks, followed by 250 mg once a week for 6 weeks.
62257621|NCT03402984|EXPERIMENTAL|Acotiamide|Acotiamide 100 mg t.i.d. for 3 weeks. Intake of medication 10 minutes before meal.
62257622|NCT03402984|PLACEBO_COMPARATOR|Placebo|Placebo tablets, t.i.d. for 3 weeks. Intake of placebo 10 minutes before meal.
62257623|NCT00810004|EXPERIMENTAL|Ferinject|Intravenous infusion of iron
62257624|NCT00810004|PLACEBO_COMPARATOR|Placebo|NaCL 0,9%
62257625|NCT02716051|EXPERIMENTAL|MRI|Wholebody MRI with cardio-pulmonary synchronization At day 1 , at the afternoon, patient will undergo an MRI analysis.
62257626|NCT02716051|ACTIVE_COMPARATOR|PET|At day 1 , in the morning, patient will undergo an PET analysis
62257627|NCT06097000|EXPERIMENTAL|Powered Exoskeleton Group|Rehabilitation exercises with powered exoskeletons
62257628|NCT06097000|NO_INTERVENTION|Traditional Group|Rehabilitation exercises without the use of powered exoskeletons
62055106|NCT04384016|EXPERIMENTAL|Evaluating the Safety of Skyvaricella Inj.|"The main target:~• Evaluating the safety of Live Attenuated Varicella Vaccine SKYVaricella injection in healthy Vietnamese children from 12 months to 12 years, with a single injection"
62839527|NCT02622178|EXPERIMENTAL|Glaucoma Patients|49 Glaucoma patients with repeatable abnormal visual fields, glaucomatous optic disc appearance (those with cup to disc ratio greater than 0.7, rim thinning or Retinal Nerve Fiber Layer defects indicative of glaucoma) and/or repeatable intra-ocular pressure of 23 mmHg or higher, in at least one eye. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
62055107|NCT04384016|EXPERIMENTAL|Evaluating the Immunogenicity of Skyvaricella Inj.|"Secondary target~• Evaluating the immunogenicity of Live Attenuated Varicella Vaccine SKYVaricella injection in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection."
62055108|NCT03360630|EXPERIMENTAL|Anti-PD-1 plus DC-CIK|
62055109|NCT03360630|ACTIVE_COMPARATOR|Anti-PD-1 alone|
62444509|NCT01833949|ACTIVE_COMPARATOR|BLOD arm (N=47)|"Bilateral laparoscopic drilling~In the comparator, BLOD group, all patients received 600 J per ovary (totaling 1200 J) through five punctures at 30 W for 4 s each (5 punctures x 4 s x 30 W = 600 J).~The ovaries in both groups were cooled after the drilling by irrigating the abdominal cavity with 200-300 mL of physiological saline."
62614665|NCT05535322||Miscellany|Other glucose-lowering agents users: all T2D adults who were not treated with GLP-1RA and/or SGLT2i and/or insulin during the study period.
62614666|NCT05919524|EXPERIMENTAL|SBRT with mpMRI guided focal boost|SBRT 36.25 Gy in 5 sessions of 7.25 Gy to the entire prostate (including seminal vesicles) with a DIL simultaneous integrated focal boost (SIB) up to 50 Gy in 5 sessions, with partial protection of the prostatic urethra and bladder trigone.
62839528|NCT02644499|ACTIVE_COMPARATOR|Combination therapy|Combination of Methotrexate (up to 25 mg per week), Leflunomide (20 mg once a day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop) will be given as bridging therapy.
62839529|NCT02644499|ACTIVE_COMPARATOR|Monotherapy|Methotrexate (up to 25 mg once a week) for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop) will be given as bridging therapy.
62839530|NCT06274918||Usual care|Patients undergoing surgery requiring general anesthesia. Usual hand hygiene devices and products will be accessible which will include but are not limited to those mounted to the wall outside of the operating room entrance and those present on the anesthesia cart.
62839531|NCT06274918||Personalized body worn alcohol dispenser|Anesthesia providers (attending anesthesiologist and their assistant (resident physician/Certified-Registered Nurse Anesthetist (CRNA), or student nurse assistant (SRNA) will receive a personalized, body worn alcohol dispenser in addition to usual hand hygiene devices/products for hand decontamination during surgery requiring general anesthesia.
62055110|NCT05753865|EXPERIMENTAL|SYHX2011|Patients will be administrated with SYHX2011 once every 3 weeks.
62055111|NCT05753865|ACTIVE_COMPARATOR|Paclitaxel for injection (albumin-bound)|Patients will be administrated with paclitaxel for injection (albumin-bound) once every 3 weeks.
62257629|NCT02916849|EXPERIMENTAL|Safe Step - Health Care Centre|Participants will be recruited informed and asked for participation in the study by health care professionals. If included in the study, and choosing the Safe Step exercise program as intervention, participants will be given a green prescription for exercise using the application Safe Step. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises in the application. During the four month intervention the participants will create weekly exercise plan, keep a digital exercise diary, and receive motivational feed-back within the system. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
62614667|NCT06220487|EXPERIMENTAL|ABC protocol|Adult patients with Ph-positive ALL eligble for this study will begin treatment with ABC protocol, as (A) olverembAtinib, (B) Blinatumomab and (C) Chidamide after pre-treatment with glucocorticoid, including induction and consolidation therapy for one year, and subsequent maintenance therapy for three years.
62614668|NCT01658397|EXPERIMENTAL|Fasting|Ten day fast
62839532|NCT06317740|EXPERIMENTAL|The intervention group|The intervention group received an intervention program.
62839533|NCT06317740|OTHER|Comparison group|The comparison group did not receive an intervention program.
62055112|NCT01237795|EXPERIMENTAL|0.01% fluorosurfactant|An experimental formula for denture hygiene containing 0.01% fluorosurfactant.
62055113|NCT01237795|EXPERIMENTAL|1.0% chloramine T|An experimental formula for denture hygiene containing 1.0% chloramine T.
62055114|NCT01237795|EXPERIMENTAL|0.2% chloramine T|An experimental formula for denture hygiene containing 0.2% chloramine T.
62055115|NCT01237795|ACTIVE_COMPARATOR|Proprietary dentifrice.|A proprietary denture-specific dentifrice.
62055116|NCT00887276|ACTIVE_COMPARATOR|Moxifloxacin|
62055117|NCT00887276|ACTIVE_COMPARATOR|Ampicillin; Amoxicillin|
62055118|NCT03401892|EXPERIMENTAL|Patients with a history of NAION|patients with a history of non-arteritic anterior ischemic optic neuropathy (NAION) in one eye
62055119|NCT03401892|EXPERIMENTAL|Healthy control subjects|healthy age-and sex- matched control subjects
62055120|NCT01970787|EXPERIMENTAL|RFA|Assess the feasibility, safety, and efficacy of RF to the anal canal using the HALO Ablation System to eradicate anal HSIL lesions
62444510|NCT06210412|EXPERIMENTAL|health education and yoga intervention group|"Health education program based on the Penderin Health Promotion Model; It consists of 10 sessions as a program focused on the management of menopause (increasing the quality of life by teaching physical, psychological and social coping methods in menopause, yoga practices and their importance). In the first week, introduction, first tests (Sociodemographic data form, MÖYKÖ), and general introduction of the program will be made. It is a program in which active education methods (question and answer, role play, demonstration, etc.) are used, with each session planned to last approximately 30 minutes. Final tests will be performed at the end of 12 weeks.~Yoga practice will be carried out as 45-minute sessions 2 days a week, which will last for 12 weeks, following the health education program.12. At the end of the week, MOQÖ and Yoga Transformation Impact Scale will be applied to those who have completed 10 weeks."
62444511|NCT06210412|NO_INTERVENTION|Control group|Voluntary consent forms, which will be informed during the interview, and a sociodemographic data form, Menopause-Specific Quality of Life Scale, will be filled in by participants who wish to participate in the research. They will then be invited to undergo final testing after 12 weeks.
62444512|NCT02337179|EXPERIMENTAL|Voluntary medical male circumcision|Eligible men will be circumcised according to protocol
62444513|NCT03291509|ACTIVE_COMPARATOR|In-person Group|Participants randomized to this group will have a health educator to their house for in-person meetings. Participants will use paper forms to track progress in other parts of the study. Participants will be asked follow the Enhanced Stop Light Diet (eSLD) and take part in structured physical activity each week.
62444514|NCT03291509|EXPERIMENTAL|Computer Group|Participants randomized to this group will use an iPad to talk to the health educator via video conference meetings. Participants will use the iPad to track progress in other parts of the study. Participants will be asked follow the Enhanced Stop Light Diet (eSLD) and take part in structured physical activity each week.
62444515|NCT03540810|ACTIVE_COMPARATOR|Hydroxychloroquine|All patients randomised in this arm will receive hydroxychloroquine with their usual treatment, which is antivitamin K anticoagulants
62444516|NCT03540810|PLACEBO_COMPARATOR|Placebo|All patients randomised in this arm will receive a placebo with their usual treatment, which is antivitamin K anticoagulants
62614669|NCT04379765||Grup 1: Exercise and physical therapy programme|30 patients with lumbar spinal stenosis will receive hot pack, transcutaneous electrical nerve stimulation and deep warming as a physical therapy modality , and lumber flexion and strengthening exercises were performed for 7 times/week for 3 weeks.
62614670|NCT04379765||Grup 2: Surgical procedure programme|30 patients with lumbar spinal stenosis underwent decompression operation of the relevant level.
62055121|NCT04678921|EXPERIMENTAL|Dose Level 1|1mg/kg Q1W
62055122|NCT04678921|EXPERIMENTAL|Dose Level 2|3 mg/kg Q1W
62055123|NCT04678921|EXPERIMENTAL|Dose Level 3|10mg/kg Q1W
62055124|NCT04678921|EXPERIMENTAL|Dose Level 4|15 mg/kg Q1W
62614671|NCT02650700|EXPERIMENTAL|spleen radiation plus spleen radiotherapy|Chemotherapy plus spleen radiotherapy Chemotherapy plus spleen radiotherapy are performed, simultaneously, to the subjects with advanced lung cancer who experienced chemotherapy induced thrombocytopenia (≧grade II CIT). The intervention is spleen radiotherapy.
62614672|NCT02650700|OTHER|chemotherapy|Chemotherapy is performed to the subjects with advanced lung cancer who experienced chemotherapy induced thrombocytopenia (≧grade II CIT). When severe CIT (≧grade III) occurs, the subjects should receive chemotherapy plus spleen radiotherapy. The intervention is spleen radiotherapy.
62055125|NCT04954313|EXPERIMENTAL|Treatment Group|The Treatment Group will receive the same periodontal treatment in addition to having subgingival chlorhexidine irrigation. All subjects will also complete a set of questionnaires (PANAS \& PMT) using an online form. A subset of 50 subjects from each group will be randomly selected to have oral images captured using an intra-oral scanner at Baseline and a subset of follow-up visits. Additionally, subjects in the Treatment Group will also receive brief behavioral advice from dental professionals focusing mainly on motivation and acknowledgement.
62055126|NCT04954313|ACTIVE_COMPARATOR|Control Group|"The Control Group will receive an initial periodontal treatment consisting of a pre-procedural rinse and scaling \& root planning (SRP).~Subjects in the Control Group will receive no products during the course of the study. They will receive a commercial connected toothbrush, toothpaste, mouthwash, proxabrush, and floss at the end of the study. Subjects will be scheduled to receive flow mediated dilation (FMD) and carotid intima media thickness (IMT) measurements prior to Baseline and approximately 4 weeks after their Baseline visit."
62055127|NCT05356598|EXPERIMENTAL|Peer-delivered|The arm will receive an intervention in the form of a peer-delivered video promoting help-seeking for musculoskeletal injuries while in ROTC. This video will be presented by a current ROTC cadet.
62055128|NCT05356598|EXPERIMENTAL|Authority-delivered|The arm will receive an intervention in the form of an authority-delivered video promoting help-seeking for musculoskeletal injuries while in ROTC. This video will be presented by a US Army Lieutenant Colonel who is currently a professor of military science for an ROTC battalion.
62055129|NCT05356598|OTHER|Control|The arm will receive no true intervention. Participants in the control arm will watch a video of a US Army First Lieutenant exercising with no reference to musculoskeletal injuries or help-seeking behavior.
62055130|NCT01974700|ACTIVE_COMPARATOR|Levetiracetam|
62055131|NCT01974700|NO_INTERVENTION|No anti-epileptic treatment|
62055132|NCT01038388|EXPERIMENTAL|Bortezomib, lenalidomide, dexamethasone, vorinostat|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11; lenalidomide by mouth once a day on days 1-14; dexamethasone by mouth once a day on days 1, 2, 4, 5, 8, 9, 11, and 12; and vorinostat by mouth on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~After 8 courses, patients may receive maintenance therapy comprising lenalidomide by mouth once a day on days 1-21, dexamethasone by mouth once a day on days 1, 2, 8, and 9, and bortezomib IV over 3-5 seconds or subcutaneously on days 1 and 8. Courses may repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62055133|NCT06273943|ACTIVE_COMPARATOR|Oral PrEP with daily or on-demand TDF/FTC|Participants randomly assigned to the oral PrEP regimen will be instructed to take a single dose combination of TDF 300 mg + FTC 200 mg (TDF/FTC), either daily or on-demand, according to their preferences.
62055134|NCT06273943|EXPERIMENTAL|Long-acting injectable PrEP with cabotegavir|Participants assigned to the cabotegravir group will initially take a 30mg oral tablet of cabotegravir daily for a four-week period. Following this initial phase, they will receive 13 intramuscular injections of 600mg (3mL) long-acting injectable cabotegravir (CAB-LA) administered every two months after an initial loading dose given one month after the last oral tablet.
62055135|NCT02491190|EXPERIMENTAL|Treatment|Empower educational module: After the patient activation measure/s are collected, for parents or patients assigned to the intervention arm, they will be given an opportunity to launch the EMPOWER video and interactive powerpoint. They will be able to pause on reviewing the educational material and come back to it, as with other assigned education, and they will be able to review it again if they would like. Discharge surveys will be assigned 24 hours prior to the estimated discharge time in Apex. Oneview will display notifications that the surveys have been assigned.
62257630|NCT02916849|ACTIVE_COMPARATOR|OEP - Health Care Centre|Participants will be recruited informed and asked for participation in the study by health care professionals. If included in the study, and choosing the Otago Exercise Program as intervention in the study participants will be given a green prescription for exercise with the Otago Home Exercise Programme-booklet. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises using the booklet for guidance. During the four month intervention the participants will keep a paper-based exercise diary that will be sent to the researchers on a monthly basis. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
62444517|NCT03709082|EXPERIMENTAL|Phase 1: Palbociclib 75 mg|Palbociclib 75 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
62614673|NCT05850104||classical prosthesis group|the effects of classical Chopart prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation
62055136|NCT02491190|NO_INTERVENTION|Control|Standard care: Those who opt to participate in the study will be randomly assigned to receive standard features of the media center (control group), or standard features plus the educational module intervention. They will complete online (1) a baseline patient activation survey (for patients old enough to complete and for caregivers) at the start of their participation, and (2) an end-of-study survey pre-discharge or at the end of the study period.
62055137|NCT03881098|OTHER|Squamous Cell Carcinoma Pre-Malignant Lesions|The prospective SCC-PML cohort is envisioned to provide a well-matched group of high-risk subjects that will provide clinically comparable subjects with lesional sites representing progressive and non-progressive disease.
62055138|NCT00180479|EXPERIMENTAL|1|XIENCE V® Everolimus Eluting Coronary Stent System
62055139|NCT00180479|ACTIVE_COMPARATOR|2|TAXUS® EXPRESS2™Paclitaxel Eluting Coronary Stent System
62055140|NCT05130125||fresh embryo|fresh embryo transfer after ovarian hyperstimulation
62055141|NCT05130125||frozen embryo|frozen embryo transfer after ovarian hyperstimulation
62055142|NCT01924611|ACTIVE_COMPARATOR|Control Group|Atraumatic Restorative Technique using cotton rolls.
62055143|NCT01924611|EXPERIMENTAL|Experimental Group|Atraumatic Restorative Technique using rubber dam.
62614674|NCT05850104||silicone prosthesis group|the effects of silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation
62614675|NCT00236899|EXPERIMENTAL|A: Docetaxel and Gemcitabine (Tri-weekly)|Docetaxel and Gemcitabine (Tri-weekly)
62614676|NCT00236899|EXPERIMENTAL|B: Paclitaxel and Gemcitabine (Tri-weekly)|Paclitaxel and Gemcitabine (Tri-weekly)
62839534|NCT06131736|EXPERIMENTAL|Tabata Training|HIIT training programs follow Tabata protocol. This protocol was created with the aim of improving the aerobic and anaerobic characteristics beyond the threshold (anaerobic). It consists of performing seven or eight repetitions at maximum intensity, alternating with ten seconds of passive recovery. The series lasts approximately four minutes (240 sec). Given the intensity of the Tabata protocol, it is necessary to finish the workout with a cool down of at least 10-15 minutes. It includes exercises like push-ups, split squats, box jumps, burpees, jumping rope, jumping jacks and more. This training program, lasting about 20 minutes, was repeated three times a week for a total of 6 weeks. The duration of this type of work is not accidental. In fact, it has been scientifically established that only after this period it is possible to find significant improvements in speed, strength and functional activity
62055144|NCT05593302|EXPERIMENTAL|Control Period - Intervention Period|Multiple baseline single case experimental design wherein all patients are first assigned to the control condition (or control period) are then assigned to the intervention condition (or intervention period) and finally to the follow-up period (control period). Patients are randomized for the time (t) at which they start with the intervention.
62839535|NCT06131736|EXPERIMENTAL|Cluster Traning|The cluster training consist squat, leg extension, leg curl, heel raise, French curl, barbell curl, Bench press, Incline bench press, behind the neck press with barbell, Overhead press with barbell. The movements were performed in 3 sets, each set containing 9 repetitions with 60-90 seconds of rest between each two sets. Each training session consisted of three steps: Warm up Basic training and Cool-down. Both groups performed the first and the third stage in 10 minutes
62839536|NCT01917630|EXPERIMENTAL|ALV003|
62839537|NCT01917630|PLACEBO_COMPARATOR|Placebo|
62839538|NCT00577798||Observational|Only had observational arm
62839539|NCT04867304||Healthy controls|Individuals without any known illnesses and normal labs./USG w/a. This group was used to compare baseline depression, magnetic resonance spectroscopy and plasma metabolites.
62839540|NCT04867304||Chronic pancreatitis without depression|This group contains patients with CP who does not have depression based on the Beck Depression inventory.
62614677|NCT00236899|EXPERIMENTAL|C: Docetaxel and Gemcitabine (Weekly)|Docetaxel and Gemcitabine (Weekly)
62839541|NCT04867304||Chronic pancreatitis with depression|This group contains patients with CP who has depression based on the Beck Depression inventory.
62839542|NCT05402488|EXPERIMENTAL|Verum stimulation|Verum condition: Auditory stimulation during sleep
62839543|NCT05402488|SHAM_COMPARATOR|Sham stimulation|Sham condition: Playing no tones during sleep but still recording brain activity (muted tones)
62055145|NCT05878119|ACTIVE_COMPARATOR|Investigational Product - MIB 626 plus usual physical activity (MIB-626- UPA)|The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.
62055146|NCT05878119|PLACEBO_COMPARATOR|Placebo plus usual physical activity (PL-UPA)|Matching placebo tablets will be provided by the study's Sponsor, Metro International Biotech, LLC.
62614678|NCT00236899|EXPERIMENTAL|D: Paclitaxel and Gemcitabine (Weekly)|Paclitaxel and Gemcitabine (Weekly)
62055147|NCT05878119|ACTIVE_COMPARATOR|MIB-626 plus standardized, progressive, high intensity, multidimensional exercise (MIB-626-Ex)|The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.
62614679|NCT00224237||A|Participants will be self-identified, adult Latino men and women from the community setting. The sample will comprise of a convenience sample from community-based organizations, including persons of Mexican, Puerto Rican, Cuban, Dominican, Central American, South American, or other Spanish-speaking culture.
62614680|NCT01492101|EXPERIMENTAL|NKTR-102|
62614681|NCT01492101|ACTIVE_COMPARATOR|Physician's Treatment of Choice|
62614682|NCT06239805|EXPERIMENTAL|Experimental intensive group|Experimental: intensive treatment
62839544|NCT02200640|EXPERIMENTAL|Low dose of Micardis®|
62839545|NCT02200640|EXPERIMENTAL|High dose of Micardis®|
62839546|NCT02200640|ACTIVE_COMPARATOR|Low dose of COZAAR®|
62839547|NCT02200640|ACTIVE_COMPARATOR|High dose of COZAAR®|
62839548|NCT03208647||AA Group|All the patients of AA group met a AA diagnostic criteria；
62839549|NCT03208647||Control Group|The control group were chosen from other departments who were under acute infection (such as pneumonia), acute abdominal emergency (such as appendicitis), cataract surgery;
62257631|NCT02916849|EXPERIMENTAL|Safe Step - Advertising|Participants are recruited through meetings at senior citizens organisations and interviewed by telephone for background data and choice of intervention before inclusion. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises in the Safe Step application. During the four month intervention the participants will create weekly exercise plan, keep a digital exercise diary, and receive motivational feed-back within the system. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time
62257632|NCT02916849|EXPERIMENTAL|Safe Step mentors- Advertising|This arm is exactly the same as the Safe Step Advertising group except the participants will be invited to attend group meetings with peer mentors, once a month during the intervention. The peer mentors are older adults earlier involved in the research project . They will act as role models and encourage the participants throughout the four months of exercise.
62614683|NCT06239805|ACTIVE_COMPARATOR|Control extensive group|extensive treatment
62257633|NCT02916849|ACTIVE_COMPARATOR|OEP - Advertising|Participants are recruited through meetings at senior citizens organisations and interviewed by telephone for background data and choice of intervention before inclusion. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises using the Otago booklet for guidance. During the four month intervention the participants will keep a paper-based exercise diary that will be sent to the researchers on a monthly basis. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
62257634|NCT03070470|ACTIVE_COMPARATOR|Ranolazine|Ranolazine 1500 mg two times per day for 2.5 days
62055148|NCT05878119|PLACEBO_COMPARATOR|Standardized, progressive, high intensity, multidimensional exercise plus placebo (PL-Ex)|Matching placebo tablets will be provided by the study's Sponsor, Metro International Biotech, LLC.
62614684|NCT06239805|SHAM_COMPARATOR|control sham group|sham group
62614685|NCT01590849|NO_INTERVENTION|No hormonal contraception|
62614686|NCT01590849|ACTIVE_COMPARATOR|Hormonal Contraceptive|healthy women, users of COC containing 20 mcg EE and 3 mg DRSP (Yaz®), 24 days of active pills, 4 days of pill-free interval (n=40).
62614687|NCT04766099|NO_INTERVENTION|Standard Treatment|Standard bedside coaching by labor and delivery staff
62614688|NCT04766099|EXPERIMENTAL|Educational Video|Patients will watch the provided coaching video in addition to standard bedside coaching by labor and delivery staff
62614689|NCT00729040|ACTIVE_COMPARATOR|1|Stepping Up to Health only
62614690|NCT00729040|EXPERIMENTAL|2|Stepping up to Health PLUS online message boards to talk with other participants
62257635|NCT03070470|ACTIVE_COMPARATOR|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3
62614691|NCT02658708|EXPERIMENTAL|Arm 1: Bright blue-green light|Complete the MEQ at screening, the day before 2nd cycle of chemo, and on the day of 3rd cycle of chemo, -21 day light intervention at home for 30 min once a day during 2nd cycle of chemo, Scores of ≤41 (evening types) on MEQ will have light delivered within 30 minutes of waking for 21 consecutive mornings. Score of ≥59 (morning types) on MEQ will have light delivered between 1900-2000 hours for 21 consecutive evenings. Light therapy will be self-administered using a light visor cap. On 2 randomly selected days ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter, Continuous ambulatory PSG for 24 hours at the participant's home before and after the light intervention, Complete the fatigue and sleep log on a daily basis and two visual analog scales (VAS) (diurnal fatigue and daytime sleepiness) within half an hour upon awakening, at 1200 hours, 1600 hours, 2000 hours, and within half an hour before going to bed
62614692|NCT02658708|ACTIVE_COMPARATOR|Arm 2: Dim red light|Complete the MEQ at screening, the day before 2nd cycle of chemo, and on the day of 3rd cycle of chemo, 21 day light intervention at home for 30 min once a day during 2nd cycle of chemo, Scores of ≤41 (evening types) on MEQ will have light delivered within 30 minutes of waking for 21 consecutive mornings. Score of ≥59 (morning types) on MEQ will have light delivered between 1900-2000 hours for 21 consecutive evenings. Light therapy will be self-administered using a light visor cap. On 2 days randomly selected days ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter, Continuous ambulatory PSG for 24 hours at the participant's home before and after the light intervention, Complete the fatigue and sleep log on a daily basis and two visual analog scales (VAS) (diurnal fatigue and daytime sleepiness) within half an hour upon awakening, at 1200 hours, 1600 hours, 2000 hours, and within half an hour before going to bed
62614693|NCT05799404||otosclerosis|otosclerosis patients
62614694|NCT05799404||chronic otitis media|otitis media with middle ear opacities
62614695|NCT05799404||controls|sudden ear loss, pre-implantatory imaging, vertigo, tympanic perforation
62614696|NCT00359294|EXPERIMENTAL|Zalypsis (PM00104)|
62614697|NCT05031377|EXPERIMENTAL|Experimental Arm: Integrated Intervention|Receive an integrated exercise and cardiovascular health education programme (HE programme)
62614698|NCT05031377|SHAM_COMPARATOR|Control|Receive usual care
62614699|NCT05626218|EXPERIMENTAL|Stress ball group|A stress ball will be applied to pregnant women with anxiety during NST.
62614700|NCT05626218|NO_INTERVENTION|Control group|Participants in this group will consist of people who do not routinely do any practice on their own to reduce anxiety symptoms.
62614701|NCT00464555|EXPERIMENTAL|Islet Transfusion and LSF|Participants assigned to this group will receive an islet transfusion and an immunosuppressive medication regimen containing LSF.
62614702|NCT05070143|EXPERIMENTAL|Brief education|"Participants will be randomly allocated to the Brief Education condition or one of the five treatment conditions (see below).~In this condition, participants only receive the learning module. This condition is included as a minimal intervention comparison condition that controls for the passage of time."
62614703|NCT05070143|EXPERIMENTAL|Treatment condition|All participants will receive the Brief Education intervention described above. Then, participants will be randomly allocated to one of the following conditions for habit formation.
62614704|NCT05584085|EXPERIMENTAL|Acceptance and commitment therapy integrated in diabetes education (ACT-DE)|"The proposed intervention is a six-week acceptance-based diabetes education programme (ACT-DE) comprising acceptance and commitment therapy and diabetes education.~Session 1: Diabetes education and introduction of ACT-DE programme Session 2: Mindfulness cultivation Session 3: Value clarification Session 4: Integrating ACT into diabetes self-management Session 5: Booster session Session length: 120 minutes Group-based (6-8 participants) and face-to-face mode of delivery"
62614705|NCT05584085|PLACEBO_COMPARATOR|Diabetes education|One session of diabetes education, group-based (6-8 participants) and 120 minutes via face-to-face delivery.
62614706|NCT00956488|EXPERIMENTAL|supported treadmill ambulation training|
62614707|NCT01797094|EXPERIMENTAL|Botulinum toxin Type A (44U)|44 units (U) botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
62614708|NCT01797094|EXPERIMENTAL|Botulinum toxin Type A (32U)|32 units (U) botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
62614709|NCT01111422|NO_INTERVENTION|Control|Age and sex matched peritoneal dialysis patients
62614710|NCT01111422|EXPERIMENTAL|N-acetylcysteine|N-acetylcysteine in stable peritoneal dialysis patients
62614711|NCT04679948|EXPERIMENTAL|Cocktail/ Cocktail + BI 730357|Cocktail treatment will be followed by the Test treatment (Cocktail + BI 730357) in a fixed sequence. The treatment periods are separated by a wash-out phase of at least 20 days between the two cocktail administrations.
62614712|NCT01507532|OTHER|Ceftazidime|pharmacokinetic monitoring
62614713|NCT00264030|OTHER|1|PTCA
62614714|NCT00264030|OTHER|2|PTCA with angioguard
62614715|NCT02739451|ACTIVE_COMPARATOR|standard oxygen group|Oxygen therapy will be delivered using any device or combination of devices that are part of usual care: nasal oxygen, and mask with or without a reservoir bag and with or without the Venturi system
62614716|NCT02739451|EXPERIMENTAL|High-flow nasal oxygen (HFNO) group|"Device that delivers humidified and warmed high-flow oxygen at flows greater than 15 L/min.~HFNO will be initiated at a flow rate of 50 L/min and 100% FiO2. If the target SpO2 is not reached, the flow rate will be increased to 60 L/min. Then, FiO2 will be tapered to target an SpO2≥95. The minimal flow rate will be 45 L/min"
62614717|NCT06133478|EXPERIMENTAL|NUV001 active|Single oral administration (treatment period 1 - SAD) and after a washout of at least 5 days, repeated once daily (q.d.) administrations for 14 days (treatment period 2 - MAD)
62257636|NCT03070470|ACTIVE_COMPARATOR|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days
62257637|NCT03070470|ACTIVE_COMPARATOR|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3
62257638|NCT03070470|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62257639|NCT03070470|ACTIVE_COMPARATOR|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
62839550|NCT05445791|PLACEBO_COMPARATOR|Placebo|Patients randomized to this study arm will be treated with tyrosine kinase inhibitors (Gefitinib 250 mg/day; afatinib 30-40 mg/day; erlotinib 150 mg/day) plus placebo 500 mg twice daily until disease progression.
62839551|NCT05445791|EXPERIMENTAL|Metformin|Patients randomized to this study arm will be treated with tyrosine kinase inhibitors (Gefitinib 250 mg/day; afatinib 30-40 mg/day; erlotinib 150 mg/day) plus metformin 500 mg twice daily until disease progression.
62839552|NCT05391490|EXPERIMENTAL|Single Arm Trial|Treatment with Lymphodepletion followed by a dose of KCAT19 T cells.
62839553|NCT00782847|ACTIVE_COMPARATOR|with DiaNe program|study subjects which participated in the DiaNe consultation and support program
62614718|NCT06133478|PLACEBO_COMPARATOR|NUV001 Placebo|Single oral administration (treatment period 1 - SAD) and after a washout of at least 5 days, repeated once daily (q.d.) administrations for 14 days (treatment period 2 - MAD)
62614719|NCT03056365|EXPERIMENTAL|Advanced Nurse (AN)|The outpatient detoxication procedure will be entirely managed by an advanced nurse team, using a predefined protocol decision algorithm. The protocol allows that the AN team autonomously manages the diazepam dosing during the detox period. Addiction physicians only intervenes in case of severe withdrawal symptoms or serious adverse events.
62055149|NCT04193501|EXPERIMENTAL|Experimental arms|Melatonin dose: 3mg/OD
62257640|NCT01487642|EXPERIMENTAL|Telephone counselling|
62839554|NCT00782847|NO_INTERVENTION|without DiaNe program|study subjects which received standard care by diabetologist and/or nephrologist
62055150|NCT04193501|PLACEBO_COMPARATOR|Control arms|Placebo
62257641|NCT01487642|EXPERIMENTAL|Proactive telephone counselling|
62839555|NCT01318980|EXPERIMENTAL|Period 1 Cohort 1 - GSK2190915 100mg|Period 1 - GSK2190915 100mg tablet.
62839556|NCT01318980|EXPERIMENTAL|Period 1 Cohort 2 - GSK2190915 100mg plus microtracer|Period 1 - GSK2190915 100mg tablet plus \[14C\] radiolabelled GSK2190915 microtracer solution.
62839557|NCT01318980|EXPERIMENTAL|Period 2 GSK2190915 100mg to proximal small bowel|100mg of ground half 200mg GSK2190915 tablet administered to the proximal small bowel via Enterion capsule.
62614720|NCT03056365|ACTIVE_COMPARATOR|General Practitioner (GP)|"The outpatient detoxication procedure is entrusted to a GP who will manage patients and diazepam dosing as he/she thinks best (as usual control group)"
62055151|NCT03019146|EXPERIMENTAL|High Intensity Interval Training (HIIT)|3 x 15 minute sessions per week for 6 weeks. Sessions include 5x intervals of cycling at 110% of Wmax derived from CPET, interspersed with 90s rest periods of unloaded cycling.
62614721|NCT02412254|ACTIVE_COMPARATOR|Hearing intervention|Best practices hearing rehabilitative treatment
62614722|NCT02412254|PLACEBO_COMPARATOR|Successful aging intervention|Successful aging intervention
62614723|NCT02622087|EXPERIMENTAL|Hormonal contraceptive|Women who receive one-session-treatment while they are on the hormonal contraceptive pill
62839558|NCT01318980|EXPERIMENTAL|Period 3 GSK2190915 100 mg to distal small bowel|100mg of ground half 200mg GSK2190915 tablet administered to the distal small bowel via Enterion capsule.
62055152|NCT03019146|EXPERIMENTAL|Isometric Handgrip (HOLD)|3x 15 minute sessions per week for 6 weeks Sessions include 4x intervals of 2minutes isometric handgrip contraction of dominant arm at 30% Maximal voluntary contraction, interspersed with 2minute rest periods
62055153|NCT03019146|EXPERIMENTAL|Remote Ischaemic Preconditioning (HUG)|3x 15 minute sessions per week for 6 weeks. Sessions include 3x intervals of 3 minutes of arm ischaemia (blood pressure cuff inflated to 200mmHg on dominant arm) interspersed with 3 minute rest periods.
62055154|NCT03019146|NO_INTERVENTION|Control|No intervention
62257642|NCT01487642|EXPERIMENTAL|web-based smoking cessation programme|
62257643|NCT01487642|ACTIVE_COMPARATOR|Self-help material|
62257644|NCT02308982|ACTIVE_COMPARATOR|Intravenous immunoglobulin|Intravenous immunoglobulin: 1g/kg per day for 2 consecutive days
62257645|NCT02308982|PLACEBO_COMPARATOR|Placebo|Equivalent volume to 1g/kg of IVIG per day for 2 consecutive days
62839559|NCT01318980|EXPERIMENTAL|Period 4 - GSK 100mg enteric-coated tablet|100mg enteric-coated GSK2190915 coated tablet.
62839560|NCT00485784|SHAM_COMPARATOR|control group|control group
62839561|NCT00485784|EXPERIMENTAL|prééclampsies group|prééclampsies group
62839562|NCT00485784|EXPERIMENTAL|RCIU group|RCIU group
62839563|NCT00485784|EXPERIMENTAL|MFIU group|MFIU group
62839564|NCT02864056|NO_INTERVENTION|Control|Usual care
62257646|NCT01815749|EXPERIMENTAL|Treatment (genetically modified T cell infusion)|Patients undergo mobilization for autologous stem cell collection with cytoreductive chemotherapy and filgrastim and/or plerixafor per current standard operating policies. Patients undergo myeloablative conditioning regimen per institutional standards beginning day -7 followed by hematopoietic stem cell transplantation on day 0. Patients receive CD19-CAR-specific/truncated EGFR lentiviral vector-transduced autologous T cells IV on day 2 or 3 (may be delayed up to day 45 if the patient is not yet eligible). Patients who experience disease progression and have not experienced DLTs at greater than or equal to 100 days post HSCT will be allowed to receive an optional second T cell infusion.
62257647|NCT01014325|EXPERIMENTAL|Allergen extract|
62257648|NCT01014325|PLACEBO_COMPARATOR|Placebo|
62614724|NCT02622087|EXPERIMENTAL|Naturally cycling- high estradiol|Naturally cycling women who receive one-session-treatment during a period of high estradiol
62614725|NCT02622087|EXPERIMENTAL|Naturally cycling-low estradiol|Naturally cycling women who receive one-session-treatment during a period of low estradiol
62614726|NCT00513357|EXPERIMENTAL|Melatonin|20 mg of Melatonin before going to sleep at night for a period of 4 weeks.
62257649|NCT01730508||Chronic Hepatitis B Participants|Hepatitis B e antigen (HBeAg) chronic hepatitis B (CHB) participants who received treatment with pegylated interferon alfa (peginterferon alfa) according to China labeling and China standard of care and were followed up to 1 year after treatment cessation.
62839565|NCT02864056|EXPERIMENTAL|Tai Chi|Completes 50 hours of Tai Chi, a combination of in-class and at-home practise.
62257650|NCT02518997|EXPERIMENTAL|All enrolled infants|All participants will have Parental Reading Aloud at the prescribed intervals while being monitored for cardio-respiratory stability.
62257651|NCT02084264||Arm 1: Robotic-guided, open approach|Robotic-guided, open approach
62444518|NCT03709082|EXPERIMENTAL|Phase 1: Palbociclib 100 mg|Palbociclib 100 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
62614727|NCT00513357|PLACEBO_COMPARATOR|Placebo|20 mg of Placebo before going to sleep at night for a period of 4 weeks.
62614728|NCT02308371|EXPERIMENTAL|Prospective|Patients in this arm will have fluid given based on standard clinical data (blood pressure, heart rate, lactate level, urine output) in addition to information provided by automated pulse pressure variation (PPV). PPV will be followed for first 48 hours after recruitment to the study. Fluid (normal saline, albumin 5%, hetastarch per the clinician preference) will be given in 5cc/kg increments for PPV\> 13 (in addition to standard clinical data) until PPV \< 13.
62614729|NCT02308371|NO_INTERVENTION|Retrospective|Patients in this arm were previously admitted to the PICU and were given fluid based on standard clinical data. PPV was not used to guide therapy in this group of patients.
62614730|NCT05743062|EXPERIMENTAL|Virtual Reality|Virtual reality intervention will be given 6 times in total and each session will last not more than 60 seconds.
62614731|NCT05743062|OTHER|Control|Participants will serve as their own controls. Participants will not be given any VR intervention at first but they are requested to fill out the survey to collect the baseline data.
62614732|NCT01465256|NO_INTERVENTION|Aspirin holding group|Aspirin holding group (group 1): the patients enrolled into group 1 can stop taking aspirin during colon polypectomy. The patients are usually taking aspirin for primary prevention of vascular disease and have no risk of thromboembolism despite of they stop taking aspirin temporary
62614733|NCT01465256|EXPERIMENTAL|Aspirin continuing group|Aspirin continuing group (group 2): the patients enrolled into group 2 should take aspirin during colon polypectomy because these patients are usually take thienopyridines and aspirin, and if they would stop taking aspirin during colon polypectomy, they have a thromboembolism risk.
62614734|NCT00723697||Patients|Patients addicted to opiates and requiring replacement treatment. Patients in this non-interventional study were prescribed treatment as per usual clinical practice.
62614735|NCT01048905|EXPERIMENTAL|Treatment: L-glutamine|Patients will receive an 8-week course of oral L-glutamine 10 grams TID
62257652|NCT02084264||Arm 2: control arm- non-robotic, open approach|control arm- non-robotic, open approach°
62257653|NCT00389792|NO_INTERVENTION|ATI-2042 200 mg|
62257654|NCT00389792|NO_INTERVENTION|ATI-2042 400 mg|
62257655|NCT00389792|NO_INTERVENTION|ATI-2042 600 mg|
62257656|NCT00389792|NO_INTERVENTION|ATI-2042 Placebo|
62257657|NCT03807349|OTHER|N-Force Screws|N-Force Screws augmented with N-Force Blue in Intracapsular Femur Fractures.
62257658|NCT01086891|EXPERIMENTAL|1|Patients with chronic obstructive pulmonary disease who show arterial oxygen desaturation to effort.
62257659|NCT01086891|EXPERIMENTAL|2|Patients with interstitial lung disease who show arterial oxygen desaturation to effort
62839566|NCT02096640|ACTIVE_COMPARATOR|Percutaneous dilatation tracheostomy: Smiths Medical|Type of surgical teqnique for tracheostomy: Percutaneous dilatation tracheostomy. The set for the tracheostomy is bought from Smiths Medical TM.
62839567|NCT02096640|ACTIVE_COMPARATOR|Open surgery tracheostomy|Type of surgical teqnique for tracheostomy: Open surgical tracheostomy
62257660|NCT01397799|EXPERIMENTAL|Treatment|Subjects will be enrolled into a 28-day dose-escalation study. If no DLT's are observed during the first 28 days, subjects are eligible to continue treatment in the Extension Phase and can remain on treatment until toxicity occurs or until disease progression.
62257661|NCT02631525|ACTIVE_COMPARATOR|REM-PRO|Total intravenous anesthesia with remifentanil and propofol, target controlled infusion based on Minto's and Marsh's pharmacokinetic models.
62257662|NCT02631525|ACTIVE_COMPARATOR|REM-DES|Balanced anesthesia with remifentanil target controlled infusion based on Minto's pharmacokinetic model and desflurane.
62444519|NCT03709082|EXPERIMENTAL|Phase 1: Palbociclib 125 mg|Palbociclib 125 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
62444520|NCT03709082|EXPERIMENTAL|Phase 2: RP2D|Recommended Phase 2 dose (RP2D; determined during Phase 1 Safety Run In) Palbociclib by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
62444521|NCT01766778|ACTIVE_COMPARATOR|LAF237 (vildagliptin) 50mg once daily (QD)|Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin
62614736|NCT05472818|ACTIVE_COMPARATOR|CUD Group|Participants will be scanned using anatomical magnetic resonance imaging (MRI) and PET. All participants will receive two PET scans, 4 weeks apart. CUD participants will be asked to abstain from cannabis for the 4 week period.
62614737|NCT05472818|ACTIVE_COMPARATOR|Healthy Controls|Participants will be scanned using anatomical magnetic resonance imaging (MRI) and PET. All participants will receive two PET scans, 4 weeks apart.
62614738|NCT04928469||P.1|Patients infected with the P.1 SARS-CoV-2 variant
62614739|NCT04928469||Other variants|Patients infected with SARS-CoV-2 variants other than P.1
62614740|NCT02773277|EXPERIMENTAL|Single intervention arm|All patients will be assigned the intervention arm and will receive head-impulse testing before and in the days after skull base surgery.
62614741|NCT02299505|EXPERIMENTAL|ceritinib 450 mg with a low-fat meal|Oral ceritinib QD (21 days/ cycle) at a dose of 450 mg (3×150 mg/capsule) administered in the morning immediately (within 30 minutes)following a low-fat meal.
62614742|NCT02299505|EXPERIMENTAL|ceritinib 600 mg with a low-fat meal|Oral ceritinib QD (21 days/ cycle) at a dose of 600 mg (4×150 mg/capsule) administered in the morning immediately (within 30 minutes) following a low-fat meal.
62614743|NCT02299505|ACTIVE_COMPARATOR|ceritinib 750 mg on an empty stomach|Oral ceritinib QD (21 days/ cycle) at a dose of 750 mg (5×150 mg/capsule) administered in the morning on an empty stomach (i.e., fasted from food and drink except water)
62614744|NCT04842643|EXPERIMENTAL|Epoch 2 in previous study: Immune Globulin Subcutaneous 20% Solution (IGSC)|Participants will receive between 50 and 200 mg/kg of Immunoglobulin Globulin subcutaneous (IGSC) infusion, 20 percent (%) once a week until the study drug becomes commercially available (approximately 3 years). All participants of this arm will have assigned Epoch 2 of previous study (TAK-664-3001). The dose of IGSC will be established in previous study.
62614745|NCT04842643|EXPERIMENTAL|Epoch 3 in previous study: Immune Globulin Subcutaneous 20% Solution (IGSC)|"Participants will receive between 100 and 400 mg/kg of Immunoglobulin Globulin subcutaneous (IGSC) infusion, 20 percent (%) once every 2 weeks until the study drug becomes commercially available (approximately 3 years). All participants of this arm will have assigned Epoch 3 of previous study (TAK-664-3001).The dose of IGSC will be established in previous study (TAK-664-3001).~For participants who discontinue Epoch 3 and enter Study TAK-664-3002, the dose regimen will be determined on a case-by-case basis."
62055155|NCT01718002|OTHER|Educational video on oral hygiene|The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
62257663|NCT03630211|EXPERIMENTAL|Autologous Stem Cell Transplantation|CD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 3 weeks, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
62055156|NCT00110890|NO_INTERVENTION|Standard of care|Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
62055157|NCT00110890|OTHER|Cinacalcet|Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg. Dose escalation of cinacalcet may occur based on iPTH values.
62055158|NCT02547870|EXPERIMENTAL|Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)|Participants will receive oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1 and intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
62055159|NCT02547870|EXPERIMENTAL|Aged RPV-LA|Participants will receive oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1 and IM injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
62055160|NCT01037842|ACTIVE_COMPARATOR|Metformin+Mitiglinide|mitiglinide 10 mg three times a day added to metformin 500 mg three times a day
62055161|NCT01037842|PLACEBO_COMPARATOR|Metformin+Placebo|placebo three times a day added to metformin 500 mg three times a day
62055162|NCT01468298|ACTIVE_COMPARATOR|Isostretching|
62055163|NCT01468298|ACTIVE_COMPARATOR|Global Posture Reeducation|
62055164|NCT03486028||ASAM Counties/non-computerized|Pre- and 1115-waived counties that are implementing the ASAM. Intervention is adherence to ASAM protocols.
62055165|NCT03486028||ASAM Counties/computerized|Counties using a computerized system to assist in intervention determination according to ASAM protocols. Intervention is adherence to ASAM protocols.
62839568|NCT01564576|NO_INTERVENTION|Conventional neuromuscular blockade|The dose of rocuronium (medication used for NMB during anesthesia)will be adjusted to maintain a depth of NMB of T1 of 10-20% as assessed by a nerve stimulator. At the end of surgery patients will receive neostigmine 2.5 mg and atropine 1 mg to reverse the effect of rocuronium. Extubation will be performed when train-of-four ratio ≥ 0.9.
62055166|NCT03486028||Non-ASAM Counties|"Pre- and non-waived control counties that are not implementing the ASAM. Intervention is non-adherence to ASAM protocols."
62055167|NCT01618474|EXPERIMENTAL|DX|DX: Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
62055168|NCT01618474|ACTIVE_COMPARATOR|XELOX|XELOX: oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
62257664|NCT03762369|EXPERIMENTAL|CKD-351|Latanoprost+D930
62839569|NCT01564576|EXPERIMENTAL|Profound neuromuscular blockade|Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
62839570|NCT06403969|EXPERIMENTAL|Single case experimental arm|ABA intervention with multiple baselines and follow up measurements
62839571|NCT01320917|ACTIVE_COMPARATOR|LNG-IUS|Insertion of a LNG-IUS device
62839572|NCT01320917|PLACEBO_COMPARATOR|Cu-IUD|Insertion of a Cu-IUD
62839573|NCT05414058|EXPERIMENTAL|Apo-Methylphenidate ER arm|Apo-Methylphenidate ER, 36 mg, oral, once a day, every morning, 4 weeks duration. Methylphenidate ER will be started at 18 mg to test tolerability and will be titrated at day 7 to a dose of 36 mg.
62839574|NCT05414058|NO_INTERVENTION|Treatment as usual arm|Participants in the treatment as usual arm will continue with their current treatment as decided by their treatment team.
62257665|NCT03762369|ACTIVE_COMPARATOR|Latanoprost|
62257666|NCT03762369|ACTIVE_COMPARATOR|D930|
62257667|NCT01241799|EXPERIMENTAL|1|Pancreatic biopsy with stylet in then stylet out
62257668|NCT01241799|EXPERIMENTAL|2|Pancreatic biopsy with stylet out then stylet in
62257669|NCT06158542||The women meeting the inclusion criteria, undergoing cesarean section|Women who meet the inclusion criteria and have undergone spinal anesthesia for cesarean section between November 2023 and March 2024
62055169|NCT03448445||High-risk MCI|This cohort will include participants with high-risk mild cognitive impairment (MCI).
62055170|NCT03448445||Low-risk MCI|This cohort will include participants with low-risk MCI.
62055171|NCT01073904|EXPERIMENTAL|Arm 1|
62055172|NCT01073904|ACTIVE_COMPARATOR|Arm 2|
62055173|NCT01302470|ACTIVE_COMPARATOR|Robotic placement of CS lead|CS leads placed epicardially in the area of increased dyssynchrony as demonstrated by low dose dobutamine stress testing.
62055174|NCT01302470|ACTIVE_COMPARATOR|Transvenous placement of CS lead|CS lead will be placed transvenously
62055175|NCT00000431|EXPERIMENTAL|1|Upon evaluation, participant will be treated with a single intra-ulcer injection of PDGF-B/Ad5 in the wound. Patients will receive only one dose, which will be administered during a 72-hour inpatient stay in a research unit at the Hospital of the University of Pennsylvania. This study will use a standard three-six dose-escalation scheme.
62257670|NCT04721470|EXPERIMENTAL|Combined therapy|Patients undergoing combined therapy
62839575|NCT01106248|OTHER|Eribulin Mesylate|
62055176|NCT02238002||normal angle|normal anterior chamber and open angle eyes underwent cataract surgery
62055177|NCT02238002||narrow angle|shallow anterior chamber and narrow angle eyes underwent cataract surgery
62839576|NCT01111799|EXPERIMENTAL|Clomiphene citrate + IUI + endometrial biopsy|Clomiphene citrate + IUI + endometrial biopsy
62839577|NCT01111799|NO_INTERVENTION|Clomiphene citrate + IUI|
62055178|NCT04425902|EXPERIMENTAL|Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254|All participants will receive a single dose of treatment A: Probe substrates (caffeine 200 milligram \[mg\], metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1; followed by treatment B- GSK3640254 200 mg on Days 11 to 20; further followed by treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.
62055179|NCT02141763|EXPERIMENTAL|240/160/160 mg of UCB4940|240 mg loading dose + 160 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
62055180|NCT02141763|EXPERIMENTAL|160/80/80 mg of UCB4940|160 mg loading dose + 80 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
62839578|NCT01111799|EXPERIMENTAL|gonadotrophines + IUI + endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
62839579|NCT01111799|NO_INTERVENTION|gonadotrophines + IUI|
62839580|NCT01111799|EXPERIMENTAL|natural cycle + IUI + endometrail biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
62839581|NCT01111799|NO_INTERVENTION|natural cycle + IUI|
62055181|NCT02141763|EXPERIMENTAL|80/40/40 mg of UCB4940|80 mg loading dose + 40 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
62055182|NCT02141763|EXPERIMENTAL|560/320/320 mg of UCB4940|560 mg loading dose + 320 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
62055183|NCT02141763|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride aqueous solution (physiological saline, preservative free) of pharmacopoeia (USP/Ph.Eur) quality in a 10 mL glass vial
62055184|NCT01037439|ACTIVE_COMPARATOR|Conventional ASV|Current adaptive servoventilation therapy algorithm for non invasive ventilation treatment of Cheyne-Stokes Respiration.
62055185|NCT01037439|EXPERIMENTAL|Modified ASV|Modified adaptive servoventilation algorithm for improved treatment of nocturnal breathing disorders
62257671|NCT04721470|ACTIVE_COMPARATOR|Transarterial chemoembolization|Patients undergoing Transarterial chemoembolization
62257672|NCT04721470|ACTIVE_COMPARATOR|Microwave ablation|Patients undergoing Microwave ablation
62257673|NCT02567253|EXPERIMENTAL|low dose, normothermic|CRS + normothermic (37°C) intraoperative intraperitoneal chemoperfusion, with 75mg/m² Cisplatin during 90min + adjuvant chemotherapy
62839582|NCT02486185|OTHER|SARC-F|screening test for sarcopenia being studied, the SARC-F
62839583|NCT03695367|EXPERIMENTAL|Cohort 1: HTX-011 + MMA Regimen|HTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen.
62839584|NCT03695367|EXPERIMENTAL|Cohort 2: HTX-011 + MMA Regimen + Ketorolac|HTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen and IV ketorolac.
62055186|NCT02342522|ACTIVE_COMPARATOR|Remote ischemic conditioning|AutoRIC device will be placed on the upper arm and an active RIC protocol will be delivered (4x5 min cycles of inflation to 200mmHg and deflation) prior to PPCI.
62257674|NCT02567253|EXPERIMENTAL|high dose, normothermic|CRS + normothermic (37°C) intraoperative intraperitoneal chemoperfusion, with 100mg/m² Cisplatin during 90min + adjuvant chemotherapy
62257675|NCT02567253|EXPERIMENTAL|low dose, hyperthermic|CRS + hyperthermic (41°C) intraoperative intraperitoneal chemoperfusion, with 75mg/m² Cisplatin during 90min + adjuvant chemotherapy
62839585|NCT02629900|EXPERIMENTAL|Intermittent fasting group|Participants will restrict their daily food intake (time restricted feeding) to an 8-hour time period between 1200 to 2000 hours. During the remaining 16-hour intermittent fasting period (2000 to 1200 hours) participants will be allowed to drink zero calorie beverages (diet soda pop, black coffee, tea, water, etc) in order to maintain normal hydration. There will be no attempt to restrict food intake. Rather simply to restrict the time period each day when food is consumed.
62614746|NCT03886389|EXPERIMENTAL|Carbohydrate/intervention group|Breast cancer patients receive 2 x preoperative carbohydrate loading \[PreOP(TM)\] before surgery; the 1st dose 18 hours before and 2nd dose 2-4 hours before surgery.
62614747|NCT03886389|NO_INTERVENTION|Control group|Breast cancer patients receive standard prep fasting procedure with nil food per os 8-10 hours before surgery, drinking tap water until 2 hours before surgery.
62614748|NCT03017521|EXPERIMENTAL|TAS-117|TAS-117, 16mg, orally, daily
62614749|NCT03863691|ACTIVE_COMPARATOR|amisulpride group|300 mg of the atypical antipsychotic drug amisulpride
62614750|NCT03863691|PLACEBO_COMPARATOR|placebo group|Similar looking capsules for placebo control
62055187|NCT02342522|SHAM_COMPARATOR|Sham control|Sham AutoRIC device will be placed on the upper arm and a sham RIC protocol will be delivered prior to PPCI.
62257676|NCT02567253|EXPERIMENTAL|high dose, hyperthermic|CRS + hyperthermic (41°C) intraoperative intraperitoneal chemoperfusion, with 100mg/m² Cisplatin during 90min + adjuvant chemotherapy
62257677|NCT06002399|OTHER|Bilateral monofocal intraocular lens|Standard treatment
62257678|NCT06002399|EXPERIMENTAL|Monofocal and contralateral extended depth-of-focus intraocular lens|Experimental treatment
62444522|NCT01766778|ACTIVE_COMPARATOR|LAF237 (vildagliptin) 50mg twice daily (BID)|Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin
62444523|NCT06303583|EXPERIMENTAL|IO|chemoradiotherapy sequential tislelizumab
62444524|NCT01136226|OTHER|Eligard (TM)|Eligard (TM) administered 22.5mg
62444525|NCT04857307|EXPERIMENTAL|Staccato alprazolam|The study participants will receive a single dose of Staccato alprazolam.
62444526|NCT02487784|EXPERIMENTAL|Particulate allograft + autogenous bone.|In the test arm of the study the treatment will include a mix of MinerOss CorticoCancellous Particulate allograft + autogenous bone chips.
62444527|NCT02487784|ACTIVE_COMPARATOR|Block allograft|The positive control treatment will include a block allograft plus Mineross corticocancellous particulate allograft.
62614751|NCT01611428|EXPERIMENTAL|Ipragliflozin - oral|open label
62614752|NCT01611428|EXPERIMENTAL|Ipragliflozin - i.v.|open label
62614753|NCT01836185|EXPERIMENTAL|Evacetrapib (Healthy)|Group 1: 130 milligrams (mg) evacetrapib administered once, orally, to participants with normal hepatic function
62614754|NCT01836185|EXPERIMENTAL|Evacetrapib (Hepatic, Mild)|Group 2: 130 mg evacetrapib administered once, orally, to participants with mild hepatic impairment
62614755|NCT01836185|EXPERIMENTAL|Evacetrapib (Hepatic, Moderate)|Group 3: 130 mg evacetrapib administered once, orally, to participants with moderate hepatic impairment
62257679|NCT01397370|EXPERIMENTAL|GLPG0492 oral solution|Multiple ascending doses once daily for 14 days, starting from 5 mg/day
62257680|NCT01397370|PLACEBO_COMPARATOR|Placebo oral solution|Once daily dosing for 14 days
62257681|NCT06476418|EXPERIMENTAL|distraction|Questionnaires and scales will be filled out by the researcher 5 minutes before blood collection. Only routine applications will be made. The scales will be filled again 5 minutes after blood collection.
62444528|NCT01812421|EXPERIMENTAL|Ischemic Stroke or TIA (ISTIA) patients|
62444529|NCT04459663|EXPERIMENTAL|JS001 combined with Axitinib|JS001 combined with Axitinib in the treatment of advanced non-small cell lung cancer without activated EGFR mutation, ALK fusion and ROS fusion after or during first-line chemotherapy
62444530|NCT02866175|EXPERIMENTAL|Edoxaban Regimen|Participants will be randomized to receive edoxaban 60 mg once-daily or 30 mg once-daily and clopidogrel 75 mg once-daily (or in the presence of a documented clinical need prasugrel \[5 mg or 10 mg once-daily\] or ticagrelor \[90 mg twice-daily\] may be used) used.
62444531|NCT02866175|ACTIVE_COMPARATOR|Vitamin K Antagonist Regimen|Participants will be randomized to receive VKA in combination with clopidogrel 75 mg once-daily (or in the presence of a documented clinical need prasugrel \[5mg or 10 mg once-daily\] or ticagrelor \[90 mg twice-daily\] may be used) and aspirin (100 mg once-daily, for a minimum of 1 month and up to 12 months duration.
62444532|NCT05218863||Confirmed AMI|Patients in whom diagnosis of acute mesenteric ischaemia (AMI) was confirmed. For these patients full data collection is required, including 1-year outcome. Maximum 500 patients in this group.
62614756|NCT01836185|EXPERIMENTAL|Evacetrapib (Hepatic, Severe)|Group 4: 130 mg evacetrapib administered once, orally, to participants with severe hepatic impairment
62614757|NCT01904747|EXPERIMENTAL|Palbociclib given to healthy volunteers|
62614758|NCT06210386|EXPERIMENTAL|Helmet noninvasive ventilation|1-hour treatment with helmet noninvasive ventilation (PEEP 12 cmH2O + pressure support 10 cmH2O).
62614759|NCT06210386|ACTIVE_COMPARATOR|Facemask noninvasive ventilation (facemask settings)|1-hour treatment with facemask noninvasive ventilation (PEEP 5 cmH2O + pressure support 10 cmH2O).
62614760|NCT06210386|ACTIVE_COMPARATOR|Facemask noninvasive ventilation (helmet settings)|1-hour treatment with facemask noninvasive ventilation (PEEP 12 cmH2O + pressure support 10 cmH2O).
62614761|NCT05476666|EXPERIMENTAL|Pressures measured|Venous pressure measured through a peripherial and a central venous catheter/cannula
62614762|NCT05380986|EXPERIMENTAL|Camrelizumab combined with apatinib mesylate|Camrelizumab 200 mg, IVGTT D1, apatinib mesylate, once daily. The specific prescription is determined by the investigator. Continued use until disease progression, unacceptable toxicity, or withdrawal for other reasons.
62614763|NCT06536322|NO_INTERVENTION|control group|Healthcare providers assess the oral health of the residents on a regular basis using the current oral health section of BelRAI LTCF and deliver (oral) care as usual.
62055188|NCT06222216|EXPERIMENTAL|Intervention Group (Chilled Needle):|Before subcutaneous injection, 26G sterile disposable needles will be kept in the cooling compartment of the refrigerator for at least 24 hours. Immediately before SC injection, the needle will be removed from the refrigerator, placed in the ice box and placed next to the patient's bed. The needle temperature will be kept at 0-2 degrees Celsius in the ice box and controlled using an LCD digital thermometer. If Enoxaparin Sodium is in the ready injector, the drug in the injector will be drawn into the injector suitable for 1 cc SC injection application without loss of dose. The needle of the prepared syringe will be replaced with a cooled needle. Afterwards, the injection will be made in the designated area (outer side of the upper arm) in accordance with the SC injection procedure steps. After the injection, the patient's pain assessment will be made and marked on the ILC, and ecchymosis assessment will be made after 24, 48 and 72 hours.
62257682|NCT06476418|NO_INTERVENTION|control|Questionnaires and scales will be filled out by the researcher 5 minutes before blood collection. The child will be allowed to play with the liquid moving, timed fountain toy 3 minutes before blood collection. During the process, the child will continue to play with the toy. The scales will be filled again 5 minutes after blood collection.
62257683|NCT05992103|EXPERIMENTAL|Single-Stage Gastric Fundic Ablation plus Endoscopic Sleeve Gastroplasty|Subjects will undergo fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the same endoscopic session
62614764|NCT06536322|EXPERIMENTAL|intervention group T1|Healthcare providers in intervention group T1 assess the oral health of the residents on a regular basis using the OHS-interRAI after completing an e-learning on how to perform the assessment.
62614765|NCT06536322|EXPERIMENTAL|Intervention group T2|Healthcare providers in intervention group T2 have the same condition as intervention group T1. Additionally they received on-site practical training to perform the assessment and can ask for support throughout the project concerning all aspects of oral health assessment and oral care.
62257684|NCT00627653|EXPERIMENTAL|1|
62257685|NCT02817971|EXPERIMENTAL|Enhanced feedback|"1. Monthly written feedback incorporating goal setting, and action planning delivered by a senior clinical coordinator for selected pneumonia indicators~2. Two-monthly written feedback on multiple quality of paediatric care indicators~3. Clinical network promoting clinical leadership linked to mentorship and peer to peer support~4. Improved use of health information on service delivery"
62614766|NCT01980745|ACTIVE_COMPARATOR|Chloroquine diphosphate|chloroquine diphosphate 250mg/day
62614767|NCT01980745|PLACEBO_COMPARATOR|sugar pill|sugar pill
62614768|NCT01232374|EXPERIMENTAL|Nimotuzumab plus chemo-irradiation|Nimotuzumab，chemotherapy(cisplatin )，radiotherapy
62444533|NCT05218863||AMI suspected but not confirmed|"Patients in whom acute mesenteric ischaemia (AMI) was suspected but not confirmed. For these patients minimal data will be collected, only hospital survival as outcome.~Maximum 2000 patients in this group."
62257686|NCT02817971|ACTIVE_COMPARATOR|Standard feedback|"1. Two-monthly written feedback on multiple quality of paediatric care indicators~2. Clinical network promoting clinical leadership linked to mentorship and peer to peer support~3. Improved use of health information on service delivery"
62444534|NCT03908021||children with type 1 diabetes mellitus|Saliva from 50 children ages 5 to 15 years old who had been diagnosed with type 1 diabetes mellitus and are followed at the Pediatric Endocrinology Clinic, Hadassah University Hospital Mt. Scopus and Ein Kerem, Jerusalem, Isreal,
62444535|NCT03908021||Control|50 healthy children, preferably their siblings, matched in age and gender.
62444536|NCT05613699|OTHER|supervised, group-based, online-social media exercise program|
62444537|NCT05613699|OTHER|unsupervised individual home-based training with an online-training app|
62257687|NCT03789942|ACTIVE_COMPARATOR|1. Local anaesthesia for oral surgery|Administration of local anesthesia, 40mg.epinephrine once. Oral surgery procedures Suturing End of procedure
62444538|NCT05613699|OTHER|supervised, in-person exercise program close to place of residence|
62614769|NCT01232374|PLACEBO_COMPARATOR|Placebo plus chemo-irradiation|Placebo，chemotherapy(cisplatin)，radiotherapy
62614770|NCT01030354|ACTIVE_COMPARATOR|Dietary Intervention and Higher protein meal replacement|A higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass
62614771|NCT01030354|ACTIVE_COMPARATOR|Dietary Intervention and Standard Protein Meal Replacement|Standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
62614772|NCT03544125|EXPERIMENTAL|Treatment (olaparib, durvalumab)|Participants receive olaparib PO twice a day BID for 28 days in the absence of disease progression or unacceptable toxicity. Participants then receive olaparib PO BID on days 1-28 and durvalumab IV over 1 hour on day 1. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Participants may continue on therapy beyond disease progression at the discretion of the investigator.
62839586|NCT04794569|EXPERIMENTAL|Tinzaparin|initial 3-week lead-in course of low molecular weight heparin (tinzaparin 175 units/Kg sc daily) followed by a direct oral anticoagulant (rivaroxaban 20mg po daily) for at least 3 months
62257688|NCT03789942|ACTIVE_COMPARATOR|2. Local anesthesia with Midazolam|"Administration of 40mg. epinephrine once, and Oral Sedation with Midazolam 0,5 mgr per kilo once.~Oral surgery procedures Suturing End of procedure"
62257689|NCT03789942|ACTIVE_COMPARATOR|3. Local anesthesia and sedation|"Administration of 40mg. epinephrine once, and Inhalation Sedation by Nitrous Oxide / Oxygen.~Nitrous oxide sedation Oral surgery procedures Suturing End of procedure Reduce nitrous oxide concentration"
62444539|NCT00174642|EXPERIMENTAL|1|Insulin Glargine + 3 bolus of Insulin Glulisine + Metformin
62444540|NCT00174642|EXPERIMENTAL|2|Insulin Glargine + 1 to 3 bolus of Insulin Glulisine + Metformin
62055189|NCT06222216|ACTIVE_COMPARATOR|Control Group:|SC injection will be administered to the control group in accordance with the clinical routine. No different procedure will be applied. Injection will be performed with a needle at room temperature without any instrument or procedure in accordance with the SC injection protocol. After the injection, the patient's pain assessment will be made and marked on the SCI, and ecchymosis assessment will be made after 24, 48 and 72 hours.
62055190|NCT00065585|NO_INTERVENTION|Usual care|
62055191|NCT00065585|PLACEBO_COMPARATOR|non needle control|
62055192|NCT00065585|SHAM_COMPARATOR|Acupuncture - Standardized Points|
62055193|NCT00065585|EXPERIMENTAL|Accupunture - Experimental Points|
62055194|NCT05493072|OTHER|1 - Control (scenarios 1-5) then intervention (scenarios 6-10)|Observation of control arm practice for scenarios 1-5, followed by intervention arm for scenarios 6-10.
62055195|NCT05493072|OTHER|2- Intervention (scenarios 6-10) then control (scenarios 1-5)|Observation of intervention arm for scenarios 6-10, followed by control arm practice for scenarios 1-5
62055196|NCT05493072|OTHER|3- Intervention (scenarios 1-5) then control (scenarios 6-10)|Observation of intervention arm practice for scenarios 1-5, followed by control arm for scenarios 6-10.
62055197|NCT05493072|OTHER|4- Control (scenarios 6-10) then intervention (scenarios 1-5)|Observation of control arm practice for scenarios 6-10, followed by intervention arm for scenarios 1-5.
62055198|NCT04345159||Patient with autoimmune disease|Selected using appropriate keywords in the Foundation Rothschild Hospital EMR, consenting to participate in the study.
62055199|NCT02464800||Higher cutting rate group|Vitrectomy with higher cutting rate instruments (5000 cut per minute) were performed in 174 eyes for proliferative diabetic retinopathy
62055200|NCT02464800||Conventional cutting rate group|Vitrectomy with conventional instruments (2500 cut per minute) were performed in 219 eyes for proliferative diabetic retinopathy
62055201|NCT02901626|EXPERIMENTAL|Arabin Cervical Pessary|Arabin pessary. Participants will also receive vaginal progesterone to be administered daily, if it is the local standard of care.
62055202|NCT02901626|NO_INTERVENTION|No Pessary|Participants will also receive vaginal progesterone to be administered daily, if it is the local standard of care.
62055203|NCT04906525|OTHER|Conventional physical activity guidelines|Participants are given recommendations on physical activity guidelines
62055204|NCT04906525|EXPERIMENTAL|Resistance training|Participants will undergo 6 weeks of supervised resistance training
62055205|NCT02149784|EXPERIMENTAL|Surgical treatment group|Unresectable mCRC patients who respond to chemotherapy will receive surgical resection of primary tumor.
62055206|NCT02149784|NO_INTERVENTION|Chemotherapy group|Unresectable mCRC patients who were respond to chemotherapy will continue with chemotherapy.
62055207|NCT01104194|EXPERIMENTAL|Fish-oil|
62055208|NCT01104194|PLACEBO_COMPARATOR|Placebo|Olive oil capsules, identical in appearance to fish oil capsules
62055209|NCT02000414|EXPERIMENTAL|intraperitoneal daptomycin|3 first patients : 200mg/day 3 following patients : 300mg/day
62055210|NCT05462535||Single arm, Single group(No interventional)|Observational
62055211|NCT03522805|EXPERIMENTAL|Non-invasive ventilation|Subjects will undergo a baseline night with standard polysomnography, followed by a treatment night using non-invasive ventilation under polysomnography
62055212|NCT00894673|EXPERIMENTAL|1|Heparin sodium Hipolabor
62055213|NCT00894673|ACTIVE_COMPARATOR|2|Heparim Sodium APP 5.000 USP
62055214|NCT00959543|OTHER|waterpolo players|30 throwing shoulders of waterpolo players
62055215|NCT00959543|OTHER|controle group|15 healthy patients (non waterpolo players); 30 shoulders
62055216|NCT02807428|EXPERIMENTAL|AYX1 Injection 660 mg/6 mL|Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery.
62055217|NCT02807428|PLACEBO_COMPARATOR|Placebo Injection 6 mL|Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
62055218|NCT04524598|EXPERIMENTAL|Limbix Spark|A 5 week CBT-based intervention
62055219|NCT04524598|ACTIVE_COMPARATOR|Psychoeducation|5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention
62055220|NCT02430467|ACTIVE_COMPARATOR|Caregiver-guided pain management training protocol (CG-PMT)|Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques
62444541|NCT00174642|EXPERIMENTAL|3|Insulin Glargine + 1 to 3 bolus of Insulin Glulisine + Metformin + Insulin secretagogue
62444542|NCT00240006|EXPERIMENTAL|1|Shared Solutions®
62444543|NCT00240006|EXPERIMENTAL|2|Shared Solutions® and MS Center/Office Practice Partnership
62444544|NCT06544434|EXPERIMENTAL|Laser acupuncture 3 month Group|
62444545|NCT06544434|SHAM_COMPARATOR|Sham acupuncture Group|
62444546|NCT06544434|OTHER|Control Group|
62444547|NCT05026983|EXPERIMENTAL|Treatment (encorafenib, binimetinib)|Patients receive encorafenib PO QD and binimetinib PO BID on day 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62444548|NCT05026515||4 years and under|Children coming at dental appointment, aged 4 years and under
62444549|NCT05026515||5 to 6 years|Children coming at dental appointment, aged 5 to 6 years
62257690|NCT02938884|ACTIVE_COMPARATOR|HidrateSpark Water Bottle|"Patients meeting the eligibility criteria who are interested in participating in the study and randomized to receive the HidrateSpark water bottle be given one at no cost. They will download the associated free software application to their smartphone and be given education in the outpatient setting regarding how to use the system.~All subjects in both cohorts will be provided the same questionnaire on two occasions, at the beginning and end of the trial, to determine their attitudes about fluids and potentially identify barriers to maintaining adequate hydration status (Appendix A). Additionally, standard information from the medical record including demographics, occupation, medical history and medications will be recorded."
62444550|NCT05026515||7 years and over|Children coming at dental appointment, aged 7 years and over
62839587|NCT04794569|ACTIVE_COMPARATOR|Rivaroxaban|Direct oral anticoagulant only (rivaroxaban 15mg po BID for 3 weeks followed by rivaroxaban 20mg po daily ) for at least 3 months
62839588|NCT01921595|EXPERIMENTAL|Valanced salt colloid group|
62055221|NCT02430467|ACTIVE_COMPARATOR|Enhanced treatment-as-usual (TAU)|Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
62055222|NCT01291147|ACTIVE_COMPARATOR|Levobupivicaine|
62055223|NCT01291147|PLACEBO_COMPARATOR|0.9% Saline|
62055224|NCT01368146|EXPERIMENTAL|IV Clear™|
62055225|NCT01368146|ACTIVE_COMPARATOR|Tegaderm CHG™|
62055226|NCT01368146|PLACEBO_COMPARATOR|Control Vehicle Dressing|
62055227|NCT02237508|EXPERIMENTAL|A-B1-B2-C-D|"Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 days followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62055228|NCT02237508|EXPERIMENTAL|B1-C-A-D-B2|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62055229|NCT02237508|EXPERIMENTAL|C-D-B1-B2-A|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62055230|NCT02237508|EXPERIMENTAL|D-B2-C-A-B1|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62055231|NCT02237508|EXPERIMENTAL|B2-A-D-B1-C|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62055232|NCT02237508|EXPERIMENTAL|D-C-B2-B1-A|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62444551|NCT05067049|EXPERIMENTAL|Connected EORTC-C30 arm (quality of life questionnaires on pad, phone,...)|The patients in this arm will have connected mobile app at home and they will regularly fill questionnaires. There are two different questionnaires : one with 14 questions about patient's quality of life and about the evolution of his surgical scar. One with 9 questions only about quality of life. They will also have meetings with physicians.
62444552|NCT05067049|OTHER|No QoL online follow-up arm|The patient haven't any questionnaires to fill at home. This is the normal management of the pathology. They only have different meeting with the specialist,as usual.
62444553|NCT05341128||Pediatric Participants With CPP|Pediatric participants who have been diagnosed with CPP per criteria set in the 2015 version of The Consensus on the Diagnosis and Treatment of Central Precocious Puberty and have received treatment or medical services in China between 07 August 2015 and 31 December 2024 will be assessed retrospectively using the Chinese CPP Big Data Platform database.
62839589|NCT01921595|ACTIVE_COMPARATOR|Valanced salt crystalloid group|
62839590|NCT01342159|ACTIVE_COMPARATOR|Intravitreal bevacizumab injection|
62839591|NCT01342159|ACTIVE_COMPARATOR|Intravitreal Triamcinolone injection|
62839592|NCT01342159|ACTIVE_COMPARATOR|intravitreal bavacizumab with triamcinolone|
62839593|NCT02013271||Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
62839594|NCT04287517|ACTIVE_COMPARATOR|Capacitive-Resistive Therapy Group|This group was treated with capacitive resistive diathermy and exercise
62839595|NCT04287517|SHAM_COMPARATOR|Sham Group|This group was treated with sham capacitive-resistive diathermy and exercise
62055233|NCT02237508|EXPERIMENTAL|B2-D-A-C-B1|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62257691|NCT02938884|NO_INTERVENTION|No Smart water bottle|All subjects in both cohorts will be provided the same questionnaire on two occasions, at the beginning and end of the trial, to determine their attitudes about fluids and potentially identify barriers to maintaining adequate hydration status (Appendix A). Additionally, standard information from the medical record including demographics, occupation, medical history and medications will be recorded.
62257692|NCT06047652|EXPERIMENTAL|Intervention group|The e-CPD device will be given to the participant group according to the criteria. Each participant is given access rights for 1 week to try all the features in e-CPD.
62257693|NCT04820972|EXPERIMENTAL|E-STAR group|
62257694|NCT04820972|NO_INTERVENTION|traditional group|
62257695|NCT03044249|EXPERIMENTAL|MP-101|"Week 0:~Participants received 20 milligrams (mg) MP-101 orally QD (1 x 20-mg caps) and 2 placebo caps.~Week 1:~Participants received 40 mg MP-101 orally QD (2 x 20-mg caps) and 1 placebo caps.~Week 2 through Week 9:~Participants received 60 mg MP-101 orally QD (3 x 20-mg caps )."
62257696|NCT03044249|PLACEBO_COMPARATOR|Placebo|Participants received 3 capsules (caps) of placebo orally once daily (QD) during Week 0, Week 1, and Week 2 through Week 9.
62257697|NCT02625233|EXPERIMENTAL|senofilcon C|Vistakon Investigational Contact Lens (Test)
62257698|NCT02625233|ACTIVE_COMPARATOR|comfilcon A|Marketed Monthly Wear Contact Lens (Control)
62257699|NCT05689970||STE patients|Patients with ST segment elevation (STE) and coronary arteries without significant lesions and without a serum troponin curve suggestive of acute necrosis (group without acute myocardial necrosis).
62257700|NCT05689970||STEMI patients|Patients with ST segment elevation with acute occlusion of at least one epicardial coronary artery and TIMI flow 0 or I (group with acute myocardial necrosis of ischemic origin), that meet the definition of myocardial infarction (STEMI) with an acute cardiac necrosis curve verified by measurement of troponin I or troponin T.
62257701|NCT03763071||Participants|Pregnant women in the 2nd or 3th trimester Patient-reported scales to measure sleep disorders
62257702|NCT00974246|EXPERIMENTAL|COPD, ECF residents, Advair diskus|open label treatment with Advair diskus in COPD patients
62257703|NCT06438484||Low risk|Patients with high aerobic capacity and good nutritional status were given the advice to eat healthy and stay active until surgery. Postoperative data were collected for evaluative purposes.
62257704|NCT06438484||High risk|High-risk patients followed an evidence-based multimodal prehabilitation program for five weeks, incorporating modalities tailored to address their impairments. Patients performed physical exercise training and/or received dietary counseling for five weeks, provided by a trained physiotherapist and dietitian (both \>15 years experience).
62839596|NCT00232752|EXPERIMENTAL|1|
62839597|NCT04655989|EXPERIMENTAL|Routine first|Group A subjects will be assigned to 4 weeks of routine dialysis (control group) followed by 4 weeks of treatment dialysis with the DBB-EXA ES Hemodialysis System (investigational group).
62839598|NCT04655989|EXPERIMENTAL|Investigational first|Group B subjects will be assigned to 4 weeks of treatment dialysis with the DBB-EXA ES Hemodialysis System (investigational group) followed by 4 weeks of routine dialysis (control group).
62839599|NCT04655989|OTHER|VARRM sub-study|Following completion of the initial 8-week treatment, subject's were eligible to participate in the sub-study, VARRM. The total participation time for the VARRM sub-study was approximately 1.5 weeks.
62839600|NCT02748083|ACTIVE_COMPARATOR|tDCS group|The active tDCS group will be stimulated with transcranial Direct Current Stimulation (tDCS).
62839601|NCT02748083|SHAM_COMPARATOR|Sham tDCS group|The sham tDCS group will have stimulation with sham transcranial Direct Current Stimulation (tDCS).
62839602|NCT06517355||Patients with cancer (ORL) treated by laryngectomy|
62257705|NCT00344721|ACTIVE_COMPARATOR|EPA/DHA/flaxseed|Study patients in the active comparator arm will take four soft-gel capsules containing omega-3 fatty acids (a nutritional supplement) orally daily for 3 months. Each daily dose contains eicosapentaenoic acid (450 mg), docosahexaenoic acid (300 mg) and flaxseed oil (1000 mg).
62257706|NCT00344721|PLACEBO_COMPARATOR|Wheat germ oil|Study patients in the placebo arm will take four doses of soft-gel capsules containing wheat germ oil orally daily for 3 months.
62839603|NCT05803733|EXPERIMENTAL|Blood flow restriction (BFR) with low load resistance training|Participants will have the routine rehabilitation protocol and as an addition participants will use a cuff placed proximal to the arm during upper extremity strengthening exercises. The cuff to be used is 175mm wide and 920mm long. After the cuff is placed, it will be inflated to the determined arterial occlusion pressure. The pressure will be adjusted to 50% of the BP in the arm during rest and increased to 60%. Exercises will be performed with the cuff inflated, at approximately 20-30% of 1RM. The first set will be 30 repetitions or at the limit of fatigue (maximum of 4/10), then three sets of 15 repetitions. The cuff will not be deflated for the 30 second rest between sets. A rehabilitation session will be held under the supervision of a physiotherapist. Exercise will be performed for 6 weeks with 3 sessions each week, with 1-2 days break between sessions.
62839604|NCT05803733|ACTIVE_COMPARATOR|Control Group|Participants only will have the rehabilitation protocol including general physiotherapeutic approaches such as range of motion exercises and strength training which is a daily part of their nursing home services.
62839605|NCT06067217|EXPERIMENTAL|Tranexamic acid|Tranexamic acid 250 mg oral three times/day
62257707|NCT06489587|ACTIVE_COMPARATOR|Placebo Supplementation|Participants given Placebo (20 grams of glucose) daily in 5-gram servings (4 capsules), 4 times per day for 2 days.
62614773|NCT04374292|EXPERIMENTAL|Intervention group|"Intervention group mothers (n = 90) attended six weekly group sessions, which were led by nutritionists and lasted 90 minutes.~The key message was that healthy dietary habits and health risks are acquired at home and that opportunities for change can be identified in the processes that surround meal times. It begins with selecting and purchasing food, followed by preparation and consumption behaviors. Mothers were encouraged to participate in the sessions which involved the use of food models, videos, slides, and, in some cases, real food. Upon completing each session, mothers were given printed material to add to a home consultation manual.~Upon concluding consultations and group sessions, mother/child pairs from both groups were asked to return for monthly follow-ups over the next three months."
62257708|NCT06489587|EXPERIMENTAL|Creatine Supplementation|Participants given Creatine (20 grams of glucose) daily in 5-gram servings (4 capsules), 4 times per day for 2 days.
62614774|NCT04374292|ACTIVE_COMPARATOR|Control group|Control group mothers and children (n = 87) were given the usual nutritional consultation and were prescribed diets that covered their energy requirements according to their age and sex. Similarly, CG mother/child pairs received information regarding food groups and portion sizes, were trained in the use of the food equivalence system to encourage variation, and were instructed on how to prepare the diet at home.
62257709|NCT00853320|EXPERIMENTAL|A|Oxycodone hydrochloride tablet 15 mg
62257710|NCT00853320|ACTIVE_COMPARATOR|B|Roxicodone™ tablet 15 mg
62257711|NCT05286021||Supine group|Children undergoing surgery in the supine position using the Ambu Auragain
62257712|NCT05286021||Prone group|Children undergoing surgery in the prone position using the Ambu Auragain
62444554|NCT00325403|ACTIVE_COMPARATOR|UT-15C (oral treprositnil)|Subjects receive UT-15C (oral treprostinil) twice daily.
62614775|NCT03306979|ACTIVE_COMPARATOR|N-acetylcysteine|Participants randomized into the N-acetylcysteine arm will be receiving N-acetylcysteine for 24 weeks.
62444555|NCT00325403|PLACEBO_COMPARATOR|Placebo|Subjects receive placebo (sugar pill) twice daily.
62444556|NCT01685970|PLACEBO_COMPARATOR|High volume Split-dose PEG|Patients who are scheduled afternoon colonoscopy ingest high volume split-dose PEG for bowel preparation
62444557|NCT01685970|ACTIVE_COMPARATOR|2 sachets of picosulfate|Patients who are scheduled afternoon colonoscopy ingest 2 sachets of picosulfate at the day of colonoscopy.
62614776|NCT03306979|PLACEBO_COMPARATOR|Placebo|Participants randomized into the placebo arm will be receiving placebo for 24 weeks.
62614777|NCT00824434|EXPERIMENTAL|Experimental Stent|
62614778|NCT03595865|EXPERIMENTAL|residual primary open angle glaucoma|Each eye will be preformed tafluprostin 0.0015% at 9 PM, 1 time daily for 6months
62257713|NCT00984971|EXPERIMENTAL|Tenofovir|
62257714|NCT00984971|PLACEBO_COMPARATOR|HEC Placebo|
62257715|NCT00984971|OTHER|Open label tenofovir tablet|
62257716|NCT06445946|EXPERIMENTAL|Metformin|Metformin as either immediate- or extended-release formulations can be utilized, and titrated to a maximum daily dose of 2,500 mg. Participants receiving metformin will have insulin added only if they have not achieved euglycemia for at least 30% of glucose values after generally receiving the maximum daily dose of metformin of 2,500 mg, or in select situations in the setting of participant intolerance due to mild gastrointestinal symptoms. Participants will be asked to continue taking metformin after treatment supplementation with insulin.
62257717|NCT06445946|EXPERIMENTAL|Insulin|Insulin will be initiated utilizing clinical standards using trimester-specific weight-based dosing criteria, including both basal and prandial insulins for up to a total of 4 daily injections. Consistent with clinical practice, some people may be managed with a single dose of intermediate- or long-acting insulin at night to treat isolated fasting hyperglycemia, while others may require additional treatment of postprandial hyperglycemia with shorter-acting insulin. The sites' insulin formularies include rapid- (Novolog and Humalog), intermediate- (Humulin N, Novolin N, and NPH), and long-acting insulins (Detemir and Lantus).
62257718|NCT04203732||Total Joint Arthroplasty|The cohort includes patients undergoing outpatient primary total joint replacement surgeries from 2017 to 2019. Primary total joint surgery is defined as patients who undergo unilateral total knee replacement or total hip replacement for the first time during the study years
62257719|NCT01984372||Tresiba® users|
62257720|NCT05840926|EXPERIMENTAL|Probiotic Streptococcus salivarius K12 Treatment Group|Children treated with Probiotic Streptococcus salivarius K12 Treatment for continuous 3-months
62257721|NCT05840926|ACTIVE_COMPARATOR|Control Group|Children who did not receive any probiotic treatment
62614779|NCT03595865|EXPERIMENTAL|residual primary angle-closure glaucoma|Each eye will be preformed tafluprostin 0.0015% at 9 PM, 1 time daily for 6months
62614780|NCT03024827|EXPERIMENTAL|Medical Cannabis Oil|CanniMed® 1:20
62614781|NCT02463006|EXPERIMENTAL|porous bone graft group|Intervention: Flap surgery procedure with porous bone grafting (Periooglass)
62614782|NCT02463006|ACTIVE_COMPARATOR|Non-porous bone gaft group|Intervention: Flap surgery procedure with non-porous bone grafting (Novabone morsels)
62257722|NCT06353100||Longitudinal analysis group 1 (no pain)|Participants (general population residing in urban areas of Chile aged 18 years or more) not reporting chronic pain in march 2023 or march 2024
62257723|NCT06353100||Longitudinal analysis group 2 (incident chronic pain)|Participants (general population residing in urban areas of Chile aged 18 years or more) not reporting chronic pain in march 2023 but reporting chronic pain in march 2024
62257724|NCT06353100||Longitudinal analysis group 3 (remitted chronic pain)|Participants (general population residing in urban areas of Chile aged 18 years or more) reporting chronic pain in march 2023 but not reporting it in march 2024
62614783|NCT03322436||AMI patients treated by PCI|AMI patient treated by PCI at risk to develop Heart Failure
62257725|NCT06353100||Longitudinal analysis group 4 (chronic pain at follow up)|Participants (general population residing in urban areas of Chile aged 18 years or more) reporting chronic pain in march 2023 and march 2024
62257726|NCT02032563|EXPERIMENTAL|Indocyanine Green|intravenous injection of 0.25mg/kg Indocyanine Green just before surgery
62257727|NCT02833012|EXPERIMENTAL|Group 1|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
62257728|NCT02833012|EXPERIMENTAL|Group 2|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
62614784|NCT04889352|EXPERIMENTAL|Access to colonoscopy web app|Approximately half of the consenting individual endoscopy physicians in the city (gastroenterologists and surgeons) will be randomized (stratified by physician specialty) to the intervention group where they are provided access to an application which indicates recommended timing of follow-up colonoscopy given values for various entered factors. In the intervention group, the application can be downloaded to smart phones for portability which will allow access in an endoscopy suite or in clinic or used as a reference at other times. It can also be accessed online (all endoscopy rooms in Winnipeg have computers with internet access for the endoscopy physicians' use). Access to the application will be password-protected, thereby avoiding exposure of the non-intervention group to the application. The clusters of patients will be defined by the endoscopy physician providing the colonoscopy.
62614785|NCT04889352|NO_INTERVENTION|Control|Approximately half of the consenting individual endoscopy physicians in the city (gastroenterologists and surgeons) will be randomized (stratified by physician specialty) to the group where they are not provided access to the application (control group).
62055234|NCT02237508|EXPERIMENTAL|A-B2-B1-D-C|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62257729|NCT02833012|EXPERIMENTAL|Group 3|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
62257730|NCT02833012|EXPERIMENTAL|Group 4|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
62614786|NCT02046278|NO_INTERVENTION|Control arm - Standard of Care|The anastomosis will be created using Standard of Care only
62257731|NCT04080570|EXPERIMENTAL|Remote Visit|After an initial physical in-home visit, the physician will see home hospitalized patients by facilitated video each day.
62257732|NCT04080570|NO_INTERVENTION|In-Home Visit|The physician will see home hospitalized patients physically in their homes each day, as is usual care.
62257733|NCT01301443|EXPERIMENTAL|Subretinally Injected RetinoStat|Subretinally injected RetinoStat
62257734|NCT04178759|ACTIVE_COMPARATOR|Control|Patients with benign liver disease, who undergo liver resection
62257735|NCT04178759|EXPERIMENTAL|Experimental|Patients with liver metastases and received chemotherapy, who undergo liver resection
62614787|NCT02046278|EXPERIMENTAL|Device arm - Standard of Care + LifeSeal™ Kit|The anastomosis will be created using SOC + LifeSeal™ Kit
62444558|NCT05248932|ACTIVE_COMPARATOR|infusion|patients will receive an infusion of norepinephrine that will be started at 2.5μg/min immediately after intrathecal injection and then manually adjusted according to monitoring of blood pressure (bp), heart rate, fluid responsiveness (thoracic volume variations and stroke volume variations), cardiac index and systemic vascular resistance by using cardiometry, with the objective of maintaining values near baseline
62444559|NCT05248932|ACTIVE_COMPARATOR|bolus|patient with no prophylactic vasopressor and a bolus of 5 μg norepinephrine will be given whenever systolic BP decreases to \<80% of the baseline value.
62444560|NCT04170699|EXPERIMENTAL|PECS 1 Block|40 patients who had PECS 1 block for peroperative analgesia in port-a-cath replacement. All patients will receive IV Midazolam (0.05mg/kg) premedication. Standard monitorization of EKG, non- invasive blood pressure and pulseoximeter will be done and recorded in every 5 minutes. After sedation and standard monitorization, 20 minutes before the intervention and in the supine positon the PECS 1 block will be done. 10 % povidone - iodin will be used for sterilization and the USG probe will be covered with sterile sheath. The block will be done as a single injection of local anaesthetic between pectoralis major and pectoralis minor muscles at the level of the 3rd rib to anaesthetise the lateral and medial pectoral nerves. The USG probe will be replaced inferior to the clavicle. Identify the pectoralis muscles with the axillary artery and axillary vein on sonography. The brachial plexus should be visible underneath. After confirmation with 20 mL %0.25 bupivacaine will be administered.
62614788|NCT00614757|NO_INTERVENTION|2|One half of the patients will take not medication for 30 days and then have labs redrawn
62257736|NCT05534425|EXPERIMENTAL|Immediate GenX|Participants immediately commence GenX program activity (intergenerational mentoring)
62257737|NCT05534425|ACTIVE_COMPARATOR|Delayed GenX|Participants engage in parallel training/educational activities, and subsequently commence GenX program activity after 3 months
62444561|NCT04170699|EXPERIMENTAL|Infiltrative Anesthesia|40 patients who had port-cath replacement will receive infiltrative anesthesia.
62614789|NCT00614757|EXPERIMENTAL|1|one half of the patients with insulin resistance will take 4ml of 20% N-acetylcysteine BID for 30 days
62444562|NCT03105609||Naive wet age-related macular degeneration|Patients recruited to the study will be patients who meet the Australian MBS criteria for treatment of exudative CNV with Lucentis. For the duration of the study, the patients will have standard induction and monthly dosing of Lucentis (Ranibizumab; intravitreal; 0.5 mg) to allow comparison with published studies. The only extra intervention for the study is the acquisition of hyperspectral mages with the hyperspectral camera and the acquisition of additional fundus autofluorescence images to the clinical norm.
62614790|NCT01080859||BAS|Patient's receiving BAS
62839606|NCT06067217|EXPERIMENTAL|Progynova|Progynova 1 mg oral three times/day
62614791|NCT01080859||EES|Patients receiving EES
62614792|NCT03647072|ACTIVE_COMPARATOR|CHOP|CHOP only
62614793|NCT03647072|ACTIVE_COMPARATOR|CHOP Plus Lanzoprazole|CHOP Plus Lanzoprazole 60 mg
62614794|NCT03647072|ACTIVE_COMPARATOR|CHOP Plus Famotidine|CHOP Plus Famotidine 40 mg
62614795|NCT02121236||Patients with benign radiolucent lesions|
62614796|NCT00913224|EXPERIMENTAL|1|Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)
62614797|NCT00913224|ACTIVE_COMPARATOR|2|Voltaren 50 mg Tablets (Geigy Pharmaceuticals)
62614798|NCT05613075|ACTIVE_COMPARATOR|tooth extraction and socket preservation with demineralized tooth graft|patients with immediate extraction sockets, filled and condensed with demineralized, autogenous dentinal graft particles, extracted and originated from the newly extracted tooth, then covered with biodegradable Gel foaming sponge.
62257738|NCT01972620|ACTIVE_COMPARATOR|Multi-modal analgesia|Thirty-one patients were enrolled in this arm. Standard analgesia according to institutional standard and 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume = 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of \~ 2 cm. Following evacuation of the pneumoperitoneum, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the 4 laparoscopic port sites (2 ml per port site) prior sutured closure.
62257739|NCT01972620|NO_INTERVENTION|Control|Thirty-two patients were enrolled in this arm. They received standard analgesia according to institutional standard of practice consisted of non-narcotic analgesia with narcotic analgesic rescue after laparoscopic cholecystectomy.
62257740|NCT05878457|EXPERIMENTAL|Repetitive transcranial magnetic stimulation|All participants will receive accelerated, high-dose repetitive transcranial magnetic stimulation (rTMS) at the medial prefrontal cortex (mPFC) delivered in runs of 600 pulses, twelve times per day, for three treatment days (contiguous or non-contiguous) within a seven-day period.
62614799|NCT05613075|EXPERIMENTAL|tooth extraction and socket preservation with demineralized tooth graft and hyaluronic acid|patients with immediate extraction sockets, filled and condensed with demineralized, autogenous dentinal graft particles, extracted and originated from the newly extracted tooth, mixed with Hyaluronic acid, in gel form, as a carrier, then covered with biodegradable Gel foaming sponge.
62614800|NCT01530724|EXPERIMENTAL|low fat diet|Weight-loss diet strategy
62614801|NCT01530724|EXPERIMENTAL|low carb diet|Weight-loss diet strategy
62257741|NCT02286414||Exposed group|Patients recieving direct oral anticoagulants (DOA)
62257742|NCT02286414||Non-exposed group|Patients recieving vitamine K antagonists (VKA)
62614802|NCT05763056|ACTIVE_COMPARATOR|McGrath videolaryngoscopy|It is a portable videoryngoscope weighing only 325 grams. The CameraStickTM component consists of a light source and a miniature camera, and the image is displayed on a 1.7 inch LCD (Liquid Crystal Display) screen mounted on top of the laryngoscope handle. At the same time, the LCD screen maintains visual contact with the patient and the laryngoscope, can be rotated up to 90°, allowing the user to work in a comfortable posture while performing tracheal intubation. The blade length is suitable for children over 5 years old and adults, thus reducing the trouble of storing different sized blades in the emergency intubation trolley. The blades are sterile and there is no risk of contamination as they are disposable.
62257743|NCT03693625|EXPERIMENTAL|Parent Study: GDC-0853|Participants (who had received 50, 150 and 200mg GDC-0853 in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.
62257744|NCT03693625|PLACEBO_COMPARATOR|Parent Study: Placebo|Participants (who had received Placebo in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.
62055235|NCT02237508|EXPERIMENTAL|B1-A-C-B2-D|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62055236|NCT02237508|EXPERIMENTAL|C-B1-D-A-B2|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62839607|NCT04292418||study group 1|(rejector group )include Paediatric living donor kidney transplant recipients (aged 4-18 years) at least 35 child recieving standard triple drug immunosuppression consisting tacrolimus an antiproliferative drug \[mycophenolate mofetil (MMF) and steroids, with biopsy proven acute rejection in the study group 1 measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test
62055237|NCT00893399|EXPERIMENTAL|1|chemotherapy in combination with ATRA with gemtuzumab ozogamicin
62055238|NCT00893399|ACTIVE_COMPARATOR|2|chemotherapy in combination with ATRA without gemtuzumab ozogamicin
62055239|NCT00726362||1|patients with hyperlipidemia newly initiating a statin; or switched from current therapy to a statin, or require dosage adjustment for statin
62055240|NCT04040257|NO_INTERVENTION|Individual Performance|Each participant will first take the exam as an individual. After a delay of 3-6 months, participants will then be randomized to take the exam again either as an individual again (control group) or as a team (exposure group).
62257745|NCT00333398|EXPERIMENTAL|1|250 subjects-Lot #1 multiple-dose vial (thimerosal-containing).
62257746|NCT00333398|EXPERIMENTAL|2|250 subjects-Lot #2 multiple-dose vial (thimerosal-containing).
62257747|NCT00333398|EXPERIMENTAL|3|250 subjects-Lot #3 multiple-dose vial (thimerosal-containing).
62257748|NCT00333398|PLACEBO_COMPARATOR|4|250 subjects-multiple-dose vial placebo (thimerosal-containing).
62257749|NCT00333398|EXPERIMENTAL|5|250 subjects-Prefilled Lot #1, #2, or #3 (TBD) (thimerosal-free).
62257750|NCT02776189|EXPERIMENTAL|Midazolam & Dexmedetomidine|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation. Intravenous dexmedetomidine 1 mcg per kg body weight over 10 minutes followed by infusion of dexmedetomidine at dose of 1 mcg per kg body weight per hour till end of procedure
62055241|NCT04040257|EXPERIMENTAL|Group Performance|Each participant will first take the exam as an individual. After a delay of 3-6 months, participants will then be randomized to take the exam again either as an individual again (control group) or as a team (exposure group).
62055242|NCT04719039|EXPERIMENTAL|Yoga Group|Restorative Yoga intervention
62055243|NCT04719039|NO_INTERVENTION|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
62055244|NCT03830190|EXPERIMENTAL|Intervention group|Parkinson's disease nurse specialist care
62055245|NCT03830190|NO_INTERVENTION|Control group|No intervention
62257751|NCT02776189|ACTIVE_COMPARATOR|Midazolam & Propofol|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation. Intravenous propofol 2 mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
62257752|NCT00579865||Group A|Patients scheduled for percutaneous drainage
62257753|NCT00579865||Group B|Patients scheduled for a surgical bypass or resection of a high bile duct tumor.
62257754|NCT01643863||Cohort|
62257755|NCT03919279|EXPERIMENTAL|active arm with active tVNS for 1 month|
62257756|NCT01708070|ACTIVE_COMPARATOR|Asthma self-management experimental|The intervention will involve a self-management workbook, contracting to improve self-management behaviors, instruction in using of a peak flow meter, and follow-up discussions based on the workbook.
62257757|NCT01708070|OTHER|Asthma self-management control|The control state will involve a self-management workbook and contracting to improve self-management behaviors.
62614803|NCT05763056|ACTIVE_COMPARATOR|C-MAC videolaryngoscopy|Considering the importance of first attempt success in intubation, their use in emergency airway management has increased due to the high first attempt success rate in C-MAC VLs. In patients with cervical spine injury, semi-rigid collars used to prevent neck extension and neck movements cause poor laryngeal vision with Direct laryngoscope and difficulty intubation. C-MAC Video laryngoscope provides a better laryngeal view in these patients
62614804|NCT05763056|ACTIVE_COMPARATOR|Direct laryngoscopy|Macintosh laryngoscopy is still one of the most commonly used advanced airway methods today. For an ideal glottis view in direct laryngoscopy, the mouth and larynx should be in alignment. For this, longitudinal flexion and head extension maneuvers are performed. Reasons such as the clinical situation during intubation and the anatomical variation in the patient may prevent this maneuver from being performed.
62257758|NCT06042400|EXPERIMENTAL|EASE Written Exposure Intervention|Assigned Intervention
62257759|NCT03196076|EXPERIMENTAL|Perflutren Lipid Microsphere (Healthy subjects)|Healthy subjects will be imaged using contrast-enhanced ultrasound (perflutren) for image optimization prior to enrolling clinical patients.
62257760|NCT03196076|EXPERIMENTAL|Perflutren Lipid Microsphere (patients with kidney lesions)|Patients with kidney lesions will be imaged using contrast-enhanced ultrasound with perflutren.
62257761|NCT03196076|NO_INTERVENTION|Controls: No interaction|Patients with kidney lesions will be included as control subjects. These patients will be followed, but will not receive any study intervention.
62257762|NCT03471975|ACTIVE_COMPARATOR|direct laryngoscope|teaching tracheal intubation using McGrath video laryngoscope as direct laryngoscope. Only trainer can see the monitor.
62257763|NCT03471975|ACTIVE_COMPARATOR|video laryngoscope|"teaching tracheal intubation using McGrath video laryngoscope using video function.~Trainer and Trainee both see the monitor."
62257764|NCT03108547||Sarcoidosis - fatigued|Men and women with sarcoidosis and a score of ≥ 22 on the Fatigue Assessment Scale. A small hair sample will be cut and the participants will be asked to complete questionnaires on fatigue, anxiety, depression, stress and quality of life.
62839608|NCT04292418||study group 2|the second group (non rejector group ) include Paediatric living donor kidney transplant recipients (aged 4-18 years) recieving standard triple drug immunosuppression consisting tacrolimus an antiproliferative drug \[mycophenolate mofetil (MMF) and steroids, with biopsy proven acute rejection in the studied group at least 35 child measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test in the study group 2
62839609|NCT02076061||GOLD stage I|
62839610|NCT02076061||GOLD Stage II|
62257765|NCT03108547||Sarcoidosis - non-fatigued|Men and women with sarcoidosis and a score of \< 22 on the Fatigue Assessment Scale. A small hair sample will be cut and the participants will be asked to complete questionnaires on fatigue, anxiety, depression, stress and quality of life.
62257766|NCT03108547||Healthy controls|Hair steroid values of a previously collected normal values study in adults will be used as healthy controls
62257767|NCT00992940|EXPERIMENTAL|Patient-Controlled Sedation/Analgesia|Patient controls the amount of sedation and analgesia delivered, according to their own requirements.
62257768|NCT00992940|ACTIVE_COMPARATOR|Anesthetist-Controlled Sedation/Analgesia|Patient sedation and analgesia requirements are delivered by the anesthetist.
62614805|NCT04719429|EXPERIMENTAL|Cricket-derived protein beverage|Ingestion of a cricket-derived protein beverage
62839611|NCT02076061||GOLD Stage III|
62055246|NCT05068869|OTHER|Dignio Digital Remote Care intervention group|Participants will receive the MyDignio app for individualized follow-up for 6 months.
62839612|NCT02076061||GOLD Stage IV|
62055247|NCT05068869|OTHER|Usual Care Control group|Participants in the control group will receive follow-up at the outpatient clinic as per their needs.
62055248|NCT03089125|ACTIVE_COMPARATOR|Usual Care|Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians.
62055249|NCT03089125|EXPERIMENTAL|Dyspnea Intervention|"Dyspnea intervention will be administered over two sessions~Patients will receive:~* Psychoeducation~* Relaxation training for reducing physiological stress~* Behavioral techniques for managing acute breathlessness"
62257769|NCT04879667|NO_INTERVENTION|group (1)|surgical management of gastrocutaneous fistula after laparoscopic sleeve gatrectomy by surgical exploration
62257770|NCT04879667|ACTIVE_COMPARATOR|group (2)|we performed upper GI endoscopy to all cases first to assess the site , size and cause of fistula . we used stents , clips , sutures and ballon dilatation to close the fistula according to size , site and cause of fistula.if the fistula had no track that was proved by CT with oral \& I.V contrast , we used the endoscopic stent. if the fistula had track that was proved by CT with oral \& I.V contrast , we used the OVASCO clip , endo suturing or ballon. Combined maneuvers may be used like ballon dilation and clipping or ballon dilatation and suturing if there was distal narrowing.
62257771|NCT04831489||deep sedation|Anesthesia will be induced using titrated doses of propofol (0.5-1.5 mg/kg) and fentanyl (25-50 μg) initially to carefully maintain spontaneous breathing yet maintaining airway patency. Once adequate jaw relaxation is achieved, the endoscopy probe will be inserted. Maintenance of sedation will be carried out using propofol infusion between 80-120 mcg/kg/min. Additional dose 25-50 mg propofol will be given to the patient if spontaneous movement occurs
62614806|NCT04719429|EXPERIMENTAL|Beef-derived protein beverage|Ingestion of a beef-derived protein beverage
62839613|NCT02076061||Smokers/ex-smokers w/o COPD|
62839614|NCT02076061||non-Smokers w/o COPD|
62839615|NCT00997776|EXPERIMENTAL|Exercise|High intensity lower extremity exercise
62839616|NCT00997776|SHAM_COMPARATOR|Attention control|lower extremity TENS
62839617|NCT04917016||Study group|Women undergoing hysteroscopy for removal of RPOC
62839618|NCT05321277|ACTIVE_COMPARATOR|Walnut diet|Participants will consume 56 g of walnuts each day at home for 3 weeks.
62055250|NCT02462902|EXPERIMENTAL|5% albumin Infusion|(250 ml over 15 to 30 minutes)
62257772|NCT04831489||Genral anesthesia|"After mask pre-oxygenation, anesthesia will be induced with (2 mg/kg) propofol and (1 μg /kg) fentanyl. The neuromuscular blockade will be achieved with (0.5 mg/kg) atracurium followed by tracheal intubation. Anesthesia will be maintained to keep the end-tidal anesthetic concentrations within 1 MAC for sevoflurane.~The neuromuscular blockade will be maintained with intermittent doses of atracurium (0.1mg/kg). Mechanical ventilation is adjusted with fresh gas flow oxygen in air 30-40% at a rate of 2 L/min to maintain end-tidal carbon dioxide of 35-40 mm Hg. Reversal of neuromuscular blockade will be achieved by intravenous administration of neostigmine 0.05 mg/kg and atropine 0.02 mg/kg."
62257773|NCT06042777|EXPERIMENTAL|Acupuncture|This is an 8-week (two 50-min sessions per week) treatment of acupuncture on the following fixed acupoints: bilateral Touwei (ST8), Sishencong (EX-HN1), Taiyang (EX-HN5), Shuaigu (GB8), Toulinqi (GB15), and unilateral Yintang (EX-HN3), Baihui (GV20). The treatment will be performed by registered acupuncturists. based on acupuncturists' clinical judgement, acupuncture can be performed on any of the following additional acupoints, including unilateral Shenting (GV24), Shenmen (HT7), Sanyinjiao (SP6), Taichong (LV3), Neiguan (PC6), AND Anmian (EX-HN22).
62257774|NCT06042777|EXPERIMENTAL|TCM-based lifestyle management|This is an integrated TCM-based training program with components of dantian breathing, Baduanjin, and self-acupressure \[Yintang (EX-HN3), Shenting (GV24), Taiyang (EX-HN5), Fengchi (GB20), Neiguan (PC6), Shenmen (HT7), and Sanyinjiao (SP6)\]. The treatment will last for 8 weeks (two 50-min sessions per week), and it will include health education and workshops to be delivered by trained research assistants.
62839619|NCT05321277|ACTIVE_COMPARATOR|No-nut diet|Participants will follow a no-nut diet for 3 weeks.
62839620|NCT06202820|EXPERIMENTAL|CV Care Program|"Study procedures will be conducted as follows:~* Standard of care androgen deprivation therapy.~* 4 week standard-of-care follow up visit in clinic with CV care education module completion.~* 12-week standard-of-care prostate cancer care visit with oncologist.~* 24-week standard-of-care post-ADT visit in clinic with CV Care module completion, surveys, and exit interview with clinical team members.~* The CV Care program will be revised through participant feedback from assessments, surveys, focus groups, and exit-interviews. The revised CV Care Program will be used in the next cohort."
62444563|NCT05399810|EXPERIMENTAL|Computer Application (ICOGNI) Training|Apart from routine physical therapy, participants in this group will be randomized to active training after baseline assessment. Participants will be given App-based training which will include multiple games with multiple levels along with routine physiotherapy. The active group will start training immediately and will have 8 weeks to perform the 40 training sessions.
62444564|NCT05399810|NO_INTERVENTION|Conventional group|Participants in are already being given routine physiotherapy which includes range of motion exercises, stretching and strengthening exercises of upper extremity, fine motor activities, functional activities, and cognitive activities (art and crafts, placing objects in specific positions, organizing objects, color sorting games, teamwork, and moving and tracing objects).
62839621|NCT06202820|EXPERIMENTAL|CV Care Program 2|"Study procedures will be conducted as follows:~* Standard of care androgen deprivation therapy.~* 4 week standard-of-care follow up visit in clinic with CV care education module completion.~* 12-week standard-of-care prostate cancer care visit with oncologist.~* 24-week standard-of-care post-ADT visit in clinic with CV Care module completion, surveys, and exit interview with clinical team members.~* Participant feedback from surveys, exit-interviews, and possibly focus groups will be collected."
62055251|NCT02462902|ACTIVE_COMPARATOR|0.9% sodium chloride solution|0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minute)
62257775|NCT06042777|EXPERIMENTAL|Acupuncture + TCM-based lifestyle management|This is a combination of the above two arms. The participants who randomly assigned to this arm will received two acupuncture sessions and two sessions on lifestyle management every week, and the intervention duration is 8 weeks.
62257776|NCT06042777|NO_INTERVENTION|Wait-list control|Participants will receive no intervention during the whole assessment period.
62257777|NCT00873340||Group 1|
62055252|NCT05356754|EXPERIMENTAL|The Vital Labs Digital Blood Pressure Monitor|The Vital Labs Digital Blood Pressure monitor is a software-as-a-medical device (SaMD) that is capable of determining blood pressure, after calibration, using waveform changes observed in photoplethysmogram signals. The VLDBPM captures PPG signals using the existing camera systems on iPhones. These PPG signals are normalized and processed to determine markers of blood pressure change. These markers, when transformed using a predetermined model, are capable of determining blood pressure changes from a known (calibration) set-point.
62055253|NCT04892784|EXPERIMENTAL|Press tack needle acupuncture|
62257778|NCT05738473||pregnant women colonized by Group B Streptococcus (GBS) and undergoing IAP|vaginal microbiome of pregnant women colonized by Group B Streptococcus (GBS)、Pregnant women undergoing IAP
62257779|NCT05738473||pregnant women does not colonized by Group B Streptococcus (GBS) and not undergoing IAP|Group B streptococcus (GBS) does not colonize the vaginal microbiome of pregnant women、Pregnant wome
62055254|NCT04892784|NO_INTERVENTION|Control|
62444565|NCT00440596|EXPERIMENTAL|Mindfulness based stress reduction|Mindfulness based stress reduction
62444566|NCT00440596|ACTIVE_COMPARATOR|Progressive Muscle Relaxation|Progressive Muscle Relaxation
62444567|NCT04899739|EXPERIMENTAL|Peripancreatic and distant lymph node assessment|All patients programmed for an endoscopic ultrasound in the context of a pancreatic cancer
62444568|NCT05652621|EXPERIMENTAL|Probiotic intervention group|"Adjuvant treatment of UC and IBS with Three-high Probiotics is given to patients three times a day, one pack of 2g, lasting for 1-4 months."
62839622|NCT04944199|NO_INTERVENTION|Control Group|
62444569|NCT01957657|EXPERIMENTAL|Healthy volunteers group 1|Healthy volunteers with normal renal function
62839623|NCT04944199|ACTIVE_COMPARATOR|Intervention Group|
62444570|NCT01957657|EXPERIMENTAL|Renal function group 2|Patients with mild renal impairment
62614807|NCT04579614|ACTIVE_COMPARATOR|Organizational Target|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own, and with the organizational target. These updates and targets are sent bi-weekly."
62839624|NCT00753181|EXPERIMENTAL|A1|Diabetes Meal Plan with Experimental Diabetes-Specific nutritional shake
62839625|NCT00753181|ACTIVE_COMPARATOR|A2|Usual diet
62839626|NCT00753181|EXPERIMENTAL|A3|Diabetes Meal Plan with Experimental Diabetes-Specific Nutritional Shake, diabetes specific Cereal, and diabetes specific snack bars.
62839627|NCT01119209|ACTIVE_COMPARATOR|Ropivacaine|
62839628|NCT01119209|PLACEBO_COMPARATOR|Saline|
62839629|NCT01862237|EXPERIMENTAL|Patients with type II diabetes|Type II diabetes patients with aortic valve stenosis referred for aortic valve replacement.
62839630|NCT01862237|EXPERIMENTAL|Patients without type II diabetes|No type II diabetes patients with aortic valve stenosis referred for aortic valve replacement.
62839631|NCT05136924|EXPERIMENTAL|OC-01|(varenicline 1.2mg/ml) nasal spray
62839632|NCT05136924|PLACEBO_COMPARATOR|Placebo|(vehicle) nasal spray
62839633|NCT02490865|EXPERIMENTAL|RNS60|Administration of nebulized RNS60 to test for systemic bioactivity
62444571|NCT01957657|EXPERIMENTAL|Renal function group 3|Patients with moderate renal impairment
62444572|NCT01957657|EXPERIMENTAL|Renal function group 4|Patients with severe renal impairment
62444573|NCT02235233|EXPERIMENTAL|Patients with NASH|Each subject will be injected with \~2.5 mCi of Technetium Tc 99M Mebrofenin
62614808|NCT04579614|EXPERIMENTAL|Achievable Target|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own. They will receive a static and achievable target based on their previous year's flu vaccination success rate."
62444574|NCT02235233|ACTIVE_COMPARATOR|Healthy Normal Volunteers|Each subject will be injected with \~2.5 mCi of Technetium Tc 99M Mebrofenin
62614809|NCT04579614|EXPERIMENTAL|Variable|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own. They will receive a variable target that will fluctuate bi-weekly, based on their previous bi-weekly flu vaccination success rate."
62614810|NCT00337779|ACTIVE_COMPARATOR|glatiramer acetate 40 mg|
62614811|NCT00337779|ACTIVE_COMPARATOR|glatiramer acetate 20 mg|
62444575|NCT04122274|SHAM_COMPARATOR|Education Sheet and Sham Intervention|Participants will be asked to fill out a pre-intervention survey to assess existing concussion knowledge, perceived norms, attitudes, and behavioral intentions. Afterward, the NCAA concussion education fact sheet will be viewed along with the viewing of the sham intervention. Following the intervention, a post-intervention survey re-assessing the constructs from the pre-intervention survey will be completed. May be completed in-person or virtually.
62614812|NCT01826045|EXPERIMENTAL|Poly-gamma Glutamic Acid|Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered Poly-gamma Glutamic Acid for 4 weeks.
62614813|NCT01826045|PLACEBO_COMPARATOR|Placebo|Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered placebo for 4 weeks.
62614814|NCT06460337|EXPERIMENTAL|Modified Otago Exercises|It is a series of 17 strength and balance exercises in addition to 30 minutes walk outside the home at the usual pace three times a week.
62839634|NCT02490865|PLACEBO_COMPARATOR|Normal Saline|Administration of normal saline used as control
62839635|NCT01760252|EXPERIMENTAL|CAPOXIRI Chemotherapy Regimen|"Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)~The proposed chemotherapy regimen CAPOXIRI is:~* Capecitabine 1000mg/m2 p.o. bid on days 1-7~* Oxaliplatin 85mg/m2 intravenously (IV) on day 1~* Irinotecan 150mg/m2 IV on day 1"
62839636|NCT01574729|ACTIVE_COMPARATOR|Surgery plus post-surgery chemotherapy|Surgery plus post-surgery chemotherapy
62839637|NCT01574729|EXPERIMENTAL|Surgery combined with rAd-p53 gene therapy|Surgery combined with the surgery wound surface injection of rAd-p53 plus post-surgery chemotherapy
62839638|NCT03390283||Observational (Online survey)|Participants complete online survey on an iPad over 20 minutes.
62839639|NCT03363490|OTHER|Control|The patients in this group will only receive health education intervention.
62839640|NCT03363490|OTHER|Neuromuscular exercise therapy|The patients in this group will receive exercise therapy intervention.Besides, health education will be performed for every group.
62839641|NCT03363490|OTHER|Self-management program|The patients in this group will receive self-management intervention.Besides, health education will be performed for every group.
62839642|NCT03363490|OTHER|Exercise therapy+self-management|The patients in this group will receive exercise therapy and self-management intervention.Besides, health education will be performed for every group.
62839643|NCT04556799|EXPERIMENTAL|Study group|3D osteotomy template for derotation osteotomy with the aid of computer-assisted simulated surgery technique
62839644|NCT04556799|EXPERIMENTAL|Control group|traditional osteotomy technique
62839645|NCT01963949||Primary Liver Cancer|Patients that have liver masses suspicious for primary liver cancer.
62839646|NCT06003270|ACTIVE_COMPARATOR|Quercetin 1000 mg/day|Quercetin 1000 mg/day Quercetin is provided as caplet and each caplet will have 500 mg of quercetin Quercetin will be administered orally twice daily, one half dose (1 caplet) in the morning after breakfast and one half dose (1 caplet) in the evening after dinner for six months.
62055255|NCT06113510||1|50 patients with myocardial infarction and non-obstructive coronary arteries
62257780|NCT02997735|EXPERIMENTAL|Electronic Quitline Referral|The electronic quitline referral will be embedded within the Tobacco Treatment CDS tool, a CDS system previously developed to help pediatricians provide smoking cessation counseling and treatment to parents who smoke, modeled off the CEASE intervention, an evidence-based approach for implementing smoking cessation treatment of parents in the pediatric setting. The parental tobacco treatment CDS tool prompts the pediatric clinician to ask the parent about smoking status and assess interest in quitting (at all well-child and acute visits), links to an electronic nicotine replacement therapy prescription for parents interested in quitting, and guides appropriate documentation. Electronic referral to the quitline will be made by clicking an automated link embedded in the tool that will send the parent smokers' names and telephone numbers (entered by the clinician) directly to the Pennsylvania (PA) Free Quitline.
62444576|NCT04122274|EXPERIMENTAL|Education Sheet and Decision-based interactive intervention|Participants will be asked to fill out a pre-intervention survey to assess existing concussion knowledge, perceived norms, attitudes, and behavioral intentions. Afterward, the NCAA concussion education fact sheet will be viewed along with the viewing of a decision- based interactive concussion education platform intervention. Following the intervention, a post-intervention survey re-assessing the constructs from the pre-intervention survey will be completed. May be completed in-person or virtually.
62444577|NCT03558100|EXPERIMENTAL|Reducing Fall Risks in Obesity|Adults with obesity will be asked to perform the obstacle crossing intervention for adults with obesity for reducing falls risk. This will involve crossing obstacles of different heights under five conditions: initial baseline walking on flat ground, crossing three obstacle heights, and final baseline walking on flat ground for a total of 25 trials. Spatio-temporal gait parameters will be collected using a gait carpet and body-worn sensors.
62614815|NCT06460337|ACTIVE_COMPARATOR|Frenkel's Exercises|It consists of simple range of motion exercises performed in different positions, i.e., lying, sitting, stride-standing and standing. Exercises are performed slowly emphasizing coordination and precision.
62614816|NCT02929615|EXPERIMENTAL|Treatment group|
62614817|NCT01029613||Rheumatoid arthritis|
62839647|NCT06003270|ACTIVE_COMPARATOR|Quercetin 500mg/day|"Quercetin 500 mg/day Quercetin is provided as caplet and each caplet will have 500 mg of quercetin Quercetin will be administered orally once daily, (1 caplet) in the morning after breakfast and matching placebo in the evening after dinner for six months.~The placebo is added to match the number of caplets with 1000 mg/day arm"
62055256|NCT06113510||2|10 patients with suspected coronary thromboembolism 10 patients with suspected spontaneous coronary artery dissection 10 patented with iatrogenic spontaneous coronary artery dissection
62444578|NCT01081184||primary Sjögren syndrome|
62444579|NCT01081184||Healthy volunteers|
62055257|NCT01696331|EXPERIMENTAL|Text Message Reminder|
62055258|NCT04601558|NO_INTERVENTION|Control group|The first group of participants was control group. The number of participant was 70, and the participants in this group after recruitment received letter with their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease.
62444580|NCT00929357||1|DMARDs
62444581|NCT00929357||2|Biologics
62444582|NCT00645619||1|Patients with pure viral pneumonia
62444583|NCT00645619||2|Patients with viral pneumonia along with secondary bacterial pneumonia
62444584|NCT00645619||3|Patients with significant bacterial pneumonia
62444585|NCT00645619||4|Patients with congenital heart disease undergoing cardiopulmonary bypass who have no pneumonia
62444586|NCT02512913|EXPERIMENTAL|Adapted/enhanced MAPS|Counseling sessions delivered by phone to the pregnant/postpartum women and to the husbands/partners
62444587|NCT02512913|NO_INTERVENTION|Usual Care|Couples in the control condition will receive usual care
62614818|NCT03350204|EXPERIMENTAL|Meniscus Injured|These participants will come in pre and post operation
62614819|NCT03350204|EXPERIMENTAL|Healthy|These participants will be used as a standardised comparison for the patient group
62614820|NCT01485302|EXPERIMENTAL|Cohort 1|Dose 1 IV infusion
62614821|NCT01485302|EXPERIMENTAL|Cohort 2|Dose 2 IV infusion
62614822|NCT01485302|EXPERIMENTAL|Cohort 3|Dose 3 IV infusion
62614823|NCT01485302|EXPERIMENTAL|Cohort 4|Dose 4 IV infusion
62614824|NCT01485302|EXPERIMENTAL|Cohort 5|Dose 1 SC injection
62614825|NCT01485302|EXPERIMENTAL|Cohort 6|Dose 2 SC injection
62614826|NCT01147003|EXPERIMENTAL|BGG492 low dose|
62614827|NCT01147003|PLACEBO_COMPARATOR|Placebo|
62614828|NCT01147003|EXPERIMENTAL|BGG492 high dose|
62055259|NCT04601558|SHAM_COMPARATOR|Passive-intervention group|The second group of participant was passive-intervention group. There were 70 participants. This group of women after recruitment received letter with their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease. After this letter, every two months, they were receiving remainder on their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease.
62055260|NCT04601558|ACTIVE_COMPARATOR|Active-intervention group|The third group of participant was active-intervention group. There were also 70 participants. This group of women after recruitment received letter with their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease. After this letter, every two months, active-intervention group were receiving Cochrane abstracts in the form of blog-shots.
62055261|NCT01755143|EXPERIMENTAL|MRI Group|Subjects randomized to the Magnetic Resonance Imaging group will undergo a series of MRI scans at the 9-12 week visit post-implant.
62055262|NCT01755143|SHAM_COMPARATOR|Control Group|Subjects randomized to the control group will not undergo a series of MRI scans but will come into the study office for a one hour waiting period at the 9-12 week post-implant visit.
62257781|NCT02997735|OTHER|Standard of Practice|All procedures implemented in the standard referral approach will be identical to those in the electronic referral approach with the exception of providing the telephone number for the Quitline to the parent (rather than electronic referral). The clinician workflow will be nearly the same, in that the clinician will use the link embedded in the tobacco treatment CDS tool to add the quitline to the patient's discharge paperwork (rather than automatically refer to the quitline).
62257782|NCT01063075|EXPERIMENTAL|Cetuximab and Carboplatin (D)|"Group D:~Cycle 1 (1 week, combination therapy):~400 milligrams per square meter (mg/m ²) cetuximab administered intravenously (I.V) on week 1,day 1. Carboplatin area under the curve (AUC=5) administered I.V on week 1,day 1.~Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/ m ²/day administered starting on week 1, day 1.~After 1 cycle, participants may then receive cetuximab as determined by clinical exam or radiological imaging studies until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~After protocol amendment February 2014, any newly enrolled participants were placed into Group D only."
62444588|NCT02576990|EXPERIMENTAL|Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)|Participants with rrPMBCL receive pembrolizumab 200 mg every 3 weeks (Q3W), intravenous infusion (IV) on Day 1 of each 3-week cycle for up to a maximum of 35 administrations (approximately 2 years).
62444589|NCT02576990|EXPERIMENTAL|Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS)|Participants with rrRS receive pembrolizumab 200 mg Q3W, IV for each 3-week cycle for up to a maximum of 35 administrations (approximately 2 years). Effective with Protocol Amendment 04, enrollment into this cohort was closed.
62614829|NCT03453996|EXPERIMENTAL|Intervention|Cardiologists will receive computerized clinical decision support information for CI-AKI prevention for patients identified above the median (\> 5%) risk of AKI based on the NCDR risk prediction model for CI-AKI.
62614830|NCT03453996|OTHER|Control|Usual care.
62055263|NCT03090867|ACTIVE_COMPARATOR|Conventional arm|The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
62444590|NCT05291143|EXPERIMENTAL|Intervention arm|This arm will get the educational video intervention
62444591|NCT05112900|NO_INTERVENTION|Usual Care|Participants will only receive unidirectional public service announcement-type text messaging on COVID-19 testing every 3 weeks such as recommendation to obtain COVID-19 testing if exposed, experience symptoms, or have an interest in preemptive testing and information on testing options through the school or district.
62444592|NCT05112900|EXPERIMENTAL|Text Messaging (TM)|This arm consists of a text message (TM) prompt asking if a participant has COVID-19 symptoms or if a participant has been exposed to a person who has tested positive for COVID-19. If a participant responds yes, they will receive a TM prompt for immediate testing and to re-test. Participants will also be asked if they have an interest in preemptive testing, regardless of symptoms or exposure Participants will be provided with information on testing options. After 24 hours, the participant will receive another TM that asks if they tested and what their results are. After 3 days, participants will be prompted to re-test. A sub group of TM participants may be offered health navigator services (TM+HN) through a brief telephone call. These calls will be conducted using Motivation and Problem Solving (MAPS).
62614831|NCT04610502|EXPERIMENTAL|Equine immunoglobulin anti SARS-CoV-2 formulation S|"Experimental equine Imunoglobulins antiSARSCov Formuation S"
62614832|NCT04610502|EXPERIMENTAL|Equine immunoglobulin anti SARS-CoV-2 formulation M|"Experimental equine Imunoglobulins antiSARSCov Formuation M"
62614833|NCT05475457||Oregon County 1|First cohort to be trained and monitored with coaching in the R3 model.
62614834|NCT05475457||Oregon County 2|Second cohort to be trained and monitored with coaching in the R3 model.
62614835|NCT04525131|EXPERIMENTAL|CPX-POM|IV over 20 minutes once per day
62614836|NCT05993091|EXPERIMENTAL|MT+AR group|The experimental group will receive 40 minutes of MT, followed by 40 minutes of AR training and 10 minutes of functional practice. Figure 2 provides an illustration of the hybrid regimen of MT+AR.
62257783|NCT01063075|EXPERIMENTAL|Cetuximab and Carboplatin (C)|"Group C: Cycle 1 (4 weeks, combination therapy): Carboplatin (AUC=5) administered I.V on week 1, day 1.1000 mg/m ²/day 5-FU administered as a 96-hour C.I. starting on week 1, day 1.~400 mg/m² cetuximab administered I.V on week 2, day 1. 250 mg/m ² cetuximab administered I.V on week 3 and 4, day 1.~Cycle 2-6 (3 weeks, combination therapy): Carboplatin (AUC=5) administered I.V on week1,day1.1000 mg/m ²/d 5-FU as a 96-hour C.I. starting on week1, day1. 250 mg/m ² cetuximab administered I.V on Week 1-3, day 1.~After 6 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
62257784|NCT01063075|EXPERIMENTAL|Cetuximab and Carboplatin (B)|"Group B:~Cycle 1 (3 weeks, single-agent cetuximab):~400 mg/m² cetuximab administered I.V on week 1, day 1. 250 mg/m ² cetuximab administered I.V on weeks 2 and 3, day 1.~Cycle 2 (3 weeks, combination therapy):~Carboplatin (AUC=5) administered I.V week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 250 mg/m ² cetuximab administered I.V weeks 1- 3,day 1.~After 6 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011,any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
62055264|NCT03090867|EXPERIMENTAL|The relative/surrogate will be encouraged to perform care|"The relative or surrogate will perform at least two cares a week . A manual will be given to the relative or surrogate, explaining the different care he can choose to perform on the patient.~The care proposed are: feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.~All care are planned and perform under the supervision or/and in collaboration with a caregiver.~Each care is written down on a collecting sheet."
62444593|NCT01811277|EXPERIMENTAL|SOX sequential S-1|4-6 cycles of SOX followed by S-1 monotherapy until disease progression
62839648|NCT06003270|PLACEBO_COMPARATOR|Placebo|"Placebo is also provided as caplets that is similar to quercetin in color, taste and texture and will contain all the stabilizers and the inactive ingredients that is present in the quercetin chews.~Placebo will be administered orally twice daily, one half dose (1caplet) in the morning after breakfast and one half dose (1 caplet) in the evening after dinner for six months."
62839649|NCT04526769||COVID-19 Patients|All patients aged 18 years and above who present to Fairview/UMN ERs or ICUs with confirmed or suspect COVID-19 based on the attending physician's judgment will be included.
62839650|NCT01260077||Experimental group|The sample was composed of 78 individuals (156 ears), 40 females (80 ears) and 38 males (76 ears).
62839651|NCT01260402|ACTIVE_COMPARATOR|Epicardial|
62444594|NCT01309009|EXPERIMENTAL|Nepadutant High Dose|
62444595|NCT01309009|EXPERIMENTAL|Nepadutant Low Dose|
62444596|NCT01309009|PLACEBO_COMPARATOR|Placebo|
62614837|NCT05993091|ACTIVE_COMPARATOR|AR group|The comparison group will receive 80 minutes of AR training combined with 10 minutes of functional practice.
62614838|NCT05993091|ACTIVE_COMPARATOR|CT group|The control group will receive 90 minutes of conventional occupational therapy, including 10 minutes of functional practice. Examples of functional practice include chopping vegetables, pouring water from a kettle, folding a towel, etc.
62614839|NCT02008006|EXPERIMENTAL|BeEAM|"High Dose Chemotherapy (HDT) containing :~* Bendamustine~* Etoposide~* Cytarabine~* Melphalan~HDT will be followed by an Autologous Stem Cell Transplantation"
62614840|NCT06096298|ACTIVE_COMPARATOR|Vitamin B12 bread|Daily dose of bread containing B12 (15 µg of vitamin B12/d) and placebo tablet (0 µg of vitamin B12/d) for 2 consecutive days.
62839652|NCT01260402|EXPERIMENTAL|Endocardial|
62839653|NCT04398927|EXPERIMENTAL|Folfirinox plus PD1|Patients treated with systemic chemotherapy(regimen: Folfirinox) plus PD1
62055265|NCT03362463||Acute Coronary Syndrom|acute coronary syndrome in a real-life setting for patients hospitalized with an ACS (i.e. STEMI, NSTEMI, unstable angina)
62614841|NCT06096298|ACTIVE_COMPARATOR|Positive control|Daily dose of control bread (0 µg of vitamin B12/d and B12 tablet (15 µg of vitamin B12/d) for 2 consecutive days.
62839654|NCT04844398|EXPERIMENTAL|Clown visits (four times)|Children and adolescents in psychiatric care participate in clown visits in a group setting on a weekly basis over four consecutive weeks.
62839655|NCT00309348|EXPERIMENTAL|Weekly measurement of graft flow|The surveillance group was measured with the FloMon instrument weekly, and all procedures related to their access-grafts recorded
62055266|NCT03262857|EXPERIMENTAL|time of start of anesthesia|
62055267|NCT03262857|EXPERIMENTAL|intensity of anesthesia|
62614842|NCT06096298|PLACEBO_COMPARATOR|Negative control|Daily dose of control bread (0 µg of vitamin B12/d and placebo tablet (0 µg of vitamin B12/d) for 2 consecutive days.
62839656|NCT00309348|NO_INTERVENTION|Control|The control group was questioned weekly with regard to their graft status and whether there had been any graft-related procedures
62614843|NCT05773625|OTHER|Test group of app|All participants will first use the app one week without receiving just-in-time notifications. Their movement patterns are collected through GPS. In the second week, they will receive just-in-time notifications based on their chosen goal. Participants will act as their own control group.
62839657|NCT05949801|EXPERIMENTAL|Investigational drug group|Neucardin+standard basic therapeutic medication
62614844|NCT02069093|EXPERIMENTAL|Dexamethasone based mouthwash|Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks. Participants remained without food or drink (NPO) for one hour after administration of the mouthwash. Also, participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations.
62839658|NCT05949801|PLACEBO_COMPARATOR|placebo group|Placebo + standard basic therapeutic medication
62839659|NCT05298553|EXPERIMENTAL|Group 1|"The order in which the wearable devices being investigated will be randomly assigned in a 1:1 fashion.~Simultaneous 12-lead ECG and single-lead ECG with the SkyLabs CART-I ring followed by the Apple Watch."
62839660|NCT05298553|EXPERIMENTAL|Group 2|"The order in which the wearable devices being investigated will be randomly assigned in a 1:1 fashion.~Simultaneous 12-lead ECG and single-lead ECG with the Apple Watch followed by the SkyLabs CART-I ring."
62839661|NCT05021861||Test group 1|FEMALE PATIENTS WITH PCOS ON CPA/EE DRUG REGIMEN FOR ATLEAST 6 MONTHS.
62055268|NCT05174793|EXPERIMENTAL|dehydration to rehydration|subjects were rehydrated following 2% dehydration
62614845|NCT05899647|EXPERIMENTAL|Enrolled Patients|Consented patients who have had an additional Pap sample taken at their visit.
62839662|NCT05021861||Test group 2|FEMALE PATIENTS WITH PCOS( NEWLY DIAGNOSED) ,NOT ON ANY MEDICATION,
62055269|NCT05174793|EXPERIMENTAL|euhydration to dehydration|subjects were dehydrated by 2% with exercise in the heat
62055270|NCT02484001|EXPERIMENTAL|ESL 800 mg|ESL will be administered orally once daily (QD)
62614846|NCT04659902|PLACEBO_COMPARATOR|CON|Participants will ingest a drink containing a control protein only
62614847|NCT04659902|ACTIVE_COMPARATOR|CON-C|Participants will ingest a drink containing a control protein plus Capolac® (9547 mg to provide 2500mg of calcium)
62839663|NCT05021861||Control group|SYSTEMICALLY HEALTHY FEMALES
62839664|NCT05686369||Cohort A: Well-controlled Celiac Disease|Cohort A: Well-controlled celiac disease participants who should be asymptomatic or mildly symptomatic
62839665|NCT05686369||Cohort B: Non-Responsive Celiac Disease|Cohort B: Celiac disease participants with persistent symptoms who are known to be symptomatic and show positivity to serum auto-antibodies even though participants have been adhering to gluten-free diet
62614848|NCT04659902|ACTIVE_COMPARATOR|PRO|Participants will ingest a drink containing an aggregate protein only
62614849|NCT04659902|ACTIVE_COMPARATOR|PRO-C|Participants will ingest a drink containing an aggregate protein plus Capolac® (9547 mg to provide 2500mg of calcium)
62839666|NCT03399188|EXPERIMENTAL|FMT group|Group who received fecal microbiome transplantation
62055271|NCT02484001|EXPERIMENTAL|ESL 1200 mg|ESL will be administered orally once daily (QD)
62055272|NCT02484001|EXPERIMENTAL|ESL 1600 mg|ESL will be administered orally once daily (QD)
62055273|NCT02484001|EXPERIMENTAL|ESL 400 mg|ESL will be administered orally once daily (QD)
62055274|NCT00582257||High Genetic Risk:|"Early Onset Gastric Cancer - diagnosis of gastric cancer before the age of 50 without a family history of the disease.~Familial Gastric Cancer - having a family history of gastric cancer as defined as one first degree relative or 2 second degree relatives.~Relative - Relatives of participants eligible for the High Genetic Risk Cohort will be eligible for participation. These relatives may also be at high risk of developing gastric cancer. These individuals will fall under the Cancer Cohort. Eligible relatives will be defined as someone having a relative who meets criteria for either the Early Onset Cancer Cohort or the Familial Gastric Cancer Cohort, or having a family history of a genetic mutation known to be associated with gastric cancer."
62055275|NCT00582257||Low Genetic Risk: Closed to Accrual|"Sporadic Gastric Cancer - gastric cancer that appears to have occurred by random or sporadic mutation. Specifically, a patient with gastric cancer not eligible for either High Genetic Risk cohort.~Control (closed to accrual) - A participant that is not a blood relative of a patient or relative participant, without gastric cancer and without a family history of a CDH1 gene mutation. Select MSK participants with Hereditary Diffuse Gastric Cancer with identified CDH1 germline genetic mutation will be invited by MSKCC only to complete the onetime Pre-implantation Genetic Diagnosis (HDGC PGD) survey. These patients may be verbally consented over the telephone."
62055276|NCT01931735|EXPERIMENTAL|Randomized Meniscectomy|This group will have a partial meniscectomy
62055277|NCT01931735|ACTIVE_COMPARATOR|Randomized Lavage|This group will have arthroscopy and lavage
62055278|NCT01931735|OTHER|Standard of Care Meniscectomy Pre-Amend|Pre-Amendment: surgeons determined standard of care option, meniscectomy, best benefited the patient. Therefore, the patient was not randomized.
62055279|NCT01931735|OTHER|Standard of Care Meniscectomy Post-Amend|Post Amendment: patients received a meniscectomy as a standard of care and were observed for 24-months post-operative.
62055280|NCT06067633|EXPERIMENTAL|Triple-Masked|For articles allocated to the blinded (masked) editorial process, the editorial assistant will delete identifiable/unmasking content of cover page and letters. All articles will be flagged as being in triplemasked editorial process arm in the document title
62257785|NCT01063075|EXPERIMENTAL|Carboplatin and Cetuximab (A)|"Group A:~Cycle 1 (3 weeks, combination therapy):~Carboplatin (AUC=5) administered I.V on week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1.~400 mg/m ² cetuximab administered I.V on week 2, day 1. 250 mg/m ² cetuximab administered I.V on week 3, day 1.~Cycle 2 (3 weeks, combination therapy):~Carboplatin (AUC=5) administered I.V on week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 250 mg/m ² cetuximab administered I.V on weeks 1- 3, day 1.~After 7 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
62257786|NCT02616549|EXPERIMENTAL|Sudarshan Kriya Yoga|
62257787|NCT02616549|NO_INTERVENTION|Waitlist Control|
62257788|NCT02292030||cardioversion+HTEA|Heart failure patients accompanied by atrial fibrillation receive the treatment of cardioversion+HTEA.
62614850|NCT02620358|EXPERIMENTAL|High Work of Breathing|"If patient has weaning criteria, a Spontaneous Breathing Trial (SBT) with T Tube for 2 hours will be done.~The patient will be extubated after the SBT if he has no criteria of SBT failure."
62839667|NCT04527770|ACTIVE_COMPARATOR|dexamethasone group|sonar guided median nerve hydrodissection by bupivacaine 0.5% and dexamethasone
62444597|NCT05830448|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT)|CBD is a model that applies learning theories to assist people when they encounter difficulties and life problems that they cannot cope with in their daily lives. It focuses on the elements that affect emotions and behaviors, that is, the thought system. CBT is a process that involves changing the automatic thoughts and evaluations that occur when people are faced with negative situations with different thoughts that can create alternatives and restructuring these thoughts. The approach essentially argues that the way events are perceived and interpreted is more important than how they happen. Systematic errors in information processing, which cause people to perceive themselves, their environment and their future negatively, cause stress and symptoms of mental disorders. There are studies showing that cognitive behavioral therapy reduces stress levels and stress symptoms.
62614851|NCT02620358|EXPERIMENTAL|Low Work of Breathing|"If patient has weaning criteria a Spontaneous Breathing Trial (SBT) with Pressure Support Ventilation of 8 cmH2O for 30 minutes will be done.~The patient will be extubated after the SBT if he has no criteria of SBT failure."
62614852|NCT01892904|EXPERIMENTAL|EE20/DRSP(BAY86-5300)-flexibel extended regimen|One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day with flexible extended regimen (24-day to 120-day active tablet intake followed by 4-day tablet free interval)
62614853|NCT01892904|ACTIVE_COMPARATOR|EE20/DRSP(BAY86-5300)-28 days cyclic regimen|One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day with 28-day cyclic regimen (24-day active tablet intake followed by 4-day placebo tablet intake)
62614854|NCT03201393|EXPERIMENTAL|Low-Dose Naltrexone and Acetaminophen Combination|
62614855|NCT03201393|PLACEBO_COMPARATOR|Placebo|
62614856|NCT05144048|ACTIVE_COMPARATOR|Induction of labour with oral misoprostol, inpatient setting|These women receive all treatment in the maternity unit.
62839668|NCT04527770|ACTIVE_COMPARATOR|midazolam group|sonar guided median nerve hydrodissection by bupivacaine 0.5% and midazolam
62614857|NCT05144048|EXPERIMENTAL|Induction of labour with oral misoprostol, outpatient setting|These women are observed 2 hours after they receive one dose of oral misoprostol before they leave the maternity unit.
62055281|NCT06067633|ACTIVE_COMPARATOR|Usual Procedures|All articles will be flagged as being in usual editorial process arm in the document title. For articles allocated to the usual (double-masked) editorial process, the editorial assistant will leave identifiable/unmasking content of cover page and letters for the editors.
62055282|NCT05197361||Global cohort|"Invasive coronary physiology parameters estimation, including:~FFR, CFR, IMR, Absolute coronary flow (AF). AF derived resistances"
62055283|NCT03764449|EXPERIMENTAL|Cohort 1|Participants received the study drug at dose level A in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.
62055284|NCT03764449|EXPERIMENTAL|Cohort 2|Participants received the study drug at dose level B in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.
62839669|NCT00580307|PLACEBO_COMPARATOR|Septoplasty|Septoplasty only
62839670|NCT00580307|EXPERIMENTAL|Septoplasty and correction|Septoplasty and endoscopic contact point correction
62055285|NCT03047928|EXPERIMENTAL|Patient group|"All patients receive the same treatment. Patients included in the protocol are treated with Nivolumab according to usual guidelines, implying outpatient IV infusions of 3 mg/kg biweekly until progression.~The vaccine is administered on the same day as the administration start of Nivolumab. The vaccination is given biweekly for a total of 6 times, then every fourth week up to week 47, whereupon no additional vaccines will be given. In total, 15 vaccines will be administered. A vaccine consist of 100 μg IDO long peptide, 100 μg PD-L1 long1 peptide and 500 microliters Montanide as adjuvant.~Patients who complete all vaccines will continue Nivolumab treatment after standard guidelines."
62257789|NCT02292030||only cardioversion|Heart failure patients accompanied by atrial fibrillation receive the treatment of cardioversion, but not with HTEA.
62257790|NCT04342754|EXPERIMENTAL|Deep Brain Stimulation ON (DBS ON)|The device will be turned ON
62257791|NCT04342754|SHAM_COMPARATOR|Deep Brain Stimulation OFF (DBS OFF)|The device will be turned OFF
62839671|NCT00695097|ACTIVE_COMPARATOR|1|Rituximab Group: The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15) and followed up monthly for 1 year. Biopsy was done Baseline and Month 3 and other labs (CBC/Diff, Platelets, HACA, PK, Serum Creatinine, 24-hour protein, HLA antibodies, flow cytometry, and serology testing). Physical exam and vital signs were done.
62839672|NCT00695097|ACTIVE_COMPARATOR|2|No Rituximab: received standard immunosuppression and was followed up monthly for 1 year. Labs (CBC/Diff, Platelets, HACA, PK, Serum Creatinine, 24-hour protein, HLA antibodies, flow cytometry, and serology testing) vital signs, and physical exam was done.
62839673|NCT01431872||Post menopausal breast cancer patients|
62257792|NCT00150826|ACTIVE_COMPARATOR|Quinapril|This arm will receive quinapril which will be started at 40mg daily and titrated to 80mg daily by the end of the first week. After treatment on the maximum tolerated dose for 16 weeks, patients will be reevaluated with coronary angiogram with coronary flow reserve measurements and assessment of angina using the Seattle Angina Questionnaire.
62257793|NCT00150826|PLACEBO_COMPARATOR|Placebo|This arm will receive placebo for 16 weeks and will be reevaluated with coronary angiogram with coronary flow reserve measurements and assessment of angina using the Seattle Angina Questionnaire.
62257794|NCT01439555|EXPERIMENTAL|Simvastatin + L-Arginine + Tetrahydrobiopterin|Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
62257795|NCT03044938|EXPERIMENTAL|Salbutamol|Salbutamol is a bronchodilator that relaxes the muscles of the airways and increases the flow of air to the lungs. With the aid of a spacer, 400mcg of the drug will be administered once during the protocol.
62614858|NCT04423575|EXPERIMENTAL|Outpatients|Health care pathway: patient education, communication to liberal nurses, first-position surgical planning, bariatric surgery (bypass or sleeve) as outpatient procedure, follow-up by home nurse twice-a-day, standardized communication to surgeons, management of possible complications
62614859|NCT04423575|NO_INTERVENTION|Inpatients|Standard care pathway with bariatric surgery (bypass or sleeve) as inpatient procedure (at least one night in the hospital)
62614860|NCT01828216|ACTIVE_COMPARATOR|Conventional polysomnography|Conventional PSG will be performed as in-patient at Prince of Wales Hospital for every subject in this group, recording electroencephalogram, electro-oculogram, submental electromyogram, bilateral anterior tibial electromyogram, electrocardiogram, chest \& abdominal wall movement by inductance plethysmography, airflow measured by a nasal pressure transducer \& supplemented by oronasal airflow thermistor, \& finger pulse oximetry.
62839674|NCT02595489|EXPERIMENTAL|Vitamin D3|Single-arm, dose-escalation starting at 1,000 IU or 2,000 IU of vitamin D3 daily for a 6 month period, followed by a conditional titration up to 4,000 IU daily for at least 6 months thereafter. No placebo.
62839675|NCT03085264|EXPERIMENTAL|Community Health Worker|Patients are paired with community health workers for 30 days after hospital discharge to assist with patient care
62839676|NCT03085264|NO_INTERVENTION|Usual Care|Patients are not paired with community health workers for 30 days after hospital discharge to assist with patient care
62839677|NCT03669783|ACTIVE_COMPARATOR|treatment VAD|Vincristin, Actinomycin-D and Doxorubicin
62257796|NCT03044938|PLACEBO_COMPARATOR|Placebo|Inoculant treatment through a substance that does not have an inherent power to produce an effect that is desired or expected. Four placebo puffs will be offered through a device similar to the salbutamol intervention device.
62257797|NCT02224716||Pre-intervention All patients admitted with a diagnosis of CAP|
62257798|NCT02224716||Post intervention All patient admitted with a diagnosis of CAP|
62257799|NCT01128127|EXPERIMENTAL|Multifaceted intervention 1|psycho-educational workshop + audit-feedback + computer-based clinical decision support system (CCDSS) + usual intervention
62444598|NCT05830448|ACTIVE_COMPARATOR|Mobile Mental Health Support System created by the Turkish Ministry of Health|"This system aims to protect and support the mental health of the health personnel of the Ministry of Health. It is a mobile application that allows video calls with a secure and official channel with voluntary adult and child-adolescent mental health and diseases specialists for himself and his children. Personnel who want to benefit from the said service will be able to access the service by downloading the Ministry of Health RUHSAD application to their mobile devices after searching for Mental Health Support System in the mobile application markets and following the instructions."
62444599|NCT03689296||Users|Person with a long-term mental disorder
62444600|NCT03689296||Caregivers|Adult helping a person with a long-term psychological disorder
62444601|NCT03689296||Primary care professionals|Primary care professional in practice following at least one person with a long-term mental disorder
62444602|NCT03689296||Psychiatric professionals|Psychiatric specialist working in a hospital or in private practice
62444603|NCT03907280|EXPERIMENTAL|T1-T2-R-T3|
62444604|NCT03907280|EXPERIMENTAL|R-T1-T2-T3|
62444605|NCT03907280|EXPERIMENTAL|T2-R-T1-T3|
62444606|NCT02752256||Intervention/Transfer|Patients who are transferred via air ambulance to a comprehensive stroke center
62444607|NCT02752256||Control|Patients presenting directly to the comprehensive stroke center
62444608|NCT02260375|EXPERIMENTAL|Mesenchymal Stromal Cells (MSC)|A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party MSC (from healthy donors) will be performed in patients assigned to the MSC procedure in addition to the liver transplantation.
62444609|NCT02260375|NO_INTERVENTION|No treatment.|
62444610|NCT00947063|EXPERIMENTAL|1|Promethazine HCl 50 mg Tablets (Sandoz, Inc)
62444611|NCT00947063|ACTIVE_COMPARATOR|2|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)
62839678|NCT03669783|EXPERIMENTAL|treatment VCE|Vincristin, Carboplatin and Etoposide
62444612|NCT00721058|OTHER|1|
62257800|NCT01128127|EXPERIMENTAL|Multifaceted intervention 2|audit-feedback + computer-based clinical decision support system (CCDSS) + usual intervention
62257801|NCT01128127|ACTIVE_COMPARATOR|Control|usual intervention
62257802|NCT00733148||1|Routine Care
62257803|NCT00733148||2|Insulin infusion based on model predictive algorithm (MPC)
62257804|NCT04943575|ACTIVE_COMPARATOR|Intervention 1|EZC Pak
62257805|NCT04943575|ACTIVE_COMPARATOR|Intervention 2|EZC Pak+D
62257806|NCT04943575|PLACEBO_COMPARATOR|Placebo|
62444613|NCT02660190|EXPERIMENTAL|PDD|PDD at flexible cystoscopy
62444614|NCT02660190|EXPERIMENTAL|WL|WL only at flexible cystoscopy
62444615|NCT06059170|OTHER|QOL, risk factor and therapeutic options|questionnaires
62444616|NCT06157307|EXPERIMENTAL|Test subjects|Four different hand placements for aortic compression.
62444617|NCT01139255|EXPERIMENTAL|Podcasting + mobile media|
62444618|NCT01139255|ACTIVE_COMPARATOR|Podcasting|
62444619|NCT05170256|EXPERIMENTAL|Treatment arm|
62444620|NCT00956033||Patients with multiple myeloma|
62444621|NCT01982487|NO_INTERVENTION|Arm A (no treatment)|Patients receive no treatment.
62444622|NCT01982487|EXPERIMENTAL|Arm B (IDO1 inhibitor INCB024360)|Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-28.
62444623|NCT01982487|EXPERIMENTAL|Arm C (vaccine, IDO1 inhibitor INCB024360)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and IDO1 inhibitor INCB024360 PO BID on days 1-28.
62257807|NCT00631020|EXPERIMENTAL|CBME +/- NRT|6 weeks CBME with optional 4 weeks NRT
62444624|NCT01982487|EXPERIMENTAL|Arm D (vaccine)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1.
62614861|NCT01828216|ACTIVE_COMPARATOR|Home sleep study|The home sleep study is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events.
62614862|NCT01448863||CONTROL|Fertile women (egg-donors)
62614863|NCT01448863||WITH PCO|Obese women with Polycystic Ovarian Syndrome
62257808|NCT02527369|EXPERIMENTAL|XP1100RF group|Subjects in the XP1100RF group will be treated with the XP1100RF device.
62257809|NCT02055651||Bayer Sao Paulo employees|Workers from Bayer in site Socorro who participate in the trial
62614864|NCT01448863||NO PCO|Obese women without Polycystic Ovarian Syndrome
62614865|NCT03084315|SHAM_COMPARATOR|E-Cig Zero Nicotine|E-Cigarette with no nicotine added
62839679|NCT05819151||HbA1c<6% (normal)|Subjects with HbA1c\<6%, i.e, non-diabetes population
62839680|NCT05819151||HbA1c 6-6.4% (prediabetes)|Subjects with HbA1c 6-6.4%, i.e, prediabetes population
62839681|NCT05819151||HbA1c 6.5-8.9% (diabetes)|Subjects with HbA1c HbA1c 6.5-8.9%, i.e. diabetes population
62839682|NCT05819151||HbA1c≥ 9% (diabetes with high HbA1c)|Subjects with HbA1c≥ 9%, i.e. diabetes population with high HbA1c
62839683|NCT05240027|OTHER|Middle, High and College students within the Dallas-Fort Worth area that may Vape|The program will be going to middle school, high school, and college campuses in the Dallas-Fort Worth (DFW) area to speak with students about vaping. The program will be implemented by community outreach, as the students will be presented with information about vaping and the resources necessary to prevent or stop vaping.
62839684|NCT01652534|ACTIVE_COMPARATOR|Amantadine|Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day
62839685|NCT01652534|PLACEBO_COMPARATOR|placebo|Sugar Pill
62839686|NCT04724109||Equfina|Participants with parkinson's disease will be administered Equfina 50 milligram (mg) tablets, orally, once daily in combination with levodopa-containing products. On the basis of symptoms, Equfina 100 mg tablet, orally, once daily may be selected for participants. All the participants will be observed for up to 24 weeks prospectively.
62839687|NCT03752567||Group study|Follow up of the patients for 12 months by the community pharmacist in the role of case manager and execution of the activities foreseen by the PAI (individual assistance plan) through telemedicine (ecg, fundus oculi, ankle arm index) and self analysis (glycated hemoglobin, lipid profile, uric acid microalbuminuria).
62839688|NCT04285970||Medullary injured|Injured Medullary users of manually driven wheelchairs for daily locomotion
62839689|NCT04285970||Healthy volunteers|Healthy volunteer with at least 2 hours' experience using a manual wheelchair
62839690|NCT03766737|OTHER|Eligible patients for AI test.|Device: An intelligent visual acuity diagnostic system for children. An artificial intelligence to evaluate children's vision.
62839691|NCT03544086||test group|First group is the first 10 patients
62257810|NCT06265675|EXPERIMENTAL|Phenol block group|
62614866|NCT03084315|ACTIVE_COMPARATOR|E-Cig 24mg Nicotine|E-cigarette with 24mg of nicotine added
62614867|NCT01122017|EXPERIMENTAL|Medial Opening-Wedge Osteotomy|Medial Opening-Wedge Osteotomy (MOWO) is an approach for the correction of malalignment of the knee
62614868|NCT02105649|EXPERIMENTAL|calf muscle strengthenig group|"experimental group~will receive the same selected physical therapy program in addition to manual and mechanical strengthening exercises and electrical stimulation program for calf muscles of both lower limbs."
62614869|NCT02105649|OTHER|No calf muscle strengthening group|"control group~will receive only the selected physical therapy program"
62839692|NCT03544086||study group|following 150 patients
62839693|NCT01364844|EXPERIMENTAL|DS7423|
62257811|NCT06265675|ACTIVE_COMPARATOR|Corticosteroid and local anesthetic|
62257812|NCT04586543|EXPERIMENTAL|Selegiline+ Docetaxel|Selegiline and plus Docetaxel
62444625|NCT01784133|ACTIVE_COMPARATOR|omiganan mid dose|omiganan mid dose once daily application for 12 weeks
62444626|NCT01784133|ACTIVE_COMPARATOR|omiganan high dose|omiganan high dose once daily application for 12 weeks
62839694|NCT03238430|EXPERIMENTAL|Ropivacaine infiltration|Continuous infiltration of local anesthetics + PCA morphine.
62839695|NCT03238430|EXPERIMENTAL|intrathecal morphine|Rachianalgesia + PCA morphine
62839696|NCT03238430|ACTIVE_COMPARATOR|morphine PCA|PCA morphine alone
62839697|NCT04063007|OTHER|Ketogenic diet|The patients follow the ordinary treatment protocol for initiation and follow-up of the ketogenic diet
62257813|NCT04586543|ACTIVE_COMPARATOR|Docetaxel|Docetaxel
62257814|NCT01792921||control waitlist|
62257815|NCT02533063|ACTIVE_COMPARATOR|Combination Treatment|"In the loading + vibration group (intervention group), subjects will be seated in the VibeTech One system and vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
62839698|NCT04182828|PLACEBO_COMPARATOR|Placebo Group(PG)|It will be normal saline 0.9%
62839699|NCT04182828|ACTIVE_COMPARATOR|Lidocaine Group(LG)|It will be lidocaine 2%
62614870|NCT05410704|EXPERIMENTAL|Study Group|Pelvic floor muscle exercises and diaphragmatic breathing exercises will be performed 3 times a week for 12 weeks. New York Posture Rating Scale and SF-36 will be applied before and after the study. International Physical Activity Questionnaire and Pelvic Floor Impact Questionnaire will be applied before the study.
62444627|NCT01784133|PLACEBO_COMPARATOR|Vehicle group|Vehicle once daily application for 12 weeks
62444628|NCT01784133|ACTIVE_COMPARATOR|omiganan low dose|omiganan low dose once daily application for 12 weeks
62444629|NCT01835145|EXPERIMENTAL|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62614871|NCT05410704|NO_INTERVENTION|Control Group|No intervention. New York Posture Rating Scale and SF-36 will be applied before and after the study. International Physical Activity Questionnaire and Pelvic Floor Impact Questionnaire will be applied before the study.
62614872|NCT05509686|EXPERIMENTAL|A single-session intermittent theta burst stimulation (iTBS)|The classical 600-pulse iTBS protocol is delivered to the motor hotspot over the ipsilesional hemisphere.
62444630|NCT01835145|EXPERIMENTAL|Arm II (temozolomide or dacarbazine)|Patients receive temozolomide PO daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. If temozolomide is not available, patients receive dacarbazine IV over 15-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62444631|NCT03387033|EXPERIMENTAL|VR intervention session|The patients will give a pain score as well as fill out GAD-7 and PHQ-9 scores initially. The VR intervention session consists of relaxation narration WITH Virtual Reality session for 20 minutes while wearing the VR device. They will then be again asked to give a pain score and fill out GAD-7, PHQ-9, and PGIC.
62444632|NCT02887209|EXPERIMENTAL|CBT-I|This is a single arm study in which all participants receive the intervention (cognitive behavioural therapy for insomnia)
62257816|NCT02533063|SHAM_COMPARATOR|Sham Treatment|"In the loading only group (control group) participants will be seated in the vibration device (VibeTech One) and will experience loading of their leg muscles through the device."
62257817|NCT01147328||1|Patients who did not have their data accessed in the VHR by a provider within 6 months after they consented will be part of the control group
62839700|NCT03520504|EXPERIMENTAL|Proton Radiation|"Patients will be enrolled to receive 30Gy (RBE) in 3Gy (RBE) or 25Gy (RBE) in 2.5Gy (RBE) fractions course of proton CSI.~The first 3 patients will be enrolled at dose level 30Gy (RBE) in 3Gy(RBE) fractions. If 1 or fewer patients develop dose-limiting toxicity (DLT), 3 additional patients will be enrolled. If 1 or fewer of the 6 patients experiences a DLT, the trial will proceed to the dose expansion cohort at 30Gy (RBE) . In contrast, if 2 or more patients experience a treatment DLT, 3 patients will be enrolled at dose level 25Gy (RBE) in 2.5Gy(RBE) fractions. If 1 or fewer patients develop a DLT, an additional three patients will be enrolled. If 2 or more patients experience a DLT at 25Gy, the study will be stopped. If 1 or fewer patients develop a DLT in these 6 patients, the trial will proceed to the dose expansion cohort at 25Gy (RBE) and the 6 patients who were treated in Phase Ib will be included in full assessment of safety and efficacy."
62839701|NCT02528552|ACTIVE_COMPARATOR|LH80 PRO|Low level laser therapy
62055286|NCT05461261|EXPERIMENTAL|Docetaxel plus platinum|Docetaxel combined with platinum-based drugs will be applied every 3 weeks for 6 cycles.
62257818|NCT01147328||2|Patients who had their data accessed in the VHR by a provider within 6 months after they consented will be part of the intervention group
62257819|NCT05726799||Cryoenergy|
62257820|NCT05726799||Classic Myectomy|
62839702|NCT02528552|SHAM_COMPARATOR|Sham device|No low level laser therapy
62839703|NCT05570669|EXPERIMENTAL|full dose|"Group A delayed full-dose regimen (study arm): intake of two large A sachets and 2 small B sachets from 20:30 to 22:00 the evening before the exam. Taking the remaining 2 envelopes A large e 2 small B envelopes from 10.30 pm to midnight the evening before the exam."
62839704|NCT05570669|OTHER|split dose|"Group B split-dose regimen (control arm): intake of two large A sachets and two small B sachets from 20.30 to 22:00 the evening before the exam. The remaining two large A envelopes and two small B envelopes will be taken 5 hours earlier than the time when the exam is scheduled on the same day as the exam."
62839705|NCT01056016|NO_INTERVENTION|Wait-list control|Wait-list control group
62839706|NCT01056016|EXPERIMENTAL|ADHD Collaborative Intervention|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a Diagnostic and Statistical Manual-IV (DSM-IV) based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales. The intervention lasts for 6 months.
62839707|NCT03284580|EXPERIMENTAL|Ergonomic intervention group|Ergonomic intervention program at home for caregivers
62839708|NCT03284580|EXPERIMENTAL|Postural + kinesiotherapy intervention group|A postural + kinesiotherapy intervention program at home for caregivers
62839709|NCT03284580|OTHER|Control or conservative group|A conservative intervention by general information for caregivers
62055287|NCT05461261|ACTIVE_COMPARATOR|Docetaxel alone|Docetaxel alone will be applied every 3 weeks for 6 cycles.
62055288|NCT02393872|EXPERIMENTAL|High-risk families component|School-based intervention and counselling sessions.
62055289|NCT02393872|EXPERIMENTAL|All-families component|School-based intervention.
62055290|NCT02393872|NO_INTERVENTION|Control|Control group.
62257821|NCT02571296|ACTIVE_COMPARATOR|group A|"subjects will recieve twice daily tablets of 100 mg of oral Micronized Progesterone from (14-18 weeks) until 36 weeks or delivery.~Subjects: 106 cases Name: Oral micron ized progesterone Form: oral tablets Dosage: one tablet Frequency: every 12 hours Duration: 14-36 weeks gestational age."
62257822|NCT02571296|PLACEBO_COMPARATOR|Group B|"subjects will receive placebo twice daily from (14-18 weeks) until 36 weeks or delivery.~Subjects: 106 cases Name: placebo Form: oral tablets Dosage: one tablet Frequency: every 12 hours Duration: 14-36 weeks gestational age."
62257823|NCT02221531|EXPERIMENTAL|Short infusion|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
62055291|NCT03718689|EXPERIMENTAL|Group L|The second group of teeth (Group L) were etched with Er:YAG laser.
62055292|NCT03718689|EXPERIMENTAL|Group A+L|The third group of teeth (Group A+L) were etched with both Er:YAG laser and phosphoric acid.
62055293|NCT03718689|NO_INTERVENTION|Group A|The first group of teeth (Group A) were not etched with Er:YAG laser.
62055294|NCT06081595|EXPERIMENTAL|Fluzoparib+Apatinib combination|
62055295|NCT01341002|EXPERIMENTAL|SCVO2 < 70%|guidelines transfusion + SCVO2 \< 70%
62444633|NCT03384745|EXPERIMENTAL|M1095 (Sonelokimab) 30mg|M1095, 30 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
62444634|NCT03384745|EXPERIMENTAL|M1095 (Sonelokimab) 60mg|M1095, 60 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
62444635|NCT03384745|EXPERIMENTAL|M1095 (Sonelokimab) 120mg - regimen 1|M1095, 120 mg, given at Week 0, 2, 4, 8, 12 and every eight weeks.
62444636|NCT03384745|EXPERIMENTAL|M1095 (Sonelokimab) 120mg - regimen 2|M1095, 120 mg, given at Week 0, 2, 4, 6, 8, 10, 12 and every four weeks.
62055296|NCT01341002|ACTIVE_COMPARATOR|currently intervention|guidelines transfusion
62444637|NCT03384745|PLACEBO_COMPARATOR|Placebo / M1095 (Sonelokimab) 120mg|Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10, then M1095, 120mg, given at Week 12, 14, 16, and every four weeks.
62444638|NCT03384745|ACTIVE_COMPARATOR|Secukinumab|Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, 8, 12 and every four weeks.
62444639|NCT02470039|EXPERIMENTAL|Oral insulin 338 and subcutaneous placebo|
62614873|NCT05509686|SHAM_COMPARATOR|A single-session sham intermittent theta burst stimulation (iTBS)|The sham stimulation is the same as that of iTBS, but the coil is placed five centimeters away from the scalp.
62257824|NCT02221531|OTHER|Bolus application|Carbetocin 100 microgram will be applied intravenously by bolus application over about 15 seconds
62257825|NCT06310681|EXPERIMENTAL|"Encompass group programme"|
62614874|NCT00600392||1|patients who meet criteria for CRT-D implantation
62614875|NCT01813734|EXPERIMENTAL|Ponatinib Treatment Arm|Ponatinib 30 mg PO daily
62614876|NCT04026334|EXPERIMENTAL|V.A.C. VERAFLO CLEANSE CHOICE™ with Normal Saline|
62614877|NCT04167683||Cohort 1 - Patients referred to myeloablative HSCT|These patients will undergo 5 assessments: a baseline-assessment 3-4 week prior to conditioning treatment, at discharge (in-patients) or at day +28 after stem cell infusion (out-patients) and follow-up assessments at 3 months, 6 months and 12 months.
62614878|NCT04167683||Cohort 2 - Patients referred to non myeloablative HSCT|These patients will undergo 5 assessments: a baseline-assessment 3-4 week prior to conditioning treatment, at discharge (in-patients) or at day +28 after stem cell infusion (out-patients) and follow-up assessments at 3 months, 6 months and 12 months.
62614879|NCT06350786|EXPERIMENTAL|Open-Label Placebo|"The intervention involves administering P-Dragees blue Lichtenstein, blue placebo pills devoid of active ingredients. Each pill contains lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; sucrose; glucose syrup; corn-starch; highly dispersed silicon dioxide; white clay; macrogol glycerol hydroxy stearate (Ph. Eur.); Gum arabic; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); calcium carbonate; macrogol 6000; patent blue V; aluminium salt (E 131).~Participants will be informed that the pills are placebos and will be instructed to pair them with opioid medication for 7 days. After 7 days until the end of the study they will be instructed to continue to pair their opioid medication with an OLP pill and take additionally placebo pills on the basis of their need.~An evidence-based rationale will be provided, explaining why the placebo treatment is deemed effective for pain. This rationale will precede the OLP intake procedure."
62257826|NCT04160455||Cohort A, group A1|40 patients on suppressive antiretroviral therapy (HIV RNA \<50 copies / ml for at least 4 years) initiated during the chronic phase : CD4 count less than 500 cells / ml at the time of inclusion in the study
62257827|NCT04160455||Cohort A, group A2|40 patients on suppressive antiretroviral therapy (HIV RNA \<50 copies / ml for at least 4 years) initiated during the chronic phase: CD4 count above 500 cells / ml at the time of inclusion in the study
62257828|NCT04160455||Cohort B|20 patients on suppressive antiretroviral therapy (HIV RNA \<50 copies / ml for at least 4 years) initiated since the primary-infection (within 4 months after acute infection)
62257829|NCT04160455||Cohort C, group C1|20 patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy: HIV diagnosis made during primary infection (within 4 months of infection)
62257830|NCT04160455||Cohort C, group C2|20 patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count above 200 cells/ml at the time of inclusion in the study
62257831|NCT04160455||Cohort C, group C3|20 patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count less than 200 cells/ml at the time of inclusion in the study
62257832|NCT04160455||Cohort D|20 patients who have undetectable plasma HIV RNA (HIV RNA \<50 copies / ml ) without antiretroviral therapy, either spontaneously (HIV controllers or elite controllers) or after treatment interruption (post-treatment controllers).
62257833|NCT05786079|EXPERIMENTAL|Footstrike modification|
62614880|NCT06350786|OTHER|Electronic monitoring (EM) control group|"EM is a method to objectively measure adherence and serves as the primary intervention component on the basis of which adherence trajectories will be discussed. The participants in the EM control group will receive an evidence-based rational designed to foster positive expectations and will be instructed on the mechanisms of EM.~The EM control group is structurally equivalent to the OLP group referring to the number and duration of contacts between participants and the study team members as well as to the format of the intervention and the quality of the interaction."
62614881|NCT06097273|EXPERIMENTAL|Cohort A1: mRNA-1083 and Placebo|Participants of age 65 years and older will receive mRNA-1083 and placebo administered as 2 intramuscular (IM) injections of on Day 1.
62055297|NCT05435755|EXPERIMENTAL|hAESCs treatment|A total of 6 times hAESCs transplants will be performed. 50 million (in 2ml) hAESCs will be transplanted into the ventricle of participants through the Ommaya sac (set as day 0 at the beginning of the trial). Subsequently, hAESCs ventricle transplants will be performed at 1 month ±5 days, 2 months ±5 days, 3 months ±5 days, 6 months ±5 days, and 9 months ±5 days after the first cell transplantation, with a volume of 50 million cells (in 2 ml) each time.
62257834|NCT05786079|ACTIVE_COMPARATOR|Control|
62257835|NCT06052163|ACTIVE_COMPARATOR|Bumetanide low dose|"15 participants will take bumetanide low dose orally for 6 months and will be evaluated on cognitive and functional tests.~Participants blood samples will be tested for levels of proteins involved in Alzheimer's disease."
62257836|NCT06052163|ACTIVE_COMPARATOR|Bumetanide high dose|"15 participants will take bumetanide high dose orally for 6 months and will be evaluated on cognitive and functional tests.~Participants blood samples will be tested for levels of proteins involved in Alzheimer's disease."
62257837|NCT06052163|PLACEBO_COMPARATOR|Placebo|"10 participants will take placebo orally for 6 months and will be evaluated on cognitive and functional tests.~Participants blood samples will be tested for levels of proteins involved in Alzheimer's disease."
62257838|NCT05699889||Patients in intensive care for SARS-CoV 2 infection with severe respiratory impairment.|
62839710|NCT05002712|EXPERIMENTAL|Heavy resistance training|Group A
62257839|NCT05699889||Patients in intensive care without SARS-CoV 2 infection with severe respiratory impairment.|
62444640|NCT02470039|ACTIVE_COMPARATOR|Subcutaneous insulin glargine and oral placebo|
62257840|NCT01786200|ACTIVE_COMPARATOR|Aspirin|20 patients randomised to aspirin 75mg PO once daily
62257841|NCT01786200|ACTIVE_COMPARATOR|Ibuprofen|20 patients randomised to ibuprofen 400mg PO three times daily
62257842|NCT01786200|NO_INTERVENTION|Control|20 patients randomised to receive no treatment
62257843|NCT06243874|ACTIVE_COMPARATOR|greater occipital nerve block|"Following intravenous access and monitoring, participants are placed in the prone position. The medial 1/3 of the line between the protuberance occipital externa and the mastoid process is palpated. The intervention area is cleaned with antiseptic solution. Then, 2 cc of 2% lidocaine is injected into the palpated area after confirming that it is not in the vascular area by negative aspiration. Participants are observed for 30 minutes for possible complications.~The participant will receive a block once a week for the first month and then once a month for the next 2 months."
62614882|NCT06097273|ACTIVE_COMPARATOR|Cohort A2: Influenza Vaccine and COVID-19 Vaccine|Participants of age 65 years and older will receive age recommended quadrivalent influenza vaccine and COVID-19 vaccine administered as 2 IM injections on Day 1.
62614883|NCT06097273|EXPERIMENTAL|Cohort B1: mRNA-1083 and Placebo|Participants of age 50 to \<65 years will receive mRNA-1083 and placebo administered as 2 IM injections of on Day 1.
62614884|NCT06097273|ACTIVE_COMPARATOR|Cohort B2: Influenza Vaccine and COVID-19 Vaccine|Participants of age 50 to \<65 years will receive age recommended quadrivalent influenza vaccine and COVID-19 vaccine administered as 2 IM injections on Day 1.
62839711|NCT05002712|EXPERIMENTAL|Contrast strength training|Group B
62839712|NCT05002712|ACTIVE_COMPARATOR|Elastic resistance training|Group C
62839713|NCT04259814|EXPERIMENTAL|Speech-Language Treatment plus mCIMT|"4 participants~Baseline phase: Speech-language treatment (SLT), 1 hour a day, 3 days a week. The length of the baseline phase will be staggered across subjects.~Treatment phase: SLT combined with modified constraint-induced movement therapy(mCIMT) 1 hour a day, 3 days a week.~Total of baseline and treatment sessions will be 20 to 30 sessions."
62257844|NCT06243874|OTHER|transnasal sphenopalatine ganglion block|"Following intravenous access and monitoring, patients are placed in the supine position. A cotton swab impregnated with 2 cc of 2% lidocaine is advanced from the nostril along the upper edge of the middle turbinate until it reaches the posterior wall of the nasopharynx. The stick impregnated with local anesthetic is kept in the target area for 20 minutes. Participants are observed for 30 minutes for possible complications.~The participant will receive a block once a week for the first month and then once a month for the next 2 months."
62257845|NCT03955302|EXPERIMENTAL|Exercise|Patients in this group will perform the water exercise protocol, 3 times a week, for 12 weeks.
62839714|NCT05115149|EXPERIMENTAL|Volga: tSCS during the exercise|Stimulation during the excercise
62257846|NCT03955302|NO_INTERVENTION|Control|Patients in this group will not perform any type of exercise during the 12 weeks of the treatment.
62257847|NCT02691975|EXPERIMENTAL|SHR3680|Tablet
62257848|NCT00625469|EXPERIMENTAL|treatment with bosentan|patients with resting or exercise induced PAH receive bosentan in a randomized open label fashion
62257849|NCT00625469|NO_INTERVENTION|PAH group with no therapy|patients with resting or exercise PAH get randomized to receive no specific therapy
62257850|NCT00625469|NO_INTERVENTION|No PAH and no therapy|patients with no evidence of either resting or exercise PAH receive no intervention but are followed until lung transplantation
62839715|NCT05115149|EXPERIMENTAL|Neva: tSCS prior to the exercise|Stimulation prior to the action
62257851|NCT00711620|EXPERIMENTAL|Thymosin alpha 1+Standard Therapy|Patients receive treatment based on SSC guideline with additional thymosin alpha1
62839716|NCT03646097|ACTIVE_COMPARATOR|Blinded-group|Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators only based on angiographic lesion evaluation (standard care)
62839717|NCT03646097|ACTIVE_COMPARATOR|OCT-group|Patients underwent OCT-imaging before PCI. Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators based on OCT findings
62839718|NCT03646097|EXPERIMENTAL|ACR-group|Patients underwent ACR-imaging before PCI. Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators based on ACR-findings
62614885|NCT01048970|OTHER|Control arm|Patients will receive nutritional assessment one week prior to treatment until completing two cycles
62614886|NCT01048970|EXPERIMENTAL|EPA-DHA arm|Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
62614887|NCT01529411|EXPERIMENTAL|Vinflunine|"Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance \< 60ml/min)~+ best suportive care, with regards clinical practice."
62614888|NCT01529411|OTHER|Best suportive care|Best suportive care
62614889|NCT04549623|EXPERIMENTAL|Group ETCO2|Novel end-tidal carbon dioxide monitoring device is used for sedation.
62614890|NCT04549623|EXPERIMENTAL|Group Reg|Peripheral oxygen saturation (SpO2) and respiratory motion are regularly monitored during sedation.
62839719|NCT04061330|EXPERIMENTAL|Ketamine Group|
62839720|NCT04061330|ACTIVE_COMPARATOR|Opioid group|
62839721|NCT01515553|EXPERIMENTAL|Formulation 4|
62839722|NCT01515553|EXPERIMENTAL|Final formulation 4|
62839723|NCT06176235|EXPERIMENTAL|Teriflunomide plus Dexamethasone|Oral Teriflunomide was given at a dose of 7 mg once daily for 24 weeks and dexamethasone was given at a dose of 40mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4). Nonresponsive participants with platelets less than 20 x10\^9/L or with active bleeding were allowed to repeat the 4-day course of dexamethasone treatment.
62839724|NCT06176235|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone was given at a dose of 40mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4). Participants in this treatment arm who failed to achieve a sustained response and had a platelet count of less than 20 x 10\^9/L or with active bleeding were also allowed to repeat the 4-day course of dexamethasone treatment.
62839725|NCT06064916||Vivity IOL Group|Patients with bilateral implantation of Vivity IOLs.
62839726|NCT04598802||Covera Plus|
62055298|NCT05435755|PLACEBO_COMPARATOR|Control group|Four times hAESCs transplants and two times placebo (cell preservation solution) injections will be performed by Ommaya sac. 50 million (in 2ml) hAESCs will be transplanted into the ventricle of participants (set as day 0 at the beginning of the trial). Subsequently, hAESCs will be transplanted into the ventricle for 3 times, respectively, at 1 month ±5 days , 2 months±5 days , and 3 months ±5 days after the first cell transplantation, with a volume of 50 million cells (in 2 ml) each time. Ventricle injection of 2 ml placebo (cell preservation solution) will be performed at 6 months ±5 days and 9 months ±5 days after the first cell transplantation.
62055299|NCT00583622|EXPERIMENTAL|Bevacizumab + High-Dose Chemotherapy|Bevacizumab 5 mg/kg by vein (IV) daily over 90 minutes for 2 Days + Carboplatin 333 mg/m\^2 by vein over 2 hours for 3 Days + Docetaxel 300 mg/m\^2 by vein over 2 hours for 1 Day + Gemcitabine 1,800 mg/m2 by vein over 3 hours for 4 Days + Melphalan 50 mg/m\^2 by vein over 15 minutes for 3 Days + Stem Cell Transplant
62055300|NCT03607188|EXPERIMENTAL|ZG0418 200mg QD|ZG0418 200mg/day,oral
62055301|NCT03607188|EXPERIMENTAL|ZG0418 300mg QD|ZG0418 300mg/day,oral
62055302|NCT03607188|EXPERIMENTAL|ZG0418 400mg QD|ZG0418 400mg/day,oral
62257852|NCT00711620|PLACEBO_COMPARATOR|normal saline+standard therapy|Patients receive treatment based on SSC guideline with additional normal saline.
62257853|NCT03333720|EXPERIMENTAL|Intervention|Intervention is phenylalanine-free protein substitute. Following a 7 day baseline period, all recruits will receive the new phenylalanine-free protein substitute daily for 28 days in addition to routine nutritional management. The study product prescription will be specified on an individual basis by the metabolic Dietitian responsible for the patient's nutritional management and will be dependent on age, bodyweight and medical condition of the patient, but will wholly replace their currently prescribed tablet protein substitute and multivitamin supplements.
62257854|NCT00530270|ACTIVE_COMPARATOR|Dexamethasone|
62257855|NCT00530270|PLACEBO_COMPARATOR|Placebo|
62257856|NCT01169298|EXPERIMENTAL|Lenalidomide|Lenalidomide: 25mg daily on day1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort) or 35 mg daily of each 28 days (3rd cohort)
62839727|NCT01915589|EXPERIMENTAL|Refametinib (BAY86-9766)|For purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Death Unacceptable toxicity Subject withdraws consent Substantial non-compliance with the protocol Treating physician determines discontinuation of treatment is in the subject's best interest. Radiological progression as determined by RECIST (Version 1.1) or mRECIST criteria or clinical progression (e.g. Eastern Cooperative Oncology group performance status - ECOG PS ≥3) patients may continue to receive study treatment if identified as having continued clinical benefit as judged by the treating physician.
62055303|NCT03607188|EXPERIMENTAL|ZG0418 500mg QD|ZG0418 500mg/day,oral
62055304|NCT03607188|EXPERIMENTAL|ZG0418 600mg QD|ZG0418 600mg/day,oral
62055305|NCT03681418|OTHER|Patients with operable breast cancer|Ultrasound-guided axillary lymph nodes FNAC and\\or CNB.
62055306|NCT01170416||12-Lead Body Surface Mapping - Focal VT .|Body surface mapping (BSM) will be completed in patients with a defined focal VT site during the EP study.
62055307|NCT01170416||12-Lead BSPM - Scar related VT, exit not identified|Body surface mapping will be competed on patients with scar related VT where the exit cannot be identified
62055308|NCT01170416||12-Lead BSPM - Scar related VT exit identified|Body surface mapping will be competed on patients with scar related VT where the exit is identified
62257857|NCT06277895|EXPERIMENTAL|cardiogenic chest pain group|cardiogenic chest pain group/acute coronary syndrome
62257858|NCT06277895|OTHER|normal group|Healthy population
62055309|NCT01170416||12-Lead BSPM - Supraventricular tachycardia|Body surface mapping will be completed on patients requiring an EP study for the treatment of symptoms related to supraventricular tachycardia
62055310|NCT04194203|EXPERIMENTAL|Treatment A|Participants will receive atezolizumab, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with atezolizumab, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.
62257859|NCT03234244|ACTIVE_COMPARATOR|Bazedoxifene 20mg|Subjects will take bazedoxifene 1 Tablet.
62257860|NCT03234244|ACTIVE_COMPARATOR|Cholecalciferol|Subjects will take Cholecalciferol 2 Tablets.
62257861|NCT03234244|EXPERIMENTAL|Bazedoxifene 20mg and Cholecalciferol|Subjects will take bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
62257862|NCT04646096|EXPERIMENTAL|Mako THA 4.0 group|Hip system used: femoral stem (Accolade II), acetabular cup (Trident II or MDM if necessary), femoral head (ceramic or metal head compatible with Accolade II), acetabular insert (X3 Trident II or MDM liner when using MDM cup). Mako THA 4.0 software also will be used.
62257863|NCT01934686||Subjects with diabetes mellitus (type 2)|
62257864|NCT02446314|PLACEBO_COMPARATOR|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
62257865|NCT02446314|EXPERIMENTAL|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine + 2.5 mg L-Glutathione + 250 mg placebo powder, once daily, in a 2-hard capsule regimen
62257866|NCT02446314|EXPERIMENTAL|Wild Blueberry Powder - 900 mg|Formulation containing containing 450 mg wild blueberry powder + 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
62257867|NCT02446314|EXPERIMENTAL|Wild Blueberry extract 100mg|Formulation containing containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
62614891|NCT01652066|PLACEBO_COMPARATOR|Placebo|oral consumption, once per day in the morning, fasting, with a glass of water
62055311|NCT04194203|PLACEBO_COMPARATOR|Treatment B|Participants will receive placebo, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with placebo, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.
62257868|NCT01473238|ACTIVE_COMPARATOR|Desktop PC|Conventional institutional Desktop Personal Computers will be used to collect data of patients via a password protected encrypted interface.
62257869|NCT01473238|EXPERIMENTAL|Mobile|Novel Mobile Clinical Trial Management System on iPads will be used to collect data of patients via a password protected encrypted interface.
62257870|NCT02440360|ACTIVE_COMPARATOR|Permanent Supportive Housing|Permanent Supportive Housing (PSH) is subsidized housing with closely linked or on-site supportive services that typically include case management, physical and mental health care, substance use treatment services and vocational support.
62257871|NCT02440360|PLACEBO_COMPARATOR|Usual Care|Usual Care consists of public benefits (e.g., General Assistance and CalFresh), integrated medical and behavioral health services provided by Valley Medical Center and the rest of the County Health \& Hospital System including those offered by Valley Homeless Healthcare Program, specialty mental health and substance abuse treatment services and housing programs, and approximately 2,000 year-round beds of emergency shelter and transitional housing.
62257872|NCT02777268|EXPERIMENTAL|Infacort 0.5 mg|Multi-particulate granules from 1 (0.5 mg) capsule
62257873|NCT02777268|EXPERIMENTAL|Infacort 2 mg|Multi-particulate granules from 1 (2 mg) capsule
62257874|NCT02777268|EXPERIMENTAL|Infacort 5 mg|Multi-particulate granules from 1 (5 mg) capsule
62444641|NCT02581800|NO_INTERVENTION|Control group|The control group includes hospital consultations (usual care) on the hospital 2-3 times a week (1-2 hours) and the possibility to call the neonatal ward 24 hours a day all week until the infant gets full nutrition from the breast or bottle and gains weight. The parents register nutrition on a paper between the visits to the hospital.
62444642|NCT02581800|EXPERIMENTAL|App group/intervention group|The intervention group will receive the Smartphone application at inclusion time and learn to use it in the hos-pital. When the families go home they will use the application and receive planned video consultations 2-3 times a week and the possibility to call the neonatal ward 24 hours a day all week whenever needed, until the infant gets full nutrition from the breast or bottle and gains weight. Parents will borrow a baby weight to weigh the baby at home.
62055312|NCT02571374|EXPERIMENTAL|symbiotic group|Symbiotic group
62055313|NCT02571374|PLACEBO_COMPARATOR|placebo group|placebo group
62055314|NCT00828308|EXPERIMENTAL|Ixabepilone|"Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.~Prostatectomy 2-8 weeks after completion \*\*\*this was standard of care and not a part of the study\*\*\*"
62055315|NCT04958330||lateral prostate capsule sparing group|Patients will be preverved the lateral prostate capsule during the resection of bladder and prostate of the operation.
62055316|NCT04958330||non nerve sparing group|Patients will receive standard radical cystectomy (not preserve the neurovascular bundles or lateral prostate capsule) during the operation.
62055317|NCT01325025|OTHER|Patients|Patients with a metachromatic leukodystrophy
62257875|NCT02777268|EXPERIMENTAL|Infacort 10 mg|Multi-particulate granules from 1 (10 mg) capsule
62257876|NCT02777268|ACTIVE_COMPARATOR|Hydrocortisone|1 (10 mg) tablet
62257877|NCT06335095||Control|Healthy volunteers
62257878|NCT06335095||Disease|
62444643|NCT02123927|EXPERIMENTAL|Step 1: TAK-438 1 mg|TAK-438 1 mg, tablets, orally, once on Day 1.
62257879|NCT05687968|EXPERIMENTAL|eHealth care group|"The eHealth group will receive instant feedback from the nutritionists and/or AI after recording their dietary food image, and receive 3D/AR MetaFood food portion and nutrition education."
62257880|NCT05687968|EXPERIMENTAL|control group|The control receive conventional health and nutrition education from state registered dietitian.
62257881|NCT01498198|EXPERIMENTAL|Expedited Surgery|Participants will have surgery within 3 months
62257882|NCT01498198|EXPERIMENTAL|Non Operative Management|Participants will undergo non operative care for as long as they are improving, and will return to the surgeon when no progression is reached.
62257883|NCT02986503||Chemotherapy for Good responder|Doxorubicin + cisplatin + ifosfamide Pre-operative and post-operative chemotherapy for patients with good responder high grade osteosarcoma
62257884|NCT02986503||Chemotherapy for Poor responder|Doxorubicin+cisplatin+ifosfamide+methotrexate Pre-operative and post-operative chemotherapy for patients with poor responder high grade osteosarcoma
62444644|NCT02123927|EXPERIMENTAL|Step 2: TAK-438 5 mg|TAK-438 5 mg, tablets, orally, once on Day 1.
62444645|NCT02123927|EXPERIMENTAL|Step 3: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once on Day 1.
62444646|NCT02123927|EXPERIMENTAL|Step 4: TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once on Day 1.
62614892|NCT01652066|EXPERIMENTAL|Mixture of probiotics|"at least 10x7 cfu/tablet of a mixture of probiotics~oral consumption, once per day in the morning, fasting, with a glass of water"
62614893|NCT04209439|ACTIVE_COMPARATOR|ultrasound guided erector spinae plane block|30 ml %0.25 ultrasound-guided erector spinae plane block at the level of T8
62614894|NCT04209439|ACTIVE_COMPARATOR|Dexketoprofen-trometamol|intravenous 50 mg dexketoprofen-trometamol
62614895|NCT05725876|EXPERIMENTAL|Ustekinumab naïve patients|
62614896|NCT05725876|EXPERIMENTAL|Ustekinumab treatment 12+ weeks|
62055318|NCT01325025|OTHER|Control|Epileptic population
62055319|NCT06182566|ACTIVE_COMPARATOR|Control|Catheter ablation including PVI and posterior wall ablation
62055320|NCT06182566|EXPERIMENTAL|Intervention|Convergent ablation Surgical epicardial ablation/ LAA clip/ ablation of ligament of Marshall Catheter Ablation including PVI and posterior wall ablation
62444647|NCT02123927|EXPERIMENTAL|Step 5: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once on Day 1.
62444648|NCT02123927|EXPERIMENTAL|Step 6: TAK-438 80 mg|TAK-438 80 mg, tablets, orally, once on Day 1.
62444649|NCT02123927|EXPERIMENTAL|Step 7: TAK-438 120 mg|TAK-438 120 mg, tablets, orally, once on Day 1.
62614897|NCT02253732|EXPERIMENTAL|'3 months exercise intervention program'|all participants will be subjected to 3 months supervised exercise intervention programme
62614898|NCT01994902|EXPERIMENTAL|First Coloplast test product|"The subjects test:~test period 1: Coloplast test product test period 2: SenSura Convex Light"
62614899|NCT01994902|EXPERIMENTAL|First SenSura Convex Light|"The subjects test:~test period 1: SenSura Convex Light test period 2: Coloplast test product"
62614900|NCT05977465|NO_INTERVENTION|Control group|include twenty-five patients who will receive placebo tablets once daily for three months, plus their antidiabetic drugs ( Dpp4 inhibitor and metformin)
62614901|NCT05977465|EXPERIMENTAL|Empagliflozin group|include twenty five patients who will receive Empagloflozin 25 mg once daily for three months, plus their antidiabetic drugs ( Dpp4 inhibitor and metformin)
62614902|NCT02215785|EXPERIMENTAL|kiwifruit cohort|Patients that presented at Primary Care Centres with registered -Roma III criteria based- constipation and who accepted to participate in the study were followed-up for two weeks before intervention and three weeks under 3-daily kiwifruit intake.
62614903|NCT04328415|EXPERIMENTAL|healthy volunteers|
62614904|NCT04328415|EXPERIMENTAL|patients with Chronic Kidney Disease|
62614905|NCT01968512|EXPERIMENTAL|Transcranial Direct Current Stimulation|Subjects will undergo to Transcranial Direct Current Stimulation with anode in left dorsolateral prefrontal cortex and cathode in right supra orbicular region. The stimulus will be 1mA for 20 minutes.
62614906|NCT01968512|SHAM_COMPARATOR|TDCS-Sham|Subjects will undergo to procedure similar to the Transcranial Direct Current Stimulation with anode in dorsolateral prefrontal cortex and left cathode region supraorbicular right. They will receive a stimulus of 1mA only in initial 30 seconds and it will change the electrical charge for 0mA after this time, however the electrodes will be kept for 20 minutes as the active arm.
62614907|NCT02488590||CHRONIC OBSTRUCTIVE PULMONARY DISEASE|"Patients with an obstructive spirometry and characteristics of chronic obstructive pulmonary disease~Clinical intervention:~Long acting B agonist (LABA) + Long acting muscarinic receptor antagonist (LAMA) inhaled therapy"
62614908|NCT02488590||ASTHMA|"patients with asthma and a normal spirometry~Clinical intervention: Inhaled corticosteroids (ICS)"
62614909|NCT02488590||ASTHMA COPD OVERLAP SYNDROME|"patients with an obstructive spirometry and characteristics of both COPD and Asthma~Clinical Intervention: LABA + LAMA + ICS"
62614910|NCT02488590||OBSTRUCTIVE ASTHMA|"patients with an obstructive spirometry and characteristics of asthma~Clinical Intervention: LABA + ICS inhaled therapy"
62614911|NCT02488590||OTHER|"patients with another diagnosis or healthy persons~clinical Intervention: undefined - according to diagnosis"
62614912|NCT02928146|ACTIVE_COMPARATOR|Lichtenstein technique|Lichtenstein inguinal hernia repair
62614913|NCT02928146|ACTIVE_COMPARATOR|TAPP|Transabdominal preperitoneal (TAPP) approach for inguinal hernia repair
62614914|NCT02928146|ACTIVE_COMPARATOR|TEP|Totally extraperitoneal (TEP) approach for inguinal hernia repair
62614915|NCT03900156|NO_INTERVENTION|comparison group|The CG received no extra care.
62839728|NCT05612828|EXPERIMENTAL|Conventional training|Combat Life Savers trained by conventional combat medicine approach.
62055321|NCT04029701|EXPERIMENTAL|Research group|"Subjects who are recruited into this group are asked to take the Ruyizhenbao Pill on the basis of routine internal medicine and rehabilitation treatment.~P.S. Ruyizhenbao Pills are provided by Jinhe Tibetan Pharmaceutical Co., Ltd. Chinese national medicine permission number:Z63020289、Z63020064. Medication method: oral 4 pills once, twice a day, 4 weeks in a row."
62055322|NCT04029701|PLACEBO_COMPARATOR|Control group|"Subjects who are recruited into this group are asked to take the placebo of Ruyizhenbao Pill on the basis of routine internal medicine and rehabilitation treatment.~P.S. Placebo is provided by Jinhe Tibetan Pharmaceutical Co., Ltd.，which is made of malt dextrin as a matrix, similar shape and same color to the Ruyizhenbao Pill. Medication method: oral 4 pills once, twice a day, 4 weeks in a row."
62055323|NCT03261128||Group D-FOG|Filling of a self-questionnaire before each chemotherapy cure
62055324|NCT00687999|OTHER|1|
62055325|NCT03536910|OTHER|General anesthesia|
62055326|NCT03536910|OTHER|Spinal anesthesia|
62444650|NCT02123927|PLACEBO_COMPARATOR|Steps 1-7: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1.
62444651|NCT02123927|EXPERIMENTAL|Step 8A: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 10 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
62444652|NCT02123927|EXPERIMENTAL|Step 8 B: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, under fed conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 10 mg, tablets, orally, under fasted conditions, once on Day 1, Period 2.
62444653|NCT02123927|EXPERIMENTAL|Step 9A: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 40 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
62444654|NCT02123927|EXPERIMENTAL|Step 9B: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, under fed conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 40 mg, tablets, orally, under fasted conditions, once on Day 1, Period 2.
62839729|NCT05612828|EXPERIMENTAL|Simulation manikin training|Training based on principles of simulation medicine.
62839730|NCT02577445||CSA patients without remedē system|For all patients diagnosed with CSA who will not move forward with remedē® system therapy, the intention is to obtain information on their alternate therapy, if any, and safety information, including all cause mortality and all cause hospitalizations during phone calls at 6, 12 and 24 months after enrollment.
62839731|NCT02577445||CSA patients with remedē system|"For all patients diagnosed with CSA and referred for implant / or have already been implanted with remedē system, information from the implant procedure will be collected.~Patients will be asked to complete quality of life questionnaires at baseline and during follow-up visits.~Patients will be evaluated at the time of therapy activation which may be followed by one or more titration visits. Patient follow-ups will be programmed at 6 and 12 months, and yearly, up to 5 years post-implant, until the last patients reach their 2-year follow-up.~Echocardiogram for patients with reduced ejection fraction (≤ 45%) and follow-up respiratory polygraphy are considered standard of care, however, to ensure sufficient data, related to the study objectives, are being collected, baseline and 12-months echocardiogram for a subgroup of patients and respiratory polygraphy at 12-month follow-up for all patients must be done when participating in this study:"
62839732|NCT02336217|EXPERIMENTAL|Functioning App|These subjects have the complete algorithm functioning and communicated via the App.
62839733|NCT02336217|PLACEBO_COMPARATOR|Non-functioning App|These subjects receive routine instructions via the App but not the complete algorithm.
62839734|NCT05824780|EXPERIMENTAL|Weigthlifting|It consists of a 4-week strength training program based on weightlifting. Participants received previously education-training program on how to correctly perform the technique.
62839735|NCT05824780|ACTIVE_COMPARATOR|Plyometric training|It consists of a 4-week strength training program based on plyometric exercises.
62839736|NCT04609670|EXPERIMENTAL|[14C]-ALXN2050|Participants will receive \[14C\]-ALXN2050.
62839737|NCT02207088|EXPERIMENTAL|3-DAA (Direct Acting Antivirals) with or without RBV|3-DAA (ombitasvir/paritaprevir/ritonavir 25 mg/150 mg/100 mg once daily \[QD\] and dasabuvir 250 mg twice daily \[BID\]) with or without ribavirin (RBV; dosed divided twice a day) for 12 or 24 weeks
62839738|NCT02462096|EXPERIMENTAL|Treatment|Subject to undergo the ReLeaf study procedure.
62839739|NCT01022528|EXPERIMENTAL|Dexamethasone|
62839740|NCT01022528|PLACEBO_COMPARATOR|Saline|
62839741|NCT02062840|EXPERIMENTAL|High intensity whole-body infrared heating and Neuroimaging|Subjects will have an fMRI the morning of their WBH session and and fill out study questionnaires. Following the fMRI session, the participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
62839742|NCT02062840|SHAM_COMPARATOR|Low intensity whole-body infrared heating and|Subjects will have an fMRI the morning of their WBH session and and fill out study questionnaires. Following the fMRI session, the participant will undergo the WBH-control intervention where subjects will be induced to levels of heat that causes only a minor increase in body temperature.
62839743|NCT04441086|EXPERIMENTAL|eMotion|The eMotion intervention is based on feasibility testing of the successful in-person program with critical refinement to improve accessibility. eMotion has undergone subsequent content validity testing with intervention development, self-management, cardiovascular health, and health information technology delivery experts. eMotion teaches a carefully selected repertoire of emotion regulation strategies well suited for aging rural adults following a first cardiac event in tandem with usual cardiac rehabilitation. The intervention helps patients recognize their emotions, balance emotional and physical wellbeing, and implement emotion regulation strategies effectively. Intervention provided in addition to usual cardiac rehabilitation.
62839744|NCT04441086|ACTIVE_COMPARATOR|Healthy living active control|Healthy living strategies based on American Heart Association education. Intervention provided in addition to usual cardiac rehabilitation.
62839745|NCT04441086|NO_INTERVENTION|Usual care|Usual cardiac rehabilitation with no additional intervention.
62444655|NCT02123927|PLACEBO_COMPARATOR|Steps 8 (A & B) and 9 (A & B): Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 placebo-matching tablets, orally, once on Day 1, Period 2.
62444656|NCT02890823|EXPERIMENTAL|EIAEDs-1000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 1000 IU once daily
62444657|NCT02890823|EXPERIMENTAL|EIAEDs-3000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 3000 IU once daily
62444658|NCT02890823|EXPERIMENTAL|EIAEDs-6000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 6000 IU once daily
62444659|NCT02890823|ACTIVE_COMPARATOR|non-EIAEDs-1000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 1000 IU once daily
62444660|NCT02890823|ACTIVE_COMPARATOR|non-EIAEDs-3000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 3000 IU once daily
62444661|NCT02890823|ACTIVE_COMPARATOR|non-EIAEDs-6000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 6000 IU once daily
62444662|NCT00232115|EXPERIMENTAL|1|Pimecrolimus
62444663|NCT00232115|PLACEBO_COMPARATOR|2|Vehicle
62444664|NCT02732561|SHAM_COMPARATOR|Sham Device|Sham device
62444665|NCT02732561|ACTIVE_COMPARATOR|Intervention|CES device. cranial electrotherapy stimulation device. Alpha Stim device
62614916|NCT03900156|EXPERIMENTAL|Intervention Group|Intervention Group, goal-setting with follow-up, will have a structured goalsetting interview using the Bangor Goal-Setting Interview ; once goals are identified and clearly expressed in accordance with SMART principles (specific, measureable, achievable, realistic, and timed)
62839746|NCT05242380|EXPERIMENTAL|Kettlebell Exercise|8-week, 3-day/week supervised training will be applied to the participants in this group. After the initial assessment, patients in this group will receive a one-session education on the pathophysiology of PAH, the benefits of physical activity, and energy conservation techniques during activities of daily living. Pharmacological treatment of patients in this group will be continued.
62839747|NCT05242380|NO_INTERVENTION|Control|Any intervention will not be performed. After the initial assessment, patients in this group will receive a one-session education on the pathophysiology of PAH, the benefits of physical activity, and energy conservation techniques during activities of daily living. Pharmacological treatment of patients in this group will be continued.
62839748|NCT06259370|EXPERIMENTAL|intervention group|The intervention measures encompass the implementation of simulated vigorous intermittent lifestyle physical activity for all participants. The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.
62839749|NCT00125164|NO_INTERVENTION|Untreated|Observational Group
62839750|NCT00125164|EXPERIMENTAL|40 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 40 μg/kg BID. Per protocol amendment these subjects were reassigned to receive 120 μg/kg BID. Due to the dose change, the efficacy results for these subjects were analysed in a separate subanalysis. For all outcome measures, mean and standard deviations were not calculated for this arm.
62839751|NCT00125164|EXPERIMENTAL|80 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 80 μg/kg BID
62839752|NCT00125164|EXPERIMENTAL|120 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 120 μg/kg BID
62839753|NCT00940953|EXPERIMENTAL|Captisol-Enabled Budesonide + Azelastine|
62055327|NCT03637452||Exclusive cigarette smokers|Exclusive cigarette smokers must smoke at least 10 cigarettes per day for the past three months and have exhaled carbon monoxide (eCO) levels of at least 6 ppm at the screening visit.
62839754|NCT00940953|ACTIVE_COMPARATOR|Rhinocort Aqua+Astelin|
62839755|NCT00940953|PLACEBO_COMPARATOR|Placebo|
62839756|NCT00470275|EXPERIMENTAL|Cytarbine|Cytarabine IV every 12 hours days 1-5 of 21 day cycle. Response evaluation after 6 cycles of therapy.
62839757|NCT02172690|EXPERIMENTAL|Laparoscopic Staging|For Patients diagnosed as Locally Advanced Gastric Cancer(cT2+NanyM0)by CT and EUS, undergo laparoscopic staging.
62839758|NCT05711212|EXPERIMENTAL|Xanthohumol|single dose of 172 mg of micellar solubilized Xanthohumol
62839759|NCT05711212|PLACEBO_COMPARATOR|Placebo|Polysorbat 80 (E433)
62839760|NCT04631250|EXPERIMENTAL|Right: daylight illumination|The right side of the face was treated using daylight PDT
62839761|NCT04631250|EXPERIMENTAL|Left face: conventional illumination with red light|The left side was treated with conventional PDT.
62839762|NCT02373683|EXPERIMENTAL|Vapotherm-Heliox|Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
62839763|NCT02373683|NO_INTERVENTION|Standard Care|Care dictated by clinical team.
62839764|NCT05169489|EXPERIMENTAL|bbT369 Experimental Arm|Open label, single arm treatment with bbT369
62055328|NCT03637452||Dual (Electronic cigarette and cigarette smoking) users|Dual e-cigarette and cigarette users must have smoked at least 5 cigarettes per day for the last 3 months and use e-cigarettes at least 15 days per month for the last 3 months.
62839765|NCT02442388|EXPERIMENTAL|Hand file|Instrumentation technique
62444666|NCT02167464|ACTIVE_COMPARATOR|Aldosterone Antagonist|Prescribe an aldosterone antagonist such as Spironolactone 12.5-25 mg daily as a starting dose with a maximum recommended dose of 50 mg daily.
62055329|NCT01548430|EXPERIMENTAL|TTP4000 1.0 mg/kg|Administered subcutaneously
62055330|NCT01548430|EXPERIMENTAL|TTP4000 3.0 mg/kg|Administered subcutaneously
62055331|NCT01548430|PLACEBO_COMPARATOR|Placebo|Administered subcutaneously
62444667|NCT02167464|ACTIVE_COMPARATOR|Referral Hypertension specialist|Referral to a hypertension specialist
62444668|NCT02167464|ACTIVE_COMPARATOR|Renin treatment-guided therapeutics|Renin treatment-guided therapeutics. A treatment algorithm is provided to guide treatment based upon renin levels.
62444669|NCT02167464|ACTIVE_COMPARATOR|Renin-guided therapeutics and referral|Renin treatment-guided therapeutics and referral to hypertension specialist. Treatment based upon algorithm for treatment related to renin level in addition to referral to a hypertension specialist.
62444670|NCT05494684|EXPERIMENTAL|Intervention Group|Children and parents receive a multisensoral nature-based intervention during venous blood sampling.
62614917|NCT03853902|EXPERIMENTAL|Mindfulness Program Online|Online 4-week mindfulness program that is intended to reduce stress and improve the quality of life of patients with metastatic prostate cancer
62839766|NCT02442388|EXPERIMENTAL|ProTaper file|Instrumentation technique
62839767|NCT02442388|EXPERIMENTAL|Wave-One file|Instrumentation technique
62839768|NCT02230995|EXPERIMENTAL|Fixed dose combination|Single dose empagliflozin/metformin
62839769|NCT02230995|ACTIVE_COMPARATOR|Single tablets combination|single doses empagliflozin and metformin
62839770|NCT00589199|EXPERIMENTAL|1|Functional Electrical Stimulation for Production of Artificial Cough
62055332|NCT01795365|ACTIVE_COMPARATOR|Epstein + (group I)|"Epstein + (Group I) PSA \<10 ng/ml; Gleason 3+3=6; Number of positive biopsies ≤3/12;~% of tumor biopsy invasion \<50% or ≤3mm; mp MRI negative; c-rTNM T1-T2a N0 M0"
62055333|NCT01795365|EXPERIMENTAL|Epstein - (group II)|"Epstein - (Group II) PSA \<15 ng/ml; Gleason score max 3+4; Number of positive biopsies ≤5/12~% of tumor biopsy invasion \<50% and ≤8mm; mp MRI positive; T1-T2c N0 M0"
62257885|NCT00003281|EXPERIMENTAL|topotecan + paclitaxel + radiotherapy|"Patients receive topotecan IV over 30 minutes on days 1-3 and paclitaxel IV over 3 hours on day 3. Courses repeat every 4 weeks.~Patients who achieve partial response or stable disease continue treatment in the absence of complete response or disease progression. Patients who develop disease progression in the CNS only should receive whole brain radiotherapy and then continue treatment. Patients who achieve complete remission receive a maximum of 6 courses of treatment. Patients may then undergo prophylactic cranial irradiation and/or thoracic radiotherapy at the discretion at the attending physician.~Patients are followed every 3 months for 2 years and then at 3 years after study."
62257886|NCT03707548|EXPERIMENTAL|Group BPT|"Six group BPT sessions (using a waiting-period comparator and pre-/post design)~A nested randomized controlled trial (RCT) is included to evaluate the short-term efficacy of smartphone-triggered bodily interventions compared with the smartphone triggered control intervention of audio-typed fairy tales."
62839771|NCT00690781|EXPERIMENTAL|Casein Pulse|"casein is the main protein consumed, it is given during 6 weeks with a pulse protein feeding pattern : 8% for breakfast, 80% for lunch, 4% around 1600h, and 8% for dinner."
62839772|NCT00690781|EXPERIMENTAL|Casein Spread|"casein is the main protein consumed, it is given during 6 weeks with a spread protein feeding pattern : 25% for breakfast, 25% for lunch, 25% around 1600h, and 25% for dinner."
62839773|NCT00690781|EXPERIMENTAL|MSP Pulse|"Milk soluble proteins (MSP) are the main protein consumed, it is given during 6 weeks with a pulse protein feeding pattern : 8% for breakfast, 80% for lunch, 4% around 1600h, and 8% for dinner."
62839774|NCT00690781|EXPERIMENTAL|MSP Spread|"Milk soluble proteins (MSP) are the main protein consumed, it is given during 6 weeks with a spread protein feeding pattern : 25% for breakfast, 25% for lunch, 25% around 1600h, and 25% for dinner."
62839775|NCT01121770|EXPERIMENTAL|Arixtra|
62839776|NCT03009396|EXPERIMENTAL|RHB-104 - patients on ACTIVE therapy in RHB-104-01 study|Subjects who were on the active therapy arm in the RHB-104-01 clinical study will continue to receive RHB-104 at 5 capsules twice a day in addition to the standard of care they received in the RHB-104-01 clinical study
62257887|NCT05851742|ACTIVE_COMPARATOR|Mfofascial release with electrical stimulation|TENS 50-280 HZ frequency and a pulse duration of 50 us for 10 minutes along with 10 minutes myofascial release.
62839777|NCT03009396|EXPERIMENTAL|RHB-104 - patients on PLACEBO therapy in RHB-104-01 study|Subjects who were on the active therapy arm in the RHB-104-01 clinical study will receive RHB-104 at 5 capsules twice a day in addition to the standard of care they received in the RHB-104-01 clinical study. The RHB-104 will be ramped up beginning at 1 capsule twice per day in week 1 increasing to 2 capsules twice per day in week 2, 3 capsules twice per day in week 3, 4 capsules per day in week 4 and achieving 5 capsules per day for the remainder of the study.
62839778|NCT04558840|ACTIVE_COMPARATOR|Enhanced Recovery After Surgery (ERAS) Arm|"ERAS Arm will undergo multimodal regiment:~Before Surgery- gabepentin 300mg and celecoxib 400mg once the day before surgery and again 3 hours prior to surgery.~During surgery- subjects will receive ketorolac 30mg IV ketorolac once (15mg for patients age 64 years and above).~Post-operatively- Gabapentin 100mg three times daily for POD0-7, ketorolac 10mg four times daily for POD1-5 days, and ondansetron 4mg as needed for nausea; patients will also have a prescription for hydrocodone-acetaminophen 5/325mg tabs that they may fill if needed for emergency/breakthrough pain."
62839779|NCT04558840|ACTIVE_COMPARATOR|Current Practice Arm|The current practice arm will include: post-operatively, hydrocodone-acetaminophen 5/325mg tabs and ibuprofen 800mg, as needed for pain. Additionally, acetaminophen may be used in conjunction with the above regiment. Ibuprofen and acetaminophen can be taken as needed or alternating every 6 hours, scheduled.
62055334|NCT00813852|EXPERIMENTAL|2|exercise training, CPAP, and inspiratory muscle strengthening program
62055335|NCT06619691|EXPERIMENTAL|FIne Motor Program participants|All enrolled participants will completed a fine motor intervention program over 8 weeks
62055336|NCT04433884|EXPERIMENTAL|Conventional MAC Laryngoscope|Patients in this group will undergo intubation using conventional macintosh laryngoscope
62055337|NCT04433884|EXPERIMENTAL|C-MAC Video laryngoscope|Patients in this group will undergo intubation using video C-Mac laryngoscope
62055338|NCT05672212|EXPERIMENTAL|ANI (Analgesia/Nociception Index) monitoring|
62055339|NCT05672212|ACTIVE_COMPARATOR|Standard monitoring|
62257888|NCT05851742|EXPERIMENTAL|Myofascial release without electrical stimulation|Release of trigger points
62257889|NCT05004636|NO_INTERVENTION|No_Mg|Ctrl Group. Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Patients in this Arm (selected randomly) will not receive Mg (the intervention) in the block; instead they will receive 0.3mL of sterile saline.
62257890|NCT05004636|EXPERIMENTAL|Mg|Treatment Group. Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Patients in this Arm (selected randomly) will receive 150 mg Mg (0.3 mL-the intervention) in the block.
62444671|NCT05494684|NO_INTERVENTION|Control Group|The control group receives the usual standard care during venous blood sampling
62839780|NCT02827929|EXPERIMENTAL|educated group|Subjects who is diagnosed as COPD or asthma by their physicians were recruited from 43 primary clinic and had been visiting each primary clinic over one year or more will be provided education of 3 times for one months about disease, inhaler use technics and action plans about exacerbation
62055340|NCT02617875|ACTIVE_COMPARATOR|Conventional EMS physician|The dispatching personnel will evaluate the emergency call severity and after exclusion of the life-threatening cases listed in a written procedure instruction, they will dispatch a conventional EMS physician, if this is the result of the randomization software.
62055341|NCT02617875|OTHER|Tele-EMS physician|The dispatching personnel will evaluate the emergency call severity and after exclusion of the life-threatening cases listed in a written procedure instruction, they will dispatch a tele-EMS physician, if this is the result of the randomization software.
62055342|NCT00508404|EXPERIMENTAL|Panitumumab plus FOLFIRI|Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until diagnosed with radiographic disease progression.
62055343|NCT05520463|EXPERIMENTAL|Ultrasound guided sacral lateral branch radiofrequency ablation|Patients in this group will receive sacral lateral branch radiofrequency ablation under ultrasound guidance.
62444672|NCT01829477|EXPERIMENTAL|TAK-875 50 mg|TAK-875 50 mg tablet, orally, once daily and glimepiride 6 mg (or Maximum Tolerated Dose), tablets, orally, once daily for up to 24 weeks.
62444673|NCT01829477|PLACEBO_COMPARATOR|Placebo|TAK-875 placebo-matching tablet, orally, once daily and glimepiride 6 mg (or Maximum Tolerated Dose), tablets, orally, once daily for up to 24 weeks.
62444674|NCT04253548|EXPERIMENTAL|iPeer2Peer Program|Participates in the iPeer2Peer Program
62444675|NCT02857881|EXPERIMENTAL|Evolutive keratoconus|
62055344|NCT05520463|ACTIVE_COMPARATOR|Fluoroscopy guided sacral lateral branch radiofrequency ablation|Patients in this group will receive sacral lateral branch radiofrequency ablation under fluoroscopy guidance.
62444676|NCT05100758|EXPERIMENTAL|Active Hexose Correlated Compound|The participants will be given Active Hexose Correlated Compound as a capsule 3 gram/ daily for 6 months
62444677|NCT05100758|NO_INTERVENTION|Control Group|Participant will be given only the tuberculosis and antiretroviral treatment
62444678|NCT02688400|EXPERIMENTAL|Diacerein|One placebo capsule once daily in the morning (breakfast) and one diacerein 50 mg capsule once daily in the evening (dinner) for the first month, then diacerein capsules twice daily with meals in the morning (breakfast) and the evening (dinner).
62614918|NCT03853902|ACTIVE_COMPARATOR|Mindfulness Program Face-to-Face|In-person 4-week mindfulness program that is intended to reduce stress and improve the quality of life of patients with metastatic prostate cancer
62839781|NCT05042414|EXPERIMENTAL|Breastmilk|Randomized intervention order.
62055345|NCT00437645|EXPERIMENTAL|Valsartan/amlodipine 160/5 mg|Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.
62444679|NCT02688400|ACTIVE_COMPARATOR|Celecoxib|One celecoxib 200 mg capsule once daily in the morning (breakfast) and one placebo capsule once daily in the evening (dinner).
62444680|NCT06302231|EXPERIMENTAL|Time-Restricted Eating and Aerobic Exercise Performed in Fasted State|"Participants will be prescribed a diet plan to promote weight loss, but no food will be provided to them.~Diets will be formulated to contain 50% energy as carbohydrate, 20% as protein, and 30 % as fat.~Participants will be instructed to divide their daily energy intake between three meals each day (lunch, afternoon snack, and dinner).~Participants will be instructed to eat from 12.00 until 20.00 (8-hour window). Aerobic exercise sessions will be carried out during the morning shift with participants in a fasted state."
62614919|NCT00630591|EXPERIMENTAL|Standardized Materials Group|
62614920|NCT00630591|EXPERIMENTAL|Independent Tailored Intervention|
62614921|NCT00630591|EXPERIMENTAL|Partner-Assisted Tailored Intervention|
62614922|NCT02061644|EXPERIMENTAL|Spinal|Spinal anesthesia for surgical procedure will be applied to the patients. Intraocular pressures will be measured before and after the procedure.
62839782|NCT03517397|EXPERIMENTAL|Mobile Contingency Management|
62839783|NCT02562677|EXPERIMENTAL|ACTIVE tNS|TNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed on the forehead just above the supraorbital foramen bilaterally. The study protocol will follow the rational of our previous trials with TNS.
62614923|NCT03476655||Participants with Chronic Lymphocytic Leukemia (CLL)|This study will collect retrospective data on effectiveness and outcome parameters for participants of CLL being managed with ibrutinib in the clinical practice. The primary data source for this observational study will be the medical records of each enrolled participant.
62614924|NCT03476655||Participants with Mantle Cell Lymphoma (MCL)|This study will collect retrospective data on effectiveness and outcome parameters for participants of MCL being managed with ibrutinib in the clinical practice. The primary data source for this observational study will be the medical records of each enrolled participant.
62839784|NCT06138496|EXPERIMENTAL|Cadonilimab combined with Lenvatinib as neoadjuvant therapy|"Lenvatinib Treatment Lenvatinib (8mg \[body weight \< 60 kg\] or 12 mg \[body weight ≥ 60 kg\]) orally once daily, with or without food.~Intravenous Infusion of Cadonilimab(Injection) Infuse Cadonilimab at a dose of 6mg/kg intravenously every two weeks, constituting one treatment cycle, a total of 6 cycles.~Radical nephrectomy; Utilization of other targeted therapies; Combination targeted therapy with immunotherapy. If not, continue medication for six cycles before surgery."
62839785|NCT06313918|ACTIVE_COMPARATOR|Standard HIT|Standard 4 x 4 min HIT at treadmill. First 7 min warm-up, then 4 sessions with 4 min walking/running at 80-95% of maximal heart rate, with 3 min of active rest in between. Ending with 5 min of cooling down. Two sessions per week for 26 weeks.
62839786|NCT06313918|EXPERIMENTAL|Short HIT|Short 1 x 4 min HIT at treadmill. Starting with 7 min warm-up walking/running, then 1 session with 4 min walking/running at 80-95% of maximal heart rate, ending with 5 min of cooling down. Two sessions per week for 26 weeks.
62839787|NCT04413461|EXPERIMENTAL|TENS|
62839788|NCT04413461|PLACEBO_COMPARATOR|TENS Sham|
62055346|NCT00437645|ACTIVE_COMPARATOR|Amlodipine 10 mg|Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.
62055347|NCT04366063|EXPERIMENTAL|Two MSC infusion|Intervention Group1(n=20). Patients will receive two doses of MSCs 100×10e6 (±10%) intravenously plus Conventional treatment.
62257891|NCT06219265|EXPERIMENTAL|Experimental group 1: people with SMD receiving dance therapy|Intervention group of people with SMD (n=26) who receive a 20-session dance therapy program for 10 weeks with 2 sessions per week in which they work for 1 hour on memory, attention and executive functions through dance and movement, ending with 10 minutes of Mindfulness.
62257892|NCT06219265|NO_INTERVENTION|Control group: people with SMD who do not receive any intervention|This group of 21 persons with SMD will not receive any intervention.
62257893|NCT03672409|OTHER|Intervention in knowledge|All participants will be offered learning sessions to improve knowledge in diabetes
62614925|NCT00427999|EXPERIMENTAL|STI571+ pioglitazone+ etoricoxib + dexamethasone + treosulfane|STI571 (imatinib) 400mg po daily + pioglitazone 60mg po daily + etoricoxib 60mg po daily + dexamethasone 1mg po daily + treosulfane 500mg po daily for 24 weeks
62614926|NCT03466879||Active device users|Users will use an active SYNUS Pain Relief device
62257894|NCT04405115|NO_INTERVENTION|No intervention arm|routine care only; will not be scheduled for comprehensive geriatric assessment
62614927|NCT03466879||Sham device users|Users will use a sham SYNUS Pain Relief device that is not providing treatment
62614928|NCT02562092|NO_INTERVENTION|Focus Group|Participants will complete a questionnaire and will be involved in a group discussion regarding good sites within the community to perform HIV testing.
62614929|NCT02562092|OTHER|Venue Testing Group- Negative Test|Participants will perform a rapid HIV test and will be asked to answer questions about their sexual life and living situation. No followup is needed for a negative HIV test.
62614930|NCT02562092|OTHER|Venue Testing Group- Positive Test|Participants will perform a rapid HIV test and will be asked to answer questions about their sexual life and living situation. Participants with a positive HIV test will receive care from a psychologist and case manager for one year.
62839789|NCT02668393|OTHER|Level 0|Nintedanib low dose with docetaxel
62839790|NCT02668393|OTHER|Level 1|Nintedanib medium dose with docetaxel
62839791|NCT02668393|OTHER|Level 2|Nintedanib high dose with docetaxel
62839792|NCT02668393|OTHER|Level 3|Nintedanib continuous high dose with docetaxel
62839793|NCT01570946|EXPERIMENTAL|Lifestyle modification|The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
62839794|NCT01570946|NO_INTERVENTION|Standard Care|Baseline 30-minute interview delivering personalised diet and exercise advice supplemented with educational material on diabetes.
62614931|NCT01794832||Elderly with severe aortic stenosis|Patients with severe symptomatic aortic stenosis referred for consideration of surgical aortic valve replacement
62614932|NCT00182000|ACTIVE_COMPARATOR|Seromycin|
62257895|NCT04405115|ACTIVE_COMPARATOR|Active comparator arm|those that will be scheduled for comprehensive geriatric assessment with a geriatric nurse practitioner or physician
62257896|NCT02781909|ACTIVE_COMPARATOR|Control: Standard of Care TB treatment|Individuals with confirmed pulmonary XDR-TB and receiving Standard of Care TB treatment according to national and WHO guidelines; n=12
62257897|NCT02781909|EXPERIMENTAL|Ibuprofen-treated|Individuals with confirmed pulmonary XDR-TB and receiving Standard of Care TB treatment according to national and WHO guidelines plus ibuprofen (400mg/day/2 months); n=12
62257898|NCT03853239|ACTIVE_COMPARATOR|face mask crossover nasal ventilation|
62257899|NCT03853239|ACTIVE_COMPARATOR|nasal ventilation crossover face mask|
62257900|NCT00986544|SHAM_COMPARATOR|Absence of drain|
62257901|NCT00986544|ACTIVE_COMPARATOR|Drain|drain positioned in the subhepatic space after laparoscopic cholecystectomy
62614933|NCT00182000|PLACEBO_COMPARATOR|Placebo|
62614934|NCT01711619|EXPERIMENTAL|SQS plus OMM|subcutaneous nerve stimulation plus optimized medical management
62257902|NCT03540784|NO_INTERVENTION|Control group|usual care treatment
62614935|NCT01711619|ACTIVE_COMPARATOR|OMM|optimized medical management
62614936|NCT05986864|EXPERIMENTAL|Phase I: Low dose|SKG0106 One-Time Intraocular Injection Dose Level 1
62614937|NCT05986864|EXPERIMENTAL|Phase I: Medium dose|SKG0106 One-Time Intraocular Injection Dose Level 2
62257903|NCT03540784|EXPERIMENTAL|Nutrition|high-protein nutrition therapy
62614938|NCT05986864|EXPERIMENTAL|Phase I: High dose|SKG0106 One-Time Intraocular Injection Dose Level 3
62614939|NCT03951753|EXPERIMENTAL|Tirzepatide 15 mg|Participants received 15 milligram (mg) tirzepatide administered subcutaneously (SC) once weekly for 28 weeks.
62614940|NCT03951753|ACTIVE_COMPARATOR|Semaglutide 1 mg|Participants received 1 mg Semaglutide administered SC once weekly for 28 weeks.
62257904|NCT03540784|EXPERIMENTAL|EMS+Nutrition|WB-EMS Training (2x/week á 20 min) + high-protein nutrition therapy
62257905|NCT00481286|EXPERIMENTAL|Group Clinic|Patients in Group Clinic arm will meet every 3rd week for 12 weeks, for a total of 4 visits. At each visit, BP will be measured, home BP and glucose measurements collected. Each visit will include group-based education and feedback sessions, with an individualized process of selecting and modifying process of care goals for systolic BP, H1C, and LDL cholesterol. Short-term health behavior change goals will also be discussed.
62257906|NCT00481286|PLACEBO_COMPARATOR|Uusual Care|Older diabetes patients will attend regular clinician visits and one targeted primary care physician visit during the 12 weeks post-enrollment. They will be enrolled in a diabetes education class. Blood pressure, H1C and lipids will be measured at enrollment, 6 weeks , and 12 weeks.
62257907|NCT01737918|EXPERIMENTAL|trans obturatorial tape (TOT)|placement of a sub-urethral tape
62257908|NCT01737918|ACTIVE_COMPARATOR|solifenacin|10 mg per day
62257909|NCT01390766||Subjects prescribed azathioprine tablet|Subjects prescribed azathioprine tablet during study period after the liver transplantation
62257910|NCT06032780|EXPERIMENTAL|Eccentric Resistive Training + Aerobic training Group|
62257911|NCT06032780|ACTIVE_COMPARATOR|Resistance Training + Aerobic training Group|
62614941|NCT03951753|PLACEBO_COMPARATOR|Placebo|Participants received Placebo administered SC once weekly for 28 weeks.
62614942|NCT00467558|ACTIVE_COMPARATOR|Naltrexone|Naltrexone 50mg-150mg by mouth per day.
62614943|NCT00467558|PLACEBO_COMPARATOR|Placebo|Placebo pills (1-3 pills daily) depending upon dose prescribed by study physician
62614944|NCT02193711|EXPERIMENTAL|Topical Arthritis Cream|1-1.5 ml applied to the skin over the knee in the morning and at bedtime over the entire study period, for a total of 2-3 ml/day.
62614945|NCT02193711|PLACEBO_COMPARATOR|Placebo|1-1.5 ml applied to the skin over the knee in the morning and at bedtime over the entire study period, for a total of 2-3 ml/day.
62614946|NCT02206737|EXPERIMENTAL|E-Cigarette|3 doses of e-cigarette to be given No nicotine Low dose nicotine High dose nicotine
62614947|NCT06524895|ACTIVE_COMPARATOR|Group A- Medical Reiki|The energy medicine will be delivered to the study participant immediately pre-op. The Reiki practitioner will hold the participant's hand for 10 minutes. This will be followed by touching the participant's upper arm along with shoulder for 20 minutes. Clinical staff will ask standard questions to assess mood while receiving the energy medicine. Because this is a medical study, the practitioner will mainly be silent for the 30 minute session.
62614948|NCT06524895|SHAM_COMPARATOR|Group B- Sham Reiki|"Patients will be recruited to receive Sham Reiki before surgery. The non-Reiki healer will hold the participant's hand for 10 minutes. This will be followed by touching the participant's upper arm along with shoulder for 20 minutes. Clinical staff will ask standard questions to assess mood while receiving the energy medicine. Because this is a medical study, the non-Reiki healer will mainly be silent for the 30 minute session."
62614949|NCT05559372|EXPERIMENTAL|Nutrabolt C4 Energy Drink Carbonated|16 oz
62614950|NCT05559372|ACTIVE_COMPARATOR|Monster Energy Original|16 oz
62614951|NCT05559372|PLACEBO_COMPARATOR|Placebo|16 oz carbonated placebo
62614952|NCT02282163|EXPERIMENTAL|Lumason|All patients were administered, Lumason (sulphur hexafluoride lipid-type A microspheres) an ultrasound contrast agent as a single 0.03 mL/kg bolus injection during echocardiography.
62614953|NCT00588939||I|participants with symptoms of acid reflux disease (heartburn)
62614954|NCT04986943||ABTHERA Advance without Wittmann patch|Patients with necrotizing pancreatitis that require an open abdomen after their initial operation will be treated with ABTHERA ADVANCE only, without the use of Wittmann patch.
62839795|NCT03669497|EXPERIMENTAL|Hypo fractionated radiotherapy|Hypo fractionated whole breast radiotherapy with simultaneous integrated boost to the tumour
62839796|NCT06184893||General cohort|
62839797|NCT06184893||RAIDbio|Sub-cohort studying biomarkers: volatile organic compounds, induced sputum and blood biomarkers
62839798|NCT06184893||RAIDomix|Sub-cohort studying radiomic patterns (based on high resolution computed tomography of the chest)
62055348|NCT04366063|EXPERIMENTAL|Two MSC infusion Plus two EVs infusion|Intervention Group 2 (n=20). Patients will receive two doses of MSCs 100×10e6 (±10%), intravenously plus two doses of EVs plus Conventional treatment
62055349|NCT04366063|NO_INTERVENTION|Control|Control (n=20). Patients will conventional therapy for virus treatment and supportive care for ARDS will be used as control.
62055350|NCT05576532|EXPERIMENTAL|bcl-2 inhibitor plus IM2 regimen|bcl-2 inhibitor plus IM2 regimen
62055351|NCT03800732|EXPERIMENTAL|Night workers.|Night workers of the military police of Minas Gerais, Uberlândia, who will participate in the three interventions of the study.
62055352|NCT01286441|PLACEBO_COMPARATOR|Placebo|Placebo for East Indian Sandalwood Oil ointment administered topically twice daily
62055353|NCT01286441|ACTIVE_COMPARATOR|10% EISO|East Indian Sandalwood Oil ointment, 10% (w/w), applied topically twice daily
62055354|NCT01286441|ACTIVE_COMPARATOR|20% EISO|East Indian Sandalwood Oil ointment, 20% (w/w), applied topically twice daily
62055355|NCT01286441|ACTIVE_COMPARATOR|30% EISO|East Indian Sandalwood Oil ointment, 30% (w/w), applied topically twice daily
62055356|NCT02500459|EXPERIMENTAL|intraparenchymally-administered topotecan|Patients will have topotecan administered directly into the tumor bed using convection-enhanced delivery (CED)
62055357|NCT01853514||Low income|Income level equal or less than 250% above the poverty level
62055358|NCT03034616|EXPERIMENTAL|ex vivo activation|"'OLIVA device' in patients that undergo oophorectomy on the cortex of the removed ovary we will perform 5 parallel slashes 3 cm long.~this will be followed by investigation by the pathologist as to the depth of cuts."
62055359|NCT03034616|ACTIVE_COMPARATOR|in vivo activation|'OLIVA device' in patients undergoing oophorectomy before the resection from is pedicle on cortex of the ovary we will perform 5 parallel slashes 3 cm long. following oophorectomy investigation by the pathologist as to the depth of cuts and proximity to blood vessels.
62055360|NCT03034616|ACTIVE_COMPARATOR|POI OLIVA|'OLIVA device' in patients with premature ovarian failure and following safety data from arm 2 activation by ovarian slashing will be performed laparoscopically by closed cutting device (OLIVA). follow-up by sonography and hormonal markers of ovarian activity
62055361|NCT03516643|EXPERIMENTAL|Shockwave|Extracorporeal Shockwave treatment on Ischemic Myocardium
62055362|NCT04377230|EXPERIMENTAL|Biliopancreatic limb 60cm|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 60cm.
62055363|NCT04377230|ACTIVE_COMPARATOR|Biliopancreatic limb 100cm|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 100cm.
62055364|NCT01057784||Bariatric Surgery Patients|Patients undergoing bariatric surgery.
62055365|NCT01057784||Reproductive-Age Women - Bariatric Surgery Patients|This subgroup of patients will include 10 reproductive-age women.
62444681|NCT06302231|ACTIVE_COMPARATOR|Time-Restricted Eating and Aerobic Exercise Performed in Fed State|"Participants will be prescribed a diet plan to promote weight loss, but no food will be provided to them.~Diets will be formulated to contain 50% energy as carbohydrate, 20% as protein, and 30 % as fat.~Participants will be instructed to divide their daily energy intake between three meals each day (lunch, afternoon snack, and dinner).~Participants will be instructed to eat from 12.00 until 20.00 (8-hour window). Aerobic exercise sessions will be carried out during the afternoon shift with participants in a fed state."
62614955|NCT02669667|EXPERIMENTAL|Cohort 1|single dose of MEDI9314 or placebo
62614956|NCT02669667|EXPERIMENTAL|Cohort 2|single dose of MEDI9314 or placebo
62614957|NCT02669667|EXPERIMENTAL|Cohort 3|single dose of MEDI9314 or placebo
62614958|NCT02669667|EXPERIMENTAL|Cohort 4|single dose of MEDI9314 or placebo
62614959|NCT02669667|EXPERIMENTAL|Japanese Cohort|single dose of MEDI9314 or placebo
62614960|NCT02669667|EXPERIMENTAL|Cohort 5|single dose of MEDI9314 or placebo
62614961|NCT00970515|EXPERIMENTAL|Laparoscopic approach|group A: Laparoscopic approach
62614962|NCT00970515|ACTIVE_COMPARATOR|Open approach|group B: Open anterior approach
62257912|NCT06032780|ACTIVE_COMPARATOR|Aerobic training Group|
62839799|NCT03437616|EXPERIMENTAL|Tulppa rehabilitation|8-10 weekly 3-hour group sessions and two follow-up sessions (6 and 12 months).
62839800|NCT03437616|NO_INTERVENTION|Control group|Control group does not receive Tulppa rehabilitation during the study.
62839801|NCT05367596|EXPERIMENTAL|Continuous Energy Restriction (CER)|Continuous energy restriction (CER; 1,200-1,500 kcal/day). Participants in both groups will have a daily late-evening snack and participate in remotely supervised exercises.
62839802|NCT05367596|EXPERIMENTAL|Alternate-Day Moderate Fasting (ADMF).|Alternate-Day Moderate Fasting (ADMF). Participants in both groups will have a daily late-evening snack and participate in remotely supervised exercises.
62839803|NCT04189887||PD+AEX|The group of people with PD which will perform aerobic exercise after motor skill acquisition
62839804|NCT04189887||PD-AEX|The group of people with PD which will not perform aerobic exercise after motor skill acquisition
62839805|NCT04189887||CON+AEX|The group of control participants which will perform aerobic exercise after motor skill acquisition
62839806|NCT04189887||CON-AEX|The group of control participants which will not perform aerobic exercise after motor skill acquisition
62839807|NCT03085602|EXPERIMENTAL|CBT Treatment|Participants receive Cognitive behavioral therapy (CBT). Participants will receive 4 one hour CBT treatments.
62257913|NCT04808570|EXPERIMENTAL|TQ-B3525 tablets|TQ-B3525 tablet administered orally.
62055366|NCT03322098|ACTIVE_COMPARATOR|Atropine group|Patients that receive atropine 0.01 mg/kg (max 0.5mg) before spinal anesthesia
62055367|NCT03322098|ACTIVE_COMPARATOR|Glycopyrrolate group|Patients that receive glycopyrrolate 0.004mg/kg (max 0.2 mg) before spinal anesthesia
62444682|NCT06302231|OTHER|Time-Restricted Eating|"Participants will be prescribed a diet plan to promote weight loss, but no food will be provided to them.~Diets will be formulated to contain 50% energy as carbohydrate, 20% as protein, and 30 % as fat.~Participants will be instructed to divide their daily energy intake between three meals each day (lunch, afternoon snack, and dinner).~Participants will be instructed to eat from 12.00 until 20.00 (8-hour window). Participants in this arm will not perform aerobic exercise training."
62055368|NCT05321355||Patient with narcolepsy treated with vagus nerve stimulation|Patient with narcolepsy treated with vagus nerve stimulation
62055369|NCT05321355||Patient without narcolepsy treated with vagus nerve stimulation|Patient without narcolepsy treated with vagus nerve stimulation
62055370|NCT04164654|EXPERIMENTAL|Experimental-Immediate Access to the Nod app|The experimental group will have immediate access to all content in the Nod app and will be free to engage with it as much or as little as they like for four weeks. They will retain access to the Nod app for an additional four weeks.
62055371|NCT04164654|OTHER|Waitlist Control-Delayed Access to the Nod app|The waitlist control group will have full access to the Nod app approximately four weeks after the experimental group gains access.
62055372|NCT00922025||1|Male patients with non-small cell lung cancer (NSCLC) of adeno histology
62055373|NCT02312856|EXPERIMENTAL|PulseRider aneurysm|Endovascular treatment of intracranial aneurysms
62055374|NCT06162143||Gelsectan®|Patients in the Gelsectan® cohort will receive one capsule of Gelsectan® twice a day (after lunch and dinner) for 28 days.
62055375|NCT02799784|EXPERIMENTAL|Sequence 1: UMEC/VI 62.5/ 25 mcg|Subjects will receive UMEC/VI 62.5/25 mcg (as one inhalation) administered QD via the ELLIPTA Inhaler for 8 weeks followed by a washout period of 3 weeks
62055376|NCT02799784|EXPERIMENTAL|Sequence 2: TIO/OLO 5/5 mcg|Subjects will receive TIO/OLO 5/5 mcg (as 2 inhalations of 2.5/2.5 mcg per inhalation) administered QD via the RESPIMAT inhaler for 8 weeks followed by a washout period of 3 weeks
62055377|NCT04437420||T-ALL|
62444683|NCT03765268|ACTIVE_COMPARATOR|Neurectomy|In this group we did mesh hernioplasty of inguinal hernia with neurectomy of iliohypogastric and ilioinguinal nerve
62055378|NCT04437420||B-ALL|
62444684|NCT03765268|ACTIVE_COMPARATOR|Nerve Sparing|In this group we did mesh hernioplasty of inguinal hernia with preservation of iliohypogastric and ilioinguinal nerve
62444685|NCT03661437|EXPERIMENTAL|Arm I (BWL)|Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo BWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
62055379|NCT05181514|PLACEBO_COMPARATOR|Normal Saline|Participants will undergo a dual labeled, 3-h oral glucose tolerance test (OGTT) during i.v. infusion of normal saline
62055380|NCT05181514|EXPERIMENTAL|20% Intralipid|Participants will undergo a dual labeled, 3-h oral glucose tolerance test (OGTT) during i.v. infusion of Intralipid 20%.
62055381|NCT04108130|NO_INTERVENTION|Usual Care|Participants in this arm will receive usual anesthetic and postoperative care as provided in each site.
62055382|NCT04108130|EXPERIMENTAL|Intervention|This arm will receive the bundle of interventions.
62055383|NCT04781361||Isotonic fluid|"Group, received isotonic maintenance fluid containing NaCl between 131 to 154 mmol/L such as:~* Dextrose 5% in 0.9% NaCl,~* Intravenous fluid containing NaCl between 131 to 154 mmol/L"
62055384|NCT04781361||Hypotonic fluid|"Group, received hypotonic maintenance fluid containing NaCl \< 130 mmol/L such as:~* Dextrose 5 % in 0.02 % NaCl,~* Dextrose 5% in 0.033 % NaCl~* Dextrose 5% in 0.045 % NaCl~* Intravenous fluid containing NaCl \< 130 mmol/L"
62055385|NCT00321048|EXPERIMENTAL|ABC (Active Breathing coordinator)|Patients are randomized to ABC arm will receive radiation with ABC. Cardiac perfusion will be assessed at baseline and 6 months after treatment and the difference will be compared to that seen in the No ABC arm.
62055386|NCT00321048|NO_INTERVENTION|No Active Breathing Coordinator|Patients randomized to the No ABC arm will receive radiation without ABC.Cardiac perfusion will be assessed at baseline and 6 months after treatment and the difference will be compared to that seen in the ABC arm.
62055387|NCT06626373|EXPERIMENTAL|Experimental: Elderberry Juice|Participants will consume elderberry juice twice/day for 1-week as well as our provided diet for 4 days.
62257914|NCT00012779|OTHER|Arm 1|
62257915|NCT03215771|EXPERIMENTAL|MyoPro + Motor Learning-Based Therapy|Subjects received 9 weeks of motor learning-based therapy in combination with use of MyoPro myoelectric elbow wrist hand orthosis, followed by 9 weeks of home use with a customized exercise program.
62257916|NCT00677820|EXPERIMENTAL|Trivalent influenza virus vaccine|Frozen trivalent vaccine containing new strains
62257917|NCT00677820|PLACEBO_COMPARATOR|Placebo|treatment with placebo
62257918|NCT01071538|EXPERIMENTAL|Buprenorphine|Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
62444686|NCT03661437|EXPERIMENTAL|Arm II (DWL)|Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo DWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
62839808|NCT03085602|ACTIVE_COMPARATOR|Control Group|Participants receive health education treatment. Participants will attend treatment sessions that match the CBT Treatment arm with respect to time and contact.
62839809|NCT03085602|NO_INTERVENTION|Control Group - Scans|Participants in this new arm to the study will receive no intervention and will receive three scans.
62839810|NCT05440552|PLACEBO_COMPARATOR|Risk score1|
62839811|NCT05440552|ACTIVE_COMPARATOR|Risk score2|
62839812|NCT05169008|EXPERIMENTAL|Vaccine Group|1000 participants，500 children aged 6-12 years and 500 adolescents aged 13-17 years, Ad5-nCoV or Ad5-nCoV-IH, ≥90 days after two doses of CoronaVac. Intramuscular injection or nebulized inhalation.
62839813|NCT04004195|EXPERIMENTAL|Healthy participants|
62839814|NCT04004195|EXPERIMENTAL|Participants with mild renal impairment|
62839815|NCT04004195|EXPERIMENTAL|Participants with moderate renal impairment|
62839816|NCT04004195|EXPERIMENTAL|Participants with severe renal impairment|
62839817|NCT00775190|ACTIVE_COMPARATOR|Ortho tricyclen™|Participant Randomized to Ortho tricyclen 1 tablet by mouth Daily
62839818|NCT00775190|ACTIVE_COMPARATOR|Trinessa™|Participant Randomized to Trinessa 1 tablet by mouth Daily
62839819|NCT02987790|EXPERIMENTAL|C-reactive Protein|In this group, the attending physicians will be instructed to follow the decision flowchart based on the CRP values. Antibiotic suspension will be encouraged when levels of this marker are \<35mg/L (if peak PCR below 100mg/L); or reduce 50% of the highest value (if PCR peak \> 100mg/L), with a limit of seven days, if there is clinical improvement. If a given patient has persistently elevated CRP levels (\> 100 mg/l or fall less than 50% relative to the time of inclusion), the investigators will encourage attending physicians to maintain antibiotics and to perform a careful search for persistent infection. In case of doubts, if the patient is well clinically and without signs of active infection, the duration of antibiotic therapy should be the same as suggested for the Best Practice group.
62839820|NCT02987790|NO_INTERVENTION|Best Practice|"Patients will be initially treated according to the current protocols used in the intensive care units. Decisions about interruption or continuation of treatment will be made according to pre-established time and also according to the clinical evolution of the patients. CRP levels will not be measured and will not be considered in the decision to discontinue antimicrobials. Any decision ultimately rests with the clinical assistants. Suggestions on the suspension of antibiotics will be provided by the researchers as follows:~* 7 full days for most infections~* 10 full days for pneumonia caused by Gram negative non-fermenting bacteria or Gram negative bacteria carbapenemase producing.~* 14 days of treatment for necrotizing pneumonia, confirmed by chest computed tomography."
62839821|NCT04494802|PLACEBO_COMPARATOR|higher pressure|During the operation, cuff pressure of LMA flexible is maintained to 50cmH2O
62839822|NCT04494802|EXPERIMENTAL|lower pressure|During the operation, cuff pressure of LMA flexible is maintained to 30cmH2O
62839823|NCT00831480|EXPERIMENTAL|1|All subjects will take everolimus
62839824|NCT02864459|EXPERIMENTAL|Muscular ultrasound|
62839825|NCT00473239|EXPERIMENTAL|cholecalciferol|A single dose of 100,000 IU vitamin D
62839826|NCT00473239|NO_INTERVENTION|Control|No drug was given
62839827|NCT03329638|EXPERIMENTAL|DE-127 Ophthalmic Solution low dose|
62839828|NCT03329638|EXPERIMENTAL|DE-127 Ophthalmic Solution medium dose|
62839829|NCT03329638|EXPERIMENTAL|DE-127 Ophthalmic Solution high dose|
62839830|NCT03329638|PLACEBO_COMPARATOR|Placebo Ophthalmic Solution|
62839831|NCT00218842|EXPERIMENTAL|exercise group|individualized exercise
62839832|NCT00218842|NO_INTERVENTION|control group|care as usal
62839833|NCT05503823|EXPERIMENTAL|Participants|Each participant will have their resting and active motor threshold measured using the transcranial magnetic stimulation (TMS) device. Participants will receive tACS for 10 minutes in the first session and tRNS in the second session.
62839834|NCT01059435|PLACEBO_COMPARATOR|Placebo|Participants were randomized to receive a single dose of matching placebo administered by subcutaneous or intravenous injection.
62839835|NCT01059435|EXPERIMENTAL|Romosozumab|Participants were randomized to receive a single dose of romosozumab administered by subcutaneous or intravenous injection. The starting dose was 0.1 mg/kg, with sequential escalation up to 10 mg/kg.
62444687|NCT05738109|EXPERIMENTAL|Self-guided journaling Intervention|Participants assigned to the waitlist group complete a 2wk, 1mo, 2mo and 3mo survey over the 91-day study period. After the 91-days they will also complete a follow-up survey and exit interview
62444688|NCT05738109|NO_INTERVENTION|Waitlist Control|Participants assigned to the waitlist group complete a 2wk, 1mo, 2mo and 3mo survey over the 91-day study period. After the 91-days they receive access to the 91-day Self-Talk Journal for their own personal use.
62839836|NCT05060029|EXPERIMENTAL|Lactobacillus Species Suppositories|Coconut oil fatty acids, hyaluronic acid, patented VagiBIOM Probiotic complex CFU (Lactobacillus crispatus Bi16, Lactobacillus gasseri Bi19, Bacillus coagulans Bi34, Lactobacillus acidophilus Bi14) hydrolyzed cellulose, oligofructose, silica gel, lactic acid
62839837|NCT05060029|PLACEBO_COMPARATOR|Coconut Oil Suppositories|Coconut oil fatty acid suppositories
62839838|NCT02561832|EXPERIMENTAL|Arm 1|Part A: ascending doses of olaparib in combination with carboplatin will be administered to investigate safety and tolerability and to define the MTD and/or RD for part B. Patients will be treated with this combination up to cycle 4, after cycle 4 they can continue with combination or monotherapy (carboplatin or olaparib). Cohorts will be started sequentially, based on SRC recommendation. Part B will start after MTD/RD identification in part A. Patients will receive olaparib and carboplatin combination for first 4 cycles (21 days per cycle), at the dose, frequency and schedule recommended from Part A. This will be followed by another 4 cycles of standard cancer therapy consisting of anthracycline and cyclophosphamide regimen. Total of 8 treatment cycles will be given before final surgery
62839839|NCT04514653|ACTIVE_COMPARATOR|Ranibizumab control|Control treatment arm
62839840|NCT04514653|EXPERIMENTAL|RGX-314 Treatment Arm (Dose 1)|RGX-314 Dose 1
62839841|NCT04514653|EXPERIMENTAL|RGX-314 Treatment Arm (Dose 2)|RGX-314 Dose 2
62839842|NCT04514653|EXPERIMENTAL|RGX-314 Treatment Arm (Dose 3)|RGX-314 Dose 3
62055388|NCT06626373|PLACEBO_COMPARATOR|Placebo Comparator: Placebo beverage|Participants will consume placebo beverage twice/day for 1-week as well as our provided diet for 4 days.
62055389|NCT05083195|EXPERIMENTAL|Telerehabilitation Group|This group will perform their exercises with pre-prepared personalized exercise videos over the telerehabilitation system 3 times a week for 8 weeks.
62055390|NCT05083195|EXPERIMENTAL|Control Group|This group will perform exercises with personalized exercise brochures defined over the telerehabilitation system 3 times a week for 8 weeks.
62257919|NCT02484976|EXPERIMENTAL|Family Based Behavioral Treatment|Central satiety brain and hormonal responses will be compared pre-and post-Family Based Behavioral Treatment, as well, as to a non-obese sample.
62257920|NCT00153712||Non NSAID non-Hp|Patient of history of peptic ulcer bleeding with Hp-ve and without prior history of taking NSAID or Aspirin within 30 days
62257921|NCT00153712||Helicobacter pylori +ve|Patient with Hp+ve at peptic ulcer bleeding
62257922|NCT00839670|ACTIVE_COMPARATOR|Modified Therapy|
62257923|NCT00839670|ACTIVE_COMPARATOR|Standard Therapy|
62444689|NCT05858385||Development and Validation of severe RIOM prediction model|This group aims to develop an artificial intelligence model using a retrospective cohort to predict severe RIOM in patients diagnosed with LA-NPC and evaluate risk factors for severe RIOM and further validate the effectiveness of this risk factor in reducing the risk of severe RIOM on risk factors for severe RIOM identified by the predictive model.The oral evaluation of all patients was conducted by the same senior dentist, who evaluated the oral mucosal radiation toxicity weekly at baseline (before RT) and after RT, and performed RIOM scores.RIOM is classified using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v5.0) .
62444690|NCT06014684|EXPERIMENTAL|AM exercise|HIIT program performed between 07:00-09:00 AM
62444691|NCT06014684|EXPERIMENTAL|PM exercise|HIIT program performed between 15:00-17:00 PM
62839843|NCT04514653|EXPERIMENTAL|RGX-314 Treatment Arm (Dose 3) and Local Steroid|RGX-314 Dose 3 and Local Steroid
62839844|NCT04514653|EXPERIMENTAL|RGX-314 Treatment Arm (Dose 3) and Topical Steroid|RGX-314 Dose 3 and Topical Steroid
62839845|NCT01936870||Fesoterodine (Toviaz)|
62055391|NCT01337557|EXPERIMENTAL|Bepotastine|
62055392|NCT04904822|EXPERIMENTAL|Study group|Vaginal bisection of uterus
62257924|NCT06090370|EXPERIMENTAL|Baseline Survey: Silicosis and Personal Protective Equipment|
62257925|NCT06090370|EXPERIMENTAL|Design of Personal Protective Equipment Training Workshop|
62257926|NCT06090370|EXPERIMENTAL|Pilot Study: Personal Protective Equipment Training Program|A small training program will be offered to brick kiln workers to determine preferred PPE type, feasibility in the work environment and proper usage of PPE.
62257927|NCT06090370|EXPERIMENTAL|Feedback Workshop on Pilot Personal Protective Equipment Training Program|
62257928|NCT00971165|ACTIVE_COMPARATOR|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily for 18 months
62257929|NCT00971165|EXPERIMENTAL|losartan|Oral losartan up to 100 mg daily, once a day, for 18 month
62257930|NCT01446406|ACTIVE_COMPARATOR|MONARCA|MONARCA self-monitoring application on a cell phone to monitor affective symptoms every day.
62257931|NCT01446406|PLACEBO_COMPARATOR|NON-MONARCA|This is the same mobile phone as the MONARCA mobile phone. Yet the MONARCA application has not been installed. The mobile phone can only be used as a normal mobile phone for communication purposes.
62839846|NCT01310075|EXPERIMENTAL|Alloderm Mesh|Alloderm Mesh - 6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
62839847|NCT01310075|EXPERIMENTAL|Surgimend Mesh|Surgimend Mesh - 10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
62055393|NCT04904822|EXPERIMENTAL|Control group|Abdominal bisection
62055394|NCT03268239|OTHER|MRI sequences|"There will be only one arm of patients with central nervous system inflammatory disease.~Each patient will be its own control. The usual and additional MRI sequences will be performed in all patients and the number of lesions obtained in usual sequences and additional sequences will be compared in the same patient."
62055395|NCT04913064|EXPERIMENTAL|Prevention (white button mushroom)|Participants receive white button mushroom PO daily for 3 months in the absence of disease progression or unacceptable toxicity.
62055396|NCT06409221||Arm A|Retrospective arm recruiting participants (n=100) who have had a complete pathological response to chemotherapy (neoadjuvant) before curative breast surgery.
62055397|NCT06409221||Arm B|Retrospective arm recruiting participants (n=100) who had residual cancer burden (non-pathological complete response) in response to chemotherapy (neoadjuvant) followed by curative breast surgery.
62055398|NCT02390726|SHAM_COMPARATOR|Control|Sham FMT and Sham Microbial Maintenance plus standard therapy
62839848|NCT01310075|NO_INTERVENTION|Control (no mesh)|
62055399|NCT02390726|EXPERIMENTAL|Treatment|FMT and microbial maintenance plus standard therapy
62257932|NCT04305522|EXPERIMENTAL|Probiotic 1 group|A commercially-available multi-strain probiotic with added magnesium and vitamin B6
62257933|NCT04305522|EXPERIMENTAL|Probiotic 2 group|A multi-strain probiotic
62257934|NCT04305522|PLACEBO_COMPARATOR|Placebo group|Identical placebo
62257935|NCT01370720|ACTIVE_COMPARATOR|Recoclix (CM&D Pharma Limited)|Recoclix: two tablets per day for 12 weeks
62257936|NCT01370720|PLACEBO_COMPARATOR|Placebo|IBS patients
62257937|NCT05514379|EXPERIMENTAL|Group cognitive training|The experimental group will undergo 60 minutes long cognitive training group sessions twice a week for 12 weeks focused on executive function, attention and working memory.
62257938|NCT05514379|ACTIVE_COMPARATOR|Home-based cognitive training|The control group will perform executive function, attention and working memory training similar to the experimental group but at home as instructed by their therapist using specialized software for cognitive training (Rehacom). This training will be dose matched to the experimental group, i.e. it will be performed four times a week for 30 minutes for 12 weeks. In this group, therapists will only provide coaching once a month.
62257939|NCT00808795|EXPERIMENTAL|N-acetylcysteine|
62839849|NCT04988243|OTHER|Prospective and retrospective study of subjects undergoing aortic valve surgery|This study is a prospective / retrospective, multicenter, and observational study after listing. The researchers can initially determine that they can be enrolled in the study according to the history diagnosis of the subjects. After fully informed, they sign informed consent form. After the evaluation of the researchers, they meet the TAVR selection requirements, and register the subjects in multiple centers at the same time
62055400|NCT06625034|ACTIVE_COMPARATOR|Arm A (human-driven treatment planning, radiation therapy)|Patients receive human-driven treatment planning and undergo radiation therapy over 15-30 minutes on 5-44 fractions per standard of care. Additionally, patients undergo MRI pre-treatment and blood sample collection and PET throughout study.
62257940|NCT00808795|PLACEBO_COMPARATOR|Placebo|
62257941|NCT00772486|EXPERIMENTAL|Experimental: ISF35 and FCR|ISF35 and FCR
62444692|NCT02454270|EXPERIMENTAL|Dose Escalation: Participants With Certain B-Cell Malignancies|During accelerated dose titration in Group 1, participant will receive duvortuxizumab starting at 0.5 nanogram per kilogram (ng/kg) for biweekly dosing. Dose will be increased by half logarithmic steps in subsequent Dose Level (DL). After safety stopping criteria are met, Dose Escalation (DE) in Group 1 will transition to 3+3 design, and will continue until the Maximum tolerated Dose (MTD) is defined. DE in Groups 2 and 3 will follow 3+3 design, begin after initial dose level in Group 1 is deemed safe and recommended phase 2 doses (RP2D) for Part 1 of study can be decided. Duvortuxizumab at a starting dose of 50 ng/kg weekly will also be investigated in Group 1 and will follow 3+3 study design continue until the MTD or Maximum administered dose (MAD) is reached. Disease-specific dose escalation in Group 2 and 3 will not be initiated until dose in Group 1 is determined safe.
62614963|NCT02982148|EXPERIMENTAL|methylene blue intradermal injection|For patients randomized to intradermal injection before surgery began, 0.5ml 0.4% methylene blue(1ml methylene blue mixed up with 1.5ml saline) would be injected sub-areola (12 o'clock , 3 o'clock , 6 o'clock , 9 o'clock) intradermally, 0.1ml respectively, or peritumoral depending on the tumor location, 10-15 minutes before skin incision. The breast was massaged for 5 minutes to facilitate the identification of blue lymphatic vessels and the lymph nodes.
62839850|NCT04016662|ACTIVE_COMPARATOR|Hybrid Closed Loop Control (HCL)|The HCL intervention arm will utilize the Tandem t:slim X2 with Control-IQ Technology and Dexcom G6 CGM
62839851|NCT04016662|ACTIVE_COMPARATOR|Predictive Low-Glucose Insulin Suspension (PLGS)|The PLGS intervention arm will utilize the Tandem t:slim X2 with Basal-IQ Technology and Dexcom G6 CGM
62839852|NCT04016662|NO_INTERVENTION|Sensor-Augmented Pump (SAP)|The SAP arm will utilize the Tandem t:slim X2 without HCL or PLGS features turned on and Dexcom G6 CGM
62839853|NCT05907057|EXPERIMENTAL|Open-Label Ivosidenib in combination with Azacitidine|All participants will receive both Ivosidenib and Azacitidine for a maximum of 28 cycles. Each cycle will be 4 weeks or 28 days long. Ivosidenib will be taken continuously throughout each cycle and Azacitidine will be taken only for 7 days at the beginning of each cycle.
62839854|NCT00686686|EXPERIMENTAL|Infliximab 5 mg/kg|Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
62839855|NCT04478006||Childhood Leukemia|Peripheral blood and bone marrow samples are collected for genetic analysis, invitro drug sensitivity test and animal experiment.
62839856|NCT02776397|ACTIVE_COMPARATOR|Hp 2-2 Vitamin E|The Haptoglobin 2-2 group randomised to Vitamin E
62839857|NCT02776397|PLACEBO_COMPARATOR|Hp 2-2 Placebo|The Haptoglobin 2-2 group randomised to placebo
62839858|NCT02776397|ACTIVE_COMPARATOR|Non Hp 2-2 Vitamin E|The Non Haptoglobin 2-2 group randomised to Vitamin E
62839859|NCT02776397|PLACEBO_COMPARATOR|Non Hp 2-2 Placebo|The Non Haptoglobin 2-2 group randomised to placebo
62839860|NCT06219408|EXPERIMENTAL|CIH Stepped Care|"A mindfulness-based and meaning-based stepped care approach for treating co-occurring chronic pain and PTSD that will begin with less intensive treatment (e.g., psychoeducation) and, based on patient response and preference, will be stepped up to more intensive treatment when appropriate."
62839861|NCT06219408|NO_INTERVENTION|Treatment as Usual|Treatment as usual at the clinic
62839862|NCT00329589|EXPERIMENTAL|CNS|Velcade (bortezomib)
62839863|NCT00329589|EXPERIMENTAL|Head and Neck|Velcade (bortezomib)
62839864|NCT00329589|EXPERIMENTAL|Cervix|Velcade (bortezomib)
62839865|NCT03270501|EXPERIMENTAL|Arm 1: Golimumab|
62839866|NCT01122797||Alcoholic liver disease|Alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution
62839867|NCT01122797||Controls|Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination.
62839868|NCT04515238|EXPERIMENTAL|BZAG|"Debulking: 2 debulking cycles (q 28d) of bendamustine will be administered unless the patient has a contraindication or a debulking is not clinically indicated~Induction: 6 cycles (q 28d) of Obinutuzumab + Zanubrutinib + Venetoclax~Maintenance: max. 8 cycles (q 84d) of Obinutuzumab + Zanubrutinib + Venetoclax~Maintenance treatment will be continued until (whichever occurs first):~* 12 weeks (approx. 3 months) after confirmation of achievement of a CR/CRi and MRD negativity~* maintenance cycle 8~* progression of CLL or start of a subsequent therapy unacceptable toxicity"
62839869|NCT04957875||urgent endoscopy group|endoscopy \<6h after admission
62839870|NCT04957875||early endoscopy group|endoscopy 6-24h after admission
62839871|NCT00842491|EXPERIMENTAL|endostar+chemotherapy|
62839872|NCT02232906|EXPERIMENTAL|intravenous ferric carboxymaltose|
62839873|NCT02125669|ACTIVE_COMPARATOR|Laser Treatment|Pulsed dye laser 595nm
62839874|NCT02125669|SHAM_COMPARATOR|SHAM Treatment|using the pulsed dye laser (PDL) laser without releasing a pulse
62839875|NCT04993157|EXPERIMENTAL|Group 1: Healthy participants with normal hepatic function|Each participant will receive a single dose of FIA586
62839876|NCT04993157|EXPERIMENTAL|Group 2: Participants with mild hepatic impairment|Each participant will receive a single dose of FIA586
62839877|NCT04993157|EXPERIMENTAL|Group 3: Participants with moderate hepatic impairment|Each participant will receive a single dose of FIA586
62839878|NCT02731235|OTHER|Control|Prophylactic stroke medication and recommendations for lifestyle changes
62257942|NCT01758796|EXPERIMENTAL|Non-operative|Non-operative treatment with six weeks in a below-the-knee cast. Partial weight-bearing (15 to 20 kilograms) for the first four weeks and then weight-bearing as tolerated for the remaining two weeks.
62839879|NCT02731235|ACTIVE_COMPARATOR|Exercise|Prophylactic stroke medication and recommendations for lifestyle changes AND high-intensity training at home, 5 days a week in 12 weeks
62839880|NCT01616095||Adults with Growth Hormone Deficiency|if multiple hormonal deficiences exist, long term adequate supplementation is provided and tightly monitored.
62257943|NCT01758796|ACTIVE_COMPARATOR|Surgery|Open reduction and internal fixation with 1/3 semitubular plate and screws. Post-operatively, surgically treated ankles are placed in a below-the-knee cast for six weeks. They are advised to carry out partial weight-bearing (15 to 20 kilograms) for the first four weeks and then weight-bear as tolerated for the remaining two weeks.
62839881|NCT01616095||Healthy Controls|matched for BMI, age, and gender
62839882|NCT02633709|PLACEBO_COMPARATOR|Part 1: Single Ascending Dose: Placebo|Participants will receive a single dose of matching placebo orally on Day 1 of Part 1.
62839883|NCT02633709|EXPERIMENTAL|Part 1: Single Ascending Dose: Risdiplam|Participants will receive a single ascending dose (SAD) of Risdiplam orally on Day 1 of Part 1.
62839884|NCT02633709|EXPERIMENTAL|Part 2: Food Effect: Fasted-Fed|This arm consists of two periods. In Period 1 participants will receive one oral dose of Risdiplam in the fasted state on Day 1. In Period 2 participants will receive one oral dose of Risdiplam in the fed state on Day 1.
62839885|NCT02633709|EXPERIMENTAL|Part 2: Food Effect: Fed-Fasted|This arm consists of two periods. In Period 1 participants will receive one oral dose of Risdiplam in the fed state on Day 1. In Period 2 participants will receive one oral dose of Risdiplam in the fasted state on Day 1.
62839886|NCT02633709|EXPERIMENTAL|Part 3: Itraconazole Interaction|In Period 1 a single oral dose of Risdiplam will be administered. After a wash-out period in Period 2 participants will be administered oral doses of itraconazole twice daily from Day 1 to Day 8. On Day 4 participants will receive a single oral dose of Risdiplam in the fed state in combination with itraconazole.
62055401|NCT06625034|EXPERIMENTAL|Arm B (RapidPlan treatment planning, radiation therapy)|Patients receive RapidPlan treatment planning and undergo radiation therapy over 15-30 minutes on 5-44 fractions per standard of care. Additionally, patients undergo MRI pre-treatment and blood sample collection and PET throughout study.
62055402|NCT04135963||Participants with MM|Participants diagnosed with MM from 8 investigative sites will be observed retrospectively for previous 5 years before enrollment until Day 1.
62055403|NCT01445808|EXPERIMENTAL|Psychodynamic Motivation and Training Program (PMT)|
62055404|NCT01445808|ACTIVE_COMPARATOR|Advice in Exercise Training|One session of advice in exercise training based on the results of spiroergometry
62257944|NCT03151720|EXPERIMENTAL|Cohort 1: Sequence 1 (ABAB)|Participants will receive 10 milligram (mg) loratadine (1\*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1\*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
62257945|NCT03151720|EXPERIMENTAL|Cohort 1: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
62257946|NCT03151720|EXPERIMENTAL|Cohort 2: Sequence 1 (ABAB)|Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
62444693|NCT02454270|EXPERIMENTAL|Dose Expansion: Diffuse-Large B-Cell Lymphoma Participants|Participants with Diffuse-Large B-Cell Lymphoma (DLBCL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
62839887|NCT04830319|EXPERIMENTAL|Test-control group (TCG)|The test-control group (TCG) will initiate the protocol with exercises of the Pilates method, which includes exercises in soil, that associate the correct respiratory movement with muscular strengthening and control, stretching from the eccentric movement, selective upper and lower trunk movements. There will be used accessories described by the method for their realization. Participants will perform the first week of awareness and body alignment exercises for 10 minutes, 10 minute breath perception, 10 minute proximal muscle accuracy and control, and 10 minute stretches; from the second week will be included selective trunk movements, with muscle strengthening of lower limbs. Rest intervals will be performed between exercises.After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. The TCG group will then conduct 20 task-oriented training sessions
62257947|NCT03151720|EXPERIMENTAL|Cohort 2: Sequence 1 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
62257948|NCT02122198|PLACEBO_COMPARATOR|Placebo|Monthly placebo injections for 6 months under parent study (FAME) protocol (NCT01712230)
62055405|NCT01445808|OTHER|Treatment as usual (TAU)|Usual care by family doctor and cardiologist
62055406|NCT04242693|EXPERIMENTAL|Experimental Group|The experimental group were asked to count the number of times they ate any red/orange vegetables and set a goal to eat one more time the next day over three days.
62055407|NCT04242693|NO_INTERVENTION|Control Group|The control group uploaded photos and/or descriptions of their meals only. They did not self-monitor their vegetable intake nor set a goal to eat more.
62055408|NCT06460558||Type 1 diabetes with insulin infusion system|
62055409|NCT02765919|EXPERIMENTAL|Radiation HDR Brachytherapy 9 Gy|High dose rate (HDR) Brachytherapy of weekly 9 Gray in two fractions in two weeks after 50 Gray of EBRT in 2 Gray per fraction of 5 weeks with chemotherapy cisplatin 40 mg /m2 weekly for five weeks in locally advanced carcinoma cervix
62055410|NCT02765919|ACTIVE_COMPARATOR|Radiation HDR Brachytherapy 7 Gy|High dose rate (HDR) brachytherapy of weekly 7 Gray in three fractions in three weeks after 50 Gray EBRT of 2 Gray per fraction of 25 fractions concurrently with weekly chemotherapy cisplatin40 mg /m2 in five weeks in locally advanced carcinoma cervix
62055411|NCT01126827|ACTIVE_COMPARATOR|Supportive Psychotherapy|
62055412|NCT01126827|ACTIVE_COMPARATOR|Mindfulness-Based Cognitive Behavioral Therapy|
62055413|NCT02295514|EXPERIMENTAL|PTP1B dosage|PTP1B dosage during sepsis
62055414|NCT03181802|EXPERIMENTAL|botulinum toxin A|
62055415|NCT03181802|PLACEBO_COMPARATOR|Placebo|
62055416|NCT02260076|EXPERIMENTAL|PEG 400|multiple rising doses
62055417|NCT02260076|PLACEBO_COMPARATOR|Placebo|
62055418|NCT03483974||neoplasm|neoplasm found in follow up
62055419|NCT03483974||non-neoplasm|non-neoplasm patients in follow up
62055420|NCT04814654|EXPERIMENTAL|CHALO! 2.0|MSM randomized to this arm will receive twice weekly digital media messages for 12 weeks about HIV, HIV-testing, prevention, and treatment and a a link to a study-specific webpage listing MSM specific testing, prevention, and care resources. Participants will also be able to interact with online outreach workers.
62055421|NCT04814654|ACTIVE_COMPARATOR|Attention-matched control (AMC)|MSM randomized to the AMC arm will receive twice weekly digital media messages for 12 weeks about general health and a link to a study-specific webpage listing testing resources and MSM-specific services. Participants will also be able to interact with online outreach workers.
62614964|NCT02982148|ACTIVE_COMPARATOR|methylene blue subcutaneous injection|For patients randomized to subcutaneous injection before surgery began, 0.5ml 100% methylene blue would be injected sub-areola subcutaneously(12 o'clock , 3 o'clock , 6 o'clock , 9 o'clock), 0.1ml respectively or peritumoral depending on the tumor location, 10-15 minutes before skin incision. The breast was massaged for 5 minutes to facilitate the identification of blue lymphatic vessels and the lymph nodes.
62614965|NCT02676635|EXPERIMENTAL|Ergonomics Training Only|Participants in this arm receive Ergonomics training only
62055422|NCT04814654|ACTIVE_COMPARATOR|Digital coupon only control (DCO)|MSM randomized to the DCO arm will receive, at study entry, a digital coupon for free HIV testing and a study specific webpage link listing testing and MSM specific services.
62055423|NCT02633930|EXPERIMENTAL|berberine quadruple therapy|Berberine 300 mg, three times daily for 14 days,lansoprazole 30 mg,amoxicillin 1000 mg, and Bismuth 220 mg by mouth, twice daily for 14 days.
62055424|NCT02633930|ACTIVE_COMPARATOR|clarithromycin quadruple therapy|Bismuth 220 mg, lansoprazole30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
62257949|NCT02122198|ACTIVE_COMPARATOR|GnRH agonist|"Monthly injections of leuprolide acetate 3.75mg for 9 months; first 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study protocol.~Weekly application of estradiol patch 0.075mg/d months 6-9.~Daily medroxyprogesterone acetate 5mg by mouth for 12 days at week 30."
62444694|NCT02454270|EXPERIMENTAL|Dose Expansion: Follicular Cell Lymphoma Participants|Participants with Follicular Cell Lymphoma (FL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
62444695|NCT02454270|EXPERIMENTAL|Dose Expansion: Mantle Cell Lymphoma Participants|Participants with Mantle Cell Lymphoma (MCL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
62614966|NCT02676635|EXPERIMENTAL|Ergonomics and Safety Voice Training|Participants in this arm receive training on both Ergonomic principles and Safety Voice training
62614967|NCT02676635|NO_INTERVENTION|Control Group|Participants in this arm will receive no additional Ergonomics or Safety Voice training
62614968|NCT02943785|EXPERIMENTAL|Edoxaban-based Regimen|Edoxaban-based regimen 60 mg and 30 mg film coated tablet for once-daily oral use, and 15 mg film coated tablet in case of transitioning at the end of treatment. Dosing must follow the locally approved label.
62614969|NCT02943785|ACTIVE_COMPARATOR|VKA-based Regimen|VKA-based regimen oral VKA tablets as selected and provided by the site and used in accordance with the local label. The Investigator will monitor the patient and adjust the VKA dose to maintain the dose within target.
62614970|NCT06212713||Questionnaire respondents|questionnaire will be administered for validation
62055425|NCT01621880|ACTIVE_COMPARATOR|Bevacizumab|Patients receive bevacizumab 5mg/kg intravenously over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62055426|NCT01621880|ACTIVE_COMPARATOR|Corticosteroid|Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
62055427|NCT00431184|ACTIVE_COMPARATOR|Pentazocine then Lorazepam|In the first leg of the study, pentazocine will be given to subjects randomly assigned to this group. On Day 1, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later. On Day 2, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two hours later.
62257950|NCT06316700|ACTIVE_COMPARATOR|Nutritional Powder Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
62257951|NCT06316700|PLACEBO_COMPARATOR|Placebo|Maltodextrin + Flavoring
62055428|NCT00431184|ACTIVE_COMPARATOR|Lorazepam then Pentazocine|In the first leg of the study, lorazepam will be given to subjects randomly assigned to this group. On Day 3, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two hours later. On Day 2, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later.
62257952|NCT06389864|ACTIVE_COMPARATOR|Real group|rTMS administered at 10 Hz directed to the right dorsolateral prefrontal cortex. The pulse intensity was set at 80% of the observed motor threshold, 4 s on-train, 26 s off inter-train interval with 2000 pulses per session(29) for 5 sessions per week, for 15 sessions total (i.e., 30,000 pulses total in treatment course).
62257953|NCT06389864|SHAM_COMPARATOR|Sham control group|the rTMS coil was tilted over the right dorsolateral pre-frontal cortex without touching the scalp administered at 10 Hz. The pulse intensity was set at 80% of the observed motor threshold, 4 s on-train, 26 s off inter-train interval with 2000 pulses per session for 5 sessions per week. for 15 sessions total.
62614971|NCT05347745|OTHER|Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit|The therascreen® KRAS RGQ PCR Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx (US) instrument for the detection of seven somatic mutations in the human KRAS oncogene, using DNA extracted from formalin-fixed, paraffin-embedded (FFPE), colorectal cancer (CRC) tissue
62614972|NCT00542100|EXPERIMENTAL|1|
62257954|NCT02876588|ACTIVE_COMPARATOR|Unrestricted|"Users have unrestricted access to open up to a maximum of 4 patient records at a time in the EHR"
62257955|NCT02876588|ACTIVE_COMPARATOR|Restricted|"Users have restricted access to open a maximum of 1 patient record at a time in the EHR"
62257956|NCT01857284|EXPERIMENTAL|Group 1|Tauroursodeoxycholic Acid Capsules,250mg,tid.
62257957|NCT01857284|ACTIVE_COMPARATOR|Group 2|Ursodeoxycholate acid capsules, 250mg,tid,
62257958|NCT04207801|EXPERIMENTAL|Arm-1 400 mg BID|400 mg AUR101 twice daily
62257959|NCT04207801|EXPERIMENTAL|Arm-2 600 mg BID|600 mg AUR101 twice daily
62257960|NCT04207801|PLACEBO_COMPARATOR|Arm-3 - Matching Placebo BID|Matching Placebo twice daily
62257961|NCT03936621|ACTIVE_COMPARATOR|Group 1: Omega 3 Fatty Acid|Omega 3 fatty acids for 6 months and then off omega 3 fatty acids for the next 6 months. In the first 6 months, you will be asked to take one capsule of Omega 3 fatty acids with breakfast and 1 with dinner/day for the first week, 2 capsules in the morning and one capsule in the evening for the second week and then 2 capsules with breakfast and 2 with dinner/day for the remaining 24 weeks. In the next 6 months (Months 7 to 12), you will have a blood test for markers of inflammation at the end of Month 7 and at Month 9 and 12 to determine if the anti-inflammatory effects of Omega 3 acids are still there after you have stopped taking it.
62257962|NCT03936621|PLACEBO_COMPARATOR|Group 2: Control Arm|No Omega 3 fatty acids for the first 6 months followed by Omega 3 fatty acids for the next 6 months. You will be asked to have a blood test for markers of inflammation at Month 1, 3 and 6 for markers of inflammation to determine the natural variation of the levels of these markers without Omega 3 fatty acid supplements. In Month 7, you will be asked to take one capsule of Omega 3 with breakfast and 1 with dinner/day for the first week, 2 capsules in the morning and one capsule in the evening for the second week and then 2 capsules with breakfast and 2 with dinner/day for the remaining 24 weeks.
62257963|NCT04961151|EXPERIMENTAL|Conductive Wrap Warming|Esophageal warming will be discontinued first
62614973|NCT00542100|EXPERIMENTAL|2|
62614974|NCT03159845|ACTIVE_COMPARATOR|Control|patients undergone autologous stem cell transplantation. They take levofloxacin 500 mg/d, aciclovir 400 mg bid, fluconazole 200 mg bid from day +10 until day +30 after stem cell transplantation
62614975|NCT03159845|EXPERIMENTAL|Zinc|patients undergone autologous stem cell transplantation. They take the same antimicrobial prophylaxis of patients of the Control group, and, in addition, a daily oral supplementation of Zinc Sulfate, 600 mg/die, uncoated tabs, from day +5 until day +100 after transplant
62614976|NCT04191122|ACTIVE_COMPARATOR|COPESS and Treatment as usual|"COPES is a brief (4 + 1 sessions, 50 minutes) psychotherapy based on psychodynamic and cognitive analytic principles that was developed to help those struggling with SH and depression. COPES is designed to be brief and accessible, and involves working collaboratively with a client to try and identify patterns or conflicts in emotional experiences and interpersonal relationships, linked to depressed mood and acts of SH. The therapist works with the client to build a shared map or understanding of these experiences. A goal of therapy is to work towards a small number of specific exits, representing helpful steps the client might make to improve their difficulties. Therapy would take place either in the participant's home or in a community setting (e.g. health centre or clinic) depending on preference.~Safety for the therapist and/or mobility for the patient will be reviewed throughout the recruitment period. Participants in the COPES arm of the trial will also receive TAU."
62055429|NCT00652938|ACTIVE_COMPARATOR|Cervarix & Engerix Group|Subjects received 3 doses of Cervarix™ (Human Papillomavirus \[HPV\] vaccine) co-administered with Engerix™ (Hepatitis B \[HBV\] vaccine) according to a 0, 1, 6-month schedule.
62257964|NCT04961151|EXPERIMENTAL|Esophageal Warming|Conductive wraps will be discontinued first
62257965|NCT02698267|EXPERIMENTAL|BIIB074|Administered orally on Day 1 and Day 11
62257966|NCT03837639|EXPERIMENTAL|Arm crank ergometer|Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
62444696|NCT02454270|EXPERIMENTAL|Dose Expansion: Chronic Lymphocytic Leukemia Participants|Participants with Chronic Lymphocytic Leukemia (CLL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
62055430|NCT00652938|EXPERIMENTAL|Cervarix Group|Subjects received 3 doses of Cervarix™ (Human Papillomavirus \[HPV\] vaccine) according to a 0, 1, 6-month schedule.
62839888|NCT04830319|ACTIVE_COMPARATOR|Control-test group (CTG)|The control-test group (CTG) will initiate the task-oriented training protocol. The task-oriented training protocol will include functional exercise drills, such as sit-up and workout, obstacle course workout, speed-and-direction workout, balance workout, work-up and downhill workout, each tasks performed for eight minutes, with two minutes of rest between them. The difficulty in carrying out the tasks will be progressively adjusted. At all times, individuals will be instructed to contract the pelvic floor musculature. After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. Next, the CTG group will perform 20 sessions of Pilates exercises.
62839889|NCT05413317||Adult patients hospitalized for suspicion of pulmonary embolism recurrence|Patients with at least one of the following symptoms: acute dyspnea or aggravation of chronic dyspnea, chest pain, hemoptysis or syncope
62839890|NCT05353153|EXPERIMENTAL|hypnosis group|
62839891|NCT05353153|ACTIVE_COMPARATOR|Control group|
62257967|NCT03837639|EXPERIMENTAL|Treadmill ergometer|Walking exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
62444697|NCT02454270|EXPERIMENTAL|Dose Expansion: Acute Lymphoblastic Leukemia Participants|Participants with Acute Lymphoblastic Leukemia (ALL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
62444698|NCT02051881|OTHER|Biopsies|Intestinal biopsies were taken in patients who underwent endoscopy.
62614977|NCT04191122|NO_INTERVENTION|Treatment as usual only|The control group will receive Treatment-as usual (TAU), defined as the standard care provided to individuals struggling with self-harm (SH) as detailed within the 'Managing SH in primary care' NICE guidelines. These include: an initial comprehensive psychosocial assessment of skills and risks; co-production of a care and risk management care plan, which should include harm reduction plans, the need for between 3 and 12 sessions of psychological intervention as well as treatment for associated mental health conditions. Primary care practices in the control arm will be asked to provide information on what constitutes TAU within their organisation. This trial may enhance TAU as researchers will provide details of NICE guidance to GP practices that may not currently be following these guidelines. We will collect data regarding the acceptability of TAU for SH offered by GPs within both treatment arms.
62839892|NCT03046862|EXPERIMENTAL|Durvalumab/Tremelimumab+chemotherapy|Durvalumab and Tremelimumab in combination with gemcitabine/cisplatin.
62839893|NCT04943653|EXPERIMENTAL|Intraperitoneal paclitaxel + XELOX|"Intraperitoneal paclitaxel Day1, Day8 + \*XELOX~\*XELOX ; Capecitabine 2000mg/m2/day(Day1-14) Oxaliplatin 100mg/m2 IV Day1 q 3 weeks"
62839894|NCT02575690|PLACEBO_COMPARATOR|Placebo group|Obese patients with well-treated hypertension that receive placebo (pure microcrystalline cellulose)
62839895|NCT02575690|EXPERIMENTAL|Spirulina group|Obese patients with well-treated hypertension that receive Hawaiian spirulina (Cyanotech Corporation, Hawaii, US)
62839896|NCT01247272|ACTIVE_COMPARATOR|Reference Listed Drug|90 mg PROZAC WEEKLY® Capsules (Eli Lilly)
62839897|NCT01247272|EXPERIMENTAL|Investigational Test Product|90 mg Fluoxetine Hydrochloride Capsules (Teva)
62839898|NCT02253446|EXPERIMENTAL|Piroksikam|20 mg of piroxicam (feldene ampoule -Pfizer-France) intramuscularly (IM) was given 200 patients,
62055431|NCT00652938|ACTIVE_COMPARATOR|Engerix Group|Subjects received 3 doses of Engerix™ (Hepatitis B \[HBV\] vaccine) according to a 0, 1, 6-month schedule.
62055432|NCT02487472||HZ cohort|All patients ≥ 50 years old with a HZ diagnosis (as the primary diagnoses and no earlier case of HZ) during approximately 6 months inclusion period will be included in the HZ cohort, until total study target is achieved.
62055433|NCT00933101||HgbA1c <8|Adolescents with HgbA1c \< or equal to 8% for the previous 12 months
62257968|NCT03837639|OTHER|Control group|Patients randomized to control group will attend to meetings with the researcher team twice a week during the 12 weeks. At these meetings, patients will perform manual tasks, with or without the use of artistic materials, cultural programs, cooking classes and home care, without any exercise component. This CG practice will be performed in order to minimize the effects of the patient's bi- weekly commitment and displacement to the training site, to minimize the influence of the patient- researcher contact and also minimize the convivial effect among the patients themselves, which will occur in the other two groups.
62257969|NCT04066491|EXPERIMENTAL|Safety Run-In Part: M7824 + Gemcitabine + Cisplatin|
62839899|NCT02253446|EXPERIMENTAL|Diclofenac Sodium|Second Group: Diclofenac sodium 75mg (Miyadren drug-ampoule -Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
62839900|NCT02856672|ACTIVE_COMPARATOR|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
62839901|NCT02856672|ACTIVE_COMPARATOR|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
62839902|NCT01823016|PLACEBO_COMPARATOR|Placebo|
62839903|NCT01823016|EXPERIMENTAL|JNJ-38518168|
62055434|NCT00933101||HgbA1c >10|Adolescents with HgbA1c \> or equal to 10% for previous 12 months
62055435|NCT06344598||Persons with normal BMD|
62055436|NCT06344598||Persons with low BMD|
62055437|NCT01599390||Influenza Group|
62055438|NCT02323087|ACTIVE_COMPARATOR|Culture and susceptibility testing|Urine culture and sensitivity testing will be performed using the FLEXICULT™ SSI-Urinary Kit
62055439|NCT02323087|ACTIVE_COMPARATOR|Culture|Point of care culture will be performed using ID FlexicultTM
62257970|NCT04066491|EXPERIMENTAL|Double-blinded Part: M7824 + Gemcitabine + Cisplatin|
62257971|NCT04066491|PLACEBO_COMPARATOR|Double-blinded Part: Placebo + Gemcitabine + Cisplatin|
62257972|NCT03702764||VP-SG 01|Study subjects that present concentric coronary plaques
62257973|NCT03702764||VP-SG 02|Study subjects that present eccentric coronary plaques
62257974|NCT05002270|EXPERIMENTAL|Arm A0, JAB-21822 monotherapy, Phase 1, Dose Escalation|Dose escalation of JAB-21822 will be administered alone to determine the MTD and RP2D
62257975|NCT05002270|EXPERIMENTAL|Arm A1, JAB-21822 monotherapy, Phare 2, Dose Expansion|JAB-21822 will be administered alone at RP2D in selected cancer type patients to evaluate the preliminary antitumor activity.
62839904|NCT01872390|EXPERIMENTAL|CIP Participants|Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients, and in addition the Combination Intervention Package (CIP) with the programmatic, structural, and psychosocial components.
62839905|NCT01872390|OTHER|SOC Participants|Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients. TB and HIV services are fully integrated in a one-stop model, while at hospitals, ART is provided in the TB clinic for TB/HIV coinfected patients.
62055440|NCT05271058|SHAM_COMPARATOR|Control group 1|23 eyes that did not receive any intraoperative steroids
62055441|NCT05271058|ACTIVE_COMPARATOR|Dexamethasone group 2|23 eyes that received intracameral dexamethasone
62839906|NCT04688008|OTHER|Treatment sequence #1|29 of 58 subjects were given single oral dose of early phase hetrombopag olamine formulation in period 1 and late phase formulation in period 2
62839907|NCT04688008|OTHER|Treatment sequence #2|29 of 58 subjects were given single oral dose of late phase hetrombopag olamine formulation in period 1 and early phase formulation in period 2
62839908|NCT03722004|ACTIVE_COMPARATOR|mOPV1 + fIPV 6 weeks|mOPV1 administered at 6, 10, and 14 weeks and fIPV at 6 weeks.
62839909|NCT03722004|ACTIVE_COMPARATOR|mOPV1 + fIPV 10 weeks|mOPV1 administered at 6, 10, and 14 weeks and fIPV at10 weeks.
62839910|NCT03722004|ACTIVE_COMPARATOR|mOPV1 only|mOPV1 administered at 6, 10, and 14 weeks.
62839911|NCT03722004|ACTIVE_COMPARATOR|bOPV only|bOPV administered at 6, 10, and 14 weeks.
62839912|NCT04751006|EXPERIMENTAL|Gaze Group|Participants performed balance training with gaze stabilization exercises
62839913|NCT04751006|OTHER|Control Group|Participants performed balance training with saccade eye exercises
62839914|NCT03415542|OTHER|Exercise Intervention|Participants receive a print-based exercise promotion program across 12 weeks and are asked to monitor their exercise behavior using an app on their cell phone.
62839915|NCT01444040|ACTIVE_COMPARATOR|iStent inject|Implantation of two iStent inject devices
62055442|NCT05271058|ACTIVE_COMPARATOR|Triamcinolone (TA) group 3|23 eyes that received intracameral triamcinolone (TA)
62614978|NCT03828682|EXPERIMENTAL|Prospective Arm|"De novo kidney transplant recipients receiving:~rabbit antithymocyte globulin induction (1.5mg/kg, dosage range 4-6mg/kg total dose over 5-10 days) 5-day steroid withdrawal (methylprednisolone 500mg IV on day 1 (day of transplant), 250mg IV on day 2, 125mg IV on day 3, prednisone 80mg PO on day 4, 60mg PO on day 5 and then no more steroids Once-daily tacrolimus XR 0.8mg/kg/day started when or when serum creatinine is \<4mg/dL or by 48 hours of transplant to target 24-hr trough levels of 8-12ng/mL up to day 30 followed by 24-hour trough targets of 5-10ng/mL Mycophenolate mofetil (1000 mg PO BID) or mycophenolic acid (720mg PO BID) twice daily started prior to surgery"
62614979|NCT03828682|ACTIVE_COMPARATOR|Comparator arm|"Historical control arm consisting of the following~De novo kidney transplant recipients receiving:~rabbit antithymocyte globulin induction (1.5mg/kg, dosage range 4-6mg/kg total dose over 5-10 days) 5-day steroid withdrawal (methylprednisolone 500mg IV on day 1 (day of transplant), 250mg IV on day 2, 125mg IV on day 3, prednisone 80mg PO on day 4, 60mg PO on day 5 and then no more steroids Twice-daily tacrolimus 0.1mg/kg/day started when or when serum creatinine is \<4mg/dL or by 48 hours of transplant to target 12-hr trough levels of 8-12ng/mL up to day 30 followed by 12-hour trough targets of 5-10ng/mL Mycophenolate mofetil (1000 mg PO BID) or mycophenolic acid (720mg PO BID) twice daily started prior to surgery"
62055443|NCT03928028|ACTIVE_COMPARATOR|Family Based Treatment (FBT)|Families will receive 15 sessions of FBT alone.
62055444|NCT03928028|EXPERIMENTAL|FBT w/ Parent-focused Cognitive Remediation Therapy|Family Based Treatment with Parent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of parent focused CRT followed Family Based Treatment over six months.
62614980|NCT03353948|ACTIVE_COMPARATOR|Metfrormin group (MET)|Drug: Metformin
62614981|NCT03353948|ACTIVE_COMPARATOR|COMBI group (COMBI)|Drug: liraglutide
62614982|NCT00817505|ACTIVE_COMPARATOR|1|AZD1656 tablet + food
62614983|NCT00817505|ACTIVE_COMPARATOR|2|AZD1656 susp. without food
62614984|NCT00817505|ACTIVE_COMPARATOR|3|AZD1656 tablet
62614985|NCT02157597|ACTIVE_COMPARATOR|Control Arm|"The control patients will have open display of the NIRS monitor in the OR, but recording without display in the CICU, along with a request to the surgical and intensive teams to react to the data in their usual way. The disparity between the OR and CICU reflect the current opinions of the clinicians in these different environments regarding the necessity of NIRS monitoring within their sphere of practice.~In this way, continuous recording of cerebral and somatic oximetry will be made in all patients. However for control patients the monitor display will be switched off in the CICU using a pre-programmed research mode, which permits both ongoing recording and also the display of technical error messages (such as inadvertent disconnections or probe displacement)."
62839916|NCT01444040|ACTIVE_COMPARATOR|Drug|Travoprost drops
62839917|NCT03200288|EXPERIMENTAL|HL-01|Single 2 ml intra-articular injection of HL-01 (solution of high and low molecular weight hyaluronic acid (HA))
62614986|NCT02157597|EXPERIMENTAL|NIRS based management|The trial interventions of NIRS based management consists of provision to the cardiac surgical and intensive care teams of a protocol to guide their interpretation of cerebral and somatic NIRS monitoring and interventions to try in the event of monitored desaturation during the pre- and post-bypass periods (when the circulation is perfused by the beating of the native heart). The investigators believe that there is insufficient data to inform an evidence-based protocol for the bypass phase of surgery, particularly regarding the interpretation of NIRS data under conditions of hypothermia.
62614987|NCT06286020|EXPERIMENTAL|The experimental group|conventional dysphagia treatment and Virtual Reality Therapy are provided
62614988|NCT06286020|ACTIVE_COMPARATOR|The control group|conventional dysphagia treatment is provided
62614989|NCT04102384|NO_INTERVENTION|Control Group|Participants will be enrolled for a period of 4 weeks. At baseline, we will collect demographic information on participants. During the study, participants will be asked to fill out daily and weekly surveys using an electronically link sent via email. Additionally, participants will be asked to fill out one survey once a week during the study period.
62839918|NCT03200288|PLACEBO_COMPARATOR|Placebo|Single 2 ml intra-articular injection of Placebo (physiological solution)
62839919|NCT05679258|EXPERIMENTAL|HLX15 group|Recombinant anti-CD38 fully human monoclonal antibody injection developed by Shanghai Henlius Biotech, Inc.
62055445|NCT03928028|EXPERIMENTAL|FBT w/Adolescent-focused Cognitive Remediation Therapy|Family Based Treatment with Adolescent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of adolescent focused CRT followed by Family Based Treatment over six months.
62055446|NCT03278535||age group 18-29 years|CAREN-based gait analysis: 20 men and 20 women aged between 18-29 years
62055447|NCT03278535||age group 30-39years|CAREN-based gait analysis: 20 men and 20 women aged between 30-39years
62055448|NCT03278535||age group 40-49years|CAREN-based gait analysis: 20 men and 20 women aged between 40-49years
62839920|NCT05679258|ACTIVE_COMPARATOR|US-sourced DARZALEX® group|Daratumumab injection
62839921|NCT05679258|ACTIVE_COMPARATOR|CN-sourced DARZALEX® group|Daratumumab injection
62839922|NCT05679258|ACTIVE_COMPARATOR|EU-sourced DARZALEX® group|Daratumumab injection
62839923|NCT03651570|EXPERIMENTAL|PTSD Coach|PTSD Coach is a mobile mental health app developed by US Veterans Affairs translated into French by Veterans Affairs Canada in partnership with the Department of National Defence and the Canadian Mental Health Association. It was developed for a male population (92% of veterans are men), as is predominantly found in HNC, and addresses the issue of mental health and stigma as found in our HNC patients. PTSD Coach can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self-Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module. The content of the first and last modules were adapted to the oncological population.
62614990|NCT04102384|EXPERIMENTAL|Intervention Group|Participants will be enrolled for a period of 4 weeks. At baseline, we will collect demographic information on participants. During the study, participants will be asked to fill out daily and weekly surveys using the e-PRO app. Additionally, participants will be asked to fill out one survey once a week during the study period. A subgroup of these participants will be asked to complete an additional interview to collect more information on their experiences using the mobile app.
62839924|NCT03651570|PLACEBO_COMPARATOR|Game application|Patients will be assigned to three apps involving playing a game (i.e., Candy Crush, Tetris, or Solitaire), during the waiting time before and between medical treatments in the hospital, on the same weekly schedule as the experimental group. The game apps contain no element of intervention and were selected based on popularity and capacity to interests.
62055449|NCT03278535||age group 50-59years|CAREN-based gait analysis: 20 men and 20 women aged between 50-59years
62055450|NCT03278535||age group 60-69years|CAREN-based gait analysis: 20 men and 20 women aged between 60-69years
62055451|NCT03278535||age group 70+|CAREN-based gait analysis: 20 men and 20 women aged between 70 years and older
62055452|NCT03556475||Disease 1|Moderate to severe COPD Patients(n=90)
62055453|NCT03556475||Disease type 2-1)|Patients with Mild/moderate AECOPD (n=60)
62055454|NCT03556475||Disease type 2-2)|Patients with Severe AECOPD( n=60)
62055455|NCT03556475||Disease type 3|Non-COPD Patients with high risk factors (n=90)
62055456|NCT04000867|ACTIVE_COMPARATOR|real TCMS treatment|Subjects with DN located in their bilateral feet that have been previously identified and have a graded average baseline score of at least 5 in each foot will receive either TCMS treatment or Sham treatment on clinic day-1 according to the contents of a sealed opaque envelope corresponding to the subject's number in the series and opened immediately before treatment on day 1. (Our statistician will have generated these envelopes and their contents in advance.) Subjects and staff evaluating the subject's response will remain blinded to treatment assignment; only the staff member setting the treatment mode will know whether it is active or sham.
62055457|NCT04000867|SHAM_COMPARATOR|Sham TCMS treatment|Patients in the sham treatment group, will use the same device. The device will be switched into sham mode by the clinician by pressing a small, non-descript button on the backside of the pulse generator. The treatment device in sham mode will produce a clicking sound once every 6 seconds like the TCMS treatment mode, but no magnetic pulses will be output.
62055458|NCT01224925|ACTIVE_COMPARATOR|Capping over carious exposure with Dycal|Total caries removal. In case of pulp exposure Direct Pulp capping with (Dycal®, Dentsply DeTrey GmbH, Konstanz, Germany)
62055459|NCT01224925|EXPERIMENTAL|Capping over carious exposure with WMTA|Total caries removal. In case of pulp exposure Direct Pulp capping with Mineral Trioxide Aggregate White ProRoot® (WMTA) (DENTSPLY, Tulsa Dental, Tulsa, OK, USA)
62055460|NCT05598242|EXPERIMENTAL|Amniotic membrane extract|patients receive amniotic membrane eye drops (AMEED) as 1 drop in each eye 6 times daily, 30 days
62055461|NCT05598242|ACTIVE_COMPARATOR|autologous serum eye drops|patients receive autologous serum eye drops (ASED) as 1 drop in each eye 6 times daily, 30 days
62055462|NCT02404389|EXPERIMENTAL|LFX453 0.1% NMC|LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications
62444699|NCT05468164|EXPERIMENTAL|Selpercatinib and omeprazole administered in ABCD treatment sequence|"Period 1: Single oral dose of Selpercatinib administered in fasted state. Period 2: Single oral dose of Selpercatinib administered in fed state. Period 3: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fasted state.~Period 4: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fed state.~Periods 1 and 2, 2 and 3 will be separated by a 7-day washout period. There will be no washout between Periods 3 and 4."
62614991|NCT00285376|EXPERIMENTAL|1|vilazodone
62614992|NCT00285376|PLACEBO_COMPARATOR|2|
62614993|NCT03525756||Cystogram on Post-Op Day 2|An indwelling Foley catheter is placed intraoperative and continued postoperative. All patients who consent to participate would undergo a cystogram on postoperative day two. The cystogram will be conducted by a radiologist and technician well-trained in the techniques and interpretation of the study. The colorectal surgery enhanced recovery protocol will be followed on all patients with the exception of the cystogram being conducted on post-op day two.
62614994|NCT04414189||Arm A|Patients with suspected sepsis at the time of admission to the ICU
62614995|NCT04414189||Arm B|Patients not currently suspected but at high risk for sepsis.
62614996|NCT05056571|EXPERIMENTAL|Relaxation exercise|Intensive care nurses will apply 20 minutes of online (zoom meeting) progressive muscle relaxation exercise twice a week, for 8 weeks, for a total of 16 group sessions. In order to support nurses' adaptation to the research, the group counselor will remind the nurses by phone twice a week during the implementation process, and their regular participation in online sessions will be supported.
62055463|NCT02404389|EXPERIMENTAL|LFX453 0.15% LCC|LFX453 0.15% liquid crystal cream (LCC) Twice daily applications
62055464|NCT02404389|PLACEBO_COMPARATOR|Vehicle to NMC|Vehicle to nanomedicinal cream (NMC) Twice daily applications
62055465|NCT02404389|PLACEBO_COMPARATOR|Vehicle to LCC|Vehicle to liquid crystal cream (LCC) Twice daily applications
62055466|NCT02404389|ACTIVE_COMPARATOR|Aldara|Aldara cream 3 applications per week
62055467|NCT04378322|ACTIVE_COMPARATOR|Nutrition and food purchasing tool + telenutrition|Participants will use an online nutrition and food purchasing tool in addition to telenutrition.
62055468|NCT04378322|ACTIVE_COMPARATOR|Nutrition and food purchasing tool|Participants will use an online nutrition and food purchasing tool.
62055469|NCT04378322|ACTIVE_COMPARATOR|Nutrition education tool|Participants will be exposed to an online nutrition education materials.
62055470|NCT01330316|EXPERIMENTAL|BI 201335 for 24 weeks|BI 201335 once daily dose for 24 weeks in combination with PegIFN/RBV for 24 or 48 weeks
62257976|NCT05002270|EXPERIMENTAL|Experimental: Arm B, JAB-21822 combination with Cetuximab, Phase 2, Dose Expansion|JAB-21822 will be administered together with Cetuximab in mCRC patients to evaluate the preliminary antitumor activity.
62257977|NCT04821037|EXPERIMENTAL|ACT|"A digitally-based ACT program will be conducted in two half-day workshops via meeting software (e.g. Zoom) consisting of:~1. mindfulness exercises, for stress reduction and to guide nurses to observe their painful thoughts and feelings that they are attempting to avoid;~2. ACT-metaphors, to let nurses realize the cost of struggling with psychological distress often create more distress;~3. experiential exercises, to guide nurses to notice their own experiences in providing nursing care throughout their nursing career and explore any special qualities;~4. explore the nurses' values with respect to different areas in their lives."
62257978|NCT00609986|EXPERIMENTAL|Intensive|The experimental group will receive the intravenous regular insulin infusion protocol for the maintenance of blood sugar levels 70-110 mg/dL while hospitalized up to 7 am post operative day #3 and after hospitalization will receive subcutaneous insulin to maintain blood sugar levels 70-140 mg/dL.
62055471|NCT05578950|ACTIVE_COMPARATOR|group A pulse therapy of itraconazole|patients with pulse therapy group recieved oral itraconazole 100 mg, two capsules twice daily for 7 days a month
62614997|NCT05056571|NO_INTERVENTION|Control|No attempt will be made during the research.
62257979|NCT00609986|ACTIVE_COMPARATOR|Control|The control group will receive subcutaneous insulin injections (NPH or glargine and aspartame) to maintain a blood sugar level between 70-180 mg/dL while hospitalized and after hospitalization subcutaneous insulin to maintain blood sugar levels 90-180 mg/dL.
62257980|NCT04024033|ACTIVE_COMPARATOR|capsule|patinets receiveing pine cone extract tablets
62055472|NCT05578950|ACTIVE_COMPARATOR|group B continous therapy of terbinafine|patients with continous therapy group , recieved continous oral 250 mg terbinafine once daily for 12 weeks continously
62614998|NCT02901301|EXPERIMENTAL|4 combination|pembrolizumab 200mg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 capecitabine 1000mg/m2, PO, BID, Day 1-14 cisplatin 80mg/m2 (level 1), IV, q3weeks, Day 1
62614999|NCT06274151|EXPERIMENTAL|Anti-inflammatory medicine|Week 2 after muscle strain injury Naproxen 500mg 2x daily
62257981|NCT04024033|PLACEBO_COMPARATOR|placebo capsule|patinets receiving placebo
62257982|NCT03831971|EXPERIMENTAL|ANS-6637 & Midazolam|Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8
62257983|NCT04597983|EXPERIMENTAL|2S-hesperidin|This group took 500 mg (capsules) per day at breakfast of 2S-hesperidin (Cardiose®) for 8 weeks
62615000|NCT06274151|PLACEBO_COMPARATOR|Placebo|Week 2 after muscle strain injury Placebo pill, no active compounds 2x daily
62615001|NCT03079076|ACTIVE_COMPARATOR|thoracolumbar interfascial plane block|Bilateral ultrasound guided thoracolumbar interfascial plane block with 20 ml %0,25 bupivacaine
62615002|NCT03079076|PLACEBO_COMPARATOR|sham block|Bilateral ultrasound guided sham block with 2 ml saline subcutaneously
62615003|NCT04833400|EXPERIMENTAL|Intelligent cardiopulmonary rehabilitation system (ICRS)|The ICRS is very likely to the conventional stationary biking, but with an algorithm that automatically controls the resistance of pedalling, considering the instant heart rate and cadence, to keep the heart rate within the targeted heart rate zone.
62615004|NCT04833400|ACTIVE_COMPARATOR|Traditional aerobic exercise training (TAET)|"The TAET is performed with stationary biking, with intensity being set as subjective rating of perceived exertion at a somewhat hard to hard level. The resistance of pedaling is ad-justed by the user or physical therapist."
62615005|NCT03955900||Participants with Multiple Myeloma (MM)|Participants with MM will be observed in real-world clinical practice settings. The primary data source for this study will be the medical records of each participant.
62615006|NCT04707560|EXPERIMENTAL|Heparin Wet first group|Heparin based wet suction method of EUS FNB will go first for 2 passes and then shift to dry suction method for another 2 passes.
62615007|NCT04707560|EXPERIMENTAL|Dry suction first group|Dry suction method of EUS FNB will go first for 2 passes and then shift to heparin base wet suction method for another 2 passes.
62055473|NCT03662074|EXPERIMENTAL|Treatment (gemcitabine, nivolumab)|Participants receive gemcitabine IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity
62055474|NCT01055730||Pulmonary rehabilitation|
62055475|NCT00449280|EXPERIMENTAL|A|Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken once a week until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.
62055476|NCT00449280|EXPERIMENTAL|B|Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.
62257984|NCT04597983|PLACEBO_COMPARATOR|Placebo|This group took 500 mg of microcellulose (capsules) per day at breakfast for 8 weeks
62257985|NCT04032600|OTHER|Full paracentesis|All ascites is drained
62257986|NCT04032600|OTHER|Fractioned paracentesis|3 Liters are drained, then the drain is clamped and the rest of the ascites is drained on the next day
62257987|NCT05773521||SILAP patients|This cohort is composed by all pediatric patients operated on for SILAP between January 1st, 2012 and August 31, 2022.
62257988|NCT04474769|EXPERIMENTAL|Educational intervention|Intervention group's preceptors is given an eight-hour education entity about orientation and preceptorship. The objective is to enhance preceptors' knowledge and skills about the orientation and to give preceptors means to precept new graduate nurses better.
62257989|NCT04474769|NO_INTERVENTION|No intervention|Nursing units at the control group continue to precept as before.
62257990|NCT01381302||Parkinson|Early onset of disease
62257991|NCT03924349|EXPERIMENTAL|ICG clip|Three clips are fixed in three directions (120 degrees apart) at the distal of the lesion (just distal) before surgery
62257992|NCT05681000|EXPERIMENTAL|Utidelone Capsule at 25 mg/m2/d for 5 days|Cohort 1: 2 subjects are planned to take Utidelone Capsule at 25 mg/m2/d by QD for 5 consecutive days in a 21-day cycle.
62444700|NCT05468164|EXPERIMENTAL|Selpercatinib and omeprazole administered in ABDC treatment sequence.|"Period 1: Single oral dose of Selpercatinib administered in fasted state. Period 2: Single oral dose of Selpercatinib administered in fed state. Period 3: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fed state.~Period 4: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fasted state.~Periods 1 and 2, 2 and 3 will be separated by a 7-day washout period. There will be no washout between Periods 3 and 4."
62615008|NCT03013985|EXPERIMENTAL|Basal bolus insulin with glargine U300 and glulisine insulin|Subjects treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as basal bolus insulin regimen with glargine U300 once daily plus rapid-acting glulisine insulin before meals. In insulin-naïve subjects treated with oral agents, the oral antidiabetic drugs will be discontinued and the bolus insulin dose described above will be given. Half of TDD will be given as glargine U300 and half as glulisine. To prevent hypoglycemia, if a subject is not able to eat, the dose of glulisine will be held.
62615009|NCT03013985|ACTIVE_COMPARATOR|Basal bolus insulin with glargine U100 and glulisine insulin|Subjects treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as basal bolus insulin regimen with glargine U100 once daily plus rapid-acting glulisine insulin before meals. In insulin-naïve subjects treated with oral agents, the oral antidiabetic drugs will be discontinued and the bolus insulin dose as described above will be given. Half of TDD will be given as glargine U100 and half as glulisine. To prevent hypoglycemia, if a subject is not able to eat, the dose of glulisine will be held.
62615010|NCT04697654|EXPERIMENTAL|TLC19 (low dose)|TLC19 2ml single dose
62055477|NCT00449280|EXPERIMENTAL|C|Rapamycin once a week starting on Day 1. Beginning on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.
62055478|NCT00449280|EXPERIMENTAL|D|Rapamycin every day beginning on Day 1. Starting on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.
62615011|NCT04697654|EXPERIMENTAL|TLC19 (medium dose)|TLC19 4ml single dose
62615012|NCT04697654|EXPERIMENTAL|TLC19 (high dose)|TLC19 6ml single dose
62615013|NCT04697654|SHAM_COMPARATOR|TLC19 Vehicle (low dose)|TLC19 Vehicle 2ml single dose
62055479|NCT03088709|EXPERIMENTAL|All patients will receive Haploidentical|"The choice of the chemotherapy treatment for transplantation will be up to the investigator. Post-transplant cyclophosphamide will serve as the backbone of the immunosuppression treatment to prevent GVHD. All patients will receive a Haplo-identical stem cell transplantation.~GVHD Prevention Treatment:~Cyclophosphamide 50mg/kg will be administered IV on Day 3 and Day 5 post transplant.~Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth starting on day of transplant and continue approximately 100 days post-transplant.~Mycophenolate mofetil 15mg/kg will be administered twice a day IV until patient can take it by mouth starting on Day 1 post transplant until 28 days."
62055480|NCT04010630|NO_INTERVENTION|control group|The physicians will resuscitate the patients according to the current critical care medicine guidelines.
62615014|NCT04697654|SHAM_COMPARATOR|TLC19 Vehicle (medium dose)|TLC19 Vehicle 4ml single dose
62615015|NCT04697654|SHAM_COMPARATOR|TLC19 Vehicle (high dose)|TLC19 Vehicle 6ml single dose
62055481|NCT04010630|EXPERIMENTAL|Sodium bicarbonate group|Patients randomly assigned to bicarbonate group will receive intravenous 4.2% sodium bicarbonate titrated from 125ml to 250ml in 30min at physician's discretion to target a pH equal or above 7.30. Bicarbonate infusion will be repeated up to 1000ml per 24h. Arterial blood gases will be repeated from 3 to 6 times during the first 24h at physician's discretion
62055482|NCT05769738|EXPERIMENTAL|Furosemide group|Inhaled furosemide
62055483|NCT05769738|PLACEBO_COMPARATOR|Placebo group|Inhaled saline
62055484|NCT03550833||Rheumatoid Arthritis patients|patients affected by RA according to ACR/EULAR 2010 criteria, with a disease duration less than 2 years
62055485|NCT03550833||control patients|patients with a visceral surgery for less than 2 years (appendectomy, cholecystectomy, bowel obstruction, hernia, eventration...)
62055486|NCT02516722|EXPERIMENTAL|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
62055487|NCT01435655|EXPERIMENTAL|open|tafamidis
62055488|NCT05904470|EXPERIMENTAL|Bemnifosbuvir and Ruzasvir|"Bemnifosbuvir (BEM; AT-527) Tablets~Ruzasvir (RZR; AT-038) Capsules"
62615016|NCT00507988|EXPERIMENTAL|A|Complex Problem Solving Training
62615017|NCT00507988|ACTIVE_COMPARATOR|B|Basic Cognitive Training
62615018|NCT00886925|ACTIVE_COMPARATOR|Albumin|
62615019|NCT00886925|PLACEBO_COMPARATOR|Saline|
62615020|NCT05553535||cases|cases of rotator cuff calcific tendinosis on imaging studies
62615021|NCT05553535||witnesses|differential diagnosis or normal cases
62615022|NCT05492422|EXPERIMENTAL|CET-then-BPT|Families receive CET in Phase 1 followed by BPT in Phase 2
62615023|NCT05492422|EXPERIMENTAL|BPT-then-CET|Families receive BPT in Phase 1 followed by CET in Phase 2
62615024|NCT05492422|EXPERIMENTAL|Waitlist then CET+BPT|Families do not receive either intervention in Phase 1 and then receive both CET and BPT concurrently in Phase 2
62615025|NCT05492422|EXPERIMENTAL|CET+BPT then 'waitlist' (follow-up)|Families receive CET and BPT concurrently in Phase 1, and then are followed in Phase 2 with not additional intervention
62615026|NCT01275963||Control|Healthy individuals without structural heart disease
62615027|NCT01275963||CAD|Patients with coronary artery disease
62615028|NCT01275963||DCM|Participants with dilated cardiomyopathy
62615029|NCT01275963||HNCM|Patients with hypertrophic non-obstructive cardiomyopathy
62257993|NCT05681000|EXPERIMENTAL|Utidelone Capsule at 50 mg/m2/d for 5 days|Cohort 2: 2 subjects are planned to take Utidelone Capsule at 50 mg/m2/d by QD for 5 consecutive days in a 21-day cycle.
62839925|NCT03651570|NO_INTERVENTION|Usually Care Control Group|The Otolaryngology - Head and Neck Surgery (OHNS) Departments do not offer systematic interventions on anxiety and self-management, neither does any intervention address stigma. However, participating recruitment centres are already offering a best-of-care approach with well-established psychosocial oncology services, including psychiatrists, psychologists, social workers, nurses, and volunteers. All participants will be free to use hospital- or community-based support throughout the study, which will be tracked in all groups via questionnaire and chart review.
62257994|NCT05681000|EXPERIMENTAL|Utidelone Capsule at 75 mg/m2/d for 5 days|Cohort 3: 3-6 subjects are planned to take Utidelone Capsule at 75 mg/m2/d by QD for 5 consecutive days in a 21-day cycle.
62615030|NCT01275963||HOCM|Patients with hypertrophic obstructive cardiomyopathy
62615031|NCT01275963||RCM|Patients with restrictive cardiomyopathy
62839926|NCT01669681||Included in the cohort COBRA|
62839927|NCT01486095|EXPERIMENTAL|AXXESS + Biomatrix|After mandatory predilatation, a self-expanding, conically shaped nickel-titanium AXXESS biolimus A9-eluting stent is placed at the level of the carina. The device is available in 3.0 and 3.5 mm calibre and 11 and 14 mm length. Depending on the lesion anatomy, additional Biomatrix™ Drug Eluting Coronary Stent Systems are placed distally if necessary. The procedure is completed with kissing balloon postdilatation using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
62839928|NCT01486095|ACTIVE_COMPARATOR|Culotte technique: Xience V/Prime|The culotte technique consists of stenting one of both branches of the bifurcation lesion first, and after balloon dilatation of the stent meshes, stenting the uncovered branch through the first stent and leaving the main vessel covered with two overlapped stents. The procedure is terminated by kissing balloon dilatation of both branches using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
62839929|NCT04016766|EXPERIMENTAL|Prepartying mobile app intervention|Mobile app intervention
62839930|NCT04016766|NO_INTERVENTION|Control|Control participants receive a personalized attention control task (i.e., listing and ranking favorite movies, music, and books), which controls for the time needed by the intervention group to view the intervention material.
62839931|NCT03238495|ACTIVE_COMPARATOR|Chemotherapy Only|Taxotere, Carboplatin, Herceptin + Pertuzumab (TCH+P)
62839932|NCT03238495|EXPERIMENTAL|Chemotherapy plus Metformin|TCH+P plus metformin
62839933|NCT02900040||patients with kidney transplantations|patients with kidney transplantations
62839934|NCT00662441|EXPERIMENTAL|Arm 1|
62444701|NCT05468164|EXPERIMENTAL|Selpercatinib and omeprazole administered in BACD treatment sequence.|"Period 1: Single oral dose of Selpercatinib administered in fed state. Period 2: Single oral dose of Selpercatinib administered in fasted state. Period 3: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fasted state.~Period 4: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fed state.~Periods 1 and 2, 2 and 3 will be separated by a 7-day washout period. There will be no washout between Periods 3 and 4."
62615032|NCT01275963||Amyloidosis|Patients with cardiac manifestation of amyloidosis
62615033|NCT01275963||HFPEF|Patients with heart failure with preserved ejection fraction (diastolic heart failure)
62623632|NCT03256357|ACTIVE_COMPARATOR|CIMT + AOT|"In a 2-week day camp model children receive constraint-induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.~Action observation training consists of 15 sessions of 1 hour. Children watch video sequences showing goal-directed actions and subsequently execute the observed actions with the affected upper limb."
62839935|NCT05400382|EXPERIMENTAL|Mindfulness|Receiving mobile, self-guided mindfulness intervention
62839936|NCT05400382|NO_INTERVENTION|Treatment as usual with monitoring|Receiving treatment as usual with monitoring by study PI and investigators.
62839937|NCT02157883|EXPERIMENTAL|AZD9291 alone, AZD9291+itraconozole|Sequential treatments of AZD9291 alone followed by AZD9291+itraconazole, with a washout period in between.
62839938|NCT01879098|PLACEBO_COMPARATOR|Placebo|Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
62839939|NCT01879098|EXPERIMENTAL|Probiotic: Bacillus subtilis|Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
62839940|NCT01879098|EXPERIMENTAL|Probiotic: Lactobacillus plantarum|Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
62839941|NCT01879098|EXPERIMENTAL|Probiotic: Bifidobacterium animalis|Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
62839942|NCT04545580|PLACEBO_COMPARATOR|Treatment period: Placebo|This arm consists of participants who complete the run-in period, and are still eligible, according to all in- and exclusion criteria for diagnosis of OAB with UUI based on bladder diary baseline data. Participants will be randomized to 12 weeks of double-blind treatment with matching placebo.
62839943|NCT04545580|EXPERIMENTAL|Treatment period: BAY1817080|This arm consists of participants who complete the run-in period, and are still eligible, according to all in- and exclusion criteria for diagnosis of OAB with UUI based on bladder diary baseline data. Participants will be randomized to 12 weeks of double-blind treatment with BAY1817080.
62257995|NCT05681000|EXPERIMENTAL|Utidelone Capsule at 100 mg/m2/d for 5 days|Cohort 4: 3-6 subjects are planned to take Utidelone Capsule at 100 mg/m2/d by QD for 5 consecutive days in a 21-day cycle.
62257996|NCT05681000|EXPERIMENTAL|Utidelone Capsule at 100 mg/m2/d for 7 days|Cohort 5: 3-6 subjects are planned to take Utidelone Capsule at 100 mg/m2/d by QD for 7 consecutive days in a 21-day cycle.
62055489|NCT05078060||VaxigripTetra®|Participant vaccinated with VaxigripTetra® as per routine clinical practice
62055490|NCT05078060||Efluelda®|Participant vaccinated with Efluelda® as per routine clinical practice
62444702|NCT05468164|EXPERIMENTAL|Selpercatinib and omeprazole administered in BADC treatment sequence.|"Period 1: Single oral dose of Selpercatinib administered in fed state. Period 2: Single oral dose of Selpercatinib administered in fasted state. Period 3: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fed state.~Period 4: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fasted state.~Periods 1 and 2, 2 and 3 will be separated by a 7-day washout period. There will be no washout between Periods 3 and 4."
62444703|NCT04928651||Clonidine|Preterm infants (\< gw 37+0) who are in need for analgesic or sedative medication will receive treatment with clonidine according to an algorithm based on pain and sedative scoring results
62444704|NCT06430879|ACTIVE_COMPARATOR|Active/Treatment|Data will be collected for athletes prior to first use of patch and then 2-3 days later with the active patch (VICTORY PATCH). Follow-up functional measurements will also be taken at 7 and 9-10 days after baseline with second crossover patch use 9-10 days post-baseline.
62055491|NCT06320301|EXPERIMENTAL|Adebrelimab + GEMOX + TKI|"Adebrelimab, 20 mg/kg, 30-minute intravenous infusion, once every 3 weeks (Q3W)~TKI:~Lenvatinib: 12 mg (3 capsules 4 mg) or 8 mg (2 capsules 4 mg) QD Apatinib: 250 mg orally, QD, 5 days on 2 days off or QOD Sorafenib: 0.4g (2 × 0.2g) twice or once daily Anlotinib: 12 mg orally before breakfast, QD. The drug was taken continuously for 2 weeks and stopped for 1 week.~GEMOX:~Gemcitabine 800mg/m2 and oxaliplatin 85mg/m2, IV, D2, D15, D29, until 6 cycles of treatment"
62055492|NCT01969019|ACTIVE_COMPARATOR|methylprednisolone|intravenous MP: 0.5g weekly for six weeks followed by 0.25g weekly for six weeks
62055493|NCT01969019|ACTIVE_COMPARATOR|methylprednisolone plus prednisone|intravenous MP 0.5g daily for three days per week, twice, followed by 0.25g daily for three days per week, twice, and followed by tapering oral prednisone (starting with 60mg/d, then10 mg less/week than each previous week for the next 3 weeks, then20mg/week at the 5th week followed with 5mg less/week than each previous week for the next 3 weeks)
62444705|NCT06430879|SHAM_COMPARATOR|Non-Active/Control|Data will be collected for athletes prior to first use of patch and then 2-3 days later with the inactive patch. Follow-up functional measurements will also be taken at 7 and 9-10 days after baseline with second crossover patch use 9-10 days post-baseline.
62444706|NCT06430879|OTHER|Crossover|Data will be collected for athletes prior to first use of patch and then 2-3 days later with the active or inactive patch. Follow-up functional measurements will also be taken at 7 and 9-10 days after baseline with second crossover patch use 9-10 days post-baseline.
62444707|NCT00453570|EXPERIMENTAL|1|DTacP IPV// PRP\~T combined vaccine at 2, 3 and 4 months of age, and a booster dose at 18-20 months of age.
62444708|NCT00453570|EXPERIMENTAL|2|DTacP-IPV// PRP\~T combined vaccine at 3, 4 and 5 months of age and a booster dose at 18-20 months of age.
62444709|NCT00453570|ACTIVE_COMPARATOR|3|Control vaccines at 3, 4 and 5 months of age and a booster dose at 18-20 months of age
62444710|NCT01022788|EXPERIMENTAL|Home-based counselling visits by volunteers|Home-based counselling in pregnancy and the first few days of life to encourage women and families to adopt key newborn care behaviours
62444711|NCT01022788|NO_INTERVENTION|Standard care through existing health system|
62444712|NCT06214897|EXPERIMENTAL|C-RUSF (Ready-to-use Supplemental Food with added choline)|A daily dose of 500 Kcal of RUSF containing 500mg choline will be provided
62444713|NCT06214897|ACTIVE_COMPARATOR|S-RUSF (Standard Ready-to-use Supplemental Food without added choline)|A daily dose of 500 Kcal of RUSF without choline
62444714|NCT04020107|ACTIVE_COMPARATOR|Compressive garment associated with physical therapy|
62444715|NCT04020107|PLACEBO_COMPARATOR|Low compressive garment associated with physical therapy|
62444716|NCT02862639|EXPERIMENTAL|injection of viscosupplementation and corticosteroid|experimental group
62444717|NCT02862639|ACTIVE_COMPARATOR|injection of corticosteroid|control group
62444718|NCT01787474|EXPERIMENTAL|Treatment (NK cells)|Patients receive filgrastim-sndz SC QD beginning on day -7 and continuing until ANC are equal or over 1000. Patients also receive fludarabine phosphate IV over 30 minutes and approximately 4 hours later followed by cytarabine IV over 1 hour on days -6 to -2 (days -6 to -3 for patients over age 60). Beginning 2-7 days after the last dose of fludarabine phosphate and cytarabine, patients receive membrane-bound interleukin-21-expanded haploidentical natural killer cells IV over 30 minutes thrice weekly for 3 doses over 4 days (Monday-Thursday only).
62444719|NCT02795104|EXPERIMENTAL|Arm I (TIDVD)|Educational Intervention via DVD: In this arm of the intervention participants watch a tailored interactive DVD program and answer questions posed by the DVD program.
62839944|NCT04079140|EXPERIMENTAL|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by the patient 12 hours before IUD insertion.
62839945|NCT04079140|PLACEBO_COMPARATOR|placebo|one tablet of placebo self-administered by the patient 12 hours before IUD insertion.
62055494|NCT03532438||NTM patient group|NTM lung disease patients living together
62055495|NCT00806234|ACTIVE_COMPARATOR|1|Participants will continue on current antipsychotic medication.
62055496|NCT00806234|EXPERIMENTAL|2|Participants will undergo a staggered switch from current antipsychotic medication to aripiprazole or perphenazine.
62055497|NCT00806234|EXPERIMENTAL|3|Participants will add metformin to current antipsychotic medication treatment.
62257997|NCT05681000|EXPERIMENTAL|Utidelone Capsule at 120 mg/m2/d for 7 days|Cohort 6: 3-6 subjects are planned to take Utidelone Capsule at 120 mg/m2/d by QD for 7 consecutive days in a 21-day cycle.
62055498|NCT01886001|EXPERIMENTAL|Povidone-Iodine (Betadine)|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
62055499|NCT01886001|EXPERIMENTAL|Chlorhexidine|Umbilical stump care. ChloraPrep® Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
62055500|NCT01886001|EXPERIMENTAL|Pluronic|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied once a day to cord stump while umbilical line(s) are in place
62055501|NCT01886001|SHAM_COMPARATOR|Control (no application)|Control arm, no product is applied, which is standard of care.
62257998|NCT00388700|EXPERIMENTAL|GM-CT-01|
62839946|NCT01463449||Obese|Obese subjects half with type 2-diabetes. Before and after gastric bypass. Expected reduction in weight 25 %. We expect a reduction in low grade inflammation in adipose tissue after weight loss.
62257999|NCT01295528||Blood Pressure, Heart Rate, Monitor|
62839947|NCT00779155|PLACEBO_COMPARATOR|Inactive Resonator Therapy|Inactive magnetic resonance therapy
62839948|NCT00779155|ACTIVE_COMPARATOR|Active Resonator Therapy|active magnetic resonance therapy
62839949|NCT05927155|EXPERIMENTAL|LABA (olodaterol)|After 4-5 days washout period, during the first visit, participants received a long-acting beta2-agonist (LABA)
62839950|NCT05927155|EXPERIMENTAL|LAMA (tiotropium)|Two days after the first visit, during the second visit , participants received a long-acting muscarinic antagonist (LAMA)
62839951|NCT02790411|EXPERIMENTAL|healthy volunteers|Imaging devices New Non Invasive Devices
62839952|NCT02062619|EXPERIMENTAL|Real tDCS|"Transcranial direct current stimulation (tDCS) administered concurrently with computer-based behavioural word reading therapy.~2mA anodal direct current stimulation applied to the left inferior frontal gyrus (IFG) for first 20 minutes of therapy."
62258000|NCT02347098|EXPERIMENTAL|intensive LDL-lowering therapy (ILLT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to LDL-apheresis and an oral daily dose of 40-80mg of Atorvastatin or equivalent.
62839953|NCT02062619|SHAM_COMPARATOR|Sham tDCS|"Transcranial direct current stimulation (tDCS) administered concurrently with computer-based behavioural word reading therapy.~Sham tDCS (periodical fade-in and fade-out stimulation routine) applied to the left inferior frontal gyrus (IFG) for first 20 minutes of therapy."
62444720|NCT02795104|EXPERIMENTAL|Arm II (TIDVD, PN)|Educational Intervention-DVD \& Telephone based Navigation: In this arm of the intervention participants watch a TIDVD and are called by a patient navigator.
62444721|NCT02795104|EXPERIMENTAL|Arm III (UC)|Educational Intervention via brochure: In this arm of the intervention participants receive brochures that explain and provide information and encouragement for cancer screening.
62258001|NCT02347098|ACTIVE_COMPARATOR|standard statin monotherapy (SMT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to an oral daily dose of 40-80mg of Atorvastatin or equivalent without LDL-apheresis
62258002|NCT02651584|EXPERIMENTAL|SL BPN/NX tabs + placebo SC injections|"SL BPN/NX: 2 mg/0.5 mg or 8 mg/2 mg BPN/naloxone tablets administered daily, at doses of 8 mg/2 mg to 32 mg/8 mg per day.~CAM2038 placebo: 0.16, 0.32, 0.48 and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w)."
62444722|NCT02916979|OTHER|Conditioning Regimen|Fludarabine, Busulfan, Rabbit ATG, Methotrexate
62839954|NCT05761548||mature|
62839955|NCT05761548||preterm|
62839956|NCT01398306||Group A|Patients with clear cell renal cell carcinoma with metastases.
62839957|NCT01398306||Group B|Patients with low grade neuro-endocrine tumours with metastases.
62839958|NCT04867096|EXPERIMENTAL|Physical activity intervention|"Arm A : standard oncologic care coupled with physical activity intervention (3 times / week)  during 3 months."
62839959|NCT04867096|NO_INTERVENTION|Control|"Arm B : standard oncologic care."
62839960|NCT02481661|EXPERIMENTAL|segmentectomy|Patients undergo anatomic segmentectomy by minimal incision thoracotomy or thoracoscopy/VATS.
62839961|NCT02481661|ACTIVE_COMPARATOR|lobectomy|Patients undergo lobectomy by minimal incision thoracotomy or thoracoscopy/VATS.
62839962|NCT02640456||Para- or retropharyngeal abscess|Patients with para- or retropharyngeal abscess.
62839963|NCT02640456||Neck abscess|Patients with neck abscess without relation to the pharynx or salivary glands.
62839964|NCT00772317|EXPERIMENTAL|HIFU|High Intensity Focused Ultrasound
62839965|NCT01796366|EXPERIMENTAL|Insulin 338 + placebo|
62839966|NCT01796366|ACTIVE_COMPARATOR|Insulin glargine + placebo|
62839967|NCT01253577|ACTIVE_COMPARATOR|Drug Coated|Sinus stent coated with steroid
62839968|NCT01253577|PLACEBO_COMPARATOR|Non coated|Sinus stent without drug coating
62839969|NCT05046561|ACTIVE_COMPARATOR|STRI Formula|STRI Formula 3 capsules by mouth twice daily for 10 days
62839970|NCT05046561|PLACEBO_COMPARATOR|Placebo|Placebo 3 capsules by mouth twice daily for 10 days
62839971|NCT05275504|EXPERIMENTAL|Dose Escalation for TT-01488|TT-01488 tablets will be administered once daily in a 28-day cycle in increasing strength in order to determine the recommended dose for dose expansion.
62055502|NCT01916655|PLACEBO_COMPARATOR|Usual Care|standard and typical PAP (Positive Airway Pressure) educational and support protocol
62055503|NCT01916655|EXPERIMENTAL|Self-Management Care|Individualized self-management educational and support protocol
62055504|NCT01916655|EXPERIMENTAL|Self-Management Mobile Care|Individualized self-management educational and support protocol delivered in part by mobile health tool
62055505|NCT03375476||Vascular surgical patients|Patients undergoing elective vascular non-cardiac surgery in general anesthesia
62055506|NCT01368900|EXPERIMENTAL|Ulthera System Treatment|Ulthera treatment to the upper face.
62055507|NCT06068231|EXPERIMENTAL|early loading group|Early Loading Group: Implants were loaded with temporary restorations between 48 hours and 3 months after implantation and had occlusal contact with opposing dentition. The early loading time point was set at 6-8 weeks after implantation in this study.
62055508|NCT06068231|ACTIVE_COMPARATOR|Conventional Loading Group|Implants were loaded at least 3 months after implantation and had occlusal contact with opposing dentition.
62055509|NCT01521962|EXPERIMENTAL|SYR-322 (Alogliptin) QD|SYR-322 25 mg, orally.
62055510|NCT01521962|PLACEBO_COMPARATOR|Insulin|injection
62055511|NCT02081950|EXPERIMENTAL|Enoxaparin sodium|Enoxaparin sodium (80mg) is administered subcutaneously as a single dose, in 2 periods.
62615034|NCT05589402|EXPERIMENTAL|Lidocaine Cream 5%|"A topical anesthetic will be used to deliver temporary inactivation of muscle sensation. Specifically, due to its high safety profile, Lidocaine Cream 5% will be used in the current sub-study. Lidocaine cream (5%) is FDA-approved and available over-the-counter. The investigators will apply the lidocaine cream 5% following FDA guidelines and previously published protocol methodology. A test will be utilized to evaluate if the approach provides complete and temporary inactivation of sensation from the biceps. The von Frey filament test will be used with filaments ranging in size (1,65 to 6,65) to be placed on the biceps muscle every 15 minutes after lidocaine application.~Based on published work, and the current investigators' pilot data, it is anticipated that all sensations from the biceps should be blocked approximately 30 to 60 minutes after lidocaine application. Complete temporary inactivation will be defined at the point when all baseline sensation can no longer be achieved."
62623633|NCT03256357|PLACEBO_COMPARATOR|CIMT + POT|"In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.~Placebo observation training consists of 15 sessions of 1 hour.This group performs the same actions after watching computer games without biological movements."
62623634|NCT06002659|EXPERIMENTAL|Treatment|CAR20(NAP)-T treatment
62623635|NCT01408082|EXPERIMENTAL|ISV-502|
62623636|NCT01408082|ACTIVE_COMPARATOR|AzaSite|
62839972|NCT05275504|EXPERIMENTAL|Dose Expansion for TT-01488|TT-01488 tablets will be administered once daily in 28-day cycles to verify the safety and preliminary efficacy as observed in the dose escalation cohorts.
62055512|NCT04828564|EXPERIMENTAL|Ribavirin Arm|"Ribavirin dosage: 200 mg oral ribavirin capsules for 5 days~Regimen: 1200 mg loading dose on day-1 (three capsules in the morning and three capsules in the evening) followed by 800 mg/day maintenance dose (two capsules in the morning and two capsules in the evening) on day-2 to day-5."
62055513|NCT04828564|ACTIVE_COMPARATOR|Favipiravir Arm|"Favipiravir dosage: 200 mg oral favipiravir tablets for 5 days~Regimen: 2x1600 mg loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5."
62623637|NCT01408082|ACTIVE_COMPARATOR|Dexamethasone|
62623638|NCT01408082|PLACEBO_COMPARATOR|Vehicle|
62055514|NCT06389201|EXPERIMENTAL|Pretreatment with an autophagy inhibitor (HCQ) before chemotherapy and radiotherapy|Hydroxychloroquine (HCQ), is used one day before chemotherapy and radiotherapy, 400-600mg, oral tablet, once. During chemotherapy and radiotherapy, HCQ maintenance dose is 200-400mg daily.
62055515|NCT06389201|PLACEBO_COMPARATOR|Receive placebo before and during chemotherapy and radiotherapy|Placebos are used one day before chemotherapy and radiotherapy, and during the therapy.
62055516|NCT04376398||COVID-19|Any pediatric or adult patient with COVID-19 or suspected of COVID-19 scheduled for any intervention
62055517|NCT00622011|EXPERIMENTAL|1|zotepine , start from 50mg/day then titrate according to individual case
62055518|NCT00622011|ACTIVE_COMPARATOR|2|Risperidone, start from 1mg/day
62055519|NCT00915135|EXPERIMENTAL|Ramelteon QD and Placebo QD (25 possible combinations total)|
62055520|NCT03915210||Candidates of HSCT|Physical activity level using a metabolic holter device, dynamic lung volumes (FEV1, FVC, FEV1/FVC, PEF, FEF25-75%) using a spirometer and quality of life using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 version 3.0 were objectively evaluated.
62615035|NCT05589402|OTHER|Rehabilitation Movement Training|"During temporary deafferentation, subjects will perform movement training. Similar to other single-session studies, the current investigators chose to pair the paradigm with movement training to bolster the effects of the approach.~A reaching task that is commonly performed in rehabilitation will be used. Task practice will be performed for 1 hour, with breaks given every 10 minutes. Past experiments in the current investigators' lab have adopted a similar protocol for task practice in SCI and found no adverse events. Movement training will also be assisted by the Bionik InMotion Arm/Hand robot, which has been studied in clinical and rehabilitative practices for over 20 years.~Movement training at 1 hour will be ceased due to issues with fatigue, as has been noted in previous SCI clinical studies. In addition, published work suggests that lidocaine has a half-life of one 1 hour. Thus, maximum benefits should be achieved at the 1-hour mark after application."
62615036|NCT05837546|EXPERIMENTAL|Real dog|presence of a real dog, contact with participant for 5 minutes
62615037|NCT05837546|ACTIVE_COMPARATOR|replica dog|presence of a replica dog, contact with participant for 5 minutes
62258003|NCT02651584|EXPERIMENTAL|CAM2038 SC injections + SL placebo tabs|"CAM2038 q1w: BPN FluidCrystal® SC injection depot for once weekly administration (50 mg/mL) at doses of 8, 16, 24 or 32 mg (BPN base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).~CAM2038 q4w: BPN FluidCrystal® SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (BPN base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).~SL placebo: tablets matching 2 mg/0.5 mg and 8 mg/2 mg SL BPN doses, administered daily"
62258004|NCT02829242||Prostatic Surgery|Patient scheduled for a robotic assisted laparoscopic prostatic surgery.
62615038|NCT05837546|ACTIVE_COMPARATOR|plant|presence of a plant, contact with participant for 5 minutes
62615039|NCT03768921|EXPERIMENTAL|PEEP Titriation|patients with respiratory distress syndrome will undergo alveolar recruitment in the mechanical ventilator and will have their final positive mechanical ventilator pressure determined by ventilator evaluation by the electrical impedance tomograph. The increase of the peep in the mechanical ventilator to perform the alveolar recruitment will be of 2 in 2 cmH2O every 2 minutes until the pressure reaches 25 cmH20, after the pressure was reduced in the same way being evaluated in the tomograph what will be the point with greater alveolar recruitment, having greater ventilation, without alveolar hyperdistension or alveolar collapse.
62258005|NCT02829242||Colorectal Surgery|Patient scheduled for a robotic assisted laparoscopic colorectal surgery.
62258006|NCT05316402|EXPERIMENTAL|training on the risks associated with sun exposure|power point on the risks associated with sun exposure
62258007|NCT04178694|EXPERIMENTAL|non-invasive ventilation|All subjects will be submitted to non-invasive ventilation with different settings. During the whole period indirect calorimetry will be performed and haemodynamic parameters will be monitored using a non-invasive device. Reversed combined RPE scale will be asked on a regular base.
62258008|NCT04082403|ACTIVE_COMPARATOR|Pre SALAD education group|Each trainee was asked to intubate a mannequin with a contaminated airway
62258009|NCT04082403|EXPERIMENTAL|Post SALAD education group|Each trainee was asked to intubate a mannequin with a contaminated airway after receiving SALAD training
62615040|NCT03230136|EXPERIMENTAL|Multimodal cardioprotection therapeutic strategy|
62258010|NCT02520687|EXPERIMENTAL|Dietary nitrate, beetroot juice|Once daily 70mL dose of beetroot juice, containing 400mg inorganic nitrate, for 7 consecutive days.
62258011|NCT02520687|PLACEBO_COMPARATOR|Nitrate-depleted beetroot juice|Once daily 70mL dose of beetroot juice, depleted of nitrate, for 7 consecutive days.
62258012|NCT06075342||elite athlete|training year \> 10 years and weekly training time \> 20 hours
62258013|NCT06075342||casual player|training year \< 10 years and weekly training time \< 20 hours
62258014|NCT06075342||healthy control|healthy participants with irregular exercise habits
62055521|NCT03915210||Healthy individuals|Physical activity level using a metabolic holter device, dynamic lung volumes (FEV1, FVC, FEV1/FVC, PEF, FEF25-75%) using a spirometer and quality of life using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 version 3.0 were objectively evaluated.
62055522|NCT03621202|EXPERIMENTAL|Saranas Early Bird Bleed Monitoring System (EBBMS)|
62055523|NCT00584935|EXPERIMENTAL|Rituximab|The Rituximab dose is 1000 mg (1gm) given as an IV infusion every two weeks for 2 doses (Days 1 and 15).
62055524|NCT05672602||LONG COVID patients|Measurement of ncRNAs and cytokines in patients with new diseases or intermittent or permanent symptoms after COVID-19 at the moment of the recruitment
62055525|NCT05672602||Controls|Measurement of ncRNAs and cytokines in Individuals who have never suffered from COVID-19 at the moment of the recruitment
62258015|NCT06075342||first responder|first responders with regular exercise training
62258016|NCT04673292|EXPERIMENTAL|Fixed site SOC testing|Fixed site Standard of Care (SOC) testing
62258017|NCT04673292|EXPERIMENTAL|Community-based testing|Community-based, mobile van testing
62258018|NCT04673292|EXPERIMENTAL|Self-collected testing|Self-collected, home-based testing
62444723|NCT01506323|EXPERIMENTAL|Mantram Repetition Program (MRP)|"A portable meditation-based Mantram Repetition Program (MRP) will be delivered individually in 8-weekly 1 hour sessions to teach a set of strategies for training attention to manage symptoms. For this study, the program targets symptoms of posttraumatic stress disorder (PTSD) in Veterans who have experienced military-related trauma."
62444724|NCT01506323|ACTIVE_COMPARATOR|Present Centered Therapy (PCT)|Present Centered Therapy (PCT) is a form of individually-delivered 8-weekly, 1 hour sessions that are problem-oriented to improve current coping. For this study, it served as an attention control arm for the non-specific effects of individual therapist interaction.
62444725|NCT01628120|EXPERIMENTAL|Epoetin Hospira|Epoetin Hospira will be administered by SC bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.
62444726|NCT00176904|EXPERIMENTAL|Treated Patients|All patients treated with protocol regimen (chemotherapy and surgery).
62444727|NCT05403411|EXPERIMENTAL|Intervention group|Distance education for nursing students on critical thinking
62444728|NCT05403411|NO_INTERVENTION|Control group|The control group was given a booklet for critical thinking.
62444729|NCT05582733|EXPERIMENTAL|Cervical spine manipulation|In spinal manipulation, the velocity, magnitude and direction of the impulse are controlled to encourage relaxation and comfort of muscle and connective tissue.
62444730|NCT05582733|EXPERIMENTAL|traction|aimed to relieve pressure on the spine
62615041|NCT03230136|ACTIVE_COMPARATOR|Traditional anesthetic and therapeutic|standard anesthetic procedure No intervention (Control).
62615042|NCT00768339|EXPERIMENTAL|1|Single agent AEG35156 as 2hr IV infusion, weekly dosing in Patients with relapsed or refractory chronic lymphocytic leukemia and indolent B-cell lymphomas
62615043|NCT03647423|EXPERIMENTAL|NANT Chordoma Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin Hydrochloride HCI, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK, avelumab, cetuximab, cyclophosphamide, SBRT.
62615044|NCT03647423|ACTIVE_COMPARATOR|Controlled Arm - Radiation|SBRT
62444731|NCT05598437||A|Left eye
62615045|NCT02401061|EXPERIMENTAL|PRTX-100|Patients will be assigned to consecutive PRTX-100 interventions as they are enrolled into the study. Between two and six patients will be enrolled per intervention level. Intervention levels range from one (1) to twenty four (24) micrograms of PRTX-100 per kilogram of patient weight. Patients may receive up to four weekly infusions of PRTX-100 over the study treatment period. PRTX-100 doses ≤ 500 μg will be infused intravenously over 30 minutes. PRTX-100 doses \> 500 μg will be infused over 60 minutes. Patients will remain under observation for 4 hours after completion of PRTX-100 dosing for safety management.
62615046|NCT00404924|PLACEBO_COMPARATOR|1|Best Supportive Care
62615047|NCT00404924|EXPERIMENTAL|2|Vandetanib + Best Supportive Care
62615048|NCT03757403|EXPERIMENTAL|RDD1609 followed by Placebo|Application on the perianal area BID
62615049|NCT03757403|EXPERIMENTAL|Placebo followed by RDD1609|Application on the perianal area BID
62615050|NCT05563935|ACTIVE_COMPARATOR|OCD group|OCD patients will receive rTMS treatment for 6 weeks.
62615051|NCT05563935|NO_INTERVENTION|HC group|Health control will not receive any treatment.
62055526|NCT05672602||Asymptomatic LONG COVID patients|Measurement of ncRNAs and cytokines in patients who have never suffered from LONG COVID symptoms or with only resolved symptoms at the moment of the recruitment
62615052|NCT04712513||Patients with coronary artery disease and hemodynamically stable|
62615053|NCT06305260|NO_INTERVENTION|Traditional Lumbar Palpation|This group will include parturients who are randomized to traditional lumbar palpation prior to epidural placement. This is the current standard of care.
62615054|NCT06305260|EXPERIMENTAL|Pre-procedural Lumbar Ultrasound|This group will include parturients who are randomized to a pre-procedural lumbar ultrasound prior to epidural placement.
62615055|NCT03865394|EXPERIMENTAL|Allogeneic ADSC cells in fibrin solution|"Application of allogeneic ADSC stem cells in fibrin gel, to cover wound surface with thin cells layer.~Therapy is based on standard procedure of diabetic foot ulcer treatment combined with application of allogeneic ADSC stem cells in fibrin solution onto the wound surface."
62615056|NCT03865394|ACTIVE_COMPARATOR|Standard care in diabetic foot ulcer with aplication of fibrin gel to cover wound surface.|Application of fibrin gel to cover wound surface.
62055527|NCT05147610|EXPERIMENTAL|patients requiring an IOP (intra-Ocular Pression) measurement|group representing adults patients in ophthalmologic consultation requiring an IOP measurement
62055528|NCT04735744||Prospective cohort|Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) that treat patients recovering from COVID-19 in Dutch primary care
62258019|NCT04026724||Exposed group|Chinese patent medicine combined with western medicine routine treatment
62258020|NCT04026724||Non-exposed group|Western medicine routine treatment
62258021|NCT02004431||Pain (experimental)|The cases are patients with significant pain on day one after surgery
62258022|NCT02004431||No pain (control)|The controls are sex, age and operation matched individuals without pain.
62055529|NCT04735744||Retrospective cohort|Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) that have been treated patients recovering from COVID-19 in Dutch primary care
62258023|NCT01636973|EXPERIMENTAL|Vaporizing humidifier|Vaporizing humidifier applying during one-lung ventilation
62055530|NCT00551070|EXPERIMENTAL|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62258024|NCT02170883|EXPERIMENTAL|Interactive SMS|"Intervention with interactive SMS (text messaging) by which patients are asked to disclose their level of agreement with the following statement I follow my asthma medication plan and pharmacist follow-up"
62444732|NCT05598437||B|Right eye
62444733|NCT06271811|ACTIVE_COMPARATOR|Control group|"The intervention protocol is centered on neuromuscular training, targeting the strengthening of key muscle groups including the quadriceps, hamstrings, and hip abductors, which are vital for knee stabilization. This approach is supported by previous research, emphasizing the importance of these muscle groups in knee joint health. Complementing this, proprioceptive exercises, such as single-leg balances and controlled knee bends, were incorporated to enhance joint position sense, aligning with the guidelines set forth by Powers et al., 2010.~The intensity of these exercises is progressively increased, tailored to each patient's tolerance and improvement. The protocol stipulates two sessions per week over eight weeks."
62615057|NCT02205697|EXPERIMENTAL|Implementation intention|The entire cohort will be asked to create an implementation intention to increase their intake of fruit and vegetables over the study period.
62615058|NCT03020394||Noninvasive ventilation|Noninvasive positive pressure ventilation is achieved by Philips Respironics V60/Vision ventilator. Choose bilevel positive airway pressure mode, and adjust the fraction of inspire oxygen(FiO2) or oxygen flow rate to maintain patient's oxygen saturation(SpO2) between 88% to 92%. Parameter adjustment and weaning of NPPV follow the protocols used before.
62615059|NCT03020394||Invasive ventilation|Intubated immediately and connected to the ventilator. Parameter adjustment and weaning of IPPV follow the protocols used before.
62615060|NCT03020394||High flow nasal cannula|High flow nasal cannula of different models (large, medium and small) are selected depending on the size and comfort of the patient's nostrils. Adjusting the oxygen flow rate (O2 Flow) maintains the patient's SpO2 88% to 92%. The flow was initially adjusted to 25 L/min and the flow was gradually adjusted to the patient's maximum tolerance. The inspiratory gas temperature (31 to 37 °C) was set to the patient's maximum tolerance level. If the patient's condition deteriorates and the tracheal intubation standard is met , the patient is recommended to undergo invasive ventilation treatment, but the choice of the final respiratory support method should be decided by the attending physician, patient and family.
62615061|NCT02055274|EXPERIMENTAL|LY03003|4 Stable doses of LY03003 14, 28, 42 and 56 mg
62055531|NCT00846638|EXPERIMENTAL|1|Diagnostic assessment with brief intervention and 3, 6, and 12 month follow-up
62055532|NCT00846638|ACTIVE_COMPARATOR|2|Diagnostic assessment with 12 month follow-up
62055533|NCT04769323|EXPERIMENTAL|Group 1|Group 1 use virtual reality.
62055534|NCT04769323|EXPERIMENTAL|Group 2|Group 2 do traditional home exercises.
62055535|NCT04769323|EXPERIMENTAL|Group 3|Group 3 do traditional home exercises and virtual reality.
62055536|NCT04504201||Early Breast Cancer Patients|Early breast cancer patients (Stage I-III) who have completed primary treatment with a current Body mass index (BMI) over 30.
62055537|NCT04504201||Medical Oncology Clinicians|Oncology providers associated with community-based practices
62055538|NCT01718743|EXPERIMENTAL|Treatment (ixazomib citrate, lenalidomide)|Beginning 60-180 days post-transplant, patients receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62258025|NCT02170883|ACTIVE_COMPARATOR|Usual care|Pharmacist conducted patient education, counseling and action-plan
62258026|NCT04468542|EXPERIMENTAL|Bupivacaine/triamcinolone injection|2-cc injection (mixture consisting of 1-cc of 0.5% Bupivacaine injection and 1cc of 40mg/cc triamcinolone acetonide suspension injection) will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
62258027|NCT04468542|PLACEBO_COMPARATOR|Saline injection|2-cc injection of normal saline will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
62055539|NCT01919359|EXPERIMENTAL|Facial filler w/vitamin,Placebo/Resurfacing w/vitamin, placebo|Multizyme 150C 2 caps 2 times/day between meals Day of tx for 30 days Cyruta Plus 90T 1 cap 3 times/day 30 days before and after tx or Multizyme 150C 2caps 2 times/day between meals Day of Tx for 30 days; SHEP 2caps 2 times/day 30 days before and after Tx Cellular Vitality 90C 1cap 3 times/day 30 days before and after Tx
62055540|NCT01919359|PLACEBO_COMPARATOR|Soft Tissue filler sugar pill|"Placebo Analog 2tabs 2 times/day between meals; Day of tx for 30 days; Placebo Analog 1tab 3 times/day 30 days before and after tx or Placebo Analog (A) 2~1cap 2 times/day between meals; Day of Tx for 30 days Placebo Analog (B) 2caps 2 times/day 30 days before and after Tx Placebo Analog (C) 1cap 3 times/day 30 days before and after Tx"
62055541|NCT00082732|EXPERIMENTAL|Arm I: Dietary Intervention|Nutritional counseling on a low-fat, high-fiber, soy supplemented diet and behavior-based activities, such as goal-setting, contracting, and stimulus control, once weekly for 6 weeks, every 3 weeks for 33 weeks, and then at weeks 44, 48, and 52.
62055542|NCT00082732|NO_INTERVENTION|Arm II: Observation|Observation every 6 weeks for 36 weeks and then every 8 weeks for 18 weeks.
62839973|NCT06232824|EXPERIMENTAL|Intervention|"Participants in the intervention group coud only view the rehabilitation content that needs to be carried out at the current phase every day and confirm whether to execute it on the application. Participants could communicate with therapists on the mobile phone application by sending text, voice, images, and videos throughout the entire experiment.~Participants in the intervention group received detailed education and rehabilitation program on the mobile phone application including text, photos, and videos. On the first day of enrollment, the doctor inform the participants of the importance of rehabilitation and how to use the mobile phone application. The postoperative rehabilitation protocol includes four phases: Phase 1 (0-2 weeks), Phase 2 (3-4 weeks), Phase 3 (5-8 weeks), Phase 4 (9-12 weeks), and Phase 5 (after 13 weeks)."
62839974|NCT06232824|NO_INTERVENTION|Control|"Participants in the control group could only receive a graphic and textual minimal postoperative rehabilitation plan on the mobile phone application. However, the participants was not informed the frequency and intensity of the rehabilitation items. They could not communicate with therapists online. Participants in the control group was expected to exercise unsupervised postoperatively.~At the 2, 4, 8, 12, and 24 weeks after ACLR, all participants went to the outpatient clinic for follow-up by physiotherapist to provide face-to-face guidance for exercise methods. Physiotherapist would clarify the content of the rehabilitation plan if any doubt, but will not provide information extending the prearranged scope."
62839975|NCT00248768|OTHER|Arm 1|
62839976|NCT03470298|ACTIVE_COMPARATOR|Mid luteal Endometrial Scratching (MLES)|Making injury to endometrium by using Manual Vacuum Aspiration cannula size 5 . At this arm scratching done at mid luteal phase (day21) of the cycle before induction for ICSI
62839977|NCT03470298|ACTIVE_COMPARATOR|Retrieval Endometrial Scratching (RES)|Making injury to endometrium by using Manual Vacuum Aspiration cannula size 5 .Here scratching done at same day of ovum pick up of ICSI cycle the difference only between arm of MLES and RES only in the timing of scratching .
62615062|NCT02055274|ACTIVE_COMPARATOR|Neupro|Neupro patch 2 mg/24 hours in the first week, and then be titrated to 4, 6 and 8 mg/24 hours at weekly intervals
62615063|NCT02055274|ACTIVE_COMPARATOR|Neupro PK|Neupro patch 2 mg/24hr in the first week then titrated to 4 and 6mg/24hr
62615064|NCT03124537|EXPERIMENTAL|App Control Condition|The control group will just have the App with the accelerometer program to set step goals and to count and record steps for 1 month
62839978|NCT06441240||Breast cancer patients underwent neoadjuvant chemotherapy|Patients undergoing neoadjuvant chemotherapy and subsequent surgical treatment. Patients must have undergone radiological evaluation by MRI at the beginning and end of chemotherapy treatment
62839979|NCT04366817|EXPERIMENTAL|women in postpartum period|
62258028|NCT00111800|PLACEBO_COMPARATOR|Placebo|Participants received oral dose of matching placebo capsule to denagliptin (DEN) once daily in the morning, 30 minutes (min) prior to breakfast during the main phase 12-weeks treatment period. Participants who were randomized to placebo in the main phase 12-weeks treatment period received oral dose of DEN 2.5 milligram (mg) once daily in the morning, 30 min prior to breakfast during the extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of placebo to the participants.
62055543|NCT02864225|EXPERIMENTAL|Scalp electrode, fetal doppler and EUM|Once in labor, the parturient will be connected to the routine fetal doppler and EUM. When necessary according to clinical indications, the scalp electrode will be connected. Tracing will be recorded simultaneously from all three devices until delivery.
62055544|NCT01538472|EXPERIMENTAL|Y Zevalin + BEAM|"Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with BCNU (300 mg/m2, intravenously (IV) day -6) VP-16 (200 mg/m2 IV every 12 hours, days -5 to -2) cytarabine (200 mg/m2 IV every 12 hours, days -5 to -2) and melphalan (140 mg/m2 IV day -1). Autologous stem cell infused on day 0 then Rituximab 1000 mg/m2 on days +1, and +8 post transplantation.~G-CSF 5 mg/kg given daily starting Day 0 till recovery of granulocytes of 4.0 \* 109/L."
62055545|NCT05602545|EXPERIMENTAL|Test-1|patients with peri-implantitis
62839980|NCT04664127||Combination therapy (Kagocel + Valacyclovir: n=25)|Therapy according to routine practice (including Kagocel). Groups will be splitted during the final data analysis.
62258029|NCT00111800|EXPERIMENTAL|DEN 2.5 mg|Participants received oral dose of DEN 2.5 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 2.5 mg to the participants.
62258030|NCT00111800|EXPERIMENTAL|DEN 7.5 mg|Participants received oral dose of DEN 7.5 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 7.5 mg to the participants.
62615065|NCT03124537|EXPERIMENTAL|App Experimental condition|The experimental condition will set step goals and have the schedule, map, and social components for 1 month.
62839981|NCT04664127||Monotherapy by Valacyclovir (n=20)|Therapy according to routine practice. Groups will be splitted during the final data analysis.
62839982|NCT04560699|ACTIVE_COMPARATOR|Physiotherapeutic group|medical care and physiotherapeutic treatment
62615066|NCT01991899|EXPERIMENTAL|MMR Bio-Manguinhos|Arm 1:1170 children will receive MMR Bio-Manguinhos, 3 diferents lots
62055546|NCT05602545|EXPERIMENTAL|Test-2|patients with peri-implant mucositis
62055547|NCT05602545|OTHER|control|patients with peri-implant health
62055548|NCT06063798|EXPERIMENTAL|Flow Controlled Ventilation Group|Ventilation by Flow Controlled Ventilation mode Patient is scheduled for elective laryngotracheal surgery under general anesthesia. The ventilation mode for this group is Flow Controlled Ventilation mode.
62055549|NCT06063798|ACTIVE_COMPARATOR|High Frequency Jet ventilation Group|Ventilation by High Frequency Jet ventilation mode Patient is scheduled for elective laryngotracheal surgery under general anesthesia. The ventilation mode for this group is High Frequency Jet ventilation mode.
62615067|NCT01991899|ACTIVE_COMPARATOR|MMR GlaxoSmithKline|Arm 2:390 children will receive MMR GlaxoSmithKline
62615068|NCT00428922|EXPERIMENTAL|Trastuzumab, Bevacizumab, and Docetaxel|Trastuzumab \[6mg/kg\], Bevacizumab \[15mg/kg\], and Docetaxel \[75 mg/M²\]
62615069|NCT02227719|EXPERIMENTAL|Test: CTI|CTI is titanium mesh
62615070|NCT02227719|ACTIVE_COMPARATOR|Control: Collagen membrane|Collagen membrane is used for ridge augmentation
62615071|NCT04843358|EXPERIMENTAL|Emotional Disclosure|Participants in the emotional disclosure arm will be told to write continuously for 20 min about their deepest thoughts and feelings regarding their breast cancer experience
62055550|NCT01718028|EXPERIMENTAL|SYSTANE® BALANCE|Propylene glycol 0.6% ocular emulsion, 1 drop in each eye 4 times a day for 30 days
62055551|NCT01718028|ACTIVE_COMPARATOR|LARMABAK®|Sodium chloride 0.9% saline solution, 1 drop in each eye 4 times a day for 30 days
62055552|NCT02249455|EXPERIMENTAL|Acapella|Acapella is given to the patients twice daily for 20 min.
62055553|NCT02249455|EXPERIMENTAL|ELTGOL|Expiration with open glottis in lateral position is done twice daily for 20 min
62615072|NCT04843358|ACTIVE_COMPARATOR|Non-Emotional Writing|Participant allocated to the control group will be asked to describe in detail their daily activities in a non-emotional manner in accord with Pennebaker's published instructions
62839983|NCT04560699|ACTIVE_COMPARATOR|medical care group|Medical care
62839984|NCT01356277|EXPERIMENTAL|Multi-component Intervention|"Multi-component Intervention consisting of:~* Adherence Support Team (patient, parent, Coach)~* standardized education on immunosuppressive medications~* identification of adherence barriers~* Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals~* 'Action-Focused Problem-Solving' to address barriers selected as most important by the patient~* text message, email, or visual cue dose reminders"
62839985|NCT01356277|NO_INTERVENTION|Attention control|Control group study visits were conducted at the same intervals as intervention visits and consisted of the Coach engaging in active listening and providing non-specific support only. Adherence was NOT discussed with control participants.
62839986|NCT02346721|EXPERIMENTAL|SOF/VEL|SOF/VEL for 12 weeks
62839987|NCT03252925|EXPERIMENTAL|Experimental Group|N-Acetylcysteine
62055554|NCT02249455|ACTIVE_COMPARATOR|conventional physiotherapy|Conventional physiotherapy like breathing exercise, active coughing, chest mobilisation was encouraged twice daily for 20 min.
62055555|NCT02461810|EXPERIMENTAL|SpineJack® system|VCF treatment system Vertebral fracture surgery
62055556|NCT02461810|ACTIVE_COMPARATOR|Balloon Kyphoplasty|VCF treatment system Vertebral fracture surgery
62055557|NCT00423384|EXPERIMENTAL|1|Ibandronate
62055558|NCT00423384|PLACEBO_COMPARATOR|2|
62055559|NCT00871637||Group One|Healthy non-smoking controls
62055560|NCT00871637||Group Two|Smoking adults with chronic bronchitis/chronic obstructive pulmonary disease
62055561|NCT00871637||Group Three|Non-smoking adults with chronic bronchitis/chronic obstructive pulmonary disease
62055562|NCT06116565|EXPERIMENTAL|CM310|
62055563|NCT03914599||Neurological Disorder|For all neurological disorder participants an electromyography (EMG) study will be done to determine nerve conduction speed, and a blood draw will be completed for genetic (DNA) testing. Motor measures, cognitive measures and surveys will be completed to assess walking and brain processing speed. Four optional assessments will be offered and only completed if the participant consents to them and include: optical coherence tomography (pictures of the back of the eye), visual evoked potential (to evaluate the nerve pathways of the eye), brain MRI, and skin biopsy. For participants with a diagnosis of Charcot Marie Tooth (CMT) disease, they will have an additional Neuropathy Score to assess disease severity.
62055564|NCT03914599||Healthy Control|An electromyography (EMG) study will be done to determine nerve conduction speed, and a blood draw will be completed for genetic (DNA) testing. Motor measures, cognitive measures and surveys will be completed to assess walking and brain processing speed. Four optional assessments will be offered and only completed if the participant consents to them and include: optical coherence tomography (pictures of the back of the eye), visual evoked potential (to evaluate the nerve pathways of the eye), brain MRI, and skin biopsy.
62258031|NCT00111800|EXPERIMENTAL|DEN 15 mg|Participants received oral dose of DEN 15 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 15 mg to the participants.
62258032|NCT00111800|EXPERIMENTAL|DEN 30 mg|Participants received oral dose of DEN 30 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 30 mg to the participants.
62258033|NCT00111800|EXPERIMENTAL|DEN 45 mg|Participants received oral dose of DEN 45 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 45 mg to the participants.
62615073|NCT01555710|EXPERIMENTAL|Palifosfamide-tris plus Carboplatin and Etoposide|Drug: palifosfamide-tris in combination with carboplatin and etoposide palifosfamide-tris: 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. carboplatin: AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a max of 6 cycles.
62615074|NCT01555710|ACTIVE_COMPARATOR|Carboplatin plus Etoposide|Drug: carboplatin in combination with etoposide carboplatin: AUC 5mg/mL/min 1 day every 21 days for a maximum of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
62623639|NCT03117361|EXPERIMENTAL|Experimental|"Plitidepsin + bortezomib + dexamethasone~Plitidepsin will be administered as a 3-hour intravenous (i.v.) infusion on Day(D) 1 and 15 , every four weeks (q4wk)~Bortezomib will be administered as a bolus subcutaneous (s.c.) injection on D 1, 4, 8 and 11,q4wk~Dexamethasone will be taken orally on D1,8,15 and 22, q4wk"
62623640|NCT00980733|ACTIVE_COMPARATOR|Fortified Yoghurt|Yoghurt with fortification of Micronutrients, yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
62839988|NCT03252925|PLACEBO_COMPARATOR|Control Group|Placebo Oral Tablet
62623641|NCT00980733|PLACEBO_COMPARATOR|Yoghurt|Plain Yoghurt same as in fortified arm but without fortification
62839989|NCT02256280|EXPERIMENTAL|S Group|Sugammadex 2 or 4 mg/kg iv once at the end of surgery
62839990|NCT02256280|ACTIVE_COMPARATOR|N Group|Neostigmine 0.05 or 0.07 mg/kg (+ atropine 0.02 mg/kg) iv once at the end of surgery
62839991|NCT03751917||APL patients|The study will be conducted using multinational data from disease registries for APL. The study participants will consist of patients with newly diagnosed, low-to intermediate-risk APL.
62839992|NCT01415414||Group 1|
62839993|NCT01075542|EXPERIMENTAL|Toric intraocular lens|Bilateral Toric intraocular lens implantation in cataract surgery
62055565|NCT03114280|EXPERIMENTAL|TPF2|docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days followed by radiotherapy (RT) combined with carboplatin
62258034|NCT00883662||Group 1|
62258035|NCT01306448|EXPERIMENTAL|vibrating capsule|
62839994|NCT01075542|OTHER|Monofocal intraocular lens|Bilateral Monofocal intraocular lens implantation in cataract surgery
62839995|NCT01340846|EXPERIMENTAL|Part A|Warfarin dosed at 15mg
62258036|NCT05690854||Case|"The study will include patients aged ≥ 18 years with the diagnosis of L-TGA and D-TGA, who:~* are admitted to IRCCS Policlinico San Donato, the Adult Congenital Heart Unit or~* are scheduled for a Cardiovascular Magnetic Resonance examination in this Institution"
62839996|NCT01340846|EXPERIMENTAL|Part B|Ketoconazole dosed at 400mg
62839997|NCT01340846|EXPERIMENTAL|Part C|Gemfibrozil dosed at 600mg
62839998|NCT01340846|EXPERIMENTAL|Part D|GSK2118436 dosed alone
62258037|NCT05690854||Control|The study will include subjects aged ≥ 18 years who will invited for a Cardiovascular Magnetic Resonance examination in our Institution. This group of control will include n=15 of adult healthy subjects. A further inclusion criteria for the control subjects are age and male proportion comparable to those of the TGA group.
62055566|NCT03821090||cases|"Eighty rheumatoid arthritis patients fulfilling American College of Rheumatology (ACR) 2010 classification criteria, all of them will be subjected to~1. History including disease duration , course and associated diseases~2. Clinical examination with specific joint examination~3. RA disease activity will be evaluated by a 28- joint DAS (DAS28). 4-12-lead ECG~5-Echocardiography 6-Carotid intima media thickness using carotid doppler 7-Venous blood will be withdrawn to do the following laboratory tests~1. Complete Blood Count(CBC)~2. Erythrocyte Sedimentation Rate (ESR) \&C Reactive Protein(CRP)~3. Rheumatoid Factor (RF)\& anti cyclic citrullinated peptide (Anti-CCP)~4. Urine analysis , Urea and creatinine ,~5. Uric acid level~6. Lipogram~7. HA1C~8. TNF α~9. hs-cTnI"
62615075|NCT06171594|ACTIVE_COMPARATOR|Active chlorhexidine|"Arm Description 2: Antibacterial CHX Mouthwash Arm~This arm involves participants who have been randomly assigned to receive an antibacterial CHX mouthwash containing 0.2% CHX (Corsodyl Mint, GlaxoSmithKline, UK). Similar to Arm 1, the intervention period spans seven days, during which participants will rinse their mouth with 10 mL of antibacterial CHX mouthwash twice daily. The active CHX mouthwash and the placebo mouthwash are indistinguishable in taste, appearance, color, texture, and smell. Participants in this arm will follow the rinse regimen for 7 days, taking the final tube the morning before their next visit (Visit 2 - 8). After the completion of Visit 8, each participant will undergo a washout period of 12 weeks before starting the 7-day reverse order of the given product administration as part of the crossover design."
62258038|NCT00503594|EXPERIMENTAL|1|Comparative evaluation of the efficiency of a new protocol of the primitive LYMPHOME of the central nervous system ( LPSNC) to the old subject, associating Methotrexate and Temozolomide with regard to a standard protocol associating Methotrexate, Procarbazine, Vincristine and Cytarabine.
62623642|NCT00980733|NO_INTERVENTION|Control|Non blinded group given no intervention
62839999|NCT01752777|EXPERIMENTAL|Infectiousness Risk Reduction|Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
62258039|NCT00503594|ACTIVE_COMPARATOR|bras conventional|bras conventional
62258040|NCT04605302|EXPERIMENTAL|Single Arm Tandem Study|Patients are assigned to swallow a magnetically controlled capsule first then undergo standard gastroscopy
62258041|NCT06211894||the urethra at the bladder neck to the nearest proximal edge of the tape: < 5 mm|Patients who achieved continence after surgery were split into two subgroups based on the distance from the posterior of the urethra at the bladder neck to the nearest proximal edge of the tape: \< 5 mm and \>5 mm. The position of the sling along the urethra was measured as a percentage of urethral length and referred to as the sling percentile. This measurement was calculated as follows: the proximal urethral length (distance from the sling's proximal point to the bladder neck) divided by the total urethral length (distance from the bladder neck to the external urethral meatus) on the sagittal plane, where the bladder neck and the external urethral meatus represent 0% and 100% of urethral length, respectively. Additionally, perineal ultrasound was used to evaluate various parameters including bladder descent, pubo-urethral distance, urethral thickness, detrusor thickness, cystocele descent, rectal descent, and uterine descent.
62444734|NCT06271811|EXPERIMENTAL|Intervention group|The application of flossing to the knee commences with a preliminary evaluation of the joint range of motion and pain perception. The band is wrapped around the knee, starting with an approximate tension of 50% for the first wrap and escalating to a tension of 60-80% in subsequent wraps. It is essential to overlap the band with each wrap, moving from a distal to the proximal direction (bottom to top), which aids in enhancing drainage. Continuous monitoring of the patient is critical to ensure that excessive pressure is not being applied. This can be achieved by palpating the pulse on the dorsum of the foot or inner ankle, and observing if the skin regains its normal color after pressing the area with fingers. Should the patient experience strong tingling or pain, the bandage must be immediately removed. The duration of the band's application varies between 2 to 5 minutes, depending on patient tolerance, a methodology informed by existing research.
62840000|NCT01752777|SHAM_COMPARATOR|General Health Improvement|Participants in this condition receive education conducted in one office session followed by 4 cell-phone-based sessions. The education sessions focus on raising awareness of health services and health improvement strategies.
62840001|NCT01704209|EXPERIMENTAL|Fibroblast Treatment|The fibroblast treatment will be randomly injected into one side of the face.
62444735|NCT00712595|EXPERIMENTAL|1|Mifepristone 10 mg daily for three months
62444736|NCT00712595|EXPERIMENTAL|2|Mifepristone 5 mg daily for three months
62444737|NCT03858881|ACTIVE_COMPARATOR|PROJECT PERSONALITY|
62444738|NCT03858881|EXPERIMENTAL|VR PERSONALITY PROJECT|
62840002|NCT01704209|PLACEBO_COMPARATOR|Vehicle|The vehicle will be injected randomly to the other side of the face.
62840003|NCT01357525|OTHER|Stereotactic Body Radiotherapy|
62840004|NCT00755183|EXPERIMENTAL|testosterone ophthalmic solution|testosterone ophthalmic solution 0.03%
62840005|NCT00755183|PLACEBO_COMPARATOR|vehicle|vehicle of testosterone ophthalmic solution
62615076|NCT06171594|PLACEBO_COMPARATOR|Placebo Chlorhexidine|"Arm Description 1: Placebo CHX Mouthwash Arm~This arm involves participants who have been randomly assigned to receive a placebo CHX mouthwash. The intervention period spans seven days, during which participants in this arm will rinse their mouth with 10 mL of CHX placebo mouthwash (ultrapure mint-flavoured water) twice daily. The placebo mouthwash is designed to be identical in taste, appearance, colour, texture, and smell to the active mouthwash, ensuring blinding during the study. Participants in this arm will follow the rinse regimen for 7 days, taking the final tube the morning before their next visit (Visit 2 - 8). After the completion of Visit 8, each participant will undergo a washout period of 12 weeks before starting the 7-day reverse order of the given product administration as part of the crossover design."
62615077|NCT00005796|EXPERIMENTAL|Single arm|PCV therapy
62615078|NCT00696228|PLACEBO_COMPARATOR|AFN A|High Fat Diet Placebo
62055567|NCT03821090||control|"Eighty healthy subjects age and sex matched will be included , all of them will be subjected to~1. History~2. Clinical examination . 3-12-lead ECG~4-Echocardiography 5-Carotid intima media thickness using carotid doppler 6-Venous blood will be withdrawn to do the following laboratory tests~1. Complete Blood Count (CBC)~2. ESR \& CRP~3. RF\& Anti-CCP~4. Urine analysis , Urea and creatinine~5. Uric acid level~6. Lipogram~7. HA1C~8. TNF α~9. hs-cTnI"
62055568|NCT01170338|EXPERIMENTAL|active Chantix|active drug to help smoking cessation
62055569|NCT01170338|PLACEBO_COMPARATOR|sugar pill|
62444739|NCT03858881|PLACEBO_COMPARATOR|SHARING FEELINGS PROGRAM|
62615079|NCT00696228|EXPERIMENTAL|AFN B|MUFA
62615080|NCT00696228|EXPERIMENTAL|AFN C|PUFA
62840006|NCT00354978|EXPERIMENTAL|FOLFIRI plus Bevacizumab|FOLFIRI \[folinic acid (leucovorin) 400 mg/m\^2 by vein (IV) Day 1; 5-FU 400 mg/m\^2 IV injection Day 1 immediately followed by 2.4 g/m\^2 IV over 46 hours over Days 1-3; Irinotecan 180 mg/m\^2 IV on Day 1\] + Bevacizumab 5 mg/kg over 90 minutes on Day 1 administered alone then 5 mg/kg IV on Day 1 of 14 day cycle.
62840007|NCT02736578|EXPERIMENTAL|Cetuximab IRDye800, 50 mg|On day 0, participants receive a 100 mg cetuximab loading dose by intravenous infusion (IV), followed 1 hour later by cetuximab-IRDye 800CW IV at 50 mg, followed by surgery with intraoperative imaging within 2 to 5 days.
62840008|NCT02736578|EXPERIMENTAL|Cetuximab IRDye800, 100 mg|On day 0, participants receive a 100 mg cetuximab loading dose by intravenous infusion (IV), followed 1 hour later by cetuximab-IRDye 800CW IV at 100 mg, followed by surgery with intraoperative imaging within 2 to 5 days.
62840009|NCT03858309|EXPERIMENTAL|Breathing Group 1|Arm 1 will receive an 8-week intervention that consists of a set of breathing practices through 60-minute weekly group on-site sessions (1day/week) with a 20-minute daily home sessions (in between on-site sessions; 6 days/week).
62840010|NCT03858309|ACTIVE_COMPARATOR|Breathing Group 2|Arm 2 will receive an 8-week intervention that consists of slow breathing practices through 60-minute weekly group on-site sessions (1day/week) with a 20-minute daily home sessions (in between on-site sessions; 6 days/week).
62840011|NCT03636893|EXPERIMENTAL|FLOT Chemotherapy regimen|"A total of four preoperative and four postoperative cycles of FLOT chemotherapy administered~A cycle consists of Day 1 5-fluorouracil(5-FU) 2600mg/M2 administered via an intravenous peripherally inserted central venous catheter(PICC) for 24 hour Leucovorin 200mg/M2 intravenous Oxaliplatin 85mg/ M2 intravenous Docetaxel 50mg/M2 intravenous~Repeated every 15th day"
62055570|NCT03287739||Single-group study|Assessment of behavioral biometric impairments
62055571|NCT00066430|EXPERIMENTAL|Infrared coagulator|
62615081|NCT00696228|EXPERIMENTAL|AFN D|SFA
62615082|NCT02372435|EXPERIMENTAL|Short interval|"Re-Implantation of the prosthesis after a short interval of 2-3 weeks after explantation (fast-track-arm)."
62615083|NCT02372435|ACTIVE_COMPARATOR|Long interval|Re-Implantation of the prosthesis after a Long interval of 6-10 weeks (standard surgical treatment).
62623643|NCT05473793|EXPERIMENTAL|Highest fiber dose|This arm receives the highest dose of the intervention product, which is 15g dried vegetable per day divided into two portions of each 7.5g, which are consumed during the course of the day in the food of choice.
62055572|NCT01473498|EXPERIMENTAL|Test group|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients (A maximum dose of 1.2 mcg / kg / min is not exceeded). Key details, e.g., for drugs include dosage form, dosage, frequency and duration."
62055573|NCT01473498|ACTIVE_COMPARATOR|Control group|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg."
62055574|NCT04520802||POCD|Patients with postoperative cognitive decline (POCD) after coronary artery bypass grafting (CABG) surgery
62444740|NCT00589095||1|
62444741|NCT03724006|EXPERIMENTAL|INTERVENTION group (I)|Group I will be composed by parents of children with the diagnosis of CHD who will receive a psychoeducational intervention plus usual routines of the Service.
62444742|NCT03724006|NO_INTERVENTION|CONTROL group (C)|Group C will be composed by parents of children with the diagnosis of CHD who will receive the usual routines of the Service. After completing the data collection, the possibility of receiving the psychoeducational intervention under study will be offered to this group.
62258042|NCT06211894||the urethra at the bladder neck to the nearest proximal edge of the tape: > 5 mm|Patients who achieved continence after surgery were split into two subgroups based on the distance from the posterior of the urethra at the bladder neck to the nearest proximal edge of the tape: \< 5 mm and \>5 mm. The position of the sling along the urethra was measured as a percentage of urethral length and referred to as the sling percentile. This measurement was calculated as follows: the proximal urethral length (distance from the sling's proximal point to the bladder neck) divided by the total urethral length (distance from the bladder neck to the external urethral meatus) on the sagittal plane, where the bladder neck and the external urethral meatus represent 0% and 100% of urethral length, respectively. Additionally, perineal ultrasound was used to evaluate various parameters including bladder descent, pubo-urethral distance, urethral thickness, detrusor thickness, cystocele descent, rectal descent, and uterine descent.
62258043|NCT04107415|EXPERIMENTAL|Yoga group|group doing yoga
62258044|NCT04107415|NO_INTERVENTION|No yoga group|group not doing yoga
62258045|NCT03525717|ACTIVE_COMPARATOR|Routine Dinner|"Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at routine dinner time (18:00) followed by a sleep study (23:00). Timing of dinner is the sole intervention distinguishing this arm from late dinner. This arm will cross-over to late dinner in random order."
62840012|NCT03636893|ACTIVE_COMPARATOR|SOX Chemotherapy regimen|"Three preoperative cycles and three postoperative cycles of SOX chemotherapy administered~A cycle consist of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily)~Repeated every 21st day"
62840013|NCT03103334|EXPERIMENTAL|Experimental A|Zeneo® - Methotrexate thigh to Methotrexate Biodim® thigh
62840014|NCT03103334|EXPERIMENTAL|Experimental B|Methotrexate Biodim® thigh to Zeneo® - Methotrexate thigh
62840015|NCT03103334|EXPERIMENTAL|Experimental C|Zeneo® - Methotrexate abdomen to Methotrexate Biodim® abdomen
62258046|NCT03525717|EXPERIMENTAL|Late Dinner|"Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (22:00) followed by a sleep study (23:00). Timing of dinner is the sole intervention distinguishing this arm from routine dinner. This arm will cross-over to routine dinner in random order."
62444743|NCT04461509|EXPERIMENTAL|ARM 1 (HIFU) - 18F-PSMA|10 mCi ±20% F18-PSMA injection
62444744|NCT04461509|EXPERIMENTAL|ARM 2 (RP) - 18F-PSMA|10 mCi ±20% F18-PSMA injection
62623644|NCT05473793|EXPERIMENTAL|Medium fiber dose|This arm receives the highest dose of the intervention product, which is 10g dried vegetable per day divided into two portions of each 5.0g, which are consumed during the course of the day in the food of choice.
62840016|NCT03103334|EXPERIMENTAL|Experimental D|Methotrexate Biodim® abdomen to Zeneo® - Methotrexate abdomen
62840017|NCT02708186|EXPERIMENTAL|Nelotanserin|Nelotanserin 80 mg
62840018|NCT02708186|PLACEBO_COMPARATOR|Placebo|Placebo
62840019|NCT03072108|EXPERIMENTAL|Bonolive|
62258047|NCT00843388|ACTIVE_COMPARATOR|1|60 days treatment with tablet hexalacton 25 mg OD.
62258048|NCT00843388|PLACEBO_COMPARATOR|2|Inactive drug of 25 mg OD
62258049|NCT03008642|EXPERIMENTAL|CO-Rebreathing|The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.
62444745|NCT00525109||1|Single family cohort
62444746|NCT02796027|EXPERIMENTAL|Experimental: BRIDGE|NSPs assigned to this arm would receive an integrated HIV service model
62444747|NCT02796027|NO_INTERVENTION|Pre-implementation|NSPs assigned to this arm would receive standard care (treatment as usual) and would not be exposed to the integrated HIV service model.
62840020|NCT03072108|PLACEBO_COMPARATOR|Placebo|
62840021|NCT05636670||SLE group|"1. The researcher signed the informed consent voluntarily;~2. Male or female patients aged 14-55 years;~3. Patients diagnosed with systemic lupus erythematosus are classified according to the European League against Rheumatism (EULAR)/American College of Rheumatology (ACR) joint classification criteria for SLE in 2019.~4. Patients who need to undergo head imaging examination according to the judgment of treating doctors, and the results of head imaging examination are not consistent with changes in cerebrovascular disease.~5. no antibiotics have been taken in the past 2 weeks;"
62840022|NCT05636670||NPSLE epilepsy group|"1. The researcher signed the informed consent voluntarily;~2. Male or female patients aged 14-55 years~3. Patients diagnosed with systemic lupus erythematosus are classified according to the European League against Rheumatism (EULAR)/American College of Rheumatology (ACR) joint classification criteria for SLE in 2019.~4. Patients who need MRI according to the judgment of the treating doctor, and reveal that the MRI suggests cerebrovascular disease;~5. no antibiotics have been taken in the past 2 weeks;"
62840023|NCT05636670||Healthy control group|"1. Male or female patient volunteers aged 14-55 from the Health Examination Center of Nanfang Hospital,~2. Voluntary signing of informed consent;~3. no systemic disease;~4. According to the judgment of the researchers, healthy volunteers matching SLE group in age, gender and education level were selected as the control group;"
62623645|NCT05473793|EXPERIMENTAL|Lowest fiber dose|This arm receives the highest dose of the intervention product, which is 5g dried vegetable per day divided into two portions of each 2.5g, which are consumed during the course of the day in the food of choice.
62840024|NCT05338814|EXPERIMENTAL|conventional neck exercises & scapular corrective exercise|isometric \& stretching exercises of neck plus scapular corrective exercise
62840025|NCT05338814|ACTIVE_COMPARATOR|conventional neck exercises|isometric \& stretching exercises of neck
62055575|NCT04520802||no POCD|Patients without postoperative cognitive decline (POCD) after coronary artery bypass grafting (CABG) surgery
62444748|NCT02444559|EXPERIMENTAL|Ropivacaine+Clonidine|Adductor Canal Block Ropivacaine 20ml 5mg/ml+ Clonidine 150ug
62444749|NCT02444559|PLACEBO_COMPARATOR|Ropivacaine+Placebo|Adductor Canal Block Ropivacaine 20ml 5mg/ml+ saline
62444750|NCT04847297||Preoperative biliary drainage and pancreatoduodenectomy|Patients receiving preoperative biliary drainage before the removal of the tumor.
62444751|NCT04847297||Pancreatoduodenectomy only|Patients undergoing only surgical intervention, without preoperative drainage.
62444752|NCT02368847|OTHER|Diagnostic tests|For any patient with a suspected urinary tract infection during the course of the study a basic questionnaire will have to be filled out and diagnostic tests (urine sample for culture, dipstick assay for the detection of nitrites and leukocyte- esterase and a POC CRP test) will have to be perform.
62840026|NCT02451709|EXPERIMENTAL|Feedback and alarms|"Standard education about importance of inhaled steroids and regular adherence to inhaled steroids after recruitment to study.~Randomized to receive an electronic adherence device ( activated smartinhaler or smartturbo - Nexus 6) with twice daily alarm reminders activated. Patient decides times, different times on weekdays and weekends if required. This device fitted to their regular preventer inhaler, patient aware of its presence and its purpose in the context of the study.~Reviewed in standard asthma clinic every 3 months for 12 months. At each clinic visit, adherence information downloaded from device and data shared with patient and family (feedback of adherence data). Discussion about adherence rates, and action planning for the next 3 months to improve adherence if necessary."
62623646|NCT05473793|PLACEBO_COMPARATOR|Control|This arm is the control arm receiving as placebo rice puff particles each day, whose amount corresponds iso-calorically to the medium fiber dosage (\~ 21 kcal/day).
62623647|NCT05499806||Acquired Brain Injury Patients|Questionnaire and, if the requirements are met, a neuropsychological assessment.
62623648|NCT05499806||Healthy volunteers|Questionnaire and, if the requirements are met, a neuropsychological assessment.
62623649|NCT02501161|EXPERIMENTAL|Insulin degludec/liraglutide QD + OAD(s)|
62055576|NCT00330915|EXPERIMENTAL|A|
62055577|NCT01694784|EXPERIMENTAL|Quantitative|In the quantitative arm, we will present harms as absolute risks in the Quantitative Information Sheet. Compared with other risk formats, absolute risks have been shown to improve understanding relative to other common risk formats.
62055578|NCT01694784|ACTIVE_COMPARATOR|Qualitative|In the qualitative arm, we will describe harms using verbal descriptors (such as rare, uncommon, fairly common, and common) in the Qualitative Information Sheet.
62055579|NCT01694784|EXPERIMENTAL|Narrative|In the narrative arm, we will present harms using patient narratives (i.e. descriptions in which patients describe their experience with decision making about potentially harmful screening services)in the Narrative Information Sheet. To address concerns in the literature that characteristics of the narrator independently influence narrative effect, we will present narratives in paper format with a banner of culturally diverse age-appropriate pictures shown at the top.
62055580|NCT01694784|EXPERIMENTAL|Framed|In the framed arm, we will frame not screening with potentially harmful services as beneficial (i.e. use a gain frame). In the Framed Information Sheet, we will highlight the harms that could be avoided by not getting screened.
62055581|NCT02427711|ACTIVE_COMPARATOR|Bipolar sealer|Prospective use of bipolar sealer for skin and knee capsule incision revisions of non-septic knee arthroplasty.
62055582|NCT02427711|PLACEBO_COMPARATOR|Scalpel|Conventional surgical incision with scalpel - data extracted from a retrospective group.
62055583|NCT01105026|EXPERIMENTAL|bioactive glass|
62055584|NCT04696913||Pulmonary Embolism Positive|As determined by CT Pulmonary Angiogram
62055585|NCT04696913||Pulmonary Embolism Negative|As determined by CT Pulmonary Angiogram
62055586|NCT03978325|ACTIVE_COMPARATOR|Control|This arm will complete a standard prehabilitation intervention.
62055587|NCT03978325|EXPERIMENTAL|HIIT Intervention|This group will complete a pre-operative high intensity interval training programme.
62055588|NCT05971914|EXPERIMENTAL|Autogenous tooth derived particulate graft and a novel split thickness papilla curtain flap|Extracted deciduous teeth were prepared immediately after removal according to the manufacturer's instructions with the Bonmaker® device. Ready to use autogenous tooth bone graft (ATB) was mixed with fibrin glue in 3D planned and printed plastic cuvettes to obtain a sticky graft closely matching the shape and extent of the bony defect. The preshaped sticky ATB graft was inserted and compacted in the cleft defect. Subsequently, the tension-free split thickness flap was repositioned by shifting all buccal surgical papillae mesially to the adjacent or the second adjacent interproximal space, depending on the horizontal extent of the cleft.
62055589|NCT06474897|EXPERIMENTAL|Ozone therapy group|Ozone therapy will be practiced to study group. Inject 10 ml of ozone gas (O2-O3) at a concentration of 10 µg/ml 3 times at one week intervals. All injections will be performed by the same experienced specialist doctor.
62055590|NCT06474897|EXPERIMENTAL|Mobilization group|Mulligan mobilization will be practiced to control group. Mobilizations will be performed once a week for 3 consecutive weeks. The first one is a seated position with the patient's arm in approximately 90° abduction. The patient will be asked to abduct the arm and at the same time the physiotherapist will perform posterio/lateral gliding of the shoulder head with the left hand.
62055591|NCT03168295|EXPERIMENTAL|Placebo first and then dapagliflozin|Renal transplant subjects with intact native kidneys with Type 2 Diabetes Mellitus receive dapagliflozin then placebo
62055592|NCT03168295|ACTIVE_COMPARATOR|Dapagliflozin first then placebo|Renal transplant subjects with intact native kidneys who are non-diabetic receive placebo then dapagliflozin
62055593|NCT03168295|OTHER|Control Group|Subjects who are type 2 diabetes mellitus who have not undergone renal transplant.
62055594|NCT01006200||Structural /dynamic airway obstruction|Obstructive granulation tissue formation after SEMS implantation was defined as granulation tissue obstructing the lumen of the SEMS under bronchoscopic examination.
62055595|NCT01199926|EXPERIMENTAL|Vitamin D|Participants in this arm consumed a 4000 IU vitamin D supplement daily for 12 weeks while participating in a resistance exercise training program.
62055596|NCT01199926|PLACEBO_COMPARATOR|Placebo|Participants in this arm consumed a placebo (microcrystalline cellulose) daily for 12 weeks while participating in a resistance exercise training program.
62055597|NCT00965926|EXPERIMENTAL|Low dose group|3 way cross-over. Fasting, normal diet and high-fat diet
62055598|NCT00965926|EXPERIMENTAL|High dose group|3 way cross-over. Fasting, normal diet and high-fat diet
62623650|NCT02501161|ACTIVE_COMPARATOR|insulin glargine QD + OAD(s)|
62840027|NCT02451709|ACTIVE_COMPARATOR|No feedback or alarms|"Standard education about importance of inhaled steroids and regular adherence to inhaled steroids after recruitment to study.~Randomized to receive an electronic adherence device. Deactivated Smartinhaler or Smartturbo.~Device not activated to play reminder alarms. This device fitted to their regular preventer inhaler, patient aware of its presence and its purpose in the context of the study.~Reviewed in standard asthma clinic every 3 months for 12 months. At each clinic visit, adherence information downloaded from device but data not shared with patient, and no adherence discussion."
62840028|NCT05295069|EXPERIMENTAL|The intervention group|To reduce postpartum depression among the primiparous puerperal women in the intervention group, and a nursing care program was implemented under the guidance of Levine's model. This program was applied with 7 home visits between the 8th and 80th postpartum days. Face-to-face training and training booklets were provided in home visits. As of the fourth home visit, Pilates exercises were performed.
62840029|NCT05295069|NO_INTERVENTION|The control group|In the control group women received routine postpartum care. No interventions were conducted other than routine postpartum care.
62840030|NCT05228951|EXPERIMENTAL|Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor dalpiciclib, trastuzumab and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
62840031|NCT04845503|EXPERIMENTAL|MR-guided Radiotherapy (5 x 7,5 Gy)|5 x 7,5 Gy prescribed on the PTV
62840032|NCT02003599|PLACEBO_COMPARATOR|Placebo|"In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .~Both arm will use institutional skin care protocol."
62444753|NCT02371798|EXPERIMENTAL|Double dose of Gadopentetate dimeglumine|Subjects with a clinical diagnosis of unilateral Meniere Disease (MD) will undergo 3T MR imaging with a double dose of intravenous (IV) gadolinium contrast injection: 0.2 mmol/kg of Gd-DTPA (Magnevist)
62444754|NCT00909727|PLACEBO_COMPARATOR|Placebo|Subjects who received placebo every 12 hours (q12h) for up to 48 weeks.
62840033|NCT02003599|EXPERIMENTAL|Laser therapy|"In the intervention group, 26 patients will be submitted a laser therapy .The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2. It will be administrated five days a week before radiotherapy.~Both arm will use institutional skin care protocol."
62840034|NCT03108326||Group 1a|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with biologics is not allowed.
62840035|NCT03108326||Group 1b|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with 1 biologics is allowed
62840036|NCT03108326||Group 2|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with ≥2 biologic is allowed.
62840037|NCT03108326||Group 3a|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with biologic is not allowed.
62840038|NCT03108326||Group 3b|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with 1 biologic is allowed.
62840039|NCT03108326||Group 4|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with ≥2 biologics is allowed.
62840040|NCT01547078|ACTIVE_COMPARATOR|Licensed Plasma|
62840041|NCT01547078|EXPERIMENTAL|Lyophilized Plasma|
62840042|NCT02753452|ACTIVE_COMPARATOR|Residential Immersive Life Skills group|Youth will take part in a residential life skills program of between one and three weeks, consisting of formal workshops, peer learning, outings in the community, one-on-one coaching and daily living tasks carried out with peers (e.g. cooking, laundry, grocery shopping).
62444755|NCT00909727|EXPERIMENTAL|150 mg Ivacaftor q12h|Subjects who received 150 mg of ivacaftor q12h for up to 48 weeks.
62055599|NCT00570674|EXPERIMENTAL|Phase I Dose Level 1: ACE-RT|Phase I Dose Level 1 participants received Abraxane 20mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. One dose (400 mg/m2 IV) of Erbitux was given prior to start of radiation, then weekly at 250 mg/m2 IV. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
62055600|NCT00570674|EXPERIMENTAL|Phase I Dose Level -1: AC-RT|Phase I Dose Level -1 participants received Abraxane 20mg/m2 IV then carboplatin AUC 1.5 weekly IV during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
62444756|NCT00215982|EXPERIMENTAL|Combination Therapy|Capecitabine in Combination with Irinotecan and Oxaliplatin
62444757|NCT00455663|EXPERIMENTAL|Cognitive Adaptation Training|In home treatment using environmental supports such as signs, labels, alarms, checklists and the organization of belongings to bypass cognitive impairment, cue and sequence adaptive behavior and improve a wide range of functional outcomes.
62444758|NCT00455663|EXPERIMENTAL|Pharm-Cognitive Adaptation Training|Uses Supports from Cognitive Adaptation Training designed only to promote adherence to medication and treatment follow up.
62055601|NCT00570674|EXPERIMENTAL|Phase I Dose Level 2: AC-RT|Phase I Dose Level 2 participants received Abraxane 30mg/m2 IV then carboplatin AUC 1.5 weekly IV during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
62055602|NCT00570674|EXPERIMENTAL|Phase I Dose Level 3: AC-RT|Phase I Dose Level 3 participants received Abraxane 40mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
62258050|NCT05099627||Prospective cohort study arm|"The questionnaire Cervical myelopathy treatment outcome questionnaire attached records information relating to co-morbidities and symptomology. The examination will be a thorough neurological examination in addition to a focused cardiovascular examination. Biochemical blood markers from existing blood markers or from GP records, which have been or would have been performed regardless of this trial. Radiological findings will be taken from routine MRI and cervical spine X-rays performed as part of the CSM diagnostic work-up.~The mJOA score and JOACMEQ score are the outcome measures for the prospective arm of the study. Good response to surgery is a 1-point improvement in mJOA score at 3 and 6 months."
62258051|NCT05099627||Retrospective cohort study arm|"The retrospective questionnaire CSM early diagnosis questionnaire contains all the questions which will be collected retrospectively via telephone. Furthermore patients from the community MSK team, those diagnosed with CM eventually and those examined for CM query, their clinical, biochemical and radiological data from the local SystemOne Databases will be collected for analysis and comparison.~Radiological confirmation of cervical myelopathy is the outcome measure for the retrospective arm."
62258052|NCT04021836|OTHER|3d evaluation of naso labial changes using alar cinch suture|
62258053|NCT04021836|OTHER|3d evaluation of nasolabial change without Alar cinch|
62258054|NCT04331795|EXPERIMENTAL|Group A|Hospitalized, non-critically ill patients with COVID-19 pneumonitis with risk factors for decompensation
62258055|NCT04331795|EXPERIMENTAL|Group B|Hospitalized, non-critically ill patients with COVID-19 pneumonitis without risk factors for decompensation
62258056|NCT03124771|EXPERIMENTAL|Rainbow Resposable Adhesive Sensors|All subjects are enrolled into the test group and all subjects received the Rainbow Resposable Adhesive Sensors.
62258057|NCT04649255|EXPERIMENTAL|Lava LES|
62258058|NCT03556553|EXPERIMENTAL|Vertise Flow|Superficial Class I cavities restored with Vertise Flow
62258059|NCT03556553|EXPERIMENTAL|LuxaFlow|Superficial Class I cavities restored with LuxaFlow
62258060|NCT01937533||Cervical Cancer|Patients with presumed early cervical cancer being considered for curative surgery
62258061|NCT02025868|EXPERIMENTAL|Adherence reinforcement before switch to 3rd-line ART|
62258062|NCT01444079||Liver transplant recipients|Recipients who will undergo liver transplantation during study period
62258063|NCT02348775|EXPERIMENTAL|GlyNAC|HIV infected subjects will be studied before and after taking oral glycine and n-acetylcysteine for 3 months
62258064|NCT05578859|EXPERIMENTAL|AMG510|Each participant will receive a single oral dose of AMG510 on Day 1 after an overnight fast.
62258065|NCT02231164|PLACEBO_COMPARATOR|Docetaxel and placebo|patients to receive backbone chemotherapy and placebo
62258066|NCT02231164|EXPERIMENTAL|Docetaxel and Nintedanib|patients to receive backbone chemotherapy and nintedanib
62258067|NCT06369103|ACTIVE_COMPARATOR|Dexmedetomidine Group|Patients will receive dexmedetomidine at a dose of 0.5-1.0 mcg/kg over 5-10 minutes, then a maintenance infusion rate of 0.2-0.5 mcg/kg/min when the bispectral index (BIS) value is between 70 and 80.
62258068|NCT06369103|ACTIVE_COMPARATOR|Propofol Group|Patients will receive propofol at a dose of 0.25-0.5 mg/kg over 5-10 minutes, then a maintenance Infusion rate of 0.5-2 mg/kg/hr when the bispectral index (BIS) value is between 70 and 80.
62258069|NCT02152085|EXPERIMENTAL|Narrow pulse|Six-week treatment of electrical stimulation applied to the calf muscles with stimulus pulses that last 0.4 ms.
62258070|NCT02152085|EXPERIMENTAL|Wide pulse|Six-week treatment of electrical stimulation applied to the calf muscles with stimulus pulses that last 1 ms.
62258071|NCT02731261|EXPERIMENTAL|Experimental|
62258072|NCT02731261|NO_INTERVENTION|Control|
62258073|NCT04701671||Normal Weight Control, no MRI-scan (30 participants)|Adolescents with a BMI percentile under 85% who are not randomly assigned to undergo MRI scans at baseline and 18-months.
62258074|NCT04701671||Normal Weight Control with MRI-scan (30 participants)|Adolescents with a BMI percentile under 85% who are randomly assigned to undergo MRI scans at baseline and 18-months.
62258075|NCT04701671||Overweight Control, no MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher who are not randomly assigned to undergo MRI scans at baseline and 18-months.
62258076|NCT04701671||Overweight Control with MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher who are randomly assigned to undergo MRI scans at baseline and 18-months.
62258077|NCT04701671||Overweight/Obese Experimental, no MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher, who report loss of control eating episodes and are not randomly assigned to undergo MRI scans at baseline and 18-months.
62258078|NCT04701671||Overweight/Obese Experimental with MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher, who report loss of control eating episodes and are randomly assigned to undergo MRI scans at baseline and 18-months.
62258079|NCT05258773|EXPERIMENTAL|A, Treatment arm|Arm A: Participants scheduled for cochlear implantation and treated with oral 43.5 mg SENS-401 (R-Azasetron Besylate) twice daily for up to 49 days.
62258080|NCT05258773|NO_INTERVENTION|B, Control arm|Arm B: Participants scheduled for cochlear implants and not treated with SENS-401 (R-Azasetron Besylate).
62258081|NCT03691025||RALPD|
62258082|NCT03119961|EXPERIMENTAL|SONOCLOUD®|BBB opening by ultrasound
62258083|NCT03426956|EXPERIMENTAL|Glucose|
62258084|NCT03426956|EXPERIMENTAL|Glucose + Canagliflozin|
62444759|NCT00455663|ACTIVE_COMPARATOR|Treatment As Usual|Medication follow up and limited case management provided by local mental health authority
62444760|NCT01200056|ACTIVE_COMPARATOR|Atorvastatin 10mg low dose|Atorvastatin 10mg daily for 6 months and compared to atorvastatin 40mg daily in the other arm. The primary endpoint of 6 months VH-IVUS findings and clinical outcomes would be monitored and compared.
62258085|NCT05997862|EXPERIMENTAL|Intervention|This group will do a 12-week high intensity exercise program. The subjects will exercise by increasing how much they lift their knees while walking on treadmill. The exercise will also involve controlling the impact of the feet on the treadmill. A TV placed in front of the treadmill shows how high individuals need to lift their knees. How much participants need to lift their knees is calculated based on real-time heart rate readings.
62615084|NCT01658904|EXPERIMENTAL|Cohort 1- CFZ 20 mg/m^2 (Day 1,2)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:~Cohort 1: add CFZ 20 mg/m\^2 intravenous (IV) on days +1, +2~Cohort 2 : add CFZ 20 mg/m\^2 IV on days: +1, +2, +8, +9~Cohort 3: add CFZ 20 mg/m\^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m\^2 IV given on days 42-43 then CFZ 56 mg/m\^2 IV given on days 49-50, 56-57, then on days 70."
62615085|NCT01658904|EXPERIMENTAL|Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:~Cohort 1: add CFZ 20 mg/m\^2 intravenous (IV) on days +1, +2~Cohort 2 : add CFZ 20 mg/m\^2 IV on days: +1, +2, +8, +9~Cohort 3: add CFZ 20 mg/m\^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m\^2 IV given on days 42-43 then CFZ 56 mg/m\^2 IV given on days 49-50, 56-57, then on days 70."
62615086|NCT01658904|EXPERIMENTAL|Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:~Cohort 1: add CFZ 20 mg/m\^2 intravenous (IV) on days +1, +2~Cohort 2 : add CFZ 20 mg/m\^2 IV on days: +1, +2, +8, +9~Cohort 3: add CFZ 20 mg/m\^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m\^2 IV given on days 42-43 then CFZ 56 mg/m\^2 IV given on days 49-50, 56-57, then on days 70."
62615087|NCT01911780|EXPERIMENTAL|telmisartan + HCTZ + amlodipine|telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
62615088|NCT01911780|ACTIVE_COMPARATOR|telmisartan + HCTZ + placebo|telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
62258086|NCT05997862|NO_INTERVENTION|Control|This group will do initially a 12-week period of no intervention. After these 12 weeks, participants will do a 12-week high intensity exercise program. The subjects will exercise by increasing how much they lift their knees while walking on treadmill. The exercise will also involve controlling the impact of the feet on the treadmill. A TV placed in front of the treadmill shows how high individuals need to lift their knees. How much participants need to lift their knees is calculated based on real-time heart rate readings.
62258087|NCT03321227|EXPERIMENTAL|Snack skipping|No snack provided
62840043|NCT02753452|ACTIVE_COMPARATOR|Non-residential life skills program|Youth will take part in programs focusing on increasing specific life skills, but taking place only during the day (i.e. non- residential).
62258088|NCT03321227|EXPERIMENTAL|Whole eggs|2 whole large eggs as a snack
62258089|NCT03321227|EXPERIMENTAL|Egg whites|2 egg whites as a snack
62258090|NCT03321227|EXPERIMENTAL|Egg yolks|2 egg yolks as a snack
62615089|NCT06031675||intervention group|The intervention measures encompass the implementation of simulated vigorous intermittent lifestyle physical activity for all participants. The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.
62840044|NCT02753452|NO_INTERVENTION|Deferred RILS applicants|Youth who applied to a Residential Immersive Life Skills program but are deferred to a subsequent year. These youth are included as a comparator group to match the motivation level required to apply to a RILS program.
62840045|NCT02753452|NO_INTERVENTION|No life skills program|Youth who did not apply or take part in any group life skills program. These youth provide a diagnosis and age matched comparator group.
62055603|NCT00570674|EXPERIMENTAL|Phase I Dose Level 4: AC-RT|Phase I Dose Level 4 participants received Abraxane 50mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
62258091|NCT03321227|ACTIVE_COMPARATOR|Yogurt|Full fat yogurt as a snack
62258092|NCT03506321|OTHER|LANS|Lesions are assessed with chromoendoscopy, HD-WL \& NBI
62258093|NCT05565716|EXPERIMENTAL|Support Person|A support person not in the study will receive the participant's weekly blood pressure performance details and will contact them at least on a weekly basis to encourage continued blood pressure monitoring. Prior to randomization, the participant will select a preference between a support person that is close to them (e.g., friend or family member) or a support person who is provided by the study, a Peer Mentor.
62258094|NCT05565716|EXPERIMENTAL|Social Norms|In this arm, participants will be texted reports of blood pressure performance statistics of the other participants in the study and also receive weekly feedback about how their blood pressure information compares to others in the study. Participants in this arm will have access to a leaderboard that displays this information.
62444761|NCT01200056|ACTIVE_COMPARATOR|Atorvastatin 40mg moderate dose|Atorvastatin 40mg daily for 6 months and compared to atorvastatin 10mg daily in the other arm. The primary endpoint of 6 months VH-IVUS findings and clinical outcomes would be monitored and compared.
62444762|NCT05998213|EXPERIMENTAL|Donor fecal microbiota transplant|
62444763|NCT05998213|PLACEBO_COMPARATOR|Autologous fecal microbiota transplant|
62444764|NCT06119607|EXPERIMENTAL|TRIFLO|
62444765|NCT05200221||Donafenib|Patients with uHCC taking donafenib in clinical treatment
62615090|NCT05175950|EXPERIMENTAL|Test group 1: primary vaccination completed with ChAdOx1 nCOV-19|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
62615091|NCT05175950|PLACEBO_COMPARATOR|Placebo group 1: primary vaccination completed with ChAdOx1 nCOV-19|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
62615092|NCT05175950|EXPERIMENTAL|Test group 2: primary vaccination completed with BNT162b2(Pfizer)|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
62615093|NCT05175950|PLACEBO_COMPARATOR|Placebo group 2: primary vaccination completed with BNT162b2(Pfizer)|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
62615094|NCT05175950|EXPERIMENTAL|Test group 3: primary vaccination completed with mRNA-1273(Moderna)|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
62615095|NCT05175950|PLACEBO_COMPARATOR|Placebo group 3: primary vaccination completed with mRNA-1273(Moderna)|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
62615096|NCT05175950|EXPERIMENTAL|Test group 4: primary vaccination completed with Ad26.COV2.S(Janssen)|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
62615097|NCT05175950|PLACEBO_COMPARATOR|Placebo group 4: primary vaccination completed with Ad26.COV2.S(Janssen)|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
62615098|NCT05175950|EXPERIMENTAL|Test group 5: primary vaccination completed with ChAdOx1 nCOV-19(AZ)-BNT162b2(Pfizer)|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
62615099|NCT05175950|PLACEBO_COMPARATOR|Placebo group 5: primary vaccination completed with ChAdOx1 nCOV-19-BNT162b2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
62615100|NCT05175950|EXPERIMENTAL|Test group 6: primary and 1st booster vaccination completed with mRNA vaccine|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
62615101|NCT05175950|PLACEBO_COMPARATOR|Placebo group 6: primary and 1st booster vaccination completed with mRNA vaccine|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
62615102|NCT05175950|EXPERIMENTAL|Test group 7: primary and 1st booster vaccination completed with ≥1 dose of non-mRNA vaccine|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
62615103|NCT05175950|PLACEBO_COMPARATOR|Placebo group 7: primary and 1st booster vaccination completed with ≥1 dose of non-mRNA vaccine|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
62615104|NCT00573586|OTHER|HIFU|"Completely destroy prostate cancer tissue, without causing damage to the intervening tissue, with a drop in PSA levels to \<0.5ng/ml.~* Result in negative biopsies for evidence of viable malignant cells after the treatment (12 months if Nadir is not reached or PSA rises from Nadir)~* Safely treat localized prostate cancer patients, with minimal and acceptable adverse effects"
62840046|NCT02501577|EXPERIMENTAL|SAD 1|FOI for placement
62840047|NCT02501577|EXPERIMENTAL|SAD 2|FOI für placement
62055604|NCT06156722|ACTIVE_COMPARATOR|The IMSI-only group|The IMSI-only group
62055605|NCT06156722|ACTIVE_COMPARATOR|IMSI with SpermSlow group|IMSI with SpermSlow group
62055606|NCT06156722|NO_INTERVENTION|Mixed embryo group|Mixed embryo group
62055607|NCT00946296|ACTIVE_COMPARATOR|Potassium Iodide|8 drops of Potassium Iodide in a glass of water, by mouth, daily for 7 days prior to operation.
62055608|NCT00946296|NO_INTERVENTION|No Treatment|The experimental group receives no treatment.
62258095|NCT01787942|ACTIVE_COMPARATOR|Blepharoplasty|"Participants under this group will undergo blepharoplasty from the oculoplastic clinic. These patients will form the case group of the cross-sectional study, and will be on follow-up for the prospective study."
62258096|NCT01787942|PLACEBO_COMPARATOR|Control|"Participants under this group will be recruited from the general ophthalmology clinic. These patients are cleared to have no lid disturbances in terms of function or anatomy, and will serve as the control group of the cross-sectional study."
62258097|NCT05723185||Internal medicine model|This group of patients will be treated at the outpatient clinic which is run by internal medicine specialists
62258098|NCT05723185||Specialist model|This group of patients will be treated at the outpatient clinic which is run by cardiologists and/or diabetologists
62258099|NCT00668070|EXPERIMENTAL|ASP9831 Low Dose|
62444766|NCT05605964|EXPERIMENTAL|Relugolix|Oral relugolix 120 mg once daily with a loading dose of 360 mg on Day 1
62615105|NCT03891823|EXPERIMENTAL|MitraClip|"Study of MitraClip in symptomatic heart failure patients with moderate (2+, 2-3+) functional mitral regurgitation and left ventricular dysfunction.~Subjects will be followed for 24 months and there will be one formal interim analysis for futility after approximately 50% of subjects have completed their 24-month follow-up."
62615106|NCT03891823|ACTIVE_COMPARATOR|Medical Therapy|"Study of medical therapy in symptomatic heart failure patients with moderate (2+, 2-3+) functional mitral regurgitation and left ventricular dysfunction.~Subjects will be followed for 24 months and there will be one formal interim analysis for futility after approximately 50% of subjects have completed their 24-month follow-up."
62615107|NCT01180049|ACTIVE_COMPARATOR|temsirolimus (Torisel) 175mg weekly x 3, then 75mg weekly|
62615108|NCT01180049|ACTIVE_COMPARATOR|temsirolimus (Torisel) 75mg weekly|
62840048|NCT01565824|EXPERIMENTAL|Web-based support|The subjects will get access to a website where they can store blood glucose levels, read specialized information concerning pregnancy and early motherhood, and access a discussion forum for peer support.
62840049|NCT01565824|NO_INTERVENTION|Usual care|
62055609|NCT05660590|ACTIVE_COMPARATOR|Low bandage pressure|Compression bandages applied with low pressure (20-30 mmHg)
62055610|NCT05660590|ACTIVE_COMPARATOR|high bandage pressure|Compression bandages applied with low pressure (45-55 mmHg)
62055611|NCT04131270|EXPERIMENTAL|Planning + Education|"3 education sessions + 1 planning session (integrated into the 3rd education session); delivered face-to-face over 3 weeks (after the baseline measurement), individually.~Planning: The planning materials and forms have sections: (a) instructions of what should be included in a good plan (the when, where, and how components), (b) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties) will be formed. After forming the plans individually, experimenters will discuss the plans with the participants."
62055612|NCT04131270|ACTIVE_COMPARATOR|Education|"3 education sessions; delivered face-to-face over 3 weeks (after the baseline measurement), individually.~The education includes extended physical activity and sedentary behavior education using participant-educator discussions and printed materials."
62055613|NCT05604716||SPN patients|
62055614|NCT01584180|ACTIVE_COMPARATOR|Cold infusions|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
62258100|NCT00668070|EXPERIMENTAL|ASP9831 Higher Dose|
62258101|NCT00668070|PLACEBO_COMPARATOR|Placebo|
62258102|NCT04066270||study group|"candidates for cochlear implantation 18 years or older, who are eligible for implantation for the indication of bilateral severe hearing loss or single sided deafness.~clinical audiometric and vestibular investigations, CT and MR imaging of petrous bone"
62444767|NCT05605964|ACTIVE_COMPARATOR|Leuprolide Acetate|Subcutaneous or intramuscular leuprolide acetate 22.5 mg 3-M depot or 45 mg 6-M injection or Leuprolide acetate injectable emulsion (42 mg injectable emulsion is not allowed)
62444768|NCT01090765|EXPERIMENTAL|TRC105 1 mg/kg every 2 weeks|Intravenous infusion at 1 mg/kg every 2 weeks
62444769|NCT01090765|EXPERIMENTAL|TRC105 3 mg/kg every 2 weeks|Intravenous infusion at 3 mg/kg every 2 weeks
62055615|NCT01584180|ACTIVE_COMPARATOR|EMCOOLS Brain.Pad|Passive external neck cooling with 1 EMCOOLS Brain.Pad (Emergency Medical Cooling Systems AG, Wien, Austria)
62055616|NCT03590340|EXPERIMENTAL|Group 1a (PfSPZ Vaccine)|"Group 1a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10\^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime, followed by a boost of 9.0x10\^5 PfSPZ Vaccine on Day 113.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
62444770|NCT01090765|EXPERIMENTAL|TRC105 10 mg/kg every 2 weeks|Intravenous infusion at 10 mg/kg every 2 weeks
62444771|NCT01090765|EXPERIMENTAL|TRC105 10 mg/kg weekly|Intravenous infusion at 10 mg/kg weekly
62444772|NCT01090765|EXPERIMENTAL|TRC105 15 mg/kg every 2 weeks|Intravenous infusion at 15 mg/kg every 2 weeks
62444773|NCT01090765|EXPERIMENTAL|TRC105 20 mg/kg every 2 weeks|Intravenous infusion at 20 mg/kg every 2 weeks
62444774|NCT00006156|EXPERIMENTAL|Control|Control for FSH stimulation test
62444775|NCT00006156|EXPERIMENTAL|Drug: FSH|FSH Stimulation Test
62444776|NCT05128188||Patients on haemodialysis|5 patients on haemodialysis will be recruited. The study involves a single dialysis session and two MRI scans (one prior and one following dialysis) and collection of clinical data.
62623651|NCT04953806|EXPERIMENTAL|Step-CBT|Participants will complete Step-CBT, an integrative 8-week physical activity and cognitive behavioral therapy (CBT) intervention, delivered by a licensed clinical psychologist. Sessions will take place once per week for 60 minutes using VA Video Connect. Each session will include core components 1) Reviewing physical activity goals, prescribing new step count goal, and problem-solving barriers and 2) The weekly CBT intervention module.
62840050|NCT03346980||Familial adenomatous polyposis|The Danish Polyposis Register is sited at Copenhagen University Hospital Hvidovre. From this registry consecutive familial adenomatous polyposis patients referred for esophagogastroduodenoscopy (EGD) will prospectively be enrolled in this single-center study. Both patients referred for endoscopic surveillance and interventional endoscopy are eligible.
62840051|NCT01558648||Pts having Minimally Invasive esophagectomy|This is a prospective non-randomized study comprising two surgical cohorts of esophageal cancer patients. Patients will be assigned to each of the two intervention groups, MIE versus OE, based on a combination of patient referral patterns, patient preference, and surgeon preference/expertise.
62258103|NCT04066270||control group|"Symptomatic DFNA9 patients carrying the p.P51S mutation in COCH, presenting the radiologic semicircular canal lesion(s) on CT and/or MR.~clinical audiometric and vestibular investigations, CT and MR imaging of petrous bone"
62444777|NCT01439503|NO_INTERVENTION|Control|Men receiving the control condition will be comprised of standard of care counseling from the clinic plus a variety of free condoms and water-based lubricants. They will also provide a specimen for STD testing, and receive text message questions for 12 weeks. The text messaging system will be used to collect self-reported dependent variables from men on a weekly basis. Texting will also serve as a constant method of contact between the PD and the enrolled men to remind them of follow-up assessments. In addition, the participants will complete the ACASI questionnaire to assess their sexual behavior, as well as demonstrate their condom application ability.
62840052|NCT01558648||Pts having open esophagectomy|This is a prospective non-randomized study comprising two surgical cohorts of esophageal cancer patients. Patients will be assigned to each of the two intervention groups, MIE versus OE, based on a combination of patient referral patterns, patient preference, and surgeon preference/expertise.
62258104|NCT01735253|EXPERIMENTAL|gastric bypass, duodenojejunal bypass|
62258105|NCT00862576||1|Burning Mouth Syndrome Group
62258106|NCT00862576||2|Control Group
62258107|NCT01534104|EXPERIMENTAL|pts who have primary or secondary brain tumors|The study will prospectively enroll subjects who have primary or secondary brain tumors located near the motor pathway (corticospinal tract) or language pathway (arcuate fasciculus). This is a nonrandomized study in which each subject will receive the standard of care as per the treating neurosurgeon.
62258108|NCT04071847||Deep brain stimulation|Subjects implanted with an Abbott DBS system
62258109|NCT02667210||No shopping behavior|
62258110|NCT02667210||Minimal shopping behavior|
62444778|NCT01439503|EXPERIMENTAL|Treatment|Men receiving the treatment condition will receive text messages each week after their enrollment date and this will continue for 12 weeks to collect self-reported dependent variables. Text messaging will also be used to confirm and remind men about the day of each follow-up assessment. Each participant will also provide a specimen for STD testing, as well complete the ACASI questionnaire to assess sexual behavior and demonstrate their condom application ability. These participants will also be provided with a variety of free condoms and water-based lubricants. In addition, men in the treatment condition will also be enrolled in an education program.
62444779|NCT00793728|ACTIVE_COMPARATOR|Antrectomy|
62444780|NCT00793728|ACTIVE_COMPARATOR|Without antrectomy|
62444781|NCT03643419|SHAM_COMPARATOR|Laminectomy|
62444782|NCT03643419|EXPERIMENTAL|Laminectomy & Irradiation|
62444783|NCT02851290|EXPERIMENTAL|Caudal block|Local anesthetic will be administered into the caudal space
62444784|NCT02851290|ACTIVE_COMPARATOR|Dorsal penile nerve block|Local anesthetic will be administered around the dorsal penile nerve
62444785|NCT02725944||Patients with cryptogenic stroke and TIA|Implantation of ICRM in all participants.
62444786|NCT03818958||active spondyloarthritis|subjects with active spondyloarthritis with a BASDAI greater than 4
62444787|NCT03818958||remission spondyloarthritis|subjects presenting with a remission spondyloarthritis defined by a BASDAI less than 4
62840053|NCT01918306|EXPERIMENTAL|1PHIbA Arm A - cisplatin + GDC - 0941|"Determine the safety and tolerability of GDC-0941 given in combination with cisplatin in patients with AR- TN MBC. Determination of the maximally tolerated dose (MTD) of GDC-0941.~Cohort 1, 3 of 3 patients received:~Cisplatin 25 mg/m2 IV D1, 8, 15 GDC-0941 260 mg PO, days 2-6, 9-13, 16-20, 23-27, 28 day cycle GDC-0941 dose to start at Max dose of 260mg.~If no patient in the first cohort of 3 experiences a DLT, an additional cohort of 3 patients will be treated at the same dose level.~1. If 1 patient experiences a DLT in the first cohort, an additional cohort of 3 patients will be treated at the same dose level.~2. If ≤1 patient has a DLT in 6 treated at this same dose, this will be considered a tolerable dose to move to phase II~If patients experience a DLT considered related to GDC-0941, the patient may remain on GDC-0941 and/or Cisplatin after resolution of the DLT. All such cases will be considered a DLT for the purposes of defining the MTD."
62840054|NCT01918306|EXPERIMENTAL|1PHIbB - Arm B - Cisplatin + GDC 0941 dose level -1|"If 2 or more patients in 3 or 6 patients treated at a given dose experience DLT, the dose will be de-escalated to the next lower dose level. Once the lowest dose level is reached, if a DLT occurs, the regimen will be considered too toxic and the corresponding cohort within the study will be discontinued.~Determination of the maximally tolerated dose (MTD) of GDC-0941."
62840055|NCT01918306|ACTIVE_COMPARATOR|2PHII1 Arm 1 - Cisplatin|"Evaluate the efficacy, as measured by the overall response rate (ORR), of Cisplatin +GDC-0941 versus Cisplatin alone in patients with AR- TN MBC.~Patients will be randomized in a 1:1 fashion to arm 1: cisplatin, or arm 2: cisplatin + GDC-0941.~Arm 1 Cisplatin Only Patient received:~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle)."
62055617|NCT03590340|EXPERIMENTAL|Group 2a (PfSPZ Vaccine)|"Group 2a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10\^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last prime dose by DVI injection."
62258111|NCT02667210||Marked shopping behavior|
62258112|NCT02667210||Extensive shopping behavior|
62444788|NCT03818958||controls without spondyloarthritis|controls without spondyloarthritis or other chronic inflammatory rheumatism and without fibromyalgia
62840056|NCT01918306|EXPERIMENTAL|2PHII2 - Arm 2 - Cisplatin + GDC - 0941|"Evaluate the efficacy, as measured by the overall response rate (ORR), of Cisplatin +GDC-0941 versus Cisplatin alone in patients with AR- TN MBC. Patients are randomized in a 1:1 fashion to arm 1: cisplatin, or arm 2: cisplatin + GDC-0941.~Arm 2 Cisplatin + GDC-0941 Patients received:~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle).~GDC-0941 260 mg PO, administered orally on days 2-6, 9-13, 16-20, 23-27 of a 28 day cycle."
62840057|NCT01918306|EXPERIMENTAL|2PHIICO|"Arm 2: Crossover post-progression~Patients who are randomized to Cisplatin alone (Arm 1) can crossover to receive Cisplatin + GDC-0941 upon disease progression.~Patient received:~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle).~GDC-0941 260 mg PO, administered orally on days 2-6, 9-13, 16-20, 23-27 of a 28 day cycle."
62840058|NCT01526681||RANGER: Avance Nerve Graft|Processed Human Nerve Graft
62840059|NCT01526681||Historical Control for Standard Treatment|Literature review for outcomes from standard treatments, i.e. Autogenous Nerve Graft.
62840060|NCT01526681||MATCH Arm: Contemporary Control|Addendum 1: Autogenous Nerve Graft and Nerve Tube Conduit
62840061|NCT01526681||Sensation-NOW Arm: Breast Neurotization|Addendum 2: Post-mastectomy autologous breast reconstruction with or without neurotization
62258113|NCT05467475|EXPERIMENTAL|esomeprazole + BI 1819479 (Test (T))/ BI 1819479 (Reference (R))|
62258114|NCT05467475|EXPERIMENTAL|BI 1819479 (R)/ esomeprazole + BI 1819479 (T)|
62258115|NCT02230384|EXPERIMENTAL|Active JNJ Drug|200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
62258116|NCT02230384|EXPERIMENTAL|Placebo Pill|Placebo pill used for one week quit attempt, as part of crossover design.
62258117|NCT06015347||Assessment|Infants at risk rated with the Alberta Infant Motor Scale between 1-18 months
62444789|NCT03818958||fibromyalgia|subjects with fibromyalgia
62444790|NCT06230120|EXPERIMENTAL|Spinal Cord Stimulation|A stimulation electrode is placed in the epidural space between the T4-T7 spinal levels and connected to an external electrical pulse generator, which is used for stimulation. The stimulus intensity is initially increased in a ramp-like fashion using high-frequency stimulation at 1000 Hz, with pulse widths of 90 microseconds and intensities increasing from 2 to 14 mA to establish the sensation threshold. After establishing the sensation threshold, the 75 % subthreshold of sensation is used as the stimulation intensity during the active stimulation period.
62444791|NCT06230120|SHAM_COMPARATOR|Sham|For sham treatment, a similar procedure for establishing the sensation threshold is used, and stimulation at the 75 % subthreshold intensity is initiated, but the stimulation device is turned off 30 seconds after the sensation subthreshold is established.
62444792|NCT03672500|ACTIVE_COMPARATOR|Bupivacaine arm|The edges of the 2PT/Epi will be infiltrated with 10ml of Bupivacaine 0.5%+Epinephrine 50mcg prior to suture placement.
62444793|NCT03672500|SHAM_COMPARATOR|Control arm|Sham injection will be done using a syringe filled with 10ml of NaCl 0.9%, but the fluid will not be injected to the edges of the laceration but discarded. The sham injection will last no less than 10 seconds.
62444794|NCT01077713|EXPERIMENTAL|1|
62444795|NCT01077713|EXPERIMENTAL|2|
62840062|NCT02259335|EXPERIMENTAL|patients under invasive ventilation|those patients failing a T-piece trial beacuse of a PaCO2 rise\>20% of baseline and/or a rapid shallow-breathing index \>100 will be reconnected to the ventilator Two hours later they will repeat a T-piece trial after connection to the CO2 removal device
62444796|NCT01001169|EXPERIMENTAL|GSK2340274A_F1 6M-9Y GROUP|Healthy male or female Japanese children, between and including 6 months to 9 years of age, who received two doses of GSK2340274A vaccine (formulation 1), administered intramuscularly into the deltoid region of the arm (intramuscularly into the anterolateral part of the thigh for subjects below 12 months of age at the entry of the study), according to 0, 21-day schedule. Within this group, enrolment of subjects was stratified by age into two subgroups, from 6 to 35 months and from 3 to 9 years.
62840063|NCT04176471|EXPERIMENTAL|Therapeutic Hypothermia|Therapeutic hypothermia will be achieved using a servo-controlled temperature regulating blanket that is approved for use in neonates and is currently used for the treatment of neonates with moderate-severe HIE. The goal target temperature is 33.5°C ± 0.5°C for 72 hours and the subject will then be rewarmed at a rate of 0.5°C per hour to a goal of 36.5°C.
62840064|NCT04176471|ACTIVE_COMPARATOR|Normothermia|Normothermia will be achieved using a servo-controlled temperature regulating blanket with the temperature goal of 36.5-37.3°C for 72 hours.
62840065|NCT05961007|ACTIVE_COMPARATOR|Aflibercept|only phase II
62840066|NCT05961007|EXPERIMENTAL|IBI302|
62840067|NCT00802256|EXPERIMENTAL|A|teeth which are treated with Mineral Trioxide Aggregate (MTA) material
62840068|NCT00802256|EXPERIMENTAL|B|teeth which are treated with new Endodontic Cement (NEC) material
62840069|NCT05865119|EXPERIMENTAL|endovascular|Transcatheter correction of a SVD with an OPTIMUS covered stent
62615109|NCT04439058|ACTIVE_COMPARATOR|Bupivacaine+lignocaine|"will receive ultrasound guided left stellate ganglion block just after induction of anesthesia with10 ml of bupivacaine 0,25%+ 5ml lignocaine 1%(20 patients).~Under complete aseptic precautions an ultrasound guided left stellate ganglion block (paratracheal technique ) The patient placed in the supine position with the head in the neutral position and slightly extended.~The US probe placed at the level of the cricoid cartilage. The transverse process of the sixth cervical vertebra identified by its prominent anterior tubercle. Also, the longus colli muscle and its overlying prevertebral fascia anterior to the C6 vertebral body and deep to the carotid artery. skin infiltration with local anesthetic, the needle inserted from lateral to medial using the in-plane technique. The aim was to inject the local anesthetics deep to the prevertebral fascia and above the longus colli"
62258118|NCT05224063|EXPERIMENTAL|Individualized CEN-targeted rTMS|Individualized CEN-targeted rTMS will combine neuronavigated rTMS and single pulse TMS-EEG to identify the region of the dlPFC making the strongest connection with the parietal node of the CEN. First, regions of the dlPFC strongly connected to the parietal CEN will be identified by applying single TMS pulses in grid-like fashion to ROIs within the dlPFC. For each anatomical dlPFC subunit probed with TMS, the TMS-EEG response will be quantified in the parietal region of the CEN. The dlPFC subunit that demonstrates the strongest TMS-EEG response in parietal cortex will be chosen for rTMS. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
62840070|NCT05865119|ACTIVE_COMPARATOR|surgery|Surgical correction of a SVD
62615110|NCT04439058|OTHER|Normal saline|"will receive ultrasound guided left stellate ganglion block just after induction of anesthesia with 15 ml of normal saline (20 patients).~US machine Mindray M5 (Shenzhen Mindray Bio-Medical Electronics Co., LTD. Shenzhen, China.) with a linear 38-mm high frequency 10-12 MHz transducer), with an imaging depth of 4 cm. A 50-mm short bevel 22-gauge insulated stimulating needle (PAJUNK® GmbH Medizin technologie, Deutschland"
62840071|NCT03485378|EXPERIMENTAL|Treatment Arm: Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease
62840072|NCT04042636||1|Patients with Bacteremia after trauma
62840073|NCT04042636||2|Patients with non-bacteremia after trauma
62840074|NCT01626872|EXPERIMENTAL|MP-214 3mg|
62840075|NCT01626872|EXPERIMENTAL|MP-214 6mg|
62840076|NCT01626872|EXPERIMENTAL|MP-214 9mg|
62840077|NCT01626872|ACTIVE_COMPARATOR|Risperidone 4mg|
62840078|NCT00663182|EXPERIMENTAL|A|Patients with decompensated HBV-related cirrhosis
62055618|NCT03590340|EXPERIMENTAL|Group 3a (PfSPZ Vaccine)|"Group 3a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10\^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime, followed by a boost of 9.0x10\^5 PfSPZ Vaccine on Day 29.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
62055619|NCT03590340|EXPERIMENTAL|Group 4a (PfSPZ Vaccine)|"Group 4a: subjects (n=21) will receive two doses of PfSPZ Vaccine (9.0 x 10\^5 PfSPZ/dose) on Days 1 and 8 as a prime, followed by a boost of 9.0x10\^5 PfSPZ Vaccine on Day 29.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
62840079|NCT00663182|NO_INTERVENTION|B|Untreated
62840080|NCT01474252|EXPERIMENTAL|RSI technique|"Intubation with RSI technique. RSI technique includes the administration of inductive and neuromuscular blocking agents to facilitate an intubation.~In this study, we have no restriction of medication use. Physicians can chose any of medication as an individual judgement."
62840081|NCT01474252|NO_INTERVENTION|Non-RSI|Intubation without RSI technique. No any medication use during intubation period.
62840082|NCT02476461|ACTIVE_COMPARATOR|xiapex|1: xiapex: 0,58 mg clostridium histolyticum administered in the dupuytrens cord as discribed in producers manual
62840083|NCT02476461|EXPERIMENTAL|PNF|percutaneous needle fasciotomi is performed at affected cords
62840084|NCT01473901|EXPERIMENTAL|BKM120 + Temozolomide (Concomitant Phase)|Cranial radiation: Days 1 - 5 every 7 days for 42 days60 Gy in 30 fractions; Temozolomide: 75 mg/m2 Daily, orally; BKM120: 0, or 40, or 60, or 80 mg/d Daily, orally or Days 1-5 every 7 days, orally
62840085|NCT01473901|EXPERIMENTAL|BKM120 + temozolomide with/without radiotherapy|"Adjuvant phase cycle 1:~Temozolomide 150 mg/m2 - Days 1 - 5 every 28 days Daily; BKM120 60, or 80, or 100 mg/d;~Adjuvant phase cycle 2+:~Temozolomide 200\* mg/m2 - Day 1 \~ 5 every 28 days Daily BKM120 0, or 40, or 60, or 80 or 100 mg/d"
62840086|NCT04551209|EXPERIMENTAL|Apical patency group|Patients in which apical patency is maintained.
62840087|NCT04551209|NO_INTERVENTION|Non- apical patency group|Patients in which apical patency is not maintained
62840088|NCT00430404|NO_INTERVENTION|Usual care (controlled group)|Usual care for management of depression
62615111|NCT01162720|EXPERIMENTAL|Short duration tourniquet|Patients allocated to this group will have the pneumatic tourniquet applied to the index limb for approximately 20-30 minutes during cement fixation of the prosthesis.
62615112|NCT01162720|ACTIVE_COMPARATOR|Long duration tourniquet|Patients randomised to this arm will have the tourniquet applied from commencement of surgery and removed just prior to skin closure.
62615113|NCT00718068|EXPERIMENTAL|Continuous|This group will receive potassium chloride by continuous infusion on a sliding-scale system based on serum potassium level.
62615114|NCT00718068|ACTIVE_COMPARATOR|Intermittent|This arm will form the control group and receive potassium chloride by intermittent infusion as per conventional management
62615115|NCT03453112|EXPERIMENTAL|Foster 100/6mg NEXThaler|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler (NEXThaler)
62615116|NCT03453112|ACTIVE_COMPARATOR|Foster 100/6mg pMDI|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with Hydrofluoroalkane ( HFA) -134a propellant.
62615117|NCT04246502|EXPERIMENTAL|A|
62615118|NCT04246502|ACTIVE_COMPARATOR|B|
62615119|NCT02769039||Parkinson's Disease participants|People with early Parkinson's disease with mild-to-moderate severity of disease.
62615120|NCT02769039||Control participants|Volunteers who are age (+/- 3 years) and sex matched to the participants with Parkinson's disease
62615121|NCT01559688|EXPERIMENTAL|ART therapy group|Participants in this arm will receive 2-5 sessions of ART therapy, depending on individual progress. Each session will last 60-90 minutes over a 2-week period.
62615122|NCT01559688|ACTIVE_COMPARATOR|Waitlist|Participants in this group will receive 2 fitness assessment or career counseling sessions. Each session will last 60-90 minutes over a 2-week period. Upon completion of this arm, participants will be offered the choice to start ART therapy.
62615123|NCT06336122|OTHER|Peer Participant Group A|Participants will self-select their peer coach and will receive contact once a week.
62055620|NCT03590340|PLACEBO_COMPARATOR|Group 1b (NS)|"Group 1b: subjects (n=5) will receive normal saline (NS) placebo on Days 1, 3, 5, 7, and 113.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
62258119|NCT05224063|ACTIVE_COMPARATOR|Neuronavigated rTMS|Neuronavigated rTMS will be delivered using neuro-navigation based on participants' own MRI images to target the dlPFC. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
62258120|NCT05224063|ACTIVE_COMPARATOR|Scalp-targeted rTMS|Scalp-targeted rTMS will be delivered using standard BEAM F3 targeting methodology to target the dlPFC. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
62258121|NCT05224063|SHAM_COMPARATOR|Sham rTMS|Sham rTMS will be delivered for one session to mimic active rTMS conditions. To maximize sham validity, both 1) a direction- sensor TMS coil will alert the operators to flip the coil if the wrong side is being used, and 2) low-intensity electrical stimulation to match the active rTMS frequency will be applied to scalp electrodes under the coil for sham and placed but not activated in the active arm. The rTMS coil will be positioned using neuro-navigation based on participants' own MRI images, mimicking active rTMS. Sham rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the sham rTMS session for adverse events and/or side effects.
62258122|NCT03677258|EXPERIMENTAL|Collagen injections|30 females with aging facial problems from 35 to 65 years old prescribed collagen ingection once every 3 weeks, cours of therapy - 3 procedures
62258123|NCT03677258|ACTIVE_COMPARATOR|Hyaluronic acid injections|30 females with aging facial problems from 35 to 65 years old prescribed hyaluronic acid ingection once every 3 weeks, cours of therapy - 3 procedures
62258124|NCT02997904|EXPERIMENTAL|Resultz Lice and Egg Elimination Kit|Resultz combing solution, head lice comb and instructions for use in a kit: apply liquid then comb out for 1 hour
62258125|NCT02997904|PLACEBO_COMPARATOR|Placebo Lice and Egg Elimination Kit|20% glycerin combing solution, comb and instructions for use in a kit: apply liquid then comb out for 1 hour
62258126|NCT01835015|EXPERIMENTAL|CLG561, Concentration Level A|Single 50 μL intravitreal injection of CLG561, Dose Level A
62258127|NCT01835015|EXPERIMENTAL|CLG561, Concentration Level B|Single 50 μL intravitreal injection of CLG561, Dose Level B
62615124|NCT06336122|OTHER|Peer Participant Group B|Participants will self-selected their peer coach and will receive contact every 2 weeks
62840089|NCT00430404|EXPERIMENTAL|collaborative care (Intervention)|Collaborative care for management of depression for intervention group. We provided multidisciplinary groups of care from psychiatrist, psychologist, social counselor, general practitioners and case managers for intervention group.
62615125|NCT06336122|OTHER|Peer Participant Group C|Participants will be matched with a peer coach and will receive contact once a week
62615126|NCT06336122|OTHER|Peer Participant Group D|Participants will be matched with a peer coach and will receive contact every 2 weeks.
62615127|NCT02269254|EXPERIMENTAL|Persona PS|Total Knee Replacement with Persona PS Knee Prosthesis by Zimmer
62615128|NCT02269254|ACTIVE_COMPARATOR|NexGen PS|Total Knee Replacement with NexGen PS Knee Prosthesis by Zimmer
62615129|NCT05415241|EXPERIMENTAL|FB2001Exploratory|"Stage 1 (Exploring the dose): FB2001 once daily for 5 consecutive days. If the drug is well tolerated but efficacy is inadequate, FB2001 BID for 5 consecutive days.~Stage 2 (Sample size expansion): FB2001 once daily or twice daily for 5 consecutive days depending on the result of stage 1."
62615130|NCT03864666|OTHER|Sequence 1|Treatment RTRT
62615131|NCT03864666|OTHER|Sequence 2|Treatment TRTR
62615132|NCT06509490|EXPERIMENTAL|KD025|This group of patients received KD025 cell injection.
62615133|NCT04953286|OTHER|Case group|The procedure, specific to the study, consists in taking samples of tears and cells at inclusion, 3 months after inclusion and 6 months after inclusion on patients with Amyotrophic Lateral Sclerosis
62615134|NCT04953286|OTHER|Control group|The procedure, specific to the study, consists in taking samples of tears and cells at inclusion, 3 months after inclusion and 6 months after inclusion on patients without neurological disease
62615135|NCT05517733|EXPERIMENTAL|Platelet Rich Fibrin (PRF)|
62055621|NCT03590340|PLACEBO_COMPARATOR|Group 2b (NS)|"Group 2b: subjects (n=5) will receive NS placebo on Days 1, 3, 5, and 7.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
62055622|NCT03590340|PLACEBO_COMPARATOR|Group 3b (NS)|"Group 3b: subjects (n=5) will receive NS placebo on Days 1, 3, 5, 7, and 29.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
62055623|NCT03590340|PLACEBO_COMPARATOR|Group 4b (NS)|"Group 4b: subjects (n=5) will receive NS placebo on Days 1 and 8.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
62055624|NCT02634788|EXPERIMENTAL|Buprenorphine 0.5 mg TID|Participants received buprenorphine 0.5 mg sublingual (under the tongue) spray three times daily (TID) for two days.
62055625|NCT02634788|EXPERIMENTAL|Buprenorphine 0.25 mg TID|Participants received buprenorphine 0.25 mg sublingual spray TID for two days.
62055626|NCT02634788|EXPERIMENTAL|Buprenorphine 0.125 mg TID|Participants received buprenorphine 0.125 mg sublingual spray TID for two days.
62840090|NCT01605799|ACTIVE_COMPARATOR|IOK Treatment|Six to eight week treatment lasting one to 1.5 hours addressing maladaptive cognitions related to killing in war.
62055627|NCT02634788|PLACEBO_COMPARATOR|Placebo|Participants received placebo-matching buprenorphine sublingual spray TID for two days.
62055628|NCT02859610|OTHER|cirrhotic patients|We prospectively included 90 cirrhotic patients .
62055629|NCT02859610|OTHER|healthy volunteers|The pilot cohort was compared with 10 healthy volunteers.
62055630|NCT02228395|EXPERIMENTAL|Cohort 1|Participants received 1 single dose of placebo, PF-04958242 0.6 mg, and PF-04958242 0.8 mg orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
62055631|NCT02228395|EXPERIMENTAL|Cohort 2|Participants received 1 single dose of PF-04958242 0.35 mg, placebo, and PF-04958242 0.8 mg orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
62055632|NCT02228395|EXPERIMENTAL|Cohort 3|Participants received 1 single dose of PF-04958242 0.35 mg, PF-04958242 0.6 mg, and placebo orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
62055633|NCT06020625|EXPERIMENTAL|Interventional|
62055634|NCT00463827|ACTIVE_COMPARATOR|2|Atorvastatin 40
62055635|NCT00463827|PLACEBO_COMPARATOR|placebo|matched placebo
62055636|NCT03502486|EXPERIMENTAL|Moderate exercise|20 minutes of cycle ergometry at 50 - 60% of heart rate max.
62055637|NCT03502486|EXPERIMENTAL|Intense Exercise|20 minutes of cycle ergometry at 70 - 80% of heart rate max.
62055638|NCT03502486|ACTIVE_COMPARATOR|Rest|20 minutes of seated reading.
62055639|NCT02103621|EXPERIMENTAL|Unifed Protocol (UP) for Discontinuation|Unified Protocol (UP) for Discontinuation is delivered in 14 weekly individual sessions of 45-60 minutes followed by 3 booster sessions scheduled at two, four and eight weeks thereafter. The UP is a cognitive behavioral treatment that focuses on increasing emotional awareness and cognitive flexibility, preventing behavioral and emotional avoidance, and situational and interoceptive emotion-focused exposure. Participants will also receive 7 biweekly medication management sessions over 14 weeks with a study psychiatrist to facilitate gradual taper of SRI medication.
62258128|NCT01835015|EXPERIMENTAL|CLG561, Concentration Level C|Single 50 μL intravitreal injection of CLG561, Dose Level C
62840091|NCT01605799|PLACEBO_COMPARATOR|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
62258129|NCT01835015|EXPERIMENTAL|CLG561, Concentration Level D|Single 50 μL intravitreal injection of CLG561, Dose Level D
62258130|NCT01835015|EXPERIMENTAL|CLG561, Concentration Level E|Single 100 μL intravitreal injection of CLG561, Dose Level E
62840092|NCT02229162||90 seconds DCC|the initial 15-20 subjects (15 enrolled subjects who complete study) will have cord clamped at 90 seconds. Then data will be analyzed and evaluated by DSMB
62840093|NCT02229162||Two minutes DCC|If Data Safety Monitoring Board (DSMB) concurs, DCC will then be practiced for 2 minutes for second group, which is the minimum amount of time recommended to be defined as DCC.
62840094|NCT00420771|EXPERIMENTAL|Gabapentin|gabapentin treatment 1200 mg three times daily
62840095|NCT00420771|PLACEBO_COMPARATOR|Placebo|Placebo condition received pills identical in appearance to experimental arm.
62615136|NCT05517733|EXPERIMENTAL|Diode laser|
62615137|NCT05107206|EXPERIMENTAL|Envi™-SR Thrombectomy Device|Mechanical Thrombectomy using the Envi™-SR Thrombectomy Device
62615138|NCT05107206|ACTIVE_COMPARATOR|Solitaire or Trevo Revascularization Device|Mechanical Thrombectomy using the Solitaire or Trevo Revascularization Device
62615139|NCT01844973|PLACEBO_COMPARATOR|Vehicle|
62840096|NCT05959356|EXPERIMENTAL|Arm A|cetuximab+envafolimab+mFOLFOXIRI up to 8 cycles followed by maintenance with cetuximab+envafolimab+5-FU/LV
62840097|NCT05959356|ACTIVE_COMPARATOR|Arm B|cetuximab+mFOLFOX6/FOLFIRI up to 8 cycles followed by maintenance with cetuximab+5-FU/LV
62840098|NCT02214134||Lung cancer|Patients with diagnosis of lung cancer at any stage
62840099|NCT02214134||Malignant pleural mesothelioma|Patients with diagnosis of malignant pleural mesothelioma at any stage
62840100|NCT02214134||Thymic malignancy|Patients with diagnosis of thymic malignancy at any stage
62840101|NCT05796375|ACTIVE_COMPARATOR|Frequent Cystoscopy|Cystoscopy is conducted at 6, 12, 18, and 24 months for patients undergoing surveillance for low grade intermediate-risk non-muscle invasive bladder cancer
62055640|NCT02103621|ACTIVE_COMPARATOR|Taper and Monitoring (TAP-M)|Taper and Monitoring (TAP-M) is delivered in biweekly individual sessions over 14 weeks, with booster sessions at two, four, and eight weeks thereafter. TAP-M consists of assessment and monitoring. Participants will also receive 7 biweekly medication management sessions over 14 weeks with a study psychiatrist to facilitate gradual taper of SRI medication.
62055641|NCT00674089|ACTIVE_COMPARATOR|1|Routine Post-partum Care and Vitamin A supplementation (50,000 IU) to the Newborn
62055642|NCT00674089|PLACEBO_COMPARATOR|2|Routine Post-partum Care with Placebo to the Newborn
62055643|NCT05440513|EXPERIMENTAL|Renal Pelvic Denervation|Using the natural orifice of the urethra, the ureters are accessed (bilaterally and in sequence), to allow for an ablation device to be placed into the renal pelvis where RF energy is delivered to ablate renal nerves.
62615140|NCT01844973|ACTIVE_COMPARATOR|M518101|
62615141|NCT03309514|EXPERIMENTAL|Treatment|
62615142|NCT00405782|ACTIVE_COMPARATOR|Immediate Exercise Group|Exercise Intervention begins immediately
62615143|NCT00405782|ACTIVE_COMPARATOR|Delayed Exercise Group|Exercise intervention delayed by 16 weeks
62615144|NCT02232555|EXPERIMENTAL|Duloxetine|
62615145|NCT02232555|PLACEBO_COMPARATOR|Placebo|
62615146|NCT00536315||COPD|Patients with cough and/or shortness of breath who may have windpipe collapse.
62615147|NCT00536315||Healthy adults|Subjects without symptoms for comparison.
62615148|NCT00536315||Tracheomalacia|Patients with cough and/or shortness of breath who may have windpipe collapse.
62615149|NCT03887429|EXPERIMENTAL|SXC-2023 200 mg followed by placebo|SXC-2023 200mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
62615150|NCT03887429|EXPERIMENTAL|Placebo followed by SXC-2023 200 mg|Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 200mg dosed once daily for 5 days.
62615151|NCT03887429|EXPERIMENTAL|SXC-2023 800 mg followed by placebo|SXC-2023 800mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
62840102|NCT05796375|EXPERIMENTAL|Xpert Urine Test|Xpert arm includes urine testing using the Xpert Bladder Cancer Monitor urine test at 6 and 18 months. Cystoscopy is conducted at 12 and 24 months for patients undergoing surveillance for low grade intermediate-risk non-muscle invasive bladder cancer
62840103|NCT05796375|EXPERIMENTAL|EpiCheck Urine Text|EpiCheck arm includes urine testing using the Bladder EpiCheck urine test at 6 and 18 months. Cystoscopy is conducted at 12 and 24 months for patients undergoing surveillance for low grade intermediate-risk non-muscle invasive bladder cancer.
62840104|NCT03241368|OTHER|MRE, Patency Capsule (if needed), CE, and IC|Single-arm study, which includes MRE procedure, Patency Capsule Procedure (if needed), PillCam Crohn's Capsule Endoscopy Procedure and Ileocolonoscopy procedure.
62840105|NCT00573300||Schizophrenia|Schizophrenia Patients
62840106|NCT00573300||Healthy Controls|Healthy Controls
62840107|NCT00561509||A|SSRIs
62840108|NCT00561509||B|Dual antidepressants
62840109|NCT00912067||hematopoietic stem cell transplantation|
62840110|NCT03854877|EXPERIMENTAL|Health behaviour intervention|Personalised health behaviour e-health intervention. The intervention uses the principles of acceptance-commitment therapy (ACT). It aims to promote health habits. Based on personal needs participants can choose tasks for physical activity, relaxation, healthy eating, sleep etc. They get regular feedback, tasks and support from their personal trainer via phone and computer.
62840111|NCT03854877|NO_INTERVENTION|Control group|Only before and after measurements
62615152|NCT03887429|EXPERIMENTAL|Placebo followed by SXC-2023 800 mg|Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 800mg dosed once daily for 5 days.
62615153|NCT01827878|ACTIVE_COMPARATOR|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA
62840112|NCT04154813|EXPERIMENTAL|Topiramate group|If fluoxetine doesn't work after 3 months, randomly assigned to 3 groups, one group is topiramate group.During this group the initial dose of 25mg/day is rapidly increased to the target dose (100mg/day) or below the maximum tolerable dose if the patient can tolerate it.
62840113|NCT04154813|EXPERIMENTAL|Fluoxetine+DBT group|If fluoxetine doesn't work after 3 months, randomly assigned to 3 groups, one group is fluoxetine+DBT group. Group cognitive behavioral therapy was performed while fluoxetine was maintained. Target dose of fluoxetine is 60mg/day.Treatment was divided into three stages: the initial stage, the main stage and the end stage. The treatment was conducted once a week for a total of 12 times, followed by maintenance treatment for 6 months.
62615154|NCT01827878|EXPERIMENTAL|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India
62258131|NCT00763750|EXPERIMENTAL|PPX +TMZ+XRT|XRT 60Gy at 2 GY/fractions x 30 fractions TMZ 75mg/m2/day PPX 40mg/m2/week x 6 weeks Days 1,8,15,22,22,29,36
62258132|NCT05610033|EXPERIMENTAL|AtaCor EV Temporary Pacing Lead System|Subjects implanted with the AtaCor StealthTrac Lead Model AC-101400
62055644|NCT01337674|EXPERIMENTAL|Panel A: MK-4618 + Met → PBO + Met|Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.
62055645|NCT01337674|EXPERIMENTAL|Panel A: PBO + Met → MK-4618 + Met|Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.
62258133|NCT00102011|EXPERIMENTAL|Study I- Arm I|Participants undergo baseline screening colonoscopy
62258134|NCT00102011|OTHER|Study I- Arm II|Participants receive standard care
62444797|NCT01001169|EXPERIMENTAL|GSK2340274A_F2 10Y-17Y GROUP|Healthy male or female Japanese children, between and including 10 to 17 years of age, who received two doses of GSK2340274A vaccine (formulation 2), administered intramuscularly into the deltoid region of the arm, according to 0, 21-day schedule.
62615155|NCT05907252|EXPERIMENTAL|Supervised Group-based Intervention|Supervised Group-based intervention involves a professional walking fitness coach and 2 assistant coach. The coach is expected to require the participants to engage in the intervention in a form of group. The intervention groups will receive an 18-week walking training (3 sessions per week, 1 hour per session )in accordance with the intervention.
62615156|NCT05907252|EXPERIMENTAL|Non-supervised Group-based Intervention|Supervised Group-based intervention involves no professional walking fitness coach; however, the research team member will ask the participants to engage in the intervention in a form of group, and complete the intervention according to goals and targets of each session. The intervention groups will receive an 18-week walking training (3 sessions per week, 1 hour per session )in accordance with the intervention.
62615157|NCT05907252|ACTIVE_COMPARATOR|Non-supervised Individual-based Intervention|Non-supervised Individual-based Intervention involves no professional walking fitness coach; and no group forming is required. The participants will engage and complete the intervention individually. The intervention groups will receive an 18-week walking training (3 sessions per week, 1 hour per session )in accordance with the intervention.
62055646|NCT01337674|EXPERIMENTAL|Panel B: MK-4618 + Amlo → PBO + Amlo|Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.
62258135|NCT00102011|EXPERIMENTAL|Study II- Arm I|Participants undergo baseline screening colonoscopy. Participants are given individualized recommendations for further surveillance based on the results of the colonoscopy.
62444798|NCT05269654|EXPERIMENTAL|injectable poly-L-lactic acid|One side of the subject's hips will be treated with injectable poly-L-lactic acid (PLLA, Sculptra® Aesthetic; Galderma Laboratories; Fort Worth, TX).
62444799|NCT05269654|SHAM_COMPARATOR|Normal Saline|One side of the subject's hips will be treated with injectable normal saline
62444800|NCT00788203||5-keys program|Counseling re family feeding behaviors.
62444801|NCT00788203||Lifestyle counseling|Counseling re healthy eating for child and family
62258136|NCT00102011|ACTIVE_COMPARATOR|Study II- Arm II|Participants undergo a baseline fecal occult blood test (FOBT). Participants are given individualized recommendations for further surveillance based on the results of the FOBT. Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT.
62258137|NCT00090194|EXPERIMENTAL|Low Dose|0.5 gm/kg at 5 days pre-transplant and 7 days post-transplant
62258138|NCT00090194|EXPERIMENTAL|Middle Dose|1.0 gm/kg at 5 days pre-transplant and 7 days post-transplant
62444802|NCT06546371|EXPERIMENTAL|Spinal cord stimulation|Patients are all included in this experimental arm, where they receive all four stimulation options consecutively, but in different orders. After receiving all four stimulation options, the patients are allowed to choose which stimulation option of the four they want to have for the following period.
62444803|NCT02445170||Below-knee amputees|The present group consists of diabetic below-knee prosthetic user
62444804|NCT02445170||Transmetatarsal amputees|The present group consists of diabetic transmetatarsal amputees
62444805|NCT04780503||Intubation Group/ Non-Intubation Group|Intubation group: Patients who failed noninvasive mechanical ventilation and who underwent endotracheal intubation Non-Intubation Group: Patients whose noninvasive mechanical ventilation is successful and endotracheal intubation is not applied
62444806|NCT04780503||Dying patients / Surviving patients|Dying patients :Patients with in-hospital mortality presenting with acute respiratory failure Surviving patients: Patients presenting and surviving due to acute respiratory failure
62444807|NCT01161641|EXPERIMENTAL|ODSH at 0.125 mg/kg/h|First cohort of 3 subjects to be administered the lowest dose of ODSH.
62444808|NCT01161641|EXPERIMENTAL|ODSH at 0.250 mg/kg/h|Second cohort of 3 subjects to receive the medium dose of ODSH
62840114|NCT04154813|EXPERIMENTAL|Fluoxetine+CBT group|If fluoxetine doesn't work after 3 months, randomly assigned to 3 groups, one group is fluoxetine+CBT group.Target dose of fluoxetine is 60mg/day. DBT therapy was performed while the original fluoxetine dose was maintained.The core treatment stage was 1 time per week, 12 times in total, and 6 months of maintenance treatment followed.
62840115|NCT00080444|EXPERIMENTAL|Part 1: Aprepitant|Day 1: aprepitant 125 mg orally (PO), ondansetron 0.15 mg/kg x 3 doses intravenously (IV), dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For 1 cycle and up to 9 subsequent optional cycles.
62615158|NCT05907252|NO_INTERVENTION|Control Group|Participants in the control group (CG) will not be arranged to participate in any walking or physical activity intervention during the whole study period (the 18-week intervention and 12-week follow-up periods), but they will be asked to keep a daily log on their physical activity, use of medicines, illness, and other health-related activities. Besides, the CG participants will be asked to report to the research resistant (RA) if a major change has been made in the aforementioned aspects. The RA will also check the daily logs of the participants through telephone or mobile phone every two weeks. Data from those who changed their normal lifestyles (especially taking up regular physical activity) will be excluded in the subsequent data analysis.
62840116|NCT00080444|ACTIVE_COMPARATOR|Part 1: Standard Therapy|Day 1: placebo to aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 16 mg PO. Day 2: placebo to aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 3: placebo for aprepitant 80 mg PO, dexamethasone 8 mg PO. Day 4: dexamethasone 8 mg PO. For 1 cycle; participants may receive open-label aprepitant for up to 9 subsequent optional cycles.
62055647|NCT01337674|EXPERIMENTAL|Panel B: PBO + Amlo → MK-4618 + Amlo|Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.
62615159|NCT01812850||Invisalign®|All subjects in the study (estimation of 40 subjects) will be treated using the Invisalign® appliance.
62840117|NCT00080444|ACTIVE_COMPARATOR|Part 2: Aprepitant|Day 1: aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For up to 10 cycles.
62840118|NCT04717219||Severe CAVD with atherosclerosis|Participants with severe CAVD and significant atherosclerosis
62840119|NCT04717219||Severe CAVS without atherosclerosis|Participants with severe CAVD without significant atherosclerosis
62840120|NCT04717219||Moderate CAVD with atherosclerosis|Participants with mild or moderate CAVD and significant atherosclerosis
62840121|NCT04717219||Moderate CAVD without atherosclerosis|Participants with mild or moderate CAVD without significant atherosclerosis
62840122|NCT04717219||Healthy controls|Healthy controls without CAVD and without a history of atherosclerotic cardiovascular events, current typical complaints of angina pectoris or intermittent claudication and overt heart failure (NYHA class III/IV).
62840123|NCT04717219||Controls with bicuspid aortic valve stenosis|Controls with bicuspid aortic valve stenosis, without a history of atherosclerotic cardiovascular events, current typical complaints of angina pectoris or intermittent claudication.
62840124|NCT05494424|EXPERIMENTAL|Goal Management Training (GMT)|Internet-delivered group-based GMT to groups of six participants in six two-hour sessions delivered weekly (five weeks). Manualized intervention.
62840125|NCT05494424|NO_INTERVENTION|Wait list|Wait list control condition
62840126|NCT06464978|EXPERIMENTAL|Stapler Reinforcement Patch Group|Participants in this group will receive gastrojejunostomy with the use of stapler reinforcement patches.
62840127|NCT06464978|ACTIVE_COMPARATOR|Standard Stapler Group|Participants in this group will receive gastrojejunostomy with the use of standard staplers.
62840128|NCT03453138|EXPERIMENTAL|LMA Protector Group|LMA Protector will be inserted by a blind researcher after standart anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale
62840129|NCT03453138|EXPERIMENTAL|Tracheal Intubation Group|Patients will be intubated after standart anesthesia induction and we will record heamodynamic variables. including mean blood pressure and heart rate
62840130|NCT01885130|EXPERIMENTAL|Cetaphil Daily Advance Ultra Hydrating Lotion|All subjects receive Cetaphil Daily Advance Ultra Hydrating Lotion
62840131|NCT05733117|ACTIVE_COMPARATOR|NanoVitD|Oral nano form of the calciferol
62840132|NCT05733117|ACTIVE_COMPARATOR|ConvVitD|Conventional oral calciferol
62055648|NCT05272891|EXPERIMENTAL|Experimental|audio book will be played
62055649|NCT05272891|NO_INTERVENTION|Control Group|No application will be made
62055650|NCT02708784||Pompe disease|Patients will perform muscle strength measurement with dynamometer and MR-imaging. After 8 months the investigations will be repeated.
62055651|NCT02708784||Myotonic Dystrophy|Patients will perform muscle strength measurement with dynamometer and MR-imaging. The investigations will not be repeated after 8 months.
62055652|NCT02708784||Healthy controls|Patients will perform muscle strength measurement with dynamometer and MR-imaging. The investigations will not be repeated after 8 months.
62055653|NCT04617184||Inflammatory Bowel Disease|any patient with IBD will be included in the registry
62615160|NCT05330585|EXPERIMENTAL|Participants with hearing loss.|Participants with hearing loss.
62615161|NCT02546076|ACTIVE_COMPARATOR|Laser coagulation|Er:YAG laser treatment with coagulation modality
62055654|NCT02978443|EXPERIMENTAL|Nivolumab-Ipilimumab Combination Therapy|All patients will receive nivolumab administered IV over 60 minutes at 1 mg/kg combined with ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks until progression, intolerable toxicity, or a maximum of 48 weeks, whichever comes first (Maintenance). Patients exhibiting complete response (CR) should continue nivolumab monotherapy at least 12 weeks beyond documentation of CR, if possible.
62055655|NCT02249819|EXPERIMENTAL|anodal tDCS, then sham tDCS|Participants received 1 single 20 min session of anodal tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of sham tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
62055656|NCT02249819|EXPERIMENTAL|sham tDCS, then anodal tDCS|Participants received 1 single 20 min session of sham tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of anodal tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
62055657|NCT01018225|EXPERIMENTAL|darifenacin|
62055658|NCT01018225|PLACEBO_COMPARATOR|Sugar Pill|
62055659|NCT02405260|EXPERIMENTAL|TTP399 400 mg|TTP399 once daily
62055660|NCT02405260|EXPERIMENTAL|TTP399 800 mg|TTP399 once daily
62055661|NCT02405260|ACTIVE_COMPARATOR|Sitagliptin 100 mg|Sitagliptin once daily
62055662|NCT02405260|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62055663|NCT05573503|EXPERIMENTAL|Intervention|Participants complete baseline assessments and are then assigned the intervention.
62615162|NCT02546076|ACTIVE_COMPARATOR|Laser w/o coagulation|Er:YAG laser treatment without coagulation modality
62615163|NCT02107950|EXPERIMENTAL|DCVAC/OvCa in parallel with chemotherapy|Combination therapy with DCVAC/OvCa and Standard of Care
62055664|NCT02725125|EXPERIMENTAL|Single-arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0days,the first day,the second day,28 days,29 days Duration:total five times
62055665|NCT00002832|EXPERIMENTAL|Decitabine + Stem Cell Transplantation|
62055666|NCT06274684|EXPERIMENTAL|Virtual Reality assistance group|Patient receiving VR headset during prostate biopsies
62055667|NCT06274684|NO_INTERVENTION|Control group|
62055668|NCT04045444|EXPERIMENTAL|women non active young people|women between 18 and 30 years practice less than 1h of physical activity per week
62615164|NCT02107950|ACTIVE_COMPARATOR|Standard of Care|Standard of Care carboplatin and gemcitabine
62615165|NCT02272153|ACTIVE_COMPARATOR|Egg refined grain|Eggs with white toast
62615166|NCT02272153|ACTIVE_COMPARATOR|Egg whole grain|Eggs with whole grain toast
62055669|NCT04045444|EXPERIMENTAL|men non active young people|men between 18 and 30 years practice less than 1h of physical activity per week
62055670|NCT04045444|EXPERIMENTAL|women non active old people|women between 60 and 85 years practice less than 1h of physical activity per week
62055671|NCT04045444|EXPERIMENTAL|men non active old people|men between 60 and 85 years practice less than 1h of physical activity per week
62055672|NCT04045444|EXPERIMENTAL|women active old people|women between 60 and 85 years practice at least 3h of physical activity per week
62055673|NCT04045444|EXPERIMENTAL|men active old people|men between 60 and 85 years practice at least 3h of physical activity per week
62055674|NCT04045444|EXPERIMENTAL|women with parkinson's disease|women between 60 and 85 years presence of the disease according to the criteria of the UK Parkinson Disease Brain Bank
62055675|NCT04045444|EXPERIMENTAL|men with parkinson's disease|men between 60 and 85 years presence of the disease according to the criteria of the UK Parkinson Disease Brain Bank
62055676|NCT00499863|EXPERIMENTAL|Methylphenidate Transdermal System|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
62444809|NCT01161641|EXPERIMENTAL|ODSH at 0.375 mg/kg/h|Third and last cohort of subject to receive the high dose of ODSH.
62444810|NCT06545071|EXPERIMENTAL|Study group|
62055677|NCT00499863|PLACEBO_COMPARATOR|2|Daily application of matching MTS Placebo Patch
62055678|NCT02081625|EXPERIMENTAL|NS-065/NCNP-01|
62055679|NCT01370512|ACTIVE_COMPARATOR|Placebo, Then Pyridostigmine|participants first receive placebo by mouth 3 times a day, for treatment day 1. Then participants receive pyridostigmine by mouth 3 times a day for treatment day 2.
62055680|NCT01370512|ACTIVE_COMPARATOR|Pyridostigmine, Then Placebo|participants first receive pyridostigmine by mouth 3 times a day, for treatment day 1. Then participants receive placebo by mouth 3 times a day for treatment day 2.
62055681|NCT01370512|EXPERIMENTAL|Drioxidopa and Placebo, Then Drioxidopa and Pyridostigmine|participants first receive placebo by mouth 3 times a day, for treatment day 3. Then participants receive Droxidopa by mouth 3 times a day for treatment day 4.
62055682|NCT01370512|EXPERIMENTAL|Droxidopa and Pyridostigmine, Then Droxidopa and Placebo|participants first receive Droxidopa by mouth 3 times a day, for treatment day 3. Then participants receive Placebo by mouth 3 times a day for treatment day 4.
62055683|NCT02243241|EXPERIMENTAL|HYD|
62055684|NCT02243241|OTHER|Moxifloxacin|Moxifloxacin is the positive control.
62055685|NCT02243241|PLACEBO_COMPARATOR|Placebo|Placebo for HYD and placebo for moxifloxacin
62258139|NCT00090194|EXPERIMENTAL|High Dose|2.0 gm/kg at 5 days pre-transplant and 7 days post-transplant
62444811|NCT05267808||Obstructive sleep apnea patients eligible for DISE|Patients with obstructive sleep apnea (AHI\>=5) will be included in the study. Subjects should be eligible for drug-induced sleep endoscopy as the next step in their clinical path.
62444812|NCT02015793|EXPERIMENTAL|Low Induction Dose|Participants received the low loading dose of adalimumab (80 mg at Week 0) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 2, 4, and 6.
62444813|NCT02015793|EXPERIMENTAL|Standard Induction Dose|Participants received the standard loading dose of adalimumab (160 mg at Week 0 and 80 mg at Week 2) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 4 and 6.
62258140|NCT04899271|EXPERIMENTAL|Ladarixin|The treatment group will receive 400 mg b.i.d. for 13 cycles of 14 days on/14 days off)
62258141|NCT04899271|PLACEBO_COMPARATOR|Placebo|The control group will receive matched placebo
62258142|NCT05554484|EXPERIMENTAL|AMI-DC|Infusion of AMI-DC + Guideline directed optimal medical therapy
62258143|NCT05554484|NO_INTERVENTION|Standard treatment|Control, Guideline directed optimal medical therapy
62258144|NCT01252745|EXPERIMENTAL|10.0 mg of TBS-1, 4.0% T.I.D.|TBS-1 syringes pre-filled with 125 μL 4.0% gel to deliver 5.0 mg of Testosterone per nostril (intra-nasal) given t.i.d. at 2100, 0700, and 1300 hours. (total dose 30 mg/day)
62258145|NCT01252745|EXPERIMENTAL|13.5 mg of TBS-1, 4.5% B.I.D|TBS-1 syringes pre-filled with 150 μL 4.5% gel to deliver 6.75 mg of Testosterone per nostril (intra-nasal) given b.i.d. at 2100 and 0700 hours. (total dose 27.0 mg/day)
62258146|NCT01252745|EXPERIMENTAL|11.25 mg of TBS-1, 4.5% T.I.D|TBS-1 syringes pre-filled with 125 μL 4.5% gel to deliver 5.625 mg of Testosterone per nostril (intra-nasal) given t.i.d. at 2100, 0700, and 1300 hours. (total dose 33.75 mg/day)
62258147|NCT01856244|EXPERIMENTAL|sensorimotor treadmill training|specific treadmill control using oscillating platform
62444814|NCT04960696||primary school/78 subjects|Determining the negative effects of distance education on eye symptoms during the pandemic period.
62615167|NCT02272153|ACTIVE_COMPARATOR|Cereal Refined grain|rice cereal with white toast
62615168|NCT00524680|EXPERIMENTAL|Arm I|Patients receive 4,000 IU of oral cholecalciferol (vitamin D3) once daily.
62615169|NCT00524680|EXPERIMENTAL|Arm II|Patients receive 6,000 IU of vitamin D3 once daily.
62615170|NCT00524680|EXPERIMENTAL|Arm III|Patients receive 8,000 IU of vitamin D3 once daily.
62258148|NCT01856244|ACTIVE_COMPARATOR|conventional treadmill training|conventional treadmill control
62444815|NCT04960696||middle school/78 subjects|Determining the negative effects of distance education on eye symptoms during the pandemic period.
62444816|NCT04960696||high school/78 subjects|Determining the negative effects of distance education on eye symptoms during the pandemic period.
62615171|NCT00524680|EXPERIMENTAL|Arm IV|Patients receive 10,000 IU of vitamin D3 once daily.
62444817|NCT04960696||university/81 subjects|Determining the negative effects of distance education on eye symptoms during the pandemic period.
62444818|NCT04643678|ACTIVE_COMPARATOR|Anakinra Group|Anakinra + Standard of Care
62615172|NCT03519113|EXPERIMENTAL|Test group 1|GC1102 80,000 IU
62258149|NCT00665899|EXPERIMENTAL|Cancer-Focused Relationship Enhancement|Cancer-Focused Relationship Enhancement
62258150|NCT00665899|EXPERIMENTAL|Couple's Cancer Education|Couple's Cancer Education
62258151|NCT00665899|NO_INTERVENTION|Usual Care|Cancer-Related Community and Internet Resources
62258152|NCT03011268|EXPERIMENTAL|Anti TNF discontinuation|Discontinuation of anti-TNF treatment (Infliximab, Adalimumab, Golimumab)
62258153|NCT03011268|ACTIVE_COMPARATOR|Anti TNF continuation|Continuation of anti-TNF treatment (Infliximab, Adalimumab, Golimumab)
62258154|NCT04031911|OTHER|Control group|Control group benefiting from standard support (AFU (Association Française d'Urologie) information sheet), but applied in a more supervised way (communication document, process studies, etc.).
62258155|NCT04031911|EXPERIMENTAL|Study group|"Study group benefiting from a short spa treatment (5 days) with hydroposturotherapy (HPT arm) in Vittel or Capvern: posturotherapy, lumbar percussion and controlled hyperdiuresis."
62258156|NCT00938808|ACTIVE_COMPARATOR|One per day, Formula diet|The Cambridge Programme. Formula diet One-daily
62444819|NCT04643678|OTHER|Standard of Care Group|Standard of Care Alone
62444820|NCT01663909|NO_INTERVENTION|Standard care|
62444821|NCT01663909|EXPERIMENTAL|Guided imagery|
62444822|NCT01342679|EXPERIMENTAL|dasatinib|
62444823|NCT00738556|ACTIVE_COMPARATOR|1|Full cover stenting of coronary lesions
62615173|NCT03519113|EXPERIMENTAL|Test group 2|GC1102 100,000 IU
62615174|NCT03519113|ACTIVE_COMPARATOR|Control group|I.V HBIG
62615175|NCT04573166|EXPERIMENTAL|CURB procedure|Personalized atrial septostomy with combined use of radiofrequency-ablation and balloon-dilation (CURB)
62615176|NCT03717415|EXPERIMENTAL|Part 1 Cohort 1 Escalation Rebastinib 50 mg + Carboplatin AUC5|Dose escalation with rebastinib 50 milligram (mg) twice daily (BID) orally (PO) in 21-day cycles in combination with carboplatin administered by intravenous (IV) infusion at area under the curve (AUC)5 at Day 1 of each 21-day cycle.
62840133|NCT03828578|EXPERIMENTAL|High flow oxygen therapy|"Patients allocated to the intervention group will receive high flow oxygen therapy via the tracheostomy tube from cessation of mechanical ventilation. The HFOT will provide oxygen therapy at a flow rate of 50-60 litres per minute at a FiO2 titrated by the bedside clinician to maintain a peripheral oxygen saturation of 95% of more (unless otherwise clinically indicated and documented by an appropriate consultant).~Once transferred to the ward patients will continue to receive HFOT 24 hours per day at a rate of 50-60 litres per minute at a maximum oxygen concentration of 40% to achieve oxygen saturations 95% and above (unless otherwise documented).~Patients may be disconnected from the HFOT for short periods for toileting, mobilising etc. Tracheostomy weaning will continue as per standard practice with an aim of cuff deflation followed by decannulation once clinically appropriate. systems. Following decannulation patients will resort to standard oxygen therapy as needed."
62840134|NCT03828578|NO_INTERVENTION|Standard Care|Patients randomised to the standard care study arm will receive routine post-operative care as currently performed within the host organisation. Following cessation of mechanical ventilation, oxygen therapy will be delivered using equipment and rates appropriate to the clinical picture. On transfer to the ward patients will continue with existing methods of oxygen therapy and will be weaned from these accordingly. Patients will continue to use heat moisture exchanges (e.g. Swedish nose or Buchannan protectors) as clinically indicated, as well as having saline nebulisers prescribed and administered as per standard. Tracheostomy weaning will continue in accordance with current practice. Data on all of the applied procedures will be recorded.
62840135|NCT04873219|ACTIVE_COMPARATOR|CAD/CAM milled complete denture|the dentures were milled out of a block of pre-polymerized PMMA resin (Avadent, Global dental Science, Netherlands)
62840136|NCT04873219|EXPERIMENTAL|CAD/CAM rapid prototyped complete denture|the dentures will be 3D-printed from a liquid PMMA, including the teeth (NexDent, Netherlands)
62840137|NCT01279161||diabetes|The study will include 1500 children with type 1 diabetes, aged 6-18 years. These will be patients from Diabetes Outpatient Clinics and patients hospitalized in Departments of Paediatrics, Endocrinology and Diabetology in University and Municipal Hospitals from Poland (Białystok, Warszawa, Łódź, Gdańsk, Wrocław, Katowice).
62840138|NCT01279161||control|Reference group will be made of 1500 children from the above mentioned Clinics and Departments in whom type 1 diabetes was excluded. In these children diagnostics procedures will be conducted for reasons other than body weigh related diseases (excluding simple obesity). The children will not receive any treatment that might influence their body weight.
62840139|NCT00731302|EXPERIMENTAL|Aspirin and Meloxicam|Arm: Aspirin and Meloxicam Each participant will receive 81 mg aspirin per day for 7 days, followed by meloxicam 7.5 mg daily plus aspirin 81 mg daily for 5 days
62615177|NCT03717415|EXPERIMENTAL|Part 1 Cohort 2 Escalation Rebastinib 100 mg + Carboplatin AUC5|Dose escalation with rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.
62615178|NCT03717415|EXPERIMENTAL|Part 1 Cohort 3 Escalation Rebastinib 100 mg + Carboplatin AUC6|Dose escalation with rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC6 at Day 1 of each 21-day cycle.
62258157|NCT00938808|EXPERIMENTAL|Repeated formula diet|Dietary instruction (low-energy diet) 3x5 weeks per year
62258158|NCT02710838|EXPERIMENTAL|Cancer group|All patients receive the infrared endoscopy after injecting indocyanine green（ICG） intravenously.
62258159|NCT02710838|OTHER|Non-cancer group|All patients receive the infrared endoscopy after injecting ICG intravenously.
62258160|NCT02340338|EXPERIMENTAL|Dose Group 1|Treatment: rTSST-1 Variant Candidate Vaccine 100 ng
62258161|NCT02340338|EXPERIMENTAL|Dose Group 2|Treatment: rTSST-1 Variant Candidate Vaccine 300 ng
62258162|NCT02340338|EXPERIMENTAL|Dose Group 3|Treatment: rTSST-1 Variant Candidate Vaccine 1 µg
62258163|NCT02340338|EXPERIMENTAL|Dose Group 4|Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
62444824|NCT00738556|ACTIVE_COMPARATOR|2|Spot-stenting of significantly stenotic parts of a coronary lesion
62444825|NCT04296864|PLACEBO_COMPARATOR|Placebo|Placebo of Dupilumab
62444826|NCT04296864|EXPERIMENTAL|Dupilumab|one loading dose of Dupilumab 600 mg followed by Dupilumab 300 mg weekly for a total of 16 weeks
62615179|NCT03717415|EXPERIMENTAL|Part 2 Cohort 1 Expansion Rebastinib 50 mg + Carboplatin AUC5|Dose expansion in triple-negative breast cancer (TNBC) participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.
62840140|NCT03336112|EXPERIMENTAL|Intervention group|5 weeks guided internet-delivered cognitive behavioral therapy program The program consists of psychoeducation, exposure to physical activity, and awareness (mindfulness) training.
62840141|NCT03336112|ACTIVE_COMPARATOR|Control group|Information program delivered by the Internet during 5 weeks.
62840142|NCT04043858|EXPERIMENTAL|Midodrine daily|Midodrine hydrochloride 2.5 mg tab once per day
62840143|NCT05079243|EXPERIMENTAL|Scaffold and adipose-derived stromal cell enriched fat grafts|Randomized and paired injections. Each participant will receive all 11 solutions.
62840144|NCT05079243|NO_INTERVENTION|Controls samples|Control samples of untreated skin
62840145|NCT05418205|EXPERIMENTAL|Intervention Group (IG)|Families with FGP support (families with disabled and/or chronically children under 18 in the greater area of Mainz, Saarbrucken and Munich (Germany)
62258164|NCT02340338|EXPERIMENTAL|Dose Group 5|Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
62258165|NCT02340338|EXPERIMENTAL|Dose Group 6|Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
62258166|NCT02340338|PLACEBO_COMPARATOR|Dose Group 0|Control: Al(OH)3 Adjuvant
62444827|NCT03629574|EXPERIMENTAL|Ventilated Group|This group will receive a protective mechanical ventilation during cardiopulmonary byass. No drugs will be administered.
62444828|NCT03629574|NO_INTERVENTION|Not-ventilated group|This group will not receive any kind of mechanical ventilation during cardiopulmonary byass. The ventilator will be switched off.
62840146|NCT05418205|NO_INTERVENTION|Control Group (CG)|Families without FGP support (standard care) under the same conditions
62840147|NCT06356896|EXPERIMENTAL|experimental: experimental group|Diaphragmatic breathing exercise will be explained practically to the patients in the experimental group in the preoperative period. Anxiety, sleep and symptom levels will be evaluated. 2-3-4 in the post-operative period. On the 5th day, the patient will be encouraged to do diaphragmatic breathing exercises. On the 5th day, anxiety, sleep and symptom levels will be evaluated.
62840148|NCT06356896|NO_INTERVENTION|control group|The standard procedure will be applied to the control group without any intervention.
62840149|NCT00659737|PLACEBO_COMPARATOR|Aprepitant|"Oral Aprepitant pill and placebo transdermal patch at least 1 hour prior to surgical procedure.~Emend (Aprepitant) + Placebo"
62840150|NCT00659737|ACTIVE_COMPARATOR|Scopolamine|Oral Aprepitant pill and Scopolamine transdermal patch at least 1 hour prior to surgical procedure.
62840151|NCT01574443||epilepsy resection patients|Patients undergoing resection for refractory epilepsy
62840152|NCT02328638|ACTIVE_COMPARATOR|Manual-based Behavioral Treatment|up to 16 weekly behavioral therapy sessions (intervention) following the CHANGE obesity manual, lasting approximately 45 minutes and nutritional therapy sessions, lasting approximately 30 to 60 minutes.
62840153|NCT02328638|PLACEBO_COMPARATOR|Parent Education Program|up to 16 weekly behavioral therapy sessions following the parent education program
62840154|NCT02117297|EXPERIMENTAL|Gemtuzumab Ozogamicin|Consolidation therapy with GO will be administered between days 60 and 180 post transplantation when the ANC is \>1000/mm3 and platelet count is \>40,000/mm3 untransfused x 3 days after AlloSCT and again at minimum 8 weeks later.
62840155|NCT02681978|ACTIVE_COMPARATOR|Ivabradine group|Ivabradine 5 mg twice daily + standard medical therapy
62258167|NCT02727985|EXPERIMENTAL|Pharmacist weaning schedule|The Neuromodulation clinic pharmacist will develop a weaning schedule for these patients. Schedules will be individualized taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
62615180|NCT03717415|EXPERIMENTAL|Part 2 Cohort 1 Expansion Rebastinib 100 mg + Carboplatin AUC5|Dose expansion in TNBC participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.
62615181|NCT03717415|EXPERIMENTAL|Part 2 Cohort 2 Expansion Rebastinib 50 mg + Carboplatin AUC5|Dose expansion in platinum-sensitive ovarian cancer participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.
62615182|NCT03717415|EXPERIMENTAL|Part 2 Cohort 2 Expansion Rebastinib 100 mg + Carboplatin AUC5|Dose expansion in platinum-sensitive ovarian cancer participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.
62840156|NCT02681978|OTHER|Control group|Standard medical therapy
62840157|NCT00220285|EXPERIMENTAL|Arm 1|
62840158|NCT00220285|EXPERIMENTAL|Arm 2|
62840159|NCT01528969|EXPERIMENTAL|Xylitol|A half of the subjects will be randomly allocated into xylitol group.
62840160|NCT01528969|ACTIVE_COMPARATOR|Sorbitol|About 40 randomly allocated subjects will chew sorbitol chewing gum (1,5, g/pellet) three times a day
62840161|NCT00689507|EXPERIMENTAL|Dose Escalation Phase(Part A):|1,10, 30, 100 or 300 mg of LY2127399 IV on day 1 of specific 21 day cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of each 21 day cycle
62840162|NCT00689507|EXPERIMENTAL|Dose Confirmation Phase (Part B1):|Dose determined by PK/PD modeling, LY2127399 IV on day 2 of Cycle 1 and on day 1 of specific cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of each cycle
62840163|NCT00689507|EXPERIMENTAL|Dose Confirmation Phase (Part B2):|Dose determined by PK/PD modeling, LY2127399 IV on day 1 of specific cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of specific cycles
62840164|NCT06315816|EXPERIMENTAL|Experimantal|The children will ask to choose a three-dimensional cartoon from the list to watch during the procedure, it will run, the mobile phone will placed into the virtual reality glasses, and the children wear the VR glasses and start watching the cartoon. During the procedure, the children's parents and the researcher will present, and the children watch the cartoon through virtual reality glasses. After the procedure, the virtual reality glasses will removed, and ten minutes after the procedure will completed, the CFS and the CAS-S will apply as a post-test.
62840165|NCT06315816|NO_INTERVENTION|Control|No intervention
62840166|NCT02135926|ACTIVE_COMPARATOR|Best medical care|Best clinical care in dedicated stroke unit
62840167|NCT02135926|ACTIVE_COMPARATOR|Thrombectomy|All subjects randomly assigned to the thrombectomy arm, except those with rapidly improving neurologic symptoms or no angiographic evidence of occlusion, will be treated with the endorsed study devices (stent retriever).
62258168|NCT02727985|NO_INTERVENTION|Self/Family Physician weaning schedule|Patients will wean off their opioids by themselves or with their family physician without the assistance of a prepared schedule.
62444829|NCT04455568||experimental group|Non-invasive Wearable Device, use ECG Wisdom bracelet
62615183|NCT03717415|EXPERIMENTAL|Part 2 Cohort 3 Expansion Rebastinib 50 mg + Carboplatin AUC5|Dose expansion in mesothelioma participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.
62840168|NCT01276054|EXPERIMENTAL|SNB plus ARM or ALND (+/- SNB) plus ARM|Patients undergo sentinel lymph node biopsy (SNB) and/or axillary lymph node biopsy (ALND) using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node. Patients then undergo an axillary reverse mapping.
62840169|NCT01276054|ACTIVE_COMPARATOR|SNB or ALND (+/- SNB)|Patients undergo SNB and/or ALND using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node.
62840170|NCT05324852|EXPERIMENTAL|Intranasal midazolam|Midazolam, 5 mg, injectable solution in 5mg/ml, if weight \< 50 kg : 5mg; if weight ≥50kg : 10mg, intranasal administration, atomize into nose with Mucosal Atomizer Device (MAD) 5mg(1ml) up each nostril , one time
62615184|NCT03717415|EXPERIMENTAL|Part 2 Cohort 3 Expansion Rebastinib 100 mg + Carboplatin AUC5|Dose expansion in mesothelioma participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.
62258169|NCT03528343|EXPERIMENTAL|Tylenol/Motrin|Group of patients who will receive instructions to use tylenol and motrin for pain control, and parents will be sent home with a paper prescription with a rescue does of standard of care narcotics. They will be instructed to only use the rescue dose if pain is uncontrolled using over the counter medications.
62258170|NCT03528343|NO_INTERVENTION|Narcotic|Group of patients who will receive the standard of care narcotic prescription filled upon discharge.
62258171|NCT01110616|EXPERIMENTAL|Sequence 1|MK3134-Lorazepam-Placebo-MK3134-Lorazepam
62258172|NCT01110616|EXPERIMENTAL|Sequence 2|MK3134-Lorazepam-Placebo-Lorazepam-MK3134
62615185|NCT01964716|EXPERIMENTAL|Multidose Vial Group|Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the multidose vial formulation. Each dose is 0.5 mL
62615186|NCT01964716|ACTIVE_COMPARATOR|Single-Dose Syringe Group|Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the single-dose syringe formulation. Each dose is 0.5 mL
62840171|NCT05324852|ACTIVE_COMPARATOR|Intramuscular loxapine|Loxapine, 100mg, injectable solution in 50mg/2ml intramuscular, intra muscular administration, one time
62258173|NCT01110616|EXPERIMENTAL|Sequence 3|MK3134-Placebo-Lorazepam-MK3134-Lorazepam
62258174|NCT01110616|EXPERIMENTAL|Sequence 4|MK3134-Placebo-Lorazepam-Lorazepam-MK3134
62615187|NCT02089087|EXPERIMENTAL|CFZ533 in healthy volunteers|CFZ533 single dose in healthy volunteers
62615188|NCT02089087|EXPERIMENTAL|CFZ533 in rheumatoid arthritis patients|CFZ533 single dose in rheumatoid arthritis patients
62615189|NCT02089087|PLACEBO_COMPARATOR|Placebo|Placebo single dose
62258175|NCT01110616|EXPERIMENTAL|Sequence 5|Lorazepam-Placebo-MK3134-MK3134-Lorazepam
62258176|NCT01110616|EXPERIMENTAL|Sequence 6|Lorazepam-Placebo-MK3134-Lorazepam-MK3134
62258177|NCT01110616|EXPERIMENTAL|Sequence 7|Lorazepam-MK3134-Placebo-MK3134-Lorazepam
62258178|NCT01110616|EXPERIMENTAL|Sequence 8|Lorazepam-MK3134-Placebo-Lorazepam-MK3134
62258179|NCT01110616|EXPERIMENTAL|Sequence 9|Placebo-MK3134-Lorazepam-MK3134-Lorazepam
62258180|NCT01110616|EXPERIMENTAL|Sequence 10|Placebo-MK3134-Lorazepam-Lorazepam-MK3134
62258181|NCT01110616|EXPERIMENTAL|Sequence 11|Placebo-Lorazepam-MK3134-MK3134-Lorazepam
62258182|NCT01110616|EXPERIMENTAL|Sequence 12|Placebo-Lorazepam-MK3134-Lorazepam-MK3134
62258183|NCT06186076|EXPERIMENTAL|Phase 1 Part A: Dose escalation in patients with EGFR sensitizing mutation|All eligible patients will receive the study treatment at selected oral dose(s) once daily, as per the assigned dose level from the pre-defined escalation scheme and SRC(Safety Review Committee) decision.
62615190|NCT06261541|EXPERIMENTAL|Gait training with exoskeleton|Participants with MS will undergo a training program with the ABLE Exoskeleton device: a total of 10 sessions, distributed 1-2 sessions/week for up to 11 weeks.
62615191|NCT02451397||Dr.Tang's research group|Chinese lifestyle associated with osteoporosis
62615192|NCT01653327|ACTIVE_COMPARATOR|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
62615193|NCT01653327|PLACEBO_COMPARATOR|Placebo|The placebo will consist of 4 ml of cherry syrup and 1 ml of normal saline.
62840172|NCT00629343|EXPERIMENTAL|Treatment|
62840173|NCT00993148|EXPERIMENTAL|Maraviroc plus darunavir/ritonavir|Single arm open label trial of maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily for 96 weeks
62840174|NCT04338802|PLACEBO_COMPARATOR|Placebo group|Empty capsules with the same appearance and ingredients as Nintedanib soft capsules: one capsule at a time, twice a day, with an interval of about 12 hours each time. Continuous medication for 8 weeks.
62840175|NCT04338802|EXPERIMENTAL|Nintedanib group|Nintedanib cloth sulfonate soft capsule treatment: According to the drug manual recommendation, give Nintedanib cloth sulfonate soft capsule 150mg twice daily with an interval of about 12 hours each time. Continuous medication for 8 weeks.
62840176|NCT04250909||Passeo 18 PTA|Previous treatment with uncoated Passeo 18 PTA balloon catheter
62840177|NCT04250909||Passeo-18 Lux DCB|Previous teatment with Passeo-18 Lux DCB
62840178|NCT05701501|EXPERIMENTAL|Vitamin B5 group|Based on the standard IBD treatment, Vitamin B5 (5mg/tablet) is given orally three times a day, four tablets each time, for 12 weeks.
62840179|NCT05701501|PLACEBO_COMPARATOR|Control group|Based on the standard IBD treatment, the same type of placebo tablets are given orally three times a day, four tablets each time, for 12 weeks.
62444830|NCT00322309|EXPERIMENTAL|Mirtazapine|"Mirtazapine administration as follows:~Days 1-4 15mg of mirtazapine daily Days 5-9 30mg of mirtazapine daily Days 10-78 45mg of mirtazapine daily Days 79-81 30mg of mirtazapine daily Days 82-84 15mg of mirtazapine daily"
62840180|NCT03639909||MSA-P|Patients with multiple systeme atrophy (MSA) with predominant parkinsonism (MSA-P) had evaluation of cardiovascular function and sweating function
62840181|NCT03639909||PD patients|Parkinson's disease (PD) patients had evaluation of cardiovascular function and sweating function
62840182|NCT00926718|EXPERIMENTAL|Dose 1a|
62840183|NCT00926718|EXPERIMENTAL|Dose 2a|
62840184|NCT00926718|EXPERIMENTAL|Dose 3a|
62840185|NCT00926718|EXPERIMENTAL|Dose 1b|
62840186|NCT00926718|EXPERIMENTAL|Dose 2b|
62840187|NCT00926718|EXPERIMENTAL|Dose 3b|
62840188|NCT05626868||Patients for spine surgery in prone position|
62840189|NCT00846092|EXPERIMENTAL|Device|"* The study will require 20 subjects.~* Each subject will have one study eye that will be designated for treatment.~* Subjects will be exposed to light emitted from Warp 10 LED's (Quantum Devices, Barneveld, WI) at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.~* Treatments involve application of the LED-generated light for 80 seconds, twice daily.~Primary efficacy and toxicity outcomes are determined by measuring excess retinal thickness via Ocular Coherence Tomography at 1 month, 3 months, and 6 months, prior to conclusion of the study.~• This protocol will be stopped if, at any point in the study, a 50% increase in excess retinal thickness is demonstrated via OCT in 25% of subjects in the experimental group."
62840190|NCT00523302|ACTIVE_COMPARATOR|Active TMS|Since cortical stimulation can be performed non-invasively by active Transcranial Magnetic Stimulation (TMS), Participants in the active TMS group, receive five 20 minute active TMS treatment sessions per week for two weeks.
62840191|NCT00523302|SHAM_COMPARATOR|Sham TMS|To prevent unwanted cortical activation, Sham TMS will be employed in the Sham TMS group. For the Sham TMS group, a specially designed sham TMS coil will be used for all sham conditions. This sham TMS coil produces auditory signals identical to active TMS coils but is shielded so that actual stimulation does not occur. This approach is currently the state-of-the-art approach to sham TMS procedures and is employed in high-quality clinical TMS trials. Participants in the sham TMS group receive five 20 minute Sham TMS treatment sessions per week for two weeks.
62840192|NCT04581694|EXPERIMENTAL|TAVI without contrast|
62840193|NCT01956929|EXPERIMENTAL|Metformin|2 weeks of Metformin use. First week 1000mg/day, Second week Max dose of 2000 mg/day.
62840194|NCT01956929|PLACEBO_COMPARATOR|Placebo|2 weeks of Placebo (lactulose pills)
62840195|NCT02784691|EXPERIMENTAL|Patients|
62840196|NCT04660916||isotretinoin|The patients aged 18-45 that were planned to begin treatment with isotretinoin for acne
62840197|NCT04660916||control|Healthy volunteers aged 18-45 without any diseases/drugs affecting the nail
62840198|NCT04583163||Neuro-critical Care Patients|"Up to 12 subjects will be recruited over a 1 year period. Patients enrolled in the study are recruited from the pool of neuro-critical care patients admitted to the surgical intensive care unit (SICU).~To meet study inclusion, transcranial Doppler (TCD) testing will be ordered as part of the standard of care for these patients. The test will not be ordered solely for research purposes. There are no known side effects from the non-invasive measurement of cerebral blood flow using ultrasound.~Three different TCD technicians will perform triplicate readings on 3 consecutive days on up to 12 patients already undergoing TCD as ordered by their treating team. Standard of care on specific neuro critical care patients (such as cerebral aneurysms) is to undergo daily TCD monitoring to assess for possible vasospasm. Patients will be in the supine position while measurements are obtained. The probe will be placed in the preauricular region of the temporal window."
62840199|NCT00140582|EXPERIMENTAL|A : rituximab maintenance|Maintenance with rituximab for 2 years
62444831|NCT00322309|PLACEBO_COMPARATOR|Placebo- Sugar pill|Matched Placebo given daily days 1-84
62444832|NCT02099500|EXPERIMENTAL|Stem Cell Injection|Non-Randomized
62840200|NCT00140582|NO_INTERVENTION|B : no maintenance|No further treatment
62840201|NCT04375085|OTHER|DESyne X2 Novolimus Eluting Coronary Stent System|
62840202|NCT06225713|EXPERIMENTAL|intervention group|In intervention group, participants will receive the whole peri-renal fat modification therapy (including peri-renal fat ultrasonic measurement and localization, focused ultrasound treatment parameters setting and initiating)
62444833|NCT00519012|ACTIVE_COMPARATOR|Arm-1|Sertraline to Paroxetine
62444834|NCT00519012|ACTIVE_COMPARATOR|2|Paroxetine to Sertraline
62444835|NCT00711906|EXPERIMENTAL|1|HIV-negative women taking CTX as chemoprophylaxis
62444836|NCT00711906|ACTIVE_COMPARATOR|2|HIV-negative women taking SP as IPT
62840203|NCT06225713|SHAM_COMPARATOR|sham-control group|In sham control group, participants will receive the sham control therapy (including peri-renal fat ultrasonic measurement and localization, focused ultrasound treatment parameters setting), however, without initiating the focused ultrasound equipment.
62444837|NCT00711906|EXPERIMENTAL|3|HIV-positive women (CD4\> 200) taking CTX as chemoprophylaxis
62444838|NCT00711906|ACTIVE_COMPARATOR|4|HIV-positive women (CD4 \> 200) taking SP as IPT
62444839|NCT04706975|ACTIVE_COMPARATOR|Difelikefalin 2.0 mg|Oral difelikefalin 2.0 mg tablet administered twice daily
62444840|NCT04706975|PLACEBO_COMPARATOR|Placebo|Oral placebo tablet administered twice daily
62840204|NCT00946621|EXPERIMENTAL|1|Ramipril 10 mg Capsule (Sandoz)
62840205|NCT00946621|ACTIVE_COMPARATOR|2|Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)
62840206|NCT05676840|OTHER|conventional niti arch wire group|all participants in this group will be placed conventional 014 niti lower archwire.
62840207|NCT05676840|OTHER|super elastic niti archwire group|all participants will be given super elastic 014 lower NiTi archwire.
62840208|NCT05676840|OTHER|thermal niti archwire group|all participants will be given thermal lower 014 niti archwire.
62840209|NCT01716052|ACTIVE_COMPARATOR|Ibuprofen|Pfizer 200 mg caplets (Advil)
62840210|NCT01716052|PLACEBO_COMPARATOR|Placebo|Lactulose
62840211|NCT05008406||Preclinical medical students|
62055686|NCT06359457||One group quasi-experimental study|"One hundred adult females with primary dysmenorrhea and non-dysmenorrhea will participate in this study. They will be recruited from outpatient clinic of Gynaecological outpatient clinic, faculty of physical therapy, Cairo university, Egypt.~All females should be regular cycle with evidence of ovulation.Taking blood samples of 3 ml through the cubit vein to examine the levels of serum progesterone Will be carried out on the 21st day of menstruation, while to assess the pain intensity of primary dysmenorrhea using the Visual Analogue Scale (VAS) and physical and psychological symptoms associated with dysmenorrhoea will be assessed by menstrual symptoms questionnaire~."
62258184|NCT06186076|EXPERIMENTAL|Phase 1 Part B: 2 dose levels of TRX-221 in patients with EGFR sensitizing mutation|All eligible patients will receive the study treatment at selected oral dose(s) once daily. Dose-levels will be selected from the Part A.
62615194|NCT02018978|EXPERIMENTAL|CTHP|"1. HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.~2. Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.~3. Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.~4. Incentives \& Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential."
62258185|NCT06186076|EXPERIMENTAL|Phase 2: Recommended Phase 2 dose(s) of TRX-221 in patients with EGFR C797X mutation|All eligible patients will receive the study treatment at selected oral dose(s) once daily.
62615195|NCT02018978|NO_INTERVENTION|Standard of Care|This arm will receive standard of care HIV-related services, including clinic-based voluntary counseling and testing and referrals to HIV care and treatment government-run facilities.
62615196|NCT01080391|ACTIVE_COMPARATOR|Lenalidomide and Dexamethasone (Rd)|Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on days 1 to 21 and dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22.
62615197|NCT01080391|EXPERIMENTAL|Carfilzomib, Lenalidomide, and Dexamethasone (CRd)|Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m² was administered intravenously (IV) on days 1 and 2 of cycle 1, escalating to 27 mg/m² on days 8, 9, 15, and 16 of cycle 1 and continuing on days 1, 2, 8, 9, 15, and 16 of cycle 2 through cycle 12 and then from cycle 13 through cycle 18, 27 mg/m² on days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on days 1 to 21 from cycle 1 through cycle 18 and from cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22 from cycle 1 through cycle 18 and from cycle 19 and higher.
62615198|NCT02945111|EXPERIMENTAL|Real-time view|Women undergoing Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) will watch the cervical images taken throughout the examination in real-time on a digital screen. The patients' anxiety level both before and after the examination will be measured using the Spielberg's State Anxiety Inventory.
62615199|NCT02945111|ACTIVE_COMPARATOR|No visual support|Women in this arm will undergo Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) without any visual support. Their anxiety level both before and after the examination will be measured using the Spielberg's State Anxiety Inventory.
62615200|NCT06446284|EXPERIMENTAL|ADHD EWM|Participants will receive EWM training sessions.
62615201|NCT06446284|PLACEBO_COMPARATOR|ADHD Placebo|Participants will receive placebo training sessions.
62615202|NCT02181218|EXPERIMENTAL|Dose Level 0 (starting dose) (8 mg/m2 romidepsin)|"* Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;~* Gemcitabine IV over 30 minutes on Day 1~* Oxaliplatin IV over 2 hours on Day 1~* Dexamethasone orally on Days 1-4~* Pegfilgrastim subcutaneously on Day 3~* Drugs may be administered in any order on Day 1.~* Each cycle is 21 days.~* May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
62615203|NCT02181218|EXPERIMENTAL|Dose Level 1 (10 mg/m2 romidepsin)|"* Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;~* Gemcitabine IV over 30 minutes on Day 1~* Oxaliplatin IV over 2 hours on Day 1~* Dexamethasone orally on Days 1-4~* Pegfilgrastim subcutaneously on Day 3~* Drugs may be administered in any order on Day 1.~* Each cycle is 21 days.~* May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
62840212|NCT05008406||Clinical medical students|
62258186|NCT01568086||AFFITOPE AD03 with adjuvant|
62258187|NCT01568086||AFFITOPE AD03 without adjuvant|
62258188|NCT01239550|EXPERIMENTAL|Insulin Detemir Treatment|"Insulin detemir treatment: Insulin detemir will be administered subcutaneously, once daily. Dose ranges from approximately 0.1 U/kg up to 0.6 u/kg or higher. The dosing regimen will employ a strategy similar to the 303algorithm, where, with close interaction with study personnel (rather than self-titration), bedtime insulin dosing will be titrated up by 3 units until AM fasting sugars within the prescribed protocol range are achieved (90-110 mg/dl). Subjects will have contact with study personnel on weekly basis for glycemia monitoring and adjustments. Similarly, documented hypoglycemia (blood sugars less than 70) will trigger a dose reduction, and it is expected that with weight loss, tolerable insulin dosages will drift downward. The treatment period is 24 weeks."
62055687|NCT01575353|ACTIVE_COMPARATOR|Venturi mask|After extubation, patients will receive oxygen therapy through the standard Venturi mask (control)
62055688|NCT01575353|ACTIVE_COMPARATOR|Nasal high-flow|After extubation, patients will receive oxygen therapy through the nasal high-flow (intervention)
62444841|NCT04648059||Lupus nephritis +ve|This group consists of patients with Lupus nephritis
62444842|NCT04648059||Lupus nephritis -ve|This group consist of patients with SLE without Lupus nephritis
62444843|NCT03868449|EXPERIMENTAL|Question Prompt List|Participants will be given a Question Prompt list that has been developed by the research team
62444844|NCT03868449|ACTIVE_COMPARATOR|3 questions list|Participants will be given 3 questions from the AskShareKnow method
62444845|NCT01590498||Salvage radiotherapy|local radiation to the prostate and metastasis following biochemical or clinical recurrence
62444846|NCT01590498||observation|did not receive salvage following biochemical or clinical recurrence
62444847|NCT01220349|EXPERIMENTAL|Echocardiographic 2D strain analysis|
62444848|NCT00743691|NO_INTERVENTION|Arm1|Make a diagnosis of Neonatal infections and refer patients according to IMNCI guideline
62444849|NCT00743691|ACTIVE_COMPARATOR|2|Health extension Workers will Make a diagnosis of Neonatal infections and treat with antibiotics when referal is not possible
62840213|NCT03207061|OTHER|3D ultrasound and MRI|All patients with confirmed endometrial cancer will recieve the gold standard pre-operative imaging (MRI) but will also be offered 3D ultrasound.
62840214|NCT02814994|EXPERIMENTAL|tidal volume guided by respiratory system compliance|effects of tidal volume guided by respiratory system compliance on mortality in patients suffering from ARDS
62055689|NCT02514421|EXPERIMENTAL|Electrochemotherapy with gemcitabine/nab-paclitaxel|During the first cycle of chemotherapy, patients will receive electroporation of the primary pancreatic tumor prior to administration of chemotherapy with gemcitabine and abraxane. The schedule of administration of gemcitabine and nab-paclitaxel will be administered as per standard of care. The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.
62055690|NCT02472652|OTHER|Abilify Maintena|Subjects will be switched to Abilify Maintena (Aripiprazole) LAI monthly doses of 400mg, 300mg, 200mg or 160mg and have their sexual functioning reevaluated over a 3 month period to determine if there is any significant sexual functioning improvement.
62055691|NCT03687801|EXPERIMENTAL|Online hearing support|The intervention group will have access to online hearing support for five weeks. The online hearing support will include a program that consists of three elements: 1) reading material; 2) reading instructions and weekly assignments related to the reading material; and 3) online and telephone interaction with a professional.
62055692|NCT03687801|ACTIVE_COMPARATOR|Standard care|"The control group will have access to traditional support that the Hearing Organization provides (standard care)."
62055693|NCT02073097|EXPERIMENTAL|rituximab, combination chemotherapy, carfilzomib|"Participants receive (every 21 day cycle):~* Rituximab IV over at least 90 minutes on day 2~* Carfilzomib IV over 30 minutes on days 1, and 2~* Cyclophosphamide IV over 30-60 minutes on day 3~* Doxorubicin hydrochloride IV over 3-5 minutes on day 3~* Vincristine sulfate IV over 1 minute on day 3~* Prednisone PO on days 3-7 any time~* Pegfilgrastim day 4~* Acyclovir 2x per day from cycle 1, 6 months after completion of cycle 6~Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity."
62055694|NCT03652974|EXPERIMENTAL|sodium valproate with clozapine|"sodium valproate, dosage form: 250 mg, dosage and frequency:250 mg/d for 1 week, 500 mg/d for week 2 , 1000 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300\~600 mg/d; duration: 12 weeks.~Intervention: Drug: sodium valproate with Clozapine"
62055695|NCT03652974|EXPERIMENTAL|Modified electroconvulsive therapy with clozapine|"12 times MECT for 12 weeks，once a week for the 12 weeks; clozapine, dosage and frequency:300\~600 mg/d; duration: 12 weeks.~Intervention: Device: modified electroconvulsive therapy(MECT) with Clozapine"
62258189|NCT01239550|NO_INTERVENTION|Comparator: No insulin|"The main hypothesis is that diabetes can be changed  with early and careful insulinization capturing effects on brain function ultimately leading to weight loss. . Seek to determine in a quantitative manner whether insulin detemir restores brain dopamine neurotransmission, a control group not treated with insulin is required. The strength of this study is our ability to test the specific molecular (D2R, DAT, functional MRI responses) and integrated output (functional brain responses, mood, cognitive function, reward responses etc.) of CNS dopaminergic pathways in order to shed unprecedented light upon mechanisms of detemir action in obesity and diabetes."
62258190|NCT03625167|EXPERIMENTAL|Treatment with petrolatum|In each healthy volunteer, one of the two forearms is randomly assigned to the intervention. This forearm is treated with petrolatum for 4 respectively 8 weeks.
62258191|NCT03625167|NO_INTERVENTION|Control|The control forearm will remain untreated throughout the study.
62444850|NCT03342898|EXPERIMENTAL|Group 1: YF-17D + Placebo/TDV/TDV|YF-17D vaccine, 0.5 mL injection, subcutaneously (SC) plus YF 17D + TDV placebo-matching 0.5 mL, injection, SC on Day 1, followed by TDV, 0.5 mL, injection, SC on Day 90 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 180 (second dose).
62258192|NCT06466148|EXPERIMENTAL|Newborn Cohort|The JessieHug device will be placed on infants two times a week to determine usability, tolerability and safety. Clinical accuracy will be assessed in one inpatient (newborn cohort) or outpatient (2 month and 4 month cohorts) session.
62258193|NCT06466148|EXPERIMENTAL|2 month Cohort|The JessieHug device will be placed on infants two times a week to determine usability, tolerability and safety. Clinical accuracy will be assessed in one inpatient (newborn cohort) or outpatient (2 month and 4 month cohorts) session.
62258194|NCT06466148|EXPERIMENTAL|4 month Cohort|The JessieHug device will be placed on infants two times a week to determine usability, tolerability and safety. Clinical accuracy will be assessed in one inpatient (newborn cohort) or outpatient (2 month and 4 month cohorts) session.
62444851|NCT03342898|EXPERIMENTAL|Group 2: TDV + Placebo/TDV/YF-17D|TDV, 0.5 mL, injection, SC plus TDV placebo-matching, 0.5 mL injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 90 (second dose), followed by YF-17D vaccine, 0.5 mL, injection, SC on Day 180.
62444852|NCT03342898|EXPERIMENTAL|Group 3: TDV + YF-17D/TDV/Placebo|TDV, 0.5 mL, injection, SC plus YF-17D vaccine, 0.5 mL, injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on day 90 (second dose), followed by TDV + YF 17D placebo-matching, 0.5 mL, injection, SC on Day 180.
62444853|NCT01950988|OTHER|Children|
62444854|NCT01950988|OTHER|Adults|
62444855|NCT01950988|OTHER|Elderly people|
62444856|NCT04756609|EXPERIMENTAL|Systematic offer of nurse-driven SARS-CoV-2 screening + usual practice|Systematic offer of nurse-driven SARS-CoV-2 screening combined with usual practice
62615204|NCT02181218|EXPERIMENTAL|Dose Level 2 (12 mg/m2 romidepsin)|"* Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;~* Gemcitabine IV over 30 minutes on Day 1~* Oxaliplatin IV over 2 hours on Day 1~* Dexamethasone orally on Days 1-4~* Pegfilgrastim subcutaneously on Day 3~* Drugs may be administered in any order on Day 1.~* Each cycle is 21 days.~* May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
62615205|NCT02781376|EXPERIMENTAL|CHICA-OSA|Two clinics will be randomized to receive the advanced CHICA-OSA computer decision support system designed to support PCPs in evidence-based identification and management of pediatric OSA. This module includes a snoring identification component (received by the control group).
62444857|NCT04756609|ACTIVE_COMPARATOR|Control group: Usual emergency department practice|Usual emergency department practice with physician-directed diagnostic testing
62444858|NCT03776903||endemic|Samples collected from areas endemic for zika. Subject specimens underwent testing with the study device and reference method.
62444859|NCT03776903||non-endemic|Samples collected from areas non-endemic for zika. Subject specimens underwent testing with the study device and reference method.
62444860|NCT06415253||Patients who had undergone Percutaneous Nephrolithotomy|
62055696|NCT03652974|EXPERIMENTAL|amisulpride|"amisulpride, dosage form: 200 mg, dosage and frequency:200 mg/d for 1 week, 400 mg/d for week 2,800 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300\~600 mg/d; duration: 12 weeks.~Intervention: Drug: amisulpride with Clozapine"
62055697|NCT03652974|PLACEBO_COMPARATOR|placebo|"The amisulpride and placebo tablets were identical in appearance. One placebo tablet for the first one week, two placebo tablets for the second week, four placebo tablets for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300\~600 mg/d; duration: 12 weeks.~Intervention: Drug: placebo with Clozapine"
62055698|NCT01778556|EXPERIMENTAL|Leptin naive|Studied for 5 days without metreleptin, then 14 days while taking metreleptin
62055699|NCT01778556|EXPERIMENTAL|On-leptin|Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal
62055700|NCT00370721|EXPERIMENTAL|I|
62444861|NCT05367856|EXPERIMENTAL|Chi-BEAM|Patients in this arm will receive Chidamide Combined With BEAM(Carmustine, Etoposide Cytarabine and Melphalan) as Pretreatment Regimen of ASCT.
62444862|NCT03636321|EXPERIMENTAL|intraductal stent|in this group ,patients candidate for living donor liver transplantation duct to duct biliary anastomosis with internal biliary stent
62615206|NCT02781376|OTHER|Control|Two clinics will be randomized to receive a control computer decision support system module that automates screening for snoring and alerts the PCP, but does not provide any additional guidance on evidence-based diagnosis or management.
62840215|NCT02814994|EXPERIMENTAL|low tidal volume|Ventilated patients with low tidal volume
62840216|NCT00004554|EXPERIMENTAL|Sertraline|sertraline
62840217|NCT00004554|EXPERIMENTAL|Naltrexone|naltrexone
62840218|NCT00004554|EXPERIMENTAL|Nal/Sert|naltrexone/sertraline
62840219|NCT00004554|PLACEBO_COMPARATOR|Placebo|Placebo
62615207|NCT00791492|EXPERIMENTAL|Fx-1006A|
62615208|NCT05091619|EXPERIMENTAL|A1|subjects aged 3 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old
62615209|NCT05091619|ACTIVE_COMPARATOR|A2|subjects aged 3 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old
62840220|NCT05322473|EXPERIMENTAL|sonelokimab dose 1|Subjects randomized to this arm will receive assigned sonelokimab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
62840221|NCT05322473|EXPERIMENTAL|sonelokimab dose 2|Subjects randomized to this arm will receive assigned sonelokimab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
62055701|NCT03534310|ACTIVE_COMPARATOR|Lifestyle modification|1 month of a VLCD with 865 kcal per day followed by a 12 kcal per kg of body weight of a high-protein, high fat diet for 11 months in association with intensive
62055702|NCT03534310|EXPERIMENTAL|Lifestyle modification plus Liraglutide 3 mg|1 month of a VLCD with 865 kcal per day followed by a 12 kcal per kg of body weight of a high-protein, high fat diet for 11 months in association with intensive. The patients will also receive Liraglutide 3 mg daily sc.
62055703|NCT03534310|ACTIVE_COMPARATOR|Sleeve Gastrectomy|The patients will undergo laparoscopic sleeve gastrectomy
62840222|NCT05322473|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and will be re-randomized to receive a sonelokimab dosage regimen during Part B.
62840223|NCT05322473|ACTIVE_COMPARATOR|adalimumab|Subjects randomized to this arm will receive adalimumab during the Double-Blind Treatment Period and will be reallocated to receive sonelokimab dosage regimen during Part B.
62840224|NCT04615026||COVID 19 patients|all patients with positive SARS-CoV 2 swap
62840225|NCT02897440||Full Repairing of soft tissue surrounding the hip|Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting
62840226|NCT02897440||Partial Repairing of soft tissue surrounding the hip|Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting
62840227|NCT04073979|EXPERIMENTAL|Mistral|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
62258195|NCT05422560|EXPERIMENTAL|Embolization of the inferior mesenteric artery|"Only one arm: Patient followed for sigmoid/rectal cancer~1. Pré-Selection Preoperative consultation, first information to the patient, Validation of IC / NIC, CT-TAP available~2. Selection Interventional radiology consultation: Consent collection + additional exams~3. Inclusion V1 - D0:~4. Follow-up visit V2 - D2: Phone call, pain assessment and analgesic treatments collection~5. Follow-up visit V3 - D7: Phone call, pain assessment and analgesic treatments collection~6. Follow-up visit V4 - D21-D30: CT-TAP~7. Follow-up visit V5 - D30: Digestive surgery consultation + additionnal exams~8. Surgery V6 - D0: Colic surgery + additional exams~9. Post-surgery visit V7 - D30: Last visit, additionnal exams"
62258196|NCT02800889|EXPERIMENTAL|Treatment: Pixantrone|Each patient will receive pixantrone monotherapy administered intravenously once on days 1, 8, and 15 up to six 28-day cycles of pixantrone monotherapy, with two additional cycles in patients who continue to benefit from treatment. At least 6 patients each from Age Cohorts 1 and 2 will be accrued into dose escalation cohorts. The study will be opened to patients of Age Cohort 3 only after at least 6 patients in Age Cohorts 1 and 2 (combined) have been evaluated for toxicity. During the dose escalation phase, participants who are inevaluable for DLT for reasons unequivocally unrelated to toxicity will be replaced. Expansion cohort accrual quota-At least 15 evaluable patients treated with the MTD/optimal dose will be accrued in total, of which 7 patients will be in Age Cohort 2.
62258197|NCT06198803|EXPERIMENTAL|l carnitine group|All aged from 1 month till 16 years old with DRE on KD.
62258198|NCT06198803|NO_INTERVENTION|non l carnitine gruop|patient with drug resistant epilepsy on ketogenic diet
62258199|NCT02969187|EXPERIMENTAL|Experimental|Patients at our Bariatric Surgery Center of Excellence fulfilling NIH criteria for bariatric surgery and planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure randomized to receive 20 ml of 1.3% Exparel + 30 ml of 0.5% Bupivacaine + 150 ml of Saline
62258200|NCT02969187|ACTIVE_COMPARATOR|Control|Patients at our Bariatric Surgery Center of Excellence fulfilling NIH criteria for bariatric surgery and planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure randomized to receive 60ml of 0.5% Bupivacaine + 140 ml of Saline.
62444863|NCT03636321|ACTIVE_COMPARATOR|stentless|in this group ,patients candidate for living donor liver transplantation duct to duct biliary anastomosis will done without internal biliary
62615210|NCT05091619|ACTIVE_COMPARATOR|A3|subjects aged 3 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old
62615211|NCT05091619|EXPERIMENTAL|B1|subjects aged 2 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old
62258201|NCT01136135||CARDIAC MRI|
62444864|NCT03993171|EXPERIMENTAL|7.5mg CNM-Au8|7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
62444865|NCT03993171|EXPERIMENTAL|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
62444866|NCT03993171|EXPERIMENTAL|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
62615212|NCT05091619|ACTIVE_COMPARATOR|B2|subjects aged 2 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old
62615213|NCT05091619|EXPERIMENTAL|B3|subjects aged 2 months receive 3 doses of vaccines with a interval of 2 months for primary immunization, and a booster dose at 18 month old
62055704|NCT05608304|EXPERIMENTAL|Formal mindfulness induction|
62055705|NCT05608304|EXPERIMENTAL|Informal mindfulness induction|
62258202|NCT04282395|EXPERIMENTAL|Resilience-Based Diabetes Self-Management Education|The RB-DSME structure involves 8 weekly classes, 8 bimonthly support group sessions, and 2 booster sessions. The RB-DSME builds on foundational resilience resources (e.g., self-efficacy, social support), infusing novel resilience resources (e.g., adaptation to stress, finding positive meaning, spiritual coping) into the RB-DSME curriculum.
62258203|NCT04282395|ACTIVE_COMPARATOR|Standard Diabetes Self-Management Education|The scope and sequence of the standard diabetes self-management education (DSME) curriculum are aligned with national standards of the American Diabetes Association. DSME groups receive a 10-month intervention: 8 weekly educational sessions, followed by 8 bimonthly support group sessions, followed by 2 booster sessions.
62258204|NCT03060044|EXPERIMENTAL|Salmeterol/fluticasone Easyhaler|single dose of Salmeterol/fluticasone Easyhaler
62258205|NCT03060044|EXPERIMENTAL|Salmeterol/fluticasone Easyhaler with charcoal|Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration
62258206|NCT03060044|ACTIVE_COMPARATOR|Seretide Diskus|Single dose of Seretide Diskus
62055706|NCT05608304|ACTIVE_COMPARATOR|Active control task|
62055707|NCT03122561|OTHER|Paracetamol 500 mg tablet at Morning|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at morning
62258207|NCT03060044|ACTIVE_COMPARATOR|Seretide Diskus with charcoal|Single dose of Seretide Diskus with concomitant charcoal administration
62258208|NCT04763642|ACTIVE_COMPARATOR|Laparoscopic Pancreaticoduodenectomy (LPD)|
62258209|NCT04763642|ACTIVE_COMPARATOR|Robotic Pancreaticoduodenectomy (RPD)|
62258210|NCT04763642|PLACEBO_COMPARATOR|Open Pancreaticoduodenectomy (OPD)|
62258211|NCT06147479|EXPERIMENTAL|CS-ADL|CS-ADL is a multi-component cognitive stimulation program that aims to enhance performance of activities of daily living (ADL) for people living with mild-to-moderate dementia.
62258212|NCT06147479|NO_INTERVENTION|Treatment as Usual (TAU)|The control group continue to receive their usual care. This may differ between individuals, but may include physiotherapy, occupational therapy, nursing, medication or attendance at a day-care centre/day hospital. This treatment is decided by their healthcare provider who is external to the research team. It is possible that 'TAU' for some individuals dictates no treatment.
62444867|NCT03993171|EXPERIMENTAL|60mg CNM-Au8|60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
62444868|NCT01915056|NO_INTERVENTION|Control Arm|Control Arm = Standard of Care. Patients who are randomized to the control arm will only have abnormal results on Geriatric Depression Scale (GDS) and cognitive evaluation communicated to their primary oncologist, as is customary. These results will be communicated to the primary team via electronic medical record and/or email communication. No other summary will be provided to oncologist.
62615214|NCT05091619|EXPERIMENTAL|C1|subjects aged 3 months receive 3 doses of lot-1 vaccines with a interval of 30 days for primary immunization
62258213|NCT04076514||patients with node negative papillary thyroid carcinoma|
62258214|NCT05988788|EXPERIMENTAL|Epigallocatechin-3-Gallate|20% Epigallocatechin-3-Gallate solution
62258215|NCT05988788|ACTIVE_COMPARATOR|sodium hypochlorite|2.5% sodium hypochlorite
62258216|NCT02305095||GNB3 TT|All subjects with the GNB3 TT genotype for the polymorphism at position 825 (T/C). They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).
62258217|NCT02305095||GNB3 C|All subjects with at least one copy of the GNB3 C allele which includes both subjects homozygous for the 825C allele (GNB3 CC genotype) and subjects who are heterozygous (GNB3 TC genotype).They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).
62258218|NCT03715699|EXPERIMENTAL|Group 1|Patients treated with single glucocorticoid
62615215|NCT05091619|EXPERIMENTAL|C2|subjects aged 3 months receive 3 doses of lot-2 vaccines with a interval of 30 days for primary immunization
62615216|NCT05091619|EXPERIMENTAL|C3|subjects aged 3 months receive 3 doses of lot-3 vaccines with a interval of 30 days for primary immunization
62615217|NCT06245798||liver resection|
62615218|NCT06245798||transarterial chemoembolisation|
62615219|NCT05921422||Case group|Children and adolescents with cerebral palsy who are 11-15 years old, diagnosed with cerebral palsy (any type), and who attend a Danish mainstream school at time of enrollment
62055708|NCT03122561|OTHER|Paracetamol 500 mg tablet at Midday|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at midday
62615220|NCT05921422||Control group|Children and adolescents without cerebral palsy in the same age range as case-participants (11-15 years old) and attend Danish mainstream schools.
62615221|NCT03030274|EXPERIMENTAL|Occlutech AFR Device|Prospective, non-randomized, pilot study to assess safety and efficacy of a novel Atrial Flow Regulator in Heart Failure Patients with with reduced Ejection Fraction (HFrEF) and Heart Failure Patients with preserved Ejection Fraction (HFpEF); the AFR-Prelieve Trial
62258219|NCT03715699|EXPERIMENTAL|Group 2|Patients treated with Leflunomide and glucocorticoid
62258220|NCT00547872|EXPERIMENTAL|1|Best medical/behavioral treatment according to guidelines suggestions plus CAD screening by ECG tolerance testing followed by revascularization in case of coronary stenosis.
62055709|NCT03122561|OTHER|Paracetamol 500 mg tablet at Night|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at night
62055710|NCT03217448|EXPERIMENTAL|Dabigatran etexilate group|Subjects in this group will take Dabigatran etexilate for 6 months after randomization
62258221|NCT00547872|NO_INTERVENTION|2|Best medical/behavioral treatment according to guidelines suggestions
62258222|NCT03112889|EXPERIMENTAL|Sodium Valproate|Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
62258223|NCT02553265|PLACEBO_COMPARATOR|Placebo|Matching placebo
62615222|NCT04475718|OTHER|Fourth Trimester Mobile Tool|Fourth Trimester Mobile Tool
62615223|NCT01194050||Cohort|
62055711|NCT03217448|ACTIVE_COMPARATOR|Warfarin group|Subjects in this group will take Warfarin for 6 months after randomization
62055712|NCT00628901|EXPERIMENTAL|Arm 1|
62055713|NCT00628901|ACTIVE_COMPARATOR|Arm 2|
62258224|NCT02553265|EXPERIMENTAL|Low-Dose Carbidopa|
62258225|NCT02553265|ACTIVE_COMPARATOR|High-Dose Carbidopa|
62258226|NCT03960775|EXPERIMENTAL|Group A (dexmedetomidine)|dexmedetomidine infusion group
62258227|NCT03960775|PLACEBO_COMPARATOR|Group B (saline)|normal saline infusion group
62258228|NCT01245504||Lower-limb amputee|Subjects with at least one lower limb amputated at teh trans-tibial level
62258229|NCT04188574|EXPERIMENTAL|BB2603-10|Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
62258230|NCT04188574|EXPERIMENTAL|BB2603-3|Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine
62258231|NCT04188574|EXPERIMENTAL|BB2603-1|Treatment with topical spray twice-daily (BID)BB2603-1: 0.01% terbinafine
62840228|NCT05631613||Water for Injection -Idarubicin -Lipiodol|"Idarubicin is first dissolved in water for injection to make a solvent of~1mg/ml, which is then mixed with lipiodol to make an emulsion with a ratio of 1:2. Lipiodol-idarubicin emulsion is slowly injected, followed by embolization with embolic agents."
62258232|NCT04188574|OTHER|Vehicle Control|0.3% polyhexanide/ 20% ethanol/ water formulation.
62444869|NCT01915056|EXPERIMENTAL|Treatment Arm|Treatment Arm = Standard care plus GA results and recommendations. For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic (GA-driven intervention). The intervention consists of providing results of geriatric assessment in a summary to oncologists.
62840229|NCT05631613||Nonionic Contrast Agent -Idarubicin -Lipiodol|"Idarubicin is first dissolved in nonionic contrast agent to make a solvent of~1mg/ml, which is then mixed with lipiodol to make an emulsion with a ratio of 1:2. Lipiodol-idarubicin emulsion is slowly injected, followed by embolization with embolic agents."
62840230|NCT04565639|EXPERIMENTAL|Experimental Power Hand Orthosis|Participants will test the improved grip strength using the powered hand orthosis system.
62840231|NCT04565639|EXPERIMENTAL|Experimental Power Hand Orthosis - Tasks of Daily Living|Participants will test the improved ability to perform tasks of daily living using the powered hand orthosis system.
62840232|NCT01119404||Metabolic Syndrome|120 men with metabolic syndrome
62444870|NCT06452810|EXPERIMENTAL|Single Group|All participants in this arm will receive the Sahajan Golden Glow Balm and will follow the same intervention protocol.
62444871|NCT05304299|EXPERIMENTAL|Cordyceps Cicadae Mycelia only|Only Cordyceps Cicadae Mycelia will be given.
62055714|NCT05873725||Follitropin delta + hCG|Combination of follitropin delta and serial hCG injections at individualized doses, where dosing regimen was determined according to AMH and weight in women undergoing an IVF antagonist cycle
62258233|NCT00820495|EXPERIMENTAL|Web + Phone|Highly interactive tailored Web-based smokeless tobacco cessation program plus phone counseling
62258234|NCT00820495|EXPERIMENTAL|Web Only|Highly interactive tailored Web-based smokeless tobacco cessation program
62258235|NCT00820495|EXPERIMENTAL|Phone Only|Phone counseling intervention for smokeless tobacco cessation
62258236|NCT00820495|EXPERIMENTAL|Control|Usual care (initial call plus self-help materials)
62258237|NCT01590550||Single arm|Single arm for all patient receiving inpatient HD
62444872|NCT05304299|EXPERIMENTAL|Cordyceps Cicadae Mycelia with Taflotan (saflutan)|Cordyceps Cicadae Mycelia with Taflotan (saflutan) will be given.
62840233|NCT01119404||Coronary Heart Disease (CHD)|120 men with angiographically verified CHD
62840234|NCT01119404||Control|80 physically active men
62840235|NCT03810924|ACTIVE_COMPARATOR|Control|Participants reads newspaper before Barlab-Exposure
62840236|NCT03810924|EXPERIMENTAL|Experimental 1 (Distress)|Participants undergo the Trier Social Stress Test before Barlab-Exposure
62840237|NCT03810924|EXPERIMENTAL|Experimental 2 (Eustress)|Participants ride an ergometer before Barlab-Exposure
62840238|NCT04978298|EXPERIMENTAL|Rasagiline group|Participants will receive rasagiline once daily (QD) for 14 days from Days 59 to 72.
62840239|NCT04978298|EXPERIMENTAL|Phenelzine group|Participants will receive phenelzine twice daily (BID) for 14 days from Days 59 to 72.
62840240|NCT04978298|EXPERIMENTAL|Ozanimod Therapeutic group|Participants will receive ozanimod QD for 65 days (including the initial 7-day dose escalation) from Days 8 to 72.
62840241|NCT04978298|EXPERIMENTAL|Ozanimod Supra-therapeutic group|Participants will receive ozanimod QD for 65 days (including the initial 10-day dose escalation) from Days 8 to 72.
62840242|NCT04978298|PLACEBO_COMPARATOR|Placebo|Participants will receive matched appropriate placebos from Days 8 to 72.
62840243|NCT06009211||Aromatherapy|Randomized crossover research study
62055715|NCT05873725||Follitropin delta + HP-hMG|Combination of follitropin delta and highly-purified human menopausal gonadotropin (HP-hMG) where dosing regimen was determined according to AMH and weight in women undergoing an IVF antagonist cycle
62055716|NCT00548730||White Light Bronchoscopy|Patients with known or suspected malignancies of the lung and with a medical indication for a bronchoscopy will have images taken with white light bronchoscopy
62055717|NCT00548730||Autofluorescence Bronchoscopy|Patients with known or suspected malignancies of the lung and with a medical indication for a bronchoscopy will have images taken with autofluorescence bronchoscopy
62055718|NCT00548730||Narrow Band Imaged Bronchoscopy|Patients with known or suspected malignancies of the lung and with a medical indication for a bronchoscopy will have images taken with narrow band imaged bronchoscopy
62444873|NCT05936879|EXPERIMENTAL|Inspiratory muscle training and early ambulation|Intervention group will be treated with Inspiratory muscle training once in a week for at least 3 weeks
62444874|NCT05936879|EXPERIMENTAL|physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs.|Control group routine physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs once in a week for at least 3 weeks
62055719|NCT01804101|EXPERIMENTAL|Arm I (lower-dose liposomal cytarabine-daunorubicin CPX-351)|"INDUCTION/RE-INDUCTION: Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRp continue on to consolidation.~CONSOLIDATION: Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1 and 3. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity."
62055720|NCT01804101|EXPERIMENTAL|Arm II (closed to accrual effective 4/21/14)|"INDUCTION/RE-INDUCTION: Patients receive higher-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRp continue on to consolidation.~CONSOLIDATION: Patients receive higher-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1 and 3. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity."
62055721|NCT02402088|ACTIVE_COMPARATOR|Normal Weight|BMI18.5-24.9 (normal range)
62055722|NCT02402088|EXPERIMENTAL|Overweight|body mass index between 25.0 - 29.9 (overweight range)
62055723|NCT02402088|EXPERIMENTAL|Obese|body mass index between 30 and 35 (obese range)
62055724|NCT01668082|EXPERIMENTAL|surgical resection of a brain tumor|"The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.~--------------------------------------------------------------------------------"
62055725|NCT03402256|EXPERIMENTAL|Text Message (TM)|"Participants will receive daily text messages and all elements of standard care. They received 3 text messages per day for the first four weeks of the study and 3 messages per week for the last four weeks. Key domains of message topics were chosen based on the content of evidence-based, relapse prevention treatment. Daily messages determined current level of functioning and provide intervention messages in response. Text messages will be sent via Google Voice on a research computer. Participants will respond to the text messages either with a specified response (e.g. YES/NO) or a generic response (e.g. 1). Some messages will ask for a specific reply in response to a question. Based on the participant's response (e.g. high, med, low), the research assistant will respond with a text message tailored to the participant's message. All text messages will be sent to the HIC in an amendment to this protocol for approval."
62444875|NCT06543147|EXPERIMENTAL|experimental group|There are 79 female participants in this group. After the pre-test, participants in the experimental group were given breast cancer and breast self-examination training. After the training, they were reminded to do breast self-examination by phone for six months. The post-test was administered six months later.
62615224|NCT01538394|EXPERIMENTAL|Varenicline & nicotine patches|"Combined therapy by using Varenicline plus nicotine patches.The intervention-phase will comprise two fasses:~* Pre-NRT: Patients take 1 week VRN impregnation (0.5mg/day during the first 3 days + 0.5mg twice daily for the next for days)~* Treatment: starting at day 8 and during the next 11 weeks patients continue taking VRN 1mg twice daily plus placebo transdermal patches of 30cm2/24 hours per 8 weeks and then 20cm2/24 hours per 3 weeks."
62615225|NCT01538394|PLACEBO_COMPARATOR|Varenicline & placebo patches|"Monotherapy by using Varenicline plus placebo patches.The intervention-phase will comprise two fasses:~* Pre-NRT: Patients take 1 week VRN impregnation (0.5mg/day during the first 3 days + 0.5mg twice daily for the next for days)~* Treatment: starting at day 8 and during the next 11 weeks patients continue taking VRN 1mg twice daily plus nicotine transdermal patches of 30cm2/24 hours per 8 weeks and then 20cm2/24 hours per 3 weeks."
62258238|NCT02300948|EXPERIMENTAL|PregVit-Folic 5®-5 mg folic acid|Prenatal multivitamin-mineral supplement called PregVit-folic 5® contains 5 mg of folic acid. All other vitamin and mineral doses are identical between the 2 supplements, except for folic acid. Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation.
62258239|NCT02300948|ACTIVE_COMPARATOR|PregVit®-1.1 mg folic acid|Prenatal multivitamin-mineral supplement called PregVit® contains 1.1 mg of folic acid. All other vitamin and mineral doses are identical between the 2 supplements, except for folic acid. Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation.
62258240|NCT02035176||Autistic children ages 6-11|Autistic children ages 6-11
62258241|NCT02035176||ADHD children ages 6-11|ADHD children ages 6-11
62840244|NCT02816385|ACTIVE_COMPARATOR|Antegrade Cardioplegia|Coronary artery bypass grafting (CABG) surgery in patients with a normal left ventricular ejection fraction (FEVG)
62840245|NCT02816385|EXPERIMENTAL|Retrograde Cardioplegia|Coronary artery bypass grafting (CABG) surgery in patients with a normal left ventricular ejection fraction (FEVG)
62840246|NCT02223858|EXPERIMENTAL|Positive Activities (PA)|Positive Activities (PA) Program
62258242|NCT02035176||Typical children ages 6-11|Typical children ages 6-11
62258243|NCT00289380||Nutrition support|Nutrition support cohort means accept nutrition support，it was defined as ≥15kal/kg/d and \< 30kal/kg/d of non-protein calories (carbohydrate and/or fat) and amino acids or protein≥1g/kg/d for 5\~28 consecutive days.
62258244|NCT00289380||Without nutritional support|Group received only intravenous 5 to 10% glucose and electrolyte infusions
62258245|NCT06491056||Focal Therapy for Prostate Cancer|Patients undergoing focal therapy (various modalities) for prostate cancer as defined by partial gland ablation of \<75% of the prostate gland.
62258246|NCT03683940|OTHER|Screening|Subjects will undergo a low dose non contrast CT chest for lung cancer screening.
62258247|NCT05145998|ACTIVE_COMPARATOR|Control - Glucola|Glucola control beverage
62258248|NCT05145998|EXPERIMENTAL|Whole peas|Whole cooked peas in a 50 gram carbohydrate meal dose
62258249|NCT05145998|EXPERIMENTAL|Pea Flour|Pea flour in a 50 gram carbohydrate meal dose
62258250|NCT05145998|EXPERIMENTAL|Whole lentils|Whole cooked lentils in a 50 gram carbohydrate meal dose
62258251|NCT05145998|EXPERIMENTAL|Lentil flour|Lentil flour in a 50 gram carbohydrate meal dose
62840247|NCT02223858|ACTIVE_COMPARATOR|Attention Control (AC)|Attention Control (AC) Program
62840248|NCT02394587|EXPERIMENTAL|Mindfulness-Based Stress Reduction|Subjects assigned to the experimental group will participate in a MBSR foundation program, which includes weekly telephonic, group-based, 60-minute MBSR sessions for 6 weeks. The foundation program will introduce subjects to the concept of mindfulness with each week focusing on a different facet. Modeled after Kabat-Zinn's original program, breath awareness (focus on breath and observing thoughts without fighting or following them), body scan (promoting mindfulness of sensations in different parts of body), walking meditation (walking as form of meditation), loving kindness (projection of friendliness and kindness towards oneself and others), and choiceness awareness (awareness of all sensations with equal interest) will be taught.
62840249|NCT02394587|OTHER|Wait-listed control group|Subjects assigned to the wait-listed control group will not receive the MBSR program, but will receive weekly reminders of their study participation, be asked to complete the same questionnaires (per telephone script) once every three weeks, and receive the same financial incentives as the MBSR group. Upon completion of the 6-week session, the wait-list control group will be offered the same MBSR program. At that time, a new series of MBSR sessions will be scheduled and offered to the wait-listed control patients. Subjects who elect to participate in MBSR will receive the same packet of materials and measures received by the intervention group and be asked to complete the measures again at baseline, 1, 3, and 6 weeks.
62840250|NCT04029077||Vapor group|Bronchoscopic lung volume reduction treatment using Vapor
62258252|NCT00708123|ACTIVE_COMPARATOR|Sodium Fluoride (NaF) toothpaste[1350 parts per million(ppm)F]|Participants to brush their natural teeth twice daily with a full ribbon of NaF toothpaste (1350 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
62258253|NCT00708123|EXPERIMENTAL|NaF/Carbopol toothpaste (1400 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaF and 0.5% carbopol toothpaste (1450 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
62258254|NCT00708123|ACTIVE_COMPARATOR|NaMFP/NaF toothpaste (1450 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaMFPand NaF toothpaste (1450 ppm F - 1000 ppm F as NaMFP and 450 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
62258255|NCT00708123|ACTIVE_COMPARATOR|NaF toothpaste (250 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaF toothpaste (250 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
62258256|NCT00708123|PLACEBO_COMPARATOR|Placebo toothpaste (0 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of fluoride free toothpaste (0 ppm F) for one timed minute, after removing their partial denture from their mouth.
62258257|NCT04072055||MOTO medial|Patients suitable fulfilling the standard criteria for the implantation of unicondylar implant.
62258258|NCT01140945||Males attending in vitro fertilization clinic|
62258259|NCT01035099|EXPERIMENTAL|Titrated dose Letrozole|Patients who are randomized to the titrated dose of Letrozole, will start gonadotropins in the evening of day #2 of their menstrual cycle with injectable follicle stimulating hormone (FSH) and human menopausal gonadotropin (HMG). Oral Letrozole will be added to the stimulation in the following titrated regimen.
62258260|NCT01035099|ACTIVE_COMPARATOR|Fixed dose Letrozole|Patients who are randomized to fixed dose Letrozole will start Letrozole 5mg daily (orally) on the second day of their menstrual cycle and then gonadotropins on the fourth day of their menstrual cycle.
62258261|NCT03182647||Non surgery|Patients were not treated with surgery initially
62258262|NCT03182647||Surgery|Patients had an initial surgical treatment
62258263|NCT06082141|ACTIVE_COMPARATOR|Ultrasound guided serratus anterior plane block|SAP block will be made with 10 ml 0.5% bupivacaine + 10 ml NaCl TTP block will be made with 10 ml NaCl
62840251|NCT05824195|EXPERIMENTAL|Quinoa1|Quinoa bread type1.
62840252|NCT05824195|EXPERIMENTAL|Quinoa 2|Quinoa bread type 2
62615226|NCT02972450|EXPERIMENTAL|Injection only: Active:placebo (3:1)|"GTU-MultiHIV B-clade + MVA HIV-B:~GTU-MultiHIV B-clade - 2 mg of DNA in 1ml encoding a multi HIV antigen (synthetic fusion protein) administered intramuscularly into the non-dominant deltoid muscle at weeks 0 and 4 and MVA HIV-B 0.5ml(1 x108 pfu/ml) MVA encoding the full-length codon-optimized sequence of Gag administered intramuscularly into the non-dominant deltoid muscle at week 12."
62615227|NCT02972450|EXPERIMENTAL|Infusion only: Active:placebo (3:1)|Vedolizumab will be administered in the participant's dominant arm as an intravenous infusion over 30 mins.
62840253|NCT05824195|EXPERIMENTAL|Quinoa 3|Quinoa bread type 3
62840254|NCT05824195|SHAM_COMPARATOR|Reference|A white wheat bread
62615228|NCT02972450|EXPERIMENTAL|Injection and Infusion: Active:placebo (3:1)|GTU-MultiHIV B-clade + MVA HIV-B + Vedolizumab
62840255|NCT05573997||Heart failure with reduced ejection fraction|Left Ventricular Ejection Fraction of ≤40%
62258264|NCT06082141|ACTIVE_COMPARATOR|Combination of ultrasound-guided serratus anterior plane block and transversus thoracis plane block|SAP block will be made with 10 ml 0.5% bupivacaine + 10 ml NaCl TTP block will be made with 5 ml 0.5% bupivacaine + 5 ml NaCl
62258265|NCT05623930|ACTIVE_COMPARATOR|laser on acupuncture points|In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
62258266|NCT05623930|ACTIVE_COMPARATOR|cupping (with scarification)|in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.
62258267|NCT00948363|ACTIVE_COMPARATOR|Kiwi fruits|
62258268|NCT00948363|PLACEBO_COMPARATOR|Apple|
62258269|NCT01668732||community heroin addicts|
62258270|NCT01222455|EXPERIMENTAL|1|Mild hepatic impairment
62258271|NCT01222455|EXPERIMENTAL|2|Moderate hepatic impairment
62615229|NCT02972450|PLACEBO_COMPARATOR|Placebo|"Placebo1 for DNA: Sodium chloride for injection, 0.9% in 1ml administered intramuscularly into the non-dominant deltoid muscle at weeks 0 and 4.~Placebo 2 for MVA: S08 buffer in 0.5ml administered intramuscularly into the non-dominant deltoid muscle at week 12.~Placebo for mAb: Sodium Chloride (NaCl) for infusion, 0.9% in 250 ml infusion bags."
62615230|NCT02489474||Recipients undergoing liver transplantation|Patients undergoing liver transplantation will be included and followed up during the first 72 hours post-liver transplantation in order to confirm the development of acute kidney injury. The patients will be divided into two groups (AKI group vs. non-AKI group) according to the development of acute kidney injury.
62615231|NCT02455713||Intervention|Alter PEEP and PIP and measure hemodynamic outcomes.
62615232|NCT03351153|OTHER|X-ray group|In the X-ray group, the changes in femoral head height were measured with X-ray in an anteroposterior position of the pelvis (healthy and affected sides of the hip) at preoperative 1 week.
62258272|NCT01222455|EXPERIMENTAL|3|Severe hepatic impairment
62840256|NCT05573997||Heart failure with mid-range ejection fraction|Left Ventricular Ejection Fraction of 41-49%
62258273|NCT01222455|EXPERIMENTAL|4|Matched healthy volunteers with normal hepatic function
62258274|NCT00434421|EXPERIMENTAL|German Cockroach Allergen Dosing Group|Glycerinated German Cockroach Allergenic Extract
62840257|NCT05573997||Heart failure with preserved ejection fraction|Left Ventricular Ejection Fraction of ≥50%
62840258|NCT06471335|EXPERIMENTAL|Patients Fetal Alcohol Spectrum Disorder|Patients with Fetal Alcohol Spectrum Disorder, male an female, aged 0 to 18 inclusive.
62840259|NCT06471335|ACTIVE_COMPARATOR|Participants without Fetal Alcohol Spectrum Disorder|Participants without Fetal Alcohol Spectrum Disorder, male an female, aged 0 to 18 inclusive.
62840260|NCT03529591|ACTIVE_COMPARATOR|180 deg selective laser trabeculoplasty|The right eye of a patient is randomized to be treated with either 180 or 360 degrees selective laser trabeculoplasty (SLT). The fellow eye is treated with the opposite treatment, that is, if the right eye is treated with 180 degrees SLT, the left eye is treated with 360 degrees SLT. Intraocular pressure (IOP) response is assessed at 2 weeks, one, three and six months post treatment and compared to the alternative treatment arm, the fellow eye.
62840261|NCT03529591|ACTIVE_COMPARATOR|360 deg selective laser trabeculoplasty|The right eye of a patient is randomized to be treated with either 180 or 360 degrees selective laser trabeculoplasty (SLT). The fellow eye is treated with the opposite treatment, that is, if the right eye is treated with 180 degrees SLT, the left eye is treated with 360 degrees SLT. Intraocular pressure (IOP) response is assessed at 2 weeks, one, three and six months post treatment and compared to the alternative treatment arm, the fellow eye.
62055726|NCT03402256|NO_INTERVENTION|Standard Care (SC)|"Participants will receive only standard care provided by the liver transplantation team. No additional behavioral or psychosocial interventions will be provided. All aspects of care received by SC participants will also provided to the TM condition participants. Medical care will be managed by medical specialty providers. SC condition participants will receive behavioral treatment within the liver transplantation clinic by psychology fellows and/or psychologists/psychiatrists. Treatment schedules and session topics will be determined by individual providers, per usual practice.~These participants will receive only study-specific assessments. Participants in this condition will complete assessments at baseline, 4-weeks and 8-weeks that measure self- reported substance use, stress, and coping skills. At each in-person assessment, participants will provide urine for EtG analysis and will be compensated."
62055727|NCT01544998|EXPERIMENTAL|Tadalafil plus Placebo, then Tadalafil plus Nesiritide|First intervention period: oral Tadalafil; after 1 hour, subcutaneous (sc) placebo given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting. There was a one week washout period. Second intervention period: oral Tadalafil; after 1 hour, sc Nesiritide given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting.
62055728|NCT01544998|EXPERIMENTAL|Tadalafil plus Nesiritide, then Tadalafil plus Placebo|First intervention period: oral Tadalafil; after 1 hour, sc Nesiritide given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting. There was a one week washout period. Second intervention period: oral Tadalafil; after 1 hour, sc placebo given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting.
62055729|NCT04807985||Ambulatory CHF patients|Patients visiting an outpatient CHF clinic
62055730|NCT04874402|ACTIVE_COMPARATOR|Prepectoral approach|Immediately following mastectomy, participants will undergo prepectoral reconstruction approach. Intraoperative filling volume will be decided by the attending surgeon based on the pocket dimension and volume capabilities. Participants will be evaluated at 6 time points during the study.
62055731|NCT04874402|EXPERIMENTAL|Partial subpectoral approach|Immediately following mastectomy, participants will undergo partial subpectoral reconstruction approach. Intraoperative filling volume will be decided by the attending surgeon based on the pocket dimension and volume capabilities. Participants will be evaluated at 6 time points during the study.
62055732|NCT01499225|EXPERIMENTAL|YH14642 A-I|
62055733|NCT01499225|EXPERIMENTAL|YH14642 A-II|
62055734|NCT01499225|EXPERIMENTAL|YH14642 A-III|
62055735|NCT01499225|ACTIVE_COMPARATOR|Active Comparator B|
62055736|NCT01499225|ACTIVE_COMPARATOR|Active Comparator C|
62055737|NCT01499225|PLACEBO_COMPARATOR|Placebo|
62055738|NCT01695824|ACTIVE_COMPARATOR|LAA occluder|
62055739|NCT01695824|ACTIVE_COMPARATOR|Warfarin|
62055740|NCT03389568|EXPERIMENTAL|Intervention for caregivers of ICU patients|
62055741|NCT01793025|EXPERIMENTAL|ATAC Therapy|
62055742|NCT06198023|EXPERIMENTAL|Educational|
62055743|NCT06198023|EXPERIMENTAL|Interactive|
62055744|NCT04056884|ACTIVE_COMPARATOR|SIBS intervention|SIBS intervention is a 5-session group intervention for siblings and parents of children with chronic illness. Sessions 1-3 are delivered in one day, and sessions 4-5 are delivered in one day one week later.
62258275|NCT01540253|EXPERIMENTAL|Treatment (enzyme inhibitor and chemotherapy)|Patients receive PI3K inhibitor BKM120 PO QD and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62258276|NCT04935099|EXPERIMENTAL|Blueberry/Placebo|In this arm, participants will receive the blueberry intervention first, followed by the placebo one week later.
62258277|NCT04935099|EXPERIMENTAL|Placebo/Blueberry|In this arm, participants will receive the placebo first, followed by the blueberry intervention one week later.
62840262|NCT04473677||Fecal Occult Blood Test|People in this group will detect hemoglobin in stool before colonoscopy by the new qFIT.
62840263|NCT02534740|EXPERIMENTAL|4 soft gel capsules of 20 mg tafamidis meglumine|
62840264|NCT02534740|EXPERIMENTAL|48.8 mg tafamidis soft gel capsule formulation 1|
62055745|NCT04056884|NO_INTERVENTION|Waitlist|Waitlist is 12 week of no intervention/usual care
62840265|NCT02534740|EXPERIMENTAL|48.8 mg tafamidis soft get capsule formulation 2|
62840266|NCT02534740|EXPERIMENTAL|61 mg tafamidis soft gel capsule formulation 1|
62840267|NCT02534740|EXPERIMENTAL|61 mg tafamidis soft gel capsule formulation 2|
62840268|NCT02379637|EXPERIMENTAL|A N-acetylcysteine|N-acetylcysteine
62840269|NCT02379637|PLACEBO_COMPARATOR|B Placebo|Placebo
62840270|NCT01962740|ACTIVE_COMPARATOR|Xience EES|This arm of patients will receive Xience Everolimus Eluting Stents(EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
62840271|NCT01962740|ACTIVE_COMPARATOR|Resolute Integrity ZES|This arm of patients will receive Resolute Integrity Zotaralimus Eluting Stents (ZES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
62840272|NCT01962740|ACTIVE_COMPARATOR|Promus Element EES|This arm of patients will receive Promus Element Everolimus Eluting Stents (EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
62840273|NCT01263847|PLACEBO_COMPARATOR|No Galactooligosaccharide|0 g galactooligosaccharide added to calcium-containing yogurt beverage
62840274|NCT01263847|ACTIVE_COMPARATOR|5 g Galactooligosaccharide|5 g galactooligosaccharide provided in two calcium-containing yogurt beverage (2.5 g in each drink) per day
62840275|NCT01263847|ACTIVE_COMPARATOR|10 g Galactooligosaccharide|10 g galactooligosaccharide added to two calcium-containing yogurt beverage (5 g in each drink) per day
62840276|NCT04617704|EXPERIMENTAL|Experimental:GC012F treatment|BCMA+ cytogenetic high-risk multiple myeloma patients be treated with a single dose of GC012F cells. Total dose of (1-5)\*10\^5/kg cells will be administered at Day 0
62840277|NCT05263778|ACTIVE_COMPARATOR|Intervention|Bempedoic acid 180 mg/ezetimibe 10 mg
62840278|NCT05263778|PLACEBO_COMPARATOR|Placebo|Matching placebo
62055746|NCT03296202||HIV patients|4500 patients infected with HIV-1
62055747|NCT00603577|PLACEBO_COMPARATOR|Placebo|
62840279|NCT00645996|EXPERIMENTAL|1|
62055748|NCT00603577|EXPERIMENTAL|Xaliproden|
62840280|NCT00645996|PLACEBO_COMPARATOR|2|Cornflour
62840281|NCT04372940|EXPERIMENTAL|Intervention Side: TXA Irrigation|2.5% tranexamic acid will be applied directly to the wound via bulb irrigation and left in place for 5 minutes in the wound bed
62840282|NCT04372940|PLACEBO_COMPARATOR|Control Side: Saline Irrigation|Contralateral side will serve as a control
62615233|NCT03351153|OTHER|CT group|In the CT group, changes of femoral head height were measured with CT scan on bilateral hips (healthy side and affected side) at preoperative 1 week.
62840283|NCT05111730|EXPERIMENTAL|The shockwave Group|Group (A) study group received medical care and standard chemotherapy and shock wave, three times / week for three successful months.
62840284|NCT05111730|NO_INTERVENTION|the traditional treatment group|group (B) control group received medical care and standard chemotherapy only.
62840285|NCT03599089|ACTIVE_COMPARATOR|CA-008 (vocacapsaicin) 0.7 mg (0.05 mg/mL concentration)|Each patient will receive a single dose of 0.7 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
62840286|NCT03599089|ACTIVE_COMPARATOR|CA-008 (vocacapsaicin) 2.1 mg (0.15 mg/mL concentration)|Each patient will receive a single dose of 2.1 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
62840287|NCT03599089|ACTIVE_COMPARATOR|CA-008 (vocacapsaicin) 4.2 mg (0.3 mg/mL concentration)|Each patient will receive a single dose of 4.2 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
62840288|NCT03599089|PLACEBO_COMPARATOR|Placebo|Each patient will receive a single dose of CA-008 vehicle (identical to active treatment but without CA-008) injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
62840289|NCT01974219||Healthy nonsmokers|Healthy nonsmokers
62840290|NCT01974219||Healthy smokers|Healthy smokers
62055749|NCT01082562|EXPERIMENTAL|Arm 1 - BMS-844421|
62055750|NCT01082562|PLACEBO_COMPARATOR|Arm 2 - 0.9% sodium chloride injection solution|
62055751|NCT01082562|EXPERIMENTAL|Arm 3 - BMS-844421|
62055752|NCT01082562|PLACEBO_COMPARATOR|Arm 4 - 0.9% sodium chloride injection solution|
62055753|NCT01082562|EXPERIMENTAL|Arm 5 - BMS-844421|
62055754|NCT01082562|PLACEBO_COMPARATOR|Arm 6 - 0.9% sodium chloride injection solution|
62055755|NCT01082562|EXPERIMENTAL|Arm 7 - BMS-844421|
62055756|NCT01082562|PLACEBO_COMPARATOR|Arm 8 - 0.9% sodium chloride injection solution|
62055757|NCT01082562|EXPERIMENTAL|Arm 9 - BMS-844421|
62055758|NCT01082562|PLACEBO_COMPARATOR|Arm 10 - 0.9% sodium chloride injection solution|
62055759|NCT01082562|EXPERIMENTAL|Arm 11 - BMS-844421|
62055760|NCT01082562|PLACEBO_COMPARATOR|Arm 12 - 0.9% sodium chloride injection solution|
62055761|NCT01082562|EXPERIMENTAL|Arm 13 - BMS-844421|
62055762|NCT01082562|PLACEBO_COMPARATOR|Arm 14 - 0.9% sodium chloride injection solution|
62055763|NCT01082562|EXPERIMENTAL|Arm 15 - BMS-844421|
62840291|NCT01974219||COPD smokers|COPD smokers
62840292|NCT02156934|EXPERIMENTAL|Muscle derived stem cell|Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
62840293|NCT03731676|ACTIVE_COMPARATOR|Rotating platform total knee arthroplasty|These patients were randomly assigned to receive a rotating platform total knee arthroplasty.
62840294|NCT03731676|ACTIVE_COMPARATOR|Fixed bearing total knee arthroplasty|These patients were randomly assigned to receive a fixed bearing total knee arthroplasty.
62615234|NCT03351153|OTHER|Specimen group|In the specimen group, femoral head on the affected side was resected during surgery and directly measured with a ruler and vernier caliper.
62615235|NCT01672294|EXPERIMENTAL|treatment|three facilitator-led end-of-life preparation and completion sessions with a facilitator with both patient and caregiver
62840295|NCT03993106|EXPERIMENTAL|Study Drug|All study participants will receive sEphB4-HSA through a needle in a vein in their arm for an hour in an outpatient clinic. All study participants will receive two doses of study drug on Days 1 and 15 of each 4 week cycle.
62840296|NCT05269667|EXPERIMENTAL|Cohort 1: treatment-naïve NMOSD patients|Patients will be treated with 120 mg satralizumab subcutaneously (SC) as monotherapy at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Week 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. All assessments (clinical, laboratory and imaging) should be performed before satralizumab administration. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
62055764|NCT01082562|PLACEBO_COMPARATOR|Arm 16 - 0.9% sodium chloride injection solution|
62055765|NCT00897130|EXPERIMENTAL|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted.
62055766|NCT04957017|ACTIVE_COMPARATOR|Intervention group|"The women with chronic disease were met, and the Descriptive Information Form, Social Hand-Washing Knowledge Form and the Nutritional Knowledge Level Scale for Adults were filled with the volunteer ones face-to-face at their homes, complying with the social distance rules before the training. After the data was collected, the women in the intervention group were trained on Hand-Washing and Nutrition during the COVID-19 period. The training on hand-washing and nutrition was given using the Hand-Washing and Nutrition Training Guide prepared by the researchers, and the Hand-Washing and Nutrition Training Manual covering the content of the training, was distributed to the women at the end of the training. The data collection forms were re-filled three months after the training."
62055767|NCT04957017|NO_INTERVENTION|Control group|The women with chronic disease were met, and the Descriptive Information Form, Social Hand-Washing Knowledge Form and the Nutritional Knowledge Level Scale for Adults were filled face-to-face at their homes with the ones volunteering to participate in the study, complying with the social distance rules. The same survey was re-filled after three months. No training was given to the women with chronic disease during the three-month period. After the research was completed, a 45 minute-training which is the same with the one provided to the intervention group was given individually to the control group, complying the social distance rules.
62055768|NCT02624739|EXPERIMENTAL|Intervention|Reassure Non-Contact Respiration Monitor: Respiration parameters transmitted by the Reassure device will be evaluated daily by the study team and participants will be contacted for further evaluation if a change in respiration patterns is noted. Participants will continue with standard of care heart failure treatment.
62055769|NCT02624739|ACTIVE_COMPARATOR|Control|Reassure Non-Contact Respiration Monitor: Respiration parameters will be transmitted and stored, but there will be no active evaluation of respiration patterns. Participants will continue with standard of care heart failure treatment.
62055770|NCT01992679|NO_INTERVENTION|Control|Participants in the control group will undergo the same assessments but receive no exercise stimulus and be asked to maintain current physical levels
62055771|NCT01992679|EXPERIMENTAL|Exercise group|The exercise program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training.
62055772|NCT01945749|EXPERIMENTAL|Intraarticular steroid + Exercise|Intra-articular corticosteroid treatment with subsequent exercise therapy. Exercise therapy is commenced 2 weeks after injection
62055773|NCT01945749|ACTIVE_COMPARATOR|Intraarticular saline+Exercise|Combined intra-articular saline injection and subsequent exercise therapy. Exercise therapy is commenced 2 weeks after injection
62055774|NCT01204268|NO_INTERVENTION|Propofol group|Patients will receive the total intravenous anesthesia with propofol infusion during the surgery.
62055775|NCT01204268|ACTIVE_COMPARATOR|Sevo-C group|Patients will receive the anesthesia with continuous inhalation of sevoflurane.
62055776|NCT01204268|EXPERIMENTAL|Sevo-I group|Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.
62055777|NCT02417064|EXPERIMENTAL|Intranasal Esketamine 84mg plus Oral Antidepressant|As part of an initial titration, participants will self-administer 56 milligrams (mg) of esketamine intranasally on Day 1, and then 84 mg from Day 4 onwards, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine extended release \[XR\]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
62055778|NCT02417064|EXPERIMENTAL|Esketamine 56 mg plus Oral Antidepressant|Starting from Day 1, participants will self-administer 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
62615236|NCT01672294|ACTIVE_COMPARATOR|attention control|three facilitator led sessions of listening to a relaxation CD.
62615237|NCT00682994|OTHER|Decision Making|Questionnaire + Interview
62615238|NCT03798392|ACTIVE_COMPARATOR|SP group|
62615239|NCT03798392|ACTIVE_COMPARATOR|Baska group|
62055779|NCT02417064|ACTIVE_COMPARATOR|Placebo plus Oral Antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
62055780|NCT05550415|EXPERIMENTAL|Simvastatin|The group received standard treatment with simvastatin 40mg in capsule by oral route, once a day, for 21 days (every cycle of the chemotherapy regiment)
62055781|NCT05550415|PLACEBO_COMPARATOR|Placebo|The group received standard treatment with placebo 40mg in capsule by oral route, once a day, for 21 days (every cycle of the chemotherapy regiment)
62258278|NCT00932204|EXPERIMENTAL|Active stimulation|"For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d)."
62615240|NCT02249689|EXPERIMENTAL|Definitive 65|The Test product were the Definitive 65 (Filcon V4) lenses. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
62840297|NCT05269667|EXPERIMENTAL|Cohort 2: NMOSD patients who are inadequate responders to previous treatment with RTX|Patients will be treated with 120 mg satralizumab subcutaneously (SC) as monotherapy at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Week 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. All assessments (clinical, laboratory and imaging) should be performed before satralizumab administration. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
62840298|NCT01011309|EXPERIMENTAL|LEISH-F2 + MPL-SE vaccine|Recombinant three antigen Leishmania polyprotein + MPL-SE adjuvant
62055782|NCT00284063|ACTIVE_COMPARATOR|Group 1: N; SPP; N|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
62055783|NCT00284063|ACTIVE_COMPARATOR|Group 2: N; SMT; N|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
62055784|NCT00284063|ACTIVE_COMPARATOR|Group 3: N; SMT; SP|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
62055785|NCT00284063|NO_INTERVENTION|Group 4: N and SP|N = neutral MRI SP = side posture MRI SPP = side posture position SMT = side posture manipulation
62258279|NCT00932204|SHAM_COMPARATOR|Sham stimulation|For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area.
62258280|NCT04424654|EXPERIMENTAL|Bipolar Androgen Therapy (BAT)|Testosterone cypionate 400 mg IM every 28 days for 3 cycles
62258281|NCT05070975||Twins|Twins identified from the birth cohort (Hospices Civils de Lyon) with at least one twin hospitalized for an acute RSV-infection
62615241|NCT02249689|ACTIVE_COMPARATOR|Definitive 74|The Control product was the commercially available Definitive 74 (Efrofilcon A) lens. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
62615242|NCT03718169||Hong Kong female smokers|Hong Kong female smokers will be invited to fill in questionnaires about their current smoking situation and quit intention.
62840299|NCT01011309|ACTIVE_COMPARATOR|Sodium stibogluconate (SSG)|20 mg/kg/day IV for 20 days
62840300|NCT02812862|EXPERIMENTAL|Treatment group|"20 male and female patients suffering from chronic heart failure and chronic obstructive pulmonary disease.~Patients will be treated with Spiolto® Respimat® (the LABA/ LAMA combination)"
62840301|NCT03683459|EXPERIMENTAL|interventional arm|Participants will be treated with FemFlow Drug-Eluting Peripheral Balloon Catheter.
62840302|NCT03279562|EXPERIMENTAL|Nalmefene and recovery coaching|Nalmefene prescribed for daily ingestion during the first 3 months of treatment; patients who maintain a successful recovery during the first 3 months of treatment will be offered an option to take Nalmefene on as needed basis, always before encountering situations or circumstances with heightened risk of alcohol or opioid use
62840303|NCT04837378|EXPERIMENTAL|Abdominal Massage Group|Abdominal massage process stage; After the preliminary test data were obtained, the hands were warmed and creamed with vaseline, abdominal massage was applied to the patient in the supine position for 15 minutes. After 24 hours, gastrointestinal complications and comfort parameters were recorded.
62055786|NCT03017430|EXPERIMENTAL|Pregabalin|This group (N= 40) receives up to 600 mg a day of Pregabalin for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
62055787|NCT03017430|ACTIVE_COMPARATOR|Clonidine|This group (N= 40) receives up to 600 micrograms of Clonidine a day for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)..
62055788|NCT00428558|ACTIVE_COMPARATOR|2|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
62055789|NCT00428558|EXPERIMENTAL|1|BRAS INDUCTION SEQUENTIAL
62258282|NCT01159028|EXPERIMENTAL|BP1001|Subjects are treated with open-label study drug (BP1001) in a dose-escalation model.
62444876|NCT06543147|NO_INTERVENTION|Control Group|There are 80 female participants in this group. A pre-test was applied to the participants in the control group. The participants in the experimental group were given an intervention for six months, while the participants in the control group were not. A post-test was applied after six months. Based on the principle of sufficient and accurate care, women in the control group were given training about breast cancer and BSE in groups of 7-9 people after posttest data were collected and given brochures at the end of training
62840304|NCT04837378|EXPERIMENTAL|In-bed Exercise Group|In-bed exercise process phase; After the pre-test data were obtained, the patient was applied passive in-bed exercises for approximately 15 minutes in all extremities in the supine position. After 24 hours, gastrointestinal complications and comfort parameters were recorded.
62840305|NCT04837378|NO_INTERVENTION|Control Group|Control group stage; Gastrointestinal complications and comfort parameters were recorded in this group at the same time as the experimental groups without any intervention.
62055790|NCT02834702|EXPERIMENTAL|Sinew acupuncture|Sinew acupuncture
62055791|NCT02834702|SHAM_COMPARATOR|Sham acupuncture|Sham acupuncture
62055792|NCT01760889|EXPERIMENTAL|SPD489 Low Dose Range|
62258283|NCT01159028|EXPERIMENTAL|BP1001 in combination with LDAC|AML subjects are treated with open-label escalating study drug (BP1001) in combination with low dose ara-C (LDAC)
62258284|NCT05063721|EXPERIMENTAL|Intra-arterial delivery of autologous MABs|Autologous mesoangioblasts (MABs) will be intra-arterially delivered to lower leg of participant
62258285|NCT05063721|NO_INTERVENTION|No intervention|intra-subject control
62444877|NCT06375590||Bicuspid aortic valve|Treated with Navitor platform
62055793|NCT01760889|EXPERIMENTAL|SPD489 High Dose Range|
62055794|NCT01760889|PLACEBO_COMPARATOR|Placebo|
62055795|NCT01126138|OTHER|Arm A|Vinorelbine plus Capecitabine
62055796|NCT01126138|OTHER|Arm B|Docetaxel plus Capecitabine
62055797|NCT01480947|EXPERIMENTAL|Bio-Three|add-on treatment of the probiotics (Bio-three)
62055798|NCT01480947|NO_INTERVENTION|control treatment|control treatment (intravenous fluid, oral rice and half strength milk formula)
62055799|NCT04751201|EXPERIMENTAL|Receiving mindfulness open and circular program|
62055800|NCT04128241||Panel of Spanish consumers|A panel of Spanish consumers recruited from various audited and validated internet databases.
62055801|NCT02967614|EXPERIMENTAL|[A]→[A]+[B]|"Period 1 : At each dosing of Treatment A eye drops is administered for 8days~Period 2 : At each dosing of Treatment A + Treatment B eye drops is administered for 92days"
62055802|NCT02967614|EXPERIMENTAL|[B]→[A]+[B]|"Period 1 : At each dosing of Treatment B eye drops is administered for 92days~Period 2 : At each dosing of Treatment A + Treatment B eye drops is administered for 8days"
62258286|NCT02946242|OTHER|General Ultrasound Exam|Each subject may elect to participate in up to five (5) study scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan. Ophthalmic scanning will be limited to no more than 15 cumulative minutes of scan time per eye, per day.
62258287|NCT02255409|EXPERIMENTAL|aQIV|Adjuvanted Quadrivalent Subunit Influenza
62258288|NCT02255409|ACTIVE_COMPARATOR|QIV|Non-Adjuvanted Quadrivalent Subunit Influenza
62258289|NCT02859181|EXPERIMENTAL|Active, Adolescent males|Subjects will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
62615243|NCT03126955||HELPS Syndrome unable to lateralize contractions|Each patient will have the following 3 diagnostic pre-operative tests: i) MRI (CISS sequence), ii) video laryngoscopy, and iii) sequential Botox injections in their throat (left side and then 3 months later on the right side).
62055803|NCT01452997|ACTIVE_COMPARATOR|Ibuprofen Gel|Ibuprofen 5% gel
62055804|NCT01452997|PLACEBO_COMPARATOR|Ibuprofen placebo|K-Y jelly
62055805|NCT01452997|ACTIVE_COMPARATOR|Eumovate|0.05% w/w clobetasone butyrate
62055806|NCT01452997|PLACEBO_COMPARATOR|Cream Placebo|Aqueous Cream B.P.
62055807|NCT05596890|EXPERIMENTAL|Neoadjuvant immunochemotherapy +/- short-term radiotherapy|Tislelizumab + cisplatin/carboplatin + albumin-bounded paclitaxel +/- radiotherapy
62055808|NCT03390699|EXPERIMENTAL|before and after partial maxillectomy|Microbial profile among patients before and after partial maxillectomy
62055809|NCT04552743|EXPERIMENTAL|MGTA-145 and Plerixafor HSC Mobilization|Patients after screening will undergo baseline evaluation during the premobilization phase up to 30 days before mobilization. Patients will undergo sequential administration of plerixafor 0.24 mg/kg subcutaneously followed 2 hours later by MGTA-145 at 0.03 mg/kg intravenously (3 to10 minute infusion). This will be followed by apheresis. A second day of mobilization and apheresis will be pursued in patients who have not collected 6.0 x 106 CD34+ cells/kg in one session.
62055810|NCT01292070|EXPERIMENTAL|Control-Experimental arm|Each subject will serve as their own control with the left arm receiving the control protein (Histamine prick, intradermal diluent and intradermal CAT) and right arm receiving the experimental protein (GFD).
62055811|NCT03184584|EXPERIMENTAL|PBI-4050|
62055812|NCT05038280|EXPERIMENTAL|Let's Talk about Children intervention|Teachers, students, and parents in Finland, that take part in the LTC -intervention.
62055813|NCT05038280|NO_INTERVENTION|Control group|The control group includes teachers who do not use the method in their work and students and parents who do not participate in the discussions.
62055814|NCT03036384|EXPERIMENTAL|Cohort 1 : HB prilocaine 2%, 45mg|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
62055815|NCT03036384|EXPERIMENTAL|Cohort 2 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
62055816|NCT03036384|EXPERIMENTAL|Cohort 3 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
62055817|NCT03036384|EXPERIMENTAL|Cohort 4 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
62258290|NCT02672436|EXPERIMENTAL|ENERGI-F703|ENERGI-F703, topical application, 2 times daily for 12 weeks
62258291|NCT02672436|PLACEBO_COMPARATOR|Placebo|ENERGI-F703 matched vehicle, topical application, 2 times daily for 12 weeks
62615244|NCT00960167|EXPERIMENTAL|Dose Level I|42 Gy in 12 fractions.
62615245|NCT00960167|EXPERIMENTAL|Dose Level II|49 Gy in 14 fractions.
62615246|NCT00960167|EXPERIMENTAL|Dose Level III|56 Gy in 16 fractions.
62615247|NCT00960167|EXPERIMENTAL|Dose Level IV|63 Gy in 18 fractions.
62615248|NCT02074332|EXPERIMENTAL|Intervention|Physical activity guidance Health education
62615249|NCT02074332|NO_INTERVENTION|Control|Receive no intervention
62615250|NCT02588664|NO_INTERVENTION|Usual Care|Participating hospitals randomized to the usual care group will provide their usual, post-acute stroke care to their patients.
62615251|NCT02588664|ACTIVE_COMPARATOR|COMPASS Intervention|Participating hospitals randomized to the intervention will change the structure and process for delivery of post-acute stroke care.
62615252|NCT05994300|EXPERIMENTAL|Moderately Hypofractionated Adaptive Radiotherapy|
62055818|NCT03036384|EXPERIMENTAL|Cohort 5 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
62258292|NCT05894174|EXPERIMENTAL|Intervention Group|"The intervention group refers to the group that will the Food Hunter board game intervention developed by the researchers to enable children to recognize healthy and unhealthy foods; to learn what vitamins and minerals are necessary for children in the growth and development period, their effects on our health and in which foods they are found."
62615253|NCT02263612||Danish Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
62615254|NCT05423366|ACTIVE_COMPARATOR|Large-Focused Extracorporeal Shock Wave Therapy|
62615255|NCT05423366|ACTIVE_COMPARATOR|Controlled-Unfocused (Radial) Extracorporeal Shock Wave Therapy|
62615256|NCT05423366|SHAM_COMPARATOR|Sham Extracorporeal Shock Wave Therapy|
62615257|NCT00691561|EXPERIMENTAL|1|Participants receive HIV counseling and testing and 8 intervention sessions to assist them with reducing unsafe sexual behaviors.
62615258|NCT00691561|NO_INTERVENTION|2|Participants receive HIV counseling and testing only.
62840306|NCT03470844||5-10 years post severe burn injury|"Interventions:~* Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~* Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~* fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~* Quality of Life Self-Assessment data."
62840307|NCT03470844||2-5 years post severe burn injury|"Interventions:~* Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~* Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~* fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~* Quality of Life Self-Assessment data."
62615259|NCT05268016|EXPERIMENTAL|ME3183 Dose 1, BID|Specified dose of ME3183 capsule for 16 weeks
62615260|NCT05268016|EXPERIMENTAL|ME3183 Dose 2, QD|Specified dose of ME3183 capsule for 16 weeks
62258293|NCT05894174|NO_INTERVENTION|Control Group|The control group refers to the group that will not receive any nutrition education intervention.
62615261|NCT05268016|EXPERIMENTAL|ME3183 Dose 3, BID|Specified dose of ME3183 capsule for 16 weeks
62615262|NCT05268016|EXPERIMENTAL|ME3183 Dose 4, QD|Specified dose of ME3183 capsule for 16 weeks
62258294|NCT01645189|EXPERIMENTAL|Test drug|Idursulfase-beta
62615263|NCT05268016|PLACEBO_COMPARATOR|Placebo|Placebo capsule of ME3183 for 16 weeks
62615264|NCT02622490|ACTIVE_COMPARATOR|Low carb. one meal|Intervention: One meal of 750 kcal with 20 % of energy content from carbohydrates
62615265|NCT02622490|ACTIVE_COMPARATOR|Low Carb. 5 small meals|Intervention: Five meals every 30 minutes of 150 kcal/each with 20 % of energy content from carbohydrates.
62615266|NCT02622490|ACTIVE_COMPARATOR|High carb. one meal|Intervention: One meal of 750 kcal with 50 % of energy content from carbohydrates
62615267|NCT02622490|EXPERIMENTAL|High carb. 5 meals|Intervention: Five meals every 30 minutes of 150 kcal/each with 50 % of energy content from carbohydrates.
62615268|NCT04494594|SHAM_COMPARATOR|Control|
62258295|NCT04266262|EXPERIMENTAL|High-Intensity interval training (HIIT)|
62258296|NCT04266262|EXPERIMENTAL|High-intensity resistance training (HIRT)|
62615269|NCT04494594|ACTIVE_COMPARATOR|Intervention|
62615270|NCT02265939|PLACEBO_COMPARATOR|0% NPO-13|Placebo
62615271|NCT02265939|ACTIVE_COMPARATOR|0.2% NPO-13|Low dose
62615272|NCT02265939|ACTIVE_COMPARATOR|0.4% NPO-13|Medium dose
62615273|NCT02265939|ACTIVE_COMPARATOR|0.8% NPO-13|High dose
62615274|NCT00110799|ACTIVE_COMPARATOR|Arm B|SB-497115-GR 30mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
62615275|NCT00110799|ACTIVE_COMPARATOR|Arm C|SB-497115-GR 50mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
62615276|NCT00110799|ACTIVE_COMPARATOR|Arm D|SB-497115-GR 75mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
62615277|NCT00110799|PLACEBO_COMPARATOR|Arm A|Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
62615278|NCT00865579|EXPERIMENTAL|1|All subjects to receive first 50mg/d Safinamide with an increase of target dose of 100mg/d after 14 days of taper period until end of treatment visit. In case of any intolerance the daily dose of 100mg might be decreased to 50mg/d. Patients permanently discontinuing treatment will enter a 7day taper phase before treatment discontinuation at a dose of 50mg/day. Subjects already taking 50mg/d may stop Safinamide immediately.
62055819|NCT03036384|EXPERIMENTAL|Cohort 6 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
62258297|NCT04266262|NO_INTERVENTION|Usual care (UC)|Provision of Cancer Care Ontario's physical activity guidelines for cancer survivors
62615279|NCT01289574|PLACEBO_COMPARATOR|Vehicle control cream|
62615280|NCT01289574|EXPERIMENTAL|0.025% ASC-J9 cream|
62615281|NCT01289574|EXPERIMENTAL|0.1% ASC-J9 cream|
62840308|NCT03470844||1-2 years post severe burn injury|"Interventions:~* Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~* Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~* fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~* Quality of Life Self-Assessment data."
62840309|NCT03470844||Control|"Healthy age, gender, socioeconomic and educational level matched control.~Interventions:~* Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~* Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~* fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~* Quality of Life Self-Assessment data."
62840310|NCT04065672|EXPERIMENTAL|Low-dose IL-2|After a 4-week screening period, patients received IL-2 at a dose of 1 million IU subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.
62840311|NCT04065672|PLACEBO_COMPARATOR|placebo|After a 4-week screening period, patients received placebo subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.
62840312|NCT03005158|OTHER|Validation Phase|All six hospital sites currently use the ARCHITECT STAT high- sensitive troponin I assay in the assessment of patients with suspected acute coronary syndrome and use sex-specific thresholds upper reference limits (99th centile) to rule out myocardial infarction. This validation phase of up to 10 months will provide baseline information for each site on patients with suspected acute coronary syndrome in whom myocardial infarction is ruled out.
62615282|NCT03009253|EXPERIMENTAL|Concurrent chemoradiotherapy(CCRT) Group|Concurrent chemoradiotherapy (Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks) Followed by chemotherapy: Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles)
62258298|NCT01438489|EXPERIMENTAL|Anifrolumab (MEDI-546) 300 mg|Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
62258299|NCT01438489|EXPERIMENTAL|Anifrolumab (MEDI-546) 1000 mg|Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
62258300|NCT01438489|PLACEBO_COMPARATOR|Matching Placebo|Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
62258301|NCT01986920|ACTIVE_COMPARATOR|A-101 25%|Low dose group
62258302|NCT01986920|ACTIVE_COMPARATOR|A-101 32.5%|Mid Dose Group
62258303|NCT01986920|ACTIVE_COMPARATOR|A-101 40%|High Dose Group
62258304|NCT01986920|PLACEBO_COMPARATOR|A-101 Vehicle|Placebo group
62615283|NCT03009253|EXPERIMENTAL|Chemotherapy Group|"Chemotherapy (Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles)~Followed by Concurrent chemoradiotherapy:~(Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks)"
62615284|NCT03749109|EXPERIMENTAL|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.
62615285|NCT03749109|PLACEBO_COMPARATOR|Placebo|Vaginal ring containing matching placebo
62615286|NCT02450422||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
62615287|NCT02450422||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
62615288|NCT02450422||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
62615289|NCT02450422||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
62840313|NCT03005158|OTHER|Randomization Phase|Participating centres will be randomized to implement the HighSTEACS pathway (intervention). The order of implementation will be randomized, with paired participating centres implementing in steps over a 6 month period.
62840314|NCT03005158|ACTIVE_COMPARATOR|Implementation Phase|A final phase of up to 10 months after implementation of the HighSTEACS pathway will be matched by calendar month in each site to that of the validation phase, allowing each participating centre to act as its own control and to adjust for seasonal differences in the incidence of myocardial infarction and mortality.
62840315|NCT02186418|EXPERIMENTAL|ARU-1801|Autologous CD34+ hematopoietic stem cells transduced ex-vivo with gamma-globin lentiviral vector. Administered via IV infusion.
62840316|NCT02904954|EXPERIMENTAL|Arm 1 (Durvalumab monotherapy)|Durvalumab (MEDI4736) 1.12 g administered pre-operatively every 3 weeks for 2 cycles followed by surgical resection. Durvalumab monotherapy 1.5 g will be given for 12 months post-operatively.
62840317|NCT02904954|EXPERIMENTAL|Arm 2 (Durvalumab plus SBRT)|Durvalumab (MEDI4736) 1.12 g administered pre-operatively every 3 weeks for 2 cycles plus radiotherapy delivered in 3 daily fractions starting concurrently with the first cycle of durvalumab (MEDI4736) followed by surgical resection. Durvalumab monotherapy 1.5 g will be given for 12 months post-operatively.
62840318|NCT06252688|OTHER|Participants|"All participants performed the same evaluation: clinical and neuropsychological assessment.~All of them are patients with an eating disorder."
62840319|NCT03775135||Children with neuromuscular diseases|Questionnaires will be administered by children with neuromuscular disease between 12 and 25 years and their parents
62840320|NCT03249116|ACTIVE_COMPARATOR|Control - interaction with a stuffed dog|Active control - interaction with a stuffed dog
62840321|NCT03249116|EXPERIMENTAL|Therapy dog - social|animal-assisted intervention - social interaction only with therapy dog during stress task.
62615290|NCT00525876|EXPERIMENTAL|Matched Sibling Transplant|Allogeneic Stem Cell Transplantation With Rituximab Containing Nonablative Conditioning Regimen: Cyclophosphamide 750 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m\^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m\^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.
62615291|NCT00525876|EXPERIMENTAL|Allo MUD & MM|Allo MUD \& MM = Allogeneic Stem Cell Transplantation, Matched unrelated donor or mismatched sibling donor transplantations: Cyclophosphamide 1000 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m\^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m\^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation. Alemtuzumab 15 mg per day given intravenously days 1 through 3 after transplantation.
62615292|NCT02651649|EXPERIMENTAL|Parturients with FGR/OSA who use CPAP|Subjects who meet criteria for FGR and OSA will be referred to a pulmonologist for referral for Continuous Positive Airway Pressure (CPAP). Women who agree with CPAP and comply with therapy will be compared to women who do not wear CPAP (eg. non-compliance).
62840322|NCT03249116|EXPERIMENTAL|Therapy dog - Social + physical|animal-assisted intervention - Social interaction and physical interaction with therapy dog during stress task.
62840323|NCT06035757|ACTIVE_COMPARATOR|group pyridostigmine|If TOF count is 1 or less, wait until it becomes 2 and then give the patient pyridostigmine dose of 350mcg/kg. If TOF count shows 4 with fade, 350mcg/kg of pyridostigmine is administered and without fade, 200mcg/kg is administered.
62840324|NCT06035757|ACTIVE_COMPARATOR|group sugammadex|If TOF count shows 0 and PTC (posttetanic count) is 1 or more, sugammadex administered dose of 4mg/kg. If TOF count shows 1 or more, 2mg/kg is administered.
62258305|NCT04856787|EXPERIMENTAL|SHR-1701 in combination with BP102 and XELOX（Phase 2）|
62055820|NCT03036384|EXPERIMENTAL|Cohort 7 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
62258306|NCT04856787|EXPERIMENTAL|SHR-1701 in combination with BP102 and XELOX （Phase 3）|
62615293|NCT02651649|NO_INTERVENTION|Parturients with FGR/OSA and no CPAP|Subjects who meet criteria for FGR and OSA will be referred to a pulmonologist for referral for CPAP. Women who agree with CPAP and comply with therapy will be compared to women who do not wear CPAP (eg. non-compliance).
62615294|NCT05540730||Obstetric brachial plexus paralysis|
62615295|NCT05540730||Control|
62615296|NCT02638376|ACTIVE_COMPARATOR|KXL treatment only|
62840325|NCT01614392|EXPERIMENTAL|High velocity low force Power Training|Lower Extremity high velocity power training performed at lower external resistance (40% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
62840326|NCT01614392|EXPERIMENTAL|Low velocity high force Power Training|Lower extremity low velocity power training performed at high external resistance (70% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
62840327|NCT04769388|EXPERIMENTAL|Osimertinib 80 mg QD and platinum-based chemotherapy|Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
62258307|NCT04856787|PLACEBO_COMPARATOR|placebo in combination with BP102 and XELOX|
62615297|NCT02638376|ACTIVE_COMPARATOR|KXL and topography-guided PRK|simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)
62615298|NCT02578849||PD_no_LID|Patients with Parkinson´s disease without dyskinesia
62615299|NCT02578849||PD_LID|Patients with Parkinson´s disease with L-DOPA induced dyskinesia
62615300|NCT02578849||HC|Health controls, age-mathced.
62615301|NCT03298308|EXPERIMENTAL|Brainwave|Brainwave analysis after cranial electric stimulation
62258308|NCT03982836|EXPERIMENTAL|Fructooligosaccharide|All the 25 volunteers received the sandwich containing 20 grams of fructooligosaccharide
62258309|NCT03982836|EXPERIMENTAL|Partially hydrolyzed guar gum|All the 25 volunteers received the sandwich containing 20 grams of partially hydrolyzed guar gum
62258310|NCT03982836|PLACEBO_COMPARATOR|Maltodextrin|All the 25 volunteers received the sandwich containing 20 grams of Maltodextrin
62258311|NCT04391036|EXPERIMENTAL|High Eudragit® Film, then Low Eudragit® Film|High (12.8%) Eudragit® content vaginal film, then low (6.4%) Eudragit® content vaginal film
62258312|NCT04391036|EXPERIMENTAL|Low Eudragit® Film, then High Eudragit® Film|Low (6.4%) Eudragit® content vaginal film, then high (12.8%) Eudragit® content vaginal film
62258313|NCT01089348|EXPERIMENTAL|Lactofiltrum|
62840328|NCT04769388|ACTIVE_COMPARATOR|Osimertinib 80mg QD|All patients randomized into this will only receive Osimertinib 80mg.
62840329|NCT01523041|EXPERIMENTAL|BIAsp 70 clinical trial formulation|
62840330|NCT01523041|EXPERIMENTAL|BIAsp 70 final formulation|
62258314|NCT01089348|ACTIVE_COMPARATOR|Control|
62615302|NCT01870297|EXPERIMENTAL|LY3025876|Part A: 0.5 milligram (mg), 1.5 mg, 5 mg, and 15 mg of LY3025876 administered as once daily (QD) subcutaneous (SQ) injections for up to 28 days.
62615303|NCT01870297|PLACEBO_COMPARATOR|Placebo|Part B: Placebo matching LY3025876 administered as QD SQ injections for up to 28 days
62615304|NCT01870297|EXPERIMENTAL|LY3025876 + Liraglutide|Part B: 5.0 mg of LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.
62615305|NCT01870297|PLACEBO_COMPARATOR|Placebo + Liraglutide|Part B: Placebo doses matching LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.
62615306|NCT06532058|EXPERIMENTAL|Part-A (Cohort 1-3)|Three dose groups were set up. The doses of QHRD107 capsules were 40 mg Q12H, 60 mg Q12H and 80 mg Q12H, respectively, combined with Venclexta and Azacitidine.
62615307|NCT06532058|EXPERIMENTAL|Part-B (Cohort 1-2)|Cohort 1： \[QHRD107 capsule 60mg Q12H D1-28\]+\[Venclexta QD D1-28\]+\[Azacitidine QD D1-7\]; Cohort 1：\[QHRD107 capsule 80mg Q12H D1-28\]+\[Venclexta QD D1-28\]+\[Azacitidine QD D1-7\] .
62615308|NCT04309903|EXPERIMENTAL|Manual Therapy|The experienced physiotherapist has applied manual therapy (MT) to the arthropathic joints. MT was started with myofascial release techniques (MRT), then continued with mobilization techniques using Kalternborn. Superficial MRT consisted of 3 strokes, via manual movement on the tissue, encourage release of the superficial fascia. In the Kalternborn mobilization technique, Grade I-II mobilization was applied with traction without using a strap. The same exercises given to the home exercise group were given to the patients in this group as well.
62840331|NCT01523041|EXPERIMENTAL|BIAsp 50 final formulation|
62840332|NCT06227104|EXPERIMENTAL|Online hemodiafiltration (OL HDF)|Prescription: Nikkiso DBB-05 or Fresenius 5008 machine, high-flux polysulfone dialyzer, BFR 200-300, DFR 500, duration 4 hrs
62615309|NCT04309903|ACTIVE_COMPARATOR|Home Exercise|The home exercises (HE) consisted of active ROM exercises, passive stretching exercises, progressive resistive exercises, weigh-bearing and stance exercises were performed by the patient for 30 minutes at home.
62615310|NCT02380859|ACTIVE_COMPARATOR|Prism adaptation|Patients will undergo twice daily adaptation to upward shifts in vision. Participants will be provided with goggles fitted with prismatic lenses that shift vision upward by 25 dioptres (about 17 degrees). While wearing the lenses, participants point to two 10cm-diameter visual targets positioned one above the other (about 20cm apart) on a wall, returning their pointing arm to their chest between each pointing movement. Participants make 50 pointing movements, as fast and as accurately as possible. Such a procedure induces a downward sensorimotor adaptation of pointing movements. Participants undergo this training twice a day (morning and evening) for two weeks in a self-guided fashion.
62615311|NCT02380859|SHAM_COMPARATOR|Sham adaptation|Participants undergo the same treatment protocol as described in the active comparator arm, with the exception that they wear goggles fitted with neutral lenses that do not induce sensorimotor adaptation.
62258315|NCT02681536|EXPERIMENTAL|Minidose long protocol|Down-regulation started on day 20 of the previous cycle by GnRH agonist triptorelin (0.5 µg Decapeptyl; Ferring). On the second day of menstruation, when down regulation was confirmed (as evidenced by endometrial thickness \<5 mm and/or E2 levels \<50 pg/mL) using transvaginal sonography (TVS) by Voluson 730 Pro (GE, Fairfield, CT) apparatus, gonadotropin (Merional; IBSA) was commenced at an initial dose of 300-450 IU/day for the first 5 days followed by individual adjustment in Gn dose according to ovarian response and the dose of Decapeptyl 50µg/day was continued until day of HCG administration.
62055821|NCT03036384|EXPERIMENTAL|Cohort 8 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
62055822|NCT03036384|EXPERIMENTAL|Cohort 9 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
62258316|NCT02681536|EXPERIMENTAL|microdose flare protocol|OCPs drospirenone /ethinyl estradiol (Yasmin, BAYER) for not less than 21 days before starting ovarian stimulation, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by HMG IM daily (Merional, 75 IU, IBSA) 3 days later. Then the same cycle adjustment was done as the minidose long protocol.
62258317|NCT01262768|EXPERIMENTAL|2D Portion Size Measurment Aids (PSMAs)|The 2D PSMAs are life-size photographs of the 3D PSMAs.
62258318|NCT01262768|EXPERIMENTAL|3D Portion Size Measurement Aids (PSMAs)|The 3D PSMAs include foam rubber replicas of a golf ball, a hockey puck, a tennis ball and a baseball.
62258319|NCT05223634||oral and/or nasal specimen samples|After each patient has been tested according to conventional SOC and has enrolled in the study, up to ten oral and/or nasal specimen samples will be collected
62615312|NCT02910934|EXPERIMENTAL|IRS|This arm is comprised of village clusters that have received indoor residual spray with Actellic CS.
62615313|NCT02910934|NO_INTERVENTION|non-IRS|This arm is comprised of village clusters that will not receive indoor residual spray
62055823|NCT03036384|EXPERIMENTAL|Cohort 10 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
62055824|NCT02613104|EXPERIMENTAL|Sad to Happy|emotion recognition modification - sad\>happy
62258320|NCT06311045|EXPERIMENTAL|NAC|Following run-in PAP therapy per standard clinical care for 12 weeks, participants randomized to the NAC arm will also receive the supplement N-acetylcysteine (NAC) for four weeks while remaining on PAP therapy.
62615314|NCT03152487|ACTIVE_COMPARATOR|Celiac Plexus Neurolysis|CPN will be undertaken at the celiac space which is located between the aorta and the celiac artery origin. A 22 or 19-gauge Fine Needle Aspiration (FNA) needle is used, and its tip is placed slightly anterior and cephalic to the origin of the celiac artery. Aspiration is first performed using a syringe to ensure that vascular puncture has not occurred. 10 mL Bupivacaine is injected first, followed by 20 mL of 98% alcohol.
62615315|NCT03152487|ACTIVE_COMPARATOR|Radiofrequency Ablation|Once the celiac ganglia are identified on EUS, a 19-gauge FNA needle is inserted into the center of the ganglion or area of celiac plexus under EUS guidance. The radiofrequency (RF) probe (EMcision, Montreal, Canada) is advanced through the FNA needle. Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest and repeated as required.
62840333|NCT06227104|NO_INTERVENTION|Intermittent hemodialysis (IHD)|Fresenius 4008 hemodialysis machine, low-flux polysulfone (Elisiio 170L) dialyzer, minimum BFR 200-300, DFR 500, duration 4 hrs
62840334|NCT03418818|EXPERIMENTAL|Arm A|Participants will complete FAZA PET/MRI scan and radiation therapy before surgery.
62055825|NCT02613104|PLACEBO_COMPARATOR|Sad control|emotion recognition modification - sad\>happy control
62055826|NCT02613104|EXPERIMENTAL|Angry to Happy|emotion recognition modification - angry\>happy
62055827|NCT02613104|PLACEBO_COMPARATOR|Angry control|emotion recognition modification - angry\>happy control
62055828|NCT03566303|ACTIVE_COMPARATOR|Rivaroxaban|Rivaroxaban 15mg BID
62055829|NCT03566303|PLACEBO_COMPARATOR|Warfarin|Warfarin dose adjusted
62055830|NCT03907163|EXPERIMENTAL|healthy subjects|
62055831|NCT03907163|PLACEBO_COMPARATOR|healthy volunteers|
62055832|NCT05674630|EXPERIMENTAL|Magic Touch drug eluting balloon based strategy - 6/12 months invasive follow up|Patients randomized to DEB-based strategy will receive treatment with DEB (Magic Touch, Concept Medical®) throughout the entire lesion length, followed by final assessment with FFR and IVUS at 6 or 12 months in a randomized fashion.
62055833|NCT05674630|ACTIVE_COMPARATOR|Drug eluting stent based strategy - 6/12 months invasive follow up|Percutaneous transluminal coronary angioplasty and drug eluting stent implantation according to local standard of care, including optimization techniques (e.g. post-dilatation) which are left at operators' discretion, followed by final assessment with FFR and IVUS at 6 or 12 months in a randomized fashion.
62055834|NCT03627364||Post stroke patients|will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals.
62055835|NCT03627364||Control group|will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in post stroke patients.
62258321|NCT06311045|EXPERIMENTAL|Placebo|Following run-in PAP therapy per standard clinical care for 12 weeks, participants randomized to the placebo arm will also receive placebo for four weeks while remaining on PAP therapy.
62258322|NCT00801645|EXPERIMENTAL|Obese exercise|
62615316|NCT06145529|EXPERIMENTAL|EG1: 15 min RT (FunctionalHIIT) circuit program|Volume: ≃10 min/day three times per week at moderate to high intensity (7-10 RPE). Intensity: During the study the children will instruct to follow the movements targeting firstly 6-7 and 9-10 at the end. Frequency: 3 times per week. Type of exercise: For the FunctionalHIIT program the participants will perform eight weight-bearing exercises in circuit format (i.e., push-ups, squats, planks, etc.). Training load variation: Initially, participants will start at an intensity level of 6-7 on the Borg's CR-10 scale, and this will increase by 1 point every two weeks until reaching 9-10 out of 10. The training duration during the main portion will increase by 5 seconds every two weeks, while the recovery interval between exercises will decrease. The exercises themselves will become progressively more challenging over the course of the training program and change every two weeks.
62258323|NCT00801645|NO_INTERVENTION|Obese Control|
62258324|NCT00801645|EXPERIMENTAL|Lean Exercise|
62258325|NCT00801645|NO_INTERVENTION|Lean Control|
62258326|NCT05177653|EXPERIMENTAL|GIPRA|
62055836|NCT05797922|EXPERIMENTAL|DWP16001 to Group A|Group A: Fasting in Period 1 / Fed in Period 2
62055837|NCT05797922|EXPERIMENTAL|DWP16001 to Group B|Group B: Fed in Period 1 / Fasting in Period 2
62258327|NCT05177653|EXPERIMENTAL|GLP-1RA|
62258328|NCT05177653|EXPERIMENTAL|GIPRA + GLP-1RA|
62258329|NCT05177653|PLACEBO_COMPARATOR|Saline|
62258330|NCT03485248|ACTIVE_COMPARATOR|Beetroot juice|Beetroot Juice cotaining on average 9mmol of nitrate per dose
62258331|NCT03485248|PLACEBO_COMPARATOR|Placebo beet juice (Nitrate depleted)|Beetroot juice nitrate depleted
62258332|NCT06264427|EXPERIMENTAL|Intervention arm|All participants will undergo examination for genom sequencing, diabetic complications and obstructive sleep apnea. Treatment for these conditions will not be randomized, but will be offered any participant who fulfills the excision treatment criteria
62258333|NCT06491108|EXPERIMENTAL|Vardenafil in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia|50 patients will take Vardenafil 5 mg tabs twice daily and will be assessed at 4th week and 12th week. Treatment efficacy will be assessed by a change in pre and post treatment Q-max, PVR (post void residual urine), IPSS, (International Prostate Symptom Score) and Sexual Health Inventory for Men (SHIM) with monitoring any side effects
62258334|NCT06491108|ACTIVE_COMPARATOR|Tadalafil in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia|50 patients will take Tadalafil 5 mg tabs once daily and will be assessed at 4th week and 12th week. Treatment efficacy will be assessed by a change in pre and post treatment Q-max, PVR (post void residual urine), IPSS, (International Prostate Symptom Score) and Sexual Health Inventory for Men (SHIM) with monitoring any side effects
62840335|NCT03418818|EXPERIMENTAL|Arm B|Participants will receive pimonidazole prior to surgery. Participants in Arm B also have the option to complete a FAZA PET/MRI scan prior to surgery.
62840336|NCT03519295|EXPERIMENTAL|ARM A - mDCF + Atezolizumab|"* MPDL3280A (atezolizumab) will be administered every 2 weeks at 800 mg for 12 months.~* Patients will receive 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5FU at 1200 mg/m2/day for 2 days) every 2 weeks"
62055838|NCT01641263|EXPERIMENTAL|Cognitive Behavioral Therapy|For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
62840337|NCT03519295|ACTIVE_COMPARATOR|ARM B - mDCF|Patients will receive 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5FU at 1200 mg/m2/day for 2 days) every 2 weeks.
62258335|NCT06491108|ACTIVE_COMPARATOR|Tamsulosin in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia|50 patients will take Tamsulosin 0.4 mg tabs once daily and will be assessed at 4th week and 12th week. Treatment efficacy will be assessed by a change in pre and post treatment Q-max, PVR (post void residual urine), IPSS, (International Prostate Symptom Score) and Sexual Health Inventory for Men (SHIM) with monitoring any side effects
62258336|NCT02324959|ACTIVE_COMPARATOR|Acupuncture|Needling of affected meridian groups in line with Traditional Chinese Medicine procedures (Baihui and Shenting).
62840338|NCT02998268|OTHER|Cohort 1|"Subjects in Cohort 1 receive conventional induction chemotherapy with taxol/ carboplatin followed by weekly chemoradiation (taxol/ carboplatin) with pembrolizumab. Following surgery, pembrolizumab is administered every 3 weeks for 1 year.~Pembrolizumab dosing is 200 mg administered as a 30 minute IV infusion."
62840339|NCT02998268|EXPERIMENTAL|Cohort 2|"Subjects in Cohort 2 receive pembrolizumab along with induction chemotherapy with taxol/ carboplatin followed by weekly chemoradiation (taxol/ carboplatin) with pembrolizumab. Following surgery, pembrolizumab is administered every 3 weeks for 1 year.~Pembrolizumab dosing is 200 mg administered as a 30 minute IV infusion."
62258337|NCT02324959|ACTIVE_COMPARATOR|Computer-based|Computer-based attention training (RehaCom).
62258338|NCT02324959|EXPERIMENTAL|ACoTrain|A combination of computer-based attention training with acupuncture.
62258339|NCT03599128|PLACEBO_COMPARATOR|Placebo|Placebo
62840340|NCT05244252|EXPERIMENTAL|Group A|Two drugs dexmeditomidine and bupivacaine will be given in TAP block
62258340|NCT03599128|EXPERIMENTAL|43.3 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
62258341|NCT03599128|EXPERIMENTAL|86.6 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
62840341|NCT05244252|ACTIVE_COMPARATOR|Group B|One drug bupivacaine will be given in TAP block
62840342|NCT02505919|EXPERIMENTAL|Treatment|AQUABEAM System
62840343|NCT02505919|ACTIVE_COMPARATOR|Active Comparator|Transurethral Resection of the Prostate (TURP)
62840344|NCT02481128|NO_INTERVENTION|A (access to lymphoscintigraphy)|Axillary sentinel lymph node biopsy with preoperative access to lymphoscintigraphy findings
62840345|NCT02481128|EXPERIMENTAL|B (no access to lymphoscintigraphy)|Axillary sentinel lymph node biopsy without preoperative access to lymphoscintigraphy findings
62615317|NCT06145529|EXPERIMENTAL|EG2: 15 min RT (FunctionalHIIT) circuit program with gamification|The EG2 training part will develop following the same protocol described in EG1.For the gamification experience, students will embark on a superhero-themed narrative journey where they must train diligently to earn points and badges, improving their avatars along the way. The ultimate goal is to defeat a super villain in the final battle after 8 weeks. The RETRAGAM study utilizes a self-created app (accessible at https://goo.su/GVgSPW) for the gamification story, point tracking, and personalization of children's avatars. As part of the flipped classroom approach, children can access the platform to preview upcoming exercises and educational content (i.e., benefits of RT, knowledge of the muscles, bones and joints involved in exercises, postural habits, etc.).
62615318|NCT06145529|NO_INTERVENTION|CG (Control group)|We will provide general advice to the CG participants though an information meeting that will indicated to maintain their lifestyle. At the end of the intervention, in order to comply with the ethical commitment, PE teachers will be instructed on the RT programme and the RETRAGAM app to allow them to carry out the intervention autonomously when they consider.
62615319|NCT02013102|EXPERIMENTAL|Arm Ⅰ|Decitabine Injection 20mg/m2/d\*5d, IV\> 1h, one cycles per 4 weeks.
62615320|NCT02013102|EXPERIMENTAL|Arm Ⅱ|Decitabine Injection 12mg/m2/d\*8d, IV\> 1h, one cycles per 4 weeks.
62615321|NCT03561545|EXPERIMENTAL|Functional capillary density|Functional capillary density during weightlessness
62615322|NCT06272695|EXPERIMENTAL|35 mg Volagidemab|Volagidemab 35 mg will be administered by subcutaneous (SC) injection once weekly for 6 weeks.
62615323|NCT06034678|EXPERIMENTAL|Food Allergy Mastery Program|Participants randomized to the Food Allergy Mastery Program arm will participate in 6 telehealth intervention sessions with a trained mental health provider pertaining to food allergy education, food allergy management, anxiety and stress management, social situations, and self-efficacy. One of the 6 sessions is a group session with peers.
62615324|NCT06034678|NO_INTERVENTION|Usual Care|Participants will receive their usual allergy care.
62615325|NCT01665482|ACTIVE_COMPARATOR|Saturated fat rich diet|
62615326|NCT01665482|ACTIVE_COMPARATOR|Monounsaturated fat rich diet|
62615327|NCT01665482|ACTIVE_COMPARATOR|Carbohydrate/ Low fat diet|
62615328|NCT03385551||ARM 1|Patients who have been prescribed by the physician within the standard clinical practice 10 micrograms of estradiol vaginal tablets. One tablet intravaginally once daily for two weeks. Thereafter one tablet twice per week with at least a 3-days interval between treatments
62615329|NCT03385551||ARM 2|Patients who have been prescribed by the physician within the standard clinical practice promestriene 10mg./g vaginal cream. 1 gr. one application once daily intravaginally for two weeks. Thereafter one application twice per week with at least a 3-days interval between treatments
62840346|NCT05700019|OTHER|Control - Standard Advertisements|In the control condition, participants will view 3 advertisements for alcohol (shown in random order) that do not mention breast cancer awareness or charities. Advertisements will be real social media posts used by alcohol companies, modified only to remove dates, likes/comments, and references to specific geographic locations.
62615330|NCT04274309||Patient's tissues exposed|Tonsil of each patient will be imaged using the medical device
62615331|NCT04274309||Patient's tissues not exposed|Tonsil of each patient will not be imaged using the medical device
62615332|NCT05235971|EXPERIMENTAL|Episodic Future thinking (EFT)|Participants will receive up to 3 messages a day that include assessment and intervention messages.The messages will describe positive, non-alcohol related events at future time points to facilitate extension of temporal consideration toward future-focused perspectives.
62615333|NCT05235971|EXPERIMENTAL|Volitional choice (VC)|VC creates structured if-then plans to dismantle context-linked alcohol use. Participants will receive up to 3 messages a day that include assessment and intervention messages.
62615334|NCT05235971|EXPERIMENTAL|Episodic Future thinking plus Volitional choice|Participants will receive both EFT and VC interventions with text messages.
62615335|NCT05235971|OTHER|Monitoring only|This is a control group in which participants will receive general psychoeducation.
62615336|NCT04626700|EXPERIMENTAL|iNAP|
62615337|NCT04626700|ACTIVE_COMPARATOR|CPAP|
62615338|NCT04723407||Exposed patients|Those who had the management strategy implemented by the service during confinement
62615339|NCT04723407||Unexposed patients|Those who could not benefit from this strategy
62615340|NCT01489059|EXPERIMENTAL|Part 1 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab|Dose Escalation
62615341|NCT01489059|EXPERIMENTAL|Part 1 - Arm 2: BMS-982470 (Weekly) + Ipilimumab|Dose Escalation
62615342|NCT01489059|EXPERIMENTAL|Part 2 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab|Cohort Expansion
62615343|NCT01489059|EXPERIMENTAL|Part 2 - Arm 2: BMS-982470 (Weekly) + Ipilimumab|Cohort Expansion
62615344|NCT01489059|ACTIVE_COMPARATOR|Part 2 - Arm 3: Ipilimumab monotherapy|Cohort Expansion
62615345|NCT03983785|EXPERIMENTAL|Pilates|
62615346|NCT03983785|EXPERIMENTAL|Elastic Taping|
62258342|NCT03599128|EXPERIMENTAL|173 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
62258343|NCT04347915|EXPERIMENTAL|Clevudine|Clevudine 120mg (4 capsules) once a day will be administered orally and can be taken regardless of food intake for 14 days (up to 21 days)
62258344|NCT04347915|PLACEBO_COMPARATOR|Placebo|Matching Placebo (4 capsules) once a day will be administered orally and can be taken regardless of food intake for 14 days (up to 21 days)
62258345|NCT01578408|ACTIVE_COMPARATOR|Uncemented HA Coated Corail stem|Surgery with an inversed hybrid arthroplasty with an uncemented hydroxyapatite coated Corail stem and a cemented Marathon cup (DePuy).
62258346|NCT01578408|ACTIVE_COMPARATOR|Cemented Lubinus SPII stem (control arm)|Surgery with a totally cemented option with a Lubinus SPII stem and a IP cup (Link).
62258347|NCT02374099|EXPERIMENTAL|CC-486 and fulvestrant|CC-486 300 mg by mouth (PO) daily on days 1-21 of each 28 day cycle and fulvestrant 500mg by intramuscular (IM) injection on Days 1 and 15 of cycle 1 and day 1 of each subsequent cycle every 28 days.
62055839|NCT01641263|ACTIVE_COMPARATOR|Sleep Seminar|Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
62055840|NCT05089032||Physicians|
62055841|NCT05089032||Nurses|
62055842|NCT03174314|EXPERIMENTAL|Visually impaired|Visually impaired subjects will provide continuity across iterations of the testing, allowing for direct comparisons of responses within an individual for a single behavioral measure across different iterations of the device architecture and output configuration.
62840347|NCT05700019|EXPERIMENTAL|Pinkwashed Advertisements|In the pinkwashed condition, participants will view 3 advertisements for alcohol (shown in random order) that associate the alcohol company with breast cancer awareness or research (e.g., indicate that a portion of sales will be directed to a breast cancer-related foundation). Advertisements will be real social media posts used by alcohol companies, modified only to remove dates, likes/comments, and references to specific geographic locations.
62840348|NCT00948441|EXPERIMENTAL|Group 1|25% ethanol for 12 weeks; wash out period for 4 weeks; heparin lock for 12 weeks
62840349|NCT00948441|EXPERIMENTAL|Group 2|heparin lock for 12 weeks; wash out period for 4 weeks; 25% ethanol lock for 12 weeks
62840350|NCT06492525|EXPERIMENTAL|Cohort 1|All subjects in this cohort will receive the same dose of Ensartinib in both periods. Subjects will receive Ensartinib Alone in Period 1 followed by Ensartinib with Rifampicin in Period 2.
62840351|NCT06492525|EXPERIMENTAL|Cohort 2|All subjects in this cohort will receive the same dose of Ensartinib in both periods. Subjects will receive Ensartinib Alone in Period 1 followed by Ensartinib with Itraconazole in Period 2.
62258348|NCT02374099|EXPERIMENTAL|Fulvestrant|Fulvestrant will be administered by intramuscular injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
62615347|NCT03983785|NO_INTERVENTION|Wait List Control|
62055843|NCT03174314|ACTIVE_COMPARATOR|Healthy controls|Healthy (naive) subjects invaluable insights as well as a range of body types, cognitive abilities, and other idiosyncrasies that will keep our design and testing process from tailoring the device to a small set of individuals rather than the broader population.
62055844|NCT03174314|EXPERIMENTAL|Thailand Site - Group A: Assistive Mode then Passive Mode|During the first 15 days, group A will go through an assistive mode and then a passive mode for the next 15 days
62055845|NCT03174314|ACTIVE_COMPARATOR|Thailand Site - Group B: Passive Mode then Assistive Mode|Group B will go through a passive mode for the first 15 days and then an assistive mode for the second half of the month
62055846|NCT01683760|EXPERIMENTAL|Population PK|
62055847|NCT06492798|EXPERIMENTAL|Treatment group|"Participants will receive intravenous infusion of MSCs once or an additional infusion on days 35-42.~Dosage: 1×10\^6 cells per kilogram of body weight Specification: 1×10\^7 cells/100ml"
62615348|NCT05271123||Study group|Children were evaluated using spirometer to assess forced expiratory volume at first second and peak expiratory flow and gross motor function classification system to assess the functional level.
62615349|NCT04558489|EXPERIMENTAL|IPR + GMI|Participants receiving IPR + GMI will complete a 30-minute on-line intervention via qualtrics that covers the following topics: (1) Educate youth and caregiver that thoughts and emotions are not fixed but are malleable and subject to change; (2) provide youth and families with a brief intervention that instills hopefulness through an action plan for managing internalizing symptoms; (3) assist with developing system of support to access during times of distress; and (4) educate the caregiver on the importance of these interventions.
62258349|NCT01066585|EXPERIMENTAL|0.5% Ivermectin Cream|
62258350|NCT01066585|PLACEBO_COMPARATOR|Vehicle control|
62258351|NCT05635799|EXPERIMENTAL|Subjects with lower limb amputations|
62615350|NCT01064635|ACTIVE_COMPARATOR|Letrozole for 3-2 years|Patients pre-treated with TAM for 2-3 years will receive letrozole 2,5 mg/die for 3-2 years. Total duration of early adjuvant endocrine therapy: 5 years
62840352|NCT03918876||Healty Dancers|Healthy adult dancers
62840353|NCT03918876||Injured Dancers|Injured adult dancers
62258352|NCT05635799|ACTIVE_COMPARATOR|Healthy volunteers|
62840354|NCT06403332|EXPERIMENTAL|Cohort A intervention|
62258353|NCT04620551|EXPERIMENTAL|PD with DBS|Patients with Parkinson's Disease who opt for DBS surgery and consent to participate in the sleep study.
62258354|NCT00625989|PLACEBO_COMPARATOR|Diluent|Inhalation challenge preformed with diluent.
62840355|NCT06403332|NO_INTERVENTION|Cohort A non intervention|
62840356|NCT06403332|EXPERIMENTAL|Cohort B intervention|
62840357|NCT06403332|NO_INTERVENTION|Cohort B no intervention|
62840358|NCT06403332|NO_INTERVENTION|Control grup no significant liver disease|
62840359|NCT06403332|NO_INTERVENTION|Control group MASLD|
62840360|NCT06403332|NO_INTERVENTION|Control group decompensated ArLD|
62840361|NCT01955330||Hybrid robotic cabg patients|Postoperative (5-7 years)Hybrid CABG robotically assisted surgical revascularization patients
62840362|NCT05974124|EXPERIMENTAL|Group A|Povidone-Iodine 0.66%
62840363|NCT05974124|EXPERIMENTAL|Group B|Chlorhexidine 0.02%
62840364|NCT02876562|EXPERIMENTAL|root coverage with collagen matrix|evaluation of root coverage achieved by collagen matrix in conjunction with modified coronally advanced tunnel in patients with multiple gingival recession
62840365|NCT02876562|ACTIVE_COMPARATOR|root coverage with connective tissue graft|evaluation of root coverage achieved by connective tissue graft in conjunction with modified coronally advanced tunnel in patients with multiple gingival recession
62258355|NCT00625989|ACTIVE_COMPARATOR|Allergen|Inhalation challenge preformed with allergen.
62258356|NCT01334151|ACTIVE_COMPARATOR|Humalog®|Humalog®, administered subcutaneously on 1 occasion
62258357|NCT01334151|EXPERIMENTAL|BIOD- 105|BIOD- 105 administered subcutaneously on 1 occasion
62258358|NCT01334151|EXPERIMENTAL|BIOD-107|BIOD-107 administered subcutaneously on 1 occasion
62840366|NCT03849508|ACTIVE_COMPARATOR|phenylephrine|Spinal anesthesia with bupivacaine, sufentanil and morphine will be performed and prophylactic infusion of phenylephrine started at an initial rate of 0,5mcg/kg/ min. The rate will be adjusted according to maternal systolic blood pressure.
62055848|NCT06492798|PLACEBO_COMPARATOR|Placebo group|Participants will receive intravenous infusion of placebo Dosage: 10ml per kilogram of body weight
62055849|NCT00048672|EXPERIMENTAL|Gleevec|Gleevec 400 mg orally daily. Dose adjustments made at discretion of treating physician within these guidelines: The highest dose acceptable is 800 mg daily. The lowest dose acceptable is 300 mg. No dose adjustment of more than 200 mg at one time is allowed. Dose adjustments to less than 300 mg may be approved after consultation with the principal investigator.
62055850|NCT00377286|PLACEBO_COMPARATOR|2|1500 mg of lite lemonade
62258359|NCT02800070|EXPERIMENTAL|Treatment Arm|Patients will receive Health Canada approved transduced autologous CD34+ cell product.
62258360|NCT01064674||before renal transplantation|Patients with CKD IV° to V° who are actually registering for a renal transplantation in our department.
62258361|NCT05872802|ACTIVE_COMPARATOR|proprioceptive neuromuscular facilitation group.|Proprioception protocol for ankle dorsiflexion.
62258362|NCT05872802|EXPERIMENTAL|Eccentric exercises and electrical stimulation group.|Eccentric exercises and strengthening currents for ankle dorsiflexion.
62258363|NCT00258011|EXPERIMENTAL|Aldurazyme (laronidase) treatment|Patients received weekly infusions of JC0498 (laronidase) at an intravenous dose of 100 Units/kg (0.58 mg/kg) body weight for up to 73 weeks.
62258364|NCT05138042|EXPERIMENTAL|Intervention side|Breast cancer patients wore frozen glove on the dominant hand for 90 minutes during their weekly treatment with paclitaxel (80 mg/m2). Treatment was continued for 12 weeks, with their non-dominant hand as the control side
62258365|NCT05138042|NO_INTERVENTION|Control side|Breast cancer patients wore frozen glove on the dominant hand for 90 minutes during their weekly treatment with paclitaxel (80 mg/m2). Treatment was continued for 12 weeks, with their non-dominant hand as the control side
62615351|NCT01064635|EXPERIMENTAL|Letrozole for 5 year|Patients pre-treated with TAM for 2-3 years will receive letrozole 2,5 mg/die for additional 5 years. Total duration of early adjuvant endocrine therapy: 7 years for patients pretreated with 2 years of TAM and 8 years for patients pre-treated with 3 years of TAM
62615352|NCT02994641||Adverse discharge disposition|Patients who were discharged to a skilled nursing facility or died in the hospital
62840367|NCT03849508|EXPERIMENTAL|Norepinephrine|Spinal anesthesia with bupivacaine, sufentanil and morphine will be performed and prophylactic infusion of norepinephrine tartrate started at an initial rate of 0,1mcg/kg/min. The rate will be adjusted according to maternal systolic blood pressure.
62055851|NCT00377286|ACTIVE_COMPARATOR|1|1500 mg glucosamine in 16 oz lite lemonade 1 time daily for 6 months
62258366|NCT02080442||Chronic Obstructive Pulmonary Disease|
62258367|NCT03250260|NO_INTERVENTION|Standard Care|Patient receives standard pre-operative preparation which involves a discussion in to the likely aesthetic outcome with their surgeon or specialist nurse
62258368|NCT03250260|EXPERIMENTAL|2-dimensional Portfolio|Patient views photographs of women matched for BMI, age, and breast volume who are 1-5 years post BCT pre-operatively.
62258369|NCT03250260|EXPERIMENTAL|3-dimensional simulation|Patient pre-operatively views a simulation of their own breast of their likely outcome after BCT.
62258370|NCT06247436|EXPERIMENTAL|Branch Chained Amino Acids-4mg|4g BCAA, solved in water, twice daily
62258371|NCT06247436|NO_INTERVENTION|Control|no consumption
62258372|NCT00851201|ACTIVE_COMPARATOR|Standard Intervention|
62258373|NCT00851201|EXPERIMENTAL|Intensive lifestyle|
62258374|NCT00585000|EXPERIMENTAL|1|
62258375|NCT03829657|EXPERIMENTAL|ampreloxetine (Open Label (OL))|Participants will receive ampreloxetine as a single, oral, daily dose of active drug for 16 weeks.
62258376|NCT03829657|EXPERIMENTAL|ampreloxetine|After completing the OL, participants randomized to ampreloxetine will receive single, oral, daily dose of active drug for a further 6 weeks.
62258377|NCT03829657|PLACEBO_COMPARATOR|Placebo|After completing the OL, participants randomized to Placebo will receive single, oral, daily dose of placebo for 6 weeks.
62258378|NCT04491539|NO_INTERVENTION|Adaptation|Site will inform the adaptation of the FRESH intervention.
62258379|NCT04491539|EXPERIMENTAL|First Receipt|Site will received the adapted FRESH intervention first.
62258380|NCT04491539|EXPERIMENTAL|Second Receipt|Site will received the adapted FRESH intervention second.
62840368|NCT05242120||Residents who completed their residency (class 2013,2014 , 2016, 2017)|Residents who completed their residency (class 2013,2014 , 2016, 2017)
62840369|NCT03519711|EXPERIMENTAL|Cohort 1: PTC923 2.5 and 10 mg/kg/day|Participants will receive PTC923 suspension 2.5 milligrams (mg)/kilogram (kg)/day (dose divided in 2 for twice daily administration) orally for 7 days in Period 1, undergo a 3 (±1) day washout period, then escalate to a dose of 10 mg/kg/day (dose divided in 2 for twice daily administration) administered orally for 7 days in Period 2 (14 days total treatment).
62840370|NCT03519711|EXPERIMENTAL|Cohort 2: PTC923 5 and 20 mg/kg/day|Participants will receive PTC923 suspension 5 mg/kg/day (dose divided in 2 for twice daily administration) orally for 7 days in Period 1, undergo a 3 (±1) day washout period, then escalate to a dose of 20 mg/kg/day (dose divided in 2 for twice daily administration) administered orally for 7 days in Period 2 (14 days total treatment).
62055852|NCT05977426|EXPERIMENTAL|Reiki|"A sociodemographic questionnaire including questions about age, last menstrual period, education level and income level, Menopause Rating Scale (MRS), Beck Depression Inventory (BDI) were utilized for the collection of research data. And a question investigating the level of being affected by menopause complaints. The question investigating the level of being affected by menopause is: At which level do menopause complaints affect you?. Women answered this question on a scale of 0 (very little/very slightly) to 10 (extreme/very much). Data were collected from women who applied to the FHC for general healthcare services after receiving service. Women in the experimental group received Reiki once a week for four weeks. No initiative was applied to the pregnant women in the control group. Each session lasted 30-40 minutes. Four weeks after the data collection tools used in the research were filled in as a pre-test, post-test data were obtained with the same measurement tools."
62055853|NCT05977426|NO_INTERVENTION|Routine checks|The researchers applied no initiative to the control group, and the women in the control group solely had the routine checks. The women in the control group filled out all pretest forms(A sociodemographic questionnaire including questions about age, last menstrual period, education level and income level, Menopause Rating Scale (MRS), Beck Depression Inventory (BDI)). The post-test forms (MRS, BDI) were re-administered 4 weeks later to women who did not receive any intervention.
62055854|NCT04947163|EXPERIMENTAL|IMT group|"* Standard exercise protocol according to ACSM's guidelines Standard exercise protocol according to ACSM's guidelines~* Balance training - Otago Exercise Program (OEP)~  * warm-up (10-15 min)~ * strengthening exercises (\~20 min)~ * balance activities (\~20 min)~ * cool-down (5-10 min) Balance training - OEP~ * warm-up (10-15 min)~ * strengthening exercises (\~20 min)~ * balance activities (\~20 min)~ * cool-down (5-10 min)~* IMT through POWERBREATHE~  * 30 quick breaths twice daily at an adjustable resistance (equivalent to \~50% of \[baseline\] MIP).~ * Will be increased up to 35 breaths as per patient's tolerance Sham IMT~ * 60 slow breaths once daily at a load setting of 0 (corresponding to \~15% \[baseline\] MIP)~ * training load adjustment will be prevented using sticky tape applied to the device's load adjuster."
62615353|NCT02994641||No adverse discharge disposition|Patients who were not discharged to a skilled nursing facility or did not die in the hospital
62055855|NCT04947163|SHAM_COMPARATOR|Sham IMT|"* Standard exercise protocol according to ACSM's guidelines Standard exercise protocol according to ACSM's guidelines~* Balance training - OEP~  * warm-up (10-15 min)~ * strengthening exercises (\~20 min)~ * balance activities (\~20 min)~ * cool-down (5-10 min) Balance training - OEP~ * warm-up (10-15 min)~ * strengthening exercises (\~20 min)~ * balance activities (\~20 min)~ * cool-down (5-10 min)~* IMT through POWERBREATHE~  * 30 quick breaths twice daily at an adjustable resistance (equivalent to \~50% of \[baseline\] MIP).~ * Will be increased up to 35 breaths as per patient's tolerance Sham IMT~ * 60 slow breaths once daily at a load setting of 0 (corresponding to \~15% \[baseline\] MIP)~ * training load adjustment will be prevented using sticky tape applied to the device's load adjuster."
62055856|NCT05403099|ACTIVE_COMPARATOR|control|Each implant was placed into the prepared implant site.
62055857|NCT05403099|EXPERIMENTAL|Hyaluronic acid|Each implant was placed after topical application of HA on its surface
62055858|NCT04990869|EXPERIMENTAL|COPD-NR|COPD patients receiving Nicotinamide Riboside
62055859|NCT04990869|PLACEBO_COMPARATOR|COPD-placebo|COPD patients receiving placebo
62055860|NCT04990869|EXPERIMENTAL|Control-NR|Lung-healthy controls receiving Nicotinamide Riboside
62055861|NCT04990869|PLACEBO_COMPARATOR|Control-placebo|Lung-healthy controls receiving placebo
62055862|NCT05088369|EXPERIMENTAL|SAD Cohorts 1 to 4: Participants receiving HM201|Each SAD cohort participant will be randomized to receive 1 of 4 escalating doses (0.01 mg/kg (2 nmol/kg); 0.03 mg/kg (5 nmol/kg); 0.06 mg/kg (10 nmol/kg); 0.12 mg/kg (20 nmol/kg).
62615354|NCT05538923||Patients with IBD|Patients with inflammatory bowel disease on remission period
62055863|NCT05088369|PLACEBO_COMPARATOR|SAD Cohorts 1 to 4: Participants Receiving Placebo|Each SAD cohort participant will be randomized to receive placebo.
62258381|NCT02524470|EXPERIMENTAL|VSP Study Participants|Vital Signs Patch system study participants. Each study participant will receive the VSP System - NEHB Configuration and then the VSP System - PAL Configuration. Vital signs will be taken and adhesive will be assessed for each participant for each configuration.
62258382|NCT04599322|EXPERIMENTAL|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
62258383|NCT04111640|EXPERIMENTAL|Experimental group|A computer-supported cognitive training for the training of logical-executive and working-memory functions (CoRe software)
62258384|NCT04111640|OTHER|Control Group|Paper and pencil cognitive training (paper-and-pencil CoRe version)
62615355|NCT05538923||Control|Age- and gender- matched healthy population
62615356|NCT05857332|EXPERIMENTAL|SG1906|SG1906 monotherapy intravenous (IV) infusion - Biweekly doses
62615357|NCT01490307|EXPERIMENTAL|FCU offered|
62615358|NCT01490307|NO_INTERVENTION|No feedback or services offered|
62615359|NCT00533559|EXPERIMENTAL|buphenyl|
62615360|NCT00533559|PLACEBO_COMPARATOR|Placebo|
62615361|NCT04467710||Success of LCBDE|Patients with a fully laparoscopic surgical treatment of common bile duct stones
62840371|NCT05529797|EXPERIMENTAL|Veovita-VR|Participants receive one VR session with positive emotional stimuli and positive behavioral activation.
62840372|NCT05529797|NO_INTERVENTION|Care as Usual|Participants receive CAU.
62055864|NCT05088369|EXPERIMENTAL|MAD Cohorts 1 to 4: Participants Receiving HM201|Each MAD cohort participant will be randomized to receive a once a week dose of 1 of 4 escalating doses (0.01 mg/kg (2 nmol/kg); 0.03 mg/kg (5 nmol/kg); 0.06 mg/kg (10 nmol/kg), 0.12 mg/kg (20 nmol/kg) for 4 weeks.
62055865|NCT05088369|PLACEBO_COMPARATOR|MAD Cohorts 1 to 4: Participants Receiving Placebo|Each MAD cohort participant will be randomized to receive placebo once a week for 4 weeks.
62055866|NCT03646032|EXPERIMENTAL|Intervention group|Intervention group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants who will receive a download of the SAAFE game and play for at least 30 minutes and as long as an hour, if desired.
62615362|NCT04467710||Failure of LCBDE|Patients with a laparoscopic cholecystectomy but an endoscopic treatment of common bile duct stone with an ERCP performed intra, per or postoperatively
62615363|NCT02452554|EXPERIMENTAL|Treatment (lorvotuzumab mertansine)|Patients receive lorvotuzumab mertansine IV over 1-1.5 hours on days 1 and 8. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
62055867|NCT03646032|ACTIVE_COMPARATOR|Control group|Control group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants. This group will receive the standard of care by launching a mobile app that will play a dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
62615364|NCT03274362|EXPERIMENTAL|Headspace Application Treatment Group|Participants in the treatment group will be given a free 3-month access code to Headspace. The app contains a series of sessions that guide the user through mindfulness training.
62615365|NCT03274362|NO_INTERVENTION|Standard Care Control Group|Participants in the control group will be provided a list of resources that provides guidance on mindfulness and general health.
62055868|NCT01003925||Usual Care|Patients randomized to the control group will be sent the post-test measures suitably modified to reflect the fact that they did not participate in the conjoint analysis program. Four weeks after the post-test measures are completed, a staff member will call the subject to complete a 10 minute follow-up questionnaire to assess if any changes in treatment have occurred and to take further measurements (same measurements given to treatment group).
62055869|NCT01003925||Conjoint Analysis Group|Patients randomized to the experimental group will meet the research staff to complete the conjoint analysis software and post-test measures. The post-test measures include preparedness for decision-making, personal uncertainty, osteoarthritis knowledge, arthritis self-efficacy, and satisfaction with the results of the conjoint analysis program. The in-person visit takes approximately 60 minutes to complete. Four weeks after the in-person visit, a staff member will call the subject to complete a 10 minute follow-up questionnaire to assess if any changes in treatment have occurred and to take further measurements (i.e. global pain assessment, arthritis self-efficacy, personal uncertainty, and osteoarthritis knowledge).
62615366|NCT04810559|EXPERIMENTAL|Investigational Device|
62615367|NCT04103515||Subjects implanted with PCR TKA|Subjects who have been implanted with a Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
62615368|NCT04103515||Subjects implanted with PS TKA|Subjects who have been implanted with a Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
62055870|NCT01638247|ACTIVE_COMPARATOR|Tamoxifen|Tamoxifen alone (daily).
62258385|NCT03428763|EXPERIMENTAL|Homebased disease monitoring (eHealth)|Participants allocated to the intervention group will be trained in self-monitoring of their RA
62055871|NCT01638247|EXPERIMENTAL|Tamoxifen and GnRH analogue|Tamoxifen (daily) + GnRH analogue (at randomisation and after three months).
62615369|NCT04176081|ACTIVE_COMPARATOR|Group 1: Radiation Therapy Only|Participants randomized to Group 1 will receive radiation therapy only.
62615370|NCT04176081|EXPERIMENTAL|Group 2: Radiation Therapy + darolutamide + degarelix|Participants randomized to Group 2 will receive radiation therapy only + darolutamide + degarelix.
62615371|NCT04186897|EXPERIMENTAL|Occlusal reduction|Occlusal contacts on the functional and non-functional cusps were reduced.
62615372|NCT04186897|SHAM_COMPARATOR|No occlusal reduction|Occlusal surfaces kept intact. No actual occlusal reduction..
62615373|NCT00624039|OTHER|1|ultrasound biomicrocopic examinations and pilocarpine instillation
62615374|NCT03593187|EXPERIMENTAL|Cal-1( LVsh5/C46) drug product|
62615375|NCT03948763|EXPERIMENTAL|V941 Monotherapy|V941(mRNA-5671/V941) administered intramuscularly (IM) once every 3 weeks (Q3W) for 9 3-week cycles
62615376|NCT03948763|EXPERIMENTAL|V941 + Pembrolizumab|V941(mRNA-5671/V941) administered IM Q3W for 9 cycles and pembrolizumab 200 mg, intravenous (IV) for 35 3-week cycles
62615377|NCT05090306||Pregnant women in their first and second trimester|Pregnant women in their first and second trimester will be examined using two-dimensional echocardiography of the fetal heart.
62615378|NCT05588999|ACTIVE_COMPARATOR|Group A (Cryotherapy Alone)|Patients in this Group were subjected to Cryotherapy Alone with liquid nitrogen and received maximum of four treatments given two to three weeks apart
62615379|NCT05588999|ACTIVE_COMPARATOR|Group B (Cryotherapy plus Salicylic Acid)|Patients in this Group were subjected to cryotherapy plus salicylic acid for a maximum of eight weeks
62840373|NCT02792829|EXPERIMENTAL|Lenvatinib 11 mg (suspension formulation)|"Arm 1 will have 2 sequences:~1. Sequence 1 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg)~2. Sequence 2 - Treatment Period 1: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg)"
62840374|NCT02792829|EXPERIMENTAL|Lenvatinib 11 mg (2 vs 5 capsules)|"Arm 2 will have 4 sequences:~1. Sequence 3 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg) WATER; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg) APPLE JUICE~2. Sequence 4 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER~3. Sequence 5 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE~4. Sequence 6 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) WATER"
62444878|NCT03602014|EXPERIMENTAL|Study 1: Dose Optimization of Northera|Subjects will be administered oral droxidopa in a dose escalation, open-label manner beginning with 200 mg. The dose will be adjusted upwards by 100 mg on subsequent visits until average Systolic Blood Pressure (SBP) recorded 60-120 minutes after dose administration is 111-139 mmHg in males and 101-139 mmHg in females, sustained elevation (≥ 30 consecutive minutes) in seated SBP ≥ 140/100 mmHg, maximum dose of 800 mg is reached without adequate SBP response. Subjects will visit the testing laboratory on as few as 1 (200 mg) and as many as 7 (800 mg) days. Seated cardiovascular assessments will be monitored and recorded at 15-minute intervals for 4-hours, and the side effects questionnaire will be administered hourly during the 4-hour study. Each study visit will take about 5 hours.
62840375|NCT02792829|EXPERIMENTAL|Lenvatinib 23 mg|"Arm 3 will have 2 sequences:~1. Sequence 7 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation~2. Sequence 8 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation"
62840376|NCT06518746|EXPERIMENTAL|Cryopreservation of gonadal tissue|Enrolled participants will undergo gonadal tissue processing, freezing and cryopreservation after the standard care (gonadectomy, gonadal tissue histologic examination)
62444879|NCT03602014|PLACEBO_COMPARATOR|Study 2: Blinded Placebo & Northera|Participants will then be administered either oral optimal dose of Northera (Droxidopa) or matching placebo in a double-blinded manner and will remain in the supine position for 60 minutes. Subjects will remain in their wheelchair for instrumentation, which will include: 1) ECG, 2) brachial BP, 3) finger arteriolar BP and 4) Cerebral Blood Flow velocity (CBFv).
62444880|NCT03554421|EXPERIMENTAL|Posterior tibial nerve stimulation|Percutaneous tibial nerve stimulation. Stimulation av posterior tibial nerve via neuromodulator for 30 minutes. 10 sessions
62840377|NCT03310853|EXPERIMENTAL|Probiotic|Combination of two probiotic strains in one capsule
62840378|NCT03310853|PLACEBO_COMPARATOR|Placebo|Non active ingredients in a capsule
62840379|NCT03339752|ACTIVE_COMPARATOR|Treatment A|Rosuvastatin Day 1
62840380|NCT03339752|EXPERIMENTAL|Treatment B1|ACT-541468 Day 5 to Day 7
62055872|NCT01638247|EXPERIMENTAL|Exemestane and GnRH analogue|Exemestane (daily) + GnRH analogue (at randomisation and after three months).
62840381|NCT03339752|OTHER|Treatment B2|Rosuvastatin Day 8; ACT-541468 Day 8 to Day 12
62055873|NCT03859414|ACTIVE_COMPARATOR|Therapeutic Dose 1|Single dose administration of CHF 5993 100/6/12.5 µg pMDI 2 inhalations. Total dose of CHF 5993 pMDI = 200/12/25 µg
62055874|NCT03859414|ACTIVE_COMPARATOR|Therapeutic Dose 2|Single dose administration of CHF 5993 200/6/12.5 µg pMDI 2 inhalations. Total dose of CHF 5993 pMDI = 400/12/25 µg
62840382|NCT05216809|ACTIVE_COMPARATOR|Young Adults|Equal sex distribution (10M/10F); ages 18-35 years old.
62840383|NCT05216809|ACTIVE_COMPARATOR|Older Adults|Equal sex distribution (6M/6F); ages 60-80 years old.
62615380|NCT02516956|EXPERIMENTAL|Breakfast meal 1|"Breakfast meal 1 is isocaloric (330 kcal) and similar for protein and fiber contents in relation to the other two experimental breakfasts. It has the same sugar and lipid profiles as Breakfast meal 2 and health-related cognitive perception as Breakfast meal 3.~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
62615381|NCT02516956|EXPERIMENTAL|Breakfast meal 2|"Breakfast meal 2 is isocaloric (330 kcal) and balanced for protein and fiber contents with regard to the other two experimental breakfasts. It has the same sugar and lipid profiles as Breakfast meal 1 but a higher health-related cognitive perception than the other two experimental breakfasts.~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
62055875|NCT03859414|ACTIVE_COMPARATOR|Supra-therapeutic Dose|Single dose administration of CHF 5993 100/6/12.5 µg pMDI 8 inhalations Total dose of CHF 5993 pMDI = 800/48/100 µg
62055876|NCT03859414|PLACEBO_COMPARATOR|Placebo|Single dose administration of CHF 5993 pMDI placebo
62055877|NCT00408148|PLACEBO_COMPARATOR|2|Administration of one rimonabant placebo tablet once daily in the morning
62258386|NCT03428763|ACTIVE_COMPARATOR|Standard clinical disease monitoring|Those allocated to the control arm of the study will continue usual clinical care (i.e. they will not self-monitor or have access to the eHealth solution). No other medication changes will be mandated and participating investigators will be asked to manage all other care according usual clinical practice. Individuals in the control group will not be given the option to self-monitor.
62444881|NCT04845061|PLACEBO_COMPARATOR|nebivolol then placebo|Comprises15 copd patients, after recruitment in study and written informed consent, patient's administered nebivolol (1.25 mg for one week then2.5mg fore another one week and 5 mg at 8am for 10 weeks)and washout period4 weeks then shifted to placebo for 12 weeks
62444882|NCT04845061|ACTIVE_COMPARATOR|placebo then nebivolol|Contain 15 copd patient's after recruitment and Written informed consent administered placebo for 12 weeks and washout period for 4 weeks then shifted to nebivolol for 12 weeks
62615382|NCT02516956|EXPERIMENTAL|Breakfast meal 3|"Breakfast meal 3 is isocaloric (330 kcal) and similar for protein and fiber contents in relation to the other two experimental breakfasts. It has the same health-related cognitive perception as Breakfast meal 1 but lower lipid and higher sugar amounts than the other two experimental breakfasts.~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
62615383|NCT02516956|PLACEBO_COMPARATOR|Breakfast meal 4|"Breakfast meal 4 is a non-caloric meal representing fasting condition (control arm).~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
62055878|NCT00408148|EXPERIMENTAL|1|Administration of one tablet containing 20 mg of active rimonabant once daily in the morning
62055879|NCT00662857|EXPERIMENTAL|1: TI Inhalation Powder A|Technosphere® Insulin Inhalation Powder, two 15 U cartridges
62055880|NCT00662857|EXPERIMENTAL|2: TI Inhalation Powder B|Technosphere® Insulin Inhalation Powder, one 30 U cartridge
62055881|NCT00662857|EXPERIMENTAL|3: RAA Population|Rapid Acting Analogue subjects received 10 IU sc Insulin Lispro
62258387|NCT04338009|EXPERIMENTAL|Discontinuation arm|The randomized intervention will be the discontinuation of ACEI/ARBs
62258388|NCT04338009|EXPERIMENTAL|Continuation arm|The randomized intervention will be the continuation of ACEI/ARBs
62258389|NCT00865397||A|
62258390|NCT02256514|EXPERIMENTAL|Daily oral dose of hepcortespenlisimut-L|Hepcortespenlisimut-L (V5) (850 mg pill) to be administered once per day for the duration of study
62258391|NCT05086536||early stage decompensation cohort|Patients occurred first decompensated events and initiating nucleoside analogs (NUCs) based treatment within 3 months were retrospectively included.
62258392|NCT03045679|EXPERIMENTAL|RYGB-group|Patients who undergo laparoscopic RYGB (150 cm alimentary limb, 50 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
62258393|NCT03045679|EXPERIMENTAL|OAGB/MGB-group|Patients who undergo laparoscopic OAGB/MGB (200 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
62258394|NCT02187172|ACTIVE_COMPARATOR|Ustekinumab (Stelara)|Ustekinumab (Stelara) subcutaneous injection 45mg (if person's weight is 100kg or less) or 90mg (if person's weight is greater than 100kg) at day 0 and week 4 followed by every 12-week dosing thereafter. Patient will receive total of 52 weeks of ustekinumab (12 weeks during RCT phase, 40 weeks post RCT phase). The end of study is at Week 52 for this arm.
62444883|NCT02637557|PLACEBO_COMPARATOR|Control|Matching placebo twice daily
62840384|NCT04969302|EXPERIMENTAL|Intervention Group|"Skin preparations will performe using Povidone 10% 1000 mL solution (Turkuaz Chemistry, İstanbul, Turkey) Povidone-iodine will heat to 37°C using a gel warmer (KGW-1 Keewell Medical Technology, Foshen, China) in the warm group.~The day before the operation, the patient will be met and informed about the study and verbal and written consent will be obtained stating that they are willing to participate in the study.~The weight tracking of the patients will be determined using a digital weight meter provided by the researcher. Patient evaluation will be made with NRS-2002 in terms of malnutrition risk.~Antibiotic prophylaxis of 1000 mg available in the operating room will be administered 30-60 minutes before the operation.~Before the incision, a wound culture sample will be taken with sterile transport swap and sent to the laboratory for culture study."
62840385|NCT04969302|NO_INTERVENTION|Control Group|"Skin preparations will performe using Povidone 10% 1000 mL solution (Turkuaz Chemistry, İstanbul, Turkey) Povidone-iodine will heat to 20°C using a gel warmer (KGW-1 Keewell Medical Technology, Foshen, China) in the room heat group.~The day before the operation, the patient will be met and informed about the study and verbal and written consent will be obtained stating that they are willing to participate in the study.~The weight tracking of the patients will be determined using a digital weight meter provided by the researcher. Patient evaluation will be made with NRS-2002 in terms of malnutrition risk.~Antibiotic prophylaxis of 1000 mg available in the operating room will be administered 30-60 minutes before the operation.~Before the incision, a wound culture sample will be taken with sterile transport swap and sent to the laboratory for culture study."
62840386|NCT00565084|ACTIVE_COMPARATOR|1|Ibuprofen
62258395|NCT02187172|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection will be given according to the same dose and schedule as the active comparator until week 12 (end of RCT phase). At week 12, ustekinumab will be administered according according to the same injection schedule as the active comparator arm for 52 weeks. Patient will receive total of 52 weeks of ustekinumab (0 weeks during RCT phase, 52 weeks post RCT phase). The end of study is at Week 64 for this arm.
62840387|NCT00565084|PLACEBO_COMPARATOR|2|Placebo 1
62840388|NCT00565084|PLACEBO_COMPARATOR|3|Placebo 2
62840389|NCT05335278|EXPERIMENTAL|Nintedanib treatment|Single arm treatment with nintedanib
62258396|NCT02820155|PLACEBO_COMPARATOR|Placebo|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
62615384|NCT02327013|EXPERIMENTAL|vortioxetine 10 mg tablet|"In Stage 1, patients will receive vortioxetine 10mg/day for 6 weeks.~In Stage 2, patients who received vortioxetine 10mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
62840390|NCT01339052|EXPERIMENTAL|Cohort 1: Surgical subjects|"Subjects scheduled for surgery~BKM120: 100 mg once daily, orally, for 8-12 days prior to surgery~Surgery: Surgery~BKM120: 100 mg once daily, orally, for 28-day cycles~Patients continued treatment until disease progression or unacceptable toxicity."
62840391|NCT01339052|EXPERIMENTAL|Cohort 2: Non-surgical subjects|"Subjects not candidates for surgery~BKM120: 100 mg once daily, orally, for 28-day cycles~Patients continued treatment until disease progression or unacceptable toxicity."
62055882|NCT02905383|EXPERIMENTAL|Exercise|This group will perform a multi-component exercise program twice a week for 16 weeks. The multi-component exercise program consists of endurance training, progressive strength exercises and balance exercises. The intervention will be individualised, but performed in groups of four to ten patients. The participants are also expected to do exercises on their own, at least once weekly.
62055883|NCT02905383|NO_INTERVENTION|Control|The participants in the control group will be encouraged to exercise on their own, according to the World Health Organization recommendations on physical activity for adults aged 65 and above.
62055884|NCT01498432|EXPERIMENTAL|Heliox21|
62055885|NCT01498432|ACTIVE_COMPARATOR|Air O2|
62055886|NCT02767063|EXPERIMENTAL|Experimental Arm_ACTOS|"TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months~PIOGLITAZONE (Actos®):~30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade \>1 related AE."
62055887|NCT02767063|NO_INTERVENTION|controled Arm|TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months
62258397|NCT02820155|EXPERIMENTAL|RGN1016_50mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
62258398|NCT02820155|EXPERIMENTAL|RGN1016_100mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
62258399|NCT02820155|EXPERIMENTAL|RGN1016_200mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
62258400|NCT02820155|EXPERIMENTAL|RGN1016_400mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
62615385|NCT02327013|EXPERIMENTAL|vortioxetine 20 mg tablet|"In Stage 1, patients will receive vortioxetine 20mg/day for 6 weeks.~In Stage 2, patients who received vortioxetine 20mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
62840392|NCT05840757|OTHER|Hemodynamic Monitoring|Simultaneous measurement of hemodynamic parameters such as Cardiac output, cardiac index and blood pressure with invasive right heart catheterization and non-invasive application of the Clearsight Finger Cuff.
62615386|NCT02327013|PLACEBO_COMPARATOR|Placebo tablet|"In Stage 1, the patients will receive placebo for 6 weeks.~In Stage 2, placebo responders will continue on placebo for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
62258401|NCT02820155|EXPERIMENTAL|RGN1016_800mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
62615387|NCT05290428||Retrospective part|This part will enroll at least 120 cases in previously preserved samples.
62615388|NCT05290428||Prospective part|This part will enroll at least 339 cases.
62840393|NCT05860309|ACTIVE_COMPARATOR|preoperative quadratous lumborum block|patients weill recieve preoperative ultrasound guided quadratous lumborum block at lateral position before start of surgery after induction of general anesthesia
62840394|NCT05860309|ACTIVE_COMPARATOR|postoperative quadratous lumborum block|patients weill recieve postoperative ultrasound guided quadratous lumborum block at lateral position at the end of surgery before recovery from general anesthesua
62840395|NCT05940090||Comparison of outlier analysis with dermatologist made biopsy decisions|Skin lesions recommended for skin biopsy by the dermatologist will be compared to lesions highlighted by the application outlier analysis.
62840396|NCT05055206|EXPERIMENTAL|Lymphatic drainage mapping in patients with oropharynx cancer|"Participants will be given 4 to 6 injections of the radiotracer 99m-Technetium Sulfur Colloid by a needle into one of the veins of the radiotracer around the tumour.~Participants will then have at least 1 or possibly 2 SPECT-CT scans (a special x-ray scan of the body from many angles that are turned into 3-dimensional pictures on a screen)."
62840397|NCT03760861|EXPERIMENTAL|Prototype Microcapsule Treatment Arm|Intervention by placement of prototype weight-loss microcapsule in the stomach. Subjects will have a weight-loss microcapsule deployed endoscpically in the stomach. The intragastric balloon in the capsule will be inflated using an external magnet..
62258402|NCT06489483||Parkinson's Disease Patients|Patients that have been diagnosed with Parkinson's Disease and are responsive to levodopa medication. Patients will complete a behavioral task.
62258403|NCT06489483||Healthy Controls|Men and women between the ages of 18-80. Spouse of PD patient who participates in this study with no history of any diagnosed neurological disease(s), including movement disorders or cognitive decline. No vision or hearing problems that impair ability to participate with the proposed tasks as assessed by the study investigators.
62258404|NCT03425214|EXPERIMENTAL|NC with RBD|fMRI and video polysmnography
62444884|NCT02637557|EXPERIMENTAL|500 mg IW-3718|500 mg IW-3718 twice daily
62444885|NCT02637557|EXPERIMENTAL|1000 mg IW-3718|1000 mg IW-3718 twice daily
62444886|NCT02637557|EXPERIMENTAL|1500 mg IW-3718|1500 mg IW-3718 twice daily
62444887|NCT03422146|EXPERIMENTAL|Cliradex® eyelid hygiene|Cliradex® is a novel over-the-counter eyelid wipe which contains the most active ingredient of TTO. Previous studies have shown the clinical and antimicrobial efficacy of eyelid hygiene with tea tree oil (TTO) in resolving chronic blepharitis.
62615389|NCT01865877||PD Cohort|Subjects diagnosed with Parkinson's disease
62615390|NCT02188524|NO_INTERVENTION|Control Group|No exercise program
62615391|NCT02188524|EXPERIMENTAL|Exercise Group|exercise program
62615392|NCT05290077|ACTIVE_COMPARATOR|Cases|group of vitiligo patients
62444888|NCT03422146|OTHER|I-Lid 'n Lash® Hygiene|Lid 'n Lash® Hygiene, is an over-the-counter eyelid wipe, without any medicinal ingredients,
62444889|NCT03857022|EXPERIMENTAL|Enhanced External Counterpulsation|"Subjects of Heart failure with 'Enhanced External Counterpulsation therapy"
62444890|NCT03857022|NO_INTERVENTION|"No 'Enhanced External Counterpulsation"|"Subjects of Heart failure without 'Enhanced External Counterpulsation therapy"
62444891|NCT01268176|ACTIVE_COMPARATOR|Low fat meal|Those subjects who receive a low fat meal prior to vitamin D3 administration
62444892|NCT01268176|ACTIVE_COMPARATOR|High fat meal|Those subjects who receive a high fat meal prior to vitamin D3 administration
62444893|NCT01268176|ACTIVE_COMPARATOR|No meal|Those subjects who do not receive a meal and continue to fast. They only receive the vitamin D3 dose.
62444894|NCT06332547|ACTIVE_COMPARATOR|Restrictive transfusion strategy|"Restrictive transfusion strategy: Blood transfusion triggers of Hb valve less than 6.0g/dL or Hct value less than 18% during CPB, Hb valve less than 7.0g/dL or Hct value less than 21% in ICU or general ward.~Red blood cell transfusion will be given when Hct values fall below 18% or Hb fall below 6.0g/dL during CPB, 2 units RBC transfusion will be administered. In ICU or general ward after surgery, RBC transfusion will be given when Hct values fall below 21% or Hb fall below 7.0g/dL during CPB, 2 unit RBC transfusion will be administered. Following administration of the 2 units transfusion a repeat HCT or Hb is performed, if their values greater than threshold, no further transfusions will be administered, or will be received 2 units RBC again."
62258405|NCT03425214|EXPERIMENTAL|NC without RBD|fMRI and video polysomnography
62258406|NCT03425214|EXPERIMENTAL|control group (healthy subjects)|fMRI
62258407|NCT01843842|EXPERIMENTAL|Ergoferon (5 ml 3 times a day)|
62258408|NCT01843842|PLACEBO_COMPARATOR|Placebo (5 ml 3 times a day)|
62258409|NCT05344794||CCS group|Patients with cerebral syndrome diagnosed by the Second Hospital of Shanxi Medical University
62258410|NCT05344794||Control group|Patients who have not had a cerebral syndrome in ischemic stroke
62615393|NCT05290077|ACTIVE_COMPARATOR|control group|healthy group
62615394|NCT00642070||Host|Women with current symptoms of a urinary tract infection
62615395|NCT05368922|EXPERIMENTAL|Experimental: Virtual Reality Group|Children will receive a virtual reality rehabilitation protocol for their most affected upper limb for four weeks, on the basis of three sessions a week, in addition to their usual care. Virtual reality will be applied to participants for 30 minutes and will be based on two perceptual-motor tasks.
62840398|NCT02441595|EXPERIMENTAL|MBCP intervention|The intervention involves eight 2.5 h weekly group sessions in which exercises in mindfulness are practiced and associated theory is taught to increase metacognition, emotional regulation and body awareness.
62258411|NCT05160961|ACTIVE_COMPARATOR|Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
62258412|NCT05160961|ACTIVE_COMPARATOR|Erector spinae plane block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 20 ml of 0.25% bupivacaine hydrochloride will be injected into the interfacial space below the erector spinae muscle, above the transverse process.
62615396|NCT05368922|NO_INTERVENTION|Control group|Children who will be randomized to the control group will follow their usual care for four weeks (usual motor activity, including classical rehabilitation and sports or physical activities). The rehabilitation protocol will be proposed after the second post-test
62258413|NCT04090008|ACTIVE_COMPARATOR|PRP gel|PRP gel was applied to the ulcer twice per week after preparation and then the ulcer was covered with Vaseline gauze, few layers of sterile gauze and crepe bandage.
62258414|NCT04090008|ACTIVE_COMPARATOR|Saline dressing|daily dressing of the ulcer with normal saline was done
62258415|NCT03357731|EXPERIMENTAL|Placebo/BMS-986231/NTG|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
62258416|NCT03357731|EXPERIMENTAL|Placebo/NTG/BMS-986231|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
62258417|NCT03357731|EXPERIMENTAL|NTG/Placebo/BMS-986231|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
62615397|NCT00926536|EXPERIMENTAL|C-arm CT + DSA as needed'|In the group of subjects randomized in this group, the image guidance component of the procedure will be conducted by the acquisition of 3D CT-like images during a trans-hepatic arterial injection of iodinated contrast agent for road mapping the tumor feeding vessels and supplemented by DSA as needed by the operating physician as imaging guidance for planning tumor(s) treatment approach.
62444895|NCT06332547|ACTIVE_COMPARATOR|Liberal Transfusion Strategy|"Liberal Transfusion Strategy: Blood transfusion triggers of Hb valve less than 8.0g/dL or Hct value less than 24% during CPB, Hb valve less than 10.0g/dL or Hct value less than 30% in ICU or general ward.~Red blood cell transfusion will be given when Hct values fall below 24% or Hb fall below 8.0g/dL during CPB, 2 units RBC transfusion will be administered. In ICU or general ward after surgery, RBC transfusion will be given when Hct values fall below 30% or Hb fall below 10.0g/dL during CPB, 2 units RBC transfusion will be administered. Following administration of the 2 units transfusion a repeat HCT or Hb is performed, if their values greater than threshold, no further transfusions will be administered, or will be received 2 units RBC again."
62840399|NCT02441595|ACTIVE_COMPARATOR|Control condition|Participants in the control condition are being offered a standardized course in psychoprophylaxis.
62840400|NCT06079710||Emergence agitation group|
62840401|NCT06079710||Non emergence agitation group|
62258418|NCT03357731|EXPERIMENTAL|NTG/BMS-986231/Placebo|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
62258419|NCT03357731|EXPERIMENTAL|BMS-986231/Placebo/NTG|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
62258420|NCT03357731|EXPERIMENTAL|BMS-986231/NTG/Placebo|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
62258421|NCT03221751|EXPERIMENTAL|Prazosin|Subjects will be titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose is 5 mg in the morning, 5 mg in the afternoon and 15 mg at bedtime.
62258422|NCT03221751|PLACEBO_COMPARATOR|Placebo|Subjects will be titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose is 5 mg in the morning, 5 mg in the afternoon and 15 mg at bedtime.
62840402|NCT00915616|NO_INTERVENTION|control|9 healthy normal subjects.
62840403|NCT00915616|ACTIVE_COMPARATOR|Group II|Included 9 patients suffering from GERD; receiving melatonin alone for treatment of GERD in a dose of 3 mg once daily at the bed time.
62840404|NCT00915616|NO_INTERVENTION|Group III, combined group|Included 9 patients suffering from GERD; receiving omeprazole alone for treatment of GERD in a dose of 20 mg twice daily.
62258423|NCT04168866|EXPERIMENTAL|Surgery|Patients who choose operations will have surgery performed to remove the appendix laparoscopically, through 3 or 4 small incisions. All patients in the operative group will receive standard perioperative antibiotics. They will also have the abscess(es) drained during the same surgery if there is one present. In some cases, the operation may be too difficult to perform laparoscopically, so an open appendectomy will be performed, involving a longer incision to remove the appendix. In some cases, both laparoscopic and open are performed. The surgeon may also choose to remove a section of the intestine with the appendix or perform additional procedures.
62840405|NCT00915616|ACTIVE_COMPARATOR|Group IV|Included 9 patients suffering from GERD receiving omeprazole and melatonin for treatment of GERD in the same dose of each of them.
62840406|NCT03995953|NO_INTERVENTION|Control|2 control zones with no intervention at the clinic or community level
62258424|NCT04168866|ACTIVE_COMPARATOR|Non-operative management|If a patient chooses non-operative management and if an abscess is present and amenable to percutaneous drainage this will be performed. If there is no abscess or it is not amenable to drainage antibiotics alone will be provided.
62258425|NCT04878770|ACTIVE_COMPARATOR|Topical corticosteroids (control)|This group will receive topical corticosteroids.
62840407|NCT03995953|EXPERIMENTAL|SHIELD: Community-based behavioral intervention|2 clinic zones where participants attend modules designed to educate and empower adolescent girls and young women (AGYWs) and their families, along with attendance at community-based youth clubs to foster peer support.
62444896|NCT04169282|EXPERIMENTAL|nPEP Recipients|Single-patient, adjustable expiratory resistance device that provides positive pressure (5 to 20 cm H2O) during expiration
62444897|NCT04559256|OTHER|Tricuspid Cardiopulmonary Exercise testing|Patient receiving cardiopulmonary exercise testing
62840408|NCT03995953|EXPERIMENTAL|SHIELD: Community- based behavioral intervention & IWC Clinic|2 clinic zones where participants receive the Support for HIV Integrated Education, Linkages to care, and Destigmatization (SHIELD) intervention along with the coupled benefits of having an integrated wellness care (IWC) clinic within health facilities where adolescent girls and young women (AGYWs) can receive sexual and reproductive health services, including HIV testing and treatment, family planning, sexually transmitted disease screening and treatment, and human papilloma virus (HPV) vaccination.
62840409|NCT00528593|ACTIVE_COMPARATOR|1|
62840410|NCT03972943|ACTIVE_COMPARATOR|Cohort I (observation)|Patients not diagnosed with OSA undergo observation for 6 months.
62258426|NCT04878770|ACTIVE_COMPARATOR|Systemic cyclosporine|This group will receive topical corticosteroids and systemic cyclosporin.
62258427|NCT04878770|ACTIVE_COMPARATOR|Systemic dupilumab|his group will receive topical corticosteroids and systemic dupilumab.
62258428|NCT02694770|EXPERIMENTAL|Neihulizumab|Patients will receive a total of 4 doses of Neihulizumab (AbGn-168H) on Day 1 (Week 0), Day 8 (Week 1), Day 15 (Week 2), and Day 22 (Week 3) by 1-hour i.v. infusion.
62444898|NCT05869097||TAS-102 plus BEV group|In TAS-102 plus BEV group, Patients received TAS-102 (35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days) and bevacizumab (5 mg /kg, intravenously, on days 1 and 15, every 28 days). Bevacizumab was approved to be a 30-minute intravenous infusion before TAS-102.
62840411|NCT03972943|EXPERIMENTAL|Cohort II: (CPAP treatment)|Patients diagnosed with OSA and prescribed a CPAP machine for treatment receive continuous treatment with CPAP for 6 months.
62840412|NCT00067106||1: Women failing therapy|Participants will have study visits at study entry, 2 weeks after changing medications, then every 4 weeks until the amount of HIV in the blood and genital tract are undetectable. Drug levels in the blood and genital tract will also be measured at the first visit and after changing medications. Once the level of HIV is undetectable, women will be seen every 3 months for 36 months. Participants in Group 1 will be followed no more than 42 months.
62840413|NCT00067106||2: Women suppressed on therapy|Participants will have study visits for blood and genital tract collections at study entry and then every 4 weeks for 12 months
62444899|NCT05869097||TAS-102 monotherapy group|In TAS-102 monotherapy group, TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days were given to patients.
62615398|NCT00926536|ACTIVE_COMPARATOR|DSA only|In the group of subjects randomized in this group, present standard of care, i.e DSA imaging only will be used by the operating physician to map out the tumor vessels and used for treatment approach. Additional 3D CT-like images will be obtained, but only used if the operator cannot perform adequate planning using DSA alone.
62258429|NCT02694770|ACTIVE_COMPARATOR|"Conventional Treatment"|Patients will receive a 2nd line therapy for aGvHD at the discretion of attending physician according to the standard practice at the study center. Currently there is no treatment for sr-aGvHD is approved in USA or Europe. There is no Standard treatment of this disease is recommended by American Society for Blood and Marrow Transplantation (ASBMT). Therefore, the study is designed to allow any established institutional practice for off-label use of a commercially available product for patients in the Conventional Treatment arm. Patients in this arm may receive treatments provided in ASBMT guidance such as ATG, TNF-alpha inhibitors (such as Etanercept and infliximab), pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis, methotrexate, basiliximab, daclizumab, inolimomab, denileukin diftitox, alemtuzumab, ATG+ etanercept, Dacliz + etanercept, Dacliz+ infliximab, and Dacliz/inflix/horse ATG.
62615399|NCT03419130|EXPERIMENTAL|Cohort I (pembrolizumab, hypofractionated RT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients also receive hypofractionated RT over 5 fractions for 14 days.
62258430|NCT03732612||Control patients|"Control patients (n=20): In individuals undergoing vascular surgery that is not associated with vascular disease (e.g. knee replacement surgery, trauma, etc), a piece of healthy vessel must sometimes be removed in order to facilitate the surgical process. The vessel biopsies from this group will be categorized as healthy vessels in our study."
62615400|NCT03419130|EXPERIMENTAL|Cohort II (pembrolizumab, conventionally fractionated RT)|Patients receive pembrolizumab as in Cohort I. Patients also receive conventionally fractionated RT over 30 fractions for 52 weeks.
62615401|NCT03213925|EXPERIMENTAL|RT|"After clinical response, breast magnetic resonance imaging (MRI) is performed and analyzed by two independent radiologists. Complete image response is defined by no enhanced tumor visible on any serial images.~Radiation therapy to the breast with or without regional nodal area is performed within 12 weeks after completion of chemotherapy with conventional dose (25x200cGy). Additional boost of 16 Gy in the primary involved tumor region."
62840414|NCT04733859|PLACEBO_COMPARATOR|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
62840415|NCT04733859|EXPERIMENTAL|red djulis drinks|subjects drank 50 ml , 1 bottle a day for 8 week
62258431|NCT03732612||Study patients|"Study patients (n=150): In individuals undergoing vascular surgery associated with peripheral arterial diseases, aneurysm and/or other manifestations of atherosclerosis, vascular tissue is sometimes excised to facilitate the surgery. Biopsies from these individuals will be categorized as vessels with vascular dysfunction."
62258432|NCT02615483|EXPERIMENTAL|Web-based platform|Access to a web-based platform
62444900|NCT06280469|EXPERIMENTAL|pilot group|endoscope and overtube equipped with a balloon are operated by one endoscopist.
62444901|NCT06280469|EXPERIMENTAL|control group|endoscope is operated by one endoscopist and overtube equipped with a balloon is operated by one assistant
62444902|NCT05269628|EXPERIMENTAL|Cannabidiol (CBD)|"Epidiolex® doses will be 0.5 mL twice daily during the first seven days of active treatment and 1 mL twice daily (b.i.d.) for the remaining days of treatment.~PLUS Placebo Tetrahydrocannabinol (TCH) capsules which contain no active ingredients. Matching placebo capsules will be taken twice per day in the same schedule and manner as active dronabinol."
62615402|NCT06445582||CANDI|China Aging and Neurodegenerative Initiative
62615403|NCT01472978|ACTIVE_COMPARATOR|Immediate antibiotic treatment|Patients will be treated with an antibiotic as soon as the aspirate obtained at the colonoscopy is found to be positive for C. diff.
62615404|NCT01472978|SHAM_COMPARATOR|Delayed treatment with an antibiotic|Treatment will be started after a delay after the aspirate obtained at the colonoscopy is found to be C. diff positive.
62055888|NCT02767063|EXPERIMENTAL|Experimental Arm_AVELUMAB|TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months AVELUMAB: 10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period.(If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
62055889|NCT06053034|SHAM_COMPARATOR|Sham device|a round device equipped with a strap for hand holding, it is to be used while connected to a socket. The device is used by an assistant (usually a family member) on the participant's back for 20 minutes while moving it around in circles on the lower back.
62258433|NCT02615483|NO_INTERVENTION|Control|Conventional
62258434|NCT03672279||Mild neurocognitive disorder|
62258435|NCT03672279||Major neurocognitive disorder|
62615405|NCT02585687|EXPERIMENTAL|liver Perfusion MRI|liver perfusion MRI will be performed in patients to assess the early response (7 days) to antiangiogenic treatments
62615406|NCT04509817|EXPERIMENTAL|Acupuncture+Usual care|Subjects in experimental group will receive a standardized acupuncture treatment, 10 times per 4 weeks for 16 weeks with a total of 40 sessions in addition to usual care.
62840416|NCT04578236|EXPERIMENTAL|Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg|Infected patients will receive aerosolized 13 cis retinoic acid in gradual one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Inhalation administration by nebulization captopril 25mg for 14 days
62840417|NCT04578236|SHAM_COMPARATOR|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
62840418|NCT01470950|EXPERIMENTAL|MotionMaker Training|Device description: MotionMaker™ is a stationary robotic system for the active mobilization of the lower limbs. With its proprietary 'Closed-Loop' technology, it is a novel and exciting development that offers a truly interactive patient training system Training 3 times a week with MotionMaker device together with conventional treatment
62840419|NCT04037696|EXPERIMENTAL|Experimental group|The experimental group will receive individual face-to-face brief MI (about 5 minutes) on a health-related lifestyle practice. The experimental group will then receive a brief MI via WhatsApp/WeChat on a smartphone during the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once every 2 to 3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering the messages via WhatsApp/WeChat will be interactive, depending on the subjects' actions and responses, and may take several sessions of chats within several days or weeks. After 6 months, minimal messages will be provided to the subjects by merely following their progress of behavioural changes and responding to their questions to maintain contact until the 1-year follow-up.
62258436|NCT03784547||multiple sclerosis patients|multiple sclerosis patients receiving ocrelizumab 600 mg endovenous every 6 months
62258437|NCT05735691|EXPERIMENTAL|High-Intensity With Pertubations|30 sessions of high-intensity treadmill training will be conducted. Perturbations that disrupt balance will be applied during the training.
62615407|NCT04509817|ACTIVE_COMPARATOR|Usual care|Subjects in control group will receive usual care only.
62055890|NCT06053034|ACTIVE_COMPARATOR|Solio Alpha Plus|The SOLIO Alfa Cure Plus Device for patients with LBP- is a round device equipped with a strap for hand holding, it is to be used while connected to a socket. The device is used by an assistant (usually a family member) on the participant's back for 20 minutes while moving it around in circles on the lower back. It should be mentioned this is the first trial in Home-RF using an external
62615408|NCT05777564|OTHER|HIIT for knee OA|high intensity exercise
62615409|NCT01303614|ACTIVE_COMPARATOR|Lidocaine-Prilocaine cream|
62615410|NCT01303614|PLACEBO_COMPARATOR|Placebo|purified water, ethylene glycol stearate, palm, palm stearate, polyethylene glycol, liquid paraffin, benzoic acid
62615411|NCT04126317|EXPERIMENTAL|intravitreal aflibercept injection (IAI)|"Treatment-naïve patients with neovascular wet age-related macular degeneration (nAMD) randomized in a 1:1 ratio"
62615412|NCT04126317|EXPERIMENTAL|High-dose aflibercept (HD)|Treatment-naïve patients with nAMD randomized in a 1:1 ratio
62258438|NCT05735691|EXPERIMENTAL|High-Intensity No Perturbations|30 sessions of high-intensity treadmill training will be conducted on a stable treadmill.
62258439|NCT05735691|EXPERIMENTAL|Moderate-Intensity With Perturbations|30 sessions of moderate-intensity treadmill training will be conducted. Perturbations that disrupt balance will be applied during the training.
62258440|NCT05735691|ACTIVE_COMPARATOR|Moderate-Intensity No Perturbations|30 sessions of moderate-intensity treadmill training will be conducted on a stable treadmill.
62258441|NCT01722604|ACTIVE_COMPARATOR|Azopt 1% ophthalmic suspension|Ophthalmic suspension
62258442|NCT01722604|EXPERIMENTAL|Brinzolamide 1% ophthalmic suspension|ophthalmic suspension
62258443|NCT06015139|ACTIVE_COMPARATOR|viscoelastic polymer pads|while the control group used a Relton-Hall prone frame with a viscoelastic polymer pads
62615413|NCT02971618||Total group|Patients T2D with dapagliflozin treatment
62615414|NCT03682029|EXPERIMENTAL|Vitamin C|Vitamin C (ascorbic acid) 500 mg/capsule. Ingestion of 2 capsules (1000 mg) daily for 12 months.
62615415|NCT03682029|PLACEBO_COMPARATOR|Placebo|Placebo capsule. Ingestion of 2 capsules daily for 12 months. Placebo will be prepared as capsules that look and taste identical to the vitamin C supplement capsules. The content of the placebo is lactose, potato starch, gelatin, magnesium stearate, and talc.
62615416|NCT03173261|OTHER|tuberculous pleural effusion|diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
62615417|NCT06257160|ACTIVE_COMPARATOR|Surgical infiltration|
62615418|NCT06257160|EXPERIMENTAL|PENG Block ultrasound-guided|
62615419|NCT02850549|OTHER|physical therapy|Physical Therapy intervention provided by therapists in phase one without training in following a neck classification system and in phase two after being trained to follow a neck pain classification system.
62615420|NCT02005627|ACTIVE_COMPARATOR|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 standardised quality units tablet (SQ-T) once daily.
62615421|NCT02005627|PLACEBO_COMPARATOR|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
62615422|NCT05643326|EXPERIMENTAL|Real tACS - Real tACS|42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks) followed by an open-label 42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks).
62840420|NCT04037696|OTHER|Control group|The control group will be given general brief advice and receive a self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs. The subjects in this group will receive the same schedule of follow-ups as in the intervention group, but they will not receive any follow-up booster intervention.
62840421|NCT05536596|EXPERIMENTAL|Citoneurone|Groups A will receive the pharmacology treatment with 1.5 mg uridine triphosphate, 2.5 mg cytidine monophosphate and 1 mg hydroxycobalamin (Citoneurone). One capsule orally three times a day for 60 days as suggested by the manufacturer for patients with trauma - compressive peripheral neural disorders.
62840422|NCT05536596|EXPERIMENTAL|Melatonin|Group B will receive the pharmacology treatment with 10 mg Melatonin. One capsule orally at night for 60 days.
62840423|NCT05536596|EXPERIMENTAL|Hydroxycobalamin|Group C will receive the pharmacology treatment with 1 mg hydroxycobalamin (vitamin B12). One capsule daily for 60 days.
62258444|NCT06015139|EXPERIMENTAL|cotton roll-coated viscoelastic polymer pads|The experimental group used a Relton-Hall prone frame with cotton roll-coated 3 cm viscoelastic polymer pads
62615423|NCT05643326|SHAM_COMPARATOR|Sham tACS - Real tACS|42 sessions of sham stimulation (5 days/week for 9 weeks) followed by an open-label 42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks).
62615424|NCT05542394|EXPERIMENTAL|Curcumin H2O SAP|Water soluble version of turmeric extract standardized to 10% curcuminoids will be administered orally (1 dose)
62258445|NCT05651165|ACTIVE_COMPARATOR|Group A|Patients receiving pharmacoactive balloon angioplasty. Lutonix®
62258446|NCT05651165|EXPERIMENTAL|Group B|Patients receiving mimetic stent. Supera®
62258447|NCT04344470|EXPERIMENTAL|Healthy Volunteers|Healthy Volunteers
62258448|NCT00702364|EXPERIMENTAL|Atomoxetine|40mg atomoxetine twice a day for 2 weeks
62258449|NCT00702364|PLACEBO_COMPARATOR|placebo|Placebo twice a day for two weeks
62840424|NCT05536596|PLACEBO_COMPARATOR|Placebo|The controls will receive 1 capsule placebo containing 5 mg starch to be taken once daily.
62840425|NCT00156676|EXPERIMENTAL|Arm 1|Cross over from body-weight support treadmill to Lokomat
62840426|NCT00156676|EXPERIMENTAL|Arm 2|Cross over from Lokomat to body-weight support treadmill
62840427|NCT03819114|EXPERIMENTAL|A: LNG 1.5 mg among participants on EFV-based ART (randomized)|Participants received 1.5 mg of LNG once orally on Day 0 and were followed post-treatment for 4 weeks.
62258450|NCT01989312|ACTIVE_COMPARATOR|supraclavicular block|A supraclavicular block with 32 mL of lidocaine 1.5% + epinephrine 5µg/mL was performed for the anaesthetic management of the forearm and hand.
62258451|NCT01989312|ACTIVE_COMPARATOR|Supraclavicular and median, ulnar, radial blocks|Patients in this group received 20 mL of lidocaine 1.5% + epinephrine 5µg/mL for supraclavicular block and after the supraclavicular block they recieved a distal median, radial, and ulnar nerve blocks using 50:50 mixture of lidocaine 2% + levobupivacaine 0.5% (4 mL/nerve).
62258452|NCT03180099|ACTIVE_COMPARATOR|Thoracolumbar Interfascial Plane Block|Bilateral ultrasound guided thoracolumbar interfascial plane block
62258453|NCT03180099|ACTIVE_COMPARATOR|Epidural Block|Epidural Block
62258454|NCT06208787|EXPERIMENTAL|Experimental group|Individuals assigned to this group will receive the experimental neurofeedback training
62258455|NCT06208787|SHAM_COMPARATOR|Control group|Individuals assigned to this group will receive the sham neurofeedback training
62258456|NCT00652366|ACTIVE_COMPARATOR|Gemcitabine, Erlotinib Standard Dose|Participants received erlotinib, 100 milligrams (mg), orally (PO), once daily until disease progression or unacceptable toxicity. Participants also received gemcitabine, 1000 mg per (/) square meter (m\^2), intravenously (IV), on Days 1, 8, and 15 of consecutive 4 week cycles until disease progression or unacceptable toxicity.
62258457|NCT00652366|EXPERIMENTAL|Gemcitabine, Erlotinib Escalating Dose|Participants received erlotinib, beginning at 150 mg/day, PO, once daily, and increasing in increments of 50 mg every 2 weeks up to a maximum of 250 mg/day, until development of a grade 2 rash, or occurrence of other, non-rash, dose-limiting toxicity; treatment was continued until disease progression, unacceptable toxicity, death or withdrawal. Participants also received gemcitabine, 1000 mg/m\^2, IV, on Days 1, 8, and 15 of consecutive 4 week cycles until disease progression or unacceptable toxicity.
62258458|NCT00927290|ACTIVE_COMPARATOR|1|Pioglitazone, 16 weeks before and during antiviral combination therapy
62615425|NCT05542394|ACTIVE_COMPARATOR|Tumeric with piperine SAP|Turmeric extract standardized to 95% curcuminoids in combination with 5 mg of piperine per capsule will be administered orally (1 dose)
62615426|NCT05542394|PLACEBO_COMPARATOR|Tumeric without piperine|Turmeric extract standardized to 95% curcuminoids without piperine will be administered orally (1 dose)
62615427|NCT01758159|EXPERIMENTAL|CFR group|The children in this group will receive complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
62615428|NCT01758159|EXPERIMENTAL|Fe group|The children in this group will receive iron supplementation 2mg/kg/day of ferric Na EDTA (in the form of syrup) daily for 24 weeks duration.
62615429|NCT01758159|EXPERIMENTAL|CFR + Fe group|The children in this group will receive both local food-based complementary feeding according to CFR and Iron supplementation for 24 weeks duration
62258459|NCT00927290|PLACEBO_COMPARATOR|2|Pioglitazone placebo, 16 weeks before and during antiviral combination therapy
62258460|NCT03268434|EXPERIMENTAL|D-MCT Group|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
62258461|NCT03268434|ACTIVE_COMPARATOR|Cognitive remediation|A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory.The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance.; 8 sessions (60min), once a week over a period of 8 weeks
62615430|NCT01758159|PLACEBO_COMPARATOR|Control group|The children in this group will receive basic health services and placebo syrup.
62615431|NCT05519072|EXPERIMENTAL|Antibiotic arm|Antibiotics will be administered for 2 days pre-treatment, on the treatment day, and 2 days post-treatment.
62615432|NCT05519072|NO_INTERVENTION|No treatment arm|No antibiotics administered.
62615433|NCT00519792|EXPERIMENTAL|1|Omega DUROS: Dose 25
62615434|NCT00519792|EXPERIMENTAL|2|Omega DUROS: Dose 50
62258462|NCT04885088||Interventions|"Device: Wisdom bracelet~Other Names:~control group (routine medical)"
62258463|NCT04885088||control|routine medical Non-invasive Wearable Device
62258464|NCT02200354|EXPERIMENTAL|pemetrexed with bevacizumab|pemetrexed rechallenge with bevacizumab pemetrexed (500mg/m2 day1) bevacizumab (15mg/kg day1)
62258465|NCT04675164|ACTIVE_COMPARATOR|LAISS group|Viable immotile testicular sperms will be selected before ICSI using laser assisted immotile sperm selection (study group).
62258466|NCT04675164|ACTIVE_COMPARATOR|HOST group|Viable immotile testicular sperms will be selected before ICSI using hypo-osmotic swelling test (control group).
62615435|NCT00360009|ACTIVE_COMPARATOR|STN DBS|Patients who underwent deep brain stimulation (DBS) of the subthalamic nucleus (STN) to treat Parkinson's disease (PD)
62615436|NCT00360009|ACTIVE_COMPARATOR|GPI DBS|Patients who underwent deep brain stimulation (DBS) of the globus pallidus interna (GPi) to treat Parkinson's disease (PD)
62615437|NCT00360009|NO_INTERVENTION|no DBS|non-DBS PD patient control group
62615438|NCT05286164|EXPERIMENTAL|Eltrombopag|Patients with bone marrow aplasia for more than 30 days after CART treatment
62615439|NCT00594386|EXPERIMENTAL|Rotigotine|
62258467|NCT01756040|OTHER|Lactulose - rhamnose solution|Preterm Infants age 24-32 weeks gestation
62258468|NCT00440479||001|Bortezomib dose as determined (observational study) by treating physician
62258469|NCT02582606|EXPERIMENTAL|Regular|Regular meal pattern
62258470|NCT02582606|EXPERIMENTAL|Irregular|Irregular meal pattern
62258471|NCT01707043|ACTIVE_COMPARATOR|Taclonex Ointment First|All subjects will use Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment once daily for three days to affected areas, then switch to Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension once daily to affected areas for three days
62258472|NCT01707043|ACTIVE_COMPARATOR|Taclonex Scalp Suspension first|All subjects will use Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension once daily to affected areas for three days, then switch to Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment once daily for three days to affected areas,
62258473|NCT01224626||Zyvox (linezolid)|Patients who have been treated with Zyvox (linezolid).
62258474|NCT02737852|EXPERIMENTAL|Healthy subject|"Healthy subject exposed to Trojan Chameleon Personal Lubricant at least four times weekly for two weeks"
62258475|NCT02087956|ACTIVE_COMPARATOR|Personalized Support for Progress (PSP)|In Personalized Support for Progress (PSP), patients meet with a navigator to prioritize their concerns using a decision aid, develop a plan based on their identified priorities, and execute the plan.
62258476|NCT02087956|ACTIVE_COMPARATOR|Enhanced Screening and Referral (ESR)|(ESR)- participant will receive personal report of their current needs and list of resources available in the community.
62840428|NCT03819114|EXPERIMENTAL|B: LNG 3.0 mg among participants on EFV-based ART (randomized)|Participants received 3mg of LNG once orally on Day 0 and were followed post-treatment for 4 weeks.
62258477|NCT05095870||CANVAS Patients|Patient with a CANVAS diagnosis with genetic evidence (RFC1+)
62258478|NCT05095870||control group|Patient with axonal sensory-motor or pure sensitive neuropathy confirmed by electroneuromyography
62258479|NCT00433914|EXPERIMENTAL|rMenB|6-8 months-old infants received 3 doses of rMenB vaccine without OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
62444903|NCT05269628|ACTIVE_COMPARATOR|Tetrahydrocannabinol (THC)|"The drug dose will be 2.5 mg b.i.d. during the first seven days of active treatment, and 5 mg b.i.d. for the following days of active treatment.~PLUS Placebo CBD (A matching placebo oral solution to Epidiolex® will be used that consists of all of the excipients in the active solution without the cannabidiol component). The placebo will be dosed in the same schedule and manner as active Epidiolex®."
62840429|NCT03819114|EXPERIMENTAL|C: LNG 1.5 mg among participants on DTG-based ART (assigned)|Participants received 1.5 mg of LNG once orally on Day 0 and were followed post-treatment for 4 weeks.
62840430|NCT03819114|EXPERIMENTAL|D: LNG 3.0 mg among participants on RIF-INH TB Therapy (assigned)|Participants received 3mg of LNG once orally on Day 0 and were followed post-treatment for 4 weeks.
62258480|NCT00433914|EXPERIMENTAL|rMenB+OMV|6-8 months-old infants received 3 doses of rMenB vaccine with OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
62258481|NCT02821611|EXPERIMENTAL|Meditation Group|Participants in the experimental group are practicing a mantra-based meditation twice daily for 20 minutes over the 8 week intervention period to reduce stress and blood pressure and enhance quality of sleep.
62258482|NCT02821611|NO_INTERVENTION|Control Group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
62258483|NCT01792804|EXPERIMENTAL|Orally administered antibiotic|First choice (MRSA and MSSA): trimethoprim-sulfamethoxazole, or Second choice (MSSA): clindamycin, or Second choice (MRSA): linezolid administered for 7-9 days
62840431|NCT04827680|EXPERIMENTAL|All subjects|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart.
62258484|NCT01792804|EXPERIMENTAL|Intravenously administered antibiotic|First choice (MSSA): flucloxacillin \[Spain: cloxacillin\], or cefazolin or Second choice (MSSA): vancomycin, or First choice (MRSA): vancomycin, or Second choice (MRSA): daptomycin administered for 7-9 days
62444904|NCT05269628|ACTIVE_COMPARATOR|CBD + THC|"Epidiolex® (CBD) doses will be 0.5 mL twice daily during the first seven days of active treatment and 1 mL twice daily (b.i.d.) for the remaining days of treatment.~The THC dose will be 2.5 mg b.i.d. during the first seven days of active treatment, and 5 mg b.i.d. for the following days of active treatment."
62615440|NCT04334889||Chronic low back pain (CLBP)|All CLBP patients should present with non-specific low back pain (pain from lower ribs to gluteal folds) for more than 3 months.
62615441|NCT04334889||Asymptomatic controls|Asymptomatic participants should have had no history of LBP requiring medical attention during the last two years and no other concomitant pain or condition that could compromise the evaluation of lumbar kinematics.
62615442|NCT04401280|ACTIVE_COMPARATOR|BiominF®|Test group
62258485|NCT02328651|EXPERIMENTAL|Ribavirin treatment plus testing drug|
62444905|NCT05269628|PLACEBO_COMPARATOR|Placebo CBD + Placebo THC|"Placebo CBD (A matching placebo oral solution to Epidiolex® will be used that consists of all of the excipients in the active solution without the cannabidiol component). The placebo will be dosed in the same schedule and manner as the active CBD.~Placebo Tetrahydrocannabinol (TCH) capsules which contain no active ingredients. Matching placebo capsules will be taken twice per day in the same schedule and manner as active drug."
62444906|NCT01272557|ACTIVE_COMPARATOR|Sorafenib 400 mg bid (oral) continuously|Sorafenib 400 mg bid (oral) continuously until progression or unacceptable toxicity).
62615443|NCT04401280|ACTIVE_COMPARATOR|Novamin®|Test group
62615444|NCT04401280|ACTIVE_COMPARATOR|CPP-ACP|Control group
62615445|NCT00208234|PLACEBO_COMPARATOR|Control|Placebo
62615446|NCT00208234|EXPERIMENTAL|2|Omalizumab
62615447|NCT02577627||Training Set|The Training Set will be used to calibrate the Predicare models and algorithms and assess its predictive potential in a retrospective manner. Patients data will be collected according to the oncological indications (NSCLC, SCLC, Prostate cancer, Breast cancer and Colon cancer) and the applied treatment protocols, and their data will be integrated and processed by the PrediCare algorithm.
62615448|NCT02577627||Validation Set|The Validation Set will be used to validate the prediction power of the device in a prospective manner. The files of patients assigned to Validation Set of the study will be used for the blind prediction of TTP under each specific treatment, based on the baseline individual information. This will be done by inputting into PrediCare the information of each individual patient, available prior to treatment onset (baseline; clinical data, imaging data, histology/cytology, oncomarkers, genetic screening, hematology, biochemistry) for creating a personalized mathematical models and predicting TTP of this specific patient. These predictions will be then compared to the clinically observed TTP for all the patients.
62615449|NCT05457114||Pulmonary artery catheter group|Patients who received pulmonary artery catheter insertion and hemodynamic monitoring by PAC-derived parameters
62615450|NCT05457114||Non-pulmonary artery catheter group|Patients who did not received pulmonary artery catheter insertion and were monitored with Flo-Trac FloTrac Vigileo
62615451|NCT04562857|ACTIVE_COMPARATOR|obstructive sleep apnea|interval exercises (intervention) on bicycle for patients with AF and OSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
62615452|NCT04562857|ACTIVE_COMPARATOR|Central sleep apnea|interval exercises (intervention) on bicycle for patients with AF and CSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
62615453|NCT04629872|EXPERIMENTAL|endovascular treatment with fingolimod|
62615454|NCT04629872|NO_INTERVENTION|endovascular treatment without fingolimod|
62615455|NCT02537652||Major Stroke|Patients diagnosed with major stroke who will undergo blood pressure assessment
62615456|NCT02537652||Minor stroke|Patients diagnosed with minor stroke who will undergo blood pressure assessment
62615457|NCT01904630||CRC high risk|Participants belong to a family with increased risk for CRC, will be analyzed with gene sequencing
62615458|NCT01246778||With/without sunitinib|Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction during 200 minutes.
62615459|NCT01246778||With/without sunitinib IP|Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction and ischemia/reperfusion
62615460|NCT01230099|EXPERIMENTAL|Supportive Information Team Group|Protocolized information and support meetings led by palliative care clinicians
62258486|NCT02328651|ACTIVE_COMPARATOR|Ribavirin treatment|
62258487|NCT06248164||Children and adolescents (sons and daughters)|The study will consist of children and adolescents from six years of age.
62258488|NCT06248164||Parents (mothers and fathers)|The study will consist of children and adolescents from six years of age and at least one of their biological parents to be evaluated.
62258489|NCT00891982|EXPERIMENTAL|CTGel plus BPO wash|Benzoyl peroxide (BPO) Wash in the morning and CTGel in the evening
62258490|NCT00891982|ACTIVE_COMPARATOR|CTGel|Soap Free Cleanser in the morning and CTGel in the evening
62258491|NCT04329702|EXPERIMENTAL|coping skills training plus therapist input|Participants will receive a CST therapist call within 48 hours of randomization to discuss the study rationale, to conduct a relaxation exercise, and to review app and study logistics. Participants will use the Blueprint mobile app for 1 month.
62615461|NCT01230099|NO_INTERVENTION|Usual Care Group|
62615462|NCT02700880||Heart failure patients with LifeVest|Subjects with ischemic cardiomyopathy and heart failure (including NYHA II, III, IV and an ejection fraction ≤ 35%) who wear a medically prescribed ZOLL LifeVest Wearable Defibrillator
62840432|NCT03216824|ACTIVE_COMPARATOR|Dressing|A dressing is maintained on the CVAD exit site.
62055891|NCT05659225|OTHER|electronic stethoscope group|"During the study, subjects who diagnosed as asthma according to Guideline for the diagnosis and optimal management of asthma in children will be assigned to the control group and the electronic stethoscope group, and receive 12 months standard treatment, prescribed by the investigators according to Guideline for the diagnosis and optimal management of asthma in children. The patient's caregiver will be instructed to use an electronic stethoscope to coordinate treatment and complete follow-up."
62055892|NCT05659225|OTHER|control group|"During the study, subjects who diagnosed as asthma according to Guideline for the diagnosis and optimal management of asthma in children will be assigned to the control group and the electronic stethoscope group, and receive 12 months standard treatment, prescribed by the investigators according to Guideline for the diagnosis and optimal management of asthma in children."
62055893|NCT01568099|EXPERIMENTAL|A: AFFITOPE® PD01A + Adjuvant|4 injections of 15µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
62615463|NCT03632538||Male|"20 male adult patients after cardiac surgery. Drawing of patients blood for measurement of biomarkers (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide) for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours)."
62840433|NCT03216824|EXPERIMENTAL|No-Dressing|The CVAD exit site is not covered with a dressing.
62840434|NCT05373914|EXPERIMENTAL|Cudetaxestat (BLD-0409) 250mg once daily|250mg once daily (orally) with food
62055894|NCT01568099|EXPERIMENTAL|B: AFFITOPE® PD01A + Adjuvant|4 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
62055895|NCT01568099|OTHER|Control|Untreated control group
62055896|NCT04062448|EXPERIMENTAL|Ibrutinib + Rituximab|Participants will receive ibrutinib 420 milligram (mg) orally, once daily, from Day 1 of Week 1 until disease progression or unacceptable toxicity in combination with rituximab 375 milligram per square meter (mg/m\^2) intravenously (IV) on Day 1 of Weeks 1 to 4 and Weeks 17 to 20.
62055897|NCT01656330|EXPERIMENTAL|Rivaroxaban + Profilnine SD|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single bolus dose of Profilnine SD 50 IU/kg.
62615464|NCT03632538||Female|"20 female adult patients after cardiac surgery. Drawing of patients blood for measurement of biomarkers (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide) for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours)."
62615465|NCT03510078|EXPERIMENTAL|Intensive glycemic control|With a target of blood glucose range of 130 mg/dL or less
62615466|NCT03510078|EXPERIMENTAL|Conventional glycemic control|With a target of blood glucose range of 130-180 mg/dL
62615467|NCT01082796|OTHER|CYP2C19 EMs group|cyp2c19\*1/\*1 carriers
62615468|NCT01082796|OTHER|CYP2C19 PMs group|cyp2c19\*2/\*2 or \*2/\*3
62840435|NCT05373914|EXPERIMENTAL|Cudetaxestat (BLD-0409) 500mg daily|500mg once daily (orally) with food
62840436|NCT05373914|EXPERIMENTAL|Cudetaxestat (BLD-0409) 500mg twice daily|500mg twice daily (orally) with food
62840437|NCT05373914|PLACEBO_COMPARATOR|Matching Placebo twice daily|Matching placebo twice daily (orally) with food
62840438|NCT00842296|EXPERIMENTAL|Seg. RF Ablation with CLF catheter|Single Arm with CLF Catheter
62840439|NCT04113421||Anticoagulation|Inpatients diagnosed with acute PE, in whom clinical providers have elected to prescribe anticoagulation alone for treatment based on clinical grounds at BWH. In this population, a single follow-up contrast-enhanced chest CT will be performed to compare off-line with the contrast-enhanced chest CT done at baseline for the diagnosis of PE.
62258492|NCT04329702|EXPERIMENTAL|coping skills training without therapist input|Participants will receive a call from a research coordinator to get them started with the trial. Participants will use the Blueprint mobile app for 1 month. No therapist calls will be provided. Chat room access in the app will be provided.
62258493|NCT04329702|NO_INTERVENTION|usual care control|Control participants will receive the same safety oversight as intervention participants and will be provided with phone and email contacts for study staff.
62258494|NCT05993936|EXPERIMENTAL|e mobile aplication|Postpartum period mobile application; It is an application that is prepared according to the Android Operating System, can be downloaded free of charge from the Google Play Store, and offers training and live counseling services for women who have given birth.
62258495|NCT05993936|NO_INTERVENTION|control|this group will only receive the standard care provided in the hospital. no intervention will be made
62444907|NCT01272557|EXPERIMENTAL|q22d: Doxorubicin 60 mg/m2 i.v d1, Sorafenib 400 mg bid d3-19|During trial therapy period in Arm-A treated patients will receive doxorubicin infusion with 60mg/m² on day 1 every 21 days for maximum of 18 weeks (or 6 cycles) until a maximal dose of 360mg/m² are reached. Sorafenib 400mg bid (oral) will be administered from day 3-19 every 21 days during the trial therapy period
62444908|NCT00898482||Healthy individuals|
62444909|NCT00898482||At risk individuals|
62444910|NCT00898482||Cancer patients|
62840440|NCT03656380|EXPERIMENTAL|Mepolizumab 300 mg|Subjects will receive Mepolizumab 300 mg subcutaneously (SQ) monthly for 6 months
62840441|NCT03656380|OTHER|Placebo, followed by Mepolizumab 100 mg|This arm will receive placebo, followed by Mepolizumab 100 mg. Subjects will receive placebo subcutaneously (SQ) monthly for 3 months, followed by Mepolizumab 100 mg subcutaneously (SQ) monthly for 3 months. Mepolizumab will be administered with 2 SQ injections of placebo and 1 SQ injection of Mepolizumab 100 mg to maintain blinding.
62840442|NCT02177149|ACTIVE_COMPARATOR|Standard of Care|DBS using standard of care.
62840443|NCT02177149|EXPERIMENTAL|DBS Clinical Support System|DBS using Clinical Support System.
62055898|NCT01656330|EXPERIMENTAL|Rivaroxaban + Beriplex P/N|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single bolus dose of Beriplex 50 IU/kg.
62258496|NCT05774236|EXPERIMENTAL|Cook´s balloon|Silicone 80 mL double-balloon cervical ripening catheter with an adjustable-length malleable stylet
62258497|NCT05774236|ACTIVE_COMPARATOR|Vaginal dinoprostone|Vaginal delivery system containing 10 mg dinoprostone (Prostaglandin E2) dispersed throughout its matrix and releasing approximately 0.3 mg/hour dinoprostone over a 24-hour period.
62258498|NCT04926051|EXPERIMENTAL|Part A: SAD|SAD = Single Ascending Dose
62258499|NCT04926051|EXPERIMENTAL|Part B: MAD|MAD = Multiple Ascending Dose
62615469|NCT05383833|EXPERIMENTAL|Creatine Monohydrate Arm|This study a single arm intervention. All participants will receive 20 grams of creatine monohydrate daily for the whole intervention (8 weeks).
62615470|NCT01738256|EXPERIMENTAL|Face-to-Face|Group meetings face-to-face using intervention for wellbeing with ACT principles.
62055899|NCT01656330|EXPERIMENTAL|Rivaroxaban + Saline|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single 100cc bolus of saline.
62258500|NCT04926051|EXPERIMENTAL|Part C: JMAD|JMAD= Japanese Multiple Ascending Dose
62258501|NCT04926051|EXPERIMENTAL|Part D: FE/BA|FE/BA = Food Effect/Relative Bioavailability
62615471|NCT01738256|EXPERIMENTAL|Mobile|Intervention for wellbeing via mobile phone application with ACT principles.
62840444|NCT00563472|ACTIVE_COMPARATOR|1|10 mg estetrol
62840445|NCT00563472|ACTIVE_COMPARATOR|2|20 mg estetrol
62840446|NCT00563472|ACTIVE_COMPARATOR|3|20 mg estetrol and 150 microg desogestrel
62840447|NCT00563472|ACTIVE_COMPARATOR|4|20 mg E4 and 200 mg progesterone
62840448|NCT02789293|EXPERIMENTAL|Focused Ultrasound treatment|Ultrasound ciliary pasty (UCP) using focused ultrasound
62840449|NCT04395742||Coffee:1,3,7-trimethylxanthine|
62840450|NCT04395742||Tea and hot chocolate with milk|
62840451|NCT03436082||Data from a mHealth platform after bariatric surgery|Patients that have undergone sleeve gastrectomy or gastric bypass will pilot test the use of the patient-led, smartphone based, mhHealth platform HUGO.
62840452|NCT03436082||Data from a mobile health platform after atrial fibrillation|Patients that have undergone a catheter-based atrial fibrillation ablation will pilot test the use of the patient-led, smartphone based, mobile health platform HUGO.
62840453|NCT06251843||Parents of children with sickle cell disorder|Parents whose child has been diagnosed with sickle cell disorder in the last 36 months
62840454|NCT06251843||Health professionals|Health professionals involved in the care of children sickle cell disorder
62055900|NCT05056870|EXPERIMENTAL|Test/Control|Eligible subjects will be randomized to the sequence, Test/Control
62840455|NCT03668899|EXPERIMENTAL|Chitosan NPs group|irrigation with Chitosan nanoparticles (final flush)
62840456|NCT03668899|EXPERIMENTAL|Chlorhexidine group|irrigation with CHX (final flush)
62840457|NCT03668899|EXPERIMENTAL|Combination group|irrigation with CHX/ nano Chitosan combination (final flush)
62840458|NCT03668899|ACTIVE_COMPARATOR|Hypochlorite group|irrigation with NaOCL (final flush)
62840459|NCT06326567|NO_INTERVENTION|Baseline Phase|Each site will complete an 18-month Baseline Phase, in which patients and sites are observed during a period of usual care, prior to introducing the C4 Program intervention. In this phase, a sample of newly diagnosed patients will be recruited and enrolled in the Baseline Group, and data will be collected on them via patient surveys and EHR data abstraction over a period of four months for most outcomes, except for overall survival, which will be assessed at 12 months after diagnosis
62615472|NCT01738256|EXPERIMENTAL|Internet|Intervention for wellbeing via Internet (Virtual Health Check and Coaching).
62615473|NCT01738256|EXPERIMENTAL|Control|Control group, no intervention.
62615474|NCT04878302|EXPERIMENTAL|Experimental: Taming Tics Together Protocol|"Families will participate in the 5-day telehealth-based intensive intervention and will receive three treatment formats which will provide CBIT and co-occurring diagnosis treatment:~1. Child/teen-only groups~2. Individual one-to-one sessions~3. Parent/caregiver-only groups"
62840460|NCT06326567|EXPERIMENTAL|Implementation|new sample of newly diagnosed patients (excluding anyone from the Baseline Phase) will be recruited and enrolled in the Implementation Group, and the same data will be collected on them that was collected in the Baseline Group, at the same time points
62840461|NCT06255613|EXPERIMENTAL|UH-Participant|Potential participants will be identified from patients scheduled for in-lab PSG at the two medical centers of University Hospitals
62840462|NCT04549129|EXPERIMENTAL|Intervention group|Participants randomized to the intervention group will receive breastfeeding education and teaching of hand expression using a breastfeeding education video and associated breastfeeding website, as well as hands-on teaching of hand expression techniques during their 36 week visit.
62840463|NCT04549129|ACTIVE_COMPARATOR|Control group|Participants randomized to the control group will receive usual breastfeeding education during their 36-week visit.
62840464|NCT02696967|EXPERIMENTAL|CLR325|Patients were assigned to one of the 2 treatment arms in fixed randomization ratio. Patients randomized to this arm received single dose of CLR325 (i.v.) in double blind manner.
62840465|NCT02696967|PLACEBO_COMPARATOR|Placebo|Patients were assigned to one of the 2 treatment arms in fixed randomization ratio. Patients randomized to this arm received single dose of placebo (i.v.) in double blind manner.
62840466|NCT00812019|EXPERIMENTAL|3.75_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
62840467|NCT00812019|EXPERIMENTAL|3.75_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
62840468|NCT00812019|EXPERIMENTAL|3.75_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
62840469|NCT00812019|EXPERIMENTAL|3.75_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
62840470|NCT00812019|EXPERIMENTAL|7.5_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
62615475|NCT04878302|NO_INTERVENTION|1-Month Waitlist Control|Families in the 1-month waitlist control group will participate in the initial intake assessment, then receive no treatment for a 1-month period. Following the 1-month period, families will participate in an assessment, then will be offered a place in a Taming Tics Together group
62055901|NCT05056870|EXPERIMENTAL|Control/Test|Eligible subjects will be randomized to the sequence, Control/Test
62615476|NCT05212779||Females with Stage II-IV epithelial ovarian cancer|"All patients, as participation requirements in this study, are required to have blood drawn at the completion of their adjuvant treatment. Blood sample should be collected within 6 weeks of receiving the last cycle of adjuvant chemotherapy.~Other optional time points which will be encouraged but not required:~1. After debulking surgery~2. Serial draws every 3 months while on maintenance or surveillance."
62615477|NCT04638803|EXPERIMENTAL|Crossover (fasted)|On Day 1 subjects are dosed with 100 µg of PRX-P4-003 and PK samples are drawn according to protocol, on Day 15 subjects are dosed with 40 µg of (-)-FCF. Both treatment will be administered under the fasted conditions.
62615478|NCT04638803|EXPERIMENTAL|Single Group (fed)|On Day 1 subjects are dosed with 100 µg of PRX-P4-003 and PK samples are drawn according to protocol. The treatment will be administered under the fed condition.
62840471|NCT00812019|EXPERIMENTAL|7.5_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
62615479|NCT02204358|EXPERIMENTAL|autologous bone marrow stem cells|Using collagen scaffold loaded with autologous bone marrow stem cells to treat severe intrauterine adhesions or endometrial dysplasia.
62840472|NCT00812019|EXPERIMENTAL|7.5_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
62055902|NCT02124343|EXPERIMENTAL|Interval Exercise|"Subjects will undertake an interval exercise session (on a harnessed treadmill) (HP Cosmos Mercury 4.0, HP Cosmos Sports and Medical Gmbh, Nussdorf-Traustein,Germany) based on the average speed calculated from the 6 minute walk test (6MWT).~Intervals are based on the work previously done by Mador et al., 2009 who used intervals of 150% (for 1 minute) followed by intervals of 75% (for 2 minutes) based on 80% average speed from the 6 minute walk test.~This study repeated these intervals 7 times with a duration of 23 minutes in total for the exercise intervention with the 75% intervals at the start and at the end of the exercise session. No warm up was undertaken for this method as it was a walking exercise test and the risk of injury was minimised with use of the harnessed treadmill."
62055903|NCT03675152|EXPERIMENTAL|Soft spinal brace|Soft spinal brace used 23 hours a day for 4 months.
62615480|NCT01874418|OTHER|Biomarker study|Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
62840473|NCT00812019|EXPERIMENTAL|7.5_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
62840474|NCT00812019|EXPERIMENTAL|15_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
62840475|NCT00812019|EXPERIMENTAL|15_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
62840476|NCT00812019|EXPERIMENTAL|15_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
62840477|NCT00812019|EXPERIMENTAL|15_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
62840478|NCT01328067|ACTIVE_COMPARATOR|Treatment|MR guided Focused Ultrasound
62840479|NCT01328067|ACTIVE_COMPARATOR|Surgery|Myomectomy
62840480|NCT02702791|EXPERIMENTAL|Intervention|Telecoaching - feasible goal setting and feedback to enhance patient's motivation and commitment - in addition to pulmonary rehabilitation.
62840481|NCT02702791|OTHER|Usual care|includes only general advices regarding physical activity.
62840482|NCT05576636|EXPERIMENTAL|Intervention group|After the pre-tests (the COVID-19 Disease Perception Scale, and the Fear of COVID-19 Scale) , the students were given simulation education for one months.
62840483|NCT05576636|EXPERIMENTAL|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
62840484|NCT02153749|EXPERIMENTAL|Cognitive Regulation of Craving|Training in craving regulation component of Cognitive Behavioral Therapy(CBT) for addictions.
62840485|NCT02153749|EXPERIMENTAL|Mindfulness-Based Regulation of Craving|Training in craving regulation component of Mindfulness Based Therapy(MBT) for addiction.
62840486|NCT02153749|NO_INTERVENTION|No training control|No training sessions will be provided in this arm.
62615481|NCT05508945|EXPERIMENTAL|Surgical Incision|Abdominoplasty Surgical Incision, Breast Reduction Surgical Incision, Mastopexy Surgical Incision, or Belt Lipectomy Surgical Incision
62615482|NCT03163459|ACTIVE_COMPARATOR|mechanical thrombectomy group|Conventional mechanical thrombectomy
62840487|NCT01267214|EXPERIMENTAL|Osteotomy plus Hyalgan|Osteotomy at Week 0 Hyalgan injection at Week 2, 3, 4, 5, 6, 24, 25, 26, 27, 28
62840488|NCT01267214|OTHER|Osteotomy alone|
62840489|NCT02354196||CCTA|Subjects who underwent a CCTA
62840490|NCT02252796|EXPERIMENTAL|Sub-group 1|HySBst to be delivered during week 1 with Chemo-radiation to be delivered weeks 2-7
62840491|NCT02252796|EXPERIMENTAL|Sub-group 2|Chemo-radiation to be delivered weeks 1-6 and HySBst to be delivered week 7
62840492|NCT06005207|EXPERIMENTAL|Vaginal progesterone supplementation|90 mg progesterone vaginal sustained-release gel is added daily to induce endometrial transformation and luteal support
62840493|NCT06005207|NO_INTERVENTION|Regular progesterone|No additional vaginal progesterone gel, routine endometrial transformation and luteal support drugs
62840494|NCT02948634|SHAM_COMPARATOR|Sham Phoenix Laser Treatment|Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy.
62840495|NCT02948634|ACTIVE_COMPARATOR|Active Phoenix Laser Treatment|Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Participants in the laser treatment group will be treated at 42 watts for up to 60 seconds at tender spots in the spine or extremities. Total treatment time is not to exceed 30 minutes.
62840496|NCT02211170|EXPERIMENTAL|BIBR 796 BS, low dose|
62055904|NCT03675152|ACTIVE_COMPARATOR|thoracolumbar orthosis|Thoracolumbar orthosis used 23 hours a day for 4 months.
62840497|NCT02211170|EXPERIMENTAL|BIBR 796 BS, high dose|
62840498|NCT02211170|PLACEBO_COMPARATOR|Placebo|
62840499|NCT00726011|EXPERIMENTAL|Tetrodotoxin|There is only one arm; active treatment with TTX
62840500|NCT04240548|EXPERIMENTAL|Arm: A|regional nodal irradiation including axillary and supraclavicular lymph node groups along with chest wall or whole breast irradiation
62840501|NCT04240548|NO_INTERVENTION|Arm: B|chest wall or whole breast only irradiation
62840502|NCT05272501|EXPERIMENTAL|Calming Touch|The calming treatment consists of deep pressure massage and gentle facilitation. The therapist works with the vertical axis, center, respiration, body boundaries and the feet.
62840503|NCT05272501|NO_INTERVENTION|Usual care|The usual care group may participate in usual activities at the nursing home e.g. physio- and occupational therapy, listening to calming music, holdning hands with care-takers.
62840504|NCT02611583|ACTIVE_COMPARATOR|Ibuprofen and TENS plus|Patients will receive 45 minutes of TENS therapy. All patients will receive ibuprofen.
62840505|NCT02611583|PLACEBO_COMPARATOR|Ibuprofen and Sham TENS plus|Patients will receive 45 minutes of sham TENS therapy. All patients will receive ibuprofen.
62840506|NCT02612519|EXPERIMENTAL|Alfapump - Substudy 1|Alfapump implantation
62840507|NCT02612519|ACTIVE_COMPARATOR|TIPS - Substudy 1|TIPS implantation
62840508|NCT02612519|EXPERIMENTAL|Alfapump - Substudy 2|Alfapump implantation
62840509|NCT02612519|NO_INTERVENTION|Standard - Substudy 2|Standard treatment
62840510|NCT02469311|SHAM_COMPARATOR|Primary Control TKA|Patients undergoing a first or primary total knee arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
62840511|NCT02469311|ACTIVE_COMPARATOR|Primary Treatment TKA|Patients undergoing a first or primary total knee arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
62055905|NCT02317393|OTHER|K5-RGD PET + FDG|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy, with a maximal delay from end of chemotherapy of 2 months. Delay between FDG and 18F-K5-RGD PET scans will not exceed 2 weeks.
62258502|NCT03631030|OTHER|Cooled radiofrequency ablation|This is a single arm study. Patients who will be undergoing cooled radiofrequency ablation for the treatment of arthritis in the cervical facet joints, thoracic facet joints, lumbar facet joints, sacroiliac (SI) region, hip and knee.
62258503|NCT03166566|OTHER|laminar drainage implant surgery|patients included and operated
62258504|NCT04172714|EXPERIMENTAL|Second mapping with low-dose Y90|Patients will undergo standard of care mapping study with 99TC-MAA to plan for Y90 radioembolization therapy. Additionally,non-standard of care, intervention will be to do a second mapping study using SIR-spheres microspheres with low-dose Y90 (15 mCi) before the therapeutic Y90 radioembolization.
62258505|NCT04660461|EXPERIMENTAL|1. Randomized placebo-controlled, parallel-group study, crossover-design|
62258506|NCT04660461|EXPERIMENTAL|2. Randomized placebo-controlled, parallel-group study, crossover-design|
62258507|NCT01786603|EXPERIMENTAL|Rasagiline|Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
62615483|NCT03163459|EXPERIMENTAL|mechanical thrombectomy plus selective brain cooling group|A microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
62258508|NCT01786603|PLACEBO_COMPARATOR|Placebo|Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
62258509|NCT05193253||Solitary HCC <= 3 cm|Treatment-naive patients with HCC \<= 3 cm
62258510|NCT04143009|EXPERIMENTAL|Enhanced Friendship Bench (EFB)|Women seeking ANC services at 2 public health centers in Lilongwe, Malawi will be enrolled into this study arm during study recruitment. Individuals enrolled in this arm will be administered the Enhanced Friendship Bench intervention from date of enrollment through 6 months post-partum.
62258511|NCT04143009|ACTIVE_COMPARATOR|Enhanced Standard Care (ESC)|Women seeking ANC services at 2 public health centers in Lilongwe, Malawi will be enrolled into this study arm during study recruitment. Individuals enrolled in this arm will received the Enhanced Standard Care intervention from date of enrollment through 6 months post-partum.
62258512|NCT04143009|EXPERIMENTAL|Adapted Friendship Bench (AFB)|Women seeking ANC services at 2 public health centers in Lilongwe, Malawi will be enrolled into this study arm during study recruitment. Individuals enrolled in this arm will be administered the Adapted Friendship Bench intervention from date of enrollment through 6 months post-partum.
62615484|NCT03358381|EXPERIMENTAL|gap balance group|The type of total knee arthroplasty will be the balance gap.The gap balance type of total knee arthroplasty will be performed.
62615485|NCT03358381|ACTIVE_COMPARATOR|measured resection group|The type of total knee arthroplasty will be the measured resection.The measured resection type of total knee arthroplasty will be performed.
62615486|NCT04052360|EXPERIMENTAL|Cenerimod / ACT-334441|
62615487|NCT04052360|PLACEBO_COMPARATOR|Matching Placebo|
62840512|NCT02469311|ACTIVE_COMPARATOR|Revision Treatment TKA|Patients undergoing a second or subsequent or a revision total knee arthroplasty will be randomized to the intervention of a chlorhexidine impregnated cloths.
62840513|NCT02469311|SHAM_COMPARATOR|Revision Control TKA|Patients undergoing a second or revision total knee arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
62840514|NCT02469311|SHAM_COMPARATOR|Primary Control THA|Patients undergoing a first or primary total hip arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
62258513|NCT02695992|ACTIVE_COMPARATOR|Metoprolol|Metoprolol, extended release tablets. 100 mg daily
62258514|NCT02695992|ACTIVE_COMPARATOR|Diltiazem|Diltiazem, extended release tablets. 360 mg daily
62258515|NCT06427200|EXPERIMENTAL|"group oral iron"|
62258516|NCT06427200|EXPERIMENTAL|"group lactoferrin"|
62840515|NCT02469311|ACTIVE_COMPARATOR|Primary Treatment THA|Patients undergoing a first or primary total hip arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
62055906|NCT04317508|ACTIVE_COMPARATOR|Intervention group|Topicale® topical anesthetic gel patch (Benzocaine 18%)
62055907|NCT04317508|PLACEBO_COMPARATOR|control group|Opahl® topical anesthetic gel (Benzocaine 20%)
62055908|NCT01612325|EXPERIMENTAL|Holmium-166 MS radioembolization|Single radioembolization met Holmium-166 polylactic microspheres administered
62055909|NCT04636658|ACTIVE_COMPARATOR|Incentive spirometer training|Incentive spirometer training
62258517|NCT06427200|EXPERIMENTAL|"group lactoferrin and oral iron"|
62258518|NCT04972396|EXPERIMENTAL|Part 1|
62258519|NCT04972396|EXPERIMENTAL|Part 2|
62258520|NCT04972396|EXPERIMENTAL|Part 3|
62258521|NCT01977599|NO_INTERVENTION|No Text Message Reminder (Control) Arm|Control Arm, in which patients are invited to breast screening as per standard West of London Breast Screening Protocol (i.e. without a text message appointment reminder). Uptake of breast screening in this group will be compared with the text message reminder group to test for significant differences.
62258522|NCT01977599|EXPERIMENTAL|Text Message Reminder Arm|Patients randomly allocated to this arm of the study will be sent a text message reminding them of the time, date and venue of their breast screening appointment 48 hours in advance.
62615488|NCT01917604|EXPERIMENTAL|open exposure and control|● surgically uncover the canine tooth and bone removal exposing the largest diameter of the ectopic canine crown make a window in the palatal soft tissue and bond bracket after 10 days
62840516|NCT02469311|SHAM_COMPARATOR|Revision Control THA|Patients undergoing a second or revision total hip arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
62055910|NCT04636658|EXPERIMENTAL|diaphragmatic resistance exercises|Incentive spirometer training with diaphragm breathing with resistance exercises. Resistance is applied through the different Thera bands and then performing the pursed lip breathing exercise. Resistance increased weekly as per tolerance by the patient
62055911|NCT05351996|ACTIVE_COMPARATOR|Kinesiotape|The participants received kinesiotape to the rectus femoris muscle.
62258523|NCT04880785|EXPERIMENTAL|Dovato (Dolutegravir+lamivudine)|Treatment: Dolutegravir 50 mg/Lamivudine 300 mg, one film coated-tablet once daily during 96 weeks
62258524|NCT02833922||Women using Dot to avoid pregnancy|Women living in the United States, ages 18-39 who have not used hormonal birth control or been pregnant in the last three months, who are in a relationship with a male sexual partner, and who wish to use the Dot app to avoid pregnancy for at least one year.
62055912|NCT05351996|SHAM_COMPARATOR|Sham-kinesiotape|Non-specific taping was applied.
62055913|NCT04737564|EXPERIMENTAL|ABC10 + SEEK|Participants assigned to this arm will receive the standard Attachment and Biobehavioral Catch-up intervention (ABC 10) as well as SEEK (Safe Environment for Every Kid).
62055914|NCT04737564|EXPERIMENTAL|ABC3 + SEEK|Participants assigned to this arm will receive an abbreviated version of the Attachment and Biobehavioral Catch-up intervention (ABC 3) as well as SEEK (Safe Environment for Every Kid).
62055915|NCT04737564|ACTIVE_COMPARATOR|SEEK Only|Participants assigned to this arm will receive SEEK (Safe Environment for Every Kid) only.
62055916|NCT02708875|EXPERIMENTAL|Mixed Meal Challenge|Participants will consume a liquid mixed meal (\~300 calories - fat, carbohydrate, and protein) for monitoring changes in glucose metabolism, plasma insulin and microvascular responses in skeletal muscle over 2 hours.
62055917|NCT02708875|ACTIVE_COMPARATOR|Glucose Challenge|Participants will consume a glucose challenge (50g glucose) for monitoring changes in glucose metabolism, plasma insulin and microvascular responses in skeletal muscle over 2 hours.
62055918|NCT01346319|ACTIVE_COMPARATOR|Testosterone undecanoate|
62055919|NCT01346319|PLACEBO_COMPARATOR|Placebo|
62055920|NCT01487278|EXPERIMENTAL|Misoprostol|600 mcg oral misoprostol administered during the third stage of labor
62258525|NCT06246565|EXPERIMENTAL|HS-10383 50mg|HS-10383 oral dose 50 mg once a day.
62258526|NCT06246565|EXPERIMENTAL|HS-10383 100mg|HS-10383 oral dose 100 mg once a day.
62258527|NCT06246565|EXPERIMENTAL|HS-10383 200ng|HS-10383 oral dose 200 mg once a day.
62258528|NCT06246565|PLACEBO_COMPARATOR|Placebo|Matching Placebo for HS-10383 oral dose once a day
62615489|NCT01917604|EXPERIMENTAL|closed exposure and control|raising a flap in the area of impacted canine,bonding an attachment and resuturing the flap
62615490|NCT02070978|EXPERIMENTAL|Atacicept 75 mg|
62615491|NCT02070978|EXPERIMENTAL|Atacicept 150 mg|
62615492|NCT02070978|EXPERIMENTAL|Placebo/Atacicept 150 mg|
62615493|NCT05409508|EXPERIMENTAL|Patients with mindfulness meditation care|
62615494|NCT05409508|ACTIVE_COMPARATOR|Patients without mindfulness meditation care|
62615495|NCT04553003|EXPERIMENTAL|glucocorticoid+hepatoprotectant group|glucocorticoid 0.4mg/kg/d+hepatoprotectant for 7d
62444911|NCT06482970|EXPERIMENTAL|Neuromuscular exercise plus Pain neuroscience education|"Neuromuscular exercise will be carried out for eight weeks, with three weekly sessions, in groups (up to five participants per group).~Each session will consist of three parts: warm-up, exercise circuit and cool down. Each part will be regulated for the abilities of the participants~Pain neuroscience education will be carried in group using visual support for Powerpoint presentations. The PNE will include five dimensions with a focus on reducing fear-avoidance beliefs and catastrophic thoughts to promote self-efficacy. Five PNE sessions will be carried out, one for each dimension, with a duration of 30-45 minutes each taught during the first five sessions of the intervention. In addition, a brochure will be delivered with the main points of each of the domains and an informative video will be made to which participants will have access (five 15-minute videos, one per domain)."
62615496|NCT04553003|ACTIVE_COMPARATOR|hepatoprotectant group|hepatoprotectant for 7d
62615497|NCT03077386|EXPERIMENTAL|ENCOMPASS program|Clinics assigned to the intervention will receive the ENCOMPASS intervention and a CHN will be matched to their clinic and be available to patients that meet the eligibility criteria.
62615498|NCT03077386|NO_INTERVENTION|Usual care|Patients not enrolled in the intervention will continue to receive care as usual until their clinic receives the intervention.
62615499|NCT06038006|EXPERIMENTAL|Participants|The only arm containing participants of this study.
62615500|NCT01528137|EXPERIMENTAL|Treatment (immunomodulator)|Patients receive talactoferrin PO BID for 12 weeks. Courses repeat every 14 weeks in the absence of disease progression or unacceptable toxicity.
62615501|NCT03208413|EXPERIMENTAL|thalidomide|Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
62840517|NCT02469311|ACTIVE_COMPARATOR|Revision Treatment THA|Patients undergoing a second or subsequent or a revision total knee arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
62444912|NCT06482970|EXPERIMENTAL|Neuromuscular exercise|"Neuromuscular exercise will be carried out for eight weeks, with three weekly sessions, in groups (up to five participants per group).~Each session will consist of three parts: warm-up, exercise circuit and cool down. Each part will be regulated for the abilities of the participants"
62055921|NCT01487278|EXPERIMENTAL|UnijectTM|10 IU oxytocin delivered IM with UnijectTM during he third stage of labor
62055922|NCT04073264|EXPERIMENTAL|monofilament|monofilament absorbable suture
62615502|NCT04296669|EXPERIMENTAL|Full desk allocation|All children within this classroom received a sit-stand stand
62055923|NCT04073264|ACTIVE_COMPARATOR|polifilament|synthetic absorbable braided (polifilament) suture
62055924|NCT04175795|EXPERIMENTAL|Dashboard group|The intervention group will receive their personal profile via this e-mail along with instructions on goal-setting and tips to improve brain health.
62615503|NCT04296669|EXPERIMENTAL|Partial desk allocation|six sit-stand desks were provided in this classroom. Children were rotated between these desks and traditional desks
62615504|NCT04296669|NO_INTERVENTION|Control|Traditional classroom furniture was used
62615505|NCT03191123|ACTIVE_COMPARATOR|Hepatic resection|Indications for Hepatic resection were the presence of appropriate residual liver volume determined by volumetric computed tomography and lack of hepatic encephalopathy.
62615506|NCT03191123|EXPERIMENTAL|Transarterial Chemoembolization(TACE)|Transarterial Chemoembolization is performed in less than one week after clinical diagnosis.
62615507|NCT02652598|EXPERIMENTAL|Open-Label|Each patient will receive a two-week specified dosing amount of tolcapone (100mg TID on Day 1; 200mg TID on Days 2-14). The patient will be instructed to take the study drug three times daily. Tolcapone will be tapered after Day 14 to avoid potential withdrawal reactions.
62615508|NCT02907619|EXPERIMENTAL|PF-06252616|Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
62615509|NCT01329666|EXPERIMENTAL|50,000 IU Vitamin D3|
62615510|NCT01329666|PLACEBO_COMPARATOR|Placebo (inactive Vitamin D3)|
62615511|NCT00846690|ACTIVE_COMPARATOR|Benzocaine|"serves as active control"
62840518|NCT01021085||Pregnant women|Pregnant women who have conceived via ART and are between days 36 and 56 of gestation
62840519|NCT01424215|EXPERIMENTAL|ICG injection with Spyscope imaging|Indocyanine Green (ICG)
62840520|NCT01424215|NO_INTERVENTION|Standard Critical View Technique|50 patients will be randomized to the no treatment arm. These patients will not get ICG injection but rather will have the standard technique for laparoscopic cholecystectomy performed including the critical view technique to expose the important structures prior to clipping and division.
62055925|NCT04175795|NO_INTERVENTION|No Dashboard group|The control group will receive only the goal-setting instructions and tips.
62258529|NCT05507775|EXPERIMENTAL|Treatment with digoxin|This arm will consist of 10 patients with radioiodine refractory non-medullary thyroid carcinoma. All participants will be treated according to the same protocol.
62258530|NCT02904915|ACTIVE_COMPARATOR|Paracervical block|Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
62258531|NCT02904915|ACTIVE_COMPARATOR|No analgesia|IUD placement with no analgesia.
62615512|NCT00846690|EXPERIMENTAL|TAC|serves as comparator
62615513|NCT01478607|EXPERIMENTAL|1. Qutenza 30 minutes + SOC|
62615514|NCT01478607|EXPERIMENTAL|2. Qutenza 60 minutes + SOC|
62840521|NCT02885025|ACTIVE_COMPARATOR|BSE + Nasal Fluticasone|"subjects will be randomized into 1 of 4 arms:~1. Broccoli Sprout Extract + Nasal Fluticasone~2. Broccoli Sprout Extract + normal saline nasal spray~3. Placebo Pill + Nasal Fluticasone~4. Placebo Pill + normal saline nasal spray"
62840522|NCT02885025|ACTIVE_COMPARATOR|Broccoli Sprout Extract + normal saline nasal spray|"subjects will be randomized into 1 of 4 arms:~1. Broccoli Sprout Extract + Nasal Fluticasone~2. Broccoli Sprout Extract + normal saline nasal spray~3. Placebo Pill + Nasal Fluticasone~4. Placebo Pill + normal saline nasal spray"
62840523|NCT02885025|ACTIVE_COMPARATOR|Placebo Pill + Nasal Fluticasone|"subjects will be randomized into 1 of 4 arms:~1. Broccoli Sprout Extract + Nasal Fluticasone 2 Broccoli Sprout Extract + normal saline nasal spray 3. Placebo Pill + Nasal Fluticasone 4. Placebo Pill + normal saline nasal spray"
62840524|NCT02885025|PLACEBO_COMPARATOR|Placebo Pill + normal saline nasal spray|"subjects will be randomized into 1 of 4 arms:~1. Broccoli Sprout Extract + Nasal Fluticasone~2. Broccoli Sprout Extract + normal saline nasal spray~3. Placebo Pill + Nasal Fluticasone~4. Placebo Pill + normal saline nasal spray"
62840525|NCT05067699||Patients|recurrent pityriasis versicolor
62055926|NCT04539821|OTHER|VCPM|VCPM is a multi-component intervention consisting of already-established care processes and materials. First, the patient is mailed or emailed (based on their preference) an informational packet prior to intake appointment. Second, using the collaborative medication management model established in VHA,3 the intake appointment is led by the CPS using a standardized intake evaluation. The CPS and physician design a plan presented to the patient. If BUP switch is offered and accepted, the physician completes additional brief evaluations, including a history, medication review, treatment planning, and discussion of other VCPM components, using two-way audio-video visits (with telephone as a back-up).
62258532|NCT02963545|EXPERIMENTAL|Patients presenting cerebral infarction|no intervention of health product administration,
62258533|NCT02963545|OTHER|Historical controls|no intervention of health product administration, patients characteristics, history, matched with patients for age, gender, tobacco consumption and season of inclusion, free of neurologic or psychiatric disease or psychotropic medications or medications known to impact on serotonin
62258534|NCT01833611|EXPERIMENTAL|ETV group|Entecavir 0.5mg at first year; then open with entecavir 0.5mg qd for 2nd, 3rd year
62258535|NCT01833611|PLACEBO_COMPARATOR|Placebo group|Placebo at first year, then opne with entecavir 0.5mg qd for 2nd, 3rd year
62258536|NCT02004262|EXPERIMENTAL|Primary Cohort: Cy/GVAX + CRS-207|"* 200 mg per square meter (mg/m\^2) cyclophosphamide (Cy) administered by intravenous (IV) infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (GVAX, 5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 colony forming units \[CFU\]) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.~* The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
62258537|NCT02004262|EXPERIMENTAL|Primary Cohort: CRS-207|"* CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16.~* The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
62615515|NCT01478607|NO_INTERVENTION|3. SOC|Subjects randomized to this group will receive treatment optimized for them on an individual basis. The investigator will be free to provide whatever pharmacological or other treatment is considered optimal for management of the subject's pain.
62615516|NCT02668159|EXPERIMENTAL|Fish peptide|
62615517|NCT02668159|EXPERIMENTAL|Vitamin D|
62615518|NCT02668159|EXPERIMENTAL|Fish peptide + Vitamin D|
62615519|NCT02668159|PLACEBO_COMPARATOR|Control|
62840526|NCT05067699||Controls|Healthy age and sex matched
62840527|NCT05243732|EXPERIMENTAL|Mindful Music Listening|"Participants in the mindful music listening group, will receive personalised music playlists based on music tracks or albums or genres suggested by the participant in the pre-intervention survey. The playlist will be created on the streaming platform they are subscribed to.~In addition to listening to their preferred music daily, they will be emailed a brief mindful music exercise to complete prior to listening to their preferred music playlist (weeks 1-4). The mindful music exercise will have spoken instructions, and focus on key element of mindfulness of paying attention to the present moment. For example, If participants were to notice any thoughts or sensations arising either during the brief exercise or during subsequent music listening, they are to allow them to pass and to gently bring their attention back to the exercise/music."
62444913|NCT06482970|NO_INTERVENTION|Usual care|Participants will be urged to continue with their life activities without changes. All participants will continue to receive routine care offered by their doctor and other health care providers. No trial interventions were provided. The possible treatments that may be provided to the participants in this group (if the primary medical team deems it appropriate) will not be influenced. However, if the participants receive any treatment from their medical staff, it will be recorded as an extra history and the participant will not be considered in the analyses. All participants in this group will be eligible to receive the experimental therapies of their choice once the study is completed.
62615520|NCT03541434||Healthy|Children with no history of adenotonsillar hypertrophy, recurrent tonsillitis, or middle ear effusion. They presented to the clinic for examination or a scheduled procedure.
62615521|NCT03541434||Recurrent tonsillitis|Children with a history of recurret tonsillitis but no adenotonsillar hypertrophy. Diagnosis was based on physical exam and complete blood count. They presented to the clinic for a sceduled tonsillectomy.
62615522|NCT03541434||Middle ear effusion|Children with chronic middle ear effusion but no adenotonsillar hypertrophy. Diagnosis was based on physical exam and tympanometry. They presented to the clinic for scheduled myringotomy with or without adenoidectomy.
62615523|NCT03541434||Adenotonsillar hypertrophy|Children with tonsillar and/or adenoidal hypertrophy. Diagnosis was based on physical exam and partly on x-ray of nasopharynx or nasopharyngoscopy. They presented to the clinic for scheduled tonsillectomy and/or adenoidectomy.
62840528|NCT05243732|ACTIVE_COMPARATOR|Music Listening|Participants in the music listening group will receive personalised playlists based on music tracks or albums or genres suggested by the participant in the pre-intervention survey. The playlist will be created on the streaming platform they are subscribed to. In contrast to the mindful-music condition, no specific listening instructions will be given to the music listening only condition.
62840529|NCT04808661|EXPERIMENTAL|Intervention group|Thoracic endovascular aortic repair plus optimal medical therapy
62840530|NCT04808661|ACTIVE_COMPARATOR|Conservative group|Optimal medical therapy
62840531|NCT03256916|EXPERIMENTAL|Nelfinavir Arm|"If patient is randomized to nelfinavir arm then nelfinavir will be given orally with food at the dose of 1250 mg bid 5-7 days prior to start of chemoradiation.~Then Pelvic EBRT (45-50 Gy/23-25 #/5weeks) + Weekly cisplatin 40mg/m2 \& ICRT 7Gy X4 # will be given."
62840532|NCT03256916|OTHER|Standard Arm|"If patient is randomized to standard arm (Cisplatin +Pelvic EBRT and Brachytherapy).~In this patient will receive Pelvic EBRT (45-50 Gy/23-25 #/5weeks) + Weekly cisplatin 40mg/m2 \& ICRT 7Gy X4 #"
62840533|NCT05982405|EXPERIMENTAL|Training group|The individuals in the training group will be performed inspiratory muscle training using an inspiratory muscle training device (PowerBreathe®) at 30-50% of the maximal inspiratory pressure.
62840534|NCT05982405|SHAM_COMPARATOR|Control group|Individuals in the control group will be performed thoracic expansion exercises.
62840535|NCT02446119||Gastroparesis|"Inclusion criteria:~1. Subjects will be of either sex, 18 to 70 years of age.~patients with an established diagnosis of gastroparesis, either diabetic or idiopathic etiology. The gastroparesis subjects will have delayed gastric emptying on gastric scintigraphy defined as greater than 60% retention at 2 hours and/or greater than 10% retention at 4 hours. This gastric emptying test would have been done prior to the endoscopy and is not part of the research study. Patients will undergo EndoFlip during upper endoscopy."
62840536|NCT02446119||Normals|"Inclusion criteria:~1. Subjects will be of either sex, 18 to 70 years of age.~control subjects will be nondiabetic patients without gastroparesis or gastroesophageal reflux symptoms undergoing upper endoscopy. Patients will undergo EndoFlip during upper endoscopy."
62840537|NCT00740311|EXPERIMENTAL|Filling|alveoli filling with an injectable calcium phosphate after extraction of mandibular molar or pre molar
62840538|NCT00740311|NO_INTERVENTION|Without filling|
62840539|NCT04858022|EXPERIMENTAL|Visual Acoustic Biofeedback for RSE via Telepractice-Treatment|"Condition1: Treatment-first~Children with RSE and typical perception will be allocated to a randomized controlled trial measuring the efficacy of online visual-acoustic biofeedback treatment. Ten children with RSE will receive 10 weeks of visual-acoustic biofeedback training via video call."
62840540|NCT04858022|EXPERIMENTAL|Visual Acoustic Biofeedback for RSE via Telepractice-Wait|"Condition 2: Waitlist-first~Following the initial evaluation, 10 children with RSE will be allocated to a 10 week no treatment condition."
62840541|NCT04788706|ACTIVE_COMPARATOR|Group I|LLLT over three weeks followed by an eight-week receiving Russian electrical stimulation
62840542|NCT04788706|PLACEBO_COMPARATOR|Group II|Placebo laser over three weeks followed by an eight-week receiving Russian electrical stimulation
62840543|NCT04788706|ACTIVE_COMPARATOR|Group III|LLLT over three weeks followed by an eight-week receiving LLLT application combined with Russian electrical stimulation
62840544|NCT04788706|PLACEBO_COMPARATOR|Group IV|Placebo laser over three weeks followed by an eight-week receiving Placebo laser application combined with Russian electrical stimulation
62258538|NCT02004262|ACTIVE_COMPARATOR|Primary Cohort: Chemotherapy|"* Investigator's choice of one of the following: gemcitabine (1000 mg/m\^2) administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle; capecitabine (1000 mg/m\^2) administered orally twice a day on Days 1 through 14 of a 21-day cycle; fluorouracil with or without leucovorin (2400 mg\^m2) administered by IV infusion over 46 hours on Days 1 and 15 of a 28-day cycle; irinotecan (150 mg/m\^2) administered by IV infusion on Days 1 and 15 of a 28-day cycle; or erlotinib (100 mg) administered orally once a day for a 21-day cycle.~* The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
62258539|NCT02004262|EXPERIMENTAL|2nd-line Cohort: Cy/GVAX + CRS-207|"* 200 mg/m\^2 Cy administered by IV infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.~* The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
62258540|NCT02004262|EXPERIMENTAL|2nd-line Cohort: CRS-207|"* CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16.~* The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
62258541|NCT02004262|ACTIVE_COMPARATOR|2nd-line Cohort: Chemotherapy|"* Investigator's choice of one of the following: gemcitabine (1000 mg/m\^2) administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle; capecitabine (1000 mg/m\^2) administered orally twice a day on Days 1 through 14 of a 21-day cycle; fluorouracil with or without leucovorin (2400 mg\^m2) administered by IV infusion over 46 hours on Days 1 and 15 of a 28-day cycle; irinotecan (150 mg/m\^2) administered by IV infusion on Days 1 and 15 of a 28-day cycle; or erlotinib (100 mg) administered orally once a day for a 21-day cycle.~* The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
62055927|NCT00111748|ACTIVE_COMPARATOR|1|"Stratification:~1. CA13/hypodiploidy at diagnosis versus no CA13/hypoploidy at diagnosis~2. Prior Velcade vs. No prior Velcade~TREATMENT:VTD Velcade 1.0 mg/m2 Days 1,4, 8,11 Thalidomide 100 mg Daily qhs Dexamethasone 20 mg Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg Days 1-14 Every 21 days"
62258542|NCT05074251|EXPERIMENTAL|HIV self testing|HIV+ women will receive HIV self-tests (2) to bring home to her partner to offer for testing
62258543|NCT05074251|ACTIVE_COMPARATOR|Standard of care|In the standard of care arm, women will receive standard of care partner referrals for HIV testing, including counselling about disclosure and referral for her partner(s) to return to the facility for testing.
62258544|NCT05964374|NO_INTERVENTION|Control|Routine post-operative clinical care.
62258545|NCT05964374|EXPERIMENTAL|Intervention|Goal-directed therapy algorithm in addition to routine post-operative clinical care.
62258546|NCT02072408|EXPERIMENTAL|polypoidal choroidal vasculopathy without polyp|
62258547|NCT03587662|EXPERIMENTAL|Treatment (ixazomib, gemcitabine, doxorubicin)|"INDUCTION: Patients receive ixazomib PO, gemcitabine IV over 90 minutes, and doxorubicin IV over 15-30 minutes on day 1. Treatment repeats every 14 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ixazomib PO and gemcitabine IV over 90 minutes. Cycles repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
62444914|NCT00783666|EXPERIMENTAL|1|Lactic Acid
62444915|NCT03878316|ACTIVE_COMPARATOR|Intranasal Oxytocin|Oxytocin, 35 IU per dose, intranasally twice-daily. One dose is defined as intranasal spray of 100 μL per each nostril x 5 sprays in alternating nostrils with a 30 second wait between sprays for a total dose volume of 500 μL. The total daily dose of oxytocin will be 70 IU/mL.
62444916|NCT03878316|PLACEBO_COMPARATOR|Instrasal Placebo|Identically matched placebo administered intranasally twice-daily. One dose is defined as intranasal spray of 100 μL per each nostril x 5 sprays in alternating nostrils with a 30 second wait between sprays for a total dose volume of 500 μL.
62444917|NCT06166472|EXPERIMENTAL|AK132|Each subject will receive a single dose of AK132 every 2-week cycle (Q2W).
62615524|NCT04794114|EXPERIMENTAL|orthosis in hemiplegia|
62444918|NCT03416595|ACTIVE_COMPARATOR|N1115 Probiotic Supplement|A probiotic supplement containing Lactobacillus paracasei N1115 \[Junlebao Lp. N1115\] Participators, who met inclusion criteria, will receive following product during 8 weeks: N1115 Probiotic Supplement in the form of powder packaged in sachet (one sachet containing 10\^9 CFU Lp. N1115).
62615525|NCT05436678|ACTIVE_COMPARATOR|PrimeC|2 PrimeC tablets (total single dose 748 mg) twice daily for 6.5 days following a meal
62615526|NCT05436678|ACTIVE_COMPARATOR|Marketed ciprofloxacin and celecoxib|750 mg of ciprofloxacin and 200 mg of celecoxib, co-administered twice daily for 6.5 days following a meal
62615527|NCT01330056|ACTIVE_COMPARATOR|FOPS|"* Functional organ preservation surgery (FOPS) group as a first-line treatment modality~* Postoperative RT or CRT may be included for the patients of this group"
62444919|NCT03416595|PLACEBO_COMPARATOR|Placebo control|Dietary Supplement: Placebo Participators, who met inclusion criteria, will receive an identical N1115 Probiotic Supplement looking and tasting placebo.
62615528|NCT01330056|ACTIVE_COMPARATOR|CRT|"* Concurrent chemoradiotherapy or radiotherapy group as a first-line treatment modality~* Salvage surgery may be applied for the patients for persistent or recurrent cancers after CRT or RT"
62615529|NCT04065581|EXPERIMENTAL|Treatment A-washout-treatment B|Subject will receive a single oral dose of acarbose/metformin FDC (Treatment A, 50 mg acarbose/500 mg metformin) in period 1, followed by a single oral dose of 50mg acarbose and 500mg metformin as loose combination (Treatment B) in period 2. Washout interval between 2 treatment periods was at least 7 days.
62615530|NCT04065581|EXPERIMENTAL|Treatment B-washout-treatment A|Subject will receive a single oral dose of 50 mg acarbose and 500 mg metformin as loose combination (Treatment B) in period 1, followed by a single oral dose of acarbose/metformin FDC (Treatment A, 50mg acarbose/500 mg metformin) in period 2. Washout interval between 2 treatment periods was at least 7 days.
62615531|NCT00408187|ACTIVE_COMPARATOR|1.|
62615532|NCT00408187|PLACEBO_COMPARATOR|3.|
62615533|NCT00408187|ACTIVE_COMPARATOR|2.|
62840545|NCT02722083|EXPERIMENTAL|BAY X002134|Subjects will be given BAY X002134
62055928|NCT00111748|ACTIVE_COMPARATOR|2|"Stratification:~1. CA13/hypodiploidy at diagnosis versus no CA13/hypoploidy at diagnosis~2. Prior Velcade vs. No prior Velcade~TREATMENT:~VATD Velcade 1.0 mg/m2 Days 1,4, 8,11 Thalidomide 100 mg Daily qhs Dexamethasone 20 mg Days 1, 2, 4,5, 8, 9, 11, 12 Adriamycin 2.5 mg/m2 Days 1-4 \& Days 9-12 Lovenox 40 mg Days 1-14 Every 21 days"
62258548|NCT04781621|EXPERIMENTAL|Robotic Gait Training|Patients in the Robotic Gait Training (RGT) group will receive 90 minutes per week of RGT once patients are deemed clinically appropriate as defined by being able to tolerate standing for 15 minutes without orthostatic intolerance. The duration of treatment will span the patient's length of stay in inpatient rehabilitation. The Ekso Bionics Ekso GT™ robotic exoskeleton will be used for RGT.
62258549|NCT04781621|ACTIVE_COMPARATOR|Usual Care Gait Training|Usual Care (UC) gait training including body weight-supported treadmill training (BWSTT) and conventional overground walking.
62444920|NCT05446727|EXPERIMENTAL|QLB|Experimental: Quadratus Lumborum block group Quadratus Lumborum block group (QL) patients will receive a bilateral Quadratus Lumborum block using Ropivacaine 0.375%
62258550|NCT02336659|PLACEBO_COMPARATOR|Saline|Mixed meal test and ad libitum meal test duing infusion of saline
62258551|NCT02336659|EXPERIMENTAL|Exendin 9-39|Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min
62615534|NCT01824121|ACTIVE_COMPARATOR|immediate stem cell therapy|patients will undergo active intervention i.e. they will be given stem cell therapy immediately. After 6 months they will undergo a sham procedure.
62055929|NCT06526403|EXPERIMENTAL|Zero fluoroscopy oval-shaped secundum ASD closure|
62055930|NCT00003835|EXPERIMENTAL|Arm I (leucovorin calcium and fluorouracil)|Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV beginning 1 hour into leucovorin calcium infusion weekly for 6 weeks. Treatment is repeated every 8 weeks for 4 courses.
62055931|NCT00003835|EXPERIMENTAL|Arm II (leucovorin calcium, fluorouracil, irinotrcan)|Patients receive irinotecan IV over 90 minutes, followed by leucovorin calcium IV, then followed by fluorouracil IV weekly for 4 weeks. Treatment is repeated every 6 weeks for 5 courses
62055932|NCT00834808|EXPERIMENTAL|1: Tramadol HCl 100mg|
62055933|NCT00834808|EXPERIMENTAL|2: Tramadol HCl 200mg|
62055934|NCT00834808|EXPERIMENTAL|3: Tramadol HCl 300mg|
62258552|NCT02336659|EXPERIMENTAL|DPP-4 Inhibition|Mixed meal test and ad libitum meal test during intake of sitagliptin 100 mg \* 2
62258553|NCT02336659|EXPERIMENTAL|Exendin 9-39 / DPP 4-Inhibition|Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min and intake of sitagliptin 100 mg \* 2
62258554|NCT01990638||DM group|
62258555|NCT01990638||non-DM group|
62840546|NCT02722083|PLACEBO_COMPARATOR|Placebo|Subjects will be given a placebo
62840547|NCT02602210|ACTIVE_COMPARATOR|group A|Group A: treated with intravenous hydrocortisone in addition to standard therapy (= treatment group)
62840548|NCT02602210|PLACEBO_COMPARATOR|group B|Group B: IV treatment with NaCL 0.9% in addition to standard therapy (= placebo group)
62840549|NCT01993121|EXPERIMENTAL|Three-month exercise training program|All subjects will perform three months of supervised exercise training.
62840550|NCT00540085|ACTIVE_COMPARATOR|A|Rocuronium dosed after ideal body weight
62258556|NCT04391348|EXPERIMENTAL|PET-TDM|PET-TDM with 18F-FDG and PET-TDM with 18F-fluorocholine
62258557|NCT00411359|EXPERIMENTAL|Cardiac rehabilitation|8-week cardiac rehabilitation programme
62444921|NCT05446727|EXPERIMENTAL|ESP|Ultrasound-guided continuous ESP block with opioid PCA A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T7/T8 spinous process. A Contiplex Echo ultra 360 18G needle with 20G × 55 cm Contiplex Echo catheter will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% ropivacaine
62444922|NCT02935959|ACTIVE_COMPARATOR|nebulized ketamine|patients will be premedicated with nebulized ketamine solution (2 mg/kg)
62840551|NCT00540085|ACTIVE_COMPARATOR|B|Rocuronium dosed after corrected body weight 20%
62840552|NCT00540085|ACTIVE_COMPARATOR|C|Rocuronium dosed after corrected body weight 40%
62615535|NCT01824121|SHAM_COMPARATOR|delayed stem cell therapy|patients allocated to delayed stem cell therapy will undergo a sham procedure (incannulation of the femoral vein and infusion of saline solution). They will receive stem cell therapy after 6 months
62258558|NCT00411359|NO_INTERVENTION|Monitoring|Carry on life as normal
62258559|NCT00888550|EXPERIMENTAL|1. Splinting|
62444923|NCT02935959|ACTIVE_COMPARATOR|nebulized dexmedetomidine|patients will be premedicated with nebulized dexmedetomidine solution (2 μg/kg)
62444924|NCT02935959|ACTIVE_COMPARATOR|nebulized midazolam|patients will be premedicated with midazolam (0.2 mg/kg) nebulized solution
62444925|NCT00727454|PLACEBO_COMPARATOR|1 Control|No treatment
62444926|NCT00727454|EXPERIMENTAL|2 CPAP|Continuous Positive Airway Pressure (CPAP) - REMStar Pro with C-Flex; Respironics, Inc., Murrysville, PA
62840553|NCT05139004|EXPERIMENTAL|Treatment (90Y-basiliximab, fludarabine, melphalan, TMLI)|Patients receive cold basiliximab IV, 111In-DOTA-anti-CD25 basiliximab IV, and 90Y-DOTA-anti-CD25 basiliximab IV on day -15. Patients also receive palifermin IV on days -11 to -9, fludarabine phosphate IV on days -4 to -2, melphalan IV on day -2, and undergo TMLI on days -8 to -5 in the absence of disease progression or unacceptable toxicity. Patients then undergo AHSCT on day 0.
62840554|NCT04670367|PLACEBO_COMPARATOR|Arm A: usual care|routine usual care
62840555|NCT04670367|EXPERIMENTAL|Arm B: walk|walk 30mins per day, 5 days per week.
62444927|NCT06057883|EXPERIMENTAL|Probiotic arm|All participants will be given the active probiotic product as this is a single arm, open-label study.
62615536|NCT00392496|EXPERIMENTAL|Arm I|This is a non-randomized, open-label, multicenter study. Patients receive sunitinib malate orally once daily on days 1-28. Treatment repeats every 4 weeks for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity.
62840556|NCT04670367|EXPERIMENTAL|Arm C: Baduanjin|Baduanjin 12 mins per day, 5 days per week.
62840557|NCT04670367|EXPERIMENTAL|Arm D: Baduanjin plus walk|walk 30mins then Baduanjin 12 mins per day, 5 days per week.
62258560|NCT00888550|ACTIVE_COMPARATOR|2. No Splinting|
62258561|NCT05560256|EXPERIMENTAL|Youth Engage with Diary|24 youth will use the Diary for one month
62258562|NCT01669161|EXPERIMENTAL|VNS|VNS (vagus nerve stimulation) paired with rehabilitation as provided by the Vivistim System.
62258563|NCT01669161|ACTIVE_COMPARATOR|Rehab Only|Rehabilitation only (no implant, no VNS)
62615537|NCT02634905|EXPERIMENTAL|Individual session therapeutic education|The children included in the active arm will undergo, along with their parents (by child's age and wish), a structured individual TPE session between W0 and W2. This session will be conducted by the nurse trained in TPE. The session will be one hour long.
62615538|NCT02634905|NO_INTERVENTION|Control|
62615539|NCT03576352|EXPERIMENTAL|Pediatric anesthesiologist|10 rapid sequence tracheostomy (RST) on rabbit cadaver
62840558|NCT05322395|EXPERIMENTAL|ESC 0/1 pathway|"A two-arm parallel group, two-centre pragmatic randomised controlled trial of 0-1-hour high sensitivity troponin T (hs cTnT) compared to a 0-3-hour pathway as rules for rapid discharge of suspected ACS. (both incorporating single presentation sample limit of detection (LOD) high sensitive troponin as a rule for discharge, or cut-off selected by manufacturer).~The power of the study is on safety rather than percent discharge achieved by 4 hours as this is the primary focus for clinicians and health care institutions. (By virtue of the earlier sampling the 0-1 hour troponin sampling is likely to allow greater discharges by 4 hours and the sample size for safety easily accommodates this aspect)."
62055935|NCT00265135|EXPERIMENTAL|Part 1 (CNTO 328)|In Part 1 of the study, 4 intravenous infusions (IV) \[injection of a substance into a vein\] of CNTO 328 will be administered to patients in 4 dose levels ranging from 1, 3, 6, and 12 mg/kg on days 1, 29, 43, and 57 to determine the maximum tolerated dose for Part 2 of the study.
62258564|NCT01156272||Replacement aortic heart valve|ATS 3f® Aortic Bioprosthesis, Model 1000, Size 19mm
62444928|NCT02267057|ACTIVE_COMPARATOR|Paracetamol or buprenorphine treatment|Paracetamol tablets 1 g three times daily or Buprenorphine transdermal system 5 micrograms/hour every 7 days, may be titrated up to 10 micrograms/hour every 7 days if clinically appropriate.
62444929|NCT02267057|PLACEBO_COMPARATOR|Paracetamol placebo or buprenorphine placebo|Paracetamol placebo tablet three times daily or buprenorphine transdermal system placebo every 7 days.
62444930|NCT03777137||TMS during heat pain stimuli|This is a single institution, single-blinded, long-term exploratory study using participant as his/her own control to evaluate and compare the analgesic effect of experimental heat pain of TMS during early versus late times on a vigilance behaviors toward pain (CPT, Continuous Performance Task). Vigilance behaviors include errors, reaction times and activation.
62444931|NCT06245174||Parkinson's disease (PD)|Individuals with mild to severe movement disorder symptoms of Parkinson's disease
62444932|NCT06393101|PLACEBO_COMPARATOR|Placebo Comparator: 1 Placebo|Half of the patients will receive PO placebo
62444933|NCT06393101|EXPERIMENTAL|Experimental: Active|Drug: BRC-002 (High Cannabidiol Botanical Extract) 100 mg/mL
62615540|NCT03576352|EXPERIMENTAL|Pediatric intensivists|10 rapid sequence tracheostomy (RST) on rabbit cadaver
62615541|NCT03576352|EXPERIMENTAL|Pediatric surgeons|10 rapid sequence tracheostomy (RST) on rabbit cadaver
62615542|NCT03576352|EXPERIMENTAL|Pediatric emergency physicians|10 rapid sequence tracheostomy (RST) on rabbit cadaver
62615543|NCT04759456|EXPERIMENTAL|Intervention group|Participants will undergo 12-week comprehensive remotely-supervised rehabilitation program along with individually titrated CPAP therapy.
62615544|NCT04759456|NO_INTERVENTION|Control group|Participants will undergo individually titrated CPAP therapy.
62615545|NCT01832818|EXPERIMENTAL|NuNec Cervical Disc|Each patient will be implanted with the NuNec Cervical Disc in a single level from C3 to C7. Postoperatively, patient evaluated at discharge, 6 weeks, 3, 6, 12 and 24 months.
62615546|NCT01438814|EXPERIMENTAL|linagliptin + metformin|patients to receive linagliptin +metformin QD
62615547|NCT01438814|ACTIVE_COMPARATOR|metformin|patients to receive metformin BID
62615548|NCT00396877|PLACEBO_COMPARATOR|Placebo|
62615549|NCT00396877|EXPERIMENTAL|Clopidogrel 0.2 mg/kg/day|
62615550|NCT02510703|OTHER|Type 2 diabetes group|Type 2 diabetes group
62615551|NCT02510703|OTHER|no diabetes|no diabetes
62615552|NCT00840736|ACTIVE_COMPARATOR|1|Laparoscopic adjustable gastric banding
62615553|NCT00840736|ACTIVE_COMPARATOR|2|vertical banded gastroplasty
62615554|NCT03321409||The general population|People who take the physical examination in Renji Hospital between 18 to 80 years old without any previously confirmed serious medical conditions or mental disorders.
62055936|NCT00265135|EXPERIMENTAL|Part 2 (CNTO 328)|In Part 2 of the study, 2 well tolerated dose levels of CNTO 328 from Part 1 of the study will be administered every 3 weeks as 4 IV infusions to patients.
62055937|NCT00265135|EXPERIMENTAL|Part 3 (CNTO 328)|In Part 3 of the study, CNTO 328 at a dose level of 6 mg/kg will be administered as IV infusion every 2 weeks for at least 6 doses.
62258565|NCT01041482|EXPERIMENTAL|sorafenib|To study the efficacy of Sorafenib as an adjuvant therapy for reducing recurrence rate in locally advanced renal-cell carcinoma (RCC) after radical nephrectomy.
62258566|NCT00870402|EXPERIMENTAL|1|
62258567|NCT00870402|PLACEBO_COMPARATOR|2|
62258568|NCT01130285||Non-Lung Cancer, Heavy Smoker|Subjects will be ≥ 50 years of age and have a ≥ 20 pack year smoking history and will be either healthy volunteers or individuals undergoing diagnostic bronchoscopy, with absence of lung cancer documented at the time of enrollment.
62055938|NCT02877602||Experience of liver disease|This is defined as either those who have had direct experience of liver disease as sufferers, or the carers of those who have had liver disease. Each individual receives an MRI (LiverMultiScan), with many also receiving a FibroScan.
62055939|NCT00677625||Liver Disease (LD)|These child subjects have some form of liver disease (including those who need a liver transplant) or have already had a liver transplant.
62258569|NCT04424446||NIH staff|NIH staff undergoing standard NIH COVID-19 screening willing to donate additional research samples.
62258570|NCT05997329|EXPERIMENTAL|MyFood (App for diet record)|Use of an App for diet record
62258571|NCT05997329|NO_INTERVENTION|Usual care|Usual care
62258572|NCT05787080|EXPERIMENTAL|Massage Group/experimental|Blood tests will be taken at the entrance of dialysis from all participants. Then, in the second hour of hemodialysis, low voltage vibrations will be applied to both calf muscles of the patients for 10 minutes, three times a week for one month.Vibration application will be made with this device 53 Hz head. The vibration application will be performed for 2.5 minutes, starting from the medial side of the gastrocnemius (calf) muscle in both legs and moving it longitudinally from distal to proximal and from back to distal in a straight line within 20 seconds. Then this treatment will be applied to the lateral side of the gastrocnemius muscle for 2.5 minutes. This cycle will be repeated twice. After the one-month application period is completed, blood tests will be taken from all participants at the entrance to hemodialysis.
62258573|NCT05787080|NO_INTERVENTION|Control Group|No intervention will be made on the patients in the control group.
62258574|NCT05023408|EXPERIMENTAL|Intralesional Bleomycin|Intralesional Bleomycin has been given to palmo plantar warts. Generic name: Bleomycin Dose: 1mg/1ml (0.1%) Frequency: every 2 weekly for 6 weeks.
62258575|NCT05023408|EXPERIMENTAL|Cryotherapy|Cryotherapy has been given to palmo plantar warts. Frequency: every 2 weekly for 6 weeks
62258576|NCT00788372|EXPERIMENTAL|Fentanyl|Fentanyl transdermal patch will be applied once daily up to 4 weeks in Treatment period 1, releasing at the rate of 12.5 microgram per hour (mcg/hr), maintained for 2 days and for another 48 weeks in Treatment period 2. The dose will be increased as per Investigators' discretion in both treatment periods and the maximum applied dose will be 300 mcg/hr. Total duration of treatment is 52 weeks.
62258577|NCT02023645|EXPERIMENTAL|Active supplement|10 mg lutein + 2 mg zeaxanthin
62258578|NCT02023645|PLACEBO_COMPARATOR|inert placebo|placebo for comparison
62258579|NCT03545763||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
62258580|NCT03545763||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
62055940|NCT03002610|ACTIVE_COMPARATOR|PLS|The control group will receive PLS: text format with simple explanation of the survey topic main findings and is intended for lay audience.
62055941|NCT03002610|EXPERIMENTAL|Infographics|Infographics format of a Cochrane systematic review summary represents the experimental intervention in the trial, where the results are presented with text and pictures.
62055942|NCT03002610|ACTIVE_COMPARATOR|Scientific abstract|Scientific abstract is the text written for the academic population and practitioners. It is also intended for control group.
62055943|NCT01489189|EXPERIMENTAL|Anti-VEGF+Deferred PRP|Anti-VEGF= Anti vascular endothelial growth factor. PRP= Panretinal photocoagulation. Intravitreal anti-VEGF with PRP only if indicated.
62055944|NCT01489189|ACTIVE_COMPARATOR|Prompt PRP|PRP= Panretinal Photocoagulation. PRP alone.
62055945|NCT04367558|EXPERIMENTAL|Interventional|Patient suffering from OSA, and found to suffer from obstruction of one or more of the following areas - Lower turbines, Soft Palate, Tonsils, Base-of-tongue.
62055946|NCT04987125|EXPERIMENTAL|Dyspnea Neuroscience education|
62055947|NCT04987125|ACTIVE_COMPARATOR|Usual care|
62055948|NCT01089322|EXPERIMENTAL|Stantardized treament|oral and inhaled corticosteroid plus LABA
62055949|NCT02235246|EXPERIMENTAL|normal saline|
62258581|NCT00432042|EXPERIMENTAL|ProQuad® + Infanrix® hexa|Pediatric (12 to 23 months of age) participants received ProQuad® and Infanrix® hexa (booster dose) concomitantly on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
62258582|NCT00432042|ACTIVE_COMPARATOR|ProQuad®|Pediatric (12 to 23 months of age) participants received ProQuad® on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
62055950|NCT02235246|ACTIVE_COMPARATOR|magnesium sulfate|
62055951|NCT04191629|EXPERIMENTAL|50K to 200K cells|
62055952|NCT04191629|EXPERIMENTAL|50K to 200K cells with endothelial brushing|
62055953|NCT04191629|EXPERIMENTAL|500K cells|
62055954|NCT04191629|EXPERIMENTAL|500K cells with endothelial brushing|
62258583|NCT00432042|ACTIVE_COMPARATOR|Infanrix® hexa|Pediatric (12 to 23 months of age) participants received Infanrix® hexa (booster dose) on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
62258584|NCT05947487|EXPERIMENTAL|CD70-targeting CAR-T cells|"Enrolled participants will be given a preconditioning regimen consisted of albumin-bound paclitaxel, cyclophosphamide and fludarabine before the infusion of CD70-CAR-T cells.~Enrolled patients in this arm will be administered CD70-CAR-T cells in 3+3 based escalation manner."
62258585|NCT01289236|PLACEBO_COMPARATOR|Placebo|Placebo BID (twice daily, approximately 12 hours apart)
62258586|NCT01289236|ACTIVE_COMPARATOR|milnacipran 200 mg|200mg- 1 100mg tablet BID (twice daily, approximately 12 hours apart)
62258587|NCT01289236|ACTIVE_COMPARATOR|milnacipran 100 mg|100mg- 1 50mg tablet BID (twice daily, approximately 12 hours apart)
62055955|NCT03627039||Truven|NOTE: In the case there are not enough patients/events data will be included from other databases (e.g., Optum, Medicare)
62615555|NCT03321409||The patients with suspected CAD|Patients with suspected CAD between 18 to 80 years old without any previously confirmed serious medical conditions or mental disorders.
62615556|NCT03927326|EXPERIMENTAL|Local infiltration|Liposomal bupivacaine (266mg) will be directly infiltrated by the surgeon into the surgical laparoscopic wound sites.
62615557|NCT03927326|EXPERIMENTAL|Transversus abdominis plane block|Liposomal bupivacaine (266mg) will be used in a ultrasound guided transversus abdominis plane block.
62840559|NCT05322395|ACTIVE_COMPARATOR|ESC 0/3 hour pathway|"A two-arm parallel group, two-centre pragmatic randomised controlled trial of 0-1-hour high sensitivity troponin T (hs cTnT) compared to a 0-3-hour pathway as rules for rapid discharge of suspected ACS. (both incorporating single presentation sample limit of detection (LOD) high sensitive troponin as a rule for discharge, or cut-off selected by manufacturer).~The power of the study is on safety rather than percent discharge achieved by 4 hours as this is the primary focus for clinicians and health care institutions. (By virtue of the earlier sampling the 0-1 hour troponin sampling is likely to allow greater discharges by 4 hours and the sample size for safety easily accommodates this aspect)."
62840560|NCT05243511|ACTIVE_COMPARATOR|Digital Acceptance and Commitment Therapy (ACT) Arm|
62615558|NCT04166292|EXPERIMENTAL|Treated face|The device will be injected on V1 (D0) in the cheekbones (upper part of the cheek) for all subjects and in the chin for 20 subjects minimum and if needed (optional areas) in the temple, and facial oval (mandibular angle and border). A touch-up is possible in one or several of these areas on V2 (M1). Optional treated areas will be at the discretion of subjects and injectors.
62055956|NCT02200263|EXPERIMENTAL|Lutein plus Zeaxanthin|Participants randomized to this arm will receive 20 mg of Lutein (L) plus 20 mg of Zeaxanthin (Z) per day: Two pills (10 mg L+ 10 mg Z per pill) for the duration of one year.
62615559|NCT03313011||Progressive Apraxia of Speech|
62840561|NCT05243511|ACTIVE_COMPARATOR|Digital Symptom Tracker|
62840562|NCT01583296|EXPERIMENTAL|CBT and HRVB|Cognitive Behavioral Therapy (CBT) and Heart Rate Variability Biofeedback (HRVB)
62840563|NCT01583296|ACTIVE_COMPARATOR|Music Relaxation Therapy (MRT)|Music Relaxation Therapy (MRT): music relaxation and breathing at resting respiration rate
62840564|NCT05417919|EXPERIMENTAL|Solution-oriented Nursing in Violence Against Women (SONVAW)|"Initiatives for the Experimental Group Personal Information Form and İSKEBE scale were given to 45 students who were determined in accordance with the research criteria and they were asked to fill in. Data were collected from students who did not come to school that day by telephone or by interviewing them the next day.~Before the solution-oriented approach program, the students were interviewed and the appropriate time and hours were determined for the program. Then, an online solution-oriented approach program was implemented, which lasted for 6 weeks at the specified hours and days. In the first week of the program, a guide form containing the activities related to the program to be applied was distributed to the students. At the end of the program, the students were asked to fill in the İSKEBE scale as a post-test. Three months after the end of the program, they were asked to fill in the İSKEBE scale again as a follow-up test."
62055957|NCT02200263|PLACEBO_COMPARATOR|Placebo softgels|Participants randomized to this arm will receive two pills per day of placebo-gels corresponding to the active compound in look and feel for the duration of one year
62055958|NCT01040702|EXPERIMENTAL|ADHD -MPH|adults with ADHD diagnosis who receive a single dose of Methylphenidate
62055959|NCT01040702|PLACEBO_COMPARATOR|ADHD-placebo|adults with ADHD diagnosis who received placebo
62055960|NCT01040702|EXPERIMENTAL|non-ADHD-MPH|healthy adults who received a single dose of Methylphenidate
62615560|NCT03245190|EXPERIMENTAL|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
62615561|NCT01226680|EXPERIMENTAL|Tasocitinib 0.005% QD|
62055961|NCT01040702|PLACEBO_COMPARATOR|non-ADHD-placebo|healthy adults who received placebo
62055962|NCT02331797|EXPERIMENTAL|Endoscopic Technique|All patients are operated under the endoscope. The endoscope passed through external auditory canal (transcanal approach) to visualize tympanic remnant.
62055963|NCT02331797|ACTIVE_COMPARATOR|Microscopic Technique|All patients are operated under the microscope.A postauricular or transcanal approach is chose depend on ear canal size and size of perforation. When the ear canal is too small, the postauricular is used.
62615562|NCT01226680|EXPERIMENTAL|Tasocitinib 0.003% QD|
62615563|NCT01226680|PLACEBO_COMPARATOR|Vehicle for Tasocitinib|
62615564|NCT05855408|EXPERIMENTAL|Group 1|Subjects are assigned to receive one dose of intramuscularly administered Ad5-nCoV vaccine as the second booster.
62055964|NCT04551092|EXPERIMENTAL|Single|Single group to receive intervention
62055965|NCT03406819|EXPERIMENTAL|Nitroprusside group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Nitroprusside Sodium via guide-catheter was performed. Then repeated administration of Nitroprusside Sodium was done prior to coronary stent implantation or post dilatation.
62615565|NCT05855408|EXPERIMENTAL|Group 2|Subjects are assigned to receive one dose of aerosolized Ad5-nCoV vaccine as the second booster.
62615566|NCT05855408|EXPERIMENTAL|Group 3|Subjects are assigned to receive two doses of DelNS1-2019-nCoV-RBD-OPT1 vaccine as the second booster.
62615567|NCT05855408|EXPERIMENTAL|Group 4|Subjects are assigned to receive one dose of SYS6006 vaccine as the second booster.
62615568|NCT05855408|NO_INTERVENTION|Group 5|Subjects are not assigned any vaccines served as a blank control.
62615569|NCT02826252||Ventavis|The study will be conducted in patients who are enrolled in the German Ventavis patient support program Ventaplus.
62615570|NCT05239117|EXPERIMENTAL|Plenhyage Thin|Sixteen patients will be administered Plenhyage® Thin for the treatment of minor -sized dermal tissue defects (scars, atrophic scars, depressed plaques, and lipodystrophy defects).
62615571|NCT05239117|EXPERIMENTAL|Plenhyage Medium|Sixteen patients will be administered Plenhyage® Medium for the treatment of medium-sized dermal tissue defects (scars, atrophic scars, depressed plaques, and lipodystrophy defects).
62258588|NCT03913052|EXPERIMENTAL|Injection|Injection containing hyaluronic acid, chondroitin sulphate and glucosamine was performed once when the knee joint was in the supine position and the knee was in the extension.
62258589|NCT03127384|EXPERIMENTAL|No-treatment control|
62615572|NCT05239117|EXPERIMENTAL|Plenhyage Strong|Sixteen patients will be administered Plenhyage® Strong for the treatment of major-sized dermal tissue defects (scars, atrophic scars, depressed plaques, and lipodystrophy defects).
62615573|NCT03573401|EXPERIMENTAL|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~Photodynamic therapy (PDT)"
62615574|NCT03573401|PLACEBO_COMPARATOR|Vehicle|Topical application of vehicle to BF-200 ALA containing no active ingredient. Photodynamic therapy (PDT)
62615575|NCT03904316|EXPERIMENTAL|Biodesign graft tympanic membrane repair|Patient's perforated tympanic membrane will be repaired with an acellular matrix derived from porcine small intestine submucosa, Biodesign Otologic graft
62615576|NCT03904316|ACTIVE_COMPARATOR|Autograft tympanic membrane repair|Patient's perforated tympanic membrane will be repaired with autologous temporalis fascia.
62615577|NCT03850405|EXPERIMENTAL|Chocolate|20 patients (matched per gender) undergoing a diet which includes 25g of dark chocolate (70%), i.e. ca. 145 kcal per day
62615578|NCT03850405|NO_INTERVENTION|Control|20 patients (matched per gender) undergoing a low-fat dietary regimen
62615579|NCT05639686|PLACEBO_COMPARATOR|Total Intravenous Anesthesia (TIVA)|Patients will be induced with fentanyl 1-2µg/kg, propofol 2mg/kg, and lidocaine 1mg/kg. After orotracheal intubation, anesthesia will be maintained with propofol 150mg/kg/min, remifentanil 0.05-2µg/kg/min, and rocuronium or succinylcholine as indicated. This is standard of care for this procedure. Within 10 minutes of induction, patients in the control group will be administered a 100mL bolus of normal saline as placebo.
62615580|NCT05639686|EXPERIMENTAL|Transexemic Acid (TXA) and Inhalational Anesthesia|Patients will be induced with fentanyl 1-2µg/kg, propofol 2mg/kg, lidocaine 1mg/kg. After orotracheal intubation, anesthesia will be maintained with isoflurane 1.5-2% or sevoflurane 1-2%, as well as rocuronium or succinylcholine as indicated. Again standard of care procedure is applied. Within 10 minutes of induction, patients in the study group will be administered 15mg/kg TXA suspended in 100mL of normal saline intravenously.
62615581|NCT05528484|EXPERIMENTAL|ERAS group|the patients accepting eras nursing protocol ;
62615582|NCT05528484|ACTIVE_COMPARATOR|non-eras group|the patients not accepting eras nursing protocol ;
62615583|NCT05876559|EXPERIMENTAL|active intervention group|Participants will receive immediate access to Joyuus selfcare mobile app
62615584|NCT05876559|ACTIVE_COMPARATOR|standard care control group|Participants will receive standard care, and will not have access to Joyuus selfcare mobile app until study completion.
62615585|NCT05544903||Mortality, ICU admission, or rapid response team activation|Carotid flow patterns and velocity time integral values, as determined by FloPatch.
62258590|NCT03127384|EXPERIMENTAL|Treatment|Intradermal injection Restylane Lidocaine
62258591|NCT03788720|EXPERIMENTAL|Suture|Women undergoing suturing of the ovarian cortex after laparoscopic enucleation of endometriomas.
62258592|NCT03788720|SHAM_COMPARATOR|No suture|Women undergoing laparoscopic enucleation of endometriomas without subsequent suture of the ovarian cortex.
62258593|NCT03000907|EXPERIMENTAL|Intervention|"* diet: assessment of nutritional status and nutritional requirements and establishment of personalized nutritional plan with monthly dietetic controls.~* physical exercise: a multi-component physical exercise program that will include aerobic exercise and strengthening, balance and flexibility exercises as well as a weekly group session of health education, during six months."
62258594|NCT03000907|NO_INTERVENTION|Control|Clinical practise
62615586|NCT05544903||No mortality, ICU admission, or rapid response team activation|Carotid flow patterns and velocity time integral values, as determined by FloPatch.
62615587|NCT02175342|EXPERIMENTAL|Tiotropium-1.25 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 0.625 mcg/puff
62615588|NCT02175342|EXPERIMENTAL|Tiotropium-2.5 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 1.25 mcg/puff
62615589|NCT02175342|EXPERIMENTAL|Tiotropium-5 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 2.5 mcg/puff
62615590|NCT02175342|EXPERIMENTAL|Tiotropium-10 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 5 mcg/puff
62258595|NCT01422915|EXPERIMENTAL|colestipol treatment|2 grams morning and bedtime for 180 days
62258596|NCT02613650|EXPERIMENTAL|MEK162 and mFOLFIRI, all patients|
62258597|NCT03588351|ACTIVE_COMPARATOR|chlorhexidine gluconate|GROUP I: - 15 teeth will be treated with specially prepared gel containing chlorhexidine gluconate as intracanal medicament .
62615591|NCT02175342|EXPERIMENTAL|Tiotropium-20 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 10 mcg/puff
62615592|NCT02175342|PLACEBO_COMPARATOR|Placebo Respimat|
62615593|NCT02175342|ACTIVE_COMPARATOR|Tiotropium-18 lactose powder Handihaler|
62615594|NCT02175342|PLACEBO_COMPARATOR|Placebo lactose powder Handihaler|
62615595|NCT02256306|EXPERIMENTAL|Young Donor Plasma|Subjects will receive 1 unit of plasma, once weekly for 4 weeks.
62615596|NCT01107873||duplex ultrasonography|conduct duplex ultrasonography after caudal block with sevoflurane anaesthesia in children
62840565|NCT05417919|NO_INTERVENTION|Control|Initiatives for the Control Group Personal Information Form and İSKEBE scale were given to 45 students who were determined in accordance with the research criteria and they were asked to fill in. Data were collected by phone calls or the next day with students who did not come to school that day. 6 weeks after the pre-test application, the students were asked to fill in the İSKEBE scale as a post-test. Three months after the post-test application, they were asked to fill out the İSKEBE scale again as a follow-up test. At the end of the follow-up test, 45 minutes of violence against women training was given to the control group students.
62840566|NCT02897856|ACTIVE_COMPARATOR|Buccal midazolam|Study subject will receive buccal midazolam and intramuscular placebo. The dose of buccal midazolam is 0.3 mg/kg
62840567|NCT02897856|ACTIVE_COMPARATOR|intramuscular midazolam|Study subject will receive intramuscular midazolam and buccal placebo. The dose of intramuscular midazolam is 0.25 mg/kg.
62258598|NCT03588351|EXPERIMENTAL|chitosan nanoparticles gel|GROUP II: - 15 teeth will be treated with specially prepared gel containing chitosan nanoparticles that ready to use as intracanal medicament.
62258599|NCT03588351|EXPERIMENTAL|chitosan gel|Group III: 15teeth will be treated with specially prepared gell containing chitosan that ready to use as intra medicament .
62615597|NCT01636947|EXPERIMENTAL|Aprepitant Regimen|Participants receive one aprepitant 125 mg capsule by mouth (PO) once daily (QD) on Day 1 and one aprepitant 80 mg capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg intravenously (IV) QD and dexamethasone 12 mg PO on Day 1 and placebo for ondansetron 8 mg PO twice daily (BID) on Days 2 and 3.
62258600|NCT04267341||Mild Stage Parkinson's Disease Patients|Modified Hoehn and Yahr stage 1-2
62258601|NCT04267341||Moderate Stage Parkinson's Disease Patients|Modified Hoehn and Yahr stage 2.5-3
62258602|NCT04267341||Healthy Control|Healthy People
62258603|NCT01160757|OTHER|ultrasound|
62258604|NCT05442255||Chemical Submission|Patients with a suspected chemical submission
62258605|NCT06441942||Case|Female patient presenting with ACS (age \>/= 18)
62258606|NCT02595164||Impulsive subjects|Subjects exhibiting impulsive symptoms Behavioral Task
62615598|NCT01636947|ACTIVE_COMPARATOR|Control Regimen|Participants receive one placebo capsule PO QD on Day 1 and one placebo capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg IV QD and dexamethasone 20 mg PO on Day 1 and ondansetron 8 mg PO BID on Days 2 and 3.
62615599|NCT05603156|EXPERIMENTAL|treatment arm|patients enrolled treated with the combination of Olverembatinib and Inotuzumab to clear the persistent MRD.
62840568|NCT04591353|EXPERIMENTAL|"Investigational group (PENG Block group)"|Participants in the pericapsular nerve group block (PENG) arm will receive a PENG block preoperatively in the block area placed under direct ultrasound guidance as follows: Parenteral midazolam and fentanyl will be titrated to patient comfort. Standard skin sterilization, prepping and draping will be applied to the area Anatomical landmarks identified using ultrasound and skin will be numbed using 2-3 cc of 2% lidocaine. Long acting local anesthetic, a bolus of 25 cc of 0.5 % Bupivacaine will be injected lateral to iliopubic eminence (IPE). A Curvilinear low frequency (2-5 MHz) ultrasound probe will be used to identify landmarks. A 22 G, 10 cm needle will be inserted using in-plane technique and advanced to target site (17).
62840569|NCT04591353|ACTIVE_COMPARATOR|Control group|"Control group participants will be transferred to the block area preoperatively, and care will proceed as if they were receiving injection.~Patients will be placed in the supine position resting comfortably. Standard noninvasive monitors will be applied, and oxygen will be administered via nasal cannula. Parenteral midazolam and fentanyl will be titrated to patient comfort. Standard skin sterilization, prepping and draping will be applied to the area. The ultrasound probe will be used to identify the iliopubic eminence (IPE). Only skin will be numbed using 2-3 cc of 2% lidocaine and NO bolus of bupivacaine will be injected."
62840570|NCT02991872|OTHER|V49_24E1 Group|Up to 225 subjects, who completed the full PEP rabies regimens in the parent study V49_24 (NCT01680016), will be invited to participate to this extension study.
62055966|NCT03406819|EXPERIMENTAL|Tirofiban group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Tirofiban Hydrochloride via guide-catheter was performed.
62258607|NCT02595164||Non-impulsive subjects|Subjects which do not exhibit impulsive symptoms Behavioral Task
62444934|NCT02752776|EXPERIMENTAL|Secukinumab|All patients are received s.c. injections of secukinumab 300 mg at Week 0, 1, 2 and 3 during the first 4 weeks followed by monthly maintenance dosing of 300 mg secukinumab starting at Week 4 until Week 48. Consideration was given to discontinuing treatment in patients who showed no response up to 16 weeks of treatment (e.g. patients who did not achieve a PASI 50 response). If discontinued, patients completed the end of study visit assessments. Some patients with an initially partial response (e.g. patients who achieved a PASI 50 response but not a PASI 75 response) subsequently improved with continued treatment beyond 16 weeks.
62444935|NCT00329602|PLACEBO_COMPARATOR|Double-blind for 12 to 26 Weeks|Double-blind (Ropinirole:Placebo) for 12 to 26 weeks
62444936|NCT00329602|OTHER|Open-label ropinirole for 40-Weeks|Open label ropinirole for 40 weeks
62444937|NCT01499121|OTHER|Sunitinib|Starting dose/schedule of Sunitinib 50 mg/28 days on, 14 days off. The intent is to maximize dose intensity of Sunitinib and minimize time off therapy based on individual tolerability using dose modification criteria.
62444938|NCT02022813|NO_INTERVENTION|Enteral nutrition only|Enteral nutrition to be progressed as soon as possible to energy target measured on day 3, and verified on day 4, using the usual facilitators (prokinetics)
62444939|NCT02022813|EXPERIMENTAL|Supplemental parenteral nutrition|"Addition of supplemental parenteral nutrition to complete the gap between energy delivered by enteral feeding and energy target measured on day 4.~Aim: 100% of this target, and not exceeding it, no catch up for energy deficit accumulated before day 4."
62444940|NCT06541366||case|The case group consisted of patients who were diagnosed in the Neonatal Intensive Care Unit (39 children), and who applied to the Physiotherapy and Rehabilitation Department from the centers outside for physiotherapy needs (9 children).
62444941|NCT06541366||Control|the children who were at the same age group between the same dates, did not have any diseases related to the neuromuscular system, and hospitalized for any other reason.
62444942|NCT03777475|EXPERIMENTAL|low dose|low oxaliplatin (85mg/m2)
62444943|NCT03777475|ACTIVE_COMPARATOR|high dose|high oxaliplatin (135mg/m2)
62444944|NCT03942510|EXPERIMENTAL|High intensity eccentric training|high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
62444945|NCT03942510|EXPERIMENTAL|High intensity eccentric training with blood flow restriction|high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) will be performed during 6 weeks, 3 times a week.
62444946|NCT03942510|EXPERIMENTAL|Low intensity eccentric training|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
62444947|NCT03942510|EXPERIMENTAL|Low intensity eccentric training with blood flow restriction|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure)will be performed during 6 weeks, 3 times a week.
62444948|NCT00409994|EXPERIMENTAL|Rapamycine|rapamycine 6 mg dd
62444949|NCT03662919||Flixabi|Infliximab naive participants or participants who were previously treated with other infliximab biologics will receive Flixabi (infliximab) as prescribed by physician according to the local prescribing procedures.
62615600|NCT01985958|EXPERIMENTAL|Single arm|In this trial, we will deliver low-dose (8Gy in a single fraction) radiotherapy (SBRT or any other acceptable delivery method as determined by the treating physician) for palliation of symptoms in patients in whom it is clinically indicated. This dose is far lower than what has been used in the definitive settings described above. This is a safe dose, and is entirely consistent with the dose range used for routine palliation. Therefore, this trial does not involve an experimental intervention; the research aspect of this protocol is the evaluation of the immune response to clinically indicated palliative radiotherapy.
62615601|NCT05296200||Observacional group|Subjects must remain to the exposure of gravity (1G) after 4h of hyperbuoyancy floatation(spine unloading)
62615602|NCT00957424|OTHER|Overall|Single-armed study
62615603|NCT01781052||Group 1|
62615604|NCT04719130|EXPERIMENTAL|Experimental Group|Will received multimodal circuit exercise group.
62615605|NCT04719130|ACTIVE_COMPARATOR|Control Group|Will received multidisciplinary lectures on pain and usual care provided by the Basic Health Units.
62615606|NCT02577926|EXPERIMENTAL|Ruxolitinib|Ruxolitinib will be administered orally at a dose of 10 mg twice daily (both PV and ET) for two consecutive years.
62258608|NCT04227314|EXPERIMENTAL|Apremilast|apremilast: 30 mg twice daily during a 12 week double blind placebo controlled period, then 30 mg twice daily during an additional 12 week active treatment period
62258609|NCT04227314|PLACEBO_COMPARATOR|Placebo|Placebo: 30 mg twice daily during the initial 12 week double blind placebo controlled period
62615607|NCT02577926|ACTIVE_COMPARATOR|Best available therapy (BAT)|BAT may include all currently used treatment options. BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc). BAT will be administrated for two consecutive years.
62615608|NCT05072587|ACTIVE_COMPARATOR|Group A - Standard ADA dietary guidelines (SADA)|Participants in this group will be given prepared meals based on standard ADA dietary guidelines for 12 weeks.
62615609|NCT05072587|EXPERIMENTAL|Group B - Plant Based ADA diet with no oxysterols (PB-ADAØ).|Participants in this group will be given prepared meals based on ADA guidelines but with no dietary cholesterol oxides/oxysterols - Plant-based ADA diet
62615610|NCT03035916|EXPERIMENTAL|Transversus abdominis plane block|The TAP group receives ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia.
62615611|NCT03035916|ACTIVE_COMPARATOR|Epidural anesthesia|The Epidural group receives epidural block (T8-9) 2 mL of 1.6% lidocaine as a test dose and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
62615612|NCT03035916|PLACEBO_COMPARATOR|Control|The Control group receives standard IV-inhaled general anesthesia.
62615613|NCT04286334|ACTIVE_COMPARATOR|Group A - control Group|Customized titanium mesh without collagen membrane 15 patients will undergo bone regeneration with custom-made mesh without a collagen membrane. (Meshes - 3D-mesh BTK, Biotec, Vicenza, Italy.) Digitally designed by an operator before the surgery (digital technique).
62615614|NCT04286334|EXPERIMENTAL|Group B - Test Group|Customized titanium mesh with collagen membrane 15 patients will undergo bone regeneration with a custom-made titanium mesh (BTK, Biotec- Vicenza, Italy). Digitally designed by an operator before the surgery (digital technique), covered by collagen membrane (Cytoplast RTM, Osteogenics, deore materials, Verona, Italy).
62615615|NCT06304402|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation Stretching|Proprioceptive Neuromuscular Facilitation Stretching Group participants will undergo one session of PNF posterior shoulder stretching exercise in the modified sleeper position.
62615616|NCT06304402|EXPERIMENTAL|The Percussive Massage Treatment|The Percussive Massage Treatment Group participants will receive a 5-minute massage on the posterior deltoid area.
62615617|NCT04950517||Wave 1 participants|The study consists of three work packages. Wave 1 participants will be included in all work packages.
62615618|NCT04950517||Wave 2 participants|The study consists of three work packages. Wave 2 participants will only be recruited for work package 2.
62055967|NCT03406819|PLACEBO_COMPARATOR|Control group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of heparinized saline via guide-catheter was performed.
62615619|NCT05475626||Treatment Of Symptomatic Pes Planus By Sinus Tarsi Screw|Treatment Of Symptomatic Pes Planus
62615620|NCT02811653|EXPERIMENTAL|Alzheimer disease|Alzheimer disease patients Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation
62615621|NCT02811653|ACTIVE_COMPARATOR|control|"Healthy age- and gender-matched volunteers will be recruited into the study from the general population.~Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation"
62615622|NCT04315844|EXPERIMENTAL|balloon|To evaluate the efficacy and security of Ewata combined with a stent device in the treatment of acute ischemic stroke within 8 hours To prove whether the clinical efficacy and safety of Ewata r is not inferior to other guidings.
62840571|NCT05751603|NO_INTERVENTION|Control group|Routine anesthetic process; sugammadex is administered when spontaneous respiration is returned (before extubation)
62055968|NCT00886639|OTHER|First of 2 6-minute-walking test with oxygen|Continuous flow of 2 liters per minute First with oxygen, second with medical air
62258610|NCT02913690|PLACEBO_COMPARATOR|Control group|Control group will be supplemented with placebo for 12 months.
62258611|NCT02913690|ACTIVE_COMPARATOR|Intervention group|The intervention arm will be supplemented with TRF for 12 months.
62258612|NCT03998111|EXPERIMENTAL|Trial|Participants will undergo one trial visit where they will ingest an oral glucose load diluted in solution (oral glucose tolerance test) and blood samples will be measured over the following 2-hours. The buffy coat layer from the baseline sample will be obtained to extract DNA.
62444950|NCT03662919||Imraldi|Adalimumab naive participants or participants who were previously treated with other adalimumab biosimilars will receive Imraldi (adalimumab) as prescribed by physician according to the local prescribing procedures.
62615623|NCT00575263||Normal Teeth|Normal molar teeth
62615624|NCT00575263||painful teeth|Painful molar teeth
62615625|NCT02053259|EXPERIMENTAL|Adaptive Goals with Immediate Reinforcement|Adaptive Physical Activity Goals, Immediate Financial Reinforcement
62615626|NCT02053259|EXPERIMENTAL|Adaptive Goals with Delayed Reinforcement|Adaptive Physical Activity Goals, Delayed Financial Reinforcement
62840572|NCT05751603|EXPERIMENTAL|Experimental group|sugammadex is administered just after extubation.
62615627|NCT02053259|EXPERIMENTAL|Static Goals with Immediate Reinforcement|Static Physical Activity Goals, Immediate Financial Reinforcement
62615628|NCT02053259|ACTIVE_COMPARATOR|Static Goals with Delayed Reinforcement|Static Physical Activity Goals, Delayed Financial Reinforcement
62615629|NCT04092088|ACTIVE_COMPARATOR|tDCS-r+TENS-r|Real transcranial direct current stimulation (tDCS-r) + real transcutaneous electrical nerve stimulation (TENS-r)
62615630|NCT04092088|EXPERIMENTAL|tDCS-r+TENS-s|Real transcranial direct current stimulation (tDCS-r) + sham transcutaneous electrical nerve stimulation (TENS-s)
62615631|NCT04092088|EXPERIMENTAL|tDCS-s+TENS-r|Sham transcranial direct current stimulation (tDCS-s) + real transcutaneous electrical nerve stimulation (TENS-r)
62615632|NCT04092088|SHAM_COMPARATOR|tDCS-s+TENS-s|Sham transcranial direct current stimulation (tDCS-s) + sham transcutaneous electrical nerve stimulation (TENS-s)
62615633|NCT05022420||Salivary gland biospy,|100 Salivary gland biospy use for the diagnosis of sjogern disease or other auto-immune disease.
62615634|NCT05022420||muscular biopsy,|muscular biospy use for the diagnosis of muscular auto-immune disease.
62615635|NCT05022420||neuro muscular biospy|neuro muscular biospy use for the diagnosis of vasculitis,muscular auto-immune disease or neuro-muscumar auto-immune disease
62615636|NCT05022420||temporal arteries biospy|temporal arteries biospy uses for the diagnosis of giant cell arteritis
62615637|NCT04093492|EXPERIMENTAL|Preemie Prep for Parents (P3) Outpatient Mobile Intervention|The P3 mobile intervention in its current form sends participants text messages according to a schedule based on their gestational age. These text messages contain links to short videos uploaded to the P3 site, focusing on topics related to preterm labor and premature infants.
62615638|NCT04093492|ACTIVE_COMPARATOR|ACOG links|Participants in the active control condition will receive links to patient education handouts about preterm birth provided by the American College of Obstetricians and Gynecologists.
62444951|NCT02363582|NO_INTERVENTION|Breast fed|healthy term infants on exclusively breast feeding , enrollment age: 30-50days old
62615639|NCT01290497|ACTIVE_COMPARATOR|Hyaluronic acid 5 x 2.5 ml|
62055969|NCT00886639|OTHER|First of 2 6-minute-walking tests with medical air|Medical air is compressed room air. First test with medical air, second with oxygen
62258613|NCT03574870|EXPERIMENTAL|Chemoraditherapy|"Patients with head and neck cancer require chemo and radiation therapy (Cohort A):~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from the time of their radiation simulation through one week following the end of radiation treatment"
62258614|NCT03574870|EXPERIMENTAL|Primary surgery w/o radiotherapy|"Patients with head and neck cancer require primary surgery alone (Cohort B-SA)~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from one week before surgery through 1 month following surgery~Patients with head and neck cancer require primary surgery and postoperative radiotherapy (Cohort B-RT)~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from one week before surgery to one week following the end of radiation treatment ."
62258615|NCT04784728|EXPERIMENTAL|Lidocaine topical system with swimming (Treatment A)|One topical system is applied to the mid- to upper-back for 12 hours. Subjects swim for 15 minutes in a heated pool 4 hours after topical system application.
62444952|NCT02363582|EXPERIMENTAL|Formula fed|healthy term infants on exclusively formula fed , enrollment age: 30-50days old
62444953|NCT01901055|EXPERIMENTAL|Active CPAP treatment|Treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP)
62444954|NCT01901055|PLACEBO_COMPARATOR|Sham-CPAP|Device that appears like the treatment of obstructive sleep apnea, a continuous positive airway pressure device, but that does not provide treatment.
62444955|NCT03622502|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
62615640|NCT01290497|EXPERIMENTAL|Hyaluronic acid 1 X 5 ml|
62615641|NCT01290497|EXPERIMENTAL|Hyaluronic acid 2 x 5 ml|
62615642|NCT00553358|EXPERIMENTAL|Arm 1 Lapatinib|1500 mg lapatinib for 6 weeks followed by lapatinib plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib.
62615643|NCT00553358|ACTIVE_COMPARATOR|Arm 2 Trastuzumab|4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks followed by 2 mg/kg trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
62615644|NCT00553358|EXPERIMENTAL|Arm 3 Lapatinib plus Trastuzumab|1000 mg lapatinib plus 4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks, followed by 750 mg lapatinib plus 2 mg/kg IV weekly trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib (1000 mg) in combination with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
62615645|NCT00570180|EXPERIMENTAL|Single Arm|Please see intervention description for Bortezomib (Velcade)
62840573|NCT02470650|EXPERIMENTAL|elvitegravir/cobicistat/emtricitabine/tenofovir|EVG / COBI / FTC / TDF (Stribild®) 150 elvitegravir, 150 cobicistat, 200 emtricitabine, 245 tenofovir disoproxil. 1 recovered tablet once a day (on a day)
62840574|NCT02470650|ACTIVE_COMPARATOR|darunavir+ritonavir+lamivudine|Darunavir 800 mg (Prezista®) 1 recovered tablet once a day Ritonavir 100 mg(Norvir® ) 1recovered tablet once a day lamivudine300 mg (Epivir®) 1 recovered tablet once a day
62615646|NCT00741585|ACTIVE_COMPARATOR|1|Treatment with all prescribed hypertension medications on awakening
62615647|NCT00741585|ACTIVE_COMPARATOR|2|Treatment with at least one prescribed hypertension medication at bedtime
62615648|NCT01456364|ACTIVE_COMPARATOR|Ticagrelor|A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily
62840575|NCT02470650|ACTIVE_COMPARATOR|abacavir/lamivudine+rilpivirine|Abacavir 600 mg +lamivudine 300mg (Kivexa®) 1tablet once a day rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
62840576|NCT00534482|EXPERIMENTAL|A, 1, I|Practice-level treatment group
62840577|NCT00534482|ACTIVE_COMPARATOR|A, 1, II|Practice-level comparison group
62840578|NCT00534482|EXPERIMENTAL|B, 1, I|Patient-level treatment group
62840579|NCT00534482|ACTIVE_COMPARATOR|B, 1, II|Patient-level comparison group
62840580|NCT01940796|EXPERIMENTAL|Brentuximab Vedotin|The dose of brentuximab Vedotin will be based on the cohort the participant is enrolled on. Dosing will be based on the participant's weight prior to each dose. Actual weight will be used except for participants weighing \> 100 kg. The dose for participants weighing \> 100 Kg will be calculated based on a weight of 100 kg. The dose should be rounded to the nearest whole number of milligrams. Brentuximab vedotin will be administered over approximately 30 minutes IV.Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
62840581|NCT01469715|EXPERIMENTAL|GBP-CGM|All participants will wear one active GBP-CGM and one inactive GBP-CGM
62055970|NCT03147235|EXPERIMENTAL|vitrectomy with music listening|Patients undergoing vitrectomy surgery will listen to a designed playlist of music during the entire duration of surgery
62055971|NCT03147235|NO_INTERVENTION|vitrectomy without music listening|Patients undergoing vitrectomy surgery will not be exposed to music listening.
62055972|NCT02098187|ACTIVE_COMPARATOR|Below target dose MP-3180|0.5 µmol/kg (0.186 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
62055973|NCT02098187|ACTIVE_COMPARATOR|2 times above target dose MP-3180|2 µmol/kg (0.744 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
62055974|NCT02098187|ACTIVE_COMPARATOR|4 times above target dose MP-3180|4 µmol/kg (1.488 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
62444956|NCT03622502|ACTIVE_COMPARATOR|Remifentanil|Normal saline was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
62840582|NCT00241839|ACTIVE_COMPARATOR|A|Chlorthalidone 25 mg and Potassium Chloride 40-50meq were given daily for 5 weeks before baseline visit for testing. After baseline testing was completed, Allopurinol 300mg daily was added for 8-10 weeks at which time testing was repeated.
62840583|NCT00241839|PLACEBO_COMPARATOR|B|Chlorthalidone 25 mg and Potassium Chloride 40-50meq were given daily for 5 weeks before baseline visit for testing. After baseline testing was completed, a Placebo,matched in appearance to Allopurinol, was added daily for 8-10 weeks, at which time testing was repeated.
62840584|NCT01033448|EXPERIMENTAL|Single arm|
62840585|NCT02127697|EXPERIMENTAL|NVA237|Participants will receive NVA237 once daily in addition to their background therapy during the 52- week treatment period. All participants will receive salbutamol/ albuterol as rescue medication.
62840586|NCT02127697|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo to NVA237 in addition to their background therapy during the 52-week treatment period. All participants will receive salbutamol/ albuterol as rescue medication.
62840587|NCT01538758|ACTIVE_COMPARATOR|Us guided needling|"Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.~After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance."
62055975|NCT02098187|ACTIVE_COMPARATOR|At target dose MP-3180|1 µmol/kg (0.186 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
62258616|NCT04784728|EXPERIMENTAL|Lidocaine topical system with showering (Treatment B)|One topical system is applied to the mid- to upper-back for 12 hours. Subjects take a 10-minute shower 8 hours after topical system application.
62444957|NCT04217226||study group|adult patients (18-59 years), ASA I-II-III, scheduled for elective surgeries under general anaesthesia.
62840588|NCT01538758|ACTIVE_COMPARATOR|corticosteroid injection|Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
62444958|NCT03238950|OTHER|Porcine Group|Training conducted on Porcine model
62444959|NCT03238950|OTHER|Synthetic|Training conducted on synthetic model
62444960|NCT02353000|EXPERIMENTAL|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases:
62444961|NCT02353000|OTHER|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases:
62444962|NCT05015556|NO_INTERVENTION|Casting|Casting of the distal radius for 6 weeks
62444963|NCT05015556|ACTIVE_COMPARATOR|Minimal invasive volar plating|Muscle sparing osteosynthesis, no casting postoperatively
62444964|NCT03604887||study group|All pregnant women who will attend the labor unit during the study period will be invited to participate in the study.
62444965|NCT03277781||Current smokers|
62444966|NCT03277781||Ex-smokers|
62444967|NCT03277781||Coronary heart disease|
62444968|NCT01665053|ACTIVE_COMPARATOR|Promus Element Plus|PROMUS Element Plus is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
62444969|NCT01665053|EXPERIMENTAL|SYNERGY|SYNERGY is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).
62840589|NCT00675610|NO_INTERVENTION|usual care|providers are not trained and patients are not coached
62840590|NCT00675610|EXPERIMENTAL|intervention arm|providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
62615649|NCT01456364|ACTIVE_COMPARATOR|Prasugrel|A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients \< 75 years or a 5 mg maintenance dose per day for patients \>= 75 years
62258617|NCT04784728|EXPERIMENTAL|Lidocaine topical system under normal conditions (Treatment C)|One topical system is applied to the mid- to upper-back for 12 hours. Topical systems are not exposed to water during this period.
62615650|NCT02300142|EXPERIMENTAL|GEN-003 Vaccine 30μg / Matrix-M 25μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
62615651|NCT02300142|EXPERIMENTAL|GEN-003 Vaccine 30μg / Matrix-M2 50μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
62615652|NCT02300142|EXPERIMENTAL|GEN-003 Vaccine 30μg / Matrix-M2 75μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
62615653|NCT02300142|EXPERIMENTAL|GEN-003 Vaccine 60μg / Matrix-M2 25μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
62615654|NCT02300142|EXPERIMENTAL|GEN-003 Vaccine 60μg / Matrix-M2 50μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
62615655|NCT02300142|EXPERIMENTAL|GEN-003 Vaccine 60μg / Matrix-M2 75μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
62615656|NCT02540967||BAY86-4875|Gadovist administration goup
62615657|NCT03601741|ACTIVE_COMPARATOR|Antimicrobial Stethoscope Diaphragm Covers|
62615658|NCT03601741|ACTIVE_COMPARATOR|Uncovered Stethoscopes|
62615659|NCT02178527|EXPERIMENTAL|Mulitfaceted podiatry Intervention|Foot and ankle exercises, foot orthoses, footwear provision
62840591|NCT03860493||Study group|Only patients who might benefit from intraoperative fluorescent tissue perfusion assessment according to the primary surgeon will be enrolled in the study. The patients will be screened and consent during their office visit with their surgeon at the Cleveland Clinic Foundation. Each surgeon will follow the standard Open surgical protocol of his/her subspecialty, and will comply with the following additional steps according to the type of surgery:
62840592|NCT05675969|EXPERIMENTAL|Pre-eclamptic women|The intervention consists of the collection of 2 additional tubes of 4.5mL of citrate blood. The sample will be collected as close as possible to the diagnosis of pre-eclampsia during a routine care assessment
62258618|NCT02582320||Study patients|Patients with Relapsed or refractory CLL or 17p deleted CLL fulfilling the eligibility criteria required by the Named Patient Program (NPP) who received at least 1 dose of Ibrutinib 420 mg daily before November, 30th 2014.
62258619|NCT01145690||Internet-based CBT|All participants in this cohort received Internet-based CBT for social anxiety disorder in 2005. All participants were Swedish adults with a DSM-IV diagnosis of social anxiety disorder.
62840593|NCT05675969|ACTIVE_COMPARATOR|Non pre-eclamptic women|The intervention consists of the collection of 2 additional tubes of 4.5mL of citrate blood. sampling will be performed during routine care according to the matching.
62840594|NCT00558649|EXPERIMENTAL|1|Low dose flu vaccine delivered intradermally using microneedles
62840595|NCT00558649|EXPERIMENTAL|2|Medium dose flu vaccine delivered intradermally using microneedles
62258620|NCT01355484|EXPERIMENTAL|GTx-024|subject will receive GTx-024 treatment for the duration of the trial
62258621|NCT01355484|PLACEBO_COMPARATOR|Placebo|subject will receive placebo for the duration of the trial
62258622|NCT02116556|ACTIVE_COMPARATOR|Prednisone|Prednisone PO 40mg/day for 30 days plus standard supportive care measurements
62258623|NCT02116556|EXPERIMENTAL|Prednisone plus Rifaximin|Prednisone PO 40mg/day for 30 days plus Rifaximin PO 1200 mg/day for 90 days plus standard supportive care measurements
62258624|NCT05970341|EXPERIMENTAL|Arm 1: Intervention + usual care|"1. Welcome package~2. Welcome information: telephone call~3. Produce delivered at their choice of time and location + Recipes customized to produce~4. E-gift cards to a grocery store of choice~5. Personalized practical, emotional \& educational support through a dedicated health partner"
62258625|NCT05970341|OTHER|Arm 2: Educational materials + usual care|"1. Welcome package~2. Welcome information: SMS/Text"
62444970|NCT03377556|EXPERIMENTAL|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62840596|NCT00558649|ACTIVE_COMPARATOR|3|Standard dose flu vaccine delivered intramuscularly with a regular needle
62840597|NCT05829226|EXPERIMENTAL|Single agent dose escalation|LYT-200 in relapsed/refractory AML or relapsed/refractory high-risk MDS, administered via IV infusion over 60 minutes every week.
62444971|NCT02938494|EXPERIMENTAL|IDP-123 Lotion|Lotion
62444972|NCT02938494|ACTIVE_COMPARATOR|Tazorac Cream|Cream
62444973|NCT02938494|ACTIVE_COMPARATOR|Vehicle Lotion|Lotion
62444974|NCT02938494|ACTIVE_COMPARATOR|Vehicle Cream|Cream
62444975|NCT01538342|OTHER|chronic plaque psoriasis|3 biopsies: 2 lesional and 1 non-lesional
62444976|NCT01538342|OTHER|pustular psoriasis|3 biopsies: 2 lesional and 1 non-lesional
62444977|NCT01538342|OTHER|erythrodermic psoriasis|3 biopsies: 2 lesional and 1 non-lesional
62444978|NCT01538342|OTHER|atopic dermatitis|2 biopsies: 1 lesional and 1 non-lesional
62444979|NCT01538342|OTHER|healthy patients|1 biopsy of healthy skin.
62444980|NCT02465411|EXPERIMENTAL|Long-term CGM|Continuous glucose monitoring with DexCom G4 platina or later generations during 12 months following participation in the CGMMDI trial
62444981|NCT04240483|EXPERIMENTAL|Intracutaneous sterile water injections (ISWI) group|
62615660|NCT02178527|PLACEBO_COMPARATOR|Usual podiatry care|Continued provision of usual NHS (National Health Service) podiatry care
62615661|NCT05559944|EXPERIMENTAL|Expressive Writing|Participants will be asked to write about the biggest body image or eating-related stressor they have experienced as a member of the LGBTQ+ community. A general list of the types of stressors and contexts commonly described will be provided to participants, given that meta-analytic research supports that providing examples enhances the efficacy of expressive writing.
62840598|NCT05829226|EXPERIMENTAL|Combination agent dose escalation|LYT-200 in relapsed/refractory AML or relapsed/refractory high-risk MDS, administered via IV infusion over 60 minutes every week, in combination with oral venetoclax Day 1, 100 mg, Day 2, 200mg, Day 3-28, 400 mg and/or azacitidine, 75 mg/m2 subcutaneously given for 7 days per cycle or decitabine 20 mg/m2 IV for 5 days per cycle.
62840599|NCT01000792|EXPERIMENTAL|Levocetirizine|Levo 5 mg o.d.
62055976|NCT05120115|EXPERIMENTAL|Weight distribution and placement|Changing where weight is distributed on belt around pelvis, specifically, bilaterally, 4th lumbar area, unilaterally on the left side. Also changing amount of weight at 0, 4, 6 and 8 kg.
62055977|NCT04049747|EXPERIMENTAL|CHRONOS A - Arm 1 (Control)|Radical therapy (radiotherapy or prostatectomy \[radiotherapy can be external beam or brachytherapy\]). In patients undergoing radiotherapy a maximum of 6-months neo-adjuvant hormonal therapy will be allowed. In patients undergoing radical prostatectomy, cytoreduction of maximum 6 months with medication will be permissible, provided this is part of local practice.
62055978|NCT04049747|EXPERIMENTAL|CHRONOS A - Arm 2 (Intervention)|Focal therapy alone (high intensity focused ultrasound \[HIFU\] or cryotherapy as per physician and centre choice). A second focal therapy session in-field, or a first focal therapy session to an out-of-field progressive or de novo lesion will be allowed as part of the focal therapy intervention.
62055979|NCT04049747|EXPERIMENTAL|CHRONOS B - Arm 3 (Control)|Focal therapy alone (high intensity focused ultrasound \[HIFU\] or cryotherapy as per physician and centre choice). A second treatment in-field, or a first focal ablation to an out-of-field progressive or de novo lesion will be allowed but will be regarded as failure events for the purpose of CHRONOS-B.
62258626|NCT00550680|EXPERIMENTAL|Mircera in Renal Anemia|Participants with chronic renal anemia who have been previously treated with erythropoiesis-stimulating agent (ESA) therapy will receive IV Mircera every 4 weeks for a total of 24 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment. Subsequent doses will be adjusted to maintain Hb concentrations within target of 10.5 and 12.5 grams per deciliter (g/dL).
62444982|NCT04240483|SHAM_COMPARATOR|Intracutaneous dry injections (IDI) group|
62615662|NCT05559944|EXPERIMENTAL|Self-Affirmation|Participants will respond to one new vignette per day describing a SM young adult experiencing severe body image stress in Alabama. Participants will be asked to write to this person and provide advice based on their own experience as a SM young adult. Vignettes will be identical across participants; however, they will be matched to participants' sexual identity, gender identity, and race/ethnicity.
62615663|NCT05559944|PLACEBO_COMPARATOR|Control|Consistent with prior research participants will write about their routine daily activities since waking up for 20 minutes each day, sans emotional content.
62615664|NCT02407587|EXPERIMENTAL|unilateral cochlear implants|"Study Group~PET scans for the mature patients with unilateral cochlear implants and preserved hearing~4 states and each state will be repeated 3 times Cochlear implant only Residual hearing only Combination of implant and residual hearing No auditory stimulation"
62615665|NCT02407587|NO_INTERVENTION|Healthy volunteers|4 states and each state will be repeated 3 times Auditory stimulation Left ear only Auditory stimulation right ear only Binaural auditory stimulation Silence
62615666|NCT04757324|EXPERIMENTAL|education arm|Breastfeeding training was given to the training arm
62840600|NCT04690452|EXPERIMENTAL|Intervention condition|Intervention group that receive a standardized 8 weeks Compassion Cultivation Training from a faculty member certified CCT© instructor (https://www.compassioninstitute.com/about-us/teacher-directory/)
62840601|NCT04690452|OTHER|Waitlist control condition|"The participants assigned to the waitlist control will fill in the same questionnaires as the intervention group at the different time points (i.e., pre, post, 2-month and 6-month follow-ups).~Two months after finishing the intervention, will become participants of a CCT© program themselves given by the same faculty member certified CCT© teacher as for the experimental group."
62840602|NCT03071042|EXPERIMENTAL|Apatinib plus Docetaxel|Each subject will receive one dose of Apatinib in the whole cycle (21 days), during which single dose induced DLT and safety monitoring will be performed. If the initial dose is well tolerated, next cycle the subject will receive more Apatinib as respectively. This study will enroll in 4 cohorts of Apatinib; cohort 1 at the dose of 425mg Apatinib, which followed by cohort 2(500mg), cohort 3(675mg) and cohort 4(750mg).
62840603|NCT04822506|EXPERIMENTAL|Routine perioperative management and PEA|Routine perioperative management and perioperative electroacupuncture (preoperative, intraoperative, postoperative)；
62840604|NCT04822506|ACTIVE_COMPARATOR|Routine perioperative management and postEA|Routine perioperative management and postoperative electroacupuncture
62840605|NCT06290570||Hypertrophic Cardiomyopathy (HCM)|Subjects with clinically validated diagnoses of HCM will be enrolled and have a clinically indicated 12-Lead ECG obtained as well as ECG tracings collected using an Apple Smart Watch (single-lead) and AliveCor KardiaMobile (6-Lead).
62055980|NCT04049747|EXPERIMENTAL|CHRONOS B - Arm 4 (Intervention):|Neoadjuvant finasteride 5mg once daily for a minimum of 12 weeks followed by focal therapy (as per CHRONOS B control arm).
62055981|NCT04049747|EXPERIMENTAL|CHRONOS B - Arm 5 (Intervention)|Neoadjuvant bicalutamide 50mg once daily therapy for a minimum of 12 weeks followed by focal therapy (as per control arm).
62258627|NCT03861936|EXPERIMENTAL|BOTOX® 72U|OnabotulinumtoxinA (botulinum toxin Type A; BOTOX®) 72 units (U) total dose administered intramuscularly to the bilateral masseter muscles on Day 1.
62258628|NCT03861936|EXPERIMENTAL|BOTOX® 48U|OnabotulinumtoxinA (botulinum toxin Type A; BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1.
62840606|NCT06290570||Athlete's Heart|Subjects with clinically validated diagnoses of Athlete's Heart will be enrolled and have a clinically indicated 12-Lead ECG obtained as well as ECG tracings collected using an Apple Smart Watch (single-lead) and AliveCor KardiaMobile (6-Lead).
62055982|NCT00992953|EXPERIMENTAL|Virtual Reality Therapy|10 Weeks of Virtual Reality Exposure with Stimulus Control, with up to twice a week, 90 min sessions
62055983|NCT00992953|ACTIVE_COMPARATOR|Treatment As Usual|Traditional Therapy and Psychiatric Medication
62055984|NCT03152955|EXPERIMENTAL|Group A|Patients in Group A will receive scalp nerve block and patient-controlled analgesia which contains sufentanil and ondansetron.
62055985|NCT03152955|EXPERIMENTAL|Group B|In Group B, patient-controlled analgesia which contains sufentanil、ondansetron and ketamine will be applied.
62258629|NCT03861936|PLACEBO_COMPARATOR|Placebo|Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1.
62258630|NCT03117075|EXPERIMENTAL|Experimental|"using device for scoring pain scale, named ANAPA®"
62258631|NCT03410433|ACTIVE_COMPARATOR|Silk 4.0|Silk suture
62258632|NCT03410433|ACTIVE_COMPARATOR|PG910 4.0|Vicryl Rapid suture
62840607|NCT04919200||modeling group|Of these 628 individuals, we set 407 patients enrolled from January 2018 to November 2019 as the modeling group
62840608|NCT04919200||verification cohort|221 patients enrolled from December 2019-December 2020 served as a prospective verification cohort
62840609|NCT04670471|EXPERIMENTAL|Remimazolam + Remifentanil plasma concentration of 2.0 ng/mL|"Each participant will receive study medication on three different occasions:~Session 1: remimazolam alone Session 2: remimazolam plus remifentanil 0.5 ng/mL Session 3 : remimazolam plus reminfentanil 2.0 ng/mL During each session remimazolam will be dosed in a step-up / step-down manner while the remifentanil target concentration will be kept constant."
62840610|NCT04670471|EXPERIMENTAL|Remimazolam + Remifentanil plasma concentration of 4.0 ng/mL|"Each participant will receive study medication on three different occasions:~Session 1: remimazolam alone Session 2: remimazolam plus remifentanil 0.5 ng/mL Session 3 : remimazolam plus reminfentanil 4.0 ng/mL During each session remimazolam will be dosed in a step-up / step-down manner while the remifentanil target concentration will be kept constant."
62840611|NCT04670471|EXPERIMENTAL|Remimazolam + Remifentanil plasma concentration of 0.1 ng/mL|"Each participant will receive study medication on three different occasions:~Session 1: remimazolam alone Session 2: remimazolam plus remifentanil 0.5 ng/mL Session 3 : remimazolam plus reminfentanil 0.1 ng/mL During each session remimazolam will be dosed in a step-up / step-down manner while the remifentanil target concentration will be kept constant."
62840612|NCT04670471|EXPERIMENTAL|Remimazolam + Remifentanil plasma concentration of 1.0 ng/ml|"Each participant will receive study medication on three different occasions:~Session 1: remimazolam alone Session 2: remimazolam plus remifentanil 0.5 ng/mL Session 3 : remimazolam plus reminfentanil 1.0 ng/mL During each session remimazolam will be dosed in a step-up / step-down manner while the remifentanil target concentration will be kept constant."
62840613|NCT03956446|ACTIVE_COMPARATOR|Doxycycline, Doxy®|Beside symptomatic therapy, patients will receive oral doxycycline 100 mg (Doxy®) twice daily. Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
62258633|NCT03410433|EXPERIMENTAL|PP 4.0|Non-absorbable polypropylene monofilament
62258634|NCT03410433|ACTIVE_COMPARATOR|Silk 5.0|Silk suture
62258635|NCT03410433|ACTIVE_COMPARATOR|PG910 5.0|Vicryl suture
62258636|NCT03410433|EXPERIMENTAL|PP 5.0|Non-absorbable polypropylene monofilament
62258637|NCT03410433|EXPERIMENTAL|APG 5.0|Antibacterial Vicryl suture
62258638|NCT03410433|EXPERIMENTAL|ePTFE 5.0|expanded polytetrafluoroethylene
62258639|NCT04918030|ACTIVE_COMPARATOR|In-hospital staged PCI|Patients randomized to in-hospital staged PCI will have treated during the index procedure (7±3 days), after revascularization of the culprit lesion, all significant non-culprit coronary lesions.
62615667|NCT04757324|NO_INTERVENTION|control arm|Breastfeeding training not given to control arm
62615668|NCT04419766|EXPERIMENTAL|intervention|Community of Tambai: Indoors and outdoors spraying with IR3535 (3-(N-acetyl-N-butyl) aminopropionic acid ethyl ester)
62258640|NCT04918030|EXPERIMENTAL|Out-hospital staged PCI|Patients randomized to out-hospital staged complete revascularization will have treated during the index procedure only the culprit lesion, and they will be hospitalized in 30±15 days for complete revascularization of all significant non-culprit coronary lesions.
62840614|NCT03956446|OTHER|No antibiotics|Patients will receive symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
62055986|NCT03152955|SHAM_COMPARATOR|Group C|In Group C, patient-controlled analgesia which contains sufentanil and ondansetron will be applied.
62258641|NCT01449461|EXPERIMENTAL|Brigatinib 30 mg QD/60 mg QD|Brigatinib 30 mg/60 mg, tablets, orally, once daily (QD) in each cycle of 28 days (Approximately up to 7.3 years).
62258642|NCT01449461|EXPERIMENTAL|Brigatinib 90 mg QD|Brigatinib 90 mg, tablets, orally, QD in each cycle of 28 days (Approximately up to 7.3 years).
62258643|NCT01449461|EXPERIMENTAL|Brigatinib 120 mg QD/60 mg BID|Brigatinib 120 mg, once daily or 60 mg, twice daily (BID), tablets, orally, in each cycle of 28 days (Approximately up to 7.3 years).
62258644|NCT01449461|EXPERIMENTAL|Brigatinib 90 mg QD-180 mg QD|Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in cycle 2 and onward cycles of 28 days.
62444983|NCT01191021|OTHER|Propofol|Volunteers will receive propofol anesthesia on the study day.
62444984|NCT05566093|EXPERIMENTAL|Nonfunctional pancreatic neuroendocrine tumors|The patients with NF-pNETs will undergo EUS-guided ethanol or lauromacrogol ablation
62615669|NCT04419766|NO_INTERVENTION|Control|Community of Micheu 1: Without spraying.
62615670|NCT06229977|EXPERIMENTAL|PEA plus Treatment as Usual (TAU)|
62615671|NCT06229977|PLACEBO_COMPARATOR|Placebo plus Treatment as Usual (TAU)|
62615672|NCT00939406|NO_INTERVENTION|Control|Control group consists of subjects randomized to the control arm who will receive lumbar decompression surgery (laminotomy or laminectomy) alone
62615673|NCT00939406|EXPERIMENTAL|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
62615674|NCT02649426|EXPERIMENTAL|Ultrasound Renal Denervation|Subjects in the TRIO or SOLO cohorts that are randomized to treatment, will receive renal denervation following a renal angiogram
62615675|NCT02649426|SHAM_COMPARATOR|Sham Procedure|For subjects in TRIO or SOLO cohorts that randomize to the sham procedure, the diagnostic renal angiogram intervention will be considered the sham procedure.
62615676|NCT05040919||with an arrythmia|patient suffering from STEMI and presenting an arrythmia
62615677|NCT05040919||without an arrythmia|patient suffering from STEMI and not presenting an arrythmia
62258645|NCT01449461|EXPERIMENTAL|Brigatinib 180 mg QD/90 mg BID|Brigatinib 180 mg, once daily or 90 mg, BID, tablets, orally in each cycle of 28 days (Approximately up to 7.3 years).
62258646|NCT01449461|EXPERIMENTAL|Brigatinib 240 mg QD/120 mg BID/300 mg QD|Brigatinib 240 mg, QD or 120 mg, BID or 300 mg once daily, tablets, orally, in each cycle of 28 days (Approximately up to 7.3 years).
62258647|NCT02908256|EXPERIMENTAL|PVI group|Monitoring of the PVI during the surgical intervention
62258648|NCT02908256|ACTIVE_COMPARATOR|Delta PP group|Monitoring of the deltaPP during the surgical intervention
62258649|NCT03015675|EXPERIMENTAL|Ascorbic Acid with mFOLFOX6 group|"Ascorbic Acid with mFOLFOX6 Ascorbic Acid (20g/day, D1-3) every 2 weeks~mFOLOX6:~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
62258650|NCT03015675|ACTIVE_COMPARATOR|mFOLFOX6 group|"mFOLOX6:~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
62444985|NCT06187922|ACTIVE_COMPARATOR|Pregabalin group|this group of patient will receive cap pregabalin 75mg as premedication and will continue as twice daily dose for 72 hrs.
62444986|NCT06187922|SHAM_COMPARATOR|Control group|This group of patient will not receive cap pregabalin but it will receive standard medical care as routine
62615678|NCT04205487|EXPERIMENTAL|Contingency Management (CM) - Only|CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
62444987|NCT00639171||1|Subjects with suspicious breast lesions that warrant further evaluation will be followed to determination and confirmation of diagnosis.
62444988|NCT00639171||2|Normal subjects used to evaluate software and to develop and optimize MR sequences will be examined.
62258651|NCT02676089|EXPERIMENTAL|CHF 5993 200/6/12.5 µg|"Treatment A:~CHF 5993 200/6/12.5 µg: 2 inhalations bid Total daily dose: 800/24/50 µg BDP/FF/GB"
62258652|NCT02676089|ACTIVE_COMPARATOR|CHF 1535 200/6 µg|"Treatment B:~CHF 1535 200/6 µg: 2 inhalations bid Total daily dose: 800/24 µg BDP/FF"
62615679|NCT04205487|EXPERIMENTAL|Motivational Interviewing (MI) - Only|Two MI sessions focusing on stimulant use, sexual risk, and PrEP use will be delivered.
62615680|NCT04205487|EXPERIMENTAL|CM+MI|CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription. Participants who do not fill a PrEP prescription at 3 months will then receive 2 sessions of MI.
62840615|NCT03956446|OTHER|Healthy controls|Patients will be asked to refer a spouse to serve as a control. If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control. Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
62840616|NCT05895812|EXPERIMENTAL|Arm 1|Mild Renal Impairment
62258653|NCT02676089|ACTIVE_COMPARATOR|CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg|"Treatment C (open-label arm):~CHF 1535 200/6 µg: 2 inhalations bid~+ Tiotropium Respimat 2.5 µg: 2 inhalations od Total daily dose: 800/24 µg BDP/FF + 5 µg Tio"
62444989|NCT01842451|EXPERIMENTAL|VX-135 High Dose with Daclatasvir|12 weeks of a high dose of VX-135 in combination with Daclatasvir
62444990|NCT01842451|EXPERIMENTAL|VX-135 Low Dose with Daclatasvir|12 weeks of a low dose of VX-135 in combination with Daclatasvir
62444991|NCT00492089|EXPERIMENTAL|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62444992|NCT00492089|PLACEBO_COMPARATOR|Arm II|Patients receive placebo IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62444993|NCT04922502|ACTIVE_COMPARATOR|Standard SPACE|12 one hour parent sessions over 12 weeks in which the therapist guides the parent to target anxious behaviors and support adaptive child behaviors.
62444994|NCT04922502|ACTIVE_COMPARATOR|Bibliotherapy, low therapist contact SPACE|"4 one hour parent sessions over 12 weeks in which the therapist supports the parent in understanding and implementing content reviewed in the book Breaking Free of Child Anxiety and OCD."
62444995|NCT01396941|EXPERIMENTAL|sleep restriction|The investigators will compare the effects of sleep restriction vs. normal sleep in healthy volunteers, using a randomized crossover study design. Each subject will undergo a period of normal sleep and a period of sleep restriction, separated by a 1-month washout period. Subjects will be randomized to receive either sleep restriction first (later followed by normal sleep) or normal sleep first (later followed by sleep restriction).
62444996|NCT02205957||Training quality|Tunisian residents in anesthesiology and intensive care
62444997|NCT04211467||Depression|Patients who have been diagnosed with depression
62444998|NCT05065463|EXPERIMENTAL|Cohort 1|Participants with severe renal impairment will receive a single dose of AZD8233 on Day 1.
62444999|NCT05065463|EXPERIMENTAL|Cohort 2|Participants who are healthy will receive a single dose of AZD8233 on Day 1.
62445000|NCT05065463|EXPERIMENTAL|Cohort 3|Participants with ESRD on dialysis will receive a single dose of AZD8233 on Day 1.
62445001|NCT01460251|EXPERIMENTAL|Drug:Diapep277|1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
62615681|NCT04205487|EXPERIMENTAL|MI+CM|Two MI sessions focusing on stimulant use, sexual risk, and PrEP use will be delivered. Participants who do not fill a PrEP prescription at 3 months will receive CM financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
62840617|NCT05895812|EXPERIMENTAL|Arm 2|Moderate Renal Impairment
62840618|NCT05895812|EXPERIMENTAL|Arm 3|Healthy subjects
62840619|NCT05467969||Traditional teaching|A group of participants learned the skills on site
62840620|NCT05467969||Teleteaching|A group of participant who joined the workshop synchronously through the online multiscreen display teleconference platform
62615682|NCT01849718||CBT - Cognitive Behavioural Therapy|"40 participants will receive cognitive behavioural therapy in a clinical setting.~The duration of the individual sessions are one hour, and there are 1-2 sessions per. week, totaling 20 hours, incl. 4 hours of transition conversations.~The conversations will be exclusively CBT-based. Number of hours for conversational therapy: 20 hours of individual psychotherapy"
62258654|NCT05024370||Multiparas, planned cesarean section|Multiparas having a planned cesarean section at the departement of Obstetrics and Gynecology in Herning Hospital. Uncomplicated pregnancy that makes early discharge possible.
62258655|NCT06290349|EXPERIMENTAL|DA5221-T1 + DA5221-R2 + DA5221-B1 + DA5221-B2|
62258656|NCT06290349|EXPERIMENTAL|DA5221-R1 + DA5221-T2 + DA5221-B1 + DA5221-B2|
62615683|NCT01849718||Nacadia Therapy|"40 participants will receive garden therapy in a designed, natural environment.~The individual sessions last three hours with two sessions per week the first and last week and three sessions per week in week 2-9. This gives a total of 96 hours, including 4 x 3 hours transition conversation and 10 x ½ hour individual interviews.~Experiences and activities related to the garden environment are integrated with mindfulness exercises. The individual conversations in the Nacadia-therapy will be mindfulness-based CBT.~10 x ½ an hour of individual psychotherapy."
62615684|NCT04956341|EXPERIMENTAL|Standard treatment from PCM or Mental Health or both + auricular acupuncture|
62615685|NCT04956341|PLACEBO_COMPARATOR|Standard treatment from Primary Care Manager (PCM) or Mental Health or both|
62615686|NCT01702922||1/Active Cancer Parents|Must have been in a partnership at the time child was diagnosed with cancer \&amp; must have been diagnosed at least 3 months prior to enrollment on this study \&amp; be currently receiving treatment
62615687|NCT01702922||2/Complete Cancer Parents|Must have been in a partnership at the time the child was diagnosed with cancer and the child has completed treatment at age 21 or younger (without evidence of disease) within the previous 3 years
62615688|NCT01702922||3/NF1 Parents|Must have been in a partnership at the time the child was diagnosed with NF1 and the child must have been diagnosed with NF1 at least 3 months prior to enrollment on this study.
62615689|NCT01906281||Inflammatory knee osteoarthritis|One group of patients with inflammatory condition in physical evaluation. We will make a blood analyse and arthrocentesis when synovial fluid were found in ultrasound examination. Ultrasound of affected knee and carotid artery will be performed.
62840621|NCT02019797|EXPERIMENTAL|Desflurane|Desflurane inhalation at 1-2 MAC during surgery.
62840622|NCT02019797|ACTIVE_COMPARATOR|Propofol|5-8 mg/kg/hr infusion during surgery.
62840623|NCT01506804|EXPERIMENTAL|Training of painful shoulder|Steroid injection X 2 and 10 weeks exercise program of painful shoulder
62840624|NCT01506804|PLACEBO_COMPARATOR|Contralateral training|Steroid injection X 2 and 10 weeks exercise program of asymptomatic shoulder
62258657|NCT06290349|PLACEBO_COMPARATOR|DA5221-R1 + DA5221-R2 + DA5221-B1 + DA5221-B2|
62258658|NCT03478553||People with IPF|
62258659|NCT03478553||Family members without IPF|
62258660|NCT06385249|EXPERIMENTAL|All subjects|The subjects are children and adolescents with anal incontinence or bowel outlet problems and deemed suitable for and in need of low-volume TAI as assessed by the investigator.
62615690|NCT01906281||Non-inflammatory knee osteoarthritis|Patients with no inflammatory condition in physical examination. We will make a blood analyse and arthrocentesis when synovial fluid were found in ultrasound examination. Ultrasound of affected knee and carotid artery will be performed.
62258661|NCT02921191||Lung cancer|Lung cancer patients receiving their first cycle of Grade III and IV myelosuppressive chemotherapy regimen treated prophylactically with G-CSF.
62615691|NCT03129711|EXPERIMENTAL|glazed Celtra Duo|zirconia reinforced lithium silicate glass ceramic is infiltrated with 10% zirconia by weight, producing zirconia reinforced lithium silicate ceramic
62258662|NCT02921191||Breast cancer|Breast cancer patients receiving their first cycle of Grade III and IV myelosuppressive chemotherapy regimen treated prophylactically with G-CSF (filgrastim, TBO-filgrastim or pegfilgrastim)
62615692|NCT03129711|ACTIVE_COMPARATOR|Glazed IPS Empress CAD|glazed Leucite based glass ceramics ,Its a glass ceramic which is etchable and proved to have good esthetics if used for laminate veneers
62615693|NCT00430456|OTHER|Arm 1|Higher Intensity, Shorter Duration Treadmill Training
62840625|NCT02550834|EXPERIMENTAL|Experimental : Curling group|
62840626|NCT02550834|NO_INTERVENTION|Control : Usual care group|
62840627|NCT03016052|EXPERIMENTAL|ABMT|The attention bias modification treatment comprises of six computerized sessions, twice a week, in purpose of modulate biases in attention for threat stimuli.
62840628|NCT01576900||Desmopressin monotherapy|Control group: Desmopressin (Minirin Tablet 0.1-0.4mg/day) + simple instruction
62840629|NCT01576900||Combination group|"Study group: Desmopressin (Minirin Tablet 0.1-0.4mg/day) + SyBeMeP~\* Patients will be randomized and assigned to each group at the ratio of 1:1."
62840630|NCT03254589|EXPERIMENTAL|Group 1|Newly diagnosed RA patients started on subcutaneous MTX - open randomisation vs. sulfasalazine. In this group, use of NSAIDs, steroids, and/or other DMARDs, is allowed, if indicated, for symptom control. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice .
62840631|NCT03254589|ACTIVE_COMPARATOR|Group 2|Newly diagnosed RA patients started on sulfasalazine - open randomisation vs. subcutaneous MTX. In this group, use of NSAIDs, steroids, and/or other DMARDs (except MTX), is allowed, if indicated, for symptom control. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
62258663|NCT04461262|EXPERIMENTAL|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed. The device is CE marked
62258664|NCT04461262|OTHER|Standard Care|Foley catheter, uncoated
62258665|NCT05211336|EXPERIMENTAL|1: VIPOR|VIPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) in 21-day cycles for up to 6 cycles
62258666|NCT05449626||Alzheimer's disease group|
62258667|NCT05449626||Healthy Group|
62258668|NCT02767440|EXPERIMENTAL|Families on Track Intervention|This is a pre-post study. Enrolled parents will receive the Families on Track intervention plus usual care at the Healthy Lifestyles clinic at Duke University.
62258669|NCT01815047|EXPERIMENTAL|200 IU Vitamin D3|A singular daily dose of 200 IU vitamin D3
62258670|NCT01815047|EXPERIMENTAL|2000 IU Vitamin D3|A singular daily dose of 2000 IU vitamin D3
62258671|NCT05796102|EXPERIMENTAL|PET-MRI|PET-MRI in esophagogastric cancers
62258672|NCT03309085|EXPERIMENTAL|Single arm|Repeated CT scan
62258673|NCT04607070||Stroke patient|This is a registry-based study that will involve consecutive adult patients with known AF who developed ischaemic stroke or TIA in years 2010, 2012, 2014, 2016 and 2018.
62258674|NCT05914636||Ruptured|Patient with a ruptured intracranial sacciform aneurysm for all location. The diagnosis of ruptured aneurysm is made on MRI, Angio-CT or digital substraction angiography with no doubt
62258675|NCT05914636||unruptured|Patient with an unruptured intracranial sacciform aneurysm for all location. The diagnosis of unuptured aneurysm is made on MRI, Angio-CT or digital substraction angiography with no doubt
62258676|NCT05598593|EXPERIMENTAL|Modified TBF Conditioning Regimen|thiotepa 5mg/kg/d d-9 to d-8, cytarabine 0-4.0 g/m2/d d-7 to d-6(adjusted according to patients' age and HCT-CI index), fludarabine 30mg/m2/d d-7 to d-3, busulfan 3.2mg/m2/d d-5 to d-3
62258677|NCT06470113|ACTIVE_COMPARATOR|simultaneous cognitive training with active transcranial magnetic stimulation group|Patients were assigned into simultaneous cognitive training with active transcranial magnetic stimulation group according to random number table
62258678|NCT06470113|SHAM_COMPARATOR|simultaneous cognitive training with sham transcranial magnetic stimulation group|Patients were assigned into simultaneous cognitive training with sham transcranial magnetic stimulation group according to random number table
62258679|NCT00139776|ACTIVE_COMPARATOR|Celecoxib - Continuous use|
62615694|NCT00430456|ACTIVE_COMPARATOR|Arm 2|Lower Intensity, Longer Duration Treadmill Training
62615695|NCT01250353|EXPERIMENTAL|conjunctival autograft|The conjunctival autograft was performed after the pterygium surgery like usual technique.
62258680|NCT00139776|ACTIVE_COMPARATOR|Celecoxib - Intermittent use|
62258681|NCT03370536|EXPERIMENTAL|Patients with AF|Patients with AF and planned to undergo first catheter procedure
62258682|NCT05763797|EXPERIMENTAL|Aim 1 (individual interview)|Participants will be interviewed
62258683|NCT05763797|EXPERIMENTAL|Aim 2 (supportive care program)|Participants will be assigned to one of two groups
62258684|NCT05763797|EXPERIMENTAL|Aim 3 (supportive care program)|Participants will be assessed regarding their program participation
62258685|NCT03120221||First trimester pregnant women|
62055987|NCT06624319|ACTIVE_COMPARATOR|tap block with 0.5 μg/kg dexmedetomidine|will receive pre-emptive ultrasound-guided tap block with 0.5 μg/kg dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.
62055988|NCT06624319|ACTIVE_COMPARATOR|tap block with 1.5 μg/kg dexmedetomidine|will receive pre-emptive ultrasound-guided tap block with 1.5 μg/kg dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.
62615696|NCT01250353|EXPERIMENTAL|latex biomembrane application|The latex biomembrane was applied after pterygium surgery to recover the bare sclera area. This device was closed to conjunctiva with running suture anchored at some places to episclera. The sutures was removed at fourteenth day after surgery.
62615697|NCT05761704|EXPERIMENTAL|Dual antiplatelet|Aspirin 100 mg + clopidogrel 75 mg for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
62615698|NCT05761704|EXPERIMENTAL|Novel oral anticoagulant|Conventional dose NOAC for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
62840632|NCT03254589|EXPERIMENTAL|Group 3|RA patients on long-term treatment (\> 1 year) with oral MTX, with or without other DMARDs, NSAIDs and/or steroids, switched to subcutaneous MTX (same dose). In these patients, treatment with other DMARDs, NSAIDs and/or steroids will continue. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
62840633|NCT03254589|ACTIVE_COMPARATOR|Group 4|RA patients on stable treatment (\> 1 year) with other (non-MTX) DMARDs, with or without NSAIDs and/or steroids, and continued on the same treatment. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
62055989|NCT06457425|EXPERIMENTAL|low dose group|Flonoltinib 50mg
62055990|NCT06457425|EXPERIMENTAL|high dose group|Flonoltinib 100mg
62055991|NCT06457425|EXPERIMENTAL|control subjects|Ruxolitinib
62055992|NCT04969237||healthy subjects 2019|subjects with diseases not influencing vitamine D values without substitution nor post-COVID
62055993|NCT04969237||healthy subjects 2020|subjects with diseases not influencing vitamine D values without substitution nor post-COVID
62055994|NCT04969237||healthy subjects 2021|subjects with diseases not influencing vitamine D values without substitution nor post-COVID
62055995|NCT04969237||post-COVID subjects 2021|subjects with diseases not influencing vitamine D values without substitution with diagnosed post-COVID syndrome
62055996|NCT01330810|ACTIVE_COMPARATOR|C3 tablet|4g C3 tablet
62055997|NCT01330810|ACTIVE_COMPARATOR|Meriva|2g Meriva powder
62055998|NCT05203120|EXPERIMENTAL|Proton Arm|All patients in the study will receive proton therapy with 67.5 Gray/15 fractions(fx) /5fx per week .
62055999|NCT02207725|EXPERIMENTAL|Andexanet|Andexanet (antidote)
62056000|NCT02207725|PLACEBO_COMPARATOR|Placebo|Placebo
62056001|NCT04531566|EXPERIMENTAL|Oral Feed Intervention Group|
62056002|NCT04531566|ACTIVE_COMPARATOR|Usual care|
62056003|NCT05477732|PLACEBO_COMPARATOR|Placebo group|Subjects in placebo group will treat with placebo.
62056004|NCT05477732|EXPERIMENTAL|Supplement group|Subjects in supplement group will treat with Bifidobacterium longum OLP-01.
62056005|NCT02766621|PLACEBO_COMPARATOR|Placebo injection SC/IV|Placebo for injection SC/IV
62056006|NCT02766621|ACTIVE_COMPARATOR|PF-06823859|Study Drug being used in the study
62056007|NCT03605433|EXPERIMENTAL|Oral Anticoagulation+Antiplatelet|Rivaroxaban 2.5 mg twice daily and Aspirin 100 mg once daily.
62056008|NCT03605433|EXPERIMENTAL|Oral Anticoagulation|Rivaroxaban 20 mg once daily
62056009|NCT03605433|ACTIVE_COMPARATOR|Antiplatet|Aspirin 100 mg once daily
62258686|NCT03834467|EXPERIMENTAL|Arm 1 - Elevation Stimulus Video|All subjects complete the Levenson Psychopathy Scale first. Arm 1 then presents the Moral Elevation stimulus video after playing the first AlAn's Short Game v.2 (session 1). Participants will then play the AlAn's Short Game v.2 (session 2) for a second time and then fill out an Adverse Childhood Experiences Questionnaire (ACES), Social Connectedness survey, and Demographics form.
62258687|NCT03834467|SHAM_COMPARATOR|Arm 2 - Control Stimulus Video|All subjects complete the Levenson Psychopathy Scale first. Arm 2 then presents the control stimulus (nature video) after playing the first AlAn's Short Game v.2 (session 1). Participants will then play the AlAn's Short Game v.2 (session 2) for a second time and then fill out an Adverse Childhood Experiences Questionnaire (ACES), Social Connectedness survey, and Demographics form.
62258688|NCT02614859|ACTIVE_COMPARATOR|Observation and Bicalutamide|Cycles 1-2: Observation without treatment Cycles 3-8: Bicalutamide 50 mg daily continuously to end of study
62615699|NCT02133833|EXPERIMENTAL|Quantum Spectrum Radiation Emitter|five pieces of Quantum Spectrum Radiation Emitter will be placed on the affected shoulder daily for three weeks.
62056010|NCT06340074|EXPERIMENTAL|HELM|"Behavioral: HELM~HELM is a 9-month, data-driven organizational and leadership implementation strategy."
62056011|NCT06340074|PLACEBO_COMPARATOR|Implementation Attention Control (IAC)|"Behavioral: Implementation Attention Control (IAC)~Schools assigned to the IAC condition received an online, self-paced, independent studies program broadly focused on leadership and management."
62056012|NCT04903171|NO_INTERVENTION|GROUP ONE|The participants do not receive incentive to visit any gardens
62056013|NCT04903171|PLACEBO_COMPARATOR|GROUP TWO|The participants receive incentives by carers to visit regularly a conventional sensory garden
62056014|NCT04903171|EXPERIMENTAL|GROUP THREE|The participants receive incentives by carers to visit regularly an enriched garden
62056015|NCT02755064|EXPERIMENTAL|Erythromycin lactobionate IV 2 mg/kg|During the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Thereafter, an infusion of 1.5 mg/kg was given over the next 50 min with the same infusion pump.
62258689|NCT02614859|EXPERIMENTAL|Metformin and Bicalutamide|Cycles 1-2: Metformin 1000mg BID Cycles 3-8: Bicalutamide 50 mg daily and Metformin 1000 mg BID
62258690|NCT04654442||Cases|30 cases will be recruited : Patient diagnosed by RT-PCR for a COVID19 at Grenoble University Hospital
62258691|NCT04654442||Controls|30 controls will be recruited : Patient suspected for a COVID-19 but negative by RT-PCR for a COVID19 at Grenoble University Hospital
62258692|NCT04360980|ACTIVE_COMPARATOR|Intervention|40 RT-PCR positive COVID-19 patients without hypoxemia administered Colchicine plus standard treatment
62258693|NCT04360980|NO_INTERVENTION|Standard treatment|40 RT-PCR positive COVID-19 patients without hypoxemia receiving vitamin C 3grams daily , 400 mg Tiamine, Selenium , Omega-3 500 mg daily, Vit A , Vit D, Azithromycine, Ceftriaxone, Kaletra 400 BID 10 days
62258694|NCT00951847|EXPERIMENTAL|1|Oxcarbazepine oral suspension 300 mg/5 mL of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
62258695|NCT00951847|ACTIVE_COMPARATOR|2|Trileptal® (oxcarbazepine) oral suspension 300 mg/5 mL of Novartis
62615700|NCT03848624|EXPERIMENTAL|Cycling Group|Intention driven motor-assisted voluntary cycling with electrical stimulation
62615701|NCT00506714|EXPERIMENTAL|Adult subjects with hip osteoarthritis|Walk with and without a single point cane at baseline and after four weeks
62615702|NCT00506714|NO_INTERVENTION|Healthy Subjects|Healthy adults walking without a cane at baseline
62615703|NCT02376140||Women|Mothers of children 36-59 months old No intervention
62840634|NCT02131649|EXPERIMENTAL|18F-FCH PET/MRI Scan|Patients will undergo an injection of 18F-fluoromethyl-choline at 3.6 MBq/kg followed by whole body PET/CT imaging. Patients will also undergo a whole body MRI including T2 weighted, Diffusion weighted and Gadolinium Contrast Enhanced sequences. Patients with suspicion for recurrence may undergo biopsy if lesions identified on PET/CT or MRI are accessible for biopsy
62056016|NCT02755064|ACTIVE_COMPARATOR|Erythromycin lactobionate IV 3 mg/kg|During the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.Thereafter, an infusion of 1.5 mg/kg was given over the next 50 min with the same infusion pump.
62615704|NCT02376140||Children|Children 36-59 months old No intervention
62840635|NCT01818011|EXPERIMENTAL|Part A GSK1322322 single dose Arm|Subjects will receive single dose of one of the following 4 GSK1322322 treatments in 4 treatment periods (one per period) with an aqueous suspension of a low dose of GSK1322322F (stable isotope labeled drug substance) PO in a fed condition: 1500 mg (fit for purpose formulation), 1500 mg (intended commercial formulation), 1500 mg (over granulated formulation), and 2000 mg (intended commercial formulation)
62840636|NCT01818011|EXPERIMENTAL|Part B Cohort 1- GSK1322322 Oral Arm|Subjects in this part will receive single dose of GSK1322322 on Day 1 of each of the three treatment periods. Subjects in Cohort 1 will receive following GSK1322322 (intended commercial formulation) doses po in fed state: 1000 mg, 1500 mg and 2000 mg
62840637|NCT01818011|EXPERIMENTAL|Part B Cohort 2 -GSK1322322 IV Arm|Subjects in this part will receive single dose of GSK1322322 on Day 1 of each of the three treatment periods. Subjects in Part B Cohort 2 will receive following GSK1322322 IV fasted doses (one per period): 600 mg, 900 mg and 1200 mg
62840638|NCT01818011|EXPERIMENTAL|Part C GSK1322322 Arm|Subjects in this arm will receive repeat doses of GSK1322322 as following: GSK1322322 1200 mg IV fasted for 4 days twice a day (BID), followed by GSK1322322 2000 mg orally fed for 6 days BID
62840639|NCT01818011|PLACEBO_COMPARATOR|Part C Placebo Arm|Subjects in this arm will receive repeat doses of Placebo IV fasted for 4 days BID, followed by placebo po fed for 6 days BID
62615705|NCT03301831|EXPERIMENTAL|Resourcefulness Training Intervention|The intervention arm will receive an intervention that includes: a face-to-face session for teaching social (help-seeking) and personal (self-help) resourcefulness skills; ongoing access to video vignettes of caregivers of technology-dependent children describing resourcefulness skill application in daily life; 4 weeks of skills' reinforcement using daily journal writing; weekly phone calls for the first 4 weeks; and booster sessions at 2 and 4 months post enrollment.
62615706|NCT03301831|NO_INTERVENTION|Attention Control|The Attention Control arm will receive weekly phone calls for the first 4 weeks and at 2 and 4 months post enrollment plus any usual care.
62840640|NCT04433416||hypertension|After admission, two or more of the three blood pressure measurements under the same period of calm state that met hypertension, and the patient reported that he had a history of hypertension and that the blood pressure reached the standard of hypertension in the previous non-medication state was included in the hypertension group
62840641|NCT04433416||non-hypertension|Patients who denied the history of hypertension and were not taking antihypertensive drugs after admission and had normal blood pressure measurements were included in the non-hypertensive group
62056017|NCT02755064|PLACEBO_COMPARATOR|Placebo IV|Saline was given as an initial bolus over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
62056018|NCT02755064|EXPERIMENTAL|Erythromycin Ethylsuccinate Suspension|In Phase 2 of the study, subjects randomized to this arm will receive Erythromycin Ethylsuccinate Suspension 250 mg tid orally for a total period of 7 days. The GEBT was performed approximately on day 7. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
62258696|NCT02888015|OTHER|Upper extremity exercise|Five upper extremity exercises will be provided to each of the 10 participants to complete on a daily basis. Exercises included shoulder flexion, elbow flexion/extension, shoulder abduction, internal/external rotation
62258697|NCT02263274|EXPERIMENTAL|Direct Cortical Measurement|Consented subjects will also have transcranial electrodes applied at four extracranial sites, below the sterile dressing and distant from the surgical skull defect. The four electrodes will be placed in uniform positions based on the standard 10-10 electrode system, at the temples bilaterally (positions F9 and F10) and at the occiput bilaterally (positions PO9 and PO10). Subjects will be stimulated according to a predetermined set of parameters which fall well within empirically and computationally determined safety thresholds, as discussed above. The entire stimulation protocol is described in detail in section 5, and is anticipated to last no longer than 30 minutes.
62258698|NCT01895907||Special Olympic athletes|
62258699|NCT03761095|EXPERIMENTAL|Unesbulin and Dacarbazine|Participants will receive unesbulin orally twice weekly in combination with dacarbazine IV once every 21 days. The first participant will receive dacarbazine 1000 mg/m\^2 IV every 21 days in combination with unesbulin 200 mg tablet orally twice weekly. For subsequent participants, the dose level at which treatment is initiated will be selected based on the TITE-CRM using the most up to date dose DLT information from all participants previously treated. Participants will receive unesbulin 300 mg twice weekly in combination with dacarbazine in the expansion cohort. Treatment will continue for each participant until evidence of unacceptable toxicity, disease progression, or treatment discontinuation for another reason.
62258700|NCT02088970|ACTIVE_COMPARATOR|antibiotic treatment alone|
62258701|NCT02088970|EXPERIMENTAL|Crosslinking + Antibiotic|"The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.~Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation."
62056019|NCT02755064|PLACEBO_COMPARATOR|Placebo Suspension|In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days. The GEBT was performed approximately on day 7. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
62056020|NCT03594539|NO_INTERVENTION|Standard|Participants will have their hyperphosphatemia managed with lanthanum carbonate 1 g with meals and 500 mg with snacks as per typical care, for 2 weeks.
62056021|NCT03594539|PLACEBO_COMPARATOR|Intervention|Participants will take a placebo instead of standard care with a phosphate binder, for 2 weeks.
62056022|NCT04185714|EXPERIMENTAL|Experimental group|Experimental group will be applied Kinesotaping , exercise programme will be given.
62056023|NCT04185714|NO_INTERVENTION|Control group|Exercise programme will be given.
62056024|NCT04185714|PLACEBO_COMPARATOR|Placebo group|Sham taping will be applied, exercise programme will be given.
62056025|NCT02153801|ACTIVE_COMPARATOR|Low Inferior Mesenterci Artery Ligation|The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.
62056026|NCT02153801|OTHER|High Inferior Mesenterci Artery Ligation|"For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.~For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter."
62056027|NCT05086016|EXPERIMENTAL|All treated|The All Treated (AT) population is defined as all subjects who signed informed consent, meet eligibility criteria and for whom a procedure was begun (defined as the initiation of vascular access with the Renata Minima system).
62056028|NCT03716921|EXPERIMENTAL|Short antibiotics treatment|patients will receive effective antibiotic treatment (IV and oral) for 3 weeks
62056029|NCT03716921|NO_INTERVENTION|Long antibiotics treatment|patients will receive effective antibiotic treatment (IV and oral) for 6 weeks according to standard care
62056030|NCT05924178|EXPERIMENTAL|experimental group|Before ACL reconstruction,40 minutes of rehabilitation training was performed 3 times a week for 6 weeks, and gotted regular treatment. The ACL reconstruction was followed by a 0.5 year rehabilitation.
62056031|NCT05924178|ACTIVE_COMPARATOR|control group|Regular rehabilitation training was not performed before ACL reconstruction, got regular treatment. The ACL reconstruction was followed by a 0.5 year rehabilitation.
62056032|NCT03818789|EXPERIMENTAL|Mindfulness|A mindfulness training is applied to see if it supports exercise endurance in-lab and during follow-up
62056033|NCT03818789|PLACEBO_COMPARATOR|Control|A study skills video is shown intended to have no effect on exercise but to match for time.
62615707|NCT01836913||Radiotherapy for esophageal cancer|Patients with histology proven esophageal cancer who are planned for high dose radiotherapy with or without chemotherapy with or without surgery.
62615708|NCT01309984|ACTIVE_COMPARATOR|arm 1|
62056034|NCT02579564|EXPERIMENTAL|chemotherapy with Oncorine and Endostar|Systemic chemotherapy with standard schemes, such as GP (Gemcitabine/Cisplatin), NP (Vinorelbine/Cisplatin), TP (Paclitaxel/Cisplatin) or PP (Pemetrexed/Cisplatin). Thoracic cavity perfusion of recombinant human adenovirus type 5 injection 1.5ml and Endostar 30mg each time, twice a week for four times.
62615709|NCT01309984|ACTIVE_COMPARATOR|arm 2|
62258702|NCT03592706|EXPERIMENTAL|IKC and TACE|IKC (Immune Killer Cells) and TACE(Transcatheter Arterial Chemoembolization)
62258703|NCT03592706|ACTIVE_COMPARATOR|TACE|TACE (Transcatheter Arterial Chemoembolization)
62258704|NCT02589899||Needle placement in different tissue types|Needle placement and impedance measurements in different tissue types
62258705|NCT04116086|OTHER|PSMA PET-CT exam|Ga 68 -PSMA PET/CT scanning will be performed using a combined PET/CT protocol with a 16-detector-row helical CT scanner (Philips Gemini GXL). This scanner allows simultaneous acquisition of up to 45 transaxial PET images with interslice spacing of 5 mm in one bed position and provides an image from the vertex to the thigh in about 10 bed positions. The use of (68)Ga-PSMA HBED-CC results in a relatively low radiation exposure, delivering organ doses that are comparable to those of other (68)Ga-labelled PSMA-inhibitors used for PET-imaging. Total effective dose is lower than for other PET-agents used for prostate cancer imaging (e.g. (11) C- and (18) F-Choline).
62056035|NCT02579564|ACTIVE_COMPARATOR|chemotherapy with cisplatin|Systemic chemotherapy with standard schemes without cisplatin, such as Gemcitabine, Vinorelbine, Paclitaxel or Pemetrexed. Thoracic cavity perfusion of cisplatin 30mg/m2 each time, twice a week for four times.
62056036|NCT01553318|ACTIVE_COMPARATOR|Active Ketotifen|After meeting the full eligibility requirement, participants will be randomized. Approximately 26 of the 51 participants will assigned to this arm of the study.
62258706|NCT03518593|EXPERIMENTAL|Intervention|Additional cash transfer and nutritional counselling
62258707|NCT03518593|NO_INTERVENTION|Control|Existing cash transfer only
62615710|NCT05254470||Pre-Low Intensity Continuous Ultrasound Treatment|Routine care for pain alleviation, range of motion and ability to return to work with traditional therapies from rehabilitation.
62615711|NCT05254470||Post-Low Intensity Continuous Ultrasound Treatment|Routine care of pain alleviation, range of motion and ability to return to work after treatment with low-intensity continuous ultrasound (LICUS) in conjunction with traditional therapies.
62615712|NCT03267602|EXPERIMENTAL|Continuous Positive Airway Pressure (CPAP) Therapy|
62615713|NCT05730348||Patients with eating disorders|
62615714|NCT03316066|EXPERIMENTAL|Group 5|stellate ganglion block with ropivacaine 0.2% 5 mL
62615715|NCT03316066|ACTIVE_COMPARATOR|Group 2|stellate ganglion block wit ropivacaine 0.2% 2 mL
62615716|NCT06234527|EXPERIMENTAL|mild to moderate melasma|adult patients suffering from mild to moderate melasma (Investigator's Global Assessment (IGA) 1 or 2)
62840642|NCT00221117|ACTIVE_COMPARATOR|Conventional Occupational Therapy (COT)|Conventional Occupational Therapy pertaining to hand function represents the current best practice activities against which the FET was compared. The COT included the following: (a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; (b) task-specific, repetitive functional training; (c) strengthening and motor control training using resistance to available arm motion to increase strength; (d) stretching exercises; (e) electrical stimulation applied primarily for muscle strengthening (this was neither FES nor FET, but electro muscular stimulation); (f) practice of activities of daily living (ADLs) including self-care where the upper extremities were used as appropriate; and (g) caregiver training.
62840643|NCT00221117|EXPERIMENTAL|Neuroprosthesis-FES Therapy|The FES Therapy began by designing stimulation protocols to generate power (circular grip and lateral pinch) and precision (opposition with 2 and 3 fingers) grasps on demand. The stimulation sequence (protocol) for power and precision grasps was developed for each patient individually using the Compex Motion electric stimulator. Compex Motion is a fully programmable transcutaneous (surface) stimulator that uses self-adhesive surface electrodes.
62840644|NCT05219552|EXPERIMENTAL|Intervention group- lactation support and unconditional cash transfers|Women in this arm will receive personal lactation support from a professional lactation specialist at 5 time points: pregnancy and at 2-weeks, 4-weeks, 6-weeks and 3-months postpartum. Women in the intervention group will also receive monthly unconditional cash transfers of 10,000 Kenyan shillings sent directly to a a mobile phone-based money transfer service accounts associated with their personal cell phone.
62258708|NCT02110368|ACTIVE_COMPARATOR|AndroGel|AndroGel (testosterone gel) 1.62% Metered-Dose Pump. One actuation 20.25 mg
62840645|NCT05219552|NO_INTERVENTION|Control group- standard care|The women enrolled in the control arm will receive standard care at a clinic similar to, but distinct from, the intervention site.
62258709|NCT02110368|EXPERIMENTAL|Testosterone Gel|Testosterone Topical Gel, 1.62% Metered Pump. One actuation of 20.25 mg.
62258710|NCT01197521|EXPERIMENTAL|Dosing Regimen A|Oral Treatment
62258711|NCT01197521|EXPERIMENTAL|Dosing Regimen B|Oral Treatment
62258712|NCT01197521|PLACEBO_COMPARATOR|Dosing Regimen C|Oral Treatment
62056037|NCT01553318|PLACEBO_COMPARATOR|Placebo for Ketotifen|After meeting the full eligibility requirement, participants will be randomized. Approximately 25 of the 51 participants will assigned to this arm of the study. Subjects in this arm will receive the placebo drug.
62056038|NCT02019628|EXPERIMENTAL|BRM4 at a dosage level of 1 gram/day|60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 1 gram/day.
62258713|NCT06018415|EXPERIMENTAL|Early time-restricted eating (eTRE)|The eTRE group is instructed to consume all calories from 7 AM to 3 PM each day and fast from 3 PM to 7 AM
62258714|NCT06018415|EXPERIMENTAL|Late time-restricted eating (lTRE)|The lTRE group is instructed toconsume all calories from 11 AM to 7 PM each day and fast from 7 PM to 11 PM
62258715|NCT05642455|EXPERIMENTAL|Afamitresgene autoleucel|
62258716|NCT04628637||Control Group|"Inclusion Criterias are consisted of; Not to have known acute, subacute or chronic disease history, Not to suffer from any infection in the last fortnight, Not to be on a particular medication, Presenting to the ED with reasons other than infectious complaints, and Giving their written consent to participate in the study.~The exclusion criteria consisted of; Diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease"
62445002|NCT04184037|EXPERIMENTAL|Auditory neurofeedback (NFB)|Participants in this arm will meditate with the help of a custom version of the Muse app, which guides users in meditation while providing auditory neurofeedback on their state of mindfulness. Participants will wear the EEG headband and headphones when completing the meditation sessions using the app. The neurofeedback consists of changing weather sounds that are heard against a background soundscape (e.g., a beach or rainforest sound). When a user is in a focused state, the weather in the soundscape is good (e.g., it is quiet or a light breeze can be heard). When a user starts mind-wandering, the weather sounds change for the worse: it begins to rain, the wind gets louder, and there may be thunder. When the user returns to a calm state, the weather sounds quiet down again and only the background soundscape is heard. Participants are asked to pay attention to the weather sounds and to use this feedback to train their mind to remain focused on the present moment.
62445003|NCT04184037|ACTIVE_COMPARATOR|No neurofeedback (no-NFB)|Participants in this arm will meditate using a custom version of the Muse app that is identical in all respects to the mobile app used by the NFB group, expect that the auditory neurofeedback is not active. Participants will wear the EEG headband and headphones when completing the meditation sessions using the app, but the soundscape during the sessions will only contain the background sounds (e.g., the breach or rainforest scene), without any changes to the weather.
62445004|NCT03238768|EXPERIMENTAL|Enhanced Nutrition|Infants randomized to the study protocol will start on higher initial amounts of calories, proteins and fats. They will also undergo faster increases of these nutrients during their first week of life.
62445005|NCT03238768|ACTIVE_COMPARATOR|Standard Nutrition|Infants randomized to the standard nutrition protocol will start on standard amounts of calories, proteins and fats per the usual NICU routine. They will also undergo standard increases of these nutrients during their first week of life.
62615717|NCT06234527|EXPERIMENTAL|mild to moderate acne induced PIHP|adult patients suffering from mild to moderate acne-induced PIHP (IGA 1 or 2) without active acne (i.e. less than 10 inflammatory lesions)
62615718|NCT06234527|EXPERIMENTAL|solar lentigo|adult patients suffering from solar lentigo with a pigmentation score \> 5
62615719|NCT00901082|ACTIVE_COMPARATOR|information and relaxation|will receive the intervention that consist of information and relaxation
62840646|NCT04350762|EXPERIMENTAL|Supplement + Fish Oil|"Participants will mix 5 scoops of powdered nutrition supplement with 8 oz of cold water (2x/day). The supplemental shake will be consumed on two separate occasions daily. Omega-3 fish oil supplement is in capsule form for intake once daily.~The NutraWell nutrition powder and OmegaRich fish oil supplement will be provided by and distributed from DoWell Laboratories (Irvine, CA - USA)."
62840647|NCT04350762|NO_INTERVENTION|Control|No dietary supplements. Participants will continue current intake.
62056039|NCT02019628|EXPERIMENTAL|BRM4 at a dosage level of 3 grams/day|60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 3 grams/day.
62445006|NCT01603290||Hospitalized Leukemia Patients|leukemia patients with chemotherapy during hospitalization
62445007|NCT05371301|EXPERIMENTAL|NACT-IDS|For patients whoes WB-DWI/MRI Suidan Standard Evaluation≥4 Neoadjuvant chemotherapy: platinum-based combination regimen 3 courses
62445008|NCT05371301|ACTIVE_COMPARATOR|PDS|For patients whoes WB-DWI/MRI Suidan Standard Evaluation\<4
62445009|NCT01569828|EXPERIMENTAL|Renal Impaired Subjects|once daily administration of 400 mg LCZ696 for 5 days
62615720|NCT00901082|NO_INTERVENTION|No intervention|No specific intervention before the medial branch block.
62840648|NCT06411314|EXPERIMENTAL|Natamycin + Lactulose 100 mg + 300 mg vaginal suppositories|
62840649|NCT06411314|ACTIVE_COMPARATOR|Lactulose 300 mg vaginal suppositories|
62615721|NCT01486186|EXPERIMENTAL|traditional chinese medicine|The experimental group will receive three type of TCM, they are Baofei granule, Bufeijianpi granule and Bufeiyishen granule.
62445010|NCT01569828|EXPERIMENTAL|Healthy Volunteers|once daily administration of 400 mg LCZ696 for 5 days
62445011|NCT02002780|EXPERIMENTAL|Subjects|"Children identified during the screening phase of the project as having elevated, but not clinically defined, levels of psychosocial stress will be invited to participate in the intervention phase of this research if they are between 8 and 11 years of age.~Screening will identify 6 girls and 6 boys eligible and willing to participate in the intervention phase of the project."
62615722|NCT01486186|PLACEBO_COMPARATOR|placebo|placebo chinese medicine in addition to best care according to clinical guidelines for COPD patients
62615723|NCT03871829|ACTIVE_COMPARATOR|Arm A: Carfilzomib+Dexamethasone (Kd)|Participants will receive carfilzomib 20 milligram per square meter (mg/m\^2) intravenously (IV) on Day 1 of Cycle 1 and then 70 mg/m\^2 on Days 8 and 15 of Cycle 1 and thereafter on Days 1, 8, 15 of Cycle 2 onwards. Participants will receive dexamethasone 20 mg on Cycle 1 Day 1, a second dose of 20 milligram (mg) will be given on Cycle 1 Day 2 and 40 mg IV or orally on Days 8, 15, 22 for Cycle 1. Patients will then receive dexamethasone 40mg on days 1, 8, 15 and 22 for cycles 2-9, then on Days 1, 8, 15 for Cycle 10 onwards, until death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study. The total duration of each cycle is 28 Days.
62840650|NCT06411314|ACTIVE_COMPARATOR|Pimafucin® (natamycin) 100 mg vaginal suppositories|
62840651|NCT02560545|ACTIVE_COMPARATOR|Cannabis oil|Cannabis oil, 20% THC 0.2 mg/kg
62056040|NCT01457781|ACTIVE_COMPARATOR|0.025 mg inhaled nitric oxide|Inhaled nitric oxide (iNO) 0.025 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L \[2440 ppm\] NO mini-cylinder; change q 24 hours) delivered via INOpulse® DS delivery device.
62056041|NCT01457781|ACTIVE_COMPARATOR|0.075 mg inhaled nitric oxide|Inhaled nitric oxide (iNO) 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (6.0 mg/L \[4880 ppm\] NO mini-cylinder; change q 24 hours) delivered via INOpulse® DS delivery device.
62840652|NCT02560545|PLACEBO_COMPARATOR|Placebo|Oil
62056042|NCT01457781|PLACEBO_COMPARATOR|placebo|Placebo 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks\* (99.999% Nitrogen \[N2\] mini-cylinder; change q 24 hours) delivered via INOpulse® DS delivery device.
62258717|NCT04628637||Covid-19 (-) Pneumonia Group|Inclusion Criterias are consisted of; Presenting to the Covid-19 outpatient policlinic of the ED with pneumonia symptoms To have CT imagings were not compatible with Covid-19 pneumonia in accordance with the Radiological Society of North America Expert Consensus (RSNAEC) criteria To have nasopharyngeal swab samples taken in the ED were negative for PCR, and To give their informed consent to participate in the study. Exclusion Criteria The exclusion criteria consisted of diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease To have a CT imagings that is compatible with Covid-19 pneumonia but whose PCR tests were negative
62840653|NCT01792752|EXPERIMENTAL|Enhanced HIV Care Access and Retention Intervention|Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. The neighborhoods will receive the intervention at different times throughout the study period, but once the intervention is initiated in a neighborhood it will continue being implemented in that neighborhood until the end of the study period.
62840654|NCT01792752|NO_INTERVENTION|Control / Neighborhood(s) not receiving the intervention|The neighborhood(s) not receiving the intervention will act as a control while the intervention is initiated and implemented in other neighborhoods. All neighborhoods will receive the intervention but at different times throughout the study period. Once the intervention is initiated in a neighborhood, that neighborhood will continue receiving the intervention until the end of the study period.
62840655|NCT02605460|OTHER|Unique|Patients will receive reduced Busulfan and Cyclophosphamide (BUCY) 2 conditioning regimen, consisting in the administration of two medications: Busulfan and Cyclophosphamide Plus: CXCR4 Antagonist. Then they will undergo a Hematopoietic Stem Cell Transplantation (Autologous or Allogeneic)
62840656|NCT01651637|EXPERIMENTAL|Synthetic Surfactant|Cohort Design
62615724|NCT03871829|EXPERIMENTAL|Arm B: Dara-SC in combination with Kd (DKd)|Participants will receive daratumumab subcutaneous (Dara-SC) 1800 mg by SC injection on Days 1, 8, 15, 22 for Cycle 1 and 2, Days 1 and 15 for Cycle 3-6, Day 1 for Cycle 7 onwards. Participants will receive carfilzomib 20 mg/m\^2 IV on Cycle 1 Day 1 and then 70 mg/m\^2 on Day 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2. Participants will receive dexamethasone 20 mg on Cycle 1 Day 1, a second dose of 20 milligram (mg) will be given on Cycle 1 Day 2 and 40 mg IV or orally on Days 8, 15, 22 for Cycle 1. Patients will then receive dexamethasone 40mg on days 1, 8, 15 and 22 for cycles 2-9, then on Days 1, 8, 15 for Cycle 10 onwards, until death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study. The total duration of each cycle is 28 Days.
62056043|NCT02561169|EXPERIMENTAL|Oseltamivir|75 mg oseltamivir orally twice daily for 5 days within 72 hours of symptom onset
62056044|NCT02561169|PLACEBO_COMPARATOR|Placebo|75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir
62056045|NCT01321541|EXPERIMENTAL|Pixantrone + Rituximab|Pixantrone and Rituximab
62056046|NCT01321541|ACTIVE_COMPARATOR|Gemcitabine + Rituximab|Gemcitabine and Rituximab
62056047|NCT02699879||Pirfenidone|Participants will receive pirfenidone orally according to the physician discretion.
62615725|NCT02743065||Device: HepaSphere Microspheres|HepaSphere Microsphere
62258718|NCT04628637||Covid-19 Infection Group|"This cohort included the patients InculUsion Criteria Presenting Whose CT imagings were normal in accordance with the RSNAEC criteria and whose PCR tests were positive To have Covid-19 PCR tests were positive as a result of contact tracing, Presenting to the ED for further examination.~The exclusion criteria consisted of; Diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease To have a CT imagings that is compatible with Covid-19 pneumonia but whose PCR tests were negative."
62258719|NCT02634151|PLACEBO_COMPARATOR|Placebo|Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.
62258720|NCT02634151|EXPERIMENTAL|Gemcabene 600 mg|Participants on stable statin therapy received 600 milligrams (mg) of Gemcabene orally, once daily for 12 weeks.
62258721|NCT01345136|EXPERIMENTAL|RAD001 Treatment|All subjects will be given RAD001 for 1 year (12 months).
62258722|NCT05558475|EXPERIMENTAL|Digital CBTi with Coaching|Virtual Coaching integrated with Digital CBTI. Includes initial enrollment contact, onboarding call, and two follow-up support calls. The coach will be available as resource for technical and other support.
62258723|NCT05558475|NO_INTERVENTION|Digital CBTi without Coaching (+ initial contact)|The control will be an enhanced treatment as usual condition where participants will receive: 1) provider referral to Digital CBTi; 2) initial enrollment contact and 3) NO virtual coaching contacts. If subjects have a question or need technical support, they will be instructed to contact study staff for assistance.
62258724|NCT01519804|EXPERIMENTAL|MetMAb+paclitaxel+platinum|
62258725|NCT01519804|ACTIVE_COMPARATOR|Placebo+paclitaxel+platinum|
62615726|NCT01717391|EXPERIMENTAL|Fluorothymidine F 18 PET/CT|Fluorothymidine F 18 (FLT) PET/CT imaging ordered pre-radiation therapy, during weeks 1 and 2 of radiation therapy, and then at 1 month and 12 months after radiation therapy. The FLT PET/CT imaging ordered pre-radiation therapy is used for bone marrow sparing IMRT radiation therapy.
62615727|NCT04787861|ACTIVE_COMPARATOR|Control group|Control group treatment is identical to treatment of the study group but without a motorized movement device.Childen in this group received chest physical therapy program including positioning, breathing exercises, and postural drainage in addition to incentive spirometer training for 20 minutes, 3 times/week for 12 weeks.
62615728|NCT04787861|EXPERIMENTAL|study group|This group received the same program given to the control group in addition to an aerobic training regimen for 25 minutes 3 times/week for 12 weeks using a motorized movement device.
62615729|NCT01132300|EXPERIMENTAL|Treatment|
62615730|NCT02544958|EXPERIMENTAL|Er:YAG laser|4 treatments of 1 month interval
62615731|NCT04774276||Group with occupational therapist|Patient with Coronary Artery Disease (CAD) will be included. They will have the cardiac rehabilitation protocol (4 weeks) with occupational therapist as usual practice. The inclusion in this group will be prospective, from January 2021.
62056048|NCT00627900|OTHER|BMS|Implantation of a bare metal stent
62056049|NCT00627900|OTHER|SES|Implantation of a sirolimus-eluting stent
62056050|NCT00942617|EXPERIMENTAL|40 mg non-enteric coated aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
62056051|NCT01719107|ACTIVE_COMPARATOR|L. reuteri DSM 17938 chewable tablets|The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri DSM 17938 is 1x108 live bacteria (CFU)/tablet.
62056052|NCT01719107|PLACEBO_COMPARATOR|Placebo chewable tablets|The placebo study product consists of an identical formulation in all respects except that the live bacteria are excluded.
62615732|NCT04774276||Group without occupational therapist|Patient with Coronary Artery Disease (CAD) will be included. They have done the cardiac rehabilitation protocol (4 weeks) without occupational therapist until december 2020. The inclusion in this group will be retrospective,
62615733|NCT02000882|EXPERIMENTAL|BKM120 plus Capecitabine|"BKM120 will be administered at a dose of 100 mg orally (PO) daily. Capecitabine will be administered at a dose of 1000 mg/m2 orally (PO) twice a day (rounded down to the nearest 500 mg pill) 14 days on and 7 days off.~For patients with HER2+ MBC only, standard every 3-weekly trastuzumab (6 mg/kg IV) will be added to the capecitabine/BKM120."
62615734|NCT06404905|EXPERIMENTAL|BT02 treatment|BT02 given intravenously administer in patients with advanced solid tumors.
62445012|NCT02002780|NO_INTERVENTION|Control|All families that were screened during the screening phase of this study will complete the final screening instrument assessment, whether or not the child participated in the day camp intervention. The control group will be comprised of those families that did not participate in the intervention.
62615735|NCT03810235|ACTIVE_COMPARATOR|Transdermal Lidocaine Patch|Drug: Including placebo The intervention is the post-operative application of a 5% lidocaine transdermal patch for women who have undergone Cesarean delivery.
62615736|NCT03810235|PLACEBO_COMPARATOR|Transdermal Hydrocolloid Placebo Patch|Drug: Including placebo The intervention is the post-operative application of a hydrocolloid transdermal patch for women who have undergone Cesarean delivery.
62615737|NCT06201208|EXPERIMENTAL|The ST-Facilitation Psychoeducation Program Group|The ST-Facilitation Psychoeducation Program is planned for mothers in the intervention group as an 80-minute session (40-minute session + 20-minute break + 40-minute session) once a week for six weeks, in groups of two to four participants.
62615738|NCT06201208|NO_INTERVENTION|Control Group|No action will be taken by the researcher during the research. Only data collection will be carried out. At the end of the research, ST-Facilitation Psychoeducation Program will be applied ethically.
62840657|NCT06400381|EXPERIMENTAL|Mindfulness-based Intervention|There are many mindfulness-based interventions protocol that can be implemented and practice by healthcare organization. In the current study, the intervention protocol the investigators will use is based on Smiths version of mindfulness meditation (Smith, 2005). This version is compromised of several components includes being mindful of breathing, thought, sounds, taste, body scan, and sitting. The initial educational session by power point presentation will be given to the participant to explain the intervention rationale and procedure of mindfulness in daily life. In addition to giving opportunity for the participant to ask questions during the educational session.
62840658|NCT06400381|NO_INTERVENTION|Control|The control group will not receive any intervention and will continue with their usual routines and work schedules. The control group completes the pretest questionnaire at the same time as the interventional group completes it, the posttest will be after the interventional group has finished the mindfulness intervention 8 weeks. The intervention sessions used in the experimental group will be delivered to the control group at the end of study.
62840659|NCT01483326||Cohort|
62258726|NCT01380730|PLACEBO_COMPARATOR|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
62258727|NCT01380730|PLACEBO_COMPARATOR|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
62258728|NCT01380730|EXPERIMENTAL|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
62258729|NCT01380730|EXPERIMENTAL|Evolocumab 105 mg Q2W|Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
62258730|NCT01380730|EXPERIMENTAL|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
62445013|NCT00918671||Medication-overuse headache|Chronic daily headache combined with medication overuse
62445014|NCT01382433|EXPERIMENTAL|Chronic Cannabis Users|
62445015|NCT01382433|EXPERIMENTAL|Control|Neurotypical subjects
62445016|NCT04535609|EXPERIMENTAL|Mavodelpar|Once daily
62615739|NCT01723020|EXPERIMENTAL|AMG 232|AMG 232 is an anti-cancer agent.
62258731|NCT01380730|EXPERIMENTAL|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
62258732|NCT01380730|EXPERIMENTAL|Evolocumab 350 mg Q4W|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
62258733|NCT01380730|EXPERIMENTAL|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
62615740|NCT01892800||Study population - lung resection|Patients with suspected lung cancer undergoing lung resection by anatomic lobectomy
62445017|NCT04535609|PLACEBO_COMPARATOR|Matched placebo|Once daily
62445018|NCT04318470||PPROM|Preterm premature rupture of membranes between 16 0/7 and 33 6/7 weeks gestation
62445019|NCT04318470||Healthy controls|Gestational-age-matched controls without preterm premature rupture of membranes or other pregnancy complications
62445020|NCT03125083|EXPERIMENTAL|skin-restricted lupus (SRL) patients|Role of inflammation in psychiatric disorders in patients with cutaneous lupus
62445021|NCT03385096|EXPERIMENTAL|BUCY+VP-16|For MM patients undergoing auto-HSCT，BUCY+VP-16 conditioning regimen was BU 3.2 mg/kg/day on days -8 and -6；CY 60 mg/kg/day on days -5 and -4; VP-16 10mg/kg/day on days -3 and -2.
62615741|NCT04865991|EXPERIMENTAL|TCI propofol group|Subjects in the TCI propofol group received TCI propofol for anesthesia maintenance, Ce value was titrated until a targeted BIS score of 40-60 achieved.
62615742|NCT04865991|ACTIVE_COMPARATOR|sevoflurane group|Subjects in the sevoflurane group received sevoflurane 2 volume%, which were titrated up/down every 5 minutes to get a targeted BIS score of 40-60.
62258734|NCT06338904|EXPERIMENTAL|Problem-solving-based psychological intervention delivered in a face-to-face format (PSPI-FF)|Participants in this group will receive a problem-solving intervention for suicide prevention in a face-to-face format. The intervention will consist of 6 sessions, approximately 90 minutes in duration each, once a week, in a group format, in person.
62615743|NCT02579317|EXPERIMENTAL|Resonance Breathing|Breathing is paced to the cardiovascular resonance frequency where heart, respiratory, and brain signals become aligned. This can potentially positively impact cognitive-emotional functioning.
62615744|NCT02579317|PLACEBO_COMPARATOR|Non-Resonance Breathing|Breathing is paced at a non-resonance frequency. It does not align heart, respiratory, and brain signals, and thus does not impact cognitive-emotional functioning.
62258735|NCT06338904|EXPERIMENTAL|Problem-solving-based psychological intervention delivered via telephone conference call (PSPI-CC)|Participants in this group will receive the intervention described in a teleconference call format, with the same duration, contents, and structure.
62258736|NCT06338904|EXPERIMENTAL|Problem-solving-based psychological intervention delivered via a smartphone app (PSPI-A)|Participants in this group will receive the intervention described adapted to be administered through a smartphone app, with equivalent duration, content, and structure (approximately 90 minutes to complete each of the 6 modules).
62258737|NCT06338904|NO_INTERVENTION|Usual care (UCCG)|Participants in this group will receive usual care. Usual treatment will include individual and group psychotherapy and/or psychiatric medication as determined by the health professionals they are currently consulting, whether in public or private facilities.
62258738|NCT02956954|EXPERIMENTAL|Patient treated with Enzyme replacement therapy|Magnetic Resonance Imaging will be done every 6 months for patient treated with Enzyme replacement therapy (Agalsidase alpha (Replagal®))
62615745|NCT00819949|EXPERIMENTAL|Arm 1|Potential eligible subjects for the trial will be individuals between ages 18-85, with a confirmed diagnosis of PD that experience freezing.
62615746|NCT00349999||1|18 males and non pregnant females, ages 18-45, with acute cholera.
62258739|NCT02956954|SHAM_COMPARATOR|Patient no treated with Enzyme replacement therapy|Magnetic Resonance Imaging will be done every 6 months for patient treated with Enzyme replacement therapy (Agalsidase alpha (Replagal®))
62258740|NCT00595556|EXPERIMENTAL|A|Zonisamide
62258741|NCT00595556|PLACEBO_COMPARATOR|B|placebo
62258742|NCT01476475|EXPERIMENTAL|Insulin glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC injected once daily (QD) for 24 weeks. Dose individually adjusted.
62258743|NCT01476475|ACTIVE_COMPARATOR|Insulin glargine|Insulin glargine QD for 24 weeks. Dose individually adjusted.
62615747|NCT02721017|EXPERIMENTAL|Cryoanalgesia|Cryoanalgesia performed thoracoscopically under general anesthesia by the patient's surgeon at the time of the Nuss procedure
62615748|NCT02721017|ACTIVE_COMPARATOR|Thoracic Epidural|Thoracic epidural (ropivicaine, fentanyl).
62615749|NCT04909814||Vaccinated women with positive screening test|All women in one Swedish county taking their first screening test within the organized cervical screening program
62615750|NCT04402450|ACTIVE_COMPARATOR|suprainguinal fascia iliaca block|Forty mL of levobupivacaine 0.25% with epinephrine 5 ug/mL will be injected cranial to the inguinal ligament between the fascia iliaca and the iliopsoas muscle.
62615751|NCT04402450|EXPERIMENTAL|Pericapsular nerve group block|Twenty mL of levobupivacaine 0.5% with epinephrine 5 ug/mL will be deposited in the anterior aspect of the iliac bone between its periosteum and the tendon of the iliopsoas muscle.
62615752|NCT06147752|EXPERIMENTAL|"Mobile internet healthcare treatment and three disciplines co-management"|"100 patients who met the enrollment conditions were randomly divided into control group and intervention group by 1:1. The intervention group adopted the intervention of mobile Internet healthcare and co-management of three disciplines (endocrinologists, dietitians and weight managers). The three disciplines team tracked and assessed the patients' daily diet and weight changes. The duration of intervention was 6 months."
62615753|NCT06147752|EXPERIMENTAL|Traditional diagnosis and treatment mode|100 patients who met the enrollment conditions were randomly divided into control group and intervention group by 1:1. The control group was treated according to the traditional mode: the diagnosis and treatment plan was formulated by the endocrinologist, and the diet education was conducted by the dietitian, and the individualized diet plan was formulated. Given a calorie-restricted diet, it is recommended to reduce daily energy intake by 500kcal on the basis of requirement. At least 150 minutes of moderate-intensity exercise per week is recommended. After the visit, the patient underwent follow-up self-weight monitoring and diet management outside the hospital.
62258744|NCT05912777|EXPERIMENTAL|Scanner Arm|A scanner must be performed by Patients
62258745|NCT05019898|EXPERIMENTAL|Diagnostic Test: pupillometry|
62258746|NCT02113085|EXPERIMENTAL|Self-determination enhancement|Self-determination enhancement through one-on-one coaching and mentoring workshops
62258747|NCT06037551|EXPERIMENTAL|Subject glucometer measurement|Blood glucose measurement BGM for personal use
62258748|NCT02214966|EXPERIMENTAL|Telmisartan/Ramipril, fed|
62840660|NCT00834093|EXPERIMENTAL|EBV-stimulated cytotoxic T-lymphocyte (EBV-CTL) Immunotherapy|Eligible participants underwent a blood draw to obtain peripheral blood mononuclear cells (PBMCs) used for preparation of the immunotherapy product \[estimated preparation time 14-16 weeks\]. Participants received palliative chemotherapy for NPC as standard of care during the period required for T-cell production. Participants who achieved a partial response or better while receiving palliative chemotherapy continued to receive chemotherapy for 3 to 6 cycles and were only eligible for immunotherapy when progressive disease (PD) was confirmed. Each participant received a minimum of 2 EBV-CTL infusions, given 2 weeks apart, at doses of 1x108 cells/m2. A 3rd infusion was offered to participants 8-12 weeks after the 2nd infusion based on response, tolerability and sufficient immunotherapy product reserves.
62840661|NCT03574012|ACTIVE_COMPARATOR|Control Group (general health information, fitness tracker)|Participants receive general information about physical activity and diet, and access to Fitbit and Healthwatch.
62840662|NCT03574012|EXPERIMENTAL|Intervention Group (individualized information, tracker)|Participants receive individualized goal-setting and coaching in relation to physical activity and diet, supplemented with peer support through the study's social media platform, over 4 months. They also have access to mHealth apps including Fitbit and Healthwatch that provide feedback on physical activity and diet.
62840663|NCT01817803|ACTIVE_COMPARATOR|1) Add furosemide/no spironolactone|
62840664|NCT01817803|ACTIVE_COMPARATOR|2) Add metolazone/no spironolactone|
62840665|NCT01817803|ACTIVE_COMPARATOR|3) Add furosemide/spironolactone|
62840666|NCT01817803|ACTIVE_COMPARATOR|4) Add metolazone/spironolactone|
62840667|NCT01748513||preoperative venous return optimizing|Morbidly obese patients scheduled for bariatric surgery
62840668|NCT02338271|OTHER|a single, open clinical trial|"a single-group, open, investigator-initiated clinical study~: autologous adipose derived mesenchymal stem cell (2 x 10\^7 cells/mL /vial or 4 x 10\^7 cells/mL /vial) plus Tissuefill (hyaluronic acid derivatives) 1mL/syringe"
62840669|NCT00705549|EXPERIMENTAL|1|Gemzar/Cisplatin
62840670|NCT00705549|EXPERIMENTAL|2|Taxotere/Cisplatin
62840671|NCT00705549|EXPERIMENTAL|3|Cisplatin/Navelbine metronomic
62840672|NCT00705549|EXPERIMENTAL|4|Taxotere/Gemzar
62840673|NCT00705549|EXPERIMENTAL|5|Gemzar
62840674|NCT00705549|EXPERIMENTAL|6|Taxotere
62840675|NCT00705549|EXPERIMENTAL|7|Navelbine metronomic
62056053|NCT01137188|EXPERIMENTAL|Intervention group|Intensive weight loss program and regular group sessions with clinical dietician. Complete dietary substitution with a low calorie diet containing 800-1000 kcal/day for 8 weeks
62258749|NCT02214966|ACTIVE_COMPARATOR|Telmisartan/Ramipril, fasted|
62258750|NCT01702714|EXPERIMENTAL|RO5083945 + carboplatin + paclitaxel|
62258751|NCT01702714|EXPERIMENTAL|RO5083945 + cisplatin +gemcitabine|
62840676|NCT00705549|EXPERIMENTAL|8|Alimta/Cisplatin
62258752|NCT03028870|EXPERIMENTAL|V120083 30 mg|V120083 30-mg capsules taken orally twice daily
62258753|NCT03028870|EXPERIMENTAL|V120083 60 mg|V120083 60-mg (2 x 30 mg) capsules taken orally twice daily
62840677|NCT00705549|EXPERIMENTAL|9|Alimta/Gemzar
62840678|NCT00705549|EXPERIMENTAL|10|Taxotere
62840679|NCT00705549|EXPERIMENTAL|11|Alimta
62840680|NCT01615913|EXPERIMENTAL|3% terbinafine patch|A 10-cm2 patch containing 3 mg terbinafine and 2 mg ketoconazole
62840681|NCT01615913|EXPERIMENTAL|6% terbinafine patch|A 10-cm2 patch containing 6 mg terbinafine and 2 mg ketoconazole
62840682|NCT01615913|EXPERIMENTAL|8% terbinafine patch|A 10-cm2 patch containing 8 mg terbinafine and 2 mg ketoconazole
62840683|NCT04469764|EXPERIMENTAL|Treatment (abemaciclib)|Patients receive abemaciclib PO BID on days 1-28. Patients with tumors that are hormone receptor positive also receive and anastrozole or letrozole per standard of care. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62840684|NCT01791712|EXPERIMENTAL|On-line hemodiafiltration|On-line hemodiafiltration is a type of renal replacement therapy that was assigned as the intervention to compare with the control arm
62840685|NCT01791712|ACTIVE_COMPARATOR|High-flux hemodialysis (control)|The standard high-flux hemodialysis is the routine renal replacement therapy in sepsis-related acute kidney injury patients and is assigned as the intervention for the control group.
62840686|NCT04723277|EXPERIMENTAL|Tealeaf - Year 1: Clusters (schools) and associated participants assigned to sequence 1|Clusters (schools) and associated participants assigned to sequence 1 will be under the EUC condition in the 1st year of trial participation and under the Tealeaf condition in all subsequent years.
62840687|NCT04723277|ACTIVE_COMPARATOR|Enhanced Usual Care - Year 1: Clusters (schools) and associated participants assigned to sequence 2|Clusters (schools) and associated participants assigned to sequence 2 will be under the EUC condition in the 1st and 2nd year of trial participation and under the Tealeaf condition in all subsequent years.
62056054|NCT01137188|NO_INTERVENTION|No intervention|Study subjects will receive routine dietary counseling for 8 weeks and will cross over to intervention upon completion
62056055|NCT02403882|EXPERIMENTAL|Order|The investigators arrange the placement of the targeted good to see if the order affects selection.
62056056|NCT02403882|EXPERIMENTAL|Packaging|The investigators adjust the packaging of the targeted good to determine the effects on selection.
62258754|NCT03028870|ACTIVE_COMPARATOR|Naproxen|Naproxen 500-mg capsules taken orally twice daily
62258755|NCT03028870|PLACEBO_COMPARATOR|Placebo|Capsules to match V120083 and/or naproxen taken orally twice daily
62258756|NCT01867060|OTHER|Personal Heart Rhythm Monitor|Automated Cardiac Event Recorder in parallel with Personal Heart Rhythm Monitor.
62258757|NCT05246436|ACTIVE_COMPARATOR|warm saline|Patients who used warm saline as a distention media in office hysteroscopy
62258758|NCT05246436|SHAM_COMPARATOR|room temperature saline|Patients who used room temprature saline as a distention media in office hysteroscopy
62258759|NCT02284789|OTHER|CAJAS evaluation|
62258760|NCT01021956|EXPERIMENTAL|WST11 (STAKEL)|Single doses of 2.5 mg/kg of STAKEL® in combination with transpupilar illumination of the macula at escalating doses from 12.5 to 75 Joules/cm².
62056057|NCT02403882|EXPERIMENTAL|Pricing|In food pantries, few products are priced. The investigators use pricing of products to determine its effect on selection.
62056058|NCT02403882|EXPERIMENTAL|Relative Proportions|The investigators adjust the proportion of the products to determine the effect on the selection of the targeted product.
62258761|NCT04135339|EXPERIMENTAL|Group A. Eccentric exercise.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
62258762|NCT04135339|EXPERIMENTAL|Group B. Concentric exercise.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
62258763|NCT04135339|EXPERIMENTAL|Group C. Isometric exercise.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
62840688|NCT04723277|EXPERIMENTAL|Tealeaf - Year 2: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
62840689|NCT04723277|ACTIVE_COMPARATOR|Enhanced Usual Care - Year 2: Clusters (schools) and associated participants assigned to sequence 2|EUC (control arm)
62840690|NCT04723277|EXPERIMENTAL|Tealeaf - Year 3: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
62840691|NCT04723277|ACTIVE_COMPARATOR|Enhanced Usual Care - Year 3: Clusters (schools) and associated participants assigned to sequence 2|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
62840692|NCT00915382|ACTIVE_COMPARATOR|3 weekly regimen of S-1 and cisplatin|
62840693|NCT00915382|ACTIVE_COMPARATOR|5 weekly regimen of S-1 and cisplatin|
62840694|NCT02584010|EXPERIMENTAL|Kelofin Aerosol|Silicon-based Aerosol that will be applied over the postoperative scar two times a day
62840695|NCT02584010|EXPERIMENTAL|Kelofin Gel|Silicon-based Gel that will be applied over the postoperative scar two times a day
62840696|NCT02584010|NO_INTERVENTION|Control|This group will not receive any intervention as a control group.
62840697|NCT03385980||Post-mortem patients|Post-mortem oncological patients (within 2-6 hrs from death, maximum time for tissue preservation).
62840698|NCT05080335|ACTIVE_COMPARATOR|TRANS-gender female instructor, with videos (TV)|Didactic materials use embedded WITH short videos of transgender youth; lesson led by a TRANS-gender woman with extensive experience as an educator on transgender health
62056059|NCT02403882|EXPERIMENTAL|Default Option|The investigators provide a targeted product to subjects at one point. Later, investigators offer subjects the possibility to exchange the targeted product for a close substitute.
62258764|NCT04135339|NO_INTERVENTION|Group D. Control.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
62056060|NCT00873938||1-supervised|
62056061|NCT00873938||2 -unsupervised|
62056062|NCT04416893||Children under 15 years of age in a community|Children under 15 years of age in a community : kindergarten, school, college, holiday center, etc.
62056063|NCT01980238|EXPERIMENTAL|cannula ileostomy|After LAR, experimental group will accept cannula ileostomy. Operation has described in the Detailed Description.
62258765|NCT03060135|NO_INTERVENTION|No Intervention: Control|A questionnaire that asks individuals what components of an online intervention they might find useful.
62258766|NCT03060135|ACTIVE_COMPARATOR|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
62258767|NCT03060135|EXPERIMENTAL|Hello Sunday Morning|Internet based program designed to assess drinking patterns, and support self-determined goals for abstinence, by providing users with an online platform and community to discuss progress and goals.
62258768|NCT05666336|EXPERIMENTAL|Experimental Group|"The treatment regimen consists of four drugs, a glucocorticoid plus Telitacicept plus hydroxychloroquine plus an immunosuppressor.~Prednisone(30mg, Qd) or Methylprednisolone(24mg, Qd) plus Telitacicept(160mg, Qw) plus Hydroxychloroquine (0.2g, Qd) plus cyclophosphamide(0.8g, Qm) or Mycophenolate Mofetil (0.5g, Bid) or Tacrolimus (1mg, Bid) The above treatment will continue for 24 weeks."
62615754|NCT04012424|EXPERIMENTAL|Drug (400mg Curcumin) Curcumin is apice|"Curcumin is an ancient coloring spice of Asia which is powerful antioxidant , it has hepatoprotective effect and traditionally used for many remedies . Interestingly, it has various pharmacological activities including analgesic, anti-inflammatory , It is even reported to have antimicrobial effect .~Medical clinical trials reported on the analgesic effect of curcuminoids in reducing postsurgical pain osteoarthritis and rheumatoid arthritis .~patients will take 400mg capsule curcumin one hour before endodontic treatment and study its effect on post endodontic pain immediately and after 8,12,24,48 hours after completion of endodontic treatment"
62258769|NCT05415475|EXPERIMENTAL|Intravenous of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x107 copy/kg
62258770|NCT05415475|EXPERIMENTAL|intraperitoneal injection of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x107 copy/kg
62258771|NCT04898270|EXPERIMENTAL|MARTAs combined with flupentixol|"Flupentixol tablets are indicated for:~• maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation, or hyperactivity.~Other Names:~Fute tables, Fluanxol~Multi-acting receptor-targeted antipsychotics (MARTAs): clozapine, olanzapine, quetiapine."
62615755|NCT04012424|PLACEBO_COMPARATOR|Starch(400mg starch) starch is sometype of carbohydrates|patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion
62258772|NCT04898270|ACTIVE_COMPARATOR|Multi-acting receptor-targeted antipsychotics (MARTAs)|clozapine, olanzapine, quetiapine
62258773|NCT03870984|EXPERIMENTAL|wNUTS, low-caloric diet plus nuts|low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
62258774|NCT03870984|OTHER|w/oNUTS, low-caloric diet without nuts|low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
62615756|NCT00853879|ACTIVE_COMPARATOR|Arm 1. B6, B12, folate|Triple therapy with folate. Intervention #1.
62615757|NCT00853879|ACTIVE_COMPARATOR|Arm 2. B6, B12, L-methylfolate|Triple therapy with L-methylfolate. Intervention #2
62615758|NCT00853879|PLACEBO_COMPARATOR|Arm 3. B6, B12, Placebo|Triple therapy with placebo. Intervention #3.
62056064|NCT01980238|ACTIVE_COMPARATOR|loop ileostomy|After LAR, active comparator group will accept loop ileostomy. This operation is well known by colorectal surgeons.
62056065|NCT03331484|OTHER|Ticagrelor and Rivaroxaban|All participants will be prescribed ticagrelor 90 mg twice daily and rivaroxaban 15 mg once daily for a year.
62258775|NCT01423162|EXPERIMENTAL|Drink with Vit C then drink without Vit C|Fortified oat drink with vitamin C on day 1 followed by fortified oat drink without vitamin C on day 2
62445022|NCT03385096|ACTIVE_COMPARATOR|Melphalan|For MM patients undergoing auto-HSCT，Melphalan conditioning regimen was Melphalan 200mg/m2 on day -2.
62445023|NCT04018144||Group-1|Healthy individuals
62445024|NCT04018144||Group-2|Periodontitis patients-stage 3-grade B
62445025|NCT04018144||Group-3|Periodontitis patients-stage 3-grade C
62445026|NCT03392597|EXPERIMENTAL|Brothers as Allie|Brothers as Allies is a strengths-based group approach to promote boys' and young men's safe and healthy passage through the pre-teen and adolescent years by addressing rigid beliefs and norms about masculinity that are harmful to the health, safety, relationships and opportunities of boys and young men. Groups of six to ten boys of similar age and development meet weekly with one or two facilitators for 1.5 to 2 hours for ten or more weeks. Meetings include warm up activities, an opportunity for check-in, experiential activities that address gender relevant topics (e.g., group challenges, games, skits, role plays), and a reflection and group dialogue component.
62445027|NCT03392597|ACTIVE_COMPARATOR|Programming-as-Usual|Usual programming implemented in afterschool programs.
62445028|NCT02292238|EXPERIMENTAL|Benfotiamine|The patients in this arm will be treated with benfotiamine
62445029|NCT02292238|PLACEBO_COMPARATOR|Placebo|The patients in this arm will be treated with placebo
62445030|NCT00977925|EXPERIMENTAL|Fibrin Pad|
62445031|NCT00977925|ACTIVE_COMPARATOR|Standard of Care|
62445032|NCT00261729|EXPERIMENTAL|1|paroxetine
62056066|NCT03520400|EXPERIMENTAL|Exercise Intervention Group|Group receives one year of exercise and lifestyle intervention
62056067|NCT03520400|NO_INTERVENTION|PCI group (usual care)|Group receives standard clinical care with no intervention
62445033|NCT00261729|PLACEBO_COMPARATOR|2|placebo
62445034|NCT00261729|EXPERIMENTAL|3|prazosin
62445035|NCT03572933|EXPERIMENTAL|Ganaxolone|ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
62445036|NCT03572933|PLACEBO_COMPARATOR|Placebo|placebo suspension 3x's /day for 17 weeks
62445037|NCT03152461||Surgical patients|Patients undergoing elective cardiac or vascular surgery involving bypass, or major spine surgery, or surgical patients presenting with acute bleeding in a post-surgical unit.
62445038|NCT04804449||Rheumatoid arthritis and psoriatic arthritis|Patients with rheumatoid arthritis or psoriatic arthritis, who require an intra-articular corticosteroid injection
62445039|NCT00762957|EXPERIMENTAL|TAK-559 16 mg QD + Metformin QD|
62445040|NCT00762957|EXPERIMENTAL|TAK-559 32 mg QD + Metformin QD|
62445041|NCT00762957|ACTIVE_COMPARATOR|Metformin QD|
62445042|NCT01717014|EXPERIMENTAL|Covidien Radial Reload Stapler with Tri-Staple Technology|Covidien Radial Reload Stapler with Tri-Staple Technology in open low anterior resection or anterior proctosigmoidectomy
62445043|NCT00770003|EXPERIMENTAL|1|
62445044|NCT00770003|PLACEBO_COMPARATOR|2|
62445045|NCT01499875|OTHER|Phenoxymethylpenicillin|It is a descriptive trial to find out about the pharmacokinetics
62445046|NCT02125188|EXPERIMENTAL|Desmopressin|Desmopressin 3ug/kg in saline 100ml ivdrip before surgery
62445047|NCT02125188|PLACEBO_COMPARATOR|saline|saline 100ml ivdrip before surgery
62615759|NCT03704012|NO_INTERVENTION|Routine Care|Control Group receives routine care.
62615760|NCT03704012|EXPERIMENTAL|Massage and kinesiotherapy|Intervention Group, receives massage and kinesiotherapy. Behavioral: Protocol of massage therapy and kinesiotherapy. Infants received massage and kinesiotherapy twice a day; 15 minutes each.
62615761|NCT02479464|NO_INTERVENTION|Part 1|This is the treatment as usual arm to monitor the current standard clinical practice
62615762|NCT02479464|OTHER|Part 2|This group will be provided with genotyping results after baseline visit to guide clinical medication management
62615763|NCT05699876|EXPERIMENTAL|Melatonin|
62615764|NCT05699876|ACTIVE_COMPARATOR|Gabapentin|
62615765|NCT00493987|ACTIVE_COMPARATOR|Testosterone enanthate|
62615766|NCT00493987|PLACEBO_COMPARATOR|Duatesteride|Duatesteride
62615767|NCT06232395||malignant group|Subjects diagnosed with gastric cancer.
62615768|NCT06232395||non-malignant group|Healthy individuals and subjects with gastritis, gastric ulcer, gastric polyp or other benign gastric diseases.
62615769|NCT06406374||Parkinson's disease patients|"Patients will present the following inclusion criteria:~* Diagnosis of idiopathic Parkinson's disease according to the 2015 Movement Disorders Society (MDS) criteria (Postuma et al. Mov Dis, 2015);~* Italian speaker;~* Mini-mental state examinations (MMSE) score \>25;~* Presence of symptoms fluctuations, as per a Wearing-off questionnaire 19 (WOQ-19) score\>=2;~* Stable antiparkinsonian medications for at least three months;~* Ability to provide informed consent."
62840699|NCT05080335|ACTIVE_COMPARATOR|CIS-gender female instructor, with videos (CV)|Didactic materials use embedded WITH short videos of transgender youth; lesson led by a CIS-gender woman with extensive experience as an educator on transgender health
62056068|NCT02480595||EVAR|Patients undergoing endovascular repair with the latest generation Aorfix™ AAA Flexible Stent Graft System for treatment of abdominal aortic and aorto-iliac aneurysms where the aorta in the aneurysm neck is bent through an angle between 0° and 90°
62056069|NCT06208085|EXPERIMENTAL|Avocado|Participants will be provided avocados and asked to consume an avocado a day for 12 weeks.
62615770|NCT02030496|ACTIVE_COMPARATOR|Closed reduction and plaster|Closed reduction will be performed and after adequate reduction has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks.
62056070|NCT06208085|NO_INTERVENTION|No Avocado|Comparison arm in which no intervention occurs.
62056071|NCT02098213|ACTIVE_COMPARATOR|Immediate Spa treatment|Three week course of spa treatment soon after randomization
62056072|NCT02098213|SHAM_COMPARATOR|Late Spa treatment|Three week course of spa treatment soon after 4,5 months visit
62056073|NCT03586583||FBP (old processing)|Filtered back projection; old processing.
62056074|NCT03586583||ISR (new processing)|Iterative super resolution; new processing.
62056075|NCT02857530|EXPERIMENTAL|rhTPO|rhTPO injection
62056076|NCT02857530|PLACEBO_COMPARATOR|control|without rhTPO injection
62615771|NCT02030496|ACTIVE_COMPARATOR|open reduction and internal fixation|The intervention group will be treated with open reduction and internal fixation with a volar locking plate.
62615772|NCT04918407|EXPERIMENTAL|Empagliflozin|Adding 25mg Empagliflozin on Insulin
62615773|NCT04918407|ACTIVE_COMPARATOR|Insulin alone|Just contriling the blood glucose with Insulin
62056077|NCT03006484||Before Period|Patients who developed in-hosptial cardiac arrest before the implementation of new legislation on life-sustaining treatments
62056078|NCT03006484||After Period|Patients who developed in-hosptial cardiac arrest after the implementation of new legislation on life-sustaining treatments
62258776|NCT01423162|EXPERIMENTAL|Drink without Vit C then drink with Vit C|Fortified oat drink without vitamin C on day 1 followed by fortified oat drink with vitamin C on day 2
62615774|NCT04466605|EXPERIMENTAL|Tele-Yoga Therapy|All patients randomized to the intervention group had one to one yoga sessions with yoga therapist twice a week for 45 minutes on secure virtual platform. Patients were encouraged with home practice to follow everyday at least for 30-mins.
62615775|NCT04466605|ACTIVE_COMPARATOR|Usual Care|Patients randomized to usual care continued to receive care for their chronic musculoskeletal pain from their primary care physician. There was no attempt by to influence clinical management unless an emergency arose
62615776|NCT06396143||Neoadjuvant chemotherapy group|a. Pathological diagnosis of gastric adenocarcinoma; b. The CT evaluation of gastric cancer is clinical stage II-IVa (≥ T3, and/or lymph node positive), with or without local tissue or organ invasion, and no distant metastasis; c. Acceptance criteria for 2-4 courses of 5-FU+platinum based neoadjuvant chemotherapy regimen. D2 gastric cancer radical surgery will be performed after the neoadjuvant treatment regimen； e. Enhanced CT images and digital images of HE stained gastroscopy biopsy sections before neoadjuvant therapy are available; f. Complete clinical diagnosis and treatment information, as well as expression information of targeted and immunotherapy related molecular markers.
62840700|NCT05080335|ACTIVE_COMPARATOR|CIS-gender female, with NO videos (CN)|Didactic materials do NOT use short videos of transgender youth \[until AFTER completion of the POST outcome measures\]; lesson is led by a CIS-gender woman with extensive experience as an educator on transgender health
62840701|NCT05080335|NO_INTERVENTION|No intervention control|Subjects randomized to this arm will complete the baseline assessment and the post assessment thirty days later, but just \*before\* receiving the intervention (TV).
62056079|NCT04457830|EXPERIMENTAL|Single arm|
62056080|NCT02594748|EXPERIMENTAL|Experimental group|Intervention is administered to patients in this Arm. The intervention is self-management education based on the theory of planned behavior(TPB). The intervention of experimental group is individual guide and face to face education based on TPB.
62056081|NCT02594748|ACTIVE_COMPARATOR|Comparison group|The comparison group will receive routine care
62258777|NCT01439321||Patient with Chronic Immune Thrombocytopenic Purpura|Patients with chronic ITP who switch from their previous treatment of corticosteroids, rituximab, or eltrombopag or romiplostim to eltrombopag or romiplostim and have been on the new treatment for at least four weeks
62840702|NCT01368913||Patients treated with orally disintegrating tablet|
62840703|NCT01368913||Patients treated with tablets|
62615777|NCT06396143||Neoadjuvant chemotherapy combined with PD1 or PDL1 group|a. Pathological diagnosis of gastric adenocarcinoma; b. The CT evaluation of gastric cancer is clinical stage II-IVa (≥ T3, and/or lymph node positive), with or without local tissue or organ invasion, and no distant metastasis; c. Acceptance criteria for a 2-4 course treatment regimen based on 5-FU+platinum neoadjuvant chemotherapy combined with anti PD-L1 therapy; d. D2 gastric cancer radical surgery was performed after the new adjuvant treatment regimen; e. Enhanced CT images and digital images of HE stained gastroscopy biopsy sections before neoadjuvant therapy are available; f. Complete clinical diagnosis and treatment information, as well as expression information of targeted and immunotherapy related molecular markers.
62615778|NCT06396143||Neoadjuvant chemotherapy combined with trastuzumab group|a. Pathological diagnosis of gastric adenocarcinoma; b. The CT evaluation of gastric cancer is clinical stage II-IVa (≥ T3, and/or lymph node positive), with or without local tissue or organ invasion, and no distant metastasis; c. Acceptance criteria for 2-4 courses of 5-FU+platinum neoadjuvant chemotherapy combined with trastuzumab regimen; d. D2 gastric cancer radical surgery was performed after the new adjuvant treatment regimen; e. Enhanced CT images and digital images of HE stained gastroscopy biopsy sections before neoadjuvant therapy are available; f. Complete clinical diagnosis and treatment information, as well as expression information of targeted and immunotherapy related molecular markers.
62615779|NCT03373461|PLACEBO_COMPARATOR|Placebo|Placebo identical to LNP023 twice a day
62615780|NCT03373461|EXPERIMENTAL|LNP023 10 mg BID|10 mg taken twice a day.
62615781|NCT03373461|EXPERIMENTAL|LNP023 50 mg BID|50 mg taken twice a day.
62615782|NCT03373461|EXPERIMENTAL|LNP023 100 mg BID - Part 2|100 mg taken twice a day.
62615783|NCT03373461|EXPERIMENTAL|LNP023 200 mg BID|200 mg taken twice a day.
62615784|NCT00282152|ACTIVE_COMPARATOR|ODT|Optimal drug therapy: The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary.
62615785|NCT00282152|EXPERIMENTAL|DBS+ODT|"Subjects receive bilateral subthalamic nucleus (B-STN) DBS and continue to take optimal drug therapy as prescribed by their treating neurologist.~B-STN DBS: Deep brain stimulation (DBS) of both the right and left sub-thalamic nucleus (STN) is an FDA approved treatment for mid- and advanced PD. DBS is not approved for early stage PD. In mid- and advanced stage Parkinson's disease, using DBS in this area of the brain lessens symptoms and allows patients to take less drug to control the disease. Dosage and frequency are not applicable to the DBS. Once the DBS is placed, unless deemed necessary, it will not be removed.~Optimal drug therapy: The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary."
62615786|NCT04148235||Patients|Patients who have been diagnosed with Celiac Disease
62615787|NCT03326752|EXPERIMENTAL|Dose Escalation Cohort 1-5|"Cohort 1-4~* DV281 - Dose Level 1-5~* DV281 in combination with nivolumab~* DV281 is administered via a breath actuated nebulizer"
62615788|NCT03326752|EXPERIMENTAL|Dose Expansion (RP2D)|"4 Cohorts~* Preliminary Recommended Phase 2 dosing of DV281 in combination with nivolumab~* Cohort 1: Non-squamous and non-EGFR/ ALK mutation and progressed on anti-PD-1/L1 therapy~* Cohort 2: Non-squamous and EGFR/ ALK mutation and progressed on targeted therapy~* Cohort 3: Squamous and anti-PD-1/ L1 therapy experienced~* Cohort 4: Squamous and anti-PD-1/L1 therapy naive~* DV281 is administered via a breath actuated nebulizer."
62615789|NCT01473706||Consumers|Adults aged ≥ 65 years; Employed part-time, unemployed, retired, full-time or a homemaker; English speaking
62615790|NCT01473706||Caregivers of Consumers|Family, relative, friend, professional caregiver of an individual age ≥ 65 years; Lives with individual aged ≥ 65 years OR Visits individual aged ≥ 65 years five or more days a week; Makes decisions or has strong influence on the individual aged ≥ 65 years' diet and medical needs; English speaking
62615791|NCT06443606|EXPERIMENTAL|Bezafibrate 400 mg group in addition to UDCA therapy|Bezafibrate 400 mg and Placebo of Bezafibrate 200 mg until 48 weeks in double blind
62615792|NCT06443606|EXPERIMENTAL|Bezafibrate 200 mg group in addition to UDCA therapy|Bezafibrate 200 mg and Placebo of Bezafibrate 400 mg until 96 weeks in double blind.
62615793|NCT06443606|PLACEBO_COMPARATOR|Placebo group in addition to UDCA therapy|Placebo of Bezafibrate 400 mg Placebo of Bezafibrate 200 mg until 48 weeks in double blind. And follow-up extension phase of bezafibrate 400 mg and bezafibrate 200 mg until 48 weeks in double blind.
62615794|NCT01313351||Device testing|Tears were collected from subjects to apply to the RPS InflammaDry detector and were clinically evaluated.
62615795|NCT04085159|EXPERIMENTAL|CART/CTL/DCvac cells to treat cancer|
62258778|NCT04303130|EXPERIMENTAL|Camrelizumab (SHR-1210) Combined With Endostar|"Carelizumab: PD-1 antibody SHR-1210: SHR-1210 is administered by intravenous infusion, a fixed dose of 200 mg, and intravenous infusion over 30 minutes 20 minutes, not longer than 60 minutes), once every 3 weeks, continued medication until the disease progresses intolerable toxicity and receive immunotherapy for a maximum of 2 years (35 cycles); Endo: once a day, 7.5 mg / m2 intravenous infusion, continuous administration for 14 days, rest for a week (or the corresponding dose using a micro-micropump), continued medication until disease progression toxicity intolerance.~The combination regimen is a medication cycle every three weeks (21 days)."
62615796|NCT00750919|EXPERIMENTAL|Esmirtazapine|Participants receive esmirtazapine 4.5 mg tablet, orally, once daily (QD) for up to 6 months.
62615797|NCT02738229|EXPERIMENTAL|Valacyclovir|"Valacyclovir will be given twice a day with following doses according to weight:~10 to 13,9 kg : Valacyclovir 250 mg PO twice per day 14 to 19,9 kg : Valacyclovir 375 mg PO twice per day 20 to 28 kg : Valacyclovir 500 mg PO twice per day"
62615798|NCT02738229|PLACEBO_COMPARATOR|control|placebo pill
62615799|NCT04746365|EXPERIMENTAL|ivermectin|ivermectin was given as a total daily dose of 36 mg on days 0, 3, 6. The daily dose was divided into 3 equal doses of 12 mg (2 tablets) every 8 hours
62258779|NCT04167046||Control|Patients in this group did not receive an erector spinae block. Data are obtained retrospectively (years 2017 and 2018).
62615800|NCT04746365|EXPERIMENTAL|hydroxychloroquine|hydroxychloroquine was given as 200 mg (one tablet) every 12 hours for 5 days
62615801|NCT04746365|PLACEBO_COMPARATOR|Placebo|Unlabelled standard treatment according to the clinical condition of patients
62615802|NCT01026337||Arm I|"Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.~Patients undergo dynamic contrast-enhanced MRI at baseline and after the first 4 weeks of sunitinib malate."
62056082|NCT02568631|EXPERIMENTAL|serious game JeStiMulE|"* Evaluation of the social cognition for adults with autism.~* The objective of the players of JeStiMulE (Educational Game for Multisensory Stimulation of Children with developmental disorders) will be to end the game after a period of learning and two periods of game (with emotional words and with idiomatic expressions understanding each three modules). The session ends when the module is carried out, what corresponds approximately at 1 am by module, that is 6 sessions of game.~* Evaluation of the social cognition for adults with autism."
62840704|NCT01227993|EXPERIMENTAL|Finasteride|Participants are treated with 5 mg oral finasteride daily when they have clinically significant subretinal fluid accumulation, defined as any subretinal fluid in the macula with a volume of at least 0.1 microliter and causing visual change such as reduced acuity, metamorphopsia, or microperimetry deficits.
62840705|NCT03862911|ACTIVE_COMPARATOR|Standard of Care Treatment (Arm 1)|Standard of care, palliative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
62840706|NCT03862911|EXPERIMENTAL|Stereotactic Arm (Arm 2)|Stereotactic ablative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
62056083|NCT02568631|PLACEBO_COMPARATOR|control video game|"* Evaluation of the social cognition for adults with autism.~* The objective of the players of the control video game will be to play 6 sessions of one hour.~* Evaluation of the social cognition for adults with autism."
62258780|NCT04167046||Erector spinae block|Patients in this group receive an erector spinae block. Data will be obtained prospectively.
62258781|NCT06185829|ACTIVE_COMPARATOR|Usual neuroleptanalgesic treatment|
62840707|NCT01364168||First ever acute ischemic stroke|Patients over 18 years and without prior stroke according to WHO criteria, displaying an ischemic stroke, onset within the last 7 days, language German
62056084|NCT02716948|EXPERIMENTAL|Treatment (nivolumab, stereotactic radiosurgery)|Patients receive nivolumab IV over 60 minutes on day 1. Patients then undergo stereotactic radiosurgery on day 8 per standard of care. Courses with nivolumab repeats every 14 days in the absence of disease progression or unacceptable toxicity.
62056085|NCT06162832|ACTIVE_COMPARATOR|Allograft|Will be used Demineralized cancellous allograft 250-1000um
62258782|NCT06185829|EXPERIMENTAL|Hypnoanalgesia|
62258783|NCT02386436|EXPERIMENTAL|Cohort 1- GSK2330811(0.1 mg/kg)|Subjects will be randomised to receive either 0.1 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
62258784|NCT02386436|EXPERIMENTAL|Cohort 2- GSK2330811(0.3 mg/kg)|Subjects will be randomised to receive either 0.3 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
62258785|NCT02386436|EXPERIMENTAL|Cohort 3- GSK2330811(1 mg/kg)|Subjects will be randomised to receive either 1 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
62258786|NCT02386436|EXPERIMENTAL|Cohort 4- GSK2330811(3 mg/kg)|Subjects will be randomised to receive either 3 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
62258787|NCT02386436|EXPERIMENTAL|Cohort 5- GSK2330811(6 mg/kg)|Subjects will be randomised to receive either 6 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
62056086|NCT06162832|SHAM_COMPARATOR|Saline Solution|The saline solution will be used for hydrate the bone graft 20 minutes before the placement at the defect
62056087|NCT06162832|EXPERIMENTAL|rhPDGF-BB (GEM21, Lynch Biologics)|The rhPDGF-BB will be used for hydrate the bone graft 20 minutes before the placement at the defect
62056088|NCT04782557|EXPERIMENTAL|EUS-guided PVA and HVA|Patient will undergo EUS-guided PVA and HVA
62258788|NCT02322125|EXPERIMENTAL|ReWalk training|ReWalk exoskeleton training: 1.5 hr/day, 4 days/week, for 12-14 weeks (approximately 50 training sessions). Participants will progress through the following: sit-to-stand, stand-to-sit, standing balance and weight shift, walking on smooth ground, stopping, turning while walking, walking on rough ground, ascending and descending slopes, ascending and descending steps and curbs.
62258789|NCT05487898|EXPERIMENTAL|Cycyling wheelchair|Volunteers join the cycling wheelchair training
62258790|NCT02450175|NO_INTERVENTION|Cases|Patients with cancer whose platelets are examined
62840708|NCT06107881|EXPERIMENTAL|Telerehabilitation with low vision provider|Low Vision Rehabilitation for use of magnification or visual assistive devices using videoconferencing for remotely delivered follow-up care
62615803|NCT01044758|EXPERIMENTAL|aMCI_62.5mg drug first, then placebo|"Amnestic MCI:~62.5mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
62840709|NCT06107881|ACTIVE_COMPARATOR|Usual Care In-Office|Low Vision Rehabilitation in-office for use of magnification or visual assistive devices
62840710|NCT06042062|EXPERIMENTAL|"Spacer group"|The subjects who are assigned to Articulating Spacers in two-stage exchange arthroplasty.
62840711|NCT06042062|EXPERIMENTAL|"Novel spacer group"|The subjects who are assigned to United Cellbrick Knee Spacer in two-stage exchange arthroplasty.
62056089|NCT05823246|EXPERIMENTAL|QLF31907|single arm with QLF31907
62056090|NCT04426864|ACTIVE_COMPARATOR|Supervised Aerobic Plus Stretching Exercises Group|The participants were instructed to perform the walking exercise at their target HR on a treadmill and stretching exercises before and after the exercise program in the Sports Rehabilitation Unit of Pamukkale University.
62056091|NCT04426864|EXPERIMENTAL|Supervised Resistance Plus Stretching Exercises Group|The participants were instructed to perform resistance exercises using weight machines and stretching exercises before and after the exercise program in the Sports Rehabilitation Unit of Pamukkale University.
62056092|NCT04426864|EXPERIMENTAL|Home-based Stretching Exercises Group|The participants were instructed to perform the stretching exercises at home.
62258791|NCT02450175|PLACEBO_COMPARATOR|Control|Patients without cancer whose platelets are examined for comparison
62258792|NCT04050670|EXPERIMENTAL|Tirzepatide - Upper Arm|Participants received 5mg Tirzepatide by subcutaneous injection on upper arm.
62258793|NCT04050670|EXPERIMENTAL|Tirzepatide - Thigh|Participants received 5mg Tirzepatide by subcutaneous injection on thigh.
62258794|NCT04050670|ACTIVE_COMPARATOR|Tirzepatide - Abdomen|Participants received 5mg Tirzepatide by subcutaneous injection on abdomen.
62840712|NCT04926389|EXPERIMENTAL|low-level laser therapy applied on days 0, 3,7,14 & every 2 weeks|
62840713|NCT04926389|ACTIVE_COMPARATOR|low-level laser therapy applied every 3 weeks|
62258795|NCT01617070|EXPERIMENTAL|LNAA, washout, Kuvan, and LNAA+Kuvan|One group of 12 subjects, each under 4 conditions (each phase is 4 weeks)
62258796|NCT06367231||Serious Computer Game Intervention|"Older Adults (healthy), Older adults with MCI, older adults with dementia~Each participant will undergo three sessions, spaced one week apart. These sessions will take place either at locations that support the research team's activities or at the participants' homes, offering flexibility to accommodate individual circumstances. The format of these sessions can vary, being either group-based or individual.~Each session is designed to last approximately one hour, with a maximum duration of 90 minutes to ensure thoroughness without overwhelming participants."
62258797|NCT03184961|EXPERIMENTAL|lung recruitment maneuver|"Heart rate, mean arterial pressure, stroke volume, pulse pressure variations, pleth variability index, and photoplethysmographic waveform were recorded before lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s), during lung recruitment maneuver when stroke volume reached its minimal value.~Cardiac index measured before and after volume expansion (10ml/kg saline, 0.9%, infused during 10 min). Patients were considered as responders to fluid administration if cardiac index increased greater than or equal to 15%."
62258798|NCT00349856|ACTIVE_COMPARATOR|1|
62840714|NCT05172908|ACTIVE_COMPARATOR|Group Dexa|"After induction of general anesthesia, an ultrasound-guided block of the ilioinguinal and iliohypogastric nerve block will be performed using 20 ml 0.5% bupivacaine. 5 mg dexamethasone in a 50 ml syringe containing normal saline will be infused within 15 minutes. A multimodal analgesia regimen will be applied postoperatively.~The syringe will be prepared by a nurse outside the research team and the study participants, care providers, and data collectors will be blinded to the allocation throughout the study"
62840715|NCT05172908|SHAM_COMPARATOR|Group S|"After induction of general anesthesia, an ultrasound-guided block of the ilioinguinal and iliohypogastric nerve block will be performed using 20 ml 0.5% bupivacaine. 50 mL normal saline in a 50 ml syringe will be infused within 15 minutes. A multimodal analgesia regimen will be applied postoperatively.~The syringe will be prepared by a nurse outside the research team and the study participants, care providers, and data collectors will be blinded to the allocation throughout the study"
62840716|NCT01103193|ACTIVE_COMPARATOR|remifentanil injected|a mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
62840717|NCT01103193|ACTIVE_COMPARATOR|sevoflurane in step up concentration|a mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
62840718|NCT01524796||Patients with peripheral neuropathic pain treated with Lyrica|
62840719|NCT04952948|EXPERIMENTAL|PILATES Method Training Group|The PILATES program at moderate intensity lasted 12 weeks, at a frequency of 3 times a week, and with duration of 60 minutes for each exercise session.
62840720|NCT04952948|SHAM_COMPARATOR|CONTROL Group|While the PILATES Group participated in the intervention with physical exercises, the CONTROL group only participated in the functional capacity and blood pressure assessments. However, at the end of the intervention in the PILATES Group, the CONTROL Group was invited to participate in a similar training program.
62840721|NCT00594815|EXPERIMENTAL|1|
62840722|NCT04793737|EXPERIMENTAL|Precision Radiation (SBRT)|Precision radiation of melanoma metastases
62840723|NCT04919798|EXPERIMENTAL|Urinating with NIBED first, without NIBED second|Urinating with NIBED first, without NIBED second
62840724|NCT04919798|EXPERIMENTAL|Urinating without NIBED first, with NIBED second|Urinating without NIBED first, with NIBED second
62840725|NCT03869697|EXPERIMENTAL|SCB-313|Cohorts in SAD phase: 5 mg, 10mg, 20mg, 40mg, 80 mg. Cohort in MAD phase: biological effective dose determined from SAD phase. 1 intrapleural injection of SCB-313 on Day 1 for the SAD cohorts, and 3 intrapleural injections of SCB-313 on Days 1, 2 and 3 for the MAD cohort.
62258799|NCT00330876|EXPERIMENTAL|Pitavastatin 2 mg QD|Pitavastatin 2 mg once daily
62258800|NCT00330876|EXPERIMENTAL|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
62258801|NCT04164836|NO_INTERVENTION|control group|nose selection will be done by random table
62258802|NCT04164836|EXPERIMENTAL|rhinoscope group|nose selection will be done by rhinoscopy
62258803|NCT04802525|EXPERIMENTAL|Moderate-intensity aerobic exercise training without dietary control group|
62258804|NCT04802525|EXPERIMENTAL|Low-fat diet program without exercise intervention group|
62258805|NCT04802525|EXPERIMENTAL|Moderate-intensity aerobic exercise training plus a low-fat diet program group|
62258806|NCT00880399|PLACEBO_COMPARATOR|Placebo|inactive placebo to match orvepitant 30 and 60 mg dosage forms
62258807|NCT00880399|EXPERIMENTAL|Orvepitant 30 mg|30 mg/day (low dose)
62258808|NCT00880399|EXPERIMENTAL|Orvepitant 60 mg|60 mg/day (high dose)
62258809|NCT01924182|OTHER|IT group (Intrathecal Morphine Sulfate)|SynchroMed Infusion System and Intrathecal Morphine Sulfate
62258810|NCT01924182|OTHER|Conventional Medical Management|Conventional Medicine, and then SynchroMed Infusion System and Intrathecal Morphine Sulfate
62840726|NCT04553380|EXPERIMENTAL|community patient group|The community doctor adjusts the basic insulin dosage daily according to the fasting blood glucose of the patient under the guidance of the specialist.
62840727|NCT04553380|ACTIVE_COMPARATOR|inpatient group|Endocrinologists in the in-patient department use the same basic insulin dose adjustment regimen to treat patients.
62840728|NCT01463085|PLACEBO_COMPARATOR|Control foods|3 servings per day of control foods
62840729|NCT01463085|EXPERIMENTAL|Low-fat dairy|3 servings per day of low-fat dairy products
62840730|NCT03179319|EXPERIMENTAL|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
62840731|NCT03179319|NO_INTERVENTION|Standard of Care|Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
62840732|NCT03749837|EXPERIMENTAL|C- MAC VS|Intubation with C- MAC VS
62840733|NCT03749837|ACTIVE_COMPARATOR|Video Endoscope|Intubation with standard fiberoptic scope
62840734|NCT04455815|EXPERIMENTAL|Camostat|Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days.
62840735|NCT04455815|NO_INTERVENTION|Control arm|Patient to receive best supportive care.
62056093|NCT03269240|EXPERIMENTAL|LDHF plus m-Mentoring|"Participants will undergo pre-training assessment comprising multiple-choice questions and objective structured clinical examination (OSCE) using manikins. Training is divided into two 4-day low-dose sessions at the health facility or onsite training. Pre-training and immediate post-training assessments results will be compared. A score of ≥80% is acceptable competence (pass). During the one-month intervals between training sessions, participants practice using manikins to reinforce their competencies through simulation-based practices, facilitated by facility-based trained Peer Practice Coordinators (PPCs). The PPCs will also receive structured, monthly half-hour mentoring calls that will provide remote support, answering questions, providing guidance and reinforcing key messages. Acquisition of knowledge and clinical skills is measured."
62258811|NCT03437382|OTHER|RFA + radioembolization|Quirem Medical Holmium-166 radioembolization microspheres
62258812|NCT01399554|NO_INTERVENTION|Assessment Only|
62258813|NCT01399554|EXPERIMENTAL|Weekly Exercise Counseling Intervention|
62258814|NCT05555043|ACTIVE_COMPARATOR|Control group|Participants receive passive ultrasonic irrigation for endodontic irrigation treatment and will be followed for 12 months after treatment to assess radiographic healing of the periapex and clinical healing of the tooth.
62258815|NCT05555043|EXPERIMENTAL|GentleWave group|Participants receive GentleWave System for endodontic irrigation treatment and will be followed for 12 months after treatment to assess radiographic healing of the periapex and clinical healing of the tooth.
62258816|NCT05555043|EXPERIMENTAL|Waterlase group|Participants receive Waterlase iPlus for endodontic irrigation treatment and will be followed for 12 months after treatment to assess radiographic healing of the periapex and clinical healing of the tooth.
62258817|NCT00634634|EXPERIMENTAL|Sorafenib and Letrozole|
62258818|NCT02520375|EXPERIMENTAL|Prebiotic|This group will be administered a prebiotic mouthrinse and toothpaste
62258819|NCT02520375|PLACEBO_COMPARATOR|Control|This group will be administered a control mouthrinse and toothpaste
62615804|NCT01044758|EXPERIMENTAL|aMCI_Placebo first, then 62.5mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 62.5mg levetiracetam twice daily (two weeks)"
62615805|NCT01044758|EXPERIMENTAL|aMCI_125mg drug first, then placebo|"Amnestic MCI:~125mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
62615806|NCT01044758|EXPERIMENTAL|aMCI_Placebo first, then 125mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 125mg levetiracetam twice daily (two weeks)"
62615807|NCT01044758|EXPERIMENTAL|aMCI_250mg drug first, then placebo|Amnestic MCI: 250mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)
62615808|NCT01044758|EXPERIMENTAL|aMCI_Placebo first, then 250mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 250mg levetiracetam twice daily (two weeks)"
62258820|NCT05773794|EXPERIMENTAL|Dietary flavonoids (soymilk, green tea, or blueberry) consumption|Each subject takes breakfast with 460 ml of soymilk, green tea, or blueberry in a single dose, and samples (plasma, urine, and stool samples) at different time points were collected following the administrations of soymilk, green tea, or blueberry blend.
62258821|NCT05773794|PLACEBO_COMPARATOR|Control group|Each subject takes breakfast with 460 ml of milk or water in a single dose, and samples (plasma, urine, and stool samples) at different time points were collected following the administration of milk or water.
62258822|NCT02701387|EXPERIMENTAL|AnyRidge Implant|Experimental implant (Megagen AnyRidge dental implant) placed in a healed edentulous site to replace a missing tooth.
62258823|NCT02701387|ACTIVE_COMPARATOR|EZ Plus Implant|Comparative implant (Megagen EZ Plus dental implant) placed in a healed edentulous site to replace a missing tooth.
62258824|NCT03785925|EXPERIMENTAL|Combination of bempegaldesleukin (NKTR-214) + nivolumab|Participants will receive bempegaldesleukin (NKTR-214) in combination with nivolumab.
62258825|NCT01573871|EXPERIMENTAL|Hydrolyzed infant formula|Hydrolyzed infant formula to be fed ad libitum
62258826|NCT02603770|EXPERIMENTAL|XueZhiKang (XZK)|XueZhiKang (XZK) 1200 mg
62258827|NCT02603770|ACTIVE_COMPARATOR|Lovastatin|Lovastatin 20 mg
62615809|NCT01044758|PLACEBO_COMPARATOR|Control_Placebo first, then placebo|"Healthy control:~placebo capsule twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
62615810|NCT02152098|EXPERIMENTAL|Chronic Exercise|Chronic Exercise
62615811|NCT02152098|EXPERIMENTAL|Acute Early onset of rehabilitation|Acute Early onset of rehabilitation
62615812|NCT02152098|EXPERIMENTAL|Chronic control|Chronic control
62615813|NCT02152098|EXPERIMENTAL|Acute Delayed onset of rehabilitation|Acute Delayed onset of rehabilitation
62258828|NCT04045288|ACTIVE_COMPARATOR|Standard Implementation|All schools in SWITCH receive training through webinars and an in-person conference to learn about the defining elements and school wellness programming in general. Consistent with the standard implementation, schools were added to the online content management system (CMS) and were given access to an online community of practice (CoP) to interact with other schools / teachers in the study. Schools were provided with resources and program materials (i.e. educational modules, trinkets, posters, etc.) but were given autonomy with regard to how they were used within their school. Weekly updates through the online CMS, the CoP, and via direct email correspondence provided information about the weekly corresponding weekly themes, implementation tips, recommended module activities to incorporate, upcoming evaluation needs, important SWITCH dates, and other program reminders.
62258829|NCT04045288|EXPERIMENTAL|Enhanced Implementation|The 'Enhanced' implementation strategy provided schools with the same training, access and resources as the standard SWITCH implementation along with more personalized, web-based training based on motivational interviewing (MI) techniques and feedback throughout the implementation process. The supplemental support was provided through participation in two online 'checkpoint sessions' that helped schools self-assess their use of the recommended quality elements and setting-specific best practices. The sessions used principles of motivational interviewing (MI) to promote autonomy and motivation for school change through the process. Schools were also provided with information about how to capitalize on support from local 4H program leaders in their county.
62258830|NCT05675878|EXPERIMENTAL|Dietary Intervention Group|Subjects will undergo a 2-hour in-depth training via Zoom on how to follow the diet and will receive a binder with helpful information. They will be give the weekend to prepare and then will start the diet the following Monday, and will continue following it for 4 weeks before being reassessed in the lab.
62258831|NCT05675878|NO_INTERVENTION|Waitlisted Control Group|The waitlisted control group will follow their usual diet for one month and then will be reassessed (as a comparator group) before being trained on the dietary intervention which they will then follow for the next month.
62258832|NCT03668886|EXPERIMENTAL|multimodal exercise program|Elderly in this group will receive multimodal exercise program. The duration of exercise is 60 minutes and frequency is 2 times/week.
62258833|NCT03668886|NO_INTERVENTION|Control group|Elderly in this group will continue to attend community activity as usual. The activity includes active activity is 60 minutes and frequency is 2 times/week.
62258834|NCT03870438|EXPERIMENTAL|Intervention|"Children infected with HIV-1 will be referred to the National Programme for confirmed HIV diagnosis and immediate ART.~For children that are not HIV-1 infected, the results on the mother's viral load will guide the next steps:~Mothers with a detectable plasma viral load (≥ 1000 copies/mL): their children will be initiated on lamivudine oral solution.~Mothers with an undetectable viral loads (\<1000 copies/mL): their children will not be initiated on lamivudine oral solution at 6-8 weeks of age. However, additional monitoring on the viral load of the mother and the diagnosis of the child will take place at 6 months: If the maternal plasmatic viral load is ≥ 1000 copies/mL, the child will be initiated on lamivudine oral solution."
62258835|NCT03870438|NO_INTERVENTION|Control|Routine Option B+ national guidelines including HIV-1 plasmatic viral load testing will be adhered to. Visits will take place at 6-8 weeks, 6 and 12 months post-partum to collect samples from the mother for the analysis of viral load results at 12 months. In addition, at 6-8 weeks, 6 and 12 months post-partum, POC tests will be done for the diagnosis of HIV-1 in their infants (by HIV-1 DNA PCR) and results will be shared within 2 hours. Children infected with HIV-1 will be referred to the National Programme for confirmed diagnosis and immediate ART.
62258836|NCT03831867|EXPERIMENTAL|Pilates|This group is the experimental group. The intervention program consisted on performance Pilates method exercise program during the sessions of Physical Education.
62615814|NCT02830932|EXPERIMENTAL|VXA-RSV-f Tablets (high dose)|Singe dose of orally administered VXA-RSV-f Tablets (high dose). VXA-RSV-f is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of respiratory illness caused by RSV. The vaccine vector encodes for a full-length F protein gene from RSV.
62840736|NCT02293317|EXPERIMENTAL|M-001 0.5mg & TIV|M-001 (0.5mg) administered intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
62615815|NCT02830932|EXPERIMENTAL|VXA-RSV-f Tablets (low dose)|Singe dose of VXA-RSV-f Tablets (low dose).VXA-RSV-f is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of respiratory illness caused by RSV. The vaccine vector encodes for a full-length F protein gene from RSV.
62615816|NCT02830932|PLACEBO_COMPARATOR|VXA Placebo Tablets|Singe dose of matching placebo tablets. The placebo tablets are small off-white tablets that are similar in size and number to the active vaccine dose being delivered.
62615817|NCT01402505||Transvaginal NOTES sleeve gastrectomy|Transvaginal NOTES sleeve gastrectomy
62615818|NCT01840800|ACTIVE_COMPARATOR|Active FEM+ONP|Nerveblock of n. femoralis (FEM) with 10 ml Ropivacaine 7.5 mg/ml and nerveblock of obturator nerveposterior branch (ONP) with 10 ml Ropivacaine 7.5 mg/ml.
62615819|NCT01840800|ACTIVE_COMPARATOR|Active SAPH+ONP|Nerveblock of n.saphenous (SAPH) with 5 ml Ropivacaine 7.5 mg/ml and nerveblock of obturator nerve, posterior branch (ONP) with 10 ml Ropivacaine 7.5 mg/ml
62840737|NCT02293317|EXPERIMENTAL|M-001 1.0mg & TIV|M-001 (1.0mg) administered intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
62615820|NCT01840800|PLACEBO_COMPARATOR|Placebo|Saline 9 mg/ml
62258837|NCT03831867|NO_INTERVENTION|Control|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
62258838|NCT01157754|EXPERIMENTAL|OCP+GnRH antagonist|Microgynon 14 to 21 tablets starting COH on day 5 post pill, rFSH + GnRH antagonist
62258839|NCT01157754|ACTIVE_COMPARATOR|long GnRH agonist|daily triptorelin starting day 21st of previous cycle
62258840|NCT05963958|EXPERIMENTAL|Active HD-tDCS|HD-tDCS is delivered on 10 consecutive weekdays, with two sessions per day (in the morning and in the afternoon). For each participant, a 3-mA current is applied via a center anode. The electric current was supplied to the active group and presented an acceleration time of 30 s, maintained at 3 mA for 30 min and then reduced for 30 s. And a maintenance dosage of dexmedetomidine (0.2 - 0.7 mcg/kg per hour).
62615821|NCT04674735|EXPERIMENTAL|APSLXR|
62615822|NCT04665518|EXPERIMENTAL|Acupressure group|The following applications will be made 10 minutes before the patients in the acupressure group. Hands are washed before applying acupressure. Before acupressure is applied, the patient is allowed to sit in a comfortable position on the sofa in the single blood collection room. Before starting the acupressure application, the arm is rubbed from fingertips to the elbow to relax, and press the acupressure points (Large Intestine Meridian 4th Point \[LI 4\], Large Intestine Meridian 11th Point \[LI 11\], and Heart Meridian 7th Point \[HT 7\]). application is carried out. 2 minutes to each acupressure point. pressure (3 to 5 kg of pressure) is applied. Only one acupressure session is given to each patient, and each acupressure session lasts 10 minutes. Venipuncture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 \* 38 mm (21G x 1½, green).
62258841|NCT05963958|PLACEBO_COMPARATOR|Sham HD-tDCS|HD-tDCS is delivered on 10 consecutive weekdays, with two sessions per day (in the morning and in the afternoon). For the simulated condition, the investigators maintained the same 30-second acceleration up to a total of 3 mA, followed immediately by a 30-second deceleration. And a maintenance dosage of dexmedetomidine (0.2 - 0.7 mcg/kg per hour).
62258842|NCT03689153|EXPERIMENTAL|Cohort 1: JNJ-63733657 or Placebo|Participants will receive a single intravenous (IV) low dose of JNJ-63733657 or matching placebo.
62258843|NCT03689153|EXPERIMENTAL|Cohort 2: JNJ-63733657 or Placebo|Participants will receive a single IV middle dose of JNJ-63733657 or matching placebo.
62258844|NCT03689153|EXPERIMENTAL|Cohort 3: JNJ-63733657 or Placebo|Participants will receive a single IV high dose of JNJ-63733657 or matching placebo.
62615823|NCT04665518|NO_INTERVENTION|Control group|Venipuncture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 \* 38 mm (21G x 1½, green).
62615824|NCT02026869|ACTIVE_COMPARATOR|Oral metformin|Metformin 850 mg tablets taken by mouth every 12 hours for 6 months
62615825|NCT02026869|ACTIVE_COMPARATOR|Vaginal metformin|Metformin 850 mg tablets taken vaginally every 12 hours for 6 months
62615826|NCT03246802|EXPERIMENTAL|HDR partial prostate brachytherapy|2 fractions of high dose rate prostate brachytherapy will be delivered to the site of recurrent disease as determined by mp-MRI
62615827|NCT03985488||Eview Fluoroscopy Machine|The Eview Fluoroscopy Machine is the standard of care fluoro machine used in endoscopy.
62615828|NCT03985488||Fluoroshield Device|The FluoroShield technology (Omega Medical Imaging) has been developed in an effort to further reduce the degree of radiation exposure to patients and provides. This technology is an additional component that can be fitted to the preexisting Eview fluoroscopy machines, in order to further filter radiation that has passed through the pre-existing machine.
62615829|NCT00858078||Previously referred|Previously-enrolled subjects from NCI Protocol 01-C-0009
62615830|NCT00858078||Self-referred|Self-referred women at increased familial risk of breast and ovarian cancer were recruited through an hereditary breast/ovarian cancer advocacy group
62615831|NCT03552042|EXPERIMENTAL|Counterclockwise Program|"Subjects will participate in an 6-day Counterclockwise Retreat in a retrofitted physical environment circa 1989, which helps the participant psychologically return to a time before diagnosis to re-experience their younger self. Groups will be composed of 10-12 participants plus 3 research assistants/facilitators. Participants will live during the week as if they were in 1989, talking about 1989 events as if they were in the present, and avoiding talking about post-1989 events. Everybody will be invited to participate in conversations and discussions about 1989 in the present tense (presente). Furniture, posters, music, television, newspapers, and technological instruments will all reflect what was available in 1989. Participants will be told not merely to reminisce about this earlier era, but to inhabit life in that era, making a psychological leap to be the person they were at the end of the 1980s."
62258845|NCT05377788||Prospective cohort|"* Inclusion criteria~  * adults over the age of 19~ * Easter Cooperative Oncology Group performance 0-4~ * Patients who are eligible for or are being treated for test medication as per permit: patients with NSCLC with local progressive or metastatic EGFR T790M mutation who have previously been treated with Generation 1 or Generation 2 EGFR TKI~ * EGFR T790M mutation allows for all results identified in tumor tissue or plasma~ * Patients with brain MR within 3 months of study participation~* After obtaining a consent form for research participation, follow-up and monitoring survival information and safety information. Survival follow-up of prospective cohorts will be followed up to the point of first occurrence during disease progression, withdrawal of consent, failure of follow-up investigation, and death."
62258846|NCT05377788||Restrospective cohort|"* Inclusion criteria~  * adults over the age of 19~ * Patients who are already using the lazertinib according to the domestic authorization of lazertinib(This includes when participants receive interventions as part of routine medical care)~* Survival information is monitored after the time when the consent form for participation in the study is obtained. Survival follow-up of retrospective cohorts will be followed up to the point of first occurrence during disease progression, withdrawal of consent, failure of follow-up investigation, and death"
62258847|NCT00865059|EXPERIMENTAL|A|Gabapentin 800 mg Tablets, single dose
62258848|NCT00865059|ACTIVE_COMPARATOR|B|NEURONTIN® 800 mg Tablets, single dose
62258849|NCT04185103||Sacubitril-Valsartan cohort|Patients with left systolic disfunction (left ventricle ejection fraction\<40%) heart failure and diagnosed with grade II heart failure that have been treated with an ACE or ARA II+betablocker at stable doses during the last 4 weeks and after being evaluated by the cardiologist start Sacubitril-Valsartan treatment.
62615832|NCT03552042|ACTIVE_COMPARATOR|Active control group|Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
62056094|NCT03269240|ACTIVE_COMPARATOR|Traditional training|The health providers will receive the same content of training in eight days, Off-site training, the way it's currently done in Nigeria. Both theoretical and practical through use of manikins - simulation. No reinforcement and further practice will take place once the participants are back in their work stations. Acquisition of knowledge and clinical skills is measured.
62056095|NCT04607655|EXPERIMENTAL|Oral GB1211, 100 mg, twice a day|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
62056096|NCT04607655|EXPERIMENTAL|Oral GB1211, 10 mg, twice a day|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
62056097|NCT04607655|PLACEBO_COMPARATOR|Oral GB1211, Placebo, twice a day|Placebo is administered as inhalation once a day
62056098|NCT01771393|EXPERIMENTAL|CBCT prior to MDCT|To avoid systematic bias in performance or image quality due to dilution of the contrast enhancement within the joint, the order of the CBCT and the MDCT will be randomized. This arm is composed of patients who will have the CBCT performed prior to the MDCT.
62056099|NCT01771393|EXPERIMENTAL|MDCT prior to CBCT|To avoid systematic bias in performance or image quality due to dilution of the contrast enhancement within the joint, the order of the CBCT and the MDCT will be randomized. This arm is composed of patients who will have the MDCT performed prior to the CBCT.
62056100|NCT05379257|EXPERIMENTAL|Random dose|Random dosage and timing of furosemide
62056101|NCT00426725|EXPERIMENTAL|A|This group uses the EasyLabour device according to the protocol
62056102|NCT00426725|NO_INTERVENTION|Control|
62056103|NCT01009879|EXPERIMENTAL|Etanercept|
62056104|NCT02198495|ACTIVE_COMPARATOR|Ferric carboxymaltose|Supplementation of ferric carboxymaltose 500 mg at week 0, 10, 20, 30
62258850|NCT01947816||Humira|Humira 40 mg (marketed product) eow for subcutaneous injection after initial dosage of 160 mg and 2nd dosage of 80 mg in two weeks after the initial administration, for up to 52 weeks.
62258851|NCT03395548|ACTIVE_COMPARATOR|Inflammatory bowel disease|"The aim is to recruit 20 persons suffering from Crohn's disease or ulcerative colitis with stable medication and stable control of the disease.~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
62615833|NCT03552042|NO_INTERVENTION|No-treatment control group|Non-treated participants will be assessed with the same timeline followed by the other groups. Participants will receive three coupons, for each assessment after the baseline (at T2, T3, and T4) for a two-night break in a location of their choice (among a selection of commercial services).
62615834|NCT04958291|EXPERIMENTAL|Administration of Dose A of CC-99677 or Placebo|Administration of Dose A of CC-99677 or Placebo
62056105|NCT02198495|ACTIVE_COMPARATOR|Iron sucrose|Supplementation of iron sucrose 100 mg at week 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38
62056106|NCT06255392|EXPERIMENTAL|Fluzoparib Combined With Apatinib|Fluzoparib combined with Apatinib group: Fluzoparib capsules oral +Apatinib Mesylate oral; each treatment cycle defined as 3 weeks (21 days).
62056107|NCT06255392|ACTIVE_COMPARATOR|Chemotherapy selected by the investigator|Control group: Control group: patients receive oral Capecitabine tablets, Vinorelbine Tartrate Capsules, or use intravenous Paclitaxel for Injection (Albumin Bound), Gemcitabine Hydrochloride for Injection, or other drugs selected by the investigator.
62056108|NCT03348579||The before period|The before period (control phase) will consist of all consecutive patients admitted to the participating ICUs before the national guidelines publication concerning hospital-acquired pneumonia.
62056109|NCT03348579||The second period|"Intensive care units are randomized in two groups:~Standard training: The centers will receive the text of the recommendation electronically. The principal investigator of each center will then train doctors, interns, nurses and physiotherapists to the use of these recommendations (team leader). A computer presentation common to all the centers will be used and a communication strategy vis-à-vis the other caregivers of the investigative services will be put in place. All doctors, interns and nurses must have attended this theoretical training during the awareness phase."
62056110|NCT03348579||The third and final period|The third and final period will consist of all consecutive patients admitted to the participating ICUs after the formal training.
62056111|NCT03435575|ACTIVE_COMPARATOR|Intervention group|Children in the intervention group will receive Boosth: Boosth activity tracker, Boosth syncc app and Boosth game app
62056112|NCT03435575|NO_INTERVENTION|Control group|Standard care
62056113|NCT04572178|EXPERIMENTAL|Cash payment and brief behavioral counseling|The intervention consists of in person counseling and cash payment. The participants receive 25 Euro per week if they have succeeded in quitting smoking. Quitting smoking is evaluated by carbon monoxide measurements twice a week.
62258852|NCT03395548|ACTIVE_COMPARATOR|Irritable bowel syndrome|"The aim is to recruit 20 persons suffering from irritable bowel syndrome (IBS) fulfilling rome criteria.~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
62258853|NCT03395548|ACTIVE_COMPARATOR|Healthy|"The aim is to recruit 20 persons without known illnesses with a comparable age to the other two groups.~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
62258854|NCT01108146|EXPERIMENTAL|Arm 1|"Drug: Hydrocortisone 10 mg~Group 1: Administration of Hydrocortisone and/or Placebo in the following order:~1 week placebo-1 week hydrocortisone 10 mg/d -1 week placebo - 1 week hydrocortisone 30 mg/d"
62258855|NCT01108146|EXPERIMENTAL|Arm 2|"Drug: Hydrocortisone 30 mg~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo"
62258856|NCT01147289|EXPERIMENTAL|dexalgen|Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose for 3 days, at least
62615835|NCT04958291|EXPERIMENTAL|Administration of Dose B of CC-99677 or Placebo|Administration of Dose B of CC-99677 or Placebo
62615836|NCT04958291|EXPERIMENTAL|Administration of Dose C of CC-99677 or Placebo|Administration of Dose C of CC-99677 or Placebo
62615837|NCT01935713|EXPERIMENTAL|Electronic Cigarette|Participants received the electronic cigarette for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
62615838|NCT01935713|EXPERIMENTAL|Dissolvable Tobacco Lozenge|Participants received the dissolvable tobacco lozenge for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
62615839|NCT01935713|EXPERIMENTAL|Dissolvable Nicotine Lozenge (Nicorette)|Participants received the dissolvable nicotine lozenge (Nicorette) for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
62615840|NCT04212832|ACTIVE_COMPARATOR|ultrasound guided quadratus lumborum block|ultrasound guided quadratus lumborum block with 0.5 ml/kg % 0.25 bupivacaine
62258857|NCT01147289|ACTIVE_COMPARATOR|Meloxicam|Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose for at least 3 days.
62056114|NCT04890535|ACTIVE_COMPARATOR|Single Ascending Dose 25 - 800 mg|single dose of TBAJ-587
62056115|NCT04890535|PLACEBO_COMPARATOR|Single Ascending Dose 25 - 800 mg placebo|single dose of placebo
62056116|NCT04890535|ACTIVE_COMPARATOR|Multiple Ascending Dose 50 - 200 mg|28 days dose of TBAJ-587
62615841|NCT04212832|OTHER|No intervention|Standard Pain Followup and Monitorization
62840738|NCT02293317|PLACEBO_COMPARATOR|Placebo & TIV|0.3ml Saline administered Intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
62840739|NCT05136950|EXPERIMENTAL|Secondary in-the-bag IOL fixation group|In-the-bag IOL fixation is the experimental arm
62840740|NCT05136950|ACTIVE_COMPARATOR|Secondary ciliary sulcus IOL fixation group|Ciliary sulcus IOL fixation is the control arm
62056117|NCT04890535|PLACEBO_COMPARATOR|Multiple Ascending Dose 50 - 200 mg Placebo|28 days dose of placebo
62258858|NCT00817232|EXPERIMENTAL|Treatment 1|50 microamp amplitude
62258859|NCT00817232|EXPERIMENTAL|Treatment 2|500 microamp amplitude
62258860|NCT02524574|EXPERIMENTAL|cardiac Rehabilitation|
62056118|NCT00664898|EXPERIMENTAL|1|
62056119|NCT01392300|EXPERIMENTAL|DB IncobotulinumtoxinA (Xeomin) (400 U)|IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment
62056120|NCT01392300|PLACEBO_COMPARATOR|DB Placebo Comparator|Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment
62056121|NCT01662063|EXPERIMENTAL|SC TCZ QW|Participants who received IV TCZ in the previous trial will be switched to SC TCZ 162 mg QW, and those who received SC TCZ will continue at their same dosage of SC TCZ 162 mg QW. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
62056122|NCT01662063|EXPERIMENTAL|SC TCZ Q2W|Participants who received SC TCZ will continue at their same dosage of SC TCZ 162 mg Q2W. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
62056123|NCT00051168|EXPERIMENTAL|Travatan|Travoprost (0.004%)
62258861|NCT01845922|EXPERIMENTAL|Low sodium diet|Low sodium diet
62258862|NCT01845922|NO_INTERVENTION|Control|Standard diet regime
62258863|NCT04376320|ACTIVE_COMPARATOR|Group 1(ceramic membrane)|using customized ceramic membranes for augmentation of vertical mandibular ridge defects in preparation for implant placement
62056124|NCT06368986|EXPERIMENTAL|Part 1- Fasted condition|VH4011499 tablet administered in fasted condition.
62615842|NCT05775861|EXPERIMENTAL|single shot interscalene brachial plexus with dexmedetomidine added to ropivacaine|A total of 150 mg of ropivacaine 0.5% will be prepared, 125 mg (25mL) will be mixed with a dose of 2 mcg/kg IBW of dexmedetomidine (100 mcg/mL dexmedetomidine hydrochloride; Precedex, Hospira Inc, Lake Forest, IL). The total of 25 mL (125 mg or ropivacaine 0.5%) with dexmedetomidine will be injected perineurally at the level of the roots and a 5 mL (25 mg) will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block.
62623652|NCT03310632|EXPERIMENTAL|Antroquinonol with SOC|"Antroquinonol will first be conducted by dose escalation(200mg TID and 300mgTID) to characterize the safety of antroquinonol in combination with the standard of care (SOC) (nab-paclitaxel + gemcitabine) and to identify the MTD of antroquinonol in patients with metastatic pancreatic cancer.~At the cohort expansion part of the study, up to an additional 40 patients will be enrolled at the MTD or MFD/RD."
62623653|NCT03264612|ACTIVE_COMPARATOR|Swimming group|"Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.~The exercise included three stages: warming up, swimming and cooling down."
62623654|NCT03264612|NO_INTERVENTION|Non swimming group|no intervention
62615843|NCT05775861|ACTIVE_COMPARATOR|continuous interscalene brachial plexus block with ropivacaine|A total of 100 mg (20 mL) of ropivacaine 0,5% will be injected perineurally at the level of the roots using the Tuohy needle. The 19 G arrow catheter will then be introduced through the Tuohy needle and we will leave 4 cm of the catheter perineurally. An additional 25 mg (5 mL) of ropivacaine 0,5% will be injected using the catheter to make sure the catheter is in a correct position. An additional 5 mL (25 mg) of ropivacaine 0.5 % will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block using an ultrasound in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany) or with a standard 25G 1 1/2 inches needle. After the surgery, an infusion of ropivacaine 0,2% at a standard rate of 5 mL/h will be started using an elastomeric pump of 300 mL (Baxter Corporation, Mississauga, Ontario).
62615844|NCT01840137|EXPERIMENTAL|Prehabilitation|The progressive, pre-operative exercise training program includes 3 supervised exercise sessions per week for 4 weeks. The first week of training will include an acclimation period accomplished via a ramping protocol. Subjects will warm-up on a treadmill for 5-minutes. Subjects will then complete 1 set of 15 repetitions exercising 8 major muscle groups during week one; during week #2 they will complete 2 sets with a goal of at least 12 repetitions; if subjects reach 15 repetitions on the second set, the resistance will be increased by 10% at the next training session to ensure progression. After completion of the resistance training portion of each session, subjects will walk on a treadmill for 30 minutes at a low/moderate intensity followed by a 5 minutes cool-down period.
62615845|NCT04959214|EXPERIMENTAL|intervention: progressive relaxation exercise practice group|intervention: progressive relaxation exercise practice group: A group of 30 intensive care nurses who will practice the progressive relaxation exercise at home 3 days a week for 1 month.
62615846|NCT04959214|NO_INTERVENTION|control: uninterrupted group|control: A group of 30 intensive care nurses who did not intervene for 1 month
62840741|NCT02052999|EXPERIMENTAL|PAC-14028 cream 1%|PAC-14028 cream 1%, twice daily for 8 weeks
62258864|NCT04376320|ACTIVE_COMPARATOR|Group 2 (modified sausage technique)|using tenting titanium screws in conjunction with particulate bone graft and collagen membrane (modified sausage technique) for augmentation of vertical mandibular ridge defects in preparation for implant placement
62258865|NCT04531696|OTHER|Standard|"UPTIDER consists of 8 substudies:~1. Pilot phase~2. Invasive Lobular Carcinoma (ILC) substudy~3. Inflammatory Breast Cancer (IBC) substudy~4. Molecular heterogeneity and treatment response substudy~5. Patient-derived xenograft (PDX) / Patient-derived Organoid (PDO) substudy~6. Metabolomics substudy~7. Liquid biopsy substudy~8. Hereditary cancer syndromes substudy The intervention, consisting of sample collection only, is identical in all substudies, however, the focus of downstream analysis of the samples may be different."
62258866|NCT03495258|EXPERIMENTAL|Clarion Evolve Laser Vaporization System|Clarion Evolve Laser Vaporization System
62615847|NCT00784056|EXPERIMENTAL|1|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)
62615848|NCT04267588||Navio App|The investigators propose to collect self-report and passively collected biological data and evaluate participants' relation to clinical and laboratory pain as well as patients' willingness to use and level of comfort with the mobile pain management digital platform and wearable biosensors. Eligible participants will be consented, given two biosensors (i.e., Apple Watch Series 1 with KardiaBand; Spire), a sleep monitoring device (actigraph watch), and a mobile app enabled smartphone, then trained on how to use the app (and device if appropriate) and biosensors. Participants will keep medications constant and not have any new pain treatment procedures over the course of the study period and 2 weeks prior to starting the study.
62615849|NCT01402986|PLACEBO_COMPARATOR|Placebo, Q2W - Cohort 1|Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
62615850|NCT01402986|EXPERIMENTAL|Tralokinumab 300 mg, Q2W - Cohort 1|Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
62615851|NCT01402986|PLACEBO_COMPARATOR|Placebo, Q2/4W - Cohort 2|Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.
62258867|NCT03495258|EXPERIMENTAL|Olympus TURis Plasma Vaporization|Olympus TURis Plasma Vaporization
62258868|NCT04033120||Cohort 1|"Cohort 1: Symptomatic hospitalized patients: 900 patients admitted to the participating hospitals whom doctors suspect to have an infection and will perform TmAg testing alongside routine diagnostics and the following additional diagnostics:~1. MycoF/lytic blood culture system~2. Fujifilm lateral flow urine lipoarabinomannan (LF-LAM) test for tuberculosis~3. Cryptotoccoal antigen in sera (CrAg) LFA for cryptococcosis~4. Histoplasma antigen in urine (HAg) LFA for histoplasmosis~We will follow patients closely for early diagnosis and treatment of culture confirmed talaromycosis over a six-month follow up period"
62615852|NCT01402986|EXPERIMENTAL|Tralokinumab 300 mg, Q2/4W - Cohort 2|Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.
62615853|NCT01027897|EXPERIMENTAL|Doripenem group|Patients will receive doripenem for the treatment of their infection
62615854|NCT04146623|PLACEBO_COMPARATOR|Normal Saline Placebo|Saline (0.9%)
62615855|NCT04146623|EXPERIMENTAL|CodaVax-H1N1|Live-attenuated influenza vaccine
62615856|NCT03061799|EXPERIMENTAL|HPC-03|"To experimental arm randomly assigned, HPC-03 will administrated twice a day , two capsules each time (total dose of HPC-03: 2g/day) for 12 weeks (84days).~\*(HPC-03: extracts of angelica gigas nakai, cnidium rhizome, and cinnamon bark.)"
62615857|NCT03061799|PLACEBO_COMPARATOR|Placebo|To control arm randomly assigned, placebo will administrated twice a day , two capsules each time for 12 weeks (84days).
62615858|NCT03142373|EXPERIMENTAL|CV4 group|CV4 technique
62615859|NCT03142373|EXPERIMENTAL|RR group|Rib Raising technique
62840742|NCT02052999|ACTIVE_COMPARATOR|Rozex gel 0.75%|Rozex gel 0.75%, twice daily for 8 weeks
62840743|NCT02052999|PLACEBO_COMPARATOR|Vehicle|Vehicle, twice daily for 8 weeks
62840744|NCT06405724|EXPERIMENTAL|Drug: Liposomal bupivacaine|Experimental group will receive PVB with LB 20 mL.
62056125|NCT06368986|EXPERIMENTAL|Part 1- Fed condition (high fat meal)|VH4011499 tablet administered in fed condition (high fat meal).
62056126|NCT06368986|EXPERIMENTAL|Part 2 - Optional - Fed condition (lower fat meal)|VH4011499 tablet administered in fed condition (lower fat meal).
62258869|NCT04033120||Cohort 2|"Cohort 2: Asymptomatic outpatients: 500 patients registered at the outpatient clinics at the participating hospitals whom doctors do not suspect of having an active infection and will perform TmAg testing alongside the following diagnostics:~1. CrAg LFA for cryptococcosis~2. HAg LFA for histoplasmosis~We will follow patients closely for early diagnosis and treatment of culture confirmed talaromycosis over a twelve-month follow up period."
62258870|NCT03324906|ACTIVE_COMPARATOR|tDCS active Prader-Willi Syndrome|The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
62258871|NCT03324906|ACTIVE_COMPARATOR|tDCS active Obese Subjects|The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation). The start ramp, when the current will be changed from zero to 2mA (two milli amps), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes.
62258872|NCT00396201|EXPERIMENTAL|Participants with Hodgkin's Disease (HD)|Participants with Hodgkin's Disease who were eligible for autologous peripheral blood stem cell transplantation.
62615860|NCT03142373|PLACEBO_COMPARATOR|Placebo group|Light touch
62615861|NCT01004458|ACTIVE_COMPARATOR|Early treatment group|The experimental group receiving CBT
62615862|NCT01004458|NO_INTERVENTION|Waiting list group|The waiting list group served as referents during the trial
62258873|NCT02221453|OTHER|Triamcinolone Acetonide Treatment|Triamcinolone Acetonide Injectable Suspension 40 mg/mL intravitreal injection
62258874|NCT03885427|EXPERIMENTAL|oral ketamine|evaluate sedative,and analgesic effects
62615863|NCT05879224|EXPERIMENTAL|Revised case management package|
62258875|NCT03885427|ACTIVE_COMPARATOR|nebulized ketamine|evaluate sedative, and analgesic effects
62615864|NCT02427802|EXPERIMENTAL|Gentamicin sponge group|Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
62615865|NCT02427802|PLACEBO_COMPARATOR|Placebo sponge group|Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
62258876|NCT05113160|NO_INTERVENTION|Treatment efficacy: Delayed Control Group|Treatment cycle 1 only.
62258877|NCT05113160|EXPERIMENTAL|Experimental: Group Size x Aphasia Severity|Outcomes will be measured for individuals who participate in large group (6-8 group members) compared to dyads (2 group members), and whether this relationship differs as a function of aphasia severity (severe vs. mild-moderate aphasia).
62258878|NCT05113160|EXPERIMENTAL|Experimental: Group composition|Outcomes will be measured for individuals who participate in homogeneous compared to heterogeneous groups (6-8 people with aphasia), based on aphasia severity (severe vs. mild-moderate aphasia).
62615866|NCT02427802|NO_INTERVENTION|No sponge group|Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
62258879|NCT01024010|EXPERIMENTAL|Arm A (PCO, closed to accrual as of 8/23/2011)|Patients receive induction therapy comprising ofatumumab IV on day 1 (days 1-2 of course 1 only), pentostatin IV over 30 minutes on day 1, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62615867|NCT01368887|EXPERIMENTAL|1|DPS-102
62615868|NCT01368887|PLACEBO_COMPARATOR|2|Vehicle
62615869|NCT01368887|ACTIVE_COMPARATOR|3|Calcipotriol Monotherapy
62615870|NCT01368887|ACTIVE_COMPARATOR|4|Nicotinamide Monotherapy
62615871|NCT01998464||Retinal Vasculitis Group|Up to 35 patients diagnosed with retinal vasculitis will be considered and evaluated for enrollment in this study.
62615872|NCT03604575|EXPERIMENTAL|Insulin Lispro|Single subcutaneous administration of Insulin Lispro in dose 0.3 IU / kg
62615873|NCT03604575|ACTIVE_COMPARATOR|Humalog®|Single subcutaneous administration of Humalog® in dose 0.3 IU / kg
62615874|NCT05052697|EXPERIMENTAL|SSA: mIRV A (dose level 1) + QIV|
62615875|NCT05052697|EXPERIMENTAL|SSA: mIRV A (dose level 2) + QIV|
62840745|NCT06405724|ACTIVE_COMPARATOR|Drug:ropivacaine|Comparator group will receive PVB with 20 mL of 0.5% ropivacaine
62840746|NCT01262196|EXPERIMENTAL|MP4OX|250-mL dose
62615876|NCT05052697|EXPERIMENTAL|SSA: mIRV A (dose level 3) + QIV|
62615877|NCT05052697|EXPERIMENTAL|SSA: mIRV A (dose level 4) + QIV|
62615878|NCT05052697|EXPERIMENTAL|SSA: mIRV B (dose level 1) + QIV|
62615879|NCT05052697|EXPERIMENTAL|SSA: mIRV B (dose level 2) + QIV|
62840747|NCT01262196|PLACEBO_COMPARATOR|Control|250-mL of normal saline solution
62840748|NCT01755819|OTHER|Biocomposite interference screw|Thirty patients treated with ACL reconstruction and graft fixation is performed using Biocomposite interference screw on tibial and femoral side. Patients are randomized to one of the two study arms.
62258880|NCT01024010|EXPERIMENTAL|Arm B (PCO with ofatumumab consolidation)|Patients receive induction therapy as in Arm A. Patients then receive consolidation therapy comprising ofatumumab IV on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62258881|NCT05244759|EXPERIMENTAL|Arm 1|Single oral dose of \[14C\]-BLU-5937
62258882|NCT02718781|EXPERIMENTAL|Talk and leaders|This group will comprise of health talk and regular contact with community leaders.
62258883|NCT02718781|EXPERIMENTAL|Talk, leaders and equipment|This group will comprise of health talk and regular contact with community leaders. Moreover, a home-based equipment (handgrip) will be delivered to them
62258884|NCT02718781|ACTIVE_COMPARATOR|Talk|This group will comprise of a health talk only.
62258885|NCT04264403|ACTIVE_COMPARATOR|Renal Denervation|All subjects will undergo a diagnostic, renal angiogram (based on clinical grounds to rule out renal artery stenosis) which should be per Institutional practice via femoral artery access. Randomization will occur following the diagnostic renal angiogram. If randomized to the Renal Denervation Group RDN procedure will be applied using the Paradise® Renal Denervation System. The Paradise® Renal Denervation System is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
62258886|NCT04264403|NO_INTERVENTION|Sham Procedere|All subjects will undergo a diagnostic, renal angiogram (based on clinical grounds to rule out renal artery stenosis) which should be per Institutional practice via femoral artery access. Randomization will occur following the diagnostic renal angiogram. In these patients no RDN will be performed.
62258887|NCT02874456|EXPERIMENTAL|virus detection|detection of ZIKA virus in blood and sperm
62258888|NCT02724254|EXPERIMENTAL|AP611074 5% gel|100 mg twice daily doses of AP611074 5% gel
62258889|NCT02724254|PLACEBO_COMPARATOR|Placebo|AP611074 matching placebo gel
62258890|NCT02961621|EXPERIMENTAL|Stress Reduction Training Group|This group will complete a 7-week online mindfulness-based resiliency training: Stress Reduction Training for 9-1-1 Telecommunicators
62258891|NCT02961621|NO_INTERVENTION|Control Group|This group is a wait-list control and will be offered the training after all data collection has been completed.
62840749|NCT01755819|OTHER|Extracortical ACL Tightrope fixation|Thirty patients treated with ACL reconstruction and graft fixation is performed using extracortical ACL Tightrope fixation on tibial and femoral side. Patients are randomized to one of the two study arms.
62840750|NCT01449968||home visit of UMG|home visit with evaluation and management of the situation (control over in-home telephone)
62258892|NCT01516970|EXPERIMENTAL|DRV/r with 2 NRTIs|DRV/r 800/100 mg q.d. with 2 NRTIs: darunavir (800 mg) in combination with low-dose ritonavir (100 mg) administered once a day for at least 28 days and a maximum of 30 days along with 2 nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs).
62840751|NCT01449968||telephone management|geriatric mobile unit provides a telephone advice only to the general practitioner with guidance and recommendations (call control)
62258893|NCT01516970|ACTIVE_COMPARATOR|Comparator standard of care HIV PEP|Comparator standard of care HIV PEP (as per German-Austrian Guidelines): Administration of the standard of care HIV PEP (postexposure prophylaxis) consisting of 2 NRTIs plus third partner.
62258894|NCT06477874|ACTIVE_COMPARATOR|Test group|The dental implants placed after bone osseodensification using densah burs
62258895|NCT06477874|ACTIVE_COMPARATOR|Control group|The dental implants placed after conventional bone drilling with the standard drills
62258896|NCT02348892||With coordinator|Elderly patients, in complex situation, taken care by coordinator
62258897|NCT02348892||Without coordinator|Elderly patients, in complex situation, taken care by the classic plan
62615880|NCT05052697|EXPERIMENTAL|SSA: mIRV B (dose level 3) + QIV|
62840752|NCT03339219|EXPERIMENTAL|Cabozantinib 60 mg|Cabozantinib 60 mg, tablet, orally, once daily (QD) in the fasted state until unacceptable toxicity or need for subsequent systemic anticancer treatment up to 2.5 years.
62840753|NCT00404222|EXPERIMENTAL|hydrocodone / acetaminophen extended release|
62840754|NCT00404222|ACTIVE_COMPARATOR|Hydrocodone/Acetaminophen Immediate Release (Norco ®)|
62840755|NCT00404222|PLACEBO_COMPARATOR|Placebo|
62258898|NCT01853995|EXPERIMENTAL|FLMGM Treatment Group|Cl II/1 patients treated with Fixed Lingual Mandibular Growth Modificator (FLMGM)
62258899|NCT01853995|NO_INTERVENTION|Untreated Class II Control Group|control group
62258900|NCT06137924|ACTIVE_COMPARATOR|ANB with 0.5% bupivacaine plus dexamethasone 8 mg|ANB will be performed using 5% bupivacaine 20 cc plus dexamethasone 8 mg as the local anesthetic.
62258901|NCT06137924|EXPERIMENTAL|ANB with 0.5% bupivacaine plus dexamethasone and a colloid|ANB will be performed in this group using 0.5% bupivacaine 20 ccs plus dexamethasone 8 mg and a plasma volume substitute (succinylated gel).
62615881|NCT05052697|EXPERIMENTAL|SSA: mIRV B (dose level 4) + QIV|
62615882|NCT05052697|EXPERIMENTAL|SSA: bIRV AB (dose level combination 1) + QIV|
62615883|NCT05052697|EXPERIMENTAL|SSA: bIRV AB (dose level combination 2) + QIV|
62615884|NCT05052697|EXPERIMENTAL|SSA: bIRV AB (dose level combination 3) + QIV|
62615885|NCT05052697|EXPERIMENTAL|SSA: bIRV AB (dose level combination 4) + QIV|
62615886|NCT05052697|EXPERIMENTAL|SSA: QIV + mIRV A strain (dose level 4)|
62615887|NCT05052697|EXPERIMENTAL|SSA: qIRV (dose level 1) + QIV|
62615888|NCT05052697|EXPERIMENTAL|SSA: QIV + mIRV B strain (dose level 4)|
62056127|NCT05809661||deney grubu|"adult patients with intestinal stoma: The first interview: the patients were informed about the purpose of the study and signed informed consent form. The training booklet was delivered to them. Their contact information was obtained and the contact information of the researcher (navigator nurse) was shared with them. They were told that they could call the navigator nurse, send a message to him/her, take a photo of the stoma and share it with his/her when necessary, when they had physical, social, and psychological problems in the stoma or in line with their changing needs. In the next 3 months, they were informed about the applications to be made within the scope of the study (phone calls, information messages and videos, guidance and appointment planning). Appointment was scheduled for the next interview in 3 months.~."
62615889|NCT05052697|EXPERIMENTAL|SSB: 2 doses of qIRV (dose level 1), 2-visit schedule|
62615890|NCT05052697|EXPERIMENTAL|SSB: 2 doses of QIV, 2-visit schedule|
62615891|NCT05052697|EXPERIMENTAL|SSB: QIV + bIRV AA (dose level combination 1), 2-visit schedule|
62056128|NCT05809661||kontrol grubu|"adult patients with intestinal stoma: The first interview: the patients were informed about the purpose of the study and signed informed consent form. All of the data collection tools were filled out. Their questions about stoma care were answered. Training booklet was handed down to them. An appointment was scheduled for the next interview 3 months later.~The second interview (3 months after the first interview): A few days before the interview, they were called up and reminded of their appointment. The relevant forms were filled out with them at the end of the 3rd month. Their questions about stoma care were answered. An appointment was scheduled for the next interview 3 months later."
62056129|NCT03163914|ACTIVE_COMPARATOR|Epinephrine|Epinephrine will prepare as 5µg/ ml and epinephrine infusion rate will adjust 30 ml/h.
62258902|NCT06137924|EXPERIMENTAL|0.5% bupivacaine plus clonidine 0.145 mcg|ANB with will be performed in this group using 0.5% bupivacaine 20 ccs plus clonidine 0.145 mcg.
62258903|NCT02266667|EXPERIMENTAL|Progressive scoliosis|Children with progressive scoliosis
62258904|NCT02266667|EXPERIMENTAL|Neuromuscular scoliosis|Children with neuromuscular scoliosis
62258905|NCT01231594|EXPERIMENTAL|Cohort A|Subjects who have received \</= 8 weeks of GSK2118436 monotherapy in the parent study
62615892|NCT05052697|EXPERIMENTAL|SSB: QIV + bIRV AA (dose level combination 2), 2-visit schedule|
62615893|NCT05052697|EXPERIMENTAL|SSB: QIV + bIRV AA (dose level combination 1), 1-visit schedule|
62615894|NCT05052697|EXPERIMENTAL|SSB: QIV + bIRV AA (dose level combination 2), 1-visit schedule|
62615895|NCT05052697|EXPERIMENTAL|SSB: qIRV (dose level 2, dose combination 1), 1-visit schedule|NOTE: Arm Description has not been entered.
62056130|NCT03163914|ACTIVE_COMPARATOR|Norepinephrine|Norepinephrine will prepare as 5µg/ ml and epinephrine infusion rate will adjust 30 ml/h.
62056131|NCT03163914|ACTIVE_COMPARATOR|Phenylephrine|Phenylephrine will prepare as 100 µg/ ml and phenylephrine infusion rate will adjust 30 ml/h.
62056132|NCT03163914|PLACEBO_COMPARATOR|Control|Saline infusion will apply at equivalent volume till the surgical operation
62258906|NCT01231594|EXPERIMENTAL|Cohort B|Subjects who have received \>8 weeks of continuous treatment with GSK2118436 either as monotherapy or combination therapy with another approved anti-cancer agent
62258907|NCT01231594|EXPERIMENTAL|Cohort C|Subjects who have received \>8 weeks of continuous treatment with GSK2118436 in combination with a MEK inhibitor, GSK1120212
62258908|NCT06482736|EXPERIMENTAL|Control group|receive exercise program for 20-30 min which include include cervical ROM to warm up,cool down, and stretching of cervical, upper thoracic spine (trapezius,levator scapula, sternocleidomastoid) and strengthening exercises (cervical isometric,concentric conctration of deep flexor muscles) each exercise consist of three sets of five to ten repetitions will be performed with 30-60S rest period between sets
62258909|NCT06482736|EXPERIMENTAL|Study group|receive Extracorporeal Shockwave Therapy and the same exercise program as group A, three sessions per week for 12 weeks (3 menstrual cycles).
62258910|NCT03804203|ACTIVE_COMPARATOR|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
62258911|NCT03804203|EXPERIMENTAL|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
62258912|NCT06185621|EXPERIMENTAL|100mg aspirin group|Patients received oral 100mg aspirin, one tablet daily for 2 years
62258913|NCT01859832||Enrolled participants|"All participants enrolled in this study will have been previously consented to the study entitled, A Comparison of Effects of Standard Dose vs Low Dose Advagraf with Il-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB-based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response. This is an observational study with only one group/cohort in which all participants have bloodwork collected pre-transplant and at various time points post-transplant and these samples are analyzed using the Cylex ImmuKnow Assay."
62615896|NCT05052697|EXPERIMENTAL|SSB: qIRV (dose level 2, dose combination 2), 1-visit schedule|NOTE: Arm Description has not been entered
62615897|NCT05052697|EXPERIMENTAL|SSB: qIRV (dose level 3), 1-visit schedule|NOTE: Arm Description has not been entered
62615898|NCT05052697|EXPERIMENTAL|SSB: bIRV AA + bIRV BB (both dose level combination 1), 1-visit schedule|NOTE: Arm Description has not been entered
62615899|NCT05052697|EXPERIMENTAL|SSB: 1 dose of QIV, 1-visit schedule|NOTE: Arm Description has not been entered
62615900|NCT05052697|EXPERIMENTAL|SSB: qIRV (dose level 1), 1-visit schedule|NOTE: Arm Description has not been entered.
62615901|NCT05052697|EXPERIMENTAL|SSB: qIRV (dose level 2), 1-visit schedule|NOTE: Arm Description has not been entered.
62615902|NCT03459859|EXPERIMENTAL|Pevonedistat 10 LDAC 20|Dose Level -1: Pevonedistat 10 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
62615903|NCT03459859|EXPERIMENTAL|Pevonedistat 15 LDAC 20|Dose Level 1 (Starting Dose): Pevonedistat 15 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
62615904|NCT03459859|EXPERIMENTAL|Pevonedistat 20 LDAC 20|Dose Level 2: Pevonedistat 20 mg/m2, low dose Cytarabine 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
62615905|NCT03459859|EXPERIMENTAL|Pevonedistat 25 LDAC 20|Dose Level 3: Pevonedistat 25 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
62615906|NCT01634451|ACTIVE_COMPARATOR|Education Package|2 ICUs; one large and one small. Randomised to receive bespoke education package for the 9 month intervention period
62615907|NCT01634451|ACTIVE_COMPARATOR|Education and Feedback|2 ICUs; one large and one small. Randomised to receive a bespoke education package and real-time,site specific, outcome process feedback they will disseminate to their staff for the 9 month intervention period.
62615908|NCT01634451|ACTIVE_COMPARATOR|Education and Sedation Monitoring|2 ICUs; one large and one small. Randomised to receive a bespoke education package and a new novel sedation (responsiveness) monitor for the 9 month intervention period.
62615909|NCT01634451|ACTIVE_COMPARATOR|Education, Feedback, Sedation Monitoring|2 ICUs; one large and one small. Randomised to receive a bespoke education package, real-time,site specific, outcome process feedback they will disseminate to their staff and a new novel sedation (responsiveness) monitor for the 9 month intervention period.
62615910|NCT03300713|EXPERIMENTAL|F+ group (Mocitraining program)|including 8 pediatricians' clusters. F+ pediatricians will attend a specific training focused on mother-child interactions, maternal psychiatric disorders, particularly PND screening and early interventions for non-psychiatric physician.
62615911|NCT03300713|SHAM_COMPARATOR|F- group (usual follow-up)|grouping 8 pediatricians' clusters. They will not receive the initial training on early interactional disorders and PND screening
62615912|NCT05933564||Chronic Pain Patients with Varying Cognitive Reserve|Community-dwelling adults aged 65-85 years with chronic pain (≥3 months) attributable to osteoarthritis or neuropathic conditions.
62615913|NCT03626324|EXPERIMENTAL|C2P Study|Clinical Evaluation of Connected Catheter 2P Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
62615914|NCT02260349|EXPERIMENTAL|patient with Indocyanine green infusion|Infusion of Indocyanine Green 0,25 mg/Kg 24h before prostatic surgery
62615915|NCT00607659||Chlamydia Positive|Adolescent females, 11-21 years old, evaluated for pelvic examinations or STI screening will be asked to participate in this study. Participants are being asked to give us permission to collect:additional cervical or vaginal swabs, rectal swabs, blood draws where three tablespoons of blood, a urine pregnancy test, and a comprehensive health history. You may be asked to provide a urine specimen at the initial visit instead of having a cervical swab. The study team will obtain a cervical swab when you come back for your follow-up appointments. If your culture is positive for Chlamydia, you will be asked attend 3 additional follow-up appointments after 3 months, 6 months, 1 year, 2 years, and 3 years .
62056133|NCT03655925||Patients with Chronic Heart Failure (CHF)|Entire cohort/ Patients with recent diagnosis of chronic heart failure as defined by the guidelines of the European Society of Cardiology (ESC) and with cardiac ejection fraction \<40
62615916|NCT00607659||Control/Chlamydia Negative|Some participants with negative cultures will be included in this study as a control group. The same specimens, exams and blood draws will apply for those subjects with visits at 3 months, 6 months, 1 year, 2 years, and 3 years
62615917|NCT04976530|SHAM_COMPARATOR|Control|Standard of care with Sham set-up
62615918|NCT04976530|EXPERIMENTAL|DrugSorb-ATR Intervention|Standard of care + DrugSorb-ATR system
62615919|NCT03609957|EXPERIMENTAL|Aerobic Exercise Training|Moderate intensity (75% heart rate reserve) cycling exercise for 32 minutes, 3 days per week for 5 weeks
62615920|NCT03609957|EXPERIMENTAL|Interval Training|High intensity (95% heart rate reserve) cycling exercise for 20 minutes, 3 days per week for 5 weeks
62615921|NCT03609957|NO_INTERVENTION|Control|Control (no exercise intervention) group
62615922|NCT02803359|EXPERIMENTAL|Planned Procedure|Endoscope will be connected to a camera and monitor. Needle electrodes will then be positioned into the false vocal fold mucosa bilaterally, under direct visualization of the needle tip on the monitor, but the needles will be passed trans-orally in the operating room. For those participating during an open-neck surgery, the surgery will commence as planned and once exposure of the superior laryngeal nerve is obtained, the surgeon will insert the electrodes directly into the nerve trunk for the purposes of recording. In Surgery or cervical lymphadenectomy, the electrode will be placed at a superficial depth and needle placement will be performed with one on each side at a location approximately mid-fold.
62615923|NCT02803359|EXPERIMENTAL|Routine Laryngoscopy|Nasolaryngoscopy will be performed in the office in the standard fashion with the use of oxymetazoline for topical decongestion of the nasal mucosa, In both settings, the electrode will be placed at a superficial depth and needle placement will be performed with one on each side at a location approximately mid-fold
62615924|NCT00435188|EXPERIMENTAL|Arm 1|Behavioral: Multi-component physical activity counseling program A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
62615925|NCT00435188|NO_INTERVENTION|Arm 2|Usual care
62615926|NCT02617134|EXPERIMENTAL|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific chimeric antigen receptor targeting MUC1 antigen by infusion.
62615927|NCT04701489|EXPERIMENTAL|Ultrasound Group|Daily ultrasound application to the spleen of approximately 10 minutes for up to 7 days, in addition to standard clinical care.
62615928|NCT04701489|NO_INTERVENTION|Control Group|Standard clinical care with no ultrasound stimulation.
62623655|NCT01544647|ACTIVE_COMPARATOR|Usual spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
62258914|NCT02871778|EXPERIMENTAL|Part A: VX-371 in Hypertonic Saline (HS), Then HS|Participants received 85 microgram (mcg) VX-371 diluted in 3 milliliter (mL) 4.2 percent (%) HS twice daily through oral nebulized inhalation from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
62056134|NCT00129922|ACTIVE_COMPARATOR|Fluorouracil+Epirubicin+Cyclophosphamide|5-FU+4-Epirubicin+Cyclophosphamide
62056135|NCT00129922|EXPERIMENTAL|FEC followed by Paclitaxel|5-FU+4-Epirubicin+Cyclophosphamide
62615929|NCT02385110|EXPERIMENTAL|Group 1: Alemtuzumab + Etoposide + Dexamethasone|"Induction Phase: Participants receive Alemtuzumab daily on Days 1 - 4 with weekly Etoposide, and Dexamethasone by vein on Days 1-7 during the 8-weeks. Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks.~Dexamethasone by vein on Days 1-7 of the induction phase.~Maintenance Phase: Starts Post Induction Phase for16 weeks. Participants receive Alemtuzumab once every 4 weeks and Dexamethasone three times per week. Participants who have evidence of budding relapse may revert back to receiving Etoposide.~If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes."
62615930|NCT02385110|EXPERIMENTAL|Group 2: Etoposide + Dexamethasone + Tocilizumab|"Induction Phase: Participants receive Tocilizumab by vein over 60 minutes on Day 1 or Day 2. Participants receive Alemtuzumab daily on Days 1 - 4 with weekly Etoposide and Dexamethasone by vein on Days 1-7 during the 8-weeks. Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks.~Maintenance Phase: Starts Post Induction Phase and will last 16 weeks. Tocilizumab not given in the Maintenance Phase. Dexamethasone three times per week.~If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes"
62615931|NCT00602446|EXPERIMENTAL|Deferasirox Treated|Includes patients that were treated with deferasirox for 6 months.
62615932|NCT02159885|EXPERIMENTAL|Telemonitoring|In this arm, subjects will receive usual care at the sleep clinic as well as telemonitoring of their use of their automatically adjusting continuous positive airway pressure pressure (APAP) machine. They will receiving phone calls for poor adherence and/or poor efficacy of treatment.
62615933|NCT02159885|NO_INTERVENTION|Usual Care|"Subjects in this arm will receive usual care for management of obstructive sleep apnea and use of automatically titrating continuous positive airway pressure."
62615934|NCT04262960|ACTIVE_COMPARATOR|active CPAP|auto-PAP with therapeutic pressure
62615935|NCT04262960|SHAM_COMPARATOR|sham-CPAP|auto-PAP with pressure less than 1cm H2O
62615936|NCT05699785|EXPERIMENTAL|patients on antiretroviral therapy with second generation anti-integrase drugs in triple therapy|
62615937|NCT05699785|EXPERIMENTAL|patients on antiretroviral therapy with second generation anti-integrase drugs in dual therapy|
62615938|NCT03813641|EXPERIMENTAL|RALOX + bevacizumab|Oxaliplatin 130mg/m2, i.v.gtt 2h, d1 Raltitrexed 3mg/m2, i.v.gtt 15min ,d1 Bevacizumab 7.5mg/kg, i.v.gtt, d1 The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
62615939|NCT03813641|ACTIVE_COMPARATOR|CAPOX + bevacizumab|Oxaliplatin 130mg/m2, i.v.gtt 2h, d1 Capecitabine 1000mg/m2, po. ,d1 Bevacizumab 7.5mg/kg, i.v.gtt, d1 The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
62615940|NCT03500926|ACTIVE_COMPARATOR|hype standard|total hip replacement with standard femoral stem
62615941|NCT03500926|EXPERIMENTAL|hype mini|total hip replacement with short uncemented femoral stem
62615942|NCT02323737|ACTIVE_COMPARATOR|Irinotecan and cisplatin|The IP regimen consisted of at most 6 cycles of irinotecan 65 mg/m2 of body-surface area on days 1, 8 and cisplatin 75mg/m2 of body-surface area on day 1.
62056136|NCT05739669|OTHER|Sequential EEG Recordings with a wet electrode device a dry electrode device in multiple settings|"* one recording per patient (epilepsy), performed by specialized staff in a clinic, with a CE-certified wet electrode EEG device (Micromed Brain Quick)~* one recording per patient (epilepsy), performed by specialized staff in a clinic, with the investigational device Atlas with dry electrodes~* multiple daily recordings from patients with epilepsy, gathered by lay people for 14 days, at home, with the investigational device Atlas with dry electrodes"
62258915|NCT02871778|EXPERIMENTAL|Part A: HS, Then VX-371 in HS|Participants received 3 mL 4.2% HS through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
62615943|NCT02323737|ACTIVE_COMPARATOR|Etoposide and Cisplatin|The EP regimen consisted of at most 6 cycles of etoposide 100 mg/m2 of body-surface area from day 1 to 3 and cisplatin 75mg/m2 of body-surface area on day 1.
62258916|NCT02871778|EXPERIMENTAL|Part A: VX-371, Then Placebo|Participants received 85 mcg VX-371 diluted in 3 mL 0.17% Saline (placebo) through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
62615944|NCT01851980|EXPERIMENTAL|CWS+Furosemide (40 mg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (40 mg)
62258917|NCT02871778|EXPERIMENTAL|Part A: Placebo, Then VX-371|Participants received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
62615945|NCT01851980|PLACEBO_COMPARATOR|CWS+0.9% saline placebo|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
62615946|NCT01851980|EXPERIMENTAL|CWS+Furosemide (120 mg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (120 mg)
62615947|NCT05788107|EXPERIMENTAL|HLX51 Group|The initial dose of HLX51 is 0.3mg/kg, and 5 dose levels are designed: 0.3 mg/kg, 1 mg/kg , 2.5mg/kg, 5mg/kg, and 10mg/kg (Q3W). Patients with good tolerability and well controlled disease will receive the treatment until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
62056137|NCT05950425|EXPERIMENTAL|Experimental I group (video training + standard training)|This group will be trained with the aspiration training video shot by the researcher on the model. The video content will include the introduction of the materials used in the aspiration application, how to maintain sterility, the position to be given to the child during aspiration, and the sterile aspiration on the model. After obtaining the consent of the mothers in Experiment I group who participated in the study and were assigned by randomization method, they will be taken to the day room of the service and the training video will be watched on the computer. After the end of the video, if they have any questions, they will be answered and they will be taken to their child's intensive care room after wearing the equipment (bonnet, shoe covers, apron, mask) necessary for the standard education and providing hand hygiene.
62258918|NCT02871778|EXPERIMENTAL|Part B: VX-371 in HS + Ivacaftor|Participants who were on 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
62258919|NCT02871778|EXPERIMENTAL|Part B: HS + Ivacaftor|Participants who were on 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
62258920|NCT02871778|EXPERIMENTAL|Part B: VX-371 + Ivacaftor|Participants who were on 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
62056138|NCT05950425|EXPERIMENTAL|Experimental II group (education booklet training + standard training)|Aspiration training will be given to this group with a picture training booklet. The training booklet includes the purpose of aspiration, the materials to be used, the position to be given to the child during aspiration, the preservation of sterility, and the application of aspiration. Expert opinion will be taken for the training booklet to be used. After obtaining the consent of the mothers in the Experimental II group, who participated in the study and were assigned with the randomization method, they will be taken to the day room of the service and aspiration training will be given with a picture training booklet. After the training, the questions of the mothers will be answered. At the end of the illustrated training booklet training, mothers will be put in the necessary equipment (bone cap, shoe covers, apron, mask) for standard practice training and hand hygiene will be provided and they will be taken to the intensive care environment to their children's rooms.
62258921|NCT02871778|PLACEBO_COMPARATOR|Part B: Placebo + Ivacaftor|Participants who were on 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
62258922|NCT00914251|ACTIVE_COMPARATOR|Hesperidin, 500 mg per day|500 mg daily of oral Hesperidin for 3 weeks
62258923|NCT00914251|PLACEBO_COMPARATOR|Placebo|
62258924|NCT02331433|EXPERIMENTAL|Experimental: 1|
62258925|NCT02331433|PLACEBO_COMPARATOR|Placebo Comparator: 2|
62445048|NCT06394323|EXPERIMENTAL|My Choice for HIV Prevention (MyChoice)|The MyChoice intervention consists of PrEP shared decision-making counseling delivered by a trained counselor. It begins with a review of HIV risk in pregnancy/breastfeeding including discussion of population-specific risk factors which may apply to the participant. Next, the counselor presents HIV prevention options including daily oral PrEP and internal and external condoms (discussing attributes and potential advantages and disadvantages of each method). This is followed by a values clarification exercise to identify which features of the competing options matter most to the participant (product attributes and personal and interpersonal implications of each method). The counselor reviews information about these valued features for each offered method. This information and checks to understand and address any unmet participant decision support needs serve as the basis for structured deliberation to collaboratively identify participant preferred method(s).
62615948|NCT04008485|EXPERIMENTAL|Asymptomatic high-risk women|Women will be scheduled to attend for MIS measurement at 20-22 weeks, to be repeated at 26-28 weeks. This measurement will be taken at the same time as the routine examination which they receive when they attend the prematurity clinic. At each study visit the patient will undergo a vaginal examination. Triple high vaginal swabs will then be taken for bacteriology and fetal fibronectin. The sterile magnetic impedance probe will then be introduced, data being captured automatically by pressing the data capture button on the handle of the device. A transvaginal scan will also be performed to measure CL.
62623656|NCT01544647|ACTIVE_COMPARATOR|Active spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
62258926|NCT05564143|ACTIVE_COMPARATOR|EUS-guided gastroenterostomy (EUS-GE)|All EUS-GE procedures were performed under general anesthesia with endotracheal intubation. A forward-viewing gastroscope or side-viewing duodenoscope is first inserted into the site of the obstruction and a 0.025- or 0.035-inch stiff GW is placed down-stream of the jejunum beyond the obstruction as far as possible. Then, oral enteral tube is placed where the jejunum intended for stent placement under fluoroscopic guidance. After exchanging to EUS endoscope, the target jejunum is visualized by EUS after continuously injection of mixed saline and contrast medium. Finally, the gastrojejunostomy stent is directly advanced from the gastric wall into the target jejunum by AXIOS-EC delivery system.
62615949|NCT04008485|EXPERIMENTAL|Symptomatic pregnant women|These women (≥ 16 years of age) will be approached when they attend the labour delivery room or triage with symptoms of preterm labour as detailed above. As a matter of clinical routine these women receive a speculum examination, triple vaginal swabs taken, and fetal fibronectin and cervical length scans as indicated. The study will be explained to them and study materials provided. They will be asked to contact research staff by telephone or through their clinical midwife if they wish to participate. They will be given time to decide. If they agree to take part, written informed consent will then be obtained by research staff who will also conduct the MIS study. If clinical assessments have not already been performed by the time of obtaining consent they will be carried out at the same time
62615950|NCT00538954|ACTIVE_COMPARATOR|1|Follow a standard Enhanced Recovery After Surgery protocol
62258927|NCT05564143|ACTIVE_COMPARATOR|Laparoscopic gastroenterostomy (LGE)|All LGE were performed in the operation room with patients under general anesthesia. After CO2 insufflation, 4 to 5 trocars were introduced. Next, the Treitz ligament was identified. An anterior, dorsal laterolateral, or side- to-side isoperistaltic gastroenteric anastomosis was constructed. The exact location of the gastroenteric anastomosis, with regard to the Treitz ligament, varied from 30 to 60 cm.
62615951|NCT00538954|EXPERIMENTAL|2|Follow a standard Enhanced Recovery After Surgery protocol and will receive 1 g of Magnesium Oxide laxative twice daily from the day after surgery until discharge
62258928|NCT05426889|OTHER|Surgical|undergo surgery
62258929|NCT05426889|OTHER|non-surgical groups|no surgery
62258930|NCT03724188||parathyroidectomy group|the parathyroidectomy group includes 40 hemodialysis patients suffering from sever secondary hyperparathyroidism undergoing surgical parathyroidectomy
62258931|NCT03724188||non parathyroidectomy group|15 hemodialysis patients with sever secondary hyperparathyroidism who were indicated for surgical parathyroidectomy but did not underwent surgery and continued on medical treatment
62258932|NCT06068270|EXPERIMENTAL|Test group|According to randomization, test group patients will receive MOPs at the beginning of the orthodontic therapy and at every other orthodontic recall appointment.
62258933|NCT06068270|NO_INTERVENTION|Control group|No MOPs performed at any stage of the orthodontic therapy
62445049|NCT06394323|ACTIVE_COMPARATOR|Standard of care (control arm)|Participants randomized to the control arm will receive PrEP counseling as based on the current standard of care (SOC). The SOC counseling will be delivered by a trained study staff member. The SOC counselor PrEP counseling according to national guidelines. Control arm participants will receive comprehensive education on both the advantages and limitations of oral PrEP, including guidance on potential side effects. The SOC counselor will assess the woman's eligibility, willingness, and readiness to start using PrEP.
62615952|NCT00538954|EXPERIMENTAL|3|Follow a standard Enhanced Recovery After Surgery protocol and will receive preconditioning with carbohydrate and fluid loading prior to surgery (800ml of Nutricia Preop the evening before surgery and 400 the morning of surgery 2 hours prior to anaesthesia) and postoperative nutritional supplements (200 ml Nutricia Fortisip twice daily) after surgery for 30 days
62615953|NCT00538954|EXPERIMENTAL|4|Follow a standard Enhanced Recovery After Surgery protocol and will receive preconditioning with carbohydrate and fluid loading prior to surgery (800ml of Nutricia Preop the evening before surgery and 400 the morning of surgery 2 hours prior to anaesthesia) and postoperative nutritional supplements (200 ml Nutricia Fortisip twice daily) after surgery for 30 days and will receive postoperative laxative in the form of 20 ml of Magnesium Oxide twice daily form the day after surgery until discharge
62615954|NCT04933617|EXPERIMENTAL|Arm 1- Dose Escalation, Original Copanlisib Intravenous (IV)|Copanlisib intravenous (IV) per dose level (30 mg, 45 mg, or 60 mg) on day 1 of each 21-day cycle in combination with standard dosing dose adjusted rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin (DA-EPOCH-R) to determine recommended phase 2 dose (RP2D) and maximum tolerated dose (MTD) of copanlisib. Up to 6 cycles total.
62615955|NCT04933617|EXPERIMENTAL|Arm 2 - Dose Expansion, Modified Copanlisib Intravenous (IV)|Copanlisib intravenous (IV) at the recommended phase 2 dose (RP2D) or maximum tolerated dose (MTD) on day 1 of each 21-day cycle in combination with standard dosing dose adjusted rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin (DA-EPOCH-R). Up to 6 cycles total.
62258934|NCT05776121|EXPERIMENTAL|ZB001 for injection|Treat different dose cohorts with four intravenous injections of ZB001
62258935|NCT06060964|EXPERIMENTAL|Intervention Group|Participants in this group will use the Breathe Easier progressive web application each day for a period of 8-weeks.
62056139|NCT05950425|NO_INTERVENTION|Control group|The routine standard training given to this group in aspiration training will be used. In this training, one-to-one telling and showing are available. After obtaining the consent of the mothers in the control group who participated in the study and were assigned by randomization method, the necessary equipment (bone cap, shoe covers, apron, mask) will be put on and hand hygiene will be provided and they will be taken to the intensive care unit. After the mother is taken to the room where the child is staying, the equipment and apparatus connected to her child (monitor, infusion pump, NG probe, foley catheter, endotracheal tube, tracheostomy, etc.) will be introduced, equipment used in the treatment process of her child (mechanical ventilator, oxygen valve, aspirator, ambu, aspiration). probe, etc.) will be introduced and physical contact with the child will be supported and ensured.
62615956|NCT06386900||Elite cyclists participating in a Grand Tour|"* Sleep metrics will be tracked by a smart ring (OURA Gen3, OURA Health Ltd, Oulu, Finland) starting from one month prior to the start till the end of the Grand Tour~* Nocturnal heart rate and heart rate variability will be collected by a smart ring (OURA Gen3, OURA Health Ltd, Oulu, Finland) starting from one month prior till the end of the Grand Tour~* Fasted whole blood samples and urine samples will be collected on the morning of (i) the first stage, (ii) the first restday, (iii) second restday, and (iv) last stage of the GrandTour (only in one Grand Tour for a total of 8 cyclists)."
62615957|NCT01080274||positive ergometry|positive ergometry as specified by a cardiologist on site.
62615958|NCT01080274||negative ergometry.|negative ergometry as specified by cardiologist on site.
62615959|NCT01080274||patients with positive stress test|100 patients with positive ergometry test as specified by the cardiologist in charge. All patients are ambulatory patients referred for routine check up.
62615960|NCT02748733|ACTIVE_COMPARATOR|Adapted double mini PET|"PET = Peritoneal Equilibration Test, a test routinely performed to measure peritoneal transport rates of solutes and water in peritoneal dialysis patients. To this end the routinely administered dialysis fluid is infused into the peritoneal cavity. The test will be modified (adapted):~A short, small cycle (0.6 mL/m² BSA, 30 min) followed by a long, large cycle (1.4 mL/m², 120 min) will be performed in each patient and compared to a standard double mini PET."
62615961|NCT02748733|PLACEBO_COMPARATOR|Standard double mini PET|The Standard double mini PET consists of two identical cycles (fill volume 1 L/m², 75 min of dwell time)
62615962|NCT03972020|EXPERIMENTAL|Mindfulness Based Intervention|8 group sessions lasting 2.5 hours each, on a weekly basis.
62615963|NCT03972020|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|8 group sessions lasting 2.5 hours each, on a weekly basis.
62840756|NCT03212144|EXPERIMENTAL|High Intensity Interval Training then Peanut Consumption|Exercise group: 4 training sessions/week, 24 hour rest-periods between each training day. 3-min low intensity warm-up, and then exercise as rapidly as possible for 20 seconds, aiming to reach 85% of their maximum heart rate established during the submaximal cardiopulmonary exercise testing. Then followed by 40 seconds of low intensity exercise. Peanut group: Regular daily caloric intake estimated using data from 24hr recalls, the Miflin-St. Jeor equation, and stress/activity factors. Participants consume dry roasted, unsalted peanuts equivalent to approximately 10% of daily energy intake twice a day, range from approximately 2.4-3.6 ounces. Daily caloric intake will not differ from participants' typical diet. Participants are asked to bring back the empty, numbered peanut packets by the end of every week and will be given new packets weekly. Additionally, subjects will be informed that they will be randomly assessed weekly for compliance.
62056140|NCT00278070|ACTIVE_COMPARATOR|1|
62056141|NCT00278070|ACTIVE_COMPARATOR|2|
62445050|NCT02776761|EXPERIMENTAL|Hantaan Vaccine:|1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
62445051|NCT02776761|EXPERIMENTAL|Puumala Vaccine:|1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
62445052|NCT02776761|EXPERIMENTAL|Hantaan/Puumala Vaccine|The HTNV and PUUV vaccine will be combined (equal volumes) before use: 1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
62445053|NCT00716183|EXPERIMENTAL|Probiotic 1|Women receiving Lactobacillus salivarius HN6
62445054|NCT00716183|EXPERIMENTAL|Probiotic 2|Women receiving Lactobacillus reuteri CR20
62445055|NCT00716183|EXPERIMENTAL|Probiotic 3|Women receiving Lactobacillus fermentum LC40
62445056|NCT00716183|ACTIVE_COMPARATOR|beta-lactam|The evolution of the women ascribed to the other three arms will be compared with that of 100 women suffering lactational mastitis that will follow a conventional antibiotic treatment as prescribed by the pediatrician/gynecologist
62615964|NCT01733823|EXPERIMENTAL|Group A|Performance scale 0-1, Charlson co-morbidity score=0 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
62056142|NCT00278070|ACTIVE_COMPARATOR|3|
62258936|NCT06060964|NO_INTERVENTION|Non-intervention Group (Control Group)|Participants in this group will receive no intervention.
62258937|NCT01517893|EXPERIMENTAL|Intervention arm|Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
62258938|NCT01517893|PLACEBO_COMPARATOR|Placebo Arm|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
62258939|NCT02854514||aspiration of endometrial secretion|intra uterine flushing of the endometrial cavity by five millilitre of saline through embryo transfer catheter then aspirated with endometrial secretion then centrifuged then analyzed for detection of concentration of tumor necrosis factor a and interleukin 1 b
62258940|NCT03569579|EXPERIMENTAL|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Memantine Tab. 10mg)\*2T, QD, PO.~Period 2: Treatment B(Memantine Tab. 10mg)\*2T + Donepezil Tab. 10mg)\*1T, QD, PO.~Each treatment period was separated by a washout period of at least 21 dyas."
62615965|NCT01733823|EXPERIMENTAL|Group B|PS 0-1 Charlson=1 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
62615966|NCT01733823|EXPERIMENTAL|Group C|PS 0-1 Charlson \>=2 Will start inclusion after Group A and B Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
62615967|NCT01733823|EXPERIMENTAL|Group D|PS 2, Charlson: Any Will start inclusion after Group C Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
62615968|NCT05173285|EXPERIMENTAL|Brief Online ACT Intervention|Intervention Condition: Participants in this arm will take part in a brief ACT intervention delivered online via Qualtrics across 4-weeks; one session per week. The first two weeks will focus on mindfulness, with participants being invited to practice formal (i.e. 3-minute breathing exercise) and informal mindfulness practices (e.g. mindful walking, mindful drink etc.) during the week. The final two weeks will focus on values, specifically supporting participants to identify their personal values and set goals relating to these values. Participants have up to 6 weeks to complete the 4-week intervention.
62615969|NCT05173285|OTHER|Waitlist Control|Control Condition: Participants in this arm will not receive an intervention. They will however, been given access to the brief online ACT intervention at the end of study.
62615970|NCT05262790||PNS group|The patients with prominently negative symptoms (PNS) had a greater score on the negative than on the positive subscale of the PANSS, a negative symptoms score \> 20, and at least one of items from PANSS negative symptoms scale ≥ 4 points
62615971|NCT05262790||PPS group|The patients with predominantly positive symptoms (PPS) had a greater score on the positive than on the negative subscale of the PANSS
62056143|NCT01033214|EXPERIMENTAL|TAArget Thoracic Stent Graft|those treated with the investigational device
62056144|NCT04840277|EXPERIMENTAL|Intervention group|Remote hearing aid adjustment. All participants in this group are offered hearing aids possible to adjust remotely.
62056145|NCT04840277|NO_INTERVENTION|Control group|Traditional hearing aid adjustment
62615972|NCT05262790||Control|Healthy control
62840757|NCT03212144|EXPERIMENTAL|Peanut Consumption then High Intensity Interval Training|Exercise group: 4 training sessions/week, 24 hour rest-periods between each training day. 3-min low intensity warm-up, and then exercise as rapidly as possible for 20 seconds, aiming to reach 85% of their maximum heart rate established during the submaximal cardiopulmonary exercise testing. Then followed by 40 seconds of low intensity exercise. Peanut group: Regular daily caloric intake estimated using data from 24hr recalls, the Miflin-St. Jeor equation, and stress/activity factors. Participants consume dry roasted, unsalted peanuts equivalent to approximately 10% of daily energy intake twice a day, range from approximately 2.4-3.6 ounces. Daily caloric intake will not differ from participants' typical diet. Participants are asked to bring back the empty, numbered peanut packets by the end of every week and will be given new packets weekly. Additionally, subjects will be informed that they will be randomly assessed weekly for compliance.
62056146|NCT05777967|EXPERIMENTAL|Single Arm|
62056147|NCT02615236|EXPERIMENTAL|PERINEAL ULTRASOUND|Perineal ultrasound with a bedside scanner by inserting a the probe into the perineum and reviewed in real-time
62840758|NCT02185495|EXPERIMENTAL|High-risk individuals|"The elder and heavy smokers, which are high-risk individuals for early lung cancer. These subjects will be examined using Observer nodule detection and  Computer-aided nodule detection."
62840759|NCT04922567|EXPERIMENTAL|lenalidomide + CHOP regimen|
62445057|NCT06441981|OTHER|Behavioral Education|Educational material is provided via WhatsApp chatbot. After being educated, respondents were given a test to determine the increase in understanding of the material.
62445058|NCT02840383|ACTIVE_COMPARATOR|Delayed Intervention|Schools not receiving intervention until two years after implementation.
62445059|NCT02840383|EXPERIMENTAL|Intervention|Schools receiving intervention at the beginning of study.
62445060|NCT03372980||Case|
62445061|NCT03372980||Control|
62445062|NCT03497533|EXPERIMENTAL|TriCAR-T-CD19|Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously
62056148|NCT02615236|ACTIVE_COMPARATOR|Clinical diagnosis|Diagnosis of OASIS will be clinically
62056149|NCT03552302||Cases|Yoga exercise for 12 weeks
62056150|NCT01910623||Patients being studied|APL patients previously enrolled in GIMEMA AIDA 0493 and AIDA 2000 studies.
62056151|NCT02609646||linezolid|patients treated with linezolid
62056152|NCT02609646||meropenem|patients treated with meropenem
62056153|NCT02609646||piperacillin/tazobactam|patients treated with piperacillin/tazobactam
62056154|NCT02609646||vancomycin|patients treated with vancomycin
62056155|NCT01744886|ACTIVE_COMPARATOR|lung surgery|"An initial baseline arterial blood gas (ABG) will be taken before anesthesia induction while breathing room air.~A second ABG will be taken on FIO2=0.5 during double lung ventilation. Then 3 ABG's will be consecutively determined each 15 min once OLV is initiated. PaO2/FIO2 is calculated on every ABG's measurement. If necessary, measures are taken to maintain oxygenation during one lung ventilation."
62056156|NCT01744886|ACTIVE_COMPARATOR|port-access cardiac surgery|"An initial baseline arterial blood gas (ABG) will be taken before anesthesia induction while breathing room air.~A second ABG will be taken on FIO2=0.5 during double lung ventilation. Then 3 ABG's will be consecutively determined each 15 min once OLV is initiated. PaO2/FIO2 is calculated on every ABG's measurement. In the port-access group, FIO2 is maintained on 1 after the stopping of the ECC, so PaO2 will become our only indicator for oxygenation. If necessary, measures are taken to maintain oxygenation during one lung ventilation."
62445063|NCT04730557|EXPERIMENTAL|Weight-Loss|Participants in the weight-loss intervention arm of the study will be enrolled in an individualized 6-month intervention designed to achieve a 10% reduction of body weight relative to baseline. Each participant receives a calorie (kcal) prescription derived from calculations of estimated total energy expenditure (TEE) based on weight, height, sex, age, and activity level using equations developed by the Institute of Medicine \[29\]. Prescribed kcal levels are adjusted downward from the TEE to achieve a weekly weight loss of 1 to 2 pounds, generally a deficit of 500-1000 kcal/day. Intervention activities include individual diet counseling, group support, goal setting, self-monitoring, stress management, and problem solving. Weekly group support and education sessions, along with daily food journaling and weekly weigh-ins, are recognized approaches for successful weight loss \[30-32\]. Once the weight loss goal is achieved, diets will be liberalized for weight maintenance.
62056157|NCT04970199|ACTIVE_COMPARATOR|group 1|thirty lupus women received laser acupuncture (active) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian (laser was applied for 1 min on every acupiont).
62056158|NCT04970199|SHAM_COMPARATOR|group 2|thirty lupus women received laser acupuncture (sham) for one month (3 days) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian (laser was be applied for 1 min on every acupiont).
62615973|NCT04575584|EXPERIMENTAL|Part 1: Molnupiravir 200 mg|200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
62615974|NCT04575584|EXPERIMENTAL|Part 1: Molnupiravir 400 mg|400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
62056159|NCT04127487||Periodontitis group|35 Generalized chronic periodontitis subjects without coronary heart diseases
62056160|NCT04127487||periodontitis with CAD group|35 Generalized chronic periodontitis subjects diagnosed with Coronary heart disease
62056161|NCT05225688||PASC patients|Non-hospitalized covid-19 patients with Post-acute Sequelae of COVID-19
62056162|NCT05225688||Healthy controls|Non-hospitalized covid-19 patients without residual symptoms
62056163|NCT05225688||ME/CFS patients|Patients with ME/CFS
62056164|NCT01937039||Breast cancer patients|Participants have a known diagnosis of breast cancer and are receiving a breast cancer evaluation and/or treatment, who agree to sample collection, access, and follow-up as part of the repository.
62056165|NCT01937039||Benign breast disease|Participants have benign breast disease and are receiving a diagnostic procedure and/or evaluation, who agree to sample collection, access, and follow-up as part of the repository.
62056166|NCT01937039||Healthy volunteer|Participants have no known diagnosis of breast disease or abnormality and are undergoing routine screening or diagnostic breast imaging procedures and/or other clinical evaluation, who agree to sample collection, access, and follow-up as part of the repository.
62615975|NCT04575584|EXPERIMENTAL|Part 1: Molnupiravir 800 mg|800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
62615976|NCT04575584|PLACEBO_COMPARATOR|Part 1: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
62615977|NCT04575584|EXPERIMENTAL|Part 2: Molnupiravir|Molnupiravir (dose to be selected) administered orally every 12 hours for 5 days (10 doses total)
62615978|NCT04575584|PLACEBO_COMPARATOR|Part 2: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
62056167|NCT02427659|OTHER|Virtual Reality Distraction|The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
62615979|NCT03681041||Pancreatic injury|Patient diagnosed with pancreatic trauma by surgery, computed tomography, Endoscopic retrograde cholangiopancreatography (ERCP) and Magnetic resonance cholangiopancreatography (MRCP) were included
62615980|NCT01325571|EXPERIMENTAL|tacrolimus group|
62615981|NCT01325571|PLACEBO_COMPARATOR|placebo group|
62615982|NCT03433859|EXPERIMENTAL|OnabotulinumtoxinA|OnabotulinumtoxinA in intradermal Injections on residual lower limb
62615983|NCT03433859|ACTIVE_COMPARATOR|Topical Aluminium Chloride|Topical Aluminium Chloride (cosmetic product) on the lower limb
62615984|NCT00824707|EXPERIMENTAL|anti-virus therapy|100 HCC patients will be allocated to receive anti-virus therapy.
62615985|NCT00824707|ACTIVE_COMPARATOR|conventional therapy|100 patients will undergo conventional therapy
62615986|NCT06432946|EXPERIMENTAL|Video followed by practice|Participants will initially view a 7-minute informational video followed by a 20-minute supervised practice session with the sensing-glove system. Acceptability and usability perception will be assessed after each intervention.
62840760|NCT04922567|ACTIVE_COMPARATOR|CHOP regimen|
62840761|NCT02721966|EXPERIMENTAL|AIN457 150mg|Secukinumab dose amount 1 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 1 sc injection every 4 weeks for remaining 44 weeks
62615987|NCT06432946|EXPERIMENTAL|Practice followed by video|Participants will initially participate in a 20-minute supervised practice session with the sensing-glove system followed by viewing a 7-minute informational video. Acceptability and usability perception will be assessed after each intervention.
62615988|NCT01262924|EXPERIMENTAL|Group A|dTPa vaccine
62615989|NCT01262924|EXPERIMENTAL|Group B|Pa vaccine
62615990|NCT01262924|ACTIVE_COMPARATOR|Group C|Tedivax-Adult™/ Td-Rix™
62615991|NCT01202552|EXPERIMENTAL|group 1|receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain
62056168|NCT02427659|OTHER|Audio (sounds of nature)|"The subjects will listen to an audio recording called Sounds of Nature during their wound care. The nurse will be doing the wound care."
62056169|NCT02427659|OTHER|control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
62615992|NCT01202552|EXPERIMENTAL|group 2|receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site
62615993|NCT01202552|EXPERIMENTAL|group 3|receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
62056170|NCT02432469|EXPERIMENTAL|Intervention group|APP specific for this study, with reminder, education materials and feedback mechanism for improving secondary medications
62056171|NCT02432469|NO_INTERVENTION|Control group|Usual Care
62056172|NCT03202043|EXPERIMENTAL|High dose vegetable juice|Subject will consume high dose vegetable juice daily for 8 weeks.
62056173|NCT03202043|EXPERIMENTAL|Medium dose vegetable juice|Subject will consume medium dose vegetable juice daily for 8 weeks.
62615994|NCT00618124|EXPERIMENTAL|A|
62258941|NCT03569579|EXPERIMENTAL|Group 1(Treatment B/Treatment A)|"Period 1: Treatment B(Memantine Tab. 10mg)\*2T + Donepezil Tab. 10mg)\*1T, QD, PO.~Period 2: Treatment A(Memantine Tab. 10mg)\*1T, QD, PO.~Each treatment period was separated by a washout period of at least 21 dyas."
62615995|NCT05391945||goiter|Patients referred for partial/total thyroidectomy for goiter
62615996|NCT03787199|EXPERIMENTAL|Andago|Application of walking over-ground with body-weight support in the Andago
62615997|NCT03787199|ACTIVE_COMPARATOR|Treadmill|Application of walking on a treadmill with body-weight support
62840762|NCT02721966|EXPERIMENTAL|AIN457 300mg|Secukinumab dose amount 2 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 2 sc injection every 4 weeks for remaining 44 weeks
62840763|NCT02721966|PLACEBO_COMPARATOR|AIN457 Placebo|Placebo sc injection weekly for 4 weeks and at week 8, followed by Secukinumab 150 mg or 300 mg sc injection every 4 week for remaining 40 weeks.
62056174|NCT03202043|EXPERIMENTAL|Low dose vegetable juice|Subject will consume low dose vegetable juice daily for 8 weeks.
62056175|NCT03202043|OTHER|Control bottled water|Subject will consume control bottled water daily for 8 weeks.
62258942|NCT01999465|ACTIVE_COMPARATOR|Standard NMES cohort|Patients who will apply standard NMES device.
62258943|NCT01999465|SHAM_COMPARATOR|Sham NMES cohort|Patients who will apply sham NMES device.
62056176|NCT00760539|EXPERIMENTAL|Travoprost/Timolol BAC-free|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
62056177|NCT00760539|ACTIVE_COMPARATOR|Travoprost/Timolol|Travoprost 0.004%/Timolol 0.5% ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
62258944|NCT00436800|EXPERIMENTAL|1|Gemcitabine on Day 1 followed by Oxaliplatin on Day 2. The regimen is given every 2 weeks to a maximum of 12 cycles.
62615998|NCT06307509||ICU patients with sepsis|Patients admitted to the Intensive Care Unit with a primary diagnosis of sepsis. They will have subcutaneous adipose tissue samples taken by needle aspiration, and blood samples taken.
62615999|NCT06307509||Surgical patients with sepsis|Patients undergoing emergency laparotomy with a diagnosis of sepsis will have subcutaneous and visceral adipose tissue samples taken intra-operatively, and blood samples taken.
62616000|NCT02897180|PLACEBO_COMPARATOR|Placebo|Subjects will receive a total of 14 capsules with Placebo
62616001|NCT02897180|EXPERIMENTAL|Nyaditum resae(R)|Subjects will receive a total of 14 capsules with Nyaditum resae(R)
62616002|NCT03131700|EXPERIMENTAL|RPH-001|A single dose of RPH-001 will be administered (IV) 5 mg/kg dose .
62616003|NCT03131700|ACTIVE_COMPARATOR|EU sourced Avastin®|A single dose of Avastin® will be administered (IV) 5 mg/kg dose .
62616004|NCT00511485|EXPERIMENTAL|Etarfolatide + Vintafolide|Screening: After completion of all screening procedures and confirmation of eligibility, all participants receive a 1- to 2-mL injection of 0.1 mg etarfolatide labeled with 20 to 25 mCi of technetium-99m. Induction phase of treatment: Two 4-week cycles; if stable disease or better at (week 8) computed tomography (CT), participant may proceed into maintenance phase. Maintenance phase of treatment: 4-week cycles with CT every 8 weeks. Participants continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit.
62616005|NCT06511271|NO_INTERVENTION|Group 1|"Patients in the control group were given only the standard procedure for laparoscopic cholecystectomy during the research period.~treatment and care were applied."
62616006|NCT06511271|EXPERIMENTAL|Group 2|The first 10-minute part of the CD audio recordings prepared by the Turkish Psychologists Association is about deep relaxation. purpose; The second 30-minute part includes instructions for relaxation exercises; The last 30 minutes are just It consists of relaxation music\[145\]. In our study, the instructions in the second part were used. - In addition to standard treatment and care for laparoscopic cholecystectomy, volunteers who accept the study Progressive relaxation exercises were applied by the researcher at the 2nd, 6th, 12th and 24th hours after surgery. When the literature review on PGE was made, it was seen that the application time and frequency of these exercises were not standard; 6th, 12th, 24th hours after surgery; It was applied on the 2nd day after surgery and the total number of sessions varied. It is seen to show. In our study, PGE was detected at the 2nd, 6t
62616007|NCT04886245|EXPERIMENTAL|facial palsy|Patient with peripheral facial palsy, irrespective of grade, whether or not previously treated
62056178|NCT00058422|EXPERIMENTAL|R-CHOP and Ibritumomab Tiuxetan (Zevalin)|"Chemotherapy: Patients receive rituximab IV over 2-5 hours, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5 or 2-6; and filgrastim (G-CSF) subcutaneously (SC) on days 7-15. Patients also receive darbepoetin alfa SC on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Radioimmunotherapy: Patients receive rituximab IV over 3-5 hours and indium In 111 ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0.~Patients undergo gamma camera imaging at 2-24 hours and 48-72 hours after the injection of IDEC-In2B8 to observe the flow of ibritumomab tiuxetan. If the flow is deemed safe, then patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7. Quality of life is assessed at baseline, before course 5 of chemotherapy, before radioimmunotherapy, and at 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
62056179|NCT02673970||observational arm|From start treatment till date of death or date of cure, the patient will be followed for survival and adverse events on pembrolizumab
62056180|NCT02693821|EXPERIMENTAL|Gabapentin|300mg of Gabapentin per day (two doses), orally during 30 days
62056181|NCT02693821|PLACEBO_COMPARATOR|Placebo|300mg of Placebo per day (two doses), orally during 30 days
62056182|NCT03366922|ACTIVE_COMPARATOR|Control Arm|Participants will be on routine HAART only. No Artemisia Annua, Moringa oleifera will be given.
62056183|NCT03366922|EXPERIMENTAL|Intervention Arm 1|Participants will be given HAART and Artemisia annua leaf powder 4 g per day. They will only receive Artemisia Annua, Moringa oleifera will not be given.
62056184|NCT03366922|EXPERIMENTAL|Intervention Arm 2|Participants will be given HAART with Artemisia annua leaf powder of 4 grams per day and Moringa oleifera leaf powder of 10 grams per day. Both Artemisia Annua, Moringa oleifera will be given.
62056185|NCT02603822|EXPERIMENTAL|Healthy Volunteers|Subjects will receive a saccharide solution of 12C mannitol 100 mg, 13C mannitol 100 mg, and lactulose 1 g in 250ml of water at visits 2, 5, and 7 prior to permeability testing. The subjects will also receive Indomethacin capsules prior to visit 5.
62056186|NCT03167684|EXPERIMENTAL|Oral appliance therapy|Oral appliance (SomnoMed) worn nightly
62056187|NCT03167684|NO_INTERVENTION|Control|Sham oral appliance device
62616008|NCT04886245|SHAM_COMPARATOR|healthy volunteers|- Subject without major facial sequelae
62616009|NCT06403904||Male and female participants with PALB2-related BC and at least 18 years of age|
62445064|NCT04730557|NO_INTERVENTION|Wellness Education|Control participants will be counseled to maintain their baseline body weight and level of physical activity. They will report weights weekly and if their weight deviates from baseline they will be asked to keep daily food logs and counseled to return calorie intakes to weight maintenance level. To document diet intakes/adherence, 3-day food records will be collected at months 0, 3, and 6 and analyzed for calorie and nutrient composition. Participants will be encouraged not to change their physical activity levels from baseline and their activity will be monitored by Actigraph activity monitors worn in 7-day periods at months 0, 3, and 6. In addition, each participant will be invited to enter the weight loss intervention after completion of the health education control course.
62056188|NCT04365517|ACTIVE_COMPARATOR|Treatment group|patients will be treated with sitagliptin add on to nutritional therapy with o without insulin treatment. The dose of sitagliptin will be established on the basis of the estimated glomerular filtrate: 100 mg in single daily administration (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2) in combination or not with insulin. Patients with stage IV and V renal failure (estimated glomerular filtration rate less than or equal to 30 mL / min / 1.73 m2) will be excluded
62056189|NCT04365517|NO_INTERVENTION|Control group|Patients who will be prescribed nutritional therapy with or without insulin treatment
62056190|NCT05444062|NO_INTERVENTION|Control Arm: CVD|"Patients diagnosed with mild to severe CAC and not on first line guideline recommended therapy.~Coronary artery Calcification (CAC) score obtained from lung cancer screening CT Scan images"
62445065|NCT05611307||Surgical/Surveillance|TCS cured with surgical resection and surveillance (surgical/surveillance, Arm 1)
62445066|NCT05611307||Cisplatin-based chemotherapy (CBCT)|TCS treat with one or more lines of cisplatin-based chemotherapy
62445067|NCT05611307||Cisplatin-based chemotherapy and Bone Marrow Transplant (CBCT/BMT)|TCS treat with one or more lines of cisplatin-based chemotherapy, and who have undergone bone marrow transplant
62616010|NCT06403904||Patient affected by BC negative for mutations|The control group will be composed by patients affected by BC tested with multigene panel and resulted negative for mutations.
62616011|NCT04375098|EXPERIMENTAL|Early COVID-19 convalescent plasma|COVID-19 convalescent plasma 200 ml day 1 and 2 at admission after confirmation of eligibility
62616012|NCT04375098|EXPERIMENTAL|COVID-19 convalescent plasma|COVID-19 convalescent plasma 200 ml day 1 and 2 only if worsening of respiratory function or persistence of COVID symptoms for \>7 days after enrolment
62056191|NCT05444062|OTHER|Intervention Arm: CVD|"Patients diagnosed with mild to severe CAC and not on first line guideline recommended therapy.~CAC score obtained from lung cancer screening CT Scan images"
62616013|NCT01200277|EXPERIMENTAL|vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
62616014|NCT01200277|SHAM_COMPARATOR|sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the bone cement is prepared to simulate the odor associated with mixing of polymethacrylate , but the needle is not placed and cement is not injected.
62056192|NCT05444062|NO_INTERVENTION|Control Arm: COPD|Patients with untreated COPD or not on first line guideline recommended therapy.
62056193|NCT05444062|OTHER|Intervention Arm: COPD|Patients with untreated COPD or not on first line guideline recommended therapy.
62056194|NCT00867022||1|Women with gestational diabetes
62056195|NCT00867022||2|Pregnant women without gestational daibetes
62056196|NCT00867022||3|Women with gestational diabetes and hypertension
62258945|NCT02034942|EXPERIMENTAL|Non-sedation|"The experimental group will not receive sedatives. Patients are thoroughly and repeatedly informed by the staff of where they are, what have happened, and what type of treatment they are going to receive.~Participants will be awake and have a natural sleep rhythm. In case these patients develop and outward delirium, it is necessary to have a nurse or other caregiver at the bedside in order to calm the patient. Patients with delirium will be treated with haloperidol."
62445068|NCT03376958|EXPERIMENTAL|Apatinib|Apatinib 500mg once daily makes an initial dose and 28 days made one treatment cycle. All patients took the drug continuously until disease progression, intolerable toxicities, and patient-requested withdrawal. Appropriate supportive care were given.
62445069|NCT00593879|PLACEBO_COMPARATOR|1|Placebo
62445070|NCT00593879|EXPERIMENTAL|2|
62445071|NCT03850509|EXPERIMENTAL|OPS-2071 150 mg BID|Participants were to receive OPS-2071 150 mg, tablets, orally, twice daily (BID) in the morning and evening (8 to 12 hours apart) with 240 milliliters (mL) of water for up to 12 weeks.
62445072|NCT03850509|EXPERIMENTAL|OPS-2071 300 mg BID|Participants received OPS-2071 300 mg, tablets, orally, BID in the morning and evening (8 to 12 hours apart) with 240 mL of water for up to 6 weeks.
62445073|NCT03850509|EXPERIMENTAL|OPS-2071 600 mg BID|Participants were to receive OPS-2071 600 mg, tablets, orally, BID in the morning and evening (8 to 12 hours apart) with 240 mL of water for up to 12 weeks.
62445074|NCT03850509|PLACEBO_COMPARATOR|Placebo|Participants received OPS-2071-matched placebo, tablets, orally, BID in morning and evening (8 to 12 hours apart) with 240 mL of water for up to 4 weeks.
62445075|NCT04659681|ACTIVE_COMPARATOR|PVI Guided Fluid Therapy|Patients will receive PVI guided fluids during surgery PVI to be maintained below 12% if PVI \>12 then colloid bolus 200ml will be given. Lung Ultrasonography will be performed post-intubation as baseline and at the end of surgery before extubation in 4 Lung zones in both lungs to measure total number of B-lines.
62445076|NCT04659681|ACTIVE_COMPARATOR|CVP Guided Fluid Therapy|Patients will receive Standard CVP Guided Fluids , CVP maintained between 10-16 cms H20 , if CVP\< 10 then colloid bolus 200ml will be given. Lung Ultrasonography will be performed post-intubation as baseline and at the end of surgery before extubation in 4 zones in both lungs to measure total number of B-lines.
62445077|NCT05887765|ACTIVE_COMPARATOR|placebo injection|5ml of 0,9% sodium chloride - before the popliteal nerve block
62445078|NCT05887765|ACTIVE_COMPARATOR|0,1mg/kg Dexamethasone|0,1mg/kg dexamethasone sodium phosphate - before the popliteal nerve block
62445079|NCT05887765|ACTIVE_COMPARATOR|0,2mg/kg Dexamethasone|0,2mg/kg dexamethasone sodium phosphate - before the popliteal nerve block
62445080|NCT04366700|ACTIVE_COMPARATOR|Bone replacement substitute and membrane|periapical surgery will be done and defect will be filled with a mixture of autograft and prf and over the defect and denuded root surface collagen membrane will be placed before closure of flap
62445081|NCT04366700|ACTIVE_COMPARATOR|membrane|periapical surgery will be done and defect will be filled with blood clot and over the defect and denuded root surface collagen membrane will be placed before closure of flap
62056197|NCT00867022||4|Non pregnant women
62056198|NCT05817266|EXPERIMENTAL|Proctosigmoiditis|Participants with confirmed proctosigmoiditis will undergo one FCI scan.
62840764|NCT05641480|EXPERIMENTAL|Subjective cognitive decline group|"Studies suggest that acupuncture point Shenting can reduce the levels of serum inflammatory factors IL-6 and TNF-α, and the activity of cholinesterase of these two inflammatory factors is increased, and the activity of cholinacetylase is inhibited, which leads to brain tissue damage, nerve damage and cognitive dysfunction. Shenting（DU24）, Benshen（BG13） and Tou Wei（ST8） are the acupoints on the forehead, which have the effect of awakening the brain. Moreover, after acupuncture, nerve and periosteum effects can be caused, so as to improve cognitive function.~Music therapy is a convenient and efficient method, and as a non-drug intervention, activate the memory to help people with Alzheimer's disease, trigger positive emotions, improve the symptoms of behavior, the moment of life in participants with Alzheimer's disease has great significance, is a good way to help participants with slow disease progression and improve the quality of life, increase happiness of life."
62840765|NCT05641480|EXPERIMENTAL|Mild cognitive impairment group|"Studies suggest that acupuncture point Shenting can reduce the levels of serum inflammatory factors IL-6 and TNF-α, and the activity of cholinesterase of these two inflammatory factors is increased, and the activity of cholinacetylase is inhibited, which leads to brain tissue damage, nerve damage and cognitive dysfunction. Shenting（DU24）, Benshen（BG13） and Tou Wei（ST8） are the acupoints on the forehead, which have the effect of awakening the brain. Moreover, after acupuncture, nerve and periosteum effects can be caused, so as to improve cognitive function.~Music therapy is a convenient and efficient method, and as a non-drug intervention, activate the memory to help people with Alzheimer's disease, trigger positive emotions, improve the symptoms of behavior, the moment of life in participants with Alzheimer's disease has great significance, is a good way to help participants with slow disease progression and improve the quality of life, increase happiness of life."
62840766|NCT05641480|EXPERIMENTAL|Mild dementia group|On the basis of the above two treatment options, oral donepezil hydrochloride tablets or carpalatine heavy tartrate tablets should be added.
62840767|NCT03678220|EXPERIMENTAL|Patients using LapAR system|
62840768|NCT00643721||D,FR|Young healthy athletes
62840769|NCT04509219|EXPERIMENTAL|Participants treated with MP pulse|Selected participants will be given MP pulse treatment
62840770|NCT03765034|EXPERIMENTAL|Constraint-induced Movement Therapy|A passive constraint cast is applied to the participant's unaffected arm to prevent use for 8 weeks.
62840771|NCT03765034|ACTIVE_COMPARATOR|Usual Occupational Therapy|Usual and standard care occupational therapy is administered for 8 weeks.
62840772|NCT03212781|EXPERIMENTAL|intravenous iron|patients will receive intravenous iron as total dose infusion
62840773|NCT03212781|ACTIVE_COMPARATOR|oral iron|patients will receive oral iron
62258946|NCT02034942|ACTIVE_COMPARATOR|Sedation with daily wake-up|"The control group will be sedated to Ramsay score 3-4. The first 48 hours the patients will be sedated with propofol, after 48 hours midazolam will be used. During daytime, the patient will be awakened as the intravenous infusion of sedatives will be discontinued. The patient will be considered to be awake when he/she can perform at least three of the following four tasks:~* Open the eyes to verbal commands.~* Follow the examiner's instructions with the eyes.~* Squeeze hands on request.~* Stick out the tongue on request.~After a successful wake-up, the infusion of sedative will be resumed, starting on half of the pre-wake-up dose and adjusted to Ramsey score 3-4."
62056199|NCT05597722|ACTIVE_COMPARATOR|Digital cognitive behavioral intervention- RxWell|"The mobile app provides users with brief skill building techniques such as relaxation, behavioral activation and exposure, distress tolerance, cognitive reframing, and mindfulness meditation, for anxiety and depression. The content of RxWell was developed based on standard CBT techniques for treating anxiety disorders and depression. The user will have the option to select either the depression or anxiety program, and the coach will have the ability to personalize the program so that the individual can utilize the proper CBT techniques that fits with their presentation.~The health coach communicates with RxWell users via asynchronous, secure within app messaging. They reinforce CBT principles, guide users through goal setting, and help users work through challenges and recognize successes. The coaches will also receive individualized cognitive rehabilitation tips from the speech therapist after their appointment with the participant."
62056200|NCT05597722|ACTIVE_COMPARATOR|Stimulant Medication|The other intervention is a stimulant medication known to reduce cognitive impairment in other chronic medical conditions, such as Inflammatory Bowel Disease. The Long-COVID psychiatrist will order the medication and the participant will be scheduled for a 6-week research tele visit with the psychiatrist to monitor for any medication side effects. Amphetamine-dextroamphetamine drug dose will be 10mg daily for 12 weeks, and no dose changes will be made. Amphetamine-dextroamphetamine is a Schedule II controlled substance that has a risk for abuse, tolerance, and psychological dependence, which can be associated with severe social disability.
62258947|NCT01974492|ACTIVE_COMPARATOR|Upper leg vein|Upper leg vein harvesting
62258948|NCT01974492|ACTIVE_COMPARATOR|Lower leg vein|Lower leg vein harvesting
62258949|NCT01489670||Lumigan® 0.01%|Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
62840774|NCT03527823||LH supplementation|luteinizing hormone administrated microdose flare up GnRH analog protocol in poor ovarian responders undergoing in vitro fertilization.
62258950|NCT03377530||Premature neonates infected with bacillus Species|The investigators studied retrospectively eleven cases of these infections in our NICU and reviewed series and report cases in literature.
62258951|NCT05467514|EXPERIMENTAL|Liraglutide|Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus
62258952|NCT05843851|EXPERIMENTAL|Tested newborns|Tested for two mutations in the CTNS gene and one mutation in the PH1 gene and PH 3.
62258953|NCT03972787|EXPERIMENTAL|Proactive Social Robot (Intervention)|Participants will have the opportunity to use ElliQ for a total of 8 weeks to determine the impacts of the system on participants' loneliness, mood, technology use, and quality of life.
62840775|NCT03527823||without LH supplementation|microdose flare up GnRH analog protocol in poor ovarian responders
62258954|NCT03972787|NO_INTERVENTION|Waitlist Control|Participants will not receive any intervention for a total of 8 weeks to determine whether any impacts noted for participants' loneliness, mood, technology use, and quality of life are unique to ElliQ or are influenced by other factors.
62616015|NCT04229199|EXPERIMENTAL|intervention group (IG)|Dyads of children and parents allocated to the IG were taken into a tour to a simulation operating room accompanied by an expert anesthesia technologist two weeks before the day of surgery. This simulation operating theater is a real operating room equipped with a surgical trolley, sealing surgical lights, anesthesia machine, vital signs monitor, stethoscope, surgical trays, surgical sink, and gas supply pendent. It was prepared with popular cartoon characters, child manikin, and face masks connected to the anesthesia circuit and re-breathing bag. After being assessed by anesthesia clinic doctors, children and their parents in the IG were given a chance to visit the simulation operating room, to receive orientation, education, and demonstration orientation about what they are going to experience in the operating room. Children were encouraged to apply vital signs monitoring, and to simulate providing mask anesthesia induction to a child manikin.
62445082|NCT04665674||Pulmonary Langerhans cell histiocytosis (PLCH)|All patients with newly diagnosed PLCH at adulthood (i.e. 18 years of age or older) referred to the French national reference centre for Histiocytoses
62616016|NCT04229199|NO_INTERVENTION|control group (CG)|Dyads assigned to the CG were provided only the standard practice on their day admission to the hospital.
62445083|NCT02586831|EXPERIMENTAL|Arm A|"Participants in this group will receive Thymoglobulin, Aldesleukin, Adalimumab, and Exenatide over a period of 52 weeks.~* Anti-Thymocyte Globulin (ATG or Thymoglobulin®) will be administered at a dose of 2.5mg/kg (2 infusions, 0.5 and 2mg/kg) Days 1 and 2~* Adalimumab (Humira®) will be administered at a dose of 50 mg every month, for 1 year~* Low-dose Interleukin 2 (Aldesleukin; IL-2 or Proleukin®) will be administered 1 million IU/dose; 5 consecutive days (days 10-14), \& then every 2 weeks, for 52 weeks~* Exenatide (Bydureon®): 2 mg SC weekly up to 52 weeks."
62616017|NCT04837105|ACTIVE_COMPARATOR|Control group|"Classic rehab (physio including strength rehab, fitness, motor activity...) + treadmill gait training 3\*/week/4weeks:~5 minutes of warm-up with gradual increase in treadmill speed, max 20 minutes of walking at 80% of maximum speed, 5 minutes of active recovery with gradual decrease in treadmill speed.~(protocol from Grecco et al.)"
62616018|NCT04837105|EXPERIMENTAL|Test group|"Classic rehab - same as control group - (physio including strength rehab, fitness, motor activity...) + overground ARROW CP gait training 3\*/week/4weeks:~walking sprint session at maximal speed with gradual increase in number of repetitions over the weeks.~(protocol from Verschuren et al.)"
62616019|NCT00006110|EXPERIMENTAL|Neo-adjuvant Herceptin with or without radiation|Chemotherapy followed by Taxol plus Herceptin followed by surgery followed by radiation (or no radiation) followed by additional Herceptin
62616020|NCT00006110|EXPERIMENTAL|Non-Herceptin with or without radiation|Chemotherapy followed by Taxol followed by surgery followed by radiation (or no radiation)
62616021|NCT06333782|EXPERIMENTAL|Genefill Contour®|Participants will be injected with the investigational device Genefill Contour at Visit 1, and Visit 2 only if touch-up needed.
62616022|NCT06333782|ACTIVE_COMPARATOR|Comparator (Desirial®Plus)|Participants would be injected with the marketed comparator (Desirial Plus) at Visit 1, and Visit 2 only if touch-up needed.
62616023|NCT01210352|EXPERIMENTAL|CII Drug|Open Label
62616024|NCT00590538|ACTIVE_COMPARATOR|Phenylbutyrate|"The standard oral adult dose is 20 g/day for 4 days.~Every participant will receive Genistein during the NPD."
62616025|NCT00590538|PLACEBO_COMPARATOR|Placebo|The placebo is given to match the active comparator for 4 days. Every participant will receive Genistein.
62616026|NCT00944307|ACTIVE_COMPARATOR|raltegravir alone|Subjects will receive a single dose of 400 mg raltegravir orally
62616027|NCT00944307|EXPERIMENTAL|raltegravir plus antacid|Subjects will receive a single dose of 400mg raltegravir orally simultaneously with an antacid
62616028|NCT02824588|EXPERIMENTAL|Intervention|Working Memory Training
62616029|NCT02824588|ACTIVE_COMPARATOR|Control|Internet use
62616030|NCT06135116||periodontally healthy|twenty persons without any signs of periodontal disease. This was determined by the absence of attachment loss and bleeding upon probing either ˂ 10% or probing depth ˂3 mm.
62616031|NCT06135116||chronic gingivitis|twenty persons exhibiting generalized chronic gingivitis exhibiting signs of erythema, bleeding on probing up to 20%, edema, probing pocket depth less than 3 mm and no periodontal attachment loss.
62445084|NCT02586831|PLACEBO_COMPARATOR|Arm B|Participants in this group will receive the placebos for Thymoglobulin, Aldesleukin, Adalimumab, Exenatide, and Neulasta over a period of 52 weeks.
62616032|NCT06135116||chronic periodontitis|twenty patients having severe generalized form of chronic periodontitis exhibiting PPD ≥ 6 mm, CAL ≥ 5mm and bone loss affecting at least six teeth as observed in dental periapical radiograph
62445085|NCT06543654|EXPERIMENTAL|Omnichroma|Monochromatic structural colored composite
62445086|NCT06543654|EXPERIMENTAL|Ceram. X Spectra|Universal multi shade composite
62445087|NCT01300845|ACTIVE_COMPARATOR|Humidification|
62445088|NCT01300845|EXPERIMENTAL|No Humidification|
62616033|NCT01340443||Cohort|
62616034|NCT00940641|EXPERIMENTAL|1|IV dose of AZD7325
62616035|NCT00940641|EXPERIMENTAL|2|14C oral dose of AZD7325
62616036|NCT00882128||1|
62616037|NCT01082393|ACTIVE_COMPARATOR|topical tacrolimus|
62616038|NCT01082393|ACTIVE_COMPARATOR|topical pimecrolimus|
62616039|NCT01082393|ACTIVE_COMPARATOR|local steroids|
62616040|NCT01082393|PLACEBO_COMPARATOR|cold cream|
62840776|NCT04682054|EXPERIMENTAL|surgically-removed eye tissue|
62840777|NCT00035932|ACTIVE_COMPARATOR|I|"ATV 300 mg + RTV 100 mg + TDF 300 mg + nucleoside of choice~ATV , RTV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
62840778|NCT00035932|ACTIVE_COMPARATOR|II|"ATV 400 mg + SQV 1200 mg + TDF 300 mg + nucleoside of choice~ATV, SQV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
62840779|NCT00035932|ACTIVE_COMPARATOR|III|"LPV/RTV 400/100 mg + TDF 300 mg + nucleoside of choice~LPV/RTV twice daily, TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
62840780|NCT05741749|EXPERIMENTAL|Socket Seal Abutment|
62840781|NCT05741749|ACTIVE_COMPARATOR|Conventional Healing abutment|
62840782|NCT03117140|ACTIVE_COMPARATOR|Plain Ropivacaine|Plain Ropivacaine 0.75%, (225 mg) total volume 32 cc for interscalene block given pre-operatively
62840783|NCT03117140|EXPERIMENTAL|Ropivacaine + Buprenorphine|A mixture of 0.75% ropivacaine with 300 mcg buprenorphine, total volume 32 cc for interscalene block given pre-operatively
62840784|NCT03117140|EXPERIMENTAL|Ropivacaine + Clonidine|A mixture of 0.75% ropivacaine with 75 mcg clonidine, total volume 32 cc for interscalene block given pre-operatively
62840785|NCT03117140|EXPERIMENTAL|Ropivaciane + Dexamethasone|A mixture of 0.75% ropivacaine with and 8 mg dexamethasone, total volume 32 cc for interscalene block given pre-operatively
62840786|NCT04216264|OTHER|Response|
62840787|NCT04216264|OTHER|Non-response|
62840788|NCT00183313|EXPERIMENTAL|1|Participants will receive nurse case management intervention
62840789|NCT00183313|ACTIVE_COMPARATOR|2|Participants will receive usual care
62840790|NCT01808833||Frail patients|
62840791|NCT01808833||Non-frail patients|
62840792|NCT01436929|EXPERIMENTAL|Silymarin|Silymarin: prophylactic administration of silymarin with anti-TB drugs Placebo: prophylactic administration of placebo with anti-TB drugs
62258955|NCT02231151|EXPERIMENTAL|Pediatric Acute Care Professionals|Individuals must work in ER or ICU setting regularly or rotate through this setting with up to date BLS/PALS/ACLS certification. The participants will be required to rate the CPR based on accuracy for each video shown. The type of CPR error(s) shown to the individuals will be randomized.
62258956|NCT00876187|EXPERIMENTAL|Tanezumab 20 mg IV|
62258957|NCT00876187|EXPERIMENTAL|Tanezumab 10 mg IV|
62258958|NCT00876187|EXPERIMENTAL|Tanezumab 5 mg IV|
62258959|NCT00876187|ACTIVE_COMPARATOR|Naproxen|
62616041|NCT01330199|EXPERIMENTAL|TDF 150mg + MVC 150mg|Subjects will receive a single dose of tenofovir 150 mg and maraviroc 150 mg.
62258960|NCT00876187|PLACEBO_COMPARATOR|Placebo|
62616042|NCT01330199|EXPERIMENTAL|TDF 300mg + MVC 300mg|Subjects will receive a single dose of tenofovir 300 mg and maraviroc 300 mg.
62616043|NCT01330199|EXPERIMENTAL|TDF 600mg +MVC 600mg|Subjects will receive a single dose of tenofovir 600 mg and maraviroc 600 mg.
62840793|NCT01436929|PLACEBO_COMPARATOR|Placebo|administration of placebo with anti-TB drugs
62840794|NCT00916331|EXPERIMENTAL|subcutaneous group|Vacuum drainage is indwelled in subcutaneous layer
62840795|NCT00916331|EXPERIMENTAL|intraarticular group|Vacuum drainage is indwelled in intraarticular space
62840796|NCT01567540|EXPERIMENTAL|DPPIV Inhibition|The study includes an initial phase of 3 weeks with administration of sitagliptin (100 mg/d) as monotherapy, followed immediately by 12 weeks of triple therapy (sitagliptin 100 mg/d combined with peg-IFN alfa-2a and ribavirin).
62840797|NCT00528034|EXPERIMENTAL|Lymphoscintigraphy|
62840798|NCT05652049||short-term peritoneal dialysis|the time of treatment of peritoneal dialysis less 12 months
62840799|NCT05652049||long-term peritoneal dialysis|the time of treatment of peritoneal dialysis more than 10 years
62840800|NCT05808361|EXPERIMENTAL|physical exercise|Rehabilitation program includes physical exercises, started in the first 3 days after the patient's body temperature returned to normal.
62840801|NCT05808361|EXPERIMENTAL|exercises and massage|Rehabilitation programs include physical exercises, and chest massage in an electrostatic field, started in the first 3 days after the patient's body temperature returned to normal.
62840802|NCT05808361|NO_INTERVENTION|Control|Patients received treatment according to the temporary guideline without any rehabilitation program.
62840803|NCT01763840|EXPERIMENTAL|Contrast enhanced Ultrasound|Presence and grade of solid organ injury on contrast enhanced ultrasound
62840804|NCT01710319||smoker with lung cancer|patients that smoke greater than 45 pack years or have end organ damage due to cigarette smoking and have lung cancer
62840805|NCT01710319||smoker without lung cancer|patients that smoke greater than 45 pack years or have end organ damage due to cigarette smoking and do not have lung cancer
62840806|NCT01710319||nonsmoker with lung cancer|patients that have smoked less than 100 cigarettes in their lifetime and have lung cancer
62840807|NCT01710319||nonsmoker without lung cancer|patients that have smoked less than 100 cigarettes in their lifetime and do not have lung cancer
62840808|NCT02670096|EXPERIMENTAL|Reference therapy|"* Baseline evaluation of subjects without acetazolamide administration~* Follow up evaluation of subjects one hour after acetazolamide administration"
62616044|NCT01330199|EXPERIMENTAL|FTC 100mg + RAL 200mg|Subjects will receive a single dose of emtricitabine 100 mg and raltegravir 200 mg.
62616045|NCT01330199|EXPERIMENTAL|FTC 200mg + RAL 400mg|Subjects will receive a single dose of emtricitabine 200 mg and raltegravir 400 mg.
62616046|NCT01330199|EXPERIMENTAL|FTC 400mg + RAL 800mg|Subjects will receive a single dose of emtricitabine 400 mg and raltegravir 800 mg.
62616047|NCT05715424|EXPERIMENTAL|Cluster A|The study population (school-based) was divided into four clusters.Each cluster will receive the same intervention.and one cluster was randomly selected as Cluster A. The intervention was administered at month 6 and monitored for two years.
62616048|NCT05715424|EXPERIMENTAL|Cluster B|The study population (school-based) was divided into four clusters. Each cluster will receive the same intervention.and one cluster was randomly selected as Cluster B. The intervention was administered at month 12 and monitored for one and a half years.
62616049|NCT05715424|EXPERIMENTAL|Cluster C|The study population (school-based) was divided into four clusters.Each cluster will receive the same intervention. and one cluster was randomly selected as Cluster C. The intervention was administered at month 18 and monitored for a continuous period of one year.
62616050|NCT05715424|EXPERIMENTAL|Cluster D|The study population (school-based) was divided into four clusters.Each cluster will receive the same intervention.and one cluster was randomly selected as Cluster D. The intervention was implemented at month 18 and an evaluation of the effect of the intervention was performed.
62616051|NCT05908747|EXPERIMENTAL|surufatinib + gemcitabine + nab-paclitaxel|
62616052|NCT06073756||1|Type 2 diabetes mellitus (T2DM) patients with good glycemic control and have HBA1C \<7and ages ranging from ≥18 old.
62616053|NCT06073756||2|Type 2 diabetes mellitus (T2DM) patients with poor glycemic control and have HBA1C ≥7 and ages rang from ≥ 18 years old
62616054|NCT02673242|NO_INTERVENTION|Control|No treatment other than medical
62616055|NCT02673242|EXPERIMENTAL|Intervention|Inspiratory muscle training
62616056|NCT02483572|EXPERIMENTAL|Functional Communication Training|Participants assigned to this condition will receive treatment immediately after assignment. The investigators will implement functional communication training (FCT) to teach the participant an appropriate request response, known as a functional communication response or FCR. FCT training will continue until the participant emits independent FCRs in at least 90% of the 30-s intervals and until destructive behavior decreases by 90% (relative to pre-treatment baseline) for two consecutive sessions.
62616057|NCT02483572|NO_INTERVENTION|Waitlist-Control Condition|Participants assigned to the waitlist-control condition will not immediately receive services. These participants will be paired with an FCT-condition participant such that the no-treatment duration for these participants is yoked to the amount of time their respective FCT-condition participants receive services (e.g., most treatment last approximately 4 months, or 16 weeks); if Participant A finishes treatment in 16 weeks, Participant B will not receive treatment for at least 16 weeks for comparative measures). After the wait period, these participants will then receive the same services as those assigned to the immediate treatment (FCT Condition).
62616058|NCT06061250|EXPERIMENTAL|Gum group|This group of patients will receive a piece of Xylitol gum (LOTTE WELLFOOD, Korea) 10 minutes before induction of anesthesia. Patients will chew it for 2 minutes and spit out. Other anesthetic care will follow routine protocol of the hospital.
62616059|NCT06061250|NO_INTERVENTION|Control group|This group of patients will instructed to swallow their saliva twice 10 minutes before induction of anesthesia. Other anesthetic care will follow routine protocol of the hospital.
62616060|NCT02152215|ACTIVE_COMPARATOR|Acellular dermal matrix membrane|An acellular dermal matrix membrane will be used as a barrier between the osseous graft and the soft tissue flap.
62056201|NCT02398968|ACTIVE_COMPARATOR|RURTI+IDA+iron therapy|children with iron deficiency anemia on therapeutic iron fumerate therapy (6mg/kg/d) for 3 months, then maintained on iron fumerate supplementation(1mg/kg/d) for 12 months
62258961|NCT04345289|ACTIVE_COMPARATOR|Convalescent plasma|Will receive active treatment with convalescent anti-SARS-CoV-2 plasma (600 ml) as a single dose iv infusion in addition to standard care.
62258962|NCT04345289|PLACEBO_COMPARATOR|Infusion placebo|Will receive placebo treatment with saline 0.9% (2 x 300 ml) as an iv single dose infusion in addition to standard care.
62258963|NCT04268251|EXPERIMENTAL|Deep learning based denoising MR|1 mm slice thickness coronal contrast-enhanced T1 weighted imaging with deep learning based denoising vs. 3 mm slice thickness coronal contrast-enhanced T1 weighted imaging
62616061|NCT02152215|EXPERIMENTAL|Polylactic acid membrane|A polylactic acid membrane will be used as a barrier between the osseous graft and the soft tissue flap.
62616062|NCT02932813|EXPERIMENTAL|Intervention Group|"THINK intervention:~The program will have activity and fitness sessions lasting two hours, three times a week for a total of nine months. Sessions will include theory, clinical laboratory activities, and physically active games to facilitate a fun environment to enhance physical and health-related fitness, improve nutrition and exercise knowledge and behaviors, and exercise enjoyment and self-confidence."
62616063|NCT02932813|NO_INTERVENTION|Control Group|This group will receive the traditional YMCA SPARK after-school program. They will undergo the same pre, mid, and post testing protocol as the intervention group, but will not receive the THINK program.
62840809|NCT06112886||with Hypothyroidism, without Hypothyroidism|
62840810|NCT02902146|ACTIVE_COMPARATOR|Bougie|On the first intubation attempt, this arm will attempt to place a bougie into the trachea, followed by an endotracheal tube.
62840811|NCT02902146|ACTIVE_COMPARATOR|No bougie (endotracheal tube first)|On the first intubation attempt, this arm will attempt to place an endotracheal tube into the trachea directly.
62840812|NCT00851058|EXPERIMENTAL|Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
62616064|NCT06377332||Chronic Obstructive Pulmonary Disease (COPD)|"Males and females; Aged 40-65 years; COPD confirmed by diagnosis or a positive lung function test (GOLD 2 minimum, FEV1~≥50%, \< 80% predicted; FEV1/FVC \< 0.7); 10-pack year smoking history; Able to perform neuropsychological and cognitive testing; Fluent in English."
62840813|NCT00851058|ACTIVE_COMPARATOR|Community Counseling|Four session of group counseling and six hours of volunteering in a local not for profit community agency.
62840814|NCT00851058|PLACEBO_COMPARATOR|Prototypic Community Service|Four hours of education about road safety and 16 hours volunteering at a local not for profit community service.
62840815|NCT04433676||Patients with surgical procedures|Adult patients undergoing surgical procedures under general or regional anesthesia and with an admission to a recovery unit for the initial postoperative care.
62840816|NCT01259960||BMI < 25|Body Mass Index (BMI) according to WHO definition. BMI \< 25 is defined as 'normal weight'.
62840817|NCT01259960||25 <= BMI < 30|Body Mass Index (BMI) according to WHO definition. BMI \>= 25 and \< 30 is defined as 'overweight'.
62840818|NCT01259960||BMI >= 30|Body Mass Index (BMI) according to WHO definition. BMI \>= 30 is defined as 'obese'.
62840819|NCT02541604|EXPERIMENTAL|Atezolizumab|Participants received intravenous (IV) infusion of atezolizumab (maximum 1200 milligrams \[mg\]) on Day 1 of each 21-day cycle.
62445089|NCT00133718|OTHER|Structured multi intervention|Structured multi intervention to reach predefined glycemic and blood pressure goals as well as activity and weight goal
62616065|NCT06377332||Overlap Syndrome (OVS)|"Males and females; Aged 40-65 years; Oximetry confirmed moderate to severe OSA based on the oxygen desaturation index (ODI) ≥15/hr OR defined by polysomnography (PSG) AHI of ≥ 15 COPD confirmed by diagnosis or a positive lung function test (GOLD 2 minimum, FEV1~≥50%, \< 80% predicted; FEV1/FVC \< 0.7); 10-pack year smoking history; Able to perform neuropsychological and cognitive testing; Fluent in English."
62056202|NCT02398968|ACTIVE_COMPARATOR|B1:RURTI+no anemia+iron maintenance|children with recurrent upper respiratory tract infection and no anemia receiving oral iron fumerate (1mg/kg/d) for 12 months
62445090|NCT00133718|OTHER|Standard of care|Standard care with or without structured care according to national guidelines
62840820|NCT03067714|EXPERIMENTAL|Active product: partially hydrolysed formula + synbiotics|
62840821|NCT03067714|ACTIVE_COMPARATOR|Control product: standard formula (intact protein)|
62445091|NCT01992107|EXPERIMENTAL|QIVc (≥4 to <18 years)|Subjects received one or two doses of QIVc-Quadrivalent Cell-based Influenza Vaccine recommended for 2013-2014 season
62840822|NCT02699424|OTHER|Radiotherapy|
62840823|NCT02350478|ACTIVE_COMPARATOR|Linagliptin|The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
62840824|NCT02350478|PLACEBO_COMPARATOR|Placebo|The subjects will receive placebo.
62840825|NCT04859933||AVNA group|Group of historical controls beeing treated with AV-node ablation
62840826|NCT04859933||AVNI group|Inculudes all patients beeing treated with AV-node isolation
62840827|NCT04628325|EXPERIMENTAL|high dose furosemide plus HSS|Patients treated high dose furosemide plus HSS
62840828|NCT04628325|ACTIVE_COMPARATOR|high dose furosemide alone|Patients treated high dose furosemide alone
62840829|NCT02901392||Artificial urinary sphincter AMS-800®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with AMS-800®
62840830|NCT02901392||AdVance/AdvanceXP®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with AdVance/AdvanceXP®
62840831|NCT02901392||VIRTUE®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with VIRTUE®
62840832|NCT02901392||INVANCE®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with INVANCE®
62840833|NCT03188419||1|Retrospective chart review of patients with inherited immunodeficiency diseases requiring allogeneic hematopoietic stem cell transplant (allo HSCT)
62840834|NCT06170099|EXPERIMENTAL|Laser group|
62840835|NCT06170099|ACTIVE_COMPARATOR|control group|
62840836|NCT03108443||Glaucoma|Subjects identified as having glaucoma. No interventions will be performed.
62840837|NCT03108443||Healthy controls|Subjects identified as having healthy eyes with no disease.
62840838|NCT01470118|ACTIVE_COMPARATOR|LASTACAFT® (alcaftadine 0.25%)|One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
62840839|NCT01470118|ACTIVE_COMPARATOR|Pataday™ (olopatadine 0.2%)|One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
62616066|NCT06377332||Obstructive Sleep Apnoea (OSA)|Males and females; Aged 40-65 years; Oximetry confirmed moderate to severe OSA based on the oxygen desaturation index (ODI) ≥15/hr OR defined by polysomnography (PSG) AHI of ≥ 15. Able to give informed consent; Ability to perform neuropsychological and cognitive testing; Fluent in English.
62616067|NCT06377332||Control|Males and females; Aged 40-65 years; Able to give informed consent; Able to perform neuropsychological and cognitive testing; Fluent in English.
62616068|NCT02475759|ACTIVE_COMPARATOR|two weeks prehabilitation group|Nutritional perioperative prehabilitation program for two weeks in malnourished congenital heart disease children
62616069|NCT02475759|ACTIVE_COMPARATOR|one week prehabilitation group|Nutritional perioperative prehabilitation program for one week in malnourished congenital heart disease children
62616070|NCT05033483|EXPERIMENTAL|Iron Supplement|65.7 mg of iron as ferrous fumarate
62616071|NCT05033483|ACTIVE_COMPARATOR|Placebo|0 mg of iron
62616072|NCT03843645|ACTIVE_COMPARATOR|general anesthesia group|patients allocated to the general anesthesia group will be subjected to general anesthesia with sevoflurane (inhalational agent) used for maintenance
62258964|NCT02215876|EXPERIMENTAL|Single Arm|Doxorubucin and Cyclophosphamide q2 or q3 weekly x 4 cycles plus Eribulin on days 1 and 8 of a 21 day cycle x 4 cycles
62616073|NCT03843645|ACTIVE_COMPARATOR|regional anesthesia group|patients allocated to the regional anesthesia group will be subjected to combined spinal-epidural anesthesia with ropivacaine and fentanyl
62616074|NCT04908475|EXPERIMENTAL|Risankizumab|Risankizumab 150 mg as a single subcutaneous (SC) injection at at Baseline (Day 1) and Week 4 (Period A) and at Weeks 16, 28, and 40 (Period B).
62616075|NCT04908475|EXPERIMENTAL|Apremilast|Participants receive apremilast 30 mg orally twice daily (BID) in Period A and re-randomized to receive either risankizumab 150 mg as a single SC injection at Weeks 16, 20, 32 in Period B or apremilast 30 mg orally BID from Week 16 up to Week 52 in Period B. For those taking apremilast in Period B, non-responders at Week 28 and Week 40 will be offered to receive risankizumab as rescue medication.
62258965|NCT05750875|ACTIVE_COMPARATOR|Loratadine|
62616076|NCT05394454|EXPERIMENTAL|Experimental Group|"* Breast milk/formula milk/water intake appropriate for the infant's age and weight will be provided 20-30 minutes before collecting the urine sample.~* Before the procedure, the infant's heart rate, saturation and Flacc scale score (by the researcher and the observer nurse) will be recorded.~* Genital area will be cleaned.~* Infants will be held under the armpit by a parent, baby boys will be held with their legs hanging down, and baby girls will be held in hip flexion position.~* Infants with spontaneous voiding during the period from the beginning of the research procedure until the infant is positioned will be excluded from the study.~* The bladder stimulation technique will be repeated sequentially for 3 minutes until micturition begins.~* After the maneuvers are started, the infants's heart rate and saturation FLACC pain scale score will be recorded at the 1st and 3rd minutes.~* The success of the procedure and the duration of the procedure will be recorded"
62616077|NCT05394454|NO_INTERVENTION|Control Group|"* Breast milk/formula milk/water intake appropriate for the infant's age and weight will be provided 20-30 minutes before collecting the urine sample.~* Before the procedure, the infant's heart rate, saturation and Flacc scale score (by the researcher and the observer nurse) will be recorded.~* Genital area will be cleaned.~* Infants will be held under the armpit by a parent, baby boys will be held with their legs hanging down, and baby girls will be held in hip flexion position.~* Infants with spontaneous voiding during the period from the beginning of the research procedure until the infant is positioned will be excluded from the study.~* Bladder stimulation technique will not be applied.~* Infants will be observed for 3 minutes. Infants's heart rate and saturation FLACC pain scale score will be recorded at the 1st and 3rd minutes.~* The success of the procedure and the duration of the procedure will be recorded"
62258966|NCT05750875|ACTIVE_COMPARATOR|Gabapentin|
62258967|NCT01753245||Non-Metabolic Syndrome|Patients without Metabolic Syndrome criteria (OMS).
62258968|NCT01753245||Metabolic Syndrome|Patients with Metabolic Syndrome criteria (OMS).
62258969|NCT03633175|ACTIVE_COMPARATOR|Vaginal progesterone group|Women will receive vaginal progesterone 400 mg \[Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt\], once at bed time starting from 26-28 weeks of gestation and till 36 weeks of gestation or delivery (which is closer).
62616078|NCT00590642||1|
62616079|NCT05192395|EXPERIMENTAL|Group A|fed state: period 1) DWJ15251, period 2) DWP16001 and DWC2021011 fased state: period 3) DWJ15251, period 4) DWP16001 and DWC2021011
62258970|NCT03633175|NO_INTERVENTION|Control group|Women with gestational age from 26-28 weeks diagnosed with placenta previa who will not receive vaginal progesterone.
62258971|NCT02730585||Acute appendicitis|all patients admitted to our hospital with a clinically suspected acute appendicitis.
62258972|NCT06296186|EXPERIMENTAL|Massed PE|Prolonged Exposure delivered in a massed format - sessions multiple times per week
62258973|NCT06296186|ACTIVE_COMPARATOR|Weekly PE|Prolonged Exposure delivered with weekly sessions
62258974|NCT03789851|EXPERIMENTAL|core needle biopsy|All patients enrolled in this study received a ultrasound-guided multipoint core needle biopsy after surgery.
62258975|NCT02722538|EXPERIMENTAL|Residual Tumor following TURBT|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the Radical Cystectomy (RC).
62445092|NCT01992107|ACTIVE_COMPARATOR|TIV1c (≥4 to <18 years)|"Subjects received one or two doses of TIV1c (Trivalent Inactivated Cell-based Influenza Vaccine containing one strain from B lineage (B1 strain) recommended for 2013-2014 season"
62445093|NCT01992107|ACTIVE_COMPARATOR|TIV2c (≥4 to <18 years)|"Subjects received one or two doses of TIV2c (Trivalent Inactivated Cell-based Influenza Vaccine containing B strain from the alternate lineage (B2 strain) recommended for 2013-2014"
62616080|NCT05192395|EXPERIMENTAL|Group B|fed state: period 1) DWP16001 and DWC2021011, period 2) DWJ15251 fased state: period 3) DWP16001 and DWC2021011, period 4) DWJ15251
62840840|NCT01470118|PLACEBO_COMPARATOR|Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)|One drop of placebo instilled in each eye at Day 0 and Day 14.
62840841|NCT05675488||Trigger Finger Patients|
62445094|NCT01375881||001|darunavir/ritonavir plus background regimen darunavir/ritonavir oral use in naive and experienced patients at approved dosages
62445095|NCT02072356|EXPERIMENTAL|Treatment (yttrium Y 90 glass microspheres)|Patients receive yttrium Y 90 glass microspheres IA on day 0. Patients may receive additional treatment 4-12 weeks after initial treatment at the discretion of the study physician.
62445096|NCT01165684|EXPERIMENTAL|Step-wise|
62840842|NCT05675488||Healthy individuals|
62840843|NCT05246358|EXPERIMENTAL|ChroniSense Polso Respiratory Rate|Comparison of respiratory rates in normal subjects as observational with end tidal CO2. No treatment or interventions will be performed
62840844|NCT01869764|EXPERIMENTAL|Arm I (omega-3 fatty acid)|Patients receive omega-3 fatty acid PO daily for 7-14 days.
62840845|NCT01869764|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO daily for 7-14 days.
62840846|NCT02009280|EXPERIMENTAL|Propofol group|Propofol group
62840847|NCT02009280|ACTIVE_COMPARATOR|Sevoflurane group|Sevoflurane group
62840848|NCT04976101|EXPERIMENTAL|Sinusoidal Galvanic Vestibular Stimulation|"Treatment:~1. Stimulation of the vestibular nerves with 0.025 Hz, 2 mA sinusoidal galvanic vestibular stimulation Depending on initial results, changes in frequency may range up to 0.1 Hz."
62840849|NCT04976101|PLACEBO_COMPARATOR|Placebo|"Treatment:~1. Placebo (sham) (no current given however the electrodes and devise is placed and computer keys pressed). Depending on initial results, changes in frequency may range up to 0.1 Hz."
62840850|NCT01851759|EXPERIMENTAL|Cinepazide, Stroke, Injection|Test drug：Methanesulfonic acid cinepazide injection（5ml/125mg）
62840851|NCT01851759|PLACEBO_COMPARATOR|palcebo,Stroke,Injection|Placebo：simulation agent of Methanesulfonic acid cinepazide injection（5ml sterile water for injection）
62840852|NCT02162199|EXPERIMENTAL|Debio 1450|Debio 1450 40 mg, capsules, orally, once in the morning under fasted conditions
62840853|NCT02162199|PLACEBO_COMPARATOR|Placebo|Placebo 0 mg, matching capsules, orally, once in the morning under fasted conditions
62258976|NCT02722538|EXPERIMENTAL|No Residual Tumor Following TURBT|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the Radical Cystectomy (RC).
62616081|NCT03632577|EXPERIMENTAL|High Flow Oxygen (HFO)|HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
62258977|NCT05993624|OTHER|Rehabilitation Group|Participants in the study played 30-minute exergame games once a week for 8 weeks and rehabilitation was applied. Before starting the application, the participants were given a demographic information form, Tampa kinesiophobia scale for kinesiophobia, BeCure balance assessment system for balance measurement, geriatric depression scale-short form for depression, mini-mental state test for cognitive functions, and lower extremity functional strength. and 5 times the risk of falling. lifting test was performed. These tests were repeated at the end of 8 sessions and before and after values were measured.
62258978|NCT01833442|ACTIVE_COMPARATOR|Kundalini Yoga Meditation|Kundalini Yoga Meditation is going to be use as therapy for OCD, and it will be compare with Relaxation Response Meditation.
62258979|NCT01833442|ACTIVE_COMPARATOR|Relaxation Response Meditation|Relaxation Response Meditation is going to be use as therapy for OCD, and it will be compare with Kundalini Yoga Meditation.
62258980|NCT06461975|EXPERIMENTAL|Tear substitute in first exam|Te first examination was done using the tear substitute eye drops and the second using the Benoxinate HCL drops given just before the ROP screening.
62258981|NCT06461975|EXPERIMENTAL|Benoxinate HCL in first exam|infants in Group B had the reversed order of the drops in the two examinations. the first examination done using the Benoxinate HCL drops and the second using the tear substitute eye drops
62840854|NCT04365608|ACTIVE_COMPARATOR|Direct laryngoscopy|Intubation will be done using direct laryngoscopy. The standard intubation procedure is to use a styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the guidelines on difficult airway management.
62840855|NCT04365608|ACTIVE_COMPARATOR|Vie Scope laryngoscopy|Intubation will be done using Vie Scope laryngoscopy
62840856|NCT02483962|PLACEBO_COMPARATOR|Gelatine capsule|Gelatine capsules containing no active ingredients, will be taken once per day, in the morning after breakfast, for 30 days. These capsules will be of identical appearance to the experimental comparator.
62258982|NCT00855985|ACTIVE_COMPARATOR|1|Pancreaticojejunostomy for reconstruction after pancreaticoduodenectomy
62445097|NCT01165684|ACTIVE_COMPARATOR|Basal-bolus|
62840857|NCT02483962|EXPERIMENTAL|Venavine Intensive®|Gelatine capsules containing the active ingredients of: 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butcher's broom extract and 3,2 mg of vitamin B6, will be taken once per day, in the morning after breakfast, for 30 days.
62840858|NCT06344962|EXPERIMENTAL|Absorbable Suture Group|All enrolled patients will accept bronchial sleeve resection and lymphadenectomy. If fast-frozen pathology of the resection margin of bronchus confirms negative, We will use the absorbable sutures for bronchial anastomosis.
62258983|NCT00855985|ACTIVE_COMPARATOR|2|Pancreaticogastrostomy for reconstruction after pancreaticoduodenectomy
62258984|NCT03200366|ACTIVE_COMPARATOR|Tailored DVD|Tailored digital video disc (DVD)
62258985|NCT03200366|ACTIVE_COMPARATOR|Tailored DVD + Patient Navigation|Tailored digital video disc (DVD) plus Patient Navigation by a population health nurse in the healthcare system
62445098|NCT01132118|OTHER|Placebo then HCQ|This arm of the study will contain half the study population after randomization. The participants in this arm will receive hydroxychloroquine for 8 weeks and then crossover to a placebo for 8 weeks. Study staff will be blinded to which order they are taking the hydroxychloroquine and placebo in.
62056203|NCT02398968|NO_INTERVENTION|B2:RURTI+no anemia|children with recurrent upper respiratory tract infection and no anemia followed up for 12 months
62258986|NCT03200366|NO_INTERVENTION|Usual Care|Care normally provided by a nurse in the endoscopy department of the healthcare system
62445099|NCT01132118|OTHER|HCQ then Placebo|This arm of the study will contain half the study population after randomization. The participants in this arm will receive hydroxychloroquine for 8 weeks and then crossover to a placebo for 8 weeks. Study staff will be blinded to which order they are taking the hydroxychloroquine and placebo in.
62056204|NCT01423682|PLACEBO_COMPARATOR|Healthy subjects|
62616082|NCT03632577|ACTIVE_COMPARATOR|Non Invasive Ventilation (NIV)|NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers
62840859|NCT06344962|EXPERIMENTAL|Non-absorbable Suture Group|All enrolled patients will accept bronchial sleeve resection and lymphadenectomy. If fast-frozen pathology of the resection margin of bronchus confirms negative, We will use the non-absorbable sutures for bronchial anastomosis.
62840860|NCT01576068|OTHER|High Risk Customers|Pharmacy customers with GOLD COPD Criteria of high-risk subjects.
62258987|NCT05016115||physiotherapy students|Totally 120 physiotherapy students at a non-governmental university in Istanbul participated in this study.
62258988|NCT05895942||Imatinib treatment group|Chinese patients with unresectable C-kit9/11-mutated GIST were selected as the research subjects, and the therapeutic effect was observed after standard treatment with imatinib mesylate
62258989|NCT05514314|EXPERIMENTAL|Icotinib|Icotinib oral 125mg tid for 2 years
62258990|NCT03449498|EXPERIMENTAL|study group|Intensive qualitative functional therapy
62840861|NCT06434142|EXPERIMENTAL|patient with zirconia copy|Group I (study group) was the group of patients with zirconia as a primary copings that attach to the abutment and PEEK as a secondary coping telescopic attachment that attaches to the fitting surface of the denture.
62840862|NCT06434142|EXPERIMENTAL|patients with cobalt chromium (CoCr) as primary copings|Group II (control group) was the group of patients with cobalt chromium (CoCr) as primary copings attached to the abutment and PEEK as a secondary coping's telescopic attachment attached to the fitting surface of the denture.
62056205|NCT01423682|ACTIVE_COMPARATOR|Rotator cuff tendinopathy|
62056206|NCT04148014|EXPERIMENTAL|Adjunctive Emotion Regulation Skills Training|Participants will receive a 5 session once a week group emotion regulation skills training adjacent to treatment as usual provided by the eating disorder unit at the child and adolescent psychiatric clinic, Linköping, Sweden.
62056207|NCT01786330|EXPERIMENTAL|Intervention|Group receives elastic abdominal binders after surgery. Binder used is Procare manufactured by DJO, LLC. Binders are to be worn for 24 hours after surgery.
62056208|NCT01786330|ACTIVE_COMPARATOR|Control|Group receives standard of care
62056209|NCT05199623|EXPERIMENTAL|CHM(Chinese herbal medicine) group|Treatment with steroid, zinc, and olfactory training for one month. And then, take CHM(Chinese herbal medicine) (tailored Guizhi decoction) and perform OT(olfactory training) for 6 months
62258991|NCT03449498|EXPERIMENTAL|control group|Intensive functional therapy
62258992|NCT05091463|EXPERIMENTAL|Transcutaneous spinal stimulation|Participants with chronic SCI will receive 60 sessions of activity based-locomotor training (AB-LT) combined with transcutaneous stimulation (scTS).
62258993|NCT01361243|EXPERIMENTAL|NOURISH+|Participants will receive a 6-week face-to-face intervention, NOURISH+. Weekly topics teach parents skills to role model and encourage healthy lifestyle behaviors for their children.
62258994|NCT01361243|PLACEBO_COMPARATOR|Wellness Group|"Participants will receive an in-person Family Wellness Night followed by 6 mailings of information regarding pediatric overweight and obesity."
62258995|NCT02319421|EXPERIMENTAL|Primary Subjects|"Physicians and nurse practitioners caring for patients in the Pediatric Intensive Care Unit (PICU). An alarm reduction script will be used to help facilitate discussion of alarm data during weekday morning team huddles."
62258996|NCT04374760|NO_INTERVENTION|in-person control|Usual care, initial screening measures conducted in-person in the Emergency Department.
62258997|NCT04374760|NO_INTERVENTION|Self-Administered Control|Usual care, initial screening measures conducted on their own via an iPad.
62623657|NCT02746094|EXPERIMENTAL|The study population|"The study population is comprised of adult men less than 80 years of age who are consulting for ED lasting for over 6 months following a prostatectomy that took place 18 to 60 months ago. The patients are currently in a stable relationship that has been going on for at least 3 months, have an IIEF-EF score between 6 and 25, and have at least a natural tumescence during sexual stimulation (EHS score ≥ 1).~Intervention: 8 bi-weekly LIESWT sessions"
62840863|NCT05595902||Young older adults|≥65-\<75 years of age
62840864|NCT05595902||Older adults|≥75-\<90 years of age
62840865|NCT05595902||≥90 years old|
62258998|NCT04374760|EXPERIMENTAL|In-person Treatment|Treatment group (receives text messages), initial screening measures conducted in-person in the Emergency Department.
62840866|NCT06519721|EXPERIMENTAL|Phase 1: Accelerated titration phase|Plan to enroll 3 patients. First, enroll 1 patient, give the initial dose of VIC-1911 25mg BID, observe for 1 week, if there is no dose-limiting toxicity (DLT), increase to 50mg BID. At the same time, enroll another 2 patients, give VIC-1911 25mg BID, observe for 1 week, if no DLT, increase to 50mg BID. Observe for 2 weeks at a dose of 50mg, if no DLT occurs, continue to increase to 75mg BID, observe for 4 weeks. If no DLT occurs, continue to increase by 25mg doses, with an observation period of 4 weeks, until one case of dose-limiting toxicity or two cases of moderate toxicity occur during the titration process, then reduce to the previous dose, and determine it as the final dosing regimen.
62840867|NCT06519721|EXPERIMENTAL|Phase 2: Expansion phase|According to the final dosing regimen selected, enroll 12 patients and observe for 3 months.
62258999|NCT04374760|EXPERIMENTAL|Self-Administered Treatment|Treatment group (receives text messages), initial screening measures conducted on their own via an iPad.
62259000|NCT05520697|ACTIVE_COMPARATOR|Control|Nutritional treatment with caloric restriction and mental exercise
62259001|NCT05520697|EXPERIMENTAL|Intervention|Nutritional treatment with caloric restriction, mental exercise, and physical training program.
62259002|NCT06310486||Fatal drowning|These patients experienced a drowning incident and died within 30 days after the incident because of their submersion injury.
62259003|NCT06310486||Non-fatal drowning|These patients experienced a drowning incident and survived until 30 days after the incident.
62616083|NCT04640038|EXPERIMENTAL|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection (if there are two injections of contrast) of the contrast agent.
62840868|NCT00078897|ACTIVE_COMPARATOR|Selenium|Participants receive oral selenium 200 mcg once daily.
62840869|NCT00078897|PLACEBO_COMPARATOR|Placebo|Participants receive oral placebo once daily.
62840870|NCT05318352|EXPERIMENTAL|Transcranial Direct Current Stimulation (tDCS)|Athletes with poor sleep quality will receive tDCS over the right and left prefrontal cortex (F3 and F4 areas) with a constant current of 1.5 mA intensity that lasts for 20 minutes, 3 times a week for 2 weeks in daytime.
62840871|NCT05318352|SHAM_COMPARATOR|Sham transcranial Direct Current Stimulation (tDCS)|Athletes with poor sleep quality will receive sham tDCS over the right and left prefrontal cortex.
62840872|NCT06456502|EXPERIMENTAL|Non-invasive neuromodulation|The real treatment group using non-invasive neuromodulation
62840873|NCT06456502|PLACEBO_COMPARATOR|PLACEBO|The placebo treatment group (simulation of non-invasive neuromodulation application).
62840874|NCT06519071|EXPERIMENTAL|Tryptophan Intake|Randomly assign the participant to receive a test tryptophan oral intake (ranging between 1 to 14 mg.kg.d) as an 8-hourly isocaloric and isonitrogenous meal that consist of a liquid formula shake and protein-free cookies.
62056210|NCT05199623|ACTIVE_COMPARATOR|OT(olfactory training) group|Treatment with steroid, zinc, and olfactory training for one month. And then, perform OT(olfactory training) only for 6 months.
62056211|NCT04012515|EXPERIMENTAL|CAVA Electrode Pad Appraisal Trial Arm|All trial participants are within this arm. All participants will wear the same selection of electrode pads and follow the same replacement schedules.
62056212|NCT03527355|EXPERIMENTAL|A (Single dose)|"One dose of Vi-DT (Typhoid conjugate vaccine) 25 µg 0.5 mL is administrated intramuscularly at first dost (Day 0).~One dose of FluQuadri™ 0.25mL is administrated intramuscularly at second dose (Week 24).~One booster dose of Vi-DT 0.5 mL is administrated 2 years apart (Week 96). MMR for age group at 9-12 months."
62056213|NCT03527355|ACTIVE_COMPARATOR|B (Two dose)|"Two doses of Vi-DT (Typhoid conjugate vaccine) 25 µg 0.5 mL is administrated intramuscularly 6 months apart (Day 0 and Day 168 (Week 24)).~MMR for age group at 9-12 months."
62445100|NCT05753657|EXPERIMENTAL|Treatment arm|treating hyperinsulinemia and hyperglycemia with pioglitazone in patients treated with Alpelisib for metastatic breast cancer
62840875|NCT03960996|EXPERIMENTAL|Dacryocystorinostomy with bicanalicular intubation|Patients with lacrimal duct obstruction enrolled into this study arm will undergo dacryocystorinostomy with bicanalicular intubation.
62840876|NCT03960996|EXPERIMENTAL|Dacryocystorinostomy without bicanalicular intubation|Patients with lacrimal duct obstruction enrolled into this study arm will undergo dacryocystorinostomy without bicanalicular intubation.
62840877|NCT02903329|ACTIVE_COMPARATOR|Protocol A|In program A, patients underwent detoxification without any acute medication during a two months period (complete stop of acute medication intake).
62840878|NCT02903329|ACTIVE_COMPARATOR|Protocol B|In program B, patients were allowed to take up to 2 days a week with analgesics or migraine medication during the two months detoxification period (restricted acute medication intake).
62840879|NCT05259280|EXPERIMENTAL|Arm 1|Arm 1: Subjects will receive 24 weeks of access to the Wellinks Solution.
62840880|NCT05259280|EXPERIMENTAL|Arm 2|Arm 1: Subjects will receive 24 weeks of access to the Wellinks Solution. The latter 12 weeks will be entirely asynchronous.
62840881|NCT00785642|EXPERIMENTAL|1|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)
62840882|NCT01295164|ACTIVE_COMPARATOR|Group 1|Measurement of aberrations in patients with keratoconus of grade 1
62840883|NCT01295164|ACTIVE_COMPARATOR|Group 2|patients with keratoconus of grade 2
62056214|NCT03527355|PLACEBO_COMPARATOR|C (Placebo/Comparator)|"One dose of Placebo (0.9% sodium chloride isotonic solution) 0.5 mL is administrated intramuscularly at first dost (Day 0).~One dose of FluQuadri™ 0.25mL is administrated intramuscularly at second dose (Day 168; Week 24).~MMR for age group at 9-12 months."
62445101|NCT01924871|ACTIVE_COMPARATOR|Desflurane group|1.5 MAC desflurane until extubation
62445102|NCT01924871|ACTIVE_COMPARATOR|Desflurane with remifentanil group|1.0 MAC desflurane with 1.0ng/ml targeted concentration infusion of remifentanil
62445103|NCT02398461|EXPERIMENTAL|rHIgM22|Patients will be enrolled sequentially in 2 separate cohorts, representing escalating dose levels. Each dose cohort will comprise 15 subjects, randomly assigned to receive either rHIgM22 (n=10) or placebo (n=5).
62616084|NCT02020070|EXPERIMENTAL|Ipilimumab & Degarelix With Radical Prostatectomy|"Week 1: Degarelix SQ injection (except patients who have already received hormonal therapy per standard of care and are not yet due for their next dose) and Ipilimumab at 3 mg/kg intravenously (IV). Surgery Radical prostatectomy (RP)will be performed during week 3 ± 1 week or after recovery to grade ≤ 1 adverse events experienced during the induction period related to treatment. Continued Androgen Depletion and Ipilimumab Weeks 5, 9, 13, 17, 21, 25, and 29: Degarelix 80 mg SQ (except patients who have already received hormonal therapy per standard of care and are not yet due for their next dose)~Week 11, 14, 17 or after sufficient wound healing and recovery post RP:~Ipilimumab 3 mg/kg IV Follow-up Twelve week intervals until Week 87."
62840884|NCT01295164|EXPERIMENTAL|Group 3|patients with keratoconus of grade 3
62840885|NCT01295164|EXPERIMENTAL|Group 4|patients with keratoconus of grade 4
62840886|NCT06521307|EXPERIMENTAL|Riboside (RN) arm|NAD Riboside 2000 mg by oral intake at enrollment 24hrs prior surgery, 3000mg prior undergoing surgery with NG tube, 3000mg 12 hrs post-surgery with NG tube and 2000mg 24 hrs after intervention by oral intake.
62840887|NCT06521307|PLACEBO_COMPARATOR|Placebo arm|NAD Riboside 2000 mg by oral intake at enrollment 24hrs prior surgery, 3000mg prior undergoing surgery with NG tube, 3000mg 12 hrs post-surgery with NG tube and 2000mg 24 hrs after intervention by oral intake.
62840888|NCT04421703|EXPERIMENTAL|Distance Collaborative|For sites randomized to the distance arm, training will be delivered via web conference, and technical assistance and assessment and feedback will be delivered by phone.
62840889|NCT04421703|EXPERIMENTAL|Blended in-person/distance collaborative|For the QI collaborative arm, training will be delivered in two in-person collaborative meetings; and the remainder of the strategies will be delivered via web-conferencing.
62840890|NCT03050385|ACTIVE_COMPARATOR|active stimulation during cognitive rehabilitation|"active transcranial direct current stimulation 20 minutes per session twice a day interval between sessions: more than 20 minutes 7 cm x 5 cm electrodes anodal electrode on F3 cathodal electrode on right forehead 2 mA(milliampere)~cognitive rehabilitation 10-minute calculation task followed by 10-minute task of local (Japanese) language test"
62056215|NCT04137354|PLACEBO_COMPARATOR|Control Iron&Vitamin A Placebo|Children randomly assigned to the placebo iron \& vitamin A control group will receive weekly three placebo tablets that are identical to the iron tablets (blinded) for the whole duration of the study (9 months of the school year). They will also receive placebo vitamin A at baseline and at mid-line (after 4.5 months).
62259004|NCT00800436|EXPERIMENTAL|Part 1: Cohort 1|Healthy male participants will receive Herceptin 6 mg/kg IV on Day 1.
62259005|NCT00800436|EXPERIMENTAL|Part 1: Cohort 2|Female participants with HER2-positive breast cancer will receive Herceptin 6 mg/kg IV on Day 1.
62259006|NCT00800436|EXPERIMENTAL|Part 1: Cohort 3|Healthy male participants will receive Herceptin 6 mg/kg SC on Day 1.
62840891|NCT03050385|SHAM_COMPARATOR|sham stimulation during cognitive rehabilitation|"sham transcranial direct current stimulation 20 minutes per session twice a day interval between sessions: more than 20 minutes 7 cm x 5 cm electrodes anodal electrode on F3 cathodal electrode on right forehead 2 mA~cognitive rehabilitation 10-minute calculation task followed by 10-minute task of local (Japanese) language test"
62259007|NCT00800436|EXPERIMENTAL|Part 1: Cohort 4|Healthy male participants will receive Herceptin 10 mg/kg SC on Day 1.
62259008|NCT00800436|EXPERIMENTAL|Part 1: Cohort 5|Healthy male participants will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohorts 1, 2, 3, and 4.
62616085|NCT02020070|EXPERIMENTAL|Ipilimumab & Degarelix With Prior With Radical Prostatectomy|Week 1: Degarelix 240 mg SQ injection and Ipilimumab at 3 mg/kg intravenously (IV) Continued Androgen Depletion and Ipilimumab Weeks 5, 9, 13, 17, 21, 25, and 29: Degarelix 80 mg SQ Week 4,7,10: Ipilimumab 3mg/kg IV Follow-up Twelve week intervals until Week 81, with MD visits at weeks 52 and 84 (12 and 20 months).
62840892|NCT01453985|EXPERIMENTAL|Full-Thickness-Gastroplication|
62840893|NCT03055130||Case group|Female IBD patients who had sexual life between 21-60 years-old were recruited.
62259009|NCT00800436|EXPERIMENTAL|Part 2: Cohort A|Female participants with HER2-positive breast cancer will receive Herceptin SC at the dose level determined in Part 1.
62259010|NCT00800436|EXPERIMENTAL|Part 2: Cohort B|Female participants with HER2-positive breast cancer will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohort A.
62445104|NCT02398461|PLACEBO_COMPARATOR|Placebo|Patients will be enrolled sequentially in 2 separate cohorts, representing escalating dose levels. Each dose cohort will comprise 15 subjects, randomly assigned to receive either rHIgM22 (n=10) or placebo (n=5).
62445105|NCT00295854|EXPERIMENTAL|MN-001|
62445106|NCT00295854|PLACEBO_COMPARATOR|MN-001 once daily|placebo tablets
62616086|NCT04858360|EXPERIMENTAL|Study group|
62840894|NCT03055130||control group|Female people who perform physical examination in our hospital between 21-60 years-old were recruited as control during the study period.
62840895|NCT01809743|ACTIVE_COMPARATOR|Regadenoson central - peripheral|First bolus regadenoson administered central, second bolus administered peripheral
62840896|NCT01809743|ACTIVE_COMPARATOR|Regadenoson peripheral - central|First bolus regadenoson administered peripheral, second bolus administered central
62616087|NCT03103217|EXPERIMENTAL|Brief CBT intervention|
62616088|NCT00427219|EXPERIMENTAL|Ozarelix|All participants completing the placebo run in period were randomized to enter the treatment phase of the study and received ozarelix on Day 0 and Day 14.
62616089|NCT00427219|PLACEBO_COMPARATOR|Placebo|All participants completing the placebo run in period were randomized to enter the treatment phase of the study and received placebo Day 0 and Day 14.
62616090|NCT06426277|EXPERIMENTAL|Brazilian Diabetes Prevention Program (face-to-face care)|Brazilian Diabetes Prevention Program will be delivered face-to-face, including guidance for improving diet and lifestyle (especially physical activity in daily life), as well as stimulating self-care.
62840897|NCT01809743|ACTIVE_COMPARATOR|Regadenoson central - central|First bolus regadenoson administered central, second bolus administered central
62840898|NCT01809743|ACTIVE_COMPARATOR|Regadenoson peripheral - peripheral|First bolus regadenoson administered peripheral, second bolus administered peripheral
62056216|NCT04137354|EXPERIMENTAL|Vitamin A & Placebo Iron Supplements|Children is this group will receive weekly three placebo tablets that are identical to the iron tablets (blinded) for the whole duration of the study (9 months of the school year). They will also receive a high dose vitamin A capsule (200,000IU) at baseline and after 4.5 months (at mid-line)
62056217|NCT04137354|EXPERIMENTAL|Intermittent Iron Supplements & Placebo Vitamin A|"Children is this group will receive weekly three tablets of iron (42mg of elemental iron once a week) for 9 months (equivalent to a one school year).~They will also receive placebo vitamin A at baseline and at mid-line (after 4.5 months)."
62056218|NCT04137354|EXPERIMENTAL|Intermittent Iron Supplements & High dose Vitamin A|Combined weekly iron supplementation (42mg of elemental iron once a week) for 9 months and high dose vitamin A (200,000IU) at baseline and after 4.5 months (mid-line).
62056219|NCT04770363|EXPERIMENTAL|Bihemispheric Stimulation Group|The first group tDCS bihemispheric stimulation consisted of 20 minutes of 2 mA direct current with the anode placed over the ipsilesional and the cathode over the contralesional motor cortex M1 (C3 and C4 of the international 10 -20 EEG electrode system).
62616091|NCT06426277|ACTIVE_COMPARATOR|Brazilian Diabetes Prevention Program (remote care)|Brazilian Diabetes Prevention Program (remote care) will be delivered either through telephone or video calls (using several media and software application), including guidance for improving diet and lifestyle (especially physical activity in daily life), as well as stimulating self-care.
62056220|NCT04770363|EXPERIMENTAL|Unihemispheric Stimulation Group|The second group unilateral stimulation, the anode placed over the ipsilesional motor cortex M1 (C3 or C4 of the international 10 -20 EEG electrode system) and the cathode over contralesional supraorbital bone.
62056221|NCT04770363|SHAM_COMPARATOR|Sham Group|The third sham group, the anode placed over the ipsilesional motor cortex M1 (C3 or C4 of the international 10 -20 EEG electrode system) and the cathode over contralesional supraorbital bone, but delivering no current.
62056222|NCT01546961|EXPERIMENTAL|Chloroquine|"Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).~Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2."
62056223|NCT03099330|EXPERIMENTAL|TQ-B3139|TQ-B3139 p.o. qd
62056224|NCT02582138|EXPERIMENTAL|Multicomponent intervention (MCI)|The multicomponent intervention will include a physical activity programme, a nutritional intervention and an information and communications intervention.
62056225|NCT02582138|ACTIVE_COMPARATOR|Healthy Aging Lifestyle Education (HALE)|The health aging lifestyle education programme will be based on workshops. Participants will receive information on a variety of topics of relevance to older persons (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
62056226|NCT04570917|EXPERIMENTAL|Intervention group (INT)|An online learning module targeted to reduce ageism will be delivered to the INT group.
62056227|NCT04570917|ACTIVE_COMPARATOR|Control group (CON)|An online learning module on diversity and cultural competence will be delivered to the CON group.
62616092|NCT06426277|ACTIVE_COMPARATOR|Diet Group|Diet prescription for weight loss.
62840899|NCT03308370|EXPERIMENTAL|Platelet rich plasma|intradermal injection of 5 ml of autologous platelet rich plasma in the lesional skin of the face of 20 melasma patients every 4 weeks for 3 times
62840900|NCT03459885|EXPERIMENTAL|PAS|The intervention is given to peripheral nerve - motor cortex pairs selected by the investigator.
62616093|NCT00916071||Eating Disorders|Study subjects will be individuals with a history of eating disorder(s) diagnosis
62840901|NCT03966638||Patients receiving platelet rich plasma|The group is composed of patients receiving an intra-meniscal injection of platelet-rich plasma, under echographic control, for isolated meniscal lesion.
62840902|NCT00614068|EXPERIMENTAL|A|Participants will receive 12 sessions of trauma-focused cognitive behavioral therapy over 3 months.
62840903|NCT00614068|ACTIVE_COMPARATOR|B|Participants will receive 12 sessions of treatment as usual over 3 months.
62840904|NCT01400880||Pregnant|In Labor
62840905|NCT05457010|EXPERIMENTAL|CD123-Specific Adapter (SPRX002) and Universal CAR-Modified T Cell (ARC-T Cells)|Arm 1: Phase 1 Study of monovalent CD123-Specific Adapter (SPRX002) and Universal CAR-Modified T cell (ARC-T Cells) for the Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
62840906|NCT01607684|OTHER|Diabetes mellitus group|Subjects with Diabetes mellitus and symptoms of diabetic gastroparesis
62840907|NCT01607684|OTHER|Control group|Healthy volunteers as matched pairs according to gender and age
62259011|NCT00787462|ACTIVE_COMPARATOR|Active|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
62259012|NCT00787462|PLACEBO_COMPARATOR|Placebo|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
62259013|NCT04245475|NO_INTERVENTION|Control Group|No treatment, side study to test the assumptions of our quantitative sensory testing pain paradigm
62259014|NCT04245475|ACTIVE_COMPARATOR|Low Tech/passive Virtual Reality first|Low Tech VR first brief test phase thermal stimulus + High Tech VR during a second test phase pain stimulus
62259015|NCT04245475|EXPERIMENTAL|High Tech/interactive Virtual Reality first|High Tech/Interactive VR during first brief test phase thermal stimulus + Low Tech VR during a second brief thermal stimulus.
62259016|NCT00841568|EXPERIMENTAL|1|
62840908|NCT03079843|EXPERIMENTAL|facemask first then no face mask|wearing of mask each day for the two hours of exposure for the first week of exposure then not wearing the mask each day for the two hours of exposure for the second week of exposure
62840909|NCT03079843|EXPERIMENTAL|no face mask followed by wearing face mask|not wearing the mask each day for the two hours of exposure for the first week of exposure then wearing the mask each day for the two hours of exposure for the second week of exposure
62840910|NCT03416543||Puncture|Patient with RA or gout or osteoarthritis and performing a puncture. The aim is evaluate the cellular composition of synovial fluid then evaluate the response to a new BI-specifiC Antibody Towards Dendritic Cells.
62840911|NCT01967329|ACTIVE_COMPARATOR|Standard Triple, treatment naive|"Standard Triple Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)~One of two treatments randomly assigned to treatment naive participants in Aklavik"
62840912|NCT01967329|ACTIVE_COMPARATOR|Sequential, treatment naive|"Sequential Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)~One of two treatments randomly assigned to treatment naive participants in Aklavik, Old Crow, Tuktoyaktuk \& Fort McPherson"
62840913|NCT01967329|ACTIVE_COMPARATOR|Quadruple, treatment naive|"Quadruple Thearpy for H. pylori:~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily~One of two treatments randomly assigned to treatment naive participants in Old Crow, Tuktoyaktuk \& Fort McPherson"
62840914|NCT01967329|ACTIVE_COMPARATOR|Sequential, previous failure(s)|"Sequential Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)~One of two treatments randomly assigned to participants who previously failed one or more treatments in Aklavik, Old Crow, Tuktoyaktuk \& Fort McPherson"
62840915|NCT01967329|ACTIVE_COMPARATOR|Quadruple, previous failure(s)|"Quadruple Therapy for H. pylori:~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily~One of two treatments randomly assigned to participants who previously failed treatment in Aklavik, Old Crow, Tuktoyaktuk \& Fort McPherson"
62840916|NCT01967329|ACTIVE_COMPARATOR|Sequential, clarithromycin-resistant|"Sequential Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)~One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik"
62840917|NCT01967329|ACTIVE_COMPARATOR|Quadruple, clarithromycin-resistant|"Quadruple Therapy for H. pylori:~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily~One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik"
62840918|NCT01655004|EXPERIMENTAL|exemestane standard treatment|Patients will receive exemestane 25mg daily orally after a meal until progression of disease, intolerable toxicities, voluntary withdrawal or termination of the study.
62840919|NCT03994848|NO_INTERVENTION|Control|
62840920|NCT03994848|EXPERIMENTAL|Spirometry Group|
62840921|NCT05398913|PLACEBO_COMPARATOR|Placebo|Two pills of placebo will be administered for 5 consecutive days, once per day.
62259017|NCT04906980|EXPERIMENTAL|JNJ-64281802|Participants will receive 2 initial loading doses of JNJ-64281802 up to Day 2, followed by a maintenance dose on Days 3, 4, and 5.
62056228|NCT01570530|ACTIVE_COMPARATOR|Atorvastatin|Patients treated with atorvastatin
62259018|NCT04906980|PLACEBO_COMPARATOR|Placebo|Participants will receive oral dose of matching placebo every 8 hour (q8h) and once daily on Day 4 and Day 5.
62259019|NCT02086786|EXPERIMENTAL|Gluteus (Risperidone ISM)|Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
62259020|NCT02086786|EXPERIMENTAL|Deltoid (Risperdione ISM)|Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
62259021|NCT00863200||Telephone Intervention Group|
62259022|NCT00863200||Standard Care Group|
62840922|NCT05398913|ACTIVE_COMPARATOR|Rimonabant 2.5 mg|One pill of placebo and one pill of Rimonabant 2.5mg will be administered for 5 consecutive days, once per day.
62056229|NCT01570530|OTHER|Without Atorvastatin|Patients treated without atorvastatin
62056230|NCT06176001|ACTIVE_COMPARATOR|Psychoeducation|Participants randomized to this arm are offered group-based psychoeducation shortly thereafter.
62056231|NCT06176001|PLACEBO_COMPARATOR|Waiting list|Participants randomized to this arm are placed on a waiting list for approximately 4 months and then offered group-based psychoeducation thereafter.
62259023|NCT04240444|EXPERIMENTAL|SeQuent® SCB|patients will receive sirolimus (rapamycin)-coated balloon (SeQuent® SCB)
62259024|NCT04240444|ACTIVE_COMPARATOR|SeQuent® Please Neo|patients will receive SeQuent® Please Neo balloon
62259025|NCT00632099|PLACEBO_COMPARATOR|Placebo|matched placebo
62259026|NCT00632099|EXPERIMENTAL|Oral micronized progesterone|Oral micronized progesterone (up to 400 mg/day)
62056232|NCT05794048|EXPERIMENTAL|Hepatocellular carcinoma|Patients with hepatocellular carcinoma
62056233|NCT05794048|EXPERIMENTAL|Pancreatic adenocarcinoma|Patients with pancreatic adenocarcinoma
62056234|NCT05794048|EXPERIMENTAL|Pancreatic neuroendocrine tumor|Patients with pancreatic neuroendocrine tumor
62259027|NCT02092675||COPD patients - frequent exacerbator|COPD patients with 2 and more exacerbation in one year
62259028|NCT02092675||COPD patients - non frequent exacerbator|COPD patients with less than 2 exacerbation during one year
62259029|NCT02092675||control group - healthy smokers|healthy smokers, they do not have COPD
62259030|NCT04793542|NO_INTERVENTION|Control|
62259031|NCT04793542|SHAM_COMPARATOR|Lukewarm Water|
62259032|NCT04793542|ACTIVE_COMPARATOR|Hot Water|
62840923|NCT05398913|ACTIVE_COMPARATOR|Rimonabant 5 mg|Two pills of Rimonabant 2.5mg will be administered for 5 consecutive days, once per day.
62056235|NCT04080752|EXPERIMENTAL|JNJ-61393215 135 milligram (mg)|Participants will receive JNJ-61393215 135 mg (3\*45 mg capsules) orally once daily for 6 weeks along with the prescribed standard oral antidepressants (without dose change) throughout the study.
62259033|NCT01987206|ACTIVE_COMPARATOR|PID algorithm with HMS|"The control algorithm, at its core, is a Proportional-Integral-Derivative (PID)controller that incorporates an Internal Model Control (IMC) based tuning rule using an explicit model of human T1DM glucose-insulin dynamics. Parameters of the model are personalized based on a priori easily available subject parameters. This controller divides the control action into three components - the proportional distance between the current measurement and the target setpoint, the accumulated integral error as expressed by the area between the current state curve and the target set point over time, and the derivative rate of change of the current measurement.~The Health Monitoring System algorithm uses the same glucose monitoring (CGM) data as the PID control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device."
62259034|NCT01987206|EXPERIMENTAL|MPC algorithm with HMS|"The first control strategy is a flavor of Model Predictive Control (MPC) algorithm. MPC employs an explicit model of the process to be controlled when optimizing the input. Specifically, MPC controllers for glycemia control use a model of a human's T1DM insulin-glucose dynamics to predict the evolution of the blood glucose values over a so-called prediction horizon of controller steps, and optimize a predicted insulin input trajectory in order to optimize a specified cost objective that penalizes unsafe glycemic values, and also insulin usage.~The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device."
62259035|NCT04340713|EXPERIMENTAL|Information support group|The experimental group was given information support program intervention on the basis of routine information communication.
62259036|NCT04340713|NO_INTERVENTION|Routine care group|The control group was given routine information communication.
62259037|NCT06490913|EXPERIMENTAL|cetuximab+chemotherapy|XELOX 1 cycle；cetuximab+chemotherapy up to 12 cycles
62840924|NCT00687427||A|Group A - 25 individuals or more, that start occupational therapy and agree to participate in the research.
62259038|NCT03658382|NO_INTERVENTION|Telephone Results Disclosure|
62840925|NCT00687427||B|Group B- 25 individuals or more, half a year after hand injury that were treated in occupational therapy at the same institute.
62056236|NCT04080752|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo for 6 weeks along with the prescribed standard oral antidepressants (without dose change) throughout the study.
62056237|NCT02144922|PLACEBO_COMPARATOR|Control|Patients continue taking their antihypertensive medication alone.
62056238|NCT02144922|ACTIVE_COMPARATOR|Pitavastatin|Pitavastatin 4 mg is given to study patients after a baseline assessment and continued for 1 year without further dose titration. Patients continue taking their antihypertensive medication during the entire follow-up period.
62056239|NCT03261102|ACTIVE_COMPARATOR|Standard clinical care|"Adalimumab induction as per standard clinical care:~* Week 0: 160 mg SC~* Week 2: 80 mg SC~* Followed by 40 mg SC every 2 weeks' maintenance therapy"
62056240|NCT03261102|ACTIVE_COMPARATOR|Active optimization|"Same as Standard clinical care Arm, except:~* If ADAL trough ≤15 μg/ml, dose escalation with 80 mg SC at week 6 followed by 40 mg SC every week~* If ADAL trough \>15 μg/ml, no dose escalation and continued standard of care dosing"
62259039|NCT03658382|EXPERIMENTAL|Virtual Visit Results Disclosure|
62056241|NCT03895411|EXPERIMENTAL|Sotalol|Oral sotalol 2.5mg/kg/time, per 12h. Combination therapy: betaloc
62056242|NCT03895411|ACTIVE_COMPARATOR|Propafenone|Oral Propafenone 5mg/kg/time, pre 8h Combination therapy: betaloc
62616094|NCT04342013|EXPERIMENTAL|Perioperative Clinical Decision Support Application|Participants will be observed performing clinical tasks and documenting medication administrations with use of the clinical decision support application in the perioperative setting.
62840926|NCT00687427||C|Group C - 25 individuals or more, a year after hand injury that were treated in occupational therapy at the same institute
62259040|NCT03185364|EXPERIMENTAL|Interventional group|Sildenafil Citrate, 20mg, tid for 12 weeks
62259041|NCT03185364|PLACEBO_COMPARATOR|Control group|placebo oral tablet, 12 weeks
62259042|NCT02598375||Children with feeding intolerance|Critically ill children having with respiratory or catecholamine support in PICU have the feeding intolerance at least for12 hours or more.
62259043|NCT02598375||Children without feeding intolerance|Critically ill children having with respiratory or catecholamine support in PICU have not the feeding intolerance signs at least for 12 hours or less
62259044|NCT03885310|EXPERIMENTAL|DCB Treatment|Stricture patients treated by DCB
62056243|NCT05976204||ToF primary repair|Patients who underwent ToF primary repair from January 2020 until December 2022
62056244|NCT04710927|ACTIVE_COMPARATOR|High Viscosity GIC (HVGIC)|Group 1
62056245|NCT04710927|EXPERIMENTAL|Silver Diamine Fluoride (SDF) + HVGIC|Group 2
62056246|NCT04710927|EXPERIMENTAL|Papain based gel + SDF + HVGIC|Group 3
62056247|NCT05644223||Exposet group|intravenous edaravone dexborneol 37.5mg twice daily
62056248|NCT05644223||Non-exposed group|standard treatment at the discretion of local clinicians
62056249|NCT01928134|EXPERIMENTAL|A|Vit K2+ Vit D3+ calcium carbonate (CaCO3)
62056250|NCT01928134|ACTIVE_COMPARATOR|B|Vit K2+CaCO3
62056251|NCT05541302||1-20 TMS sessions|PHQ 9 ratings during this treatment period
62056252|NCT05541302||21 - 29 TMS sessions|PHQ 9 ratings during this treatment period
62056253|NCT05541302||30 TMS Sessions|PHQ 9 ratings during this treatment period
62056254|NCT05541302||31-36 TMS Sessions|PHQ 9 ratings during this treatment period
62056255|NCT05541302||extended treatment 36 and beyond|PHQ 9 ratings during this treatment period
62056256|NCT04115007|EXPERIMENTAL|Arm A|Standard of care + Stereotactic Body Radiotherapy to oligometastases
62056257|NCT04115007|ACTIVE_COMPARATOR|Arm B|Standard of care
62259045|NCT01260012|EXPERIMENTAL|praziquantel+antioxidant|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In additions, antioxidant suppliment will be given daily for a period of one year
62259046|NCT01260012|ACTIVE_COMPARATOR|Praziquantel +placebo 2mths then antioxidant for 10 months|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.
62616095|NCT04342013|NO_INTERVENTION|No Perioperative Clinical Decision Support Application|Participants will be observed performing clinical tasks and documenting medication administrations without use of the clinical decision support application in the perioperative setting.
62616096|NCT02792335||patients naive to oral anticoagulant treatment|NVAF patients naïve to oral anticoagulant treatment (Naïve)
62616097|NCT02792335||patients with prior warfarin therapy|NVAF patients with prior warfarin therapy (Warfarin treated)
62616098|NCT00983138|EXPERIMENTAL|recombinant asparaginase|
62259047|NCT01260012|NO_INTERVENTION|Praziquantel therapy with placebo supplement|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for a period of one year.
62259048|NCT03089593|EXPERIMENTAL|Extract of ginger|Healthy and eutrophic women will receive two capsules of 200 mg of ginger extract (5% gingerols) to be taken along with a standardized breakfast.
62259049|NCT03089593|PLACEBO_COMPARATOR|Cellulose|Healthy and eutrophic women will receive two capsules of 200 mg of placebo (cellulose) to be taken along with a standardized breakfast.
62259050|NCT02137512|EXPERIMENTAL|Closed-Loop Control System|Use of an investigational control-to-range automated insulin management (artificial pancreas) system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes in the home environment.
62259051|NCT02137512|ACTIVE_COMPARATOR|Sensor-Augmented Pump (SAP)|Use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump
62616099|NCT02981732|EXPERIMENTAL|Shen (Kidney) yin deficiency|Shen (Kidney) yin deficiency
62616100|NCT02981732|NO_INTERVENTION|the control group|the control group,there is no intervention
62056258|NCT03576768|EXPERIMENTAL|Real cTBS to the vmPFC|Ten sessions of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
62056259|NCT03576768|SHAM_COMPARATOR|Sham cTBS to the vmPFC|Ten sessions of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
62056260|NCT03576768|EXPERIMENTAL|Real iTBS to the dlPFC|Ten sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
62056261|NCT03576768|SHAM_COMPARATOR|Sham iTBS to the dlPFC|Ten sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
62056262|NCT00895882|EXPERIMENTAL|1|vaniprevir 300 mg b.i.d. + peg-IFN + RBV for 12 weeks, followed by placebo to vaniprevir + peg-IFN + RBV for 12 weeks
62056263|NCT00895882|EXPERIMENTAL|2|vaniprevir 300 mg b.i.d. + peg-IFN + RBV for 24 weeks
62056264|NCT00895882|EXPERIMENTAL|3|vaniprevir 600 mg b.i.d. + peg-IFN + RBV for 12 weeks, followed by placebo to vaniprevir + peg-IFN + RBV for 12 weeks
62056265|NCT00895882|EXPERIMENTAL|4|vaniprevir 600 mg b.i.d. + peg-IFN + RBV for 24 weeks
62056266|NCT00895882|EXPERIMENTAL|5|vaniprevir 600 mg q.d. + peg-IFN + RBV for 24 weeks
62259052|NCT06236295|EXPERIMENTAL|SHR6508|
62259053|NCT01908023|EXPERIMENTAL|exercise|
62259054|NCT02690857|EXPERIMENTAL|Docosahexaenoic acid|"Each capsule of DHA contains 100 mg DHA in triglycerides from algal oil, 0.125 mg alpha-tocopherol and 0.125 mg ascorbic acid.~Subjects receive an orally and daily ingestion of DHA capsules (5mg/kg for 15 days followed by 10 mg/kg for another 15 days without interruption between the 2 periods)."
62259055|NCT02690857|PLACEBO_COMPARATOR|Sunflower oil|Placebo capsules contain the same quantities of antioxidants and triglycerides of sunflower oil. Subjects receive an orally and daily ingestion of placebo capsules for 28 days.
62259056|NCT05999370|OTHER|Nutrition and exercise|"The nutrition intervention will be based on a comprehensive nutrition assessment by a dietitian at baseline, enabling individualized caloric and protein targets.~The exercise intervention will be personalized based on a comprehensive assessment to include both a resistance and an aerobic component in the form of a snack."
62616101|NCT04886388|EXPERIMENTAL|BT-001 + Standard of Care|BT-001 is a software program used with physician guidance, being investigated to improve glycemic control. Patients randomized to this arm of the study will interact with the BT-001 software program in addition to receiving Standard of Care for type 2 diabetes
62056267|NCT00895882|PLACEBO_COMPARATOR|6|Placebo to vaniprevir + peg-IFN + RBV for 24 weeks, followed by peg-IFN + RBV for 24 weeks
62056268|NCT04615130|EXPERIMENTAL|Intervention|Patients will undergo 6 weeks of outpatient rehabilitation.
62056269|NCT04615130|NO_INTERVENTION|Control|Patients will receive no intervention throughout the 6 weeks period.
62056270|NCT03408275||Pregnant women|Pregnant women enrolled in ALSPAC
62056271|NCT00521144|EXPERIMENTAL|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive obatoclax mesylate IV over 3 hours on day 1 OR days 1 and 3 and topotecan hydrochloride IV over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity
62616102|NCT04886388|ACTIVE_COMPARATOR|Standard of Care|Patients randomized to the Standard of Care arm will receive Standard of Care treatment for type 2 diabetes under the guidance of a physician
62840927|NCT03045796||Maintenance Hemodialysis Patients|Following the initial recruitment, all individuals who are willing to participate and sign the informed consent document will be provided with a medical history form to complete. In addition, we will ask them to sign a HIPAA authorization form in order to look into their medical records for monthly blood work (blood chemistry), anthropometric data (height and weight), interdialytic weight gain (weight gain since last treatment) history, and current medications.
62840928|NCT02795403|EXPERIMENTAL|Viraemic|
62840929|NCT02795403|EXPERIMENTAL|responder group|
62840930|NCT06296329||Cases|Participants with Anorexia Nervosa
62840931|NCT06296329||Controls|Not-hospitalized participants with a healthy weight
62840932|NCT01077050|OTHER|SciBase III|Subjects with suspected malignant melanoma or lesions designated for total excision were included into the study. To ensure no selection bias, all eligible lesions from a subject were included into the study. All study eligible skin lesion(s) were examined with the investigational device, photographed and removed by an excisional biopsy.
62840933|NCT04712630|EXPERIMENTAL|NIPSA without grafting biomaterial|A single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the enamel matrix derivates will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
62840934|NCT04712630|ACTIVE_COMPARATOR|NIPSA with grafting biomaterial|A single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the enamel matrix derivates will be applied and the bone defect will be filled with a composite of xenograft and enamel matrix derivates. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
62056272|NCT03464487|ACTIVE_COMPARATOR|Daily LGIT|The children with drug resistant epilepsy in this arm will receive Low Glycemic Index Therapy diet everyday along with the antiepileptic drugs.
62259057|NCT05999370|OTHER|Nutrition only|The nutrition intervention will be based on a comprehensive nutrition assessment by a dietitian at baseline, enabling individualized caloric and protein targets.
62259058|NCT00159991|EXPERIMENTAL|A|Total arterial revascularization
62840935|NCT04982185||Deep block|Deep neuromuscular block before initial (V1) vagal stimulation.
62840936|NCT04982185||Moderate block|Moderate neuromuscular block before initial (V1) vagal stimulation.
62840937|NCT05368012|OTHER|Active MIDCAB|USG with a 25G needle, Bupivacaine 0.5% 30ml with 4mg preservative free dexamethasone divided as follows into the following 5 nerves: Posterior Tibial nerve (10ml), Saphenous nerve (5ml), Deep peroneal Nerve (5ml), Superficial peroneal nerve (5 ml), and Sural Nerve (5ml).
62840938|NCT04236609|ACTIVE_COMPARATOR|Abluminus DES+ sirolimus- eluting stents (SES)|Enrolled patients will undergo angioplasty with Abluminus DES+ sirolimus- eluting stents (SES) and will be followed for two years. The DES procedure will be conducted in accordance with the CE mark instructions for use for the Abluminus DES+ sirolimus- eluting stents (SES).
62056273|NCT03464487|ACTIVE_COMPARATOR|Intermittent LGIT|The children with drug resistant epilepsy in this arm will receive Low Glycemic Index Therapy Diet on five days of each week along with antiepileptic drugs. Rest of the two days, they will receive a liberal diet.
62056274|NCT03886259|EXPERIMENTAL|Exercise and pain neuroscience education|Subjects with chronic pain after total knee replacement will receive 24 sessions of neuromuscular exercise therapy, supervised by a physiotherapist, and two sessions of pain neuroscience education, conducted by a physiotherapist
62056275|NCT03886259|ACTIVE_COMPARATOR|Pain neuroscience education|Subjects with chronic pain after total knee replacement will receive two sessions of pain neuroscience education, conducted by a physiotherapist
62056276|NCT01712100|EXPERIMENTAL|irbesartan|300 mg tablet
62056277|NCT01712100|ACTIVE_COMPARATOR|Avapro|300 mg tablet
62056278|NCT02293772|ACTIVE_COMPARATOR|Hypoxic ambulatory|Ambulatory in normobaric hypoxia
62056279|NCT02293772|EXPERIMENTAL|Hypoxic Bedrest|Bedrest in normobaric hypoxia
62056280|NCT02293772|ACTIVE_COMPARATOR|Normoxic bedrest|Bedrest in normobaric normoxia
62056281|NCT05648825|EXPERIMENTAL|Experimental: Apical Hypertrophic Cardiomyopathy|Transapical beating-heart myectomy for the treatment of apical hypertrophic cardiomyopathy
62056282|NCT00071721|EXPERIMENTAL|1|
62056283|NCT00071721|PLACEBO_COMPARATOR|2|
62056284|NCT01407211|ACTIVE_COMPARATOR|with Multiple Sclerosis/ vitamin A|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A
62056285|NCT01407211|PLACEBO_COMPARATOR|with Multiple Sclerosis/ placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day
62056286|NCT06170775|EXPERIMENTAL|Sodiumhexametaphosphate|
62056287|NCT06170775|ACTIVE_COMPARATOR|MTA|
62259059|NCT00159991|ACTIVE_COMPARATOR|B|Conventional revascularization
62259060|NCT01182402|EXPERIMENTAL|Electronic compliance monitoring|Suboxone treated patients in Kuopio city area get their unsupervised Suboxone doses in electronic compliance monitoring devices during the 4 month study.
62616103|NCT03310892|NO_INTERVENTION|Usual Care|Participants in this arm will Usual scheduling process without any intervention
62056288|NCT03608280|ACTIVE_COMPARATOR|Autograft|Reconstructive surgery by autologous bone graft (bone autograft). It is the gold standard strategy.
62840939|NCT04236609|ACTIVE_COMPARATOR|XIENCE Everolimus-Eluting Stents (EES)|Enrolled patients will undergo angioplasty with XIENCE Everolimus-Eluting Stents (EES) and will be followed for two years. The DES procedure will be conducted in accordance with the CE mark instructions for use for the XIENCE Everolimus-Eluting Stents (EES).
62056289|NCT03608280|EXPERIMENTAL|3D implant|"Orbital reconstruction by 3D-printed porous titanium implant (PorousiTi®, laboratoire OBL/MATERIALISE).~The device is a custom-made porous titanium implant processed by selective laser melting (SLM technique)"
62056290|NCT00944047|EXPERIMENTAL|Intervention Arm|Nab-paclitaxel, trastuzumab, doxorubicin, cyclophosphamide, Growth Factor Support, Surgery
62056291|NCT03110341|EXPERIMENTAL|Erythropoietin|Erythropoietin is administered 750U/kg intravenously every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections regardless of gestational age), starting with the first dose within 72 hours after birth. A single dose consisted of 750U EPO per kg of birth weight dissolved in 3mL/kg normal saline was administered intravenously during a period of 5 minutes.
62259061|NCT04161820|EXPERIMENTAL|Education and telephone follow ups based on the CCM|"After the pre-tests (self-management, quality of life and patient satisfaction were assessed by scales at the first interview), the patients were given discharge training with a booklet prepared based on the Chronic Care Model (CCM) and containing information and recommendations on self-management strategies during their stay in the hospital (0 months). Trainings were performed in a single session and in the patient room at the clinic, not to exceed 45-50 minutes. The patients who were included in the intervention group were followed up by phone on the 7th day, 15th day, 1st month and 2nd month after discharge. Patients were referred to the hospital in unexpected / unpredictable situations during the three-month period.~Self-management, quality of life and patient satisfaction were assessed by scales at the first interview and 3 months later. Metabolic variables of the patients were obtained from the patient clinical information system at the first interview and 3 months later."
62259062|NCT04631575|EXPERIMENTAL|Healthy participants|Intervention: Drug: SHR6390 single dose
62259063|NCT04631575|EXPERIMENTAL|Mild liver impairment|Intervention: Drug: SHR6390 single dose
62840940|NCT01079299|EXPERIMENTAL|IPC plus standard compression|
62840941|NCT01079299|ACTIVE_COMPARATOR|Standard compression alone|
62259064|NCT04631575|EXPERIMENTAL|Moderate liver impairment|Intervention: Drug: SHR6390 single dose
62259065|NCT03641872||Acute-on-Chronic Liver Disease|"1. chronic liver disease: including chronic liver hepatitis patients without cirrhosis, compensated cirrhosis patients, decompensated cirrhosis patients and non-alcoholic fatty liver disease patients.~2. ALI(acute liver injury): including \[ALT \> 3 ULN(upper limited of normal),AST \> 3 ULN or TB \> 2 ULN within 1 week before enrollment\] or AD(acute decompensation) : including \[(having ascites, hepatic encephalopathy, bacterial infection, gastrointestinal bleeding and/or jaundice(TB \> 5 ULN) within 1 month before enrollment)\].~3. Standary therapy for chronic liver disease with ATI and/or AD"
62259066|NCT02092012|ACTIVE_COMPARATOR|dexketoprofen trometamol|ıv 50 mg dexketoprofen trometamol after anesthesia induction
62840942|NCT04960657|ACTIVE_COMPARATOR|PACAP38 and glibenclamide|Participants will receive glibenclamide after PACAP38 infusion
62259067|NCT02092012|ACTIVE_COMPARATOR|dexmedetomidine|ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
62616104|NCT03310892|EXPERIMENTAL|Generic Message|"Participants in this arm will receive a telephone call from a study team member, and if no answer, up to two additional attempts will be made. During the telephone call, the study team member will ask the participant a series of 7 questions then receive a generic message encouraging colonoscopy scheduling."
62616105|NCT03310892|EXPERIMENTAL|Tailored Message|"Participants in this arm will receive a telephone call from a study team member, and if no answer, up to two additional attempts will be made. During the telephone call, the participant will answer a series of 7 questions then receive a tailored message encouraging colonoscopy scheduling, which will be determined by their responses to the preceding questions."
62616106|NCT01072578|EXPERIMENTAL|1|
62840943|NCT04960657|ACTIVE_COMPARATOR|PACAP38 and placebo|Participants will receive placebo after PACAP38 infusion
62840944|NCT04910997|EXPERIMENTAL|HRV Group|Heart rate variability training group
62056292|NCT03110341|PLACEBO_COMPARATOR|Normal saline|Normal saline is administered 3ml/kg intravenously every other day for 2 weeks, starting with the first dose within 72 hours after birth. Similarly, the placebo dose consisted of 3mL of normal saline per kilogram birth weight was administered intravenously during a period of 5 minutes.
62056293|NCT00105235|EXPERIMENTAL|Alemtuzumab|Liver transplant, with two in-patient infused doses of alemtuzumab; followed by maintenance immunotherapy with cyclosporine, mycophenolate mofetil, and/or tacrolimus; with possible immunosuppression withdrawal
62056294|NCT02656576|OTHER|patient with suspected lesions of the tonsillar region|patients will have a tonsil biopsy and a smear
62616107|NCT01072578|EXPERIMENTAL|2|
62616108|NCT01636089|EXPERIMENTAL|bicarbonates|sodium bicarbonates 1,4%
62616109|NCT01636089|ACTIVE_COMPARATOR|saline|sodium chloride 0,9%
62840945|NCT04910997|ACTIVE_COMPARATOR|Traditional Exercise Group|Traditional (e.g. standard) exercise training
62840946|NCT04910997|NO_INTERVENTION|Control Group|Usual care
62840947|NCT01809119|EXPERIMENTAL|Laparoscopic Partial Nephrectomy|Patients with kidney neoplasms submitted to laparoscopic partial nephrectomy
62840948|NCT01809119|ACTIVE_COMPARATOR|Open Partial Nephrectomy|Patients with kidney neoplasms submitted to open partial nephrectomy
62840949|NCT00092443|EXPERIMENTAL|RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)|"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent)~administered 28 to 70 days apart."
62840950|NCT00092443|PLACEBO_COMPARATOR|Placebo matching RotaTeq™|Placebo matching RotaTeq™ administered 28 to 70 days apart.
62056295|NCT05850780|EXPERIMENTAL|Photobiomodulation|
62840951|NCT03082625|EXPERIMENTAL|Transdermal Magnesium|5 sprays each on the 2 most effected areas for muscle cramps twice a day
62840952|NCT03082625|PLACEBO_COMPARATOR|Placebo|5 sprays each on the 2 most effected areas for muscle cramps twice a day
62840953|NCT05494164|EXPERIMENTAL|Study group|Nigella sativa nasal oil drops
62056296|NCT05850780|ACTIVE_COMPARATOR|Mineral Trioxide Aggregate (MTA)|
62056297|NCT03117348|EXPERIMENTAL|Gradual goal-dose EN|Patients in Gradual Goal-dose EN group will receive increased calories gradually by enteral nutrition and will reach the 80% of target energy by enteral nutrition at day 8.
62056298|NCT03117348|EXPERIMENTAL|Immediate goal-dose EN|Patients in immediate Goal-dose EN group will reach the 100% of target energy by enteral nutrition at day 3 after abdominal surgery.
62056299|NCT05378984|ACTIVE_COMPARATOR|Dark Chocolate|
62056300|NCT05378984|ACTIVE_COMPARATOR|Milk Chocolate|
62056301|NCT05378984|ACTIVE_COMPARATOR|White Chocolate|
62056302|NCT01770210||Cardiovascular events|Patients on atorvastatin treatment hospitalised due to cardiovascular events
62056303|NCT03753295||Group I (normal subjects)|30 individuals (15 male, and 15 female students) with (BMI\<25 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
62259068|NCT00473343|EXPERIMENTAL|Metvix® PDT|Participants with basal cell carcinoma (BCC) lesions were administered to photodynamic therapy (PDT) with Metvix® cream 160 milligrams per gram (mg/g) applied for three hours, followed by illumination using non-coherent light with a fluency of 75 Joule per centimeter square (J/cm\*2) and fluency rate of 70-200 milliwatt per centimeter square (mW/cm\*2) up to 13 weeks.
62840954|NCT05494164|OTHER|Control group|standard treatment
62840955|NCT01684865||Non-Hodgkin's Lymphoma Participants|Participants initiated on rituximab maintenance therapy according to the standard of care and in line with the current summary of product characteristics will receive rituximab for maximum two years or until disease progression. Participants will be followed for one year after last dose of rituximab administered as maintenance.
62840956|NCT05820191|EXPERIMENTAL|AMY-GBM|Amyvid-PET scan will be performed. According to approved protocol for Alzheimer's disease diagnostics, 370MBq (10mCi) absorbed dose 7mSv of Amyvid will be introduced intravenously and 30-50 minutes after the PET images will be acquired.
62056304|NCT03753295||Group II (overweight subjects)|30 individuals (15 male, and 15 female students) with (BMI, 25-30 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
62056305|NCT03753295||Group III (obese subjects)|30 individuals (15 male, and 15 female students) (BMI\>30 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
62056306|NCT02518854||study|children aged 6-18 years with pre-metabolic syndrome
62056307|NCT02518854||control|children aged 6-18 years without pre-metabolic syndrome
62616110|NCT03439410||Internal Medicine ward|The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.
62056308|NCT01224158|EXPERIMENTAL|PR-009577 Toothbrush|Experimental Power Toothbrush
62056309|NCT01224158|ACTIVE_COMPARATOR|PR-000172 Toothbrush|Flat trimmed Manual Toothbrush
62056310|NCT02173054|PLACEBO_COMPARATOR|Adapalene gel|"Evening~* Wash face by prepared facial foam and dry your face~* Apply adapalene gel all over the face"
62616111|NCT03439410||Subacute ward|The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.
62616112|NCT06040216||Stage 2 ERM|
62056311|NCT02173054|PLACEBO_COMPARATOR|Adapalene gel with placebo moisturizer|"Morning~* Wash face by prepared facial foam and dry their face~* Apply placebo cream all over the face~Evening~* Wash face by prepared facial foam and dry your face~* Apply adapalene gel all over the face~* Apply placebo cream all over the face"
62056312|NCT02173054|ACTIVE_COMPARATOR|Adapalene gel with Eucerin|"Morning~* Wash face by prepared facial foam and dry their face~* Apply Eucerin cream all over the face~Evening~* Wash face by prepared facial foam and dry your face~* Apply adapalene gel all over the face~* Apply Eucerin cream all over the face"
62616113|NCT06040216||Stage 3 ERM|
62616114|NCT06040216||Stage 4 ERM|
62616115|NCT03132974|EXPERIMENTAL|SGHH|Admission to Sogyeonghwalhyeol-tang granule
62616116|NCT03132974|EXPERIMENTAL|SGHH with manipulation therapy|Admission to Sogyeonghwalhyeol-tang granule and manipulation therapy
62616117|NCT03132974|PLACEBO_COMPARATOR|Placebo with manipulation therapy|
62616118|NCT01556932|EXPERIMENTAL|Placebo then ABH|"All subjects randomized to two sequences of treatments: either placebo-ABH or ABH-placebo. All participants will receive both drug A and drug B.~After applying gel, Drug A or B, on wrists for 2 minutes, time 0. From baseline to 60 minutes of treatment two options will occur. At 60 minutes, if patients have at least 1 point reduction in their nausea score, they must wait 4 hours before switching to opposite drug. After administration of drug, the study procedures will be repeated. Or, at 60 minutes, if no change or increase in nausea score has been recorded, alternative treatment will be given. If the second treatment is ineffective at one hour (total time 2 hours) then alternative usual medications will be given. After completion of study treatment, patients are followed up for up to 8 hours."
62616119|NCT01556932|EXPERIMENTAL|ABH then placebo|"All subjects randomized to two sequences of treatments: either placebo-ABH or ABH-placebo. All participants will receive both drug A and drug B.~After applying gel, Drug A or B, on wrists for 2 minutes, time 0. From baseline to 60 minutes of treatment two options will occur. At 60 minutes, if patients have at least 1 point reduction in their nausea score, they must wait 4 hours before switching to opposite drug. After administration of drug, the study procedures will be repeated. Or, at 60 minutes, if no change or increase in nausea score has been recorded, alternative treatment will be given. If the second treatment is ineffective at one hour (total time 2 hours) then alternative usual medications will be given. After completion of study treatment, patients are followed up for up to 8 hours."
62616120|NCT01776177||Continue Therapy Group|Patients who continued to recieve Omalizumab therapy beyond 6 month period
62616121|NCT01776177||Discontinued Therapy group|Patients who discontinued Omalizumab therapy prior to 6 month period from the start of therapy
62616122|NCT06367777|EXPERIMENTAL|Anodal cervical tsDCS|"Participants will receive:~1. 20 minutes of 2.5 milliamperes (mA) anodal tsDCS at the cervical level.~2. 20 minutes of sham tsDCS at the low-thoracic level."
62616123|NCT06367777|EXPERIMENTAL|Anodal thoracic tsDCS|"Participants will receive:~1. 20 minutes of sham tsDCS at the cervical level.~2. 20 minutes of 2.5 milliamperes (mA) anodal tsDCS at the low-thoracic level."
62616124|NCT06367777|SHAM_COMPARATOR|Sham tsDCS|"Participants will receive:~1. 20 minutes of sham tsDCS at the cervical level.~2. 20 minutes of sham tsDCS at the low-thoracic level."
62616125|NCT05275634|EXPERIMENTAL|Standard treatment and interferential current with carrier frequency 2 KHz|Standard treatment and interferential current with carrier frequency 2 KHz will be received three times a week for four weeks.
62056313|NCT06361901|EXPERIMENTAL|Language therapy group with language rehabilitation program|In addition to 5-session conventional language therapy, we provide a 5-session language rehabilitation program using an AI-based computerized cognitive and language training program. A cognitive evaluation is conducted before starting treatment, and K-Western Aphasia Battery and Functional Near infrared spectroscopy are performed before and after the treatment.
62259069|NCT06306625|EXPERIMENTAL|Remote ischemic conditioning|A brachial cuff is positioned around one arm of the patient. Remote ischemic conditioning consists of alternating inflations and deflations of the brachial cuff. Four cycles of ischemic conditioning (5-min brachial cuff inflation at 200 millimetres of mercury (mmHg) followed by 5-min cuff deflation) are started as soon as possible after inclusion. The intervention is repeated 12 and 24 hours after inclusion.
62259070|NCT06306625|OTHER|Control group|A brachial cuff is positioned around one arm of the patient. Neither inflation nor deflation is performed.
62259071|NCT03383484|NO_INTERVENTION|No intervention|No OMT, yoga, acupuncture, or other interventions.
62616126|NCT05275634|EXPERIMENTAL|Standard treatment and interferential current with carrier frequency 4 KHz|Standard treatment and interferential current with carrier frequency 4 KHz will be received three times a week for four weeks.
62259072|NCT03383484|EXPERIMENTAL|OMT intervention|Weekly OMT for 3 months
62259073|NCT03383484|EXPERIMENTAL|Yoga intervention|Yoga 3 times per week for 3 months
62259074|NCT01034007|EXPERIMENTAL|Tissue Engineered Vascular Grafts|
62259075|NCT00873171||1. OMT|This procedure consist of Sacral rocking is performed by placing the heel of the practitioner's hand over the sacrum and by using the palpatory skills of an osteopathic physician; rock the sacrum into a position with no restriction. Myofascial release will utilize various physical motions to place the patients lumbosacral region in a position of maximal comfort and tissue release.
62259076|NCT00873171||2. Attention control OMT|The procedure consist of light pressure applied to certain painful areas of the body and back to decrease pain and help patient relax. The physician will look for areas of the body that hurt, lay his/her hands on the those places, and apply light pressure.
62259077|NCT00873171||3. Standard of Care|This procedure consists of various conservative treatments that can help reduce stress. Those include dietary modifications, pharmaceuticals, bladder training, and neuromodulation. If these treatments are not successful, minimally invasive surgical procedures is performed.
62616127|NCT05275634|EXPERIMENTAL|Standard treatment and interferential current with carrier frequency 8 KHz|Standard treatment and interferential current with carrier frequency 8 KHz will be received three times a week for four weeks.
62840957|NCT04759326|ACTIVE_COMPARATOR|Hippotherapy treated group|The hippotherapy protocol will comprise three cycles. The first one consists of one session per day for 2 weeks allowing (i) to evaluate the patient and his neuro-functional skills, and (ii) to determine and carry out the treatment taking into account the silent barriers that may exist (PSTD, fatigue, pain, fear...) and strongly interfere with functional outcome (developing ways to overcome them). After a 9-week 'wash out' period (during which the patient consolidates the new patterns, translates them into daily activities and identifies new needs) where the patient continues his or her outpatient neurorehabilitation care, a further intermediate 1-week daily capacity building hippotherapy cycle follows. Then, after a second 9-week 'wash out' period (where the patient once again consolidates the new patterns, translates them into daily activities and identifies new needs), a final 1-week daily capacity building hippotherapy cycle will be carried out. Protocol will last 22 weeks.
62840958|NCT04759326|PLACEBO_COMPARATOR|Conventional neurorehabilitation treated group|Patients in the control group will receive standard outpatient rehabilitation treatment consisting of a program of physiotherapy (motor training, functional training), occupational therapy, language therapy, psychological and social support per week corresponding to the four weeks in which the treated group will be in hippotherapy. For the remaining 18 weeks, the treatment options for each patient, regardless of the group, will also include physiotherapy (motor training, functional training), occupational therapy, language therapy, psychological and social support.
62616128|NCT05275634|PLACEBO_COMPARATOR|Standard treatment and placebo interferential current|Standard treatment and placebo interferential current will be received three times a week for four weeks.
62616129|NCT06001853|ACTIVE_COMPARATOR|Arm A Treatment|Participants in Arm A will be scheduled for a single set of intra-articular injections of allogeneic, culture-expanded BM-MSCs at the dose 10 x106 in 1 ml per facet joint, for a total of 2 joints to be injected. BM-MSC injections will be performed using fluoroscopic guidance.
62616130|NCT06001853|PLACEBO_COMPARATOR|Arm B: DMSO Crossover|Participants in Arm B will receive a DMSO injection. Following the BM-MSC or DMSO injection, each subject will be followed for study endpoints using a predetermined protocol. A final visit for evaluation and imaging will be conducted at the end of the study.
62616131|NCT04432454|EXPERIMENTAL|Treatment|Women who have locally advanced or metastatic ER+/HER2- breast cancer and disease progression on first and/or 2nd lines of hormonal treatment for metastatic disease and have an ESR1 mutation
62616132|NCT05128045|EXPERIMENTAL|Experimental: NEW-R Intervention|NEW-R Intervention plus services as usual
62840959|NCT03623529|EXPERIMENTAL|Active Comparator: LJPC-501|LJPC-501 Angiotensin II Solution for infusion
62616133|NCT05128045|NO_INTERVENTION|Control|Services as usual
62616134|NCT02268682|NO_INTERVENTION|Standard of Care (Control)|Patients randomized to the standard of care condition will not receive any educational materials from our program and will only participate in the survey portion of the investigation. Dialysis providers will be asked to continue their current practices throughout the study period without change. While Control patients will be free to ask additional questions or solicit more information from their dialysis educators at any point during the study period, no additional educational interventions will be added to what is currently being done.
62623658|NCT01696656||Intestinal insufficiency|Patients with variable categories of major intestinal resection due to benign diseases,suffering from intestinal insufficiency and maintained with home nutritional support. Only clinically stable and nonhospitalized subjects will be recruited.
62840960|NCT03623529|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|0.9% sodium chloride solution
62056314|NCT06361901|ACTIVE_COMPARATOR|Conventional language therapy group|We provide a 10-session conventional language therapy. A cognitive evaluation is conducted before starting treatment, and K-Western Aphasia Battery and Functional Near infrared spectroscopy are performed before and after the treatment.
62840961|NCT01212341|EXPERIMENTAL|Singe-dose infusion|Cohort 1: 1x10\^6 cells/kg Cohort 2: 1x10\^7 cells/kg
62056315|NCT02500329|EXPERIMENTAL|gemigliptin|gemigliptin for 4 weeks
62840962|NCT01212341|EXPERIMENTAL|Repeated dose infusion|Cohort 3: 1x10\^6 cells/kg Cohort 4: 3x10\^6 cells/kg Cohort 5: 1x10\^7 cells/kg Cohort 6: 3x10\^7 cells/kg
62259078|NCT06116500|EXPERIMENTAL|Modified twin block appliance with expander group|For 24 patients with class II division malocclusion in their growing stages, using a 2 mm biocompatible and rigid PET-G thermoforming material to create two clear appliances for each patient. The material will be adapted separately on maxillary and mandibular casts using a pressure molding vacuum machine. Then, the appliances will be trimmed and finished and transferred to the articulator with the aid of a pre-existing working wax bite. The ramps will be made of cold cure acrylic on the thermoplastic sheets. Next, the expansion screw will be placed in the midline of the maxillary cast, and the maxillary appliance will be split midpalatally to fit the patient's individual needs.
62259079|NCT06116500|EXPERIMENTAL|Conventional twin block appliance with expander group|For 24 patients in a growing stage with class II division 1 malocclusion, these appliances will consist of removable maxillary and mandibular appliances. These will have a labial bow, Adam's clasps on the first molars, ball end clasps with incisal capping and expansion screw. The inclined bite blocks (ramps) will act as a guide to move the mandible forward.
62840963|NCT02876601|ACTIVE_COMPARATOR|Defibrotide/LPS|"2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
62445107|NCT01766674|EXPERIMENTAL|Kyphosis spinal exercises|Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
62445108|NCT01766674|NO_INTERVENTION|Control|Control group will be enrolled in the usual care waitlist group
62840964|NCT02876601|PLACEBO_COMPARATOR|Placebo/LPS|"2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
62056316|NCT02500329|ACTIVE_COMPARATOR|acarbose|acarbose for 4 weeks
62445109|NCT03635853|EXPERIMENTAL|patients with palmar arsenical keratosis|patients are given an ointment containing extract from cock's comb twice daily for three months
62445110|NCT05492071|EXPERIMENTAL|Local Vibration Application Following Flow-Mediated Dilation Application|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure). Vibration is applied with a commercially available vibration plate to forearm at 20 hz and 3 mm of vertical amplitude for 5 minutes, 30 minutes after termination of FMD.
62056317|NCT00740961||Patients with cancer|Patients ≥ 65 years with new stage I-III breast or colon cancer seeking care. Patients will be matched on baseline scores, age and sex. Patients will be age and sex matched due to the known relation between inflammatory markers and demographic characteristics39,40, and will be matched on baseline VES scores to ensure similar baseline VES-13 scores between groups and which will then allow us to then assess effect of cancer treatment on outcomes.
62056318|NCT00740961||Patients without cancer|non-cancer patients, seeking care at out-patient clinics
62445111|NCT05492071|EXPERIMENTAL|Flow-Mediated Dilation Application|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure).
62445112|NCT00297271||Mild cognitive impairment or dementia|Patients with mild cognitive impairment or dementia.
62445113|NCT02491788|EXPERIMENTAL|Drug|10 mg of suvorexant 30 minutes prior to daytime sleep opportunity
62840965|NCT02876601|OTHER|Defibrotide/Placebo|"Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
62840966|NCT02876601|OTHER|Placebo/Placebo|"Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
62840967|NCT00111852|EXPERIMENTAL|Desmoteplase, low dose|Desmoteplase 90 mcg/kg, intravenous administration.
62840968|NCT00111852|EXPERIMENTAL|Desmoteplase, high dose|Desmoteplase 125 mcg/kg, intravenous administration.
62840969|NCT00111852|PLACEBO_COMPARATOR|Placebo|Dose-Match Placebo, intravenous administration.
62056319|NCT00800202|EXPERIMENTAL|1|
62056320|NCT00800202|EXPERIMENTAL|2|
62259080|NCT00182156||1|conventional HD
62259081|NCT00182156||2|short daily HD
62259082|NCT00182156||3|PD
62259083|NCT01317862|ACTIVE_COMPARATOR|Transcervical foley catheter|
62840970|NCT00891670|ACTIVE_COMPARATOR|triple group|received cilostazol 100 mg twice daily in addition to aspirin 100mg and clopidogrel 75mg once daily
62056321|NCT06524999|EXPERIMENTAL|Progressive muscle relaxation|"The researcher provided the intervention group participants face-to-face training on progressive relaxation exercises (PREs) at the first hospitalization. She had developed A Guide to Progressive Relaxation Exercises based on a literature review. The guide consisted of 22 steps. After the briefing, the researcher asked each intervention group participant to perform the PREs with voice instructions. The study continued with participants who performed the PRE steps correctly. While the participant was performing PREs, the researcher guided her verbally in line with the guide. After the nurse teaches the PRE technique once, the individual can apply it.~Progressive relaxation exercises are performed for about 15-30 minutes."
62056322|NCT06524999|NO_INTERVENTION|Control|In this group, participant were assessed without any other intervention.
62259084|NCT01317862|ACTIVE_COMPARATOR|Prostaglandins|
62056323|NCT01055925|ACTIVE_COMPARATOR|MPV|
62056324|NCT01055925|ACTIVE_COMPARATOR|Aquacel|
62056325|NCT04543006|OTHER|Covid-19|only arm: Covid-19 proven by PCR
62259085|NCT04518462|EXPERIMENTAL|EXPAREL arm|Subjects randomized to this treatment arm will receive 20 mL (266 mg)EXPAREL mixed with 20 mL saline
62445114|NCT02491788|PLACEBO_COMPARATOR|Placebo|Placebo pill 30 minutes prior to daytime sleep opportunity
62840971|NCT00891670|ACTIVE_COMPARATOR|high maintenance dose group|received clopidogrel 150 mg/day with aspirin 100mg once daily
62840972|NCT06369727|EXPERIMENTAL|MOB015B|Patches were applied to the infrascapular area
62840973|NCT06369727|PLACEBO_COMPARATOR|Vehicle|Patches were applied to the infrascapular area
62445115|NCT03982433|EXPERIMENTAL|Intervention|participants all receive the intervention
62445116|NCT03290534|EXPERIMENTAL|CivaSheet Directional LDR Brachytherapy|FDA Cleared CivaSheet directional Pd-103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
62056326|NCT02310022|EXPERIMENTAL|Drug Omega 3|4g (4 capsules) once a day, administered with food Other name MAT9001
62056327|NCT02310022|ACTIVE_COMPARATOR|Drug Omega 3 Comparator|4g (4 capsules) once a day, administered with food Other name Omega 3 Active Comparator
62056328|NCT02273284|EXPERIMENTAL|Buzzy|Participants will use the Buzzy, a small vibration device during their Botulinum toxin treatments. The Buzzy will be held over the injection site for 30 sec prior to the injection, then will be moved more rostral during the actual injection. The Buzzy will be applied in the same fashion to each targeted muscle.
62056329|NCT02273284|NO_INTERVENTION|control - no Buzzy|Participants in the control group will receive their regular Botulinum toxin treatment without the use of the Buzzy
62840974|NCT06369727|OTHER|Negative irritant solution (0.9% saline)|Patches were applied to the infrascapular area
62259086|NCT04518462|EXPERIMENTAL|EXPAREL admix arm|subjects randomized to this treatment arm will receive 20 mL (266 mg)EXPAREL admixed with 20 mL (50 mg) 0.25% bupivacaine HCl.
62259087|NCT04518462|ACTIVE_COMPARATOR|Bupivacaine HCl Arm|subjects randomized to this treatment arm will receive 40 mL (100 mg)0.25% bupivacaine HCl.
62259088|NCT02373059|EXPERIMENTAL|Pharmaceutical care with shared decision making|Use of Diabetes Issue Cards Decision Aids
62259089|NCT02373059|ACTIVE_COMPARATOR|Usual Pharmaceutical care|Usual Care
62259090|NCT02841397|EXPERIMENTAL|Test group|All subjects will be enrolled into the test group and will receive Masimo Pulse CO-Oximeter for measurement of various physiological parameters.
62840975|NCT04449263|EXPERIMENTAL|Lens A (Test)|Subjects will be randomized to wear Lens A (test) the control Lens B for 2 weeks in this randomized, cross-over bilateral dispensing study.
62840976|NCT04449263|ACTIVE_COMPARATOR|Lens B (Control)|Subjects will be randomized to wear Lens B (control) and Lens A (Test) for 2 weeks in this randomized, cross-over bilateral dispensing study.
62840977|NCT04449263|ACTIVE_COMPARATOR|Habitual Lenses|All subjects will wear their habitual lenses for two weeks prior to randomization of Test lens A and control lens B.
62840978|NCT04655352||Bacillus subtilis MB40|1-week placebo (maltodextrin and excipients) lead-in followed by MB40 intervention
62259091|NCT02613962|EXPERIMENTAL|relapsed or refractory pediatric tumor|This is a prospective, international, multicentric clinical proof-of-concept study to stratify targeted therapies adapted to molecular profiling of relapsed or refractory pediatric tumors. The molecular screening will be done on a newly biopsied or resected tumor sample obtained at the time of relapse/progression, using high-throughput technologies, primarily WES and RNA Sequencing, and bioinformatics analysis.
62259092|NCT00402649|EXPERIMENTAL|1|All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.
62259093|NCT02839265|EXPERIMENTAL|SBRT + FLT3 Ligand Immunotherapy|"Patients will be treated with stereotactic body radiotherapy (SBRT) to a single pulmonary or extrapulmonary lesion as well as FLT3 immunotherapy.~FLT3 Ligand Therapy (CDX-301)~* Daily subcutaneous injections of CDX-301 (75 ug/kg) will be administered for 5 days, beginning on the first day of SBRT.~* Additional cycles of SBRT (to distinct lesions) and CDX-301 may be administered every 2-4 months to subjects who demonstrate evidence of clinical benefit (lack of treatment-related toxicity and no disease progression).~* Study therapy will be discontinued in cases of treatment-related toxicity or disease progression."
62259094|NCT02076997|EXPERIMENTAL|Individualized High Dose Methotrexate|Individualized high dose methotrexate given as a 24-hour infusion.
62259095|NCT01737385||Type 1|One segment fracture
62259096|NCT01737385||Type 2|Two segment fracture
62259097|NCT01737385||Type 3|Three segment fracture
62259098|NCT01737385||Type 4|Four segment fracture
62259099|NCT03947489|EXPERIMENTAL|Anpl-one SR Tab. 300mg|a single oral dose administration in healthy volunteers under fasting condition
62616135|NCT02268682|EXPERIMENTAL|Patient-Guided|Over an 8-month period, patients in the Patient-Guided intervention condition will receive four educational modules and twelve transplant education postcards in the mail. Modules will be mailed once every other month and consist of an introductory letter, a transplant video, and printed resources. Transplant education postcard will be mailed every two weeks following the mailing of each module, for a total of three postcards over the course of 6-weeks.
62616136|NCT02268682|EXPERIMENTAL|Educator-Guided|Patients in the Educator-Guided intervention condition will receive the same intervention components as those in the Patient-Guided condition; however, the key difference in this condition is that Educator-Guided patients will also receive telephonic support from an experienced clinical social worker in the role of a Transplant Educator to maximally facilitate learning. Telephonic meetings with the Transplant Educator will occur after the mailing of each study module, for a total of four calls, each lasting 20-minutes, totaling 1 hour and 20 minutes. Finally, Patient-Guided and Educator-Guided patients will have the option of enrolling in an educational text messaging service designed to supplement the ET education they are receiving in the mail.
62840979|NCT02149901|EXPERIMENTAL|Pseudoephedrine + 480 ml water|Pseudoephedrine 30 mg PO 45 minutes before water 480 ml
62840980|NCT02149901|PLACEBO_COMPARATOR|Pseudoephedrine + 50 ml water|Pseudoephedrine 30 mg PO 45 minutes before water 50 ml
62840981|NCT02149901|EXPERIMENTAL|Placebo + 480 ml water (optional)|Placebo PO 45 minutes before water 480 ml
62840982|NCT02149901|PLACEBO_COMPARATOR|Placebo + 50 ml water (optional)|Placebo PO 45 minutes before water 50 ml
62840983|NCT04021641||Participants with Typical Hearing|From 5 age groups from their 6 years of age to adulthood
62840984|NCT04021641||Participants with Hearing Impairment|Participants with various degree of hearing impairment
62840985|NCT05060601|EXPERIMENTAL|Gracey micro-curettes|Subgingival mechanical debridement will be performed using an ultrasonic scaler with specific thin tips and Gracey micro-curette.
62840986|NCT05060601|ACTIVE_COMPARATOR|Standard Gracey curettes|Subgingival mechanical debridement will be performed using a conventional ultrasonic scaler and standard Gracey curettes.
62840987|NCT03358264|EXPERIMENTAL|Type 2 diabetic patients|L-citrulline at a dose of 2000 mg per day for a period of 1 month will be administered to type 2 diabetic patients with HbA1c\>6
62840988|NCT03358264|EXPERIMENTAL|Healthy volunteers|L-citrulline at a dose of 2000 mg per day for a period of 1 month will be administered to non-diabetic healthy volunteers
62840989|NCT04367818|ACTIVE_COMPARATOR|Peri-anal local anaesthetic infiltration|Patients in this group will receive the prepared anesthetic mixture (bupivacaine 0.25% in dose of 1ml\\kg plus dexametomidine 2ug\\kg diluted in 0.5ml of normal saline) in a syringe will be connected to 22_ gauge short, beveled needle. The technique of the block will be done guided by Nystrom et al.
62840990|NCT04367818|ACTIVE_COMPARATOR|caudal anaesthesia|Patients in this group will receive caudal block using 22_gauge short, beveled cannula or needle, The prepared anesthetic mixture (bupivacaine 0.25% in dose of 1ml\\kg plus dexametomidine 2ug\\kg diluted in 0.5ml of normal saline).
62840991|NCT05411952|EXPERIMENTAL|education-mother and child dyad|Mother and child dyad have received dietary intervention for 6 months
62259100|NCT03947489|ACTIVE_COMPARATOR|Sarpodipil SR Tab. 300mg|a single oral dose administration in healthy volunteers under fasting condition
62259101|NCT05767177|EXPERIMENTAL|High Carbohydrate Diet vs High Fat Diet|"In the current project, the situation applies to individuals with obesity (body mass index (BMI) 35 to 45 kg/m2). In one case the diet is of the type high-carbohydrate diet and in the other case high-fat diet. The idea is that the research subjects should subsist on these diets for the respective 14 days. The energy content of the diet periods must be the same and correspond to the participants' daily needs. Each participant is drawn to one diet for 2 weeks. After a break of at least 3 weeks, the second diet is taken for 2 weeks."
62840992|NCT05411952|EXPERIMENTAL|education-only child|Children have received dietary intervention for 6 months. But their mothers didn't receive any dietary intervention
62840993|NCT05411952|EXPERIMENTAL|control|Control group did't receive any dietary intervention during the study
62840994|NCT04265105|ACTIVE_COMPARATOR|standard of care|Short acting beta agonist or inhaled corticosteroids
62259102|NCT03027362|EXPERIMENTAL|Cognitive behavioral therapy (CBT) and medication|Following clinical ketamine treatment, the intervention includes sixteen CBT sessions over 14 weeks. In addition, standard of care medications for treatment of depression, will be prescribed by the principal investigator or by a psychiatrist unaffiliated with the trial. Participants will remain on the medication they were prescribed when they entered the study and will be expected not to adjust the medication unless clinically urgent.
62259103|NCT03027362|ACTIVE_COMPARATOR|Psychoeducation and medication|Following clinical ketamine treatment, the intervention includes psychoeducational sessions over 14 weeks.In addition, standard of care medications for treatment of depression, will be prescribed by the principal investigator or a by psychiatrist unaffiliated with the trial.
62616137|NCT03907670||CML patients who will receive imatinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment (imatinib)measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
62259104|NCT00393887|EXPERIMENTAL|1|Biodesign IHM Graft placement
62259105|NCT00393887|ACTIVE_COMPARATOR|2|Polypropylene mesh placement
62259106|NCT01991990|PLACEBO_COMPARATOR|Placebo|
62259107|NCT01991990|EXPERIMENTAL|RoActemra/Actemra|
62616138|NCT03907670||CML patients who will receive nilotinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment(nilotinib)measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
62616139|NCT03907670||CML patients who will receive dasatinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment(dasatinib) measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
62616140|NCT02380963|EXPERIMENTAL|Colorado Diet with soy protein|
62259108|NCT02001961||Heart failure|Patients will be recruited from the heart failure clinic by their consultant. These will include patients who are due to have a MRI scan for clinical reasons and those who volunteer to participate. Voluntary subjects will be over 8 years.
62259109|NCT02001961||Control|Control subjects will be identified after being referred for an MRI scan and being allocated to a non-cardiac MRI with gadolinium contrast.
62259110|NCT01049685|ACTIVE_COMPARATOR|Efavirenz Group|Naïve-treatment HIV patients, who started therapy with Efavirenz
62259111|NCT01049685|ACTIVE_COMPARATOR|Lopinavir/r Group|Naïve-treatment HIV patients, who started therapy with Lopinavir/ritonavir
62259112|NCT06140004||HBPC Site 1: Northern/East California|This site implemented an evidence-based model of HBPC that consists of home visits by a trained, interdisciplinary palliative care team composed of a physician, nurse, social worker, and spiritual counselor. At this site, this core team was housed in an independent hospice agency and was also convened in-house by the ACO contract or MA plan. The insurance provider contracts with the core team, using a per member per month payment for patients enrolled in HBPC. The core team will provide pain and symptom management, psychosocial support, advanced care planning, disease management education, spiritual counseling, grief counseling, and other services in response to patient and caregiver needs. HBPC patients and their caregivers also will have access to a 24/7 helpline.
62616141|NCT02380963|ACTIVE_COMPARATOR|Colorado Diet|
62616142|NCT02764203|EXPERIMENTAL|Chocolate consumption|Subjects will consume 50g of dark chocolate for 2 weeks and have their blood pressure compared before chocolate and after chocolate
62840995|NCT04265105|EXPERIMENTAL|fluticasone-vilanterol|LABA-ICS A combination of Long acting beta agonist and inhaled corticosteroid
62840996|NCT02223845|EXPERIMENTAL|Music|Played music during embryo transfer
62840997|NCT02223845|NO_INTERVENTION|Control|No music played during embryo transfer
62840998|NCT04350957|EXPERIMENTAL|Low-dose Imaging|Enrolled patients will undergo two separate dynamic contrast-enhanced MRI's, one with 25% of the contrast dose and one with 100% of the contrast dose recommended by weight. During the first visit, the subject will receive 25% of the standard dose of contrast media 0.1 mM/kg will be administered at 2 mls/second followed by the acquisition of a series of DCE images. On the second visit, the subject will receive 100% of the contrast media followed by the same imaging protocol as the one subsequent to the first contrast administration.
62840999|NCT02747498|ACTIVE_COMPARATOR|circumferential pulmonary vein isolation|Procedure with circumferential pulmonary vein isolation for atrial fibrillation
62841000|NCT02747498|EXPERIMENTAL|Posterior box isolation in addiction to pulmonary vein isolation|Posterior box isolation in addiction to circumferential pulmonary vein isolation
62841001|NCT03414931|EXPERIMENTAL|NMDAE|An NMDA enhancer
62841002|NCT03414931|ACTIVE_COMPARATOR|SSRI|Sertraline
62841003|NCT03414931|PLACEBO_COMPARATOR|Placebo|Placebo
62841004|NCT01696188|EXPERIMENTAL|In-plane group|This group will receive an interscalene catheter placed with in-plane approach.
62841005|NCT01696188|EXPERIMENTAL|Out-of-plane group|This group will receive an interscalene catheter with an out-of-plan approach.
62841006|NCT02559804||patients NB with SCI|Survival and late effects. Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse/progression).
62841007|NCT00032552||1|
62841008|NCT04781959|ACTIVE_COMPARATOR|5 Days of Filgrastim|Receive filgrastim subcutaneous injection once daily for five consecutive days starting 24-72 hours after chemotherapy.
62841009|NCT04781959|ACTIVE_COMPARATOR|Pegfilgrastim|Receive pegfilgrastim as a single dose subcutaneous injection 24-72 hours after chemotherapy
62841010|NCT01694797|EXPERIMENTAL|Metoprolol Succinate ER Tablets, 50 mg|Metoprolol Succinate ER Tablets, 50 mg of Dr.Reddy's Laboratories Ltd
62841011|NCT01694797|ACTIVE_COMPARATOR|TOPROL-XL ER Tablets 50 mg|TOPROL-XL ER Tablets 50 mg of AstraZeneca
62841012|NCT05191420||Virtual topical discussion guide|Study will pilot test this virtual topical discussion guide to assess feasibility and acceptability by diverse patient populations.
62841013|NCT01531569|EXPERIMENTAL|BeneFlax|BeneFlax given as a single oral dose to assess pharmacokinetics
62259113|NCT06140004||HBPC Site 2: Northern/West California|This site implemented an evidence-based model of HBPC that consists of home visits by a trained, interdisciplinary palliative care team composed of a physician, nurse, social worker, and spiritual counselor. At this site, this core team was housed in an independent hospice agency and was also convened in-house by the ACO contract or MA plan. The insurance provider contracts with the core team, using a per member per month payment for patients enrolled in HBPC. The core team will provide pain and symptom management, psychosocial support, advanced care planning, disease management education, spiritual counseling, grief counseling, and other services in response to patient and caregiver needs. HBPC patients and their caregivers also will have access to a 24/7 helpline.
62616143|NCT01162122|EXPERIMENTAL|aTIV|Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).
62616144|NCT01162122|EXPERIMENTAL|Licensed TIV|Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).
62616145|NCT00135590|EXPERIMENTAL|1|Protein pulse-feeding
62616146|NCT00135590|ACTIVE_COMPARATOR|2|Spread diet
62616147|NCT03067259|NO_INTERVENTION|Control Group|It comprises patients who will not undergo any surgical / anesthetic act
62616148|NCT03067259|OTHER|Exposure Group|It comprises those patients that will undergo sedation for diagnostic procedure or some surgical / anesthetic process
62616149|NCT06337747|ACTIVE_COMPARATOR|Traditional technique|
62259114|NCT06140004||HBPC Site 3: Southern California|This site implemented an evidence-based model of HBPC that consists of home visits by a trained, interdisciplinary palliative care team composed of a physician, nurse, social worker, and spiritual counselor. At this site, this core team was housed in an independent hospice and home health agency and was also convened in-house by the ACO contract or MA plan. The insurance provider contracts with the core team, using a per member per month payment for patients enrolled in HBPC. The core team will provide pain and symptom management, psychosocial support, advanced care planning, disease management education, spiritual counseling, grief counseling, and other services in response to patient and caregiver needs. HBPC patients and their caregivers also will have access to a 24/7 helpline.
62259115|NCT05883462|EXPERIMENTAL|Single arm treated by Airiver Nasal DCB|Subjects with recurrent symptomatic nasal obstruction will be treated by Airiver Nasal Drug Coated Balloon (DCB) Catheter at the index procedure. The balloon is coated with a paclitaxel drug (3.5ug/mm2).
62259116|NCT04986306||clinical tumor stage 1-3 (cT1-3) and nodal stage 1 (cN1) breast cancer patients|Patients who will undergo neoadjuvant chemotherapy were asked to participate in this study. Informed consent will be given. Clip will be placed over the positive lymph node by surgeon which was proven by fine-needle aspiration cytology. After completion of neoadjuvant chemotherapy, surgery of the breast and the axilla was executed in the same session. Different surgeons performed the procedure.
62259117|NCT01402609|PLACEBO_COMPARATOR|Control group, usual care|Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
62056330|NCT06325748|EXPERIMENTAL|SENTI-202 CAR NK cell therapy|"Part 1 Dose Finding: Sequential cohorts will receive doses of SENTI-202 using a modified 3+3 study design to determine the recommended phase 2 dose (RP2D). The starting dose will be 1 billion cells. Other doses may be explored depending on study data.~Part 2 Cohort Expansion: After determination of the RP2D, additional subjects will be enrolled in disease-specific expansion cohorts at that dose to further explore safety, biodynamics, and anti-cancer activity of SENTI-202"
62056331|NCT00704301|EXPERIMENTAL|1|Haloperidol: aged 70 years or less: 1 mg haloperidol three times a day i.v. older than 70 years: 0,5 mg haloperidol three times a day i.v. Rivastigmine: two times 1,5 mg a day; The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
62259118|NCT01402609|EXPERIMENTAL|electronic discharge communication tool|Patients allocated to the experimental arm will receive a copy of the discharge summary that is generated by the electronic discharge communication tool. The same copy is shared with their healthcare providers using an electronic, web-based, communication platform that allows communication between acute-care and community -care physicians. The electronic discharge communication tool allows physicians to start generating the discharge summary from time of admission to hospital.
62616150|NCT06337747|EXPERIMENTAL|Extended technique|
62616151|NCT02548884|ACTIVE_COMPARATOR|Pancreatic sphincterotomy|Pancreatic sphincterotomy technique used in difficult biliary cannulation
62616152|NCT02548884|ACTIVE_COMPARATOR|Double guide wire|Double guide wire technique used in difficult biliary cannulation
62841014|NCT02668536|EXPERIMENTAL|UV Filter + BNP|A UV filtering agent and bioadhesive nanoparticles (BNPs) will comprise the experimental condition in this study. Participants will have 5 sites on their torso where they will have these placed.
62841015|NCT02668536|SHAM_COMPARATOR|BNP only|A placebo bioadhesive nanoparticles (BNPs) (strips with no UV filtering) will comprise the sham comparison in this study. Participants will have 5 sites on their torso where they will have these placed.
62616153|NCT06311526||Stroke patients suffering a spastic upper limb paresis|
62616154|NCT04468815|EXPERIMENTAL|Treatment A: BMS-986278 suspension, fasted|
62616155|NCT04468815|EXPERIMENTAL|Treatment B: BMS-986278 tablet, fasted|
62616156|NCT04468815|EXPERIMENTAL|Treatment C: BMS-986278 tablet, fed|
62616157|NCT04468815|EXPERIMENTAL|Treatment D: BMS-986278 tablet + esomeprazole capsule, fasted|
62841016|NCT02668536|ACTIVE_COMPARATOR|Standard|As the active comparator, participants will have 5 sites on their torso where they will have standard sunscreen applied.
62616158|NCT04544553|OTHER|SMS reminder|This arm receive SMS reminder for the follow-up of DR Screening
62616159|NCT04544553|OTHER|No SMS reminder|This arm did not receive SMS reminder for the follow-up of DR Screening
62616160|NCT05562141||With lidocaine|Patient with injection of a 1.5 mg/kg bolus of lidocaine at induction of anaesthesia
62616161|NCT05562141||Without lidocaine|Patient without injection of a 1.5 mg/kg bolus of lidocaine at induction of anaesthesia
62616162|NCT04891627||Healthy control groups|individuals with clinically healthy gingiva BOP score less than 10% and PD≤3mm
62841017|NCT02668536|NO_INTERVENTION|Control|Participants will have 5 sites on their torso where no agent will be applied.
62841018|NCT01724632|ACTIVE_COMPARATOR|Group Treatment|Participants who are assigned to group treatment will attend group meetings weekly for the first 6 months, then every 2 weeks for 6 months, and then monthly for the final 6 months. Participants will be weighed individually at the start of each group meeting.
62841019|NCT01724632|ACTIVE_COMPARATOR|Individual Treatment|Participants who are assigned to individual treatment will attend one-on-one sessions with a weight loss counselor every month for 18 months.
62841020|NCT01724632|EXPERIMENTAL|Smartphone Treatment|Participants who are assigned to smartphone treatment will use a smartphone to learn and practice weight loss skills. They will also attend one-on-one sessions with a weight loss counselor every month for 18 months.
62841021|NCT05828485|EXPERIMENTAL|Sequence 1 : AB|6 subjects were given a single dose of MY008211A tablets in the fasting state and, after a 5-day washout period, a single dose of MY008211A tablet was administered after taking a standard high-fat and high-calorie fed.
62841022|NCT05828485|EXPERIMENTAL|Sequence 1 : BA|6 subjects were given a single dose of MY008211A tablet after taking a standard high-fat and high-calorie fed and, after a 5-day washout period, a single dose of MY008211A tablet in the fasting state.
62841023|NCT03959267|NO_INTERVENTION|Usual Care|Participants will continue with their usual medical care. Usual care may vary at different sites. Based on the investigator's preliminary data usual care can result in not GCRA referral, referral directly to testing, or referral to genetic counseling with an interpreter. The investigators will document usual care for participants from the sites randomized to usual care.
62841024|NCT03959267|OTHER|Telephone Genetic Counseling|Participants will receive telephone genetic counseling with the culturally adapted protocol and booklet
62841025|NCT03171467|EXPERIMENTAL|Salpingectomy|Opportunistic salpingectomy at the time of laparoscopic cholecystectomy
62259119|NCT03631784|EXPERIMENTAL|Cohort A|Participants received 1 cycle of carboplatin area under the curve (AUC) 6 mg/mL/min with paclitaxel 200 mg/m\^2 and pembrolizumab 200 mg on Day 1. Approximately 3 weeks later, participants received carboplatin AUC 2 mg/mL/min with paclitaxel 45 mg/ m\^2 administered weekly for 6 weeks along with 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) in conjunction with standard thoracic radiotherapy (TRT) (60 Gray \[Gy\] in 2 Gy fractions administered 5 days per week for 6 weeks). Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days.
62259120|NCT03631784|EXPERIMENTAL|Cohort B|Participants received 3 cycles of cisplatin 75 mg/m\^2 with pemetrexed 500 mg/m\^2 and pembrolizumab 200 mg on Day 1 of each cycle. Treatment was given in conjunction with standard TRT (60 Gy in 2 Gy fractions administered 5 days per week for 6 weeks) in cycles 2 and 3. Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days.
62259121|NCT03061032|EXPERIMENTAL|Sofosbuvir/Ledipasvir for 12W|"Patients without cirrhosis and previous history of treatment will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks."
62259122|NCT03061032|EXPERIMENTAL|Sofosbuvir/Ledipasvir+Ribavirin for 12W|"Patients with compensated cirrhosis and/or previous history of treatment will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks."
62259123|NCT03061032|EXPERIMENTAL|Sofosbuvir/Ledipasvir for 24W|"Patients with compensated or decompensated cirrhosis and/or previous history of treatment and with contraindication of Ribavirin will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks."
62259124|NCT03061032|EXPERIMENTAL|Sofosbuvir/Ledipasvir+Ribavirin for 24W|Patients with decompensated cirrhosis will be treated with this regimen. Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
62616163|NCT04891627||Periodontitis group|interdental AL ≥5 mm
62616164|NCT04891627||Periodontitis with diabetes group|HbA1c ≥6.5%
62616165|NCT05232799|EXPERIMENTAL|Care Anywhere with Community Paramedics program|Subjects will be discharged from a pre-hospital setting, Emergency Department or the hospital with community paramedic services ordered and overseen by the treating clinical team per current standard of care.
62259125|NCT03203044|NO_INTERVENTION|Regular Diet Arm|Maintains a regular diet for the duration of the study.
62259126|NCT03203044|EXPERIMENTAL|Soylent Diet Arm|Receives a Soylent dietary intervention on days 3-6 of the study.
62259127|NCT06087796|ACTIVE_COMPARATOR|Topical betamethasone|"Group A will include 20 patients and will receive topical betamethasone valerate 0.1% cream.~Treatment will be applied twice daily for 6 months or until complete resolution, whichever is sooner."
62616166|NCT05232799|NO_INTERVENTION|Standard of Care|Subjects will receive continued usual care
62616167|NCT00123656|ACTIVE_COMPARATOR|1|fluticasone
62616168|NCT00123656|ACTIVE_COMPARATOR|2|esomeprazole
62841026|NCT05785442|PLACEBO_COMPARATOR|Placebo|Treatment Arm 1: patients receiving placebo (N/S 0.9% w/v) subcutaneously once daily for 10 days plus Standard of Care
62841027|NCT05785442|ACTIVE_COMPARATOR|Anakinra|Treatment Arm 2: patients receiving anakinra subcutaneously 100 mg once daily for 10 days plus Standard of Care
62616169|NCT01244217|EXPERIMENTAL|Age 6 months - 2 years|Patients between 6 months and 2 years old
62616170|NCT01244217|EXPERIMENTAL|Age 2 - 11 years|Patients between 2 and 11 years (and under 10.5 kg)
62616171|NCT01244217|EXPERIMENTAL|Age 2 - 11 years (and over 10.5 kg)|Patients between 2 and 11 years (and over 10.5 kg)
62616172|NCT05063526||Group B|"40 patients who are mechanically ventilated due to pulmonary disease at respiratory ICU had their diagnosis as follows: 21 (53%) had COPD, 8 (20%) had asthma, 5 (13%) had bronchiectasis, 5 (13%) had pneumonia and~1 (3%) had viral influenza H1N1. Out of group B patients, 11 patients (13.75%) had failed weaning, of which 6 patients needed reintubation and 5 patients needed non-invasive positive ventilation of which 3 patients were re-intubated and 2 patients died."
62841028|NCT03714152|EXPERIMENTAL|ABI-H2158|ABI-H2158 in varying doses of tablets by mouth without and with food for 1 day or 10 days
62841029|NCT03714152|PLACEBO_COMPARATOR|Matching Placebo for ABI-H2158|Matching Placebo in varying doses of tablets by mouth without and with food for 1 day or 10 days
62056332|NCT00704301|PLACEBO_COMPARATOR|2|Haloperidol: aged 70 years or less: 1 mg haloperidol three times a day i.v. older than 70 years: 0,5 mg haloperidol three times a day i.v. Placebo: 2 times a day
62616173|NCT05063526||Group A|40 patients on mechanical ventilation due to non-pulmonary disease at respiratory ICU had their diagnosis as follows: 24 (60%) had congestive heart failure, 4 (10%) had diabetes mellitus, 4 (10%) had sepsis other than pneumonia, 2 (5%) had epilepsy, 2 (5%) had embolic hemiplegia, and 4 (10%) had chronic renal failure. Out of group A patient, 9 patients (11.25%) had failed weaning of which 4 patients needed reintubation and 5 patients needed non-invasive positive ventilation of which 2 patients were reintubated and 3 patients died.
62259128|NCT06087796|EXPERIMENTAL|Topical pentoxifylline|"Group B will include 20 patients who will receive topical pentoxifylline 2% gel.~Treatment will be applied twice daily for 6 months or until complete resolution, whichever is sooner."
62259129|NCT06087796|EXPERIMENTAL|Topical metformin|Group C will include 20 patients who will receive topical metformin 10% gel. Treatment will be applied twice daily for 6 months or until complete resolution, whichever is sooner.
62259130|NCT00800293||Cohort Group 1|Subject Numbers 1 to 29
62259131|NCT00800293||Cohort Group 2|Subject Numbers 20 to 59
62259132|NCT00800293||Cohort Group 3|Subject Numbers 60 to 89
62259133|NCT00800293||Cohort Group 4|Subject Numbers 90 to 116
62259134|NCT02835001|OTHER|Patient with severe emphysema|Patients with severe emphysema, stable, symptomatic, not controlled despite of international recommendations treatments will have bronchoscopy
62259135|NCT00923130|EXPERIMENTAL|Bevacizumab with Ixabepilone|Bevacizumab 15mg/kg every 3 weeks Ixabepilone given on days 1,2,3,4 and 5 of each three week cycle at a dose of 6mg/m(2)/day
62259136|NCT04819152||Exposed|Several studies will be performed based on this cohort. I each study the exposed group will be a group of tobacco users evaluatedin the relevant study. This could be a vulnarable group tobacco users such as: users without a job, with short or no education, without permanent housing, diagnosed with mental illness, diagnosed with chronic obstructive pulmonary disease (COPD), undergoing surgery, adolescents, elderly, migrants, or pregnant women.
62259137|NCT04819152||Unexposed|In each study the unexposed group will consist of tobacco user from the study cohort without the condition examined in the relevant study.
62259138|NCT03380455|EXPERIMENTAL|Treatment period A & B|"Treatment period A: Subjects receive a single oral dose of 500 mg lucerastat on Day 1 under fasted conditions.~Treatment period B: From Day 3 to Day 9, subjects receive a b.i.d. (every 12 h) oral dose of 800 mg cimetidine under fasted conditions (Treatment period B1; from Day 3 to Day 5). On Day 6, subjects receive a single oral dose of 500 mg lucerastat concomitantly with the morning dose of 800 mg cimetidine under fasted conditions (Treatment period B2; from Day 6 to Day 10)."
62259139|NCT00614887||2|Patients scheduled for elective cerebral aneurysmal surgery
62259140|NCT00614887||1|Patients with subarachnoid hemorrhage
62616174|NCT05063526||control group.|40 patients Chronic obstructive pulmonary disease (COPD) from Outpatient Clinic
62056333|NCT05367063|ACTIVE_COMPARATOR|Canagliflozin group|On the basis of the original metformin medication, the experimental group took canagliflozin 1 tablet (100 mg) orally once a day (qd) before the first meal of the day, and the dosing cycle lasts 6 months.
62259141|NCT01217632|PLACEBO_COMPARATOR|FG-3019 Placebo|Placebo will be administered at 15-45 mg/kg every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
62259142|NCT01217632|EXPERIMENTAL|FG-3019|FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
62259143|NCT04623684|EXPERIMENTAL|Study Group|Mydriasis with microdrops
62259144|NCT04623684|ACTIVE_COMPARATOR|Control Group|Mydriasis with standard drops
62259145|NCT01666431|OTHER|Lapatinib|
62259146|NCT00816426|OTHER|1|Dosing 2 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
62259147|NCT00816426|OTHER|2|Dosing 4 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
62259148|NCT00816426|OTHER|3|Dosing 8 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
62445117|NCT06031584|EXPERIMENTAL|Study treatment|Participants received BL-M07D1 therapy in the first cycle (3 weeks). Participants who had a clinical benefit could receive additional cycles of additional treatment. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
62616175|NCT06428994||ORN|ORN in this study is defined as exposed irradiated bone tissue that fails to heal over a period of three months without residual or recurrent tumors.
62616176|NCT06428994||non-ORN|Patients without ORN.
62616177|NCT04012307|OTHER|Sequence AB|20 subjects assigned to the sequence AB will receive a single 32 mg dose of the test product Candesartan Cilexetil (1 x 32 mg tablet), marked as A in the sequence, in Period 1 and a single 32 mg dose of the reference product Atacand® PROTECT (1 x 32 mg tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62056334|NCT05367063|PLACEBO_COMPARATOR|Sitagliptin group|On the basis of the original metformin medication, the experimental group took Sitagliptin 1 tablet (100 mg) orally once a day (qd) before the first meal of the day, and the dosing cycle lasts 6 months.
62056335|NCT04932499|ACTIVE_COMPARATOR|Control group|Standard of care
62056336|NCT04932499|EXPERIMENTAL|Mindfulness Meditation|Mindfulness meditation in addition to standard of care
62056337|NCT01875354|PLACEBO_COMPARATOR|Placebo and Low Fat Eating Plan|"Placebo Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Placebo Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Placebo Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)~The placebo group will be instructed to consume every day, a low fat standard of care eating plan delivering approximately 1200-1500 Kcals."
62056338|NCT01875354|EXPERIMENTAL|Dietary Supplements and TR90 Eating Plan|"Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)~Experimental group will be instructed to consume every day, dietary supplements and a moderate protein eating plan delivering approximately 1200-1500 Kcals."
62056339|NCT00264979|OTHER|1|Simultaneous surgery of colorectal cancer and synchronous liver metastases
62259149|NCT00816426|OTHER|4|Dosing 12 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
62259150|NCT00816426|OTHER|5|Dosing 24 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
62445118|NCT03179618|EXPERIMENTAL|Qi stagnation and blood stasis|Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.
62616178|NCT04012307|OTHER|Sequence BA|20 subjects assigned to the sequence BA will receive a single 32 mg dose of the reference product Atacand® PROTECT (1 x 32 mg tablet), marked as B in the sequence, in Period 1 and a single 32 mg dose of the test product Candesartan Cilexetil (1 x 32 mg tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62056340|NCT00264979|OTHER|2|Sequential surgeries of colorectal cancer and synchronous liver metastases
62056341|NCT04810221|EXPERIMENTAL|Experimental|Measure of SpO2 and HR obtained in enrolled subjects using BrOxy M and a reference pulse oximeter in paired observations
62056342|NCT00809692|ACTIVE_COMPARATOR|1|50 subjects with allergic disease receiving histamine challenges by the prick test and iontophoresis technique (serial assessment of blood flow using validated Doppler technique)
62056343|NCT00809692|EXPERIMENTAL|2|150 additional subjects with allergic disease; undergo genotyping; laser Dopper assessment
62259151|NCT01485939|PLACEBO_COMPARATOR|placebo patch|
62259152|NCT01485939|ACTIVE_COMPARATOR|lidocaine patch|
62616179|NCT04620694||Radial artery cannulation|Patients whom radial artery was cannulated at the beginning of the surgery.
62616180|NCT04620694||Aortic cannulation (brachial or femoral artery)|"Patients whom femoral or brachial artery was cannulated at the beginning of the surgery.~Active comparator"
62616181|NCT04823806|EXPERIMENTAL|Healthy participants and participants with depressive disorder: dietary spermidine supplementation|Dietary Supplement: Polyamine 21 days of spermidine supplementation (3 sachets/day = 6mg spermidine/day)
62616182|NCT04823806|PLACEBO_COMPARATOR|Healthy participants and participants with depressive disorder: dietary placebo supplementation|Dietary Supplement: Placebo 21 days of Placebo supplementation (3 sachets/day)
62616183|NCT03527862|NO_INTERVENTION|Control group|No intervention is performed. Lung ultrasonography is performed within 4 hours after surgery for diagnostic purpose.
62056344|NCT05706090|EXPERIMENTAL|Group USP|The group using ultrasound and injection pressure manometer was named USP
62056345|NCT05706090|EXPERIMENTAL|Group USPN|The group using ultrasound , injection pressure manometer , and neurostimulator was named USPN
62056346|NCT04532723|EXPERIMENTAL|ExoAtlet II|Safety/feasibility of utilizing the ExoAtlet II in a clinical setting with a group of individuals with SCI
62056347|NCT01936701|OTHER|acrylic 3-piece IOL|same-day bilateral cataract surgery with implantation of intraocular lens Domilens KS-XS in one eye
62259153|NCT02278900|EXPERIMENTAL|Communication aids|Patients in the intervention group will receive the QPL at home in advance of the consultation along with information about the clinic.The consultations will be recorded in both the control and intervention group. The recording will be done on the computer, and the patients in the intervention group will be given the recording immediately after the consultation on a memory stick.
62445119|NCT03179618|OTHER|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
62445120|NCT02346201|ACTIVE_COMPARATOR|Methylphenidate|Methylphenidate, target dose 20 mg per day (range 10-20 mg per day), in 5 mg over-capsulated tablets, and psychosocial intervention
62445121|NCT02346201|PLACEBO_COMPARATOR|Placebo|Matching over-encapsulated placebo and psychosocial intervention
62259154|NCT02278900|NO_INTERVENTION|Control group|No intervention.
62259155|NCT00257725|EXPERIMENTAL|ADHD Treatment Group|Single-arm, open-label, once-daily-dosing of long-duration beaded MPH (B-MPH) at 10-30 mg (flexible titration) in 4-to-5 year old children with ADHD.
62259156|NCT01403818|EXPERIMENTAL|Part 1|"Subjects will receive ASP1941 alone and ASP1941 + Mitiglinide calcium hydrate in different orders."
62259157|NCT01403818|EXPERIMENTAL|Part 2|"Subjects will receive Mitiglinide calcium hydrate alone and ASP1941 + Mitiglinide calcium hydrate in different orders."
62259158|NCT02952274|ACTIVE_COMPARATOR|locater attachment|mandibular overdenture retained with single midline implant using locator attachment
62259159|NCT02952274|ACTIVE_COMPARATOR|ball attachment|mandibular overdenture retained with single midline implant using ball attachment
62259160|NCT06092554|EXPERIMENTAL|Interventional: Probiotics|Patients will receive a four probiotic preparation (LactoLevure, UniPharma, Athens, Greece).) in capsules containing: Lactobacillus acidophilus LA-5 \[1.75 × 109 colony-forming units (cfu)\], Lactobacillus plantarum (0.5 × 109 cfu), Bifidobacterium lactis BB12 (1.75 × 109 cfu) and Saccharomyces boulardii (1.5 × 109 cfu).
62259161|NCT06092554|PLACEBO_COMPARATOR|Control: Placebo|Patients will receive a placebo in capsules containing powdered glucose polymer.
62259162|NCT02716987|EXPERIMENTAL|Set A: TAK-831 100 mg|TAK-831 100 milligram (mg), suspension, orally, once on Day 1 and up to 100 megabecquerel (MBq) of Positron Emission Tomography (PET) ligand PGM028299 labeled with \[18F\] (\[18F\]PGM299) with a maximal mass up to 12.5 microgram (mcg), injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
62259163|NCT02716987|EXPERIMENTAL|Set A: TAK-831 200 mg|TAK-831 200 mg, suspension, orally, once on Day 1 and up to 100 MBq of \[18F\]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
62259164|NCT02716987|EXPERIMENTAL|Set A: TAK-831 250 mg|TAK-831 250 mg, suspension, orally, once on Day 1 and up to 100 MBq of \[18F\]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
62259165|NCT02716987|EXPERIMENTAL|Set A: TAK-831 500 mg|TAK-831 500 mg, suspension, orally, once on Day 1 and up to 100 MBq of \[18F\]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
62259166|NCT02716987|EXPERIMENTAL|Set B: [18F]PGM299|\[18F\]PGM299 up to 100 MBq (with a maximal mass up to 12.5 mcg), injection, intravenously, prior to PET imaging on Days 1 and 10.
62445122|NCT02097121|EXPERIMENTAL|Botox 25 U|Participants randomized to receive 25 Units (U) BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits occurred at Weeks 2, 6, and 12. Participants could request retreatment from Week 12 and 12 weeks after each subsequent treatment for up to 4 cycles. The retreatment dose was determined by the Investigator and could be at the same dose or at the next higher dose compared with the preceding treatment.
62616184|NCT03527862|EXPERIMENTAL|lung ultrasonography group|Lung ultrasonography is performed three times; after tracheal intubation, before surgery end, and within 4 hours after surgery. In this group, respiratory management is performed according to diagnosis.
62616185|NCT05073861|EXPERIMENTAL|App-based STEM online learning group|Participants in the experimental group will receive a 2.5-month intervention with the blended STEM learning app.
62259167|NCT04928859||the albumin group|The albumin group, the patients who used albumin for resuscitation during their hospitalization in the burn ward constituted the albumin group.
62259168|NCT04928859||the control group|The control group, the patients who did not use albumin during their hospitalization in the burn ward constituted the control group.
62259169|NCT02011282|EXPERIMENTAL|Electro-Neuro-Muscular Stimulation|Patients will receive daily sessions of electrostimulation with a commercially available device (En-Stimulation 4, Netherlands) in the quadriceps muscle for 10 days
62259170|NCT02011282|NO_INTERVENTION|Control|Patients in this arm will receive the usual standard treatment
62056348|NCT01936701|OTHER|silicone 3-piece IOL|same-day bilateral cataract surgery with implantation of intraocular lens Domilens KS-3Ai in one eye
62056349|NCT02489110|EXPERIMENTAL|Webnovela|Caregivers will watch the Webnovela and read related information. The Webnovela is a short online Telenovela in Spanish, specifically designed for Hispanic caregivers on how to cope with dementia caregiving. A DVD will be available to participants without Internet access.
62616186|NCT05073861|ACTIVE_COMPARATOR|E-book learning group|The control group receive e-book chapters about STEM for learning for the same period of 2.5-month as the experimental group.
62616187|NCT05368909|EXPERIMENTAL|Arm 1 before Cross Over|Participants were randomized and divided into two groups: Supplement Group and Placebo Group. In this Arm 1, participants first go through a 1-week washout period, and then take either Supplement or Placebo as assigned for 2 week.
62056350|NCT02489110|ACTIVE_COMPARATOR|Control|Caregivers will be directed to existing web sites, such as NIA Alzheimer's and Dementia Resources in Spanish. Participants will receive related materials in Spanish language.
62056351|NCT01249469|PLACEBO_COMPARATOR|Vehicle|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand.
62056352|NCT01249469|EXPERIMENTAL|Skin whitening cosmetic product|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand.
62056353|NCT01905644|EXPERIMENTAL|With ultrasound|"Patients in this group will have perineal ultrasound for the detection of anal sphincter ruptures.~Intervention: Perineal ultrasound"
62056354|NCT01905644|NO_INTERVENTION|Without ultrasound|Patients in this group will not have perineal ultrasound for the detection of anal sphincter ruptures.
62056355|NCT05930197|EXPERIMENTAL|Interventional|The oral suspension formulation of BSS will be used in this study. It is self administered at 1050mg 4 times per day (1 to 6 hours apart) for 2 days.
62056356|NCT05490121|ACTIVE_COMPARATOR|Facilitator-Led VEGA|"Facilitator-led VEGA uses a group-based approach where participants complete the Violence, Evidence, Guidance, Action Project (VEGA) content as a virtual or face-to-face workshop. In this study, all workshops will be virtual to prevent social gathering during COVID-19.~If a participant is randomized to this arm, the active control (AC) arm, they will be informed that they need to attend a facilitator-led VEGA session via virtual workshop format. The AC intervention will be facilitated via Zoom technology, by two trained facilitators with between 10 to 20 participants in each workshop (keeping the recommended 10:1 participant-to-facilitator ratio) and will last approximately 3 hours. The workshop approach is delivered by trained facilitators and is standardized via the use of a flexibly structured facilitator's guide. Facilitator-led VEGA will deliver material didactically with synchronous lecturing, use case-based role play, and include group-based polling."
62616188|NCT05368909|EXPERIMENTAL|Arm 2 after Cross Over|In Arm 2, Supplement Group and Placebo Group cross over. After a 1-week washout period, and both group will take whatever product they did not take in Arm 2, for 2 week.
62056357|NCT05490121|EXPERIMENTAL|Self-Directed VEGA|"Self-directed VEGA uses an approach where participants complete the Violence, Evidence, Guidance, Action Project (VEGA) content online as a self-directed educational activity, at their own pace in a series of modules. Individuals will register to access the VEGA Educational Resources site. Participants have the option of completing the self-directed VEGA arm in either English or French as the VEGA Educational Resources site offers the content in French and English.~If a participant is randomized to the experimental arm, they will be asked to complete the self-directed VEGA at their convenience, within one week of when they are informed they have been asked to complete the self-directed VEGA program. It will take approximately 3 hours for participants to complete all modules.~Participants will read didactic material, complete case-based animated simulations, and complete individual multiple-choice questions with response feedback."
62056358|NCT05842655|EXPERIMENTAL|Patients thats were chosen in order to rehabilitate partial edentulism by dental implants.|
62056359|NCT05535543||Baseline slope of phase iii|Severe ARDS patients who are intubated and mechanically ventilated and will undergo prone positioning
62056360|NCT05278559||Adolescents living with HIV|- ALHIV with a viral load result of less than \<1000 copies/mL and aged between 13-19 years
62056361|NCT06624514|EXPERIMENTAL|Training Group|This arm receives a version of the AAT used as an Approach Bias Modification (ABM) intervention, to retrain participants' implicit biases toward or away from stimuli by presenting the target stimuli predominantly in one format (e.g., push or pull).
62616189|NCT01063894|EXPERIMENTAL|breakfast cereal|breakfast cereal and milk
62616190|NCT01063894|PLACEBO_COMPARATOR|water|water
62616191|NCT06413745|EXPERIMENTAL|SHR-A1811|
62841030|NCT03644472|ACTIVE_COMPARATOR|Nitrate rich beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
62056362|NCT06624514|SHAM_COMPARATOR|Control|No treatment version of the AAT used as an Approach Bias Modification (ABM) intervention will be used in this group.
62056363|NCT00682643|PLACEBO_COMPARATOR|vehicle placebo nasal spray|
62259171|NCT03329911|ACTIVE_COMPARATOR|EU Avastin®|"Drug:EU Avastin® 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months.~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
62841031|NCT03644472|PLACEBO_COMPARATOR|Nitrate depleted beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.
62056364|NCT00682643|ACTIVE_COMPARATOR|fluticasone furoate nasal spray|
62056365|NCT01705262||u-65 M|Male patients under 65
62841032|NCT04145232||NSCLC|This cohort will consist of 30 patients with non-small cell lung cancer (NSCLC).
62259172|NCT03329911|EXPERIMENTAL|BAT1706|"BAT1706 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with BAT1706 up to a maximum of 8 months.~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
62259173|NCT00737256|EXPERIMENTAL|1|
62259174|NCT00737256|ACTIVE_COMPARATOR|2|
62259175|NCT04973436|EXPERIMENTAL|LiveWell: A Dialectical Behavioral Therapy Skills Training Protocol|"The intervention, LiveWell will teach participants dialectical behavioral therapy-based skills to reduce psychological distress through improved physical symptom management, emotion regulation, and tolerance of uncertainty. Informed by feedback from patients and providers collected in Phase of of the study, the LiveWell intervention consists of of 8 sessions delivered one-on-one, approximately weekly. Sessions will last approximately 45-60 minutes each."
62616192|NCT04184778|EXPERIMENTAL|Woman tube size 6.0|Smaller tube than normal
62616193|NCT04184778|NO_INTERVENTION|Woman tube size 7.0|Usual tube size
62841033|NCT05328349||Education Program|All participants will have to present shoulder symptoms related to rotator cuff related shoulder pain, which is defined as pain over the deltoid and/or upper arm region, pain associated with arm movement, and familiar pain reproduced with loading or resisted testing during abduction and/or external rotation of the arm.
62841034|NCT06248749|EXPERIMENTAL|Iron Infusion Arm|Group A: Treatment study group All patients will be treated with iron infusion for Hgb lower than 100 g/L and/or TSAT \< 20%.
62259176|NCT05486351||Mantainance of anticoagulation therapy|Patients with acute ischemic stroke of cardioembolic source and previosly anticoagulated in which anticoagulant therapy is mantained
62259177|NCT05486351||Interruption of anticoagulation therapy|Patients with acute ischemic stroke of cardioembolic source and previosly anticoagulated in which anticoagulant therapy is interrupted.
62259178|NCT00354770|ACTIVE_COMPARATOR|N-Acetyl Cysteine|N-Acetyl Cysteine
62259179|NCT00354770|PLACEBO_COMPARATOR|2|Placebo
62056366|NCT01705262||u-65 K|Female patients under 65 years old
62056367|NCT01705262||o-65 -K|Female patients over 65 years
62056368|NCT01705262||O-65 M|Male patients over 65 years
62056369|NCT00466102|ACTIVE_COMPARATOR|1|Patients with stable disease after 8 week run in randomized to RAD001 (blinded)
62259180|NCT00823498||African American Parents|
62616194|NCT04184778|EXPERIMENTAL|Man tube size 7.0|Smaller tube than normal
62056370|NCT00466102|PLACEBO_COMPARATOR|2|Patients with stable disease after 8 week run in receive placebo (blinded)
62056371|NCT00859651|ACTIVE_COMPARATOR|20,000 IU weekly|"Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 20,000 IU weekly, for one year.~Cholecalciferol 20,000 IU (2 active capsules + 1 matching placebo capsule)"
62616195|NCT04184778|NO_INTERVENTION|Man tube size 8.0|Usual tube size
62616196|NCT01865604|EXPERIMENTAL|Anodal tDCS|anaodal transcranial direct current stimulation
62616197|NCT01865604|ACTIVE_COMPARATOR|Cathodal tDCS|cathodal transcranial direct current stimulation
62616198|NCT01865604|SHAM_COMPARATOR|Sham tDCS|no stimulation
62056372|NCT00859651|ACTIVE_COMPARATOR|30,000 IU weekly|"Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 30,000 IU weekly, for one year.~Cholecalciferol 30,000 IU (3 active capsules)"
62259181|NCT00823498||African American Youth|African American Youth between ages of 12-15 Years Old
62259182|NCT03436459|ACTIVE_COMPARATOR|Extracorporeal shock wave therapy group|Patients in the shock wave therapy group received total of 1000 shock waves for each treatment at the frequency of 10Hz, with 2 Bar pressure and energy flux density (EFD) of 0.25 mJ/mm2 per minute by using BTL-6000 SWT Topline Power® 3 times with a week's interval between the treatments.
62616199|NCT00280813|ACTIVE_COMPARATOR|Supportive Treatment in Alcohol Recovery (STAR)|
62445123|NCT02097121|EXPERIMENTAL|Botox 50 U|Participants randomized to receive 50 Units (U) BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits occurred at Weeks 2, 6, and 12. Participants could request retreatment from Week 12 and 12 weeks after each subsequent treatment for up to 4 cycles. The retreatment dose was determined by the Investigator and could be at the same dose or at the next higher dose compared with the preceding treatment.
62841035|NCT06248749|NO_INTERVENTION|No Iron Infusion|Group B: No iron Infusion
62841036|NCT05461534|EXPERIMENTAL|Intervention group: mindfulness yoga|an 8-week structured mindfulness yoga program
62616200|NCT00445744|EXPERIMENTAL|Treatment (cyclophosphamide, busulfan, transplant)|"CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11."
62841037|NCT05461534|NO_INTERVENTION|Waiting-list control group|provided the 8-week structured mindfulness yoga upon their completion of the study
62616201|NCT02346994|EXPERIMENTAL|Melt test blend 3.2|
62616202|NCT02346994|ACTIVE_COMPARATOR|Corn Oil|
62616203|NCT05707949|EXPERIMENTAL|Atogepant Dose A (12-17 yrs)|Participant aged 12-17 will receive oral tablets of atogepant Dose A once a day for up to 52 weeks.
62616204|NCT05707949|EXPERIMENTAL|Atogepant Dose B (6-11 yrs)|Participants aged 6-11 will receive the highest dose of oral tablets of atogepant tested in the lead-in study M21-201.
62616205|NCT04616846|NO_INTERVENTION|Control cohort|
62616206|NCT04616846|EXPERIMENTAL|Infected cohort|
62616207|NCT01304303|EXPERIMENTAL|SPARC1023 I|
62616208|NCT01304303|EXPERIMENTAL|SPARC1023 II|
62616209|NCT00262002|EXPERIMENTAL|UK234+ (MenACWY Ad+ at 2, 3, 4 m)|Three doses of MenACWY Ad+ vaccine were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age in the UK group. A fourth dose of MenACWY Ad+ was given at 12 months of age.
62841038|NCT04038021|EXPERIMENTAL|PEth-based CM|PEth-based CM participants will receive gift cards (starting at $30) each time they submit a blood spot sample (via finger prick ) with a negative alcohol result. They will receive an additional $5 (building on the previous amount) for each additional negative alcohol result in a row. There is a cap at $100 for each negative result.
62841039|NCT04038021|ACTIVE_COMPARATOR|Non-contingent Control|Non-contingent control participants will receive gift cards each visit if they provide a pinprick blood sample regardless of whether the results are positive or negative for alcohol. Their level of reinforcement (amount in gift cards) will be equal to the average weekly CM earnings from the previous month.
62056373|NCT04899245|EXPERIMENTAL|School Staff|"50 school staff from Waisman Early Childhood Program (WECP) will be recruited to participate in this study. School staff will send a letter to all WECP staff inviting them to participate. Staff new to the school or who initially decline participation and then reconsider may join at any time.~Additionally, staff who are vaccinated will be asked to participate in testing."
62616210|NCT00262002|EXPERIMENTAL|UK24+ (MenACWY Ad+ at 2, 4 m)|Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.
62616211|NCT00262002|EXPERIMENTAL|UKMenC (Menjugate at 2, 4 m)|Two doses of Menjugate were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine was given at 12 months of age.
62259183|NCT03436459|ACTIVE_COMPARATOR|Low Level Laser Therapy group|Patients in the laser therapy group received LLLT once a day for three weeks (altogether 15 working days) to the trigger points and around them in the upper trapezius. The type of laser used: PR999 4 Watt (W) scanning laser; Medical Italia®, around trigger points with 3 Joule /centimeter² (J/cm²), power 800 milliwatt (mW), frequency 2000 Hertz (Hz), on trigger points with 9 J/cm², power 2000mW, frequency 5000Hz for total of 2 minutes on each spot.
62259184|NCT05068570|EXPERIMENTAL|EXPERMINTAL GROUP|start with cycle at a pace of 15-25 cycles per minute without resistance and end with cycle 45cycles per minute
62259185|NCT05068570|NO_INTERVENTION|CONTROL GROUP|selected respiratory exercise program
62616212|NCT00262002|EXPERIMENTAL|CA246+ (MenACWY Ad+ at 2, 4, 6 m)|Three doses of MenACWY Ad+ vaccine were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age of the Canadian group (Prevnar at 6 months was optional and was given if available).One subgroup of subjects was given a reduced dose (1/5) of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.
62056374|NCT04899245|EXPERIMENTAL|Parent/Child with Children with medical complexity (CMC)|"65 children and their parents will be recruited to participate. School staff will send a letter to all parents with children enrolled in the Waisman Early Childhood Program (WECP) inviting them to participate. Families new to the school or who initially decline participation and then reconsider may join at any time. Participants will also be offered the option of as needed symptomatic home testing.~Additionally, parents who are vaccinated will be asked to participate in testing. Siblings may be enrolled in the study."
62056375|NCT00524199|PLACEBO_COMPARATOR|Placebo|Saline IV infusion over five minutes at the beginning of dialysis.
62259186|NCT03260088||patients with pleural effusion|In patients with pleural effusion that remains undiagnosed with common diagnostic algorithm, immunoglobulin G4 will be done in pleural fluid
62259187|NCT01560780|EXPERIMENTAL|Arm 1: Prasugrel|prasugrel 10 mg by mouth daily
62259188|NCT01560780|PLACEBO_COMPARATOR|Arm 2: Placebo|placebo by mouth once daily
62259189|NCT03339206|EXPERIMENTAL|Constituent message with FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
62259190|NCT03339206|EXPERIMENTAL|Constituent message without FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
62259191|NCT03339206|OTHER|Littering message (Control)|Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
62259192|NCT04345536||Patients hospitalized with confirmed Covid-19|All patients hospitalized with confirmed Covid-19
62259193|NCT04558411|NO_INTERVENTION|Control Group (assessment only)|This group will receive assessments only.
62616213|NCT00262002|EXPERIMENTAL|CA24+ (MenACWY Ad+ at 2, 4 m)|Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad+ vaccine or one reduced dose (1/5) of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.
62616214|NCT00262002|EXPERIMENTAL|UK24- (MenACWY Ad- at 2, 4 m)|Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.
62616215|NCT00262002|EXPERIMENTAL|CA24- (MenACWY Ad- at 2, 4 m)|Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.
62616216|NCT06224036|EXPERIMENTAL|First group|JDB0131 Benzenesulfonate tablets,100mg BID group,12 cases
62616217|NCT06224036|EXPERIMENTAL|Second group|JDB0131 Benzenesulfonate tablets 200mg QD group,12 cases
62616218|NCT06224036|EXPERIMENTAL|Third group|JDB0131 Benzenesulfonate tablets 200mg BID group,12 cases
62616219|NCT06224036|ACTIVE_COMPARATOR|Forth group|Ethylpyrazine rifampicide (II) QD group,8 cases
62616220|NCT06224036|ACTIVE_COMPARATOR|Fifth group|Delamanid Tablets 100mg BID group,8 cases
62616221|NCT03089801||Tablet Recipients|Veteran patients who have received a VA-issued tablet for tablet-enabled video telehealth.
62445124|NCT02097121|EXPERIMENTAL|Botox 100 U|Participants randomized to receive 100 Units (U) BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits occurred at Weeks 2, 6, and 12. Participants could request retreatment from Week 12 and 12 weeks after each subsequent treatment for up to 4 cycles. The retreatment dose was determined by the Investigator and could be at the same dose or at the next higher dose compared with the preceding treatment.
62445125|NCT05033301|NO_INTERVENTION|Specialist-led Ned Clinic|Participants enrolled in specialist-led version of the Ned Virtual Clinic will be prompted to complete their PROs (EPIC-26 survey) and PSA/testosterone lab tests in accordance to their pre-specified follow-up surveillance protocol determined by the specialist for one year.
62616222|NCT03089801||Usual Care|Veteran patients who match tablet recipients based on sociodemographic/clinical characteristics but have not received a VA-issued tablet.
62616223|NCT05689008|NO_INTERVENTION|control|Participants will receive standard therapy, including oxygen therapy，glucocorticoid and other antiinflammatory drugs and supportive treatments according the ninth edition of Chinese guidelines for the treatment of COVID-19 infection.
62445126|NCT05033301|EXPERIMENTAL|Nurse-led Ned Clinic|Participants enrolled in the nurse-led version of the Ned Virtual Clinic will be prompted to complete their PROs (EPIC-26 survey) and PSA/testosterone lab tests in accordance to their pre-specified follow-up surveillance protocol determined by the specialist. In addition, men will be asked to complete another set of PROs that will be monitored by a trained oncology nurse, in between their specialist visits.
62616224|NCT05689008|EXPERIMENTAL|UC-MSCs treatment|Participants will receive two doses of UC-MSCs instillation at the first and fourth day after the assignment on the basis of standard treatment.
62616225|NCT05995951|OTHER|Deep Bran Stimulation (DBS) - Treatment group|"Treatment group will undergo Deep Bran Stimulation (DBS) for OCD (targeting the amSTN) for four months.~At the end of four months treatment, the groups will be crossed-over for another four months. Thus, the sham group will start active stimulation and the treatment group will start sham treatment for four months."
62259194|NCT04558411|EXPERIMENTAL|Assessment + Intervention Group|This group will receive assessments and the 14 brief intervention videos.
62259195|NCT01389375|EXPERIMENTAL|FemoSeal®|Device: FemoSeal®
62259196|NCT01389375|EXPERIMENTAL|ExoSeal®|Device: ExoSeal®
62445127|NCT03437759|EXPERIMENTAL|Experimental group|Our intervention is to add treatment of exosomes derived from mesenchymal stem cells (MSC-Exo) after pars plana vitrectomy(PPV) and ILM peeling.
62445128|NCT03437759|NO_INTERVENTION|Control group|Control group that receives treatment of only pars plana vitrectomy(PPV) and ILM peeling.
62841040|NCT06256380|EXPERIMENTAL|Enhanced cognitive-behavior therapy for adolescents with an eating disorder (CBT-E)|CBT-E posits the eating problem as belonging to the individual, and is designed to encourage the adolescent, rather than their parent, to take control of the problem. Parents are not excluded from participating in treatment, but their involvement is limited to helping to create a family environment that allows for recovery. Patients are actively involved in all phases of treatment, including the decision to address weight regain and/or binge eating and purging, with the goal of promoting self-management. A primary goal of CBT-E is to address the patient's eating disorder psychopathology, i.e. patients' concerns about shape, weight, dietary restraint and restriction, and other extreme weight control behaviors. Following manualized CBT-E guidelines, for patients in the lower weight cohort, treatment involves 40 sessions over 9-12 months. For those in the higher weight cohort, treatment involves 20 sessions over the course of 6 months.
62056376|NCT00524199|ACTIVE_COMPARATOR|Mesna|12 mg/kg mesna IV infusion over five minutes at the beginning of dialysis.
62445129|NCT01733719|ACTIVE_COMPARATOR|ER plus RFA|Initial Endoscopic Resection of visible neoplasia/HGD in Barrett's esophagus followed by 4 x 2 monthly interventions (either ER of residual/metachronous visible lesions or RadioFrequency Ablation of 'flat' dysplastic or non-dysplastic Barrett's esophagus)
62056377|NCT06432933|EXPERIMENTAL|Without preventive oxygen therapy|
62056378|NCT06432933|ACTIVE_COMPARATOR|With preventive oxygentherapy|
62056379|NCT02789683|EXPERIMENTAL|Fine emulsion|Emulsion with small lipid droplet size served together with white bread
62056380|NCT02789683|EXPERIMENTAL|Coarse emulsion|Emulsion with large lipid droplet size served together with white bread
62056381|NCT02789683|EXPERIMENTAL|Control|Non-emulsified oil and water served together with white bread
62056382|NCT05668169|EXPERIMENTAL|Family-centered support program for caregivers of stroke survivors|Participants receive usual hospital care and our intervention
62445130|NCT01733719|ACTIVE_COMPARATOR|ER plus APC|Initial Endoscopic Resection of visible neoplasia/HGD in Barrett's esophagus followed by 4 x 2 monthly interventions (either ER of residual/metachronous visible lesions or Argon Plasma Coagulation of 'flat' dysplastic or non-dysplastic Barrett's esophagus)
62445131|NCT05694325|OTHER|Biological evaluation|characterization of biological features of enrolled ITP patients
62445132|NCT04715607|ACTIVE_COMPARATOR|Nasopharyngeal swab, oropharyngeal swab, and salvia collection|"The participants will first be tested with nasopharyngeal swabs followed by oropharyngeal swab and saliva collection.~The collection material, virus transport medium and laboratory equipment for each method is the same in both arms"
62445133|NCT04715607|ACTIVE_COMPARATOR|Oropharyngeal swab, salvia collection, and nasopharyngeal swab|"The participants will first be tested with oropharyngeal swabs followed by saliva collection and nasopharyngeal swab.~The collection material, virus transport medium and laboratory equipment for each method is the same in both arms"
62445134|NCT04715607|ACTIVE_COMPARATOR|Salvia collection, nasopharyngeal swab, and oropharyngeal swab|"The participants will first be tested with saliva collection followed by nasopharyngeal swab and oropharyngeal swabs.~The collection material, virus transport medium and laboratory equipment for each method is the same in both arms"
62841041|NCT06256380|ACTIVE_COMPARATOR|Family-based treatment for adolescents with an eating disorder (FBT)|FBT for adolescent eating disorders usually includes all members of the adolescent's immediate family. Treatment progresses through three phases, with the first (∼10 sessions) focusing mainly on guiding the parents to support their adolescent toward weight restoration (when appropriate), and disrupting eating disorder behaviors (e.g. binge eating and purging). The second phase (∼5-7 sessions) focuses on assisting the parents to restore food choices to the adolescent, with an emphasis on the developmental stage of the adolescent. Phase 3 is brief (2-3 sessions), focusing on adolescent developmental matters and helping the parents and their offspring navigate these tasks largely in the absence of acute eating disorder symptoms. Twenty treatment sessions are provided over a span of approximately 6 months.
62056383|NCT05668169|NO_INTERVENTION|No Intervention: Control group|Participants receive only usual hospital care
62056384|NCT02316769|ACTIVE_COMPARATOR|King Vision Video Laryngoscope|Patient intubated with the King Vision Video Laryngoscope
62623659|NCT04365075|EXPERIMENTAL|Excimer Laser Combined with DCB|Using excimer laser combined with drug-coated baloons to treat infrapopliteal lesions in patients with critical limb ischemia.
62056385|NCT02316769|ACTIVE_COMPARATOR|McGrath MAC Video Laryngoscope|Patient intubated with the McGrath MAC Video Laryngoscope
62056386|NCT03988634|EXPERIMENTAL|sacubitril/valsartan (LCZ696)|"Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg twice daily (Dose Level 3).~Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan , and one tablet of valsartan matching placebo)"
62056387|NCT03988634|ACTIVE_COMPARATOR|valsartan|"Study treatment was titrated to the target dose of valsartan 160 mg twice daily (Dose Level 3).~Patients were required to take a total of two tablets twice daily (one tablet of active valsartan, and one tablet of sacubitril and valsartan matching placebo)"
62056388|NCT05401643|EXPERIMENTAL|mHealth intervention|Installation of the mHealth application Xemio in the participant's smartphones. Voluntary use of the application for 12 months. Outcome measures collected every 3 months.
62056389|NCT05401643|NO_INTERVENTION|Control|No application installed. Outcome measures collected every 3 months.
62056390|NCT04887792|ACTIVE_COMPARATOR|Acetazolamide|acetazolamide capsules
62616226|NCT05995951|OTHER|Sham-control|"sham stimulation for four months.~At the end of four months treatment, the groups will be crossed-over for another fourmonths. Thus, the sham group will start active stimulation and the treatment group will start sham treatment for four months."
62259197|NCT01389375|ACTIVE_COMPARATOR|Manual compression|Other: Manual compression
62616227|NCT04780243|NO_INTERVENTION|Pre-intervention group|Pre-intervention group: women participated during the base line assessment will be labeled as Pre-intervention group
62616228|NCT04780243|EXPERIMENTAL|postintervention group|Postintervention group: women participated after the intervention was initiated will be labeled as postintervention group.
62616229|NCT06303414||Carotid Endarterectomy (CEA)|Patients who are treated with CEA.
62259198|NCT04349774|ACTIVE_COMPARATOR|Control Group|Continuous Erector Spinae Plane block with 20ml 0.375% Bupivacaine and continuous infusion of 0.25% Lidocaine @ 12ml/hr, with single shot Serratus Anterior Plane block with 20ml 0.375% Bupivacaine
62616230|NCT06303414||Carotid Artery Stenting (CAS)|Patients who are treated with CAS.
62616231|NCT06303414||Hybrid Surgery|Patients who are treated with Hybrid Surgery.
62616232|NCT04748848|EXPERIMENTAL|CC-90011 in combination with Venetoclax and Azacitidine in Dose Escalation|CC-90011 in combination with venetoclax and azacitidine in dose escalation
62616233|NCT04748848|EXPERIMENTAL|Venetoclax and Azacitidine|Venetoclax and Azacitidine control arm in dose expansion. The participants will be randomized to the treatment arm or control arm at a 2:1 ratio.
62616234|NCT04748848|EXPERIMENTAL|CC-90011 in combination with Venetoclax and Azacitidine in Dose Expansion|CC-90011 in combination with venetoclax and azacitidine in dose expansion
62056391|NCT04887792|ACTIVE_COMPARATOR|Placebo|Identical gelatin capsules
62259199|NCT04349774|ACTIVE_COMPARATOR|Treatment Group|Continuous Erector Spinae Plane block with 20ml 0.375% Bupivacaine and continuous infusion of 0.25% Lidocaine @ 12ml/hr, with single shot Serratus Anterior Plane block with 20ml Normal Saline.
62259200|NCT05325151|EXPERIMENTAL|Arm I (GCPP intervention)|Patients receive GCPP intervention consisting of a series of educational videos on pre-genetic test information.
62259201|NCT05325151|ACTIVE_COMPARATOR|Arm II (conventional genetic counseling)|Patients receive conventional genetic counseling.
62616235|NCT04686812|EXPERIMENTAL|Worksite health promotion program|Participants had a baseline health risk assessment (HRA) after which they were invited to participate in a workplace health promotion program. The intervention lasted six months and included the following components: nutrition counseling, physical activity, and stress management. HRAs were performed 6 and 12 months after intervention onset.
62616236|NCT04686812|NO_INTERVENTION|Control|Participants only had a baseline and follow-up health risk assessments at 6 and 12 months.
62616237|NCT01422707|EXPERIMENTAL|hydrocortisone|4 weeks hydrocortisone with pre- and post-intervention Dexamethasone and Cosyntropin to perform standardized adrenal stimulation testing
62616238|NCT01056913|OTHER|NITI CAR27 (ColonRing)|
62616239|NCT06333483|EXPERIMENTAL|AUTO1|
62056392|NCT02260401|EXPERIMENTAL|Individualized report|Each patient in this group will receive an individualized report with their own outcome data (pain and function) during the first year of the LESS trial. They will receive these reports at 18 months.
62259202|NCT05489731|EXPERIMENTAL|Dose escalation phase-Dose group 1 VIC-1911 Tablets with Osimertinib Mesylate Tablets|Advanced NSCLC patients who experienced first/second-generation EGFR-TKI failure with T790M mutation negative or who experienced third-generation EGFR-TKI failure and a subsequent platinum-based doublet chemotherapy failure
62259203|NCT05489731|EXPERIMENTAL|Dose escalation stage - Dose group 2 VIC-1911 Tablets with Osimertinib Mesylate Tablets|Advanced NSCLC patients who experienced first/second-generation EGFR-TKI failure with T790M mutation negative or who experienced third-generation EGFR-TKI failure and a subsequent platinum-based doublet chemotherapy failure
62259204|NCT05489731|EXPERIMENTAL|Dose expansion phase VIC-1911 Tablets with Osimertinib Mesylate Tablets|Cohort 1: NSCLC patients who experienced first/second-generation EGFR-TKI failure with T790M mutation positive; Cohort 2: NSCLC patients who experienced third-generation EGFR-TKI failure
62445135|NCT02304120|EXPERIMENTAL|Sensorimotor|"The experimental group will receive added PPT to the conventional physiotherapy. PPT will be applied by means of a neuro-orthopaedic medical device (Posturomed®, see section 3.2). The Posturomed allows adaptive oscillation in the horizontal plane. Therapy instructions advise seven stages of difficulty. In all stages the patient is asked to provoke oscillation by stepping on site. After three steps, the patient must stand still on one leg for 2 seconds before he or she repeats the steps. Difficulty is increased by a) decreasing the damping through release of the breaks and b) through added juggling of a ball during the motor task (dual-task and divided attention). The next stage is reached once stabilisation in the previous stage is secured."
62259205|NCT05739786|ACTIVE_COMPARATOR|Group A liquid nitrogen|liquid nitrogen In Group A patients were subjected to liquid nitrogen cryotherapy (-196 0C) for 3 sessions at every 3 weeks interval. Effectiveness in was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
62445136|NCT02304120|ACTIVE_COMPARATOR|Low-intensity activity|Added to conventional therapy, as administered to all participants, the control group will do added treadmill walking. The control intervention will consist of 10 minutes of walking at comfortable pace. The patient will be instructed in treadmill functions and asked to set the speed between 2 and 4 km/h. The speed should be adjusted to the level where the patient would still be able to talk comfortably.
62445137|NCT06503237|EXPERIMENTAL|Anti-CD19 CART|Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CART infusion. A dose of Anti-CD19 CART will be infused on day 0.
62445138|NCT02114307|ACTIVE_COMPARATOR|REVITIVE IX: actual device|Trial participants will receive the true Revitive IX device
62056393|NCT02260401|NO_INTERVENTION|Individualized Reports after 24 months|Patients in this group will receive the individualized report, but will not receive it until after the conclusion of the study at 24 months. They will serve as the control group.
62056394|NCT03540355|EXPERIMENTAL|Cipros 20|"The study is double-masked, the patient will take 2 tablets, as follow:~1 tablet Cipros 20 association; and~1 tablet crestor placebo. Oral, once a day"
62056395|NCT03540355|ACTIVE_COMPARATOR|Crestor|"The study is double-masked, the patient will take 2 tablets, as follow:~1 tablet Crestor 20 mg; and~1 tablet cipros association placebo. Oral, once a day"
62445139|NCT02114307|SHAM_COMPARATOR|REVITIVE IX: sham device|Trial participants will receive a sham device
62841042|NCT00088764|EXPERIMENTAL|1|Education: Either coping skills training or arthritis education interventions
62841043|NCT00088764|EXPERIMENTAL|2|Writing: Either emotional disclosure writing or health behavior writing
62616240|NCT04337476|EXPERIMENTAL|mother's song|At the suggestion of the music therapist, the mothers of each child will record two lullabies sung by themselves; lullabies will be part of traditional classical literature. The songs will be recorded and loaded on a simplified digital software to modify any background noise or pauses. The recording will be inserted in the usb / sd flash drive used directly by the PAL device. During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit
62616241|NCT04337476|EXPERIMENTAL|father's song|At the suggestion of the music therapist, the fathers of each child will record two lullabies sung by themselves; lullabies will be part of traditional classical literature. The songs will be recorded and loaded on a simplified digital software to modify any background noise or pauses. The recording will be inserted in the usb / sd flash drive used directly by the PAL device. During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit
62259206|NCT05739786|ACTIVE_COMPARATOR|Group B intralesional Vit D3|intralesional Vit D3 Group B were subjected to vitamin D3 (5mg/ml) for 3 sessions at every 3 weeks interval. Effectiveness was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
62616242|NCT04337476|EXPERIMENTAL|singing of the music therapist|Music therapist will record two lullabies sung by themselves; lullabies will be part of traditional classical literature. The songs will be recorded and loaded on a simplified digital software to modify any background noise or pauses. The recording will be inserted in the usb / sd flash drive used directly by the PAL device. During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit
62616243|NCT04337476|NO_INTERVENTION|No singing|Control group (not subjected to musical stimulation- no singing). During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit.
62616244|NCT01941537|EXPERIMENTAL|ILV-094|Forty patients will be enrolled in the ILV-094 treatment arm. A loading IV dose of 600 mg of ILV-094 will be given at baseline (Day 0), followed by five additional IV doses of 300 mg of ILV-094 every two weeks (Weeks 2, 4, 6, 8, and 10).
62616245|NCT01941537|PLACEBO_COMPARATOR|Placebo comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
62616246|NCT02127736|EXPERIMENTAL|Experimental group|
62616247|NCT02127736|PLACEBO_COMPARATOR|Control group|
62616248|NCT01381380|OTHER|single-arm studies|Manual therapy for one group
62616249|NCT00649246||1|"controls:~healthy individuals with no family history of type 1 diabetes"
62841044|NCT00566696|EXPERIMENTAL|High-Risk Hematologic Malignancies|"Participants meeting eligibility criteria undergo haploidentical stem cell transplantation along with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (after January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.~Grafts from suitable haploidentical donors are processed using the CliniMACS system."
62056396|NCT04085302|EXPERIMENTAL|All subjects|
62056397|NCT06391684||Autistic adults|Participants who have an autism diagnosis.
62056398|NCT06391684||Non autistic adults|Participants who do not have an autism diagnosis
62616250|NCT00649246||2|"high-risk:~Subjects with islet autoantibodies or high-risk diabetes genes"
62616251|NCT00649246||3|"type 1 diabetes:~subjects with type 1 diabetes"
62616252|NCT03486964||DPP-4 plus other therapies|Patients in therapy with DPP-4 inhibitors in addition to sulfonylureas and/or biguanides and/or thiazolidinediones and/or insulin
62259207|NCT05455112|EXPERIMENTAL|RUTI|Single injection of RUTI 25µg of FCMtb at day 0.
62616253|NCT03486964||Other therapies|Patients in therapy with other hypoglycemic classes, such as sulphonylureas and/or biguanides and/or thiazolidinediones and/or insulin.
62616254|NCT01587625|EXPERIMENTAL|High dose of oxytocin infusion|Oxytocin: High dose infusion
62616255|NCT01587625|ACTIVE_COMPARATOR|Low dose of oxytocin infusion|Oxytocin: Low dose infusion
62616256|NCT00808470|EXPERIMENTAL|Nutrients|Subjects in University of Florida music player study who are assigned to nutrient condition(beta-carotene, vitamins C and E, magnesium). Nutrient tablets are consumed for 4 days.
62616257|NCT00808470|PLACEBO_COMPARATOR|Placebo for nutrients|Subjects in University of Florida music player study who are assigned to control (placebo) condition. Placebo tablets are consumed for 4 days.
62616258|NCT03300180|NO_INTERVENTION|Control|The patients in this group will receive no AD screening
62623660|NCT04365075|ACTIVE_COMPARATOR|Angioplasty Alone|Using angioplasty alone to treat infrapopliteal lesions in patients with critical limb ischemia.
62623661|NCT04742881|EXPERIMENTAL|Low pressure + microsurgical instruments|Low pressure pneumoperitoneum ((≤ 8 mmHg) and use of microsurgical instruments (3mm and 5mm instruments)
62056399|NCT03771430|EXPERIMENTAL|Non-surgical group|Osteoarthritis education, exercise and eCBT
62056400|NCT03771430|EXPERIMENTAL|Combined group|Total knee arthroplasty + osteoarthritis education, exercise and eCBT
62259208|NCT05455112|PLACEBO_COMPARATOR|Placebo|Single injection of saline at day 0.
62616259|NCT03300180|ACTIVE_COMPARATOR|Screening Only|The patients in this group will receive screening for AD. Patients and family members will receive a letter about how the patient performed on the screening. If they screen positive (e.g. ≤5 on the MIS-T or ≤2 on the Mini-Cog), the patient and family member will receive an infographic and some information about local clinical resources for them to peruse regarding follow-up care. The patient's PCP is also be notified of the screening results via EHR message.
62623662|NCT04742881|ACTIVE_COMPARATOR|Low pressure + standard instruments|Low pressure pneumoperitoneum ((≤ 8 mmHg) and use of standard instruments (5mm and 10mm instruments)
62841045|NCT00684008|EXPERIMENTAL|I|"Single arm dose escalation study. Three successive cohorts of 3 patients each. Doses to be evaluated: 10, 20, and 30 mcg/kg/dose for 3 consecutive doses.~CYT107 is a recombinant protein belonging to the class of growth factors known as cytokines.~CYT107 is a heavily glycosylated and sialylated form of recombinant human Interleukin-7.~CYT107 is supplied as a sterile colorless liquid at a concentration of 4 mg/ml."
62056401|NCT03771430|ACTIVE_COMPARATOR|Surgery only (standard care)|Total knee arthroplasty + standard physiotherapy
62056402|NCT06624527|NO_INTERVENTION|Control Group|No intervention will be made to the control group. This group will be given a first test using the scales specified in the data collection, and a final test will be given 30 days later using the same scales.
62056403|NCT06624527|EXPERIMENTAL|Intervention group|After the first test application with the scales specified in the data collection, 8 sessions of Cognitive Behavior Therapy-based psycho-education sessions will be applied to the intervention group. At the end of the 8 sessions (which will last 30 days on average), a final test will be applied.
62259209|NCT03483142|EXPERIMENTAL|misoprostol group|misoprostol group ( study group ) ( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation
62841046|NCT04154189|EXPERIMENTAL|Randomization Phase: Lenvatinib + Ifosfamide + Etoposide|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
62841047|NCT04154189|ACTIVE_COMPARATOR|Randomization Phase: Ifosfamide + Etoposide|Participants with relapsed or refractory osteosarcoma will receive ifosfamide with etoposide. Participants with relapsed or refractory osteosarcoma may receive optional lenvatinib plus or minus chemotherapy (Ifosfamide and Etoposide) if disease progression is observed in study.
62841048|NCT01610934|EXPERIMENTAL|liraglutide|
62841049|NCT01610934|ACTIVE_COMPARATOR|glimepiride|
62841050|NCT02213861|EXPERIMENTAL|1.0% SHAPE Gelled Solution once daily|
62841051|NCT02213861|EXPERIMENTAL|0.5% SHAPE Gelled Solution twice daily|
62841052|NCT02213861|EXPERIMENTAL|1.0% SHAPE Gelled Solution twice daily|
62841053|NCT01938716|EXPERIMENTAL|Gemcitabine Infusion|Gemcitabine administered intravenously as a dose of 500 mg/m2 at a fixed dose rate of 10 mg/m2/min for the first 5 patients (to validate hematologic safety). Next 15 subsequent patients receive 750 mg/m2 at a fixed dose rate of 10 mg/m2/min. The drug infusion started 50-75 minutes prior to complete gross tumor removal (timing dependent on dose) in order to have drug administration complete at tumor removal.
62056404|NCT05647525||status epilepticus with autoimmune encephalitis; status epilepticus without autoimmune encephalitis|To study the relationship between autoimmune-related antibody titres and prognosis during the six-month follow-up
62259210|NCT03483142|PLACEBO_COMPARATOR|placebo group|( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol.
62841054|NCT02411097|EXPERIMENTAL|femoral nerve block|femoral nerve block will be administered before or after the surgery
62259211|NCT00881803||Group 1|Ascorbic Acid Supplementation Only
62259212|NCT00881803||Group 2|Iron Supplementation Only
62259213|NCT00881803||Group 3|Concurrent Ascorbic Acid \& Iron Supplementation
62259214|NCT00112671|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62841055|NCT01006993|EXPERIMENTAL|NeuroFlo Treatment|
62841056|NCT00056069|EXPERIMENTAL|Observational|Questionnaire Administration: Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
62841057|NCT06422897||cases after surgical management|cases are assessed by Anterior segment optical coherence tomography 1 month after surgical managemnt
62841058|NCT01497561|EXPERIMENTAL|insulin detemir|
62841059|NCT01497561|ACTIVE_COMPARATOR|insulin NPH|
62841060|NCT03001817|PLACEBO_COMPARATOR|12 Week Efficacy|K-877 or placebo comparator twice daily for 12 weeks
62056405|NCT00853502|ACTIVE_COMPARATOR|testosterone cypionate|
62259215|NCT06343948|EXPERIMENTAL|BL-B01D1|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62259216|NCT06343948|EXPERIMENTAL|Eribulin or Vinorelbine or Gemcitabine or Capecitabine|Participants receive Eribulin or Vinorelbine or Gemcitabine or Capecitabine in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62259217|NCT03982004|EXPERIMENTAL|Epicutaneous cryoimmunotherapy+imiquimod+pembrolizumab+GM-CSF|"* Epicutaneous cryoimmunotherapy treatments (6 total) during weeks 1-15 (every 2 weeks for the first 2 treatments, then every 3 weeks until week 15)~* Topical imiquimod will be applied 5 days per week (5 days on, 2 days off from weeks 1-15)~* Pembrolizumab will be given every 3 weeks for a minimum of 4 cycles starting at Week 3 until disease progression or unacceptable toxicity.~* Intra-lesional GM-CSF 250 mcg every 2 weeks x 2 doses then every 3 weeks for 3 doses"
62259218|NCT01230242|EXPERIMENTAL|Mirena IUD Placement Immediately Post-delivery|Participants enrolling in this study agree to have the IUD placed immediately post-delivery versus waiting the standard 6 weeks.
62259219|NCT05109065||Individuals with primary psychotic disorders|"Participants who have received any of the following diagnoses: schizophrenia, schizoaffective disorder, or schizophreniform disorder.~Participants will have urine toxicology screen, vitals recorded, and blood drawn in a single visit."
62259220|NCT05109065||Healthy Controls|"Healthy participants who do not have any exclusion criteria will undergo an assessment to confirm absence of psychiatric disorder.~Participants will have urine toxicology screen, vitals recorded, and blood drawn in a single visit."
62616260|NCT03300180|EXPERIMENTAL|Collaborative Dementia Care Program|The patients in this group will receive screening for AD, Patients and family members will receive a letter about how the patient performed on the screening. If they screen positive (e.g. ≤5 on the MIS-T or ≤2 on the Mini-Cog), the patient and family member will receive an infographic. Also, the family member will receive two follow-up phone calls. One from the COADS Study Coordinator and one from a care coordinator at the Aging Brain Care Program (ABC). This phone call will include an opportunity for the family to ask questions and a conversation about the program and diagnostic evaluation and management. Dyads have the option to refuse the follow-up visit. The patient's PCP is also be notified of the screening results via EHR message,
62616261|NCT04333225|EXPERIMENTAL|Hydroxychloroquine|Subjects who chose to enter the HCQ arm received a loading dose of 800 mg HCQ on day 1 followed by two 200 mg tablets once a week for a total of 7 weeks
62616262|NCT04333225|NO_INTERVENTION|Control|Subjects who declined taking HCQ were considered as controls
62841061|NCT03001817|ACTIVE_COMPARATOR|40 Week Extension|K-877 with placebo matching fenofibrate or fenofibrate with placebo matching K-877 for 40 weeks
62841062|NCT03841201|EXPERIMENTAL|Treatment|"* Lenvatinib peroral qd (8 mg for patients with body weight \<60kg and 12 mg for patients with body weight ≥ 60kg)~* Nivolumab i.v. q2w (240mg fixed dose IV) max. 36 cycles"
62841063|NCT01614483|EXPERIMENTAL|Yellow cassava + placebo capsule|
62841064|NCT01614483|PLACEBO_COMPARATOR|White cassava + placebo capsule|
62841065|NCT01614483|ACTIVE_COMPARATOR|White cassava + B-carotene capsule|
62841066|NCT00068419|EXPERIMENTAL|Treatment (enzyme inhibitor therapy, anti-estrogen therapy)|Patients receive oral sulindac and oral tamoxifen citrate twice daily for up to 12 months (four 3-month courses) in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 1 additional month of treatment beyond documentation of CR.
62841067|NCT02670811|EXPERIMENTAL|Intervention|Daily consumption of 150 mL of fermented milk with Lactococcus lactis for 8 weeks
62841068|NCT02670811|PLACEBO_COMPARATOR|Placebo|Daily consumption of 150 mL of artificially acidified milk
62841069|NCT04316988||Ultrasonography|Ultrasonography group in whom after endotracheal intubation, the endotracheal tube position was confirmed by ultrasound machine over the trachea.
62259221|NCT06113900|EXPERIMENTAL|Drug as Dapagliflozin 10 mg orally for 6 months is given|25 lupus nephritis patients will receive SGLT2is as dapagliflozin 10mg beside there usual treatment of lupus for 6 months
62259222|NCT06113900|NO_INTERVENTION|On there conventional lupus nephritis treatment|25 lupus nephritis patients didn't receive SGLT2i and continue on their conventional lupus nephritis treatment
62259223|NCT03988348|EXPERIMENTAL|study group|infraumbilical transverse incision will be done
62259224|NCT03988348|ACTIVE_COMPARATOR|control group|Direct intraumbilical transverse incision will be done
62841070|NCT04316988||Capnography|Capnography group in whom after endotracheal intubation, the endotracheal tube position was confirmed by capnograph, evaluationg the graph character and end tidal CO2 value.
62841071|NCT02713152||Patients with OAG|Patients with a diagnosis of Open Angle Glaucoma
62841072|NCT02713152||Controls|Controls without a diagnosis of Open Angle Glaucoma
62056406|NCT00853502|NO_INTERVENTION|bone monitoring|
62056407|NCT03291886|EXPERIMENTAL|Arm A (exemestane, Entinostat)|"5 mg KHK2375 will be administered to subjects once weekly. EXE001 will be administered at a dose of 25 mg once daily orally.~Pre/perimenopausal female patients also receive luteinizing hormone-releasing hormone (LH-RH) agonist."
62056408|NCT03291886|PLACEBO_COMPARATOR|Arm B (exemestane, Entinostat(placebo))|"KHK2375 Placebo will be administered to subjects once weekly. EXE001 will be administered at a dose of 25 mg once daily orally.~Pre/perimenopausal female patients also receive luteinizing hormone-releasing hormone (LH-RH) agonist."
62056409|NCT02424084|EXPERIMENTAL|Intact scaphoid bone|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62259225|NCT04729985|NO_INTERVENTION|Standard Care|A blinded CGM will be placed to review glucoses after discharge in the Standard Care arm.
62259226|NCT04729985|ACTIVE_COMPARATOR|Diabetic education and CGM monitoring|Treatment arm will get diabetic education, active CGM use with patient feedback for 14 days, active access to the PI for concerns relating to hospitalization. They will also receive a brief, 15 minute phone call from the PI on day 3-4, 6-7, 9-10 and day 14-15.
62616263|NCT04624542||group 1|Thirty individuals diagnosed with unilateral chronic PFPS from both genders and age between 18-35 years who will be referred from an orthopedic surgeon.
62616264|NCT04624542||control group|-30 healthy active individuals ranging from 18-36 yrs as a controlled group
62616265|NCT04368832||Experimental group|During prenatal monitoring, at least one consultation by remote consultation (phone or teleconsultation)
62841073|NCT04101942|EXPERIMENTAL|Internet-based CBT|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in the experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 36 hours on weekdays
62841074|NCT04101942|NO_INTERVENTION|Control condition (assessment only)|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment after 7 weeks.
62616266|NCT04368832||Control group|"Prenatal monitoring by face-to-face consultations adapted to confinement (absence of clinical signs or notion of travel, occupation, contact, clustering (TOCC), no attendant, limited movements inside the hospital and precautions of droplet and contact type)"
62841075|NCT02970903|EXPERIMENTAL|VitalPAD|Using VitalPAD prototype device
62841076|NCT02970903|ACTIVE_COMPARATOR|Control|Using traditional tools (monitors, paper records)
62841077|NCT01933685|EXPERIMENTAL|AIDSVAX B/E|AIDSVAX B/E at Weeks 0, 4, 24 and 48
62841078|NCT01933685|PLACEBO_COMPARATOR|AIDSVAX B/E Placebo|AIDSVAX B/E Placebo at Weeks 0, 4, 24 and 48
62259227|NCT06068712|EXPERIMENTAL|Within-Subjects Attentional Information|All Participants receive all levels of the attentional cue (target, distractor, or neutral cue).
62841079|NCT03607266||Group I (Ibuprofen)|Ibuprofen Group will receive 800 mg iv ibuprofen in 100 cc of isotonic solution within 30 min before the procedure
62259228|NCT05218512||WB-EMS|Young recreationally active males without any disease.
62616267|NCT01421992|PLACEBO_COMPARATOR|Arm 1: Methylphenidate versus baseline|
62616268|NCT01421992|PLACEBO_COMPARATOR|Arm 2: Placebo versus baseline|One table placebo per day during 3 week
62841080|NCT03607266||Group D (Dexketoprofen|Dexketoprofen Group will receive 50 mg iv dexketoprofen in addition to 100 cc of isotonic solution within 30 min before the procedure
62841081|NCT03607266||Placebo Group|will receive 100 cc of isotonic solution within 30 min before the procedure
62841082|NCT06532149||Cohort A|Male patients diagnosed with advanced/metastatic ALK+ o ROS-1+ NSCLC, who are receving active anticancer treatment
62841083|NCT06532149||Cohort B|Male patients diagnosed with advanced/metastatic oncogene-addicted NSCLC (other than ALK and ROS-1), who are receving active anticancer treatment
62616269|NCT00574691|OTHER|1|Vascular Closure Device
62616270|NCT06142734|OTHER|mini-incision open dismembered pyeloplasty|Open surgery
62616271|NCT06142734|OTHER|Laparoscopic dismembered pyeloplasty|Minimally invasive surgery
62445140|NCT01319682|ACTIVE_COMPARATOR|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
62616272|NCT01858259||cyclophosphamide|Patients receiving cyclophosphamide
62616273|NCT01858259||azathioprine|Patients receiving azathioprine
62616274|NCT01858259||mycophenolate mofetil|Patients receiving mycophenolate mofetil
62616275|NCT01858259||methotrexate|Patients receiving methotrexate
62616276|NCT01858259||no therapy|Patients receiving no immunosuppressive therapy
62445141|NCT01319682|PLACEBO_COMPARATOR|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
62445142|NCT05106933|PLACEBO_COMPARATOR|Plain water|Group A patient will be given 400cc of plain water, 2 hours prior to gastroscopy
62616277|NCT06347393|OTHER|Observational Prospective Cohort|Mammography and breast ultrasound
62616278|NCT05680142|ACTIVE_COMPARATOR|Group sCPB|Superficial cervical plexus block, patients who applied sCPB for postoperative pain
62616279|NCT05680142|ACTIVE_COMPARATOR|Group cESP|Cervical erector spinae plane block, patients who applied cervical ESP block for postoperative pain
62616280|NCT05975918|EXPERIMENTAL|Motivational İnterview|The participants in the experimental group will be informed about the study through pre-interviews and data (Caregiver Identifying Characteristics Form, Patient Identifying Characteristics Form, Depression, Anxiety and Stress Scale (DASS-21), Coping Attitudes Assessment Scale) will be collected through pre-tests. A motivational interview intervention consisting of a total of 6 interviews will be conducted.Then, data will be collected with posttest (Caregiver Descriptive Characteristics Form, Patient Descriptive Characteristics Form, Depression Anxiety and Stress Scale (DASS-21), Coping Attitudes Assessment Scale).
62623663|NCT00957099||Imaging|Women diagnosed with breast cancer having pre-treatment MRI for spread of disease
62841084|NCT06532149||Cohort C|Male patients diagnosed with advanced/metastatic non oncogene-addicted NSCLC, who are receving immunotherapy (single agent or combintions without cytotoxic agents)
62841085|NCT06532149||Cohort D|Male patients diagnosed with advanced/metastatic non oncogene-addicted NSCLC, who are receving chemotherapy alone or in combination with immunotherapy
62841086|NCT00792064||1|Kidney-Tx-recipients
62841087|NCT00792064||2|Liver-Tx-recipients
62841088|NCT00792064||3|Heart-Tx-recipients
62841089|NCT00792064||4|Lung-Tx-recipients
62259229|NCT03769246|EXPERIMENTAL|Upright Go Device Group|"Patients receiving the Upright device will have a brief training on the use of the device and proper posture. They will be asked to download the Upright app on their phone from the Playstore.~Patients will wear the device once daily for training. They will attach the device applying an adhesive on their upper back, as instructed, and the device will be attached to the adhesive by velcro. Once completed they should remove adhesive."
62259230|NCT03769246|ACTIVE_COMPARATOR|Control Group|The control group will receive a 15-20 minute instruction on proper posture by the physician and will receive an ergonomic handout.
62259231|NCT02369848|EXPERIMENTAL|Lithoplasty Treatment|Shockwave Lithoplasty System
62445143|NCT05106933|EXPERIMENTAL|Carborie|Group B patient will be given 400cc of carborie (carbohydrate drink), 2 hours prior to gastroscopy
62445144|NCT06262698|EXPERIMENTAL|experimental|"Based on the SIM model, the intervention group will receive 6 sessions of training (each session lasting 40 minutes). The training sessions will be as follows:~1. st Session: Traditional/Alternative medical systems~2. nd Session: Mental-physical interventions~3. rd Session: Biologically based treatments~4. th Session: Manipulative and physical-based therapies~5. th Session: Energy therapies~6. th Session: Training on proper prescription drug use"
62445145|NCT06262698|OTHER|Control|Nursing students will receive their regular semester courses; no additional intervention will be implemented.
62445146|NCT00816088||neutropenia|Patients undergoing stem cell transplantation or chemotherapy likely to lead to prolonged neutropenia.
62445147|NCT03495869||Individuals with Cocaine Use Disorder|"This group will consist of individuals who are determined to have DSM5 diagnosis of Cocaine Use Disorder (n=50).~Individuals will be recruited from an existing registry (VCU IRB HMHM20000294, Keyser-Marcus, PI)"
62445148|NCT03495869||Individuals with Opioid Use Disorder|This group will consist of individuals who are determined to have DSM5 diagnosis of Opioid Use Disorder (n=200).
62445149|NCT03495869||Individuals with Marijuana Use Disorder|This group will consist of individuals who are determined to have DSM5 diagnosis of Marijuana Use Disorder (n=50).
62445150|NCT03495869||Healthy Controls|This group will consist of individuals who are determined to be non-drug using healthy controls (n=100).
62616281|NCT05975918|OTHER|Control|Participants in the control group will be informed about the study through pre-interviews and data (Caregiver Identifying Characteristics Form, Patient Identifying Characteristics Form, Depression, Anxiety and Stress Scale (DASS-21), Coping Attitudes Assessment Scale) will be collected through pre-tests. 2 hours of training on coping with stress and problem solving skills will be provided. Then, data will be collected with posttest (Caregiver Descriptive Characteristics Form, Patient Descriptive Characteristics Form, Depression Anxiety and Stress Scale (DASS-21), Coping Attitudes Assessment Scale).
62616282|NCT02637388|PLACEBO_COMPARATOR|Placebo Comparator: Control Breakfast|Breakfast cereal and yoghurt only (placebo, negative control)
62616283|NCT02637388|EXPERIMENTAL|Experimental: beta-Glucan Breakfast|Breakfast cereal and yoghurt with the addition of 4g beta-glucan (14.7g Oatwell28 powder)
62616284|NCT01857102|ACTIVE_COMPARATOR|etafilcon A/etafilcon A for Astigmatism|Subjects were randomized to one of two sequences of lens wear.
62616285|NCT01857102|EXPERIMENTAL|etafilcon A for Astigmatism/etafilcon A|Subjects were randomized to one of two sequences of lens wear.
62616286|NCT01074255||Korean Participants Treated With EMEND (aprepitant)|Participants receiving EMEND on Treatment Days 1, 2, and 3 concomitantly with a corticosteroid and a 5-hydroxytryptamine 3 (5-HT3) antagonist.
62616287|NCT01873157|PLACEBO_COMPARATOR|Placebo (NaCl solution)|"Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11."
62616288|NCT01873157|ACTIVE_COMPARATOR|Bortezomib (Velcade®)|"Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11."
62616289|NCT01197014|EXPERIMENTAL|Amlodipine plus Losartan|
62259232|NCT02329964|EXPERIMENTAL|R-S group|"Rocuronium-Sugammadex group~1. Induction of anesthesia : 1% propofol 1.5-2.5 mg/kg with fentanyl 1.5 mcg/kg~2. Muscle relaxant agent : Rocuronium 1mg/kg~3. After endotracheal intubation : normal saline(0.025 ml/kg)~4. Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery : Rocuronium 0.15mg/kg~5. Relaxant agent reversal. at the the end of surgery : sugammadex 2mg/kg"
62445151|NCT00913757||Group 1|400 patients with primary HCC (Hepatocellular carcinoma)
62445152|NCT00913757||Group 2|800 patients with chronic liver disease (high risk non-cancer cases)
62445153|NCT00913757||Group 3|800 population-based controls, identified through a OMV database that will match cases by age, gender, race, and county of residency
62445154|NCT06144814|EXPERIMENTAL|Hyaluronic acid|The objective of this randomized controlled trial was to compare the effect of Hyaluronic acid and Estradiol and to determine the effect on VHI.
62445155|NCT06144814|ACTIVE_COMPARATOR|Estradiol|Secondary objective was to investigate the effect of Hyaluronic acid to VVA/GSM on symptoms.
62445156|NCT01350063|EXPERIMENTAL|Aquatabs and Safe Storage Vessel|Households in this group will receive Aquatabs for water purification, a safe water storage container to prevent contamination during storage in the home, and training and encouragement to treat and safely store their water using the provided products.
62445157|NCT01350063|EXPERIMENTAL|Safe Storage Vessel|Households in this group will receive a safe water storage container, and training and encouragement to safely store their water using the provided products. If our study shows that treatment of tubewell water at the household level is effective in protecting children's health, they will receive a six-month supply of water treatment tablets at the end of the study.
62445158|NCT01350063|OTHER|Standard practice|Households in this group will not receive any water treatment or storage intervention during the study. They will continue their usual water collection and storage practices. If our study shows that treatment and safe storage of tubewell water at the household level is effective in protecting children's health, they will receive the same safe water storage container as Groups 1 and 2 as well as a six-month supply of water treatment tablets at the end of the study.
62445159|NCT00929708|EXPERIMENTAL|1|AZD3199 low dose
62445160|NCT00929708|EXPERIMENTAL|2|AZD3199 intermediate dose
62445161|NCT00929708|EXPERIMENTAL|3|AZD3199 high dose
62445162|NCT00929708|ACTIVE_COMPARATOR|4|Formoterol 2x4.5 microgram bid
62445163|NCT00929708|PLACEBO_COMPARATOR|5|Placebo
62616290|NCT01197014|ACTIVE_COMPARATOR|Amlodipine, Losartan|
62616291|NCT00816322|ACTIVE_COMPARATOR|omega-3 fatty acids|EPA 2.1 g/d+DHA 1.1 g/d
62259233|NCT02329964|ACTIVE_COMPARATOR|S-C-N group|"Succinylcholine-Cisatracurium-Neostigmine group~1. Induction of anesthesia :1% propofol 1.5-2.5 mg/kg with fentanyl 1.5 mcg/kg~2. Muscle relaxant agent :Succinylcholine 1mg/kg~3. After endotracheal intubation : Cisatracurium 0.08mg/kg~4. Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery : Succinylcholine 10mg~5. Relaxant agent reversal at the appearance of second TOF twitch (T2) : Neostigmine 0.2mg/kg with atropine 10 mcg/kg (for preventing side effects of neostigmine)"
62056410|NCT02424084|EXPERIMENTAL|Intact metacarpal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62056411|NCT02424084|EXPERIMENTAL|Fractured scaphoid bone|"Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62056412|NCT02424084|EXPERIMENTAL|Fractured metacarpal bone|"Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62056413|NCT02424084|EXPERIMENTAL|Intact metatarsal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metatarsal bone.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
62056414|NCT04953364|EXPERIMENTAL|SMART|The experimental group will receive access to SMART online platform (6 weeks). SMART includes mental and physical wellness, residual/prosthetic limb managements, use of a prosthesis and weekly peer-support calls or video call over Zoom, hosted by University of British Columbia, depends on participant's preference, promoting motivation and establishing goal setting and action planning. SMART will also allow asynchronous contact with trainers through a secure website.
62056415|NCT04953364|ACTIVE_COMPARATOR|Control|The control group will receive a care booklet and weekly contacts for 6 weeks.
62056416|NCT01898702|EXPERIMENTAL|Diabetes expert patients programme|Diabetes expert patients programme: Participate in a scheduled and standardized expert patients programme course
62056417|NCT01898702|PLACEBO_COMPARATOR|No intervention|Don't participate in a scheduled and standardized expert patients programme course
62056418|NCT04867356|ACTIVE_COMPARATOR|Spinal Stabilization Exercises (SSE)|
62056419|NCT04867356|EXPERIMENTAL|Spinal Stabilization Exercises (SSE) & Latissimus Dorsi Stretching (LDS)|
62445164|NCT06099314||Fruquintinib Rechallenge|"1. third-line treatment with fruquintinib combined with PD-1 inhibitors~2. fourth-line treatment with fruquintinib combined with TAS-102"
62616292|NCT00816322|PLACEBO_COMPARATOR|Placebo|high oleic oil
62616293|NCT06434688||Individuals experiencing neck pain|"Study Group Inclusion Criteria:~* Having chronic neck pain for at least 3 months.~* Being between 18 and 65 years of age.~* Scoring 5 and above on the Neck Disability Questionnaire.~* Scoring 24 and above on the Mini Mental Status Examination.~* Being able to read and write.~* Being willing to participate in the study.~Study Group Exclusion Criteria:~* Participation in any physical therapy program in the last 3 months.~* Having the following problems:~* Radiculopathy, myleopathy (motor and sensory loss) and other neurologic diseases.~* Inflammatory diseases~* History of malignancy.~* Congenital spinal cord anomaly and congenital spinal deformities~* Spinal pathologies, traumatic medulla spinalis injury and other medulla spinalis pathologies.~* Vestibular disorders.~* Diagnosed psychiatric disorders such as bipolar disorder and panic attacks.~* Vision problems that do not improve despite vision aids.~* Pregnancy"
62616294|NCT06434688||Healthy individuals without neck pain|"Control Group Inclusion Criteria:~* Age between 18 and 65 years.~* Scoring 24 and above on the Mini Mental State Examination.~* To be able to read and write.~* Volunteering to participate in the study.~Control Group Exclusion Criteria:~* Having chronic pain in the spine, especially in the neck.~* Exclusion criteria for the study group"
62616295|NCT05366296|ACTIVE_COMPARATOR|: A Lyophilized COVID-19 mRNA Vaccine(RH109)|Participants received A Lyophilized COVID-19 mRNA Vaccine 0.5ml reconstituted by sterile water, 1 shots at Day0, intramuscular injection
62056420|NCT04676425|EXPERIMENTAL|Moderate Hepatic Impairment Participants|Participants with hepatic impairment will receive a single dose of MK-8189 4 mg orally on Day 1.
62056421|NCT04676425|EXPERIMENTAL|Healthy Participants|Healthy participants will receive a single dose of MK-8189 4 mg orally on Day 1.
62056422|NCT04968691|EXPERIMENTAL|Telerehabilitation group|The group to which a structured exercise program supported by telerehabilitation will be treated.
62056423|NCT04968691|ACTIVE_COMPARATOR|Control group|The group to which the home exercise program will be treated.
62056424|NCT02835339|ACTIVE_COMPARATOR|MgSO4 4g load, 1g/hr infusion|Once their obstetrician prescribes magnesium sulfate, participant will be assigned by 50/50 chance to one of two treatment regimens. Participant will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete.
62056425|NCT02835339|EXPERIMENTAL|MgSO4 6g load, 2g/hr infusion|Once their obstetrician prescribes magnesium sulfate, participant will be assigned by 50/50 chance to one of two treatment regimens. Participant will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete.
62056426|NCT06343311|OTHER|EB103|Approximately six (6) subjects will be treated to determine the RP2D. At the designated RP2D, approximately fifteen (15) additional subjects will be treated.
62259234|NCT06468397|EXPERIMENTAL|Retinal Thermofusion|Surgical treatment using the iSeelr™ medical device for retinal detachment repair
62259235|NCT05785156||acute stroke patients|
62445165|NCT04316858|ACTIVE_COMPARATOR|Water|Water will be used as solvent for sodium phosphate
62445166|NCT04316858|ACTIVE_COMPARATOR|Zero calorie carbonated drink|Zero calorie carbonated drink will be used as solvent for sodium phosphate
62445167|NCT02030574|EXPERIMENTAL|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----\> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
62445168|NCT05544513|EXPERIMENTAL|Group I|participants will receive one ferrous sulfate capsule (120 mg of elemental iron) on Mondays, Wednesdays and Fridays
62445169|NCT05544513|ACTIVE_COMPARATOR|Group II|participants will receive one ferrous sulfate (120 mg of elemental iron) capsule daily (except on Sundays)
62616296|NCT05366296|PLACEBO_COMPARATOR|Placebo control|Participants received placebo of 0.5ml normal saline (0.9% sodium chloride solution), 1 shots at Day0, intramuscular injection
62616297|NCT03027245||Eribulin-treated participants|Participants treated with eribulin according to Fachinformation and managed according to clinical practice
62841090|NCT03812276||Study Group|Neodent Acqua GM Helix dental implants will be placed. Multiple implants may be placed in a single subject.
62841091|NCT06453889|EXPERIMENTAL|Multimode thermal therapy|Percutaneous multimode thermal therapy
62841092|NCT02283762|EXPERIMENTAL|Riociguat|Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period.
62841093|NCT02283762|PLACEBO_COMPARATOR|Placebo|Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.
62841094|NCT01036048||cabg disease|pts with saphenous vein graft disease
62841095|NCT04411732||patients with neuromuscular disorder|cohort of patients with neuromuscular disorder
62841096|NCT04411732||healthy controls|cohort of healthy controls
62841097|NCT06444841|EXPERIMENTAL|Smartphone-based app|Participants will use Google Calendar, an off-the-shelf app that is free and user-friendly, to provide reminders on their smartphone to perform prospective memory tasks at the appropriate time. In the current study, participants will offload their personal and experimentally assigned tasks into the digital calendar with reminders enabled.
62841098|NCT06444841|ACTIVE_COMPARATOR|Paper-based notebook|Participants will use a Memory Support System, which is an established paper-based calendar and note taking system that can fit into one's pocket. In the current study they will use the system to offload personal and experimentally assigned tasks and notes into the schedule, to-do list, and journal sections of the notebook.
62841099|NCT04466670|NO_INTERVENTION|phase 1|Observational arm
62841100|NCT04466670|EXPERIMENTAL|phase 2A|Acetylsalicylic acid
62841101|NCT04466670|EXPERIMENTAL|phase 2B|inhaled unfractionated heparin
62841102|NCT04466670|PLACEBO_COMPARATOR|Placebo|Placebo arm for Phase 2A
62841103|NCT03126513|EXPERIMENTAL|G-POEM in refractory gastroparesis|Participants with refractory gastroparesis will be confirmed by endoscopy, clinical and scintigraphy studies.
62841104|NCT02043808||Dabigatran|
62841105|NCT02043808||Warfarin|
62841106|NCT03590041|ACTIVE_COMPARATOR|Standardized SMA|The standardized SMA model includes the same TTIM curriculum as in the patient-driven model, but it is delivered in a standardized way (order of and time spent on topics are set) across all participating practices.
62841107|NCT03590041|ACTIVE_COMPARATOR|Patient-driven SMA|In the patient-driven SMA model, patients receive the same TTIM curriculum, but patients at each practice are able to set the order of the curriculum and dictate how long to spend on each topic.
62445170|NCT05544513|ACTIVE_COMPARATOR|Group III|participants will receive one ferrous sulfate capsule (240mg of elemental iron) on Mondays, Wednesdays and fridays
62445171|NCT02498522|EXPERIMENTAL|metformin arm|83 patients will continue metformin until end of 1st trimester (14 weeks gestation)
62616298|NCT01189708|EXPERIMENTAL|Mesh implantation|Ultrapro® Mesh implantation
62616299|NCT01189708|ACTIVE_COMPARATOR|Standard wound closure without a mesh|Standard wound closure
62616300|NCT04789057|EXPERIMENTAL|Statins|Atorvastatin 40 mg treatment, p.o., QD
62841108|NCT04417699|EXPERIMENTAL|TAS102 plus Oxaliplatin|Oxaliplatin 85mg/m2 IV over 2 hours and TAS-102 (35 mg/m2/dose) orally BID
62841109|NCT04473287|EXPERIMENTAL|intervention group|Reflexology was applied to the intervention group during the procedure for 45 minutes.
62841110|NCT04473287|NO_INTERVENTION|control group|Reflexology was not applied to the control group during the procedure. The control group received standard care and treatment.
62841111|NCT02061371|EXPERIMENTAL|virtual therapy|Group 1 (G1) included 20 patients who will carry out the virtual therapy.
62841112|NCT02061371|EXPERIMENTAL|conventional physiotherapy|Group 2 (G2) included 20 patients who hold conventional physiotherapy.
62841113|NCT05330299|EXPERIMENTAL|COMPASS (single arm)|Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of IBD.
62841114|NCT06165289|EXPERIMENTAL|PRP high concentration group|Endoscopic balloon dilatation combined with autologous platelet-rich plasma (PRP) injection with high concentration (platlet 2\*10\^6/μL)
62056427|NCT03716817|EXPERIMENTAL|Tetric CAD Crown|Tetri CAD crowns will hand polished and cemented with a dual cured resin cement (Variolink Esthetic by Ivoclar Vivadent).
62616301|NCT04789057|PLACEBO_COMPARATOR|Placebo|Placebo tablet, p.o., QD
62841115|NCT06165289|EXPERIMENTAL|PRP low concentration group|Endoscopic balloon dilatation combined with autologous platelet-rich plasma (PRP) injection with low concentration (platlet 1\*10\^6/μL)
62841116|NCT02433470|ACTIVE_COMPARATOR|Active tDCS|Active transcranial direct current stimulation
62841117|NCT02433470|SHAM_COMPARATOR|Sham tDCS|Sham transcranial direct current stimulation
62841118|NCT01966848|ACTIVE_COMPARATOR|Vanguard CR|Patients will receive the posterior cruciate retaining Vanguard CR prosthesis
62841119|NCT01966848|ACTIVE_COMPARATOR|Vanguard XP|Patients will receive the bi-cruciate retaining Vanguard xp prosthesis
62841120|NCT04460001|ACTIVE_COMPARATOR|Ranibizumab|intravetreal injection of Ranibizumab alone for treatment of patients with macular oedema after CRVO once per month and follow up
62841121|NCT04460001|ACTIVE_COMPARATOR|Ranibizumab and triamcinolone acetate|intravetreal injection of Ranibizumab and triamcinolone acetate for treatment of patients with macular oedema after CRVO once per month and follow up
62841122|NCT03078218|NO_INTERVENTION|Before period group|Strictly observational in order to assess the current screening strategy as it is conducted in real life
62841123|NCT03078218|EXPERIMENTAL|After period group|Consist in a systematic pulse oximetry screening where all eligible newborns will be included in the same maternity wards
62056428|NCT02661100|EXPERIMENTAL|CDX-1401 + Poly-ICLC + Pembrolizumab followed by Pembrolizumab|Patients receive CDX-1401, Poly-ICLC and Pembrolizumab for 4 cycles (Q 3 weeks) followed by Pembrolizumab alone (Q 3 weeks) until disease progression.
62056429|NCT05178121|EXPERIMENTAL|Project WISE eLearning Training in Suicide Safety Planning|
62056430|NCT01208298|EXPERIMENTAL|# 1727|Cold sore Patch
62445172|NCT02498522|PLACEBO_COMPARATOR|control arm|83 patients will stop metformin at diagnosis of pregnancy ( 5-6 weeks gestation)
62841124|NCT04326283|EXPERIMENTAL|Trametinib (0.5 mg)|One tablet of trametinib 0.5 mg per day
62056431|NCT03472456||Articaïne|
62259236|NCT05785156||cognitive neurodegenerative disorders|cognitive neurodegenerative disorders (Alzheimer Disease (AD), Lewy Body disease (LBD), FrontoTemporal lobar degeneration (FTLD), Cortico Basal Degeneration (CBD) and Progressive Supra Nuclear Palsy (PSNP)
62259237|NCT05821764||The cohort for the TransAc study|Pregnant women followed for their pregnancy in the 3 Gynecology-Obstetrics department participating in the study
62616302|NCT05484596||Observational Group|Subjects will undergo clinically indicated investigations and tests. The research part of the study is measuring the VA coupling using high fidelity catheters. That is expected to increase the duration of the cardiac catheterization for 30 minutes.
62841125|NCT04326283|EXPERIMENTAL|Trametinib (1 mg)|Two tablets of trametinib 0.5 mg per day
62616303|NCT04103034|EXPERIMENTAL|BT200 0.18mg|Subjects will receive a single subcutaneous dose of BT200 0.18mg
62841126|NCT04326283|ACTIVE_COMPARATOR|Riluzole (100 mg)|One tablet of riluzole 50 mg taken twice per day
62841127|NCT02400385|EXPERIMENTAL|Treatment|Sunitinib 50mg/day, 4 weeks on and 2 weeks off, and concurrent nivolumab 3mg/kg iv every 2 weeks, both for three years if tolerated.
62841128|NCT00654550|EXPERIMENTAL|1|
62616304|NCT04103034|EXPERIMENTAL|BT200 0.6mg|Subjects will receive a single subcutaneous dose of BT200 0.6mg
62841129|NCT04014517|ACTIVE_COMPARATOR|Standard of Care|Standard of Care is represented by the best standard peri-operative treatment already planned for the study population: as for ERAS guidelines, it is represented by fast restoration of liquid and solid diet after surgery (approximately 24 hours after surgery) and pre-operative and post-operative dietary counselling whenever indicated by the surgeon or gastroenterologist
62259238|NCT05217199||1/high risk of infants for cp|1/ high risk of infants for cp was evaulated.
62259239|NCT02960230|EXPERIMENTAL|Stratum A: Newly Diagnosed DIPG|Newly diagnosed children with diffuse intrinsic pontine glioma who are positive for HLA-A2 and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid (TT) peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks.
62259240|NCT02960230|EXPERIMENTAL|Stratum B: Newly Diagnosed Glioma (non-DIPG)|Newly diagnosed children with gliomas other than DIPG who are positive for HLA-A2 and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks.
62616305|NCT04103034|EXPERIMENTAL|BT200 1.8mg|Subjects will receive a single subcutaneous dose of BT200 1.8mg
62616306|NCT04103034|EXPERIMENTAL|BT200 6.0mg|Subjects will receive a single subcutaneous dose of BT200 6.0mg
62616307|NCT04103034|EXPERIMENTAL|BT200 12.0mg|Subjects will receive a single subcutaneous dose of BT200 12.0mg
62841130|NCT04014517|EXPERIMENTAL|Immunonutrition|Impact
62841131|NCT04160754|EXPERIMENTAL|MBRP|The experimental group will receive treatment as usual plus eight Mindfulness based relapse prevention (MBRP) therapy sessions.
62841132|NCT04160754|ACTIVE_COMPARATOR|Control (CTL)|The CTL group will receive treatment as usual plus information on the neurobiology of addiction and healthy behaviors.
62056432|NCT03472456||Eugénol|
62056433|NCT06154343|EXPERIMENTAL|Dose Escalation|"GQ1005 will be administered intravenously every 21 days. Dose Escalation will be guided by Bayesian Optimal Interval (BOIN) Design.~Multiple dose grouping"
62056434|NCT06154343|EXPERIMENTAL|Dose Expansion|GQ1005 at the recommended phase II dose (RP2D) will be administered intravenously every 21 days. Dose expansion will further evaluate the MTD or RP2D in different types of malignant solid tumor in four cohorts.
62056435|NCT06501157||after implementation|Patients undergoing emergency surgery at Peking Union Medical College Hospital after Emergency Surgery Triage and Checklist Management System
62056436|NCT06037590|EXPERIMENTAL|Test 1 - Levodopa Cyclops™ 45 mg|1 pre-filled single-use Levodopa Cyclops™ (= 45 mg levodopa)
62056437|NCT06037590|EXPERIMENTAL|Test 2 - Levodopa Cyclops™ 90 mg|2 pre-filled single-use Levodopa Cyclops™ devices (= 90 mg levodopa)
62616308|NCT04103034|EXPERIMENTAL|BT200 24.0mg|Subjects will receive a single subcutaneous dose of BT200 24.0mg
62841133|NCT04049149|OTHER|JADE-PRISM group|Only applicable in part 3 which is a randomized controlled trial. Part 1 and part 2 are the prospective cohort studies.
62841134|NCT04049149|OTHER|JADE group|Only applicable in part 3 which is a randomized controlled trial. Part 1 and part 2 are the prospective cohort studies.
62259241|NCT02960230|EXPERIMENTAL|Stratum C: Newly Diagnosed DIPG or other Midline Glioma|Newly diagnosed children with DIPG or other midline gliomas (excluding primary spinal cord tumors) who are positive for HLA-A2 (02:01) and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Nivolumab will also be given via IV. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks. Nivolumab will continue to be given every 3 weeks throughout all of treatment.
62841135|NCT04328077|EXPERIMENTAL|TERN-101 dose level 1|Orally administered.
62616309|NCT04103034|EXPERIMENTAL|BT200 24.0mg rep|Subjects will receive a single subcutaneous (SC) dose of BT200 24.0mg by gradual SC infusion
62616310|NCT04103034|PLACEBO_COMPARATOR|Placebo SAD|Subjects will receive a single subcutaneous dose of placebo
62841136|NCT04328077|EXPERIMENTAL|TERN-101 dose level 2|Orally administered.
62841137|NCT04328077|EXPERIMENTAL|TERN-101 dose level 3|Orally administered.
62259242|NCT05984342|EXPERIMENTAL|Adjuvant Chemotherapy in Combination With Immunotherapy|Adjuvant Chemotherapy in Combination With Tislelizumab was used in patients with Lymph Node-Positive Esophageal Squamous Cell Carcinoma after surgery
62259243|NCT02159729|PLACEBO_COMPARATOR|Placebo|Participants treated with placebo in previous ATX-101 studies
62259244|NCT02159729|EXPERIMENTAL|ATX-101 (1 mg/cm^2)|Participants treated with ATX-101 (1 mg/cm\^2) in previous phase 2 studies
62259245|NCT02159729|EXPERIMENTAL|ATX-101 (2 mg/cm^2)|Participants treated with ATX-101 (2 mg/cm\^2) in previous phase 2 studies
62259246|NCT02159729|EXPERIMENTAL|ATX-101 (4 mg/cm^2)|Participants treated with ATX-101 (4 mg/cm\^2) in previous phase 2 studies
62259247|NCT05360459||Control|Healthy postmenopausal patients (more than 12 months from the last 37 menstrual period).
62445173|NCT04430270||Comparison of Perceptions of X-ray, CT and 3D Model|The study group consisted of 11 orthopaedic residents of University Hospital. Selection criteria for the 4 cases was the involved patients who required orthopaedic surgery. 4 cases for orthopaedic procedures were determined with the consensus of experts. As data collection tool was used to evaluate the perceptions of each of these imaging methods in terms of their usefulness in seeing the surgical problem, their efficiency in differential diagnosis and presurgical planning. CT images were converted into in the 3D model was prepared. The survey utilized by our group, addressed the issues in understanding bone anatomy, seeing pathology, and preparation for unexpected events. A multi-item survey was prepared to assess fellow's perception of residency training. Residents who completed their examination in the stations answered the questions on a scale of 10. Descriptive statistics and Friedman test were used for comparison analysis using IBM SPSS Statistics, version 24.
62841138|NCT04328077|PLACEBO_COMPARATOR|Placebo|Orally administered.
62259248|NCT05360459||Gynecological Cancer|Women affected by cervical or endometrial cancer, in early stages, with a good prognosis for life, who have received radiotherapy with or without brachytherapy (radiotherapy) with or without concurrent chemotherapy.
62616311|NCT04103034|EXPERIMENTAL|BT200 loading dose 12.0mg, maintenance doses of 12.0 mg|Subjects will receive an initial subcutaneous loading doses of BT200 12.0mg followed by 4 weekly (every 7 days) maintenance doses of BT200 12.0mg
62616312|NCT04103034|EXPERIMENTAL|BT200 loading doses 24.0mg, maintenance doses of 24.0 mg|Subjects will receive an initial subcutaneous loading dose of BT200 24mg followed by 4 weekly (every 7 days) maintenance doses of BT200 24mg
62841139|NCT03944317|ACTIVE_COMPARATOR|Sulfadoxine pyrimethamine|SP 1500/75mg tablet orally once starting from 16 weeks, at least at four weekly interval until delivery.
62841140|NCT03944317|ACTIVE_COMPARATOR|Azithromycin|A total of 1500mg Azithromycin tablets taken orally as 500mg daily for three consecutive days starting starting from 16weeks of pregnancy and to be repeated once at least after 4 weeks
62841141|NCT06437743||NoL Visible|Patients in this group will undergo laparoscopic abdominal surgery with the nociception level (NoL) monitor visible to the anesthesiologist. The NoL monitor provides an estimation of nociception through a multi-parameter sensor placed on the patient's finger. The anesthesiologist will adjust the doses of analgesic drugs based on the values observed on the NoL monitor, aiming to maintain the values between 10 and 25 during the surgery.
62259249|NCT02085889||food intolerance|lactose intolerance fructose intolerance neither intolerance
62616313|NCT04103034|PLACEBO_COMPARATOR|Placebo MAD|Subjects will receive an initial subcutaneous loading dose of Placebo followed by 4 weekly (every 7 days) maintenance doses of placebo
62841142|NCT06437743||NoL Not Visible|Patients in this group will undergo laparoscopic abdominal surgery with the NoL monitor not visible to the anesthesiologist. The monitor will still be in place and collecting data, but its values will not be displayed during the surgery. The anesthesiologist will manage analgesia based on standard hemodynamic parameters such as heart rate and blood pressure, without access to the NoL values. The intervention includes the same standard anesthetic protocol as the NoL Visible group.
62841143|NCT04989868|EXPERIMENTAL|Trans-Nasal Afferent Loop Decompression Arm|Patients will receive trans-nasal afferent loop decompression after pancreaticoduodenectomy.
62841144|NCT04989868|ACTIVE_COMPARATOR|No Trans-Nasal Afferent Loop Decompression Arm|Patients will NOT receive trans-nasal afferent loop decompression after pancreaticoduodenectomy.
62841145|NCT03124004||Direct Oral Anticoagulants|assuming Pradaxa or Eliquis or Apixaban or Xarelto; undergoing periodontal debridement
62056438|NCT06037590|EXPERIMENTAL|Test 3 - Levodopa Cyclops™ 135 mg|3 pre-filled single-use Levodopa Cyclops™ devices (= 135 mg levodopa)
62056439|NCT06037590|ACTIVE_COMPARATOR|Reference - Inbrija® 84 mg|2 Inbrija® capsules (42 mg levodopa per capsule) from the Arcus® dry powder inhaler
62056440|NCT01109823|ACTIVE_COMPARATOR|patients with normal renal function|Patients with normal renal function hospitalized at the Department Intensive Care Unit who are being treated with levofloxacin I.V. (500mg, twice daily) for an infection.
62841146|NCT03124004||oral anticoagulant therapy|assuming Coumadin or Sintrom; undergoing periodontal debridement
62056441|NCT01109823|ACTIVE_COMPARATOR|patients with hyperfiltration|Patients with hyperfiltration hospitalized at the Department Intensive Care Unit who are being treated with levofloxacin I.V. (500mg, twice daily) for an infection.
62841147|NCT00387790|EXPERIMENTAL|Arm I|Patients receive motexafin gadolinium IV over 5-10 minutes once daily (prior to radiotherapy) 5 days a week for 6 weeks. Patients undergo focal cranial radiotherapy once daily 5 days a week for 6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62841148|NCT02941718|EXPERIMENTAL|Sleep Advancement Counseling|"Participants will receive a 15-week intervention targeting smoking cessation and sleep counseling intervention.~Smoking Cessation intervention components include:~* 6 individual smoking cessation sessions over 15 weeks (week 1, 3, 4, 7, 11, 15)~* 12 weeks of the quit-smoking drug chantix. The standard dosing will be used - 0.5 mg once per day for days 1-3, 0.5my twice per day for days 4-7; and 1mg twice per day from week 3 until the end of treatment.~Sleep counseling components in the form of CBT for insomnia will be given as part of the smoking cessation counseling."
62259250|NCT06073015|EXPERIMENTAL|Experimental group|Esketamine (0.25mg/kg)
62259251|NCT06073015|NO_INTERVENTION|Control group|the same volume of normal saline
62259252|NCT03662880|OTHER|Cardiac Magnetic Resonance &Trans-esophageal echo|patients undergo Percutaneous Mitral Commissurotomy will do cardiac magnetic resonance and trans esophageal echo for detection of left atrial thrombus
62259253|NCT01643629|OTHER|Study arm A|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
62259254|NCT01643629|OTHER|Control Arm B|Control arm B will include subjects receiving Standard therapy
62445174|NCT03876574|EXPERIMENTAL|Treatment|"Patients undergo DSA-guided implantation of hepatic artery infusion pump. All patients receive the intervention Hepatic artery infusion of gemcitabine and floxuridine the next day after pump implantation. The HAI therapy is initiated on day 1, 8: Gemcitabine 1g/m2 for 30 minutes, followed by a blended solution which comprised floxuridine (FUDR) at 0.15 mg/kg/day, dexa-methasone (DXM) at 1 mg/m2/day, low molecular heparin 3200U and saline, lasted for 7 days continuously.Standard treatments of NPC, including radiotherapy and chemotherapy (induction chemotherapy, concurrent chemotherapy and adjuvant chemotherapy) are performed as desired."
62616314|NCT04103034|EXPERIMENTAL|BT200 48.0mg + desmopressin challenge|Subjects will receive a single subcutaneous dose of BT200 48.0mg followed by IV infusion (over 30 min) of 0.3µg/kg desmopressin administered 24 hours after single dose of BT200
62616315|NCT04103034|PLACEBO_COMPARATOR|Placebo + desmopressin challenge dose|Subjects will receive a single subcutaneous dose of placebo followed by IV infusion (over 30 min of 0.3µg/kg desmopressin administered 24 hours after single dose of placebo
62616316|NCT04103034|PLACEBO_COMPARATOR|Placebo infusion|Subjects will receive a single IV dose of placebo administered over 24 hours
62056442|NCT01987817|EXPERIMENTAL|AR101 powder provided in capsules|Study product provided as peanut protein in pull-apart capsules
62056443|NCT01987817|PLACEBO_COMPARATOR|Placebo powder provided in capsules|Placebo formulation in pull-apart capsules containing only inactive ingredients
62056444|NCT00817999|EXPERIMENTAL|Loading Dose|Participants received a 300 mg dose of clopidogrel with or without GFJ.
62259255|NCT00603109|EXPERIMENTAL|I|Subjects receive rimonabant 20 mg per day PO
62259256|NCT00603109|PLACEBO_COMPARATOR|II|Subjects take placebo capsule one a day PO
62259257|NCT00825162|EXPERIMENTAL|Cohort A|Participants aged 6 months to less than 3 years
62259258|NCT00825162|EXPERIMENTAL|Cohort B|Participants aged 3 years to less than 9 years
62056445|NCT00817999|EXPERIMENTAL|Maintenance Dose|Participants received clopidogrel 75 mg/day for 7 days with or without GFJ
62056446|NCT06286124||Incisional Hernia patients|Patients with an Incisional Hernia, who present in the participating center
62259259|NCT00825162|EXPERIMENTAL|Cohort C|Participants aged 9 years to less than 18 years
62259260|NCT04047810|EXPERIMENTAL|Subjects with Advanced Chronic Obstructive Pulmonary Disease|Subjects diagnosed with severe or very severe COPD will be infused intravenously with Mesenchymal Stem Cells (MSC)
62259261|NCT04841707|EXPERIMENTAL|COVID-19 patients|
62616317|NCT04103034|EXPERIMENTAL|BT200 36.0mg|Subjects will receive a single subcutaneous (SC) dose of BT200 36.0mg by gradual SC infusion
62616318|NCT04103034|EXPERIMENTAL|BT200 48.0 mg|Subjects will receive a single subcutaneous dose (SC) of BT200 48.0mg by gradual SC infusion
62616319|NCT04103034|EXPERIMENTAL|BT200 18.0 mg|Subjects will receive a single subcutaneous (SC) dose of BT200 18.0mg by gradual SC infusion
62616320|NCT04103034|EXPERIMENTAL|BT200 24mg IV infusion|Subjects will receive a single IV dose of BT200 24mg administered over 24 hours
62616321|NCT05054686|EXPERIMENTAL|Combination of Stretching and Aerobic Exercises at Clinic|Combination of Stretching and Aerobic Exercises at Clinic and Strengthening and Aerobic Exercises at Home
62841149|NCT02941718|ACTIVE_COMPARATOR|General Health Intervention|"Participants will receive a 15-week intervention targeting smoking cessation and general health information.~Smoking Cessation intervention components include:~* 6 individual smoking cessation sessions over 15 weeks (week 1, 3, 4, 7, 11, 15)~* 12 weeks of the quit-smoking drug chantix. The standard dosing will be used - 0.5 mg once per day for days 1-3, 0.5my twice per day for days 4-7; and 1mg twice per day from week 3 until the end of treatment.~The general health information counseling will be given as part of the smoking cessation counseling and topics include diet, physical activity, oral health, cancer screening and skin protection."
62841150|NCT04002492|EXPERIMENTAL|Addition of bodyweight training|All participants in this study fall into this non randomized single group. These participants will complete a total of 12 bodyweight training sessions over a six to eight week time period. Participants will attend one session per week at Holy Name Medical Center's Physical Therapy Center and will train for one session at their home or chosen location with the aid of a video guide.
62841151|NCT03070964|EXPERIMENTAL|Plitidepsin|
62841152|NCT02763280|EXPERIMENTAL|Ginseng extract 1g|Ginseng extract 1g
62841153|NCT02763280|EXPERIMENTAL|Ginseng extract 3g|Ginseng extract 3g
62841154|NCT02763280|PLACEBO_COMPARATOR|Placebo|Placebo
62259262|NCT04013529|PLACEBO_COMPARATOR|Control|Participate in technology-enabled care without regret lottery
62616322|NCT05054686|ACTIVE_COMPARATOR|Combination of Strengthening and Aerobic Exercises at Clinic|Combination of Strengthening and Aerobic Exercises at Clinic and Stretching and Aerobic Exercises at Home
62841155|NCT02510560|EXPERIMENTAL|NTRA-2112 A|NTRA-2112 A - Dose 1 To be administered orally with daily feed for 28 days or until discharge from hospital.
62616323|NCT05054686|ACTIVE_COMPARATOR|Combination of Strengthening, Stretching and Aerobic Exercises at Clinic|Combination of Strengthening, Stretching and Aerobic Exercises at Clinic and Aerobic Exercises at Home
62616324|NCT01807728|EXPERIMENTAL|Group 1 Training Program|For Group 1, participants will aim to be recruited within the first week of their inpatient rehabilitation stay (admission time point).
62616325|NCT01807728|EXPERIMENTAL|Group 2 Training Program|For Group 2, individuals may be enrolled in the study at any time over their inpatient rehabilitation stay. Data collection may occur at admission (Group 2 only), just prior to discharge and at 3, 6 and 12 months after discharge.
62841156|NCT02510560|EXPERIMENTAL|NTRA-2112 B|NTRA-2112 B - Dose 2 To be administered orally with daily feed for 28 days or until discharge from hospital.
62841157|NCT02510560|PLACEBO_COMPARATOR|Placebo|Placebo To be administered orally with daily feed for 28 days or until discharge from hospital.
62841158|NCT03951662||With alcoholic hepatitis|HIV-positive patients receiving antiretroviral therapy and who are heavy drinkers with high bilirubin and AST levels.
62841159|NCT03951662||Without alcoholic hepatitis|HIV-positive patients receiving antiretroviral therapy and who are heavy drinkers without high bilirubin and AST levels.
62259263|NCT04013529|EXPERIMENTAL|Experimental|Participate in technology-enabled care with regret lottery
62259264|NCT01547169|PLACEBO_COMPARATOR|Saline|
62259265|NCT01547169|EXPERIMENTAL|Low Dose Insulin Detemir (10IU bid)|
62259266|NCT01547169|EXPERIMENTAL|High Dose Insulin Detemir (20IU bid)|
62841160|NCT02781259|EXPERIMENTAL|Selective Lymph Node Dissection|10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery. Routine axillary lymph node dissection is performed. Acquired lymph nodes are separated to fluorescent positive lymph nodes and fluorescent negative lymph nodes with imaging devices.
62259267|NCT05679128|ACTIVE_COMPARATOR|palpation|digital palpation used to identify the cricothyroid membrane
62259268|NCT05679128|EXPERIMENTAL|ultrasonography|Ultrasonography used to identify the cricothyroid membrane
62445175|NCT03463525|EXPERIMENTAL|[11C]osimertinib + oral osimertinib|IV microdose administrations of \[11C\]osimertinib co-administered with 80 mg daily oral osimertinib.
62445176|NCT03799601|EXPERIMENTAL|combination of docetaxel, carboplatin and anlotinib|
62445177|NCT05120011|EXPERIMENTAL|carnitine + leucine|1000 mg L-carnitine with 3000 mg L-leucine per day for 24 weeks
62841161|NCT02087696|OTHER|Naive biological treatment|"Rheumatoid arthritis patients with intolerance or poor compliance or contraindication to methotrexate and who have not received previous biological treatment.~Tocilizumab dose 8mg/kg administered every 4 weeks for 24 weeks"
62259269|NCT06490640||Spontaneous subarachnoid haemorrhage survival cohort|Demographic and clinical data derived and analyzed included age, sex, smoking history, comorbidities. Presenting signs and symptoms, diagnoses responsible for spontaneous SAH (aneurysm, arterial malformation, etc.), site of aneurysm, risk factors, location of the aneurysm, risk factors, blood pressure during ICU admission, and scores from grading systems indicating clinical and radiological severity of the disease were recorded. Procedures for spontaneous SAH, complications during ICU follow-up (vasospasm, meningitis, electrolyte disturbances, rebleeding, DCI, VIP, sepsis/septic shock) and treatments, duration of ICU stay and mechanical ventilation, ICU outcome (survival or mortality), causes of mortality and brain death status were recorded.
62259270|NCT06490640||Spontaneous subarachnoid haemorrhage mortality cohort|Demographic and clinical data derived and analyzed included age, sex, smoking history, comorbidities. Presenting signs and symptoms, diagnoses responsible for spontaneous SAH (aneurysm, arterial malformation, etc.), site of aneurysm, risk factors, location of the aneurysm, risk factors, blood pressure during ICU admission, and scores from grading systems indicating clinical and radiological severity of the disease were recorded. Procedures for spontaneous SAH, complications during ICU follow-up (vasospasm, meningitis, electrolyte disturbances, rebleeding, DCI, VIP, sepsis/septic shock) and treatments, duration of ICU stay and mechanical ventilation, ICU outcome (survival or mortality), causes of mortality and brain death status were recorded.
62259271|NCT04597736|EXPERIMENTAL|cohort|Biological collection with nasopharyngeal samples, saliva, blood, stool and urine
62616326|NCT03409939|EXPERIMENTAL|Aromatic Amino Acid Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
62841162|NCT02087696|OTHER|Previous Biological treatment|"Rheumatoid arthritis patients with intolerance or poor compliance or contraindication to methotrexate and who have not received more than two previous biological treatments.~Tocilizumab dose 8mg/kg administered every 4 weeks for 24 weeks"
62841163|NCT00392769|EXPERIMENTAL|Cetuximab|400 mg/m\^2 intravenous (IV) over 120 Minutes, followed by weekly infusions at 250 mg/m\^2 IV over 60 minutes.
62841164|NCT01160822|EXPERIMENTAL|Part A: Canakinumab|In this ascending dose part, participants received a single intra-articular injection of canakinumab. The beginning dose was 150 mg, escalating to the 300 mg dose and then to 600 mg.
62841165|NCT01160822|PLACEBO_COMPARATOR|Part A: Placebo|Participants received a single intra-articular injection of canakinumab-matching placebo.
62841166|NCT01160822|EXPERIMENTAL|Part B: Canakinumab|Participants received a single intra-articular injection of canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.
62616327|NCT04912414|EXPERIMENTAL|Brief Family Therapy (BFT) for the treatment of psychosomatic symptoms in Rwanda|The participants from the control group were assigned to the Brief Family Therapy for reducing the medically unexplained symptoms. But the control group was not assigned to the intervention (BFT).
62841167|NCT01160822|PLACEBO_COMPARATOR|Part B: Placebo|Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.
62841168|NCT01160822|ACTIVE_COMPARATOR|Part B: Naproxen|Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.
62841169|NCT05775276|EXPERIMENTAL|Incidence Of Mesh Infection After proline mesh Hernioplasty|Cases presented with strangulated or obstructed hernia
62259272|NCT04226690|EXPERIMENTAL|Active Dose 1|Participants will receive the most tolerable CBD/THC dose with repeated dosing for 7 days. On day 1 and 6/7 of the 7-day dosing, subjects will complete laboratory sessions.
62259273|NCT04226690|PLACEBO_COMPARATOR|Matching Placebo|Participants will receive a placebo with repeated dosing for 7 days. On day 1 and 6/7 of the 7-day dosing, subjects will complete laboratory sessions.
62259274|NCT04226690|EXPERIMENTAL|Active Dose 2|Participants will receive the second most tolerable CBD/THC dose with repeated dosing for 7 days. On day 1 and 6/7 of the 7-day dosing, subjects will complete laboratory sessions
62841170|NCT03419923|PLACEBO_COMPARATOR|saline flushes|saline flushes with 250 mL were carried out every 30 min.
62841171|NCT03419923|ACTIVE_COMPARATOR|one stage regional citrate|one stage regional citrate:4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
62841172|NCT03419923|EXPERIMENTAL|two stage regional citrate|two stage regional citrate:4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
62259275|NCT03194282|EXPERIMENTAL|chronic stroke patient with insole|Poor balance capacity is one of clinical symptoms of stroke patient.Poor balance, or postural stability, is significant predictors the risk of fall.
62259276|NCT03194282|SHAM_COMPARATOR|chronic stroke patient without insole|Poor balance capacity is one of clinical symptoms of stroke patient.Poor balance, or postural stability, is significant predictors the risk of fall.
62259277|NCT01325922|OTHER|50/50% Tilt|
62259278|NCT03016325|EXPERIMENTAL|Part 1 Cohort 1 HNO Donor|
62259279|NCT03016325|PLACEBO_COMPARATOR|Placebo Part 1 Cohort 1|
62259280|NCT03016325|EXPERIMENTAL|Part 2 Cohort 2 HNO Donor- low dose|
62259281|NCT03016325|EXPERIMENTAL|Part 2 Cohort 2 HNO Donor- high dose|
62259282|NCT03016325|PLACEBO_COMPARATOR|Placebo Part 2 Cohort 2|
62616328|NCT04102488|EXPERIMENTAL|6-step hygiene technique, application time of 30 seconds|
62616329|NCT04102488|EXPERIMENTAL|6-step hygiene technique, application time of 15 seconds|
62841173|NCT03212313|ACTIVE_COMPARATOR|Healthy Subjects|Study dose of 120 mg
62841174|NCT03212313|EXPERIMENTAL|Mild Hepatic Impairment|Study dose of 120 mg
62841175|NCT03212313|EXPERIMENTAL|Moderate Hepatic Impairment|Study dose of 120 mg
62841176|NCT03212313|EXPERIMENTAL|Severe Hepatic Impairment|Up to a maximum study dose of 120 mg
62616330|NCT04102488|EXPERIMENTAL|3-step hygiene technique, application time of 30 seconds|
62259283|NCT04163796|EXPERIMENTAL|UPnRIDE Training|During each session, heart rate (HR), blood pressure (BP), total session time, time in standing posture, count of sit-to-stand positioning, total distance of overground movement, and rating of perceived exertion (Borg scale) for mobility skills will be monitored. At all study visits during the training period, participants will be asked to answer general health questions about the occurrence of any pressure ulcers or infections.
62259284|NCT03443076|EXPERIMENTAL|EPA + DHA in SMEDS Formulation|Subject will receive a single 500 mg oral dose of EPA + DHA in a SMEDS formulation
62616331|NCT04102488|EXPERIMENTAL|3-step hygiene technique, application time of 15 seconds|
62841177|NCT03031015|EXPERIMENTAL|Cemented K-wire Fixation|The mean age of group A was 41 years (range, 18-63 years). There were 56 male and 11 female patients. The mean time from injury to operation was 5±4.53 days. Injured digits included index (n=24), long (n=19), ring (n=9), and little (n=15) fingers. Types of fractures were transversal (n=31), oblique or spiral (n=14), and comminuted (n=22) fractures. The patients were treated with Cemented K-wire Fixation.
62841178|NCT03031015|ACTIVE_COMPARATOR|Plating|The mean age of group A was 39 years (range, 19-61 years). There were 51 male and 13 female patients. The mean time from injury to operation was 6±5.53 days. Injured digits included index (n=21), long (n=17), ring (n=10), and little (n=16) fingers. Types of fractures were transversal (n=34), oblique or spiral (n=11), and comminuted (n=19) fractures.The patients were treated with Plating.
62445178|NCT05120011|PLACEBO_COMPARATOR|leucine|4000 mg L-leucine per day for 24 weeks
62056447|NCT00779974||s/p Total Shoulder Arthroplasty|The subject population for this study consists of adult patients with a primary diagnosis of osteoarthritis who have had a total shoulder arthroplasty preformed by the PI between September 2003 through December 2007.
62259285|NCT03443076|ACTIVE_COMPARATOR|EPA + DHA (Lovaza)|Subject will receive a single 840 mg oral dose of EPA + DHA as Lovaza
62259286|NCT00003351|EXPERIMENTAL|Arm I: irinotecan|"Patients receive irinotecan intravenously over 90 minutes every week for 4 weeks followed by a 2 week rest period. Treatment is repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before and during treatment. Patients are followed every 3 months for 2 years, then annually for 1 year."
62445179|NCT05151835|EXPERIMENTAL|Robotic Surgery|Prospective single arm study to investigate effect of a novel robotic surgical system on safety, efficacy and outcomes for performance of minimally invasive surgery across urology, upper and lower GI surgery.
62445180|NCT01937364|PLACEBO_COMPARATOR|Placebo|Placebo every eight hours as inpatients for 72 hours or until discharge if less than 72 hours.
62445181|NCT01937364|ACTIVE_COMPARATOR|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
62616332|NCT04764383|EXPERIMENTAL|PK/PD Group|Participants in the Pharmacokinetic (PK)/pharmacodynamic (PD) Group will receive L-Histidine and Lodosyn daily for 7 consecutive days.
62616333|NCT04764383|PLACEBO_COMPARATOR|L-Histidine and Lodosyn followed by Placebo Group|Participants in this group will receive L-Histidine and Lodosyn daily for 2 consecutive weeks followed by Placebo for an additional 2 consecutive weeks with a 1-week wash-out period in between.
62616334|NCT04764383|EXPERIMENTAL|Placebo followed by L-Histidine and Lodosyn Group|Participants in this group will receive Placebo daily for 2 consecutive weeks followed by L-Histidine and Lodosyn for an additional 2 consecutive weeks with a 1 week wash out period in between.
62616335|NCT04792047||Lesions with perivasular FAI greater than ≥-70.1|
62616336|NCT04792047||Lesions with perivasular FAI greater than <-70.1|
62616337|NCT03491397|EXPERIMENTAL|GAE OA|Subjects will be treated with a genicular artery embolization (GAE) procedure performed with Embozene Microspheres. The microspheres will be delivered in a saline-contrast medium solution and will be delivered to the arteries supplying the areas of the subject's pain.
62616338|NCT01994473|EXPERIMENTAL|SEP-363856|Dosing will be initiated at 10 mg SEP-363856 as a single oral dose. Subsequent cohorts will be dosed at 25, 50, and 100 of SEP-363856.
62616339|NCT01994473|PLACEBO_COMPARATOR|Placebo|An oral of matched placebo
62259287|NCT00003351|EXPERIMENTAL|Arm II: irinotecan|"Patients receive irinotecan intravenously over 90 minutes every 3 weeks for 6 weeks. Treatment is repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before and during treatment. Patients are followed every 3 months for 2 years, then annually for 1 year."
62259288|NCT04592640|EXPERIMENTAL|Uremic Calciphylaxis Patients|Human amniotic mesenchymal stem cells (hAMSCs)
62259289|NCT05380011|EXPERIMENTAL|Group A (CIMT and Bimanual Task Training)|Constraint Induced Movement Therapy and Bimanual Task Training
62259290|NCT05380011|EXPERIMENTAL|Group B (Bimanual Task Training)|Bimanual Task Training
62259291|NCT04790877|ACTIVE_COMPARATOR|First sub-study: Glucose beverage|This intervention entails the intake of a beverage including 25 g of glucose.
62259292|NCT04790877|EXPERIMENTAL|First sub-study: Regular alcohol-free beer|This intervention entails the intake of regular alcohol-free beer including 25 of carbohydrates.
62259293|NCT04790877|EXPERIMENTAL|First sub-study: Alcohol-free beer with modified composition (isomaltulose + maltodextrin)|This intervention entails the intake of an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with isomaltulose (2.5 g/100 mL) and a resistant maltodextrin (0.8 g/100 mL) (IMB). This beverage included 25 g of carbohydrates.
62259294|NCT04790877|EXPERIMENTAL|First sub-study: Alcohol-free beer with modified composition (++ maltodextrin)|This intervention entails the intake of an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with a resistant maltodextrin (2.0 g/100 mL) (MB). This beverage included 25 g of carbohydrates.
62259295|NCT04790877|ACTIVE_COMPARATOR|Second sub-study: White bread + Water|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and water.
62259296|NCT04790877|EXPERIMENTAL|Second sub-study: White bread + Regular alcohol-free beer|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and regular alcohol-free beer (providing 14.3 g of carbohydrates).
62259297|NCT04790877|EXPERIMENTAL|Second sub-study: White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin)|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with isomaltulose (2.5 g/100 mL) and a resistant maltodextrin (0.8 g/100 mL) (IMB). This beverage included 14.3 g of carbohydrates.
62259298|NCT04790877|EXPERIMENTAL|Second sub-study: White bread + Alcohol-free beer enriched with ++ maltodextrin|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched a resistant maltodextrin (2.0 g/100 mL) (MB). This beverage included 14.3 g of carbohydrates.
62259299|NCT04790877|ACTIVE_COMPARATOR|Second sub-study: Extra-White bread + Water|This intervention entails the intake of white bread which provides 64.3 g (50 g + 14.3 g) of carbohydrates and water. This intervention would be the comparator in carbohydrates-equally conditions.
62259300|NCT03283826|EXPERIMENTAL|ATA188|Participants in Parts 1 and 2 will receive ATA188 intravenously as described in the Detailed Description.
62259301|NCT03283826|PLACEBO_COMPARATOR|Placebo|Participants in Part 2 will receive placebo matching to ATA188 intravenously as described in the Detailed Description (i.e., will receive placebo only in the first year, and thereafter will receive ATA188 for the remainder of the study).
62259302|NCT02238704|EXPERIMENTAL|Regimen A|500mg elemental calcium (as CaCO3) + 200 microgram Vit D per administration, administered 2 times a day, at least 2hours apart with one administration of 60mg elemental iron (as FeSO4) at any time of the day
62259303|NCT02238704|ACTIVE_COMPARATOR|Regimen B|500mg elemental calcium (as CaCO3) + 200 microgram Vit D per administration, administered 3 times a day, at least 2hours apart with one administration of 60mg elemental iron (as FeSO4) at any time of the day
62616340|NCT01994473|EXPERIMENTAL|SEP-363856 Open Label|75 mg SEP-363856 given once-daily
62259304|NCT05936684|EXPERIMENTAL|Effect of ProlEx breathing on decision-making if applied before the Eupnea condition|Intervention (behavioral): Block 1: ProlEx, Block 2: Eupnea/Control during decision-making
62259305|NCT05936684|EXPERIMENTAL|Effect of Eupnea breathing on decision-making if applied before the ProlEx condition|Intervention (behavioral): Block 1: Eupnea/Control, Block 2: ProlEx during decision-making
62259306|NCT04496622|EXPERIMENTAL|Whole Body Vibration Technique|WBV training with the frequency of 16-25 Hz along with conventional treatment.
62259307|NCT04496622|ACTIVE_COMPARATOR|WBV Technique|WBV training with the frequency of 26-35 Hz along with conventional treatment.
62259308|NCT01255644|EXPERIMENTAL|Antiviral drug|
62259309|NCT00732277|EXPERIMENTAL|Treatment|Patients in this arm will be given the following IMP intraveneously at 6 hour intervals - hydrocortisone (100mg/m2/24 hours)
62259310|NCT00732277|NO_INTERVENTION|Control|in each phase of study 15 patients will receive no IMP as control arm
62841179|NCT05384431|ACTIVE_COMPARATOR|Muscle5 and TRIM7|"MUSCLE5 and TRIM7 natural health product supplementation~Name of natural health product (brand name, generic) - MUSCLE 5, chocolate Is this a market-approved natural health product (per Health Canada)? - Yes Dose - 1 scoop Ingredients (per dose) - Whey protein isolate (24g), milk protein isolate (16g), Creatine (3g), Calcium (450mg), Vitamin D (1000 IU) Frequency of administration - Once/day Duration (e.g., six weeks) - 12 weeks Route of administration - Oral~Name of natural health product (brand name, generic) - TRIM7 Is this a market-approved natural health product (as per Health Canada)? Yes Dose - 3 capsules Ingredients (per dose) - Alpha lipoic acid (200mg), CoEnzyme Q10 (100mg), beet root extract (250mg), green coffee bean extract (250mg), green tea extract (250mg), forskolin (25mg), Vitamin E (22 mg AT) Frequency of administration - Twice/day Duration (e.g., six weeks) - 12 weeks Route of administration - Oral"
62841180|NCT05384431|PLACEBO_COMPARATOR|Placebo|"Placebo collagen and microcrystalline cellulose intake~Placebo Control 1 (Counter to MUSCLE5) Dose - 1 scoop Ingredients (per dose) - Collagen (40g) Frequency of administration - once/day Duration - 12 weeks Route of administration - Oral~Placebo Control 2 (Counter to TRIM7) Dose - 3 capsules Ingredients (per dose) - Microcrystalline cellulose (400 mg) Frequency of administration - twice/day Duration - 12 weeks Route of administration - Oral"
62841181|NCT04000854|ACTIVE_COMPARATOR|Calcium hydroxide|Root canal dressing with Ca(OH)2 (Calasept)
62841182|NCT04000854|ACTIVE_COMPARATOR|Chlorhexidine|Root canal dressing with clorhexidine digluconate 2 % gel
62259311|NCT03402529|OTHER|CESM|
62259312|NCT05957666|EXPERIMENTAL|oral misoprostol|oral misoprostol will be given in a dose of 50microgram and repeated after 6 hours if required.Maximum 2 doses will be given
62616341|NCT06482619|EXPERIMENTAL|Creatine supplementation|Creatine monohydrate (Creapure®, Crown Sport Nutrition, Arnedo, Spain) ingested 3 capsules daily (3 g/day)
62616342|NCT06482619|PLACEBO_COMPARATOR|Placebo supplementation|Sucrose ingested 3 capsules daily (3 g/day)
62616343|NCT02085070|EXPERIMENTAL|Melanoma patients|"After establishing eligibility criteria, for patients with melanoma the investigator will determine at least one lesion that requires local therapy (surgical resection or LITT) based on size, location, and/or risk of hemorrhage; this will be considered the surgical lesion. All other eligible brain lesions will be considered clinically evaluable lesions and will be followed by modified RECIST (mRECIST) criteria to determine best response."
62616344|NCT02085070|OTHER|Non-small cell lung cancer patients|"NSCLC patients are not required to have a surgical lesion but must have at least one clinically evaluable lesion in the central nervous system. Patients on NSCLC are required to have formalin-fixed, paraffin-embedded tumor tissue available for biomarker analysis."
62616345|NCT03620383|EXPERIMENTAL|Heat|Distal topical heat application
62616346|NCT03620383|NO_INTERVENTION|No Heat|Inactive heat pack to blind the investigator.
62616347|NCT02476864|EXPERIMENTAL|Sequence AB|Subjects receive treatment A in Period 1 followed by treatment B in Period 2 with a washout phase of 10 to 14 days between the two treatment periods
62259313|NCT05957666|ACTIVE_COMPARATOR|vaginal misoprostol|vaginal misoprostol will be given in a dose of 50 microgram and repeated after 6 hours if required.Maximum 2 doses will be given
62259314|NCT03187431|EXPERIMENTAL|IPF patients|autologous bone marrow mesenchymal stem cells
62259315|NCT02685241||General population|General population
62259316|NCT01294202|EXPERIMENTAL|AT13387 and imatinib|AT13387 administered on days 1, 8 and 15, imatinib administered daily
62259317|NCT05051904||Warfarin|"All eligible Japanese on-valvular atrial fibrillation (NVAF) patients with concomitant Coronary Artery Disease (CAD), who were prescribed with warfarin. From existing data from the Japan Medical Data Vision Co. Ltd. (MDV) database, which covered all insurance types and a large population size.~The study period started on April 18th, 2011 (start of data collection) to December 31st, 2020 (end of data collection)."
62259318|NCT05051904||Dabigatran|"All eligible Japanese on-valvular atrial fibrillation (NVAF) patients with concomitant Coronary Artery Disease (CAD), who were prescribed with dabigatran. From existing data from the Japan Medical Data Vision Co. Ltd. (MDV) database, which covered all insurance types and a large population size.~The study period started on April 18th, 2011 (start of data collection) to December 31st, 2020 (end of data collection)."
62616348|NCT02476864|EXPERIMENTAL|Sequence BA|Subjects receive treatment B in Period 1 followed by treatment A in Period 2 with a washout phase of 10 to 14 days between the two treatment periods
62616349|NCT05804253|ACTIVE_COMPARATOR|bovine bone|Patients received maxillary sinus augmentation grafting with bovine bone mineral
62616350|NCT05804253|ACTIVE_COMPARATOR|Porcine bone mineral|patients received maxillary sinus augmentation grafting with porcine bone mineral
62616351|NCT01537991|EXPERIMENTAL|Group 1A|Group 1A is where less than or equal to 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.
62616352|NCT01537991|EXPERIMENTAL|Group 1B|Group 1A is where more than 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.
62259319|NCT05051904||Rivaroxaban|"All eligible Japanese on-valvular atrial fibrillation (NVAF) patients with concomitant Coronary Artery Disease (CAD), who were prescribed with rivaroxaban. From existing data from the Japan Medical Data Vision Co. Ltd. (MDV) database, which covered all insurance types and a large population size.~The study period started on April 18th, 2011 (start of data collection) to December 31st, 2020 (end of data collection)."
62616353|NCT01537991|EXPERIMENTAL|Phase II|All patients will receive radiotherapy to a maximum dose of 65Gy in 20 fractions. The dose to the individual patient will be determined by their individual dose constraints for organs at risk.
62841183|NCT06143904|EXPERIMENTAL|Treatment Period 1 -2|Single-dose Intravenous (IV) Genz-112638 Day 1 followed by single dose GenZ-112638 oral capsules Day 8
62841184|NCT06143904|EXPERIMENTAL|Treatment Period 1-4|Single-dose Intravenous (IV) Genz-112638 Day 1; single dose GenZ-112638 oral capsules Day 8; oral capsule Genz-112638 Days 9-14; single dose \[14C\]-Genz-112638 oral solution Day 15
62841185|NCT02891135|NO_INTERVENTION|Standard|Patients randomized to the standard arm will receive standard procedures for initiating antiretroviral therapy for HIV.
62841186|NCT02891135|EXPERIMENTAL|Intervention|Patients randomized to the intervention arm will be offered immediate treatment initiation under the intervention algorithm (SLATE).
62841187|NCT00986037|EXPERIMENTAL|IV ABT-308 in asthmatics|ABT-308 single escalating doses in mild to moderate asthmatics
62841188|NCT00986037|EXPERIMENTAL|SC ABT-308 in asthmatics|ABT-308 multiple SQ doses in mild to moderate asthmatics
62841189|NCT00986037|EXPERIMENTAL|IV ABT-308 in healthy volunteers|ABT-308 single escalating IV doses in healthy volunteers
62841190|NCT00751608|EXPERIMENTAL|1|
62841191|NCT00751608|ACTIVE_COMPARATOR|2|
62841192|NCT00751608|PLACEBO_COMPARATOR|3|
62841193|NCT01164072||HIGH NICOTINE|Well characterized group of 100 regular smokers experimenting the E-Cigarette loaded with 7.2 mg nicotine cartridges (high nicotine group).
62841194|NCT04885777|ACTIVE_COMPARATOR|Lidocaine group|One ml of a solution containing 20 mg/ml of lidocaine was applied to each nostril of the participants in the Lidocaine group. Thus, a total of 40 mg of lidocaine, 20 mg for each nostril, was given to the individuals of the Lidocaine group.
62841195|NCT04885777|PLACEBO_COMPARATOR|Placebo group|The Placebo group received only a total of 2 ml of 0.9% NaCl (one ml for each nostril).
62841196|NCT02052492|EXPERIMENTAL|Cohort A: EF-022 100 ng once weekly|Intra-Muscular injections of EF-022 100 ng once weekly for a period of 8 weeks
62841197|NCT02052492|EXPERIMENTAL|Cohort B: EF-022 500 ng once weekly|Intra-Muscular injections of EF-022 500 ng once weekly for a period of 8 weeks
62841198|NCT02052492|EXPERIMENTAL|Cohort C: EF-022 1000 ng once weekly|Intra-Muscular injections of EF-022 1000 ng once weekly for a period of 8 weeks
62841199|NCT02052492|EXPERIMENTAL|Expanded Cohort|the expanded cohort, 24 Patients will be allocated to receive either 100ng, 500ng or 1000ng weekly treatment as detailed below: The first 18 patients will be assigned to alternating doses of either 100ng or 500ng in a sequential manner (each patient will be assigned to a single dose). A decision regarding adding a 1000ng dose cohort vs. continuing with the 100ng and 500ng doses will be based on a discussion of the interim analysis results.
62841200|NCT06013046|ACTIVE_COMPARATOR|Intensity-controlled physical activity training (IPAT)|A group provided education on physical activity recommendations for people with disabilities, access to a community-based accessible gym, and an intensity-controlled 14-week one-on-one supervised physical activity training intervention.
62841201|NCT06013046|PLACEBO_COMPARATOR|Education and Access (EA)|A group provided education on physical activity recommendations for people with disabilities and access to a community-based accessible gym in order to independently complete a 14-week physical activity program.
62841202|NCT01607255|EXPERIMENTAL|water (exchange) method|Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.
62056448|NCT00403897|EXPERIMENTAL|1|Ages 2 - 6: Day 1= 1 sachet/day; Day 3= 1 sachet BID; Day 5= 1 sachet TID Ages 7 - 11: Day 1= 1 sachet BID; Days 3 \& 5 = 2 sachets BID;
62616354|NCT02261831|EXPERIMENTAL|obese patients|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
62616355|NCT02261831|EXPERIMENTAL|Diabetic patients|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
62616356|NCT02261831|EXPERIMENTAL|Patients free of obesity and diabetes|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
62616357|NCT02261831|EXPERIMENTAL|patients free type 2 diabetes.|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
62616358|NCT02087137|ACTIVE_COMPARATOR|Memory and Aging Program|The Memory and Aging Program intervention consists of five 2-hour sessions conducted over five consecutive weeks. The content of the program includes: (a) the provision of factual information (i.e., about memory, age-related memory changes, lifestyle factors affecting memory, and memory strategies) in an informal lecture format; and (b) memory intervention (i.e., practice and application of several evidence-based memory strategies) in a hands-on interactive format.
62841203|NCT01607255|EXPERIMENTAL|water (exchange) plus dye method|Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions
62841204|NCT01607255|ACTIVE_COMPARATOR|air method|The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.
62056449|NCT05392023|EXPERIMENTAL|Group A|Scapular Stabilization exercise program
62841205|NCT03605485|EXPERIMENTAL|Trial Continuous Positive Airway Pressure (CPAP) mask|Trial nasal pillows CPAP mask
62841206|NCT06062342|EXPERIMENTAL|FPI Group|Participants in this group will receive the FPI intervention at any FPI coordinated outreach event (4-5 hours) during a 21 month period
62841207|NCT06062342|NO_INTERVENTION|Pre-intervention Assessment Group|We will conduct pre-assessment events (4-5 hours) during 1.5 months in each zip code (prior to the introduction of the FPI intervention) to capture information from residents /participants via survey.
62616359|NCT02087137|NO_INTERVENTION|Wait-list Control|Participants randomized to the wait-list control group will receive no intervention following randomization. They will be offered the intervention immediately following completion of the week 14 outcome testing session.
62616360|NCT05480553|EXPERIMENTAL|NPC-06|
62616361|NCT05480553|PLACEBO_COMPARATOR|Placebo|
62616362|NCT01256385|EXPERIMENTAL|Arm A (cetuximab and temsirolimus)|Patients receive temsirolimus IV over 30-60 minutes and cetuximab IV over 1-2 hours once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62616363|NCT01256385|EXPERIMENTAL|Arm B (temsirolimus)|Patients receive temsirolimus as in Arm A. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over to Arm A.
62841208|NCT03319758|EXPERIMENTAL|thin or dehiscences buccal plate|Immediate implant placement used bone augmentation in combination with an absorbable collagen membrane with thin or dehiscences buccal plate.
62616364|NCT00153816|EXPERIMENTAL|Full Factorial Placebo|subjects in 2X2 factorial design; randomized to daily placebo
62841209|NCT05346666|ACTIVE_COMPARATOR|Control Group|Group 1 received the conventional treatment for Status Epilepticus including propofol (loading dose is 3 to 5 mg/kg with maintenance of 1 to 15 mg/kg/h), phenobarbital (initial loading dose is 5 to 15 mg/kg over 1 hour. Infusion rates can be maintained at 0.5 to 15 mg/kg/h), and midazolam (a loading dose of 0.2 mg/kg is given with maintenance doses ranging between 0.05 and 2.0 mg/kg/h).
62616365|NCT00153816|EXPERIMENTAL|Full Factorial Calcium|subjects in 2X2 factorial design; randomized to daily 1200 mg as calcium carbonate
62616366|NCT00153816|EXPERIMENTAL|Full Factorial Vitamin D|Subjects in 2X2 factorial design; randomized to daily 1000 IU vitamin D3
62616367|NCT00153816|EXPERIMENTAL|Full Factorial Calcium Plus Vitamin D|Subjects in 2X2 factorial design; randomized to daily 1200 mg as calcium carbonate and 1000 IU vitamin D3
62841210|NCT05346666|EXPERIMENTAL|Tocilizumab Group|Group 2 received the same treatment in group 1 in addition to tocilizumab that was initiated at a dose of 4mg/kg administered twice monthly with 1-week intervals for 3 months. A monthly dose (8mg/kg) of tocilizumab was added if needed.
62841211|NCT00351429|EXPERIMENTAL|1|
62616368|NCT00153816|EXPERIMENTAL|Two Arm Placebo|Women choosing to take daily 1200 mg as calcium carbonate randomized to daily placebo
62616369|NCT00153816|EXPERIMENTAL|Two Arm Vitamin D|Women choosing to take daily 1200 mg as calcium carbonate randomized to daily 1000 IU vitamin D3
62616370|NCT04735159|ACTIVE_COMPARATOR|Study group-SCS Impanted|30 patients with chronic pain (at least 6 months) with pre- and post-surgery evaluation (imaging and clinical evaluation) implanted with Precision SpectraTM for the validation study and for the construction of the predictive model.
62616371|NCT04735159|NO_INTERVENTION|Comparator-chronic pain|20 patients with chronic pain (at least 6 months) with degenerative spine pain. Non-specific low-back pain, nociceptive pain / mixed neuropathic. This will be the comparator group
62616372|NCT04735159|NO_INTERVENTION|Control-healthy volunteers|10 volunteers without pain or related disease, age less than 25 years, to establish a control group whose pattern is used as a comparator with chronic pain groups. This is the control group
62841212|NCT00123422|EXPERIMENTAL|Breathing retraining|Exercise training with computerized training program
62841213|NCT00123422|EXPERIMENTAL|Heliox|Exercise training with helium oxygen combination
62841214|NCT00123422|ACTIVE_COMPARATOR|Exercise|Exercise training
62841215|NCT02616796|EXPERIMENTAL|Social gaze training|Appropriate social gaze behavior will be reinforced using the principles of Applied Behavior Analysis.
62841216|NCT02616796|NO_INTERVENTION|No Training|Appropriate social gaze behavior will not be reinforced.
62616373|NCT02838589|ACTIVE_COMPARATOR|Byetta|"Pre- and post treatment investigations:~1. Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler~2. Cerebral cortical oxygination by near infrared spectroscopy (NIRS)~3. Endothelial function/response by the methods:~   * Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)~  * EndoPAT2000~  * Ankle-brachial index"
62616374|NCT02838589|PLACEBO_COMPARATOR|Isotonic saline|"Pre- and post treatment investigations:~1. Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler~2. Cerebral cortical oxygination by near infrared spectroscopy (NIRS)~3. Endothelial function/response by the methods:~   * Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)~  * EndoPAT2000~  * Ankle-brachial index"
62616375|NCT01864252|SHAM_COMPARATOR|Group 1 Control (65 patients)|Sham Remote ischaemic preconditioning with IV normal saline 2-5ml/hour.
62616376|NCT01864252|ACTIVE_COMPARATOR|Group 2 (65 patients)|Patients administered a Remote Ischaemic preconditioning protocol (three-5 min cycles of simultaneous inflation to cuffs placed on upper arm and thigh) prior to surgery and IV normal saline 2-5 mL/h during surgery.
62616377|NCT01864252|EXPERIMENTAL|Group 3 GTN (65 patients):|Patients administered sham simulated Remote Ischaemic Preconditioning protocol prior to surgery and IV Glyceryl Trinitrate 2-5ml/h during surgery.
62259320|NCT02159703|EXPERIMENTAL|Single Arm Phase 2|
62259321|NCT03847129|EXPERIMENTAL|Biofeedback training group|The participants in the biofeedback training group attend a 30 minute biofeedback protocol per session, two times a week for six to eight weeks that is also combined with the regular diabetic care treatment in the Occupational Therapy Room.
62616378|NCT01864252|EXPERIMENTAL|• Group 4 RIPC+GTN (65 patients):|Patients administered Remote Ischaemic Preconditioning protocol and IV Glyceryl Trinitrate during surgery
62616379|NCT04159324|EXPERIMENTAL|StroCare treatment group|Optimized cross-sectoral, structured and coordinated treatment pathway that integrates a patient-centred outcome evaluation
62616380|NCT04159324|NO_INTERVENTION|control group|routine aftercare stroke treatment
62616381|NCT05951920|EXPERIMENTAL|Lymph node aspiration / Blood sampling|
62616382|NCT04239196|EXPERIMENTAL|tocilizumab and IV steroids combination|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months. Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week).
62616383|NCT04239196|OTHER|IV steroids combination alone|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
62616384|NCT02614404|EXPERIMENTAL|Imatinib combination therapy|Administration of imatinib (400 mg/day) plus dihydroartemisinin (40 mg/day) plus piperaquine (320 mg/day) to uncomplicated adult male malaria patients. Normal health parameters will be monitored continuously to evaluate safety and the decrease in peripheral blood parasitemia with time will be quantitated to assess efficacy.
62616385|NCT02614404|ACTIVE_COMPARATOR|dihydroartemisinin plus piperaquine|Administration of dihydroartemisinin (40 mg/day) plus piperaquine (320 mg/day) to uncomplicated adult male malaria patients. Normal health parameters will be monitored continuously to evaluate safety and the decrease in peripheral blood parasitemia with time will be quantitated to assess efficacy.
62616386|NCT05574907|EXPERIMENTAL|68Ga-FAPI PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
62616387|NCT04631237||Focus Groups|N=52
62616388|NCT04631237||Cognitive Interviews|N=24
62056450|NCT05392023|OTHER|Group B|Relaxation Exercises of cervico- scapular region
62259322|NCT03847129|ACTIVE_COMPARATOR|Home-based training group|The participants in this group receive similar doses of home-based tendon gliding exercises and resistance training with an anti-stress ball for 30 minutes at a frequency of 2 times a week for 6 to 8 weeks, also combined with the regular diabetic care treatment.
62056451|NCT04411602|EXPERIMENTAL|Treatment with Convalescent Plasma|SARS-CoV-2 convalescent plasma from approved donors will be transfused into severely ill patients with confirmed COVID-19 severe respiratory distress. Plasma will be administered on days 0, 2,4, 6 and 8.
62616389|NCT04631237||Survey|N=600
62616390|NCT02760121|EXPERIMENTAL|Acetazolamide|Participants will be dosed 250mg Acetazolamide (p.o.) three times per day for two days prior to and a single dose on the day of study.
62616391|NCT02760121|EXPERIMENTAL|Methazolamide|Participants will be dosed 100mg Methazolamide (p.o.) twice daily separated by a placebo for two days prior to and a single dose on the day of study. The placebo dose is provided to match the dosing schedule between conditions.
62841217|NCT06015152|EXPERIMENTAL|GROUP A Tazarotene 0.045%|"Topical tazarotene 0.045% and halobetasol Propionate 0.01% . TAZ is the first receptor-selective retinoid used externally to treat plaque psoriasis . The major metabolite of tazarotene, tazarotenic acid, is quickly formed after application and binds to retinoic acid receptors (RARs) in the nucleus. Tazarotenic acid has a weak affinity for retinoid X receptors and prefers to bind to RARs b and g.~Halobetasol propionate is a medication used to treat scalp psoriasis. It is a form of topical corticosteroid, which means it works by suppressing the immune system and reducing inflammation."
62841218|NCT06015152|EXPERIMENTAL|GROUP B Halobetasol Propionate 0.01%|"Topical tazarotene 0.045% and halobetasol Propionate 0.01% . TAZ is the first receptor-selective retinoid used externally to treat plaque psoriasis . The major metabolite of tazarotene, tazarotenic acid, is quickly formed after application and binds to retinoic acid receptors (RARs) in the nucleus. Tazarotenic acid has a weak affinity for retinoid X receptors and prefers to bind to RARs b and g.~Halobetasol propionate is a medication used to treat scalp psoriasis. It is a form of topical corticosteroid, which means it works by suppressing the immune system and reducing inflammation.~."
62259323|NCT03847129|NO_INTERVENTION|Control group|The participants in the control group receive only diabetes disease prevention consultation once and outcome assessments twice.
62259324|NCT03411720|EXPERIMENTAL|FES-row-training|Subjects will perform 4 months of FES-row-raining
62259325|NCT03411720|OTHER|Wait-list time control|Subjects will wait 4 months before performing being allowed to engage in 4 months of FES-row-training
62259326|NCT03411720|ACTIVE_COMPARATOR|Arms-only-row-training|Subjects will perform 4 months of arms-only row training before being allowed to engage in 4 months of FES-row-training
62259327|NCT00050609|PLACEBO_COMPARATOR|1|
62259328|NCT00050609|ACTIVE_COMPARATOR|2|5 mg tadalafil
62259329|NCT00050609|ACTIVE_COMPARATOR|3|20 mg tadalafil
62616392|NCT02760121|PLACEBO_COMPARATOR|Placebo|Participants will take (p.o.) placebo pills three times per day for two days prior to and a single dose on the day of study.
62616393|NCT02066077|EXPERIMENTAL|Bilateral temporal and propofol|During the MECT treatment, electrodes are placed at bilateral temporal, with propofol 2mg/kg to Induce anesthesia.
62616394|NCT02066077|EXPERIMENTAL|Bilateral temporal and etomidate|During the MECT treatment, electrodes are placed at bilateral temporal, with etomidate 0.3mg/kg to Induce anesthesia.
62616395|NCT02066077|EXPERIMENTAL|The right temporal and propofol|During the MECT treatment, electrodes are placed at the right temporal, with propofol 2mg/kg to Induce anesthesia.
62616396|NCT02066077|EXPERIMENTAL|The right temporal and etomidate|During the MECT treatment, electrodes are placed at the right temporal, with etomidate 0.3mg/kg to Induce anesthesia.
62616397|NCT02066077|EXPERIMENTAL|Bilateral frontal and propofol|During the MECT treatment, electrodes are placed at bilateral frontal, with propofol 2mg/kg to Induce anesthesia.
62616398|NCT02066077|EXPERIMENTAL|Bilateral frontal and etomidate|During the MECT treatment, electrodes are placed at bilateral frontal, with etomidate 0.3mg/kg to Induce anesthesia.
62616399|NCT02066077|ACTIVE_COMPARATOR|Standard-therapy Group|During the MECT treatment, electrodes are placed at bilateral temporal, with etomidate 0.3mg/kg to Induce anesthesia.
62259330|NCT00900458|ACTIVE_COMPARATOR|1|formerly preeclamptic women with low plasma volume
62259331|NCT00900458|ACTIVE_COMPARATOR|2|formerly preeclamptic women with normal plasma volume
62056452|NCT01105923|EXPERIMENTAL|Receive CDS intervention|Providers in clinics that will receive the CDS alert, as their clinic was randomized into our study.
62056453|NCT01105923|NO_INTERVENTION|No CDS intervention|
62056454|NCT02228954||Renal Cell Cancer|
62259332|NCT00900458|OTHER|3|Healthy controls
62259333|NCT04992819|NO_INTERVENTION|Control Group|"Preterm infants in NICU are fed with breast milk and bottle. Although the date is written on expressed breast milk, it is usually not given by checking its suitability for the time of day. Experiment is about labeling breast milk by time of day before giving it to babies. There is no extra intervention during feeding. The breastmilk of the control group patients will be given without matching according to the clinical routine practice.~Demographic data, anthropometric measurements (weight, height, head circumference of all babies will be recorded in the Baby Monitoring Form created by the researcher."
62616400|NCT00777192||Symptoms in Colorectal Cancer|Colorectal Cancer Patients Receiving Oxaliplatin Chemotherapy
62616401|NCT02749799|EXPERIMENTAL|DFD-01 (betamethasone dipropionate) Spray, 0.05%|DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.
62616402|NCT05619380|ACTIVE_COMPARATOR|Physiotherapeutic procedures: auto-therapy (therapeutic exercises)|"Specialized therapeutic exercises:~1. Gerry's exercise - Starting position: tongue placed on the palate. Movement: slowly opening and closing the mouth. The number of repetitions: 6 times a day for 10 movements.~2. Active lateral movements of the mandible:~   Starting position: separable teeth. Movement: slow movements of the lower jaw to the right and left. The number of repetitions: 6 times a day for 10 movements.~3. Protrusion and mouth opening:~Starting position: teeth separated. Movement: a) lowering the jaw forward, b) opening the mouth c) closing the mouth d) retracting the lower jaw.~Number of repetitions: 6 times a day for 10 movements."
62841219|NCT05270252|NO_INTERVENTION|Control group|no intervention
62259334|NCT04992819|EXPERIMENTAL|Chronobiological Approach Nutrition Model|"Preterm infants in NICU are fed with breast milk and bottle. Although the date is written on expressed breast milk, it is usually not given by checking its suitability for the time of day. The milk of the intervention group patients will be matched circadian and given to the babies. Intervention group's breast milk is labeling by time of day before the each feeding. In the intervention group, a label containing the time of expressed breastmilk will be affixed. Circadian matched milk will be provided at each feeding.~intervention is;n the intervention group, a label containing the time of expressed breastmilk will be affixed. In the milk preparation room, breast milk will be stored in a separate refrigerator as 08:00-19:59 day milk and 20:00-07:59 night milk.~Demographic data, anthropometric measurements (weight, height, head circumference of all babies will be recorded in the Baby Monitoring Form created by the researcher."
62259335|NCT04564742|EXPERIMENTAL|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo
62259336|NCT04564742|PLACEBO_COMPARATOR|Placebo|Placebo matching dapagliflozin
62259337|NCT03821025|ACTIVE_COMPARATOR|Multiple Plastic Stents|Patients will receive two 8.5Fr Platic biliary stents placed side by side across the biliary stricture.
62259338|NCT03821025|ACTIVE_COMPARATOR|Self-expandable Metal Stents|Patients will receive a fully covered Self-expandable Metal Stents (10mm) across the biliary stricture
62259339|NCT03255681|EXPERIMENTAL|Split face study|Split face study with the left side of the face receiving PRP injections and the right side of the face receiving PRP with 0.1cc of 10% calcium chloride per 1mL of PRP. The volume of PRP will be used upon the discretion of the provider for treatment of the cosmetic facial deformity but will be in equal amounts for each side on every patient participating in the study.
62259340|NCT03757286|EXPERIMENTAL|FSF with CAD\CAM customized cutting guide|Maxillary reconstruction using free scapular flap with CAD/CAM customized osteotomy guide.
62259341|NCT03757286|ACTIVE_COMPARATOR|FSF without customized cutting guide|maxillary reconstruction using free scapular flap without customized osteotomy guide. CAD/CAM 3D model for maxilla will be used.
62259342|NCT04758442|EXPERIMENTAL|Vancomycin|Subjects with hematologic cancer who received intravenous vancomycin for a suspected or confirmed infection.
62259343|NCT01732302|EXPERIMENTAL|Educational intervention|Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
62259344|NCT01732302|NO_INTERVENTION|Delayed educational intervention|Primary health care centers in the delayed intervention group will receive the same intervention as described above with 9 months delay.
62259345|NCT04283136|ACTIVE_COMPARATOR|Type 1 tablet - part 1|Subjects will receive a single dose of padsevonil Type 1 tablet in the period defined by the pre-specified sequence they were randomized on to.
62259346|NCT04283136|EXPERIMENTAL|Type 2 tablet - part 1|Subjects will receive a single dose of padsevonil Type 2 tablet in the period defined by the pre-specified sequence they were randomized on to.
62259347|NCT04283136|EXPERIMENTAL|Type 3 tablet - part 1|Subjects will receive a single dose of padsevonil Type 3 tablet in the period defined by the pre-specified sequence they were randomized on to.
62259348|NCT04283136|EXPERIMENTAL|Type 4 tablet - part 1|Subjects will receive a single dose of padsevonil Type 4 tablet in the period defined by the pre-specified sequence they were randomized on to.
62259349|NCT04283136|EXPERIMENTAL|Type 5 tablet - part 1|Subjects will receive a single dose of padsevonil Type 5 tablet in the period defined by the pre-specified sequence they were randomized on to.
62259350|NCT04283136|ACTIVE_COMPARATOR|Type 1 tablet - part 2 (2 x 200 mg fasted)|Subjects will receive a single 2 x 200 mg dose of padsevonil Type 1 tablet under fasting conditions in the period defined by the pre-specified sequence they were randomized on to.
62259351|NCT04283136|ACTIVE_COMPARATOR|Type 1 tablet - part 2 (2 x 200 mg fed)|Subjects will receive a single 2 x 200 mg dose of padsevonil Type 1 tablet under fed conditions in the period defined by the pre-specified sequence they were randomized on to.
62259352|NCT04283136|ACTIVE_COMPARATOR|Type 1 tablet - part 2 (200 mg fasted)|Subjects will receive a single 200 mg dose of padsevonil Type 1 tablet under fasting conditions in the period defined by the pre-specified sequence they were randomized on to.
62259353|NCT04283136|ACTIVE_COMPARATOR|Type 1 tablet - part 2 (200 mg fed)|Subjects will receive a single 200 mg dose of padsevonil Type 1 tablet under fed conditions in the period defined by the pre-specified sequence they were randomized on to.
62841220|NCT05270252|EXPERIMENTAL|Intervention group|Interdisciplinary educational intervention with a combination of active educational methods.
62259354|NCT05917561|EXPERIMENTAL|Phototherapy associated with active treatment|Anifrolumab 300mg/infusion/month for 36 weeks + UVB TL01: 2 times a week during 24 weeks. (Phototherapy will be started 12 weeks after the beginning of anifrolumab)
62259355|NCT05917561|PLACEBO_COMPARATOR|Phototherapy associated with placebo|Placebo once a month infusion for 36 weeks + UVB TL01: 2 times a week during 24 weeks.
62259356|NCT03113656|EXPERIMENTAL|Weighted Blanket First|This group will receive the Weighted Blanket first and then the Non-weighted blanket
62259357|NCT03113656|EXPERIMENTAL|Non-weighted Blanket First|This group will receive the Non-weighted Blanket first and then the Weighted blanket
62616403|NCT05619380|ACTIVE_COMPARATOR|Physiotherapeutic procedures: manual therapy (massage) and auto-therapy (therapeutic exercises)|"Manual therapy of soft tissues in the masseter muscle:~1. Extraoral massage of the masseter muscle (duration 5 minutes)~2. Intraoral massage of the masseter muscle (duration 5 minutes)~3. Functional massage of the masseter muscle (duration 5 minutes)~Auto-therapy: The patient will receive instructions on how to perform therapeutic exercises at home."
62616404|NCT05619380|ACTIVE_COMPARATOR|Physiotherapeutic procedures: manual therapy (PIR) and auto-therapy (therapeutic exercises)|"Manual therapy of soft tissues in the masseter muscle:~1. Post-isometric relaxation of the masseter muscle (duration 15 minutes).~Auto-therapy: The patient will receive instructions on how to perform therapeutic exercises at home."
62616405|NCT03294200|EXPERIMENTAL|Tricinch Coil System treatment|
62056455|NCT01114204|EXPERIMENTAL|Ferumoxytol|Participants received a total of 2 doses of IV ferumoxytol 510 milligrams (mg) (17 milliliters \[mL\]). The first IV 510 mg dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose, for a total cumulative dose of 1.02 grams (g).
62056456|NCT01114204|ACTIVE_COMPARATOR|Iron Sucrose|Participants received an IV injection or infusion of iron sucrose 200 mg (10 mL) on Day 1 (Baseline) and on 4 other non-consecutive days over a 14-day period, for a total cumulative dose of 1.0 g. Participants receiving their first ever exposure to IV iron sucrose, received a test dose on Day 1 prior to receiving the remainder of the first dose, as prescribed in the package insert for some countries.
62056457|NCT05416255|ACTIVE_COMPARATOR|Dextrose injection|Injection of 10 ml of 12.5% dextrose
62056458|NCT05416255|ACTIVE_COMPARATOR|Hematopoietic stem cells|Injection of 10 ml of of 7.5 ml hematopoietic stem cells, 2 ml of 25% dextrose (5% diluted), 0.5 ml of 1% lidocaine (0.05% diluted),and 0.25 ml dexamethasone (1.5 mg)
62259358|NCT06153875|EXPERIMENTAL|Sensory Threshold, Burst High Frequency|The technique consists of percutaneous peripheral electrical stimulation on the Spinal or Inferior Gluteal and Tibial Nerve through a ultrasound-guided needle.
62259359|NCT06153875|EXPERIMENTAL|Theta-Burst Stimulation|The technique consists of percutaneous peripheral electrical stimulation on the Spinal or Inferior Gluteal and Tibial Nerve through a ultrasound-guided needle.
62056459|NCT05416255|ACTIVE_COMPARATOR|Platelet Rich Plasma injection|Injection of 10 ml of leukocyte rich platelet rich plasma
62056460|NCT05416255|ACTIVE_COMPARATOR|No injection|Aspiration of synovial fluid may be an active comparator.
62056461|NCT00962351|OTHER|Metal-on-Polyethylene|
62056462|NCT00962351|OTHER|Metal-on-Metal, 28mm femoral head|
62259360|NCT06153875|ACTIVE_COMPARATOR|Transcutaneous Electrical Nerve Stimulation|The technique consists of transcutaneous electrical nerve stimulation on the trapezius or low back and internal calf muscles through surface electrodes.
62259361|NCT04707742|EXPERIMENTAL|Povidone-iodine 2% (Betadine© bucal 100 mg/ml)|"Povidone-iodine 2% (Betadine© bucal 100 mg/ml) (Mylan Pharmaceuticals, S.L., Spain).~The concentration was adjusted to those previously indicated by diluting commercial formulas with distilled water minutes before rinsing (3 mL of povidone-iodine 10% for oral use - Betadine© with 12 mL of distilled water)."
62259362|NCT04707742|EXPERIMENTAL|Hydrogen peroxide 1% (Oximen® 3%)|Hydrogen peroxide 1% (Oximen® 3%) (Reig Jofré, S.A., Spain). The concentration was adjusted to those previously indicated by diluting commercial formulas with distilled water minutes before rinsing (5 mL of hydrogen peroxide 3% - Oximen© with 10 mL of distilled water).
62616406|NCT02635009|ACTIVE_COMPARATOR|PCI using 3DCRT|Prophylactic cranial irradiation (PCI) using three-dimensional conformal radiation therapy (3DCRT) for 2 weeks, 5 fractions/week.
62056463|NCT00962351|OTHER|Metal-on-Metal, 36mm femoral head|
62056464|NCT02569437|EXPERIMENTAL|Doxycycline|Doxycycline plus oral methylprednisolone and nasal saline sprays
62056465|NCT02569437|PLACEBO_COMPARATOR|Sugar pill|placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.
62056466|NCT01616394||children with congenital heart disease|
62056467|NCT04406480|OTHER|90 trios (270 subjects: 90 fetus, 90 mothers, 90 fathers)|
62056468|NCT01933451|EXPERIMENTAL|Restrictive intraoperative fluid therapy|To Keep intraoperative pulse pressure variation above 18%.
62056469|NCT01933451|OTHER|Liberal intraoperative fluid therapy|To keep intraoperative pulse pressure variation below 13%.
62259363|NCT04707742|EXPERIMENTAL|Clorhexidine 0,12% (Clorhexidine Dental PHB©)|"Clorhexidine 0,12% (Clorhexidine Dental PHB©) contains clorhexidine (C22H30N10Cl2).~Rinses were ready to use in their commercial formulas."
62259364|NCT04707742|EXPERIMENTAL|Cetylpyridinium chloride 0,07% (Vitis Xtra Forte©)|"Cetylpyridinium chloride 0,07% (Vitis Xtra Forte©) contains cetylpyridinium chloride (C21H38ClN).~Rinses were ready to use in their commercial formulas."
62259365|NCT04707742|PLACEBO_COMPARATOR|Control (Distilled Water)|Distilled water.
62259366|NCT06418607|EXPERIMENTAL|Sequence 1|Venglustat hard capsule administered in period 1 followed by tablet administered in period 2.
62056470|NCT03270514|EXPERIMENTAL|Exparel Injectable Product|Liposomal Bupivacaine (Exparel) Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the liposomal bupivacaine (Exparel) group (\~30).
62056471|NCT03270514|ACTIVE_COMPARATOR|Bupivacaine Hydrochloride|Bupivacaine Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the bupivacaine group (\~30).
62056472|NCT04729894|EXPERIMENTAL|Safe Medication Storage Device + Education|
62056473|NCT04729894|ACTIVE_COMPARATOR|Education|
62616407|NCT02635009|EXPERIMENTAL|PCI with HA using IMRT|PCI with hippocampal avoidance (HA) using intensity-modulated radiation therapy (IMRT) for 2 weeks, 5 fractions/week.
62616408|NCT01130324||VIBATIV treated pregnant women|Women treated with telavancin (any dose or duration) during pregnancy.
62616409|NCT00482599|ACTIVE_COMPARATOR|Normal renal function|Org 25969 given to subjects with normal renal function
62616410|NCT00482599|EXPERIMENTAL|Impaired renal function|Org 25969 given to subjects with impaired renal function
62056474|NCT04773158|EXPERIMENTAL|Intervention Arm|The intervention clinic sites will be provided access to both the Functional gastrointestinal disorders (FGIDs) Screening Module and the Treatment Module
62259367|NCT06418607|EXPERIMENTAL|Sequence 2|Venglustat tablet administered in period 1 followed by hard capsule administered in period 2.
62259368|NCT02768337|OTHER|Arm 1: Afatinib only at Recommended Phase 2 dose (RP2D)|No targeted radiotherapy. Afatinib at Recommended Phase 2 Dose for 11 days.
62259369|NCT02768337|EXPERIMENTAL|Arm 2: Afatinib RP2D + 2 Gy targeted radiotherapy|Patient will receive the RP2D of afatinib for 11 days and will receive targeted radiotherapy at a dose level of 2 Gy on Day 10 of treatment.
62616411|NCT02249507|NO_INTERVENTION|Control|sited rest for 45 minutes
62616412|NCT02249507|EXPERIMENTAL|higher intensity aerobic exercise|45 minutes of aerobic exercise at 75%HRmax
62259370|NCT02768337|EXPERIMENTAL|Arm 3: Afatinib RP2D + 4 Gy targeted radiotherapy|Patient will receive the RP2D of afatinib for 11 days and will receive targeted radiotherapy at a dose level of 4 Gy on Day 10 of treatment.
62616413|NCT02249507|EXPERIMENTAL|lower intensity aerobic exercise|45 minutes of aerobic exercise at 50%HRmax
62616414|NCT03421275|EXPERIMENTAL|Esketamine|intravenous anaesthetic and analgetic
62616415|NCT03421275|ACTIVE_COMPARATOR|Fentanyl Citrate|intravenous opioid analgetic
62616416|NCT03421275|PLACEBO_COMPARATOR|Saline Nasal|"intravenous Natriumklorid b. Braun 9 mg/ml"
62259371|NCT00842738|ACTIVE_COMPARATOR|Mindfulness meditation|Women with mild dysplasia offered mindfulness meditation
62259372|NCT00842738|OTHER|No meditation|Women with mild dysplasia offered health care services as usual
62616417|NCT04649034||86 patients ischemic DCM|A cohort of 86 patients with ischemic dilated cardiomyopathy in sinus rhythm and ejection fraction (EF) of LV less than 45%
62259373|NCT00842738|OTHER|Controls|Women with normal cervical cells
62616418|NCT04649034||86 patients non ischemic DCM|A cohort of 86 patients with non-ischemic dilated cardiomyopathy in sinus rhythm and ejection fraction (EF) of LV less than 45%
62616419|NCT04649034||86 patients hypertrophic cardiomyopathy|A cohort of 86 patients with hypertrophic cardiomyopathy in sinus rhythm and ejection fraction (EF) of LV less than 55% or with an apical aneurism diagnosed in an image test
62616420|NCT00615147||1|Patients to have a CT pulmonary angiogram for suspected pulmonary embolism will have a d-dimer drawn as is routinely done.
62259374|NCT05021250|EXPERIMENTAL|Lipiodol marking|HCC patients treated with TACE and lipiodol marking, followed by SBRT with DIBH.
62259375|NCT04788251|EXPERIMENTAL|Exercise-based fall prevention intervention|To receive 7 weeks of exercise-based programme
62259376|NCT04788251|OTHER|Wait-list controls|To receive fall prevention resources while waiting for programme
62616421|NCT02146820|EXPERIMENTAL|Picosecond Laser System|
62616422|NCT04946526|ACTIVE_COMPARATOR|Broccoli seed extract|A single dose dietary supplement made up of 385 mg broccoli seed extract delivering 50 mg GR (115 umol GR) and 100 mg vitamin C (as ascorbic acid).
62616423|NCT04946526|EXPERIMENTAL|Broccoli seed extract with mustard seed powder|A single dose dietary supplement made up of a mixture of 385 mg broccoli seed extract delivering 50 mg GR (115 umol GR), 145 mg mustard seed powder containing enough active myrosinase (enzyme) to fully hydrolyze the GR in the capsule to SF post-ingestion (\~30 units myrosinase activity) and 100 mg vitamin C (as ascorbic acid).
62616424|NCT05904132|PLACEBO_COMPARATOR|Healthy Controls|
62616425|NCT05904132|EXPERIMENTAL|MCI Subjects|
62616426|NCT01179646|ACTIVE_COMPARATOR|Protonix|Protonix 40 mg DR Tablet
62616427|NCT01179646|EXPERIMENTAL|Pantoprazole|Pantoprazole 40 mg DR Tablet
62616428|NCT00904917|EXPERIMENTAL|Adapted PIP|"Participants (both mother and children) participated in an adapted cognitive family prevention program for the families of children with a depressed African American mother.~The intervention was the Prevention Intervention Project."
62616429|NCT00904917|ACTIVE_COMPARATOR|Lecture|"Mothers received psychoeducation about depression.~The intervention was psychoeducation."
62616430|NCT02376205|EXPERIMENTAL|bupivacaine hydrochloride 0.5% solution|Bupivacaine hydrochloride 0.5% 10 mL solution poured into the retropharyngeal space intraoperatively before wound closure during anterior cervical discectomy and fusion procedure
62616431|NCT02376205|PLACEBO_COMPARATOR|0.9% NaCl solution|0.9% NaCl 10 mL solution poured into the retropharyngeal space intraoperatively before wound closureduring anterior cervical discectomy and fusion procedure
62056475|NCT04773158|NO_INTERVENTION|Control Arm|The control clinics will have the Functional gastrointestinal disorders (FGIDs) Screening Module. However, control clinics will not have access to the FGIDs Treatment Module. These clinic sites will be given access to the pre-screener form section of the module, so that providers are made aware of a positive screen for a FGID.
62056476|NCT00740558|ACTIVE_COMPARATOR|1|Two groups received a traditional chiropractic adjustment of the lumbar 5 and the other group received a manually assisted mechanical force adjustment of the lumbar 5.
62259377|NCT05023096|ACTIVE_COMPARATOR|Menthol+Tobacco|Menthol+Tobacco - where both menthol and tobacco flavored liquids for electronic nicotine delivery systems are available to choose from
62616432|NCT03585946||Cyclosporine|
62616433|NCT03585946||Intravenous Immunoglobulin|
62616434|NCT03585946||Etanercept|
62841221|NCT04207632||Intervention|The Group of patients will receive routine treatment of muscle hypertonia with botulinum toxin type A in their elbow flexors.
62259378|NCT05023096|EXPERIMENTAL|Tobacco|Tobacco - where only tobacco flavored liquid is available for electronic nicotine delivery systems
62259379|NCT05023096|EXPERIMENTAL|Unflavored|Unflavored - where only unflavored liquid is available for electronic nicotine delivery systems
62259380|NCT00549939|PLACEBO_COMPARATOR|Placebo|Matching placebo 0.1 mg/kg/day or 0.2 mg/kg/day
62259381|NCT00549939|EXPERIMENTAL|Alfuzosin 0.1 mg/kg/day|
62259382|NCT00549939|EXPERIMENTAL|Alfuzosin 0.2 mg/kg/day|
62616435|NCT03585946||Steroids|
62616436|NCT04723836|ACTIVE_COMPARATOR|TT genotype active comparator group|5mg riboflavin per day from 16th gestational week
62616437|NCT04723836|EXPERIMENTAL|TT genotype experimental group|5mg riboflavin + 400µg 5-methyltetrahydrofolate per day from 16th gestational week
62841222|NCT03931252|EXPERIMENTAL|High fat|Boost VHC (Very High Calorie), Nestle, 8 ounce can
62841223|NCT03931252|EXPERIMENTAL|High protein|Ensure High Protein 8 ounce can
62259383|NCT01576770|ACTIVE_COMPARATOR|ethyl chloride vapocoolant spray|"Half of the patients will randomly be assigned to receive Gebauer's ethyl choride topical anesthetic vapo-coolant spray immediately prior to placing a 22 gauge intravenous catheter.~Pain in this group will be evaluated at the time of IV placement by an independent observer (unblinded) and the patient on a 0-10 scale. Pain will again be evaluated when propofol is injected at anesthesia induction by a blinded observer and the staff anesthesiologist (also blinded) on a scale of 1-4.~Blinding will occur following IV placement by draping and securing the hand and IV site with Coban self-adherent elastic wrap to cover any skin changes due to the ethyl chloride or the patch."
62259384|NCT01576770|EXPERIMENTAL|Synera Patch|"The other half of the patients will randomly be assigned to receive Synera Patches, to be applied to the dorsum of both hands, at least 30 minutes before placing a 22 gauge intravenous catheter.~Pain in this group will be evaluated at the time of IV placement by an independent observer (unblinded) and the patient on a 0-10 scale. Pain will again be evaluated when propofol is injected at anesthesia induction by a blinded observer and the staff anesthesiologist (also blinded) on a scale of 1-4.~Blinding will occur following IV placement by draping and securing the hand and IV site with Coban self-adherent elastic wrap to cover any skin changes due to the patch or ethyl chloride."
62259385|NCT03823066|EXPERIMENTAL|Coach Pepper|Pepper is a humanoid socially assistive robot
62259386|NCT02238873|ACTIVE_COMPARATOR|Pegfilgrastim +1|Pegfilgrastim will be given 24 hours (day +1) after completion of salvage chemotherapy
62259387|NCT02238873|EXPERIMENTAL|Pegfilgrastim +3|Pegfilgrastim will be given 72 hours (day +3) after completion of salvage chemotherapy
62259388|NCT03901079||CTO BridgePoint system|"BridgePoint CTO System:~* CrossBoss Catheter~* Stingray LP Catheter~* Stingray Guidewire and Extension Wire"
62259389|NCT00366964|NO_INTERVENTION|Device|
62259390|NCT03705637|EXPERIMENTAL|Exparel Arm|20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.
62259391|NCT00524342|EXPERIMENTAL|Oprelvekin, Interleukin 11, IL-11|25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
62259392|NCT00833950|EXPERIMENTAL|narrow band noise|Phase out in narrow band noise tinnitus patients
62259393|NCT05988775|EXPERIMENTAL|Leg training|Participants sat on a chair with their left heel resting on the table with the push button switches. participants performed 10 blocks of the aforementioned sequence with their leg, with a 30s break between each block.
62259394|NCT05988775|ACTIVE_COMPARATOR|Sequence observation|Participants observed 10 blocks of the sequence with the lights alternating automatically, with a 30s break between each block.
62259395|NCT05988775|OTHER|Nature movie watching|"Participants watched a scenic relaxation film, for 10 minutes, with a 30s break after every minute."
62259396|NCT04800562|EXPERIMENTAL|PCS499 900mg BID|PCS499 900mg twice a day with food
62259397|NCT04800562|PLACEBO_COMPARATOR|Placebo|similar in appearance to active study drug
62259398|NCT02771704|EXPERIMENTAL|Silver diamine fluoride|Intervention: Silver diamine fluoride will be applied in vivo on carious dentine lesions
62259399|NCT02771704|EXPERIMENTAL|Potassium iodide|Potassium iodide will be applied in vivo on carious dentine lesions.
62259400|NCT02771704|EXPERIMENTAL|Chlorhexidine|Chlorhexidine will be applied in vivo on carious dentine lesions
62259401|NCT02771704|EXPERIMENTAL|Silver diamine fluoride+Potassium iodide|Silver diamine fluoride and potassium iodide mixture will be applied in vivo on carious dentine lesions
62841224|NCT03131609||A: Container + Castile-soap wipe|Sterile urine collection container and Castile-soap wipe given to patient to self-obtain a clean catch mid-stream urine specimen - Control group represents usual care in the Emergency Department.
62841225|NCT03131609||B: Container + Silver impregnated wipe|Sterile urine collection container and silver-impregnated cloth-wipe given to patient to self-obtain a clean catch mid-stream urine specimen
62259402|NCT02771704|EXPERIMENTAL|Saline|Sterile physiological saline will be applied in vivo on carious dentine lesions
62259403|NCT00975299|EXPERIMENTAL|Arm 1|
62259404|NCT00975299|EXPERIMENTAL|Arm 2|
62259405|NCT03290833|EXPERIMENTAL|Robotic|The experimental group will receive 30 minutes robotic training sessions, 3 times per week for a total of 30 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive schedule (1-hour sessions, 3 times/week, 30 total sessions) of conventional therapy from an occupational therapist.
62259406|NCT03290833|ACTIVE_COMPARATOR|Conventional|In conventional therapy group, participants will receive an one-hour of one-on-one treatment (1-hour sessions, 3 times/week, 30 total sessions) from an occupational therapist, focusing on arm and hand function.
62259407|NCT02324920|EXPERIMENTAL|DDD+CLS|The pacemaker will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON.
62259408|NCT02324920|PLACEBO_COMPARATOR|ODO|The pacemaker will be programmed in ODO mode.
62259409|NCT00817882|EXPERIMENTAL|1|individually targeted vocational rehabilitation
62259410|NCT00817882|ACTIVE_COMPARATOR|2|routine back pain rehabilitation
62616438|NCT04723836|PLACEBO_COMPARATOR|TT genotype placebo group|Placebo supplement from 16th gestational week
62616439|NCT04723836|ACTIVE_COMPARATOR|CT genotype active comparator group|5mg riboflavin per day from 16th gestational week
62259411|NCT00247000|ACTIVE_COMPARATOR|1|Home teleheatlh for heart failure management
62616440|NCT04723836|EXPERIMENTAL|CT genotype experimental group|5mg riboflavin + 400µg 5-methyltetrahydrofolate per day from 16th gestational week
62616441|NCT04723836|PLACEBO_COMPARATOR|CT genotype placebo group|Placebo supplement from 16th gestational week
62616442|NCT05572892||Adult patients hospitalised in the Neurology Department of Caen University Hospital|Measurement of walking dependency according to the FAC scale (in the first week after stroke by physiotherapists, at 6 weeks, 12 weeks and 6 months by telephone).
62616443|NCT04122625|EXPERIMENTAL|Part A - Debio 1143 150 mg + Nivolumab|Participants received Debio 1143, 150 milligrams (mg) capsules, orally once on Days 1 to 10 and Days 15 to 24 of each 28-day treatment cycle along with nivolumab 240 mg, intravenous (IV) infusion on Days 1 and 15 of each 28-day treatment cycle allowed for a maximum of 26 cycles.
62616444|NCT04122625|EXPERIMENTAL|Part A - Debio 1143 200 mg + Nivolumab|Participants received Debio 1143, 200 mg capsules, orally once on Days 1 to 10 and Days 15 to 24 of each 28-day treatment cycle along with nivolumab 240 mg, IV infusion on Days 1 and 15 of each 28-day treatment cycle allowed for a maximum of 26 cycles.
62616445|NCT04122625|EXPERIMENTAL|Part B - Cohort 1 (SCLC): Debio 1143 200 mg + Nivolumab|Participants with small-cell lung cancer (SCLC) received Debio 1143, 200 mg capsules, orally once on Days 1 to 28 in each 28-day treatment cycle along with nivolumab 240 mg, IV infusion on Days 1 and 15 of each 28-day treatment cycle allowed for a maximum of 26 cycles.
62616446|NCT04122625|EXPERIMENTAL|Part B - Cohort 2 (SCCHN): Debio 1143 200 mg + Nivolumab|Participants with squamous cell carcinoma of the head and neck (SCCHN) received Debio 1143, 200 mg capsules, orally once on Days 1 to 28 in each 28-day treatment cycle along with nivolumab 240 mg, IV infusion on Days 1 and 15 of each 28-day treatment cycle allowed for a maximum of 26 cycles.
62616447|NCT04122625|EXPERIMENTAL|Part B - Cohort 3 (GI Cancers): Debio 1143 200 mg + Nivolumab|Participants with gastrointestinal (GI) cancers received Debio 1143, 200 mg capsules, orally once on Days 1 to 28 in each 28-day treatment cycle along with nivolumab 240 mg, IV infusion on Days 1 and 15 of each 28-day treatment cycle allowed for a maximum of 26 cycles.
62616448|NCT04122625|EXPERIMENTAL|Part B - Cohort 4 (Gynecologic Cancers): Debio 1143 200 mg + Nivolumab|Participants with gynecologic cancers received Debio 1143, 200 mg capsules, orally once on Days 1 to 28 in each 28-day treatment cycle along with nivolumab 240 mg, IV infusion on Days 1 and 15 of each 28-day treatment cycle allowed for a maximum of 26 cycles.
62616449|NCT04401202|EXPERIMENTAL|NSO|Nigella sativa oil 500mg softgel capsules in oral twice daily dose for 10 days
62056477|NCT00740558|SHAM_COMPARATOR|2|The investigators had two groups, one for each chiropractic technique used in the research project and we had a control group
62616450|NCT04401202|NO_INTERVENTION|Control|Standard of care
62616451|NCT01529294|EXPERIMENTAL|Iloperidone|Eligible subjects receive a single oral dose of 2 mg iloperidone as a tablet
62616452|NCT01118988|EXPERIMENTAL|Mentorship|"Subjects randomly assigned to this arm received the specified Mentorship Intervention"
62616453|NCT01118988|NO_INTERVENTION|Control|Subjects randomly assigned to this control group receive treatment as usual (TAU).
62616454|NCT01118988|NO_INTERVENTION|Mentors|"Subjects recruited to the Mentor arm of the study are UCLA Pediatric Pain Program patients between the ages of 14 and 18. These mentors are identified by the Principal Investigator as children who have not necessarily eliminated pain, but have learned how to cope with pain and maintain appropriate functioning in daily life. Mentors undergo an in depth training from doctoral level psychologists who are members of the research team. Mentors present pain coping information developed by the research team, provide support, and encourage mentees to attend pain management therapies. They are also monitored by doctoral level psychologists throughout the duration of the study to ensure safety and appropriate contact with mentees via telephone."
62616455|NCT04171141|EXPERIMENTAL|Dose Escalation|Single Agent Dose Escalation
62616456|NCT04171141|EXPERIMENTAL|Dose Finding Anti-PD-1 Combination|Part 1B PF-07062119 plus anti-PD-1
62616457|NCT04171141|EXPERIMENTAL|Dose Finding anti-VEGF Combination|Part 1B PF-07062119 plus anti-VEGF
62616458|NCT04171141|EXPERIMENTAL|Dose Expansion Arm A|PF-07062119 as a Single Agent in CRC
62616459|NCT04171141|EXPERIMENTAL|Dose Expansion Arm B|PF-07062119 in Combination with anti-PD-1 in CRC
62616460|NCT04171141|EXPERIMENTAL|Dose Expansion Arm C|PF-07062119 in Combination with anti-VEGF in CRC
62616461|NCT04171141|EXPERIMENTAL|Dose Expansion Arm D|PF-07062119 in Combination with either anti-PD-1 or anti-VEGF in various Tumor Types
62616462|NCT00825981||coronary artery bypass graft|patients undergoing elective coronary artery bypass graft with or without cardiopulmonary bypass
62616463|NCT02375828|EXPERIMENTAL|Patients with neonatal diabetes|Patients with neonatal diabetes
62616464|NCT04577222|EXPERIMENTAL|Adipose Flap|Covering neurovascular bundle with fat
62616465|NCT04577222|NO_INTERVENTION|Control|No adipose flap
62841226|NCT03131609||C: Funnel + Castile-soap wipe|Sterile urine collection funnel and Castile-soap wipe given to patient to self-obtain a clean catch mid-stream urine specimen
62841227|NCT03131609||D: Funnel + Silver-impregnated wipe|Urine collection funnel and sliver impregnated cloth-wipe given to patient to self-obtain a clean catch mid-stream urine specimen
62841228|NCT01047553|EXPERIMENTAL|1|Formoterol 9 μg/dose
62841229|NCT01623050|EXPERIMENTAL|SinuSys Dilation System|Maxillary Sinus Dilation
62841230|NCT04141436|EXPERIMENTAL|Intervention|Intervention Based on Hypnofertility
62841231|NCT04141436|ACTIVE_COMPARATOR|Control|Routine clinical procedure
62841232|NCT02425943|EXPERIMENTAL|Sculptra Aesthetic|
62259412|NCT00247000|ACTIVE_COMPARATOR|2|Usual care for the management of Heart Failure
62616466|NCT05560009||Observational (18F-DOPA PET/MRI)|Patients receive 18F-DOPA IV and undergo PET/MRI over 60 minutes before standard of care radiotherapy and/or before standard of care surgery.
62616467|NCT03834714|ACTIVE_COMPARATOR|Noise Stimulus and Infrared Light|All participants will receive noise stimulus at each of the 4 visits. In addition, they will receive infrared light therapy for 2 out of the 4 visits and sham infrared light therapy for the other 2 visits.
62616468|NCT03834714|SHAM_COMPARATOR|Noise Stimulus and Sham|All participants will receive noise stimulus at each of the 4 visits. In addition, they will receive sham infrared light therapy for 2 out of the 4 visits and infrared light therapy for the other 2 visits.
62616469|NCT01584505|EXPERIMENTAL|CHF5993 HFA pMDI dose 1, BID|CHF5993 HFA pMDI dose 1, BID
62616470|NCT01584505|EXPERIMENTAL|CHF5993 HFA pMDI dose 2, BID|CHF5993 HFA pMDI dose 2, BID
62616471|NCT01584505|ACTIVE_COMPARATOR|CHF1535 HFA pMDI + Placebo|CHF1535 HFA pMDI BID plus placebo BID
62616472|NCT05047484|EXPERIMENTAL|Cohort 1: 40 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo twice daily (BID) on Day 1 through Day 14 in a fasted state.
62616473|NCT05047484|EXPERIMENTAL|Cohort 2: 80 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo BID on Day 1 through Day 14 in a fasted state.
62616474|NCT05047484|EXPERIMENTAL|Cohort 3: 120 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo BID on Day 1 through Day 14 in a fasted state.
62616475|NCT05047484|EXPERIMENTAL|Cohort 4: 200 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo BID on Day 1 through Day 14 in a fasted state.
62616476|NCT05047484|EXPERIMENTAL|Cohort 5: 120 mg ALXN2050/Placebo|Participants randomized to receive a single dose of ALXN2050 or placebo on Day 1 in a fed state.
62616477|NCT05047484|EXPERIMENTAL|Cohort 6: 240 mg ALXN2050/Placebo|Participants randomized to receive a single dose of ALXN2050 or placebo on Day 1 in a fasted state.
62616478|NCT01544764|NO_INTERVENTION|Control|This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. Practices in this arm were randomly assigned to receive no AFIX visit.
62259413|NCT05265078||Participants Diagnosed With VWD|Participants who have been diagnosed with VWD and prescribed VEYVONDI for the approved indications for the index infusion (first eligible VEYVONDI infusion) will be assessed using secondary data obtained from medical records to evaluate the safety of VEYVONDI in real-world clinical practice. All study data will be retrospectively abstracted from medical records by dedicated clinical research staff in partnership with the treating physician. The data window for this study will begin on 01 January 2019 and end one day before site activation at each site.
62259414|NCT02317861|EXPERIMENTAL|Cohort 1|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
62259415|NCT02317861|EXPERIMENTAL|Cohort 2|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
62616479|NCT01544764|EXPERIMENTAL|AFIX In-Person Visit|"This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. These practices received an in-person AFIX visit from a North Carolina Immunization Branch employee.~Intervention:~Other: Assessment , Feedback, Incentives, and eXchange Program"
62616480|NCT01544764|EXPERIMENTAL|AFIX Webinar Visit|"This arm includes 31 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. These practices received a webinar during which a North Carolina Immunization Branch employee completed the components of an AFIX visit.~Intervention:~Other: Assessment , Feedback, Incentives, and eXchange Program"
62616481|NCT01421394||single group study|
62616482|NCT05461365|EXPERIMENTAL|intranasal insulin|For each selected participant (n=27), a baseline olfactory measurement was performed with Sniffin Sticks® (12 items) and a capillary glucose measurement was obtained with Dextrostix® NF before and after the intervention, in order to guarantee patient safety and reduce the risk of hypoglycemia. The initial and final measurements were divided into three subsections with a different number of correct answers for each section Subsequently, Gelfoam® cottonoids soaked in 40 IU of NPH insulin were placed on the nasal roof (between the nasal septum and the middle meatus) of each nostril. These remained in place for 15 minutes and were later removed. This procedure was performed in three visits one week apart. During the fourth and last visit (one week after the previous visit), olfaction was reevaluated using the measures previously described.
62616483|NCT01047124|EXPERIMENTAL|Intervention|Specialist mood disorders team: treatment plan according to need
62616484|NCT01047124|NO_INTERVENTION|Treatment as usual|
62841233|NCT05053204||unipolar depression group|In accordance with the diagnostic criteria of ICD-10 Unipolar depressive disorder, outpatients or inpatients in the Department of mood Disorders, Mental Health Center of Pudong New area.
62841234|NCT05053204||bipolar depression group|In accordance with the diagnostic criteria of ICD-10 Bipolar depression , outpatients or inpatients in the Department of mood Disorders, Mental Health Center of Pudong New area.
62056478|NCT04660422||Pre-COVID-19 ACP baseline|"Two six-month control periods prior to the wide-scale implementation of the intervention, allow us to measure a baseline rate of ACP activity and identify the pre-COVID-19 ACP baseline rate and a COVID-19 ACP baseline rate.~September 15, 2019 - March 14, 2020,"
62056479|NCT04660422||COVID-19 rate|"Two six-month control periods prior to the wide-scale implementation of the intervention, allow us to measure a baseline rate of ACP activity and identify the pre-COVID-19 ACP baseline rate and a COVID-19 ACP baseline rate.~March 15, 2020 - September 14, 2020"
62616485|NCT03571022|EXPERIMENTAL|USE-MI System|Immediate use of the USE-MI smartwatch and smartphone app.
62616486|NCT05964439|EXPERIMENTAL|HoloUS app for ultrasound visualization|This is a single-arm study. Each study participant will evaluate HoloUS app and serve as their own control.
62616487|NCT01247506||1|tumor tissues of HCC patients
62841235|NCT05053204||healthy control group|Any mental disorder that does not meet the diagnosis of ICD-10, and the society recruits healthy controls who match the sex, age and education level of the patients in the case-group.
62259416|NCT02317861|EXPERIMENTAL|Cohort 3|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.
62259417|NCT02317861|EXPERIMENTAL|Cohort 4|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.
62259418|NCT02317861|EXPERIMENTAL|Cohort 5|RDEA3170 2.5mg, RDEA3170 5mg, RDEA3170 10mg, RDEA3170 15mg
62259419|NCT02317861|EXPERIMENTAL|Cohort 6|The half of patients randomized to this cohort will be dosed in the order of Benzbromarone 50 mg, Febuxostat 10mg+RDEA3170 2.5 mg, then Febuxostat 20mg+RDEA3170 5 mg. The other half will be dosed in the order of Febuxostat 10mg+RDEA3170 2.5 mg, Febuxostat 20mg+RDEA3170 5 mg, then Benzbromarone 50mg.
62259420|NCT03536988|EXPERIMENTAL|TAMIS-IPAA|In TAMIS-IPAA group, transanal minimally invasive surgery of proctectomy with IPAA will be performed.
62445182|NCT04572568||experimental group|"Ruptured AVMs:~1. AVMs not involved vital eloquent areas, or more than 5 mm away from functional fiber bundles, microsurgery or hybrid surgery can be performed;~2. Targeted embolization for hemorrhagic predictors could be considered as a monotherapy; embolization can be used as an adjunctive strategy to reduce flow or volume before microsurgery or stereotactic radiosurgery (SRS).~3. SRS for patients with a volume less than 10ml and not in the acute phase(\< 3months) of hemorrhage. Volume-stage or dose-stage can be used for giant AVMs involving important eloquent areas.~4. Conservation can be used for AVMs that are prone to severe disability due to intervention.~Unruptured AVMs:~Interventions are recommended if unruptured AVMs are assessed as being at high rupture risk, or have refractory epilepsy or acceptable postoperative neurological deficits, otherwise conservative treatment is recommended. The choice of intervention strategy was the same as for ruptured AVM."
62616488|NCT01247506||2|paired nontumor tissues of HCC patients
62841236|NCT02518295|ACTIVE_COMPARATOR|Positive control|Ultra high temperature (UHT) milk containing 18 g total lactose
62445183|NCT04572568||control group|Patients who had not received a multidisciplinary assessment to develop a treatment plan were included in the control group. It should be noted that the multidisciplinary team for AVM was formed in June 2018, so the prospective AVM cohort from August 2011 to June 2018 and the AVM cohort after June 2018 without comprehensive evaluation of treatment regimens by the multidisciplinary team served as the control group.
62445184|NCT02717221|EXPERIMENTAL|18F-MPG:EGFR+|Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study.
62841237|NCT02518295|ACTIVE_COMPARATOR|Positive control with S. thermophilus|UHT milk containing 18 g total lactose+ S. thermophilus
62841238|NCT02518295|ACTIVE_COMPARATOR|Positive control with B. longum|UHT milk containing 18 g total lactose+ B. longum
62841239|NCT02518295|PLACEBO_COMPARATOR|Negative control|Lactose free milk
62445185|NCT02717221|EXPERIMENTAL|18F-MPG:post-TKI EGFR+|Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study.
62056480|NCT04660422||ACP rate|ACP rate during the implementation period, which begins December 15, 2020 and continues for six months, to the rates in the previous two control periods December 15, 2020-June 15, 2021
62616489|NCT03494244||ADM|Patients having undergone direct-to-implant breast reconstruction using acellular dermal matrix.
62056481|NCT00893243||1Tears Again/Control|
62056482|NCT00893243||2Opticol/Control|
62056483|NCT00893243||3Optive/Control|
62259421|NCT03536988|ACTIVE_COMPARATOR|Lap-IPAA|In Lap-IPAA group, transabdominal minimally invasive surgery of proctectomy with IPAA will be performed.
62259422|NCT05270070||Digital Booking|Patients bookings done through digital booking system.
62259423|NCT05270070||Traditional Booking|Patients bookings done through traditional booking like telephone or secure email.
62259424|NCT04858230|EXPERIMENTAL|LymphoPilot|Patient will be implanted with the medical device under investigation, LymphoPilot, through a surgical procedure performed in loco-regional or general anesthesia. Lymphedema outcomes will be monitored for 8 weeks after implantation and compared to baseline values before device implantation. Safety data will be collected throughout the study.
62259425|NCT00507390|ACTIVE_COMPARATOR|A1|n-3 PUFAs
62259426|NCT00507390|PLACEBO_COMPARATOR|A2|olive oil capsules
62259427|NCT05949775|EXPERIMENTAL|single arm|Neoantigen mRNA Personalised Cancer in combination with Stintilimab Injection. Participants will receive a total of 9 cycles of PCV every 21 days
62616490|NCT03494244||Non-ADM (Vicryl)|Patients having undergone direct-to-implant breast reconstruction using non-acellular dermal matrix mesh (Vicryl mesh).
62841240|NCT03766152|OTHER|Adhear|Patients will be fitted with an adhesive bone conduction device for three weeks
62841241|NCT02745080|EXPERIMENTAL|Secukinumab 300 mg s.c.|Secukinumab 300 mg administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 48.
62841242|NCT02745080|ACTIVE_COMPARATOR|Adalimumab 40 mg s.c.|Adalimumab 40 mg administered at Baseline followed by dosing every 2 weeks until Week 50.
62841243|NCT00235365|EXPERIMENTAL|meta-cognitive therapy|meta-cognitive therapy
62841244|NCT00235365|ACTIVE_COMPARATOR|waiting list|waiting list control
62841245|NCT06016777|EXPERIMENTAL|PVB+PCIA group|
62841246|NCT06016777|EXPERIMENTAL|ESB+PCIA group|
62841247|NCT06016777|ACTIVE_COMPARATOR|PCIA group|
62841248|NCT01694407|ACTIVE_COMPARATOR|TFV Alone Vaginal Tablet|
62841249|NCT01694407|ACTIVE_COMPARATOR|Emtricitabine (FTC) Alone Vaginal Tablet|
62841250|NCT01694407|ACTIVE_COMPARATOR|TFV Combined with FTC Vaginal Tablet|
62841251|NCT01694407|PLACEBO_COMPARATOR|Placebo Vaginal Tablet|
62841252|NCT05785676||Vena Cava Filter|Participants implanted with the vena cava filter OATF (ALN)
62056484|NCT00893243||4Tears Again/Opticol|
62056485|NCT00893243||5Tears Again/Optive|
62056486|NCT00893243||6Opticol/Optive|
62056487|NCT01074606|EXPERIMENTAL|Toric|AcrySof Toric Intraocular Lens (IOL)
62056488|NCT04978974|EXPERIMENTAL|Patients with type 2 Diabetes mellitus and Hypertension|patients with type 2 diabetes mellitus and hypertension were selected by using purposive sampling technique to apply stress management program
62259428|NCT04241211|ACTIVE_COMPARATOR|Control group|
62259429|NCT04241211|EXPERIMENTAL|TP group|
62445186|NCT02717221|EXPERIMENTAL|18F-MPG:post-chemo EGFR+|Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study.
62841253|NCT01039883|EXPERIMENTAL|1|Subjects randomized to study product sequence 1 will receive the single albaconazole 400-mg tablet during the first dosing period and the four 100-mg albaconazole capsules during the second dosing period.
62841254|NCT01039883|EXPERIMENTAL|2|Subjects randomized to study product sequence 2 will receive the four 100-mg albaconazole capsules during the first dosing period and the single albaconazole 400-mg tablet during the second dosing period.
62841255|NCT06140862|EXPERIMENTAL|calf muscle exercise|the initial treatment plane was open and closed chain strengthening exercises for the calf muscle. The strengthening exercises include; double leg calf raise (i.e., straight and bent knees), single leg calf raise (i.e., straight and bent knee), seated calf raise, and wall sit calf raise. Calf stretching exercises were added to maintain the flexibility of the muscle and its Achilles tendon. Gait training protocol was also performed for correction of chronically adapted abnormal gait pattern especially at the mid stance and terminal stance sub-phases of GC
62841256|NCT06140862|OTHER|lower back exercise|lumbar stabilization exercises, core strength training, myofascial release therapy for lower back, and stretching exercises for hamstring muscle.
62841257|NCT01976741|EXPERIMENTAL|Rogaratinib total dose escalation|Participants with any type of solid tumor received escalating doses of Rogaratinib oral solution or tablet. The actual dose-escalation cohorts were 100 mg (50 mg BID), 200 mg (100 mg BID), 400 mg (200 mg BID), 800 mg (400 mg BID), 1200 mg (600 mg BID), and 1600 mg (800 mg BID). The participants in the 100 mg and 200 mg dose-escalation cohorts received oral solution and the participants in all the subsequent dose-escalation cohorts received tablet. And as an exception, on C1D-3 in the 200 mg dose-escalation cohort, the participants received tablet instead of oral solution.
62841258|NCT01976741|EXPERIMENTAL|Rogaratinib dose expansion (All Comers)|"Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet b.i.d.~(1600 mg/day) in 21-days cycles."
62841259|NCT01976741|EXPERIMENTAL|Rogaratinib dose expansion (BC)|Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
62841260|NCT01976741|EXPERIMENTAL|Rogaratinib dose expansion (SCCHN)|Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
62841261|NCT01976741|EXPERIMENTAL|Rogaratinib dose expansion (sqNSCLC)|Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
62841262|NCT05699694|EXPERIMENTAL|Experimental Stemregen|Experimental product encapsulated will be consumed orally with a glass of water. Six capsules per day will be consumed daily for 6 months.
62841263|NCT03822559|EXPERIMENTAL|DE-111A eye drops|
62841264|NCT03822559|ACTIVE_COMPARATOR|0.0015% tafluprost eye drops|
62841265|NCT03433040|OTHER|non obese|250mg 17 OHP-C
62841266|NCT03433040|OTHER|obese - control|250mg 17 OHP-C
62616491|NCT03510221|ACTIVE_COMPARATOR|Antioxidants|Subjects received 3 antioxidant capsules (1 capsule of blueberry + 1 capsule of cranberry + 1 capsule pomegranate - a day) during 4 weeks.
62616492|NCT03510221|PLACEBO_COMPARATOR|Placebo|Subjects received 3 placebo capsules during 4 weeks.
62616493|NCT00914082|EXPERIMENTAL|antenatal classes in self hypnosis|3 antenatal classes in self hypnosis. 3 audio compact discs for homework in self hypnosis and 1 audio compact disc for birth
62056489|NCT06342180||Controls|Healthy controls between aged 18 and 35 years
62616494|NCT00914082|ACTIVE_COMPARATOR|relaxation and awareness|3 antenatal classes including training in relaxation methods and mindfulness.3 audio compact discs for homework and 1 for birth.
62616495|NCT00914082|OTHER|Control|Only receive ordinary antenatal care and no additional interventions
62616496|NCT04045990|EXPERIMENTAL|Active stimulation|Active rTMS will be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). Active rTMS will be delivered at 80-120% of a patient's resting or active motor threshold. rTMS will be administered in an excitatory pattern as 20Hz. Stimulation parameters will remain well within established safety guidelines (Rossi et al. 2009).
62056490|NCT06342180||PCOS Subtype 1|Hyperandrogenemia+oligoanovulation+PCO appearance on USG
62056491|NCT06342180||PCOS Subtype 2|Hyperandrogenemia+oligoanovulation
62056492|NCT06342180||PCOS Subtype 3|Hyperandrogenemia+ PCO appearance on USG
62056493|NCT06342180||PCOS Subtype 4|Oligoanovulation+ PCO appearance on USG
62056494|NCT01279343|EXPERIMENTAL|Foley Bulb plus Misoprostol|
62056495|NCT01279343|NO_INTERVENTION|Misoprostol|
62056496|NCT05943769|EXPERIMENTAL|MTA|Root end filling material is MTA without bone graft in the defect.
62056497|NCT05943769|EXPERIMENTAL|TotalFill|Root end filling material is TotalFill without bone graft in the defect.
62056498|NCT05943769|EXPERIMENTAL|MTA & bone|Root end filling material is MTA with the addition of composite bone graft in the defect.
62056499|NCT05943769|EXPERIMENTAL|TotalFill & bone|Root end filling material is TotalFill with the addition of composite bone graft in the defect.
62056500|NCT04999644|EXPERIMENTAL|Full Nicotine Expectancy, Reduced Nicotine Dose|Receive reduced nicotine cigarette expecting full
62056501|NCT04999644|EXPERIMENTAL|Full Nicotine Expectancy, Full Nicotine Dose|Receive full nicotine cigarette expecting full
62056502|NCT04999644|EXPERIMENTAL|Reduced Nicotine Expectancy, Full Nicotine Dose|Receive full nicotine cigarette expecting reduced
62056503|NCT04999644|EXPERIMENTAL|Reduced Nicotine Expectancy, Reduced Nicotine Dose|Receive reduced nicotine cigarette expecting reduced
62259430|NCT03106246||New onset T1DM|Newly diagnosed Type I diabetic patients who are hyperglycemic but still C-peptide positive
62259431|NCT03106246||T1DM|Patients with established type I diabetes. they are hyperglycemic but C-peptide negative
62259432|NCT03106246||T2DM|Patients with established type II diabetes.
62623664|NCT03070275|EXPERIMENTAL|Group-A|In the experimental Group (Group-A), a two-stage implant will be placed in parallel with an overlying biocomplex (aBM-MSCs/fibrin glue/collagen fleece) that comprises autologous alveolar bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue.
62623665|NCT03070275|ACTIVE_COMPARATOR|Control Group-B|In Group-B, a two-stage surgical implant placement on the alveolar crest is followed based on the manufacturer's guidelines with no use of adjunctive grafting materials.
62841267|NCT03433040|EXPERIMENTAL|obese|500mg 17 OHP-C
62259433|NCT03106246||Islet Transplant|Patients who received an islet transplantation for type I diabetes
62623666|NCT06491017|EXPERIMENTAL|MI-E intervention protocol|The optimized MI-E setting will consist of in-expiratory pressures defined during the previous short-period test to achieve inspiratory volumes of ≥1 liter and PEF ≥80 L/min
62623667|NCT06491017|ACTIVE_COMPARATOR|Standard MI-E setting|The standard MI-E setting will consist of in-expiratory pressures of +40/-40 cmH2O, medium inspiratory flow, with 3 seconds and 2 seconds of in-expiratory time, respectively, and 1-second pause
62259434|NCT03106246||Healthy Volunteers|Normoglycemic healthy volunteers
62259435|NCT04581564|EXPERIMENTAL|Rhythm intervention|
62259436|NCT04581564|ACTIVE_COMPARATOR|Non-rhythm intervention|
62841268|NCT03064061|SHAM_COMPARATOR|Virtual Reality Neutral|neutral VR session before oocytes retrieval
62259437|NCT02820792|ACTIVE_COMPARATOR|LMA ProtectorTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
62259438|NCT02820792|ACTIVE_COMPARATOR|Ambu AuraGainTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
62259439|NCT06115772||Observational|Participants complete surveys, watch an educational video on HPV vaccination and undergo collection of blood and saliva samples on study. Patients also undergo cervical screening per standard of care and may receive a referral to gynecology if not up to date on anogenital screening.
62259440|NCT01098552||High-risk radical prostatectomy patients|
62445187|NCT02717221|EXPERIMENTAL|18F-MPG:EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
62445188|NCT02717221|EXPERIMENTAL|18F-MPG:post-chemo EGFR wild type|Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study.
62259441|NCT01098552||Primary external beam radiotherapy patients|
62259442|NCT01098552||Primary prostate brachytherapy patients|
62259443|NCT01098552||Hormone refractory prostate cancer patients|
62259444|NCT01098552||Active Surveillance|
62259445|NCT01098552||Prostate biopsy patients|
62259446|NCT05895149|EXPERIMENTAL|Experimental group|In each participant, HRV will be measured for 2 minutes, then the flying buttress technique will be applied. After the technique, HRV will be recorded for 2 minutes, and 5 minutes later, HRV will be measured again for 2 minutes.
62259447|NCT05895149|PLACEBO_COMPARATOR|Control group|In each participant, HRV will be measured for 2 minutes, then the placebo technique will be applied. After the technique, HRV will be recorded for 2 minutes, and 5 minutes later, HRV will be measured again for 2 minutes.
62259448|NCT05993650|EXPERIMENTAL|Training Group|The individuals in the training group will be performed inspiratory muscle training using an inspiratory muscle training device (PowerBreathe®) at 30-50% of the maximal inspiratory pressure.
62259449|NCT05993650|SHAM_COMPARATOR|Control Group|Individuals in this group will be given thoracic expansion exercises and patient education.
62259450|NCT06261398|EXPERIMENTAL|BETTER Intervention|Patients in the intervention group will receive one motivational interviewing session immediately after randomization and biweekly text messages until delivery to encourage them to connect to resources to address their social needs.
62259451|NCT06261398|ACTIVE_COMPARATOR|Standard of care|No motivational interviewing or text messages will be provided.
62445189|NCT02717221|EXPERIMENTAL|18F-MPG:unknown EGFR mutational status|Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group
62445190|NCT04524039|EXPERIMENTAL|iTBS stimulation|iTBS stimulation to left dorsolateral prefrontal cortex (DLPFC), twice daily, 10 days
62445191|NCT04524039|SHAM_COMPARATOR|sham iTBS stimulation|sham iTBS stimulation to left dorsolateral prefrontal cortex (DLPFC), twice daily, 10 days
62623668|NCT06344546||Refeeding hypophosphatemia|ICU patients who fulfill diagnostic criteria for refeeding hypophosphatemia.
62841269|NCT03064061|ACTIVE_COMPARATOR|Virtual reality Anxiety|VR session with the goal of reducing anxiety before oocytes retrieval
62841270|NCT04730219|EXPERIMENTAL|Tislelizumab and Nab Paclitaxel|Tislelizumab 200mg IV on day 1 in combination with nab paclitaxel 200mg IV on day 2 every 3 weeks for 3 cycles followed by surgery.
62841271|NCT02167139|EXPERIMENTAL|SB5 (proposed biosimilar to adalimumab)|SB5 40 mg every other week via subcutaneous injection
62841272|NCT02167139|ACTIVE_COMPARATOR|Humira (adalimumab)|Humira 40 mg every other week via subcutaneous injection
62841273|NCT00850239|EXPERIMENTAL|1|dutogliptin/PHX1149T
62841274|NCT00850239|PLACEBO_COMPARATOR|2|Plabeco
62841275|NCT05985369|EXPERIMENTAL|Vegan diet|Participants will be allocated to a fully controlled 1-week vegan diet containing 0.8 g/kg BW/day of protein where all protein provided will be derived from non-animal-derived protein sources.
62259452|NCT04960982||PCOS-RM|PCOS women with history of RM
62616497|NCT04045990|SHAM_COMPARATOR|SHAM stimulation|SHAM stimulation will also be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). SHAM rTMS will be delivered at 80-120% of a patient's resting or active motor threshold. SHAM stimulation will be delivered to the exact same cortical targets as active rTMS. While no electromagnetic stimulation will be delivered during SHAM, the sounds will approximate active stimulation and skin electrodes will approximate the sensation of active rTMS. Inclusion of a sham condition in this protocol is critical to measure whether or not the stimulation is improving memory or language performance, or whether practice effects or other non-specific effects are responsible for any changes in memory or language performance which may be observed.
62259453|NCT04960982||Non PCOS RM|Non PCOS women with history of RM
62259454|NCT04960982||Control|women with no history of RM
62259455|NCT01168648|EXPERIMENTAL|Yoga as stress management|The intervention consists of following a program of yoga at least three times a week for three months. The yoga program has been designed to reduce stress.
62259456|NCT01168648|ACTIVE_COMPARATOR|Control group|The group rests without using any specific program for relaxation at least three times a week for three months.
62259457|NCT01168648|OTHER|Yoga as stress management fewer tests|Eight persons participated in the same intervention as the experimental arm but did not undergo the full range of tests because they did not meet all the inclusion criteria for the study, most commonly because of medication use or body mass index.
62445192|NCT03075137|EXPERIMENTAL|External Counter Pulsation (ECP) group|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
62445193|NCT03075137|NO_INTERVENTION|Control group|Guideline-driven standard medical treatment
62616498|NCT01807468|EXPERIMENTAL|HaploSC+NK|
62616499|NCT04104997|EXPERIMENTAL|The A group in 5% GLH8NDE|Three times administration both eyes, each 1 drop in Korean
62259458|NCT03427047|ACTIVE_COMPARATOR|MyKnee with single use Efficiency Instrument|Patients randomized in this group will undergo Total Knee Arthroplasty utilizing patient matched cutting blocks and single use instruments. Customization will be by a CT scan of patients knee.
62445194|NCT00672971|EXPERIMENTAL|1|4% dimethicone foam
62841276|NCT05985369|EXPERIMENTAL|Omnivorous diet|Participants will be allocated to a fully controlled 1-week omnivorous diet containing 0.8 g/kg BW/day of protein where the majority of protein will be derived from animal-derived protein sources.
62445195|NCT00672971|ACTIVE_COMPARATOR|2|1% permethrin
62616500|NCT04104997|PLACEBO_COMPARATOR|The A group in placebo|Three times administration both eyes, each 1 drop in Korean
62616501|NCT04104997|EXPERIMENTAL|The B group in 5% GLH8NDE|Six administration both eyes, each 1 drop in Korean
62616502|NCT04104997|PLACEBO_COMPARATOR|The B group in placebo|Six administration both eyes, each 1 drop in Korean
62841277|NCT03048578|EXPERIMENTAL|Saxenda|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
62841278|NCT03048578|PLACEBO_COMPARATOR|Placebo|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
62445196|NCT02494128|ACTIVE_COMPARATOR|Intervention group|Education in group leadership
62445197|NCT02494128|NO_INTERVENTION|Control group|This group fills in the questionnaire. No intervention given.
62616503|NCT04104997|EXPERIMENTAL|The C group in 5% GLH8NDE|Six administration both eyes, each 2 drop in Korean
62616504|NCT04104997|PLACEBO_COMPARATOR|The C group in placebo|Six administration both eyes, each 2 drop in Korean
62841279|NCT06413849|EXPERIMENTAL|Graphic narrative bibliotherapy|Eight weekly sessions of telephone-coached graphic narrative bibliotherapy
62841280|NCT06413849|SHAM_COMPARATOR|Control group|Reading an educational booklet
62841281|NCT01272063||Dry AMD with macular drusen|Patients diagnosed with dry AMD with macular drusen
62445198|NCT04253561|EXPERIMENTAL|Ipatasertib + Trastuzumab + Pertuzumab|"Ipatasertib will be given from Day 1 to Day 21 in every 28-day cycles. The starting dose is 400 mg orally (PO) QD and may be decreased to 300 mg QD and further to 200 mg QD (dose levels 1, - 1 and -2, respectively).~Pertuzumab will be given IV every 21 days at the dose of 420 mg.~Trastuzumab will be given SC every 21 days at the dose of 600mg. Intravenous (IV) Trastuzumab"
62445199|NCT04834245|EXPERIMENTAL|hydrogel/nano silver-based dressing|hydrogel/nano silver-based dressing
62445200|NCT03605706|EXPERIMENTAL|SHR-1210|SHR-1210+FOLFOX4
62616505|NCT04104997|EXPERIMENTAL|The D group in 5% GLH8NDE|Six administration both eyes, each 2 drop in Caucasian
62616506|NCT04104997|PLACEBO_COMPARATOR|The D group in placebo|Six administration both eyes, each 2 drop in Caucasian
62616507|NCT01742416|EXPERIMENTAL|Ultrasound|
62841282|NCT01994096|EXPERIMENTAL|Caspofungin|1 arm, dose adjustment of caspofungin when exposure is inadequate
62841283|NCT05997303|OTHER|Continuous norepinephrine administration|continuous norepinephrine infusion via an infusion pump; norepinephrine dose will be at the discretion of the treating anesthesiologists
62841284|NCT05997303|OTHER|Manual bolus norepinephrine administration|manual bolus norepinephrine administration; norepinephrine dose will be at the discretion of the treating anesthesiologists
62841285|NCT04722419|EXPERIMENTAL|Functional dyspepsia|
62445201|NCT03605706|EXPERIMENTAL|CONTROL|SHR-1210+Placebo
62445202|NCT06170580||Participants with carotid artery stenosis|
62445203|NCT06170580||Healthy controls|Participants without carotid artery stenosis
62445204|NCT05403021|EXPERIMENTAL|GETCare Intervention|
62445205|NCT04447976||Patients undergoing ERCP by formally trained Endoscopists|No intervention has been used and this is an observational study of evaluation of a TIP duodenoscope performance overall.
62445206|NCT05799872|EXPERIMENTAL|Positive Affect Treatment for Anorexia Nervosa (PAT-AN):|
62445207|NCT05799872|ACTIVE_COMPARATOR|Psychoeducational and Behavioral Therapy (PBT):|
62445208|NCT00314171|EXPERIMENTAL|Brinzolamide + Timolol|
62445209|NCT00314171|ACTIVE_COMPARATOR|Dorzolamide + Timolol|
62445210|NCT04317625|EXPERIMENTAL|participants|All of the participants tested serum PSA, some of them conducted mpMRI with/without prostate biopsy under instruction.
62445211|NCT06215781|EXPERIMENTAL|Fully digital workflow|Patients of this group are subjected to entire digital workflow, from the digital planning to the delivery of definitive zirconia fixed dental prosthesis
62445212|NCT06215781|EXPERIMENTAL|Combined digital-conventional workflows|"Patients of this group were subjected to every digital steps as the fully digital workflow arm, except for the impression that includes analog material (silicones)."
62445213|NCT06215781|ACTIVE_COMPARATOR|Fully conventional workflow|Patients of this group follow the entire analog protocol. All the procedures exclude digital involvement.
62445214|NCT01505465|EXPERIMENTAL|Study: Melatonin|
62445215|NCT01505465|PLACEBO_COMPARATOR|Control: Placebo|
62445216|NCT03872037|ACTIVE_COMPARATOR|Control|Molars subjected to selective removal and restored with Ketac Molar Easymix
62445217|NCT03872037|EXPERIMENTAL|Selective removal of caries and restoration with Maxxion|Molars subjected to selective removal and restored with Maxxion
62445218|NCT00651456|ACTIVE_COMPARATOR|1|Standard Chemotherapy
62445219|NCT00651456|EXPERIMENTAL|2|Standard Chemotherapy + bevacizumab (Avastin)
62445220|NCT01250158|EXPERIMENTAL|Liver-PILP kit|Liver-PILP kit
62445221|NCT04523805|EXPERIMENTAL|AUTJUDO-O1|"The judo sessions are performing in a large and well-ventilated space suitable for athletic activities in general and for judo in particular, such that the safety of the participants was maintained. Each participant is outfitted with a judogi (a traditional uniform consisting of a cotton jacket and trousers and a belt).~The sessions are 75 minutes in duration and were held once a week. Two judo teachers, with degrees in pedagogy and sports sciences and 7th and 6th degree black belts, respectively, led each session, and at least four volunteer judo instructors are present to lend support. The sessions are divided into warm-up, main exercise and cool-down activities. The instructional methodology apply the principles of gradual progression and the main exercise content of the sessions includes: different types of movements and falling techniques, ground control techniques, judo techniques and games."
62445222|NCT03721848|EXPERIMENTAL|Healthy Community Clinic: NCD+MH|The arm of this study consists of a 28 session intervention, which are 45 minutes and meet 2-3 times a month providing health awareness on non-communicable diseases diabetes, hypertension, obesity, reproductive health, cardiovascular diseases, allergies; smoking; traumatic stress reactions, individual strategies for coping with stress and traumatic events and collective strategies for coping with stress and trauma.
62445223|NCT03721848|ACTIVE_COMPARATOR|Healthy Community Clinic: NCD|The arm of this study consists of a 24 session intervention, which are 45 minutes and meet 2 times a month providing health awareness on non-communicable disease diabetes, hypertension, obesity, reproductive health, cardiovascular diseases, allergies; smoking.
62616508|NCT01742416|ACTIVE_COMPARATOR|Palpation Method|
62616509|NCT01476397|ACTIVE_COMPARATOR|control infant formula|partially hydrolyzed whey infant formula
62616510|NCT01476397|EXPERIMENTAL|test infant formula|partially hydrolyzed whey infant formula with probiotic
62841286|NCT04722419|ACTIVE_COMPARATOR|Healthy subjects|
62841287|NCT05613465|EXPERIMENTAL|intervention|Codonopsis pilosula Nnannf
62841288|NCT05613465|PLACEBO_COMPARATOR|Control group|Placebo
62841289|NCT05475080||Antiplatelet|
62841290|NCT05475080||Anticoagulant|
62841291|NCT05475080||Endovascular|
62841292|NCT05475080||Surgical (endarterectomy)|
62841293|NCT01636518||Atrial Fibrillation|Patients with Atrial Fibrillation that undergo standard of care procedure at the University of Kansas Hospital
62841294|NCT01280708||Capture data|
62616511|NCT03888326|EXPERIMENTAL|Robotic Rehabilitation plus 1x1 anodal tDCS|Receive 10 days of 1hr robotic rehabilitation with the KINARM Exoskeleton, in addition to 20 minutes, 2mA anodal tDCS (Soterix 1x1 tDCS) over the ipsilesional sensory cortex during the first 20 minutes of each robotic session. Current is ramped up to 2mA over 30 seconds and ramped back down over 30 seconds at the end of the 20 minutes.
62616512|NCT03888326|SHAM_COMPARATOR|Robotic Rehabilitation plus sham tDCS|Receive 10 days of 1hr robotic rehabilitation with the KINARM Exoskeleton, in addition to sham anodal tDCS over the ipsilesional sensory cortex. Current is ramped up to 2mA over 30 seconds and immediately ramped back down over 30 seconds. This is repeated after 20 minutes.
62616513|NCT03888326|NO_INTERVENTION|Standard of Care Rehabilitation|No additional therapy/treatment provided. The individual continues with their normal daily routine
62616514|NCT04688606||Two groups|"1. Initial diagnosis of suspected hepatocellular carcinoma;~2. patients undergoing liver transplantation, radical resection or ablation of liver cancer"
62841295|NCT05039983|EXPERIMENTAL|EGCG application|We have chosen a dose of 880 umol/L as the lower limit for this phase I study by referring to previous studies. Six dose levels for EGCG were defined as following: 880, 1760, 2640, 3430, and 4400 umol/L per dose. Dose escalation proceeded according to a standard phase I design with three patients initially treated on each tier. If, on any dose tier of EGCG, two of three patients or two of six patients experienced a more than grade II toxicity due to EGCG, dose escalation of EGCG would cease. The maximally tolerated dose (MTD) was defined as the highest dose with fewer than one-third of patients experiencing a dose-limiting toxicity (DLT) due to EGCG. EGCG solution was given continuously for 7 days before anti-tumor treatment.
62445224|NCT03721848|NO_INTERVENTION|Treatment as usual|This is treatment as usual where there is no intervention, but patients attend the clinic for treatment of non-communicable diseases.
62445225|NCT03330756|ACTIVE_COMPARATOR|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
62259459|NCT03427047|ACTIVE_COMPARATOR|Stryker Navigational with conventional metal instruments|Patients randomized in this group will undergo Total Knee Arthroplasty with conventional metal instruments. CT scan are not utilized with this arm.
62445226|NCT03330756|EXPERIMENTAL|Laparoscopic Mini Gastric Bypass|laparoscopic Mini gastric bypass
62445227|NCT04326842||Carotid artery stenosis|Patients with carotid artery stenosis. Procedure: Carotid artery revascularization procedure
62445228|NCT04326842||Control|Patients without carotid artery stenosis
62259460|NCT01087775|EXPERIMENTAL|Cognitive Training|Plasticity Based Adaptive Cognitive Remediation (PACR)
62259461|NCT01018433|EXPERIMENTAL|T-SIB|Treatment for self-injurious behaviors; study intervention
62259462|NCT01018433|OTHER|Treatment as Usual|
62259463|NCT00124059|EXPERIMENTAL|Type A SERO|
62259464|NCT00124059|EXPERIMENTAL|Type B SERO|
62259465|NCT00124059|PLACEBO_COMPARATOR|Type A PLA|
62259466|NCT00124059|PLACEBO_COMPARATOR|Type B PLA|
62259467|NCT04562207|EXPERIMENTAL|Patients|Addition of a nasopharyngeal swab before surgery
62259468|NCT03449589||Smokers|RA patients currently smoking
62259469|NCT03449589||Former smokers|RA patients who previously smoked
62445229|NCT05737056||Children diagnosed with rheumatoid purpura at the pediatric emergency department|Children diagnosed with rheumatoid purpura from admission to the pediatric emergency department up to two years of follow-up by general practitioners after hospital discharge.
62445230|NCT04850638|EXPERIMENTAL|SHR4640 tablets|
62445231|NCT04738279|EXPERIMENTAL|Phase I: Soft Launch (120 days)|The study will conduct a soft launch on the first five HF patients enrolled to finetune process and protocol.
62445232|NCT04738279|EXPERIMENTAL|Phase II: Calibration (210 days)|After learning from the soft launch and updating the protocol, the study will continue to enroll 15 HF patients for calibration purposes
62445233|NCT04120194|EXPERIMENTAL|NanoFlu|NanoFlu will be administered as a single dose (0.5 mL) in the arm muscle on Day 0.
62445234|NCT04120194|ACTIVE_COMPARATOR|Fluzone Quadrivalent|Fluzone Quadrivalent will be administered as a single dose (0.5 mL) in the arm muscle on Day 0.
62445235|NCT00294723|EXPERIMENTAL|Lira 1.8|Liraglutide 1.8 mg once daily + glimepiride placebo 8 mg once daily, weeks 0-52 (double-blinded period) and open-label liraglutide 1.8 mg once daily in the extension periods (weeks 52-195).
62445236|NCT00294723|EXPERIMENTAL|Lira 1.2|Liraglutide 1.2 mg once daily + glimepiride placebo 8 mg once daily, weeks 0-52 (double-blinded period) and open-label liraglutide 1.2 mg once daily in the extension periods (weeks 52-195).
62445237|NCT00294723|ACTIVE_COMPARATOR|Glimepiride - 1|Glimepiride 8 mg once daily + liraglutide placebo 200 mcl, weeks 0-52 (double-blinded period) and open-label glimepiride 8 mg once daily in the extension periods (weeks 52-195).
62445238|NCT00294723|ACTIVE_COMPARATOR|Glimepiride - 2|Glimepiride 8 mg once daily + liraglutide placebo 300 mcl, weeks 0-52 (double-blinded period) and open-label glimepiride 8 mg once daily in the extension periods (weeks 52-195).
62445239|NCT03845179|PLACEBO_COMPARATOR|Placebo|Placebo tablet for placebo treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
62445240|NCT03845179|ACTIVE_COMPARATOR|DPP-4 inhibitor|DPP-4 inhibitor treatment for active treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
62445241|NCT05711030|ACTIVE_COMPARATOR|Thoracic paravertebral block multiple (3) injections|"Patients will either be in the sitting or prone position for the block. The block will be performed with the ultrasound transducer in the sagittal position about 2.5 to 3 centimeters (cm) lateral to the spinous process using a caudal to cranial in-plane needle approach. The thoracic vertebral levels will be identified by finding the first rib under ultrasound guidance and counting down levels appropriately.~The needle (80 mm 22-gauge echogenic SonoPlex needle from Pajunk) will be introduced in-plane in a caudal to cranial direction until it punctures the costotransverse ligament. Saline in 1 ml increments will be injected to confirm correct placement of the needle tip. Injection of saline or local anesthetics deep to the costotransverse ligament will lead to an anterior displacement of the parietal pleura.~For the 3-level technique, injections will be done at the levels of T2-T3, T3-T4, and T4-T5 with 10 ml of ropivacaine 0.5% at each level."
62616515|NCT06018922|EXPERIMENTAL|Psychological therapy for Gaming Disorder|They will be offered a module-based psychological treatment that combines Cognitive behavioral therapy (CBT) and Family therapy (FT).
62616516|NCT00520052|ACTIVE_COMPARATOR|LHRH Group|Patients on LHRH agonists and zoledronic acid
62616517|NCT00520052|ACTIVE_COMPARATOR|Bicalutamide Group|Patients on Bicalutamide and zoledronic acid
62616518|NCT05890300|EXPERIMENTAL|Intervention (INT)|Group receiving intervention
62616519|NCT05890300|NO_INTERVENTION|Control (CON)|Group receiving no intervention
62616520|NCT06216405|EXPERIMENTAL|AI-aided colonoscopy|Experimental arm : patients receive a colonoscopy using GI Genius™ intelligent endoscopy system (Medtronic Inc., Minneapolis, Minnesota, USA)
62616521|NCT06216405|ACTIVE_COMPARATOR|Standard colonoscopy|Control arm :The artificial intelligence is not activated during the colonoscopy exam,the patient receive a standard high definition colonoscopy
62616522|NCT03387501|EXPERIMENTAL|PRGF|Plasma rich in growth factors (PRGF) administration
62616523|NCT00072904|PLACEBO_COMPARATOR|III|Placebo take half tab with meals tid
62616524|NCT03015194|EXPERIMENTAL|Laceration of Anterior Mitral Leaflet in Mitral Valve Failure Participants With no Surgical Option|The LAMPOON procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TMVR. These are all guided by fluoroscopy combined with transesophageal echocardiogram (TEE) or intracardiac echocardiography.
62616525|NCT06156137||adverse outcomes|The composite adverse outcomes are defined as either a \>20-day length of stay intensive care unit admission, mechanical ventilation use, or death.
62616526|NCT06156137||favorable outcomes|favorable outcomes the patient are defined as discharged with improvement and hospitalization less than 20 days.
62616527|NCT02750085||2-point and 6-point PK sampling|
62616528|NCT02143167|EXPERIMENTAL|SR-fampridine/placebo|24 weeks of SR-fampridine followed by four weeks of inactive placebo.
62616529|NCT02143167|EXPERIMENTAL|Placebo/SR-fampridine|24 weeks of inactive placebo followed by four weeks of SR-fampridine
62616530|NCT02419794||Group with endovascular treatment|Group with additional endovascular treatment
62616531|NCT02419794||Group without endovascular treatment|Group without additional endovascular treatment
62616532|NCT04656366||No-touch|"Participants that operated at the time of the coronary artery bypass grafting with a no-touch venous graft."
62616533|NCT04656366||Conventional|"Participants that operated at the time of the coronary artery bypass grafting with a conventional venous graft."
62616534|NCT03406988|EXPERIMENTAL|Autologous fat grafting|Implantation of 0.5-1 ml of autologous AT at the base of the finger with DU.
62616535|NCT03406988|PLACEBO_COMPARATOR|Sham procedure|False liposuction followed by the injection of 0.5-1 ml of 0.9% saline solution at the base of the affected finger.
62616536|NCT01294059|PLACEBO_COMPARATOR|Sugar pill|One sugar pill twice daily over 6 weeks
62616537|NCT01294059|ACTIVE_COMPARATOR|Milnacipran|Milnacipran 50 mg bid over 6 weeks
62616538|NCT05905133|EXPERIMENTAL|CBP-201|The subjects will receive CBP-201 600 mg (4 mL in total, 2 injections of 2 mL each in different sites) on Day1, begin to receive a subcutaneous injection of CBP-201 300 mg (2 mL) from Week2, and receive CBP-201 300 mg (2 mL) every 2 weeks thereafter until Week10.
62616539|NCT02623517||Enrolled Subjects|The Enrolled Subjects group will comprise of 75 individuals who will be followed for 12 months for their atrial fibrillation condition. Data will be collected from subjects' devices for 12 months, and any needed changes or additions to therapy will be done. (ie: ablation, pacemaker setting changes, medication control).
62616540|NCT02623517||Registry Subjects|The Registry Subjects group will comprise of screened patients who do not exhibit symptoms of atrial fibrillation at the time of screening. The already collected data from the patient's device during the screening visit will be kept and put into a registry.
62616541|NCT01129804|EXPERIMENTAL|Network Support|Network Support treatment is aimed at helping patients change their social support network so that it supports abstinence. In this treatment patients will be encouraged to attend AA meetings and engage in other activities that would involve non-drinkers. These activities would be determined by the patient, with help from the therapist. Patients would learn about methods of avoiding drinking, making new friends, and getting enjoyment from activities other than drinking. In addition patients will learn specific skills intended to help them make new acquaintances and change their circle of friends.
62616542|NCT01129804|ACTIVE_COMPARATOR|Packaged Cognitive-Behavioral Treatment|The purpose of Packaged Cognitive-Behavioral Treatment (PCBT) is to train patients in a variety of skills that they can use to keep themselves from drinking.
62616543|NCT03259906|ACTIVE_COMPARATOR|Osteosynthesis using a posterior plate|
62616544|NCT03259906|ACTIVE_COMPARATOR|Osteosynthesis using an anterior plate|
62616545|NCT05018988|EXPERIMENTAL|Oral vitamin D3 spray|10µg/day for 12 weeks (BetterYou ltd.)
62616546|NCT05018988|PLACEBO_COMPARATOR|Placebo Comparator|Xylitol (BetterYou ltd.)
62616547|NCT03081299||Total Knee Arthroplasty|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
62616548|NCT03081299||Total Hip Arthroplasty|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
62616549|NCT03081299||Mastectomy|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
62616550|NCT03081299||Thoracic Surgery|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
62616551|NCT03081299||Major Abdominal Surgery|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
62259470|NCT03449589||Non smokers|Non smoking RA patients
62259471|NCT03737383|EXPERIMENTAL|Feasibility and Preliminary Efficacy|We will be administering Narrative Exposure Therapy to determine participant responses to the intervention, whether the intervention can be delivered successfully in this setting, and preliminary outcomes.
62259472|NCT06190652||Arm A|Chemotherapy combined with immunotherapy group
62616552|NCT03081299||Spinal Fusion|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
62616553|NCT03862092|EXPERIMENTAL|Patients with acute abdominal pain|Salivary VZV-DNA PCR was performed in patients who visited the emergency room due to acute abdominal pain.
62616554|NCT04968522|PLACEBO_COMPARATOR|Placebo comparator 2|Participants will be allocated a randomly allocated sequence of treatment. The randomisation will be in two-week pairs - so the order of treatment (A) and placebo (P) to be randomly assigned within each two-week cycle (over 8 weeks). Placebo will be matched in dose to their stimulant dose at enrolment to the trial as determined and titrated by their primary paediatrician. This dose will remain constant for the course of the trial (8 weeks). Placebo will be orally administered, unless this is not possible for clinical reasons.
62616555|NCT04968522|EXPERIMENTAL|Stimulant|"The stimulants used in the trial are commercially available and will be used in accordance with the approved labelling. Participants must be on a stable dose of stimulant medication for at last 1 month prior to the study. The dose is individualized and titrated by treating primary paediatrician. This will represent the starting dose for the trial, and this will remain stable through the course of the 8-week trial. This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. Based on pilot data from this group, psychostimulant medications prescribed in this population may include:~* Methylphenidate IR~* Methylphenidate LA~* Dexamphetamine~Children will take the required number of capsules to match the total prescribed dose (e.g. 30mg Ritalin LA is 3x10mg capsules)."
62616556|NCT04489732|EXPERIMENTAL|Treatment with MSCs|"A single dose of MSCs injected into the submandibular glands of patients with radiation-induced xerostomia (primary objective)~Following primary outcomes, a second injection of 10 (8 - 12) x 106 MSCs will be offered for injection into each participant's contralateral submandibular gland."
62616557|NCT01558713|ACTIVE_COMPARATOR|Group BFS|Group B: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
62616558|NCT01558713|ACTIVE_COMPARATOR|Group RFS|Group R : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
62259473|NCT06190652||Arm B|Chemotherapy combined with immunotherapy + radiotherapy group
62259474|NCT05858021||Anal HSIL|Participants must have histologically proven diagnosis of Anal HSIL.
62259475|NCT03542006|EXPERIMENTAL|Topical brinzolamide|Brinzolamide ophthalmic, given bd for 3 months
62616559|NCT01558713|ACTIVE_COMPARATOR|Group LFS|Group L: LEVO-BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
62616560|NCT01558713|ACTIVE_COMPARATOR|BupivacaineF|Group BupivacaineF: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY
62616561|NCT01558713|ACTIVE_COMPARATOR|RopivacaineF|Group RopivacaineF : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY.
62616562|NCT01558713|ACTIVE_COMPARATOR|LevobupivacaineF|Group LevobupivacaineF: LEVO-BUPIVACAINE 0,5% (2ml) + 10μg FENTANYL(0,2ml) INTRATHECALLY.
62616563|NCT02720159|EXPERIMENTAL|TREATMENT|
62616564|NCT00032630|OTHER|Arm 1|Coronary artery bypass - on-pump
62616565|NCT00032630|OTHER|Arm 2|Coronary artery bypass - off-pump
62616566|NCT02550925|EXPERIMENTAL|Acceptance and Commitment Therapy Group|
62616567|NCT02550925|ACTIVE_COMPARATOR|Usual Care|
62616568|NCT05241444|EXPERIMENTAL|Cohort A (≥12 years)|"The first participant in Dose Level 1 will be administered 1.0 x 10\^6 CD4\^LVFOXP3 /kg (± 20%).~If there is no toxicity observed in the first participant, the following participants in Dose Level 1 will be administered the same dose of 1.0 x 10\^6 CD4\^LVFOXP3 /kg (± 20%).~If there is no toxicity observed in any participants in Dose Level 1, participants will be enrolled into Dose Level 2 and administered 3 x 10\^6 CD4\^LVFOXP3 /kg (± 20%).~If there is no toxicity observed in any participants in Dose Level 2, participants will be enrolled into Dose Level 3 and administered 10 x 10\^6 CD4\^LVFOXP3 /kg (± 20%).~If in any dose level 1 of 2 participants show toxicity, that dose level will be expanded to 6 participants."
62616569|NCT05241444|EXPERIMENTAL|Cohort B (<12 years)|"Participants in Cohort B will always follow treatment of participants in Cohort A for the same dose level.~Cohort B will start at Dose Level 2 and be administered 3 x 10\^6 CD4\^LVFOXP3 /kg (± 20%).~If there is no toxicity observed in any participants in Dose Level 2, participants will be enrolled into Dose Level 3 and administered 10 x 10\^6 CD4\^LVFOXP3 /kg (± 20%).~If in any dose level 1 of 2 participants show toxicity, that dose level will be expanded to 6 participants."
62616570|NCT05559684|NO_INTERVENTION|Control|"Patients in this group will receive fentanyl infusion at a dose of (0.5 μg/kg/h) all through the whole operation; in addition to~1μg/kg during skin incision, sternotomy, aortic cannulation and increase in MBP or HR more than 20% of the baseline readings."
62616571|NCT05559684|ACTIVE_COMPARATOR|Erector Spinae Plane Block|This group will receive fentanyl infusion at a dose of (0.5 μg/kg / h) all through the whole operation plus Ultrasound guided bilateral ESPB which will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side
62616572|NCT05559684|EXPERIMENTAL|Transversus Thoracis Plane Block|This group will receive fentanyl infusion at a dose of (0.5 μg/kg / h) all through the whole operation plus ultrasound guided bilateral TTPB which will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side
62616573|NCT03472521|EXPERIMENTAL|Gabapentin|Gabapentin 300 mg capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
62616574|NCT03472521|PLACEBO_COMPARATOR|Control|Matched placebo capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
62616575|NCT01530802|EXPERIMENTAL|Uterine artery clipped|Both uterine arteries are temporarily clipped by Yasargil clips during laparoscopic myomectomy.
62616576|NCT01530802|NO_INTERVENTION|Control group|Conventional laparoscopic myomectomy is performed. (No intervention to temporarily occlude uterine arteries is made)
62616577|NCT02603107|EXPERIMENTAL|B/F/TAF|"Randomized Phase: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks, without regard to food.~Extension Phase: After Week 48, participants in countries where B/F/TAF is not available will be given the option to receive B/F/TAF for up to 96 additional weeks or until the product becomes accessible to participants through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first."
62616578|NCT02603107|EXPERIMENTAL|Stay on Baseline Regimen (SBR)|"Randomized Phase: Participants remained on current antiretroviral (ARV) regimen consisting of ritonavir (RTV)-boosted or cobicistat (COBI)-boosted atazanavir (ATV) or darunavir (DRV), plus either emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) for at least 48 weeks with food.~Extension Phase: After Week 48, participants in countries where B/F/TAF is not available will be given the option to receive B/F/TAF for up to 96 additional weeks or until the product becomes accessible to participants through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first."
62616579|NCT04393207|ACTIVE_COMPARATOR|Control group (Bupivacaine)|Patient will receive intrathecal morphine and TAP block with plain bupivacaine.
62259476|NCT01572116|PLACEBO_COMPARATOR|Lidocaine with Epinephrine+ Normal saline|
62259477|NCT01572116|ACTIVE_COMPARATOR|Lidocaine with Epinephrine + sufentanil|
62259478|NCT01353820|ACTIVE_COMPARATOR|1 = Tested product|
62259479|NCT01353820|SHAM_COMPARATOR|2 = Control product|
62259480|NCT02151955|EXPERIMENTAL|Individual parent infant intervention|Children and parents will be offered an assessment and then a tailored individual 10 to 15 week based attachment and parent intervention to promote parent child relationship.
62616580|NCT04393207|EXPERIMENTAL|Liposomal Bupivacaine|Patient will receive intrathecal morphine + TAP block with Liposomal bupivacaine and bupivacaine 0.25%
62616581|NCT04393207|ACTIVE_COMPARATOR|Bupivacaine + dexamethasone and methylprednisolone|Patient will receive intrathecal morphine + TAP block with only bupivacaine.
62623669|NCT06344546||Controls|ICU patients without refeeding hypophosphatemia. Controls selected to match for sex, age, severity of illness and nutritional delivery prior to refeeding hypophosphatemia.
62259481|NCT04243590||Neonatal brachial plexus palsy|"25 patients will be included. The level of the brachial plexus lesion will be recorded. Parents of all patients were asked to fill in the Turkish version of the Hand-at-Home Questionnaire and in addition, the upper extremity section of the Pediatric Outcomes Data Collection Instrument (PODCI) in patients with OBP."
62841296|NCT04968769|EXPERIMENTAL|ischemic compression and exercise|"Individuals were positioned in a comfortable position in a chair with back support. By palpating the UT muscle, first the taut band and then the active TP on the muscle were determined. Before starting the treatment, , a statement was made to the individual that you will soon feel a high level of pain with pressure, and at the same time, you may feel pain, tingling, pricking in additional areas (head-neck-shoulder-arm), after a while the pain will decrease and disappear. In this process, try to stay as steady as possible and breathe regularly and calmly.'' The highest level of pressure that the patient could tolerate was applied to the determined TP with the thumb. Pressure time will be in the range of at least 10-20 seconds and at most 60 seconds; It was terminated after the therapist felt complete relaxation in the tissue under his thumb or after the patient received the return of pain completely disappeared"
62841297|NCT04968769|EXPERIMENTAL|kinesio taping and exercise|While performing KT, the individual was seated in a comfortable and upright position in a chair with back support. The subject was asked to bring his hand to his back in internal rotation of the shoulder of the taped side and to bring his head to the contralateral lateral flexion and contralateral rotation so that the UT muscle was in a tense position. KT was applied using 'muscle inhibition technique' to ensure correct contraction of the muscle with muscle length/tension optimization, to target the reduction of excessive muscle tension, and to increase circulation with the effects of the tape on the skin. In this technique, to inhibit the muscle, the tape direction is from the muscle insertion to the origin. KT was performed 5 cm below the acromion to the protuberantia occipitalis with 10% tension
62841298|NCT04968769|ACTIVE_COMPARATOR|exercise|In order for all the exercises to be done correctly and not to cause any pain, the individuals were asked to perform the movements in front of the mirror. Posture exercises given the individuals for scapular retraction. During the posture exercises individual was positioned in a chair without back support. By counting 5 it was requested to do 10 repetitions of each exercise. For the UT muscle stretching, individuals were asked to hold their right ear with their left hand over their head while sitting on a back-supported chair with their hips and back fully resting on the chair, and to bring their left ear closer to their left shoulder with the help of their hand and count to 20 from the outside.
62841299|NCT04282408|EXPERIMENTAL|Treatment|Group treated with 3D printed brace
62841300|NCT03658681|EXPERIMENTAL|Test meal 1: Saturated fat 14.9 E%|Test meal with saturated fat 14.9 E%
62841301|NCT03658681|EXPERIMENTAL|Test meal 2: Polyunsaturated fat 13.6 E%|Test meal with polyunsaturated fat 13,6 E%
62841302|NCT04600661|EXPERIMENTAL|control group (Traditional therapy group)|control group (Traditional therapy group) (n=21): patients will receive traditional training exercises (high load resistance training
62841303|NCT04600661|EXPERIMENTAL|Experimental group I (BFR training group)|Experimental group I (BFR training group) (n=21): patients will receive LLRT with BFR.
62841304|NCT04600661|EXPERIMENTAL|Experimental group II (Neuromuscular training group)|Experimental group II (Neuromuscular training group) (n=21): patients will receive neuromuscular training exercises
62841305|NCT01963416|PLACEBO_COMPARATOR|Control|macro- and micro-nutrient matched control (240 ml)
62259482|NCT04243590||Unilateral cerebral palsy|"25 patients will be included. The level of Manual Ability Classification System (MACS) will be recorded. Parents of all patients were asked to fill out the Turkish version of the Hand-at-Home Questionnaire at Home, as well as the Children's Hand-Use Experience Questionnaire (CHEQ) in patients with CP."
62259483|NCT00094770|EXPERIMENTAL|Sitagliptin 100 mg|Sitagliptin 100 mg oral tablets of sitagliptin once daily.
62841306|NCT01963416|EXPERIMENTAL|Orange juice|commercial orange juice (240 ml)
62259484|NCT00094770|ACTIVE_COMPARATOR|Glipizide|Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
62259485|NCT05688436||Diroximel Fumarate (DRF)|Pregnant women with MS who were exposed to DRF.
62841307|NCT01963416|EXPERIMENTAL|whole orange|whole orange fruit (240 ml)
62841308|NCT01963416|EXPERIMENTAL|processed whole orange|processed whole orange (240 ml)
62841309|NCT02554461||female players|national team players
62841310|NCT02554461||male players|national team players
62841311|NCT03409224||Adults 18-99|Adults who are undergoing cryoablation
62841312|NCT04462627|EXPERIMENTAL|Covid 19 positive patients|
62841313|NCT04462627|EXPERIMENTAL|Covid 19 negative patients|
62259486|NCT05688436||Non-DRF|Pregnant women with MS who were exposed to disease-modifying therapies (DMTs) other than DRF.
62259487|NCT05688436||Non-DMT|Pregnant women with MS who were not exposed to DMTs.
62259488|NCT05293834|EXPERIMENTAL|VRAPT intervention group|"Data collection process:~1. Pre-intervention (t0): patients self-reports and staff observation;~2. VRAPT: 8-16 weeks;~3. Post-intervention (t1): patients self-reports, staff observations, and qualitative interview with participants and VRAPT therapists conducted by research staff;~4. Follow-up 12 weeks after completion of the intervention (t2): patients self-reports and staff observations."
62259489|NCT03615677|EXPERIMENTAL|LXI-15028 50mg group (n=130)|
62259490|NCT03615677|ACTIVE_COMPARATOR|Esomeprazole 40mg group (n=130)|
62259491|NCT03186677|EXPERIMENTAL|Cohort 1|Single intravenous administration of BeneFIX (75 IU/kg) with 72 hours of observation, followed by single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation
62841314|NCT04462627|EXPERIMENTAL|Untested healthy volunteers|
62841315|NCT04857164|EXPERIMENTAL|Pembrolizumab combined with Chemotherapy|"Chemotherapy regimen\* is as follows, selected by the investigator, 3 weeks (21 days) is a cycle，combined with pembrolizumab 200 mg intravenously on day 1, every 21 days is a treatment cycle until the disease progresses or the toxicity cannot be tolerated(Less than or equal to 35 cycle)~\*1) Cisplatin(75 mg/m2) + albumin-bound paclitaxel(260 mg/m2) 2)Cisplatin(25 mg/m2,d1-d3) + albumin-bound paclitaxel(260 mg/m2) 3)Carboplatin(AUC5) + Albumin-bound Paclitaxel(260 mg/m2)"
62841316|NCT01168037||Open repair|Open Surgical Repair (aortic replacement with revascularization of visceral arteries)
62841317|NCT01168037||Endovascular (Windows 1)|Endovascular therapy branched or fenestrated stent-graft
62841318|NCT01168037||Endovascular (Windows 3)|Endovascular therapy branched or fenestrated stent-graft (vascutek anaconda)
62841319|NCT00574522|OTHER|1|Infrared Radiation, wavelength between 5 and 20 microns
62841320|NCT06237504|ACTIVE_COMPARATOR|Ambu Auragain|Patients receiving general anesthesia with airway maintained with the 2nd generation SAD, Ambu Auragain.
62616582|NCT03570008|EXPERIMENTAL|Sp-Ex|a 9 days spa residential program including physical activity. 3 sessions of 10 minutes per day of physical exercise for bone health improvements supervised by a professional of adapted physical activity. Participants will benefit advices from national plan for physical activity and nutrition (NPPN)
62259492|NCT03186677|EXPERIMENTAL|Cohort 2|Single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation
62616583|NCT03570008|ACTIVE_COMPARATOR|Sp-alone|Participants will benefit a short term spa residential program of 9 days. In addition they will benefit advices from national plan for physical activity and nutrition (NPPN)
62259493|NCT03186677|EXPERIMENTAL|Cohort 3|Single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) with 120 hours of observation
62616584|NCT03570008|ACTIVE_COMPARATOR|Ex-alone|Participants will benefit 3 sessions of 10 minutes per day of physical exercise for bone health improvements supervised by a professional of adapted physical activity. Participants will benefit advices from national plan for physical activity and nutrition (NPPN)
62259494|NCT03186677|EXPERIMENTAL|Cohort 4|One subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) per day for 6 days with 240 hours of observation
62259495|NCT03186677|EXPERIMENTAL|Cohort 5|One intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) followed by subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) once daily for 9 days with 312 hours of observation
62259496|NCT06119490|OTHER|Arocitinib-arm|Evaluation of the efficacy and safety of methylprednisolone combined with abrocitinib in toxic epidermal necrolysis. Methylprednisolone 1 mg/kg body weight per day in combination with Arocitinib 200 mg daily.
62616585|NCT01146561|EXPERIMENTAL|Tanezumab 20 mg|
62616586|NCT01146561|PLACEBO_COMPARATOR|Placebo|
62616587|NCT00502099|ACTIVE_COMPARATOR|1|Pegylated interferon alpha 2a plus ribavirin
62841321|NCT06237504|EXPERIMENTAL|SaCoVLM|Patients receiving general anesthesia with airway maintained with the video LMA, SaCoVLM.
62841322|NCT02317367||adult women|Women who drink seven or more drinks per week
62841323|NCT02317367||adults a|Individuals who eat fewer than five servings of fruits and vegetables per day, on average, based on an NCI screener for fruit and vegetable consumption.
62616588|NCT00502099|ACTIVE_COMPARATOR|2|Pegylated interferon alpha 2b plus ribavirin
62616589|NCT02131636|EXPERIMENTAL|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
62616590|NCT02131636|PLACEBO_COMPARATOR|Vehicle|Vehicle to AGN-199201 applied to the face once daily for 29 days.
62841324|NCT02317367||adults b|Individuals who exercise (moderate or vigorous intensity) less than 75 minutes per week.
62841325|NCT04195893|EXPERIMENTAL|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses for one week and then switch to etafilcon A daily disposable lenses for one week.
62841326|NCT04195893|ACTIVE_COMPARATOR|etafilcon A|Subjects will be randomized to wear etafilcon A daily disposable lenses for one week and then switch to somofilcon A daily disposable lenses for one week.
62616591|NCT05746767|EXPERIMENTAL|Treatment|Participants randomly assigned to this condition will be provided all features of the SilverCloud platform as well as be assigned a peer-supporter who will provide regular support.
62616592|NCT05746767|ACTIVE_COMPARATOR|Control|Participants randomly assigned to this condition will be provided all features of the SilverCloud platform with the exception of the peer supporter.
62616593|NCT03836456|EXPERIMENTAL|Experimental Intervention|Mindfulness Based Stress Resilience Training: This approach will be conducted with study participants for 4 weeks. One evening per week.
62616594|NCT03836456|ACTIVE_COMPARATOR|Active Control Intervention|Health Enhancement Program: This is a validated active comparator used in Mindfulness-based training studies. It will be conducted with the participants one evening per week for 4 weeks.
62616595|NCT02599337|EXPERIMENTAL|sorafenib|Sorafenib is the test product.In period 1, period 2 and period 3, 12 of 36 Subjects were given Single oral dose (1 x 200 mg) sarofenib.
62841327|NCT01010867|EXPERIMENTAL|Lactobacillus plantarum|There is a single intervention arm in this study. Target accrual for the intervention is 30 subjects. Subjects receive supplementation with Lactobacillus plantarum strains 299 and 299v.
62841328|NCT06378216||Myotonic Dystrophy type 1|Myotonic Dystrophy type 1 -congenital form Myotonic Dystrophy type 1-infantile form
62616596|NCT02599337|ACTIVE_COMPARATOR|Nexavar|Nexavar is the reference product.In period 1, period 2 and period 3, 24 of 36 Subjects were given Single oral dose (1 x 200 mg) Nexavar .
62841329|NCT04946981|OTHER|Randomized Crossover_Sequence 1|Participants who meet the eligibility criteria will be randomized and will receive first the experimental product Turmipure GOLD® during the first study phase and then the placebo control during the second study phase. Both study phases are separated by a washout period of minimum 14 days.
62841330|NCT04946981|OTHER|Randomized Crossover_Sequence 2|Participants who meet the eligibility criteria will be randomized and will receive first the placebo control during the first study phase and then the experimental product Turmipure GOLD® during the second study phase. Both study phases are separated by a washout period of minimum 14 days.
62616597|NCT00650286|EXPERIMENTAL|1|Modafinil Tablets 200 mg
62616598|NCT00650286|ACTIVE_COMPARATOR|2|Provigil® Tablets 200 mg
62841331|NCT06266832|EXPERIMENTAL|Total Neoadjuvant Therapy with Short-course Radiation followed by Adebrelimab plus CAPEOX|"The enrolled patients with MSS-type advanced ultra low rectal adenocarcinoma will receive a combined regimen of neoadjuvant chemoradiotherapy combined with immunotherapy and biopsy or local excision.~Radiotherapy uses a short-range mode, irradiating the primary tumor and high-risk areas with dose of 25 Gy.~After radiotherapy, PD-L1 antibody (20mg/kg, intravenously guttae, 2courses) immunotherapy combined with 2 courses of CAPEOX chemotherapy was performed.~1-4 weeks after the end of the combined treatment plan in step 2), biopsy or local excision of the lesion is performed."
62259497|NCT06119490|OTHER|Tofacitinib-arm|Evaluation of the efficacy and safety of methylprednisolone combined with tofacitinib in toxic epidermal necrolysis. Methylprednisolone 1 mg/kg body weight per day in combination with tofacitinib 10 mg daily.
62259498|NCT00129324|OTHER|Lead Reduction Arm|random assignment to receive lead hazard control intervention. Assessing lead hazards in the home. Reducing lead hazards by cleaning, painting, covering, and/or replacing/repairing interior and exterior components of the home.
62616599|NCT00865657|EXPERIMENTAL|A|Alprazolam 3 mg Extended Release Tablets, single dose
62616600|NCT00865657|ACTIVE_COMPARATOR|B|XANAX XR® 3 mg tablets, single dose
62616601|NCT05926414||patient diagnosed with type2 diabetes mellitus|patient diagnosed with type2 diabetes mellitus
62616602|NCT00910117|EXPERIMENTAL|nimotuzumab|nimotuzumab plus PF regimen
62616603|NCT01937715|EXPERIMENTAL|Arm A|PF-05212384 plus FOLFIRI
62616604|NCT01937715|ACTIVE_COMPARATOR|Arm B|Bevacizumab plus FOLFIRI
62616605|NCT04698083||Group1:normal SpO2(NS,n = 80) and low SpO2(LS, n = 80).|Patients with normal oxygen saturation (SpO2; ≥ 90%) who did not receive oxygen therapy and patients with low SpO2(\<90%) who received nasal oxygen therapy were included in this study
62616606|NCT04698083||Group2:Rightward axis shift(Rws) and Leftward axis shift (Lws)|Both groups were divided into two main subgroups:patients with Rws and patients with leftward shift(Lws) of the QRS axis.The patient numbers were as follows: NS Rws (n=37),NS Lws(n=43),LS Rws (n=40),andLS Lws (n=40)
62616607|NCT02111681|EXPERIMENTAL|Calypso-based Deep Inspiration Breath Hold (DIBH)|"This trial will investigate the feasibility of implanted anchored Beacon ® electromagnetic lung transponders (Calypso ®) to guide and monitor deep-inspiration breathhold (DIBH) treatments in patients with inoperable thoracic malignancies.~Bronchoscopic Calypso Beacon Implantation, Simulation - Free-breathing scan - 4D CT scan,- DIBH CT scan Radiation - Treatment setup, - Calypso signal recording, - RT treatment with DIBH with or without visual biofeedback Follow-up - 3 and 6 months after RT with diagnostic CT chest"
62616608|NCT03706976|EXPERIMENTAL|CTOM|
62616609|NCT05376020|EXPERIMENTAL|Densah Burs|Intervention Group
62616610|NCT05376020|ACTIVE_COMPARATOR|Conventional Burs|Control Group
62616611|NCT04272957|EXPERIMENTAL|HMPL-306|HMPL-306 administered continuously as a single agent orally every day in a 28-day cycle.
62616612|NCT05096598|EXPERIMENTAL|ZP8396|Up to 10 single dose cohorts are planned with 8 subjects in each; 6 participants in each cohort will receive active treatment.
62616613|NCT05096598|PLACEBO_COMPARATOR|Placebo (ZP8396)|In each of the 10 single dose cohorts, 2 subjects will receive placebo.
62841332|NCT02502617||Weight Improvement|Patients (n = 30) with severe AN, refered to the specialized medical nutrition section at Odense University Hospital are tested three times during nutritional rehabilitation: At admission, at discharge (or drop out) and two-four months after discharge. The first study is carried out not before the third day of hospitalization after acclimatization and water electrolyte correction.
62841333|NCT02502617||Weight-stable|To investigate the re-test effects of the the surveys, outpatients with a stable weight (less than 5%/3 months) with eating disorders (n = 15) are tested twice with 4-6 weeks interval.
62841334|NCT05326269|ACTIVE_COMPARATOR|Intervention group|Terbutaline 0.5 mls (0.25 mg) , subcutaneously
62841335|NCT05326269|PLACEBO_COMPARATOR|Control group|Placebo (normal saline) 0.5 mls , subcutaneously
62841336|NCT06208943||NeuroCOVID Group|Individuals (ages 18-70 years) who endorse a reported change in concentration, memory, feelings anxiety or depression since initial COVID infection.
62616614|NCT04964167|PLACEBO_COMPARATOR|Group I (Standard Root Planning)|
62056504|NCT06056609|ACTIVE_COMPARATOR|Yoga - Intervention Group|"The participants in the intervention group (n.20) will obtain access to an eight-week online mother and baby programme. They will be given access to one video per week and asked to complete the session at least once within the week. The participants are also free to repeat the session as many times as they wish.~The researchers will record the participants access to the online videos. All participants will be asked to complete a daily activity diary.~The participants will be asked to complete pre, intermediate, and post intervention questionnaires relating to maternal mental health, body satisfaction, and their feelings about the mother and infant bond.~A subset of participants will also undergo a telephone interview upon completion of the study, which will be subject to qualitative analysis. A short two weekly questionnaire will be sent to all participants for the duration of the study to monitor participant mood and allow for follow up should it be deemed necessary."
62056505|NCT06056609|NO_INTERVENTION|Control Group|The participants in the control group (n. 20) will follow the usual standard care pathway and will be offered access to the programme at the end of the study.
62056506|NCT03642938|EXPERIMENTAL|Low Dose Exercise|The Low Dose Exercise group will perform treadmill walking exercise, three times per week for one week.
62056507|NCT03642938|EXPERIMENTAL|Moderate Dose Exercise|The Moderate Dose Exercise group will perform treadmill walking exercise, five times per week for one week.
62259499|NCT00129324|OTHER|Injury Reduction Arm|random assignment to receive injury hazard control intervention. Assessing home for potential injury hazards. Controlling hazards by 1) installing safety equipment such as stairway gates, cabinet locks, smoke \& CO detectors, etc. 2) removing the hazards from the reach of a child and/or 3) restricting access to the hazards.
62259500|NCT02547350|NO_INTERVENTION|Blank control|do not use prophylactic intravesical chemotherapy
62259501|NCT02547350|EXPERIMENTAL|single intravesical instillation|intravesical instillation within 24 hours postoperatively
62259502|NCT02547350|EXPERIMENTAL|multiple intravesical instillation|intravesical instillation every 1 week for the first 2 months, then once a month for the rest 10 months
62616615|NCT04964167|ACTIVE_COMPARATOR|Group II (Standard Root Planning + Photodynamic Therapy)|
62616616|NCT04964167|EXPERIMENTAL|Group III (Standard Root Planning + Aloe Vera)|
62259503|NCT04882306|OTHER|Main study group|
62259504|NCT06042218|EXPERIMENTAL|Experimental group who trained one day a week|This intervention group will attend a weekly sixty-minute training session with the Xiaxi machine during the twelve weeks of the intervention. The sessions will include flexibility and strength-resistance work, as well as postural awareness.
62616617|NCT02027857|NO_INTERVENTION|mannitol empirical therapy|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the empirical therapy by doctors.
62616618|NCT02027857|EXPERIMENTAL|EIT monitoring|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the results of Electrical impedance tomography monitoring.
62616619|NCT02027857|OTHER|non-invasive ICP monitoring|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the results of non-invasive intracranial pressure monitoring.
62616620|NCT02007278|ACTIVE_COMPARATOR|vildagliptin and metformin|Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks
62616621|NCT02007278|ACTIVE_COMPARATOR|glimepiride and metformin|Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin
62841337|NCT06208943||COVID Control Group|Individuals (ages 18-70 years) who do not feel any different since recovering from initial COVID infection.
62841338|NCT01538667|EXPERIMENTAL|Arm 1|
62841339|NCT01538667|EXPERIMENTAL|Arm 2|
62841340|NCT01538667|EXPERIMENTAL|Arm 3|
62841341|NCT01538667|EXPERIMENTAL|Arm 4|
62841342|NCT05577117|ACTIVE_COMPARATOR|opioid free (OFA) group|1000 mg paracetamol + dexmedetomidine 1 µg/kg over 10 min as loading dose and dexamethasone 0.1 mg/kg and lidocaine 1 mg/kg IV bolus Then continuous infusion of dexmedetomidine at a rate of 0.5 µg/kg/h with lidocaine 2 mg/kg/hr and magnesium sulfate 1.5 g/hr during surgery .
62841343|NCT05577117|NO_INTERVENTION|fentanyl (F) group|fentanyl 2 µg/kg as loading dose followed by continuous infusion at a rate of 1 µg/kg/h during surgery.
62841344|NCT01630538|EXPERIMENTAL|Cyclophosphamide|Cyclophosphamide 1.5 mg/kg orally daily for 180 days (26 weeks) adjusted for renal function.
62259505|NCT06042218|EXPERIMENTAL|Experimental group who trained two days a week|This intervention group will attend two weekly sixty-minute training sessions with the Xiaxi machine during the twelve weeks of the intervention. The sessions will include flexibility and strength-resistance work, as well as postural awareness.
62841345|NCT01493076||Baby-S group|The baby-sphincterotome was in patients in whom biliary sphincterotomy was clinically indicated but in whom after standard techniques to gain biliary access had failed (study population).
62841346|NCT04287270|OTHER|Assesment of MSA patients and healthy controls|Demographic information (sex, age, occupation, height, bodyweight ...), clinical and medical status, diagnosis date and Mini-Mental Status Scale data of all participants will be recorded at the first visit. Inspiratory muscle strength will be evaluated with sniff nasal inspiratory pressure and maximal inspiratory mouth pressure, expiratory muscle strength will be evaluated with expiratory mouth pressure. Also, the pulmonary function test will be applied.
62841347|NCT04133688|EXPERIMENTAL|Mobile application (ASC)|mobile app / devise
62841348|NCT04133688|ACTIVE_COMPARATOR|Paper diary|paper diary
62841349|NCT06288100||Observations|"number of patients, sex, age, Bodi Mass Index , Range of Motion ,type of plate \& Screws used , Degree of deformity .~Digital radiography (General Electric Healthcare ) functional scores software T-tests, One-way analysis of variance."
62841350|NCT04953728|EXPERIMENTAL|Subjects with IBS-C|All participants will receive all treatment options. Each participant will receive all of the following treatments; 100 Hz ST36, 100 Hz PC6, 25 Hz ST36, 25 Hz PC6, as well as the sham comparator. Each administration will be performed on different dates, between 1 and 3 weeks apart.
62841351|NCT02231931|EXPERIMENTAL|A (Reference 1) Digoxin|1 tablet as single dose, fasted
62445242|NCT05711030|EXPERIMENTAL|Thoracic paravertebral block single injection|"Patients will either be in the sitting or prone position for the block. The block will be performed with the ultrasound transducer in the sagittal position about 2.5 to 3 cm lateral to the spinous process using a caudal to cranial in-plane needle approach. The thoracic vertebral levels will be identified by finding the first rib under ultrasound guidance and counting down levels appropriately.~The needle (80 mm 22-gauge Pajunk) will be introduced in-plane in a caudal to cranial direction until it punctures the costotransverse ligament. Saline in 1 ml increments will be injected to confirm correct placement of the needle tip. Injection of saline or local anesthetics deep to the costotransverse ligament will lead to an anterior displacement of the parietal pleura.~For the single-injection technique, injection of 30 ml of ropivacaine 0.5% will be done at the T3-T4 paravertebral space after negative aspiration."
62841352|NCT02231931|EXPERIMENTAL|B (Reference 2) Furosemide|oral solution, as single dose, fasted
62841353|NCT02231931|EXPERIMENTAL|C (Reference 3) Metformin hydrochloride|1 film-coated tablet as single dose, fasted
62259506|NCT06042218|NO_INTERVENTION|Control Group|They will not attend any type of intervention. They will continue to perform their daily activities without intervention.
62259507|NCT03814486||patient transfused in platelet in the 6 last months of life|patient with hematological malignancies follow or hospitalised at least once in CHU of Besancon died in the period of the study transfused at least once in the 6 months of life
62841354|NCT02231931|EXPERIMENTAL|D (Reference 4) Rosuvastatin|1 film-coated tablet as single dose, fasted
62259508|NCT04247061|EXPERIMENTAL|Smoking Cessation intervention|At a dental cleaning visit, participants will watch a brief educational video that provides guidance and advice on smoking cessation. Participants will then interact with a text program for a month to motivate them to use smoking cessation resources. Participants will also be required to make contact with the resources in order to demonstrate feasibility of study flow.
62259509|NCT01805531||Rivaroxaban|
62259510|NCT03481114|ACTIVE_COMPARATOR|Standard chemoradiotherapy|Patients receiving standard radiotherapy will receive a total dose of 60 Gy in 30 fractions over 6 weeks, delivered to all involved lesions (tumors and lymph nodes).
62259511|NCT03481114|EXPERIMENTAL|PET-based, dose-painted, accelerated chemoradiotherapy,|For patients receiving PET-based, dose-painted, accelerated chemoradiotherapy, lesions with MTV exceeding 20 cc will be treated with 55 Gy in 20 fractions over 4 weeks, while lesions with MTV below 20 cc will receive 44 Gy in 20 fractions over the same 4 weeks.
62445243|NCT02550756|EXPERIMENTAL|0.2 mg of CNTX-4975|CNTX-4975 will be provided at a capsaicin concentration of 2.0 mg/ml and will be diluted to final concentration using sterile water and 30% PEG 300. Dose volume 1.0 mL-2.0 mL will be used at the discretion of the investigator. Capsaicin concentration will be 0.1 to 0.2 mg/ml
62623670|NCT04298879|EXPERIMENTAL|IBI376|IBI376 will be administered orally at a dose of 20 mg once daily for 8 weeks followed by 2.5 mg once daily.
62841355|NCT02231931|EXPERIMENTAL|E (Test) 1|Digoxin (1 tablet), Furosemide (0.5 mL oral solution), Metformin hydrochloride (1 film-coated tablet), Rosuvastatin (1 film-coated tablet), fasted
62841356|NCT02231931|EXPERIMENTAL|F (Test 2)|Digoxin (1 tablet), Furosemide (0.5 mL oral solution), Metformin hydrochloride (2 film-coated tablets), Rosuvastatin (1 film-coated tablet), fasted
62841357|NCT02231931|EXPERIMENTAL|G (Test 3)|Digoxin (1 tablet), Furosemide (2.0 mL oral solution), Metformin hydrochloride (1 film-coated tablet), Rosuvastatin (1 film-coated tablet), fasted
62841358|NCT05404932|EXPERIMENTAL|Intervention arm (aliquoted plasma application into the conjunctiva)|"This is the only arm of the study. The intervention is administration of aliquoted plasma provided by Canadian Blood Services in eye droppers (3 ml aliquots in 7 ml vials) in the patient's conjunctiva.~The duration of therapy can be 2 to 6 months depending on response The intra-ocular drops will be administered every 1-5 hours daily in the affected eye based on disease severity and may be repeated"
62841359|NCT00267566|EXPERIMENTAL|Treatment|50% random assignment to receive Family Help Anxiety Treatment
62056508|NCT03642938|EXPERIMENTAL|High Dose Exercise|The High Dose Exercise group will perform treadmill walking exercise, ten times per week for one week.
62056509|NCT03642938|SHAM_COMPARATOR|Control|The Control group will perform quiet rest, three times per week for one week.
62056510|NCT00485225|EXPERIMENTAL|Transdermal patch (EN3270) - Titration 1|
62056511|NCT00485225|EXPERIMENTAL|Transdermal patch (EN3270) - Titration 2|
62259512|NCT02170233||Sepsis|This group will contain patients meeting criteria for sepsis for enrollment in the study (target population).
62445244|NCT02550756|EXPERIMENTAL|0.6 mg of CNTX-4975|CNTX-4975 will be provided at a capsaicin concentration of 2.0 mg/ml and will be diluted to final concentration using sterile water and 30% PEG 300. Dose volume 1.0 mL-2.0 mL will be used at the discretion of the investigator. Capsaicin concentration will be 0.3 to 0.6 mg/ml
62259513|NCT02170233||Normals|This group will be healthy patients who will have data points recorded for controls for the study to assess the reliability of these measures on healthy patients.
62259514|NCT02264483||COPD exacerbation|"No intervention.~The subjects will be divided in 2 subgroups according to the image study:~* COPD exacerbation with pneumonia~* COPD exacerbation without pneumonia"
62259515|NCT02264483||COPD stable patients|
62259516|NCT00889265|EXPERIMENTAL|CopiOs Pericardium Membrane|Subject's study site must exhibit a partially edentulous ridge of the maxilla or mandible with at least one tooth-span in length and less than 5.5mm in its smallest buccolingual dimension as measured by ridge-mapping calipers.
62259517|NCT04049838|ACTIVE_COMPARATOR|lateral transversus abdominis block|patients will take lateral transversus abdominis plan block. The block will be done unilaterally on the same side of proposed surery with 0.25% bupivacaine at a volume of 1 ml·kg-1
62259518|NCT04049838|ACTIVE_COMPARATOR|posterior tansversus abodominis plane block|patients will take posterior transversus abdominis plane block. The block will be done unilaterally on the same side of proposed surery with 0.25% bupivacaine at a volume of 1 ml·kg-1
62259519|NCT04049838|ACTIVE_COMPARATOR|convential analgesia|conventional analgesia in form of 1 micrograms. Kg-1 fentanyl and paracetamol 15 mg. Kg-1 suppositories
62259520|NCT03753646|EXPERIMENTAL|Lactating allowance and psycho social stimulation|Mothers will receive lactating allowance and psycho social stimulation
62445245|NCT01530685|EXPERIMENTAL|Glycabiane, gelule|
62445246|NCT01530685|PLACEBO_COMPARATOR|Placebo|
62445247|NCT01919294|EXPERIMENTAL|testosterone undecanoate|Open label testosterone injection. Testosterone Undecanoate (1 g in 4 ml oily base) will be given as slow (2 minute) intramuscular injections (Nebido, manufactured by Bayer-Schering). These will be administered by the study investigator or designated research nurse at time zero (baseline visit 2) and after 6, 18, 30 and 42 weeks.
62445248|NCT03818503||OligoCare|Patients with oligometastatic disease treated with radical radiotherapy
62445249|NCT03818503||ReCare|Patients treated with high-dose Re-irradiation
62445250|NCT01333033|EXPERIMENTAL|Arm I (FOLFOX regimen)|Patients receive modified FOLFOX-6 therapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously on days 1-5. Treatment repeats every 14 days for 3 courses. Patients then undergo PET/CT scan. Patients with responsive disease (tumor metabolic activity decreased by \>= 35%) receive 3 additional courses of FOLFOX-6 therapy and undergo concurrent RT (3D-conformal or intensity-modulated) once daily, 5 days a week, for approximately 6 weeks. Patients without responsive disease (tumor metabolic activity did not decrease by 35%) cross over to Arm II during RT.
62616622|NCT03927586|EXPERIMENTAL|cognitive training (COG group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). Each cognitive intervention session will last for 90 minutes. The COG group received computerized cognitive based training which include memory, executive function, visuospatial , language and attention trainings.
62616623|NCT03927586|EXPERIMENTAL|physical exercise training (PE group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). Each physical exercise intervention session will last for 90 minutes. The entire exercise program for the PE group will contain 10 minutes of warm-up, 70 minutes of physical exercise, and 10 minutes of cool-down. The PE group received multimodal exercise program which includes aerobic exercise, balance and muscle strength training.
62056512|NCT00485225|EXPERIMENTAL|Transdermal patch (EN3270) - Titration 3|
62259521|NCT03753646|NO_INTERVENTION|Only lactating allowance|Mothers will receive only lactating allowance
62259522|NCT05744765|EXPERIMENTAL|Breathing exercises|First evaluation - breathing exercises (1 session) - second evaluation - breathing exercises (11 sessions) - third evaluation
62259523|NCT05744765|NO_INTERVENTION|No exercise|First evaluation - no intervention (1 session) - second evaluation - no intervention (11 sessions) - third evaluation
62259524|NCT05768451||benign|
62259525|NCT05768451||malignant|
62259526|NCT05468554|EXPERIMENTAL|Metformin|patients qualified to receive metformin and 131I treatment
62259527|NCT05468554|ACTIVE_COMPARATOR|Placebo|patients receiving placebo and 131 I treatment
62259528|NCT05468554|NO_INTERVENTION|Observational|observation group, patients after thyroidectomy, characterized by low risk of cancer progression, in this case, not qualified for 131I treatment
62259529|NCT00822731|EXPERIMENTAL|Lymphoma|patients diagnosed as lymphoma
62259530|NCT04056572|EXPERIMENTAL|TQ-B3139|TQ-B3139 tablet 600mg administered orally, twice daily.
62259531|NCT04694664||Pregnant Women|Pregnant women who are 18 years of age or older.
62841360|NCT00267566|EXPERIMENTAL|Control|50% random assignment to control group to receive usual/standard care for anxiety
62056513|NCT00485225|EXPERIMENTAL|Transdermal patch (EN3270) - Titration 4|
62056514|NCT01623258||Standard of Care|Standard histopathological evaluation using conventional paraffin embedding, sectioning and hematoxylin and eosin staining and microscopy without sentinel lymph node ultrastaging
62056515|NCT01623258||Research|SOC with sentinel lymph node analysis
62056516|NCT04539314|PLACEBO_COMPARATOR|Control group|TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%)
62056517|NCT04539314|ACTIVE_COMPARATOR|Dexmedetomidine 0.5 μg group|TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%) plus dexmedetomidine 0.5 μg / kg as an adjuvant
62056518|NCT04539314|ACTIVE_COMPARATOR|Dexmedetomidine 1 μg group|TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%) plus dexmedetomidine 1 μg / kg as an adjuvant
62056519|NCT02231866|EXPERIMENTAL|Group 1|cAd3-EBO at 2x10(10)PU IM
62056520|NCT02231866|EXPERIMENTAL|Group 2|cAd3-EBO at 2x10(11)PU IM
62056521|NCT02231866|EXPERIMENTAL|Group 3|cAd3-EBO at 2x10(11)PU IM boost of Ebola DNA WT vaccine (VRC 206 participants)
62056522|NCT02231866|EXPERIMENTAL|Group 4A|cAd3-EBOZ at 1x10(10)PU IM
62056523|NCT02231866|EXPERIMENTAL|Group 4B|cAd3-EBOZ at 1x10(11)PU IM
62056524|NCT02231866|EXPERIMENTAL|Group 5|cAd3-EBO at 2x10(11)PU IM
62445251|NCT01333033|EXPERIMENTAL|Arm II (carboplatin + paclitaxel + radiation)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 2 courses. Patients then undergo PET/CT scan. Patients with responsive disease (tumor metabolic activity decreases \>= 35%) continue to receive carboplatin IV over 30 minutes and paclitaxel IV over 1 hour once weekly for 5 weeks and undergo RT (3D-conformal or intensity-modulated) once a day, 5 days a week, for approximately 6 weeks. Patients without responsive disease (metabolic activity did not decrease by 35%) cross over to Arm I during RT
62445252|NCT01895920|EXPERIMENTAL|HIV infection|20 HIV infected subjects
62445253|NCT00854009|EXPERIMENTAL|1|BLI-489
62841361|NCT03164239|EXPERIMENTAL|Intervention group - telephone and print exercise intervention|The intervention group (IG) received a total of three intervention packages, one every second month, during the intervention period. The first intervention package was distributed at intervention start. The intervention package consisted of a tailored exercise program, national recommendations for physical activity, prompts and reminders. Additionally the IG received fortnightly supportive motivational contact every two weeks, alternately by telephone og email
62056525|NCT04098406|PLACEBO_COMPARATOR|Placebo|The matched placebo used in this study consisted of water, sodium bicarbonate, and food coloring to match volume and color of the experimental treatment
62056526|NCT04098406|EXPERIMENTAL|30 mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
62056527|NCT03337932|ACTIVE_COMPARATOR|MEM-7 days doxycycline|
62056528|NCT03337932|ACTIVE_COMPARATOR|MEM-14 days doxycycline|
62056529|NCT03337932|PLACEBO_COMPARATOR|Controls|
62056530|NCT03587142|ACTIVE_COMPARATOR|Buspirone|Buspirone HCl 10 mg capsule orally three times daily, 30 minutes before each meal, for 4-weeks
62056531|NCT03587142|PLACEBO_COMPARATOR|Placebo|Placebo capsule orally three times daily, 30 minutes before each meal, for 4-weeks; manufactured to look identical to buspirone capsule
62056532|NCT01892345|EXPERIMENTAL|Eculizumab|Biological/Vaccine: Eculizumab; Induction Period: Participants received eculizumab (900 milligrams \[mg\]) via intravenous (IV) infusion once a week (every 7 ± 2 days) for 4 weeks followed by eculizumab 1200 mg for the fifth dose (Week 4). This was followed by the Maintenance Period: Participants received eculizumab (1200 mg) via IV infusion every 2 weeks (every 14 ± 2 days) from the sixth dose (Week 6) onwards.
62445254|NCT00854009|PLACEBO_COMPARATOR|2|Placebo
62445255|NCT06545292|EXPERIMENTAL|Microsampling arm|Patients who use an oral oncolytic will be asked to provide twelve microsamples obtained by finger prick (eight dried blood spots (DBS) and four wet blood samples in microtainer EDTA) and four paired whole blood (WB) samples obtained by venapuncture.
62445256|NCT02883790|EXPERIMENTAL|Somnage|Group A-Melatonin 1mg, Zinc, Magnesium Oral administration o.d.
62445257|NCT02883790|PLACEBO_COMPARATOR|Placebo|Oral administration o.d.
62841362|NCT03164239|NO_INTERVENTION|Control group|The control group (CG) were encouraged to continue previous lifestyle.
62841363|NCT04080167|OTHER|Arm 1 (InCharge Health app)|Patient receives the InCharge Health app for 6 months
62056533|NCT01892345|PLACEBO_COMPARATOR|Placebo|Placebo contains the same buffer components without the active ingredient. Induction Period: Participants received matching placebo (900 mg) via IV infusion once a week (every 7 ± 2 days) for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose (Week 4). This was followed by the Maintenance Period: Participants received matching placebo (1200 mg) via IV infusion every 2 weeks (every 14 ± 2 days) from the sixth dose (Week 6) onwards.
62445258|NCT03895099|EXPERIMENTAL|A - Early follicular phase|Treatment by desogestrel at day 1 to day 3
62056534|NCT02953743|EXPERIMENTAL|Lenvatinib 12 mg|Participants weighing ≥ 60 kg will be enrolled in this arm.
62056535|NCT02953743|EXPERIMENTAL|Lenvatinib 8 mg|Participants weighing \< 60 kg will be enrolled in this arm.
62259532|NCT04694664||Post-partum women|Women who have at least one child younger than 18 years of age.
62259533|NCT03844984|ACTIVE_COMPARATOR|Ketamine group|This group will receive induction of anesthesia using ketamie full dose 1 mg/kg, midazolam 0.05 mg/Kg, and normal saline 10 mL.
62259534|NCT03844984|EXPERIMENTAL|Lidocaine-ketamine group|This group will receive induction of anesthesia using Ketamie half dose 0.5 mg/kg, midazolam 0.05 mg/Kg, and lidocaine 1 mg/Kg.
62259535|NCT02735395|PLACEBO_COMPARATOR|Control|Scaling and root planing (SRP) + two placebo pills thrice a day (TID) for 14 days (control group)
62259536|NCT02735395|ACTIVE_COMPARATOR|MTZ 250 (7 days)|SRP + MTZ (250mg/TID) + AMX, for 7 days and placebos for another 7 days
62259537|NCT02735395|ACTIVE_COMPARATOR|MTZ 400 (7 days)|SRP + MTZ (400mg/TID) + AMX, for 7 days and placebos for another 7 days
62259538|NCT02735395|ACTIVE_COMPARATOR|MTZ 250 (14 days)|SRP +MTZ (250mg/TID) + AMX for 14 days
62259539|NCT02735395|ACTIVE_COMPARATOR|MTZ 400 (14 days)|SRP +MTZ (400mg/TID) + AMX for 14 days
62259540|NCT01940471|EXPERIMENTAL|TAF 25 mg|TAF + TDF placebo for 96 weeks (per amendment 1 \& 2) or 144 weeks (per amendment 3).
62259541|NCT01940471|ACTIVE_COMPARATOR|TDF 300 mg|TDF + TAF placebo for 96 weeks (per amendment 1 \& 2) or 144 weeks (per amendment 3).
62259542|NCT01940471|EXPERIMENTAL|Open-label TAF|"All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study.~After the end of study treatment, participants can either switch to commercially available anti-HBV treatments in their country or will be followed every 4 weeks, for up to 24 weeks off treatment (treatment-free follow-up (TFFU)) for safety assessment."
62259543|NCT02349048|EXPERIMENTAL|Arm A|Chronic hepatitis C virus (HCV) genotype 1 infected participants with early stages of liver fibrosis, will receive Simeprevir (SMV) 150 milligram (mg), Daclatasvir (DCV) 60 mg and Sofosbuvir (SOF) 400 mg once daily for 6 weeks.
62259544|NCT02349048|EXPERIMENTAL|Arm B|Chronic HCV genotype 1 infected participants with cirrhosis, will receive SMV 150 mg, DCV 60 mg and SOF 400 mg once daily for 8 weeks.
62259545|NCT02943564|EXPERIMENTAL|Rapastinel 225 mg|Rapastinel 225 milligram (mg) weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
62056536|NCT04392063|OTHER|Cerebral palsy|Not included
62259546|NCT02943564|EXPERIMENTAL|Rapastinel 450 mg|Rapastinel 450 mg weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
62841364|NCT04080167|OTHER|Arm 2 (HU Toolbox app)|Provider receives the HU Toolbox app for 9 months
62841365|NCT00568386|EXPERIMENTAL|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop in each eye one time
62841366|NCT00568386|ACTIVE_COMPARATOR|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each one time
62056537|NCT03306901|EXPERIMENTAL|Concurrent Chemoradiotherapy|"Patients receive 2 courses (every 3 weeks) of chemotherapy including cisplatin (45-60mg/m2) intravenously over 1 hour on day 1 and 5-fluorouracil (3,200 \~ 4,000mg/m2) intravenously for 4 to 5 days.~Patients receive a total of 45 Gy radiation therapy (5 days a week for 5 weeks)."
62056538|NCT03306901|ACTIVE_COMPARATOR|Esophagectomy|Patients receive surgical resection, including Ivor Lewis esophagectomy or McKeown esophagectomy and systematic lymphadenectomy.
62259547|NCT02943564|PLACEBO_COMPARATOR|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
62259548|NCT00502138|EXPERIMENTAL|A|Interventional, continuous pramlintide infusion at 9 micrograms/hr plus 60 microgram meal bolus plus continuous insulin basal-bolus subcutaneous infusion
62259549|NCT02725983|EXPERIMENTAL|Intra Oral Camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation (Bardet et al. 1999), as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback as described by Newton and Asimakopoulou (2015). Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.
62445259|NCT03895099|EXPERIMENTAL|B - Medium follicular phase|Treatment by desogestrel at day 4 to day 7
62445260|NCT03895099|EXPERIMENTAL|C - Late follicular phase|Treatment by desogestrel at day 7 to day 11
62445261|NCT03895099|EXPERIMENTAL|D - Ovulatory Phase|Treatment by desogestrel at day 12 to day 15
62445262|NCT03895099|EXPERIMENTAL|E - Luteal phase|Treatment by desogestrel at day 16 to day 30
62445263|NCT06369415||IVM children|Children born from in-vitro maturation.
62445264|NCT06369415||IVF children|Children born from conventiona in-vitro fertilization.
62841367|NCT05343624|OTHER|CGM Arm|continuous glucose meter is placed on the abdomen
62841368|NCT00124514|EXPERIMENTAL|Triptorelin T1|Triptorelin Pamoate 25 μg/kg body weight
62841369|NCT00124514|EXPERIMENTAL|Triptorelin T2|Triptorelin Pamoate 50 μg/kg body weight
62056539|NCT03884114|OTHER|All participants|All participants are evaluated on a scenario of pediatric asthma exacerbation using three different evaluation tools: (i) the simulation game EfficAsthme developed to train individuals on the management of pediatric asthma exacerbations; (ii) a MCQ on the same subject developed for the purpose of the study and (iii) HF-simulation, considered as the gold-standard for its enhanced realism.
62259550|NCT02725983|ACTIVE_COMPARATOR|No Intra Oral camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation (Bardet et al. 1999), as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback as described by Newton and Asimakopoulou (2015) and considered crucial to the accomplishment of long term behavior change. Moreover, special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation) in order to focus patients´ attention on the varied facets of oral health care and increase their perception of the treatment needs. In this group, the device SOPROCARE® by Acteon was not used.
62056540|NCT03753451|NO_INTERVENTION|Group 1|20 patients without periodontal disease and coronary artery disease
62616624|NCT03927586|EXPERIMENTAL|sequential training (SEQ group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). The participants in the SEQ group will first undergo physical exercise training for 45 minutes followed by 45 minutes of cognitive-based training. The participants will first perform 10 minutes of warm-up followed by 25 minutes of physical exercise, and end with 10 minutes of cool-down. The exercise intensity will be similar to the PE group. Following the physical exercise, the participants will take part in 45 minutes of cognitive training. The same tasks used in the COG group will be practiced.
62841370|NCT00124514|EXPERIMENTAL|Triptorelin T3|Triptorelin Pamoate 75 μg/kg body weight T3
62841371|NCT00124514|EXPERIMENTAL|Triptorelin T4|Triptorelin Pamoate 100 μg/kg body weight T4
62841372|NCT00124514|PLACEBO_COMPARATOR|Placebo|Normal Saline
62056541|NCT03753451|NO_INTERVENTION|Group 2|20 patients without periodontal disease and with coronary artery disease
62056542|NCT03753451|ACTIVE_COMPARATOR|Group 3|20 patients with periodontal disease and with coronary artery disease received treatment of periodontal disease
62056543|NCT03753451|ACTIVE_COMPARATOR|Group 4|20 patients with periodontal disease and without coronary artery disease received treatment of periodontal disease
62056544|NCT05516225|EXPERIMENTAL|PBCLN-003, 1.8 g daily in 3 divided oral doses for 7 days|
62056545|NCT05516225|EXPERIMENTAL|PBCLN-003, 3.6 g daily in 3 divided oral doses for 7 days|
62259551|NCT02404623|EXPERIMENTAL|Intervention Group|800 IU of Vitamin D once daily
62259552|NCT02404623|OTHER|Control Group|400 IU of Vitamin D once daily, the standard of care
62056546|NCT05516225|EXPERIMENTAL|PBCLN-003, 9 g daily in 3 divided oral doses for 7 days|
62259553|NCT02446431|EXPERIMENTAL|Metronomic Therapy|"There is only one arm in this study. All subjects receive the same therapy for a period of 420 days (42 day cycles x 10 cycles).~1. Bevacizumab: IV, 10 mg/kg, Days 1, 8~2. Cyclophosphamide: PO, 25 mg/m2 Days 1-14 (max dose = 50mg/dose)~3. Valproic Acid: PO, 5 mg/kg, three times per day (TID), Days 22-35~4. Temsirolimus: IV, 25 mg/m2, Days 22, 29"
62259554|NCT03015571|EXPERIMENTAL|NBI|Use of Narrow Band Imaging with regular care of cervical inlet patches detection.
62259555|NCT03015571|PLACEBO_COMPARATOR|WL|Use of High Definition White Light (WL) with regular care of cervical inlet patches detection.
62841373|NCT01539460|EXPERIMENTAL|minimally invasive surgery|There is only one arm to this study. All patients will receive treatment with the minimally invasive surgery for their axillary bromidrosis
62841374|NCT05225805|EXPERIMENTAL|Group A|Group A will receive one dose of 150 mg lefamulin IV followed by one dose of 600 mg lefamulin oral
62056547|NCT05516225|EXPERIMENTAL|PBCLN-003, 18 g daily in 3 divided oral doses for 7 days|
62056548|NCT02800967|ACTIVE_COMPARATOR|Pure Aronia juice|Participants will consume 100 ml of pure Aronia juice per day for 28 days
62056549|NCT02800967|ACTIVE_COMPARATOR|Aronia juice-based beverage|Participants will consume 100 ml of Aronia juice-based beverage per day for 28 days.
62056550|NCT02800967|PLACEBO_COMPARATOR|Placebo beverage|Participants will consume 100 ml of Placebo beverage per day for 28 days
62259556|NCT03015571|EXPERIMENTAL|NBI increased care|Use of Narrow Band Imaging with increased care of cervical inlet patches detection.
62259557|NCT03015571|PLACEBO_COMPARATOR|WL increased care|Use of High Definition White Light (WL) with increased care of cervical inlet patches detection.
62623671|NCT01968499||All recruited patients|Patients who receive stent implantation and aged \>18 years.
62841375|NCT05225805|EXPERIMENTAL|Group B|Group B will receive one dose of 600 mg lefamulin oral followed by one dose of 150 mg lefamulin IV
62841376|NCT00851227|EXPERIMENTAL|1. Mildly Hepatic Impaired Subjects|
62841377|NCT00851227|EXPERIMENTAL|2. Moderately Hepatic Impaired Subjects|
62841378|NCT00851227|EXPERIMENTAL|3. Subjects with Normal Hepatic Function|
62841379|NCT06364488|OTHER|Device Related Adverse Events|The primary aim of the study is to demonstrate that use of the TrueBlue app to monitor depression is safe
62841380|NCT02597478|EXPERIMENTAL|Low-Dose Fentanyl Spray Group|Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving low-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. Low-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
62259558|NCT02240979||Adults able to undergo cardiac MRI exam|Adults able to undergo cardiac MRI
62259559|NCT01231659|EXPERIMENTAL|Everolimus + Letrozole|All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol.
62259560|NCT04744207|EXPERIMENTAL|GS-248|GS-248, capsule, 120 mg, once daily for 4 weeks
62259561|NCT04744207|PLACEBO_COMPARATOR|Placebo|placebo, capsule, once daily for 4 weeks
62259562|NCT00721474|EXPERIMENTAL|1|Bosutinib fasting
62841381|NCT02597478|EXPERIMENTAL|High-Dose Fentanyl Spray Group|Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving high-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. High-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
62841382|NCT00839319|EXPERIMENTAL|Acyline plus Placebo|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous placebo hCG injection (inj) every other day (5 doses) for 10 days
62841383|NCT00839319|EXPERIMENTAL|Acyline plus 15 IU hCG|Acyline 300 ug/kg (SQ) inj(s) on Day 1 plus subcutaneous 15 IU hCG injection (inj) every other day (5 doses) for 10 days
62841384|NCT00839319|EXPERIMENTAL|Acyline plus 60 IU hCG|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 60 IU hCG injection (inj) every other day (5 doses) for 10 days
62841385|NCT00839319|EXPERIMENTAL|Acyline plus 125 IU hCG|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 125 IU hCG injection (inj) every other day (5 doses) for 10 days
62841386|NCT00839319|EXPERIMENTAL|Acyline plus Testosterone gel|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus Testosterone gel 75 mg/day daily for 10 days
62841387|NCT06230211|EXPERIMENTAL|music therapy|"In the group where music therapy will be applied, the endotracheal aspiration and study to be performed will be explained to the child's family, and after obtaining consent, the music therapy applied to the child will be applied 5 minutes before, during and after the procedure. Meanwhile, the data will be recorded on the form by the observer. The song The Happiest Child, developed by creating rhythms by Fulya Merve KOS, one of the researchers who has the RhythmotherapistTM certificate issued by the Ministry of National Education, will be used in music therapy. The sound will be adjusted to 45 db. The speaker will be placed at the end of the foot, approximately 30 cm from the child's ear, five minutes before the procedure and will be played to the child during the procedure."
62841388|NCT06230211|EXPERIMENTAL|Mother's voice|In the group where the mother's voice will be listened to, it will be explained to the child's parents that the mother's voice will be used for pain relief in the research. In the study, the researcher will take a voice from the mother of each child admitted to intensive care and record it on a voice recorder. Measurements will be made by placing the voice recorder 50 cm closer to the child to listen to the mother's voice. The volume of the mother's voice will be adjusted to an average of 45 decibels. The speaker will be placed at the end of the foot, approximately 30 cm from the child's ear, five minutes before the procedure and will be played to the child during the procedure.
62841389|NCT03838432|EXPERIMENTAL|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
62259563|NCT00721474|EXPERIMENTAL|2|Bosutinib fed
62445265|NCT02410252|EXPERIMENTAL|iThermonitor|Participants are asked to use the iThermonitor device for two weeks to monitor their temperature. Participants are asked to wear the device for as many hours as they can but at a minimum to wear while sleeping.
62445266|NCT02466100|EXPERIMENTAL|Goc Intervention|Patient education materials, study nurse phone call, tip sheet, provider tip sheet
62445267|NCT02466100|NO_INTERVENTION|usual care|care as usual in the community
62056551|NCT06441747|EXPERIMENTAL|Durvalumab and Olaparib|This is a trial of Durvalumab in combination with olaparib. Durvalumab will be administered at a dose of 1500mg intravenously every 4 weeks. Olaparib will be administered orally at a dose of 300mg twice daily continuously. This combination will be administered for a maximum of two years unless unacceptable toxicities or progressive disease.
62056552|NCT04192084|EXPERIMENTAL|Traumatic amputations of the digits|we will perform microvascular partial toe transfer for patients with traumatic amputations of one or more digits
62056553|NCT00659490|EXPERIMENTAL|AZD1940|AZD1940 800ug given predose
62056554|NCT00659490|ACTIVE_COMPARATOR|Naproxen|Naproxen 500mg given pre-surgery
62056555|NCT00659490|PLACEBO_COMPARATOR|Placebo|Placebo given pre-surgery
62056556|NCT06246448|EXPERIMENTAL|Robotic-assisted radical cholecystectomy|
62056557|NCT06246448|ACTIVE_COMPARATOR|Open radical cholecystectomy|
62056558|NCT04194567|EXPERIMENTAL|Black Ragi|During one week of the study, participants are to consume pancakes made from the dark variety of ragi.
62056559|NCT04194567|EXPERIMENTAL|White Ragi|During the second week of the study, participants are to consume pancakes made from the white variety of ragi
62056560|NCT06057207||obese|This group will include patients with BMI \> 25 kg/m2
62056561|NCT06057207||non obese|This group will include patients with BMI \< 25 kg/m2
62841390|NCT03959176|EXPERIMENTAL|Group 1|"The right eye will receive a sham drop followed by 1 drop of Tropicamide 1%/Phenylephrine 2.5% five minutes after the sham drop is administered. A one minute wait will occur followed by a second drop of Tropicamide 1%/Phenylephrine 2.5%.~The left eye will receive 2 drops of Brimonidine 0.2% followed by a five minute wait time. One drop of Tropicamide 1%/Phenylephrine 2.5% will then be administered followed by a one minute wait time. A second drop of Tropicamide 1%/Phenylephrine 2.5% will be administered."
62841391|NCT03959176|EXPERIMENTAL|Group 2|"The right eye will receive 1 drop of Tropicamide 1%/Phenylephrine 2.5% followed by a one minute wait. A second drop of Tropicamide 1%/Phenylephrine 2.5% will be administered followed by a 15 second wait after which a sham drop will be administered.~The left eye will receive 1 drop of Tropicamide 1%/Phenylephrine 2.5% followed by a one minute wait. A second drop of Tropicamide 1%/Phenylephrine 2.5% will then be administered followed by a 15 second wait after which 2 drops of Brimonidine will be administered."
62841392|NCT04153396|EXPERIMENTAL|The Treatment Group|The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine.
62841393|NCT04153396|ACTIVE_COMPARATOR|The Control group|The local infiltration solution in the control group will consist of ropivacaine.
62841394|NCT02795702|EXPERIMENTAL|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
62841395|NCT02795702|SHAM_COMPARATOR|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
62056562|NCT03367507|EXPERIMENTAL|80% Sub-symptom threshold aerobic exercise|The moderate intensity intervention group will exercise at 80% of the maximum symptom free heart rate identified by their most recent graded treadmill test. The target heart rate zone will be within of the heart rate at which they experienced an increase in symptoms. The participants will be instructed to follow a program of moderate intensity activity in the form of their choice, we will recommend the following: stationary cycling, brisk walking, light jogging or the use of any available cardiovascular exercise equipment where they can control and monitor their heart rate wearing both the Actigraph and Polar HR monitor provided.
62056563|NCT03367507|ACTIVE_COMPARATOR|60% Sub-symptom aerobic exercise|The light (conservative) intensity intervention group will exercise at 60% of the maximum symptom free heart rate identified by their most recent graded treadmill test. The target heart rate zone will be within of the heart rate at which they experienced an increase in symptoms. The low intensity group will perform their exercise program at their own discrepancy however we will advise either of the following activities: light walking, stationary cycling or the use of any available cardiovascular exercise equipment where they can control and monitor their heart rate while simultaneously wearing both the Actigraph and polar HR monitor.
62056564|NCT03909178|ACTIVE_COMPARATOR|Hip Arthroscopy Surgery with Acetabular Labral Repair|Hip Arthroscopy Surgery with Acetabular Labral Repair
62056565|NCT03909178|ACTIVE_COMPARATOR|Physical Therapy Focused on the Hip and Hemi-pelvis|Physical Therapy focusing on the hemipelvis strengthening, including the lower back, lower abdominal core, quadriceps, hamstrings, and gluteal muscles.
62056566|NCT04294992|EXPERIMENTAL|Granisteron group|
62056567|NCT04294992|ACTIVE_COMPARATOR|Ondansetron group|
62259564|NCT04247958||Robotic-assisted colorectal resection|Subjects with either a suspected or confirmed benign or malignant disease of the colon and rectum who are scheduled to undergo a robotic-assisted resection of the colon or rectum.
62259565|NCT02670824|EXPERIMENTAL|CN-105 Active Drug|"The CN-105 drug administered via IV at an escalating scale of mg/kg.~A1-0.01 mg/kg A2-0.03 mg/kg A3-0.1 mg/kg A4-0.3 mg/kg A5-1.0 mg/kg B1-1.0 mg/kg"
62259566|NCT02670824|PLACEBO_COMPARATOR|Placebo|Normal Saline
62259567|NCT04686175|EXPERIMENTAL|INZ-701|"The study design of the Dose Evaluation Period is a MAD 3 + 3 with 3 dose cohorts. Additional cohorts may be added to evaluate an intermediate dose and/or an alternative dosing regimen of an existing dose level.~Based on nonclinical findings and nonclinical pharmacology modeling, the initial planned doses will be 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg all twice weekly, not to exceed 3.6 mg/kg weekly.~During the Extension Period, visits will be every 4 weeks until Week 48 and then every 12 weeks until the subject leaves the study. Subjects will complete an End of Study (EOS) Visit (Safety Follow-up Visit) 30 days after their last dose of INZ-701 (greater than 5 half-lives of INZ-701) for all subjects."
62259568|NCT01779037||Inpatient Rehabilitation Patients|
62259569|NCT01262378|OTHER|Harmonic knife|surgery using the Harmonic knife
62259570|NCT01262378|ACTIVE_COMPARATOR|HF knife|
62259571|NCT00792194|EXPERIMENTAL|training group|supervised training program 3 times a week with coach.
62616625|NCT03927586|EXPERIMENTAL|dual-task training (Dual group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). The participants in the DUAL group will be instructed to perform physical exercise and cognitive tasks simultaneously (e.g., math calculation while stepping). The difficulty of the cognitive tasks will increase as the participants improve in their performance. The 90 minutes of training session will be break up into 2 to 3 parts, and the participants can rest as needed.
62616626|NCT06509347|EXPERIMENTAL|Pressure release|Application of pressure on the trigger point of the flexor digitorum brevis until remission of referred pain for a minimum of 90 seconds, at least 3 cycles.
62056568|NCT01718093|ACTIVE_COMPARATOR|Insulin plus sitagliptin|The subjects continued their usual insulin regimen throughout the study. Sitagliptin was started and continued at 50 mg orally twice daily
62259572|NCT00792194|NO_INTERVENTION|group without training|a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.
62259573|NCT06307821|EXPERIMENTAL|Probiotics|5 billion CFU/day BC99 and protein powder; Storage: sealed, protected from light, placed in a cool and dry place.
62259574|NCT06307821|PLACEBO_COMPARATOR|placebo|Protein powder, 8 bags per day; Storage: sealed, protected from light, placed in a cool and dry place.
62259575|NCT01214928|ACTIVE_COMPARATOR|Cholecalciferol|Cholecalciferol 50,000IU po once weekly for 12 continuous weeks.
62259576|NCT01214928|PLACEBO_COMPARATOR|Placebo|Matching placebo po once weekly for 12 continuous weeks
62259577|NCT04507542|EXPERIMENTAL|Enriched Music-Supported Therapy group|Participants in the eMST-group will follow a 10-week program of Enriched Music-Supported Therapy. The program comprises 3 individual self-training sessions and 1 group session per week (total program duration: 40 hours).
62259578|NCT04507542|ACTIVE_COMPARATOR|Control group|Participants in the control intervention group will follow the Graded Repetitive Arm Supplementary Program (GRASP, Harris et al., 2009). They will be asked to complete 4 weekly one-hour session for 10 weeks (total program duration: 40 hours).
62616627|NCT06509347|SHAM_COMPARATOR|Non-emision Laser|Application of a non-emitting laser for 5 minutes on the trigger point of the flexor digitorum brevis muscle.
62259579|NCT02976714|OTHER|CF patients|CF patients carry a spontaneous sputum that is made in the context of bronchial drainage sessions conducted as part of usual care.
62841396|NCT03261752||patient with cancer|blood sample will be collected from patient before and after treatment (surgery or chemotherapy)
62841397|NCT03261752||healthy people|blood sample will be collected for comparison
62841398|NCT02694692||Follow-up|No further interventions are planned for this trial and the three pain management interventions from the original study (NCT01561457) will remain our comparison groups (Kangaroo Mother Care alone, Sucrose alone, and Kangaroo Mother Care \& Sucrose). All participants will be invited to back to the IWK Health Centre to receive their Vaccinations at 2, 6, 12 and 18 month time points as well as for their Neurodevelopment assessment at 18 corrected age (BSID-III).
62259580|NCT01650961|EXPERIMENTAL|Palonosetron|Intravenous administration of palonosetron 0.075 mg before the induction of general anesthesia
62259581|NCT01650961|PLACEBO_COMPARATOR|Control|Intravenous administration of normal saline before the induction of general anesthesia
62259582|NCT01141842|EXPERIMENTAL|lung cancer|breath samples of patients with confirmed lung cancer
62259583|NCT01141842|ACTIVE_COMPARATOR|underlying lung disease|patients with underlying lung disease and impairment in lung function
62259584|NCT01141842|SHAM_COMPARATOR|healthy individual|healthy individual with no lung disease and no history of cancer including lung cancer
62259585|NCT05567497|ACTIVE_COMPARATOR|Trigeminal Nerve Block (TNB)|patients will receive general anesthesia followed 5 ml of 0.25% Bupivacaine for TGB under USG after induction of anesthesia (Block Group).
62445268|NCT01643148||breast cancer patients (cases)|36 subjects
62445269|NCT01643148||controls|36 subjects
62445270|NCT05197712|EXPERIMENTAL|25 μg Baiya SARS-CoV-2 Vax 2|Experimental: 25 μg Baiya SARS-CoV-2 Vax 2, Adult Participants 2 doses of Baiya SARS-CoV-2 Vax 2 (25 μg), each on Day 1 and Day 22 for adult participants (18 - 64 years old)
62445271|NCT05197712|EXPERIMENTAL|50 μg Baiya SARS-CoV-2 Vax 2|Experimental: 50 μg Baiya SARS-CoV-2 Vax 2, Adult Participants 2 doses of Baiya SARS-CoV-2 Vax 2 (50 μg), each on Day 1 and Day 22 for adult participants (18 - 64 years old)
62056569|NCT01718093|ACTIVE_COMPARATOR|Insulin plus metformin|The subjects continued their usual insulin regimen throughout the study. Metformin was started at 500 mg orally daily. The dose was increased over a 2 week period up to 2,000 mg per day as tolerated.
62056570|NCT01718093|ACTIVE_COMPARATOR|Insulin plus sitagliptin and metformin|The subjects continued their usual insulin regimen throughout the study. Sitagliptin was started and continued at 50 mg orally twice daily. Metformin was started at 500 mg orally daily. The dose was increased over a 2 week period up to 2,000 mg per day as tolerated.
62056571|NCT05731089|ACTIVE_COMPARATOR|group A|Patients in group A were planned to defer the cataract surgery until receiving two injections of Aflibercept at monthly interval, the third injection was then given intra-operatively.
62259586|NCT05567497|NO_INTERVENTION|control|patients will receive general anesthesia only (Control Group).
62259587|NCT04101279|EXPERIMENTAL|Midurethral synthetic tape with tension control mechanism|
62259588|NCT04101279|ACTIVE_COMPARATOR|midurethral tension free tape|
62259589|NCT04776733|EXPERIMENTAL|prepackaged group|"All colonoscopy were performed in the afternoon. The day before the colonoscopy: 3 bags of pre-packaged food were used for diet preparation. All the patients drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at a rate of 250 ml every 15 min in the evening.~On the day of the colonoscopy: a bag of pre-packaged food were used for breakfast. All the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 2L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
62445272|NCT06301997|EXPERIMENTAL|Topical ZAX.1400.P03|ZAX.1400.P03, applied topically twice daily for 3 weeks after enrolment
62445273|NCT06301997|PLACEBO_COMPARATOR|Placebo|Placebo, applied topically twice daily for 3 weeks after enrolment
62445274|NCT02213796|OTHER|1h infusion of 1 g meropenem|
62445275|NCT06032351|OTHER|conventional teaching group|conventional teaching methods
62616628|NCT02731170|EXPERIMENTAL|rehabilitation treatment (MIRT)|MIRT consists of a 4-week physical therapy. daily sessions are subdivided in: motor treatment (2 hour), occupational therapy (1 hour) and speech Therapy (1 hour)
62259590|NCT04776733|ACTIVE_COMPARATOR|restricted diet group|"All colonoscopy were performed in the afternoon. The day before the colonoscopy: restricted diet prepared by patients were used for diet preparation. All the patients drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at a rate of 250 ml every 15 min in the evening.~On the day of the colonoscopy: restricted diet prepared by patients were used for breakfast. All the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 2L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
62259591|NCT01439464|ACTIVE_COMPARATOR|Control device|
62259592|NCT01439464|EXPERIMENTAL|Investigational device|
62259593|NCT02902354|OTHER|Nifedipine for tocolysis|Only women receiving nifedipine (as standard of care) for tocolysis
62259594|NCT02361541||HCV screening|All adult patients of an existing HIV cohort
62259595|NCT03739398|EXPERIMENTAL|LUTRONIC GENUS laser with LASEMD laser|
62259596|NCT03739398|ACTIVE_COMPARATOR|LUTRONIC GENUS laser without LASEMD laser|
62259597|NCT03328702|EXPERIMENTAL|Continue Positive Airway Pressure|Continue Positive Airway Pressure during VFSE
62841399|NCT03221153|NO_INTERVENTION|No Intervention|This is the control group. Participants in this group will take the usual course without simulation techniques.
62841400|NCT03221153|EXPERIMENTAL|Simulation|This is the intervention group. Participants in this group will to take the course with simulation techniques.
62841401|NCT00345748|ACTIVE_COMPARATOR|Abatacept 2 mg/kg|
62259598|NCT04467944||NS Group|Patients without pre-existing degeneration at L3/4 segment will be classified into control group (NS group).
62259599|NCT04467944||D Group|Patients with pre-existing disc factors (Pfirrmann grade≥3, Hiz or vacuum sign) at L3/4 segment will be classified into group D.
62259600|NCT04467944||C Group|Patients with pre-existing canal stenosis factors (cerebrospinal fluid occlusion≥1) at L3/4 segment will be classified into group C.
62259601|NCT04055714|EXPERIMENTAL|Treatment arm|Balloon dilation of the Eustachian Tube(s) with Acclarent Aera Balloon
62259602|NCT00662402|EXPERIMENTAL|1-Extensive Consultations|Intervention- Receives extensive consulting services
62259603|NCT00662402|NO_INTERVENTION|2-Regular levels of service|Control - Receives regular levels of service; one hour free services from each of the 4 units, with option to pay for more.
62841402|NCT00345748|ACTIVE_COMPARATOR|Abatacept 10 mg/kg|
62259604|NCT06535243|EXPERIMENTAL|LI Therapy|"LI Therapy will be delivered in two recruiting centers by experienced LI Therapy trained psychologists or psychiatrists (a minimum level three of training is required) The intervention will consist in delivering 15 Basic Protocol therapy sessions targeting symptoms of complex PTSD The study contains one single arm. One extra-session called PTSD protocol could be optionally delivered if the patient had a very recent trauma that could exacerbate his PTSD symptoms. This session is delivered in the beginning of the research protocol."
62259605|NCT05886790|EXPERIMENTAL|1. Ad5-NCO5T-IH|Vaccinated using Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation
62445276|NCT06032351|EXPERIMENTAL|curriculum integration Group|The curriculum integration group will receive two intervention phases, including an innovation-integrated curriculum for dementia care and an innovation-integrated curriculum for care management with Entrustable Professional Activities (EPAs) to guide learning and assessment of competency performance to equip students with dementia care management competency.
62841403|NCT00345748|PLACEBO_COMPARATOR|Placebo|
62841404|NCT04182646|EXPERIMENTAL|Single arm|The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required.
62841405|NCT02519985|EXPERIMENTAL|Repeatability and Reproducibility of ArcScan Insight 100|"For repeatability and reproducibility in normal eyes (n=20):~Firstly, 5 consecutive repeated ArcScan Insight 100 scans of the cornea and anterior segment will be performed by the first operator.~After a break of about 30 minutes, 5 consecutive repeated ArcScan Insight 100 scans of the cornea and anterior segment will be performed by the second operator.~For repeatability and reproducibility in eyes after laser refractive surgery (n=20):~Firstly, 5 consecutive repeated ArcScan Insight 100 scans of the cornea will be performed by the first operator.~After a break of about 30 minutes, 5 consecutive repeated ArcScan Insight 100 scans of the cornea will be performed by the second operator."
62841406|NCT04723797|NO_INTERVENTION|Control group|The participants in the control group will be asked to maintain their lifestyle as before the study.
62841407|NCT04723797|EXPERIMENTAL|Moderate-intensity group|Participants will be asked to perform a physical activity program, consisting of cycling and/or running for 6 weeks of at least 150min/week. This at a moderate intensity, which means a slightly increased heart rate and breathing also talking is possible.
62841408|NCT04723797|EXPERIMENTAL|Vigorous-intensity group|Participants will be asked to perform a physical activity program, consisting of cycling and/or running for 6 weeks of at least 75min/week. This at a vigorous intensity, which means increased heart rate and breathing also talking is possible.
62841409|NCT00597324|ACTIVE_COMPARATOR|1|Patients with normal Allen's test
62259606|NCT05886790|EXPERIMENTAL|2. mbO5|Vaccinated using Bivalent COVID-19 mRNA Vaccine
62259607|NCT05886790|OTHER|3. Ad5-nCoV-IH|Vaccinated using Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation
62259608|NCT00644774|ACTIVE_COMPARATOR|1|
62259609|NCT00644774|ACTIVE_COMPARATOR|2|
62259610|NCT00616122|EXPERIMENTAL|Sunitinib, Cyclophosphamide, and Methotrexate|
62259611|NCT00939783|EXPERIMENTAL|Dimebon 20 mg TID|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
62259612|NCT04782544|ACTIVE_COMPARATOR|Treatment|5 grams of buttermilk powder daily for 10 weeks, oral.
62259613|NCT04782544|PLACEBO_COMPARATOR|Placebo|5 grams of milk powder (10% buttermilk powder, 90% anhydrous milk fat) daily for 10 weeks, oral.
62259614|NCT05645874||Control (no underlying neurological disorder)|
62259615|NCT05645874||Neurodevelopmental disorder_Genetic cause known|
62259616|NCT05645874||Neurodevelopmental disorder_Acquird (cause known)|
62259617|NCT05645874||Neurodevelopmental disorder_Cause unknown|
62841410|NCT00597324|EXPERIMENTAL|2|Patients with intermediate Allen's test
62841411|NCT00597324|EXPERIMENTAL|3|Patients with abnormal Allen's test
62841412|NCT02693132|EXPERIMENTAL|Supervised (SUP-PA)|Weight loss intervention that focuses on supervised physical activity and involves an energy restricted diet. Physical activity will be supervised by trained staff.
62056572|NCT05731089|ACTIVE_COMPARATOR|group B|Patients in group B were planned to undergo cataract surgery first and received the first injection intra-operatively, then received two post-operative injections with a monthly interval.
62841413|NCT02693132|EXPERIMENTAL|Unsupervised (UNSUP-PA)|Weight loss intervention that focuses on unsupervised physical activity (identical dose to SUP-PA) and involves an energy restricted diet (identical diet to SUP-PA). Physical activity will be self-monitored but no activity tracker will be used as an intervention tool.
62056573|NCT06038955|EXPERIMENTAL|Virtual reality Based Cognitive Remediation|The cognitive remediation program has a duration of four weeks and involves two weekly 1,5-hour virtual reality-based cognitive training sessions with a therapist accompanied by additional between-session virtual reality training at home and homework assignments consisting of cognitively challenging daily life tasks.
62841414|NCT02693132|EXPERIMENTAL|Step-based (STEP)|Weight loss intervention that focuses on unsupervised physical activity prescribed as steps/day and involves an energy restricted diet (identical diet to SUP-PA and UNSUP-PA). Physical activity will be self-monitored and a pedometer will be used to track steps/day.
62841415|NCT04539769|ACTIVE_COMPARATOR|BI group|Conventional Billroth I reconstruction
62841416|NCT04539769|EXPERIMENTAL|BII group|Billroth II reconstruction with 100-cm long biliopancreatic limb
62841417|NCT04539769|EXPERIMENTAL|RY group|Roux-en-Y reconstruction with 100-cm long Roux limb
62056574|NCT06038955|SHAM_COMPARATOR|Virtual reality control treatment|The control treatment program also has a duration of four weeks and involves one weekly 2-hour session with a therapist.
62056575|NCT00746096|EXPERIMENTAL|IKH-01|ethinyl estradiol 0.035mg and norethisterone 1mg
62056576|NCT00746096|PLACEBO_COMPARATOR|Placebo|Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
62056577|NCT04654039||Treatment of Infertility|Non intervention
62056578|NCT00847405|EXPERIMENTAL|1|
62056579|NCT00847405|ACTIVE_COMPARATOR|2|
62056580|NCT04484025|EXPERIMENTAL|SPI-1005 400 mg BID|Oral administration of SPI-1005 400 mg BID for 7 days, with 30-day follow-up
62259618|NCT00606203|EXPERIMENTAL|A|The aims of this study are to investigate the prophylactic effect of milnacipran in post stroke depression.
62445277|NCT05140642|ACTIVE_COMPARATOR|Sonographer Annotation|Currently, sonographer technicians provide preliminary interpretations prior to validation and overreading by cardiologists. This staggered, stepwise evaluation allows for the introduction of AI decision support with minimal impact on patient care. Physicians are already used to adjusting the preliminary report given the variable training of sonographers and on the lookout for changes, variation, or adjustments that need to be made.
62259619|NCT00606203|PLACEBO_COMPARATOR|B|Placebo
62056581|NCT04484025|EXPERIMENTAL|SPI-1005 800 mg BID|Oral administration of SPI-1005 800 mg BID for 7 days, with 30-day follow-up
62623672|NCT05984173|EXPERIMENTAL|study group|patients received vitamin E inside the socket after extraction (study group)
62623673|NCT05984173|NO_INTERVENTION|control|patients didn't receive vitamin E after extraction (control group).
62841418|NCT05155514||Group H|"Hypertension group (Group H):~* Patients with a previous diagnosis of hypertension~* Patients receiving antihypertensive therapy~* Systolic blood pressure (SBP) ≥140mmHg and/or diastolic blood pressure (DBP) ≥90mmHg"
62056582|NCT04484025|PLACEBO_COMPARATOR|Placebo|Oral administration of matching placebo BID for 7 days, with 30-day follow-up
62259620|NCT05074264|EXPERIMENTAL|Imaging, biospecimen collection, anoscopy and/or colposcopy|Patients undergo collection of cervical images (if applicable), 3 cervical anal swabs (if applicable) and 3 anal swabs for real-time testing of HPV or hrHPV over 90 minutes. Patients with a positive HPV or hrHPV test on undergo biopsies of visible lesions. Patients with a negative hrHPV test on their cervical swab may undergo a colposcopy. Patients with a positive hrHPV test on their anal swab undergo high-resolution anoscopy at a later visit within 1 month. Patients with a negative hrHPV on their anal swabs may undergo a high-resolution anoscopy and biopsies of visible lesions, and those with a positive anal cytology for LSIL or worse undergo a high-resolution anoscopy and biopsies within 1 month. Patients may be given a diagnosis and treatment at the second visit. Patients diagnosed with HSIL may undergo SOC treatment or enroll in additional studies when they are open to accrual
62841419|NCT05155514||Group N|Normotensive group (Group N): Other non-hypertensive patients
62841420|NCT02118441|ACTIVE_COMPARATOR|direct palpation|Radial artery catheter insertion will be conducted by direct palpation and use of anatomic knowledge by the Anesthesiologist.
62841421|NCT02118441|ACTIVE_COMPARATOR|Ultrasound|"Radial artery catheter insertion will be conducted by ultrasound guidance. A Sono-site ilook 25 Ultrasound (Sono-site, Inc., Bothell, WA, USA) with a 10-5 MHz linear array ultrasound transducer will be used.~At the discretion on the Anesthesiologist, an out-of-plane (i.e. needle plane at right angles to ultrasound plane) will be used. Colour flow doppler may also be used to identify the artery if necessary."
62841422|NCT06310941|ACTIVE_COMPARATOR|Standard of Care|Standard of care: Systemic antibiotic therapy according to local protocol and at the discretion of the attending intensivist.
62841423|NCT06310941|EXPERIMENTAL|Mechanical insufflation-exsufflation with hypertonic saline/hyaluronic acid comination|Systemic antibiotic therapy choice according to local protocol and at the discretion of the attending intensivist plus Mechanical insufflation-exsufflation (MI-E sessión tid during the first 48 hours, followed by MI-E if secretions are present or suspected; recommended settings +50 cmH2O/-50 cmH2O) with simultaneous nebulization of hypertonic saline (7%) with hyaluronic acid (0.1%).
62259621|NCT03523728|PLACEBO_COMPARATOR|Stage 1- Placebo|Participants from Stage 1 were randomized to receive 2 capsules of placebo matched to venglustat once daily for treatment period of 24 months.
62841424|NCT06310941|EXPERIMENTAL|Mechanical insufflation-exsufflation|Systemic antibiotic therapy choice according to local protocol and at the discretion of the attending intensivist plus Mechanical insufflation-exsufflation (MI-E sessión tid during the first 48 hours, followed by MI-E if secretions are present or suspected; recommended settings +50 cmH2O/-50 cmH2O)
62841425|NCT01339572|EXPERIMENTAL|Plerixafor|All subjects will receive filgrastim as part of their primary mobilization regimen. If a subject does not meet minimum peripheral blood CD34+ cell count levels or fails to adequately collect a threshold number of CD34+ cells, plerixafor will be added to the mobilization regimen.
62841426|NCT01339572|ACTIVE_COMPARATOR|Observation|All subjects will receive filgrastim as part of their primary mobilization regimen. If the subject meets minimum peripheral blood CD34+ cell count levels or adequately collects a threshold number of CD34+ cells, plerixafor will not be added to the mobilization regimen.
62841427|NCT01341613|EXPERIMENTAL|Cardioviva™ supplement capsule|
62841428|NCT01341613|PLACEBO_COMPARATOR|Placebo capsule|
62841429|NCT04151576|EXPERIMENTAL|Experimental|The patients received medical treatment. The intervention: An aromatic oil mixture (lavender and peppermint) was massaged for 15 minutes on the temple and root of the neck of the patients, and this application continued for three weeks
62841430|NCT04151576|NO_INTERVENTION|Control|The patients received only medical treatment
62841431|NCT02118961|EXPERIMENTAL|BK1301|
62841432|NCT02118961|ACTIVE_COMPARATOR|DT toxoid|
62841433|NCT05475756|EXPERIMENTAL|Experimental Group|Material：Small intestinal submucosa Specifications：A、B、C、D、E Dosage: investigator selects the specification and quantity(dosage) according to the postoperative uterine cavity volume Frequency：one time after the operation Duration：Single-use
62841434|NCT05475756|ACTIVE_COMPARATOR|Control Group|Material: auto-crosslinked HA gel Specifications: 1 ml, 1.25 ml, 1.5 ml, 1.75 ml, 2 ml, 2.25 ml, 2.5 ml, 2.75 ml, 3 ml, 3.25 ml, 3.75 ml, 4 ml, 4.25 ml, 4.5 ml, 5 ml, 6 ml, 8ml Dosage: investigator selects the specification and quantity(dosage) according to the postoperative uterine cavity volume Frequency：one time after the operation Duration：Single-use
62841435|NCT03339843|EXPERIMENTAL|Abemaciclib|"This study contains 2 stages; during the 1st stage, a maximum of 17 patients will be enrolled in each tumour type cohort. After 13 evaluable patients have been enrolled, an interim analysis will be performed. If 3 or more patients are seen to have experienced a treatment success, then the cohort will pass into the 2nd stage in which a maximum of 20 more patients are enrolled. If 2 or less patients are seen to have experienced a treatment success, then that cohort will be closed and will not proceed into the 2nd stage.~Subjects will receive 200 mg of abemaciclib orally, twice a day, during cycles of 28 days each. The subject will undergo: A baseline FDG-PET/CT and a baseline CT scan and A blinded early FDG-PET/CT at D14 +/- 2 days of study treatment.~A treatment success is defined as a patient who has metabolic response according to PERCIST with a response cut off set at 15% at the early FDG-PET/CT and a morphological disease control after 2 cycles measured by RECIST v1.1."
62841436|NCT01881672||Coma patients in ICU under mechanical ventilation|
62841437|NCT03053167|EXPERIMENTAL|Irinotecan & Raltitrexed|"advanced colorectal cancer patients treated with irinotecan plus raltitrexed as second-line treatment.~Irinotecan:180mg/㎡+NS250ml, ivgtt, 90min, d1~Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks"
62841438|NCT00647959|EXPERIMENTAL|1|Doxycycline Tablets, 150mg
62841439|NCT00647959|ACTIVE_COMPARATOR|2|Adoxa Tablets 150 mg
62841440|NCT03446404||MOST Cohort|"One portion of the cohort will be age 62-92 years, average age approximately 71 years, at the start of this study. This cohort will consist of participants who already have symptomatic knee OA, in many cases advanced disease, or who had risk factors at the start of the Multicenter Osteoarthritis Study but have not developed symptomatic knee OA. All of the existing cohort who have 1 or 2 native knees will be approached providing native knees are not considered to be Kellgren-Lawrence grade 4 (bone on bone). The other portion of the cohort will consist of subjects with knee pain, aching or stiffness at baseline and participants without any knee symptoms in the previous 30 days. Both knees with Kellgren-Lawrence grades of radiographic OA of 0, 1, or 2 in the tibiofemoral (TF) and patellofemoral (PF) compartments."
62841441|NCT01781299|ACTIVE_COMPARATOR|AlloDerm RTU|Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement.
62841442|NCT01781299|ACTIVE_COMPARATOR|SurgiMend PRS|Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement.
62841443|NCT00557856|EXPERIMENTAL|1|
62259622|NCT03523728|EXPERIMENTAL|Stage 1- Venglustat 8 mg|Participants from Stage 1 were randomized to receive venglustat 8 milligrams (mg) (i.e., 2 capsules of 4 mg) once daily for treatment period of 24 months.
62259623|NCT03523728|EXPERIMENTAL|Stage 1- Venglustat 15 mg|Participants from Stage 1 were randomized to receive 1 capsule of venglustat 15 mg and 1 capsule of placebo matched to venglustat once daily for treatment period of 24 months.
62259624|NCT03523728|PLACEBO_COMPARATOR|Stage 2- Placebo|Participants from Stage 2 were randomized to receive 1 capsule of placebo matched to venglustat once daily for treatment period of 24 months.
62259625|NCT03523728|EXPERIMENTAL|Stage 2- Venglustat 15 mg|Participants from Stage 2 were randomized to receive 1 capsule of venglustat 15 mg once daily for treatment period of 24 months.
62259626|NCT00441974|EXPERIMENTAL|Single arm adefovir dipivoxil|adefovir dipivoxil once daily orally 10 mg
62259627|NCT03692000||Men with a history of prostate cancer|Men with a history of prostate cancer invited to participate in design-workshops , interviews or usabilitytesting.
62259628|NCT04688736|EXPERIMENTAL|Placebo|Each recruited subject will oral 8mg placebo 20 minutes before blood transfusion.
62056583|NCT02986607|EXPERIMENTAL|Hypoparathyroidism|"Subcutaneous 24h microdialysis before PTH treatment and during continous subcutaneous PTH treatment. PTH, Natpara (parathyroid hormone 1-84) 50 µg doses with a concentration of 800 µg/ml, will be delivered by an insulin-pump (OmniPod) which delivers the infusion gear continous subcutaneously based on units (U) of insulin. 1 µg Natpara equals 0.125 U of infusion. The starting dose for pump treatment will be 0.50 µg per kilo per day and adjusted according to Calcium levels.~Controls: patients With hyperparathyroidism and healthy volunteers will perform 24h microdialysis."
62259629|NCT04688736|ACTIVE_COMPARATOR|Chlorpheniramine|Each recruited subject will oral 8mg chlorpheniramine 20 minutes before blood transfusion.
62259630|NCT01606267|NO_INTERVENTION|Routine HEP|This arm includes routine care provided under the health extension program provided to rural Ethiopian villages with limited access to health facilities.
62259631|NCT01606267|EXPERIMENTAL|HEP+ICCM|This arm includes routine care provided under the Health Extension Program plus the HEWs will be assessing and treating childhood pneumonia cases in rural Ethiopian villages with limited access to health facilities.
62259632|NCT05623579|EXPERIMENTAL|Intervention|Pain Education plus Exercise
62259633|NCT05623579|ACTIVE_COMPARATOR|Control|Exercise
62259634|NCT00645593|ACTIVE_COMPARATOR|Arm 1, Gemcitabine and Cisplatin|Gemcitabine and Cisplatin, as described in the intervention
62259635|NCT00645593|EXPERIMENTAL|Arm 2, Cetuximab, Gemcitabine and Cisplatin|Gemcitabine and Cisplatin with Cetuximab, as described in the intervention
62259636|NCT04187638|EXPERIMENTAL|Olive oil|Participants will receive 30ml/day of olive oil for two weeks
62259637|NCT04187638|PLACEBO_COMPARATOR|Butter|Participants will receive 30g/day of butter also for two weeks.
62259638|NCT05502042|NO_INTERVENTION|Usual Care|Referral to a health facility (HC III, IV, or district hospital) that provide secondary antibiotic prophylaxis (every-28-day intramuscular benzathine benzylpenicillin G, BPG), receipt of a Ministry of Health secondary prophylaxis adherence booklet, and education for patient and family about the importance of SAP.
62259639|NCT05502042|EXPERIMENTAL|Peer Group + Case Manager|Usual care + an assigned village health team member to provide weekly short message (SMS) (weeks 1-3) and phone (week 4) support for attendance of SAP visits and a VHT (village health team member) led peer support group held at the assigned SAP clinic of participants, that includes games/peer support/education.
62445278|NCT05140642|EXPERIMENTAL|Artificial Intelligence Annotation|In preliminary work, a novel AI algorithm developed to assess LVEF was shown to be more precise than human interpretation in 10,030 echocardiograms done at Stanford University (Ouyang et al. Nature, 2020). With randomization, a proportion of the preliminary interpretations will be done by AI technology and the study team will assess how different this preliminary interpretation is from the final interpretation.
62445279|NCT01094444|EXPERIMENTAL|Vitamin K3-lotion|A lotion containing 1.5 mM Vitamin K3.
62445280|NCT01094444|NO_INTERVENTION|B|Standard lotion without Vitamin K3
62445281|NCT01897974||Seizure disorder|Patients that are on medications for seizure disorder.
62445282|NCT05763966||Early stage psychosis patients (EPP)|Diagnosis of psychotic disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) with onset of less than 2 years prior to inclusion.
62445283|NCT05763966||Individuals at clinical high risk for psychosis (CHR-P)|Fulfills criteria for clinical high risk for psychosis according to Structured Interview for Psychosis-risk Syndromes (SIPS).
62259640|NCT04821466|EXPERIMENTAL|Virtual Reality Headset|VR headset, programmed with a selection of 7 wellbeing programs to identify if use will improve participants wellbeing
62259641|NCT02989831|EXPERIMENTAL|Vibrating insoles 'on'|Duration: 30-60 seconds
62259642|NCT02989831|NO_INTERVENTION|Vibrating insoles 'off'|Duration: 30-60 seconds
62259643|NCT00959036|EXPERIMENTAL|Treatment Group 1|ATN-103 10 mg every 4 weeks until week 12
62445284|NCT05763966||Healthy controls (HC)|Age- and sexmatched controls.
62445285|NCT00759148|EXPERIMENTAL|Moxifloxacin AF|Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%, 1 drop in each eye twice daily for 3 days
62445286|NCT00759148|PLACEBO_COMPARATOR|Vehicle|Moxifloxacin AF vehicle, 1 drop in each eye twice daily for 3 days
62259644|NCT00959036|EXPERIMENTAL|Treatment Group 2|ATN-103 10 mg every 8 weeks until week 12
62445287|NCT03229252|PLACEBO_COMPARATOR|Placebo|Placebo Inhalation solution twice daily for 28 days.
62445288|NCT03229252|EXPERIMENTAL|SPX-101 Low Dose|Inhalation solution twice daily for 28 days.
62445289|NCT03229252|EXPERIMENTAL|SPX-101 High Dose|Inhalation solution twice daily for 28 days.
62259645|NCT00959036|EXPERIMENTAL|Treatment Group 3|ATN-103 30 mg every 4 weeks until week 12
62445290|NCT06222710|EXPERIMENTAL|Patients with ultrasound-guided pharmacoacupuncture|20 patients with ultrasound-guided pharmacoacupuncture
62445291|NCT06222710|ACTIVE_COMPARATOR|Patients with blind pharmacoacupuncture|20 patients who treat pharmacoacupuncture without checking ultrasound images
62445292|NCT02557945|EXPERIMENTAL|Gabapentin|Gabapentin 3600mg PO daily
62056584|NCT01715974|PLACEBO_COMPARATOR|CONTROL|patients with recurrent implantation failure treated with PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test
62259646|NCT00959036|EXPERIMENTAL|Treatment Group 4|ATN-103 80 mg every 4 weeks until week 12
62259647|NCT00959036|EXPERIMENTAL|Treatment Group 5|ATN-103 80 mg every 8 weeks until week 12
62259648|NCT00959036|PLACEBO_COMPARATOR|Treatment Group 6|Placebo every 4 weeks
62259649|NCT05825703||PPMV|GROUP OF PATIENT POPULATION WHO HAD PROLONGED POST-OPERATIVE MECHANICAL VENTILATION
62259650|NCT05825703||NON PPMV|GROUP OF PATIENT POPULATION WHO DID NOT HAVE PROLONGED POST-OPERATIVE MECHANICAL VENTILATION
62445293|NCT02557945|PLACEBO_COMPARATOR|Placebo|Matching placebo PO daily
62445294|NCT06313047||HCC patients|Each of the patients was given Doxorubicin and followed up for one year.
62445295|NCT03262974||CML patients with MMR|CYP3A5\*3 , CYP2C8\*3 , ABCG2 421 C\>A and SLC22A1 1222A \> G SNPs on the plasma level by HPLC-UV and molecular response of imatinib by PCR
62616629|NCT04269824|EXPERIMENTAL|Intervention Group|Residents of the peri-urban ward randomized to this group will receive the norm and network-centric intervention package that includes individual, household, group and community-level interventions. No hardware will be provided. Behavior change components will focus on shifting empirical expectations of improved sanitation behaviors in their wards as well as building capacity to achieve toilet construction and behavioral goals.
62616630|NCT04269824|NO_INTERVENTION|Control Group|Residents of these wards will not receive any intervention. They may be exposed to other WASH interventions promoted by the government and/or other parties independent of this study.
62616631|NCT04123379|EXPERIMENTAL|Cohort A|NSCLC: Nivolumab + BMS-813160
62841444|NCT05357248|EXPERIMENTAL|Intervention- BT-NCBT-00x|"The treatment, BT-NCBT-00x, consists of a software as a medical device developed by the study Sponsor, Better Therapeutics. It delivers treatment to participants with cardiometabolic disease, using behavioral therapy that targets individual behaviors related to improving dietary quality and physical activity. BT-NCBT-00x is accessed via the participants' smartphone after downloading from the phone's corresponding app store.~Participants will receive behavioral support by the Better Therapeutics patient services team in the form of phone calls as necessary or requested by the patient"
62056585|NCT01715974|EXPERIMENTAL|GM-CSF group|patients with recurrent implantation failure treated with GM-CSF (30 micrograms/day) from the day of embryo transfer through the day of beta hCG test
62259651|NCT03970694|EXPERIMENTAL|Neoadjuvant chemoradiotherapy group|Neoadjuvant chemoradiotherapy（XELOX \* 4 + radiotherapy）→ Surgery (if possible) → post-surgery chemotherapy.
62841445|NCT01571518|EXPERIMENTAL|early injection|injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
62056586|NCT01875939|OTHER|Oral WCK 2349 fed/fasting|This is a single center, randomized, open label, 2X2 oral IV cross over, food-effect and absolute bioavailability study. The study will be conducted in three parts i.e., Period 1 and Period 2 (foodeffect study) and Period 3 (absolute bioavailability study).
62445296|NCT03262974||CML patients without MMR|CYP3A5\*3 , CYP2C8\*3 , ABCG2 421 C\>A and SLC22A1 1222A \> G SNPs on the plasma level by HPLC-UV and molecular response of imatinib by PCR
62056587|NCT01875939|OTHER|IV WCK771|This is a single center, randomized, open label, 2X2 oral IV cross over, food-effect and absolute bioavailability study. The study will be conducted in three parts i.e., Period 1 and Period 2 (foodeffect study) and Period 3 (absolute bioavailability study).
62056588|NCT00335257||1|Users of OCs containing DRSP
62056589|NCT00335257||2|Users of OCs containing other progestins
62056590|NCT05631184|EXPERIMENTAL|Self-administered acupressure group|The participants in the self-administered acupressure group will attend an acupressure training course (2 sessions, 2 h each) to learn self-administered acupressure from an acupuncturist in a classroom at the School Nursing, the Hong Kong Polytechnic University. Each class will be conducted in a small group of 4 to 7 participants to enhance interaction and ensure the quality of teaching. Participants will then practice two times a day for 8 weeks.
62056591|NCT05631184|ACTIVE_COMPARATOR|Mental health education group|The participants in the comparison group will receive mental health education group from a registered nurse with the same frequency as those in the treatment group (2 sessions, 2 h each) in a classroom at the School Nursing, the Hong Kong Polytechnic University, and will be reminded to follow the mental health practice daily for 8 weeks.
62445297|NCT03379077|EXPERIMENTAL|LTP Plus Supported Implementation|LTP Plus Supported Implementation group participants will receive intervention by trained LHWs of HANDS, co-facilitated and supervised by senior trained PILL researchers, expert in delivering LTP plus intervention
62445298|NCT03379077|ACTIVE_COMPARATOR|LTP Plus|Participants in LTP Plus arm will receive LTP plus intervention by trained LHWs of Health and Nutrition Development Society (HANDS).
62445299|NCT01026961|EXPERIMENTAL|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate
62259652|NCT03970694|OTHER|Neoadjuvant chemotherapy group|Arm Type: control. Neoadjuvant chemotherapy（XELOX \* 4）→ Surgery (if possible) → post-surgery chemotherapy.
62445300|NCT01026961|ACTIVE_COMPARATOR|Phenylephrine hydrochloride|Phenylephrine hydrochloride 10mg
62259653|NCT03912142||Three dimensional transperineal ultrasound|"This is a single arm study. All women who delivered vaginally will be included in the study .~The planned interventions are:~Clinical vaginal and rectal examination Three dimensional transperineal ultrasound."
62259654|NCT04169750|EXPERIMENTAL|Exergames|
62445301|NCT01527448|EXPERIMENTAL|Atypical antipsychotic treatment|Quetiapine XR is given to postpartum women diagnosed with bipolar disorder II. Starting dose is 50mg, maximum dose is 300mg/day.
62259655|NCT04169750|ACTIVE_COMPARATOR|Adaptive COGNI-TRAcK|
62259656|NCT04169750|SHAM_COMPARATOR|Sham COGNI-TRAcK|
62445302|NCT01482156|EXPERIMENTAL|RAD001 + BEZ235|Patients will receive first dose of RAD001 at 2.5mg/5mg/10 mg weekly or 2.5mg/5mg daily in combination of BEZ235 at 50 mg/100 mg/200 mg/300 mg/400 mg twice a day. In the initial cohort of the dose finding phase, patients will receive a single 2.5 mg dose of RAD001 on Cycle 1 Day 1 and the combination therapy of RAD001 2.5 mg/week and BEZ235 200 mg bid starting on Cycle 1 Day 8. Dose escalation phase: patients will start RAD001 and BEZ235 on Cycle 1 Day 1 with both study drugs being administered at the center. Dose expansion phase: the first 15 patients enrolled at selected sites will take RAD001 as monotherapy from Day 1 to Day 7 (for PK sampling). The combination therapy of RAD001 and BEZ235 will start on Day 8. All remaining patients will receive the combination therapy of RAD001 and BEZ235 starting on Cycle 1 Day 1.
62445303|NCT01236833|NO_INTERVENTION|Fasting|
62445304|NCT01236833|ACTIVE_COMPARATOR|Lactated Ringer's Solution|
62445305|NCT04416984|EXPERIMENTAL|ALLO-501A, ALLO-647|
62445306|NCT04795661|EXPERIMENTAL|Cohort Colorectal cancer (CRC)|Pembrolizumab prior to surgery
62445307|NCT04795661|EXPERIMENTAL|Cohort Oesogastric cancer|Pembrolizumab prior to surgery
62445308|NCT04795661|EXPERIMENTAL|Cohort Other cancer|Pembrolizumab prior to surgery
62616632|NCT04123379|EXPERIMENTAL|Cohort B|NSCLC: Nivolumab + BMS-986253
62616633|NCT04123379|EXPERIMENTAL|Cohort C|HCC: Nivolumab
62616634|NCT04123379|EXPERIMENTAL|Cohort D|HCC: Nivolumab + BMS-813160
62841446|NCT01571518|SHAM_COMPARATOR|late injection|injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
62841447|NCT00556504|EXPERIMENTAL|TCM-700C|an add-on drug (2 tablets/t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
62056592|NCT06580015|EXPERIMENTAL|Device Feasibility ([18F]-rhPSMA PET-CT, X1 RMRS PET-CT)|Patients receive SOC flotufolastat F-18 gallium IV and undergo PET-CT on study. Patients then undergo X1 RMRS PET-CT imaging-only session 120 minutes post-injection.
62259657|NCT02644564||Ultrasonography|Patients will undergo structured clinical examination and ultrasonography of both shoulders on the day of inclusion. They also fill out an injury registration form, Oxford Shoulder Score and QuickDASH. Follow-up at 3, 6 and 12 months will be identical, but without ultrasonography and injury registration form.
62259658|NCT00734799|NO_INTERVENTION|2|Usual Care/Wait-List Control
62259659|NCT00734799|EXPERIMENTAL|1|Sleep Intervention for PTSD (SIP)
62445309|NCT03929939|EXPERIMENTAL|Lifestyle Modification Group|
62841448|NCT00556504|PLACEBO_COMPARATOR|Placebo|placebo add on(2 tablets/t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
62841449|NCT03478098|EXPERIMENTAL|10 Roux-en-Y Gastric Bypass patients|4 study days in randomized order are conducted with interventions: Low GI mealtest, High GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest and subsequent exercise
62841450|NCT03478098|EXPERIMENTAL|10 control subjects|4 study days in randomized order are conducted with interventions: Low GI mealtest, High GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest and subsequent exercise
62056593|NCT03135665|OTHER|ScoE|This is a cross-sectional study on screened school children recommended for radiographic assessment in the scoliosis screening program of SHS in Hong Kong. Both x-ray, ultrasound and ATR measurement of the spine will be performed on the same day at Prince of Wales Hospital.
62056594|NCT05593757|EXPERIMENTAL|Quinidine in period A, verapamil in period B|For this arm, patients will be treated with quinidine 200 mg thrice daily during period A. During period B, patients will be treated with verapamil 320-480mg daily during period B. The duration of the periods is different for each patient and depends on the time of inclusion.
62841451|NCT05731063|OTHER|Ridge augmentation surgery|Computer guided simultaneous implant placement with tri-cortical ridge augmentation using chin cortical bone struts in anterior atrophic maxilla
62056595|NCT05593757|EXPERIMENTAL|Verapamil in period A, quinidine in period B|For this arm, patients will be treated with verapamil 320-480mg daily during period A. During period B, patients will be treated with quinidine 200 mg thrice daily during period A. The duration of the periods is different for each patient and depends on the time of inclusion.
62259660|NCT01969994|EXPERIMENTAL|Controlled dietary background & (-)-[2-14C]epicatechin intake|
62259661|NCT01563770|EXPERIMENTAL|Salvia miltiorrhiza extract (Danshen)|p.o. Salvia miltiorrhiza extract, 1.5 g twice daily for four consecutive weeks
62259662|NCT01563770|PLACEBO_COMPARATOR|placebo|p.o. placebo, twice daily
62841452|NCT03551561|ACTIVE_COMPARATOR|CSAAC group|The CSAAC group (chlorhexidine-based soap + ethyl alcohol + alcoholic chlorhexidine): skin preparation process with 4% chlorhexidine-based soap for a period of 5 minutes, followed by a sterile and soaked with 70% alcohol compress. After removing the chlorhexidine-based soap excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns. Cultures were performed in the mannitol and EMB (Eosin Methylene Blue) media after being collected at the pre-skin preparation, post-skin preparation process and end of the surgical procedure.
62259663|NCT01505348|EXPERIMENTAL|Fasting|Overnight fast
62259664|NCT01505348|NO_INTERVENTION|Feeding|Normal breakfast
62259665|NCT04629820|EXPERIMENTAL|Intervention|Workers assigned to the intervention group will receive free spectacles of a design they select, based on the worker's measured refractive power and dispensed one week later at the factory by the study ophthalmic personnel.
62259666|NCT04629820|NO_INTERVENTION|Control|Workers assigned to the Control group will receive similar free glasses at the end of the study assessment (3 months).
62445310|NCT03929939|NO_INTERVENTION|Control Group|
62445311|NCT02335970|EXPERIMENTAL|Training group|Training program: Daily exercises for 3 months
62841453|NCT03551561|ACTIVE_COMPARATOR|CSAC group|The CSAC group (chlorhexidine-based soap + alcoholic chlorhexidine): skin preparation process with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns. Cultures were performed in the mannitol and EMB media after being collected at the pre-skin preparation, post-skin preparation process and end of the surgical procedure.
62841454|NCT03713346|OTHER|Lactose digester|
62841455|NCT03713346|OTHER|Lactose maldigester|
62841456|NCT03393988|ACTIVE_COMPARATOR|Group F|Fentanyl infusion (0.5 µg/kg/hr)
62841457|NCT03393988|ACTIVE_COMPARATOR|Group (TAP-Dex)|"Ultrasound guided TAP block and Dexmedetomidine~* Ultrasound guided subcostal oblique TAP block with 0.25 % bupivacaine~* Dexmedetomidine infusion(200 µg in 2 ml diluted in 48 ml of saline)~* Fentanyl infusion (0.5 µg/kg/hr)."
62445312|NCT02335970|NO_INTERVENTION|Controls|Standard care
62445313|NCT05181982||Intervention Group|Patients being treated at the FIT hospital (Pfalzklinikum) between January 2020 and December 2023
62445314|NCT05181982||Control group|Patients being treated in standard care (control hospitals) in the German federal state Rheinland-Pfalz
62616635|NCT04123379|EXPERIMENTAL|Cohort E|HCC: Nivolumab + BMS-986253
62056596|NCT03295903|PLACEBO_COMPARATOR|Placebo|Sugar pill that will have no effect.
62056597|NCT03295903|ACTIVE_COMPARATOR|Cannabidiol and herbal capsules (1 dose)|Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
62056598|NCT03295903|ACTIVE_COMPARATOR|Cannabidiol (1 dose)|Only cannabidiol supplement.
62056599|NCT03295903|ACTIVE_COMPARATOR|Cannabidiol and herbal capsules (2 dose)|Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
62056600|NCT03295903|ACTIVE_COMPARATOR|Cannabidiol only (2 dose)|Only cannabidiol supplement.
62616636|NCT05485233||Presencial|At day 3th and 10th after surgery, each patient will undergo face-to-face examination of their surgical wound by a physician or a nurse, who will confirme the presence or absence of complications and they will fill in the questionnarie to compare the reponses with the aplication
62616637|NCT05485233||Telematic|At day 3th and 10th after surgery, each patient will upload an image of the surgical wound via RedScar© aplication using their own smartphone device. RedScar© aplication will evaluate the risk of complications of the surgical wound and will assign patients to 2 different groups: potential complications requiring new consultation or satisfactory evolution and discharge.
62841458|NCT05446064|EXPERIMENTAL|Enhanced Treatment|Participants will receive the stigma-reduction intervention as well as typical services including care co-ordination and linkage to public health nurses in local communities.
62259667|NCT03650816||Alzheimer Disease|"Patients with Alzheimer's disease, as defined by the established clinical consensus criteria (DSM IV-TR and NINCDS-ADRDA)~Doppler ultrasonography will be used in these patients to assess CVR CO2 , as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.~Biospecimen collection will be performed in these patients : a blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care, to determine plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity"
62259668|NCT03650816||Subjective Cognitive impairment|"Patients with subjective cognitive impairment, who consulted for cognitive complaint without cognitive impairment on neuropsychological tests and normal performances according to daily life activities scores.~Doppler ultrasonography will be used in these patients to assess CVR CO2 , as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.~Biospecimen collection will be performed in these patients : a blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care, to determine plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity"
62445315|NCT04806984||Call center phone call|Participants randomized to this arm will receive a phone call from the call center reminding them to schedule their appointments.
62056601|NCT03112941|EXPERIMENTAL|control group|Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.
62259669|NCT02094456|EXPERIMENTAL|Endoscopic clipping of diverticula|Endoscopic clipping of diverticula Follow-up colonoscopy
62259670|NCT04125550|EXPERIMENTAL|Group P|In Group P, 2-3 mg/kg propofol, 5 µg/kg iv fentanyl will be administered for anesthesia induction and 0.6 mg/kg rocuronium will be used as muscle relaxants. 10 mg/kg/h propofol infusion and 5 µg/kg/h fentanyl infusion will be administered.
62841459|NCT05446064|NO_INTERVENTION|Treatment-as-Usual|Participants will receive typical services including care co-ordination and linkage to public health nurses in local communities.
62841460|NCT01356251|EXPERIMENTAL|Surgical group with mesothelioma|The study proposed here has two parts: part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life through a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. In part 2, patients are invited to participate in an Internet-based discussion group.
62841461|NCT01356251|EXPERIMENTAL|Non Surgical group with mesothelioma|The study proposed here has two parts: part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life through a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. In part 2, patients are invited to participate in an Internet-based discussion group
62841462|NCT02225691|EXPERIMENTAL|paired testing of blood glucose|Patient will be randomly assigned to one of 2 arms, namely (i) paired testing (PT) arm; and (ii) control (CL) arm. Paired testing arm will undergo paired testing of blood glucose.
62841463|NCT02225691|NO_INTERVENTION|control arm|Non-insulin patients will be randomly assigned to one of 2 arms, namely (i) paired testing (PT) arm; and (ii) control (CL) arm. Patients in the control arms will not undergo paired testing and will be managed as before.
62841464|NCT01867177|OTHER|HIV testing|Identification of HIV infection among recently infected adults
62445316|NCT04806984||No call center phone call|Participants randomized to this arm will not receive a phone call from the call center reminding them to schedule their appointments.
62445317|NCT04806984||MyChart message|Participants randomized to this arm will receive an automated MyChart message reminding them to schedule their appointments.
62445318|NCT04806984||No MyChart message|Participants randomized to this arm will not receive an automated MyChart message reminding them to schedule their appointments.
62616638|NCT01072747|EXPERIMENTAL|heparin of bovine origin|Laboratory Bergamo Ltda. 5.000UI/mL bottle with 5mL
62616639|NCT01072747|ACTIVE_COMPARATOR|heparin of porcine origin|APP Pharmaceuticals
62056602|NCT03112941|EXPERIMENTAL|hyperbaric oxygen group|Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
62056603|NCT03852238||Cases: patients with hepatocellular carcinoma on non-cirrhotic|Blood test and self-administrated questionnaires (medical history of the participant and his / her family, tobacco consumption, alcoholic and non-alcoholic beverages consumption, eating habits, type of employment and exposure, stays abroad longer than 1 month
62841465|NCT01867177|EXPERIMENTAL|HIV care utilization|Improved access to HIV care and HIV care utilization, particularly among newly diagnosed adults
62841466|NCT01867177|ACTIVE_COMPARATOR|standard of care|Standard of HIV care; standard of linkage to HIV care
62056604|NCT03852238||Control: patients without hepatocellular carcinoma|Blood test and self-administrated questionnaires (medical history of the participant and his / her family, tobacco consumption, alcoholic and non-alcoholic beverages consumption, eating habits, type of employment and exposure, stays abroad longer than 1 month
62259671|NCT04125550|ACTIVE_COMPARATOR|Group S|In Group S, sevoflurane inhalation (2-8%), 5 microgr/kg intravenous (iv) fentanyl will be administered for anesthesia induction and 0.6 mg/kg rocuronium will be used as muscle relaxants. 2% sevoflurane inhalation and 5 µg/kg/h fentanyl infusion will be administered for the maintenance of anesthesia.
62445319|NCT00696709|EXPERIMENTAL|Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine|Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine A; 4-dose regimen administered \~30 days apart.
62445320|NCT00696709|EXPERIMENTAL|Part 1: Gamma- Irradiated VZV Vaccine A|Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered \~30 days apart.
62841467|NCT04775940|EXPERIMENTAL|Perforated collagen membrane|
62841468|NCT04775940|ACTIVE_COMPARATOR|Occlusive collagen membrane|
62841469|NCT00742144|EXPERIMENTAL|ofatumumab|Japanese patients with CD20 positive follicular lymphoma or chronic lymphocytic leukemia
62056605|NCT02329184|EXPERIMENTAL|MYK-461|
62259672|NCT04540146||Case|End Stage Colorectal Cancer patients with intraabdominal ascites
62259673|NCT04540146||Control|Congestive heart failure and liver cirrhosis patient who had intraabdominal ascites
62445321|NCT00696709|PLACEBO_COMPARATOR|Part 1: Placebo|Participants received a 4-dose placebo regimen administered \~30 days apart.
62445322|NCT00696709|EXPERIMENTAL|Part 2: Gamma- Irradiated VZV Vaccine B|Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered \~30 days apart.
62445323|NCT00696709|EXPERIMENTAL|Part 2: Gamma- Irradiated VZV Vaccine C|Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine C; 4-dose regimen administered \~30 days apart.
62445324|NCT01273610|EXPERIMENTAL|Lapatinib and trastuzumab|Patients receive lapatinib ditosylate PO QD and trastuzumab IV once weekly OR once every 3 weeks. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62616640|NCT03879551|ACTIVE_COMPARATOR|Real rTMS|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere on the hand motor area for 10 consecutive sessions totally over period of 10 days.
62616641|NCT03879551|SHAM_COMPARATOR|Sham rTMS|Sham rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere with coil perpendicular on scalp for 10 consecutive sessions totally over period of 10 days.
62616642|NCT01122459|ACTIVE_COMPARATOR|Hartmanns|These patients will receive Hartmanns during anaesthesia
62616643|NCT01122459|ACTIVE_COMPARATOR|Voluven 6%|
62841470|NCT00419952|EXPERIMENTAL|Symbicort|Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
62841471|NCT00419952|EXPERIMENTAL|Budesonide|Budesonide HFA pMDI 160 ug x 2 actuations BID
62841472|NCT05949437|EXPERIMENTAL|Group (I)|consists of 30 patients with iron deficiency anemia and will receive medical treatment of anemia, Dietary advices and 50 minutes yoga therapy 6 days a week for 12 weeks
62616644|NCT02875717||Control|
62056606|NCT05292534|ACTIVE_COMPARATOR|Amplification-only|Hearing aid will be fit to prescribed participant hearing loss.
62056607|NCT05292534|ACTIVE_COMPARATOR|Amplification with added sound|Hearing aid will be fit to prescribed participant hearing loss and an added sound will be activated on the hearing aid.
62056608|NCT05292534|NO_INTERVENTION|No intervention|Participants will return to their original unaided state.
62056609|NCT02106585|EXPERIMENTAL|Dose 1 JTT-251 or Placebo|Tablets, single dose in fed condition
62056610|NCT02106585|EXPERIMENTAL|Dose 2 JTT-251 or Placebo|Tablets, single dose in fed condition
62259674|NCT05597475|OTHER|Patients|Patients with hypoglycemia
62445325|NCT05939661|EXPERIMENTAL|TNT|Neoadjuvant radiation therapy : 5Gyx5 Neoadjuvant chemo therapy : CAPOX (Oxaliplatin 130mg/m2, Capecitabine2000mg/m2/day, d1-14, 3week)x6cycles Operation: Total methorectum excision wiht radical lymph node dissection
62445326|NCT06404593||Group 1|Blood sampling 7 days after surgery
62445327|NCT06404593||Group 2|Blood sampling 1 month after surgery
62445328|NCT06404593||Group 3|Blood sampling 3 to 6 months after surgery
62445329|NCT06404593||Group 4|Blood sampling 6 to 9 months after surgery
62445330|NCT06404593||Group 5|Blood sampling 9 to 12 months after surgery
62616645|NCT02875717||Acetylsalicylic acid|Patients that were on medication with Acetylsalicylic acid on the date of shockwave lithotripsy
62616646|NCT02875717||Low Molecular weight heparin|Patients that were on medication with low molecular heparin on the date of shockwave lithotripsy
62841473|NCT05949437|OTHER|Group (II)|consists of 30 patients with iron deficiency anemia and will receive medical treatment for anemia, Diet advices and 30 minutes of aerobic exercises in form of treadmill according to the target exercise heart rate for 12 weeks.
62841474|NCT00679796||Group A|Subjects with PCR confirmed varicella
62841475|NCT00679796||Group B|Age- and practice-matched control subjects
62841476|NCT02392819|EXPERIMENTAL|test product|Arm: Panax ginseng
62841477|NCT02392819|PLACEBO_COMPARATOR|placebo product|Arm: a placebo with similar appearance but without Panax ginseng. The tablet include all the other non-active bulk ingredients.
62841478|NCT00633503||A-Observation|All patients undergoing pedicle and free tissue transfer.
62259675|NCT05597475|OTHER|Controls|Patients without post-bariatric hypoglycemia
62056611|NCT02106585|EXPERIMENTAL|Dose 3 JTT-251 or Placebo|Tablets, single dose in fed condition
62259676|NCT06022731||Filling|
62259677|NCT06022731||Overhanging Filling|
62259678|NCT04572984|EXPERIMENTAL|EBUS-TBNA-TBMCB|endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was followed by endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy (EBUS-TBMCB)
62259679|NCT04572984|NO_INTERVENTION|EBUS-TBNA|endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was performed
62259680|NCT02897700|EXPERIMENTAL|Mono-chemotherapy|"A mono-chemotherapy (a single chemotherapeutic agent out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (or CDEFM) was performed 30\~60 days prior to surgery for patients who had no history of receiving either local or systemic cancer-associated chemotherapy.~Interventions: cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate."
62259681|NCT02897700|EXPERIMENTAL|Combined chemotherapy|"Combined chemotherapy (random combination of two breast cancer chemotherapeutic agents including cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate, or CDEFM) was performed 30\~60 days prior to surgery for patients who had no history of receiving either local or systemic chemotherapy for cancer.~Interventions: cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate."
62259682|NCT02897700|PLACEBO_COMPARATOR|Placebo treatment|No chemotherapeutic regimes using any cytotoxic agent was done for patients who have infiltrating ductal carcinoma of breast. Placebo was used instead.
62259683|NCT01361035|NO_INTERVENTION|No communication training|Physicians enrolled in the control arm do not undergo training in health literacy, cancer screening and shared decision making
62259684|NCT01361035|OTHER|Cancer risk ommunication skills training|Physicians enrolled in the intervention arm undergo training in health literacy, cancer screening and shared decision making
62259685|NCT02121262|OTHER|Laser Photocoagulation|Laser photocoagulation was administered in the study eye on Day 1, and on Months 3, 6, and 9, if retreatment indicated.
62259686|NCT02121262|EXPERIMENTAL|Dexamethasone|Dexamethasone 700 μg was administered as intravitreal injection in the study eye on Day 1, Months 5, and 10.
62259687|NCT04462562|EXPERIMENTAL|quantitative ultrasound imaging parameters|"quantitative ultrasound imaging parameters~* tissue attenuation imaging (TAI) parameter~* tissue scatter-distribution imaging (TSI) parameter~* Hepatorenal index (semi-auto, EzHRI)"
62841479|NCT01906606|EXPERIMENTAL|Parenting Program|12 session community-based parenting program
62259688|NCT01189188|EXPERIMENTAL|With ultrasound guidance|In this group of patients, ultrasound guidance will be used when drawing blood from the radial artery.
62259689|NCT01189188|ACTIVE_COMPARATOR|Without ultrasound guidance|In this group of patients, no ultrasound guidance will be used when drawing blood from the radial artery.
62259690|NCT04221932||Pre Intervention|Retrospective evaluation of data from 2 years prior to the implementation of our CRRT KPI reports. This will include approximately 1500 participants.
62259691|NCT04221932||Post Intervention|This will be a prospective evaluation of all new ICU patients receiving CRRT in Alberta over a 2 year periods. This will include approximately 1500 participants
62056612|NCT02106585|EXPERIMENTAL|Dose 4 JTT-251 or Placebo|Tablets, single dose in fed condition
62056613|NCT02106585|EXPERIMENTAL|Dose 5 JTT-251 or Placebo|Tablets, single dose in fed condition
62056614|NCT02106585|EXPERIMENTAL|Dose 6 JTT-251 or Placebo|Tablets, single dose in fed condition
62056615|NCT02106585|EXPERIMENTAL|Dose 7 JTT-251 or Placebo|Tablets, single dose in fed condition
62056616|NCT02106585|EXPERIMENTAL|Dose 8 JTT-251 or Placebo|Tablets, single dose in fed condition
62056617|NCT02106585|EXPERIMENTAL|Dose 9 JTT-251 or Placebo|Tablets, single dose in fasted or fed condition followed by a single dose in the alternate fed or fasted condition
62259692|NCT04001621|EXPERIMENTAL|Pyrotinib plus capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m\^2 daily, 1000 mg/m\^2 BID)
62259693|NCT04113200|EXPERIMENTAL|F+ALG|An alginate containing feed: MerMed One (Kaneka Corporation). 300mls administered nasogastrically over one hour.
62259694|NCT04113200|OTHER|F-ALG|A standard enteral feed commonly used in practice. Nutricomp Soy Fibre (B.Braun). 300mls administered nasogastrically over one hour.
62259695|NCT06020586|EXPERIMENTAL|hair lotion|
62259696|NCT00649883|EXPERIMENTAL|1|
62259697|NCT00649883|ACTIVE_COMPARATOR|2|
62259698|NCT03331770|EXPERIMENTAL|BAK-free latanoprost ophthalmic emulsion|Patients with primary open-angle glaucoma who were using BAK-containing latanoprost ophthalmic solution for ≥ 6 months (baseline), switched to a new formulation of latanoprost ophthalmic product
62259699|NCT00320008|ACTIVE_COMPARATOR|Standard Treatment Arm|This arm will at any time during the active intervention period follow treatment guidelines by the Danish Medical Association for the treatment of type 2 diabetes.
62841480|NCT01906606|NO_INTERVENTION|Control Group|received visual aids on nutrition
62445331|NCT03830983||Stroke of likely cardioembolic cause or undetected mechanism|Lesions in at least one territory on MRI \& absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels \>50% in arteries supplying the ischemic area(s) \& absence of severe small vessel disease including micro-bleeds on Patients with central retinal artery occlusion documented by perimeter and absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels \>50% \& absence of severe small vessel disease including micro-bleeds on MRI are included independent of acute MRI findings.
62445332|NCT03830983||Atherosclerotic stroke|Large vessel stroke: Acute lesions in one vascular territory on MRI, significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels \>50% leading to the infarcted territory \& absence of severe small vessel disease including micro-bleeds on MRI Small Vessel stroke: MRI documenting lacunar infarction, absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels \>50% and presence of severe small vessel disease possibly including micro bleeds.
62616647|NCT04659317|ACTIVE_COMPARATOR|Opioid Group|"Participants will receive encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed after surgery Safety Prescription: Oxycodone5 mg po q6 hours as needed for pain"
62616648|NCT04659317|EXPERIMENTAL|Placebo Group|"Participants will receive encapsulated placebo tablets x24, to take po q6 hours as need for pain after surgery Safety Prescription: Oxycodone5 mg po q6 hours as needed for pain"
62616649|NCT01858025|EXPERIMENTAL|Pencil Beam Scanning Radiation|Pencil Beam Radiation daily, Monday-Friday, for 5-6 weeks Mitomycin-C via IV on Days 1 and 29 5-Fluorouracil via infusion pump over 4 days, starting Day 1 and 29 of chemotherapy
62445333|NCT03830983||Controls|Age and sex matched healthy controls with no history of stroke or AF.
62445334|NCT05169164||Single group|All adult patients (aged 18 years or older) undergoing elective or emergency surgery with a planned overnight stay. No interventions, only observational.
62056618|NCT03156322|ACTIVE_COMPARATOR|Group 5|5 mL epidural initiation volume (bupivacaine + fentanyl)
62056619|NCT03156322|ACTIVE_COMPARATOR|Group 10|10 mL epidural initiation volume (bupivacaine + fentanyl)
62445335|NCT01199406|PLACEBO_COMPARATOR|normal saline|80 mL 0.9% NaCl
62616650|NCT01773018|EXPERIMENTAL|Volitinib(HMPL-504)|"There are six dose cohorts,including 100, 200, 400, 600,800 and 1000 mg/day, HMPL-504 will be administered orally to patients once daily for each dose cohort.~An alternative dosing schedule of twice every day (BID) may be investigated if pharmacokinetic studies indicate faster than anticipated clearance of Volitinib(HMPL-504)."
62616651|NCT01689753|EXPERIMENTAL|TEGO® connector|The TEGO® connector is used during 3 consecutive hemodialyse. After each dialysis session, the dead space of the catheter is flushed with NaCl 0.9%.
62616652|NCT01689753|ACTIVE_COMPARATOR|Trisodium citrate|After each dialysis, the dead space of the catheter is filled with trisodium citrate 46.7% (Citralock®).
62616653|NCT04671355|EXPERIMENTAL|Trimbow|Pressurized metered dose inhaler
62616654|NCT04671355|ACTIVE_COMPARATOR|Relvar|Dry powder inhaler
62616655|NCT05905250|EXPERIMENTAL|Intervention|The intervention utilizes an empirically supported protocol, further refined with evidence-based strategies targeting the needs of young adult (YA) survivors. Its long-term goal is to promote hopeful thinking, and ultimately enhance other long-term markers of quality of life (QOL) (including mental health and health behaviors). The intervention follows 8 weekly curricula, reinforced through psychoeducation and skill-building, homework/practical application, and self-monitoring. Its 8-week design was informed by cognitive behavioral therapy and positive psychology intervention literature.
62056620|NCT03156322|ACTIVE_COMPARATOR|Group 20|20 mL epidural initiation volume (bupivacaine + fentanyl)
62056621|NCT04413591|EXPERIMENTAL|Intervention Area|Participants are assigned to the intervention area or the control area based on the location they were recruited in.
62445336|NCT01199406|EXPERIMENTAL|Levobupivacaine|80mL 0.125% levobupivacaine
62445337|NCT06256250|EXPERIMENTAL|group (1): the adaptive xp endo shaper|the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using the adaptive xp endo shaper. it is single file technique saves time and help with patient cooperation.
62445338|NCT06256250|EXPERIMENTAL|group (2): Fanta AF baby file|the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using FANTA AF baby files. it is pediatric rotary system consists of 4 files specialized for primary molars.
62056622|NCT04413591|NO_INTERVENTION|Control Area|Participants are assigned to the intervention area or the control area based on the location they were recruited in.
62056623|NCT05556174|EXPERIMENTAL|Intensive intraoperative lung-protective ventilation|intraoperative lung-protective ventilation with periodic lung recruitment maneuvers
62445339|NCT06256250|ACTIVE_COMPARATOR|group (3): hand k files|the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using hand k files. they are manual files, they are standard for root canal treatment (control group)
62616656|NCT05905250|ACTIVE_COMPARATOR|Attention Control|Health education regarding maintaining a healthy weight, physical activity, and nutrition, based on American Cancer Society and NCI guidelines/recommendations.
62841481|NCT01875406|EXPERIMENTAL|diagnostic exercises|The three diagnostic exercises will be administered in random order to minimize effects of order and period on the results. Enrollment logs and study randomization will be administered electronically via a respective REDCap data modules. The enrollment, randomization and diagnostic tests will be administered by research coordinator or PI. The patients will be independently evaluated and scheduled for SIJ injection by Cleveland Clinic pain clinic staff and fellow pain physicians.
62841482|NCT01255436|EXPERIMENTAL|SMS text reminders|Participants in this arm will receive SMS text messages on top of the usual care they receive from their physicians.
62445340|NCT03726190||OLLIF|Patients who underwent Oblique Lateral Lumbar Interbody Fusion
62445341|NCT05065879|EXPERIMENTAL|Hypertension group|Hypertension group will enroll 330 subjects with hypertension (aged 60 years or older).
62445342|NCT05065879|EXPERIMENTAL|Diabetes group|Diabetes group will enroll 330 subjects with diabetes (aged 60 years or older).
62445343|NCT05065879|EXPERIMENTAL|Combined Diseases group|Combined Diseases group will enroll 300 subjects with both hypertension and diabetes (aged 60 years or older).
62445344|NCT05065879|ACTIVE_COMPARATOR|Healthy people group|Healthy people group will enroll 480 subjects with no medical history of hypertension or diabetes (aged 60 years or older).
62445345|NCT03604120|EXPERIMENTAL|Preoxygenation with high flow therapy by nasal cannula|High flow oxygen therapy by nasal cannula.
62445346|NCT03604120|ACTIVE_COMPARATOR|Preoxygenation by standard Facial mask|"Patients randomized in STANDARD FACIAL MASK group will receive a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction or Fiber-optic intubation under spontaneous ventilation."
62841483|NCT01255436|OTHER|Usual Care|Participants in this arm will receive the usual care they receive from their physicians.
62841484|NCT00990197|ACTIVE_COMPARATOR|Day 1|Patients randomized to wearing the patch on day 1 will apply a patch on the morning of their treatment day and keep it on for 24 hours. These patients will not wear a patch on day 2.
62445347|NCT01776593||Lower urinary tract symptoms|
62445348|NCT05600374|EXPERIMENTAL|Personalized stimulation|Each 100 Hz triplet is triggered when a real-time analyzed EEG-defined state of high corticospinal excitability is detected (i.e., the negative peak of the ongoing sensorimotor \~10 Hz μ-oscillation).
62445349|NCT05600374|NO_INTERVENTION|Non-personalized stimulation|The identical rTMS protocol as in Arm 1, but 100 Hz triplets are not synchronized to the ongoing sensorimotor μ-oscillation.
62841485|NCT00990197|ACTIVE_COMPARATOR|Day 2|Patients randomized to wearing the patch on day 2 will apply a patch on the morning of their treatment day and keep it on for 24 hours. These patients will not wear a patch on day 1.
62841486|NCT02930018|PLACEBO_COMPARATOR|Placebo|Drug vehicle only
62841487|NCT02930018|EXPERIMENTAL|Nerinetide (NA-1), 2.6 mg/kg|
62841488|NCT04610593|EXPERIMENTAL|Intervention Group|This group will receive a Mindfulness-based intervention for 8 weeks, and after the intervention this participants will continuous their treatment as usual
62056624|NCT05556174|NO_INTERVENTION|Moderate intraoperative lung-protective ventilation|intraoperative lung-protective ventilation without periodic lung recruitment maneuvers
62056625|NCT01446484|EXPERIMENTAL|T reg therapy|Kidney transplantation, followed by immunotherapy given along with autologous CD4+CD25+CD127lowFoxP3+ T regulatory cells infusions
62056626|NCT01446484|ACTIVE_COMPARATOR|Immunosuppression|Patients will undergo immunosuppressive therapy followed by living related kidney transplantation
62056627|NCT06484270|EXPERIMENTAL|Experimental group|Nurses receiving simulation-based training Patients receiving care from these nurses
62056628|NCT06484270|NO_INTERVENTION|Control group|Nurses receiving theoritical education Patients receiving care from these nurses
62056629|NCT04392778|NO_INTERVENTION|Untreated|Group 1: patients that are not on a ventilator (n=10) No extra intervention will be done.
62056630|NCT04392778|SHAM_COMPARATOR|Saline Control|Group 2: patients that are on a ventilator and will receive saline injections (n=10) as control for MSC transplantation group (3).
62056631|NCT04392778|EXPERIMENTAL|Experimental UC-MSCs|Group 3: patients that are on a ventilator and will receive MSC transplantation injections (n=10)
62445350|NCT05600374|NO_INTERVENTION|Sham stimulation|The same protocol as in arm 1 synchronized to the EEG-defined high excitability state, but with ineffective rTMS, using the sham side of an active/placebo TMS coil designed for double-blind clinical trials. Conditions/arm 2 and 3 are control conditions. Arm 2 controls for the specific effect of Condition/arm 1 to synchronize stimulation to the ongoing μ-oscillation. Arm 3 tests if auditory or somatosensory inputs (which are identical in the real and sham stimulation conditions) synchronized with the ongoing μ-oscillation are relevant for the effects of Arm 1.
62445351|NCT04495491||Pupillary block group|According to the configurations of angle closure, the pupillary block group is defined as the iris bombe.
62445352|NCT04495491||plateau iris group|According to the configurations of angle closure, the plateau iris group is defined as the thickness of the peripheral iris.
62623674|NCT03678194|EXPERIMENTAL|Smartphone application|This group of subjects receives mobile support system and conventional treatment (clinical evaluation and follow-up). The smartphone application will be downloaded on patients' smartphone to daily evaluate symptomatology, medication adherence...
62616657|NCT03706469|EXPERIMENTAL|Fasted (T2 50 mg+T3 50 mg+T3 600 mg+T2 600 mg)+Fed (T3 600 mg)|TAK-831 T2 50 milligram (mg), tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
62616658|NCT03706469|EXPERIMENTAL|Fasted (T3 50 mg+T2 600 mg+T2 50 mg+T3 600 mg)+Fed (T3 600 mg)|TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
62616659|NCT03706469|EXPERIMENTAL|Fasted (T2 600 mg+T3 600 mg+T3 50 mg+T2 50 mg)+Fed (T3 600 mg)|TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
62616660|NCT03706469|EXPERIMENTAL|Fasted (T3 600 mg+T2 50 mg+T2 600 mg+T3 50 mg)+Fed (T3 600 mg)|TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
62616661|NCT02084433|ACTIVE_COMPARATOR|conventional anasthesia|para-apical maxillary and locoregional mandibular (Articaine 1/100000) anaesthesia
62841489|NCT04610593|NO_INTERVENTION|Treatment as Usual|Patients in the control group received treatment as usual in the hemodialysis setting: Carry out hemodialysis sessions three times a week, on alternate days, for approximately 4 hours added to appointments and procedures performed by professionals from different areas (medicine, nursing, nutrition, physical education, social work, pharmacy, psychology).
62841490|NCT03185962||Successful extubation|extubated successfully
62841491|NCT03185962||Extubation failure|reintubated within 48 hours
62259700|NCT00320008|EXPERIMENTAL|Intensive Treatment Arm|This arm will during the active intervention period be treated according to intensified multiple risk factor intervention following strict guidelines set out by the study protocol.
62616662|NCT02084433|EXPERIMENTAL|intraosseous anaesthesia|"intraosseous anaesthesia using a computerized system (Quicksleeper) 1 / Anesthesia of periosteum (Articaine 1/100000) 2 / penetration of the needle rotated to the apex 3 / osteocentral injection "
62616663|NCT03275389|EXPERIMENTAL|D-SUIV Adjuvanted Group 1|Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
62616664|NCT03275389|EXPERIMENTAL|D-SUIV Adjuvanted Group 2|Subjects received one dose of D-SUIV cH5/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
62841492|NCT03185962||NPPV/NHF|use of non-invasive positive pressure ventilation (NPPV) or nasal high flow (NHF) within 48 hours after extubation
62841493|NCT03702283|EXPERIMENTAL|Penicillin Allergic ICU Patients|The intervention will provide access to a best-practices alert containing a penicillin allergy risk stratification tool and recommendations on whether to use an oral amoxicillin test dose challenge order set for patients who stratify as low risk.
62259701|NCT04342000|EXPERIMENTAL|Intervention Group|Movement Education Workshop
62259702|NCT04342000|SHAM_COMPARATOR|Control Group|Sham Education Workshop
62259703|NCT06037733|EXPERIMENTAL|CTV-omitted|CTV was omitted for primary tumor radiotherapy for advanced NSCLC who responded to therapy with immunotherapy and chemotherapy.
62259704|NCT06037733|ACTIVE_COMPARATOR|CTV-delineated|CTV was delineated for primary tumor radiotherapy for advanced NSCLC who responded to induction therapy with immunotherapy and chemotherapy.
62259705|NCT01035775|EXPERIMENTAL|Insertion|Inspection on colonoscope insertion in addition to inspection during withdrawal from the cecum.
62259706|NCT01035775|ACTIVE_COMPARATOR|Withdrawal|Inspection during withdrawal (usual care) without deliberate inspection during insertion.
62259707|NCT01361776|ACTIVE_COMPARATOR|TBE vaccine at 0+30 days|This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later
62259708|NCT01361776|ACTIVE_COMPARATOR|TBE vaccine at 0+7+21 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later
62616665|NCT03275389|EXPERIMENTAL|D-SUIV Adjuvanted Group 3|Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose D-SUIV cH5/1N1+AS03 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
62616666|NCT03275389|EXPERIMENTAL|D-SUIV Adjuvanted Group 4|Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
62616667|NCT03275389|EXPERIMENTAL|D-SUIV Adjuvanted Group 5|Subjects received one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
62616668|NCT03275389|EXPERIMENTAL|D-SUIV Adjuvanted Group 6|Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
62841494|NCT06414993|EXPERIMENTAL|Contingency Management for Emerging Adults (CM-EA) Only|The parents in this group will receive CM-EA delivered virtually by a parent coach approximately weekly (20-40 minute sessions) for 6 months.
62056632|NCT03108157|EXPERIMENTAL|GROUP A: intervention group|Patients will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before the embryo transfer and then they will follow the conventional preparation protocol to receive embryos coming from an egg donation treatment.
62445353|NCT04495491||mixed mechanism group|According to the configurations of angle closure, the mixing mechanism group is defined as the iris bombe plus thickening of the peripheral iris.
62616669|NCT03275389|EXPERIMENTAL|D-SUIV Unadjuvanted Group 1|Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
62445354|NCT03091166|ACTIVE_COMPARATOR|Dexmedetomidine|
62445355|NCT03091166|NO_INTERVENTION|No Dexmedetomidine|
62616670|NCT03275389|EXPERIMENTAL|D-SUIV Unadjuvanted Group 2|Subjects received one dose of D-SUIV cH5/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
62841495|NCT06414993|EXPERIMENTAL|Standard Peer Recovery Support Services (PRSS)+Vocational/Educational (V/E) Skill Building|The EAs in this group will receive PRSS+Vocational/Educational (V/E) Skill Building delivered by peer workers in-person in the local community approximately weekly (1 hour sessions) for 6 months.
62445356|NCT02471300||1|stable mild-moderate asthmatic subjects
62445357|NCT00093964|EXPERIMENTAL|Cilengitide 500 Milligram (mg)|
62841496|NCT06414993|EXPERIMENTAL|CM-EA and PRSS+V/E|Families receive both CM-EA and PRSS + V/E as described above.
62841497|NCT00511368|PLACEBO_COMPARATOR|1|placebo
62841498|NCT00511368|EXPERIMENTAL|2|Bevirimat
62841499|NCT01926262|EXPERIMENTAL|Physical Exercise Group|Specific Strength Training for the Neck and Shoulder muscles
62841500|NCT01926262|NO_INTERVENTION|Reference group|No Specific Strength Training
62259709|NCT01361776|ACTIVE_COMPARATOR|TBE vaccinte at 0+30+90 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later
62259710|NCT01361776|ACTIVE_COMPARATOR|younger participants|This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later
62259711|NCT02690662|EXPERIMENTAL|Obese with kidney stones|Hypocaloric diet for 3 months
62259712|NCT03728075|NO_INTERVENTION|Control group|standard protocol for cardiac rehabilitation
62445358|NCT00093964|EXPERIMENTAL|Cilengitide 2000 mg|
62445359|NCT03294512|EXPERIMENTAL|Heart Failure Patients|Patients who are seen at Intermountain Medical Center with heart failure, based on the Intermountain-specific Heart Failure Identification and Risk Stratification, will be screened for this study. The Principal Investigator and/or his delegate will confirm the presence of heart failure, based on established standard of care criteria for diagnosis.
62445360|NCT04385446|ACTIVE_COMPARATOR|Amniotic membrane transplantation|Amniotic membrane transplantation was used as covering material in the area where the pterygium tissue was removed during the surgery.
62445361|NCT04385446|NO_INTERVENTION|conjnctival autograft.|Conjunctival autograft was used as a covering material in the area where the pterygium tissue was removed during the surgery.
62445362|NCT00861783|EXPERIMENTAL|Group A - irinotecan|"Note: As of Amendment 2 (March 2009), treatment in the irinotecan arm of the study (Group A) is closed to enrollment.~Treatment with escalating doses of ON 01910.Na in combination with irinotecan."
62616671|NCT03275389|EXPERIMENTAL|D-SUIV Unadjuvanted Group 3|Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of D-SUIV cH5/1N1 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
62616672|NCT03275389|ACTIVE_COMPARATOR|IIV4 Group|Subjects received one dose of Fluarix Quadrivalent (IIV4) vaccine at Day 1, one dose of Placebo at Day 57 and one dose of Fluarix Quadrivalent vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
62056633|NCT03108157|NO_INTERVENTION|GROUP B: no intervention group|Patients will receive the conventional preparation protocol to receive embryos coming from an egg donation treatment.
62056634|NCT00181571|ACTIVE_COMPARATOR|1|Concerta
62056635|NCT00181571|PLACEBO_COMPARATOR|2|Placebo
62056636|NCT01450748|EXPERIMENTAL|Sodium alginate|oral suspension, 50 mg/ml
62056637|NCT01450748|PLACEBO_COMPARATOR|Placebo|oral suspension without active ingredient
62056638|NCT02955030|EXPERIMENTAL|NSV0001(Cohort1)|15 µg of hemagglutinin \[HA\] antigen per strain with 150 µg of ND002 adjuvant, administration by sublingual route
62056639|NCT02955030|EXPERIMENTAL|NSV0001(Cohort2)|30 µg of hemagglutinin\[HA\] antigen per strain with 300 µg of ND002 adjuvant, administration by sublingual route
62445363|NCT00861783|EXPERIMENTAL|Group B - oxaliplatin|Treatment with escalating doses of ON 01910.Na in combination with oxaliplatin.
62445364|NCT00585351|EXPERIMENTAL|I|Advanced Notification + Ranitidine
62445365|NCT00585351|ACTIVE_COMPARATOR|II|Advanced Notification + Placebo
62445366|NCT00585351|ACTIVE_COMPARATOR|III|No advanced notification + Ranitidine
62445367|NCT00585351|PLACEBO_COMPARATOR|IV|No advanced notification + Placebo
62445368|NCT04522414||Preterm infant|
62445369|NCT01968109|EXPERIMENTAL|Relatlimab|Relatlimab (BMS-986016) specified dose on specified days
62445370|NCT01968109|EXPERIMENTAL|Relatlimab + Nivolumab|Relatlimab (BMS-986016) + Nivolumab (BMS-936558) specified dose on specified days
62445371|NCT01968109|EXPERIMENTAL|BMS-986213|Relatlimab (BMS-986016) + Nivolumab (BMS-936558)
62445372|NCT03267264|EXPERIMENTAL|Group 1|
62445373|NCT03267264|EXPERIMENTAL|Group 2|
62445374|NCT03267264|EXPERIMENTAL|Group 3|
62445375|NCT03267264|EXPERIMENTAL|Group 4|
62445376|NCT03368989||treatment with radium-223 Dichloride (Xofigo)|
62445377|NCT02546713|OTHER|Group 1|Abutments with a concave configuration of the subcritical contour (emergence shape).
62445378|NCT02546713|OTHER|Group 2|Abutments with convex configuration of the subcritical contour (emergence shape)
62445379|NCT01886456|EXPERIMENTAL|PLT|patients treated with patterned laser trabeculoplasty
62445380|NCT01886456|ACTIVE_COMPARATOR|SLT|patients treated with selective laser trabeculoplasty
62445381|NCT01798745|EXPERIMENTAL|Cohort A: JNJ-54452840 20 mg|Each patient will receive 20 mg of JNJ-54452840 as a single dose.
62445382|NCT01798745|EXPERIMENTAL|Cohort A: JNJ-54452840 80 mg|Each patient will receive 80 mg of JNJ-54452840 as a single dose.
62445383|NCT01798745|EXPERIMENTAL|Cohort A: JNJ-54452840 160 mg|Each patient will receive 160 mg of JNJ-54452840 as a single dose.
62445384|NCT01798745|PLACEBO_COMPARATOR|Cohort A: Placebo|Each patient will receive matching placebo as a single dose.
62445385|NCT01798745|EXPERIMENTAL|Cohort B: JNJ-54452840 <= 240 mg|Each patient will receive JNJ-54452840 at a dose of less than or equal to 240 mg as a single dose (dose determined by the Data Monitoring Committee).
62445386|NCT01798745|PLACEBO_COMPARATOR|Cohort B: Placebo|Each patient will receive matching placebo as a single dose.
62445387|NCT01798745|EXPERIMENTAL|Cohort C: JNJ-54452840 for 3 days|Each patient will receive JNJ-54452840 once daily for 3 days at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
62445388|NCT01798745|PLACEBO_COMPARATOR|Cohort C: Placebo|Each patient will receive matching placebo once daily for 3 days.
62259713|NCT03728075|EXPERIMENTAL|Intervention group|standard protocol for cardiac rehabilitation plus neuromuscular electrical stimulation (NMES)
62259714|NCT00365456|EXPERIMENTAL|PTH (1-84)|
62056640|NCT02955030|EXPERIMENTAL|NSV0001(Cohort3)|60 µg of hemagglutinin\[HA\] antigen per strain with 600 µg of ND002 adjuvant, administration by sublingual route
62841501|NCT05226637|SHAM_COMPARATOR|Control group|"In addition to standard of care, with BoNTA injections, the randomly selected control group will be treated with a sham head to the flexor muscles of the upper extremity. The sham component made by the manufacturers is designed such that the internal pneumatic projectile is physically blocked from providing high energy impact with the contact surface, however the handset looks and sounds identical. In doing so, the sham head still actuates and makes the same sounds but produces no shockwave~ESWT will be apply on every candidate over the anterior region of the upper extremity injected with the BoNTA."
62841502|NCT05226637|EXPERIMENTAL|Experimental group with ESWT|"The randomly selected Study group will be comprised of patients who will receive the appropriate treatment with BoNTA in addition to actual ESWT (extra-corporeal shock wave therapy.~ESWT is an existing technology that uses a device that generates high intensity shockwaves. These shock waves are generated outside of the body (extra corporeal) but penetrate through the skin surface to underlying structures and tissue. ESWT has been historically used safely and for many years to treat common musculoskeletal (MSK) conditions.~For the purpose of the study these variables are standardized. We will treated with the Storz Duolith SD1 and we will use the D15 head 3000 number of shocks, 2.5 bar, 15 Hz over the same area of upper extremity described for the control group."
62841503|NCT06516536|NO_INTERVENTION|Control Group (CG)|A control group (CG) that will not undergo treatment, which will be evaluated in the pre and post phase of the study.
62841504|NCT06516536|EXPERIMENTAL|Experimental Group|In-person MBI: Intervention from Monday to Thursday, carried out in the first 20 minutes of class. Approach to mindfulness meditation, body scanning and simple yoga postures.
62056641|NCT02955030|PLACEBO_COMPARATOR|Placebo|0 µg of hemagglutinin\[HA\] antigen per strain with 0 µg of ND002 adjuvant, administration by sublingual route
62056642|NCT02955030|ACTIVE_COMPARATOR|"Influenza HA vaccine Biken HA"|Seasonal quadrivalent influenza vaccine, administration by subcutaneous injection route
62056643|NCT01848379|EXPERIMENTAL|Antidiabetic Therapy(ADT)+Full Mouth Decontamination(FD)|"ADT:~(Par-)enteral, anti-diabetic medication, diet and dietetic supervision, physiotherapy and physical exercises~FD:~The oral use of topical antiseptics prior and after mechanical tooth debridement, tooth as well as root surface planing and soft tissue decontamination in combination with systemic antibiotics (a combination of amoxicillin and metronidazole - if no microbial resistances were detected)"
62259715|NCT00365456|ACTIVE_COMPARATOR|Risedronate|
62259716|NCT02287389|EXPERIMENTAL|balloon dilation|give the cases balloon dilation as the intervention
62841505|NCT02425852|ACTIVE_COMPARATOR|Combination therapy arm|Infliximab 5 mg/kg plus Azathioprine 2-2.5 mg/kg/day. Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible to 2.5 mg/kg/d, or to 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake.
62841506|NCT02425852|ACTIVE_COMPARATOR|Azathioprine arm|"Intravenous steroids will be continue until day 2. Then, steroid therapy will be orally administered at a dose of 40-60 mg/day ou 1 mg/kg/day prednisolone (or equivalent) and progressively reduced by 10mg step every week to 20mg per day, and then reduced by 5mg step every week until stopped. Hydrocortisone intake to prevent steroid weaning will be authorized until supradrenal function normalization.~In patients with clinical response at day 7, Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible of 2.5 mg/kg/d, or of 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake."
62841507|NCT04413617|EXPERIMENTAL|PF-06650833 + tofacitinib|
62841508|NCT04413617|EXPERIMENTAL|PF-06650833 + PF-06651600|
62841509|NCT04413617|EXPERIMENTAL|PF-06650833|
62259717|NCT02287389|EXPERIMENTAL|balloon dilation plus cryotherapy|give the cases balloon dilation plus cryotherapy as the intervention
62259718|NCT02287389|EXPERIMENTAL|BD plus spiculiform electrosurgery|give the cases balloon dilation plus spiculiform electrosurgery as the intervention
62259719|NCT02287389|EXPERIMENTAL|BD plus mitomycin C|give the cases Balloon dilation plus mitomycin C as the intervention
62259720|NCT02515110|EXPERIMENTAL|Treatment (EBRT)|"External Beam Radiation Therapy (EBRT). Within 10 weeks after the last breast cancer surgery or the last dose of adjuvant chemotherapy, patients undergo hypofractionated RNI five days a week over 3-4 weeks.~The two subgroups are Cohort (A) sentinel lymph node (SLN) and Cohort (B) axillary lymph node (ALN) dissection. They are categorized depending on type of axillary surgery and treatment group. The type of axillary surgery is Sentinel lymph node (SLN) biopsy only vs axillary dissection with or without previous SLN biopsy. The treatment groups are lumpectomy vs mastectomy vs mastectomy/reconstruction."
62259721|NCT03111082||Lean|BMI less than or equal to 29.9
62259722|NCT03111082||Obese|BMI between 30.0 and 39.9
62259723|NCT03111082||Morbidly Obese|BMI greater than or equal to 40.0
62445389|NCT01798745|EXPERIMENTAL|Cohort D: JNJ-54452840 for 5 days|Each patient will receive JNJ-54452840 once daily for 5 days at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
62259724|NCT01659242|ACTIVE_COMPARATOR|Methotrexate plus sulfasalazine|"ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose."
62259725|NCT01659242|ACTIVE_COMPARATOR|Leflunomide|"ARM 2:Leflunomide(LEF)~LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.~Methotrexate:Off"
62259726|NCT00998894||decision-support alerts|In patients experiencing a Triple Low (a combination of low MAC, low MAP, and low BIS), a warning alert will be generated for clinicians.
62259727|NCT00998894||routine practice|In patients experiencing a Triple Low (a combination of low MAC, low MAP, and low BIS), a warning alert will not be generated for clinicians.
62259728|NCT02407262|ACTIVE_COMPARATOR|Treatment|"Black seed oil capsules~1g/day for 4 weeks"
62259729|NCT02407262|PLACEBO_COMPARATOR|Placebo|"Placebo (olive oil) capsules~1g/day for 4 weeks"
62259730|NCT01756534|NO_INTERVENTION|CONVENTIONAL HEMOSTASIS|patients for whom conventional surgical procedures (i. e., ligatures and bipolar electrocautery alone) were used to achieve hemostasis
62259731|NCT01756534|ACTIVE_COMPARATOR|SURGICEL|patients will receive an oxidized cellulose patch (Surgicel®) in addition to conventional surgical procedures (i. e., ligatures and bipolar electrocautery alone)
62259732|NCT06098612|EXPERIMENTAL|evaluation of alpha synuclein aggregates in the brain|
62445390|NCT01798745|PLACEBO_COMPARATOR|Cohort D: Placebo|Each patient will receive matching placebo once daily for 5 days.
62841510|NCT04413617|EXPERIMENTAL|PF-06651600|
62841511|NCT04413617|EXPERIMENTAL|Tofacitinib|
62841512|NCT00965861||1|The SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date.
62841513|NCT05569070|EXPERIMENTAL|Guided Young United Parents! (YUP!) Website Intervention|The Guided YUP! website intervention is the treatment condition, which will involve two months of directed use of the YUP! website.
62841514|NCT05569070|SHAM_COMPARATOR|Nutrition Website|The nutrition website is the control condition.
62841515|NCT02433808|EXPERIMENTAL|Neostigmine Group|Neostigmine will be administered at the conclusion of the surgical procedure
62841516|NCT02433808|PLACEBO_COMPARATOR|No Neostigmine group|Saline will be administered at the conclusion of the surgical procedure
62841517|NCT00734877|ACTIVE_COMPARATOR|ARM A|The standard TT3 Regimen (S-TT3) will consist of 2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
62841518|NCT00734877|EXPERIMENTAL|ARM B|The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD- PACE
62841519|NCT05548322|EXPERIMENTAL|Study of tactile afferent responses to natural surfaces|
62259733|NCT06120400|EXPERIMENTAL|Healthy Diet + Eggs (HD+E)|2020-2025 Dietary Guidelines for Americans adherent dietary pattern containing 2 eggs/day/2000 kcal
62259734|NCT06120400|ACTIVE_COMPARATOR|Healthy Diet (HD)|2020-2025 Dietary Guidelines for Americans adherent dietary pattern containing 3 eggs/week/2000 kcal (HD)
62259735|NCT03653273|EXPERIMENTAL|DMT withdrawal|DMT will be immediately stopped after randomization.These patients will be followed for 2 years.
62259736|NCT03653273|ACTIVE_COMPARATOR|DMT continuation|The previously established therapy will be continued at the same dose during two years.
62445391|NCT01798745|EXPERIMENTAL|Cohort E: JNJ-54452840 weekly|Each patient will receive JNJ-54452840 once weekly on Days 1, 8, 15, and 22 at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
62445392|NCT01798745|PLACEBO_COMPARATOR|Cohort E: Placebo|Each patient will receive matching placebo once weekly on Days 1, 8, 15, and 22.
62841520|NCT05548322|EXPERIMENTAL|Modulation of touch according to the emotional state|
62841521|NCT05548322|EXPERIMENTAL|Effect of temperature on tactile sensitivity|
62841522|NCT05548322|EXPERIMENTAL|Origin of wetness perception|
62841523|NCT05548322|EXPERIMENTAL|Aging and tactile sensitivity|
62841524|NCT05548322|EXPERIMENTAL|Tactile perceptions induced by the stimulation of single sensory fibers|
62841525|NCT05548322|EXPERIMENTAL|Study of tactile feedback after amputation|
62841526|NCT04660565|EXPERIMENTAL|Glucocorticoid monotherapy Group|Patients treated with single glucocorticoid
62841527|NCT04660565|EXPERIMENTAL|Combination therapy Group|Patients treated with Belimumab and glucocorticoid
62841528|NCT05812313||vocational trainees in health and care professions|
62841529|NCT05812313||vocational educators in health and care professions.|
62841530|NCT00126724|ACTIVE_COMPARATOR|1|1x10\^11 DRP/mL tgAAC94
62841531|NCT00126724|ACTIVE_COMPARATOR|2|1x10\^12 DRP/mL tgAAC94
62841532|NCT00126724|ACTIVE_COMPARATOR|3|1x10\^13 DRP/mL tgAAC94
62841533|NCT00126724|PLACEBO_COMPARATOR|4|
62841534|NCT04683614|EXPERIMENTAL|Fresh frozen plasma|early administration of fresh frozen plasma
62259737|NCT02301182|ACTIVE_COMPARATOR|ADM X3-MoP Cup|THA: ADM dual-mobility hydroxyapatite coated cups with X3TM HXLPE liners on 28mm BIOLOX® delta femoral heads (Stryker) with femoral stems being 2nd generation Accolade stems of the taper lock type, proximal circumferential coated with a 50µm plasma-spray PureFix HA coating to aid the mechanical engagement in bone coating (Stryker)
62259738|NCT02301182|ACTIVE_COMPARATOR|CoC Cup|THA: CoC BIOLOX® delta-delta large-head single-mobility cementless fiber-mesh titanium coated acetabular system from Zimmer (Zimmer TrilogyIT cup/CLS spotorno stem) with a grit-blasted osteophilic titanium alloy CLS® Spotorno femoral stems (Zimmer) that has a three-dimensional wedge shape and sharpened ribs in the proximal region
62259739|NCT02754895|EXPERIMENTAL|PP-weekly|Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per week.
62259740|NCT02754895|EXPERIMENTAL|PP-daily|Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per day.
62259741|NCT02754895|EXPERIMENTAL|Shortened PP-weekly plus MI|Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per week.
62259742|NCT02754895|EXPERIMENTAL|Shortened PP-daily plus MI|Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per day.
62259743|NCT02754895|EXPERIMENTAL|PP-weekly with boosters|"Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per week. Participants will also receive three booster phone calls following the completion of the 8 week intervention."
62259744|NCT02754895|EXPERIMENTAL|PP-daily with boosters|"Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per day. Participants will also receive three booster phone calls following the completion of the 8 week intervention."
62259745|NCT02754895|EXPERIMENTAL|Shortened PP-weekly plus MI + boosters|"Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per week. Participants will also receive three additional booster phone calls following the completion of the 8 week intervention."
62259746|NCT02754895|EXPERIMENTAL|Shortened PP-daily plus MI with boosters|"Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per day. Participants will also receive three additional booster phone calls following the completion of the 8 week intervention."
62841535|NCT04683614|EXPERIMENTAL|Low dose norepinephrine|low dose epinephrine 5 mic/kg/hr
62056644|NCT01848379|ACTIVE_COMPARATOR|Full Mouth Deconatamination(FD)|"FD:~The oral use of topical antiseptics prior and after mechanical tooth debridement, tooth as well as root surface planing and soft tissue decontamination in combination with systemic antibiotics (a combination of amoxicillin and metronidazole - if no microbial resistances were detected)"
62056645|NCT01848379|NO_INTERVENTION|No Treatment|Healthy individuals to be monitored cross-sectional
62259747|NCT04411485||Group of Ankylosing Spondylitis|Patient with ankylosing spondylitis diagnosed by a rheumatologist
62259748|NCT04411485||Group of control|Healthy volunteers of the same age and gender as patients
62259749|NCT05502575|EXPERIMENTAL|Self-monitoring and individualized stress management|Self-monitoring and individualized stress management materials available on a smartphone.
62259750|NCT05502575|ACTIVE_COMPARATOR|Self-monitoring and general stress management|Self-monitoring and general stress management materials available on a smartphone.
62445393|NCT01798745|EXPERIMENTAL|Cohort F: JNJ-54452840 multiple dose|Each patient will receive JNJ-54452840 once daily (for 3 or 5 days) or once weekly (up to Day 22) as determined by the Data Monitoring Committee and as explored in Cohorts C, D, and E (daily dose not exceeding 240 mg).
62445394|NCT01798745|PLACEBO_COMPARATOR|Cohort F: Placebo|Each patient will receive matching placebo once daily (for 3 or 5 days) or once weekly (up to Day 22).
62445395|NCT02404597|EXPERIMENTAL|NICOM|"Subjects with burns greater than 20% total body surface area (TBSA) will have a NICOM placed on them after the first 24 hours of admission if subject has an episode of hypotension (mean arterial pressure \< 65 or a systolic blood pressure \< 90mmHg). The NICOM will generate a number that reflects stroke volume of the heart. If the number is greater than 10 percent, subject will be given a bolus of crystalloid fluids. If the number is less than 10 percent, subject will start a medication to raise the blood pressure.~Physicians may also use traditional endpoints of resuscitation include base deficit values and urine output goals of 0.5cc/kg/hr as indications of adequate intravenous fluid resuscitation."
62445396|NCT02404597|NO_INTERVENTION|Control|This is a retrospective comparison control group of patients with burns greater than 20% total body surface area (TBSA) admitted to the hospital from 7/1/2014-12/31/2014.
62841536|NCT00845117|EXPERIMENTAL|Limbal Stem Cell Transplant|The cornea is debrided of all superficial fibrovascular tissue and the cultivated stem cell graft is glued onto the cornea.
62841537|NCT02747836||Healthy Volunteers|Ultrasound of the wrist
62841538|NCT02747836||Participants with Carpal Tunnel Syndrome|Ultrasound of the wrist
62841539|NCT01919983||Primary Prevention of Sudden Cardiac Death|No intervention will be administered. This is an observational study testing the association of inflammation and cardiac sympathetic innervation using I-123-MIBG gamma scintigraphy
62841540|NCT01964820|EXPERIMENTAL|Positive affect skills intervention|Participants receive a 5-week intervention providing training in 8 skills for generating positive affect.
62841541|NCT01964820|NO_INTERVENTION|Emotion reporting|Participants report emotions on the same regular basis as intervention participants, but receive no intervention.
62841542|NCT05669261|EXPERIMENTAL|ATCell Treatment Group|"A single administration of expanded autologous lines at a total dose exposure of 150 million cells (ATCell™) will be administered to this group."
62841543|NCT05669261|PLACEBO_COMPARATOR|Placebo|a single administration of Placebo (Sham Treatment) IV infusion of Ringers Lactate with 5% Dextrose will be administered to this group.
62056646|NCT04462315||Everolimus Arm|Everolimus Eluting Coronary Stent System
62056647|NCT04462315||Non-drug eluting stent Arm|Cobalt chromium balloon-expandable stent
62056648|NCT06001502|EXPERIMENTAL|Virtual Reality group|Virtual Reality distraction therapy on post-operative days 1,2 and 3.
62056649|NCT06001502|NO_INTERVENTION|Control Group|Conventional post-operative pain and anxiety management
62445397|NCT01641744|EXPERIMENTAL|Group Attachment Based Intervention (GABI)|
62841544|NCT03929380|EXPERIMENTAL|10x10 squat protocol|
62841545|NCT03929380|EXPERIMENTAL|As Fast As Possible 100 squat protocol|
62841546|NCT05453591|EXPERIMENTAL|Sample collection|This is a prospective study in which urine samples will be collected from healthy volunteers and urine samples and a blood sample from cancer patients with breast cancer. The participants will be asked to provide a urine sample collected with the ColliPee® device and fill out an online questionnaire to collect usability data. Thereafter, the urine sample will be aliquoted to be used in the study to investigate the different urinary analytes.
62841547|NCT02817568||Aggressive Periodontitis (case)|Single intervention has been performed for each subject. Peripheral blood sample was obtained in conjunction with clinical measurements in this intervention.(Drawing Blood)
62841548|NCT02817568||Healthy (Control)|Single intervention has been performed for each subject. Peripheral blood sample was obtained in conjunction with clinical measurements in this intervention. (Drawing Blood)
62841549|NCT02050893|EXPERIMENTAL|Midazolam|Midazolam infused at a 0.03mg/kg loading dose ,and 0.02-0.1mg/kg.h maintenance dose to achieve Ramsay score of 4
62841550|NCT02050893|EXPERIMENTAL|Propofol|Propofol infuse at a loading dose of 0.5mg/kg，and 0.5-2.0mg/kg.h maintenance dose to achieve Ramsay score of 4
62841551|NCT02025413|OTHER|Metastatic progressive castration-resistant prostate cancer|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
62841552|NCT02025413|OTHER|Metastatic progressive breast cancer|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
62841553|NCT04239014|EXPERIMENTAL|Arm 1 (ceralasertib+olaparib)|Participants received ceralasertib 160 mg QD PO on Days 1 to 7 plus olaparib 300 mg BD PO continuous (28 day cycle).
62841554|NCT04239014|EXPERIMENTAL|Arm 2 (olaparib monotherapy)|Olaparib 300 mg BD PO daily continuous.
62445398|NCT01641744|ACTIVE_COMPARATOR|Systematic Training for Effective Parenting (STEP)|
62445399|NCT00278200|EXPERIMENTAL|EBV Seronegative|Inactivated EBV-infected vaccine given at Week 0 and Week 4. This arm included all participants who were negative for Epstein-Barr Virus (EBV) at baseline.
62445400|NCT00278200|EXPERIMENTAL|EBV Seropositive|Inactivated EBV-infected vaccine given at Week 0 and Week 4. This arm included all participants who were positive for Epstein-Barr Virus (EBV) at baseline.
62841555|NCT04239014|EXPERIMENTAL|Arm 3 (placebo)|Placebo to match olaparib BD PO daily continuous.
62841556|NCT01847027|ACTIVE_COMPARATOR|Active supplement|NutraStem, 2 tablets daily, Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg).
62841557|NCT01847027|PLACEBO_COMPARATOR|Sugar pill|"The placebo is identical in appearance to the NutraStem® supplement and contains the following ingredients in a Vegi Capsule:~MCC200 DICALCIUM PHOSPHATE BROWN LAKE BLEND (SENSIENT # 09127 ) RED DYE DB-088 (COLORCON) MAGNESIUM STEARATE BLUE #1 ALUM LAKE (POWDER)"
62445401|NCT05522608||patients with postoperative pain|Patients with postoperative pain after transabdominal preperitoneal hernia repair
62445402|NCT05522608||patients without postoperative pain|Patients without postoperative pain after transabdominal preperitoneal hernia repair
62616673|NCT04974606|EXPERIMENTAL|Coffeeberry 100 mg beverage|Appearance-matched to the other beverages
62616674|NCT04974606|EXPERIMENTAL|Coffeeberry 300 mg beverage|Appearance-matched to the other beverages
62841558|NCT03898557|EXPERIMENTAL|Usual Care|"Participants randomized to this arm will receive a card with information to report results via WhatsApp, similar to the existing card used in the STAR program. This card will have a dedicated Usual Care WhatsApp number (different from the existing STAR program numbers).~Potential self-test recipients will be shown the WhatsApp card and instructed on how to anonymously report use of self-test to the WhatsApp number. Recipients will be instructed to message the WhatsApp number for the following reasons:~1. So study staff know the self-test recipients used the test and it went ok. 2. So study staff can help the self-test recipients understand the results of the test. 3. If the self-test recipients need support from study staff to access care and services."
62056650|NCT03319784|ACTIVE_COMPARATOR|Ketorolac (Toradol) Injection Group|Patients will be randomized into two patient groups: Ketorolac (Toradol) injection group (n=30) and or Steroid injection group (n=30). Patients assigned to Ketorolac group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000. Patients will be blinded to the kind of injection they receive, but the physicians who perform the injection will not be blinded for the medical record purposes. The injection will be done under ultrasound guidance to the subacromial space.
62056651|NCT03319784|ACTIVE_COMPARATOR|Steroid Injection Group|Patients will be randomized into two patient groups: Ketorolac (Toradol) injection group (n=30) and or Steroid injection group (n=30). Patients assigned to Steroid group will receive a single dose of 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000. Patients will be blinded to the kind of injection they receive, but the physicians who perform the injection will not be blinded for the medical record purposes. The injection will be done under ultrasound guidance to the subacromial space.
62056652|NCT02301351|OTHER|Graphic Warning Label|Days 5-50: Participants will receive cigarette packs as per the study randomization schema (e.g. three15-day periods of red, gold, and plain packs; order counterbalanced within subject) with FDA-approved graphic warning labels.
62056653|NCT02301351|OTHER|Text Warning Label|Days 5-50: Participants will receive cigarette packs as per the study randomization schema (e.g. three15-day periods of red, gold, and plain packs; order counterbalanced within subject) with standard text warning labels.
62056654|NCT01750879|ACTIVE_COMPARATOR|Peanut Flour|Oral Immunotherapy with peanut flour.
62445403|NCT01127009|EXPERIMENTAL|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11; and mitoxantrone IV, etoposide IV over 1 hour, and intermediate-dose cytarabine IV over 6 hours on days 1-6. Treatment continues in the absence of disease progression or unacceptable toxicity.
62056655|NCT01750879|PLACEBO_COMPARATOR|Oat Flour|Oral Immunotherapy with oat flour.
62616675|NCT04974606|PLACEBO_COMPARATOR|Placebo beverage|Appearance-matched to the other beverages
62616676|NCT04974606|ACTIVE_COMPARATOR|Caffeine 75 mg beverage|Appearance-matched to the other beverages
62616677|NCT00701571|EXPERIMENTAL|1|3 cohorts: 18-21 years, 40-60 years, and older than 60 years
62616678|NCT04344522|EXPERIMENTAL|sequential 2 stage procedure|In this arm , the procedure will be performed in two stages ; the first stage will include performing IOL exchange together with iridoplasty ( if required) and inferior peripheral iridectomy (PI) and the second stage is performing DMEK one month later
62841559|NCT03898557|EXPERIMENTAL|Plan and Pledge|"Participants randomized to this arm will revive the Usual Care WhatsApp card and and a brief template to make a plan and make a pledge for test completion and results reporting, to take the HIV self-test. The card will include a dedicated Plan and Pledge WhatsApp number.~Potential self-tester recipients will be shown the WhatsApp card, including Plan and Pledge statements, and will be encouraged by STAR field staff to use the card in their own time to make a plan and sign the pledge as part of receiving the test kit and instructions for how to complete the card. Importantly, testers will be able to keep the card for themselves. There is no expectation to share the plan or the pledge signature with the STAR field staff who distribute self-tests. Field staff will clarify for self-tests recipients that the Plan and Pledge process and card do not change the confidentiality of testing in any way."
62841560|NCT06355232|EXPERIMENTAL|Covid-19 vaccine group|Subjects in this group will receive two sublingual doses of COVID-19 vaccine two weeks apart. Three months after the second dose they will receive two sublingual doses of influenza vaccine two weeks apart.
62259751|NCT03121911|EXPERIMENTAL|Group 1 - Interval Training (IT)|"All participants will be submitted to several exams of cardiac and pulmonary functions. Then, group 1 (IT) will participate in a physical training program for 12 weeks and will be re-evaluated after this period. After discharge, they will be monitored for an aditional period of 6 months, with returns every two months to measure the energy expenditure (accelerometer). At the end of this period all the tests will be repeated.~Each exercise session will last for 60 minutes and will be divided into three parts as follows: warm up (10 minutes); interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold found in CPET (70%, 80%, 100% and 110%); cooling down (10 minutes)."
62259752|NCT03121911|EXPERIMENTAL|Group 2 - IT + IMT|"All participants will be submitted to the same evaluations before and after training, and 6 months after discharge. Group 2 (IT + inspiratory muscle training (IMT)) will participate in a 12 week physical training program. After discharge, they will be monitored for an aditional period of 6 months, with returns every two months to measure the energy expenditure.~The group 2 will perform the IMT session at the end of the warm-up exercises, prior to the beginning of the IT on a cycloergometer. IMT session consists of 2 series of 12 inspirations with a 60% of MIP. Participant will be asked to inhale quickly and deeply, as quickly as possible, with a 2 minutes interval between series. All the others exercises will be identical between group 1 and 2."
62841561|NCT06355232|EXPERIMENTAL|Influenza vaccine group|Subjects in this group will receive two sublingual doses of influenza vaccine two weeks apart. Three months after the second dose they will receive two sublingual doses of COVID-19 vaccine two weeks apart.
62259753|NCT03121911|NO_INTERVENTION|Group 3 - Absence of rehabilitation|Group 3 (absence of rehabilitation) will be made up of those patients who for any reason do not agree to participate in the rehabilitation program, such as those who do not live in the city, and will remain without intervention. All participants in this group will perform all the evaluations procedures, comprised of: heart rate variability, hematological and biochemical profile, erythrocytes membrane deformability and stability, inflammatory markers, respiratory pressures, plethysmography, spirometry, carbon monoxide diffusion capacity, ankle brachial index, electrical bioimpedance, echocardiogram, quality of life questionnaires (SF-36 and MacNew QLMI), cardiopulmonary exercise testing and constant load tests.
62841562|NCT06355232|EXPERIMENTAL|Combined vaccine group|Subjects in this group will receive two sublingual doses of combined COVID-19 and influenza vaccine two weeks apart. Three months after the second dose they will receive two sublingual doses of placebo vaccine two weeks apart.
62841563|NCT01130935||1|
62841564|NCT05410873|EXPERIMENTAL|MitoQ|Mitoquinol mesylate 40mg daily
62841565|NCT05410873|PLACEBO_COMPARATOR|Placebo|
62841566|NCT05266170||Normal adults|aerobic and anaerobic exercises
62841567|NCT00372593|ACTIVE_COMPARATOR|Arm A: Standard Arm - No GMTZ, AML Pts w/out Down Syndrome|"Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9."
62056656|NCT06229834|EXPERIMENTAL|Chiropractic Care|4 sessions of chiropractic care (6 sessions of chiropractic care over 3 weeks followed by 8 sessions of chiropractic care over 12 weeks); participants will be allowed to continue usual care throughout the study.
62056657|NCT06229834|OTHER|Headache Health Education (HHE)|Participants randomized to Headache Health Education (HHE) will receive 14 interactive 15-minute education sessions delivered via videoconference.
62056658|NCT04149990|ACTIVE_COMPARATOR|Entresto|Combination of valsartan and sacubitril titrated to 103+97 mg B.I.D. for 26 weeks
62056659|NCT04149990|PLACEBO_COMPARATOR|Placebo|Matching placebo B.I.D. for 26 weeks
62841568|NCT00372593|EXPERIMENTAL|Arm B: Experimental - with GMTZ, AML Pts w/out Down Syndrome|Pts receive IT ARA-C at diagnosis or on day 1 of treatment or twice a week for up to six doses. They also receive an infusion of ARA-C on days 1-10; a 6-hr infusion of daunorubicin on days 1, 3, \& 5; a 4-hr infusion of etoposide on days 1-5; and a 2-hr infusion of GMTZ - gemtuzumab ozogamicin (Mylotarg) on day 6. After 3 wks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5. After 3 wks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hr infusion of mitoxantrone hydrochloride on days 3-6. They also receive a 2-hr infusion of gemtuzumab on day 7. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9.
62841569|NCT00372593|ACTIVE_COMPARATOR|Arm A: Standard Arm - No GMTZ, AML Patients with Down Syndrome|"Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9."
62841570|NCT01568242|EXPERIMENTAL|Thermoprobe|Determination of vitreous temperature with a thermoprobe
62841571|NCT01898260|OTHER|BYO Daily, then MyDay|Ultrafilcon B contact lenses, followed by stenfilcon A contact lenses. Each product worn bilaterally for 1 week in a daily wear, daily disposable modality.
62841572|NCT01898260|OTHER|MyDay, then BYO Daily|Stenfilcon A contact lenses, followed by ultrafilcon B contact lenses. Each product worn bilaterally for 1 week in a daily wear, daily disposable modality.
62841573|NCT01638871|EXPERIMENTAL|Intervention Group|Study arm will complete the 8-week Internet-based pain coping skills program.
62841574|NCT01638871|NO_INTERVENTION|Control Group|This study arm will only provide demographic and pain-related information.
62841575|NCT01521403|ACTIVE_COMPARATOR|Metronidazole|Metronidazole 3x500 mg per day for 10 days
62841576|NCT01521403|PLACEBO_COMPARATOR|Placebo|Placebo 3x1 tablet per day for 10 days
62841577|NCT04587661|ACTIVE_COMPARATOR|off-the-shelf digital CBT|standard implementation strategy that has no content or references to SCD, chronic pain, or the unique challenges facing minority groups
62841578|NCT04587661|EXPERIMENTAL|adapted digital CBT|has content or references to SCD, chronic pain, and the unique challenges facing minority groups
62056660|NCT05217095|OTHER|Interventional Group|Each patient will be treated for one session of dialysis after enrolled. Each of them will have only one treatment in the middle of the week (Wednesday or Thursday). The patients will be treated using 4008A dialysis machines in combination with a sidecar and the convergence dialyzer as investigational devices.Each patient will be treated according their regular treatment and laboratory analysis will be taken. The blood level of free hemoglobin ( fHb ) will be taken on 30 min by use of HemoCue device. ACT time will be measured on 15 min and for that 0.5 ml blood from venous line will be taken.
62056661|NCT05634239|EXPERIMENTAL|Health check|
62056662|NCT02044627|EXPERIMENTAL|1 dose of [14C-ETC-1002]|
62259754|NCT05953142|NO_INTERVENTION|Control|Patients in this group will receive the usual treatment according to the Surviving Sepsis Campaign guidelines.
62259755|NCT05953142|EXPERIMENTAL|Dobutamine|Patients in this group will receive, in addition to usual care, dobutamine in continuous infusion for a period of 48 hours after the randomization.
62259756|NCT03959332|EXPERIMENTAL|Baloxavir Marboxil 40 mg|
62445404|NCT03761836|EXPERIMENTAL|ShangRing|Males aged 13 years and above will undergo circumcision through ShangRing procedure, with regular follow-up visits to evaluate pain, wound healing and incidence of adverse events. The ShangRing will be removed after 7 days, with a last follow-up visit at 60 days.
62445405|NCT06422117|EXPERIMENTAL|HSK16149 20mg-40mg bid|Oral administration of 20mg twice daily for 12 weeks can be adjusted to 40mg twice daily based on the efficacy and tolerability of the subject
62445406|NCT06422117|PLACEBO_COMPARATOR|Placebo|Placebo,Oral,2 capsules, twice daily for 12 weeks
62841579|NCT01113866||heart failure|
62841580|NCT02222948|EXPERIMENTAL|Vatelizumab Dose 1|Vatelizumab dose 1 at Weeks 0, 2, 4 and 8
62841581|NCT02222948|EXPERIMENTAL|Vatelizumab Dose 2|Vatelizumab dose 2 at Weeks 0, 2, 4 and 8
62259757|NCT03959332|EXPERIMENTAL|Baloxavir Marboxil 80 mg|
62259758|NCT02441465|EXPERIMENTAL|Vemurafenib|Participants will receive oral vemurafenib BID from Day 1 to Day 28 and a single IV infusion of 14C-labeled vemurafenib on Day 21.
62259759|NCT04945668|OTHER|Pericapsular nerve group block|combined ultrasound and fluoroscopy-guided technique for pericapsular nerve group block
62259760|NCT01733628||Bevacizumab + Chemotherapy|Patients who received the addition of Bevacizumab (BV) every 2-3 weeks to Chemotherapy (CT) with either oxaliplatin or irinotecan plus fluoropyrimidines in patients with Metastatic Colorectal Cancer (MCRC), either paclitaxel or capecitabine in patients with Metastatic Breast Cancer (MBC), as first-line therapy.
62259761|NCT01916876|NO_INTERVENTION|Standard Care|At discharge, patients will be given a discharge plan by their attending caregiver as deemed appropriate.
62259762|NCT01916876|OTHER|Integrative medical follow-up package|"At discharge, patients will receive a discharge plan by their attending caregiver.~Thereafter, if randomised to this study arm they will receive the intervention as outlined elsewhere.~Integrated Medical Follow-up package"
62259763|NCT05970198|ACTIVE_COMPARATOR|Autologous hematopoietic stem cell transplantation|Porting method melphalan: recommended dose of 70 mg/m2/day with 2 consecutive days (days -2 and -1) intravenous (IV) for more than 30 minutes each prior to autologous hematopoietic stem cell transplantation (ASCT, day 0).
62259764|NCT05970198|EXPERIMENTAL|Radiotherapy combined with autologous hematopoietic stem cell transplantation|"TMI radiation dose On the 5th day (-5 days) before transplantation, an irradiation dose of 8 Gy is given.~TMI uses a 6-18MV linear accelerator, the patient lies on his side in a single irradiation field, covered with a 1 cm thick plexiglass frame, and the radioactive source is 4 meters away from the body surface of the human side. The anterior and anterior positions were alternately irradiated, and the horizontal beam was irradiated in the opposite direction, and the actual irradiation dose was detected by the thermo-optical element of the 2570 roentgen dosimeter scale, and the irradiation dose of all parts of the body was adjusted to make the abdominal irradiation dose difference within 10%, the total dose was 8Gy, divided into 2 times a day, with an interval of 5 hours, and the dose rate was 4.99-6.96cGy/min.Porting method melphalan."
62616679|NCT04344522|EXPERIMENTAL|combined single stage procedure|In this arm, both IOL exchange and DMEK will be performed in the same setting
62616680|NCT05363813|EXPERIMENTAL|Laparoscopic Surgical Patients|"1. Adult subjects, male or female, ≥18 years old~2. Subjects who have been scheduled for a laparoscopic surgery using the clip~3. Subjects who had provided written informed consent form~4. Ability and willingness to comply with all study requirements to be evaluated for each study visit"
62616681|NCT00893971|EXPERIMENTAL|1|Inhaled PT001 18 μg
62616682|NCT00893971|EXPERIMENTAL|2|Inhaled PT005 2.4 μg
62616683|NCT00893971|EXPERIMENTAL|3|Inhaled PT003 (PT001 18 μg / 2.4 μg PT005)
62841582|NCT02222948|EXPERIMENTAL|Vatelizumab Dose 3|Vatelizumab dose 3 at Weeks 0, 2, 4 and 8
62259765|NCT06494696||Experimental|
62259766|NCT02216864|EXPERIMENTAL|Multiple Subcision|Subjects will receive multiple subcision treatments to their randomized side of the face 5 times total spaced 4 weeks apart.
62259767|NCT02216864|NO_INTERVENTION|Control|Subjects will receive no intervention control on the other side of the face.
62616684|NCT00893971|EXPERIMENTAL|4|PT001 18 μg + PT005 2.4 μg
62616685|NCT03947775|EXPERIMENTAL|Immediate Vaccination|Administration of dose #1 of 9-valent HPV vaccination will be given at baseline visit, dose #2 at month 2, and dose #3 at month 6.
62841583|NCT02222948|EXPERIMENTAL|Vatelizumab Dose 4|Vatelizumab dose 4 at Weeks 0, 2, 4 and 8
62841584|NCT02222948|PLACEBO_COMPARATOR|Placebo|Placebo (for Vatelizumab) at Weeks 0, 2, 4 and 8
62841585|NCT00649909||Observation|Type 2 diabetic patients with reduced laboratory response to aspirin.(Aspirin Resistance)and with HbA1c \>8%.
62841586|NCT01955148||Prior sPTB or PROM|Women who have had a previous delivery of a live born singleton between 20 weeks, 0 days and 36 weeks, 6 days due to spontaneous preterm premature labor or preterm rupture of fetal membranes
62841587|NCT01955148||Short cervical length|Short cervical length (≤25 mm) determined by transvaginal ultrasound
62841588|NCT01955148||Twin Pregnancy|Current twin pregnancy
62259768|NCT02745587|EXPERIMENTAL|Prostate(bed) only|external beam radiotherapy limited to the prostate(bed)
62259769|NCT02745587|ACTIVE_COMPARATOR|Prostate(bed) and pelvis|external beam radiotherapy to the prostate(bed) and pelvic lymph node regions
62259770|NCT04716452|EXPERIMENTAL|Open Label Administration of Ceramide NanoLiposome|Ceramide NanoLiposome will be administered by Intravenous Dosing twice per week in accordance with the protocol relative to dose escalation. There is no placebo group or arm of the study.
62445407|NCT00482313|EXPERIMENTAL|Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
62445408|NCT00482313|PLACEBO_COMPARATOR|Sugar pill|Placebo given orally once daily for 5 weeks.
62445409|NCT03613350||Urodynamic stress incontinence|Urodynamic study incontinence Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.
62616686|NCT03947775|ACTIVE_COMPARATOR|Delayed Vaccination|Administration of dose #1 of 9-valent HPV vaccination will be given at month 12, dose #2 at month 14, and dose #3 at month 18.
62616687|NCT04505306|ACTIVE_COMPARATOR|Subthreshold Laser 30%|Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with 30% EndPoint algorithm.
62616688|NCT04505306|ACTIVE_COMPARATOR|Subtreshold Laser 50%|Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with 50% EndPoint algorithm.
62841589|NCT01955148||Prior cervicdal surgeries|Cervical cerclage in a prior pregnancy or prior cone biopsy or prior LEEP
62841590|NCT02817009|NO_INTERVENTION|Nutrition Group|This group will go through standard of care and visit the nutritionist on a monthly basis for the three months that they are a part of the study.
62056663|NCT05873543|EXPERIMENTAL|smartphone-assisted hybrid cardiac rehabilitation (SHCR)|Participants receive a 12-wk case manager-led smartphone-assisted hybrid cardiac rehabilitation with follow-up at 12 week and 6 months.
62259771|NCT03641963|EXPERIMENTAL|Stroke patients with ICP measurement|All patients with the possibility to evolve a malignant MCA infarct according to the initial assessment, will be included in our study, to measure ICP non-invasive. The ICP will be measured non-invasive with the Vittamed 205 Non-invasive intracranial pressure (ICP) meter.
62841591|NCT02817009|EXPERIMENTAL|Healthy Families Group|Participants and their families will attend a weekly nutrition session, social support session and physical activity session for 12 weeks.
62841592|NCT03125616|ACTIVE_COMPARATOR|Standard UK 4CMenB vaccine|4CMenB (Bexsero®) vaccination at 2 and 4 months and a booster at 12 months .
62841593|NCT03125616|EXPERIMENTAL|Additional 4CMenB Vaccine|4CMenB (Bexsero®) vaccination at 2, 3 and 4 months and a booster at 12 months.
62841594|NCT04752904|EXPERIMENTAL|ClearSight group|Non-invasive, continuous blood pressure is monitored using ClearSight Sytem, with a finger cuff around the middle finger, and the anesthesiologist manages blood pressure based on this.
62841595|NCT04752904|NO_INTERVENTION|Control group|The blood pressure is measured at 1-minute intervals by non-invasive blood pressure monitor using the arm cuff, and the anesthesiologist in charge manages the blood pressure based on the measured blood pressure.
62841596|NCT06445985|NO_INTERVENTION|Control|Participants will have a 12 week period where they will continue with their habitual physical activity behaviour. Diet and physical activity will be monitored
62841597|NCT06445985|ACTIVE_COMPARATOR|Hydrotherapy|Participants will complete 12-weeks of hydrotherapy, involving up to 60 mins of hydrotherapy once a week. Diet and physical activity will be monitored.
62841598|NCT02386644|EXPERIMENTAL|Suspected Membrane Rupture Arm|Women with suspected membrane rupture will be subject to following interventions; Ultrasound amniotic fluid index measurement, ultrasound transperineal assessment, nitrazine test, speculum examination, PAMG-1 Immunoassay
62841599|NCT05480267|EXPERIMENTAL|UBE|The patient treated with unilateral biportal endoscopy (UBE)
62841600|NCT05480267|ACTIVE_COMPARATOR|MIS-TLIF|The patient treated with classical minimally invasive posterior spinal interbody fusion (MIS-TLIF)
62841601|NCT02112071|EXPERIMENTAL|Exercise|blended supervised-hombased exercise training 3-4 times/week for 12 weeks
62841602|NCT02112071|NO_INTERVENTION|control|control group asked to continue usual activities
62841603|NCT05631483|EXPERIMENTAL|DAISe|DAISe Thrombectomy Device
62841604|NCT01576809|EXPERIMENTAL|Upper Respiratory Tract Infection|
62841605|NCT04410952||no EES|Patients with a Type-C pelvic ring fracture who underwent no external emergency stabilization (EES) for the posterior pelvic ring
62841606|NCT04410952||Pelvic binder|Patients with a Type-C pelvic ring fracture who received a pelvic binder for emergency stabilization of the posterior pelvic ring
62841607|NCT04410952||Pelvic C-clamp|Patients with a Type-C pelvic ring fracture who received a pelvic C-clamp for emergency stabilization of the posterior pelvic ring
62841608|NCT00993330||1|20 healthy subjects between 18 and 40 years
62841609|NCT00993330||2|20 healthy subjects between 41 and 50 years
62056664|NCT05873543|NO_INTERVENTION|Usual care|Participants receive usual care including general education and exercise suggestion.
62056665|NCT00946335|EXPERIMENTAL|Treatment (veliparib, temozolomide)|"Patients receive oral ABT-888 twice daily and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for 13-26 courses in the absence of disease progression or unacceptable toxicity.~Blood samples are collected for pharmacokinetics and further laboratory analysis."
62056666|NCT00286117|EXPERIMENTAL|1|Anastrozole
62056667|NCT00286117|ACTIVE_COMPARATOR|2|Tamoxifen
62841610|NCT00993330||3|20 healthy subjects between 51 and 60 years
62056668|NCT05809713|EXPERIMENTAL|Technology enabled Team Care|Ongoing Team-based, Pharmacist led telephonic management of uncontrolled high blood pressure involving cellular-enabled home BP monitoring, medications, diet and exercise, and referral for social problems
62259772|NCT05515250|OTHER|Patient open label intervention arm|
62259773|NCT00019708|EXPERIMENTAL|Treatment (tanespimycin)|Patients will receive infusions of tanespimycin analogue twice a week in weeks 1 and 3.
62259774|NCT02340585|EXPERIMENTAL|Next Generation Neuroform Stent System|The Next Generation Stent System is a self-expanding, open cell, nitinol stent designed to provide support of the coil mass within the aneurysm and minimize stent deflection.
62259775|NCT06540781|EXPERIMENTAL|Intervention Group|The intervention group will receive one session of WCT. Before, during and after the WCT application cerebral oxygenation levels will be measured by NIRS device.
62841611|NCT00993330||4|20 healthy subjects between 61 and 70 years
62841612|NCT00993330||5|20 healthy subjects between 71 and 80 years
62841613|NCT00993330||6|20 healthy subjects between 81 and 90 years
62841614|NCT03674905|OTHER|Intra-articular injection|Intra-articular injection at the completion of TAA procedure.
62841615|NCT03674905|OTHER|Peripheral nerve block|Pre-operative peripheral nerve block.
62841616|NCT05021068||COPD Patients|"The respiratory functions of the participants will be measured in accordance with the ATS-ERS criteria. After measurement; forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC, total lung capacity (TLC), residual volume (RV), inspiratory capacity (IC), vital capacity (VC) parameters will be recorded.~Spinal structure and mobility will be evaluated with the Spinal Mouse device in the sagittal and frontal planes in standing and sitting positions. For the sagittal plane, the measurements were first in the neutral, then in the maximum flexion and extension positions, for the frontal plane; neutral, right and left lateral flexions will be performed.~Patients will be asked to mark the level of activity that causes dyspnea on the Medical Council Research Scale (MMRC) Dyspnea Score."
62841617|NCT05021068||Control Group|"The respiratory functions of the participants will be measured in accordance with the ATS-ERS criteria. After measurement; forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC, total lung capacity (TLC), residual volume (RV), inspiratory capacity (IC), vital capacity (VC) parameters will be recorded.~Spinal structure and mobility will be evaluated with the Spinal Mouse device in the sagittal and frontal planes in standing and sitting positions. For the sagittal plane, the measurements were first in the neutral, then in the maximum flexion and extension positions, for the frontal plane; neutral, right and left lateral flexions will be performed.~Patients will be asked to mark the level of activity that causes dyspnea on the Medical Council Research Scale (MMRC) Dyspnea Score."
62841618|NCT03646461|EXPERIMENTAL|Arm A: Ibrutinib + Cetuximab|Ibrutinib 560mg PO daily (Imbruvica) PLUS Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
62056669|NCT05809713|ACTIVE_COMPARATOR|Enhanced Usual Care|Home BP monitoring device provided along with BP log, basic diet and exercise instruction, and care provided by the patient's usual doctor/provider
62056670|NCT03091686|EXPERIMENTAL|Experimental Group (HAPA SB)|"Experimental (same outcome questionnaire but with informational slideshow focusing on sedentary behaviour and diabetes risk)~HAPA SB Intervention Slideshow"
62056671|NCT03091686|ACTIVE_COMPARATOR|Attention-Control Group (HAPA MVPA)|"Attention-Control (same outcome questionnaire but with slideshow focusing on benefits of moderate-vigorous physical activity)~HAPA MVPA Intervention Slideshow"
62056672|NCT03091686|NO_INTERVENTION|Control Group|"Control (outcome questionnaire without any slideshow)~Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaire."
62056673|NCT00446069|EXPERIMENTAL|Egalet® morphine|
62056674|NCT00446069|ACTIVE_COMPARATOR|MST Continus®|
62259776|NCT05654597||Participants aged 40 or more, without diagnosis of COPD or asthma|Men and women attending aged 40 or more, without previous diagnosis of chronic obstructive pulmonary disease or asthma.
62259777|NCT05896254|EXPERIMENTAL|MAR001|Subcutaneous injection
62259778|NCT05896254|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection
62259779|NCT04648605|EXPERIMENTAL|Questionary|Questionary for all parents
62259780|NCT02088112|EXPERIMENTAL|Escalation|MEDI4736 will be combined with gefitinib to assess safety and tolerability
62616689|NCT04505306|ACTIVE_COMPARATOR|Micropulse Laser|Patients in the STMP group were treated with the 810-nm diode micropulse scanning laser TxCell™ (IRIDEX Corporation, Mountain View, CA, USA) at 15% duty cycle.
62841619|NCT03646461|EXPERIMENTAL|Arm B: Ibrutinib + Nivolumab|Ibrutinib 560mg PO daily (Imbruvica) PLUS Nivolumab 3mg/kg biweekly 28 day cycle
62841620|NCT03692299|ACTIVE_COMPARATOR|Saccaromyces boulardii oral tablet|Saccharomyces boulardii Oral Tablet 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
62841621|NCT03692299|ACTIVE_COMPARATOR|Metronidazole plus S. boulardii|Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months.
62841622|NCT03692299|ACTIVE_COMPARATOR|Metronidazole|Metronidazole 500 mg b.i.d during 1 week, plus Saccharomyces boulardii 200 mg b.i.d. during 1 week, follow for only Saccharomyces 200 mg b.i.d. for one another week, 2-week rest period and then this regimen is repeated for two consecutive months.
62841623|NCT00522769|ACTIVE_COMPARATOR|Delayed Intervention|1/2 of participants are randomized to immediate intervention that starts within a week of randomization. The other 1/2 of the participants are randomized to delayed intervention which starts 6 months after randomization.
62841624|NCT00522769|EXPERIMENTAL|Immediate intervention|Immediate intervention starts within two weeks of randomization. Delayed interventions starts 6 months after randomization.
62841625|NCT04988581|EXPERIMENTAL|Intensively Integrated Care of Microvascular Risk Factors|intensively integrated care of microvascular risk factors (glycated hemoglobin \[HbA1C\], urinary albumin-to-creatinine ratio \[ACR\], blood pressure \[BP\], estimated glomerular filtration rate \[eGFR\], uric acid \[UA\] and low-density lipoprotein cholesterol \[LDL\])
62841626|NCT04988581|NO_INTERVENTION|Usual Care of Microvascular Risk Factors|Usual care among patients with diabetes
62841627|NCT01776580||Lower urinary tract symptoms|Women with lower urinary tract symptoms
62841628|NCT04669444|EXPERIMENTAL|Low Driving Pressure Protocol|The patients ventilator driving pressure will be decreased (as tolerated by the patient) for 2 hours while on extracorporeal membrane oxygenation (ECMO) support.
62259781|NCT02088112|EXPERIMENTAL|Expansion Arm|MEDI4736 will be combined with gefitinib
62616690|NCT01051726|EXPERIMENTAL|Aromatherapy group 1|Participants will be given essential oil consisting of (Peppermint, Lavender, Clary Sage and Frankincense) together with a swab to put the oil on.
62616691|NCT01051726|PLACEBO_COMPARATOR|Control group 2|Participants receive a bottle of non essential oil and a swab.
62616692|NCT01051726|NO_INTERVENTION|Control group 3|Standard maternity care to measure baseline.
62841629|NCT02386540|EXPERIMENTAL|Health Coaching|Patients randomized to the experimental arm receive six months of post-ED health coaching from the Alameda County Health Coach Program (ACHCP) in addition to usual care in the emergency department at enrollment.
62841630|NCT02386540|NO_INTERVENTION|Usual Care|Patients randomized to the control arm receive usual care in the emergency department at enrollment.
62056675|NCT01908465|ACTIVE_COMPARATOR|Ebastine|Ebastine
62616693|NCT03825185|EXPERIMENTAL|Transcervical Thymectomy|50 patients were randomized to transcervical thymectomy for treatment of myasthenia gravis.
62616694|NCT03825185|EXPERIMENTAL|TranssternalThymectomy|50 patients were randomized to transternal thymectomy for treatment of myasthenia gravis.
62841631|NCT06516094|EXPERIMENTAL|Celecoxib+Pregabalin+Vitamin B(thiamine mononitrate/pyridoxone hydrochloride/cyanocobalamin)+Placebo|Administered orally, 1 tablet + 1 capsule a day, for 3 months.
62056676|NCT01908465|PLACEBO_COMPARATOR|placebo|Placebo
62616695|NCT02703896|PLACEBO_COMPARATOR|Group C (placebo)|"Drug intervention Two doses of Placebo at 8.00 pm and then at 6.00 am~1. Group C (placebo)~2. Group C (placebo)~3. Group C (placebo)~4. Group C (placebo)~5. Group C (placebo)~6. Group C (placebo)~7. Group C (placebo)~8. Group C (placebo)~9. Group C (placebo)~10. Group C (placebo)"
62056677|NCT00666432||1|Controls
62056678|NCT00666432||2|Patient Family
62056679|NCT00666432||3|Patients
62056680|NCT03224221|EXPERIMENTAL|Apatinib with Chemotherapy|Apatinib with Chemotherapy(Fluorouracil and platinum)，patients will receive Apatinib at 500mg/times,oral one times daily for 28 days.the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
62056681|NCT03224221|ACTIVE_COMPARATOR|Chemotherapy|Chemotherapy (Fluorouracil and platinum)，the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients.
62056682|NCT05514080|OTHER|Insulin alone closed-loop|
62056683|NCT01106053|EXPERIMENTAL|Pramipexole|Open-label trial of pramipexole.
62056684|NCT03899168|EXPERIMENTAL|Social Tag Popularity|Popularity of Social Tags (antidepressants more popular vs. psychotherapy more popular)
62056685|NCT03899168|EXPERIMENTAL|Confidence in Prior Attitudes|Confidence in prior attitudes (high vs. low: recalling situations in which participants were confident or uncertain about their thoughts)
62056686|NCT03899168|EXPERIMENTAL|Source Credibility|Credibility of the source (tagging community: experts - many years of professional experience vs. novices - students in the first semester)
62259782|NCT05241392|EXPERIMENTAL|CAR-T cell therapy|"Dose-escalation phase:~A 3+3 dose-escalation design is used to determine MTD \& R2PD. Anti-B7-H3 autologous CAR-T cells were given biweekly to patients at the following doses for each cycle, and 4 cycles as one course. Dose1: 3 patients at a dose of 20 million cells for each cycle. Dose 2: 3 patients at a dose of 60 million cells for each cycle. Dose 3: 3 patients at a dose of 150 million cells for each cycle. Dose 4: 3 patients at a dose of 450 million cells for each cycle. Dose 5: 3 patients at a dose of 900 million cells for each cycle.~R2PD confirmation phase:~Determine the R2PD based on the results from the previous dose-escalation study; Treat another 12 patients with anti-B7-H3 autologous CAR-T cells biweekly at the R2PD to further confirm the safety of R2PD.~At each dose phase, if the patients show tolerate and response to the treatment, these patients would receive several courses of treatment at PI's discretion."
62616696|NCT02703896|ACTIVE_COMPARATOR|Either PPIs or H2RAs|"Drug Intervention Two doses at 8.00 pm and then at 6.00 am~1. Group L (lansoprazole 15 mg)~2. Group E(esomeprazole 20 mg)~3. Group P (pantoprazole 20 mg)~4. Group R (rabeprazole 10 mg)~5. Group O (omeprazole 20 mg)~6. Group T (cimetidine 200 mg)~7. Group F (famotidine 20 mg)~8. Group N (nizatidine 150 mg)~9. Group Z (ranitidine 150 mg)~10. Group S (lafutidine 10 mg)"
62616697|NCT02703896|ACTIVE_COMPARATOR|Either PPIs or H2RAs+prokinetics|"Drug intervention Two doses at 8.00 pm and then at 6.00 am~1. Group L D (lansoprazole 15 mg+ domperidone 10 mg)~2. Group EM (esomeprazole 20 mg+metoclopramide 10 mg)~3. Group PD (pantoprazole 20 mg+domperidone 10)~4. Group RM (rabeprazole 10 mg+metoclopramide 10 mg)~5. Group OD (omeprazole 20 mg+domperidone 10)~6. Group TD (cimetidine 200 mg+domperidone 10)~7. Group FM (famotidine 20 mg+metoclopramide 10 mg)~8. Group NM (nizatidine 150 mg+metoclopramide 10 mg)~9. Group ZD (ranitidine 150 mg+ domperidone 10 mg)~10. Group SD (lafutidine 10 mg+domperidone 10 mg)"
62841632|NCT06516094|ACTIVE_COMPARATOR|Celecoxib + Vitamin B (thiamine mononitrate/ pyridoxone hydrochloride/ cyanocobalamin)|Administered orally, 1 capsule + 1 tablet a day, for 3 months
62841633|NCT06516094|ACTIVE_COMPARATOR|Pregabalin + Vitamin B (thiamine mononitrate/ pyridoxone hydrochloride/ cyanocobalamin)|Administered orally, 1 capsule + 1 tablet a day, for 3 months
62056687|NCT02946840||Solid pancreatic masses|Consecutive patients with solid pancreatic masses, submitted to FNA with 25 G Beacon needle (Medtronic, Newton, MA, USA)
62056688|NCT05322525|EXPERIMENTAL|ON101 Cream|"Single arm of VLU group for ON101 Cream~Test drug:~1. Name: ON101~2. Dosage form: Topical cream~3. Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica~4. Dose(s): Apply 1 cc per 5 cm2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day"
62056689|NCT00724464||Participants with Chronic Hepatitis C|Treatment-naïve participants with chronic hepatitis C, undergoing treatment with a standard treatment regimen of PegIntron and Rebetol in clinical practice at approximately 28 sites in Greece
62056690|NCT04751422||Observational (data collection)|Patients' medical data is collected retrospectively.
62056691|NCT03299686|EXPERIMENTAL|CJM112|Study treatment
62056692|NCT03299686|PLACEBO_COMPARATOR|Placebo to CJM112|Placebo
62056693|NCT06468033|EXPERIMENTAL|Ropeginterferon alfa-2b (P1101)|Ropeginterferon alfa-2b (P1101) is administrated subcutaneously (SC) every two weeks (± 3 days) until 80 weeks.
62056694|NCT06468033|PLACEBO_COMPARATOR|Placebo control|Placebo is administrated subcutaneously (SC) every two weeks (± 3 days) until 80 weeks.
62056695|NCT06510725|EXPERIMENTAL|Mutitarget tDCS|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to DLPFC and M1 alternately for ten consecutive weekdays, with each target stimulated for 5 sessions.
62056696|NCT06510725|EXPERIMENTAL|Single-target tDCS|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to M1 for ten consecutive weekdays.
62056697|NCT06510725|SHAM_COMPARATOR|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation. Ramps up and down will be applied for 15 seconds each at the beginning and end of the session. The current will be 0 mA during the interval between the initial and final ramps. Subjects will undergo stimulation once a day for ten consecutive weekdays.
62056698|NCT01780935|EXPERIMENTAL|RBZ 0.5 mg: VA only (Group I)|RBZ 0.5 mg: Visual Acuity (VA) only (Group I) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA) loss due to neovascular (wet) age-related macular degeneration (nAMD)
62841634|NCT05677113|EXPERIMENTAL|QBECO|QBECO is an SSI formulated from inactivated E. coli bacteria that is specifically designed to target pathologies of the gastrointestinal (GI) tract and related organs, such as the liver. This trial will test the hypothesis that in patients undergoing resection of colorectal liver metastases (CRLMs), perioperative treatment with QBECO will attenuate the postoperative immune suppression and will improve progression-free survival (PFS).
62841635|NCT05677113|PLACEBO_COMPARATOR|Placebo|A placebo is a liquid that looks like the study drug, but contains no medication.
62616698|NCT02703896|ACTIVE_COMPARATOR|Either PPIs or H2RAs+Prokinetic|Drug intervention Two doses at 8.00 pm and then at 6.00 am Group OM (omeprazole 20 mg +metoclopramide 10 mg) Group SM (lafutidine 10 mg + metoclopramide 10 mg )
62616699|NCT02703896|OTHER|Intervention Orogastric intubation|After general anesthesia, an oro-gastric tube was inserted through another endotracheal tube placed in upper esophagus into the stomach for aspiration of gastric contents.
62841636|NCT00773214|EXPERIMENTAL|exercise|
62056699|NCT01780935|EXPERIMENTAL|RBZ 0.5 mg: VA and/or OCT (Group II)|RBZ 0.5 mg: VA and/or OCT (Group II) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA)loss due to neovascular (wet) age-related macular degeneration (nAMD) and/or signs of wet AMD disease activity on optical coherence tomography (OCT).
62616700|NCT01941251|ACTIVE_COMPARATOR|Navigated individualized αTMS|navigated Transcranial Magnetic Stimulation
62841637|NCT03307876||groups that are fac + and -|autologous PPP injection is given to all patients. Prior to injection, a lavage of the disc space is taken to test for FAC.
62259783|NCT02988453|EXPERIMENTAL|MBT-CD|Mentalization-based treatment program
62259784|NCT01432873|EXPERIMENTAL|Experimental|Oral selenium therapy arm
62616701|NCT01941251|SHAM_COMPARATOR|Sham TMS|navigated Transcranial Magnetic Stimulation using sham coil
62841638|NCT01750229|SHAM_COMPARATOR|Sham|Frequency Setting - Sham
62841639|NCT01750229|EXPERIMENTAL|1200 Hz|Frequency Setting - 1200 Hz
62841640|NCT01750229|EXPERIMENTAL|3030 Hz|Frequency Setting - 3030 Hz
62841641|NCT01750229|EXPERIMENTAL|5882 Hz|Frequency Setting - 5882 Hz
62841642|NCT02124993||Sleeve gastrectomy surgery Participants|Male or female who will undergo a sleeve gastrectomy for obesity by Dr. Drake Bellanger.
62841643|NCT01885598||Nonvalvular Atrial Fibrillation patients with risk of Stroke|Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release
62056700|NCT00595504|EXPERIMENTAL|1|Ramelteon 8mg/day
62259785|NCT01432873|PLACEBO_COMPARATOR|Placebo|Oral placebo
62616702|NCT03529708|EXPERIMENTAL|SBRT boost|Standard radiotherapy (3D conformal, urgent palliative radiotherapy) plus stereotactic body radiotherapy (SBRT) boost
62616703|NCT05396352|EXPERIMENTAL|Right cerebellum|Participants (neurotypical, autistic) in this arm will receive tDCS targeting the right posterolateral cerebellum (lobule VII). All participants will receive anodal, cathodal and sham tDCS.
62616704|NCT05396352|EXPERIMENTAL|Posterior vermis|Participants (neurotypical, autistic) in this arm will receive tDCS targeting the posterior cerebellar vermis. All participants will receive anodal, cathodal and sham tDCS.
62616705|NCT00755950|EXPERIMENTAL|1|280 mg of Silymarin administered three times daily for 4 weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
62616706|NCT00755950|PLACEBO_COMPARATOR|3|Placebo: Lactose monohydrate; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
62616707|NCT00755950|EXPERIMENTAL|2.|420 mg silymarin three times daily for four weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
62616708|NCT02242019|EXPERIMENTAL|Erchonia LUNULA|The Erchonia LUNULA emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
62616709|NCT01997996||PROLIFT+M|Patients that undergo surgery due to prolapse POP ≥ stage II with PROLIFT+M device having had ≥ 2x/4 weeks sexual intercourse before surgery.
62841644|NCT04752241|EXPERIMENTAL|IMAP|Inferior Mesenteric Artery Preservation Performing left hemicolectomy and anterior rectal resection the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
62841645|NCT04752241|ACTIVE_COMPARATOR|IMAS|Inferior Mesenteric Artery Ligation Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
62056701|NCT00595504|PLACEBO_COMPARATOR|2|sugar pill
62056702|NCT03243162|EXPERIMENTAL|CBPT-ACLR|CBPT-ACLR program consisting of weekly phone calls.
62056703|NCT03243162|ACTIVE_COMPARATOR|Education|Education program consisting of weekly phone calls.
62056704|NCT02076984|OTHER|Group A|laparoscopic incisional or ventral hernia repair use of lightweight polypropylene mesh fixed by titanium tacks
62259786|NCT06096402||anterior gastropexy, no fundoplication|patients with indication of operative management of a paraesophageal hernia
62259787|NCT06096402||anterior gastropexy and fundoplication|patients with indication of operative management of a paraesophageal hernia
62259788|NCT01545479|OTHER|Captopril 25mg|To study the renal blood oxygenation, the subjects took captopril (25mg).
62259789|NCT01870427|EXPERIMENTAL|Aflibercept (2.0 mg)|Intravitreal Aflibercept (2.0 mg)
62259790|NCT02068742|EXPERIMENTAL|General Anesthesia patients battery neuropsychological tests|Mini Mental State Examination, Geriatric Index of Comorbidity, Geriatric Depression Scale, Trail Making Test B-A, Digit Span, Digit Symbol Substitution Test Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
62616710|NCT03688802|ACTIVE_COMPARATOR|OC-01 (varenicline) nasal spray, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/mL, one time dosing
62841646|NCT00495248|EXPERIMENTAL|1|
62841647|NCT00495248|ACTIVE_COMPARATOR|2|
62841648|NCT05317741|EXPERIMENTAL|A mg IA-14069 or Placebo|
62841649|NCT05317741|EXPERIMENTAL|B mg IA-14069 or Placebo|
62841650|NCT05317741|EXPERIMENTAL|C mg IA-14069 or Placebo|Period 1: Fasted condition → Period 2: Fed condition
62841651|NCT05317741|EXPERIMENTAL|D mg IA-14069 or Placebo|
62841652|NCT05317741|EXPERIMENTAL|E mg IA-14069 or Placebo|
62841653|NCT05166200|EXPERIMENTAL|Experimental Formula|One 237 ml serving of study product
62841654|NCT05166200|ACTIVE_COMPARATOR|Test Meal|48 g Instant oatmeal
62259791|NCT02068742|ACTIVE_COMPARATOR|Regular recovery patients|Mini Mental State Examination, Geriatric Index of Comorbidity, Geriatric Depression Scale, Trail Making Test B-A, Digit Span, Digit Symbol Substitution Test Application of the scores will be on the day 0 (the day after the hospital admission), day 2 and day 4 (days after the hospital admission).
62616711|NCT03688802|PLACEBO_COMPARATOR|Placebo (vehicle control) nasal spray|Placebo (vehicle control) nasal spray, one time dosing
62841655|NCT05644522|EXPERIMENTAL|Group A|Group A receives the intervention Nomad KAFO first; fitting \& training will occur with the intervention and will then be used for a 3 month home trial, followed by outcomes testing. Group A then will cross over and train with their own Traditional Assistive Device and will then use their own device for a 3 month home trial, followed by outcomes testing.
62841656|NCT05644522|ACTIVE_COMPARATOR|Group B|Group B receives training in their own Traditional Assistive Device first; training will occur with their own Traditional Assistive Device and will then use their own device for a 3 month home trial, followed by outcomes testing. Group B then will cross over and receive the intervention Nomad KAFO; fitting \& training will occur with the intervention and will then be used for a 3 month home trial, followed by outcomes testing.
62841657|NCT04673019|EXPERIMENTAL|Immediate Intervention|"The immediate intervention group will receive the intervention at the time of consent (baseline) and will be enrolled in the intervention for a total of 6 months:~* Months 1- 3 (Approximately Day 1-Day 90)~  * Participant will receive the Echo Show, a pedometer (to track their steps) and an exercise band (to complete the exercise interventions).~ * Use of Nurse AMIE while receiving intervention phone calls from a study facilitator. We are interested in learning whether the phone calls are necessary or if the Nurse AMIE platform can stand alone and see the same effect.~* Months 4-6 (Approximately Day 91-180) o Participant will continue to use Nurse AMIE, but without phone calls from study facilitator"
62841658|NCT04673019|OTHER|Delayed Intervention|"The delayed intervention group will receive the intervention 3 months after consent (3 months of no intervention followed by with 3 months of intervention, for a total of 6 months); the participant will follow the pattern listed below:~* Months 1- 3 Approximately (Day 1-Day 90)~  o No use of Nurse AMIE~* Months 4-6 (Approximately Day 91-180)~  * Participant will receive the Echo Show, a pedometer (to track their steps) and an exercise band (to complete the exercise interventions).~ * Use of Nurse AMIE while receiving intervention phone calls from a study facilitator"
62841659|NCT02964169|EXPERIMENTAL|Family Planning Support|Family planning voucher and phone reminders
62841660|NCT02964169|NO_INTERVENTION|No Family Planning Support|Routine care
62841661|NCT03751930||Patients with Autism Spectre Disorders|Taken biological samples on patients with Autism Spectre Disorders
62841662|NCT03751930||Healthy volunteers|Taken biological samples on patients healthy volunteers
62841663|NCT06146361|EXPERIMENTAL|COVID-19 Group Problem Solving|
62841664|NCT06146361|ACTIVE_COMPARATOR|Standard of Care|
62841665|NCT06146361|EXPERIMENTAL|Group Problem Solving Plus Booster Session|
62056705|NCT02076984|OTHER|Group B|laparoscopic incisional or ventral hernia repair use of lightweight polypropylene mesh fixed by U shaped absorbable tacks
62259792|NCT02866279|EXPERIMENTAL|Postplacental|contraceptive implant placed within 30 minutes of placental delivery
62616712|NCT00423813|PLACEBO_COMPARATOR|1|
62616713|NCT00423813|EXPERIMENTAL|2|
62616714|NCT04418089|EXPERIMENTAL|Simvastatin|The group received standard treatment with the oral administration of Simvastatin
62259793|NCT02866279|EXPERIMENTAL|Immediate Postpartum|Contraceptive Implant placed 1-3 days postpartum
62259794|NCT02866279|ACTIVE_COMPARATOR|Delayed|Contraceptive Implant placed 6 or more weeks postpartum
62616715|NCT04418089|EXPERIMENTAL|Placebo|The group received standard treatment with the oral administration of Placebo
62616716|NCT01017757||Renal transplant patients|
62616717|NCT03518398|EXPERIMENTAL|IPL group|IPL 9-13 J/cm2 according to Fitzpatrick's skin type on day 0, 15, 45
62616718|NCT03518398|SHAM_COMPARATOR|sham-IPL group|IPL 0 J/cm2 according to Fitzpatrick's skin type on day 0, 15, 45
62259795|NCT02113436|EXPERIMENTAL|Fluticasone propionate (FP)/ Salmeterol xinafoate (SLM)|Subject will receive 1 or 2 inhalation of SLM 25mcg plus FP 50mcg twice daily in the first treatment period for 8 weeks and will continue to receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.
62259796|NCT02113436|ACTIVE_COMPARATOR|Fluticasone propionate (FP)|Subject will receive 1 or 2 inhalation of FP 50mcg twice daily in the first treatment period for 8 weeks and will receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.
62259797|NCT04967300||First Visit|Children who visit dentist at first time
62259798|NCT04967300||Second Visit|Children who visit dentist at second time
62259799|NCT02877368||gastrointestinal stromal tumours|Patients with advanced or high-risk resected gastrointestinal stromal tumours (GIST) .
62259800|NCT00428909|OTHER|Drug-Drug interaction|
62616719|NCT01900899|EXPERIMENTAL|ACWY-TT group|Subjects primed and boosted with the MenACWY-TT vaccine.
62616720|NCT01900899|ACTIVE_COMPARATOR|MenCCRM group|Subjects primed and boosted with the Meningitec vaccine.
62841666|NCT04163211||Group 1|Patients with complicated appendicitis who had a drain inserted
62841667|NCT04163211||Group 2|Patients with complicated appendicitis who did not have a drain inserted
62841668|NCT01469377|PLACEBO_COMPARATOR|Placebo|Participants received placebo orally once a day for 8 weeks. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
62841669|NCT01469377|EXPERIMENTAL|Cariprazine 1-2 mg|Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2 and 1.0 mg on Days 3-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 1.0 or 1.5 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 1.0, 1.5, or 2.0 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
62841670|NCT01469377|EXPERIMENTAL|Cariprazine 2-4.5 mg|Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2, 1.0 mg on Day 3, 1.5 mg on Day 4, and 2.0 mg on Days 5-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 2.0 or 3.0 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 2.0, 3.0, or 4.5 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
62841671|NCT03532867|EXPERIMENTAL|Healthy volunteers|"After an ophthalmic consultation, the healthy volunteers are summoned to perform the exercise test in the form of an aerobic exercise on an ergometric bicycle with 3 different intensity levels calculated on the theoretical maximum aerobic power.~The OCT examination in the EDI mode, centered on the macular and peri-papillary region, as well as the systolic and diastolic blood pressure and the heart rate.~In healthy patients performing aerobic physical exercise in the Department of Sports Medicine , the investigators will perform the following Intervention :~* Examination of pressures before stopping the exercise~* Examination of pressure during the exercise~* Examination of pressures after stopping the exercise"
62616721|NCT03153345|EXPERIMENTAL|Intervention group|The intervention group participated in a conventional stroke rehabilitation program, which consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training. This program was performed for 30 minutes twice a day 5 days a week, over for at least 3 weeks. During the same period, the intervention group also took part in bedside respiratory muscle training twice a day for 7 days a week over a 3-week period.
62056706|NCT01691521|EXPERIMENTAL|Mepolizumab IV|Mepolizumab 75 mg will be administered intravenously approximately every 4 weeks with the last dose at week 32. Subjects in the Mepolizumab IV arm will receive mepolizumab 75 mg intravenously and placebo SC once every 4 weeks with the last dose at Week 28 (total of 8 doses)
62259801|NCT04231149|EXPERIMENTAL|Test product 2|Test catheter 2
62616722|NCT03153345|ACTIVE_COMPARATOR|Control group|The control group participated only in a conventional stroke rehabilitation program, which consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training. This program was performed for 30 minutes twice a day 5 days a week, over for at least 3 weeks.
62616723|NCT04716036|ACTIVE_COMPARATOR|Alcohol|Participants will be dosed to a 0.08g% blood alcohol concentration.
62056707|NCT01691521|EXPERIMENTAL|Mepolizumab SC|Subjects in the Mepolizumab SC arm will receive mepolizumab 100 mg SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
62259802|NCT04231149|EXPERIMENTAL|Test product 3|Test catheter 3
62259803|NCT04231149|ACTIVE_COMPARATOR|Comparator|SpeediCath Flex
62259804|NCT02147600||Chronic plaque psoriasis|Patients suffering from chronic plaque psoriasis, treated with adalimumab (40mg) subcutaneously every other week after an initial dose of 80 mg. Treatment duration of at least 24 weeks.
62445410|NCT03613350||USI+BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.BO was defined as \<300 mL of the volume at strong desire to void during filling cystometry. Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at a cystometric capacity that usually results in voiding.
62259805|NCT05275374|EXPERIMENTAL|Part 1 - XP-102 Dose Escalation|XP-102
62259806|NCT05275374|EXPERIMENTAL|Part 2 - XP-102 + Trametinib Dose Escalation|XP-102 plus Trametinib
62259807|NCT05275374|EXPERIMENTAL|Part 3 - XP-102 + Trametinib Dose Expansion|XP-102 plus Trametinib
62445411|NCT03613350||BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. BO was defined as \<300 mL of the volume at strong desire to void during filling cystometry. Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at a cystometric capacity that usually results in voiding.
62616724|NCT04716036|PLACEBO_COMPARATOR|Placebo|Participants will receive a low dose of alcohol (placebo condition).
62841672|NCT04056390|ACTIVE_COMPARATOR|Substrate Modification|After obtaining a voltage map of the LA, substrate modification by catheter ablation using an irrigated radio frequency current ablation catheter will be performed aiming at low-voltage areas (LVA) \< 0.5mV.
62841673|NCT04056390|ACTIVE_COMPARATOR|LAA Isolation|Patients will undergo LAA-isolation using the cryoballoon (CB). Six weeks later patients will undergo re-mapping. In case of residual conduction LAA-reisolation will be performed. In case of durable LAA isolation, interventional LAA occlusion is recommended.
62616725|NCT03200977||Exposed to nivolumab prior to allogeneic HCT|patients who were treated with nivolumab-based regimen prior to an allogeneic HCT
62616726|NCT03200977||Unexposed to nivolumab prior to allogeneic HCT|patients who were not treated with nivolumab-based regimen prior to an allogeneic HCT
62616727|NCT03289299|EXPERIMENTAL|Arm A|Non-high dose treatment in 3 phases Induction 6 cycles: carfilzomib, lenalidomide, daratumumab, dexamethasone Consolidation 6 cycles: carfilzomib, lenalidomide, daratumumab, dexamethasone Maintenance 12 cycles: lenalidomide, daratumumab
62616728|NCT03435159|EXPERIMENTAL|Manual Chiropractic Spinal Manipulation|Demographic informations, pain, previous trauma, diseases, current medicine, past surgical operations, pregnancy, smoking use and cervical artery dissection history in family are questioned. Cervical flexion, extension, right and left rotations, right and left lateral flexions are measured by physiotherapist, in sitting position and with goniometer.Upper extremity muscle strength was measured with manual muscle testing in sitting position by physical therapist. The muscles innervated by C4, C5, C6, C7, C8 and T1 cervical nerves were examined bilaterally. Cervical foraminal compression test was used to eliminate cervical root compression.Vertebrobasilar artery was assessed by premanipulative vertebrobasilar insufficiency test.Neck Disability Index was used to evaluate the functional neck status of the participants. After all assessments, participants who were eligible for this study were undertaken Doppler Ultrasonography before and after manual manipulative intervention.
62616729|NCT03435159|EXPERIMENTAL|Instrumental Chiropractic Spinal Manipulation|The same assessments were applied to determine the eligibility of participants for this study. After all assessments, participants who were eligible for this study were undertaken Doppler Ultrasonography before and after instrumental manipulative intervention.
62841674|NCT01662609||Endoscopic Ultrasound (EUS) Participants|High-risk for Pancreatic Cancer: Patients with 2 or more relatives with pancreatic cancer and a first degree relationship with at least one of the relatives with pancreatic cancer.
62841675|NCT02342236|OTHER|cemented|Primary hip arthroplasty with bone cement use.
62841676|NCT02342236|OTHER|cementless|Primary hip arthroplasty without bone cement use.
62841677|NCT03868813||Interview with People with Diabetes|One-on-One interview with people with diabetes
62841678|NCT03868813||Interview with Health Coaches|One-on-One interview with health coaches
62841679|NCT00702299|EXPERIMENTAL|Receiving Treatment|Dose escalation of day 1 i.p. pemetrexed disodium accrued three patients to each of five dose levels (60-1,000 mg/m2), along with day 2 i.p. cisplatin (75 mg/m2) and day 8 i.p. paclitaxel (60 mg/m2) with a biologic sample preservation procedure
62841680|NCT05593068||Dialysed patients with suspicion of hepatic iron|Patients on dialysis at Claude Galien Private Hospital who had one or more MRI scans to monitor possible hepatic iron overload between May 2012 and March 2018.
62841681|NCT00746057|OTHER|1|Patients aged 18 to 65 years old receiving a first cadaveric renal graft.
62841682|NCT00101452|EXPERIMENTAL|S-adenosyl-l-methionine (SAMe)|A natural substance
62841683|NCT00101452|ACTIVE_COMPARATOR|2. Escitalopram|A selective serotonin reuptake inhibitor (SSRI)
62056708|NCT01691521|PLACEBO_COMPARATOR|Placebo|Subjects in the Placebo arm will receive matching placebo SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
62259808|NCT00562952|ACTIVE_COMPARATOR|1|Patient will receive cardiac therapy to decrease NT-proBNP levels. This will be primarily RAAS-Antagonists and Betablocker. Blood pressure will be lowered to target values. A decrease of NT-proBNP is also known form life-style changes. Thus the patient will be educated to be trained
62259809|NCT00562952|PLACEBO_COMPARATOR|2|Patients will be followed 2 years. Care will be given by the responsible unit ( Dept.of Endocrinology) as clinical appropriate. Event rates will be obtained. After one year NT-proBNP will be measured.
62259810|NCT04944511|EXPERIMENTAL|PD-1 antibody for mixed chimerism|PD-1 antibody (Toripalimab Injection) used for mixed chimerism in HLH patients after allo-HCT
62259811|NCT01012375|EXPERIMENTAL|1|AZD1446 tid
62259812|NCT01012375|EXPERIMENTAL|2|AZD1446 tid
62259813|NCT01012375|EXPERIMENTAL|3|AZD1446 qd
62841684|NCT00101452|PLACEBO_COMPARATOR|3. placebo|Sugar pill- contains no active ingredients
62841685|NCT03881527|EXPERIMENTAL|Resection of the aortic valve leaflets with device|Patients in which the aortic valve has been resected using the nitinol blade
62841686|NCT03881527|OTHER|Resection of the aortic valve leaflets in standard fashion|Patients in which the aortic valve has been resected using a conventional blade or scissor
62841687|NCT05178797|EXPERIMENTAL|K-tapping and exercise (Group A)|Group A will be given kinesiology taping technique and exercise therapy
62841688|NCT05178797|ACTIVE_COMPARATOR|Compression decongestive therapy (Group B )|Group B will be given compression decongestive therapy (manual lymphatic drainage, short stretch bandage and exercise therapy)
62841689|NCT03078140|ACTIVE_COMPARATOR|Triferdine|Triferdine 1 tablet by mouth daily. Start after 1st trimester until delivery
62841690|NCT03078140|ACTIVE_COMPARATOR|Triferdine/Ferli-6|Triferdine or ferli-6 1 tablet by mouth daily base on iodine status. The supplement will give after 1st trimester until delivery
62841691|NCT04436848||PD patients positive for LRRK2 G2385R|
62259814|NCT01012375|PLACEBO_COMPARATOR|4|Matching placebo capsule
62841692|NCT04436848||PD patients negative for LRRK2 G2385R|
62841693|NCT04436848||Non-PD controls negative for LRRK2 G2385R|
62841694|NCT01072604|EXPERIMENTAL|Arm 1|
62841695|NCT01072604|EXPERIMENTAL|Arm 2|
62056709|NCT00626366|EXPERIMENTAL|Nasal spray|This arm of the study will contain subjects who will spray 2-4 sprays of a nasal contrast solution in their nares. Following administration of the spray, the subjects will then have a Xoran mini-CAT scan of their sinuses.
62056710|NCT00626366|EXPERIMENTAL|Nasal drop|This arm will contain subjects who will place two drops of a nasal contrast solution in each nose. Following administration of the nasal contrast, the subjects will then have a Xoran miniCAT scan of their sinuses.
62056711|NCT00582946|EXPERIMENTAL|Magnetic Contact Hearing Aid|Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss. Acute performance and safety assessed at 4 months compared to unaided baseline pre-treatment, followed by longer-term assessment of safety up to 10 months.
62056712|NCT04151784||Pulmonary Group|Pulmonary Group who have evidence of pulmonary diseases
62056713|NCT04151784||Healthy Control|Health Group who have no evidence of pulmonary diseases
62259815|NCT05120895||Mevalotin|Korean menopausal women aged 50 years or more who required treatment of dyslipidemia and received Mevalotin® tablets.
62056714|NCT04465279|EXPERIMENTAL|Trifocal Diffractive Intraocular Lens (FineVision)|36 eyes having implantation of trifocal diffractive IOL (FineVision)
62056715|NCT04368650|EXPERIMENTAL|Main treatment group|The in situ BMP-2 gel was prepared to a concentration of approximately 0.5 μg/ml and were stored at 4oC. The gel was then dispensed at site of interest in the study.
62259816|NCT04449055|EXPERIMENTAL|DPFC first|Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TMS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use. This arm will receive the dorsolateral prefrontal cortex stimulation first.
62056716|NCT04368650|ACTIVE_COMPARATOR|Control|In patients selected for control group, after degranulation, sticky bone was used to fill the defect. The surgical site was protected and covered using a periodontal dressing.
62445412|NCT03613350||No demonstrated USI+BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. No urodynamic stress incontinence, no bladder oversensitivity nor detrusor overactivity was noted in this group.
62616730|NCT02419651|ACTIVE_COMPARATOR|Tramadol|Women will receive oral Tramadol 100 mg before the procedure
62056717|NCT04246983|EXPERIMENTAL|Patients with HIV undergoing point of care ultrasound|
62841696|NCT01072604|ACTIVE_COMPARATOR|Arm 3|
62056718|NCT01729884|EXPERIMENTAL|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID once monthly for 3 months.
62056719|NCT06066281||Healthy volunteers|480 healthy subjects between the ages of 18 and 75, Italian native speakers, willing and able to comply with study procedures.
62445413|NCT02444312|EXPERIMENTAL|Benefit-finding Writing Activity|For two weeks, on six days of their choice, caregivers will be instructed to write about their thoughts and feelings in a diary/ notebook about the benefits of caring.
62445414|NCT02444312|ACTIVE_COMPARATOR|Neutral Writing activity|For two weeks, on six days of their choice, caregivers will be instructed to write about a neutral topic.
62841697|NCT01072604|ACTIVE_COMPARATOR|Arm 4|
62841698|NCT03458104|EXPERIMENTAL|Vocal Cord Atrophy|Quantify changes in aerodynamic and aeroacoustics patterns in patients with vocal cord atrophy (VCA) before and after voice therapy. To evaluate changes, subjects will have Laryngovideostroboscopy, Acoustic/Auerodynamic testing, and Cone Beam CT scans of the larynx before and after voice therapy.
62841699|NCT03458104|ACTIVE_COMPARATOR|Healthy Volunteer|Develop a validated computational model for assessing normative laryngeal aerodynamic and aeroacoustic patterns in healthy elderly individuals. To assess normal laryngeal aerodynamic and aeroacoustic patterns in this cohort, subjects will subjects will have Laryngovideostroboscopy, Acoustic/Auerodynamic testing, and Cone Beam CT scans of the larynx.
62841700|NCT00728403|EXPERIMENTAL|1|American Ginseng and American Red Ginseng Capsules
62841701|NCT00728403|EXPERIMENTAL|2|American Ginseng Capsules
62841702|NCT00728403|PLACEBO_COMPARATOR|3|Placebo Capsules
62841703|NCT00135499|EXPERIMENTAL|R-ACVBP|Rituximab, Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
62841704|NCT00135499|ACTIVE_COMPARATOR|R-CHOP|Rituximab, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone
62056720|NCT05718843|EXPERIMENTAL|Group 1: Participants with severe renal impairment|
62056721|NCT05718843|EXPERIMENTAL|Group 2: Participants with normal renal function individually matched to participants of Group 1|
62056722|NCT05718843|EXPERIMENTAL|Group 3: Participants with moderate renal impairment|
62056723|NCT05718843|EXPERIMENTAL|Group 4: Participants with normal renal function matching Group 3|
62616731|NCT02419651|ACTIVE_COMPARATOR|Diclofenac|Women will receive oral diclofenac 100 mg before the procedure
62841705|NCT02336529|EXPERIMENTAL|ICBN, active|Ultrasound guided injection of bupivacain, 10mL, 0.5% in proximity of the ICBN
62841706|NCT02336529|PLACEBO_COMPARATOR|ICBN, placebo|Ultrasound guided injection of NaCl, 10mL in proximity of the ICBN
62841707|NCT02336529|EXPERIMENTAL|Tenderpoint, active|Ultrasound guided injection of bupivacain, 20mL, 0.25% in the tenderpoint
62841708|NCT02336529|PLACEBO_COMPARATOR|Tenderpoint, placebo|Ultrasound guided injection of NaCl, 20mL in the tenderpoint
62445415|NCT02281409|EXPERIMENTAL|Phase I: Mogamulizumab (KW-0761)|Patients will be enrolled to receive a weekly intravenous (IV) dose of KW-0761 ranging from 0.5 mg/kg to 10.0 mg/kg as feasible starting on Day 1 for 4 weeks. In the absence of toxicity or progression of disease, patients may continue receiving KW-0761 for up to 12 months. Subsequent treatment courses will consist of an infusion every other week. Following end of treatment or treatment completion date, a 24-week short term follow-up (STFU) period of observation will begin.
62445416|NCT02281409|EXPERIMENTAL|Phase II: Mogamulizumab (KW-0761)|Phase II of the study will enroll a total of 48 subjects, 16 patients in 3 tumor-specific expansion cohorts each treated at the RP2D (MTD, or highest dose tested in Phase I part of trial).
62616732|NCT02419651|PLACEBO_COMPARATOR|Placebo|Women will receive oral placebo 1 hour before the procedure.
62841709|NCT00351052|EXPERIMENTAL|1|Pimecrolimus
62841710|NCT00351052|PLACEBO_COMPARATOR|2|Vehicle
62841711|NCT05939843|ACTIVE_COMPARATOR|Pain Coping Information|
62841712|NCT05939843|EXPERIMENTAL|Mindfulness Practice (alone)|
62841713|NCT05939843|EXPERIMENTAL|Mindfulness Introduction + Mindfulness Practice|
62841714|NCT05939843|EXPERIMENTAL|Pain Introduction + Mindfulness Introduction + Mindfulness Practice|
62841715|NCT00774566|ACTIVE_COMPARATOR|1|segmental PVI using an irrigated tip catheter
62616733|NCT02859519|EXPERIMENTAL|MOB015B|Subjects will treat all affected fingernails and/or toenails with MOB015B for 48 weeks once daily at bedtime.
62841716|NCT00774566|ACTIVE_COMPARATOR|2|PVI using the Cryo-Balloon
62841717|NCT02335788|OTHER|Single arm - EMBA PED|The EMBA Peripheral Embolization Device when indicated for arterial and venous embolization in the peripheral vasculature.
62841718|NCT02974543|OTHER|Sham 1st (Auditory only) then Active (Bimodal)|"To mitigate potential placebo effects, subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
62841719|NCT02974543|OTHER|Active (Bimodal) then Sham (Auditory only)|"During active treatment, the device will deliver electric somatosensory and auditory stimulation.~To mitigate potential placebo effects, subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab."
62841720|NCT03855488|EXPERIMENTAL|Standard cognitive bias modification|Listen to descriptions of ambiguous scenarios that resolve positively
62841721|NCT03855488|EXPERIMENTAL|Imagery enhanced cognitive bias modification|Listen to descriptions of ambiguous scenarios that resolve positively while engaging in imagery
62841722|NCT03855488|PLACEBO_COMPARATOR|Neutral Control Condition|Listen to descriptions of neutral scenarios
62056724|NCT05718843|EXPERIMENTAL|Group 5: Participants with mild renal impairment|
62056725|NCT05718843|EXPERIMENTAL|Group 6: Participants with normal renal function matching Group 5|
62056726|NCT04444635|ACTIVE_COMPARATOR|Serratus Anterior Plan block plus fentanyl infusion|The patients will receive serratus anterior block in addition to continous intraoperative fentanyl infusion.
62056727|NCT04444635|ACTIVE_COMPARATOR|Fentanyl infusion only|The patient will receive fentanyl infusion only.
62616734|NCT02859519|PLACEBO_COMPARATOR|MOB015B Vehicle|Subjects will treat all affected fingernails and/or toenails with MOB015B Vehicle for 48 weeks once daily at bedtime.
62616735|NCT02557516|EXPERIMENTAL|Phase 1 Level 1 - 1 mg/kg|In phase 1, Monalizumab given at the first dose level of 1 mg/kg.
62616736|NCT02557516|EXPERIMENTAL|Phase 1 Level 2 - 2 mg/kg|In phase 1, Monalizumab given at the second dose level of 2 mg/kg.
62841723|NCT03007225|ACTIVE_COMPARATOR|group 1 Drug eluting beads intervention|Twenty-five patients underwent Chemoembolization with Drug eluting beads. using Drug eluting Doxorubicin hydrochloride (100-150 mg)
62841724|NCT03007225|ACTIVE_COMPARATOR|group 2 Conventional TACE intervention|Twenty-five patients underwent conventional Chemoembolization (cTACE) using the standard TACE technique
62841725|NCT06245980||With SGLT2I|
62841726|NCT06245980||Without SGLT2i|
62841727|NCT02728167|EXPERIMENTAL|Pre-coagulation by HIFU-AR|Pre-coagulation of the liver parenchyma with HIFU and standard liver resection
62841728|NCT02728167|NO_INTERVENTION|Standard liver resection|Standard liver resection
62841729|NCT00865280|EXPERIMENTAL|PTK 0796|PTK 0796 100 mg for injection; PTK 0796 tablet, 300 mg (2 x 150 mg tablets)
62841730|NCT00865280|ACTIVE_COMPARATOR|Linezolid|Gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; Gram negative treatment: moxifloxacin 400 mg tablet and moxifloxacin 400 mg IV infusion solution
62841731|NCT03358524|EXPERIMENTAL|Vitamin E 400 IU|Vitamin-E Capsule (alpha-tocopherol) 400 IU once per day orally for 8 weeks
62259817|NCT04449055|EXPERIMENTAL|MPFC first|Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TMS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use. This arm will receive the medial prefrontal cortex stimulation first.
62259818|NCT02242578|EXPERIMENTAL|Active|Active rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
62841732|NCT03358524|PLACEBO_COMPARATOR|Placebo|Placebo capsule once per day orally for 8 weeks
62841733|NCT05346068|EXPERIMENTAL|Study Device|
62841734|NCT05346068|ACTIVE_COMPARATOR|Control Device|
62841735|NCT04485351||Diabetic patients from the University Hospital of Nancy|
62841736|NCT06254885|EXPERIMENTAL|Sub-crestal|Implants will be placed 1mm under the bone crest level
62841737|NCT06254885|ACTIVE_COMPARATOR|Equi-crestal|Implants will be placed at the bone crest level
62841738|NCT05102032|ACTIVE_COMPARATOR|Conventional approach|Conventional approach to laparoscopic hysterectomy
62841739|NCT05102032|EXPERIMENTAL|Mini-invasive approach|Mini-invasive approach to laparoscopic hysterectomy
62841740|NCT00273793|EXPERIMENTAL|1|Shaping intervention for hard-to-treat smokers
62841741|NCT00273793|ACTIVE_COMPARATOR|2|fixed criterion intervention for hard-to-treat smokers
62841742|NCT00273793|OTHER|3|Non contingent incentives available to hard to treat smokers
62259819|NCT02242578|EXPERIMENTAL|Placebo|Sham rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
62259820|NCT04096209|EXPERIMENTAL|Graft-less and grafting using xenograft and autograft|Extraction of badly decayed teeth with immediate implant placement using graft-less and grafting using autogenous bone and xenograft between the implant and labial socket bone
62259821|NCT01996475|EXPERIMENTAL|Torrent's of Escitalopram Oxalate Tablet 20 mg|
62445417|NCT02384681||Exposed|Medical regulation assistants working with headset
62445418|NCT02384681||Non-Exposed|Participants working without headset
62445419|NCT01573091||Heart failure patients|Patients with a CRT device according to current guidelines
62841743|NCT00273793|EXPERIMENTAL|4|Ascending incentives values used in Smokers with Early Success
62445420|NCT00425815|EXPERIMENTAL|Org 24448 250 mg|Two capsules (one Org 24448 250 mg capsule and one placebo capsule that is identical to the active treatment) will be ingested orally daily for eight weeks.
62841744|NCT00273793|ACTIVE_COMPARATOR|5|fixed value incentives are used in Smokers with Early Success
62445421|NCT00425815|EXPERIMENTAL|Og 244448 500 mg|Two capsules (two Org 24448 250 mg capsules) will be ingested orally daily for eight weeks.
62445422|NCT00425815|PLACEBO_COMPARATOR|Inactive Capsule|Two capsules (two placebo capsules that are identical to the active treatment) will be ingested orally daily for eight weeks.
62841745|NCT00273793|OTHER|6|Non contingent incentives are available to Smokers with Early Success
62259822|NCT02385981|EXPERIMENTAL|Stivax|an intermittent stimulation of afferent vagus nerve at earlap
62259823|NCT05775640|NO_INTERVENTION|control group|Sociodemographic data collection form, Clinical Information Form, The child medical fears scale, State and Trait Anxiety Inventory for Children were administered to the children in the control group, and the State-Trait Anxiety Inventory (STAI) was administered to the parents of the children in the control group on the 0th day of hospitalization. The standard clinical hospitalization process was not interfered with. On the third day of hospitalization, the children in the control group were administered the Clinical Information Form, the The child medical fears scale, the State and Trait Anxiety Inventory for Children, and the State-Trait Anxiety Inventory (STAI) for their parents. After the study, the link of the game was sent to the control group so that they could play the game in order to avoid ethical problems.
62259824|NCT05775640|EXPERIMENTAL|intervention group|
62841746|NCT01574183|EXPERIMENTAL|Vilazodone|Flexible dose up to 40 mg capsule daily
62841747|NCT01574183|PLACEBO_COMPARATOR|Placebo|Flexible dose up to 40 mg capsule daily
62445423|NCT00679783|EXPERIMENTAL|1|"Triple negative breast Cancer with unknown BRCA mutation status: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally~AZD2281, PARP inhibitor Olaparib tablets, oral"
62841748|NCT00299390|EXPERIMENTAL|Sagopilone|
62841749|NCT03816293|ACTIVE_COMPARATOR|Negative Pressure Wound Therapy|NPWT use on closed incision for 7 days after c-section, abdominal hysterectomy, and colon surgery in patients with diabetes and/or obesity
62841750|NCT03816293|NO_INTERVENTION|Control Dressing|Standard dressing on closed incisions after c-section, abdominal hysterectomy, and colon surgery in patients with diabetes and/or obesity
62841751|NCT05741619||Anti-GABABr encephalitis|This is a non-interventional study involving clinical data. This data are information of medical follow up on patient like diagnosis, symptoms, biological results, cancer, treatments.
62841752|NCT04159207||A Longitudinal Study of Inflammatory Pathways in Depression|We target to recruit 80 patients with Major Depression Disorder diagnosis and 80 patients with Major Depression Disorder with suicidal behavior.
62841753|NCT02232568|EXPERIMENTAL|Feedback Arm|Orthopedic surgeons in the Feedback Arm will receive monthly reports providing individualized data on compliance with the FOCUS trial RBC transfusion guideline (pretransfusion Hb \<8 g/dL for hip surgery patients in the postoperative period.) Feedback data will be anonymized, but surgeons will be able to see their own data in comparison with their peers.
62841754|NCT02232568|NO_INTERVENTION|Control Arm|Orthopedic surgeons in the Control Arm will not receive any feedback on their use of RBC transfusion in hip surgery patients.
62841755|NCT06251882|EXPERIMENTAL|D5W group|The patients received one session of ultrasound-guided 10ml D5W injection around the lateral femoral cutaneous nerve as it exited the pelvis.
62841756|NCT01614691|EXPERIMENTAL|SPARC1203 low dose|
62841757|NCT01614691|EXPERIMENTAL|SPARC1203 mid dose|
62841758|NCT01614691|EXPERIMENTAL|SPARC1203 high dose|
62841759|NCT01614691|PLACEBO_COMPARATOR|Placebo|
62841760|NCT01411891|NO_INTERVENTION|Control|Patients assigned to this study group will not have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
62841761|NCT01411891|EXPERIMENTAL|Chlorhexidine impregnated patch.|Patients assigned to this study group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
62616737|NCT02557516|EXPERIMENTAL|Phase 1 Level 3 - 4 mg/kg|In phase 1, Monalizumab given at the third dose level of 4 mg/kg.
62616738|NCT02557516|EXPERIMENTAL|Phase 2 RP2D - 2 mg/kg|In phase 2, Monalizumab given at the Recommended Phase 2 Dose (RP2D) of 2 mg/kg, selected by a safety committee.
62445424|NCT00679783|EXPERIMENTAL|2|"Known BRCA mutation positive breast cancer: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) to be administered orally~AZD2281, PARP inhibitor Olaparib tablets, oral"
62445425|NCT00679783|EXPERIMENTAL|3|"High grade serous/undifferentiated tubo-ovarian carcinoma with unknown BRCA status: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally~AZD2281, PARP inhibitor Olaparib tablets, oral"
62445426|NCT00679783|EXPERIMENTAL|4|"Known BRCA mutation positive ovarian cancer: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally~AZD2281, PARP inhibitor Olaparib tablets, oral"
62445427|NCT03591549|EXPERIMENTAL|fulvestrant arm|patients will receive fulvestrant + zoladex intramuscular monthly with an assessment every three months to assess the response and progression
62445428|NCT00836927|EXPERIMENTAL|Ridaforolimus 10 mg Days 1-5|Ridaforolimus 10 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus intravenous (IV) infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
62445429|NCT00836927|EXPERIMENTAL|Ridaforolimus 10 mg Days 1-6|Ridaforolimus 10 mg administered orally once daily on Days 1-6 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
62445430|NCT00836927|EXPERIMENTAL|Ridaforolimus 20 mg Days 1-5|Ridaforolimus 20 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
62445431|NCT00836927|EXPERIMENTAL|Ridaforolimus 30 mg Days 1-5|Ridaforolimus 30 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
62445432|NCT00836927|EXPERIMENTAL|Ridaforolimus 40 mg Days 1-5|Ridaforolimus 40 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
62445433|NCT03596996|EXPERIMENTAL|Ferrous Sulfate|Children 6 to 23 months of age will receive a tablet that contains the equivalent of 12.5 mg of elemental iron. Children over 24 months will receive a tablet that contains the equivalent of 30 mg of elemental iron.
62445434|NCT03596996|PLACEBO_COMPARATOR|Placebo|
62445435|NCT03425864|OTHER|immediate implant|patient will receive immediate implant alone.
62445436|NCT03425864|ACTIVE_COMPARATOR|immediate implant with connective tissue graft|patient will receive immediate implant and connective tissue gaft
62445437|NCT03304509|NO_INTERVENTION|Face-to-face follow-up|Face-to-face follow-up after hospital discharge
62445438|NCT03304509|EXPERIMENTAL|Telematic follow-up|Telematic follow-up after hospital discharge
62445439|NCT00598559|EXPERIMENTAL|1 g IV Acetaminophen|1 g q6h IV Acetaminophen
62445440|NCT00598559|EXPERIMENTAL|650 mg IV Acetaminophen|650 mg q4h IV Acetaminophen
62445441|NCT00598559|OTHER|Standard of Care|The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
62445442|NCT05671289||Patients with confirmed bladder tumor|Patients with bladder tumor, confirmed by cystoscopy and radiology. Age ranging from 18 to 80 years old. Women of childbearing age should have negative urine pregnancy test.
62445443|NCT05671289||Healthy volunteers|Individuals with no known disease and normal urinalysis. Age ranging from 18 to 80 years old. Women of childbearing age should have negative urine pregnancy test.
62445444|NCT01502618|EXPERIMENTAL|Focus Group|The focus group participants for this study will be Black Young Men who have Sex with Men (B-YMSM) ages 16-24 years (inclusive) who are diagnosed as HIV-positive and receive medical care at one of the two participating AMTUs or their community partners.
62445445|NCT03788577|EXPERIMENTAL|Oligonol intake group|This experimental arm will be applied for Oligonol 200mg/tab 1 tab per day. The program will last for 12 weeks.
62445446|NCT03788577|PLACEBO_COMPARATOR|Placebo group|This Placebo arm will be given capsules made of starch 1 tab per day. The program will last for 12 weeks.
62445447|NCT02607800|EXPERIMENTAL|SOF/VEL/VOX|SOF/VEL/VOX tablet for 8 weeks
62445448|NCT02607800|ACTIVE_COMPARATOR|SOF/VEL 12 weeks|SOF/VEL tablet for 12 weeks
62445449|NCT01840956|EXPERIMENTAL|HAVG|Surgical placement of HAVG
62445450|NCT06545513||Patients with chronic pain|The patients have completed surveys prior or during their visit at the chronic pain outpatient clinic.
62445451|NCT04244747|ACTIVE_COMPARATOR|induction of labour by breast stimulation|women at term with previous cesarean section and an indication to induce labor. In order to induce labour by breast stimulation, an electrical pump was used. The cup was alternated between the nipples every 15 minutes, with a pause of 15 minutes after each 30 minutes, with a total induction time of 6 hours.
62445452|NCT04244747|ACTIVE_COMPARATOR|induction of labour by catheter balloon|women at term with previous cesarean section and an indication to induce labor. In the catheter balloon group, a 16-F Foley catheter was inserted into the cervical canal and inflated with 60 cc sterile saline solution and was kept in place for 12 hours.
62445453|NCT04244747|NO_INTERVENTION|spontaneous labour|women in latent phase of spontaneous labour .
62445454|NCT03247296||Group A|Patients taking Sofosbuvir and Daclatasvir
62445455|NCT03247296||Group B|Patients taking Sofosbuvir,Daclatasvir, and Ribavirin
62616739|NCT00609713|EXPERIMENTAL|1|Comprehensive 12-month family-based obesity treatment with separate adolescents and parents group sessions
62445456|NCT04521959|ACTIVE_COMPARATOR|Blood Flow Restricted Aerobic and Resistance Exercise Group|kan akımı kısıtlanarak.direnç ve bisikletle aerobik egzersiz uygulanacak
62445457|NCT04521959|ACTIVE_COMPARATOR|Normal aerobik ve direnç egzersiz grubu|Normal şartlarda aerobik ve direnç egzersizi uygulanacak
62445458|NCT03339037|ACTIVE_COMPARATOR|Hyperbaric oxygen therapy|"60 Hyperbaric oxygen sessions in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). each session 1.5 ATA of 100% oxygen for 1 hour.~1 meter per minute compression and decompression."
62445459|NCT03339037|SHAM_COMPARATOR|Normobaric air SHAM|"60 sessions in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session at 1 ATA of 21% oxygen (air) for 1 hour.~1 meter per minute compression and decompression. after 3 months, patients will be crossed over and treated with 60 sessions of treatment"
62445460|NCT01871779|EXPERIMENTAL|Standard Treadmill Exercise|The first group would undergo standard treadmill exercise to the point of pain and repeat these cycles for a total period of 35-45 minutes twice weekly for 12 weeks
62445461|NCT01871779|EXPERIMENTAL|Intermittent Treadmill & Resistance Training|The second group would have a combination of intermittent treadmill and some resistance training with weights. They will undergo repeated cycles to a maximum of 35-45 minutes twice weekly for 12 weeks
62445462|NCT04895410|EXPERIMENTAL|Dose Escalation: Lemzoparlimab|Participants will receive lemzoparlimab in 28 day cycles.
62445463|NCT04895410|EXPERIMENTAL|Dose Escalation: Lemzoparlimab + Pomalidomide + Dexamethasone|Participants will receive lemzoparlimab + pomalidomide + dexamethasone in 28 day cycles.
62445464|NCT04895410|EXPERIMENTAL|Dose Escalation: Lemzoparlimab + Carfilzomib + Dexamethasone|Participants will receive lemzoparlimab + carfilzomib + dexamethasone in 28 day cycles.
62445465|NCT04895410|EXPERIMENTAL|Dose Escalation: Lemzoparlimab + Daratumumab + Dexamethasone|Participants will receive lemzoparlimab + daratumumab + dexamethasone in 28 day cycles.
62445466|NCT04895410|EXPERIMENTAL|Dose Expansion: Lemzoparlimab|Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion in 28 day cycles.
62445467|NCT04895410|EXPERIMENTAL|Dose Expansion: Lemzoparlimab + Dexamethasone|Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + dexamethasone in 28 day cycles.
62445468|NCT04895410|EXPERIMENTAL|Dose Expansion: Lemzoparlimab + Pomalidomide + Dexamethasone|Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + pomalidomide + dexamethasone in 28 day cycles.
62616740|NCT00609713|ACTIVE_COMPARATOR|2|Individual 12-month nutrition education program
62616741|NCT05546814|EXPERIMENTAL|Sodium algorithm|Starting at 2 weeks of age, the sodium algorithm group will be started based on their sodium levels. This will be adjusted weekly based on weight gain and sodium levels.
62445469|NCT04895410|EXPERIMENTAL|Dose Expansion: Lemzoparlimab + Carfilzomib + Dexamethasone|Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + carfilzomib + dexamethasone in 28 day cycles.
62616742|NCT05546814|NO_INTERVENTION|Control|Subjects will be cared for by current protocols
62445470|NCT04895410|EXPERIMENTAL|Dose Expansion: Lemzoparlimab + Daratamumab + Dexamethasone|Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + daratamumab + dexamethasone in 28 day cycles.
62445471|NCT03843957|EXPERIMENTAL|"Clinic Patients Eligible for CRC Screening on high touch Strategy (Post-Implementation)"|"English or Spanish-speaking patients aged 50-74 who are eligible for CRC screening who are seen in the study clinics randomized to mPATH utilizing the high touch implementation strategy in the 12 months after implementation."
62445472|NCT03843957|EXPERIMENTAL|"Clinic Patients Eligible for CRC Screening on low touch Strategy (Post-Implementation)"|"English or Spanish-speaking patients aged 50-74 who are eligible for CRC screening who are seen in the study clinics randomized to mPATH utilizing the low touch implementation strategy in the 12 months after implementation."
62445473|NCT03843957|EXPERIMENTAL|"Clinic personnel on high touch Strategy (Post-Implementation)"|"Clinic personnel (e.g., administrators, nurses, providers) who are involved with the implementation of mPATH-CRC, in the study clinics randomized to mPATH utilizing the high touch implementation strategy in the 12 months after implementation."
62445474|NCT03843957|EXPERIMENTAL|"Clinic personnel on low touch Strategy (Post-Implementation)"|"Clinic personnel (e.g., administrators, nurses, providers) who are involved with the implementation of mPATH-CRC, in the study clinics randomized to mPATH utilizing the low touch implementation strategy in the 12 months after implementation."
62616743|NCT04091204|EXPERIMENTAL|Olaparib|Olaparib is given orally at the dose of 300 mg bid continually as maintenance therapy after a platinum based chemotherapy
62616744|NCT05637190|EXPERIMENTAL|Expressive Arts Therapy group|The Expressive Arts Therapy group will receive the Expressive Arts intervention via face-to-face workshops for 2 consecutive weeks (2 hours per session). there are a total of 3 batches (around 15 participants per batch) for the intervention.
62616745|NCT05637190|NO_INTERVENTION|Waitlist control group|The Waitlist control group will not receive any intervention during the study, but they will receive self-help art therapy materials after the whole study procedure.
62616746|NCT02481180|EXPERIMENTAL|T0001|
62616747|NCT02481180|ACTIVE_COMPARATOR|Enbrel|
62616748|NCT02254798||Transplanted patients|No intervention Prospective registration of patients receiving an allogeneic hematopoietic stem cell transplant
62616749|NCT00892515|EXPERIMENTAL|exercise|
62841762|NCT02515721|EXPERIMENTAL|pCLE-TB|Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.
62841763|NCT02515721|EXPERIMENTAL|Virtual Chromoendoscopy -SB|Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
62841764|NCT03666364|EXPERIMENTAL|Magnetic nanoparticle selection for teratozoospermia|
62841765|NCT03666364|NO_INTERVENTION|Density gradient centrifugation for teratozoospermia|
62841766|NCT02790892|OTHER|Art therapy - pre and post test measures|20 young adults aged 15-24 years with diabetes (10 with type 1 diabetes and 10 with type 2 diabetes) receiving 12 weeks of group art therapy. Participants serve as their own controls.
62841767|NCT01600144||data collection|
62841768|NCT05933382|EXPERIMENTAL|Corticosteroid Group|A conventional treatment program will be applied to individuals in both groups 5 days a week for 3 weeks. The conventional exercise program will consist of wand exercises, Codman exercises, stretching exercises for all ranges of motion, and TENS (100Hz, 15 minutes). A corticosteroid injection will be administered to the shoulder region of the first group prior to treatment.
62841769|NCT05933382|EXPERIMENTAL|Mulligan Group|A conventional treatment program will be applied to individuals in both groups 5 days a week for 3 weeks. The conventional exercise program will consist of wand exercises, Codman exercises, stretching exercises for all ranges of motion, and TENS (100Hz, 15 minutes). In addition to the conventional treatment program, a mobilization technique with movement will be applied twice a week, with 10 repetitions.
62841770|NCT03313037|EXPERIMENTAL|Multivalent|Pneumococcal conjugate vaccine
62056728|NCT06225856|EXPERIMENTAL|Study treatment|Method of Administration: Single dose period: Single oral administration under fasting state; Multiple dose period: Oral administration under fasting state, QD.
62056729|NCT00591201|EXPERIMENTAL|A|Infliximab
62841771|NCT03313037|ACTIVE_COMPARATOR|Control|Prevnar 13 and PPSV23
62841772|NCT02214394|EXPERIMENTAL|Propofol|Subjects will be given Propofol during routine surgery and then using the SMART Device the breath will be captured and compared to blood plasma using High-performance liquid chromatography Analysis.
62841773|NCT01646489|EXPERIMENTAL|Miravirsen sodium|
62841774|NCT01646489|ACTIVE_COMPARATOR|Telaprevir|
62841775|NCT00975780|EXPERIMENTAL|enhanced oral care|
62841776|NCT00975780|ACTIVE_COMPARATOR|Usual care|The usual oral care provided at the nursing home
62841777|NCT04704596|ACTIVE_COMPARATOR|dynamic lung compliance for detection of optimum PEEP|detection of optimum PEEP by measurement of the dynamic lung compliance (by the ventilator machine) after lung recruitment
62841778|NCT04704596|ACTIVE_COMPARATOR|Lung ultrasound for detection of the optimum PEEP|Lung ultrasound will be used to detect the optimum PEEP after lung recruitment
62841779|NCT05814172||Death by 1 y|patients who dieded within 1-year after discharge due to hip fracture surgery
62841780|NCT05814172||Alive at 1 y|patients who survived 1-year after discharge due to hip fracture surgery
62841781|NCT03105752|EXPERIMENTAL|Research participants|"Each participant of a clinical trial completed the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) about its understanding of the information received. This questionnaire was retrieved immediately on the day of consent, with no possibility of referring to the content of information letter."
62841782|NCT04618848||Adult Oncology Patients|Adult oncology patients
62841783|NCT00470886||Group 1|
62056730|NCT00591201|PLACEBO_COMPARATOR|B|Placebo
62056731|NCT01934803|ACTIVE_COMPARATOR|Zinc gluconate|Study participants will receive zinc gluconate supplements (15 mg for men and 12 mg for women) and will be instructed to take one pill daily for 18 months.
62056732|NCT01934803|PLACEBO_COMPARATOR|Placebo|Study participants will receive identically packaged placebo (sucrose) pills and will be instructed to take one pill daily for 18 months.
62056733|NCT01536041|EXPERIMENTAL|Experimental 200 mg dose|
62259825|NCT03529721|EXPERIMENTAL|zumba dance group|females in this group will be instructed to engage into12 classes of 60-minute Zumba® fitness over an 8-week period of continuous dance movements to Latin music with varying intensity level throughout the sessions. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced.
62259826|NCT03529721|PLACEBO_COMPARATOR|non zumba dance group|the control group will be required to carry on doing their normal daily activities throughout the 8-week period.
62259827|NCT02014350||DePuy Delta Xtend RTSA|
62445475|NCT03843957|EXPERIMENTAL|"All Adult Clinic Patients on high touch Strategy (Post-Implementation)"|"English or Spanish-speaking patients aged 18 or older who are seen in the study clinics randomized to mPATH utilizing the high touch implementation strategy in the 12 months after implementation."
62445476|NCT03843957|EXPERIMENTAL|"All Adult Clinic Patients on low touch Strategy (Post-Implementation)"|"English or Spanish-speaking patients aged 18 or older who are seen in the study clinics randomized to mPATH utilizing the low touch implementation strategy in the 12 months after implementation."
62616750|NCT01317524|EXPERIMENTAL|Homogenized Milk|900 mL homogenized milk is consumed within a mixed meal
62056734|NCT01536041|EXPERIMENTAL|Experimental 20 mg dose|
62056735|NCT01536041|ACTIVE_COMPARATOR|Active Comparator Montelukast|
62056736|NCT01536041|PLACEBO_COMPARATOR|Placebo Comparator|
62056737|NCT01847170|EXPERIMENTAL|Fecal Microbial Transplantation|
62056738|NCT02565719|EXPERIMENTAL|REP 2139-Mg with Viread and Pegasys|REP 2139-Mg in combination with tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys).
62056739|NCT02565719|EXPERIMENTAL|REP 2165-Mg with Viread and Pegasys|REP 2165-Mg in combination with tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys).
62056740|NCT02565719|ACTIVE_COMPARATOR|Viread and Pegasys with crossover to REP 2139-Mg and Pegasys|Tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys) - crossover into add-on REP 2139-Mg therapy (triple combination) in patients with \< 3 log reduction in serum HBsAg from baseline after 24 weeks of Pegasys exposure.
62056741|NCT02565719|ACTIVE_COMPARATOR|Viread and Pegasys with crossover to REP 2165-Mg and Pegasys|Tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys) - crossover into add-on REP 2165-Mg therapy (triple combination) in patients with \< 3 log reduction in serum HBsAg from baseline after 24 weeks of Pegasys exposure.
62056742|NCT02174887|EXPERIMENTAL|Nab-paclitaxel + Gemcitabine|Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days The patients will receive 2 cycles of treatment every 28 days
62056743|NCT01564368|EXPERIMENTAL|Diffusion Weighted-MRI|Participants on all arms of the I-SPY II trial will undergo diffusion-weighted magnetic resonance imaging as described in the ACRIN 6698 protocol. The experimental component/intervention is whether DW-MRI can predict therapeutic response in neoadjuvant treatment for breast cancer.
62056744|NCT05924399|EXPERIMENTAL|Affect Labeling Training|Participants complete a total of six training sessions, twice a week for three consecutive weeks. In each session, they spend 40 minutes completing computer-based inhibitory regulation training utilizing four strategies.
62056745|NCT02985762|OTHER|EXPAREL 266 mg/20 mL|Eligible subjects, whose surgical incision must be at least 8 cm in length, will receive a single dose of EXPAREL (266 mg/20 mL) expanded in volume with 20-60 mL normal saline, depending on the size of the incision
62056746|NCT00525525|EXPERIMENTAL|Efficacy Group|Patients treated with the combination of radiation plus temozolomide (75 mg/m2 daily during radiotherapy) plus bevacizumab (10 mg/kg IV every two weeks during radiotherapy) plus tarceva (dose based upon use of EIAED, either 200 mg daily or 500 mg daily; given daily); all treatment begins at the start of radiotherapy and continues until tumor progression, death or excessive toxicity
62841784|NCT01147913|EXPERIMENTAL|Positive Interpretation Training|Four sessions of positive information-processing training for interpretation of ambiguous scenarios relevant to themes of depression.
62841785|NCT01147913|SHAM_COMPARATOR|Attention Control Training|"Four sessions of interpretation training for filler or neutral scenarios, unrelated to themes associated with depression."
62841786|NCT01723033||EEG acquisition|15 PTSD patients and 15 OCD patients who will, while wearing a net of electrodes for EEG acquisition on their heads, perform three error detection tasks.
62841787|NCT01723033||Control|Previously collected healthy student's data
62841788|NCT03843554|PLACEBO_COMPARATOR|Standard of Care Oral Hygiene|Standard of Care Oral Hygiene group (SOC-OH): Subjects assigned to SOC-OH will attend weekly oral care visits where they will have their teeth brushed with a soft bristled toothbrush by the interventionist. No treatment to the oral mucosa will be provided to this group as part of the intervention. Subjects will receive oral care instructions and will be asked to follow SOC oral hygiene instructions at home.
62841789|NCT03843554|EXPERIMENTAL|Oral Mucosal Deterging and Dental Prophylaxis (OMDP)|Oral Mucosal Deterging \& Dental Prophylaxis (OMDP) protocol: Subjects assigned to OMDP will attend weekly intervention visits during which they will have their teeth cleaned and will receive the OMDP intervention as follows: subjects will receive a professional dental prophylaxis including periodontal surface debridement and deterging of the oral mucosal surfaces. Subjects will be asked to follow OMDP oral hygiene instructions at home.
62841790|NCT03544177|EXPERIMENTAL|BFR-Walking|Interval walking training with blood flow restriction.
62841791|NCT03544177|ACTIVE_COMPARATOR|Conventional therapy|Conventional therapy
62841792|NCT06406296|EXPERIMENTAL|ACT group|8 individual weekly sessions which included ACT methods
62841793|NCT06406296|NO_INTERVENTION|Waiting list|Participants assigned to Waiting List arm waited for 5 months before receiving treatment
62841794|NCT00923572||Group 1|
62841795|NCT06246201||Patients with Coronary Artery Disease|Having been diagnosed with coronary artery disease
62841796|NCT00644800|EXPERIMENTAL|Arm A|
62841797|NCT00276523|ACTIVE_COMPARATOR|Control|Control (no treatment), conventional surgery.
62841798|NCT00276523|EXPERIMENTAL|PEG-Intron 0.5 mg/kg|PEG-interferon alfa-2b 0.5 mg/kg subcutaneously (SQ) once a week for 3 weeks, plus surgery.
62841799|NCT00276523|EXPERIMENTAL|PEG-Intron 2.5 mg/kg|PEG-interferon alfa-2b 2.5 mg/kg SQ once a week for 3 weeks, plus surgery.
62259828|NCT02534688|EXPERIMENTAL|LNG-IUS group|Single intervention LNG IUS
62841800|NCT00276523|EXPERIMENTAL|PEG-Intron 5.0 mg/kg|PEG-interferon Alfa-2b 5 mg/kg SQ once a week for 3 weeks, plus surgery.
62259829|NCT02534688|EXPERIMENTAL|DMPA group|Three intervention DmPA 12 wk apart
62259830|NCT04103684|EXPERIMENTAL|Patients will receive steroid pulse therapy|
62841801|NCT03646396|EXPERIMENTAL|Sofosbuvir-daclatasvir|Sofosbuvir-daclatasvir for 3 months
62841802|NCT06156748||Hepatectomy alone|
62841803|NCT06156748||PA-TACE|
62445477|NCT03843957|OTHER|"Clinic Patients Eligible for CRC Screening on high touch Strategy (Pre-Implementation)"|"English or Spanish-speaking patients aged 50-74 who are eligible for CRC screening who are seen in the study clinics randomized to mPATH utilizing the high touch implementation strategy but in 8 months before implementation."
62841804|NCT01500720|EXPERIMENTAL|Cabazitaxel|
62445478|NCT03843957|OTHER|"Clinic Patients Eligible for CRC Screening on low touch Strategy (Pre-Implementation)"|"English or Spanish-speaking patients aged 50-74 who are eligible for CRC screening who are seen in the study clinics randomized to mPATH utilizing the low touch implementation strategy but in 8 months before implementation."
62445479|NCT01006707|OTHER|Ondansetron, then Placebo|Some participants received ondansetron pretreatment during the second session, and then placebo during the third session.
62445480|NCT01006707|OTHER|Placebo, then Ondansetron|Some participants received placebo pretreatment during the second session, and then ondansetron pretreatment during the third session.
62841805|NCT01500720|ACTIVE_COMPARATOR|Topotecan|
62841806|NCT02223377|ACTIVE_COMPARATOR|Morphine|"Analgesia with equipotent doses of Morphine and Hydromorphone will be administered in titrated doses. Doses are 1ml=1mg of morphine or 0.2 mg of hydromorphone. Potency ratio of 1:5 (M: HM).~0.05mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml)"
62841807|NCT02223377|ACTIVE_COMPARATOR|Hydromorphone|"Analgesia with equipotent doses of Morphine and Hydromorphone will be administered in titrated doses. Doses are 1ml=1mg of morphine or 0.2 mg of hydromorphone. Potency ratio of 1:5 (M: HM).~0.05mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml)"
62841808|NCT02794532|NO_INTERVENTION|Pre oxygenation with 100% oxygen via tight fitting mask|Pre Oxygenation will be done using a tight mask
62841809|NCT02794532|EXPERIMENTAL|Pre oxygenation with 100% oxygen in high-flow nasal cannula|Pre Oxygenation will be done using high-flow nasal canula
62841810|NCT05133310|NO_INTERVENTION|Standard Care Group|Patients will receive the standard chemotherapy regimen assigned for their treatment and, they will be followed and monitored until the end of treatment and hospitalization.
62841811|NCT05133310|EXPERIMENTAL|Simvastatin Treatment Group|Patients will combine the standard CALGB treatment scheme plus Simvastatin 10mg orally every 24 hours during the first 7 days of treatment and then continue with 20mg every 24 hours until the end of treatment and hospitalization.
62841812|NCT04271397|OTHER|Active tuberculosis|
62841813|NCT04271397|OTHER|Latent tuberculosis infection|
62841814|NCT02314819|ACTIVE_COMPARATOR|treatment arm|treatment arm- subjects will receive Fruquintinib 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
62616751|NCT01317524|EXPERIMENTAL|Unhomogenized Milk|900 mL unhomogenized milk is consumed within a mixed meal
62616752|NCT01317524|EXPERIMENTAL|Skimmed Milk|900 mL skimmed milk and 44 g of butter are consumed within a mixed meal
62616753|NCT03054285|NO_INTERVENTION|No seizure prophylaxis|Participants randomized to this arm will not receive anti-seizure prophylaxis
62616754|NCT03054285|EXPERIMENTAL|Seizure Prophylaxis|Participants randomized to this arm will receive the anti-seizure prophylaxis drug Levetiracetam for seven days post traumatic brain injury.
62616755|NCT00634686|EXPERIMENTAL|1|
62616756|NCT00634686|PLACEBO_COMPARATOR|2|
62841815|NCT02314819|PLACEBO_COMPARATOR|control arm|control arm- subjects will receive Fruquintinib placebo 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
62841816|NCT04499924|EXPERIMENTAL|Phase 2 Arm|Tucatinib + trastuzumab + ramucirumab + paclitaxel
62259831|NCT04103684|ACTIVE_COMPARATOR|Patients will receive low dose steroids|
62259832|NCT00282334|EXPERIMENTAL|Home blood pressure telemonitoring|
62259833|NCT00282334|NO_INTERVENTION|Conventional blood pressure monitoring|
62259834|NCT04503499|EXPERIMENTAL|Study Group|The group to which the manuel therapy will be applied.
62259835|NCT04503499|NO_INTERVENTION|Control Group|The control group where only the evaluations will be made.
62259836|NCT01982474|EXPERIMENTAL|Grass pollen extract injection|Grass pollen extract injected intralymphatically q 4 weeks x 3
62259837|NCT01982474|PLACEBO_COMPARATOR|Placebo injection|Normal saline injected intralymphatically q 4 weeks x 3
62259838|NCT01982474|NO_INTERVENTION|Observational group|Subjects already receiving traditional subcutaneous allergy immunotherapy for grass pollen, being observed for safety of their subcutaneous injections. Not receiving active intervention during this study.
62616757|NCT01897792|EXPERIMENTAL|Vitamins C and E|Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
62616758|NCT01897792|PLACEBO_COMPARATOR|0.9% saline and sugar pill|100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
62616759|NCT01146028|EXPERIMENTAL|Tizanidine HCl 4 mg|Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited
62616760|NCT01146028|ACTIVE_COMPARATOR|Zanaflex|Zanaflex 4 mg Tablets
62616761|NCT06052514||Post COVID patient diagnosed with sleep apnea with AHI > 5|Patients with post COVID syndrome diagnosed with sleep apnea starting CPAP
62616762|NCT03653312|ACTIVE_COMPARATOR|NMES|"2 weeks (weekdays) of Neuromuscular Electrical Stimulation of the paretic lower limb during exercise.~Each exercise session will last for 12 minutes and will consist of either walk or sit and raise from a chair."
62616763|NCT03653312|NO_INTERVENTION|training|Participants will undergo 2 weeks of exercise every weekday. Each exercise session will last for 12 minutes and will consist of either walk or sit and raise from a chair.
62616764|NCT02983253||Patients with HHT|blood sample of patients with HHT
62616765|NCT02983253||probands|blood sample of healthy controls
62259839|NCT02302976|EXPERIMENTAL|acute pre-treatment with exenatide|This arm plans to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide vs. placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. We propose to study 24 subjects in a within-subject (two-day, randomized, placebo-controlled) human laboratory study of self-regulated cocaine administration. We hypothesize that acute treatment with exenatide will reduce cocaine-induced euphoria and self-regulated cocaine administration as compared to placebo
62445481|NCT02916173|EXPERIMENTAL|Human chorionic gonadotrophin group|Patients will receive Human chorionic gonadotrohpin injection 5000 unit
62445482|NCT02916173|ACTIVE_COMPARATOR|Human chorionic gonadotrophin + agonist group|patients will receive both Human chorionic gonadotrophin (2500 unit) and gonadotrophin releasing hormone agonist 1mg leuprolide acetate
62445483|NCT04652570|EXPERIMENTAL|VB119 dose escalation|Dose escalation phase followed by a dose expansion phase. VB119 to be administered as intravenous infusions.
62616766|NCT04178616|OTHER|systemic sclerosis patients population|All the patients with systemic sclerosis disease followed in day-care in a tertiary hospital are eligible to be enrolled in the study.
62616767|NCT03609190|EXPERIMENTAL|Ketamine|i.v. infusion of 0.25 mg/kg S-ketamine over 40 min
62616768|NCT03609190|PLACEBO_COMPARATOR|Placebo|i.v. infusion of NaCl over 40 min
62623675|NCT03678194|NO_INTERVENTION|Standard services|This group of patients receives conventional treatment only. Clinical evaluations are provided at the same endpoint. Patients still receive standard services for depression.
62623676|NCT00688025||1|Insomniacs: Individuals reporting difficulty falling asleep or staying asleep within the past month for more than 3 days per week. Individuals much also meet screening criteria based on an overnight polysomnograph of latency to persistent sleep \>20 minutes and/or \>60 minutes of wake after sleep onset.
62623677|NCT00688025||2|Controls: Individuals reporting no difficulty falling asleep or staying asleep and objective sleep measures based on an overnight polysomnograph of latency to persistent sleep \<20 minutes and/or \<60 minutes of wake after sleep onset.
62616769|NCT05464082|EXPERIMENTAL|Treatment: All Patients|"Patient derived xenografts (PDX) are grown in mice. Organoids may generated from patient tumor(PDO) and PDX(PDxO). Organoids will be used for drug profiling. PDX, organoid establishment and drug profiling will occur while patient is undergoing preoperative chemo, surgery, radiation, and may extend into disease-free interval. Patients receive first line therapy in the metastatic setting per SOC or in separate clinical trial. Results of PDM drug profiling, tumor genomic, and circulating tumor DNA results will be returned to treating physician to inform 2nd line therapy. At progression on the first line therapy, the patient will begin new therapy as directed by the treating physician. Any subsequent therapy (aligned or unaligned with report recommendations) that a patient starts after the return of results will be deemed informed."
62616770|NCT05464082|NO_INTERVENTION|Physician Questionnaire|"Prior to the return of results, treating physicians will be asked to complete the PRE-Information Provider Survey on Functional Precision Oncology. After review of the FPO results, treating physicians will be asked to complete the POST-Information Provider Survey on Functional Precision Oncology to assess the potential effect that the FPO results have on the selection of therapy. These surveys will be administered to assess the impact the results have on the selection of therapy.~Physicians are not mandated to select the treatment recommended by the FPO data since the FPO results are not from a CLIA certified laboratory. Information regarding whether the physician chose to switch to the recommended drug or not for the next line of therapy and patient outcomes (progression-free survival) according to treatment selection (treatment selected aligned with FPO recommendation vs. not) will be captured."
62623678|NCT06187233|EXPERIMENTAL|binaural music group|The music group listened to music containing binaural beats during the colonoscopy
62056747|NCT00525525|OTHER|Safety Lead-in Group|"Fractionated radiotherapy in daily doses of 1.8-2.0 Gy delivered 5 days per week over \~6 weeks, to a total dose of 59.4 to 60 Gy.~Adjuvant temozolomide 200 mg/m\^2/d x 5 d per 28-d cycle; Erlotinib 150-200 mg/d (or 500-600 mg/d for patients on enzyme-inducing antiepileptic drugs) on a continuous basis 7 days per week; Bevacizumab 10 mg/kg every 2 weeks"
62056748|NCT02609321|EXPERIMENTAL|Thoracic Paravertebral Block|to identify the thoracic T3, a parallel line 2.5 cm from the spinous process is drawn and in this place the ultrasound sensor is placed. Ultrasonograph image identifies the transverse process, the intercostal cost-transverse ligament, the pleura and lung. We proceed to insert a needle between the two corresponding transverse processes and positions after passing the cost-ligament posterior intercostal and transverse to the parietal pleura. After negative aspiration for blood, 0.5% bupivacaine anesthetic is administered at doses of 1.5 mg/kg slowly. The volume is defined by the anesthesiologist. The injection of anesthetic is displayed, as well as confirmation of the correct location of the needle because the volume injected above pushes the pleura.
62056749|NCT02609321|ACTIVE_COMPARATOR|Surgical Wound Infiltration|before the close of the skin, it proceeds to infiltrate the subcutaneous tissue and skin with 0.5% bupivacaine at doses of 1.5 mg/kg, generating the widest possible dissemination of the bupivacaine in the surgical area.
62056750|NCT03719794|ACTIVE_COMPARATOR|Probiotics arm|The active comparator arm will be of a 12-week probiotic supplement regimen (one capsule daily, containing 20 x 109 CFU of Bifidobacterium animalis ssp. Lactis Lafti®B94 and Lactobacillus plantarum R1012)
62056751|NCT03719794|PLACEBO_COMPARATOR|Placebo arm|The placebo comparator arm will be of a 12-week placebo supplement regimen.
62056752|NCT05968014|EXPERIMENTAL|PENG block|Participants enrolled in this group received a pericapsular nerve group block with 20 ml of 0.2% ropivacaine. The block was performed with a 100 mm needle, inserted with an in-plane lateral to medial approach. Operator used a low frequency curvilinear probe.
62259840|NCT02302976|EXPERIMENTAL|sub-chronic (5 day) treatment with exenatide|This arm plans to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug. Upon completion of arm 1, subjects may opt to be randomized to five days of treatment with either exenatide or placebo, followed by a one-day human laboratory study of self-regulated cocaine administration. We hypothesize that subjects treated with exenatide (up to N=12) will demonstrate decreased self-regulated cocaine administration as compared to subjects treated with placebo (up to N=12).
62445484|NCT03954028|ACTIVE_COMPARATOR|CTG Group|Patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. In this group, the autogenous connective tissue graft (CTG) material will be randomized to transplant to one side of the arch.
62056753|NCT05968014|EXPERIMENTAL|FIC block|Patients allocated in this group received a fascia iliaca compartment block with 20 mL of 0.2% ropivacaine, using a 50 mm needle inserted with an in-plane approach. Operator used a linear probe.
62056754|NCT01036308|EXPERIMENTAL|TypTop|Lupinus albus Typ Top (lupin kernel fibre, dietary fibre content: 83%)
62259841|NCT02302976|PLACEBO_COMPARATOR|acute pre-treatment with placebo|This arm plans to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide vs. placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. We propose to study 24 subjects in a within-subject (two-day, randomized, placebo-controlled) human laboratory study of self-regulated cocaine administration. We hypothesize that acute treatment with exenatide will reduce cocaine-induced euphoria and self-regulated cocaine administration as compared to placebo
62616771|NCT05479851||UK National Health Service Patient Postal Survey Participants|Patients who have agreed to participate in the study after receiving a postal invitation
62841817|NCT04499924|EXPERIMENTAL|Arm 3A|Tucatinib + trastuzumab + ramucirumab + paclitaxel
62259842|NCT02302976|PLACEBO_COMPARATOR|sub-chronic (5 day) treatment with placebo|This arm plans to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug. Upon completion of arm 1, subjects may opt to be randomized to five days of treatment with either exenatide or placebo, followed by a one-day human laboratory study of self-regulated cocaine administration. We hypothesize that subjects treated with exenatide (up to N=12) will demonstrate decreased self-regulated cocaine administration as compared to subjects treated with placebo (up to N=12).
62259843|NCT03156920|ACTIVE_COMPARATOR|Sumatriptan|Headache is induced with Cilostazol. This headache is pre-treated double-blinded with 2 tablets of sumatriptan 50 mg
62616772|NCT03307187|EXPERIMENTAL|GLB-AIM|GLB-AIM (Group Lifestyle Balance program, Adapted for individuals with Impaired Mobility) is a 12-month intervention that promotes 5% weight loss by reducing calories and increasing exercise (150 minutes of moderate physical activity). The 23 GLB-AIM sessions were delivered through monthly in-person and teleconference calls and participants were encouraged to self-monitor daily caloric/fat intake and physical activity using materials to accurately measure daily calories and exercise, which included a food scale, measuring cups and spoons and a loaned Garmin vívofit® activity tracker and heart rate monitor. Participants shared their logs with lifestyle coaches over the 13 core sessions and lifestyle coaches provided positive reinforcement, feedback, and problem solving techniques as needed.
62616773|NCT03307187|NO_INTERVENTION|wait-list control|During the initial 6 month intervention period the control group received several contacts from the study staff via mail that included information on general health (e.g., managing stress, getting good sleep), holiday cards, and scheduling reminders for the 3 and 6 month testing.
62616774|NCT03996226|EXPERIMENTAL|E7386: Fed + Fast|Participants will receive a single oral dose of E7386 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
62616775|NCT03996226|EXPERIMENTAL|E7386: Fast + Fed|Participants will receive a single oral dose of E7386 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
62623679|NCT06187233|NO_INTERVENTION|control|The control group had headphones without sound during the procedure.
62623680|NCT00616447|EXPERIMENTAL|1|
62056755|NCT01036308|EXPERIMENTAL|Soy fibre|Glycine max Hefeng (soy fibre; dietary fibre content: 77%)
62056756|NCT01036308|EXPERIMENTAL|Boregine|Lupinus angustifolius Boregine (lupin kernel fibre, dietary fibre content: 87%)
62056757|NCT03975764||Preterm birth|Delivery between 24-32 weeks of gestation
62259844|NCT03156920|PLACEBO_COMPARATOR|Placebo|Headache is induced with Cilostazol. This headache is pre-treated double-blinded with 2 tablets of placebo
62259845|NCT04854434|EXPERIMENTAL|Arm A: Selinexor 80 mg|Participants received a single dose of selinexor 80 mg (4 tablets of 20 mg) orally QW on Day 1 of each week of a 42-day cycle (i.e., on Days 1, 8, 15, 22, 29, and 36 of each 42-day cycle) until PD, intolerable toxicity, or withdrawal from the study (maximum exposure: 33 weeks).
62445485|NCT03954028|ACTIVE_COMPARATOR|ADM Group|The patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. In this group, the commercial acellular dermal matrix (ADM) materials will be transplanted to the opposite side of the arch with CTG transplants.
62623681|NCT00616447|SHAM_COMPARATOR|2|
62623682|NCT00459771|PLACEBO_COMPARATOR|Placebo|Placebo
62841818|NCT04499924|ACTIVE_COMPARATOR|Arm 3B|Ramucirumab + paclitaxel + tucatinib placebo + trastuzumab placebo
62841819|NCT04499924|EXPERIMENTAL|Arm 3C|Tucatinib + ramucirumab + paclitaxel + trastuzumab placebo
62841820|NCT06213103||o Patient cohort|Patient with moleculary proven mitochondrial disorder
62841821|NCT06213103||o Control cohort|People without moleculary proven mitochondrial disorder
62841822|NCT01043367|EXPERIMENTAL|A|Deprexil
62056758|NCT03975764||Term delivery|Delivery between 37-41 weeks of gastation
62056759|NCT01379976|PLACEBO_COMPARATOR|CHT cisplatin containing + placebo|
62056760|NCT01379976|EXPERIMENTAL|CHT cisplatin containing + acetyl-L-carnitina|
62841823|NCT01043367|PLACEBO_COMPARATOR|B|Placebo
62841824|NCT04621149|PLACEBO_COMPARATOR|placebo|1 liter of filtered water
62056761|NCT03298282||Imaging Registry|Imaging cohort: Patients with intermediate lesions
62259846|NCT04854434|EXPERIMENTAL|Arm B: Selinexor 80 mg and Pembrolizumab 400 mg|Participants received a single dose of selinexor 80 mg (4 tablets of 20 mg) orally QW on Day 1 of each week of a 42-day cycle (i.e., on Days 1, 8, 15, 22, 29, and 36 of each 42-day cycle) in combination with pembrolizumab 400 mg IV once every 6 weeks of each 42-day cycle until PD, intolerable toxicity, or withdrawal from the study (maximum exposure: 30 weeks).
62259847|NCT04854434|ACTIVE_COMPARATOR|Arm C: Standard of care (SOC)|Participants received combination of trifluridine and tipiracil 35 mg/m\^2/dose tablets orally BID (maximum 80 mg per dose) as SOC on Days 1 through 5 and Days 8 through 12 of each 28-day cycle until PD, intolerable toxicity, or withdrawal from the study (maximum exposure: 11 weeks).
62259848|NCT01417195|EXPERIMENTAL|Menopur and Bravelle combination|The initial daily dose consisted of 225 IU of gonadotropins, mixed in the same syringe and administered by subcutaneous (SC) injection for 5 days. The initial daily dose, based on the Investigator's judgment, consisted of either 150 IU of Menopur and 75 IU of Bravelle or 150 IU of Bravelle and 75 IU of Menopur. Dosing adjustments were allowed as of day 6. Dose could vary between 150-450 IU daily and was always to include at least 75 IU of Menopur and 75 IU of Bravelle. Treatment could not continue beyond day 20.
62445486|NCT03602690|EXPERIMENTAL|Dolutegravir + Darunavir/ritonavir + optimized NRTI|"All patients will receive ART regimen every day including:~Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)"
62056762|NCT03778034||Female with forward head posture|post-pubertal females suffering from (FHP) with Craniovertebral angle (CVA) less than 49 degrees(study group)
62056763|NCT03778034||healthy female without (FHP)|post-pubertal females expected to exhibit an average normal CVA within 10degrees range from 49 to 59 (control group)
62056764|NCT04000620||cancer cell involvement predicted by deep learning|the participants with lesions of lung, lymph node or other sites predicted as positive for cancer cell involvement by imaging based deep learning.
62056765|NCT04000620||no cancer cell involvement predicted by deep learning|the participants with lesions of lung, lymph node or other sites predicted as negative for cancer cell involvement by imaging based deep learning.
62056766|NCT01323179||Strong opioids|Patients taking strong opioids preoperatively
62056767|NCT01323179||Weak opioids|Patients taking weak opioids preoperatively
62056768|NCT01323179||Opioid native|Patients not taking opioids preoperatively
62056769|NCT04433962|ACTIVE_COMPARATOR|conventional rehabilitation group|the conventional rehabilitation group completed hip joint range of motion and muscle strengthening exercises
62056770|NCT04433962|EXPERIMENTAL|conventional rehabilitation + balance training group|The conventional rehabilitation + balance training group completed hip joint range of motion and muscle strengthening exercises and 12 balance exercises.
62056771|NCT02201056|EXPERIMENTAL|Cohort 1: TAK-935 15 mg|TAK-935 15 mg solution, orally, once, on Day 1.
62056772|NCT02201056|EXPERIMENTAL|Cohort 2: TAK-935 50 mg|TAK-935 50 mg solution, orally, once, on Day 1.
62056773|NCT02201056|EXPERIMENTAL|Cohort 3: TAK-935 200 mg|TAK-935 200 mg solution, orally, once, on Day 1.
62056774|NCT02201056|EXPERIMENTAL|Cohort 4: TAK-935 600 mg|TAK-935 600 mg solution, orally, once, on Day 1.
62259849|NCT01417195|ACTIVE_COMPARATOR|Menopur alone|The initial daily dose consisted of 225 IU of Menopur administered by subcutaneous (SC) injection for 5 days. Dosing adjustments were allowed as of day 6. Dose could vary between 150-450 IU daily and treatment could not continue beyond day 20.
62259850|NCT00871520||Palliative Therapy|Patients referred to the oncology / radiation oncology departments for palliative therapy.
62445487|NCT04562649|EXPERIMENTAL|Intervention|Wise App that delivers medication adherence reminders and community health worker sessions
62445488|NCT04562649|NO_INTERVENTION|Control|Standard of care
62445489|NCT01767597|ACTIVE_COMPARATOR|ELISA testing|HBV infection status determined by enzyme-linked immuno-assay (ELISA)
62445490|NCT01767597|EXPERIMENTAL|Rapid testing|HBV infection status determined initially by a rapid test, then confirmed by enzyme-linked immuno-assay (ELISA).
62445491|NCT00582309|ACTIVE_COMPARATOR|Glucommander|Glucommander-Guided Intravenous Insulin Infusion
62445492|NCT00582309|ACTIVE_COMPARATOR|Standard|Standard Intravenous Insulin Infusion Algorithm consists of four levels (Algorithm 1-3 and a doubling of the insulin rate). Most patients begin in algorithm 1, where the insulin rate varies from 0.2 units per hour for BG in the range 70-109 mg/dl up to 6 units/hr for BG \> 360 mg/dl. If algorithm 1 fails to bring the patient's BG into target range in 2 hrs, then the patient is moved up to algorithm 2, where the insulin rate varies from 0.5 to 12 units/hr; and if that fails, the patient moved up to algorithm 3, where insulin rate varies from 1 to 16 units/hr depending on the latest BG. Algorithm failure is a blood glucose outside the target range for 2 hrs, and the blood glucose does not decrease by at least 60 mg/dl within 1 hr. If algorithm 3 fails, the insulin rate is doubled.
62623683|NCT00459771|ACTIVE_COMPARATOR|Candesartan|Candasartan
62056775|NCT02201056|EXPERIMENTAL|Cohort 5: TAK-935 900 mg|TAK-935 900 mg solution, orally, once, on Day 1.
62056776|NCT02201056|EXPERIMENTAL|Cohort 6: TAK-935 1350 mg|TAK-935 1350 mg solution, orally, once, on Day 1.
62056777|NCT02201056|PLACEBO_COMPARATOR|Cohorts 1-6: Placebo|TAK-935 placebo-matching solution, orally, once, on Day 1.
62056778|NCT02484170|ACTIVE_COMPARATOR|mannitol in vehicle cream /vehicle cream|one week on the mannitol cream (mannitol 30% in vehicle cream), a 3 day washout period, and one week on the placebo cream (vehicle cream alone). To be applied over the painful area as needed for pain. Usual frequency is 2 to 3 times daily.
62056779|NCT02484170|ACTIVE_COMPARATOR|vehicle cream /mannitol in vehicle cream|one week on the placebo cream (vehicle cream alone), a 3 day washout period, and one week on the mannitol cream (mannitol 30% in vehicle cream).To be applied over the painful area as needed for pain. Usual frequency is unknown.
62056780|NCT01191840|EXPERIMENTAL|Algorithm-determined therapy|
62056781|NCT01191840|ACTIVE_COMPARATOR|Standard of Care|
62056782|NCT01210521|NO_INTERVENTION|Prior to intervention with Vitamin D|Patients will be analyzed for clinical, serological and immunological parameters before starting the interventional drug, Vitamin D.
62056783|NCT01210521|ACTIVE_COMPARATOR|Vitamin D Intervention|Patients will be analyzed for clinical, serological and immunological parameters after one month taking Vitamin D.
62056784|NCT00758459|EXPERIMENTAL|1|
62259851|NCT00545727|OTHER|HGI|High/standard glycemic index diet
62616776|NCT04229056|EXPERIMENTAL|Specific computer-based cognitive rehabilitation|350 patients (200 with stroke, 100 with Parkinson's disease and 50 with heart attack) will be allocated to specific computer-based cognitive rehabilitation. This group will train with 10 exercises from the cognitive rehabilitation software 'Scientific Brain training PRO'. These 10 exercises are designed to train various executive functions.
62445493|NCT00582309|ACTIVE_COMPARATOR|Simple|Simple Calculated Intravenous Insulin Infusion consists of an initial insulin infusion rate varying from 0.5 units per hour for BG in the target range 80-120 mg/dl up to 8 units/hour for BG \> 400 mg/dl. After the initial insulin rate and if BG is still \> 120 mg/dl, then the insulin rate is increased by 1-2 units every 1 hour until BG is in the target range. If BG is still \>120 mg/dl in 2 hours, then the insulin rate is doubled.
62445494|NCT04657484|ACTIVE_COMPARATOR|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 2 weeks, 10 mg/day for 2 weeks
62616777|NCT04229056|ACTIVE_COMPARATOR|General computer-based cognitive stimulation|350 patients (200 with stroke, 100 with Parkinson's disease and 50 with heart attack) will be allocated to general computer-based cognitive stimulation. This group will train with 10 generally mentally stimulating games on a website specifically designed for this trial. These 10 games are chosen because they are believed to have a low load on executive functions but stimulate over-all concentration and visuoperceptual abilities.
62616778|NCT03214549|ACTIVE_COMPARATOR|gull wing preparation veneers|intervention: gull wing preparation in laminates veneers proximal margin of the preparation is placed toward the lingual .The area of the proximal margin between the contact area and the gingival papilla is placed even further to the lingual. This preparation design helps to hide the margin when the restorations are viewed from an angle.
62616779|NCT03214549|ACTIVE_COMPARATOR|conventional preparation veneers|intervention: conventional preparation in laminates veneers preparation of veneers without lingual extension of preparation in mesial and distal areas
62616780|NCT03776526||Postoperative Hip fracture patients|The target population will include patients aged 65 years or older admitted with hip fracture to the orthopedic ward at the Juravinski Hospital, a site of Hamilton Health Sciences Corporation in Ontario, Canada.
62616781|NCT02334384|EXPERIMENTAL|Antimicrobial TheraGauze|Antimicrobial TheraGauze (i.e. tobramycin impregnated TheraGauze) will be used as a wound packing after incision and drainage of skin abscess (i.e. furunculosis). Antimicrobial TheraGauze will be administered once.
62616782|NCT02334384|NO_INTERVENTION|Standard of care - standard wound packing|In this control arm the subject will receive standard of care with standard wound packing. The ED physician will have the choice to use plain cotton wick or iodoform wick. Standard wound packing will be administered once.
62616783|NCT02720861||non embolic ischemic stroke|acute ischemic stroke from atherosclerosis or lacunar stroke
62445495|NCT04657484|ACTIVE_COMPARATOR|Low dose prednisolone|A dose of 10 mg/day of prednisolone will be administered for 6 weeks
62445496|NCT05325242|EXPERIMENTAL|Elbow Artery Embolization (EAE)|Patients will undergo EAE with Embozene microspheres (75 micron). The microspheres will be delivered in a saline-contrast medium solution and will be delivered to the arteries supplying the areas of the patient's pain.
62616784|NCT04290377|ACTIVE_COMPARATOR|Conventional OT + Motor Imagery OT|Conventional OT (30 minutes/day) plus Motor Imagery OT (30 minutes/day) for 10 days.
62616785|NCT04290377|EXPERIMENTAL|Conventional OT + BMI-assisted Motor Imagery OT|Conventional OT (30 minutes/day) plus BMI-assisted motor imagery OT (30 minutes/day) for 10 days.
62616786|NCT04060771|EXPERIMENTAL|Group P|During general anesthesia patients will receive a single intravenous dose of palonosetron 1 mcg.Kg-1.
62841825|NCT04621149|ACTIVE_COMPARATOR|chlorine dioxide aqueous solution (AS)|1 liter of filtered water with AS
62841826|NCT04621149|ACTIVE_COMPARATOR|placebo with zinc acetate (ZA)|1 liter of filtered water with ZA
62259852|NCT00545727|EXPERIMENTAL|LGI|Low glycemic index diet
62259853|NCT00198380|EXPERIMENTAL|1|
62259854|NCT03193697|EXPERIMENTAL|control group|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
62259855|NCT03193697|EXPERIMENTAL|trial group|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
62259856|NCT06398548|OTHER|Control Group|This group undergoes the same testing protocols as the intervention groups, but is prescribed no additional exercise.
62259857|NCT06398548|EXPERIMENTAL|Moderate Intensity Continuous Training|In this allocation, participants cycle at 70% the resistance associated with their lactate threshold
62445497|NCT01118728|EXPERIMENTAL|Sarilumab|Sarilumab 150 mg subcutaneous (SC) injection every week (or every other week in case of safety issue) for 260 weeks, or until commercially available, or until discontinuation of the project, whichever came first.
62616787|NCT04060771|ACTIVE_COMPARATOR|Group D|During general anesthesia patients will receive a single intravenous dose of dexamethasone 0.2 mg.Kg-1.
62616788|NCT02508415|EXPERIMENTAL|Non Surgical Periodontal Therapy|Will receive oral hygiene education, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine mouth rinse twice a day
62616789|NCT02508415|NO_INTERVENTION|No Non Surgical Periodontal Therapy|No treatment received
62616790|NCT00635986|EXPERIMENTAL|A|group 1 (n = 14) patients received 5 mL of a 100 mcg Fentanyl solution in saline without preservative by the epidural route and 2 mL saline intravenously. Group 2 (n = 15) patients received 5 mL saline by the epidural route and 2 mL (100 mcg) Fentanyl intravenously
62616791|NCT03055494|EXPERIMENTAL|Secukinumab|Eligible patients received secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3 and 4 followed by monthly dosing up to Week 48
62616792|NCT03055494|PLACEBO_COMPARATOR|Placebo|Eligible patients received placebo at randomization, Weeks 1, 2, 3, 4, and 8. At Week 12, patients were switched to treatment with secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
62623684|NCT00582426|EXPERIMENTAL|Octreotide Long Acting Release|Prevention of Chemotherapy Induced Diarrhea (CID)
62841827|NCT04621149|ACTIVE_COMPARATOR|AS with ZA|1 liter of filtered water with AS and ZA
62841828|NCT04621149|ACTIVE_COMPARATOR|placebo with famotidine, lactoferrin and green tea extract (FLG)|1 liter of filtered water with FLG
62616793|NCT02305524|EXPERIMENTAL|ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
62616794|NCT02305524|EXPERIMENTAL|ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
62616795|NCT00653978|EXPERIMENTAL|1|patients receiving one stent
62616796|NCT00653978|ACTIVE_COMPARATOR|2|patients receiving two stents
62616797|NCT04938596|EXPERIMENTAL|Respiratory Bundle Group|The intervention consists of a bundle of measures for respiratory transmission prevention that will be provided during the first 2 weeks of TB treatment of index case.
62616798|NCT04938596|NO_INTERVENTION|Standard of care|Under current national guidelines, no systematic recommendation regarding respiratory protection is given for household contacts of TB cases.
62841829|NCT04621149|ACTIVE_COMPARATOR|AS with FLG|1 liter of filtered water with AS and FLG
62445498|NCT02219191|EXPERIMENTAL|puerarin tablet 50 mg|Patients were orally administrated with 50 mg puerarin tablet three times a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
62445499|NCT02219191|ACTIVE_COMPARATOR|Atorvastatin tablet 20 mg|Patients were orally administrated with 20 mg Atorvastatin tablet once a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
62445500|NCT02946957|EXPERIMENTAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia is delivered by trained sleep therapists in six telephone sessions.
62445501|NCT02946957|ACTIVE_COMPARATOR|Education Control|Education Only Control is delivered by trained sleep therapists in six telephone sessions.
62841830|NCT04621149|ACTIVE_COMPARATOR|placebo with ZA and FLG|1 liter of filtered water with ZA and FLG
62445502|NCT05808556|EXPERIMENTAL|Sticker pads containing lavender and ylang ylang oil|The subjects in the sticker pad group attached an sticker pad (0.3% lavender oil and 0.7% ylang ylang oil) to their shirt, close to the right side of the neck, for 14 days
62616799|NCT01560715|EXPERIMENTAL|Experimental: Test group|Retinitis pigmentosa patients with best-corrected visual acuity (BCVA) worse than 20/200 or visual field less than 20 degrees
62616800|NCT05058092|EXPERIMENTAL|Intervention|"The Remedee Solution consists of:~* a wristband designed to deliver millimeter wave~* a mobile application that allows the patient to follow his treatment sessions~* a personalized support to improve patient adherence to the technology and to increase compliance and effectiveness of the treatment~The use of the Remedee Solution start at the randomization day (D0)"
62616801|NCT05058092|OTHER|Control|"The Remedee Solution consists of:~* a wristband designed to deliver millimeter wave~* a mobile application that allows the patient to follow his treatment sessions~* a personalized support to improve patient adherence to the technology and to increase compliance and effectiveness of the treatment~The use of the Remedee Solution start at three months (M3) after randomization day"
62616802|NCT05437016|EXPERIMENTAL|HUBER rehabilitation group|centre-based and will last 6 weeks, with 4 sessions of 2 hours each per week. All the sessions will be supervised by a physiotherapist and will include: 1h of physiotherapy, 30min of balneotherapy and 30min on the HUBER platform to perform exercises
62841831|NCT04621149|ACTIVE_COMPARATOR|AS with ZA and FLG|1 liter of filtered water with AS, ZA, and FLG
62841832|NCT06186843|EXPERIMENTAL|Plant-based diet|The group will follow a plant-based diet. Compliance will be checked with dietary questionnaires.
62056785|NCT00758459|PLACEBO_COMPARATOR|2|
62056786|NCT01226511|EXPERIMENTAL|Duloxetine|30-120 mg flexible dosing once daily for 10 weeks. At the end of the 10 week blinded treatment period, participants may participate in an 18 week extension
62259858|NCT06398548|EXPERIMENTAL|Heavy Intensity Continuous Training|In this allocation, participants cycle at the resistance associated with their lactate threshold, with an additional 10% of the difference between their LT and maximal achieved watts during the test.
62445503|NCT05808556|PLACEBO_COMPARATOR|Placebo group|The placebo group attached a sticker pad without lavender and ylang ylang oil to their shirt, close to the right side of the neck, for 14 days.
62445504|NCT01533428|EXPERIMENTAL|Capsaicin 8%|Capsaicin 8% patch was applied for 30 minutes to the painful area(s) on Day 1
62445505|NCT01533428|PLACEBO_COMPARATOR|Placebo|Placebo patch was applied for 30 minutes to the painful area(s) on Day 1
62616803|NCT05437016|ACTIVE_COMPARATOR|Standard rehabilitation group|centre-based and will last 6 weeks, with 4 sessions of 2 hours each per week. All the sessions will be supervised by a physiotherapist and will include: 1h of physiotherapy, 30min of balneotherapy and 30min of exercise on cycloergometer.
62616804|NCT03557814|ACTIVE_COMPARATOR|LED01|Conventional non-surgical periodontal therapy plus LED light irradiation from T0-T1
62445506|NCT04990830|EXPERIMENTAL|Inhalation Treatment|"Treatment: Inhaled Low molecular weight heparin + Standard COVID-19 treatment,~Inhaled Low molecular weight heparin (4000 IU given twice a day for 10 days)"
62445507|NCT04990830|OTHER|Control Group|Treatment: Standard COVID-19 treatment
62445508|NCT02521675|OTHER|Diabrasport then Rest|Between each period, the patient should respect a wash-out period of at least one week, during which they will be asked not to practice physical activity.
62616805|NCT03557814|ACTIVE_COMPARATOR|LED02|Conventional non-surgical periodontal therapy plus LED light irradiation from T1-T2
62616806|NCT03557814|SHAM_COMPARATOR|Control|Conventional non-surgical periodontal therapy without LED light irradiation
62616807|NCT02773420|EXPERIMENTAL|HET application arm|Patients with grade I-II internal hemorrhoids will undergo HET application
62616808|NCT03501654|EXPERIMENTAL|TecnisSymfony intraocular lens insertion group|
62616809|NCT02584959|EXPERIMENTAL|Experimental/Placebo|Subjects will be randomized to receive C1 Esterase Inhibitor in the 1st Treatment period and then switch to Placebo in the 2nd treatment period.
62616810|NCT02584959|EXPERIMENTAL|Placebo/Experimental|Subjects will be randomized to receive a placebo treatment in the 1st Treatment period and then switch to receive C1 Esterase Inhibitor in the 2nd treatment period.
62616811|NCT02584959|EXPERIMENTAL|Experimental/ Experimental|Subjects will be randomized and receive C1 Esterase Inhibitor in both 1st as well as the 2nd treatment period
62056787|NCT01226511|PLACEBO_COMPARATOR|Placebo|Administered once daily for 10 weeks. At the end of the 10 week blinded treatment period, placebo participants receive duloxetine in the 18 week extension
62056788|NCT02380222||ASM|
62445509|NCT02521675|OTHER|Rest then Diabrasport|Between each period, the patient should respect a wash-out period of at least one week, during which they will be asked not to practice physical activity.
62616812|NCT00830583|OTHER|1|pompe's disease suspected patient
62616813|NCT03510429|ACTIVE_COMPARATOR|Routine post-op care|Routine post-op care (N=20)
62841833|NCT00976924|EXPERIMENTAL|Andon|Andon blood glucose test strips with test meter
62056789|NCT02380222||SM-AHNMD|
62056790|NCT02380222||MCL|
62056791|NCT02380222||SSM|
62056792|NCT02380222||ISM|
62056793|NCT02434289|EXPERIMENTAL|Resistance exercise and protein products|Practice intervention trial including resistance exercise training and intake of dietary protein products in (frail) elderly, implemented by health care professionals.
62056794|NCT02346396|EXPERIMENTAL|Patients with neuropathic chronic pain|
62056795|NCT01091402||chronic urticaria|
62056796|NCT01091402||asthma|
62056797|NCT01091402||seasonal allergic rhinitis|
62056798|NCT01091402||normal controls|
62056799|NCT06487598|ACTIVE_COMPARATOR|Arm1-Only insulin treatment for type 1 Diabetes patients|Arm1:-Insulin treatment- 4 times a day (Basal Bolus insulin) Inj Actrapid from Novo-Nordisk company and Inj Lantus from Sanofi company given as per body weight of patient for 3 months.
62056800|NCT06487598|ACTIVE_COMPARATOR|Arm2-Insulin with Nisha-Amalaki tablets|Arm2:-Insulin treatment- 4 times a day (Basal Bolus insulin) Inj Actrapid from Novo-Nordisk company and Inj Lantus from Sanofi company given as per body weight of patient with Tab Nisha-Amalaki Dhootpapeshwar GMP certified 500 mg twice a day for 3 months.
62259859|NCT01922687|EXPERIMENTAL|Amlodipine Plus Atorvastatin (Caduet)|amlodipine plus atorvastatin in a single tablet (Caduet, Pfizer, USA) was given once daily
62259860|NCT01922687|ACTIVE_COMPARATOR|Amlodipine (Norvasc)|amlodipine(Norvasc, Pfizer, USA) given once daily
62259861|NCT01424111||Treatment|Those receiving an open-label, 10-20 mg/day, flexible-dose of escitalopram. The treatment period is 8 weeks long.
62259862|NCT01424111||Healthy Control|Those not receiving treatment.
62841834|NCT00976924|ACTIVE_COMPARATOR|Lifescan|Lifescan blood glucose test strips with test meter
62259863|NCT05521230|PLACEBO_COMPARATOR|Placebo|Participants rinsed 10 ml of placebo mouthwash for a period of 60 seconds, three times a day with an interval of 7-9 hours in between, for 4 days (period 1)
62259864|NCT05521230|EXPERIMENTAL|Cymenol (test)|Participants applied a 10 ml rinse of 0.1% cymenol mouthwash for a period of 60 seconds, three times a day with a 7-9 hour interval in between, for 4 days (period 1) and 4 days more (period 2)
62259865|NCT01251848|ACTIVE_COMPARATOR|Treatment A|
62259866|NCT01251848|ACTIVE_COMPARATOR|Treatment B|
62259867|NCT01251848|EXPERIMENTAL|Treatment C|
62259868|NCT05216679|EXPERIMENTAL|Main study|This is the only arm of the study. It is a 6 week period where the participants will either be using night splints or the TESS device to treat their plantar fasciitis symptoms.
62616814|NCT03510429|EXPERIMENTAL|Routine post-op care with Nutritional supplement|Routine post-op care + Nutritional supplement by specific product (N=20)
62616815|NCT04136262|EXPERIMENTAL|Tripterygium wilfordii Hook F (TwHF) plus methotrexate (MTX)|Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks. Oral methotrexate 10 mg per week for 24 weeks.
62616816|NCT04136262|PLACEBO_COMPARATOR|TwHF (dummy) plus MTX|Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks. Oral methotrexate 10 mg per week for 24 weeks.
62616817|NCT01743196||Normal weight|Women with BMI 18.5 to 24.9 kg/m2
62259869|NCT03704142|EXPERIMENTAL|Tweak Focus|Speech understanding and listening effort will be assessed using the Tweak Focus personal sound amplifiers.
62259870|NCT03704142|EXPERIMENTAL|IQ Earbuds|Speech understanding and listening effort will be assessed using the IQEarbuds personal sound amplifiers.
62445510|NCT06321146||V-P shunt group|Comatose TBI patients who underwent V-P shunt surgery
62445511|NCT06321146||Cranioplasty group|Comatose TBI patients who underwent cranioplasty surgery
62259871|NCT03704142|EXPERIMENTAL|Sound World Solutions CS50+|Speech understanding and listening effort will be assessed using the Sound World Solutions CS50+ personal sound amplifiers.
62259872|NCT03704142|EXPERIMENTAL|Bose Hearphones|Speech understanding and listening effort will be assessed using the Sound World Solutions CS50+ personal sound amplifiers.
62259873|NCT05067322|EXPERIMENTAL|Minecraft|This group played the video game under development in Minecraft
62259874|NCT05067322|PLACEBO_COMPARATOR|Control|This group played another game.
62259875|NCT02004496|NO_INTERVENTION|Group A: no app|no use of an mobile application while treatment
62259876|NCT02004496|ACTIVE_COMPARATOR|Group B: only app|Patients, who use independently the mobile application named Consilium without involvement of the physician.
62259877|NCT02004496|ACTIVE_COMPARATOR|Group C: app and physician|Patients use the mobile application named Consilium in collaboration with the physician.
62259878|NCT01104038|ACTIVE_COMPARATOR|Nutrition Education/Lifestyle Counseling|Children in this group will receive weekly group nutrition sessions , 30 minutes per week for 12 weeks, identical to those provided for the EXCEL intervention group and delivered by a registered dietician.
62259879|NCT01104038|EXPERIMENTAL|EXCEL|The EXCEL arm is the experimental arm of the study. Participants in this arm will receive supervised physical activity in the form of novel gaming (technology-mediated physical activity, 60 minutes per session, three times per week , for 12 weeks and 12 weeks of group nutrition education sessions.
62259880|NCT03642756|PLACEBO_COMPARATOR|20 gauge|
62259881|NCT03642756|ACTIVE_COMPARATOR|22 gauge|
62259882|NCT03642756|ACTIVE_COMPARATOR|24 gauge|
62445512|NCT06321146||SCS group|Comatose TBI patients who underwent spinal cord stimulation
62445513|NCT06321146||RMNS group|Comatose TBI patients who underwent right median nerve stimulation
62445514|NCT06321146||DAI group|Comatose TBI patients with diffuse axonal injury
62445515|NCT04902807||Patients|"based on the potential for inclusion of patient's cohort followed in Necker hospital with PIDs and poly-autoimmunity related to known genetic defects. Recruitments will be made at Pediatric Rheumatology Immuno Hematology department, and paediatric Gastroenterology department (n=250).~Collection of blood, urine and stools at inclusion and blood at 12 months consultation/ follow-up."
62445516|NCT04902807||Patients' relatives (control)|Brothers or sisters of the patients (n=125). Collection of blood, urine and stools at inclusion.
62445517|NCT04902807||Patients with unrelated diseases (control)|"Recruitments will be made at the Paediatric Gastroenterology Department, in the Department of Paediatric Visceral and Urologic Surgery and the Department of Maxillofacial Surgery and Paediatric Plastic Surgery at Necker's Hospital. Participants will be included if not diagnosed PIDs and poly-autoimmunity (n=125).~Collection of blood, urine and stools."
62445518|NCT02717975|ACTIVE_COMPARATOR|Without valve|"Trial removal of catheter without catheter valve in patients with urinary retention. These are those patients who have catheter on free drainage, attend the clinic for catheter removal and bladder to be filled naturally ( which may take upto 4-5 hours). After removal of catheter they will be asked to drink plenty of fluids while waiting for the bladder to fill up.~This is the traditional method of catheter removal."
62445519|NCT02717975|EXPERIMENTAL|With valve|"Trial removal of catheter in patients with urinary retention with closed catheter valve. These patients will be asked to close the valve 3-4 hours before attending the clinic prior to catheter removal. Here the intervention is catheter valve that allows bladder to be comfortably full by the time patient arrives in the clinic. By this intervention the investigators hypothesise that the investigators can save the clinic time as the patient will not need to wait for natural bladder filling which generally takes 4-5 hours.~Intervention: Urinary catheter valve"
62445520|NCT00870909|ACTIVE_COMPARATOR|active tDCS|"tDCS active; - Intensity = 2 milliamps (mA) during 20 minutes. ramp up/ramp down 30sec anodal tDCS applied over the left DLPFC combined with cathodal tDCS applied over the left temporoparietal junction (TPJ).~10 sessions, 2 per day"
62445521|NCT00870909|PLACEBO_COMPARATOR|sham tDCS|tDCS placebo same electrode montage than in the active group. 30 sec of active tDCS in the beginning of the stimulation sessions; ramp up/ramp down 30 sec
62445522|NCT03999437|EXPERIMENTAL|Treatment # 1|
62445523|NCT03999437|EXPERIMENTAL|Treatment # 2|
62445524|NCT03999437|PLACEBO_COMPARATOR|Placebo Control|
62445525|NCT03712657|EXPERIMENTAL|ERAS group|interventions: 1.preoperative pain control; 2.avoiding application of ureter; 3.avoiding application of gastric tube; 4.avoiding application of irrigation; 5.avoiding application of drainage; 6.early exercising postoperatively; 7.early oral feeding postoperatively; 8.early discharging.
62445526|NCT03712657|NO_INTERVENTION|control group|normal treatment
62445527|NCT03557138|EXPERIMENTAL|Me4FDG|Intravenous injection of alpha-Methyl-4-deoxy-4-\[(18)F\]fluoro-D-glucopyranoside (Me4FDG) and FDG for evaluation the kidney kinetic model of FDG and Me4FDG in type 2 diabetic patients with SGLT2-inhibitor therapies.
62616818|NCT01743196||Obese|Women with BMI \> 30 kg/m2
62616819|NCT02414789|EXPERIMENTAL|SRM / MS-MS|
62445528|NCT01048333|EXPERIMENTAL|Formoterol, then Salmeterol, then Placebo|Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Placebo Diskus and Placebo Turbuhaler
62445529|NCT01048333|EXPERIMENTAL|Salmeterol, then Palcebo, then Formoterol|Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Placebo Diskus and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus
62445530|NCT01048333|EXPERIMENTAL|Placebo, then Formoterol, then Salmeterol|Placebo Diskus and Placebo Turbuhaler first,then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
62616820|NCT01938989|OTHER|Clear, then Blue Light Filter|Clear clip-on glasses first, followed by blue light filter clip-on glasses, as worn over habitual correction
62616821|NCT01938989|OTHER|Blue Light Filter, then Clear|Blue light filter clip-on glasses first, followed by clear clip-on glasses, as worn over habitual correction
62445531|NCT01048333|EXPERIMENTAL|Formoterol, then Placebo, then Salmeterol|Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Placebo Diskus and Placebo Turbuhaler, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
62445532|NCT01048333|EXPERIMENTAL|Salmeterol, then Formoterol, then Placebo|Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Placebo Diskus and Placebo Turbuhaler
62445533|NCT01048333|EXPERIMENTAL|Placebo, then Salmeterol, then Formoterol|Placebo Diskus and Placebo Turbuhaler first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus
62445534|NCT03890874||First year medical students|First year medical students of jubilee mission medical college and research institute
62445535|NCT04037566|EXPERIMENTAL|XYF19 CAR-T cell|"One arm study consisting of 3 + 3 dose escalation study design followed by dose expansion phase at determined MTD."
62259883|NCT01131533|EXPERIMENTAL|Erythropoietin|patients with chronic macular edema associated with diabetic retinopathy
62445536|NCT02398318|ACTIVE_COMPARATOR|Bilateral Nucleus Accumbens DBS|6 month period of active bilateral nucleus accumbens DBS
62445537|NCT02398318|SHAM_COMPARATOR|Sham Bilateral Nucleus Accumbens DBS|6 month period of sham bilateral nucleus accumbens DBS
62445538|NCT01787825|OTHER|PillCam SB2 then CapsoCam SV-1|PillCam SB2 capsule then CapsoCam SV-1 capsule
62445539|NCT01787825|OTHER|CapsoCam SV-1 then PillCam SB2|CapsoCam SV-1 capsule then PillCam SB2 capsule
62445540|NCT05760079|EXPERIMENTAL|Lactoferrin Supplementation|750mg lactoferrin (three 250mg tablets) per day for 30 days
62445541|NCT02318927|EXPERIMENTAL|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
62445542|NCT04082975|EXPERIMENTAL|NVP-1203|NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose
62616822|NCT00166049|PLACEBO_COMPARATOR|Usual Care Attention Control|Usual care with provision of supplemental printed educational material on HF self care
62616823|NCT00166049|EXPERIMENTAL|Group 2 Patient Family Education PFE|Patient Family Education PFE Heart Failure Patients and family member dyads were provided with an educational and counseling session, and attended a 2 hour patient-family education session on heart failure self management with emphasis on dietary sodium and medication taking behaviors.
62445543|NCT04082975|ACTIVE_COMPARATOR|NVP-1203-R|NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose
62616824|NCT00166049|EXPERIMENTAL|Group 3 Family Partnership Intervention|Patient and family member received one individual dyadic education/counseling session, and two group sessions focused on developing family approaches to HF self management. the emphasis of the two group sessions was on developing autonomy supportive approaches to family support.
62616825|NCT02219386|ACTIVE_COMPARATOR|Deep dry needling|The group of DDN receive this treatment and stretch
62259884|NCT05505162|EXPERIMENTAL|Zibotentan and EE/LNG|"Participants will receive two tablets of combined oral EE/LNG on Day 1 with PK samples obtained from pre-dose on Day 1 until post-dose on Day 6.~Participants will receive two capsules of zibotentan orally QD from Day 6 to Day 14. From Day 15 until Day 19 participants will continue to receive two capsules of zibotentan QD administered orally.~On Day 15, participants will receive two tablets of combined oral EE and LNG with PK samples obtained pre-dose on Day 15 until post-dose (Day 20)."
62259885|NCT06490458|ACTIVE_COMPARATOR|Group A :( Study group)|Underwent balance training and cardiac rehabilitation program for a duration of 25-30 min (total session) at a frequency of three times/week (every other day). The balance training was: a- Functional strength exercise b- Stance exercise c- Transition exercise D-Gait training e- Cardiac rehabilitation program .
62259886|NCT06490458|ACTIVE_COMPARATOR|Group B (control group)|"underwent cardiac rehabilitation program only for a duration of 25-30 min (total session) at a frequency of three times/week (day after day).~the control group, received cardiac rehabilitation program only."
62259887|NCT03115736|EXPERIMENTAL|Switch|Patients are switched from a TDF-containing antiretroviral therapy regimen to a TAF-containing regimen
62259888|NCT02793440|ACTIVE_COMPARATOR|cortivazol|anti-inflammatory therapy and epidural
62259889|NCT02793440|EXPERIMENTAL|Traction arm|Medical treatment associated with 5 lumbar traction sessions
62259890|NCT06503575||Patient with adolescent idiopathic scoliosis|
62259891|NCT06503575||Healthy control|
62259892|NCT04383873|EXPERIMENTAL|Intervention|17 cervical Spinal Cord injured patients daily receive 1 hour of upper extremity therapy
62259893|NCT04383873|ACTIVE_COMPARATOR|Control|17 cervical Spinal Cord injured patients daily receive 1 hour of upper extremity therapy
62259894|NCT01352832|EXPERIMENTAL|Interactive DVD|"Patients randomized to this arm will receive a DVD DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate stories through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor."
62259895|NCT01352832|PLACEBO_COMPARATOR|Usual Care|Patients randomized to this arm receive their usual care.
62445544|NCT05502315|EXPERIMENTAL|Experimental Group|"40 mg of cabozantinib taken orally every day (days 1-28) of a 28 day cycle~480 mg of nivolumab given intravenously on the first day (day 1) of each 28 day cycle"
62445545|NCT03849781|ACTIVE_COMPARATOR|Intervention|NeoBeat will be placed on all newborns immediately after birth to assess the heartrate for at least 5 minutes, or longer if the newborn needs resuscitation. Intervention subjects will have a visible display of the heart rate on the NeoBeat, to guide healthcare providers in further management of the newborn.
62616826|NCT02219386|OTHER|muscle stretch|The stretch applied was as described by Simons et al. (Simons et al., 1999). During the stretch the physiotherapist took up the slack, avoiding pain elicitation, maintaining the tension for four seconds and releasing the tension for eight seconds; this cycle was repeated three times
62616827|NCT03774394|EXPERIMENTAL|Diabetes Mellitus patients with Chronic Kidney Disease|"Patients with CKD will be administered a 600-mg LD of Clopidogrel followed by a single 75-mg MD administered after 24 hours.~Blood samples collected at baseline will be incubated with clopidogrel active metabolite."
62259896|NCT05540002|ACTIVE_COMPARATOR|High Intensity Stimulation|Patients will be randomly assigned to the High Intensity Quell group and will receive higher intensity stimulation every day for 12 weeks.
62259897|NCT05540002|SHAM_COMPARATOR|Low Intensity Stimulation|Patients will be randomly assigned to the Low intensity Quell group and will receive lower intensity stimulation every day for 12 weeks.
62259898|NCT00607386|OTHER|Idursulfase|Open-label treatment with idursulfase
62259899|NCT06469996|EXPERIMENTAL|Connective tissue massage group|Connective tissue massage will be applied by an experienced physiotherapist for a total of 12 sessions 2 days a week for 6 weeks. While the patients are in sitting position, starting from the lumbosacral region, the lower thoracic, scapular, interscapular and cervical regions will be included in the treatment respectively.
62259900|NCT06469996|EXPERIMENTAL|Self myofascial relaxation group|Self myofascial relaxation will be applied using foam roller. The practice will continue two days a week for 6 weeks. Foam roller exercise is performed in the supine position with knees bent, hands locked behind the neck and foam roller is placed between the shoulder blades.
62841835|NCT06265662|EXPERIMENTAL|The Intervention Arm|"Participants will engage in various activities, including:~* Attending four group health education sessions, each lasting one hour, over a six-month period.~* Having access to individual chat consultations with a healthcare team, including doctors, dietitians, fitness coaches, and psychologists, available from 9:00 AM to 5:00 PM on workdays, excluding public holidays, with no limit on consultation times."
62841836|NCT01635426|ACTIVE_COMPARATOR|Aspirin|
62841837|NCT01635426|ACTIVE_COMPARATOR|Clopidogrel|
62841838|NCT03037580|EXPERIMENTAL|Oral treprostinil|Sustained-release oral tablets for TID administration
62445546|NCT03849781|NO_INTERVENTION|Standard Care|NeoBeat will be placed on the newborn to collect information on heart rate, but heart rate is not displayed to the healthcare providers. If the newborn is in need of resuscitation to initiate spontaneous respiration, the baby will be transferred to the resuscitation bay. According to recommendations the heart rate should be assessed and positive pressure ventilation initiated within one minute of life. Standard care is to assess heart rate by conventional ECG and/or pulse oximetry, alternatively auscultation of the heart.
62841839|NCT03037580|PLACEBO_COMPARATOR|Placebo|Placebo (sugar pill) for TID oral administration
62841840|NCT05036421|EXPERIMENTAL|Study Group|Empagliflozin
62841841|NCT02689362|EXPERIMENTAL|Evogliptin 2.5mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 2.5 mg. The participants randomized to this group will receive 1 tablet daily of EVO 2.5 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
62841842|NCT02689362|EXPERIMENTAL|Evogliptin 5.0mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 5.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 5.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
62259901|NCT04719650|EXPERIMENTAL|zoledronic acid 1mg|Add 20 mL of Zoledronic acid injection (100mL : 5mg) with 80 mL of normal saline to 100 mL. Infusion 20 minutes with constant speed. Administration only once.
62259902|NCT04719650|EXPERIMENTAL|zoledronic acid 2.5mg|Add 50 mL of Zoledronic acid injection (100mL : 5mg) with 50 mL of normal saline to 100 mL. Infusion 20 minutes with constant speed. Administration only once.
62259903|NCT04719650|EXPERIMENTAL|zoledronic acid 5mg|Infusion 100 mL of Zoledronic acid injection (100mL : 5mg) with constant speed in 20 minutes. Administration only once.
62445547|NCT00880282|EXPERIMENTAL|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 60 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.
62445548|NCT02051127|EXPERIMENTAL|Exercise|Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate \> 75% of maximum heart rate determined by exercise test before start of the intervention
62445549|NCT02051127|NO_INTERVENTION|Control|Instructed to continue with their sedentary behavior for another 6 months.
62056801|NCT02268695|ACTIVE_COMPARATOR|EXTREME: Cisplatin, 5-FU and Cetuximab|"Chemotherapy: 6 cycles (every 3 weeks) of Cisplatin (100 mg/m² iv on Day1), 5FU (4000 mg/m² total dose starting on day 1 and during 96h in continuous infusion), and Cetuximab (loading dose of 400 mg/m² iv on Day1, then 250 mg/m² iv weekly).~If cisplatin is not tolerated and/or when the total cumulative dose of cisplatin (including prior administration) reaches 600 mg/m², cisplatin has to be replaced by carboplatin, AUC 5 (but not exceeding 750 mg), except in the case of bleeding tumor.~Cetuximab maintenance : cetuximab continuation (250 mg/m² iv weekly) will begin only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until PD or unacceptable toxicity."
62259904|NCT04719650|PLACEBO_COMPARATOR|placebo|Infusion 100 mL of normal saline with constant speed in 20 minutes. Administration only once.
62259905|NCT02218281|EXPERIMENTAL|C2Q-Teen app|Smoking cessation treatment delivered through a smartphone app via mindfulness training.
62445550|NCT02210884|EXPERIMENTAL|Vitamin D|Weekly oral dose of 15,000 IU of Vitamin D3
62445551|NCT02210884|PLACEBO_COMPARATOR|Placebo|Placebo capsule containing no vitamin D
62445552|NCT00952484|ACTIVE_COMPARATOR|2 mg/kg|2 mg/kg subcutaneous injection three times per week.
62445553|NCT00952484|ACTIVE_COMPARATOR|3 mg/kg|3 mg/kg subcutaneous injection three times per week.
62445554|NCT01919268|EXPERIMENTAL|Electrotherapy|Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
62445555|NCT01919268|ACTIVE_COMPARATOR|Pilates|Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of six weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
62445556|NCT05396456|EXPERIMENTAL|Muscle Fiber Fragment (MFF) injections|autologous muscle fiber fragment injections, harvested in an autologous fashion from the quadriceps muscle, for the treatment of Fecal Incontinence (FI) symptoms in men and women with a demonstrated anal sphincter defect and who have failed conservative treatments
62445557|NCT05914519|ACTIVE_COMPARATOR|Group 1|
62841843|NCT02689362|EXPERIMENTAL|Evogliptin 10.0mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 10.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 10.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
62841844|NCT02689362|ACTIVE_COMPARATOR|Sitagliptin 100mg+Placebo Evogliptin|SITA at a daily oral dose of 100 mg. The participants randomized to this group will receive 1 tablet daily of SITA 100 mg + 1 tablet of EVO placebo for 12 weeks.
62841845|NCT03083873|EXPERIMENTAL|Cohort 1|Treatment with LN-145, Generation 1 (Gen 1), non-cryopreserved TIL
62841846|NCT03083873|EXPERIMENTAL|Cohort 2|Treatment with LN-145 Generation 2 (Gen 2), cryopreserved TIL
62445558|NCT05914519|ACTIVE_COMPARATOR|Group 2|
62841847|NCT03083873|EXPERIMENTAL|Cohort 3|Treatment with LN-145 Generation 3 (Gen 3), cryopreserved TIL
62841848|NCT03083873|EXPERIMENTAL|Cohort 4|Treatment with LN-145-S1 cryopreserved TIL
62841849|NCT03083873|EXPERIMENTAL|Cohort 5|LN-145 cryopreserved/LN-145-S1 cryopreserved TIL re-treatment
62841850|NCT01691222|OTHER|Double lumen endotracheal tube tracheostomy|Tracheostomy with a dedicated double lumen endotracheal tube
62841851|NCT05998057|ACTIVE_COMPARATOR|control group|The control group was asked to continue the standard (routine) classical training training (5 days/12 weeks).
62259906|NCT02218281|ACTIVE_COMPARATOR|NCI's QuitSTART app|Smoking cessation treatment delivered through a smartphone app by NCI, without mindfulness training.
62056802|NCT02268695|EXPERIMENTAL|TPEx: Cisplatin, Docetaxel and Cetuximab|"Chemotherapy: 4 cycles (every 3 weeks) of Cisplatin (75 mg/m² iv on Day1), Docetaxel (75 mg/m² iv on Day1), and Cetuximab (loading dose of 400 mg/m² iv on Day1, then 250 mg/m² iv weekly).~If Cisplatin is not tolerated, cisplatin is replaced by carboplatin, AUC 5 (but not exceeding 750 mg), except in the case of bleeding tumor.~Primary prophylactic administration of GCSF must be administered systematically after each cycle of chemotherapy.~Cetuximab maintenance : cetuximab continuation (500 mg/m² iv every two weeks) will begin only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until PD or unacceptable toxicity."
62259907|NCT02218281|ACTIVE_COMPARATOR|Written smoking cessation materials only|Receipt of written smoking cessation materials.
62616828|NCT03774394|ACTIVE_COMPARATOR|Diabetes Mellitus patients without Chronic Kidney Disease|"Patients without CKD will be administered a 600-mg LD of Clopidogrel followed by a single 75-mg MD administered after 24 hours.~Blood samples collected at baseline will be incubated with clopidogrel active metabolite."
62616829|NCT02445131|EXPERIMENTAL|Bendamustine + GA101 + CAL-101|Bendamustine: 70 mg/m2 i.v. GA101: 1000 mg CAL-101: 150 mg p.o.
62259908|NCT03549156|ACTIVE_COMPARATOR|C-RUSF|Control/Standard RUSF
62259909|NCT03549156|ACTIVE_COMPARATOR|HIPRO RUSF|New RUSF product
62259910|NCT05725070|EXPERIMENTAL|Drug|212Pb-NG001
62259911|NCT00272909|EXPERIMENTAL|1|piclozotan IV infusion, low dose, for 72 hours.
62259912|NCT00272909|EXPERIMENTAL|2|piclozotan IV infusion, high dose, for 72 hours.
62259913|NCT00272909|PLACEBO_COMPARATOR|3|placebo (normal saline) IV infusion, for 72 hours.
62259914|NCT04719143|ACTIVE_COMPARATOR|CBT-I|
62259915|NCT04719143|NO_INTERVENTION|Waitlist Control|
62445559|NCT04615156|EXPERIMENTAL|Evaluation for adverse events from 18F-2-fluoro-2-deoxy-D-glucose produced by a new manufacturer|
62056803|NCT01986881|EXPERIMENTAL|Ertugliflozin, 15 mg|Ertugliflozin 15 mg administered orally once daily for up to approximately 6 years
62259916|NCT00917150|EXPERIMENTAL|OPC-6535 12.5mg|
62259917|NCT00917150|EXPERIMENTAL|OPC-6535 25mg|
62259918|NCT00917150|EXPERIMENTAL|OPC-6535 50mg|
62259919|NCT00917150|PLACEBO_COMPARATOR|placebo|
62259920|NCT03956914|EXPERIMENTAL|DSW (deep sea water) group|DSW, 440 ml/day for 8 weeks
62259921|NCT03956914|PLACEBO_COMPARATOR|Placebo group|Placebo, 440 ml/day for 8 weeks
62259922|NCT02015884||All patients admitted to the ophthalmologic emergency unit.|
62445560|NCT05233683|EXPERIMENTAL|Caudal block and circumcision with Plastibell,|Caudal block will be performed with 0.75ml/kg of 0.25% bupivacaine containing 1 mic/kg dexmedetomidine. Circumcision will be done using plastibell. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective.
62445561|NCT05233683|EXPERIMENTAL|Caudal block and circumcision with conventional dissection method|Caudal block will be performed with 0.75ml/kg of 0.25% bupivacaine containing 1 mic/kg dexmedetomidine. Circumcision will be done using the conventional dissection method. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective.
62445562|NCT05233683|ACTIVE_COMPARATOR|Dorsal penile nerve block plus ring block and circumcision with Plastibell|Dorsal penile nerve block plus ring block with 0.25% bupivacaine. Circumcision will be done using plastibell.
62445563|NCT05233683|ACTIVE_COMPARATOR|Dorsal penile nerve block plus ring block and circumcision with conventional dissection method|Dorsal penile nerve block plus ring block with 0.25% bupivacaine. Circumcision will be done using the conventional dissection method
62445564|NCT00003520|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62445565|NCT01614509|EXPERIMENTAL|Monotherapy group|The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.
62445566|NCT01614509|EXPERIMENTAL|Combined group|The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The Bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
62445567|NCT02957279||Sepsis group|The patients were admitted to the Jinling Hospital, who met the diagnosis of sepsis(Sepsis 3.0).
62445568|NCT02957279||Healthy control group|Healthy volunteers.
62445569|NCT06337006||Group S|The LMA was successfully placed after the first attempt.
62445570|NCT06337006||Group non-S|The LMA was not placed successfully after the first attempt.
62445571|NCT05417048||Breat cancer|Histologically confirmed breast cancer patients(Stage I-III)
62623685|NCT00582426|OTHER|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
62841852|NCT05998057|EXPERIMENTAL|exercise group|The neuromuscular training program has been adapted to ice hockey players. The content of the program includes core stabilization, balance and plyometric exercises. The session duration was set to be approximately 60-90 minutes. An average session is 15 minutes of warm-up, followed by 30-40 minutes. continued with neuromuscular training program, 15 min. It was ended with cooling and stretching exercises. Since all exercises are done with body weight, no extra equipment is needed.
62841853|NCT05862103||optimized group|the patients received at least one optimized treatment
62841854|NCT05862103||un-optimized group|the patients didn't receive optimized treatment
62841855|NCT02431962|EXPERIMENTAL|Screening arm|Annual low dose screening chest CT scan x 3.
62445572|NCT05417048||Benign breast disease|Histologically confirmed breast fibroma, intraductal papilloma,mammary hyperplasia, breast cyst etc
62841856|NCT02431962|EXPERIMENTAL|Smoking cessation counseling|Active smokers randomized to this arm will be contacted by a trained smoking cessation counselor and offered cessation support and advice.
62056804|NCT01986881|EXPERIMENTAL|Ertugliflozin, 5 mg|Ertugliflozin 5 mg administered orally once daily for up to approximately 6 years
62056805|NCT01986881|PLACEBO_COMPARATOR|Placebo|Matching placebo to ertugliflozin administered orally once daily for up to approximately 6 years
62056806|NCT06520943||Group 1|After intubation, a fresh gas flow of 3 L/min will be applied for the first 20 minutes and then reduced to 0.5 L/min.
62445573|NCT05417048||Healthy control|No breast lesions detected by clinical examination/mammography/ultrasound/breast magnetic resonance imaging (MRI)
62616830|NCT04895488|EXPERIMENTAL|Arm A: Vortioxetine+Usual antipsychotic treatment (TAU)|"Drug:~First treatment phase: Vortioxetine 10 mg 1 tablet/d for 2 weeks added to Usual antipsychotic treatment, followed by Vortioxetine 20mg 1tablet/d for 22 weeks added to Usual antipsychotic treatment.~Wash-out period 2 weeks"
62616831|NCT04895488|ACTIVE_COMPARATOR|Arm B: Usual antipsychotic treatment (TAU)|Second treatment phase: Usual antipsychotic treatment: Allows for whatever medication, routine support, or referral to other services was felt appropriate by the clinician.
62841857|NCT02431962|ACTIVE_COMPARATOR|Smoking cessation control|Active smokers randomized to this arm will receive general information on available smoking cessation resources.
62841858|NCT04149756||overweight or obese adults|overweight or obese adults who participate the trial (NCT03675191)
62056807|NCT06520943||Group 2|After intubation, a fresh gas flow of 3 L/min will be applied for the first 20 minutes and then reduced to 1 L/min.
62056808|NCT03354364|ACTIVE_COMPARATOR|Group 1|Receives pea hull fiber snack for the first 4 weeks and then control snack for the last 4 weeks of the study with 4-week washout between them.
62056809|NCT03354364|ACTIVE_COMPARATOR|Group 2|Receives control snack for the first 4 weeks and then pea hull fiber snack for the last 4 weeks of the study with 4-week washout between them
62056810|NCT04896333||Robot interaction|"EBO is a robotic platform consisting of the following: A screen display capable of generating emotions (sadness, joy, neutral, anger, disgust and surprise), RGB camera, basic navigation system.~EBO must be controlled by a teleoperator through a user-friendly and simple interface. Communication should be as immediate as possible, as well as predefined. In any case, the dialogue flow can be modified if necessary. The interface, at the same time, allows the possibility of sending emotions and small movements to the robot, to accompany the dialogue with certain elements of emotionality.~The experiment replicates the Wizard of Oz technique. In this technique, the human tele-operator controls the robot without the person noticing it as he is in another room. For this purpose, a user interface will be displayed on the teleoperator's terminal and the commands will be reproduced by the EBO robot"
62056811|NCT03559088|EXPERIMENTAL|Migraine Participants Using Application (App)|Participants with migraine history or a recent prescription for a common migraine medication will use a migraine app linked to their electronic health record (EHR) with results reported in their EHR.
62056812|NCT03559088|NO_INTERVENTION|Controls Not Using App|Observational history on contemporaneous matched controls at similar sites without migraine app linked to their EHR.
62445574|NCT03482479|EXPERIMENTAL|Naltrexone Hydrochloride|Naltrexone hydrochloride for oral use, 4.5 mg per capsule, taken once a day for 6 weeks.
62445575|NCT03482479|PLACEBO_COMPARATOR|Placebo Comparator|Placebo to match naltrexone for oral use to be taken once a day for 6 weeks.
62445576|NCT00927810|EXPERIMENTAL|canakinumab|
62616832|NCT01990716|OTHER|IBD patients|Patients (diagnosed with IBD) having a screening colonic biopsy
62616833|NCT01990716|OTHER|Control Group|individuals undergoing screening colonic biopsy for colon cancer or polyp detection, who have not been diagnosed with any intestinal pathology.
62445577|NCT02450565||Neuropathic pain subjects|The diagnosis of neuropathic pain will be made by pain specialists based on a detailed history, physical examination, investigation results and medical records.
62445578|NCT02450565||Nociceptive pain subjects|The diagnosis of nociceptive pain will be made by pain specialists based on a detailed history, physical examination, investigation results and medical records.
62445579|NCT03177356|EXPERIMENTAL|extraction,implant placement,PRF|Extraction of Mandibular first molar and Implant placement followed by Placement of placement of Platelet rich fibrin as space filling material
62445580|NCT03177356|ACTIVE_COMPARATOR|Exctraction,Implant placement,Bone graft|Extraction of mandibular first molar followed by implant placement and xenogenic bone graft as space filling material
62445581|NCT01549288|EXPERIMENTAL|modified Atkins diet|
62445582|NCT01549288|OTHER|control arm|the control arm continues the anti-epileptic drugs without any added dietetic input
62616834|NCT06498726||1|This prospective cross-sectional will include 18 patients who are diagnosed with sickle cell anemia of either sex aged 1 to 18 years old; free from neurological disorders.
62616835|NCT03489200|EXPERIMENTAL|EH301|
62841859|NCT04565704|EXPERIMENTAL|Development of novel optical imaging technologies|Consented participants will allow their endoscopist to collect 3 additional biopsies from the participants. These biopsies will be used to develop our imaging techniques at our lab. We will use the standard of care histology images from the endoscopy procedure as a control comparison.
62841860|NCT02280408|EXPERIMENTAL|3x10^6 plaque-forming units (pfu) Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 3x10\^6 pfu in the deltoid on Day 0 and Day 28.
62841861|NCT02280408|EXPERIMENTAL|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 2x10\^7 pfu in the deltoid on Day 0 and Day 28.
62616836|NCT03489200|PLACEBO_COMPARATOR|Placebo|
62616837|NCT05049473|EXPERIMENTAL|Chemotherapy|"Pts with biological age up to 55 y with advanced stage will receive 6 cycles of intensive treatment: blocks (A1-B1-C1-A2-B2-C2). If after A1 and B1 cycles CR is observed, the rest of the cycles will be administered with reduced doses.~In pts with biological age \>55 y with advanced stage block will receive A and B with attenuated doses (A1\*-B1\*-A2\*-B2\*-A3\*-B3\*).~Pts with biological age up to 55 y with localized stage (non-bulky I or II) with CR after 2 cycles will finish treatment after 4 blocks. If CR is not reached, patients will complete the 6 treatment cycles.~Pts with a biological age \>55 y with localized stage (non-bulky I or II) with CR after 2 cycles will finish treatment after 4 attenuated blocks (A1\*-B1\*-A2\*-B2\*). If CR is not reached, patients will complete the 6 cycles of treatment."
62616838|NCT05900583||MRD positive group|
62616839|NCT05900583||MRD negative group|
62616840|NCT03036982||Use of Mobile ACT|Will answer ACT (or cACT) and other asthma questions using mobile app
62616841|NCT04114656|PLACEBO_COMPARATOR|Participants receiving Placebo|All participants will receive a single dose of placebo in either one or two of the three study periods, as per the randomization schedule.
62616842|NCT04114656|EXPERIMENTAL|Participants receiving GSK3858279|All participants will receive a single dose of GSK3858279 in either one or two of the three study periods, as per the randomization schedule.
62616843|NCT02470663|EXPERIMENTAL|Study group|Children recieving DENSITYTM caplets (marketed as Amorphical) 200 mg BID for 12 months
62841862|NCT02280408|EXPERIMENTAL|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 1x10\^8 pfu in the deltoid on Day 0 and Day 28.
62616844|NCT02470663|ACTIVE_COMPARATOR|Control group|Children recieving Calcium carbonate 600 mg once daily for 12 months
62616845|NCT04881279||Control|Trauma admissions in April-June 2016.
62841863|NCT02280408|PLACEBO_COMPARATOR|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0 and Day 28.
62259923|NCT02173860|ACTIVE_COMPARATOR|FFR-guided revascularization|Patients with valvular heart disease scheduled for elective cardiac surgery and concomitant significant coronary artery disease will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions in vessels pre-specified as suitable for surgical revascularization. If the FFR is ≤0.80, then CABG will be performed. If the FFR is \>0.80 then no graft will be placed in that particular vessel. Patients in whom FFR of a particular lesion is not possible can be included if at least one additional lesion is suitable for FFR measurement and grafting.
62259924|NCT02173860|ACTIVE_COMPARATOR|Angio-guided revascularization|Concomitant CABG will be performed as per clinical routine in all vessels with at least one stenosis \> 50%. The vessel should be pre-specified as suitable for surgical revascularization before randomization. An internal mammary graft to the LAD should be attempted in all cases, if possible. Further revascularization strategy is left to the discretion of each center.
62259925|NCT02692365|EXPERIMENTAL|Calcium channels|Magnetic Resonance assessment Hemodynamics + + infusion of manganese chloride
62259926|NCT02692365|EXPERIMENTAL|Tumor perfusion|Magnetic Resonance + hemodynamic + infusion of gadolinium
62259927|NCT03187938||Pregnant women at 24-28 weeks gestation|Pregnant women, aged 18 and older, who are seen for their prenatal care and who are between 24w0d and 28w6d weeks gestation.Their alkaline phosphatase levels will be tested in this study.
62445583|NCT04133181|EXPERIMENTAL|Guided endodontic surgery|Use of a 3D surgical guide in endodontic surgery
62616846|NCT04881279||Ransomware Group|Trauma admissions in April-June 2017.
62841864|NCT04041167|ACTIVE_COMPARATOR|Alpha lipoic acid|All patients will be assigned intravenous alpha lipoic acid 600mg within 24 hours of symptom onset. Patients will receive intravenous alpha lipoic acid 600mg/day for one week, followed by an oral pill of alpha lipoic acid 600mg/day for three months.
62259928|NCT06281470|EXPERIMENTAL|Single Ascending Dose(SAD) Treatment 1|WS016 single dose（6g）
62259929|NCT06281470|EXPERIMENTAL|SAD Treatment 2|WS016 single dose（12g）
62445584|NCT04133181|PLACEBO_COMPARATOR|Conventional endodontic surgery|Use of a mock guide in endodontic surgery
62445585|NCT05287880||Non-N0 stage|Patients with malignant lymph nodes.
62616847|NCT03066778|EXPERIMENTAL|Pembrolizumab+EP|During each 21-day cycle, participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 PLUS etoposide 100 mg/m\^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum therapy (carboplatin titrated to an area under the plasma drug concentration-time curve \[AUC\] 5 IV on Day 1 OR cisplatin 75 mg/m\^2 IV on Day 1). Participants who stop pembrolizumab as a result of obtaining a response of stable disease (SD), partial response (PR), complete response (CR) or those who stop after receiving pembrolizumab for 24 months for reasons other than disease progression or intolerability, are eligible for up to an additional 1 year of treatment after progressive disease if they meet the criteria for retreatment.
62616848|NCT03066778|ACTIVE_COMPARATOR|Placebo+EP|During each 21-day cycle, participants receive placebo (normal saline solution) IV on Day 1 PLUS etoposide 100 mg/m\^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum therapy (carboplatin titrated to an AUC 5 IV on Day 1 OR cisplatin 75 mg/m\^2 IV on Day 1).
62616849|NCT01096498|EXPERIMENTAL|Arm 1|
62616850|NCT01096498|ACTIVE_COMPARATOR|Arm 2|
62616851|NCT01348100|EXPERIMENTAL|Iloperidone 50 mg crystalline formulation - Phase A|Participants received a crystalline formulation of iloperidone 50 mg in a depot intramuscular (IM) injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.
62616852|NCT01348100|EXPERIMENTAL|Iloperidone 125 mg crystalline formulation - Phase A|Participants received a crystalline formulation of iloperidone 125 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.
62841865|NCT04041167|PLACEBO_COMPARATOR|Normal saline|All patients will receive intravenous normal saline within 24 hours of symptom onset.
62616853|NCT01348100|EXPERIMENTAL|Iloperidone 250 mg crystalline formulation - Phase B|Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
62616854|NCT01348100|EXPERIMENTAL|Iloperidone 250 mg microparticle formulation - Phase B|Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
62616855|NCT01348100|EXPERIMENTAL|Iloperidone 250 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
62616856|NCT01348100|EXPERIMENTAL|Iloperidone 500 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 500 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
62616857|NCT01348100|EXPERIMENTAL|Iloperidone 625 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
62616858|NCT06275737|OTHER|Cohort 1 and Cohort 2|"Cohort 1 - Patients with PDAC~Cohort 2 - Patients with OGC"
62616859|NCT03051373|EXPERIMENTAL|nab-paclitaxel plus S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
62841866|NCT05201300|EXPERIMENTAL|Remimazolam 6|Remimazolam starts at 6 mg/kg/hr until loss of consciousness
62445586|NCT05287880||N0 stage|Patients without malignant lymph nodes.
62445587|NCT05092347|EXPERIMENTAL|REGN5459|REGN5459 escalating dose
62445588|NCT05092347|EXPERIMENTAL|REGN5458|REGN5458 escalating dose
62616860|NCT03051373|ACTIVE_COMPARATOR|Gemcitabine plus cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
62616861|NCT06396299||Patients diagnosed with atrial fibrillation|
62616862|NCT00123682|EXPERIMENTAL|Arm 1 - proactive, intensive counseling|Proactive outreach to counseling; multi-session counseling from California Smokers' Helpline
62616863|NCT00123682|EXPERIMENTAL|Arm 2 - reactive, intensive counseling|Reactive outreach to counseling; multi-session counseling from California Smokers' Helpline
62841867|NCT05201300|EXPERIMENTAL|Remimazolam 12|Remimazolam starts at 12 mg/kg/hr until loss of consciousness
62841868|NCT05201300|ACTIVE_COMPARATOR|Propofol|Propofol starts at a target controlled infusion 4 µg/ml until loss of consciousness.
62841869|NCT05066048||The appendectomy group|
62841870|NCT05066048||Colorectal cancer group|
62841871|NCT05066048||Normal group|
62841872|NCT01957306|EXPERIMENTAL|Dr. Tagliaferri's Menoapause Formula|Administered as 2 grams PO BID.
62056813|NCT02416492|EXPERIMENTAL|SB623 Cells|SB623 Cells: 2.5, 5 or 10 million cells
62056814|NCT02416492|SHAM_COMPARATOR|Sham Surgery|Control Sham Surgery
62445589|NCT02437214|EXPERIMENTAL|Use of music for anxiety in children|Children in the Exp group received the usual medical care in combination with the intervention. The intervention was started by the patients nurse without the knowledge of the research associate. In the intervention group, music was played until the CT scan was completed.
62445590|NCT02437214|NO_INTERVENTION|Control|Children in the Con group received the usual medical care without listening to the music intervention.
62841873|NCT00552435|EXPERIMENTAL|1|Micropulse 810nm diode laser
62259930|NCT06281470|EXPERIMENTAL|SAD Treatment 3|WS016 single dose（24g）
62259931|NCT06281470|EXPERIMENTAL|SAD Treatment 4|WS016 single dose（36g）
62259932|NCT06281470|EXPERIMENTAL|SAD Treatment 5|WS016 single dose（48g）
62445591|NCT05265026|EXPERIMENTAL|Exercise Intervention Arm|Three high intensity interval exercise sessions per week of 40 minutes duration per session. Exercise will be performed on ergometerbikes.
62445592|NCT05265026|NO_INTERVENTION|No Intervention|No lifestyle changes
62841874|NCT00552435|ACTIVE_COMPARATOR|2|Argon laser photocoagulation
62841875|NCT01153334|EXPERIMENTAL|Early intensive rosuvastatin therapy|
62841876|NCT01153334|PLACEBO_COMPARATOR|Conventional statin therapy|
62445593|NCT05611268|NO_INTERVENTION|No treatment group|24 patients that will continue receiving routine treatment for PAH
62445594|NCT05611268|OTHER|Pentoxifylline|24 patients that will receive pentoxifylline and the routine treatment for PAH
62445595|NCT02933593|ACTIVE_COMPARATOR|labetalol|labetalol
62445596|NCT02933593|ACTIVE_COMPARATOR|hydralazine|Hydralazine
62445597|NCT02933593|ACTIVE_COMPARATOR|nifedipine|nifedipine
62841877|NCT02506348|EXPERIMENTAL|Diclofenac+Nepafenac|one drop Diclofenac in one eye one drop Nepafenac in other eye
62841878|NCT02835079|OTHER|open label study|one arm open label study
62259933|NCT06281470|PLACEBO_COMPARATOR|SAD matching placebo|SAD Matching placebo
62259934|NCT06281470|EXPERIMENTAL|Multiple Ascending Dose(MAD) Treatment 1|WS016 multiple dose(MAD Low Dose)
62445598|NCT00940199||Standard of Care|I:Application of L-M-X topical anesthetic cream 4% to the breast within one hour of sub-areaolar injection of 4 ml 99mTc-sulfur colloid (1 mCi in normal saline)
62841879|NCT02186093||Korea|patients in South of Korea
62841880|NCT02186093||United Kingdom|patients in England
62841881|NCT02186093||Spain|patients in Spain
62259935|NCT06281470|EXPERIMENTAL|MAD Treatment 2|WS016 multiple dose(MAD Medium Dose)
62259936|NCT06281470|EXPERIMENTAL|MAD Treatment 3|WS016 multiple dose(MAD High Dose)
62259937|NCT06281470|PLACEBO_COMPARATOR|MAD matching placebo|MAD matching placebo
62259938|NCT01975740|EXPERIMENTAL|Manual diaphragm release technique|
62445599|NCT00940199||1 mCi in sodium bicarbonate|II. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in sodium bicarbonate)
62259939|NCT01975740|OTHER|Sham manual diaphragm release technique|
62259940|NCT06320691||General Anesthesia Group|The group that underwent direct anterior total hip arthroplasty with general-systemic anesthesia
62445600|NCT00940199||1 mCi in 1% Lidocaine|III. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in 1% Lidocaine)
62445601|NCT00940199||1 mCi in sodium bicarbonate + 1% Lidocaine|IV. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in sodium bicarbonate + 1% Lidocaine)
62445602|NCT00601484|EXPERIMENTAL|1|
62445603|NCT00601484|PLACEBO_COMPARATOR|2|
62445604|NCT04834557|PLACEBO_COMPARATOR|Control|Participants in this arm will receive Placebo with the current DMARDs treatments for rheumatoid arthritis for 24 weeks.
62445605|NCT04834557|EXPERIMENTAL|Digoxin|Participants in this arm will receive digoxin 0.25 mg every other day + DMARDs for 24 weeks.
62445606|NCT04834557|EXPERIMENTAL|Ursodeoxycholic acid (UDCA)|Participants in this arm will receive ursodeoxycholic acid (UDCA) 500 mg/day + DMARDs for 24 weeks.
62445607|NCT03674008|EXPERIMENTAL|HSK3486|0.4mg/kg/0.2 mg/kg
62445608|NCT03674008|ACTIVE_COMPARATOR|Propofol|1.5mg/kg/0.75mg/kg
62445609|NCT06380465|EXPERIMENTAL|1:1 water extract of purple sweet potato|subjects were blindly and randomly assigned the pure water extract of purple sweet potato for 14 days. The water extract of purple sweet potato with a concentration ratio of 1:1
62445610|NCT06380465|PLACEBO_COMPARATOR|1:6 water extract of purple sweet potato|subjects were blindly and randomly assigned the lower concentration of water extract of purple sweet potato for 14 days. The water extract of purple sweet potato with a concentration ratio of 1:6
62445611|NCT02896465|ACTIVE_COMPARATOR|ORS+ZINC|Oral rehydration solution + Zinc
62841882|NCT02186093||United State of America|patients in USA
62841883|NCT02533453|EXPERIMENTAL|Bydureon|exenatide once weekly
62841884|NCT03830619||lung cancer patients|
62259941|NCT06320691||Spinal Anesthesia Group|The group that underwent direct anterior total hip arthroplasty with spinal-neuraxial anesthesia
62259942|NCT05003622|EXPERIMENTAL|encorafenib|Encorafenib hard capsule will be orally self-administered. A fixed-flat dose of 300 mg (4 x 75 mg) Per Oral (PO) encorafenib will be administered once-daily (QD).
62259943|NCT00141024|EXPERIMENTAL|1|Group 1 will receive 4 vaccinations of the EP-1043 vaccine or placebo. Vaccinations will be given at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
62259944|NCT00141024|EXPERIMENTAL|2|Group 2 will receive 4 vaccinations of the EP-1043 vaccine or placebo. Vaccinations will be given at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
62445612|NCT02896465|EXPERIMENTAL|ORS+ZINC+HMO|Oral rehydration solution + Zinc + Human milk oligosaccharides
62445613|NCT02896465|PLACEBO_COMPARATOR|ORS+ZINC+Breastfeeding|Oral rehydration solution + Zinc + Breastfeeding
62445614|NCT05751629|EXPERIMENTAL|Cohort A (Dostarlimab + Bevacizumab + Niraparib)|
62445615|NCT01977430|EXPERIMENTAL|Diuretics arm|The diuretic arm's patients will receive combined thiazide-furosemide therapy for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
62445616|NCT01977430|NO_INTERVENTION|Control Arm|
62841885|NCT03830619||normol volunteers|
62841886|NCT02838394|EXPERIMENTAL|Dry Needling|Trigger points found in the gluteal region of one side (e.g. right) will be dry needled; presence of muscle twitching (which would signify appropriate needle insertion) will be documented.
62841887|NCT02838394|SHAM_COMPARATOR|Sham Dry Needling|Trigger points found in the gluteal region of one side (e.g. right) will be SHAM dry needled with blunted needles, no actual penetration through the skin will occur.
62056815|NCT06451822|EXPERIMENTAL|mIntense L+AS|The investigated product mIntense L+AS was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. Both sessions were conducted within 14 day intervals.
62259945|NCT00141024|EXPERIMENTAL|3|In Part B, Group 3 will receive 4 vaccinations of either the EP-1043 vaccine or placebo. Vaccinations will occur at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
62259946|NCT00141024|EXPERIMENTAL|4|In Part B, Group 4 will receive 4 vaccinations of either the DNA vaccine EP-HIV-1090 or placebo. Vaccinations will occur at Months 0, 1, 3, and 6.
62616864|NCT00123682|EXPERIMENTAL|Arm 3 - proactive, self-help|Proactive outreach to engage smoker in treatment; mailed self-help materials
62616865|NCT00123682|EXPERIMENTAL|Arm 4 - reactive, self-help|Reactive approach to engaging smoker in treatment; mailed self-help materials
62616866|NCT02074319|PLACEBO_COMPARATOR|Placebo|Matching placebo for methotrexate
62616867|NCT02074319|EXPERIMENTAL|Methotrexate|Methotrexate 10 mg once a week orally
62616868|NCT06209762|ACTIVE_COMPARATOR|Control Group|
62616869|NCT06209762|EXPERIMENTAL|Inspiratuar Muscle Education Group|Patients in this group will have 10 repetitions of slow diaphragmatic deep breathing exercises followed by core stabilization exercises. Then, IMT will be applied with a respiratory muscle training device. In this training, the difficulty of the exercise will be increased by starting from 40% of the MIP value measured during the evaluation and following the values of 60% and 80% according to tolerance. In addition to physical therapy sessions three days a week for eight weeks, patients will be asked to do this exercise five days a week in the morning and evening.
62616870|NCT04284163|EXPERIMENTAL|Gamification group|Problem solving based methodology
62056816|NCT05343416||Open abdomen procedure|All patients underwent to open abdomen procedure
62056817|NCT04074200||Open Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using an open surgical approach.
62056818|NCT04074200||Laparoscopic Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using a laparoscopic surgical approach.
62056819|NCT04074200||Robotic-assisted Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using a robotic-assisted surgical approach.
62056820|NCT00743561|OTHER|1|
62056821|NCT05756231|EXPERIMENTAL|Turkish Adaptation Study of Free and Cued Selective Reminding Test (SIHT-16)|Outcomes of Turkish adaptation of Free and cued selective reminding test (SIHT-16) is compared with memory and non-memory test in three alternative lists: a,b, and c parallel lists. The participants are assessed in neurological diagnosis routine.
62056822|NCT03338621|EXPERIMENTAL|Drug Sensitive BPaMZ|Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 9 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 17 weeks (Total treatment duration 4 months
62056823|NCT03338621|ACTIVE_COMPARATOR|Drug Sensitive Standard Treatment|isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9 to 26
62259947|NCT00141024|EXPERIMENTAL|5|In Part B, Group 5 will receive 4 vaccinations of either the protein vaccine EP-1043 plus DNA vaccine EP-HIV- 1090 or placebo. Vaccinations will occur at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
62259948|NCT01785160|ACTIVE_COMPARATOR|Raltegravir|coated tablets, oral administration with 240 ml water
62259949|NCT01785160|EXPERIMENTAL|Raltegravir + Faldaprevir|coated tablets and soft gelatine capsule, oral administration with 240 ml water
62259950|NCT05046405|EXPERIMENTAL|home-based remotely supervised tDCS|The intervention combines home-based tDCS (1 or 2 cycles of 15 daily sessions for 3 weeks/cycle at 2 mA for 30 minutes) with tele-health for remote supervision and e-health for self-monitoring of depressive symptoms.
62616871|NCT04284163|ACTIVE_COMPARATOR|Traditional teaching group|Master lesson methodology
62616872|NCT06255600|EXPERIMENTAL|Experimental HD-tDCs|Patients will be randomly enrolled into this group. They will receive stimulation in the portion of the left primary motor cortex (M1) by HD-tDCS (lasting 20 minutes of 4x1 tDCS-HD) with anodal stimulus, twice a week for five weeks. The electric current will be supplied with an acceleration time of 30 seconds and will be maintained for 20 minutes and then reduced by 30 seconds
62616873|NCT06255600|EXPERIMENTAL|Experimental HD-tDCS and Chlorella|Patients will be randomly enrolled into this group. They will receive stimulation in the portion of the left primary motor cortex (M1) by HD-tDCS (lasting 20 minutes of 4x1 tDCS-HD) with anodal stimulus, twice a week for five weeks. The electric current will be supplied with an acceleration time of 30 seconds and will be maintained for 20 minutes and then reduced by 30 seconds. In addition, they will receive functional food that will be provided in the form of 10 tablets per day of Chlorella Pyrenoidosa (5g/day) containing 4mcg of B12, organically pressed into tablets (Registration with ANVISA/MS: 6.7273.000) for five weeks.
62616874|NCT06255600|EXPERIMENTAL|Experimental Chlorella|Patients will be randomly enrolled into this group. They will receive the functional food that will be provided in the form of 10 tablets per day of Chlorella Pyrenoidosa (5g/day) containing 4mcg of B12, organically pressed into tablets (Registration with ANVISA/MS: 6.7273.000) for five weeks.
62616875|NCT06255600|SHAM_COMPARATOR|Placebo/Sham|Patients allocated to this group will receive a simulated 3mA current with 30 seconds of acceleration and 30 seconds of deceleration minutes of anodal HD-tDCS (4x1) for 10 sessions (twice a week in five weeks) and/or Placebo with maltodextrin (5g/day) being 10 capsules per day for five weeks.
62841888|NCT00606437|EXPERIMENTAL|I|Total Body Irradiation (TBI)/Flu Conditioning followed by combined UCB
62259951|NCT04438083|EXPERIMENTAL|CTX130|Administered by IV infusion following lymphodepleting chemotherapy.
62259952|NCT00131469|ACTIVE_COMPARATOR|Teriparatide (FORTEO)|Once daily SQ administration of Teriparatide (FORTEO) 20 ug for 18 months
62259953|NCT00131469|PLACEBO_COMPARATOR|Placebo|Daily SQ placebo for 18 months
62056824|NCT03338621|EXPERIMENTAL|Drug Resistant BPaMZ|Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 18 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 26 weeks (Total treatment duration 6 months)
62259954|NCT03709238||Alzheimers diseased patients|Behavioral: Different thermal stimulation. Recording of facial expression during thermal stimulation.
62259955|NCT03709238||Healthy participants|Behavioral: Different thermal stimulation. Recording of facial expression during thermal stimulation.
62841889|NCT02369172|OTHER|Bupropion + ASP2151|400 mg ASP2151 followed by 150 mg Bupropion
62841890|NCT01348516|EXPERIMENTAL|KM-023|
62841891|NCT01348516|PLACEBO_COMPARATOR|Placebo for KM-023|
62259956|NCT06144476||Airways Disease|Patients with or suspected airways disease including COPD or asthma
62259957|NCT06144476||Healthy Volunteers|Participants with no significant illness
62259958|NCT02572726|ACTIVE_COMPARATOR|active rTMS|active repeated transcranial magnetic stimulation over primary motor cortex along 5-10 daily sessions
62259959|NCT02572726|SHAM_COMPARATOR|'sham' rTMS|'sham' repeated transcranial magnetic stimulation over primary motor cortex along 5-10 daily sessions
62259960|NCT02947152|EXPERIMENTAL|Dose escalation part|Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer) and clear cell or papillary renal cell carcinoma
62445617|NCT00850902|ACTIVE_COMPARATOR|Moderate Humidity (MH)|
62841892|NCT04052152|EXPERIMENTAL|Group A|"Patients in the study group will receive the following treatment:~21 days as a treatment cycle, Anlotinib 12mg/day(D1-D14 ) and Sintilimab injection 200mg Q3W (D1). Sintilimab injection will be administered until disease progressioncor un-tolerable toxicity. Anlotinib will be administered until disease progression. If anlotinib is not tolerated, the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again"
62841893|NCT01025518|EXPERIMENTAL|resistance training and dietary supplement|
62841894|NCT01025518|PLACEBO_COMPARATOR|Resistance training and placebo ingestion|12 weeks of resistance training and placebo ingestion
62841895|NCT00882297|ACTIVE_COMPARATOR|1|Transversal approach guided placement
62841896|NCT00882297|ACTIVE_COMPARATOR|2|Longitudinal approach guided placement
62056825|NCT04772222|EXPERIMENTAL|Dexmedetomidine (DMT)|Subjects randomized to DMT arm in a 1:1 ratio. A loading dose of 1 mcg/kg will be given followed by 0.1 to 0.5 mcg/kg/h continuous infusion. The Neonatal Pain, Agitation, and Sedation Scale (N-PASS) will be used to determine infusion rate.
62056826|NCT04772222|ACTIVE_COMPARATOR|Morphine|Subjects randomized to morphine in a 1:1 ratio. Intermittent dosing every 3-4 hours of 0.02-0.05 mg/kg/dose or continuous infusion of 0.005 to 0.01 mg/kg/hr. The N-PASS will be used to determine dosing and frequency.
62056827|NCT01834105|EXPERIMENTAL|Liuwei Dihuang Pills|
62259961|NCT02947152|EXPERIMENTAL|Dose expansion part (RCC arm)|Includes patients with clear cell or papillary renal cell carcinoma
62259962|NCT02947152|EXPERIMENTAL|Dose expansion part (ovarian cancer arm)|Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer)
62259963|NCT02869282||Prospective cohort|Levels of CXCL1, CCL5, CXCL8 and CXCL12 chemokines and of IL-6 cytokine by ELISA or Luminex technology.
62445618|NCT00850902|EXPERIMENTAL|High Humidity|
62445619|NCT03820193|EXPERIMENTAL|Post-Operative Non Opioid Pain Protocol|Patients will be administered a post-operative non-opioid pain protocol consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
62445620|NCT03820193|ACTIVE_COMPARATOR|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen
62445621|NCT05770258|EXPERIMENTAL|The mild periodontitis and one treatment|Participants with mild periodontitis accompanied by gingival discomfort will receive one treatment with the device and complete the questionnaire.
62616876|NCT02509078|ACTIVE_COMPARATOR|Early Neuromuscular Blockade (NMB)|Patients will receive cisatracurium besylate for the first 48 hours of the trial.
62616877|NCT02509078|NO_INTERVENTION|Control: No Routine Early NMB|Use of non-study NMB will be discouraged.
62616878|NCT01916070||patients with syncope|
62616879|NCT01916070||patients with near syncope|
62616880|NCT05077813|ACTIVE_COMPARATOR|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
62616881|NCT05077813|ACTIVE_COMPARATOR|9 cis retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 9 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
62841897|NCT02911831|EXPERIMENTAL|Tranexamic Acid: Abdominal Hysterectomy|"Agent/Device: Tranexamic acid. Patients undergoing abdominal hysterectomy who consent to the study may be randomized to this arm.~· Protocol dose: 1g in solution to be given intravenously, within 1 hour prior to procedure"
62841898|NCT02911831|PLACEBO_COMPARATOR|Sodium chloride (placebo): Abdominal Hysterectomy|"Agent/Device: 0.9% sodium chloride solution. Patients undergoing abdominal hysterectomy who consent to the study may be randomized to this arm.~· Protocol dose: 100ml to be given intravenously, within 1 hour prior to procedure"
62841899|NCT05978843|ACTIVE_COMPARATOR|Arm 1 - 10% TFP|Participants will receive $40/month in fruit and vegetable benefits for 6 months ($240 total).
62841900|NCT05978843|ACTIVE_COMPARATOR|Arm 2 - 20% TFP|Participants will receive $80/month in fruit and vegetable benefits for 6 months ($480 total).
62841901|NCT05978843|ACTIVE_COMPARATOR|Arm 3 - 30% TFP|Participants will receive $110/month in fruit and vegetable benefits for 6 months ($660).
62841902|NCT03180918|EXPERIMENTAL|testicular tissue cryopreservation|
62445622|NCT01876186|EXPERIMENTAL|Solifenacin for 12 weeks group|Solifenacin (5 mg qd) for 12 weeks
62445623|NCT01876186|ACTIVE_COMPARATOR|Solifenacin for 24 weeks group|Solifenacin (5 mg qd) for 24 weeks
62445624|NCT05277727|EXPERIMENTAL|Fucoidan|"Fucoidan in Capsule~Intervention: Dietary Supplement: Probiotic"
62445625|NCT05277727|PLACEBO_COMPARATOR|Placebo|"Non active ingredients in a capsule~Intervention: Other: Placebo"
62445626|NCT00599183|OTHER|1|Participants will receive baseline conventional MRI of the cervical spine as part of their clinical care with an additional diffusion tensor imaging (DTI)sequence as part of the research; they will complete an anonymized questionnaire about their condition. Participants will receive an MRI with DTI and tractography as part of the research and will complete an anonymized questionnaire about their condition. The baseline and follow up data will be compared.
62445627|NCT03822052|ACTIVE_COMPARATOR|Primiparous Patient, Unfavorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
62445628|NCT03822052|ACTIVE_COMPARATOR|Primiparous Patient, Favorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
62445629|NCT03822052|ACTIVE_COMPARATOR|Multiparous patient, Unfavorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
62445630|NCT03822052|ACTIVE_COMPARATOR|Multiparous patient, Favorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
62623686|NCT02757625|EXPERIMENTAL|DA-9501|A single vial contains an injection solution with 2 mL of dexmedetomidine hydrochloride solution (100 µg/mL as dexmedetomidine) dissolved in physiological saline
62445631|NCT05882474||baseline group|PaCO2 35\~40mmHg
62445632|NCT05882474||High-CO2 group|PACO2 increases by 5-10mmHg compared to baseline value and \>40mmHg
62623687|NCT03942887|ACTIVE_COMPARATOR|Rituximab|Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg.
62841903|NCT03439384|EXPERIMENTAL|Experimental: Home Telemonitoring|Patients will receive home telemonitoring equipment and monitor their health for 60 days post-enrollment. A monitoring nurse will receive and review the patients health data on a daily basis for the 60 day duration and provide remote care, counseling and education.
62841904|NCT03439384|NO_INTERVENTION|Control: No Home Telemonitoring|The patient will not receive any home telemonitoring once enrolled and will continue to receive the usual care he/she can expect as part of his/her care plan.
62841905|NCT05083117|EXPERIMENTAL|XW001|Treatment arm patients will receive inhaled XW001 1 mg, once daily, using a commercially available nebulizer (Aerogen Solo, Aerogen Ireland) for up to 14 days. Treatment should be continued until discharge or progression to score 6 or higher but maximum up to 14 days. Dosing must be started within 48 hours of hospitalization.
62445633|NCT01016652|OTHER|etafilcon A multifocal / etafilcon A sphere|period 1: etafilcon A multifocal worn, period 2: etafilcon A sphere worn.
62445634|NCT01016652|OTHER|etafilcon A sphere / etafilcon A multifocal|period 1: etafilcon A sphere worn, period 2: etafilcon A multifocal worn.
62445635|NCT06504472|EXPERIMENTAL|Intervention (ProstaThrive™)|Participants will take three capsules daily after the final meal of the day for 90 days.
62259964|NCT02794324|EXPERIMENTAL|Voluntary deep-inspiratory breath hold|Stage 1A: Voluntary deep-inspiratory breath hold (v_DIBH) vs Active-breathing-controlled deep-inspiratory breathhold (ABC_DIBH)
62259965|NCT02794324|ACTIVE_COMPARATOR|Active-breathing-controlled deep-inspiratory breathhold|Stage 1A: Voluntary deep-inspiratory breath hold (v_DIBH) vs Active-breathing-controlled deep-inspiratory breathhold (ABC_DIBH)
62259966|NCT02794324|ACTIVE_COMPARATOR|Prone treatment|Stage 1B: Optimised supine DIBH vs prone position
62259967|NCT05693636||Total Wrist Fusion|Patients with end-stage wrist arthritis treated with total wrist fusion.
62259968|NCT05693636||Total Wrist Arthroplasty|Patients with end-stage wrist arthritis treated with total wrist arthroplasty of the fourth generation
62259969|NCT05877053|EXPERIMENTAL|CK-4021586 for SAD Cohort|Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of CK-4021586
62259970|NCT05877053|PLACEBO_COMPARATOR|Placebo for SAD Cohort|Subjects will be assigned to one of approximately 8 planned cohorts and receive single doses of placebo
62623688|NCT03942887|ACTIVE_COMPARATOR|Rituximab plus low-dose cyclophosphamide|5.1.2. Cyclophosphamide Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
62056828|NCT04766086|EXPERIMENTAL|GBS6 and Tdap|Multivalent group B streptococcus vaccine and Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
62259971|NCT05877053|EXPERIMENTAL|CK-4021586 for MAD Cohort|Subjects will be assigned to one of 4 planned dose cohorts and receive multiple doses of CK-4021586
62259972|NCT05877053|PLACEBO_COMPARATOR|Placebo for MAD Cohort|Subjects will be assigned to one of approximately 4 planned cohorts and receive multiple of placebo
62259973|NCT05877053|EXPERIMENTAL|Food Effect|Healthy subjects will be administered CK-4021586 with and without food in a cross-over fashion
62259974|NCT03846986|ACTIVE_COMPARATOR|Apple Juice1|100% Apple Juice
62259975|NCT03846986|EXPERIMENTAL|Apple Juice2|100% Apple Juice with enzyme-treated apple pomace fiber
62259976|NCT03846986|PLACEBO_COMPARATOR|Raw Apple|Raw Apple
62259977|NCT03095794|EXPERIMENTAL|neural mechanisms of decision making|Previous studies on how brain manages a value-based decision have been bounded to individual decisions. The current study will extend the understanding of social dimensions by answering four questions.
62841906|NCT05083117|PLACEBO_COMPARATOR|Placebo|Placebo arm patients will receive volume-matching placebo 1 mL, once daily, using a commercially available nebulizer (Aerogen Solo, Aerogen Ireland) for up to 14 days. Treatment should be continued until discharge or progression to score 6 or higher but maximum up to 14 days. Dosing must be started within 48 hours of hospitalization.
62841907|NCT01032122|EXPERIMENTAL|rituximab|
62841908|NCT06090136|EXPERIMENTAL|TPN171H|5 mg TPN171H tablets，single dose,oral
62841909|NCT04911608|EXPERIMENTAL|cervical manipulation|"The cervical spinal manipulation will consist of one session of a standard technique that will be performed by an experienced (\>10 years) doctor of physical therapy practitioner. The technique is described by Gibbons and Tehan as a high-velocity, mid-range, low amplitude force at the segment of pain and/or segmental restrcition. The participant will lay comfortably in a supine position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual thrust at those levels. A maximum of 2 attempts for each side of the cervical spine will be allowed regardless of the having achieved joint cavitation. This type of cervical manipulation procedure is described by Gibbons and Tehan as Minimal Leverage Thrust and it results in optimal patient comfort while receiving the treatment thus reducing post-treatment soreness/pain."
62259978|NCT02290873|EXPERIMENTAL|Remimazolam|"Remimazolam iv 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
62259979|NCT02290873|PLACEBO_COMPARATOR|Placebo|"Inactive control arm~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
62259980|NCT02290873|ACTIVE_COMPARATOR|Midazolam|"Midazolam iv 1.75 mg\* for sedation induction and 1.0 mg\* for sedation maintenance.~\*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
62259981|NCT00573989|EXPERIMENTAL|Erlotinib|Erlotinib
62056829|NCT04766086|EXPERIMENTAL|GBS6 and Placebo|Multivalent group B streptococcus vaccine and Placebo
62056830|NCT04766086|EXPERIMENTAL|Placebo and Tdap|Placebo and Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
62056831|NCT03371641|OTHER|Alcoholic exposure group|Blood sample (mother) Cord blood sample Placenta sample ASQ parental questionnaire WPPSI - IV and NEPSY development scales Scale of Conners SCQ questionnaire
62259982|NCT04095650|EXPERIMENTAL|Intervention|Participants will engage in a 7-week chronic pain self-management program.
62259983|NCT01268358|EXPERIMENTAL|Lamazym 6.25|
62259984|NCT01268358|EXPERIMENTAL|Lamazym 12.5|
62259985|NCT01268358|EXPERIMENTAL|Lamazym 25|
62259986|NCT01268358|EXPERIMENTAL|Lamazym 50|
62259987|NCT01268358|EXPERIMENTAL|Lamazym 100|
62259988|NCT05645497||Patient with medical device FACET FIXATION|The FACET FIXATION group include all the patients with Lumbar Spinal Stenosis who underwent an open technique for decompression, specifically laminectomies, concomitant to FACET FIXATION from November 2017 (and having more than 2 years postop to date).
62445636|NCT06504472|PLACEBO_COMPARATOR|Placebo|Participants will take three placebo capsules daily after the final meal of the day for 90 days.
62616882|NCT05077813|ACTIVE_COMPARATOR|All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
62616883|NCT05077813|ACTIVE_COMPARATOR|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
62616884|NCT05077813|ACTIVE_COMPARATOR|All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
62056832|NCT03371641|OTHER|Control|Blood sample (mother) Cord blood sample Placenta sample ASQ parental questionnaire WPPSI - IV and NEPSY development scales Scale of Conners SCQ questionnaire
62056833|NCT02382718|EXPERIMENTAL|FAST fish mCyp c 1|"Subcutaneous injections of investigational medicinal product mCyp c 1 formulated in a solution (suspension) with aluminium.~Up-dosing (build-up) phase: each subject will receive 10 injections of active or placebo treatment. The first three injections will be given on the first day. For those on active treatment the dosing will begin at 6ng and conclude on week 8 with the administration of 60μg.~Maintenance phase: the maintenance dose of 60μg will be repeated once at two weeks and then monthly for a period of four months (four monthly injections)."
62259989|NCT05645497||Patient with medical device Pedicle Screw|The Pedicle Screw group consiste of all the patients with Lumbar Spinal Stenosis who underwent an open technique for decompression, specifically laminectomies, concomitant to Pedicle Screw fixation from 2015 to 2016.
62841910|NCT04911608|EXPERIMENTAL|cervical mobilization|The cervical spinal mobilization treatment will also consist of one session of a standard technique that will be performed by an experienced (\>10 years) doctor of physical therapy practitioner. For this procedure, the participant will lay comfortably in a prone position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual forces at those segments. The magnitude of a mobilization-or how hard the therapist pushes on the spine-is usually reported as the magnitude of force. For an oscillatory posterior-anterior (PA) mobilization technique, the maximum magnitude of applied force is usually reported as the mean of the force peaks that occur during a specified period.34 The cervical mobilization will consist of oscillations of 1Hz and magnitude forces of 30 Newtons (N) for 30 seconds, 90N for 120 seconds and 30N for 30 seconds at the localized segment.
62056834|NCT02382718|PLACEBO_COMPARATOR|Placebo|Subcutaneous injections of exactly the same dosage, frequency and duration as Active Arm but all injections will be performed with placebo (has the same composition as the active drug suspension but no allergen mCyp c 1 is added).
62259990|NCT02164929|ACTIVE_COMPARATOR|Paravertebral block|Bilateral PVB will be placed between T7-T10 interspaces preoperatively. Patients will be in a sitting position which allows easy identification of landmarks, and the patients are often more comfortable. Ultrasound will be used to identify the paravertebral space. At the appropriate dermatome under aseptic precautions, the needle (22-gauge, 8-10-cm short beveled spinal needle) will inserted 2.5-3 cm lateral to the most cephalad aspect of the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process 3 of the vertebra below at a variable depth (2-4 cm). A 10 mL ropivacaine 0.25% will be injected at both T7 and T9 levels on each side (40 mL in total).
62445637|NCT05149742|EXPERIMENTAL|Cases: Patients with severe to profound hearing loss|Patients aged between 45 to 64 years with severe to profound bilateral post-lingual sensorineural hearing loss with a maximum intelligibility of 70% (disyllabic words) in free-field silence with hearing aids at 60 dB SPL
62056835|NCT05274932|ACTIVE_COMPARATOR|Placebo|Knee extensions with 30% 1RM and no occlusion pressure.
62056836|NCT05274932|EXPERIMENTAL|BFR at 40% AOP|Knee extensions with 30% 1RM and BFR at 40% AOP.
62056837|NCT05274932|EXPERIMENTAL|BFR at 80% AOP|Knee extensions with 30% 1RM and BFR at 80% AOP.
62056838|NCT03956290|EXPERIMENTAL|TREAT pilot study|Metabolically unhealthy overweight or obese potential participants who pass an in-person screen will enroll in a 2-week run-in period when they will use the app, to assess meal patterns under habitual living conditions.
62056839|NCT03538483|ACTIVE_COMPARATOR|ultrasound guided serratus plane block|Ultrasound Guided Serratus Plane Block 30 ml %0.25 Bupivacaine
62445638|NCT05149742|ACTIVE_COMPARATOR|Controls: 90 matched subjects with normal hearing|Healthy controls aged between 45 to 64 years with normal hearing on pure-tone audiometry (as function of ISO 7029 reference)
62056840|NCT03538483|ACTIVE_COMPARATOR|ultrasound guided erector spinae plane block|Ultrasound Guided Erector Spinae Plane Block 20 ml %0.25 Bupivacaine
62056841|NCT01677702|ACTIVE_COMPARATOR|Yili Lactoferrin ShuHua Milk (lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
62056842|NCT01677702|ACTIVE_COMPARATOR|Yili Lactoferrin ShuHua Milk (lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
62259991|NCT02164929|ACTIVE_COMPARATOR|TAP block|Bilateral posterior and subcostal TAP blocks guided by ultrasound will be performed in the preoperative holding area. A total of 80 mL ropivacaine 0.25% (4 injections, 20 mL per injection) will be injected evenly upon identification of the appropriate planes. In the event the placement of block is uncomfortable for the patients, it will be performed after induction of anesthesia. This approach is currently practiced in the OR. Extent and degree of anesthetic blockage will be measured using a 5-point sensation scale following the procedure at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).
62445639|NCT03184454|EXPERIMENTAL|Medtronic Percept Deep Brain Stimulation|"Single open label arm.~Patients with severe, treatment-refractory obsessive-compulsive disorder (OCD) will receive stimulation in two separate, but related, brain regions, the dorsolateral prefrontal cortex (dlPFC) and the ventral anterior limb of the internal capsule and adjacent ventral striatum (VC/VS) with a novel Medtronic Percept deep brain stimulation (DBS) system."
62445640|NCT01879839|NO_INTERVENTION|Control Group|Patients who don't follow a special diet.
62445641|NCT01879839|OTHER|Diet Group|Patients who subsist on a special diet.
62841911|NCT04911608|NO_INTERVENTION|postural correction education|Participants will be presented with a standardized educational short video regarding the importance of postural correction movements.
62841912|NCT05013541||Patients included|"Patients with lower urinary tract disorders assessed with multichannel cystometry and presence of rectal contractions.~Measure of amplitude and frequency of rectal contractions function of the bladder sensation and volume of bladder filling."
62841913|NCT01873534|EXPERIMENTAL|FMX-8 (0.5 mg/kg)|0.5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
62841914|NCT01873534|EXPERIMENTAL|FMX-8 (5 mg/kg)|5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
62841915|NCT01873534|EXPERIMENTAL|FMX-8 (15 mg/kg)|15 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
62841916|NCT00074490|EXPERIMENTAL|Arm IVD cohort 1 (Th2 DLI)|Patients receive low intensity fludarabine phosphate intravenous (IV) and cyclophosphamide IV on days -6 to -3. Patients undergo donor lymphocyte infusion (DLI) with sirolimus generated donor T-helper 2 (Th2) cells on day 14 (single T-Rapa cell DLI in patients with cluster of differentiation 4 (CD4) count between 100 and 200 inclusive)
62841917|NCT00074490|EXPERIMENTAL|Arm IVD cohort 2 (conventional DLI)|Patients receive low intensity fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3. Patients undergo DLI with unmanipulated donor T-cells on day 14 (single T- cell DLI in patients with low CD4 count between 100 and 200 inclusive)
62841918|NCT00074490|EXPERIMENTAL|Arm IVD cohort 3 (multiple Th2 DLI)|Patients with nonlymphoma diagnosis or rapidly progressive lymphoma undergo DLI with multiple infusions of sirolimus generated donor Th2 cells beginning on day 14 (multiple T-Rapa cell DLI in patients with CD4 count lower than 100 or ALC lower than 300)
62056843|NCT01677702|PLACEBO_COMPARATOR|Recombined low-protein milk|Total 250mL placebo milk will be taken once per day at 10am daily during the 84 days intervention.
62056844|NCT02168764|EXPERIMENTAL|Treatment|Both arms of the study receive the ATI Neurostimulation System. Subjects are implanted with the ATI Neurostimulator and instructed to use the ATI Remote Controller to treat cluster attacks of at least moderate intensity by stimulating for 15 minutes before using any acute medications.
62056845|NCT02168764|ACTIVE_COMPARATOR|Control|Both arms of the study receive the ATI Neurostimulation System. Subjects are implanted with the ATI Neurostimulator and instructed to use the ATI Remote Controller to treat cluster attacks of at least moderate intensity by stimulating for 15 minutes before using any acute medications.
62841919|NCT00074490|EXPERIMENTAL|Arm IVA (12-day expanded Th2 DLI)|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine by mouth twice a day (PO BID) on days -4 to 100, and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic peripheral blood stem cells (PBSC) on day 0. Patients undergo DLI with 12-day expanded sirolimus-generated donor Th2 cells on day 14.
62841920|NCT00074490|EXPERIMENTAL|Arm IVB (6-day expanded Th2 DLI)|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -4 to 100, and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic PBSC or bone marrow transplant on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14.
62056846|NCT04665154|EXPERIMENTAL|MAS825 dose A|single i.v. dose
62056847|NCT04665154|EXPERIMENTAL|MAS825 dose B|single s.c. dose
62445642|NCT04845074|EXPERIMENTAL|TSA-group|Surgery
62445643|NCT04845074|EXPERIMENTAL|Exercise-group|Exercise
62445644|NCT03204591||LC with SALI|cirrhosis patients with severe acute liver injury
62616885|NCT05077813|PLACEBO_COMPARATOR|The standard therapy|The standard therapy 100 infected patients with confection of COVID-19 and MDR-TB will receive the standard therapy for tuberculosis for 30 days 50- 50-
62259992|NCT02164929|ACTIVE_COMPARATOR|Epidural|"An epidural catheter will be inserted between T8-10 in the preoperative holding area, and a test dose of 1.5% lidocaine with 1:200,000 epinephrine will be given. Extent and degree of anesthetic blockage will be measured using a 5-point sensation following the procedure and postoperatively at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).~A bolus does of epidural hydromorphone (400-800 mcg) will be given preoperatively. An infusion of bupivacaine 0.25% at 4-6 ml/hour will be commenced before incision, and if tolerated, continued throughout surgery. Adjustments that may be required secondary to specific patient hemodynamic status will be left to the discretion of the individual anesthesiologist and guided by the specific patient requirements."
62841921|NCT00074490|EXPERIMENTAL|Arm IVC (6-day expanded Th2 DLI and High-Dose Sirolimus)|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -7 to 100 and high dose sirolimus PO on days -4 to 7, Patients undergo mobilized allogeneic PBSC on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14.
62841922|NCT00787267|EXPERIMENTAL|Dasatinib|"After a biopsy is done to obtain fresh frozen tumor tissue (Stage I), dasatinib is to be administered as an oral dose of 70 mg twice daily on a continuous basis for 6 weeks. Every 6 weeks radiologic exam will be done to assess response. Treatment will continue until progression of disease, intolerable toxicity or patient withdrawal.~For Stage II, a biopsy to obtain fresh frozen tumor tissue will also be done. Depending on results from Stage I and results of biopsy, treatment with dasatinib will be determined."
62841923|NCT02236936|ACTIVE_COMPARATOR|Arm A - Standard of care|"Standard care of parenteral nutrition (with or without parenteral nutrition during radio-chemotherapy or radio-immunotherapy in combination with Cetuximab or Cisplatin.~Concomitant radiotherapy and immunotherapy (radio-immunotherapy) with Cetuximab or concomitant radiotherapy and chemotherapy (radio-chemotherapy) with Cisplatin"
62259993|NCT02164929|ACTIVE_COMPARATOR|No block (PCA alone)|Premedication with midazolam up to 2 mg. General anesthesia is induced with propofol 1-2.5 mg/kg. Dexamethasone 4 mg IV will be administered after induction of anesthesia. Anesthesia will be maintained with sevoflurane to keep a bispectral index of between 40-60. Neuromuscular blocking drug and reversal agent of choice may be used. Local infiltration with 10 mL of plain ropivacaine 0.25% will be administered at the surgical incision site at the end of surgery. Acetaminophen 1g IV will be administered following induction of anesthesia will be administered at the end of the procedure
62259994|NCT00254462|EXPERIMENTAL|atomoxetine and parent training|atomoxetine capsules, dose 0.5mg/kg/day to 1.8mg/kg/day administered once daily for 8 weeks
62259995|NCT00254462|PLACEBO_COMPARATOR|placebo and parent training|matching placebo capsules, dose 0.5mg/kg/day to 1.8mg/kg/day administered once daily for 8 weeks
62259996|NCT06379737|ACTIVE_COMPARATOR|Home-based rehabilitation|Perform home-based rehabilitation
62841924|NCT02236936|EXPERIMENTAL|Arm B - Parenteral over night nutrition|"Parenteral over night nutrition with ZentroOLIMEL 5.7% parenteral over night with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) 15 ml/kg body weight/day (weight loss \>5% from baseline; parenteral nutrition increased up to 25 ml/kg body weight per day) during radio-chemotherapy or radio-immunotherapy in combination with Cetuximab or Cisplatin.~Concomitant radiotherapy and immunotherapy (radio-immunotherapy) with Cetuximab or concomitant radiotherapy and chemotherapy (radio-chemotherapy) with Cisplatin"
62841925|NCT04286048|EXPERIMENTAL|Experimental group|"Each session will last 15 minutes, taking place for 2 days a week, over a period of 4 weeks. The intervention will take place at the beginning of the training session.~Prior to training, each pitcher will perform his normal warm-up routine, notifying the investigator when he feels ready to perform the training. The intervention through weight implements will consist in the application of the protocol described by Fleising et al. The objective of the application of the technique is to produce an increase in the speed of the throws."
62841926|NCT04286048|NO_INTERVENTION|Control group|Athletes included in the control group will conduct their training and activities on a daily basis
62259997|NCT06379737|EXPERIMENTAL|Health resort medicine rehabilitation|Perform Health resort medicine rehabilitation
62259998|NCT02672670|EXPERIMENTAL|Coping-oriented supportive programme|Coping-oriented supportive programme: education of the SCI disease information, learning from role model by watching a well-established DVD, discussion about how to break down stressors and used appropriate coping strategies (problem-solving training, cognitive re-constructing, relaxation exercises, and activity scheduling) to manage the stressors relating to SCI. Social skills training and ways of maintaining and improving social support will also be discussed and practiced in the COSP.
62259999|NCT02672670|ACTIVE_COMPARATOR|A didactic group|Usual rehabilitation care--routine inpatient rehabilitation care and brief education in groups (structured by both the rehabilitation nurses and the researcher), which will consist of similar professional contacts as the intervention (COSP) group, and thus can balance between the two study groups for the effect of social contacts and attention to SCI patients during group sessions. The intervention in the comparison group will be conducted by a rehabilitation nurse in the SCI wards. The knowledge/didactic education presented to the patients in the comparison group will be the basic health education and relevant information provided by the rehabilitation nurses in their routine care (mainly including knowledge of SCI, nutritional needs, skin care, bowel and bladder training, and other physical and psychological care of patients with SCI provided by the inpatient rehabilitation wards).
62260000|NCT05259865||Patients with chronic pain|Patients seen in clinic agreeing to participate in trial by completing clinical questionnaires and genetic testing
62260001|NCT01035385|EXPERIMENTAL|FOFLOX4,resectable liver metastasis from CRC|
62260002|NCT02589691|EXPERIMENTAL|Rocuronium|Intra-venous injection during induction anesthesia of 0.3 mg/kg (1 mL/kg) of rocuronium
62841927|NCT03915093|EXPERIMENTAL|study group|receive educational nursing protocol
62260003|NCT02589691|PLACEBO_COMPARATOR|Placebo|Intra-venous injection during induction anesthesia of 1 mL/kg of sodium chloride 0.9%
62260004|NCT00185744|EXPERIMENTAL|Accelerated Partial Breast Irradiation|lumpectomy with accelerated partial breast irradiation
62841928|NCT03915093|ACTIVE_COMPARATOR|control group|receive routine hospital care
62841929|NCT02479646|EXPERIMENTAL|Treatment A|MYL-1401H: single subcutaneous injection (2mg)
62260005|NCT00185744|ACTIVE_COMPARATOR|Standard Therapy|lumpectomy and whole breast irradiation
62260006|NCT00960843|ACTIVE_COMPARATOR|Conventional Adjustment Group|Subject whose band adjustments will be made via conventional standard of care (e.g., volume, hunger).
62260007|NCT00960843|ACTIVE_COMPARATOR|Intraband Pressure Arm|Subjects whose band adjustments will be guided by intraband pressure readings.
62260008|NCT05138016|EXPERIMENTAL|Exercise testing with soft exosuit assistance|Progressive cardiovascular exercise testing on a treadmill with soft exosuit assistance.
62260009|NCT05138016|ACTIVE_COMPARATOR|Exercise testing without soft exosuit assistance|Progressive cardiovascular exercise testing on a treadmill.
62260010|NCT02060682||Navvus Catheter FFR|The Navvus Catheter is a rapid exchange microcatheter with a pressure sensor at the distal tip that measures Fractional Flow Reserve measurements to guide PCI treatment strategy.
62260011|NCT00641550|EXPERIMENTAL|2|Pregnant women starting to practice physical exercise at 13 weeks(Walking moderate activity)
62260012|NCT00641550|EXPERIMENTAL|3|Pregnant women starting exercise at 20 weeks
62260013|NCT00641550|NO_INTERVENTION|1|Pregnant women without exercise practice.
62260014|NCT00375336||1|Patients with aortic stenosis (mean transvalvular aortic gradient ≥30 mm Hg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
62260015|NCT00375336||2|Patients with nonobstructive aortic sclerosis (mean gradient ≤10 mmHg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
62260016|NCT00375336||3|Patients with normal aortic valve plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
62260017|NCT03300674|ACTIVE_COMPARATOR|Intravenous hydromorphone|Intravenous hydromorphone 1mg. A second dose can be administered at 30 minutes.
62260018|NCT03300674|ACTIVE_COMPARATOR|Intravenous lidocaine|Intravenous lidocaine 120 mg. A second dose can be administered at 30 minutes
62260019|NCT05018832|EXPERIMENTAL|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
62260020|NCT02227602|EXPERIMENTAL|Mango|Mango polyphenolics
62260021|NCT00670670|EXPERIMENTAL|1|CPP-ACP (GC Tooth Mousse)
62260022|NCT00670670|EXPERIMENTAL|2|CPP-ACP (GC MI Paste Plus)
62260023|NCT00670670|NO_INTERVENTION|3|Control group
62260024|NCT04050982|EXPERIMENTAL|Pilot Testing|Patients interface with the digital application, providing feedback on usability and satisfaction.
62260025|NCT04050982|ACTIVE_COMPARATOR|AF CARE plus Usual Care|Patients will interface with the digital application.
62260026|NCT04050982|ACTIVE_COMPARATOR|Usual Care then AF Care|After a 6 month period of usual care only, patients will interface with the digital application.
62260027|NCT03096730|PLACEBO_COMPARATOR|Normal Saline|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
62260028|NCT03096730|SHAM_COMPARATOR|Sufentanil|Normal saline is intravenously admistrated before anesthesia induction and intraoperative pain management was with sufentanil
62260029|NCT03096730|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine is intravenously administrated at a dose of 0.5ug/kg 10min before anesthesia induction and intraoperative pain management was with remifentanil
62260030|NCT03096730|ACTIVE_COMPARATOR|Nalmefene|Nalmefene is intravenously administrated at a dose of 0.2ug/kg before anesthesia induction and intraoperative pain management was with remifentanil
62260031|NCT03096730|ACTIVE_COMPARATOR|Dexmedetomidine-Nalmefene|A dose of 0.1ug/kg nalmefene and a dose of 0.25ug/kg dexmedetomidine for 10 minutes before anesthesia induction and intraoperative pain management was with remifentanil
62260032|NCT01868880|EXPERIMENTAL|ivabradine plus beta-blocker(bisoprolol)|Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
62260033|NCT01868880|ACTIVE_COMPARATOR|beta-blocker (bisoprolol) titration|Beta blocker Bisoprolol will be titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
62616886|NCT01682018|EXPERIMENTAL|intervention group|Patients that underwent dingle lung transplantation due to emphysema and developed native lung overinflation as demonstrated by chest CT and decline in pulmonary lung function tests (FEV1 ) shall undergo valves placement to the native lung
62841930|NCT02479646|ACTIVE_COMPARATOR|Treatment B|EU-Neulasta: single subcutaneous injection (2mg)
62841931|NCT02479646|ACTIVE_COMPARATOR|Treatment C|US-Neulasta: single subcutaneous injection (2mg)
62260034|NCT00004138|EXPERIMENTAL|FDG-PET scan + surgery|"Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later by positron emission tomography (PET) imaging. Confirmatory studies, such as biopsy, fine needle aspiration, or other imaging studies are then conducted to confirm the PET findings.~Patients with no mediastinal nodal or distant metastases identified by FDG-PET scan may undergo thoracotomy and pulmonary resection within 1 month of evaluation.~Patients are followed at 5-6 months after surgery."
62260035|NCT01556139|EXPERIMENTAL|Spirotiger|Patients belonging to this group perform 20 sessions of usual training (cyclette and calisthenic exercises) and additional 20 sessions of a specific training for respiratory muscles with Spirotiger
62260036|NCT01556139|NO_INTERVENTION|Control|Control group with a placebo device
62616887|NCT02259829|EXPERIMENTAL|Telmisartan/Amlodipine fixed dose combination|
62616888|NCT02259829|ACTIVE_COMPARATOR|Telmisartan and Amlodipine monocomponents|
62056848|NCT04665154|PLACEBO_COMPARATOR|Placebo dose A|single i.v. dose
62260037|NCT04714242||Patients underwent anti-VEGF therapy|intravitreal Anti-VEGF therapy: Three monthly intravitreal injections
62260038|NCT04714242||Control Group|Healthy eyes without actual and previous ocular diseases
62260039|NCT04936360||Patient Group|Patients with non-progressive non-neurodegenerative acquired brain damage, who were over 18 years of age, who could establish voluntary social communication will be included in the study.
62260040|NCT04936360||Caregivers Group|Caregivers over the age of 18, who took care of the patient for at least 1 month, and who did not have premorbid medical or psychological problems will be included in the study.
62260041|NCT02953353|ACTIVE_COMPARATOR|Active group|Active transcranial direct current stimulation (tDCS) and hypocaloric diet.
62260042|NCT02953353|SHAM_COMPARATOR|Control group|Sham transcranial direct current stimulation (tDCS) and hypocaloric diet.
62260043|NCT02799823|EXPERIMENTAL|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
62260044|NCT01048762|ACTIVE_COMPARATOR|supervised exercise training|Intervention: supervised exercise training and dyspnea counseling in groups for 10 weeks Instruction on home based exercise training
62445645|NCT02660411|ACTIVE_COMPARATOR|Sevoflurane group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol, and rocuronium.~Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
62445646|NCT02660411|EXPERIMENTAL|Propofol group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol, and rocuronium.~Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
62841932|NCT05438472||healthcare professionals with COVID-19 mRNA vaccine booster|Consecutive individuals that received a COVID-19 mRNA vaccine booster and undergo a systematic approach to detect myocarditis at the University Hospital Basel. The project population includes mainly healthcare workers, aged between 16-65, most of them with presumable no comorbidities. Baseline characteristics include age, divided in several groups (16-20 years, 21-25 years, 26-30 years, 31-35 years, 36-40 years, 41-45 years, 46-50 years, 51-55 years, 56-60 years, 61-65 years).
62841933|NCT04405453|ACTIVE_COMPARATOR|Trapezius Muscle İnjection (TMI) group|TMI group will receive ultrasound guided trapezius muscle injection two times with one week interval. Pain severity of the patients will evaluate by visual analog scale before (week 0) and after (week 1,2,3,4) the injections
62841934|NCT04405453|ACTIVE_COMPARATOR|Erector Spina Plane Block (ESPB) group|ESPB group in the 1th week will receive ultrasound guided trapezius muscle injection and in the 2nd week ultrasound guided erector spina plane block will receive. Pain severity of the patients will evaluate by visual analog scale before (week 0) and after (week 1,2,3,4) the injections
62260045|NCT01048762|SHAM_COMPARATOR|one instruction on homebased exercises|One instruction on home based exercise training and dyspnea management
62841935|NCT02888119|ACTIVE_COMPARATOR|High Risk for Osteoarthritis|"High risk of developing knee OA has been defined by having knee pain but normal radiographs (Kellgren-Lawrence score 0 i.e. KL0) on both knees but at least one abnormal finding on clinical MR protocol such as overweight, prior knee injury (ligaments or menisci) or traumatic bone marrow edema lesions."
62841936|NCT02888119|ACTIVE_COMPARATOR|Mild Osteoarthritis|
62841937|NCT02888119|ACTIVE_COMPARATOR|Healthy Controls|Controls will be age/gender matched to patients within 2 years of age.
62841938|NCT06057467|EXPERIMENTAL|Early initiation of anticoagulation|"For patients with NIHSS 0-3, anticoagulation therapy will be initiated within 0-3 days of onset.~For patients with NIHSS 4-8, anticoagulation therapy will be initiated within 4-6 days of onset."
62841939|NCT06057467|ACTIVE_COMPARATOR|Late initiation of anticoagulation|"For patients with NIHSS 0-3, anticoagulation therapy will be initiated within 4-12 days of onset.~For patients with NIHSS 4-8, anticoagulation therapy will be initiated within 7-12 days of onset."
62056849|NCT04665154|PLACEBO_COMPARATOR|Placebo dose B|single s.c. dose
62056850|NCT03339284|ACTIVE_COMPARATOR|QLB with dexamethasone|Single sided US-guided QLB using ropivacaine 3,75 mg/ml 20 ml and dexamethasone 5 mg/ml 0,4 ml
62260046|NCT03805945|EXPERIMENTAL|dexmedetomidine group|After umbilical cord was cut, a loading dose of dexmedetomidine was pumped at 0.5ug/kg within 10min, followed by a further infusion of dexmedetomidine at 0.5ug /kg/h until the end of the surgery.Then connected with patient-controlled intravenous analgesia pump (dexmedetomidine 2ug/kg + sufentanil 1.5ug/kg + dolasetron 25mg/100ml saline).
62260047|NCT03805945|PLACEBO_COMPARATOR|control group|Continuous infusion of saline after the umbilical cord was cut until the end of the operation.Then connected with patient-controlled intravenous analgesia pump (sufentanil 1.5ug/kg + dolasetron 25mg/100ml saline).
62260048|NCT01984385||Patients with a hip fracture|
62260049|NCT01607736|NO_INTERVENTION|Inactive Comparator|
62260050|NCT01607736|EXPERIMENTAL|Virtual Gait Training|
62445647|NCT01305083|ACTIVE_COMPARATOR|Udenafil|Active Ingredient
62841940|NCT05657808|PLACEBO_COMPARATOR|Placebo Control 1|Rest Product Form 1 - control
62841941|NCT05657808|PLACEBO_COMPARATOR|Placebo Control 2|Rest Product Form 2 - control
62841942|NCT05657808|EXPERIMENTAL|Active Product 1.1|Rest Product Form 1 - active product 1
62841943|NCT05657808|EXPERIMENTAL|Active Product 1.2|Rest Product Form 1 - active product 2
62056851|NCT03339284|ACTIVE_COMPARATOR|QLB without dexamethasone|Single sided US-guided QLB using ropivacaine 3,75 mg/ml 20 ml and isotonic natriumchloride solution (NaCl 0,9%) 0,4 ml
62841944|NCT05657808|EXPERIMENTAL|Active Product 2.1|Rest Product Form 2 - active product 1
62841945|NCT05657808|EXPERIMENTAL|Active Product 2.2|Rest Product Form 2 - active product 2
62056852|NCT03339284|PLACEBO_COMPARATOR|Placebo|Single sided US-guided QLB using isotonic natriumchloride solution (NaCl 0,9%) 20,4 ml
62260051|NCT04438161|ACTIVE_COMPARATOR|Low Risk|"Low risk natural history study (n=250\*)~\*Participants will be randomized 2:1 PERCCS:Control, and the randomization will be within successive sets of three families who fall in either high risk counts (n=105) families for child maltreatment or low risk counts (n=45) families."
62260052|NCT04438161|EXPERIMENTAL|High Risk|"High risk families in prospective longitudinal study of newborns (n=150\*).~\*Participants will be randomized 2:1 PERCCS:Control, and the randomization will be within successive sets of three families who fall in either high risk counts (n=105) families for child maltreatment or low risk counts (n=45) families.~Participants in this arm will be randomized to:~1. PERCCS (see attached figure and table for details)~2. Care as Usual"
62260053|NCT00932347|EXPERIMENTAL|Mouthwash A|Mouthwash A: Camellia sinensis mouthwash
62616889|NCT02483494|EXPERIMENTAL|APN-led Telemedicine|Participants will receive APN-led Telemedicine in addition to usual care.
62841946|NCT05657808|PLACEBO_COMPARATOR|Placebo Control 3|Rest Product Form 3 - control
62841947|NCT05657808|EXPERIMENTAL|Active Product 3.1|Rest Product Form 3 - active product 1
62841948|NCT05657808|PLACEBO_COMPARATOR|Placebo Control 4|Rest Product Form 4 - control
62841949|NCT05657808|EXPERIMENTAL|Active Product 4.1|Rest Product Form 4 - active product 1
62056853|NCT04728308|ACTIVE_COMPARATOR|Experimental group|20ml of 0.5% bupivacaine is infiltrated in the subcutaneous tissue around the incision site
62056854|NCT04728308|PLACEBO_COMPARATOR|Placebo group|20 ml of distill water is infiltrated in the subcutaneous tissue around the incision site
62056855|NCT03361995|EXPERIMENTAL|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Thermogard XP3 IVTM System before and after PCI.
62841950|NCT05657808|EXPERIMENTAL|Active Product 4.2|Rest Product Form 4 - active product 2
62841951|NCT05657808|EXPERIMENTAL|Active Product 4.3|Rest Product Form 4 - active product 3
62841952|NCT06521762|EXPERIMENTAL|Etrasimod plus corticosteroids|Participants will receive Etrasimod plus corticosteroids, to be given up to 120 days, to treat IMDC.
62841953|NCT06521762|PLACEBO_COMPARATOR|Placebo plus corticosteroids|Participants will receive Placebo plus corticosteroids, to be given up to 120 days, to treat IMDC.
62841954|NCT04987788|EXPERIMENTAL|Motívate group|Participants will engage with an app on an iPad, smartphone or computer.
62260054|NCT00932347|PLACEBO_COMPARATOR|Mouthwash B|Mouthwash B: Placebo mouthwash
62445648|NCT01305083|PLACEBO_COMPARATOR|Placebo|Placebo
62445649|NCT00210626|ACTIVE_COMPARATOR|PROCRIT|
62445650|NCT00210626|PLACEBO_COMPARATOR|Placebo|
62616890|NCT02483494|NO_INTERVENTION|Usual care|Participants will receive the standard of care which includes education by cardiac care nurses and face-to-face consultations.
62616891|NCT03078309|EXPERIMENTAL|healthy|All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.
62841955|NCT04987788|ACTIVE_COMPARATOR|Control Group|Participant receive a link to watch a general health information video.
62841956|NCT05465252|EXPERIMENTAL|krill oil|Subjects will take 3 capsules/1500mg of krill oil per day for 6 month
62841957|NCT05465252|PLACEBO_COMPARATOR|olive oil|Subjects will take 3 capsules/1500mg of olive oil per day for 6 month
62841958|NCT04502680|EXPERIMENTAL|Eribulin Mesylate|Patients receive eribulin mesylate following standard adjuvant chemotherapy.
62841959|NCT04502680|NO_INTERVENTION|Observation|Observation. No intervention.
62841960|NCT04150861|EXPERIMENTAL|Follitropin delta 12 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 12 μg on Day 1.
62260055|NCT02075372||Data registration of CTO-PCI patients|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will register data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry.
62616892|NCT03078309|EXPERIMENTAL|Retinitis Pigmentosa|All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.
62616893|NCT00841308|ACTIVE_COMPARATOR|Usual care|
62260056|NCT02734836|EXPERIMENTAL|Zilver PTX Stent|Diagnostic assessment of the lesion after implantation of drug eluting stent with Balloon Angioplasty and placement of the Zilver PTX Stent with Optical Coherence Tomography (OCT)
62616894|NCT00841308|ACTIVE_COMPARATOR|Home blood pressure monitoring|
62616895|NCT04940585|EXPERIMENTAL|Rose Program Group|ROSE is a 7-session intervention. Participants will attend 6 weekly group sessions virtually, through a program on the computer called WebEx or at the clinic, and then one individual session after delivery. Participants will complete a few questionnaires at three different timepoints, including demographics, stress, social support, physical and mental health, and trauma.
62616896|NCT04940585|NO_INTERVENTION|Comparison Group|Participants will complete three sets of questionnaires including demographics, stress, social support, physical and mental health, and trauma.
62616897|NCT01068587|ACTIVE_COMPARATOR|Erlotinib|
62616898|NCT01068587|ACTIVE_COMPARATOR|Foretinib plus Erlotinib|
62616899|NCT04338243|EXPERIMENTAL|Glumetinib+Osimertinib|The investigational product Glumetinib will be orally administrated when fasting at dose level of 300mg QD and Osimertinib will be orally administrated when fasting at dose level of 80mg QD
62841961|NCT04150861|EXPERIMENTAL|Follitropin delta 18 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 18 μg on Day 1.
62841962|NCT04150861|EXPERIMENTAL|Follitropin delta 24 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 24 μg on Day 1.
62056856|NCT03361995|ACTIVE_COMPARATOR|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
62616900|NCT02032771|EXPERIMENTAL|M22 IPL and ResurFX|The procedure will include an intense pulse light (IPL) treatment followed by fractional non-ablative (FNA) treatment.
62616901|NCT01487239|EXPERIMENTAL|A|\[14C\]-GDC-0980 administered as a 10-mg oral dose
62616902|NCT05695820|EXPERIMENTAL|Concentric|Concentric group
62841963|NCT02591225|EXPERIMENTAL|Dabigatranetexilate|Dabigatran capsula 150 mg; oral; bid; treatment period 12 months
62841964|NCT02591225|ACTIVE_COMPARATOR|Phenprocoumon|Phenprocoumon INR adjusted; oral; once daily; treatment period 12 months
62260057|NCT05437003|EXPERIMENTAL|PD patients visiting clinic|All patients will undergo a NeuraLight session for oculometric evaluation along with eye-tracking recordings. All assessments will be performed during a clinic visit unless authorized to be conducted remotely.
62260058|NCT05437003|EXPERIMENTAL|Healthy subjects|All patients will undergo a NeuraLight session for oculometric evaluation along with eye-tracking recordings. All assessments will be performed during a visit unless authorized to be conducted remotely.
62260059|NCT01349465|OTHER|Group 1: TMC 435 - Patients With SVR at LPVPS|Patients with sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) \[Phase IIb or Phase III\] in which they received a TMC435-containing regimen for the treatment of HCV infection.
62260060|NCT01349465|OTHER|Group 2: TMC 435 - Patients With No SVR at LPVPS|Patients with no sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) \[Phase IIb or Phase III\] in which they received a TMC435-containing regimen for the treatment of HCV infection.
62260061|NCT01587911|ACTIVE_COMPARATOR|Whey protein|Complete whey protein.
62616903|NCT05695820|EXPERIMENTAL|Isometric|Isometric group
62616904|NCT05695820|EXPERIMENTAL|Eccentric|Eccentric group
62616905|NCT01687842||Turner syndrome patients|Evaluation of 45,X Turner syndrome patients
62623689|NCT02916953|EXPERIMENTAL|Treatment|All subjects who meet the inclusion and exclusion criteria will receive the AGN1 Femoral Local Osteo-Enhancement Procedure (LOEP™) treatment
62841965|NCT04306861||Treatment Naïve PDAC Patients|Patient presenting with treatment-naïve, biopsy-proven pancreatic ductal adenocarcinoma (PDAC) who qualifies for neoadjuvant chemo-radiation therapy.
62841966|NCT06322654|EXPERIMENTAL|Robotically Assisted Locomotion|
62841967|NCT06322654|ACTIVE_COMPARATOR|Robotically Assisted Verticalization|
62056857|NCT04157101|EXPERIMENTAL|Health Coaching|The 12-session remote health coaching intervention assists Veterans in developing and maintaining health behaviors that meet their life goals. Veterans begin by discussing their symptoms, the impact of their symptoms, and their beliefs about Pain-CMI. Next, the Veteran identifies discrepancies between where they are and where they want to be for 5 lifestyle factors. The first half of treatment focuses on providing education about the 5 lifestyle factors. Veterans are introduced to behavior change/health coaching principles. The major focus is on behavior change and development of long-term healthy habits. During the last session, Veterans develop a long-term plan to maintain behavioral changes after the 12-week program and identify the skills that they can utilize moving forward.
62445651|NCT04732299||Acute thrombus group|Within 14 days after onset
62445652|NCT04732299||Subacute thrombus group|During 15-30 days after onset
62445653|NCT04732299||Chronic thrombosis group|More than 15-30 days after onset
62445654|NCT03872284||1|Patients in the study group have a diagnosis of autoimmune encephalitis, are 18 to 70 years old, and have no significant comorbidity such as psychiatric, neurological conditions and able to understand the aim of this study.
62260062|NCT01587911|ACTIVE_COMPARATOR|Whey-CMP|Complete whey protein missing the CMP (aka GMP) portion of the peptide.
62260063|NCT01587911|PLACEBO_COMPARATOR|Control|Placebo preload control, matched for energy.
62445655|NCT02710461|EXPERIMENTAL|Subjects with abdominal obesity|Intervention with grape pomace and pomegranate pomace
62445656|NCT01102205||healthy|
62445657|NCT01102205||euthyroid hashimoto|
62445658|NCT01102205||hypothyroid hashimoto|
62616906|NCT02929134|ACTIVE_COMPARATOR|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg).
62841968|NCT00607490|EXPERIMENTAL|Cognitive-behavioral Therapy|10 weekly individual 60-minute sessions
62841969|NCT00607490|ACTIVE_COMPARATOR|Supportive Psychotherapy|10 weekly individual 60-minute sessions
62841970|NCT06425692|OTHER|Education on basic palliative care|Blended learning for ICU staff and online webinars. The aim is to teach the basics of palliative care on a cognitive, affective and psychomotor level.
62841971|NCT01621802|EXPERIMENTAL|Inv _MMR_CO Group|Subjects received one dose of the study vaccine Priorix along with Kinrix and ProQuad vaccines at Visit 1 (Day 0).
62841972|NCT01621802|ACTIVE_COMPARATOR|Com_MMR_CO Group|Subjects received one dose of the licensed vaccine M-M-R II (also known as M-M-R Vax Pro) Lot 1 or Lot 2 along with Kinrix and ProQuad vaccines at Visit 1 (Day 0).
62260064|NCT01587911|ACTIVE_COMPARATOR|CMP (casinomacropeptide)|Small peptide cleaved from complete whey protein.
62260065|NCT01587911|ACTIVE_COMPARATOR|MPI|Complete milk protein.
62260066|NCT01587911|ACTIVE_COMPARATOR|CPI (casein)|Preload containing casein.
62260067|NCT04046432|EXPERIMENTAL|Vigiis 101-LAB|The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were made into capsules (Vigiis 101-LAB capsule I) containing 5 billion bacteria per capsule for the gut flora clinical trial 1. The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were also mixed into capsules (Vigiis 101-LAB capsule II) containing 10 billion bacteria per capsule for clinical trial 2.
62260068|NCT04046432|PLACEBO_COMPARATOR|placebo|Maltodextrin was used as a placebo.
62260069|NCT01077648||Women diagnosed with advanced breast cancer|Women diagnosed with advanced breast cancer during January 1, 1995-December 31, 2007 and treated as part of the Henry Ford Health System
62260070|NCT05371977|EXPERIMENTAL|Deep sclerectomy|
62623690|NCT02648464|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine 300 mg tablet by mouth daily for 6 months. Patients under the weight of 60 kg: hydroxychloroquine 300 mg tablet daily for 5 days per week for 6 months.
62841973|NCT01621802|EXPERIMENTAL|Inv_MMR_I Group|Subjects received one dose of Priorix at Visit 1 (Day 0).
62841974|NCT01621802|ACTIVE_COMPARATOR|Com_MMR_I Group|Subjects received one dose of M-M-R II (also known as M-M-R Vax Pro) vaccine from Lot 1 or Lot 2 at Visit 1 (Day 0).
62056858|NCT04157101|PLACEBO_COMPARATOR|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was . ) in order to help identify experiences for discussion in session. The control consists of 12 weekly sessions delivered via telephone or video and will be delivered by bachelor's, or master's level providers."
62056859|NCT04984057|EXPERIMENTAL|PS is stopped when the pressure is equal between bPDA and aPDA|PS is given and stopped when the pressure is equal between bPDA and aPDA. the pressure is measured using ultrasound
62056860|NCT04984057|ACTIVE_COMPARATOR|PS is given according to the 2019 European RDS management guideline|PS is given according to the 2019 European RDS management guideline
62056861|NCT04318158|EXPERIMENTAL|Group(B)|Patients will receive single shot US guided TAP block using 20 ml bupivacaine 0.25% on each side.
62260071|NCT05371977|ACTIVE_COMPARATOR|Trabeculectomy|
62260072|NCT00349375|EXPERIMENTAL|1|
62260073|NCT00349375|EXPERIMENTAL|2|
62260074|NCT00349375|ACTIVE_COMPARATOR|3|
62260075|NCT04701138|EXPERIMENTAL|Dietary Supplement|All subjects will receive the intervention (SPM Active Supplement)
62260076|NCT02428842|OTHER|Tumor biopsies and blood sampling|"Patient will undergo standard care with tumor and blood sampling before and after treatment.~Blood and tumor sampling will also be performed at disease progression/relapse."
62260077|NCT05245331|ACTIVE_COMPARATOR|High-volume TAI|This group will be instructed on High-volume TAI to be perform daily or every 2 days for 2 months. After 15 days of wash-out they will switch to Low-TAI treatment for 2 months.
62260078|NCT05245331|ACTIVE_COMPARATOR|Low volume - TAI|This group will be instructed on Low-volume TAI to be perform daily or every 2 days for 2 months. After 15 days of wash-out they will switch to the Low-TAI treatment for 2 months.
62260079|NCT02031497|EXPERIMENTAL|Drink with sweeteners|
62260080|NCT02031497|ACTIVE_COMPARATOR|Drink without sweeteners|
62841975|NCT01621802|EXPERIMENTAL|Inv _MMR_S Group|Subjects in this safety cohort received one dose of Priorix at Visit 1 (Day 0).
62841976|NCT01621802|ACTIVE_COMPARATOR|Com_MMR_S Group|Subjects in this safety cohort received one dose of M-M-R II (also known as M-M-R Vax Pro) vaccine from Lot 1 or Lot 2 at Visit 1 (Day 0).
62841977|NCT00999778|ACTIVE_COMPARATOR|Caregiver Education Intervention|10 1:1,one hour sessions weekly for 10 weeks with parent and interventionist. Behavioral education strategies will be targeted
62616907|NCT02929134|PLACEBO_COMPARATOR|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
62616908|NCT01858623|OTHER|Losartan / Hydrochlorothiazide100 mg/25mg|Losartan / Hydrochlorothiazide100 mg/25mg fixed dose combination
62616909|NCT01858623|OTHER|Losartan 100 mg|Losartan 100 mg alone
62616910|NCT01858623|OTHER|hydrochlorothiazide 25 mg|hydrochlorothiazide 25 mg alone
62616911|NCT04663932|PLACEBO_COMPARATOR|immediate stenting group|Patients assigned to the immediate stenting group will undergo appropriate stent implantation based on characteristics of the lesions.
62616912|NCT04663932|EXPERIMENTAL|deferred stenting group|Patients assigned to the deferred stenting group will be sent back to the ward after PCI to receive standard anticoagulant and antiplatelet therapies, and the CAG will be repeated 5 to 7 days after initial intervention, followed by treatment with stent implantation.
62616913|NCT04754399|EXPERIMENTAL|Cannabidiol (CBD)|Oral solution given 2x daily.
62260081|NCT05354011|EXPERIMENTAL|Kinesiotaping|Kinesiotape will be applied toward the start of the week, to remain on for 5 days with a multi day rest for an aggregate of about a month.
62260082|NCT05354011|EXPERIMENTAL|Active Release Technique|kinesiotaping and active release technique will be applied 3 times a week for 2 week
62616914|NCT03749408|ACTIVE_COMPARATOR|bupivacaine plus mannitol|0.5% bupivacaine with 1:200,000 epinephrine plus 1.5 ml of 0.5 mol/L mannitol
62616915|NCT03749408|EXPERIMENTAL|bupivacaine alone|0.5% bupivacaine with 1:200,000epinephrine alone
62616916|NCT05513755|EXPERIMENTAL|Cardioneuroablation|
62616917|NCT05513755|NO_INTERVENTION|Conventional treatment (counter-pressurre maneuver, drugs or pacemaker)|
62616918|NCT03145051|EXPERIMENTAL|Respimer Netiflow mineral salts solution|Nasal irrigation with Respimer Netiflow mineral salts solution, 4 times/day during 8 weeks using Respimer Netiflow class I medical device
62841978|NCT00999778|ACTIVE_COMPARATOR|Caregiver-Mediated Intervention|One hour 1:1 with parent, child and interventionist, each week, for 10 weeks social communication and joint engagement strategies will be targeted
62841979|NCT03894813|EXPERIMENTAL|Probiotics and Metronidazole|Probiotics: Oral probiotics(Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) ) (qd, 30 days); Metronidazole: Metronidazole vaginal suppositories (qd,7 days)
62616919|NCT03145051|ACTIVE_COMPARATOR|Saline solution|Nasal irrigation with saline solution , 4 times/day during 8 weeks using Respimer Netiflow class I medical device
62616920|NCT02910726|EXPERIMENTAL|Sentinel Lymph Node Biopsy|This is a single-center clinical trial to evaluate non-inferiority of ICG-guided SLN biopsy compared with the gold standard TcL-guided SLN biopsy in pediatric patients with solid tumors. Each patient will undergo TcL, consistent with the standard of care, but the surgeon will be blinded to the results preoperatively. Intraoperatively, ICG injection and transdermal lymphography will be used to identify the draining nodal basin and the position of the sentinel nodes. ICG transdermal lymphography will be considered successful if SLNs can be visualized on near-infrared imaging. After the transdermal lymphography results have been recorded, the surgeon will be unblinded to the TcL mapping.
62616921|NCT03103685|PLACEBO_COMPARATOR|ASA alone|The patient in this arm will be ask to stop P2Y12 inhibitor before dental procedure, 5 days for clopidogrel and ticagrelol and 7 days for prasugrel.
62616922|NCT03103685|EXPERIMENTAL|Uninterrupted DAPT|The patient in this arm will continue dual anti platelet until the date of dental procedure.
62616923|NCT02366403|EXPERIMENTAL|SKY|a standardized meditation program
62616924|NCT02366403|ACTIVE_COMPARATOR|CPT-C|CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
62616925|NCT01196377|ACTIVE_COMPARATOR|Nebulized albuterol 10mg/hr continuous|Active control arm, 10mg/hr continuous.
62616926|NCT01196377|EXPERIMENTAL|10mg/hr pulsed|Experimental 10mg/hr pulsed albuterol regimen.
62616927|NCT01196377|EXPERIMENTAL|25mg/hr continuous|Experimental 25mg/hr continuous albuterol.
62616928|NCT01196377|EXPERIMENTAL|25mg/hr pulsed|Experimental 25mg/hr pulsed albuterol
62616929|NCT04261010|EXPERIMENTAL|Ustekinumab|Group 1 (n=12): ustekinumab 45 mg (or 90 mg for patients \> 100 kg) subcutaneously at baseline (W0), 4 weeks later (W4), and every 12 weeks until week 24 (i.e. W0, W4, and W16).
62841980|NCT03894813|ACTIVE_COMPARATOR|Metronidazole vaginal|Metronidazole vaginal suppositories(1 suppositories,qd,7 days )
62841981|NCT02329418|EXPERIMENTAL|Written document|Accompanying relatives with a written document when discussing withholding and withdrawing life-sustaining therapies . All other procedures are standard.
62841982|NCT02329418|ACTIVE_COMPARATOR|Standard|Discussing withholding and withdrawing life-sustaining therapies following standard procedure without written document
62056862|NCT04318158|ACTIVE_COMPARATOR|Group(BD)|Patients will receive single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg dexmedetomedine on each side.
62260083|NCT01244555|EXPERIMENTAL|Massage treatment|
62260084|NCT01244555|EXPERIMENTAL|Ultrasound|
62260085|NCT01244555|NO_INTERVENTION|Wait-list|
62260086|NCT01971073|EXPERIMENTAL|bilateral Anodal-L/R Cathodal-R/L tDCS|"bilateral Anodal-left and cathodal-right tDCS over DLPFC or bilateral Anodal-right and cathodal-left tDCS over DLPFC.~Intervention: Device: transcranial direct current stimulation"
62260087|NCT01971073|SHAM_COMPARATOR|Sham tDCS|Sham tDCS
62616930|NCT04261010|EXPERIMENTAL|Guselkumab|Group 2 (n=12): guselkumab 100 mg subcutaneously (regardless of the weight of the patient) at weeks 0 and 4, followed by a maintenance dose every 8 weeks through week 24 (i.e. W0, W4, W12 and W20).
62616931|NCT04261010|ACTIVE_COMPARATOR|ADALIMUMAB|Group 3 (n=12): adalimumab 40 mg (regardless of the weight of the patient), subcutaneously every other week, starting from the baseline until week 24 (i.e.W0, W2, W4, W6, W8, W10, W12, W14, W16, W18, W20 and W22).
62623691|NCT02648464|PLACEBO_COMPARATOR|Placebo|Placebo tablet by mouth daily for 6 months. Patients under the weight of 60 kg: placebo tablet daily for 5 days per week for 6 months.
62260088|NCT04077307|EXPERIMENTAL|Dose escalation|Karonudib is an oral inhibitor of MTH1 and will be supplied as an oral solution to be taken every other day. There are three planned dose cohorts. Patients will be given every second day dosing.
62260089|NCT01529437|ACTIVE_COMPARATOR|Sublingual immunotherapy|Subjects will take sublingual immunotherapy who have dust mite and timothy grass allergies
62260090|NCT01529437|PLACEBO_COMPARATOR|placebo arm|The placebo arm will be double blinded and is an important control in SLIT therapies
62260091|NCT03677830|ACTIVE_COMPARATOR|Intravenous Acetaminophen|Infants randomized to the intervention arm will receive scheduled IV acetaminophen per LexiComp dosing guideline (28 0/7-32 6/7 weeks 10 mg/kg/dose every 12 hours; 33 0/7-38 6/7 weeks 10 mg/kg/dose every 8 hours; \>39 0/7 weeks 10 mg/kg/dose every 6 hours). N-PASS scores will guide administration of IV morphine. Continuous infusion of morphine will be started if an infant requires 3 doses of morphine within a 6-hour period and titrated as needed per N-PASS scores.
62445659|NCT00886483|ACTIVE_COMPARATOR|Active neurofeedback|In the active neurofeedback condition, the intervention is active neurofeedback (actual neurofeedback) either twice weekly or three times a week (randomized to frequency), with the same amount of total treatment over 40 sessions, varying only in frequency. Neurofeedback will be via the CyberLearning technology, using videogame race car speed and steering as feedback governed by EEG theta-beta ratio through the interface. the game controller is used in the usual fashion, but maximal speed is capped by the threshold theta-beta ratio, which changes from minute-to-minute by fuzzy logic based on the previous minute's ratio. If theta power exceeds a threshold, the rumble function of the controller comes on as a warning. The feedback is transparent to the patient, who just plays the videogame.
62623692|NCT04931771|EXPERIMENTAL|vFFR guided revascularization|
62056863|NCT04318158|ACTIVE_COMPARATOR|Group(BF)|Patients will receive single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg fentanyl on each side.
62056864|NCT04531163|EXPERIMENTAL|Interventional|"First arm is experimental, given (NAC) for 2 months in 1200mg/day dosing.~Both arms are assigned to pre-treatment analytical tests and post treatment all test analysis are repeated to compare drug effect with placebo group."
62056865|NCT04531163|NO_INTERVENTION|Non-interventional|Second arm has no intervention. It is only used to compare results of analytical tests with the first interventional arm.
62056866|NCT02886806|EXPERIMENTAL|high risk vascular surgery|Patients scheduled for high risk vascular surgery under automated total closed loop intravenous anesthesia and fluid management
62056867|NCT04382924|EXPERIMENTAL|Treatment Arm A|NP-120 (Ifenprodil) 20 mg TID + Standard of Care
62056868|NCT04382924|NO_INTERVENTION|Control Arm|Standard of Care only
62056869|NCT04382924|EXPERIMENTAL|Treatment Arm B|NP-120 (Ifenprodil) 40 mg TID + Standard of Care
62056870|NCT03361748|EXPERIMENTAL|Administration of bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 15 - 450 x 10\^6 CAR+ T cells after receiving lymphodepleting chemotherapy.
62056871|NCT01241383|EXPERIMENTAL|Bosentan|Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
62056872|NCT02609880|EXPERIMENTAL|Cognitive Behavioral Therapy|This group will receive Cognitive Behavioral Therapy to optimize sleep, pain, and mood in women with gynecologic cancers. The therapy will be provided on a one-on-one basis, for 2 hours once a week for six weeks by a trained therapist with a master's degree in Clinical Psychology.
62056873|NCT02609880|PLACEBO_COMPARATOR|Psychoeducation|This group will receive Psychoeducation which is aimed at providing information, resources, and non-specific support related to adapting well to cancer. The education will be provided on a one-on-one basis, for 2 hours once a week for six weeks by a trained therapist with a master's degree in Clinical Psychology.
62056874|NCT06019689|EXPERIMENTAL|Intervention|Digitally delivered CMAP intervention through App. CMAP is a manual-assisted intervention which has been adapted from a self-help guide called Life After Self-Harm based on the principles of Cognitive behavioral therapy (CBT).
62056875|NCT06019689|NO_INTERVENTION|Standard Routine Care|Local medical, psychiatric and primary care services providing standard routine care to participant patients. Participants receiving an initial assessment along with TAU as ascertained by their treating doctor at the hospital or their primary care physician (general practitioner (GP)
62616932|NCT01415375|EXPERIMENTAL|Prostate Cancer Screening Education|Men in the experimental intervention group received an educational pamphlet on prostate cancer testing as well as tailored telephone education in which the interventionist provided information, answered questions, and conducted a values clarification exercise with the participant.
62616933|NCT01415375|OTHER|Fruit and Vegetable Intake Education|Men in the attention control group received an educational pamphlet on daily recommended servings of fruits and vegetables as well as tailored telephone education in which the interventionist provided information, answered participant's questions, and discussed any barriers to eating fruits and vegetables.
62616934|NCT00344656||Subjects and Controls|Patients with DSM-IV Anorexia Nervosa
62616935|NCT05136430|EXPERIMENTAL|Self-Regulation strategies + large changes (SR)|This arm will receive the Self-Regulation strategies + large changes (SR) intervention followed by smoking cessation treatment
62056876|NCT05794633|EXPERIMENTAL|Acupuncture Group|"The patients will be recieved two days a week for 8 sessions with sterile 25\*40 mm needles.Selected points are as local points, 2 painful points (ahshi point) in the shoulder region, Large intestine 4, 15, Gallbladder 21, Triple warmer 5, 14 Small intestine 9; as distant points Gallbladder 34 and Stomach 38.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
62260092|NCT03677830|PLACEBO_COMPARATOR|Intravenous Placebo|Infants randomized to the control arm will receive normal saline placebo IV at the appropriate volume and times for the gestational age. IV acetaminophen is concentrated at 10 mg/ml; corresponding saline volumes will be 1 ml to 5 ml, approximately, based on subject weight. Control infants will also have N-PASS scores assessed using the same protocol following the surgical procedure for 72 hours. Dosing of IV morphine will be the same as the dosing for the intervention arm.
62260093|NCT00967551|ACTIVE_COMPARATOR|Micronutrient Sprinkles without zinc|Micronutrient sprinkles without zinc
62260094|NCT00967551|EXPERIMENTAL|Micronutrient sprinkles with zinc|Micronutrient sprinkles with zinc gluconate
62260095|NCT02355899|EXPERIMENTAL|PD P 506 A-PDT|One PD P 506 A-patch will be administered to each great toenail for 4 hours. After removal of the study medication the study nail(s) s will be illuminated with red light of defined wavelength (PDT).
62260096|NCT06238167|EXPERIMENTAL|Arm A|"Treatment arm(Tislelizumab+S-1/SOX)~Enrolled patients will receive chemotherapy combined with tislelizumab postoperative adjuvant therapy. Chemotherapy regimens were determined by the investigator as S-1 therapy or low dose SOX therapy"
62260097|NCT05758675||≥ 60 years old population|around 2000 subjects will be screened.
62260098|NCT05758675||18~59 years old population|around 3000 subjects will be screened.
62260099|NCT05758675||< 18 years old|around 15000 subjects will be screened.
62616936|NCT05136430|ACTIVE_COMPARATOR|Healthy Lifestyle Education (LE)|This arm will receive the healthy Lifestyle Education (LE) intervention followed by smoking cessation treatment
62616937|NCT04875871|EXPERIMENTAL|High-dose group|3 fractions of 12 Gy Relative Biological Effectiveness (RBE)
62260100|NCT02411162|EXPERIMENTAL|Open Label Arm|In Cohort 1, study medication (Cream A, 1%) will be applied as a thin layer onto a predefined area of the volar region of the forearm that is large enough to image and collect 3 biopsies (4 mm per biopsy). Vehicle will be applied on Day 1 only, onto a symmetrical location on the opposite forearm from Cream A. In cohort 2, subjects will be enrolled to evaluate Cream A (1%) and a different GSK2894512 Cream, Cream B (1%). Cream A, 1% and Cream B, 1% will be applied as a thin layer to the opposite forearms of the subject. Vehicle will be applied only on Day 1 to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied. Both Cream A and Cream B will continue to be applied OD to the same area of the same forearm for 7 days.
62260101|NCT06179758|EXPERIMENTAL|open-label interventional arm|
62260102|NCT05587855|EXPERIMENTAL|eCulinary Medicine Group (E-group)|The intervention group will receive weekly cooking demonstrations and education videos via electronic links to use herbs and spices to increase vegetables and reduce sodium in the diet over six weeks
62260103|NCT05587855|NO_INTERVENTION|Control Group (C-group)|The control group participants will receive usual care from their physician's clinic and the recipes but without the eCulinary intervention over 6 weeks.
62616938|NCT04875871|EXPERIMENTAL|Reduced-dose group|3 fractions of 8-10 Gy RBE
62616939|NCT02283320|EXPERIMENTAL|BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)|
62260104|NCT01342835|ACTIVE_COMPARATOR|drug: propofol|Drug:Propofol and sevoflurane The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
62260105|NCT01342835|ACTIVE_COMPARATOR|Sevoflurane group:sevoflurane|Drug:Sevoflurane and Propofol Mask induction is perform with sevoflurane (4-6%) follow by 1.5-2% sevoflurane in a 50:50 mixture of N2O and O2.
62445660|NCT00886483|SHAM_COMPARATOR|Sham Neurofeedback|The sham condition will appear identical to the neurofeedback in all aspects: equipment, duration, frequency, and videogame choices. The only difference is that the interface module will be pre-programmed to give random feedback rather than contingent on the participant's brainwave power spectrum.
62445661|NCT00778557|EXPERIMENTAL|1|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL (Ranbaxy Laboratories Limited, India)
62445662|NCT00778557|ACTIVE_COMPARATOR|2|Cefzil TM (CEFPROZIL) for oral suspension equivalent to 250mg/5mL anhydrous, cefprozil (Bristol-Myers Squibb Company, New Jersey USA)
62841983|NCT02922049|OTHER|pCLE vs. biopsies with histopathology|"The investigators will compare diagnostic accuracy and sensitivity of pCLE with standard biopsies in patients with esophageal and gastric lesions and in patients after completed endoscopic treatment of BORN.~All samples taken by biopsies will be correlated with the images taken by pCLE in the detection of lesions, intestinal metaplasia, dysplasia and buried glands."
62841984|NCT04277923|EXPERIMENTAL|SMOF lipid emulsion|the SMOF lipid emulsion is SMOFlipid.
62841985|NCT04277923|EXPERIMENTAL|MCT/LCT lipid emulsion|the MCT/LCT lipid emulsion is Lipofundin.
62445663|NCT00778557|ACTIVE_COMPARATOR|3|Cefzil TM (CEFPROZIL) for oral suspension equivalent to 250mg/5mL anhydrous, cefprozil (Bristol-Myers Squibb Company, New Jersey USA)
62616940|NCT03447106|EXPERIMENTAL|Open|
62616941|NCT03447106|EXPERIMENTAL|Laparoscopic|
62841986|NCT02399163|EXPERIMENTAL|Placebo dentifrice/Fluoride rinse|Twice daily brushing with a non-fluoride (placebo) toothpaste followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride
62841987|NCT02399163|PLACEBO_COMPARATOR|Placebo dentifrice/No rinse|Twice daily brushing with a non-fluoride (placebo) toothpaste
62841988|NCT02399163|ACTIVE_COMPARATOR|Fluoride dentifrice/No rinse|Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride
62841989|NCT02399163|EXPERIMENTAL|Fluoride dentifrice/Fluoride rinse|Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride, followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride.
62841990|NCT02509026|EXPERIMENTAL|Etanercept|etanercept 50 mg QW
62056877|NCT05794633|PLACEBO_COMPARATOR|Placebo Acupuncture Group|"The patients will be recieved two days a week for 8 sessions with placebo needle. Selected points are Large intestine 15 Triple warmer 14 gallbladder 21 and small intestine 9. We will use the Placebo needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time will be the same as those in the acupuncture group. The specialist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
62056878|NCT04606095|EXPERIMENTAL|Aim 1 - Healthy control|Participants will have three visits for this part along with a run-in observation period. An EEG with Quantitative Sensory Testing (QST) will be performed at visit 1 along with other measures. Additionally, the an MRI will be done at visit 2 along with other measures.
62056879|NCT04606095|EXPERIMENTAL|Aim 1 - Fibromyalgia participant|Participants will have three visits for this part along with a run-in observation period. An EEG with Quantitative Sensory Testing (QST) will be performed at visit 1 along with other measures. Additionally, the an MRI will be done at visit 2 along with other measures.
62056880|NCT04606095|EXPERIMENTAL|Aim 3 - HD-tDCS of M1|There will be two weeks of treatment in which participants will have 5 daily sessions of focused HD-tDCS or Sham per week.
62056881|NCT04606095|EXPERIMENTAL|Aim 3- HD-tDCS of ES|There will be two weeks of treatment in which participants will have 5 daily sessions of focused HD-tDCS or Sham per week.
62056882|NCT04606095|SHAM_COMPARATOR|Aim 3 - Sham|There will be two weeks of treatment in which participants will have 5 daily sessions of focused HD-tDCS or Sham per week.
62056883|NCT05287555|ACTIVE_COMPARATOR|Control|"Home non-invasive mask ventilation with prisma VENT device. Modem for the daily transmission of specific therapy parameters.~Standard care according to clinical standard (technical support by the provider and three hospital follow-up appointments after 2, 6 and after 12 months) with assessment of health status and NIV therapy settings.~Study specific: During visits, recording of HRQOL by SGRQ and S3NIV questionnaires, hospitalizaion and physician visits.~Therapy data from NIV device."
62260106|NCT06148376||MDI T2DM|Patients wit type 2 diabetes (T2DM) treated with multiple dose insulin therapy (MDI)
62260107|NCT00351013|EXPERIMENTAL|1|
62260108|NCT01431196|EXPERIMENTAL|DENDRITIC CELL VACCINATION|Px will receive standard neoadjuvant chemotherapy plus active vaccination. we will compare results with an historic cohort of patients treated with the same chemotherapy without the vaccines
62260109|NCT04983407|EXPERIMENTAL|Phase 1b: batiraxcept+ nab-paclitaxel and gemcitabine|Up to three dose levels of bactiraxcept plus nab-paclitaxel and gemcitabine
62260110|NCT04983407|EXPERIMENTAL|Phase 2: batiraxcept+ nab-paclitaxel and gemcitabine|
62260111|NCT04983407|ACTIVE_COMPARATOR|Phase 2: nab-paclitaxel and gemcitabine alone|
62260112|NCT05489835||Employees|Employees in Austrian companies affected by digitalization
62260113|NCT00455689|EXPERIMENTAL|Developed hot flashes|Subjects who developed hot flashes after receiving leuprolide acetate (3.75 mg intramuscular injection)
62616942|NCT03447106|EXPERIMENTAL|Robotic|
62056884|NCT05287555|EXPERIMENTAL|Telemonitoring|"Home non-invasive mask ventilation with prisma VENT device. Modem for the daily transmission of specific therapy parameters. An electronic feedback system provides patients with feedback and recommendations on their therapy based on the data submitted.~The study center regularly reviews and reacts to all therapy data and other information according to the remote care scheme of intervention.~Telemonitoring care patients also receive an SpO2 sensor for monitoring of oxygen saturation.~Ambulantory implementation of three blood gas analyses to check the health status after 2, 6 and 12 months. There are no regular routine inpatient stays.~Study specific: During visits, recording of HRQOL by SGRQ and S3NIV questionnaires, hospitalizaion and physician visits."
62056885|NCT02434458||Fibromyalgia case group|Patients diagnosed with fibromyalgia from the department of rheumatology will be subject to sudoscan evaluation and NCS studies.
62056886|NCT02434458||Control|Healthy control subjects
62056887|NCT02434458||Rheumatoid arthritis group|Patients diagnosed with rheumatoid arthritis at the department of rheumatology will be subject to sudoscan evaluation and NCS studies.
62056888|NCT02397239||Six cycles|Maintenance pemetrexed 500 mg/m2 every 3 weeks for six cycles
62056889|NCT02397239||Until disease progression|Maintenance pemetrexed 500 mg/m2 every 3 weeks until disease progression
62056890|NCT04975022|EXPERIMENTAL|T group|
62056891|NCT04975022|ACTIVE_COMPARATOR|R group|
62056892|NCT01291537|EXPERIMENTAL|Duodopa|
62056893|NCT01291537|ACTIVE_COMPARATOR|Best medical treatment|
62260114|NCT00455689|EXPERIMENTAL|Did not develop hot flashes|Subjects who did not develop hot flashes after receiving leuprolide acetate (3.75 mg intramuscular injection)
62260115|NCT02311153|ACTIVE_COMPARATOR|Endotracheal intubation|Endotracheal intubation for airway management and ventilation during sinonasal surgical procedure
62260116|NCT02311153|EXPERIMENTAL|Laryngeal mask airway|Laryngeal mask for airway management and ventilation during sinonasal surgical procedure
62260117|NCT04095364|EXPERIMENTAL|Arm I (paclitaxel, carboplatin, letrozole)|Patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Cycles repeat every 21 days for up to 6 cycles. Patients then receive letrozole PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo blood collection and tumor biopsy during screening as well as medical imaging throughout the study.
62260118|NCT04095364|EXPERIMENTAL|Arm II (letrozole)|Patients receive letrozole PO QD. Cycles repeat every 21 days for up to 6 cycles. Patients then receive letrozole orally PO QD in the absence of disease progression or unacceptable toxicity as maintenance therapy. Patients undergo blood collection and tumor biopsy during screening as well as medical imaging throughout the study.
62616943|NCT01600599|ACTIVE_COMPARATOR|IV & topical TA|patients in this group will receive both intravenous \& topical tranexamic acid
62616944|NCT01600599|PLACEBO_COMPARATOR|IV tranexamic acid & Topical Saline|
62623693|NCT04931771|ACTIVE_COMPARATOR|FFR guided revascularization|
62260119|NCT06075836||Readers/Participants|"Reader Selection: 30 readers will be selected from the following five clinical specialty groups:~* emergency medicine (ED)~* adult intensive care (ICU)~* adult general medicine (AGM)~* radiographers (Rad)~* general radiologists~Each specialty group consists of 6 members of ranked seniority. For the physicians this consists of:~* Two 'Juniors' (Foundation Year 1 - Specialty Training 2 years)~* Two 'Middle Grades' (Registrar from Specialty Training 3 to 6 years)~* Two Consultants~For the radiographers, this consists of:~* Two 'Junior/Newly qualified radiographers' (up to 18 months experience post qualification)~* Two 'Mid-experience radiographers' (approx. 3 years' experience)~* Two 'Reporting radiographers' (5+ years' experience)"
62260120|NCT06075836||Ground truthers|Two consultant thoracic radiologists. A third senior thoracic radiologist's opinion (\>20 years experience) will undertake arbitration.
62260121|NCT01528111|EXPERIMENTAL|Low dose LX7101|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
62260122|NCT01528111|EXPERIMENTAL|High dose LX7101|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
62260123|NCT01528111|PLACEBO_COMPARATOR|LX7101 Vehicle|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
62260124|NCT00779480|EXPERIMENTAL|KW-2449|Sequential dose escalation in separate cohorts of 3+3 design from 450 mg/day to 800 mg/day total daily dose.
62260125|NCT04565886|SHAM_COMPARATOR|control|Non-surgical mechanical instrumentation 3x. Each time the laser will be held in place but will not be activated.
62260126|NCT04565886|EXPERIMENTAL|laser|Non-surgical mechanical instrumentation 3x with adjunctive diode laser application according to the protocol of the Department of Periodontology, University of Bern
62260127|NCT03203057||control group|10 individuals get randomised to control group.
62260128|NCT03203057||short ischemic time|10 individuals get randomised to a controlled coronary occlusion for 30 seconds
62260129|NCT03203057||intermediate ischemic time|10 individuals get randomised to a controlled coronary occlusion for 60 seconds
62260130|NCT03203057||long ischemic time|10 individuals get randomised to a controlled coronary occlusion for 90 seconds
62260131|NCT04114149|ACTIVE_COMPARATOR|TENS (transcutaneous electrical nerve stimulation)|High frequency, high intensity TENS treatment. Patients who report postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 during the time spent in post-anesthesia care unit.
62260132|NCT04114149|ACTIVE_COMPARATOR|Conventional treatment with iv opioid|Patients who report postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 during the time spent in post-anesthesia care unit.
62445664|NCT04839588||Usability study, healthy volunteers and those with cognitive impairments following chemotherapy|"2 elderly healthy volunteers and 2 participants with lasting cognitive impairments following chemotherapy for breast cancer. All will perform evaluation of a computer-based experimental system. Participants will be~* Female Either healthy or breast cancer survivor;~* Age 20 to 65 years;~* Have st least 12 years of formal education;~* Be English speakers;"
62445665|NCT02336997|EXPERIMENTAL|FAT-GRAFT|Fat graft transplantation
62056894|NCT05842512|EXPERIMENTAL|Drug: ADI-PEG 20|Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)
62260133|NCT04114149|NO_INTERVENTION|Control|Patients who report postoperative pain intensity according to NRS (numeric rating scale) \< 3 during the time spent in post-anesthesia care unit.
62445666|NCT02336997|EXPERIMENTAL|SVF-TRANSPLANTATION|Transplantation of resuspended SVF
62445667|NCT02336997|PLACEBO_COMPARATOR|CONTROL|Same volume saline injection
62445668|NCT02577354|EXPERIMENTAL|Treatment|
62445669|NCT02577354|EXPERIMENTAL|Control|
62445670|NCT04941222|EXPERIMENTAL|"With robotic seal PARO"|The robot will be made available to the patient by the caregiver in charge of the patient for 5 minutes before a toilet and for the duration of the treatment (about 10 minutes), twice a week for 16 weeks.
62445671|NCT04941222|NO_INTERVENTION|"Without robotic seal PARO"|The care of the patient during the toilet will be carried out according to the modalities currently in use in the facility.
62445672|NCT03393858|EXPERIMENTAL|Immunotherapy plus Hyperthermia|
62056895|NCT05842512|PLACEBO_COMPARATOR|Drug: Placebo|Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)
62056896|NCT06300255||H.O.O.V.E.S. Healing Intensives Participants|Veterans enrolled in a H.O.O.V.E.S. healing intensives program and must have served in the military.
62260134|NCT04271059||TBI without polytrauma|Subjects who have experienced a severe traumatic brain injury (Glasgow Coma Scale (GCS) 3-13) within the last 12 hours, without additional polytrauma.
62260135|NCT04271059||TBI with polytrauma|Subjects who have experienced a severe traumatic brain injury (Glasgow Coma Scale (GCS) 3-13) and polytrauma, including major trauma to the chest, abdomen, pelvis or extremities. within the last 12 hours.
62260136|NCT04271059||Healthy Control|Subjects who have not experienced any TBIs within the last six months.
62260137|NCT04464395|EXPERIMENTAL|CPI-006 Dose Escalation|CPI-006 + Standard of Care
62260138|NCT04464395|OTHER|Control Arm|Standard of Care Only
62260139|NCT00844753|ACTIVE_COMPARATOR|1|Atomoxetine + Parent Management Training
62260140|NCT00844753|ACTIVE_COMPARATOR|2|Atomoxetine without Parent Management Training
62260141|NCT00844753|PLACEBO_COMPARATOR|3|Placebo + Parent Management Training
62260142|NCT00844753|PLACEBO_COMPARATOR|4|Placebo without Parent Management Training
62260143|NCT06119867|EXPERIMENTAL|Japanese pathological investigation method group|The surgeon will be involved into the Japanese pathological investigation method. The surgeon will perform the intraoperative markings and the postoperative lymph node harvest, after which the specimen will be assessed by the pathologist.
62445673|NCT03322462|EXPERIMENTAL|Flortaucipir PET Scan|
62445674|NCT04093661||Children below 1 year|Children \<= 1 year for elective surgery
62260144|NCT06119867|ACTIVE_COMPARATOR|European pathological investigation method group|After receiving the resected specimen, the entire process will be independently managed by the pathologist.
62260145|NCT00331045|PLACEBO_COMPARATOR|Placebo|
62445675|NCT02811809|EXPERIMENTAL|Apalutamide + IHT|Participants will be treated with 240 mg (4-60 mg tablets) oral Apalutamide daily plus 22.5 mg 3-month depot intramuscular leuprolide intermittently.
62445676|NCT02811809|ACTIVE_COMPARATOR|IHT only|Participants will receive 22.5 mg 3-month depot intramuscular leuprolide until PSA progression, then they will crossover to Apalutamide + IHT
62260146|NCT00331045|EXPERIMENTAL|Alvimopan 0.25 mg/yday|
62260147|NCT00331045|EXPERIMENTAL|Alviompan 0.5 mg/day|
62056897|NCT06384612|NO_INTERVENTION|control group|The control group consisted of students enrolled in the Care of a Child with Special Needs course in the 2021-2022 fall semester and enrolled in one of the branches. Students were informed about the research in the first week of the 2021-2022 fall semester, their written consent was obtained, and they were allowed to fill out the introductory information form and the Self-Efficacy Perception Scale (pre-test) in the second week. Routine course content was followed with these students throughout the course period. No intervention was made to the students. The course process was not disrupted during the research. Midterm and final exams were held on the dates determined by the faculty in order to evaluate the success of the course. The grade point averages of the students were evaluated by taking the exam table from the student information system. In the last week of the 2021-2022 fall semester, students were allowed to fill out the Self-Efficacy Perception Scale (posttest) again.
62260148|NCT00331045|EXPERIMENTAL|Alvimopan 1 mg/day|
62260149|NCT06098365|EXPERIMENTAL|Cervical Stabilization Exercise Group|After applying traditional treatment for 40 minutes to the cases in Group A, additional segmental cervical stabilization exercises (20 minutes) will be applied.
62260150|NCT06098365|OTHER|Cervical Isometric Exercise Group|After applying traditional treatment for 40 minutes to the cases in Group B, additional cervical isometric exercises (20 minutes) will be applied.
62260151|NCT01378507|EXPERIMENTAL|Endoscopic Submucosal Dissection|Single-arm for ESD procedure and retrospective surgical procedure(Laparoscopy, Open surgery)data collection
62445677|NCT06103409|EXPERIMENTAL|Allogenic MSCs|All Patients will receive conservative treatment before transplantation of allogenic MSCs embedded in autologous platelet rich plasma clot.
62445678|NCT03542136|OTHER|Patients receiving chemotherapy treatment with oxaliplatin.|
62445679|NCT02979379||Pain|Individuals with COPD who experience chronic pain (episodes of daily pain for a duration greater than three months)
62445680|NCT02979379||No Pain|Individuals with COPD who do not experience pain on a regular basis.
62445681|NCT00914433|EXPERIMENTAL|TPI 1100|Drug to be given by inhalation.
62623694|NCT05309694|OTHER|Group 1|Paragard® T380A Intrauterine Copper Contraceptive with new inserter Non parous and parous female subjects of child bearing potential
62841991|NCT04785469|EXPERIMENTAL|Eccentric training group|
62260152|NCT02039375|EXPERIMENTAL|"Hopkins post tPA monitoring protocol"|"Patients treated with IV tPA (intravenous tissue Plasminogen Activator) for acute stroke will be monitored in a non-ICU setting following the Hopkins post tPA monitoring protocol, a new schedule for vital signs and neurochecks. These patients will have vital signs and neurochecks every 15 minutes for two hours, then once upon admission to the stroke unit and after one hour, then every two hours for 8 hours and then every four hours until 24 hours post tPA."
62260153|NCT01427985|EXPERIMENTAL|Relaxation followed by analgosedation|Give Atropin, then Mivacurium, immediately followed by Fentanyl
62260154|NCT01427985|ACTIVE_COMPARATOR|Analgosedation followed by Relaxation|Give atropin, then Fentanyl, then Mivacurium
62260155|NCT01057407|EXPERIMENTAL|ASP group|
62260156|NCT01057407|ACTIVE_COMPARATOR|Sevelamer group|
62260157|NCT05884203|EXPERIMENTAL|Caregiver socket|Participants will wear a prosthetic socket whose shape was captured by a study helper using digital methods (i.e., a 3D scanner).
62260158|NCT05884203|EXPERIMENTAL|Prosthetist socket|Participants will wear a prosthetic socket whose shape was captured by a prosthetist using traditional, hand casting methods.
62260159|NCT01833637|NO_INTERVENTION|Arm A: Control Group|Patients randomized to the control group will be asked to fill out a patient symptom questionnaire using an iPad at the time of registration and then every 24 hours until released from the hospital. It should take about 10 minutes to complete the questions each time. The survey will not interfere with the care the healthcare team will be providing. Patients will be asked to fill our a Patient Satisfaction Questionnaire at the time of discharge.
62260160|NCT01833637|ACTIVE_COMPARATOR|Arm B: APN Intervention Group|Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
62260161|NCT00533832|ACTIVE_COMPARATOR|1|Patients implanted with the vagus nerve stimulation (VNS) device and receiving VNS Intervention: vagus nerve stimulation (VNS)
62260162|NCT00533832|PLACEBO_COMPARATOR|2|Implanted with vagus nerve stimulation (VNS) device, but not receiving VNS
62445682|NCT05271539|ACTIVE_COMPARATOR|The first group, Lucentis alone group|The first group received 3 monthly intravitreal injections of 0.5 mg in 0.05 mL ranibizumab alone (Lucentis, by Novartis), aspirated from vial through 5-micron sterile filter needle (19-gauge × 1-1/2 inch), with a 1-mL syringe and injected through a 30-gauge × ½ inch sterile injection needle.
62056898|NCT06384612|EXPERIMENTAL|pocket cards group|The study group consisted of students enrolled in the Care of a Child with Special Needs course in the 2021-2022 spring semester. Introductory information form and Self-Efficacy Perception Scale were filled out. A common day was determined with the students and a 15-minute training was given on the example of preparing a pocket card. A total of nine groups of seven people were formed and they were prepared for the next week. At the end of each lesson, student groups were asked to prepare a pocket card on a 22 cm piece of paper. A WhatsApp group and an Instagram page were established to check whether the students had made their pocket cards and, if so, whether it was accurate. The cards were shared in their final form on Instagram and each student was told to turn on page notifications and like the post when they saw it so that they could instantly follow the post. In the last week, students were asked to fill out the Self-Efficacy Perception Scale again.
62056899|NCT01457378||Healthy volunteers|100 healthy volunteers
62056900|NCT01457378||IBS Subjects|100 IBS Subjects
62841992|NCT04785469|ACTIVE_COMPARATOR|Control group|
62841993|NCT02663037||1|"Subjects will be recruited from a pool of elderly patients who present to the Emergency Department.~To be eligible for participation in the study, patients must meet ALL of the following criteria:~1. Age ≥ 55 years old~2. Triaged as P2 or P3 in the Emergency Department~3. Singapore citizen or Permanent Resident~4. Provision of Informed consent~5. Not previously already enrolled in this study"
62841994|NCT01794767|ACTIVE_COMPARATOR|0,9% NaCl flush|for children enrolled in this group, the nurse will perform the flushing of peripheral venous catheter using flush-solution as a bolus with saline 0.9% NaCl in the amount (ml) needed to fill the entire circuit of the catheter. The flushing will be performed routinely at the end of each fleboclisis
62841995|NCT01794767|EXPERIMENTAL|Heparin 50U/ml|for children enrolled in this group, the nurse will perform the washing of peripheral venous catheter using flush-solution as a bolus with heparin 50U/ml in the amount (ml) needed to fill the entire circuit of the catheter. The washing will be performed routinely at the end of each fleboclis
62841996|NCT00458978|EXPERIMENTAL|Treatment (enzyme inhibitor)|Patients receive oral cediranib maleate once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62841997|NCT00176917|EXPERIMENTAL|Treatment Arm|All patients treated with chemotherapy and transplantation.
62841998|NCT02532738|EXPERIMENTAL|MSC-1|Patients in this arms receive routine treatment with 3×10E6/kg of MSC
62841999|NCT02532738|EXPERIMENTAL|MSC-2|Patients in this arms receive routine treatment with 6×10E6/kg of MSC
62842000|NCT02532738|PLACEBO_COMPARATOR|Ctrl|Patients in this arms receive routine treatment with NS injection
62842001|NCT05459857|EXPERIMENTAL|Product sequence ABCD|Subjects use Product A on Day 1, Product B on Day 2, Product C on Day 3 and Product D on Day 4
62842002|NCT05459857|EXPERIMENTAL|Product sequence BDAC|Subjects use Product B on Day 1, Product D on Day 2, Product A on Day 3 and Product C on Day 4
62842003|NCT05459857|EXPERIMENTAL|Product sequence CADB|Subjects use Product C on Day 1, Product A on Day 2, Product D on Day 3 and Product B on Day 4
62842004|NCT05459857|EXPERIMENTAL|Product sequence DCBA|Subjects use Product D on Day 1, Product C on Day 2, Product B on Day 3 and Product A on Day 4
62842005|NCT02170415|ACTIVE_COMPARATOR|Intervention limb|"Medical review and analgesic optimisation.~Pain education (in the form of leaflet and website recommendations)~Psychological input for patients with evidence of psychological morbidity.~Protective analgesia - one pre-procedure dose of 150mg oral pregabalin.~Five days post-procedure oral pregablin twice daily at a dose of 75mg twice a day.~Patients offered a paravertebral block, local anaesthetic infiltrated around the wound by the surgeon.~Daily, focused visits from the hospital pain team.~Any patient displaying concerning pain symptoms, behaviour or who underwent prolonged (\>3 hours surgery) may be booked for early 'preemptive' review in pain clinic."
62842006|NCT02170415|NO_INTERVENTION|Usual care|These partcipants will receive usual care before, during and after their breast surgery
62842007|NCT02302014|EXPERIMENTAL|Palliative Care Intervention|Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
62842008|NCT02302014|NO_INTERVENTION|Usual Care|Usual Care
62260163|NCT05732090|EXPERIMENTAL|Control group (A)|The control group will receive a therapeutic exercise program (3 sessions per week for two months).
62260164|NCT05732090|EXPERIMENTAL|study Group (B)|study group will received the same intervention in control group in addition to diaphragmatic myofascial release (3 sessions/week/two months).
62260165|NCT03614754||Successes|Patients with reduction of symptoms \>50% during the test procedure for sacral neuromodulation.
62623695|NCT01831427|EXPERIMENTAL|Andecaliximab 0.3 mg/kg IV single ascending dose (SAD)|Participants will receive andecaliximab 0.3 milligrams per kilogram (mg/kg) on Day 1.
62842009|NCT04678219|EXPERIMENTAL|Low-Protein/Vegan/Low-Sulfur Diet|This is a specific diet that is both vegan and low in protein. The vegan diet eliminates all animal products, (including meats, eggs, dairy products) and animal by-products such as honey.
62842010|NCT04678219|EXPERIMENTAL|Specific Carbohydrate Diet|"The Specific Carbohydrate Diet emphasizes consumption of specific carbohydrates that require minimal digestion. Therefore, it eliminates most carbohydrates, including grains, starches, dairy and sugars.~The idea behind this diet is that it reshapes the microbiome of the intestines. The diet restricts the intake of certain carbohydrates that may increase the growth of bad bacteria possibly contributing to inflammation. By restricting the amount of these carbohydrates in the microbiome, the diet aims to reduce their activity in the gut and reduce inflammation."
62842011|NCT03839797|EXPERIMENTAL|Cadet Healthy Personal Skills|Cadet Healthy Personal Skills
62842012|NCT03839797|ACTIVE_COMPARATOR|Standard Health Education|Standard Health Education
62056901|NCT02094014||Aphasic/Apraxic Participants|"The aphasic/apraxic participant group will include 30 adults who have had strokes affecting their ability to communicate verbally, broadly classified as aphasic and including individuals with and without apraxia of speech (AOS).~Participants will speak under Masked Auditory Feedback, Altered Auditory Feedback, and Normal Auditory Feedback."
62260166|NCT03614754||Failures|Patients with reduction of symptoms \<50% during the test procedure for sacral neuromodulation.
62260167|NCT00867321|EXPERIMENTAL|Arm I (Phase II)|Patients receive oral sorafenib tosylate on days 1-28 twice daily and bevacizumab IV on days 1 and 15.
62260168|NCT00867321|EXPERIMENTAL|Arm II (Phase II)|Patients receive oral sorafenib tosylate twice daily on days 1-28.
62260169|NCT03535467||Conventional Rehabilitation|
62260170|NCT03535467||Robotic Therapy|
62260171|NCT03077685|EXPERIMENTAL|Dose Escalation: NanoPac® 6 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
62260172|NCT03077685|EXPERIMENTAL|Dose Escalation: NanoPac® 10 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
62623696|NCT01831427|EXPERIMENTAL|Andecaliximab 1.0 mg/kg IV (SAD)|Participants will receive andecaliximab 1.0 mg/kg on Day 1.
62842013|NCT06287099|EXPERIMENTAL|BRL-101|Autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the BCL11A gene. Subjects will receive a single infusion of BRL-101.
62056902|NCT02094014||Neurologically Healthy Participants|"The neurologically healthy participant group will include 15 adults with no history of stroke or developmental speech or language disorder.~Participants will speak under Masked Auditory Feedback, Altered Auditory Feedback, and Normal Auditory Feedback."
62056903|NCT01185093||Fourth grade students|Each participant will attend two presentations and six hands-on activities led by St. Jude faculty and research staff on topics within their expertise, such as cells and cancer, and healthy living. The pre-test will take place within 7±1 days before the program presentations and before students receive copies of the printed material. Two post-tests will take place. The first post-test will be administered within 7±1 days after the final scheduled program presentation and will be a measure of knowledge acquisition. The second post-test will take place 90±7 days post-intervention and will be a measure of knowledge retention.
62260173|NCT03077685|EXPERIMENTAL|Dose Escalation: NanoPac® 15 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
62260174|NCT03077685|EXPERIMENTAL|Second Phase: NanoPac® at Best Dose|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® administrations, with the second injection administered one month after the first injection.
62445683|NCT05271539|ACTIVE_COMPARATOR|The second group, Lucentis dexamethasone group|The second group received monthly intravitreal injections of the same dose of ranibizumab combined with 0.4 mg in 0.1 ml dexamethasone (Dexamethasone sodium phosphate, Amriya Pharmaceuticals, Cairo, Egypt) in a separate 1ml syringe with 27- gauge × ½ inch sterile injection needle, followed by 2 Intravitreal ranibizumab, 1 month apart (with dexamethasone if follow up OCT shows less than 10% improvement from baseline i.e., PRN).
62842014|NCT00845897|PLACEBO_COMPARATOR|1|Placebo (saline) injections into 6 sites in the calf muscle
62260175|NCT03077685|EXPERIMENTAL|Third Phase: NanoPac® at Best Dose|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the third phase will be determined during the dose escalation phase. Subjects will receive four NanoPac® administrations, with the injections administered one month apart.
62260176|NCT01982032|ACTIVE_COMPARATOR|Edwards SAPIEN bioprosthesis|Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
62260177|NCT01982032|ACTIVE_COMPARATOR|Medtronic CoreValve® system|Transcatheter aortic valve replacement with the Medtronic CoreValve system
62445684|NCT04571242|ACTIVE_COMPARATOR|DTM-SCS programming|This SCS group will be programmed under the direction of physicians with support of clinical representatives of the Test treatments, which may identify the type of treatment to study participants. DTM-SCS programming has at least two programs with different pulse rate in the 50 to 1,000 Hz range and each having a maximum pulse width of 1 ms.
62842015|NCT00845897|ACTIVE_COMPARATOR|2|Total 200 units of Botulinum Toxin injected into 6 sites into the calf muscles.
62056904|NCT03520595|ACTIVE_COMPARATOR|Arnica Group|Study group 1 CLP with ostectomy Arnica 200 drug 3 pills,3 times daily for 3 days
62056905|NCT03520595|ACTIVE_COMPARATOR|Diclofenac Sodium group|Study group 2 CLP with ostectomy Diclofenac Sodium 50mg twice daily after meals with plain water
62056906|NCT03520595|PLACEBO_COMPARATOR|Placebo Group|Study group 3 CLP with ostectomy Placebo pills and distilled water 3 pills,3 times daily
62056907|NCT04416698||Youth smokers|Participants of Youth Quitline
62056908|NCT00238030|ACTIVE_COMPARATOR|po thyroxine|placebo is iv
62260178|NCT03007368|EXPERIMENTAL|Rice|Cooked white rice and tomato-based sauce
62260179|NCT03007368|EXPERIMENTAL|Potato|Cooked white peeled potato and tomato-based sauce
62260180|NCT03007368|EXPERIMENTAL|Pasta|Cooked macaroni product and tomato-based sauce
62260181|NCT03007368|EXPERIMENTAL|Sorghum thick porridge|Sorghum thick porridge and tomato-based sauce
62260182|NCT03007368|EXPERIMENTAL|Millet thick porridge|Millet thick porridge and tomato-based sauce
62842016|NCT00845897|ACTIVE_COMPARATOR|3|300 units of botulinum toxin injected into 6 sites in the calf muscle
62842017|NCT02905227|EXPERIMENTAL|Adult Asthmatics|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult asthmatics
62842018|NCT02905227|EXPERIMENTAL|Adult Smokers|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult smokers.
62842019|NCT02905227|EXPERIMENTAL|Adult Healthy Volunteers|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult healthy volunteers.
62842020|NCT01149018|EXPERIMENTAL|Tetrahydrocannabinol|
62842021|NCT01149018|PLACEBO_COMPARATOR|Placebo|
62056909|NCT00238030|ACTIVE_COMPARATOR|iv thyroxine|placebo is po
62260183|NCT03007368|EXPERIMENTAL|Millet couscous|Cooked millet couscous and tomato-based sauce
62260184|NCT03007368|EXPERIMENTAL|Millet thin porridge|Millet thin porridge
62260185|NCT03007368|EXPERIMENTAL|Millet thin monikuru porridge|Millet thin porridge containing cooked millet granules (monikuru)
62260186|NCT03257670|ACTIVE_COMPARATOR|CO2RE Laser|This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
62842022|NCT00452816|EXPERIMENTAL|Intervention|Intervention Group - Workplace Solutions Consulting
62842023|NCT00452816|ACTIVE_COMPARATOR|2|Delayed Intervention
62842024|NCT04475887|ACTIVE_COMPARATOR|Group A|IV administration of iron-III-carboxymaltose according to iron deficit every 4 weeks.
62842025|NCT04475887|PLACEBO_COMPARATOR|Group B|IV administration of 1000ml 0.9% NaCl every 4 weeks.
62842026|NCT00364104|EXPERIMENTAL|A|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
62842027|NCT00364104|EXPERIMENTAL|B|The 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
62056910|NCT00045435|EXPERIMENTAL|Treatment (nonmyeloablative donor PBSC transplant)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANT: Patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive CSP PO BID on days -3 to 56 with taper to day 77. Patients also receive MMF PO BID on days 0-27."
62842028|NCT00364104|EXPERIMENTAL|C|6-weeks of iron supplementation only plus 10-days of matching placebo of Hp infection eradication therapy
62260187|NCT03257670|ACTIVE_COMPARATOR|4% Topical Lidocaine Gel|This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
62260188|NCT03029143|EXPERIMENTAL|Lead-in Period: Vedolizumab 300 mg|Vedolizumab 300 mg intravenous (IV) infusion once at Day 1 and at Week 2. Participants who were non-responders based on partial Mayo score at Week 6 and who had high vedolizumab clearance (\>0.14 L/day) at Week 5 were eligible for Randomized Treatment Period (RTP). Participants who were responders (Lead-In Failures) entered the 18-week follow-up period and discontinued the study.
62260189|NCT03029143|EXPERIMENTAL|Randomized Treatment Period (RTP): Standard Treatment Arm|Following Lead-in Period, participants received vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) at Weeks 6, 14 and 22 as standard treatment plus 18 weeks follow-up.
62842029|NCT00364104|PLACEBO_COMPARATOR|D|
62260190|NCT03029143|EXPERIMENTAL|RTP: Dose Optimized Arm|Following Lead-in Period, participants received vedolizumab 600 mg, IV infusion at Week 6, followed by Regimen A: vedolizumab 300 mg once in every 4 weeks (Q4W) thereafter (Weeks 10, 14, 18, 22 and 26) plus 18 weeks follow-up, or Regimen B: vedolizumab 600 mg, IV infusion Q4W (Weeks 10, 14, 18, 22 and 26) plus 18 weeks follow-up based on drug clearance.
62842030|NCT00226759|EXPERIMENTAL|OMS103HP irrigation solution|Drug
62260191|NCT00889148|EXPERIMENTAL|Gabapentin|600mg of gabapentin will be given orally two hours preoperatively and 200mg for 3 times a day after surgery for three days.
62842031|NCT00226759|PLACEBO_COMPARATOR|vehicle irrigation solution|Vehicle
62842032|NCT05242198|OTHER|Rectus sheath block group (Group R)|Patients who underwent rectus sheath block
62842033|NCT05242198|OTHER|Control group (Group C)|The patients that did not apply any fascial plane block
62842034|NCT03429270|EXPERIMENTAL|Urodynamics Arm|
62842035|NCT04542018|EXPERIMENTAL|Study patients with IBS-D|Patients with diarrhea-predominant IBS who will undergo a low FODMAP diet for 4 weeks
62056911|NCT05325255|EXPERIMENTAL|Maitland mobilization with myofascial trigger point release group|"Maitland technique: caudal, anteroposterior (AP), and posteroanterior (PA) glides 5 sets of 2-3 glides per second of Grade III and IV for 30 seconds with a rest interval of 30 second between sets.~Ischemic Compression technique: on subscapularis trigger points for 90 secs thrice a week for 2 weeks.~Stretching exercises in direction of abduction, external rotation (ER), internal rotation (IR), and flexion. 6 repetitions of each stretch for 10 seconds Cold pack for 20 mins"
62260192|NCT00889148|PLACEBO_COMPARATOR|Placebo|
62260193|NCT01315860||Pregnant Females|Pregnant females in their second or third trimester that meet the inclusion and exclusion criteria.
62842036|NCT04980339||ASO group|All participants with TGA/TBA after ASO
62842037|NCT05063448|EXPERIMENTAL|DadSpace Intervention|Participants will take part in a 12-hour educational discussion-based mentoring program intervention over 8 weeks. The intervention will be facilitated by a trained father facilitator and will include education and support on topics relevant to perinatal fathers. Topics include father identity, stress management, infant development, co-parenting, masculinity and caregiving, healthy communication, and work-life balance. Participants will additionally have access to a brief educational podcast series on related topics. Participants will also be invited to monthly follow-up daddy/baby drop-in groups.
62260194|NCT03628053|EXPERIMENTAL|Tisagenlecleucel arm|Patient to receive tisagenlecleucel after optional bridging therapy and lymphodepleting chemotherapy.
62260195|NCT03628053|ACTIVE_COMPARATOR|Control arm|blinatumomab or inotuzumab per investigator's discretion after optional bridging chemotherapy
62260196|NCT03383536||Phase 1|Healthy control participants will provide neuroeconomic game responses to form a pool of potential responses for participants to interact with during Phase 2.
62445685|NCT04571242|ACTIVE_COMPARATOR|Conventional SCS programming|This SCS group will be programmed under the direction of physicians with support of clinical representatives of the Control treatments, which may identify the type of treatment to study participants. Conventional SCS programming is stimulation parameters in the 40-250 Hz frequency range and will be trialed according to standard practice as described in the Intellis labeling/manuals
62842038|NCT03586557|EXPERIMENTAL|Corticosteroid & Plasma Exchange|1000mg intravenous methylprednisolone daily for 3\~5 days and subsequent taper, combined with plasma exchange every other day for five times in all
62842039|NCT03586557|ACTIVE_COMPARATOR|Corticosteroid|1000mg intravenous methylprednisolone daily for 3\~5 days, and subsequent corticosteroid decrement.
62842040|NCT00990548||Cardiovascular Service Line patients|Patients admitted to the Cardiovascular Service Line at a major teaching hospital during a consecutive 11-month period.
62842041|NCT02829567|EXPERIMENTAL|Oral hygiene counseling and motivational interviewing|This group will receive a session of oral hygiene counseling and a single session of motivational interviewing to increase the readiness of change.
62842042|NCT02829567|NO_INTERVENTION|Oral hygiene counseling|
62842043|NCT00934362|OTHER|Lucinactant first, then placebo|Active treatment first, then washout period, then placebo treatment
62842044|NCT00934362|OTHER|Placebo treatment first, then lucinactant treatment|0.9% NaCl vehicle treatment first, then washout period, then lucinactant treatment
62842045|NCT05461508|ACTIVE_COMPARATOR|Amoxicillin combined with vonoprazan|The subjects will be given 20mg vonoprazan twice a day and 1000mg amoxicillin three times a day. These two drugs were taken continuously for 14 days
62842046|NCT05461508|EXPERIMENTAL|Amoxicillin combined with vonoprazan and fucoidan|The subjects will be given 20mg vonoprazan twice a day, 1000mg amoxicillin three times a day and fucoidan 1000mg twice a day. These three drugs were taken continuously for 14 days.
62260197|NCT03383536||Phase 2: PTS-SA|posttraumatic spectrum-socially anhedonic
62056912|NCT05325255|ACTIVE_COMPARATOR|Maitland mobilization alone group|"Maitland technique: caudal, anteroposterior (AP), and posteroanterior (PA) glides 5 sets of 2-3 glides per second of Grade III and IV for 30 seconds with a rest interval of 30 second between sets.~Stretching exercises in direction of abduction, external rotation (ER), internal rotation (IR), and flexion. 6 repetitions of each stretch for 10 seconds Cold pack for 20 mins"
62842047|NCT04279626||LETS-M|Women who were older than 20 years old and had not reached menopause, with symptomatic uterine myomas, such as hypermenorrhea, infertility, a mass effect-related urinary frequency, and constipation, received LETS-M.
62056913|NCT02252432|ACTIVE_COMPARATOR|Ketamine|A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min))
62056914|NCT02252432|ACTIVE_COMPARATOR|Methadone|Will receive a single dose of IV methadone (0.2 mg/kg) preinduction
62056915|NCT02252432|EXPERIMENTAL|Ketamine + methadone|Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
62056916|NCT02028559|EXPERIMENTAL|Treatment with Ultrasonic Propulsion|Subjects receive treatment with the Propulse 1 device. Intervention consists of the non-invasive application of ultrasound to move stones within the kidney and ureter.
62056917|NCT02028559|NO_INTERVENTION|Control|Subject follow same protocol as treatment group but do not receive the ultrasonic propulsion intervention.
62056918|NCT00820274|EXPERIMENTAL|amniotic membranes|
62056919|NCT04410068|EXPERIMENTAL|Electrical heating pad|"Electrical heating pad (WARMTAC device). Patients will be randomized to one arm.~In this arm, the WARMTAC device will be conected and warmed to 41 degrees before patients lay down."
62056920|NCT04410068|EXPERIMENTAL|forced-air warming device|Forced-air warming device (3M device). In this arm, the 3M blanket will be conected to forced-air machine and warmed to 41 degrees before patients lay down.
62445686|NCT03939169|OTHER|Skin-to-skin support|The newborn is dressed in one layer of clothing with a hat, he is placed in the ventral position directly on the mother's chest, covered with a warm blanket and held in place with a band during the insertion of the naso-gastric feeding tube.
62056921|NCT02897479|EXPERIMENTAL|Savolitinib|Pulmonary Sarcomatoid Carcinomas
62056922|NCT06320626|OTHER|Conventional dosing - open label|Patients will be followed 6 months retrospectively and 6 months prospectively on conventional dosing.
62056923|NCT06320626|OTHER|PK-guided dosing - open label|Patients with emicizumab concentration of ≥ 40 μg/mL will receive individualized PK-guided dose reduction of emicizumab targeted at a Ctrough of 30μg/mL. Patients will be followed for 12 months on reduced dosing.
62056924|NCT06320626|OTHER|No intervention continuation - open label|Patients with emicizumab concentration of 25-39 μg/mL will continue on their current dose regimen. Patients will be followed for 12 months on current dosing.
62260198|NCT03383536||Phase 2: PTS-nonSA|posttraumatic spectrum-non-socially anhedonic
62445687|NCT03939169|OTHER|Holding|The newborn is held in his mother's arms during insertion of the naso-gastric feeding tube.
62445688|NCT03939169|OTHER|Four hands care|Carried out by two professionals: one health-care professional supports the child and helps stabilize the newborn whilst the other professional inserts the naso-gastric feeding tube.
62842048|NCT05163899|ACTIVE_COMPARATOR|Surgery|Filum release
62842049|NCT05163899|NO_INTERVENTION|Observation|Medical Management only
62842050|NCT03763877|EXPERIMENTAL|Group 1|PXL770 Dose 1
62842051|NCT03763877|EXPERIMENTAL|Group 2|PXL770 Dose 2
62842052|NCT03763877|EXPERIMENTAL|Group 3|PXL770 Dose 3
62842053|NCT03763877|PLACEBO_COMPARATOR|Group 4|Placebo oral capsule
62842054|NCT02110043|EXPERIMENTAL|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with anodal transcranial direct current stimulation (tDCS)
62842055|NCT02110043|SHAM_COMPARATOR|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
62842056|NCT06142214||Endometriosis- Case group|Patients between the ages of 18-45, who applied to the Gynecology outpatient clinic of Etlik City Hospital and were followed up in our hospital, who were suspected of endometriosis on ultrasound or MRI or CT, and who were operated and whose postoperative pathology was compatible with endometriosis will be included in the study.
62056925|NCT06320626|OTHER|No intervention adjusted - open label|Patients with emicizumab plasma concentration \< 25 μg/mL will be adjusted in dosing regimen according to local protocol. Patients will be followed for selective safety data only.
62056926|NCT04860518|EXPERIMENTAL|IV IFN beta-1a|Patients receiving active drug: will receive two separate bolus injections one containing IFN-beta -1a and another injection containing Saline.
62260199|NCT03383536||Phase 2: HC|healthy controls
62260200|NCT03186690|EXPERIMENTAL|Biodentine|This includes teeth that were treated with Biodntine cement
62260201|NCT03186690|EXPERIMENTAL|Mineral Trioxide Aggregate|This includes teeth that were treated with Mineral Trioxide Aggregate (MTA) cement
62260202|NCT06255704|EXPERIMENTAL|Zanubrutinib and RCHOP/RDHAP|Patients will receive zanubrutinib and RCHOP alternating with RDHAP for a total of 6 cycles of induction therapy, and patients who achieve complete response after 6 cycles of induction therapy will be eligible to enter a 2-year maintenance treatment period of zanubrutinib in combination with rituximab
62260203|NCT02410668|ACTIVE_COMPARATOR|Flaxseed|30 grams Flaxseed powder combine with dietary and exercise recommendation
62260204|NCT02410668|PLACEBO_COMPARATOR|control|dietary and exercise recommendation
62260205|NCT01718561|NO_INTERVENTION|Control|Usual clinical airway evaluation and usual registration in Danish Anaesthesia Database (without SARI registration)
62623697|NCT01831427|EXPERIMENTAL|Andecaliximab 2.5 mg/kg IV (SAD)|Participants will receive andecaliximab 2.5 mg/kg on Day 1.
62260206|NCT01718561|EXPERIMENTAL|SARI|Registration of Modified SARI score and predictors for difficult mask ventilation in Danish Anaesthesia Database
62842057|NCT06142214||Healthy patients-Control|Patients who underwent bilateral tubal ligation in our Gynecology Clinic and who did not have any pelvic pathology will be included as the control group.
62842058|NCT04812717|ACTIVE_COMPARATOR|CytoSorb-Yes|Heart failure patients that will receive intraoperative treatment with CytoSorb.
62260207|NCT01230541|PLACEBO_COMPARATOR|Placebo|Placebo
62260208|NCT01230541|ACTIVE_COMPARATOR|Udenafil|Udenafil daily tablet
62445689|NCT03939169|OTHER|Containing support with equipment|Carried out by one healthcare Professional, who places the newborn in such a manner that he will be held in the optimum position (using a soft sheet) during the insertion of the naso-gastric feeding tube.
62616945|NCT05387512||Camrelizumab treatment group|The primary treatment is Camrelizumab combined with Pemetrexed and Platinum, secondary treatment with standard chemotherapy after progression. Reference regimen of Camrelizumab 200mg/3 weeks; Carboplatin reference regimen was AUC = 5 mg/mL/min; Cisplatin reference regimen was 75 mg/m2; Pemetrexed reference regimen was 500 mg/m2; paclitaxel liposome reference regimen is 135-175 mg/m2.
62842059|NCT04812717|NO_INTERVENTION|CytoSorb-No|Heart failure patients that will not receive intraoperative treatment with CytoSorb.
62842060|NCT03169725|EXPERIMENTAL|Test group 1|Low dose (Stage2: Lot A) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
62842061|NCT03169725|EXPERIMENTAL|Test group 2|Middle dose (Stage2: Lot B) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
62842062|NCT03169725|EXPERIMENTAL|Test group 3|High dose (Stage2: Lot C) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
62842063|NCT03169725|ACTIVE_COMPARATOR|Comparator|Cormmercialized inactivated poliomyelitis vaccine based on Sabin strains (Imovax Polio)
62842064|NCT02640508|EXPERIMENTAL|Combination Eribulin and lenvatinib|Eribulin will be given on days 1 and 8. Lenvatinib will be given daily in each 28 day cycle.
62842065|NCT04658199|EXPERIMENTAL|UCB0107 (bepranemab)|Subjects in this study arm will receive Intravenous UCB0107.
62056927|NCT04860518|ACTIVE_COMPARATOR|IV Dexamethasone|Patients receiving active comparator: will receive two separate bolus injections one containing saline and another injection containing Dexamethasone.
62260209|NCT05896085|EXPERIMENTAL|REThink game|Participants will complete the online standardized scales and then complete the REThink therapeutic game's assessment system in 3D or VR version.
62260210|NCT01731379||Surgical resections|Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy, patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
62260211|NCT06005870|EXPERIMENTAL|Z-RCHOP|Patients with newly diagnosed DLBCL with p53 expression were treated with a combination of Zanubrutinib and RCHOP.
62260212|NCT00061542|EXPERIMENTAL|Betaxolol|Two doses daily for 12 weeks
62260213|NCT00061542|EXPERIMENTAL|TGFS 0.25%|Two doses daily for 12 weeks
62260214|NCT00061542|EXPERIMENTAL|TGFS 0.5%|Two doses daily for 12 weeks
62842066|NCT03293368|EXPERIMENTAL|Platelet rich plasma|0.5 ml of autologous platelet rich plasma prepared using a double spin technique described by Mostafa et al., 2013 will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.
62842067|NCT03293368|ACTIVE_COMPARATOR|Croticosteroids|0.5 ml of triamcinolone acetonide 40 mg will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.
62842068|NCT03098004|EXPERIMENTAL|Sweet-Flavored e-Cigarette|Participants will self-administer a sweet-flavored e-cigarette containing 3 mg/mL of nicotine.
62260215|NCT01887067|EXPERIMENTAL|Renal denervation therapy|
62260216|NCT03820414|EXPERIMENTAL|CRV101 Group 1|Subjects receive 2 doses of the candidate CRV-101 formulation 1, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
62260217|NCT03820414|EXPERIMENTAL|CRV 101 Group 2|Subjects receive 2 doses of the candidate CRV-101 formulation 2, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
62260218|NCT03820414|EXPERIMENTAL|CRV 101 Group 3|Subjects receive 2 doses of the candidate CRV-101 formulation 3, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
62842069|NCT03098004|ACTIVE_COMPARATOR|Tobacco-Flavored e-Cigarette|Participants will self-administer a tobacco-flavored e-cigarette containing 3 mg/mL of nicotine.
62842070|NCT02611089||Radial dysplasia patients|Recruited participants will have 2-3 small tissue biopsy samples taken during 1-2 of their planned reconstructive surgical procedures for radial dysplasia, whilst under general anaesthesia in the operating theatre. Samples will be taken by scalpel or scissors, by the operating surgeon, from within the surgical site in the forearm and hand. The skin incision and deep dissection will have to be made as part of the normal course of reconstructive surgery, regardless of participation in this study.
62260219|NCT03820414|EXPERIMENTAL|CRV 101 Group 4|Subjects receive 2 doses of the candidate CRV-101 formulation 4, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
62842071|NCT02611089||Control patients|Recruited participants will have 2-3 small tissue biopsy samples taken during their planned reconstructive surgery for hand trauma, whilst under general anaesthesia in the operating theatre. Samples will be taken by scalpel or scissors, by the operating surgeon, from within the surgical site in the forearm and hand. The skin incision and deep dissection will have to be made as part of the normal course of reconstructive surgery, regardless of participation in this study.
62842072|NCT05119634|EXPERIMENTAL|case group|patients will receive whole body vibration training 3 days in a week for 8 weeks
62842073|NCT05119634|ACTIVE_COMPARATOR|control group|participants will receive a home based exercise program
62616946|NCT05387512||Control treatment group|The primary treatment is Pemetrexed and Platinum plus anti-angiogenic drugs, Secondary treatment is standard chemotherapy regimens after progression. Reference regimen of Carilizumab 200mg/3 weeks; Carboplatin reference regimen was AUC = 5 mg/mL/min; Cisplatin reference regimen was 75 mg/m2; Pemetrexed reference regimen was 500 mg/m2; paclitaxel liposome reference regimen is 135-175 mg/m2.
62842074|NCT02586649|EXPERIMENTAL|Tiotropium Bromide group|The study participants will be randomly assigned to receive Tiotropium bromide,single dose (inhalation capsule - 18 mcg) over the course of 24 hours on day one of visit 1 or during visit 3.On the day of the first scheduled visit ( visit 1 ),study participants will be asked to arrive between 12-1 pm at the pulmonary laboratory at the JJPVAMC (7A-13). Baseline blood pressure (BP) and heart rate (HR) measurements will be obtained prior to drug administration. Tiotropium bromide capsule containing active ingredients will be orally inhaled through a SPIRIVA HandiHaler. Measurements of exhaled nitric oxide, pulmonary function ( spirometry , static lung volumes and specific airway conductance) will be performed at 20 and 24 hours. The same schedule will be followed for visits 3 and 4;vists 3 and 4 will be scheduled between 14 and 21 days after visit 2.
62056928|NCT01436201|EXPERIMENTAL|Digoxin + Dulaglutide|"Digoxin: Two 0.5-milligram (mg) doses, oral, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, oral, once daily on Day 2 to Day 17.~Dulaglutide (LY2189265): 1.5 mg, subcutaneous injection, once on Day 8 and once on Day 15."
62260220|NCT03820414|PLACEBO_COMPARATOR|Control Group|Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
62260221|NCT02751203|EXPERIMENTAL|Make Safe Happen App Intervention|Pre- and post-test delivered to online survey panel participants. Instruction to download and use the intervention (Make Safe Happen Mobile App) for 1 week.
62056929|NCT04948450|EXPERIMENTAL|Intervention group|"Physical activity intervention:~Progressive resistance training (PRT) for the physical intervention will be provided at the nursing home.~Cognitive stimulation intervention:~The study subjects will receive cognitive intervention based on Cognitive Stimulation Therapy with rehabilitation experts.~Social intervention:~The social intervention will be combined with physical and cognitive interventions by doing in a group.~Metabolic and vascular risk factors:~Metabolic and vascular risk factors of the intervention group will be evaluated by cardiologists and endocrinologists in the study."
62056930|NCT04948450|NO_INTERVENTION|Control group|The control group will receive general health advice every 3 months based on their physical examination and blood results. They will be provided information on the vascular risk factors for dementia and will receive instruction and handouts on diet and exercise.
62056931|NCT02392325|EXPERIMENTAL|rDEN1Δ30 and rDEN2Δ30-7169|Participants will receive the rDEN1Δ30 vaccine at Day 0. They will receive the rDEN2Δ30-7169 vaccine at Day 270.
62260222|NCT02751203|NO_INTERVENTION|Make Safe Happen App Control|A subset of online survey panel participants (n=200) will complete a pre- and post-test survey but will receive a non-safety app (e.g. a free recipe app). After the study, participants will be asked to download the intervention app.
62260223|NCT02431702|ACTIVE_COMPARATOR|Part-1: Oral Antipsychotics (OAP)|All Participants will receive Paliperidone Extended Release (ER) 1.5 to 12 milligram (mg) or risperidone 1 to 6 mg once daily orally for 2 months. Subjects who tolerate paliperidone ER/risperidone but find it inadequately efficacious after treatment for an adequate duration at an adequate dosage (per clinical judgment), may be switched to another protocol-specified OAP at the discretion of the investigator.
62260224|NCT02431702|EXPERIMENTAL|Part-2: Paliperidone Palmitate (PP)|Participants who will complete Part-1 will be randomized to receive oral Paliperidone Palmitate (PP) treatment. Participants will receive 5 doses of PP1M (paliperidone palmitate once-monthly injection). First dose at a starting dose of 234 mg on Day 1 and thereafter second dose in second week and then, every month up to Day 92. Participants will be subsequently switched to PP3M (paliperidone palmitate three-monthly injection) following a minimum of 5 injections of PP1M. Participants receiving PP3M may go back to treatment with PP1M (monthly injections of 78, 117, 156 or 234 mg, flexibly dosed) for further dose adjustment or for the duration of the study with the approval of the medical monitor.
62260225|NCT02431702|ACTIVE_COMPARATOR|Part-2: OAP|Participants who will complete Part-1 will be randomized to receive Oral Antipsychotics for 9 months.
62260226|NCT02431702|EXPERIMENTAL|Part-3: PP - PP|Participants who will complete Part-2 (with PP treatment) will continue to receive Paliperidone Palmitate for 9 months.
62260227|NCT02431702|EXPERIMENTAL|Part-3: OAP - Delayed Start Paliperidone Palmitate (PP)|Participants who will complete Part-2 (with OAP treatment) will be randomized to receive PP treatment for 9 months. PP treatment includes PP1M and PP3M. Participants will be subsequently switched to PP3M following a minimum of 5 injections of PP1M. Participants receiving PP3M may go back to treatment with PP1M (monthly injections of 78, 117, 156 or 234 mg, flexibly dosed) for further dose adjustment or for the duration of the study with the approval of the medical monitor.
62260228|NCT02431702|ACTIVE_COMPARATOR|Part-3: OAP - OAP|Participants who will complete Part-2 (with OAP treatment) will be randomized to receive OAP treatment for additional 9 months.
62260229|NCT03433872|OTHER|Caregivers|"Caregiver refers to teachers and child care providers in infant and toddler classrooms in center-based or FCC settings. All caregivers in the study will be assigned to the intervention. The PD providers supporting these caregivers will be trained in the We Grow Together: The Q-CCIIT Professional Development System."
62842075|NCT02586649|PLACEBO_COMPARATOR|Placebo|The study participants will be randomly assigned to receive placebo , single dose (inhalation capsule - 18 mcg) over the course of 24 hours on day one of visit 1 or during visit 3.On the day of the first scheduled visit ( visit 1 ),study participants will be asked to arrive between 12-1 pm at the pulmonary laboratory at the JJPVAMC (7A-13). Baseline blood pressure (BP) and heart rate (HR) measurements will be obtained prior to drug administration. Placebo capsule containing active ingredients will be orally inhaled through a SPIRIVA HandiHaler. Measurements of exhaled nitric oxide, pulmonary function ( spirometry , static lung volumes and specific airway conductance) will be performed at 20 and 24 hours. The same schedule will be followed for visits 3 and 4;vists 3 and 4 will be scheduled between 14 and 21 days after visit 2.
62842076|NCT03208985|EXPERIMENTAL|Use Phase (Ulipristal Acetate, 30 mg)|One tablet of 30 mg of ulipristal acetate for emergency contraception
62260230|NCT05676359||Cases|Patients with rheumatic diseases from the outpatient clinic at a tertiary care level in Mexico City
62260231|NCT05676359||Controls|Two patients´ relatives of the same sex, age ± five years and who are known to be healthy
62260232|NCT02164695|ACTIVE_COMPARATOR|PPCI plus RIPC|The patients randomized to PPCI plus RIPC group will receive RIPC during PPCI.
62445690|NCT02045628|EXPERIMENTAL|Investment intervention|Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
62445691|NCT02045628|NO_INTERVENTION|Control|Those in the control group will receive usual care.
62842077|NCT02921841|EXPERIMENTAL|DSTAR|Digital HIV Prevention intervention developed to specifically address the needs of youth in mental health treatment. Sessions introduce affect regulation and cognitive monitoring in sexual situations, and provide basic sexual health skills and education.
62842078|NCT02921841|ACTIVE_COMPARATOR|DHEALTH|Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
62260233|NCT02164695|SHAM_COMPARATOR|PPCI only|The patients randomized to PPCI only group will receive PPCI only but the sham procedure of RIPC.
62260234|NCT05771220|EXPERIMENTAL|radial extracorporeal shockwave therapy+ evidence-based physical therapy|radial extracorporeal shockwave therapy + evidence-based physical therapy
62260235|NCT05771220|PLACEBO_COMPARATOR|sham radial extracorporeal shockwave therapy + evidence-based physical therapy|sham radial extracorporeal shockwave therapy+ evidence-based physical therapy
62260236|NCT03270189|EXPERIMENTAL|orthoptic treatment|Patients with cervical dystonia occuring only during handwriting.
62616947|NCT00675337|ACTIVE_COMPARATOR|perineum|infants maintained at the level of the perineum until umbilical cord clamping
62616948|NCT00675337|EXPERIMENTAL|abdomen|infants placed on the maternal abdomen prior to cord clamping
62842079|NCT01733680|ACTIVE_COMPARATOR|Amiloride|"Drug: Subjects will take 5mg qd Amiloride for 2 weeks, 10mg qd Amiloride for 3 weeks, 15 mg qd Amiloride for 3 weeks.~Behavioral: Each week subjects will complete the AISRS, BRIEF-A, and CGI."
62842080|NCT01733680|PLACEBO_COMPARATOR|Placebo|Drug: Subjects will take placebo for 8 weeks Behavioral: Each week subjects will complete questionnaires: AISRS, BRIEF-A, and CGI
62842081|NCT01347619|ACTIVE_COMPARATOR|Arm 1. Toolkit only with Web Access|NHs in this arm will receive the toolkit only and web access to the materials.
62056932|NCT02392325|EXPERIMENTAL|Placebo and rDEN2Δ30-7169|Participants will receive placebo vaccine at Day 0. They will receive the rDEN2Δ30-7169 vaccine at Day 270.
62842082|NCT01347619|ACTIVE_COMPARATOR|Arm 2.Toolkit, Audit/Feedback, Education|NHs in the second arm will receive the toolkit, web access, periodic audit and feedback reports of antipsychotic prescribing to NH leadership, and faxed educational messages adapted from the AHRQ atypical antipsychotic CERSG to prescribers.
62842083|NCT01347619|ACTIVE_COMPARATOR|Arm 3. All above plus academic detailing|NHs in the third arm will receive the previous items plus face-to-face academic detailing.
62842084|NCT05890716||Train group|Consecutive patients admitted to the hospital due to cardiac disorders (retrospective and prospective) with at least one relevant ECG record \>10 sec in raw data will be used to design new methodologies and algorithms for cardiac patterns recognition.
62056933|NCT05771337||breast cancer leasion|
62056934|NCT05771337||benign breast lesion|
62056935|NCT01713543|EXPERIMENTAL|Intervention Group|The intervention consists of a tailored physical therapy focused on progressive strength, balance and gait training for a period of 3 months.
62056936|NCT01713543|NO_INTERVENTION|Control Group|Usual care by physician.
62260237|NCT03270189|NO_INTERVENTION|Controls|Patients without cervical dystonia.
62260238|NCT05248568|EXPERIMENTAL|Swiss ball|Swiss ball practice can create an unstable environment and play an important role in promoting the development of muscle function and joint stability. It can effectively train the core muscles. Swiss ball practice will be involved in intermediate level training to develop participants' stability and muscle endurance。
62260239|NCT05248568|EXPERIMENTAL|Kettlebell|"Kettlebell training can strengthen the anti rotation ability of the trunk. For example, Kettlebell training has many actions like kettlebell swing. This movement is easy to cause imbalance in the human body, so they can further exercise the trunk stability and anti rotation ability required by athletes."
62260240|NCT05248568|EXPERIMENTAL|Barbell|Barbell is a commonly used and multifunctional strength training instrument. It is usually used as the main instrument to develop the maximum muscle strength and muscle explosiveness. Therefore, this study will involve barbell practice in upper intermediate training and advanced level training
62260241|NCT05248568|EXPERIMENTAL|Medicine balls|Medicine balls are often used to assist patients in injury recovery, rehabilitation and strength training, and play an important role in the field of sports medicine. Its special design and construction make training more functional and in line with the movement chain theory, such as throwing training, so the medicine ball is often used in explosive force and core training. Therefore, this study will involve medicine balls practice in upper intermediate training and advanced level training
62616949|NCT03666949|OTHER|All General anesthesia|"Use of a hypnotic(propofol 2.5mg/kg), morphine(remifentanil1yg/kg) and curare(atracurium0.5mg/kg), with the support of orotracheal intubation and mechanical ventilation"
62616950|NCT03666949|OTHER|All Locoregional anesthesia|"Use of a local anesthetic( xylocaine 1%) for the realization of scalp nerve block"
62616951|NCT01310244|EXPERIMENTAL|Single arm, open label|"At the study entry each patient will receive a dose level assignment which will include a specific dose level and the dose of IV belinostat in mg/m2 to be administered during the study treatment.~Belinostat will be infused over 30 minutes once daily on Days 1-5 of each 21-day cycle. On Day 3, the infusion of belinostat must be completed at least 1 hour prior to the start of the paclitaxel infusion. Dose of belinostat will be assigned at study entry. The same dose and level will remain throughout the entire study for each patient and no dose adjustment will be allowed, except due to toxicity."
62056937|NCT03472222|EXPERIMENTAL|Arsha Vidya Program|Arsha Vidya outreach community program was conducted with children. An unique well-planned teaching program developed to educate Indian cultural values \& heritage to young children and adults with yoga, chants, religious and spiritual practices through stories, group activities and plays.
62056938|NCT03517592|EXPERIMENTAL|EMDR Therapy|EMDR: 20 individual sessions 60 minutes each for 6 months
62260242|NCT01023633|ACTIVE_COMPARATOR|Arm A: FOLFOX 4 continuous (Oxaliplatin, LV, 5-FU)|The arm A (FOLFOX4 continuous arm):receive FOLFOX4 every 2 weeks until progression or for maximum 24 cycles.
62260243|NCT01023633|EXPERIMENTAL|Arm B: FOLFOX4 Stop and go (Oxaliplatin, LV, 5-FU)|The arm B will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles
62260244|NCT02424032|EXPERIMENTAL|Exercise and connective tissue massage|Stabilization exercise and connective tissue massage have been applied
62260245|NCT02424032|ACTIVE_COMPARATOR|Exercise|Only stabilization exercise has been applied
62260246|NCT00894062|ACTIVE_COMPARATOR|1|ZES resolute (Endeavor® resolute)
62260247|NCT00894062|ACTIVE_COMPARATOR|2|EES (Xience®)
62842085|NCT05890716||Test group|Consecutive patients admitted to the hospital due to cardiac disorders (retrospective and prospective) with at least one relevant ECG record \>10 sec in raw data will be used to evaluate performance of methodologies aiming to avoid overfitting. Every 10 patients included in Train group; a new patient is included in the test group.
62842086|NCT03959397|EXPERIMENTAL|nab-paclitaxel|nab-paclitaxel monotherapy or combination therapeutic regimen
62842087|NCT00161343|EXPERIMENTAL|1|Small interactive groups on preventing HIV infections using an Information-Behavioral Skills-Motivational model
62842088|NCT00161343|PLACEBO_COMPARATOR|2|Small interactive groups on general health-promotion topics using an Information-Behavioral Skills-Motivational model
62842089|NCT01773759|EXPERIMENTAL|Intervention child care programs|Intervention child care programs will receive immunization outreach and education.
62842090|NCT01773759|NO_INTERVENTION|Control child care programs|Control programs will receive no more than usual training regarding childhood immunization requirements.
62842091|NCT05092308||Parents and their children with Behavioral insomnia|Parents and their children aged 6-36 months with sleep problems will be invited to participate into the study from Sleep Outpatient Clinic
62842092|NCT05092308||Parents and their children without sleep problem|Parents and their children aged 6-36 months without sleep problems will be invited to participate into the study followed up in Well Child Clinic
62842093|NCT02516969|EXPERIMENTAL|Stereotactic Body Radiotherapy|Subjects will receive Stereotactic Body Radiotherapy at the following levels: Treatment Volumes \<25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.
62260248|NCT06148688|EXPERIMENTAL|Intervention Group|In addition to the standard training, digital story videos were watched in the intervention group. Digital story videos created in line with four main topics related to diabetes self-management were sent to women via online platforms. During the follow-up period, reminder videos were sent once a week regarding the topics. Pre-test and post-test were administered face to face.
62260249|NCT06148688|NO_INTERVENTION|Control Group|The control group received only standard training.
62842094|NCT04754659|EXPERIMENTAL|Suprarenal|Individuals that are treated with a suprarenal stentgraft for a previously diagnosed AAA.
62842095|NCT04754659|ACTIVE_COMPARATOR|Infrarenal|Individuals that are treated with an infrarenal stentgraft for a previously diagnosed AAA.
62842096|NCT04571567|EXPERIMENTAL|Secukinumab|300mg subcutaneously
62842097|NCT05454917||Patients undergoing surgery|Mechanical measures, VQ mismatch evaluation
62842098|NCT06079970|EXPERIMENTAL|nCLE arm|Diagnostic bronchoscopy is done according to institutional practice with the addition of nCLE
62842099|NCT06079970|ACTIVE_COMPARATOR|Control arm|Diagnostic bronchoscopy is done according to institutional practice without the addition of nCLE
62842100|NCT04861168|EXPERIMENTAL|Driving pressure guided ventilation|Patients will be mechanically ventilated with driving pressure guided ventilation with VT 6-8 ml /kg of predicted body weight, and after recruitment we will return to the baseline PEEP 5 cmH2O that will be increased by 2 cmH2O until reaching the lowest possible driving pressure for every patient. Each PEEP level will be applied for 10 respiratory cycles and DP will be calculated at the last cycle.
62842101|NCT04861168|ACTIVE_COMPARATOR|Conventional protective lung strategy|Patients will be mechanically ventilated with conventional protective lung strategy with VT 6-8 ml /kg of predicted body weight, after recruitment, we will return to the baseline PEEP 5 cmH2O and will be maintained until the end of surgery.
62842102|NCT04323657|EXPERIMENTAL|Phase 1|The Phase 1 portion of the study will proceed according to a standard 3 + 3 dose escalation schema. Patients will be enrolled into 3 cohorts based on disease: NHL cohort, low tumor burden ALL cohort, and high tumor burden ALL cohort.
62842103|NCT04323657|EXPERIMENTAL|Phase 2|The phase 2 portion of the study will evaluate the efficacy of TC-110 T cells administered at the RP2D, preceded by a lymphodepleting regimen.
62842104|NCT02037230|EXPERIMENTAL|MK-1775/ Gemcitabine/ Radiation Therapy|
62842105|NCT04986319||Adequately sun-exposed healthy population|Healthy coastal fishermen of Cox's Bazar district of Bangladesh
62842106|NCT04986319||Inadequately sun-exposed healthy population|Healthcare workers of the selected hospitals of Dhaka, Bangladesh
62056939|NCT03517592|OTHER|Treatment as Usual|The TAU condition includes follow-up visits with the psychiatry, psychology and with the nursing service. Visits with the psychiatrist consist to evaluate clinical status and readjust the pharmacological treatment if necessary while visits with the psychologist consist to assess and detect risk situations and to prevent relapses using a cognitive behavioral approach. Finally, the nursing service will provide health and care habits and will carry out the abstinence controls.
62056940|NCT03670225|OTHER|Invia Motion Endure|
62260250|NCT01486849|EXPERIMENTAL|Dose Titration of CK-2017357 (Group 1)|Dose titration of active drug as add-on therapy to riluzole
62260251|NCT01486849|PLACEBO_COMPARATOR|Matching Placebo (Group 2)|Placebo as add-on therapy to riluzole
62260252|NCT04455763|EXPERIMENTAL|SVF|Thumb carpometacarpal injection with adipose-derived SVF combined with splinting
62260253|NCT04455763|ACTIVE_COMPARATOR|Splint|Thumb carpometacarpal osteoarthrosis treated with splinting only
62260254|NCT04944654|EXPERIMENTAL|Assigned intervention|Biktarvy OD for 96 weeks
62842107|NCT04200352|EXPERIMENTAL|TEV-50717|The dose of the TEV-50717 should be increased on a weekly basis to reach a clinically meaningful reduction in dyskinesia, as indicated by a reduction in the Clinical Global Impression of Improvement;(CGI-I).
62842108|NCT00004101|EXPERIMENTAL|Arm I|Patients receive monoclonal antibody Hu1D10 IV over 2-4 hours on days 1, 8, 15, and 22. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of monoclonal antibody Hu1D10 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose limiting toxicity. Once the MTD is determined, an additional cohort of 3-6 patients receive Hu1D10 IV over 2-4 hours on days 1-5.
62842109|NCT02569788|EXPERIMENTAL|CIRT Arm|Patients included in this arm were treated with carbon ion radiotherapy (CIRT).
62260255|NCT03144245|EXPERIMENTAL|AMV564|Continuous infusion or subcutaneous dosing of AMV564 at increasing dose levels
62260256|NCT03144245|EXPERIMENTAL|Combination AMV564|Continuous infusion or subcutaneous dosing of AMV564 at increasing dose levels in combination with pembrolizumab
62260257|NCT06114784||Severe pneumonia|Definition of severe pneumonia: New infection that meets one of the following definitions: the patient receives mechanical ventilation (invasive or non-invasive) due to acute respiratory failure, with a PEEP level of 5cm or above; The patient receives high flow oxygen therapy with a FiO2 of 50% or more and a PaO2: FiO2 ratio of less than 300; The patient receives oxygen treatment with a partial respiration mask with an air storage bag, provided that PaO2 is lower than the pre-specified indicator.
62260258|NCT05963789|EXPERIMENTAL|Group A or cervical proprioception group CPG|Patients will receive traditional exercises for shoulder impingement plus cervical proprioception exercises using laser pointer
62445692|NCT02067780|EXPERIMENTAL|The intervention (CRP-guided) group|500 mg (one tablet) of oral levofloxacin daily of levofloxacin for 7 days unless the serum CRP decrease by at least 50% from baseline value. Measurements of serum CRP were done at ED admission, at day-2, day-4 and day-6 and made available to the attending physicians.
62445693|NCT02067780|EXPERIMENTAL|The standard care (control) group|500 mg of levofloxacin per day for the first two days. Thereafter, oral tablet of placebo was prescribed according to CRP values as in CRP guided group to keep the blindness of the study.
62445694|NCT04665076|EXPERIMENTAL|Auto CAR-T|Patients will be treated with Auto CAR-T cells
62445695|NCT04041765|EXPERIMENTAL|Treatment Group|IgM-enriched IVIG given with dose of 0.25g/kg over 3 hours for 3 days in addition to Antibiotics
62445696|NCT04041765|PLACEBO_COMPARATOR|Placebo Group|Antibiotics only
62445697|NCT05742581||The rotator cuff tear group|
62445698|NCT05742581||Control group|
62445699|NCT01107535||Infants receiving Synagis (palivizumab) immunoprophylaxis|Infants born \<= 32 weeks of gestation and are younger than 6 months of age, children with bronchopulmonary dysplasia who have received medical treatment in the last 6 months until the first year of life, and children 12 months or younger with hemodynamically significant acyanotic congenital heart disease (pulmonary hypertension or heart failure in treatment) prescribed Synagis (palivizumab) immunoprophylaxis according to the usual clinical practice.
62445700|NCT06479304|EXPERIMENTAL|HCQ plus Pred group|This group is experiment group. Participants will take Pred every day for 6 weeks with HCQ twice a day for 1 year
62445701|NCT06479304|PLACEBO_COMPARATOR|Pred group|This group is control group. Participants will take Pred every day for 6 weeks.
62445702|NCT01608009|EXPERIMENTAL|Pazopanib and paclitaxel|
62445703|NCT04550195|EXPERIMENTAL|Part A Single Ascending Dose (SAD) Cohort A1|
62445704|NCT04550195|EXPERIMENTAL|Part A SAD Cohort A2|
62445705|NCT04550195|EXPERIMENTAL|Part A SAD Cohort A3|
62445706|NCT04550195|EXPERIMENTAL|Part A SAD Cohort A4|
62445707|NCT04550195|EXPERIMENTAL|Part A SAD Cohort A5|
62842110|NCT04151056||Patients without social determinant of health|"Patients without any of the five selected social determinants of health / Patients without any of the five selected social diagnosis. Patient with a registered diagnostic  Health check (Z00.00)"
62445708|NCT04550195|EXPERIMENTAL|Part A SAD Cohort A6|
62445709|NCT04550195|EXPERIMENTAL|Part B Multiple Ascending Dose (MAD) Cohort B1|
62445710|NCT04550195|EXPERIMENTAL|Part B MAD Cohort B2|
62445711|NCT04550195|EXPERIMENTAL|Part B MAD Cohort B3|
62445712|NCT04550195|EXPERIMENTAL|Part B MAD Cohort B4|
62445713|NCT04550195|EXPERIMENTAL|Part C MAD in Japanese Healthy participants Cohort C1|
62445714|NCT04550195|EXPERIMENTAL|Part C MAD in Japanese Healthy participants Cohort C2|
62445715|NCT04550195|EXPERIMENTAL|Part C MAD in Japanese Healthy participants Cohort C3|
62445716|NCT06277258|EXPERIMENTAL|Patient Empowerment Model|Patients will be empowered to manage gestational diabetes mellitus themselves by acquiring knowledge and skill to monitor blood sugar levels, adjusting meals and daily activities.
62842111|NCT04151056||"Patients with the social determinantstressful work hours"|"Patients with the selected social determinant of health. Patients with a registered diagnostic stressful work hours  (Z56.3)"
62260259|NCT05963789|ACTIVE_COMPARATOR|Group B or control group CG|Patients will receive traditional exercises for shoulder impingement (stretching, strengthening, stabilization)
62260260|NCT05404464||Infertile couples|Infertile couples who came to the hospital for ART treatment
62260261|NCT05576389|EXPERIMENTAL|Camrelizumab+Fluzoparib|
62260262|NCT00861068|EXPERIMENTAL|1|
62260263|NCT00861068|PLACEBO_COMPARATOR|2|
62260264|NCT03817775|NO_INTERVENTION|Control|The control group will undergo coronary angiography without music intervention.
62445717|NCT06277258|NO_INTERVENTION|Standard of care|Patients will get the conventional way of management where patients get advice about a diet chart with a fixed menu and injection of insulin to control blood sugar levels.
62445718|NCT03031522|EXPERIMENTAL|18F-IRS : EGFR+ Patients|Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study.
62445719|NCT03031522|EXPERIMENTAL|18F-IRS :post-TKI EGFR+ Patients|Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study .
62445720|NCT03031522|EXPERIMENTAL|18F-IRS:post-chemo EGFR+|18F-IRS:post-chemo EGFR+ Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study.
62445721|NCT03031522|EXPERIMENTAL|18F-IRS:EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
62445722|NCT03031522|EXPERIMENTAL|18F-IRS:post-chemo EGFR wild type|Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study.
62445723|NCT03031522|EXPERIMENTAL|18F-IRS:unknown EGFR mutational status|Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group
62445724|NCT05652920|EXPERIMENTAL|Ori-C101 ( GPC3-directed chimeric antigen receptor modified T cells )|
62445725|NCT03051685|EXPERIMENTAL|DFN-15 Dose 1|
62445726|NCT03051685|EXPERIMENTAL|DFN-15 Dose 2|
62445727|NCT03051685|EXPERIMENTAL|DFN-15 Dose 3|
62445728|NCT03051685|ACTIVE_COMPARATOR|Active Comparator|
62445729|NCT05304637|EXPERIMENTAL|Therapy Arm|Patient receive iTEAR100 treatment
62445730|NCT00638170|ACTIVE_COMPARATOR|A|Cranberry juice
62260265|NCT03817775|EXPERIMENTAL|Music therapy|The intervention group will also undergo coronary angiography and will administer music therapy between 10 minutes prior to the beginning of the procedure until its end.
62260266|NCT02993874|EXPERIMENTAL|Creatine|Creatine monohydrate (Cr) Loading - 4 doses of 5g / day for 7 days Maintenance - 1 dose of 3g / day for 49 days Clinical treatment (30-45 minutes of walking, 3 times per week)
62260267|NCT02993874|PLACEBO_COMPARATOR|Placebo|Dextrose Loading - 4 doses of 5g / day for 7 days Maintenance - 1 dose of 3g / day for 49 days Clinical treatment (30-45 minutes of walking, 3 times per week)
62445731|NCT00638170|PLACEBO_COMPARATOR|B|Placebo juice
62260268|NCT00472264||Single arm study (Healthy volunteers & COPD subjects)|A single arm study PET imaging is carried out twice during the first week of the study and again 4 weeks later in both Healthy volunteers and COPD subjects.
62260269|NCT01347554|ACTIVE_COMPARATOR|Xience V stent group|Xience V (Everolimus eluting stent) insertion in patients with acute myocardial infarction
62260270|NCT01347554|ACTIVE_COMPARATOR|Endeavor resolute group|Endeavor resolute (Zotarolimus eluting stent) insertion in patients with acute myocardial infarction
62260271|NCT04046107|EXPERIMENTAL|Cohort 1: Cemiplimab (0.3 mg/kg)|Participants will receive cemiplimab 0.3 mg/kg dosed in two infusions, one infusion at Week 6 and Week 12.
62260272|NCT04046107|EXPERIMENTAL|Cohort 2: Cemiplimab (1 mg/kg)|Participants will receive cemiplimab 1 mg/kg dosed in two infusions, one infusion at Week 6 and Week 12.
62445732|NCT06483373|EXPERIMENTAL|SPH7854|
62260273|NCT04046107|EXPERIMENTAL|Cohort 3: Cemiplimab (3 mg/kg)|Participants will receive cemiplimab 3 mg/kg dosed in two infusions, one infusion at Week 6 and Week 12.
62616952|NCT01356329|EXPERIMENTAL|Lovenox|Group A : Low Molecular Weight Heparin (LMWH), LovenoxTM (Enoxaparin)
62260274|NCT03413189||PREDICT participants|This cohort is obtained from the PREDICT study enrolment (approx. 500) and a review of their medical records will be conducted
62260275|NCT03413189||PREDITCABLE participants|This is a nested cohort of patients recruited into PREDICT (approx. 40) that consent for a physiotherapist home visit to assess their physical and cognitive function and perform and interview to obtain themes regarding recovery
62260276|NCT04194528|EXPERIMENTAL|Oxycodone/acetaminophen (5/325 mg) DMP|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
62260277|NCT02431091|EXPERIMENTAL|Definite Case|"Patients with abnormal response on both the screening questions and at least one of the cognitive screening tests.~Optical Coherence Tomography is performed in all definite cases"
62260278|NCT02431091|ACTIVE_COMPARATOR|Control|"Patients with normal response on both the screening questions and all the cognitive screening tests.~Optical Coherence Tomography is performed in matched control A patients"
62260279|NCT04852328|EXPERIMENTAL|Schedule A: CUE-101|"* In Schedule A, CUE-101 will be administered during the neoadjuvant phase as a single dose given 14 days prior to initiation of standard of care (SOC) therapy.~* Standard of care therapy consists of surgery and postoperative adjuvant (cisplatin) and radiation therapy or cisplatin and radiation therapy (definitive-chemoradiation therapy)"
62260280|NCT04852328|EXPERIMENTAL|Schedule B: CUE-101|"* In Schedule B, CUE-101 will be administered during the neoadjuvant phase as two doses: one dose given 14 days and one dose given 7 days prior to initiation of standard of care (SOC) therapy.~* Standard of care therapy consists of surgery and postoperative adjuvant (cisplatin) and radiation therapy or cisplatin and radiation therapy (definitive-chemoradiation therapy)"
62260281|NCT04852328|EXPERIMENTAL|Schedule C: CUE-101|"In Schedule C, CUE-101 will be administered during the neoadjuvant phase as a single dose given 7 days prior to initiation of standard of care (SOC) therapy.~-Standard of care therapy consists of surgery and postoperative adjuvant (cisplatin) and radiation therapy or cisplatin and radiation therapy (definitive-chemoradiation therapy)"
62260282|NCT01530204|ACTIVE_COMPARATOR|Physical Therapy|8-12 sessions of knee-focused physical therapy and a home-based conditioning program.
62260283|NCT01530204|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy for Pain|8-12 session pain-focused Cognitive Behavioral Therapy
62260284|NCT01530204|ACTIVE_COMPARATOR|Enhanced Treatment as Usual|Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
62260285|NCT02225470|EXPERIMENTAL|Arm A, E7389 (Eribulin Mesylate)|The eribulin mesylate dose will be 1.4 mg/m2 administered as an intravenous bolus over 2 to 5 minutes on Days 1 and 8 of each 21-day cycle.
62445733|NCT06483373|PLACEBO_COMPARATOR|Placebo|
62445734|NCT04884659|EXPERIMENTAL|Timed restricted feeding|"Time restricted feeding then usual feeding pattern Day 1, testing~Day 2-7 all meals will be consumed as follows:~80% of calories consumed before 2 PM with remaining 20% consumed by 4PM. Fasting except for water, non caloric drinks for 14-16 hours Same number of calories consumed as in usual feeding pattern arm. Day 8 testing. Day 9-14 crossover to usual feeding pattern arm (meals consumed ad lib with 50% of calories consumed after 4 PM) for 6 days."
62445735|NCT04884659|EXPERIMENTAL|Usual feeding pattern|"Usual feeding pattern, then time restricted feeding Day 1 testing~Day 2-7 all meals will be consumed as follows:~Meals consumed ad lib with 50% of calories consumed after 4 PM. Day 8 testing. Day 9-14 crossover to time restricted feeding arm with all meals consumed as follows:~80% of calories consumed before 2 PM with remaining 20% consumed by 4PM. Fasting except for water, non caloric drinks for 14-16 hours Same number of calories consumed as in usual feeding pattern arm for 6 days."
62616953|NCT01356329|EXPERIMENTAL|Heparin|Group B:HeparinTM (Unfractionated Heparin)
62445736|NCT02545998|NO_INTERVENTION|Standard care|Patients will receive a face-to-face asthma review
62616954|NCT01046357|EXPERIMENTAL|Active|AZD7687 oral suspension
62616955|NCT01046357|EXPERIMENTAL|Placebo|placebo oral suspension
62616956|NCT04290325|EXPERIMENTAL|HMPL-453|HMPL-453
62623698|NCT01831427|EXPERIMENTAL|Andecaliximab 5.0 mg/kg IV (SAD)|Participants will receive andecaliximab 5.0 mg/kg on Day 1.
62623699|NCT01831427|PLACEBO_COMPARATOR|Placebo Pooled (SAD)|Participants will receive placebo on Day 1.
62623700|NCT01831427|EXPERIMENTAL|Andecaliximab 0.3 mg/kg IV multiple ascending doses (MAD)|Participants will receive andecaliximab 0.3 mg/kg on Days 1, 15, and 29.
62842112|NCT04151056||"Patients with the social determinant of health living alone"|"Patients with the select social determinant of health . Patients with the selected social determinant of health . Patients with a registered diagnostic  living alone problems (Z60.2)"
62260286|NCT02225470|ACTIVE_COMPARATOR|Arm B, Vinorelbine injection|The vinorelbine dose will be 25 mg/m2 administered as an intravenous bolus on Days 1, 8, and 15 of each 21-day treatment cycle.
62260287|NCT02498015|EXPERIMENTAL|"3D regimen"|"The 3D regimen contain two tablets of co-formulated paritepravir/ritonavir/ombitasvir (75/50/12.5 mg) once daily, and one dasabuvir tablet (250 mg) twice daily for genotype 1b without cirrhosis. Treatment will be 12 weeks."
62260288|NCT02498015|EXPERIMENTAL|"3D regimen with ribavirin"|"The 3D regimen with ribavirin contain two tablets of co-formulated paritepravir/ritonavir/ombitasvir (75/50/12.5 mg) once daily, one dasabuvir tablet (250 mg) twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a (with/without) and genotype 1b with cirrhosis. Treatment will be for 12 weeks."
62445737|NCT02545998|ACTIVE_COMPARATOR|Telehealthcare|Patients will receive a telephone consultation and e-mail with attached PAAP and video link
62445738|NCT01236820||Normal|Healthy population
62056941|NCT01106443|ACTIVE_COMPARATOR|Total Thyroidectomy - CLND|Total thyroidectomy without central lymph node dissection.
62056942|NCT01106443|EXPERIMENTAL|Total Thyroidectomy +CLND|Total thyroidectomy with central lymph node dissection.
62260289|NCT02031562|ACTIVE_COMPARATOR|Chiropractic|Chiropractic
62445739|NCT01236820||CKD Patients|Chronic Kidney Disease, in Stage III-V
62445740|NCT01236820||HD patients|End-stage renal disease patients undergoing hemodialysis
62445741|NCT05040685|EXPERIMENTAL|Axillary mapping reverse|Application of axillary mapping reverse technique
62260290|NCT02031562|ACTIVE_COMPARATOR|Physical therapy|Physical therapy
62445742|NCT01164423|EXPERIMENTAL|1|Space TGC system with incorporated eMPC advised insulin infusion to establish glycaemic control
62842113|NCT04151056||"Patients with the social determinant of health acculturation"|"Patients with the selected social determinant of health. Patients with a registered diagnostic difficulty acculturation  (Z60.3)"
62260291|NCT00954720||Patient undergoing transplant|Patients with acute leukemia or MDS undergoing ablative stem cell transplantation. No intervention.
62260292|NCT05626998|NO_INTERVENTION|Control|The participants will not receive premedication
62260293|NCT05626998|ACTIVE_COMPARATOR|Dexmedetomidine|The participants will receive intramuscular dexmedetomidine injection (1 µg/kg) diluted in 2ml normal saline thirty minutes before surgery in the ward
62260294|NCT05626998|ACTIVE_COMPARATOR|Gabapentin|The participants will receive 600 mg gabapentin (two capsules each containing 300 mg) thirty minutes before surgery in the ward
62445743|NCT03503357|EXPERIMENTAL|IFT Testing 1|Participants will be fitted with and IFT cuff and randomized to command list A intra-operatively to assess awareness.
62445744|NCT03503357|EXPERIMENTAL|IFT Testing 2|Participants will be fitted with and IFT cuff and randomized to command list B intra-operatively to assess awareness.
62445745|NCT03503357|EXPERIMENTAL|IFT Testing 3|Participants will be fitted with and IFT cuff and randomized to command list C intra-operatively to assess awareness.
62445746|NCT03503357|EXPERIMENTAL|IFT Testing 4|Participants will be fitted with and IFT cuff and randomized to command list D intra-operatively to assess awareness.
62445747|NCT05575960|EXPERIMENTAL|Interpersonal Psychotherapy|"Interpersonal Psychotherapy for Adolescents according to the manual by Mufson (2004).~Mufson, L. (2004). Interpersonal psychotherapy for depressed adolescents. Guilford Press."
62445748|NCT04459546|EXPERIMENTAL|Study group|Study group intervention consists patient education, training booklet and 3 month follow-up.
62842114|NCT04151056||"Patients with the social determinant near surrounding"|"Patients with the selected social determinant of health. Patients with a registered diagnostic other specific problems related to the nearest surroundings (Z63.8)"
62842115|NCT04151056||"Patients with the social determinant unemployment"|"Patients with the selected social determinant of health. Patients with a registered diagnostic unemployment not specified (Z56.0)"
62056943|NCT01106443|EXPERIMENTAL|Hemi-thyroidectomy + CLND|Hemi-thyroidectomy with central lymph node dissection.
62260295|NCT00143312|EXPERIMENTAL|1|
62445749|NCT04459546|NO_INTERVENTION|Control group|Control group received only general care
62260296|NCT06170138|EXPERIMENTAL|Ampli-01, 3 mg, nicotine pouch|Subjects will report to the study site for a screening visit followed by 3 visits with a single IP use (Visits 2 to 4) on separate days.There will be at least 1 day between Visits 2, 3 and 4, respectively, where the subjects are allowed ad libitum use of their own nicotine product of choice. Each visit will last one day.
62260297|NCT06170138|EXPERIMENTAL|Ampli-01, 6 mg, nicotine pouch|Subjects will report to the study site for a screening visit followed by 3 visits with a single IP use (Visits 2 to 4) on separate days.There will be at least 1 day between Visits 2, 3 and 4, respectively, where the subjects are allowed ad libitum use of their own nicotine product of choice. Each visit will last one day.
62445750|NCT00904020|EXPERIMENTAL|(1) Lidoderm|(1) Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
62445751|NCT01170364|EXPERIMENTAL|Sibutramine|Participants in this arm receive sibutramine 15mg for one week followed by two weeks of placebo.
62623701|NCT01831427|EXPERIMENTAL|Andecaliximab 1.0 mg/kg IV (MAD)|Participants will receive andecaliximab 1.0 mg/kg on Days 1, 15, and 29.
62056944|NCT01106443|ACTIVE_COMPARATOR|Hemi-thyroidectomy - CLND|Hemi-thyroidectomy without central lymph node dissection.
62056945|NCT06108401|EXPERIMENTAL|Goat milk formula-fed group|79 participants
62056946|NCT06108401|PLACEBO_COMPARATOR|Cow milk formula-fed group|79 participants
62056947|NCT05547425|EXPERIMENTAL|Blur obfuscation|Blurring is applied to objects and people in the background of images.
62056948|NCT05547425|EXPERIMENTAL|Edge obfuscation|Objects and people in the background of images are replaced with an outline of the object.
62056949|NCT05547425|EXPERIMENTAL|Cartoon obfuscation|Blurring is applied to objects and people in the background of images and the wearer's face is concealed with cartoon faces.
62842116|NCT03367637|ACTIVE_COMPARATOR|Standard Care|"Patients in this arm will receive standard palliative care currently provided at the Rwanda Palliative and Hospice Care Organization (RPCHO).~Standard care also includes regular follow-up phone calls and home visits by the RPCHO staff, though the timing of these calls is variable and is selected by the discretion of the team. In addition, patients can contact providers on a landline number available during business hours and staffed by an on-call palliative care provider as and when needed."
62842117|NCT03367637|EXPERIMENTAL|Intervention|Patients in this arm, in addition to the standard palliative care currently provided at the RPCHO, will receive biweekly frequency reminders to fill out the African Palliative Care Outcomes Scale (APCA POS) on the new smart phone based symptom evaluation application on their phones. It is a short symptom assessment questionnaire with responses on 5-point severity scale. In addition to bi-weekly, patients can complete the symptom assessment at any time they feel their symptoms are poorly controlled. The team at RPCHO will be able to track all enrolled patients on a desktop dashboard. Any score of 2 or higher will be flagged. The providers at RPCHO will respond to such patients during business hours via call or text and will advise the patients as indicated or triage to a fellow team member.
62842118|NCT05181436||Malaysian children aged ≥ 6 months to ≤ 36 months|The study population consists of Malaysian children aged ≥ 6 months to ≤ 36 months seen at Mother and Child Health Clinic (MCHC).
62842119|NCT03748004|EXPERIMENTAL|Adults living in the DTES|"36 out of the 72 recruited participants who live in the DTES will be randomly assigned to the intervention group (IPS \& Peer Support). The IPS and Peer Support will actively work and support with each of the 36 participants in seeking employment and education for 16 weeks. IPS/SP will help participants identify their employment and educational goals, identify potential employers, help prepare their resumes and for interviews, and provide ongoing support during the 16 weeks.~36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services."
62842120|NCT03748004|PLACEBO_COMPARATOR|Individuals 19 yrs or older settled in DTES|"36 out of the 72 recruited participants who live in the DTES will be randomly assigned to the intervention group (IPS \& Peer Support). The IPS and Peer Support will actively work and support with each of the 36 participants in seeking employment and education for 16 weeks. IPS/SP will help participants identify their employment and educational goals, identify potential employers, help prepare their resumes and for interviews, and provide ongoing support during the 16 weeks.~36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services."
62056950|NCT05547425|EXPERIMENTAL|Raw images|No editing is performed on images.
62056951|NCT04070625||Communication book group|Speech therapy with communication book
62056952|NCT04070625||Control group|Simple speech therapy
62056953|NCT03324893|EXPERIMENTAL|[F18]-FCH PET/MRI|Patients with primary hyperparathyroidism planned for parathyroidectomy
62056954|NCT01737099|EXPERIMENTAL|DHA-O|
62056955|NCT01737099|ACTIVE_COMPARATOR|Fish oil|
62260298|NCT06170138|ACTIVE_COMPARATOR|ZYN Cool Mint Mini Dry, 6 mg nicotine /pouch|Subjects will report to the study site for a screening visit followed by 3 visits with a single IP use (Visits 2 to 4) on separate days.There will be at least 1 day between Visits 2, 3 and 4, respectively, where the subjects are allowed ad libitum use of their own nicotine product of choice. Each visit will last one day.
62260299|NCT03860675|ACTIVE_COMPARATOR|persons with Multiple Sclerosis (MS)|
62842121|NCT03391921|ACTIVE_COMPARATOR|ARM B: 3 doses (0, 2 and 6 months)|ARM B: All patients will receive the 9-valent vaccine against HPV (Gardasil9) 3 doses at 0,2 and 6 months intramuscularly
62260300|NCT03860675|PLACEBO_COMPARATOR|Healthy controls|
62260301|NCT02461550|EXPERIMENTAL|IRE procedure|The IRE procedure will be performed in the operating room at the time of scheduled clinical resection of colorectal lung metastases by the surgeon with guidance from the Interventional Radiologist.
62260302|NCT02838966|ACTIVE_COMPARATOR|Nestle IMPACT Advanced Recovery 1|1 can per day for 5 days prior to surgery
62260303|NCT02838966|ACTIVE_COMPARATOR|Nestle IMPACT Advanced Recovery 2|2 cans per day for 5 days prior to surgery
62445752|NCT01170364|EXPERIMENTAL|Placebo|Participants are prescribed two weeks of placebo, followed by one week of 15mg sibutramine.
62056956|NCT01737099|PLACEBO_COMPARATOR|Placebo|
62056957|NCT06626113||Obese|
62056958|NCT02130284|EXPERIMENTAL|Predictive Low Glucose Management (PLGM)|To evaluate the safety of the Predictive Low Glucose Management feature in insulin pump algorithm with the Enlite 3 Sensor
62056959|NCT02348684||Radiation therapy groups|Risk groups based on dosimetric radiation parameters.
62056960|NCT00384059|EXPERIMENTAL|1|13-valent pneumococcal vaccine
62056961|NCT00384059|ACTIVE_COMPARATOR|2|7-valent pneumococcal vaccine
62056962|NCT06248398|EXPERIMENTAL|Experimental arm|Patient having cochlear implantation surgery with RobOtol®.
62056963|NCT06248398|OTHER|Control arm|Patient having conventional manual cochlear implantation surgery.
62056964|NCT03175627|ACTIVE_COMPARATOR|Filtek One|Bulk fill composite material used for posterior tooth fillings.
62056965|NCT03175627|ACTIVE_COMPARATOR|Filtek Z250|Composite material used for incremental filling of posterior teeth.
62056966|NCT05782725||1|PCOS and SCH
62056967|NCT05782725||2|PCOH without SCH
62056968|NCT05782725||3|HPOD and SCH
62260304|NCT02838966|ACTIVE_COMPARATOR|Nestle IMPACT Advanced Recovery 3|3 cans per day for 5 days prior to surgery
62056969|NCT05782725||4|HPOD without SCH
62260305|NCT02838966|ACTIVE_COMPARATOR|Nestle Boost High Protein Drink - Control Arm|4 cans per day for 5 days prior to surgery
62260306|NCT05425615|EXPERIMENTAL|Active TMS|Deymed DuoMag XT-100 rTMS system (DM-XT100) connected to a 70-mm figure-of-eight coil with built-in cooling fans (also known as an air-cooled coil) will be used for delivering active repetitive or rapid TMS to the target site.
62260307|NCT05425615|ACTIVE_COMPARATOR|Control TMS|Deymed DuoMag XT-100 rTMS system (DM-XT100) connected to a 70-mm figure-of-eight coil with built-in cooling fans will be used for delivering active repetitive or rapid TMS to the control site.
62445753|NCT05815043|EXPERIMENTAL|Low- and high-sodium intake|Participants will consume two different quantities of sodium per day for 3 days each.
62445754|NCT00319956|ACTIVE_COMPARATOR|Azithromycin Group|Group receives azithromycin
62056970|NCT05035914|EXPERIMENTAL|Experimental: anlotinib+mXELIRI|"Dose-escalation phase:~A: anlotinib 8 mg, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;~B: anlotinib 10 mg, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;~C: anlotinib 12 mg, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;~Dose-expansion phase:~anlotinib RP2D, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;"
62056971|NCT00622843|EXPERIMENTAL|Group 1|PCV, 210 patients
62056972|NCT00622843|ACTIVE_COMPARATOR|Group 2|PPV, 110 patients
62056973|NCT00622843|ACTIVE_COMPARATOR|Group 3|PPV, HIV-negative, 25 patients
62445755|NCT00319956|PLACEBO_COMPARATOR|Placebo Group|Group receives placebo
62056974|NCT00681616|PLACEBO_COMPARATOR|1|Compartment Monitoring System with Active Fluid Removal
62260308|NCT05425615|SHAM_COMPARATOR|Sham TMS|Deymed DuoMag XT-100 rTMS system (DM-XT100) connected to a 70-mm figure-of-eight coil with built-in cooling fans will be used for delivering sham repetitive or rapid TMS to the control or target site.
62056975|NCT00681616|ACTIVE_COMPARATOR|2|Compartment Monitoring System (CMS) without fluid removal
62056976|NCT06043986||Bed bay A|"Time from nurse call system activated by the novel nurse call system to initial response time T1 and time to complete task T2.~Reason for nurse call system activated: Toilet/Pain/Medication/ /Need a nurse/Other"
62056977|NCT06043986||Bed bay B|Time from nurse call system activated by standard system to initial response timeT1 and time to complete task T2.
62260309|NCT01508702|EXPERIMENTAL|lesinurad 400 mg|
62260310|NCT01508702|PLACEBO_COMPARATOR|placebo|
62260311|NCT05110703|ACTIVE_COMPARATOR|Dietary supplement: Prebiotic fiber meal replacement shake|Prebiotic fiber meal replacement shake
62260312|NCT05110703|PLACEBO_COMPARATOR|Dietary supplement: Placebo meal replacement shake|Placebo meal replacement shake
62623702|NCT01831427|EXPERIMENTAL|Andecaliximab 2.5 mg/kg IV (MAD)|Participants will receive andecaliximab 2.5 mg/kg on Days 1, 15, and 29.
62260313|NCT05110703|OTHER|Dietary guidelines|Dietary guidelines
62056978|NCT04281186||Cross-sectional cohort|Up to 720 type 2 diabetic patients (\>5 years duration), older than 65 years of age are expected to be recruited in orfer to asure the sample of 168 patients with MCI and 63 normocognitive fulfilling criteria for the prospective study.
62056979|NCT04281186||Prospective study-MCI|Target 168 Patients from the cross-sectional cohort diagnosed with mild cognitive impairment during the cross-sectional evaluation
62056980|NCT04281186||Prospective study normocognitive|63 Patients from the cross-sectional cohort without mild cognitive impairment evaluated during the cross-sectional evaluation
62056981|NCT00538928|EXPERIMENTAL|1|Intervention: Implantation of the iLA - adaptation of the ventilation strategy, explantation of the iLA after corresponding improvement (see treatment plan for details) - weaning from the ventilation and extubation according to specified criteria.
62056982|NCT00538928|ACTIVE_COMPARATOR|2|no device: Ventilation strategy based on the concept of lung-protective ventilation without extracorporeal support, weaning from the ventilation and extubation according to specified criteria (see treatment plan for details).
62056983|NCT00534222||Quetiapine|
62056984|NCT00534222||Olanzapine|
62056985|NCT00534222||Risperidone|
62260314|NCT03134599|ACTIVE_COMPARATOR|etafilcon A|
62056986|NCT00524225|EXPERIMENTAL|Neumega (Interleukin 11, IL-11)|Neumega (Oprelvekin, Interleukin 11, IL-11) 25 mcg/kg subcutaneously, given for 4 days preoperatively, and on day 5 preoperatively, and for up to 2 days postoperatively
62842122|NCT03391921|EXPERIMENTAL|ARM A: 2 doses (0 and 6 months )|ARM A: All patients will receive the 9-valent vaccine against HPV (Gardasil9) 2 doses at 0 and 6 months intramuscularly. A third facultative dose will be given if antibodies measured at month 7 are insufficent.
62056987|NCT06262061|ACTIVE_COMPARATOR|Propranolol Group|The propranolol group will receive 20mg of oral propranolol twice daily for 14 days (or until hospital discharge or death).
62842123|NCT02537015|EXPERIMENTAL|13 mg Bimatoprost Ocular Insert|13 mg Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new 13 mg Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
62842124|NCT04516889|EXPERIMENTAL|Intervention|The intervention arm will undergo the modified sutured SFIOL technique with double Prolene sutures instead of a single Prolene suture
62260315|NCT03134599|ACTIVE_COMPARATOR|methafilcon A - Interozzo|
62445756|NCT06152627||First Year of RTSS-Voice use|These 300 patients from five Voice Centers will receive standard of care voice therapy where their treating clinicians will be trained to use the RTSS-Voice in their documentation.
62445757|NCT06152627||Second Year of RTSS-Voice use|These 300 patients from five Voice Centers will receive standard of care voice therapy where their treating clinicians have already been trained to use the RTSS-Voice in their documentation.
62056988|NCT06262061|PLACEBO_COMPARATOR|Control Group|Control group will receive an oral placebo.
62056989|NCT03253484|EXPERIMENTAL|NAFL-treated wounds|NAFL treated wounds
62260316|NCT03134599|ACTIVE_COMPARATOR|methafilcon A - CVI|
62260317|NCT00766038|EXPERIMENTAL|1|The GH treatment arm will receive a starting dose of 400 microgramsg/day, with increases (or decreases) in dose by 100-200 micrograms/day each month, monitoring for side effects, until goal IGF-1 (in the upper quartile of the range for age and body weight) is reached up to maximum dose of 1,000 microgramsg/day. Dose adjustments may be modified by the investigators for participants receiving oral estrogens or other circumstances know to influence GH dosing or atypical responses to treatment.
62260318|NCT00766038|PLACEBO_COMPARATOR|2|Doses for participants receiving placebo will also be adjusted monthly to maintain the blinding.
62260319|NCT04636827|EXPERIMENTAL|group 1 (sIPV+DTaP+HepA)|150 subjects; simultaneously administration of sIPV+DTaP+HepA as booster immunization at the age of 18 months old, 0.5 ml each, respectively
62260320|NCT04636827|ACTIVE_COMPARATOR|group 2 (sIPV)|150 subjects; vaccination of 0.5 ml sIPV as booster immunization at the age of 18 months old
62445758|NCT02129374|EXPERIMENTAL|Direct repair of pars defect|The pars defect was repaired with 4.5mm cortical screw.
62445759|NCT02129374|NO_INTERVENTION|Conservative treatment|The pars defect of spondylolysis was not repaired with cortical screw.
62445760|NCT02184000||1. the control group healthy adult volunteers|
62445761|NCT02184000||2. patients with chronic hepatitis B or C|
62842125|NCT02146534|EXPERIMENTAL|fampridine|extended release fampridine 10mg BID PO for 14 weeks
62842126|NCT02146534|PLACEBO_COMPARATOR|placebo|placebo pill BID PO for 14 weeks
62842127|NCT02896413|EXPERIMENTAL|Dexmedetomidine Group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
62842128|NCT02896413|PLACEBO_COMPARATOR|Control Group|0.9% saline infusion
62056990|NCT03253484|NO_INTERVENTION|Control|untreated control wound
62056991|NCT02317939|EXPERIMENTAL|online instruction at followup visits|patients in this group will be subjected to view video instructions online prior to performing the follow-up joint scoring at home
62056992|NCT02317939|ACTIVE_COMPARATOR|standard baseline instruction|after the initial training patients in this group will not be subjected to any subsequent instructions prior to performing the follow-up joint scoring at home
62842129|NCT01545505|OTHER|In remission phase of PTSD|Patients having suffered from PTSD in the past and in remission od PTSD and their parents
62842130|NCT01545505|OTHER|Activ PTSD|patients suffering from PTSD (Post-traumatic Stress Disorder) and their parents
62616957|NCT05721183|EXPERIMENTAL|NOST|"The intervention is to implement NOST, which includes:~observation and recording of compliance with hand hygiene recommendations identification of areas for improvement training or other actions taken to improve IPC in general or compliance with hand hygiene.~Thus, the intervention includes both observation of compliance and any additional improvement measures initiated as a result of the introduced NOST.~When the intervention group has implemented and followed NOST for a year, the investigators will measure compliance with hand hygiene recommendations and reported HAIs, in wards that have had NOST and in wards that have not introduced NOST.~The intervention arm will be followed over time with repeated measurements of both compliance with hand hygiene and other outcome measures, to see if the effect increases in line with implemented observations and quality improvement measures, or if the effect decreases during the study period."
62616958|NCT05721183|NO_INTERVENTION|Control|Participants in the no intervention arm arm are asked not to implement NOST.
62260321|NCT04636827|ACTIVE_COMPARATOR|group 3 (DTaP)|150 subjects; vaccination of 0.5 ml DTaP as booster immunization at the age of 18 months old
62616959|NCT01560572|ACTIVE_COMPARATOR|standard immunosuupression|triple maintenance immunosuppression with tacrolimus OD (maintenance 6-10 ng/ml), mycophenolic acid 2 dd 540mg and prednisolone 7.5 mg
62056993|NCT02843256||Patients receiving intravenous nutrition|Patients will blow into a bag that will capture 500 mL of their exhaled air daily for 7 days or the length of the parenteral nutrition, whichever is shorter. The Isomark Canary will analyze the air to generate a breath delta value.
62056994|NCT06100510|NO_INTERVENTION|Placebo (non-intervention) Arm|Participants who will have PFA 100 testing performed without the ingestion of aspirin.
62056995|NCT06100510|ACTIVE_COMPARATOR|Aspirin Arm|Participants who will have PFA 100 testing performed after the ingestion of aspirin.
62445762|NCT02184000||3. pacients with liver cirrhosis type B or C|
62445763|NCT01580761|EXPERIMENTAL|Sleep restriction|Sleep restriction
62445764|NCT01580761|NO_INTERVENTION|Normal sleep|Normal sleep
62616960|NCT01560572|EXPERIMENTAL|steroidfree|maintenance immunosuppression with tacrolimus OD (target range 6-10 ng/ml), mycophenolic acid (2 dd 540 mg)
62616961|NCT01560572|EXPERIMENTAL|low dose tacrolimus|triple maintenance immunosuppression with tacrolimus OD (maintenance 6-10 ng/ml), mycophenolic acid 2 dd 540mg and prednisolone 7.5 mg. After 6 months lowering of tacrolimus OD maintenance 3-5 ng/ml
62616962|NCT02453659|EXPERIMENTAL|Distress Tolerance Treatment for Weight Concern (DT-W)|DT-W is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes distress tolerance intervention for weight concern plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
62056996|NCT01147484|EXPERIMENTAL|Foretinib|
62445765|NCT01368276|ACTIVE_COMPARATOR|GM-CSF|Granulocyte macrophage colony-stimulating factor (GM-CSF) was administered at a dose of 125 μg/m²/day subcutaneously for 14 consecutive days followed by 14 days of rest, in 28-day treatment cycles for up to 12 months or until a complete response, occurrence of an unacceptable toxicity, death or another criterion for withdrawal from treatment was met. Participants who demonstrated a partial response after being on treatment for 12 months could continue to be treated until disease progression or another treatment discontinuation criterion was met.
62445766|NCT01368276|EXPERIMENTAL|Talimogene Laherparepvec|Talimogene laherparepvec was administered at a concentration of 10⁸ plaque forming units (PFU)/mL injected into 1 or more skin or subcutaneous tumors on Days 1 and 15 of each 28-day cycle for up to 12 months or until a complete response, occurrence of an unacceptable toxicity, death or another criterion for withdrawal from treatment was met. Participants who demonstrated a partial response after being on treatment for 12 months could continue to be treated until disease progression or another treatment discontinuation criterion was met.
62445767|NCT00730522|ACTIVE_COMPARATOR|1|CPP-109 vigabatrin tablets
62623703|NCT01831427|EXPERIMENTAL|Andecaliximab 5.0 mg/kg IV (MAD)|Participants will receive andecaliximab 5.0 mg/kg on Days 1, 15, and 29.
62623704|NCT01831427|EXPERIMENTAL|Andecaliximab 150 mg SC (Adaptive MAD)|Participants will receive andecaliximab 150 mg on Days 1, 8, 15, 22, and 29.
62445768|NCT00730522|PLACEBO_COMPARATOR|2|Matching Placebo Tablets
62056997|NCT02277743|EXPERIMENTAL|Placebo|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
62260322|NCT04636827|ACTIVE_COMPARATOR|group 4 (HepA)|150 subjects; vaccination of 0.5 ml HepA as booster immunization at the age of 18 months old
62260323|NCT01923285|EXPERIMENTAL|AXIUM Neurostimulator System|The AXIUM Neurostimulator System is an investigational spinal cord stimulation device that is designed to stimulate the dorsal root ganglion (DRG) of the spine located on the back surface of the spinal cord where nerves exit the backbone. The device has 2 parts that are placed surgically (implanted) : 1) a pulse generator which is placed under the skin in the buttocks or abdomen, and 2) up to four wires (leads) that have one end attached to the pulse generator, and the other end secured to the tissue near the target treatment area.
62056998|NCT02277743|EXPERIMENTAL|Dupilumab 300 mg once weekly (qw)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
62056999|NCT02277743|EXPERIMENTAL|Dupilumab 300 mg every 2 weeks (q2w)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a placebo alternating with single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
62057000|NCT04904770|EXPERIMENTAL|Scoop stretcher|A scoop stretcher will be used as device to perform spinal stabilization
62057001|NCT04904770|ACTIVE_COMPARATOR|Vacuum mattress|A vacuum mattress will be used as device to perform spinal stabilization
62057002|NCT06178861|EXPERIMENTAL|Group wearing a bra|Patients wear a bra while receiving radiotherapy.
62445769|NCT01910766|EXPERIMENTAL|Coenzyme Q10/CC group|"Intervention:~Coenzyme Q10 (CoQ10) and clomiphene citrate group (55 patients, 82 cycles) Patients in CoQ10/CC group took CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6, and CoQ10 Mepaco, Enshas Elraml, Sharkhia, Egypt), in a dose of 60 mg 3 times day capsules orally starting on cycle day 2 and continued till the day of human chorionic gonadotropin (hCG) administration"
62445770|NCT01910766|ACTIVE_COMPARATOR|CC alone group|"Intervention:~CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6"
62057003|NCT06178861|NO_INTERVENTION|Group not wearing a bra|Patients do not wear a bra while receiving radiotherapy.
62057004|NCT03220399|EXPERIMENTAL|NVP-1603-1 (P)|"Drug: NVP-1603-1~1capsule, oral dosing"
62057005|NCT03220399|EXPERIMENTAL|NVP-1603-2(T)|"Drug: NVP-1603-2~1Tablet, oral dosing"
62057006|NCT03220399|EXPERIMENTAL|NVP-1603-1and NVP-1603-2 (P+T)|Drug: NVP-1603-1, 1capsule and NVP-1603-2, 1Tablet co-adminstration (oral dosing)
62057007|NCT03381404|EXPERIMENTAL|[14C] MT-8554|
62057008|NCT00871689|EXPERIMENTAL|UCBT With Post-Transplant IL-2|Patients receive cyclophosphamide, fludarabine phosphate, total-body irradiation, T cell depleted umbilical cord blood transplantation (UCBT), followed by interleukin-2 (IL-2, aldesleukin) every other day beginning day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
62057009|NCT01203670|EXPERIMENTAL|Soft capsules of Phytalgic|Phytalgic is a food supplement. Its galenic form is soft capsule.
62057010|NCT01963338|EXPERIMENTAL|Intradermal group|These group participants received two intradermal injections with the newly developed device, one in the forearm and one in the upper arm (deltoid region).
62057011|NCT01963338|EXPERIMENTAL|Intramuscular group|These group participants received one intramuscular injection in the upper arm(deltoid region) using needle and syringe and one intradermal injection in the forearm using the newly developed device.
62057012|NCT03786952|EXPERIMENTAL|Stress, immediate, males|Stress immediately before learning in males
62057013|NCT03786952|EXPERIMENTAL|Stress, delayed, males|Stress 30 minutes before learning in males
62057014|NCT03786952|SHAM_COMPARATOR|Sham control, immediate, males|Sham control immediately before learning in males
62057015|NCT03786952|SHAM_COMPARATOR|Sham control, delayed, males|Sham control 30 minutes before learning in males
62445771|NCT03358459||EP|For diagnosis non-acquired epilepsy;
62445772|NCT05974748|ACTIVE_COMPARATOR|Sodium Hypochlorite|5.25% sodium hypochlorite is the gold standard endodontic irrigant. Other Name: NaOCl
62057016|NCT03786952|EXPERIMENTAL|Stress, immediate, females|Stress immediately before learning in females
62057017|NCT03786952|EXPERIMENTAL|Stress, delayed, females|Stress 30 minutes before learning in females
62057018|NCT03786952|SHAM_COMPARATOR|Sham control, immediate, females|Sham control immediately before learning in females
62057019|NCT03786952|SHAM_COMPARATOR|Sham control, delayed, females|Sham control 30 minutes before learning in females
62616963|NCT02453659|ACTIVE_COMPARATOR|Health Education (HE)|HE is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes smoking health education program plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
62260324|NCT01923285|ACTIVE_COMPARATOR|Control Spinal Cord Stimulation Device|The Control Spinal Cord Stimulation Device is a commercially available spinal cord stimulator indicated for the treatment of chronic lower limb pain.
62445773|NCT05974748|EXPERIMENTAL|Propolis|Hydroalcoholic 20% propolis will be used as an endodontic irrigant. Other Name: Bee glue
62445774|NCT05102279|EXPERIMENTAL|Early administration of high-phosphorus diet test group|Group A: 1500 mg phosphorus diet was given on day 1-2, 2500 mg phosphorus diet on day 3-5, 1500 mg phosphorus diet on day 6-7 and 500 mg phosphorus diet on day 8-10
62616964|NCT06366698|ACTIVE_COMPARATOR|Intravenous iron|Venofer 200 mg will be given every other day until the patient reaches their calculated in deficit dose. The does of IV iron will be calculated according to the Ganzoni formula: total iron dose (mg) = body weight (kg) x (target Hgb - baseline Hgb (g/dL)) × 0.24 + 500 mg.14 Our target Hgb will be 11.0 g/dL. The determination of the treatment duration and dosage will be based on the calculation of the iron deficit.
62623705|NCT01831427|PLACEBO_COMPARATOR|Placebo Pooled (MAD)|Participants will receive placebo on Days 1, 15, and 29.
62842131|NCT06029855|ACTIVE_COMPARATOR|Kabat Therapy|Kabat exercises primarily assist functional response in defective muscles through the general structure of muscles experiencing resistance. After 6th week, resting and voluntary symmetries were recorded.
62842132|NCT06029855|EXPERIMENTAL|Mime Therapy|Mime therapy utilizes emotional input to access better movement patterns. It is beneficial as it improves circulation and maintains muscle properties.
62842133|NCT03021343|ACTIVE_COMPARATOR|Colchicine|Colchicine 2 mg 12-24 hours prior to surgery and 1 mg 4 hours before or immediately after surgery and then continued at a dose of 0.5 mg twice daily until hospital discharge. Half the dose was given to patients weighing \<70 kg or intolerant to the full dose.
62842134|NCT03021343|NO_INTERVENTION|No colchicine|In this arm no active medication was administered
62842135|NCT00201188|EXPERIMENTAL|1|Participants will receive feedback and peak flow monitoring reports from their doctors.
62842136|NCT00201188|NO_INTERVENTION|2|Participants will receive usual care.
62842137|NCT06172062||LPD cohort|surgical videos of laparoscopic pancreaticoduodenectomy with label to build and test the algorithms.
62842138|NCT01085006|EXPERIMENTAL|Tranexamic acid|
62842139|NCT01085006|PLACEBO_COMPARATOR|normal saline infusion|
62842140|NCT01742117|EXPERIMENTAL|Genotype-Guided Therapy|Subjects will be genotyped prospectively for CYP2C19\*2, \*3 and \*17 alleles and will receive treatment based on their genotype. In this group, patients who have the CYP2C19 reduced function allele \[i.e., \*2 allele (heterozygous or homozygous) or \*3 allele (heterozygous or homozygous)\] patients will receive ticagrelor 90 mg bid. The WT YP2C19 patients will receive clopidogrel 75 mg once daily.
62842141|NCT01742117|ACTIVE_COMPARATOR|Conventional Therapy|Subjects will receive clopidogrel once daily after the index PCI and will be retrospectively genotyped for CYP2C19\*2, \*3 and \*17 alleles after completion of one year of treatment with clopidogrel.
62842142|NCT02405468||case|patients with a myocardial infarction within one month to one year before the inclusion
62842143|NCT02405468||control|"patients without history of myocardial infarction, free of coronary disease in the view of one of the following test performed within one year before the inclusion : Effort test Echocardiographic stress test Myocardial perfusion scintigraphy Coronarography with \>= 2 major cardiovascular risk factors :~* Treated hypertension~* Treated dyslipidemia~* Current smoking~* Diabetes mellitus"
62260325|NCT04628338|EXPERIMENTAL|IFN-γ|100mcg IFN-γ subcutaneously three times per week (Weeks 0-7), once per week (Weeks 8-12) (or per protocol guidance based on tolerability, response, or DLI infusions)
62260326|NCT06001658|EXPERIMENTAL|Gemcitabine, Cisplatin and Pembrolizumab|
62260327|NCT03516526|OTHER|All patients in this study|Patients treated with natalizumab with a minimum of 1 year, without signs of disease activity (relapses, new T2 lesions on MRI) for a minimum of 1 year.
62616965|NCT06366698|PLACEBO_COMPARATOR|Oral iron|Ferrous sulfate 325 mg orally every other day on an empty stomach with lemon/orange water until delivery.
62057020|NCT00117156|EXPERIMENTAL|Fludarabine and Rituximab|"Fludarabine:~25 mg/m2 on days 1-5 of 28 day cycle up to 6 cycles~Rituximab:~375 mg/m2 on day 1 of 28 day cycle up to 6 cycles Rituximab dose was split between days 1 and 3 for patients with absolute lymphocyte counts \> 10x10\^9/L~Patients received three cycles of therapy followed by re-staging with chest/ abdomen/ pelvic CT scan. Patients with progressive disease discontinued treatment. Patients with stable or responding disease continued therapy for another 3 cycles."
62057021|NCT04242433||Viremic Person living with HCV|All persons enrolled in the MMPHCRF treatment programme are provided free of charge direct acting antiviral agents and followed up for outcomes.
62260328|NCT01236573|EXPERIMENTAL|Group 1 - CD8 + TIL expressing IL-12 1x10^6|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of interleukin-12 (IL-12) gene-transduced tumor infiltrating lymphocytes (TIL).
62260329|NCT01236573|EXPERIMENTAL|Group 2 - CD8 + TIL expressing IL-12 3x10^6|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
62260330|NCT01236573|EXPERIMENTAL|Group 3 - CD8 + TIL expressing IL-12 1x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
62260331|NCT01236573|EXPERIMENTAL|Group 4- CD8+TIL expressing IL-12 3x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
62260332|NCT01236573|EXPERIMENTAL|Group 5 - Bulk TIL expressing IL-12 1x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
62260333|NCT01236573|EXPERIMENTAL|Group 6 - Bulk TIL expressing IL-12 3x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
62445775|NCT05102279|ACTIVE_COMPARATOR|Early administration of low-phosphorus diet test group|Group B: 1500 mg phosphorus diet was given on day 1-2, 500 mg phosphorus diet on day 3-5, 1500 mg phosphorus diet on day 6-7 and 3500 mg phosphorus diet on day 8-10
62260334|NCT01236573|EXPERIMENTAL|Group 7- Bulk TIL expressing IL-12 1x10^8|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
62260335|NCT01236573|EXPERIMENTAL|Group 8 - Bulk TIL expressing IL-12 3x10^8|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
62260336|NCT01236573|EXPERIMENTAL|Group 9 - Bulk TIL expressing IL-12 1x10^9|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
62445776|NCT05678348|EXPERIMENTAL|Pyrimethamine|Pyrimethamine will be taken by mouth at a dose of 50 mg once daily for 14 days (+/-2 days) with the last dose the day prior to surgery.
62445777|NCT02215694|EXPERIMENTAL|probiotic group|consumed 2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
62445778|NCT02215694|PLACEBO_COMPARATOR|placebo group|consumed 2g of powder daily without probiotics
62445779|NCT01488032||high-tension glaucoma|subjects with IOP\>22 mmHg without eyedrops and signs of glaucomatous optic nerve damage
62445780|NCT01488032||low-tension glaucoma|subjects with IOP\<22 mmHg without eyedrops and signs of glaucomatous optic nerve damage
62445781|NCT01574989|EXPERIMENTAL|Active low-frequency rTMS/sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the rTMS will be active, low-frequency, and the tDCS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
62616966|NCT05150080||cardiotoxicity|subjects with heart failure, coronary artery disease, valvular heart disease, arrhythmia, hypertension, thromboembolic disease, peripheral vascular disease and stroke, pulmonary hypertension and pericardial disease after hematopoietic stem cell transplantation.
62616967|NCT05150080||non-cardiotoxicity|subjects with on heart failure, coronary artery disease, valvular heart disease, arrhythmia, hypertension, thromboembolic disease, peripheral vascular disease and stroke, pulmonary hypertension and pericardial disease after hematopoietic stem cell transplantation.
62616968|NCT03209518||Leuprorelin acetate|Usually, for adults, 22.5 mg of Leuprorelin acetate was subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants received Leuprorelin as part of routine medical care.
62057022|NCT03420924|EXPERIMENTAL|Thermal suit|
62445782|NCT01574989|EXPERIMENTAL|Active high-frequency rTMS/sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the rTMS will be active, high-frequency, and the tDCS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
62445783|NCT01574989|EXPERIMENTAL|Sham rTMS/active anodal tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the tDCS will be active, anodal, and the TMS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
62445784|NCT01574989|EXPERIMENTAL|Sham rTMS/active cathodal tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the tDCS will be active, cathodal, and the TMS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
62445785|NCT01574989|SHAM_COMPARATOR|Sham rTMS/Sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, and both interventions will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
62616969|NCT04819750|ACTIVE_COMPARATOR|MusicCare® device|The device is a touch tablet with a headset that allows noise reduction. The patient can choose the music they prefer. The selected U-shaped sequence uses the principles of hypnoanalgesia to accompany the patient into a state of deep relaxation.
62057023|NCT03420924|ACTIVE_COMPARATOR|Conventional hospital clothes|
62616970|NCT04819750|PLACEBO_COMPARATOR|Headphones with noise reduction|Headphones with noise reduction without music
62616971|NCT06291623|EXPERIMENTAL|Pre disinfection (30% H2O2, followed by 2.5% NaOCl) NaOCl inactivated with 5% sodium thiosulfate.|sample was taken before pre disinfection protocol (30% H2O2, followed by 2.5% NaOCl) NaOCl will be inactivated with 5% sodium thiosulfate.
62616972|NCT06291623|EXPERIMENTAL|Post disinfection (30% H2O2, followed by 2.5% NaOCl) NaOCl inactivated with 5% sodium thiosulfate.|sample was taken after pre disinfection protocol, to check the sterility of the disinfected tooth surface and access
62616973|NCT06291623|EXPERIMENTAL|Group 1 (n = 10): Ca(OH)2|3 samples was taken before and after the treatment. Sample 1 was taken before Chemomechanical procedures Sample 2 was taken immediately after Chemomechanical procedures, intracanal medication was placed for 1 week Sample 3 was taken immediately after intracanal medication was removed
62842144|NCT03018262||Healthy Volunteers - Sub-study 1|Healthy Volunteers
62842145|NCT03018262||Healthy Volunteers - Sub-study 2|Healthy Volunteers
62057024|NCT05354843|EXPERIMENTAL|Dose Escalation and Dose Expansion|ET0038 will be administered orally once daily in 21 days treatment cycles.
62616974|NCT06291623|EXPERIMENTAL|Group 2 (n = 10): Glycyrrhizin|3 samples was taken before and after the treatment. Sample 1 was taken before Chemomechanical procedures Sample 2 was taken immediately after Chemomechanical procedures, intracanal medication was placed for 1 week Sample 3 was taken immediately after intracanal medication was removed
62057025|NCT06065878|NO_INTERVENTION|IPACK block|In the IPACK block group, a 20 mL solution containing 50 mg of 0.25% bupivacaine (Buvicaine®, Polifarma, Tekirdağ, Turkey) and 8 mg of dexamethasone (Dekort®, Deva, Istanbul, Turkey) was infiltrated between the popliteal artery and femur, starting 2 cm distal to the popliteal artery and being withdrawn while infiltrating proximally.
62057026|NCT06065878|ACTIVE_COMPARATOR|IPACK + Genicular Nerve Block|In the IPACK+GNB group, 12 mL of the same solution was used for the IPACK block infiltration. Then, the patient was positioned supine, and an ultrasound (Logiq e®, GE, Boston, USA) linear probe was placed approximately 2-3 cm above the patella, in the midline of the femur, with a sagittal plane angle of 45 degrees to visualize the femur and genicular artery . The visible needle was advanced in-plane towards the genicular artery, and 4 mL of local anesthetic solution was injected on the surface of the femur. The same procedure was repeated for the superior lateral genicular nerve block, creating a mirror image on the lateral side of the femur.
62057027|NCT02755597|EXPERIMENTAL|Venetoclax + Bortezomib and Dexamethasone|Cycles 1-8: Venetoclax 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\^2 subcutaneously or IV on Days 1, 4, 8 \& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \& 12; Cycles 9 and beyond: Venetoclax 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 and 23
62260337|NCT01236573|EXPERIMENTAL|Group 10- Bulk TIL expressing IL12 3x10^9|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
62260338|NCT01236573|EXPERIMENTAL|Group 11 - Bulk TIL expressing MTD 1x10^9 (Phase 2)|Maximum tolerated dose (MTD). Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
62616975|NCT01141166|EXPERIMENTAL|nutritional and physical rehabilitation plan|
62616976|NCT03580395|EXPERIMENTAL|apatinib+TP|TP neoadjuvant chemotherapy (paclitaxel 165mg/m2 day 1, cisplatin 40mg, day 1-3) combined with apatinib (received TP concurrently with apatinib 500mg, day1-21).
62616977|NCT03580395|SHAM_COMPARATOR|TP|TP neoadjuvant chemotherapy alone (paclitaxel 165mg/m2 day 1, cisplatin 40mg, day 1-3).
62842146|NCT03018262||Healthy Volunteers - Sub-study 3|Healthy Volunteers
62842147|NCT01262989|ACTIVE_COMPARATOR|tamsulosin Reference|Reference drug administration followed by Test drug administration
62842148|NCT01262989|ACTIVE_COMPARATOR|tamsulosin Test|Test drug administration followed by Reference drug administration
62842149|NCT01766258|ACTIVE_COMPARATOR|Stalevo|levodopa/carbidopa/entacapone
62842150|NCT01766258|EXPERIMENTAL|ODM-101 65mg Carbidopa|levodopa/carbidopa/entacapone
62842151|NCT01766258|EXPERIMENTAL|ODM-101 105mg Carbidopa|levodopa/carbidopa/entacapone
62260339|NCT03765138|EXPERIMENTAL|PE/Pramipexole|Experimental: Prolonged Exposure/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. In addition to receiving PE as described above, patients will have Pramipexole treatment.
62057028|NCT02755597|PLACEBO_COMPARATOR|Placebo + Bortezomib and Dexamethasone|Cycles 1-8: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\^2 subcutaneously or IV on Days 1, 4, 8 \& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \& 12; Cycles 9 and beyond: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 \& 23
62260340|NCT00802542||1|Adult patients with mild or moderate essential hypertension who do not tolerate ACE inhibitors because of cough, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal and the doctor has decided to increase the Atacand dose to 16mg as per SmPC.
62260341|NCT05397626|ACTIVE_COMPARATOR|Heart Rhythm Biofeedback|Heart rhythm biofeedback is a non-invasive physiological treatment that is administered via an app downloaded to personal smart phones. It involves participants attaching a wireless sensor to the ear that monitors heart rate that is displayed on the phone screen app. The participant is actively involved in modifying the heart biofeedback to achieve optimal levels of heart rate variability, an established indicator of health and well-being and a potential factor in chronic fatigue syndrome. The treatment lasts 8 weeks.
62260342|NCT05397626|ACTIVE_COMPARATOR|Hydrogen Water|Hydrogen pills are mixed in a water glass that is ingested up to 3 times a day for 8 weeks. The hydrogen supplement is intended to reduce oxidative stress and inflammation both of which are implicated in the pathophysiology of chronic fatigue syndrome. This is an 8 week treatment.
62260343|NCT05397626|ACTIVE_COMPARATOR|Combined treatment: Heart rhythm biofeedback plus hydrogen water|This condition combines heart rhythm biofeedback and hydrogen water, as described above, which is intended to assess any additive or synergistic effects of the two treatments. This is an 8 week treatment.
62445786|NCT02523911|ACTIVE_COMPARATOR|Simethicone Group|Early in the evening prior to colonoscopy, patients will be instructed to consume one 6 ounce bottle of oral sodium sulfate/potassium sulfate/magnesium sulfate (Suprep) solution (containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, and magnesium sulfate 1.6 grams) diluted with 16 ounces of water over one hour. Over the next hour, the patient will be instructed to drink an additional 32 ounces of water. On the day of colonoscopy, the same procedure will be repeated. Patients will take 2.4 mL simethicone in a half glass of water immediately after consuming each dose of the Suprep. All of the bowel preparation solution and required water should be consumed at least 2 hours prior to colonoscopy.
62616978|NCT00595101|EXPERIMENTAL|PF-03187207 High Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
62616979|NCT00595101|EXPERIMENTAL|Latanoprost 0.005% and PF-03187207 Vehicle|A single drop of each, once daily in study eye for 28 days
62842152|NCT04490096|OTHER|[11C]-PBR28 ALS|Neuroinflammatory pathways have been implicated in a variety of neurodegenerative disorders including amyotrophic lateral sclerosis (ALS), but the vast majority of this evidence is from animal or ex vivo human studies. In vivo measurement of the 18 kDa translocator protein (TSPO) has become possible with \[11C\]-PBR28 PET imaging. Briefly, TSPO expression is increased when microglial are activated. Cross-sectional studies have demonstrated that \[11C\]-PBR28 uptake is elevated in ALS compared to controls, is correlated with upper motor neuron severity, and that microglial activation is associated with more severe upper motor neuron disease and faster disease progression. We are only aware of a single 6-month study of 10 patients evaluating longitudinal change of \[11C\]-PBR28 in ALS. We hypothesize that we will observe increased \[11C\]-PBR28 uptake over a 6-month period in motor cortex and prefrontal cortex in ALS. This portion of the study will be performed at UPenn only.
62842153|NCT01970098|EXPERIMENTAL|KPS-0373|
62842154|NCT01970098|PLACEBO_COMPARATOR|Placebo|
62842155|NCT00895206|EXPERIMENTAL|1|individual adapted immunosuppression
62842156|NCT00895206|ACTIVE_COMPARATOR|2|golden standard therapy
62842157|NCT04791306|EXPERIMENTAL|Exercise Training|All participants should increase their physical activity level to at least 150 min per week, guided with once a week supervised in-house training as well as an application for planning and documentation for home-based physical activity
62057029|NCT04302376||Catheter-related thrombosis|The presence of occlusive or nonocclusive thrombus in the insertion vein ad identified on Doppler and compression ultrasonography and compression ultrasound.
62260344|NCT00957528|PLACEBO_COMPARATOR|Placebo|Weekly placebo treatment for a duration of 5 months.
62260345|NCT00957528|EXPERIMENTAL|Monthly Cycled Testosterone|A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.
62616980|NCT00595101|EXPERIMENTAL|PF-03187207 Medium Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
62616981|NCT00595101|EXPERIMENTAL|PF-03187207 Low Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
62616982|NCT02986698|EXPERIMENTAL|in utero hematopoietic stem cell transplantation|"Perform in utero hematopoietic stem cell transplantation at the time of intrauterine transplantation in fetuses with alpha-thalassemia major. The cellular product is: Semi-allogeneic, Related, Maternal Bone Marrow-Derived, Miltenyi CliniMACS Plus enriched CD34+ hematopoietic stem cells administered in utero at a dose of 1 x 10\^7-10\^9 cells/kg fetal weight with equal to or less than 1% CD3+ T cells (equivalent to 10\^5-10\^7 T cells/kg fetal weight) in a final volume of 2-5ml suspended in 5% human serum albumin in Normosol buffer (Hospira, Inc.).~Stem cells will be administered immediately before the red blood cells intravenously via the umbilical vein during the clinically indicated IUT. All participants will receive one dose of stem cells but may receive additional transfusions as clinically indicated."
62616983|NCT02981563|EXPERIMENTAL|Time Together|"Time Together as described under Interventions"
62260346|NCT00957528|EXPERIMENTAL|Continuous Testosterone|Weekly testosterone treatment for a duration of 5 months
62260347|NCT04591275|EXPERIMENTAL|CMAB807|60mg, every 6 months, subcutaneously for twice. dietary supplement: elemental calcium orally, 600mg, daily, and vitamin D orally, 400IU, daily
62260348|NCT04591275|ACTIVE_COMPARATOR|Prolia®|60mg, every 6 months, subcutaneously for twice. dietary supplement: elemental calcium orally, 600mg, daily, and vitamin D orally, 400IU, daily
62616984|NCT01658254|EXPERIMENTAL|Survey by email|One arm of investigators will receive the survey to answer by email, reminding the necessity of posting basic results
62616985|NCT01658254|NO_INTERVENTION|Non interventional arm|This arm will receive no intervention (no email with the survey)
62616986|NCT04059341|EXPERIMENTAL|Active LI-ESWT|Active group receives five sessions of low intensity extracorporeal shockwave treatment, once per week for five consecutive weeks. Treatment is initiated three weeks after radical prostatectomy and is given using DUOLITH® SD1 manufactured by STORZ MEDICAL AG.
62057030|NCT04302376||No catheter-related thrombosis|The absence of occlusive or nonocclusive thrombus in the insertion vein ad identified on Doppler and compression ultrasonography and compression ultrasound.
62057031|NCT01970852|EXPERIMENTAL|Standard tablet computer|Patient will receive tablet computer within 18 hours of admission and will continue to have access to it for the rest of his/her stay. Tablet has typical applications including access to the internet and entertainment.
62057032|NCT01970852|NO_INTERVENTION|Usual Care|Patients will receive usual care and will answer surveys during the usual time-frame specified.
62057033|NCT01970852|EXPERIMENTAL|Enhanced tablet computer|Patients will receive a tablet computer within 18 hours of admission. Tablet will give access to a personalized inpatient personal health record portal. Will also provide access to standard tablet applications (e.g. video calling, streaming movies, etc.)
62057034|NCT06014138|ACTIVE_COMPARATOR|Conventional intravenous sedation|Conventional intravenous sedation (e.g. propofol) with short acting opioid, titrated to a clinically prescribed sedation score. Period of observation will be 2 hours pre-cross over and 2 hours post cross over.
62057035|NCT06014138|ACTIVE_COMPARATOR|Inhaled volatile sedation|Inhaled volatile sedation (Isoflurane) delivered via the AnaConDa device for a 6 hour period (2 hours washout of intravenous sedation / wash-in of volatile to achieve stable baseline, followed by 4 hours of observations at steady state) titrated to an equivalent sedation score. During this period opioid infusion should be maintained at baseline level unless clinical indication for titration of dose.
62057036|NCT04012060|ACTIVE_COMPARATOR|Conventional group|All patients undergoing aortic valve replacement through full sternotomy.
62057037|NCT04012060|EXPERIMENTAL|Limited access group|All patients undergoing aortic valve replacement through partial upper hemisternotomy.
62057038|NCT04012060|OTHER|Registry group|"All patients unwilling or unable to participate in the randomized part of the trial.~All patients will undergo aortic valve replacement through median full sternotomy."
62616987|NCT04059341|SHAM_COMPARATOR|Sham|Sham group receives five sessions of sham low intensity extracorporeal shockwave treatment, once per week for five consecutive weeks. Treatment is initiated three weeks after radical prostatectomy and is given using DUOLITH® SD1 manufactured by STORZ MEDICAL AG with a shockwave absorbing adapter.
62057039|NCT00983632|EXPERIMENTAL|vagus stimulation|electrical vagus stimulation to X.nerve on neck
62057040|NCT06624579|OTHER|confocal endomicroscopy|"Endoscopic confocal microscopy with fluorescein injection is a medical imaging technique that combines endoscopy with confocal microscopy and the injection of fluorescein, a fluorescent dye.~During colonoscopy or rettosigmoidoscopy, confocal microscopy is used, which provides high-resolution images of tissues at a cellular level. This technology uses a thin probe with a laser light source and a detection system to analyze specific layers of tissue. During the examination, a solution of fluorescein is injected into the patient's peripheric vein. Fluorescein is a dye that binds to cellular structures, making them fluorescent when exposed to laser light. This allows to visualize cellular details in real-time during endoscopy"
62616988|NCT04527978|OTHER|PRECISION1, then Biotrue ONEday|Verofilcon A contact lenses worn first, with nesofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
62616989|NCT04527978|OTHER|Biotrue ONEday, then PRECISION1|Nesofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
62616990|NCT01124370|EXPERIMENTAL|Treatment|All enrolled subjects will undergo attempted system implantation and therapeutic assessment. Subjects' baseline assessment values will serve as control parameters for the therapy evaluation.
62616991|NCT03326232|EXPERIMENTAL|Blinded continuous glucose monitoring|The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter).
62616992|NCT03326232|EXPERIMENTAL|Real time continuous glucose monitoring|The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)
62616993|NCT05790642||Participants with sinus rhythm|
62616994|NCT05790642||Participants with atrial fibrillation|
62616995|NCT05790642||Participants with extra systoles|
62616996|NCT05790642||Participants with heart failure with reduced ejection fraction|
62057041|NCT02730182|EXPERIMENTAL|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
62616997|NCT05790642||Participants with mildly reduced or preserved ejection fraction|
62057042|NCT04341961|EXPERIMENTAL|Pom Juice|The study participants will all be asked to drink pomegranate juice for 2 weeks, and 4 weeks of continued usual diet and avoid pomegranate juice (other than what is given to you), berries (strawberries, blackberries, raspberries (red, black, yellow), cranberries), walnuts, pecans, hazelnuts, pecans, chestnuts, red and white guava, pomegranates, flaxseeds, dark chocolate and cocoa, coffee, tea, rose hip, olives, artichoke, dried herbs and beefsteak tongue mushrooms).
62057043|NCT01437163|SHAM_COMPARATOR|Red Incandescent light source|
62616998|NCT03525808|EXPERIMENTAL|AXIOS|Patients will receive the AXIOS stent for the treatment of walled-off pancreatic necrosis.
62616999|NCT00350779|EXPERIMENTAL|1|Sitagliptin
62617000|NCT00350779|PLACEBO_COMPARATOR|2|Placebo
62617001|NCT01318746||Healthy group|15 persons with normal renal function
62617002|NCT01318746||Renal failure|15 persons with renal failure (GFR \< 60 ml/min)
62617003|NCT06327360||Patients with Pulmonary Fibrosis at the Don Gnocchi Foundation (Milan)|42 patients
62617004|NCT06327360||Patients with Pulmonary Fibrosis at the Policlinico (Milano)|42
62617005|NCT06327360||Patients with Pulmonary Fibrosis at the FIMARP ONLUS|46
62617006|NCT02518841|ACTIVE_COMPARATOR|Achilles Tendon Stretching|This is the arm of participants who will first be assigned to perform 6 weeks of achilles tendon stretching as demonstrated in the protocol. As this is a crossover design study, this arm will then switch to 6 weeks of ThermaWedge TM stretching.
62617007|NCT02518841|EXPERIMENTAL|ThermaWedge TM|This is the arm of participants who will first be assigned to perform 6 weeks of ThermaWedge TM stretching as demonstrated in the protocol. As this is a crossover design study this arm will then switch to 6 weeks of Achilles Tendon Stretching
62617008|NCT05112159|EXPERIMENTAL|IPG1094 100mg|Four subjects in this cohort will receive a single dose of IPG1094 100 mg qd and two subjects will receive a single dose of placebo 100mg qd orally. Sentinel subjects (i.e. 1 subject will be dosed with IPG1094 and 1 with placebo before the remainder of the cohort is dosed) will be used in the cohort.
62617009|NCT05112159|EXPERIMENTAL|IPG1094 300mg|Six subjects in this cohort will receive a single dose of IPG1094 300 mg qd and two subjects will receive a single dose of placebo 300mg qd orally.
62057044|NCT01437163|ACTIVE_COMPARATOR|TopHat 655|
62057045|NCT03625986|EXPERIMENTAL|Nicotine-Containing Electronic Cigarette|The experimental group will be provided with and encouraged to use a Standardized Research Electronic Cigarette (SREC) with liquid containing 58 mg/ml nicotine for the duration of 6 weeks.
62057046|NCT03625986|PLACEBO_COMPARATOR|Non-Nicotine Electronic Cigarette|The placebo group will be provided with and encouraged to use a Standardized Research Electronic Cigarette (SREC) with liquid containing 0 mg/ml nicotine for the duration of 6 weeks.
62057047|NCT04980664|EXPERIMENTAL|Integrated intervention strategies|
62057048|NCT01618734||Romiplostim and eltrombopag in ITP|ITP patients who received alternatively romiplostim or eltrombopag with at least two months of follow-up for each period.
62617010|NCT05112159|EXPERIMENTAL|IPG1094 600mg|Six subjects in this cohort will receive a single dose of IPG1094 600 mg qd and two subjects will receive a single dose of placebo 600mg qd orally.
62617011|NCT05112159|EXPERIMENTAL|IPG1094 900mg|Six subjects in this cohort will receive a single dose of IPG1094 900 mg qd and two subjects will receive a single dose of placebo 900mg qd orally.
62617012|NCT05112159|EXPERIMENTAL|IPG1094 1200mg|Six subjects in this cohort will receive a single dose of IPG1094 1200 mg qd and two subjects will receive a single dose of placebo 1200 mg qd orally.
62617013|NCT05112159|EXPERIMENTAL|IPG1094 1500mg|Six subjects in this cohort will receive a single dose of IPG1094 1500 mg qd and two subjects will receive a single dose of placebo 1500mg qd orally.
62617014|NCT05418660||Cohort 1|The cohort includes patients who discontinue the treatment at 24 months and continue the follow-up at least for 3 months
62617015|NCT05418660||Cohort 2|The cohort includes patients who continue the treatment beyond 24 months until unacceptable toxicity or progression.
62617016|NCT02748629|ACTIVE_COMPARATOR|ProGrip Mesh Repair|80 patients are randomized to inguinal hernia repair using selfgripping ProGrip Mesh (Covidien Parietex ProGrip Self-Fixating Mesh) - sutureless fixation.
62617017|NCT02748629|ACTIVE_COMPARATOR|Lichtenstein Operation|80 patients are randomized to inguinal hernia repair using lightweight polypropylene mesh (\<40 g/m2) with standard Lichtenstein technique.
62617018|NCT04856397|OTHER|Control group|"Responders will be in this category. These patients will be maintained on intravitreal anti-VEGF therapy for 1 year, with a monthly PRN (as needed) treatment regimen post 5 monthly loading doses."
62057049|NCT05680337|ACTIVE_COMPARATOR|Active TENS|Active will be performed with using a TENS device with an ear clip attached to the tragus of the left ear (which is innervated by auricular branch of the vagus nerve) at 20 Hz, 200 μs at a current just below discomfort threshold.
62445787|NCT02523911|PLACEBO_COMPARATOR|Placebo Group|Early in the evening prior to colonoscopy, patients will be instructed to consume one 6 ounce bottle of oral sodium sulfate/potassium sulfate/magnesium sulfate (Suprep) solution (containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, and magnesium sulfate 1.6 grams) diluted with 16 ounces of water over one hour. Over the next hour, the patient will be instructed to drink an additional 32 ounces of water. On the day of colonoscopy, the same procedure will be repeated. Patients will take 2.4 mL of placebo (identical in appearance to simethicone) in a half glass of water immediately after consuming each dose of the Suprep. All of the bowel preparation solution and required water should be consumed at least 2 hours prior to colonoscopy.
62842158|NCT01926496|EXPERIMENTAL|Ingenol Mebutate|Arm A: Ingenol mebutate gel 0.015% applied daily for 3 consecutive days to the selected treatment area followed by 8 weeks' rest. Retreatment for another 3 consecutive days if the treatment field is not completely cleared of AKs at Week 8
62057050|NCT05680337|SHAM_COMPARATOR|Sham TENS|Sham will be performed with using a TENS device with an ear clip attached to the left earlobe (which is devoid of vegas innervation) at 20 Hz, 200 μs at a current just below discomfort threshold.
62057051|NCT05064787|OTHER|Single Arm Cohort Receiving Digital Health Coaching|All study participants will be enrolled in a 6-month digital health coaching program.
62057052|NCT01410370|EXPERIMENTAL|treatment|Radiotherapy plus Endostar
62057053|NCT01410370|ACTIVE_COMPARATOR|control|Radiotherapy
62057054|NCT05416905|EXPERIMENTAL|STN-DBS|The patients in this group will be treated with STN-DBS.
62057055|NCT05416905|ACTIVE_COMPARATOR|GPi-DBS|The patients in this group will be treated with GPi-DBS.
62057056|NCT04461327|EXPERIMENTAL|Major Depressive patients|"3 groups:~* Women having recently attempted suicide (less than 72 hours).~* Women having a past suicide attempt (more than 72 hours).~* Women without lifetime history of suicidal behaviour."
62057057|NCT01557322||Biologic|
62057058|NCT01557322||non-biologic DMARD|
62057059|NCT00462137||1|control group
62057060|NCT00462137||2|hypnotic group
62445788|NCT02511236|EXPERIMENTAL|Group Cognitive Behavioral Therapy|Participants may receive 8 group cognitive behavioral therapy (CBT) sessions and eight weeks of transdermal nicotine patches (TNP) \[21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)\].
62057061|NCT02740075||Hand-ventilated|This group will be transported from the operating room to the intensive care unit with the anesthesia provider ventilating the patient by hand via Mapleson circuit and supplemental oxygen. Vital signs and end-tidal carbon dioxide will be monitored and recorded by one of the investigators. The anesthesia provider will be blinded to the end-tidal carbon dioxide levels and respiratory rate.
62057062|NCT02740075||Mechanically ventilated|This group will be transported from the operating room to the intensive care unit with the patient being ventilated by a transport ventilator with controlled tidal volume, respiratory rate, and positive end-expiratory pressure. Vital signs and end-tidal carbon dioxide will be monitored and recorded by one of the investigators.
62057063|NCT02980926|EXPERIMENTAL|Mepivacaine Spinal Anesthetic|Mepivacaine 3 mL intrathecal injection of 2% solution
62057064|NCT02980926|ACTIVE_COMPARATOR|Bupivacaine Spinal Anesthetic|Bupivacaine 12 mg of 8.25% solution
62445789|NCT02511236|ACTIVE_COMPARATOR|General Health Education|Participants may receive group general health education (GHE) sessions and eight weeks of transdermal nicotine patches (TNP) \[21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)\].
62842159|NCT01926496|ACTIVE_COMPARATOR|Imiquimod|Arm B: Imiquimod 5% cream applied 3 days per week for 4 weeks to the selected treatment area followed by 4 weeks' rest. Retreatment for another 4 weeks if the treatment field is not completely cleared of AKs at Week 8
62057065|NCT01971164|EXPERIMENTAL|Dose 1 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
62445790|NCT03699709|EXPERIMENTAL|Intervention Arm|
62445791|NCT03699709|NO_INTERVENTION|Control Arm|
62445792|NCT04576767||Experimental group|interventions:general anesthesia drugs:propofol、muscle relaxant、pain relievers(fentanbyl、sufentanil)
62057066|NCT01971164|EXPERIMENTAL|Dose 2 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
62057067|NCT01971164|EXPERIMENTAL|Dose 3 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
62057068|NCT01971164|EXPERIMENTAL|Dose 4 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
62057069|NCT05144932|EXPERIMENTAL|StrokeAlarm use|This is a single arm study. All participants will be instructed to use the StrokeAlarm medical device for 1 month.
62842160|NCT04656327||Non interventional group|Community-dwelling elders dependent for care
62842161|NCT03870243|ACTIVE_COMPARATOR|Bubble CPAP|6 hospitals will be selected randomly for this arm
62842162|NCT03870243|ACTIVE_COMPARATOR|Low flow oxygen|6 hospitals will be selected for low flow oxygen therapy
62057070|NCT03430141|EXPERIMENTAL|Intervention for all participants|Nutritarian Diet-style: Intervention for all participants: All participants are exposed to the same nutrition treatment/intervention protocol.
62260349|NCT02250274|OTHER|LAIV 2014-15|Will receive LAIV this year. Includes 5-8 year olds and approximately half of the 9-17 year olds. Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, all ages.
62260350|NCT02250274|OTHER|IIV 2014-15|Will receive IIV this year. Includes only 9-17 year olds (unless shortages of LAIV encountered). Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, only 9-17 year olds.
62260351|NCT04152577|EXPERIMENTAL|R2-combination chemotherapy|"R2-CHOP/CHOPE/DA-EPOCH/HD MTX~R2-CHOP :~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R2-DA-EPOCH:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R2-HD MTX:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
62260352|NCT04152577|ACTIVE_COMPARATOR|R-combination chemotherapy|"R-CHOP/CHOPE/DA-EPOCH/HD MTX~R-CHOP :~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R-DA-EPOCH:~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R-HD MTX:~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
62260353|NCT03075800|NO_INTERVENTION|Assertive Community Treatment (ACT) - Only|ACT is a multidisciplinary, team-based approach to providing a range of treatment, rehabilitation, and support services to high-need, high-risk people with severe mental illness who tend not to use clinic-based services; most services are provided on an outreach basis (e.g., in the person's home) and services are available 24 /7(27).
62260354|NCT03075800|EXPERIMENTAL|Assertive Community Treatment+Illness Management and Recovery|IMR follows a manualized curriculum to help clients pursue personal recovery goals and to teach them information, strategies, and skills over 11 modules (e.g., using medications, coping with stress) to manage their psychiatric illness. IMR can be provided in individual or group formats. The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
62260355|NCT06071507||Enteral Stenting|Endoscopic placement of enteral Self-Expandable Metal Stents (SEMS). The procedure implies endoscopic identification of the stricture, placement of a guidewire through the stricture and placement of a SEMS through the stricture under fluoroscopic control.
62260356|NCT06071507||EUS-guided Gastrojejunostomy|The procedure implies distention of the jejunal loop and EUS-guided placement of an electrocautery-enhanced (EC) LAMS connecting the stomach to a jejunal loop distal to the stenosis. Any technique for EUS-GE will be allowed, provided that an EC-LAMS \>15mm will be used.
62260357|NCT06071507||Surgical Gastrojejunostomy|The procedure implies a surgical anastomosis between gastric wall and a jejunal loop. The procedure can be performed either through laparoscopy or open surgery.
62260358|NCT00755274|EXPERIMENTAL|Group 1: Primed|Have received 2 or more lifetime Flu Vaccinations Prior to Visit 1
62260359|NCT00755274|EXPERIMENTAL|Group 2: Naive/Inadequately Primed|Never Received or Received Only 1 Lifetime Flu Vaccination Prior to Visit 1
62260360|NCT00788281|EXPERIMENTAL|A|laparoscopic surgery plus postsurgery adjuvant chemotherapy of FOLFOX4
62260361|NCT00788281|ACTIVE_COMPARATOR|B|open surgery plus postsurgery adjuvant chemotherapy of FOLFOX4
62260362|NCT01131676|EXPERIMENTAL|BI 10773 low dose|BI 10773 tablets once daily
62260363|NCT01131676|EXPERIMENTAL|BI 10773 high dose|BI 10773 tablets once daily
62260364|NCT01131676|PLACEBO_COMPARATOR|Placebo|Placebo tablets matching BI 10773
62260365|NCT00574288|EXPERIMENTAL|Dose Escalation: Daratumumab|
62260366|NCT00574288|EXPERIMENTAL|Dose Expansion: Daratumumab|
62617019|NCT04856397|EXPERIMENTAL|Early switch|Suboptimal responders who are switched to intravitreal Ozurdex (monitored monthly and treated PRN at a potential 2-6 month interval) injections after the first 3 monthly loading intravitreal eylea.
62260367|NCT05169151||Observational (physical activity tracking)|Patients utilize smartphone application to monitor physical activity and mobility up to 180 days during treatment or post-treatment.
62617020|NCT04856397|EXPERIMENTAL|Late switch|Suboptimal responders who are switched to intravitreal Ozurdex (monitored monthly and treated PRN at a potential 2-6 month interval) injections after the first 6 monthly loading intravitreal eylea
62617021|NCT04856397|OTHER|Non-switch|Suboptimal responders who continue to receive monthly intravitreal anti-VEGF injections.
62617022|NCT01067001||2 Way Crossover|2 Way Crossover bioequivalence study
62057071|NCT05234359||CHILD Cohort Study|"CHILD Cohort Study, a general population cohort of 3500 families (n\~12,000) with children born in BC, AB, MB and ON between 2009-12. CHILD has dense longitudinal data (pregnancy to children aged 5-8 years) on physical and mental health, emotional wellbeing, child behaviour problems, and parenting stress, providing the powerful opportunity to identify and study changes in these parameters during the pandemic. CHILD participants have also granted permission for data linkage, providing the opportunity to link study data with administrative health data including clinical diagnoses, hospitalization and medication use. In this grant, the investigators will monitor SARS-CoV-2 seroprevalence among CHILD families and collect information about how they are experiencing the COVID-19 pandemic over the next 12 months.~Interventions - Diagnostic Testing via home kit at 2 timepoints:~Blood sample, Saliva sample, Stool sample"
62057072|NCT03880630|EXPERIMENTAL|Chronic respiratory disease|Patients with chronic respiratory disease with inspiratory muscle weakness will be recruited for the study
62057073|NCT01567358|EXPERIMENTAL|NI-071|
62057074|NCT01567358|ACTIVE_COMPARATOR|Remicade|
62057075|NCT01455207|OTHER|alcoholic patients|
62617023|NCT01067001||Subjects will be randomly divided in to 2 groups.|A total of 18 normal, healthy, adult, human subjects will be enrolled in the study.
62617024|NCT05529732|EXPERIMENTAL|Application Group|Oral and written consent will be obtained from the patients by face-to-face interview technique at least one day before the surgery. Then, face-to-face interview technique and data collection tools (Personal Information Form and Trait Anxiety Scale) will be applied. It is estimated that the process of obtaining consent and filling out the form will take approximately 5 minutes. The mobile application will be installed on the mobile devices of the patients and the user name and password will be defined by the researcher so that they can log into the mobile application. In the application, a patient warning notification will be sent on the 3rd, 7th and 10th days to remind the patients to fill in the State Anxiety Scale and Daily Living Activities Evaluation and Follow-up Form, which are included in the questionnaires menu and will be active when the day comes.
62617025|NCT05529732|NO_INTERVENTION|Control Group|Written consent will be obtained from the patients through a face-to-face interview at least one day before the surgery and the data collection form (Personal Information Form and Trait Anxiety Scale) will be filled. During this period, standard care and follow-up protocols will be applied to the patients by the clinic. Patients in the control group will be called by phone on the 3rd, 7th and 10th days of discharge. State Anxiety Scale and Daily Living Activities Evaluation and Follow-up Form will be applied by the researcher. The process is estimated to take 15 minutes.
62057076|NCT01455207|OTHER|korsakoff patients|
62057077|NCT01455207|OTHER|healthy controls|
62260368|NCT01497470|EXPERIMENTAL|Paclitaxel/carboplatin with custirsen|Custirsen added to standard paclitaxel/carboplatin chemotherapy
62260369|NCT01651624|EXPERIMENTAL|Computed tomographic colonography (CTC), reduced prep|Subjects invited to undergo CTC with reduced cathartic preparation
62617026|NCT03634202|EXPERIMENTAL|IMRT + oral chemotherapy|Radiotherapy = IMRT with SIB. The overall duration of irradiation is 5 to 7 weeks Chemotherapy = oral capecitabine. Chemotherapy is taken in concomitance as radiotherapy days
62617027|NCT02966821|EXPERIMENTAL|Surufatinib|Surufatinib 300mg once-daily
62057078|NCT06171230|EXPERIMENTAL|Eye Movement Desensitization and Reprocessing|Participants will undergo six 90-minute EMDR sessions. The EMDR treatment concludes when the selected target images attain a Subjective Units of Disturbance (SUD) score of 0 or when three consecutive sessions show no further decrease in the SUD. Between the baseline phase (phase A) and the intervention phase (phase C), an attention control phase is introduced (phase B). This phase controls for the non-specific effects of the intervention, such as attention, treatment contact, and social support.
62057079|NCT00638235||Phase I (IntePro, US only)|AMS Apogee™ with IntePro(Began May 2006 - Closed)
62057080|NCT00638235||Phase I (InteXen LP, US only)|AMS Apogee™ with InteXen LP (Began May 2006 - Closed)
62617028|NCT01302210||Intervention|Active surveillance testing for MRSA and decolonization of positive subjects
62057081|NCT00638235||Phase II (France only)|AMS Perigee™ with IntePro (Began February 2007 - Closed)
62057082|NCT00638235||Phase III/IV (Perigee IntePro Lite, US only)|AMS Perigee™ with IntePro Lite (Began April 2007 - Closed)
62057083|NCT00638235||Phase III/IV (Apogee IntePro Lite, US only)|AMS Apogee™ with IntePro Lite (Began April 2007 - Closed)
62057084|NCT00638235||Phase V (Elevate Posterior IntePro Lite, US & EU)|AMS Elevate™ Apical \& Posteiror with IntePro Lite (Began April 2008 - Closed)
62617029|NCT01302210||control|Usual standard of care
62617030|NCT02777424|EXPERIMENTAL|Prothrombin Complex Concentrate|Administration of a single dose of prothrombin complex concentrate (25 U/kg equivalent factor IX)
62057085|NCT00638235||Phase V (Elevate Posterior InteXen, US only)|AMS Elevate™ Apical \& Posteiror with IntXen LP (Began April 2008 - Closed)
62057086|NCT00638235||Phase VI (Elevate Anterior Gen 1, For Study Use Only, EU only)|AMS Elevate™ Anterior \& Apical with IntePro Lite (Generation 1, For Study Use Only, Began October 2008 - Closed)
62057087|NCT00638235||Phase VII (Elevate Anterior Gen 2, US & EU)|AMS Elevate™ Anterior \& Apical with IntePro Lite (Generation 2, Began April 2009 - Closed)
62057088|NCT05775679||Test-retest reliability|50 patients answer CLEFT-Q twice with 1-2 weeks in between.
62057089|NCT05775679||Secondary Nose Surgery|50 patients answer CLEFT-Q before and 6 months after secondary nose surgery.
62057090|NCT05775679||Secondary Lip Surgery|50 patients answer CLEFT-Q before and 6 months after secondary lip surgery.
62617031|NCT02777424|ACTIVE_COMPARATOR|Fresh Frozen Plasma|Administration of a single dose of fresh frozen plasma of 15 mL/kg
62617032|NCT04260568||Persistent Postural Perceptual Dizziness|Semi-structured interviews
62617033|NCT03845400||Type I or Type II HAE Participants|Participants with Type I or Type II HAE will be followed for 24 or 36 months depending upon enrollment date. Data collection will cease at the end of follow-up period, at the time of withdrawal, lost to follow-up, or death whichever comes first.
62057091|NCT05775679||Jaw Surgery|50 patients answer CLEFT-Q before and 1 year after jaw surgery.
62445793|NCT04576767||control group|interventions:intraspinal anesthesia drugs:ropivacaine、pain relievers(fentanbyl、sufentanil)
62445794|NCT00752791|EXPERIMENTAL|Peginesatide|
62617034|NCT03905681|ACTIVE_COMPARATOR|"Active TENS Group Group A"|After all necessary data collection forms are obtained, a pre-VAS score will be obtained. The participant will point to the area of maximum subjective pain, and then four TENS pads will be applied directly around the point of maximal pain that was determined by the patient, located at least 3 centimeters but no more than 6 centimeters from the area in a square or frame-like placement. While the device is off, it will be set at the following settings: The selector switch will be set to 'Milli' or milliamperes, and the frequency dial will be rotated to 100 Hertz. The participant will be instructed to rotate both dials in a clockwise direction if more intensity is desired, or counter-clockwise if less intensity is desired. The participant will wear the device and pads for a 30-minute duration; upon completion, post-VAS scores and a patient satisfaction survey will be obtained.
62617035|NCT03905681|PLACEBO_COMPARATOR|"Placebo TENS Group Group B"|After all necessary data collection forms are obtained, a pre-VAS score will be obtained. The participant will point to the area of maximum subjective pain, and then four TENS pads will be applied directly around the point of maximal pain that was determined by the patient, located at least 3 centimeters but no more than 6 centimeters from the area in a square or frame-like placement. However, no electrical stimulation will be provided. The participant will also wear the device and pads for a 30-minute duration; upon completion, post-VAS scores and a patient satisfaction survey will be obtained.
62057092|NCT05775679||Secondary Speech Improving Surgery|50 patients answer CLEFT-Q before and 1 year after secondary speech improving surgery.
62057093|NCT05775679||Health care professionals|20 health care professionals will be interviewed about their experiences on working with CLEFT-Q.
62057094|NCT03280771|EXPERIMENTAL|Hope Soap group|Children in treatment households received a bi-monthly delivery of HOPE SOAP©, a colourful, translucent bar of soap with a toy embedded in its centre
62057095|NCT03280771|ACTIVE_COMPARATOR|Control group|Children in control households received a colourful, translucent bar or soap with the toy alongside it.
62057096|NCT04849221||Patients|Head trauma, patient operated on for an intracranial lesion, or other condition (hemorrhagic stroke)
62057097|NCT04849221||healthy subjects|No otologic or neurological history
62057098|NCT00963911|EXPERIMENTAL|Included patients|Screening tests (G8 and VES-13)
62057099|NCT02468635|OTHER|without training for upper limb|Receive treatment from traditional pulmonary rehabilitation and without resistive training for upper limb (UL)
62057100|NCT02468635|OTHER|upper limb exercises|Receive the same treatment control with additional upper limb resistance training.
62057101|NCT06483425||Ovarian cancer pateitns|Patients diagnosed with Ovarian cancer in Tongji Hospital, Wuhan.
62057102|NCT01704625|EXPERIMENTAL|Osteopathic Manipulative Treatment|The osteopathic treatment group will have performed on them 3 standardized osteopathic manipulative treatments. If at any time the patient is unable to tolerate a treatment secondary to pain that particular study will be stopped. If the patient's nurse enters the room with medication, the study will be stopped and patient will not be included in the study. At no time will the patient's medical treatment in the emergency department be delayed to perform OMT
62057103|NCT01704625|SHAM_COMPARATOR|Sham Osteopathic Manipulative Treatment|The sham group will receive 3 sham treatments. If at any time the patient is unable to tolerate a treatment secondary to pain that particular study will be stopped. If the patient's nurse enters the room with medication, the study will be stopped and patient will not be included in the study. At no time will the patient's medical treatment in the emergency department be delayed to perform OMT.
62057104|NCT01520402|EXPERIMENTAL|Warfarin|Healthy subjects age 18-74 with no medical indication for warfarin therapy, who are free of medications and co-morbid medical conditions with the potential to interfere with warfarin metabolism, and who are willing to follow a fixed vitamin K diet (men 120 micrograms/day, women 90 micrograms/day) are included.
62057105|NCT01827826|ACTIVE_COMPARATOR|Intervention|Participants assigned to the intervention group worked with the study interventionist over the phone to reduce their risk for developing Diabetes Mellitus, Type 2. The intervention lasted for 24 weeks, with weekly phone calls for the first 12 weeks and 4 maintenance calls over the second 12 weeks. Study measurements were taken at baseline, 12 weeks, 24 weeks, and 52 weeks. After 24 weeks, the investigators randomly divided the intervention group in half. The first group did not receive any more phone calls from the interventionist. The second group continued to receive monthly 20-minute phone calls from the interventionist. At 52 weeks post-baseline participants from both groups had their labs drawn, wore a pedometer for 3 days, and called in with a self-reported weight.
62057106|NCT01827826|NO_INTERVENTION|Control|Participants randomized into this group did not receive any intervention, although they were encouraged to follow-up with their doctor and follow through with usual clinical care.
62057107|NCT03897062|ACTIVE_COMPARATOR|Treatment group|Patients (n=64): 20mg tablets of suvorexant nocte daily for six months
62057108|NCT03897062|PLACEBO_COMPARATOR|Placebo group|Placebo control group: Patients (n=64): 1 placebo tablet nocte daily for six months in addition to treatment as usual
62445795|NCT02352337|ACTIVE_COMPARATOR|FOLFIRINOX|Every two weeks (maximum of 12 cycles) : Oxaliplatin 85 mg / m2 Day1 in 2 hours - then Irinotecan 180 mg / m2 Day1 in 90 minutes - Folinic acid 400 mg / m2 Day1 in 2 h (during the irinotecan infusion) - 5-FU bolus 400 mg / m² Day1 followed by continuous 5-FU 2400 mg / m2 total over 46 hours
62445796|NCT02352337|EXPERIMENTAL|FOLFIRINOX + LV5FU2 in maintenance|"Folfirinox during 4 months followed by LV5FU2 maintenance until progression:~Folfirinox (as described in arm FOLFIRINOX) LV5FU2 : Folinic acid 400 mg/m² (200 mg/m² if Elvorine), in perfusion over 2 hours the 5FU 400 mg/m² in bolus over 10 mn followed by 5FU 2400 mg/m² in perfusion over 46 hours."
62445797|NCT02352337|EXPERIMENTAL|FIRGEM|"Alternance of 2 months of FOLFIRI.3 with 2 months of GEMCITABINE:~Folfiri.3: Irinotécan 90 mg/m² at day 1 in perfusion over 60 minutes in parralel of folinic acid Folinic acid 400 mg/m² (or 200 mg/m² Elvorine) at day 1 in perfusion over 2 hours 5FU continue 2000 mg/m² over 46 heures then irinotécan at 90 mg/m² (1h) at day 3 when 5U perfusion is over~Gemcitabine: 1000 mg/m² in perfusion over 30 mn at day 1,8,15,29,36 and 43 over (1 injection per week during 3 weeks followed with 7 days of rest )"
62057109|NCT05601934|EXPERIMENTAL|Neurophysiological Facilitation Techniques|
62057110|NCT05601934|EXPERIMENTAL|Respiratory exercises|
62057111|NCT01042028|EXPERIMENTAL|Phase II: Arm A|Regime A-ICE On progression or unacceptable toxicity patients can cross-over from regime A to regime B
62057112|NCT01042028|ACTIVE_COMPARATOR|Arm B|Arm B: CapOx On progression or unacceptable toxicity patients can cross-over from regime B to regime A.
62057113|NCT02476955|EXPERIMENTAL|ARQ 092 + anastrozole|ARQ 092 will be administered orally at 150 milligrams (mg) every day (QD), 5 days on/9 days off of a 28 day cycle in combination with anastrozole which will be administered orally at 1 mg QD continuously. The combination treatment will continue until progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria is documented.
62057114|NCT02617992||EMR Surveillance|Patients who are referred for Endoscopic Mucosal Resection of Upper Gastrointestinal Lesions undertaking a surveillance visit will be included in this cohort.
62057115|NCT01618084|EXPERIMENTAL|Tritanium cup|
62445798|NCT06041464||cancer epithelial cell|cancer epithelial cells culture
62445799|NCT06041464||cancer fibroblast culture|cancer fibroblast cells culture
62617036|NCT00528073|EXPERIMENTAL|A|Rifaximin-EIR tablet 1x400 mg + Placebo 2 tablets bid
62617037|NCT00528073|EXPERIMENTAL|B|Rifaximin-EIR tablet 2x400 mg + Placebo 1 tablet bid
62842163|NCT06456996|EXPERIMENTAL|Intervention arm|Within the intervention arm, all medical practitioners will be under a pay-for-population mechanism to incentivize them to care for the overall population health within their township. For High-risk COPD population in the intervention arm, we provide community-based spirometry pulmonary function test (PFT) and education; If individuals whose post-bronchodilator FEV1/FVC\<0.7, they will be spirometry-defined COPD patients and will be encouraged to seek treatment and medication to the superior hospitals. Additionally, we provide (1) two digital health intervention programs to smokers and individuals with mental health issues; (2) CBT-based health education for study participants with abnormal BMI; (3) active recruitment into National Essential Public Health Program in China for those with abnormal blood pressure and blood glucose. Intensive follow-ups will be conducted at month 3 (telephone interview), month 6 (face-to-face with full steps of physical examination), and month 12.
62842164|NCT06456996|NO_INTERVENTION|Control Arm|Those who are assigned in the control arm, we will ask them to finish the same COPD-SQ online questionnaire with notification of his or her COPD high risk status and a face-to-face survey. No physical examinations, community-based pulmonary function tests will be given at baseline. However, at month 12, we will provide community-based pulmonary function tests and physical examinations besides face-to-face survey.
62842165|NCT04427982|EXPERIMENTAL|Experimental Group|All participants will attend a 2-month weekly light-to-moderate intensity dance workshop followed by a brief diabetes education and discussion session.
62842166|NCT05538715|EXPERIMENTAL|Split-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a split-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
62842167|NCT05538715|EXPERIMENTAL|Full-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a full-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
62842168|NCT02074683|ACTIVE_COMPARATOR|YEAR A PATHWAY|"Operative Procedure will occur after screening visit.~Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. In brief, fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.~Follow-up visits:~1. Post op Visit 1 (2 weeks +/- 5 days)~2. Post op study visit 2 (1 month)~3. Post op study visit 3 (2 month)~4. Post op study visit 4 (6 month)~5. Post op study visit 5 (12 month) CROSSOVER to YEAR B PathWay~6. Post op study visit 6 (18 months)~7. Post op study visit 7 (24 months)"
62842169|NCT02074683|ACTIVE_COMPARATOR|Year B Pathway|"Observational visits at 6 and 12 months with fat grafting procedures during year 2.~1. Study visit 1 (month 6)~2. Study Visit 2 (month 12)~   1. Collection of subject's medication profile, vital signs (Temp, HR, Resp, BP), and weight to calculate BMI,~  2. Limited physical exam with a foot exam completed by the PI and /or the Coinvestigator~  3. Adverse Event Reporting~  4. Ultrasound~  5. Pedobarograph~  6. 2D Photographs~  7. Foot Pain Assessment Questionnaire~  8. Medical chart review including review of records from SOC podiatrists~3. Operative Visit Followed by Post op study visits 2-5 as described in Year A Pathway"
62842170|NCT02459483|EXPERIMENTAL|Nurse phone call|a nurse will interview patients by phone every 14 +/- 2 days for 6 months
62842171|NCT02459483|NO_INTERVENTION|Control Group|Common practice
62842172|NCT01924949|EXPERIMENTAL|LDV/SOF|Participants will receive LDV/SOF FDC for 12 weeks.
62842173|NCT02722304|EXPERIMENTAL|ARALAST NP 60 mg/kg|60 mg/kg body weight/week
62842174|NCT02722304|EXPERIMENTAL|ARALAST NP 120 mg/kg|120 mg/kg body weight/week
62842175|NCT02722304|EXPERIMENTAL|GLASSIA 60 mg/kg|60 mg/kg body weight/week
62842176|NCT02722304|EXPERIMENTAL|GLASSIA 120 mg/kg|120 mg/kg body weight/week
62842177|NCT02722304|PLACEBO_COMPARATOR|Placebo|Human Albumin 2%
62842178|NCT04924881|EXPERIMENTAL|Active Arm|COVID Rehab Formula granules once daily for 8 weeks
62445800|NCT02102165|EXPERIMENTAL|metastatic lesion biopsy|biopsy of metastatic lesion will be performed at program inclusion or maximum 6 months prior to inclusion. Sample of primary tumor must be available at inclusion.
62842179|NCT04924881|PLACEBO_COMPARATOR|Placebo Arm|Placebo granules once daily for 8 weeks
62057116|NCT01618084|ACTIVE_COMPARATOR|Trident HA cup|
62445801|NCT03502642|PLACEBO_COMPARATOR|Placebo (P)|Placebo group parturients will receive spinal anesthesia with intrathecal morphine and will have continuous normal saline wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain).
62445802|NCT03502642|ACTIVE_COMPARATOR|Ropivacaine (R)|Ropivacaine group parturients will receive spinal anesthesia without intrathecal morphine and will have continuous ropivacaine (Ropivacaina Molteni®) wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain).
62617038|NCT00528073|EXPERIMENTAL|C|Rifaximin-EIR tablet 3x400 mg bid
62617039|NCT00528073|PLACEBO_COMPARATOR|D|Placebo 3 tablets bid
62617040|NCT05489549||V122I TTR carriers|"Carriers and controls will undergo standardized, detailed CMRI assessments to test the hypothesis that V122I TTR carrier status will be associated with greater evidence of pathological amyloid progression in comparison with non-carriers.~In addition to the CMRI assessments, carriers and controls enrolled at UT Southwestern will undergo standardized exercise CMRI assessments during the same study visit.~V122I TTR carriers will undergo detailed biomarker assessments. These will be compared with controls and patients with symptomatic V122I hATTR-CA ."
62057117|NCT05166525|ACTIVE_COMPARATOR|Medically tailored meals only|Receive medically-tailored meals only (1 meal per day for total of 10 weeks) customized to the participant's nutrition-sensitive medical condition(s).
62623706|NCT06163014||Patients|Patients with persistent physical symptoms consulting their GP and referred to the My Symptoms eHealth programme.
62842180|NCT04203186|ACTIVE_COMPARATOR|Group 1 - PfSPZ, (NF54) strain|Group 1 (N=9) will receive PfSPZ Challenge (NF54) A one-time dose of 3,200 aseptic, purified, cryopreserved, non-attenuated Plasmodium falciparum (Pf) NF54 sporozoites (Pf SPZ Challenge) Mode of administration: Direct venous inoculation (DVI) through a 25 gauge needle and syringe
62057118|NCT05166525|ACTIVE_COMPARATOR|Medically tailored meals plus enhanced nutritional counseling|Receive medically-tailored meals only (1 meal per day for total of 10 weeks) with up to 3 remotely delivered enhanced nutritional counseling sessions that are customized to the participant's nutrition-sensitive medical condition(s).
62842181|NCT04203186|ACTIVE_COMPARATOR|Group 2 - PfSPZ, (7G8) strain|Group 2 (N=9) will receive PfSPZ Challenge (7G8) A one-time dose of 3,200 aseptic, purified, cryopreserved, non-attenuated Plasmodium falciparum 7G8 sporozoites (Pf SPZ Challenge) Mode of administration: Direct venous inoculation (DVI) through a 25 gauge needle and syringe
62445803|NCT03246932|EXPERIMENTAL|Peer-led psycho-education group|A structured, researcher-designed peer expert-led psycho-education program (6 months), comprised of 12 bi-weekly, 2-hour group sessions (10-12 patients per group). The program was based on the psycho-education and self-help, problem-solving programs by Chien et al. (2010) and Lehman et al. (2004).
62445804|NCT03246932|OTHER|Routine psychiatric care|Routine psychiatric outpatient care, including medication, psychiatric consultation in outpatient clinic, brief education by psychiatric nurses, financial and social welfare advices by social workers, and individual counseling by clinical psychologist.
62842182|NCT06380413|EXPERIMENTAL|Tai Chi Chuan Plus Walking|Tai Chi Chuan plus walking program twice a week
62842183|NCT06380413|ACTIVE_COMPARATOR|Walking|Walking program twice a week
62057119|NCT05166525|PLACEBO_COMPARATOR|Usual care|Receive usual standard of care.
62445805|NCT03246932|ACTIVE_COMPARATOR|Profession-led psycho-education group|A psycho-education group program (12 sessions, bi-weekly) based on Dr. Macpherson's Family Psychoeducation Program in 1996 and Chien and Bressington's one in 2014/15 will be used.
62445806|NCT01650324|EXPERIMENTAL|DBPR108|
62842184|NCT03962504|EXPERIMENTAL|written exposure therapy|The WET condition consists of 5-7 weekly treatment sessions, with the first session lasting 1 hour and each subsequent session lasting approximately 40 minutes. The first session consists of education about common trauma reactions and the WET rationale. The participant is then given general instructions for completing the trauma narratives and specific instructions for completing the first 30-minute narrative writing session. All WET sessions begin with the therapist reading the specific writing instructions, clarifying any questions the person has, and leaving the instructions with the participant during the 30-minute writing session. Writing instructions begin with a focus on the details of the trauma and then shift to the meaning of the trauma event. After 30 minutes of writing, the therapist stops the writing and conducts a 5-10 minute check-in regarding how the writing session went for the participant.
62057120|NCT01706302||Cohort Group|
62057121|NCT03080116|EXPERIMENTAL|ARN-509 + degarelix|Treatment period of 12 weeks before RP + PLND.
62623707|NCT01201447||Questionable occlusal lesions|
62623708|NCT03547258||AML patients|Clinical and Molecular data collection of AML Patients with FLT3 mutations (ITD or TKD)
62057122|NCT03080116|ACTIVE_COMPARATOR|placebo + degarelix|Treatment period of 12 weeks before RP + PLND.
62057123|NCT00612534|EXPERIMENTAL|1|
62057124|NCT00612534|EXPERIMENTAL|2|
62057125|NCT00612534|EXPERIMENTAL|3|
62623709|NCT00298883|EXPERIMENTAL|Treatment|This is a single arm, interventional trial.
62617041|NCT05489549||Age-, sex-, and race-matched non-carrier controls|"Carriers and controls will undergo standardized, detailed CMRI assessments to test the hypothesis that V122I TTR carrier status will be associated with greater evidence of pathological amyloid progression in comparison with non-carriers.~In addition to the CMRI assessments, carriers and controls enrolled at UT Southwestern will undergo standardized exercise CMRI assessments during the same study visit.~Controls will undergo detailed biomarker assessments. These will be compared with V122I TTR carriers and patients with symptomatic V122I hATTR-CA ."
62617042|NCT05489549||Patients with symptomatic V122I hATTR-CA|Patients with symptomatic V122I hATTR-CA will undergo detailed biomarker assessments. These will be compared with V122I TTR carriers and controls.
62842185|NCT03962504|ACTIVE_COMPARATOR|Prolonged Exposure|Prolonged Exposure (PE) is a 8-15, 90 minute trauma-focused treatment which consists of imaginal and in vivo exposures
62842186|NCT06521905|EXPERIMENTAL|experimental group|intravascular lithotripsy is used on the basis of high-pressure balloon dilation
62842187|NCT06521905|ACTIVE_COMPARATOR|control group|only use more positive high-pressure ballon dilation
62842188|NCT03690752|SHAM_COMPARATOR|weighted|"The weighted group uses the same Alter-G Treadmill as the unweighted group but were not allowed to use the unweighting function of the treadmill.~Intervention: unweighting using Alter-G Anti-Gravity Treadmill"
62842189|NCT03690752|EXPERIMENTAL|unweighted|"The unweighted group uses the same Alter-G Anti-Gravity Treadmill as the weight group but is allowed to adjust their weight using the weight control feature.~Intervention: normal weight using Alter-G Anti-Gravity Treadmill"
62842190|NCT03920319|EXPERIMENTAL|Bupropion|Participants assigned to 150mg of bupropion daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.
62842191|NCT03920319|PLACEBO_COMPARATOR|Placebo|Participants assigned to pill placebo daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.
62842192|NCT05461144||Type1diabetes patients|Males and females diagnosed with T1D, aged over 18 years old who are currently under the care of the Warwickshire Institute for the Study of Diabetes, Endocrinolgy and Metabolism (WISDEM) at the University Hospitals Coventry and Warwickshire.
62842193|NCT02637037|EXPERIMENTAL|Treatment A|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
62842194|NCT02637037|ACTIVE_COMPARATOR|Treatment B|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
62842195|NCT02637037|EXPERIMENTAL|Treatment C|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
62842196|NCT02637037|ACTIVE_COMPARATOR|Treatment D|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
62057126|NCT00612534|PLACEBO_COMPARATOR|4|
62057127|NCT00797979|EXPERIMENTAL|1|Skull Grip bone fixation
62057128|NCT00797979|ACTIVE_COMPARATOR|2|Standard skull bon flap fixation, sutures
62057129|NCT01842113|ACTIVE_COMPARATOR|Lactulose and Rifaximin Placebo|Standard portal hypertension care, standard nutritional advice, Lactulose 30ml three times a day and Rifaximin (Xifaxan) Placebo twice a day.
62617043|NCT04853966|EXPERIMENTAL|Counseling group|
62057130|NCT01842113|ACTIVE_COMPARATOR|Rifaximin and Lactulose Placebo|Rifaximin (Xifaxan) twice a day and Lactulose Placebo three times a day.
62057131|NCT02541825|EXPERIMENTAL|the stent of diameter of 7mm|Procedure/Surgery:Jugular vein puncture and catheterization. Device:RUPS-100(COOK Company)sheath ,7mm balloon,Pigtail catheter,the stent of diameter of 7mm (Bard,Fluency) Drug(including placebo):No Biological/Vaccine:No
62260370|NCT01651624|EXPERIMENTAL|Computed tomographic colonography (CTC), standard prep|Subjects invited to undergo CTC with standard bowel preparation
62260371|NCT01651624|ACTIVE_COMPARATOR|Faecal occult blood test (FOBT)|Subjects invited to undergo FOBT
62260372|NCT01651624|EXPERIMENTAL|Colonoscopy|Subjects invited to undergo colonoscopy
62260373|NCT00633906|EXPERIMENTAL|1|HORIZONS HIV Intervention. Two-session, group-based interactive intervention.
62842197|NCT02637037|EXPERIMENTAL|Treatment E|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
62842198|NCT02637037|ACTIVE_COMPARATOR|Treatment F|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
62842199|NCT02637037|EXPERIMENTAL|Treatment G|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
62842200|NCT02637037|ACTIVE_COMPARATOR|Treatment H|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
62842201|NCT01260532||Graves' disease|no intervention
62842202|NCT01260532||Hashimoto's thyroiditis|no intervention
62842203|NCT01260532||Healthy subjects|no intervention
62842204|NCT05711563||Autoimmune Encephalitis (Ireland)|
62842205|NCT05711563||Autoimmune Encephalitis (UK)|
62842206|NCT05711563||Other neurological controls|
62842207|NCT02970942|EXPERIMENTAL|Semaglutide 0,1 mg|
62842208|NCT02970942|EXPERIMENTAL|Semaglutide 0,2 mg|
62842209|NCT02970942|EXPERIMENTAL|Semaglutide 0,4 mg|
62842210|NCT02970942|PLACEBO_COMPARATOR|Placebo 1|
62842211|NCT02970942|PLACEBO_COMPARATOR|Placebo 2|
62842212|NCT02970942|PLACEBO_COMPARATOR|Placebo 3|
62842213|NCT01377337|ACTIVE_COMPARATOR|Sodium bicarbonate|1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR.
62842214|NCT01377337|PLACEBO_COMPARATOR|0.9% NaCl|1 ml/kg of 0.9% NaCl (Blinded label)
62445807|NCT01650324|PLACEBO_COMPARATOR|matching placebo|
62057132|NCT02541825|OTHER|the stent of diameter of 8mm|Procedure/Surgery:Jugular vein puncture and catheterization. Device:RUPS-100(COOK Company)sheath ,8mm balloon,Pigtail catheter,the stent of diameter of 8mm (Bard,Fluency) Drug(including placebo):No Biological/Vaccine:No
62057133|NCT00943306|EXPERIMENTAL|lomitapide|Maximum tolerated dose of lomitapide in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.
62260374|NCT00633906|ACTIVE_COMPARATOR|2|Enhanced standard-of-care session. One hour, video-based and brief discussion.
62842215|NCT04036396|ACTIVE_COMPARATOR|Standard of Care|A client-centered assessment of priorities and needs and customized prevention and testing referrals.
62842216|NCT04036396|EXPERIMENTAL|Mobile Enhanced Prevention Support|Standard of Care in addition to a client-centered assessment of priorities and needs and customized prevention and testing referrals, and the Mobile Enhanced Prevention Support Program
62842217|NCT04442061|ACTIVE_COMPARATOR|Active transcranial magnetic stimulation|excitatory TMS will be applied to the right posterior STS
62842218|NCT04442061|SHAM_COMPARATOR|Sham transcranial magnetic stimulation|The sham TMS follows the same procedure of the active TMS without stimulating cortical tissue
62445808|NCT02696811|PLACEBO_COMPARATOR|Oat biscuits|Participants will eat 3 oat biscuits per day for 6 weeks
62445809|NCT02696811|EXPERIMENTAL|White Carrots|Participants will eat 100g (cooked weight) of white carrots per day for 6 weeks
62057134|NCT04606537|EXPERIMENTAL|Cohort 1 (Effects of CYP3A4 inhibition on KBP-5074)|
62445810|NCT03467334|EXPERIMENTAL|B. breve|Group that will receive B. breve CECT7263 one dose per day in a capsule to open and suspend the powder in infant milk or water.
62057135|NCT04606537|EXPERIMENTAL|Cohort 2 (Effects of CYP3A4 induction on KBP-5074)|
62057136|NCT03760770|EXPERIMENTAL|Riboflavin at 4ºC|patients treated with Riboflavin at 4ºC in crosslinking (cases).
62057137|NCT03760770|EXPERIMENTAL|Riboflavin at room temperature|patients treated with Riboflavin at room temperature in crosslinking (controls)
62057138|NCT01830088|EXPERIMENTAL|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
62260375|NCT02505503|ACTIVE_COMPARATOR|Unloading shoes|The unloading shoe will be a trainer-type shoe with a cosmetically-shaped rocker sole. The sole will have three circular curves whose arc centres are positioned at the anatomical ankle, hip and knee respectively; assuming a vertical lower limb. This is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
62260376|NCT02505503|PLACEBO_COMPARATOR|Unadapted control shoes|The control shoes will be similar in appearance to the unloading shoes, but they will not contain the altered sole.
62260377|NCT04354480|EXPERIMENTAL|RSV Vaccine|Participants will receive a single intramuscular (IM) injection of an adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV) vaccine at a single dose level on Day 1.
62260378|NCT04354480|PLACEBO_COMPARATOR|Placebo|Participants will receive single IM injection in the deltoid muscle of matching placebo on Day 1.
62260379|NCT06275763|EXPERIMENTAL|Eplerenone (+placebo of Spironolactone and placebo of Torasemide)|Phase C. Participants randomly assigned to this arm take Eplerenone and placebos of Spironolactone and Torasemide
62260380|NCT06275763|EXPERIMENTAL|Spironolactone (+placebo of Eplerenone and placebo of Torasemide)|Phase C. Participants randomly assigned to this arm take Spironolactone and placebos of Eplerenone and Torasemide
62445811|NCT03467334|EXPERIMENTAL|B. breve plus L. fermentum|Group that will receive B. breve CECT7263 and L. fermentum CECT5716 in one dose per day in a capsule to open and suspend the powder in infant milk or water.
62445812|NCT03467334|ACTIVE_COMPARATOR|Simethicone 20 mg|Control group that will receive simethicone 4 times (10 drops) a day.
62842219|NCT03725618|EXPERIMENTAL|One-fifth fractional dose|One-fifth fractional dose (0.1 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
62842220|NCT03725618|EXPERIMENTAL|One-half fractional dose|One-half fractional dose (0.25 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
62842221|NCT03725618|EXPERIMENTAL|Full dose|Full dose (0.5 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
62842222|NCT06066632||"Group 1 - Dual Pathology"|"* Age \>65 years~* Severe aortic stenosis at echocardiographic examination~* TAVI o SAVR planned or already undergone TAVI/SAVR~* ECG-gated cardiac CT and echocardiographic examinations available before TAVI/SAVR~* Cardiac uptake at bone tracer scintigraphy with a Perugini score of 2 or 3."
62842223|NCT06066632||"Group 2- Control Group"|"* Age \>65 years~* Severe aortic stenosis at echocardiographic examination~* TAVI o SAVR planned or already undergone TAVI/SAVR~* ECG-gated cardiac CT and echocardiographic examinations available before TAVI/SAVR~* Patients with no cardiac uptake at scintigraphy with bone tracer."
62842224|NCT02344524|EXPERIMENTAL|Small bore chest drain|Intercostal drainage for traumatic hemothorax and pneumothorax using small bore chest drain
62842225|NCT02344524|ACTIVE_COMPARATOR|Large bore chest drain|Intercostal drainage for traumatic hemothorax and pneumothorax using large bore chest drain
62842226|NCT06193226|EXPERIMENTAL|Cryotherapy|"Cryotherapy can be done in two ways:~1. Open technique: Using cotton swabs or a cryogun spray, the cryogen is delivered directly to the lesion in this technique.~2. Closed technique: Cryo-probes are used to apply the cryogen to the lesion in this procedure."
62842227|NCT04187183|EXPERIMENTAL|Fresh PRP with concentrate Leukocyte|"Three infiltrations of fresh Platelet Rich Plasma with concentrated Leukocytes~1 infiltration weekly, for 3 weeks."
62842228|NCT04187183|ACTIVE_COMPARATOR|Fresh PRP without concentrated Leukocyte|"Three infiltrations of fresh Platelet Rich Plasma without concentrated Leukocyte.~1 infiltration weekly, for 3 weeks."
62057139|NCT01830088|ACTIVE_COMPARATOR|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
62057140|NCT02222480|EXPERIMENTAL|Fimasartan 60 mg, Hydrochlorothiazide 12.5 mg|Combination of Fimasartan/Hydrochlorothiazide 60/12.5mg
62057141|NCT02222480|EXPERIMENTAL|Fimasartan 60 mg, Hydrochlorothiazide 25 mg|Combination of Fimasartan/Hydrochlorothiazide 60/25mg
62842229|NCT04579939|EXPERIMENTAL|Experimental|All 10 participants will go through the experimental arm receiving the dextrose candy oral glucose tolerance test.
62842230|NCT01145261||Anxiety|Children with anxiety disorders
62842231|NCT01145261||healthy controls|children without anxiety disorders
62842232|NCT06307197|EXPERIMENTAL|older adults|
62842233|NCT06248723|EXPERIMENTAL|Active intervention arm|"* Physical exercise regime~* Mediterranean diet-based nutritional plan~* Cognitive training~* Regular medical check-ups~* Oral hygiene treatments and counseling~* Counseling on sleep hygiene and treatment~* Control of cardiovascular, metabolic, and infectious risk factors~* Adjustment of drug therapy~* Suggestions for improving social interactions~Physical exercise and cognitive training interventions will be monitored and partially administered through wearable devices and digital tools. Sleep quality will be monitored through wearable devices. Social interactions will be encouraged through a validated app."
62842234|NCT06248723|ACTIVE_COMPARATOR|Self-administered intervention arm|"Subjects in the control group will receive regular health advice in the same domains as the intervention group, via dedicated app and/or access to the dedicated portal on the Age-It website.~In addition, participants randomized to the self-guided intervention will receive an initial 30-60 minute counseling session on all domains covered by the study, in which guidelines for healthy diet, physical and cognitive activity, benefits of social activity, information on cardiovascular risk factors, as well as sleep, oral hygiene will be explained.~Subjects will therefore be treated as per normal clinical practice, albeit with the help of dedicated apps and counseling session."
62057142|NCT02222480|EXPERIMENTAL|Fimasartan 120 mg, Hydrochlorothiazide 12.5 mg|Combination of Fimasartan/Hydrochlorothiazide 120/12.5mg
62057143|NCT02222480|EXPERIMENTAL|Fimasartan 120 mg, Hydrochlorothiazide 25 mg|Combination of Fimasartan/Hydrochlorothiazide 120/25mg
62057144|NCT02222480|PLACEBO_COMPARATOR|Placebo|placebo
62057145|NCT01551602|EXPERIMENTAL|AK159 SD 1|Single administration of AK159 dose level 1
62057146|NCT01551602|EXPERIMENTAL|AK159 SD 2|Single administration of AK159 dose level 2
62057147|NCT01551602|EXPERIMENTAL|AK159 SD 3|Single administration of AK159 dose level 3
62057148|NCT01551602|EXPERIMENTAL|AK159 SD 4|Single administration of AK159 dose level 4
62057149|NCT01551602|ACTIVE_COMPARATOR|MN-10-T SD|Single administration of MN-10-T
62057150|NCT01551602|EXPERIMENTAL|AK159 MD 1|Multiple administration of AK159 dose level 1
62057151|NCT01551602|EXPERIMENTAL|AK159 MD 2|Multiple administration of AK159 dose level 2
62057152|NCT01551602|EXPERIMENTAL|AK159 MD 3|Multiple administration of AK159 dose level 3
62057153|NCT01551602|EXPERIMENTAL|AK159 MD 4|Multiple administration of AK159 dose level 4
62057154|NCT01551602|ACTIVE_COMPARATOR|MN-10-T MD|Multiple administration of MN-10-T
62057155|NCT01551602|PLACEBO_COMPARATOR|Placebo MD|Multiple administration of placebo AK159
62057156|NCT06496191|EXPERIMENTAL|FMT + SMT|Therapy with Fecal microbiota transplantation with SMT (Baclofen + AUD counselling). - Single dose (30gm/90ml) of FMT will be given via upper GI gastroduodenoscope at D4.
62057157|NCT06496191|ACTIVE_COMPARATOR|Placebo + SMT|Placebo therapy with SMT (Baclofen + AUD counselling)
62445813|NCT03517137|EXPERIMENTAL|Treatment|
62057158|NCT04623073||Patients who underwent DAA THA|Patients who underwent DAA THA by a single surgeon who routinely documents the distance from the should of the stem to the upper end of the EO footprint
62057159|NCT06403579|EXPERIMENTAL|virtual reality application|Experimental: virtual reality application virtual reality goggles will be implemented.
62057160|NCT06403579|SHAM_COMPARATOR|control|No Intervention: control group no intervention will be made
62057161|NCT01265901|ACTIVE_COMPARATOR|Sunitinib|Sunitib as Standard therapy per Label.
62057162|NCT01265901|EXPERIMENTAL|IMA901 plus GM-CSF added to sunitinib after single dose of cy|After 1 cycle of sunitinib, intradermal vaccinations with IMA901 plus GM-CSF as adjuvant after a single dose of cyclophosphamide will be applied for a period of 4 months while continuing treatment with sunitinib
62057163|NCT01974037|ACTIVE_COMPARATOR|Capsaicin_effect subgroup 1|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of water with capsaicin.
62057164|NCT01974037|EXPERIMENTAL|Capsaicin_effect subgroup 2|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 100 mmol/L NaCl with capsaicin.
62057165|NCT01974037|EXPERIMENTAL|Capsaicin_effect subgroup 3|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 150 mmol/L NaCl with capsaicin.
62057166|NCT01974037|NO_INTERVENTION|Capsaicin_effect subgroup 4|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 200 mmol/L NaCl.
62057167|NCT01974037|NO_INTERVENTION|Salt_effect subgroup 1|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of water.
62057168|NCT01974037|EXPERIMENTAL|Salt_effect subgroup 2|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 100 mmol/L NaCl.
62057169|NCT01974037|EXPERIMENTAL|Salt_effect subgroup 3|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 150 mmol/L NaCl.
62260381|NCT06275763|EXPERIMENTAL|Torasemide (+placebo of Eplerenone and placebo of Spironolactone )|Phase C. Participants randomly assigned to this arm take Torasemide and placebos of Eplerenone and Spironolactone
62057170|NCT01974037|EXPERIMENTAL|Salt_effect subgroup 4|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 200 mmol/L NaCl.
62057171|NCT01732081||Patients with chronic hepatitis B virus infection|Patients chronically infected with hepatitis B virus (HBV), and followed in university hospital of Strasbourg, France
62057172|NCT01521884||RA Patients treated with SC anti-TNF|
62057173|NCT03299764|EXPERIMENTAL|Intervention|Non-invasive ventilation with pursed lip breathing ventilation device
62057174|NCT03299764|ACTIVE_COMPARATOR|Control|Non-invasive ventilation with standard non-invasive ventilation device
62445814|NCT01709383|ACTIVE_COMPARATOR|Transcranial Direct Current Stimulation|TDCS was applied bilaterally, with the anodal electrode on the left temple and cathodal electrode on the right. TDCS was applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period
62445815|NCT01709383|SHAM_COMPARATOR|Sham Stimulation|Sham tDCS was applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
62617044|NCT04853966|NO_INTERVENTION|Control Group|
62057175|NCT04131790|EXPERIMENTAL|Tele-Behavioral Activation|Manualized Behavioral Activation (BA) protocol delivered via videoconferencing by a trained BA interventionist; 5 sessions over 5 weeks, up to 1-hour in length. The interventionist guides participants in learning BA skills, focusing on strategies to decrease barriers to social connectedness (e.g., limited mobility, inadequate caregiving resources).
62057176|NCT04131790|ACTIVE_COMPARATOR|Tele-Friendly Visiting|Friendly Visitor (FV) calls delivered via videoconferencing by a trained FV interventionist; 5 sessions over 5 weeks, up to 1-hour in length. The interventionist provides social support to participants through good listening and provision of genuine regard.
62057177|NCT02323646|PLACEBO_COMPARATOR|Placebo|Following the baseline assessment no treatment period, matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
62057178|NCT02323646|EXPERIMENTAL|Telapristone Acetate 6 mg|Following the baseline assessment no treatment period, telapristone acetate 6 milligrams (mg), vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
62057179|NCT02323646|EXPERIMENTAL|Telapristone Acetate 12 mg|Following the baseline assessment no treatment period, telapristone acetate 12mg, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
62057180|NCT04288635||Septic shock admitted in Angers' ICU|Patients aged more than 18, admitted in University Hospital of Angers, who meet the full criteria of septic shock
62617045|NCT04500678|EXPERIMENTAL|Metformin|Metformin 500 mg Extended Release (ER) qd increasing to 1000 mg ER qd at week 4 and continued to week 48.
62842235|NCT05397158|EXPERIMENTAL|Single administration of low dose polyethylene glycol group|The patients take 30ml lactulose in the morning 1 day before the examination, and eat without residue in lunch and dinner; Take 2L PEG in the morning of the examination day and fast at breakfast and lunch of the day.
62842236|NCT05397158|ACTIVE_COMPARATOR|control group|The patients in control group take 2L PEG the day before the examination, fast at dinner (patients without diabetes) and eat without residue (patients with diabetes). Patients take 2L PEG again in the morning of the examination day, and fasted at breakfast and lunch of the day.
62842237|NCT05762068||Airway management experts|The Steering Committee selected Experts from across the globe based on pre-defined criteria and will conduct iterative Delphi rounds to generate consensus among the experts.
62842238|NCT01497288|EXPERIMENTAL|Sequence 1 (A-B-C)|"* A: single dose of 200 μg INFS (100 μL) (Instanyl®), administered on Day 1~* B: single dose of 400 μg INFS (100 μL), administered 4 hours after the first treatment~* C: two single doses of 400 μg INFS (100 μL) (10 min apart), administered 24 hours after the first treatment (Day 2)"
62842239|NCT01497288|EXPERIMENTAL|Sequence 2 (A-C-B)|"* A: single dose of 200 μg INFS (100 μL) (Instanyl®), administered on Day 1~* C: two single doses of 400 μg INFS (100 μL) (10 min apart), administered 4 hours after the first treatment~* B: single dose of 400 μg INFS (100 μL), administered 24 hours after the first treatment (Day 2)"
62057181|NCT04363099||outpatients COVID 19 positive|
62057182|NCT05319106|EXPERIMENTAL|Stem cell preparation combined with silver ion dressing|
62057183|NCT05319106|PLACEBO_COMPARATOR|silver ion dressing|
62260382|NCT06275763|ACTIVE_COMPARATOR|Open-label|Phase B Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC) based on optimally combined antihypertensive drugs: perindopril + indapamide + amlodipine (P+I+A) or olmesartan + hydrocholothiazide + amlodipine (O+H+A).
62260383|NCT06275763|OTHER|Screening|Phase A. Confirmation of the true ineffectiveness of antihypertensive therapy based on 3 or more antihypertensive drugs (single or dual drug preparations) using ABPM and home BP measurements.
62617046|NCT04500678|NO_INTERVENTION|Observation|Observed without metformin
62842240|NCT03346694|ACTIVE_COMPARATOR|Dressing 1: Standard Island Dressing|Standard dressing that is applied on most patients with a sternotomy wound incision immediately after cardiovascular surgery before leaving the operating room. Dressing will be removed 48 hours after surgery.
62057184|NCT03021668|EXPERIMENTAL|Prevena Peel & Place Dressing for wound closure|In the participants randomized to this arm the surgical site will be closed using Prevena Peel \& Place Dressing.
62617047|NCT02105519|NO_INTERVENTION|The group receiving no influenza vaccine|Participants in this group will not receive any influenza vaccine (negative control group).
62617048|NCT02105519|EXPERIMENTAL|One dose of AdimFlu-S group|Participants in this group will receive one dose of the seasonal trivalent influenza vaccine (one dose of AdimFlu-S group), formulation 2013-2014, at the initiation of the study. Each administered dose contain 15 ug virus antigen for each virus strain.
62617049|NCT02105519|EXPERIMENTAL|Two dose of AdimFlu-S group|Participants in this group (Two dose of AdimFlu-S group)will receive the seasonal trivalent influenza vaccine, formulation 2013-2014, at the week 0 and 4 weeks after the initiation of the study. Each administered dose contain 15 ug virus antigen for each virus strain.
62057185|NCT03021668|PLACEBO_COMPARATOR|Standard closure of the wound|In the participants randomized to this arm the surgical site will be closed using the standard closure technique.
62057186|NCT05742243|ACTIVE_COMPARATOR|Abatacept and nasal insulin|Abatacept (CTLA4-Ig; 50 mg for participant weight \<25 kg, 87.5 mg for participant weight 25-50 kg, 125 mg for participant weight \>50 kg) will be injected subcutaneously once per week and nasal insulin (Humulin R®, 100 Units/mL) will be inhaled for 10 consecutive days initially and twice per week thereafter, for 48-weeks.
62617050|NCT01838772|OTHER|Pegylated-Interferon and Ribavirin|"Pegylated-interferon 1.5 microgr/kg, subcutaneously, once weekly for 48 weeks\*. Ribavirin, weight-based dosage, divided in two daily doses for 48 weeks\*.~\*patients with genotype 2 and 3, moderate liver fibrosis, and rapid virologic response will receive therapy for 24 weeks."
62057187|NCT05742243|PLACEBO_COMPARATOR|Abatacept and nasal placebo|Abatacept (CTLA4-Ig; 50 mg for participant weight \<25 kg, 87.5 mg for participant weight 25-50 kg, 125 mg for participant weight \>50 kg) will be injected subcutaneously once per week and nasal placebo (0.9% sodium chloride) will be inhaled for 10 consecutive days initially and twice per week thereafter, for 48-weeks.
62260384|NCT01863940|EXPERIMENTAL|Wound catheter|Wound catheters will be placed subcutaneously in the skin graft donor site in the lateral thigh while the patient remain intra-operative. The patients will receive a continuous infusion of procaine 0.5% at 4-5mL/hr using an elastomeric infusion device for 48 hours. Patients will be asked to asses pain on a 0-10 scale immediately prior to dressing changes, during dressing changes and 1 hour post dressing changes.
62260385|NCT01863940|NO_INTERVENTION|Control|Patients will receive the standard of care pain medication regimen of Analgin/Metamizole 1 g IM and Ketorolac 3%- 30 mg IM for post-operative pain treatment. The patients will be asked to rate pain on a scale of 0-10 immediately prior to dressing changes, during dressing changes and 1 hour after dressing changes.
62445816|NCT02130466|EXPERIMENTAL|Part 1:pembrolizumab 2 mg/kg+dabrafenib150 mg+trametinib 2 mg|Participants with BRAF mutant melanoma received 2 mg/kg pembrolizumab administered by intravenous (IV) infusion on Days 1 and 22 of each 6-week cycle (Q6W); 150 mg/day total dabrafenib orally, in a divided dose, twice a day (BID) starting on Day 1 and continuing up until study treatment discontinuation; and 2 mg trametinib orally once a day (QD) starting on Day 1 and continuing up until study treatment discontinuation.
62617051|NCT04100590|EXPERIMENTAL|Active Cannabis|In this session, the participant will smoke two-thirds of one active cannabis cigarette (7% THC) according to our paced-puff procedure (Foltin et al. 1987). They will complete an eye task battery (5 minutes per battery) 15 minutes prior to smoking as a baseline measure in each session, and again at the following timepoints: 0, 15, 30, 45, 60, 75, 90, 105, 120, and 165 minutes post-cannabis. Baseline assessments will be compared to those at post-cannabis timepoints.
62617052|NCT04100590|PLACEBO_COMPARATOR|Placebo Cannabis|In this session, the participant will smoke two-thirds of one inactive placebo cannabis cigarette (0% THC) according to our paced-puff procedure (Foltin et al. 1987). They will complete an eye task battery (5 minutes per battery) 15 minutes prior to smoking as a baseline measure in each session, and again at the following timepoints: 0, 15, 30, 45, 60, 75, 90, 105, 120, and 165 minutes post-cannabis. Baseline assessments will be compared to those at post-cannabis timepoints.
62057188|NCT04591990|EXPERIMENTAL|AVP + placebo hydrocortisone|REVERPLEG® 40 IU/2mL+ Placebo of hydrocortisone.
62057189|NCT04591990|EXPERIMENTAL|placebo AVP + hydrocortisone|Placebo of REVERPLEG® 40 IU/2mL + Hydrocortisone 100mg UPJOHN®.
62057190|NCT04591990|EXPERIMENTAL|AVP + hydrocortisone|REVERPLEG® 40 IU/2mL + Hydrocortisone 100mg UPJOHN®.
62057191|NCT04591990|EXPERIMENTAL|placebo AVP + placebo hydrocortisone|Placebo of REVERPLEG® 40 IU/2mL + placebo of hydrocortisone
62057192|NCT01124721|EXPERIMENTAL|Cogmed cognitive training|Computerized working memory, attention and cognitive tasks
62057193|NCT01124721|ACTIVE_COMPARATOR|Active placebo|Cognitive training, however the training does not increase in difficulty, or does so to a minimal degree.
62057194|NCT03823222|EXPERIMENTAL|Duckweed protein|20 gram of isolated protein
62057195|NCT03823222|EXPERIMENTAL|Whey protein|20 gram of isolated protein
62057196|NCT01370681|EXPERIMENTAL|Group1|
62057197|NCT01370681|EXPERIMENTAL|Group2|
62260386|NCT00840086|EXPERIMENTAL|rFVIII|
62260387|NCT02718742|EXPERIMENTAL|Treatment (nab-paclitaxel)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62260388|NCT03129087|EXPERIMENTAL|Vocal activity|The vocal activity arm will require the participant to remain in the clinic and read aloud continuously for a period of one hour after a botulinum toxin injection
62260389|NCT03129087|EXPERIMENTAL|Vocal rest|The vocal rest arm will require the participant to remain in the clinic and remain on complete vocal rest for a period of one hour after a botulinum toxin injection
62260390|NCT06254911|EXPERIMENTAL|Treatment (Atezolizumab)|Patients receive atezolizumab IV while on study. Patients undergo CT scan and MRI throughout the study. Patients may undergo tumor biopsy while on study.
62260391|NCT02097615|EXPERIMENTAL|chlorhexidine gluconate|application every 24 hours, six weeks
62260392|NCT02097615|OTHER|Other: deionized water|application every 24 hours, six weeks
62057198|NCT02020239|EXPERIMENTAL|Prescribed exercise|Participants will be asked to choose one activity and stick to it for the duration of the intervention. Participants will be able to choose between brisk walking/slow jogging or cycling. The intervention will require the completion of 30 minutes of chosen activity on 5 days of the week, which will be recorded in a physical activity diary.
62057199|NCT02020239|EXPERIMENTAL|Points-based physical activity|Participants will be asked to achieve a pre-set, individualised points target for physical activity each week. Points are acquired through the completion of a minimum 10 minutes of activity, choosing from the extensive list of activities provided; for example, 10 minutes of jogging achieves 4.5 points, whereas 10 minutes of washing a car achieves 1.5 points. The target will be 35-40 points per week, which equates to approximately 6 points per day. Any combination of activity, duration and frequency can be selected.
62617053|NCT03479138||Neutrophilic asthma|Patients 18 to 80 years old diagnosed of severe asthma, requiring treatment at least with long acting beta agonists (LABA) + high doses inhaled corticosteroids (ICS) with eosinophil count in blood\<300/mm3. They must be ex-smokers with less than 10 packs-year and no other relevant pulmonary disease.
62057200|NCT02020239|NO_INTERVENTION|Waiting list control|Participants will be asked to maintain their normal activities and diet. They will be added to a waiting list to receive either exercise intervention after completing the 24-week trial period, so that they do not miss out on the opportunity to receive the exercise intervention.
62057201|NCT02699502|EXPERIMENTAL|patients with osteoporotic hip fractures|The intervention includes matching an appropriate drug to patients with hip fractures. All the relevant parameters regarding the patients with osteoporotic hip fractures will be reviewed (age, kidney function, previous treatment) and an appropriate anti osteoporosis medication will be determined. A recommendation regarding treatment will be sent to the local regulatory authorities, which will send the approved recommendation the the family physician.
62057202|NCT05719948|ACTIVE_COMPARATOR|Flouroscopic guidance cervical medial branch continous RF ablation|"After the patient lying prone we obtaining the posterior approach with PA view then lateral 15 degrees the C shaped edge of the cervical vertebrae were appeared and then we advance the needle till reaching this C shaped till hitting the bone then slipping the active tip slightly therafter we obtaining lateral view to determine the depth of the needle over the cervical pedicle.~patients in the continous radiofrequency group will be underwent continous radiofrequency at 80°C for 90 seconds for 2 cycles"
62057203|NCT05719948|ACTIVE_COMPARATOR|Flouroscopic guidance cervical medial branch combined pulsed and continous RF ablation|"After the patient lying prone we obtaining the posterior approach with PA view then lateral 15 degrees the C shaped edge of the cervical vertebrae were appeared and then we advance the needle till reaching this C shaped till hitting the bone then slipping the active tip slightly therafter we obtaining lateral view to determine the depth of the needle over the cervical pedicle.~patients in the continous and pulsed group will be underwent continous and pulsed radiofrequency at 80°C for 90 seconds for 1 cycle followed by pulsed radiofrequency at 42°C for 120 seconds for 1 cycle"
62057204|NCT06445790|EXPERIMENTAL|Group A|It will receive 12 sessions of Cognitive Behavior Therapy for Chronic Pelvic Pain.
62057205|NCT06445790|NO_INTERVENTION|Group B|Group B will be control group.
62057206|NCT05395988|NO_INTERVENTION|Control group|The control group receives no screen next to the sink.
62445817|NCT02130466|EXPERIMENTAL|Part 1:pembrolizumab 2 mg/kg+trametinib 2 mg|Participants with BRAF wild-type melanoma received 2 mg/kg pembrolizumab administered by IV infusion on Days 1 and 22 Q6W and 2 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
62445818|NCT02130466|EXPERIMENTAL|Part 1:pembrolizumab 2 mg/kg+trametinib 1.5 mg|Participants with BRAF wild-type melanoma received 2 mg/kg pembrolizumab administered by IV infusion on Days 1 and 22 Q6W and 1.5 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
62445819|NCT02130466|EXPERIMENTAL|Part 2:pembrolizumab 2 mg/kg+dabrafenib 150 mg+trametinib 2 mg|Participants with BRAF mutant melanoma received 2 mg/kg pembrolizumab administered by IV infusion on Days 1 and 22 Q6W; 150 mg/day total dabrafenib orally, in a divided dose, BID starting on Day 1 and continuing up until study treatment discontinuation; and 2 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
62623710|NCT00178646|EXPERIMENTAL|1 - Low Volume, High Dose|Botox (onabotulinumtoxinA), 150 units prepared as 100 units per 1 ml of preservative-free normal saline
62842241|NCT03346694|ACTIVE_COMPARATOR|Dressing 2: Prevena negative pressure|Prevena negative pressure wound suction machine dressing applied to sternotomy wound incision immediately after cardiovascular surgery. Dressing will be in use for 7 days or removed sooner if participant is discharged before end of 7 day post-operative time period.
62842242|NCT03346694|ACTIVE_COMPARATOR|Dressing 3: Mepilex Border Post-Op Ag|Mepilex Border PostOp AG dressing impregnated with silver ions. Dressing will be in use for 7 days or removed earlier if patient is discharged before end of 7 days post0operative time period.
62842243|NCT00630123||1|Electroconvulsive Therapy (ECT): blood sample taken from this group at start and after therapy; subjects not randomized to therapy option.
62842244|NCT00630123||2|Transcranial Magnetic Stimulation (TMS): blood sample taken from this group at start and after therapy; subjects not randomized to therapy option.
62842245|NCT01794286|ACTIVE_COMPARATOR|Control Group|Trigger alerts only
62260393|NCT03300999|EXPERIMENTAL|Ginger Tea|"* End of the second menstruation cycle - Start of the third menstruation cycle: Subjects will take ginger tea daily, avoid home remedies, refrain from taking pain medications and supplements, and keep track of ginger tea intake by placing a check mark each day in the daily log checklist.~* Start of the third menstruation cycle - End of the third menstruation cycle: Subjects will drink ginger tea daily. Subjects will rate discomfort using the visual analog pain scales and the symptom checklist at the end of each day during menstruation.~* After the third menstruation cycle ends: Subjects will meet with student investigators at a location convenient to the subject to turn in daily logs, visual analog pain scales, and symptom checklists."
62260394|NCT03300999|NO_INTERVENTION|No Ginger Tea|"* End of the first menstruation cycle - Start of the second menstruation cycle: Subjects will not take ginger tea, avoid home remedies, and refrain from taking pain medications or supplements.~* Start of the second menstruation cycle - End of the second menstruation cycle: Subjects will rate discomfort using the visual analog pain scales and symptom checklist during menstruation. Subjects will meet with student investigators at a convenient location to the subject and will complete surveys and questionnaires. Subjects will be given daily logs, visual analog pain scales, symptom checklists, and supplies for the ginger tea."
62260395|NCT02346032|EXPERIMENTAL|refametinib|refametinib medication
62445820|NCT02130466|EXPERIMENTAL|Part 2:pembrolizumab 2 mg/kg+trametinib 1.5 mg|Participants with BRAF wild-type melanoma received 2 mg/kg pembrolizumab administered by IV infusion on Days 1 and 22 Q6W and 1.5 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
62445821|NCT02130466|EXPERIMENTAL|Part 3:pembrolizumab 2 mg/kg+dabrafenib 150 mg+trametinib 2 mg|Participants with BRAF mutant melanoma received 2 mg/kg pembrolizumab administered by IV infusion on Days 1 and 22 Q6W; 150 mg/day total dabrafenib orally, in a divided dose, BID starting on Day 1 and continuing up until study treatment discontinuation; and 2 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
62445822|NCT02130466|PLACEBO_COMPARATOR|Part 3:placebo+dabrafenib 150 mg+trametinib 2 mg|Participants with BRAF mutant melanoma received saline placebo administered by IV infusion on Days 1 and 22 Q6W; 150 mg/day total dabrafenib orally, in a divided dose, BID starting on Day 1 and continuing up until study treatment discontinuation; and 2 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
62445823|NCT02130466|EXPERIMENTAL|Part 4:trametinib 2 mg for 4 weeks+pembrolizumab 200 mg+trametinib 2 mg concurrent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 2 mg trametinib orally QD for 4 weeks. Starting with Week 5, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 of each 3-week cycle (Q3W) and a concurrent dosing schedule of 2 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
62445824|NCT02130466|EXPERIMENTAL|Part 4:trametinib 1.5 mg for 2 weeks+pembrolizumab 200 mg+trametinib 1.5 mg concurrent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 1.5 mg trametinib orally QD for 2 weeks. Starting with Week 3, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and a concurrent dosing schedule of 1.5 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
62445825|NCT02130466|EXPERIMENTAL|Part 4:trametinib 1.5 mg for 4 weeks+pembrolizumab 200 mg+trametinib 1.5 mg concurrent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 1.5 mg trametinib orally QD for 4 weeks. Starting with Week 5, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and a concurrent dosing schedule of 1.5 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
62445826|NCT02130466|EXPERIMENTAL|Part 4:trametinib 2 mg for 2 weeks+pembrolizumab 200 mg+trametinib 2 mg intermittent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 2 mg trametinib orally QD for 2 weeks. Starting with Week 3, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and an intermittent dose schedule of 2 mg trametinib orally QD with 1 week OFF trametinib and 2 weeks ON trametinib continuing up until study treatment discontinuation.
62445827|NCT02130466|EXPERIMENTAL|Part 4:trametinib 1.5 mg for 2 weeks+pembrolizumab 200 mg+trametinib 1.5 mg intermittent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 1.5 mg trametinib orally QD for 2 weeks. Starting with Week 3, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and an intermittent dose schedule of 1.5 mg trametinib orally QD with 1 week OFF trametinib and 2 weeks ON trametinib continuing up until study treatment discontinuation.
62445828|NCT02130466|EXPERIMENTAL|Part 5:trametinib 1.5 mg for 2 weeks+pembrolizumab 200 mg+trametinib 1.5 mg concurrent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 1.5 mg trametinib orally QD for 2 weeks. Starting with Week 3, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and a concurrent dosing schedule of 1.5 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
62445829|NCT02130466|EXPERIMENTAL|Part 5:trametinib 2 mg for 2 weeks+pembrolizumab 200 mg+trametinib 2 mg intermittent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 2 mg trametinib orally QD for 2 weeks. Starting with Week 3, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and an intermittent dose schedule of 2 mg trametinib orally QD with 1 week OFF trametinib and 2 weeks ON trametinib continuing up until study treatment discontinuation.
62445830|NCT02003040||St. Michael's Hospital Patients|Patients admitted to the Cardiology ward at St Michael's Hospital with a main diagnosis of acute decompensated heart failure
62445831|NCT00582036|ACTIVE_COMPARATOR|Arm 1|Regular Sliding Scale Insulin administration for hyperglycemia
62445832|NCT00582036|EXPERIMENTAL|Arm 2|MiniMed Paradigm monitoring device for hyperglycemia
62057207|NCT05395988|EXPERIMENTAL|Instruction group|The reward group receives a screen next to each sink in kindergarten. On the screen, hand washing instructions are shown during hand washing. After a defined time period, the screen is removed.
62842246|NCT01794286|EXPERIMENTAL|Intervention Group|Trigger alerts + provider bulletins
62842247|NCT02720731||children|aged from 1 to 18 years with motor disorder
62842248|NCT02720731||adults|aged from 18 to 80 years with motor disorder
62842249|NCT06205368|OTHER|Combine app with all features except the ability to order self-test kits|Participants will receive a modified standard of care which consists of the Combine app with all features except the ability to order self-test kits. The HIV/STI testing locator in the app will be available.
62057208|NCT05395988|EXPERIMENTAL|Reward group|"The reward group receives a screen next to each sink in kindergarten. On the screen, hand washing instructions are shown during hand washing. If hands are washed correctly (time and soap usage), a reward (animal animation) is shown on the screen.~After a defined time period, the screen is removed."
62057209|NCT05395988|EXPERIMENTAL|Reward plus instruction-only group|"The reward plus instruction group receives a screen next to each sink in kindergarten.~On the screen, hand washing instructions are shown during hand washing. If hands are washed correctly (time and soap usage), a reward (animal animation) is shown on the screen.~After a defined time period, the screen only shows instructions, the reward is not shown anymore.~After a defined time period, the screen is removed."
62842250|NCT06205368|OTHER|Combine app + motivational interview|In addition to the other Combine app features, participants will receive a motivational interview within 4 weeks of downloading the app.
62057210|NCT00714376|EXPERIMENTAL|Docetaxel|Docetaxel (Taxotere) 75 mg/m² IV every 3 weeks for 8 cycles.
62057211|NCT01007864|EXPERIMENTAL|piribedil|
62057212|NCT01007864|ACTIVE_COMPARATOR|pramipexole or ropinirole|
62057213|NCT02736825|ACTIVE_COMPARATOR|Group A, Ulthera System with standard transducers|"Subjects randomized to Group A will receive an Ultherapy® treatment to the lower face and neck with a total minimum pulse count of 672 pulses (+5%) at the 4.5mm and 3.0mm depths using standard transducers. Energy levels for each transducer will be set to EL2:~* Deep-See (DS) 4-4.5 at 0.9 Joules (J) with pitch of 1.5mm and 17 Thermal Coagulation Points (TCP)s per line~* DS 7-3.0 at 0.30J with pitch of 1.1mm and 23 TCPs per line"
62057214|NCT02736825|EXPERIMENTAL|Group B, Ulthera System with prototype 2 simulines transducers|"Subjects randomized to Group B will receive a Ultherapy® treatment with a total minimum pulse count of 336 pulses (+5%) using the prototype 2 simulines transducers at the 4.5mm and 3.0mm depths. Energy levels for each transducer will be set to EL2:~* Deep-See 4-4.5 Simulines (DS 4-4.5S) at 1.23J with pitch of 1.5mm and 17 TCPs per line~* DS 4-3.0S at 0.88J with pitch of 1.3mm and 20 TCPs per line"
62260396|NCT00079404|EXPERIMENTAL|Arm I|Patients with solid tumors receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 60-120 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
62260397|NCT00637520||1|Subjects with NAFLD
62842251|NCT06205368|OTHER|Combine app + ability to order up 2 free HIV/STI self-test kits|In addition to the other Combine app features, participants in this arm will be able to order up to two HIV/STI self-test kits at no charge during each year of follow-up.
62842252|NCT06205368|OTHER|Combine app + motivational interview + ability to order HIV/STI test kits via the app|In addition to the other Combine app features, participants in this arm will receive both the motivational interview and the ability to order HIV/STI test kits via the app.
62842253|NCT02499757|EXPERIMENTAL|flavor and sweetener|E-cigarette with a novel flavor and sweetener added
62842254|NCT02499757|EXPERIMENTAL|flavor and nicotine|E-cigarette with a novel flavor and 12 mg nicotine added
62842255|NCT02499757|EXPERIMENTAL|flavor, nicotine and sweetener|E-cigarette with a novel flavor, sweetener, and 12 mg nicotine added
62842256|NCT02499757|EXPERIMENTAL|flavor|E-cigarette with a novel flavor: without a sweetener and 12 mg nicotine added
62842257|NCT00245752|ACTIVE_COMPARATOR|A|in points bilaterally inBL 67, LI 4, SP6, one in GV20.
62842258|NCT00245752|SHAM_COMPARATOR|2|sham acupuncture
62842259|NCT00981058|EXPERIMENTAL|Necitumumab + Gemcitabine + Cisplatin|
62842260|NCT00981058|ACTIVE_COMPARATOR|Gemcitabine + Cisplatin|
62260398|NCT00637520||2|Subjects without liver disease
62260399|NCT00637520||3|Subjects with non-steatotic hepatitis
62260400|NCT03450005||emerging Candida isolates|Web-based registry of invasive infections by Candida species
62842261|NCT03965390|NO_INTERVENTION|Classical care pathway|"Patients are following classical care pathway. Before brain surgery patients will be included after oral, medical and life quality evaluation.~After randomization in the control group, patients will be evaluated at 6 and 12months after surgery, during classical follow up visits."
62842262|NCT03965390|EXPERIMENTAL|Oral education|"Patients are following classical care pathway but combined at each visit with an oral education Before brain surgery patients will be included after oral, medical and life quality evaluation.~After randomization in the experimental group, patients will be evaluated at 6 and 12 months after surgery, during classical follow up visits. At each timepoint an oral education will be realized in parallel."
62260401|NCT04702776|EXPERIMENTAL|Arm 1; Humylub Ofteno® PF|Humylub Ofteno® PF (sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) ophthalmic solution applied QID for 30 days.
62260402|NCT04702776|ACTIVE_COMPARATOR|Arm 2; Hyabak®|Hyabak® PF (sodium hyaluronate 0.15%) ophthalmic solution applied QID for 30 days.
62057215|NCT02462954|EXPERIMENTAL|ContraGel|ContraGel, a personal lubricant has a Conformite Europeenne (CE) mark and has been used with barrier devices in Europe and other countries outside the US, but it is not currently approved by the US FDA.
62057216|NCT02462954|PLACEBO_COMPARATOR|HEC Placebo|The placebo gel is supplied by CONRAD in pre-filled individual applicators, each applicator containing 4.0 mL of HEC gel. Placebo gel contains HEC as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide.
62057217|NCT05654792||NOP-LBBB|Patients with new-onset persistent left bundle branch block after transcatheter aortic valve implantation
62260403|NCT04702776|ACTIVE_COMPARATOR|Arm 3; Lagricel Ofteno® PF|Lagricel Ofteno® PF (sodium hyaluronate 0.4%) ophthalmic solution applied QID for 30 days.
62260404|NCT04244656|EXPERIMENTAL|CTX120|Administered by IV infusion following lymphodepleting chemotherapy.
62842263|NCT00518089|EXPERIMENTAL|Gatifloxacin 0.5% Eye Drops|Gatifloxacin 0.5% Eye Drops
62842264|NCT00518089|PLACEBO_COMPARATOR|Placebo Eye Drops|Placebo Eye Drops
62260405|NCT05479253|EXPERIMENTAL|with Artificial intelligence assistant system|Endoscopists would complete the endoscopy report with the assistance of the artificial intelligence system.
62842265|NCT01572285|SHAM_COMPARATOR|Sham|Sham arm received a simulation of transforaminal injection using a non-penetrating needle
62842266|NCT01572285|EXPERIMENTAL|Transforaminal|Subjects received TF with infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml
62260406|NCT05479253|NO_INTERVENTION|without Artificial intelligence assistant system|Endoscopists would complete the endoscopy report without special prompts.
62260407|NCT00728975||1|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Vancouver Centre,
62260408|NCT00728975||2|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Centre for Southern Interior
62260409|NCT00728975||3|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Fraser Valley Centre
62260410|NCT00728975||4|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Vancouver Island Centre
62842267|NCT06262126|OTHER|VR Arm|Viritual Reality therapy arm. All patients will receive virtual reality therapy.
62842268|NCT06297811|EXPERIMENTAL|Trilaciclib group|
62057218|NCT02498353|EXPERIMENTAL|study group|"Preoperative short-course radiotherapy with local boost ,the dose of radiotherapy is PTV-CTV 25Gy/5F with local boost of PTV-GTV 30Gy/5F.~TME surgery after radiotherapy."
62057219|NCT02498353|ACTIVE_COMPARATOR|control group|"Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F without local boost.~TME surgery after radiotherapy."
62057220|NCT03074214||STEMI patients receiving PCI|patients with STEMI receiving percutaneous coronary intervention
62057221|NCT05662384||Patients hospitalized with small bowel obstruction|Patients hospitalized with a certain diagnosis during a certain period of time
62057222|NCT06509451|ACTIVE_COMPARATOR|Giomer pit and fissure sealant without etching|In the control group, an adequate amount of primer is applied onto the enamel surface with a microbrush, left undisturbed for 5 s and then air-dried gently to avoid blowing it away. Beautisealant is applied directly from the syringe into pits and fissures and light-cured for 10 s, according to the manufacturer's instructions.
62057223|NCT06509451|EXPERIMENTAL|Giomer pit and fissure sealant with etching|In the intervention group, the same steps are done except for an additional initial etching step with phosphoric acid etching for 30 s (for the uncut enamel) before primer and sealant application.
62057224|NCT02136433|EXPERIMENTAL|Tablet - self exercise|"Existing tablet Apps that encourage finger movement in a fun manner while playing a game will be used. The apps will be taught to the participants and then they will be requested to exercise alone (or with family) everyday for one hour in addition to their regular rehabilitation sessions (Occupational, Physical Therapy, speech).~The intervention will include 15-20 sessions of 60 minutes of self-training using a tablet."
62260411|NCT00728975||5|Vancouver Coastal Cottage Hospice inpatients
62617054|NCT03479138||Non neutrophilic asthma|Patients 18 to 80 years old diagnosed of severe asthma, requiring treatment at least with LABA+ high doses ICS, with eosinophil count in blood\<300/mm3. They must be ex-smokers with less than 10 packs-year and no other relevant pulmonary disease.
62260412|NCT00728975||6|Vancouver Coastal Richmond Palliative Care Program patients
62260413|NCT00728975||7|Vancouver Coastal Lions Gate Palliative Care Unit inpatients
62260414|NCT00728975||8|Providence Health St Paul's Hospital Palliative Care Unit inpatients
62260415|NCT00728975||9|Providence Health Marion Hospice inpatients
62260416|NCT00728975||10|Vancouver Island Health Authority Victoria Hospice inpatients
62260417|NCT00728975||11|Fraser Health Burnaby Hospital Tertiary Palliative Care Unit inpatients
62260418|NCT00728975||12|Fraser Health Mission Hospice inpatients
62260419|NCT00728975||13|Fraser Health Langley Hospice inpatients
62260420|NCT03234387||Cystic fibrosis (CF) with established CF-related diabetes|"Cystic fibrosis (CF) with established CF-related diabetes~Inclusion criteria:~* Males and females ≥ 12 years of age~* CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride \> 60 mmol·L-1 \> 100 mg sweat) and, where possible, diagnostic genotyping~* Established CFRD in accordance with the most recent American Diabetes Association positional statement\]. This statement recommends CFRD is diagnosed using a 2 hour OGTT. However, the present study will also include those based on fasting plasma glucose and glycated hemoglobin levels, when symptoms of diabetes are also present:~  * 2 hour OGTT plasma glucose ≥ 200 mg.dL-1 (11.1 mmol.L-1)~ * Fasting plasma glucose ≥ 126 mg.dL-1 (7.0 mmol.L-1)~ * Glycated hemoglobin ≥ 48 mmol/mol~* No contraindications to performing exhaustive exercise~* Can understand and cooperate with the study protocol~* No increase in symptoms or weight loss in the preceding 2 weeks"
62617055|NCT02017652||Preterm Infants|Preterm infants 32 to 36 weeks will be eligible for this study
62842269|NCT06297811|ACTIVE_COMPARATOR|Control group|
62842270|NCT02578303|EXPERIMENTAL|Dementia group|"Assessed by the insertion of an interaction parameter between cerebral blood flow and the group label(dementia or no-dementia).~ROC method will be used to find a threshold value of IAH that separates the two groups.~Interventions:~* Vascular flow measurement by PC-MRI~* Neuropsychological assessment~* Registration of sleep apnea~* Registration of blood pressure~* ECG holters~* Blood test~* Geriatric standard evaluation"
62617056|NCT00651144|EXPERIMENTAL|Ezetimibe + Rosuvastatin|
62842271|NCT02578303|OTHER|control group|"Assessed by the insertion of an interaction parameter between cerebral blood flow and the group label(dementia or no-dementia).~ROC method will be used to find a threshold value of IAH that separates the two groups.~Interventions:~* Vascular flow measurement by PC-MRI~* Neuropsychological assessment~* Registration of sleep apnea~* Registration of blood pressure~* ECG holters~* Blood test~* Geriatric standard evaluation"
62842272|NCT02382380|EXPERIMENTAL|Gadoterate|Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
62842273|NCT02382380|OTHER|No Gadoterate|Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. MRI protocols utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
62842274|NCT02608671|NO_INTERVENTION|Continuous skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
62057225|NCT02136433|ACTIVE_COMPARATOR|GRASP self exercise|"GRASP (Graded Repetitive Arm Supplementary Program)(Harris et al., 2009)is an arm and hand exercise program developed for individuals with stroke with upper extremity impairments GRASP provides a method for patients to undertake a self-directed arm and hand exercise program.~The exercises will be taught to the participants and then they will be requested to exercise alone (or with family) everyday for one hour in addition to their regular rehabilitation sessions (Occupational, Physical Therapy, speech).~The intervention will include 15-20 sessions of 60 minutes of self-training"
62617057|NCT00651144|ACTIVE_COMPARATOR|Ezetimibe|
62617058|NCT00651144|ACTIVE_COMPARATOR|Rosuvastatin|
62842275|NCT02608671|EXPERIMENTAL|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
62617059|NCT00651144|PLACEBO_COMPARATOR|Placebo|
62617060|NCT03917979|EXPERIMENTAL|Individual GIM|Participants are provided with a series of individual GIM sessions.
62617061|NCT03917979|OTHER|Waitlist Control|Participants complete an initial wait list period, then are provided with a series of Group GIM sessions.
62617062|NCT04618809|EXPERIMENTAL|Provider Didactic Intervention|"* Phase 1 - Providers complete a needs assessment questionnaire, which evaluates the approach to older mGC patients at each site.~* Phase 2 - Providers participate in an hour-long didactic session and begin enrolling eligible metastatic gastric cancer (mGC) patients. Enrolled mGC patients complete a comprehensive geriatric assessment (CGA). Providers complete the treatment plan and review of geriatric assessment questionnaires, which also includes an evaluation of their overall view of the utility of the geriatric assessment.~* Phase 3 - Follow-up chart reviews (2-3 months post intervention) are completed to assess for actual implementation of recommended interventions identified by the geriatric assessment."
62617063|NCT04607681|EXPERIMENTAL|1 GROUP|"Patients who agree to participate in the study will be informed about the study and their written and verbal consent will be obtained. At this stage, which will last 6 weeks for each patient;~* On the first day, the patients will be evaluated first by filling the Individual Descriptive Features Form, Information Need Determination Question Form, COPD and Asthma Fatigue Scale, Medication Compliance Notification Scale, Asthma Control Test (ACT), Form for evaluation of the skills of using inhalation devices,~* In order for the patients in the intervention group to use the web-based asthma education program, a web-based asthma education program will be introduced by giving their username and password.~After 6 weeks of training, second data will be collected on the web in the intervention group."
62623711|NCT00178646|ACTIVE_COMPARATOR|2 - High Volume, High Dose|Botox (onabotulinumtoxinA), 150 units prepared as 50 units per 1 ml of preservative-free normal saline
62623712|NCT00178646|OTHER|3 - High Volume, Low Dose|Botox (onabotulinumtoxinA), 75 units prepared as 25 units per 1 ml of preservative-free normal saline
62057226|NCT04182854|EXPERIMENTAL|diuretics|
62057227|NCT06135311|EXPERIMENTAL|Pulse Width 260us|electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 260us, intensity setting to patient's tolerance, duration 30 days
62260421|NCT03234387||Cystic fibrosis (CF) without established CF-related diabetes|"Cystic fibrosis (CF) without established CF-related diabetes~Inclusion criteria:~* Males and females ≥ 12 years of age~* CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride \> 60 mmol·L-1 \> 100 mg sweat), where possible, diagnostic genotyping would also be desired~* No evidence of established, gestational or exacerbation induced CFRD in accordance with the American Diabetes Association criteria (stated above; \[110\]).~* No contraindications to performing exhaustive exercise~* Can understand and cooperate with the study protocol~* No increase in symptoms or weight loss in the preceding 2 weeks"
62260422|NCT03234387||Healthy controls|Age- and gender-matched healthy control participants.
62260423|NCT00490451|EXPERIMENTAL|LY573636|
62260424|NCT06201897|OTHER|Treatment Arm|Children receiving ACTH therapy for West Syndrome
62260425|NCT03426371|EXPERIMENTAL|Experimental|All eligible subjects will receive KL-140 in combination with mFOLFOX-6 chemotherapy regimen.
62260426|NCT03426371|PLACEBO_COMPARATOR|Placebo Comparator|All eligible subjects will receive Placebo in combination with mFOLFOX-6 chemotherapy regimen.
62260427|NCT04186494|ACTIVE_COMPARATOR|Continuous positive airway pressure (CPAP)|Standard CPAP Therapy
62260428|NCT04186494|EXPERIMENTAL|Liraglutide-based weight loss regimen|Once daily s.c. injections of Liraglutide, starting at a dose of 0.6 mg with weekly 0.6 mg increments to 3.0 mg in adjunct to advice on a weight-reduction diet and physical exercise
62260429|NCT04186494|EXPERIMENTAL|Combination CPAP/Liraglutide|Combination of both interventions
62260430|NCT01467843|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Participants randomized to the CBT intervention will attend eight weekly 2 hour sessions.
62260431|NCT01467843|ACTIVE_COMPARATOR|Mindfulness-Based Stress Reduction|Participants randomized to the MBSR arm will attend eight weekly 2 hour MBSR sessions.
62260432|NCT01467843|NO_INTERVENTION|Usual Care|Participants randomized to Usual Care will continue to receive care for their low back pain as prescribed by his/her Primary Care Physician.
62623713|NCT01770808|EXPERIMENTAL|AquaCal|AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg).
62623714|NCT01770808|EXPERIMENTAL|AquaPT|AquaPT are produced by Marigot Ltd. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract.
62623715|NCT01770808|PLACEBO_COMPARATOR|Placebo|Produced by Marigot Ltd
62842276|NCT03304938|ACTIVE_COMPARATOR|Lavender oil|
62842277|NCT03304938|PLACEBO_COMPARATOR|vehicle (Almond oil)|
62842278|NCT04947085|ACTIVE_COMPARATOR|IV SDK|intravenous ketamine administration in sub-dissociative doses (SDK) administered at 0.3 mg/kg over 15 minutes to patients presenting to the ED of Maimonides Medical Center with acute and chronic painful conditions.
62842279|NCT04947085|ACTIVE_COMPARATOR|K-BAN|nebulized ketamine at 0.75mg/kg administered via BAN to patients presenting to the ED of Maimonides Medical Center with acute and chronic painful conditions.
62842280|NCT01146795|EXPERIMENTAL|Carboplatin, Paclitaxel, and Bevacizumab|"Three 21 day cycles of carboplatin, paclitaxel, and bevacizumab.~After 3 cycles of chemotherapy patients will be considered for surgical cytoreduction. Patients must fulfill all criteria to be considered eligible for surgical exploration: 1) ≥50% reduction in pretreatment cancer antigen 125 (CA-125) and 2) No medical contraindications to surgery.~After surgical cytoreduction all patients will receive an additional 6 cycles of chemotherapy (cycles 4-9) regardless of disease status at the time of exploration. Chemotherapy should be re-instituted within 6 weeks of the surgical procedure. Bevacizumab will be omitted from cycle 4 of chemotherapy. Patients who do NOT undergo surgical resection should receive cycles 4-9 of therapy. In this instance bevacizumab may be included in cycle 4."
62842281|NCT02925299|EXPERIMENTAL|24/7 closed loop insulin delivery|The study system includes (1) a CGM that measures glucose levels, (2) a computer program on a smartphone that determines how much insulin is needed, and (3) an insulin pump that delivers the insulin. The name of this closed-loop system used in the US is FlorenceM (Medtronic 640G pump and Guardian3 sensor). The name of this closed-loop system in the UK is FlorenceX (DANA pump and Dexcom sensor). Half of the individuals taking part in the study will use the closed-loop study system for 6 months.
62842282|NCT02925299|ACTIVE_COMPARATOR|Insulin pump therapy|Half of the Subjects will continue using their own insulin pump for 6 months.
62842283|NCT05968729|ACTIVE_COMPARATOR|0.25 m/s asymmetric session first|Participants will perform three 15-minute sessions of walking with a 0.25 m/s asymmetric walking gait speed difference where one limb is set at 1.0 m/s and the other limb is set at 1.25 m/s. Each of these sessions will be followed by 5-minute de-adaptation sessions where they will perform a symmetric walking trial at 1.0 m/s.
62842284|NCT05968729|ACTIVE_COMPARATOR|0.50 m/s asymmetric walking session first|Participants will perform three 15-minute sessions of walking with a 0.50 m/s asymmetric walking gait speed difference where one limb is set at 1.0 m/s and the other limb is set at 1.5 m/s. Each of these sessions will be followed by 5-minute de-adaptation sessions where they will perform a symmetric walking trial at 1.0 m/s.
62842285|NCT00409734||Children with pyloric stenosis|Male or female children age two to nine weeks with history of vomiting and feeding intolerance, and abdominal sonogram showing presence of pyloric stenosis
62842286|NCT00409734||Children without pyloric stenosis|Male or female children age two to nine weeks without pyloric stenosis admitted to the hospital for other reasons
62842287|NCT02988895|EXPERIMENTAL|episcleral brachytherapy|single fraction of 24 Gy Strontium90 episcleral brachytherapy
62842288|NCT01744080|ACTIVE_COMPARATOR|Early Surgery|
62057228|NCT06135311|EXPERIMENTAL|Pulse Width 50us|electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 50us, intensity setting to patient's tolerance, duration 30 days
62057229|NCT00215540|EXPERIMENTAL|SURFAXIN High Dose|SURFAXIN (lucinactant) at 175 mg/kg
62260433|NCT05800184||Individuals with a shoulder injury|Individuals from a population based sample of 600 individuals aged 40 to 75 years that sustain a shoulder injury or a sudden onset of significant shoulder symptoms.
62842289|NCT01744080|EXPERIMENTAL|Regular Wait Time|
62842290|NCT02188888||Tachycardic patients|Patients will receive a continuous esmolol infusion to maintain heart rate between 94 and 80 bpm. Norepinephrine will be titrated to achieve a MAP between 65 and 75 mmHg.
62057230|NCT00215540|EXPERIMENTAL|SURFAXIN Low Dose|SURFAXIN (lucinactant) at 90 mg/kg
62057231|NCT00215540|PLACEBO_COMPARATOR|Placebo|Sham air using 3.0 mL/kg volume of air
62057232|NCT01817374|OTHER|2D US grayscale plus quantitative VCEUS|"Patients with breast cancer receiving neoadjuvant chemotherapy will undergo a 2D grayscale imaging followed by quantitative VCEUS imaging:~1. prior to initiation of treatment (baseline);~2. at 14 (± 4 days) after initiation of neoadjuvant chemotherapy (early treatment);~3. at 28 days (± 4 days) after initiation of neoadjuvant chemotherapy (inter-regimen);~4. at completion of therapy prior to definitive surgery (usually 2-3 months after initiation of treatment). Each patient will undergo a total of four VCEUS examinations."
62057233|NCT03745222|EXPERIMENTAL|Arm 1:Tislelizumab + cCRT followed by tislelizumab monotherapy|Tislelizumab 200 mg is administered by intravenous (IV) administration and given together upfront with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by tislelizumab 200 mg by IV adminstration monotherapy. The standard platinum-based chemotherapy options include carboplatin/ paclitaxel and cisplatin/etoposide
62057234|NCT03745222|EXPERIMENTAL|Arm 2: Placebo + cCRT followed by tislelizumab monotherapy|Placebo is given with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by tislelizumab 200 mg by IV administration monotherapy. The standard platinum-based chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide.
62057235|NCT03745222|PLACEBO_COMPARATOR|Arm 3: Placebo + cCRT followed by placebo monotherapy|Placebo is given with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by placebo monotherapy. The standard platinum-based chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide.
62057236|NCT03883516|PLACEBO_COMPARATOR|No pre-briefing prior to the simulation training|No pre-briefing prior to the simulation training
62057237|NCT03883516|ACTIVE_COMPARATOR|Pre-briefing with the current SE treatment guidelines|pre-briefing with the current SE treatment Guidelines published by the American Epilepsy Society
62842291|NCT05773170||Pharmacological cardioversion with Refralon|"1. Refralon® 0.1% solution administration at a dose of 10 μg/kg of body weight intravenously (IV) for 2-3 minutes; It is allowed to divide the first Refralon® bolus into two consecutive injections: the first dose administration - 5 μg/kg of body weight, if the AF/AFL persists, administer the second dose - 5 μg/kg of body weight (total dose 10 μg/kg) in 15 minutes.~2. If no effect is registered (no sinus rhythm restoration), repeat IV administration of Refralon® 0.1% solution at a dose of 10 μg/kg of body weight (total dose: 20 μg/kg of body weight) in 15 minutes;~3. If no effect is registered, repeat IV administration of Refralon® 0.1% solution at a dose of 10 μg/kg of body weight (total dose: 30 μg/kg of body weight) in 15 minutes.~In case of AF/AFL recurrence after the sinus rhythm restoration (with no contraindications), it is possible to re-administer Refralon®, while the maximum total drug daily dose (from the first administration) should not exceed 30 μg/kg of body weight."
62842292|NCT02590224|ACTIVE_COMPARATOR|Ferrous bis-glycinate group|The patients will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets (Pharaferro 27 tablets) once daily for eight consecutive weeks.
62623716|NCT01790802|EXPERIMENTAL|Active laser|Twelve 2RT nanosecond laser shots in two arcs of 6 shots superiorly and 6 shots inferiorly, inside the retinal vascular arcades at an approximate distance from the fovea of 3000 microns, with approximately one laser spot diameter between them.
62842293|NCT02590224|ACTIVE_COMPARATOR|Ferrous glycine sulphate group|The patients will receive 567.6 mg of ferrous glycine sulphate capsules (Ferrosanol duodenale capsules, Schwarz) once daily for eight consecutive weeks.
62057238|NCT03883516|ACTIVE_COMPARATOR|pre- briefing with consolidated SE treatment guideline|"pre-briefing with the consolidated one page SE treatment guideline"
62057239|NCT05301504|EXPERIMENTAL|Group 1|n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 5×10\^9 vp
62260434|NCT06290375|EXPERIMENTAL|HSK21542 tablet 2mg|
62842294|NCT04199130|EXPERIMENTAL|Intervention Group 1|This arm will receive BrainHQ for the first four weeks of the study, and Goal Management Training for the second four weeks.
62842295|NCT04199130|EXPERIMENTAL|Intervention Group 2|This arm will receive Goal Management Training for the first four weeks of the study, and BrainHQ for the second four weeks.
62057240|NCT05301504|EXPERIMENTAL|Group 2|"n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 2.5×10\^10 vp~Note: The DSMB may recommend increasing the size of group 2 to n=9 in the event of higher than expected reactogenicity"
62057241|NCT05301504|EXPERIMENTAL|Group 3|n=11 participants vaccinated with a single dose of ChAdOx1 biEBOV 5×10\^10 vp
62057242|NCT05301504|EXPERIMENTAL|Group 4|"n=25 participants vaccinated with a two doses of ChAdOx1 biEBOV at the final selected dose, based on safety data for groups1-3. The second dose is administered after 12 weeks.~Note:The dose for group 4 will be selected following a review of safety data to 28 days post vaccination for all previous participants (groups 1 to 3"
62057243|NCT05011643||Symptomatic statin users|Statin users with self-reported muscle symptoms
62057244|NCT05011643||Asymptomatic statin users|Statin users without muscle symptoms
62057245|NCT05011643||Non-statin using controls|Participants not using statins
62057246|NCT03737786|ACTIVE_COMPARATOR|GA with mild hypercarbia (GAH)|Controlled ventilation with target end-tidal CO2 levels 50 (±5%)
62057247|NCT03737786|ACTIVE_COMPARATOR|GA with normocarbia (GAN)|Controlled ventilation with target end-tidal CO2 levels 40 (±5%)
62057248|NCT04931641|EXPERIMENTAL|50 mg oral iron as ferrous fumarate (FeFum) with 7.5 g galacto-oligosaccharides|
62057249|NCT04931641|PLACEBO_COMPARATOR|50 mg oral iron as ferrous fumarate (FeFum) with 7.5 g maltodextrin|
62057250|NCT01768208|EXPERIMENTAL|Saxagliptin|
62260435|NCT06290375|EXPERIMENTAL|Placebo|
62617064|NCT04607681|NO_INTERVENTION|2 GROUP|"Written and verbal consents will be obtained from patients who agree to participate in the study by providing information about the study.~At this stage, which will take 6 weeks for each patient; On the first day, the patients will first be evaluated by filling the Individual Descriptive Characteristics Form, Information Requirement Determination Question Form, COPD and Asthma Fatigue Scale, Medication Compliance Notification Scale, Asthma Control Test (ACT), Form for evaluation of the skills of using inhalation devices, Second data after 6 weeks will be collected in the control group via Google form or phone call"
62842296|NCT04199130|NO_INTERVENTION|Treatment-as-usual|
62842297|NCT05648032|EXPERIMENTAL|PLT (lyophilized platelet) with steroid|PLT (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide, once
62842298|NCT05648032|EXPERIMENTAL|PLT (lyophilized platelet)|PLT (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL normal saline, once
62842299|NCT05648032|ACTIVE_COMPARATOR|Steroid|1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide, once
62057251|NCT01250535|EXPERIMENTAL|Warfarin plus lovastatin|Warfarin plus lovastatin
62057252|NCT01250535|PLACEBO_COMPARATOR|Warfarin plus placebo|Warfarin plus placebo
62057253|NCT00312702|EXPERIMENTAL|10µg dose FMP011|Falciparum Malaria Protein 11 with AS02A adjuvant
62057254|NCT00312702|EXPERIMENTAL|50µg dose FMP011|Falciparum Malaria Protein 11 with AS02A adjuvant
62842300|NCT03534180|EXPERIMENTAL|Treatment (venetoclax, romidepsin)|Patients receive venetoclax PO QD on days 1-28 and romidepsin IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
62057255|NCT02959086||1|Patients were diagnosed since January 2002.
62842301|NCT04673396|EXPERIMENTAL|Tolerance test|The design is based on 3+3 dose escalation: three subjects were enrolled in each dose group, administered once a day for 2 weeks, and were observed for 7 days after withdrawal. If dose-limiting toxicity (DLT) was not observed, the dose was incresed to the next dose group. If dose-limiting toxicity (DLT) was found in 2 or more patients in a given dose group, the climbing test was terminated and the dose was reduced by 1 dose. If there were only three subjects, three more subjects were observed, so that the MTD dose group had at least six evaluable subjects.If DLT occurs in 1 patient in a given dose group, 3 more subjects should be added to that dose group. If DLT occurs in 1 or more of these 3 subjects, the climb will be stopped and the dose group will be reduced by 1 dose group. If there are only 3 subjects, 3 more subjects will be observed, so that at least 6 patients in the MTD dose group can be evaluated.
62260436|NCT04423874|EXPERIMENTAL|Healthy adult population aged 18 to 60 years.|Their pain tolerance will be tested using the Cold Pressor Task while listening to vocalisations. Physiological measures will be taken using two techniques: Nociception Level Index and video pupillometry.
62617065|NCT03287011|ACTIVE_COMPARATOR|Control tooth paste|controlled fluoridated toothpaste will be provided for brushing to both the groups initially
62057256|NCT02361125|EXPERIMENTAL|Methylphenidate|"Participants given a 7 day supply of 5 mg methylphenidate tablets (to take a maximum of 20 mg/day, for total of 28 tablets). Directions for use are to take one 5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue (maximum of 4 tablets/day).~Evaluation of fatigue, ability to sleep, and general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment."
62057257|NCT01424475|OTHER|PKD Patients|PKD Patients with LRRK2 mutation
62057258|NCT01424475|OTHER|Healthy Controls|Healthy Controls with no LRRK2 mutation
62057259|NCT06084559|SHAM_COMPARATOR|Placebo (ambient hypoxic air at 2840m)|Ambient hypoxic air at 2840 m will be applied via a facial mask with reservoir
62057260|NCT06084559|EXPERIMENTAL|SOT (high flow supplemental oxygen therapy)|SOT (supplemental oxygen therapy) at a flow of 10 l/min will be applied via a facial mask with reservoir
62057261|NCT03364855|ACTIVE_COMPARATOR|SEBT exercise group|Star Excursion Balance Test will be used
62057262|NCT03364855|ACTIVE_COMPARATOR|KAT 2000 exercise group|Kinesthetic ability trainer will be used
62057263|NCT03364855|ACTIVE_COMPARATOR|combined exercise group|Both star Excursion Balance Test exercise and Kinesthetic ability trainer will be used.
62057264|NCT01586559||Control group|Nulliparous women
62057265|NCT01586559||Diastasis|Patients after rectus sheath plication due to diastasis
62057266|NCT05517200||Normal Control|These participants are normal control in good mental and psychiatric health.
62260437|NCT01737476|SHAM_COMPARATOR|control|control-sham
62057267|NCT05517200||Migraine|These participants have migraines according to ICHD-3 criteria.
62057268|NCT00409695|EXPERIMENTAL|High Dose Thymoglobulin (ATG)|High Dose Thymoglobulin (ATG): 1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
62057269|NCT00409695|EXPERIMENTAL|Low Dose Thymoglobulin (ATG)|Low Dose Thymoglobulin (ATG): 2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
62057270|NCT00881881||1|Patients with early RA
62057271|NCT05673408||Subject Group 1|Neonates, Infant, Children \<3 years of age
62057272|NCT05673408||Subject Group 2|Children 3-12 years of age
62057273|NCT05673408||Subject Group 3|Adolescent/Adult \>12 years of age
62057274|NCT04332510|EXPERIMENTAL|Infant milk 1|
62057275|NCT04332510|EXPERIMENTAL|Infant milk 2|
62057276|NCT04332510|EXPERIMENTAL|Infant milk 3|
62057277|NCT04332510|EXPERIMENTAL|Infant milk 4|
62057278|NCT05490264|EXPERIMENTAL|[68Ga]Ga-NOTA-SNA002|A dose of 1mCi-5mCi of \[68Ga\]Ga-NOTA-SNA002 between 0.1mg to 0.9mg will be administered intravenously over 5minutes in Day 1 of subject enrollment
62057279|NCT03143114|EXPERIMENTAL|Myomectomy|Women will be subjected to laparotomy to remove the myomas
62617066|NCT03287011|EXPERIMENTAL|Shoplaque tooth paste|Fluoridated toothpaste with organic plaque disclosing dye will be given to the test group second visit
62842302|NCT04673396|EXPERIMENTAL|Pharmacokinetic studies|At the same time of tolerance test, blood PK sampling was performed. At the end of the tolerance test in each group, on the premise of good safety, and after evaluation by the researchers, additional cases were selected from the three dose groups (low, medium and high) for pharmacokinetic study, so as to ensure that at least 8 patients could be evaluated for PK in each group.
62842303|NCT04673396|ACTIVE_COMPARATOR|Comparative Study|It is planned to select the 20mg dose of norcantharidin sodium for injection to carry out pharmacokinetic study of 8 cases. The specific research design will be formulated after the tolerance and pharmacokinetic test of norcantharidin lipid microsphere injection is completed.
62057280|NCT03143114|NO_INTERVENTION|Conservative management|Women will not be subjected to surgery (conservative management)
62057281|NCT06458920|EXPERIMENTAL|Social regulation|Participants will regulate emotion with the help of a friend
62617067|NCT05454852||Participants|Adult patients within 6 months of ART initiation or re-initiation
62842304|NCT02765581|EXPERIMENTAL|Verum acupuncture (VA)|Participants will be treated by verum acupuncture and usual care. They will be treated every other day to fulfill a 10-session treatment course, and another course will begin after resting 9 days. Each acupuncture treatment session for patients will be 30 minutes in duration.
62842305|NCT02765581|SHAM_COMPARATOR|Sham acupuncture (SA)|Participants will be treated by sham acupuncture and usual care. They will be treated every other day to fulfill a 10-session treatment course, and another course will begin after resting 9 days. Each acupuncture treatment session for patients will be 30 minutes in duration.
62842306|NCT02765581|PLACEBO_COMPARATOR|Usual care (UA)|Participants will undergo a clinical interview once a month, complete the headache diary assessment, have counseling and health education, and rescue medication if necessary. In addition, they will be scheduled to receive 20 sessions of verum acupuncture treatments for free after a waiting period of 24 weeks.
62842307|NCT01594216|EXPERIMENTAL|First Stage|Ruxolitinib at 25 mg orally, twice daily and Exemestane, 25 mg orally once daily
62260438|NCT01737476|ACTIVE_COMPARATOR|Deep TMS PFC Lt|Deep TMS PFC left
62617068|NCT02420483|EXPERIMENTAL|Patients|Cardiopulmonary resuscitation with measurement of tidal volume, airway pressure and flow by a pneumotachograph and airway, oesophageal pressure sensors
62617069|NCT06024707||Asthma patients|All asthma patients will be observed and receive their regular treatment
62617070|NCT00719394|EXPERIMENTAL|GSI 136|
62617071|NCT00719394|PLACEBO_COMPARATOR|placebo|
62617072|NCT00530790|EXPERIMENTAL|ropinirole CR-RLS|"Subjects will orally take ropinirole CR-RLS tablet(s) once daily 1-2 hours before the onset of RLS symptoms at about the same time of the day. The time of taking ropinirole must be after 16:00.Adjustment of the Ropinirole CR-RLS tablets should be completed after the Week 1 visit up to the Week 10 visit. The dose will be increased at intervals of at least one week until sufficient efficacy is obtained (use much improved as a guide) without safety problem. Dose escalation will start at the initial dose 0.5 mg/day to 1 mg/day; after 1 mg/day, the dose will be increased by 1 mg/day to the maximum 6 mg/day."
62057282|NCT06458920|EXPERIMENTAL|Cognitive regulation|Participants will regulate emotion on their own
62057283|NCT01673763|ACTIVE_COMPARATOR|Stent|Stent insertion into the main pancreatic duct
62057284|NCT01673763|NO_INTERVENTION|No stent|No stent insertion into the main pancreatic duct
62057285|NCT01518946|ACTIVE_COMPARATOR|Midodrine HCl|
62057286|NCT01518946|PLACEBO_COMPARATOR|Placebo|
62057287|NCT05518383|EXPERIMENTAL|R1: stage I and II|R1: resection status: complete, stage I and II
62057288|NCT05518383|EXPERIMENTAL|R2: incomplete, stage I and II|R2: resection status: incomplete, stage I and II
62057289|NCT05518383|EXPERIMENTAL|R3: incomplete, stage III and LDH < 2 x ULN|R3: resection status: incomplete, stage III and LDH \< 2 x ULN
62057290|NCT05518383|EXPERIMENTAL|R4: stage III and LDH ≥ 2 x ULN, stage IV/B-AL and CNS negative; CNS +|R4: resection status: incomplete, stage III and LDH ≥ 2 x ULN, stage IV/B-AL and CNS negative; CNS +
62057291|NCT06437197|ACTIVE_COMPARATOR|Hydraulic Calcium Silicate Cement|Pulpotomy of adult teeth using Hydraulic Calcium Silicate Cement.
62057292|NCT06437197|EXPERIMENTAL|platelet rich fibrin (PRF)|Pulpotomy of adult teeth using platelet Rich fibrin.
62057293|NCT01269905||Group A|Group A patients received mechanical heart valve replacement MHVR (and were educated in INR self-management using the Coagu-Check monitor.
62057294|NCT01269905||Group B|Group B patients received MHVR and their anticoagulation was managed by their general practitioners.
62057295|NCT01269905||Group C|Group C patients received stentless bioprosthesis, with initial 6 weeks on oral anticoagulation managed by their general practitioners.
62057296|NCT03269994|ACTIVE_COMPARATOR|Cefoxitin|
62260439|NCT01737476|ACTIVE_COMPARATOR|DEEP TMS PFC Rt|DEEP TMS PFC Rt
62260440|NCT01737476|ACTIVE_COMPARATOR|Superficial TMS PFC Lt|Superficial TMS PFC Lt
62260441|NCT01737476|ACTIVE_COMPARATOR|superficial TMS PFC Rt|superficial TMS PFC Rt
62617073|NCT00772187|EXPERIMENTAL|1|General anesthesia + I.V pca
62617074|NCT00772187|EXPERIMENTAL|2|General anesthesia + spinal analgesia + I.V pca
62617075|NCT04053244|EXPERIMENTAL|treatment|all participants will be assigned to the treatment, consisting of therapist-assisted iCBT.
62617076|NCT01410240|ACTIVE_COMPARATOR|Standard of Care (SoC)|SoC: conventional hemostatic techniques such as cautery and manual compression
62842308|NCT01594216|EXPERIMENTAL|Second Stage|Ruxolitinib at 15 mg orally, twice daily and Exemestane, 25 mg orally once daily
62842309|NCT03612752|EXPERIMENTAL|Active arm|CMI-168
62842310|NCT03612752|PLACEBO_COMPARATOR|Placebo arm|Placebo
62842311|NCT03160235|EXPERIMENTAL|Development of MRI protocols|MRI exam to grade differents interventions for future research
62842312|NCT03160235|EXPERIMENTAL|Development of EEG protocols|EEF exam to grade differents interventions for future research
62842313|NCT03160235|EXPERIMENTAL|Development of NIRS protocols|NIRS exam to grade differents interventions for future research
62842314|NCT03746158|EXPERIMENTAL|Curcumin|subjects will be assigned to consume one capsule of curcumin (330 mg of curcumin per capsule) three times a day (one capsule with each meal).
62842315|NCT01266187|EXPERIMENTAL|Arm B|"12 weeks FOLFOX + cetuximab -\> 4 weeks rest -\> surgery~-\> 4-8 weeks rest -\> 12 weeks FOLFOX + cetuximab"
62842316|NCT01266187|ACTIVE_COMPARATOR|Arm A|surgery -\> 4-8 weeks rest -\> 24 weeks FOLFOX + cetuximab
62842317|NCT05252091|EXPERIMENTAL|herombopag olamine tablets|
62842318|NCT01277380||Experimental Group|
62842319|NCT01277380||Control Group|
62842320|NCT01277380||Negative control group|
62057297|NCT03269994|EXPERIMENTAL|Piperacillin-tazobactam|
62057298|NCT05300971|EXPERIMENTAL|Heat therapy|Hot water immersion \~3x per week for 12 weeks
62842321|NCT04112381|EXPERIMENTAL|Exablate Secondary Procedure|Thalamotomy
62842322|NCT01855061||Irinotecan|"Patients will be subjected to a their metastatic solid tumor. Radiological response will be evaluated after each 2 cycles: 1. percentage change in radiological volume of the index lesion (radiological measurable lesion that underwent biopsy) after the first two cycles of irinotecan; 2. radiological response according to RECIST 1.1 after each 2 cycles. Patients are intended to receive irinotecan until progressive disease or unacceptable toxicity. Patients will be subjected to another biopsy of the index lesion at definitive discontinuation of irinotecan. Patients will also be subjected to blood draws for determining patient's genetic background variation.~Side studies include:~* pharmacogenetics~* pharmacokinetics of SN-38~* carboxylesterase activity in the index lesion~* midazolam clearance test (only in Rotterdam patients)"
62842323|NCT01988285||Dysphagia and GERD controls|"The cross-sectional arm will consist of patients who are having a clinically indicated endoscopy for reflux and/or dysphagia.~Cross-sectional participants will have specimens collected and complete a questionnaire."
62842324|NCT01988285||Prospective Longitudinal EoE Cases|"The prospective longitudinal group will be subjects who have a positive EoE diagnosis during initial endoscopy. This prospective group will be followed up at their clinically indicated endoscopy after their standard of care clinical therapy of swallowed steroids.~Prospective longitudinal participants will have specimens collected and complete questionnaires s prior to their standard of care clinical therapy of swallowed steroids and at their clinically indicated follow up upper endoscopy."
62842325|NCT04066231|EXPERIMENTAL|VIPUN GMS|Single arm study.
62842326|NCT02053376|EXPERIMENTAL|regorafenib|Patients with advanced and metastatic biliary tract adenocarcinoma (cholangiocarcinoma) who had been treated with and failed first-line chemotherapy will be treated with regorafenib (120 mg) (160 mg for second and subsequent treatment cycles) orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle
62842327|NCT04761224|NO_INTERVENTION|control group|heated blanket + unheated NaCL instillation (operating room ambient temperature: around 17°C).
62842328|NCT04761224|EXPERIMENTAL|Heated group|heating blanket + instillation of NaCl at 38-39°C by Fluido® Irrigation fluid heating system
62842329|NCT02721472|OTHER|sickle cell disease patients|Sickle cell disease patients included in the study and Plasma DNA levels will be analyzed and compared in patients with a reactive hyperaemia index (RHI) \< 1.67 (endothelial dysfunction) assessed by Endo-PAT 2000 versus those recorded in patients with a RHI ≥ 1.67 (no endothelial dysfunction).
62842330|NCT00842751|PLACEBO_COMPARATOR|Testosterone Undecanoate + placebo finasteride|Acyline 300mcg/kg subcutaneous on days 1, 15 and 29 + Testosterone Undecanoate (TU)200mg twice daily, orally for 7 days + placebo finasteride twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)
62842331|NCT00842751|EXPERIMENTAL|Testosterone Undecanoate + Finasteride 0.5mg|Acyline 300mcg/kg subcutaneous on days 1, 15 \& 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 0.5mg twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)
62057299|NCT05300971|SHAM_COMPARATOR|Thermoneutral water immersion|Thermoneutral water immersion \~3x per week for 12 weeks
62057300|NCT05703984|EXPERIMENTAL|GC2129A + Reference drugs|Period 1: GC2129A Period 2: Individual Components
62057301|NCT05703984|EXPERIMENTAL|Reference drugs + GC2129A|Period 1: Individual Components Period 2: GC2129A
62842332|NCT00842751|EXPERIMENTAL|Testosterone Undecanoate + Finasteride 1mg|Acyline 300mcg/kg subcutaneous on days 1, 15 \& 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 1mg twice daily, orally for 7 days during one of the three intervention periods ((First Intervention, Second Intervention or Third Intervention)
62842333|NCT05291715|EXPERIMENTAL|group 1, test group|This group will receive ozone therapy after harvesting of the free gingival graft from the palatal donor site.
62842334|NCT05291715|NO_INTERVENTION|group 2, control group|Following harvesting of the free gingival graft, the palatal donor site ozone application will be simulated without starting of the ozone generator and the covered ( protected) by a periodontal pack.
62842335|NCT03101332|EXPERIMENTAL|VR-CBT|Virtual Reality cognitive behavior therapy. 10-12 sessions of individual Cognitive Behavior Therapy with exposure tasks carried out through Virtual Reality.
62057302|NCT05937425|EXPERIMENTAL|Intervention group|Effects of nurse navigation program on patients with lung cancer
62057303|NCT05937425|NO_INTERVENTION|Control group|An information note will be given to the control group.
62617077|NCT01410240|EXPERIMENTAL|FLOSEAL + Standard of Care (SoC)|"FLOSEAL: consists of bovine-derived gelatin granules and a human plasma-derived thrombin component.~SoC: conventional hemostatic techniques such as cautery and manual compression"
62842336|NCT05306756|ACTIVE_COMPARATOR|Fetal Blood Sampling (FBS)|"Fetal capillary blood samples will be collected in heparinised tubes and analysed in the delivery suite using the locally available gas analyser. The result of the first technically reliable sample, or the lowest reliable sample if multiple samples are tested, will be interpreted and acted upon according to the protocol, taking account of the clinical circumstances and the stage of labour:~pH ≥7.25 normal, continue and if indicated repeat in 60 minutes; pH 7.21-7.24 borderline, repeat in 30 minutes; pH ≤ 7.20 abnormal, deliver."
62842337|NCT05306756|ACTIVE_COMPARATOR|digital Fetal Scalp Stimulation (dFSS)|"The examiner will stimulate the fetal scalp digitally with the index and middle finger over a period of 30-60 seconds.The CTG will be observed over a 5-10 minutes interval after the dFSS and if a fetal heart rate acceleration (\>15 bpm for 15 seconds) is observed the test will be considered normal. If there is an episode of normal variability (5-25 bpm) but there is no clear acceleration, the test will be considered borderline. If there is no FHR acceleration and no episode of normal variability with ongoing abnormal features, the test should be interpreted as abnormal in the same way as an abnormal FBS result.~FHR acceleration normal, if indicated repeat in 60 min; Uncertain acceleration/ normal variability borderline, repeat in 30 minutes; No Acceleration/ongoing abnormal features abnormal, deliver."
62057304|NCT02904616|EXPERIMENTAL|Healthy volunteers|"Healthy volunteers wash their hands with a traditional soap. Every healthy volunteers pose with palm of hand three times on the device in order to measure basal level of fluorescence of the skin.~Healthy volunteers repeated three times this procedure in order to assess the reproducibility of the measurement."
62057305|NCT02573480|EXPERIMENTAL|Wraparound Care|Wraparound care initiated in the ED at the time of injury and continuing for approximately 1 year in the community.
62057306|NCT06186206|EXPERIMENTAL|Social Media Messaging Only|In this arm of the clinical trial, four selected communities will receive a culturally tailored social media campaign designed to increase childhood routine and HPV vaccine confidence and uptake. The campaign will be deployed via Facebook and will geographically target these communities. This arm serves as the first intervention group.
62842338|NCT05353504|ACTIVE_COMPARATOR|prebiotic dietary supplement|high-dose daily inulin
62842339|NCT05353504|EXPERIMENTAL|behavioural lifestyle intervention|new educational program to change eating behaviour, provided through weekly sessions.
62842340|NCT05353504|PLACEBO_COMPARATOR|placebo dietary supplement|equicaloric daily maltodextrin
62057307|NCT06186206|EXPERIMENTAL|Social Media and Health Worker WhatsApp|In this arm, another set of four communities will receive both the culturally tailored social media campaign (deployed via Facebook) and WhatsApp-based vaccine training for community healthcare workers. This arm serves as the second intervention group.
62617078|NCT04879836||Teething Ring + Teething Gel|
62842341|NCT00583895|ACTIVE_COMPARATOR|1|Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
62842342|NCT00583895|PLACEBO_COMPARATOR|2|Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
62617079|NCT04879836||Teething Ring|
62617080|NCT00671047||1|SLE subjects with flares in the last 12 months in specific organ systems.
62617081|NCT04622072|EXPERIMENTAL|Experimental group|For dose escalation phase, subjects are enrolled for different doses of the experimental drug.
62617082|NCT01043133|EXPERIMENTAL|Intervention group|
62617083|NCT01043133|NO_INTERVENTION|Control Group|
62260442|NCT00929175|ACTIVE_COMPARATOR|active CPAP|auto-PAP with therapeutic pressure
62260443|NCT00929175|SHAM_COMPARATOR|sham-CPAP|auto-PAP with pressure less than 1cm H2O
62617084|NCT00840034|EXPERIMENTAL|LY2216684|
62617085|NCT00840034|PLACEBO_COMPARATOR|Placebo|
62617086|NCT00309023|EXPERIMENTAL|dose escalation|
62617087|NCT03872817|EXPERIMENTAL|Intervention ProLiSMentAl|"Experimental Group receive mental health literacy psychoeducational intervention called ProLiSMentAl that consist of 4 sessions of 90 minutes."
62617088|NCT03872817|NO_INTERVENTION|Control Group|Control Group receive usual approach.
62617089|NCT04015752||diabetics|"1. Full history with special attention to:~   Causes of admission to ICU . Duration of DM when present, medication used, controlled or not.~2. Complete physical examination with special attention to :~   Vital signs ( MAP, pulse, temp, RR). Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, JV canula,..).~3. Laboratory investigations includes :~CBC , Liver and kidney functions → baseline and follow up. Arterial Blood Gases (ABG). Lactic acid level. HBA1C. ESR, CRP →baseline and follow up.~Culture :~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
62617090|NCT04015752||non diabetics|"1. Full history with special attention to:~   Causes of admission to ICU . Duration of DM when present medication used, controlled or not.~2. Complete physical examination with special attention to :~   Vital signs ( MAP, pulse, temp, RR) Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, JV canula,..).~3. Laboratory investigations CBC , Liver and kidney functions → baseline and follow up HBA1C. ESR, CRP →baseline and follow up.~Culture :~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
62617091|NCT04015752||patients devoloped hyperglycemia in ICU only|"Full history with special attention to:~Causes of admission to ICU . Duration of DM when present medication used, controlled or not. 2. Complete physical examination with special attention to : Vital signs ( MAP, pulse, temp, RR) Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, CVP,..). 3. Laboratory investigations CBC , Liver and kidney functions → baseline and follow up HBA1C. ESR, CRP →baseline and follow up.~Culture :~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
62617092|NCT01100190|EXPERIMENTAL|NUVANCE Facial Rejuvenation System|
62617093|NCT02417961|EXPERIMENTAL|Benralizumab 30 mg|Benralizumab administered subcutaneously every 4 weeks
62617094|NCT04092829|NO_INTERVENTION|FROZEN EMBRYO TRANSFER IN NATURAL CYCLE|After confirming ovarian rest (follicles \< 10 mm) with menstruation by means of vaginal ultrasound, an ultrasound control of the natural cycle will be carried out, inducing ovulation when an ovulatory follicle of size ≥ 17mm and an endometrium ≥ 7mm are found. Serum estradiol and progesterone values will be determined that day. This induction will be carried out with an ampoule of 250 μg of rHCG (Ovitrelle®). After the injection of Ovitrelle®, the administration of micronized vaginal progesterone (Progeffik® or Utrogestan®) 200 mg/ 12 hours and 7 days after the injection, thawing and transfer of a frozen euploid blastocyst will begin 48 hours later.
62623717|NCT01790802|SHAM_COMPARATOR|Sham laser procedure|The maximum illumination button on hte 2RT laser will be briefly pressed by the operating physician at each of the 12 locations where and when the laser would normally be applied. The laser remains in standby mode preventing accidental laser firing.
62623718|NCT04855331|EXPERIMENTAL|Laparoscopic pancreatoduodenectomy|Laparoscopic pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer
62623719|NCT04855331|ACTIVE_COMPARATOR|Open pancreatoduodenectomy|Open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer
62057308|NCT06186206|NO_INTERVENTION|No Intervention (Control)|
62057309|NCT03573661|EXPERIMENTAL|Breast Cancer Locator (BCL)|The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
62057310|NCT01569659|ACTIVE_COMPARATOR|Standard dose of lurasidone|
62623720|NCT00156091|ACTIVE_COMPARATOR|1|Olanzapine 20 mg QD
62057311|NCT01569659|EXPERIMENTAL|High dose of lurasidone|
62057312|NCT02305641||Cohort|Method of continuous surveillance per standard of care
62260444|NCT03957265|EXPERIMENTAL|Syncone|Tapered abutment connection
62260445|NCT02887664||Blood test in Mothers of SGA Infants|In mothers of Small for Gestational Age (SGA) Infants, maternal and cord blood test will be performed
62260446|NCT02887664||Blood test in Mothers of AGA infants|In mothers of Appropriate for Gestational Age (AGA) Infants, maternal and cord blood test will be performed
62260447|NCT03898375|EXPERIMENTAL|VR-enhanced treadmill walking|Participants will be tested during 4 sessions of 20 minutes treadmill walking.
62623721|NCT00156091|EXPERIMENTAL|2|Asenapine 5 or 10 mg BID
62260448|NCT05445375|NO_INTERVENTION|Current education regimen|Participants will be given a PAD pamphlet and ad hoc verbal teaching by vascular providers.
62260449|NCT05445375|ACTIVE_COMPARATOR|Intervention|Participants will be given the current education regimen and watch a 20 minute online PAD education video.
62617095|NCT04092829|ACTIVE_COMPARATOR|FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE|After confirming ovarian rest (follicles \< 10 mm) with menstruation by vaginal ultrasound, hormone replacement therapy with oestrogens (6 mg/day of oral oestradiol valerate - Progynova® or Progyluton®- or 150 ug/48 h of oestradiol in patches - Evopad®) will be started on day 2-3 of the cycle. On day 10-15 of treatment an ultrasound scan will be performed to assess endometrial growth and ovarian rest. After confirming an endometrial thickness ≥ 7mm by vaginal ultrasound, ovaries with follicles smaller than 10 mm, blood estradiol \>100 pg/ml and serum progesterone \< 1 ng/ml, luteal phase support will begin with the administration of 400 mg of micronized vaginal progesterone every 12 hours, a total of 10 shots, prior to embryo transfer of a thawed euploid blastocyst. same day. If the level of serum progesterone on the day of transfer is less than 9.2 ng/ml, a daily injection of subcutaneous progesterone (Prolutex®) will be added on the same day.
62617096|NCT02795468|ACTIVE_COMPARATOR|Palpation group|The operator will use the pulsation of the radial artery as a guide for the cannulation.
62617097|NCT02795468|EXPERIMENTAL|Ultrasound group|The ultrasound guided technique will be used to find a radial artery and insert a radial arterial catheter.
62617098|NCT05709405|EXPERIMENTAL|Reading Intervention|"The reading material is made based on the research of Professor Janice Light and Professor David McNaughton at Penn State University. The reading material Lesing for alle (Reading for all) contains all the principles, strategies, and methods that form the basis of Accessible Literacy Learning (ALL). The intervention is conducted by trained teachers, in a place known to the students. The material contains: tasks in sound blending, letter-sound correspondence, phoneme- segmentation, sight words, single-word decoding, and shared reading.~Due to the multiple single baseline design, each participant will be regarded as being in the control condition, and then will be randonly assigned to four different baselines starting the intervention individually after the 2nd, 3rd, 4th, and 5th month."
62617099|NCT04081857|EXPERIMENTAL|Sequence 1|Period 1 : Fasted state + HGP1810 Period 2 : Fasted state + HCP1704
62617100|NCT04081857|EXPERIMENTAL|Sequence 2|Period 1 : Fasted state + HCP1704 Period 2 : Fasted state + HGP1810
62617101|NCT04699370|EXPERIMENTAL|cognition-targeted exercise|"The patients in this group will receive cognitive behavior therapy in addition to cognition-targeted exercise .~Cognitive behavior therapy will be designed on the basis of van Kessel's model . The main objective of this treatment will be challenging all external factors (e.g. behavioral, cognitive, and affective factors) envisioned to play a role in the development and persistence of fatigue in MS patients. The treatment sessions will be directed individually.~For Cognition- targeted exercise , all standardized physical therapy exercises will be performed in a time-contingent rather than in a symptom-contingent way ."
62617102|NCT04699370|ACTIVE_COMPARATOR|symptom-targeted exercise|"The patients in this group will receive cognitive behavior therapy in addition to symptom-targeted exercise .~Cognitive behavior therapy will be designed on the basis of van Kessel's model . The main objective of this treatment will be challenging all external factors (e.g. behavioral, cognitive, and affective factors) envisioned to play a role in the development and persistence of fatigue in MS patients. The treatment sessions will be directed individually.~For symptom- targeted exercise, All Standardized physical therapy exercises will be performed in a symptom-contingent way (Stop or adjust the exercise when it hurts)."
62617103|NCT00927225|ACTIVE_COMPARATOR|active|subcutaneous wound infiltration with 50 mL ropivacaine 0.2%
62617104|NCT00927225|PLACEBO_COMPARATOR|placebo|subcutaneous wound infiltration with 50 mL saline
62057313|NCT03264703||Participants with RA with cDMARD, but no anti-TNF experience|Male and female participants diagnosed with rheumatoid arthritis (RA), who have no experience with anti-tumor necrosis factor (anti-TNF) and who have experienced two or more Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) of a stable dose for at least 3 months.
62617105|NCT00869973|EXPERIMENTAL|1|Aprepitant
62617106|NCT00869973|ACTIVE_COMPARATOR|2|dexamethasone
62617107|NCT01955915||Choroidal Tumor Group|15 patients diagnosed with small posterior choroidal tumors will be considered and evaluated for enrollment into this study
62617108|NCT04066322||system treatment|Patients continue to receive standard system treatment, including SSA, targeted therapy and chemotherapy.
62842343|NCT06157138||Patients undergoing open abdominal surgery|Patients older than 18 years undergoing open abdominal surgery. They will be followed by a protocol of pulmonary echography during and after surgery in the postoperative care unit
62057314|NCT02318043|ACTIVE_COMPARATOR|AMP-BPT|Methods of AMP-BPT, by applying dosimeters, resembled that reported previously \[see references 21-25\]. Briefly, dilutions were delivered via nebulizers (output: 160 μl/min) using automated APS pro system (JAEGER, Hochburg, Germany). Inhalation challenge with normal saline served as control step. Challenge steps were proceeded if FEV1 fall \<15% and restored to \<10% within 1 minute. Subsequent inhalation challenges were performed at 1-minute intervals, and ceased when FEV1 fell by ≥20%. Salbutamol was administered via spacer (Volumatic, Allen \& Hanbury's, UK). Spirometry was reexamined at minutes 3, 5, 10 and thereafter, to ensure safety, before discharge.
62842344|NCT01802138|EXPERIMENTAL|Activated T-lymphocyte|"This was designed as a single-center, single group clinical trial, and subjects include patients with refractory refractory/relapsed neuroblastoma.~If subjects agree to participate in the clinical trial by signing a written consent, only appropriate subjects, who meet the criteria on the examinations and tests, will undergo this clinical trial. To participate in the clinical trial, subject's blood of more than 60 ml should be withdrawn to make a study drug at least 3 weeks before administration. Subjects should visit to hospital according to the protocol and receive a study drug. Therapeutic response rate, overall survival rate, time to progression should be investigated."
62842345|NCT00409552|EXPERIMENTAL|1|Virtual Reality with head display
62842346|NCT00409552|ACTIVE_COMPARATOR|2|Virtual Reality with flat projection display
62842347|NCT00409552|ACTIVE_COMPARATOR|3|non-interactive video with head display
62842348|NCT00409552|ACTIVE_COMPARATOR|4|non-interactive video with flat projection display
62842349|NCT00409552|NO_INTERVENTION|5|No distraction
62842350|NCT03464175|ACTIVE_COMPARATOR|Heated-humidifier left on during nebulization|
62842351|NCT03464175|ACTIVE_COMPARATOR|Heated-humidifier turned off 30 minutes before nebulization|
62445833|NCT03408366|EXPERIMENTAL|Women having a Laparotomy|The first 10 patients enrolled will undergo skin closure with staples. The next 10 patients enrolled will undergo skin closure with a running subcuticular suture.to evaluate skin perfusion using the Spectrum NIR imaging system following intravenous injection of ICG in all patients. Patients will be assigned skin closure with either running subcuticular suture or skin staples in a sequential, nonrandomized fashion before the procedure. After the planned surgical procedure is complete, ICG will be injected intravenously. Video of the incision will be recorded. After skin closure is complete, a second intravenous bolus of ICG (same dose as previously injected) will be given. Video of the incision will again be recorded. Measurement of perfusion will subsequently be performed by video analysis at the previously described three predefined points along the incision after surgery is complete and again after skin closure.
62445834|NCT00915057|EXPERIMENTAL|NRL972|Single 2mg intravenous dose of NRL972, administered on up to seven occasions
62617109|NCT04066322||system treatment and Surgery|Patients receive synchronous resection of primary tumor and metastasis after system treatment. and treatment after surgery is based on the clinical decision.
62617110|NCT04059939|EXPERIMENTAL|Reading Plus Attention Control|
62842352|NCT03464175|ACTIVE_COMPARATOR|Use of a heat and moisture exchanger (HME) filter|
62842353|NCT03464175|ACTIVE_COMPARATOR|Use of a dry ventilator circuit specific for aerosol therapy|
62842354|NCT02757417|ACTIVE_COMPARATOR|Sodium Fluorescein|Patients will receive an intravenous dose of 0.25 mL of 10% (500 mg, 5 mL) sodium fluorescein at the time of cystoscope insertion, for a total dose of 25 mg. Cystoscopy will be performed in the standard fashion during the course of the operation.
62842355|NCT02757417|ACTIVE_COMPARATOR|oral phenazopyridine|Patients randomized to the phenazopyridine arm will be given a 200 mg pill with a sip of water in the pre-operative area 1 hour before their scheduled procedure. Cystoscopy will be performed in the standard fashion during the course of the operation.
62842356|NCT03320577|ACTIVE_COMPARATOR|Class instruction of breathing exercises|Class participation/instruction weekly for 6 weeks and requested to practice Pranayama breathing exercises of 15 minute duration for an additional 4x during the week; completed log that indicated time/date/duration of practice; weekly blood pressure measurements and turn in logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
62842357|NCT03320577|ACTIVE_COMPARATOR|DVD instruction of breathing exercises|Received DVD with instructions and 15 minute Pranayama breathing exercises of 15 minute duration. Participants requested to practice breathing exercises 5x during the week for 6 week intervention; completed log that indicated time/date/duration of practice; weekly blood pressure measurements and turn in logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
62842358|NCT03320577|PLACEBO_COMPARATOR|Control|Completed log that indicated time of eating dinner; weekly blood pressure measurements for the 6 week intervention; control participants also turned in dinner time logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
62842359|NCT01163227|PLACEBO_COMPARATOR|Placebo|
62842360|NCT01163227|EXPERIMENTAL|AQW051 Dose 1|
62842361|NCT01163227|EXPERIMENTAL|AQW051 Dose 2|
62842362|NCT01163227|EXPERIMENTAL|AQW051 Dose 3|
62445835|NCT03104790|EXPERIMENTAL|naive|Children who have never received any influenza vaccine (The two groups are defined by immunisation history, all receive the same intervention in the study)
62445836|NCT03104790|EXPERIMENTAL|prior vaccinees|Children who have received at least two doses of Fluenz Tetra previously (The two groups are defined by immunisation history, all receive the same intervention in the study)
62445837|NCT00408733|NO_INTERVENTION|1|
62445838|NCT00408733|EXPERIMENTAL|2|Intervention
62617111|NCT04059939|EXPERIMENTAL|Reading Plus Anxiety|
62617112|NCT04059939|ACTIVE_COMPARATOR|BAU|
62617113|NCT01393106|EXPERIMENTAL|Idelalisib|Participants will receive up to 300 mg of idelalisib twice daily.
62617114|NCT06321497||Adult patients (18 years or older) with diagnosis of ARDS as per Berlin Definition|
62617115|NCT04940689|ACTIVE_COMPARATOR|Standard arm|"General anesthesia strategy with morphine:~* Within 10 minutes before the induction of general anesthesia: administration of a placebo of 50 mL of 0.9% NaCl by slow IV~* The anesthetic induction will be carried out by an intravenous hypnotic (propofol or etomidate) combined with IV curare and remifentanil (morphine derivative) IV for a concentration target of 4 ng / mL.~* Maintenance of anesthesia will be carried out with propofol or a halogenated gas (sevoflurane or desflurane) in continuous administration (qs bispectral index 40-60) and remifentanil (target concentration 1-10 ng / mL). The administration of curare will be carried out as needed. In order to anticipate the sudden end of the analgesia, an administration of morphine 0.15 mg / kg IV will be carried out 30 minutes before the end of the intervention as recommended"
62623722|NCT00156091|OTHER|3|Double-Blind subjects randomized to only placebo medication for 6 weeks in the short-term 041021 or 041022 asenapine trials, were randomized (double-blind) Into the long-term 041512 asenapine extension trial and received asenapine 5 mg BID for Week 1. After Week 1, subjects received asenapine (either 5 mg BID or 10 mg BID) for the remainder of the 52 week trial.
62617116|NCT04940689|EXPERIMENTAL|OFA arm|"General anesthesia strategy without morphine~* Within 10 minutes before the induction of general anesthesia: pre-induction dose of dexmedetomidine 0.5 g / kg and lidocaine 1.5 mg / kg by slow IV.~* The anesthetic induction will be carried out by an intravenous hypnotic (propofol or etomidate) combined with an IV curare~* The maintenance of the anesthesia will be carried out by propofol or a halogenated gas (sevoflurane or desflurane) in continuous administration (qsp bispectral index 40-60), dexmedetomidine 0.5-1.0 g / kg / h, lidocaine 2 mg / kg / h. The administration of curare will be carried out as needed."
62445839|NCT01773512|EXPERIMENTAL|Rosuvastatin|All patients will be using rosuvastatin 40 mg
62445840|NCT00794183|ACTIVE_COMPARATOR|1|AVD set by taking the larger of 0.50ms or A-V interval 0.30
62617117|NCT06404515|EXPERIMENTAL|Telehealth Counseling|Telehealth sessions
62057315|NCT02318043|ACTIVE_COMPARATOR|His-BPT|Methods of His-BPT, by applying dosimeters, resembled that reported previously \[see references 21-25\]. Briefly, dilutions were delivered via nebulizers (output: 160 μl/min) using automated APS pro system (JAEGER, Hochburg, Germany). Inhalation challenge with normal saline served as control step. Challenge steps were proceeded if FEV1 fall \<15% and restored to \<10% within 1 minute. Subsequent inhalation challenges were performed at 1-minute intervals, and ceased when FEV1 fell by ≥20%. Salbutamol was administered via spacer (Volumatic, Allen \& Hanbury's, UK). Spirometry was reexamined at minutes 3, 5, 10 and thereafter, to ensure safety, before discharge.
62445841|NCT00794183|ACTIVE_COMPARATOR|2|AVD set by taking the larger of 0.50ms or A-V interval 0.50
62445842|NCT00794183|ACTIVE_COMPARATOR|3|AVD set by taking the larger of 0.50ms or A-V interval 0.70
62445843|NCT06484972||Quality improvement project arm|The Quality improvement project(QIP) arm will perform QIP intervention. Patients in the QIP arm will be enrolled after about 3-month QIP intervention. The QIP interventions include: establish a coaching committee, quality improvement workshop, implementation of quality improvement measures, as well as evaluation periodically and feedback.
62445844|NCT06484972||Control arm|The control arm will not receive intervention and continue with usual care.
62445845|NCT01292109||PICOPREP®|
62445846|NCT01448135|EXPERIMENTAL|Vital AF|
62445847|NCT01448135|ACTIVE_COMPARATOR|Osmolite 1.2|
62445848|NCT03211156|PLACEBO_COMPARATOR|Placebo arm|Placebo 2 capsules PO twice a day for 7 days, n=49
62445849|NCT03211156|EXPERIMENTAL|Treatment arm|Amoxicillin 2 x 250 mg capsules PO twice a day for 7 days, n=49
62617118|NCT02028962|EXPERIMENTAL|Lifestyle counseling|The experimental group will receive three letters with advices for smoking cessation-the first letter after the enrolment in the study, the second one one month after the first letter, the third one three months after the first letter
62617119|NCT02028962|NO_INTERVENTION|Control|
62617120|NCT02748291|EXPERIMENTAL|Walking|Randomised participants will be instructed to walk 6,000 steps per day and throughout the day for 12 weeks. Step counts will be monitored by an issued pedometer. A 12 week paper diary will be provided for daily recording of step counts.
62623723|NCT00802321|EXPERIMENTAL|dutasteride|
62445850|NCT06298435||GA group|Adult patients having undergone surgery under general anesthesia with IPPV in the UMCG between 01-01-2018 and 01-04-2023
62445851|NCT02322528|OTHER|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to both eyes to induce an inflammatory mediated response.
62445852|NCT02099279||echocardiography examination|
62445853|NCT05779150|EXPERIMENTAL|Case group|Routine treatment together with once applicating CeraVe® Moisturising Cream after daily bath.
62445854|NCT05779150|PLACEBO_COMPARATOR|Control Group|Routine treatment together with once applicating Standard Cream after daily bath.
62445855|NCT03673059|EXPERIMENTAL|OTC Eczema Moisturizer Regimen|Subjects who were assigned to use an over-the-counter (OTC), oatmeal-containing eczema therapy moisturizing cream. The product is classified as an OTC monograph drug.
62445856|NCT03673059|EXPERIMENTAL|Cosmetic Moisturizer Regimen|Subjects who were assigned to use a non-fragranced, dry skin daily moisturizer classified as a cosmetic (i.e. non-OTC).
62445857|NCT01544166|EXPERIMENTAL|Overall study|
62445858|NCT05105165||Antibody positive group|
62445859|NCT05105165||Antibody negative group|
62445860|NCT05105165||Health Group|
62445861|NCT00779077||cystic fibrosis|adults and children with cystic fibrosis
62445862|NCT04683822|EXPERIMENTAL|Exercise group|Patients who receive telerehabilitaton
62260450|NCT04700839|EXPERIMENTAL|SGLT2 inhibitors group|Intervention with SGLT2 inhibitors (100mg/d) for 3 months
62617121|NCT02748291|ACTIVE_COMPARATOR|Control|Department of Health (United Kingdom) Physical Activity Guidelines flyer (current standard of care).
62842363|NCT02751489|EXPERIMENTAL|Bain De Soliel - Solid|All subjects are patched with the same product
62842364|NCT04212962|EXPERIMENTAL|Treatment group|The treatment group receives the TCM intervention while in the hospital and during the first 90 days after returning to the community.
62842365|NCT04212962|EXPERIMENTAL|Control group|The control group receives usual discharge planning and post-discharge care.
62057316|NCT05107960||Azilsartan|Azilsartan tablets or granules formulation, orally once daily. For children aged 6 years or older, the usual initial oral dosage of azilsartan is 2.5 mg and 5 mg once daily for those weighing \<50 kg and \>=50 kg, respectively.
62057317|NCT02535364|EXPERIMENTAL|JCAR015 (CD19-targeted CAR T cells)|JCAR015 was administered as two intravenous (IV) infusions separated by 14 to 28 days.
62057318|NCT01861457|EXPERIMENTAL|Nozin® Nasal Sanitizer®|Non-antibiotic, alcohol-based antiseptic
62057319|NCT01861457|PLACEBO_COMPARATOR|Phosphate-buffered saline|Placebo
62260451|NCT04700839|ACTIVE_COMPARATOR|Metformin group|Intervention with metformin (1500-2000mg/d) for 3 months
62260452|NCT02898532|ACTIVE_COMPARATOR|Intervention group|The intervention is organised in collaboration between the local school, the Danish Shooting Association, and the national DGI (The Danish Gymnastics and Sporting Organization). The intervention is available geographical nationwide. The children will practise target-shooting sport in local Shooting Association once a week during school hours for a period of 6 months. Selected schools are either special schools or municipal schools with special educational programmes for children diagnosed with either ADHD or severe difficulties of hyperactivity, inattention and impulsivity. Teachers accompany the children to the Shooting Association where the instructors meet them.
62842366|NCT04239612|OTHER|Physical exercise|Specified circular training, 60 minutes, 1-3 times/week
62842367|NCT01067196||Observation and quality of life|Central Nervous System Tumors
62057320|NCT03904030|EXPERIMENTAL|Anti-Gravity Treadmill rehabilitation|Patients in the intervention group are participating to the Alter G exercises (n=27). The groups are randomized, so after patients have signed consent, an envelop will be opened and there can be seen in which groups patients will participate.
62057321|NCT03904030|ACTIVE_COMPARATOR|Traditional rehabilitation|Traditional exercises with instructions are given to the patients (n=27) (as a control group).
62057322|NCT05446610|EXPERIMENTAL|Gut barrier function treatments|Stressor, fibre, combination of treatments.
62057323|NCT03732118||Minimal hepatic encephalopathy|
62057324|NCT03732118||No hepatic encephalopathy (minimal or clinical)|
62057325|NCT02335008|EXPERIMENTAL|Sucralose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucralose.
62057326|NCT02335008|EXPERIMENTAL|Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucrose.
62260453|NCT02898532|NO_INTERVENTION|Control group|The same target group as children in the intervention group. In the control group children are not practicing target shooting sport, neither in school or free time.
62842368|NCT00942526|NO_INTERVENTION|1|no intervention with perioperative oral anti-infective agent or water for gargling
62842369|NCT00942526|SHAM_COMPARATOR|2|perioperative gargling with water
62842370|NCT00942526|EXPERIMENTAL|3|perioperative oral gargling with oral anti-infective agent for seven days
62057327|NCT04007458|ACTIVE_COMPARATOR|Letter|Patients will receive a letter reminding them that they are overdue for repeat annual screening.
62057328|NCT04007458|EXPERIMENTAL|Community Health Worker phone call|Patients will receive a phone call from community health worker, offering to help them overcome barriers to repeat annual screening and offering to help them schedule their screening.
62057329|NCT03833635|EXPERIMENTAL|OMT|
62057330|NCT03833635|PLACEBO_COMPARATOR|Control|
62057331|NCT05127148||Adolescents and young adults Ph-negative ALL patients in first-line|Adolescents and young adults patients (18-40 years old) with recent diagnosis of Ph-negative acute lymphoblastic leukemia who receive argentinian pediatric-like treatment depending on risk category.
62057332|NCT02150720|EXPERIMENTAL|Tranexamic acid|Tranexamic acid, 1g intra-articular before closing the surgery wound
62057333|NCT02150720|EXPERIMENTAL|Fibrin glue|One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery,
62260454|NCT02808000|ACTIVE_COMPARATOR|Group 1 (also called Group A )|Group 1/A will use standard catheter during the first \~6 months (observational period 1). Then the patients in this group will switch to the noble metal alloy urinary catheter (BIP Foley catheter of latex or silicone produced by Bactiguard AB) and be observed for another \~6 months (the second observational period).
62445863|NCT04683822|NO_INTERVENTION|Control|Patients with routine care
62617122|NCT01351948|EXPERIMENTAL|Group 1|AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
62617123|NCT01351948|EXPERIMENTAL|Group 2|AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
62617124|NCT01351948|EXPERIMENTAL|Group 3|AdCh63 AMA1 + AMA1-C1/Alhydrogel®
62617125|NCT01351948|EXPERIMENTAL|Group 4|AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909
62623724|NCT00551174|EXPERIMENTAL|1|
62842371|NCT05179356|ACTIVE_COMPARATOR|Dapagliflozin 10 mg once daily|Dapagliflozin 10 mg (Farxiga 10 mg) given once daily for three months
62842372|NCT05179356|PLACEBO_COMPARATOR|Matching placebo|Placebo given once daily for three months
62842373|NCT05545540|EXPERIMENTAL|Intervention arm|Patients will be issued Mp3 players and speakers with music files in Mp3 formatted by the randomization team. The intervention arm will be issued the first movement (8 minutes, 22 seconds) of Mozart's Sonata for Two Pianos in D Major, K448. They will be exposed to it once a day during wakefulness for two consecutive months.
62842374|NCT05545540|PLACEBO_COMPARATOR|Control arm|Patients will be issued Mp3 players and speakers with music files in Mp3 formatted by the randomization team. The control arm will receive the first movement (8 minutes, 34 seconds) of Mozart's Fantasia for Piano in C Minor, K 475. Although from the same composer, the control sonata has been found not to have neurostimulating properties. They will be exposed to it once a day during wakefulness for two consecutive months.
62842375|NCT02127957|OTHER|Exercise|Exercise group will have 6 visit and 8 phone call. Subject will have to do prescribed exercice for 1h, 3 times a week for 12 weeks.
62057334|NCT02150720|ACTIVE_COMPARATOR|Usual hemostasia|Electrocauterization
62057335|NCT01337986|ACTIVE_COMPARATOR|Group B: Dalfampridine First|Dalfampridine/Placebo: Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.
62057336|NCT01337986|ACTIVE_COMPARATOR|Group A: Dalfampridine Second|Placebo/Dalfampridine: Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks
62057337|NCT05358678||cases with cs niche|133 cases with cs niche undergoing ART will be included. Pituitary suppression will be achieved by long or antagonist protocol. For long protocol, GnRH agonist will be administered for 10-14 days starting from mid-luteal phase of preceding cycle. After confirmation of down regulation, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). Gonadotropins therapy will be tailored according to age, BMI, antral follicle count, antimullerian hormone and previous response. In antagonist protocol, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). GnRH antagonist will be adjusted according to patient response. On the 5th -6th day of stimulation, sonography will be performed and repeated every 1-3 days with regular estradiol assessment. When at least 3 follicles reach ≥ 17 mm in mean diameter, trigger will be given. Oocytes pick up will be performed 34-36 hour after triggering.
62057338|NCT05358678||cases without cs niche|133 cases without cs niche undergoing ART will be included. Pituitary suppression will be achieved by long or antagonist protocol. For long protocol, GnRH agonist will be administered for 10-14 days starting from mid-luteal phase of preceding cycle. After confirmation of down regulation, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). Gonadotropins therapy will be tailored according to age, BMI, antral follicle count, antimullerian hormone and previous response. In antagonist protocol, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). GnRH antagonist will be adjusted according to patient response. On the 5th -6th day of stimulation, sonography will be performed and repeated every 1-3 days with regular estradiol assessment. When at least 3 follicles reach ≥ 17 mm in mean diameter, trigger will be given. Oocytes pick up will be performed 34-36 hour after triggering.
62057339|NCT01633125|EXPERIMENTAL|Group music therapy|Participants in the experimental group will take part in biweekly group music therapy for 10 weeks (20 sessions). Each group will be formed by 6 to 8 people, and each session will last for 90 minutes.The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The active techniques will include musical improvisation as a medium to work with participants according to therapeutic goals and participants' needs.
62057340|NCT01633125|NO_INTERVENTION|No music therapy|Participants assigned to the control group will not receive any specific treatment in this study. The usual care that is normally available at the prison will continue to be available for all participants during the study.Due to ethical considerations, the control group will receive group music therapy or psychotherapy by academically qualified therapists for 5 weeks after the study is finished.
62842376|NCT02127957|NO_INTERVENTION|Control|Control group will have 4 visit and 3 phone call. They will receive standard counselling for exercise in cystic fibrosis, but no prescribed exercice will be given.
62842377|NCT01544335||BIS|Subjects evaluated using Bioimpedance Spectroscopy
62842378|NCT00932178|EXPERIMENTAL|Calmer Life|Skills-based intervention to reduce anxiety and worry in adults age 50+.
62842379|NCT04980092||Post-ICU group|Observational foolow-up
62842380|NCT05213767|EXPERIMENTAL|TQB2916 injection|2.5mg/ quaque die (QD) was used as the initial dose, 21 days as a treatment cycle. The drug is administered on the first day of each cycle until the disease progresses or the investigator judges that it is not suitable for subject to continue to take medicine.
62842381|NCT02714972|ACTIVE_COMPARATOR|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
62260455|NCT02808000|EXPERIMENTAL|Group 2 (also called Group B)|Group 2/B will use the BIP Foley (latex or silicone) during the first \~6 months (observational period 1). Then the patients in this group will switch to the standard catheter and be observed for another \~6 months (the second observational period).
62260456|NCT04053868|EXPERIMENTAL|Electronic Cigarette|The participants will participate in a standardized vaping session using a JUUL E-cigarette device with a JUUL e-liquid pod.
62842382|NCT02714972|NO_INTERVENTION|Predictive Low Glucose Suspend|The control algorithm will run passively and not dose additional insulin. If hypoglycemia is predicted, the system will suspend the pump.
62842383|NCT00611026|ACTIVE_COMPARATOR|1|
62842384|NCT00611026|PLACEBO_COMPARATOR|2|
62842385|NCT00611026|EXPERIMENTAL|3|
62842386|NCT00342108|EXPERIMENTAL|1|Diagnosis: CP, moderate to severe MR and CVI
62842387|NCT00342108|EXPERIMENTAL|2|Diagnosis: CP, Moderate to severe MR, no visual impairment
62842388|NCT02023697|EXPERIMENTAL|Radium-223 dichloride (Standard dose)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update).
62842389|NCT02023697|EXPERIMENTAL|Radium-223 dichloride (High dose)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 80 kBq/kg body weight (88 kBq/kg after implementation of NIST update).
62842390|NCT02023697|EXPERIMENTAL|Radium-223 dichloride (Extended standard dose)|One injection to be administered every 4 weeks up to 12 injections. The dose per injection is 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update).
62842391|NCT00554632|ACTIVE_COMPARATOR|1|Use of transdermal hormonal contraceptive
62842392|NCT00554632|ACTIVE_COMPARATOR|2|Use of oral hormonal contraceptive
62842393|NCT02549365|EXPERIMENTAL|Intervention|Administration of Live attenuated influenza vaccine (LAIV) as per national guidance. Surveillance thereafter through nasal swabbing in the event of influenza-like illness.
62842394|NCT02549365|OTHER|Controls|Surveillance in siblings of participants in the Intervention arm, through nasal swabbing in the event of influenza-like illness, irrespective of their vaccination status.
62842395|NCT02358941|EXPERIMENTAL|Training in a school setting|"A minimum of 30 sessions (45 min.) over at least 12 weeks in the schools of the participants.~Half of the children will be assigned to NF training, the other half to CCT."
62842396|NCT02358941|EXPERIMENTAL|Training in a clinical setting|"A minimum of 30 sessions (45 min.) over approx. 12 weeks at the Department of Child and Adolescent Psychiatry (treatment as usual).~Half of the children will be assigned to NF training, the other half to CCT."
62842397|NCT04509661|EXPERIMENTAL|Experimental group|Indacaterol-Glycopyrronium (110ug/50ug QD inhalation) for one year.
62842398|NCT04509661|PLACEBO_COMPARATOR|Control group|Placebo treatment for the airway limitation.
62842399|NCT01519869|EXPERIMENTAL|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
62842400|NCT02295670|EXPERIMENTAL|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
62842401|NCT02295670|EXPERIMENTAL|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
62842402|NCT02592096|EXPERIMENTAL|0.1% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
62842403|NCT02592096|EXPERIMENTAL|0.3% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
62842404|NCT02592096|EXPERIMENTAL|0.5% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
62842405|NCT02592096|ACTIVE_COMPARATOR|Pazufloxacin mesilate injection|0.3g, 30 minutes for ventricular injection
62842406|NCT01685515|EXPERIMENTAL|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Tetrahydrouridine
62842407|NCT01685515|PLACEBO_COMPARATOR|Placebo|Placebo
62842408|NCT05593562|EXPERIMENTAL|SPH3127|Oral 100 mg \[14 c\] SPH3127 mixed suspension
62057341|NCT01058317|EXPERIMENTAL|Children treated with propranolol|
62617126|NCT01351948|EXPERIMENTAL|Group 5|AdCh63 AMA1 + MVA AMA1
62057342|NCT02008591|ACTIVE_COMPARATOR|Epidural Technique|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 15 mL load over 5 min
62842409|NCT00607373|EXPERIMENTAL|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
62842410|NCT00607373|PLACEBO_COMPARATOR|Placebo|Participants received placebo as a subcutaneous injection once a week for 26 weeks.
62842411|NCT04640220|EXPERIMENTAL|Adhesive capsulitis in breast cancer survivors|Intra-articular steroid injection
62842412|NCT06311097|EXPERIMENTAL|Fermented dairy|The fermented dairy product is Arla A38® naturel 1,5% yogurt. The yogurt contains Lactobacillus acidophilus culture.
62842413|NCT06311097|PLACEBO_COMPARATOR|Non-fermented dairy|The non-fermented dairy product is Arla® Letmælk 1,5% (semi-skimmed milk). The fermented- and non-fermented dairy products are isocaloric and matched in macronutrient content.
62842414|NCT03111186|ACTIVE_COMPARATOR|Opiate group|Group receiving oxycodone alone (oxycodone HCl 5 mg up to six times daily as needed for pain)
62842415|NCT03111186|ACTIVE_COMPARATOR|Non-opiate group|Group receiving ibuprofen and acetaminophen (acetaminophen 650 mg up to four times daily and ibuprofen 400 mg up to six times daily as need for pain)
62842416|NCT05389540||members of selected households at the time of survey|371 households will be randomly selected from each site in Bangladesh, Cambodia, Myanmar, and Thailand. Assuming each household has an average of 4.5 members and all members will be sampled, 1500 participants will be recruited per site.
62842417|NCT02212951|EXPERIMENTAL|BIOD-531 pre-meal|Subcutaneous injection of 0.6 U/kg immediately before the start of the standardized breakfast
62842418|NCT02212951|ACTIVE_COMPARATOR|Humalog Mix 75/25 pre-meal|Subcutaneous injection of 0.6 U/kg immediately before the start of the standardized breakfast
62842419|NCT02212951|ACTIVE_COMPARATOR|Humulin R U-500|Subcutaneous injection of 0.6 U/kg immediately before the start of a standardized breakfast
62057343|NCT02008591|ACTIVE_COMPARATOR|Combined Spinal Epidural Technique|Bupivacaine 2.5 mg with Fentanyl 25 mcg
62057344|NCT02008591|ACTIVE_COMPARATOR|Dural Puncture Epidural Technique|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 15 mL load over 5 min
62842420|NCT02212951|EXPERIMENTAL|BIOD-531 post-meal|Subcutaneous injection of 0.6 U/kg 20 minutes after the start of the standardized breakfast
62057345|NCT03943589|EXPERIMENTAL|Imlifidase|"One (1) dose of imlifidase, 0.25 mg/kg, will be administered IV over 30 minutes, Day 1.~IVIg, 0.4 g/kg, will be administered for 5 consecutive Days, starting on Day 3 at least 48 h after imlifidase administration."
62057346|NCT02106130|EXPERIMENTAL|R - R+M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
62445864|NCT02484820|EXPERIMENTAL|Pessary|Silicone pessary is associated with standard care Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
62445865|NCT02484820|NO_INTERVENTION|Control|Standard care only, No silicone pessary will be placed in the vagina.
62842421|NCT02967783|ACTIVE_COMPARATOR|ID Needle and Syringe|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered using a needle and syringe
62842422|NCT02967783|EXPERIMENTAL|ID Adaptor (Helm)|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered using a needle and syringe with an ID adaptor
62057347|NCT02106130|EXPERIMENTAL|R+M - R|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
62057348|NCT02106130|EXPERIMENTAL|M - R+M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
62057349|NCT02106130|EXPERIMENTAL|R+M - M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
62057350|NCT02613221|EXPERIMENTAL|panitumumab + TAS-102 combination therapy|Panitumumab 6 mg/kg every 2 weeks, plus TAS-102 35 mg/m² given orally twice a day in 5 days followed by a 2-day rest period for 2-week cycle, and then a 14-day rest period (28 days per 1 course).
62842423|NCT02967783|EXPERIMENTAL|ID Jet Injector (Tropis, Pharmajet)|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered by needle and syringe with a disposable syringe jet injecto
62057351|NCT00637130|EXPERIMENTAL|Travoprost 0.0008%|Travoprost ophthalmic solution, 0.0008%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
62057352|NCT00637130|EXPERIMENTAL|Travoprost 0.001%|Travoprost ophthalmic solution, 0.001%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
62057353|NCT00637130|EXPERIMENTAL|Travoprost 0.0012%|Travoprost ophthalmic solution, 0.0012%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
62057354|NCT00637130|ACTIVE_COMPARATOR|TRAVATAN + Vehicle|TRAVATAN, one drop in study eye(s) once daily (8 PM), and Vehicle, one drop in study eye(s) once daily (8 AM), for two weeks
62057355|NCT00637130|PLACEBO_COMPARATOR|Vehicle|Vehicle, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
62057356|NCT05445154|EXPERIMENTAL|SKLB1028 Dose Escalation|"Part1:Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and the experimental drug SKLB1028.SKLB1028 capsules beginning at 100 mg bid.~Part2: Once the appropriate therapeutic schedule has been established in Part 1, up to 20 subjects will be enrolled into an expansion cohort."
62057357|NCT05505474||IVF with Neria™ Guard device|Patients undergoing IVF with the use of the Neria™ Guard subcutaneous catheter
62057358|NCT06003465|EXPERIMENTAL|LY3437943 - Test|A single dose of LY3437943 administered by subcutaneous (SC) injection via a test device (test formulation)
62842424|NCT02422459|EXPERIMENTAL|COMMENCE|ChrOnic pain self-ManageMent support with pain science EducatioN and exerCisE (COMMENCE)
62842425|NCT02422459|NO_INTERVENTION|Wait-list control|No treatment assigned
62057359|NCT06003465|ACTIVE_COMPARATOR|LY3437943 - Reference|A single dose of LY3437943 administered by SC injection via a reference device (reference formulation)
62057360|NCT03633929||KIOS OUD|
62617127|NCT00881283||cured Cushing's disease|
62617128|NCT05302947||Baricitinib|group included patients received Baricitinib in addition to standard of care therapy
62842426|NCT01151904|EXPERIMENTAL|COMBIGAN® with Latanoprost|Patients on current latanoprost monotherapy that qualify for study entry will have COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) added to the latanoprost for 12 additional weeks.
62842427|NCT03810105|EXPERIMENTAL|Castration Sensitive Biochemically Recurrent Prostate Cancer|Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer
62842428|NCT05242627|NO_INTERVENTION|DGSOM Class of 2023|
62842429|NCT05242627|EXPERIMENTAL|DGSOM Class of 2024|
62842430|NCT04301804|EXPERIMENTAL|Dose level 1|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 1
62842431|NCT04301804|EXPERIMENTAL|Dose level 2|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 2
62842432|NCT04301804|EXPERIMENTAL|Dose level 3|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 3
62260457|NCT04053868|EXPERIMENTAL|Tobacco Cigarette|The participants will participate in a standardized smoking session using commercial tobacco cigarettes.
62260458|NCT04738812|EXPERIMENTAL|Intensified TB treatment|"* Increased doses of rifampicin (R) to 35±5 mg/kg daily and isoniazid (H) 10±2 mg/kg daily together with standard-dose of pyrazinamide (Z) 20-30 mg/kg daily + ethambutol (E) 15-20 mg/kg daily for 8 weeks (initial phase of TB treatment).~* Prednisone 40 to 80 mg once a day (OD) according to weight bands for 2 weeks, followed by 20 to 40 mg OD according to weight bands for 2 weeks, then 10 to 20 mg OD according to weight bands for the last 2 weeks (total duration: 6 weeks). Because of the corticosteroid treatment, albendazole 400 mg OD will be given to participants for 3 days.~* Continuation phase: 16 weeks of RH."
62617129|NCT05302947||Tocilizumab|group included patients received Tocilizumab in addition to standard of care therapy
62617130|NCT05302947||Netakimab|group included patients received Netakimab in addition to standard of care therapy
62842433|NCT00334113|EXPERIMENTAL|Arm 1|Participants in this arm will meet with an exercise physiologist and obtain an exercise prescription for a walking program. In addition, they will recieve an intervention that will be delivered over an automated telephone system (TLC-PED). These automated phone calls with voice response and voice recognition capabilities will occur weekly over a 6 month period. During these calls, participants' physical activity will be monitored, new physical activities goals will be set, information about physical activity and the associated health benefits will be provided, and barriers to physical activity will be explored.
62260459|NCT04738812|ACTIVE_COMPARATOR|WHO standard TB treatment|"* Standard-dose of R 8-12 mg/kg daily + H 4-6 mg/kg daily + Z 20-30 mg/kg daily + E 15-20 mg/kg daily for 8 weeks.~* Continuation phase: 16 weeks of RH."
62260460|NCT06170424||experimental gourp|The patients who used the autologous skin cell suspension combined with skin grafting.
62260461|NCT06170424||Control group|The patients who used split-thickness skin grafting.
62260462|NCT04754880||non-CTO|This group was defined as no chronic obstruction, except for non-critical stenosis, who underwent coronary angiography with the diagnosis of stable angina pectoris.
62260463|NCT04754880||CTO|This group was defined as the presence of complete occlusion in one artery and no critical lesions (\> 50%) in the other arteries undergoing coronary angiography with the diagnosis of stable angina pectoris.
62260464|NCT01967628|EXPERIMENTAL|Vitamin D3 (cholecalciferol)|Vitamin D3 (1000 international units) daily for 3 months.
62445866|NCT03244020|EXPERIMENTAL|LMWH for Soft Tissue Sarcoma|Patients undergoing surgery for pelvic/lower extremity soft tissue sarcomas and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
62445867|NCT03244020|EXPERIMENTAL|ASA for Soft Tissue Sarcoma|Patients undergoing surgery for pelvic/lower extremity soft tissue sarcomas and are randomized to aspirin 325 mg po daily for VTE prophylaxis
62445868|NCT03244020|EXPERIMENTAL|LMWH for Primary Bone Tumor|Patients undergoing surgery for pelvic/lower extremity primary bone tumor and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
62445869|NCT03244020|EXPERIMENTAL|ASA for Primary Bone Tumor|Patients undergoing surgery for pelvic/lower extremity primary bone tumor and are randomized to aspirin 325 mg po daily for VTE prophylaxis
62445870|NCT03244020|EXPERIMENTAL|LMWH for Metastatic Disease|Patients undergoing surgery for pelvic/lower extremity metastatic bone disease and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
62445871|NCT03244020|EXPERIMENTAL|ASA for Metastatic Disease|Patients undergoing surgery for pelvic/lower extremity metastatic bone disease and are randomized to aspirin 325 mg po daily for VTE prophylaxis
62445872|NCT03198013|EXPERIMENTAL|Module A|Single Ascending Dose
62842434|NCT00334113|NO_INTERVENTION|Arm 2|"This is the treatment as usual condition. Participants in this condition will also have 2 sessions with an exercise physiologist and will receive an exercise prescription for a home based walking program. The will not receive the automated phone calls each week that are designed to motivate physical activity."
62260465|NCT01967628|PLACEBO_COMPARATOR|Sugar capsule|Placebo comparator made of sugar in a capsule
62445873|NCT03198013|EXPERIMENTAL|Module B|Multiple Ascending Dose
62445874|NCT04579926|EXPERIMENTAL|Pinpoint App|Tablet and smartphone application.
62445875|NCT00198497|EXPERIMENTAL|Vitrase|Single Hyaluronidase ophthalmic intravitreal injection
62445876|NCT00198497|PLACEBO_COMPARATOR|Placebo|Single Saline solution intravitreal injection
62445877|NCT02079792|ACTIVE_COMPARATOR|Lying Head Back Position|Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort. Subjects will be instructed to administer budesonide 1mg/2cc nebules daily for 12 weeks using the MAD syringe, in the head position to which they were randomized.
62445878|NCT02079792|EXPERIMENTAL|Head Down and Forward Position|Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards. Subjects will be instructed to administer budesonide 1mg/2cc nebules daily for 12 weeks using the MAD syringe, in the head position to which they were randomized.
62842435|NCT00867815|OTHER|Arm 1|
62617131|NCT05302947||Control|group included patients received only standard of care therapy at the time of hospital admission according to the corresponding COVID-19 Russian guidelines 2020.
62617132|NCT00230165||Normal|Normal, healthy volunteers 18 years of age or older of either sex and any ethnic background
62617133|NCT00230165||Glanzmann thrombasthenia|Patients with Glanzmann thrombasthenia or their relatives, inherited qualitative and/or quantitative platelet disorders, inherited disorders of white blood cells, inherited disorders of coagulation
62623725|NCT00551174|ACTIVE_COMPARATOR|2|
62842436|NCT02138448|EXPERIMENTAL|Intervention practices|Intervention practices will implement an interactive preventive health record in addition to their standard personal health record functionality.
62842437|NCT02138448|NO_INTERVENTION|Control practices|Control practices will continue to field their existing personal health record
62842438|NCT03048006||All included patients|All included patients underwent MRI with Dotarem
62842439|NCT00692263|EXPERIMENTAL|A|Escitalopram - tramadol
62842440|NCT00692263|EXPERIMENTAL|B|Placebo - tramadol
62842441|NCT00692263|EXPERIMENTAL|C|placebo - placebo
62842442|NCT02872935|PLACEBO_COMPARATOR|Placebo: Normal Saline|1ml of Normal Saline will be given intravenously with the administering of the spinal dose
62842443|NCT02872935|EXPERIMENTAL|Glycopyrrolate group|1ml of Glycopyrrolate ( .2mg /ml) will be given intravenously with the administering of the spinal dose
62842444|NCT03103477||Office|"Patients presenting for a routine office visit will be asked to donate at least 50 ml of urine. The urine specimen will be aliquoted in containers, one with and one without a PAF-AH inhibitor and kept at room temperature.~The aliquots (2mL) will be frozen at predetermined intervals of 5, 10, 20, 40 and 60 min from time of collection in liquid nitrogen and then later stored in -80 freezer."
62842445|NCT03103477||Surgery|A separate group of patients undergoing surgery lasting more than 60 min operating time, will be consented as well. These patients have Foley catheters in place during the surgery. Five cc's of urine will be collected from the catheter at pre-determined intervals 5, 10, 20, 40 and 60 minutes, aliquoted (2mL) and frozen in liquid nitrogen and later stored in the -80 freezer.
62260466|NCT01759550||LigaSure Device|In this prospective observational study, 60 patients scheduled to undergo a Roux-en-Y or gastric reduction procedure (sleeve gastrectomy or plication) will have hemostasis controlled with LigaSure Advance ™ Pistol Grip or LigaSure™ Blunt Tip, respectively. Both devices are regularly used at Duke in the Bariatric Surgery division. The surgeon will select which device is used. There will be no randomization. The device decision tree will be based upon the procedure. Cases that require enterotomy will utilize the AdvanceTM pistol grip. Cases which don't need enterotomy will utilize the 5 Blunt Tip. The LigaSure AdvanceTM pistol grip and LigaSureTM Blunt Tip are used exclusively with the Force TriadTM Energy platform. There is no simultaneous use.
62260467|NCT01439672|EXPERIMENTAL|Insulin Sensitivity|Single arm. Each subject will consume a mixed meal beverage along with insulin administration in order to calculate insulin sensitivity.
62260468|NCT03807804|EXPERIMENTAL|HLCM051 group【ARDS caused by pneumonia cohort】|"* Patients will receive the standard therapy~* A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute"
62260469|NCT03807804|NO_INTERVENTION|Standard treatment group【ARDS caused by pneumonia cohort】|•Patients will receive the standard therapy
62260470|NCT03807804|EXPERIMENTAL|HLCM051 group【ARDS caused by COVID-19 cohort 】|"* Patients will receive the standard therapy~* A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute"
62842446|NCT02692638|EXPERIMENTAL|Early laparoscopic enterolysis|Patient randomized to the early laparoscopy arm will undergo diagnostic laparoscopy within 24 hours of admission (depending on surgeon and operating room availability). Standard laparoscopy will be performed including supine positioning, sequential compression devices, and appropriate pre-incision antibiotics. Trocar placement will be at the surgeon's discretion and as appropriate for the patient's previous incisions. The necessity for conversion will be left to the discretion of the attending surgeon. Post operative management will conform to the standards of care. Nasogastric tubes will not be routinely placed.
62842447|NCT02692638|ACTIVE_COMPARATOR|trial of nonoperative management|Patients randomized to the trial of nonoperative management arm will undergo standard therapy including nil per os (NPO), nasogastric decompression only if actively vomiting, intravenous fluids while awaiting return of bowel function. Patients who do not achieve return of bowel function within 72 hours of admission will undergo attempted laparoscopic enterolysis with the understanding that conversion to open procedure may be necessary.
62842448|NCT03578783|EXPERIMENTAL|PSD502|PSD502 spray contains a eutectic-like mixture of lidocaine and prilocaine, and a propellant (norflurane) which also serves as a solvent. Each spray contains 7.5 mg lidocaine and 2.5 mg prilocaine. A single dose consists of 3 sprays applied to the glans penis.
62842449|NCT03578783|PLACEBO_COMPARATOR|Placebo|The placebo is a metered dose spray, identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine (instead it contains PEG600 and Povidone).
62842450|NCT00006289|ACTIVE_COMPARATOR|Placebo first, then Neurotropin (G-1)|Double blind cross-over study: receive placebo for 5 weeks and then Neurotropin for 5 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
62842451|NCT00006289|ACTIVE_COMPARATOR|Neurotropin first, then Placebo (G-2)|Double blind cross-over study: receive Neurotropin for 5 weeks and then placebo for 5 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
62842452|NCT05592587|EXPERIMENTAL|Distraction using eye massage device producing both vibrations and nature sounds.|
62842453|NCT05592587|EXPERIMENTAL|Distraction using eye massage device producing vibratory stimulations only.|
62842454|NCT05592587|OTHER|Using basic behavior guidance techniques and without using any type of distraction aids.|
62842455|NCT01091220|PLACEBO_COMPARATOR|Placebo|0.9% saline
62842456|NCT01091220|EXPERIMENTAL|Certolizumab pegol|Certolizumab pegol 400 mg
62842457|NCT01880138|EXPERIMENTAL|watching animated cartoon|
62842458|NCT01880138|PLACEBO_COMPARATOR|not watching animated cartoon|
62260471|NCT03761615||type 1 diabetes and pregnancy|Pregnant women with T1D on insulin pumps (CSII/SAP/PLGS) will be offered enrollment in a prospective study that will capture: 1) Dexcom G6 CGM data, 2) self-monitoring of blood glucose (SMBG), 3) insulin pump settings, 4) insulin delivery records, and 5) maternal and fetal outcomes.
62617134|NCT01728571|ACTIVE_COMPARATOR|Vitamin D3 + fish oil|Dietary Supplement: vitamin D3 Drug: omega-3 fatty acids (fish oil)
62617135|NCT01728571|ACTIVE_COMPARATOR|Vitamin D3 + fish oil placebo|Dietary Supplement: vitamin D3 Dietary Supplement: fish oil placebo
62617136|NCT01728571|ACTIVE_COMPARATOR|Vitamin D3 placebo + fish oil|Drug: omega-3 fatty acids (fish oil) Dietary Supplement: vitamin D3 placebo
62057361|NCT03782090|ACTIVE_COMPARATOR|Control|Endobronchial intubation using conventional technique with left-sided double-lumen endotracheal tube (Shiley®, Covidien, Mansfield, MA, USA)
62617137|NCT01728571|PLACEBO_COMPARATOR|Vitamin D3 placebo + fish oil placebo|Dietary Supplement: vitamin D3 placebo Dietary Supplement: fish oil placebo
62617138|NCT03182491||Anaphylaxis|
62057362|NCT03782090|EXPERIMENTAL|Experimental|Endobronchial intubation using novel left-sided double-lumen endobronchial tube (Ankor®,Insung Medical, Wonjou, S. Korea)
62057363|NCT02496338|EXPERIMENTAL|Intervention group|Training program about menopausal health isues
62057364|NCT02496338|NO_INTERVENTION|Control group|No training program about menopausal health isues
62057365|NCT05276167|EXPERIMENTAL|The experimental group|Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy.
62057366|NCT05276167|NO_INTERVENTION|The control group|Participants in the control group will receive radical cystectomy alone.
62260472|NCT04500782||Patients|Group of patients with CP aged 4 to 10 years.
62057367|NCT00708435|EXPERIMENTAL|Beriplex® P/N|
62057368|NCT00708435|ACTIVE_COMPARATOR|Fresh frozen plasma|
62260473|NCT01022242|PLACEBO_COMPARATOR|Placebo|Placebo is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
62445879|NCT03402893|EXPERIMENTAL|single arm Onexton gel application|Onexton gel will be supplied to all subjects and applied once daily to the face
62445880|NCT03651115||Neonates with gentamicin|
62445881|NCT03651115||Neonates with vancomycin|
62445882|NCT05945199|EXPERIMENTAL|tDCS active|
62445883|NCT05945199|PLACEBO_COMPARATOR|Sham tDCS|
62445884|NCT01461200||Non allergics|
62445885|NCT01461200||allergics|
62445886|NCT04081480|OTHER|Valacyclovir oral solution|Valacyclovir oral solution as administered in standard of care. Dosage: 10 mg/kg BID for children weighing less than 40 kg and 500 mg BID for children weighing 40 kg or more.
62445887|NCT00630565|EXPERIMENTAL|Bone Marrow Transplant (2-70 Years old)|Patients over the age of two will receive a cytoreductive regimen of total-body irradiation and cyclophosphamide (TBI/CY) as well as sargramostim, dexamethasone, etoposide, transplantation (bone marrow transplantation/hematopoietic stem cell transplantation/peripheral blood stem cell transplantation).
62445888|NCT00630565|EXPERIMENTAL|Bone Marrow Transplant (less and 2 years old)|Patients under the age of two, and patients who cannot receive total body irradiation (TBI), will receive a cytoreductive regimen of Busulfan and cyclophosphamide (BU/CY) as per the Johns Hopkins University Hospital regimen as well as sargramostim, dexamethasone, etoposide, transplantation (bone marrow transplantation/hematopoietic stem cell transplantation/peripheral blood stem cell transplantation).
62445889|NCT05561309|EXPERIMENTAL|dose 1|"Experimental: HR18034 190mg (10ml)~Intervention: Drug: HR18034~Active Comparator: Ropivacaine Hydrochloride Injection~Ropivacaine Hydrochloride Injection 50mg (10mL)~Intervention: Drug: Ropivacaine Hydrochloride Injection"
62445890|NCT05561309|EXPERIMENTAL|dose 2|"Experimental: HR18034 285mg (15ml)~Intervention: Drug: HR18034~Active Comparator: Ropivacaine Hydrochloride Injection~Ropivacaine Hydrochloride Injection 75mg (15mL)~Intervention: Drug: Ropivacaine Hydrochloride Injection"
62445891|NCT05561309|EXPERIMENTAL|dose 3|"Experimental:HR18034 380mg (20ml)~Intervention: Drug: HR18034~Active Comparator: Ropivacaine Hydrochloride Injection~Ropivacaine Hydrochloride Injection 100mg (20mL)~Intervention: Drug: Ropivacaine Hydrochloride Injection"
62445892|NCT04293666|EXPERIMENTAL|Kefir drink|(2) The first phase of Kefir, the second phase of the placebo group (hereinafter referred to as group B
62445893|NCT04293666|PLACEBO_COMPARATOR|placebo|(1) first-stage placebo and second-stage Kefir group (hereinafter referred to as group A).
62445894|NCT05695248|EXPERIMENTAL|Cohort 1 - Single Dose|Participants will receive 1 dose of STAR-0215.
62445895|NCT05695248|EXPERIMENTAL|Cohort 2 - Multiple Dose|Participants will receive 2 doses of STAR-0215 administered 3 months apart.
62445896|NCT05695248|EXPERIMENTAL|Cohort 3 - Multiple Dose|Participants will receive 2 doses of STAR-0215 administered 1 month apart.
62445897|NCT01939119||retinal vascular occlusion|Patients with retinal vascular occlusion undergo a hematocrit dependent 5 day hemodilution
62445898|NCT02641613|ACTIVE_COMPARATOR|supraclavicular|patients receive a supraclavicular block for forearm or hand surgery with 30 ml of a mixture of ropivacaine 0.5 % and mepivacaine 1 %
62445899|NCT02641613|EXPERIMENTAL|retroclavicular block|patients receive a retroclavicular block for forearm or hand surgery with 30 ml of a mixture of ropivacaine 0.5 % and mepivacaine 1 %
62445900|NCT04867525||Colorectal Cancer Metastatic|
62445901|NCT06483295|EXPERIMENTAL|Group A|Mobile Internet Platform Follow-up Group
62445902|NCT06483295|NO_INTERVENTION|Group B|Traditional Outpatient Follow-up Group
62617139|NCT03182491||Febrile transfusion reactions|
62617140|NCT03182491||Mild allergic reactions|
62617141|NCT03182491||Healthy controls|
62842459|NCT02309905||Control group before telemedicine|Inmates of prisons not having telemedicine before implementation of telemedicine in prisons having telemedicine
62842460|NCT02309905||Control group after telemedicine|Inmates of prisons not having telemedicine after implementation of telemedicine in prisons having telemedicine
62842461|NCT02309905||Exposed group, before telemedicine|Inmates of prisons having telemedicine before implementation of telemedicine
62842462|NCT02309905||Exposed group, after telemedicine|Inmates of prisons having telemedicine after implementation of telemedicine
62842463|NCT02744404||POC EID|Point of Care Early Infant Diagnosis qualitative technologies (Alere q) will be implemented. Sample collection and testing will happen in the same location within the health care facility.
62260474|NCT01022242|EXPERIMENTAL|PXL01|PXL01 is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
62260475|NCT03518879|EXPERIMENTAL|ASTHMA-Educator arm|The ASTHMA-Educator mobile application for patient-centered asthma education. The application is administered via on-site iPad (tablet).
62260476|NCT03688880|ACTIVE_COMPARATOR|Dermabond Advanced|Dermabond Advanced (a topical skin adhesive) was applied on Day 0. Dermabond Advanced was applied in 1 continuous layer onto a dry wound through painting motions; the wound was held for 60 seconds to allow for complete polymerization.
62260477|NCT03688880|EXPERIMENTAL|MAR-CUTIS|MAR-CUTIS (polyurethane-based skin adhesive) was applied on Day 0. MAR-CUTIS was applied in 1 to 2 millimeter (mm) thick layer ensuring that at least 1 cm of the glue is applied over the length of the wound on each side; the wound was held for approximately 30 seconds to allow for initial polymerization.
62260478|NCT01430455|EXPERIMENTAL|Tranylcypromine|Active, open-label tranylcypromine treatment
62842464|NCT02744404||Laboratory-based testing|Conventional laboratory-based testing using the Abbott m2000 technology will continue to be used per standard of care in Malawi. Dried blood spot samples will be collected at health care facilities and transported within the national network to centralized laboratories for testing.
62842465|NCT02417506|EXPERIMENTAL|E-OA-07 (Lanconone)|500 mg two capsules to be taken stat at the site
62842466|NCT02417506|ACTIVE_COMPARATOR|Ibuprofen|200 mg two capsule to be taken stat at the site
62842467|NCT02410564|ACTIVE_COMPARATOR|CBTI treatment|cognitive behavioral therapy for insomnia (CBTI) treatment is a validated web based version of CBT-I, which will take place over seven weeks and will include a combination of face-to-face and telephone sessions, and email updates
62842468|NCT02410564|PLACEBO_COMPARATOR|Waitlist control condition|No advice regarding sleep will be given to the control group and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
62842469|NCT06276504|EXPERIMENTAL|Pembrolizumab|Pembrolizumab (commercial name: KEYTRUDA; MSD), 25 mg/ml solution for intravenous (IV) injection
62842470|NCT04638361||No laryngeal mobility disorder post cardiac surgery|No Follow up, no questionnaires and no nasofibroscopic control.
62057369|NCT04547088|EXPERIMENTAL|Camrelizumab+Apatinib|Patients with recurrent or metastatic nasopharyngeal carcinoma who failed to first-line platinum-based chemotherapy. Every patient will receive Apatinib 250mg orally every day and Camrelizumab 200mg iv every 3 weeks until disease progression or intolerance of side effects.
62842471|NCT04638361||Laryngeal mobility disorder post cardiac surgery|During a follow-up consultation, questionnaires will be offered to assess the child's quality of life.
62842472|NCT05007535||HD-IVUS-guided primary PCI|Prospective, single arm, observational
62842473|NCT02950467|EXPERIMENTAL|Group therapy plus psilocybin|Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.
62842474|NCT03313167||Atrial Fibrillation-potential Patients|individuals 65 years of age or older with moderate-to-high risk of stroke
62842475|NCT00464776|EXPERIMENTAL|1|Various sequences of 3 doses of Aliskiren plus placebo
62842476|NCT00464776|EXPERIMENTAL|2|Various sequences of 3 doses of Aliskiren plus placebo
62842477|NCT00464776|EXPERIMENTAL|3|Various sequences of 3 doses of Aliskiren plus placebo
62842478|NCT00464776|EXPERIMENTAL|4|Various sequences of 3 doses of Aliskiren plus placebo
62842479|NCT00003439|EXPERIMENTAL|Arm I|Cohorts of 3-6 patients each receive escalating doses of intraperitoneal recombinant human interleukin-12 (rhIL-12) administered weekly for 9 weeks. If a patient tolerates rhIL-12 and shows evidence of objective response or stable disease, patient may receive up to 9 additional weeks of treatment. Treatment continues in the absence of unacceptable toxicity or disease progression. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which no more than 1 of 6 patients experiences dose limiting toxicity.
62842480|NCT03365349|EXPERIMENTAL|living theatre|One session consisting for the patient of telling a story about his/her own life with diabetes , which is first written and then transformed to a script to be played by professional actors co-directed by the patient with the support of the Director to create a little play.
62057370|NCT01991821|EXPERIMENTAL|APD421|IV APD421 single dose
62057371|NCT01991821|PLACEBO_COMPARATOR|Placebo|IV placebo single dose
62260479|NCT05312177||DS with CAVSD Repair|Children ages 5 through 12 years with Down syndrome who had Complete atrioventricular septal defect (CAVSD) repair in the first year of life and their parent(s) will be administered the Stanford-Binet Intelligence Scales, Fifth Edition (SB-5), Peabody Picture Vocabulary Test, Fifth Edition (PPVT-5), Expressive Vocabulary Test, Third Edition (EVT-3), Leiter International Performance Scale, Third Edition (Leiter-3), Vineland-3 Q-global Comprehensive Report (Vineland-3) ,Social Communication Questionnaire, Current version (SCQ), Aberrant Behavior Checklist, Second Edition, (ABC-2) and Repetitive Behavior Scale, Revised (RBS-R)
62445903|NCT05247710||Patients diagnosed with non-superficial basal cell carcinoma|
62842481|NCT03365349|ACTIVE_COMPARATOR|writing workshop|"one session consisting for the patient of writing a Letter to his/her own diabetes and then to read it to the group of patients and the healthcare providers."
62842482|NCT05932667|EXPERIMENTAL|Single arm: combination of Milademetan at the recommended dose and fulvestrant|"In the safety run-in, 6 patients will be included milademetan at dose D and fulvestrant 500mg IM at Day1, Day15 of cycle 1, then Day1 of every 28 day-cycle. In case of unacceptable toxicity at the D-dose, a D-1 dose will be investigated, followed by a D-2 dose in case of unacceptable toxicity at D-1 dose.~In the phase II, patients will be treated at the milademetan dose recommended in the safety run-in. Dose reductions will be allowed on subsequent cycles in case of toxicity."
62842483|NCT02918513|EXPERIMENTAL|Wellness Intervention|WILD 5 Wellness is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
62842484|NCT01229267|EXPERIMENTAL|V212 Consistency Lot 1|Participants randomized to receive V212 consistency Lot 1 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
62842485|NCT01229267|EXPERIMENTAL|V212 Consistency Lot 2|Participants randomized to receive V212 consistency Lot 2 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
62842486|NCT01229267|EXPERIMENTAL|V212 Consistency Lot 3|Participants randomized to receive V212 consistency Lot 3 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
62842487|NCT01229267|EXPERIMENTAL|V212 High Antigen Lot|Participants randomized to receive V212 High Antigen Lot given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
62842488|NCT01229267|PLACEBO_COMPARATOR|Placebo|Participants randomized to receive matching placebo given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
62842489|NCT02901704|EXPERIMENTAL|renal denervation|Iberis Multielectrode Renal Denervation System (AngioCare)
62842490|NCT02901704|SHAM_COMPARATOR|Sham procedure|Renal anigography
62842491|NCT05739201|ACTIVE_COMPARATOR|Group (I)|30 patients will receive interscalene nerve block.
62842492|NCT05739201|ACTIVE_COMPARATOR|Group (II)|30 Patients will receive anterior suprascapular nerve block.
62842493|NCT05739201|ACTIVE_COMPARATOR|Group (III)|30 atients will receive pericapsular nerve group block around shoulder surgery
62842494|NCT05674305|EXPERIMENTAL|Radiotherapy alone|Patients with undectable plazma EBV DNA after first cycle neoadjuvant chemotherapy using GP regimen (gemcitabine 1000mg/m2 d1,8+ cisplatin 25mg/m2 d1-3) and without rebound during the course of second and third cycle received definitive radiotherapy to head and neck region.
62842495|NCT05674305|ACTIVE_COMPARATOR|Concurrent chemoradiotherapy|Patients with undectable plazma EBV DNA after first cycle neoadjuvant chemotherapy using GP regimen (gemcitabine 1000mg/m2 d1,8+ cisplatin 25mg/m2 d1-3) and without rebound during the course of second and third cycle received definitive radiotherapy to head and neck region plus two cycles of concurent chemotherapy （cisplatin 80mg/m2）
62842496|NCT02064101||Adolescent idiopathic scoliosis|Patients with adolescent idiopathic scoliosis undergoing spinal fusion
62057372|NCT05903222||Posterior Pericardiotomy|All patients who were randomized to receive posterior pericardiotomy (intervention) in the original PALACS trial.
62842497|NCT06462105|EXPERIMENTAL|Liposomal irinotecan + Carboplatin + Serplulimab|Liposomal irinotecan: 50mg/m2, ivgtt, d1; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable.
62842498|NCT06462105|EXPERIMENTAL|Etoposide + Carboplatin + Serplulimab|Etoposide: 100 mg/m2, ivgtt, d1-3; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable.
62842499|NCT01608945||steroid,liver function I/R|
62842500|NCT00899431|ACTIVE_COMPARATOR|Group 1: Lenalidomide|Chemotherapy, Plus Lenalidomide - Lenalidomide starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months. Fludarabine 30 mg/m\^2 intravenously daily on days -5, -4, -3. Rituximab 375 mg/m2 intravenously on day -13, and 1000 mg/m\^2 on days -6, +1 and +8. Thymoglobulin 1.0 mg/kg intravenously over 4 hours (day -2 and -1). On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes. Bendamustine 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine). Allopurinol 300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
62842501|NCT00899431|ACTIVE_COMPARATOR|Group 2: No Lenalidomide|Chemotherapy Treatment, No Lenalidomide - Fludarabine 30 mg/m\^2 intravenously daily on days -5, -4, -3. Rituximab 375 mg/m2 intravenously on day -13, and 1000 mg/m\^2 on days -6, +1 and +8. Thymoglobulin 1.0 mg/kg intravenously over 4 hours (day -2 and -1). On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes. Bendamustine 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
62842502|NCT02967224|EXPERIMENTAL|Toujeo|Toujeo will be administered once daily in addition to noninsulin antidiabetic agents
62842503|NCT02967224|ACTIVE_COMPARATOR|"Standard of care commercially available basal insulin"|Lantus, Humulin Neutral Protamine Hagedorn (NPH), Levemir or Tresiba or other basal insulin, including biosimilar insulin will be administered once or twice daily according to label in addition to noninsulin antidiabetic agents
62842504|NCT00632606|ACTIVE_COMPARATOR|Arm 1|magnesium sulfate 2 grams intravenously w/ acetaminophen 1 gram orally
62842505|NCT00632606|ACTIVE_COMPARATOR|Arm 2|metoclopramide 10 mg intravenously w/ 1 gram acetominophen orally
62057373|NCT05903222||No Posterior Pericardiotomy (control)|All patients who were randomized to receive no intervention/no posterior pericardiotomy in the original PALACS trial
62057374|NCT01755702|PLACEBO_COMPARATOR|Arm 1|Placebo
62842506|NCT06020989|EXPERIMENTAL|A|Lazertinib + chemotherapy combination
62842507|NCT06020989|ACTIVE_COMPARATOR|B|Lazertinib monotherapy
62842508|NCT06020989|ACTIVE_COMPARATOR|C|Lazertinib monotherapy
62842509|NCT02544516|EXPERIMENTAL|Patients|patients suffering schizophrenic disorders and who will perform cognitive tasks + PANSS+ IQ
62842510|NCT02544516|ACTIVE_COMPARATOR|control group|healthy patients who will perform cognitive tasks
62842511|NCT05936697|SHAM_COMPARATOR|Sham Group|During training, participants will be asked to follow the instructions on a computer screen and complete five rounds of task. Each round starts with a 30-s rest phase followed by 4.5 min of self-regulation phase. At the rest phase, a fixed cross will appear onscreen, and participants will be instructed to sit still and relax. At the regulation phase, they will be asked to make the person smile (as an intrinsic social reward) but without tips. The intensity of smiling will be manipulated by morphing photographs of a neutral and a happy face and will represent the increase in either frontal alpha asymmetry or frontal oxyhaemoglobin asymmetry. The values at the moment will be compared against the baseline. Participants will undergo a 3-min rest period before and after each training session to track changes in resting-state brain activity. In the sham condition, participants will receive visual feedback based on pre-recordings and/or other participants' recordings.
62842512|NCT05936697|EXPERIMENTAL|fNIRS Group|During training, participants will be asked to follow the instructions on a computer screen and complete five rounds of task. Each round starts with a 30-s rest phase followed by 4.5 min of self-regulation phase. At the rest phase, a fixed cross will appear onscreen, and participants will be instructed to sit still and relax. At the regulation phase, they will be asked to make the person smile (as an intrinsic social reward) but without tips. The intensity of smiling will be manipulated by morphing photographs of a neutral and a happy face and will represent the increase in either frontal alpha asymmetry or frontal oxyhaemoglobin asymmetry. The values at the moment will be compared against the baseline. Participants will undergo a 3-min rest period before and after each training session to track changes in resting-state brain activity. In the fNIRS condition, participants will receive visual feedback based on their own fNIRS recordings.
62617142|NCT04112550|ACTIVE_COMPARATOR|Methadone|This cohort will receive oral methadone 15mg po tablet pre-operatively
62445904|NCT02833402||UUI patients undergoing SNM|Urine specimens, questionnaire, and medical data will be collected from subjects that have UUI and are undergoing InterStim placement (SNM).
62617143|NCT04112550|ACTIVE_COMPARATOR|Oxycodone|This cohort will receive oxycodone/acetaminophen 10/325 po tablet pre-operatively
62057375|NCT01755702|ACTIVE_COMPARATOR|Arm 2|paracetamol marketed forumulation
62057376|NCT01755702|ACTIVE_COMPARATOR|Arm 3|ibuprofen marketed formulation
62445905|NCT04553575||CoViD-19 patients cohort|Patients are followed for 2 years after diagnosis. The only one intervention is blood samples withdrawn for serologies
62617144|NCT05420831|ACTIVE_COMPARATOR|Sacrospinous fixation of the vaginal apex with the synthetic mesh|
62617145|NCT05420831|ACTIVE_COMPARATOR|Laparoscopic sacrocolpopexy|
62057377|NCT01755702|EXPERIMENTAL|Arm 4|experimental paracetamol + caffeine formulation
62617146|NCT06180083|EXPERIMENTAL|Azelastine Hydrochloride/ Fluticasone propionate nasal spray|Azelastine Hydrochloride/ Fluticasone propionate 137 microgram/50 microgram nasal spray
62617147|NCT06180083|ACTIVE_COMPARATOR|'DYMISTA' Nasal Spray|'DYMISTA' (Azelastine Hydrochloride/ Fluticasone Propionate) Nasal Spray 137 microgram/50 microgram
62617148|NCT00752141|EXPERIMENTAL|1|oral oxybutynin
62617149|NCT00752141|EXPERIMENTAL|2|oxybutynin topical gel
62617150|NCT00752141|PLACEBO_COMPARATOR|3|placebo tablets plus placebo gel
62617151|NCT01635309||Non-cardiac surgical patients|\>= 45 years old, undergoing non-cardiac surgery requiring regional or general anaesthetic and an overnight stay with cardiac risk factors
62617152|NCT03497767|EXPERIMENTAL|Osimertinib|80mg Osimerinib taken once daily
62617153|NCT03497767|EXPERIMENTAL|Stereotactic Radiosurgery + Osimertinib|Upfront Stereotactic Radiosurgery (SRS) followed by 80mg Osimerinib taken once daily
62617154|NCT05741814|ACTIVE_COMPARATOR|Propofol|Patients receive gynaecologist guided individualised propofol sedation
62617155|NCT05741814|ACTIVE_COMPARATOR|Anaesthetic guided anaesthesia|Patients receive anaesthetist guided full anaesthesia
62617156|NCT04273932|EXPERIMENTAL|Lithium aspartate 15mg a day|15mg of elemental lithium administered every morning by mouth.
62057378|NCT03009682|OTHER|Olaparib 300 mg|Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days
62057379|NCT06325423||MIBC patients who received NAC|Patients with muscle-invasive bladder cancer who received neoadjuvant chemotherapy before radical cystectomy or bladder preservation
62057380|NCT03707639|EXPERIMENTAL|Experimental: Apatinib plus POF|Apatinib (500 mg qd p.o.) plus POF until disease progression or intolerable toxicity or refused by the patients.
62057381|NCT04446897|EXPERIMENTAL|mesenchymal stem cells|standard treatment according to clinical protocols plus mesenchymal stem cells
62617157|NCT04273932|EXPERIMENTAL|Lithium aspartate 45mg a day|20mg every morning and 25mg every evening of elemental lithium administered by mouth.
62617158|NCT04273932|EXPERIMENTAL|Lithium carbonate|The dose will be titrated based on weekly blood tests to achieve a target serum level of 0.40-0.50mmol/L, which represents an elemental lithium dose of about 85-170mg a day.
62617159|NCT04273932|NO_INTERVENTION|No lithium treatment|Control arm
62617160|NCT04578509||Salicov|Ambulatory adults or children requiring screening for SARS-CoV-2 by nasopharyngeal swab
62617161|NCT04578509||SalicovII (ancillary study)|Ancillar study : Children and teachers / staff from middle and high schools in Ile de France Saliva samples is collected as part of care. Only a self-rated questionnaire is collected.
62617162|NCT05491395|EXPERIMENTAL|Post Mastectomy Hypofractionated Radiotherapy Arm|Post Mastectomy Hypofractionated Radiotherapy Arm
62617163|NCT05491395|NO_INTERVENTION|Post Mastectomy Conventional Radiotherapy|Post Mastectomy Conventional Radiotherapy
62617164|NCT03127761||Allogeneic HCT|Prospectively enrolled cohort of patients receiving allogeneic hematopoietic cell transplantation for multiple myeloma
62617165|NCT03127761||Historical autoHCT|Historical cohort of patients with autologous hematopoietic cell transplantation between 2010 and 2016
62617166|NCT02215499|ACTIVE_COMPARATOR|Xyrem®|Oral suspension
62057382|NCT04446897|ACTIVE_COMPARATOR|standard treatment|standard treatment according to clinical protocols
62057383|NCT00493077|EXPERIMENTAL|1|
62057384|NCT05365243|EXPERIMENTAL|Interventional|All patients will use AMMA
62617167|NCT02215499|EXPERIMENTAL|JZP-386|Oral suspension
62617168|NCT02215499|PLACEBO_COMPARATOR|Placebo|Oral suspension
62057385|NCT01127880|ACTIVE_COMPARATOR|Ancef 1 gm or Clindamycin 300 mg|Group A will receive Ancef 1gm or Clindamycin 300mg if penicillin or bet-lactam allergy exists
62057386|NCT01127880|PLACEBO_COMPARATOR|Placebo|Group B will receive .9% Normal Saline as a placebo.
62057387|NCT01478009|EXPERIMENTAL|KRG Extract|
62057388|NCT01478009|PLACEBO_COMPARATOR|Placebo|
62057389|NCT01105702|EXPERIMENTAL|TBL/RT|"Cycle 1(One 42-day cycle)~* Temozolomide 75 mg/m\^2 orally (42 consecutive days), beginning the night prior to the first radiation treatment~* Radiation within 3-5 weeks of surgery~* Bevacizumab 10mg/kg, IV, starting 29 (+3) days post surgery and every 2 weeks~Treatment Cycles 2-7 (28 days per cycle)~* Temozolomide at a dose of 150 mg/m\^2 on Days 1-7~* Bevacizumab 10 mg/kg on Day 8 and Day 22~* Initiate Lithium carbonate treatment at 300 mg, orally, twice a day; dose increased every 7 days up to 600mg, orally, twice a day, to a serum lithium level of 0.8-1.2 mEq/L."
62445906|NCT01011647||Acute coronary conditions|"Patients hospitalized with the following conditions~* Unstable angina~* Acute myocardial infarction~* Congestive heart failure"
62445907|NCT02044172|ACTIVE_COMPARATOR|Radical prostatectomy|Radical prostatectomy
62445908|NCT02044172|ACTIVE_COMPARATOR|Conformal radiation therapy|Conformal radiation therapy External beam radiation therapy
62445909|NCT02044172|ACTIVE_COMPARATOR|Active monitoring|Active monitoring of prostate specific antigen levels and disease surveillance
62445910|NCT02250560|EXPERIMENTAL|Replenine®-VF|
62445911|NCT05913336|EXPERIMENTAL|Remimazolam Tosilate|IV of Remimazolam Tosilate
62445912|NCT06038513|EXPERIMENTAL|Transnasal Thermal Regulating Device|Consented subjects who develop fever will undergo cooling via transnasal thermal regulating device for a period of 24 hours
62445913|NCT01577511||30 Patients|"Patients with operable, stage III or IV, adenocarcino-type colorectal cancer treated at the Nîmes University Hospital.~Intervention: Samples and follow up"
62445914|NCT03781297|ACTIVE_COMPARATOR|Intervention: NET+G|In addition to usual care, participants will receive six sessions of Narrative Exposure Therapy over six weeks plus the option to receive genealogical services.
62445915|NCT03781297|ACTIVE_COMPARATOR|Intervention: NET|In addition to usual care, participants will receive six sessions of Narrative Exposure Therapy over six weeks.
62445916|NCT05059535|EXPERIMENTAL|cryoneurolysis of the saphenous nerve|A cryoneurolysis of the saphenous nerve will be performed between 7 days and 5 days before the knee arthroplasty
62445917|NCT05059535|EXPERIMENTAL|cryoneurolysis of geniculate nerves|A cryoneurolysis of geniculate nerves will be performed between 7 days and 5 days before the knee arthroplasty
62445918|NCT05059535|PLACEBO_COMPARATOR|control|No cryoneurolysis will be performed before the knee arthroplasty
62445919|NCT05083650|EXPERIMENTAL|Amniotic membrane without internal limiting membrane peeling|The surgery performed will be phacoemulsification + vitrectomy using an amniotic membrane to plug the macular hole using air as tamponade.
62445920|NCT05083650|ACTIVE_COMPARATOR|Amniotic membrane with internal limiting membrane peeling|The surgery performed will be phacoemulsification + vitrectomy + internal limiting membrane peeling using an amniotic membrane to plug the macular hole using air as tamponade.
62445921|NCT03467477|EXPERIMENTAL|Flortaucipir PET Scan|
62617169|NCT05068011||Spinal cord stimulation|Patients will receive differential target multiplexed spinal cord stimulation
62617170|NCT01741571|ACTIVE_COMPARATOR|EBUS guided FNA with suction|"Device/procedure: lymph node tissue collection using fine needle aspiration with suction applied.~Four fine needle aspirations will be taken sequentially from each lymph node. Two with suction and two without suction applied."
62617171|NCT01741571|EXPERIMENTAL|EBUS guided FNA without suction|"Device/procedure: lymph node tissue collection using fine needle aspiration without suction applied.~Four fine needle aspirations will be taken sequentially from each lymph node. Two with suction and two without suction applied."
62057390|NCT02601534|EXPERIMENTAL|Zero-time Exercise (PA) group|"The intervention arm (PA group) aims to improve family communication and well-being, reduce sedentary behavior and increase physical activity. The programme includes a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months after the first session as well as biweekly/monthly mobile messages.~The holistic health session is not a part of the cRCT, it aims to collect one-year feedback from participants and provides additional health information to improve dietary habits."
62445922|NCT00686036|EXPERIMENTAL|vandetanib|300 mg orally, once daily for up to 18 months
62445923|NCT00686036|PLACEBO_COMPARATOR|Placebo|orally, once daily for up to 18 months
62445924|NCT02710071|EXPERIMENTAL|Placebo, Nebivolol, Hydrochlorothyazide|Sequence: Placebo, Then Nebivolol 5mg for 2 weeks followed by nebivolol 10 mg for 4 weeks,Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
62445925|NCT02710071|EXPERIMENTAL|Placebo, Hydrochlorothyazide, Nebivolol|Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Nebivolol 5mg for 2 weeks followed by nebivolol 10 mg for 4 weeks.
62445926|NCT05730140||patients undergoing general anesthesia|patients undergoing general anesthesia
62842513|NCT05936697|EXPERIMENTAL|EEG Group|During training, participants will be asked to follow the instructions on a computer screen and complete five rounds of task. Each round starts with a 30-s rest phase followed by 4.5 min of self-regulation phase. At the rest phase, a fixed cross will appear onscreen, and participants will be instructed to sit still and relax. At the regulation phase, they will be asked to make the person smile (as an intrinsic social reward) but without tips. The intensity of smiling will be manipulated by morphing photographs of a neutral and a happy face and will represent the increase in either frontal alpha asymmetry or frontal oxyhaemoglobin asymmetry. The values at the moment will be compared against the baseline. Participants will undergo a 3-min rest period before and after each training session to track changes in resting-state brain activity. In the EEG condition, participants will receive visual feedback based on their own EEG recordings.
62842514|NCT05008965|EXPERIMENTAL|FB825|"FB825 will be administered at 8 mg/kg for the first dose and 4 mg/kg for the other five doses.~FB825 will be administered as 1-hour IV- infusions every 4 weeks."
62842515|NCT05008965|PLACEBO_COMPARATOR|Placebo|"Placebo will be administered at 8 mg/kg for the first dose and 4 mg/kg for the other five doses.~Placebo will be administered as 1-hour IV- infusions every 4 weeks."
62842516|NCT04635540|EXPERIMENTAL|Interventional Arm|The Interventional Arm will receive the educational brochure and complete the study tasks and questionnaires.
62842517|NCT03061006|EXPERIMENTAL|Dabigatran Etexilate|150 mg BID (CrCL \> 30 mL/min) or 75 mg BID (CrCL 15-30 mL/min)
62057391|NCT02601534|PLACEBO_COMPARATOR|Healthy Eating (HE) group|"The control arm (HE group) aims to improve family communication and well-being and enhance healthy eating habits. Participants are required to engage their family members in their activities. The programme includes a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months after the first session as well as biweekly/monthly mobile messages.~The holistic health session is not a part of the cRCT, it aims to collect one-year feedback from participants and provides additional health information to improve physical activity habit."
62057392|NCT04128293|EXPERIMENTAL|Sequence 1 - Treatment ABCD|Participants will receive a single dose of GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in fourth intervention period. There will be at least 7 days wash out period between each dose of study intervention.
62057393|NCT04128293|EXPERIMENTAL|Sequence 2 - Treatment BADC|Participants will receive a single dose of GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in fourth intervention period. There will be at least 7 days wash out period between each dose of study intervention.
62057394|NCT04128293|EXPERIMENTAL|Sequence 3 - Treatment CDAB|Participants will receive a single dose of GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period. There will be at least 7 days wash out period between each dose of study intervention.
62057395|NCT04128293|EXPERIMENTAL|Sequence 4 - Treatment DCBA|Participants will receive a single dose of GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period. There will be at least 7 days wash out period between each dose of study intervention.
62057396|NCT02307201|EXPERIMENTAL|Postpartum Magnesium sulfate|The patient will receive magnesium sulfate as usual for 24 hours postpartum
62057397|NCT02307201|NO_INTERVENTION|No postpartum treatment|The patient did not receive postpartum magnesium sulfate or other anticonvulsant during 24 hours postpartum
62057398|NCT00530803|ACTIVE_COMPARATOR|EMLA Cream|Participants will have a dose of EMLA Cream applied to the venipuncture site 1 hour before the procedure. Dosage based on age and weight: 4-6 years old and heavier than 10kg will receive 10g of EMLA; 7-12 years old and more than 20kg will receive 20g of EMLA.
62057399|NCT00530803|ACTIVE_COMPARATOR|Synera Patch|Participants will have a Synera Patch applied to the venipuncture site 20 minutes prior to the procedure.
62057400|NCT03962244||SEMS Group|The outcome of using self-expanding metal stents (SEMS) in the treatment of postoperative leakage after esophagogastrostomy
62617172|NCT05176613|EXPERIMENTAL|HF-rTMS and ML|High frequency Repetitive Transcranial Magnetic Stimulation and Motor Learning(Experimental group)
62617173|NCT05176613|SHAM_COMPARATOR|Sham-rTMS and ML|Sham Repetitive Transcranial Magnetic Stimulation and Motor Learning
62842518|NCT03061006|ACTIVE_COMPARATOR|Warfarin|Dose-adjusted warfarin (INR: 2.0-3.0)
62842519|NCT03396263|EXPERIMENTAL|Online personalised advice|Online (web-based) delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive online personalised reports.
62842520|NCT03396263|EXPERIMENTAL|Face-to-face personalised advice|Face-to-face delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive nutritional advice face-to-face (in person or via video chat).
62617174|NCT05160298|EXPERIMENTAL|Ropivacaine group|Performance of an echo-guided bilateral erector spinae block at the arrival in the intensive care unit with 20ml of Ropivacaine 2mg/ml in each side.
62842521|NCT03396263|PLACEBO_COMPARATOR|Control|Non-personalised advice Control group. Online (web-based) delivery of non- personalised dietary, weight and physical activity advice based on the UK general health guidelines. This arm will be using the e-Nutri web application. Participants in this group will receive online general recommendations (non- personalised).
62842522|NCT05360121|EXPERIMENTAL|Muscle energy technique+ Thermotherapy +Back Strengthening exercise|
62057401|NCT03962244||EVT Group|The outcome of using endoscopic vacuum therapy (EVT) in the treatment of postoperative leakage after esophagogastrostomy
62057402|NCT04612946|EXPERIMENTAL|Intervention Arm|Patients in the intervention arm will be invited to complete a telemedicine LCS counseling visit and asked for permission to be referred (name and phone number) to the LCS navigator at Penn Medicine to schedule a telemedicine visit. Patients will also be given the option to directly contact the LCS navigator.
62842523|NCT05360121|ACTIVE_COMPARATOR|General stretching+ Thermotherapy +Back Strengthening exercise|
62842524|NCT01359085|ACTIVE_COMPARATOR|Pregabalin|
62842525|NCT01359085|ACTIVE_COMPARATOR|ISBPB|Interscalene brachial plexus block
62842526|NCT00992797|EXPERIMENTAL|Cholecalciferol|
62842527|NCT00992797|PLACEBO_COMPARATOR|Placebo|
62057403|NCT04612946|ACTIVE_COMPARATOR|Control Arm|Patients in the usual care arm will be provided with contact information for the Penn LCS Program and encouraged to discuss LCS with their primary care providers.
62057404|NCT04190628|EXPERIMENTAL|Monotherapy Dose Escalation|"A classic 3+3 design will be used to determine MTD and RP2D. Three to six patients per treatment cohort will be assigned to receive sequentially higher oral doses of ABM-1310 on a twice daily schedule (bid) for 28-day cycles, starting at a dose of 25 mg bid. Patients will receive twice daily oral doses of ABM-1310 continuously until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met."
62617175|NCT05160298|SHAM_COMPARATOR|Control group|Performance of a sham block at the arrival in the intensive care unit with no drugs administration
62617176|NCT04971083|NO_INTERVENTION|Usual Care|"Control (CG): receives Usual Care. Observational data regarding energy and fluid intake, weight, quality of life, symptoms, and distress status will be recorded in the Electronic Health Platform. They will have to ability to print and share this documentation with their HCP at their own discretion.~Inflammation status will be recorded when data from routine blood draws is available"
62842528|NCT04743986|EXPERIMENTAL|Platelet Rich Plasma (PRP)|Patients had 10ml venous blood drawn. Injection was performed under ultrasound guidance by one of two musculoskeletal radiologists. Injection was 3-5ml at the site of tendon pathology with the remainder of the PRP preparation infiltrated into the subacromial space. A leukocyte-poor preparation was used from a pre-packaged kit (RegenLab, Lausanne, Switzerland). The samples were centrifuged at 1500g for 5 mins to yield approx 5.5ml of 80% platelets at 1.6x concentration. The supernatant was then resuspended by inverting the tube several times and was drawn into a separate 5-ml syringe for subacromial injection.
62842529|NCT04743986|ACTIVE_COMPARATOR|Corticosteroid (CS)|Patients had 10ml venous blood drawn. Injection was performed under ultrasound guidance by one of two musculoskeletal radiologists. The blood sample was kept for a similar time delay for centrifugation prior to injection, and was then discarded. 1ml of 40-mg/ml triamcinolone was suspended in 2ml of 0.5% bupivicaine. Injection was performed through a lateral subacromial approach after needle fenestration of the supraspinatus tendon under ultrasound visualization. CS was infiltrated into the subacromial bursa and not the tendon itself.
62842530|NCT02644603|EXPERIMENTAL|Enhanced Recovery After Surgery|Patients underwent ERAS protocol
62842531|NCT02644603|NO_INTERVENTION|Conventional Treatment|Patients underwent conventional treatment
62842532|NCT05389904|ACTIVE_COMPARATOR|Patients colonized with toxigenic C. difficile who do not receive the prevention bundle|Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, who receive standard of care
62842533|NCT05389904|ACTIVE_COMPARATOR|Patients colonized with toxigenic C. difficile who receive the prevention bundle|Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, who receive a preemptive prevention bundle for C. difficile including enhanced room cleaning, C. difficile precautions, pharmacist review and optimization of antibiotics and antacids, and consideration of vancomycin prophylaxis.
62842534|NCT05915481|EXPERIMENTAL|SBRT plus Cadonilimab|Participants will receive SBRT combined with Cadonilimab. Cadonilimab will be administered, 6mg/kg, twice a week, intravenous until disease progression or intolerable toxicities or death. The first cycle of Cadonilimab was started within 3 days before and after the first fraction of SBRT treatment.
62842535|NCT04348916|EXPERIMENTAL|Dose escalation of ONCR-177 by intratumoral injection in subjects with surface lesions|Dose escalation of ONCR-177 intratumoral injections alone in four cohorts in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
62842536|NCT04348916|EXPERIMENTAL|Dose expansion of ONCR-177 in subjects with surface lesions|Dose expansion of ONCR-177 intratumoral injections alone at the recommended phase 2 dose (RP2D) in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
62260480|NCT05312177||DS without major CHD|Children ages 5 through 12 years with Down syndrome without major Congenital Heart Disease(CHD) and their parent(s) will be administered the Stanford-Binet Intelligence Scales, Fifth Edition (SB-5), Peabody Picture Vocabulary Test, Fifth Edition (PPVT-5), Expressive Vocabulary Test, Third Edition (EVT-3), Leiter International Performance Scale, Third Edition (Leiter-3), Vineland-3 Q-global Comprehensive Report (Vineland-3) ,Social Communication Questionnaire, Current version (SCQ), Aberrant Behavior Checklist, Second Edition, (ABC-2) and Repetitive Behavior Scale, Revised (RBS-R)
62260481|NCT04484298|EXPERIMENTAL|reference group|"patients presenting to the emergency department with acute onset dyspnea are assessed for acute heart failure using the bio impedance technology (BIOPAC system) to measure the cardiac output in different clinical situations.~FIRST: the cardiac output (CO) is measured at the reference position. Inbetween each step the patient was put in the reference position during 5 minutes."
62260482|NCT04484298|EXPERIMENTAL|TRINITRINE|0.6 mg of nitroglycerin was given to the patient sublingual and we measure the cardiac output by BIOPAC system(0.6 mg of Nitroglycerin was administered sublingually and CO was evaluated.
62260483|NCT04049591|ACTIVE_COMPARATOR|Higher Dose Unfractionated Heparin Treatment Period|A centre wide policy of administering 100 U/kg bolus of intravenous unfractionated heparin (UFH) for elective percutaneous coronary intervention (PCI) procedures will be implemented during the Higher Dose UFH treatment period.
62260484|NCT04049591|ACTIVE_COMPARATOR|Lower Dose Unfractionated Heparin Treatment Period|A centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures will be implemented during the Lower Dose UFH treatment period.
62260485|NCT03707067|EXPERIMENTAL|Custom fitted compression garments|Made-to-measure compression garments providing high pressures (\> 30 mmHg at the ankle and \>20 mmHg at the thigh - equivalent to European class-2 stockings)
62260486|NCT03707067|SHAM_COMPARATOR|Sham recovery drink|"Non-caloric beverage, labelled as a recovery drink to enhance athletic recovery. Aspartame/acesulfame-k based sweetener, providing 0.5 g carbohydrate and 2 Kcal per serving"
62260487|NCT04674020|EXPERIMENTAL|Single-Arm|Erenumab packed in a SureClick® Autoinjector Pen (AI).
62057405|NCT04190628|EXPERIMENTAL|Combination Therapy Dose Escalation|"A classic 3+3 design will guide the dose escalation in Part B. At each dose level, ABM-1310 will be administered in combination with cobimetinib (Cotellic ®) once daily (qd) for the first 21 days of each 28-day treatment cycle. The starting dose of ABM-1310 will be a dose below the MTD that has been demonstrated to be safe in Part A Monotherapy."
62842537|NCT04348916|EXPERIMENTAL|Dose expansion of ONCR-177 and pembrolizumab in subjects with surface lesions|Dose expansion of ONCR-177 intratumoral injections at the RP2D in combination with pembrolizumab in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
62842538|NCT04348916|EXPERIMENTAL|Dose escalation of ONCR-177 by intratumoral injection in subjects with liver metastases|Dose escalation of ONCR-177 intratumoral injections alone in four cohorts in subjects with advanced and/or refractory solid tumor cancer with liver metastases
62842539|NCT04348916|EXPERIMENTAL|Dose expansion of ONCR-177 by intratumoral injection in subjects with liver metastases|Dose expansion of ONCR-177 intratumoral injections alone at the recommended phase 2 dose (RP2D) in subjects with advanced and/or refractory solid tumor cancer with liver metastases
62842540|NCT04348916|EXPERIMENTAL|Dose expansion of ONCR-177 and pembrolizumab in subjects with liver metastases|Dose expansion of ONCR-177 intratumoral injections at the RP2D in combination with pembrolizumab in subjects with advanced and/or refractory solid tumor cancer with liver metastases
62260488|NCT05758519|EXPERIMENTAL|QLS1128|
62260489|NCT05758519|PLACEBO_COMPARATOR|Placebo|
62260490|NCT05798442|EXPERIMENTAL|mHealth app-based intervention group|The app-based intervention group will be given access to a mHealth app that will be specifically designed to motivate the users to increase their physical activity and healthy diet intake while reducing smoking and alcohol intake. The app provides the patients with standardized dietary and exercise guidelines and sends them frequent advice and reminders to follow the guidelines. Changes in the CVD risk factors of the participants will be assessed based on blood biochemical and anthropometric measurements collected every 4 months over a period of 20 months. The app will be designed to include interactive functions which allow the patients to insert their daily caloric intake and exercise, biometric data, track the improvement in their CVD risk factors and CVD risk score.
62842541|NCT04743778|EXPERIMENTAL|Virtual Diabetes Self-Management Education and Support|Participants will receive one hour of DSME/S delivered by a Certified Diabetes Care and Education Specialist (CDCES) per week for 10 weeks delivered via the Zoom for Health at U-M service may be used for Protected Health Information (PHI, regulated by HIPAA). To ensure treatment fidelity, three DSME/S sessions will be selected at random and recorded and rated for fidelity to the above content by our research team.
62842542|NCT06278441|EXPERIMENTAL|White noise group|After the newborns in the WNG group were taken to the blood collection department, white noise (55 dB) was played through a speaker standing 1 meter away from the newborn. The sound level was adjusted to 55 dB with a decibel meter. A heel lancing was performed after the newborn started listening to white noise and calmed down.
62057406|NCT04190628|EXPERIMENTAL|Monotherapy Therapy Dose Expansion-1|- In C-1(Monotherapy - Primary CNS Tumors), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
62260491|NCT05798442|NO_INTERVENTION|face-to-face consultation group|This group of patients will not have access to mHealth app and will receive the traditional face to face intervention.
62260492|NCT05254431|EXPERIMENTAL|Exercise|The Experimental Design is a randomized trial of Moderate intensity interval training (5-minute intervals at 50% VO2peak 3 times weekly for 12 weeks) in Veterans with COPD and OSA compared with standard of care controls
62260493|NCT05254431|NO_INTERVENTION|Usual Care|Participants in the control group will be instructed to maintain their routine activity level for 12 weeks
62260494|NCT04278339|EXPERIMENTAL|CONTROLLED SUBJECTS|In this arm, only controlled subjects (pathological-free) will be investigated.
62260495|NCT04278339|EXPERIMENTAL|PATIENTS|In this arm, only patients with scyzophrenic syndrome will be investigated.
62260496|NCT02512224||Parenteral nutrition|investigators selected participants aged 20 years or older who had undergoneparenteral nutrition by central venous port insertion between April 1, 2012, and March 31, 2013.
62260497|NCT02512224||Enteral nutrition|investigators selected participants aged 20 years or older who had undergone enteral nutrition by percutaneous endoscopic gastrostomy, percutaneous transesophageal gastrotubing, or ileostomy between April 1, 2012, and March 31, 2013.
62617177|NCT04971083|ACTIVE_COMPARATOR|Intervention Group|"Intervention Group (IG): The intervention consists of a built-in automated analysis that provide patient-tailored nutrition recommendations and behavioural tipps. Described in detail this means that dependent on the severity of the nutrition related symptom burden (NRSB) recorded, the patients in the intervention group only are, for example provided with detailed written nutrition information and cooking recipes and/or asked to discuss the symptoms with their health care provider, dietitian, and/or physician, or even asked to seek immediate medical care.~Analog to the control group, observational data regarding energy and fluid intake, weight, quality of life, symptoms, and distress status will be recorded in the Electronic Health Platform. They will have to ability to print and share this documentation with their HCP at their own discretion.~Inflammation status will be recorded when data from routine blood draws is available"
62842543|NCT06278441|EXPERIMENTAL|Kangaroo care group|Kangaroo care was started 15 minutes before heel lancing for newborns included in KCG, and heel lancing was performed.
62842544|NCT06278441|NO_INTERVENTION|Control group|Control group newborns underwent routine heel lancing, and no intervention was performed.
62842545|NCT03727308||Women recruited from pharmacies|"Investigators will enroll women seeking medical abortion pills without prescription from pharmacies.~- Medical abortion pills sourced from pharmacies"
62842546|NCT03727308||Women recruited from health clinics|"Investigators will enroll women seeking medical abortion pills from clinics.~- Medical abortion pills sourced from health clinics"
62617178|NCT05854849|EXPERIMENTAL|GAP|
62617179|NCT05854849|ACTIVE_COMPARATOR|GPP|
62617180|NCT04151901|EXPERIMENTAL|Male Rehabilitation (M-REHAB)|Disuse + resistance exercise rehabilitation
62617181|NCT04151901|EXPERIMENTAL|Male Control (M-CON)|Disuse + ambulatory control rehabilitation
62617182|NCT04151901|EXPERIMENTAL|Female Rehabilitation (F-REHAB)|Disuse + resistance exercise rehabilitation
62617183|NCT04151901|EXPERIMENTAL|Female Control (F-CON)|Disuse + ambulatory control rehabilitation
62617184|NCT01733992|ACTIVE_COMPARATOR|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
62260498|NCT05536310||Trilogy TAVI|Patients receiving JenaValve Trilogy Heart Valve System for management of symptomatic, severe aortic stenosis (AS)/ aortic regurgitation (AR) who are at high risk for surgical aortic valve replacement (SAVR)
62260499|NCT01237834||Heavy smokers, 15 or more cigarettes/day|Nicotine dependent.
62260500|NCT01237834||Light smokers (chippers)|Less than 2 cigarettes/day, at least 2 days/week. Non nicotine-dependent.
62260501|NCT01237834||Non smokers|
62260502|NCT06084520||Test group - patients with chronic pain treated with opioids|Patients with long-term, non-cancer-related pain (\>3 months) at least 3 days a week, age 18-75 years, who have been treated with opioids for at least 1 month and who can speak, read and write in Swedish, recruited within Uppsala County Primary, Secondary and Tertiary Care.
62842547|NCT02004678|OTHER|Cohort 1, 7.5 mg DS-1150b|"Dosing will occur over two periods. Subjects will receive either~* a dose of placebo in Period 1 followed by a single dose of 7.5 mg DS-1150b in Period 2; or~* a single dose of 7.5 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2."
62842548|NCT02004678|OTHER|Cohort 2, 15 mg DS-1150b|"Dosing will occur over two periods. Subjects will receive either~* a dose of placebo in Period 1 followed by a single dose of 15 mg DS-1150b in Period 2; or~* a single dose of 15 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2."
62842549|NCT04550429|ACTIVE_COMPARATOR|60 mmHg MyoSure Hysteroscopic Morcellator Device|The rationale for this experimental arm is that the pressurization can result in excess fluid being absorbed by the patient without a substantial benefit to surgical outcome. Minimizing the pressure from 80 mmHg (which is standard of care) to 60 mmHg used during this procedure may optimize outcome without compromising visualization of the surgeon. The research procedure will take place in the operating room of the minimally invasive gynecologic surgery department.
62842550|NCT04550429|SHAM_COMPARATOR|80 mmHg MyoSure Hysteroscopic Morcellator Device|This is the standard of care pressurization for this procedure at Northwestern Medicine and will be the control group for the study
62842551|NCT05938205|EXPERIMENTAL|Exe-H + placebo|high intensity physical exercise combined with placebo
62260503|NCT06084520||Control group - patients with chronic pain not-treated with opioids|Patients with long-term, non-cancer-related pain (\>3 months) at least 3 days a week, age 18-75 years, who are not treated with opioids (at inclusion and during the last 3 months) and who can speak, read and write in Swedish, recruited within Uppsala County Primary, Secondary and Tertiary Care.
62260504|NCT00794599|EXPERIMENTAL|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
62617185|NCT01733992|ACTIVE_COMPARATOR|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
62617186|NCT01733992|ACTIVE_COMPARATOR|R348 Ophthalmic Solution, 1.0%|R348 Ophthalmic Solution, 1.0%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
62260505|NCT00794599|EXPERIMENTAL|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
62260506|NCT01334528||OEF/OIF Veterans mTBI|Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF) Veterans with a history of mild traumatic brain injury (mTBI) with persistent self-reported symptoms.
62260507|NCT04228042|EXPERIMENTAL|Treatment (infigratinib, surgery)|Patients receive infigratinib PO QD on days 1-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. During weeks 8-9 (at least 48 hours after last dose of infigratinib), patients undergo surgery.
62260508|NCT06478069|OTHER|Group A|
62260509|NCT06478069|EXPERIMENTAL|Group B|
62842552|NCT05938205|EXPERIMENTAL|Exe-H + AA-1|high intensity physical exercise combined with low dose of aminoacids
62842553|NCT05938205|EXPERIMENTAL|Exe-H + AA-2|high intensity physical exercise combined with high dose of aminoacids
62842554|NCT04003948|EXPERIMENTAL|Fixed dose|Ibogaine Hydrochloride 100 mg on each administration.
62842555|NCT04003948|EXPERIMENTAL|Ascending dose|Ibogaine Hydrochloride on ascending doses (100-200-300-400-500-600).
62842556|NCT02877771|EXPERIMENTAL|t:slim insulin pump with predictive low glucose suspend|To assess the functionality of a predictive low glucose suspend (PLGS) system that uses CGM values to suspend basal insulin delivery when hypoglycemia is predicted as well as resume basal insulin delivery once Continuous Glucose Monitoring (CGM) values begin to increase.
62842557|NCT03452163|EXPERIMENTAL|Anesthesia, General|Subjects under anesthesia that are expected to stay for at least 24 hours in the ICU/NICU will be monitored by the PMD-200 device. An EEG monitor device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.
62842558|NCT03034070|OTHER|Diagnostic performance 3D T1|A 3D T1-weighted GE mDixon MR imaging sequence will be added to the routine 3D T1-weighted FSE sequence. mDixon sub-sequences (Fat and In Phase) are compared to 3D T1-weighted FSE in terms of diagnostic accuracy for M and N staging in prostate cancer patients: Fat, In Phase, Fat+In Phase and the routine 3D T1 will be analyzed separately, blindly and randomly.
62842559|NCT03915652|EXPERIMENTAL|Rheum iCMP Wave 1|20 patients enrolled immediately in Rheum iCMP
62842560|NCT03915652|EXPERIMENTAL|Rheum iCMP Wave 2|20 patients enrolled in Rheum iCMP after 4 months; will receive monthly lupus educational materials mailed to their home during the first 4 months
62842561|NCT00423917|EXPERIMENTAL|fulvestrant + bevacizumab|"Patients receive fulvestrant intramuscularly on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, prior to every other course, and at the completion of study treatment.~After completion of study treatment, patients are followed every 3-6 months for 5 years."
62842562|NCT02406534||Normal Pulmonary Function|
62842563|NCT02406534||Reduced Pulmonary Function|
62842564|NCT03124342|EXPERIMENTAL|VANDERBILT ICU RECOVERY PROGRAM (VIP)|Patients assigned to the Vanderbilt ICU Recovery Program (VIP) group will receive the components of the ICU Recovery Program intervention.
62842565|NCT03124342|NO_INTERVENTION|Usual care|Patients in the usual care group will receive care as dictated by their clinical team. In usual care in the study institution, patients frequently receive medication reconciliation by and ICU pharmacist at the time of transfer out of the ICU to the hospital ward, medication reconciliation by a physician at the time of hospital discharge, and follow up with their primary care physician within two weeks of hospital discharge. Usual care does not currently include an in-person assessment of the patient's cognitive and functional status or anticipated post-ICU needs by a nurse practitioner between ICU transfer and hospital discharge, access to a 24/7 contact line after hospital discharge, or assessment in a multi-disciplinary ICU Recovery Clinic.
62260510|NCT01669070|EXPERIMENTAL|FF 50 mcg powder inhalation|Each subject will receive a single dose of 300 mcg FF (6 inhalations of 50 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 50 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
62260511|NCT01669070|EXPERIMENTAL|FF 100 mcg powder inhalation|Each subject will receive a single dose of 600 mcg FF (6 inhalations of 100 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 100 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
62260512|NCT01669070|EXPERIMENTAL|FF 200 mcg powder inhalation|Each subject will receive a single dose of 1200 mcg FF (6 inhalations of 200 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 200 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
62260513|NCT01669070|EXPERIMENTAL|FF 250 mcg IV|Each subject will receive a single dose of 250 mcg FF, administered as an IV infusion over 20 minutes on Day 1 of the respective period per randomization sequence.
62260514|NCT05754385|ACTIVE_COMPARATOR|Ambulatory liver fat monitoring|A novel portable, home-based device called the Gense-EIT liver scan will be given to each participant to practice ambulatory liver fat monitoring
62260515|NCT05754385|PLACEBO_COMPARATOR|Standard of care|Subjects will have follow-up every 6 months by hepatologists for routine care
62260516|NCT05703971|EXPERIMENTAL|Phase 1|"Up to 2 sequential dose selection cohorts will be treated with quaratusugene ozeplasmid (intravenous (IV) administration once every 21 days) plus atezolizumab (1200 mg IV administration once every 21 days) until disease progression or unacceptable toxicity.~Quaratusugene ozeplasmid doses will be evaluated (0.09 \[starting dose\], and 0.12 mg/kg) until the RP2D is identified."
62842566|NCT04239391|EXPERIMENTAL|Triferic via IV and Hemodialysate|Upon completion of the Baseline observational periods, all enrolled patients will transition to the interventional period where they will then receive Triferic. The Triferic will be administered via the liquid bicarbonate concentrate at a dialysate concentration of 2 uM or via IV at a dose of 0.1 mg Fe/kg, if the patient does not receive dialysis using liquid bicarbonate, for up to an additional 36 weeks (depending on duration of observational Baseline period). Hgb and CHr will continue to be measured bi-weekly and iron profiles will be obtained at 4 week intervals. In the Triferic phase of the study,changes in ESA dose will be allowed according to the study site existing protocol. IV iron will only be administered if ferritin meets the criteria for iron deficiency. Patients will remain in the interventional period for either 36 or 28 weeks (depending on randomization assignment), at which time a final study visit will take place
62057407|NCT04190628|EXPERIMENTAL|Monotherapy Therapy Dose Expansion-2|- In C-2 (Monotherapy - Advanced or Metastatic Solid Tumors excluding Primary CNS Tumor with or without Brain Metastasis), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
62057408|NCT04190628|EXPERIMENTAL|Combination Therapy Dose Expansion-1|- In C-3 (Combination therapy - Advanced/Metastatic Solid Tumors including Primary CNS tumors but excluding Melanoma with Brain metastasis), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B, in combination with cobimetinib (Cotellic®) 60 mg administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
62057409|NCT04190628|EXPERIMENTAL|Combination Therapy Dose Expansion-2|- In C-4 (Combination therapy - Melanoma with Brain Metastasis), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B, in combination with cobimetinib (Cotellic®) 60 mg administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
62057410|NCT02020525|EXPERIMENTAL|restrictive transfusion strategy|Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.
62057411|NCT02020525|ACTIVE_COMPARATOR|liberal transfusion strategy|Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
62057412|NCT02124889|EXPERIMENTAL|Weekly surveys|Subjects will take the multivitamin, and will also receive weekly Internet surveys asking them questions about the multivitamin treatment.
62057413|NCT02124889|NO_INTERVENTION|No Survey|Subjects will take the multivitamin.
62057414|NCT01432496|EXPERIMENTAL|Ropivacaine 150 mg|Nebulization of Ropivacaine 150 mg in the peritoneal cavity with the Aeroneb Pro system
62057415|NCT01432496|PLACEBO_COMPARATOR|Saline 15 ml|Nebulization of Saline 15 ml in the peritoneal cavity with the Aeroneb Pro system
62057416|NCT03326960||Sevoflurane|Patients in Sevoflurane group are maintained with sevoflurane from an anesthesia machine through the laryngeal mask airway guided by Narcrotrend index monitoring.
62057417|NCT03326960||Propofol|Patients in Propofol group are maintained with propofol through intravenous administration guided by Narcrotrend index monitoring.
62057418|NCT03326960||Desflurane|Patients in Desflurane group are maintained with desflurane from an anesthesia machine through the laryngeal mask airway guided by Narcrotrend index monitoring.
62057419|NCT01925625|NO_INTERVENTION|Control|participants monitored for 10 years for lung cancer incidence.
62057420|NCT01925625|ACTIVE_COMPARATOR|Early CDT Lung Test|Early CDT lung blood test
62057421|NCT04581421|EXPERIMENTAL|High Carb first|
62057422|NCT04581421|EXPERIMENTAL|Low Carb first|
62057423|NCT05993702||TAS-102 in combination with regorafenib|(TAS102): Trifluridine tepipiridine tablets 35 mg/m2 twice a day, D1-5, D15-D19, 28 days as a cycle; (TKI: regorafenib: regorafenib capsules administered at a dose of 80 mg (2 tablets, each containing 40 mg regorafenib) once daily for a 28-day cycle)
62057424|NCT05993702||TAS-102 in combination with fruquintinib|TAS102: Trifluridine tepipiridine tablets 35 mg/m2 twice a day, D1-5, D15-D19, 28 days as a cycle; Fruquintinib: a dose of 3mg/dose administered orally once daily, continuously for 28 days as a cycle.
62057425|NCT04449848|EXPERIMENTAL|Sitting after intra tympanic injection|Patients with Sudden hearing loss sitting after intra tympanic injection of steroids
62057426|NCT00524030|EXPERIMENTAL|1|
62057427|NCT00524030|EXPERIMENTAL|2|
62057428|NCT01965379|ACTIVE_COMPARATOR|Intervention|Restriction on food containing phosphorus additives.
62057429|NCT01965379|PLACEBO_COMPARATOR|Control|Standard care.
62057430|NCT05041153|EXPERIMENTAL|Treatment (pembrolizumab, lenvatinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and lenvatinib PO QD, Treatment repeats every 42 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
62057431|NCT04186845|EXPERIMENTAL|Patients|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
62057432|NCT01677364|ACTIVE_COMPARATOR|induction of labour|drug- infusion of 30U oxytocin diluted in 500ml normal saline given at rate of 3mU/min and subsequently dose increased 3mU/min every 45 min
62057433|NCT01677364|NO_INTERVENTION|Spontaneous Labour|patients were allowed to go into spontaneous labour
62617187|NCT01733992|PLACEBO_COMPARATOR|Placebo|Placebo, single (1 day) or multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
62260517|NCT05703971|EXPERIMENTAL|Phase 2|Patients will be treated with the RP2D of quaratusugene ozeplasmid (IV administration once every 21 days) plus atezolizumab (1200 mg IV administration once every 21 days) until disease progression or unacceptable toxicity
62617188|NCT00715520|EXPERIMENTAL|Aim 1|Healthy adult female and male subjects will receive study drugs and TMS training to measure M1 excitability.
62842567|NCT04239391|NO_INTERVENTION|Historic Control Observational Arm|Up to 75 patients will be enrolled in the Observational Arm. Patients who participate in the historical control observational arm will not receive any study medication, but will have Hgb, CHr and serum iron profiles collected at 4 week intervals for up to a total of 44 weeks.
62842568|NCT02726854|EXPERIMENTAL|Apatinib|Patients will be offered with Apatinib (850mg daily,orally)until their disease have progressed.
62842569|NCT04916691|OTHER|EPSB for rib fractures|EPSB for rib fractures
62842570|NCT02985528||TUS positive|Ultrasound detection of pleuro-pulmonary disease and further diagnostic and imaging when needed
62842571|NCT02985528||CXR positive|Radiographic detection of pleuro-pulmonary disease and further diagnostic and imaging when needed
62057434|NCT00829335||HCC patients|According with the investigators previously reported selection flow-chart , patients suitable for surgical approach were those with HCC without ascites, without or with esophageal varices for which preoperative endoscopic eradication could be carried out successfully, and with serum bilirubin level lower than 1.5 mg/dl. Potential candidates to systematic segmental or subsegmental resection by IOUS-guided finger compression were considered patients with single HCC located in one or 2 adjacent segments without portal thrombosis, and anyway not demanding for its complete removal a sectional resection or wider.
62842572|NCT02861001|ACTIVE_COMPARATOR|bronchoscopic guidance|optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy
62842573|NCT02861001|EXPERIMENTAL|tube mounted camera guidance|optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
62842574|NCT05241548|EXPERIMENTAL|Intervention Group|Ridge augmentation of horizontally deficient alveolar ridge in aesthetic zone by BMAC on PCL scaffold
62842575|NCT00249899|EXPERIMENTAL|Lapaquistat Acetate 100 mg QD|(and stable statin therapy)
62842576|NCT00249899|ACTIVE_COMPARATOR|Stable statin therapy|
62842577|NCT00610480|ACTIVE_COMPARATOR|Optive, then Systane Artificial Tears|Artificial Tears (Optive, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, artificial tears (Systane, 40 microliters) will be administered using the same procedure protocol.
62842578|NCT00610480|ACTIVE_COMPARATOR|Systane, then Optive Artificial Tears|Artificial Tears (Systane, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, artificial tears (Optive, 40 microliters) will be administered using the same procedure protocol.
62842579|NCT06005064|EXPERIMENTAL|Intervention|Krill oil 4g/day for 24 weeks
62842580|NCT06005064|PLACEBO_COMPARATOR|Placebo|Vegetable oil 4g/day for 24 weeks
62842581|NCT01179113|PLACEBO_COMPARATOR|Placebo|Placebo: Will receive a normal saline bolus during induction, and an infusion of normal saline intraoperatively
62842582|NCT01179113|ACTIVE_COMPARATOR|Esmolol|Will receive Esmolol Loading: 0.5 mg/kg bolus during induction Infusion: 15 mcg /kg/min, infusion intraoperatively
62842583|NCT03024099|EXPERIMENTAL|Hippotherapy once a week|Hippotherapy once a week;
62842584|NCT03024099|EXPERIMENTAL|Hippotherapy twice a week|hippotherapy twice a week
62842585|NCT01650597|EXPERIMENTAL|Part 1 - Panel 1|The participants will receive 3 or 4 ascending doses (2.5, 10, 30, 100, 250, 500 mg) of JNJ-42165279 and placebo during the study.
62842586|NCT01650597|EXPERIMENTAL|Part 1 - Panel 2|The participants will receive 3 or 4 ascending doses (2.5, 10, 30, 100, 250, 500 mg) of JNJ-42165279 and placebo during the study.
62842587|NCT01650597|EXPERIMENTAL|Part 2 (parallel)- additional cohort|The participants will receive repeated daily dosing of 100 mg JNJ-42165279 or placebo for 6 consecutive days.
62842588|NCT00941590||Patients with tick borne encephalitis.|
62260518|NCT05548621||Pre-test|Patients with RCC receiving usual care (without use of the decision aids)
62260519|NCT05548621||Post-test|Patients with RCC using the decision aids
62260520|NCT06398847|OTHER|HIV-associated Chronic Pain Patients|The participants will be enrolled into an open label arm to determine feasibility and useability of the combination device.
62842589|NCT01079052|EXPERIMENTAL|Test|Famotidine Tablets, USP 20 mg of OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
62842590|NCT01079052|ACTIVE_COMPARATOR|Reference|Pepcid® AC Acid reducer famotidine tablets 20 mg of Johnson \& Johnson. Merck Consumer Pharmaceutical Co. Fort Washington, PA 19034 USA
62842591|NCT02086500|EXPERIMENTAL|Prehospital Tranexamic Acid|1 gram of Tranexamic Acid will be given during emergency medical transport
62842592|NCT02086500|PLACEBO_COMPARATOR|Control|Identical volume of saline during emergency medical transport
62260521|NCT02054897|EXPERIMENTAL|Semaglutide 1.0 mg|
62260522|NCT02054897|EXPERIMENTAL|Semaglutide 0.5 mg|
62260523|NCT02054897|PLACEBO_COMPARATOR|Semaglutide placebo 1.0 mg|
62617189|NCT00715520|EXPERIMENTAL|Aim 2|Healthy adult female and male subjects will receive repetitive TMS (rTMS) at different times or frequencies with respect to the training movement or sham stimulation.
62617190|NCT00715520|EXPERIMENTAL|Aim 3|Female and male subjects who have experienced a cerebral ischemic infarction, will receive study drugs and TMS to measure M1 excitability.
62842593|NCT02352155|ACTIVE_COMPARATOR|Second look endoscopy|Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
62842594|NCT02352155|PLACEBO_COMPARATOR|observation only|NO second look endoscopy (Observation)
62842595|NCT02198404|EXPERIMENTAL|sedation with propofol|propofol injection: induction with propofol at 20 mg/kg/h. When patient is sleeping, the dosage is deceased to 6 mg/kg/h
62842596|NCT05750446|OTHER|Riociguat / Placebo|Riociguat or Placebo as oral capsule in randomized order
62842597|NCT05750446|OTHER|Placebo / Riociguat|Riociguat or Placebo as oral capsule in randomized order
62842598|NCT03677453|ACTIVE_COMPARATOR|IPTP|Patients will have access to the web-based interactive teaching tool.
62260524|NCT02054897|PLACEBO_COMPARATOR|Semaglutide placebo 0.5 mg|
62260525|NCT05073614|OTHER|patients with chronic gastritis|patients with symptomatic chronic gastritis will undergo upper endoscopy, gastric biopsies will be obtained to establish giagnosis of chronic gastritis, detection of h.pylori and assessment of heparanase expression.
62260526|NCT01518218|EXPERIMENTAL|laying-on-of-hands|Patients of this arm received laying-on-of-hands twice a day (45 minutes each) every weekday for 1year, and received conventional medical treatment if necessary.
62260527|NCT01518218|NO_INTERVENTION|control group|Patients of this arm did not receive any alternatives other than conventional treatment.
62260528|NCT03220542|EXPERIMENTAL|Probiotics|Saccharomyces boulardii + Esomeprazole + Amoxicillin + Clarithromycin
62260529|NCT03220542|EXPERIMENTAL|Broccoli|Broccoli Sprouts Extract + Esomeprazole + Amoxicillin + Clarithromycin
62842599|NCT03677453|NO_INTERVENTION|Non-IPTP|Patients will not have access to the web-based interactive teaching tool.
62260530|NCT03220542|ACTIVE_COMPARATOR|Triple Therapy|Esomeprazole + Amoxicillin + Clarithromycin
62260531|NCT01418807|EXPERIMENTAL|TRANSVAGINAL EXTRACTION|
62260532|NCT01418807|ACTIVE_COMPARATOR|TRANSUMBILICAL EXTRACTION|
62260533|NCT06047340|EXPERIMENTAL|Early AD|"10 participants with early AD~Intervention: Game"
62260534|NCT06047340|EXPERIMENTAL|MCI|"10 participants with mild cognitive impairment~Intervention: Game"
62617191|NCT04008264||Standard post operative pain regimen|There will be a 3 month pre-intervention phase where participants will be placed on a standard post-operative analgesic regimen consisting of an opioid, a NSAID, and acetaminophen. Patients will record their narcotic and non-opioid analgesic usage patterns in the two weeks following outpatient hand surgery.
62842600|NCT01039376|EXPERIMENTAL|ARM A: Ofatumumab|300 mg IV Week 1 followed by 1000 mg IV Week 2 1000 mg IV (a dose every 8 weeks for up to 2 years following the first 1000 mg dose)
62842601|NCT01039376|OTHER|ARM B: Observation and assessments as per Arm A|Disease status assessments to determine subject response or progression performed approximately every 8 weeks for up to 2 years for both arms according to IWCLL criteria
62842602|NCT04816669|EXPERIMENTAL|Lyophilized SDV|
62260535|NCT06047340|ACTIVE_COMPARATOR|Health Control|"10 healthy control participants~Intervention: Game"
62842603|NCT04816669|EXPERIMENTAL|Frozen liquid MDV (control for lyo SDV)|Control for lyophilized SDV
62842604|NCT04816669|EXPERIMENTAL|Frozen-liquid with LNP size at the upper end of specification|
62842605|NCT04816669|EXPERIMENTAL|RTU|
62260536|NCT04425291|EXPERIMENTAL|4-valent HPV Vaccine|Participants in this arm would receive 4-valent Human Papillomavirus (Types 6, 11, 16 and18) Recombinant Vaccine (Hansenula Polymorpha)
62260537|NCT04425291|EXPERIMENTAL|9-valent HPV Vaccine|Participants in this arm would receive 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
62260538|NCT04425291|ACTIVE_COMPARATOR|GARDASIL®|Participants in this arm would receive GARDASIL®
62260539|NCT06100822|PLACEBO_COMPARATOR|Placebo Group, Placebo Capsules|Placebo Group (n=20) Week 1: One placebo capsule (500 mg) daily Week 2: Two placebo capsules (1,000 mg) daily Week 3: Three placebo capsules (1,500 mg) daily Week 4-16: Four placebo capsules (2,000 mg) daily
62260540|NCT06100822|EXPERIMENTAL|Treatment Group, Metformin Capsules|Treatment Group (n=20) Week 1: One metformin ER capsule (500 mg) daily Week 2: Two metformin (ER) capsules (1,000 mg) daily Week 3: Three metformin (ER) capsules (1,500 mg) daily Week 4-16: Four metformin (ER) capsules (2,000 mg) daily
62260541|NCT01035554|ACTIVE_COMPARATOR|Usual Care (UC) + Printed Materials (PM)|If the participant is assigned to UC, they will receive standard care. They will not receive a HBPM to use for the study, but will be given one to keep at the 3 month Follow-Up Visit. If they are also assigned to PM, they will then be given written materials (pamphlets from the NIH) and will be asked to review the information in its entirety. The coordinator will be available to answer any questions they might have.
62260542|NCT01035554|EXPERIMENTAL|UC + Self-Paced Program Instruction (SPPI)|If the participant is assigned to UC, they will receive standard care. They will not receive a HBPM to use for the study, but will be given one to keep at the 3 month Follow-Up Visit. If they are also assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials from the National Institutes of Health.
62260543|NCT01035554|EXPERIMENTAL|Home Blood Pressure Monitor (HBPM) + PM|If the participant is assigned to HBPM, they will be asked to use the monitor once a day in the morning and once before they go to bed any 3 days of the week, each week of the study (total = 12 weeks). They will be asked to record their BP values in diaries they will be given to take home with them. If they are also assigned to PM, they will then be given written materials (pamphlets from the NIH) regarding hypertension education and will be asked to review the information in its entirety. The coordinator will be available to answer any questions they might have.
62842606|NCT04816669|EXPERIMENTAL|Frozen liquid MDV (given as third dose following a primary series of lyophilized BNT162b2)|Additional vaccine dose, using the frozen-liquid formulation, offered to participants who originally received 2 doses of the lyophilized formulation of BNT162b2
62842607|NCT01732237|EXPERIMENTAL|JNJ-42396302|Patients will receive JNJ-42396302 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
62842608|NCT01732237|EXPERIMENTAL|JNJ-42692507|Patients will receive JNJ-42692507 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
62842609|NCT01732237|EXPERIMENTAL|JNJ-53773187|Patients will receive JNJ-53773187 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
62842610|NCT02395159|EXPERIMENTAL|Prevena™ IMS|The patients in the experimental arm will be treated with the Prevena™ IMS seven days after the surgery
62842611|NCT02395159|OTHER|sterile plaster dressings|The wound will be treated with the conventional wound management method of sterile plaster dressing.
62842612|NCT04240834|EXPERIMENTAL|LD group|Low-dose Aspirin(50mg qd) + Ticagrelor( 90mg bid) for 12 months
62617192|NCT04008264||Scopolomine group|During the observational phase, patients will be on scopolamine for a total 6 day course (one patch applied at time of surgery, prescription for one patch), and patients will record their narcotic and non-opioid analgesic usage patterns in the two weeks following outpatient hand surgery. The patients who incorporate scopolamine into their post operative analgesia regimen will be eligible for inclusion in the study.
62617193|NCT06147323|ACTIVE_COMPARATOR|Normal Healthy Diet group|Participants aged 18-65 years in general good health will be following the Eatwell booklet advice\*and NICE/NHS guidelines (https://www.nice.org.uk/).
62617194|NCT06147323|PLACEBO_COMPARATOR|Placebo Group|Participants aged 18-65 prediabetics will take 2 capsules/day (750mg Maltodextrin placebo comparator) before each of the two main meals without any advice on the diet to follow.
62842613|NCT04240834|ACTIVE_COMPARATOR|Control group|Regular Aspirin(75mg qd) + Ticagrelor(90mg bid) for 12 months
62445927|NCT06126809|EXPERIMENTAL|Steep-tRAS,|Transcranial random aperiodic stimulation (tRAS) delivers 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA at the return electrode. The condition of interest, steep-tRAS, mimics a steep slope of the aperiodic signal characterized by greater low relative to high frequency power. Participants receive all three types of stimulation in an intermixed, balanced, and randomized order. There are twelve total blocks of approximately five minutes of stimulation with four blocks of each type of stimulation.
62617195|NCT06147323|ACTIVE_COMPARATOR|Seaweed Group|Participants aged 18-65 prediabetics will take 2 seaweeds brown extract capsules/day (information detailed in the safety product sheet, total dose of 700 mg before each of the two main meals. All participants will be advised on product storage and use conditions prior to use to ensure product consistency throughout the period of the study.
62617196|NCT00912106||HA injection|Patients with osteoarthritis of knee. They are going to received HA injection 1 vial per week for 5 weeks.
62617197|NCT04390308||Intervention|The cortex of selected ovary will be punctured up to ten times. In the surgical report, the surgeon will state how many punctures have been done.
62617198|NCT04390308||Control|No intervention
62617199|NCT04691687|NO_INTERVENTION|Standard of Care (Group 1)|Patients in Group 1 received standard of care treatment per heart failure guidelines at the discretion of the primary cardiologist involved in the patient's care.
62617200|NCT04691687|PLACEBO_COMPARATOR|IV Placebo Infusion|Patients in Group 2 received IV saline infusion (20-40 ml) concentrated by the pharmacist to minimize fluid intake.The infusions were continuous over 3 hours, biweekly over a one-month period.
62842614|NCT03843840||Diseased Retina|
62842615|NCT05676021|EXPERIMENTAL|intervention group|"On the second day of the COVID-19 antiviral drug treatment, the participant assigned to the intervention group was interviewed face-to-face during the home visit by providing isolation measures. In the face-to-face meeting, the COVID-19 Medication Use Brochure was given and it was stated that the participants would be video-talked about the topics included in the booklet at an appropriate time on the same day, and time was planned. In the interview, it was decided to allow the participant to tell about their antiviral drug use, to learn about their feelings, thoughts and behaviors about drug use, to reveal their feelings of indecision and anxiety about treatment, to determine their resistance to drug use, to reveal their intrinsic motivation, to support them and to change their behavior. It was intended to take action to advance the cycle of change."
62842616|NCT05676021|NO_INTERVENTION|control group|After randomization, the participants in the control group continued to receive health care according to the standard COVID-19 drug treatment procedures determined by the Ministry of Health. No other intervention was performed apart from the participant standard COVID-19 drug therapy procedures in the control group.
62842617|NCT02347137|ACTIVE_COMPARATOR|Isolated Whey Protein|20 g isolated whey protein + 15 g non-essential amino acids
62842618|NCT02347137|EXPERIMENTAL|Micellar Whey Protein|20 g micellar whey protein + 15 g non-essential amino acids
62842619|NCT02347137|EXPERIMENTAL|Micellar Whey Protein + Citrulline|20 g micellar whey protein + 5 g citrulline
62842620|NCT01610778|PLACEBO_COMPARATOR|Placebo|
62842621|NCT01610778|EXPERIMENTAL|Supplement|
62842622|NCT04981990|ACTIVE_COMPARATOR|Single lung ventilation|Using double lumen endotracheal tube and lung isolation
62842623|NCT04981990|ACTIVE_COMPARATOR|Two lung ventilation|Using conventional single lumen endotracheal tube and intermittent two lung ventilation
62260544|NCT01035554|EXPERIMENTAL|HBPM + SPPI|"If the participant is assigned to HBPM, they will be asked to use the monitor once a day in the morning and once before they go to bed any 3 days of the week, each week of the study (total = 12 weeks). They will be asked to record their BP values in diaries they will be given to take home with them.~If they are also assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the PM from the National Institutes of Health."
62260545|NCT03113240|EXPERIMENTAL|Glutamin|Intervention patients will be received enteral formula and glutamine 0.3 g/kg/day given via nasogastric tube as boluses q 4hrs.
62842624|NCT06246045|EXPERIMENTAL|Early-Invasive Strategy|Patients who do not clearly qualify for early intervention (including catheter-directed therapies, systemic thrombolysis, or invasive hemodynamic support) based on assessment by PERT members, will undergo walk testing on the first day of admission. If the subject meets criteria based on pre-specified hemodynamic changes, then the patient will be randomized in a 2:1 fashion to early invasive strategy with catheter-directed therapies as treatment arm.
62842625|NCT06246045|ACTIVE_COMPARATOR|Traditional Medical Therapy|Patients who do not clearly qualify for early intervention (including catheter-directed therapies, systemic thrombolysis, or invasive hemodynamic support) based on assessment by PERT members, will undergo walk testing on the first day of admission. If the subject meets criteria based on pre-specified hemodynamic changes, then the patient will be randomized (2:1, treatment to control) to traditional routine care with medical therapy.
62842626|NCT05743959||Patients with stage I-III biliary tract cancers|Patients with stage I-III biliary tract cancers eligible for curative surgical resection
62842627|NCT00459732|PLACEBO_COMPARATOR|Placebo Capsule|placebo capsule, similar in size, shape and color to zinc capsule, taken once daily for 18 months
62842628|NCT00459732|ACTIVE_COMPARATOR|Zinc (25 mg/d)|25 mg of elemental Zinc as zinc sulphate taken once daily for 18 months
62842629|NCT01438736|EXPERIMENTAL|Desogestrel, Etonogestrel|Arm 1: 75 microgr desogestrel POP (cerazette) daily for 3 months followed by etonogestrel implant (Nexplanon, 68 mg etonogestrel) for following 6 months
62842630|NCT01438736|EXPERIMENTAL|Etonogestrel|Arm 2: Women staring straight with Nexplanon implant for 6 months
62842631|NCT06517628||Pregnant people with cardiovascular disease|Any pregnant patient with acquired or congenital cardiovascular disease upon presentation to a cardio-obstetrics clinic.
62260546|NCT03113240|PLACEBO_COMPARATOR|maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
62260547|NCT00838773|EXPERIMENTAL|YMSM|Young Men Who Have Sex with Men
62260548|NCT00838773|EXPERIMENTAL|YHA|Young Heterosexual Adults
62842632|NCT00786591||Acute Pancreatitis Patients|Patients presenting with clinical features compatible with acute pancreatitis
62260549|NCT00838773|EXPERIMENTAL|ROMA|Gypsies (Bulgarian)
62617201|NCT04691687|EXPERIMENTAL|IV Furosemide Infusion|The dose assignments were categorized into low dose (20 mg bolus with 20 mg/hour infusion sessions and 2 ml saline), intermediate dose (40 mg bolus with 40 mg/hour infusion sessions and 4 ml saline) and high dose (80 mg bolus with 80 mg/hour infusion sessions). The infusions were continuous over 3 hours, biweekly over a one-month period.Infusions were held at the discretion of the physician utilizing a written protocol (creatinine 25% above baseline, SBP \<80 mmHg or symptoms of presyncope).
62260550|NCT00838773|NO_INTERVENTION|Control|All study participants (including those in control condition networks) receive HIV/AIDS/STD risk reduction counseling at baseline, as well as testing and treatment or treatment referral for STDs and HIV infection. STD/HIV testing and treatment or treatment referral are provided at each followup point. This constitutes the control intervention.
62260551|NCT02827864|EXPERIMENTAL|sequentially apply tDCS and MT|The participants in the SEQ group will first receive a-tDCS applied over M1 lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.
62617202|NCT03001466|EXPERIMENTAL|urea-loaded nanoparticles eye drops|This arm include 40 cases (67 eyes) received urea-loaded nanoparticles eye drops (one drop five times a day for 8 weeks)
62617203|NCT03001466|PLACEBO_COMPARATOR|Balance Salt Solution eye drops|This arm include 11 cases (22 eyes) recieved Balance Salt Solution eye drops (one drop five times a day for 8 weeks)
62842633|NCT00786591||Control|Preoperative patients going for elective cholecystectomy
62842634|NCT04173494|EXPERIMENTAL|Momelotinib|Participants will receive momelotinib plus placebo to match danazol
62842635|NCT04173494|ACTIVE_COMPARATOR|Danazol|Participants will receive danazol plus placebo to match momelotinib
62842636|NCT04510818|EXPERIMENTAL|Experimental|Capecitabine 500mg bid. po. Camrelizumab 200mg ivgtt. d1 q2w
62842637|NCT02398435|EXPERIMENTAL|Cohort 80 mg|Cohort 1 included 10 patients. Patients received Tadekinig alfa s.c with a dosage of 80mg. Safety assessments were conducted by data safety monitoring board. Non-responder patients were upscaled to next dose (160mg) after 3 weeks of treatment.
62842638|NCT02398435|EXPERIMENTAL|Cohort 160 mg|Cohort 2 included 13 patients. all patients were treated with Tadekinig alfa s.c with a dosage of 160mg. Safety was evaluated by data safety monitoring board.
62842639|NCT01810536|EXPERIMENTAL|Hi-flow nasal cannula|This group will receive supplemental oxygen by nasal cannula using the Optiflow system, with high flows of 100% humidified oxygen
62842640|NCT01810536|ACTIVE_COMPARATOR|Venturi mask|This group will receive supplemental oxygen by the current standard in our Institution: Venturi masks
62842641|NCT02925884|EXPERIMENTAL|Gunnar OTC Glasses Condition|Intervention: Gunnar Over-The-Counter Glasses with lens (subjects will wear the glasses with lens while performing visual tasks on computers.
62842642|NCT02925884|NO_INTERVENTION|Control Condition|Subjects will be wearing an identical frame without any lens while performing visual tasks on computers.
62260552|NCT02827864|EXPERIMENTAL|apply tDCS concurrently|"For the participants in the CON group, sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS.~Similar to the SEQ group, the participants will also practice functional tasks for 30 minutes after MT."
62842643|NCT02065258|ACTIVE_COMPARATOR|Breathing Exercise|It will be based on Yoga´s breathing technique (Eliade, 1996) and will be focus on to stimulate nasal and diaphragmatic breathings, to increase expiratory time, to slow respiratory flow and to regulate the breathing rhythm. Breathing exercises will be divided into 3 phases (lasting one month each) with progressive intensity every 8 sessions and will be part of the routine of breathing exercises the following exercises: I) Kapalabhati ; II) Uddhiyana ;III) Surya Bedhana
62842644|NCT02065258|ACTIVE_COMPARATOR|Aerobic Exercise|Exercise will be performed on a treadmill, with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957).Aerobic training sessions that will consist in 40 minutes divided in 5 minutes of warm-up, 35 minutes of aerobic training and 5 minutes of cool down. Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. The program will be performed twice a week, for 3 months.
62842645|NCT00619814|OTHER|Cohort group|Cohort group of asymptomatic patients 50-80 years old with a positive fecal occult blood test done for colorectal cancer screening.
62842646|NCT00732537|EXPERIMENTAL|Inhaled Nitric Oxide|iNO started at 20 ppm for 1 hour. The gas was then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off).
62842647|NCT00732537|PLACEBO_COMPARATOR|Placebo|The Oxygen at high concentration (\>90%), which was standard therapy for PPHN, was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda).
62842648|NCT01798108|EXPERIMENTAL|Radium-223 dichloride|The study had 2 parts. Part 1a was designed with single injections of Radium-223 given to cohorts of 5 patients for each of 5 pre-defined dose levels. Part 1b was designed to retreat and fractionate the dose of Radium-223 in multiple injections.Based on the revised correction factor by calibration, recalculations verified that the single injection doses administered in the part 1a were : 46, 93, 163, 213 and 250 kBq/kg b.w. Two re-treated patients (dose group 6) received a second dose that resulted in a total dose of 250 kBq/kg b.w. The fractionated doses were 1/5 and ½ of the highest dose in part1b (i.e. 250kBq so 5 x 50 and 2 x 125 kBq/kg b.w. respectively).
62842649|NCT01526759|EXPERIMENTAL|pectin|10 gram high gelling-high viscous fiber, added to a drink
62842650|NCT01526759|PLACEBO_COMPARATOR|control|10g gelatin, added to a drink
62842651|NCT00990704|EXPERIMENTAL|Paricalcitol|2 mcg adjusted by +/- 1 mcg, up to a maximum of 7 mcg, administered 3 times per week through intravenous catheter immediately before completion of dialysis
62617204|NCT01863732|EXPERIMENTAL|Secukinumab (AIN457) 75mg Grp1|Group 1: AIN457 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 75 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
62842652|NCT00990704|ACTIVE_COMPARATOR|Maxacalcitol|5 or 10 mcg adjusted by +/- 2.5 mcg, up to a maximum of 20 mcg, administered 3 times per week through intravenous catheter immediately before completion of dialysis
62842653|NCT01777113|EXPERIMENTAL|High Intensity Aerobic training|The subjects will perform a high intensity treadmill training
62842654|NCT01777113|EXPERIMENTAL|High Intensity Strength Training|The subjects will perform and high intensity training on the same leg horizontal press.
62842655|NCT01777113|ACTIVE_COMPARATOR|Mixed Training|Conventional training consisted of group mobility, balance and stretching exercises.
62842656|NCT01437566|PLACEBO_COMPARATOR|GDC-0941 Matching Placebo + Fulvestrant (Arm E)|Participants with PIK3CA mutation will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 matching placebo QD orally starting on Day 1 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
62842657|NCT01437566|EXPERIMENTAL|GDC-0941-260 mg + Fulvestrant (Arm D)|Participants with PIK3CA mutation will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 260 mg QD orally starting on Day 1 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
62842658|NCT01437566|EXPERIMENTAL|GDC-0941-340 mg + Fulvestrant (Arm A)|Participants will receive fulvestrant 500 milligrams (mg) as 2 intramuscular (IM) injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 340 mg once daily (QD) orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
62842659|NCT01437566|PLACEBO_COMPARATOR|GDC-0948 or GDC-0980 Matching Placebo + Fulvestrant (Arm C)|Participants will be randomized in 1:1 ratio to receive GDC-0948 matching placebo or GDC-0980 matching placebo with fulvestrant. Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0948 or GDC-0980 matching placebo QD orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
62842660|NCT01437566|EXPERIMENTAL|GDC-0980-30 mg + Fulvestrant (Arm B)|Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0980 30 mg QD orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
62842661|NCT04440527|EXPERIMENTAL|Microshunt|Patients will be treated with Preserflo / Innfocus Microshunt (Santen Pharmaceutical Co., Ltd.).
62260553|NCT02827864|SHAM_COMPARATOR|MT with sham tDCS|For the SHAM group, the training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
62260554|NCT00058812|EXPERIMENTAL|EBV specific T cells|EBV specific T cells
62617205|NCT01863732|EXPERIMENTAL|Secukinumab (AIN457) 75 to 150mg Grp1|Group 1: AIN457 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), was up titrated to AIN457 150 mg only. Secukinumab in PFS for s.c. self-administration Q4W
62617206|NCT01863732|EXPERIMENTAL|Secukinumab (AIN457) 150mg Grp2|Group 2: AIN457 150 mg plus placebo 75 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 150 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
62617207|NCT01863732|EXPERIMENTAL|Pbo in Core then AIN457 75mg Grp1|Participants were on Placebo (Pbo) in Core and then in extension randomized to Group 1: secukinumab (AIN457) 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 75 mg was dosed.Secukinumab in PFS for s.c. self-administration Q4W
62260555|NCT04428021|ACTIVE_COMPARATOR|Standard therapy protocol (STP)|STP is defined as the best evidence based therapy approved for treatment of COVID-19 patients by Regional Health System emergency committee. STP could be updated during the trial.
62617208|NCT01863732|EXPERIMENTAL|Pbo in Core then AIN457 75 to 150mg Grp1|Participants were on Placebo in Core and then in extension randomized to Group 1: secukinumab (AIN457) 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), was up titrated to AIN457 150 mg only. Secukinumab in PFS for s.c. self-administration Q4W
62617209|NCT01863732|EXPERIMENTAL|Pbo in Core then AIN457 150mg Grp2|Participants were on Placebo (Pbo) in Core and then in extension randomized to Group 2: AIN457 150 mg plus placebo 75 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 150 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
62617210|NCT03463252|ACTIVE_COMPARATOR|MPA for EC without progesterone contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
62617211|NCT03463252|EXPERIMENTAL|MPA+Mirena® for EC without contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
62617212|NCT03463252|EXPERIMENTAL|Mirena® for EC without contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
62617213|NCT03463252|ACTIVE_COMPARATOR|GnRH agonist+Mirena® for EC with contraindication|The enrolled patient (endometrial cancer with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
62617214|NCT03463252|EXPERIMENTAL|Mirena® for EC with contraindication|The enrolled patient (endometrial cancer with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
62842662|NCT04440527|ACTIVE_COMPARATOR|Trabeculectomy|Patients will be treated with trabeculectomy.
62842663|NCT05457803||In-persom kratom users|10 subjects that use kratom an additional cross-sectional evaluation: one session day at the NIDA IRP preceded by a consent session day; 2 visits at our BRC building total.
62260556|NCT04428021|EXPERIMENTAL|STP + Standard Plasma (SP)|STP + 3 units on day 1-3-5 of Standard Plasma collected in pre-COVID era (January-September 2019)
62260557|NCT04428021|EXPERIMENTAL|STP + COVID-19 Convalescent Plasma (CP)|STP + 3 units on day 1-3-5 of COVID-19 Convalescent Plasma containing neutralizing SARS-Cov-2 antibodies
62260558|NCT02941016|EXPERIMENTAL|Lipid lowering|
62260559|NCT06043232||glioma patients with routine surgery|surgery
62260560|NCT06043232||glioma patients with DC vaccine|surgery and DC vaccine
62260561|NCT01911442|EXPERIMENTAL|Lurasidone 20 mg|Lurasidone 20 mg once daily
62260562|NCT01911442|EXPERIMENTAL|Lurasidone 60 mg|Lurasidone 60 mg once daily
62260563|NCT01911442|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62260564|NCT06466915|EXPERIMENTAL|Group Dex|Group Dex received 1 mcg/kg of dexmedetomidine intra-nasal 10 minutes before the surgical procedure ended.
62260565|NCT06466915|EXPERIMENTAL|Group Pofol|Group Pofol received 1 mg/kg propofol IV before the extubation.
62260566|NCT06466915|EXPERIMENTAL|Group PoDex|Group PoDex received 1 mcg/kg of dexmedetomidine intra-nasal 10 minutes before the surgical procedure ended and 1 mg/kg propofol IV before the extubation.
62260567|NCT02242084|EXPERIMENTAL|Alteplase treatment|All subject who enter the trial will receive treatment with Alteplase along with questionnaire.
62260568|NCT04620044|EXPERIMENTAL|Kaledo Game|Kaledo game, which is a board game, has been developed to inform children about healthy eating. The aim of this game is to teach children calorie balance through the calorie values of foods. Kaledo game gives children the opportunity to stay motivated and have fun. While children are having fun, they also gain the knowledge necessary for healthy eating behavior change. The game is played with 2-4 people. A game session takes 15-30 minutes Children in the playgroup played 15-30 minutes (1 round) Kaledo game every week for 12 weeks.
62260569|NCT04620044|EXPERIMENTAL|Education|"The students in the training group were trained for 20 minutes once a week for 12 weeks. Training subjects were prepared in line with health belief model components.~The following subjects were included in the training content. What is obesity?Risk factors for obesity, Characteristics of obese individuals, What is a healthy diet?Relationship between unhealthy nutrition and obesity, The consequences of unhealthy diet Health problems caused by obesity, What should be done to prevent and control obesity. How should nutrition be to lose weight? Positive results which show up with weight loss, Barriers to a healthy diet, Ways to reduce and eliminate barriers How to take action to lose weight?, Benefits of weight loss, Success stories in the fight against obesity, How are eating habits changed?, How can we achieve self-efficacy to change eating habits?"
62260570|NCT04620044|EXPERIMENTAL|Control|There was no intervention in the control group.
62445928|NCT06126809|ACTIVE_COMPARATOR|Flat-tRAS|Transcranial random aperiodic stimulation (tRAS) delivers 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA at the return electrode. The active control, flat-tRAS, mimics a flat slope aperiodic signal characterized by greater high relative to low frequency power. Participants receive all three types of stimulation in an intermixed, balanced, and randomized order. There are twelve total blocks of approximately five minutes of stimulation with four blocks of each type of stimulation.
62445929|NCT06126809|SHAM_COMPARATOR|Sham-tRAS|Transcranial random aperiodic stimulation (tRAS) delivers 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA at the return electrode. For active sham stimulation, steep-tRAS or flat-tRAS is delivered for only 15 seconds at the beginning and end of the block. This mimics the skin sensations (e.g., itching, burning, tingling) to assist with blinding the participant. Participants receive all three types of stimulation in an intermixed, balanced, and randomized order. There are twelve total blocks of approximately five minutes of stimulation with four blocks of each type of stimulation.
62617215|NCT03463252|ACTIVE_COMPARATOR|Mirena® for EAH without progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia without contraindication of oral high dose progesterone) is allocated to either MPA or LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
62617216|NCT03463252|EXPERIMENTAL|MPA for EAH without progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia without contraindication of oral high dose progesterone) is allocated to either MPA or LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
62842664|NCT05457803||Online kratom users|240 subjects that use kratom, prospective observational cohort study in which each participant provides intensive longitudinal data on kratom use for 15 consecutive days via smartphone app
62842665|NCT02301416|EXPERIMENTAL|Phentermine/topiramate|All subjects enrolled in the study will be placed on the study medication.
62842666|NCT02301416|NO_INTERVENTION|Historical Control|Historical controls who had sleeve gastrectomy during the same time frame without phentermine/topiramate treatment
62842667|NCT03145870|OTHER|Patient with multiple symptomatic myeloma|
62445930|NCT00600197|EXPERIMENTAL|Back school|a kind of educational program for low back pain
62445931|NCT00600197|EXPERIMENTAL|back school|
62842668|NCT04772612|EXPERIMENTAL|Sitravatinib in healthy subjects|Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in healthy subjects.
62842669|NCT04772612|EXPERIMENTAL|Sitravatinib in subjects with mild hepatic impairment|Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with mild hepatic impairment
62260571|NCT00621478|ACTIVE_COMPARATOR|Cohort 1|"Cohort 1 (preconsented) patients will involve obtaining informed consent from the legally authorized representative of a potential study subject before they present to the ED in SE. Patient assent will be obtained for patients as per local IRB rules. The consent document (enclosed in this application) will inform parents that if their child comes to the ED and qualifies for the study based on study inclusion/exclusion criteria, they will be enrolled.~Patients who cannot be contacted to confirm consent will be enrolled in Cohort 2 (EFIC) as detailed below.~Patients in Cohort 1 will be randomized in a blinded fashion to either lorazepam 0.1 mg/kg or diazepam 0.2 mg/kg"
62260572|NCT00621478|ACTIVE_COMPARATOR|Cohort 2|"Cohort 2 (EFIC) will include patients who appear in the ED with SE and qualify for the study but have not given prior consent. These patients will be enrolled under the EFIC regulations. The parent/guardian will be given the opportunity to object to participation or ask additional questions.~The child will be enrolled (dosed) with study medication under an EFIC. Once the child is stabilized, a research staff member will approach the parent or LAR to obtain informed consent to continue the child's participation in the study. If a parent or LAR refuses continued participation, then no further study procedures will be performed. Safety and data will be collected in accordance with federal regulations.~Cohort 2 will be randomized, like Cohort 1, to either lorazepam 0.1 mg/kg or diazepam 0.2 mg/kg"
62260573|NCT02532894|EXPERIMENTAL|Esmoke|Inhaling e-cigarette vapor
62260574|NCT02532894|NO_INTERVENTION|Control|
62260575|NCT02227628|PLACEBO_COMPARATOR|Sugary Beverage|Sugary Beverage
62260576|NCT02227628|EXPERIMENTAL|Acai beverage|Acai Polyphenolics
62445932|NCT02497677|EXPERIMENTAL|Circle of Security-Parenting|Circle of Security-Parenting (COS-P) is a brief educative group program for parents
62445933|NCT02497677|ACTIVE_COMPARATOR|Care as Usual (CAU)|Care as usual (CAU) i.e. the active control condition will be standard practices for infants and families at risk in Copenhagen.
62445934|NCT01230151|ACTIVE_COMPARATOR|Clinical|Stimulation settings predetermined clinically (Clinical)
62445935|NCT01230151|EXPERIMENTAL|Model|stimulation settings derived from a patient-specific computer-based model (Model)
62445936|NCT01000740|EXPERIMENTAL|1|Long term survivors who has been used IRESSA for more than 3 years and are still on gefitinib treatment
62445937|NCT01000740|NO_INTERVENTION|2|Long term survivors who has been used IRESSA for more than 3 years but have already terminated from EAP
62445938|NCT01000740|NO_INTERVENTION|3|Fast-progressors who defined as no more than 1 follow-up visit after recruitment with the reason of discontinuation being
62445939|NCT02133456||SIBP's vaccine|SIBP's vaccine group is the population injected with this vaccine.
62445940|NCT03967249|EXPERIMENTAL|IONIS GHR-LRx + Somatostatin Receptor Ligand (SRL)|IONIS GHR-LRx (as per dose in previous study) will be administered subcutaneously once every 28 days for 53 weeks.
62445941|NCT00766207|EXPERIMENTAL|multi-faceted decision support|Multi-faceted decision support
62445942|NCT00766207|ACTIVE_COMPARATOR|control|stream-lined clinical alert
62445943|NCT00458302|EXPERIMENTAL|darunavir monotherapy|darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
62445944|NCT00458302|EXPERIMENTAL|darunavir + 2 NRTI|darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
62445945|NCT03381248|EXPERIMENTAL|Cooled Radiofrequency|Cooled radiofrequency energy will be delivered to study subjects' knees to ablate culprit sensory nerves and reduce knee pain. Subjects in this group will be followed for 12 months post-procedure.
62445946|NCT03381248|ACTIVE_COMPARATOR|Hyaluronic Acid, then Cooled Radiofrequency|Hyaluronic acid injections will be administered to study subjects' knees to reduce knee pain. Subjects in this group will have the option to crossover to receive cooled radiofrequency after 6-months. Crossover subjects will be followed for an additional 6 months post-procedure. Non-crossover subjects will continue to be followed until the 12-month timepoint.
62445947|NCT01201746|EXPERIMENTAL|Periodontal Therapy|Scaling Root planing and oral hygiene instructions
62445948|NCT01201746|PLACEBO_COMPARATOR|Delayed treatment|Scaling Root planing and oral hygiene instructions
62445949|NCT04203407|EXPERIMENTAL|ACP game|Participants in the intervention group will be divided into groups of 4 participants to play a 1-hour culturally-sensitive theory-driven ACP board game with 15-minute debriefing delivered by facilitators. The ACP board game is developed by the principle investigator in a previous project.
62445950|NCT04203407|ACTIVE_COMPARATOR|Usual care|Participants in the control group will receive a 1-hour board game about health lifestyle.
62445951|NCT05647083|EXPERIMENTAL|Intervention group|A total of 24 massage sessions will be applied to the intervention group, 2 times a week during the 12-week working period. Sesame oil will be used as the main oil in the massage application. Massage times are recommended as 10-15 minutes for upper extremity massage and 15-20 minutes for lower extremity massage.
62445952|NCT05647083|NO_INTERVENTION|Control group|Participants in the control group will continue their medical treatment protocols and massage will not be applied. Measurement tools and physiological measurements will be evaluated at the frequency specified in the intervention group, using the same measurement tools and the same measurement methods.
62445953|NCT05728632|EXPERIMENTAL|Nebivolol|nebivolol, capsule, 5 mg once daily, for 12 months
62445954|NCT05728632|PLACEBO_COMPARATOR|Placebo|placebo, capsule, once daily, for 12 months
62445955|NCT01883089|OTHER|Other|Participants will be recruited to complete a 90 day daily monitoring study during which time will be invited to participate in a 4 week brief alcohol intervention during days 31-60 (i.e., second month).
62445956|NCT05305209|EXPERIMENTAL|Intervention group|They will receive the k-laser treatment with the k-laser Cube Plus 30 device
62445957|NCT05305209|PLACEBO_COMPARATOR|Control Group|They will receive a sham treatment with the k-laser Cube Plus 30 device turned off
62445958|NCT00551564|EXPERIMENTAL|Subjects in healthy normal and overweight control arm|Subjects in the Healthy Normal or Overweight Control Population will be included in this arm and they will receive Rosiglitazone 4 milligram twice daily.
62617217|NCT03463252|ACTIVE_COMPARATOR|Mirena® for EAH with progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
62617218|NCT03463252|EXPERIMENTAL|GnRH-a+Mirena® for EAH with progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
62617219|NCT04361097|EXPERIMENTAL|Faecal microbiota transplant|This group will receive frozen capsules to be ingested orally constituted of TMF with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
62617220|NCT04361097|PLACEBO_COMPARATOR|Placebo|This group will receive frozen capsules to be ingested orally placebo with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
62617221|NCT01256580|ACTIVE_COMPARATOR|Monotherapy|Bevacizumab (Avastin; Genentech, Inc.)1.25 mg by intravitreal injection on day 0 and then prn (as-needed) based on ophthalmic examination and OCT findings
62617222|NCT01256580|ACTIVE_COMPARATOR|Combination therapy|Intravitreal injection of bevacizumab 1.25 mg (Avastin; Genentech, Inc.) combined with reduced fluence PDT(Visudyne®; Novartis,) and 200 ug of intravitreal dexamethasone(4mg/ml, American regent, Inc) on Day 0 and then monthly retreatment with bevacizumab as-needed and triple therapy every 3 months as-needed.
62617223|NCT04992624|PLACEBO_COMPARATOR|Placebo|
62617224|NCT04992624|EXPERIMENTAL|Cannabidiol (CBD)|Up to 150 mg/day.
62617225|NCT04992624|EXPERIMENTAL|Tetrahydrocannabinol (THC)|Up to 10 mg/day.
62617226|NCT04992624|EXPERIMENTAL|CBD plus THC|Up to 150 mg/day CBD plus up to 10 mg/day THC.
62842670|NCT04772612|EXPERIMENTAL|Sitravatinib in subjects with moderate hepatic impairment|Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with moderate hepatic impairment
62260577|NCT05617833|EXPERIMENTAL|MLT+EPO|"Melatonin 3 mg/mL oral syringe enterally every evening. For neonates weighing less than 1200 g, divide the dose in half and administer each half 30 minutes apart.~High dose epoetin alfa epbx recombinant (1000 units/kg) syringe IV every 48 hours for 10 doses.~Low dose epoetin alfa-epbx recombinant (400 units/kg) subcutaneously or intravenously three times weekly on Monday, Wednesday, and Friday until age 33-6/7wk."
62445959|NCT00551564|EXPERIMENTAL|Subjects in healthy obese with T2DM arm|Subjects who are in the Healthy Obese or T2DM Population will be included in this arm and they will receive Rosiglitazone 4 milligram twice daily.
62445960|NCT04984018|EXPERIMENTAL|Chidamide plus Camrelizumab|Pts received 200 mg camrelizumab intravenously every 2 weeks and Chidamide 30mg orally twice (biw) per week for 4 consecutive weeks every 6 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
62445961|NCT04472975||Multiple sclerosis (MS) cohort|Individuals with multiple sclerosis without any exposure to disease-mofidying drugs (DMDs) and with exposure to one or more DMDs.
62445962|NCT05476874|ACTIVE_COMPARATOR|Open Mini-laparotomy Group (OLG)|Distal shunt placement through open mini-laparotomy.
62445963|NCT05476874|EXPERIMENTAL|Abdominal Puncture Group （APG）|Distal shunt placement through abdominal puncture.
62445964|NCT05461820|ACTIVE_COMPARATOR|Conventional treatment group|According to the thyroid function, if the initial free thyroxine(FT4) ≥ 3 times the normal value, the initial dose of methimazole is 30mg/ day, the thyroid function will be tested every four weeks, and the dose will be reduced when thyroid stimulating hormone(TSH) \> normal lower limit or free triiodothyronine(FT3) \< normal lower limit or FT4 \< normal lower limit. The dose will be reduced according to the clinical routine, specifically, every day (30 mg→20 mg→10 mg→5mg→2.5 mg) If the initial FT4 is less than 3 times the normal value, the initial dose of methimazole is 15mg/ day, and the thyroid function is tested every four weeks. When TSH is greater than the normal lower limit or FT3 is less than the normal lower limit or FT4 is less than the normal lower limit, the dose will be reduced according to the clinical routine, specifically every day for 24 months. If TSH \> 100 mIU/L occurs during the treatment, the reduction speed will be accelerated, and 1-2 dose levels can be skipped.
62445965|NCT05461820|ACTIVE_COMPARATOR|Intensive treatment group|If the initial FT4≥ 3 times of normal value, the initial dose of methimazole was 30mg/ day, and the thyroid function and antibodies were detected every four weeks. When TSH≥4.2 mIU/L, the amount of methimazole began to decrease, specifically in a daily manner (30 mg→20 mg→15mg). The dose was maintained after the decrease to 15 mg. In the case of hypothyroidism, levothyroxine was added until the three antibodies (TPOAb, TGAb and TRAb) were negative. The dose was maintained for six months, and then the doses of methimazole and levothyroxine were gradually reduced until drug discontinuation (each month). If the initial FT4 was less than 3 times of normal level, the initial dose of methimazole was 15 mg/ day, and levothyroxine was added when hypothyroidism occurred. After all three antibodies were negative, the doses were gradually reduced to the point of drug discontinuation.
62260578|NCT05617833|PLACEBO_COMPARATOR|Placebo|"Placebo oral syringe enterally every evening.~Placebo syringe IV every 48 hours for 10 doses.~Placebo subcutaneously or intravenously three times weekly on Monday, Wednesday, and Friday until age 33-6/7wk."
62260579|NCT03247270|EXPERIMENTAL|Intervention I|Physical exercise intervention: 12 week exercise program with low-intensity fitness training 3 times per week.
62260580|NCT03247270|EXPERIMENTAL|Intervention II|Physical exercise intervention:12 week exercise program with moderate to high-intensity fitness training 3 times per week
62445966|NCT02110771|EXPERIMENTAL|GAÏA - facial affect recognition targeted|"GAÏA:20hours individual cognitive remediation with therapist, 10 tasks at home, 10 week-treatment cognitive remediation targeted on facial affects recognition. exercises were designed by Gaudelus and Franck (2012) and tutoractiv'company. It includes photos, computer and role games exercises.Computer based exercises have 5 difficulty levels.~2 sessions of one hour per week with therapist.~Tasks at home are given once a week and targeting functional outcomes associated with facial affects recognition impairment."
62445967|NCT02110771|ACTIVE_COMPARATOR|RECOS - attentional process targeted|"RECOS (Cognitive REmediation for Schizophrenia): 20 hours individual cognitive remediation with therapist, 10 tasks at home, 10 week-treatment.~RECOS is a validated cognitive remediation program, developed by P. Vianin and SBT company. It includes paper and pen and computer based exercises. The original program proposes 5 modules targeting 5 cognitive functions, each patient participated in the module corresponding to his/her most altered cognitive function. In this study, all patients randomized in this arm are allocated in the attentional module.Every computer exercises have 10 difficulty levels.~2 sessions of one hour per week with therapist.~Tasks at home are given once a week and targeting functional outcome"
62445968|NCT03828123|EXPERIMENTAL|Autologous Multipotent MSC|Patients with intrathecal administration of Suspension of human autologous MSC 3P in 1.5 ml
62445969|NCT03757455|EXPERIMENTAL|Enchanced recovery after surgery protocol|ERAS-protocol as described in low risk patients after pancreaticoduodenectomy or total pancreatectomy
62445970|NCT03757455|NO_INTERVENTION|Standard protocol|Standard recovery protocol after pancreaticoduodenectomy or total pancreatectomy
62445971|NCT04072718|OTHER|Single arm|
62445972|NCT01740700|EXPERIMENTAL|p-Branch®|
62445973|NCT04741035|EXPERIMENTAL|Modified sternal precautions|Interventional group (Modified sternal precautions)
62445974|NCT04741035|ACTIVE_COMPARATOR|Conventional sternal precautions|Control group (Conventional sternal precautions)
62445975|NCT05942612|EXPERIMENTAL|Cohort 1|A single subcutaneous injection of SHR-2001/placebo dose 1 in healthy subjects
62445976|NCT05942612|EXPERIMENTAL|Cohort 2|A single subcutaneous injection of SHR-2001/placebo dose 2 in healthy subjects
62445977|NCT05942612|EXPERIMENTAL|Cohort 3|A single subcutaneous injection of SHR-2001/placebo dose 3 in healthy subjects
62445978|NCT05942612|EXPERIMENTAL|Cohort 4|A single subcutaneous injection of SHR-2001/placebo dose 4 in healthy subjects
62445979|NCT05942612|EXPERIMENTAL|Cohort 5|A single subcutaneous injection of SHR-2001/placebo dose 5 in healthy subjects
62445980|NCT05942612|EXPERIMENTAL|Cohort 6|A single subcutaneous injection of SHR-2001/placebo dose 6 in healthy subjects
62445981|NCT05942612|EXPERIMENTAL|Experimental: Cohort 7|A single subcutaneous injection of SHR-2001/placebo dose 7 in healthy subjects
62445982|NCT00804609|ACTIVE_COMPARATOR|DepoDur following epidural lidocaine|Epidural DepoDur was administered 60 minutes after an epidural Lidocaine top-up for surgical anesthetic in cesarean section patients.
62445983|NCT00804609|ACTIVE_COMPARATOR|DepoDur following spinal anesthetic|Epidural DepoDur was administered 60 minutes after a standard spinal anesthetic. No prior epidural local anesthetic was used prior to DepoDur in this group assignment.
62842671|NCT04772612|EXPERIMENTAL|Sitravatinib in subjects with severe hepatic impairment|Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with severe hepatic impairment
62260581|NCT03247270|NO_INTERVENTION|Control group|Control group, who will have a physiotherapy session once and will be given general advice about physical activity.
62445984|NCT00193778|EXPERIMENTAL|Loco Regional Treatment Arm (LRT)|Surgery for breast cancer. (MRM/BCT)
62445985|NCT00193778|ACTIVE_COMPARATOR|No Loco-regional Treatment Arm|No surgery for Breast cancer
62445986|NCT04025034|EXPERIMENTAL|Study Group|Use of SONOPET(R) to orbital surgery.
62445987|NCT01679132|EXPERIMENTAL|BAROSTIM NEO System|Subjects implanted with the BAROSTIM NEO System.
62445988|NCT02229006||Aneurysm surveillance|Radiation: 18F-NaF PET-CT
62445989|NCT02229006||Control patients|Radiation: 18F-NaF PET-CT
62445990|NCT02437799||Caesarean section spinal anaesthesia|Dicrotic Wave analysis of pulse oximeter of Women undergoing planned caesarean section under spinal anaesthesia.
62445991|NCT05834790|EXPERIMENTAL|MAR group|The participants in this group will attend the MAR oral health education program
62445992|NCT05834790|ACTIVE_COMPARATOR|lecture-based group|The participants in this group will attend the lecture oral health education program
62617227|NCT03236571|EXPERIMENTAL|Rehabilitation Program|It will consist of 2 sessions of 40 minutes per week, for 12 weeks on ergometric bicycle. Each session of 40 min will include 5 minutes of warm-up, 5 minutes of recovery and 6 sequences of 5 min. Each 5-minute sequence will alternate between 4 minutes of pedaling at a load corresponding to the 1st ventilatory threshold (determined in the initial maximum cardiorespiratory effort test) and 1 minute of pedaling at a load corresponding to 2nd ventilatory threshold (determined in the initial maximum cardiopulmonary stress test).
62057435|NCT06413316||Autism Spectrum Disorder|"During Screening Visits, Diagnosis of ASD will be based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the BOSA or Autism Diagnostic Observation Schedule (ADOS-2) and short form (ADI-R) scored age appropriately.~Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist."
62057436|NCT06413316||Typical Development|Typically Developing (TD) participants from each site will be roughly matched by age and sex to the ASD group.
62057437|NCT03761537|EXPERIMENTAL|Tralokinumab + TCS|4 subcutaneous (SC) injections of tralokinumab 150 mg as a loading dose on Day 0, followed by 2 SC injections of tralokinumab 150 mg every 2 weeks (Q2W) regimen for 26 weeks. The last administration of the Investigational Medicinal Product (IMP) occurred at Week 24. From Day 0 to Week 24, a Topical corticosteroid (TCS) cream was dispensed to the participants at each IMP dosing visit (e.g., Q2W). Participants were instructed to treat active lesions as needed and to discontinue the TCS treatment when control was achieved.
62057438|NCT03761537|PLACEBO_COMPARATOR|Placebo + TCS|4 subcutaneous (SC) injections of placebo as a loading dose on Day 0, followed by 2 SC injections of placebo every 2 weeks (Q2W) regimen for 26 weeks. The last administration of the Investigational Medicinal Product (IMP) occurred at Week 24. From Day 0 to Week 24, a Topical corticosteroid (TCS) cream was dispensed to the participants at each IMP dosing visit (e.g., Q2W). Participants were instructed to treat active lesions as needed and to discontinue the TCS treatment when control was achieved.
62057439|NCT02769234||Alzheimer's disease|Subjects with a diagnosis of Alzheimer's disease that successfully performed an ERP/EEG test with the COGNISION(TM) System prior to enrollment for the current study are eligible to participate.
62057440|NCT05558865|EXPERIMENTAL|somnovia|somnovia is a digital health application for people with Insomnia Disorder. Content is continuously adapted to patients' concerns and needs. somnovia is a comprehensive program, which is conceptually and substantially based on the Cognitive Behavioral Therapy for Insomnia (CBT-I) used in patients with Insomnia Disorder. It contains interactive dialogues that can be accessed via computer or smartphone, illustrations, audio recordings and motivating text messages. Techniques to cope with insomnia symptoms (e.g., psychoeducation about causes and basic emotional needs in addition to relevant strategies to improve sleep quality) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
62057441|NCT05558865|NO_INTERVENTION|Care as Usual|Care as Usual: In the CAU control group, participants are free to continue to engage with any treatment they require. However, they will be offered access to somnovia after 6 months post-baseline.
62617228|NCT05080725|EXPERIMENTAL|Generalized sarcopenia group|Older adults will be recruited from local community centers, physician offices, and retirement communities via flyers. Participants will complete 16 sessions of standard of care swallowing exercises 2 times per week for 8 weeks. All sessions will be conducted via Webex. During each session, a series of standard of care swallow exercises will be performed following a demonstration from a trained speech-language pathologist.
62057442|NCT05509725|EXPERIMENTAL|Intervention|Participants in this group will be randomized to receive probiotic formulation for the following 8 weeks.
62057443|NCT05509725|PLACEBO_COMPARATOR|Control|Participants in this group will be randomized to receive placebo for the following 8 weeks.
62057444|NCT03171480|EXPERIMENTAL|Monoket pill|Isosorbide mononitrate is a drug used principally in the treatment of angina pectoris\[1\] and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold in the USA by Kremers Urban under the trade name Monoket, also sold in the USA under the name Imdur,
62057445|NCT03171480|PLACEBO_COMPARATOR|Placebo pill|The pharmacy has compounded an identical appearing placebo
62057446|NCT04963374||respiratory inpatient|respiratory inpatient with VTE
62260582|NCT06490627|NO_INTERVENTION|Control|in this group, patient will not receive any interventional drug or treatment drug so simply they will blood transfusion dependent.
62617229|NCT04034316|EXPERIMENTAL|MSC|"During the first part of the study, 11 SDNS pediatric patients will receive 3 intravenous infusions of CB-MSCs at the dosage of 1.5 x 10\^6/kg at a time interval of 1 to 2 weeks. The ongoing immunosuppressive treatment will be gradually tapered off after the first CB-MSC administration, as follows:~* 25% reduction of the ongoing immunosuppressive treatment following the first administration;~* 50% reduction of the ongoing immunosuppressive treatment following the second administration;~* interruption of the ongoing immunosuppressive treatment following the third administration.~In the case that the hypothesis that P ≥ 0.600 is rejected and therefore the second part of the study will be required, 11 additional pediatric patients with SDNS will be treated with 3 intravenous infusions of CB-MSCs at the dosage of 2x10\^6/kg at a time interval of 1 to 2 weeks."
62842672|NCT06045156|ACTIVE_COMPARATOR|Tirofiban group|Tirofiban infused with 0.4μg/kg/min for 30min and 0.1μg/kg/min until 24h after IVT
62842673|NCT06045156|PLACEBO_COMPARATOR|Tirofiban simulant group|Tirofiban simulant infused with 0.4μg/kg/min for 30min and 0.1μg/kg/min until 24h after IVT
62260583|NCT06490627|EXPERIMENTAL|Group 1 Thalidomide|In this group , thalassemia patients will receive thalidomide at the dose of 5-6mg/kg/day at night with aspirin.
62260584|NCT06490627|ACTIVE_COMPARATOR|Group 2 Thalidomide|In this group , thalassemia patients will receive thalidomide at the dose of 7-8mg/kg/day at night with aspirin
62617230|NCT03337906||Participants infected with HIV-1|Persons who become HIV-1 infected after enrollment in HIV-1 vaccine trials
62260585|NCT02851381|OTHER|FG-3019|Treatment of Pancreatic Cancer with FG-3019
62260586|NCT06356298|EXPERIMENTAL|FLMA group|In the FLMA group, a FLMA was applied.
62260587|NCT06356298|EXPERIMENTAL|ETT group|In the ETT group, guided by a visual laryngoscope, a ETT was intubated.
62260588|NCT04016480|ACTIVE_COMPARATOR|High Flow Nasal Cannula|High Flow Nasal cannula is a system to deliver heated and humidified oxygen with an inspired oxygen fraction between 21 and 100% through large bore nasal cannula. The system delivers a flow up to 60 liters/min.
62260589|NCT04016480|ACTIVE_COMPARATOR|Conventional Oxygen Therapy|Conventional oxygen therapy will be administered through common nasal cannula with a flow up to 6 Liters per minute
62260590|NCT05970874||pregnant covid 19 patients|pregnant covid 19 patients
62260591|NCT06295939|EXPERIMENTAL|Group 1, the control group|Group 1 the control group receive routine nursing care from the assigned nurse.
62260592|NCT06295939|EXPERIMENTAL|Group 2: the experimental group|Group 2, the experimental group, will receive regular nursing care from the assigned nurse and a social support program provided by the researcher Phase 1 (Before Pregnancy Termination) Phase 2 (After Pregnancy Termination, Before Returning Home)
62260593|NCT02093806||CT of the temporal bone|
62260594|NCT02140697|EXPERIMENTAL|Hippophae rhamnoides L. Leaf Extract|Hippophae rhamnoides L. Leaf Extract 3g/day
62057447|NCT06191809|ACTIVE_COMPARATOR|PPOS protocol|Ovarian stimulation protocol used progestin as premature LH surge inhibitor
62617231|NCT05786599|EXPERIMENTAL|methadone|Methadone is a strong opioid that is μ-opioid receptor agonist like other opioids; however, it is additionally a N-methyl-D- aspartate antagonist with serotonin and norepinephrine reuptake inhibition; these attributes enable its efficacy in neuropathic pain and may prevent opioid tolerance over time. It is commonly used to treat opioid use disorder, as well as to treat severe pain. This medication is taken orally every 8 hours when used to treat pain. It has not been studied to treat chemotherapy-induced peripheral neuropathy.
62617232|NCT05786599|ACTIVE_COMPARATOR|duloxetine|Duloxetine is a serotonin and norepinephrine reuptake inhibitor that is commonly used to treat major depressive disorder, generalized anxiety disorder, and neuropathic pain. This medication is taken orally once daily for all of its indications. It is the only well-studied medication that is recommended internationally to treat chemotherapy-induced peripheral neuropathy.
62260595|NCT02140697|PLACEBO_COMPARATOR|Placebo|Placebo 3g/day
62617233|NCT05112757|EXPERIMENTAL|Intervention|Smartphone app use
62617234|NCT04606667|EXPERIMENTAL|Multi component program|"The intervention lasted 16 weeks, with the evaluations carried out at baseline, after 8 weeks and at the end.~The multi-component exercise program took place in day centers or collective residences. It was supervised by physiotherapists. The classes took place 3 times a week, at the same hour and on alternate days, for 45-60 minutes, for a total of 48 sessions. The program consisted on a warm-up (5 min) with exercises and walking, a balance and strength training (35-40 min) with exercises repeated 3 times and held for 15 seconds flexibility / relaxation (5 to 10 mins) periods. The strength training is performed with the resistance of the body weight or accessible and low cost equipment, with two series of 10 to 15 repetitions, after maximum resistance was calculated.~The flexibility and cooling training consists of 3 repetitions maintained for 15 seconds."
62260596|NCT00128479|EXPERIMENTAL|mifepristone 300 mg|
62260597|NCT00128479|PLACEBO_COMPARATOR|placebo|
62260598|NCT00128479|EXPERIMENTAL|mifepristone 600 mg|
62260599|NCT00128479|EXPERIMENTAL|mifepristone 1200 mg|
62260600|NCT05362903||Oral LLT|Patients who newly initiated oral Lipid lowering treatment (LLT) on top of a statin
62260601|NCT05362903||Inclisiran|"Patients who newly initiated Inclisiran~1. Inclisiran in a PCSK9-treatment naive cohort~2. Inclisiran in patients with prior PCSK9-antibody treatment"
62260602|NCT05362903||Apheresis plus Inclisiran|Patients who newly initiated Inclisiran on top of lipid apheresis
62617235|NCT05196477||Olokizumab treatment group|Subjects with the infection caused by SARS-CoV-2 who received olokizumab injection in addition to the standard therapy.
62617236|NCT05196477||Standard treatment group|Subjects with the infection caused by SARS-CoV-2 who received the standard therapy without monoclonal antibodies (mAbs).
62617237|NCT01501032|EXPERIMENTAL|Closed Loop Control- MD-Logic|The MD-Logic artificial pancreas system will be used in conjunction with continuous glucose monitoring and insulin pump delivery to manage the subject's blood glucose.
62260603|NCT02520323||Blood only|20 sarcoidosis subjects and 20 healthy controls will complete lifestyle questionnaires and have blood drawn for microbiome analyses.
62260604|NCT02520323||Blood and BAL|10 sarcoidosis subjects, 10 healthy controls, and 10 subjects with non-sarcoid interstitial lung disease will complete lifestyle questionnaires and undergo blood sampling for microbiome analyses as well as bronchoscopy for bronchoalveolar lavage microbiome analyses.
62260605|NCT03745274|EXPERIMENTAL|GHB04L1|GHB04L1 is administered as intranasal aerosol at a dose of 6.8 log10 or 7.5 log10 TCID50/dose/subject on day 1 and on day 29.
62260606|NCT03745274|PLACEBO_COMPARATOR|Placebo|Placebo (buffer) is administered as intranasal aerosol on day 1 and on day 29.
62260607|NCT04933331||Curodont Repair Fluoride Plus (Curodont) cohort|The effectiveness of Curodont treatment in this group will be compared to other treatment options and cohorts. Curodont will be professionally applied in the dental clinic. The treatment time takes about 5 minutes. Patients receive one professional dose application and be provided with homecare instructions and will be instructed to return for regular dental visits and exams according to the frequency determined by their dental team, usually every 6 months.
62057448|NCT06191809|ACTIVE_COMPARATOR|GnRH-ant protocol|Ovarian stimulation protocol used GnRH antagonist as premature LH surge inhibitor
62057449|NCT02595216|EXPERIMENTAL|all subjects|"All subjects in this study will receive a single Profound system treatment to the submental area with the profound device; subjects will return to four follow- up visits: 1 week post treatment, 1, 3 and 6 months post treatment.~Prior to treatment, tissue will be treated with injected tumescence or local dermal infiltration solution according to the protocol."
62057450|NCT05218993||Development of the new dual task test|the new two different method of dual task measurement and a traditional dual task measurement method and also, cognitive and performance measurement test will be conducted.
62260608|NCT04933331||Other tooth-specific initial lesion interventional treatments cohort(s)|"Silver Diamine Fluoride (SDF). The treatment time is about 2 minutes.~Glass Ionomer Sealants: The treatment time takes about 5 minutes per sealant. Typically four sealants are completed in one visit.~All patients will be provided with homecare instructions and will be instructed to return for regular dental visits and exams according to the frequency determined by their dental team, usually every 6 months."
62260609|NCT04933331||Control cohort, no tooth-specific treatment or whole mouth treatment.|If a patient or their caregivers choose no tooth-specific treatment, they will be included in the control cohort. This group includes patients who chose to receive no treatment at all, as well as those who choose whole mouth treatments such as: 2.26% fluoride varnish, 1.23% fluoride foam, and 5000 ppm fluoride prescription toothpaste.
62445993|NCT05834790|NO_INTERVENTION|controlled group|The participants in this group will not attend any oral health education program
62445994|NCT04840407|EXPERIMENTAL|SHARP coach arm|The SHARP Peer Coach supports the direct care HHA and indirectly support the patient/family caregiver to enhance the patient's post-stroke recovery through two main pathways: 1) culturally sensitive, patient-centered reinforcement of rehabilitation regimens (prescribed physical/occupational exercises/training); and 2) early recognition and reporting of barriers to the rehabilitation therapist regarding adherence and recovery, including: a) environmental obstacles, b) family-related issues, c) psychological/clinical barriers (e.g., depression/anxiety).
62445995|NCT04840407|NO_INTERVENTION|Usual care arm|
62842674|NCT01915836|EXPERIMENTAL|Alpha game testers and questionaires|"This a video game designed to help smokers quit \& remain non-smokers. Before the start the game,the participant will fill out a brief questionnaire.~It should take about 5 minutes to complete. Once this is done, the game play should last about 30 minutes \& will present with different scenes. These scenes will show situations that may trigger smoking urges such as walking into a room where another person is smoking. In the game, the participant will be able to use different ways of coping with urges to smoke such as taking several deep breaths or listening to music. The participant will be asked to talk aloud about what they think of the game. The participant will be video \&/or audio recorded while doing this. Once finished testing the game, we will then ask you a few questions about what you thought of the game. We will also ask you how relevant different situations are to you as a smoker or someone who is trying to avoid smoking. The entire visit is expected to last about 1.5 hours."
62842675|NCT01869153||Preterm infants|Preterm infants born at either \<32 weeks gestation or \< 1750g birth weight
62842676|NCT00504972|EXPERIMENTAL|Study Treatment|This study is a single arm study
62842677|NCT01785485||Primary care patients|Primary care patients who are members of UAIHC.
62842678|NCT03111641|EXPERIMENTAL|Lung ultrasonography|
62842679|NCT05513209|ACTIVE_COMPARATOR|opioid based multimodal anesthesia|One hundred and twenty pediatric patients will do elective tonsillectomy or adenotonsillectomy surgery using opioid based multimodal anesthesia.
62445996|NCT04661137|EXPERIMENTAL|Carfilzomib-containing Regimen|"Carfilzomib 56 mg/m2 on days 1, 8 and 15. Dexamethasone 20 mg if ≥ 75 years old and 40 mg if \< 75 years old on days 1, 8, 15 and 22.~Selinexor 80 mg on days 1, 8 and 15."
62445997|NCT04661137|EXPERIMENTAL|Pomalidomide-containing Regimen|"Pomalidomide 4 mg po daily for 21 days. Dexamethasone 20 mg if ≥ 75 years old and 40 mg if \< 75 years old on days 1, 8, 15 and 22.~Selinexor 60 mg on days 1, 8 and 15."
62617238|NCT04745507||Arm 1 / C1|This cohort (C1) consists of 180 patients who receive IEHT in the recruiting sites, fulfil inclusion criteria and gave informed consent regarding their study participation.
62617239|NCT04745507||Arm 2 / C2|"This cohort (C2) consist of 180 patients receiving standard inpatient care (TAU) from the IEHT delivering hospital who fulfil inclusion criteria, are identified through a propensity score (PS) function as optimal control user or rather a PS match and gave informed consent regarding their study participation"
62842680|NCT05513209|ACTIVE_COMPARATOR|opioid free pterygopalatine ganglion block based multimodal anesthesia|One hundred and twenty pediatric patients will do elective tonsillectomy or adenotonsillectomy surgery using opioid free pterygopalatine ganglion block based multimodal anesthesia.
62842681|NCT04470076|EXPERIMENTAL|neoadjuvant afatinib combination with chemotherapy|"Neoadjuvant treatment (chemotherapy+afatinib) will start within 1-3 days from enrollment/randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment (including dynamic 18F-FDG PET/CT) will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3) Adjuvant treatment (afatinib): Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the first week (+ 7 days) from surgery and up to 2 years."
62842682|NCT01122121|EXPERIMENTAL|Combined Radiotherapy and Hormone Therapy|Leuprorelin 11.25 milligram (mg) sustained release (SR), injection, subcutaneously, once every 3 months up to 3 years and flutamide 250 mg, tablet, orally, thrice daily for 30 days from the first dose of leuprorelin. Radiotherapy 70 +/- 4 Gray (Gy) in 35 fractions at a rate of 5 fractions of 2 Gy per week up to 3 years. An interval of a maximum of 2 weeks is authorized between radiation of the pelvis with 50 Gy (±4) (5 weeks) and radiation of the prostate with an additional 20 Gy.
62617240|NCT04745507||Arm 3|360 close relatives or informal caregivers living in the same household of the participating patients who gave informed consent regarding their study participation. Thereby, one relative of each patients who is participating in the trial will be assessed (C1 = 180, C2 = 180).
62842683|NCT01122121|ACTIVE_COMPARATOR|Hormone Therapy alone|Leuprorelin 11.25 mg SR, injection, subcutaneously, once every 3 months up to 3 years and flutamide 250 mg, tablet, orally, thrice daily for 30 days from the first dose of leuprorelin.
62842684|NCT02759367|EXPERIMENTAL|High potassium diet group|Individuals in this arm were asked to increase dietary potassium intake over a 4 week period. This was achieved through an increase in consumption of fruits and vegetables.
62842685|NCT02759367|NO_INTERVENTION|Usual diet group|Individuals in this group were asked to continue habitual dietary intake.
62842686|NCT01873976||Incident DCM|A case of dilated cardiomyopathy that presents to the study site for the first time.
62057451|NCT05218993||Collecting the normative values|Better dual task measurement method (from the two methods) will be conducted at different football levels.
62617241|NCT04745507||Arm 4:|Staff members of participating study cites as well as local and political stakeholders engaged with IEHT who gave informed consent (approximately n = 100 participants overall).
62260610|NCT04933331||Orthodontic cohort|Patients in active orthodontic care will be analyzed separately from other patients to account for the impact of orthodontic appliances on treatment outcomes. Orthodontic appliances are recognized by the American Dental Association Caries Risk Assessment as a risk factor for caries because they create dental plaque stagnation areas that are difficult to clean. Initial caries lesions are very frequently seen immediately surrounding orthodontic brackets (braces), yet continued plaque stagnation over the treated areas may heavily influence the success of any treatment. All groups/cohorts above will be represented in the orthodontic cohort in parallel.
62842687|NCT01873976||Incident/Recent HCM|A new or existing diagnosis of idiopathic or familial hypertrophic cardiomyopathy, diagnosed within the past 2 months and with a cMRI within 2 months of diagnosis.
62260611|NCT02905370|EXPERIMENTAL|Progressive Multi-Component (PMC)|High intensity strength training protocol, daily protein supplementation, functionally enhanced transitions of care
62260612|NCT02905370|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|"Low intensity rehabilitation protocol, standard education for nutrition, standard transitions of care~Name of Participant Arm updated to Enhanced Usual Care from Usual Care effective 8/16/18 to distinguish from Passive Comparator True Usual Care group."
62260613|NCT02905370|NO_INTERVENTION|True Usual Care (TUC)|"Real-world home health rehabilitation, real-world education for nutrition, real-world transitions of care, non-randomized observation~Participants in the True Usual Care group will receive physical therapy following discharge from acute hospitalization. Activities and number of visits are not protocolized and are provided by real world home health care providers per physician orders.~Participant Arm added effective 8/16/18."
62842688|NCT01873976||Prevalent HCM or DCM|Any child with a diagnosis of dilated cardiomyopathy or idiopathic or familial hypertrophic cardiomyopathy who has survived transplant-free at least 24 months from the date of cardiomyopathy diagnosis.
62842689|NCT00673738|EXPERIMENTAL|Cetuximab Plus Radiotherapy|Concurrent Cetuximab plus Conformal Thoracic Radiotherapy (CTRT). Patients were treated with definitive radiotherapy (70 Gy in 35 fractions, per our currently-existing institutional standard) with concurrent cetuximab followed by 3 cycles of consolidation docetaxel plus cetuximab.
62842690|NCT00629889|ACTIVE_COMPARATOR|Levetiracetam|Patients assigned to Levetiracetam are treated with the initial dose of 2 x 250mg per day up to one year
62842691|NCT00629889|ACTIVE_COMPARATOR|Pregabalin|Patients assigned to Pregabalin are treated with the initial dose of 2 x 75mg per day up to one year
62842692|NCT02299843|ACTIVE_COMPARATOR|ALPPS|Using ALPPS for the the treatment of hepatocellular carcinoma.
62842693|NCT02299843|EXPERIMENTAL|RALPPS|Using radiofrequency ablation instead of in-situ split of liver in ALPPS stage I（RALPPS）.Habib 4X was used in RFA.
62842694|NCT01632618|EXPERIMENTAL|Trunk Muscle Training+NMES|Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals
62260614|NCT01070732|EXPERIMENTAL|Paracetamol|All patients will receive one single dose of 1000mg paracetamol.
62260615|NCT03990064|EXPERIMENTAL|musicotherapy|daily sessions of music listening during 2 months, associated with their standard treatment,
62842695|NCT01632618|ACTIVE_COMPARATOR|Passive control intervention|Passive physical therapy interventions, including moist heat, ultrasound, massage and flexibility exercises
62842696|NCT05428397||Contrast enhanced X-ray based examination with Ultravist|Patients who received a contrast enhanced X-ray based examination with Ultravist for various clinical reasons and having experienced a hypersensitivity reaction.
62260616|NCT03990064|NO_INTERVENTION|waiting list|waiting list
62260617|NCT01148199|ACTIVE_COMPARATOR|Multiple plastic stents|Multiple plastic stents placement after sphincterotomy and stricutre dilation. ERCP repeated every 3 - 4 months during 1-year
62260618|NCT01148199|EXPERIMENTAL|Self-expandable metalic stent|Self-expandable metalic stent after sphincterotomy. Stent removal scheduled for 6 months
62260619|NCT00867399|ACTIVE_COMPARATOR|20mg of ABT-126 QD|20 mg of ABT-126 QD for 10 days
62842697|NCT05428397||Control group|Patient who received contrast enhanced X-ray based examination with Ultravist for various indications who had not adverse event.
62842698|NCT03711695||Group A|Subjects presenting for catheter ablation for cardiac arrhythmias (e.g. atrial fibrillation, supraventricular tachycardia, or ventricular tachycardia)
62260620|NCT00867399|ACTIVE_COMPARATOR|30mg and 45mg ABT-126 QD|30 mg and 45mg of ABT-126 QD for 21 days
62260621|NCT01880671|EXPERIMENTAL|Migraine Medical Device|
62260622|NCT01880671|PLACEBO_COMPARATOR|Inactive Migraine Medical Device|
62260623|NCT05913570|EXPERIMENTAL|Experimental: Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody|Neoadjuvant therapy with Cadonilimab
62842699|NCT03711695||Group B|Subjects judged based on the clinical evaluation of high, greater than 75%, atrial pacing or ventricular pacing burden or known pacing dependence with planned device interrogation for: 1) pacemaker (single or dual chamber), 2) implantable cardioverter-defibrillator (single or dual chamber), or 3) cardiac resynchronization therapy with or without defibrillator (single or dual chamber plus left ventricular pacing).
62842700|NCT03711695||Group C|Subjects for clinically indicated defibrillation threshold testing (DFT) (with a transvenous or subcutaneous implantable cardioverter defibrillator (ICD) lead system)
62842701|NCT05185713||Ctrl HPV (-)|Patients with normal cervix and HPV negative
62842702|NCT05185713||Ctrl HPV (+)|Patients with normal cervix and HPV positive
62842703|NCT05185713||LSIL group|Patients with low-grade squamous Intraepithelial lesion
62445998|NCT04661137|EXPERIMENTAL|Exploratory/Daratumumab-containing Regimen|"Daratumumab on current schedule (16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on).~Dexamethasone 20 mg if ≥ 75 years old and 40 mg if \< 75 years old on days 1, 8, 15 and 22.~Selinexor 100 mg on days 1, 8, 15 and 22."
62260624|NCT04194359|EXPERIMENTAL|Sintilimab (IBI308) plus Bevacizumab, Oxaliplatin and Capecitabine|Sintilimab (IBI308)：200MG, once every three weeks; Bevacizumab:7.5mg/kg, once every three weeks; oxplatin: 135 mg per square meter body surface, once every three weeks; Capecitabine : Capecitabine 1 gram per square meter body surface area, from the first day to the 14th day
62445999|NCT02127047|EXPERIMENTAL|Sitagliptin|Patients receive Sitagliptin (100mg/d) without further intervention
62446000|NCT02127047|EXPERIMENTAL|Sitagliptin and exercise|Patients receive sitagliptin (100mg/d) and follow a physical training intervention program
62446001|NCT05747079|EXPERIMENTAL|Conservative treatment|Rehabilitation and optional delayed ACL reconstruction
62446002|NCT05747079|EXPERIMENTAL|Immediate ACL reconstruction|Immediate ACL reconstruction + rehabilitation
62057452|NCT05218993||Measurement of the athletes in return to sport stage|new dual task measurement method and other return to sport measurements will be conducted on athletes who wish to return to sport.
62446003|NCT00313885|EXPERIMENTAL|1|1 mg daily
62446004|NCT00313885|EXPERIMENTAL|2|5 mg daily
62446005|NCT00313885|PLACEBO_COMPARATOR|3|
62446006|NCT01751412|EXPERIMENTAL|Proton Radiation|Delivered daily (Monday-Friday) for two to five weeks.
62446007|NCT05498285|EXPERIMENTAL|Intervention|Use of UPSCALER App
62446008|NCT05498285|NO_INTERVENTION|Control|No app used. Conventional treatment.
62446009|NCT02294656|EXPERIMENTAL|RANIBIZUMAB|Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
62446010|NCT02294656|ACTIVE_COMPARATOR|TRIAMCINOLONE ACETONIDE|Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
62842704|NCT05185713||HSIL group|Patients with high-grade squamous Intraepithelial lesion
62842705|NCT05185713||ICC group|Patients newly diagnosed invasive cervical cancer
62842706|NCT02405377|EXPERIMENTAL|CVP guided hydration|The fluid rate was adjusted according to the CVP dynamically
62842707|NCT02405377|ACTIVE_COMPARATOR|Control|The control group was hydrated at 1 mL/kg per h.
62842708|NCT02835976|EXPERIMENTAL|Olesoxime|Participants will receive a single dose of liquid suspension of 14C-labeled olesoxime containing an equivalent of 600 milligrams (mg) of the compound. The total amount of administered radiocarbon will be 93 microcuries (mcCi), or 3.447 megabecquerels (MBq).
62842709|NCT04413006|EXPERIMENTAL|Treatment Arm|Participants who will receive the 6-session Group-Based Virtual Self-Compassion for Chronic Pain treatment
62842710|NCT01586130|OTHER|isokinetic exercises in eccentric mode|
62842711|NCT01586130|OTHER|isokinetic exercises in concentric mode|
62842712|NCT04607317|EXPERIMENTAL|Exercise Intervention|Participants in this arm will be enrolled in a telehealth-delivered exercise program with the goal of progressing to 150 min/week (5 days per week, 30 minutes of steady state walking per day). Participants will meet weekly 1:1 with a trained health coach via a Webex platform. Weekly exercise goals will be tailored to the individual's abilities and specific barriers. Coaching will utilize social cognitive theory and self-determination theory to develop self-efficacy for sustainable behavior change.
62842713|NCT04607317|ACTIVE_COMPARATOR|Control|Participants randomized to the wait-list attention control group will continue to undergo standard care for 12 weeks. They will continue to wear the Garmin activity tracker and can view their activity but will not be given an exercise program. They will be contacted by a study coordinator via telephone every 2 weeks for health education. During this time, they will review resources and healthy lifestyle guidelines for people with epilepsy, including healthy diet, medication compliance, seizure precautions, stress management, and sleep hygiene.
62842714|NCT02652858|EXPERIMENTAL|Pulse wave's speed observational arm|Whole patients for who the pulse wave's speed are measured during a cardiopulmonary bypass during cardiac surgery
62842715|NCT01255683||Chronic rhinosinusitis|
62446011|NCT02387320|EXPERIMENTAL|Self-Care Toolkit|Women randomized to self-care toolkit group will receive a toolkit which includes a spiral-bound instruction manual, a section of the manual that can be used as a journal, a portable mp3 player with 8 audiofile tracks with guided meditations to reduce stress and anxiety, and two acupressure wristbands to help prevent nausea.
62842716|NCT02685137|EXPERIMENTAL|Active drug-Stannsoporfin|"Stannsoporfin, single dose 4.5mg/kg administered Intramuscular (parental injection in the thigh) for treatment of jaundice~20 mg/mL 1.5 mL/vial"
62842717|NCT02685137|SHAM_COMPARATOR|Reference Therapy-Sham|Sham Injection, no injection followed by a Band-Aid to thigh
62842718|NCT00808080|EXPERIMENTAL|Biologic|AML_CTL cells
62842719|NCT02139007|ACTIVE_COMPARATOR|Continuation Arm|Alendronate continuation arm
62842720|NCT02139007|ACTIVE_COMPARATOR|Discontinuation Arm|Alendronate discontinuation arm
62842721|NCT03617224|EXPERIMENTAL|TSEBT and pembrolizumab|Dose regimens are sequential therapy of TSEBT with Pembrolizumab.
62842722|NCT03617224|EXPERIMENTAL|Radiation: TSEBT|"The regimen includes a rule-based 3+3 design for escalating regimen intensity of combined TSEBT and pembrolizumab."
62446012|NCT02387320|NO_INTERVENTION|Standard Care|Women randomized to the standard care group will be informed that they will continue to receive standard of care as delivered by the SAMMC Oncology Department. The research team will inform women randomized to standard care that they will receive the self-care toolkit at their two week post-operative visit and will be able to use it subsequently if they choose to.
62446013|NCT02347878|EXPERIMENTAL|treatment arm|this treatment arm will received aprepitant 1 hour before lumbar puncture and intrathecal treatment.
62446014|NCT02347878|NO_INTERVENTION|control arm|this arm will received nothing 1 hour before lumbar puncture
62446015|NCT03880526||Semi-Structured Interview|Participants will choose to participant in an individual in-depth interview to be conducted by investigators to gain information about the participant's background, cancer status and treatment.
62446016|NCT03880526||Focus Groups|Participants may choose to participate in one of three focus groups of no more than 10 participants in each group to to gain information about the participant's background, cancer status and treatment.
62446017|NCT04584125|EXPERIMENTAL|Ex vivo cross linking of donor corneal tissue|Treatment Arm: The donor corneal tissue used in the PK or DALK procedures will previously undergo ex vivo crosslinking.
62446018|NCT04584125|SHAM_COMPARATOR|Non-cross-linked donor corneal tissue for keratoplasty|Control Arm: The donor corneal tissue used in the PK or DALK procedures will not previously undergo ex vivo crosslinking.
62446019|NCT03616613||Men|Men born in 1952 in Barcelona in health areas depending from Hospital de la Santa Creu i Sant Pau.
62446020|NCT03616613||Women|Aleatory sample of women born in 1952 in Barcelona in health areas depending from Hospital de la Santa Creu i Sant Pau.
62446021|NCT03283709|EXPERIMENTAL|Full-contour monolithic Zirconia crowns|If participants assigned to this arm are in need of surveyed crowns on RPD abutment teeth they will be fabricated from multi-layered monolithic zirconia
62446022|NCT03283709|OTHER|Conventional abutment crowns|If participants assigned to this arm are in need of surveyed crowns on RPD abutment teeth they will be fabricated from type III gold or high-noble metal veneered with feldspathic porcelain
62446023|NCT04809870||LC (liver cirrhotic patients)|Patients with concomitant liver cirrhosis
62446024|NCT04809870||Non-LC (non liver cirrhotic patients)|Patients without concomitant liver cirrhosis
62446025|NCT01783106|ACTIVE_COMPARATOR|budesonide|Oral Budesonide 9mg per day for 8 weeks followed by 6mg per day for 2 weeks and subsequent 3mg per day over a further 2 weeks
62617242|NCT01172808|EXPERIMENTAL|tiotropium low dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
62842723|NCT05289895||1|Sequence I (Retrospective study: proteomic analysis of pathological specimens and information collection of previous patients with pancreatic cancer)
62842724|NCT05289895||2|Sequence 2 (Non-interventional prospective study, sample and information collection in patients with pancreatic cancer)
62842725|NCT05289895||3|Sequence 3 (Non-intervention study, healthy subjects sample and information collection)
62842726|NCT01171482|EXPERIMENTAL|The FM group|Patients in the FM group will be administered 5-FU plus mitomycin
62842727|NCT01171482|ACTIVE_COMPARATOR|The sorafenib group|Patients in the sorafenib group will be administered sorafenib
62842728|NCT02780128|OTHER|Molecular Analysis|All participants with relapsed or refractory neuroblastoma will have a tumor biopsy to identify genetic mutations. There is no drug given in this arm of the trial.
62617243|NCT01172808|EXPERIMENTAL|tiotropium high dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
62057453|NCT01712009|EXPERIMENTAL|Prophylactic naproxen|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
62260625|NCT01517529||10 Hepatitis C infected subjects|10 chronically HCV-infected patients who fail the standard peg-IFN and Ribavirin therapy (NR) and are therefore eligible for combined treatment with Protease Inhibitor therapy.
62260626|NCT01357096|NO_INTERVENTION|Comparison group|
62446026|NCT01783106|EXPERIMENTAL|Ciprofloxacine, doxycycline and hydroxychloroquine|Oral Ciprofloxacin 500mg bd plus Doxycycline 100mg bd and Hydroxychloroquine 200mg tds followed by a further 20 weeks continued therapy with Doxycycline 100mg bd and Hydroxychloroquine 200mg tds
62446027|NCT05157321|ACTIVE_COMPARATOR|Study Group|The patients in this group will receive active repetitive transcranial magnetic stimulation sessions for 4 weeks.
62446028|NCT05157321|SHAM_COMPARATOR|control group|The patients in this group will receive sham repetitive transcranial magnetic stimulation sessions for 4 weeks.
62446029|NCT03845920|OTHER|tDCS sham + placebo|tDCS= transcranial direct current stimulation drugs= placebo (cellulose \[2 grams\])
62446030|NCT03845920|EXPERIMENTAL|tDCS sham + tyrosine|tDCS= transcranial direct current stimulation drugs= tyrosine (2 grams)
62446031|NCT03845920|EXPERIMENTAL|tDCS anodal + placebo|tDCS= anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex drugs= placebo (cellulose \[2 grams\])
62446032|NCT03845920|EXPERIMENTAL|tDCS anodal +tyrosine|tDCS= anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex drugs= tyrosine (2 grams)
62446033|NCT03571308|EXPERIMENTAL|R-CHOP + Acalabrutinib|"Open-label non-randomised phase Ib/II study conducted in two stages. Phase I will see two doses of acalabrutinib tested. R-CHOP + acalabrutinib will be given for 6 cycles on a 21 day cycle and then two cycles of acalabrutinib only for a total of 56 days. Acalabrutinib will be introduced at Cycle 2.~Phase II will see the recommended phase 2 dose used on the same treatment regimen."
62446034|NCT05738356|ACTIVE_COMPARATOR|Three-step adhesive|The orthodontic appliances were bonded to the patients teeth using conventional 3 step adhesive (3M™ Transbond™ XT, 3M Unitek, United States)
62446035|NCT05738356|EXPERIMENTAL|Self-etch primer adhesive|The orthodontic appliances were bonded to the patients teeth using self-etch primer (3M™ Transbond™ Plus, 3M Unitek, United States).
62446036|NCT05738356|EXPERIMENTAL|One-step adhesive system|The orthodontic appliances were bonded to the patients teeth using one-step adhesive system (GC Ortho Connect™, GC Orthodontics, Germany)
62446037|NCT04999514|EXPERIMENTAL|Mindful Parenting Program|The Mindful Parenting program as developed by Bögels and Restifo (2013), is selected as one of the parenting intervention programs in this study. It is an 8-week program that trains parents in mindfulness and support them to apply mindfulness in parenting context.
62617244|NCT01172808|ACTIVE_COMPARATOR|50 mcg salmeterol|Twice daily, delivered with HFA MDI (+ inhalation of placebo Respimat® inhaler once daily)
62617245|NCT01172808|PLACEBO_COMPARATOR|placebo|Once daily, delivered with Respimat® inhaler + twice daily delivered with HFA MDI
62057454|NCT01712009|EXPERIMENTAL|Prophylactic loratadine|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic loratadine 10 mg once a day (QD) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
62260627|NCT01357096|EXPERIMENTAL|Integrated health care team|
62260628|NCT04339907|SHAM_COMPARATOR|Cataract surgery only|Participants needing cataract surgery, without glaucoma or any other corneal diseases.
62260629|NCT04339907|SHAM_COMPARATOR|Glaucoma surgery only|Participants needing glaucoma filtration surgery, without any prior corneal transplantation.
62617246|NCT05135793|EXPERIMENTAL|A test|Test drug (Topoprazan) 1 tablet contains 20 mg vonoprazan
62617247|NCT05135793|ACTIVE_COMPARATOR|B reference|Reference drug (Takecab) 1 tablets contains 20 mg vonoprazan
62617248|NCT04399538|PLACEBO_COMPARATOR|Placebo|Participants will receive medication for 6 weeks
62617249|NCT04399538|EXPERIMENTAL|DGAT2i (25 mg BID) + ACCi (10 mg BID)|Participants will receive medication for 6 weeks
62617250|NCT04399538|EXPERIMENTAL|DGAT2i (100 mg BID) + ACCi (10 mg BID)|Participants will receive medication for 6 weeks
62617251|NCT04399538|EXPERIMENTAL|DGAT2i (300 mg QD) + ACCi (20 mg QD)|Participants will receive medication for 6 weeks
62057455|NCT01712009|OTHER|No prophylactic treatment|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis.
62057456|NCT02991482|EXPERIMENTAL|Pembrolizumab arm|Pembrolizumab is administrated at 200 mg fixed dose i.v. on day 1 of every 3 week cycle for a maximum or 2 years (expected maximum of 36 doses), or until progression of disease determined according to RECIST 1.1 criteria or lack of tolerability, or until the patient declines further treatment.
62057457|NCT02991482|ACTIVE_COMPARATOR|Standard chemotherapy arm|"Gemcitabine (i.v. 1000 mg/m2) or vinorelbine (i.v. 30 mg/m2, or p.o 60/80 mg/m2) chemotherapy will be chosen on a per patient basis and delivered according to local standards. Chemotherapy will be administered on days 1 and 8 of every 3-week cycle. A maximum number of treatment cycles is not mandated.~Patients randomised to the control arm will be allowed to cross over to receive pembrolizumab at progression, if cross-over criteria are met. Pembrolizumab administration will follow the same schedule as for patients in the experimental arm, i.e. 200 mg fixed dose i.v. on day 1 of every 3-week cycle for a maximum of 2 years or until trial termination."
62260630|NCT04339907|EXPERIMENTAL|Corneal transplantation|"Participants needing corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis), with or without glaucoma.~This allows analyzing samples at baseline (time 0), at the time of the corneal transplantation procedure."
62260631|NCT04339907|EXPERIMENTAL|Intraocular surgery following corneal transplantation|"Participants needing intraocular surgery (cataract, retina or glaucoma), with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis).~This allows analyzing samples during the potential development or progression of glaucoma in participants who have previously undergone corneal transplantation."
62260632|NCT04339907|EXPERIMENTAL|Glaucoma surgery following corneal transplantation|"Participants needing glaucoma filtration surgery, with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis).~This allows analyzing samples once glaucoma is confirmed in participants who have previously undergone corneal transplantation."
62260633|NCT00933673|EXPERIMENTAL|L-DICE|
62260634|NCT06475066|EXPERIMENTAL|Contrast-enhanced spectral mammography arm|Subjects receiving contrast-enhanced spectral mammography (CESM) within 28 days of MRI examination.
62260635|NCT00128856|EXPERIMENTAL|Gemcitabine + Adriamycine + Paclitaxel|Neoadjuvant chemotherapy consisted of adriamycine 40 mg/m2, administered on day 1 as an i.v. infusion. Paclitaxel 150 mg/m2 was administered on day 2 as an i.v infusion followed by gemcitabine 2000 mg/m2 as an i.v. infusion. The three drugs were administered every two weeks for 6 cycles.
62617252|NCT04399538|EXPERIMENTAL|DGAT2i (300 mg BID) + ACCi (10 mg BID)|Participants will receive medication for 6 weeks
62617253|NCT05127928|EXPERIMENTAL|Supplementation|Vitamin C and Vitamin E before exercise
62617254|NCT05127928|PLACEBO_COMPARATOR|Placebo|Placebo before exercise
62617255|NCT00617513|ACTIVE_COMPARATOR|1|
62446038|NCT04999514|EXPERIMENTAL|Tuning in to Kids Program|The Tuning in to Kids program as developed by Havighurst and colleagues (2010), is selected as one of the parenting intervention programs in this study. It will be extended to 8-week program that aims at equipping parents with emotion coaching skills.
62446039|NCT04999514|NO_INTERVENTION|Waitlist Control Group|The waitlist control group will not receive any intervention until the intervention arms complete their training. Depending on the availability of the program instructor, either the Mindful Parenting or Tuning in to Kids program will be offered to this group.
62446040|NCT00581620|ACTIVE_COMPARATOR|G1|G1: HIV+
62446041|NCT00581620|ACTIVE_COMPARATOR|G2|G2: Sicle Cell disease
62446042|NCT00581620|ACTIVE_COMPARATOR|G3|G3: neprotic symdrome
62446043|NCT00581620|ACTIVE_COMPARATOR|G4|G4: Chronic pulmonary disease
62446044|NCT01417897|EXPERIMENTAL|Insulin Glulisine: bolus injections before each main meal|Patients are already on an Insulin Glargine therapy when they start and will them after randomization receive additionally Insulin Glulisine bolus injections before each of the main meals.
62617256|NCT00617513|ACTIVE_COMPARATOR|2|
62617257|NCT00617513|ACTIVE_COMPARATOR|3|
62617258|NCT00617513|PLACEBO_COMPARATOR|4|
62617259|NCT00693615|EXPERIMENTAL|Group A|Formulation 1 of the vaccine (MEDI-517 HPV-16/18 VLP AS04 vaccine)
62617260|NCT00693615|EXPERIMENTAL|Group B|Formulation 2 of the vaccine \[with Al(OH)3\]
62617261|NCT00693615|EXPERIMENTAL|Group C|Formulation 3 of the vaccine (without adjuvant)
62842729|NCT02780128|EXPERIMENTAL|Group 1: ALK|"Qualified participants whose tumors show certain mutations in the anaplastic lymphoma kinase (ALK) pathway (based on genetic sequencing results) will receive a combination therapy of ceritinib and ribociclib, to be administered orally in 28-day cycles.~Two different doses of ceritinib and three different doses of ribociclib will be evaluated. Once the investigators have identified the highest safe dose of both drugs that can be given at the same time, additional participants will be enrolled in the study at this dose level.~It is possible that if starting at a lower dose, participants may take a higher dose once that dose has been deemed safe."
62842730|NCT03210337|EXPERIMENTAL|Active|A-101 Topical Solution
62842731|NCT03210337|PLACEBO_COMPARATOR|Vehicle|Vehicle
62842732|NCT02296645|EXPERIMENTAL|ZuraPrep|Isopropyl alcohol (IPA) (70%)
62842733|NCT02296645|ACTIVE_COMPARATOR|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
62617262|NCT04591457|EXPERIMENTAL|Insulin Glargine Sansulin|Drug product Insulin Glargine, Sansulin Log-G 100 IU/mL (PT. Sanbe Farma)
62617263|NCT04591457|ACTIVE_COMPARATOR|Insulin Glargine Lantus|Drug product Insulin Glargine, Pen Injector \[Lantus\] 100 IU/mL (PT. Sanofi-Aventis)
62617264|NCT00946127||Shunt Arm|Ventriculoperitoneal Shunt
62617265|NCT00946127||ETV arm|Endoscopic Third Ventriculostomy
62617266|NCT00604422||A|Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease
62842734|NCT05434780|ACTIVE_COMPARATOR|(Intervention 1 or group A)|Facilitatory kinesiology taping on calf muscles
62842735|NCT05434780|EXPERIMENTAL|(Intervention 2 or group B)|Inhibitory kinesiology taping on calf Muscles combined with Facilitatory kinesiology taping on Tibialis Anterior
62260636|NCT02234479|ACTIVE_COMPARATOR|Hydrophor (Group A)|Group A (current standard of care): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily, starting at the onset of radiation therapy (RT) and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Hydrophor application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Hydrophor within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.
62842736|NCT05927649|EXPERIMENTAL|Sequence ABC|Subjects receive three treatments (A: omaveloxolone 450 mg, B: omaveloxolone matching placebo 450 mg and C: moxifloxacin 400 mg) administered in a single dose with the standard FDA high-fat meal in three periods. Treatment A (Period 1 from Day 1 - 15), Treatment B (Period 2 from Day 15 - 29), and Treatment C(Period 3 from Day 29 -32)
62842737|NCT05927649|EXPERIMENTAL|Sequence BAC|Subjects receive three treatments (A: omaveloxolone 450 mg, B: omaveloxolone matching placebo 450 mg and C: moxifloxacin 400 mg) administered in a single dose with the standard FDA high-fat meal in three periods. Treatment B (Period 1 from Day 1-15), Treatment A (Period 2 from Day 15 - 29, and Treatment C (Period 3 from Day 29 to 32)
62842738|NCT05927649|EXPERIMENTAL|Sequence ACB|Subjects receive three treatments (A: omaveloxolone 450 mg, B: omaveloxolone matching placebo 450 mg and C: moxifloxacin 400 mg) administered in a single dose with the standard FDA high-fat meal in three periods. Treatment A (Period 1 from Day 1-15), Treatment C (Period 2 from Day 15 -18), and Treatment B (Period 3from Day 18 - 32)
62842739|NCT05927649|EXPERIMENTAL|Sequence BCA|Subjects receive three treatments (A: omaveloxolone 450 mg, B: omaveloxolone matching placebo and C: moxifloxacin 400 mg) administered in a single dose with the standard FDA high-fat meal in three periods. Treatment B (Period 1 from Day 1 - 15), Treatment C (Period 2 from Day 15 to 18), and Treatment A (Period 3 from Day 18 - 32)
62842740|NCT05927649|EXPERIMENTAL|Sequence CAB|Subjects receive three treatments (A: omaveloxolone 450 mg, B: omaveloxolone matching placebo and C: moxifloxacin 400 mg) administered in a single dose with the standard FDA high-fat meal in three periods. Treatment C (Period 1 from Day 1 - 4), Treatment A (Period 2 from Day 4 - 18), and Treatment B (Period 3 from Day 18 - 32)
62842741|NCT05927649|EXPERIMENTAL|Sequence CBA|Subjects receive three treatments (A: omaveloxolone 450 mg, B: omaveloxolone matching placebo and C: moxifloxacin 400 mg) administered in a single dose with the standard FDA high-fat meal in three periods. Treatment C (Period 1 from Day 1 - 4), Treatment B (Period 2 from Day 4 - 18), and Treatment A (Period 3 from Day 18 - 32)
62842742|NCT02660983|PLACEBO_COMPARATOR|Double Blind Phase: Placebo|Participants will receive donepezil matching placebo, once daily in the evening during the double blind period.
62842743|NCT02660983|EXPERIMENTAL|Double Blind Phase: Donepezil|Participants will receive donepezil 5 milligram (mg), once daily in the evening during the titration phase and then the dose will be increased to 10 mg at Week 4 during the double blind period. During the maintenance period, dose reduction to 5 mg/day will be permitted only when 10 mg/day is intolerable due to adverse events.
62260637|NCT02234479|EXPERIMENTAL|MediHoney (Group B)|Group B (study target): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Medihoney daily, starting at the onset of RT and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Medihoney application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Medihoney within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.
62260638|NCT04272658||value of 4D body-to-whole dynamic acquisition in FDG|"differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this unconfirmed progression after 2 new treatment cures of immune checkpoint inhibitors in metastatic melanoma"
62260639|NCT01083355||Mechanical ventilation|Critical care patients
62260640|NCT00679510|ACTIVE_COMPARATOR|rosuvastatin|Rosuvastatin Patients were randomly allocated rosuvastatin (crestor) 10 mgs. The drugs (rosuvastatin and placebo) were provided by Astra Zeneca Ltd.
62057458|NCT01645748|EXPERIMENTAL|S-1, induction chemotherapy|Cisplatin and 5-FU is the standard treatment for patients with head and neck cancer. Recently,docetaxel was used into CF, and it showed the prolongation of survival. Oral 5-FU showed similar or enhanced response rate, safety than intravenous 5-FU. S-1 showed promising preliminary result in combination with cisplatin in head and neck cancer. In patients with gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid, 60mg/m2 (D1) and 60mg/m2 (D1), respectively. And weekly docetaxel can reduce adverse events compared to 3 week regimen. The aim of this study was to evaluate the efficacy and safety of weekly docetaxel, cisplatin and S-1 combination chemotherapy
62057459|NCT03665844|PLACEBO_COMPARATOR|SmartSleep Boost Off|Participants wear the device for baseline data collection in boost off mode. There is no intervention. This is known as SmartSleep Boost Off mode.
62057460|NCT03665844|ACTIVE_COMPARATOR|SmartSleep Boost On|Participants wear the device for 3 weeks in boost on mode. This is known as SmartSleep Boost On mode.
62057461|NCT02380443|EXPERIMENTAL|Dosing Schedule A|"* The priming step with ID injections of AlloStim on Days 0, 7, and 14~* The vaccination step with cryoablation and IT (intratumoral) injection of AlloStim on Day 21~* The activation step with IV infusion of AlloStim on Day 28~* The booster step with two IV booster infusions of AlloStim on Days 56 and 84~Protocol follow-up procedures continue until day 112. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
62057462|NCT02380443|EXPERIMENTAL|Dosing Schedule B|"* The priming step with ID injections of AlloStim on Days 0, 3 and days 7 and 10~* The vaccination step with cryoablation and IT (intratumoral) injection of AlloStim on Day 14~* The activation step with IV infusion of AlloStim on Day 21~* The booster step with two IV booster infusions of AlloStim on Days 49 and 77~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
62057463|NCT02380443|EXPERIMENTAL|Dosing Schedule C|"* The priming step with ID injections of AlloStim on Days 0, 3, 7, 10 and day 14~* IV AlloStim on Day 21~* The booster step with two IV booster infusions of AlloStim on Days 49 and 77~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
62260641|NCT00679510|PLACEBO_COMPARATOR|Placebo|Placebo. Patients were randomly allocated placebo. The drugs (rosuvastatin and placebo) were provided by Astra Zeneca Ltd.
62446045|NCT01417897|ACTIVE_COMPARATOR|Insulin Aspart: bolus injections before each main meal|Patients are already on an Insulin Glargine ± metformin therapy when they start the start and will them after randomization receive additionally Insulin Aspart bolus injections before each of the main meals.
62617267|NCT05202860|EXPERIMENTAL|HPV vaccine|Commercially available nonavalent HPV vaccine (Gardasil(R) 9) given intramuscularly at baseline, month 2 and month 6
62057464|NCT02380443|EXPERIMENTAL|Dosing Schedule D (reducing dose)|"The priming step with ID injections of AlloStim on Days 0, 3, 7, 10 and day 14~* IV AlloStim on Day 21~* The booster step with two IV booster infusions of AlloStim on Days 49 and 77~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
62446046|NCT01417897|ACTIVE_COMPARATOR|Regular human insulin:bolus injections before each main meal|Patients are already on an Insulin Glargine ± metformin therapy when they start the start and will them after randomization receive additionally regular human insulin bolus injections before each of the main meals.
62446047|NCT03510299|PLACEBO_COMPARATOR|Control group|
62617268|NCT05202860|PLACEBO_COMPARATOR|Isotonic Saltwater Vaccine|0.9% NaCl given intramuscularly at baseline, month 2 and month 6
62617269|NCT03811054|EXPERIMENTAL|Apatinib combined with EGFR-TKI|Apatinib 250 millgram（mg/day（d））combined with EGFR-TKI
62842744|NCT02660983|EXPERIMENTAL|Open-Label Extension Phase: Donepezil|All participants who will complete the double-blind phase and want to continue the study participation, can be enrolled in the 24-week open-label extension phase. In this phase, treatment will be initiated at 5 mg/day, and the dose will be maintained until Week 6 (Day 28-42). After assessing clinical response during the period by examination, the dose can be increased to 10 mg/day. Dose reduction (from 10 mg/day to 5 mg/day) will be permitted when the investigator judges it difficult to continue the 10 mg/day administration. It will be possible to increase the dose to 10 mg/day again.
62842745|NCT01829152|NO_INTERVENTION|Control|Subjects in the Control Group will receive Heart Failure care as routinely delivered by the SMH HF clinicians according to their standards of care.
62617270|NCT05679297||Patients with thalamic CPSP (central post-stroke pain)|Patients with CPSP of thalamic origin due to stroke.
62617271|NCT05679297||Patients with thalamic stroke without CPSP|Patients with thalamic stroke at least 2 years ago, but without CPSP or other chronic pain disorders
62617272|NCT05679297||Patients with migraine|Patients with migraine (other central pain disorder)
62617273|NCT05679297||Healthy controls|Age- and gender-matched healthy control subjects
62842746|NCT01829152|EXPERIMENTAL|CHM Intervention Group|The Intervention Group subjects will receive Converged Health Management (CHM) in addition to continuing to receive care as routinely delivered by the SMH HF clinicians.
62842747|NCT04388254|EXPERIMENTAL|Simufilam 100 mg oral tablets throughout|Simufilam 100 mg oral tablets administered twice daily (BID) for the full 24 months (including the randomized period Month 12 to Month 18)
62842748|NCT04388254|PLACEBO_COMPARATOR|Simufilam 100 mg oral tablets / Placebo / Simufilam 100 mg oral tablets|This placebo arm is only for Month 12 to Month 18. Day 1 to Month 12, as well as Month 18 to Month 24 are open-label treatment periods of simufilam 100 mg b.i.d. for all subjects.
62842749|NCT05170880|EXPERIMENTAL|Treatment Group|After fulfilling the eligibility criteria, patients will be informed about the study and written consent to participate in the study will be acquired from each patient after explaining risks, benefits and alternative treatments.The endodontic treatment for all patients will be performed by a single operator (S.A) following a standardized protocol.
62842750|NCT05170880|NO_INTERVENTION|Control Group|The control group will receive no endodontic treatment during the study period. After completion of the study, these patients will be given primary non-surgical endodontic treatment.
62617274|NCT02148315|EXPERIMENTAL|garden intervention|garden kit and access to garden-based lessons
62057465|NCT01900262|EXPERIMENTAL|Strengthening|Novice recreational runners from the Calgary area.
62617275|NCT02148315|NO_INTERVENTION|no garden|control - receives garden and lessons at end of study
62617276|NCT05911672|EXPERIMENTAL|Full Intervention|This group will receive the app (PRICE) which will collect their PROMs (pain, fatigue and stress) three times a day for 2 weeks. They will be prompted each time they have elevated levels of pain, fatigue and stress to use the VR glasses (EMI). This is the EMI provided: https://dl.acm.org/doi/abs/10.1145/3491101.3503562?casa_token=tC5fSN8-k5EAAAAA:56_TMf6HitVQXZypY2j9FCCcroIFZW9kxxzCEt0yJNFJmNrv79m9W7htznSzMWqGLwE4eimBU0vkLA
62617277|NCT05911672|ACTIVE_COMPARATOR|Partial Intervention|This group will receive the EMA app and the EMI but they will not be prompted to use the EMI according to their EMA data.
62617278|NCT05911672|NO_INTERVENTION|Control|This group will receive the EMA but no the EMI.
62617279|NCT02927496|ACTIVE_COMPARATOR|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg).
62617280|NCT02927496|PLACEBO_COMPARATOR|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
62617281|NCT04293172|EXPERIMENTAL|Ticagrelor|The double-blinded study drug dose will be weight dependent.
62617282|NCT04293172|PLACEBO_COMPARATOR|Placebo|The double-blinded study drug dose will be weight dependent
62842751|NCT01162837|OTHER|All subjects|All subjects are enrolled in this arm and will use the BEAM device on one side of the face and the other side of the face will be the control
62057466|NCT01900262|EXPERIMENTAL|Balance Training|Novice recreational runners from the Calgary area.
62057467|NCT01900262|EXPERIMENTAL|Stretching|Novice recreational runners from the Calgary area.
62057468|NCT02515565|EXPERIMENTAL|Experimental group|Patients with a clinical diagnosis of pneumonia will be included in this group. They will be included in a physiotherapy program added to the standard medical treatment.
62057469|NCT02515565|OTHER|Control group|Patients with a clinical diagnosis of pneumonia will be included in this group. They will receive only the standard medical treatment based on cephalosporin with or without erythromycin.
62617283|NCT06215144|EXPERIMENTAL|Experimental Arm|Up to 2,000 mg/day
62617284|NCT06215144|PLACEBO_COMPARATOR|Control Arm|Matching placebo
62057470|NCT03519750|ACTIVE_COMPARATOR|Intravenous melatonin|Intravenous administration, making it possible to calculate bioavailability for other routes of administration
62057471|NCT03519750|EXPERIMENTAL|Rectal melatonin|Rectal administration of melatonin
62057472|NCT03519750|EXPERIMENTAL|Intravesical melatonin|Intravesical administration of melatonin
62057473|NCT03519750|EXPERIMENTAL|Vaginal melatonin|Vaginal administration of melatonin
62260642|NCT02628236|EXPERIMENTAL|ALA|20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment
62260643|NCT05592912|EXPERIMENTAL|Low dose HydroLenz treatment|
62842752|NCT05271773||Mayo 0|Patients with an established diagnosis of UC through regular criteria (clinical, analytical, endoscopic, radiological and/or histological ones), in clinical remission (partial Mayo score ≤2) for at least three months, who had undergone surveillance colonoscopy after 12 months from the study outset, with a Mayo 0 endoscopic activity.
62057474|NCT03519750|EXPERIMENTAL|Transdermal melatonin|Transdermal administration of melatonin
62057475|NCT01787097|ACTIVE_COMPARATOR|COPD|Participants with COPD
62057476|NCT01787097|ACTIVE_COMPARATOR|Symbicort® total dose 400ug/12ug|Symbicort® total dose 400ug/12ug: is a combination of FORM (6ug) and ICS (Budesonide, (BUD) 200ug)
62057477|NCT01787097|ACTIVE_COMPARATOR|Symbicort® total dose 800ug/24ug|Symbicort® total dose 800ug/24ug: is a combination FORM (12ug) and BUD (400ug) at a higher-dose
62057478|NCT01787097|ACTIVE_COMPARATOR|BUD total dose 800ug|BUD total dose 800ug: is an intermediate dose of ICS
62057479|NCT05276232|EXPERIMENTAL|Baseline followed by 5-10% THC Validation|
62057480|NCT05276232|EXPERIMENTAL|Baseline followed by 5-10% THC Verification|
62057481|NCT05279456|EXPERIMENTAL|Spikogen vaccine - accelerated arm|Spikogen vaccine 25 micrograms by intramuscular injection on study months 0, 1 and 2
62057482|NCT05279456|EXPERIMENTAL|Spikogen vaccine - standard arm|Spikogen vaccine 25 micrograms by intramuscular injection on study months 0, 1 and 4
62057483|NCT03651102|EXPERIMENTAL|Thalidomide in combination with hydroxyurea|All the study patients refractory to hydroxyurea will be given thalidomide at an average dose of 2mg/kg/day (range 1-4mg/kg/day). Participants will also be continued on hydroxyurea at a dose of 10-20 mg/kg/day.
62260644|NCT05592912|EXPERIMENTAL|High dose HydroLenz treatment|
62057484|NCT00642837||001|
62057485|NCT00642837||002|
62057486|NCT00642837||003|
62057487|NCT00642837||004|
62057488|NCT00642837||005|
62057489|NCT00642837||006|
62057490|NCT00642837||007|
62057491|NCT00642837||008|
62057492|NCT00642837||009|
62057493|NCT01969422||observation group|observation
62057494|NCT03122119|EXPERIMENTAL|Platelet Rich Plasma Joint Injection|Venous blood will be drawn from the patient receiving injection treatment. It will be spun down to form PRP and reinjected back into the SI joint.
62057495|NCT05542810|EXPERIMENTAL|Sports drinks are polyethylene glycol solvents|
62057496|NCT05542810|NO_INTERVENTION|Water is a polyethylene glycol solvent|
62260645|NCT05592912|PLACEBO_COMPARATOR|Control, i.e., no HydroLenz treatment|
62260646|NCT04133792|EXPERIMENTAL|Simvastatin|Simvastatin 40 mg administered orally daily for 5 years.
62260647|NCT04133792|PLACEBO_COMPARATOR|Placebo|Placebo for Simvastatin 40 mg administered orally daily for 5 years.
62260648|NCT02471703||SMF mini-stem hip replacement recipient|Received the device via total hip arthroplasty
62260649|NCT01305642|EXPERIMENTAL|Individualized fortification of breast milk|
62260650|NCT04723121|OTHER|High risk NMIBC|Patients with primary or recurrent NMIBC for whom primary TURBT was done and intravesical BCG was administered
62260651|NCT04462094|ACTIVE_COMPARATOR|End-of-surgery|Low-dose ketamine (0.3 mg/kg) in 3 ml normal saline solution given at the end of surgery
62260652|NCT04462094|PLACEBO_COMPARATOR|Induction|Low-dose ketamine (0.3 mg/kg) in 3 ml normal saline solution given at induction
62446048|NCT03510299|EXPERIMENTAL|McGrath group|
62842753|NCT05271773||Mayo 1|Patients with an established diagnosis of UC through regular criteria (clinical, analytical, endoscopic, radiological and/or histological ones), in clinical remission (partial Mayo score ≤2) for at least three months, who had undergone surveillance colonoscopy after 12 months from the study outset, with a Mayo 1 endoscopic activity.
62842754|NCT00641368|EXPERIMENTAL|1|R4Power Program
62842755|NCT00641368|OTHER|2|Waitlist Control
62260653|NCT02195024|ACTIVE_COMPARATOR|cardiac MRI group|• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
62260654|NCT02195024|NO_INTERVENTION|No MRI group|Patients that refuse to undergo cMRI for any reason but accept to attend the trial can be further observed according to the protocol
62260655|NCT05554419|ACTIVE_COMPARATOR|ARM A (cytarabine)|Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
62260656|NCT05554419|EXPERIMENTAL|ARM B (cytarabine, venetoclax)|Patients receive cytarabine IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
62260657|NCT05554419|EXPERIMENTAL|ARM C (liposomal daunorubicin-cytarabine, venetoclax)|Patients receive liposome-encapsulated daunorubicin-cytarabine IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
62260658|NCT05554419|EXPERIMENTAL|ARM D (azacitidine, venetoclax)|Patients receive azacitidine IV or SC and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
62617285|NCT04752306||residents|"10 residents~* Minimum 1x \> 1week had experience with incontinence material~* MMSE score \>23~* good verbal communication"
62617286|NCT04752306||healthcare workers|8 healthcare workers working in setting, no exclusion criteria
62446049|NCT03149913|EXPERIMENTAL|Drug coated balloon|SeQuentPlease OTW paclitaxel coated balloon catheter
62446050|NCT03149913|ACTIVE_COMPARATOR|uncoated PTA balloon catheter|Standard of care uncoated BTK balloon catheter
62617287|NCT04752306||policymakers|2 policymakers responsible for the purchase of incontinence material
62617288|NCT05023070|EXPERIMENTAL|Test condition 1|Cannabidiol 200 mg with standard meal
62617289|NCT05023070|EXPERIMENTAL|Test condition 2|Cannabidiol 400 mg with standard meal
62842756|NCT00701883|PLACEBO_COMPARATOR|Placebo/Placebo|
62842757|NCT00701883|EXPERIMENTAL|MBX-8025 50 mg/Placebo|
62617290|NCT05023070|EXPERIMENTAL|Test condition 3|Epidiolex 400 mg with standard meal
62617291|NCT05023070|EXPERIMENTAL|Test condition 4|Cannabidiol 400 mg with high fat meal
62617292|NCT04735796|EXPERIMENTAL|LM102 Dose Escalation Level 1, 3mg/kg|LM102 Dose Escalation Level 1, 3mg/kg, enrolled CLDN 18.2 positive advanced solid tumors
62617293|NCT04735796|EXPERIMENTAL|LM102 Dose Escalation Level 2, 10mg/kg|LM102 Dose Escalation Level 2, 10mg/kg,enrolled CLDN 18.2 positive advanced solid tumors
62617294|NCT04735796|EXPERIMENTAL|LM102 Dose Escalation Level 3, 20mg/kg|LM102 Dose Escalation Level 3, 20mg/kg,enrolled CLDN 18.2 positive advanced solid tumors
62617295|NCT04735796|EXPERIMENTAL|LM102 Dose Escalation Level 4, 30mg/kg|LM102 Dose Escalation Level 4, 30mg/kg,enrolled CLDN 18.2 positive advanced solid tumors
62617296|NCT04735796|EXPERIMENTAL|LM102 Dose Escalation Level 5, 40mg/kg|LM102 Dose Escalation Level 5, 40mg/kg,enrolled CLDN 18.2 positive advanced solid tumors
62617297|NCT02797418|EXPERIMENTAL|Cognitus and Me|Cognitus \& Me is a cognitiv remediation program focused on the functions of attention and visuospatial that is to say that can move in space, to perceive objects of our environment and organize them, to mentally imagine a physically absent operation object very involved in social behavior, in order to limit the presence of behavioral disorders among children with intellectual disabilities.
62842758|NCT00701883|EXPERIMENTAL|MBX-8025 100 mg/Placebo|
62842759|NCT00701883|ACTIVE_COMPARATOR|Placebo/Atorvastatin 20 mg|
62842760|NCT00701883|EXPERIMENTAL|MBX-8025 50 mg/Atorvastatin 20 mg|
62842761|NCT00701883|EXPERIMENTAL|MBX-8025 100 mg/Atorvastatin 20 mg|
62842762|NCT01075685|EXPERIMENTAL|Web-based alcohol programme|"Participants could log on to their account and access the programme whenever they wanted to.~They received automated email reminders inviting them to use follow-up tools, especially the diary in order to register their alcohol intake on the previous week:~* 4 weeks after starting the programme, so that they would take advantage of the monitoring stage in case they had not spontaneously done so.~* 2 weeks later for 6-week follow-up."
62842763|NCT01075685|PLACEBO_COMPARATOR|Minimum information|Participants could log on to their account and access the programme whenever they wanted to. At 6 week follow-up they received an automated email reminder inviting them to use the diary in order to register their alcohol intake on the previous week.
62842764|NCT02527421|EXPERIMENTAL|DFD01 Spray Group 1|DFD01 spray, twice daily, 15 days
62842765|NCT02527421|EXPERIMENTAL|DFD01 Spray Group 2|DFD01 spray, twice daily, 29 days
62842766|NCT00114517|ACTIVE_COMPARATOR|17B-estradiol|Oral 17B-estradiol 1 mg daily
62842767|NCT00114517|PLACEBO_COMPARATOR|Placebo|Matching oral 17B-estradiol placebo daily
62842768|NCT02510677|OTHER|myocardial perfusion scintigraphy|Low-dose dobutamine gated SPECT and CZT camera for the assessment of parameters of left ventricular dyssynchrony in heart failure patients eligible for the implantation of a cardiac resynchronization device.
62842769|NCT03052426|ACTIVE_COMPARATOR|30 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 30 minutes throughout their workday.
62842770|NCT03052426|ACTIVE_COMPARATOR|60 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 60 minutes throughout their workday.
62842771|NCT03052426|ACTIVE_COMPARATOR|90 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 90 minutes throughout their workday.
62842772|NCT04013659|EXPERIMENTAL|G1 - Permanence of the Whitening Gel|Permanence of the Whitening Gel (Biological Product: 35% Hydrogen Peroxide) on the tooth enamel during the 15 minutes of dental-bleaching
62842773|NCT04013659|EXPERIMENTAL|G2 - Renewal of the Whitening Gel|3 Whitening Gel (Biological Product: 35% Hydrogen Peroxide) renewal every 5 minutes during the 15 minutes of dental-bleaching
62842774|NCT03736642||restrictive anorexia nervosa with hunger|
62842775|NCT03736642||restrictive anorexia nervosa without hunger|
62842776|NCT03736642||constitutional thinness|
62446051|NCT05170555|EXPERIMENTAL|68Ga-PSMA, PET/CT and 177Lu-EB- PSMA-617 therapy|All patients diagnosed with RCC underwent 68Ga-PSMA PET/CT scan. If the PET/CT showed high PSMA expression in tumor lesions of some patients, they would intravenously injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 for therapy.
62446052|NCT04215055|ACTIVE_COMPARATOR|study group|Group I (study group); children receiving intraoral injection of local anasethia using the vibration assisted syringe.
62842777|NCT03736642||control subjects without eating disorders|
62842778|NCT00475956|EXPERIMENTAL|1|AZD2171 Monotherapy
62842779|NCT00475956|EXPERIMENTAL|2|AZD2171 + AZD0530
62842780|NCT01666041|PLACEBO_COMPARATOR|placebo|placebo
62842781|NCT01666041|ACTIVE_COMPARATOR|fenofibrate/omega|fenofibrate/omega
62842782|NCT01666041|ACTIVE_COMPARATOR|fenofibrate|fenofibrate
62842783|NCT05429385|EXPERIMENTAL|HLX70 3 mg/kg or Placebo|Random allocation to HLX70 3 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
62842784|NCT05429385|EXPERIMENTAL|HLX70 10 mg/kg or Placebo|Random allocation to HLX70 10 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
62842785|NCT05429385|EXPERIMENTAL|HLX70 30 mg/kg or Placebo|Random allocation to HLX70 30 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
62617298|NCT02797418|ACTIVE_COMPARATOR|control group|the control management that involves fine motor skills and research computer information,management control is usually done
62617299|NCT00878605|EXPERIMENTAL|Cyclo-Z (minimally effective)|3mg CHP plus 20mg zinc containing gel capsule;
62617300|NCT00878605|EXPERIMENTAL|Cyclo-Z (maximally effective)|9mg CHP plus 20mg zinc containing gel capsule;
62617301|NCT00878605|EXPERIMENTAL|Cyclo-Z (not additionally effective)|15mg CHP plus 20mg zinc containing gel capsule
62617302|NCT00878605|PLACEBO_COMPARATOR|Placebo (for CHP)|Placebo capsules containing no zinc or CHP
62260659|NCT06218095|EXPERIMENTAL|Experimental|"3rd grade midwifery students experimental group Diagnostic Information Form and Thromboembolism Information Form were applied before the theory training.~Pregnancy and postpartum thromboembolism theory training was given,~1. st application: Deep vein thrombosis management scenario during pregnancy A high-validity simulation scenario was implemented. Student Satisfaction and Self-Confidence Scale in Learning after the application, Simulation Design Scale implemented~2. nd application: It will be done after 2 weeks. Postpartum Embolism Management Scenario was implemented Student Satisfaction and Self-Confidence Scale in Learning after the application, Simulation Design Scale will be applied. Thromboembolism Information Form - Posttest Done After 2 Weeks After 2 months, Thromboembolism Information Form - Persistence Test was performed."
62842786|NCT00363480|EXPERIMENTAL|SFC 50/250 mcg|Participants received the combination product, fluticasone 250 microgram (mcg) plus salmeterol 50 mcg (SFC 50/250 mcg) for 12 weeks. Study treatment was received using DISKUS™ powder inhalers, one dose in morning and evening. Study medication was dispensed at visits 3, 4, and 5 for 30 days each. The participants were provided with salbutamol rescue medication if they developed acute asthmatic symptoms. This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol. Use of rescue medications was recorded in the participant's asthma diaries. Stable dosages of other concomitant medications were allowed if they had no impact on the outcome criteria.
62617303|NCT05872880||TPExtreme induced chemotherapy was followed by modified radical surgery and radiotherapy|"The effect was evaluated at three weeks after 2 cycles of TPExtreme(albumin-paclitaxel+cisplatin+cetuximab) induction chemotherapy according to the RECIST 1.1 guideline, lesion reduction by at least 50% can be included in our study. Patients choose modified radical surgery based on the tumor invasion scope after induction chemotherapy.~In this group, the incisal margin was located 1\~1.5cm outside the boundary of the residual tumor lesion after induced chemotherapy. At the same time, improved radical neck dissection was performed on both sides of the affected neck. Postoperative conventional radiotherapy(or chemoradiotherapy) was performed within 4 to 6 weeks after surgery."
62617304|NCT05872880||TPExtreme induced chemotherapy was followed by radical surgery and radiotherapy|"The effect was evaluated at three weeks after 2 cycles of TPExtreme(albumin-paclitaxel+cisplatin+cetuximab) induction chemotherapy according to the RECIST 1.1 guideline, lesion reduction by at least 50% can be included in our study. Patients choose radical surgery based on the tumor invasion scope before induction chemotherapy.~In this group, the incisal margin was located 1\~1.5cm outside the boundary of the tumor lesion before induced chemotherapy. At the same time, radical neck dissection was performed on both sides of the affected neck. Postoperative conventional radiotherapy(or chemoradiotherapy) was performed within 4 to 6 weeks after surgery."
62446053|NCT04215055|ACTIVE_COMPARATOR|control group|Group II (control group): children receiving intraoral injection of local anasethia using the standard syringe.
62617305|NCT05047614|EXPERIMENTAL|Study 1|Twelve patients in study group 1 receiving lumbar repositioning feedback training
62617306|NCT05047614|EXPERIMENTAL|Study 2|Twelve patients in study group 2 receiving transverses abdominis training
62446054|NCT05753774|ACTIVE_COMPARATOR|fecal microbiota transplantation|Fecal microbiota transplantation routes include the upper digestive tract, lower digestive tract, or oral fecal microbiota transplantation capsules
62617307|NCT05047614|EXPERIMENTAL|Study 3|Twelve patients in study group 3 receiving both lumbar repositioning feedback training and tranversus abdominis training
62617308|NCT05047614|EXPERIMENTAL|Control|Twelve patients in control group receiving conventional lumbar propriception physical therapy program .
62842787|NCT00517088|OTHER|Other|Group Description
62617309|NCT04304261|EXPERIMENTAL|Canagliflozin|12 weeks of Canagliflozin(100mg/day) treatment, randomly
62842788|NCT05986396||All Subjects|Subjects that have received the INSPIRIS Resilia device.
62446055|NCT05753774|SHAM_COMPARATOR|Conventional drug intervention|Conventional drugs include: probiotics and omeprazole, and cyproheptadine and moxapride.
62446056|NCT04102774|EXPERIMENTAL|myAIRVO2|Patients will receive a myAIRVO2 at home over-night with humidifier on top of standard therapy for bronchiectasis according to international guidelines (ERS 2017).
62446057|NCT04102774|NO_INTERVENTION|Control|Patients will receive standard therapy for bronchiectasis according to international guidelines (ERS 2017).
62617310|NCT04304261|EXPERIMENTAL|Sitagliptin|12 weeks of Sitagliptin (100mg/day) treatment, randomly
62617311|NCT04118777|ACTIVE_COMPARATOR|0.2 % Ropivacaine|An ON-Q pain pump will be placed into the pelvic cavity and 0.2% Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr.
62617312|NCT04118777|PLACEBO_COMPARATOR|Saline|An ON-Q pain pump will be placed into the pelvic cavity and saline will be continuously administered intraperitoneally at a rate of 6 mL/hr
62617313|NCT00549601|EXPERIMENTAL|Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|
62842789|NCT01569893|NO_INTERVENTION|Control group|Usual care: treatment as usual
62842790|NCT01569893|EXPERIMENTAL|Self-monitoring for patients with Dibetes mellitus type 2|Self-monitoring for patients with Dibetes mellitus type 2
62842791|NCT05688475|EXPERIMENTAL|CC-122 and Dexamethasone|
62617314|NCT00549601|EXPERIMENTAL|Rivastigmine patch (9.5 mg/day)|
62617315|NCT00549601|ACTIVE_COMPARATOR|Rivastigmine capsules (6 mg to 12 mg/day)|
62617316|NCT03280316|EXPERIMENTAL|patients with SVMs undergoing SNM|patients with SVMs are of consistent OAB (Overactive Bladder) after surgery and undergo sacral neuromodulation (SNM)
62617317|NCT03280316|EXPERIMENTAL|patients with SVMs receiving BTXA|patients with SVMs are of consistent OAB after surgery and accept botulinum toxin A (BTXA) injection
62617318|NCT03280316|EXPERIMENTAL|patients with SVMs receiving drug|patients with SVMs are of consistent OAB (Overactive Bladder) after surgery and accept M receptor antagonist
62617319|NCT04129125|EXPERIMENTAL|Zoom Reperfusion System|"The subject will undergo the endovascular thrombectomy procedure under general anesthesia or conscious sedation. The Imperative Care .088 Catheter will be used to gain access to the vasculature and direct aspiration of the clot will be attempted where feasible. The Zoom Reperfusion System must be the initial and primary device used to remove thrombus."
62057497|NCT04955847||PGE2|In period 1, the service protocol for induction at term on an unfavorable cervix indicated the use of a PGE2. In nulliparous women, Propess® was introduced intra-vaginally for 24 hours or until regular painful uterine contractions occurred. In the case of a multiparous woman, Prostine® gel, one or two mg depending on the cervical conditions at the time of induction, was introduced intravaginally and the cervix was reassessed after six hours. If the cervix remained unfavorable and the kinetics of the contractions were not optimal, a new dose of Prostine® one or two mg was administered to the patient.
62057498|NCT04955847||misoprostol|In period 2, patients who were induced with an unfavorable cervix at term were induced with misoprostol. Regardless of parity, the patient received oral misoprostol 25 μg, one tablet orally every two hours until a maximum of eight tablets per day, or 200 µg, was reached, with cessation of the tablets when painful, regular contractions were obtained.
62260660|NCT06218095|NO_INTERVENTION|control group|"3rd grade midwifery students Control group Diagnostic Information Form and Thromboembolism Information Form were applied before the theory training.~Thromboembolism Information Form-Posttest was applied 1 month later. After the Last Test, Thromboembolism Information Form - Persistence Test was applied 2 months later."
62260661|NCT00366275|EXPERIMENTAL|In vivo purging autotransplant|
62260662|NCT05453058||Patients diagnosed with possible or probable MSA|This protocol does not mandate the use of any treatments. No study medication will be administered as part of study participation. Any treatment that study patients receive will be prescribed according to the recommendations given in the local SmPCs.
62260663|NCT03539055|EXPERIMENTAL|Treatment arm|"Dabigatran 75 or 150mg BID x 90 days plus ASA 81mg daily.~Single arm, prospective unblinded study on post Watchman LAA closure device implant anti-coagulation management at a primary center (Vanderbilt Medical Center) and up to 5 additional high volume LAA implant centers. This trial will be designed to evaluate the use of dabigatran for 90 days post implantation of an LAA closure device (Watchman LAA Closure Device, Boston Scientific Inc.)"
62617320|NCT04006678|EXPERIMENTAL|computer guided sandwich osteotomy|segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
62617321|NCT04006678|ACTIVE_COMPARATOR|conventional sandwich osteotomy|:conventional segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla.
62617322|NCT01741155|EXPERIMENTAL|Single Arm Part: SPI-1620 & Docetaxel|Patients will receive 11 μg/m2 of SPI-1620 IV followed by docetaxel 75 mg/m2 IV. Cycles will continue every 3 weeks until progression or intolerable toxicity.
62617323|NCT01741155|EXPERIMENTAL|Randomized Part: SPI-1620 & Docetaxel|Patients will receive 11 μg/m\^2 of SPI-1620 intravenous (IV) followed by docetaxel 75 mg/m\^2 IV administered in 3-week cycles until progression or intolerable toxicity.
62617324|NCT01741155|ACTIVE_COMPARATOR|Randomized Part: Docetaxel|Patients will receive 75 mg/m\^2 docetaxel in 3-week cycles until progression or intolerable toxicity.
62617325|NCT03761004|EXPERIMENTAL|WD-1603 single dose|"WD-1603 single dose:~A single WD-1603 tablet after breakfast. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 16 and 24 hours post-dose."
62617326|NCT03761004|EXPERIMENTAL|WD-1603 BID dose|"WD-1603 BID dose:~A single WD-1603 tablet after breakfast, and a second WD-1603 tablet approximately 3 hours after completing lunch.~Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 4.5, 5, 6, 7, 7.25, 7.5, 7.75, 8, 8.5, 9, 10, 10.5 11, 12, 16 and 24 hours post-dose."
62617327|NCT03761004|ACTIVE_COMPARATOR|Sinemet single dose|"Sinemet single dose:~A single oral dose of Sinemet after breakfast. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 6, 7, 8, 10, 12, 16 and 24 hours post-dose."
62617328|NCT00478088|EXPERIMENTAL|1|NeoDisc
62617329|NCT00478088|ACTIVE_COMPARATOR|2|ACDF
62842792|NCT05430997|ACTIVE_COMPARATOR|Group A: conventional management|The ambient temperature of the operating room was set at 23±2 ℃ and the relative humidity was 50% to 60%. Intraoperative infusion fluids, blood products and rinsing fluid were warmed. Patients were given quilts to cover after entering the operating room, and the quilts covered from the neck to both the feet.
62842793|NCT05430997|EXPERIMENTAL|Group B: Hypothermia Risk Prediction Joint Active Insulation Management|"In the test group, after the assessment of the Intraoperative Hypothermia Risk Prediction APP, patients who were prompted/recommended to use active warming measures were actively warmed by inflatable warming (IOB Warming Unit (WU505) + Inflatable Warming Blanket) after admission to the room. Warming Unit (WU505) + Warming Blanket (IOB Warming Blanket)) was used for active warming. The air inlet was connected to the air catheter, and the host temperature was set at 38 ℃ with high air speed. During the operation, the thermal blanket is covered with non-surgical sterilization area (such as both shoulders, torso, healthy limbs, etc.), and the host temperature is adjusted to 38 ℃ for thermal insulation. The temperature and wind speed were adjusted in time to maintain the oropharyngeal temperature at 36.2℃～37.2℃ by monitoring the body temperature at any time during the operation."
62842794|NCT00644982|EXPERIMENTAL|Sertaline group|
62842795|NCT00644982|ACTIVE_COMPARATOR|Venlafaxine group|
62617330|NCT03613688|EXPERIMENTAL|Deepure Group A|Visit 3: Warm water without Deepure; Visit 4: Warm water with 1 g Deepure; Visit 5: Warm water with 1.5 g Deepure; Visit 6: Warm water with 2 g Deepure.
62057499|NCT01117389||Mothers of Childhood cancer survivors|Mothers or female primary caregivers of active patients (aged 9-17) and young adult female patients aged 18-26 in the After Completion of Therapy (ACT) clinic at SJCRH. Mothers or female primary caregivers of active patients (aged 9-17) and young adult female patients aged 18-26 in the ACT clinic surviving childhood cancer will be asked to complete a questionnaire which queries sociodemographic, medical, and psychological variables which may relate to HPV vaccination.
62057500|NCT01117389||Acquaintance control Group|"Mothers or female primary caregivers ( with daughters aged 9-17) and young adult females aged 18-26 referred for study participation by participants from the ACT clinic. Participants have daughters aged 9-17 years or young adult females aged 18-26 at the time of study enrollment For those acquaintance controls electing to complete the paper-and-pencil questionnaire, the study team will send it to them in the mail along with a pre-addressed, stamped, return envelope. For those electing to complete the on-line questionnaire, the participant's email address will be collected and a secured link to our on-line questionnaire will be sent to them in an email.~A supplemental community control sample (meeting the inclusion and exclusion criteria outlined above) will also be utilized via the subject pool in the Department of Psychology at The University of Memphis."
62617331|NCT03613688|EXPERIMENTAL|Deepure Group B|Visit 3: Warm water with 1 g Deepure; Visit 4: Warm water with 1.5 g Deepure; Visit 5: Warm water with 2 g Deepure; Visit 6: Warm water without Deepure.
62260664|NCT01270308|EXPERIMENTAL|Lansoprazole DR Capsules 30 mg|Lansoprazole DR Capsules 30 mg of Dr.Reddy's Laboratories Limited
62260665|NCT01270308|ACTIVE_COMPARATOR|Prevacid 30 mg Capsules|Prevacid 30 mg Capsules of TAP Pharmaceuticals Inc. USA
62260666|NCT05291676|ACTIVE_COMPARATOR|21-30 standard dose Fluad|Participants age 21-30 years will receive the standard dose Fluad
62617332|NCT03613688|EXPERIMENTAL|Deepure Group C|Visit 3: Warm water with 1.5 g Deepure; Visit 4: Warm water with 2 g Deepure; Visit 5: Warm water without Deepure; Visit 6: Warm water with 1 g Deepure.
62617333|NCT03613688|EXPERIMENTAL|Deepure Group D|Visit 3: Warm water with 2 g Deepure; Visit 4: Warm water without Deepure; Visit 5: Warm water with 1 g Deepure; Visit 6: Warm water with 1.5 g Deepure.
62617334|NCT01786031|EXPERIMENTAL|experimental|metastasis biopsy
62260667|NCT05291676|ACTIVE_COMPARATOR|21-30 high dose Fluzone|Participants age 21-30 years will receive the high dose Fluzone
62260668|NCT05291676|EXPERIMENTAL|≥65 years standard dose Fluad|Participants age ≥65 years will receive standard dose Fluad
62617335|NCT02171832|EXPERIMENTAL|Mildly liver impaired patients|
62617336|NCT02171832|EXPERIMENTAL|Moderately liver impaired patients|
62617337|NCT02171832|EXPERIMENTAL|Healthy volunteers|
62842796|NCT03214666|EXPERIMENTAL|GTB-3550 TriKE® (Phase I: Dose Finding Component)|Patients receive a single course of GTB-3550 TriKE® at their assigned dose as 3 weekly treatment blocks. Each block consists of four consecutive 24 hour continuous infusions (over approximately 96 hours) of GTB-3550 TriKE® followed by a 72 hour break after Block #1 and #2. All treatment is given as an inpatient. The assigned dose will be calculated on a weight obtained within 5 days prior to or on day of the 1st dose. The dose is not be recalculated for subsequent treatment blocks.
62617338|NCT01123772|PLACEBO_COMPARATOR|Control|Vehicle control
62617339|NCT01123772|EXPERIMENTAL|INO-8875|Active drug
62617340|NCT04347655|EXPERIMENTAL|HFrEF|patients with heart failure with reduced ejection fraction
62057501|NCT03515382|EXPERIMENTAL|Treatment A|single dose GLPG1690.
62057502|NCT03515382|EXPERIMENTAL|Treatment B|Single dose itraconazole + single dose GLPG1690.
62617341|NCT04347655|EXPERIMENTAL|HFpEF|heart failure with preserved ejection fraction
62617342|NCT04347655|ACTIVE_COMPARATOR|Control|healthy (no heart failure) control participants
62617343|NCT04859309|EXPERIMENTAL|ActiveHip Intervention|"The ActiveHip tele-rehabilitation mobile application.~The program consists of a multidisciplinary home-based tele-rehabilitation program delivered through a mobile application. It is comprised by an occupational therapy program and a physical exercise program.~The intervention group have the opportunity to perform three online-based sessions per week (two sessions of physical exercise and one of occupational therapy), each lasting 30-60 min. It is able to realize a fourth session, called bonus session.~In addition, the intervention group will receive the educational program, which has a total of 7 modules. 5 modules are for patients and caregivers, and 2 modules are specific for caregivers."
62617344|NCT04859309|ACTIVE_COMPARATOR|Standard care|Participants of this group will receive the standard care for hip fracture patients at hospital discharge.
62617345|NCT03149822|EXPERIMENTAL|Phase 1: Pembrolizumab 200 mg plus Cabozantinib 40mg|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib 40 mg orally once daily until disease progression, unacceptable toxicity, or consent withdrawal.
62617346|NCT03149822|EXPERIMENTAL|Phase 1: Pembrolizumab 200 mg plus Cabozantinib 60mg|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib 60 mg orally once daily until disease progression, unacceptable toxicity, or consent withdrawal.
62617347|NCT03149822|EXPERIMENTAL|Phase 2: Pembrolizumab 200 mg plus Cabozantinib at the RP2D|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib at the RP2D orally once daily for up to 35 cycles, until disease progression, unacceptable toxicity, or consent withdrawal. All participants who stop pembrolizumab after 35 cycles with SD or better may be eligible for up to an additional 17 cycles (approximately 1 year) of pembrolizumab treatment if they progress after stopping pembrolizumab from the initial treatment phase.
62842797|NCT03214666|EXPERIMENTAL|GTB-3550 TriKE® Only (Phase II: Extended Component)|The treatment schedule is identical to the dose finding component. The extended component uses a Simon's MiniMax two-stage design for continued enrollment using the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
62842798|NCT04858048||Group with general anesthesia performed during the forefoot surgery|
62842799|NCT04858048||Group with WALANT anesthesia performed during the forefoot surgery|
62842800|NCT04454853||Lung cancer with positive methylated DNA|Blood DNA methylation abnormalities are found in lung cancer.
62842801|NCT04454853||Lung cancer with negative methylated DNA|Blood DNA methylation abnormalities are not found in lung cancer.
62057503|NCT03515382|EXPERIMENTAL|Treatment C|Single dose voriconazole + single dose GLPG1690.
62260669|NCT05291676|EXPERIMENTAL|≥65 years high dose Fluzone|Participants age ≥65 years will receive high dose Fluzone
62260670|NCT03804333|ACTIVE_COMPARATOR|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fractions
62260671|NCT03804333|EXPERIMENTAL|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
62260672|NCT06190067|EXPERIMENTAL|Azacitidine Plus PD-1 therapy|Patients were treated by Azacitidine plus PD-1 therapy
62260673|NCT00964535|EXPERIMENTAL|Budesonide/formoterol Easyhaler|
62260674|NCT00964535|EXPERIMENTAL|Charcoal and Budesonide/formoterol EH|
62260675|NCT00964535|ACTIVE_COMPARATOR|Symbicort Turbohaler|
62260676|NCT00964535|ACTIVE_COMPARATOR|Charcoal and Symbicort Turbohaler|
62260677|NCT05931237|EXPERIMENTAL|Cranberry extract capsules (PREBIOCRAN(TM))|Cranberry extract capsules consumed twice a day providing 82.3 mg of flavan-3-ols daily.
62260678|NCT03521375|EXPERIMENTAL|VATS lobectomy|VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
62842802|NCT04454853||Suspected lung cancer with positive methylated DNA|Blood DNA methylation abnormalities are found in suspected lung cancer.
62842803|NCT04454853||Suspected lung cancer with negative methylated DNA|Blood DNA methylation abnormalities are not found in suspected lung cancer.
62842804|NCT01150188|ACTIVE_COMPARATOR|Amino acids|Amino acid supplementation between meals for eight weeks
62842805|NCT01150188|PLACEBO_COMPARATOR|Placebo|Supplementation of placebo (inert components) between meals for eight weeks
62057504|NCT00998907|ACTIVE_COMPARATOR|PDS II|PDS II® loop suture is used for abdominal wall closure
62260679|NCT03521375|ACTIVE_COMPARATOR|Open lobectomy|Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.
62057505|NCT00998907|EXPERIMENTAL|PDS plus|"antibacterial coated PDS plus is used for abdominal wall closure"
62260680|NCT06033573|EXPERIMENTAL|Contrast-enhanced spectral mammography arm|Subjects receiving contrast-enhanced spectral mammography (CESM) 4-6 hours after the routine iopromide 370 mgI/ml-enhanced ductography
62260681|NCT02316340|EXPERIMENTAL|Study Arm - VOR with HCQ|Patients will be given vorinostat 400 mg daily and hydroxychloroquine 600 mg daily in 4 week cycles.
62260682|NCT02316340|ACTIVE_COMPARATOR|Control Arm - Regorafenib|Patients will be given oral RGF 160 mg daily for 3 weeks in 4 week cycles.
62260683|NCT03503877|OTHER|SAGE Media|SAGE single-step MEDIA
62260684|NCT03503877|OTHER|GLOBAL Media|LIFE GLOBAL single-step MEDIA
62446058|NCT00492206|EXPERIMENTAL|Cetuximab|"Cetuximab 400 mg/m2 IV week 0 only~External beam radiation weeks 1 - 7~Cetuximab 250 mg/m2 IV weekly thereafter weeks 1 - 7~Cetuximab 250 mg/m2 IV weekly weeks 8 - 26~Carboplatin AUC = 6 IV Paclitaxel 200 mg/m2 IV Every 3 weeks x 3 Cycles"
62446059|NCT05063955||Chronic Heart Failure|Patients with heart failure with preserved, mid-range or reduced ejection fraction (NYHA I-IV) according to European Society of Cardiology guidelines.
62446060|NCT05063955||Controls|Age and sex matched control group. Individuals with no history of cardiovascular disease or severe lung, musculoskeletal or neurological disease.
62446061|NCT05646121||wounds at risk of infection|Ideally 71 patients with wounds at risk of infection (W.A.R. Score ≥ 3) to be included.
62446062|NCT05646121||infected wounds|Ideally 28 patients with infected wounds (TILI Score ≥ 5) to be included.
62446063|NCT04693065||Ponseti|Patients treated by ponseti method
62446064|NCT03259581|EXPERIMENTAL|Transarterial chemoembolization|Transarterial chemoembolization
62446065|NCT01645800|EXPERIMENTAL|Lysozyme hydrochloride|
62446066|NCT01645800|PLACEBO_COMPARATOR|Placebo|
62446067|NCT00374413|EXPERIMENTAL|Kineflex-C|
62446068|NCT00374413|ACTIVE_COMPARATOR|ACDF|
62446069|NCT02435979|EXPERIMENTAL|Proximal strengthening + hand therapy|Patients in this group will perform traditional hand therapy for 30 minutes and proximal strengthening of the core, cervical spine, and shoulder complex for up to 30 minutes
62446070|NCT02435979|ACTIVE_COMPARATOR|Traditional hand therapy|This group will receive traditional hand therapy for 45-60 minutes each session.
62446071|NCT01285531|NO_INTERVENTION|Lumbar puncture|The participants randomly assigned to this arm will receive a lumbar puncture using standard procedures and equipment
62617348|NCT02217800|OTHER|Saline, then DG3173, then octreotide|Interventions: saline, DG3173 and octreotide. Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
62260685|NCT02603120|EXPERIMENTAL|Blinded Phase: B/F/TAF|B/F/TAF + ABC/DTG/3TC placebo for at least 48 weeks
62446072|NCT01285531|EXPERIMENTAL|Lumbar puncture with the Compass device|The participants randomly assigned to this group will receive a lumbar puncture with the use of the Compass device.
62446073|NCT02346968||All study participants|Patients with end stage renal disease (ESRD) planned to undergo kidney transplantation.
62446074|NCT03718455|EXPERIMENTAL|Axillary Magseed|Single cohort of twenty women receiving neoadjuvant chemotherapy with breast cancer will have a Magseed inserted into a biopsy proven metastatic axillary lymph node for pre-surgical localization.
62446075|NCT01656889|EXPERIMENTAL|HP802-247|HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
62617349|NCT05521113||Home Rehabilitation Monitoring System|Subjects will complete a home pulmonary rehabilitation program while using a home rehabilitation monitoring system and completing health coaching calls.
62260686|NCT02603120|ACTIVE_COMPARATOR|Blinded Phase: ABC/DTG/3TC|ABC/DTG/3TC + B/F/TAF placebo for at least 48 weeks
62446076|NCT01656889|PLACEBO_COMPARATOR|Vehicle|Vehicle Control (fibrinogen solution \& thrombin solution without cells)
62446077|NCT00601354|EXPERIMENTAL|Emotion Regulation Group therapy + alli|Group taking the weight loss medication orlistat (alli), in conjunction with the alli weight loss program, plus 12 weekly sessions of guided self-help group psychotherapy
62260687|NCT02603120|EXPERIMENTAL|Open-Label Phase|At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.
62260688|NCT03317795|ACTIVE_COMPARATOR|Levonorgestrel IUS|Levonorgestrel-releasing intrauterine system (Mirena) contains 52 mg of levonorgestrel, a progestin, and is intended to provide an initial release of approximately 20 mcg/day. Levonorgestrel intrauterine system is effective immediately upon placement in the uterus and can be kept in place for up to 5 years.
62260689|NCT03317795|ACTIVE_COMPARATOR|Tranexamic Acid|Tranexamic Acid (Lysteda) is an antifibrinolytic drug. Tranexamic Acid will be dosed at 1300mg by mouth three times a day at the start of menses and used during the days that bleeding is heaviest (not to exceed 5 days per menstrual cycle).
62446078|NCT00601354|ACTIVE_COMPARATOR|Orlistat/alli program meds only|Group taking the weight loss medication orlistat (alli), in conjunction with the alli weight loss program alone
62446079|NCT04750811||Small Bowel obstruction|Patients admitted with a diagnosis of small bowel obstruction at 1 of the 6 participating centres
62260690|NCT04543071|EXPERIMENTAL|Motixafortide, Cemiplimab, Gemcitabine, Nab-Paclitaxel|Participants will receive standard FDA-approved doses of gemcitabine and nab-paclitaxel for pancreas cancer and cemiplimab at the dose that is approved for participants with skin cancer. Participants will also receive motixafortide at a dose that has been deemed safe in previous studies when used in combination with immunotherapy and chemotherapy. If the combination study treatment causes a serious side effect in participants, the study treatment will be modified.
62446080|NCT03734965|ACTIVE_COMPARATOR|AWAKEN INTUBATION FIBEROPTIC|awaken intubation
62446081|NCT03734965|EXPERIMENTAL|AWAKEN INTUBATION VIDEOLARYNGOSCOPY|awaken intubation
62446082|NCT03323554|EXPERIMENTAL|Ustrap®|Ustrap is a new adjustable-pressure 4-arm device
62842806|NCT05833607||ALL PATIENTS|"All patients are monitored with the transcranial Doppler helmet and the 2Hz probe in one of the middle cerebral hemispheres and the Brain 4 care on the other side.~Necessary monitoring: arterial line, electrocardiographic monitor, pulse oximetry, temperature. ETCO2 monitoring whenever possible.~Step 1: Test arterial line circuit, ensure proper temperature, arterial blood gases Step 2: Record data with the patient's baseline pressure (data from the monitor, transcranial doppler and brain4care), for 5 min Step 3: Vasopressor titrant for 3 MAP targets (65, 75 and 85 mmHg) , record data with the patient's baseline pressure (data from the monitor, transcranial doppler and brain4care), each target record for 3 minutes Step 4: Arterial blood gases, gradually restore PAM to baseline value"
62842807|NCT01949818|EXPERIMENTAL|Yangzhengxiaoji Capsule combined with CHOP regimen|Yangzhengxiaoji Capsule combined with CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
62842808|NCT01949818|EXPERIMENTAL|CHOP regimen|CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
62057506|NCT05780814|EXPERIMENTAL|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|"The proposed intervention consists of 6 remotely-delivered sessions; Weeks 1, 2, 4, 6, 7, and 8, with weeks 3 and 5 being rest weeks. Session 1 will be 60-90 mins, Session 2 will be \~60 mins, and remaining visits are \~45 mins. The investigators propose a methodological innovation for CBT-I, which involves conducting 15-minute sessions every other month during the BWL intervention. Prior to these maintenance sessions, participants in the CBT-I+BWL group will complete electronic sleep diaries for one week and interventionists will use this information in sessions to sustain and enhance long-term outcomes by using MI to reinforce application of CBT-I session content."
62260691|NCT02363140|NO_INTERVENTION|Group One patients in age group 18--20 years,|"1. Patients should be aged 18--20 years or 35--45years~2. Asymptomatic knee for past 6 months.~3. Painless flexion-extension movements at knee joint."
62260692|NCT02363140|ACTIVE_COMPARATOR|Group Two patients in age group 35-45 years,|"1. Patients should be aged 18--20 years or 35--45years~2. Asymptomatic knee for past 6 months.~3. Painless flexion-extension movements at knee joint."
62260693|NCT02363140|ACTIVE_COMPARATOR|Group Three Patients aged 75|"1. Patients should be aged 75 or older~2. Knee X-ray showing no more than Kellgren-Lawrence grade II osteoarthrtis~3. No clinical suspicion of meniscus tear~4. Painless flexion-extension movements at knee joint."
62260694|NCT02363140|ACTIVE_COMPARATOR|Group Four, any age due to undergo a surgical meniscus repair|1. Patients should have presented with clinical signs to suggest meniscus tear indicating potential need for surgical meniscus repair
62260695|NCT03506711|ACTIVE_COMPARATOR|T1DM Children and adolescents|Children and adolescents with Type 1 Diabetes Mellitus
62260696|NCT03506711|ACTIVE_COMPARATOR|Healthy Children and adolescents|Healthy community-dwelling children on no medication
62617350|NCT02686788|EXPERIMENTAL|TMP001|600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
62842809|NCT02657603|ACTIVE_COMPARATOR|LAX insertion of catheter|Lidocaine 10mg/ml, 15 ml injected into the adductor canal
62260697|NCT00507299|EXPERIMENTAL|Model Care (SEEK)|Residents in this group received special training on addressing pyschosocial problems. They then used a parent screening questionnaire, and addressed identified problems. A study social worker was also part of this intervention. Thus, this group provided enhanced pediatric primary care.
62446083|NCT03323554|ACTIVE_COMPARATOR|AMS 800®|Artificial sphincter currently considered the gold standard device in this field
62842810|NCT02657603|ACTIVE_COMPARATOR|SAX insertion of catheter|Lidocaine 10mg/ml, 15 ml injected into the contralateral adductor canal
62842811|NCT04059588|EXPERIMENTAL|Injection of 2141-V11|Open label study drug 2141-V11 at escalating doses until MTD is determined, and expansion utilizing the MTD.
62842812|NCT06048640|PLACEBO_COMPARATOR|Placebo|100 mg of placebo (cellulose)
62260698|NCT00507299|ACTIVE_COMPARATOR|Standard pediatric primary care|This arm involved residents receiving the regular education through the program. They did not use the screening questionnaire to identify psychosocial problems, and did not have a dedicated social worker to assist them. Instead, residents in this group provided standard pediatric primary care
62260699|NCT03173794|NO_INTERVENTION|Usual Care Only|The control group will receive usual care, no CommunityRx-H intervention
62842813|NCT06048640|ACTIVE_COMPARATOR|Active|100 mg of Dynamine (methylliberine)
62842814|NCT03756324|EXPERIMENTAL|CHPM (Chinese Herbal Patent Medicine )|"CHPM (Chinese Herbal Patent Medicine ): Pugongying (Herba Taraxaci) Granules, 15g/tid for 3 days, follow-up for 7 days.~Education, basic medical order."
62842815|NCT03756324|EXPERIMENTAL|CHPM & Antibiotics Cefdinir Capsules|"CHPM (Chinese Herbal Patent Medicine): Pugongying (Herba Taraxaci) granules, 15g/tid for 3 days, follow-up for 7 days.~Antibiotics: Cefdinir Capsules, 0.1g/tid for 2 days, follow-up for 7 days.~Education, basic medical order."
62057507|NCT05780814|PLACEBO_COMPARATOR|Sleep Education Control (EDU)|The EDU intervention will parallel the CBT-I intervention in number, format and length of all sessions, including maintenance sessions. It provides basic information about sleep and cancer, widely available to the public. EDU content does not include any individualized behavioral instructions, sleep diary monitoring during the intervention, or behavior change counseling. Content is presented didactically only.
62617351|NCT03371056|EXPERIMENTAL|Woman at low risk of infection|Women with systematic vaginal sample for detection of GBS will be included.
62842816|NCT03756324|ACTIVE_COMPARATOR|Antibiotics Cefdinir Capsules|"Antibiotics: Cefdinir Capsules, 0.1g/tid for 3 days, follow-up for 7 days.~Education, basic medical order."
62057508|NCT00998400|NO_INTERVENTION|Clinical Management|Control group
62057509|NCT00998400|EXPERIMENTAL|CBT + WBT|Patients treated with Cognitive-Behavioral Therapy in combination with Well-Being Therapy and lifestyle modification
62842817|NCT06394141|EXPERIMENTAL|Real-time triggers|The first intervention group (n= 30 professional drivers) will receive real-time triggers related to acute stress and sleepiness/fatigue. The real-time feedback involves giving relevant triggers when exceeding some critical stress values or detecting events of 'energy-takers' based on accurate measurements of mental energy in a fully automated way. The selected triggers will be based on the co-creation workshops with drivers (e.g., auditive, visual) in order to select the most efficient (type or combination of) trigger(s) for the real-time feedback. The warning messages will be tailored to the preferences of the driver (e.g., personalized comfort- and safety-related settings) and aim to generate a warning message/signal meant to alert drivers and prevent they might end up with high stress levels.
62057510|NCT05476055||conventional NBS+ infants|Disease diagnosis is carried out using conventional diagnosis and treatment methods.
62057511|NCT05476055||conventional NBS+ infants (NGS)|Disease diagnosis is carried out using conventional diagnosis and treatment methods, as well as NGS.
62057512|NCT05476055||NICU infants|Disease diagnosis is carried out using conventional diagnosis and treatment methods.
62057513|NCT05476055||NICU infants (NGS)|Disease diagnosis is carried out using conventional diagnosis and treatment methods, as well as NGS.
62260700|NCT03173794|EXPERIMENTAL|Usual Care and Intervention|The intervention arm will receive the CommunityRx-H intervention, an information-based intervention that provides referrals to community resources
62260701|NCT00970853|ACTIVE_COMPARATOR|Control|Control group
62260702|NCT00970853|EXPERIMENTAL|MOM Program home visiting|Mixed professional support home visiting program.
62260703|NCT01170520|EXPERIMENTAL|rTMS|
62260704|NCT01303042|EXPERIMENTAL|Insulin lispro mix 50/50|
62446084|NCT06380946|EXPERIMENTAL|Experimental:iPRF group closure of premolar extraction space|closure ofpremolar extraction space that will be performed with iPRFapplication according to a standardized protocol
62057514|NCT05476055||Premature infants|Disease diagnosis is carried out using conventional diagnosis and treatment methods.
62446085|NCT06380946|NO_INTERVENTION|intervention group|iPRFgroup closure of premolar extraction space control side
62617352|NCT03371056|EXPERIMENTAL|Woman with high risk of infection > 37 SA|Women with premature rupture of membranes (\> 12 hours before labor) but \> 37 SA will be included.
62617353|NCT03371056|EXPERIMENTAL|Women with premature rupture of membranes (<37SA)|Woman with high risk of infection \<37SA
62617354|NCT03371056|EXPERIMENTAL|Women with premature delivery or premature delivery threat|Woman with high risk of infection \<37SA and Women with premature delivery or premature delivery threat
62842818|NCT06394141|EXPERIMENTAL|Personalized tailored feedback|The second intervention group (n= 30 professional drivers) will receive personalized tailored feedback to reduce chronic stress and sleepiness/fatigue. The advice involves personalized (semi-)automatic feedback to drivers about a reduced stress level via the mobile app with automatic reports, as well as post-intervention during the next work break or at the end of the workday, based on the preferences of the driver. The (semi-)automatic feedback is based on the theory of Stages of Change, by which a driver will only receive relevant feedback based on their attitude and willingness during daily life.
62842819|NCT06394141|EXPERIMENTAL|Real-time triggers + Personalized tailored feedback|The third intervention group (n= 30 professional drivers) will receive both real-time feedback related to acute stress and sleepiness/fatigue, as well as personalized tailored feedback related to chronic stress and sleepiness/fatigue, similar as in the first and second intervention groups.
62842820|NCT06394141|EXPERIMENTAL|App-supported exercise therapy|The fourth intervention group (n= 30 professional drivers) will receive app-supported exercise therapy. The intervention will be based on principles of high-intensity training exercises that focus on the improvement of cardiorespiratory exercise capacity, as well as on the reduction of stress levels during work. Participants will receive instructions via the app to do some short, vigorous exercises adapted to their work environment at regular intervals, e.g., bending-and-stretching exercises with a weight in their hands, walking up and down the stairs of their vehicle for a few minutes, etc.
62842821|NCT06394141|ACTIVE_COMPARATOR|Conventional intervention|The active control group (n= 20 professional drivers) will get a conventional intervention to reduce stress, e.g., mindfulness.
62842822|NCT06394141|NO_INTERVENTION|Control group|The passive control group (n= 20 professional drivers) will get no intervention and will continue as normal without receiving any feedback.
62842823|NCT05205889|EXPERIMENTAL|Mobile based values intervention for people with chronic pain|
62842824|NCT01136980|PLACEBO_COMPARATOR|Sham placebo procedure|Sham Procedure: SHAM/PPI's An upper GI Endoscopy is performed with a standard endoscope, during 30-45 minutes. The patient is under general anesthesia. EGD explores the esophagus, the stomach, and the GEJ.
62446086|NCT06380946|EXPERIMENTAL|Experimental: iPRFgroup: distalization intervntion side|distalization will be commenced with application of iPRF according to a standardized protocol
62057515|NCT05476055||Premature infants (NGS)|Disease diagnosis is carried out using conventional diagnosis and treatment methods, as well as NGS.
62617355|NCT00441987|EXPERIMENTAL|Single Dose of GSI-953|
62842825|NCT01136980|ACTIVE_COMPARATOR|TIF Transoral Fundoplication|Intervention: TIF 2.0/Placebo TIF Transoral Incisionless Fundoplication: A fundoplication of 270 degrees and 3cm in length was created. The EsophyX device is introduced over a standard endoscope, through the mouth, into the stomach.
62842826|NCT03967353|NO_INTERVENTION|Routine Treatment Group|Routine treatment group(6 months treatment regimen-2HRZE/4HR); Routine health education; Dose-taken supervised by family members
62842827|NCT03967353|EXPERIMENTAL|Intervention Group|Using mobile technology management means to manage newly treated smear-positive tuberculosis patients, to guide patients'treatment, infection control, doctor-patient communication, and to strengthen health education on infection control of patients.
62842828|NCT01657240|EXPERIMENTAL|PRO-118|pro-118 ophthalmic solution, instill one drop in each eye once a day for 21 days
62842829|NCT01657240|ACTIVE_COMPARATOR|Olopatadine Hydrochloride|Olopatadine Hydrochloride ophthalmic solution 2%, instill one drop in each eye once a day for 21 days
62842830|NCT05753696|EXPERIMENTAL|azilsartan group|the initial dose of azilsartan is 20mg/day, if not reached the goal of blood pressure, azilsartan was adjust to 40mg/day
62260705|NCT02655965|EXPERIMENTAL|Ropivacaine + Clonidine|"A pecs block of Ropivacaine 3.5 mg/ml and Clonidine 5 µg/ml will be injected to the patients prior surgery. 10 ml of the drug combination will be injected between pectoral muscles and 20 ml of the drug combination will be injected between the muscles pectoralis minor and serratus anterior.~After surgery, subjects in both arms will receive one dose of Paracetamol (1g) and Diclofenac (75 mg) and one dose 0.05 mg/kg Piritramide as well as PCIA (Patient Controlled Intravenous Analgesia)-Piritramide for 24 hrs post-surgery."
62260706|NCT02655965|PLACEBO_COMPARATOR|Sodium Chloride|"A pecs block of Placebo (Sodium Chloride 0.9%) will be injected to the patients prior surgery. 10 ml of the Sodium chloride solution will be injected between pectoral muscles and 20 ml of the Sodium chloride solution will be injected between the muscles pectoralis minor and serratus anterior).~After surgery, subjects in both arms will receive one dose of Paracetamol (1g) and Diclofenac (75 mg) and one dose 0.05 mg/kg Piritramide as well as PCIA (Patient Controlled Intravenous Analgesia)-Piritramide for 24 hrs post-surgery."
62446087|NCT06380946|NO_INTERVENTION|No Intervention: iPRF group: distalization control side|distalization will be commenced without application of iPRF according to a standardized protocol
62446088|NCT06380946|EXPERIMENTAL|Experimental: iPRF group: leveling and alignment|leveling and alignment be commenced with application of iPRF according to a standardized protocol
62446089|NCT06380946|NO_INTERVENTION|No Intervention: leveling and alignment without intervention|leveling and alignment without intervention
62842831|NCT05753696|ACTIVE_COMPARATOR|losartan group|the initial dose of losartan is 40mg/day, if not reached the goal of blood pressure, losartan was adjust to 80mg/day
62842832|NCT04693624||Hormonal levels|Blood samples are collected for analysis of progesterone, hCG, inhibin-A, and 17-OH-Progesterone levels.
62842833|NCT01965678|EXPERIMENTAL|OMT|
62842834|NCT03544762|EXPERIMENTAL|18F-FES PET|PET/CT
62842835|NCT06458478|ACTIVE_COMPARATOR|Hyper-oxygenated Gel|"Patients undergoing lower third molar extraction. Post-operatively, the antibiotic (amoxicillin + clavulanic acid) and the painkiller (paracetamol 1000mg x 2 times a day x 7 days) are prescribed.~Furthermore, patients will have to use the Novox drop at the post-extraction site 3 times a day for 7 days (without taking liquids for 30 minutes after use)."
62842836|NCT06458478|PLACEBO_COMPARATOR|Placebo|"Patients undergoing lower third molar extraction. Post-operatively, the antibiotic (amoxicillin + clavulanic acid) and the painkiller (paracetamol 1000 mg x 2 times a day x 7 days) are prescribed.~Furthermore, patients will have to use the Placebo, glycerin based gel, at the post-extraction site 3 times a day for 7 days (without taking liquids for 30 minutes after use)."
62842837|NCT03371043||users of analgesic medications|Children and adolescents who are users of analgesic medications, 2012 to 2015
62446090|NCT06380946|EXPERIMENTAL|Experimental: iPRF group: Intrusion|intrusion assisted with application of iPRF according to a standardized protocol
62842838|NCT03495245||Opioid Usage|Patients that are currently diagnosed with fibromyalgia and taking opioids.
62842839|NCT03495245||No Opioid Usage|Patients that are currently diagnosed with fibromyalgia and are not taking opioids.
62842840|NCT04106076|EXPERIMENTAL|Dose escalation|Several tested doses of UCART123 until the Maximum Tolerated Dose (MTD) is identified.
62842841|NCT06268756||students|students
62842842|NCT04146636|OTHER|Diagnostic Test: e-LIFT|only one arm because diagnostic study evaluating blood test using elastometry and liver biopsy as reference
62617356|NCT01634568|EXPERIMENTAL|Single Ascending Dose|Single Ascending Doses of V81444 compared to placebo
62842843|NCT05425940|EXPERIMENTAL|Experimental Arm|Subjects with mCRC will receive XL092 + atezolizumab
62842844|NCT05425940|ACTIVE_COMPARATOR|Control Arm|Subjects with mCRC will receive active comparator of regorafenib
62842845|NCT03347955|EXPERIMENTAL|Neural implantation group|Human embryonic dopamine neurons were implanted into brains of half the randomized participants (n = 20). Participants were evaluated at baseline, 4, 8, and 12 months after surgery.
62842846|NCT03347955|SHAM_COMPARATOR|Sham Surgery group|This group (n = 20) received sham surgery with a steel frame affixed to their heads and four burr holes drilled into their foreheads without crossing the blood/brain barrier. Participants were assessed at baseline, 4, 8, and 12 months after surgery.
62842847|NCT04651842||HOMA IR high|classified based on equal tertile of HOMA IR level into 3 equal groups ( high\>6.6)
62842848|NCT04651842||HOMA IR intermediate|classified based on equal tertile of HOMA IR level into 3 equal groups ( intermediate 4.6-6.6, )
62842849|NCT04651842||HOMA IR low|classified based on equal tertile of HOMA IR level into 3 equal groups (low ≤ 4.6, )
62842850|NCT03990558||Primary ICH|Subject with acute brain injury will have data collected, including EEG, behavioral, clinical, and outcome measures.
62842851|NCT04338776|EXPERIMENTAL|UroLift|Patient randomized to the UroLift arm will receive the FDA-approved UroLift procedure.
62842852|NCT04338776|EXPERIMENTAL|Rezūm|Patient randomized to the Rezūm arm will receive the FDA-approved Rezūm procedure.
62842853|NCT02981615|EXPERIMENTAL|treatment arm|Subjects allocated to the treatment arm of the study will be administrated Levofloxacin 500mg/d given p.o. once a day, starting on day 10 from beginning of each cycle until day 28 on an ambulatory basis. Levofloxacin will be continued in the first 4 Azacytidine cycles.
62260707|NCT02847195|EXPERIMENTAL|pediatric intensive care|"When aspiration is planned, pain assessment will be performed thrice :~3-5 minutes before aspiration, during aspiration, and 3-5 minutes after aspiration.~Pain assessment will be performed with both methods:~* COMFORT B scale (routinely performed by nurses, and lasts less than one minute)~* Simultaneously pupillometry is assessed using the device (Neurolight) (one measurement per eye, this also lasts less than one minute) These measurements can occur at any time during stay in ICU, and can be repeated."
62842854|NCT02981615|PLACEBO_COMPARATOR|placebo|Subject allocated to the placebo arm will be treated with placebo once a day, starting on day 10 from beginning until day 28 of each of the first 4 cycles.
62842855|NCT06032325||Neutrophil Gelatinase Associated Lipocalin and Kidney Injury Molecule-1|
62842856|NCT03134703|EXPERIMENTAL|Methadone Treatment Group|NAS infants treated for withdrawal symptoms with methadone
62617357|NCT01634568|EXPERIMENTAL|Multiple Ascending Doses|Multiple ascending doses of V81444 compared to placebo
62617358|NCT03001245|EXPERIMENTAL|IPC|Interpersonal Counseling
62260708|NCT04340986||patients with Hepatocellular carcinoma|
62260709|NCT04340986||patients with Cholangiocarcinoma|
62842857|NCT03134703|ACTIVE_COMPARATOR|Comparison Group|NAS infants treated for withdrawal symptoms with morphine (standard of care at Johns Hopkins All Children's Hospital)
62260710|NCT03230552|EXPERIMENTAL|Video group|Residents assigned to this group will watch an instructional surgical video prior to LSO surgery.
62617359|NCT03001245|ACTIVE_COMPARATOR|ST|Standard treatment
62842858|NCT02110836|ACTIVE_COMPARATOR|Glucose ingestion|Glucose ingestion during exercise at a rate of 1.8 g/min.
62842859|NCT02110836|EXPERIMENTAL|Sucrose ingestion|Sucrose ingestion during exercise at a rate of 1.8 g/min.
62842860|NCT01398709|ACTIVE_COMPARATOR|Slow rewarming strategy|Slow rewarming strategy (0.24 degrees C/min)
62260711|NCT03230552|NO_INTERVENTION|No video group|Residents assigned to this group will not watch an instructional surgical video prior to LSO surgery.
62617360|NCT04808414|EXPERIMENTAL|QPX9003 for IV infusion|IV novel polymyxin antibiotic Single and Multiple IV doses x 7 days via IV infusion q6hrs
62617361|NCT04808414|PLACEBO_COMPARATOR|Placebo for Infusion|IV saline Single and Multiple IV doses x 7 days via IV infusion q6hrs
62842861|NCT01398709|ACTIVE_COMPARATOR|Fast rewarming strategy|Fast rewarming strategy (0.5 degrees C/min)
62842862|NCT03500224|EXPERIMENTAL|[14C]-TAK-954 0.5 mg|\[14C\]-TAK-954 0.5 milligram (mg), (containing approximately 1.5 microcurie \[µCi\] of radioactive tracer), administered as 60-minute infusion, intravenously, once on Day 1.
62842863|NCT03831906|NO_INTERVENTION|Control|"All children admitted in the hospital and presenting with WHO-defined severe pneumonia will be immediately managed as part of routine care per the WHO Standard of Care (SOC), including broad spectrum antibiotics, oxygen therapy if required, additional supportive care and specific therapies for comorbidities such as HIV infection.~For research purposes, children will benefit from HIV testing, malaria testing, and complete blood count (CBC) if not systematically performed as routine care in the country/hospital, as well as from a digitalized chest X-ray (CXR). Additionally, samples will be collected for future biomarkers studies (biobank)."
62842864|NCT03831906|EXPERIMENTAL|Interventional|Children will benefit from the WHO SOC and additional strategies for research purposes (HIV and malaria testing, CBC, CXR, and biobank) as described in the control arm, plus the study intervention.
62057516|NCT06072222|PLACEBO_COMPARATOR|Group A|patients of group A Continue on the conventional way of ventilation and . Microbiological results collected from patients of group A through qualitative sputum.
62617362|NCT02372942|EXPERIMENTAL|Lattoferrin|Use of Lattoferin for prevention of preterm delivery
62617363|NCT02372942|EXPERIMENTAL|Progesterone|Use of Progesterone for prevention of preterm delivery
62617364|NCT01464619|EXPERIMENTAL|Delayed Intervention|Those assigned to the delayed intervention arm will receive enhanced mental health referrals, monthly follow-up phone calls, and will be assigned to the parenting intervention 3-4 months after enrollment.
62260712|NCT00814892|EXPERIMENTAL|DC-APCC|Patients undergo standard leukapheresis to harvest peripheral blood mononuclear cells for dendritic cell vaccine preparation. Patients receive the APCC vaccine and autologous dendritic cells derived from CD14-positive myeloid peripheral blood cells ID on days 0, 14, and 28 and then every 28 days for up to 14 courses in the absence of disease progression or unacceptable toxicity.
62617365|NCT01464619|EXPERIMENTAL|Intervention|Caregivers assigned to the intervention arm will be assigned to the Incredible Years parenting intervention immediately after enrollment. They will also receive enhanced mental health referrals and monthly follow-up phone calls.
62842865|NCT00858104|ACTIVE_COMPARATOR|1|Laser thermal ablation
62260713|NCT03501667|ACTIVE_COMPARATOR|Use of decision support tool|Trainee using decision support tool while assessing a clinical case. This intervention will affect the study participant fund of knowledge on the case.
62260714|NCT03501667|ACTIVE_COMPARATOR|Use of UpToDate|Control group, participants using current literature prior to assessing a clinical case. Allowing 10 minutes to read on a topic during clinical care is an active intervention in the study participant fund of knowledge.
62260715|NCT01392911|ACTIVE_COMPARATOR|10 mg/kg rifampicin|7 Days monotherapy with 10 mg/kg rifampicin followed by 7 days standard TB treatment, i.e. Rifafour® e275 once daily including the standard dose of rifampicin.
62260716|NCT01392911|EXPERIMENTAL|20 mg/kg Rifampicin|7 Days monotherapy with 20 mg/kg rifampicin followed by 7 days combination therapy consisting of 20 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
62260717|NCT01392911|EXPERIMENTAL|25 mg/kg Rifampicin|7 Days monotherapy with 25 mg/kg rifampicin followed by 7 days combination therapy consisting of 25 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
62260718|NCT01392911|EXPERIMENTAL|30 mg/kg Rifampicin|7 Days monotherapy with 30 mg/kg rifampicin followed by 7 days combination therapy consisting of 30 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
62446091|NCT06380946|NO_INTERVENTION|No Intervention: intrusion control group|intrusion without intervention
62446092|NCT01032395|EXPERIMENTAL|Chronic Disease Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria® or Fluad®), the first on Study Day 1, and the second on Study Day 22.
62617366|NCT02815150|EXPERIMENTAL|Treatment group|Preoperative oral carbohydrate drink: patients drink 5% glucose solution 250ml 2-3 hours before surgery.
62617367|NCT02815150|NO_INTERVENTION|Control group|Patients undergo 6-8 hours of preoperative fasting.
62617368|NCT03850691|EXPERIMENTAL|Cohort 1: Nivolumab|
62617369|NCT03850691|EXPERIMENTAL|Cohort 2: Nivolumab & Ipilimumab|
62617370|NCT01796314|EXPERIMENTAL|Group A : intervention|"85 dyads patient/caregiver in witch the patient suffers from mild to moderately severe Alzheimer's disease patients (MMSE 11 to 26), and lives at home with a caregiver"
62617371|NCT01796314|NO_INTERVENTION|Group B : Control|There si no associated intervention
62617372|NCT02175329|EXPERIMENTAL|CAD/CAM veneering|CAD/CAM manufactured e.max CAD veneers on zirconia framework
62842866|NCT00858104|NO_INTERVENTION|2|Follow-up
62260719|NCT01392911|EXPERIMENTAL|35 mg/kg Rifampicin|7 Days monotherapy with 35 mg/kg rifampicin followed by 7 days combination therapy consisting of 35 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
62260720|NCT01392911|EXPERIMENTAL|40 mg/kg Rifampicin|7 Days monotherapy with 40 mg/kg rifampicin followed by 7 days combination therapy consisting of 40 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
62842867|NCT00770159|EXPERIMENTAL|1|MK0822
62842868|NCT00770159|PLACEBO_COMPARATOR|2|Placebo to MK0822
62842869|NCT05406635|NO_INTERVENTION|Standard imaging monitored treatment|Standard care + biomarkers, which are blinded until end of study.
62842870|NCT05406635|EXPERIMENTAL|Intervention biomarker monitored treatment|biomarker monitored treatment + imaging, which is blinded until end of study
62842871|NCT05925868|EXPERIMENTAL|Mobile app|Parents will be given access the Headspace, a mobile mindfulness app, and instructed to use it at least 4 days a week for a minimum of 10 minutes
62260721|NCT01392911|EXPERIMENTAL|45 mg/kg Rifampicin|7 Days monotherapy with 45 mg/kg rifampicin followed by 7 days combination therapy consisting of 45mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
62446093|NCT01032395|EXPERIMENTAL|Chronic Disease Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.
62617373|NCT02175329|ACTIVE_COMPARATOR|manually layered|Manually layered veneering on CAD/CAM fabricated zirconia bridge framework
62617374|NCT05849792|EXPERIMENTAL|Exercise group|Group where the participants realize an intervention based on exercise and psychology.
62617375|NCT05849792|NO_INTERVENTION|Control|Group where the subjects do not realize the intervention.
62617376|NCT01400906|PLACEBO_COMPARATOR|3 periods cross-over study|Each subject will receive each intervention BID during a 7 days period. The treatment periods are separated by 14 days washout. The sequence in which the interventions are administered are at random and double blind.
62617377|NCT06059729|EXPERIMENTAL|Experimental group|Al-Lisaan digital application will be given to participants for self assessment and management
62617378|NCT06059729|OTHER|Controlled group|Home plan will be given
62617379|NCT04346771|EXPERIMENTAL|Maintaining Positive Working memory|Maintaining positive working memory training is based on visual positive works n-back task.In this training, positive words are presented on the pictures of happy face.According to the rules, subjects are required to identify whether the word present currently is as the same type as the word presented n before then click the keys correspondingly.Each training session contains 15 blocks which are consisted with 20+n trails.
62260722|NCT01392911|EXPERIMENTAL|50 mg/kg rifampicin|7 Days monotherapy with 50 mg/kg rifampicin followed by 7 days combination therapy consisting of 50 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
62260723|NCT01392911|EXPERIMENTAL|55 mg/kg Rifampicin|7 Days monotherapy with 55 mg/kg rifampicin followed by 7 days combination therapy consisting of 55 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
62260724|NCT04818736|EXPERIMENTAL|COVID-19|mRNA-1273 vaccine
62260725|NCT04818736|EXPERIMENTAL|Control|Usual care
62260726|NCT06094634|NO_INTERVENTION|Assessment-only control|Participants receive study assessment visits and standard of care from providers at the PrEP clinic.
62260727|NCT06094634|EXPERIMENTAL|The Brief Alcohol Intervention (BAI)|Participants receive the Brief Alcohol Intervention (2 in-person sessions and 2 phone sessions), study assessment visits, and standard of care from providers at the PrEP clinic.
62617380|NCT04346771|PLACEBO_COMPARATOR|Positive Attention Bias Modification|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. 90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position.
62842872|NCT06445114|EXPERIMENTAL|Single Arm|"Low risk pathology with post-op HPV DNA (-): cisplatin-based chemoradiation with 30 Gy in 15 fractions and 3 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, and 15 of radiation.~Low risk pathology with post-op HPV DNA (+): cisplatin-based chemoradiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation.~High risk pathology with post-op HPV DNA (-), excluding patients with both 5 LN+ and ENE+ or pre-op HPV DNA≤12 copies/mL: cisplatin-based radiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation.~High risk pathology with post-op HPV DNA (+) OR pre-op HPV DNA≤12 copies/mL OR both 5 or more LN+ and ENE+: cisplatin-based radiation with 50 Gy in 25 fractions with 5 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, 22, and 29 of radiation."
62260728|NCT04216459|NO_INTERVENTION|Low risk group|no specific treatment will be given
62260729|NCT04216459|NO_INTERVENTION|High risk control|no specific treatment will be given
62842873|NCT03331640|EXPERIMENTAL|OFF|
62260730|NCT04216459|ACTIVE_COMPARATOR|High risk DP|patients will receive one intramuscular (IM) injection of 400,000 IU of cholecalciferol on day- 1 Also, starting from day 1 and till day 6 (for consequential 6 days), patients will receive lactobacillus probiotics (10 billion colony forming unit) in a dose of 6 sachets per day
62842874|NCT03331640|EXPERIMENTAL|FOLFIRI|
62260731|NCT04216459|ACTIVE_COMPARATOR|High risk CB|Patients will receive vitamin C plus thiamine starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
62260732|NCT02947035|EXPERIMENTAL|Low Risk|Molecular testing and ultrasound features will be used to predict if thyroid cancer is low risk. Intervention will be to perform thyroid lobectomy.
62260733|NCT02947035|EXPERIMENTAL|High Risk|Molecular testing and ultrasound features will be used to predict if thyroid cancer is high risk. Intervention will be to perform more aggressive surgery to include total thyroidectomy with CCND.
62260734|NCT00906087|OTHER|Cosopt|Intraocular pressure and blood pressure measurements will be compared under the following conditions: 1) after washout of clinical treatment, 2) after treatment with Cosopt, and 3) after another washout of Cosopt.
62842875|NCT02901678|ACTIVE_COMPARATOR|Intrusion by 200 g|Applying 200 g intrusive force for the maxillary posterior segment intrusion using miniscrews
62842876|NCT02901678|EXPERIMENTAL|Intrusion by 400 g|Applying 400 g of Intrusive force for the maxillary posterior segment intrusion using miniscrews
62260735|NCT04398342||Children with Cerebral Palsy in Denmark|Children diagnosed with cerebral palsy born 2003 - 2020 and registered in the Danish Cerebral Palsy Follow-up Program.
62260736|NCT02025907|EXPERIMENTAL|Canagliflozin (JNJ-28431754)|Each participant will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 6 weeks, then the dose may be increased to 300 mg once daily.
62842877|NCT04121663|EXPERIMENTAL|Full seam anchor|
62260737|NCT02025907|PLACEBO_COMPARATOR|Placebo|Each participant will receive placebo (inactive medication) once daily for 28 weeks.
62260738|NCT04694495||volunteers from health examination center|volunteers(n = 50/center) doing gynecologial examination recruited from health examination center, who shows no symptoms and signs in reproductive tract and are potentially regarded as the healthy controls
62260739|NCT04694495||volunteers from gynecology outpatient|volunteers(n = 150/center) recruited from gynecology outpatient, who show abnormal symptoms and signs in reproductive tract and are potentially regarded as the cases with conditions in reproductive tract
62842878|NCT04121663|ACTIVE_COMPARATOR|Polyether ether ketone bone anchor|
62260740|NCT00575198|EXPERIMENTAL|1|No drainage threshold
62260741|NCT00575198|ACTIVE_COMPARATOR|2|Drainage \<2 mL/kg
62842879|NCT03443570|EXPERIMENTAL|combination treatment group|100 enrolled patients are randomly picked up to take rituximab in combination with bortezomib at the indicated dose
62842880|NCT03443570|ACTIVE_COMPARATOR|control group|100 enrolled patients are randomly picked up to take rituximabalone at the indicated dose
62842881|NCT00268853|EXPERIMENTAL|1|
62842882|NCT00268853|ACTIVE_COMPARATOR|2|
62842883|NCT00357682|EXPERIMENTAL|Arm A|20mg Esomeprazole
62842884|NCT00357682|EXPERIMENTAL|Arm B|80mg Esomeprazole
62842885|NCT00357682|EXPERIMENTAL|Arm C|20mg Esomeprazole + 300mg Aspirin
62842886|NCT00357682|EXPERIMENTAL|Arm D|80mg Esomeprazole + 300mg Aspirin
62842887|NCT05875506|EXPERIMENTAL|Ozone gel|(Ozene; Premier Research Labs, lp, 3500-b Wadley pl, Austin, TX, USA. 78728)
62842888|NCT05875506|EXPERIMENTAL|doxycycline hyclate saturated chitosan dressing|doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA)
62260742|NCT03624699|EXPERIMENTAL|Glaukos iStent inject®|Patients suffering from cataract and open-angle glaucoma. Glaukos iStent inject® is implanted during routine cataract surgery. The effect on IOP/glaucoma medications is monitored.
62260743|NCT02424942|EXPERIMENTAL|GZ389988|Single intraarticular injection of GZ389988 in the knee joint
62260744|NCT02424942|PLACEBO_COMPARATOR|Placebo|Single intraarticular injection of placebo for GZ389988 in the knee joint
62260745|NCT05823675|EXPERIMENTAL|Itolizumab Dose Level 1|Itolizumab of 25 mg administered by intravenous infusion every 2 weeks for a total of 5 doses.
62260746|NCT05823675|EXPERIMENTAL|Itolizumab Dose Level 2|Itolizumab of 50 mg administered by intravenous infusion every 2 weeks for a total of 5 doses.
62260747|NCT05823675|EXPERIMENTAL|Itolizumab Dose Level 3|Itolizumab of 100 mg administered by intravenous infusion every 2 weeks for a total of 5 doses.
62260748|NCT05823675|EXPERIMENTAL|Itolizumab Dose Level 4|Itolizumab of 150 mg administered by intravenous infusion every 2 weeks for a total of 5 doses.
62260749|NCT02244567|ACTIVE_COMPARATOR|Metformin|Cidophage 850 mg twice daily for three months will be given to the patientwith PCOS.
62260750|NCT02244567|ACTIVE_COMPARATOR|Serum under-carboxylated osteocalcin|Serum uc-oc will be measured before and after 3 months of treatment with cidophage.
62260751|NCT02244567|ACTIVE_COMPARATOR|Placebo|Other group of patients with high serum UC-OC will be given a placebo.
62842889|NCT05875506|ACTIVE_COMPARATOR|Alveogyl paste|Alveogyl paste ( Septodont, inc, france)
62842890|NCT02969148|EXPERIMENTAL|The bursectomy and D2 lymphadenectomy|Laparoscopic bursectomy and D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.The key of this approach are that anterior lobe of transverse mesocolon and capsula pancreatis will be dissected with the D2 lymphadenectomy according to the guidelines of National Comprehensive Cancer Network(NCCN)
62842891|NCT02969148|ACTIVE_COMPARATOR|The D2 lymphadenectomy|Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.The key of this approach is that D2 lymphadenectomy is carried out according to the guidelines of National Comprehensive Cancer Network(NCCN) without dissociation of anterior lobe of transverse mesocolon and capsula pancreatis.
62260752|NCT03172845|EXPERIMENTAL|Vulnerable plaque|Thin-cap fibro atheroma (TCFA) was defined as a lipid-rich plaque with the thinnest fibrous cap thickness\<65um. Plaque rupture was identified by the presence of fibrous cap discontinuity with a clear cavity formation inside the plaque. Plaque erosion is characterized by luminal thrombus and absence of the endothelium or without evidence of fibrous cap disruption. Fibro calcific plaque contains OCT evidence of fibrous tissue along with calcium that appears as a signal-poor or heterogeneous region with a sharply delineated border which is applied to larger calcifications. Calcified nodule is characterized as a signal or multiple regions of calcium protruding into the lumen, superficial calcification accompanied by substantive calcium proximal and or distal to the lesion. Thrombus is defined as a mass attached to luminal surface or floating within the lumen. It is seen as a protrusion inside the lumen of the artery with signal attenuation.
62260753|NCT03172845|ACTIVE_COMPARATOR|Without any vulnerable plaqueStable plaque|patient with bifurcation lesion undergoing baseline coronary angiography and baseline OCT.
62260754|NCT00350948|EXPERIMENTAL|Telcyta + Liposomal Doxorubicin|Telcyta at 1000 mg/m2 followed by Liposomal Doxorubicin at 50 mg/m2 on Day 1 of each four-week treatment cycle
62260755|NCT00350948|ACTIVE_COMPARATOR|Liposomal Doxorubicin|Liposomal Doxorubicin at 50 mg/m2 on Day 1 of each four-week treatment cycle
62260756|NCT02325284||Healthy adults|
62260757|NCT03535259|EXPERIMENTAL|Sorafenib and IMRT|Concurrent sorafenib and IMRT, followed sorafenib maintenance for advanced hepatocellular carcinoma with portal vein or hepatic vein tumor thrombosis or lymph node involved
62260758|NCT02953340|EXPERIMENTAL|(Arm 1): SPI-2012 and TC|At each cycle for 4 cycles, participants received SPI-2012 at a fixed dose of 13.2 milligrams (mg)/0.6 milliliter (mL), \[3.6 mg granulocyte colony-stimulating factor {G-CSF}\] subcutaneously (SC) approximately 24-26 hours after receiving intravenous (IV) infusion of docetaxel 75 mg/m\^2 and cyclophosphamide 600 mg/m\^2 IV infusion per institute's standard of care. All participants were followed for 35 (±5) days after last study treatment or patient discontinuation and long-term safety follow-up continued for 12 months after last dose of study treatment.
62446094|NCT01032395|EXPERIMENTAL|Healthy Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria® or Flaud®), the first on Study Day 1, and the second on Study Day 22.
62446095|NCT01032395|EXPERIMENTAL|Healthy Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.
62446096|NCT04455659|EXPERIMENTAL|TENS + Conventional physical therapy exercise|
62260759|NCT02953340|EXPERIMENTAL|(Arm 2): Pegfilgrastim and TC|At each cycle for 4 cycles, participants received pegfilgrastim 6 mg (6 mg/0.6 mL GCSF) SC approximately 24-26 hours after receiving IV infusion of docetaxel 75 mg/m\^2 and cyclophosphamide 600 mg/m\^2 IV infusion per institute's standard of care. All participants were followed for 35 (±5) days after last study treatment or patient discontinuation and long-term safety follow-up continued for 12 months after last dose of study treatment.
62260760|NCT02422420|EXPERIMENTAL|Individual Incentive|Participants receive a financial incentive every time they attend a class session and goal-based incentives for attending 75% of Core sessions, 75% of Post-Core sessions, separately achieving 5%, 7%, and 10% weight loss during the Core period (i.e. separate financial incentives for each goal reached at any point during the Core period), and 5%, 7%, or 10% weight loss by the end of Post-Core Session 8 (i.e., one financial incentive based on final weight loss).
62260761|NCT02422420|EXPERIMENTAL|Group Incentive|This arm receives the same routine attendance incentives as the Individual Incentive arm. Group goal-based incentives include 5% weight loss by an individual during the Core period and, separately, during the Post-Core period. Financial incentives are also received if the entire DPP group achieves 75% Core session attendance, 75% of Post-Core session attendance, 7% or 10% weight loss from baseline during the Core, and 7% or 10% weight loss from baseline at the end of the Post-Core period.
62260762|NCT02422420|OTHER|Minimal Incentive|Participants receive the full Diabetes Prevention Program (DPP), but receive a nominal $25 financial incentive for attendance only at the first DPP session and no other incentives for attendance or weight loss.
62260763|NCT01931657|EXPERIMENTAL|Mifepristone prior to Mirena|Pretreatment with mifepristone prior to Mirena insertion
62260764|NCT01931657|PLACEBO_COMPARATOR|Placebo prior to Mirena|Pretreatment with placebo prior to Mirena insertion
62260765|NCT05086731|EXPERIMENTAL|Group I (SMRxT smart pill bottle)|Patients receive a SMRxT smart pill bottle, report symptoms weekly, and receive reminders for missing or incorrect dose for standard of care 3-week capecitabine/Xeloda treatment cycles.
62260766|NCT05086731|ACTIVE_COMPARATOR|Group II (standard of care)|Patients receive a SMRxT smart pill bottle and standard of care.
62446097|NCT04455659|ACTIVE_COMPARATOR|conventional physical therapy exercise|
62617381|NCT02342600|EXPERIMENTAL|Trametinib with Pazopanib|Participants will take pazopanib (800mg) and trametinib (2mg) by mouth daily for a 28 day cycle.
62617382|NCT02806830|EXPERIMENTAL|Optive after the second anti-VEGF injection|Naive patients requiring intravitreal injection. Patients will be enrolled in this study within the 2 first intravitreal injections to assess quality of life and ocular discomfort without wetting agent (ie after the first injection) and with wetting agent (ie after the second injection)
62617383|NCT01234701||Primary liver tumors, non-cirrhotic|This single Cohort/Group will include all consecutive patients that received pre-operative Magnetic Resonance Imaging (MRI) and underwent resection for primary liver tumors.
62446098|NCT06200896|EXPERIMENTAL|SFM in Obese Patients, When Used to Create a Duodenal-Ileal Anastomosis Post Sleeve Gastrectomy|Duodenal-Ileal Anastomosis Post Sleeve Gastrectomy created with Self Forming Magnets (SFM)
62446099|NCT06200896|EXPERIMENTAL|SFM in Obese subjects when Used to Create a Jejuno-Jejunostomy (J-J) Anastomosis|Jejuno-Jejunostomy (J-J) Anastomosis created with Self Forming Magnets (SFM) as part of a Roux-en-Y gastric bypass
62260767|NCT04442945|EXPERIMENTAL|ANAVEX3-71 Oral|Up to four single ascending doses of ANAVEX3-71 administered orally
62260768|NCT04442945|PLACEBO_COMPARATOR|Placebo arm Oral|Placebo administered orally
62260769|NCT00748280|EXPERIMENTAL|1|ORCT
62260770|NCT00748280|EXPERIMENTAL|2|PCEM/PMTA
62446100|NCT02944643|EXPERIMENTAL|Active group|Will get the mindfulness and support groups
62617384|NCT06292130|EXPERIMENTAL|App users|All participants will be provided with access to the intervention app (refresh).
62617385|NCT02682511|EXPERIMENTAL|Patients with dcSSc|Patients with dcSSc will be randomized to receive either oral ifetroban or oral placebo daily for 365 days
62057517|NCT06072222|ACTIVE_COMPARATOR|Group B|had three times bronchoscopy one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period to confirm both clinical and bacteriological cure. Bronchoscopy done with the following precautions: we used flexible bronchoscopy Olympus BF-160 adult size, patients kept sedated with both midazolam and fentanyl, 4 syringe of normal isotonic saline used for wash every one 10 ml and suction done immediately after injection, suction of the fluid and small airway secretion after only the first injection of isotonic saline syringe used for BAL and sent for qualitative culture
62057518|NCT04077957|EXPERIMENTAL|Group 1. Experimental|Etanercept 50mg per week plus conventional synthetic DMARDs(csDMARDs, methotrexate 10mg per week, sulfasalazine 2.25g per day, hydroxychloroquine 0.2g per day) for 4 weeks when in high disease activity; etanercept 50mg per week plus csDMARDs for 2 weeks and continue with csDMARDs only for 2 weeks when in low disease activity; csDMARDs only for 4 weeks when in disease remission status.
62260771|NCT03711656|EXPERIMENTAL|isCGM and Physical exercise tracker|"Participants will perform CGM during 12 weeks using an isCGM (intermittently scanned Continuous Glucose Monitoring), Freestyle Libre, (Abbott Diabetes Care, Witney, Oxon, UK). Insulin dose (rapid-acting and long acting), carbohydrates and Self-monitoring blood glucose (SMBG) per day will be recorded by the patient in the reader or in the App (LibreLink, Abbott Diabetes Care, Witney, Oxon, UK). Moreover, participants will be instructed to collect data about moderate or high intensity exercise, illness and other disturbances occurring during the study period at home.~Patients will wear a physical exercise tracker (Fitbit Alta HR® wristband (Fitbit, Inc., San Francisco, California, USA)) to track physiological variables such as heart rate, steps, activity level and sleep quality."
62260772|NCT01916928||Non-viable pregnancy|Women presenting with stillbirth, defined as fetal death occurring after 20 weeks gestation or with miscarriage, defined as fetal death prior to 20 weeks gestation.
62260773|NCT05957991||Met -lifestyle intervention|Girls with overweight and early puberty aged 8-9 years Treatment with metformin without lifestyle intervention (diet, training)
62057519|NCT04077957|ACTIVE_COMPARATOR|Group 2. Positive Control|Etanercept 50mg per week for first 12 weeks; etanercept 50mg per ten days for second 12 weeks; etanercept 25mg per week for next 12 weeks; etanercept 25mg per two week for next 12 weeks.
62260774|NCT05957991||Met + lifestyle intervention|Girls with overweight and early puberty aged 8-9 years Treatment with metformin with lifestyle intervention (diet, training)
62260775|NCT05957991||Placebo-lifestyle intervention|Girls with overweight and early puberty aged 8-9 years Treatment with placebo without lifestyle intervention (diet, training)
62260776|NCT05957991||Placebo+lifestyle intervention|Girls with overweight and early puberty aged 8-9 years Treatment with placebo with lifestyle intervention (diet, training)
62260777|NCT01741675|EXPERIMENTAL|Monetary incentive|The intervention group will receive a postal questionnaire together with a voucher worth €15 for the largest supermarket chain in Denmark. Non-responders will after three weeks receive a reminder together with another copy of the questionnaire. In both cases the questionnaire will be sent with a cover letter and a reply paid return envelope.
62260778|NCT01741675|OTHER|Control|The control group will only receive a postal questionnaire. Non-responders will after three weeks receive a reminder together with another copy of the questionnaire. In both cases the questionnaire will be sent with a cover letter and a reply paid return envelope.
62260779|NCT05944315|EXPERIMENTAL|Teddy Bear Injury Prevention Clinic|receiving injury prevention education
62057520|NCT03447080|OTHER|Control 1|White bread
62057521|NCT03447080|OTHER|Control 2|White bread
62057522|NCT03447080|EXPERIMENTAL|Rice bran soybean milk|White Bread with 195ml of rice bran soybean mil
62057523|NCT03447080|EXPERIMENTAL|Soybean milk|White Bread with 195ml of soybean milk
62260780|NCT05944315|ACTIVE_COMPARATOR|Teddy Bear Hospital Education Clinic|receiving hospital based education
62260781|NCT04302194||Patients with Phenylketonuria|
62260782|NCT04302194||normal healthy children|
62057524|NCT02614443|EXPERIMENTAL|Depression Condition|Participants in this group will be offered the Space from Depression programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
62057525|NCT02614443|EXPERIMENTAL|Anxiety Condition|Participants in this group will be offered the Space from Anxiety programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
62617386|NCT02682511|EXPERIMENTAL|Patients with SSc-PAH|Patients with SSc-PAH will be randomized to receive either oral ifetroban or oral placebo daily for 365 days
62057526|NCT02614443|EXPERIMENTAL|Stress Condition|Participants in this group will be offered the Space from Stress programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
62057527|NCT05497713|NO_INTERVENTION|Control Condition|No Mindset.
62260783|NCT00576459|EXPERIMENTAL|Fluocinolone acetonide 0.59 mg|0.59 mg fluocinolone acetonide intravitreal implant
62260784|NCT00576459|EXPERIMENTAL|Fluocinolone acetonide 2.1 mg|2.1 mg fluocinolone acetonide intravitreal implant
62057528|NCT05497713|EXPERIMENTAL|Egoistic x Proximal|"Mindset: This is my 5-minute exercise."
62057529|NCT05497713|EXPERIMENTAL|Egoistic x Distal|"Mindset: I am doing this for my health."
62260785|NCT00576459|ACTIVE_COMPARATOR|Laser photocoagulation|standard of care laser photocoagulation
62260786|NCT06037798||Bruxism|subjects with known bruxism, no TMD, primary headache or neck pain
62842892|NCT01580215||Main cohort|"* Patients of both genders of at least 18 years of age~* Who understand and voluntarily sign an informed consent form~* FEV1 \> 15% predicted and \< 45% predicted~* RV \>180% predicted~* Diagnosis of emphysema with CT evidence of hyperinflation~* Absence of collateral ventilation according to Chartis Assessment System~* Treated with Zephyr Endobronchial Valve (EBV)"
62842893|NCT01043913|EXPERIMENTAL|Guaraná extract 50mg q12 hours|Guaraná extract pills of 50mg q12 hours for 21 days
62842894|NCT01043913|PLACEBO_COMPARATOR|Placebo 1 tab q12 hours|Placebo pills 1 tab q12 hours for 21 days
62842895|NCT04118738||ZIKV-Exposed|Children born to women with documented confirmed or presumptive in-utero ZIKV exposure during pregnancy through delivery or the children's laboratory documentation of confirmed or presumptive in-utero ZIKV exposure within five days of birth.
62260787|NCT06037798||healthy|non-bruxism, no primary headache, TMD or neck pain
62260788|NCT06407167||Neuropathic Pain|All patients will undergo lumbar decompression at stenosis levels (clinically and MRI confirmed) regardless of study group
62260789|NCT06407167||No Neuropathic Pain|All patients will undergo lumbar decompression at stenosis levels (clinically and MRI confirmed) regardless of study group
62260790|NCT00176605|EXPERIMENTAL|Arm 1 (Etoposide + Cyclophosphamide)|Therapy will be divided into 4 cycles. Each cycle will be composed of 6 weeks of therapy. Total duration of therapy is 24 weeks. Administration of etoposide (50 mg po qd) and cyclophosphamide (50 mg po qd) will alternate in 21 day intervals. Starting with etoposide, patients will receive 21 days of therapy, upon completion of etoposide therapy patients will then receive 21 days of cyclophosphamide therapy. Therapy will continue in this alternating manner for 24 weeks. Week 1 of each cycle, begins with etoposide; Week 4 of each cycle, begins with cyclophosphamide.
62260791|NCT04412850|EXPERIMENTAL|Control group|Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form. The regiment chosen for this study is designed to double serum magnesium concentration to twice physiological concentration for therapeutic effects in humans, Serum levels between 4.8mg/dl-6mg/dl are considered to have an optimal neuroprotective effect.
62260792|NCT04412850|PLACEBO_COMPARATOR|placebo group|Normal Saline in equal volume as the control group.
62260793|NCT06266728|EXPERIMENTAL|Total 30 for astigmatism contact lenses|Total30 for Astigmatism Monthly Replacement Contact Lenses
62842896|NCT04118738||ZIKV-Unexposed|Children born to women without documented confirmed or presumptive in-utero ZIKV exposure during pregnancy through delivery and the children have no laboratory documentation of confirmed or presumptive in-utero ZIKV exposure at any time prior to ZIP 2.0 enrollment, if testing was performed prior to enrollment.
62842897|NCT04150848|EXPERIMENTAL|Goal Focused Emotion-Regulation Therapy (GET)|GET is a 6-session intervention delivered over 8 weeks to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses. GET has an emphasis on goal navigation skill building. This includes work on goal setting with a focus on assessing progress toward achieving specific, realistic, and measurable goals. Emotion regulation components include basic cognitive restructuring skills, cognitive distancing, and coping efficacy skills (matching the correct coping skill to specific circumstances).
62842898|NCT04150848|ACTIVE_COMPARATOR|Individual Supportive Psychotherapy (ISP)|"ISP includes 6-sessions of individual supportive psychotherapy and includes components of genuineness, unconditional positive regard, and empathic understanding through reassurance, explanation, guidance, suggestion, encouragement, affecting changes in patient's environment, and permission for catharsis. ISP emphasizes maintaining focus on the cancer experience, supporting participants in the here and now, fostering expression of emotion and discussion of difficult topics, and creating a sense of being understood."
62057530|NCT05497713|EXPERIMENTAL|Altruistic x Proximal|"Mindset: I am saving one kilo of CO2: "
62260794|NCT00960336|EXPERIMENTAL|single arm|
62617387|NCT01922856|EXPERIMENTAL|Challenge (Vaccinated)|"The vaccine will be administered via the ID route to alternating upper arms on days 0, 21, and 42.~On the morning of challenge, subjects will drink 120 mL of bicarbonate buffer. Approximately 1 minute later, subjects will drink a solution of virulent H10407 bacteria suspended in the remaining 30 mL of bicarbonate buffer (2 x 10P7P cfu)."
62842899|NCT01957046|OTHER|Oral Laxative|
62842900|NCT00746512|EXPERIMENTAL|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days
62842901|NCT00746512|PLACEBO_COMPARATOR|Placebo 15 mg|Prednisone 15 mg placebo tablets once daily for 15 days
62842902|NCT00746512|EXPERIMENTAL|Prednisone 7.5 mg|"Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis."
62057531|NCT05497713|EXPERIMENTAL|Altruistic x Distal|"Mindset: I am doing this to fight climate change."
62260795|NCT04848558|EXPERIMENTAL|Part 1: Single Dose Cohorts|Participants will receive subcutaneous (SC) injection or intravenous (IV) infusion of nipocalimab or placebo in single ascending doses on Day 1 in Cohorts 1-6 and SC administration in optional Cohorts 7-8.
62260796|NCT04848558|EXPERIMENTAL|Part 2: Multiple Dose Cohorts|Participants will receive up to 4 weekly SC injections of nipocalimab or placebo on Days 1, 8, 15, and 22 in Cohort 1 or 4 biweekly SC injections on Days 1, 15, 29, and 43 in optional Cohort 2.
62842903|NCT00746512|PLACEBO_COMPARATOR|Placebo 7.5 mg|"Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis."
62057532|NCT05375123||Trial group|A total of 660 singleton pregnant women in the first trimester (gestational age of 6-13 weeks + 6 days), who had normal results in various examinations and experienced regular obstetric examinations throughout the pregnancy, were selected from the obstetric outpatients in 33 centers, with 20 cases in each center.
62057533|NCT02493400||Exercise group|A follow up from 3 months detraining from the exercise group. Patients follows their earlier randomisation.
62057534|NCT02493400||Active Comparator: PAP group|A follow up from 3 months detraining from the active comparator group. Patients follows their earlier randomisation.
62057535|NCT05388058|EXPERIMENTAL|Arm I (cannabidiol, placebo)|Patients apply cannabidiol cream topically to affected areas BID for 14 days. Patients then apply placebo cream topically to affected areas BID for 14 days.
62260797|NCT02749773|ACTIVE_COMPARATOR|Oocyte aspiration with 17G needle|Oocyte Aspiration with 17G needle.
62057536|NCT05388058|EXPERIMENTAL|Arm II (placebo, cannabidiol)|Patients apply placebo cream topically to affected areas BID for 14 days. Patients then apply cannabidiol cream topically to affected areas BID for 14 days.
62057537|NCT03760601|NO_INTERVENTION|Baseline phase ('A')|Measurements collected in a pen-and-paper diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.
62260798|NCT02749773|ACTIVE_COMPARATOR|Oocyte aspiration with (20-17G) needle|Oocyte Aspiration (20-17G) needle.
62260799|NCT01290874|EXPERIMENTAL|Tiotropium|Tiotropium bromide will be evaluated as a treatment for asthma.
62446101|NCT04574583|EXPERIMENTAL|Phase I Dose Level 1(DL1) 25mg SX-682 monotherapy sequentially foll/by 1200mg BinTraFusp Alfa +CV301|"Participants with any solid tumor will receive a 2- week monotherapy lead-in of SX-682 DL2 50 mg by mouth (PO) twice a day (BID) followed sequentially by treatment with a dual combination of + BinTrafusp Alfa (M7824) 1200 mg fixed dose intravenous (IV) + BN-CV301.~Participants will be evaluated for dose-limiting toxicities at the completion of the dose level before enrollment to the next dose level begins"
62842904|NCT01823913|EXPERIMENTAL|Test and reference formulations|Test formulation and reference formulation given orally 14 days apart in a fasted state
62842905|NCT03944252|EXPERIMENTAL|A (avelumab)|avelumab 10 mg/kg iv day 1; To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
62842906|NCT03944252|EXPERIMENTAL|B (cetuximab + avelumab)|cetuximab 500 mg/m2 plus avelumab 10 mg/kg iv day 1. To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
62260800|NCT01290874|ACTIVE_COMPARATOR|Salmeterol or Formoterol|Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
62260801|NCT00520884|PLACEBO_COMPARATOR|Healthy 70+ Women Placebo Infusion|Healthy and Frail Women 70 and Older Receive a 3 hour Placebo Infusion of Saline administered in a stepwise fashion in amounts equivalent to the ghrelin infusion.
62842907|NCT00706342|EXPERIMENTAL|1|
62260802|NCT00520884|PLACEBO_COMPARATOR|Frail 70+ Women Placebo Infusion|Frail Women 70 and Older Receive a 3 hour Placebo Infusion of Saline administered in a stepwise fashion in amounts equivalent to the ghrelin infusion.
62260803|NCT00520884|ACTIVE_COMPARATOR|Healthy 70+ Women Ghrelin Infusion|Healthy Women 70 and Older are administered a 3 hour graded Ghrelin Infusion (the first hour of the ghrelin infusion a dose of 2.5 pmol/kg/min, increased to a dose of 5.0 pmol/kg/min for one hour, and then increased to the dose of 10 pmol/kg/min for the final hour of the infusion).
62260804|NCT00520884|ACTIVE_COMPARATOR|Frail 70+ Women Ghrelin Infusion|Frail Women 70 and Older are administered a 3 hour graded Ghrelin Infusion (the first hour of the ghrelin infusion at a dose of 2.5 pmol/kg/min, increased to a dose of 5.0 pmol/kg/min for one hour, and then increased to the dose of 10 pmol/kg/min for the final hour of the infusion).
62260805|NCT02458963|ACTIVE_COMPARATOR|IVF group|Women will undergo one full IVF cycle
62842908|NCT03655249|EXPERIMENTAL|Asl + CPT|Aerosotherapy + Autogenic drainage
62842909|NCT03655249|ACTIVE_COMPARATOR|Asl|Aerosoltherapy alone
62842910|NCT03925779|ACTIVE_COMPARATOR|(Dexmedetomidine)Dex group|The patients will be administered a loading dose of i.v. dexmedetomidine 1 μg/kg over 10 min, followed by a continuous infusion of 0.2-1 μg/kg/h, titrated according to the sedation score, till the end of the procedure
62842911|NCT03925779|ACTIVE_COMPARATOR|Propofol-Remifentanil (P-R) group|Propofol will be started by a loading dose of 0.5 mg/kg over 3-5 minutes then a maintenance infusion of 25-75 μg kg/min. Remifentanil infusion will be started at 1 μg kg over one minute then and 0.01-0.1 μg kg/min.
62842912|NCT06182956|EXPERIMENTAL|NIV + CPAP + HFO|The patient will be placed under noninvasive mechanical ventilation during 30 min, then continuous positive airway pressure during 30 min and then nasal high-flow oxygen during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
62842913|NCT06182956|EXPERIMENTAL|NIV + HFO + CPAP|The patient will be placed under noninvasive mechanical ventilation during 30 min, then nasal high-flow oxygen during 30 min and then continuous positive airway pressure during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
62842914|NCT06182956|EXPERIMENTAL|CPAP + NIV + HFO|The patient will be placed under continuous positive airway pressure during 30 min, then noninvasive mechanical ventilation during 30 min and then nasal high-flow oxygen during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
62842915|NCT06182956|EXPERIMENTAL|CPAP + HFO + NIV|The patient will be placed under continuous positive airway pressure during 30 min, then nasal high-flow oxygen during 30 min and then noninvasive mechanical ventilation during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
62446102|NCT04574583|EXPERIMENTAL|Phase I Dose Level 2 (DL2) 50 mg SX-682 sequentially followed by 1200mg BinTraFusp Alfa + CV301|"Participants with any solid tumor will receive a 2- week monotherapy lead-in of SX-682 DL2 50 mg by mouth (PO) twice a day (BID) followed sequentially by treatment with a dual combination of + BinTrafusp Alfa (M7824) 1200 mg fixed dose intravenous (IV) + BN-CV301.~Participants will be evaluated for dose-limiting toxicities at the completion of the dose level before enrollment to the next dose level begins"
62842916|NCT06182956|EXPERIMENTAL|HFO + CPAP + NIV|The patient will be placed under nasal high-flow oxygen during 30 min, then continuous positive airway pressure during 30 min and then noninvasive mechanical ventilation during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
62842917|NCT06182956|EXPERIMENTAL|HFO + NIV + CPAP|The patient will be placed under nasal high-flow oxygen during 30 min, then noninvasive mechanical ventilation during 30 min and then continuous positive airway pressure during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
62446103|NCT04574583|EXPERIMENTAL|Phase I Dose Level 3 (DL3) 100 mg SX-682 sequentially followed by 1200mg BinTraFusp Alfa +CV301|"Participants with any solid tumor will receive a 2- week monotherapy lead-in of SX-682 DL1 100 mg by mouth (PO) twice a day (BID) followed sequentially by treatment with a dual combination of + BinTrafusp Alfa (M7824) 1200 mg fixed dose intravenous (IV) + BN-CV301.~Participants will be evaluated for dose-limiting toxicities at the completion of the dose level before enrolling onto the next dose level."
62446104|NCT03299153|EXPERIMENTAL|Intervention group|patients in this group were received 200 ml/d barberry juice for tow month
62446105|NCT03299153|NO_INTERVENTION|control group|patients in this group received no intervention
62446106|NCT04222205|ACTIVE_COMPARATOR|Crossover sequence 1|"Cluster-randomization crossover sequence 1:~T-piece during odd-numbered months and inspiratory pressure augmentation during even-numbered months."
62446107|NCT04222205|EXPERIMENTAL|Crossover sequence 2|"Cluster-randomization crossover sequence 2:~T-piece during even-numbered months and inspiratory pressure augmentation during odd-numbered months."
62446108|NCT01455714||A, B, C|Group A- 40 patients without symptoms of heart failure Group B- 40 patients with exertional dyspnoea Group C - 40 patients with overt heart failure
62446109|NCT02849925|EXPERIMENTAL|Glass Ionomer Sealant|Sealants to arrest microcavitated caries. 75 microcavitated ICDAS 3 lesions will be sealed by the use of Glass ionomer sealant, EQUIA (GC) in first permanent molars.
62446110|NCT02849925|ACTIVE_COMPARATOR|Resin Sealant|Sealants to arrest microcavitated caries. 75 microcavitated ICDAS 3 lesions will be sealed by the use of resin sealant, Clinpro (3M-ESPE) in first permanent molars
62617388|NCT01922856|EXPERIMENTAL|Challenge (Unvaccinated)|On the morning of challenge, subjects will drink 120 mL of bicarbonate buffer. Approximately 1 minute later, subjects will drink a solution of virulent H10407 bacteria suspended in the remaining 30 mL of bicarbonate buffer (2 x 10P7P cfu).
62842918|NCT02865213|EXPERIMENTAL|Miniplates + OBA|"The intrusion of posterior teeth using Miniplates + OBA will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth and miniplates.~The miniplates are for Jeil Dual top® anchor system, Jeil medical corporation, #702,kolon science valley 2nd, 811, Guro-Dong, Guro-Gu, Seoul, 152-050, Korea. Tel: 82.2.850.3500. Fax: 82.2.850.3537. homepage: www.jeilmed.co.kr/ E-mail: mktg@jeilmed.co.kr"
62842919|NCT02865213|EXPERIMENTAL|Miniscrews + OBA|"The intrusion of posterior teeth using Miniscrews + OBA will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth and miniscrews.~The miniscrews are for Denxy ® dental orthodontic products, Denxy technology co, limited . 404,Lihuabuilding,Furongroad, Changsha, Hunan, China. Tel: 0086-731-89717339. Fax: 0086-731-82237315. Homepage: www.denxy-orthodontic.com/email: DENXYDENTALBOSS@126.COM"
62842920|NCT02865213|EXPERIMENTAL|Only OBA|The intrusion of posterior teeth using OBA only will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth only.
62842921|NCT06342505||De novo kidney transplant recipients|Intervention: Two extra venipunctures for the collection of blood. Drug: Once-daily extended-release tacrolimus formulation with a standard, body-weight-based starting dose of 0.14 mg/kg/day
62842922|NCT02181244|EXPERIMENTAL|Egg, one a day, for breakfast|The intervention consists in feeding the subjects egg, one a day for breakfast during 5 weeks. At the end of the intervention, blood will be obtained to measure plasma lipids, glucose, insulin and inflammatory markers. All measurements will be finished 24 weeks after the intervention is finished. All data will be reported 1 year after completion of the study.
62260806|NCT02458963|ACTIVE_COMPARATOR|Gonadotropin group|Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol.
62260807|NCT02234284|EXPERIMENTAL|Health Coaching|Patients randomized to the health coaching intervention would work with a trained health coach who would provide patient education self-management support, use action planning to help patient make changes to reach goals, as well as help coordinate patient care between the primary care provider and pulmonary specialist, identify gaps in care, and help patient access needed services
62260808|NCT02234284|NO_INTERVENTION|Usual care|Usual care was chosen as the comparison group to provide maximum generalizability of the study, as usual care is the practical alternative for the target population. Usual care includes patient education classes, smoking cessation classes, psychosocial medicine and nutritional counseling.
62842923|NCT02181244|EXPERIMENTAL|Oatmeal, one cup a day|In this arm, subjects will consume oatmeal for a period of 5 weeks. Blood samples will be taken and different parameters will be measured including plasma lipids, glucose, insulin and inflammatory markers. All these measurements will be finished 24 weeks after completion of the study. All data will be reported 1 year after completion of the study.
62260809|NCT04964427|EXPERIMENTAL|anodal tDCS- sham tDCS- MPH|(A) anodal tDCS at t1 (B) sham tDCS at t2 (C) MPH at t3
62260810|NCT04964427|EXPERIMENTAL|anodal tDCS- MPH- sham tDCS|(A) anodal tDCS at t1 (C) MPH at t2 (B) sham tDCS at t3
62260811|NCT04964427|EXPERIMENTAL|sham tDCS- anodal tDCS- MPH|(B) sham tDCS at t1 (A) anodal tDCS at t2 (C) MPH at t3
62260812|NCT04964427|EXPERIMENTAL|sham tDCS- MPH- anodal tDCS|(B) sham tDCS at t1 (C) MPH at t2 (A) anodal tDCS at t3
62260813|NCT04964427|EXPERIMENTAL|MPH- anodal tDCS- sham tDCS|(C) MPH at t1 (A) anodal tDCS at t2 (B) sham tDCS at t3
62446111|NCT04529148|EXPERIMENTAL|The treatment group|Ginkgo biloba dropping pills (63mg / pill), oral, 5 pills each time, three times a day,12 weeks totally. ( Continued to receive the best western medicine treatment for stable angina pectoris of coronary heart disease during the observation period.)
62617389|NCT02017626|EXPERIMENTAL|group 1|5 patients will receive 10 single rising doses of mCyp c 1 (modified allergen)from 0.6 ng to 6 ug and two maintenance doses, and 2 patients will receive placebo
62260814|NCT04964427|EXPERIMENTAL|MPH- sham tDCS- anodal tDCS|(C) MPH at t1 (B) sham tDCS at t2 (A) anodal tDCS at t3
62260815|NCT00912002|EXPERIMENTAL|MK-0941|MK-0941
62260816|NCT00400881|NO_INTERVENTION|Continuous PAP (CPAP)|CPAP (continuous positive airway pressure). 5 cm H2O.
62617390|NCT02017626|EXPERIMENTAL|Group 2|6 patients will receive 10 single rising doses of mCyp c 1 from 6 ng to 60 ug and two maintenance doses, and two patients will receive placebo.
62617391|NCT04542278|ACTIVE_COMPARATOR|Steroids|Participants randomized to the steroid arm will be given a prescription for prednisone 20mg daily for 7 days prior to surgery, otherwise, pre-operative standard of care
62617392|NCT04542278|NO_INTERVENTION|No Steroids|Pre-operative Standard of Care
62617393|NCT00770666|EXPERIMENTAL|1|Nicotine patch, nicotine inhaler, bupropion
62617394|NCT00770666|ACTIVE_COMPARATOR|2|Nicotine patch
62617395|NCT02886884|EXPERIMENTAL|Pilot Phase 20 million allogeneic hMSCs|Participants in this group will receive one peripheral intravenous infusion of 20 million allogeneic Mesenchymal Human Stem Cells (hMSCs)
62446112|NCT04529148|PLACEBO_COMPARATOR|The control group|Mimetic drug of ginkgo biloba dropping pills (63mg / pill),oral, 5 pills each time, three times a day,12 weeks totally.( Continued to receive the best western medicine treatment for stable angina pectoris of coronary heart disease during the observation period.)
62617396|NCT02886884|EXPERIMENTAL|Pilot Phase 100 million hMSCs|Participants in this group will receive one peripheral intravenous infusion of 100 million allogeneic Mesenchymal Human Stem Cells (hMSCs)
62617397|NCT02886884|EXPERIMENTAL|Randomized Phase 20 million allogeneic hMSCs|Participants in this group will receive one peripheral intravenous infusion of 20 million allogeneic Mesenchymal Human Stem Cells (hMSCs)
62617398|NCT02886884|EXPERIMENTAL|Randomized Phase 100 million allogeneic hMSCs|Participants in this group will receive one peripheral intravenous infusion of 100 million allogeneic Mesenchymal Human Stem Cells (hMSCs)
62617399|NCT00564317|EXPERIMENTAL|1 KIDNET|Narrative Exposure Therapy for Children
62617400|NCT00564317|EXPERIMENTAL|2 Meditation/Relaxation|mixed Meditation/Relaxation Protocol
62617401|NCT00564317|EXPERIMENTAL|3 KIDNET + Meditation/Relaxation|KIDNET according to protocol, waiting time of 5 months, then Meditation/Relaxation according to protocol
62617402|NCT00564317|EXPERIMENTAL|4 Meditation/Relaxation + KIDNET|Med/Relax according to protocol, 5 months waiting time, KIDNET according to protocol
62617403|NCT00386230|EXPERIMENTAL|1|Maternal ZDV treatment starting at 35 weeks Gestational Age (GA) and continuing through labor and delivery, and three days of infant ZDV treatment starting at birth (Smother-Sinfant)
62057538|NCT03760601|EXPERIMENTAL|Intervention phase ('B')|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game-play) followed by instructions to engage in the task selfguided over the subsequent week. Measurements collected in a pen-and-paper diary four times a day over one week following the intervention for the primary outcome (occurrence of intrusive memories of trauma).
62446113|NCT01172600|ACTIVE_COMPARATOR|Entonox|Patients will receive inhaled Entonox along with the interventional block they are scheduled.
62446114|NCT01172600|PLACEBO_COMPARATOR|Oxygen|Patients will receive inhaled oxygen along with the interventional block they are scheduled.
62446115|NCT00567281|EXPERIMENTAL|1|Active bilateral rTMS to left/right Wernicke's area and opposite side middle temporal gyrus
62446116|NCT00567281|ACTIVE_COMPARATOR|2|Active rTMS to left/right Wernicke's region plus sham rTMS to opposite hemisphere middle temporal cortex
62446117|NCT05621642|EXPERIMENTAL|Online Group|Trainings will be given to the intervention group patients by the researchers. Respiratory, balance and strengthening exercises suitable for the patients will be applied over an online platform under the supervision of a physiotherapist.
62617404|NCT00386230|EXPERIMENTAL|2|Maternal ZDV treatment starting at 35 weeks Gestational Age (GA) and continuing through labor and delivery, and six weeks of infant ZDV treatment starting at birth (Smother-Linfant)
62617405|NCT00386230|EXPERIMENTAL|3|Maternal ZDV treatment starting at 28 weeks Gestational Age (GA) and continuing through labor and delivery, and three days of infant ZDV treatment starting at birth (Lmother-Sinfant)
62057539|NCT06379191|PLACEBO_COMPARATOR|usual care group|Upon admission, patients were provided with admission counselling, explained the complications associated with chemotherapy, and given a chemotherapy care booklet and a leaflet on diet and nutrition. Before discharge, the patients were given the nutritional guidebook again. Responsible nurses made one telephone follow-up visit between chemotherapy sessions.
62446118|NCT05621642|ACTIVE_COMPARATOR|Offline Group|The exercises will be video recorded gradually every two weeks and the exercise program of each week will be sent to the patient. The patient will do respiratory, balance and strengthening exercises accompanied by video.
62446119|NCT04480723|OTHER|Participants with Low or Intermediate Probability of PH|Participants who underwent a work-up for the suspicion of PH that includes transthoracic echocardiography (TTE) and who were considered to have a low or intermediate probability of PH according to TTE (local interpretation) will be enrolled. Blood samples will be taken and a cardiac magnetic resonance imaging (MRI) will be performed to evaluate the presence of Pulmonary Hypertension (PH). The TTEs that were performed by local standards will be collected and undergo central interpretation using European society of Cardiology / European respiratory society (ESC/ERS) guidelines to confirm the local interpretation.
62617406|NCT00386230|ACTIVE_COMPARATOR|4|Maternal ZDV treatment starting at 28 weeks Gestational Age (GA) and continuing through labor and delivery, and six weeks of infant ZDV treatment starting at birth (Lmother-Linfant). This study arm was the reference regimen.
62617407|NCT04848753|ACTIVE_COMPARATOR|Experimental Group|Toripalimab combined with cisplatin and paclitaxel
62617408|NCT04848753|PLACEBO_COMPARATOR|Control Group|Placebo combined with cisplatin and paclitaxel
62617409|NCT01309750||C. diff|Patients with Clostridium difficile colitis admitted to the intensive care unit will be the study group.
62617410|NCT01024361|NO_INTERVENTION|Routine|Routine protocol of the service
62617411|NCT01024361|EXPERIMENTAL|CPAP-DR|Infants randomized to this arm will have nasal CPAP installation at delivery room before the 15th minute of life
62617412|NCT04957199||Community|Individuals with or without COVID-19 in society
62617413|NCT02510820|ACTIVE_COMPARATOR|Synergi / comfilcon A|Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study.
62617414|NCT02510820|ACTIVE_COMPARATOR|Biotrue / comfilcon A|Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study.
62617415|NCT04352738||Healthy adults (group I)|
62617416|NCT04352738||Adults with type 1 diabetes (group II)|"* T1D for ≥2 years or evidence of undetectable C-peptide (\<100pmol/l with concomitant plasma glucose≥4.0mmol/l).~* HbA1c≤8.0mmol/l (64mmol/mol)."
62260817|NCT00400881|EXPERIMENTAL|Automatic tube compensation (ATC)|ATC is a new mode of ventilation being compared with traditional one (CPAP). ATC is a mode of ventilation of the same device (mechanical ventilator), not a new device. The pressure in this modes varies according the mechanical parameters of the respiratory system that are automatically calculated by this mode. This is the intervention arm.
62260818|NCT03278184|SHAM_COMPARATOR|tDCS sham motor cortex|25 participants will have sham stimulation for 20 minutes using transcranial direct current stimulation device.
62617417|NCT04352738||Adults after bariatric surgery (group III)|"* Female.~* Bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) ≥1 year ago.~* Lack of a history of diabetes or pre-diabetes (HbA1c≤5.6% in the absence of anaemia)."
62617418|NCT02003989||patients|HIV patients infected for more than ten years with undetectable viral load, undergoing ophthalmologic examination and MRI
62617419|NCT02003989||control|non HIV patients (same gender and age) undergoing ophthalmologic examination and MRI
62617420|NCT02986347|ACTIVE_COMPARATOR|Intravenous regional anesthesia (Bier)|The anesthetic technique described by Bier will be done by the anesthesiologist. The following steps were followed: 1)Placement double tourniquet on the proximal portion of the arm 2)Asepsis and antisepsis of the operative limb 3)Puncture and venous catheterization most distal in the limb 4)Elevation of limb for 1 to 2 minutes, next the limb will be spirally wrapped with Esmarch from the distal to proximal 5)The proximal cuff will be inflated 6)Withdrawal of Esmarch and injection of 40ml of lidocaine without epinephrine at 0.5% 7)Removal the canula until the distal cuff is inflated and the proximal cuff is emptied 8)Removal of the club must be done after the surgery, at least 40 minutes after the injection of the anesthetic.
62617421|NCT02986347|ACTIVE_COMPARATOR|Local anesthesia with adrenaline|Patients will be anesthetized by surgeons, who are familiar with the technique described by Lalonde. Around thirty minutes before surgery, will be infused with 20 ml of an anesthetic solution. The infiltrated solution is composed of 1% lidocaine with epinephrine in 1: 100,000. Initially 10 mL of the solution will be applied slowly in the flexion fold region of the wrist just below the skin and subfascial plane. The needle is moved slowly. The needle is then redirected to the radial side of the proximal palmar region for infiltration of another 2-3 mL of the subcutaneous solution. The remaining 7-8mL in the subdermal plane and anterior to the transverse carpal ligament.
62617422|NCT06463379|EXPERIMENTAL|pulse steroid|108 patients will receive 125 mg solumedrol intravenous pulse for 2 consecutive days plus their concomitant medication.
62057540|NCT06379191|EXPERIMENTAL|Intervention group|"Patients were instructed to search for the Good Nutrition applet on WeChat and added it to their My Applets for easy access. The patient was informed of the users' nameand password. The patient was introduced to the main functional sections of the applet and the content settings of each section to become familiar with the applet. Patients were invited to join our nutrition management group chat. At the same time, patients were allowed to choose to have a private chat with a member of the nutrition management team via WeChat at any time."
62057541|NCT02907814|EXPERIMENTAL|Uveitis and Cataract Imaging Group|Subjects will undergo up to three optical coherence tomography scans.
62057542|NCT02907814|EXPERIMENTAL|Control|Control subjects will undergo a brief, non-contact eye exam and then undergo up to three optical coherence tomography scans.
62057543|NCT01696448|EXPERIMENTAL|Experimental Group|CAR-191: Berberine 200mg, Alpha-lipoic Acid 150mg, Picrorhiza 100mg each in a separate capsule, to be taken 3 times a day, 30 minutes before breakfast, lunch and dinner. Total 9 capsules per day.
62057544|NCT01696448|PLACEBO_COMPARATOR|Control Group|3 placebo capsules, to be taken 3 times a day, 30 minutes before breakfast, lunch and dinner. Total 9 capsules per day.
62057545|NCT00006002|EXPERIMENTAL|Arm B|dexamethasone followed by SU5416 done twice weekly (Monday and Thursday or Tuesday and Friday) every week for 4 weeks (a total of 8 doses). Four weeks of treatment (8 doses) is considered 1 cycle of treatment if tumor grows.
62057546|NCT00006002|EXPERIMENTAL|Arm A|SU5416 done twice weekly (Monday and Thursday or Tuesday and Friday) every week for 4 weeks (a total of 8 doses). Four weeks of treatment (8 doses) is considered 1 cycle of treatment
62057547|NCT05227755|ACTIVE_COMPARATOR|Whey protein isolate|Participants will receive 120 mls of whey protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
62057548|NCT05227755|EXPERIMENTAL|Soy protein isolate|Participants will receive 120 mls of soy protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
62057549|NCT00483834|EXPERIMENTAL|Bevacizumab, Irinotecan and Capecitabine|Evaluate the efficacy and toxicity of bevacizumab, irinotecan and capecitabine as first-line treatment for patients with metastatic colorectal cancer
62057550|NCT06447350|ACTIVE_COMPARATOR|control (MI)|A motivational Interview will be conducted with participant.
62260819|NCT03278184|ACTIVE_COMPARATOR|Active motor cortex stimulation|25 participants will have active stimulation targeting the left motor cortex for 20 minutes using transcranial direct current stimulation device.
62057551|NCT06447350|EXPERIMENTAL|IH|motivational Interview + IH task
62057552|NCT06447350|EXPERIMENTAL|SIM|motivational Interview + SIM task
62057553|NCT06447350|EXPERIMENTAL|MM|motivational Interview + MM task
62057554|NCT03727009||Hematologic Malignancy|Subjects with clinically confirmed hematologic malignancy and who are treatment naive will provide a blood sample at the time of enrollment. No additional blood draws will occur.
62260820|NCT03278184|ACTIVE_COMPARATOR|active prefrontal cortex stimulation|25 participants will have active stimulation targeting the left dorsolateral prefrontal cortex for 20 minutes using transcranial direct current stimulation device.
62260821|NCT01781715|EXPERIMENTAL|Multivessel stenting|This group comprises the patients who undergo a one-time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions
62260822|NCT01781715|ACTIVE_COMPARATOR|Staged revascularization|This group comprises the patients who undergo PCI of only the culprit lesion and staged nonculprit PCI at a later date (3-15 days)
62260823|NCT04320732||Individuals with COVID-19 infection|"Confirmed by routine laboratory diagnosis. All types of COVID-19 disease from asymptomatic carriers to hospitalized patients can be included.~Only subjects \>18 years old will be included in the study."
62260824|NCT04320732||Individuals tested for COVID-19 infection with negative test|Confirmed by routine laboratory diagnosis
62260825|NCT04320732||Healthy individuals|Recruitet from the general population
62260826|NCT04320732||Risk groups for COVID-19 exposure|Including, but not limited to healthcare workers.
62842924|NCT03916900|EXPERIMENTAL|Pulpotomy|"Group A (Experimental group) Pulpotomy:~The teeth will be anesthetized with 4% articaine 1:100,000 epinephrine (Artinibsa®; Inibsa Dental, Lliçà de Vall, Spain) by inferior alveolar nerve block.Under rubber dam isolation, pulpotomy will be performed with a large sterile round end bur in a high speed hand piece with copious irrigation; pulp tissue will be removed by a sharp spoon excavator to the orifice level. Hemostasis will be achieved by the application of a wet cotton pellet moistened with 2.5% NaOCL for 2 min and repeated if needed.~After hemostasis, Biodentine (Septodont, Saint Maur des Fausses, France) will be mixed according to the manufacturer's instructions and gently placed over the pulp to thickness of 2-3 mm.Biodentine will be covered by resin modified glass-ionomer and teeth will be restored using composite resin.A postoperative radiograph will be taken by parallel technique."
62260827|NCT04320732||Patients admitted to hospital|Without COVID-19 infection.
62260828|NCT01794611|EXPERIMENTAL|Laryngoscopy|Patients will be intubated by an experienced anesthesiologists. Anesthesiologist first uses Macintosh laryngoscope then KingsVision videolaryngoscope and lastly C-MAC videolaryngoscope to intubate patients. Cormack-Lehane scores, the time from the start of laryngoscopy to visualization of the vocal cords and the time from the visualization of the vocals from the successful intubation will be recorded. The success of the intubation will be assessed with bilateral chest auscultation. If visualization of the vocal cords or placing of the endotracheal tube was not successful after 60 seconds with a particular laryngoscope, it will be left out and patient will be ventilated for 1 minutes and then pass to other laryngoscopes.
62446120|NCT06113796||Robotic sphincter-preserving rectal resection|Patients with robotic anterior or low anterior rectal resection and primary anastomosis for rectal cancer.
62446121|NCT06113796||Robotic abdominoperineal rectal resection|Patients with robotic abdominoperineal rectal resection for rectal cancer.
62446122|NCT02410525|EXPERIMENTAL|[11C]PF-06427878|Single intravenous infusion of \[11C\]PF-06427878 in Periods 1, 2 and 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
62446123|NCT02410525|EXPERIMENTAL|PF-06427878 10 mg|Single oral dose of 10 mg PF-06427878 in Period 2 or 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
62446124|NCT02410525|EXPERIMENTAL|PF-06427878 600 mg|Single oral dose of 600 mg PF-06427878 in Period 2 or 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
62446125|NCT02832609|NO_INTERVENTION|sitting position|measurement in the sitting position
62446126|NCT02832609|ACTIVE_COMPARATOR|supine position|measurement in the sitting position
62446127|NCT04110522|EXPERIMENTAL|Intervention with Direct Access to Rheumatologist|Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions on how to directly schedule a rheumatologic evaluation
62446128|NCT04110522|EXPERIMENTAL|Intervention with Standard of Care Referral|Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions to talk with their doctor about a referral to a rheumatologist
62446129|NCT04110522|NO_INTERVENTION|Control|Psoriasis patients with no prior diagnosis of PsA randomized to not receive an intervention PsA questionnaire
62446130|NCT02253277|EXPERIMENTAL|Nilotinib and Ruxolitinib|The study included two strata, which were to be treated in parallel. The first stratum consisted of CML-patients in CP, which had been on nilotinib treatment before entering the study. These patients did not optimally respond to the previous treatment. The second stratum consisted of patients with CML in AP or BC and patients with relapsed/refractory Ph+ ALL and Ph+ ALL patients with MRD, with or without previous nilotinib treatment. Patients were treated with 300mg nilotinib BID during the escalation phase (12 months) with increasing doses of ruxolitinib. The dose expansion phase (12 months) began following the determination of the MTD of the combination and the decision to explore the cohort for confirmation of RPIID. In this phase, safety and tolerability of the MTD and/or potential RPIID was to be further evaluated, with the purpose of establishing that this dose is suitable for use in this patient group.
62446131|NCT04040010|EXPERIMENTAL|Postmenopausal women colostrum supplement|
62446132|NCT04040010|EXPERIMENTAL|Osteoporosis patients colostrum supplement|
62446133|NCT04040010|EXPERIMENTAL|Osteopenia patients colostrum supplement|
62446134|NCT04040010|PLACEBO_COMPARATOR|Postmenopausal women placebo|
62446135|NCT04040010|PLACEBO_COMPARATOR|Osteoporosis patients placebo|
62446136|NCT04040010|PLACEBO_COMPARATOR|Osteopenia patients placebo|
62617423|NCT06463379|PLACEBO_COMPARATOR|without pulse|107 patients will not receive any additional medications.
62617424|NCT04084899||Continuous Positive Airway Pressure|Patient treated with continuous positive airway pressure
62617425|NCT03046056|EXPERIMENTAL|Filgotinib 200 mg|Filgotinib 200 mg tablet + placebo to match (PTM) filgotinib 100 mg tablet for up to 27 weeks.
62617426|NCT03046056|EXPERIMENTAL|Filgotinib 100 mg|Filgotinib 100 mg tablet + PTM filgotinib 200 mg tablet for up to 26.3 weeks.
62617427|NCT03046056|PLACEBO_COMPARATOR|Placebo|PTM filgotinib 200 mg tablet + PTM filgotinib 100 mg tablet for up to 28.7 weeks.
62617428|NCT00742027|EXPERIMENTAL|Panobinostat|Participants received panobinostat 40 mg, capsules, orally, thrice every week (i.e. days 1, 3 and 5), in each cycle of 21 days until unacceptable toxicity, disease progression, start of new anti-cancer therapy or withdrawal of consent (up to approximately 48 months).
62617429|NCT04893187|EXPERIMENTAL|Part 1: Single Dose Escalation SSS17|Escalating doses of SSS17, single dose administration
62617430|NCT04893187|PLACEBO_COMPARATOR|Part 1: Single Dose Escalation matching Placebo|Escalating doses of matching placebo, single dose administration
62617431|NCT04893187|EXPERIMENTAL|Part 2: Multiple Dose Escalation SSS17|Escalating doses of SSS17, multiple dose administration
62617432|NCT04893187|PLACEBO_COMPARATOR|Part 2: Multiple Dose Escalation matching Placebo|Escalating doses of matching placebo, multiple dose administration
62617433|NCT04893187|EXPERIMENTAL|Part 3: Treatment Sequence 1 (A to B)|The subjects in the first cycle received oral administration of SSS17 on an empty stomach, and subjects in the second cycle received oral administration of SSS17 after a high-fat meal
62617434|NCT04893187|EXPERIMENTAL|Part 3: Treatment Sequence 2 (B to A)|The subjects in the first cycle received oral administration of SSS17 after a high-fat meal, and the subjects in the second cycle received oral administration of SSS17 on an empty stomach
62617435|NCT03437161|EXPERIMENTAL|Radiation Therapy (RT)|Patients attend a simulation visit and undergo two CT scans, one in the prone position and one in the supine position with DIBH. Within 1 week after the simulation visit, patients undergo radiation therapy either in the supine position with DIBH or in the prone position daily for 15-30 consecutive days as per physician's prescription.
62842925|NCT03916900|ACTIVE_COMPARATOR|Root canal treatment|"Group B (control group) Root canal treatment:~The teeth were anesthetized with 4% articaine 1:100,000 epinephrine (Artinibsa®; Inibsa Dental, Lliçà de Vall, Spain).Under rubber dam isolation, root canal treatment will be performed in single visit.Working length will be determined using stainless steel k-files (Mani, Inc.) keeping 0.5 to 1.0 mm short of the apex using a RootZX apex locator (J. Morita, Irvine, CA) and confirmed radiographically. Mechanical preparation will be achieved by a crown-down technique using using the M-PRO system (IMD, Shanghai, China) and irrigation with 5 mL 2.5% NaOCl between instruments.Obturation will be done with gutta-percha (Meta Biomed Co. Ltd, Cheongwongun, Chungbuk, Korea) and resin sealer ADseal (Meta Biomed CO., LTD, Korea) using cold lateral condensation technique and restored with composite resin with a base of glass-ionomer cement. A postoperative radiograph will be taken by parallel technique."
62057555|NCT02863211||Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease|One-thousand women 55 years of age or older will be recruited to be screened through the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease protocol. This involves the cardiovascular assessment of resting blood pressure, blood pressure response to 3-min of moderate intensity exercise and large and small arterial elasticity. The participants will be classified into risk categories based on these measures. The incidence of the following adverse cardiovascular outcomes will be assessed in the five-year period after screening in both groups: Ischemic heart disease, acute myocardial infarction, stroke, percutaneous coronary intervention, coronary bypass surgery, congestive heart failure, and hypertension.
62057556|NCT00695786|EXPERIMENTAL|Schedule A (lenalidomide, rituximab)|Participants receive lenalidomide PO on days 1-21 and rituximab IV over 4-8 hours on day 1 of courses 1-12. Courses repeat every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity
62617436|NCT05930405|EXPERIMENTAL|programmed intermittent epidural bolus group|All subjects received a standardised epidural solution containing 0.2% ropivacaine and 0.4（male）/0.3（famale）μg/ml sufentanil. The PIEB group is programmed for intermittent infusion with （0.1\*kg）ml pumped every two hours. The lockout time for both groups is 60 min.
62617437|NCT05930405|ACTIVE_COMPARATOR|continuous epidural infusion group|All subjects received a standardised epidural solution containing 0.2% ropivacaine and 0.4（male）/0.3（famale）μg/ml sufentanil. The CEI group was infused continuously at a rate of （0.05\*kg）ml/h. The lockout time for both groups was 60 min.
62617438|NCT01660802|EXPERIMENTAL|700 μg Dexamethasone|700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
62617439|NCT01660802|SHAM_COMPARATOR|Sham|Sham administered in the study eye on Day 1.
62617440|NCT01734083|EXPERIMENTAL|Whole body vibration exercise|The experimental group will receive 2 sessions of whole body vibration exercise training and conventional exercise per week for a period of 9 weeks. The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration frequency and amplitude used will be 30 Hz and 1 mm, respectively.
62617441|NCT01734083|ACTIVE_COMPARATOR|Conventional exercise|This group will receive 2 sessions of conventional exercise training per week for a period of 9 weeks.
62617442|NCT00703118|EXPERIMENTAL|Group A: T12/PR48|Participants will receive 12 weeks of 750 mg telaprevir eight hourly followed by 4 weeks of Placebo in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
62617443|NCT00703118|EXPERIMENTAL|Group B: T12(DS)/PR48|Participants will receive 4 weeks of Placebo followed by 12 weeks of 750 mg telaprevir eight hourly in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
62617444|NCT00703118|EXPERIMENTAL|Group C: Pbo/PR48|Participants will receive placebo in combination with Peg- IFN-alfa-2a and ribavirin for 16 weeks. Participants will receive Peg- IFN-alfa-2a and ribavirin for next 32 weeks.
62617445|NCT03765229|EXPERIMENTAL|Single Arm: Entinostat + Pembrolizumab|Subjects in this trial will be administered entinostat, 5mg PO, once weekly (D1, D8, D15 of a 21-day cycle) starting on day 1 of study treatment. Pembrolizumab, 200 mg will be administered intravenously (IV) every 3 weeks and initiated at cycle 2 after the mandatory research tumor biopsy in the end of cycle 1, beginning of cycle 2 (day 21±2 days),. Combination therapy with both agents will continue if subject is receiving clinical benefit from therapy for up to 27 weeks (8 cycles of combination therapy or approximately 6 months). Study therapy will be discontinued for intolerable toxicity, disease progression or for other reasons at the discretion of the investigator.
62260829|NCT03462576|EXPERIMENTAL|Emricasan 25mg|The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.
62842926|NCT05226494|EXPERIMENTAL|Treatment (fb-PMT)|Daily subcutaneous injection of fb-PMT in four escalating cohorts to determine maximum tolerated dose, followed by treatment of up to 10 additional patients at maximum tolerated dose.
62842927|NCT05418543|EXPERIMENTAL|EUS-FNA|
62842928|NCT05418543|EXPERIMENTAL|CH-EUS-FNA|
62842929|NCT01033799|SHAM_COMPARATOR|Control Product|
62260830|NCT03462576|EXPERIMENTAL|Emricasan 5mg|The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.
62842930|NCT01033799|ACTIVE_COMPARATOR|Tested Product|
62842931|NCT04106206|EXPERIMENTAL|LY3372689|LY3372689 administered orally
62842932|NCT04106206|PLACEBO_COMPARATOR|Placebo|Placebo administered orally
62842933|NCT00643162|EXPERIMENTAL|Swedish Massage|Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.
62842934|NCT00643162|SHAM_COMPARATOR|Light-Touch|Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.
62260831|NCT03462576|PLACEBO_COMPARATOR|Placebo|The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.
62260832|NCT00950768|ACTIVE_COMPARATOR|Mel100|
62446137|NCT05849610|EXPERIMENTAL|Induction VRD-Dara + Intensification Tec-Dara + Maintenance Tec-Dara + ERI Tal-Dara|"Induction (4 cycles) D-VRD. After Induction, all patients recieve 1st INTENSIFICATION treatment (6 cycles of Tec-Dara). Cycles will be of 28 days (4-week cycles) in duration for daratumumab and for Teclistamab. At the end of 1st Intensification timepoint treatments depends on MRD status:~1. MRD negative patients in CR at the end of Intensification will receive MAINTENANCE therapy with Tec-Dara continuously for 2 years. Crossover: patients who convert MRD positive or relapse from CR any time during Teclistamab maintenance will receive the same treatment as MRD positive individuals (early rescue intervention, ERI).~2. MRD positive patients or patients who didn't achieve CR despite MRD negativity, will have ERI (Tal-Dara 6 cycles). MRD and response will be evaluated again after 6 cycles treatment with Tal-Dara. MRD negative patients in CR will receive continuous treatment with Tal-Dara for 2 years."
62446138|NCT04310410|EXPERIMENTAL|Combined Focused Ultrasound and Radiotherapy|Combination of focused ultrasound and external beam radiotherapy
62446139|NCT05117892|EXPERIMENTAL|Trained vendors|"The intervention consists of a Training, Certification and Marketing scheme for dairy vendors operating in the informal sector. This scheme includes a 12hr training offered at the beginning of the study, followed by 2 quarterly visits where milk will be tested for microbiological quality and results will be discussed with participants.~The training will include three main components: (i) milk hygiene and quality; (ii) business skills; (iii) milk marketing.~Trainings will be offered free of charge. The trainings will be given by business development service (BDS) providers, who will be trained through a training of trainers ahead of the intervention. Quarterly visits will involve the collection of a milk sample from each participant in the experimental arm in an unannounced visit and results on the microbiological quality of the milk reported back individually and explained to each vendor"
62446140|NCT05117892|NO_INTERVENTION|Untrained vendors|Participants in the no-intervention arm will receive the same unannounced quarterly visits, where milk will be sampled and tested for microbiological quality, but results will not be shared with the participants. The participants in this arm will only receive the training upon completion of the endline survey (i.e. when the study is finished)
62446141|NCT04568447|EXPERIMENTAL|IMOOVE|Patients will undergo IMOOVE® treatment for 6 weeks, two times per week for a total of 12 treatments.
62446142|NCT05038813|EXPERIMENTAL|Anlotinib combined with TQB2450|Anlotinib: 12mg, capsule, once a day. TQB2450: 1200mg, Injection, Once every three weeks.
62446143|NCT05933096|EXPERIMENTAL|Breakfast 1|Breakfast 1 is composed of 500 ml of water, mixed with 50 mg of ICG
62446144|NCT05933096|EXPERIMENTAL|Breakfast 2|Breakfast 2 is composed of 200ml of yoghurt, mixed with 50 mg of ICG
62446145|NCT05933096|EXPERIMENTAL|Breakfast 3|Breakfast 3 is composed of two slices white toast, two fried eggs and 30 g of jam, mixed with 50 mg of ICG
62842935|NCT00773604|OTHER|Treatment|Deep Brain Stimulation
62842936|NCT01286051|ACTIVE_COMPARATOR|Follistim|standard treatment
62260833|NCT00950768|EXPERIMENTAL|Mel200|
62260834|NCT04123782|ACTIVE_COMPARATOR|Group A (F-ESWT group)|3 sessions, one per week, of electromagnetic focused extracorporeal shockwave treatment (3000 impulses at 0.12 mJ/mm2 per session)
62842937|NCT01286051|EXPERIMENTAL|Follistim plus single ganirelix injection|
62842938|NCT05475730|EXPERIMENTAL|Bone regeneration|Minimally invasive horizontal bone augmentation using hyaluronic acid, deproteinized bovine bone and dermal matrix.
62842939|NCT06248775|OTHER|Nursing prehabilitation intervention group|Patients all undergo the intervention aimed at lifestyle improvement and glucose regulation
62842940|NCT01694498|ACTIVE_COMPARATOR|A. Desmopressin 25 µg|1 orally disintegrating tablet every night during study period
62842941|NCT01694498|ACTIVE_COMPARATOR|B. Desmopressin 50 µg|1 orally disintegrating tablet every night during study period
62842942|NCT01694498|PLACEBO_COMPARATOR|C. Placebo|1 orally disintegrating tablet every night during study period
62842943|NCT04354636|EXPERIMENTAL|Silver modified atraumatic restorative treatment|Using silver diamine fluoride incorporated with atraumatic restorative treatment
62842944|NCT04354636|ACTIVE_COMPARATOR|Atraumatic restorative treatment|Using atraumatic restorative treatment without the application of silver diamine fluoride
62842945|NCT04363424||Validation cohort|Patients with alcoholic cirrhosis with reliable self-reported alcohol use.
62842946|NCT04363424||Clinical application cohort|Patients with alcoholic cirrhosis who deny moderate or excessive alcohol use in the previous 3 months.
62842947|NCT01344525|NO_INTERVENTION|Control group|Nutritional counselings every 6 months, no further intervention
62842948|NCT01344525|EXPERIMENTAL|"low-calorie-diet (LCD)-based lifestyle intervention"|12 months multidisciplinary weight loss program including three months low-calorie formula diet (800 kcal) (OPTIFAST®52 program)
62842949|NCT01344525|EXPERIMENTAL|Laparoscopic gastric sleeve intervention|
62842950|NCT01344525|EXPERIMENTAL|Conventional bariatric surgery|Gastric Banding and Gastric Bypass
62842951|NCT03068585|EXPERIMENTAL|Neovasculgen|DNA encoding the 165-amino-acid isoform of human vascular endothelial growth factor (pCMV - VEGF165)
62842952|NCT03068585|NO_INTERVENTION|Control|Control therapy
62842953|NCT05829369|EXPERIMENTAL|Intrinsic foot muscle exercise|This group will perform intrinsic foot muscle strengthening exercises
62842954|NCT05829369|ACTIVE_COMPARATOR|Minimal Footwear|This group will perform prescribed walking in and daily wear of minimally cushioned footwear
62842955|NCT05829369|SHAM_COMPARATOR|Control|This group will be given a falls prevention brochure and seated upper extremity and lower extremity active range of motion activities.
62842956|NCT04986514||Patients with systemic sclerosis|
62842957|NCT06423274||artificial intelligence-assisted fundus photography|Artificial intelligence-assisted fundus photography in patients with diabetic retinopathy
62842958|NCT06423274||optical coherence tomography|optical coherence tomography in patients with diabetic retinopathy
62842959|NCT06423274||fundus fluorescence angiography|fundus fluorescence angiography in patients with diabetic retinopathy
62842960|NCT04028401|EXPERIMENTAL|5 % benzoyl peroxide topical treatment|Application of 5% benzoyl peroxide
62842961|NCT04028401|NO_INTERVENTION|No topical treatment|No intervention
62446146|NCT06192082|EXPERIMENTAL|The conscious sedation group|conscious sedation
62842962|NCT01169818|EXPERIMENTAL|Intervention group|Initiation on a fixed dose of insulin glargine, then subjects will self-adjusted their basal insulin dose every 3 days
62842963|NCT01169818|ACTIVE_COMPARATOR|Usual standard of care group|Initiation on a fixed dose of insulin glargine, then basal insulin dose is adjusted at each visit by a physician
62842964|NCT03620877|EXPERIMENTAL|personalized intervention|Personalized intervention by a preventive nurse, relying on validated prevention models, in improving participation in the colonoscopic screening of siblings
62842965|NCT00973232|EXPERIMENTAL|Part A, Arm A|
62842966|NCT00973232|EXPERIMENTAL|Part A, Arm B|
62842967|NCT00973232|ACTIVE_COMPARATOR|Part A, Arm C|
62842968|NCT00973232|ACTIVE_COMPARATOR|Part A, Arm D|
62842969|NCT00973232|EXPERIMENTAL|Part B, Arm E|
62842970|NCT00973232|ACTIVE_COMPARATOR|Part B, Arm F|
62842971|NCT00973232|ACTIVE_COMPARATOR|Part B, Arm G|
62842972|NCT05150899||Tamsulosin 0.4mg|group A receive Tamsulosin 0.4mg in combination of NSAI drug if patient present with colic, if not in renal colic at bed time Tamsulosin 0.4mg with analgesic on demand.
62842973|NCT05150899||fexofenadine 180 mg in combination of Tamsulosin 0.4mg|group B receive pheniramine maleate 50mg injection every 12hr for 24 hr in combination of Tamsulosin 0.4mg and NSAI drug then fexofenadine 180 mg in combination of Tamsulosin 0.4mg and NSAI drug on demand if patient present with colic. if not in renal colic at bed time fexofenadine 180 mg in combination of Tamsulosin with NSAI on demand.
62260835|NCT04123782|PLACEBO_COMPARATOR|Group B (placebo group)|3 sessions, one per week, of electromagnetic focused extracorporeal shockwave treatment (3000 impulses at 0.01 mJ/mm2 per session)
62842974|NCT00947882|PLACEBO_COMPARATOR|Placebo|
62842975|NCT00947882|EXPERIMENTAL|Degarelix 10 mg|
62842976|NCT00947882|EXPERIMENTAL|Degarelix 20 mg|
62842977|NCT00947882|EXPERIMENTAL|Degarelix 30 mg|
62842978|NCT00545259|EXPERIMENTAL|1|AEB071
62842979|NCT03290599||No Post operative cognitive dysfunction|Patients who did not have any change or a change less than 4 points between MMT1 and MMT3
62842980|NCT03290599||Post operative cognitive dysfunction|Patients with a difference more than 4 points between MMT1 and MMT3
62842981|NCT03073941|ACTIVE_COMPARATOR|Persona CR Total Knee System|All patients randomized into this group will have the Intervention: Persona total knee system
62842982|NCT03073941|ACTIVE_COMPARATOR|NexGen CR Total Knee System|All patients randomized into this group will have the Intervention: Nexgen total knee system
62842983|NCT05214820|EXPERIMENTAL|Single arm with 68Ga-PSMA|All participants will undergo a PET scan with 68Ga-PSMA
62842984|NCT02843516||patients with stroke|patients with stroke
62842985|NCT02843516||patients without stroke|patients without stroke
62842986|NCT02239549|EXPERIMENTAL|Jumbo cold forceps polypectomy group|Polypectomy conducted with jumbo cold forceps
62842987|NCT02239549|EXPERIMENTAL|Cold snare polypectomy group|Polypectomy conducted with cold snare
62842988|NCT02820766||Journey II BCS Knee|Physical Therapy Observational
62260836|NCT05358756|EXPERIMENTAL|Treatment A :Fasted|A single adminstration of SACT-1 (150 mg rilpivirine oral suspension) after a supervised overnight fast of at least 10 hours.
62842989|NCT02820766||All Other Posterior Stabilized Knees|Physical Therapy Observational
62842990|NCT04532606|EXPERIMENTAL|Remimazolam group|Remimazolam is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain Bispectral Index (BIS) value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
62842991|NCT04532606|ACTIVE_COMPARATOR|Propofol group|Propofol is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
62842992|NCT04685889|ACTIVE_COMPARATOR|Icon Group|Icon® resin infiltration treatment was performed on 58 permanent central teeth with MIH and evaluated before; immediately after; and 1, 3, and 6 months after the procedure.
62617446|NCT03230838|EXPERIMENTAL|Ceftolozane/Tazobactam|Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum 1 g and 0.5 g/dose) administered intravenously (IV) every 8 hours for 7-14 days
62617447|NCT03230838|ACTIVE_COMPARATOR|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for 7-14 days
62617448|NCT03278847||Enteral nutrition comparison|This comparison refers to differences in enteral nutrition during therapeutic hypothermia
62617449|NCT03278847||Parenteral nutrition comparison|This comparison refers to differences in parenteral nutrition during therapeutic hypothermia
62617450|NCT05828797||Shoulder elastography on the hemiplegic side of patients|Patients over the age of 18 who apply to our clinic and have hemiplegia complaints will be evaluated. Patients' age, gender, occupation, habits, disease duration, upper extremity with complaints, dominant upper extremity, additional disease, weight and height values will be recorded. In the physical medicine and rehabilitation department examination of the patients, the patients will be evaluated with the brunnstrom staging used in hemiplegic patients. The elastography of the shoulder on the side with hemiplegia and the elastography of the shoulder on the side without complaints will be examined. Thus, the patient's side with the complaint will be checked by comparing the healthy side.
62617451|NCT05828797||Shoulder elastography on the non-hemiplegia side of patients|Patients over the age of 18 who apply to our clinic and have hemiplegia complaints will be evaluated. Patients' age, gender, occupation, habits, disease duration, upper extremity with complaints, dominant upper extremity, additional disease, weight and height values will be recorded. In the physical medicine and rehabilitation department examination of the patients, the patients will be evaluated with the brunnstrom staging used in hemiplegic patients. The elastography of the shoulder on the side with hemiplegia and the elastography of the shoulder on the side without complaints will be examined. Thus, the patient's side with the complaint will be checked by comparing the healthy side.
62617452|NCT02634944|EXPERIMENTAL|mTBI|mTBI (concussed) participants will be administered the VOMS after concussive event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
62617453|NCT02634944|SHAM_COMPARATOR|Healthy Control|Healthy controls will be administered the VOMS tool. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
62617454|NCT02634944|EXPERIMENTAL|BLAST mTBI|Blast mTBI (concussed) participants will be administered the VOMS after concussive blast event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
62617455|NCT02634944|EXPERIMENTAL|BLUNT mTBI|Blunt mTBI (concussed) participants will be administered the VOMS after concussive blunt event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
62617456|NCT06455345|EXPERIMENTAL|Self-guided Online ACT|The intervention is a self-guided ACT program delivered on an online platform. The program is developed based on the psychologist-guided ACT group intervention for chronic pain and opioid use after surgery.
62617457|NCT06455345|ACTIVE_COMPARATOR|Psychologist-guided Online ACT|The psychologist-guided ACT group workshop is an evidence-based psychology intervention for chronic pain and opioid use after surgery.
62617458|NCT00523523|EXPERIMENTAL|A|This group will complete a 2 week program of functional task practice with auditory rhythm cuing.
62617459|NCT00523523|ACTIVE_COMPARATOR|F|This group will complete a 2 week program of functional task practice without auditory rhythm cuing.
62617460|NCT01313221|ACTIVE_COMPARATOR|Etanercept 50 mg BIW|Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg etanercept twice weekly for 12 weeks.
62617461|NCT01313221|EXPERIMENTAL|Etanercept 50 mg QW + Topical|Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg etanercept once weekly plus as needed topical agents.
62617462|NCT05837702|EXPERIMENTAL|Erector Spinae Plane Block (ESPB)|The spinous processes of the vertebrae were marked up to T8 level. After providing antisepsis of the skin with 10% povidone iodine, the ultrasound probe was placed at T8 level parallel to the vertebral spine at T8. The transverse process (TP) and hyperechoic pleura were observed 2.5cm right lateral of the spinous process. Using the in-plane approach, the needle was placed in the caudal direction. After confirming displacement of the pleura with 0.5-1ml local anaesthetic (LA), 20ml 0.25% bupivacaine was administered for the block .
62842993|NCT04685889|NO_INTERVENTION|Control Group|No treatment was performed on healthy teeth. However, similar to the treated teeth, 58 healthy permanent central teeth of the same individuals were evaluated before; immediately after; and 1, 3, and 6 months after the procedure.
62842994|NCT01747291||Atypical femur fracture cohort|
62446147|NCT06192082|ACTIVE_COMPARATOR|Intravenous general anesthesia group|Intravenous general anesthesia
62842995|NCT03436290|EXPERIMENTAL|Palliative Care Intervention|
62842996|NCT03436290|NO_INTERVENTION|Standard of Care|
62842997|NCT02736318|EXPERIMENTAL|processed osteochondral allograft|Implantation of 1 to 3 osteochondral products in osteochondral lesion of talus.
62842998|NCT04615052|EXPERIMENTAL|Exercise group|
62842999|NCT04615052|NO_INTERVENTION|Control group|The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels.
62843000|NCT05855148||Lung Transplant Candidates|patients enlisted for lung transplant
62843001|NCT01317277|EXPERIMENTAL|Personalized Reminder Texting (iTAB) + Psychoeducation|Participants in the individualized Texting for Adherence Building (iTAB) arm will receive daily text messaging reminders for antiretroviral medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Participants will also receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV medications.
62843002|NCT01317277|ACTIVE_COMPARATOR|Psychoeducation (CTRL)|Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV medications. They will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.
62843003|NCT05363306||thin crestal mucosa|Based upon vertical mucosa thickness measured at implant placement, implants were placed: 2mm below the crestal bone in presence of thin mucosa (\< 2.5mm)
62843004|NCT05363306||medium crestal mucosa|Based upon vertical mucosa thickness measured at implant placement, implants were placed: 2) 1mm below the crestal bone in presence of medium mucosa (2.5-3.5mm);
62843005|NCT05363306||thick crestal mucosa|Based upon vertical mucosa thickness measured at implant placement, implants were placed: 1) at crestal level in presence of thick mucosa (\> 3.5 mm);
62446148|NCT01508026|EXPERIMENTAL|Nebivolol and Valsartan Fixed Dose Combination 1|Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg
62446149|NCT01508026|EXPERIMENTAL|Nebivolol and Valsartan Fixed Dose Combination 2|Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg
62446150|NCT01508026|EXPERIMENTAL|Nebivolol and Valsartan Fixed Dose Combination 3|Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg
62446151|NCT01508026|EXPERIMENTAL|Nebivolol Low Dose|Nebivolol Monotherapy 5 mg
62446152|NCT01508026|EXPERIMENTAL|Nebivolol High Dose|Nebivolol Monotherapy 20 mg
62446153|NCT01508026|EXPERIMENTAL|Valsartan Low Dose|Valsartan Monotherapy 80 mg
62446154|NCT01508026|EXPERIMENTAL|Valsartan High Dose|Valsartan Monotherapy 160 mg
62446155|NCT01508026|PLACEBO_COMPARATOR|Placebo|Dose Matched placebo
62446156|NCT00939445|ACTIVE_COMPARATOR|Online HDF|Online HDF
62446157|NCT00939445|ACTIVE_COMPARATOR|Short Daily Hemodialysis|Short Daily Hemodialysis
62446158|NCT05634187||Patients suffering from symptoms suggestive for gastroesophageal reflux disease|Patients suffering from dysphasia, heartburn, laryngitis or pharyngitis suggestive for gastroesophageal reflux disease
62446159|NCT05433428|EXPERIMENTAL|Cataract patients with dry eye - standard treatment|Standard pre and postop medication, preservative eye drops.
62446160|NCT05433428|OTHER|Cataract patients with dry eye - intensive treatment|More prolonged use of lubricant eye drops as well as the use of preservative free eye drops.
62446161|NCT05433428|OTHER|Cataract patients without dry eye disease / control group|Standard pre and postop medication, control group.
62446162|NCT01046253|EXPERIMENTAL|Investigational Test Product|Lansoprazole 30 mg Delayed-Release Capsule
62446163|NCT01046253|ACTIVE_COMPARATOR|Reference Listed Drug|Prevacid® 30 mg Delayed-Release Capsule
62446164|NCT02174939|ACTIVE_COMPARATOR|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
62446165|NCT02174939|PLACEBO_COMPARATOR|Dummy Placebo|One tablet twice per day for 12 weeks
62446166|NCT02185781|EXPERIMENTAL|Autologous NK Cells infusions|
62446167|NCT02062047|EXPERIMENTAL|FMSRP+CLX|Full-mouth scaling and root planing in a maximum of 24 hours, application and irrigation of chlorhexidine 2% gel, rinsing chlorhexidine 0.12% solution during 60 days
62446168|NCT02062047|PLACEBO_COMPARATOR|FMSRP + placebo group|Full-mouth scaling and root planing in a maximum of 24 hours, application and irrigation of placebo, rinsing placebo solution during 60 days
62446169|NCT02062047|ACTIVE_COMPARATOR|PMSRP group|Partial-mouth scaling and root planing in 4-6 sessions in a maximum of 2 weeks
62446170|NCT05164549|EXPERIMENTAL|XR-Bup|Extended-Release Buprenorphine, monthly, 300mg or 100mg
62446171|NCT05164549|ACTIVE_COMPARATOR|Bup/Met|Standard of Care; either Buprenorphine (including Subutex, Suboxone \& Espranor) or Methadone (Participant Preference).
62446172|NCT05164549|EXPERIMENTAL|XR-Bup + PSI|Extended-Release Buprenorphine, monthly, 300mg or 100mg + Personalised Psychosocial Intervention (PSI)
62446173|NCT05164549|ACTIVE_COMPARATOR|Bup/Met + PSI|Standard of Care; either Buprenorphine (including Subutex, Suboxone \& Espranor) or Methadone (Participant Preference) + Personalised Psychosocial Intervention (PSI)
62446174|NCT03486613|OTHER|Group AT|PROM registration via the DANBIO App on a smartphone and thereafter the touch screen solution
62446175|NCT03486613|OTHER|Group TA|PROM registration via the touch screen solution and thereafter the DANBIO App
62446176|NCT02034799|OTHER|Standard of Care (SoC)|Standard of Care (SoC) include any active or inactive adjunctive treatment to hemostasis methods currently used based on each surgeons surgical practice except for the use of other fibrin sealants.
62446177|NCT02034799|EXPERIMENTAL|Bioseal Fibrin Sealant|A porcine-derived fibrin sealant consisting of thrombin and fibrinogen
62057557|NCT00695786|EXPERIMENTAL|Schedule B (lenalidomide, rituximab)|Participants receive lenalidomide PO on days 2-22 and rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of course 1 and on day 1 of all subsequent courses. Courses repeat every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62057558|NCT04458623|ACTIVE_COMPARATOR|positive air test|postoperative in the recovery room.patients received supplemental oxygen through a venture mask with a jet and flow adjusted to a theoretical fio2 of 100% for 10 min. The Air-Test was then performed by removing the oxygen mask and leaving the patients breathing room air for 10 min while continuously monitoring SpO2 with a pulse oximeter finger probe. The Air-Test result was considered positive when the recorded SpO2 was ≤96%.
62446178|NCT00192699||Group 1: Cemented Bi-Metric femoral stem|Cemented Bi-Metric femoral stem
62843006|NCT06335563|EXPERIMENTAL|AR glasses-assisted pulmonary nodule puncture localization|Combined with placing positioning marks on the patient's body surface and tracing the needle entry point with the assistance of a CT scan gantry laser. Disinfect the area around the puncture needle point, and use 2% lidocaine for local infiltration anesthesia. The doctor wears augmented reality (AR) glasses, completes the connection between the AR glasses and the puncture target, and clicks on the puncture point plane through the puncture target needle tip. Calibrate the puncture position at any two points. After confirming that the patient has held his breath, quickly puncture the needle into the pleura and advance it to the planned puncture position according to the screen prompts. After the second CT scan is performed to confirm that the puncture needle is positioned at a reasonable position, the positioning hook wire is released and the puncture needle sheath is withdrawn.
62843007|NCT06335563|ACTIVE_COMPARATOR|CT-guided pulmonary nodule puncture localization|Positioning markers are placed on the patient's surface and the first CT scan is performed. The needle insertion point and needle insertion depth are designed based on the two-dimensional CT scan image and the positioning marks. The location of the needle entry point was traced with the laser assistance of the CT gantry. Disinfect and puncture around the needle point, and use 2% lidocaine for local infiltration anesthesia. According to the designed needle path angle, the needle is first inserted under the skin, and a second CT scan is performed to confirm that the extension line of the puncture needle is within the nodule range. Then the needle is inserted to the target depth, and the third CT scan is performed. After confirming that the puncture needle is positioned at a reasonable position, the positioning hook wire is released and the puncture needle sheath is withdrawn.
62843008|NCT02212691||Sickle cell disease|Patients diagnosed with sickle cell disease
62843009|NCT02212691||Healthy control|Healthy individuals recruited through fliers and have no history of cognitive disorders
62843010|NCT05290285|EXPERIMENTAL|EAA supplementation|"The EAA blend consists of a complex blend of essential amino acids, including some precursors of neurotransmitters that are important for regulating mood. In particular, phenylalanine, a precursor of tyrosine (non-essential amino acid) is involved in the biosynthesis of catecholamines (noradrenaline, adrenaline, dopamine) and tryptophan is the precursor of serotonin. Furthermore, the amino acids present in the mixture and the precursors of the Krebs cycle (citrate, malate, succinate) are able to stimulate mitochondrial bioenergetics by improving metabolism and muscle function.~The EAA blend will be administered orally at 4.5 g twice daily (two sachets of Amino-Ther Pro per day)."
62843011|NCT05290285|PLACEBO_COMPARATOR|Placebo|Placebo is an isocaloric product containing maltodextrins instead of amino acids (Acquilani et al., 2011). The placebo will be administered orally 4.5 g twice daily.
62843012|NCT02824796|EXPERIMENTAL|Schema Parent Behavioral Training|An enhanced protocol which combines a Schema Focused Therapy (SFT) and Behavioral Parent Training (PBT)
62843013|NCT02824796|ACTIVE_COMPARATOR|Parent Behavioral Training|Usually medication \& The usual PBT treatment
62843014|NCT02528812|EXPERIMENTAL|Ipsi-R|Intervention group 1 included participants receiving heavy roller massage via the TheraBand Roller Massager on the calf that exhibited the higher tenderness (Ipsilateral Rolling: Ipsi-R)
62843015|NCT02528812|EXPERIMENTAL|Contra-R|Intervention group 2 included participants receiving heavy roller massage via the TheraBand Roller Massager on the calf of the contralateral limb (Contralateral Rolling: Contra-R)
62843016|NCT02528812|SHAM_COMPARATOR|Sham group|The sham group received light stroking of the skin with TheraBand roller massager on the calf that exhibited the higher tenderness
62843017|NCT02528812|EXPERIMENTAL|Ipsi-M|Intervention group 3 included participants receiving manual massage on the calf that exhibited the higher tenderness (Ipsilateral Manual: Ipsi-M)
62843018|NCT02528812|NO_INTERVENTION|control group|received no intervention
62843019|NCT05835817|EXPERIMENTAL|Adults|
62843020|NCT05835817|EXPERIMENTAL|full term neonates|
62843021|NCT05835817|EXPERIMENTAL|premature neonates|
62843022|NCT05835817|EXPERIMENTAL|pregnant women|
62843023|NCT01360736|EXPERIMENTAL|Safety Planning - Military (SAFE-MIL)|Brief Safety Planning Using Stanley and Brown (2012) Model
62843024|NCT01360736|NO_INTERVENTION|E-CARE|Treatment As Usual and Assessment Services of Study; Control Condition
62843025|NCT00560196||1|Patients with panic anxiety disorder without pain
62843026|NCT00560196||2|Patients with depression without pain
62843027|NCT00560196||3|Healthy controls
62843028|NCT01319552|OTHER|Fresh transfusion|1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
62843029|NCT01319552|EXPERIMENTAL|Old transfusion|1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
62057559|NCT04458623|ACTIVE_COMPARATOR|negative air test|negative when SpO2 was \>96 %.
62446179|NCT05378906|EXPERIMENTAL|Treatment Sequence AB|Participants will receive a single oral dose of darunavir (DRV) and cobicistat (COBI) as one fixed dose combination (FDC) tablet dispersed in water (Treatment A \[test\]) in Treatment Period 1, followed by a single dose DRV suspension and COBI tablet (Treatment B \[Reference\]) in Treatment Period 2 on Day 1 of each Treatment Period under fed conditions. There will be a washout period of at least 7 days from dosing on Day 1 of each Treatment Period.
62843030|NCT01415336|ACTIVE_COMPARATOR|AC|doxorubicin 60 mg/m², iv, day 1 Cyclophosphamide 600 mg/m², iv, day 1 every 3 weeks for 4 cycles
62843031|NCT01415336|EXPERIMENTAL|AX|doxorubicin 60 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 4 cycles
62260837|NCT05358756|EXPERIMENTAL|Treatment B: Fed|A single adminstration of SACT-1 (150 mg rilpivirine oral suspension) after a supervised overnight fast of at least 10 hours followed by a high-fat, high calorie meal (fed).Subjects started the standardized high-fat, high-calorie breakfast 30 minutes prior to dosing and consumed this meal within the 30 minutes before dosing.
62446180|NCT05378906|EXPERIMENTAL|Treatment Sequence BA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2 on Day 1 of each Treatment Period under fed conditions. There will be a washout period of at least 7 days from dosing on Day 1 of each Treatment Period
62617463|NCT05837702|ACTIVE_COMPARATOR|Paravertebral Block (PVB)|After sterilisation of the skin with povidone iodine, the probe covered with a sterile sheath was placed 3cm lateral of the T8 spinous process. The trapezius, rhomboid major, and erector spinae muscles, and the TP of the vertebrae were visualised. The needle was placed craniocaudally within the fascial plane of the deep surface of the erector spina muscle above the bone shadow of the TP. The fluid dissemination was confirmed by raising the placement of the needle tip towards the erector spina muscle. 20ml 0.25% bupivacaine was applied to this region and the spread of local anaesthetic was observed
62057560|NCT04496999|EXPERIMENTAL|Midostaurin with HDM201 dose escalation.|Midostaurin 50mg bid d1-28 (morning, evening) and HDM201
62057561|NCT04274270|EXPERIMENTAL|experimental group|Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.
62617464|NCT05837702|ACTIVE_COMPARATOR|Control|No block has been done
62617465|NCT02412878|EXPERIMENTAL|Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone|"Participants received carfilzomib administered by intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle (20 mg/m² on day 1 of cycle 1 and 70 mg/m² thereafter).~Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15."
62057562|NCT03631225||Guided-Care Arm|Physicians will use the reported Vectra score to guide treatment decisions
62057563|NCT03631225||Usual Care Arm|Physicians will treat patient per standard of care without the use of the Vectra score
62057564|NCT02178059|EXPERIMENTAL|Bricanyl Turbuhaler M3|0.4 mg terbutaline sulphate (delivered dose) per inhalation
62057565|NCT02178059|ACTIVE_COMPARATOR|Bricanyl Turbuhaler M2|0.5 mg terbutaline sulphate (metered dose) per inhalation
62057566|NCT00420758|NO_INTERVENTION|Control|
62057567|NCT00420758|EXPERIMENTAL|LNS|Lipid-based nutrient supplement
62617466|NCT02412878|EXPERIMENTAL|Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone|"Participants received carfilzomib administered by IV infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter).~Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15."
62843032|NCT02624986|EXPERIMENTAL|DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).
62057568|NCT00420758|EXPERIMENTAL|CSB|Corn-soy blend supplement
62057569|NCT05073042|EXPERIMENTAL|Morning exercise|Participants will have a daily exercise goal, receive nightly surveys, receive weekly emails, and wear a physical activity sensor daily.
62057570|NCT05073042|EXPERIMENTAL|Evening exercise|Participants will have a daily exercise goal, receive nightly surveys, receive weekly emails, and wear a physical activity sensor daily.
62057571|NCT05073042|ACTIVE_COMPARATOR|Time of choice exercise|Participants will have a daily exercise goal, receive nightly surveys, receive weekly emails, and wear a physical activity sensor daily.
62260838|NCT05358756|ACTIVE_COMPARATOR|Treatment C: Fed|Adminstartion of Edurant, 150 mg (6 × 25 mg rilpivirine, oral tablets), after a supervised overnight fast of at least 10 hours followed by a high-fat, high calorie meal (fed).Subjects started the standardized high-fat, high-calorie breakfast 30 minutes prior to dosing and consumed this meal within the 30 minutes before dosing.
62617467|NCT00908596|EXPERIMENTAL|Gadoxetic acid disodium (Primovist/Eovist, BAY86-4873)|Participants received Primovist at a dose of 0.025 mmol/kg body weight (BW) intravenously.
62446181|NCT01053273|ACTIVE_COMPARATOR|Caudal epidural Injection|Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
62617468|NCT06188845|EXPERIMENTAL|KT group|Participants in the KT group were applied I-shaped Kinesio tape to the wrist extensor and pronator teres of the hemiplegic forearm for 2 days. Throughout the 2-day experiment, all participants received regular conventional rehabilitation.
62617469|NCT06188845|NO_INTERVENTION|CT group|Participants in the CT group did not receive tape intervention but received regular conventional therapy.
62617470|NCT06009289|ACTIVE_COMPARATOR|Standard of care|One hour of daily bright light exposure beginning one hour after wake time.
62617471|NCT06009289|EXPERIMENTAL|Stepped care|One hour of daily bright light exposure in the afternoon
62617472|NCT04282720|OTHER|SurgiMend Mesh|"SurgiMend Mesh - FDA approved noncross-linked bovine dermis biologic mesh. SurgiMend Mesh will be used according to FDA approved recommendations for the use of abdominal wall hernia reinforcement.~SurgiMend is intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes. SurgiMend is specifically indicated for:~Hernia repair including abdominal, inguinal, femoral, diaphragmatic, scrotal, umbilical, and incisional hernias."
62446182|NCT01053273|ACTIVE_COMPARATOR|Percutaneous Adhesiolysis|Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone
62446183|NCT05987046|EXPERIMENTAL|Contrast training sessions|Participants will perform three contrast training sessions for a week.
62446184|NCT02583542|EXPERIMENTAL|Dose Escalation Phase (Phase Ib)|This phase will investigate two different dosing schedules of AZD2014: a continuous daily schedule (CC-Schedule) and an intermittent schedule of 2 days on and 5 days off treatment (IC-Schedule). The dose of Selumetinib (AZD6244) will remain unchanged in both schedules. The outcome of this investigation will determine whether an additional schedule of combined intermittent Selumetinib (AZD6244) (3 days on and 4 days off treatment) with intermittent AZD2014 will be considered (II-Schedule). The II-Schedule will be initiated following the completion of the corresponding continuous regimens and will only be investigated if escalation of the AZD2014 dose in the IC-Schedule is not feasible with the corresponding continuous Selumetinib (AZD6244) regimen. Up to three individual dose levels of Selumetinib (AZD6244) might subsequently be explored within the intermittent schedule of Selumetinib (AZD6244).
62446185|NCT02583542|EXPERIMENTAL|Dose Expansion Phase (Phase IIa)|"Following the definition of the recommended Phase 2 Dose (RP2D), three NSCLC and one TNBC dose expansion cohorts are planned to perform a preliminary assessment of the anti-tumour efficacy in different molecular settings and to further establish the safety profile of the selected RP2D. These cohorts are:~* Triple-negative breast cancer (TNBC)~* Squamous cell lung cancers~* Non-squamous cell lung cancers with KRAS mutations~* Non-squamous cell lung cancers with wild-type KRAS"
62446186|NCT00274209||IBD patients at risk for neoplasia|Patients with long-standing ulcerative colitis or Crohn's colitis at risk for neoplasia.
62446187|NCT03486977||Establishments with telemedicine system|Establishments equipped for telemedicine (teleconsultation, casualty) as part of the regional project of the Aquitaine regional program telemedicine device deployment.
62446188|NCT03486977||Establishments without telemedicine system|"Defined and equipped for telemedicine EHPAD after mating on the number of residents, the GMP (average weighted GIR), the PMP (weighted average PATHOS), the distance to a hospital with an emergency shelter service.~The rate of unscheduled hospitalizations will be collected during follow-up visits in clinical departments of the healthcare of the Gironde by a research staff"
62446189|NCT02477566|EXPERIMENTAL|Long-acting Triptorelin|Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal
62446190|NCT02477566|ACTIVE_COMPARATOR|Short-acting Triptorelin|Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2\<40pg/ml in serum, was initiated during the luteal phase
62446191|NCT02386410|EXPERIMENTAL|Group parent training|The intervention Group parent training for anxious parents is delivered in groups of about five, in 90 minutes per session, for eight consecutive weeks. The parent training is delivered by a licensed psychologist.
62446192|NCT02386410|EXPERIMENTAL|Internet delivered parent training|In the internet delivered parent training for anxious parents, parents are asked to work with one chapter each week, for eight consecutive weeks. Each chapter mirrors a session in the group format. Parents are able to e-mail a licensed psychologist during the intervention.
62446193|NCT02386410|NO_INTERVENTION|Wait-list|Parents in the wait-list condition will receive the intervention after 12-month follow-up.
62617473|NCT03582514|EXPERIMENTAL|Dose or volume radiation escalation|"Patients with a new radiological diagnosis of GBM (judged by the neuro-oncology multidisciplinary team) are to be considered for this study.~This study arm will use 5 radiotherapy doses (6 Gy, 8 Gy, 10 Gy, 12 Gy and 14 Gy) and three treatment volumes (\<30 cm3, 30-60 cm3 and \>60 cm3). The study will use 6 dosing levels based on a combination of radiotherapy dose and treatment volume. The stepwise inclusion process allows for variation in tumour volume and location. The study will commence with dosing level 1: 8 Gy to \<30 cm3 and 6 Gy to 30-60 cm3. In collaboration with the Clinical Trials Unit, the Trial Management Group will enter outcome data for patients at a given dose level into the CRM model. The model output will then guide dose escalation to determine the next dose level. After the single fraction of radiotherapy, patients will receive the standard treatment."
62617474|NCT02197442|EXPERIMENTAL|Test|Valsartan Tablets USP 320 mg DIVIS
62617475|NCT02197442|ACTIVE_COMPARATOR|Reference|Diovan® (Valsartan) 320 Tablets
62617476|NCT02313285||GZ402668|Patient who received GZ402668 in prior study (TDU13475 or TDU14981)
62617477|NCT02313285||Placebo|Patient who received placebo in prior study (TDU13475 or TDU14981)
62260839|NCT04030923|ACTIVE_COMPARATOR|Real rTMS|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses on the left DLPFC for 10 consecutive sessions totally over period of 10 days.
62617478|NCT01243177|EXPERIMENTAL|Lacosamide|
62617479|NCT01243177|ACTIVE_COMPARATOR|Carbamazepine-Controlled Release (CBZ-CR)|
62617480|NCT06118333|EXPERIMENTAL|Experimental group|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62057572|NCT05073042|NO_INTERVENTION|No exercise period|"During the two-week washout (i.e., break) periods between the exercise interventions, participants will not have an exercise goal. Participants will continue to receive weekly emails and wear a physical activity sensor daily."
62260840|NCT04030923|SHAM_COMPARATOR|sham rTMS|Sham rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses with coil perpendicular on scalp over the occipital cortex for 10 consecutive sessions totally over period of 10 days.
62260841|NCT02860364|EXPERIMENTAL|Mild Hypothermic Circulatory Arrest|During aortic hemiarch surgery, mild hypothermia (32°C) will be used during circulatory arrest.
62260842|NCT02860364|ACTIVE_COMPARATOR|Moderate Hypothermic Circulatory Arrest|During aortic hemiarch surgery, moderate hypothermia (26°C) will be used during circulatory arrest.
62260843|NCT05352204||micronecrosis(+) group|
62446194|NCT04806009|EXPERIMENTAL|'Mindful Living With Insomnia (MLWI)' Intervention via WeChat mini-program|Participants in the Intervention Group will receive the MLWI Intervention after follow the WeChat mini-program. The MLWI Intervention was developed and presented by the Principle Investigator (PI) who is a psychiatrist and have completed the Training of Mindfulness Facilitation (TMF) program at the Mindful Awareness Research Center of University of California, Los Angeles.
62617481|NCT06118333|EXPERIMENTAL|Control group|Participants receive capecitabine, gemcitabine, docetaxel in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62617482|NCT01583270|EXPERIMENTAL|Arabinoxylan|Porridge rich in arabinoxylan. 50 g available carbohydrate
62260844|NCT05352204||micronecrosis(-) group|
62260845|NCT02103998|EXPERIMENTAL|T4 + KI|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
62260846|NCT02103998|PLACEBO_COMPARATOR|D5W - 5% dextrose water|Receive the same volume as study drug but as D5W placebo
62260847|NCT04639856|ACTIVE_COMPARATOR|on-pump CABG|CABG using Cardiopulmonary Bypass Machine
62260848|NCT04639856|ACTIVE_COMPARATOR|off-pump CABG|CABG without Cardiopulmonary Bypass Machine
62260849|NCT03133689||EPIC-Norfolk|This cohort comprises 25,636 residents of a predefined English healthcare region (11,606 men and 14,030 women). Participants in this cohort study were originally recruited from 35 general practices in Norfolk, England as part of an investigation into diet and cancer, but the study's scope was subsequently widened to include additional outcomes including cardiovascular diseases.
62617483|NCT01583270|EXPERIMENTAL|rye kernels|Porridge made from rye kernels. 50 g available carbohydrate
62617484|NCT01583270|EXPERIMENTAL|arabinoxylan and rye kernels|Porridge made of rye kernels and arabinoxylan. 50g available carbohydrate
62617485|NCT01583270|EXPERIMENTAL|semolina|Semoline porridge. 50 g available carbohydrate
62617486|NCT04413942|ACTIVE_COMPARATOR|FB825|FB825
62617487|NCT04413942|PLACEBO_COMPARATOR|Placebo|Formulation buffer
62260850|NCT03133689||GAZEL|This cohort comprises 20,625 employees of French gas and electricity companies (15,011 men and 5,614 women). The cohort commenced data collection in 1989 and follow-up assessments were subsequently completed on an annual basis. The data have undergone linkage to national health administrative datasets.
62446195|NCT04806009|ACTIVE_COMPARATOR|'Cognitive Behavioral Therapy for insomnia (CBT-I)'via WeChat mini-program|Participants in the Control Group will receive CBT-I after follow the WeChat mini-program. The CBT-I was developed and presented by a researcher who is a psychiatrist/psychologist and have many years' experiences in CBT.
62617488|NCT01160380|EXPERIMENTAL|Armodafinil|The patients receive armodafinil for all 56 days of the study.
62843033|NCT02624986|EXPERIMENTAL|DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
62843034|NCT02624986|EXPERIMENTAL|DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
62843035|NCT02624986|EXPERIMENTAL|DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2|Participants with diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m\^2) IV for 6 cycles (1 cycle = 28 days).
62260851|NCT03133689||NSHD|This dataset comes from the 1946 National Birth Cohort study, which comprises all persons born in England, Scotland and Wales in one week in March 1946. The cohort comprises 5,362 individuals (2,815 men and 2,547 women). Data have been collected from participants on a regular basis throughout their life, including information on lifestyle and, in combination with administrative datasets, on health outcomes.
62260852|NCT03133689||Twenty-07-1930s|This cohort comprises 1,551 Scottish participants (702 men and 849 women) born around 1932 who were recruited in 1986 as part of a study of health inequalities. The repeated nature of the data collection will enable identification of longitudinal alcohol intake patterns, while linkage to Scottish health system records will enable identification of coronary heart disease onset.
62843036|NCT02624986|EXPERIMENTAL|DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2|Participants with diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m\^2 IV for 6 cycles (1 cycle = 28 days).
62843037|NCT02624986|EXPERIMENTAL|FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).
62843038|NCT02624986|EXPERIMENTAL|FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
62260853|NCT03133689||Twenty-07-1950s|This cohort comprises 1,444 Scottish participants (656 men and 788 women) born around 1952 who were recruited in 1986, alongside the T-07-1930s' cohort, as part of a study of health inequalities. Participant health was tracked through linkage with national health records.
62260854|NCT03133689||Whitehall II|This cohort comprises 10,308 British civil servants (6,895 men and 3,413 women). The cohort study commenced data collection in 1985 and participants have since undergone questionnaire and clinical assessments across regular intervals. Additional tracking of health outcomes has been performed through linkage with administrative databases. Demographic, behavioural and clinical data will be sourced from this cohort for the purposes of the current study.
62260855|NCT01439282|EXPERIMENTAL|Eribulin + Capecitabine|
62260856|NCT05156970|EXPERIMENTAL|Camrelizumab + Chemotherapy|Participants receive Camrelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for up to 24 months;plus cisplatin 75 mg/m\^2 IV or carboplatin at a target area under the curve of 5 (AUC 5) IV, per Investigator's choice, on Day 1 of each 3-week cycle (6 cycle maximum); plus docetaxel 75 mg/m\^2 IV on Day 1 of each 3-week cycle (6 cycle maximum).
62446196|NCT01126515||Hyperbaric oxygen|In this open-label feasibility study, all subjects will receive 60 hyperbaric oxygen sessions (100% oxygen, 1.5 atmospheres absolute (atm abs), for 60 minutes), delivered daily, five days per week.
62446197|NCT05155800||TBI patients with intracranial bleeding|
62446198|NCT05155800||TBI patients without intracranial bleeding|
62446199|NCT05155800||Control Subjects with normal brain health|
62446200|NCT03065361||Group A|"Group composed of 21 children and adolescents aged between 9 and 19 years old, treated by hemodialysis in two hospitals of Belo Horizonte. Just in case of some evidence of difference in the results within group A, because of the two types of dialysis (via fistula or catheter), this group can be subdivided in subgroups A1 (n=10) and A2 (n=11), respectively.~Group A was already on hemodialysis, the intervention was not performed by the researcher. Our goal was only to evaluate some characteristics of these individuals."
62446201|NCT03065361||Group B|Group composed of 21 children and adolescents matching age and gender for the Group A participants. The individuals were recruited in schools of Belo Horizonte.
62446202|NCT00949130|EXPERIMENTAL|NXL103|BID for 7-14 days orally
62446203|NCT00949130|ACTIVE_COMPARATOR|Linezolid|BID for 7-14 days orally
62617489|NCT01160380|PLACEBO_COMPARATOR|Placebo-First|These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
62617490|NCT02946489|EXPERIMENTAL|CI-581a+MET+MBRP|Administration of CI-581a during wk 2 and possibly at wk 3 or 4 at 0.71 mg/kg in the context of a 2 wk course of MET followed by a 4 wk course of MBRP
62617491|NCT02114294|EXPERIMENTAL|Isolated hip strengthening|Isolated hip strengthening (abduction, external rotation, extension)
62843039|NCT02624986|EXPERIMENTAL|FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
62260857|NCT05156970|EXPERIMENTAL|Camrelizumab +Apatinib mesylate|Participants receive Camrelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for up to 24 months;plus Apatinib 250mg qd for up to 24 months.
62260858|NCT01386359||Adult de novo EBV-seropositive kidney-transplant recipients|Adult de novo EBV-seropositive kidney-transplant recipients treated with Nulojix (belatacept)
62617492|NCT02114294|ACTIVE_COMPARATOR|Quadriceps based training|Quadriceps based training (mini-squat, straight leg raising, terminal extensions)
62843040|NCT00853632|OTHER|Device - CEP Mitral Valve|
62260859|NCT00527475|ACTIVE_COMPARATOR|Group I|Group I will receive 0.5 mg. ranibizumab intraocularly initially. This will be repeated monthly for 3 months total and then as needed over the period of one year.
62260860|NCT00527475|EXPERIMENTAL|Group II|Group II will receive Reduced Fluence-PDT (25 Joules) followed by 0.5 mg. of ranibizumab intraocularly on the same day. The second group will receive the combination of ranibizumab and RF-PDT as needed over a period of one year.
62260861|NCT00199550|ACTIVE_COMPARATOR|2|Bipolar Electrosurgical Unit
62446204|NCT04833712|EXPERIMENTAL|Stereotactic Radioablation|"Noninvasive Stereotactic Radioablation will be delivered in a single fraction to electrical isolate the pulmonary veins under CT-guidance.~Pulmonary vein isolation will be assessed by using Cardioinsight non-invasive mapping system"
62446205|NCT02964728|EXPERIMENTAL|Botulinum toxin type A|Botulinum neurotoxin injections
62446206|NCT02964728|PLACEBO_COMPARATOR|Placebo|Normal saline solution injections
62446207|NCT01150448|EXPERIMENTAL|001|Paliperidone palmitate Treatment A All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
62446208|NCT01150448|EXPERIMENTAL|002|Paliperidone palmitate Treatment B Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq patients who do not wish to have multiple blood samples collected will also be assigned to Treatment B
62446209|NCT04523558|EXPERIMENTAL|Bilateral implantation of LuxSmart hydrophobic IOL|"Cataract surgery will be carried out using standard phacoemulsification technique with a 2.2 mm incision. Investigators will target a 5.5 mm diameter capsulorhexis to allow the optic to be fully overlapped by the anterior capsular rim.~The intended target of the post-operative refraction will be emmetropia. The patient will be implanted with LuxSmart hydrophobic IOLs in both eyes and followed up for 6 months"
62446210|NCT01241942|EXPERIMENTAL|EVLP with STEEN Solution™|The perfusion of the lungs will be performed using STEEN Solution™ and then physiologically assessed. Lungs deemed suitable will be transplanted after Ex-vivo Perfusion w/ STEEN Solution™.
62446211|NCT01241942|ACTIVE_COMPARATOR|Conventional Lung transplant|No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
62446212|NCT05710185|EXPERIMENTAL|Subjects with Palmoplantar pustulosis|All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.
62843041|NCT04259619|EXPERIMENTAL|Low-Level Laser Therapy|During 2-3 days this group receives three low-level laser therapy (LLLT) treatments with the Soft Power Laser carried out by a specially trained breastfeeding consultant.
62843042|NCT04259619|PLACEBO_COMPARATOR|Placebo Therapy|During 2-3 days this group receives three placebo treatments with an identically looking laser, which in contrast submits only red colored light. The therapy is also carried out by a specially trained breastfeeding consultant.
62843043|NCT02617472|EXPERIMENTAL|Pelvic floor exercise|Pelvic floor exerciser, daily use
62260862|NCT00199550|ACTIVE_COMPARATOR|1|Monopolar Electrosurgical Unit
62260863|NCT02826642|EXPERIMENTAL|Arm 1: Medically fit for induction|IDH305 + Standard of care for patients that are medically fit for induction.
62260864|NCT02826642|EXPERIMENTAL|Arm 2 Medically unfit for induction|IDH305 + Standard of care for patients that are medically unfit for induction.
62260865|NCT00143715|EXPERIMENTAL|1|Low dose oral vitamin K + warfarin cessation
62260866|NCT00143715|PLACEBO_COMPARATOR|2|
62260867|NCT05551715|OTHER|Untreated eyes|Participants in the untreated arm will undergo an ophthalmic examination only once.
62260868|NCT05551715|OTHER|Refractive surgery|Participants on this arm will undergo two ophthalmic examinations, one before and one after surgery. For refractive surgery participants, refractive surgery will be performed as part of the habitual clinical practice. All other additional tests performed as part of the clinical trial are all non-invasive.
62446213|NCT02405507|EXPERIMENTAL|wheat bread with wheat germ|wheat bread with wheat germ supplementation
62446214|NCT02405507|PLACEBO_COMPARATOR|wheat bread without wheat germ|wheat bread without wheat germ supplementation
62446215|NCT03029533|EXPERIMENTAL|DWJ108J (leuprolide acetate)|DWJ108J (leuprolide acetate)
62446216|NCT03029533|ACTIVE_COMPARATOR|Leuplin DPS Inj|Leuplin DPS Inj
62446217|NCT05391399|EXPERIMENTAL|group A Interlocking detachable coils system|The coil is designed with mechanical release, which can be recovered and repositioned at any time when the release process meets certain conditions.
62617493|NCT02114294|OTHER|Active control|Patients receive standardised information concerning patellofemoral pain syndrome, but receive no prescribed exercise regime. They are encouraged to remain active.
62617494|NCT02169388|EXPERIMENTAL|Probiotic|Microbial composition using Probiotic，3 capsules / times, 2 times / day for 4 weeks
62617495|NCT02169388|PLACEBO_COMPARATOR|placebo|Microbiota modulation using placebo，3 capsules / times, 2 times / day for 4 weeks
62617496|NCT03472001|EXPERIMENTAL|Training group|2-hour training based on reflection and feedback
62617497|NCT03472001|ACTIVE_COMPARATOR|Lecture group|1-hour lecture
62617498|NCT03472001|NO_INTERVENTION|Control group|The remaining students only attending dermatology electives
62057573|NCT04760522|EXPERIMENTAL|WGS Diagnostic|"Both underage and adult persons (male and female) with diagnostically unsolved rare diseases who have been or are included into diagnostic care at the University Hospital Tübingen, Germany (UKT) and who are suspected of having a genetic cause of the disease.~Study related procedures: Blood sampling, anamnesis including pedigree, Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics)."
62260869|NCT05551715|OTHER|Cataract surgery|Participants on this arm will undergo two ophthalmic examinations, one before and one after surgery. For cataract surgery participants, cataract surgery will be performed as part of the habitual clinical practice. All other additional tests performed as part of the clinical trial are all non-invasive.
62260870|NCT06054191|EXPERIMENTAL|Cohort 1: BRAF V600 mutation|Dabrafenib + Trametinib
62260871|NCT06054191|EXPERIMENTAL|Cohort 2: MET ex14 skip mutation|Capmatinib
62260872|NCT04216277|EXPERIMENTAL|Procalcitonin in addition to usual care|Procalcitonin values will be disclosed to the attending physician and assist in antibiotic guidance in addition to usual care
62260873|NCT04216277|NO_INTERVENTION|Usual care|Usual best standard care. No procalcitonin values disclosed to attending physician .
62260874|NCT05023356||Contact vital signs monitoring|Routine monitors with cables
62260875|NCT05023356||Non-contact vital signs monitoring|Camera
62617499|NCT01412892|EXPERIMENTAL|Everolimus|RAD001: Everolimus
62617500|NCT00502853|EXPERIMENTAL|1|
62617501|NCT01956864|EXPERIMENTAL|Dose VD 1|Vitamin D
62843044|NCT02178137|ACTIVE_COMPARATOR|Glucosamine/Chondroitin|"Glucosamine/Chondroitin twice a day for a daily total dose of 1500 mg of Glucosamine and 1200 mg of Chondroitin.~Tablets will have 750 mg Glucosamine Sulphate and 600 mg of Chondroitin Sulphate. These will be taken twice a day after breakfast and dinner."
62843045|NCT02178137|ACTIVE_COMPARATOR|Diacerien|Diacerien 50 mg twice a day in capsule form. To be taken twice a day after breakfast and dinner
62843046|NCT02178137|PLACEBO_COMPARATOR|Placebo pill|Placebo tablets with Zinc sulfate twice a day. These will contain pharamacologically non active ingredients (Usually expedients).
62843047|NCT03251313|EXPERIMENTAL|JS001 120mg+GP|Level 1: JS001 120mg +GP q3w,\*6 cycles, then JS001 120mg q3w for maintenance therapy for up to approximately 2 years.
62843048|NCT03251313|EXPERIMENTAL|JS001 240mg+GP|Level 2: JS001 240mg +GP q3w,\*6 cycles, then JS001 240mg q3w for maintenance therapy for up to approximately 2 years.
62260876|NCT02538874|EXPERIMENTAL|Part A: Single Ascending Dose (SAD)|BMS-986171 or Placebo on specified days
62260877|NCT02538874|EXPERIMENTAL|Part B: Multiple Ascending Dose (MAD)|BMS-986171 or Placebo on specified days
62843049|NCT03251313|EXPERIMENTAL|JS001 480mg +GP|Level 3: JS001 480mg+GP q3w,\*6 cycles, then JS001 480mg q3w for maintenance therapy for up to approximately 2 years.
62843050|NCT03251313|EXPERIMENTAL|GP followed by JS001|sequential treatment: Patients receive 6 cycles of GP without JS001 and then receive JS001 maintenance therapy for up to approximately 2 years. JS001 will be given at RP2D.
62843051|NCT03200080|PLACEBO_COMPARATOR|Treatment A|Placebo oral tablet and Placebo oral capsule
62260878|NCT02538874|EXPERIMENTAL|Part C: Multiple Ascending Dose in Japanese subjects (J-MAD)|BMS-986171 or Placebo on specified days
62260879|NCT02268279|EXPERIMENTAL|solithromycin|oral dosing (capsules and powder for suspension) by weight once per day intravenous dosing by weight once per day
62260880|NCT04863846||Clinical standard (first study phase)|Current clinical standard, non-algorithm-based decision-making (prior to implementation of the algorithm)
62260881|NCT04863846||Algorithm-based allocation (second study phase)|New algorithm-based allocation to an intubation technique (after implementation of the algorithm)
62843052|NCT03200080|EXPERIMENTAL|Treatment B|Tozadenant 120 mg
62843053|NCT03200080|EXPERIMENTAL|Treatment C|Tozadenant 240 mg
62260882|NCT04276428|EXPERIMENTAL|LY3209590|LY3209590 administered subcutaneously (SC).
62260883|NCT04276428|ACTIVE_COMPARATOR|Insulin Degludec|Insulin degludec administered SC.
62617502|NCT01956864|EXPERIMENTAL|Dose VD 2|Vitamin D
62057574|NCT01013610|ACTIVE_COMPARATOR|Multiple Dose|
62057575|NCT01013610|PLACEBO_COMPARATOR|Placebo|
62617503|NCT01956864|EXPERIMENTAL|Dose VD 3|Vitamin D
62617504|NCT01956864|EXPERIMENTAL|Dose VD 4|Vitamin D
62617505|NCT01956864|EXPERIMENTAL|Dose VD 5|Vitamin D
62617506|NCT01956864|EXPERIMENTAL|VD 6 Month Treatment|Vitamin D
62617507|NCT04641702|EXPERIMENTAL|Pharmacologic challenge|Measurement of esophageal response to atropine using functional lumen imaging probe (FLIP)
62617508|NCT04465656||[PCR-COVID 19-Pos] group|Having a microbiological diagnosis confirming COVID-19 infection (ie positive RT-PCR on nasopharyngeal swab) and/or clinical/CT signs
62617509|NCT04465656||[PCR-COVID 19-Neg] group|Having a microbiological diagnosis confirming the absence of COVID-19 infection (ie negative RT-PCR on nasopharyngeal swab) and absence of clinical /CT signs
62617510|NCT04465656||[PCR-COVID 19-Neg & Sero-COVID 19-Pos] group|"* Having a microbiological diagnosis confirming the absence of COVID-19 infection (ie negative RT-PCR on nasopharyngeal swab) and absence of clinical /CT signs~* Having been tested positive in a serological test for COVID-19 at M3"
62843054|NCT03200080|EXPERIMENTAL|Treatment D|Tozadenant 480 mg
62843055|NCT03200080|ACTIVE_COMPARATOR|Treatment E|d-amphetamine 20 mg
62843056|NCT03200080|ACTIVE_COMPARATOR|Treatment F|d-amphetamine 40 mg
62260884|NCT02861209|NO_INTERVENTION|Non-care pathway|"This arm comprises patients before the implementation of the care pathway. Patients starting with an oral anticancer therapy participate in the current care process. Outcomes are assessed at start of treatment, after 1 and after 3 months.~The decision to start with an oral anticancer therapy depends solely on the treating physician."
62260885|NCT02861209|EXPERIMENTAL|Care Pathway|"This arm comprises patients after the implementation of the care pathway. Patients starting with an oral anticancer therapy in this arm, receive care as is described by the novel designed care pathway. Outcomes are again assessed at start of treatment, after 1 and after 3 months.~The decision to start with an oral anticancer therapy depends solely on the treating physician."
62260886|NCT01030770|EXPERIMENTAL|Arm A (treatment)|Arm A: Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls) (Lucentis®)
62260887|NCT01030770|PLACEBO_COMPARATOR|Arm B (control):|Arm B: Single subconjunctival injection of 0.05mls of 0.9% sodium chloride (Minims Saline®)
62260888|NCT01511276|EXPERIMENTAL|Diet-induced weight loss|The diet-induced weight loss group will follow a calorie restricted diet. They are asked to keep their habitual sedentary lifestyle. The aim of this group is to loose 5-6 kg of body weight in 14 weeks time.
62446218|NCT05391399|ACTIVE_COMPARATOR|group B Interlock Fibered IDC Occlusion System|The coil adopts the design of mechanical release, and can be recovered, repositioned and released at any time when the release process meets certain conditions.
62446219|NCT05465213||Retrospective cohort|Patients who have initiated treatment with dapagliflozin for HFrEF between 1st of March 2021 and 31st of October 2021 (prior to study initiation date).
62446220|NCT05465213||Prospective Cohort|Patients who have started treatment with dapagliflozin for HFrEF from 1st April 2022 onwards. At least 30 days must have elapsed (but no more than 60 days) from first prescription of dapagliflozin before a patient can be enrolled.
62843057|NCT01195532||Gliclazide/2|60 mg\*1 for T 30 mg\*2 For R
62260889|NCT01511276|EXPERIMENTAL|Mainly exercise induced weight loss|"Participants in the exercise- plus diet-induced weight loss group are enrolled in an exercise programme. Next to the exercise programme, they will follow a calorie restricted diet.~The aim of this group is to loose 5-6 kg of body weight in 14 weeks time."
62260890|NCT01511276|NO_INTERVENTION|Control, stable weight|The control group is asked to follow a baseline isocaloric diet and to not change their habitual sedentary lifestyle.
62260891|NCT06324006|EXPERIMENTAL|LIB-01|LIB-01 oral suspension
62446221|NCT05180578|EXPERIMENTAL|Tolerability of goat milk consumption in patients with EOE triggered by milk allergy|Elimination of cow milk from diet . Goat milk containing diet.
62446222|NCT04538040|EXPERIMENTAL|Biktarvy + Doravirine Switch|bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets + doravirine 100mg tablets taken orally once per day
62446223|NCT00642538|EXPERIMENTAL|1|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
62446224|NCT00642538|EXPERIMENTAL|2|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
62843058|NCT01195532||Reference and test drug|Reference: 30 mg \*2 Test: 60 mg \*1
62843059|NCT01742286|EXPERIMENTAL|LDK378|All participants were administered a single-agent LDK378 (Ceritinib) orally, once daily, continuously in fasted or fed conditions.
62446225|NCT00642538|EXPERIMENTAL|3|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
62446226|NCT00642538|PLACEBO_COMPARATOR|4|TIP (placebo comparison)
62057576|NCT04732052|ACTIVE_COMPARATOR|Active tDCS|Transcranial Direct Current Stimulation: Soterix tDCS kit will be used to deliver the stimulation using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise of left anodal Dorsal Lateral Prefrontal cortex (DLPFC) stimulation. The anodal electrode will be placed over the area corresponding to the left DLPFC (F5 of the EEG10-20 international system) and the reference (cathodal) electrode over the right supraorbital ridge. The active stimulation condition will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively. The duration a single tDCS session will be 20 minutes.
62260892|NCT06324006|PLACEBO_COMPARATOR|Placebo|Placebo oral suspension
62260893|NCT03119714|ACTIVE_COMPARATOR|Pemirolast|Pemirolast 200mg bid 14-16 days
62260894|NCT03119714|PLACEBO_COMPARATOR|Placebo Oral Tablet|Matching placebo bid 14-16 days
62260895|NCT02989415||Mechanical Ventilation|Patients undergoing mechanical ventilation during robotic surgery
62260896|NCT05270590||group A|periareolar approach
62260897|NCT05270590||group B|submamary approach
62260898|NCT03147716|ACTIVE_COMPARATOR|Enrollment Flyer|Participants in this condition received one of the strategies in the Parent Engagement Package: an enrollment flyer that provided information about the Triple P Positive Parenting Program being offered at their child's school, including the location of meetings, free childcare, topics covered, choice of days/times and English or Spanish groups, and an enrollment form. Parents who returned the enrollment form received automated text, email and/or phone reminders and a confirmation letter prior to each parenting program session.
62260899|NCT03147716|EXPERIMENTAL|Enrollment Flyer & Testimonial Booklet|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus a two-page, testimonial booklet that included photos and quotes from parents and children describing benefits other parents reported after participating in the Triple P Positive Parenting Program and fun activities children reported about the childcare. The booklet also contained the location of meetings, free childcare, choice of days/times and English or Spanish groups, and an enrollment form.
62260900|NCT03147716|EXPERIMENTAL|Enrollment Flyer & Teacher Endorsement|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus a teacher endorsement of the Triple P Positive Parenting Program. The teacher also gave the participant a colorful brochure that included information about the location of meetings, free childcare, topics covered, choice of days/times and English or Spanish groups, and an enrollment form.
62260901|NCT03147716|EXPERIMENTAL|Enrollment Flyer & Engagement Call|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus an engagement call from a Triple P provider. Providers followed a manualized protocol for implementing the engagement call, which included strategies to increase parental motivation to participate in Triple P and reduce barriers to participation.
62260902|NCT03147716|EXPERIMENTAL|All Engagement Strategies|Participants in this condition received all engagement strategies in the Parent Engagement Package: enrollment flyer, testimonial booklet, teacher endorsement, and provider engagement call.
62260903|NCT02693561|ACTIVE_COMPARATOR|Deep Breathing Exercises|Technical Deep Breathing.
62260904|NCT02693561|ACTIVE_COMPARATOR|Self-Help Book|Reading the self-help book.
62446227|NCT00642538|ACTIVE_COMPARATOR|5|10 ug subcutaneous control
62446228|NCT02767388||HM - Chemotherapy|Study patients diagnosed with HM that are scheduled to receive chemotherapy treatment.
62446229|NCT02767388||HM - No Chemotherapy|Study patients diagnosed with HM that are scheduled to receive non-chemotherapy treatment options.
62446230|NCT02767388||Healthy Controls|Study participants that are demographically matched to HM study patients and meet all inclusion criteria
62446231|NCT01204320|EXPERIMENTAL|Paclitaxel-coated Balloon|Paclitaxel-coated Balloon Angioplasty
62446232|NCT01204320|ACTIVE_COMPARATOR|Paclitaxel-eluting Stent|Paclitaxel-eluting Stent Implantation
62446233|NCT00317499|EXPERIMENTAL|Etanercept|
62446234|NCT00317499|PLACEBO_COMPARATOR|Placebo|
62446235|NCT06105281|NO_INTERVENTION|Control group|The participants that only get the standard care in the pain clinic.
62446236|NCT06105281|EXPERIMENTAL|The consultation with a pain specialist nurse|When the participant receives a consultation with the pain specialist nurse ,there will be assessed if the patient knows what the procedure involves and what they can expect of it. To meet de expectations of the patient the nurse will explain the procedure and what they can expect. Further there will be an short education about what pain is and the physiology of chronic pain. Because chronic pain has a lot of influencing factors the nurse will explain the main factors.
62446237|NCT04295395||group1|preterm infant with closed ductus arteriosus, \<32 weeks birth weight \< 1500g, and \> 72 hours of age
62446238|NCT04295395||group2|preterm infant with PDA \< 32 weeks, birth weight \< 1500g, and \> 72 hours of age
62446239|NCT04295395||group3|preterm infant with hemodynamically significant PDA \< 32 weeks, birth weight \< 1500g, and \> 72 hours of age
62446240|NCT04881955|EXPERIMENTAL|[14C]-Ecopipam|Single oral capsule dose of 200 mg ecopipam HCl containing approximately 88.5 µCi of \[14C\]-ecopipam HCl
62446241|NCT01918878|EXPERIMENTAL|Aflibercept (EYLEA)|Intravitreal injection of aflibercept (EYLEA) 2mg/0.05ml at enrolment (day 0), 4 weeks, 8 weeks, 16 weeks and 24 weeks. Aflibercept will be provided for total period of 24 weeks
62843060|NCT04956107||HIPEC cohort|Patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer with peritoneal metastases
62260905|NCT02693561|ACTIVE_COMPARATOR|Deep Breathing Exercises and Book|"Technical Deep Breathing and Reading the self-help book.~Reading the self-help book and will be trained by the physical therapist to perform deep breathing."
62260906|NCT02693561|NO_INTERVENTION|Control|Not suffer any intervention
62260907|NCT01234974|EXPERIMENTAL|Pasireotide|Pasireotide 60 mg day 1 every 28 days
62260908|NCT02084303|OTHER|Ferumoxytol MRI|Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI.
62446242|NCT04758650|EXPERIMENTAL|Cancer, lymphoma, carotid plaque, patients suspected for HLH, sarcoidosis|"Cohort 1: Patients diagnosed with pathology malignancies of the head and neck~Cohort 2: Patients diagnosed with any malignancy with a solid component~Cohort 3: Patients diagnosed with carotid plaque, planned for SOC carotid endarterectomy~Cohort 4: Patients with a biopsy-proven Hodgkin or non-Hodgkin lymphoma~Cohort 5: Patients suspected for HLH, planned for (SOC) bone marrow in case it is not done before~Cohort 6 : Patients with endomyocardial biopsy proven or suspected cardiac sarcoïdosis~Cohort 7 : Patients with biopsy-proven sarcoïdosis"
62446243|NCT06037200||Patients with suspected DOAC intake|Stroke patients with safe or suspected intake of direct oral anticoagulants
62446244|NCT06037200||Patients without DOAC intake|Stroke patients without intake of direct oral anticoagulants
62446245|NCT03004521|ACTIVE_COMPARATOR|Lithium|Lithium will be prescribed to patients in this arm as an augmenter on top of a patient's existing antidepressant treatment.
62446246|NCT03004521|EXPERIMENTAL|Quetiapine|Quetiapine will be prescribed to patients in this arm as an augmenter on top of a patient's existing antidepressant treatment.
62446247|NCT02391428|EXPERIMENTAL|Children who diagnosed with ADHD|The ADHD children will be asked to consume omega3 capsules for 6 months. Blood will be taken for omega3 analysis in day 0, after 3 and 6 months.
62446248|NCT02391428|EXPERIMENTAL|Control group of children without ADHD|"Blood test:~The control group of 30 children (age and gender match) without ADHD and related neuropsychiatric syndromes, who were hospitalized due to surgical or orthopedic problems. Only when blood will be taken for clinical purposes, the investigators will ask the children and their parents to allow the collection of an additional small blood tube."
62446249|NCT05460442|EXPERIMENTAL|Caudal Block group|25 patients will receive ultrasound-guided caudal block with bupivacaine 0.25% (0.5 mL/kg) after induction of anesthesia.
62446250|NCT05460442|EXPERIMENTAL|Pericapsular nerve group block|25 patients will receive ipsilateral ultrasound-guided Pericapsular nerve group block with bupivacaine 0.25% (0.5 mL/kg) after induction of anesthesia.
62446251|NCT05460442|EXPERIMENTAL|Fascia iliaca group|25 patients will receive ipsilateral ultrasound-guided Fascia iliaca compartment block with bupivacaine 0.25% (0.5 m. L/kg) after induction of anesthesia.
62446252|NCT02699580|EXPERIMENTAL|Biodegradable collagen implant|Both eyes are needed to correct strabismus. One eye is randomly selected for the placement of biodegradable collagen implant.
62446253|NCT02699580|ACTIVE_COMPARATOR|Without biodegradable collagen implant|Strabismus surgery is done without placing of biodegradable collagen implant in the other eye.
62446254|NCT00995137|EXPERIMENTAL|relapse B-Lineage ALL|"All patients meeting the eligibility criteria.~Intervention: NK Cell Infusion"
62446255|NCT04266691||Driver gene mutation-positive|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation positive.
62446256|NCT04266691||Driver gene mutation-negative|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation negative.
62446257|NCT04170179|EXPERIMENTAL|Systemic chemotherapy plus lenvatinib and toripalimab|Systemic chemotherapy of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 240mg intravenously every 3 weeks.
62446258|NCT05694091||Patients in the control group were followed up without delirium postoperatively.|If the 3D-CAM scale all show a negative resluts
62446259|NCT05694091||Patients in the case group were followed up with delirium postoperatively.|If the 3D-CAM assessment is positive at any time point after surgery
62446260|NCT03896217|ACTIVE_COMPARATOR|Simvastatin|Simvastatin is part of the pharmacotherapeutic group of HMG-CoA reductase inhibitors (ATC-Code: C10A A01). Simvastatin is licensed within the EU for hypercholesterolemia and cardiovascular prevention but for this trial its use will be outside its licensed indication. Oral Simvastatin will be taken 40mg daily (one tablet in the evening) for 4 weeks and then at week 4 up titrated to 80mg daily (two tablets in the evening.
62446261|NCT03896217|PLACEBO_COMPARATOR|Placebo|Matched Placebo (one tablet in the evening) for 4 weeks and then at week 4 up titrated to two tablets daily in the evening.
62446262|NCT05262621|EXPERIMENTAL|Music intervention combined with progressive muscle relaxation|Music intervention combined with progressive muscle relaxation.
62446263|NCT05262621|NO_INTERVENTION|Control group|no music therapy will be done.
62446264|NCT05426720||patients with pulmonary tuberculosis|male patients aged 25-60 with active pulmonary tuberculosis
62446265|NCT00491504|EXPERIMENTAL|Mometasone Furoate Nasal Spray (MFNS)|MFNS 200 mcg total dose (2 sprays each nostril)
62843061|NCT04956107||PE cohort|Patients undergoing pelvic exenteration (PE) for colorectal cancer with involvement of the urinary bladder
62057577|NCT04732052|SHAM_COMPARATOR|Sham tDCS|Sham Transcranial Direct Current Stimulation: Soterix tDCS kit will be used to deliver the sham stimulation using two sponge electrodes soaked in a saline solution. The sham stimulation montage will comprise of left anodal Dorsal Lateral Prefrontal cortex (DLPFC) stimulation for 10s only. The anodal electrode will be placed over the area corresponding to the left DLPFC (F5 of the EEG10-20 international system) and the reference (cathodal) electrode over the right supraorbital ridge. The sham tDCS is identical to the active tDCS except that the current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The duration of each sham tDCS session will be 20 minutes.
62057578|NCT03215901|EXPERIMENTAL|A Beautiful Future Video|Participants randomized to intervention will view intervention video.
62057579|NCT03215901|SHAM_COMPARATOR|Active Control Video|Participants randomized to control will watch a video of similar length as the intervention video on a different topic.
62057580|NCT03215901|NO_INTERVENTION|Pure Control|Participants view no video.
62057581|NCT01064908||Carotid endarterectomy|Patients who are undergoing elective carotid endarterectomy under local anaesthesia
62057582|NCT01522534|EXPERIMENTAL|Blind block with mepivacaine|Blind block with mepivacaine and intravenous morphine
62057583|NCT01522534|ACTIVE_COMPARATOR|Morphine|Intravenous Morphine and placebo blind block
62057584|NCT01373632|EXPERIMENTAL|Firebird 2 stent group|the patients who receive Firebird 2 stent
62446266|NCT00491504|PLACEBO_COMPARATOR|Placebo|Placebo (2 sprays each nostril)
62446267|NCT02206204|EXPERIMENTAL|Group A|Subjects in Group A receive selexipag on Days 3 to 23 and moxifloxacin-matching placebo on Days 2 and 24. Selexipag administered orally, twice a day, for 21 days according to the following multiple dose up-titration regimen: 400 μg on Days 3-5, 600 μg on Days 6-8, 800 μg on Days 9-11, 1000 μg on Days 12-14, 1200 μg on Days 15-17, 1400 μg on Days 18-20, and 1600 μg on Days 21-23 (only morning dose on Day 23).
62446268|NCT02206204|EXPERIMENTAL|Group B1|Subjects in Group B1 receive 400 mg moxifloxacin, orally on Day 2 and moxifloxacin-matching placebo, orally on Day 24. Subjects receive placebo for selexipag, orally on Days 3 to 23.
62446269|NCT02206204|EXPERIMENTAL|Group B2|Subjects in Group B2 receive moxifloxacin-matching placebo, orally on Day 2 and 400 mg moxifloxacin, orally on Day 24. Subjects receive placebo for selexipag, orally on Days 3 to 23.
62446270|NCT05116020||Chiropractic patient participants|Usual chiropractic care
62446271|NCT04209972|ACTIVE_COMPARATOR|Patients on CT1|Patients will undergo two pre-contrast scans, and will be in between the two scans be off and on the table at a standard CT scanner. (Aquilion One Genesis, Canon Medical Systems)
62057585|NCT01373632|ACTIVE_COMPARATOR|Excel stent group|the patients who receive Excel stent
62057586|NCT01976065|OTHER|Mineral Trioxide Aggregate (MTA)|Standard Treatment group consisting of placement of Mineral Trioxide Aggregate (MTA), an FDA approved dental material at the end of an immature root followed by a composite restoration (crown).
62057587|NCT01976065|EXPERIMENTAL|Revascularization Treatment (REVASC)|Consists of standard treatment procedure PLUS disinfection of the canal space with Triple Antibiotic Paste study medication followed by placement of Collaplug, an FDA approved material to help promote clotting. A composite restoration in then placed.
62057588|NCT01976065|EXPERIMENTAL|Regeneration Treatment (REGENDO)|Consists of standard treatment procedure PLUS Triple Antibiotic Paste study medication PLUS use of Emdogain, an FDA approved medication used in an FDA approved manner, that is a growth factor to help surrounding tissues to grow together and heal.
62057589|NCT01238640|EXPERIMENTAL|Code STD|"An experimental 2 mg nicotine product coded STD"
62057590|NCT01238640|EXPERIMENTAL|Code STE|"An experimental 2 mg nicotine product coded STE"
62057591|NCT01238640|ACTIVE_COMPARATOR|Nicorette Microtab|A comparative 2 mg marketed nicotine product called Nicorette Microtab
62057592|NCT01724645|EXPERIMENTAL|Korean traditional diets|Korean traditional diets (calorie 2,100kcal) for 12weeks
62446272|NCT04209972|ACTIVE_COMPARATOR|Patients on CT2|Patients will undergo two pre-contrast scans, and will be in between the two scans be off and on the table at a UHRCT scanner. (Aquilion One Precision, Canon Medical Systems)
62617511|NCT04465656||[PCR-COVID 19-Neg & Sero-COVID 19-Neg] group|"* Having a microbiological diagnosis confirming the absence of COVID-19 infection (ie negative RT-PCR on nasopharyngeal swab) and absence of clinical /CT signs~* Having been tested negative in a serological test for COVID-19 at M3"
62617512|NCT02020512|EXPERIMENTAL|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
62843062|NCT02544581||Mandated impaired professionals|Physicians and other licensed healthcare professionals in mandated monitoring programs by State licensing boards due to Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment.
62843063|NCT02544581||Non-mandated adults|A general population of adults in aftercare following residential treatment for Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment.
62843064|NCT00540332|PLACEBO_COMPARATOR|Placebo|"Approximately 17 subjects to receive palifermin. Subjects will be enrolled as follows:~* PK cohort will be randomized in a 3:1 ratio \[palifermin: placebo\] in at least 12 subjects~* Non-PK cohort will be randomized in a 1:1 ratio \[palifermin: placebo\] in up to 28 subjects."
62843065|NCT00540332|EXPERIMENTAL|Palifermin|"Approximately 23 subjects to receive palifermin. Subjects will be enrolled as follows:~* PK cohort will be randomized in a 3:1 ratio \[palifermin: placebo\] in at least 12 subjects~* Non-PK cohort will be randomized in a 1:1 ratio \[palifermin: placebo\] in up to 28 subjects."
62843066|NCT00787618|ACTIVE_COMPARATOR|50 mg Proellex Mild impairment|50 mg Proellex single dose Female subjects with mild renal impairment function.
62843067|NCT00787618|ACTIVE_COMPARATOR|50 mg Proellex Moderate|50 mg Proellex, Female subjects with moderate renal impairment function.
62843068|NCT00787618|ACTIVE_COMPARATOR|50 mg Proellex, Normal|50 mg Proellex, Female subjects with normal renal function.
62057593|NCT01724645|ACTIVE_COMPARATOR|Control group|"Control group : told to eat as usal diet) for 12weeks"
62843069|NCT03330249|EXPERIMENTAL|Split Cisplatin and radiotherapy|25 mg/m2/day IV infusion at D1 to D4, at D22 to D25, at D43 to D46 during the radiotherapy
62057594|NCT02465502|EXPERIMENTAL|Regorafenib (BAY73-4506)|Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
62260909|NCT02690870|EXPERIMENTAL|tamoxifen|All patients will have serum hormone examination and be monitored by transvaginal ultrasound for ovaries on the day 3 of the menses（D3）.Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from D3 for 5 days.All patients will check serum E2 and be monitored by transvaginal ultrasound for the mean follicular diameter and endometrial thickness on the day 8 of the cycle. The investigators will add HMG and GnRH-ant according to follicular diameter,E2 and LH. Human chorionic gonadotropin(hCG) (5000-10000 IU IM) will be given when one follicle measured at least 18 mm is found. IVF or ICSI will be performed 34-36 h after hCG administration. All patients will receive luteal phase support with progesterone 60 mg im qd for 2 weeks.
62260910|NCT02690870|ACTIVE_COMPARATOR|clomiphene|All patients will have serum hormone examination and be monitored by transvaginal ultrasound for ovaries on the day 3 of the menses（D3）.Patients in clomiphene group will take 100 mg of CC oral tablets daily from D3 for 5 days.All patients will have sexual hormone determination and be monitored by transvaginal ultrasound for the mean follicular diameter and endometrial thickness on the day 8 of the cycle.The investigators will add HMG and GnRH-ant according to follicular diameter,E2 and LH. Human chorionic gonadotropin(hCG) (5000-10000 IU IM) will be given when one follicle measured at least 18 mm is found. IVF or ICSI will be performed 34-36 h after hCG injection. All patients will receive luteal phase support with progesterone 60 mg im qd for 2 weeks.
62260911|NCT02226107|EXPERIMENTAL|Peer-PN|Peer Patient Navigation
62260912|NCT02226107|ACTIVE_COMPARATOR|Pro-PN|Professional Patient Navigation
62260913|NCT01433848||Child A liver cirrhosis|
62260914|NCT01433848||Child B liver cirrhosis|
62260915|NCT01433848||Child C liver cirrhosis|
62260916|NCT02613936|EXPERIMENTAL|Active anodal tDCS + cognitive training|In this arm, patients with mmTBI will undergo 10 sessions of active tDCS x 30 minutes combined with simultaneous cognitive training on consecutive weekdays.
62260917|NCT02613936|SHAM_COMPARATOR|Placebo anodal tDCS + cognitive training|In this arm, patients with mmTBI will undergo 10 sessions of placebo tDCS x 30 minutes combined with simultaneous cognitive training on consecutive weekdays.
62260918|NCT01443520|PLACEBO_COMPARATOR|Placebo|
62260919|NCT01443520|ACTIVE_COMPARATOR|Duloxetine|
62843070|NCT03330249|ACTIVE_COMPARATOR|Cisplatin and radiotherapy|100 mg/m2/day IV infusion at D1, D22 and D43 during the radiotherapy
62843071|NCT02390505|EXPERIMENTAL|Vitamin C|Patients receive vitamin C at a daily dose of 500 mg orally: 7 days before and during 6 weeks after surgery
62843072|NCT02390505|PLACEBO_COMPARATOR|Placebo|Patients receive placebo at a daily dose of 500 mg orally: 7 days before and during 6 weeks after surgery
62843073|NCT00210951||Participants Receiving Epoetin Alfa or Another Erythropoietin|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
62843074|NCT05048095||Screened women in Region Östergötland Linkoping|
62843075|NCT01243580|ACTIVE_COMPARATOR|Ortho-Cyclen®|Ortho-Cyclen® is a comparator drug intervention
62843076|NCT01243580|EXPERIMENTAL|AG200-15|AG200-15 is an investigational transdermal contraceptive delivery system that is a drug intervention
62843077|NCT00635999|EXPERIMENTAL|Purely Behavioral therapy|Participants will receive treatment with progressive and applied relaxation and self-control desensitization.
62843078|NCT00635999|EXPERIMENTAL|Cognitive-Behavioral Therapy|Participants will receive treatment with cognitive therapy, progressive and applied relaxation, and self-control desensitization
62843079|NCT00635999|EXPERIMENTAL|Cognitive Therapy (CT)|Participants will receive purely cognitive therapy including identification of maladaptive thought processes and training in cognitive restructuring.
62843080|NCT04972617||observational group|"In patients with intravenous furosemide administration, an additional 15 ml of blood is taken for the analysis of specific parameters as part of the blood sampling necessary for the treatment of the patient.~The effect of furosemide is assessed on the basis of the patient's urine excretion. For this purpose, fluid intake and excretion are balanced over 6 hours. The blood sample is taken at the beginning of the balancing period.~In addition, the albumin concentration, ABiC, as well as the total and free concentration of furosemide in the collected urine are determined."
62843081|NCT06424652|OTHER|Single Participant with Evidence of cognitive impairment.|
62057595|NCT03234153|EXPERIMENTAL|Durvalumab and Tremelimumab|Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
62057596|NCT03996408|EXPERIMENTAL|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
62617513|NCT04606875||Control Group|Subjects will have no personal or family psychiatric history and no suicide attempts.
62617514|NCT04606875||Patients with Suicidal Ideation and Low Acquired Capability|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item \>2) and reported low acquired capability for suicide (Acquired Capability for Suicide Scale \<20)
62260920|NCT01443520|ACTIVE_COMPARATOR|Venlafaxine|
62260921|NCT06039124||HHT patients previously included in BABH study|Clinical and therapeutic follow-up of HHT patients for one year after the end of a clinical trial using bevacizumab.
62260922|NCT03362970|ACTIVE_COMPARATOR|Standard of Care|For children randomized to the standard of care arm, the treating physician will be informed to proceed as per their usual practice and treatment patterns. If stool is unavailable a rectal swab will be collected and sent to Calgary Laboratory Services (CLS) for routine culture. A routine stool specimen for back-up culture will still be requested as per standard of care. Home stool collection will be performed for those unable to provide a sample at enrolment and will be achieved by providing families with collection kits.
62617515|NCT04606875||Patients with Suicidal Ideation and High Acquired Capability|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item \>2) and reported high acquired capability for suicide (Acquired Capability for Suicide Scale \>60)
62617516|NCT06124105|OTHER|urine PO2|
62617517|NCT04958161|EXPERIMENTAL|Exercise Therapy|Exercise therapy will be performed three times per week for 12 weeks.
62617518|NCT04958161|NO_INTERVENTION|Wait List Control|Wait-list-control participants will be asked to continue their normal activities over the 12 week period.
62617519|NCT04861441|EXPERIMENTAL|Continuous Cryotherapy|Subjects will use continuous cryotherapy post operative for pain control
62057597|NCT00317889|EXPERIMENTAL|Compaction|Compaction technique for femoral bone preparation prior to cementless femoral stem insertion.
62260923|NCT03362970|EXPERIMENTAL|BioFire Gastrointestinal Panel FilmArray|For children randomized to the BioFire FilmArray arm, stool, if available, will be sent STAT to Calgary Laboratory Services (CLS) for the performance of the BioFire FilmArray test and routine culture. If stool is unavailable, a rectal swab will be performed and sent to CLS for the performance of the BioFire FilmArray test and routine culture. A routine stool specimen for back-up culture will still be requested as per standard of care once it is available. Treatment decisions will be at the sole discretion of the ED treating physician who receives the result.
62260924|NCT02409589|EXPERIMENTAL|ECG-guided PICC Tip Placement|New intracavitary ECG guiding method
62057598|NCT00317889|ACTIVE_COMPARATOR|Broaching|Broaching technique for femoral bone preparation prior to cementless femoral stem insertion.
62057599|NCT05154123|EXPERIMENTAL|AT-527 + rosuvastatin (simultaneous) n=14|
62260925|NCT02409589|ACTIVE_COMPARATOR|Conventional|Surface prediction length method
62260926|NCT01514487|EXPERIMENTAL|pH 7.7|
62260927|NCT01514487|EXPERIMENTAL|pH 7.9|
62260928|NCT01514487|EXPERIMENTAL|pH 8.15|
62260929|NCT03371615|ACTIVE_COMPARATOR|Fermented IF + LBG + Gos Fos|Fermented infant formula with Locust bean gum and Gos Fos
62260930|NCT03371615|PLACEBO_COMPARATOR|Fermented IF +LBG|Fermented infant formula with Locust bean gum
62057600|NCT05154123|EXPERIMENTAL|AT-527 + rosuvastatin (staggered) n=14|
62260931|NCT02808754|NO_INTERVENTION|Usual Care|Patients in the usual care arm will undergo CEA without RIPC.
62260932|NCT02808754|EXPERIMENTAL|Remote Ischemic Preconditioning|Patients in the RIPC arm will undergo CEA with RIPC.
62260933|NCT02104986|EXPERIMENTAL|3 courses of Velbe-Bleomycin-Cisplatin|3 VBP (Velbe-Bleomycin-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
62617520|NCT04861441|ACTIVE_COMPARATOR|Icepack|Subjects will use standard icepacks post operative for pain control
62260934|NCT02104986|EXPERIMENTAL|4 courses of Velbe-Bleomycin-Cisplatin|4 VBP (Velbe-Bleomycin-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
62260935|NCT02104986|EXPERIMENTAL|3 courses Vepeside-ifosfamide-Cisplatin|3 VIP (Vepeside-ifosfamide-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
62260936|NCT02104986|EXPERIMENTAL|4 courses Vepeside-ifosfamide-Cisplatin|4 VIP (Vepeside-ifosfamide-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
62260937|NCT02998775|OTHER|6 participants with mild renal impairment|Renal Impairment Mild: creatinine clearance, 50 to 80 milliliters per minute (mL/min)
62260938|NCT02998775|OTHER|6 participants with moderate renal impairment|Renal Impairment Moderate: creatinine clearance, 30 to 49 mL/min
62260939|NCT02998775|OTHER|6 participants with severe renal impairment|Renal Impairment Severe: creatinine clearance, 15 to 29 mL/min
62260940|NCT02998775|OTHER|8 participants normal renal status|Renal status normal as defined by creatinine clearance ≥ 81 mL/min, otherwise age, gender, and smoking characteristics matching renal-impaired participants
62617521|NCT04599192||Women Presenting with Cardiac Ischemia|Women presenting with cardiac ischemia as indicated by standard of care non-invasive stress testing with cardiac magnetic resonance (CMR), SPECT myocardial perfusion, and PET myocardial perfusion imaging. This cohort of women must also meet the clinical criteria to undergo coronary angiography. Women may be approached for consent either before or after their coronary angiography procedure.
62617522|NCT00897975|EXPERIMENTAL|red yeast rice (RYR) plus phytosterol|arm will take red yeast rice and phytosterol supplement
62617523|NCT00897975|PLACEBO_COMPARATOR|red yeast rice plus placebo|
62617524|NCT00897975|ACTIVE_COMPARATOR|TLC plus red yeast rice plus placebo|subjects attend 12 week therapeutic lifestyle program and take above supplement
62617525|NCT00897975|EXPERIMENTAL|TLC plus RYR plus phytosterol|Therapeutic lifestyle program for 12 weeks plus red yeast rice plus phytosterol
62617526|NCT04054726|EXPERIMENTAL|Real tPCS|Patients of degenerative ataxia will be randomly allocated into both the arms. Real tPCS arm will receive active tPCS. Then they will be crossed over to Sham tPCS arm.
62617527|NCT04054726|SHAM_COMPARATOR|Sham tPCS|Patients of degenerative ataxia will be randomly allocated into both the arms. Sham tPCS arm will receive sham tPCS. Then they will be crossed over to Real tPCS arm.
62617528|NCT02708797|OTHER|Migraine with aura Patients|Patients with migraine with aura will be studied 30 days after the pre inclusion visit with both magnetic resonance imaging and Transcranial Doppler.
62843082|NCT02109185|ACTIVE_COMPARATOR|Mometasone Furoate Monohydrate Nasal Spray,50 μg/act.|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Mometasone Furoate Monohydrate Nasal Spray per nostril once daily for 14 days. Total Daily Dose = 4 × 50 μg = 200 μg.
62843083|NCT02109185|ACTIVE_COMPARATOR|Nasonex® Nasal Spray, 50 μg/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Nasonex® Nasal Spray per nostril once daily for 14 days, Total Daily Dose = 4 × 50 μg = 200 μg.
62843084|NCT02109185|ACTIVE_COMPARATOR|Nasonex® Nasal Spray Suspnsn, 50 μg/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Nasonex® Nasal Spray Suspension per nostril once daily for 14 days, Total Daily Dose = 4 × 50 μg = 200 μg.
62843085|NCT02109185|PLACEBO_COMPARATOR|Placebo Nasal Spray, 50 μL/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays of placebo nasal spray per nostril once daily.
62843086|NCT05562219|EXPERIMENTAL|Treatment group(QA108 granules)|QA108 granules, 7.5 g/bag,2 bags/time, BID
62843087|NCT05562219|PLACEBO_COMPARATOR|Placebo group(QA108 granule simulants)|QA108 granule simulants, 7.5 g/bag,2 bags/time, BID
62843088|NCT04803396|PLACEBO_COMPARATOR|Placebo RS/PKS/PDS/SS|Placebo was administered once a day (oad) as matching oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
62843089|NCT04803396|EXPERIMENTAL|DF2755A 50 mg - RS/PKS/PDS/SS|"The experimental drug was administered once a day (oad) as one oral capsule of 50 mg.~The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions."
62260941|NCT02998775|OTHER|6 participants with mild hepatic impairment|Hepatic impairment mild: total score on the Child-Pugh classification system between 5 and 6
62260942|NCT02998775|OTHER|6 participants with moderate hepatic impairment|Hepatic impairment moderate: total score on the Child-Pugh classification system between 7 and 9
62617529|NCT02708797|OTHER|Controls|Control group with healthy volunteers will be studied 30 days after the pre inclusion visit with both magnetic resonance imaging and Transcranial Doppler.
62843090|NCT04803396|EXPERIMENTAL|DF2755A 150 mg - RS/PKS/PDS/SS|The experimental drug was administered once a day (oad) as oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
62617530|NCT00968188|EXPERIMENTAL|Active intervention|Highly interactive, motivational, culturally tailored, online HIV prevention.
62617531|NCT00968188|ACTIVE_COMPARATOR|Information only|Medically fact based online intervention.
62843091|NCT04803396|EXPERIMENTAL|DF2755A 300 mg - RS/PKS/PDS/SS|The experimental drug was administered once a day (oad) as oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
62843092|NCT04803396|EXPERIMENTAL|DF2755A 600 mg - RS/PKS/PDS/SS|The experimental drug was administered once a day (oad) as oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
62843093|NCT03603262|EXPERIMENTAL|SH-1028|Oral Once-Daily Administration of SH-1028
62843094|NCT05366738|EXPERIMENTAL|Treatment Sequence 1|Participants assigned to Treatment Sequence 1 will receive vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of pudding on Day 1 of Treatment Period 1, vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of applesauce on Day 1 of Treatment Period 2, and vonoprazan 20 mg as a tablet on Day 1 of Treatment Period 3.
62843095|NCT05366738|EXPERIMENTAL|Treatment Sequence 2|Participants assigned to Treatment Sequence 2 will receive vonoprazan 20 mg as a tablet on Day 1 of Treatment Period 1, vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of pudding on Day 1 of Treatment Period 2, and vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of applesauce on Day 1 of Treatment Period 3.
62843096|NCT05366738|EXPERIMENTAL|Treatment Sequence 3|Participants assigned to Treatment Sequence 3 will receive vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of applesauce on Day 1 of Treatment Period 1, vonoprazan 20 mg as a tablet on Day 1 of Treatment Period 2, and vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of pudding on Day 1 of Treatment Period 3.
62843097|NCT04208971||BEAGLE Participants|Adult patients who have not been previously diagnosed with AF, are eligible for anticoagulation and have AI-predicted risks based on a normal sinus rhythm ECG.
62617532|NCT05521152|EXPERIMENTAL|(Group N)|1 mg norepinephrine will be diluted in dextrose 5% in a 50 mL syringe using a nomogram based on the infant body weight so that 1mL= 0.05 µg/kg/min norepinephrine infusion and the syringe will be set on 2 ml/h
62843098|NCT05179590||General anesthesia Group|
62057601|NCT02707458|EXPERIMENTAL|Single arm|All subjects will receive probucol, starting with a fixed dose of 600 mg daily following the evening meal. The variable plasma concentrations achieved and the resulting modification in concentration of CSF apoE will suggest an ideal range of plasma concentrations for use of the drug as an inducer of increased availability of apoE in the CSF. The known dose-proportionality of the drug in plasma will then be used to estimate an ideal individualized dose for each participant. The effects of such individualized dosage will be tested over 1 year of follow-up observations, searching for treatment effects on CSF apoE and for evidence of other treatment effects, particularly including adverse effects.
62260943|NCT02998775|OTHER|6 participants with severe hepatic impairment|Hepatic impairment severe: total score on the Child-Pugh classification system between 10 and 15
62260944|NCT02998775|OTHER|8 participants normal hepatic status|Hepatic status normal, otherwise age, gender, and smoking characteristics matching hepatic-impaired participants
62260945|NCT01631136|ACTIVE_COMPARATOR|Continuous maintenance Therapy|Induction chemotherapy by cisplatin + pemetrexed and maintenance therapy by pemetrexed
62617533|NCT05521152|PLACEBO_COMPARATOR|(Group S)|equivalent volume of saline will be prepared in 50 mL syringe and the infusion will be set on 2ml/kg
62843099|NCT01154257|EXPERIMENTAL|Cleaning teeth with toothbrush|Following randomisation one side of the mouth (split mouth study) will be assigned to cleaning teeth with a toothbrush
62843100|NCT01154257|EXPERIMENTAL|Cleaning teeth with foam swab|Following randomisation one side of the mouth (split mouth study) will be assigned to cleaning teeth with a faom swab
62260946|NCT01631136|EXPERIMENTAL|Maintenance according to the response of induction|"Induction chemotherapy by cisplatin + gemcitabine followed by :~* continuous maintenance therapy by gemcitabine if response disease~* switch maintenance therapy by pemetrexed if stable disease"
62843101|NCT05115071|EXPERIMENTAL|Experimental|
62843102|NCT05115071|NO_INTERVENTION|No intervention|
62843103|NCT00542282||1, 2, 3|known moderate to severe COPD, known moderate or severe Asthma, suspected obstructive moderate to severe airways disease
62843104|NCT00786370|ACTIVE_COMPARATOR|Propofol|
62446273|NCT01346423|EXPERIMENTAL|Intervention group|Treatment team with a physician, a physiotherapist, a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The patient meets at the outpatient clinic three times; at baseline, after 2 weeks and after 3 months. One year after baseline the patient has a telephone-follow-up. At baseline, the patient and the team works out a rehabilitation plan and in this process a new visual, educational tool is central.
62617534|NCT01979237|EXPERIMENTAL|SPASO method, FARES method|Reduction method: SPASO method, FARES method
62843105|NCT00786370|EXPERIMENTAL|Dexmedetomidine|
62446274|NCT01346423|ACTIVE_COMPARATOR|Controll group|The brief intervention is a standardized intervention based on the studies by Indahl and Hagen. Therapist treatment manuals will be written for the intervention. The essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. Unless symptoms and clinical findings indicate some serious disease, the patients will be informed about the good prognosis, and the importance of staying active to avoid development of muscle dysfunction.
62617535|NCT04099537|EXPERIMENTAL|Approach cognitive training|This training is a single session training. Each session lasts about 30 minutes where participants are to pull the joystick toward (approach) them when seeing skin stimuli on a computer screen.
62617536|NCT04099537|EXPERIMENTAL|Avoidance cognitive training|This training is a single session training. Each session lasts about 30 minutes where participants are to push the joystick away (avoidance) from them when seeing skin stimuli on a computer screen.
62617537|NCT04099537|PLACEBO_COMPARATOR|Placebo cognitive training|This training is a single session training. Each session lasts about 30 minutes where participants are to push and pull the joystick towards or away from them (no rule) when seeing skin stimuli on a computer screen.
62617538|NCT04438798|PLACEBO_COMPARATOR|face mask group|Pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.
62617539|NCT04438798|ACTIVE_COMPARATOR|THRIVE group|High-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.
62617540|NCT00954200|PLACEBO_COMPARATOR|Placebo|
62617541|NCT00954200|ACTIVE_COMPARATOR|ibuprofen|
62843106|NCT02328365|NO_INTERVENTION|Standard|Patients screened positive for cardiopulmonary disease and having a medical (pulmonary and/or cardiology) visit preoperatively, but randomized to standard follow-up
62843107|NCT02328365|EXPERIMENTAL|Intervention|Patients screened positive for cardiopulmonary disease and having a medical (pulmonary and/or cardiology) visit preoperatively, but randomized to structured medical follow-up after operation
62057602|NCT03391765|EXPERIMENTAL|M15-562 ABBV-8E12 2000 mg/M15-563 ABBV-8E12 2000 mg|Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).
62057603|NCT03391765|EXPERIMENTAL|M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg|Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).
62057604|NCT03391765|EXPERIMENTAL|M15-562 Placebo/M15-563 ABBV-8E12 2000 mg|Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.
62446275|NCT05894863|EXPERIMENTAL|Smart flex stent group|Smart flex stent will be used for patients with femoropopliteal lesions receiving endovascular treatment.
62446276|NCT01579474|EXPERIMENTAL|1. BI 201335 low dose plus PegIFN/RBV|low dose BI 201335 NA once daily for 12 or 24 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
62446277|NCT01579474|EXPERIMENTAL|2. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 12 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
62446278|NCT01579474|EXPERIMENTAL|3. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 24 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-experienced (relapser) patients
62446279|NCT01579474|EXPERIMENTAL|4. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 24 weeks combined with PegIFN/RBV for 48 weeks in treatment-experienced (null responder, partial responder, breakthrough) patients
62057605|NCT03391765|EXPERIMENTAL|M15-562 Placebo/M15-563 ABBV-8E12 4000 mg|Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.
62057606|NCT04770064|EXPERIMENTAL|High-dose/short-duration Fisetin (FIS-hi)|
62057607|NCT04770064|EXPERIMENTAL|Low-dose/sustained duration Fisetin (FIS-lo)|
62057608|NCT04770064|PLACEBO_COMPARATOR|Placebo|
62446280|NCT00992264|EXPERIMENTAL|Message Tone|"Prescriptive or Motivational~Persons are randomized to receive intervention content written in either a prescriptive or motivational tone."
62617542|NCT05812430|EXPERIMENTAL|anlotinib+TQB2450+nab-paclitaxel+cisplatin|
62843108|NCT04462614|EXPERIMENTAL|single-arm study|Chronic hemodialysis patients for at least 3 months at Reims University Hospital, treated by long-term anticoagulation with VKA and dialysed with the HeprAN ™ membrane
62843109|NCT02914301|ACTIVE_COMPARATOR|Babyscripts Prenatal App|For patients allocated to the experimental group, they will be assisted in downloading the BRx app to their smartphone and set up the connected weight scale and blood pressure cuff. At time of enrollment, research assistant will also collect baseline demographic and clinical data. For patients allocated to this study arm, the clinician will be informed and therefore, will be receiving regular app-based education while the clinician will be receiving regular blood pressure and weight measurements. Following that communication, it will be the physicians' judgement to reduce in-person visits from usual care.
62446281|NCT00992264|EXPERIMENTAL|Testimonials|Persons are randomized to receive a personally tailored testimonial or not.
62446282|NCT00992264|EXPERIMENTAL|Navigation|"Dictated or Non-Dictated~Persons are randomly assigned to be able to freely navigate the website or to have their navigation of the website pre-determined based on their baseline readiness to quit smoking."
62446283|NCT00992264|EXPERIMENTAL|Proactive Outreach|"Email or No-Email communication~Persons are randomized to receive periodic email reminders to return to the intervention website or not."
62617543|NCT03147807|EXPERIMENTAL|betaLACTA® result given to physician|In the experimental group, betaLACTA® rapid diagnostic test guided de-escalation result will be given to physician at Day 0 and empirical carbapenems will be de-escalated to Cefepime or Ceftazidime +/- Amikacin since the second dose.
62617544|NCT03147807|NO_INTERVENTION|betaLACTA® result NOT given to physician|In the control group, betaLACTA® result will not be given to physician and patients will receive empirical carbapenem during the time required to obtain final results of antibiotic susceptibility test
62617545|NCT06207760|EXPERIMENTAL|Minocycline|All subjects will receive Minocycline over 8 weeks in addition to their current antidepressant treatment.
62617546|NCT05314179|EXPERIMENTAL|Doula-Patient engagement|"Four hours/week of Ubuntu ambassador/Doula and Patient engagement. The nature and type of visits will be determined by the patient and doula.~The doula will formulate weekly reports for each assigned patient. Weekly progress reporting - Weeks 2- 24."
62617547|NCT01308996|EXPERIMENTAL|INFUSE® Bone Graft|
62617548|NCT01308996|ACTIVE_COMPARATOR|Autogenous bone graft|
62617549|NCT03642600|ACTIVE_COMPARATOR|dietary advice plus myo-inositol and folic acid|2gram myo-inositol and folic acid twice daily orally lack of consistent evidence for myo-inositol as treatment of women with PCOS
62617550|NCT03642600|ACTIVE_COMPARATOR|dietary advice plus liraglutide pen injector|liraglutide starting at 0.6 mg, gradually increasing up to a dose of 3 mg daily after four weeks no evidence for weight loss in women with PCOS
62617551|NCT04485637|OTHER|Communication with basic table|Blood pressure communication showing a basic table representing only the normal range of blood pressure readings
62617552|NCT04485637|OTHER|Communication with enhanced table|Communication showing an enhanced table (Fig 1B) with more reference information for interpreting blood pressure readings, including how combinations of diastolic and systolic blood pressure reflect normal, elevated and hypertension ranges (adapted from the American Heart Association)
62617553|NCT04485637|OTHER|Communication with enhanced graph|Communication showing an enhanced graph (adapted from Blood Pressure UK) for interpreting blood pressure readings, showing the same color-coded ranges as the enhanced table, with diastolic blood pressure on the x-axis and systolic blood pressure on the y-axis
62617554|NCT04965428|EXPERIMENTAL|Fear-focused Self-Compassion Therapy|Experimental group receives group face-to-face Fear-focused Self-Compassion Therapy for eight weeks.
62446284|NCT02809183|PLACEBO_COMPARATOR|Placebo-BID|Administered twice daily (BID) for 14 days
62617555|NCT04965428|NO_INTERVENTION|Usual care|The no intervention group receives usual care supported by hospital or coming from elsewhere for eight weeks.
62617556|NCT02230826||Patients with Hip arthroplasty|Patients with Hip implants.
62617557|NCT03268512|EXPERIMENTAL|L-PRF|One socket will be filled with L-PRF membranes and covered with at least 2 L-PRF membranes. A modified horizontal mattress will be place as suture to keep the L-PRF in place.
62617558|NCT03268512|EXPERIMENTAL|A-PRF|One socket will be filled with A-PRF membranes and covered with at least 2 A-PRF membranes. A modified horizontal mattress will be place as suture to keep the A-PRF in place.
62617559|NCT03268512|NO_INTERVENTION|Control|The socket will be filled with a natural blood clot. A modified horizontal mattress will be place as suture.
62617560|NCT02711020|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy delivered in individual format.
62617561|NCT02711020|EXPERIMENTAL|Personal Construct Therapy|Personal Constructs Therapy delivered in individual format.
62617562|NCT02533297|EXPERIMENTAL|clinical education|the researcher used the checklist to assess the student's mastery level skill l while changing a skill and recorded his score on the learning curve based on a 1 (no mastery) to 100 (complete mastery) scoring scale. This procedure continued until the learning curve reached to a plateau state, i.e. either reaching to the full mastery score (100) or revealing no significant change in three subsequent sessions. All the students achieved mastery (the plateau state) after performing the task for at most ten times.
62617563|NCT01703559|PLACEBO_COMPARATOR|Placebo|Administered once daily in both eyes for 15 days
62617564|NCT01703559|EXPERIMENTAL|Phentolamine Mesylate Ophthalmic Solution 0.5%|Administered once daily in both eyes for 15 days
62446285|NCT02809183|EXPERIMENTAL|TRC101 (1.5g BID)|Administered twice daily (BID) for 14 days
62617565|NCT01703559|EXPERIMENTAL|Phentolamine Mesylate Ophthalmic Solution 1.0%|Administered once daily in both eyes for 15 days
62446286|NCT02809183|EXPERIMENTAL|TRC101 (3g BID)|Administered twice daily (BID) for 14 days
62617566|NCT02978612|EXPERIMENTAL|Arm Capecitabine|Capecitabine 1000 mg/m2 bid day 1-14 q3 weeks, 8 cycles
62617567|NCT02978612|NO_INTERVENTION|Arm No treatment|no chemotherapy, observation
62617568|NCT05230199|ACTIVE_COMPARATOR|Monitored standard of care|At the study site, much like other contemporary NICUs, parents are encouraged to be present 24 hours per day, with significant variability in the amount, types and timing of parent engagement. Infant holding is supported, provided the infant can maintain physiological stability during handling. Parents can hold infants on mechanical ventilation, but holding is not encouraged during times when the infant is on oscillatory ventilation and/or when chest tubes are in place. Holding time may be restricted in infants \<32 weeks due to temperature instability. Nurses and therapists foster parent participation through instruction on caregiving and developmentally appropriate interactions, but these are balanced with other priorities of care. With standard of care, there is no targeted and set amount of positive sensory exposure, and practices vary based on the comfort level of nurses, the medical team, and the parents.
62057609|NCT06184243|EXPERIMENTAL|Parent-Implemented Video Modeling|Parent intervention teaches the skills to implement video modeling intervention for their young child with a developmental delay. Video modeling intervention teaches the young child new play and conversation skills.
62057610|NCT01299155|EXPERIMENTAL|ReSTOR +3|Bilateral implantation of a ReSTOR +3 Intraocular Lens (IOL) Model SN6AD1
62057611|NCT01299155|ACTIVE_COMPARATOR|LENTIS MPlus|Bilateral implantation of a LENTIS MPlus Intraocular Lens (IOL) Model
62260947|NCT04071574|ACTIVE_COMPARATOR|"Protocol A"|"Protocol with gonadotropins alone without agonist or antagonist:~Gonadotropin treatment begins after spontaneous menses. The gonadotropins (e.g. Menopur, 150-225IU) are injected daily from D2/3 of the cycle (Gonadotropin dose varies based on the follicular response). The moment to trigger ovulation by administration of HCG (e.g. Ovitrelle or Pregnyl, 10.000IU) is determined by monitoring ovulation (folliculogenesis) approximately 14 days after gonadotropins regimen and the presence of at least 3 follicles with 18 mm sizes and at least the levels of E2 reaches 250-300 pg/ml. 36 h after HCG triggering, the mature oocytes are retrieved."
62843110|NCT02914301|PLACEBO_COMPARATOR|Placebo|For patients cared for by clinicians allocated to the control (usual care) arm, the clinician will discuss the management options and scheduling procedures with the patient in that clinician's usual fashion. The patient will not be given access to the BRx app but will consent to the study data collection and survey administration. All potential study subjects will receive standard medical care per DoD/VA Clinical Practice Guidelines for Management of the uncomplicated pregnancy (REF) and local preference by board-certified OB/GYN physicians.
62843111|NCT04274946|ACTIVE_COMPARATOR|RAI+PB+US|Sentinel lymph node mapping with dual tracer (radioisotope and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
62843112|NCT04274946|EXPERIMENTAL|RAI+ICG+US|Sentinel lymph node mapping with dual tracer (radioisotope and ICG) and intraoperative ultrasound to identify SLN in the breast cancer patients
62843113|NCT04274946|EXPERIMENTAL|RAI+PB+ICG+US|Sentinel lymph node mapping with triple tracer (radioisotope,ICG and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
62843114|NCT04274946|EXPERIMENTAL|PB+ICG+US|Sentinel lymph node mapping with triple tracer (ICG and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
62843115|NCT01063283|ACTIVE_COMPARATOR|Group A|Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg once, followed three weeks later by Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg and bevacizumab every 3 weeks for two doses
62843116|NCT01063283|ACTIVE_COMPARATOR|Group B|Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg once, followed three weeks later by Carboplatin+Pemetrexed+Bevacizumab 15 mg/kg and bevacizumab every 3 weeks for two doses
62446287|NCT02809183|EXPERIMENTAL|TRC101 (4.5g BID)|Administered twice daily (BID) for 14 days
62057612|NCT05386667||Control|Patients were not given anything after FGG.
62446288|NCT02809183|EXPERIMENTAL|TRC101 (6g QD)|Administered once daily (QD) for 14 days
62446289|NCT02809183|PLACEBO_COMPARATOR|Placebo-QD|Administered once daily (QD) for 14 days
62446290|NCT03847558||sexual maturation in patient receiving iron chelation|assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
62617569|NCT05230199|EXPERIMENTAL|SENSE multisensory program|The SENSE program includes the provision of specific types and amounts of evidence-based tactile, auditory, visual, vestibular/kinesthetic, and olfactory interventions to be conducted by parents with their preterm infants, with a specific amount defined for each day of hospitalization. The program changes across PMA and an infant's tolerance of the prescribed activities. A sensory support team can fill in the gaps in intervention for infants in the SENSE group when parents are not available. The parent education materials identify specific doses of sensory inputs at each PMA. Feasibility has been established, with provision of an average of 155 hours of sensory exposures across NICU hospitalization.
62617570|NCT02992184||HCV patients|228 HCV patients
62617571|NCT02992184||control|189 controls
62617572|NCT01222663|OTHER|Standard therapy|Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate
62617573|NCT01222663|EXPERIMENTAL|Hemoperfusion|standard therapy + 2 sessions of hemoperfusion within the first 24 hours
62617574|NCT01459393|EXPERIMENTAL|5-ALA Photodynamic Therapy|Topical application of a 2mm of thickness layer of 20% 5-aminolevulinic acid (5-ALA) associated with 20% dimethyl sulfoxide (DMSO) and 3% ethylene diamine acid (EDTA) emulsion, over the actinic keratosis lesion and over a 0,5 cm margin around it. After a 4 hours interval under light protection with plastic film and aluminum foil, the light protection and the emulsion is removed. Then the lesion is lightened with a red (630 nm) incoherent LED lamp AKTILITE CL 128 (PhotoCure ASA, Oslo, Norway) with a total light dose of 37J/cm2.After that dressings are done and kept for 24H, and removed at patient home.
62617575|NCT01459393|ACTIVE_COMPARATOR|Cryotherapy with liquid nitrogen|Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
62617576|NCT02572960|PLACEBO_COMPARATOR|Cholecalciferol|Cholecalciferol 70 mcg/day for 12 weeks Placebo Valsartan daily for 2 weeks
62446291|NCT05819567|EXPERIMENTAL|Healthy Subjects|"Students and employees of the Vrije Universiteit Brussel as well as people from outside this institution will be recruited (via Flyer), contacted and asked if they will want to participate. No gender restrictions will be applied, the participants must be adult (18\<age \<60) and healthy.~Inclusion Criteria:~* Healthy volunteers;~* 18\<Age\<60;~* Exclusion Criteria:~* Symptoms in their lower limbs in the past 6 months~* History of foot and/or ankle conditions and/or surgery~* Pregnancy"
62446292|NCT00343980|EXPERIMENTAL|A|
62617577|NCT02572960|ACTIVE_COMPARATOR|Valsartan|Placebo cholecalciferol/day for 12 weeks Valsartan 80 mg/day for 2 weeks
62617578|NCT02572960|PLACEBO_COMPARATOR|Placebo|Placebo cholecalciferol/day for 12 weeks Placebo Valsartan daily for 2 weeks
62617579|NCT02572960|ACTIVE_COMPARATOR|Cholecalciferol and Valsartan|Cholecalciferol 70 mcg/day for 12 weeks Valsartan 80 mg/day for 2 weeks
62617580|NCT05460078|EXPERIMENTAL|Virtual program|Seen at a location where the virtual program is being offered
62617581|NCT05460078|NO_INTERVENTION|Standard care|Seen at a location where standard care is offered
62057613|NCT05386667||Flurbiprofen|Oral spray containing 0.075 g flurbiprofen administered after FGG
62446293|NCT00343980|ACTIVE_COMPARATOR|B|
62446294|NCT05065970|PLACEBO_COMPARATOR|Placebo|
62446295|NCT05065970|EXPERIMENTAL|Felzartamab Arm #1|
62843117|NCT04108637|EXPERIMENTAL|penicillin allergy assessment pathway|"Those in the PAAP intervention arm will complete stage 2\&3 of the PAAP pathway:~* Stage-2 assessed for skin testing (ST) and ST done or straight to stage 3~* Stage-3 oral challenge test (OCT) All completing PAAP will receive a letter from the immunology clinic giving the results of the test. Also, patients who have tested negative will receive the Post-test Intervention Booklet and Patient Intervention Card Materials.~Additionally, all participants in the PAAP arm will be called by the trial team at days 4-6 and 28-30 post testing to collect safety data. During the call at days 28-30 patients will complete the patient questionnaire on allergy beliefs.~Practices will be informed of the test result and instructed to update the participant's electronic health records accordingly."
62843118|NCT04108637|NO_INTERVENTION|Control Arm|The usual care arm receive no intervention but will be followed up as per intervention arm with monitoring of any symptoms following an antibiotic prescription.
62843119|NCT00539864|EXPERIMENTAL|FluBlok|"Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004~135μg total"
62843120|NCT00539864|ACTIVE_COMPARATOR|TIV (Fluzone)|"Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004~45μg total~(Fluzone, sanofi pasteur)"
62843121|NCT02122757|PLACEBO_COMPARATOR|Sham Anodal Cefaly tDCS|2 mA placebo anodal tDCS (the direct current is delivered just for 30 seconds) is applied over the visual cortex for 20 minutes, everyday for 2 months, in 15 patients
62057614|NCT05386667||Hypochlorous acid|Oral spray containing hypochlorous acid applied after FGG
62446296|NCT05065970|EXPERIMENTAL|Felzartamab Arm #2|
62843122|NCT02122757|ACTIVE_COMPARATOR|Anodal Cefaly tDCS|2 mA anodal tDCS is delivered over the visual cortex, for 20 minutes, everyday for 2 months, in 15 patients.
62843123|NCT02685267|ACTIVE_COMPARATOR|Docetaxel/Prednisone|Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout
62843124|NCT02685267|ACTIVE_COMPARATOR|Docetaxel/Prednisone + Enzalutamide|Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout plus Enzalutamide 160 mg daily throughout. Subjects will continue enzalutamide until PD after 10 cycles of docetaxel.
62843125|NCT05633017||Pulmonary Rehab Patients|Patients who attend respiratory therapy at John Muir Pulmonary Rehab facility
62843126|NCT05633017||Control|Healthy adults, 18+
62843127|NCT00609037||1|Individuals who has had a weight reduction procedure such as gastric bypass and have body contouring surgery to remove the excessive skin due to the weight loss
62843128|NCT00609037||2|Normal controls include individuals who schecule to have an abdominoplasty and are within normal for height and weight
62843129|NCT03734913|EXPERIMENTAL|Part 1|Participants with advanced solid tumors including basal cell carcinoma and medulloblastoma, regardless of SMO or Gli1 alteration status.
62446297|NCT05065970|EXPERIMENTAL|Felzartamab Arm #3|
62446298|NCT00421096|EXPERIMENTAL|patient with cervix cancer|will receive gemcitabine + cisplatin + radiotherapy
62843130|NCT03734913|EXPERIMENTAL|Part 2 Cohort A|Participants with Adenocarcinoma of Esophagogastric Junction with SMO or Gli1 protein overexpression alteration.
62843131|NCT03734913|EXPERIMENTAL|Part 2 Cohort B|Participants with basal cell carcinoma, small cell lung cancer, neuroendocrine neoplasm and glioblastoma with SMO or Gli1 protein overexpression alteration.
62843132|NCT00176267|EXPERIMENTAL|1|
62843133|NCT00631943|EXPERIMENTAL|1|
62843134|NCT01090661|EXPERIMENTAL|mipomersen IV (supra-therapeutic dose)|200 mg of mipomersen IV / placebo SC
62843135|NCT01090661|EXPERIMENTAL|mipomersen SC (therapeutic dose)|200 mg of mipomersen SC / placebo IV
62843136|NCT01090661|ACTIVE_COMPARATOR|moxifloxacin IV|400 mg of moxifloxacin IV / placebo SC
62617582|NCT01942811|EXPERIMENTAL|Intervention|The Quit Using Drugs Intervention Trial (QUIT) experimental arm includes: screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
62843137|NCT01090661|PLACEBO_COMPARATOR|placebo|Placebo IV / placebo SC
62843138|NCT00859911|ACTIVE_COMPARATOR|2|Thiamine Mononitrate 5mg, Riboflavin 2 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg
62843139|NCT00859911|EXPERIMENTAL|1|Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocobalamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
62843140|NCT02644876|EXPERIMENTAL|Penehyclidine group|Penehyclidine inhalation will be administered (penehyclidine hydrochloride 0.5 mg/0.5 ml + normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
62843141|NCT02644876|PLACEBO_COMPARATOR|Control group|Placebo inhalation will be administered by inhalation (water for injection 0.5 ml + normal saline 5.5 ml ) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
62843142|NCT02327663|EXPERIMENTAL|HBeAg positive CHB group|1000 patients take generic emtricitabine capsule(200 mg one time per day) for 96 weeks,and for patients who have HBV DNA \> 500 copies/ml, adefovir dipivoxil were combined
62843143|NCT02327663|EXPERIMENTAL|HBeAg negativie CHB group|1000 patients take generic emtricitabine capsule(200 mg one time per day) for 96 weeks,and for patients who have HBV DNA \> 500 copies/ml, adefovir dipivoxil were combined
62843144|NCT01416324|EXPERIMENTAL|GSK2330672|experimental study drug
62057615|NCT05386667||Hyaluronic acid|An oral spray containing the main component of the product is hyaluronic acid (sodium salt) with a high molecular weight of 30 mg / 100 g was given to patients after FGG
62057616|NCT04461743||Patients with normal lac|
62446299|NCT04482114|OTHER|ultra-low dose CT|All the examinations are part of the routine care. Addition of the ULD CT protocol does not require injection of contrast agent and does not extend the duration of the examination.
62617583|NCT01942811|NO_INTERVENTION|Control|Usual care and a health education booklet and video on cancer prevention
62446300|NCT02165670||Ischemic heart disease|Patients undergoing percutaneous coronary intervention (PCI)
62260948|NCT04071574|ACTIVE_COMPARATOR|"Protocol B"|"Short GnRH agonist protocol:~For the short GnRH agonist protocol, the administration of gonadotropins begins at the same time as that of the agonist, which makes it possible to take advantage of the action of endogenous gonadotropins released by the flare-up effect of the agonist. A low dose of GnRH agonist (e.g., triptorelin (Decapeptyl 0.1mg/day)) is administered in parallel to gonadotropin (e.g. Menopur, 150-225 IU) daily starting on cycle-day 2 (Gonadotropin dose varies based on the follicular development). Continual administration of GnRH agonist and gonadotropin lasts until HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU), \~14 days post GnRH agonist regimen when follicles size reached 16-18 mm and at least the levels of E2 reaches 250-300 pg/ml. 36 h after HCG triggering, the mature oocytes are retrieved."
62617584|NCT06187272|NO_INTERVENTION|Group one with no music|Graduate students with no music
62446301|NCT06104696||Non-frail|Group of patients which will meet the criteria for non-frail according to the result of functional examination.
62446302|NCT06104696||Pre-frail|Group of patients which will meet the criteria for pre-frail according to the result of functional examination.
62617585|NCT06187272|EXPERIMENTAL|Group Two with music|Graduate students listening to music
62843145|NCT01416324|PLACEBO_COMPARATOR|Placebo|placebo
62446303|NCT06104696||Frail|Group of patients which will meet the criteria for frail according to the result of functional examination.
62617586|NCT03910140|EXPERIMENTAL|TILA-TACE group|
62617587|NCT05994053|ACTIVE_COMPARATOR|Active HD-tACS|HD-tACS of OFC
62617588|NCT05994053|SHAM_COMPARATOR|Sham HD-tACS|HD-tACS of OFC
62617589|NCT01462539||OSAS group|
62617590|NCT01462539||Non-OSAS group|
62843146|NCT05381857||Individual from the initial Milieu Intérieur study|Individual who provided samples for the initial Milieu Intérieur study
62617591|NCT01915550|ACTIVE_COMPARATOR|metformin|metformin was added without raising the insulin dose
62617592|NCT01915550|ACTIVE_COMPARATOR|Raising Insulin|insulin dose is raised
62617593|NCT04123249|EXPERIMENTAL|Group Propofol|In the Group P, propofol 4-6 mg/kg/h and remifentanil 0.2μg/kg/min were infused by intravenous pump separately for assisted sedation and assisted analgesia.
62617594|NCT04123249|EXPERIMENTAL|Group Sevoflurane|sevoflurane (concentration: 2%-3%, mixed with 50% air and 50% oxygen to keep the minimum alveolar concentration (MAC) at 1.0-1.1) was inhaled to maintain assisted sedation, and remifentanil 0.2 μg/kg/min was infused by intravenous pump for assisted analgesia.
62843147|NCT01918618||Levosimendan|study group
62843148|NCT01918618||No Levosimendan|Control group
62617595|NCT05029245|EXPERIMENTAL|Sinovac 2 dosage followed by Comirnaty® 6 microgram Intradermal|Patients who had history of Coronavac vaccine 2 dosage at least 1 month before enrollment will received Intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
62617596|NCT05029245|ACTIVE_COMPARATOR|Sinovac 2 dosage followed by Comirnaty® 30 microgram Intramuscular|Patients who had history of Coronavac vaccine 2 dosage at least 1 month before enrollment will received Intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
62617597|NCT05029245|EXPERIMENTAL|Aztrazeneca 1 dosage followed by Comirnaty® 6 microgram Intradermal|Patients who had history of ChAdOX1 Cov-19 vaccine 1 dosage at least 1 month before enrollment will received Intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
62617598|NCT05029245|ACTIVE_COMPARATOR|Aztrazeneca 1 dosage followed by Comirnaty® 30 microgram Intramuscular|Patients who had history of ChAdOX1 Cov-19 vaccine 1 dosage at least 1 month before enrollment will received intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
62617599|NCT05029245|EXPERIMENTAL|Naive vaccine followed by Comirnaty® 6 microgram Intradermal|Patients who had no history SAR-CoV vaccine before enrollment will received intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
62617600|NCT05029245|ACTIVE_COMPARATOR|Naive vaccine followed by Comirnaty® 30 microgram Intramuscular|Patients who had no history SAR-CoV vaccine before enrollment will received intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
62617601|NCT05029245|EXPERIMENTAL|Any history of vaccination with Anti-RBD< 650AU/ml followed by Comirnaty® 6 microgram Intradermal|Patients who had history of any SAR-CoV vaccine at least 1 month before enrollment will received intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
62260949|NCT04071574|ACTIVE_COMPARATOR|"Protocol C"|"Multiple-dose antagonist protocol:~For the GnRH antagonist protocol, a low dose of GnRH antagonist (0.25 mg/day) is administered. The protocol starts with the administration of gonadotropin (e.g. Menopur, 150-225 IU) daily which is initiated after monitoring of patients' follicles sizes on cycle-day 2/3 (Gonadotropin dose varies based on the follicular response). Almost after the 6th days of gonadotropin injection or when follicular size reaches more than or equal to 14 mm, GnRH antagonist (e.g., cetrorelix (cetrotide) or ganirelix (orgulatron) 0.25mg) begins by subcutaneous administration every day till HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU). 36 h after HCG triggering, the mature oocytes are retrieved."
62617602|NCT05029245|ACTIVE_COMPARATOR|Any history of vaccination with Anti-RBD <650AU/ml followed by Comirnaty® 30 microgram Intramuscular|Patients who had history of any SAR-CoV vaccine at least 1 month before enrollment will received intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
62617603|NCT06486285|EXPERIMENTAL|Auditory-cognitive dual-task training (ACDT)|The new auditory-cognitive dual-task training (ACDT) is a 12-week program (5 times/week, 60 minutes per day). Auditory training (i.e., speech-in-noise training, rapid speech training and competing speaking training) will be incorporated with cognitive exercises involving the domains of executive function, perceptual-motor ability, memory, and complex attention.
62617604|NCT06486285|NO_INTERVENTION|Control|"no specific treatment. This is a wait list group, participants can choose either the Auditory-cognitive dual-task training or the cognitive training after 12 weeks."
62617605|NCT02346695||Hypertensives|Untreated consecutive patients with newly diagnosed essential hypertension
62617606|NCT02346695||Controls|Normotensive individuals
62057617|NCT04461743||Patients with abnormal lac|
62057618|NCT05982665|EXPERIMENTAL|Molecular hydrogen|Molecular hydrogen inhalation for 60 min at 48 h, 24 h, and 60 min pre-exercise and for 30 min post-exercise and 24 h post exercise.
62617607|NCT04616040||unresectable locally advanced/recurrent or metastatic esophageal cancer|
62617608|NCT02665923||Newborn (gastric emptying)|A total of 100 healthy newborns who will be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying. Follow up of these newborns at two later time intervals will be performed (between ages 4-6 months, and 9-12 months).
62617609|NCT02665923||Infants (4-6mons)|50 Patients will undergowill be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying.
62617610|NCT02665923||Infants (9-12 months)|50 Patients will undergowill be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying.
62617611|NCT01300156|EXPERIMENTAL|ESHAOx arm|Patients who are planned to be treated with ESHAOx chemotherapy
62617612|NCT03033927||Participants with Stage IV Pancreatic Cancer|
62617613|NCT02454868|EXPERIMENTAL|Study arm|There is a single study arm. Remifentanil will be infused before intubation. The first patient will receive remifentanil 2mg/kg. If a success occurs the next patient's dose will be decreased by 0.25mg/kg and else it will be increased by 0.25mg/kg. This rule will apply recursively as Dixon's Up-And-Down Method.
62617614|NCT01693185|EXPERIMENTAL|Remifentanil|remifentanil of 0.04 mcg/kg/min with placebo (for midazolam) and placebo (for meperidine)
62617615|NCT01693185|ACTIVE_COMPARATOR|midazolam and meperidine|a bolus midazolam of 0.03 mg/kg a bolus meperidine of 1.0 mg/kg placebo (for remifentanil)
62617616|NCT04750278|EXPERIMENTAL|FP-025 100 mg|Low dose for patient treatment.
62617617|NCT04750278|EXPERIMENTAL|FP-025 300 mg|High dose for patient treatment.
62617618|NCT04750278|PLACEBO_COMPARATOR|Placebo|Dose without any study drug, to make it a controlled study.
62617619|NCT02208050|OTHER|Group 1|Patients will be randomised to a 8 week treatment period with the active drug followed by a 2 week washout period before an 8 week treatment period with placebo.
62057619|NCT05982665|PLACEBO_COMPARATOR|Placebo|Placebo inhalation for 60 min at 48 h, 24 h, and 60 min pre-exercise and for 30 min post-exercise and 24 h post exercise.
62057620|NCT02415699|EXPERIMENTAL|DC-CIK Immunotherapy Plus Chemotherapy|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy will receive 12 cycles of DC-CIK therapy in this group
62057621|NCT02415699|ACTIVE_COMPARATOR|Chemotherapy Alone|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy alone.
62057622|NCT02240108|EXPERIMENTAL|Rifaximin EIR 800 mg|Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
62260950|NCT04071574|ACTIVE_COMPARATOR|"Protocol D"|"Long GnRH agonist protocol:~For the long GnRH agonist protocol, a low dose of GnRH agonist (e.g., triptorelin (Decapeptyl 0.1mg)) is administered on cycle-day 21 followed by gonadotropin (e.g. Menopur, 150-225 IU) daily starting on cycle-day 2 after menses (Gonadotropin dose varies based on the follicular development). Continual administration of GnRH agonist and gonadotropin lasts until HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU), \~14 days post GnRH agonist regimen when follicles size reached 16-18 mm. 36 h after HCG triggering, the mature oocytes are retrieved."
62260951|NCT04071574|ACTIVE_COMPARATOR|"Protocol E"|"Combined GnRH antagonist and agonist protocol:~For the combined protocol, it starts with the administration of gonadotropin (e.g. Menopur, 150-225 IU) daily which is initiated after monitoring of patients' follicles sizes on cycle-day 2/3 (Gonadotropin dose varies based on the follicular response). Almost after the 6th days of gonadotropin injection or when follicular size reaches more than or equal to 14 mm, GnRH antagonist (e.g., cetrorelix (cetrotide) or ganirelix (orgulatron) 0.25mg) begins by subcutaneous administration every day till GnRH agonist injection (e.g., triptorelin (Decapeptyl 0.1mg/day)). 36 h after agonist injection, the mature oocytes are retrieved."
62057623|NCT02240108|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.
62446304|NCT02459054|EXPERIMENTAL|Primary Pediatric Arm|Cardiac transplant-eligible pediatric patients at imminent risk of death from biventricular failure who are 10 - 18 years old at time of TAH-t implant. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
62446305|NCT02459054|EXPERIMENTAL|Primary Adult Arm|Cardiac transplant-eligible adult patients at imminent risk of death from biventricular failure who are 19 - 75 years old at time of TAH-t implant. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
62446306|NCT02459054|EXPERIMENTAL|Secondary Arm|Cardiac transplant-eligible pediatric and adult patients at imminent risk of death from biventricular failure who do not meet enrollment criteria for a Primary Arm, but meet less restrictive enrollment criteria for the Secondary Arm. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
62446307|NCT04138459||Qualitative exploration|Ten community mental health service users will be interviewed with their most important mental health worker to explore how recovery orientation of services affects roles and collaboration.
62617620|NCT02208050|OTHER|Group 2|Patients will be randomised to a 8 week treatment period with the placebo, followed by a 2 week washout period and a further 8 week treatment period with the active drug.
62617621|NCT06266299|EXPERIMENTAL|Part 1|KK2269 will be administered at each dose level, intravenous infusion.
62057624|NCT05404425|EXPERIMENTAL|Visioconference: live visual injury evaluation|For patients randomized in the intervention group, a live visual evaluation of the injury is performed by the Emergency Medical Call Center physician using a dedicated, secure smartphone app
62057625|NCT05404425|OTHER|Standard Procedure|Usual management of patients
62057626|NCT02668016|EXPERIMENTAL|Atorvastatin 20mg Daily|Atorvastatin 20mg daily for 1 month
62057627|NCT02668016|PLACEBO_COMPARATOR|Placebo|Placebo daily for 1 month
62057628|NCT02668016|NO_INTERVENTION|No Treatment|No Atorvastatin or placebo for 1 month
62446308|NCT00617110|SHAM_COMPARATOR|allergic clean air|subjects with allergic rhinitis will be exposed to clean air followed by LAIV
62057629|NCT02206490|ACTIVE_COMPARATOR|Naltrexone Study Drug|Subjects will take naltrexone 4.5 mg daily for three months.
62057630|NCT02206490|PLACEBO_COMPARATOR|Naltrexone placebo|Subjects will take a 3 month course of a placebo pill identical in appearance to the naltrexone study drug.
62057631|NCT02206490|ACTIVE_COMPARATOR|dextromethrophan study drug|subjects will take a sustained release dextromethorphan pill twice a day.
62446309|NCT00617110|ACTIVE_COMPARATOR|Allergic diesel|subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
62617622|NCT06266299|EXPERIMENTAL|Part 2|"KK2269 will be administered at each dose level intravenously in combination with docetaxel.~Docetaxel will be administered intravenously (Q3W)."
62057632|NCT02206490|PLACEBO_COMPARATOR|dextromethoprhan placebo|Subjects will take a 3 month course of a placebo pill identical in appearance to the dextromethorphan study drug.
62057633|NCT02857426|EXPERIMENTAL|Nivolumab for population with PCNSL|Specified dose on specified days
62057634|NCT02857426|EXPERIMENTAL|Nivolumab for population with PTL|Specified dose on specified days
62617623|NCT05831709|EXPERIMENTAL|Supervised training + immediate hormone substitution therapy|
62057635|NCT03916744|EXPERIMENTAL|Giredestrant 10 mg|
62057636|NCT03916744|EXPERIMENTAL|Giredestrant 30 mg|
62057637|NCT03916744|EXPERIMENTAL|Giredestrant 100 mg|
62617624|NCT05831709|EXPERIMENTAL|Supervised training + delayed hormone substitution therapy|
62617625|NCT05831709|ACTIVE_COMPARATOR|Delayed supervised training + immediate hormone substitution therapy|
62617626|NCT03911947|ACTIVE_COMPARATOR|SaO2 (oxygen status)|Measurment 4 times per day, ABA (acid-bases analyses)
62617627|NCT03911947|ACTIVE_COMPARATOR|PaO2/FiO2 (respiratory index)|Measurment 4 times per day, ABA (acid-bases analyses)
62617628|NCT03911947|ACTIVE_COMPARATOR|AB (actual bicarbonat level)|Measurment 4 times per day, ABA (acid-bases analyses)
62617629|NCT02839382|ACTIVE_COMPARATOR|Coaching|External facilitation by a practice coach for 15 months
62057638|NCT01646190|ACTIVE_COMPARATOR|Standard care|Preoperative: Fasting state after midnight, no intake of oral carbohydrate load Preanesthetic medication No preoperative utilization of inspirex Intraoperative: Effective perioperative analgesia Routine nasogastric tube and abdominal drainage at surgeon discretion Postoperative: Removal of the nasogastric tube after return of bowel function removal of abdominal drainage at surgeon discretion or if volume \<50cc Oral liquids and stepwise oral nutrition (water to others liquids to progressive normal or low-fiber nutrition Switch to oral medication after oral nutrition tolerance Urinary catheter removal when the mobilization is satisfactory Mobilization: non standardized and encouraged stepwise mobilization Discharge criteria discussed at surgeon discretion
62057639|NCT01646190|EXPERIMENTAL|FT perioperative care|Preoperative carbohydrate load No preanesthetic medication General anesthesia and intravenous analgesia Transoesophageal US-Doppler for individualized i.v fluids therapy POD 0: No Nasogastric tube postoperatively Oral liquids 0.3-0.5L 6h after extubation First mobilization 6h after surgery (2h) Stimulation of inspirex utilization (6-8t/d) POD 1: Free oral liquids; progressive normal or low-fiber diet Switch to oral medication Urinary catheter removal Mobilization: \>4 h out of bed (walking, chair) inspirex utilization POD 2: Free oral liquids; normal or low-fiber diet Mobilization: \>6 h out of bed (walking, chair), inspirex utilization POD 3: Complete mobilization as preoperatively First evaluation of discharge criteria in the afternoon
62057640|NCT04491812|EXPERIMENTAL|Kinesiotaping|kinesiotaping of the triceps muscle applied to the study group alongside the physical therapy program
62057641|NCT04491812|PLACEBO_COMPARATOR|physical therapy program|the control group recieved only the physical therapy program
62057642|NCT05810207||Adult patients undergoing colorectal resection with the construction of an anastomosis|The exposure of interest in the current study regards the occurrence of anastomotic leakage in patients undergoing colorectal resection with the construction of an anastomosis. Information on the exposure of interest is gained by obtaining data from the patient files.
62057643|NCT04119453|EXPERIMENTAL|Rivoceranib|Participants will receive an oral dose of rivoceranib once per day during 28-day cycles.
62617630|NCT02839382|ACTIVE_COMPARATOR|Educational Outreach|Academic detailing phone calls to support implementation of a cardiovascular risk calculator/estimator in each clinic
62057644|NCT01271569|OTHER|In the treatment arm|
62057645|NCT02596126|ACTIVE_COMPARATOR|Treatment Prevention for Secondary CV|Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the ESC guidelines. Drugs and doses will be left at the discretion of the treating physicians..
62057646|NCT02596126|EXPERIMENTAL|Cardiovascular Polypill|Patients allocated to the experimental arm will receive a cardiovascular polypill containing aspirin 100 mg, atorvastatin (40 or 20 mg) and ramipril (2.5, 5 or 10 mg) taken orally once a day.
62057647|NCT00622180|ACTIVE_COMPARATOR|Daavlin Right vs. Excilite Left|Right hand treated with narrow-band UVB light and left hand treated with focal 308nm light.
62260952|NCT02742428|EXPERIMENTAL|Ascites drainage before surgery.|A group of patients with (or suspected for) advanced ovarian cancer and significant ascites. An indwelling catheter insertion into abdominal cavity and slow, systematic ascites evacuation for 7 or more days before surgery (if it cannot be scheduled immediately) will be performed. Patients will undergo an interview, will be asked to fill in questionnaires concerning a quality of life and nutritional status. If available noninvasive bioimpedance analysis will be performed and 2ml of blood will be taken for serum prealbumin concentration evaluation. If possible 20ml of ascitic fluid will be taken for cytology examination.
62446310|NCT00617110|SHAM_COMPARATOR|control clean air|Healthy control subjects will be exposed to clean air followed by LAIV
62446311|NCT00617110|SHAM_COMPARATOR|Control diesel|Healthy control will be exposed to diesel followed by LAIV
62057648|NCT00622180|ACTIVE_COMPARATOR|Excilite Right vs. Daavlin Left|Right hand treated with focal 308-nm light and left hand treated with narrow-band UVB light
62260953|NCT02742428|OTHER|Observation.|A group of patients with (or suspected for) advanced ovarian cancer and significant ascites. A standard of care: observation or acute paracentesis (\>5000ml) will be performed while waiting for the surgery (if it cannot be scheduled immediately). Patients will undergo an interview, will be asked to fill in questionnaires concerning a quality of life and nutritional status. If available noninvasive bioimpedance analysis will be performed and 2ml of blood will be taken for serum prealbumin concentration evaluation. If possible 20ml of ascitic fluid will be taken for cytology examination.
62617631|NCT02839382|ACTIVE_COMPARATOR|Site Visit|"Site visits made by practices to 'exemplar practices to learn innovative approaches to quality improvement"
62617632|NCT02839382|ACTIVE_COMPARATOR|Educational Outreach and Site Visit|In this arm of the study, practices will be offered both educational outreach and an opportunity for a site visit
62617633|NCT06011096|EXPERIMENTAL|the group with skin-to-skin contact and delayed cord clamping|In this arm, skin-to-skin contact and delayed cord clamping are performed between mother and baby.
62617634|NCT06011096|EXPERIMENTAL|The group without skin-to-skin contact and early cord clamping|In this arm, skin-to-skin contact and delayed cord clamping are not performed between mother and baby.
62057649|NCT01939886|EXPERIMENTAL|Artemether- Lumefantrine|Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h \[+/-90 min\] after the initiation of treatment). AL is currently the first line treatment in Tanzania Other Name: Coartem;
62057650|NCT01939886|ACTIVE_COMPARATOR|Drug: Mefloquine-Artesunate, an alternative ACT|Treatment with the paediatric fixed dose combination Mefloquine-Artesunate (MQ-AS; Artequin; Mepha, Aesch, Basel, Switzerland, artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, given in three daily doses. The weight range of enrolled children is chosen to be recommended for this fixed dose combination. MQ-AS is available in Kenya as Artequin and has been extensively tested in uncomplicated malaria in children.
62260954|NCT02902250|EXPERIMENTAL|Decompression|bone marrow decompression at fractured vertebral body
62260955|NCT02902250|ACTIVE_COMPARATOR|Conservative Treatment|Conservative Treatment for compression fracture
62260956|NCT01432249||Enbrel|The patients who are prescribed Enbrel for pediatric psoriasis
62260957|NCT05354583||Acquired Interferon-gamma Autoantibody Syndrome|"Patients infected with M. abscessus at any site, who have acquired interferon-gamma autoantibody syndrome defined as one of the following features:~1. The M. abscessus infection site is lymph node.~2. The M. abscessus infection is disseminated (more than 1 organ of infection or blood culture positive for M. abscessus).~3. The M. abscessus infection is accompanied by one of reactive skin diseases which are Sweet's syndrome, pustular psoriasis, erythema nodosum.~4. History of opportunistic infection such as salmonellosis, penicillosis, histoplasmosis, cryptococcosis, melioidosis~The patients must not be infected with HIV, in-hospital M. abscessus infection, diagnosed with cancer, or receiving immunosuppressants."
62260958|NCT05354583||Chronic Lung Disease|"Patients with one of chronic lung diseases which are COPD, chronic bronchiectasis, history of pulmonary tuberculosis and diagnosed with Pulmonary M. abscessus infection.~Pulmonary M. abscessus infection diagnosis must be met all of the following criteria:~1. Symptoms and signs are correlated with the pulmonary M. abscessus infection.~2. One of the radiological evidences:~   2.1) nodular infiltration or cavitary lesion on plain chest radiography~   2.2) bronchiectasis and multiple small nodules on chest computerized tomography~3. Mycobacterial culture from respiratory tract specimen is positive for M. abscessus"
62057651|NCT02034825||Practicing urologic surgeons|"* US board-certified~* Practicing urologic surgeons~* Performing at least 40 radical prostate surgeries annually~Urologists will be excluded from participating in the study if:~* They are unable to identify a the required number of eligible patient cases with available clinical data and tissue specimens;~* They have spent less than 3 years in practice or perform less than 40 RP's per year~All participants will be asked to complete a questionnaire based on a random selection of retroactively selected cases."
62843149|NCT01069900|EXPERIMENTAL|Moxifloxacin (Avelox, BAY12-8039)|Subjects randomized to the moxifloxacin arm of this study received intravenous moxifloxacin plus ertapenem placebo (0.9 % sodium chloride \[NaCl solution\]) for a minimum of 3 days and, if switched to oral treatment, PO moxifloxacin plus PO amoxicillin/clavulanate placebo. Total treatment duration is 5-14 days.
62843150|NCT01069900|ACTIVE_COMPARATOR|Comparator Ertapenem|Subjects randomized to the comparator arm of this study received intravenous ertapenem plus moxifloxacin placebo (0.9 % NaCl solution) for a minimum of 3 days and, if switched to oral treatment, amoxicillin/clavulanate as an oral suspension plus PO moxifloxacin placebo. Total treatment duration is 5-14 days.
62843151|NCT01432925|OTHER|evaluation surgical intervention at week 8|
62843152|NCT01432925|OTHER|evaluation surgical intervention at week 14|
62843153|NCT05471271|OTHER|[18AlF]-RESCA-IL2 PET imaging|
62843154|NCT06044077|EXPERIMENTAL|Experimental Group|1 dose vaccination of study vaccine
62057652|NCT03674554|EXPERIMENTAL|titanium bases group|full-arch screw-retained implant prosthesis on titanium bases using intra oral luting cement technique
62057653|NCT03674554|EXPERIMENTAL|transmucosal abutment group|a full-arch screw-retained implant prosthesis with transmucosal abutment
62057654|NCT03161457|EXPERIMENTAL|JHL1101|Each subject will receive 2 intravenous infusions of 1000 mg JHL1101: the first infusion on Baseline and the second on Day 15.
62057655|NCT03161457|ACTIVE_COMPARATOR|MabThera|Each subject will receive 2 intravenous infusions of 1000 mg MabThera: the first infusion on Baseline and the second on Day 15 (Visit 5).
62260959|NCT00376870|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone 30mg/d
62260960|NCT00376870|PLACEBO_COMPARATOR|Placebo|
62260961|NCT03891264|EXPERIMENTAL|CBD Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 4-week trial of a liquid formulation of CBD.
62843155|NCT06044077|OTHER|Control Group|1 dose vaccination of control vaccine
62843156|NCT03583385|EXPERIMENTAL|First Glucophage XR (Test), Then Glucophage XR (Comparator)|Participants received single oral dose of 750 milligram (mg) Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) in treatment period 1 followed by single oral dose of 750 mg Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) in treatment period 2 under fasting conditions. The two periods were separated by a 7-day wash-out period.
62843157|NCT03583385|EXPERIMENTAL|First Glucophage XR (Comparator), Then Glucophage XR (Test)|Participants received single oral dose of 750 milligram (mg) Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) in treatment period 1 followed by single oral dose of 750 mg Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) in treatment period 2 under fasting conditions. The two periods were separated by a 7-day wash-out period.
62057656|NCT02450630|EXPERIMENTAL|training on diagnosis, treatment and referral of children|Intervention Arm : training in diagnosis, treatment and referral of sick children
62057657|NCT02450630|NO_INTERVENTION|Presumptive treament of sick children|Control Arm - Training of private providers in completing study tools i.e. filling in register and referral forms. No training in diagnosis, treatment and referral and no community awareness on referral
62260962|NCT01439204|ACTIVE_COMPARATOR|Abatacept (BMS-188667) manufactured at Lonza, NH facility|
62057658|NCT05305014||Patient with conversive motor disorder|Patients with paralysis, motor weakness or abnormal movements meeting the DSM-IV criteria of conversive motor disorder consulting the SAU or the Neurology departments of the CHU of Nîmes and Montpellier included in the HYCORE parent study (RCB ID 2014-A01159-38, NCT02329626)
62057659|NCT04336748|ACTIVE_COMPARATOR|Hydroxychloroquine|200mg once daily
62057660|NCT04336748|PLACEBO_COMPARATOR|Placebo|Placebo
62260963|NCT01439204|EXPERIMENTAL|Abatacept (BMS-188667) manufactured at Devens, MA facility|
62260964|NCT01438164||oncologic patients|initial staging
62260965|NCT04712110|EXPERIMENTAL|TAK-019|TAK-019 0.5 mL, intramuscular injection in the upper arm
62617635|NCT05880225|ACTIVE_COMPARATOR|Reciprocal Imitation Training (RIT)|Children (n=20) receive 30 sessions of Reciprocal Imitation Training (RIT), delivered in 40-60 minute sessions 2-3 times/week.
62843158|NCT01098513|EXPERIMENTAL|Part A|Subjects will be randomized in a three-way crossover design to receive a single dose of each of three different tablet formulations of GSK1349572 50 mg (2 tablets). Formulation AP, AW and AX.
62843159|NCT01098513|EXPERIMENTAL|Part B|A total of 18 subjects who complete Part A will return for Part B. Subjects from Part A will be asked to participate on a first come first served basis until there are 18 subjects, at which time enrolment to Part B will be closed. Part B will be a three way crossover design using either formulation AW or AX depending upon the results from Part A. Subjects will receive a single dose of 50 mg GSK1349572 with either a low fat, moderate fat or high fat meal in each period.
62057661|NCT05210829||High Parent Anxiety|Stationary and Trait Anxiety Scale ≥ 44 points
62057662|NCT05210829||Low Parent Anxiety|Stationary and Trait Anxiety Scale \< 44 points
62057663|NCT00714922|ACTIVE_COMPARATOR|1|PRK
62057664|NCT00714922|ACTIVE_COMPARATOR|2|SBK
62057665|NCT00593125|EXPERIMENTAL|1|levetiracetam
62057666|NCT04829721|EXPERIMENTAL|Educational Video Workshop|A single 20 minute video workshop on pelvic floor disorders.
62057667|NCT01605760|NO_INTERVENTION|non immunotherapy treatment|
62057668|NCT01605760|ACTIVE_COMPARATOR|sublingual immunotherapy course|
62260966|NCT04712110|PLACEBO_COMPARATOR|Placebo|TAK-019 Matching Placebo, intramuscular injection in the upper arm
62260967|NCT00918034|EXPERIMENTAL|LS11 (talaporfin sodium)|
62260968|NCT00631774|ACTIVE_COMPARATOR|1|a meal replacement program with Glucerna SR on top of the exchange-diet plan
62446312|NCT04345978|PLACEBO_COMPARATOR|Normal Fasting|The patient starts fasting 8 hours before the operation,and does not take any solid or liquid foods and nutrients during the fasting process.The fasting period does not strictly limit the consumption of pure water,After surgery 8 hours,the patients was allowed to feeding.
62057669|NCT01919970|EXPERIMENTAL|Cognitive Behavioral Therapy Condition|This arm is the experimental condition; it consists of 12 weekly CBT sessions. The therapy protocol will begin with an introductory education session which will include development of a fear hierarchy, followed by 11 sessions of in vivo exposures to feared triggers.
62057670|NCT01919970|ACTIVE_COMPARATOR|Treatment as Usual|This arm acts as the comparison condition. Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
62260969|NCT00631774|ACTIVE_COMPARATOR|2|an caloric-matched exchange-diet plan only.
62260970|NCT04530942|EXPERIMENTAL|Active DBS then Sham DBS|After more than 6 months open-lable period, some patients will take DBS ON for two weeks with the optimal stimulation parameters and then take DBS OFF for two weeks.
62260971|NCT04530942|EXPERIMENTAL|Sham DBS then Active DBS|After more than 6 months open-lable period, some patients will take DBS OFF for two weeks and then take DBS ON for two weeks with the optimal stimulation parameters.
62260972|NCT02703311|OTHER|Cardioband procedure|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
62260973|NCT00691002|EXPERIMENTAL|LEO 80190|Calcipotriol 25 mcg/g plus 10 mg/g hydrocortisone ointment (LEO 80190)
62260974|NCT00691002|PLACEBO_COMPARATOR|LEO 80190 vehicle|Ointment Vehicle
62260975|NCT00691002|ACTIVE_COMPARATOR|Calcipotriol|Calcipotriol 25 mcg/g in the ointment vehicle
62260976|NCT00691002|ACTIVE_COMPARATOR|Hydrocortisone|Hydrocortisone 10 mg/g in the ointment vehicle
62260977|NCT05762380|ACTIVE_COMPARATOR|Ferrous sulfate (FeSO4)|FeSO4 supplements containing 54 mg elemental iron
62260978|NCT05762380|EXPERIMENTAL|Ferrous sulfate-enriched Aspergillus oryzae (Ao iron)|Ao iron supplements containing 54 mg elemental iron
62260979|NCT02810665||Normal vision group|Individuals with VA 20/20 to 20/25
62446313|NCT04345978|EXPERIMENTAL|Prolong Fasting|The patient starts fasting 24 hours before the operation, and does not take any solid or liquid foods and nutrients during the fasting process. The fasting period does not strictly limit the consumption of pure water.After surgery 24 hours,the patients was allowed to feeding.
62617636|NCT05880225|EXPERIMENTAL|Music-Enhanced Reciprocal Imitation Training (meRIT)|Children (n=20) receive 30 sessions of music-enhanced Reciprocal Imitation Training (meRIT), delivered in 40-60 minute sessions 2-3 times/week.
62843160|NCT04052633||Cholangiography success|From January 2018 to August 2018 all consecutive elective and emergency cholecystectomies performed with intraoperative success of cholangiography
62446314|NCT03150979|EXPERIMENTAL|Provision of a cane|The experimental group will receive a single-point cane, with ergonomic handgrip, which will be individually adjusted to the participant's height. A physiotherapist will provide instructions on how to walk with the cane and the participants will practice for about 15 minutes or until they feel comfortable with the device. Then, they will take the cane home and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.
62843161|NCT04052633||Cholangiography failure|From January 2018 to August 2018 all consecutive elective and emergency cholecystectomies performed with intraoperative failure of cholangiography
62843162|NCT00148096|PLACEBO_COMPARATOR|1|Mechanical heat recovery ventilation units installed but not fully functional
62843163|NCT00148096|ACTIVE_COMPARATOR|2|Mechanical heat recovery ventilation unit installed and active
62843164|NCT02446899|EXPERIMENTAL|Anifrolumab|Anifrolumab 300 mg intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
62057671|NCT03454165|EXPERIMENTAL|Single Arm|Evaluate the MTD of BNC105P in combination with ibrutinib in patients with relapsed/refractory CLL. Treatment will be administered on an outpatient basis but will also be permitted inpatient. BNC105P will be administered as a single agent prior to initiation of ibrutinib. Beginning with cycle 2, ibrutinib will be administered concomitantly with BNC105P at a starting dose of 420 mg PO daily. Each cycle will last for 21 days. Provided no toxicities occur, each patient will be treated for 6 cycles.
62057672|NCT01468441|EXPERIMENTAL|GnRH agonist|Administration of GnRH agonist in alternate days, recombinant FSH and hCG microdose for ovarian stimulation.
62057673|NCT01468441|ACTIVE_COMPARATOR|GnRH antagonist|Daily administration of GnRH antagonist, recombinant FSH and hCG microdose for ovarian stimulation.
62057674|NCT00575445||1|Pediatric patients with previously diagnosed asthma
62057675|NCT02597465|EXPERIMENTAL|SPARC1507|SPARC1507
62446315|NCT03150979|OTHER|Control|The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
62446316|NCT00688285|ACTIVE_COMPARATOR|1|education and automated clinical alerts
62446317|NCT00688285|ACTIVE_COMPARATOR|2|education session alone
62843165|NCT02446899|PLACEBO_COMPARATOR|Placebo|Placebo intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
62057676|NCT02597465|EXPERIMENTAL|Chemotherapy|Chemotherapy
62057677|NCT03737084|EXPERIMENTAL|CBCT Intervention|The compassion intervention (CBCT) will be performed during the period of hospitalization, in the hospital room, and will be applied simultaneously to the patient his caregiver. The training consists of six weekly sessions. The participant will receive six guided meditation audio, relative to each session, to practice during the week.
62057678|NCT03737084|NO_INTERVENTION|Control group|Control group participants will receive standard hospital care. Patients and caregivers of the control group will receive the same CBCT intervention at the end of the study.
62446318|NCT04586647|EXPERIMENTAL|Noom Health Weight Program|
62446319|NCT04586647|NO_INTERVENTION|Wait List Control|
62446320|NCT01572649|PLACEBO_COMPARATOR|Placebo|1 single administration (volume matched to the dose lixisenatide: 50 µL or 100µL) once a day subcutaneously
62446321|NCT01572649|EXPERIMENTAL|Dose 1|1 single administration of 5 µg lixisenatide (50 µL) once a day subcutaneously
62446322|NCT01572649|EXPERIMENTAL|Dose 2|1 single administration of 10 µg lixisenatide (100 µL) once a day subcutaneously
62843166|NCT01657916||5 year sling implants|Patients who underwent implant of the Align Urethral Support System between June 2007 and December 2008
62843167|NCT05370937|ACTIVE_COMPARATOR|ELEVATOR|After knotting the posterior root of the medial meniscus with a fiber rope, a tunnel will be opened for the rope to pass through the medial of the proximal crest of the tibia. Then, arthroscopically, the rope will be taken through the joint and passed through the tunnel, and the knot will be fixed to the tibia by using the endobutton elevator system
62843168|NCT05370937|ACTIVE_COMPARATOR|FREE KNOT|The first stage of fixation is the same, and fixation to the tibia will be done with an endobutton by tying a free knot without using an elevator system.
62843169|NCT01167244|EXPERIMENTAL|BMS-690514|
62843170|NCT01026324|EXPERIMENTAL|Treatment (dinaciclib)|Patients receive dinaciclib IV over 4 hours on day 1. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
62843171|NCT05808569||Breast cancer patients undergoing radiotherapy in adjuvant setting|
62057679|NCT05885659|OTHER|Control group (waiting list)|T2DM in the control group will receive brief psychoeducation advice about smoking cessation as well as a general smoking cessation brochure/ booklet.
62260980|NCT02810665||Impaired vision group|Individuals with impaired vision: VA of 20/32 to 20/200 due to either cataract, diabetic macular edema, or age-related macular degeneration
62617637|NCT02003261|EXPERIMENTAL|Unified Protocol with Treatment As Usual|Unified Protocol is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. During this treatment period, the participants continue the Treatment As Usual.
62617638|NCT02003261|OTHER|Waitlist Control with Treatment As Usual|Waitlist participants will not receive treatment during a 20-week waitlist period, but will receive the unified protocol immediately following the 20 week waiting period. During the waitlist period, the waitlist participants continue the treatment as usual.
62843172|NCT04761666||static verticalization device|children with severe cerebral palsy (GMFCS IV \& V) with static verticalization device
62843173|NCT04761666||non verticalization device|children with severe cerebral palsy (GMFCS IV \& V) without static verticalization device
62260981|NCT03516682|NO_INTERVENTION|Usual Care|Parents will receive usual care for their child at Kaiser Permanente Colorado. This includes recommendations for well child visits at 2, 4, 6 and 12 months of age as well as automated reminders for age eligible children to receive the flu shot during flu season.
62446323|NCT03805828|EXPERIMENTAL|Expermental|In the intervention group, the educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism.
62446324|NCT03805828|ACTIVE_COMPARATOR|Control|In the control group, the educational about communicable disease among childhood deliver as a one-day event in four sessions: (1) introduction and background communicable disease of childhood,(2) communicable diseases of childhood (Chicken Pox, Diphtheria,and pertussis\[a whooping cough\]),(3) communicable diseases of childhood (Measles,Mumps,rubella\[German Measles\]and Poliomyelitis(,and (4) infection control.
62843174|NCT04909281||Long-term non-attenders in the cervical screening program|All women who had not attended tthe cervical screening program in Sweden for at least 10 years were eligeble.
62843175|NCT00713297||Observation|Those who will use the new CPOE system
62843176|NCT04234412|EXPERIMENTAL|Osteoarthritic knee patients|Osteoarthritic Knee of the patients who will be treated wth high tibial osteotomy and implantation of allogenic human umbilical cord blood-derived stem cells.
62843177|NCT01890252|EXPERIMENTAL|Hyper CL|Hyper osmotic contact lens
62843178|NCT01890252|EXPERIMENTAL|Hyper CL + Saline solution|combined treatment of hyper osmotic contact lens+ hypertonic solution
62446325|NCT06366256|EXPERIMENTAL|Traditional-then-Simplified|This arm consists of participants who will be engaging in two blocks of therapy. The first block will be traditional ultrasound biofeedback therapy (T-UBT), then after that block of therapy sessions with T-UBT, they will switch to gamified/simplified ultrasound biofeedback therapy (S-UBT). The participants will finish their second block all with S-UBT. Each block will consist of five sessions. Participants will attend speech therapy either 1x/week for five weeks (per block) or 5x/week for one week (per block).
62446326|NCT06366256|EXPERIMENTAL|Simplified-then-Traditional|This arm consists of participants who will be engaging in two blocks of therapy. The first block will be simplified ultrasound biofeedback therapy (S-UBT), then after that block of therapy sessions with S-UBT, they will switch to traditional ultrasound biofeedback therapy (T-UBT). The participants will finish their second block with T-UBT. Each block will consist of five sessions. Participants will attend speech therapy either 1x/week for five weeks (per block) or 5x/week for one week (per block).
62446327|NCT02261428|EXPERIMENTAL|Catheter Tiemann|We tested the ability of Tiemman catheter to access trachea and aspirate bronchial secretions, measuring number of attempts and time required for the intervention
62446328|NCT02261428|ACTIVE_COMPARATOR|Suction catheter|We tested the ability of suction catheter to access trachea and aspirate bronchial secretions, measuring number of attempts and time required for the intervention
62843179|NCT01890252|ACTIVE_COMPARATOR|saline solution|hypertonic solution
62843180|NCT01262820|EXPERIMENTAL|Single Intervention|Subjects will take Pazopanib, 800 mg daily by mouth throughout the time in study
62057680|NCT05885659|ACTIVE_COMPARATOR|Experimental 1: Cognitive-behavioral treatment (CBT) for smoking cessation|CBT for smoking cessation, implemented in group-based sessions over an eight-week period. Includes three different stages: (1) Motivational interviewing to stop smoking; (2) Smoking cessation, focused on nicotine fading from the first to the fourth session; (3) Maintenance of abstinence and relapse prevention strategies from the fifth session onwards.
62617639|NCT06137911|EXPERIMENTAL|Group A:JYP0061 15mg|Experimental: JYP0061 Single ascending dose
62057681|NCT05885659|ACTIVE_COMPARATOR|Experimental 2: CBT for smoking cessation + DiMeSALUD2 protocol|In this group, a training protocol on healthy lifestyle habits and self-management of T2DM will be carried out added to usual care (CBT for smoking cessation), including healthy lifestyle habits (dietary control and healthy nutrition, physical exercise, and glycemic control).
62057682|NCT03364348|EXPERIMENTAL|Cohort 1A (trastuzumab + utomilumab)|Utomilumab 20 mg IV + trastuzumab 6 mg/kg IV every 3 weeks. 3 subjects will be treated at this dose level. If no DLT events are recorded, then utomilumab dose will be increased to 100 mg (Dose Level 1B).
62057683|NCT03364348|EXPERIMENTAL|Cohort 1B (trastuzumab + utomilumab)|Utomilumab 100 mg IV + trastuzumab 6 mg/kg IV every 3 weeks.
62057684|NCT03364348|EXPERIMENTAL|Cohort 2A (ado-trastuzumab emtansine + utomilumab)|Utomilumab 20 mg IV + ado-trastuzumab emtansine 3.6 mg/kg IV every 3 weeks.
62057685|NCT03364348|EXPERIMENTAL|Cohort 2B (ado-trastuzumab emtansine + utomilumab)|Utomilumab 100 mg IV + ado-trastuzumab emtansine 3.6 mg/kg IV every 3 weeks.
62057686|NCT04032535|EXPERIMENTAL|SAD|"Single Ascending Dose of 2 cohorts:~Cohort A will be administered three ascending dose levels: 0.2 mg (dose 1), 2 mg (anticipated dose 3), 8 mg (anticipated dose 5) or placebo; Cohort B will be administered three ascending dose levels: 1 mg (anticipated dose 2), 4 mg (anticipated dose 4), 14 mg (anticipated dose 6, maximum dose) or placebo."
62446329|NCT05816330|EXPERIMENTAL|Arm 1: 900 mg of L9LS SC|Participants will receive 900 mg of L9LS SC.
62446330|NCT05816330|PLACEBO_COMPARATOR|Arm 2: Placebo (normal saline) SC|Participants will receive placebo of Normal Saline for comparison.
62446331|NCT01998321|EXPERIMENTAL|TKA using PSI|Total Knee Arthroplasty using Patient Specific Instrument
62843181|NCT05680688|EXPERIMENTAL|Painful Manual Therapy|Manual therapy treatment shall be carried out at a high intensity that causes pain to the patient. The aim is to provoke a medium intensity pain to the patient of 5/10 in the NRS. The physiotherapist will ask every 30 seconds the pain provoked by the treatment with the numeric rating scale (NRS) and the patient will give continuous feedback. Based on this, the physiotherapist will adapt the intensity of the treatment to provoke a medium intensity pain.
62057687|NCT04032535|EXPERIMENTAL|MAD|"Multiple Ascending Dose of 4 cohorts:~Cohort A will be administered with 2 mg (anticipated dose 1) or placebo; Cohort B will be administered with 4 mg (anticipated dose 2) or placebo; Cohort C will be administered with 8 mg (anticipated dose 3) or placebo; Cohort D will be administered with 12 mg (anticipated dose 4) or placebo;"
62057688|NCT04032535|EXPERIMENTAL|2way crossover|Two 28-day treatment periods (Period 1 and Period 2), separated each by 32 days (up to 40 days) wash-out period, in crossover design. The treatment period will consist in repeated administrations of CHF 6523 at one dose level or placebo.
62057689|NCT05966402|EXPERIMENTAL|Virtual Reality|
62057690|NCT05966402|NO_INTERVENTION|standard care|
62057691|NCT02723058|EXPERIMENTAL|ICMHM|ICMHM mothers receive services of a primary care clinician (PCP) and a care manager both trained in depression care management in a shelter-based primary care clinic.
62057692|NCT02723058|NO_INTERVENTION|Treatment as Usual|Treatment as Usual mothers receive usual services of a PCP and case manager from a shelter-based primary care clinic. .
62057693|NCT03119727|OTHER|Automated oxygen adjustment|All patient in this study have automatic oxygen titration and automatic oxygen weanning
62057694|NCT05865613|EXPERIMENTAL|Magnetic group|Participants were randomized into either the PEMF group or sham treatment group by a computer-generated random number. The participants were treated using PEMF (20 G,7H for 10min). treatment was delivered for one month.
62057695|NCT05865613|SHAM_COMPARATOR|Sham magnetic group|Participants were randomized into either the PEMF group or sham treatment group by a computer-generated random number. The participants were treated using PEMF without adjusting the output. treatment was delivered for one month.
62057696|NCT00836602|ACTIVE_COMPARATOR|BMS-779788 or Placebo (Arm 1)|
62057697|NCT00836602|ACTIVE_COMPARATOR|BMS-779788 or Placebo (Arm 2)|
62057698|NCT00836602|ACTIVE_COMPARATOR|BMS-779788 or Placebo (Arm 3)|
62057699|NCT01888211|EXPERIMENTAL|Omega 3 fatty acid supplementation|Omacor 2 grams daily
62057700|NCT01888211|PLACEBO_COMPARATOR|Olive Oil|Olive Oil capsule 2 grams daily
62057701|NCT00838799|EXPERIMENTAL|1|
62057702|NCT00838799|EXPERIMENTAL|2|
62057703|NCT00838799|EXPERIMENTAL|3|
62057704|NCT00838799|ACTIVE_COMPARATOR|4|
62057705|NCT00838799|PLACEBO_COMPARATOR|5|
62057706|NCT00642902|EXPERIMENTAL|Atacicept 25 mg|
62057707|NCT00642902|EXPERIMENTAL|Atacicept 75 mg|
62057708|NCT00642902|EXPERIMENTAL|Atacicept 150 mg|
62057709|NCT00642902|PLACEBO_COMPARATOR|Placebo|
62446332|NCT01998321|EXPERIMENTAL|2 TKA using conditional technique.|Total Knee Arthroplasty using conditional technique.
62446333|NCT03345316|EXPERIMENTAL|FFI-1010|
62446334|NCT00663559|OTHER|1|This study has only one arm with Sunitinib
62446335|NCT05688930|EXPERIMENTAL|PENMT (Experimental Group)|The neuromuscular injury prevention intervention protocol contains field work activities that involve proprioceptive exercises, flexibility, and specific and general muscle strength of the MMII and trunk.
62446336|NCT05688930|ACTIVE_COMPARATOR|FIFA 11+ (Control Group)|Treatment or experimental condition. 1: FIFA 11+ Program
62446337|NCT03972982|EXPERIMENTAL|Simplified regimen group|Short-term continuous subcutaneous insulin infusion will be adminstrated to maintained euglycemia for 1 week，Then subsequent therapy using basal insulin plus metformin will be administrated. After withdrawal of the medicine, wearable devices and smart apps will be used for long-term management.
62617640|NCT06137911|PLACEBO_COMPARATOR|Group B:JYP0061 placebo comparator 15mg|Placebo comparator: JYP0061 placebo comparator Single ascending dose
62617641|NCT06137911|EXPERIMENTAL|Group C:JYP0061 food influence group 15mg|Food influence group
62260982|NCT03516682|EXPERIMENTAL|Reminders|Parents randomized to the reminder arm will receive automated reminders to complete a 6 month and 12 month vaccine visit for their child. They will receive 2 reminders before the child is 6 and 12 months of age and 2 reminders after their child is 6 and 12 months of age. Reminders will not occur if they have received vaccines within the eligible time frame to receive a vaccine or have a visit scheduled. After randomization, participants in the intervention arm will have an opportunity to provide their preference on how they receive reminders (text, phone and/or email). Participants not providing a preference will receive text reminders. If a child is randomized into the study after the child is 7 months of age, the parent will only be eligible for reminders for the 12 month vaccine visit.
62260983|NCT03009032|EXPERIMENTAL|PMT25341|A mixture of prebiotics, probiotics, oligonutrients, essential aminoacids, omega-3 fatty acids
62260984|NCT03009032|PLACEBO_COMPARATOR|PLACEBO|Lactose
62260985|NCT03059238|EXPERIMENTAL|Celecoxib group|Celecoxib 200mg oral capsule, 200 mg, orally one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
62617642|NCT06137911|EXPERIMENTAL|Group D:JYP0061 multiple ascending doses 30mg|Multiple ascending doses
62617643|NCT06137911|PLACEBO_COMPARATOR|Group E:JYP0061 placebo comparator food influence group 30mg|Food influence group
62617644|NCT06137911|PLACEBO_COMPARATOR|Group F:JYP0061 placebo comparator multiple ascending doses 30mg|Multiple ascending doses
62617645|NCT06363994|ACTIVE_COMPARATOR|Arm A|
62617646|NCT06363994|ACTIVE_COMPARATOR|Arm B|
62617647|NCT00546689||1 , 2|those with HIV
62617648|NCT05096962||Arm IKEM|"Arm IKEM (Institute for Clinical and Experimental Medicine) is represented by two subcohorts:~* participants with chronic illness (adults only), which are part of the research project of the Institute of Clinical and Experimental Medicine (the expected number of participants in the study - 3 000)~* healthy subjects from the Study of Czech Academy of Science, who are following up in the Institute of Clinical and Experimental Medicine (the expected number of subjects in the study - 2000) The subjects will be contacted based on the Hospital study database."
62260986|NCT03059238|EXPERIMENTAL|Parecoxib group|Parecoxib sodium , 40 mg, dissolved in 3 mL 0.9% sodium chloride intravenously one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
62260987|NCT03059238|EXPERIMENTAL|Oxycodone group|Controlled-release oxycodone, 10 mg, orally one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
62617649|NCT05096962||Arm FTN|Arm FTN (Thomayer University Hospital) is represented by the healthcare staff of the Hospital (the expected number of subjects in the study - 1800).
62617650|NCT05096962||Arm Olomouc|"Arm Olomouc is represented by participants, who participated in the Study Herd Immunity Study SARS-CoV-2-CZ-Preval in May 2020 and at the same time subjects who will be willing to participate in this study. The involvement of subjects from two localities is expected:~* Olomouc~* Litovel, Uničov and Červenka. The expected number of subjects in the study is approximately 2500."
62617651|NCT01135836|EXPERIMENTAL|pulmonary recruitment maneuver|a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anestheiologist held the fifth positive pressure inflation for approximately 5 seconds.
62617652|NCT01135836|EXPERIMENTAL|intraperitoneal normal saline|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity
62617653|NCT01135836|PLACEBO_COMPARATOR|Control group|CO2 was removed by passive exsufflation through the port site.
62617654|NCT02087943|EXPERIMENTAL|Apremilast 40 mg|Apremilast 40 mg administered orally twice daily (BID) for 12 weeks (following dose titration) during the placebo controlled phase followed by 40 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
62057710|NCT01807650|EXPERIMENTAL|Oleogel-S10, non-adhesive wound dressing|A split-thickness skin graft (STSG) donor site wound \>15cm2 in size was divided in 2 halves. One half was randomized to Oleogel-S10 treatment and non-adhesive wound dressing (intra-individual comparison). Oleogel-S10 was administered (1 cm or 100 mg per cm2 wound area corresponding to thickness of about 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
62446338|NCT03972982|ACTIVE_COMPARATOR|Routine group|Inpaitent short-term continuous subcutaneous insulin infusion will be administered to maintained euglycemia for 2 weeks, Then subjects will be follow-up routinely.
62446339|NCT03270176|EXPERIMENTAL|Debio 1143 and Avelumab|"Part A: Participants will receive Debio 1143 100 to 250 milligram (mg) capsule orally at an escalating dose levels for 10 days every 2 weeks along with avelumab 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion every 2 weeks.~Part B: Participants will receive Debio 1143 capsules orally at a recommended phase 2 dose (RP2D) of 200 mg/day (days 1-10 and 15-24 every 28 days (\[q4w\]) in combination with avelumab IV infusion at the standard dose unless disease progression or unacceptable toxicity occurs, as judged by investigators up to 26 cycles (each cycle is of 28 days)."
62446340|NCT05834712|EXPERIMENTAL|Mobile Platform Intervention Group|The mobile platform is used to evaluate the nutrition of patients 2 weeks after the first course of induction chemotherapy, before radiotherapy, during radiotherapy, after radiotherapy, and 1 month after radiotherapy. The doctor pushes individualized nutrition education, oral advice, medication advice, etc. .
62446341|NCT05834712|ACTIVE_COMPARATOR|Non-mobile Platform Intervention Group|Nutritional assessment of patients was performed at 2 weeks after 1 course of induction chemotherapy, before radiotherapy, during radiotherapy, at the end of radiotherapy, and at 1 month after the end of radiotherapy.
62446342|NCT03567720|EXPERIMENTAL|TAVO-EP plus IV pembrolizumab|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab (Cohort enrollment completed)
62446343|NCT03567720|EXPERIMENTAL|TAVO-EP plus IV pembrolizumab with chemotherapy|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab along with treatment of an approved chemotherapy per standard of care (either nab-paclitaxel or gemcitabine plus carboplatin)
62057711|NCT01807650|OTHER|Non-adhesive wound dressing only|A STSG donor site wound \>15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days.
62260988|NCT04444999|EXPERIMENTAL|Endovascular abdominal aortic aneurysm repair|a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA).
62260989|NCT05709964||Study group|All patients included in this study. Investigators will record both self-reported and measured height, weight, and neck circumference in all of these patients.
62260990|NCT03705728|EXPERIMENTAL|Intravenous group|"Propofol \& remifentanil administration using the closed-loop controller with the Easy-TIVA platfrom."
62260991|NCT03705728|ACTIVE_COMPARATOR|volatile anesthesia group|Sevoflurane will be administered manually according to the BIS values. Remifentanil will be administered manually using a Target Controlled Infusion pump using the Minto model.
62260992|NCT03211702||Elderly DLBCL patients|Elderly DLBCL patients (age\>=65 years) treated with R-CHOP chemotherapy
62260993|NCT04750642|EXPERIMENTAL|CI632D Investigational Medical Device (IMD)|
62843182|NCT05680688|ACTIVE_COMPARATOR|Painless Manual Therapy|Manual therapy treatment shall be performed at a low intensity that does not cause pain to the patient. The aim is for the patient to report a pain intensity of 0/10 in NRS throughout treatment. The physiotherapist will ask every 30 seconds the pain provoked by the treatment with NRS and the patient will give continuous feedback. Based on this, the physiotherapist will adapt the intensity of the treatment to be performed below the pain threshold.
62057712|NCT06071065|ACTIVE_COMPARATOR|Basic|"Basic intervention included the usual counselling by a clinical pharmacist e.g.~1. Patients Education~   * Pharmacist counseling regarding their disease type and severity~  * Pharmacist counseling (15- to 20-minute sessions) on the proper use of medication~  * Pharmacist counseling regarding the importance of their therapy (treatment)~  * Labeling of medication packs to assist pill sorting. Labels included instructions on dose and frequency/ timing of medication doses~2. Optimizing therapy monitoring~   * Prescription information quality (incomplete prescription)~  * wrong dose~  * wrong frequency etc."
62057713|NCT06071065|EXPERIMENTAL|Advanced|"In addition to Basic Intervention:~1. Preventing drug interactions :~   • Detection or assessment of potential DDIs by a pharmacist prior to the start of treatment and recommendations for their management.~2. Patient Education regarding Medications :~   * Pharmacist counseling (15- to 20-minute sessions) on the proper use of medication.~  * Pharmacist counseling on the safe use of medication (self-medication or over-the-counter \[OTC\] medicines)~3. Preventing an adverse drug event~   • Monitoring, and prompt detection of adverse drug events (ADEs)~4. Education on lifestyle modifications~   * Education on lifestyle e.g. regarding exercise~  * Renal diet plan will be given to patients~5. Renal Dose Adjustments :~   * Detection or assessment of potential nephrotoxic drugs by a pharmacist prior to start of treatment and recommendations for their renal dose adjustment."
62057714|NCT04473690|EXPERIMENTAL|Low Dose KBP-COVID-19 and adjuvant|"Two age groups.~Part A (18-49 years).~Part B (50-85 years).~All subjects in these groups will receive the low dose of KBP-COVID-19"
62057715|NCT04473690|EXPERIMENTAL|High Dose KBP-COVID-19 and adjuvant|"Two age groups.~Part A (18-49 years).~Part B (50-85 years).~All subjects in these groups will receive the high dose of KBP-COVID-19"
62057716|NCT04473690|PLACEBO_COMPARATOR|Placebo|"Two age groups.~Part A (18-49 years).~Part B (50-85 years).~All subjects in these groups will receive placebo"
62057717|NCT00571766|EXPERIMENTAL|1|Oral L-Arginine 2 g twice a day for 14 weeks
62260994|NCT04750642|PLACEBO_COMPARATOR|CI632 Comparator Device|
62260995|NCT03496428|OTHER|Dental implant Impression Techniques|"Dental implant impressions- Different Techniques An customized impression coping will be created based on the provisional crown emergence profile which will be used to perform a silicone implant impression. A conventional cast will be created based on the silicone impression and an extra-oral scanner reading will be performed with a 3shape D2000.~An intra-oral scanner (Trios, 3Shape) will be used to scan the entire arch. The STL file created will be compared and tooth positions and soft tissues discrepancies will be determined"
62057718|NCT00571766|PLACEBO_COMPARATOR|2|Placebo 2 g, twice a day for 14 weeks
62260996|NCT03478514|EXPERIMENTAL|Single Arm|"All patients will receive palbociclib at 100 mg oral once a day for 21 days, followed by 7 days off.~Ibrutinib will be administered at 560 mg oral continuously."
62260997|NCT04804787|EXPERIMENTAL|Experimental group : patients with multiple sclerosis|The experimental group will be constituted of patients with multiple sclerosis.
62260998|NCT04804787|ACTIVE_COMPARATOR|Control group : volunteers|The control group will be constituted of healthy volunteers with the same characteristics concerning age, sex, education's level as experimental group's patients
62260999|NCT04555824|EXPERIMENTAL|Recombinant Human Thymosin β4 Dose 1 group|Two subjects in this group will receive NL005 for 0.05ug/kg respective in D1.
62261000|NCT04555824|EXPERIMENTAL|Dose 2 groupRecombinant Human Thymosin β4|Two subjects in this group will receive NL005 for 0.25ug/kg respective in D1.
62261001|NCT04555824|EXPERIMENTAL|Dose 3 groupRecombinant Human Thymosin β4|Eight subjects in this group will receive NL005 for 0.5ug/kg respective in D1.
62446344|NCT03933657|EXPERIMENTAL|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System-Peripheral is indicated to facilitate the intraluminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions via atherectomy.
62261002|NCT04555824|EXPERIMENTAL|Dose 4 groupRecombinant Human Thymosin β4|Eight subjects in this group will receive NL005 for 2ug/kg respective in D1.
62446345|NCT03256799|EXPERIMENTAL|Ivacaftor/Ataluren|
62446346|NCT03318770||All patients|All eligible patients enrolled in the GIMEMA LAL2116 study who have completed 12 months follow-up will be included in this group.
62843183|NCT05846737|EXPERIMENTAL|BCMA CAR-T in high-risk MM with detectable MRD after first-line ASCT|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10\^6 anti-BCMA CAR+T cells/kg.
62843184|NCT03062540|EXPERIMENTAL|TNX-102 SL Tablet, 5.6 mg|2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
62617655|NCT02087943|EXPERIMENTAL|Apremilast 30 mg|Apremilast 30 mg administered orally BID for 12 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
62617656|NCT02087943|EXPERIMENTAL|Placebo + Apremilast 40 mg|Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 40 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
62617657|NCT02087943|EXPERIMENTAL|Placebo + Apremilast 30 mg|Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 30 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
62617658|NCT02087943|PLACEBO_COMPARATOR|Placebo|Oral Placebo tablets administered twice daily (BID) for 12 weeks during the placebo-controlled phase.
62843185|NCT03062540|PLACEBO_COMPARATOR|Placebo SL Tablet|2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
62843186|NCT00280748|OTHER|Single Arm Study|Single Arm Study
62843187|NCT03254511|EXPERIMENTAL|enoxaparin|In the enoxaparin group, patients are going to receive radiotherapy (median treatment dose will be 50.40 Gy in 25 to 32 fractions) with weekly concurrent chemotherapeutic combinations (paclitaxel \[50 mg/m2\] plus carboplatin \[area under the carve=2\]) with Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable (40 mg daily).
62057719|NCT03170167||Patients|This is a pre-post survey study of Communitas, a pre-existing integrative medicine and mind-body skills group visit for adolescents living with chronic illness and their parents. Approximately 50-100 patient enrollees of the Communitas group visits will be recruited to participate in this survey study optionally.
62446347|NCT04675710|EXPERIMENTAL|Treatment (dabrafenib, trametinib, pembrolizumab)|Patients receive 21-day cycles of dabrafenib 150 mg orally (PO) twice daily from Days 1-21, trametinib 2mg PO once daily from Days 1-21, and pembrolizumab 200mg intravenously (IV) on Day 1 of each cycle.
62446348|NCT00780520|EXPERIMENTAL|1|
62057720|NCT03170167||Parents|This is a pre-post survey study of Communitas, a pre-existing integrative medicine and mind-body skills group visit for adolescents living with chronic illness and their parents. Approximately 50-100 parent enrollees of the Communitas group visits will be recruited to participate in this survey study optionally.
62057721|NCT01253863|OTHER|determining damaged tissue|
62057722|NCT02452086|ACTIVE_COMPARATOR|Low Level Laser Therapy|"In laser therapy group, group who received interventions was the patients received laser with 2 Joule/centimeters2, 90 milliwatt~, 3 days/week, for 4 weeks (12 sessions)"
62057723|NCT02452086|PLACEBO_COMPARATOR|Placebo|In the placebo group, the treatment procedure was the same as that the LLLT group, but the laser light was off and Guiding light was laser was on
62057724|NCT01331460|EXPERIMENTAL|RBT Experimental|
62057725|NCT01331460|ACTIVE_COMPARATOR|Case-Management: Treatment as Usual|
62057726|NCT01856712|ACTIVE_COMPARATOR|oral naltrexone|an initial 50 mg oral dose of naltrexone prior to hospital discharge plus a 30-day prescription for oral naltrexone
62057727|NCT01856712|EXPERIMENTAL|injectable naltrexone|a single 380 mg intramuscular injection of naltrexone (duration of action = 30 days)prior to hospital discharge followed by a second injection one month later.
62057728|NCT00677443|EXPERIMENTAL|S-1 and Oxaliplatin|"S-1 and Oxaliplatin~S-1 : 80 mg/m2/day D1-14 Oxaliplatin : 130 mg/m2/day D1 Repeated every 3 weeks"
62446349|NCT00780520|PLACEBO_COMPARATOR|2|
62446350|NCT00870922|EXPERIMENTAL|TMD group|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
62843188|NCT03254511|ACTIVE_COMPARATOR|control|In the control group, patients are going to receive radiotherapy (median treatment dose will be 50.40 Gy in 25 to 32 fractions) with weekly concurrent chemotherapeutic combinations (paclitaxel \[50 mg/m2\] plus carboplatin \[area under the carve=2\]) alone.
62843189|NCT04096599|EXPERIMENTAL|Test group|
62843190|NCT04096599|ACTIVE_COMPARATOR|Control group|
62843191|NCT01369524||ICUpatient with need of fluid|age \> 18 - haemodynamic monitoring - informed consent - admission on ICU
62843192|NCT04756908|EXPERIMENTAL|Opira AIOL|
62446351|NCT02160197|NO_INTERVENTION|No Immobilisation|No immobilisation post op, allowing patients to weight bear as tolerated.
62446352|NCT02160197|ACTIVE_COMPARATOR|Functional Bracing|Immobilise patients in Functional brace, allowing patients to weight bear as tolerated.
62446353|NCT02160197|ACTIVE_COMPARATOR|Plaster Immobilisation|Immobilise patients in plaster, allowing patients to weight bear as tolerated.
62617659|NCT02110628|EXPERIMENTAL|Roux-en-Y+Pouch Group|Abdominal approach D2 total gastrectomy with Roux-en-Y+Pouch anastomosis. Roux-en-Y+Pouch anastomosis: closed the stump of duodenum, cut off the jejunum from the 20cm of Treitz ligament, pouch reconstruction a J pouch with a length of 15 cm was constructed by connecting the 2 Jejunal lumina, œsophago-P type jejunum Storage bag anastomosis (duct-to-duct / duct-to-duct, before the colon/after the colon), jejunum - jejunum anastomosis (duct-to-duct / duct-to-duct), the distance between anastomotic were 40cm-60cm.
62843193|NCT04756908|ACTIVE_COMPARATOR|Monofocal AIOL|
62843194|NCT04756908|ACTIVE_COMPARATOR|Multifocal AIOL|
62843195|NCT04816110|EXPERIMENTAL|mineralized plasmatic matrix with collagen membrane|
62843196|NCT04816110|ACTIVE_COMPARATOR|mineralized plasmatic matrix without collagen membrane|
62843197|NCT05095103||Stable Immunosuppressed|Acetylcholine repector antibody positvie myasthenia gravis, stable for two years on prednsiolone \<5mg/day and azathioprine or mycophenolate.
62843198|NCT05095103||Stable Non-immunosuppressed|Acetylcholine repector antibody positvie myasthenia gravis, stable for two years on ≤120mg pyridostigmine/day and no immunosuppression.
62843199|NCT05095103||Refractory|Acetylcholine repector antibody positvie myasthenia gravis, meeting the NHS England criteria for Rituximab
62617660|NCT02110628|EXPERIMENTAL|Roux-en-Y group|Abdominal approach D2 total gastrectomy with Roux-en-Y anastomosis. Roux-en-Y anastomosis : closed the stump of duodenum, cut off the jejunum from the 20cm of Treitz ligament, œsophago-jejunal anastomosis (duct-to-duct / duct-to-duct, before the colon/after the colon), jejunum - jejunum anastomosis (duct-to-duct / duct-to-duct), the distance between anastomotic were 40cm-60cm
62617661|NCT00477204|ACTIVE_COMPARATOR|Simvastatin|Zocor(simvastatin)(20 mg)daily for 6 months along with Placebo (sugar pill)of active comparator (Vytorin \[simvastatin\] + Zetia \[ezetimibe\].
62617662|NCT00477204|ACTIVE_COMPARATOR|Ezetimibe/Simvastatin|Vytorin(simvastatin \[Zocor} + ezetimibe \[Zetia\])(20 mg)daily for 6 months along with placebo (sugar pill)of comparator (Vytorin \[simvastatin\]).
62843200|NCT05095103||Healthy Controls|No autoimmune disease or current solid organ or haematological malignancy.
62261003|NCT04555824|EXPERIMENTAL|Dose 5 groupRecombinant Human Thymosin β4|Eight subjects in this group will receive NL005 for 5ug/kg respective in D1.
62261004|NCT04555824|EXPERIMENTAL|Recombinant Human Thymosin β4 Dose 6 group|Eight subjects in this group will receive NL005 for 12.5ug/kg respective in D1.
62261005|NCT04555824|EXPERIMENTAL|Recombinant Human Thymosin β4 Dose 7 group|Eight subjects in this group will receive NL005 for 25ug/kg respective in D1.
62446354|NCT04876196|ACTIVE_COMPARATOR|Intervention Group|Web-based intervention (Selfapy for Bulimia Nervosa)
62446355|NCT04876196|NO_INTERVENTION|Waitlist Control Group|12-week waiting period
62446356|NCT03304080|EXPERIMENTAL|HR-positive, Her2-positive Metastatic Breast Cancer|Women and men with HR-positive, HER2-positive Metastatic Breast Cancer on trial of anastrozole, palbociclib, trastuzumab and pertuzumab
62446357|NCT04252469|EXPERIMENTAL|intervention|receiving oral care with 20mL of 0.12% CHX by medicine cup, gargling 30 seconds.
62446358|NCT04252469|NO_INTERVENTION|Control|Standardized care
62617663|NCT02377128|EXPERIMENTAL|Bilateral salpingectomy|Cesarean section with bilateral salpingectomy
62617664|NCT02377128|ACTIVE_COMPARATOR|Tubal ligation|Cesarean section with tubal ligation
62617665|NCT02377128|NO_INTERVENTION|No intervention|Cesarean section with no additional intervention
62843201|NCT04321707|EXPERIMENTAL|15O-H2O PET/MR|All included patients will have two 15O-H2O PET/MR scan performed.
62057729|NCT00677443|ACTIVE_COMPARATOR|Capecitabine and Oxaliplatin|Capecitabine and Oxaliplatin
62617666|NCT02452814||Cohort|
62843202|NCT04396561|EXPERIMENTAL|Paravertebral group (group P):|After induction of general anesthesia and stabilization of the patients, they were positioned in lateral decubitus position with the side to be blocked uppermost.
62843203|NCT04396561|EXPERIMENTAL|Control group (group C):|Patients underwent surgery under general anesthesia and received the perioperative routine protocol of analgesia (IV fentanyl 2 μcg/kg at induction and 1 gm of IV paracetamol).
62843204|NCT00405600|ACTIVE_COMPARATOR|Device|Device used in surgery with or without instrumentation
62843205|NCT01458041||Group 1|
62843206|NCT01429740|EXPERIMENTAL|PF-05180999|
62843207|NCT01429740|PLACEBO_COMPARATOR|Placebo|
62843208|NCT02670239||EVLP group|All lungs from brain dead donors that were considered at high-risk for transplantation and underwent EVLP in the Turin lung transplantation program
62843209|NCT06210321|OTHER|Intervention arm|Adjustment of antidepressant treatment according to pharmacogenetic results obtained by genetic testing for cytochrome CYP 2C19 (alleles \*2, \*3 and \*17)
62057730|NCT04069130|EXPERIMENTAL|BIA 5|single oral dose of 400 mg as an oral capsule
62057731|NCT03156933||Splicing variants|Sample of acute myeloid leukaemia primary cells
62057732|NCT00385411|EXPERIMENTAL|valproate|
62057733|NCT01840553|ACTIVE_COMPARATOR|polyethylene glycol|4 Liters of PEG administered split in 2 doses
62261006|NCT04555824|PLACEBO_COMPARATOR|Placebo|Two subjects in each dose group（0.5/2/5/12.5/25ug/kg）were given placebo respective in D1. A total of 10 subjects were given placebos.
62261007|NCT05386901|EXPERIMENTAL|Conventional positive end-expiratory pressure(PEEP)|Once the patient is intubated and after initiating ventilation in a pressure control mode(PCV) using an airway pressure of 20-25mmHg with tidal volume not exceeding 6ml/kg of predicted body weight (PBW) and an inspiration: expiration ratio of 1:2;a respiratory rate of 20-30 breaths per minute to maintain the etCO2 at 35-40 mmHg.The investigators will set the PEEP value to 5 cmH2O until the end of the operation.
62261008|NCT05386901|EXPERIMENTAL|Lung dynamic compliance guided positive end-expiratory pressure(PEEP)|Once the patient is intubated and after initiating ventilation in a pressure control mode(PCV) using an airway pressure of 20-25mmHg with tidal volume not exceeding 6ml/kg of predicted body weight (PBW) and an inspiration: expiration ratio of 1:2;a respiratory rate of 20-30 breaths per minute to maintain the etCO2 at 35-40 mmHg.The investigators will set initial PEEP to 0cmH2O,and the PEEP is increased by 2 cmH2O every 2 minutes.Observing the PEEP value corresponding to the maximum lung dynamic compliance during the process that lung dynamic compliance=Vt/(Pplat-PEEP).After the incremental PEEP process is completed, setting the PEEP value for ventilation until the end of the operation.
62261009|NCT01123499||Healthy Volunteers|Any healthy volunteers that are eligible to donate blood.
62446359|NCT04774081||Study group|Participants will be recruited among those whose insulin sensitivity has been previously measured by a high-dose euglycemic-hyperinsulinemic clamp at Pennington Biomedical during the last 5 years and indicated their wiliness to be re-contacted for future research
62617667|NCT03268005|EXPERIMENTAL|Faster aspart + insulin degludec with or without metformin|
62617668|NCT03268005|ACTIVE_COMPARATOR|NovoRapid/NovoLog + insulin degludec with or without metformin|
62843210|NCT06210321|NO_INTERVENTION|Control arm|Delivery of escitalopram treatment as prescribed. Genetic analysis will be performed in batch at the end of the follow-up period.
62843211|NCT01780220|EXPERIMENTAL|abiraterone|Abiraterone acetate (three dose levels in phase I) + prednisone (10mg/day)+LHRH + Radiotherapy
62057734|NCT01840553|EXPERIMENTAL|oral sodium phosphate tablets|oral Sodium Phosphate tablets administered as 32 tablets (20+12) with 2 Liters of liquid
62057735|NCT01086202||Tornier Reversed Shoulder Arthroplasty Medial Offset|
62843212|NCT00080899|EXPERIMENTAL|Treatment (fenretinide)|Patients receive oral fenretinide twice daily on days 1-7. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
62843213|NCT06133062|EXPERIMENTAL|Atezolizumab and bevacizumab with proton radiotherapy|Patients undergo Atezolizumab and Bevacizumab with proton radiotherapy.
62843214|NCT00685568|EXPERIMENTAL|Arm I|Patients receive oral celecoxib twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
62843215|NCT00685568|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
62843216|NCT01915069|EXPERIMENTAL|Cilostazol|The primary aim of the study is to assess the affects of oral Cilostazol taken at the FDA approved dose of 100mg PO bid on human oocyte maturation.
62843217|NCT05252780|EXPERIMENTAL|Intervention group|My Body, My Rhythm, My Voice
62057736|NCT01086202||Lateral offset arthroplasty|
62057737|NCT02691182|EXPERIMENTAL|Open-label treatment with SPN-810|"Subjects aged 6-17 years were treated with SPN-810 starting on day 1 with 18 mg/day. The clinician was able to adjust the dose of SPN-810 throughout the study based on subject's response and tolerability within the limits of 6 mg/day and 36 mg/day or, up to 54 mg/day for subjects with a body weight ≥ 30 kg.~The subjects were given a choice of extending their participation in the study every 6-month period for up to 36 months"
62057738|NCT00070135|EXPERIMENTAL|Treatment (fludarabine, busulfan, allogeneic PBSC)|"PREPARATIVE REGIMEN: Patients receive fludarabine IV over 30 minutes on days -7 to -3 and busulfan IV over 2 hours 4 times per day (every 6 hours) on days -4 and -3.~GVHD PROPHYLAXIS: Patients receive tacrolimus PO or IV BID on days -2 with taper between days 90-120, and stopping by days 150-180. Patients also receive methotrexate IV on days 1, 3, 6, and 11 and rabbit antithymocyte globulin IV over 4-6 hours on days -4 through -2.~ALLOGENEIC PBSC: Patients undergo allogeneic PBSC transplant on day 0. Patients then receive filgrastim SC daily beginning on day 12 and continuing until blood counts recover."
62057739|NCT05343338|EXPERIMENTAL|sivelestat sodium on the basis of the original treatment|In the perioperative period, sivelestat sodium was added, and on the basis of not terminating and changing the original treatment plans.
62057740|NCT05343338|NO_INTERVENTION|the original treatment|Only accept the original clinical diagnosis and treatment and clinical management.
62261010|NCT02162836|EXPERIMENTAL|Cohort 1|Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
62261011|NCT04117243|ACTIVE_COMPARATOR|Tranexamic group|patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision).
62446360|NCT02553239|EXPERIMENTAL|Cryoablation|Cryoablation with the CoolLoop® catheter
62446361|NCT03701828|EXPERIMENTAL|Weight loss|Participants will undergo weight loss surgery
62617669|NCT02034760|ACTIVE_COMPARATOR|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
62617670|NCT02034760|EXPERIMENTAL|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
62617671|NCT02034760|ACTIVE_COMPARATOR|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
62617672|NCT02034760|ACTIVE_COMPARATOR|Protein Collagen|Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.
62617673|NCT02034760|PLACEBO_COMPARATOR|Carbohydrate|Two daily 30g carbohydrate supplementations for 52 weeks.
62843218|NCT05252780|NO_INTERVENTION|Control group|No intervention
62843219|NCT02074410|EXPERIMENTAL|OMS643762 Low Dose without food|Orally administering OMS643762 low dose daily without food for 28 days
62843220|NCT02074410|EXPERIMENTAL|OMS643762 Medium Dose without food|Orally administering OMS643762 medium dose daily without food for 28 days
62057741|NCT02426723|EXPERIMENTAL|CWP232291|"Phase 1a: single administration of CWP232291 ,~Phase 1b: CWP232291 combination with Lenalidomide and Dexamethasone"
62057742|NCT02826967|EXPERIMENTAL|Colonic Irrigation|A designated health professional will administer to the patient the colonic irrigation procedure -using the Hydro-San Plus colon therapy system, an FDA approved and ISO certified device for colonic irrigation and cleansing before endoscopic procedures (FDA #2027347).
62057743|NCT05116423||ITP inpatients|The study population included nonsplenectomized primary ITP inpatients 18 years of age or older. Patients who had a diagnosis of connective tissue disease, cancer (solid tumor or leukemia), or primary immune deficiency were excluded.
62446362|NCT02419677|OTHER|RFA alone|Patients undergo radiofrequency ablation alone.
62843221|NCT02074410|EXPERIMENTAL|OMS643762 Medium Dose with food|Orally administering OMS643762 Medium dose daily with food for 28 days
62843222|NCT02074410|PLACEBO_COMPARATOR|Placebo|Orally administering placebo daily for 28 days
62843223|NCT03116152|EXPERIMENTAL|IBI308|IBI308 200mg Intravenous drip every three weeks
62843224|NCT03116152|ACTIVE_COMPARATOR|paclitaxel/irinotecan|paclitaxel 175mg/㎡ Intravenous drip every three weeks； irinotecan 180mg/㎡ Intravenous drip every two weeks
62843225|NCT05959148|EXPERIMENTAL|MIRE group|Participants in this group underwent MIRE application in addition to the traditional physical therapy program
62843226|NCT05959148|ACTIVE_COMPARATOR|Control|Participants in this group received the traditional physical therapy program only.
62843227|NCT02210494|EXPERIMENTAL|Secretrol|
62843228|NCT01901913|EXPERIMENTAL|MD-bolus calculator for pre meal bolus|closed loop session with MD-bolus calculator for pre-meal bolus.
62843229|NCT01901913|ACTIVE_COMPARATOR|No MD-bolus calculator for pre-meal bolus|closed loop session without MD-bolus calculator for pre-meal bolus
62843230|NCT02840799|EXPERIMENTAL|Potassium Nitrate (KNO3)|Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.
62843231|NCT02840799|PLACEBO_COMPARATOR|Potassium Chloride (KCl)|"Potassium Chloride (KCl) is the placebo (control drug) in this trial.~Potassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks."
62843232|NCT03173001||Patients with colorectal cancer|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
62057744|NCT00916461|ACTIVE_COMPARATOR|Minocycline|
62057745|NCT00916461|PLACEBO_COMPARATOR|Sugar Pill|
62057746|NCT04894734|EXPERIMENTAL|EES on|Patients will undergo epidural electrical stimulation (EES) and be randomized in a 1:1 allocation to EES on. Both the patient and the provider will be formally blinded to treatment assignment. Only the biostatistician and programming team will be unblinded to treatment assignments.
62617674|NCT06229899||metabolically healthy individuals with obesity|Individuals with BMI ≥30 , those without criteria of metabolic syndrome other than an increase in waist circumference (blood pressure ≥130/85 mmHg, fasting blood sugar ≥100 mg/dl, triglycerides ≥150 mg/dl, HDL-cholesterol \<40 mg/dl in men and \<50 mg/dl in women) and without prediabetes
62843233|NCT03173001||Population|The control group includes residents of Tashkent city without any complaints from gastrointestinal tract matched by gender and age to the patients with colorectal cancer.
62617675|NCT06229899||metabolically unhealthy individuals with obesity|Individuals with BMI ≥30 , and have one of the followings: blood pressure ≥130/85 mmHg, fasting blood sugar ≥100 mg/dl, triglycerides ≥150 mg/dl, HDL-cholesterol \<40 mg/dl in men and \<50 mg/dl in women
62617676|NCT03611101|EXPERIMENTAL|BMS-986036 Dose Level 1|Administered by subcutaneous injection
62843234|NCT03173001||Patients with CRC without metastases|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
62057747|NCT04894734|PLACEBO_COMPARATOR|EES off|Patients will undergo epidural electrical stimulation (EES) and be randomized in a 1:1 allocation to EES off. Both the patient and the provider will be formally blinded to treatment assignment. Only the biostatistician and programming team will be unblinded to treatment assignments.ES off. Those in the EES off category will have their EES turned on at the 9-month timepoint.
62261012|NCT04117243|ACTIVE_COMPARATOR|Misoprostol group|patients will be given 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) sublingually immediately before starting skin incision.
62446363|NCT02419677|EXPERIMENTAL|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA.
62446364|NCT06172842||primary electrical disease|
62446365|NCT06172842||control|
62617677|NCT03611101|EXPERIMENTAL|BMS-986036 Dose Level 2|Administered by subcutaneous injection
62617678|NCT03611101|EXPERIMENTAL|BMS-986036 Dose Level 3|Administered by subcutaneous injection
62617679|NCT03611101|PLACEBO_COMPARATOR|Placebo|Administered by subcutaneous injection
62843235|NCT03173001||Patients with CRC with metastases|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
62843236|NCT03173001||Patients with CRC before operation|Patients hospitalized with colorectal cancer before operation at the Department of Coloproctology of Republican Oncology Research Center.
62843237|NCT03173001||Patients with CRC after operation|Patients hospitalized with colorectal cancer after operation at the Department of Coloproctology of Republican Oncology Research Center.
62843238|NCT03173001||Patients with CRC before chemotherapy|Patients hospitalized with colorectal cancer before operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.
62843239|NCT03173001||Patients with CRC after chemotherapy|Patients hospitalized with colorectal cancer after operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.
62843240|NCT00724087|EXPERIMENTAL|5.5-hour bedtime|
62843241|NCT00724087|EXPERIMENTAL|8.5-hour bedtime|
62617680|NCT04962035||Alprem RTF Brain Follow-up|Neurocognitive Follow-up of children previously having participated in the Alprem RTF study
62057748|NCT02621346|EXPERIMENTAL|Imagery Group|The imagery group, will sit on the leg press and image completing 3 sets of leg press. The imagery group will be asked to fill out the Movement Imagery Questionnaire -revised as this gives us a measure of imagery ability. The imagery group will be given an imagery script prior to imaging. Weekly manipulation checks will be completed to ensure that participants are imagining what they are supposed to.
62057749|NCT02621346|ACTIVE_COMPARATOR|Maintenance Group|The maintenance group will continue to perform the leg press three times per week at 1/3rd of final strength assessment. This is the percentage of intensity recommended to maintain muscle mass and strength gains by the American College of Sports Medicine.
62057750|NCT02621346|ACTIVE_COMPARATOR|Control Group|Control group will come in 3 times per week for 20 minutes and complete 3 sets of 8-12 of a bicep curl 1/3 of predicted 1 RM
62057751|NCT05096208|EXPERIMENTAL|RSVpreF vaccine Group 1|RSVpreF
62446366|NCT05224921||Very low birth weight infants|Include very low birth weight infants admitted into NICU in Children's hospital of Fudan University, and prospectively observe whether they get late onset sepsis.
62446367|NCT05621486|EXPERIMENTAL|B4T2-001 CAR T cells|Single Arm and Open Label study consisting of dose escalation study design followed by dose expansion phase at determined MTD. Treatment follows a lymphodepleting chemotherapy regimen
62843242|NCT06458699||Hirschsprung's Disease|Patients with Hirschsprung's Disease who had a stoma in the first 3 months of life
62843243|NCT06458699||Anorectal MAlformations|Patients with Anorectal MAlformations who had a stoma in the first 3 months of life
62843244|NCT06458699||Intestinal Atresia|Patients with Intestinal Atresia who had a stoma in the first 3 months of life
62843245|NCT06458699||Necrotizing Enterocolitis|Patients with Necrotizing Enterocolitis who had a stoma in the first 3 months of life
62843246|NCT06458699||Intestinal Perforations|Patients with Intestinal Perforations who had a stoma in the first 3 months of life
62057752|NCT05096208|EXPERIMENTAL|RSVpreF vaccine Group 2|RSVpreF
62057753|NCT05096208|EXPERIMENTAL|RSVpreF vaccine Group 3|RSVpreF
62057754|NCT05096208|PLACEBO_COMPARATOR|Placebo dose|Placebo
62057755|NCT05064826|NO_INTERVENTION|Standard visit|Participants will have standard Emergency Department visit as per standard operating procedures which should last approximately 3 -5 hours.
62446368|NCT05158114|EXPERIMENTAL|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
62446369|NCT04203680|SHAM_COMPARATOR|HTK group|Patients received 30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg
62617681|NCT02882464|EXPERIMENTAL|2PRF+CAF|"Two tubes of blood samples were centrifuged by PC-02 Centrifuged device. This centrifuged device is used with 2700 rpm and for 12 minutes( PC-02 Centrifuge, Process,France). PRF were prepared for patients in 2 layer platelet rich fibrin membrane with coronally advanced flap group (2PRF+CAF).~Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In 2PRF+CAF group: two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ and flpa is positioned coronally."
62843247|NCT01518764|EXPERIMENTAL|Red Wine Polyphenols|Red Wine Polyphenols 600mg/day (capsules)
62843248|NCT01518764|PLACEBO_COMPARATOR|placebo|placebo (capsules)
62843249|NCT02083913|EXPERIMENTAL|Supervised physical activity|
62843250|NCT06293651|EXPERIMENTAL|Monotherapy|Phase 1a: Dose escalation Phase 1b: Dose expansion Phase 2a: Pharmacodynamic Biomarkers
62843251|NCT06293651|EXPERIMENTAL|Combination with Pembrolizumab|Phase 1a: Dose escalation Phase 1b: Dose expansion Phase 2a: Proof of concept Phase 2a: Pharmacodynamic Biomarkers
62057756|NCT05064826|EXPERIMENTAL|Extended visit with Observation|Participants will have extended Emergency Department visit by having an observation (which could be up to 23 hours) time in addition to the standard ED visit. In addition, information will be gathered about about the participants, use of opioids, healthcare visits, the quality of health, life, and treatment, and other topics. Urine or saliva or both may also be collected.
62057757|NCT01253525|EXPERIMENTAL|Ramucirumab (IMC-1121B ) and Pacitaxel|Each treatment cycle is 4 weeks (28 days)
62057758|NCT01209637|NO_INTERVENTION|control|standard care of coronary artery diseases incl. recommended home based exercise 3x/week
62261013|NCT04117243|ACTIVE_COMPARATOR|oxytocin only group|patients will receive an intravenous bolus of 5 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby
62261014|NCT01513538||TherapyGuide|Patients implanted with a dual chamber pacemaker featuring the TherapyGuide function
62261015|NCT02467738|EXPERIMENTAL|Cesium-131 Brachytherapy|Patients undergo brachytherapy using Cesium-131 during surgical resection
62261016|NCT02975895|OTHER|Hydrophobic IOL: Vivinex (HOYA)|Intraocular lens with hydrophobic properties: Vivinex (HOYA).
62261017|NCT02975895|OTHER|Hydrophilic IOL: INCISE (Bausch+Lomb)|Intraocular lens with hydrophilic properties: INCISE (Bausch+Lomb).
62617682|NCT02882464|EXPERIMENTAL|4PRF+CAF|Four tubes of blood samples were centrifuged by PC-02 Centrifuged device,four layers of PRF membranes were prepared for patients in 4 layer platelet rich fibrin membrane with coronally advanced flap.(4PRF+CAF). This centrifuged device is used with 2700 rpm and for 12 minutes( PC-02 Centrifuge, Process,France) Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In 4PRF+CAF group: four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ and flap is coronally positioned.
62617683|NCT02882464|ACTIVE_COMPARATOR|CTG+CAF|"The surgical technique in coronally advanced flap with subepithelial connective tissue graft (CTG+CAF) group was envelope technique as described by Raetzke. The papillae were dis epithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. The connective tissue graft was harvested from the palate using trap-door technique described by Edel. Epithelial layer was elevated with a horizontal and two vertical incisions. The connective tissue graft was harvested as 1 mm by using a standard caliper, then epithelial layer was sutured by resorbable suture. The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ."
62617684|NCT00143468|EXPERIMENTAL|1|ALI/ARDS patients and healthy subjects
62617685|NCT04555252||Cephalic Duodenopancreatectomy|Patients who underwent scheduled cephalic duodenopancreatectomy and hospitalized in intensive care.
62617686|NCT00384371|EXPERIMENTAL|1|Botulinum Toxin A
62261018|NCT03053700|ACTIVE_COMPARATOR|Treatment with bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would recieve this treatment alone.
62261019|NCT03053700|ACTIVE_COMPARATOR|Treatment with bromonide 0.33% gel & IPL|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
62261020|NCT05650814|EXPERIMENTAL|ButterfLife|The patient will be recommended to take the measurement of five vital parameters once a day by ButterfLife device. Daily telemonitoring will be conducted in addition to standard home care.
62261021|NCT05650814|OTHER|Control|The patients will receive standard home care.
62261022|NCT04798599|EXPERIMENTAL|Intervention|In the intervention group there will be the application of the intervention - use of telemonitoring and teleorientation applied to children in primary care in Dentistry.
62261023|NCT04798599|ACTIVE_COMPARATOR|Waiting list|In the control group, children waiting to be booked to the intervention (in implementation in the unit because of the pandemic) will be evaluated for the outcomes. Only after the evaluation, the control group's children will be invited to perform the teleconsultation (proposed intervention).
62617687|NCT00384371|PLACEBO_COMPARATOR|2|Placebo
62617688|NCT00731731|EXPERIMENTAL|Treatment (radiation therapy, vorinostat, temozolomide)|Patients undergo radiotherapy and receive vorinostat PO QD on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Patients also receive temozolomide PO QD on days 1-42. Beginning 4-6 weeks later, patients receive vorinostat PO QD on days 1-7 and 15-21 and temozolomide PO QD on days 1-5. Treatment with vorinostat and temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62617689|NCT01421745|EXPERIMENTAL|Cultural Competence Module|The module will include lecture, case studies, and discussion of cultural competence.
62617690|NCT02679456|ACTIVE_COMPARATOR|Treatment Group 1 (Fluconazole)|Fluconazole
62617691|NCT02679456|EXPERIMENTAL|Treatment Group 2: (SCY-078)|Dose regimen 1
62057759|NCT01209637|ACTIVE_COMPARATOR|Exercise training|exercise training for 4 weeks at 70% of ischemia free individual threshold within a rehabilitation care center
62057760|NCT01209637|ACTIVE_COMPARATOR|intensive exercise training|intensive exercise training incl. interval training
62057761|NCT01440686|EXPERIMENTAL|HL-032 30mg|A single dose 30mg administered orally
62261024|NCT02371447|EXPERIMENTAL|VPM1002BC Induction|"Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)~Maintenance: 3 instillations of VPM1002BC at months 3, 6 and 12"
62057762|NCT01440686|EXPERIMENTAL|HL-032 60mg|A single dose 60mg administered orally
62057763|NCT01440686|EXPERIMENTAL|HL-032 120mg|A single dose 120mg administered orally
62261025|NCT01152320|NO_INTERVENTION|Standard of Care|
62261026|NCT01152320|EXPERIMENTAL|Intervention|Spirometry Fundamentals™ CD training program
62261027|NCT03962101|EXPERIMENTAL|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.
62261028|NCT00525993|EXPERIMENTAL|A|
62261029|NCT00525993|ACTIVE_COMPARATOR|B|
62261030|NCT03820648|EXPERIMENTAL|Alexis® device|In this group, we will be used WP dual-ring Alexis® (Figure 1). The Alexis® 's size will be decided on the basis of abdominal incision (Alexis® X-Large or Alexis® XX-Large will be used for 11-17cm or 17-25 cm incision length respectively)
62261031|NCT03820648|ACTIVE_COMPARATOR|Standard 3M™ Steri-Drape 2|In this group, we will be used Standard 3M™ Steri-Drape 2
62446370|NCT04203680|ACTIVE_COMPARATOR|blood cardioplegia group|patients received one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins
62446371|NCT01824251|EXPERIMENTAL|NPB-01|Intravenous immunoglobulin
62446372|NCT05493111|EXPERIMENTAL|AR-15512 Ophthalmic Solution (0.003%)|0.003% AR-15512 to be administered BID for 365 days. Both eyes will be treated.
62617692|NCT02679456|EXPERIMENTAL|Treatment Group 3 (SCY-078)|Dose regimen 2
62617693|NCT05318833|EXPERIMENTAL|HRS7415|
62617694|NCT03120494|EXPERIMENTAL|Subjects at risk of HIV|25 high risk MSM and 50 negative partners in a sero-discordant couple will be recruited and emtricitabine and tenofovir (Truvada) for PrEP will be provided, per guidelines, for one year
62057764|NCT06127576||paraboloid geometry double and triple dental abutment-implant|
62057765|NCT03746054|EXPERIMENTAL|active prevention|optimal medical treatment
62057766|NCT03746054|SHAM_COMPARATOR|usual clinical practice|usual clinical practice in each center
62057767|NCT06521164|OTHER|study subjects|1-arm study
62057768|NCT01936896|EXPERIMENTAL|Alpha-1 anti-trypsin (AAT)|We will use plasma derived AAT 60 mg/Kg, single infusion, within 12 hours of hospital admission for ST-segment elevation myocardial infarction (STEMI)
62057769|NCT02030730|EXPERIMENTAL|Triple P Seminar Series|Intervention parents received the Seminar Series (Selected TripleP); three 90-minute seminars ('The Power of Positive Parenting', 'Raising Confident, Competent Children', and 'Raising Resilient Children'), including 60 minutes of scripted presentation material and 30 minutes question time for discussion. Parents received tip sheets with the material presented at the end of each seminar. The seminars were free of charge. The delivery of each seminar was 2 to 4 weeks apart.
62261032|NCT05533528|ACTIVE_COMPARATOR|Control|Access flap periodontal surgery
62446373|NCT05493111|PLACEBO_COMPARATOR|Vehicle|AR-15512 vehicle to be administered BID for 365 days. Both eyes will be treated.
62057770|NCT02030730|NO_INTERVENTION|Leaflets on child health and development|An attention control group received leaflet information on child health and development provided by the Greek National Health Services of the Ministry of Health. They cover topics such as vaccinations, common childhood illnesses, first aid guide on severe injuries and cuts, and nutrition. The topics did not overlap with the topics of the Seminar Series or the general purpose of the study. Control families received the seminar tip sheets after 6-month follow-up.
62057771|NCT04305288||Gemox|The patients received conventional chemotherapy Gemox
62057772|NCT04305288||mFOLFIRINOX|The patients received chemotherapy modified FOLFIRINOX
62057773|NCT01041014|EXPERIMENTAL|Professional medical interpreter|Limited English proficient Spanish-speaking patients seen in the treatment arm were provided with the services of a professionally-trained medical interpreter to facilitate communication between the patient and emergency department staff
62261033|NCT05533528|EXPERIMENTAL|Test|Access flap periodontal surgery and periodontal granulation tissue debridement.
62261034|NCT00133991|EXPERIMENTAL|R-CVP + HiCy|Protocol intervention consists of two fifteen-day cycles of cyclophosphamide (Cy), vincristine (V), prednisone (P), rituximab (R), with filgrastim support. CNS intervention consists of three days of cytarabine and hydrocortisone and one day of methotrexate (with leucovorin support) for each cycle. After those two cycles, rituximab and high-dose cyclophosphamide (HiCy) will be given.
62446374|NCT00635154|EXPERIMENTAL|Anakinra with/without Dexamethasone|"Anakinra was given alone for 6 months at which time response was assessed.~If participants achieved a minor response or better they continued on Anakinra alone until disease progression.~If participants achieved stable disease, they added low dose Dexamethasone to Anakinra until progression.~If at any time a participant progresses, they were administered high dose Dexamethasone with Anakinra."
62446375|NCT02381821||pregnant|women undergoing ICSI who became pregnant
62446376|NCT02381821||Not pregnant|women undergoing ICSI who fail to achieve pregnancy
62446377|NCT04862390||Normal Pregnancy|Pregnant women with no diabetes
62446378|NCT04862390||Gestational diabetes on diet alone|
62617695|NCT02548715|PLACEBO_COMPARATOR|Control|Daily placebo
62617696|NCT02548715|EXPERIMENTAL|Treatment|Participants administered daily levothyroxine at 1.6mcg/kg to a target normal TSH, measured at 6 weeks after the initiation of therapy
62617697|NCT02500771|EXPERIMENTAL|children and tutors using V-Motive|"The following intervention will be administered:~ABA therapy enhanced with V-Motive software~Tutors treating children with Applied Behavioral Analysis therapy will use the V-Motive software to enhance therapy sessions. Children will receive therapy as usual, but half of their current behavioral programs (skills/goals) will have been selected for enhanced prompting through video modeling."
62617698|NCT03363308|EXPERIMENTAL|Phase 1|training for health care workers supplemented by QI teams
62617699|NCT03363308|NO_INTERVENTION|Phase 2|
62617700|NCT02443272|ACTIVE_COMPARATOR|Control Arm|Receive standard incision and drainage
62057774|NCT01041014|NO_INTERVENTION|Control, Usual Language Services|Patients randomized to the control arm receive the services of the emergency departments' usual language services (i.e., a telephone language line or ad hoc interpreters).
62446379|NCT04862390||Gestational diabetes on diet + Metformin therapy|
62446380|NCT03083483|EXPERIMENTAL|Bilateral M1, active tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants randomized to this cohort had tdcs applied over the bilateral M1 areas of the brain by measurement of 20% length of periauricular distance left and right of the vertex. The anode was placed on the left side and the cathode was placed on the right side.
62446381|NCT03083483|EXPERIMENTAL|SMA, active tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants randomized to this cohort had tdcs applied over the supplementary motor area. The cathode was placed 10% of nasion-inion distance above the nasion and 15% of nasion-inion distance anterior to the vertex.
62617701|NCT02443272|EXPERIMENTAL|Intervention Arm|Receive minimal invasive loop drainage using the Vesi-loop device
62261035|NCT04858477|OTHER|Colonoscopy Patients + their Gastroenterology Fellows|Inpatient and outpatient colonoscopies performed by fellows at NYU Langone Health, NYU Langone Hospital Brooklyn, Bellevue Hospital Center, and Manhattan VA Medical Center from October 2020 - March 2021. These will include all colonoscopies with polyps done in adults age 45 and above.
62261036|NCT03921424|EXPERIMENTAL|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
62261037|NCT03921424|ACTIVE_COMPARATOR|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
62261038|NCT02483663||27 Monozygotic Pairs|
62617702|NCT01048099|EXPERIMENTAL|PRO Onc Assay and Treatment|Blood specimens tested for circulating tumor cells followed by systemic treatment based on assay results with either trastuzumab or pertuzumab
62617703|NCT04170101|EXPERIMENTAL|a continuous deep NMB (group A)|after 0,6 mg/kg LBW Rocuronium for intubation Rocuronium is given in a continuous infusion starting at 1 mg/kg/h and adapted to keep PTC below 5 and note.
62617704|NCT04170101|PLACEBO_COMPARATOR|non deep NMB (group B)|after 0,6 mg/kg LBW Rocuronium for intubation no extra NMB is given and depth is measured by TOF/PTC to note depth.
62617705|NCT05180565|EXPERIMENTAL|Colovac|Patients receive Colovac device during colorectal surgery
62617706|NCT05292612|EXPERIMENTAL|Standard therapist-guided iCT-SAD vs. Waitlist|"to examine if standard iCT-SAD delivered in Chinese is superior to waitlist.~participants in the experimental group would receive iCBT(C\&W) for SAD under the guidance of trained therapist."
62617707|NCT05292612|EXPERIMENTAL|Guided self-help iCT-SAD vs. Waitlist|"to examine if guided self-help iCT-SAD delivered in Chinese is superior to waitlist.~participants in the experimental group would receive iCBT(C\&W) for SAD under the guidance of trained coaches."
62617708|NCT05292612|EXPERIMENTAL|Standard therapist-guided iCT-SAD vs. Guided self-help iCT-SAD|"to examine if guided self-help iCT-SAD is noninferior to standard iCT-SAD.~participants would be randomised into two groups. one group of participants would receive iCBT(C\&W) for SAD under the guidance of trained therapist while the other group of participants would receive iCBT(C\&W) for SAD under the guidance of trained coaches."
62617709|NCT06352125||Liver Transplant|
62617710|NCT06352125||CV Surgery|
62617711|NCT05704283|EXPERIMENTAL|Diagnostic (3D-US)|Patients undergo 3D-US on study. Patients who have a lymph node clip placed and undergoing neoadjuvant chemotherapy undergo imaging of the clipped node before surgery.
62617712|NCT01016574|OTHER|women with stage I or II breast cancer|
62617713|NCT04775719|OTHER|Outcome Prediction Group|Patient-Specific Prediction of Functional Outcome and Standard Pre-Operative Total Knee Arthroplasty Information
62617714|NCT04775719|OTHER|Standard Care Group|Standard Pre-Operative Total Knee Arthroplasty Information
62843252|NCT02153619|EXPERIMENTAL|Meaning-Centered Grief Therapy (MCGT)|Part 1: Open Trials. Participants (n = 5 for Step 1 \& n = 5 for Step 2) will receive 16 1-hour (approx) weekly sessions MCGT, \& all therapy sessions will be audio recorded. Will make every effort to complete 16 sessions in 16 weeks, due to normal life activities, this is considered an approximation (i.e. there may be weeks where sessions don't take place \&/or weeks where more than 1 session takes place in a week). If participant provides us with permission, we will also video record the sessions. Assessments will be administered at 4 time points: pre-intervention (T1), mid-intervention (T2), post-intervention (T3), \& at 3-months post-intervention (T4). They will provide their feedback about MCGT \& the measures. PI will review the open trial sessions to help refine the MCGT manual \& treatment integrity forms. Sessions for Step 1 participants in Part 1 will be held at the MSK Counseling Center. Sessions for Step 2 participants in Part 1 will be conducted via videoconferencing.
62843253|NCT02153619|EXPERIMENTAL|MCGT or Supportive Psychotherapy|Part 2: Pilot RCT. Will randomize 66 parents to 16 weekly 60-90 minute (approx) sessions of MCGT or SP delivered via videoconferencing. Again, sessions will be audio recorded. If the participant provides us with permission, we also audio/video record the sessions. We will examine aspects of study implementation \& therapy process, including a) recruitment progress, b) implementation of the intervention, c) administration of the assessments, \& d) retention. We will also examine acceptability, defined as measures of satisfaction at T3. Psychosocial outcomes will be assessed with self-report measures at 4 time points: pre-intervention (T1), mid-intervention (T2), post-intervention (T3), \& at 3-months post-intervention (T4). Post-intervention qualitative exit interviews will assess acceptability of the intervention. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention .
62617715|NCT06155032|EXPERIMENTAL|Endovascular therapy|"Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.~In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment."
62617716|NCT06155032|ACTIVE_COMPARATOR|Best medical management|Patients in this group will receive best medical management alone. All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
62261039|NCT02483663||27 Dizygotic Pairs|
62261040|NCT04539210|EXPERIMENTAL|Electric Welded Metal Framework|A preexisting or prepared flat surface area of the welding abutment of implant at central incisor position at one side (right or left) will serve as the welding point. A titanium bar will be shaped following the curvature of the implants positioned. At this point, temporary titanium implant abutments will be welded with the titanium bar in the oral cavity, using the Syncrystallization Unit. Finally, the prosthetic framework, created by welding the titanium bar to the implant abutments, will be removed and opaque will be applied in order to avoid metal shining through the acrylic resin. The framework is picked up to denture with hard liner, and screwed to the denture.
62057775|NCT03954743|EXPERIMENTAL|HRV PCV-free Liq Group|Subjects aged 6 to 12 weeks at the time of first vaccination, who received two doses of oral live-attenuated human rotavirus (HRV) porcine circovirus (PCV)-free vaccine in liquid formulation, one at Day 1 and one at Month 1 or Month 2, according to the immunization schedule for rotavirus (RV) vaccine administration in participating countries. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
62057776|NCT03954743|ACTIVE_COMPARATOR|HRV Lyo group|Subjects aged 6 to 12 weeks at the time of first vaccination, who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in lyophilized formulation, one at Day 1 and one at Month 1 or Month 2, according to the immunization schedule for rotavirus (RV) vaccine administration in participating countries.
62057777|NCT05908214|EXPERIMENTAL|Stroke patients - training group|Participants in this group will take part in a 6-week WPHF NMES training period and plantar flexor neuromuscular function will be assessed before and after training.
62057778|NCT05908214|NO_INTERVENTION|stroke patients - control group|Participants in this group will keep their daily life activities for 6 weeks and plantar flexor neuromuscular function will be assessed before and after training.
62057779|NCT04444648||One groupe without distinction of age, sexe, and pathology.|"Patients with strok in coma, with or without wake up, and with disorder of consciousness. No limit in age (maybe give the younger age).~We obtain this data from medical record. Every assessment was made of clinical purposes.~We use the Glasgow coma recovery scale for assessment of behavior to check the variation of wakefulness. The scale was performed by the nursing staff every 2 to 8 hours depending on the severity of the medical condition.~The continuous analysis of neurophysiologic data was based on EEG with a bipolar montage composed of the less noisy electrodes per recording period.~The EEG features will include: spectral analysis (relative and absolute power in 4 canonical bands: Delta/Theta/Alpha/Beta) and complexity analysis (DFA, determinism, SVD entropy and permutation entropy).~The patient outcome at the ICU and hospital discharges were collected from the medical files."
62617717|NCT05743647||Young|40 right handed healthy subject aged between 18 and 40
62617718|NCT05743647||Old|40 right handed healthy subject aged between 41 and 75
62057780|NCT00691808|EXPERIMENTAL|High Dose|
62057781|NCT00691808|EXPERIMENTAL|Low Dose|
62261041|NCT04539210|EXPERIMENTAL|cast metal framework|On a verified analogue model, occlusion blocks will be constructed for adjustment of vertical dimension and bite registration. Afterwards, CCM abutments will be fastened over the analogues of the placed implants, followed by waxing, spruing and casting. The resultant cast metal framework will be inserted inside the patient's mouth on the right or left installed implants to insure passivity of fit. In case of framework misfit, separation will be performed using a disc, followed by intraoral splinting and soldering. After framework soldering, another try-in will be done to insure framework fit.
62261042|NCT05379348||General study participants (patients)|
62617719|NCT00288444|ACTIVE_COMPARATOR|Docetaxel 36 mg/ m2 IV weekly and Lonafarnib 150 mg|Docetaxel 36 mg/ m\^2 Intravenously weekly and Lonafarnib 150 mg by mouth twice a day daily.
62057782|NCT00691808|PLACEBO_COMPARATOR|Placebo|
62057783|NCT04043962|EXPERIMENTAL|Web-based CBT (Web-MAP)|The eight child modules include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) deep breathing and relaxation, 4) implementing coping skills at school, 5) cognitive skills (e.g., reducing negative thoughts), 6) lifestyle interventions, 7) staying active (e.g., pleasant activity scheduling), 8) relapse prevention. The eight parent modules are: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I (using attention and praise to increase coping), 4) operant strategies II (using rewards to increase positive coping and reach school goals), 5) modeling, 6) lifestyle, 7) communication, 8) relapse prevention.
62057784|NCT05306093|EXPERIMENTAL|Nutraceutical|"Daily, 2 dietary supplements will be taken orally with some water, the first one during the breakfast and the second one during the dinner.~Dietary supplements in capsule form"
62057785|NCT05306093|PLACEBO_COMPARATOR|Maltodextrin|"Daily, 2 dietary supplements will be taken orally with some water, the first one during the breakfast and the second one during the dinner.~Dietary supplements in capsule form"
62057786|NCT03437395|OTHER|Partial Breast Irradiation|All participants will be treated with partial breast irradiation by utilizing 3D conformal external beam irradiation or balloon brachytherapy. This is not a randomized study.
62261043|NCT05379348||Healthcare Practitioners|
62261044|NCT05379348||Pre-Program Chart Audits (100 patients what will be chart audited)|
62261045|NCT02431065|EXPERIMENTAL|Group 3, Direct injection group|Test group 2, Rectus sheath block will be performed under direct visualization. Ropivacaine (0.75%, 10ml) will be directly injected into the right and left rectus sheath at the end of the operation.
62261046|NCT02431065|ACTIVE_COMPARATOR|Group 2, ultrasonography group|Test group 1, Rectus sheath block will be performed under sonographic guidance. Ropivacaine (0.75%, 10ml) will be injected into the right and left rectus sheath under ultrasonographic guidance at the end of the operation.
62261047|NCT02431065|PLACEBO_COMPARATOR|Group 1|Control group, Rectus sheath block will be performed under sonographic guidance. Normal saline 10 ml will be injected into the right, left rectus sheath under ultrasonography guidance at the end of the operation.
62261048|NCT04548726||Sapien 3|Patients with aortic stenosis treated with Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) TAVI
62261049|NCT04548726||Myval|Patients with aortic stenosis treated with Myval (Meril Life Sciences Pvt. Ltd., India) TAVI
62261050|NCT04539639|EXPERIMENTAL|Jaktinib 50mg Bid|Jaktinib 50mg Bid+ Placebo 50mg Bid+Placebo 75mg Bid
62261051|NCT04539639|EXPERIMENTAL|Jaktinib 75mg Bid|Jaktinib 75mg Bid+ Placebo 100mg Bid
62617720|NCT00288444|ACTIVE_COMPARATOR|Docetaxel 30 mg/ m2and Lonafarnib 150 mg|Docetaxel 30 mg/ m\^2 Intravenously weekly and Lonafarnib 150 mg by mouth twice a day daily.
62617721|NCT00288444|ACTIVE_COMPARATOR|Docetaxel 36 mg/ m2 and Lonafarnib 100 mg|Docetaxel 36 mg/ m\^2 Intravenously weekly and Lonafarnib 100 mg by mouth twice a day daily
62617722|NCT00288444|ACTIVE_COMPARATOR|Docetaxel 30 mg/m2 and Lonafarnib 100 mg|Docetaxel30 mg/m\^2 Intravenously weekly and Lonafarnib 100 mg by mouth twice a day daily.
62617723|NCT01387945|NO_INTERVENTION|HBPM only|
62617724|NCT01387945|EXPERIMENTAL|HBPM+website+patient navigator|
62617725|NCT03518502|ACTIVE_COMPARATOR|Sorafenib monotherapy arm|The sorafenib monotherapy group receives sorafenib immediately after randomization.
62057787|NCT02084537|ACTIVE_COMPARATOR|Endoscopic treatment|Treated by single or multiple transmural cystogastrostomy tracts, 15mm balloon dilation, two 7 French (Fr) double pigtail plastic stents or lumen-apposing metal stents and nasocystic drainage catheter, with or without endoscopic necrosectomy as needed.
62057788|NCT02084537|ACTIVE_COMPARATOR|Minimally invasive surgical necrosectomy|Video-assisted retroperitoneal debridement (VARD) or laparoscopic approach. This includes laparoscopic cystogastrostomy with internal debridement.
62057789|NCT04580563|EXPERIMENTAL|Experimental group|"The experimental group will receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.~OctaplasLG® is a donor plasma product, with unique features compared to standard fresh frozen plasma: standardized concentrations of natural pro-/anti-coagulation factors; a standardized volume; pathogen free. OctaplasLG® should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma."
62057790|NCT04580563|PLACEBO_COMPARATOR|Control group|The control group will receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
62057791|NCT04603976|EXPERIMENTAL|Single-Arm|Erenumab packed in a SureClick® Autoinjector Pen (AI)
62057792|NCT00604838|EXPERIMENTAL|I|
62057793|NCT03921190|ACTIVE_COMPARATOR|Open-mouth|Patients receiving maxillary buccal infiltration anesthesia (MBIA) with their mouth wide open
62057794|NCT03921190|EXPERIMENTAL|Closed-mouth|Patients receiving MBIA using a closed-mouth technique
62057795|NCT04210414|EXPERIMENTAL|Day 3 transfer|Transfer on day 3 when only one embryo is available
62261052|NCT04539639|EXPERIMENTAL|Jaktinib 100mg Bid|Jaktinib 100mg Bid+ Placebo 75mg Bid
62446382|NCT03083483|SHAM_COMPARATOR|sham tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants in this group were either randomized into either Bilateral or SMA configurations using the same measurements, but did not receive active stimulation. Half of these subjects will be placed in the SMA configuration and the other half in the bilateral M1 electrode configuration.
62446383|NCT02097446|EXPERIMENTAL|GUARDIX-FL|Patients will be treated with 1 or 2 sheet of GUARDIX-FL after ovarian cystectomy(Operative Day).
62446384|NCT02097446|ACTIVE_COMPARATOR|Interceed|Patients will be treated with 1 or 2 sheet of interceed after ovarian cystectomy(Operative Day).
62617726|NCT03518502|EXPERIMENTAL|TACE-sorafenib sequential therapy arm|TACE(transarterial chemoembolization )-sorafenib group receives 2\~4 times of TACE before starting sorafenib.
62057796|NCT04210414|EXPERIMENTAL|Day 5 transfer|Transfer on day 5 when only one embryo is available
62057797|NCT00514943|EXPERIMENTAL|BIBW 2992|once daily taken orally
62446385|NCT01387282|ACTIVE_COMPARATOR|100 mg QD|Investigational: Anamorelin HCl; 100 mg tablets; oral administration QD for 12 weeks, at least 1 hour before the first meal of the day.
62446386|NCT01387282|PLACEBO_COMPARATOR|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
62617727|NCT01590316|EXPERIMENTAL|Cerebral NIRS oximetry + treatment guideline based on reading|
62617728|NCT01590316|NO_INTERVENTION|Blinded cerebral NIRS oximetry|
62057798|NCT00514943|ACTIVE_COMPARATOR|Cetuximab|once every week by intravenous injection
62057799|NCT03725839|EXPERIMENTAL|Arm|F\&P Interface will be used by OSA participants in-home for 2 weeks.
62057800|NCT04709601|EXPERIMENTAL|Group 1 - Patients with negative and positive urine culture|
62057801|NCT02643576|NO_INTERVENTION|Control|Usual SNAP-like food benefits
62261053|NCT04539639|PLACEBO_COMPARATOR|placebo|Placebo 100mg Bid+ Placebo 75mg Bid
62261054|NCT03015259|EXPERIMENTAL|Treatment 1|Generic Budesonide/Formoterol Fumarate Dihydrate (80mcg/4.5mcg) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
62446387|NCT04190654|EXPERIMENTAL|Mild Hepatic Impairment|Subjects with mild hepatic impairment (Child-Pugh class A score of 5 or 6)
62057802|NCT02643576|EXPERIMENTAL|Rewards|Usual SNAP-like food benefits, plus a modification to this food benefit program that entails a 30% bonus on eligible fruit and vegetable purchases (i.e. F\&V bonus)
62057803|NCT02643576|EXPERIMENTAL|Restrictions|Usual SNAP-like food benefits, plus a modification that requires no sugar-sweetened beverages, candy, or sweet baked goods be purchased
62261055|NCT03015259|ACTIVE_COMPARATOR|Treatment 2|Symbicort (Budesonide/Formoterol Fumarate Dihydrate) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
62261056|NCT03015259|PLACEBO_COMPARATOR|Treatment 3|Placebo Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
62446388|NCT04190654|EXPERIMENTAL|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment (Child-Pugh class B score of 7 to 9)
62446389|NCT04190654|EXPERIMENTAL|Healthy Subjects|Healthy adults matched with the subjects in Group A and Group B at 1:1 for age (± 10 years), sex, and BMI (± 20%)
62446390|NCT00696358|ACTIVE_COMPARATOR|A|308 nm excimer lamp
62446391|NCT00696358|ACTIVE_COMPARATOR|B|308 nm excimer laser
62617729|NCT01066871|EXPERIMENTAL|Sprifermin (AS902330) 10 mcg|
62617730|NCT01066871|EXPERIMENTAL|Sprifermin (AS902330) 30 mcg|
62261057|NCT01199029|EXPERIMENTAL|(Part 1) 10 mg PF-04308515 (8hrs)|
62261058|NCT01199029|EXPERIMENTAL|(Part 1) 10 mg PF-04308515 (12hrs)|
62057804|NCT02643576|EXPERIMENTAL|Rewards plus restrictions|Usual SNAP-like food benefits, plus two modifications to this food benefit program: one modification includes a 30% bonus on eligible fruit and vegetable purchases and the other modification is that sugar-sweetened beverages, candy, or sweet baked goods are not allowed to be purchased (i.e. Bonus \& Restriction)
62057805|NCT02767583|EXPERIMENTAL|Non diabetic obese|Non diabetic obese with BMI 35-55 kg / m2 consulting for the first time at the Centre of obesity of Paris Saint Joseph Hospital Group will got a themotest and Sudoscan exams de determine their neuropathology.
62261059|NCT01199029|ACTIVE_COMPARATOR|(Part 1) 5 mg Prednisone|
62261060|NCT01199029|EXPERIMENTAL|(Part 2) X mg PF-04308515|
62057806|NCT02401464|EXPERIMENTAL|Dry syrup formulation (Group a)|One pack of the dry syrup formulation of TAK-536, containing 10 milligram (mg) of TAK-536, will be orally administered with water (200 milliliter \[mL\]) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
62261061|NCT01199029|EXPERIMENTAL|(Part 2) Y mg PF-04308515|
62261062|NCT01199029|ACTIVE_COMPARATOR|(Part 2) 5 mg Prednisone|
62261063|NCT01199029|ACTIVE_COMPARATOR|(Part 2) 20 mg Prednisone|
62261064|NCT05206942|EXPERIMENTAL|Ultrasound|Patients receiving standard of care immune checkpoint inhibitor are followed with the ultrasound studies at treatment baseline, 3 weeks and 6 weeks.
62261065|NCT00707928|ACTIVE_COMPARATOR|1|1=nitroglycerine 100 microgram intravenous100-200 microgram of IV.
62261066|NCT00707928|PLACEBO_COMPARATOR|2|2=placebo with the same volume as NTG 100-200 microgram of IV.
62261067|NCT01127568|EXPERIMENTAL|Propranolol|Propranolol is a beta-blocker (blocking beta- adrenergic receptors) that reduces sympathetic activity. It is a well-known drug typically prescribed to individuals suffering from hypertension, tachycardia, cardiac arrhythmia, tremors, thyroid disease, or migraine.
62261068|NCT01127568|PLACEBO_COMPARATOR|Placebo|The placebo is an inactive capsule that will have no medication effect, but looks exactly like the medication.
62261069|NCT01119300|ACTIVE_COMPARATOR|Standard care|Standard care
62261070|NCT01119300|EXPERIMENTAL|Genotype-guided dosing algorithm|Genotyping for CYP2C9\*2, CYP2C9\*3, and VKORC1 (-1639G→A) was performed with the use of a point-of-care test. For patients assigned to the genotype-guided group, warfarin doses were prescribed according to pharmacogenetic-based algorithms for the first 5 days.
62261071|NCT06175403|EXPERIMENTAL|Upper body obesity|Subjects identify with upper body obesity will receive Niacin to lean how fat cells in different regions of the body the response.
62261072|NCT06175403|EXPERIMENTAL|Normal weight|Subjects identify with normal body weight will receive Niacin to lean how fat cells in different regions of the body the response.
62261073|NCT05203497|EXPERIMENTAL|The tested injected doses of 99mTc-ZHER2:41071 500 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose.~Subjects withdrawn from the study for any reason will be replaced."
62446392|NCT05053698||Initial gas tamponade|Primary vitrectomy and fluid-air exchange with SF6 or C2F6 gas tamponade
62446393|NCT05053698||Initial silicone oil tamponade|Primary vitrectomy and fluid-air exchange with silicone oil tamponade
62261074|NCT05203497|EXPERIMENTAL|The tested injected doses of 99mTc-ZHER2:41071 1000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose.~Subjects withdrawn from the study for any reason will be replaced."
62057807|NCT02401464|EXPERIMENTAL|Dry syrup formulation (Group b)|One 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one pack of the dry syrup formulation of TAK-536, containing 10 mg of TAK-536, will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
62057808|NCT02401464|EXPERIMENTAL|Granule formulation (Group a)|One pack of the granule formulation of TAK-536, containing 10 mg of TAK-536,will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
62057809|NCT02401464|EXPERIMENTAL|Granule formulation (Group b)|One 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one pack of the granule formulation of TAK-536, containing 10 mg of TAK-536, will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
62057810|NCT06624696|EXPERIMENTAL|The penehyclidine hydrochloride group|Inhaling penehyclidine hydrochloride (a dose of 0.05 mg/kg, diluted and mixed with normal saline to a total volume of 5 ml) for nebulization therapy within 30 min prior to surgery.
62057811|NCT06624696|PLACEBO_COMPARATOR|The normal saline group|Inhaling normal saline in a total volume of 5 ml for nebulization therapy within 30 min prior to surgery.
62057812|NCT06248138||Progression|There is at least one major coronary artery (left main artery, left anterior descending artery, left circumflex artery or the right coronary artery) had non-target lesions, and the coronary artery stenosis rate reached the progressive level on follow-up angiography.
62057813|NCT06248138||Non-progression|The rate of coronary stenosis of the non-target lesion did not reach progressive levels during the repeat angiography.
62261075|NCT02963389|EXPERIMENTAL|Tripegfilgrastim 60ug/kg, >=6 and <12-year-old patients|A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy
62261076|NCT02963389|EXPERIMENTAL|Tripegfilgrastim 60ug/kg, >=12 and <19-year-old patients|A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy
62261077|NCT02963389|EXPERIMENTAL|Tripegfilgrastim 100ug/kg, >=6 and <12-year-old patients|A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy
62261078|NCT02963389|EXPERIMENTAL|Tripegfilgrastim 100ug/kg, >=12 and <19-year-old patients|A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy
62446394|NCT05053698||Relapse treated with gas tamponade|Secondary vitrectomy and fluid-air exchange with SF6 or C2F6 or C3F8 gas tamponade
62446395|NCT05053698||Relapse treated with silicone oil tamponade|Secondary vitrectomy and fluid-air exchange with silicone oil tamponade
62617731|NCT01066871|EXPERIMENTAL|Sprifermin (AS902330) 100 mcg|
62057814|NCT04396002||Primary Open-Angle Glaucoma|Patients diagnosed with primary open-angle glaucoma.
62057815|NCT04396002||Control|Participants with healthy eyes.
62261079|NCT00505440|EXPERIMENTAL|Computerized screening and referral|Computerized screening and referral: Intervention is a web-based screening and assessment tool completed by adolescents during primary care visits. Patient reported screening provided to primary care physicians in real time with recommendations for behavioral referrals.
62261080|NCT00505440|ACTIVE_COMPARATOR|Delayed feedback from screening|Active comparator is Usual pediatric care plus mailed screening results from computerized waiting room screens that arrive three days after screening.
62617732|NCT01066871|PLACEBO_COMPARATOR|Placebo|
62057816|NCT00294099|EXPERIMENTAL|2|120 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
62261081|NCT04989114|NO_INTERVENTION|standard care|In this arm, oxygen inhalation will be provided without positive end expiratory pressure
62261082|NCT04989114|EXPERIMENTAL|nasal continuous positive airway pressure|In this arm, positive end expiratory pressure will be provided by nasal continuous positive airway pressure
62261083|NCT03212053|OTHER|Patients with Essential Thrombocythemia|"patients who come in consultation at diagnosis or during the follow-up for an Essential Thrombocythemia.~They will have biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)"
62261084|NCT01326182|EXPERIMENTAL|MAADRE|Group-based intervention combining asthma education and cognitive behavioral treatment for depressive symptoms
62617733|NCT04702997|EXPERIMENTAL|Bardoxolone methyl|"Patients randomized to receive bardoxolone methyl capsules orally once daily for 12 weeks at a starting dose of 5 mg and titrated up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g)~Patients will be scheduled to be assessed during treatment at Day 1, Weeks 1, 2, 4, 6, 8, and 12 and by telephone contact on Days 3, 10, 21, 31, 35, and 45. Patients will not receive any drug during a 5-week off-treatment period between Weeks 12 and 17. Patients will be assessed on Day 3 off-treatment (OT), Day 7 OT, Day 14 OT, Day 21 OT, Day 28 OT, and Day 35 OT. The OT day corresponds to days after last dose.~Patients will be assessed at and end-of-study (EOS) visit on Week 17."
62843254|NCT01254760|OTHER|Investigational multifocal / Commercial multifocal|Investigational multifocal contact lenses worn first, with commercial multifocal contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 5 days.
62261085|NCT01326182|ACTIVE_COMPARATOR|MAAS|Group-based treatment combining asthma education and general information regarding child health
62261086|NCT06050174|EXPERIMENTAL|Azadirachta Indica|Azadirachta Indica (neem) gel are locally delivered to deepest part of the periodontal pocket by syringe with blunted tip gently and removed slowly in order not to harm the tissue for group 1 patients after phase 1 therapy by two weeks.
62057817|NCT00294099|EXPERIMENTAL|3|60 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
62057818|NCT00294099|EXPERIMENTAL|4|60 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
62057819|NCT00294099|EXPERIMENTAL|8|60 subjects to receive 3.75 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
62057820|NCT00294099|EXPERIMENTAL|7|60 subjects to receive 3.75 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
62057821|NCT00294099|EXPERIMENTAL|1|120 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
62261087|NCT06050174|PLACEBO_COMPARATOR|Non Surgical Periodontal Therapy|The patients will receive full mouth one stage debridement using ultrasonic scalers, manual scalers and curettes with oral hygiene instructions and education.
62261088|NCT04340375|EXPERIMENTAL|AP green tea extracts|8 weeks
62261089|NCT03532594|OTHER|Standard Care|At the conclusion of cardiopulmonary bypass, protamine administration will be undertaken at surgical request. For patients in the control group, protamine will be dosed on a 1:1 ratio according to the total dose of heparin initially required to establish a therapeutic activated clotting time (ACT) (i.e. if 30,000 IU were required prior to initiating cardiopulmonary bypass, then the protamine dose will be 300mg).
62057822|NCT00294099|EXPERIMENTAL|5|60 subjects to receive 7.5 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
62057823|NCT00294099|EXPERIMENTAL|6|60 subjects to receive 7.5 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
62057824|NCT04235790|NO_INTERVENTION|Medical Student or Resident|Subjects will perform simulated central venous catheters (CVC) insertions.
62057825|NCT04235790|OTHER|Novice and Expert IBP Teachers|Expert teachers will be identified based on years as faculty, number of supervised procedures, prior teacher awards, and participation in IBP teaching at international conferences. Novice teachers will include those that have performed less than 50 CVCs. Teachers will supervise 3 simulated central venous catheters (CVC) insertions with increased complexity while wearing an eye tracking device.
62057826|NCT00187915|OTHER|CellCept + Prograf|Standard of Care Regime
62057827|NCT00187915|OTHER|CellCept + Neoral|Standard of Care Regime
62057828|NCT04876794|EXPERIMENTAL|Arm 1|Participants with SCI will undergo a training programme with the ABLE Exoskeleton device three times a week for four to six weeks for a total of 12 sessions.
62261090|NCT03532594|EXPERIMENTAL|Algorithm|For patients in the intervention group, protamine will be administered according to the PRODOSE algorithm, which has been incorporated into an Excel spread sheet for ease of use (Microsoft Corporation).
62261091|NCT02193399|EXPERIMENTAL|Physiotherapy exercises|Strength exercises for the muscles proximal upper limbs and lower limbs and proprioception exercises
62261092|NCT02193399|NO_INTERVENTION|Control group|Patients undergoing allogeneic transplantation without treatment of physiotherapy
62261093|NCT00864994||1|• 30 healthy subjects with 20 pack years smoking who have no signs of COPD (age 40-75 years)
62261094|NCT00864994||2|• 30 COPD patients with GOLD stage II (age 40-75 years)
62261095|NCT02666339|EXPERIMENTAL|Hortitherapy group|Hortitherapy + Usual care
62261096|NCT02666339|ACTIVE_COMPARATOR|Control group|Usual care
62261097|NCT04117971||Staff members|Staff members in different clinical departments at Faculty of Dentistry, Cairo University.
62261098|NCT04117971||PhD students|PhD candidates in different clinical departments at Faculty of Dentistry, Cairo University.
62261099|NCT04117971||Master's students|Master's candidates in in different clinical departments at Faculty of Dentistry, Cairo University.
62261100|NCT03962374|EXPERIMENTAL|Frova|Frova will be used to facilitate the endotracheal intubation.
62261101|NCT03962374|ACTIVE_COMPARATOR|Stylet|Stylet will be used to facilitate the endotracheal intubation.
62261102|NCT00761007|EXPERIMENTAL|Ibodutant 10 mg|
62261103|NCT00761007|EXPERIMENTAL|Ibodutant 30 mg|
62261104|NCT00761007|EXPERIMENTAL|Ibodutant 60 mg|
62261105|NCT00761007|PLACEBO_COMPARATOR|Placebo|
62261106|NCT03488173|EXPERIMENTAL|Lansoprazole Capsules|Lansoprazole Capsules 30 mg of Beijing Sihuan Pharm
62617734|NCT04702997|PLACEBO_COMPARATOR|Placebo|"Patients who received placebo, once-daily, orally, remained on placebo throughout the study duration of 12 weeks and followed the same titration to maintain the blind,~Patients will be scheduled to be assessed during treatment at Day 1, Weeks 1, 2, 4, 6, 8, and 12 and by telephone contact on Days 3, 10, 21, 31, 35, and 45. Patients will not receive any drug during a 5-week off-treatment period between Weeks 12 and 17. Patients will be assessed on Day 3 off-treatment (OT), Day 7 OT, Day 14 OT, Day 21 OT, Day 28 OT, and Day 35 OT. The OT day corresponds to days after last dose.~Patients will be assessed at and end-of-study (EOS) visit on Week 17."
62617735|NCT03107533||Video recording of clinical visit|Investigators will enroll patients from the Department of Orthopedic Surgery for enrollment. The shared decision group will provide staff for data analysis.
62843255|NCT01254760|OTHER|Commercial multifocal / Investigational multifocal|Commercial multifocal contact lenses worn first, with investigational multifocal contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 5 days.
62843256|NCT04812392|EXPERIMENTAL|Acute Physical Inactivity|Subjects will undergo 3 days of reduced physical activity.
62843257|NCT06362057||Titanium framework group|Virtual design for Titanium subperiosteal framework group on atrophied maxilla.
62057829|NCT02243644|ACTIVE_COMPARATOR|Group A|7 days of albendazole 15 mg/kg/day
62261107|NCT03488173|ACTIVE_COMPARATOR|Lansoprazole enteric-coated Capsules|Lansoprazole enteric-coated Capsules 30 mg of Takeda Pharmaceutical Company Limited
62057830|NCT02243644|ACTIVE_COMPARATOR|Group B|28 days of albendazole 15 mg/kg/day
62261108|NCT03371446||Smokers/Non-smokers|It was an experimental study with parallel controls, comparing two groups, a group with patients who smoked for more than 10 years, consuming 10 more cigarettes per day and diagnosing chronic periodontitis (case) and another group (control) were non-smokers with chronic periodontitis, according to the standard of World Health Organization (WHO) definition of the smoking population
62261109|NCT01300169|EXPERIMENTAL|CAMS--Collaborative Driver-Treatment|"The Collaborative Assessment and Management of Suicidality (CAMS) is a suicide-specific clinical intervention that targets and treats patient-defined suicidal drivers over the course of clinical care."
62261110|NCT01300169|ACTIVE_COMPARATOR|Enhanced Care as Usual--E-CAU|This control group treatment will reflect current clinical practices for treating suicidal soldiers in the research site setting. These are providers were on site clinicians who provided care according to their usual and customary practices for working with suicidal risk within outpatient care.
62261111|NCT02304107|ACTIVE_COMPARATOR|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9 mm the dose will be increased by 37.5 IU every 7 days.
62446396|NCT02460848|EXPERIMENTAL|Outpatient therapeutic program, counseling and cash transfer|Ten outpatient therapeutic program sites (OTP) will be randomly allocated to unconditional cash transfer for children admitted for treatment of SAM according to the integrated management of acute malnutrition national protocol which will be associated with counseling on infant and young child feeding (IYCF).
62617736|NCT03927833|ACTIVE_COMPARATOR|Continuous Phototherapy|Continuous phototherapy
62617737|NCT03927833|EXPERIMENTAL|Cycled Phototherapy|Cycled phototherapy at timed intervals, dependent upon total serum bilirum (TSB) levels.
62617738|NCT06298578||In person follow up|
62617739|NCT06298578||mobile app follow up|
62843258|NCT06362057||PEEK framework group|Virtual design for PEEK subperiosteal framework group on atrophied maxilla.
62057831|NCT04073810||Myocardial infarction|Patients with recent MI
62057832|NCT01438125|ACTIVE_COMPARATOR|MF-4181|Scar halves randomized to treatment with device, opposite side treated per standard of care
62057833|NCT01438125|ACTIVE_COMPARATOR|Standard surgical wound closure|
62261112|NCT02304107|ACTIVE_COMPARATOR|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
62261113|NCT04278209|EXPERIMENTAL|Breakfast 1 - Breakfast 2|Participants will receive Breakfast 1 then Breakfast 2.
62261114|NCT04278209|EXPERIMENTAL|Breakfast 1 - water|Participants will receive Breakfast 1, then water.
62261115|NCT04278209|EXPERIMENTAL|Breakfast 2 - water|Participants will receive Breakfast 2, then water.
62261116|NCT04278209|EXPERIMENTAL|Breakfast 2 - Breakfast 1|Participants will receive 2 servings, then 1 serving of the study product.
62261117|NCT04278209|EXPERIMENTAL|Water - Breakfast 1|Participants will receive water, then Breakfast 1.
62261118|NCT04278209|EXPERIMENTAL|Water - Breakfast 2|Participants will receive water, then Breakfast 2.
62843259|NCT06362057||PEKK framework group|Virtual design for PEKK subperiosteal framework group on atrophied maxilla.
62261119|NCT00708149|ACTIVE_COMPARATOR|1|lansprazole 30 mg qd from NG route or orally
62261120|NCT00708149|PLACEBO_COMPARATOR|2|control group without any PPI, H2 blockers or other medications for treating peptic ulcers.
62261121|NCT04772040|EXPERIMENTAL|Young loading dose group|Participants (18-35) will receive a loading dose of fish oil supplementation during the first 4 weeks of the intervention period of the study. In the last 8 weeks participants will receive a maintenance dose of fish oil supplementation. The total amount of EPA/DHA received throughout the supplementation period will be the same as the old group.
62261122|NCT04772040|EXPERIMENTAL|Old loading dose group|Participants (60y+) will receive a loading dose of fish oil supplementation during the first 4 weeks of the intervention period of the study. In the last 8 weeks participants will receive a maintenance dose of fish oil supplementation. The total amount of EPA/DHA received throughout the supplementation period will be the same as the young group.
62261123|NCT04772040|EXPERIMENTAL|Young constant dose group|Participants (18-35y) will receive a constant dose of fish oil supplementation throughout the intervention period of the study. Total amount of EPA/DHA received throughout the 12 weeks supplementation period will be the same as the loading groups.
62261124|NCT04772040|EXPERIMENTAL|Old constant dose group|Participants (60y+) will receive a constant dose of fish oil supplementation throughout the intervention period of the study. Total amount of EPA/DHA received throughout the 12 weeks supplementation period will be the same as the loading groups.
62261125|NCT04035551||patients receiving home parenteral nutrition|Includes patients receiving home parenteral nutrition for any indication.
62261126|NCT05155202||Nicardipine|Major patients hospitalized in intensive care unit, with systolic hypertension, requiring administration of intravenous Nicardipine.
62261127|NCT05155202||Urapidil|Major patients hospitalized in intensive care unit, with systolic hypertension, requiring administration of intravenous Urapidil.
62261128|NCT06466447||Obsessive-Compulsive Disorder|adolescents and children with obsessive-compulsive disorder
62617740|NCT01765608|EXPERIMENTAL|Zonisamide|Zonisamide (Zonegran®) 300 mg. Hard white capsule. The total length of zonisamide treatment will be 20 and 24 weeks ± 2 weeks including one or two 4 week titration phases in the placebo and zonisamide groups respectively. Dosing will be down titrated after finished study during 2-3 weeks.The maximum dose after titration will be administrated once daily. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
62617741|NCT01765608|ACTIVE_COMPARATOR|Placebo|Matched for Zonisamide. Hard white capsule. Manufactured by Eisai Inc. Placebo tablets will be administered according to a forced stepwise weekly titration scheme with weekly 1 tablet escalations from 1 to 3 tablets daily matching the Zonisamide (Zonegran ®) dosing regimen for a total duration of 4 weeks. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
62446397|NCT02460848|ACTIVE_COMPARATOR|Outpatient therapeutic program and counseling|Ten outpatient therapeutic program sites (OTP) will be randomly allocated for children admitted for treatment of SAM according to the integrated management of acute malnutrition national protocol which will be associated with counseling on infant and young child feeding (IYCF).
62446398|NCT02304874|OTHER|Phlebotomy|Phlebotomies will be performed every 14 days at the Clinical Investigation Unit (CIU) until the value of ferritin level is below 50 µg/mL and/or the value of hemoglobin level is below 12 g/dL.
62261129|NCT03076385|EXPERIMENTAL|VAL-506440|
62261130|NCT03076385|PLACEBO_COMPARATOR|Placebo|
62261131|NCT00996268|EXPERIMENTAL|Part A|Three groups of sixteen healthy subjects will be randomized to single doses of 3 different formulations of GSK2212836.
62261132|NCT00996268|EXPERIMENTAL|Part B|Four cohorts of at least 10 subjects will participate in a 2-week repeat dose period with 4 dose levels (based on data obtained in Part A) of the GSK2212836 test formulations or placebo.
62057834|NCT01322789|EXPERIMENTAL|Intravenous mesenchymal stem cell|This group wil receive 8 intravenous infusions of mesenchymal stem cells. Four infusions 1 week apart and 4 infusions a month apart
62057835|NCT05600049|EXPERIMENTAL|Condition 1 : prototypes from (815-v1 001) to (815-v1 050) every day|Application on the brown spots of the face and/or hands for the prototypes (815-v1 001) to (815-v1 050) at D0, D1, D2, D3, D4 and D5.
62261133|NCT06394011|EXPERIMENTAL|VA combined with HAAG|This cohort will determine the safety and efficacy of venetoclax, azacitidine combined with HAAG regimen in newly diagnosed intermediate and high-risk AML patients.
62261134|NCT04405154|EXPERIMENTAL|Investigational Arm|Camrelizumab every 2 weeks in combination with 6-7 weeks of radiation therapy and every 3 weeks cisplatin.
62261135|NCT02718755|EXPERIMENTAL|Fludarabine + Cytarabine + Erwinase|"Induction Phase: Participants receive 1-2 cycles during the Induction phase.~Participants receive 1-2 cycles during the Induction phase.~Participants receive Fludarabine by vein on Days 1-5 and Cytarabine by vein.~Participants receive Erwinase by vein or as an injection into the muscle on Days 1-7.~Consolidation Phase: Participants receive up to 3 cycles during the Consolidation phase.~Participants receive Fludarabine by vein on Days 1-4 and Cytarabine by vein.~On Day 1 and then every other day for 15 days (3, 5, 7 and so on), participant receives Erwinase by vein or as an injection into the muscle."
62261136|NCT01925690|ACTIVE_COMPARATOR|Brief Education|Patients receive a brief educational packet along with treatment as usual
62057836|NCT05600049|EXPERIMENTAL|Condition 2 : prototypes from (815-v1 051) to (815-v1 100) every week|Application on the brown spots of the face and/or hands for the prototypes (815-v1 051) to (815-v1 100) at D0, D7, D14, D21, D28 and D35.
62057837|NCT05600049|EXPERIMENTAL|Conditions 3 : prototypes from (815-v1 101) to (815-v1 150) every two weeks|Application on the brown spots of the face and/or hands for the prototypes (815-v1 101) to (815-v1 150) at D0, D14, D28, D42, D56 and D70.
62261137|NCT01925690|EXPERIMENTAL|MI-CBT Treatment|Patients receive five 20 minute phone sessions of motivational interviewing/cognitive behavioral therapy weekly along with a brief educational packet.
62446399|NCT06109558|EXPERIMENTAL|Cohort A|Patients with MET amplication（by FISH, NGS or IHC）
62446400|NCT06109558|EXPERIMENTAL|Cohort B|Patients with RET fusion.
62446401|NCT04866589|EXPERIMENTAL|Distribution of free face masks|Face masks will be handed out for free to all customers entering the grocery stores.
62843260|NCT05114252|EXPERIMENTAL|Participants with amblyopia in the serious games intervention|Participants with amblyopia receiving the experimental intervention consisting of serious videogames focusing on binocular function (with image modification) in a virtual reality environment.
62843261|NCT05114252|ACTIVE_COMPARATOR|Participants with amblyopia in the standard care intervention|Participants with amblyopia receiving the standard care intervention consisting of wearing spectacles with individualized refractive correction.
62843262|NCT05114252|ACTIVE_COMPARATOR|Healthy participants|Participants without amblyopia or other conditions receiving the experimental intervention consisting of serious videogames focusing on binocular function (without any image modification) in a virtual reality environment.
62843263|NCT01657019|EXPERIMENTAL|Lisdexamfetamine dimesylate|
62843264|NCT03110913|EXPERIMENTAL|Methionine bioavailability in lentils|"Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods).~You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or a lentil stew with or without rice, which will be provided by the investigators"
62843265|NCT05428657|EXPERIMENTAL|Eye-tracking Training Group|EC Brain After-school Program- computerised eye-tracking training program
62843266|NCT05428657|ACTIVE_COMPARATOR|Conventional Training Group|Conventional intervention program for special educational needs
62843267|NCT00393861|EXPERIMENTAL|oxaliplatin & bevacizumab|
62843268|NCT03823313|EXPERIMENTAL|Spiritual Care Assessment and Intervention|
62843269|NCT01474018|NO_INTERVENTION|Metformin + Insulin|5 patients to continue on usual type 2 diabetic treatment consisting of 70/30 insulin, metformin and exercise and nutrition counseling.
62843270|NCT01474018|EXPERIMENTAL|QR-Bromocriptine +metformin+insulin|study drug add-on the usual therapy
62843271|NCT04216797|ACTIVE_COMPARATOR|Oral Administration|10 mg diazepam tablets to be taken orally once daily for 4 weeks.
62057838|NCT05600049|EXPERIMENTAL|Condition 4 : prototypes from (815-v1 151) to (815-v1 200) every two weeks|Application on the brown spots of the face and/or hands for the prototypes (815-v1 151) to (815-v1 200) at D0, D14, D28, D42, D56 and D70.
62057839|NCT05254639|EXPERIMENTAL|Donepezil|5 mg/day for 4 weeks then 10 mg/day for 12 weeks
62261138|NCT04998435|ACTIVE_COMPARATOR|ESPB group|Erector Spinae Plain Block
62261139|NCT04998435|ACTIVE_COMPARATOR|PV group|Paravertebral Block
62261140|NCT05214859|EXPERIMENTAL|Intervention|Participants in the intervention arm will receive Dyadic Expressive Arts Group Therapy as an intervention.
62261141|NCT05214859|NO_INTERVENTION|The Treatment-as-usual Waitlist Control Group|Participants in the control group will continue their routine healthcare and social services. Upon completion of the 8-month study period, participants will be invited to a similar intervention group program.
62261142|NCT01290861||pre-manifest HD|
62057840|NCT05254639|PLACEBO_COMPARATOR|Placebo|5 mg/day for 4 weeks then 10 mg/day for 12 weeks
62843272|NCT04216797|ACTIVE_COMPARATOR|Rectal Administration|10 mg diazepam tablets to be taken rectally once daily for 4 weeks.
62843273|NCT05147090|ACTIVE_COMPARATOR|Empagliflozin group|Empagliflozin 10mg daily for 156 weeks
62843274|NCT05147090|PLACEBO_COMPARATOR|Placebo group|Placebo pills (identical in appearance to empagliflozin 10mg) daily for 156 weeks
62843275|NCT03710200|ACTIVE_COMPARATOR|Bologna 00+S. cerevisiae yeast|Bread made with Bologna flour (type 00) (modern variety)+S. cerevisiae yeast
62843276|NCT03710200|EXPERIMENTAL|Bologna 1+S. cerevisiae yeast|Bread made with Bologna flour (type 1) (modern variety)+S. cerevisiae yeast
62843277|NCT03710200|EXPERIMENTAL|Bio2+S. cerevisiae yeast|Bread made with mix Bio2 flour (type 1) (heritage mix varieties)+S. cerevisiae yeast
62057841|NCT00861601|EXPERIMENTAL|low dose|eltrombopag 12.5 mg/day
62057842|NCT00861601|EXPERIMENTAL|middle dose|eltrombopag 25 mg/day
62057843|NCT00861601|EXPERIMENTAL|high dose|eltrombopag 37.5 mg/day
62261143|NCT01290861||early manifest HD|
62261144|NCT01290861||healthy controls|
62261145|NCT06042153|EXPERIMENTAL|Arm 1 - Semaglutide|Participants will receive semaglutide as an adjunct to standard-of-care.
62261146|NCT06042153|PLACEBO_COMPARATOR|Arm 2- Placebo|Participants will receive placebo (semaglutide) as an adjunct to standard-of-care.
62843278|NCT03710200|EXPERIMENTAL|ICARDA+S. cerevisiae yeast|Bread made with Icarda mix (type 1) (heritage mix varieties)+S. cerevisiae yeast
62843279|NCT03710200|EXPERIMENTAL|Bologna 1+sourdough|Bread made with Bologna flour (type 1) (modern variety)+sourdough
62843280|NCT03710200|EXPERIMENTAL|Bio2+sourdough|Bread made with mix Bio2 flour (type 1) (heritage mix varieties)+sourdough
62843281|NCT03710200|EXPERIMENTAL|ICARDA+sourdough|Bread made with mix Icarda flour (type 1) (heritage mix varieties)+sourdough
62843282|NCT03710200|EXPERIMENTAL|Grossi+sourdough|Bread made with mix Grossi flour (type 1) (heritage mix varieties)+sourdough
62843283|NCT05334212|EXPERIMENTAL|Evaluation of usefulness|To evaluate usefulness of Surgical Theater's Patient Engagement 360VR platform in helping align patient expectations and improve patient satisfaction and understanding in spinal surgery consults.
62843284|NCT02422199|EXPERIMENTAL|pyrotinib plus capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m\^2 daily, 1000 mg/m\^2 BID)
62843285|NCT02422199|ACTIVE_COMPARATOR|lapatinib plus capecitabine|lapatinib (1250 mg once daily) + capecitabine (2000 mg/m\^2 daily, 1000 mg/m\^2 BID)
62617742|NCT01765608|ACTIVE_COMPARATOR|nCPAP|Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S8 or S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed within the first 4 weeks of treatment initiation. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 24 weeks.
62617743|NCT02812225||BrainPulse|BrainPulse recordings will be obtained from patients when they come in to the ED after a trauma event. BrainPulse recordings will be also obtained from those subjects who also consent for follow-up.
62617744|NCT00179764|OTHER|Reduced Intensity Conditioning Regimen|
62617745|NCT02888275|EXPERIMENTAL|DEX|dexmedetomidine 1mcg/kg for 10min. loading and continuous infusion during the surgery 0.5mcg/kg/hr.
62617746|NCT02888275|ACTIVE_COMPARATOR|no_DEX|Normal saline 1mcg/kg for 10min. and continuous infusion during the surgery 0.5mcg/kg/hr.
62617747|NCT03577132|EXPERIMENTAL|Luminal type|Luminal type in previous transurethral resection of bladder tumor pathology. Luminal type in Immunohistochemistry (KRT5/6-KRT14-FOXA1+GATA3+)
62261147|NCT03514628|EXPERIMENTAL|Valsalva Assist Device (VAD)|Intervention is the use of Valsalva Assist Device (VAD) to deliver the Valsalva strain
62617748|NCT03577132|EXPERIMENTAL|Basal typr|Basal type in previous transurethral resection of bladder tumor pathology. Basal type in Immunohistochemistry (KRT5/6+KRT14+FOXA1-GATA3-)
62261148|NCT03514628|ACTIVE_COMPARATOR|Standard Care|Intervention is the use of Standard technique to deliver Valsalva strain eg blowing on empty syringe
62617749|NCT05163730|OTHER|Panbio™ COVID-19/ Flu A&B Rapid Panel|"One nasal swab sample will be collected from both nostrils by operators and will be used to perform the Panbio™ COVID-19/ Flu A\&B Rapid Panel test either in a laboratory or in a non-laboratory setting (e.g. GP centre or hospital clinic). Each Panbio™ COVID-19/ Flu A\&B Rapid Panel result will be photographed by the observer at the time of test interpretation.~Nasopharyngeal samples will be collected and used for RT-PCR testing as per local procedures.~Nasal samples must always be collected prior to the Nasopharyngeal sampling."
62617750|NCT01059019|SHAM_COMPARATOR|Control|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients.
62446402|NCT04866589|NO_INTERVENTION|Control|Business as usual.
62446403|NCT02020603|ACTIVE_COMPARATOR|APC group|epinephrine injection plus argon plasma coagulation
62446404|NCT02020603|ACTIVE_COMPARATOR|Forceps group|epinephrine injection plus soft coagulation using hemostatic forceps
62446405|NCT04411459||COVID-19 pneumonia patients|Patients needing intubation and mechanical ventilation for COVID-19 related pneumonia without other primary causes of ICU admission
62446406|NCT04769466|EXPERIMENTAL|Staff|Staff will be trained in the platform, and complete life story interviews with residents at their facilities. Upon completion of training, staff will complete surveys regarding it's effectiveness and utility, and following the completion of the interview, the resident's life story books, summary materials, and staff tools will be delivered four weeks later. Life story materials are meant to assist staff in providing more personalized care and a mechanism for residents to feel more deeply understood.
62446407|NCT04769466|EXPERIMENTAL|Residents|Residents will be screened for their cognitive status and compete interviews with a researcher prior to participation in the life story interview. Residents will then be interviewed again at T3 about four weeks after the life story books, summaries, and staff materials have been delivered.
62446408|NCT01206842|EXPERIMENTAL|social cognition training|
62446409|NCT01206842|NO_INTERVENTION|treatment as usual|
62446410|NCT00004143|EXPERIMENTAL|Campath SCT for hemoglobinopathies|Campath, Chemo and/or TBI Allo SCT
62446411|NCT00004143|EXPERIMENTAL|Campath SCT for Bone Marrow Failure|Campath, Chemo and/or TBI Allo SCT
62446412|NCT05311852|EXPERIMENTAL|PEA-LUT|patients were required to assume granulated PEA-LUT 700/70 mg, 2 time/day for 8 weeks
62446413|NCT05311852|PLACEBO_COMPARATOR|Placebo|patients were required to assume granulated placebo, 2 time/day for 8 weeks
62446414|NCT03027661|PLACEBO_COMPARATOR|Control Group|Injection of 10 mL of 0.9% sodium chloride into the cervical stroma divided between 3 and 9 o'clock
62446415|NCT03027661|ACTIVE_COMPARATOR|Study Group|Injection of 10 mL of 0.5% bupivacaine into the cervical stroma divided between 3 and 9 o'clock.
62446416|NCT00246974|ACTIVE_COMPARATOR|1|Cisplatin + Gemcitabin
62446417|NCT00246974|EXPERIMENTAL|2|Cisplatin + Gemcitabin + Gefitinib
62446418|NCT05055921|EXPERIMENTAL|Multi Pulse Therapy as delivered from the Cardialen External Stimulation System|Subjects will have AF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia.
62446419|NCT06546787|EXPERIMENTAL|Psychotherapy|IPT will be administered by the researcher who has completed the interpersonal relations psychotherapy training.
62446420|NCT06546787|NO_INTERVENTION|Observation|Patients in the control group will be asked to complete the post-tests at the same time after the experimental group interviews are completed. However, no intervention will be made to the control group.
62446421|NCT03985592|OTHER|Educational Intervention for ICU-Based Clinicians|ICU-based clinicians (e.g. physicians, RNs, and social workers) will be provided with educational modules related to bereavement support for family members. Following the modules a survey will be provided to participants to assess their perceived usefulness of the modules.
62057844|NCT01839422|EXPERIMENTAL|Controls|Memory assessment. Brain imaging examination MRI.
62261149|NCT00268489|EXPERIMENTAL|pemetrexed + bevacizumab|"Patients receive pemetrexed disodium IV over 10 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed periodically for 5 years."
62261150|NCT05607368||SLE group|"1. Voluntary signing of informed consent;~2. Age greater than 18 years old, less than 50 years old, gender is not limited;~3. Patients with SLE who meet diagnostic criteria."
62446422|NCT03985592|EXPERIMENTAL|Educational material and personalized card of condolence|Members of the ICU team who cared for deceased ICU patients will be asked to send a letter of condolence to family members listed as the patient's primary contact and provide them with educational modules related to bereavement support for family members.
62261151|NCT05607368||NPSLE epilepsy group|"1. Voluntary signing of informed consent.~2. Age greater than 18 years old, less than 50 years old, gender is not limited.~3. Patients with NPSLE epilepsy who meet diagnostic criteria."
62617751|NCT01059019|EXPERIMENTAL|Treatment|20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day
62617752|NCT04170036||Protein supplement group|The group of subjects who use protein supplements at least for the preceding three months
62617753|NCT04170036||Control group|The group of subjects who never used protein supplements
62617754|NCT05187559|EXPERIMENTAL|First Group|Neuromuscular exercise program with standard physiotherapy with no visual feedback.
62617755|NCT05187559|EXPERIMENTAL|Second Group|Neuromuscular exercise program with physiotherapy with visual feedback using Biodex platform
62617756|NCT00857961|EXPERIMENTAL|3 mL (30 mg) of 1% Testosterone MD-Lotion|Applied once daily for 7 days to both axilla (1.5 mL to each axilla). All study participants are randomized to each of the 4 study treatments.
62617757|NCT00857961|EXPERIMENTAL|1.5 mL (30 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days to one axilla. All study participants are randomized to each of the 4 study treatments.
62617758|NCT00857961|EXPERIMENTAL|3 mL (60 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days to both axilla (1.5 mL to each axilla). All study participants are randomized to each of the 4 study treatments.
62843286|NCT00554216|EXPERIMENTAL|VI-0521 Low|VI-0521; low dose phentermine/topiramate (PHEN/TPM 3.75 mg/23 mg)
62843287|NCT00554216|EXPERIMENTAL|VI-0521 Top|Top Dose VI-0521 consisting of 15 mg of Phentermine and 92 mg of Topiramate.
62843288|NCT00554216|PLACEBO_COMPARATOR|Placebo|Placebo to match
62843289|NCT00971152|ACTIVE_COMPARATOR|450 IU daily dose of gonadotrophin|
62057845|NCT01839422|EXPERIMENTAL|Beginner Alzheimer's Disease patients|Memory assessment. Brain imaging examination MRI.
62261152|NCT05607368||Healthy control group|"1. Voluntary signing of informed consent;~2. Healthy volunteers older than 18 years old and less than 50 years old, regardless of gender;~3. No systemic diseases and neurological symptoms and signs;~4. According to the judge's judgment, healthy volunteers matching the NPSLE epilepsy group in terms of gender, age, and education level were selected as the control group."
62261153|NCT01246570|EXPERIMENTAL|Maintenance program|"Patients will attend a motivational exercise session once monthly. They will also be tested (exercise test with measurement of peak oxygen uptake) every third months."
62617759|NCT00857961|EXPERIMENTAL|4.5 mL (90 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days by three doses to both axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla). All study participants are randomized to each of the 4 study treatments.
62617760|NCT04150653||AAA patients|"All patients enrolled in phase 1 will undergo:~* Multiphase scan CT~* Non-invasive vascular ultrasound elastography by ultrasound (NIVE)"
62617761|NCT05176925|EXPERIMENTAL|Tislelizumab combined with sitravatinib|
62843290|NCT00971152|EXPERIMENTAL|600 IU daily dose of gonadotrophin|
62843291|NCT04228380||Inclusion|Inclusion criteria: The cohort is made up of adult patients over 65 years of age, admitted to an intensive care unit in Sweden, for other reason than postoperative care or simple monitoring.
62843292|NCT04228380||Exclusion|Exclusion criteria: Declined consent to participate.
62843293|NCT05002075|NO_INTERVENTION|Usual care arm|Participants in the usual control group will receive standard of care per their providers' discretion.
62843294|NCT05002075|EXPERIMENTAL|m-health cardiac rehabilitation intervention arm|Participants randomized to m-Health cardiac rehabilitation will receive a 24-week home-based exercise program
62057846|NCT01839422|EXPERIMENTAL|Severe Alzheimer's Disease patients|Memory assessment. Brain imaging examination MRI.
62057847|NCT04197648|EXPERIMENTAL|Exercise group|24 week, supervised exercise program at the PPMC (pavillon de prevention des maladies cardiaques). 3x/week. Blood pressure response evaluated during every session.
62057848|NCT04197648|NO_INTERVENTION|Control goup|No exercise program. Continuation of the daily life activities. Consultation with a kinesiologist at baseline, 3 months and 6 months for advice on physical activities and lifestyle habits.
62446423|NCT03985592|EXPERIMENTAL|Virtual meeting with the care team to address unmet needs|At 8-12 weeks post-death, we will contact FMs and invite them to meet virtually with the care team. Our observational studies indicated that the most common need reported by bereaved FMs was the desire to meet with the care team to review events during the ICU stay and particularly the events that led to death, and that this was the type of support that ICU clinicians were most comfortable providing.
62057849|NCT02716337|OTHER|Intervention group|In the intervention group VLBW infants were fed target fortified human milk Growth and safety were compared to a historical group of VLBW infants fed with standard fortified human milk
62057850|NCT05259787|EXPERIMENTAL|Etomidate combined with propofol（EP）|0.2ml/kg IV
62057851|NCT05259787|ACTIVE_COMPARATOR|Propofol（P）|0.2ml/kg IV
62057852|NCT05976425|EXPERIMENTAL|Blood pressure readings|Using the data acquisition software provided, a reading for the subject will be started. The tool will automatically record the pre invasive blood pressure readings, then take the NIBP measurement with the device under test, and it will follow up with a post invasive blood pressure reading.
62057853|NCT02041689||Participants|"Patients at St. Jude Children's Research Hospital between the ages of 7 and 11 years who have a working diagnosis or initial diagnosis of a bone or soft tissue sarcoma.~Interventions: two unstructured life-story interview sessions, observations, and guided activities."
62057854|NCT05965063|OTHER|Dietary avoidance for allergy food|strict avoidance of the specific allergenic food
62057855|NCT05965063|EXPERIMENTAL|bifidobacterium intervention|Bifidobacterium M-16V for 12 weeks while strictly avoidance of the specific allergenic food
62261154|NCT01246570|ACTIVE_COMPARATOR|Control|Usual care. The patients will receive the usual care provided by the hospital and community health services
62617762|NCT03630133|EXPERIMENTAL|Intracept System Ablation|Single Arm
62617763|NCT02673294|EXPERIMENTAL|intervention (6-12 months)|Participants with a chronicity between 6-12 months
62617764|NCT02673294|EXPERIMENTAL|Intervention (12-24 months)|Participants with a chronicity between 12-24 months
62843295|NCT06241391|EXPERIMENTAL|Efficiency of 68 Ga-PSMA-11 PET-CT in detection of recurrent gliomas|"Primary objective Detection of sensitivity and specificity of 68Ga PSMA-11 PET-CT to diagnose disease recurrence in gliomas Secondary objectives~1. Comparison of tumor SUVmax between 68Ga-PSMA and 18F-FDG PET-CT images~2. Comparison of sensitivity and specificity of Ga-68 PSMA-11 PET-CT with that of CEMRI in diagnosing disease recurrence in gliomas~3. Correlation between WHO tumor grade in histology and SUVmax of the recurrent lesion on 68Ga- PSMA PET-CT scan~4. Correlation between PSMA expression in histopathology specimen (using IHC) and SUVmax of recurrent lesion on 68Ga- PSMA PET-CT scan.~5. Any adverse events of Ga-68 PSMA-11 will be recorded according to CTCAE"
62843296|NCT04373252|EXPERIMENTAL|Fecal Microbiota Transplant|All participants will receive two fecal microbiota transplants one week apart. The transplant will occur via antegrade enema and the enema transplant material will be provided by OpenBiome, the product used is FMT Lower Delivery (FMP 30).
62843297|NCT04159753|OTHER|Spinal Cord Stimulator|Burst neurostimulation
62843298|NCT00330967||Group 1|healthy subjects
62843299|NCT00330967||Group 2|healthy subjects different from group 1
62057856|NCT05965063|NO_INTERVENTION|Healthy control|without intervention
62057857|NCT05655026|EXPERIMENTAL|x≤300 HFNO or standard oxygen supplementation|bronchoscopy, taking blood gas, taking blood for blood test
62057858|NCT05655026|EXPERIMENTAL|100<x≤200 NIV or HFNO|bronchoscopy, taking blood gas, taking blood for blood test
62057859|NCT05655026|EXPERIMENTAL|x≤100 NIV or intubation|bronchoscopy, taking blood gas, taking blood for blood test, intubation
62261155|NCT05959395|EXPERIMENTAL|VectRx Thermal Therapy|Device performance
62261156|NCT05259371|EXPERIMENTAL|Transcutaneous Pulsed Electrical Stimulation Treatment|Patients wear our clinical trial device 30mins once a day for 16weeks. Device: Nu eyne M02
62261157|NCT00483561|EXPERIMENTAL|Gefitinib plus Etoposide|"Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial.~Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple)."
62261158|NCT04145167||Medical Treatment|This group will include all patients with a diagnose of coronary chronic total occlusions who will be treated by medical therapy only, for any clinical/angiographic/instrumental indication.
62617765|NCT02673294|EXPERIMENTAL|Intervention (>24 months)|Participants with a chronicity \>24 months
62617766|NCT06201468|EXPERIMENTAL|group A|"Group A (n = 21): will receive scapular mobilization combined with mobilization with movement (MWM) and capsular stretch for 4 weeks.~Mulligan Mobilization with Movement for peripheral joints combines sustained manual application of 'gliding' force to a joint, with the aim of repositioning the positional faults with concurrent physiological motion of the joint, either performed actively by the subject or passively by the therapist"
62057860|NCT03266614|EXPERIMENTAL|Recovery 4 US|This group receives a smartphone with the Recovery 4 US application and access to the application website.
62057861|NCT03266614|NO_INTERVENTION|Services as usual|This group receives a smartphone but no access to the Recovery 4 US application.
62057862|NCT05114330||Cohort 1|Systemic (= localized outside the CNS) lymphoma with secondary CNS involvement at initial diagnosis
62057863|NCT05114330||Cohort 2|CNS relapse of previously systemic lymphoma
62057864|NCT06255015|ACTIVE_COMPARATOR|Breastfeeding toolkit card|"50% of participants will be allocated to the intervention group, and receive a breastfeeding toolkit card at the 24 week appointment.~The Breastfeeding toolkit provides advice on circumventing common breastfeeding problems and contact details for breastfeeding support services."
62057865|NCT06255015|NO_INTERVENTION|No planning card|50% of women will receive routine antenatal care only.
62057866|NCT00768430|EXPERIMENTAL|1|Ketamine
62057867|NCT00768430|ACTIVE_COMPARATOR|2|Midazolam
62057868|NCT04243070|OTHER|3-channel Holter ECG recording for EPS patient|Patients participating in an EPS will undergo a 3-channel Holter ECG recording in parallel to the standard 12-channel Holter ECG recording during the EPS followed by an optional 24 h observation period
62057869|NCT04243070|OTHER|12-channel Holter ECG recording for non-EPS patients|Patients scheduled for a follow-up for their heart disease will undergo a 12-channel Holter ECG recording while participating in a Body Motion test followed by a 24 h observation period
62057870|NCT01609816|EXPERIMENTAL|Dasatinib|This is a phase 1 dose escalation study, using a standard 3+3 design. Dasatinib is administered orally once daily in the outpatient setting. The starting dose of dasatinib is 20 mg daily. The increment of dose escalation is 20 mg per dose level. Thus, there will be 5 dose levels (20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively) with 3 patients in each cohort. Patients will continue on dasatinib for 6 months
62057871|NCT01533363|ACTIVE_COMPARATOR|Stapled hemorrhoidopexy|surgical procedure to treat hemorrhoids
62057872|NCT01533363|ACTIVE_COMPARATOR|Milligan Morgan|surgical procedure to treat hemorrhoids
62057873|NCT01720732|EXPERIMENTAL|Lifeline NET|Lifeline-NET (Short Version of NET)
62057874|NCT01720732|NO_INTERVENTION|TAU|Treatment as Usual
62057875|NCT01909414|EXPERIMENTAL|Arm A: GEO-D03 DNA and MVA/HIV62B vaccines|At study entry and Week 8, participants will receive the GEO-D03 DNA vaccine administered as 1 mL intramuscularly (IM) in either deltoid. At Weeks 16 and 24, they will receive the MVA/HIV62B vaccine administered as 1 mL IM in either deltoid.
62057876|NCT01909414|PLACEBO_COMPARATOR|Arm B: Placebo for GEO-D03 and MVA/HIV62B|At study entry and Week 8, participants will receive the placebo for GEO-D03 DNA vaccine administered as 1 mL IM in either deltoid. At Weeks 16 and 24, they will receive the placebo for MVA/HIV62B vaccine administered as 1 mL IM in either deltoid.
62057877|NCT05927025|EXPERIMENTAL|Hand K-files|NiTi K type hand file (Perfect Medical Instrument Co., Ltd. Shenzhen, China), Contrary to stainless steel files, turning is produced with the buckling method. torsional resistance and bending resistance of files compared to stainless steel files found more successful in comparison. 16 mm of the files are finished It has the edge. Our Work is 25mm long; 15K (white), 20K (yellow), 25K (red), 30 K (blue) files were used. NiTi K type #15, #20, #25, and #30 hand files were used with a quarter-turn pulling motion, respectively.
62261159|NCT04145167||Percutaneous intervention|This group will include all patients with a diagnose of coronary chronic total occlusions who will be treated by percutaneous intervention (CTO-PCI), as indicated by the heart-team.
62261160|NCT04145167||Surgical treatment|This group will include all patients with a diagnose of coronary chronic total occlusions (generally not isolated) who will be treated by means of coronary artery by-pass grafting (CABG), as indicated by heart-team decision.
62261161|NCT03475745||Aphasia|Post stroke aphasia patients without any additional interventions for research purposes.
62261162|NCT03475745||Control|Healthy controls
62261163|NCT02729142|EXPERIMENTAL|Tibial cortical density evaluation|
62261164|NCT01662674|EXPERIMENTAL|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
62261165|NCT01662674|EXPERIMENTAL|C|Combination of gemigliptin50mg/metformin HCl extended release 1000mg
62261166|NCT03019042|EXPERIMENTAL|Hou Gu Mi Xi|Patients in this arm receive Hou Gu Mi Xi, with oral dose of 30 g/day (contain 10.1 herb materials) during entire follow up period (2 years). HGMX is composed of 10 dietary Chinese herbs (including ginseng (Renshen), tuckahoe (Fuling), coixenolide (Yiyiren), Chinese yam (Shanyao), lotus seed (Lianzi), amomum (Sharen), platycodon (Jiegen), white hyacinth bean (Baibiandou), licorice (Gancao), and orange peel (Jupi)), early rice, and oats.
62261167|NCT03019042|PLACEBO_COMPARATOR|placebo|Patients in this arm receive placebo, with oral dose of 30 g/day during entire follow up period (2 years). The placebo is only consist of early rice and oats.
62617767|NCT06201468|EXPERIMENTAL|group B|"Group B (n = 21): will receive scapular proprioceptive neuromuscular facilitation combined with (MWM) and capsular stretch for 4 weeks.~Scapular PNF incorporates functional or diagonal patterns (anterior elevation - posterior depression and posterior elevation - anterior depression) for performing the exercises and can be used to stretch or strengthen the muscles selectively. These techniques help the muscles to relearn the normal timing of recruitment and the amount of activation to sustain the balance between different groups of muscles"
62057878|NCT05927025|EXPERIMENTAL|ProTaper Next|The ProTaper Next (PTN) system is produced by adding M-Wire alloy to the ProTaper Universal (PU) system. With the M-Wire alloy, it is aimed to increase the flexibility and cyclic fatigue resistance of the files. The combination of three important design features in PTN files, including changing taper on a single file, M-wire technology and offset design, is one of the important features that distinguish it from other files. PTN X1 and X2 files have both an ascending and a descending conical design on a single file; PTN X3, X4 and X5 files have a constant taper from D1-D3, then taper design that tapers off over the rest of their active segments.
62057879|NCT05927025|EXPERIMENTAL|WaveOne Gold|They are produced by applying Gold-wire process to the WaveOne (WO) system. The WOG file system exhibits repetitive back-and-forth mutual 'reciprocation' motion during preparation, in contrast to the continuous rotational motion. While rotating 150° counterclockwise during the reciprocating motion, clockwise It turns 30° in the direction of, and after 3 cycles, it completes 1 full cycle. Thus, it contributed positively to the file reaching the apical without applying excessive pressure, increasing the cutting efficiency, and accelerating the coronal movement of the debris. Small (yellow-20/0.07), WO Primary (red-25/0.07), and WOG Medium (green-35/0.06) files were used with the appropriate speed and torque values recommended by the manufacturer (300 rpm and 2.0 Ncm) by applying crown down technique. WOG files were operated in a reciprocating motion (150° counterclockwise, 30° clockwise).
62057880|NCT05927025|EXPERIMENTAL|AF Baby Rotary File|AF Baby rotary file is specially designed for milk teeth. Entry file 11 mm other the files are 16 mm long and consist of 4 different rotary instruments; (17/.08), (20/.04), (25/.04) and (30/.04).The cross-sections of the files are triangular and heat treatment is applied to the NiTi wire. produced as a result. Thus, an increase in resistance to cyclic fatigue and an increase in dentin It is aimed to reduce screwing. Root canal thanks to its flexibility It adapts very well to the curvatures in its anatomy. AF Baby rotary files #20, #25, and #30 were used with the crown down technique with the appropriate speed and torque values (350 rpm and 2.0 Ncm) recommended by the manufacturer.
62057881|NCT05927025|EXPERIMENTAL|EndoArt NiTi Pedo Golf File|EndoArt NiTi Pedo Gold file is specially designed for primary teeth. 18mm length consists of 4 different rotary tools: (15/06) white, (20/04) yellow, (25/04) red, (30/04) blue. The cross-sections of the files are triangular, and Gold wire technology is used in the production phase. were produced using Thus, a titanium oxide layer on the surface of the instrument Happened. Thus, it is more flexible and more flexible than conventional NiTi alloys. resistant and 2 times better cyclic fatigue resistance than conventional files exists. EndoArt NiTi Pedo Golf File; EndoArt NiTi Pedo Gold #15, #20, and #30 files were used with the crown down technique with the appropriate speed and torque values recommended by the manufacturer (350 rpm and 2.0 Ncm).
62057882|NCT02768454||inpatient under broad-spectrum antibiotics|medical review
62057883|NCT05297890|EXPERIMENTAL|Lorlatinib|Drug：Lorlatinib 100mg, oral, Quaque Die (QD), continuous administration in 21 days as a cycle
62057884|NCT03249506||Cohort 1: Non-SGLT2i new Users|This is a retrospective cohort study identifying participants with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease using the Military Health System (MHS) over a 3-year period. Cohort 1 included participants with incident exposure of one or more non-sodium glucose co-transporter 2 inhibitor (SGLT2i) anti-hyperglycemic agent (AHA) therapy during the study period with no prior or subsequent SGLT2i exposure throughout the study period. New users are defined as participants whose first exposure to any non-metformin AHA medication occurs greater than or equal to (\>=) 365 days after their start of observation in the database with no prior exposure to any medication within the same AHA medication class in the prior 365 days.
62057885|NCT03249506||Cohort 2: SGLT2i new Users|Cohort 2 included participants with incident SGLT2i exposure during the study period regardless of prior or concurrent exposure to one or more additional AHA therapy. New users are defined as participants whose first exposure to SGLT2i medication occurs \>= 365 days after their start of observation in the database with no prior exposure to the same AHA medication class in the prior 365 days.
62057886|NCT03021577|ACTIVE_COMPARATOR|Orbital Atherectomy System (OAS) Group|Subjects randomized to OAS. In a subset of patients (n= 20) a baseline cardiac magnetic Resonance Imaging (MRI) scan will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
62057887|NCT03021577|ACTIVE_COMPARATOR|Rotational Atherectomy (RA) Group|Subjects randomized to RA using the Rotablator Rotational Atherectomy System. In a subset of patients (n= 20) a baseline cardiac magnetic Resonance Imaging (MRI) scan will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
62057888|NCT02372721||Sepsis with Severe AKI|"History of a pediatric admission with sepsis related AKI which lead to classification of injury or failure. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry."
62261168|NCT02334449|EXPERIMENTAL|Single dose study part|there will be 8 cohorts of healthy volunteers dosed with single doses of LML134 (8 planned dose levels) or with placebo and 2 potential additional cohorts (also dosed with single dose of LML134 or placebo)
62261169|NCT02334449|EXPERIMENTAL|Multiple dose study part|there will be 3 cohorts of healthy volunteers dosed with multiple doses of LML134 (3 planned dose levels) or placebo and one potential additional cohort (also dosed with multiple doses of LML134 or placebo)
62261170|NCT06504537|EXPERIMENTAL|GROUP A: THERAGUN PERCUSSION THERAPY AND ROUTINE PHYSICAL THERAPY|Patients will receive Theragun Percussion Therapy for 25 minutes along with Routine Physical Therapy Treatment for 20 minutes
62261171|NCT06504537|EXPERIMENTAL|GROUP B: COMPRESSION THERAPY AND ROUTINE PHYSICAL THERAPY|Compression therapy will be administered to the patients by migraine relief gel cap for 25 minutes during migraine attacks along with Routine Physical Therapy Treatment for 20 minutes.
62261172|NCT05648994|EXPERIMENTAL|TCR-T cells|TCR-T cells will be infused to patients with advanced solid tumors after non-myeloablative lymphocyte-depleting preparative regimen.
62261173|NCT00842426|NO_INTERVENTION|Usual Care|Usual Care
62261174|NCT00842426|EXPERIMENTAL|Self-Management Program|Online Self-Management.
62261175|NCT00842426|EXPERIMENTAL|Care Management Program|Care management lifestyle modification program with intensive intervention phase with exercise and nutrition specialist. Followed by a online self-management phase.
62261176|NCT01547533||Lactating Women with Chagas disease|Women with Chagas disease who fulfill clinical criteria for treatment with benznidazole, and who are also lactating
62843300|NCT03372681|EXPERIMENTAL|Antiperistaltic|In this group patients undergo the distal gestrectomy with antiperistaltic Billroth II + Braun anastomosis
62843301|NCT03372681|ACTIVE_COMPARATOR|Isoperistaltic|In this group patients undergo the distal gestrectomy with isoperistaltic Billroth II + Braun anastomosis
62843302|NCT05156021|EXPERIMENTAL|pre-vitrectomy anti-VEGF injection group|Patient in this group receive an intravitreal injection of anti-VEGF drug 3-5 days before surgery, followed by PPV combined with PRP and pressure-reducing valve implantation
62843303|NCT05156021|EXPERIMENTAL|pre and post-vitrectomy anti-VEGF injection group|Patient in this group receive two intravitreal injections of anti-VEGF drugs. One is injected 3-5 days before surgery, the other is at the same time as the PPV combined with PRP and pressure reducing valve implantation is completed.
62057889|NCT02372721||Sepsis without AKI|History of a pediatric admission with sepsis which lead to no classification of AKI. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry.
62843304|NCT04851262|EXPERIMENTAL|Intervention|The intervention is a 12-week home-based resistance training programme with phased progression. The intervention will have three phases: (i) an initial phase focused on training the target muscle(s)/movements with minimal or no external weight; (ii) an intermediate phase targeting muscle strength with increased practice resistance; and (iii) an advanced phase targeting the further enhancement of muscle strength by challenging multiple muscle groups. Each phase will involve exercises targeting the trunk, back, hip, upper-limb and lower-limb muscles.
62843305|NCT04851262|OTHER|Waitlist control|The waitlist control participants will start the intervention 12 weeks after the baseline assessment.
62057890|NCT02372721||Control|No history of an admission for AKI. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry.
62057891|NCT05917301|EXPERIMENTAL|Pre-operative hypofractionated proton therapy|Patients will have 5 fractions of proton therapy prior to surgical resection of their sarcoma.
62057892|NCT01396317|EXPERIMENTAL|Tocilizumab|This is a single-arm study. All subjects will receive the active study treatment for 12 months, and will then be evaluated for 3 months of long-term follow-up.
62057893|NCT02092558||Female 1|Owing to the absence of an established treatment modality for squamous metaplasia of the urinary bladder in children, we developed our own treatment modalities. Children presenting with recurrent urinary tract infections on medical interview, were subjected to ultrasonography of the urinary system, repeated urinalysis, and urine culture tests. Then, on the basis of antibiogram findings, antibiotic and chemotherapeutic treatment was administered to eliminate the bacteriological factors. Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months.
62057894|NCT02092558||Male 2|Owing to the absence of an established treatment modality for squamous metaplasia of the urinary bladder in children, we developed our own treatment modalities. Children presenting with recurrent urinary tract infections on medical interview, were subjected to ultrasonography of the urinary system, repeated urinalysis, and urine culture tests. Then, on the basis of antibiogram findings, antibiotic and chemotherapeutic treatment was administered to eliminate the bacteriological factors. Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months.
62057895|NCT04567511|EXPERIMENTAL|Single Arm|Patients with mild hemophilia A (without inhibitors) will be treated with prophylactic emicizumab. The clinical hemostatic efficacy and safety will be assessed. Secondary outcomes will assess changes in quality of life and joint health in treated patients.
62057896|NCT04576364|ACTIVE_COMPARATOR|12-hour postpartum Mgso4|Patients having preeclampsia with severe features will receive 12-hour postpartum Mgso4
62057897|NCT04576364|ACTIVE_COMPARATOR|24-hour postpartum Mgso4|Patients having preeclampsia with severe features will receive 24-hour postpartum Mgso4
62057898|NCT01665339|EXPERIMENTAL|preload|subjects in preload group consumed salad, yogurt and water 15 minutes before the main meal.
62057899|NCT01665339|EXPERIMENTAL|control|subjects in control group consumed salad and yogurt with meal.
62057900|NCT05458375|NO_INTERVENTION|Control Group|Participants will receive standard pessary care. Participation requires follow up visit 6 months from initial baseline visit. At this visit, participants are asked about vaginal bleeding, degree of bother due to vaginal discharge, and degree of pessary discomfort and a physical exam is performed.
62057901|NCT05458375|EXPERIMENTAL|Estrogen Group|Participants will receive standard pessary care, and those participants randomized to the experimental group will then be given a prescription for vaginal estradiol and instructed to apply it in the vagina nightly for two weeks and then twice weekly thereafter. Participation requires follow up visit 6 months from initial baseline visit. At this visit, participants are asked about vaginal bleeding, degree of bother due to vaginal discharge, and degree of pessary discomfort and a physical exam is performed.
62057902|NCT06374940|NO_INTERVENTION|conventional abdominal hysterectomy|The surgical technique of conventional abdominal hysterectomy was described in the literature.
62261177|NCT01775735|EXPERIMENTAL|Treatment|The treatment is continuous stimulation with an occipital nerve stimulator, specifically the BSC Precision™ ONS System for 6 months post-randomization
62843306|NCT01170572||Long bone fracture|Patients presenting to accident and emergency during the study period with long bone or clavicle fracture
62843307|NCT01561313|ACTIVE_COMPARATOR|Current formulation adalimumab|One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
62843308|NCT01561313|EXPERIMENTAL|New formulation of adalimumab|One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe
62843309|NCT03464539|OTHER|CD patients|PG low molecular weight chitosan 3 times per day
62843310|NCT06104436|EXPERIMENTAL|Individualized music playlist|Composed of preferred music genres sequenced according to the ISO-Principle in addition to usual care.
62843311|NCT06104436|ACTIVE_COMPARATOR|Preferred music|Preferred music genres played in random sequence in addition to usual care.
62843312|NCT06104436|SHAM_COMPARATOR|Treatment as usual|Usual care for agitation management.
62843313|NCT01099449|EXPERIMENTAL|Arm I|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and after oxaliplatin administration (part of FOLFOX chemotherapy comprising leucovorin calcium, fluorouracil, and oxaliplatin).
62261178|NCT01775735|ACTIVE_COMPARATOR|Control|The control is intermittent stimulation for 20 seconds every 90 minutes with an occipital nerve stimulator, specifically the BSC Precision™ ONS System for 6 months post-randomization
62261179|NCT02081040||Infratentorial dysphagia patients|Infratentorial brain lesion patients with confirmed evidence of dysphagia
62261180|NCT02081040||Supratentorial dysphagia patients|Supratentorial brain lesions\\ patients with confirmed evidence of dysphagia
62261181|NCT02081040||Brain lesion patients without dysphagia|Brain lesion patients with no evidence of dysphagia
62261182|NCT02595476|EXPERIMENTAL|BIS 55|"1. Induction:~   TCI propofol (6 µg/ml) - remifentanil (4 ng/ml) Atracurium IV (0.5 mg/kg)~2. Orotracheal Intubation~3. Remifentanil target decreased to 1 ng/ml~4. Propofol target adjustment to reach BIS 55~5. 10 minutes steady state~6. Tetanic stimulation (ulnar nerve): 100 Hz, 60 milliamps, 5 seconds~7. Pupillary dilation recording (videopupillometer Algiscan)"
62261183|NCT02595476|ACTIVE_COMPARATOR|BIS 25|"1. Induction:~   TCI propofol (6 µg/ml) - remifentanil (4 ng/ml) Atracurium IV (0.5 mg/kg)~2. Orotracheal Intubation~3. Remifentanil target decreased to 1 ng/ml~4. Propofol target adjustment to reach BIS 25~5. 10 minutes steady state~6. Tetanic stimulation (ulnar nerve): 100 Hz, 60 milliamps, 5 seconds~7. Pupillary dilation recording (videopupillometer Algiscan)"
62057903|NCT06374940|OTHER|Manipulator-assisted Abdominal Hysterectomy|In manipulator-assisted abdominal hysterectomy tecnique, a uterine manipulator (SecuFix ® , Richard Wolf) was inserted into the cervix. Conventional hysterectomy steps were performed until the vaginal colpotomy incision. A circular colpotomy incision was made directly over the manipulator silicone cup using a monopolar cautery set at 30W cutting mode without interfering with the cardinal ligament or sacrouterine ligament. The vaginal cuff was sutured using polyglactin 910 (no:1) as a single layer running suture.
62057904|NCT02871960|EXPERIMENTAL|Robotic colectomy|Patients undergoing robotic colectomy for colorectal cancer
62261184|NCT03886051|EXPERIMENTAL|test group|Connective Tissue Graft before Orthodontic treatment
62261185|NCT03886051|ACTIVE_COMPARATOR|control group|Orthodontic treatment only
62261186|NCT04168944|EXPERIMENTAL|lenvatinib group|Participants are given the same anti-rejection therapy as the control group after liver transplantation. 1-2 months after liver transplantation, participants are given lenvatinib with an initial dose of 8 mgor 12 mg orally once a day. The initial dose was 8 mgor 12 mg orally once a day.
62261187|NCT04168944|PLACEBO_COMPARATOR|Placebo group|Immunosuppressive regimen consisting of calcineurin inhibitor, mycophenolate mofetil, sirolimus or ivermus
62261188|NCT01227044|ACTIVE_COMPARATOR|NTX + MM/MC|Naltrexone + Medical Management/Medication Coaching
62261189|NCT01227044|PLACEBO_COMPARATOR|Placebo + MM/MC|Placebo plus Medical Management/Medication Coaching
62261190|NCT05348148|ACTIVE_COMPARATOR|Oral Levocetirizine|Patients in Levocetirizine group will use oral antihistamine (Levocetirizine) only
62261191|NCT05348148|ACTIVE_COMPARATOR|Combined Intranasal Mometasone Furoate with oral Levocetirizine|Patients in combined Intranasal Mometasone Furoate with oral Levocetirizineintranasal group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine)
62261192|NCT05348148|ACTIVE_COMPARATOR|Combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline|The other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline)
62261193|NCT06141369|EXPERIMENTAL|mRNA-0523-L001|individualized mRNA neoantigen vaccine (mRNA-0523-L001)
62261194|NCT01443104|ACTIVE_COMPARATOR|Orsiro Stent|Sirolimus-eluting Stent with a Biodegradable Polymer
62057905|NCT02871960|ACTIVE_COMPARATOR|Laparoscopic colectomy|Patients undergoing laparoscopic colectomy for colorectal cancer
62057906|NCT03265054||re-thrombosis|adult patients with a VTE history with at least 3 months of anticoagulant treatment, which suffered from a re-thrombosis within 5 years after stopping the anticoagulant treatment
62057907|NCT03265054||no thrombosis recurrence|adult patients with a VTE history with at least 3 months of anticoagulant treatment, without thrombosis recurrence
62057908|NCT01704469|EXPERIMENTAL|The local anesthetic injection group|
62057909|NCT00782496|EXPERIMENTAL|Level1 Basic Meter Features|Adults with type 1 and type 2 diabetes use only basic features (Level 1) to test their blood. The CONTOUR meter has the basic features such as small meter size, easy to use , No Coding™ technology, 5-second test time, small sample size (0.6 µL), automatic control solution marking, 480 reading memory capacity.
62057910|NCT00782496|EXPERIMENTAL|Level 2 Advanced Meter Features|Adults with type 1 and type 2 diabetes additionally access and use more advanced meter features(Level 2)during blood glucose testing. The advanced features include ability to mark blood glucose values as obtained before or after meals or to set an audible reminder to test.
62261195|NCT01443104|ACTIVE_COMPARATOR|Xience Prime Stent|Everolimus-eluting Stent with a Durable Polymer
62261196|NCT06174623|EXPERIMENTAL|ModulHeart System|
62261197|NCT05290155|EXPERIMENTAL|Anti-CD7 CAR T cells|Administration with anti-CD7 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients
62261198|NCT05699161|EXPERIMENTAL|Single group assignment.|"Bilateral treatment.~Subdermal plane injection of SVF cells into the submuscular aponeurotic fascia of the face."
62261199|NCT06442579||Stroke|Persons with a unilateral first ever ischemic stroke
62261200|NCT06442579||Control|Age and gender matched healthy controls
62261201|NCT01502709|EXPERIMENTAL|Caloric Vestibular Neurostimulation|Subjects received caloric vestibular neurostimulation
62261202|NCT01502709|PLACEBO_COMPARATOR|Placebo Arm|Subjects received placebo
62261203|NCT03381716||male|Drug:Beta-blocker,Angiotensin II receptor blocker,Angiotensin-converting enzyme,Calcium-channel blocker,Aspirin,Statin
62261204|NCT03381716||female|Drug:Beta-blocker,Angiotensin II receptor blocker,Angiotensin-converting enzyme,Calcium-channel blocker,Aspirin,Statin
62261205|NCT04359628||BOA|Patients with osteoarthritis registered in the Better BOA register
62261206|NCT04359628||Swedankle|Patients who underwent ankle replacement, fusion or osteotomies and registered in the Swedish ankle registry
62261207|NCT04359628||xBase|Patients with cruciate ligament injuries who received surgical treatment and were registered in the Anterior Cruciate Ligament Register
62261208|NCT04359628||SFR|Patients who received treatment in the Swedish Fracture Register
62057911|NCT01864928||Stroke population|Adults with ischemic stroke.
62057912|NCT03417947|PLACEBO_COMPARATOR|Placebo|Placebo identical to the vitamin D bolus in taste and appearance. The placebo will be administered once, at the beginning of the study. The oral liquid placebo will be prepared at the Pharmacy in coded syringes and will be administered to the participants by a nurse at the sickle cell disease Clinic.
62617768|NCT04424030||Multimodality imaging|Patients who have undergone echocardiography and cardiac MRI as part of their clinical management A research cardiac CT scan will be performed in eligible participants
62057913|NCT03417947|EXPERIMENTAL|Vitamin D bolus|The vitamin D bolus is an oral liquid supplement that will be administered once, at the beginning of the study. The oral liquid vitamin D bolus will be prepared at the Pharmacy in coded syringes and will be administered to the participants by a nurse at the sickle cell disease Clinic.The dose of vitamin D3 contained in the bolus is 300 000 IU.
62057914|NCT03552133|EXPERIMENTAL|Smart CO2|Effects of rebreathe device over two sleep nights on sleep apnea, hypoxemia, sleep state, and blood pressure.
62261209|NCT04359628||SHAR|Patients who underwent hip replacement therapy and registered in the Swedish Hip Arthroplasty Register
62261210|NCT04359628||SKAR|Patients with knee osteoarthritis and other diagnoses who underwent knee replacement or osteotomies and were registered in the Swedish Knee Arthroplasty Register
62261211|NCT04359628||Bipolär|Patients with Bipolar disorder receiving treatment and were registered in the Swedish National Register for Bipolar Disorder
62261212|NCT04359628||Swedevox|Patients with respiratory failure receiving technical respiratory assistance and were registered in the Swedish National Registry for Respiratory Failure
62446424|NCT03985592|EXPERIMENTAL|Offering a facilitated storytelling intervention session|At six months post-death, we will contact FMs and administer the Inventory of Complicated Grief-Revised (ICG-r), Brief Grief Questionnaire (BGQ), Impact of Events Scale - Revised (IES-r), Patient Health Questionnaire-9 (PHQ-9), and the Bereavement Dependency Scale (BDS). FMs who complete all questionnaires will be invited to participate in a 1-2-hour narrative exploration of their grief and bereavement experience, regardless of the severity of their symptoms. Those with severe symptoms will be notified of symptom severity, with a suggestion to participate in the narrative exploration of their grief and bereavement experience. Storytelling interventions require specialized resources but the results of Barnato et al., as well as the response to our qualitative interviews, suggest that this intervention may only be helpful for selected FMs. Storytelling interventions have been shown to reduce healthcare utilization and improve subjective health following a traumatic experience.
62446425|NCT01773564|ACTIVE_COMPARATOR|Available current hospital dressing|Control group: depending on the type of dressing available at the hospital, either 3M™ HP Dressing or Smith \& Nephew IV3000 ™
62446426|NCT01773564|EXPERIMENTAL|3M™ IV Advanced Securement dressing|New generation transparent dressing
62446427|NCT05234437|EXPERIMENTAL|Single arm open label|Single or multiple Intratumoural treatment of tigilanol tiglate at 3.6mg/m2 given at a minimum of 28-day intervals.
62617769|NCT04017871|EXPERIMENTAL|Interventional|10 days of intensive and structured motor therapy, 5 hours a day = 50h
62617770|NCT04017871|PLACEBO_COMPARATOR|Control|10 days of care and classic activities
62617771|NCT05933694|NO_INTERVENTION|Control|Participants to report 50 spirometry records alone
62057915|NCT03552133|NO_INTERVENTION|No intervention|Effects of control night, i.e. no intervention on sleep apnea, hypoxemia, sleep state, and blood pressure.
62261213|NCT04359628||PsoReg|Patients receiving systemic treatment for psoriasis and were registered in the Swedish Registry for Systematic Psoriasis Treatment
62261214|NCT04359628||SRQ|Patients with rheumatic disease receiving medical treatment and rehabilitation and were registered in the Swedish Rheumatology Quality Register
62261215|NCT04359628||SwedeHF|Patients who received treatments of different types in the Swedish Heart Failure Registry
62261216|NCT04359628||Swespine|Patients with spinal stenosis, disc hernia and related diagnoses receiving surgical spine treatment and were registered in the Swedish Spine Register
62261217|NCT04359628||Population health survey|Data of members of the general population who answered population surveys using the EQ-5D-3L instrument
62261218|NCT01433575|EXPERIMENTAL|A|
62261219|NCT01433575|EXPERIMENTAL|B|
62261220|NCT05096923||UNC-CAYACC|Children, adolescents, and young adults diagnosed with cancer before the age of 40 enrolled at any point during the diagnosis-treatment-survivorship continuum.
62261221|NCT01823042|EXPERIMENTAL|enteral nutrition+azathioprine|Patients is fasting and receive enteral nutrition and azathioprine treatment.
62261222|NCT01823042|EXPERIMENTAL|azathioprine|Patients have regular diet and receive only azathioprine treatment.
62261223|NCT06306521|EXPERIMENTAL|Enrollees|Enrolled infants will receive the BeginNGS test in addition to the state newborn screen.
62261224|NCT05454371|EXPERIMENTAL|Sample collection|This is a prospective study in which urine samples will be collected from healthy volunteers and urine samples and a blood sample from cancer patients with breast- or prostate cancer. The participants will be asked to provide a urine sample collected with the ColliPee® device and fill out an online questionnaire to collect usability data.
62261225|NCT05648890||Group 1|Patients above 65 years old undergoing surgery in general or regional anesthesia.
62261226|NCT03655184||MOH group|Patients with medication overuse headache
62261227|NCT03655184||Episodic migraine group|Patients with episodic migraine
62261228|NCT03655184||Healthy group|No headache or other special medical history
62261229|NCT06433609|EXPERIMENTAL|SHR-A1811+adebrelimab|
62057916|NCT06260735|EXPERIMENTAL|Treadmill training combined with muscle and spinal cord stimulation|Locomotor training is defined as walking on a treadmill with appropriate bodyweight support and augmented with muscle activation either by electrical nerve or muscle stimulation based on individual needs. Then, spinal stimulation will be integrated during training with on/off bouts alternating.
62261230|NCT06433609|EXPERIMENTAL|SHR-A1921+adebrelimab|
62261231|NCT05473403|EXPERIMENTAL|Corticosteroid therapy|Prednisone or Prednisolone or Methylprednisolone : Patient with ASAIH will be treated in oral or intravenous (IV) with high doses ( ≥ 1mg/kg/day) of corticosteroids (Prednisone or Prednisolone or Methylprednisolone) until relapse (confirmed by blood tests and clinical status) requiring an emergency Liver Transplantation (LT) or death.
62261232|NCT05473403|NO_INTERVENTION|Patient without corticosteroid therapy|Patient not treated will undergo to emergency Liver Transplantation (LT) or death.
62446428|NCT05267756|EXPERIMENTAL|intervention Group|"Patient will be receive .~1. usual care that included the education patients(e.g., information, and behavior modification advice techniques) based on the latest clinical practice guidelines (Qaseem et al., 2017 ; Delitto et al., 2012). Also, Patients understood their back problem by reassurance that the condition is not a serious disease and information about the nature of the disorder and prognosis and course of recovery. And what should be done to reduce worry (e.g., stay active and returning to normal activities as soon as possible, avoid worry, coping with having a sore back, and positive attitudes towards back pain are important). The given pamphlets produced by the Saudi Spine Society.~2. The intervention group will have in addition to the usual care, virtual reality immersive based-exercise game, the participants will download (kurki-application), and will given VR glasses"
62617772|NCT05933694|EXPERIMENTAL|Intervention|Participants report the same 50 spirometry records provided in the control arm with an artificial intelligence-powered spirometry interpretation report
62617773|NCT03039608|EXPERIMENTAL|combination group|combination of local steroid injection（triamcinolone ）with oral steroid administration（prednisone）
62617774|NCT03039608|ACTIVE_COMPARATOR|control group|oral steroid administration（prednisone）
62617775|NCT02033278|EXPERIMENTAL|Infusion of autologous mononuclear bone marrow cells|Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)
62617776|NCT02033278|PLACEBO_COMPARATOR|Placebo infusion|Placebo infusion plus conventional medical treatment (as indicated by clinician)
62617777|NCT04350177|ACTIVE_COMPARATOR|Single Ascending Dose (SAD)|In Part A, cohorts will consist of eight (8) subjects; six (6) of whom will receive treatment with IkT-148009 and two (2) with matching placebo.
62617778|NCT04350177|ACTIVE_COMPARATOR|Multiple Ascending Dose (MAD)|In Part B, cohorts will consist of eight (8) subjects; six (6) of whom will receive treatment with IkT-148009 and two (2) with matching placebo.
62617779|NCT04350177|ACTIVE_COMPARATOR|Multiple Ascending Dose (MAD) Parkinson's patients|In Part C, cohorts will consist of eight (8) patients; six (6) of whom will receive treatment with IkT-148009 and two (2) with matching placebo.
62617780|NCT03564093|EXPERIMENTAL|Dexmedetomidine|1µg/kg intranasal dexmedetomidine
62617781|NCT03564093|PLACEBO_COMPARATOR|Placebo|0,01ml/kg intranasal 4,5% saline
62057917|NCT02936050|OTHER|Intervention|"Experimental: Addition of diagnostic ultrasound performed by nurses at the outpatient heart failure clinic. Interpretation by specialist per telemedicine.~No Control arm"
62057918|NCT00962143|ACTIVE_COMPARATOR|Achilles repair without OrthADAPT Augmentation|Achilles repair without OrthADAPT Augmentation
62617782|NCT01101256||Fondaparinux Prophylaxis group|
62617783|NCT01101256||Fondaparinux Therapy group|
62617784|NCT02109445|EXPERIMENTAL|Phase 1|PF-03084014 in combination with gemcitabine and nab-paclitaxel
62617785|NCT02109445|EXPERIMENTAL|Phase 2 Arm A|PF-03084014 in combination with gemcitabine and nab-paclitaxel
62617786|NCT02109445|ACTIVE_COMPARATOR|Phase 2 Arm B|Gemcitabine plus nab-Paclitaxel
62617787|NCT01957943|PLACEBO_COMPARATOR|Control|38 patients Will receive standard oral diet 3 days before the operation will receive similar volume of 10% glucose solution Will receive same solution for 5 days postoperatively
62617788|NCT01957943|ACTIVE_COMPARATOR|OMEGA_PRE|38 patients Will receive standard oral diet 3 days before the operation will receive lipid supplementation 2 days before the operation with omega 3 enriched lipid emulsion (SMOFlipid) Will receive omega 3 enriched lipid emulsion (SMOFlipid) supplementation for 5 days postoperatively
62617789|NCT01957943|ACTIVE_COMPARATOR|OMEGA_POST|38 patients Will receive standard oral diet 3 days before the operation will receive glucose 10% solution 2 days before the operation Will receive omega 3 enriched lipid emulsion (SMOFlipid 20%) supplementation for 5 days postoperatively
62843314|NCT01099449|PLACEBO_COMPARATOR|Arm II|Patients receive placebo IV over 30 minutes immediately before and after oxaliplatin administration (part of FOLFOX chemotherapy).
62843315|NCT01099449|EXPERIMENTAL|Arm III|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and placebo IV over 30 minutes immediately after oxaliplatin administration (part of FOLFOX chemotherapy).
62843316|NCT06314828|EXPERIMENTAL|RJMty19 (CD19-CAR-DNT Cells)|The trial is divided into two parts: Part A is a dose escalation trial with four dose groups (5×10\^6 CAR+ cells/kg, 1×10\^7 CAR+ cells/kg, 2×10\^7 CAR+ cells/kg and 4×10\^7 CAR+ cells/kg at day 0), with 8-24 patients planned to be enrolled. Part B is a dose-expansion trial in which 3\~6 patients will receive RJMty19 infusions at RP2D dose levels.
62843317|NCT00734539|EXPERIMENTAL|1|fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
62843318|NCT00734539|PLACEBO_COMPARATOR|2|Placebo IV or PO twice weekly for 6 weeks
62843319|NCT02627261||patients with multiple myeloma|blood samples and bone marrow aspirates will be collected in patients at different time point
62843320|NCT01385527|EXPERIMENTAL|Weekly Internet survey w medication|Weekly survey via email plus topical triamcinolone
62843321|NCT01385527|ACTIVE_COMPARATOR|Topical triamcinolone only|Standard of care
62843322|NCT03298659|EXPERIMENTAL|Active iFR-guided revascularization|Decision to treat the nonculprit coronary stenosis if there is a significant pressure drop over the stenosis, as measured by intracoronary iFR assessment
62843323|NCT03298659|ACTIVE_COMPARATOR|Deferred CMR-guided revascularization|Decision to treat the nonculprit coronary stenosis if perfusion defect visible in corresponding coronary territory as visualized on stress perfusion CMR imaging
62057919|NCT00962143|EXPERIMENTAL|Achilles repair with OrthADAPT augmentation|Achilles repair with OrthADAPT augmentation
62057920|NCT06259643|EXPERIMENTAL|Power wheelchair soccer|soccer game performed with a wheelchair
62617790|NCT03765853|OTHER|Stretching Postural®|
62843324|NCT03566485|EXPERIMENTAL|Phase 2 (atezolizumab, cobimetinib)|Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62843325|NCT03566485|EXPERIMENTAL|Phase 1b - Atezolizumab 840mg IV + Idasanutlin 100mg PO|
62057921|NCT02056860||Group 1 will receive 15 Hz|Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
62057922|NCT02056860||Group 2 will receive 30 Hz|Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
62057923|NCT02056860||Group 3 will receive 60 Hz|Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz 2 .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
62057924|NCT02056860||Group 4 will receive 100 Hz|Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
62057925|NCT02056860||Phase II Optimal Frequency|Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
62617791|NCT03765853|NO_INTERVENTION|Control|
62617792|NCT02704559|EXPERIMENTAL|Study effect of DWC20156 on DWC20155 PK|To study effect of DWC20156 on DWC20155 PK
62057926|NCT04182763|EXPERIMENTAL|CoA-Z dose 1|6 months of CoA-Z at the highest assigned dose followed by 18 months of CoA-Z at dose 2
62057927|NCT04182763|EXPERIMENTAL|CoA-Z dose 2|6 months of CoA-Z at the medium assigned dose followed by 18 months of CoA-Z at dose 2
62057928|NCT04182763|EXPERIMENTAL|CoA-Z dose 3|6 months of CoA-Z at the lowest assigned dose followed by 18 months of CoA-Z at dose 2
62057929|NCT04182763|PLACEBO_COMPARATOR|Placebo|6 months of placebo, followed by 18 months of CoA-Z at dose 2 (medium dose)
62057930|NCT04182763|EXPERIMENTAL|Open-label arm|Up to 24 months of CoA-Z at dose 2
62057931|NCT05916976|OTHER|rTOF-patients|rTOF-patients with age 16 and above enrolled in Adult Congenital Heart Disease (ACHD)-outpatient clinics program with regularly scheduled MRI-exam
62057932|NCT01191203|ACTIVE_COMPARATOR|Depo Medroxyprogesterone Acetate|
62057933|NCT01191203|ACTIVE_COMPARATOR|Copper IUD (CuT360)|
62057934|NCT02676596|OTHER|Cohort 1|Japanese and Non-Japanese subjects receiving K-312 50 mg QD
62617793|NCT02704559|EXPERIMENTAL|Study effect of DWC20155 on DWC20156 PK|To study effect of DWC20155 on DWC20156 PK
62617794|NCT05229627||healthy control|healthy controls, screened by K-SADS-PL
62617795|NCT05229627||MPH induced Remission|patients show remission after 8-12 weeks of treatment with MPH
62617796|NCT05229627||non responder to MPH|patients don't show remission after 8-12 weeks of treatment with MPH
62617797|NCT05229627||ATX induced remission|patients show remission after 8-12 weeks of treatment with ATX
62843326|NCT02093819|EXPERIMENTAL|BI 416970 single rising dose part|single rising dose given as tablet
62843327|NCT04333719||terminally ill patients in specialized palliative|terminally ill patients in specialized palliative care facilities
62843328|NCT02677519|EXPERIMENTAL|10 mg Aptensio XR|10 mg methylphenidate, extended release
62843329|NCT02677519|EXPERIMENTAL|15 mg Aptensio XR|15 mg methylphenidate, extended release
62843330|NCT02677519|EXPERIMENTAL|20 mg Aptensio XR|20 mg methylphenidate, extended release once daily
62843331|NCT02677519|EXPERIMENTAL|30 mg Aptensio XR|30 mg methylphenidate, extended release
62843332|NCT02677519|EXPERIMENTAL|40 mg Aptensio XR|40 mg methylphenidate, extended release
62261233|NCT04851587|EXPERIMENTAL|In-Person (or Remote) Intervention Visits|Participants will initially complete a baseline assessment assessing study eligibility. The intervention includes 8 core in-person group sessions and 8 optional in-person group sessions (1.5 hours each) targeting standard weight loss and pain treatment content and eight individual phone calls (30 minutes each) focusing primarily on increasing environmental reward and positive affect. Intervention sessions may be delivered online through protected health information (PHI) Zoom. Group sessions will be delivered every-other week and phone calls will occur every-other week (during weeks with no group). Sessions will be administered by a study interventionist with bachelors- or masters-level training and certification in health education or a related field (e.g., Certified Health Education Specialist), and materials will be developed to be appropriate for delivery by this level of training, given the potential for greater availability of these types of health professionals.
62617798|NCT05229627||non responder to ATX|patients don't show remission after 8-12 weeks of treatment with ATX
62617799|NCT05968690|EXPERIMENTAL|Cohort 1 - Propranolol|"Patients will receive intravenous ipilimumab 3 mg/kg + nivolumab 1 mg/kg every 21 days for up to 4 cycles followed by intravenous nivolumab monotherapy 480 mg every 28 days.~Propranolol will be administered as 30 mg orally twice a day, continuously."
62261234|NCT01063374|ACTIVE_COMPARATOR|low glycemic index, diabetic diet|low glycemic index, diabetic diet
62617800|NCT05968690|EXPERIMENTAL|Cohort 2 - Propranolol + Naltrexone 4.5 mg|"Patients will receive intravenous ipilimumab 3 mg/kg + nivolumab 1 mg/kg every 21 days for up to 4 cycles followed by intravenous nivolumab monotherapy 480 mg every 28 days.~Propranolol will be administered as 30 mg orally twice a day, continuously.~Naltrexone will be administered as 4.5 mg orally once a day, continuously."
62617801|NCT05968690|EXPERIMENTAL|Cohort 3 - Propranolol + Naltrexone 9 mg|"Patients will receive intravenous ipilimumab 3 mg/kg + nivolumab 1 mg/kg every 21 days for up to 4 cycles followed by intravenous nivolumab monotherapy 480 mg every 28 days.~Propranolol will be administered as 30 mg orally twice a day, continuously.~Naltrexone will be administered as 9 mg orally once a day, continuously."
62617802|NCT05968690|EXPERIMENTAL|Cohort 4 - Propranolol + Naltrexone 25 mg|"Patients will receive intravenous ipilimumab 3 mg/kg + nivolumab 1 mg/kg every 21 days for up to 4 cycles followed by intravenous nivolumab monotherapy 480 mg every 28 days.~Propranolol will be administered as 30 mg orally twice a day, continuously.~Naltrexone will be administered as 25 mg orally once a day, continuously."
62617803|NCT05237739|EXPERIMENTAL|Test Group|Ten participants will be randomised to receive surgical periodontal treatment in the form of open flap debridement (OFD).
62843333|NCT02677519|EXPERIMENTAL|50 mg Aptensio XR|50 mg methylphenidate, extended release
62843334|NCT02677519|EXPERIMENTAL|60 mg Aptensio XR|60 mg methylphenidate, extended release
62617804|NCT05237739|ACTIVE_COMPARATOR|Control Group|Ten participants will be randomised to receive non-surgical periodontal treatment (NSPT). All treatment will be carried out by the same therapist, including oral hygiene.
62843335|NCT01734603|ACTIVE_COMPARATOR|conventional rehabilitation program|conventional rehabilitation program 20 patients are expected in this arm. Patients perform walking treadmill exercises with complete rest.
62843336|NCT01734603|EXPERIMENTAL|experimental rehabilitation program|experimental rehabilitation program 20 patients are expected in this arm. Patients perform walking treadmill exercises with active recovery (no stop walking).
62843337|NCT01080365|EXPERIMENTAL|1|Commercial Tablet
62843338|NCT01080365|EXPERIMENTAL|2|Clinical Tablet
62843339|NCT03112577|EXPERIMENTAL|REGN3500|REGN3500: masked and randomized dosing regimen per protocol (part 1 only)
62057935|NCT02676596|OTHER|Cohort 2|Japanese and Non-Japanese subjects receiving K-312 100 mg QD
62057936|NCT02676596|OTHER|Cohort 3|Japanese and Non-Japanese subjects receiving K-312 200 mg QD
62261235|NCT01063374|ACTIVE_COMPARATOR|high cereal fibre, diabetic diet|high cereal fibre, diabetic diet
62843340|NCT03112577|EXPERIMENTAL|Dupilumab|Dupilumab: masked and randomized dosing regimen per protocol (part 1 only)
62843341|NCT03112577|EXPERIMENTAL|REGN3500 plus dupilumab|REGN3500 plus dupilumab: masked and randomized dosing regimen per protocol (part 1 only)
62057937|NCT02676596|OTHER|Cohort 4|Japanese and Non-Japanese subjects receiving K-312 400 mg QD
62057938|NCT02676596|OTHER|Cohort 5|Japanese and Non-Japanese subjects receiving K-312 25 mg QD
62057939|NCT02676596|OTHER|Cohort 6|Japanese and Non-Japanese subjects receiving K-312 10 mg QD
62617805|NCT02493530|EXPERIMENTAL|Escalation and expansion|TGR1202 and Ruxolitinib combination
62617806|NCT00942539|EXPERIMENTAL|Midazolam|Administration of Midazolam prior Lumbar Puncture
62843342|NCT03112577|EXPERIMENTAL|Placebo|Placebo: masked and randomized dosing regimen per protocol (part 1 only)
62843343|NCT03112577|ACTIVE_COMPARATOR|Fluticasone propionate|Fluticasone propionate: open label dosing regimen per protocol (part 2 only)
62617807|NCT02234336||Subjects with HCM|All subjects will undergo noncontrast echocardiography, contrast echocardiography and cardiac MRI.
62617808|NCT03477721||Group with cancer cachexia (CTB)|For diagnosis of cachexia it will be used the following criteria (Evans et al., 2008)
62617809|NCT03477721||Group without cancer cachexia (TB)|
62617810|NCT02061423|EXPERIMENTAL|HER-2 Pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months.
62843344|NCT06519851|ACTIVE_COMPARATOR|• SSNB & SHAC|patients will receive general anesthesia + ultrasound guided suprascapular nerve block (SSNB) with 10 ml bupivacaine 0.25% deep to the transverse scapular ligament and Shoulder anterior capsule (SHAC) block with 30 ml bupivacaine 0.25% (20 ml deep to the deltoid muscle between the deltoid and subscapularis tendon \&10mL in the pericapsular space)
62843345|NCT06519851|PLACEBO_COMPARATOR|• Interscalene|patients will receive general anesthesia + ultrasound guided interscalene brachial plexus block (ISB) with 20 ml bupivacaine 0.25% around C5-C6-C7 nerve roots of the brachial plexus.
62843346|NCT03039712||Micra leadless pacemaker therapy|All Medicare patients implanted with Micra leadless pacemaker system
62843347|NCT03039712||Single Chamber Transvenous pacemaker|All Medicare patients implanted with full system (e.g. lead and generator) single- chamber ventricular transvenous pacemakers
62843348|NCT03665727|EXPERIMENTAL|Mindfulness|15 minute mindfulness session
62843349|NCT03665727|EXPERIMENTAL|Suggestion|15 minute therapeutic suggestion session
62843350|NCT03665727|ACTIVE_COMPARATOR|Psychoeducation|15 minute psychoeducation session
62261236|NCT05144035|EXPERIMENTAL|GH treatment group|GH treatment group (n = 68): the subjects were given PEG-rhGH injection 0.2 mg / kg / week (initial dose), once a week, subcutaneously before going to bed for 104 weeks. Each follow-up, the researchers adjusted the dosage according to the IGF-1 results of the center and other individual conditions.
62261237|NCT05144035|NO_INTERVENTION|Control group|Control group (n = 68): no treatment, only follow-up examination and growth and development related evaluation, and the follow-up time was 104 weeks.
62261238|NCT01952561|EXPERIMENTAL|2 weeks|
62617811|NCT04595084|EXPERIMENTAL|MBCT-R + CHA-MW|Mindfulness-Based Cognitive Therapy (MBCT) is an effective group intervention for depression and anxiety that combines mindfulness training with elements of cognitive therapy. This will be delivered with CHAMindWell mental wellness monitoring with CAT-MH and telephone coaching as needed.
62446429|NCT05267756|NO_INTERVENTION|Control Group|"Patient will be receive .~1. usual care that included the education patients(e.g., information, and behavior modification advice techniques) based on the latest clinical practice guidelines (Qaseem et al., 2017 ; Delitto et al., 2012). Also, Patients understood their back problem by reassurance that the condition is not a serious disease and information about the nature of the disorder and prognosis and course of recovery. And what should be done to reduce worry (e.g., stay active and returning to normal activities as soon as possible, avoid worry, coping with having a sore back, and positive attitudes towards back pain are important). The given pamphlets produced by the Saudi Spine Society.~2. The control group will have in addition to usual care that included the education patients, a Brochure for LBP therapeutic exercises"
62261239|NCT01952561|EXPERIMENTAL|1 week|
62261240|NCT01952561|EXPERIMENTAL|4 weeks|
62057940|NCT02947438|ACTIVE_COMPARATOR|Reference group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form:Injection Strength: 2000IU, 3000IU, 4000IU~Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks."
62446430|NCT04828161|EXPERIMENTAL|Phase 2 / Part A, ensovibep active treatment arm 1|Phase 2 / Part A: ensovibep active treatment arm 1
62057941|NCT02947438|EXPERIMENTAL|Experimental group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form: Injection Strength: 2000IU, 3000IU, 4000IU~Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks."
62057942|NCT01194284||High-grade osteosarcoma patients|
62057943|NCT02104492|EXPERIMENTAL|Intervention group|a 12-week respiratory muscles training program (RMTP) with ORYGEN Dual® device and peripheric resistive muscle training program
62261241|NCT01952561|EXPERIMENTAL|8 weeks|
62261242|NCT01952561|EXPERIMENTAL|12 weeks|
62261243|NCT02832973|EXPERIMENTAL|Spironolactone, Furosemide Amiloride|Spironolactone 25 mg qd, Furosemide 20 mg qd, Furosemide 40 mg qd, Amiloride 5 mg qd
62261244|NCT02832973|ACTIVE_COMPARATOR|Ramipril, Bisoprolol|Ramipril 5 mg qd, Ramipril 10 mg qd, Bisoprolol 5 mg qd, Bisoprolol 10 mg qd
62261245|NCT06090214|EXPERIMENTAL|Cases: adenocarcinoma of the ethmoid Group1|Liquid biopsy at the inclusion (V0), d8-d10 (V1) and m2-m3 (V2) of postoperative follow-up.
62261246|NCT06090214|ACTIVE_COMPARATOR|Age-matched controls Group 2|Liquid biopsy at the inclusion (V0) only
62261247|NCT06090214|ACTIVE_COMPARATOR|Exposition-matched controls Group 3|Liquid biopsy at the inclusion (V0) only
62446431|NCT04828161|EXPERIMENTAL|Phase 2 / Part A, ensovibep active treatment arm 2|Phase 2 / Part A: ensovibep active treatment arm 2
62617812|NCT04595084|ACTIVE_COMPARATOR|iCBT (MoodGym) + CHA-MW|MoodGym is a form of iCBT, which an evidence-based online program for depression, anxiety, stress and general psychological well-being. This will be delivered with CHAMindWell mental wellness monitoring with CAT-MH and telephone coaching as needed.
62617813|NCT04595084|ACTIVE_COMPARATOR|CHA-MW|Participants randomized to the CHA-MW arm will only receive CHAMindWell mental wellness monitoring with CAT-MH and telephone coaching as needed.
62617814|NCT01638195|EXPERIMENTAL|Externally Focused Ultrasound|
62843351|NCT03665727|NO_INTERVENTION|Usual Care|The usual care comparison group was comprised of patients who underwent total joint arthroplasty of the hip or knee at the same academic medical center during the study period but who did not attend Joint Academy.
62843352|NCT01214733|EXPERIMENTAL|1|
62843353|NCT01134705|EXPERIMENTAL|BDP HFA 320 µg/day|During the 6-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.
62843354|NCT01134705|PLACEBO_COMPARATOR|Placebo|During the 6-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.
62617815|NCT03731026|OTHER|Group 1|Patient will receive an IV injection of up to 200MBq 68Ga-RM2. Each patient will have torso PET/CT imaging at 2 timepoints. Alternate patients will have imaging at 1 and 2h post-injection then the next patientat 1 and 3h post-injection, with axillary gamma probe measurements (using a collimator) of 68Ga-RM2 at the same time points.
62843355|NCT05825352|EXPERIMENTAL|Eyedrops treatment arm|
62261248|NCT02909075||PET/CT scans and MRI|Eligible patients will be enrolled onto the study, and will undergo 3 limited field of view (FOV) FDG-PET/CT scans and MRI of the chest: at baseline (within 4 weeks prior to transplantation), and approximately 3 months (+/-2 weeks) and 6 months (+/-2 weeks) after transplant. PET/CT and MR imaging can be completed on the same day. We will also offer the exams on other days if this is easier for the patient. The PET/CT and MR should be performed within 2 weeks of each other.
62843356|NCT05296109|EXPERIMENTAL|Imaging group|patients with parotid tumour being imaged
62261249|NCT02093013|EXPERIMENTAL|Integrated care program|
62261250|NCT02093013|NO_INTERVENTION|Control group|This group kept receiving usual care from their health care professionals.
62261251|NCT04075474|EXPERIMENTAL|silver diamine fluoride|38% silver diamine fluoride
62261252|NCT04075474|ACTIVE_COMPARATOR|sodium fluoride|5% sodium fluoride
62261253|NCT02813694|EXPERIMENTAL|lefamulin|oral lefamulin, 600mg
62261254|NCT02813694|ACTIVE_COMPARATOR|Moxifloxacin|oral moxifloxacin, 400mg
62446432|NCT04828161|EXPERIMENTAL|Phase 2 / Part A, ensovibep active treatment arm 3|Phase 2 / Part A: ensovibep active treatment arm 3
62446433|NCT04828161|PLACEBO_COMPARATOR|Phase 2 / Part A, Placebo|Phase 2 / Part A: Placebo
62446434|NCT04828161|EXPERIMENTAL|Phase 3/ Part B, ensovibep active treatment arm 4|Phase 3/ Part B: ensovibep active treatment. Part B was not initiated.
62446435|NCT04828161|PLACEBO_COMPARATOR|Phase 3/ Part B, Placebo arm|Phase 3/ Part B: Placebo. Part B was not initiated.
62446436|NCT01132456|EXPERIMENTAL|Different patient subset|Patients with dual vessel treatment where each vessel has a lesion with length ≤ 27 mm and reference vessel diameters between 2.25 mm and 4.0 mm.
62446437|NCT01132456|EXPERIMENTAL|38 mm Cohort|Patients with at least one lesion amenable to treatment with a 38 mm length Endeavor Resolute stent. Patients may have one or two lesions, if the two lesions are located in separate target vessels.
62446438|NCT03640156|EXPERIMENTAL|Oxytocin (OXT) spray|Syntocinon nasal spray (product code RVG 03716) will be used to intranasally administer one single dose (24 IU) of OXT (3 puffs of 4 IU per nostril).
62446439|NCT03640156|PLACEBO_COMPARATOR|Placebo (PL) spray|Physiological water (a solution of sodium chloride (NaCl) in water) will be used to intranasally administer one single dose (24 IU) of PL (3 puffs of 4 IU per nostril).
62446440|NCT04592354|ACTIVE_COMPARATOR|Oxaloacetate Therapeutic Arm|"* Anhydrous Enol-Oxaloacetate~* A 500 mg oxaloacetate capsule taken by mouth twice a day~* Planned study duration is 6 weeks with an interim assessment at the end of 2 weeks and final assessment at 6 weeks"
62446441|NCT04592354|PLACEBO_COMPARATOR|Placebo Arm|"* Rice Flour~* A 500 mg rice flour capsule taken by mouth twice a day"
62446442|NCT04816097|ACTIVE_COMPARATOR|Steroid Group|Participants will receive 4 doses of dexamethasone 6mg IM 48h before elective CS.
62446443|NCT04816097|NO_INTERVENTION|No Steroid Group|Participants will receive No treatment before elective CS.
62446444|NCT06362993|NO_INTERVENTION|Control|Women in this arm receive education on breast cancer and are offered clinical breast exam free of charge at their local clinic for 6 months following the education session.
62843357|NCT06070961||Patients enrolled|Patient affected by advanced Follicular Lymphoma undergoing front-line immunochemotherapy and antiCD-20 maintenance in the FIL_FOLL19 trial
62057944|NCT02104492|ACTIVE_COMPARATOR|Control Group|Peripheric resistive muscle training program and Health Education Program.
62057945|NCT04138836|EXPERIMENTAL|Midazolam|
62057946|NCT04138836|EXPERIMENTAL|Itraconazole|
62446445|NCT06362993|EXPERIMENTAL|Bundling|Women in this arm receive education on breast cancer, diabetes, and hypertension, and are offered clinical breast exam and screening for diabetes and hypertension free of charge at their local clinic for 6 months following the education session.
62446446|NCT06362993|EXPERIMENTAL|Male Engagement in Gender and Health (MEGH)|Women in this arm receive education on breast cancer and are offered clinical breast exam free of charge at their local clinic for 6 months following the education session. In addition, women are requested to invite their male partners to attend the breast cancer education session and 7 weekly discussion group sessions (5 men-only and 2 with women). The discussion sessions aim to enable men to change gender attitudes and behaviors that deter women's healthcare utilization.
62843358|NCT01620216|EXPERIMENTAL|Group I (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62057947|NCT04138836|EXPERIMENTAL|Esomeprazole|
62057948|NCT01563848|ACTIVE_COMPARATOR|Group 1 (RFA CTI+Reveal)|assessing the incidence of atrial fibrillation in patients with atrial flutter
62261255|NCT00442780|PLACEBO_COMPARATOR|1|Dose Level A of BIIB014
62261256|NCT00442780|PLACEBO_COMPARATOR|2|Dose Level B of BIIB014
62261257|NCT00442780|PLACEBO_COMPARATOR|3|Dose Level C of BIIB014
62261258|NCT00442780|PLACEBO_COMPARATOR|4|Dose Level D of BIIB014
62261259|NCT03832491|OTHER|Control Group|"Home Based Therapy: 16 patients with PCD~Airway clearence techniques, everday of the week, during eight weeks"
62446447|NCT03565211|EXPERIMENTAL|Progesterone vaginal ring (PVR)|Treatment started on the day following oocyte retrieval and could be continued through Week 12 of pregnancy (10 weeks post-oocyte retrieval), depending on the participants pregnancy assessment. A new PVR was inserted every 7 days with up to 10 PVRs used.
62843359|NCT01620216|EXPERIMENTAL|Group II (sutinib malate)|Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62843360|NCT01620216|EXPERIMENTAL|Group III (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62057949|NCT01563848|ACTIVE_COMPARATOR|Group 2 (RFA CTI+Cryo PVI+Reveal)|efficacy of cryoablation in patients with atrial flutter
62446448|NCT02234297|EXPERIMENTAL|BLZ-100|
62446449|NCT01758302|ACTIVE_COMPARATOR|No physical task + Taste cookies|Participants in this arm do not engage in a physical activity task. They are asked to taste test chocolate chip cookies.
62843361|NCT01620216|EXPERIMENTAL|Group IV (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
62057950|NCT00889057|EXPERIMENTAL|sorafenib|
62057951|NCT02470858|EXPERIMENTAL|LDV/SOF+ASV|Participants with genotype 1b HCV infection will receive LDV/SOF FDC + ASV 3 weeks.
62446450|NCT01758302|ACTIVE_COMPARATOR|No physical task + Taste vegetable|Participant does not complete a physical activity. Asked to taste test raw celery or radishes.
62843362|NCT01620216|EXPERIMENTAL|Group V (pacritinib)|Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62843363|NCT01620216|EXPERIMENTAL|Group VI (ruxolitinib)|Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62843364|NCT01620216|EXPERIMENTAL|Group VII (idelalisib)|Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62843365|NCT00955916|EXPERIMENTAL|CLAG Regimen with Gleevec®|Combined chemotherapy treatment (CLAG regimen) with Gleevec® (imatinib mesylate).
62843366|NCT06370403|EXPERIMENTAL|Cooling of the head and neck in multiple sclerosis and healthy subjects|Multiple sclerosis and healthy male subjects participated in the head and neck cooling program. During cooling procedure, the participant performed fatiguing isometric motor task with a head and neck cooling helmet at (18°C next to the head and neck skin).
62843367|NCT06370403|EXPERIMENTAL|Heating of the head and neck in multiple sclerosis and healthy subjects|Multiple sclerosis and healthy male subjects participated in the head and heating program. During heating procedure, the participant performed fatiguing isometric motor task with a head and neck heating helmet at (43°C± 1°C next to the head and neck skin).
62843368|NCT03241719|EXPERIMENTAL|Treatment|Subjects who receive transplantation and undergo IL-2 treatment
62843369|NCT02724748|EXPERIMENTAL|Educational intervention|Beside usual care the intervention will encourage collaborative practices between staff, patients and family members to adopt more human patient-centred approach on the unit. The intervention is designed to impact on treatment culture and thereby treatment practices on the study wards.
62843370|NCT02724748|NO_INTERVENTION|Treatment as usual|Wards allocated to comparison wards continue with their usual care. No restrictions on how nursing staff works in these wards, although participation in corresponding projects is not supported.
62057952|NCT02470858|EXPERIMENTAL|SOF+DCV+SMV|Participants with genotype 1b HCV infection will receive SOF + DCV + SMV for 3 weeks.
62057953|NCT02470858|EXPERIMENTAL|SOF+DCV+ASV|Participants with genotype 1b HCV infection will receive SOF + DCV + ASV for 3 weeks
62843371|NCT01867697|ACTIVE_COMPARATOR|Biweekly cetuximab with continuously FOLFIRI|Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI (irinotecan 180 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)
62057954|NCT01546467|EXPERIMENTAL|Cognitive remediation|30 hour computer based cognitive remediation integrated in participants current rehabilitation program (school, work, day program)
62843372|NCT01867697|EXPERIMENTAL|Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6|Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI alternating with FOLFOX6 (Oxaliplatin: 85 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)
62843373|NCT03699215|PLACEBO_COMPARATOR|placebo|solution for intravenous infusion, with similar organoleptic characteristics than active treatment.
62057955|NCT01546467|NO_INTERVENTION|Wait list control group|Participant continues in treatment/rehabilitation program as usual until 9 month assessment when participant receives the same cognitive remediation program as the experimental group.
62057956|NCT03988582|EXPERIMENTAL|HCT (hematopoietic cell transplant) recipients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
62446451|NCT01758302|ACTIVE_COMPARATOR|Simple physical task + Taste vegetables|Participants are asked to complete a simple physical task and are asked to taste test raw celery or radishes.
62843374|NCT03699215|EXPERIMENTAL|levosimendan|Concentrate for solution for perfusion. Pack with a 5 ml vial
62843375|NCT00578734|EXPERIMENTAL|Lucinactant|SURFAXIN® (lucinactant) for intratracheal instillation
62843376|NCT00578734|SHAM_COMPARATOR|Sham Air|Sham air (placebo) instillation
62843377|NCT02709382|EXPERIMENTAL|FEP-TAZ|Cefepime and Tazobactam combination; IV infusion over a period of 90 minutes Healthy subjects, Mild and Moderate RI: 4 g (2 g FEP and 2 g TAZ) Severe RI and patients on HD: 2 g (1 g FEP and 1 g TAZ)
62843378|NCT02135913|EXPERIMENTAL|Viatamin D|All children enrolled into the study will be prescribed standard of care vitamin D.
62446452|NCT01758302|ACTIVE_COMPARATOR|Complex physical task + Taste vegetables|Participants complete a more complex physical task that is novel and challenging. They are asked to taste test raw celery or radishes.
62843379|NCT04870489|ACTIVE_COMPARATOR|Isotretinoin + Co2 ablative laser|Isotretinoin treatment while being treated with CO2 laser
62843380|NCT04870489|ACTIVE_COMPARATOR|Co2 ablative laser|6 months to 1 year without isotretinoin treatments to start second side of face with CO2 ablative laser only
62446453|NCT01011322|EXPERIMENTAL|LT-02 Dose 1|0.2g IMP per dose
62843381|NCT00742261|EXPERIMENTAL|GSK1363089|Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
62843382|NCT06223165|EXPERIMENTAL|Foundations, Condoms & Contraception, Family Strengthening, and Gender & Relationships|This arm receives the constant session (Foundations in Sexual Risk Prevention) and all three other workshop sessions: 1) Condoms \& Contraception, 2) Family Strengthening, and 3) Gender \& Relationships.
62446454|NCT01011322|EXPERIMENTAL|LT-02 Dose 2|0.4g IMP per dose
62446455|NCT01011322|EXPERIMENTAL|LT-02 Dose 3|0.8g IMP per dose
62446456|NCT01011322|PLACEBO_COMPARATOR|Sugar pill|placebo matching to 0g of IMP,
62617816|NCT03731026|EXPERIMENTAL|Group 2|WLE will be performed as per standard of care but will also include Intraoperative LightPath® Imaging with 68Ga-RM2. Group 2 scans will acquire LightPath® images of both intact and incised cancer specimens with varying parameters to optimise imaging.
62617817|NCT03731026|EXPERIMENTAL|Group 3|WLE will be performed as per standard of care but will also include Intraoperative LightPath® Imaging with 68Ga-RM2. Group 3 scans will acquire LightPath® images of intact and incised cancer specimens using a final and consistent imaging procedure.
62617818|NCT02392702|ACTIVE_COMPARATOR|C-10355, 25 mg|single oral dose.
62617819|NCT02392702|ACTIVE_COMPARATOR|C-10358, 25 mg|single oral dose.
62617820|NCT02392702|ACTIVE_COMPARATOR|C-10355 or C-10358, 75 mg|single oral dose.
62617821|NCT02392702|ACTIVE_COMPARATOR|C-10355 or C-10358, 150 mg|single oral dose.
62261260|NCT03832491|EXPERIMENTAL|Game and home based therapy group|"Game based approach programme: 16 patients with PCD~Game based approach programme will be done using the exergame with the game console, fourty minutes three times per week for eight weeks.~Exergame includes five games selected from two kinects games CD. Each game will be played for five games set.~Airway clearence techniques, everday of the week, during eight weeks"
62617822|NCT02392702|ACTIVE_COMPARATOR|Kalydeco, 150 mg|single oral dose.
62617823|NCT02392702|ACTIVE_COMPARATOR|C-10355 or C-10358, 300 mg|single oral dose.
62617824|NCT01539928||lung cancer or high suspicion of lung cancer|After initial work-up (chest x-ray, CT of thorax and upper abdomen, spirometry) found to have surgically resectable lung cancer
62617825|NCT02756598|ACTIVE_COMPARATOR|Sufentanil I|"Randomized arm moderate sufentanil I: bolus 1 microgram/kg propofol I: infusion 0.03 mg/kg/min"
62617826|NCT02756598|ACTIVE_COMPARATOR|Sufentanil II|"Randomized arm low sufentanil II bolus 0.5 microgram/kg propofol II: infusion 0.06 mg/kg/min"
62843383|NCT06223165|EXPERIMENTAL|Foundations, Condoms & Contraception, and Family Strengthening|This arm receives the constant session (Foundations in Sexual Risk Prevention) and two other workshop sessions: 1) Condoms \& Contraception and 2) Family Strengthening.
62843384|NCT06223165|EXPERIMENTAL|Foundations, Condoms & Contraception, Gender & Relationships|This arm receives the constant session (Foundations in Sexual Risk Prevention) and two other workshop sessions: 1) Condoms \& Contraception and 2) Gender \& Relationships.
62843385|NCT06223165|EXPERIMENTAL|Foundations, Family Strengthening, and Gender & Relationships|This arm receives the constant session (Foundations in Sexual Risk Prevention) and two other workshop sessions: 1) Family Strengthening and 2) Gender \& Relationships.
62261261|NCT03912675|EXPERIMENTAL|RigeneraTM protocol|Teatment with Integra® dermal substitute enriched with the autologous dermal micro-grafts obtained with RigeneraTM protocol.
62617827|NCT04437446|EXPERIMENTAL|Case Group|"The Case group corresponds to patients with glaucoma following the clinical criteria for glaucoma:~* papilla excavation\> 5/10 with altered ISNT rule, or neuro-retinal rhyme characteristic of glaucoma, or fiber alterations characteristic of glaucoma.~* OCT with typical alterations (loss of the layer of nerve fibers or loss of these ganglion cells), loss of fibers typical of glaucoma.~* Humphrey 24: 2 visual fields produced, reliable and typical of glaucoma.~The assignment to the Cas group will be carried out by an ophthalmologist specializing in glaucoma according to the following criteria:~- The intraocular pressure must be increased before the start of treatment (21 mmHg or more), except in cases of normal pressure glaucoma.~The additional examination corresponds to an OCTA alone leading to an extension of the duration of the consultation by 5 minutes."
62617828|NCT04437446|EXPERIMENTAL|Control Groupe|"The Control group corresponds to patients with no glaucoma, no suspicion or history of glaucoma, ocular hypertension, or alterations detected during the ophthalmological consultation.~Witnesses will be matched to cases by age (+/- 5 years) and gender.~For patients in this group, the additional examinations correspond to a visual field, an OCT and an OCTA leading to an extension of the duration of the consultation by 35 minutes."
62843386|NCT06223165|EXPERIMENTAL|Foundations and Condoms & Contraception|This arm receives the constant session (Foundations in Sexual Risk Prevention) and one other workshop session: Condoms \& Contraception.
62843387|NCT06223165|EXPERIMENTAL|Foundations and Family Strengthening|This arm receives the constant session (Foundations in Sexual Risk Prevention) and one other workshop session: Family Strengthening.
62261262|NCT03912675|EXPERIMENTAL|Control|Treatment with Integra® dermal substitute only.
62261263|NCT06072326|EXPERIMENTAL|Treatment order 1|Subjects will start with 4 weeks of Ambrisentan in treatment period 1. In period 2 subjects will receive Sotagliflozin. In period 3 subjects will receive a combination of Ambrisentan and Sotagliflozin. Between treatment periods there is a 4-week wash-out.
62261264|NCT06072326|EXPERIMENTAL|Treatment order 2|Subjects will start with 4 weeks of Ambrisentan in treatment period 1. In period 2 subjects will receive a combination of Ambrisentan and Sotagliflozin. In period 3 subjects will receive Sotagliflozin. Between treatment periods there is a 4-week wash-out.
62617829|NCT01140412|EXPERIMENTAL|Cohort 1|Twice daily regimen
62617830|NCT01140412|EXPERIMENTAL|Cohort 2|Once daily regimen
62617831|NCT02814617|EXPERIMENTAL|Cordyceps sinensis mycelium culture extract|Cordyceps sinensis mycelium culture extract 1.68 g
62617832|NCT02814617|PLACEBO_COMPARATOR|Placebo|Placebo
62843388|NCT06223165|EXPERIMENTAL|Foundations and Gender & Partner Relationships|This arm receives the constant session (Foundations in Sexual Risk Prevention) and one other workshop session: Gender \& Relationships.
62617833|NCT06200272|EXPERIMENTAL|Test group with standard whole wheat breads (Germ and Carob Molasses Pulp added)|Bread will be produced by adding germ (obtained after processing the wheat grain), which has a high antioxidant capacity and is rich in vitamins and dietary fiber, and carob pulp (Carob Molasses Pulp, CMP), which is not considered waste after the production of carob molasses, to the formulation of wheat bread, which has been widely consumed in recent years.
62843389|NCT06223165|EXPERIMENTAL|Foundations|This arm receives the constant session (Foundations in Sexual Risk Prevention) only.
62057957|NCT03988582|EXPERIMENTAL|SOT (solid organ transplant) recipients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
62057958|NCT03988582|EXPERIMENTAL|Other immune competent or immune compromised patients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
62057959|NCT06296823|EXPERIMENTAL|Meal timing|Three days of meals, bedtimes and wake times scheduled to occur 5h earlier.
62617834|NCT06200272|NO_INTERVENTION|Control group with standard whole wheat breads|control bread (whole wheat bread) made based on a standard recipe
62057960|NCT06296823|EXPERIMENTAL|Bright light|Three days of exposure to bright light of \~3,000 lux, which is less than one-third the brightness of a sunrise or sunset (timed to start earlier by 1h each day) with scheduled bed and wake times timed 5h earlier.
62261265|NCT06072326|EXPERIMENTAL|Treatment order 3|Subjects will start with 4 weeks of Sotagliflozine in treatment period 1. In period 2 subjects will receive a combination of Ambrisentan and Sotagliflozine. In period 3 subjects will receive Ambrisentan. Between treatment periods there is a 4-week wash-out.
62843390|NCT05386407|EXPERIMENTAL|telemedically assisted guided oropharyngeal + nasal (OP+N) self-sampling (GSS): OP+N GSS|After performing the telemedically assisted OP+N GSS procedure, the patients will continue to be sampled by HCP OP+N and HCP NP.
62843391|NCT05386407|EXPERIMENTAL|unsupervised OP+N self-sampling (USS): OP+N USS|"Written instructions on how to perform a self-test will be provided, representing the instructions that come along with a commercially available rapid test set. An instructional online video tutorial or similar would also account as the latest state of the art.30 However, this has not yet been implemented comprehensively with all available test sets.~After performing the OP+N USS procedure, the patients will continue to be sampled by HCP OP+N and HCP NP."
62057961|NCT02996357||Cases|Patients with IAD Category 2 (red skin with skin breakdown)
62057962|NCT02996357||Controls|Patients with IAD Cat. 0 (at risk, no redness and skin intact)
62057963|NCT05760807|EXPERIMENTAL|Intranasal oxytocin|Participants will receive oxytocin by intranasal spray under clinician supervision (1 insufflation equating to an active dose of 24 IU) twice daily (i.e., 48 IU per day), delivered over 7 days of a residential inpatient withdrawal admission.
62843392|NCT00479427|EXPERIMENTAL|Overall study|overall study population
62057964|NCT02643862|ACTIVE_COMPARATOR|xolair|Pts will be randomized to receive xolair at a 3 active:1 placebo ratio
62057965|NCT02643862|PLACEBO_COMPARATOR|Placebo|This is a placebo that looks similar to Xolair and is given as a subcutaneous shot, just like Xolair
62057966|NCT04038528||Telemedicine Group|Patients in this group monitor blood sugar levels at home and upload their data through a telemedicine systems.
62057967|NCT04038528||Control Group|The control group will attend their routine appointments scheduled by their GPs and specialists in outpatient clinics and will record blood sugar levels according to the traditional method as per GP or specialist physician's indications.
62446457|NCT01880333|EXPERIMENTAL|Children on Modified Atkin Diet|
62843393|NCT00126490|EXPERIMENTAL|Treatment (bevacizumab, aldesleukin)|Patients receive bevacizumab IV over 30-90 minutes on day 1 in weeks 1, 3, 5, 7, 9, and 11. Patients also receive interleukin-2 subcutaneously on days 1-5 in weeks 5-10. Treatment repeats every 12 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease then receive bevacizumab alone in weeks 1, 3, 5, 7, 9, and 11. Courses with bevacizumab alone repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
62057968|NCT00634816||Chemotherapy recipients|Subjects who have undergone chemotherapy will receive DXA scan
62057969|NCT04441281|ACTIVE_COMPARATOR|Single-tooth tenaculum (Pozzi forceps)|In the control arm, a single-tooth tenaculum, Pozzi forceps, used during routine IUD insertion, is employed to hold and stabilize the cervix.
62057970|NCT04441281|EXPERIMENTAL|AspivixTM cervical vacuum tenaculum|In the experimental arm, the investigational AspivixTM cervical vacuum tenaculum is employed to hold and stabilize the cervix.
62057971|NCT00448890|EXPERIMENTAL|GSK729327|Dose escalation from 1.0mg to 6 mg.
62057972|NCT00448890|PLACEBO_COMPARATOR|Placebo|
62261266|NCT06072326|EXPERIMENTAL|Treatment order 4|Subjects will start with 4 weeks of Sotagliflozine in treatment period 1. In period 2 subjects will receive Ambrisentan. In period 3 subjects will receive a combination of Ambrisentan and Sotagliflozin. Between treatment periods there is a 4-week wash-out.
62446458|NCT00434161|ACTIVE_COMPARATOR|Palifermin before only|Subjects received palifermin before-high dose chemotherapy (total 3 doses) and matched placebo after-high dose chemotherapy (total 3 doses)
62446459|NCT00434161|PLACEBO_COMPARATOR|Placebo (suger pill)|Subjects received matched placebo before- and after-high dose chemotherapy
62446460|NCT00434161|ACTIVE_COMPARATOR|Palifermin before and after|Subjects received palifermin before- and after-high dose chemotherapy (total of 6 doses)
62446461|NCT04782830|EXPERIMENTAL|placebo|Placebo pill will be taken for 7 days at the same frequency as their regular treatment with either midodrine or atomoxetine.
62446462|NCT04782830|ACTIVE_COMPARATOR|Standard treatment|Either midodrine or atomoxetine at their regular dose.
62446463|NCT01385410|ACTIVE_COMPARATOR|CPS, cell phone based peer support|Cell phone base peer mother support for continued exclusive breastfeeding
62843394|NCT01579136|NO_INTERVENTION|Control group|This group will not get a home blood pressure monitor.
62843395|NCT01579136|EXPERIMENTAL|Home monitors|This group will be given a home blood pressure monitor to use.
62843396|NCT06032793|EXPERIMENTAL|Deep breathing exercise|"This group will perform following exercises:~Pursed lip breathing, Diaphragmatic breathing and powered breathing for 3-4 times a day for 6 weeks."
62057973|NCT03404102||university clinic|"* Enrollment: 200 Subjects will be enrolled from women attending family planning clinic for Cu- IUD insertion~* Informed Consent: All participants will give their informed consent prior to enrollment.~* Data collection \& recording: Data of each patient will be recorded in a Case Record Form (CRF).~* Follow up visits /questionnaire: will be conducted from each subject at 6 months and 12 months after Cu-IUD insertion. User satisfaction score and haemoglobin serum level will be included in the questionnaire."
62057974|NCT03404102||primary healthcare unit clinic|"* Enrollment: 200 Subjects will be enrolled from women attending family planning clinic for Cu- IUD insertion~* Informed Consent: All participants will give their informed consent prior to enrollment.~* Data collection \& recording: Data of each patient will be recorded in a Case Record Form (CRF).~* Follow up visits /questionnaire: will be conducted from each subject at 6 months and 12 months after Cu-IUD insertion. User satisfaction score and haemoglobin serum level will be included in the questionnaire."
62261267|NCT06072326|EXPERIMENTAL|Treatment order 5|Subjects will start with 4 weeks of a combination of Ambrisentan and Sotagliflozin in period 1. In period 2 subjects will receive Ambrisentan. In period 3 subjects will receive Sotagliflozin. Between treatment periods there is a 4-week wash-out.
62843397|NCT06032793|NO_INTERVENTION|No Intervention|This group will not perform any exercise.
62057975|NCT05285462|ACTIVE_COMPARATOR|Usual Care PT|Patients will attend normal course of PT without influence from study team.
62057976|NCT05285462|EXPERIMENTAL|Usual Care PT + VR Pain Education|Patients will attend normal course of PT without influence of duration or frequency of care. Patients will also receive up to 12 session of pain education delivered via VR headset
62261268|NCT06072326|EXPERIMENTAL|Treatment order 6|Subjects will start with 4 weeks of a combination of Ambrisentan and Sotagliflozin in period 1. In period 2 subjects will receive Sotagliflozin. In period 3 subjects will receive Ambrisentan. Between treatment periods there is a 4-week wash-out.
62261269|NCT05279144|EXPERIMENTAL|Experimental|Ventrogluteal region IM injection will be applied to the children in the intervention group, which is recommended by the literatureIn order to ensure that the children in the groups are similar in terms of two factors (same drug, same nurse) in the assignment, they will be assigned to the groups first by stratified sampling method and then by simple random sampling (http://www1.assumption.edu/users/avadum/applets/RandAssin/Groupgen). .html). In the case of a 5% margin of error and an effect width of 0.70 at 80% power, the total number of patients, including 40 control and 40 intervention groups, who met the inclusion criteria of the study, was determined as 80.
62843398|NCT00629369|EXPERIMENTAL|A|subjects with Occlusion Support Device with active pushing in the second stage of labor
62843399|NCT00629369|NO_INTERVENTION|2|Subjects without Occlusal Support Device with active pushing in the second stage of labor
62843400|NCT00426244|SHAM_COMPARATOR|Placebo Ultrasound|"In addition to controlling for physician attention during the treatment visit, the SUT used a nonfunctional ultrasound therapy unit that was modified for research purposes to provide both visible and auditory cues that could potentially elicit a placebo response. The physician provided the SUT by placing the applicator head over the subject's clothing and applying sufficient pressure for tactile stimulation of the skin and underlying tissues in the same anatomical distributions as would generally be addressed if the subject were being treated with OMT.~The subjects assigned to the UOBC only group did not receive any study treatments beyond conventional obstetrical care; however, they were expected to complete data collection forms on the same schedule as all other trial subjects."
62843401|NCT00426244|ACTIVE_COMPARATOR|Osteopathic Manipulative Treatment|OMT is a complementary and alternative body-based treatment method in which the patient is evaluated and treated including the musculoskeletal system to improve physiologic functioning and remove impediments to optimal health and functioning.
62843402|NCT00426244|NO_INTERVENTION|Standard Care|Subject only receives care from her OB provider. Subjects were allowed to receive conventional obstetrical care with the exception of OMT, massage therapy, physical therapy, chiropractic manipulation, or therapeutic ultrasound intended to treat musculoskeletal disorders.
62843403|NCT03929497|EXPERIMENTAL|Lu AF11167|
62843404|NCT03008200||RDS +|postpartum RDS developed group
62261270|NCT05279144|NO_INTERVENTION|No Intervention|Vastus Lateralis IM injection, which is the routine practice of the clinic, will be applied to the children in the control group of the study. In order to ensure that the children in the groups are similar in terms of two factors (same drug, same nurse) in the assignment, they will be assigned to the groups first by stratified sampling method and then by simple random sampling (http://www1.assumption.edu/users/avadum/applets/RandAssin/Groupgen). .html). In the case of a 5% margin of error and an effect width of 0.70 at 80% power, the total number of patients, including 40 control and 40 intervention groups, who met the inclusion criteria of the study, was determined as 80.
62617835|NCT02350699||Control|Nautilus BrainPulse
62843405|NCT03008200||RDS -|postpartum RDS undeveloped group
62057977|NCT05133050|EXPERIMENTAL|Experimental group|Drug: Ramipril The initial dose of ramipril is 2.5 mg /d. The blood pressure, blood potassium and blood creatinine is measured every 1-2 weeks. If the blood pressure is normal, the dose of ramipril is adjusted to 5 mg /d after 2 weeks. If the blood pressure is low, the dose of ramipril is reduced to 1.25 mg /d until the blood pressure becomes normal, otherwise, stop ramipril using. If the blood potassium is high (\>5.5mmol/L), the dose of ramipril is reduced to 1.25 mg /d until the blood potassium becomes normal, otherwise, stop ramipril using. If the blood creatinine is higher before therapy (≥30%), the dose of ramipril is reduced to 1.25 mg /d until the blood creatinine becomes normal, otherwise, stop ramipril using.
62057978|NCT05133050|NO_INTERVENTION|Control group|No angiotensin converting enzyme inhibitor (ACEI) and other renin-angiotensin system inhibitors (including angiotensin II receptor antagonists, etc.) treatment.
62057979|NCT05912140||Trunk Aesthetic Clinical Evaluation|
62261271|NCT03521024|ACTIVE_COMPARATOR|lithium disilicate crowns|lithium disilicate crowns are well documented in the literatures as successful restoration modality.
62261272|NCT03521024|EXPERIMENTAL|poly ether ketone ketone crowns|pekkton
62261273|NCT02511730|EXPERIMENTAL|FFDM Plus DBT|Breast Images with FFDM and DBT
62261274|NCT02511730|ACTIVE_COMPARATOR|FFDM Alone|Breast Images with FFDM alone
62261275|NCT06475417|EXPERIMENTAL|Adebrelimab combined with DOS|After signing the informed consent, they are screened to meet the inclusion criteria. After receiving the standard dose of adebrelimab combined with DOS regimen for 3 courses of treatment before surgery, and within 3-6 weeks after the completion of the third administration, preoperative imaging examination is used to evaluate the efficacy of new adjuvant treatment and the possibility of radical D2 resection, The patient underwent radical surgical treatment for gastric cancer and observed pCR.
62057980|NCT02943941|OTHER|All participants|All participants enrolled in a single arm to evaluate effect of variables (posture, respiration, exertion) on pulmonary artery pressure (PAP)
62057981|NCT01772784|EXPERIMENTAL|phenolic acids|Maltodextrine + Phenolic acids
62057982|NCT01772784|PLACEBO_COMPARATOR|placebo|Maltodextrine
62057983|NCT01772784|EXPERIMENTAL|phenolic acid|Maltodextrine + Phenolic acids
62057984|NCT01772784|ACTIVE_COMPARATOR|polyphenol|
62057985|NCT01438788|EXPERIMENTAL|All patients on a low protein diet|
62057986|NCT06383780|ACTIVE_COMPARATOR|GP combined with Tislelizumab|Gemcitabine combined with cisplatin regimen combined with Tislelizumab
62057987|NCT06383780|EXPERIMENTAL|TPC combined with Tislelizumab|cisplatin, nab-paclitaxel and capecitabine regimen combined with Tislelizumab
62261276|NCT03227900|ACTIVE_COMPARATOR|Lidocaine|LIdocaine dissolved in water for injections
62261277|NCT03227900|PLACEBO_COMPARATOR|Placebo|Water for injections
62057988|NCT06212908|OTHER|Breast cancer|"The division was made into 2 groups: Patients with breast cancer and gingivitis (BC/G) (n=20); and control patients with gingivitis only (G) (n=20).~Clinical periodontal examinations were carried out by a single trained and calibrated examiner. Clinical periodontal, hematological and salivary flow parameters were assessed at baseline, 6 weeks, 12 and 24 weeks."
62617836|NCT04114214||patients with suspected infection or sepsis|All patients admitted with suspected infection or sepsis from January 2018 to February 2018 at Prince of Wales Hospital
62617837|NCT04125940|PLACEBO_COMPARATOR|Placebo-controlled Arm|Placebo - 12oz water with food coloring
62617838|NCT04125940|ACTIVE_COMPARATOR|1 serving Resync Arm|12oz water + 7.5g Resync
62617839|NCT04125940|ACTIVE_COMPARATOR|2 servings Resync Arm|12oz water + 15g Resync
62843406|NCT03448913||PECS block+ General anesthesia|Patients undergoing mastectomy, partial mastectomy and/or axillary clearance who received PECS block AND general anesthesia for the surgery.
62843407|NCT03448913||General anesthesia|Patients undergoing mastectomy, partial mastectomy and/or axillary clearance who received general anesthesia only for the surgery.
62843408|NCT00551278||1|Patients with previous diagnosis of breast cancer scheduled for sentinel lymph node dissection.
62843409|NCT03282214|EXPERIMENTAL|Self-management energy conservation|Thai women with breast cancer randomized to the group will receive four sessions approximately every three weeks with the PI. The women will be instructed on how to do a self-management energy conservation program.
62261278|NCT05959135||Diabetic term pregnant patients|Compare the antral cross-sectional area (CSA) with gastric ultrasonography and estimated gastric volumes calculated with Perlas and Roukhomovsky mathematical models
62446464|NCT01385410|ACTIVE_COMPARATOR|PSG, group meeting based peer support|Group based peer Cell phone base peer mother support for continued exclusive breastfeeding
62057989|NCT00968435|EXPERIMENTAL|(IMRT) + cisplatin + bevacizumab + cetuximab|This is a single-institution, non-randomized, phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab + cetuximab.
62057990|NCT03661502|EXPERIMENTAL|variable tidal volume ventilation (VVV)|the intervention is using a ventilation mode with variable tidal volume. The average tidal volume is 6 ml/kg and respiratory rate adapted to reach an end tidalCO2 concentration between 30 and 50 mmHg. Lung recruitment is given when dynamic lung compliance drops below 40. No drug is given. No other treatment or intervention is given.
62261279|NCT05959135||Non-Diabetic term pregnant patients|Compare the antral cross-sectional area (CSA) with gastric ultrasonography and estimated gastric volumes calculated with Perlas and Roukhomovsky mathematical models
62446465|NCT01385410|NO_INTERVENTION|Control|Current standard of care and support (national health system)
62446466|NCT03495648|EXPERIMENTAL|Walking Group (Low Engagers)|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market. Low engagers are defined as those participants who walked to the market two or fewer times during the program.
62446467|NCT03495648|EXPERIMENTAL|Walking Group (High Engagers)|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market. High engagers are defined as those participants who walked to the market three or more times during the program.
62446468|NCT03231839|PLACEBO_COMPARATOR|Caloric restriction (control)|daily reduction of caloric intake aimed at 400 kcal/day
62446469|NCT03231839|ACTIVE_COMPARATOR|No red meat|daily reduction of caloric intake aimed at 400 kcal/day plus no red meat intake
62446470|NCT03231839|ACTIVE_COMPARATOR|Increased fiber intake|daily reduction of caloric intake aimed at 400 kcal/day plus increased fiber intake (aim: 40gr/day)
62446471|NCT01512381|EXPERIMENTAL|CRT|
62446472|NCT01512381|ACTIVE_COMPARATOR|pacemaker|
62446473|NCT01442909|ACTIVE_COMPARATOR|D followed by P|Docetaxel 60 mg/m2 intravenous infusion (IV) day 1 every 3 weeks for 4-6 cycles (stable disease up to 4 cycles, partial or complete response up to 6 cycles), followed by pemetrexed 500 mg/m2 IV day 1 every 3 weeks for 4-6 cycles (stable disease up to 4 cycles, partial or complete response up to 6 cycles).
62446474|NCT01442909|ACTIVE_COMPARATOR|P followed by D|"Pemetrexed treatment followed by docetael (in reverse sequence of Arm D followed by P"
62446475|NCT00720850|EXPERIMENTAL|lenalidomide|lenalidomide therapy p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT
62446476|NCT01683617|EXPERIMENTAL|A treatment based on CBT and new technologies|Individuals will receive a treatment based on cognitive behavioral therapy and new technologies (virtual reality, virtual reality combined to biofeedback and mobile phones). Relaxation will be induced through the immersion in different virtual environments (e.g., lake) which will be customized with different pre-recorded audio narratives that describe the specific setting and that guide the execution of a series of relaxation exercises. During biofeedback exercises a wearable biosensor system will provide suggestions to the trainer based on the reactions of the participants, and the biosensor data will directly modify the virtual reality experience in real time.
62446477|NCT01683617|ACTIVE_COMPARATOR|Traditional treatment based on CBT|Participants will receive a treatment based on traditional cognitive behavioral therapy techniques for stress management, without the use of new technologies. Relaxation will be induced by guided imagery, through auditory narratives.
62446478|NCT02736227|EXPERIMENTAL|Tacrolimus Withdrawal and Everolimus Monotherapy|Tacrolimus will be tapered while continual use of everolimus.
62446479|NCT01101009|ACTIVE_COMPARATOR|Perindopril+amlodipine|
62446480|NCT01101009|ACTIVE_COMPARATOR|Olmesartan/amlodipine|
62446481|NCT02627027|EXPERIMENTAL|RT group|R: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T) T: Test drug(CKD-395 0.25/750 mg 2T)
62617840|NCT04125940|ACTIVE_COMPARATOR|1 servings Resync+Collagen Arm|12oz water + 17g collagen + 2g Resync + 1g Carbohydrates
62446482|NCT02627027|EXPERIMENTAL|TR group|T: Test drug(CKD-395 0.25/750 mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T)
62446483|NCT00992069|EXPERIMENTAL|TMC207 alone and with EFV|Participants will receive single-dose TMC207 alone and then single-dose TMC207 with EFV.
62446484|NCT04147754||Epidural anesthesia|At physician discretion (observational study)
62446485|NCT04147754||Intrathecal morphine|At physician discretion (observational study)
62446486|NCT04147754||Erector spinae block|At physician discretion (observational study)
62446487|NCT01889511|EXPERIMENTAL|Intervention group - texts|The intervention group will receive text messages for 21 days that are tailored to their oral agent regimen.
62617841|NCT03637530|EXPERIMENTAL|intervention group|in this group of patients, inverse ratio ventilation is provided during general anaesthesia
62617842|NCT03637530|NO_INTERVENTION|control group|in this group of patients, conventional ventilation is provided during general anaesthesia
62446488|NCT01889511|NO_INTERVENTION|Control group|The control group will receive usual care, which consists of standard care and materials provided by the oncology office or pharmacy. In general, this includes instructions and information on the oral agent regimen (i.e., amount and timing), common side effects, how to manage symptoms, general ways to remember to take your pill (e.g., calendar or pill box), medication safety (i.e., storage), and how to contact a clinician for problems that arise.
62446489|NCT02307383|EXPERIMENTAL|Lactitol and Lactobacillus|"Lactitol monohydrated 10g (Emportal®), 1 sachet dissolved in water, three times a day for 21 days.~Lactobacillus acidophilus, 1 x 109 UFC and Lactobacillus Biphidus 1 x 109 UFC, (Infloran Berna), 2 tablets by mouth, three times a day for 21 days."
62446490|NCT00221897||Healthy individuals|healthy controls with or without myopia
62446491|NCT00221897||Persons at risk for or with primary open angle glaucoma|with or without myopia with a diagnosis of glaucoma, glaucoma suspect and ocular hypertension
62446492|NCT00822198|EXPERIMENTAL|plantar vibration|Subject will use Juvent plantar vibration device daily in the home or office for six months.
62446493|NCT00429923|EXPERIMENTAL|Difluprednate 0.05% BID|Difluprednate 0.05% 1 drop BID for 14 days.
62843410|NCT03282214|NO_INTERVENTION|Control|The participants will be given two pamphlets (general issues about breast cancer and self-care activities for patients receiving chemotherapy) provided by the health care team at the study sites. The participants in the control group will be encouraged to maintain their current daily activities during the 12-week period The participants will wear a pedometer to record the number of steps which is one of the activity outcomes.
62843411|NCT06445270|NO_INTERVENTION|Control|This arm consists of standard of care counseling for diet and exercise.
62057991|NCT03661502|EXPERIMENTAL|Pressure controlled ventilation (PCV)|the intervention is using ventilation mode with constant pressure and constant tidal volume. The tidal volume is 6 ml/kg and respiratory rate is adapted to reach end tidal CO2 concentrations between 30 and 50 mmHg. Lung recruitment is given when dynamic lung compliance drops below 40. No drug is given. No other treatment or intervention is given.
62446494|NCT00429923|EXPERIMENTAL|Difluprednate 0.05% QID|Difluprednate 0.05% 1 drop QID for 14 days.
62446495|NCT00429923|PLACEBO_COMPARATOR|Placebo|Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.
62843412|NCT06445270|EXPERIMENTAL|GDM Prevention Program|This arm consists of a more intensive exercise and monitoring program. .
62843413|NCT00986687||Vitrified oocytes|
62843414|NCT00986687||Control oocytes|
62843415|NCT00922012|EXPERIMENTAL|Electromagnetic stimulation|Electromagnetic stimulation therapy
62843416|NCT03275350|ACTIVE_COMPARATOR|XR-NTX|Extended-release naltrexone
62057992|NCT03895489|EXPERIMENTAL|Journey II|Smith and Nephew Richards (SNR) Journey II Knee prosthesis
62057993|NCT03895489|ACTIVE_COMPARATOR|Stryker|Stryker Triathlon Total Knee prosthesis
62446496|NCT02123992|ACTIVE_COMPARATOR|Elevate Apical and Posterior|The experimental arm of the study will include the implantation of the Elevate Posterior surgical mesh for the treatment of posterior vaginal prolapse
62446497|NCT02123992|ACTIVE_COMPARATOR|Native Tissue Repair|The control arm of the study will include the treatment of posterior vaginal prolapse using standard surgical sutures
62843417|NCT03275350|ACTIVE_COMPARATOR|TAU|Treatment as usual
62446498|NCT03294356|EXPERIMENTAL|FT210771 Group|7 day at-home use of electronic cigarette FT210771 followed by a 2 day in-clinic period.
62843418|NCT03858816|EXPERIMENTAL|Mixture probiotics|The probiotic contain 1 ×10\^9 CFU/1 capsule of mixture probiotics, taking 1 probiotic capsule for up to 4 months after birth.
62843419|NCT03858816|PLACEBO_COMPARATOR|Placebo|Taking 1 placebo capsule for up to 4 months after birth.
62843420|NCT05463848|EXPERIMENTAL|Cohort 1 (Safety Lead In): pembrolizumab plus olaparib and temozolomide|"Following a 3 + 3 dose escalation design 6-18 participants will receive:~* Olaparib 2x daily on Days 1-7 of each 21-day study cycle.~* Temozolomide 1x daily on Days 1-7 of each 21-day study cycle.~* Pembrolizumab on Day 1 of every other 21-day cycle (once every 6 weeks)."
62261280|NCT04751890|EXPERIMENTAL|Structured home-based exercise|Program will include two 10-minute sessions/day (6 days/week) of intermittent walking (1-minute work and 1-minute rest while seated) at a prescribed speed converted into a walking cadence and followed at home using a metronome. The walking sessions will be preferably performed indoors at home or on a treadmill. During the study, 2 follow-up visits (at weeks 8 and 16) will be performed to evaluate patient adherence to the program and to update the exercise program with the duration of each session that remained constant. The walking intensity of each exercise regime will be progressively modified to increase the training load. The patients will be asked to fill out a daily training record indicating completion of the exercise and any associated symptoms. Patients will have the ability to contact the rehabilitation team, composed of a physician and a sports science expert, throughout the entire study period via phone.
62261281|NCT04751890|ACTIVE_COMPARATOR|Walking advice|Patients will receive advice to walk as suggested by the guidelines. In particular, a team member will recommend patients to gather almost 30 minutes of walking at least 3 times per week; when the patient will face claudication pain, he/she will be allowed to rest, and restart walking as soon as possible. A daily log to be compiled will be provided to each patients to record the amount of walk performed.
62261282|NCT05501561|EXPERIMENTAL|IIV-A Investigational|
62261283|NCT05501561|EXPERIMENTAL|aIIV-B Investigational|
62261284|NCT05501561|EXPERIMENTAL|aIIV-C Investigational|
62261285|NCT05501561|ACTIVE_COMPARATOR|Licensed IIV|
62261286|NCT01246583|EXPERIMENTAL|Treatment Group A|
62261287|NCT01246583|PLACEBO_COMPARATOR|Treatment Group B|
62261288|NCT01246583|EXPERIMENTAL|Treatment Group C|
62446499|NCT03294356|EXPERIMENTAL|FT210751 Group|7 day at-home use of electronic cigarette FT210751 followed by a 2 day in-clinic period.
62446500|NCT03294356|EXPERIMENTAL|6T30134157764 Group|7 day at-home use of electronic cigarette 6T30134157764 followed by a 2 day in-clinic period.
62617843|NCT05175820||Dentists|"* Graduated from the Faculty of Dentistry,~* Continuing/not continuing dental education (master, doctor, doctorate) after graduation,~* Working in practice or outpatient clinic, private or public hospital, private polyclinic or public health or university hospital,~* Dentists who registered in Turkish Dental Association"
62617844|NCT04273867||Chronic Hypersensitivity Pneumonitis Patients|
62617845|NCT04842552|ACTIVE_COMPARATOR|Hydralazine hydrochloride 25mg|Hydralazine hydrochloride (25mg tablets) every eight hours (TDS)
62057994|NCT03895489|ACTIVE_COMPARATOR|Zimmer|Zimmer Persona® The Personalized Knee prosthesis
62057995|NCT04732208||Diabetic patients|
62261289|NCT01246583|PLACEBO_COMPARATOR|Treatment Group D|
62261290|NCT02577146|EXPERIMENTAL|Study ultrasound|Study ultrasound with ureteral jet assessment will be obtained after CT diagnosis of ureteral calculus is made. Ureteral jet data will be documented and patients will be followed prospectively for 42 days for spontaneous stone passage or need for surgical intervention.
62261291|NCT00476411|EXPERIMENTAL|1|HBV vaccine
62261292|NCT02448602|OTHER|Single point group (Shenmen)|Patients will be acupuncture with Shenmen(HT7).
62261293|NCT02448602|OTHER|Sancai coordinated points group|Patients in Sancai coordinated points group, will be acupuncture with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6).
62261294|NCT02448602|OTHER|Control group|Patients in Control group, will be acupuncture with at the junction of deltoid and biceps.
62261295|NCT02167750|PLACEBO_COMPARATOR|Cherry flavored beverage - Mix 1|Mix 1 flavored still beverage
62446501|NCT03294356|EXPERIMENTAL|G41A7C071 Group|7 day at-home use of electronic cigarette G41A7C071 followed by a 2 day in-clinic period.
62446502|NCT03294356|EXPERIMENTAL|M011161212 Group|7 day at-home use of electronic cigarette M011161212 followed by a 2 day in-clinic period.
62617846|NCT04842552|PLACEBO_COMPARATOR|Placebo|Placebo tablets (identical in shape to the active comparator) every eight hours (TDS)
62446503|NCT03294356|EXPERIMENTAL|FT21002 Group|7 day at-home use of combustible cigarette FT21002 followed by a 2 day in-clinic period.
62446504|NCT02006485|EXPERIMENTAL|Ublituximab + TGR-1202|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose
62617847|NCT04542811|EXPERIMENTAL|Intervention group|Intervention group will take 12 sessions of acupuncture addition to their prophylaxis treatment. Acupuncture points will be bilateral LI-4, LI-11, ST-8, ST-44, SP-6, GB-1, GB-14, GB-20, LR-3, and GV-14, GV-20. Sterile and single-use stainless steel acupuncture needles measuring 0.25x25 mm will be inserted to a depth of 10 mm and be retained for 30 minute without any further stimulation. Acupuncture will be performed by an acupuncturist with an acupuncture practitioner licence from the Turkish Ministry of Health. Adverse events will be monitored for all acupuncture sessions.
62261296|NCT02167750|EXPERIMENTAL|Cherry Flavored Beverage - Mix 2|Mix 2 flavored still beverage with phytochmicals and caffeine
62261297|NCT02167750|EXPERIMENTAL|Cherry Flavored Beverage - Mix 3|Mix 3 flavored still beverage with phytochemicals and caffeine
62261298|NCT02167750|EXPERIMENTAL|Cherry Flavored Beverage - Mix 4|Mix 4 flavored still beverage with phytochemicals and caffeine
62261299|NCT02167750|EXPERIMENTAL|Cherry Flavored Beverage - Mix 5|Mix 5 flavored still beverage with phytochemicals and caffeine
62261300|NCT02167750|EXPERIMENTAL|Cherry Flavored Beverage - Mix 6|Mix 6 flavored still beverage with caffeine
62261301|NCT02255422|EXPERIMENTAL|omaveloxolone Capsules 2.5 mg and 5 mg|omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally once daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
62261302|NCT02255422|EXPERIMENTAL|omaveloxolone Capsules 10 mg|omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 12 weeks
62261303|NCT02255422|PLACEBO_COMPARATOR|Placebo Capsules|Placebo capsules taken orally once daily for 12 weeks
62261304|NCT02255422|EXPERIMENTAL|omaveloxolone Capsules 20 mg|omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks.
62261305|NCT02255422|EXPERIMENTAL|omaveloxolone Capsules 40 mg|omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks.
62261306|NCT02255422|EXPERIMENTAL|omaveloxolone Capsules 80 mg|omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks.
62261307|NCT02255422|EXPERIMENTAL|omaveloxolone Capsules 160 mg|omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks.
62446505|NCT02006485|EXPERIMENTAL|Ublituximab + TGR-1202 + ibrutinib|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose ibrutinib oral daily dose
62617848|NCT04542811|NO_INTERVENTION|Control Group|Control group will take only their migraine prophylaxis treatment. Participants will followed-up 3 months.
62617849|NCT03790618|PLACEBO_COMPARATOR|Placebo|Subjects will attend one session during which they will receive a placebo capsule.
62261308|NCT02238275||Patients with hypertension|
62261309|NCT01392534||Group 1|
62617850|NCT03790618|EXPERIMENTAL|Low dose MDMA|Subjects will attend one session during which they will receive 0.75mg/kg MDMA.
62617851|NCT03790618|EXPERIMENTAL|High dose MDMA|Subjects will attend one session during which they will receive 1.5mg/kg MDMA.
62261310|NCT01389167|EXPERIMENTAL|Vivitrol + BDRC|
62261311|NCT01389167|EXPERIMENTAL|Vivitrol + Medical Management|
62446506|NCT02006485|EXPERIMENTAL|Ublituximab + TGR-1202 + bendamustine|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Bendamustine at a fixed IV infusion on Days 1 \& 2
62446507|NCT06177678|EXPERIMENTAL|TFC-003|Dorzolamide 20mg/Timolol 5mg/Brimonidine 2mg combination drug. Participants will be administered 1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.
62446508|NCT06177678|ACTIVE_COMPARATOR|COSOPT ophthalmic solution|Dorzolamide 20mg/Timolol 5mg combination drug. Participants will be administered 1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.
62446509|NCT05813782|NO_INTERVENTION|No intervention arms|Primiparous mothers in this group answered the postpartum depression scale (pre-test) before discharge from the hospital. No intervention was made in addition to routine postnatal care. Primiparous mothers answered the maternal attachment scale and the postpartum depression scale (post-test) on postpartum 42nd day.
62843421|NCT05463848|EXPERIMENTAL|Cohort 2 (Surgical Cohort): Arm A - Pembrolizumab plus olaparib and temozolomide|"Cohort 2 participants will be randomized into either group a or b (1:1):~Group A participants will receive pembrolizumab, olaparib, and temozolomide before and after surgery.~* Olaparib 2x daily on Days 1-7 of each 21-day study cycle.~* Temozolomide 1x daily on Days 1-7 of each 21-day study cycle.~* Pembrolizumab on Day 1 of every other 21-day cycle (once every 6 weeks)."
62617852|NCT03790618|EXPERIMENTAL|Methamphetamine|Subjects will attend one session during which they will receive 20mg methamphetamine.
62617853|NCT03699878||patients undergoing robotic esophagectomy|Patients 20 years or older who undergo robotic esophagectomy
62843422|NCT05463848|EXPERIMENTAL|Cohort 2 (Surgical Cohort): Arm B - Pembrolizumab monotherapy|"Cohort 2 participants will be randomized into either group a or b (1:1):~Group B participants will receive pembrolizumab monotherapy before and after surgery.~* Pembrolizumab Before Surgery: Day 1 of the pre-surgical treatment cycle.~* Pembrolizumab After Surgery: Day 1 of every other 21-day cycle (once every 6 weeks)."
62843423|NCT01185665|ACTIVE_COMPARATOR|TENS|FBSS patients treated with TENS
62843424|NCT01185665|PLACEBO_COMPARATOR|Sham-TENS|patients treated with Sham-Tens
62843425|NCT01347411|NO_INTERVENTION|Control|Usual treatment
62261312|NCT01389167|EXPERIMENTAL|Naltrexone (oral)+BDRC|
62261313|NCT01389167|EXPERIMENTAL|Naltrexone (oral) + Medical Management|
62261314|NCT03910829|EXPERIMENTAL|Action Observation|This group receives an action observation training through the visualization of a video of cervical movements.
62261315|NCT03910829|EXPERIMENTAL|Motor Imagery|This group receives an motor imagery through the imagery process of cervical movements.
62261316|NCT03910829|PLACEBO_COMPARATOR|Placebo Group|This group receives a placebo action observation training through the visualization of a video of a documentary video
62617854|NCT02389374|OTHER|chloroquine primaquine 14days|P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
62617855|NCT02389374|OTHER|artemether-lumefantrine primaquine 1day|P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
62617856|NCT02389374|OTHER|artemether-lumefantrine primaquine 14days|mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
62843426|NCT01347411|EXPERIMENTAL|CPAP|Treatment with CPAP
62843427|NCT00906711||Group I|(G1): 10 - 18 years old
62843428|NCT00906711||Group II|(G2): 20 - 35 years old
62843429|NCT00906711||Group III|(G3): 45 - 60 years old
62617857|NCT02924805||Telemedicine group|Cases of hypertensive emergencies and urgencies in which the prehospital emergency care was performed by on-scene paramedics, guided by a qualified physician in a teleconsultation center.
62261317|NCT04156971|EXPERIMENTAL|Intervention Group|stage-based lifestyle modification intervention and fish oil supplement (omega-3). Stage-based Lifestyle Modification consists of several activities that include nutrition counselling, aerobic sessions, a hands-on activity 'Let's Play' and 'Sharing is Caring' Participants in the intervention group were also given fish oil capsules containing n-3 LCPUFA (DHA and EPA) for a duration of 16 weeks. The participants were required to consume two fish oil capsules, providing 1320 mg n-3 LCPUFA (792 mg EPA, 20:5n-3 and 528 mg DHA, 22:6n-3), and 6 IU vitamin E (D-alpha tocopherol) daily. The EPA and DHA ratio was 1.5:1.
62261318|NCT04156971|OTHER|Control Group|Only received Stage-based Lifestyle Modification consists of several activities that include nutrition counselling, aerobic sessions, a hands-on activity 'Let's Play' and 'Sharing is Caring'
62261319|NCT03332823|EXPERIMENTAL|SME Ambassadors training & program|- SME Ambassadors will participate in train-the-ambassador workshops and provide voluntary services and promote mental well-being activities to vulnerable groups.
62261320|NCT01079897|ACTIVE_COMPARATOR|Atopiclair|
62261321|NCT01079897|EXPERIMENTAL|EHK02-01|Ectoine containing cream
62446510|NCT05813782|EXPERIMENTAL|Experimental arms|"Primiparous mothers in the experimental group answered the postpartum depression scale before baby massage training. Afterwards, baby massage training (30 min.) was given. Baby model, baby massage video CD and brochure were used in the training. Primiparous mothers were told to apply baby massage regularly for 15 minutes, once a day, every day from the 5th to 42nd day after birth. An Baby Massage Follow-up Form was given to primiparous mothers to record the days of massage. Baby massage application order was provided by phone calls twice a week. Primiparous mothers answered the maternal attachment scale and the postpartum depression scale (post-test) on postpartum 42nd day."
62446511|NCT02784106|PLACEBO_COMPARATOR|Placebo: Double-Blind Treatment Period|
62446512|NCT02784106|EXPERIMENTAL|M2951: Double-Blind Treatment Period|
62446513|NCT02784106|EXPERIMENTAL|Placebo/M2951: Open Label Extension Period|
62446514|NCT02784106|EXPERIMENTAL|M2951/M2951: Open Label Extension Period|
62446515|NCT04352413|EXPERIMENTAL|Cohort A: PLM60|20 mg/m2, 4 weeks/cycle, administered on day 1 of each cycle
62446516|NCT04352413|EXPERIMENTAL|Cohort B: PLM60|15mg/m2, 3 weeks/cycle, administered on day 1 of each cycle
62446517|NCT03167099|EXPERIMENTAL|Full Weight Bearing|Participants assigned to full weight bearing after fixation of distal femur fracture.
62446518|NCT03167099|NO_INTERVENTION|Partial Weight Bearing|Participants assigned to partial weight bearing, standard of care, after fixation of distal femur fracture.
62446519|NCT02277652|EXPERIMENTAL|Scenario 1: Uninterrupted chest compressions|Endotracheal intubation (ETI) during pediatric manikin with uninterrupted chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control, USA).
62446520|NCT02277652|EXPERIMENTAL|Scenario 2: Neutral position|ETI performed in neutral mannikin head position
62617858|NCT02924805||Control group|Historical cases of of hypertensive emergencies and urgencies in which the prehospital emergency care was carried out by on-scene emergency medical service physicians (conventional care).
62843430|NCT00906711||Group IV|(G4): 65 - 85 years old
62261322|NCT03045770|EXPERIMENTAL|mFOLFOX|The mFOLFOX regimen consisted of oxaliplatin (85 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
62261323|NCT03045770|EXPERIMENTAL|mFOLFIRI|The mFOLFIRI regimen consisted of irinotecan (180 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
62261324|NCT03045770|EXPERIMENTAL|FOLFPTX|The FOLFPTX regimen consisted of paclitaxel (95 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
62261325|NCT03891173|EXPERIMENTAL|L-DOS47 in combination with cisplatin + vinorelbine|L-DOS47 (6/9/12 µg/kg) is administered by iv on Day 1 and 8 of each 21-day treatment cycle, in combination with iv administration of standard cisplatin (80 mg/m2) on Day 2 + vinorelbine (30 mg/m2) on Day 2 and 9.
62261326|NCT03891173|ACTIVE_COMPARATOR|Cisplatin + vinorelbine alone|Administration by iv of standard Cisplatin (80 mg/m2) on Day 1 + vinorelbine (30 mg/m2) on Day 1 and 8 of each 21-day treatment cycle.
62261327|NCT02281643|EXPERIMENTAL|Early doxycycline administered|Early doxycycline administered - volunteers will be treated immediately with 200mg daily doxycycline for 6 weeks
62261328|NCT02281643|ACTIVE_COMPARATOR|Delayed doxycycline administered|Delayed doxycycline administered-volunteers will be treated six months after the early group has received treatment with 200mg daily doxycycline for 6 weeks
62261329|NCT01841242|ACTIVE_COMPARATOR|alcoholic povidone iodine|Betadine Alcoolique 5% One cutaneous application before implant procedure
62446521|NCT02277652|EXPERIMENTAL|Scenario 3: Sniffing position|ETI performed in sniffing mannikin head position
62446522|NCT02277652|EXPERIMENTAL|Scenario 4: Pharyngeal swelling|ETI performed during mannikin pharyngeal swelling scenario
62446523|NCT02277652|EXPERIMENTAL|Scenario 5: Swollen tongue|ETI performed during mannikin swollen tongue scenario
62446524|NCT02277652|EXPERIMENTAL|Scenario 6: Immobilized cervical spine|ETI performed during mannikin immobilized cervical spine scenario
62446525|NCT01813461|EXPERIMENTAL|14C-labeled prodrug isavuconazonium sulfate|single dose
62617859|NCT06268496|EXPERIMENTAL|mild to moderate melasma|adult patients suffering from mild to moderate melasma (Investigator's Global Assessment (IGA) 1 or 2)
62617860|NCT06268496|EXPERIMENTAL|mild to moderate acne induced PIHP|adult patients suffering from mild to moderate acne-induced PIHP (IGA 1 or 2) without active acne (i.e., less than 10 inflammatory lesions)
62617861|NCT06268496|EXPERIMENTAL|solar lentigo|adult patients suffering from solar lentigo with a pigmentation score \> 5
62617862|NCT02611765|EXPERIMENTAL|Enhanced therapy|Benzathine penicillin G intramuscular 7.2 million units Three doses of 2.4 million units of intramuscular benzathine penicillin G administered weekly (a total of 7.2 million units)
62261330|NCT01841242|EXPERIMENTAL|alcoholic chlorhexidine|ChloraPrep 2% One cutaneous application before implant procedure
62261331|NCT03831841|EXPERIMENTAL|Intervention|Multicomponent exercise programe involving all physical fitness paramenters and consisting on sesions of 1 hour, 3 days a week.
62843431|NCT04896515||Standard Nutrition Arm|"In INTENT (the parent study) participants will be randomised to the i) Standard Nutrition or ii) Intensive Nutrition arm. A brief description of each is below.~In ICU:~1. After enrolment, patients allocated to the standard nutrition therapy (control) group will commence or continue nutrition via an enteral tube to a target rate according to unit protocol including the use of promotility agents and the placement of nasojejunal feeding tubes if required.~2. Parenteral Nutrition (PN) will only be used if the above methods have been attempted, or an absolute contraindication to enteral nutrition (EN) develops.~After ICU:~1. Nutrition management will be as per usual site management at that hospital."
62261332|NCT03831841|NO_INTERVENTION|Control|Control group with no intervention programe
62261333|NCT00440947|OTHER|Simplification|Atazanavir (ATV) 400 mg QD + abacavir (ABC) 600 mg/lamivudine (3TC) 300 mg fixed dose combination (FDC) QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.
62261334|NCT00440947|OTHER|Continuation|Atazanavir (ATV) 300 mg QD + ritonavir (/r) 100 mg QD + abacavir (ABC) 600mg/lamivuidine (3TC )300 mg FDC QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.
62261335|NCT00695448|EXPERIMENTAL|Cohorts|The starting dose is 6mg once daily (QD); dose is to be escalated using a standard 3 + 3 dose escalation scheme.
62617863|NCT02611765|ACTIVE_COMPARATOR|Standard therapy|Benzathine penicillin G intramuscular 2.4 million units A single intramuscular injection of 2.4 million units of benzathine penicillin G
62617864|NCT06324526||People undergoing bariatric surgery|People under going primary bariatric surgery between 1st June 2017 and 23rd November 2022 with complete health-related quality of life records (EQ-5D) with one pre-operative and at least one follow-up record within 1 year of surgery.
62617865|NCT05253118|EXPERIMENTAL|Treatment|Tislelizumab (BGB-A317) 200mg will be administered on Day 1 of each 21-day cycle (once every 3 weeks) in combination with pemetrexed. And pemetrexed 500 mg/m2 will be administered on Day 1 of each 21-day cycle (once every 3 weeks).
62617866|NCT04710368|EXPERIMENTAL|Treatment|Evolocumab subcutaneously administered 140 mg every 2 weeks for 26 weeks
62261336|NCT04577950|EXPERIMENTAL|Arm with procedure: identification of lymphatic drainage of the uterus following 3 sites injections|A radiocolloid (Nanocoll® marked with Technetium 99), a fluorochrome (ICG) and a blue dye (Bleu Patenté®) will be injected in submucosal tissue to see the differences in lymphatic drainage between three different injection sites. Indeed, ICG will be injected under the endometrium, whereas Nanocoll® will be injected in the cervix and Bleu Patenté® in the uterine isthmus, at the transition between the cervix and the uterine corpus.
62261337|NCT03199820|ACTIVE_COMPARATOR|Cook Cervical balloon|Cook cervical double balloon catheter
62261338|NCT03199820|ACTIVE_COMPARATOR|Prostin E2 Vaginal suppository|Prostaglandin E2 sustained release vaginal insert
62261339|NCT03119909|OTHER|Learning of actions-events associations|Each subject will conduct 4 sessions, i.e. a training session and three fMRI sessions. The first session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
62261340|NCT03119909|OTHER|Learning of action-event associations not linked to action|"This study is divided into two parts: a pilot behavioral study to determine the learning characteristics of non-action events and an fMRI study to study the neural networks involved in this type of learning.~30 subjects will participate in the behavioral study and 60 will participate in the fMRI study)"
62261341|NCT04234906|ACTIVE_COMPARATOR|Stage 1, Group 1 - Dexmedetomidine|Dexmedetomidine: 1 mcg/kg administered at end of cardiopulmonary bypass, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
62261342|NCT04234906|ACTIVE_COMPARATOR|Stage 1, Group 2- Magnesium|Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.
62261343|NCT04234906|ACTIVE_COMPARATOR|Stage 2, AMIODARONE|AMIODARONE I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
62261344|NCT04234906|ACTIVE_COMPARATOR|Stage 2, PROCAINAMIDE|PROCAINAMIDE IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
62261345|NCT02817321|EXPERIMENTAL|Single-injection TPVB +continuous TPVB|Single-injection of TPVB is given preoperatively followed with continuous infusion+ postoperative IPCA.
62261346|NCT02817321|ACTIVE_COMPARATOR|IPCA|postoperative IPCA is given alone
62261347|NCT05174468||Screen-eligible Subjects|High-risk for lung cancer population who meet the USPSTF eligibility. One 10-L breath sample will be collected from each subject. During breath collection, subjects will be asked to exhale into a portable breath sampling device through a single use filter. Subjects will not be contacted to donate additional/serial breath specimens after the initial breath samples. Subjects will fill out a medical questionnaire and medical records will also be reviewed to extract low-dose CT scan (LDCT) screening results and any additional tumour-related information including histologic subtype, tumor stage, and sites of disease.
62446526|NCT04497480|EXPERIMENTAL|experimental group|
62446527|NCT04497480|NO_INTERVENTION|controlled group|
62261348|NCT03484767||Methylmalonic Acidemia Participants|Individuals with isolated MMA (mut0 and mut-)
62261349|NCT03484767||Propionic Acidemia Participants|Individuals with isolated PA
62261350|NCT00202787|EXPERIMENTAL|1|FOLFOX-4+cetuximab
62843432|NCT04896515||Intensive Nutrition Arm|"In ICU:~1. Supplemental PN will be commenced within 2 hours of randomisation. The starting dose will be determined by the amount of energy received in the 24 hours prior to randomisation~2. The need for the intervention will be based on the adequacy of nutrition provision and assessed daily until ICU discharge~3. If there is an interruption of EN for greater than 2 hours the PN must be run at 20 kcal/kg calculated body weight until EN is recommenced. After the interruption, EN should be recommenced as per local protocol.~After ICU:~1. An intensive nutrition intervention will be provided on the ward.~The goal of nutrition care across the hospital stay will be to ensure 80-100% of participant's estimated energy requirements are met."
62843433|NCT02557880|EXPERIMENTAL|Sleep Application Diary|A sleep application diary which will automatically report results back to sleep doctor is used in addition to standard sleep hygiene counseling.
62446528|NCT05374863|EXPERIMENTAL|Experimental Group|Neuromuscular electrical stimulation (NMES) active in the upper limbs for 20 minutes and aerobic exercises on the cycle ergometer for 30 minutes.
62843434|NCT02557880|ACTIVE_COMPARATOR|Treatment as Usual|Sleep hygiene counseling
62843435|NCT04119466|EXPERIMENTAL|Protrusion Group|20 session of stabilizing training based on the principles developed by Richardson over four weeks.
62843436|NCT04119466|EXPERIMENTAL|Extrusion Group|20 session of stabilizing training based on the principles developed by Richardson over four weeks.
62057996|NCT04987632|EXPERIMENTAL|Letrozole combined with acupuncture and Du Meridian moxibustion group|Letrozole combined with acupuncture and Du Meridian moxibustion was taken from 3-5 days of menstrual period (spontaneous menstruation or progesterone withdrawal bleeding). The acupuncture treatment was 3 times / week, with an interval of 2-4 days, 12 times a week, 30 minutes each time; Du Meridian moxibustion is 20 minutes each time, once a week, four times a week. The initial dose of letrozole was 2.5mg/day for 5 consecutive days. The follow-up dose was determined according to the response of the subjects to the initial dose, with one month as a cycle. If not pregnant, the subjects received letrozole for up to 4 cycles to induce ovulation with acupuncture plus Du Meridian moxibustion.
62057997|NCT04987632|ACTIVE_COMPARATOR|Letrozole group|Letrozole was taken 3-5 days after menstruation (spontaneous menstruation or progesterone withdrawal bleeding). The initial dose of letrozole was 2.5mg/day for 5 consecutive days. The follow-up dose was determined according to the response of the subjects to the initial dose, with one month as a cycle. In the absence of pregnancy, subjects were treated with letrozole for up to four cycles.
62261351|NCT00202787|ACTIVE_COMPARATOR|2|FOLFOX-4
62261352|NCT06460402|EXPERIMENTAL|Ice packing|Participants in this arm will receive cryotherapy in the form of ice pack applications to the perianal area for 20 minutes every 2 hours during the first 48 hours after hemorrhoidectomy. The ice packs will be applied externally to the surgical site to reduce pain, swelling, and inflammation. Participants will be instructed on proper ice pack application techniques and will be provided with the necessary supplies. Postoperative pain levels, analgesic consumption, wound healing, and other outcomes will be assessed at various time points.
62446529|NCT05374863|PLACEBO_COMPARATOR|Control Group|NMES-Sham in upper limbs for 20 minutes and aerobic exercises on a cycle ergometer for 30 minutes.
62446530|NCT02636127|EXPERIMENTAL|Systemic Sclerosis (SSc) patient|15 patients whose diagnosis of SSc is made according to the revised ACR/EULAR ( American College of Rheumatology ) criteria 2013 will be recruited and blood samples will be obtained
62843437|NCT04609462|ACTIVE_COMPARATOR|Conventional oxygen therapy (COT) group|Oxygen therapy will be delivered by conventional nasal cannula / prongs, venturi mask, or mask with reservoir, with flows between 3 and 15 liters / minute, to ensure SpO2 ≥ 92%.
62261353|NCT06460402|ACTIVE_COMPARATOR|Warm sitz bath|Participants in this arm will receive warm water sitz baths as the standard postoperative care after hemorrhoidectomy. They will be instructed to sit in a bathtub or a special sitz bath basin filled with warm water for 15-20 minutes, 2-3 times daily, starting from the first postoperative day. The warm water is believed to promote blood flow, relax the anal sphincter, and soothe the perianal area, potentially aiding in pain relief and wound healing. Participants will be provided with instructions on proper sitz bath techniques and will be assessed for postoperative pain, analgesic consumption, wound healing, and other outcomes at various time points, similar to the cryotherapy arm.
62843438|NCT04609462|EXPERIMENTAL|High-flow nasal cannula (HFNC) group|Breathing support with High-Flow oxygen therapy, flow will be initiated between 50 and 60 liters / minute. FiO2 60% to 100% with the objective of reaching SpO2 ≥ 92%. Adequate wetting of the system should be ensured according to the recommendations of the HFNC device manufacturer. FiO2 may be decreased gradually according to the patient's individual condition, trying to maintain SpO2 ≥ 92%.
62843439|NCT03188497|EXPERIMENTAL|Experience group 1|The dose of lobaplatin is 25mg/m2 on d1,d22,d43.
62843440|NCT03188497|EXPERIMENTAL|Experience group 2|The dose of lobaplatin is on d1,d22,d43.
62261354|NCT04417036|EXPERIMENTAL|Part A - Active Drug Dose 1|Participants will receive Active Drug Dose 1 for a maximum of 14 days in study phase Part A
62261355|NCT04417036|EXPERIMENTAL|Part A - Active Drug Dose 2|Participants will receive Active Drug Dose 2 for a maximum of 14 days in study phase Part A
62446531|NCT02636127|OTHER|healthy patient|15 healthy patients will be recruited and blood samples will be obtained
62446532|NCT00508586|EXPERIMENTAL|1|PTC299 with an aromatase inhibitor
62446533|NCT01966042|EXPERIMENTAL|Stem Cell Therapy|"All subjects enrolled in the study underwent:~Local Sedation; Bone Marrow Aspiration; Minithoracotomy; Autologous bone marrow mononuclear cells infusion."
62446534|NCT04228510||Study group|ST elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention who will be followed up in Assiut University hospital.
62446535|NCT05713474||Healthy controls|
62446536|NCT05713474||Patients previously diagnosed with motor neurone disease|
62446537|NCT05713474||Patients previously diagnosed with sarcopenia|
62446538|NCT05713474||Patients previously diagnosed with post-polio syndrome|
62446539|NCT05713474||Patients previously diagnosed with myasthenia gravis|
62446540|NCT04272021|EXPERIMENTAL|ADHD sample|Children with a diagnosis of ADHD
62843441|NCT03188497|EXPERIMENTAL|Experience group 3|The dose of lobaplatin is on d1,d22,d43.
62261356|NCT04417036|PLACEBO_COMPARATOR|Part A - Placebo|Participants will receive Placebo for a maximum of 14 days in study phase Part A
62261357|NCT04417036|EXPERIMENTAL|Part B - Active Drug Dose|Participants will receive Active Drug 1 or 2 for a maximum of 14 days in study phase Part B
62446541|NCT06053099|EXPERIMENTAL|Plasma ctDNA and FFPE blocks|
62446542|NCT06084507|EXPERIMENTAL|Treatment A|Single oral dose of ritonavir at -12 hours prior to GST-HG171/ritonavir dosing, followed by single oral dose of GST-HG171/ritonavir under fasted conditions. Ritonavir will continue to be dosed at 12 hours and 24 hours GST-HG171 dosing.
62843442|NCT03188497|EXPERIMENTAL|Experience group 4|The dose of lobaplatin is 40mg/m2 on d1,d22,d43.
62843443|NCT03188497|EXPERIMENTAL|Experience group 5|The dose of lobaplatin is 45mg/m2 on d1,d22,d43.
62843444|NCT03188497|EXPERIMENTAL|Experience group 6|The dose of lobaplatin is 50mg/m2 on d1,d22,d43.
62843445|NCT00233064|ACTIVE_COMPARATOR|1|Liquid Palivizumab
62843446|NCT00233064|ACTIVE_COMPARATOR|2|Lyophilized Palivizumab
62843447|NCT01578876|EXPERIMENTAL|CSWT for 3 month|A group
62843448|NCT01578876|EXPERIMENTAL|CSWT for 1 month|B group
62843449|NCT01578876|NO_INTERVENTION|Control group|C group
62843450|NCT06359444|ACTIVE_COMPARATOR|Combined strength + aerobic training|The patients in this group will exercise for 14 weeks. It is a combination of strength and aerobic exercise.
62843451|NCT06359444|EXPERIMENTAL|Combined strength + HIIT|"The patients in this group will exercise for 14 weeks. The first 6 weeks consists of combined aerobic and strength exercise, following the protocol from the active comparator group.~They will switch to combined strength and HIIT exercise for the remaining 8 weeks."
62843452|NCT00806819|EXPERIMENTAL|nintedanib (BIBF1120) plus pemetrexed|nintedanib (BIBF1120) along with standard therapy of pemetrexed
62843453|NCT00806819|PLACEBO_COMPARATOR|Placebo plus pemetrexed|Pemetrexed standard therapy
62843454|NCT00806819|EXPERIMENTAL|nintedanib (BIBF1120) monotherapy|nintedanib (BIBF1120) monotherapy only for patients who discontinue pemetrexed
62843455|NCT00806819|ACTIVE_COMPARATOR|pemetrexed monotherapy|pemetrexed monotherapy only for patients who discontinue nintedanib (BIBF1120) or placebo
62843456|NCT00806819|PLACEBO_COMPARATOR|placebo monotherapy|placebo monotherapy only for patients who discontinue pemetrexed
62843457|NCT04288284||Emergency group|Patients presented to emergency by complicated colorectal cancer ( Obstruction, bleeding or perforation)
62843458|NCT04288284||Elective group|Patients presented with uncomplicated colorectal cancer for resection treatment
62843459|NCT04097574|ACTIVE_COMPARATOR|NPO-13 0.8%|Low dose
62843460|NCT04097574|ACTIVE_COMPARATOR|NPO-13 1.6%|High dose
62843461|NCT04097574|PLACEBO_COMPARATOR|NPO-13 0%|Placebo
62843462|NCT00677989||LA|LA group: patients with perforated appendicitis treated by laparoscopic operation intentionally
62843463|NCT00677989||OA|OA group:patients with perforated appendicitis treated by open approach
62843464|NCT01379508|EXPERIMENTAL|telbivudine|telbivudine 600 mg tablet orally (p.o.) once daily for up to 156 weeks. Patients with HBV DNA ≥ 300 copies/mL at Week 24 were to initiate add-on therapy with tenofovir 300 mg tablets p.o. once daily for the remaining weeks of treatment. The investigator was to initiate tenofovir add-on therapy within 2 weeks of central laboratory confirmation. Patients with HBV DNA \< 300 copies/mL at Week 24 were to continue to receive telbivudine monotherapy
62261358|NCT04417036|PLACEBO_COMPARATOR|Part B - Placebo|Participants will receive Placebo for a maximum of 14 days in study phase Part B
62843465|NCT01379508|ACTIVE_COMPARATOR|tenofovir|tenofovir 300 mg tablets p.o. once daily for up to 156 weeks. Patients with HBV DNA ≥ 300 copies/mL at Week 24 were to initiate add-on therapy with telbivudine 600 mg tablet p.o. once daily for the remaining weeks of treatment. The investigator was to initiate telbivudine add-on therapy within 2 weeks of central laboratory confirmation. Patients with HBV DNA \< 300 copies/mL at Week 24 were to continue to receive tenofovir monotherapy
62843466|NCT02469545|ACTIVE_COMPARATOR|SSRI and probiotic|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and probiotic (Lactobacillus Plantarum 299v) to a group of patients diagnosed with depression (n=30).
62843467|NCT02469545|PLACEBO_COMPARATOR|SSRI and placebo of probiotic|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and placebo of probiotic (crystalline cellulose powder) to a group of patients diagnosed with depression (n=30).
62843468|NCT06516419|EXPERIMENTAL|Group A (Secretom group)|Group A, the treatment group, used Secretom 2ml Intradermal injection, Sunscreen in the morning and used Tretinoin cream 0,05% at night and cleanser which was used in the morning and evening before using the cream.
62843469|NCT06516419|EXPERIMENTAL|Group B (Triple Combination Group)|Group B, the treatment group, getting sunscreen cream in the morning and triple combination (Refaquin) cream at night and facial soap that can be used in the morning and evening.
62261359|NCT02987036|EXPERIMENTAL|Aerogen|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Aerogen
62446543|NCT06084507|EXPERIMENTAL|Treatment B|Single oral dose of ritonavir at -12 hours prior to GST-HG171/ritonavir dosing, followed by single oral dose of GST-HG171/ritonavir under fed conditions. Ritonavir will continue to be dosed at 12 hours and 24 hours GST-HG171 dosing.
62446544|NCT06483152|EXPERIMENTAL|Intervention Group|The intervention group will be provided a transit pass for the Minneapolis Metro transit system that will be paid for by the study for 6 months.
62446545|NCT06483152|ACTIVE_COMPARATOR|Control|The control group will receive the current standard of care, in which people are eligible to receive up to two $10 bus cards from their case manager per month.
62617867|NCT01066793||Cohort|Participants chronically infected with the hepatitis C virus including genotypes 1 to 6
62617868|NCT04118179||Suspected Sepsis Group|Participants suspected of potential to develop sepsis recruited at the emergency department.
62261360|NCT02987036|OTHER|Jet Nebulizer|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet Nebulizer
62261361|NCT04279275||Survey|Knowledge survey
62843470|NCT06516419|EXPERIMENTAL|Group C (Tranexamic Acid Group)|Group C, the treatment group, used Intradermal Injection of Tranexamic Acid 10mg/mL and 25mg/mL split face , Sunscreen in the morning and used Tretinoin cream 0,05% at night and cleanser which was used in the morning and evening before using the cream.
62617869|NCT04118179||Surgical Group|Participants undergoing non-emergency scheduled surgery, including ear/nose and throat cases, orthopaedic surgery of the major joints including hip, knee, ankle, shoulder, and wrist.
62617870|NCT04118179||Healthy Group|Healthy participants
62617871|NCT02599064|EXPERIMENTAL|RXI-109|Intravitreal injections of RXI-109 in one eye given on Day 1 and at monthly intervals through Month 3 for a total of four doses
62843471|NCT06355700|EXPERIMENTAL|Hepatocellular Carcinoma|Participants undergo to a liver biopsy, a venous blood sampling and a fecal sample collecting
62843472|NCT05760469|OTHER|Screening Rash|This is an exploratory study to assess the usefulness and reliability of the ITD-IAD-M for diagnosing, tracking, and treating IAD and ITD in hospitals.Participants for the study will be identified by nursing staff from admitted patients. After informed consent, the primary care nurse will collect qualitative information from the patient based on the history of their skin condition, whether the rash is new or recurring for them, and their pain, irritation, and discomfort measures. All patients participating in the study will receive the standard of care for patients presenting with MASD as prescribed by their primary care physician. The nurse will complete the ITD-IAD-M tool daily along with routine patient care. Each day the nurse documents the rash status and whether the treatment can be stopped based on the nursing assessment. The nurse/research assistant will also take a standardized digital live picture of the rash (without any identifying features) daily for a maximum of 7 days.
62057998|NCT02931201|EXPERIMENTAL|DLBCL patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
62057999|NCT03150498|EXPERIMENTAL|BTD-001 (fed)|
62058000|NCT03150498|EXPERIMENTAL|BTD-001 (fasted)|
62843473|NCT05911685|EXPERIMENTAL|Left atrial appendage occlusion|
62843474|NCT02722018|EXPERIMENTAL|Part 1: GDC-0810 dose level A - Low Fat Meal|Participants will receive a single dose of GDC-0810 dose level A on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal in the form of Phase II tablet or one of three Phase III prototype tablets (Prototype 1, 2 or 3) in a crossover fashion.
62058001|NCT00061516|EXPERIMENTAL|Brinzolamide suspension, 1%|Dosed twice daily for 12 weeks
62058002|NCT00061516|EXPERIMENTAL|Levobetaxolol suspension, 0.5%|Dosed twice daily for 12 weeks
62446546|NCT06464809|EXPERIMENTAL|kinesio taping (KT) group|Three precut KT I strips with a width of 5 cm were used. The first strip is applied with the subject's wrist in fully extended hand position. Middle and ring fingers through the holes with the base of the tape as anchored to the knuckles, and then the tape was applied with 15%-25% tension covering the palm and the wrist, and the remainder of the tape without any tension from the wrist up to the forearm. The same process is repeated for the second I-strip, which was applied from the dorsum of the hand to wrist while the wrist in a downward flexed position. The final strip was applied to the carpal tunnel region with 25%-35% tension.
62058003|NCT02564302|NO_INTERVENTION|Control|These patients will not receive a device, but have to fill out a quality of life questionnaire at the time of enrollment and 3 months after their procedure.
62058004|NCT02564302|EXPERIMENTAL|Treatment Group|These patients will receive the device. they are expected to use it for at least 5 minutes per day. Patients in this arm will fill out a quality of life questionnaire at the time of enrollment and 3 months after their procedure.
62617872|NCT02782754|EXPERIMENTAL|Intracranial germinoma|"1. Four cycles of chemotherapy with carboplatin, etoposide, (+ bleomycin) and cyclophosphamide, etoposide, (+ bleomycin) regimen~2. Reduced dose of radiotherapy~   * Without seeding: 18 Gy to ventricle + 12.6 Gy to primary site~  * With seeding: craniospinal irradiation 18 Gy + 12.6 Gy to primary site"
62617873|NCT06314412|EXPERIMENTAL|Patients with Multiple Sclerosis|Patients with Multiple Sclerosis
62617874|NCT03749421||Prosigna Assay|"* Biopsy specimen will be subject to molecular profiling via the Prosigna PAM-50 assay~* The results of Prosigna assay will be provided to the study team in a standardized report.~* This report will include the patient's intrinsic subtype, ROR score, and general risk (high, intermediate, low)."
62617875|NCT05365334|EXPERIMENTAL|low-intensity continuous exercise|subjects will exercise at 30% maximal oxygen consumption (VO2max) for 45-60 minutes
62617876|NCT05365334|EXPERIMENTAL|moderate-intensity continuous exercise|subjects will exercise at 65% maximal oxygen consumption (VO2max) for 30-45 minutes
62058005|NCT04923555|EXPERIMENTAL|Group/Cohort1|33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt rich in cysteine, leucine and arginine (VP, vegetable proteins) only once during the visit
62058006|NCT04923555|EXPERIMENTAL|Group/Cohort2|33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt rich in animal proteins (AP) only once during the visit
62058007|NCT04923555|PLACEBO_COMPARATOR|Group/Cohort3|33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt without any proteins (T) only once during the visit
62058008|NCT00849914||1|Patients with actinic keratoses of the skin
62058009|NCT00849914||2|Patients with basal cell carcinoma of the skin
62058010|NCT00849914||3|Patients with squamous cell carcinoma of the skin
62058011|NCT02799472|EXPERIMENTAL|GSK3196165 + MTX arm|Subjects will receive GSK3196165 (initially weekly, then every other week) in combination with MTX (15-25 mg/week) and folic (or folinic) acid (\>=5 mg/week).
62843475|NCT02722018|EXPERIMENTAL|Part 2 (Optional): GDC-0810 dose level A - Low Fat Meal|Participants will receive a single dose of GDC-0810 dose level A on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal in the form of Phase II tablet or one of two Phase III prototype tablets (Prototype 4 or 5) in a crossover fashion.
62843476|NCT02722018|EXPERIMENTAL|Part 3: GDC-0810 dose level B - Low Fat Meal/Fasted|Participants will receive a single dose of GDC-0810 dose level B on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal or under fasted condition either as Phase II tablet (with low fat meal) or as the Phase III prototype tablet selected from Parts 1 or 2 (with low fat meal or under fasted conditions), in a crossover fashion.
62843477|NCT02796313|EXPERIMENTAL|Intervention Group|Participants in the intervention group will receive tailored advice on adopting a low-sodium DASH diet, comprising nutritional education and ongoing guidance for purchasing heart-healthy foods, plus a weekly $35 credit for groceries.
62843478|NCT02796313|ACTIVE_COMPARATOR|Control Group|Participants in the control group will receive printed educational materials with general information about low-salt diets plus a weekly $35 credit for groceries.
62843479|NCT02459834|EXPERIMENTAL|Allulose + 75g OGTT|Allulose added to a 75 g OGTT of 500 mL at 2 doses (5g and 10g). The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
62843480|NCT02459834|EXPERIMENTAL|Fructose + 75g OGTT|Fructose added to a 75 g OGTT of 500 mL at 2 doses (5g and 10g). The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
62261362|NCT01549002|EXPERIMENTAL|Intranasal Fentanyl|"Patients in this arm will receive intranasal Fentanyl (50 micrograms/mL) as their pre-I\&D analgesic. The one time total dose to be used is 2 micrograms / kilogram, to a maximum of 100 micrograms. The medication will be delivered intranasally via an atomizer in 4 equally divided aliquots (2 per nare).~The abscess I\&D will be followed according to protocol using topical and local anesthetic."
62446547|NCT06464809|ACTIVE_COMPARATOR|transcutaneous electrical nerve stimulation (TENS) group|A portable TENS unit (Gem-Stim, Gemore Technology Co., LTD. Taiwan) was used, and delivered a bi-phasic symmetric waveform at a continuous frequency of 100 Hz and phase duration of 200 µsec. The intensity was gradually adjusted up to a strong but comfortable l level, as reported by the subject. Two electrodes were placed 2 cm apart, respectively attached to the carpal ligament of the affected side and the proximal end along the direction of the median nerve.
62843481|NCT02459834|ACTIVE_COMPARATOR|75g OGTT (Control)|A 75 g OGTT (alone) of 500 mL will be given to each participant. The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
62843482|NCT03289585||Hidradenitis Suppurativa Cohort|Patients with Hidradenitis Suppurativa (ages 18-99 years old) will be asked to complete a series of questionnaires on how Hidradenitis Suppurativa impacts quality of life.
62446548|NCT00553540|NO_INTERVENTION|Control Group|Patients in this group will receive physical therapy and posture education for low back pain
62617877|NCT05365334|EXPERIMENTAL|high-intensity interval exercise|subjects will completed 10x1minute exercise intervals at maximal oxygen consumption (VO2max) with 1 minute active recovery between
62617878|NCT00882661|EXPERIMENTAL|SECURE-C Cervical Artificial Disc|Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc
62843483|NCT01018940||Plavix|
62843484|NCT01018940||Prasugrel|
62058012|NCT02799472|PLACEBO_COMPARATOR|Placebo + MTX arm|Subjects will receive placebo (initially weekly, then every other week) in combination with MTX (15-25 mg/week) and folic (or folinic) acid (\>=5 mg/week).
62058013|NCT04238312|EXPERIMENTAL|RESPeRATE™|RESPeRATE™: 2breathe Tech. Ltd., Eshtaol, Israel. The device includes a belt-type respiration sensor worn outside of the clothing that is placed around the torso. It is connected to a computerized box that generates musical patterns listened through an earbud. The device guides the user interactively to slow breathing with a relatively prolonged expiration.
62058014|NCT04238312|ACTIVE_COMPARATOR|Tell, Show and Do technique|
62058015|NCT04409067||TMD-pain group|The TMD-pain group consisted of 30 children aged between 7.1 and 12.3 with a pain-related TMD diagnosis. All the patients in the TMD-pain group had myogenous or arthrogenous TMD according to the RDC/TMD protocol.
62058016|NCT04409067||pain-free TMD group|The pain-free TMD group consisted of 30 children between 7.3 and 12.6 years of age. To be included in the pain-free TMD group the participants had to meet Axis I of the RDC/TMD criteria for a pain-free diagnosis.
62843485|NCT02014337|EXPERIMENTAL|Mifepristone and Eribulin in combination|Single Arm
62843486|NCT02411890|EXPERIMENTAL|Adductor canal block|Adductor canal block (active) + Femoral nerve block (sham block)
62058017|NCT04409067||non-TMD group|The non-TMD group comprised 30 children aged between 7.2 and 12.5 without any recognised TMD based on RDC/TMD, Axis I.
62058018|NCT03384264|EXPERIMENTAL|TG|
62446549|NCT00553540|ACTIVE_COMPARATOR|Test Group|Patients in this group will receive spinal / back supports in addition to physical therapy and posture education for low back pain
62446550|NCT05150509||Patients with Progressive Disease and without Progressive Disease|"1. Patients with Progressive Disease Patients with metastasis and/or recurrent OSCC were considered as a group of subjects with progressive disease.~2. Patients with without Progressive Disease Patients without metastasis and/or recurrent OSCC were considered as a group of subjects without progressive disease."
62446551|NCT03044158|NO_INTERVENTION|Control group|Onsite ZN or LED fluorescence microscopy + hub-based GeneXpert testing per existing protocols
62446552|NCT03044158|EXPERIMENTAL|Intervention|Onsite molecular testing for TB with GeneXpert I + process redesign to facilitate same-day TB diagnosis and treatment + performance feedback
62446553|NCT05147454||Trigeminal Neuralgia|Patients with a definite diagnosis of Classical or Idiopathic Trigeminal Neuralgia
62446554|NCT05147454||Persistent Idiopathic Facial Pain|Patients with a definite diagnosis of Persistent Idiopathic Facial Pain
62843487|NCT02411890|ACTIVE_COMPARATOR|Femoral nerve block|Femoral nerve block (active) + Adductor canal block (sham block)
62843488|NCT05581524|EXPERIMENTAL|VELEX|Treatment of varicose veins of lower limbs by means of chemical ablation or empty-vein sclerotherapy
62446555|NCT05266456|EXPERIMENTAL|VAX-24 Low Dose|Participants will receive a single dose of VAX-24 1.1 mcg administered as an intramuscular injection on Day 1.
62617879|NCT00882661|ACTIVE_COMPARATOR|ASSURE Cervical plate and an allograft interbody spacer|Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
62617880|NCT03207308|EXPERIMENTAL|Vitamin A supplementation|55 children will receive a Mega-dose of preformed Vitamin A as recommended by the Senegalese Ministry of Health
62617881|NCT03236129|EXPERIMENTAL|Treg depleted DLI|Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by Treg depleted (Donor Lymphocytes Infusion (DLI)
62446556|NCT05266456|EXPERIMENTAL|VAX-24 Mid Dose|Participants will receive a single dose of VAX-24 2.2 mcg administered as an intramuscular injection on Day 1.
62446557|NCT05266456|EXPERIMENTAL|VAX-24 Mixed Dose|Participants will receive a single dose of VAX-24 2.2 mcg/4.4 mcg administered as an intramuscular injection on Day 1.
62446558|NCT05266456|ACTIVE_COMPARATOR|PCV20|Participants will receive a single intramuscular injection of the standard dose of PCV20 on Day 1.
62446559|NCT05822518|NO_INTERVENTION|conventional protocol group|patients who are enrolled in conventional pre and post operative routine preparation for surgery protocol.
62446560|NCT05822518|ACTIVE_COMPARATOR|immune enhancing nutrition protocol group|patients who are enrolled in pre and post operative routine preparation for surgery protocol plus immune enhancing nutrition administration pre and post operatively.
62617882|NCT03236129|ACTIVE_COMPARATOR|Unmanipulated DLI|Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by a standard DLI (unmanipulated)
62617883|NCT02474134|OTHER|PF530/Betaferon|Single subcutaneous injection of two interferon beta-1b products (PF530 and Betaferon) 0.25 mg
62058019|NCT03384264|NO_INTERVENTION|CG|the CG maintained their normal physical activity habits over the study
62617884|NCT02474134|OTHER|Betaferon/PF530|Single subcutaneous injection of two interferon beta-1b products (Betaferon and PF530) 0.25 mg
62617885|NCT02536274|EXPERIMENTAL|Schwertbad Aachen|20 Patients with specific back pain will get Lumbo Sensa® bandage. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
62617886|NCT02536274|EXPERIMENTAL|Schön Klinik Fürth|20 Patients with specific back pain will get Dynaflex® flexion orthosis. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
62058020|NCT05538195|EXPERIMENTAL|Intravenous of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 3-10x10\^6 cells/kg
62446561|NCT01215942|EXPERIMENTAL|120 milligrams (mg) of LY2127399|"Given every 4 weeks for 240 weeks for those participants from Study BCDO or Study BCDV. Participants who had been receiving placebo immediately prior to enrollment will receive a 240 mg loading dose when initiating treatment.~Or~Given every 4 weeks for 168 weeks for those participants from Study BCDM."
62058021|NCT05538195|EXPERIMENTAL|intraperitoneal injection of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg
62261363|NCT01549002|ACTIVE_COMPARATOR|Intravenous Morphine|"Patients in this arm will receive intravenous morphine as their pre-I\&D analgesic. The one time total dose to be used is 0.1 milligrams / kilogram, to a maximum of 8 milligrams. The medication will be delivered via slow IV push.~The abscess I\&D will be followed according to protocol using topical and local anesthetic."
62261364|NCT03831594|EXPERIMENTAL|Standard Physiotherapy and Galvanic Vestibular Stimulation|Standard physiotherapy concurrently with Galvanic Vestibular Stimulation for 45 minutes a day for two weeks (five days per week)
62261365|NCT03831594|ACTIVE_COMPARATOR|Standard Physiotherapy|Standard Physiotherapy for 45 minutes a day for two weeks (five days per week)
62261366|NCT02431936|EXPERIMENTAL|Prazosin|Prescription for 1mg oral Prazosin twice per day will be administered for 71/2 days.
62261367|NCT02431936|PLACEBO_COMPARATOR|Placebo|Prescription for placebo identical to Prazosin dosage will be administered for twice daily for 71/2 days.
62261368|NCT00676390|OTHER|1|Congestive Heart failure patients
62261369|NCT03978507|EXPERIMENTAL|DeFOG group|feedback number of steps + cueing
62261370|NCT03978507|ACTIVE_COMPARATOR|Control group|feedback number of steps
62261371|NCT06494293||Data collection|Collection of medical data from MICU intervention file and patient medical files from participating centres
62261372|NCT02670863|EXPERIMENTAL|Experimental Infant Formula|Experimental Infant Formula containing a prebiotic
62261373|NCT02670863|ACTIVE_COMPARATOR|Standard Infant Formula|Standard bovine milk-based term infant formula
62617887|NCT02536274|NO_INTERVENTION|Schön Klinik Fürth & Schwertbad Aachen|20 Patients with specific back pain will get no intervention. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
62058022|NCT02960399|EXPERIMENTAL|Antibody Deficient Patients|Zostavax® vaccine administered to antibody deficient patients 60 years of age and older.
62058023|NCT02960399|ACTIVE_COMPARATOR|Healthy Subjects|Zostavax® vaccine administered per standard of care to healthy adults 60 years of age and older.
62058024|NCT03074812|SHAM_COMPARATOR|Sham tDCS|Sham transcranial direct current stimulation where current will be reduced to zero after standardized ramp up to 2 mA
62058025|NCT03074812|EXPERIMENTAL|Active tDCS|Transcranial direct current stimulation according to protocol maintained for 30 minutes after ramping up to 2 mA
62261374|NCT00635479|EXPERIMENTAL|VAC Device placement|will have the VAC device used for post-operative management of acetabular fractures and pelvic fractures.
62261375|NCT00635479|ACTIVE_COMPARATOR|Gauze dressing|will receive current traditional surgical wound management with daily dressing changes in post operative management of acetabular fractures and pelvic fractures.
62261376|NCT02860312|ACTIVE_COMPARATOR|Exercisers|Intradialytic exercise on stationary bicycles
62261377|NCT02860312|PLACEBO_COMPARATOR|Non Exercisers|No intradialytic exercise
62261378|NCT03066128|EXPERIMENTAL|Intervention|Participants in the Intervention Group will receive chronic ART management from a Professional Nurse and/or Enrolled Nurse every 2 months, and if stable after 6 months, community pharmacy ART collection through CCMDD. Viral load monitoring will be by a point-of-care viral load testing.
62261379|NCT03066128|EXPERIMENTAL|Standard of Care|Participants in the Standard-of-Care control arm will receive the standard-of-care for the clinic consisting of visits with a professional clinician (Physician or Professional Nurse) and once stable, community pharmacy ART collection through CCMDD.Viral load monitoring will be by lab-based viral load testing
62261380|NCT01100515|EXPERIMENTAL|Experimental arm|Hyperbaric oxygen therapy at 2 absolute atmosphere (1-hour plateau) followed by 4 hours of normobaric oxygen therapy
62261381|NCT01100515|ACTIVE_COMPARATOR|Control|6 hours course of normobaric oxygen therapy via a face full mask
62261382|NCT02263079|EXPERIMENTAL|Peg-IFN-Alfa-2A + Lamivudine or Entecavir|Participants will receive lamivudine or entecavir alone for 8 weeks followed by peg-IFN-alfa-2A in combination with lamivudine or entecavir for 48 weeks.
62261383|NCT02263079|NO_INTERVENTION|Untreated Control Participants|Untreated control participants will be observed up to 80 weeks.
62261384|NCT02263079|EXPERIMENTAL|Peg-INF-Alfa-2A Monotherapy|Participants will receive Peginterferon Alfa 2A subcutaneously once weekly with dosing based on body surface area (BSA) categories for 48 weeks.
62261385|NCT04162821|EXPERIMENTAL|60mg group|
62261386|NCT04162821|EXPERIMENTAL|90mg group|
62843489|NCT02164708|EXPERIMENTAL|Mindfulness Meditation|"The program progressively trained students in mindfulness of breathing, a form of meditation frequently employed secularly. The tutorials were held on campus five times weekly, led by a faculty member and a graduate student who were trained, experienced MM practitioners. The tutorials were one hour in duration and typically involved 40-45 minutes of guided MM followed by a question-answer period that addressed recent research findings. Program participation required attendance at one tutorial per week, and participants were encouraged to maintain autonomous MM practice."
62843490|NCT02223494|EXPERIMENTAL|Terbogrel|
62261387|NCT04162821|EXPERIMENTAL|120mg group|
62058026|NCT06424730|OTHER|Interview Group|Black patients or their family members; Black community faith leaders; primary care providers and research coordinators
62058027|NCT06424730|EXPERIMENTAL|Team based Equity conscious Telemedicine Hypertension (TET-HTN) intervention|Black patients with systolic blood pressure \>140 mmHg on the last two clinic visits plus baseline systolic blood pressure \>130 mmHg - deliver the TET-HTN intervention over six months
62261388|NCT02474212|ACTIVE_COMPARATOR|Enoxaparin 40 mg s.c.|Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 40 mg thromboprophylaxis every 24 hours for three days (72 hours)
62446562|NCT01215942|EXPERIMENTAL|90 mg LY2127399|"Given every 2 weeks for 240 weeks for those participants from Study BCDO or Study BCDV. Participants who had been receiving placebo immediately prior to enrollment will receive a 180 mg loading dose when initiating treatment.~Or~Given every 2 weeks for 168 weeks for those participants from Study BCDM."
62843491|NCT04298476|PLACEBO_COMPARATOR|A|Saline will be placed in syringe instead of ropivicaine 0.2% and the nerve block will be placed in the adductor canal at the desired location by the anesthesiologist
62843492|NCT04298476|ACTIVE_COMPARATOR|B|An adductor canal block will be placed with local anesthetic in the proximal 1/3 of the operative leg
62843493|NCT04298476|ACTIVE_COMPARATOR|C|An adductor canal block will be placed with local anesthetic in the middle 1/3 of the operative leg
62843494|NCT04298476|ACTIVE_COMPARATOR|D|An adductor canal block will be placed with local anesthetic in the distal 1/3 of the operative leg
62843495|NCT00992472|EXPERIMENTAL|Prochlorperazine suppositories, 25mg|
62843496|NCT00992472|ACTIVE_COMPARATOR|Compazine® suppositories, 25mg|
62843497|NCT02015962|EXPERIMENTAL|Intravenous potassium|Patients in this arm will be administered intravenous potassium if they develop hypokalemia. As per CICU protocol 1-ml blood sample from already placed art-line or central venous line is sent for analysis of serum potassium concentration in all the immediate post operative patients. In the IVPR group, potassium will be given according to the hospital protocol through a central line. As per a previously established protocol and bioavailability data, repeat serum potassium will be sent 1 hour after replacement in the IVPR group.
62843498|NCT02015962|EXPERIMENTAL|Enteral potassium (ERP)|Once included in the study, patients in this arm will be given oral potassium if they develop an episode of hypokalemia. As per CICU protocol 1-ml blood sample from already placed art-line or central venous line is sent for analysis of serum potassium concentration in all the immediate post operative patients. As per a previously established protocol and bioavailability data, repeat serum potassium will be sent 2 hours after replacement in the EPR group. Replacement and serum level monitoring will be done till the episode of hypokalemia is resolved
62843499|NCT06101589|EXPERIMENTAL|experimental arm in which we will give the active Vitamin D to participants|the intervention will be the Vitamin D in its active form 200,00 IU 25(OH)D3.route of administration is oral.
62843500|NCT06101589|PLACEBO_COMPARATOR|placebo arm in which we will give the placebo|olive oil will be the placebo medicine. the placebo medicine have similar taste and quantity. the route of administration is oral.
62058028|NCT06424730|OTHER|Usual Care|Black patients with systolic blood pressure \>140 mmHg on the last two clinic visits plus baseline systolic blood pressure \>130 mmHg - usual clinic based hypertension care using routinely available clinic services including community health worker/social worker. Clinicians can offer self-management support (e.g., dietician referral) or recommend a home blood pressure monitor. These activities mirror current primary care practice.
62261389|NCT02474212|ACTIVE_COMPARATOR|Enoxaparin 40 mg i.v.|Enoxaparin thromboprophylaxis (40 mg) daily as continuous intravenous infusion for three days (72 hours)
62058029|NCT03092375|EXPERIMENTAL|Arm A: G/P 300 mg/120 mg QD for 12 Wks|Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg Tablets once-daily by mouth) for 12 weeks.
62261390|NCT02474212|ACTIVE_COMPARATOR|Enoxaparin 0.5 mg/kg s.c.|Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 0.5 mg/kg thromboprophylaxis twice a day for three days (72 hours)
62261391|NCT02474212|ACTIVE_COMPARATOR|Enoxaparin 1 mg/kg i.v.|Enoxaparin thromboprophylaxis 1 mg/kg daily as continuous intravenous infusion for three days (72 hours)
62261392|NCT00714285|EXPERIMENTAL|Quadrivalent influenza vaccine GSK 2115160A Group 1|Subjects in this group received 1 full dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
62261393|NCT00714285|EXPERIMENTAL|Quadrivalent influenza vaccine GSK 2115160A Group 2|Subjects in this group received 1 low dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
62446563|NCT03051256|EXPERIMENTAL|REL-1017 25 mg|REL-1017 75 mg of powder in 100 mL of Ocean Spray® Diet Cranberry Juice daily on Day 1, 25 mg of powder in 100 mL Ocean Spray® Diet Cranberry Juice daily on Day 2-7.
62446564|NCT03051256|EXPERIMENTAL|REL-1017 50 mg|REL-1017 100 mg of powder in 100 mL of Ocean Spray® Diet Cranberry Juice daily on Day 1, 50 mg of powder in 100 mL Ocean Spray® Diet Cranberry Juice daily on Day 2-7.
62617888|NCT02536274|NO_INTERVENTION|RPE|20 healthy Subjects of the same age without back pain participate in the course for one time to prove the significance of the procedures. (control group) Study related procedures include a course with 6 exercises: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
62617889|NCT01322698||The study population|The target population includes patients in ICUs at the Nîmes and Montpellier University hospitals. This is a population of non-neutropenic patients (polynuclear neutrophils \> 500/mm3) at risk of developing invasive candidiasis.
62261394|NCT00714285|ACTIVE_COMPARATOR|Trivalent influenza vaccine GSK 2115160A Group 1|Subjects in this group received 1 low dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
62617890|NCT04292145|EXPERIMENTAL|Relaxation Application|Participants will follow the relaxation application.
62058030|NCT03092375|EXPERIMENTAL|Arm B: G/P 300 mg/120 mg QD for 16 Wks|Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)
62058031|NCT03092375|EXPERIMENTAL|Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks|Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily plus Ribavirin 200Mg Tablet (2-3 tablets) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)
62058032|NCT03092375|EXPERIMENTAL|Arm D: G/P 300 mg/120 mg QD for 16 Wks|Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)
62058033|NCT02848482|ACTIVE_COMPARATOR|Control group|Plastic curette will be used to perform the mechanical debridement. Then, irrigation (2% chlorhexidine) will be performed at contaminated sites.
62058034|NCT02848482|EXPERIMENTAL|Test group|Plastic curette will be used to perform the mechanical debridement. Then, the addition photodynamic therapy (PDT) will be performed. This will be performed with a set-up for PDT (HELBO Photodynamic Systems, German).
62617891|NCT04292145|ACTIVE_COMPARATOR|Relaxation Only|Participants will use any relaxation technique they normally use to relax.
62058035|NCT01460498|EXPERIMENTAL|Dose Escalation Group (AZA)|Azacitidine (AZA) starting dose 50 mg/m2 a day for 3 days subcutaneous or intravenous of 28 day cycle. TKI at dose received during last 6 months.
62261395|NCT00714285|ACTIVE_COMPARATOR|Trivalent influenza vaccine GSK 2115160A Group 2|Subjects in this group received 1 full dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
62261396|NCT01140451|EXPERIMENTAL|Ataluren/Ataluren|Participants who received double-blind ataluren during Study 009 will continue to receive open-label ataluren 3 times per day TID: 10 milligram (mg)/kilogram (kg) of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total dose 40 mg/kg/day), for up to 96 weeks. Participants will be followed for 4 weeks after treatment.
62843501|NCT05525481|EXPERIMENTAL|Intervention arm|This is a single-arm trial. We only have one experimental arm. The control arm will be provided by another study.
62843502|NCT00309491|EXPERIMENTAL|Group I|Tamoxifen alone
62843503|NCT00309491|EXPERIMENTAL|Group II|Tamoxifen + Aminoglutethimide
62843504|NCT02163941|EXPERIMENTAL|Compassion Training|8 weeks of training in Cognitively-Based Compassion Training (CBCT). Classes will meet once per week for 2 hours and participants will be asked to meditate at home for 20 minute each day.
62843505|NCT00380653|EXPERIMENTAL|sapacitabine low dose|sapacitabine administered every 12 hours for 7 days followed by 14 days of rest or every 12 hours for 3 consecutive days per week for 2 weeks followed by 7 days of rest in patients with advanced leukemias or myelodysplastic syndromes The starting dose is (A) 75 mg twice daily x 7 days followed by 14 days of rest; Evaluated doses: 75mg, 100mg, 125mg, 175mg, 225mg, 275mg, 325mg and 375mg
62261397|NCT01140451|EXPERIMENTAL|Placebo/Ataluren|Participants who received double-blind placebo during Study 009 will receive open-label ataluren TID: 10 mg/kg of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total dose 40 mg/kg/day), for up to 96 weeks. Participants will be followed for 4 weeks after treatment.
62261398|NCT05559489|EXPERIMENTAL|Enteral-based Protocolized Resuscitation|Administration of Enteral-based Resuscitation using Oral Rehydration Solution (ORS) either by mouth or via naso-enteric access for moderate sized burn injuries (15-40% TBSA) per resuscitation protocol for burn-injured patients. Resuscitation will be administered in the acute resuscitation phase of burn injury (24-72 hours post injury). Patients will receive supplemental Intravenous Fluid (IV Fluid) resuscitation using Lactated Ringer's solution as needed per protocol.
62446565|NCT03051256|PLACEBO_COMPARATOR|Placebo|100 mL Ocean Spray® Diet Cranberry Juice will be administered as a single oral dose daily for 7 days.
62843506|NCT00380653|EXPERIMENTAL|sapacitabine high dose|"The starting dose is 375 mg twice daily x 3 consecutive days per week for 2 weeks followed by 7days of rest.~Evaluated doses: 375mg, 425mg and 475mg"
62843507|NCT03167632||dental patients|
62261399|NCT05559489|ACTIVE_COMPARATOR|Intravenous Fluid Protocolized Resuscitation|Administration of Intravenous Fluid using Lactated Ringer's solution per standard of care resuscitation protocol for patients with moderate sized burn injuries (15-40% TBSA).
62261400|NCT00873977|ACTIVE_COMPARATOR|C-flex|
62617892|NCT02205294|NO_INTERVENTION|Assessment Only|Subjects will have an osteopathic assessment to determine areas of tension in specific areas of the body. These areas include: the thoracic diaphragm, the heart and pericardium, the iliac fascia, the femoral sheath, the sartorius muscle, the pelvic diaphragm and the interosseous membrane (IM) of the lower extremity
62843508|NCT01019083|PLACEBO_COMPARATOR|zinc supplementation-Placebo|Determine if the immunogenicity of oral typhoid can be enhanced in children by introducing zinc supplementation: Our recent studies on the interactions of oral cholera vaccine with breast milk and zinc provide some basis for improving immunogenicity, but additional work is needed to improve many of the oral vaccines. In this study we also plan to evaluate if the immune response to Cholera and Vivotif can be enhanced by supplementation with zinc using methods described earlier. We would like to study children, 2-5 years of age for this purpose.
62843509|NCT01019083|PLACEBO_COMPARATOR|Anti Parasite Drug- Placebo|There is a high burden of enteric parasites in the gut of people living in densely populated areas of less developed countries. The effect of concurrent parasitic infestations on immune responses has not been studied widely, although it is an area of utmost importance for natural protection as well as vaccine immuno-prophylaxis. In this study we plan to determine the impact of pretreatment with antiparasitic agents (albendazole and secnidazole) on the immunogenicity of the oral cholera and typhoid vaccines in children, 2-5 years of age
62058036|NCT01460498|EXPERIMENTAL|Expansion Group (AZA MTD)|Dose Escalation Group plus additional 36 participants for Azacitidine 75 mg/m2 (or Phase I MTD) either subcutaneous or intravenous every day for 3 days of 28 day cycle. TKI at dose received during last 6 months.
62261401|NCT00873977|ACTIVE_COMPARATOR|A-flex|
62058037|NCT01995539|EXPERIMENTAL|iPro2 Use|All subjects wearing iPro2, having therapy regimens, and having baseline and EOS A1C tests
62058038|NCT06625671|EXPERIMENTAL|Dose Level 1|
62446566|NCT02334059|ACTIVE_COMPARATOR|Ketamine|Ketamine: 0.5 mg/kg IV dose
62261402|NCT00873977|NO_INTERVENTION|Auto-CPAP|
62446567|NCT02334059|ACTIVE_COMPARATOR|Ketamine plus magnesium|Ketamine plus magnesium group: 0.5 mg/kg IV dose as well as Magnesium 2 grams IV
62446568|NCT02334059|PLACEBO_COMPARATOR|Placebo|Placebo (normal saline)
62446569|NCT03029520|ACTIVE_COMPARATOR|pain iRoot SP sealer Vital Pulp|Evaluation of Postoperative pain after root canal obturation with iRoot SP sealer (Innovative BioCeramix Inc., Vancouver, Canada) with patients who has (mandibular premolar/molar) vital pulp.
62446570|NCT03029520|ACTIVE_COMPARATOR|pain iRoot SP sealer Devital pulp|Evaluation of Postoperative pain after root canal obturation with iRoot SP sealer (Innovative BioCeramix Inc., Vancouver, Canada) with patients who has (mandibular premolar/molar) devital pulp.
62446571|NCT03029520|ACTIVE_COMPARATOR|pain AHPlus Vital pulp|Evaluation of Postoperative pain after root canal obturation with AH Plus sealer (Dentsply Maillefer, Ballaigues, Switzerland) with patients who has (mandibular premolar/molar) vital pulp.
62617893|NCT02205294|ACTIVE_COMPARATOR|Assessment and Treatment|Subjects will have an osteopathic assessment to determine areas of tension in specific areas of the body. These areas of tension will receive osteopathic treatment, using myofascial release techniques. These areas include: the thoracic diaphragm, the heart and pericardium, the iliac fascia, the femoral sheath, the sartorius muscle, the pelvic diaphragm and the interosseous membrane (IM) of the lower extremity
62617894|NCT04397549|ACTIVE_COMPARATOR|Block group|Cervical Erector Spinae Plane Block administered group
62058039|NCT06625671|EXPERIMENTAL|Dose Level 2|
62058040|NCT06625671|EXPERIMENTAL|Dose Level 3|
62058041|NCT06625671|EXPERIMENTAL|Dose Level 4|
62261403|NCT03095742|PLACEBO_COMPARATOR|Low MAP|Low mean arterial pressure. 30 patients were blindly randomized to normal range (MAP 65 mmHg) during the peri-cardiac arrest period.
62261404|NCT03095742|ACTIVE_COMPARATOR|High MAP|High mean arterial pressure. 30 patients were blindly randomized to intervention group (MAP 75 mmHg) during the peri-cardiac arrest period.
62261405|NCT03412175|EXPERIMENTAL|Behavioral Intervention|Participants in the lifestyle intervention arm will receive 6 individual visits with a CREATION Health Specialist over a 3 month period, and one follow up visit at 6 months. The visits include one 2 hour-long initial assessment, four 60-minute motivational interview sessions, and two 60-minute reassessments. Visits will focus on tailoring the intervention care plan to each individual, goal-setting, action plans, self-monitoring, identification of personal and social barriers to change, self-regulatory techniques, and provision of psychosocial support using motivational interviewing techniques.
62617895|NCT04397549|SHAM_COMPARATOR|Control group|Control group
62058042|NCT06625671|EXPERIMENTAL|Dose Level 5|
62058043|NCT02016404|ACTIVE_COMPARATOR|Low-sodium, high-potassium salt|Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, mono sodium glutamate (MSG), sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation
62058044|NCT02016404|PLACEBO_COMPARATOR|Regular salt|Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
62446572|NCT03029520|ACTIVE_COMPARATOR|pain AHPlus Devital Pulp|Evaluation of Postoperative pain after root canal obturation with AH Plus sealer (Dentsply Maillefer, Ballaigues, Switzerland) with patients who has (mandibular premolar/molar) devital pulp.
62617896|NCT04150120|ACTIVE_COMPARATOR|Reconstructive paediatric surgery (Area I)|The overall incidence of congenital malformations in the gastrointestinal and urinary tract needing surgical interventions is about 1:1000 (Swedish national malformation registers) with a morbidity during childhood about 20-60%. Advanced paediatric surgery for the diagnosis Hirschsprung's disease, anorectal malformations, bladder extrophy, congenital diaphragmal hernia, and esophageal atresia is from July 2018 only performed at two NCSM in Sweden. The NCSM at Skåne University Hospital (SUS) in Lund forms one context. The quality of postoperative care is of immense importance both for short and long-term outcome. Legal guardians describe their situation after leaving the hospital as extremely stressful as they have not only to take responsibility for their new-born child but also of surgical wounds, medications, treatments, and special nutritional needs.
62058045|NCT04074967|EXPERIMENTAL|Phase Ib ARRY-614 + nivolumab|"Participants with advanced solid tumors will receive ARRY-614 in combination with nivolumab.~(histologically confirmed metastatic or unresectable malignancy with lacking curative measures; nivolumab must be available and appropriate for proposed therapy)"
62058046|NCT04074967|EXPERIMENTAL|Phase Ib ARRY-614 + nivolumab + ipilimumab|"Participants with advanced solid tumors will received ARRY-614 in combination with nivolumab + ipilimumab.~(histologically confirmed metastatic or unresectable malignancy with lacking curative measures; nivolumab and ipilimumab must be available and appropriate for proposed therapy)"
62058047|NCT04074967|EXPERIMENTAL|Phase II ARRY-614 + nivolumab|Participants with of NSCLC and HNSCCC will receive ARRY-614 combined with nivolumab.
62058048|NCT04074967|EXPERIMENTAL|Phase II ARRY-614 + nivolumab + ipilimumab (melanoma)|Participants with melanoma will receive ARRY-614 combined with nivolumab + ipilimumab.
62058049|NCT04074967|EXPERIMENTAL|Phase II ARRY-614 + nivolumab + ipilimumab (RCC)|Participants with RCC will receive ARRY-614 combined with nivolumab + ipilimumab.
62058050|NCT02026648||cases with cervical cancer|
62058051|NCT03131960|EXPERIMENTAL|VNS + Rehabilitation (1)|Study treatment is vagus nerve stimulation (VNS) delivered during rehabilitation.
62058052|NCT03131960|ACTIVE_COMPARATOR|Control VNS|Active control treatment is rehabilitation (standard-of-care treatment) with only a minimal amount of VNS at the start of each session intended to support blinding.
62058053|NCT02413060|EXPERIMENTAL|Resistance training|Patients of treatment group will undergo resistance training every week sessions
62058054|NCT02413060|OTHER|Lifestyle counseling|Patients of control group will get the lifestyle counseling every 3 month
62058055|NCT02119143|ACTIVE_COMPARATOR|Vitamines and minerals|41 middel aged subjects receive vitamin and mineral supplementation
62058056|NCT02119143|PLACEBO_COMPARATOR|cellulose|41 middle aged subjects get the placebo
62058057|NCT02802501|EXPERIMENTAL|DHA-PQP plus tafenoquine 300 mg single dose|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to the body weight) from Day 1 to Day 3. They will receive double-blind 300 mg single dose of tafenoquine (TQ) on Day 1 and matched-placebo for primaquine (PQ) from Day 1 to Day 14.
62058058|NCT02802501|ACTIVE_COMPARATOR|DHA-PQP plus primaquine 15 mg for 14 days|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind 15 mg primaquine (PQ) from Day 1 to Day 14 and matched-placebo for tafenoquine (TQ) on Day 1.
62261406|NCT03412175|NO_INTERVENTION|Control Group|Participants in the control group will receive usual care as provided by their primary care physician. Participants in the control group will complete biometrics, surveys, and assessments at Visits 0, 5 and 6.
62058059|NCT02802501|PLACEBO_COMPARATOR|DHA-PQP alone (placebo arm)|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind matched-placebo for tafenoquine (TQ) on Day 1 and matched-placebo for primaquine (PQ) from Day 1 to Day 14.
62261407|NCT05062876|ACTIVE_COMPARATOR|R-T|Period 1 : Test Drug(AD-214) Period 2 : Reference Drug(AD-2141)
62261408|NCT05062876|ACTIVE_COMPARATOR|T-R|Period 1 : Reference Drug(AD-2141) Period 2 : Test Drug(AD-214)
62261409|NCT01142401|EXPERIMENTAL|Arm A (fulvestrant)|Patients receive fulvestrant IM on day 1 (days -14, 1, and 15 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may crossover to arm C.
62261410|NCT01142401|EXPERIMENTAL|Arm B (fulvestrant, bortezomib)|Patients receive fulvestrant as in arm A and bortezomib IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62261411|NCT01142401|EXPERIMENTAL|Arm C (fulvestrant, bortezomib)|Patients receive fulvestrant IV on day 1 and bortezomib IM on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62446573|NCT01304446|EXPERIMENTAL|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
62446574|NCT03872648||TW-VP (centralized delivery structure)|Trans women seeking penile inversion vaginoplasty (TW-VP) assessing THC in a specialized clinic with a centralized structure
62446575|NCT03872648||TW-VP (decentralized delivery structure)|Trans women seeking penile inversion vaginoplasty (TW-VP) assessing THC from different medical locations (decentralized structure)
62446576|NCT04753736|NO_INTERVENTION|No recurrent implantation failure|
62446577|NCT04753736|EXPERIMENTAL|Recurrent implantation failures|
62261412|NCT03418428||Test group|Patients who underwent total or subtotal gastrectomy for the treatment of gastric cancer
62261413|NCT03418428||Control group 1|Patients who underwent endoscopic mucosal resection/submucosal dissection for the treatment of gastric cancer
62261414|NCT03418428||Control group 2|In-house relatives of Test group and Control group 1 participants
62261415|NCT03418428||Control group 3|Patients with long-term history of proton pump inhibitor usage
62261416|NCT03523481||NHF use|
62261417|NCT05288738|ACTIVE_COMPARATOR|Group D1|PCA morphine 1mg/ml
62261418|NCT05288738|ACTIVE_COMPARATOR|Group D2|PCA morphine 1mg/ml
62261419|NCT04046003|EXPERIMENTAL|Tai Chi intervention|24-form Yang style Tai Chi
62261420|NCT02289742|OTHER|Arm1: Presbyopes|Nelfilcon A contact lenses (multifocal and sphere) worn as randomized in a crossover design during Periods 1 and 2, with nelfilcon A sphere contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 12 hours.
62261421|NCT02289742|OTHER|Arm2: Astigmats|Nelfilcon A contact lenses (toric and sphere) worn as randomized in a crossover design during Periods 1 and 2, with nelfilcon A sphere contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 12 hours.
62261422|NCT04044300|EXPERIMENTAL|Operative|A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level.
62261423|NCT04044300|EXPERIMENTAL|Non-operative|Continued pain management and physical therapy
62261424|NCT03024970|EXPERIMENTAL|stenfilcon A lens with solution additive (test)|Participants were randomized to wear the stenfilcon A lens with solution additive (test) for 1 month during the cross over study.
62261425|NCT03024970|ACTIVE_COMPARATOR|stenfilcon A lens (control)|Participants were randomized to wear stenfilcon A (control) lens pair for 1 month during the cross over study.
62261426|NCT03894670|ACTIVE_COMPARATOR|SmartBar™|The wireless capsule technology, SmartPill™, is usually ingested together with a SmartBar™ which is a snack bar with a nutrient composition that differs substantially from a normal western diet.
62261427|NCT03894670|EXPERIMENTAL|Standard mixed breakfast meal|The SmartPill™ is ingested together with a standard mixed breakfast meal and the outcomes of interest will be compared with the SmartBar™ condition (reference).
62446578|NCT04753736|EXPERIMENTAL|Recurrent miscarriage|
62446579|NCT05559411||Wire-guided Localization|
62446580|NCT05559411||Intraoperative Ultrasound|
62446581|NCT05559411||Magnetic Localization|
62446582|NCT05559411||Radar Reflector Localization|
62446583|NCT05559411||Radiofrequency Localization|
62446584|NCT05559411||Radioactive Localization|
62446585|NCT05559411||Ink Localization|
62446586|NCT02752945|EXPERIMENTAL|One-day CBT workshop (+Usual Care)|"One-day CBT-based workshop (DISCOVER), followed by up to three brief telephone contacts to review goals set in workshop."
62446587|NCT02752945|ACTIVE_COMPARATOR|Usual care|Usual care afforded by local CAMHS services
62446588|NCT00916890|ACTIVE_COMPARATOR|Oral extended-release morphine|
62446589|NCT00916890|ACTIVE_COMPARATOR|Oral extended-release oxycodone|
62843510|NCT01019083|EXPERIMENTAL|Effect of Arsenic in Dukoral- Control|In this study, we aim to evaluate if immunogenicity of the oral cholera vaccine is modified in children living in a high arsenic contaminated area in Bangladesh. The plan is to study children 2-5 year old living in Shahrasti thana near Matlab where the tubewell water is highly contaminated with arsenic and this study will not be randomized double-blind, and compare their responses with responses of age matched children living in arsenic free area, such as in Mirpur area of Dhaka city. We only plan to study the effect of Dukoral vaccinees since this vaccine has been widely studied in Bangladesh. If an impact of arsenic is seen on immune response to this vaccine, future studies could be done with other vaccines including Vivotif.
62843511|NCT01019083|EXPERIMENTAL|zinc supplementation|Determine if the immunogenicity of oral typhoid can be enhanced in children by introducing zinc supplementation: Our recent studies on the interactions of oral cholera vaccine with breast milk and zinc provide some basis for improving immunogenicity, but additional work is needed to improve many of the oral vaccines. In this study we also plan to evaluate if the immune response to Cholera and Vivotif can be enhanced by supplementation with zinc using methods described earlier. We would like to study children, 2-5 years of age for this purpose.
62843512|NCT01019083|EXPERIMENTAL|administration of antiparasitic drugs|There is a high burden of enteric parasites in the gut of people living in densely populated areas of less developed countries. The effect of concurrent parasitic infestations on immune responses has not been studied widely, although it is an area of utmost importance for natural protection as well as vaccine immuno-prophylaxis. In this study we plan to determine the impact of pretreatment with antiparasitic agents (albendazole and secnidazole) on the immunogenicity of the oral cholera and typhoid vaccines in children, 2-5 years of age
62261428|NCT02011659|ACTIVE_COMPARATOR|Ramosetron|
62261429|NCT05311124|EXPERIMENTAL|Single-arm prospective|Single-arm prospective pilot study. All patients receive Integra dermal regeneration template (IDRT) that sign an inform consent.
62261430|NCT05285241|EXPERIMENTAL|Multidirectional exercise group|Multidirectional stepping exercises along with conventional physiotherapy were provided to the patients. Conventional physiotherapy included one-to-one range of motion exercises (10min), Strengthening exercises (10 min), Functional mat exercises (10 min), Stretching exercises (5 min), and Gait exercises (10 min).
62261431|NCT05285241|ACTIVE_COMPARATOR|Conventional Physiotherapy Group|One-to-one range of motion exercises (10min), Strengthening exercises (10 min), Functional mat exercises (10 min), Stretching exercises (5 min), and Gait exercises (10 min) were provided to the patients.
62261432|NCT04266275|EXPERIMENTAL|Curcumin Arm|Participants in this arm will use 2000 mg of intravaginal curcumin once a week for 20 weeks
62261433|NCT04266275|PLACEBO_COMPARATOR|Placebo Arm|Participants in this arm will use 2000 mg of intravaginal placebo once a week for 20 weeks
62261434|NCT03459911|EXPERIMENTAL|Losartan potassium 100 mg Tablets|Losartan potassium is the test product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Losartan potassium.
62261435|NCT03459911|ACTIVE_COMPARATOR|Cozaar® (Losartan potassium)100 mg Tablets|Cozaar® (Losartan potassium) is the reference product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Cozaar®.
62261436|NCT01206062|EXPERIMENTAL|Intensive Control of SBP|"Participants randomized into the Intensive BP arm will have a goal of SBP \<120 mm Hg. 2-drug therapy initiated in most Intensive participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP \<120 mm Hg; at periodic milepost visits: addition of another drug required if not at goal."
62446590|NCT00916890|ACTIVE_COMPARATOR|Transdermal fentanyl|
62446591|NCT00916890|ACTIVE_COMPARATOR|Transdermal buprenorphine|
62446592|NCT01226277|EXPERIMENTAL|A|
62058060|NCT04369001|EXPERIMENTAL|Intervention Group|(Program ACTIVE n=20) Participants randomized into the Program ACTIVE group will receive a gym membership to a local, Detroit-based community recreation facility where they will complete 150 minutes of exercise per week for 12 weeks and will receive 10 sessions (once weekly) of CBT therapy sessions. Exercise per week will be documented using exercise logs. Exercise logs will be given to research staff at the end of the 12-week timeframe; all exercise logs will be kept organized respective to the participant identification number and related documents (questionnaires and surveys). To ensure treatment fidelity, three CBT and three physical activity sessions will be selected at random and recorded and rated for fidelity to the above content by our research team.
62058061|NCT04369001|NO_INTERVENTION|Enhanced Usual Care|(EUC n=20) Participants randomized to enhanced usual care will receive referrals to community mental health providers, pedometers, gym memberships to a community-based venue, and intervention patient manuals. Participants will not be required to report any use of resources offered or change their course of treatment in any way. Based on several years of experience in Detroit, providing all participants with referrals, pedometers, gym access and educational materials minimizes ethical concerns regarding assignment of underserved populations to receive a no-treatment control.
62058062|NCT03917940|EXPERIMENTAL|Omega 3 + glimepiride|group 1: 35 patients treated with (Omega - 3 1000mg / day oral plus glimepiride 2mg or 3mg /day.
62058063|NCT03917940|PLACEBO_COMPARATOR|Control|group 2: 35 patients treated with glimepiride 2mg or 3mg /day.
62058064|NCT00106184|EXPERIMENTAL|Adult Study Group 1|Refractory adult polymyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
62058065|NCT00106184|EXPERIMENTAL|Adult Study Group 2|Refractory adult polymyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
62058066|NCT00106184|EXPERIMENTAL|Adult Study Group 3|Adult dermatomyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
62058067|NCT00106184|EXPERIMENTAL|Adult Study Group 4|Adult dermatomyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
62058068|NCT00106184|EXPERIMENTAL|JDM Study Group 1|Refractory juvenile dermatomyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
62058069|NCT00106184|EXPERIMENTAL|JDM Study Group 2|Refractory juvenile dermatomyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
62058070|NCT01490125|EXPERIMENTAL|QVA149 + placebo to tiotropium|Participants received QVA149 plus placebo to tiotropium during 1 of 3 treatment periods, once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
62058071|NCT01490125|ACTIVE_COMPARATOR|Tiotropium + placebo to QVA149|Participants received tiotropium 18 μg plus placebo to QVA149 during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
62261437|NCT01206062|ACTIVE_COMPARATOR|Standard Control of SBP|Participants randomized into the Standard arm will have a goal of SBP \<140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP \<130 mm Hg @ 1 visit; \<135 mm Hg @ 2 consecutive visits
62261438|NCT03716401||Bari: Biopsy Arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.~Additionally, participants at the Bari site will have an additional renal biopsy at baseline."
62261439|NCT03716401||Bordeaux: MRI Follow-up arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.~Additionally, participants at the Bordeaux site will have an additional ultrasound US and MRI in Follow-up year 2."
62058072|NCT01490125|PLACEBO_COMPARATOR|Placebo|Participants received placebo to QVA149 plus placebo to tiotropium during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
62058073|NCT04009590|EXPERIMENTAL|GROUP I (Quit4Health)|Participants utilize Quit4Health intervention that includes interactive features, coping strategies and games related to cigarettes and other tobacco products for 1 month.
62058074|NCT04009590|ACTIVE_COMPARATOR|Group II (educational booklet)|Participants read an educational booklet about cigarettes and other tobacco products for 1 month.
62058075|NCT04846023|EXPERIMENTAL|amplitude EEG (aEEG) via VEEGix|Amplitude-Integrated EEG can be achieved with a limited number of frontal electrodes.
62261440|NCT03716401||Exeter: Microvascular arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.~Participants at the Exeter site will undergo microvascular measurements including estimating glycocalyx thickness at baseline and at 2 years follow-up."
62261441|NCT03716401||Leeds: Microstructure MRI arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection.~Participants at the Leeds' site will have an extended MRI scan at baseline including novel microstructure MRI measurements."
62058076|NCT04837859|EXPERIMENTAL|Arm A age 18-60|Patients at the age of 18-60 years at enrollment will receive 2 initial doses of 200 mg tislelizumab in 21-day intervals followed by an interim positron emission tomography (PET-2). Following a PET-guided approach, patients with a negative PET-2 (i.e. Deauville score 1-3) according to central review will continue receiving tislelizumab for another 4 doses of 300 mg in 28-day intervals. Patients with a positive PET-2 (i.e. Deauville score \>3) will receive 4 cycles of combined 300 mg tislelizumab on day 1 and AVD chemotherapy on day 1 and 15 in 28-day cycles (4x T-AVD). For all patients, 30 Gy involved-site radiotherapy (IS-RT) will only be applied in case of PET positivity after completion of (chemo-) immunotherapy.
62058077|NCT04837859|EXPERIMENTAL|Arm B Age 60+|Patients above the age of 60 years will be enrolled in a separate, exploratory cohort and receive PET-guided treatment with tislelizumab or T-AVD as described above. However, all patients in the exploratory cohort for older patients will receive consolidating 30 Gy IS-RT.
62058078|NCT01661556|EXPERIMENTAL|Miconazole|OTC topical prescription used for fungal treatment that can be useful to the treatment of melasma due to its depigmenting properties.
62261442|NCT03716401||Turku: PET arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.~Additionally, participants at the Turku site will undergo a renal Positron Emission Tomography (PET) scan at the baseline timepoint."
62617897|NCT04150120|ACTIVE_COMPARATOR|Congenital heart disease (Area II)|In Sweden, about 8-10 in 1000 children per year are born with congenital heart disease (CHD). CHD is a birth defect that leads to frequent hospitalisation, long hospital stays, and extreme anxiety for parents (18). In Sweden, paediatric heart surgery is concentrated to two NCSM of which one is situated at SUS, Lund where 250-300 children have cardiac surgery every year. Children with complicated CHD require contact and follow-up visits for a long time after the heart surgery and many families have to travel long for surgery (for example from Iceland), postoperative care and follow-up visits. Telemedicine after reconstructive cardiac surgery in children is shown to be feasible, although challenging and reduced unscheduled visits.
62617898|NCT04150120|ACTIVE_COMPARATOR|Preterm born (Area III)|Most prematurely born children grow up to be healthy, but as a group, they are at a greater risk of developing cognitive, emotional and behavioural problems. Every year 7% of all children are born prematurely (gestational age of less than 37 weeks) and the numbers of preterm births are rising in Sweden as well as internationally. Preterm births often involve long hospitalisations for children and parents, and discharge from the hospital often means a difficult transition for parents in both short and long-term perspectives. Traditionally, communication with parents following discharge has been through home visits or telephone calls. By communicating through digital technology, it may be possible to improve the support to parents and thereby make the transition from hospital to home less stressful.
62617899|NCT04150120|ACTIVE_COMPARATOR|Paediatric oncology (Area IV)|For children with cancer, treatment and follow-up at home is common. At the same time, families wish to minimize the negative impact on family members' social and everyday life. Home medication management is a high-risk area and medication errors are common, particularly among parents of children with cancer. Thus, parents are responsible for complex care and regular follow-up in their home with an increased need for education as well as clinical management support. At present, there are no, or limited, professional outreach support to support them and their families. Communication with parents following discharge has been through e-mail and/ or telephone calls. By communicating through digital technology, it may be possible to improve the support to children and parents.
62843513|NCT01019083|EXPERIMENTAL|Effect of arsenic on Dukoral response|In this study, we aim to evaluate if immunogenicity of the oral cholera vaccine is modified in children living in a high arsenic contaminated area in Bangladesh. The plan is to study children 2-5 year old living in Shahrasti thana near Matlab where the tubewell water is highly contaminated with arsenic and this study will not be randomized double-blind, and compare their responses with responses of age matched children living in arsenic free area, such as in Mirpur area of Dhaka city. We only plan to study the effect of Dukoral vaccinees since this vaccine has been widely studied in Bangladesh. If an impact of arsenic is seen on immune response to this vaccine, future studies could be done with other vaccines including Vivotif.
62843514|NCT02920242|EXPERIMENTAL|Rifaximin|Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.
62843515|NCT02920242|ACTIVE_COMPARATOR|Xifaxan|Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.
62058079|NCT01661556|ACTIVE_COMPARATOR|Hydroquinone|Hydroquinone 4% cream (Topical use) a depigmenting agent used as reference will be used as control. It will be applied twice a day for 9 weeks.
62058080|NCT01661556|PLACEBO_COMPARATOR|Placebo|Moisturizer cream without pharmacological effects will be used as a control.
62058081|NCT05249062|EXPERIMENTAL|intervention|The intervention being piloted in this study is a novel system of supporting older individuals with multiple long-term conditions to self-manage their chronic conditions through the daily use of a digital health product that can also facilitate the remote monitoring of a person's health status.
62058082|NCT00298922|ACTIVE_COMPARATOR|Azithromycin|participants taking 500 mg tablets orally thrice weekly for 24 weeks
62058083|NCT00298922|PLACEBO_COMPARATOR|Placebo|Participants taking 500 mg tablets orally thrice weekly for 24 weeks
62261443|NCT03286062|EXPERIMENTAL|VM110|Escalating dose of agent VM110 given to patients to visualize occult cancer with laproscopic infra red detect
62261444|NCT02738983|EXPERIMENTAL|Bioradiotherapy|Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day) with concurrent radiotherapy to a total radiation dose of 60-66 Gray (Gy).
62261445|NCT04261790|OTHER|Ocrelizumab|Patients will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.
62617900|NCT04150120|ACTIVE_COMPARATOR|Intravenous infusion therapy at home (Area V)|For children with LTI administration of intravenous infusion therapy at home is an increasingly important area. Home medication management is a high-risk area and medication errors are common, particularly among parents of children with cancer. Thus, parents are responsible for complex care in their home with an increased need for educational as well as clinical management support during home infusion therapy. At present, children and adolescents with LTI at the University Hospital of Copenhagen receive home infusion therapy by a portable pump with no assistance from an outreaching team to support them and their families.
62617901|NCT04150120|ACTIVE_COMPARATOR|Children with cerebral palsy (VI)|Cerebral palsy (CP) is the most common physical disability in childhood. Approximately 2-2.5/1000 children have CP with affected muscle tone, movement and motor skills, often accompanied by pain, epilepsy and intellectual, communicational and behavioural impairment. Early detection is challenging but important for minimizing the consequences from neurodevelopmental impairment by an early and right treatment. General Movement Assessment (GMA), an observational method for classification of spontaneous movements in young infants, is currently the most accurate method for early identification of CP. Video recordings are taken with a standardised video set-up in the hospitals regular follow-up clinics when the child is 10 to 20 weeks post-term age. Performing video recordings at home by the parents at a time, which suits the family and the child, would optimize the chances for a successful recording.
62617902|NCT01030718|EXPERIMENTAL|dasatinib (CML-CP)|CML - Chronic Phase
62617903|NCT01030718|EXPERIMENTAL|dasatinib (CML-AP/BP)|CML - Accelerated Phase and Blast Phase
62058084|NCT00978484|ACTIVE_COMPARATOR|Static Virtual Reality|Exposure Therapy using a still computer image
62261446|NCT05482464|OTHER|Casein glycomacropeptide (CGMP)|"The subjects will receive a daily oral intake of CGMP-protein-shake for 3 weeks with a 1 week wash-in and a 3 week wash-out.~Intervention: Dietary Supplement: Casein glycomacropeptide (CGMP)"
62261447|NCT05060822|EXPERIMENTAL|HEC585 dose A|Drug: HEC585 dose A once daily, up to 24 weeks-120 weeks
62261448|NCT05060822|EXPERIMENTAL|HEC585 dose B|Drug: HEC585 dose B once daily, up to 24 weeks-120 weeks
62261449|NCT05060822|EXPERIMENTAL|HEC585 dose C|Drug: HEC585 dose C once daily, up to 24 weeks-120 weeks
62446593|NCT05263583|EXPERIMENTAL|Cohort 1|Cohort 1 will receive a dose of 3.6 mg/m2/day of sepantronium bromide
62617904|NCT01030718|EXPERIMENTAL|dasatinib (Ph+ ALL)|Ph+ Acute Lymphoblastic Leukemia
62617905|NCT04157049||Alpha-1 Diagnosed Individuals|Larger patient cohorts are needed to support the clinical trials coming in the next 3-5 years. Despite widespread invitations to the Alpha-1 community from the Alpha-1 Foundation Research Registry, it is estimated that the Alpha-1 Foundation Research Registry now contains \<40% of the identified PiZZ individuals in the US.
62617906|NCT04157049||Carriers of Alpha-1|Larger patient cohorts are needed to support the clinical trials coming in the next 3-5 years. Despite widespread invitations to the Alpha-1 community from the Alpha-1 Foundation Research Registry, it is estimated that the Alpha-1 Foundation Research Registry now contains \<40% of the identified PiZZ individuals in the US.
62617907|NCT05430685|EXPERIMENTAL|Ashwagandha|Generic name: ashwagandha root extract Dose form: Chloroform capsule Dose: 1 capsule 350 mg ashwagandha root extract Frequency: 2 times per day (one capsule in the morning, one capsule in the evening). Total: 700 mg ashwagandha root extract per day Duration: 30 days
62843516|NCT02920242|PLACEBO_COMPARATOR|Placebo|Patients received placebo tablet 3 times per day for 3 days.
62058085|NCT00978484|EXPERIMENTAL|Dynamic Virtual Reality|Virtual Reality Exposure Therapy using full, immersive Virtual Reality
62261450|NCT05060822|ACTIVE_COMPARATOR|pirfenidone|Drug: pirfenidone three times a day (target dose), up to 24 weeks
62261451|NCT05060822|PLACEBO_COMPARATOR|placebo|Drug: placebo once daily, up to 24 weeks-120 weeks
62261452|NCT04836975||SCLC|Patient Diagnosed with Small Cell Lung Cancer- (extensive or limited)
62261453|NCT04836975||NSCLC|Patient diagnosed with primary stage III Non-Small cell lung Cancer
62446594|NCT05263583|EXPERIMENTAL|Cohort 2|Cohort 1 will receive a dose of 4.8 mg/m2/day of sepantronium bromide
62446595|NCT05263583|EXPERIMENTAL|Recommended Phase 2 Dose - Cohort 3|The recommended Phase 2 dose will be established based on the safety, pharmacokinetic and pharmacodynamic data from Cohort 1 and Cohort 2
62058086|NCT00459342|EXPERIMENTAL|Arm I|Patients received oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62058087|NCT05108649|EXPERIMENTAL|Nicotine Corrective Messaging|After completing a 7-day baseline period, participants will be randomized to a 28-day experimental period and will view nicotine corrective messaging at each in-person session.
62058088|NCT05108649|EXPERIMENTAL|Delayed Control Messaging|After completing a 7-day baseline period, participants will be randomized to a 28-day experimental period and will not view nicotine messaging until the final study session (Delayed Control Messaging).
62058089|NCT05108649|EXPERIMENTAL|Normal Nicotine Content (NNC) cigarettes|After completing a 7-day baseline period of smoking own brand cigarettes, participants will be randomized to a 28-day experimental period and will receive normal nicotine content cigarettes.
62261454|NCT02600832|EXPERIMENTAL|AABM Training|Immediately following screening, patients will be randomly assigned to receive 9 sessions of real AABM training (16 subjects each) taking place over three weeks.
62261455|NCT02600832|SHAM_COMPARATOR|Sham Training|Immediately following screening, patients will be randomly assigned to receive 9 sessions of sham training (16 subjects each) taking place over three weeks.
62446596|NCT01255371|ACTIVE_COMPARATOR|Arm A : Lopinavir|"Emtricitabine/tenofovir :~* TDF300mg.FTC200mg (Fixed Dose Combination)~* 1 tablet per day~Lopinavir/ritonavir :~* LPV200mg/RTV50mg~* 2 tablets twice a day"
62446597|NCT01255371|EXPERIMENTAL|Arm B : Atazanavir|"Lamivudine/tenofovir :~* 3TC300mg/TDF300mg (Fixed Dose Combination)~* 1 tablet per day~Atazanavir/ritonavir :~* ATV300mg/RTV100mg~* 2 tablets once a day"
62446598|NCT04272359||Group 1|SGLT2 inibitori +/- Metformin
62446599|NCT04272359||Group 2|DPP4 inibitori +/- Metformin
62446600|NCT04272359||Group 3|GLP1-RA + Long-Acting Insulin +/- Metformin
62617908|NCT05430685|PLACEBO_COMPARATOR|Placebo|Generic name: placebo Dose form: Glycerin equivalent weight to ashwagandha Dose: 1 capsule Frequency: one capsule, 2 times per day (one capsule in morning and one in evening) Duration: 30 dys
62843517|NCT03240549|NO_INTERVENTION|conventional therapy group|Treatment with previous regimen of combined chemotherapy
62843518|NCT03240549|EXPERIMENTAL|bevacizumab group|Adding bevacizumab to the previous regimen of combined chemotherapy
62843519|NCT01974635|EXPERIMENTAL|AMES Therapy and Diagnostic|During treatment, the AMES device rotates the hand, into flexion and extension, while the patient assists with this motion,and while the lengthening muscle(s) are vibrated mechanically. At the end of the treatment, several diagnostic tests are performed to measure the participant's level of proprioceptive perception. This study provides for 25 AMES treatments and diagnostic tests over 8-13 weeks, at a rate of 2-3 sessions per week.
62843520|NCT06208371|EXPERIMENTAL|Liver-localized treatment group|Participants in this group will undergo liver-localized interventions, which may include surgical resection and/or ablation therapy and/or SBRT, aiming to achieve NED.
62058090|NCT05108649|EXPERIMENTAL|Reduced Nicotine Content (RNC) cigarettes|After completing a 7-day baseline period of smoking own brand cigarettes, participants will be randomized to a 28-day experimental period and will receive reduced nicotine content cigarettes.
62058091|NCT02277990|ACTIVE_COMPARATOR|TYRX™ envelope|The Medtronic TYRX™ Absorbable Antibacterial Envelope is an absorbable sterile prosthesis designed to hold a pacemaker pulse generator or defibrillator to create a stable environment when implanted in the body. The purpose of the absorbable coating is to act as a carrier for the antimicrobial agents.
62058092|NCT02277990|NO_INTERVENTION|Control|No TYRX™ envelope, bare CIED
62058093|NCT01439607|EXPERIMENTAL|Bone marrow and blood sampling|
62058094|NCT01465607|EXPERIMENTAL|Theory-based counseling (Mujer Segura)|Will consist of 40 FSWs at each of 12 clinics, randomized into this condition from a pool of 80 eligible participants.
62261456|NCT01720342||Aortic valve stenosis, aortic valve insufficiency|Patients with aortic valve insufficiency and/or aortic valve stenosis who require AVR.
62261457|NCT06223659|PLACEBO_COMPARATOR|Cohort 2 (placebo cream)|Patients apply placebo cream topically to skin 30 minutes prior to Tc99 lymphoscintigraphy procedure.
62261458|NCT06223659|EXPERIMENTAL|Cohort 1 (EMLA cream)|Patients apply EMLA cream topically to skin 30 minutes prior to Tc99 lymphoscintigraphy procedure.
62446601|NCT04272359||Group 4|SGLT2 inibitori + DPP4 inibitori +/- Metformin
62446602|NCT01144910||BHR non-atopy|Patients from the outpatient Department of Allergy, Pneumology and Cystic fibrosis, children's hospital, Goethe-University, Frankfurt, Germany. Over a time-span of 5 years the investigators will explore the lung function and the bronchial hyperresponsiveness. Bronchial methacholine challenges will be performed at baseline and after 1, 3 and 5 years.
62446603|NCT01144910||BHR atopy|Patients from the outpatient Department of Allergy, Pneumology and Cystic fibrosis, children's hospital, Goethe-University, Frankfurt, Germany. Over a time-span of 5 years the investigators will explore the lung function and the bronchial hyperresponsiveness. Bronchial methacholine challenges will be performed at baseline and after 1, 3 and 5 years.
62446604|NCT00041574|EXPERIMENTAL|1|Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
62446605|NCT06126796||Arm A: CxBladder followed by cystoscopy|Arm A will undergo testing with CxBladder 3 months after randomization followed by a cystoscopy 3 months thereafter
62617909|NCT00817674||1|CKD subjects
62617910|NCT00817674||2|Healthy Controls
62058095|NCT01465607|ACTIVE_COMPARATOR|CENSIDA counseling program (didactic)|Will consist of 40 FSWs at each of 12 clinics, randomized into this condition from a pool of 80 eligible participants.
62261459|NCT00562354|EXPERIMENTAL|1|Stratum 1: \>= 65 years of age
62261460|NCT00562354|EXPERIMENTAL|2|Stratum 2: 50 to 64 years of age
62261461|NCT00522353|ACTIVE_COMPARATOR|1|Oligofructose
62261462|NCT00522353|PLACEBO_COMPARATOR|2|Placebo
62446606|NCT06126796||Arm B: cystoscopy followed by CxBladder|Arm B will undergo cystoscopy 3 months after randomization followed by testing with CxBladder 3 months thereafter.
62446607|NCT05178355|EXPERIMENTAL|Part A - KVD824 - 10 mg|6 participants were administered10 mg of KVD824 in capsule form (1 x 10 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
62617911|NCT02336347|EXPERIMENTAL|Group 1 - Period 1|Twice daily dosing of AVP-786 orally for 8 days
62617912|NCT02336347|ACTIVE_COMPARATOR|Group 1 - Period 2|Twice daily dosing of AVP-923 orally for 8 days
62617913|NCT02336347|ACTIVE_COMPARATOR|Group 2 - Period 1|Twice daily dosing of AVP-923 orally for 8 days
62617914|NCT02336347|EXPERIMENTAL|Group 2 - Period 2|Twice daily dosing of AVP-786 orally for 8 days
62617915|NCT02836951||Patient|This group consists of patients that are hospitalized due to a head injury. Samples of blood, urine and plasma will taken from these subjects and the fluids will be analyzed for novel biomarkers using a biochemical assay.
62843521|NCT06208371|ACTIVE_COMPARATOR|Palliative chemotherapy only group|Participants in this group will receive standard palliative chemotherapy. The focus is on managing symptoms and controlling the progression of the disease.
62843522|NCT02661334|PLACEBO_COMPARATOR|Placebo|30g white rice flour
62843523|NCT02661334|EXPERIMENTAL|Low dose|5g/day Creatine Monohydrate (25g white rice flour) for 28 days
62843524|NCT02661334|EXPERIMENTAL|Loading dose|Creatine Monohydrate 20g/day (10g white rice flour) for 7 days, followed by maintenance dose of Creatine Monohydrate 5g/day (25g white rice flour) for the remaining 21 days
62617916|NCT02836951||Healthy controls|This group consists of healthy volunteers. Samples of blood, urine and plasma will taken from these subjects and the fluids will be analyzed for novel biomarkers using a biochemical assay.
62843525|NCT02661334|EXPERIMENTAL|High dose|High dose of Creatine Monohydrate 20g/day (10g white rice flour) for the entire 28 day period
62261463|NCT02189161|EXPERIMENTAL|Radiofrequency Ablation|circumferential radiofrequency ablation (RFA) to the anal canal
62446608|NCT05178355|EXPERIMENTAL|Part A - KVD824 - 20 mg|6 participants were administered 20mg of KVD824 in capsule form ( 2 x 10 mg capsules) on one occasion on Day 1. 2 participants received matching placebo.
62843526|NCT00002618|ACTIVE_COMPARATOR|Regimen A|Patients begin radiotherapy (5 days a week for 4.5 weeks) to residual tumor on day 1 of maintenance.
62261464|NCT03853681|OTHER|additional blood sampling|
62261465|NCT05227638|ACTIVE_COMPARATOR|Schroth group|The Schroth group performed Schroth exercises
62261466|NCT05227638|ACTIVE_COMPARATOR|PNF group|"PNF group (PG) performed chop and lift exercises"
62261467|NCT02707783||Bioresorbable vascular scaffold (BVS) implantation|Patients with un/stable angina that require coronary revascularization undergoing the BVS implantation
62261468|NCT02288936|EXPERIMENTAL|Enzalutamide|Enzalutamide 160 mg/day
62261469|NCT03076203|EXPERIMENTAL|Treatment (niraparib, radium Ra 223 dichloride)|Patients receive niraparib orally daily and radium Ra 223 dichloride IV over 1 minute every 4 weeks. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62446609|NCT05178355|EXPERIMENTAL|Part A - KVD824 - 40 mg|6 participants were administered 40mg of KVD824 in capsule form (1 x 40 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
62446610|NCT05178355|EXPERIMENTAL|Part A - KVD824 - 80 mg|6 participants were administered 80mg of KVD824 in capsule form (2 x 40 mg capsules) on one occasion on Day 1. 2 participants received matching placebo.
62446611|NCT05178355|EXPERIMENTAL|Part A - KVD824 - 160mg|6 participants were administered 160mg of KVD824 in capsule form (1 x 160 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
62446612|NCT05178355|EXPERIMENTAL|Part A - KVD824 - 320 mg|6 participants were administered 320mg of KVD824 in capsule form (1 x 320 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
62446613|NCT05178355|EXPERIMENTAL|Part A - KVD824 - 640 mg|6 participants were administered 640 mg of KVD824 in capsule form (2 x 320 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
62446614|NCT05178355|EXPERIMENTAL|Part A - KVD824 - 1280 mg|6 participants were administered 1280 mg of KVD824 in capsule form (4 x 320 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
62446615|NCT05178355|EXPERIMENTAL|Part B - KVD824 - 80 mg Multi-Dose|6 participants were administered 80 mg of KVD824 in capsule form (2 x 40 mg capsules) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
62446616|NCT05178355|EXPERIMENTAL|Part B - KVD824 - 160 mg Multi-Dose|6 participants were administered 160mg of KVD824 in capsule form (1 x 160 mg capsule) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
62446617|NCT05178355|EXPERIMENTAL|Part B - KVD824 - 320 mg Multi-Dose|6 participants were administered 320mg of KVD824 in capsule form (1 x 320 mg capsule) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
62446618|NCT05178355|EXPERIMENTAL|Part B - KVD824 - 640 mg Multi-Dose|6 participants were administered 640mg of KVD824 in capsule form (2 x 320 mg capsules) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
62446619|NCT05178355|EXPERIMENTAL|Part C - KVD824 - 320 mg Fasted|12 participants were administered 320 mg of KVD824 in capsule form (1 x 320 mg capsule) on one occasion on Day 1 in a fasted state.
62446620|NCT05178355|EXPERIMENTAL|Part C - KVD824 - 320 mg High fat breakfast|12 participants were administered 320 mg of KVD824 in capsule form (1 x 320 mg capsule) on one occasion on Day 1 following consumption of a high fat breakfast.
62446621|NCT04459195|EXPERIMENTAL|2 Minute Static stretching|Stretching applications will be applied to the first group for 2 minutes .
62446622|NCT04459195|EXPERIMENTAL|5 Minute Static stretching|Stretching applications will be applied to the first group for 5 minutes.
62843527|NCT00002618|ACTIVE_COMPARATOR|Regimen B|Patients receive whole brain irradiation (5 days a week for 3.1 weeks) beginning on day 1 of maintenance. Patients are followed monthly for 6 months, every 3 months for 18 months, every 6 months for 3 years, and annually thereafter.
62446623|NCT01701128|EXPERIMENTAL|Speed TT|Walk on treadmill with progressive increases in speed
62446624|NCT01701128|EXPERIMENTAL|Mixed TT|Walk on treadmill with progressive increases in speed and incline
62446625|NCT01701128|ACTIVE_COMPARATOR|Control|Light-intensity exercise group, work flexibility and coordination
62446626|NCT03175120|EXPERIMENTAL|Insulin degludec/liraglutide|
62843528|NCT04337918|NO_INTERVENTION|Prevention - Standard Precautions|Participants COVID-19 negative at baseline will be randomized to receive standard COVID-19 screening and protection (per their facility or organization's protocols).
62843529|NCT04337918|EXPERIMENTAL|Prevention - NORS + Standard Precautions|Participants COVID-19 negative at baseline will be randomized to receive standard COVID-19 screening and protection (per their facility or organization's protocols) plus daily NORS treatment for 14 days.
62261470|NCT02738970|ACTIVE_COMPARATOR|Part 1-Cohort 1: Pertuzumab 420 Milligrams (mg) IV|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 420 mg IV.
62261471|NCT02738970|EXPERIMENTAL|Part 1-Cohort 2: Pertuzumab 400 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 400 mg SC.
62261472|NCT02738970|EXPERIMENTAL|Part 1-Cohort 3: Pertuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 600 mg SC.
62261473|NCT02738970|EXPERIMENTAL|Part 1-Cohort 4: Pertuzumab 1200 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 1200 mg SC.
62261474|NCT02738970|ACTIVE_COMPARATOR|Part 1-Cohort 5: Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of trastuzumab 600 mg SC.
62261475|NCT02738970|EXPERIMENTAL|Part 1-Cohort 6: Pertuzumab 400 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 400 mg and trastuzumab 600 mg SC.
62261476|NCT02738970|EXPERIMENTAL|Part 1-Cohort 7: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC.
62261477|NCT02738970|EXPERIMENTAL|Part 1-Cohort 8: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC without recombinant human hyaluronidase (rHuPH20) excipient.
62058096|NCT01815528|EXPERIMENTAL|Catumaxomab|Catumaxomab treatment followed by an established chemotherapy regimen
62261478|NCT02738970|EXPERIMENTAL|Part 2-Cohort A: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohort A will be enrolled only if FDC of pertuzumab and trastuzumab is not feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC administered separately. The dose of pertuzumab will be identified during Part 1.
62261479|NCT02738970|EXPERIMENTAL|Part 2-Cohort B: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents administered in one injection (co-mixed). The dose of pertuzumab will be identified during Part 1.
62617917|NCT03699540|EXPERIMENTAL|Active Marijuana Dose|Participants will receive experimental/non-therapeutic dose(s) of active marijuana, under double-blind conditions
62261480|NCT02738970|EXPERIMENTAL|Part 2-Cohort C: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents formulated together and administered in one injection (FDC). The dose of pertuzumab will be identified during Part 1.
62261481|NCT03023527|EXPERIMENTAL|nivo-pom-dex|Nivolumab in combination with Pomalidomide and low dose dexamethasone
62261482|NCT03023527|EXPERIMENTAL|nivo-pom-dex-elo|Pomalidomide in combination with Nivolumab , dexamethasone and elotuzumab
62446627|NCT03175120|ACTIVE_COMPARATOR|Insulin degludec|
62446628|NCT05205850|EXPERIMENTAL|RC118-ADC|Participants will be allocated to one of the following dose groups: 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0mg/kg, and receive a treatment of RC118-ADC followed by 14 days of dose limited toxicity (DLT) observation period.
62617918|NCT03699540|PLACEBO_COMPARATOR|Inactive Marijuana Dose|Participants will receive experimental/non-therapeutic dose(s) of inactive marijuana, under double-blind conditions
62446629|NCT06486597|EXPERIMENTAL|Meal intervention with stable isotopes|A liquid mixed meal are gived adjusted by weight. The meal consists of: Intrinsically labelled D5-Phenylalanine and D3-Leucine labelled casein protein, 13C16palmitate, 13C6-Glucose in a mix of glucose, casein protein and rape seed oil dissolved in water in an energy density of 50% CHO, 35% fat and 15% protein. Blood samples are drawn frequently to measure fat, glucose and protein metabolism.
62617919|NCT03699540|ACTIVE_COMPARATOR|Active Alcohol Dose|Participants will receive experimental/non-therapeutic dose(s) of active alcohol, under double-blind conditions
62843530|NCT04337918|OTHER|Treatment Sub-Study|"Volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. Ten participants can be directly enrolled in the Treatment sub-study.~Participants enrolled in the Prevention study who meet the criteria in this section will roll over into the Treatment Sub-Study but must remain in their randomly assigned group."
62843531|NCT02858505|ACTIVE_COMPARATOR|27 mg elemental iron group|received 27 mg elemental iron once daily starting at 12 weeks until 36 weeks
62261483|NCT01556425|EXPERIMENTAL|Vivitrol Only|The VIVITROL group will be offered one injection of VIVITROL every 4 weeks. Participants in the VIVITROL group will be required to take their scheduled injections to work and earn wages. If a participant misses a scheduled VIVITROL injection (more than 3 days from the scheduled date of administration), the participant will not be allowed to work until the injection is accepted. Additionally, missing a scheduled injection will result in a base pay reset from $8 per hour to $1 per hour. After the reset, the participant's base pay will increase by $1/hour to the maximum of $8/hour for every day that the participant works at least 5 minutes.
62446630|NCT00444795||1|patients diagnosed as GIST after disease progression on or intolerance to imatinib mesylate
62843532|NCT02858505|ACTIVE_COMPARATOR|54 mg elemental iron group|received 54 mg elemental iron once daily starting at 12 weeks until 36 weeks
62843533|NCT02038361|EXPERIMENTAL|blood sample|
62843534|NCT06471348|EXPERIMENTAL|Local infiltration with liposomal bupivacaine|Patients randomized into the liposomal bupivacaine group will receive anesthesia and undergo standard posterior spinal fusion surgery. The local infiltration would occur in a single stage, after instrumentation and correction maneuver is performed, just prior to closure of the deep fascial layer. The dose would be injected via multiple small volume injections into the paraspinal musculature, spaced approximately 1 cm apart.
62843535|NCT06471348|ACTIVE_COMPARATOR|Local infiltration with 0.25% bupivacaine with epinephrine|Patients randomized into the 0.25% bupivacaine with epinephrine group will receive anesthesia and undergo standard posterior spinal fusion surgery under the same condition as the intervention group with one exception: the local infiltration will be made up of equal volume of 0.25% bupivacaine with epinephrine. The equal volume of 0.25% bupivacaine with epinephrine will be used in the exact same administration technique as the liposomal bupivacaine group, involving multiple small-volume injections to the paraspinal musculature spaced approximately 1 centimeter apart.
62843536|NCT01879124||Kidney transplant recipients|All de novo renal allograft recipients transplanted at the University Hospitals Leuven between March 2004 and October 2007
62446631|NCT00444795||2|patients diagnosed as advanced RCC
62446632|NCT00444795||3|patients diagnosed as unresectable, well-differentiated advanced and/or metastatic pancreatic neuroendocrine carcinoma
62446633|NCT00760383|EXPERIMENTAL|EAA+PT|20 g EAA daily for 7 days prior to TKA surgery and for 14 days after surgery.
62446634|NCT00760383|PLACEBO_COMPARATOR|ALA+PT|20 g NEAA daily for 7 days prior to TKA surgery and for 14 days after surgery.
62617920|NCT03699540|PLACEBO_COMPARATOR|Inactive Alcohol Dose|Participants will receive experimental/non-therapeutic dose(s) of inactive alcohol, under double-blind conditions
62617921|NCT04796207|EXPERIMENTAL|Fish Oil Capsules|Participants in the treatment arm will receive 3 grams of DHA and EPA (2:1 weight ratio) 3 times a week for 25-weeks during regular football season.
62617922|NCT04796207|PLACEBO_COMPARATOR|Safflower Oil Capsules|Participants in the treatment arm will receive 3 grams of high-oleic safflower oil) in a 1:1 allocation ratio for 25-weeks during regular football season.
62617923|NCT02933528|EXPERIMENTAL|Dsxs topical product|treatment with DSXS once daily for 28 days
62446635|NCT02059993|OTHER|continuous positive airway pressure|mean continuous positive airway pressure use was at least 4 hours per night; continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
62446636|NCT02059993|NO_INTERVENTION|Control|The control subjects received standardised anti-hypertension medications according to the current guildline.
62617924|NCT01494701|EXPERIMENTAL|Cohort 1 (n=6)|
62617925|NCT01494701|EXPERIMENTAL|Cohort 2 (n=6)|
62261484|NCT01556425|EXPERIMENTAL|VIVITROL&Opiate Abstinence Reinforcement|This group will be offered VIVITROL and will be required to take it to attend the workplace and to maintain maximum pay. This group will also receive employment-based opiate abstinence reinforcement. This contingency will require participants to provide opiate-negative urine samples on M,W, and F to maintain their maximum pay. If a participant in this group provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
62261485|NCT01556425|EXPERIMENTAL|Opiate Abstinence Reinforcement Only|This group would receive employment-based opiate abstinence reinforcement, but this group will not receive VIVITROL.
62261486|NCT01556425|OTHER|Usual Care Control|This group will receive neither abstinence reinforcement nor VIVITROL injections, but they will be invited to attend the workplace and outpatient drug abuse counseling.
62261487|NCT01265797|ACTIVE_COMPARATOR|Cranial Electrostimulator|wears active cranial electrostimulation device for 20 minutes daily for 28 days
62261488|NCT01265797|SHAM_COMPARATOR|Sham device|wears sham device for 20 minutes daily for 28 days
62261489|NCT04291443|EXPERIMENTAL|Upper First Premolar One Side|Heavy force (225 g)
62261490|NCT04291443|EXPERIMENTAL|Upper First Premolar Other Side|Light Force (25 g)
62843537|NCT02111759|OTHER|knee flexion angle 2|30 degrees of knee flexion during ACL graft fixation
62843538|NCT02111759|OTHER|knee flexion angle 1|0 degrees of knee flexion during ACL graft fixation
62843539|NCT02707822||kidney or liver transplantation|Renal or liver transplant recipients with tacrolimus as immunosuppressive drugs.
62058097|NCT02850822||Therapy pre-transplantation|Chemotherapy regimen and/or demethylation drugs(such as decitabine) were given pre-transplantation for patients with RAEB-1, REAB-2 and AML Secondary to MDS (bone marrow blast cells less than 50%).
62058098|NCT02850822||No Therapy pre-transplantation|No therapy (chemotherapy or demethylation drugs) was given pre-transplantation for patients with RAEB-1, REAB-2 and AML Secondary to MDS (bone marrow blast cells less than 50%).
62261491|NCT01705171||IBS patients with fructose intolerance|analysis of biopsies
62261492|NCT01705171||Control group: no IBS or fructose intolerance|analysis of biopsies
62261493|NCT03882970|EXPERIMENTAL|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
62261494|NCT03882970|EXPERIMENTAL|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
62261495|NCT03882970|EXPERIMENTAL|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
62261496|NCT03882970|ACTIVE_COMPARATOR|Insulin Degludec|Insulin degludec administered SC once a day.
62261497|NCT02594306|EXPERIMENTAL|Non operation|Recording the event related potential of drug addicts when they receive the stimulus of Emotional pictures stimulation system.
62261498|NCT02594306|EXPERIMENTAL|Deep brain stimulation|Recording the event related potential after the deep brain stimulation operation.Recording the local field potential of drug addiction people when we conduct a test of adjacent contact stimulation in the deep brain stimulation operation. Recording the waveform of bilateral NAc/ALIC after puting the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule
62843540|NCT00621348|ACTIVE_COMPARATOR|Isotonic fluid group|Normal saline in 5% dextrose at standard maintenance rate
62843541|NCT00621348|ACTIVE_COMPARATOR|Fluid restriction group|Reduced volume (2/3 maintenance rate) of N/5 saline in 5% dextrose
62843542|NCT00621348|ACTIVE_COMPARATOR|Hypotonic fluid group|N/5 saline in 5% dextrose at standard maintenance rate
62843543|NCT04462588||Medical Treatment Group|Medical treatment group of uncomplicated acute appendisitis
62843544|NCT04462588||Surgery|Operated group of uncomplicated acute appendisitis
62843545|NCT03460262|ACTIVE_COMPARATOR|Standard dressing-Cutiplast®|
62843546|NCT03460262|EXPERIMENTAL|Negative pressure wound therapy-PICO®|
62843547|NCT04371393|EXPERIMENTAL|Remestemcel-L Plus Standard of Care|Intravenous infusion of remestemcel-L 2x10\^6 MSC/kg of body weight plus standard of care
62843548|NCT04371393|PLACEBO_COMPARATOR|Placebo Plus Standard of Care|Placebo (Plasma-Lyte) plus standard of care
62617926|NCT01494701|EXPERIMENTAL|Cohort 3 (n=6)|
62617927|NCT01494701|EXPERIMENTAL|Cohort 4 (n=10)|
62617928|NCT00898326||Biopsy 36 month after breacchytherapy|Biopsy 36 month after breacchytherapy on protocol JUSMH-BRI-GU05-01.
62261499|NCT02594306|ACTIVE_COMPARATOR|Standard Control|Recording the event related potential of normal people when they receive the stimulus of emotional pictures stimulation system.
62617929|NCT05573464|EXPERIMENTAL|BGF MDI HFO 320/14.4/9.6μg|Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO (HFO-1234ze)
62617930|NCT05573464|ACTIVE_COMPARATOR|BGF MDI HFA 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFA
62617931|NCT03340298|EXPERIMENTAL|grain|25 gram fiber from whole grain products and 10 gram fiber from fruits and vegetables
62617932|NCT03340298|EXPERIMENTAL|fruits and vegetables|25 gram fiber from fruits and vegetables as main supplier and the remaining 10 grams from whole grain sources
62617933|NCT03340298|EXPERIMENTAL|grain-fruits and vegetables|17.5 gram fiber from whole grain and 17.5 gram fiber from fruits and vegetables
62617934|NCT00770471|EXPERIMENTAL|Dose Escalation|
62617935|NCT02735473|EXPERIMENTAL|Choline bitartrate|Powdered drink mix containing choline bitartrate 19 mg. per kg.
62261500|NCT00919100|OTHER|Standard Care|venipuncture with vapocoolant spray offered
62261501|NCT00919100|EXPERIMENTAL|Buzzy|Vibrating device with cold pack held to arm with tourniquet proximal to venipuncture site, optional distraction cards.
62261502|NCT00823407|OTHER|MDA|
62617936|NCT02735473|PLACEBO_COMPARATOR|Placebo|Powdered drink mix containing matching placebo
62617937|NCT00462449|NO_INTERVENTION|1|Individuals randomized into this group will only receive specialized therapy associated with this population.
62617938|NCT00462449|EXPERIMENTAL|2|In addition to appropriate therapy, this group will receive the FES device and be given instruction on how to complete specialized exercises utilizing this device.
62617939|NCT03576209|ACTIVE_COMPARATOR|Intervention Group|12 week intervention
62617940|NCT03576209|NO_INTERVENTION|Control Group|No walking program
62617941|NCT05629676|EXPERIMENTAL|BMT-VR Group|"* Participants will complete the BMT-VR intervention during their BMT hospitalization, which contains six sections.~* Participants will receive usual transplant care by their BMT team~* Participants will complete study questionnaires to assess their quality of life and psychological outcomes~* 10-20 participants will complete exit interviews to ascertain more feedback on the BMT-VR intervention."
62617942|NCT05629676|NO_INTERVENTION|Usual care|"* Participants will receive usual transplant care by their BMT team~* Participants will complete study questionnaires to assess their quality of life and psychological outcomes"
62843549|NCT03599219|OTHER|case|donors with an hemorrhagic score \>2 and / or hematoma (more than 4 cm) that occurred during blood donation
62261503|NCT01852994|OTHER|Exercise training|Aerobic and strength exercise training
62261504|NCT01852994|OTHER|Testosterone replacement|Testosterone replacement will be done quarterly
62617943|NCT06111001|ACTIVE_COMPARATOR|Active Study Group|Participants actively using the AirEmail v1 Digital Tool features.
62617944|NCT06111001|PLACEBO_COMPARATOR|Contemporary Observational Group|Participants whose email use data is collected via the AirEmail v1 Digital Tool
62617945|NCT01614106|EXPERIMENTAL|Intervention|The Retention Clinic will incorporate HIV primary care and mental health services with on-site substance abuse treatment and patient navigation. The central components will include: Primary HIV Care; Mental Health Services; Skill-building; and On-Site substance abuse treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
62617946|NCT01614106|NO_INTERVENTION|Treatment as Usual (TAU)|The treatment as usual (TAU) group condition will represent standard of care at both of the participating clinics. Standard of care at both clinics includes primary HIV care, the provision of mental health services, and the assignment of a clinic case manager. These case managers meet with patients when they first come to clinic and then meet with them as needed and typically offer substance-using patients a referral to substance abuse treatment in the community as needed. Case managers usually do not follow up to determine the uptake of these referrals.
62058099|NCT01960647|OTHER|Uncoated PTA balloon catheter|Dilatation with uncoated PTA balloon catheter
62058100|NCT01960647|ACTIVE_COMPARATOR|Freeway Paclitaxel balloon catheter|Dilatation with Freeway Paclitaxel (3 µg/mm2) coated balloon catheter
62058101|NCT01448694||Blood donors|Healthy volunteers who are donating a pint of whole blood
62261505|NCT01852994|OTHER|Testosterone replacement+Exercise|Both Testosterone replacement and Exercise will done
62261506|NCT02170285|EXPERIMENTAL|Interventional tDCS|The primary intervention will be cathodal (inhibitory) tDCS (see below).
62623726|NCT02763917|ACTIVE_COMPARATOR|Active Air Purifier|Two portable air purifiers containing HEPA filters will be placed in the bedroom and room where the participant reports spending the most time. We have chosen to deploy two air purifiers because we have observed a 50% reduction in indoor PM concentrations with two air purifiers. Participants will be instructed to run the air purifiers continually. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies. Participants will also receive educational materials about health benefits of maintaining a normal weight.
62843550|NCT03599219|OTHER|control|donors with an hemorrhagic score \<2.
62843551|NCT01219283||Control (no PGD)|Receive their planned IVF treatment without PGD. 2 morphologically best embryos are transferred.
62843552|NCT01219283||Case (PGD)|Receive PGD in addition to their planned IVF Cycle. 2 morphologically best PGD normal embryos are transferred.
62843553|NCT01923272|SHAM_COMPARATOR|Sham Device|inactive AlphaCore device
62843554|NCT01923272|ACTIVE_COMPARATOR|AlphaCore|Active AlphaCore device
62617947|NCT04656678|EXPERIMENTAL|DynaCAD / UroNAV|This is a single arm study to evaluate feasibility of UroNAV Ablation system aided cryo-ablation treatment of low and intermediate risk, organ-confined prostate cancer. UroNav is a stereotaxic accessory for image-guided interventional and diagnostic procedures of the prostate gland. It provides 2D and 3D visualization of Ultrasound (US) images and the ability to fuse and register these images with those from other imaging modalities such as Magnetic Resonance (MR), Computed Tomography, etc. It also provides the ability to display a simulated image of a tracked insertion tool on a computer monitor screen that shows images of the target organ and the current and the projected future path of the interventional instrument. DynaCAD 5.0 is an image analysis and planning system that will provide off station, pre planning and review of interventional study data. It interfaces with the Uronav 4.0 fusion guidance system.
62617948|NCT02587754|ACTIVE_COMPARATOR|Verum acupuncture|10 sessions of verum acupuncture
62843555|NCT01877252||Endovascular treatment|Angioplasty +/- stent
62843556|NCT01877252||Open treatment|Bypass (vein or prosthetic)
62843557|NCT01877252||Patchplasty/Hybrid treatment|Femoral artery patchplasty +/- profundoplasty +/- endovascular treatment
62843558|NCT01877252||Conservative treatment|no vascular intervention
62843559|NCT02238652|NO_INTERVENTION|Control|
62843560|NCT02238652|ACTIVE_COMPARATOR|Intervention|Communication Systematic Pain Assessment and Treatment Medication Review Occupational therapy Safety
62843561|NCT04472832|PLACEBO_COMPARATOR|Treatment A|Participants will receive a single oral dose of mitapivat-matching placebo under fasted conditions on Day 1 of each of 4 periods.
62843562|NCT04472832|EXPERIMENTAL|Treatment B|Participants will receive a single oral dose of mitapivat 100 milligrams (mg) and placebo under fasted conditions on Day 1 of each of 4 periods.
62843563|NCT04472832|EXPERIMENTAL|Treatment C|Participants will receive a single oral dose of mitapivat 100 mg and placebo under high-fat meal conditions on Day 1 of each of 4 periods.
62843564|NCT04472832|EXPERIMENTAL|Treatment D|Participants will receive a single oral dose of mitapivat 300 mg under fasted conditions on Day 1 of each of 4 periods.
62843565|NCT05091775|PLACEBO_COMPARATOR|Standard management of acute fissure(Diltiazem Jelly,supportive care,placebo suppository, sitz bath)|Patients in the first group underwent for 14 consecutive days treatment with diltiazem gel 2 times a day, a basin of warm water 2 times a day and drink daily 8-12 a glass of water will be placed with a placebo suppository.
62843566|NCT05091775|EXPERIMENTAL|Intervention group (Asacol suppository, supportive care, placebo suppository, sitz bath)|Patients in the second group or treatment group will be treated with diltiazem gel topically 3 times a day for 14 consecutive days, pelvis of warm water 2 times a day and drink daily 8-12 glasses of water plus Asacol anal suppository (mesalazine) are taken 1 piece every night.
62843567|NCT05053958|NO_INTERVENTION|Implant planning without using superimposition of intraoral scan and CBCT.|Patients will receive a pre-operative CBCT examination. Implants will be inserted using freehand drilling protocol. The implants will be placed using flapless technique with the reference of neighboring teeth and 3D radiographic information.
62843568|NCT05053958|ACTIVE_COMPARATOR|Implant planning using superimposition of intraoral scan and CBCT.|Patients will receive a pre-operative CBCT examination and optical scan of the oral tissues by intra-oral scanner. Digital Imaging and Communications in Medicine (DICOM) file from the CBCT examination and the Standard Tessellation Language (STL) file from the optical scan will be imported and merged in implant planning software. The virtual implant planning will be performed. The surgical guide and prosthesis are designed according to the virtual plan.
62058102|NCT04202926|EXPERIMENTAL|10hz group|a high frequency stimulation
62617949|NCT02587754|PLACEBO_COMPARATOR|Placebo acupuncture|10 sessions of placebo acupuncture via use of placebo acupuncture needles
62617950|NCT05012410|EXPERIMENTAL|Immediate treatment group with High-Intensity Prompts|Caregivers will use the WeCareAdvisor tool for six months and receive telephone and email prompts.
62843569|NCT03753113|EXPERIMENTAL|Treatment group|The patients will be applied 1 mL of solutions(Herbal and Minoxidil) at morning and evening intervals to the thinning hair areas of the scalp for 36 weeks.
62843570|NCT03753113|ACTIVE_COMPARATOR|Control group|The patients will be applied 1 mL of Minoxidil 5% solutions at morning and evening intervals to the thinning hair areas of the scalp for 36 weeks.
62843571|NCT00939393|ACTIVE_COMPARATOR|FESS in OR with or without balloons|Functional Endoscopy Sinus Surgery
62843572|NCT00939393|ACTIVE_COMPARATOR|Balloon sinuplasty in physician office|Balloon Sinuplasty in physician office using Acclarent devices
62058103|NCT04202926|SHAM_COMPARATOR|sham group|a sham coil which frequency is 10hz but do not induce stimulation
62617951|NCT05012410|EXPERIMENTAL|Immediate treatment group with Low-Intensity Prompts|Caregivers will use the WeCareAdvisor tool for six months and receive email prompts only.
62617952|NCT05012410|EXPERIMENTAL|Waitlist Control after three months with high-Intensity prompts|After three months, caregivers will receive WeCareAdvisor and telephone and email prompts.
62843573|NCT04681976|EXPERIMENTAL|Intervention group|Intervention Group participants will perform a 3-month telematic dance program based on choreographic work, 2 times per week
62843574|NCT04681976|NO_INTERVENTION|Control group|Control group will follow their daily routine without added exercise
62843575|NCT04235751|EXPERIMENTAL|Immediate Coaching Intervention|Subjects will receive 6 professional coaching sessions
62843576|NCT04235751|EXPERIMENTAL|Delayed Coaching Intervention|Subjects will receive no coaching for the first six months of the study, at which point they cross over and receive 6 professional coaching sessions
62843577|NCT04207619|EXPERIMENTAL|Arm 1|Participants will have their glial acetate metabolism measured by carbon-13 magnetic resonance spectroscopy as well as their neuroendocrine response to hypoglycemia 3 days later.
62843578|NCT01549418|ACTIVE_COMPARATOR|Aspirin|Patients with at least one large polyps taking aspirin in dose 75 mg daily for 21 days (7 days before and 14 days after polypectomy)
62261507|NCT02170285|SHAM_COMPARATOR|Sham tDCS|Sham subjects will undergo exactly the same tDCS protocol as outlined above. This includes the initial stimulation sequence, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist to automatically ramp down to off over 30 seconds after 120 seconds of stimulation.
62261508|NCT02797340|EXPERIMENTAL|Interventional|All participants
62261509|NCT03134170|NO_INTERVENTION|No intervention|The no intervention group will serve as control group. This group will receive standard care and will be an active comparator. At the end of the study they may join the intervention group
62058104|NCT02093455|ACTIVE_COMPARATOR|Chardonnay Seed Flour (CSF)|Prepackaged capsules taken 3 times per day. During the first month, the total dose will be 15 g/d. For months 2-4, the total dose will be 30 g/d.
62261510|NCT03134170|OTHER|Intervention group|The intervention group will be seen by a pharmacist iin addition to their normal provider. The pharmacist will provide medication therapy review of the patient's therapy. The pharmacist will make recommendations to make revisions in the patient's therapy.
62261511|NCT05065502|ACTIVE_COMPARATOR|Academic Detailing (AD) Only|One-on-one educational outreach to employees and providers.
62261512|NCT05065502|EXPERIMENTAL|AD + LEAP Combined|This arm combines use of AD plus the Learn. Engage. Act. Process (LEAP) program. LEAP is a 6-month quality improvement coaching program plus a 6-month monthly follow-up.
62261513|NCT02232373|SHAM_COMPARATOR|Normal FODMAP arm|Low FODMAP dietary advice; participants to supplement diet with oligofructose, a poorly digested carbohydrate that will restore FODMAP content to the diet.
62261514|NCT02232373|EXPERIMENTAL|Low FODMAP arm|Low FODMAP dietary advice; participants to supplement with maltodextrin (easily digestible carbohydrate)
62261515|NCT01359709|EXPERIMENTAL|Contingency Management|
62261516|NCT01359709|PLACEBO_COMPARATOR|Noncontingent control|
62617953|NCT05012410|EXPERIMENTAL|Waitlist Control after three months with Low-Intensity Prompts|After three months, caregivers will receive WeCareAdvisor and email prompts only.
62617954|NCT03942367|EXPERIMENTAL|Group A (Active Device Group)|Patients will receive a fully functioning vPatch device, pre-configured to deliver stimulation intensity according to the subjective motor threshold intensity reported by the Patients. Pre-configured stimulation intensity cannot be changed by the Patient.
62617955|NCT03942367|SHAM_COMPARATOR|Group B (Sham Device Group)|Patients will receive a vPatch device pre-configured to deliver the sensory electrical stimulation according to the subjective sensory threshold that is ineffective for muscle activation. Pre-configured stimulation intensity cannot be changed by the Patient.
62617956|NCT02150681|EXPERIMENTAL|Mindfulness-based cognitive therapy|8 class sessions of mindfulness therapy given in a group setting, with one 2-hr session per week for 8 weeks.
62617957|NCT02801370|EXPERIMENTAL|OTO-201|
62843579|NCT01549418|PLACEBO_COMPARATOR|Placebo|Patients with at least one large polyps taking placebo daily for 21 days (7 days before and 14 days after polypectomy)
62843580|NCT04197219|EXPERIMENTAL|Pembrolizumab & axitinib|All participants enrolled will receive pembrolizumab as standard of care (SOC) combined with axitinib. Axitinib will be self-administered orally twice daily at 5 mg. On days when both drugs are administered, axitinib will be administered first, followed by pembrolizumab. Treatment will continue until disease progression or unacceptable grade 3/4 toxicities. For patients with a complete response to therapy, maintenance therapy with both drugs will be continued for 12 months.
62843581|NCT01519167|EXPERIMENTAL|Dexmedetomidine|
62843582|NCT02228980|EXPERIMENTAL|Subjects aged 6 to 35 months (Group 1)|Participants aged 6 months to 35 months will receive two 0.25 mL doses of SP Shz TIV given 28 days apart.
62843583|NCT02228980|EXPERIMENTAL|Subjects aged 3 to 17 years (Group 2)|Participants aged 3 years to 17 years will receive a single 0.5 mL dose of SP Shz TIV
62843584|NCT02228980|EXPERIMENTAL|Subjects aged 18 to 60 years (Group 3)|Participants aged 18 years to 60 years will receive a single 0.5 mL dose of SP Shz TIV
62843585|NCT02228980|EXPERIMENTAL|Subjects aged 61 years or older (Group 4)|Participants aged 61 years or older will receive a single 0.5 mL dose of SP Shz TIV
62843586|NCT03098732|EXPERIMENTAL|Magnetically Enhanced Diffusion (MED)|The Experimental Treatment will receive the complete MED System Procedure consisting of MED MicroBeads and the MED Workstation magnet procedure for 60 minutes in addition to IV tissue plasminogen activator (tPA or Alteplase).
62843587|NCT03098732|SHAM_COMPARATOR|MED Workstation Magnet Sham Control|The MED Workstation Magnet Sham Comparator will not receive MED MicroBeads while the MED Workstation Magnet will be activated as a Sham control for 60 minutes in addition to IV tissue plasminogen activator (tPA or Alteplase).
62446637|NCT04223505|ACTIVE_COMPARATOR|TEE arm|TEE will be performed as per clinical routine using multiple standard tomographic planes to rule-out LA/LAA thrombus. Echocardiographic analysis will include: LAA-emptying velocity, and grading the severity of LAA spontaneous ECHO. The severity of the SEC will be graded on a 4 point scale with 1 = minor homogeneous contrast enhancement, 2 = significant homogeneous contrast enhancement, 3 = significant, dense, and inhomogeneous, slow-moving contrast, and 4 = dense slow-moving contrast.
62843588|NCT04772560|EXPERIMENTAL|Toric, Then Sphere|Participants who received Toric contact lenses first and spherical lenses after 10 days
62261517|NCT06177964|EXPERIMENTAL|Lerapolturev Arm (Stage 1)|"Lerapolturev (intratumoral) will be dosed by Convection Enhanced Delivery (CED), infused twice, 4 days apart, in the remaining disease of recurrent Glioblastoma (rGBM) subjects following maximal safe resection of the disease recurrence.~To assess treatment response and/or immunologic responses in the brain, a tissue biopsy of the area infused will be recommended 5 weeks (± 1 week) after the 2nd lerapolturev infusion via CED, in the event that changes suggestive of tumor progression are seen on the MRI obtained 4-5 weeks after the 2nd lerapolturev infusion via CED.~."
62617958|NCT02801370|SHAM_COMPARATOR|Control|
62843589|NCT04772560|EXPERIMENTAL|Sphere, Then Toric|Participants who received Spherical contact lenses first and Toric lenses after 10 days
62843590|NCT01934595|EXPERIMENTAL|Varying amounts of Beneprotein|1.5grams/kg/day, 2.0 grams/kg/day, and 2.5 grams/kg, day
62843591|NCT01934595|ACTIVE_COMPARATOR|1 Gram - Standard Therapy given in ICU|1 gram/kg/day of protein
62843592|NCT03572608|EXPERIMENTAL|Acupuncture Treatment|Acupuncture group will receive 3 acupuncture sessions. The first session will be one week before embryo transfer. The second session will be 30 minute before embryo transfer. And the last session will be 30 minute after embryo transfer.
62058105|NCT02093455|PLACEBO_COMPARATOR|Placebo|Pre-packaged capsules taken 3 times per day. For the first month, a total of 15 g/d. During months 2 - 4, a total of 30 g/d.
62058106|NCT03185559|ACTIVE_COMPARATOR|Relievion device- Treatment stimulation|Relievion Device- Treatment combined occipital and supraorbital transcutaneous nerve stimulation
62058107|NCT03185559|SHAM_COMPARATOR|Relievion device- Sham Stimulation|Relievion Device- Sham combined occipital and supraorbital transcutaneous nerve stimulation
62058108|NCT01264380|EXPERIMENTAL|1|
62843593|NCT03572608|NO_INTERVENTION|Control Group|Control Group will not receive any acupuncture session before or after embryo transfer.
62058109|NCT01264380|EXPERIMENTAL|2|
62617959|NCT05111938|ACTIVE_COMPARATOR|Arm A: Standard Care followed by F3A-App|The first portion of Arm A is a Standard Care (SC) office visit. Changes over time in Arm A represent a typical delivery channel in which a physician provides brief education and then encourages use of the F3A-App program. The SC intervention included a brief, structured office visit designed to replicate what would typically occur in a follow-up visit in an allergy clinic, and include provision standardized educational handouts available from the Food Allergy Research \& Education (FARE) website. The second phase of Arm A is use of the F3A-App.
62617960|NCT05111938|ACTIVE_COMPARATOR|Arm B: F3A-App followed by Standard Care|"The first portion of Arm B is the use of the F3A-App for 2 weeks. Changes over time in Arm B represent an alternative delivery channel in which families use the F3A-App on their own and then have a follow-up office visit after using the self-guided program. The second phase of Arm B is the standard care office visit.~F3A-App efficacy vs. SC is evaluated after the first intervention period on primary outcomes."
62617961|NCT02446535|EXPERIMENTAL|BIA DW assessment|All patients have undergone a Clinical DW assessment. Then, they undergo HD sessions in which BIA DW is determined reducing body weight (kg): when flattening of the BIA resistance occurs, the BIA DW is achieved and compared with the Clinical DW
62617962|NCT05194943||1. UOC Chirurgia Bariatrica, Policlinico San Marco, Zingonia, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
62617963|NCT05194943||2. UOC di Chirurgia Bariatrica e Metabolica, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
62617964|NCT05194943||3. UOSD Week Surgery, Chirurgia Bariatrica, Azienda Ospedale-Università di Padova, Padova, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
62617965|NCT05194943||4. Unita di Chirurgia dell'Obesità e Metabolica, Azienda Ospedaliero-Universitaria, Bologna, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
62617966|NCT05194943||5. UO Chirurgia Generale, Policlinico San Marco di Zingonia, Zingonia, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
62617967|NCT05194943||6. UOC Chirurgia Bariatrica e Metabolica, Ospedale San Carlo di Nancy , Roma, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
62843594|NCT02424578|EXPERIMENTAL|Diclofenac Capsules low dose|Diclofenac Capsules low dose three times daily for up to three days
62843595|NCT02424578|EXPERIMENTAL|Diclofenac Capsules high dose|Diclofenac Capsules high dose three times daily for up to three days
62843596|NCT02037685|ACTIVE_COMPARATOR|Usual care|Subjects randomized to usual care will receive a brochure once a year on the importance and impact of controlling cardiovascular risk factors, tips to improve statin adherence and smoking cessation strategies and public services. Subjects will also receive a letter every 6 months to remind about study participation along with educational material.
62843597|NCT02037685|EXPERIMENTAL|Motivational Interviewing (MINT)|"The MINT intervention will consist of 6 to 9 telephone encounters between a counselor trained in Motivational interviewing. All subjects in the MINT arm will be contacted every 3 months; however subjects who are not filling medication appropriately will receive additional calls.~Each telephone encounter will last from 20 to 30 minutes and have a patient centered approach having the following basic structure and goals:~* Establishing a connection and reinforcing autonomy: .~* Empathizing with ambivalence and rolling with resistance.~* Coach the subject towards expressions of commitment."
62058110|NCT01264380|EXPERIMENTAL|C|
62058111|NCT05285384|EXPERIMENTAL|SpikoGen COVID-19 Vaccine|
62058112|NCT02209012||ALA|Subjects who received ALA in CP0108
62058113|NCT02209012||Vehicle|Subjects who received Vehicle in CP0108
62058114|NCT00327184|EXPERIMENTAL|Group Hib-MenC|Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of Hib-MenC + Infanrix™ penta vaccines.
62843598|NCT03800147|ACTIVE_COMPARATOR|High-fat diet|"Participants will follow a high-fat diet. During the intervention phase, they will inoculate Mutaflor Suspension (E. coli Nissle 1917) (Single dose, 5 ml = 5x10\^8 CFU).~Blood samples, stool samples and clinical information will be collected during the study."
62617968|NCT05194943||7. Dipartimento di Scienze Chirurgiche, Azienda Ospedaliera Universitaria, Torino, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
62843599|NCT03800147|ACTIVE_COMPARATOR|Low-fat diet|"Participants will follow a low-fat diet. During the intervention phase, they will inoculate Mutaflor Suspension (E. coli Nissle 1917) (Single dose, 5 ml = 5x10\^8 CFU).~Blood samples, stool samples and clinical information will be collected during the study."
62843600|NCT01518270||Healthy Females|Healthy Females
62843601|NCT00757471|ACTIVE_COMPARATOR|Group 1|Brillant Blue
62843602|NCT00757471|ACTIVE_COMPARATOR|Group 2|Indocyanine Green
62843603|NCT02285608|EXPERIMENTAL|PIMM/SAM|Partnership in Medication Management (PIMM): The nurse and the attending physician will meet with the patient and ask how s/he administers medication at home (i.e., blister pack). Initial education session: the nurse will teach the patient about his/her medications, dosage, purpose, when and how to take them. Nurse and patient will establish reminders to take his/her medication. Following the education session, patients will be required to notify the nurse when it is time to take their medications, where their medications are, dosage, purpose and side effects. Self-Administered Medication (SAM): Patients will transition to SAM once the clinical team feels that no further medication changes are required. SAM is also the model that the participants will follow after discharge.
62843604|NCT02285608|NO_INTERVENTION|Standard Prescribing Practice(SPP)|Standard prescribing practice (SPP): medication administration will proceed as standard practice. Patients will not receive a personalized medication training. The nurse will administer the patient's medications. However, patients are encouraged to ask any questions regarding his/her medications.Patients will not be provided with any tool to help them to remember when to take their medications. The nurse will record the patient's knowledge regarding his/her medications.
62843605|NCT04159298|EXPERIMENTAL|Intervention|Intervention group who will undergo the Top Spin 360 study protocol.
62843606|NCT04159298|NO_INTERVENTION|Traditional|Control group who undergo traditional usual clinical care comprised of bi-weekly physiotherapy sessions and home-based exercise programs.
62843607|NCT04270370|EXPERIMENTAL|LY3478045 (Part A)|Participants received single ascending oral dose of 20 milligram (mg), 60mg, 180 mg, 500 mg, 700 mg LY3478045 on Day 1.
62058115|NCT00327184|ACTIVE_COMPARATOR|Group NeisVac-C|Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of NeisVac-C™ + Infanrix™ hexa vaccines.
62058116|NCT01928316|EXPERIMENTAL|Sequence A|Healthy male volunteers will receive single oral dose of 10 mg imported mizolastine tablet on Day 1 and single oral dose of 10 mg domestic (made in China) mizolastine tablet on Day 8.
62617969|NCT05194943||8. UO di Chirurgia Bariatrica, Humanitas Research Hospital, Rozzano, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
62843608|NCT04270370|PLACEBO_COMPARATOR|Placebo (Part A)|Participants received single oral dose of placebo on Day 1.
62843609|NCT04270370|EXPERIMENTAL|LY3478045 (Part B)|Participants received multiple ascending oral dose of 60mg and 300 mg LY3478045 once-daily (QD)for 14 days.
62843610|NCT04270370|PLACEBO_COMPARATOR|Placebo (Part B)|Participants received oral dose of placebo QD for 14 days.
62843611|NCT04270370|EXPERIMENTAL|LY3478045 + Atorvastatin (Part B)|Participants received multiple ascending oral doses of 160 mg, 360 mg LY3478045 QD for 14 days and 40 mg atorvastatin administered orally 4 hours after breakfast on Day -2 and 4 hours after LY3478045 administration on Day 7.
62843612|NCT04270370|PLACEBO_COMPARATOR|Placebo + Atorvastatin (Part B)|Participants received oral dose of placebo QD for 14 days and 40 mg atorvastatin administered orally 4 hours after breakfast on Day -2 and 4 hours after LY3478045 administration on Day 7.
62843613|NCT02292836||rosacea patients|Questionnaire testing on routine dermatologist patient population
62058117|NCT01928316|EXPERIMENTAL|Sequence B|Healthy male volunteers will receive single oral dose of 10 mg domestic (made in China) mizolastine tablet on Day 1 and single oral dose of 10 mg imported mizolastine tablet on Day 8.
62843614|NCT02292836||non-rosacea patients|Questionnaire testing on routine dermatologist patient population
62843615|NCT00710541|EXPERIMENTAL|NPPV group|Subjects in this arm receive standard COPD treatment, LTOT if indicated, and NPPV with ventilators designed for 'non invasive ventilation'(Resmed VPAP III ST-A, Weinmann Ventimotion, Tyco Healthcare Knight Star 330)
62843616|NCT00710541|NO_INTERVENTION|control gorup|Subjects in this arm receive standard COPD treatment and LTOT if indicated.
62843617|NCT01493167|OTHER|limb casting/splinting|Patient age 0-90 years. Patient treatment requires extremity immobilization
62843618|NCT02923297|OTHER|Parkinson's disease patients|blood sampling
62843619|NCT04121793||Parkinson's Disease|Parkinson's Disease patients
62843620|NCT00900952||1|Infected elderly patients
62843621|NCT03859583|EXPERIMENTAL|Capsaicin|4 tsp of cayenne pepper in a 60g omelette
62843622|NCT03859583|PLACEBO_COMPARATOR|Control|60 g omelette
62843623|NCT05235867||dumpers|"* male and female patients~* age 13-24 years~* diagnosis of restrictive-type anorexia nervosa~* hospitalization for nutritional support~* \>4 cc/kg/day of urine output (a.k.a. fluid dumpers; n=5)"
62843624|NCT05235867||non-dumpers|"* male and female patients~* age 13-24 years~* diagnosis of restrictive-type anorexia nervosa~* hospitalization for nutritional support~* \<2 cc/kg/d of urine output (a.k.a. non-dumpers; n=5)"
62843625|NCT00653926|ACTIVE_COMPARATOR|A|Group A (Active) receives a multimodal injection intra- and postoperatively
62843626|NCT00653926|PLACEBO_COMPARATOR|P|Group P (Placebo) receives no injection intraoperatively and a saline injection postoperatively
62058118|NCT02678325|ACTIVE_COMPARATOR|Standardized normal protein enteral nutrition formula|Standardized enteral nutrition formula with a caloric density of 1.2 kcal/ml and protein percentage 20% of the total caloric intake
62058119|NCT02678325|EXPERIMENTAL|Standardized high protein enteral nutrition formula|Standardized enteral nutrition formula with a caloric density of 1.2 kcal/ml and protein percentage 33% of the total caloric intake
62058120|NCT00461292|EXPERIMENTAL|1|botulinum toxin Type A (200U)
62058121|NCT00461292|EXPERIMENTAL|2|botulinum toxin Type A (300U)
62058122|NCT00461292|OTHER|3|placebo; botulinum toxin Type A (200U)
62617970|NCT05194943||9. UOC Chirurgia Generale & Bariatric Center of Excellence IFSO-EC, Latina, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
62843627|NCT01161199||Untreated non-controllers|
62843628|NCT01161199||Elite controllers|
62843629|NCT01161199||HAART-suppressed|
62843630|NCT05138952|EXPERIMENTAL|Mindfulness Meditation|30-day program of mindfulness meditation comprising weekly group meditation tuition and support sessions and daily app-based mediation practice.
62843631|NCT02192281|EXPERIMENTAL|Playworks|Playworks was implemented during the entire school year, and outcome measures were collected in spring of the school year.
62843632|NCT02192281|NO_INTERVENTION|Control|Playworks was not implemented at these schools.
62843633|NCT03803241|EXPERIMENTAL|PVE + CD133|preop portal vein embolization + stem cells infusion
62843634|NCT03803241|SHAM_COMPARATOR|PVE|only preop portal vein embolization
62843635|NCT01032109|EXPERIMENTAL|Bevacizumab|
62843636|NCT02587273|OTHER|Fentanyl|This is a pharmacokinetics study with a single arm. All participants will will undergo the intervention described under the intervention section
62843637|NCT05360797|EXPERIMENTAL|Outpatient|The Mild AP patient is discharged and contacted daily for 4 consecutive days by the study investigators in each center.
62843638|NCT05360797|EXPERIMENTAL|Medical home care|The mild AP patient is discharged and contacted daily for 4 consecutive days by the medical home care department in each center.
62843639|NCT05360797|ACTIVE_COMPARATOR|Hospitalization|The mild AP patient is hospitalized
62843640|NCT01209325|EXPERIMENTAL|Vaccination|Gardasil (quadrivalent HPV types 6, 11, 16, 18) vaccination at weeks 0, 8, 24.
62843641|NCT02913456||HER2-positive unresectable LA/mBC|Participants with HER2-positive unresectable LA/mBC diagnosed up to 6 months prior to enrollment will be included in the study. Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LA/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site.
62617971|NCT05194943||10. UOC Chirurgia Generale, Ospedale Villa d'Agri, Potenza, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
62261518|NCT06177964|EXPERIMENTAL|Lerapolturev Arm (Stage 2 - Arm 1)|Lerapolturev (intratumoral) will be given by Convection Enhanced Delivery (CED), infused twice, 4 days apart, in the remaining disease of recurrent Glioblastoma (rGBM) subjects following maximal safe resection of their disease recurrence. This will be followed by subcutaneous injections of lerapolturev in the cervical perilymphatic (CPL) area on the same side as their tumor, weekly for 4 weeks and afterward every 3 weeks for about a year.
62261519|NCT06177964|ACTIVE_COMPARATOR|Lomustone (Stage 2 Arm 2)|Following maximal safe resection of their tumor recurrence subjects will receive Lomustine as a single oral dose of 110 mg/m2 every six weeks for up to 9 cycles.
62617972|NCT05194943||11. UOC di Chirurgia Generale e d'Urgenza, Presidio Ospedaliero ARNAS, Catania, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
62617973|NCT02365038|EXPERIMENTAL|Driving pressure limited ventilation|Driving pressure limited ventilation
62617974|NCT02365038|ACTIVE_COMPARATOR|Conventional ventilation|Mechanical ventilation as proposed in the ARDSNet protocol.
62617975|NCT04586465|EXPERIMENTAL|Neoadjuvant ICI combination with chemotherapy for stage Ⅱ-Ⅲ NSCLC|Eligible patients with clinical stage Ⅱ-Ⅲ NSCLC will receive dynamic PET-CT before and after 3 cycles neoadjuvant pembrolizumab plus chemotherapy, then patients receive surgical resection. Changes in tumor size were evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Net uptake rate constant of FDG-Ki value based on dynamic PET will be calculated to evaluate Ki changes before and after treatment. Pathological tumor response were evaluated according to IASLC recommendations. Dynamic PET will be compared with RECIST whether it can better predict the pathological tumor response and disease free survival.
62617976|NCT00514982|OTHER|1/Drug #1|Oral mesalamine will be used as initial therapy in patients who are not taking any medication or have not received any prior treatment for their IBD. Dosing will begin at 2.4 g PO QD and will be increased to 4.8 g QD within 2 weeks. Topical mesalamine (enema 4 g PR HS/BID or suppository 1 g PR HS/BID) may be added for patients with inflammation that is limited to the rectum (proctitis) or who have prominent complaints of urgency, incomplete evacuation or rectal bleeding.
62617977|NCT00514982|OTHER|1/Drug#2|Add oral corticosteroids (prednisone) to mesalamine. The standard induction dose will be 40 mg/day. After 1 week of therapy, if the total SCCAI score has decreased by greater than or equal to 2 points the patient will continue on another week of therapy. If the SCCAI has not decreased by greater than or equal to 2 points (indicative of a reduction in symptoms) at one week, then the dose will be increased to 60 mg/day. Patients on either dosage will have another SCCAI assessment done a week later (2 weeks after beginning corticosteroids), and if they are found to be in remission (SCCAI less than or equal to 2), a steroid-tapering schedule will be initiated.
62617978|NCT00514982|OTHER|1/Drug#3|Infliximab and 6-MP will be added to patients with a SCCAI greater than 2 at week 8. The first infusion of infliximab (5 mg/kg) will be given during that week. In addition, 6-MP will be initiated at doses of 1.0-1.5 mg/kg PO QD to reduce the incidence of infliximab antibody formation and facilitate steroid tapering (the target dose of 6-MP will be decreased accordingly if patients are found to have low TMPT levels/activity by genotypic or phenotypic testing). Also, steroids will also be rapidly tapered off at this time.
62261520|NCT00760019|ACTIVE_COMPARATOR|Salsalate first, then Placebo|In this crossover study, this group was randomly allocated therapy with salsalate first, a 4 week washout, then 4 weeks of placebo therapy in a double-blinded fashion.
62261521|NCT00760019|PLACEBO_COMPARATOR|Placebo first, then Salsalate|In this crossover study, this group was randomly allocated therapy with placebo first, a 4 week washout, then 4 weeks of salsalate therapy in a double-blinded fashion.
62617979|NCT00514982|OTHER|1/Drug#4|Infliximab and 6-MP will be added to patients with a SCCAI greater than 2 at week 8. The first infusion of infliximab (5 mg/kg) will be given during that week. In addition, 6-MP will be initiated at doses of 1.0-1.5 mg/kg PO QD to reduce the incidence of infliximab antibody formation and facilitate steroid tapering (the target dose of 6-MP will be decreased accordingly if patients are found to have low TMPT levels/activity by genotypic or phenotypic testing). Also, steroids will also be rapidly tapered off at this time.
62617980|NCT00514982|OTHER|1/Drug#5|Subjects with a SCCAI greater than 2 after 3 doses of infliximab will continue 6-MP, discontinue infliximab infusions and start adalimumab injections approximately 2 weeks after the 3rd dose of infliximab. Induction dosing will consist of a 160 Micro/g subcutaneous injection, followed by 80 Micro/g 2 weeks after.
62617981|NCT00514982|OTHER|1/Drug#6|Patients who have a SCCAI greater than 2 after 2 doses of adalimumab will continue 6-MP, discontinue adalimumab, and start therapy with tacrolimus 0.01 mg/kg PO BID approximately 2 weeks after the second dose of adalimumab.
62058123|NCT00461292|OTHER|4|placebo; botulinum toxin Type A (300U)
62261522|NCT02554019|EXPERIMENTAL|BT063|50 mg BT063 administered by intravenous (IV) infusion 8 times
62261523|NCT02554019|PLACEBO_COMPARATOR|Placebo|Placebo administered by IV infusion 8 times
62617982|NCT04091815|ACTIVE_COMPARATOR|I group - general anaesthesia|General anesthesia, induction with fentanyl, propofol, roqurium. Maintenance - sevoflurane (BIS ranges 40 - 60), opioids (fentanyl and morphine), roqurium. Intraoperative fluid administration - 2000ml sterofundine, 500ml Gelaspan. 75mg intravenous diclofenac sodium on anesthesia induction, 1000mg intravenous acetaminophen at the start of wound closure. Surgical site infiltration, bupivacaine, 0.25%-10 ml, after the last suture.
62617983|NCT04091815|EXPERIMENTAL|II group - combined - spinal and general anaesthesia|"Spinal anesthesia: L3-4 interspace, 27G needle, bupivacaine hyperbaric, 16 mg, morphine sulfate 0.1% - 0.1ml.~General anesthesia, induction with fentanyl, propofol, roqurium. Maintenance - sevoflurane (BIS ranges 40 - 60), roqurium. Intraoperative fluid administration - 2000ml sterofundine, 500ml Gelaspan. 75mg intravenous diclofenac sodium on anesthesia induction, 1000mg intravenous acetaminophen at the start of wound closure. Surgical site infiltration, bupivacaine, 0.25%-10 ml, after the last suture."
62617984|NCT03734445|EXPERIMENTAL|Vitamin supplement|Effervescent tablets containing Vitamin C, Vitamin D and zinc
62617985|NCT03734445|PLACEBO_COMPARATOR|Placebo|Effervescent tablets not containing Vitamin C, Vitamin D and zinc
62617986|NCT00341549||Myopia|The subject population will be adult individuals and their children, in good health with the exception of myopia.
62617987|NCT04100655|EXPERIMENTAL|GM-CSF|"Hysteroscopy will be arranged to confirm the uterine cavity is normal and there is no significant intrauterine adhesion.~3ml GM-CSF gel will be irrigated into the uterine cavity immediately when hysteroscopy is complete. Then same dose gel will be given every other day twice."
62617988|NCT04100655|EXPERIMENTAL|Control|"Hysteroscopy will be arranged to confirm the uterine cavity is normal and there is no significant intrauterine adhesion.~After hysteroscopy examination, nothing was applied to the uterine cavity."
62261524|NCT01668251||Fetal ascertainment|Girls who are diagnosed with Turner syndrome because of concerns raised by an abnormal fetal ultrasound.
62617989|NCT03420222|EXPERIMENTAL|AVP-786|Participants were to receive AVP-786-28 (deudextromethorphan hydrobromide \[d6-DM\] 28 milligrams \[mg\]/quinidine sulfate \[Q\] 4.9 mg) once daily (OD) for the first 7 days, followed by AVP-786-28 twice daily (BID) for the next 7 days. Beginning on Day 15, participants were to receive AVP-786-42.63 (d6-DM 42.63 mg/Q 4.9 mg) BID for 10 weeks.
62617990|NCT03420222|PLACEBO_COMPARATOR|Placebo|Participants were to receive placebo BID for 12 weeks.
62617991|NCT02867800|EXPERIMENTAL|Standard GVHD Prophylaxis + Abatacept|"Subjects will receive~* premedication (Diphenhydramine, Acetaminophen, Methylprednisolone; and Meperidine as needed)~* immunosuppression (Alemtuzumab, or Thymoglobulin)~* conditioning regimen (Fludarabine, Thiotepa, and Melphalan)~* GVHD prophylaxis: calcineurin inhibitor (Cyclosporine,Tacrolimus, Sirolimus or Mycophenolate Mofetil with permission of the sponsor) and Methotrexate plus Abatacept on days -1, +5, +14 and +28, and a marrow infusion on day 0."
62617992|NCT00719940|EXPERIMENTAL|1|Cognitive behavioral therapy
62617993|NCT00719940|PLACEBO_COMPARATOR|2|Waiting group
62617994|NCT03748121|EXPERIMENTAL|Pranayama assisted Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|To prepare patients for the TF-CBT, they received 5-10 minutes of pranayama at the begin of each of the 10 TF-CBT units.
62617995|NCT03748121|ACTIVE_COMPARATOR|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|Patients wait for 10 TF-CBT units and then are offered to learn pranayama.
62617996|NCT00549471|EXPERIMENTAL|BG|cooperative quadriplegic CP children ages 8-11 years, gross motor function level 4 with troublesome hypertonia that will respond to treatment. BG children will be given Botulinum Toxin A, as clinically required, in addition to an equivalent program of intensive therapy
62617997|NCT00549471|NO_INTERVENTION|Control Group|control group: Twenty cooperative quadriplegic CP children ages 8-11 years, gross motor function level 4 with troublesome hypertonia that will respond to treatment.CG children will undergo a program of intensive therapy.
62617998|NCT00661453|EXPERIMENTAL|1|All patients will receive VPA and carnitine.
62617999|NCT03728621|EXPERIMENTAL|Individual-based lifestyle intervention|Promotion of normocaloric \& balanced diet and physical activity
62618000|NCT03728621|EXPERIMENTAL|Group-based lifestyle intervention|Promotion of normocaloric \& balanced diet and physical activity
62618001|NCT02874833|EXPERIMENTAL|Exercise Group|Experimental arm type will assess whether a newly developed, supervised 8-week individualized, internet-based exercise therapy is effective in reducing depressive symptoms.
62618002|NCT02874833|NO_INTERVENTION|Treatment as usual group|Treatment as usual. Other form of therapy (e.g. antidepressive medication) will not be affected.
62618003|NCT00450853|EXPERIMENTAL|Granisetron SC-Granisetron IV|Granisetron SC followed by Granisetron IV
62618004|NCT03571724|EXPERIMENTAL|Usual Brand (UB) non-mentholated filtered cigarettes|Usual Brand (UB) mentholated filtered cigarettes Usual Brand (UB) non-mentholated filtered cigarettes or to very low nicotine non-mentholated cigarettes
62618005|NCT03571724|EXPERIMENTAL|Usual Brand (UB) mentholated filtered cigarettes|Subjects will be randomized to continue to smoke Usual Brand (UB) mentholated filtered cigarettes or to very low nicotine mentholated cigarettes
62618006|NCT05745753|EXPERIMENTAL|Partecipants with cardiovascular disease|The research program will examine imaging and clinical biomarkers associated with plasma and cellular determinants of cardiovascular disease, taking into account the potential effects of COVID-19 infection. This will make it possible to re-evaluate the cardiovascular risk profile of subjects with cardiovascular diseases.
62843642|NCT02404025|EXPERIMENTAL|Eltrombopag+rabbit ATG/CsA arm|Subjects received rabbit ATG diluted by 500 mL of saline or 5% glucose injection at a dose of 2.5 to 3.75 mg per kilogram (kg) per day for 5 days as a slow intravenous infusion over 6 hours. CsA was administered at a dose of 3 mg per kg twice a day from day 0. The dose level was adjusted based on the monitoring of blood level or renal function. Eltrombopag was initiated on day 14 and it could be delayed up to 2 weeks if the subject had infection, serum sickness, or other adverse events. Eltrombopag wasadministered orally once a day at fasting at an initial dose of 75 mg, and the dose adjusted every 2 weeks according to the platelet count. Eltrombopag and CsA were continued until Week 26.After Week 26, eligible subjects received eltrombopag; and CsA was tapered or maintained as per the investigator's discretion.
62843643|NCT04190888||Sickle Cell Disease|Patients with sickle cell disease will be followed prospectively
62843644|NCT04729023|EXPERIMENTAL|Combined surgery group|In this group, all eligible patients will receive pars plana vitrectomy combined with phacoemulsification cataract surgery.
62618007|NCT05745753|EXPERIMENTAL|Partecip with cardiovascular disease and affected by COVID-19|In this arm we investigate the immune dysregulation that may play a role in the evolution of cardiovascular disease characteristics of chronic and convalescent COVID-19 participants, in this field we will perform detailed clinical cardiological and immunological phenotyping on enrolled patients.
62843645|NCT04729023|ACTIVE_COMPARATOR|Subsequent surgery group|In this group, all eligible patients will receive pars plana vitrectomy first. And a subsequent phacoemulsification will be systematically performed 6 months after the PPV surgery.
62843646|NCT00874419|EXPERIMENTAL|erlotinib|Arm 1 receive erlotinib 150 mg oral, once a day until progression or unacceptable toxicity
62843647|NCT00874419|ACTIVE_COMPARATOR|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
62843648|NCT02659891|ACTIVE_COMPARATOR|Group 1 (Treatment)|Intravenous immune globulin (IVIg; Privigen®) 1g/kg monthly for 2 months with immunosuppression reduction.
62843649|NCT02659891|PLACEBO_COMPARATOR|Group 2 (Control)|Placebo infusion monthly for 2 months with immunosuppression reduction
62843650|NCT04074408|EXPERIMENTAL|Cohort 1|low dose hUMSCs or high dose hUMSCs
62843651|NCT04074408|EXPERIMENTAL|Cohort 2|best dose of hUMSCs (from cohort 1) or placebo
62843652|NCT02758483|OTHER|Test diet|"Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).~Note: Both diets had the same calories, carbohydrates, proteins, fat, and fiber, and were prescribed according to the American Diabetes Association recommendations."
62261525|NCT01668251||Maternal ascertainment|Girls who are diagnosed with Turner syndrome because their mothers had an amniocentesis for a reason other than an abnormal fetal ultrasound concerning for Turner syndrome. For example an amniocentesis was done because of advanced maternal age or because of an abnormal triple screen or because another condition was being screened for such as trisomy 21.
62618008|NCT01249586|PLACEBO_COMPARATOR|Traditional teaching|A traditional class of blindness prevention.
62261526|NCT04124913|EXPERIMENTAL|Dydrogesterone|
62618009|NCT05373030|EXPERIMENTAL|Recombinant adenovirus type-5-vectored COVID-19 vaccine|
62843653|NCT02758483|OTHER|Control diet|"Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).~Note: Both diets had the same calories, carbohydrates, proteins, fat, and fiber, and were prescribed according to the American Diabetes Association recommendations."
62843654|NCT01406613||Particpants of previous TRIO study|All participants to this study are being observed as a follow up to a previous study which involved 4 arms. All participants to this follow up study will be subject to identical study procedures.
62843655|NCT03481686|EXPERIMENTAL|Patients with injections of ESA|Patients with injections of ESA
62843656|NCT00329797|EXPERIMENTAL|Zoledronic Acid|Zoledronic acid q 6 months plus Vitamin D and calcium supplement for 3 years in addition to concurrent radiation therapy and LHRH therapy.
62843657|NCT00329797|ACTIVE_COMPARATOR|Control|Vitamin D and calcium supplement everyday for 3 years in addition to concurrent radiation therapy and LHRH therapy.
62843658|NCT00674713|EXPERIMENTAL|A|Patients receiving acupuncture at P6 point plus physiological saline solution
62843659|NCT00674713|ACTIVE_COMPARATOR|B|Patients receiving ondansetron plus sham acupuncture
62843660|NCT00674713|OTHER|C|Patients receiving ondansetron plus acupuncture at P6 point
62261527|NCT04124913|ACTIVE_COMPARATOR|Vaginal progesterone|
62618010|NCT05373030|ACTIVE_COMPARATOR|Inactivated COVID-19 vaccine|
62618011|NCT00565175|EXPERIMENTAL|famotidine|
62618012|NCT00565175|PLACEBO_COMPARATOR|Placebo|
62618013|NCT05061433|NO_INTERVENTION|Usual Care|Participants receive standard of care.
62843661|NCT00674713|PLACEBO_COMPARATOR|D|Patients receiving physiological saline solution plus sham acupuncture
62843662|NCT01984528|EXPERIMENTAL|Prick Test|Alternaria alternata allergen extract Positve control Negative control
62843663|NCT02659397|EXPERIMENTAL|ETC-1002 + Atorvastatin|ETC-1002 180 mg treatment, oral once daily added-on to Atorvastatin 80 mg once daily
62843664|NCT02659397|PLACEBO_COMPARATOR|Placebo + Atorvastatin|Placebo treatment, oral once daily added-on to Atorvastatin 80 mg once daily
62446638|NCT04223505|EXPERIMENTAL|CCT arm|As per local protocol, a non-contrast enhanced prospective ECG-triggered image acquisition will be acquired. This will be followed by a contrast-enhanced prospective ECG-triggered will be acquired using a tri-phasic contrast protocols. Delayed CT images will be acquired 60 seconds after the initial contrast-enhanced CT scan.Cardiac CT image interpretation will be performed as per clinical routine. The LA and LAA will be assess for filling defects and characterized based upon attenuation values. If LA/LAA thrombus cannot be excluded, filling defects will be assessed on the delay images. Increases in attenuation would be consistent with pseudo-thrombus from 'slow flow' and 'incomplete opacification'. Areas where attenuation does not change significantly (persistent filling defect) will be diagnosed as thrombus. It will be recommended that patients with thrombus will undergo TEE.
62843665|NCT05828329|EXPERIMENTAL|Experimental group 1|The program with virtual reality will consist of a 30-minutes guided visualization session through virtual reality glasses. Students will visualize a 360º video that simulates the entire experience of an exam, from first person perspective.
62843666|NCT05828329|ACTIVE_COMPARATOR|Experimental group 2|The 4-weeks program will consist of a 30-minutes traditional guided visualization session, by listening only the part of the audio used for EG1.
62843667|NCT05828329|NO_INTERVENTION|Control group|This group will not receive any intervention, as the most used strategy to cope with exams among students.
62843668|NCT00776243||wDM|Early diabetes
62843669|NCT00776243||pDM|Poorly controlled diabetic patients
62261528|NCT01848288|EXPERIMENTAL|CENTURION|First surgical eye randomized to CENTURION® Vision System, with second surgical eye (fellow eye) assigned to INFINITI® Vision System. Second eye surgery conducted within 14 days of the first eye surgery. Duration of surgery less than 30 minutes each eye.
62261529|NCT01848288|ACTIVE_COMPARATOR|INFINITI|First surgical eye randomized to INFINITI® Vision System, with second surgical eye (fellow eye) assigned to CENTURION® Vision System. Second eye surgery conducted within 14 days of the first eye surgery. Duration of surgery less than 30 minutes each eye.
62843670|NCT03507946|EXPERIMENTAL|Test|"Subject self control; Plaque 1: Dermawrap - combined 460nm, 633nm, and 830nm LED therapyDaily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.~Plaque 2: No Intervention"
62261530|NCT01925573|OTHER|Optune+RT+Bevacuzimab|"Part 1:~Bevacizumab every 2 weeks plus Optune daily for 4 week cycles.~Part 2:~RT will begin post 3 round of Bevacizumab (hypofractionated radiotherapy: 30 Gy in 5 fractions or 35 Gy in 10 fractions) per physician choice.~Part 3:~Adjuvant Bevacizumab and Optune"
62261531|NCT01203540|EXPERIMENTAL|Naaga in ABAK system|
62261532|NCT01203540|PLACEBO_COMPARATOR|Saline solution|
62261533|NCT04841421|EXPERIMENTAL|89Zr-CD147 1mCi±10% 10mg dose group|The activity administered was 1mCi±10% and the mass of radiolabeled CD147 was 10 mg.
62261534|NCT04841421|EXPERIMENTAL|89Zr-CD147 3mCi±10% 10mg dose group|The activity administered was 3mCi±10% and the mass of radiolabeled CD147 was 10 mg.
62843671|NCT03926611|EXPERIMENTAL|LOU064 Arm 1|10 mg LOU064 qd capsule once daily
62843672|NCT03926611|EXPERIMENTAL|LOU064 Arm 2|35 mg capsule qd LOU064 once daily
62843673|NCT03926611|EXPERIMENTAL|LOU064 Arm 3|100 mg capsule qd LOU064 once daily
62843674|NCT03926611|EXPERIMENTAL|LOU064 Arm 4|10 mg capsule LOU064 bid
62843675|NCT03926611|EXPERIMENTAL|LOU064 Arm 5|25 mg capsule LOU064 bid
62843676|NCT03926611|EXPERIMENTAL|LOU064 Arm 6|100 mg capsule LOU064 bid
62843677|NCT03926611|PLACEBO_COMPARATOR|Placebo Arm|Participants took matching placebo twice daily
62261535|NCT04841421|EXPERIMENTAL|89Zr-CD147 5mCi±10% 10mg dose group|The activity administered was 5mCi±10% and the mass of radiolabeled CD147 was 10 mg.
62261536|NCT04542759|ACTIVE_COMPARATOR|Besifloxacin|1 DROP 4 TIMES A DAY FOR 3 DAYS PRIOR SURGERY
62261537|NCT04542759|PLACEBO_COMPARATOR|Hydroxypropyl methylcellulose|1 DROP 4 TIMES A DAY FOR 3 DAYS PRIOR SURGERY
62261538|NCT05127837|NO_INTERVENTION|Treatment as Usual (TAU)|CBT for psychosis distance learning course.
62261539|NCT05127837|EXPERIMENTAL|CBTpro|In addition to TAU, clinicians and clients receive the CBTpro training.
62261540|NCT01908764|EXPERIMENTAL|AL-60371/Posology 1|AL-60371 otic suspension, single dose of 200 µL following surgical insertion of tympanostomy tubes
62261541|NCT01908764|EXPERIMENTAL|AL-60371/Posology 2|AL-60371 otic suspension, single dose of 4 drops following surgical insertion of tympanostomy tubes
62843678|NCT01452841|EXPERIMENTAL|Grapefruit Consumption|
62843679|NCT01452841|ACTIVE_COMPARATOR|Control|
62843680|NCT05941195|EXPERIMENTAL|psychoeducation applied experimental group|The patients in the experimental group received a total of 5 weeks (9 sessions) of cognitive-behavioral-based psychoeducation, consisting of 45-60 minutes, 2 sessions per week and the first session preparation session. In the sessions, the topics determined by using learning activities such as lecture, discussion, summarization, role-play, question/answer and exercises were explained and discussed. At the end of each session, homework was given to facilitate the patient's cognitive and behavioral change between sessions.
62843681|NCT05941195|NO_INTERVENTION|non-intervention control group|Control group: The control group continued to receive the routine care.
62261542|NCT04866693||Service users|Up to 20 people with current or recent experience of using community-based mental health services will be recruited to the study. Participants will take part in one in-depth interview or focus group discussion.
62446639|NCT01968733|ACTIVE_COMPARATOR|Moxifloxacin|Intravenous with the potential step-down to oral moxifloxacin
62446640|NCT01968733|EXPERIMENTAL|Solithromycin|Intravenous with potential step-down to oral solithromycin
62446641|NCT02495961||Low risk population|Colombian children, between 6 and 12 years old, regular students of a Primary school.
62446642|NCT02495961||High risk population|Mexican children, between 6 and 12 years old, regular students of a Primary school.
62446643|NCT04247490||Pediatric AIH|Patients diagnosed with hepatitis type 1 and type 2 formulated between the ages of 0 and 18.
62446644|NCT06094868|EXPERIMENTAL|Fruquintinib in combination with Sintilimab and XELOX|"Fruquintinib: 4mg, QD, PO, D1-D14, Q3W; Sintilimab: weight \< 60kg, 3mg/kg; weight≥60kg, 200 mg; I.V.， D1，Q3W； XELOX regimen: oxaliplatin: 130 mg/m2, ivgtt, D1, Q3W; Capecitabine: 1000 mg/m2, bid, D1-D14, Q3W; After 6 cycles of treatment, chemotherapy was given and maintenance treatment was given with fuquitinib combined with sindillizumab. The above medication regimen can be adjusted according to the adverse reaction tolerance of the subjects.~\* Maintenance of treatment until disease progression, or intolerable toxic reactions, or other conditions determined by the investigator"
62446645|NCT04342923||Complete cohort|All patients undergoing PD during study period in all participating center/units in Spain.
62446646|NCT01832805|EXPERIMENTAL|Theta burst stimulation|Specific developed sham coil.
62261543|NCT04866693||Carers|Up to 20 family members/ carers with experience of supporting another adult who is accessing community-based mental health services, will be recruited to the study. Participants will take part in one in-depth interview or focus group discussion.
62261544|NCT04866693||Healthcare professionals|Up to 20 healthcare professionals from different disciplinary backgrounds and community-based mental health services will be recruited to the study. Participants will take part in one in-depth interview or focus group discussion.
62261545|NCT03986385|EXPERIMENTAL|A(apatinib Xelox)|Preoperative: apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w） Postoperative: Capecitabine 1000mg/m2 bid d1-14 q3w 2 cycles
62261546|NCT03986385|ACTIVE_COMPARATOR|B(Xelox)|Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w） Postoperative: Capecitabine 1000mg/m2 bid d1-14 q3w 6 cycles
62261547|NCT06035653||A|Minimum of 12 patients who required total radiotherapy replan
62446647|NCT03641898||Morphometric assessment of FNLs|After FFR-guided PCI, the morphometric characteristics of FNLs (FFR\>0.8) are assessment by intravascular ultrasound.
62446648|NCT01059071|EXPERIMENTAL|DFMO and Etoposide|
62446649|NCT02004379||Patients with hepatitis C, genotype 1|Patients with hepatitis C, genotype 1, treated with telaprevir or boceprevir
62446650|NCT03940430|ACTIVE_COMPARATOR|Lactoferrin in iron deficiency anemia|lactoferrin ( pravotin) 100mg twice daily
62446651|NCT03940430|ACTIVE_COMPARATOR|Ferrous sulfate in iron deficiency anemia|ferrous sulphate (hemojet)
62446652|NCT03940430|ACTIVE_COMPARATOR|Lactoferrin and ferrous sulfate in iron deficiency anemia|Lactoferrin 100 mg twice daily and ferrous sulfate
62446653|NCT03141099|ACTIVE_COMPARATOR|Low normal MAP and low normal PaO2|MAP 63 mmHg and PaO2 9-10 kPa during targeted temperature management (36 hours) after OHCA.
62446654|NCT03141099|ACTIVE_COMPARATOR|High normal MAP and low normal PaO2|MAP 77 mmHg and PaO2 9-10 kPa during targeted temperature management (36 hours) after OHCA.
62446655|NCT03141099|ACTIVE_COMPARATOR|Low normal MAP and high normal PaO2|MAP 63 mmHg and PaO2 13-14 kPa during targeted temperature management (36 hours) after OHCA.
62261548|NCT06035653||B|Minimum of 28 patients who were reviewed in the multi-professional meeting but did not require full replan
62261549|NCT00606320|EXPERIMENTAL|Aripiprazole|
62446656|NCT03141099|ACTIVE_COMPARATOR|High normal MAP and high normal PaO2|MAP 77 mmHg and PaO2 13-14 kPa during targeted temperature management (36 hours) after OHCA.
62446657|NCT03616834|EXPERIMENTAL|Tomivosertib (eFT-508)|Tomivosertib (eFT-508) will be taken at 200 mg twice daily (bid). Subjects will continue their anti-PD-1/anti-PD-L1 therapy, which they had already initiated per standard of care according to the package insert.
62446658|NCT04648475|EXPERIMENTAL|Arm 1|CD19 and CD22 targeted CAR-T cells treat
62446659|NCT06244303|ACTIVE_COMPARATOR|Group I|manual Tooth Brush + Colgate Total TP (0.454% SnF, 1100 ppm F) Brush 2 x day / 2 mins Colgate Total Mouthwash (CPC+Zn) Swish 20 mL / 30 secs
62446660|NCT06244303|PLACEBO_COMPARATOR|Group II|Manual Toothbrush +Colgate Great Regular Flavor Toothpaste Brush w/ full ribbon, 2x day / 2mins
62446661|NCT01727479|EXPERIMENTAL|Ribose|After each of the 3km time trial (3 in total), consumption of ribose incorporated in a sports drink.
62446662|NCT01727479|PLACEBO_COMPARATOR|Placebo|After each of the 3km time trial (3 in total), consumption of placebo incorporated in a sports drink.
62446663|NCT01851070|PLACEBO_COMPARATOR|Normal Saline Placebo|Placebo will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
62446664|NCT01851070|ACTIVE_COMPARATOR|Allogeneic Mesenchymal Precursor Cells|Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
62843682|NCT06050824|ACTIVE_COMPARATOR|concomitant|Clarithro -pantoprazole- Metronidazole - Amoxicyllin
62618014|NCT05061433|EXPERIMENTAL|Intervention|"Initial Home Visit: MIH/CP provider team will visit the patient's home at the scheduled time following a specific General Followup Protocol involving 1. Assessment of patient understanding of recent illness and medical therapy including reinforcement of medical adherence, 2. Any other disease-specific concerns, 3. Performance of a home safety evaluation, 4. If patients have concerns relating to their ability to manage their disease process at home, 5. MIH/CP providers and an on-call social worker will provide assistance in the form of on-site, telephone, and electronic referrals or provision of appointments with appropriate services.~Subsequent visits: The MIH/CP team will decide in conjunction with Medical Control and the PMD if further followup is needed, and the most appropriate followup interval., At 30 days from initial hospital discharge, the patient will be discharged from the MIH/CP program in conjunction with the PMD."
62843683|NCT06050824|ACTIVE_COMPARATOR|LOAD|Levofloxacin -omeprazole- nitazoxanide- Doxycycline
62261550|NCT04988412|ACTIVE_COMPARATOR|CoMSM LD|Participants will receive investigational product 1 containing collagen (5 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL).
62618015|NCT03753178||patients|70 participants presented with clinical and motor electrophysiological evidence of common peroneal neuropathy at the fibular neck
62843684|NCT03472261|EXPERIMENTAL|Experimental Group|Patients treated by Botulinum toxin A and twister and specific home exercise program
62843685|NCT03472261|ACTIVE_COMPARATOR|Conventional Therapy Group|Patients treated by Botulinum toxin A and specific home exercise program
62843686|NCT00593190|EXPERIMENTAL|1|
62843687|NCT05070715||Group 1: FGR group|Estimated fetal weight \<10th percentile
62843688|NCT05070715||Group 2: Control group|Healthy pregnants who will give birth 37th and after gestational week
62843689|NCT04223219|ACTIVE_COMPARATOR|High Opioid Group|-The patients will receive fentanyl infusion at a rate of 1 µg/kg/h and fentanyl bolus 20-40 µg according to patient hemodynamics. (tachycardia: increase of heart rate \>20% of baseline or hypertension: increase of mean blood pressure \>20% of baseline).
62843690|NCT04223219|PLACEBO_COMPARATOR|Low Opioid Group|The patients will receive fentanyl bolus 20 µg/hr and propofol 20 mg at the time of surgical stimulation and according to patient hemodynamics (repeated as required).
62843691|NCT04223219|EXPERIMENTAL|Non-Opioid Group|The patients will receive infusions of dexmedetomidine 0.2 µg/kg/h, ketamine 2 µg/kg/min, and magnesium sulfate 5 mg/kg/h.
62843692|NCT02728492|EXPERIMENTAL|Quisinostat 8 mg & Paclitaxel & Carboplatin|Quisinostat 8 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х \[GFR (ml/min) + 25\] on Day 7 of every 3-weeks course up to 6 cycles
62843693|NCT02728492|EXPERIMENTAL|Quisinostat 10 mg & Paclitaxel & Carboplatin|Quisinostat 10 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х \[GFR (ml/min) + 25\] on Day 7 of every 3-weeks course up to 6 cycles
62261551|NCT04988412|PLACEBO_COMPARATOR|Placebo group|Placebo group participants will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, vitamin C: 0 mg); continous administration of placebo product for 12 weeks.
62618016|NCT03753178||controls|70 controls
62843694|NCT02728492|EXPERIMENTAL|Quisinostat 12 mg & Paclitaxel & Carboplatin|Quisinostat 12 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х \[GFR (ml/min) + 25\] on Day 7 of every 3-weeks course up to 6 cycles
62843695|NCT02728492|EXPERIMENTAL|Quisinostat 8 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 8 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
62843696|NCT02728492|EXPERIMENTAL|Quisinostat 10 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 10 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
62843697|NCT02728492|EXPERIMENTAL|Quisinostat 12 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 12 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
62843698|NCT02728492|EXPERIMENTAL|Quisinostat 12 mg & Gemcitabine 1250 mg/m2 & Cisplatin|Quisinostat 12 mg capsule every other day and Gemcitabine 1250 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
62843699|NCT05358769|EXPERIMENTAL|Incoxil supplement group|Incoxil supplement-group: receive daily oral Incoxil supplementation and perform pelvic floor muscle exercise (PFME) for 6 weeks.
62843700|NCT05358769|ACTIVE_COMPARATOR|Control group|Control group: receive placebo oral daily supplementation and perform pelvic floor muscle exercise (PFME) for 6 weeks.
62843701|NCT05048966|EXPERIMENTAL|Group Wellness Class 1|
62843702|NCT05048966|ACTIVE_COMPARATOR|Group Wellness Class 2|
62843703|NCT05298449|EXPERIMENTAL|HU-045 group|"HU-045 Injection group will receive intramuscular injection of HU-045 to a total of 5 glabellar line sites 4 U/0.1ml each.~HU-045 will be reconstituted from a powder into liquid form by adding 2.5cc of 0.9% sterile saline to the vial, and appropriate volumes will be administered."
62261552|NCT04988412|ACTIVE_COMPARATOR|Co HD|Participants will receive investigational product 2 containing collagen (10 g/ 25 mL) and vitamin C (80 mg/ 25 mL).
62843704|NCT05298449|ACTIVE_COMPARATOR|Xeomin® group|"Xeomin® Injection group will receive intramuscular injection of Xeomin® to a total of 5 glabellar line sites 4 U/0.1ml each.~Xeomin® will be reconstituted from a powder into liquid form by adding 2.5cc of 0.9% sterile saline to the vial, and appropriate volumes will be administered."
62843705|NCT03462693||Group 1|Dry needling plus standard physiotherapy treatment
62618017|NCT05409755|ACTIVE_COMPARATOR|Fractional microneedling radiofrequency|Device
62618018|NCT05409755|ACTIVE_COMPARATOR|Fractional microneedling radiofrequency followed by minoxidil application|Device and drug
62618019|NCT05409755|ACTIVE_COMPARATOR|Minoxidil|Topical drug
62618020|NCT06351553|ACTIVE_COMPARATOR|Pulmonary vein isolation exclusively with radiofrequency|The ablation of the anterior and posterior wall will be performed with radiofrequency.
62261553|NCT04988412|ACTIVE_COMPARATOR|CoMSM HD|Participants will receive investigational product 3 containing collagen (10 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL).
62261554|NCT01086462|EXPERIMENTAL|GSK2239633|Single dose infusion of study drug over 15 minutes
62261555|NCT04092712|EXPERIMENTAL|Investigational Product|\[14C\]-CTP-543
62446665|NCT04674098||Usual Care|Every patient who is admitted or transferred to the target unit during both the baseline and intervention phases of the study will be approached by a member of the research staff to be a subject in the study. The patient will be informed of the overall study objectives and be requested to provide informed consent to participate. The patient's involvement in the study will include having the research staff access and extract relevant outcome variables collected from their electronic health record (EHR) (AEs, admissions to the ICU, hospital length of stay and activation of the rapid response team) as a result of their hospital stay.
62446666|NCT04674098||Intervention|If the patient provides consent during the intervention phase, the BAS technology will passively monitor their vital signs generated by the Philips vital sign monitor by relaying their deidentified vital signs data to the CLU, proprietary Cloud server, and subsequently Lumori® on a study-issued cell phone of the RN who is primarily responsible for the patient's care. Patient's admitted or transferred to the targeted unit will NOT be excluded from being approached to participate in the study.
62446667|NCT02006706|EXPERIMENTAL|MabThera/Rituxan|
62618021|NCT06351553|EXPERIMENTAL|Pulmonary vein isolation exclusively with pulsed field ablation|The ablation of the anterior and posterior wall will be performed with pulsed field ablation.
62843706|NCT03462693||Group 2|Standard physiotherapy treatment
62446668|NCT02634060|EXPERIMENTAL|Home Based Fecal Calprotectin|"IBDoc® at week 0, 4 and 8 using smartphone. All material will be provided by the third party The same stool sample of the home base faecal calprotectin will be brought to the hospital and used for ELISA faecal calprotectin measurement at week 0, 4 and 8 for UC patients and week 0 and 4 for CD patients.~IBDoc® results will be forwarded to the patient and the health care professional."
62446669|NCT02708277|EXPERIMENTAL|Group A|At the end of the procedure the surgery loop-shaped intrauterine contraceptive device (IUCD) was placed in the uterine cavity.
62446670|NCT02708277|EXPERIMENTAL|Group B|At the end of the procedure the surgery an intrauterine balloon (Cook Medical) was placed in the uterine cavity.
62446671|NCT03586336|EXPERIMENTAL|ReDS-Guided|Patients in the intervention arm will undergo daily measurements of lung fluid content at the bedside with the ReDS vest. The values will be shared with the treating clinicians, who can use the measurements in addition to other standard data to guide diuresis. Patients should be discharged only once their lung fluid content falls within the normal range of 20-35%.
62446672|NCT03586336|SHAM_COMPARATOR|Control|Patients in the control arm will also undergo daily measurements of lung fluid content at the beside with the ReDS vest. However, the values will not be shared with the treating clinicians, who will direct management based on standard clinical tools
62618022|NCT06351553|EXPERIMENTAL|Combined pulmonary vein isolation|The ablation of the anterior wall will be performed with radiofrequency, and the posterior wall with pulsed field ablation.
62261556|NCT05352126|EXPERIMENTAL|Puressentiel Purifying spray|"Puressentiel Air Purifying Spray with 41 essential oils~Capacity: 200 ml~BIOCIDE Product type 2: Disinfectants used in the private and public health sector~Composition: Ethanol (CAS no. 64-17-5) 75% m/m and 41 essential oils"
62623727|NCT02763917|PLACEBO_COMPARATOR|Placebo Air Purifier|Homes in the control group will receive placebo air purifiers that have the internal air filters removed, but which will run normally. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight. At the end of the study, participants in the control group will receive active air purifiers. A control group is needed to ensure that reduced pollutant levels and health effects are not due to temporal trends and 'placebo effects' of being enrolled in an intervention trial. Participants will also be informed that being in the study does not prevent them from purchasing and using air cleaners during the study period.
62843707|NCT04499352|EXPERIMENTAL|treatment arm A|
62843708|NCT04499352|EXPERIMENTAL|treatment arm B|
62843709|NCT02098668||Normal, pathological cycle, infertility|healthy women PCOS Endometriosis hyperprolactinemia fertility treatment
62843710|NCT02331277|EXPERIMENTAL|BI 655064|Subjects received BI 655064 240 milligram (mg) via subcutaneous injection every week, until 4 weeks.
62843711|NCT02331277|PLACEBO_COMPARATOR|Placebo|Subjects received placebo matching to BI 655064 via subcutaneous injection every week, until 4 weeks.
62261557|NCT05352126|PLACEBO_COMPARATOR|Placebo|Saline spray in the similar device as Puressentiel Purifying spray
62261558|NCT01309542|EXPERIMENTAL|DVS|
62261559|NCT03784079|EXPERIMENTAL|Part 1: GSK3640254 10 mg|Participants will receive GSK3640254 10 milligram (mg), capsules, orally for 10 days.
62261560|NCT03784079|EXPERIMENTAL|Part 1: GSK3640254 200 mg|Participants will receive GSK3640254 200 mg, capsules, orally for 10 days.
62618023|NCT06178562|EXPERIMENTAL|IOE group|IOE groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
62261561|NCT03784079|PLACEBO_COMPARATOR|Part 1: Placebo|Participants will receive placebo capsules, orally for 10 days.
62261562|NCT03784079|EXPERIMENTAL|Part 2: GSK3640254 40 mg|Participants will receive GSK3640254 40 mg, capsules, orally for 7 days.
62623728|NCT05903755|EXPERIMENTAL|speed dependent treadmill training on moderate speed|speed dependent treadmill training on moderate speed along with strengthening, stretching and range of motion exercises.
62261563|NCT03784079|EXPERIMENTAL|Part 2: GSK3640254 80 mg|Participants will receive GSK3640254 80 mg, capsules, orally for 7 days.
62261564|NCT03784079|EXPERIMENTAL|Part 2: GSK3640254 140 mg|Participants will receive GSK3640254 140 mg, capsules, orally for 7 days.
62843712|NCT03755804|EXPERIMENTAL|Low-Risk|Participants receive 2 cycles of BEABOVP: bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine and prednisone. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements may be done.
62261565|NCT03784079|PLACEBO_COMPARATOR|Part 2: Placebo|Participants will receive placebo capsules, orally for 7 days.
62446673|NCT03819686|EXPERIMENTAL|Living ACTS website|In addition to the provision of standard transplant education procedures, a patient will watch the Living ACTS video (embedded in the Living ACTS website) along with any family members or friends who are accompanying a patient. Plus minimum of 5 minutes navigating the website (aside from watching the 20-minute video).
62623729|NCT05903755|ACTIVE_COMPARATOR|speed dependent treadmill training on slow speed|Speed dependent treadmill training on slow speed along with physiotherapy.
62843713|NCT03755804|EXPERIMENTAL|Intermediate-Risk|Participants receive 3 cycles of BEABOVP: bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine and prednisone. For patients with an AR after 2 cycles of therapy, steroids will be omitted from their subsequent cycles of therapy. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements may be done.
62843714|NCT03755804|EXPERIMENTAL|High-Risk|Participants receive 2 cycles of AEPA: Adcedris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) and 4 cycles of CAPDac: cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dacarbazine® (DTIC). For patients with an AR after 2 cycles of therapy, steroids will be omitted from their subsequent cycles of therapy. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements may be done.
62843715|NCT04424264|EXPERIMENTAL|Tenofovir Alafenamide|TAF 25 mg once-daily administered with RIF/INH 600\*/300mg
62261566|NCT05921994||secukinumab|Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.
62623730|NCT03382405|EXPERIMENTAL|mRNA-1647|
62623731|NCT03382405|EXPERIMENTAL|mRNA-1443|
62623732|NCT03382405|PLACEBO_COMPARATOR|Placebo|
62623733|NCT01719159|EXPERIMENTAL|Rituximab|Rituximab, 25 mg, is administrated intrathecal three times one week apart
62261567|NCT03676621|EXPERIMENTAL|study group|patients will receive buccal misoprostol
62261568|NCT03676621|ACTIVE_COMPARATOR|control group|patients will receive intravenous oxytocin
62058124|NCT04798443|ACTIVE_COMPARATOR|Subureteral endoscopic injection|The endoscopic procedure was done under general anesthesia, and all patients received antibiotic prophylaxis. We used the subureteral injection technique (STING), as described by O'Donnell and Puri (1984). The volume of Dx/HA was injected until ureteral orifice collapse in all patients. The needle was held for 30 s.
62058125|NCT04798443|ACTIVE_COMPARATOR|open ureteral reimplantation (lich-gregoir)|extravesical ureteral reimplantation (lich-gregoir) by open surgery
62261569|NCT05149898|EXPERIMENTAL|Open-label|Open-label
62261570|NCT06241092||TCGA|
62261571|NCT06241092||SYSMH|
62058126|NCT04604301|EXPERIMENTAL|Crown, 1.0mm thickness, Calcium Aluminate Ionomer Cement|occlusal thickness of 1.0 mm delivered with a conventional Calcium Aluminate Ionomer cement
62058127|NCT04604301|EXPERIMENTAL|Crown, 1.5mm thickness, Calcium Aluminate Ionomer Cement|occlusal thickness of 1.5 mm delivered with a conventional Calcium Aluminate Ionomer cement
62843716|NCT02749084|EXPERIMENTAL|T reg DLI|"This is a INTERVENTIONAL TRANSPLANTATION STUDY WITHOUT DRUGS.~The INTERVENTION is represented by the INFUSION of DONOR T REGULATORY CELL-ENRICHED LYMPHOCYTES to PATIENTS suffering from REFRACTORY CHRONIC GVHD after ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.~The study is single center single arm open label and includes a DOSE ESCALATION phase followed by an EXTENDED PHASE with the MAXIMUM TOLERATED DOSE (MTD).~During the dose escalation phase each patient will receive three doses of purified donor T reg cells each administered intravenously 1 month apart. Dose levels of purified Tregs will be 5x10e5/kg, 1x10e6/kg and 2x10e6/kg, resulting in three doses of 1.7x10e5/kg, 3.3x10e5/kg and 6.6x10e5/kg, respectively.~In the dose escalation study at least 9 patients will be required depending on the occurrence of adverse events during the study).~Patients in the MTD study should be about 10, according to Fleming."
62843717|NCT02874976|EXPERIMENTAL|Experimental: Group A|"Active and Active Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group A, received program 1 before aerobic training, and the same program 1 after training"
62843718|NCT02874976|EXPERIMENTAL|Experimental: Group B|"Active and Placebo Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 1 before aerobic training, and program 2 after training."
62261572|NCT04191330|NO_INTERVENTION|Control|Subjects in the Control Arm will receive standard of care as normally provided in the clinical center where the study is being conducted.
62058128|NCT04604301|EXPERIMENTAL|Crown, 1.0mm thickness, dual cure resin cement|occlusal thickness of 1.0 mm delivered with Prime and Bond elect Universal Bond in total etch mode with a dual cure resin cement
62058129|NCT04604301|EXPERIMENTAL|Crown, 1.5mm thickness, dual cure resin cement|occlusal thickness of 1.5 mm delivered with Prime and Bond elect Universal Bond in total etch mode with a dual cure resin cement
62058130|NCT01092481|ACTIVE_COMPARATOR|FOLFOX_12 or CAPOX_8|6 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX
62843719|NCT02874976|EXPERIMENTAL|Experimental: Group C|"Placebo and Active Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group C, received program 2 before aerobic training, and program 1 after training."
62843720|NCT02874976|EXPERIMENTAL|Experimental: Group D|"Placebo and Placebo Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 2 before strength training, and the same program 2 after training."
62843721|NCT05532306|EXPERIMENTAL|Test product (T)|Subjects were served a standardized high caloric meal 30 minutes before the administration of a single film-coated tablet containing 400 mg Ribavirin (1\*400mg) with approximately 240 ml of water
62843722|NCT05532306|ACTIVE_COMPARATOR|Reference product (R)|Subjects were served a standardized high caloric meal 30 minutes before the administration of two film-coated tablets each containing 200 mg Ribavirin (2\*200mg) with approximately 240 ml of water
62058131|NCT01092481|EXPERIMENTAL|FOLFOX_6 or CAPOX_4|3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX
62261573|NCT04191330|EXPERIMENTAL|Intervention|Subjects randomized to the Intervention Arm will be remotely monitored for 90 days using the BiovitalsHF platform to manage initiation and titration of GDMT with and outside of normal or traditional clinical encounters.
62843723|NCT04444440|ACTIVE_COMPARATOR|Treatment Arm|Ciprofloxacin 500 mg PO every 12 hrs for 3 days following the procedure
62843724|NCT04444440|PLACEBO_COMPARATOR|Placebo Arm|Placebo pill PO every 12 hrs for 3 days following the procedure
62261574|NCT00255970|EXPERIMENTAL|Regenafil graft|Regenafil
62058132|NCT04305002|EXPERIMENTAL|Exenatide|
62058133|NCT04305002|PLACEBO_COMPARATOR|Placebo|
62261575|NCT00255970|ACTIVE_COMPARATOR|DFDBA|Demineralized Freeze Dried Bone Allograft
62261576|NCT03235648|EXPERIMENTAL|cardiophrenic nodes excision in ovarian cancer|We are going to evaluate the comorbidites and impact of cardiophrenic lymph nodes excision in cases of advanced ovarian cancer with positive cardiophrenic lymph nodes
62058134|NCT04680325|PLACEBO_COMPARATOR|Placebo juice|
62058135|NCT04680325|ACTIVE_COMPARATOR|Cranberry juice|
62058136|NCT03952221|ACTIVE_COMPARATOR|Usual physiotherapy and continuous ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and continuous ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 1,5 W/cm2 SATA intensity) every working day for two weeks (10 occasions).
62058137|NCT03952221|ACTIVE_COMPARATOR|Usual physiotherapy and pulsed ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and pulsed ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 1,5 W/cm2 SATA intensity, 50% duty cycle) every working day for two weeks (10 occasions).
62261577|NCT02970825|EXPERIMENTAL|Exercise|The experimental, intensive exercise regime will include 50-min sessions four times a week during five weeks (for a total of about 17 hours) combining structured aerobic exercise (at least 20 minutes jogging and moderate to high intensity active games) and anaerobic lactic resistance exercise (power training with gymn weights).
62843725|NCT04213248|EXPERIMENTAL|UMSC-exo treatment|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo intervention for 2 weeks.
62843726|NCT01417377||Cohort|Mircera
62058138|NCT03952221|ACTIVE_COMPARATOR|Usual physiotherapy and sonotens therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and sonotens therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 0,5 W/cm2 SATA intensity, transcutanous electrical nerve stimulation) every working day for two weeks (10 occasions).
62843727|NCT01235741|EXPERIMENTAL|Group A|Pramlintide+Metreleptin
62843728|NCT01235741|PLACEBO_COMPARATOR|Group B|Placebo
62058139|NCT03952221|PLACEBO_COMPARATOR|Usual physiotherapy and sham ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and sham ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 0 MHz frequency, 0 W/cm2 SATA intensity) every working day for two weeks (10 occasions).
62058140|NCT05946980|EXPERIMENTAL|Intervention arm for primary health care facilities in Mali and Burkina Faso|This arm receives the multi-component intervention for primary health care facilities described under interventions
62058141|NCT05946980|NO_INTERVENTION|Control arm for primary health care facilities in Mali and Burkina Faso|No intervention until the end of the cRCT. After completion of data collection, this arm will receive the same intervention as the intervention arm has received previously.
62261578|NCT02970825|ACTIVE_COMPARATOR|Relaxation|The control activity will include 50-min sessions four times a week during five weeks (for a total of about 17 hours) combining mindfulness, stretching and low intensity active games (breath control, proprioception, walking, social relaxation, flexibility training).
62261579|NCT00837941|EXPERIMENTAL|1|sequence 1 - Pregabalin, Duloxetine hydrochloride, Diphenhydramine hydrochloride
62261580|NCT00837941|EXPERIMENTAL|2|sequence 2 - Duloxetine hydrochloride, Pregabalin, Diphenhydramine hydrochloride
62261581|NCT00837941|EXPERIMENTAL|3|sequence 3 - Diphenhydramine hydrochloride, Duloxetine hydrochloride, Pregabalin
62261582|NCT00837941|EXPERIMENTAL|4|sequence 4 - Pregabalin, Diphenhydramine hydrochloride, Duloxetine hydrochloride
62843729|NCT03573271|EXPERIMENTAL|Micro-coring of facial/neck skin with MCD|Micro coring of facial and neck skin will be conducted in up to 2 treatments and followed 90 days post treatment with MCD
62843730|NCT03777891|EXPERIMENTAL|group A|received Silicone gel phonophoresis: Silicone gel (strataderm) was applied to the scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes. The Ultrasound Device is Sonopulse 590: Nonius, sonopuls 590, S.NO.03-202 type 14663.900 was a therapeutic ultrasound device manufactured by Enraf Holland.
62058142|NCT04834700|NO_INTERVENTION|hands-on group|The doctors who participated in the study will be educated ocular ultrasound scanning method by hands-on about 20 minutes, and perform ocular ultrasound scans on two standard patients.
62261583|NCT00837941|EXPERIMENTAL|5|sequence 5 - Duloxetine hydrochloride, Diphenhydramine hydrochloride, Pregabalin
62261584|NCT00837941|EXPERIMENTAL|6|sequence 6 - Diphenhydramine hydrochloride, Pregabalin, Duloxetine hydrochloride
62843731|NCT03777891|EXPERIMENTAL|group B|received Contractubex phonophoresis: Contractubex (Merz Pharma, Frankfurt, Germany was applied to the scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes.
62261585|NCT01821651|EXPERIMENTAL|HeartNavigator|Group with HeartNavigator-Software
62843732|NCT03777891|EXPERIMENTAL|group C|received Corticosteroid phonophoresis: A thin film of coupling medium (gel) was put on the hypertrophic scar and sufficient quantity of Triamcinolone was put by a syringe over the whole scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes
62843733|NCT06022692|EXPERIMENTAL|hyperthermia combined with immune checkpoint inhibitor group|The patients were treated with whole-body hyperthermia on days 1 and 8 of each HIT cycle along with administration of tislelizumab 200 mg on day 2 (24 h after the hyperthermia at day 1).
62843734|NCT00818701|PLACEBO_COMPARATOR|1: low dose BNP alone|low dose BNP with placebo
62058143|NCT04834700|OTHER|online group|The doctors who participated in the study will be educated ocular ultrasound scanning method by online lecture about 20 minutes, and perform ocular ultrasound scans on two standard patients.
62261586|NCT01821651|ACTIVE_COMPARATOR|Control|Control-group without HeartNavigator-Software
62261587|NCT01821651|EXPERIMENTAL|EchoNav|Group with EchoNav-Software
62261588|NCT01821651|ACTIVE_COMPARATOR|Conrol|Control-group without EchoNav-Software
62261589|NCT05914142|EXPERIMENTAL|Proton radiation therapy group|Experimental: single-arm objective performance criteria, OPC
62843735|NCT00818701|ACTIVE_COMPARATOR|2: low dose BNP + PDEVI|low dose BNpo + PDEVI
62843736|NCT02169427|EXPERIMENTAL|Opicapone (OPC)|100 mg OPC
62058144|NCT06245122|EXPERIMENTAL|Dose escalation|"Single ascending dose (SAD): Participants will receive CS23546 once on the first day (D1).~Multiple ascending dose (MAD): Participants will receive CS23546 once daily from the 7th day (C1D1)."
62261590|NCT04384562|EXPERIMENTAL|Dopamine reuptake inhibitor|Participants in the dopamine reuptake inhibitor group will be asked to take one pill containing 20 mg methylphenidate 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
62618024|NCT06178562|ACTIVE_COMPARATOR|PNG group|PNG groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
62618025|NCT00884845|EXPERIMENTAL|Arm 1|Administration of i.v. infusions of PM02734 (on Days 1, 8 and 15) every three weeks and a daily oral dose of erlotinib
62618026|NCT03884309|EXPERIMENTAL|Experimental Hydrolyzed Protein Infant Formula|hydrolyzed protein infant formula powder in cans
62618027|NCT03002532|ACTIVE_COMPARATOR|Whole-brain radiotherapy (WBRT) group|Conventional whole-brain radiotherapy for brain metastases from breast cancer with dose of 37.5 Gy in 15 fractions.
62618028|NCT03002532|EXPERIMENTAL|Hippocampal-sparing WBRT (HS-WBRT) group|Hippocampal-sparing whole brain radiotherapy is performed using modern intensity-modulated radiotherapy (IMRT) technique to avoid conformally the hippocampal neural stem-cell structure during WBRT. Prescription dose is 37.5 Gy in 15 fractions.
62618029|NCT03420287|EXPERIMENTAL|MPM prepared from allogenic bone graft|All patients in this group will receive MPM prepared from allogenic bone graft
62843737|NCT00500435||Laparoscopy Procedure|Laparoscopy procedure in abdomen to remove para aortic lymph nodes of patients diagnosed with cervical cancer.
62843738|NCT04828343|EXPERIMENTAL|Cohort 1 <50 kg|Study participants randomized to Cohort 1 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.
62843739|NCT04828343|EXPERIMENTAL|Cohort 2 <50 kg|Study participants randomized to Cohort 2 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.
62843740|NCT04828343|EXPERIMENTAL|Cohort 3 >=50 kg|Study participants randomized to Cohort 3 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.
62843741|NCT04828343|EXPERIMENTAL|Cohort 4 >=50 kg|Study participants randomized to Cohort 4 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.
62843742|NCT02681354|EXPERIMENTAL|A additional BioRescue training|Using a playful rehabilitation, BioRescue
62843743|NCT02681354|NO_INTERVENTION|Regular training|
62843744|NCT02464280||Patients scheduled for lung imaging|"Patients with lung changes and scheduled for lung imaging will undergo:~* the scheduled conventional X-ray examination~* the scheduled CT scan~* the tomosynthesis scan"
62058145|NCT06245122|EXPERIMENTAL|Dose expansion|Dose expansion is planned to begin when the recommended Phase 2 dose (RP2D) will be determined.
62058146|NCT01262326|EXPERIMENTAL|Low Carbohydrate Diet|Subjects are placed on a low carbohydrate diet where only 5% of energy intake is derived from dietary carbohydrate.
62618030|NCT03420287|ACTIVE_COMPARATOR|Autogenous bone graft group|All patients in this group will receive autogenous bone graft only
62618031|NCT06384235|EXPERIMENTAL|PHASE 1|Enrollment of 10 consecutive evaluable CRC subjects with failure of existing standard therapy or lack of effective treatment Treated with LTC004 in Phase I
62618032|NCT06384235|EXPERIMENTAL|PHASE 2|If ≥2 subjects experience objective remission in PHASE 1, proceed to Phase II to enroll an additional 20 evaluable subjects to further evaluation of the safety and efficacy of LTC004
62618033|NCT04270695|EXPERIMENTAL|blood flow restriction|An inflatable cuff (14 cm in width \* 84 cm in length) is warped around abdominal muscles below ribs which may cause to at least 60% restriction of blood flow detected by Power Doppler ultrasonography. All participants are instructed to perform abdominal draw-in maneuver both condition of BFR and BFR-free twice a week, for six weeks.
62618034|NCT04270695|SHAM_COMPARATOR|sham blood flow restriction|an inflatable cuff (14 cm in width \* 84 cm in length) is warped around abdominal muscles below ribs without inflation. All participants are instructed to perform abdominal draw-in maneuver.
62618035|NCT03339557|ACTIVE_COMPARATOR|PFC Total Knee Replacement|PFC, Conventional design Perioperative treatment will be carried out according to routine protocol of the hospital.
62618036|NCT03339557|ACTIVE_COMPARATOR|NexGen Total Knee Replacement|NexGen, Conventional design Perioperative treatment will be carried out according to routine protocol of the hospital.
62618037|NCT03339557|ACTIVE_COMPARATOR|Persona Total Knee Replacement|Persona, Novel design Perioperative treatment will be carried out according to routine protocol of the hospital.
62618038|NCT00490672|OTHER|Control Arm|Conventional Patient Management on Hypertension, Diabetes Mellitus and Hyperlipidaemia by Malaysian GP
62618039|NCT00490672|ACTIVE_COMPARATOR|CORFIS Arm|Community based Multiple Risk Factor Intervention Strategies
62618040|NCT03206840|EXPERIMENTAL|Group 1|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
62618041|NCT03206840|EXPERIMENTAL|Group 2|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
62618042|NCT03958474|EXPERIMENTAL|Active treatment followed by placebo treatment|Participants complete a gambling task during oxycodone administration and then complete the same gambling task during placebo administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.
62618043|NCT03958474|EXPERIMENTAL|Placebo treatment followed by active treatment|Participants complete a gambling task during placebo administration and then complete the same gambling task during oxycodone administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.
62618044|NCT06227715|OTHER|selective etch|In SLE mode, only enamel margin was etched for 15 seconds, washed for 15 seconds and dried, and the adhesive was applied to the dentin and enamel by rubbing for 20 seconds.
62618045|NCT06227715|OTHER|Total etch|Each mode of the universal adhesive used in the mouth of each of the patients evaluated was applied to at least two teeth. In accordance with the recommendations of the manufacturer; in TE mode, enamel and dentin were etched with 37% orthophosphoric acid for 15 seconds, washed for 15 seconds, and after air-drying, the adhesive was applied to enamel and dentin by rubbing for 20 seconds.
62058147|NCT01262326|ACTIVE_COMPARATOR|Low Calorie Diet|Subjects have there caloric intake reduced to 1200 or 1500 kcal/day (women and men respectively).
62058148|NCT05373797||experimental and control group|experimental: 26 control group:26
62058149|NCT02575898|OTHER|One|"Creative writing and questionnaires interventions:~First Session, Second Session, Third through Sixth Sessions"
62058150|NCT00336141|EXPERIMENTAL|Vorinostat|
62618046|NCT06227715|OTHER|self etch|In SE mode, the adhesive was applied to the dentin and enamel by rubbing for 20 seconds.
62058151|NCT03207139|EXPERIMENTAL|Ga-68 PSMA ligand|Diagnostic performance of \[Ga68\] PSMA-11
62618047|NCT00441363|ACTIVE_COMPARATOR|Bromocriptine Mesylate|Bromocriptine mesylate 0.8 mg
62058152|NCT05581680|EXPERIMENTAL|patients with facial palsy|
62058153|NCT05581680|ACTIVE_COMPARATOR|healthy volunteers|
62058154|NCT01568346|ACTIVE_COMPARATOR|MRI|MRI
62058155|NCT01568346|NO_INTERVENTION|No MRI|No MRI
62618048|NCT00441363|PLACEBO_COMPARATOR|Placebo|Bromocriptine mesylate 0.8 mg matching placebo
62618049|NCT03594955|EXPERIMENTAL|SAR440234|SAR440234 was administered as intravenous infusion once weekly for 6 weeks per Cycle. Per plan, participants were to receive first 2 to 3 doses as Lead-in doses followed by a fixed dose until the end of treatment or unless the dose needs to be decreased for safety reasons. Due to early study termination, all participants received only 1 treatment cycle at a dose of 1 nanogram per kilogram (ng/kg) once weekly.
62618050|NCT05961189|EXPERIMENTAL|Antibiotics and exercise|Participants will be tested before and after 5 days of azithromycin, per manufacturer's instructions, to determine if that impacts exercise performance and the gut microbiome and gut/serum metabolome.
62618051|NCT05610475|ACTIVE_COMPARATOR|Lung injury group|
62843745|NCT02464280||Patients scheduled for wrist imaging|"Patients with wrist fracture or with osteoprotetic material in the wrist and scheduled for wrist imaging will undergo:~* the scheduled conventional X-ray examination~* the scheduled CT scan~* the tomosynthesis scan"
62843746|NCT02175030|ACTIVE_COMPARATOR|Copper T380 IUD|Randomized to copper T380 IUD for EC (emergency contraception)
62843747|NCT02175030|ACTIVE_COMPARATOR|LNG20 IUD|Randomized to LNG20 IUD for EC (emergency contraception)
62261591|NCT04384562|EXPERIMENTAL|Noradrenaline reuptake inhibitor|Participants in the noradrenaline reuptake inhibitor group will be asked to take one pill containing 4 mg reboxetine 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
62618052|NCT05610475|SHAM_COMPARATOR|Non-lung injury group|
62843748|NCT03975478|ACTIVE_COMPARATOR|Gastric bypass|Bariatric surgery by gastric bypass (GB)
62843749|NCT03975478|EXPERIMENTAL|Sleeve gastrectomy|Bariatric surgery by sleeve gastrectomy (SG)
62261592|NCT04384562|EXPERIMENTAL|Cholinergic receptor agonist|Participants in the cholinergic receptor agonist group will be asked to take a placebo pill 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a gum with 2 mg of nicotine.
62261593|NCT04384562|PLACEBO_COMPARATOR|Placebo|Participants in the placebo group will be asked to take a placebo pill 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
62843750|NCT00220636|EXPERIMENTAL|Aripiprazole|Aripiprazole 5 to 30 mg/day
62618053|NCT05618158|EXPERIMENTAL|4 Corners Rural Cancer Prevention|Four separate Facebook groups, which provide information via posts within the private groups about cancer risk factors (e.g. reducing alcohol consumption, tobacco use cessation, increasing physical activity), behavioral skills to reduce them, benefits of, social support for, and ways to reduce social/financial costs of cancer prevention, and advice from health care providers to decrease barriers. Posts will seek to improve self- and response-efficacy and perceived risk, and link cancer prevention to personal goals.
62618054|NCT02362425|ACTIVE_COMPARATOR|RYR1-RM Patients Administered N-acetylcysteine|N-acetylcysteine
62618055|NCT02362425|PLACEBO_COMPARATOR|RYR1-RM Patients Administered Placebo|Placebo
62618056|NCT02362425|NO_INTERVENTION|Healthy Volunteers|Healthy volunteers who had physical exam, study biomarker, Near Infrared Spectroscopy (NIRS) testing and muscle ultrasound only, in one visit.
62618057|NCT02547896|EXPERIMENTAL|Pain control using codeine + diclofenac|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, receiving for pain relief after the procedure 50mg of codeine + 50mg of diclofenac
62618058|NCT02547896|EXPERIMENTAL|Pain control using diclofenac|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, receiving for pain relief after the procedure 50mg of diclofenac
62618059|NCT01885663|EXPERIMENTAL|Umbilical cord blood therapy|Umbilical cord blood therapy
62618060|NCT02148016|EXPERIMENTAL|LSCs and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
62261594|NCT02094690|ACTIVE_COMPARATOR|Device Hyperboloid|"5 min of bilateral mastication alternated with the device hyperboloid The exercises should begin one day before the onset of Radiotherapy (RT) and kept until the end of RT.~Repeated 4x a day (after breakfast, lunch, dinner and before going to bed)."
62618061|NCT02148016|ACTIVE_COMPARATOR|Amniotic membrane only (Traditional Technique)|Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.
62618062|NCT02148016|EXPERIMENTAL|PRK, LSCs, and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
62618063|NCT02148016|ACTIVE_COMPARATOR|PRK only (Traditional Technique)|PRK alone will be performed.
62618064|NCT00073645|EXPERIMENTAL|1|Family/Parents CBT (FCBT) for 14 to 16 weekly sessions
62618065|NCT00073645|ACTIVE_COMPARATOR|2|Peer/Group CBT (GCBT) for 14 to 16 weekly sessions
62618066|NCT01773356|PLACEBO_COMPARATOR|Placebo 0 mg/d|0 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers
62618067|NCT01773356|ACTIVE_COMPARATOR|Dihydrocapsiate 9 mg/d|9 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers
62618068|NCT03085771|ACTIVE_COMPARATOR|Desferal treatment|Patients will be randomized (by block randomization) to Desferal (DFO) treatment.
62261595|NCT02094690|ACTIVE_COMPARATOR|Device Therabite|"* 10 repetitions holding the device Therabite for 30 seconds~* 5 min of bilateral mastication alternated with the device hyperboloid The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT.~Repeated 4x a day (after breakfast, lunch, dinner and before going to bed)."
62618069|NCT03085771|PLACEBO_COMPARATOR|Isotonic saline treatment|Patients will be randomized (by block randomization) to isotonic saline treatment.
62618070|NCT00681265|EXPERIMENTAL|glycerin|One eye will randomly receive a single instillation of one drop of a new formulation of an artificial tear containing glycerin 1% as an active with polylysine-graft-polyethylene glycol as an excipient.
62618071|NCT00681265|ACTIVE_COMPARATOR|polyethylene glycol 400/propylene glycol|The other eye will receive a single instillation of one drop of an artificial tear with propylene glycol (0.3%) and polyethylene glycol (0.4%) as active ingredients with hydroxypropyl-guar as a gelling agent.
62618072|NCT03972241|EXPERIMENTAL|Intervention|different interventions including foot insole or kinetic training
62618073|NCT03972241|NO_INTERVENTION|control|No intervention
62618074|NCT02960477|EXPERIMENTAL|Pain Neuroscience education|A PNE session covers the neurobiology, neurophysiology and processing of pain. Topics addressed during the educational sessions will include the characteristics of acute versus chronic pain; how pain becomes chronic (plasticity of the nervous system, modulation, modification, central sensitization, etc.); potential sustaining factors of central sensitization like emotions, stress, pain cognitions, and pain behaviour; the decision to have shoulder surgery; surgical experiences and environmental issues' effects on nerve sensitivity; recovery after shoulder surgery; scientific evidence for the PNE content; and the opportunity to reflect and write questions to ask the surgeon prior to surgery.
62618075|NCT02960477|ACTIVE_COMPARATOR|Biomedical Education|A biomedical session covers the normal course of shoulder pain; anatomy, physiology and biomechanics of the shoulder; the expected course of postoperative shoulder pain; and the importance of self-care. Also, professional and leisure time activities will be discussed. Ergonomic advices will be given: e.g. how is the best way to catch a container, how I should move my shoulder in this sport/activity, what is a good work posture? The content of the biomedical education will be biomedically-/biomechanically-focussed.
62618076|NCT02844036|EXPERIMENTAL|Patients with a pulmonary hypertension|Pulmonary hypertension group 4 of Dana point, chronic thromboses lesions, thromboembolic.
62618077|NCT05029609|OTHER|Group A|Group A will receive nasal Foralumab Dose 1 daily for 14 days (n=9) or placebo (n=3)
62618078|NCT05029609|OTHER|Group B|Group B will receive nasal Foralumab Dose 2 tiw for 14 days (n=9) or placebo (n=3)
62843751|NCT03791957||Group A - Healthy Periodontium|Absence of clinical signs of inflammation like bleeding on probing, erythema, edema, attachment loss, bone loss, patient symptoms, (bone levels at 1-3mm apical to CEJ) n=20
62618079|NCT05029609|OTHER|Group C|Group C will receive nasal Foralumab Dose 3 daily for 14 days (n=9) or placebo (n=3)
62843752|NCT03791957||Group B - Gingivitis|Presence of cardinal signs of inflammation along with, bleeding and discomfort on gentle probing, loss of knife-edged margin and blunting of papilla, n=20
62261596|NCT02094690|NO_INTERVENTION|Control|The control group (GEC) will not receive any of the protocols tested in the study, but together with the other groups, will receive the regular treatment offered by the institution, which is made up of guidance and advice given by the hospital´s nursing team about the radiotherapy treatment. Currently, patients do not receive any information as far as trismus is concerned.
62261597|NCT03638154|PLACEBO_COMPARATOR|GroupI|safety with received beta-tricalcium phosphate (β TCP) bone substitute only. (Bioresorb, Sybron, implant solutions GmbH Bremen, Germany)
62261598|NCT03638154|ACTIVE_COMPARATOR|GroupII|"safety with surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane and received a mixture of gingival fibroblast(GF) and gingival mesenchymal stem cells(GMSCs) carried on a vehicle of β TCP covered by a resorbable collagen membrane.~(Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Jersey, USA)."
62261599|NCT01336582|EXPERIMENTAL|docetaxel|
62843753|NCT03791957||Group C - Periodontitis|Presence of cardinal signs of inflammation along with, bleeding and discomfort on gentle probing, loss of knife-edged margin and blunting of papilla,periodontal pocketing, clinical attachment loss, radiographically assessed bone loss n=20
62843754|NCT02707575||Ranibizumab|Intravitreal Ranibizumab
62261600|NCT01336582|ACTIVE_COMPARATOR|Taxotere|Docetaxel-PM 75 mg/m2 (70 mg/m2 for age of ≥ 65) Taxotere 75mg/m2 (70 mg/m2 for age of ≥ 65)
62446674|NCT03819686|OTHER|Standard transplant education procedures|Usual Care, which involves the provision of standard transplant education procedures at each transplant center, which entail reviewing a packet of information with the pre-transplant coordinator. The packet serves to inform transplant candidates and their families about the option living donor kidney transplantation (LDKT). In addition, participants will be provided an iPad/tablet to watch two 10-minute National Kidney Foundation videos about kidney disease and transplantation in their private room during their regularly scheduled KT evaluation. This video discusses information about transplant, but does not specifically address LDKT and is not culturally-sensitive to African American population.
62058156|NCT04508452|EXPERIMENTAL|mXELOXIRI+Bev reintroduction|"Patients will receive mXELOXIRI+BEV as first-line therapy (to be repeated every 2 weeks for a maximum of 12 cycles), followed to initiate a MDT to determine whether to perform a surgery or receive maintenance therapy. Maintenance treatment: CAP+BEV. The following CAP+BEV therapy will be repeated in 2-week cycles.~At the time of disease progression, patients will be re-introduced XELOXIRI plus bev at the same doses and schedule previously tolerated, for a maximum of 12 cycles. If no progression occurs during XELOXIRI plus bev, patients will receive maintenance CAP+BEV at the same dose used in the last cycle of the induction treatment."
62058157|NCT01175889|EXPERIMENTAL|one side ACE blade|
62058158|NCT01175889|ACTIVE_COMPARATOR|one side scalpel|
62261601|NCT04319575|EXPERIMENTAL|Chitosan calcium hyroxide paste|after the access preparation and cleaning and shaping, chitosan calcium hydroxide paste will be placed in the canal and kept for 4 weeks.
62261602|NCT04319575|ACTIVE_COMPARATOR|triple antibiotic paste|after the access preparation and cleaning and shaping, ciprofloxacin metronidazole minocycline paste will be :placed in the canal and kept for 4 weeks.
62261603|NCT01109914|EXPERIMENTAL|Renal transplant recipients (MMF)|"Renal transplant recipients using prednisolone and mycophenolate mofetil (MMF) but no other immunosuppressive drug.~Intervention: vaccination with Dukoral"
62261604|NCT01109914|EXPERIMENTAL|Renal transplant recipients (CNI)|"Renal transplant recipients using prednisolone and a calcineurin inhibitor (cyclosporine or tacrolimus) but no other immunosuppressive drug.~Intervention: vaccination with Dukoral"
62261605|NCT01109914|EXPERIMENTAL|Healthy volunteers|"Healthy volunteers (partners, brothers or sisters of the renal transplant recipients).~Intervention: vaccination with Dukoral"
62261606|NCT02529787|EXPERIMENTAL|A Test|Test drug (Doxirazole) 1 capsule contains 60 mg of Dexlansoprazole
62261607|NCT02529787|ACTIVE_COMPARATOR|B Reference|Reference drug (Dexilant) 1 capsule contains 60 mg of Dexlansoprazole
62261608|NCT01550146|EXPERIMENTAL|Dexamethasone, 0.1 mg/kg|The patients in the Dexamethasone group get iv 0.1 mg/kg dexamethasone preoperative.
62261609|NCT01550146|PLACEBO_COMPARATOR|Placebo|In the Placebo group the patients get 0.1 ml/kg normal saline.
62446675|NCT04426409|NO_INTERVENTION|control group|
62446676|NCT04426409|EXPERIMENTAL|ointment group|Ointment group should apply a nasal ointment to both noses using a cotton swab the night before surgery and the morning of surgery.
62446677|NCT03265496|EXPERIMENTAL|study procedure|Clinical exam. Liquid biopsy. Diagnostic exam (biopsy and imagery). 1st line treatment. tumor evaluation. Biopsy
62843755|NCT03768648|EXPERIMENTAL|patient|RRMS diagnosis according to McDonald criteria (Polman et al.,2005);
62843756|NCT03768648|ACTIVE_COMPARATOR|Control|40 Healthy controls (HC)
62843757|NCT01920672|EXPERIMENTAL|Timed Planned Activity (TPA)|The TPA provides meaningful activities delivered at specific times in the daily diurnal cycle; it is theory-based, its components have been tested in pilot work; and it is portable and replicable (e..g, protocols are standardized). It involves involved 8 contacts (6 home visits and 2 phone calls) over 4 days. At baseline the CG completes the Pleasant Event Activity Survey. From the survey a careplan of meaningful activities are developed for the CG to administer. The suggested activities match the capabilities of an individual with moderate stage AD ie., based on repetitive motion (e.g., folding towels) and integrating multi-sensory stimulation (e.g., soft music, objects pleasant to touch). CG are instructed to introduce these activities during the late morning and early evening.
62058159|NCT02768662|EXPERIMENTAL|OTO-104|12 mg dexamethasone
62058160|NCT05434845|NO_INTERVENTION|UA and PC ratio on original sample|Original urine sample
62058161|NCT05434845|ACTIVE_COMPARATOR|UA and PC ratio with 1 mL of whole blood added|1 mL of whole blood added to 20 mLs of urine
62058162|NCT05434845|ACTIVE_COMPARATOR|UA and PC ratio with 2 mL of whole blood added|2 mL of whole blood added to 20 mLs of urine
62058163|NCT05434845|ACTIVE_COMPARATOR|UA and PC ratio with 5 mL of whole blood added|5 mL of whole blood added to 20 mLs of urine
62261610|NCT03743311||Surgical treatment of Hemmorhoid|Patients after surgical treatment (Instrumental Invasive Surgical Procedures or Thrombectomy, Hemorrhoidectomy etc.)
62261611|NCT03743311||Conservative treatment of Hemmorhoid|Patients taken conservative treatment (Detralex)
62618080|NCT05029609|OTHER|Group D|Group D will receive nasal Foralumab Dose 4 daily for 14 days (n=9) or placebo (n=3)
62261612|NCT03743311||Combined treatment of Hemmorhoid|Combined treatment patients (surgery and conservative treatment)
62261613|NCT00621699|EXPERIMENTAL|C|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg tacrolimus)
62618081|NCT05885776|EXPERIMENTAL|Targeted combined endocrine therapy|Subjects who met the inclusion criteria underwent surgery after 6 cycles of treatment with pyrrolitinib+trastuzumab+AI, and their pathological remission was evaluated after surgery
62058164|NCT05492825|EXPERIMENTAL|Yoga|Participants in the yoga group will receive a manualized intervention of 12 weekly, group-based, 60-minute yoga classes, and guided home practice.
62261614|NCT00621699|ACTIVE_COMPARATOR|A|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe)
62261615|NCT00621699|ACTIVE_COMPARATOR|B|administration of 1 capsule Prograf(R) (5 mg tacrolimus)
62261616|NCT02331082|ACTIVE_COMPARATOR|Control|Existing healthcare system
62618082|NCT05941624|EXPERIMENTAL|Ha-330 Hemoperfusion Filter Hemodialysis|Participants underwent therapy using Ha-330 Hemoperfusion Filter Hemodialysis for 4 hours, 3 times a week, with two days apart between dialysis.
62618083|NCT05941624|ACTIVE_COMPARATOR|Conventional hemodialysis|Participants underwent therapy using Conventional Hemodialysis for 4 hours, 3 times a week, with two days apart between dialysis.
62618084|NCT06553963|NO_INTERVENTION|Control group|All participants followed their coaches' regular training plans for daily training (actual pre-competition training environment), without altering their personal routines or lifestyle habits.
62618085|NCT06553963|EXPERIMENTAL|Experimental group|"Participants in the experimental group received a four-week tailored nutrition program, developed by sports nutritionists based on athletes' biochemical profiles, body weight, training intensity, and dietary habits. The program included:~Daily Dietary Logs: Monitoring food intake for immediate nutritional adjustments.~Weekly Nutritional Consultations: Strategy refinement discussions with experts. Customized Nutritional Supplements: Zinc Magnesium Multi-Vitamin Sports Nutrition Powder was used to improve blood urea, cortisol, and hemoglobin levels, containing ingredients like rice bran lipid alcohol, magnesium, zinc, and B vitamins.~Performance-Specific Supplements: Endurance Sugar Pump to lower creatine kinase levels during training and Testosterone Synthesis Pump to enhance testosterone, both by Weite Beijing Co., Ltd.~Sleep Aid: Melatonin Tablets to ensure restful sleep, containing vitamin B6 and melatonin, produced by Dongli Beijing Co., Ltd."
62843758|NCT01920672|ACTIVE_COMPARATOR|Home Safety and Education Program|The active comparator intervention will be delivered by interventionists who will provide social attention, empathy and engagement similar to that afforded to the experimental group. The length of time spent will be comparable to the length of time spent in the treatment arm. The attention-control group will involve 6 in-home visits in the afternoon and 2 brief telephone education sessions in the morning. Control group subjects will be provided a copy of Mace and Rabins, The 36-Hour Day, a well-known practical guidebook for families caring for AD patients. Each contact will provide helpful education based on a specific book chapter including information about home safety, health promotion, and advanced care planning
62843759|NCT00958906|EXPERIMENTAL|Intravitreal infliximab|
62261617|NCT02331082|EXPERIMENTAL|Health System Improvement|Structured Quality Improvement Chronic Care Model Integrated Electronic Medical Record Solar-powered electrical supply Performance-based financing
62261618|NCT00972673|EXPERIMENTAL|arm 1|In Arm 1 subjects will receive 200, 400 or 800 microgram of powdered inhalation of GW685698X once daily for 7 days from Day 5 to Day 11.
62261619|NCT00972673|PLACEBO_COMPARATOR|arm 2|In Arm 2 subjects will receive Placebo powdered inhalation once daily for 7 days from Day 5 to Day 11.
62843760|NCT03323281||Diabetic Type 1 or Type 2 with foot wound|Type 1 or type 2 diabetic patients with hospitalization for foot wounds having an interview with a neuropsychologist or a physician trained in neuropsychological assessments
62058165|NCT05492825|EXPERIMENTAL|Physical Therapy|Participants in the PT group will receive a manualized intervention of 12 weekly, individual, 60-minute PT sessions, with home practice, based on the Saper protocol.
62261620|NCT04501185||UTS Stem|The subjects who received UTS Stem in total hip arthroplasty.
62261621|NCT04501185||UTF-reduced Stem|The subjects who received UTF-reduced Stem in total hip arthroplasty.
62261622|NCT00761514|EXPERIMENTAL|1|All subjects will receive Adalimumab
62261623|NCT00397813|EXPERIMENTAL|Arm A - Dose Level 1|"Arm A - patients with MPD or MDS-RA/RARS Dose Level 1 - 300 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
62261624|NCT00397813|EXPERIMENTAL|Arm A - Dose Level 2|"Arm A - patients with MPD or MDS-RA/RARS Dose Level 2 - 400 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
62058166|NCT05492825|OTHER|Treatment As Usual|Participants in the Treatment As Usual group will receive routine clinical care. This includes: 1) pain assessment using a 10-point scale, at OTP admission and annual physical exams. This is documented on a templated form in the OTP electronic health record, as well as whether pain is acute vs chronic pain, and a treatment plan (e.g., on-site care, outside primary care clinician, pain management referral). 2) clinical treatment of pain by participants' on-site or outside clinicians.
62058167|NCT01555190|ACTIVE_COMPARATOR|myo-inositol 1500 gr|6 months treatment with myo-inositol 1500 gr
62058168|NCT01555190|ACTIVE_COMPARATOR|myo-inositol 2000gr + folic acid 200 mcg|
62261625|NCT00397813|EXPERIMENTAL|Arm A - Dose Level 3|"Arm A - patients with MPD or MDS-RA/RARS Dose Level 3 - 450 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
62261626|NCT00397813|EXPERIMENTAL|Arm B - Dose Level 1|"Arm B - patients with MDS-RAEB or CMML Dose Level 1 - 300 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
62843761|NCT03323281||Diabetic Type 1 or Type 2 without a foot wound or antecedent|Type 1 or Type 2 diabetic patients with no foot wounds or history of foot wounds having an interview with a neuropsychologist or a physician trained in neuropsychological assessments
62618086|NCT01758718|ACTIVE_COMPARATOR|Entropion with Down's syndrome|Eyelash resection surgery was performed for entropion with Down's syndrome
62618087|NCT03484403|ACTIVE_COMPARATOR|Control Group|Study participants will not receive a back brace but will receive back school education and the same physical therapy exercise instruction as the treatment group.
62843762|NCT02663713|EXPERIMENTAL|Ticagrelor|Ticagrelor 60 mg twice daily
62843763|NCT02663713|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 75 mg once daily
62843764|NCT05470023|ACTIVE_COMPARATOR|Brushing with LivFresh Dental Gel|Subjects will brush twice daily for the study duration with LivFresh Dental Gel with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
62058169|NCT00745706|OTHER|A|Implantable Loop Recorder (ILR) implant
62058170|NCT02039986||all subjects|all subjects enrolled in same cohort
62058171|NCT04382703|EXPERIMENTAL|Intervention|Given the associated questionnaire which has the embedded self-affirmation exercise.
62058172|NCT04382703|ACTIVE_COMPARATOR|Control|Given the associated questionnaire without the embedded self-affirmation exercise.
62058173|NCT04768842|EXPERIMENTAL|LY3209590 Lyophilized Formulation|LY3209590 as lyophilized formulation administered subcutaneously (SC) in one of the two study periods.
62058174|NCT04768842|EXPERIMENTAL|LY3209590 Solution Formulation|LY3209590 as solution formulation administered SC in one of the two study periods.
62058175|NCT04665024|ACTIVE_COMPARATOR|Group 1|"G1 included patients undergoing planned surgery who performed chest physiotherapy at home in two weeks period before the surgical operation pre and postoperative chest physiotherapy was performed in G1.~The chest physiotherapy included the following steps~1. Snipping through the nose several times, then breathe out through the mouth~2. Taking a deep breath through the nose, hold the air in, push it down in the stomach, than back to the chest, and in the end breath out through the mouth~3. Put both hands on the shoulders. Lift the elbows to the sides and take a deep breath through the nose, then lower them, breathe out through the mouth. This procedure was done for the other side as well.~4. Put both hands on your hips. Lift your right arm to the side, turn backwards with it and take a deep breath through the nose, then turn back, put your hand back to the hip and breathe out through the mouth.This procedure was done for the other side as well"
62058176|NCT04665024|ACTIVE_COMPARATOR|Group 2|"G2 included patients who patients undergoing planned surgery but did not perform preoperative chest physiotherapy at home.only postoperative chest physiotherapy made in G2.~The patient was seen on the first day after surgery in the intensive care unit and was asked if he had performed breathing exercises at home before surgery and then re-evaluation of both groups with respect to respiratory functions and oxygen saturation values from the first day until the seventh after surgery. Also, a daily chest physical therapy program was introduced in accordance with the hospital's policy until the patient's discharge.~Postoperative chest physiotherapy made in both two groups was similar to the preoperative chest physiotherapy mentioned above but this was achieved by physiotherapists and made once a day for 10-25 minutes depending on the lectures of postoperative days.~The exercises were repeated 10 times and performed 3-4 times per day."
62058177|NCT06038435|EXPERIMENTAL|Cognitive Orientation Approach + Ayres Sensory Integration Therapy|Cognitive Orientation Approach on Daily Occupational Performance (CO-OP) and Ayres Sensory Integration (ASI) Therapy will be applied together
62058178|NCT06038435|ACTIVE_COMPARATOR|Ayres Sensory Integration Therapy Only|Only Ayres Sensory Integration (ASI) Therapy will be applied
62058179|NCT01657266|EXPERIMENTAL|PRO-155|"Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye~Maintenance therapy: 1 drop 3 times a day for 30 days"
62261627|NCT00397813|EXPERIMENTAL|Arm B - Dose Level 2|"Arm B - patients with MDS-RAEB or CMML Dose Level 2 - 400 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
62618088|NCT03484403|EXPERIMENTAL|Treatment Group|Study participants in this group will receive a lumbar support back brace and will receive back school education and the same physical therapy exercise instruction as the control group.
62261628|NCT00397813|EXPERIMENTAL|Arm B - Dose Level 3|"Arm B - patients with MDS-RAEB or CMML Dose Level 3 - 450 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
62261629|NCT03546530|EXPERIMENTAL|Interferon|Interferon 1.5ug/kg/week, 48weeks
62261630|NCT03546530|EXPERIMENTAL|Interferon+resveratrol|Interferon 1.5ug/kg/week,resveratrol 1000mg/day, 48weeks
62618089|NCT06465771|EXPERIMENTAL|Youth-led NCD risk reduction initiative|Students of grades 5 and 6 will receive NCD risk reduction intervention from youth (students of grades 9 and 10). The shared risk factors will include unhealthy diet, physical activity, and tobacco use. The NCDs will cover diabetes, cardiovascular disease, hypertension, and cancers.
62618090|NCT04749537||Ankylosing Spondylitis|100 patients who were diagnosed with AS between the ages of 18-65
62618091|NCT04749537||Healthy Volunteers|100 healthy volunteers compatible with age.
62843765|NCT05470023|ACTIVE_COMPARATOR|Brushing with LivFree Dental Gel|Subjects will brush twice daily for the study duration with LivFree Dental Gel with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
62618092|NCT01870167|PLACEBO_COMPARATOR|placebo|Placebo
62618093|NCT01870167|EXPERIMENTAL|co-amoxiclav|co-amoxiclav is a combination antibiotic consisting of amoxicillin trihydrate, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor
62261631|NCT05054114|EXPERIMENTAL|Drug: Interferon Gamma|IFN-G administered for 2 10-day courses with a 1-week pause between the courses.
62618094|NCT01496417|EXPERIMENTAL|Belatacept therapy|20 Patients receiving belatacept based immunosuppressive protocol for 12 months post-transplantation.
62618095|NCT01209273||APD group|which can be 3 to 5 exchanges daily, and up to 20 liters daily( including up to two daytime exchanges)
62058180|NCT01657266|ACTIVE_COMPARATOR|Nevanac|"Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension~Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye~Maintenance therapy: 1 drop 3 times a day for 30 days"
62058181|NCT00482820|EXPERIMENTAL|1|attention training away from threat
62618096|NCT01209273||CAPD group|which can be 1 to 4 exchanges daily and up to 16 liters daily(including up to two daytime exchanges)
62618097|NCT03471806|EXPERIMENTAL|Bulimia Nervosa patients|Bulimia Nervosa patient group: Assessment of dopamine release to food reward at baseline (before treatment) and to food reward after treatment.
62618098|NCT03471806|EXPERIMENTAL|Healthy controls|Healthy control group: Assessment of dopamine release to food reward at baseline, for comparison with Bulimia Nervosa patients.
62058182|NCT00482820|PLACEBO_COMPARATOR|2|placebo attention training
62058183|NCT02345525|ACTIVE_COMPARATOR|mCIMT|2 hours intensive upper limb practice with shaping techniques supervised by an experienced physiotherapist + 2 hours ADLs at home (supervised by a caregiver) Patients are supposed to wear a mitt on the unaffected hand for 4 hours daily.
62618099|NCT06452290|EXPERIMENTAL|Brain 18F-FDG PET-CT|The strategy under investigation is a medical device: a PET/CT scanner using the radiopharmaceutical 18F-FDG.
62843766|NCT05470023|ACTIVE_COMPARATOR|Brushing with AIM Dental Gel|Subjects will brush twice daily for the study duration with AIM Dental Gels with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
62261632|NCT05054114|NO_INTERVENTION|Control: No intervention|Any preventive method including a variety of pharmacologic therapies against COVID-19, alongside the use of antiviral and immunomodulating agents, with the exception of drugs prescribed off-label or for research purposes, and IFN-G as well.
62446678|NCT00962000|OTHER|600 mL/min|Dialysis Flow Rate Start 600mL/min Subject starting dialysis flow rate set at 600mL/min. ABAB sequence where A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min and B represents three consecutive treatments with a dialysate flow rate of 800 mL/min.
62446679|NCT00962000|OTHER|800 mL/min|Dialysis Flow Rate Start 800mL/min Subject starting dialysis flow rate set at 800mL/min. BABA sequence where B represents three consecutive treatments with a dialysate flow rate of 800 mL/min and A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min.
62261633|NCT05774379|EXPERIMENTAL|virtual reality and fatigue education|watching the application by wearing virtual glasses for 3 days and Providing training on fatigue to all children (1 session, average 45 minutes) (using role-play, exercise, games, coloring books and activity materials)
62261634|NCT05774379|EXPERIMENTAL|fatigue education|Providing training on fatigue to all children (1 session, average 45 minutes) (using role-play, exercise, games, coloring books and activity materials)
62446680|NCT06143735|EXPERIMENTAL|experimental group（primary prevention）|Efgbemalenograstim alfa, 20 mg, subcutaneous injection, administered 48±4 hours after the completion of each chemotherapy cycle.
62446681|NCT06143735|ACTIVE_COMPARATOR|control group（secondary prevention）|Efgbemalenograstim alfa, 20 mg, subcutaneous injection, administered 48±4 hours after the completion of the next chemotherapy cycle if ≥ Grade 3 ANC reduction occurs in the preceding chemotherapy cycle.
62446682|NCT00788619|ACTIVE_COMPARATOR|Day 3 transfer|Subjects in this arm will have two embryos transferred three days after fertilization. Embryos will be selected based on the concentration of nitric oxide metabolites in the culture medium.
62058184|NCT02345525|EXPERIMENTAL|hCIMT|"2 hours intensive upper limb practice with shaping techniques + 2 hours ADLs supervised by a caregiver.~Patients are supposed to wear a mitt on the unaffected hand for 4 hours daily."
62058185|NCT05540314||Subjects that have undergone robotic bariatric surgery|Subjects that have undergone robotic bariatric surgery between January 2018 and December 2019
62058186|NCT05555992|EXPERIMENTAL|Treatment|
62058187|NCT00771225|OTHER|prolapse surgery with fascial repair|
62058188|NCT00771225|OTHER|prolapse surgery with mesh repair|
62843767|NCT05470023|ACTIVE_COMPARATOR|Brushing with Crest Prohealth Dental Gel|Subjects will brush twice daily for the study duration with Crest Prohealth Dental Gel with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
62058189|NCT00079911|EXPERIMENTAL|Suppressive + Episodic Therapy|Valaciclovir (VAL) 500mg twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 days or 10 days, when required for treatment of a genital herpes recurrence.
62058190|NCT00079911|PLACEBO_COMPARATOR|Episodic Therapy|Matching placebo twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 or 10 days, when required for treatment of a genital herpes recurrence.
62058191|NCT01319799||Surgical aortic valve replacement|Single observational study. Count of microembolic signals during open heart surgery and measurement of properative vs postoperative levels of markers in cerebrospinal fluid of neuronal damge.
62058192|NCT02079064|EXPERIMENTAL|Desflurane|Desflurane at 1 MAC and
62058193|NCT02079064|EXPERIMENTAL|propofol|propofol TCI (target controlled infusion) infusion of to keep a target plasma concentration between 2 and 5 µg ml-1
62058194|NCT03077984|EXPERIMENTAL|the cohort of Chinese medicine treatment|The cohort of Chinese medicine treatment uses its comprehensive program of TCM on the basis of treatment with western medicine, including Chinese Herbs, acupuncture and acupoint application therapies.
62058195|NCT03077984|NO_INTERVENTION|the cohort of western medicine treatment|The cohort of Western medicine treatment refers to the treatment of cerebrovascular disease prevention and cure guideline of China-related programmes, including anti-platelet aggregation, blood pressure,blood glucose,Blood Lipids lowering therapies.
62058196|NCT03016910||Type 2 diabetes|This group will consist of 300 patients with type 2 diabetes mellitus without symptoms or known coronary heart disease. The group will be followed for one year and CCTA will be performed at baseline and after one year.
62058197|NCT03016910||Type 1 diabetes|This group will consist of 50-100 patients with type 1 diabetes mellitus without symptoms or known coronary heart disease. The group will be followed for one year. CCTA will be performed at baseline and after one year.
62058198|NCT06100315||Bupivacaine|30 patients will receive SMB using bupivacaine 0.125% of 0.2 ml/kg on each side (with maximum volume of 4 ml).
62058199|NCT06100315||Bupivacaine and Nalbuphine|30 patients will receive SMB using bupivacaine 0.125 of 0.2 ml/kg + 0.1 mg/kg nalbuphine on each side (with maximum volume of 4 ml).
62058200|NCT01725269|EXPERIMENTAL|80mg AIR001, nebulized four times daily|AIR001, 80 mg into nebulizer
62058201|NCT01725269|EXPERIMENTAL|46 mg AIR001, nebulized four times daily|AIR001, 46 mg into nebulizer
62058202|NCT01725269|EXPERIMENTAL|80mg AIR001, nebulized once daily|AIR001, 80 mg into nebulizer
62058203|NCT03340584|EXPERIMENTAL|The intervention group|The intervention group will be received the Nine Castle Net Format taping and the traditional rehabilitation throughout all hospitalization period.We will exchange the new taping for Every two days.
62058204|NCT03340584|OTHER|The control group|The control group will be received the traditional rehabilitation during the hospitalization period.The traditional rehabilitation included occupational therapy and physical therapy.
62058205|NCT05161325||Cohort 1|Participants with untreated advanced or recurrent non-small cell lung cancer (NSCLC) receiving first-line nivolumab plus ipilimumab with or without chemotherapy
62058206|NCT00212381|EXPERIMENTAL|oral DIM (Active agent)|2mg/kg/day po of DIM
62058207|NCT00212381|ACTIVE_COMPARATOR|Red rice bran (Placebo)|this agent is not generally thought to be active but may be
62058208|NCT02014818|EXPERIMENTAL|3 month OCT follow-up, CoCr-EES|Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 3 months after the index procedure.
62058209|NCT02014818|EXPERIMENTAL|1 month OCT follow-up, CoCr-EES|Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 1 months after the index procedure.
62058210|NCT01500330|EXPERIMENTAL|cupping massage|12 weeks home use of cupping massage (delivered by the partner or friend) twice a week for 20 minutes
62058211|NCT01500330|ACTIVE_COMPARATOR|control group|progressive muscle relaxation twice a week for 20 minutes
62618100|NCT01210222|EXPERIMENTAL|Treatment (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62618101|NCT04605926|EXPERIMENTAL|EQ001|EQ001 administered in a blinded fashion by intravenous infusion on Day 1 and Day 8 for a total of 2 doses.
62618102|NCT04605926|PLACEBO_COMPARATOR|EQ001 Placebo|Placebo administered in a blinded fashion by intravenous infusion on Day 1 and Day 8 for a total of 2 doses.
62618103|NCT05777083|EXPERIMENTAL|Inferior STEMI group|Patients who undergo emergent coronary angiography for ST-elevation myocardial infarction.
62618104|NCT05777083|ACTIVE_COMPARATOR|Control group|Patients who undergo elective coronary angiography to differentiate angina symptom. ST-elevation myocardial infarction will be excluded.
62618105|NCT06364202|NO_INTERVENTION|Control|Did not receive peanut butter, maintained normal diet and activity. Asked to stop eating 2 hours prior to bed for 7 weeks.
62618106|NCT06364202|EXPERIMENTAL|Peanut Butter|Received and asked to consume 2 tbsp of peanut butter 2 hours before bedtime 5 nights per week for 7 weeks and to stop eating after that before bed. Other than that, asked to maintain normal diet and activity.
62618107|NCT05538936|EXPERIMENTAL|Baby SPA|Baby SPA application time: It is done regularly from the first month, at least once a month. The ideal time for application is the first six months. The water in the tub is prepared to be 33°C. The baby, whose clothes are taken off, wearing a waterproof diaper suitable for the tub and a neck ring, is taken into the tub. The application usually takes 10-15 minutes, depending on the baby's reactions to the water for the first time. After the parent and baby get used to the process, the time can be increased to 30 minutes. In this process, the baby's hands, abdomen, and legs are made to recognize the water and the baby's movements are monitored. Care is taken that the baby does not drink the water. After the application period is over, the baby is removed from the tub and dried with a towel. Finally, the baby is massaged for 10-15 minutes and dressed.
62618108|NCT05538936|EXPERIMENTAL|Massage|Massage can be applied to all age periods. Before starting the massage application in babies, some preparations are made. Ambient temperature (24-26 OC) is adjusted, it is regulated so that there is no airflow, dim light, and low noise levels are ensured. 1-2 towels, a soft cushion or massage table, baby oil lotion, clean diapers, and clean clothes are prepared for the massage. There is no standard time interval for the application of massage. It can be done at least one hour after the baby's feeding, at any time of the day when he is not stressed and sleeps. Massage application time is 15-30 minutes depending on the baby's reactions may vary between.
62618109|NCT05538936|NO_INTERVENTION|Control|It is the control group in which no intervention was applied.
62058212|NCT03666884|ACTIVE_COMPARATOR|dry eye patients 1|dry eye patients treated for 1 month and patient symptoms after 1 month
62058213|NCT03666884|ACTIVE_COMPARATOR|dry eye patients 2|dry eye patients treated for 1 month and patient symptoms after 1 month
62058214|NCT03425448|ACTIVE_COMPARATOR|Heparin group|
62058215|NCT03425448|EXPERIMENTAL|Neotrolin Group|
62058216|NCT02247336|EXPERIMENTAL|Immediate|Patients will complete a family health history platform at enrollment
62618110|NCT01530711|EXPERIMENTAL|terlipressin|
62058217|NCT02247336|ACTIVE_COMPARATOR|Delayed|Patients will complete a family health history platform 12 months following enrollment
62058218|NCT06624540|EXPERIMENTAL|Experimental: Study 2: All Nurses in GICU; Study 3: All patients admitted in the general GICU|Nurses: All nurses who work at GICU of DMCH Patients: all patients who will admit at the assigned GICU during the study period of DMCH
62058219|NCT03994458|EXPERIMENTAL|Experimental|Participants get the full program for 6 weeks.
62058220|NCT03994458|PLACEBO_COMPARATOR|Placebo|Participants get the placebo program for 6 weeks.
62058221|NCT05788835|EXPERIMENTAL|DEB-TACE-HAIC|Drug-eluting bead transarterial chemoembolization Sequential with FOLFOX-based chemotherapy hepatic artery infusion
62058222|NCT05788835|ACTIVE_COMPARATOR|DEB-TACE|Drug-eluting bead transarterial chemoembolization
62058223|NCT03503825|EXPERIMENTAL|Healthy Volunteers|Healthy volunteers will be administered \[Tc-99m\]-RPI-T-087 Injection, single IV dose of 555 MBq and will be monitored for safety, knee image evaluation, and radioactivity biodistribution and dosimetry.
62058224|NCT03503825|EXPERIMENTAL|Osteo Arthritis of the knee|Subjects with knee osteoarthritis will be administered \[Tc-99m\]-RPI-T-087 Injection, single IV dose of 555 MBq and will be monitored for safety and knee image evaluation.
62446683|NCT00788619|ACTIVE_COMPARATOR|Day 5 transfer|Subjects will have two embryos transferred on day 5 after fertilization with selection of embryos based on morphologic criteria.
62618111|NCT01415726|EXPERIMENTAL|Cord blood stem cell|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations. Stem Cell Educator will be used for isolation and purification of cord blood stem cells for the treatment.
62618112|NCT01415726|EXPERIMENTAL|Stem Cell Educator|used for the isolation and purification of cord blood stem cells.
62261635|NCT04075838|OTHER|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the PTR (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001). The group gathered for a one-hour session once a week for 18 weeks.
62261636|NCT03014778|EXPERIMENTAL|The Chlorhexidine gluconate arm|35 women undergoing surgery will be vaginally pre-op washed by 0.05% chlorhexidine gluconate, 50 cc for 1 minute. 3 samples will be taken for culture: before, 10 minutes and 30 minutes after the wash.
62261637|NCT03014778|ACTIVE_COMPARATOR|The Povidone iodine arm|35 women undergoing surgery will be vaginally pre-op washed by 10% Povidone iodine, 50 cc for 1 minute. 3 samples will be taken for culture: before, 10 minutes and 30 minutes after the wash.
62618113|NCT04046263|EXPERIMENTAL|Intervention|Open-label, one arm study. Patients receive sucroferric oxyhydroxide three times daily and dose is titrated to keep serum phosphate at goal.
62618114|NCT00937092|ACTIVE_COMPARATOR|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
62058225|NCT06525402|PLACEBO_COMPARATOR|Sodium Bicarbonate Group (Usual care)|General routine oral care. In the clinic where the research was conducted, a guideline is routinely applied for the care of oral mucositis in line with the stages of oral mucositis. Sodium bicarbonate is used in line with this guideline. The first group will receive routine oral care in the clinic with sodium bicarbonate. It will be applied as a 5 ml mouthwash four times a day, after meals and before going to bed at night.
62058226|NCT06525402|EXPERIMENTAL|Saline Group|It will be applied as a 5 ml mouthwash four times a day, after meals and before going to bed at night.
62058227|NCT06525402|EXPERIMENTAL|Black Mulberry Syrup Group|It will be applied as a 5 ml mouthwash four times a day, after meals and before going to bed at night.
62058228|NCT01887470|EXPERIMENTAL|Full dose preparation; AM colonoscopy|Four hourly doses of lactulose for oral solution are taken in the evening. The colonoscopy is initiated prior to noon on the following day.
62058229|NCT01887470|EXPERIMENTAL|Full dose preparation; PM colonoscopy|Four hourly doses of lactulose for oral solution are taken in the evening. The colonoscopy is initiated after noon on the following day.
62058230|NCT01887470|EXPERIMENTAL|Split dose preparation; AM colonoscopy|Three hourly doses of lactulose for oral solution are taken in the evening prior to the day of the colonoscopy procedure; one dose is taken on the morning of the procedure. The colonoscopy is initiated prior to noon.
62618115|NCT00937092|ACTIVE_COMPARATOR|low-dose dopamine + low-dose furosemide|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
62058231|NCT01887470|EXPERIMENTAL|Split dose preparation; PM colonoscopy|Three hourly doses of lactulose for oral solution are taken in the evening prior to the day of the colonoscopy procedure; one dose is taken on the morning of the procedure. The colonoscopy is initiated after noon.
62618116|NCT04191343|EXPERIMENTAL|The control group|
62618117|NCT01075464|EXPERIMENTAL|A|
62618118|NCT01075464|EXPERIMENTAL|B|
62058232|NCT01390714|EXPERIMENTAL|1|
62058233|NCT01390714|EXPERIMENTAL|2|
62058234|NCT04189263|EXPERIMENTAL|Dietary intervention|Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day) + standard of care aromatase inhibitors
62261638|NCT02075099|EXPERIMENTAL|Isotonic drink|"Predonation hydratation with 500 ml of isotonic drink, to drinking in immediate predonation.~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
62261639|NCT02075099|EXPERIMENTAL|mineral water|"Predonation hydratation with 500 ml of mineral water to drinking in immediate predonation whole blood.~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
62261640|NCT02075099|ACTIVE_COMPARATOR|Advices|"Advices of drinking water or fruit juice glass(es) in immediate predonation whole blood.~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
62618119|NCT01527708||Keratoconus Group (KCG)|Keratoconus group (KCG) included patients with progressive keratoconus.
62058235|NCT04189263|ACTIVE_COMPARATOR|No dietary intervention|Standard of care aromatase inhibitors
62058236|NCT01146301|ACTIVE_COMPARATOR|300 mg Loading dose clopidogrel|
62261641|NCT01121315||1|Diabetes type II patients, according to medical records, prescriptions or lab results, followed for \>6 months after diagnosis.
62843768|NCT05470023|ACTIVE_COMPARATOR|Brushing with Parodontax Dental Gel|Subjects will brush twice daily for the study duration with Parodontax Dental Gel with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
62261642|NCT02192203|EXPERIMENTAL|Diclofenac + Menthol Gel|1% diclofenac, 3% menthol
62058237|NCT01146301|EXPERIMENTAL|600 mg Loading dose of clopidogrel|
62261643|NCT02192203|ACTIVE_COMPARATOR|Diclofenac Only Gel|1% diclofenac, 0.09% menthol
62446684|NCT02249884|EXPERIMENTAL|Urea Dose A|Topical application of the urea cream in concentration A. The product should be applied on the skin three times daily over 3 weeks.
62058238|NCT02291523|SHAM_COMPARATOR|Patient Stool Transplant|Arm 1 will get FMT (Fecal Microbial Transplant) placebo and high dose 5-ASA (Pentasa). The FMT is done through colonoscopy.
62058239|NCT02291523|ACTIVE_COMPARATOR|Donor Stool Transplant|Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool and high dose 5-ASA (Pentasa). The FMT is done through colonoscopy.
62261644|NCT02192203|ACTIVE_COMPARATOR|Menthol Only Gel|3% menthol
62446685|NCT02249884|EXPERIMENTAL|Urea Dose B|Topical application of the urea cream in concentration B. The product should be applied on the skin three times daily over 3 weeks.
62618120|NCT01527708||Collagen-Cross-linking group (CXLG)|Collagen-Cross-linking group (CXLG) included keratoconus patients that had been treated with uneventful corneal collagen cross-linking (CXL) at least on year prior to their enrolment in the study.
62618121|NCT01527708||Normal Group (NG)|Normal group (NG) was formed by refractive surgery candidates who visited EIT's refractive surgery service for their preoperative examination. Eligibility for participation in the NG was confirmed by consecutive topographies, while all NG participants had to present uneventful ophthalmologic history, no indications of corneal pathology in slit-lamp biomicroscopy and Placido disk-based videokeratography.
62058240|NCT02552290|ACTIVE_COMPARATOR|Cervicothoracic manipulation|Description of a Right C7/T1 manipulation. The subject will lie prone. The therapist will stand on the L side of the subject facing in a cephalic direction (towards the patient's head). The therapist's right hand makes contact with the thumb on the right side of the spinous process of the first thoracic vertebra. The therapist left hand supports the head making contact on the temporal bone. The hand/neck is gently laterally flexed to the right, until slight tension is palpated in the tissues. A high-velocity low-amplitude thrust will be applied towards the subjects left side. If cavitation does not occur (an audible pop) the subject will be repositioned and the manipulation attempted a second time. A maximum of 2 attempts will be performed for each side of the neck.
62261645|NCT02192203|PLACEBO_COMPARATOR|Placebo Only Gel|0.09% menthol
62261646|NCT04035070|EXPERIMENTAL|Root canal irrigation with co-amoxiclav-clindamycin solution|Alternate irrigation with 1 mL antibiotic-containing solution followed by 4 mL 2.5% sodium hypochlorite solution between each size instrument and the consequent one. The antibiotic-containing solution will be prepared by mixing equal quantities of 1.2 gm Co-amoxiclav solution and 600 mg Clindamycin solution at a ratio of 1:1 by volume.
62261647|NCT04035070|EXPERIMENTAL|Root canal irrigation with MTAD|Irrigation with 5 mL MTAD irrigating solution for 5 minutes between each size instrument and the consequent one.
62446686|NCT02249884|EXPERIMENTAL|Urea Dose C|Topical application of the urea cream in concentration C. The product should be applied on the skin three times daily over 3 weeks.
62446687|NCT02249884|EXPERIMENTAL|Chamomile Dose A|Topical application of chamomile recutita gel in concentration A. The product should be applied on the skin three times daily over 3 weeks.
62446688|NCT02249884|EXPERIMENTAL|Chamomile Dose B|Topical application of chamomile recutita gel in concentration B. The product should be applied on the skin three times daily over 3 weeks.
62618122|NCT00534417|EXPERIMENTAL|Capecitabine and fulvestrant|"Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po AM and 500 mg po PM in patients of body weight \< 80 kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 kg.~Fulvestrant will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days."
62058241|NCT02552290|ACTIVE_COMPARATOR|Upper trapezius stretch|"The subjects will be in a supine position. A researcher will passively place the subject's head into flexion, side-bending away and rotation towards the side to be stretched until the muscle barrier is met. The researcher will depress the subject's shoulder with 100 Newtons of force measured with a Micro FET pressure dynamometer (Hoggan Health Industries, Salt Lake City, UT).) Once this pressure amount is achieved the stretch will be held for 30 seconds. This will be repeated two times on each side.~The subject will be asked to provide continuous feedback about the stretch felt and the degree of discomfort (if any) felt during the 30 second stretches."
62058242|NCT02552290|OTHER|Control group|Subjects assigned to the control group will receive no intervention. They will stay behind the curtained research area for approximately 3 minutes in a seated position.
62261648|NCT04035070|ACTIVE_COMPARATOR|Root canal irrigation with 2.5% sodium hypochlorite|Irrigation with 5 mL 2.5% sodium hypochlorite irrigating solution between each size instrument and the consequent one.
62618123|NCT05277389|SHAM_COMPARATOR|Control|Individuals in this group will practice object manipulation tasks without the START (Startle Adjuvant Rehabilitation Therapy) intervention
62618124|NCT05277389|EXPERIMENTAL|START|Individuals in this group with practice object manipulation tasks with the START condition (startling acoustic stimuli applied during 33% of trials)
62446689|NCT02249884|EXPERIMENTAL|Chamomile Dose C|Topical application of chamomile recutita gel in concentration C. The product should be applied on the skin three times daily over 3 weeks.
62446690|NCT06100237|EXPERIMENTAL|Cohort A: Tec-Dara|Participants will receive the recommended dosage combination treatment Tec-Dara.
62446691|NCT06100237|EXPERIMENTAL|Cohort B: Tal-Dara|Dosing and treatment schedule for participants in this group will be determined after Cohort A is completed.
62446692|NCT06203899|EXPERIMENTAL|Intervention group|"Participating adolescents receive the preventive group training Op Volle Kracht. It is an altered program for adolescents in the special educational sector, based on the eponymous program for general education. It consists of eight meetings of 45 minutes each and one short follow-up meeting each week to offer repetition. It will take place at school during school hours. A trained psychologist of the STORM approach will facilitate the training with a trained school psychologist.~Participants will undergo a clinical interview at baseline and at 6-month follow-up to detect clinical depression, and will fill in questionnaires at baseline, post-intervention and follow-up at 6 and 12 months after intervention. Assessments will be conducted through a 30-minute self-report questionnaire.~All teachers will be educated on how to recognize and address depressive symptoms and suicidality in adolescents (gatekeeperstraining)."
62446693|NCT06203899|ACTIVE_COMPARATOR|Control group|"Participating adolescents will undergo a clinical interview at baseline to detect clinical depression, and will fill in questionnaires at baseline, 12 weeks/'post-intervention' and follow-up at 6 and 12 months 'post-intervention'. Besides, participants will undergo a second clinical interview on depressive symptoms at 6 months follow-up.~All teachers will be educated on how to recognize and address depressive symptoms and suicidality in adolescents (gatekeeperstraining).~Concerning Op Volle Kracht: Adolescents are offered the training after data collection of the study has ended and when the intervention has shown to be effective."
62446694|NCT01390883||Patients prescribed fondaparinux|Patients undergoing abdominal surgery in urology, obstetrics and gynecology departments prescribed fondaparinux during study period
62446695|NCT01058161|OTHER|Suspects or affected by rheumatoid polyarthritis|
62446696|NCT01058161|OTHER|stiffening spondylitis with axial and peripheral infringement|
62446697|NCT01058161|OTHER|polyarthralgies with or without arthritis|Affected by connectivity with anti-nuclear antibody positive and / or specific antibodies, suffering of polyarthralgias with or without arthritis
62446698|NCT01058161|OTHER|Healthy control|
62446699|NCT01058161|OTHER|not inflammatory control|Presenting a degenerative osteoarthritis of the wrist traumatic comment, noticed radiologically, which will serve as not inflammatory control.
62446700|NCT04964999|EXPERIMENTAL|Exercise|Participants will perform aerobic and strength exercises for 2 weeks.
62446701|NCT04964999|NO_INTERVENTION|No exercise|Participants will not perform any exercises.
62446702|NCT03314766||IC-8 IOL|Patients previously implanted with an IC-8 IOL contralaterally or bilaterally under the protocol ACU-P14-029
62843769|NCT05470023|ACTIVE_COMPARATOR|Brushing with Colgate Total Dental Gel|Subjects will brush twice daily for the study duration with Colgate Total Dental Gel with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
62446703|NCT00673491|EXPERIMENTAL|1|Patients treated according to clinical pathways
62446704|NCT00673491|NO_INTERVENTION|2|Patients treated according to usual care
62843770|NCT05470023|ACTIVE_COMPARATOR|Rinsing with Lumineux or Listerine Mouthwashes|Subjects will be asked to rinse twice daily with 1 capful for 1 minute with Lumineux or Listerine Mouthwashes directly after brushing their teeth, while continuing with their usual oral hygiene protocol. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
62261649|NCT04782271|EXPERIMENTAL|Single administration Low Dose once daily|1 treatment day
62843771|NCT04153552|OTHER|Study Participants who Suffer from Heartburn or indigestion|Subjects who meet the inclusion/exclusion criteria for the trial will be invited to participate in the trial. Subjects will be asked to sign a consent and complete screening survey. At the onset on an episode of the subject will start a symptom diary and completed and rate the symptoms using a 4-point Likert scale for each symptom. The participant will take 2 capsules per indigestion and heartburn episode. With a max of 6 capsules per day. • After taking the test product, the participant will complete a 4-point Likert scale assessment for each symptom at 15 minutes, 30 minutes, and 1 hour after taking the test product.
62843772|NCT03593616||Lens Phacoemulsification Group|insertion of intra-ocular lens
62843773|NCT06271954||control|(1) Understanding the content of the questionnaire. (2) Healthy adolescents aged 15 to less than 18 years and healthy adults aged 18 to 24 years.
62843774|NCT06271954||experimental|(1) Understanding the content of the questionnaire. (2) Adolescents aged 15 to less than 18 years and adults aged 18 to 24 years. (3) Diagnosed with major depressive disorder, anxiety disorder, attention deficit hyperactivity disorder (ADHD), or adjustment disorder according to DSM-5.
62261650|NCT04782271|EXPERIMENTAL|Single administration Middle Dose once daily|1 treatment day
62618125|NCT05940766|EXPERIMENTAL|"Intervention With CFM alerts arm"|"* Routine clinical care, which includes, among others, discrete fever measurements using ear thermometers in case of clinical deterioration or suspected fever, at the discretion of patients where applicable, parents and the treating team~* Plus CFM with a CORE® WD running, with alerts being sent automatically to participants if the CFM detects an estimated core body temperature fulfilling the fever criterion of the respective study site (≥38.5°C or 39.0°C)."
62843775|NCT04341519||Family members|"* Age\>18y~* Non-opposition to participate to the telephone interviews~* One family member per patient: the family member the most implicated in the patient's care~  3 groups of Family members will be enrolled in the study corresponding to patients with COVID-19, patients with seasonal flu and patients with community acquired pneumonia (See below). 1 family member per patient will be recruited."
62843776|NCT04341519||Patients|"Patients:~* Age\>18y~* Admission to the participating ICUs for any cause of acute respiratory failure during the COVID-19 pandemic~* Having received invasive or noninvasive mechanical ventilation~* Non-opposition to participate to the telephone interviews.~  3 groups of patients will be enrolled in the study: patients with COVID-19, patients with seasonal flu and patients with community acquired pneumonia.~* COVID group : Patients admitted to the ICU for acute respiratory failure and having a positive 2019-nCOV RT PCR in a respiratory / nasal swab sample (GROUP COVID-19)~* Group FLU : patients admitted to the ICU for acute respiratory failure and having a confirmed influenza pneumonia~* Group CAP (Community-acquired pneumonia) : patients admitted to the ICU for acute respiratory failure and having a clinically or microbiologically documental community acquired pneumonia with negative COVID-19 and Influenza PCRs."
62058243|NCT05586464|EXPERIMENTAL|Traditional Chinese Medicine group|"Patients in the case group will take Ban xia xie xin Decoction and bismuth quadruplicate for 14 days. H. pylori was rechecked one month after drug withdrawal, and H. pylori clearance rate and adverse reactions were observed in the reorganized patients.~Ban xia xie xin Decoction includes 10g of banxia, 10g of huangqin, 6g of coptis chinensis, 6g of dried ginger, 6g of ginseng, 6g of roasted licorice, 6g of Chinese jujube. One dose in the morning and one dose in the evening, and take after meals.~Bismuth quadruplicate includes esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid)."
62261651|NCT04782271|EXPERIMENTAL|Single administration High Dose once daily|1 treatment day
62261652|NCT04782271|EXPERIMENTAL|Single administration High Dose twice daily|1 treatment day
62261653|NCT04782271|EXPERIMENTAL|Multiple administrations Low Dose once daily|7 treatment days
62261654|NCT04782271|EXPERIMENTAL|Multiple administrations Middle Dose once daily|7 treatment days
62261655|NCT04782271|EXPERIMENTAL|Multiple administrations High Dose once daily|7 treatment days
62261656|NCT04782271|EXPERIMENTAL|Multiple administrations High Dose twice daily|7 treatment days
62261657|NCT01161264|EXPERIMENTAL|18-60 YOA|
62261658|NCT01161264|EXPERIMENTAL|≥ 60 YOA|
62261659|NCT05447468|EXPERIMENTAL|scapular muscles strengthning group|Patients in this group A will receive scapular muscles (lower trapezius, middle trapezius and serratus anterior) strengthening along with conventional physiotherapy (pulsed ultrasound, static stretching of ECRB muscle and eccentric exercises of wrist extensors) for 6 weeks.
62446705|NCT01033162|NO_INTERVENTION|Usual Care|A group using a Basic ICCS provided by KPNW
62618126|NCT05940766|NO_INTERVENTION|"Control Without CFM alerts arm"|"* Routine clinical care as in With CFM alerts~* Plus CFM with a CORE® WD running as in With CFM alerts, but with alerts being sent only if a clinically dangerous temperature of ≥40.0°C is detected, which will very rarely be the case before fever is detected by routine clinical care."
62618127|NCT02288481|EXPERIMENTAL|Cohort 1 10 mg TBA-354|
62058244|NCT05586464|ACTIVE_COMPARATOR|Bismuth quadruplicate group|"Patients in the control group will take bismuth quadruplicate for 14 days. H. pylori was rechecked one month after drug withdrawal, and H. pylori clearance rate and adverse reactions were observed in the reorganized patients.~Bismuth quadruplicate includes esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid)."
62058245|NCT03573908|EXPERIMENTAL|Linaclotide 290 µg|Participants receive linaclotide 290 µg orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are rerandomized to receive either linaclotide 290 µg or placebo for 4 weeks in the Randomized Withdrawal Period.
62058246|NCT03573908|PLACEBO_COMPARATOR|Placebo|Participants receive placebo to linaclotide orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are switched to receive linaclotide 290 µg for 4 weeks during the Randomized Withdrawal Period.
62261660|NCT05447468|ACTIVE_COMPARATOR|conventional physiotherapy group|Patients in this group B will receive conventional physiotherapy only (pulsed ultrasound, static stretching of ECRB muscle and eccentric exercises of wrist extensors) 3 sessions per week for 6 weeks.
62261661|NCT04248101|ACTIVE_COMPARATOR|Group 1|88 cases of umbilical granulomas who were treated with double ligation
62261662|NCT04248101|ACTIVE_COMPARATOR|Group 2|88 cases of umbilical granulomas who were treated with topical silver nitrate
62261663|NCT02921620|EXPERIMENTAL|PRX-102|PRX-102 infusions every 2 weeks
62446706|NCT01033162|EXPERIMENTAL|Intervention|A group using an enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)
62446707|NCT04383990|ACTIVE_COMPARATOR|Early Glargine|To take insulin Glargine at 6-7 pm
62843777|NCT04341519||healthcare providers|Two months after the official end of the COVID-19 peak in France, the local investigator will receive a set of 100 questionnaires. He/she will be responsible for proposing survey participation to volunteer healthcare providers. Those who are interested will be given the information letter and the questionnaires in an envelope. Once completed anonymously, they will seal the envelope and give it to the local investigator who will then send us all completed questionnaires by registered post.
62843778|NCT01851603|EXPERIMENTAL|AVL-3288|Oral administration of AVL-3288
62843779|NCT01851603|PLACEBO_COMPARATOR|Sugar pill|Placebo
62843780|NCT03245489|EXPERIMENTAL|Group 1|Group 1 will be treated with Regimen A, followed by Regimen B. Regimen A is pembrolizumab, ASA and clopidogrel daily for 6 weeks. Regimen B is pembrolizumab alone for 6 weeks.
62843781|NCT03245489|EXPERIMENTAL|Group 2|Group 2 will be treated with Regimen B, followed by Regimen A. Regimen B is pembrolizumab alone for 6 weeks. Regimen A is pembrolizumab, ASA and clopidogrel daily for 6 weeks.
62843782|NCT00106899||1|Mild Cognitive Impairment (MCI); scans performed at screening/baseline, 6, 12, 18, 24, and 36 months
62058247|NCT00651196||1|Type 1 diabetics
62058248|NCT00651196||Healthy controls|Healthy age and sex matched controls
62058249|NCT04649346||SGA type 1|Observe the function of SGA type 1
62058250|NCT04649346||SGA type 2|Observe the function of SGA type 2
62058251|NCT02731625|EXPERIMENTAL|Kettlebell Training|Army Physical Readiness Training (PRT) with kettlebell training in place of strength training circuits
62058252|NCT02731625|ACTIVE_COMPARATOR|Army Physical Readiness Training|Army Physical Readiness Training (PRT) per Army Field Manual 7-22
62058253|NCT04247997|EXPERIMENTAL|Group D|disconnect pulmonary vague nerve branches
62058254|NCT04247997|NO_INTERVENTION|Group P|preserve the pulmonary vague nerve branches
62058255|NCT03842410|OTHER|Single-Incision Sling|Intervention with in office solyx suburethral sling DISST
62058256|NCT03896009|EXPERIMENTAL|AXS-07|Taken once upon a qualifying migraine
62058257|NCT03896009|ACTIVE_COMPARATOR|Meloxicam|Taken once upon a qualifying migraine
62261664|NCT02921620|PLACEBO_COMPARATOR|Placebo|Placebo infusions every 2 weeks
62261665|NCT01767454|EXPERIMENTAL|Doublet arm|Subjects will be started with dabrafenib 150 mg twice daily (BID) orally for 2 weeks (run-in). The doublet arm will comprise 2 cohorts. Cohort A1 (Dabrafenib 150 mg BID + ipilimumab). Cohort A-1 (Dabrafenib 100 mg BID +ipilimumab). Ipilimumab will be administered as 3 mg/kg every 3 weeks (Q3W) for a total of 4 infusions over approximately 12-16 weeks. Dabrafenib will be continued through combination with ipilimumab and post-ipilimumab until no longer of clinical benefit, in the opinion of the treating physician, or until unacceptable AE or death
62261666|NCT01767454|EXPERIMENTAL|Triplet arm|This arm will be initiated using dabrafenib and ipilimumab doses established in the doublet dose-finding. Subjects will be started with dabrafenib and trametinib orally for 2 weeks (run-in), followed by ipilimumab 3 mg/kg Q3W for a total of 4 infusions over approximately 12-16 weeks. The triplet arm will comprise 3 planned cohorts. Cohort B-1: Dabrafenib 100 mg BID + trametinib 1 mg once daily + ipilimumab, Cohort B1: Dabrafenib 150 mg BID + trametinib 1 mg once daily+ ipilimumab, Cohort B2: Dabrafenib 150 mg BID + trametinib 2 mg once daily + ipilimumab. Dabrafenib and trametinib wil be continued through combination with ipilimumab and post-ipilimumab until no longer of clinical benefit, in the opinion of the treating physician, or until unacceptable AE or death
62446708|NCT04383990|ACTIVE_COMPARATOR|Late Glargine|To take insulin Glargine at 10-12 pm
62446709|NCT00149292|EXPERIMENTAL|LY2140023|40 mg LY2140023 BID for 28 days
62618128|NCT02288481|PLACEBO_COMPARATOR|Cohort 1 placebo|Placebo Suspension
62618129|NCT02288481|EXPERIMENTAL|Cohort 2 25 mg TBA-354|
62618130|NCT02288481|PLACEBO_COMPARATOR|Cohort 2 placebo|Placebo Suspension
62618131|NCT02288481|EXPERIMENTAL|Cohort 3 60 mg TBA-354|
62261667|NCT02141685||IVF patients undergoing aCGH Testing|Women undergoing fresh IVF treatment and array-comparative genomic hybridization testing (aCGH), as recommended based on medical need by the clinical site reproductive endocrinologist.
62618132|NCT02288481|PLACEBO_COMPARATOR|Cohort 3 placebo|Placebo Suspension
62618133|NCT02288481|EXPERIMENTAL|Cohort 4 150 mg TBA-354|
62618134|NCT02288481|PLACEBO_COMPARATOR|Cohort 4 placebo|Placebo Suspension
62618135|NCT02288481|EXPERIMENTAL|Cohort 5 400 mg TBA-354|
62618136|NCT02288481|PLACEBO_COMPARATOR|Cohort 5 placebo|Placebo Suspension
62618137|NCT02288481|EXPERIMENTAL|Cohort 6 1000 mg TBA-354|
62618138|NCT02288481|PLACEBO_COMPARATOR|Cohort 6 placebo|Placebo Suspension
62843783|NCT00106899||2|Early Alzheimer's disease (AD); scans performed at screening/baseline, 6, 12, and 24 months
62843784|NCT00106899||3|Unaffected/normal controls; scans performed at baseline/screening, 6, 12, 24, and 36 months
62843785|NCT03633539|ACTIVE_COMPARATOR|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（multi-ports）.
62843786|NCT03633539|EXPERIMENTAL|Single-incision Laparoscopic Surgery|Patients with colorectal cancer undergo single-incision laparoscopic surgery.
62843787|NCT04835506|EXPERIMENTAL|proactive infliximab optimization|proactive infliximab optimization using a pharmacokinetic dashboard
62843788|NCT04835506|EXPERIMENTAL|standard of care infliximab dosing|standard of care infliximab dosing
62843789|NCT04521504|EXPERIMENTAL|Biofeedback|Patients were treated with an experimental rehabilitation protocol, based on shoulder kinematic biofeedback.
62843790|NCT04521504|NO_INTERVENTION|Control|Patients were treated with a standard rehabilitation protocol, based on hospital guidelines.
62843791|NCT03572595||Staging|Patients with pathologically proven colorectal cancer presented for pre-operative staging, underwent standard routine conventional radiological imaging i.e MRI , then will be subjected to be imaged by F-18 FDG-PET/CT from skullbase to midthigh, then interpretating the results of the hybrid PET/CT by two nuclear physicians then comparing with other conventional images.
62261668|NCT01187186|EXPERIMENTAL|Moderate Hepatic Impairment|Subjects with Moderate Hepatic Impairment
62261669|NCT01187186|EXPERIMENTAL|Normal Hepatic Function|Subjects with Normal Hepatic Function
62261670|NCT00812058|EXPERIMENTAL|RG2417|Oral RG2417 taken twice daily for 8 weeks
62261671|NCT00812058|PLACEBO_COMPARATOR|Placebo|Oral placebo taken twice daily for 8 weeks
62261672|NCT03812640|EXPERIMENTAL|Vicryl|Vicryl suture
62261673|NCT03812640|ACTIVE_COMPARATOR|Nylon|Nylon suture
62261674|NCT00005039|EXPERIMENTAL|Arm I|Patients receive recombinant fowlpox-PSA vaccine IM at the MTD from the safety cohort every 4 weeks for 3 courses. Patients then receive recombinant vaccinia-PSA vaccine intradermally every 4 weeks for 2 courses.
62618139|NCT01090141|ACTIVE_COMPARATOR|Subjects recieving 100 mg of Micafungin|
62618140|NCT01090141|ACTIVE_COMPARATOR|Subjects recieving 300 mg of Micafungin|
62618141|NCT06165913|EXPERIMENTAL|Group (1): Early implant placement(type II) group.|Patients will be scheduled for tooth extraction then performing implant placement between 4-8 weeks later after soft tissue healing.
62618142|NCT06165913|EXPERIMENTAL|Group (2): Early implant placement (type III) group.|Patients will be scheduled for tooth extraction and performing implant placement between 12-16 weeks with partial bone healing.
62618143|NCT00679224||ambrisentan prescribed subjects|ambrisentan prescribed subjects
62618144|NCT05626075|EXPERIMENTAL|group Low Myopia|"1. Patients with low myopia aging more than 15 years old~2. All patients are with visual acuity (uncorrected, with habitual correction, and best spectacle correction).~3. There is no restrictions on the range and regularity of keratometry"
62618145|NCT05626075|EXPERIMENTAL|group high myopia|"1. Patients with high myopia aging more than 15 years old~2. All patients are with visual acuity (uncorrected, with habitual correction, and best spectacle correction).~3. There is no restrictions on the range and regularity of keratometry"
62618146|NCT05626075|EXPERIMENTAL|group Hypermetropia|"1. Patients with hypermetropia aging more than 15 years old~2. All patients are with visual acuity (uncorrected, with habitual correction, and best spectacle correction).~3. There is no restrictions on the range and regularity of keratometry"
62618147|NCT05626075|EXPERIMENTAL|group mixed astigmatism|"1. Patients with mixed astigmatism aging more than 15 years old~2. All patients are with visual acuity (uncorrected, with habitual correction, and best spectacle correction).~3. There is no restrictions on the range and regularity of keratometry"
62618148|NCT02119806|ACTIVE_COMPARATOR|Benzodiazepine group|"1. Premedication 0.02mg/kg-0.1mg/kg of Benzodiazepine ;~2. Maintenance 0.8 minimum alveolar concentration of inhaled anesthetic (MAC) and 10-30mcg/kg of fentanyl;~3. Postoperative 10-100mcg/kg/min of propofol"
62843792|NCT03572595||Recurrent|"Patients with treated colorectal cancer, suspecting of recurrence , will be subjected to be imaged by F-18 FDG-PET/CT from skull base to midthigh, interpretating the results of the hybrid PET/CT by two nuclear physicians.~Then refer back to the treating physicians , another biopsy will be taken from the suspected recurrence and then results will be compared with hybrid PET/CT images.~comparing the results with histopathology ."
62843793|NCT01148979|EXPERIMENTAL|Adjunct Lisdexamfetamine (Vyvanse)|Participants receive Lisdexamfetamine Dimesylate 20-50 mg capsule each morning for 4 weeks. After a washout period of 2 weeks, they receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) capsule) each morning for 4 weeks.
62618149|NCT02119806|ACTIVE_COMPARATOR|Non-benzodiazepine group|"1. Premedication 0-50mg of propofol and/or 0-250mcg of fentanyl;~2. Maintenance 0.8 minimum alveolar concentration of inhaled anesthetic (MAC) and 10-30mcg/kg of fentanyl;~3. Postoperative 10-100mcg/kg/min of propofol"
62618150|NCT04482738||Lean subjects|24 hours before the study visit, participants will be asked to refrain from alcohol and strenuous exercise. Patients will be asked to remain fasted 10 hours before the study visit takes place. On the day of the study visit, patients will be admitted to the hospital and, after intake of the study meal, blood samples will be taken.
62261675|NCT00005039|EXPERIMENTAL|Arm II|Patients receive the same vaccines as in arm I but in reverse order.
62261676|NCT04171375|EXPERIMENTAL|trans-spinal Electrical Stimulation (tsES)|
62618151|NCT04482738||Obese subjects|24 hours before the study visit, participants will be asked to refrain from alcohol and strenuous exercise. Patients will be asked to remain fasted 10 hours before the study visit takes place. On the day of the study visit, patients will be admitted to the hospital and, after intake of the study meal, blood samples will be taken.
62261677|NCT00547170|EXPERIMENTAL|1|Half of enrolled women will be randomly assigned to group 1.
62261678|NCT00547170|ACTIVE_COMPARATOR|2|Half of enrolled women will be randomly assigned to group 2
62261679|NCT03554876|ACTIVE_COMPARATOR|Multi-Im Machined|Multi-Im Machined
62618152|NCT04231968|EXPERIMENTAL|AK0529|Participants who are randomized to the experimental arm will receive AK0529 twice daily for five days .
62618153|NCT04231968|PLACEBO_COMPARATOR|Placebo|Participants in the control arm will be administered placebo at the matching dosage levels of active medications.
62618154|NCT03271099|NO_INTERVENTION|Usual Care|Usual care
62618155|NCT03271099|EXPERIMENTAL|Navigator|Patient navigator services provided as part of survivorship care plan
62618156|NCT02399969|EXPERIMENTAL|Battlefield Acupuncture Plus Standard of Care|Patients with low back pain that will receive ear acupuncture based on the Battlefield Acupuncture protocol.
62618157|NCT02399969|NO_INTERVENTION|Standard of Care Alone|Patients with low back pain that will receive standard of care without study intervention.
62843794|NCT01148979|PLACEBO_COMPARATOR|Adjunct Placebo|Participants receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) 20-50 mg capsule) each morning for 4 weeks. After a washout period of 2 weeks, they receive Lisdexamfetamine Dimesylate capsule each morning for 4 weeks.
62843795|NCT03196349|ACTIVE_COMPARATOR|Warfarin|Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
62843796|NCT03196349|ACTIVE_COMPARATOR|Apixaban|Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
62843797|NCT03196349|ACTIVE_COMPARATOR|Rivaroxaban|Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
62843798|NCT01017380|EXPERIMENTAL|placebo|identical placebo
62261680|NCT03554876|EXPERIMENTAL|Multi-Im® nanogolden|Multi-Im® nanogolden
62261681|NCT03554876|EXPERIMENTAL|Multi-Im T-Golden|Multi-Im T-Golden
62261682|NCT03045861|EXPERIMENTAL|Cohort 1-GSK2838232 100 mg + Cobicistat 150 mg in Part A|During Part A (Cohort 1), subjects will receive a single dose of GSK2838232 100 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
62058258|NCT03896009|ACTIVE_COMPARATOR|Rizatriptan|Taken once upon a qualifying migraine
62261683|NCT03045861|EXPERIMENTAL|Cohort 2-GSK2838232 200 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 2), subjects will receive a single dose of GSK2838232 200 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
62261684|NCT03045861|EXPERIMENTAL|Cohort 3-GSK2838232 50 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 3), subjects will receive a single dose of GSK2838232 50 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
62261685|NCT03045861|EXPERIMENTAL|Cohort 4-GSK2838232 20 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 4), subjects will receive a single dose of GSK2838232 20 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
62618158|NCT00106977||Family|Family members (typically parents or siblings) of probands with Muenke syndrome are alsoeligible to participate.
62618159|NCT00106977||Patient|Subjects who have had confirmation of a p. Pro250Arg mutation in FGFR3 by a CLIA-certified laboratory.
62618160|NCT04219839|NO_INTERVENTION|SOC only patient education post- kidney transplant|Participants in this group will receive only SOC patient education following kidney transplant
62618161|NCT04219839|EXPERIMENTAL|SOC + Videos for patient education post-kidney transplant|Participants in this group receive SOC patient education following kidney transplant and access to educational videos designed specifically for post-kidney transplant patients.
62618162|NCT04308044||Chronic MSK Pain|Participants who have chronic musculoskeletal pain.The pain profile of the patient will be assessed, including biological sample analysis (blood), quantitative sensory testing, electroencephalogram (EEG), and psychological state via the completion of questionnaires by the patient.
62843799|NCT04783090|EXPERIMENTAL|1st cohort|MT1013 injection at 2.5 mg.
62058259|NCT03896009|PLACEBO_COMPARATOR|Placebo|Taken once upon a qualifying migraine
62618163|NCT04308044||Healthy Control|Participants who do not have chronic musculoskeletal pain.The pain profile of the patient will be assessed, including biological sample analysis (blood), quantitative sensory testing, electroencephalogram (EEG), insole assessment (40 healthy control participants), and psychological state via the completion of questionnaires by the patient.
62618164|NCT01229813|ACTIVE_COMPARATOR|bevacizumab and erlotinib (KRAS WT)|
62618165|NCT01229813|ACTIVE_COMPARATOR|bevacizumab (KRAS WT)|
62261686|NCT00617500|ACTIVE_COMPARATOR|Hormone|
62261687|NCT00617500|EXPERIMENTAL|flower therapy|
62261688|NCT00617500|EXPERIMENTAL|therapeutic touch|
62261689|NCT00617500|EXPERIMENTAL|auriculotherapy|
62618166|NCT01229813|ACTIVE_COMPARATOR|bevacizumab (KRAS mutated)|
62618167|NCT01229813|ACTIVE_COMPARATOR|low dose capecitabine (KRAS mutated)|
62618168|NCT00346567|ACTIVE_COMPARATOR|1|AZT from week 28 or asap thereafter. Intrapartum AZT and 3TC + Single dose NVP Postpartum Combivir tail for 7 days twice daily
62618169|NCT00346567|EXPERIMENTAL|2|AZT from week 28 or asap thereafter. Intrapartum Single dose Truvada + Single dose NVP
62618170|NCT00467207|ACTIVE_COMPARATOR|BoNT A|Botulinum toxin A injections in muscles of the arm (biceps brachii and brachialis)
62618171|NCT00467207|EXPERIMENTAL|Resistance training|8 weeks resistance training
62843800|NCT04783090|EXPERIMENTAL|2nd cohort|MT1013 injection at 5 mg.
62843801|NCT04783090|EXPERIMENTAL|3rd cohort|MT1013 injection at 10 mg.
62261690|NCT03024554|EXPERIMENTAL|treatment|aortic aneurysm involving iliac arteries treatment with the Bifurcated Multilayer Flow Modulator (BMFM)
62618172|NCT01937585|ACTIVE_COMPARATOR|CDC brochure only condition|Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
62618173|NCT01937585|EXPERIMENTAL|Partner and CDC brochure condition|Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
62261691|NCT01914874|EXPERIMENTAL|Mindfulness Meditation|12 weekly sessions in group format
62261692|NCT01914874|NO_INTERVENTION|Wait-list|Patients will receive the mindfulness intervention after a 12-week wait period
62618174|NCT04624802|EXPERIMENTAL|maternal exercise training group|Pregnant women in experimental group are invited to participate in 16 exercise weekly classes for 40 min including 15 min aerobic exercise，10 min relaxation exercise, and 15 min aerobic exercise, from week 16 to week 32 of gestation, and receive antenatal care and examination regularly.
62843802|NCT04783090|EXPERIMENTAL|4th cohort|MT1013 injection at 15 mg.
62843803|NCT04783090|EXPERIMENTAL|5th cohort|MT1013 injection at 20 mg.
62843804|NCT05636449|ACTIVE_COMPARATOR|Group Suprainguinal fascia iliaca block|Suprainguinal fascia iliaca block after the surgery
62843805|NCT05636449|ACTIVE_COMPARATOR|Group Periarticular Infiltration Group|A local anesthetic will be applied to the medial and lateral capsule, the medial and lateral meniscus margins, the deep part of the medial ligament, the medial and lateral synovial space, and the patellar ligament and quadriceps tendon.
62843806|NCT00509145|EXPERIMENTAL|Laquinimod|Laquinimod 0.6 mg, oral
62843807|NCT00509145|PLACEBO_COMPARATOR|Placebo|Matching placebo
62843808|NCT01350791||Promus Element stent|Patients receiving Promus Element stents
62843809|NCT04059315||Retrospective cross sectional study|"This is an Epidemiological observational analytic study where the subjects sustained with oral and maxillofacial trauma will be divided into the two-time-frame;~1st, retrospective study between 1 June 2011 to 31 May 2019"
62843810|NCT04059315||Prospective cohort study|2nd prospective study on 1 June 2019 to 1 June 2021.
62843811|NCT03399929||TBI + Rehabilitation|Traumatic Brain Injury patients that received post acute rehabilitation
62058260|NCT04307433|EXPERIMENTAL|Arm 1|ST Narrative + mHealth: Storytelling narrative video on tablets
62446710|NCT00149292|ACTIVE_COMPARATOR|Olanzapine|15 mg Olanzapine once daily (QD) for 28 days
62446711|NCT00149292|PLACEBO_COMPARATOR|Placebo|placebo for 28 days
62446712|NCT03777410||Vanguard|(CLOSED TO ENROLLMENT) Bone marrow (BM) from this cohort of up to 30 treatment naïve subjects with a diagnosis of multiple myeloma (MM) will first be used to define sample processing pipeline performance and optimal drug dosages before sites on the study proceed to mass accumulation rate (MAR) testing of BM from the relapsed/refractory MM (RRMM) subject cohort.
62618175|NCT04624802|NO_INTERVENTION|antenatal care group|Pregnant women in antenatal care group receive antenatal care and examination regularly.
62843812|NCT03399929||TBI + No Rehabilitation|Traumatic Brain Injury patients that did not receive post acute rehabilitation
62843813|NCT03399929||CVA + Rehabilitation|Stroke patients that received post acute rehabilitation
62843814|NCT03399929||CVA + No Rehabilitation|Stroke patients that did not received post acute rehabilitation
62446713|NCT03777410||Relapsed/Refractory MM|BM from this cohort of 100 relapsed subjects with a diagnosis of MM will be used to test the MAR assay's accuracy of condition by matching conditions tested in vitro to the patient's planned course of therapy. This is the main study cohort described in the Eligibility section.
62446714|NCT00208156|EXPERIMENTAL|mifepristone|
62058261|NCT04307433|ACTIVE_COMPARATOR|Arm 2|mHealth: a video with a voice over presenting didactic materials on tablets
62058262|NCT04307433|PLACEBO_COMPARATOR|Arm 3|Control: non-narrative educational materials will be read
62058263|NCT00586170|EXPERIMENTAL|EBI Bone Healing System + Surgery|Subject will be using the EBI Bone Healing System (active device) in conjunction with ORIF surgery of the nonunion site.
62843815|NCT04437667|EXPERIMENTAL|Intervention Arm|Adolescents participants enrolled in the intervention arm will receive the intervention, Tumaini, loaded on a low-cost Android smartphone, during the long November-December school holidays for the first three years of the study.
62843816|NCT04437667|ACTIVE_COMPARATOR|Control Arm|Adolescent participants enrolled in the control arm will receive a commercially available age- and language-appropriate educational game or knowledge quiz loaded on a study-provided low-cost Android smartphone.
62058264|NCT00586170|PLACEBO_COMPARATOR|Placebo Device + Surgery|Subject will be using a placebo device in conjunction with ORIF surgery of the nonunion site.
62058265|NCT00671905|ACTIVE_COMPARATOR|1|Circumferential PV isolation
62058266|NCT00671905|ACTIVE_COMPARATOR|2|HF stimulation-guided and anatomic ablation of the main right and left atrial GP.
62058267|NCT00671905|ACTIVE_COMPARATOR|3|HF stimulation-guided and anatomic ablation of the main right and left atrial GP followed by circumferential PV isolation
62058268|NCT02080104|ACTIVE_COMPARATOR|intravenous 10 ıu oxytocin|group which 2 ampul prophylactic oxytocin given for third stage of labour intravenously after vaginal delivery
62446715|NCT04174924||Phakic intraocular lens (pIOL) explantation|Patients with pIOLs where a combined pIOL explantation and cataract surgery is needed.
62446716|NCT04174924||Cataract extraction|Healthy control group of patients scheduled for regular cataract surgery without comorbidities affecting an immune response.
62618176|NCT05207085|EXPERIMENTAL|Valbenazine|Participants randomized1:1 to receive valbenazine
62618177|NCT05207085|PLACEBO_COMPARATOR|Placebo|Participants randomized 1:1 to receive placebo
62843817|NCT00000955|OTHER|A|All eligible study participants
62261693|NCT04647591|EXPERIMENTAL|ENT Barotrauma incidence and link with risk factors|
62261694|NCT04427007|EXPERIMENTAL|Experimental Prosthetic Liner|Participants will test the experimental liner in combination with the active cooling socket (ICE System). Prosthetic liners and socket will be tested by walking on a treadmill.
62261695|NCT04427007|OTHER|Control Prosthetic Liner|Participants will test the control liner in combination with the active cooling socket (ICE System). Prosthetic liners and socket will be tested by walking on a treadmill.
62261696|NCT03731650|EXPERIMENTAL|active comparator|
62261697|NCT03731650|EXPERIMENTAL|placebo|
62261698|NCT05020171|EXPERIMENTAL|intervention group|group focus on lower limb strength training with a seated robotic device
62261699|NCT05020171|ACTIVE_COMPARATOR|control group|physiotherapy group as usual, not focused on strength training
62261700|NCT01590940||Parietex mesh|Enrolled patients who met criteria for inclusion would have undergone open inguinal hernia repair using the Parietex plug and patch hernia system
62261701|NCT06236477|ACTIVE_COMPARATOR|Personalized Music Group|Those assigned to receive music will be asked to provide a short list of 5-10 songs familiar/well-known to the patient (specifically the song title and artist for each song). Songs will be downloaded onto an electronic mp3 player by the research staff member. The mp3 player will then be provided along with a portable Bluetooth speaker for use during the patient's perioperative period, loaded with the songs of their choice.
62058269|NCT02080104|EXPERIMENTAL|intramusculer 10 ıu oxytocin|group which oxytocin administered intramusculary after vaginal delivery
62261702|NCT06236477|PLACEBO_COMPARATOR|No Music Group|Those not assigned to the personalized music group will receive standard care without music.
62058270|NCT00336843|EXPERIMENTAL|Zevalin-BuCyE|histologically confirmed, relapsed or refractory CD20 positive B-cell NHL including diffuse large B-cell, follicular, mantle cell, and Burkitt lymphomas.
62058271|NCT02819102|EXPERIMENTAL|Metabolic Probes and BCX7353|"Day 1: 1 mg midazolam will be administered as an IV bolus simultaneously to administration of 500 mg tolbutamide, 40 mg omeprazole, and 30 mg dextromethorphan orally.~Day 2: a single oral dose of 2 mg midazolam. Days 3 to 9: 350 mg BCX7353 once a day. Day 10: 1 mg midazolam will be administered as an IV bolus simultaneously to administration of 500 mg tolbutamide, 40 mg omeprazole, 30 mg dextromethorphan and 350 mg BCX7353, orally.~Day 11: a single oral dose of 2 mg of midazolam along with 350 mg BCX7353."
62058272|NCT03274739||Pregnant women|Pregnant women
62058273|NCT05297474||SSc patiant|We recruited 95 patients with systemic sclerosis
62058274|NCT05297474||health control|We recruited 95 healthy people for control
62058275|NCT03803891||Endoscopic full-thickness resection|Patients with neoplastic lesions less than 30mm unresectable en bloc by other less invasive endoscopic techniques, including lesions suggestive of T1 colorectal cancer, subepithelial tumors, lesions with diverticular involvement, lesions with no-lifting sign (recurrent, incomplete prior resection or untreated lesions).
62261703|NCT02427074|ACTIVE_COMPARATOR|Balloon Compression Rhizotomy|Patients that are submitted to Balloon Compression Rhizotomy
62261704|NCT02427074|ACTIVE_COMPARATOR|Radiofrequency Thermal Coagulation Rhizotomy|Patients that are submitted to Radiofrequency Thermal Coagulation Rhizotomy
62261705|NCT01283074||Cohort|
62261706|NCT04514523|EXPERIMENTAL|Implementation Arm|
62261707|NCT01748175||Longitudinal follow up|Patients will undergo a characterization phase, which includes a baseline evaluation (1 visit), and a steroid responsiveness evaluation (2 visits). The longitudinal phase will include 3 office visits (annually) over 36 months with bi-annual phone calls. During the study patients will answer questionnaires, perform lung function testing and provide blood, urine, sputum and exhaled breath condensate samples.
62261708|NCT03107520|EXPERIMENTAL|DDH Surgical Reduction Patients|Infants treated for DDH who failed conservative measures and are undergoing intraoperative open or closed hip reduction. Intraoperative contrast-enhanced ultrasound using Lumason contrast agent will be administered to improve visualization of the epiphyseal vascularity after hip reduction and during placement of the spica cast.
62261709|NCT05627375|EXPERIMENTAL|strategy of full-dose anticoagulant therapy alone (AC)|"The experimental group receiving full-dose anticoagulant therapy alone (AC).~Anticoagulant (AC) therapy :at the investigator's discretion in accordance with international recommendations for the management of DVT/PE Antiplatelet therapy will be stopped."
62261710|NCT05627375|ACTIVE_COMPARATOR|strategy of combined full-dose anticoagulant and antiplatelet therapies (AC+AP)|"The control group receiving the standard of care: Antiplatelet therapy will be combined to full-dose anticoagulant therapy.~Anticoagulant (AC) therapy :at the investigator's discretion in accordance with international recommendations for the management of DVT/PE~Antiplatelet (AP) therapy : Aspirin or Clopidogrel"
62261711|NCT01515761|ACTIVE_COMPARATOR|Postero-lateral|Left ventricular lateral wall lead position
62261712|NCT01515761|ACTIVE_COMPARATOR|Antero-lateral|Left ventricular lateral wall lead position
62261713|NCT04720235|OTHER|Subject Self-Collection and Specimen Testing|Subjects will be provided with the Lucira COVID-19 Test Kit and collect one (1) nasal swab according to the QRI and test the sample on the Lucira COVID-19 All-In-One Test. HCP will observe subject during this process and document any observations and deviations from the QRI.
62058276|NCT04609202|EXPERIMENTAL|Nurse led person centred care|Participants in the nurse led, person centred care arm will receive person centred follow up after hospitalization for atrial fibrillation. The person centred care and usual care routines are provided by nurses.
62261714|NCT05790109|EXPERIMENTAL|RF biopsy track cautery|This study is designed as an open-label, single arm study, wherein all study participants will undergo RF track cautery during percutaneous liver, kidney, or spleen biopsy.
62058277|NCT04609202|ACTIVE_COMPARATOR|Usual care|Participants in the usual care arm will receive care as usual, ie follow up by doctors after hospitalization for atrial fibrillation.
62058278|NCT06244810|EXPERIMENTAL|lingual retainer made of fiber made using cad cam Technique|lingual retainer made of fiber manufactured using CAD-CAM technique applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
62058279|NCT06244810|EXPERIMENTAL|lingual retainer made of metal made using cad cam Technique|lingual retainer made of metal manufactured using CAD-CAM technique applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months
62058280|NCT06244810|EXPERIMENTAL|Traditional lingual retainer made of braided stainless steel wire|lingual retainer made of braided stainless steel wire applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
62058281|NCT05400512|EXPERIMENTAL|Cognitive Training + Active Stimulation|This arm receives cognitive training combined with active tDCS.
62058282|NCT05400512|EXPERIMENTAL|Cognitive Training + Sham Stimulation|This arm receives cognitive training combined with sham tDCS.
62058283|NCT03361891|NO_INTERVENTION|Control|Patients receive no intervention
62058284|NCT03361891|EXPERIMENTAL|WalkMORE group|WalkMORE Ambulation program. Patients will ambulate with a trained WalkMORE Volunteer Coach two times per day; once in the morning (0900-1200hrs) and once in the afternoon (1300-1700hrs), Monday- Friday, until hospital discharge.
62058285|NCT03582605|PLACEBO_COMPARATOR|Control Group|All participants will be weighed. This group will receive a placebo (glucose) 1 hour prior to insertion of mini-screw implants.
62261715|NCT04490863|EXPERIMENTAL|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter \& DCI Mini sensor for measurement of hemoglobin.
62261716|NCT02134483|EXPERIMENTAL|Parathyroid allo-transplantation|patients who have permanent hypoparatyroidism
62261717|NCT04344938||medical personel|
62261718|NCT04344938||non medical personel|
62446717|NCT02985151|ACTIVE_COMPARATOR|High Energy Treatment Group|Subjects in this group will receive at least two Syneron-Candela CO2RE laser treatments set at either the Mid mode or the Deep mode of the laser at visits three months apart. Thereafter, individuals in this group will be offered a third optional treatment at one of these settings.
62261719|NCT02350972|EXPERIMENTAL|Autologous cytokiines|Autologous cytokines obtained from patients' blood mononuclear cells injected in volumes of 0.1 ml
62618178|NCT02770768|ACTIVE_COMPARATOR|Flibanserin|"Drug: Flibanserin~* 8 weeks~* 100mg once daily at bedtime"
62618179|NCT02770768|PLACEBO_COMPARATOR|Placebo|Drug: Matching Placebo Matching placebo capsules taken in same amount of pills as the active medication (for 8 weeks once daily at bedtime)
62058286|NCT03582605|EXPERIMENTAL|Experimental Group|All participants will be weighed so that appropriate dosing can be ensured and will receive 2 grams of Amoxicillin 1 hour prior to mini-screw insertion. Patients weighing less than 40 kg will be given 50mg/kg of Amoxicillin.
62261720|NCT03034564|ACTIVE_COMPARATOR|1|Active group started 100 mg TID, increased by 100 mg per interval (i.e. 100 TID) every 2 days till on 600 TID, or until intolerable dose is achieved at which time the next highest dose will be maintained (increments of 100 TID will be used).
62261721|NCT03034564|PLACEBO_COMPARATOR|2|Dosing regimen identical to active group
62618180|NCT02786706||Optic nerve ultrasound|All patients will undergo Optic Nerve Ultrasound (ONUS), with measurement of Optic Nerve Sheath Diameter (ONSD) by both an expert investigator as well as by the automated image analysis algorithm.
62058287|NCT05252845|EXPERIMENTAL|R21/Matrix-M + DHA-PIP+PQ|The R21/Matrix-M vaccine (IM injection) + co-formulated Dihydroartemisinin/Piperaquine tablets + one single low dose of Primaquine
62058288|NCT05252845|EXPERIMENTAL|R21/Matrix-M only|The R21/Matrix-M vaccine (IM injection) only
62058289|NCT05252845|ACTIVE_COMPARATOR|DHA-PIP+PQ only|Co-formulated Dihydroartemisinin/Piperaquine tablets + one single low dose of Primaquine
62058290|NCT03875625|EXPERIMENTAL|Morbid obesity- Bariatric surgery group|Morbid obese subjects who will consent to bariatric surgery
62058291|NCT03875625|EXPERIMENTAL|Morbid obesity-Dietitian led life style intervention group|Morbid obese subjects who will not consent to bariatric surgery but instead opt for dietitian led life style intervention
62261722|NCT04451577||EMPLOYEES WITHOUT COVID-19 INFECTION|"Humanitas group employees (including ICH, Humanitas University and Gavazzeni), and two validation cohorts.~Negativity to COVOD-19 will be tested by peripheral blood samples every month for 6 months (or until seroconversion). If they are positive for anti- covid 19 antibodies, a test for positivity of the virus will be carried out. T"
62618181|NCT02844894|EXPERIMENTAL|dexmedetomidine|0.5 mcg/kg dexmedetomidine in 20 ml normal saline will be infused in 5 minutes before intubation
62058292|NCT03875625|EXPERIMENTAL|Mild obesity-Dietitian led life style intervention group|Mild- Moderate subjects assigned through a randomized controlled trial to the dietitian led life style intervention
62261723|NCT04451577||EMPLOYEES WITH COVID-19 INFECTION|"Humanitas group employees (including ICH, Humanitas University and Gavazzeni), and two validation cohorts.~employees that are Sars-Cov-2 positive both symptomatic and asymptomatic, there will be at least 2 peripheral blood samples (5 and 3 ml) at every control visit until ascertained negativity. They will also undergo a pharyngeal swab for viral titers and microbiota analysis at enrollment and at negativity. In addition, a sample of saliva/sputum will be collected for most of the employees at positivity and at every control visit.~For employees hospitalized but not requiring intensive care the following samples will be collected:~* an aliquot of samples from the respiratory tract (e.g., bronchial aspirate, bronchoalveolar lavage) residual from the normal clinical practice~* saliva/sputum~* pharyngeal swab not used for diagnosis both at admission and at the first check up~* blood sample in EDTA for plasma and peripheral blood mononuclear cell (PBMC)"
62261724|NCT06020677|EXPERIMENTAL|L-WebTIPS|
62261725|NCT06020677|NO_INTERVENTION|L-WebINFO|
62261726|NCT05898100|EXPERIMENTAL|Virtual Reality Distraction|Use of virtual reality (VR) during dental procedure.
62261727|NCT05898100|ACTIVE_COMPARATOR|Standard Treatment|Dental Clinic's standard treatment during dental procedure.
62261728|NCT03126942|EXPERIMENTAL|Novaloc, then Locator|Participants will receive the Novaloc attachment on a single implant inserted in the mandibular midline. This attachment will be used for 3 months and then changed by the Locator attachment. The second attachment will be used for another 3-month period. Participants will keep preferred attachment for further 12 months
62261729|NCT03126942|ACTIVE_COMPARATOR|Locator, then Novaloc|Participants will receive the Locator attachment on a single implant inserted in the mandibular midline. This attachment will be used for 3 months and then changed by the Novaloc attachment. The second attachment will be used for another 3-month period. Participants will keep preferred attachment for further 12 months
62261730|NCT02132208||Trauma|Severe trauma patients admitted in the resuscitation room of our emergency department.
62261731|NCT04941950|EXPERIMENTAL|PlaySmart|Video game intervention.
62261732|NCT04941950|OTHER|Control Game|Control video game intervention.
62618182|NCT02844894|EXPERIMENTAL|Esmolol|0.5 mg/kg esmolol in 20 ml normal saline will be infused in 5 minutes before intubation
62618183|NCT02844894|PLACEBO_COMPARATOR|Placebo|20 ml normal saline infused in 5 minutes before intubation
62618184|NCT00093977|EXPERIMENTAL|darbepoetin alfa SF|
62618185|NCT01962623|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Participants who are not randomly assigned to the IPT-MBD group will continue with treatment at usual, which is considered routine care.
62618186|NCT01962623|OTHER|IPT-MBD|Weekly Interpersonal Therapy for SMD/DMDD (IPT-MBD) sessions, which emphasizes building skills in managing relationships, helping with problem solving, strengthening communication skills and other skills.
62058293|NCT03875625|EXPERIMENTAL|Mild obesity-Conventional care group (control)|Mild- Moderate subjects assigned through a randomized controlled trial to conventional care
62058294|NCT06303154|EXPERIMENTAL|Mobiderm Intimate Bra group|All the patients will wear MOBIDERM Intimate bra composed of a bra and a MOBIDERM pad
62058295|NCT02540694|ACTIVE_COMPARATOR|EBUS-TBNA using 22G needle|EBUS-TBNA using 22G needle (transbronchial route)
62058296|NCT02540694|ACTIVE_COMPARATOR|EBUS-TBNA using 25G ProCore needle|EBUS-TBNA using 25G ProCore needle (transbronchial route)
62618187|NCT05332717|EXPERIMENTAL|Melatonin Group (Experimental)|Patients who will take one (1) 5mg Melatonin tablet 30 minutes before bedtime daily for the 6 weeks following surgery.
62058297|NCT02540694|ACTIVE_COMPARATOR|EUS-B-FNA using 22G needle|EUS-B-FNA using 22G needle (transoesophageal route)
62058298|NCT02540694|ACTIVE_COMPARATOR|EUS-B-FNA using 25G ProCOre needle|EUS-B-FNA using 25G ProCOre needle (transoesophageal route)
62058299|NCT04173767|EXPERIMENTAL|HFNC|
62058300|NCT06096545|ACTIVE_COMPARATOR|Group 1 = Fine needle aspiration biopsy|In Group A, patients with axillary metastasis identified by FNAB were subjected to repeat ultrasound-guided FNAB after completion of neoadjuvant treatment, The obtained biopsies were sent for histopathological evaluation without revealing patient names to avoid influencing the research results, and the surgical team was not informed of the biopsy results. During surgery, both dyed lymph nodes and clipped lymph nodes were excised for SLNB and assessed by frozen section evaluation.
62261733|NCT00677014|ACTIVE_COMPARATOR|Echo optimized AV delay|Echo optimized AV delay
62261734|NCT00677014|ACTIVE_COMPARATOR|Algorithm optimized AV delay|Algorithm optimized AV delay
62261735|NCT00677014|ACTIVE_COMPARATOR|Fixed AV Delay|Fixed AV Delay
62618188|NCT05332717|SHAM_COMPARATOR|Placebo Group (Control)|Patients who will take one (1) placebo (Vitamin C) tablet 30 minutes before bedtime daily for the 6 weeks following surgery.
62618189|NCT04594109|ACTIVE_COMPARATOR|Standard of Care|One-time standard of care in-person behavioral counseling lasting approximately one hour, plus a 30-day supply of nicotine replacement therapy consisting of nicotine patches and nicotine gum (dosage according to current smoking intensity according to manufacturers instructions). The standard of care behavioral counseling was adapted from the current U.S. clinical practice guidelines.
62623734|NCT02373423|EXPERIMENTAL|Advocacy program|A series of commonly used advocacy actions which will incorporate a theory of change model. Each advocacy action is targeted to change organizational capability, opportunity, or motivation of food companies to reduce salt in processed packaged foods. The intervention will span 24 months from 2013-2015.
62623735|NCT02373423|NO_INTERVENTION|Control|No intervention program
62261736|NCT06194136|EXPERIMENTAL|PBM Intervention|Application of commercially-available PBM over the skin of first the right breast and chest tissue and then the left breast and chest tissue, each for 30 seconds in single application. This intervention is to applied once per day, for a total of three times per week, with a minimum of 24 hours between each application.
62261737|NCT00822757|EXPERIMENTAL|1|V710
62261738|NCT00822757|PLACEBO_COMPARATOR|2|Placebo
62261739|NCT04624711|EXPERIMENTAL|Eribulin Mesylate Combined With Anlotinib|Patients receive eribulin mesylate plus anlotinib.
62618190|NCT04594109|EXPERIMENTAL|Tailored Counseling|Participants in the intervention arm were provided a one-time tailored cognitive-behavioral therapy in-person cessation counseling intervention lasting approximately one hour, a 30-day supply of nicotine replacement therapy (consisting of nicotine patches and nicotine gum; dosage according to current smoking intensity according to manufacturers instructions), and a tailored bi-directional text messaging program delivering two messages per day for four weeks. The TI session was adapted from the clinical practice guidelines to include behavioral elements rooted in the minority stress model. The intervention used addressed issues of stress related to HIV stigma, minority status and socioeconomic condition.
62618191|NCT02860507|ACTIVE_COMPARATOR|Neostigmine + Glycopyrrolate|Neostigmine 0.06 mg/kg and Glycopyrrolate 0.04mg/kg iv
62618192|NCT02860507|EXPERIMENTAL|sugammadex|Sugammadex 4mg/kg
62618193|NCT03151213|ACTIVE_COMPARATOR|Pregabalin|Pregabalin 150 mg before intervention
62618194|NCT03151213|PLACEBO_COMPARATOR|Placebo|Placebo before intervention
62618195|NCT03183479|EXPERIMENTAL|Treatment group|The patients in treatment group will receive Fibrinogen Concentrate Human administration.
62618196|NCT03183479|PLACEBO_COMPARATOR|Control group|The patients in control group will be administered with normal saline solution as placebo.
62618197|NCT04539756|ACTIVE_COMPARATOR|Active control condition|Participants in the active control condition will receive the same number of text message reminders and will complete the same number of writing activities as the intervention group. The writing activity for the active control condition will ask them to list their activities for that day.
62618198|NCT04539756|EXPERIMENTAL|Positive psychological intervention|Participants will be asked to complete writing activities every other day. They will choose which activity they would like to complete each day, from a menu of six different activities. Each activity is a different positive psychology exercise.
62618199|NCT05020704|EXPERIMENTAL|empagliflozin|empagliflozin 10mg once daily
62618200|NCT05020704|PLACEBO_COMPARATOR|Placebo|matched placebo
62261740|NCT05705609|EXPERIMENTAL|Mandala art therapy|Mandala art therapy applied group
62261741|NCT05705609|NO_INTERVENTION|Standard of care|group without Mandala art therapy
62261742|NCT00634309|ACTIVE_COMPARATOR|1|
62261743|NCT00634309|PLACEBO_COMPARATOR|2|
62261744|NCT01724840|EXPERIMENTAL|GraftJacket|GraftJAcket is used as interpositional material
62261745|NCT01724840|ACTIVE_COMPARATOR|Tendon Interposition|Flexor carpi radialis tendon is used as interpositional material
62261746|NCT04632758|EXPERIMENTAL|WX-0593 Tablets|Eligible patients with ALK+ NSCLC will receive WX-0593 tablets without food until documented disease progression or unacceptable toxicity. 60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.
62261747|NCT04632758|ACTIVE_COMPARATOR|crizotinib|Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID without food until documented disease progression or unacceptable toxicity.
62618201|NCT04611776|EXPERIMENTAL|Arm A: Atezolizumab + platinum-doublet followed by atezolizumab maintenance|
62843818|NCT01192685|OTHER|Depressed outpatients treated with TMS|This a 12- week study (1-4 week screening, 6 weeks treatment, 2 weeks follow-up) outpatient open label clinical trial. Twenty-five subjects diagnosed with depression with a Montgomery Asberg Depression Rating Scale (MADRAS) score of 26 or higher, will be enrolled into this trial, up to fifty subjects will be consented. Transcranial Magnetic Stimulation (TMS) will be administered to subjects 5 days a week for 6 weeks. Near infrared spectroscopy (NIRS), a spectroscopic method that uses the near infrared region of the electromagnetic spectrum (from about 700 nm to 2500 nm), will be used to assess blood flow in the brain.
62843819|NCT05405686|ACTIVE_COMPARATOR|Control arm|In the control group, 225 IU of recombinant FSH will be administered in a fixed antagonist protocol.
62843820|NCT05405686|EXPERIMENTAL|Study arm|In the study group, 225 IU of recombinant FSH plus 112,5 IU of recombinant LH will be administered.
62843821|NCT05357001|EXPERIMENTAL|Connective tissue manipulation|technique to remove muscle spasticity
62058301|NCT06096545|ACTIVE_COMPARATOR|Group 2 = Core biopsy|in Group B, patients with axillary metastasis identified by CNB underwent repeat biopsy using the same method after completing neoadjuvant treatment.The obtained biopsies were sent for histopathological evaluation without revealing patient names to avoid influencing the research results, and the surgical team was not informed of the biopsy results. During surgery, both dyed lymph nodes and clipped lymph nodes were excised for SLNB and assessed by frozen section evaluation.
62618202|NCT04611776|PLACEBO_COMPARATOR|Arm B: Placebo + platinum-doublet followed by placebo maintenance|
62618203|NCT05964127|ACTIVE_COMPARATOR|Group A - Non-surgical hand instruments|After appropriate local anaesthesia of the treatment site supragingival, subgingival and implant surface debridement will be undertaken with Hu-Friedy titanium implant hand instruments only. Any remaining supragingival deposits will be polished using a contra-angle handpiece, rubber cup and Cleanic polishing paste.
62618204|NCT05964127|ACTIVE_COMPARATOR|Group B - Non-surgical Air-flow|After appropriate local anaesthesia of the treatment site supragingival, subgingival and implant surface debridement will be undertaken using EMS PerioFlow with Plus powder (Erythritol) and supplemented with EMS Piezon and EMS AirFlow and Plus powder as required.
62843822|NCT05357001|EXPERIMENTAL|stretching exercise|exercises to remove muscle spasticity
62843823|NCT02814552|OTHER|High Blood Pressure Consented|Participants will have the following performed: medical history and blood pressure levels will be collected, and blood samples. Then using the HTN PRA App recommendation regarding standard of care medication dosing will be adjusted for optimal blood pressure control.
62843824|NCT02814552|NO_INTERVENTION|De-identified historical data|De-identified historical data will be collect based on age (no dates), blood pressure of treated (noted with medications), blood pressure of non-treated (noted without medications), and list of medications. The data will be compared to the High Blood Pressure Consented group to determine the effect of using the HTN PRA App.
62843825|NCT01644357|NO_INTERVENTION|Dispensing only|Non clinical pharmacists will dispense drugs to patients and usual care will be offered.
62843826|NCT01644357|EXPERIMENTAL|Pharmaceutical care|Patients on experimental group will receive counseling and education on the asthma condition, medication and lifestyle issues. In all visits, the inhaler technique will be reviewed, adherence to treatment and drug related problems were checked. If necessary the patient will be referred to the respiratory specialist to change the medication or to prescribe dose adjustment. Pharmacists document their initial and monthly follow up encounters using a specified form.
62058302|NCT01084512||Healthy group|control subjects
62058303|NCT01084512||Paraplegic group|Paraplegic subjects
62618205|NCT05964127|ACTIVE_COMPARATOR|Group C - Surgical Air-flow|After appropriate local anaesthesia of the treatment site a full thickness mucoperiosteal flap will be raised to adequately expose the tissue defect. Supragingival, subgingival and implant surface debridement will be undertaken using EMS PerioFlow with Plus powder (Erythritol) and supplemented with EMS Piezon and EMS AirFlow and Plus powder as required.
62618206|NCT04723056|NO_INTERVENTION|Control Group (TAU only)|Treatment as Usual (TAU) for IBS patients are tailored to each individual's needs and may involve treatment such as: dietary modification, exercise, medication, and anti-diarrheal therapy.
62618207|NCT04723056|EXPERIMENTAL|Experimental (TAU plus CBT)|Subjects who are in the Experimental Group will receive 8 weeks of CBT from the Zemedy mobile application in addition to their treatment as usual (TAU).
62618208|NCT02983461|PLACEBO_COMPARATOR|Placebo|Double Blind Placebo 3 times a day for 10 weeks.
62618209|NCT02983461|ACTIVE_COMPARATOR|Sildenafil|Double Blind Sildenafil, 20mg x 3 times a day, 10 weeks.
62618210|NCT03592784|EXPERIMENTAL|Food Order Therapy + Medical Nutrition Therapy|
62618211|NCT03592784|ACTIVE_COMPARATOR|Medical Nutrition Therapy Alone|
62618212|NCT02432144|EXPERIMENTAL|UX003|4 mg/kg UX003 every other week (QOW)
62618213|NCT01915771|EXPERIMENTAL|lomitapide|It will comprise of 2 single oral doses with at least a 14-day washout between doses.
62843827|NCT01677377|EXPERIMENTAL|Cohort 1, RBP-7000 60 mg|Participants who were stable on 2 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 60 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 2 mg oral daily risperidone on days 85-87.
62843828|NCT01677377|EXPERIMENTAL|Cohort 2, RBP-7000 90 mg|Participants who were stable on 3 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 90 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 3 mg oral daily risperidone on days 85-87.
62843829|NCT01677377|EXPERIMENTAL|Cohort 3, RBP-7000 120 mg|Participants who were stable on 4 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 120 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 4 mg oral daily risperidone on days 85-87.
62843830|NCT02516852|EXPERIMENTAL|Intervention|
62843831|NCT02516852|NO_INTERVENTION|Control|
62843832|NCT01757925|EXPERIMENTAL|Active Gaming|Participants will receivce a weight management program plus active gaming device
62843833|NCT01757925|ACTIVE_COMPARATOR|Control Group|Participants will receive a weight management program without active gaming
62843834|NCT01186341||Chronic Pain|New or existing patients of the center who are seeking their initial treatment at the Integrative Medicine center for chronic pain (chronic \> 3 months) who report their average pain level over the past month to be at least a 4 of 10 on the Visual Analog Scale.
62843835|NCT00473382|EXPERIMENTAL|Ranibizumab 0.3 mg|Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata \[PRN\]) for up to 24 additional months.
62843836|NCT00473382|EXPERIMENTAL|Ranibizumab 0.5 mg|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata \[PRN\]) for up to 24 additional months.
62843837|NCT00473382|SHAM_COMPARATOR|Sham injection/ranibizumab 0.5 mg|Patients received a sham intravitreal injection monthly for 24 months. Patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata \[PRN\]) for up to 24 additional months.
62843838|NCT04786535|ACTIVE_COMPARATOR|Hemodiafiltration|
62843839|NCT04786535|EXPERIMENTAL|Expanded hemodialysis|
62843840|NCT04786535|EXPERIMENTAL|Conventional high-flux hemodialysis|
62843841|NCT01980667|EXPERIMENTAL|lurbinectedin (PM01183) / cisplatin|Patients will receive cisplatin as a 90-min i.v. infusion. In addition, patients will receive PM01183 as an i.v. infusion over 1-hour.
62618214|NCT01096680|EXPERIMENTAL|SPD489 20 mg|
62843842|NCT05345340|EXPERIMENTAL|Telemedicine Group|Patients will receive an individualized intensive 5-day rehabilitation program (2 hours/day, five days/week, one week) by a qualified physiotherapist at the USD Parkinson's Disease and Movement Disorders Unit of Verona (Italy) followed by an individualized self-management program implemented with the Digital Telemedicine platform support ((PHOEMA G.P.I PLATFORM, GPI spa, Trento, Italy). Telemedicine will consist of 24 tele-sessions (1 h/day, one day/week, 24 weeks) and two self-management sessions (1 h/day, two days/week, 24 weeks). For each patient, the duration of the activity, number of steps taken, distance traveled (km), Kcal consumed, duration of inactivity, total hours of sleep, and number of training sessions performed will be monitored through Polar Vantage M devices.
62843843|NCT05345340|ACTIVE_COMPARATOR|Control Group|Patients will receive the same individualized intensive 5-day rehabilitation program (2 hours/day, 5 days/week, 1 week) of the Telemedicine Group by a qualified physiotherapist at the USD Parkinson's Disease and Movement Disorders Unit of Verona (Italy) followed by a home-based self-management plan (Treatment, as usual, 1 h/day, 3 days/week, 24 weeks) without any Digital Telemedicine platform support.
62618215|NCT01096680|EXPERIMENTAL|SPD489 50 mg|
62618216|NCT01096680|EXPERIMENTAL|SPD489 70 mg|
62618217|NCT01096680|ACTIVE_COMPARATOR|Armodafinil|
62618218|NCT01096680|PLACEBO_COMPARATOR|Placebo|
62843844|NCT03181529|EXPERIMENTAL|Immediate Treatment|Participants will begin psilocybin intervention immediately after study enrollment.
62843845|NCT03181529|EXPERIMENTAL|Delayed Treatment|Participants will begin the psilocybin intervention 8 weeks after study enrollment.
62843846|NCT03924167|EXPERIMENTAL|Families Receiving Weaving Healthy Families Intervention|The Weaving Healthy Families curriculum is a cognitive-behavioral, support group model for high-risk families related to alcohol, tobacco, or other drugs (ATOD) and/or or domestic violence, child abuse, or neglect. This curriculum is tailored for all ages (i.e., (a) parents/caregivers; (b) early childhood (5-7); (c) children (8-11); and (d) adolescent (12-17) and is aimed at reducing alcohol and other drug (AOD) abuse, promote unity, address mental health problems, strengthen parenting skills, and bolster wellness and resilience.
62446718|NCT02985151|PLACEBO_COMPARATOR|Low Energy Placebo Group|Subjects in this group will receive at least two Syneron-Candela CO2RE laser treatments set at the Light mode of the laser at visits three months apart. The Light mode is a low energy setting that superficially cleanses the skin, and would not affect the scar, which is deeper in the skin. Individuals in this group will be offered two optional high energy treatments subsequent to receiving the two light energy treatments.
62446719|NCT01336894|ACTIVE_COMPARATOR|Arm I (SR+Brachytherapy)|Patients undergo sublobar resection comprising either a wedge resection or anatomical segmentectomy with or without intraoperative brachytherapy comprising an iodine I 125 implant at the resection margin.
62618219|NCT05296070|EXPERIMENTAL|Loncastuximab tesirine Cycles 1-6|Patients will be treated with loncastuximab tesirine for a total of 6 cycles on Day 1 (+/-3) of each 21 day (3 week) cycle. The total duration of treatment is approximately 18 weeks (4.5 months)
62618220|NCT05831306|EXPERIMENTAL|Diet A|Modified Diet A
62446720|NCT01336894|EXPERIMENTAL|Arm II (SBRT)|Patients undergo 3 fractions of stereotactic body radiation therapy at 2-8 days apart.
62618221|NCT05831306|EXPERIMENTAL|Diet B|Modified Diet B
62843847|NCT03924167|NO_INTERVENTION|Families who have not yet receive the Weaving Healthy Families|Baseline group --data will be collected prior to receiving the intervention in this stepped-wedge trial design.
62446721|NCT04259606|ACTIVE_COMPARATOR|Cassia Cinnamon|Cassia cinnamon, capsule of 1 gram each, taken every 8 hours before meals for 90 days.
62618222|NCT04685096||Asian skin|Twice-daily application for 55 Days
62618223|NCT04685096||African-American skin|Twice-daily application for 55 Days
62618224|NCT03231137|EXPERIMENTAL|PRGF/ATV|Included 10 patients undergoing single tooth extraction and platelet rich in growth factors fibrin scaffold loaded with Atorvastatin powder (PRGF/ATV) were placed to fill the extraction socket.
62618225|NCT03231137|EXPERIMENTAL|ATV gel|Included 10 patients undergoing single tooth extraction and Atorvastatin gel were placed to fill the extraction socket.
62843848|NCT01885585||Patients with risk of VTE|Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release
62843849|NCT06514495|ACTIVE_COMPARATOR|Virtual reality exposure|Agoraphobic patients receive exposure therapy in virtual reality
62843850|NCT06514495|ACTIVE_COMPARATOR|In vivo exposure|Agoraphobic patients receive exposure therapy in vivo
62843851|NCT02100696|EXPERIMENTAL|Cohort 1: Etrolizumab (Open-Label Induction (OLI) Phase)|Participants assigned to this arm will receive treatment with open-label etrolizumab 105 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) for 14 weeks during the induction phase.
62843852|NCT02100696|PLACEBO_COMPARATOR|Cohort 2: Placebo (Double-Blind Induction Phase)|Participants randomized to this arm will receive treatment with double-blind placebo SC injection Q4W for 14 weeks during the induction phase.
62843853|NCT02100696|EXPERIMENTAL|Cohort 2: Etrolizumab (Double-Blind Induction Phase)|Participants randomized to this arm will receive treatment with double-blind etrolizumab 105 mg SC injection Q4W for 14 weeks during the induction phase.
62618226|NCT03231137|EXPERIMENTAL|PRF|Included 10 patients undergoing single tooth extraction and platelet rich fibrin (PRF) were placed to fill the extraction socket.
62446722|NCT04259606|PLACEBO_COMPARATOR|Calcined Magnesia|Placebo consists in calcined magnesia, capsule of 1 gram each, taken every 8 hours before meals for 90 days.
62618227|NCT03231137|EXPERIMENTAL|PRGF|Included 10 patients undergoing single tooth extraction and plasma rich in growth factors (PRGF) were placed to fill the extraction socket.
62843854|NCT02100696|PLACEBO_COMPARATOR|Placebo Responders: Placebo (Maintenance Phase)|Participants who received placebo during the induction phase, Cohort 2: Placebo (Double-Blind Induction Phase), and achieve a clinical response with placebo at Week 14 will continue to receive blinded placebo from Week 16 up to Week 66 during the maintenance phase.
62843855|NCT02100696|PLACEBO_COMPARATOR|Etrolizumab Responders: Placebo (Maintenance Phase)|Participants who received etrolizumab during the induction phase, Cohort 1: Etrolizumab (Open-Label Induction Phase) and Cohort 2: Etrolizumab (Double-Blind Induction Phase), and achieved a clinical response at Week 14 will be re-randomized by Week 16 for the double-blind maintenance phase. Clinical responders re-randomized to this arm will receive placebo SC injection Q4W from Week 16 up to Week 66.
62058304|NCT01084512||Tetraplegic group|tetraplegic subjects
62058305|NCT04916964|EXPERIMENTAL|Test & Exercise home-based program (T&E)|Eight home-based physiotherapy sessions will occur in two months, once a week
62261748|NCT04039893|OTHER|Node-positive breast cancer patients|All patients with positive lymph nodes for who an axillary node clearance is proposed as part of the surgical treatment
62446723|NCT02587442|EXPERIMENTAL|RadProtect®|RadProtect® is not a full-closed micelle, and uses ferrous iron to provide linkage between PEG-b-PGA and amifostine. Transferrin and other related proteins can chelate with ferrous iron and break the micelle releasing amifostine into the blood stream.
62446724|NCT03265470|EXPERIMENTAL|Dexmedetomidine|Patients received intravenous infusion of dexmedetomidine
62446725|NCT03265470|ACTIVE_COMPARATOR|Fentanyl|Patients received intravenous infusion of fentanyl
62446726|NCT05236075|EXPERIMENTAL|patients with polysomnography diagnostic of obstructive sleep disorders moderate to severe|
62618228|NCT03231137|NO_INTERVENTION|Control|Spontaneously healed socket
62843856|NCT02100696|EXPERIMENTAL|Etrolizumab Responders: Etrolizumab (Maintenance Phase)|Participants who received etrolizumab during the induction phase, Cohort 1: Etrolizumab (Open-Label Induction Phase) and Cohort 2: Etrolizumab (Double-Blind Induction Phase), and achieved a clinical response at Week 14 will be re-randomized by Week 16 for the double-blind maintenance phase. Clinical responders re-randomized to this arm will receive etrolizumab 105 mg SC injection Q4W from Week 16 up to Week 66.
62843857|NCT06338137|OTHER|high-energy patients|Use high energy in stone management
62843858|NCT06338137|OTHER|Low energy patient|Use low energy in stone management
62843859|NCT03494504|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%)|
62843860|NCT03494504|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.5%)|
62843861|NCT03494504|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution|
62618229|NCT05392595|EXPERIMENTAL|Group A|Caw-throne and Cooksey exercise, Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.
62618230|NCT05392595|OTHER|Group B|Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.
62843862|NCT04564157|EXPERIMENTAL|Adjuvant treatment + Adjuvant maintenance treatment|"Adjuvant treatment:~* Paclitaxel: 200mg/m2 infusion over 3 hours~* Carboplatin: AUC5 at the end of the Paclitaxel infusion~* Nivolumab: 360 mg intravenous Q3W~It has to start within 3-10 weeks from surgery and the first administration has to be done within 1-3 days from randomization. 4 cycles will be administered at 21day intervals (QW3) after surgery. A CT-SAN must be done after the 4 cycles of adjuvant treatment. Patients must discontinue treatment if there is evidence of disease relapse.~After the 4 cycles of chemo-immunotherapy the patient will receive:~Adjuvant maintenance treatment: Nivolumab: 480 mg IV Q4W It will start after 4 weeks from day 1 cycle 4 of adjuvant treatment. 6 cycles will be administered every 28 days. A CT-SAN must be done within +/- 7 days from day 28 of the 3rd cycle of adjuvant maintenance treatment and within +/- 7 days at the end of the 6th cycle. Patients must discontinue treatment if there is evidence of disease relapse at 3rd cycle CT-SCAN."
62843863|NCT04564157|ACTIVE_COMPARATOR|Control arm: Adjuvant treatment|"Adjuvant treatment:~* Paclitaxel: 200mg/m2 infusion over 3 hours~* Carboplatin: AUC5 at the end of the Paclitaxel infusion Adjuvant treatment has to start within 3-10 weeks from surgery and the first administration and has to be done within 1-3 days from randomization. 4 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) after surgery. A CT-SAN must be done after the 4 cycles of adjuvant treatment.~Observation: 2 observation visits will be done at 3 months and at 6 months from day 21 of cycle 4 of adjuvant treatment."
62843864|NCT06341920|EXPERIMENTAL|BoneFit intervention|Participants will receive a personalised care plan comprising exercise, nutrition and psychological wellbeing based on individual need in the 8-week period prior to surgery
62618231|NCT04657094|EXPERIMENTAL|Treatment (acalabrutinib)|Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Treatment with acalabrutinib may be continued beyond 12 cycles for a maximum of 36 cycles if, in the opinion of the treating physician, the patient might benefit from ongoing therapy.
62843865|NCT06341920|PLACEBO_COMPARATOR|Control|Participants who are allocated to this group will receive baseline tests and will be invited to re-attend 3 months post surgery to re-do tests. This group will receive usual care (no intervention). The groups will be compared.
62843866|NCT02029248||Children 6-7|Patients who are between 6 and 7 years old
62843867|NCT02029248||Children 8-11|Patients who are between 8 and 11 years old
62843868|NCT02029248||Children 12-16|Patients who are between 12 and 16 years old
62843869|NCT02029248||Patients 17-30|Patients who are between 17 and 30 years old
62843870|NCT01774409|EXPERIMENTAL|Blood and tumor samples|
62618232|NCT03637309|EXPERIMENTAL|BeReady2Smile Video and App|This arm will test the feasibility of the BeReady2Smile Video and App to promote dental health of young children with a parent education program.
62618233|NCT03942926|EXPERIMENTAL|Sirolimus|Patients in sirolimus group will receive sirolimus for 6 months.
62843871|NCT05868434|EXPERIMENTAL|Main arm of the study|Medial Patellofemoral Ligament Reconstruction (MPFLR) With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy will be performed in these patients.
62843872|NCT04440865|ACTIVE_COMPARATOR|Arm 1- Standard colonoscopy|Standard colonoscopy is performed
62843873|NCT04440865|ACTIVE_COMPARATOR|Arm 2- Colonoscopy assisted by Genius|Colonoscopy assisted by Genius artificial intelligence system is performed
62843874|NCT00737815|ACTIVE_COMPARATOR|A|Magnesium citrate: a total of 500 mg of elemental magnesium
62843875|NCT00737815|PLACEBO_COMPARATOR|B|Placebo pills
62843876|NCT06338969|EXPERIMENTAL|Carbohydrate Restriction after a Gastric Bypass: 51-75% deficit in carbohydrates|In the postoperative period, the amount of carbohydrate intake was reduced by counting carbohydrates in a glucose solution in the first three days after surgery and counting carbohydrates in food. Created a carbohydrate deficit of 51-75%.
62843877|NCT06338969|ACTIVE_COMPARATOR|Carbohydrate Restriction after a Gastric Bypass: 26-50% deficit in carbohydrates|In the postoperative period, the amount of carbohydrate intake was reduced by counting carbohydrates in a glucose solution in the first three days after surgery and counting carbohydrates in food. Created a carbohydrate deficit: 26-50% deficit in carbohydrates.
62843878|NCT06338969|ACTIVE_COMPARATOR|Carbohydrate Restriction after a Gastric Bypass:1-25% deficit in carbohydrates|In the postoperative period, the amount of carbohydrate intake was reduced by counting carbohydrates in a glucose solution in the first three days after surgery and counting carbohydrates in food. Created a carbohydrate deficit:1-25% deficit in carbohydrates.
62843879|NCT02476539|EXPERIMENTAL|Hemay022|"Part one: Dose Escalation Group Hemay022 tablets will be taken orally once daily in doses of 50mg, 100mg, 200mg, 300mg,400mg or 500mg daily for 28 days.~Part two: Extension Group Hemay022 tablets will be taken in three dose groups that had been assessed by Part one for 28 days."
62843880|NCT02453672|EXPERIMENTAL|SB8|SB8, single dose of 3 mg/kg, IV infusion
62843881|NCT02453672|ACTIVE_COMPARATOR|EU Sourced Avastin®|EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
62446727|NCT01146132|OTHER|Luxembourg diet + wine|Luxembourg variant of the mediterranean Diet, physical activity with wine consumption
62446728|NCT01146132|OTHER|conventional + wine|conventional Diet with red wine
62446729|NCT01146132|OTHER|conventional|conventional diet without wine
62446730|NCT01146132|OTHER|Luxembourg diet|Luxembourg variant of the mediterranean Diet, physical activity with wine consumption
62446731|NCT02320474|EXPERIMENTAL|Aflibercept|
62618234|NCT02020837|EXPERIMENTAL|Lymphaticovenous Micro-Anastomosis|
62618235|NCT01648192|EXPERIMENTAL|2.5 mg|Losmapimod for single dose
62843882|NCT02453672|ACTIVE_COMPARATOR|US Sourced Avastin®|US Sourced Avastin®, single dose of 3 mg/kg, IV infusion
62843883|NCT04776655|EXPERIMENTAL|Bevacizumab in combination with FOLFIRI chemotherapy|"Bevacizumab will be administrered at a dose of 5 mg/kg iv every 2 weeks. The first dose of Bevacizumab will be administered over 90 minutes. Then, if the first infusion is well tolerated without infusion-related reaction, the second dose will be administered over 60 minutes. Then, if the second dose is also well tolerated without an infusion reaction, all subsequent doses will be administered over 30 minutes.~Dosage form: Intravenous use All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
62843884|NCT04776655|ACTIVE_COMPARATOR|Cetuximab in combination with FOLFIRI chemotherapy|Cetuximab will be administered at a dose of 500 mg/m² iv every 2 week (14 days/cycle) Dosage form: Intravenous use All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
62843885|NCT01311141|EXPERIMENTAL|Doripenem i.v.|no comparator, PK study
62618236|NCT01648192|EXPERIMENTAL|7.5 mg|Losmapimod for single dose
62618237|NCT01648192|EXPERIMENTAL|20 mg|Losmapimod for single dose
62618238|NCT01648192|PLACEBO_COMPARATOR|Placebo|Placebo
62843886|NCT01711216||women received dydrogesterone for irregular menstrual cycle|Adult women received dydrogesterone for irregular menstrual cycle as per standard clinical practice of the treating physician
62843887|NCT00968513|ACTIVE_COMPARATOR|Usual Care|(N=150) brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
62843888|NCT00968513|EXPERIMENTAL|Brief Treatment|(N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization.
62446732|NCT06545123|ACTIVE_COMPARATOR|Resistance exercise training|The main part of RES group session will include free weights, weight machines and calisthenics. Loads will be set and adjusted based on 1 repetition maximum (1RM) method (details are described in Table 2). Exercises will be standardized but exercises may be adapted according to participants limitations. For RES group, the intervention was divided in 2 periods: a) 3- weeks adaptation phase (7-10 exercises; 1-2 sets; 15-20 reps; 40-60% 1RM); b) 9-weeks training phase (8 exercises; 3 sets; 6-12 reps; 70% 1RM; intensity measured by the rate of perceived exertion (RPE) 3-5 on category ratio 10 (CR10) scale progressing to RPE 6-8; resting 60-120 s between sets; 3-5 min between exercises) as recommended (29). Each session will aim at two anatomical regions (upper limbs, torso, back, lower limbs).
62446733|NCT06545123|ACTIVE_COMPARATOR|Aerobic exercise training|The main part of AER group sessions will include treadmill, stationary and elliptical bikes. The intensity throughout these sessions will be measured by heart rate maximum (HRmax) and by RPE 3-5 on CR10 scale progressing to RPE 6-8. The main part of AER group was divided in 3 periods; a) from week 1-2 (50% HRmax: 3x15 min+3min rest); b) week 3-4 (60% HRmax: 2x23min+5min rest); c) week \> 5 (70% HRmax: continuous).
62261749|NCT01692275|ACTIVE_COMPARATOR|Medical Care + Chiropractic Care|Medical care plus chiropractic manipulative therapy
62618239|NCT01648192|EXPERIMENTAL|7.5 mg BID|Losmapimod for repeat dose (14 days)
62618240|NCT01648192|PLACEBO_COMPARATOR|Placebo BID|Placebo
62618241|NCT01841034||Conceptio|Any patient receipt within the framework of the coverage(care) of an infertility in the pole ORG, whatever is the étiologie and the type of treatment proposing and presenting during at least two spermogrammes an oligospermie and\\or an asthénospermie. The necessity of realizing 2 spermogrammes different to determine the pathological character of the values of a spermogramme takes into account the personal variability of the results.
62618242|NCT03538704|EXPERIMENTAL|BMI≥25 group with metformin|Patients with BMI≥25kg/m2 in the experimental group are treated with medroxyprogesterone acetate (MPA) 0.25g/d plus metformin and are followed-up of baseline data, hormone levels,
62618243|NCT03538704|NO_INTERVENTION|BMI≥25 group without metformin|Patients with BMI≥25kg/m2 in the none intervention group are treated with MPA 0.25g/d alone and are followed-up of baseline data, hormone levels, and endometrial pathology every 3 months until 12 months.
62618244|NCT05337995||Non-Specific Low Back Pain patients|Participants must have pain located between the thoracolumbar hinge and the lower gluteal fold, with or without pain in either leg, present for more than 12 weeks, on a daily or almost daily basis (at least 4 days out of 7).
62618245|NCT05337995||Control group|Participant with no current or past chronic pain
62618246|NCT00452153|EXPERIMENTAL|Characterization Legionnella|Characterization Legionnella by polymerase chain reaction (PCR)
62843889|NCT00968513|EXPERIMENTAL|Extended Treatment|(N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
62843890|NCT01585506||Questionnaire responders|
62843891|NCT04535778|EXPERIMENTAL|COMPASS|Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of long-term conditions. Participants will also have access to the standard charity resources.
62843892|NCT04535778|ACTIVE_COMPARATOR|Standard charity resources|Participants will be directed to the standard resources provided by the charities involved in the study.
62843893|NCT03348228|PLACEBO_COMPARATOR|Control Group|Participants willrecord a self-selected diet for 3 days and then perform two 24-hour urine collections on the last 2 days of this diet. HCA will be administered afterwards to both groups (see methods below) for 7 days
62843894|NCT03348228|ACTIVE_COMPARATOR|Calcium Stone Formers|Participants willrecord a self-selected diet for 3 days and then perform two 24-hour urine collections on the last 2 days of this diet. HCA will be administered afterwards to both groups (see methods below) for 7 days
62843895|NCT05615519||Eligible participants for smartphone-based strabismus measurement and diagnosis|Facial videos dataset Facial videos were collected using smartphone and following the programmatic cover tests.
62843896|NCT05219370|EXPERIMENTAL|CBD rich|Cannabis oil oral drops containing 95 mg/ml CBD; 5 mg/ml THC; 15 mg/ml CBDV ; no CBG, once daily Titration from 0.3 to 1.8 ml/day during 21 days
62843897|NCT05219370|EXPERIMENTAL|CBG rich|"Cannabis oil oral drops containing no CBD; 5 mg/ml THC; no CBDV; 95 mg/ml CBG, once daily.~Titration from 0.3 to 1.8 ml/day during 21 days"
62446734|NCT06545123|ACTIVE_COMPARATOR|Concurrent exercise training|The main part of RES+AER group sessions will combine both exercise training protocols. The main parts of this group will start with resistance training using weights, weight machines and calisthenics combined with a main part of moderate aerobic exercises in the treadmill, stationary and elliptical bikes. This intervention was divided into 2 phases: a) a 3-week adaptation period (4-6 exercises; 1-2 sets; 15-20 reps; 40-60% 1RM); b) 9-weeks training phase (4 exercises; 3 sets; 6-12 reps; 60-70% 1RM; intensity measured by the RPE 3-5 on CR10 scale progressing to RPE 6-8; resting 60-120 s between sets; 3-5 min between exercises). Afterward, the moderate aerobic exercise training part will include three phases: 50% HRmax: 1x15 min); b) week 3-4 (60% HRmax: 1x23min); c) week \> 5 (70% HRmax: continuous).
62618247|NCT01026818|EXPERIMENTAL|Tadalafil daily [5 milligrams (mg)]|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
62618248|NCT01026818|EXPERIMENTAL|Tadalafil on demand (20 mg)|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
62843898|NCT05219370|EXPERIMENTAL|CBD & CBG rich|"Cannabis oil oral drops containing 47.5 mg/ml CBD; 2.5 mg/ml THC; 7.5 mg/ml CBDV; 47.5 mg/ml CBG, once daily.~Titration from 0.3 to 1.8 ml/day during 21 days"
62843899|NCT05219370|PLACEBO_COMPARATOR|placebo|Placebo oil oral drops once daily. Titration from 0.3 to 1.8 ml/day during 21 days
62843900|NCT05181293|EXPERIMENTAL|Experimental|A mobile gaming app (BabyThrive) will be disseminated to teenage mothers to help them learn about exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency and dietary diversity. BabyThrive will also demonstrate how to prepare 30 nutritious recipes for complementary feeding; create a calendar and set reminders to prompt mothers to access child health services; and plot growth patterns of the baby to facilitate growth monitoring.
62843901|NCT05181293|NO_INTERVENTION|No Intervention|In addition to routine health services, teenage mothers will receive the BabyThrive app after the intervention is completed. Participants will learn about exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency and dietary diversity. BabyThrive also will demonstrate how to prepare 30 nutritious recipes for complementary feeding; create a calendar and set reminders to prompt mothers to access child health services; and plot growth patterns of baby to facilitate growth monitoring.
62446735|NCT01033474||donor eggs|
62843902|NCT02583737|ACTIVE_COMPARATOR|group lyophilized bone allograft|sinus lifting with tissue bank lyophilized bone filling
62843903|NCT02583737|ACTIVE_COMPARATOR|group freeze bone allograft|sinus lifting with freeze bone bank filling
62843904|NCT06451198|EXPERIMENTAL|indobufen plus ticagrelor|Patients meeting the criteria are randomized before discharge from the hospital and given indobufen 100 mg bid and ticagrelor 90mg bid the second day after randomization. The administration shall last 12 months.
62843905|NCT06451198|ACTIVE_COMPARATOR|aspirin plus ticagrelor|Patients meeting the criteria are randomized before discharge from the hospital and continued aspirin 100 mg qd and ticagrelor 90mg bid. The administration shall last 12 months.
62843906|NCT06444191|EXPERIMENTAL|Cohort 1: Rilzabrutinib|
62843907|NCT06444191|EXPERIMENTAL|Cohort 2: Rilzabrutinib|
62843908|NCT04267484||Older adults with mild cognitive impairment|"WP1, older adults with cognitive impairment will use a GPS tracker for 2 weeks, during which they are asked 1) to keep a daily diary about their activity (travel diary), 2) take the researcher on a walk that they often do (walking interview), and 3) participate in an in-depth interview after 2 weeks, in which their experience with the GPS ans the travel diary data are discussed.~WP2, older adults with mild cognitive impairment, caregivers, health professionals and technology developers will collaborate during group discussion meeting to co-design the e-decision support platform to be adapted.~WP3, older adults with mild cognitive impairment, caregivers and health professionals will then be asked to use the adapted e-decision support platform and fill a survey."
62843909|NCT04155580|EXPERIMENTAL|Part 1|ASTX660 once daily (Days 1-7 and 15-21 per 28-day cycle) + ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
62843910|NCT04155580|EXPERIMENTAL|Part 2|ASTX660 once daily (Days 1-7 and 15-21 per 28-day cycle) as a single agent or in combination with ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
62843911|NCT04155580|EXPERIMENTAL|Part 3|ASTX660 at the recommended dose for expansion identified in Part 2 + ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
62843912|NCT03892304||Adult women with Cystic Fibrosis|Cohort of 164 women diagnosed with Cystic Fibrosis (CF) who were patients at the Cystic Fibrosis Adult Referral Centre in Lyon, France in 2017 (compared to 155 in 2014). Women attending the CF adult centre in 2017 were asked to complete a written questionnaire.
62843913|NCT02670148|EXPERIMENTAL|Chiropractic Care (CC)|Participants in the CC group will receive evaluation and treatment (chiropractic manipulative therapy) from a doctor of chiropractic over a 4 week period.
62843914|NCT02670148|NO_INTERVENTION|Waitlist control group (WC)|Participants allocated to the waitlist control group will not receive any chiropractic treatment during the active study period. These individuals will be scheduled for one additional study visit following allocation. This final study visit will be scheduled 4 weeks after allocation (± 7 days). WC participants are not restricted from receiving any other healthcare during study participation. However, participants in the WC group will be asked not to receive any chiropractic care or spinal manipulation by any other provider during the 4 week intervention period. After WC participants complete the final study visit, they will be offered chiropractic care. This treatment will not be part of the study and no data will be collected at these visits.
62843915|NCT02252939|EXPERIMENTAL|Patients with Trapeziometacarpal (TMC) Arthrosis|Patients presenting to the Orthopaedic Hand Service not seeking care for TMC Arthrosis
62843916|NCT02569749||Group 1|Patients with pacemaker indication (pacemaker already implanted or to be implanted)
62843917|NCT02569749||Group 2|Patients with ICD or CRTD therapy indication (device already implanted or to be implanted)
62618249|NCT01026818|PLACEBO_COMPARATOR|Placebo|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
62843918|NCT02569749||Group 3|Patients with heart failure an preserved LVEF (40-50%)
62843919|NCT02569749||Group 4|Patients with heart failure and reduced LVEF (\<40%)
62446736|NCT01033474||infertile patients|
62446737|NCT00656500|ACTIVE_COMPARATOR|1|Brief assistance with smoking abstinence
62261750|NCT01692275|ACTIVE_COMPARATOR|Conventional Medical Care Only|Conventional medical care only
62261751|NCT01236300|EXPERIMENTAL|Cellvizio system|
62261752|NCT01628471|EXPERIMENTAL|Decitabine + genistein single arm|decitabine injectable, by infusion, 5 ascending doses (60 to 500 mg/m2) genisteine capsules, 3 x 50 mg capsules twice a day
62618250|NCT04598971||Cystitis|Patients with lower UTI will be included in this group
62618251|NCT04598971||Pyelonephritis|Patients with higher UTI will be included in this group
62058306|NCT02727686|EXPERIMENTAL|Water Load (WL) Post-Operative Day 1|All enrolled subjects passing conditions outlined in Intervention are eligible to be included. WL will be calculated (20 mL/kg body weight) and supplied at the bedside. Patient will have 30 minutes to consume WL, or will be excluded.
62058307|NCT03460457|EXPERIMENTAL|TQB2450|
62058308|NCT03076944|ACTIVE_COMPARATOR|Neural agent|UltraEZ. Prophylaxis of the teeth; an application every 48 hours; 4 sessions
62843920|NCT01575626|ACTIVE_COMPARATOR|first sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 0%, 7%, 4%
62843921|NCT01575626|ACTIVE_COMPARATOR|second sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 4%, 7%, 0%
62058309|NCT03076944|ACTIVE_COMPARATOR|Obliterator agent|Enamelast. Prophylaxis of the teeth; an application every 48 hours; 4 sessions
62261753|NCT02443363||Patients After Kidney Transplantation|A total of 300 consecutive patients admitted to routine visit in Transplant Centre with functioning graft longer than 3 months to 10 years
62261754|NCT00767091|ACTIVE_COMPARATOR|Active treatment|A: transdermal rivastigmine at 4.6 mg per day during one month then 9.5 mg per day during 5 months.
62261755|NCT00767091|PLACEBO_COMPARATOR|placebo|transdermal patch of placebo
62261756|NCT01076049|ACTIVE_COMPARATOR|Standard of Care (SoC)|For subjects randomized to the control group, the preferred irrigation solution was chosen by the site's emergency department physician(s).
62261757|NCT01076049|ACTIVE_COMPARATOR|Irrisept|For subjects randomized to the investigational group, Irrisept was used.
62843922|NCT01575626|ACTIVE_COMPARATOR|third sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 7%, 4%, 0%
62843923|NCT01575626|ACTIVE_COMPARATOR|Propofol|General anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model).Following tracheal intubation, concentration of propofol will be decreased till 0.
62261758|NCT00868062|EXPERIMENTAL|1|
62261759|NCT05073107|EXPERIMENTAL|Test: With Dental Monitoring|"Dental Monitoring (DM) Kit + 2-month DM subscription~Required to take intra-oral videos (which will be translated into photographs) using the DM application weekly and it will be monitored by the delegated team members:~* Day 0 (To be taken at the clinic)~* Day 7 (To be taken in the evening after brushing teeth)~* Day 14 (To be taken in the evening after brushing teeth)~* Day 21(To be taken in the evening after brushing teeth)~* Day 28 (To be taken before study Visit 2)~There is a window period of +1 day for the intra-oral videos."
62261760|NCT05073107|NO_INTERVENTION|Control: Without Dental Monitoring|No DM Kit
62261761|NCT05142475|EXPERIMENTAL|Tumor Infiltrating Lymphocytes (TIL)|1x10\^9-5x10\^10 in vitro expanded autologous TILs will be infused i.v. to patients with advanced breast cancer after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
62843924|NCT03770988|EXPERIMENTAL|poziotinib single arm study|Single Arm study
62843925|NCT05942235||Control grup 1|"Among the students enrolled in the surgical diseases nursing course in the fall semester, 42 students will be selected using the research randomizer program. Then, students will be asked to fill in the Wound Healing Process and Care Information Form and the Student Information Form. Then, the wound healing process course will be given as a trainer presentation."
62261762|NCT03023020|OTHER|Abbreviated antiplatelet regimen|"Dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and a single antiplatelet agent is continued until at least 11 months post randomization (i.e. 12 months post stent implantation).~In patients on oral anticoagulants, dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and either Aspirin or Clopidogrel is continued until 5 months post randomization (i.e. 6 months post stent implantation). Oral anticoagulation is continued until at least 11 months post randomization (i.e. 12 months post stent implantation)"
62446738|NCT00656500|EXPERIMENTAL|2|Brief intervention to promote quitline utilization
62446739|NCT04909632|EXPERIMENTAL|To establish metabolite pattern and biomarkers of tongue fur in DM|
62446740|NCT03756753|EXPERIMENTAL|Intervention group- results known|Providers of patients enrolled in this arm of the study will be notified of the point of care respiratory testing results
62446741|NCT03756753|NO_INTERVENTION|Control group- results not known|Providers of patients enrolled in the study will not be notified of the point of care respiratory testing results
62446742|NCT01133821|PLACEBO_COMPARATOR|Placebo|Subjects will receive 20 weeks of an experimental psychotherapy called interpersonal and social rhythm therapy (IPSRT) plus placebo (sugar pill). This condition will be called IPSRT-PLA.
62446743|NCT01133821|EXPERIMENTAL|IPSRT plus quetiapine|Subjects will receive 20 weeks of an experimental psychotherapy called interpersonal and social rhythm therapy (IPSRT) plus the FDA approved medication quetiapine (Seroquel). This condition will be called IPSRT-QUE.
62446744|NCT04782102|EXPERIMENTAL|SOPHIE Intervention|SOPHIE is an online-intervention aiming to reduce social anxiety in adolescents. SOPHIE has 8 modules, one module per week, which lasts about 60 minutes. SOPHIE includes elements of evidence-based psychotherapeutic interventions to reduce social anxiety and of an existing online-intervention for adults with social anxiety adopted to the needs of adolescents. The intervention consists of psychoeducation (how social anxieties arise), application examples (e.g. setting up a personal anxiety cycle or anxiety pyramid, imagination exercise: journey to a safe place), and contains weekly tasks for which regular repetition in everyday life is important (e.g. progressive muscle relaxation, observing anxiety in everyday life, exposures in various situations). At the end of each module, a short quiz allows participants to recall and consolidate what they have learned. The content is presented in video inputs, short explanatory texts, application tasks and quizzes.
62843926|NCT05942235||Experimental 1|The population of the study will consist of students enrolled in the Surgical Diseases Nursing course in the fall and springs semester of the 2022-2023 academic year in the Department of Nursing at the Faculty of Health Sciences of Karadeniz Technical University. The students enrolled in the Surgical Diseases Nursing course in the fall semester will form the control group, while the students enrolled in the spring semester will form the experimental group.
62058310|NCT03076944|ACTIVE_COMPARATOR|Associative approach|UltraEZ and Enamelast. Prophylaxis of the teeth; an application every 48 hours; 4 sessions. In each session, fistly the UltraEZ (neural agent) will be applied and after the Enamelast (obliterator agent.)
62261763|NCT03023020|OTHER|Prolonged antiplatelet regimen|"Aspirin is continued for at least 11 months post randomization (i.e. 12 months post stent implantation), the P2Y12 inhibitor being taken at the time of randomization is continued for at least 5 months and up to 11 months post randomization (i.e. 12 months post stent implantation).~In patients on oral anticoagulants, aspirin and Clopidogrel are continued for at least 2 months post randomization (i.e. 3 months post stent implantation) and up to 11 months post randomization (i.e. 12 months after stent implantation). Either aspirin or Clopidogrel is continued up to 11 months post randomization (i.e. 12 months post stent implantation)"
62261764|NCT05779137|EXPERIMENTAL|Mindfulness based cognitive therapy (MBCT)|62 patients will receive a mindfulness based intervention.
62261765|NCT05779137|NO_INTERVENTION|Treatment as usual (TAU)|62 patients will receive treatment as usual, this will form a (passive) control group to the MBCT group.
62261766|NCT00985803|NO_INTERVENTION|Group Control|
62261767|NCT00985803|EXPERIMENTAL|Endurance|
62261768|NCT00985803|EXPERIMENTAL|Cardiovascular|
62843927|NCT03099278|EXPERIMENTAL|Ezetimibe|
62843928|NCT00233883|EXPERIMENTAL|1|
62843929|NCT00233883|ACTIVE_COMPARATOR|2|
62058311|NCT02536638||Pyelonephritis Group|patients with pyelonephritis
62261769|NCT02967081||Pulp necrosis|
62261770|NCT02967081||Pulpitis (painless)|In this group the dentinal fluid will be sampled/collected twice: Firstly after the removal of the primary caries lesion. Subsequently the cavity will be temporized. Secondly, after removal of the temporary filling material (before final restoration).
62261771|NCT02967081||Irreversible pulpitis|
62261772|NCT02967081||Normal pulp|
62261773|NCT05106322||Liver transplants|Whole liver transplants proposed for organ harvesting from brain-dead donors and assigned by the Biomedicine Agency.
62843930|NCT00710580|EXPERIMENTAL|A|
62843931|NCT00710580|ACTIVE_COMPARATOR|B|
62058312|NCT02536638||Without pyelonephritis Group|patients without pyelonephritis
62261774|NCT04419610|EXPERIMENTAL|Patients with confirmed/suspected C19 given intervention|Intravenous infusion of either placebo or TRV027 at 12mg/hr. Treatment will continue until discharge or for 7 days (whichever is sooner).
62446745|NCT04782102|NO_INTERVENTION|Care-as-usual|Care-As-Usual: all other kinds of interventions are allowed and will be recorded using the Client Sociodemographic and Service Receipt Inventory (Chisholm et al., 2000; Roick et al., 2001)
62843932|NCT00710580|PLACEBO_COMPARATOR|C|
62843933|NCT05380401|OTHER|DHA/ARA supplement|"DHA/ARA supplement throughout the duration of the protocol, d-on"
62843934|NCT05380401|NO_INTERVENTION|No DHA/ARA supplement|"no DHA/ARA supplement throughout the duration of the protocol, d-off"
62058313|NCT02301156|EXPERIMENTAL|Ublituximab + Ibrutinib|Participants will receive ublituximab intravenous (IV) infusion, up to 150 milligrams (mg) once on Day 1, 750 mg on Day 2, 900 mg on Days 8 and 15 of Cycle 1 (Cycle duration=28 days) followed by 900 mg on Day 1 of Cycles 2 to 6 and 900 mg on Day 1 of every 3rd cycle thereafter for up to 62 months along with ibrutinib 420 mg capsules, orally, once daily (QD) in each 28-day cycle for up to 62 months.
62261775|NCT04419610|PLACEBO_COMPARATOR|Patients with confirmed/suspected C19 given no intervention|Saline infusion.
62261776|NCT04994951|EXPERIMENTAL|Qing-Re-Liang-Xue Decoction.|One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation. Triamcinolone Acetonide Acetate and Urea Cream,10g/tube and Calcipotriol Ointment,10g/tube are used alternately. The period of treatment will be 10 weeks.
62261777|NCT04994951|ACTIVE_COMPARATOR|control group|Topical steroids. Triamcinolone Acetonide Acetate and Urea Cream,10g/tube and Calcipotriol Ointment,10g/tube are used alternately. The period of treatment will be 10 weeks.
62261778|NCT05706896|EXPERIMENTAL|Monthly injection|The patients will recive 12 intravitreal injections in one eye and 12 sham injections in the other eye each month
62261779|NCT05706896|EXPERIMENTAL|Bimonthly injection|The patients will receive 6 intravitreal injections in one eye and 6 sham injections in the other eye each two months
62261780|NCT05706896|EXPERIMENTAL|Quarterly injection|The patients will receive 4 intravitreal injections in one eye and 4 sham injections in the other eye each three months
62261781|NCT06438978|EXPERIMENTAL|MTBVAC|30 healthy, BCG vaccinated, HIV negative, adults, aged 18 - 65 years, in whom LTB Infection has been excluded by negative QuantiFERON® (QFT) Gold-Plus assay.
62446746|NCT03603756|EXPERIMENTAL|Cohort 1|Patients with advanced or metastatic esophageal squamous cell carcinoma are to receive SHR-1210 with apatinib and irinotecan injection in cohort 1.
62446747|NCT03603756|EXPERIMENTAL|Cohort 2|Patients with advanced or metastatic esophageal squamous cell carcinoma are to receive SHR-1210 with apatinib and paclitaxel liposome plus nedaplatin in cohort 2.
62446748|NCT00124020|EXPERIMENTAL|Telavancin|
62446749|NCT00124020|ACTIVE_COMPARATOR|Vancomycin|
62446750|NCT01836835||Hyperemesis gravidarum|Women diagnosed with hyperemesis gravidarum admitted to hospital Pregnancy Unique Questionnaire of Emesis (PUQE) and 24 hours self-reported nutritional intake form administered
62446751|NCT01836835||Healthy pregnant women|Women with presumed normal pregnancy Pregnancy Unique Questionnaire of Emesis (PUQE) and 24 hours self-reported nutritional intake form administered
62446752|NCT00783406|EXPERIMENTAL|PF- 00610355|
62446753|NCT00783406|EXPERIMENTAL|PF-00610355|
62446754|NCT00783406|EXPERIMENTAL|PF -00610355|
62446755|NCT00783406|PLACEBO_COMPARATOR|Placebo|
62446756|NCT05067257|EXPERIMENTAL|Resiniferatoxin|15 mcg, 20 mcg, or 25 mcg in 2mL injected once into the epidural space
62446757|NCT05067257|PLACEBO_COMPARATOR|Placebo|2mL injected once into the epidural space
62446758|NCT05067257|NO_INTERVENTION|Concurrent Control|No intervention
62618252|NCT02624622|ACTIVE_COMPARATOR|CHW applies chlorhexidine|Intervention: Chlorhexidine gel 7.1% topical 3 gm applied to the umbilical cord stump in one application. The community health worker is given the chlorhexidine to apply to the umbilical cord stump within 24 hours of delivery of the newborn infant.
62618253|NCT02624622|EXPERIMENTAL|Mother applies chlorhexidine|Intervention: Chlorhexidine gel 7.1% topical 3 gm applied to the umbilical cord stump in one application. Mother is given the chlorhexidine during the first prenatal care visit to apply to the umbilical cord stump within 24 hours of delivery of the newborn infant.
62618254|NCT06313554|EXPERIMENTAL|Surufatinib Combined With Toripalimab and HAIC|"The first week dose of solantinib was 150mg, the second week and the subsequent cycle was 200 mg once a day (QD) orally, Q3W, and the drug was suspended for one day on the day of HAIC;~Toripalimab: 240mg intravenous infusion d1, Q3W;~HAIC: All patients received HAIC treatment on D1. Hepatic arterial perfusion therapy (HAIC) : a treatment cycle every 3 weeks for 4-6 consecutive cycles:~Surufatinib and Toripalimab were administered continuously until intolerable toxicity, disease progression, withdrawal of informed consent, loss of follow-up, and investigator judgment that medication should be discontinued (whichever occurred first)."
62261782|NCT05222373|NO_INTERVENTION|Standard care|Standard care: will include the CHW curriculum focused on diabetes education and connecting individuals to appropriate resources in the community (materials in Spanish and English).
62261783|NCT05222373|ACTIVE_COMPARATOR|CBT-based lifestyle intervention group|CBT-based lifestyle intervention: standard care plus a theoretically-based, diet, activity, and mental health lifestyle intervention integrated within a culturally sensitive curriculum (materials in Spanish and English).
62618255|NCT02284386|EXPERIMENTAL|Bupivacaine SNB + EXPAREL Infiltration|Spinal block with bupivacaine HCl 7.5 mg/mL. Local infiltration of EXPAREL 266 mg.
62618256|NCT01422746|EXPERIMENTAL|metformin|12 weeks metformin, with pre- and post- dexamethasone and ACTH to perform standardized adrenal stimulation testing; dexamethasone and rhCG to perform standardized ovarian stimulation testing
62618257|NCT04478760||Masculinising therapy|Healthy transgender (including non-binary) adults who are on testosterone-containing hormone therapies.
62618258|NCT04478760||Feminising therapy|Healthy transgender (including non-binary) adults who are on oestrogen-containing hormone therapies.
62618259|NCT05476640||National multicenter screening|NGS was performed based on conventional NBS. The relationship between NGS detected gene variation and disease occurrence was studied through follow-up.
62618260|NCT04588844|EXPERIMENTAL|Growth Hormone group|Growth Hormone pretreatment for 6 weeks before ovarian stimulation
62618261|NCT04588844|NO_INTERVENTION|Control group|No pretreatment before ovarian stimulation
62843935|NCT05380401|OTHER|DHA/ARA initially then no supplement|"DHA/ARA supplement from enrollment to 31 6/7 weeks post-menstrual age (PMA) then no supplement from 32 to 36 weeks' PMA, x- on/off"
62618262|NCT04659057|ACTIVE_COMPARATOR|Group L|Lidocaine group; 45 randomly assigned patients.
62618263|NCT04659057|ACTIVE_COMPARATOR|Group D|Demedetomidine group; 45 randomly assigned patients.
62843936|NCT05380401|OTHER|No supplement initially then DHA/ARA supplement|"No DHA/ARA supplement till 31 6/7 weeks' then long-chain polyunsaturated fatty acids (LCPUFA) supplement from 32 to 36 weeks PMA, x-off/on"
62058314|NCT02301156|ACTIVE_COMPARATOR|Ibrutinib|Participants will receive ibrutinib 420 mg capsules, orally, QD in each 28-day cycle up to 62 months.
62261784|NCT05775185||Orbital radiotherapy|The study includes only one group of patients treated with orbital radiotherapy for 2-week period, a total dose of 20 Gy, 2Gy for each session.
62446759|NCT05073575|EXPERIMENTAL|Hyaluronic acid Group|Hyaluronic acid gel will be applied to exposed dental roots surfaces, after scaling and root planing therapy
62446760|NCT05073575|ACTIVE_COMPARATOR|No-hyaluronic acid Group|Only scaling and root planning will be performed on the exposed dental roots surfaces
62446761|NCT01696591||NEUROSTEM®-AD|"A single administration of human umbilical cord blood-derived mesenchymal stem cells through a brain surgery~DOSE A - 250,000 cells per entry site, 3 million cells per brain; DOSE B - 500,000 cells per entry site, 6 million cells per brain"
62618264|NCT04659057|ACTIVE_COMPARATOR|Group DL|Combined lidocaine and dexmedetomidine group. 45 randomly assigned patients.
62618265|NCT04659057|PLACEBO_COMPARATOR|Group C|Control group; 45 randomly assigned patients.
62618266|NCT03404934|EXPERIMENTAL|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid and C-REX DMH/DMHC included in the C-REX Ring-locking Procedure.
62618267|NCT02716922|EXPERIMENTAL|Cervical cerclage|Women randomized to receive cerclage should receive cervical cerclage Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
62618268|NCT02716922|NO_INTERVENTION|No intervention|No cerclage Women randomized to not receive cerclage represent the control arm
62618269|NCT03125850|EXPERIMENTAL|day-ward group|
62843937|NCT02969655|EXPERIMENTAL|Daprodustat|Subjects will receive oral daprodustat once daily and intravenous (IV) darbepoetin alfa placebo once weekly for 52 weeks
62618270|NCT03125850|ACTIVE_COMPARATOR|inpatient group|
62618271|NCT03353181|EXPERIMENTAL|Endoscopic scissors|Endoscopic nasobiliary drainage for malignant hilar biliary strictures at first， and application of endoscopic cutting technique followed.
62618272|NCT03353181|ACTIVE_COMPARATOR|Stent|Standard placement of biliary stent for malignant hilar biliary strictures.
62843938|NCT02969655|ACTIVE_COMPARATOR|Darbepoetin alfa|Subjects will receive IV darbepoetin alfa once weekly and oral daprodustat placebo once daily for 52 weeks
62843939|NCT00887211|ACTIVE_COMPARATOR|ProStent|implant ProStent drug-eluting stents
62261785|NCT06030388|ACTIVE_COMPARATOR|Strength training|"Standardised programme with the following exercises: chest press, leg press, row, leg curl, latissimus dorsi pull down and leg extension in seated resistance machines. Training will be preceded by 7-10 minutes of warm-up and followed by two body-weight exercises for the abdominal and back muscles for two sets as many repetitions as possible, and thereafter cool down and stretches. The set-up of each machine will be recorded in the training diary.~Weeks 1-3 will include two sets of training with 15-20 repetition-maximum (RM) and weeks 4-15 two sets with 8-12 RM. Throughout the intervention, loads will be adjusted to achieve muscle fatigue and approach training to failure during each set with the intent to maximize beta-endorphin release."
62261786|NCT06030388|ACTIVE_COMPARATOR|High-intensity aerobic training|Participants will be recommended to attend spinning classes three times per week. During their first visit to the training venue, they will meet a sports physiotherapist or personal trainer to be introduced to the spinning bike intervention. The intended intensity is ≥ 14 on the Borg rating of perceived exertion scale, equivalent to high intensity training (\>70% of VO2max) with the aim of attaining sufficient stimulus for beta-endorphin release. During weeks 1-3 participants will attend spinning classes for beginners with lower intensity and predominantly seated cycling. They will progress to higher intensity classes with greater variation between seated and standing cycling during week 4-15.
62618273|NCT03416010|NO_INTERVENTION|Control|In addition to standard prenatal care the PregnancyPlus attention control group for 6 weeks will receive 1.5 hours of ACOG-designed patient education pamphlets. Material will include prenatal and post-partum education.. Dr. Gennaro will conduct the training of the attention control group midwives. The same protocol for assessing fidelity for COPE-P also will be used for assessing fidelity to the attention control intervention
62618274|NCT03416010|ACTIVE_COMPARATOR|Intervention|In addition to standard prenatal care the COPE-P intervention group will also receive 1.5 hours each week for 6 weeks the cognitive-behavior skills building program driven by CBT as the theoretical framework by health care providers trained in COPE-P by Dr. Melnyk. The content of the COPE program is driven by the literature review, the theoretical framework, previous studies of COPE interventions with mothers of preterm infants and prior work with pregnant minority women by our team.
62843940|NCT00887211|ACTIVE_COMPARATOR|Firebird|implant Firebird drug-eluting stents
62843941|NCT04951635|EXPERIMENTAL|Almonertinib|
62843942|NCT04951635|PLACEBO_COMPARATOR|Placebo Almonertinib|
62843943|NCT02961101|EXPERIMENTAL|Anti-PD-1 antibody+decitabine|Decitabine will be administrated at 10mg/d on day1 to 5, followed by Anti-PD-1 antibody 200mg on day8 IV Q3 weeks until progression.
62843944|NCT02961101|EXPERIMENTAL|Anti-PD-1 antibody|Anti-PD-1 antibody 200mg IV Q3 weeks until progression.
62261787|NCT06030388|NO_INTERVENTION|Control group|The control group will be recommended to carry on physical activity as usual and not to change their training or dietary habits during the 15-week study period. The control group will be contacted every fourth weeks by a research nurse to follow up on their general well-being and any questions they might have about menopause. After the study period they will be offered individual advise about training from a physiotherapist or personal trainer.
62261788|NCT01294579|EXPERIMENTAL|ofatumumab and bendamustine|"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase and 1000 mg IV every 2 months for 2 years.~Bendamustine 90 mg/m2 was given on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)"
62843945|NCT02961101|EXPERIMENTAL|Anti-PD-1 antibody+chemotherapy|Chemotherapy will be given depends on the cancer type and treatment regimen before enrollment. Chemotherapy was administrated on day1 , followed by Anti-PD-1 antibody 200mg on day2 IV Q3 weeks until progression.
62843946|NCT03158285|EXPERIMENTAL|Group 1: Guselkumab|Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 100.
62058315|NCT04131530||Colon mucosa observed by pCLE|pCLE is used to evaluate the inflammation activity in different parts of the colon mucosa
62261789|NCT04375202|EXPERIMENTAL|Colchicine plus current care|Colchicine 0.5 mg three times a day if weight is less than 100 kg; 1 mg twice a day if weight is more than 100 kg for 30 days or up to discharge. Reduce based on gastrointestinal symptoms appearance at discretion of the Investigator.
62261790|NCT04375202|NO_INTERVENTION|Current care alone|Current care
62261791|NCT06132386||Healthy Volunteers, not taking Tenofovir (TFV) based PrEP|
62261792|NCT06132386||Healthy volunteers, steady state Tenofovir (TFV) based regimen|
62261793|NCT06132386||Persons infected with HIV taking Tenofovir (TFV) and emtricitabine (FTC) based HIV treatment|
62446762|NCT01696591||Control Group|"A group of subjects with comparable demographics (age and gender) and disease characteristics \[Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB)\] as the NEUROSTEM®-AD-treated group, but did not receive the treatment with NEUROSTEM®-AD and were continued on conventional therapy. Restrictions in the concurrent use of drug therapy are as follows:~Patients are, in principle, permitted to continue the drug therapy they were on prior to the enrollment, for the treatment of concurrent illnesses other than Dementia, such as hypertension, diabetes mellitus, or hyperlipidemia.~For drugs used in the treatment of dementia, behavior-modifying drugs can be added to the pharmacological regimen of a subject during the course of the study. However, adding a new cognitive enhancer, such as donepezil, memantine, galantamine, rivastigmine, is not permitted while dose adjustment is permitted given that the drug had been in use prior to the initiation of the study."
62446763|NCT03885102|EXPERIMENTAL|Intervention|12 months intradialytic exercise intervention
62446764|NCT03885102|ACTIVE_COMPARATOR|Usual care|Usual care according to current guidelines
62446765|NCT01795781||Patients receiving a new anticoagulant|Patients are receiving dabigatran for atrial fibrillation or rivaroxaban for osteoarthritis of hip or knee undergoing total hip or knee replacement respectively
62446766|NCT01448083||Neuroendocrine tumor patients|
62446767|NCT01919632|EXPERIMENTAL|Lifestyle|The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. (?) jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
62446768|NCT02311023|EXPERIMENTAL|Intermittent fasting|Patients consume their normal diet for 5 days in the week. On 2 days they only consume 500 Cals if female and 600 Cals if male.
62843947|NCT03158285|EXPERIMENTAL|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab 100 mg at Weeks 0 and 4 then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, and 100) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, and 96) to maintain the blind.
62843948|NCT03158285|EXPERIMENTAL|Group 3: Placebo Followed by Guselkumab|Participants will receive SC placebo q4w from Week 0 to Week 20 and will cross over at Week 24 to receive SC guselkumab 100 mg q4w from Week 24 through Week 100.
62261794|NCT04652323||Control|Twenty-one empty polyethylene tubes remained empty to bewere used as in the control group.
62261795|NCT04652323||ProRoot MTA|ProRoot White MTA mixed according to the manufacturer's' instructions were filled placed into sterile p olyethylene tubules (internal diameter: 1.3 mm internal diameter, x external diameter: 1.6 mm external diameter, x length: 5.0 mm length) sterilized with ethylene oxide gas, as specified by ISO , with using a sterile Llentulo.
62261796|NCT04652323||Medcem MTA|Medcem MTA mixed according to the manufacturer's' instructions were filled placed into sterile p olyethylene tubules (internal diameter: 1.3 mm internal diameter, x external diameter: 1.6 mm external diameter, x length: 5.0 mm length) sterilized with ethylene oxide gas, as specified by ISO , with using a sterile Llentulo.
62446769|NCT02236130|ACTIVE_COMPARATOR|General|General Anesthesia only
62446770|NCT02236130|EXPERIMENTAL|Regional|General Anesthesia combined with regional block
62446771|NCT05543200||All Participants|All men who have a primary diagnosis of BPH with LUTS that are prescribed BPH medications or a surgical intervention.
62446772|NCT00910182||1|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 and treated non-operatively
62446773|NCT00910182||2|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 who underwent emergency surgical treatment
62446774|NCT00910182||3|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 treated non-operatively plus transcatheter arterial embolisation
62446775|NCT01319656|ACTIVE_COMPARATOR|Group A|Intervention group(n = 163)
62446776|NCT01319656|ACTIVE_COMPARATOR|Group B|Delayed intervention (n = 163)
62446777|NCT01319656|NO_INTERVENTION|Group C|No intervention group (n = 163)
62446778|NCT05895253|ACTIVE_COMPARATOR|Control-Vibration|Participants were assessed before and after 60 days of no additional intervention to any ongoing treatment, after seven days of washout, and after receiving 60 days of vibrotactile ground-contact feedback.
62058316|NCT01626222|EXPERIMENTAL|Everolimus & Exemestane|This study will be performed in 300 postmenopausal women with hormone receptor positive locally advanced or metastatic breast cancer progressing following prior therapy with non-steroidal aromatase inhibitors (NSAI) as defined by: 1. Recurrence while on or after completion of an adjuvant treatment including Letrozole or Anastrozole, or 2. Progression while on or following the completion of Letrozole or Anastrozole treatment for locally advanced or metastatic breast cancer. Except for prior use of mTOR inhibitors, there are no restrictions as to the last anticancer treatment prior to enrollment. Patients must have documented evidence of recurrence or progression on last therapy prior to enrollment. Written informed consent must be obtained prior to any screening procedures. The investigator or designee must ensure that only patients who meet all the following inclusion and none of the exclusion criteria are offered enrollment in the study.
62261797|NCT04652323||Medcem Pure Portland Cement|Medcem Pure Portland Cement mixed according to the manufacturer's' instructions were filled placed into sterile p olyethylene tubules (internal diameter: 1.3 mm internal diameter, x external diameter: 1.6 mm external diameter, x length: 5.0 mm length) sterilized with ethylene oxide gas, as specified by ISO , with using a sterile Llentulo.
62261798|NCT06159868|EXPERIMENTAL|Intervention|Structured and individualised physiotherapy in combination with optimised nutrition delivered by s specialist critical care rehabilitation team
62618275|NCT01401543|ACTIVE_COMPARATOR|5 mg LY2452473 + 5 mg Tadalafil|5-mg LY2452473 oral capsule and 5-mg tadalafil oral tablet, administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.
62843949|NCT00498771|ACTIVE_COMPARATOR|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference \& volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
62843950|NCT00498771|NO_INTERVENTION|Control - No Exercise Arm|No exercise will be performed in Control arm. Participants will be evaluated for Circumference \& volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL) at baseline, 6 week, 6 and 12 month.
62843951|NCT01719497||Alcohol|Subjects diagnosed with alcohol dependence
62843952|NCT01719497||Obese|Subjects diagnosed with obesity
62843953|NCT01719497||High Stress|Subjects diagnosed with high stress
62843954|NCT01719497||Healthy|Subjects deemed medically healthy
62843955|NCT01684813|ACTIVE_COMPARATOR|Clopidogrel|This group will receive after PCI the standard dose of clopidogrel, a daily dose of 75 mg.
62261799|NCT06159868|ACTIVE_COMPARATOR|Control|Standard ward based care
62261800|NCT05241730|EXPERIMENTAL|Low GI|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from low glycaemic index carbohydrates per day, the other E-% are fats and proteins.
62261801|NCT05241730|ACTIVE_COMPARATOR|High GI|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from high glycaemic index carbohydrates per day, the other E-% are fats and proteins.
62261802|NCT05241730|EXPERIMENTAL|Low Carb High Fat|The subjects eat ≥ 65 E-% fats and a maximum of 50 g carbohydrates per day.
62843956|NCT01684813|EXPERIMENTAL|Prasugrel|This group will receive after PCI a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by a daily dose of prasugrel (10 mg tablet).
62261803|NCT02657395|EXPERIMENTAL|PriMatrix|Use of PriMatrix as a substitute for a subepithelial connective tissue graft under a coronal positioned flap for root coverage.
62261804|NCT05115838|EXPERIMENTAL|Islatravir 47 mg|Participants receive an ISL 47 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
62843957|NCT04297527|EXPERIMENTAL|Conventional Physiotherapy Group|Group I (18 subjects) received 15 sessions of Conventional Physiotherapy program (CPP) 5 times per week.
62843958|NCT04297527|EXPERIMENTAL|Mulligan Mobilization Group|Mulligan Mobilization was administered 9 sessions (3 days a week, for 3 weeks). .
62843959|NCT04297527|EXPERIMENTAL|Conventional Physiotherapy plus Mulligan Mobilization Group|Conventional Physiotherapy (15 session) plus Mulligan Mobilization Programme (9 session) were applied in this group. CP were applied 5 days a week and CP+MM 3 days a week for 3 weeks.
62843960|NCT00357669|PLACEBO_COMPARATOR|Placebo|
62843961|NCT00357669|EXPERIMENTAL|Brivaracetam 50 mg/day|BRV 50 mg/day
62843962|NCT00357669|EXPERIMENTAL|Brivaracetam 150 mg/day|BRV 150 mg/day
62843963|NCT05942495|EXPERIMENTAL|SFGT|Whitin subject design with one arm; SFGT groep intervention
62843964|NCT01534897|EXPERIMENTAL|GSK2118436|Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.
62261805|NCT05115838|EXPERIMENTAL|Islatravir 52 mg|Participants receive an ISL 52 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
62843965|NCT05388292|OTHER|Development of triage decision support system|"This is a quasi-experimental study with a single-group pre-test and post-test design.~The study consisted of three stages. In the first stage, a structured Query Language Script was developed to evaluate the accuracy and duration of pre-and post-DSS triage decisions. In the second stage (pre-test), the accuracy and duration of pre-DSS triage decisions were evaluated. In the second stage, a DSS was prepared with rule-based decision trees method using the ESI and ATS algorithms and was integrated into the HIMS. In the third and last stage (post-test), the effect of the developed Emergency Triage Decision Support System on triage management was evaluated against the accuracy and duration of triage decisions."
62843966|NCT02586558|ACTIVE_COMPARATOR|Experimental Infant Formula|Milk-based infant formula with prebiotics
62058317|NCT04212364|EXPERIMENTAL|Peer Education|"* During Session 1, participants will be trained in Peer Education and how to use Nasal Narcan. They will be given two Nasal Narcan kit that includes 2 doses. One kit if for their use and one kit is to give someone in their social network after they have trained them in how to use it.~* A week after Session 1, participants will be scheduled for Session 2.~* During session 1 and 2 participants, Index participants will be taught information and skills pertaining to overdose prevention and response and how to train network members in overdose prevention and response.~* At the 2nd session, index participants will be given 1 coupon to give to 1 member from their social network to attend Session 3.~* Session 3 will be a dyad session where Index participants will use their peer mentors' skills to train their network member in overdose prevention and response.~* Index participants will also be invited to up to 3 Booster Session (monthly) after they complete Sessions 1-3."
62843967|NCT02586558|PLACEBO_COMPARATOR|Reference group|Milk-based infant formula without prebiotics
62843968|NCT01157689||Coartem, chloroquine, quinine|All children with a positive malaria test will included. Results will be subanalysed acording to treatment given by routine health staff.
62058318|NCT04212364|ACTIVE_COMPARATOR|Standard of care|"* Participants randomized to this condition will participate in one 1-hour session. This session will be an individual session where the participant will meet with a trained staff member in a private room at the Lighthouse.~* This session will be standard overdose prevention and response information. Participants will also be trained in Narcan administration. Participants will be given 1 nasal Narcan kit.~* At the end of this session, participants will be asked to refer a network member to the study for survey visits"
62058319|NCT03017326|OTHER|Group A Very Low Risk HB|Patients with well differentiated foetal histology will receive 2 cycles of Cisplatin (2x 100mg/m2). Patients will non-well differentiated histology will be followed up only (no intervention).
62058320|NCT03017326|ACTIVE_COMPARATOR|Group B Low Risk HB|Patients who are resected after 2 cycles of Cisplatin will be randomised to receive 4 or 6 cycles of Cisplatin overall (80mg/m2). Patients who are not resected will continue to receive up to 6 cycles of Cisplatin (80mg/m2) until resection.
62261806|NCT05115838|EXPERIMENTAL|Islatravir 57 mg|Participants receive an ISL 57 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
62261807|NCT05115838|PLACEBO_COMPARATOR|Placebo|Participants receive a placebo implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
62446779|NCT05895253|ACTIVE_COMPARATOR|Vibration-Control|Participants were assessed before and after receiving 60 days of vibrotactile ground-contact feedback, after seven days of washout, and after 60 days of no additional intervention to any ongoing treatment.
62446780|NCT02725970||Children's Nutrition Research Center|Survey, no intervention.
62446781|NCT02725970||Western Human Nutrition Research Center|Survey, no intervention.
62623736|NCT04613440|OTHER|Standard of care - Proband-mediated cascade testing|Probands randomized to the standard of care group will be instructed to share a family letter (providing information on the familial mutation) with their FDRs and encourage FDRs to complete genetic testing.
62843969|NCT04128813|ACTIVE_COMPARATOR|Vertical whole body vibration platform.|Use of a rotational whole body vibration platform.
62843970|NCT04128813|ACTIVE_COMPARATOR|Rotational whole body vibration platform|Use of a rotational whole body vibration platform.
62843971|NCT04128813|NO_INTERVENTION|Control group|No intervention.
62446782|NCT02725970||Human Nutrition Research Center On Aging|Survey, no intervention.
62446783|NCT02725970||Delta Obesity Prevention Research Center|Survey, no intervention.
62446784|NCT02725970||Beltsville Human Nutr Research Center|Survey, no intervention.
62843972|NCT05987995|EXPERIMENTAL|Endometrial injury group|Endometrial injury was done on day 3-5 of stimulation, just after the cessation of menstruation. After the insertion of a vaginal speculum, the cervix was cleaned using a sterile saline solution. A pipelle endometrial sampler was introduced gently into the uterine cavity. The inner piston of the catheter was withdrawn to create suction, and injury (scratching) of the endometrium was done by moving the pipelle catheter up and down within the uterine cavity. The obtained tissues were seen in a transparent tube. If no tissues were seen in the tube, the procedure was repeated.
62843973|NCT05987995|NO_INTERVENTION|Control group|no thing is done for this group
62058321|NCT03017326|ACTIVE_COMPARATOR|Group C Intermediate Risk HB|Patients will be randomised to receive Cisplatin (80mg/m2), Carboplatin (500mg/m2) and Doxorubicin (60mg/m2) as SIOPEL-3HR (5 cycles), Cisplatin (100mg/m2), Doxorubicin (60mg/m2) 5-Fluorouracil (600mg/m2) and Vincristine (4.5mg/m2) as C5VD (6 cycles), or 6 cycles of high dose Cisplatin (100mg/m2)
62058322|NCT03017326|ACTIVE_COMPARATOR|Group D High Risk HB|Patients will receive SIOPEL-4 regimen (Cisplatin 70mg/m2, Doxorubicin 30mg/m2) then have surgery. Post surgery, patients with remaining metastases will be randomised to receive 6 cycles of either Carboplatin (500mg/m2) and Doxorubicin (40mg/m2) alternating with Carboplatin (800mg/m2) and Etoposide (400mg/m2), or Carboplatin (500mg/m2) and Doxorubicin (40mg/m2) alternating with Vincristine (3mg/m2) and Irinotecan (250mg/m2). Patients with no metastases will receive the standard treatment of 3 cycles of Carboplatin (500mg/m2) and Doxorubicin (40mg/m2).
62058323|NCT03017326|OTHER|Group E Resected HCC|Patients with an underlying predisposition to HCC through genetic, viral or metabolic conditions will be followed up (no intervention). De novo or fibrolamellar HCC patients will receive 4 cycles of PLADO regimen (Cisplatin (80mg/m2) and Doxorubicin (60mg/m2)) over 4 cycles.
62843974|NCT04587765|EXPERIMENTAL|Extra sports group|The group follows the schedule of school teaching programme. Extra-curricular sports classes will be organized and provided in this group of schools in the afternoon after school until 6 p.m. (Monday to Friday).
62843975|NCT04587765|NO_INTERVENTION|Conventional group|The group follows the schedule of school teaching programme. Students arrange their own after-school time after school.
62843976|NCT03817697||Drug users|The cohort will be constituted of adult patients drug users, substituted/weaned or not, consulting at the Croix-Rousse CSAPA
62058324|NCT03017326|ACTIVE_COMPARATOR|Group F Unresected HCC|Patients will be randomised to receive up to 6 cycles of PLADO (Cisplatin 80mg/m2, Doxorubicin 60mg/m2) with Sorafenib (300mg/m2) or up to 8 cycles of PLADO with Sorafenib and GEMOX (Gemcitabine 1000mg/m2, Oxaliplatin 100mg/m2) with Sorafenib (300mg/m2)
62058325|NCT04836221|EXPERIMENTAL|Intervention|Will receive mHealth support for comorbidity and support from a Community Health Worker by phone
62058326|NCT00259922|PLACEBO_COMPARATOR|Placebo|
62058327|NCT00259922|EXPERIMENTAL|Alvimopan 0.5 mg once daily|0.5 mg once daily (QD)
62058328|NCT00259922|EXPERIMENTAL|Alvimopan 0.5 mg twice daily|0.5 mg twice daily (BID)
62446785|NCT02725970||Grand Forks Human Nutr Research Center|Survey, no intervention.
62446786|NCT05336084|EXPERIMENTAL|Ultradian Sleep/Wake protocol|This study uses an ultradian sleep/wake protocol to examine circadian and homeostatic sleep systems and their contributions to reward and cognitive control function. All participants will undergo the ultradian sleep/wake protocol following a night of sleep in the lab (measured with polysomnography) for 36 hours. The ultradian sleep/wake protocol will last for 36 h, during which every 120-minutes, there will be an 80-minute period of waking, followed by a 40-minute sleep opportunity. A repeat night of sleep will occur at the end of the 36-hour ultradian sleep/wake protocol.
62058329|NCT00369538|ACTIVE_COMPARATOR|1|losartan, hydrochlorothiazide
62446787|NCT02233179|EXPERIMENTAL|Removable Cast Walker|An offloading device that can be removed by the patients
62446788|NCT02233179|ACTIVE_COMPARATOR|Irremovable Cast Walker|A removable cast rendered irremovable using instant total contact cast, so patients cannot remove offloading device.
62843977|NCT01740453|NO_INTERVENTION|Single (no catheter)|ropivacaine single injection : 5 mg/ml 15 ml
62058330|NCT00369538|ACTIVE_COMPARATOR|2|hydrochlorothiazide, losartan
62446789|NCT03445975|EXPERIMENTAL|Experimental|The 3-in-1 perineal care washcloth procedure has been adopted to deliver hygiene care (total or perineal) or baths
62843978|NCT01740453|EXPERIMENTAL|Continuous infusion|Single injection with continuous injection ropivacaine 2 mg/ml 8 ml/h
62843979|NCT04146428|EXPERIMENTAL|clinician-mediated JASPER|This group will consist of the child and therapist having one-on-one, JASPER sessions, twice a week.
62843980|NCT04146428|EXPERIMENTAL|parent-mediated JASPER|This group will consist of the therapist assisting the parent implement JASPER on the child twice a week.
62843981|NCT02679118|EXPERIMENTAL|Sentire|The patients will undergo their laparoscopic gastric bypass, during the operative period at pre-defined time points, a small amount of gas from the abdomen will be withdrawn and analyzed for the device. The laparoscopic gastric bypass will proceed without interference or effect from the device.
62843982|NCT00312195|EXPERIMENTAL|BTDS (5, 10 or 20)|Buprenorphine transdermal patch
62843983|NCT00312195|PLACEBO_COMPARATOR|Placebo to match BTDS|Placebo to match buprenorphine transdermal patch
62843984|NCT00598000||1|Determine the impact, in terms of quality of life (QOL), of minimally invasive, video-assisted thoracic surgery (VATS)
62843985|NCT00598000||2|Determine the impact, in terms of quality of life (QOL), in traditional thoracotomy and anatomic lung resection in early stage lung cancer.
62843986|NCT04303039|EXPERIMENTAL|Treatment A|Single 1.0 mg dose of ABP-671 in the fasted state.
62843987|NCT04303039|EXPERIMENTAL|Treatment B|Single 1.0 mg dose of ABP-671 in the fed state, after a standardized breakfast.
62843988|NCT00916929|OTHER|Implantable Cardioverter Defibrillator (ICD)|Impedance Monitoring Feature in an Implantable Cardioverter Defibrillator (ICD).
62446790|NCT03445975|NO_INTERVENTION|standard|The deliver of hygiene care (total or perineal) or baths has been performed using water and pH neutral soap
62446791|NCT04187651|EXPERIMENTAL|PRP gel application|PRP application for perianal fistula
62446792|NCT01638936|EXPERIMENTAL|BT062|BT062 administered intravenously on days 1, 8 and 15 of each 28-day cycle, and lenalidomide or pomalidomide and dexamethasone administered orally to subjects with relapsed or relapsed/refractory MM
62843989|NCT00916929|OTHER|Cardiac Resynchronization Therapy (CRT-D)|Impedance Monitoring Feature in a Cardiac Resynchronization Therapy (CRT-D) device.
62058331|NCT05786729|EXPERIMENTAL|Intervention Aerobic Exercise (AER)|Consented participants will be randomly assigned to aerobic exercise regimen (AER) + Standard Rehabilitation(R+AER) or Standard Rehabilitation only (R) group. In order to determine the necessary time window for AER exercise treatment, TBI subjects will partake in supervised AER sessions for a period of 12 weeks. After a baseline evaluations follow-ups will take place at take place at weeks 4, 8 and 12. Thus each participants will be evaluated 4 times.
62058332|NCT05786729|ACTIVE_COMPARATOR|Rehabilitation (R)|Participants with traumatic brain injury that are enrolled in a comprehensive rehabilitation program. These participants will receive standard rehabilitation. Given that the duration of the rehabilitative program is variable the duration of participation will be no less than 4 weeks and will not exceed 12 weeks. Activity levels will be monitored.
62618276|NCT01401543|EXPERIMENTAL|LY900010 (particle size #1)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a smaller particle size (d90 = 10 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
62843990|NCT03970915|EXPERIMENTAL|ON (standard warming process + body warmer)|Patients included during the ON periods will constitute the experimental group. Warming will be provided by the body warmer in addition to the standard warming procedure (survival blanket and heating in the emergency vehicle).
62058333|NCT05786729|NO_INTERVENTION|Control (C)|Healthy volunteers' responsiveness to exercise will be compared to TBI responsiveness.
62843991|NCT03970915|SHAM_COMPARATOR|OFF / Control group (standard warming process )|Patients included during the OFF periods will constitute the control group. Warming will be provided by the standard warming procedure : survival blanket and heating in the emergency vehicle.
62843992|NCT03220321|ACTIVE_COMPARATOR|IPS e.max hybrid abutment crown|
62446793|NCT05236946|ACTIVE_COMPARATOR|Upfront Cranial Radiotherapy|Stereotactic radiosurgery or Whole brain radiotherapy upfront in asymptomatic brain metastases
62446794|NCT05236946|EXPERIMENTAL|Observation (Delayed Cranial Radiotherapy)|Observation (Delayed Cranial radiotherapy) of Asymptomatic brain metastases
62446795|NCT06124430||Control Group|Students will take part in the ECOS of the departments scheduled at the end of their internship. Students will use the various revision methods usually offered to them by the faculty or in the emergency department, apart from the ECOX tool. Revision methods are left to their own discretion.
62843993|NCT03220321|EXPERIMENTAL|VITA Enamic hybrid abutment crown|
62843994|NCT02879188|EXPERIMENTAL|Ambulation|Patients will initiate inpatient physical therapy on the day of their surgery including attempted ambulation with an assistive device that is supervised by a physical therapist.
62058334|NCT05358925|EXPERIMENTAL|BPD Videos and Feedback|Ten daily 4-10 minute psychoeducational videos about BPD and personalized feedback about performance on neuropsychological tasks.
62058335|NCT05358925|EXPERIMENTAL|BPD Videos and No Feedback|Ten daily 4-10 minute psychoeducational videos about BPD.
62058336|NCT05358925|SHAM_COMPARATOR|Non-BPD Videos and No Feedback|Ten daily 4-10 minute educational videos about health-related topics other than BPD.
62058337|NCT05083143||COVID-19 Testicular Cancer|Patients diagnosed with testicular cancer in the COVID-19 period
62446796|NCT06124430||ECOX Interventional Group|Students will take part in the ECOS of the departments scheduled at the end of their internship. Students will use the ECOX tool available in the emergency department to practice before taking the on-duty OSCEs.
62446797|NCT00913965|EXPERIMENTAL|1|Atenolol Tablets 100 mg (Cord Laboratories)
62446798|NCT00913965|ACTIVE_COMPARATOR|2|Atenolol Tablets 100 mg (Stuart Pharmaceutical)
62446799|NCT02518685|EXPERIMENTAL|TransPyloric Shuttle (TPS)|TransPyloric Shuttle plus Lifestyle Counseling
62446800|NCT02518685|SHAM_COMPARATOR|Control|Sham procedure plus Lifestyle Counseling
62446801|NCT01375933|ACTIVE_COMPARATOR|NicVAX - Phase 3 Lot|NicVAX - Phase 3 Lot
62446802|NCT01375933|ACTIVE_COMPARATOR|NicVAX - Commercial Lot|NicVAX - Commercial Lot
62261808|NCT02281370|EXPERIMENTAL|SEQUENCE D0, D1, D2|Participants will receive treatment D0 in treatment period 1, D1 in treatment period 2 and D2 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 milligram (mg), D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
62261809|NCT02281370|EXPERIMENTAL|SEQUENCE D1, D0, D2|Participants will receive treatment D1 in treatment period 1, D0 in treatment period 2 and D2 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 mg, D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
62261810|NCT02281370|EXPERIMENTAL|SEQUENCE D1, D2, D0|Participants will receive treatment D1 in treatment period 1, D2 in treatment period 2 and D0 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 mg, D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
62261811|NCT01667770|ACTIVE_COMPARATOR|surgery - autologous graft|surgical intervention: decompression of Chiari malformation by suboccipital craniectomy using autologous graft
62446803|NCT01047345|EXPERIMENTAL|9vHPV Vaccine|Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.
62261812|NCT01667770|ACTIVE_COMPARATOR|surgery - non-autologous graft|surgical intervention: decompression of Chiari malformation by suboccipital craniectomy using using non-autologous graft
62618277|NCT01401543|EXPERIMENTAL|LY900010 (particle size #2)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with an intermediate particle size (d90 = 25 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
62843995|NCT02879188|ACTIVE_COMPARATOR|Standing|Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
62843996|NCT02757716|OTHER|Sleeve Gastrectomy|Obese patients who undergo sleeve gastrectomy fill in questionnaire
62843997|NCT02757716|OTHER|Roux-en-Y-Gastric Bypass|Obese patients who undergo roux-en-y-gastric bypass fill in questionnaire
62843998|NCT02757716|OTHER|One anastomosis-Gastric Bypass|Obese patients who undergo one anastomosis gastric bypass fill in questionnaire
62843999|NCT04473469|EXPERIMENTAL|Cystometrogram|The bladder will be filled to different volumes and electrical stimulation will be applied to the pudendal nerve via the implanted neurostimulator.
62844000|NCT01273753|ACTIVE_COMPARATOR|Exercise|After baseline measurements, all subjects will undergo a phase involving intradialytic exercise. Subjects will serve as their own controls.
62261813|NCT05559190|EXPERIMENTAL|Pulsed electromagnetic field and selected graduated abdominal exercises (group A)|The interventions were done preoperatively, received pulsed electromagnetic therapy (PEMFT) on abdominal muscles,15 Hz frequency, 20 gauss amplitude with a rectangular waveform, for 20 minutes then they performed the selected graduated abdominal strengthening exercises for 30 minutes, three sessions per week for six weeks.
62261814|NCT05559190|ACTIVE_COMPARATOR|Selected graduated abdominal exercises (group B)|The interventions were done preoperatively, patients performed the selected graduated abdominal strengthening exercises for 30 minutes, three sessions per week for six weeks.
62844001|NCT01500681||Maintenance PLEX|
62261815|NCT05559190|ACTIVE_COMPARATOR|Pulsed electromagnetic field (group C)|The interventions were done preoperatively, they received pulsed electromagnetic therapy (PEMFT) on abdominal muscles,15 Hz frequency, 20 gauss amplitude with a rectangular waveform, for 20 minutes only.
62844002|NCT04894331||SNAS patients|Patients with (a) history of SNAS (coexistence of typical cutaneous and gastrointestinal symptoms); (b) positive Ni-patch test; (c) clinical improvement of at least 70% from baseline after 4 weeks of low-Ni diet; (d) positivity of a double-blind placebo-controlled oral Ni challenge (DBPCO). Exclusion criteria include (a) age \< 18 years and \>65 years; (b) other organic gastrointestinal diseases, such as peptic ulcer, inflammatory bowel diseases, celiac disease, gastrointestinal infections, and small intestinal bacterial overgrowth; (c) diabetes mellitus; (d) hepatic, renal or cardiac dysfunction; (e) thyroid disease or tumour; (f) concomitant treatment with steroids and/or antihistamines in the previous 4 weeks; (g) pregnancy and lactation; (h) smoking, abuse of alcohol, coffee, tea, and cola intake, and (i) inability to give written informed consent.
62844003|NCT01306344||Patients|Heterogeneous groups of patients (age, gender)
62844004|NCT01306344||Nurses|Heterogeneous groups of nurses (age, gender, working experience)
62844005|NCT01306344||Physicians|Heterogeneous groups of physicians (age, gender, working experience)
62844006|NCT04580992||Ajmaline group|
62844007|NCT03759353|ACTIVE_COMPARATOR|Lactoferrin Group|Includes 49 pregnant women receiving lactoferrin 100 mg one sachet twice daily for 30 days to be dissolved in 1/4 glass of water before meals (Pravotin (R) , Hygint pharmaceuticals). Baseline ferritin level will be obtained and compared to follow up ferritin level after 30 days of treatment.
62058338|NCT05083143||PreCOVID-19 Testicular Cancer|Patients diagnosed with testicular cancer before the COVID-19 period
62261816|NCT05559190|NO_INTERVENTION|Control group|Patients were instructed to presume in normal activities of daily living preoperatively, without any abdominal exercises or PEMFT.
62261817|NCT05035615||Remnant/ Leftover specimens|Specimens that meet inclusion/exclusions criteria, are leftover from routine flow cytometry testing, and are from subjects having or suspected of having a hematological or non-hematological disorder.
62446804|NCT01047345|PLACEBO_COMPARATOR|Placebo|Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.
62844008|NCT03759353|ACTIVE_COMPARATOR|Ferrous Sulfate Group|Includes 49 pregnant women receiving 200 mg of dried ferrous sulfate tablet once daily for 30 days on empty stomach but may be taken with meals to avoid stomach upset (Feosol (R) , Meda pharmaceuticals). Baseline ferritin level will be obtained and compared to follow up ferritin level after 30 days of treatment.
62058339|NCT00903786|EXPERIMENTAL|Perampanel|"Participants were treated with the perampanel dose that was administered in maintenance period of Study E2007-J081-231 (Study 231) \[NCT00849212\]. In some instances, a 1-step down-titration from the viewpoint of safety and up-titration to the maintenance dose of Study 231 was allowed. In general, 1 to 6 tablets of perampanel was administered orally as a 2-milligram (mg) tablet (2 mg to 12 mg) once daily before bedtime (under fed conditions as much as possible).~The investigator, or subinvestigator, was allowed to complete the treatment by tapering the study drug after end of treatment or discontinuation (Follow-up Period), as appropriate. The taper period was 4 weeks at the longest."
62058340|NCT02504125|EXPERIMENTAL|Receving TXA, Study group|Tranexamic acid, Study group tranexamic acid 1g, intravenous injection, pre-operationally
62058341|NCT02504125|PLACEBO_COMPARATOR|Normal saline, Control group|Not receiving tranexamic acid, Control group Normal saline 100mL, intravenous injection, pre-operationally
62058342|NCT04199260||Papilocare|all patients gonna received papilocare treatment as per usual practice.
62058343|NCT02421562|EXPERIMENTAL|training in hypnoanalgesia|training nurses in hypnoanalgesia to perform painful procedure in children
62058344|NCT04437095|EXPERIMENTAL|PSBPS Audiorecording|Thirty minute daily administration of audio recording containing messages of psychological support based on positive suggestion delivered via headphones
62058345|NCT04437095|NO_INTERVENTION|Control|Standard of care
62058346|NCT02712125|ACTIVE_COMPARATOR|isosorbide mononitrate|Received 20 mg isosorbid mononitrate (IMN) (Effox, Mina Pharma Co, Egypt; under license of Schwartz Pharma, Germany) vaginally once daily until delivery
62058347|NCT02712125|PLACEBO_COMPARATOR|Control|Received placebo vaginal tablets once daily until delivery
62058348|NCT04918225||Progressive Multiple Sclerosis patients|Progressive Multiple Sclerosis patients
62058349|NCT04918225||Healthy Volunteers|Healthy Volunteers
62058350|NCT04196998|ACTIVE_COMPARATOR|ETV group|50 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
62058351|NCT04196998|ACTIVE_COMPARATOR|TDF group|50 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
62058352|NCT04196998|EXPERIMENTAL|TAF group|50 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
62058353|NCT04074590|EXPERIMENTAL|LYS006|Experimental drug
62058354|NCT04074590|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62058355|NCT02810093||Breast cancer patients between 2000 and 2016|Patients treated for a breast cancer between 2000 and 2016 in the Hospital of Strasbourg (France).
62058356|NCT05319249|EXPERIMENTAL|NK cells combined with PARP inhibition|Combination of NK cell therapy and PARP inhibition by Talazoparib after immunosuppression with cyclophosphamide and fludarabine
62058357|NCT03393832||Oral Care with Mother's Milk|All infants admitted to the Texas Children's Hospital NICUs who have mother's milk available will receive oral care with mother's milk.
62058358|NCT03393832||Oral Care with Sterile Water|Infants will receive oral care with sterile water when mother's milk is not available.
62058359|NCT06363422||Surgical|
62058360|NCT04802343|EXPERIMENTAL|BAY1817080 dose escalation|Healthy male subjects will receive BAY1817080 dose 1 and dose 2 as a single oral dose and BAY1817080 dose 3 as a single oral dose on Day 1 and twice daily (BID) from Day 7 to Day 16 followed by a last dose in the morning of Day 17.
62261818|NCT05564975||Hospital-acquired pressure injury group|According to the hospital adverse event management system, patients diagnosed with pressure injury in the hospital were included in the HAPI group, and patients who reported high risk of pressure injury during the same period were selected and included in the non-HAPI group.
62058361|NCT04802343|PLACEBO_COMPARATOR|Placebo|Healthy male subjects will received corresponding placebo.
62058362|NCT02184702||shoulder arthroscopy|
62058363|NCT01463280|EXPERIMENTAL|tumescent lidocaine infiltration|Assess Platelet function with respect to dosage of tumescent lidocaine There is only one arm.
62058364|NCT03245385|EXPERIMENTAL|Treatment with topical halobetasol spray 0.05%|Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.
62058365|NCT06197906|OTHER|DM self-control group|
62058366|NCT02600884|EXPERIMENTAL|Families Talking Together Plus (FTT+HPV)|Parents in the experimental group will attend a 1-hour intervention session, receive program materials to use with youth at home, and receive 2 booster phone calls post-intervention. Content of the experimental intervention includes parent-child sexual health communication and HPV vaccination navigation.
62058367|NCT02600884|ACTIVE_COMPARATOR|Brief motivational interviewing (BMI)|Parents in the brief motivational interviewing (BMI) group will attend a 1-hour intervention session, receive program materials to use with youth at home, and receive 2 booster phone calls post-intervention. Content of the control intervention includes obesity prevention strategies using motivational interviewing.
62844009|NCT05904418|OTHER|Young, healthy volunteers|"1. Medical History (20 minutes)~2. Clinical examination (20 minutes)~3. Clothes changing time (15 minutes)~4. ULD CT scan of the vertebra L1 to S1 (30 minutes)~5. Clothes changing time (15 minutes)~6. Handheld US scan of the vertebra L1 to S1 (20 minutes)~7. Platform changing time (15 minutes)~8. Path planning and robot-assisted US Scan of the vertebra L1 to S1 (40 minutes)~9. Clothes changing time (15 minutes)~10. Volunteer Questionnaire (10 minutes)~Total study time per volunteer: 3 Hours 20 minutes"
62844010|NCT05755243||Biopsy performed|after 10 days of use, the sensor is removed and the biopsy performed
62844011|NCT04014868|EXPERIMENTAL|Nasal high-flow|"Patients will perform a constant workload exercise testing (75% of the maximal workload achieved during a previously performed incremental cardiopulmonary exercise testing) with active nasal high-flow :~Flow : 30 L/min; Temperature : 34°C;~The device will be out of sight of the patient. The device allow for oxygen supplementation (fitting on the back of the device). Usual oxygen prescription (if any) will be adjusted to reach a transcutaneous oxygen saturation superior to 90%. A second fitting will be placed just before the nasal canula to allow for oxygen supplementation during the sham nasal high-flow (device turned OFF) test.~Due to the cross-over design of the study, all patients will perform both interventions."
62844012|NCT04014868|SHAM_COMPARATOR|Sham nasal high-flow|"Patients will perform a constant workload exercise testing (75% of the maximal workload achieved during a previously performed incremental cardiopulmonary exercise testing) with a sham nasal high-flow :~The procedure will be exactly the same but the device (out of sight of the patient) will be turned OFF. Oxygen supplementation will be possible through the fitting placed just before the nasal canula.~Due to the cross-over design of the study, all patients will perform both interventions."
62844013|NCT01732718|EXPERIMENTAL|Atorvastatin, then Placebo|Participants first received Atorvastatin 40 mg tablets once daily for 6 weeks. After a washout period of 4 weeks, they then received placebo (matching Atorvastatin 40 mg tablets) once daily for 6 weeks.
62844014|NCT01732718|PLACEBO_COMPARATOR|Placebo, Then Atorvastatin|Participants first received Placebo (matching Atorvastatin 40 mg tablets) once daily for 6 weeks. After a washout period of 4 weeks, they then received Atorvastatin 40 mg tablets once daily for 6 weeks.
62844015|NCT01890603|EXPERIMENTAL|Care Coordination Arm|
62058368|NCT03617848||Cohort|A cohort of participants with suspected stable HFpEF will be recruited from the primary care setting. HFpEF diagnosis will be confirmed as per the 2016 European Society of Cardiology (ESC) guidelines for diagnosing HFpEF. All participants will undergo a series of assessments including but not limited to pulse wave velocity, 6 minute walk test, blood tests including natriuretic peptides (NT-Pro-BNP), ECG, physical assessments and a series of questionnaires. Those with confirmed HFpEF will be followed up at 6 and 12 months.
62844016|NCT01890603|ACTIVE_COMPARATOR|Quality Measure Improvement|
62446805|NCT02688894||Small cell lung cancers|To provide molecular characteristics of Small cell lung cancers to proceed SUKSES trial, To assess success rate of molecular profiling of Small cell lung cancers
62446806|NCT03714100|EXPERIMENTAL|MFBB intervention|All participants will attend Tai Ji Quan: Moving for Better Balance classes twice a week for 16 weeks. Groups of participants will gather at a local community site that has videoconferencing capabilities. The instructor will be teaching the class from a different location via a live video feed.
62844017|NCT05066932||Familial Hypercholesterolemia and hyperTriglyceridemia|Patients with Familial Hypercholesterolemia and hyperTriglyceridemia
62844018|NCT05066932||Familial Hypercholesterolemia without hyperTriglyceridemia|Patients with Familial Hypercholesterolemia and without hyperTriglyceridemia
62058369|NCT05199363|ACTIVE_COMPARATOR|Information leaflet|"Before examination study participant will obtain an information leaflet which includes descriptive and illustrative sections Information for young patients and their caregivers. What is Magnetic Resonance Imaging and what is the examination like?"
62844019|NCT01512511|EXPERIMENTAL|nitrous oxide|use nitrous oxide for pneumoperitoneum creation
62844020|NCT01512511|PLACEBO_COMPARATOR|carbon dioxide|use carbon dioxide for pneumoperitoneum creation
62844021|NCT00433043|ACTIVE_COMPARATOR|1|CRT and b-blocker uptitration to target dose
62844022|NCT00433043|ACTIVE_COMPARATOR|2|CRT and continuation of entry b-blocker dose to 6 month evaluation
62844023|NCT02427464|EXPERIMENTAL|Engensis (VM202)|"Subjects randomized to the Engensis (VM202) treatment arm received the following intramuscular injections in each calf:~* Day 0 - 16 injections of 0.5mL of VM202 / calf~* Day 14 - 16 injections of 0.5mL of VM202 / calf~* Day 90 - 16 injections of 0.5mL of VM202 / calf~* Day 104 - 16 injections of 0.5mL of VM202 / calf"
62844024|NCT02427464|PLACEBO_COMPARATOR|Placebo|"Subjects in the placebo control group received the following intramuscular injections in each calf:~* Day 0 - 16 injections of 0.5mL of VM202 vehicle / calf~* Day 14 - 16 injections of 0.5mL of VM202 vehicle / calf~* Day 90 - 16 injections of 0.5mL of VM202 vehicle / calf~* Day 104 - 16 injections of 0.5mL of VM202 vehicle / calf"
62058370|NCT05199363|ACTIVE_COMPARATOR|Educational movie|"Before examination study participant will be shown educational video with an radiology technologist and actors who role play the examination What is MRI and what is the examination like?"
62261819|NCT05564975||No-hospital-acquired pressure injury group|According to the hospital adverse event management system, patients diagnosed with pressure injury in the hospital were included in the HAPI group, and patients who reported high risk of pressure injury during the same period were selected and included in the non-HAPI group.
62261820|NCT06210074|EXPERIMENTAL|Main Study Arm|Women attending for routine colposcopy clinics as part of standard of care will be provided with the opportunity to participate and get tested with the Daye Diagnostic Tampon. Initial notice of the study will be via a patient information sheet sent with the colposcopy invitation
62844025|NCT02578758|EXPERIMENTAL|Transdiagnostic Internet-Based Protocol|Intervention group that carries out the Transdiagnostic Internet-Based Protocol and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages).
62261821|NCT01555528||Growth Disorders|
62261822|NCT02648802|EXPERIMENTAL|Cavity shaving and CM assessment|Standardized BCS with additional cavity shaving before CM assessment.
62261823|NCT02648802|PLACEBO_COMPARATOR|CM assessment|Standardized BCS with CM assessment.
62058371|NCT05199363|ACTIVE_COMPARATOR|Demonstration|"Before examination study participant will take a part in scenario-based demonstration with the use of props such as the scanner model and a multimedia presentation Scenario for a demonstration before a Magnetic Resonance examination for young patients and their caregivers."
62058372|NCT05199363|NO_INTERVENTION|Control|Study participant will obtain standard information about magnetic resonance imaging before examination.
62844026|NCT02578758|EXPERIMENTAL|Transdiagnostic Internet-Based Protocol+Positive Affect|Intervention group that carries out the Transdiagnostic Internet-Based Protocol+Positive Affect component and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages).
62844027|NCT02578758|OTHER|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
62844028|NCT03723304||Direct liver transplant|All the cases listed for liver transplantation and then transplanted/dropped-out without undergoing any neo-adjuvant loco-regional treatment
62844029|NCT03723304||Bridging followed by transplant|All the cases listed for liver transplantation and then transplanted/dropped-out after undergoing at least one neo-adjuvant loco-regional treatment
62058373|NCT05239325|ACTIVE_COMPARATOR|Intervention Group|"Participants having previously attended at least once in previous years the World Cancer Day Walk will be considered as the group exposed to the health education intervention (returning)."
62058374|NCT05239325|NO_INTERVENTION|Control Group|"The control/non-exposed group will be the participants who are attending the World Cancer Day Walk for the first time in 2022 (first timers) and have not yet received health education information."
62058375|NCT06016010|EXPERIMENTAL|Standard-dose USL group|2 tablets(1 USL, 1 placebo) b.i.d for 12 weeks
62261824|NCT02700724|OTHER|Observation|Patients will not undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Surgery will commence after 12 months of observation or sooner if cystoscopic evidence of disease progression or patient desire.
62446807|NCT04529642||Stroke Group|Inclusion criteria were as follows: age above 18, Mini-Mental State Examination ≥ 24, ability to provide written informed consent and to understand the test instructions, and the presence of a single stroke. Exclusion criteria were as follows: more than one stroke, stroke area other than the cerebral cortex, or concomitant neurological disease and pathology of the locomotor system. This group has been analysed also dividing the subjects according to the stroke phase in 3 subgroups: Acute phase group, Subacute phase group, Chronic stroke group
62446808|NCT04529642||Healthy Group|Healthy subjects age matched with the stroke group
62844030|NCT02615639|EXPERIMENTAL|HPDC-T cells & entecavir|HPDC-T cells 1-5×10\^5 intravenous injection, every 2 weeks for 24 weeks , and entecavir(ETV) 0.5mg tablet by mouth, every night.
62844031|NCT02615639|ACTIVE_COMPARATOR|entecavir|entecavir 0.5mg tablet by mouth, every night.
62844032|NCT02615639|EXPERIMENTAL|HPDC-T cells & IFN-a-2a|HPDC-T cells 1-5×10\^5 intravenous injection, every 2 weeks for 24 weeks ,and IFN-a-2a 180ug subcutaneous injection， every week for 9 months.
62844033|NCT02615639|ACTIVE_COMPARATOR|IFN-a-2a|IFN-a-2a 180ug subcutaneous injection， every week for 9 months.
62058376|NCT06016010|EXPERIMENTAL|High-dose USL group|2 tablets(2 USL) b.i.d for 12 weeks
62058377|NCT06016010|PLACEBO_COMPARATOR|Placebo group|2 tablets(2 placebo) b.i.d for 12 weeks
62058378|NCT02916602|EXPERIMENTAL|Treatment|HCP1401
62058379|NCT02916602|ACTIVE_COMPARATOR|Reference|HCP0605
62058380|NCT04618601|ACTIVE_COMPARATOR|High-dose spironolactone|Participants in this arm will receive high doses of per os spironolactone, defined as doses ≥100 mg daily, on top of standard of care treatment for acute heart failure
62058381|NCT04618601|NO_INTERVENTION|Standard of care|Participants in this arm will standard of care treatment for acute heart failure, which may include per os spironolactone at a maximum dose of 50 mg daily
62058382|NCT03919812|EXPERIMENTAL|Vitamin D supplementation according to baseline Vitamin D|The intervention provided according to the participants' state of vitamin D sufficiency. vitamin D sufficient participants received 800 IU cholecalciferol (syrup containing 400 IU cholecalciferol per measuring spoon, Gracia Pharmindo, Indonesia) daily for 8 weeks, while those who had insufficient or deficient vitamin D level consumed 2000 IU daily. Compliance was systematically monitored using drug monitoring diary evaluated by researchers. Blood samples for the study objectives were taken at enrollment and after eight weeks of cholecalciferol supplementation during routinely scheduled visits to the clinic.
62058383|NCT00228696|NO_INTERVENTION|screening|this is a screening study and no intervention.
62058384|NCT02985983|EXPERIMENTAL|Brodalumab|Brodalumab administered SC
62058385|NCT02985983|PLACEBO_COMPARATOR|Placebo|Placebo administered SC
62058386|NCT04797091||Patients with SARS-CoV-2-infection|Patients with evidence of SARS-CoV-2-infection
62446809|NCT03252795|EXPERIMENTAL|Uterus transplantation|
62844034|NCT02615639|EXPERIMENTAL|HPDC-T cells & Telbivudine|HPDC-T cells 1-5×10\^5 intravenous injection, every 2 weeks for 24 weeks ,and Telbivudine 600mg tablet by mouth, every night.
62844035|NCT02615639|ACTIVE_COMPARATOR|Telbivudine|Telbivudine 600mg tablet by mouth, every night.
62618278|NCT01401543|EXPERIMENTAL|LY900010 (particle size #3)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a larger particle size (d90 = 40 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
62618279|NCT03529799|EXPERIMENTAL|Injured Participants|Participants with mild traumatic brain injury (mTBI) tested using the I-PAS goggles
62618280|NCT03529799|ACTIVE_COMPARATOR|Uninjured Participants|Participants with no mild traumatic brain injury (mTBI) tested using the I-PAS goggles
62618281|NCT05382013|EXPERIMENTAL|Trial Group|30 patients receive treatment of avatrombopag, DPMAS, LPE, and comprehensive internal medical treatment.
62618282|NCT05382013|ACTIVE_COMPARATOR|Control Group|30 patients receive treatment of DPMAS, LPE, and comprehensive internal medical treatment.
62618283|NCT03326518|EXPERIMENTAL|Lumentin® 44|Contrast agent
62618284|NCT03326518|ACTIVE_COMPARATOR|Diluted Omnipaque®|Contrast agent
62618285|NCT03326518|ACTIVE_COMPARATOR|Movprep®|Contrast agent
62058387|NCT04797091||Control group|Controls will be identified retrospectively at the same hospitals that based on matching of demographics, underlying diseases and duration of hospitalization.
62058388|NCT05322070|EXPERIMENTAL|Fluocinolone Acetonide 0.18 mg|Fluocinolone Acetonide Intravitreal Implant 0.18 mg
62058389|NCT00711815||UA|HPV positive
62058390|NCT04816019|EXPERIMENTAL|Group 1a: Low Dose|"A single, Covid-19 vaccine naive volunteer will receive a single dose of 5x10\^9vp ChAdOx1 nCOV-19 IN.~Volunteers in Group 1a \& b will be randomized to receive booster dose of 5 x 10\^9vp ChAdOx1 IN or no booster"
62618286|NCT00433017|EXPERIMENTAL|Verteporfin + Ranibizumab|Verteporfin (6 mg/m\^2) photodynamic therapy (PDT) and ranibizumab (0.5 mg). Patients received three consecutive monthly ranibizumab injections starting on Day 1, and then as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).
62058391|NCT04816019|EXPERIMENTAL|Group 1b: Low dose|"5 Covid-19 vaccine naive volunteers will receive a single dose of 5x10\^9vp ChAdOx1 nCOV-19 IN.~Volunteers in Group 1a \& b will be randomized to receive booster dose of 5 x 10\^9vp ChAdOx1 IN or no booster"
62446810|NCT03083210|EXPERIMENTAL|Lanreotide|Lanreotide, at a dose of 120mg will be administered without dose adjustment, by means of deep subcutaneous injection every 28 days.
62618287|NCT00433017|ACTIVE_COMPARATOR|Ranibizumab Monotherapy|Patients received three consecutive monthly ranibizumab injections starting on Day 1 and then as needed from Month 3 based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).
62618288|NCT01109628|EXPERIMENTAL|Protein drink|
62618289|NCT01109628|PLACEBO_COMPARATOR|Placebo drink|
62618290|NCT00154843|EXPERIMENTAL|A|Lycopene 15 mg/day
62618291|NCT00154843|EXPERIMENTAL|B|Lycopene 30 mg/day
62618292|NCT02333422|EXPERIMENTAL|NIRS Neurofeedback|NIRS Neurofeedback training of frontal and pre frontal lobes activation. The intervention consist of 24 NIRS neurofeedback sessions over 12 weeks, 2 sessions per week.
62058392|NCT04816019|EXPERIMENTAL|Group 2a: High Dose|"3 Covid-19 vaccine naivevolunteers will receive a single dose of 5x10\^10vp ChAdOx1 nCOV-19 IN.~Volunteers in Group 2a \& b will be randomized to receive booster dose of 5 x 10\^10vp ChAdOx1 IN or no booster"
62058393|NCT04816019|EXPERIMENTAL|Group 2b: High Dose|"Up to 15 Covid-19 vaccine naive volunteers will receive a single dose of 5x10\^10vp ChAdOx1 nCOV-19 IN.~Volunteers in Group 2a \& b will be randomized to receive booster dose of 5 x 10\^10vp ChAdOx1 IN or no booster"
62058394|NCT04816019|EXPERIMENTAL|Group 3: Intermediate Dose|"Up to 18 Covid-19 vaccine naive volunteers will receive a single dose of 2x10\^10vp ChAdOx1 nCOV-19 IN.~Volunteers will be randomized to receive booster dose of 2 x 10\^10vp ChAdOx1 IN or no booster"
62618293|NCT00481013|PLACEBO_COMPARATOR|1a|For six months, half of patients are randomized into placebo . After 6 months, all patients are on treatment.
62618294|NCT00481013|ACTIVE_COMPARATOR|1b|Cohort 1b patients are randomized onto treatment. After 6 months, all patients are on drug.
62618295|NCT03121794||Low BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI 18.5 - 25 kg/m2
62618296|NCT03121794||Moderate BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI 30-35 kg/m2 will receive ultrasound exam.
62618297|NCT03121794||High BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI \> 40 kg/m2 will receive ultrasound exam.
62618298|NCT01441856|ACTIVE_COMPARATOR|Open or Laparocopic Left|Open or Laparoscopic left hemihepatectomy
62058395|NCT04816019|EXPERIMENTAL|Group 4: High Dose, vaccinated boost|6 volunteers, previously vaccinated with two doses of ChAdOx1 nCoV-19 IM will receive a single dose of 5x10\^10vp ChAdOx1 nCoV-19 IN.
62058396|NCT04816019|EXPERIMENTAL|Group 5: High Dose, vaccinated boost|6 volunteers, previously vaccinated with two doses of BNT162b IM will receive a single dose of 5x10\^10vp ChAdOx1 nCoV-19 IN.
62058397|NCT04178057|EXPERIMENTAL|GB222 3mg/kg|GB222 3mg/kg
62058398|NCT04178057|EXPERIMENTAL|GB222 5mg/kg|GB222 5mg/kg
62058399|NCT04178057|EXPERIMENTAL|GB222 7.5mg/kg|GB222 7.5mg/kg
62058400|NCT04178057|EXPERIMENTAL|GB222 10mg/kg|GB222 10mg/kg
62446811|NCT00795561|EXPERIMENTAL|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
62446812|NCT00795561|ACTIVE_COMPARATOR|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
62844036|NCT03565419|NO_INTERVENTION|Control|Participants conduct the ultrasound-guided peripheral cannulation while they confirm real-time images displayed on the viewer next to the phantom.
62618299|NCT01441856|ACTIVE_COMPARATOR|Open or Laparoscopic Right|Open or Laparoscopic right hemihepatectomy
62618300|NCT01441856|ACTIVE_COMPARATOR|Prospective registry|Prospective registry of patients that cannot be randomized (both open and laparoscopic left + right hemihepatectomy)
62058401|NCT04327141|EXPERIMENTAL|Protein pacing and intermittent fasting|During the 8-week weight loss (WL) phase, participants assigned to the P-IF will consist of P days, whereby female participants will consume four and male participants will consume five meals/snacks total, two of which (breakfast and lunch) will include a protein powder meal replacement mixed with water (240-400 kcals per meal) along with an evening dinner meal (\~500 kcals), an afternoon snack (men only), and an evening snack (250 kcals). Subjects will be calorie restricted to \~1500 and \~1800 calories per day, women and men, respectively during P days. For each IF day, subjects will be provided a variety of supplements/snacks made by Isagenix International LLC. The P-IF group will be further divided into two subgroups for weeks 1-4. One subgroup will consist of five days of P and two days of IF, and the second subgroup will consist of six days of P and one day of IF. For weeks 5-8 both subgroups will follow 6 days of a P diet and 1 day IF.
62618301|NCT02215746|EXPERIMENTAL|Treatment A|BI 44370 TA drinking solution 100 mg fasted
62058402|NCT04327141|EXPERIMENTAL|Heart Healthy|The HH group will observe the dietary guidelines in compliance with the National Cholesterol Education Program Therapeutic Lifestyle Changes (TLC) diet. This diet consists of consuming \<35% of kcal as fat; 50%-60% of kcal as carbohydrates; \<200 mg/dL of dietary cholesterol; and 20-30 g/day of fiber. The total calorie intake will be 1200 and 1500 calories per day, women and men, respectively during the weight loss phase (weeks 0-8).
62618302|NCT02215746|EXPERIMENTAL|Treatment B|BI 44370 TA drinking solution 100 mg fed
62058403|NCT00222001||HMO Patients|Measurement of telephone triage outcome.
62058404|NCT03124199|EXPERIMENTAL|Rifaximin|Patient with Helicobacter pylori infection with standard triple therapy prescribed by clinical practice.
62058405|NCT03852849|NO_INTERVENTION|routine care group|Medical institutions will provide patients routine care according to the national program standard.
62058406|NCT03852849|EXPERIMENTAL|medicine intervention group|The dosage of 400 mg EFV will be used in the antiviral therapy.
62618303|NCT02215746|EXPERIMENTAL|Treatment C|BI 44370 TA drinking solution 200 mg fasted
62618304|NCT02215746|EXPERIMENTAL|Treatment D|BI 44370 TA drinking solution 200 mg fed
62618305|NCT02215746|EXPERIMENTAL|Treatment E|100 mg BI 44370 BS as two tablets 50 mg fasted
62618306|NCT02215746|EXPERIMENTAL|Treatment F|100 mg BI 44370 BS as two tablets 50 mg fed
62618307|NCT01375374|EXPERIMENTAL|Lacosamide|commercial 50 mg (pinkish) and 100 mg (yellow) tablets
62618308|NCT01962246|ACTIVE_COMPARATOR|postoperative chemotherapy,XELOX|
62618309|NCT01962246|EXPERIMENTAL|Preoperative Concurrent Chemoradiotherapy|
62618310|NCT01437371|OTHER|optimized|The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
62618311|NCT01437371|OTHER|usual care|
62618312|NCT03957902|EXPERIMENTAL|Arm 1 (100 mg/24h)|
62618313|NCT03957902|EXPERIMENTAL|Arm 2 (300 mg/24h)|
62844037|NCT03565419|EXPERIMENTAL|Intervention|Participants conduct the ultrasound-guided peripheral cannulation wearing smart glasses. They confirm real-time images displayed on the viewer of smart glasses.
62844038|NCT05828056||BP|100 patients with mood disorders from the psychiatric ward and outpatient services of the Department of Psychiatry, National Taiwan University Hospital
62844039|NCT05770089|EXPERIMENTAL|AM-APA|The group following the Adapted Physical Activity program via videoconferencing in addition to the outpatient care.
62844040|NCT05770089|NO_INTERVENTION|AM-T|The group without additional intervention other than the outpatient care.
62844041|NCT02436837|ACTIVE_COMPARATOR|young|20 to 30 years old individuals used as a comparator for elderly group
62844042|NCT02436837|EXPERIMENTAL|elderly|target of treatment to improve the balance.
62844043|NCT03465969|OTHER|Liver or kidney transplant participants of Advagraf|Transplant participants will provide 1 whole blood venepuncture sample and 1 whole blood finger prick MITRA sample at pre-dose of participant's usual oral dose of commercial Advagraf and at approximately 1 and 3 hours post-dose.
62261825|NCT02700724|OTHER|Immediate Surgery|Patients will undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Repeated surgery will be offered for additional recurrences.
62618314|NCT03957902|EXPERIMENTAL|Arm 3 (100 mg/12h)|
62618315|NCT05327088|ACTIVE_COMPARATOR|Group A (Dexmedetomidine group)|a bolus dose of 11ml of 0.25% bupivacaine + 0.5μg/ml preservative free dexmedetomidine (1ml volume) will be injected via the epidural catheter. For top up 5 ml of 0.25% bupivacaine + 0.5μg/ml dexmedetomidine (1ml volume) will be given when VAS score becomes 4 or more.
62058407|NCT03852849|EXPERIMENTAL|consolidated intervention group|Medical institutions will provide personal involved intervention strategies as well as the providing of dosage form of 400 mgEFV in their antiviral therapy.
62058408|NCT06339060|EXPERIMENTAL|Arm1 Organ preservation|"A: Camrelizumab 200mg IV on days 1 and 22 B: Carboplatin (AUC=2) IV and Paclitaxel-albumin (50mg/m²) IV on day 1,8,15,22,29.~C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.~A+B+C=neoadjuvant therapy Patients will undergo clinical response evaluations (CREs) after neoadjuvant therapy(A+B+C）, If cancer is detected, surgery will be performed. Patients with clinical complete response （cCR） are eligible for active surveillance where regular CREs are performed to detect regrowth of cancer.Postoperative adjuvant therapy will follow the NCCN guideline."
62058409|NCT06339060|ACTIVE_COMPARATOR|Arm 2 Surgery|"A: Camrelizumab 200mg IV on days 1 and 22 B: Carboplatin (AUC=2) IV and Paclitaxel-albumin (50mg/m²) IV on day 1,8,15,22,29.~C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.~Oesophagectomy will be offered to patients without contraindication.Postoperative adjuvant therapy will follow the NCCN guideline."
62261826|NCT06359873||Discovery dataset|The electronic medical records of inpatients with primary hypertension from March 2012 to February 2018 were collected from the electronic medical record system of the Second Affiliated Hospital of Chongqing Medical University, and the data were derived from electronic case reports. To ensure robustness, the investigators applied the createDataPartition function in the caret package to randomly split the dataset into a discovery dataset (70%) and an internal validation dataset (30%).
62446813|NCT06188390|EXPERIMENTAL|Hyaluronic acid group|Hyaluronic acidwas injected under ultrasound guidance around wrist median nerve
62058410|NCT06203184|EXPERIMENTAL|video game based exercise training|Breathing Games; developed by a company called \&amp;amp;Breathing Labs\&amp;amp;; allow breathing exercises to be implemented based on video games. Studies have reported that breathing exercises accompanied by visual feedback provide additional benefits, and it has been stated that the virtual reality-based approach is an effective method in this respect.
62058411|NCT06203184|OTHER|control group|No intervention will be made to the control group.
62618316|NCT05327088|ACTIVE_COMPARATOR|Group B (Nalbuphine group)|a bolus dose of 11ml of 0.25% bupivacaine + 10mg preservative free nalbuphine (1ml volume) will be injected via the epidural catheter. For top up 5 ml of 0.25% bupivacaine + 2mg nalbuphine (1ml volume) will be given when VAS score becomes 4 or more.
62618317|NCT02797678|EXPERIMENTAL|Powersleep Stim, PowerSleep Sham|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night for one week. Participants will then be crossed over and will wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers for one week
62618318|NCT02797678|SHAM_COMPARATOR|Powersleep Sham, PowerSleep Stim|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers for one week. Participants will then wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night for one week.
62618319|NCT05545085||Group 1|All included patients meeting the eligibility criteria and scheduled to undergo a lobectomy in the Medical Centre Leeuwarden.
62618320|NCT04116606|ACTIVE_COMPARATOR|Active JNJ-54175446|JNJ-54175446 is an unlicensed drug currently being developed by Janssen Pharmaceuticals. The drug is presented in oral capsules, each capsule containing 50 mg of JNJ-54175446. Participants will be asked to self-administer one capsule daily for 8 weeks.
62618321|NCT04116606|PLACEBO_COMPARATOR|Matching placebo|
62261827|NCT06359873||Internal validation dataset|The datasets utilized in this study were sourced from the electronic medical record system of the Second Affiliated Hospital of Chongqing Medical University. The investigators applied the createDataPartition function in the caret package to randomly split the dataset into a discovery dataset (70%) and an internal validation dataset (30%).
62261828|NCT06359873||External validation dataset|The electronic medical record data of patients who came from other hospitals based in Chongqing from October 2011 to November 2021 were extracted from the DEMR database of the Medical Data Institute of Chongqing Medical University as external validation dataset.
62261829|NCT06287970|EXPERIMENTAL|taVNS Group|"Bilateral auricular points of Xin (CO15) and Shen (CO10) will be stimulated by electrical stimulation. A disperse-dense wave will be used with a frequency of 4Hz/20Hz, a pulse width of 0.2ms will be set, and the current intensity will be modulated by the tolerance of the patient.~note: taVNS, transcutaneous auricular vagus nerve stimulation"
62446814|NCT06188390|ACTIVE_COMPARATOR|Dextrose group|Dextrose was injected under ultrasound guidance around wrist median nerve
62618322|NCT03690362|EXPERIMENTAL|Group 1 - Control|Healthy control subjects will be matched by gender, weight, and age to subjects with renal impairment
62618323|NCT03690362|EXPERIMENTAL|Group 2 - Mild Renal Impairment|Mild renal impairment
62618324|NCT03690362|EXPERIMENTAL|Group 3 - Moderate Renal Impairment|Moderate Renal Impairment
62058412|NCT05587244|EXPERIMENTAL|Total Hip Arthroplasty Treatment Group|This study will enroll (implant) up to 202 hips in total according to the IFU and surgical technique. Of these, up to 135 will be revision hips and up to 67 will be primary hips. This is a dual cohort study (primary and revision); each subject will receive the G7 Acetabular System with the Freedom Constrained Vivacit-E bearing. To minimize potential bias and to maximize our ability to assess inter-site differences, each study site will target up to 27 primary hip arthroplasties and up to 54 revision hip arthroplasties (not exceed 81 implanted hips or 40% of total study population). Each site is encouraged to enroll (implant) both primary and revision subjects.
62618325|NCT03690362|EXPERIMENTAL|Group 4 - Severe Renal Impairment|Severe Renal Impairment
62618326|NCT03690362|EXPERIMENTAL|Group 5 - ESRD|End Stage Renal Disease undergoing chronic intermittent hemodialysis
62058413|NCT02228967|NO_INTERVENTION|Usual Care|Those participants assigned to the usual care control group will be given a brochure on safe drinking limits, will be reminded of the 6-month follow-up, and thanked for their time.
62058414|NCT02228967|ACTIVE_COMPARATOR|SBIRT|"Those assigned to the SBIRT intervention group will receive 1 of 3 tracks:~1. Brief Intervention (BI) for At Risk Individuals (scores lower than 15) - Brief motivational intervention with feedback related to their use and change strategies.~2. Brief Treatment (BT) for High Risk Individuals (scores of 16-19) - Brief Intervention on site and be offered 6 individual confidential sessions with a civilian Brief Treatment Counselor over the phone.~3. Referral to Treatment (RT) for Severe Risk Individuals (scores of 20-40) - Brief Intervention on site and will be given a list of services where they may self-refer for further assessment and support."
62058415|NCT06140901|ACTIVE_COMPARATOR|Arm non PIBO|children hospitalized for adenovirus or rhinovirus infection with non progressing to PIBO
62058416|NCT06140901|ACTIVE_COMPARATOR|Arm PIBO|Children hospitalized for adenovirus or rhinovirus infection with progressing to PIBO in evolution.
62058417|NCT06273111|EXPERIMENTAL|5% simvastatin ointment|Participants will be applied 5% simvastatin ointment on IH lesion
62058418|NCT02417532|EXPERIMENTAL|Rehabilitation using REX|Exercises using Rex mobility assist device
62058419|NCT05290844|OTHER|Pediatric cricoid force|one arm ( 3 groups)120 pediatric patients
62261830|NCT06287970|SHAM_COMPARATOR|Sham-taVNS Group|"Bilateral ear lobes will be stimulated by electrical stimulation. A disperse-dense wave will be used with a frequency of 4Hz/20Hz, a pulse width of 0.2ms and a current intensity of 0.1mA will be set.~note: taVNS, transcutaneous auricular vagus nerve stimulation"
62261831|NCT05413486||SCH, OB|People with obesity (BMI \> 30 kg/m2) and a medical diagnosis of schizophrenia spectrum disorder.
62261832|NCT05413486||BD, OB|People with obesity (BMI \> 30 kg/m2) and a medical diagnosis of bipolar spectrum disorder.
62618327|NCT04571385|EXPERIMENTAL|Part 1: AP30663|Participants will receive single dose of AP30663.
62618328|NCT04571385|PLACEBO_COMPARATOR|Part 1: Placebo|Participants will receive placebo matched to AP30663.
62261833|NCT05413486||Control, OB|Control group with obesity. People with obesity (BMI \> 30 kg/m2) without psychiatric disease or sleep disorders.
62261834|NCT05413486||Control, non-OB|Normal weight (BMI 18.5 - 25kg/m2) control group without psychiatric disease.
62261835|NCT04565964|OTHER|Health behaviors|Health behavior intervention for one month will be provided to every participant. We will teach children's guardians (care-giver) how to change the health behaviors to clean indoor environment, including the health behaviors in bedroom, kitchen room, restroom, refrigerator, washing machine, and incense burning hall.
62618329|NCT04571385|EXPERIMENTAL|Part 2: AP30663|Participants will receive a single dose of one of the multiple dose levels of AP30663.
62618330|NCT04571385|PLACEBO_COMPARATOR|Part 2: Placebo|Participants will receive placebo matched to AP30663.
62618331|NCT03062397|EXPERIMENTAL|Low-dose group|JPI-289 Low dose or placebo
62618332|NCT03062397|EXPERIMENTAL|High-dose group|JPI-289 High dose or placebo
62261836|NCT03260504|EXPERIMENTAL|Treatment (pembrolizumab, aldesleukin)|Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Patients also receive aldesleukin subcutaneously (SC) 5 days per week for 6 weeks; or aldesleukin IV on days 2-6 of pembrolizumab cycles 1 and 2. Pembrolizumab treatment repeats every 3 weeks for 4 cycles per treatment course in the absence of clinical disease progression or unacceptable toxicity.
62261837|NCT04169880|EXPERIMENTAL|HILT Group|HILT Group (n=15)
62261838|NCT04169880|EXPERIMENTAL|HILT & EXERCISE Group|HILT\&Exercise Group (n=15)
62618333|NCT03062397|PLACEBO_COMPARATOR|Placebo group|Same dosage of JPI-289 low and high dose
62618334|NCT05579132|EXPERIMENTAL|CN201|"By study design, planned target CN201 dose levels in adults are 600μg, 1200 μg, 2500 μg , 5000 μg, 10000μg, and 20000μg. Planned target CN201 dose levels in pediatric subjects are 5000μg and 10000μg. Consider enrollment of pediatric subjects only if safety data are available for the corresponding target dose group in adults which demonstrates safety.~Subjects will receive CN201 by intravenous infusion (IV), once per week, four weeks per treatment cycle."
62618335|NCT05003830||AD group|Patients who meet the core clinical diagnostic criteria for Alzheimer's disease as defined by NIA-AA for mild cognitive decline or probable Alzheimer's disease.
62618336|NCT05003830||Healthy control group|Age-matched subjects, who are healthy and have no clinically significant related abnormalities in their physical examinations, laboratory tests, vital signs, or ECG. In addition, no first-degree family history of early-onset AD or other neurodegenerative diseases related to dementia.
62618337|NCT04617483|EXPERIMENTAL|Aged 26-45, Commercial Scale|Commercial scale inactivated SARS-CoV-2 vaccine in adults aged 26-45 years.
62618338|NCT04617483|EXPERIMENTAL|Aged 18-59, Pilot Scale|Pilot scale inactivated SARS-CoV-2 vaccine in adults aged 18-59 years.
62058420|NCT01807156|EXPERIMENTAL|Tivozanib|Patients would receive Tivozanib 1.0 mg/day orally, 3 weeks on, one week off, for one cycle starting day 1. If no adverse event is encountered, patients will continue subsequent cycles of Tivozanib 1.5 mg/day orally; 3 weeks on/1 week off, dosing schedule. Patients will continue on treatment until disease progression, unacceptable toxicity, or patient withdrawal from the study.
62618339|NCT04617483|EXPERIMENTAL|Aged ≥60, Pilot Scale|Pilot scale inactivated SARS-CoV-2 vaccine in elderly aged above 60 years.
62618340|NCT03634813|EXPERIMENTAL|High Blood Pressure Monitoring and Counseling|"Enrolled patients will be fitted with a HBPM device and instructed in its use. Patients will be asked to return the HBPM device on the morning of surgery. At the same time they receive the HBPM device, they will also be provided with the National Institutes of Health (NIH) booklet called Your guide on lowering blood pressure, which has several guidelines regarding diet, exercise and lifestyle changes that can be implemented to improve blood pressure control."
62618341|NCT03634813|ACTIVE_COMPARATOR|Usual Care|The usual care group will receive brief counseling after the PAT visit which will review their blood pressure readings taken at the clinic and how they compare with the American Heart Association (AHA) blood pressure guidelines. They will be offered the suggestion that they should follow up with their primary care doctor 2-4 weeks after their surgical episode is completed, or at their earliest convenience.
62618342|NCT05276960|ACTIVE_COMPARATOR|Regular supplementation|Baseline dose of 2000 IU of vitamin D3, based on Cystic Fibrosis Foundation (CFF) treatment guidelines. According to serum vitamin D levels, 2000 IU increments will be performed whenever 25-OH-VitD (25-hydroxy vitamin D) values \< 30 ng/ml are found.
62618343|NCT05276960|EXPERIMENTAL|Enhanced Supplementation|Basal dose of 4000 IU of vitamin D3. According to serum vitamin D levels, increments of 4000 IU will be made each time 25-OH-VitD values \< 30 ng/ml are found.
62618344|NCT02352376|OTHER|Conventional ventilator|30 minutes of non-invasive ventilation was performed with conventional ventilator.The order of the procedures was determined by randomization.
62618345|NCT02352376|OTHER|Specific ventilator|30 minutes of non-invasive ventilation was performed with specific respirator. The order of the procedures was determined by randomization.
62618346|NCT04862832|EXPERIMENTAL|CPT - LLM - MLM|On day 1: CPT On day 2: LLM On day 3: MLM
62844044|NCT02714322|EXPERIMENTAL|MYL-1401A (Adalimumab)|MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
62058421|NCT00245102|EXPERIMENTAL|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62058422|NCT01544959|ACTIVE_COMPARATOR|fentanyl|
62058423|NCT01544959|EXPERIMENTAL|beta-blocker|Instead of narcotics (fentanyl), esmolol and lopressor are being used for hemodynamic control
62058424|NCT03725540||I-gel group|Patients will be anesthetized using an appropriate sized I-gel mask according to the manufacturer's recommendations after lubrication with a water-soluble lubricant.
62058425|NCT03725540||BASKA Group|Patients will be anesthetized using BASKA mask after lubrication with a water-soluble lubricant.
62618347|NCT04862832|EXPERIMENTAL|CPT - MLM - LLM|On day 1: CPT On day 2: MLM On day 3: LLM
62058426|NCT05699421||CITEMB project participants|This is a single cohort, observational prospective multicenter study. The participating centers of the Barcelona Northern Metropolitan Area are primary attention centers - ASSIR Muntanya, ASSIR Esquerra, ASSIR Santa Coloma de Gramenet, ASSIR Badalona-Sant Adrià and hospitals - Vall d'Hebron University Hospital in Barcelona, BCNatal, Hospital Clínic /Hospital Sant Joan de Déu University of Barcelona and Trias i Pujol University Hospital.
62618348|NCT01685385|ACTIVE_COMPARATOR|Diagnostic intervention group A|Patients who will receive the BNP test
62058427|NCT06382714|EXPERIMENTAL|Art Therapy Intervention Group|"A total of five sessions of museum visits will applied to the patients in the intervention group, lasting 20-30 minutes during dialysis. The scales will administered to the individuals in the intervention groups three times in total.~The intervention group is the group in which museum visit will applied. They receives 3 sessions of hemodialysis per week."
62058428|NCT06382714|NO_INTERVENTION|Control Group|No virtual museum visit was applied to the control group. Scales were applied to individuals. For the control group, evaluations were made with scales three times in total.
62058429|NCT01491139|EXPERIMENTAL|single arm|"All patients will receive induction chemotherapy (cisplatin and 5-FU), followed by cisplatin chemotherapy and radiotherapy in addition to oral olaparib.~Induction chemotherapy (21 day cycle)~* Drug: cisplatin 80mg/m2 (day 1)~* Drug: 5-FU (fluorouracil) 1000mg/m2/day (day 1-4 continuous infusion)~olaparib plus chemoradiotherapy (8 weeks)~* Drug: olaparib~* Drug: Cisplatin~* Radiation"
62058430|NCT03183102|NO_INTERVENTION|Estrogen suppression no flax|Control subjects will not consume flaxseed, but will receive GnRH suppression
62058431|NCT03183102|EXPERIMENTAL|Estrogen suppression with flax|Flax subjects will consume flaxseed for 2 months in addition to GnRH suppression
62058432|NCT00953537|OTHER|capecitabine|
62618349|NCT01685385|NO_INTERVENTION|Group B|Patients who will not receive the BNP test.
62618350|NCT05656885|EXPERIMENTAL|Lens A|All participants wore Lens A for 15 minutes (Period 1)
62618351|NCT05656885|EXPERIMENTAL|Lens B|All participants wore Lens B for 15 minutes (Period 2)
62618352|NCT04295213|EXPERIMENTAL|oligosaccharide group|intervention with oligosaccharides, total duration of study is 13 weeks
62844045|NCT02714322|ACTIVE_COMPARATOR|Humira® (Adalimumab)|Humira® initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
62844046|NCT03100552||Study population|Patients referred to a tertiary endoscopic resection practice found to have an SSP \>= 8mm. Endoscopic imaging applied to the sessile serrated polyp (SSP) to determine the presence or absence of dysplasia.
62618353|NCT04295213|PLACEBO_COMPARATOR|placebo group|Placebo comparator, total duration of study is 13 weeks
62844047|NCT00038818|EXPERIMENTAL|CD8 DLI|CD8 depleted DLI (Depleted Donor Lymphocyte Infusions)
62618354|NCT01533688|ACTIVE_COMPARATOR|Golytely + placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely)+ placebo pill
62618355|NCT01533688|PLACEBO_COMPARATOR|Golytely Split + placebo|split dose(2 L day before procedure and 2 L day of procedure) of 4 liters of Golytely + placebo pill
62618356|NCT01533688|EXPERIMENTAL|Golytely Split + Bisacodyl|split dose (2 L day prior to procedure and 2 L day of procedure) of 4 liters of Golytely + bisacodyl 10 mg
62618357|NCT00813436|EXPERIMENTAL|1|Oxytocin
62618358|NCT00813436|PLACEBO_COMPARATOR|2|Placebo
62618359|NCT05610579|EXPERIMENTAL|remedial exercises with compression bandage|
62618360|NCT05610579|ACTIVE_COMPARATOR|remedial exercises|
62618361|NCT03423147|EXPERIMENTAL|Chlorhexidine gluconate vaginal scrub and cloth|Patients will have a 2% chlorhexidine gluconate cloth applied to their abdomen as well as 4% chlorhexidine gluconate vaginal scrub applied as a vaginal cleanse in the operating room prior to cesarean section
62058433|NCT01426243|ACTIVE_COMPARATOR|Voluntary HIV positive subjects|40 HIV positive adults under HAART for at least one year (and stable on treatment for at least 3 months prior to enrolment), \> 350 CD4/mm3 (with half of them a nadir \< 200 CD4/mm3) and a viral load \< 50 copies/mL for at least 6 months. Patients were HCV negative or non-replicative and treated for at least 2 years with normal ALT and negative HBs antigen.
62261839|NCT03591640|ACTIVE_COMPARATOR|Pregnant with hemoglobinopathy|Standard of care with blood test before active labor
62618362|NCT03423147|ACTIVE_COMPARATOR|Standard Treatment|Patients who are not in the intervention arm will receive the standard of care prior to a cesarean section. In the operating room the patient will receive an abdominal cleanse with 2% Chloraprep solution (2% chlorhexidine gluconate) in addition to routine IV antibiotics.
62618363|NCT01013389|EXPERIMENTAL|Actifuse ABX|Actifuse ABX bone substitute
62618364|NCT01013389|ACTIVE_COMPARATOR|INFUSE, plus master granules (MGG)|synthetic bone substitute used in posterolateral instrumented lumber fusion with interbody fusion
62618365|NCT06366438|EXPERIMENTAL|ABC-teen|The ABC-teen is a universal parenting program where two trained leaders meet parents meet in groups (10-15 parents) at four occasions (2.5 hours each). One or two follow-up meetings are also offered. The themes that are covered during the meetings include: spending time together, communication, parental stress management and emotion regulation, and problem solving/conflict resolution.
62618366|NCT06366438|EXPERIMENTAL|ParentWeb|ParentWeb is an online-based program where parents individually work with material online (text, images, clips, quizzes), while they receive support from a parent guide through asynchronous text messages. The program includes four main modules that are expected to be covered in eight weeks. The themes of the modules include: spending time together, communication, problem solving/conflict resolution, and keeping in touch while letting go of control.
62618367|NCT06366438|NO_INTERVENTION|Wait-List|The parents will be on a six months wait-list control group.
62618368|NCT01483456|OTHER|Usual care|
62618369|NCT04102332||Before arm|usual infusion practices (neutral solvent-purged infusers)
62844048|NCT05633342||Healthy average-risk cohort|Individuals representing the general population who self-declare to have no cancer history and have no indications suggestive of underlying cancer development. Subjects will be recruited from a state-of-the-art population study.
62261840|NCT03591640|ACTIVE_COMPARATOR|Pregnant without known hemoglobinopathy|Standard of care with blood test before active labor
62618370|NCT04102332||After arm|Safe Infusion Device
62618371|NCT00507065|EXPERIMENTAL|Adderall XR (10 mg)|
62618372|NCT00507065|EXPERIMENTAL|Adderall XR (20 mg)|
62618373|NCT00507065|EXPERIMENTAL|Adderall XR (30 mg)|
62618374|NCT00507065|EXPERIMENTAL|Adderall XR (40 mg)|
62618375|NCT00507065|PLACEBO_COMPARATOR|placebo|
62618376|NCT01281943|EXPERIMENTAL|Temsirolimus and Pegylated Liposomal Doxorubicin|Temsirolimus 25mg andPegylated liposomal doxorubicin 25mg/m2
62618377|NCT02400892||PFO|Subjects with a bedside Transthoracic Echocardiogram (TTE) bubble study positive for a PFO
62618378|NCT02400892||Control|Subjects with a bedside TTE bubble study negative for a PFO
62844049|NCT05633342||Increased-risk (genetic/familial) cohort|Individuals carrying certain germline mutations that predispose the subjects to an increased risk of having cancer than the general population. Subjects will be recruited from Cancer Genetics Service (CGS).
62844050|NCT05633342||High-risk cohort|Individuals diagnosed with diseases that have a high risk of progressing to cancer.
62844051|NCT05633342||Malignant cohort|Individuals diagnosed with cancer.
62618379|NCT02247297||Pregnant Women|Healthy pregnant women and women with preeclampsia, HELLP syndrom, amniotic infection syndrome, or preterm premature rupture of membranes
62618380|NCT01729221||HCV infected patients treated by stem cell therap|Hepatitis C virus infected patients treated by stem cell therapy
62618381|NCT01729221||HCV infected patients treated by standared line of care|Hepatitis C virus infected patients treated by standared line of care
62844052|NCT05586269|EXPERIMENTAL|Meal Kits|Families receive weekly healthy meal kits with fresh ingredients and simple recipes (6 weeks duration), followed by a washout period of 2 weeks, and then receive a newsletter and food pantry referral.
62261841|NCT05513989|ACTIVE_COMPARATOR|modified Magill forceps group|One hundred and ten patients for whom modified pediatric Magill forceps was used to assist nasotracheal intubation
62261842|NCT05513989|ACTIVE_COMPARATOR|Magill forceps group|One hundred and ten patients for whom Magill forceps was used to assist nasotracheal intubation.
62261843|NCT01579448|EXPERIMENTAL|Vaccine to past vaccinated participants|The first arm includes subjects, who were immunized with two Shanchol™ doses, five years prior. In this study, arm one will receive one Shanchol™ booster dose at baseline and one booster dose on day fourteen.
62261844|NCT01579448|ACTIVE_COMPARATOR|Vaccine to past placebo recipients|The second arm includes subjects, who received two placebo doses, five years prior. Arm two will receive a primary immunization series consisting of one Shanchol™ dose at baseline and one at day fourteen
62261845|NCT01579448|PLACEBO_COMPARATOR|No intervention to past placebo recipients|The third arm includes subjects, who received two placebo doses, five years prior. This third arm will not receive any intervention and will serve to represent a baseline immune response by vaccine naïve individuals exposed to natural exposure.
62261846|NCT01632995|EXPERIMENTAL|Emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
62261847|NCT05265312|ACTIVE_COMPARATOR|Intervention clinic|Patients with prediabetes seen for routine care at intervention clinic
62618382|NCT04422964|EXPERIMENTAL|Intervention group (3D protective obturator)|Patients enrolled in the intervention group will have an intraoral scan of the palate, alveolar arch, and upper vestibular area before surgery. Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer, in cooperation with the Faculty of Mechanical Engineering (Department of Mechanics of Bodies, Mechatronics and Biomechanics) of Brno University of Technology. For the production of the obturator, a silicone certified for use in the oral cavity will be used.
62618383|NCT04422964|NO_INTERVENTION|control group|The standard procedure without the 3D obturator.
62844053|NCT05586269|EXPERIMENTAL|Delayed Meal Kits|Families receive a newsletter and food pantry referral. After 8 weeks, families will receive weekly healthy meal kits with fresh ingredients and simple recipes (6 weeks duration).
62261848|NCT05265312|NO_INTERVENTION|Control clinic|Patients with prediabetes seen for routine care at control clinic
62261849|NCT05595187|EXPERIMENTAL|Tricuspid repair|Tricuspid repair techniques included suture placement and the type of prosthetic annuloplasty with specified the use of an approved rigid, incomplete, nonplanar, and undersized (ranging 26, 28, or 30, 32, 34 mm) ring.
62261850|NCT05595187|NO_INTERVENTION|Blank control|
62261851|NCT00413647|EXPERIMENTAL|CardioPET|
62261852|NCT05601375||Pregnancy with a healthy fetus|3 times echocardiography in pregnancy once echocardiography after birth
62844054|NCT04549298||Patients with grade 2 and 3 LV diastolic dysfunction|Patients with high filling pressure
62844055|NCT04549298||Patients with normal and grade 1 LV diastolic dysfunction|Patients with normal filling pressure
62844056|NCT03152929|ACTIVE_COMPARATOR|Paravertebral Block|The Paravertebral Block is performed along the spine utilizing ultrasound guided technique (20-30 mL 0.5% Ropivacaine)
62844057|NCT03152929|ACTIVE_COMPARATOR|Pectoral Nerve Block|The Pectoral Nerve Block is performed anteriorly, at the level of the axillary line, also utilizing ultrasound guided technique (20-30 mL 0.5% Ropivacaine)
62844058|NCT06517004|EXPERIMENTAL|JWCAR201 Treatment Arm|Patients will be administrated with autologous CD19/CD20-directed CAR-T cells after lymphocyte depletion by fludarabine and cyclophosphamide.
62261853|NCT05601375||Pregnancy with a fetus with a structural heart disease|3 times echocardiography in pregnancy once echocardiography after birth
62261854|NCT05601375||Pregnancy with a fetus with a fetal growth restriction|3 times echocardiography in pregnancy once echocardiography after birth
62446815|NCT03658135|EXPERIMENTAL|BIIB092|The investigational drug, BIIB092, will be given intravenously, every 4 weeks for 20 weeks
62446816|NCT03658135|PLACEBO_COMPARATOR|Placebo|Inactive ingredient
62618384|NCT00496587|EXPERIMENTAL|Capecitabine + Gemcitabine + Bevacizumab|Capecitabine 800 mg/m\^2 By Mouth Twice Daily On Days 1-21. Gemcitabine 900 mg/m\^2 By Vein Over 30 Minutes on Days 1 and 15. Bevacizumab 10 mg/kg By Vein On Days 1 and 15.
62618385|NCT01504672|EXPERIMENTAL|Medication review|
62618386|NCT01504672|NO_INTERVENTION|Usual care|
62618387|NCT05926466|ACTIVE_COMPARATOR|Arm 1|Drug: Moxifloxacin Moxifloxacin will be dosed at the licensed dose of 400 mg orally once daily for 16 weeks Drug: Bedaquiline Bedaquiline will be dosed at 400 mg orally once daily for the first 2 weeks, followed by 100 mg orally once daily for 14 weeks Drug: Delamanid Delamanid will be dosed at 300 mg orally once daily for 16 weeks
62261855|NCT04457050|EXPERIMENTAL|Non-Diabetic Hepatitis C infected patients|"1. clinical examination,~2. measurement of weight (Kg), height (meter), and waist circumference (cm).~3. Calculation of the body mass index.~4. Ultrasound abdominal examination.~5. Laboratory Investigations including Complete blood count, Serum aspartate and alanine aminotransferases, serum albumin, serum bilirubin, serum gamma-glutamyl transpeptidase, and international normalization ratio. HCV-RNA quantification before treatment and 12 weeks after the end of therapy.. Serum lipid profile, fasting and post-prandial blood sugar, glycated hemoglobin A1c also included.~6. Treatment of all patients with the available generic direct antivirals in Egypt (sofosbuvir/ledipasvir ± ribavirin or sofosbuvir plus daclatasvir ± ribavirin).~7. Evaluation of insulin resistance using the homeostasis model assessment of insulin resistance before and 12 weeks after end of treatment.~8. measurement of serum levels of resistin before and at 12 weeks after treatment."
62261856|NCT02820285|OTHER|Morbid obese patients|
62261857|NCT02820285|OTHER|Control patients|
62261858|NCT02820285|OTHER|Patients with overweight, steatosis and steatohepatitis|
62261859|NCT05251181|ACTIVE_COMPARATOR|Normal saline|Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
62446817|NCT00003213|EXPERIMENTAL|Oral Granisetron + Dexamethasone|"1 mg Granisetron in the morning~1 Metoclopramide placebo in the afternoon~1 mg Granisetron in the evening 4 mg Dexamethasone in the morning"
62618388|NCT05926466|EXPERIMENTAL|Arm 2|Drug: Bedaquiline Bedaquiline will be dosed at 400 mg orally once daily for the first 2 weeks, followed by 100 mg orally once daily for 14 weeks Drug: Delamanid Delamanid will be dosed at 300 mg orally once daily for 16 weeks Drug: BTZ-043 BTZ-043 will be dosed at 500 mg orally once daily for 16 weeks
62058434|NCT01426243|OTHER|HIV negative subjects|Voluntary HIV negative subjects matched according to age (18-40 years and 40-55 years) and with HIV positive subjects, vaccinated at J0 and followed over one year
62058435|NCT06103214|NO_INTERVENTION|Control Group|In control group ，patients had undergone similar surgical and anesthesia procedures in the same time period but whose hemodynamic management was carried out according to the clinical decision of the attending anesthesiologist.
62261860|NCT05251181|EXPERIMENTAL|Centhaquine|Hypovolemic shock patients will be provided the standard of care. Following randomization centhaquine (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.
62261861|NCT05698082|EXPERIMENTAL|Test group-stained by FOS antibody|Sixty colorectal cancer tissue sections were included. The tissue was cut to 5 μm thick and placed on a glass slide for staining. Endogenous peroxidase activity was inhibited and blocked by deparaffin, rehydration, and treatment with 5% bovine serum albumin for 30 min at 37 ° C. The treated sections were incubated with anti-FOS (promab 30360) overnight at 4 ° C and washed three times with PBS. After that, it was required to incubate with secondary anti-peroxidation sunflower for 30 min at 37 ° C. After washing three times with PBS, the images were developed in diamine benzidine and micrographs were obtained under a light microscope.
62261862|NCT06276361|EXPERIMENTAL|Cohort 1/2|Patient will recieve oral risperidone for one week followed by a single IM injection of Risperidone QUAR out of two possible formulations (F1/F2) with a level 1 dose.
62261863|NCT06276361|EXPERIMENTAL|Cohort 1a/2a|Patient will recieve oral risperidone for one week followed by a single IM injection of Risperidone QUAR out of two possible formulations (F1/F2) with a level 2 dose.
62261864|NCT06276361|EXPERIMENTAL|Cohort 1b//2b|Patient will recieve oral risperidone for one week followed by a single IM injection of Risperidone QUAR out of two possible formulations (F1/F2) with a level 3 dose.
62261865|NCT06276361|EXPERIMENTAL|Cohort 1c/2c|Patient will recieve oral risperidone for one week followed by a single IM injection of Risperidone QUAR out of two possible formulations (F1/F2) with a level 3 dose.
62261866|NCT03295370|EXPERIMENTAL|Active Group|Needle electrical stimulation of accessory spinal nerve
62446818|NCT00003213|EXPERIMENTAL|Metoclopramide + Dexamethasone|20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening) 4 mg Dexamethasone in the morning
62446819|NCT06384144||Expectant Management of Miscarriage|Cohort that chose to pursue expectant management of miscarriage, final outcome success or failure by day 14 from management choice
62446820|NCT06384144||Medical Management of Miscarriage|Cohort that chose to pursue medical management of miscarriage, final outcome success or failure by day 14 from management choice
62261867|NCT03295370|SHAM_COMPARATOR|Sham Group|Needle of accessory spinal nerve without electrical stimulation
62261868|NCT05404620|EXPERIMENTAL|Schroth exercises|"Mobilization in the spine between ribs will be performed to increase the mobility of joints. To strengthen the muscles such as erector spinae, iliopsoas, and the quadratus lumborum, muscle activation will be done. Then the four exercises of the Schroth method which are the 50 x Swiss ball exercise, Prone exercise, Sail exercise, and the Muscle-cylinder exercise will be performed. This will be followed by hot pack and static stretching of muscles."
62446821|NCT04641429|EXPERIMENTAL|Qigong|Participants in the experimental group receive Qigong exercise training.
62844059|NCT06318013||Control|Group receiving only local anesthesia
62261869|NCT05404620|EXPERIMENTAL|PNF technique|This technique involves the specific program and pattern of PNF that are deep breathing, pelvic posterior tilting, DI flexion \& Extension of UL and D2 flexion, and extension of LL. + Hot pack + static stretching of the involved muscles.
62261870|NCT04754698|OTHER|Patients with rheumatic diseases|CoronaVac 2-dose schedule with 21-28-day interval and a booster dose (third dose of CoronaVac) 6 months after the primary vaccination
62261871|NCT04754698|OTHER|Patients with PLWHA|CoronaVac 2-dose schedule with 21-28-day interval
62446822|NCT04641429|ACTIVE_COMPARATOR|stretching|Participants in the control group receive stretching exercise training.
62261872|NCT04754698|OTHER|Healthy controls|CoronaVac 2-dose schedule with 21-28-day interval and a booster dose (third dose of CoronaVac) 6 months after the primary vaccination
62446823|NCT01568489|EXPERIMENTAL|HL-009 Liposomal Gel (0.07%)|
62446824|NCT01568489|EXPERIMENTAL|HL-009 Liposomal Gel (0.15%)|
62618389|NCT05926466|EXPERIMENTAL|Arm 3|Drug: Bedaquiline Bedaquiline will be dosed at 400 mg orally once daily for the first 2 weeks, followed by 100 mg orally once daily for 14 weeks Drug: Delamanid Delamanid will be dosed at 300 mg orally once daily for 16 weeks Drug: BTZ-043 BTZ-043 will be dosed at 1000 mg orally once daily for 16 weeks
62844060|NCT06318013||Intravenous Dexamethasone|Group using dexamethasone IV
62261873|NCT04933851|EXPERIMENTAL|ACT1VATE|Participants assigned to the intervention group will be offered a psychological intervention specifically designed to address diabetes-related emotional distress.
62261874|NCT04933851|ACTIVE_COMPARATOR|DSME/S (usual care)|Participants randomized to the usual care group will be offered standard diabetes self-management education and support (DSME/S).
62618390|NCT05926466|EXPERIMENTAL|Arm 4|Drug: Bedaquiline Bedaquiline will be dosed at 400 mg orally once daily for the first 2 weeks, followed by 100 mg orally once daily for 14 weeks Drug: Delamanid Delamanid will be dosed at 300 mg orally once daily for 16 weeks Drug: BTZ-043 BTZ-043 will be dosed at 1500 mg orally once daily for 16 weeks
62261875|NCT01515137|EXPERIMENTAL|Arm A erlotinib plus sulindac|erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A),
62261876|NCT01515137|EXPERIMENTAL|Arm B erlotinib|erlotinib (150 mg PO QD) (Arm B)
62844061|NCT06318013||Perineural Dexamethasone|group administered perineural dexamethasone
62261877|NCT01515137|EXPERIMENTAL|Arm C|placebo (for Erlotinib) QD (Arm C).
62261878|NCT01921751|EXPERIMENTAL|Chemotherapy + high intensity radiation|Induction chemotherapy with four cycles of gemcitabine and nab-paclitaxel \[randomized to this arm after 3rd cycle and no progression\]; followed by concurrent high intensity radiation therapy and capecitabine; followed by consolidation chemotherapy with gemcitabine and nab-paclitaxel until progression or unacceptable toxicity
62446825|NCT01568489|EXPERIMENTAL|HL-009 Liposomal Gel (0.30%)|
62446826|NCT01568489|PLACEBO_COMPARATOR|HL-009 Liposomal Gel (Placebo)|
62446827|NCT00604409|EXPERIMENTAL|Treatment (SIRT and capecitabine)|Patients receive capecitabine PO twice daily on days 1-14. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients undergo SIRT on day 2 and may undergo a second course of SIRT on day 58.
62446828|NCT02907112|NO_INTERVENTION|Control|Participants to continue on their habitual diet for 4 weeks
62446829|NCT02907112|EXPERIMENTAL|Meat Reduction|Participants asked to reduce their red and processed meat intake by 50% for 12 weeks
62446830|NCT02720952|EXPERIMENTAL|Infacort|"Infacort® is a dry granule formulation of hydrocortisone stored in capsules that will be available in different strengths (0.5, 1.0, 2.0 and 5.0mg).~The clinically-appropriate dose, based on standard individualised treatment, will be administered, given as a single dose orally. This will usually be equivalent to the previous day's dose."
62446831|NCT02903056||Rett Syndrome|Rett Syndrome is a neurodevelopmental disease that primarily affects girls. Clinically, patients are normal before six months to one and half years old, and then develop progressive severe problems with communication, learning, co-ordination and neurodevelopment, with loss of motor skills around the age of two. At the same time, stereotyped hand movement typically appears.
62844062|NCT04995367|EXPERIMENTAL|Implementation of a BCI system integrated to the T-FLEX lower-limb exoskeleton in post-stroke|The participants will carry out tests for the evaluation of the functionality of the BCI system integrated to the T-FLEX device. The test consists of 1 session that includes four conditional experiments. Real Movement, Continuous Stationary Therapy, Motor Imagery Detection with Visual Stimulation, and Motor Imagery Detection with Tactile Stimulation.
62844063|NCT06254365|EXPERIMENTAL|LEAP2 infusion then placebo infusion|"Participants are randomized to either first recieve LEAP2 infusion and then LEAP2 infusion or th other way around.~This arm describes - first LEAP2 infusion and then placebo infusion"
62844064|NCT06254365|EXPERIMENTAL|Placebo infusion then LEAP2 infusion|"Participants are randomized to either first recieve LEAP2 infusion and then LEAP2 infusion or th other way around.~This arm describes - first placebo infusion and then LEAP2 infusion"
62844065|NCT00012844|OTHER|Arm 1|
62844066|NCT05313334|EXPERIMENTAL|PTSD Group|The PTSD Group will receive the GAMBIT intervention and complete all study tasks and assessments at every study visit (Visits 0-4). N=20 participants will be recruited for this arm.
62844067|NCT05313334|EXPERIMENTAL|Healthy Control Group|The Healthy Control Group will receive the GAMBIT intervention and complete all study tasks and assessments at every study visit (Visits 0-4). N=20 participants will be recruited for this arm. Additionally, N=10 Healthy Control participants will be recruited for the Pilot Phase of the study.
62844068|NCT05249517|EXPERIMENTAL|Pain Neuroscience Education (PNE)|Telerehabilitation based pain neuroscience education
62261879|NCT01921751|EXPERIMENTAL|Chemotherapy + low intensity radiation|Induction chemotherapy with four cycles of gemcitabine and nab-paclitaxel \[randomized to this arm after 3rd cycle and no progression\]; followed by concurrent low intensity radiation therapy and capecitabine; followed by consolidation chemotherapy with gemcitabine and nab-paclitaxel until progression or unacceptable toxicity
62261880|NCT01921751|ACTIVE_COMPARATOR|Chemotherapy|Gemcitabine and nab-paclitaxel until progression or unacceptable toxicity \[randomized to this arm after 3rd cycle and no progression\]
62446832|NCT02903056||Control-normal|Healthy people
62618391|NCT03747718|EXPERIMENTAL|Fecal Microbiota Follow up Enemas|In this arm subjects will receive 3 fecal microbiota transplants at 1 monthly intervals at 1.5, 2.5 and 3.5 months (+/- 2 weeks) after transplant
62261881|NCT05768945||Semaglutide|Exposure group
62261882|NCT05768945||DPP4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin)|Reference group
62261883|NCT00823355|EXPERIMENTAL|BCX1777|
62261884|NCT05153083||patient undergoing open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA)|Subjects undergoing open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA) using cryoablation of intercostal nerves
62446833|NCT02322047|EXPERIMENTAL|Praz/Nal|"Prazosin and Naltrexone.~Prazosin will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
62844069|NCT05249517|ACTIVE_COMPARATOR|Exercise + PNE|Telerehabilitation based progressive submaximal exercise program and PNE
62261885|NCT03339011|EXPERIMENTAL|SMS text message|"The content of the text messages is developed based on recommendation and advice from the Danish Health Authority about the importance of regular daily physical activity.~For 6 weeks, the text messages will be send three times per week, twice during the week days and once in the weekend, based on previous experience with SMS as motivation for chronic pain patients."
62261886|NCT03339011|NO_INTERVENTION|No intervention|No attention from the study
62261887|NCT03222206|EXPERIMENTAL|Salsalate|17 patients received continuous medication with salsalate 2g/day after run-in period
62261888|NCT03222206|PLACEBO_COMPARATOR|Placebo|17 patients received continuous medication with Placebo 2g/day after run-in period
62618392|NCT03747718|PLACEBO_COMPARATOR|Placebo Enemas|In this arm subjects will receive 3 placebo transplants at 1 monthly intervals at 1.5, 2.5 and 3.5 months (+/- 2 weeks) after transplant
62618393|NCT02349282|EXPERIMENTAL|Calcifediol 10 ug/day|Capsule with 10 ug/day Calcifediol taken together with breakfast for a total period of 24 weeks.
62618394|NCT02349282|EXPERIMENTAL|Vitamin D3 20 ug/day|Capsule with 20 ug/day Vitamin D3 taken together with breakfast for a total period of 24 weeks.
62618395|NCT02349282|PLACEBO_COMPARATOR|Placebo|Capsule without active ingredients, taken together with breakfast for a total period of 24 weeks.
62618396|NCT02247232|PLACEBO_COMPARATOR|Placebo|
62618397|NCT02247232|EXPERIMENTAL|Z-100|
62618398|NCT01041274|EXPERIMENTAL|Citalopram|Participants will receive a daily dose of citalopram, with flexible dosing as determined by clinician, for 12 months.
62618399|NCT01041274|PLACEBO_COMPARATOR|Placebo|Participants will receive a daily dose of placebo for 12 months.
62618400|NCT06465628|EXPERIMENTAL|Self-administered acupressure|Participants will attend a 90-min self-administered acupressure training session by a registered Traditional Chinese Medicine practitioner. A follow-up session will be arranged in the second week to reinforce learning and to make sure all participants can locate the proposed acupoints correctly. The follow up session will be conducted face to face (prioritized mode), or by phone/video call based on patients' preference. The acupoints are chosen for inclusion in the protocol based on literature review \[25, 29, 34, 35, 39\] and expert experience of the PI \[40-43\]. The location of acupoints (nine in total) include face and neck (Ren 23, Ren 24, ST5, ST6, ST7, TE17), upper limbs (LI2, LI4), and lower limbs (KI6). All acupoints should be massaged bilaterally except Ren 23 and Ren 24. After the training, participants are encouraged to self-administered acupressure on the acupoints twice daily for 12 weeks, each point lasting for 1 minute.
62618401|NCT06465628|ACTIVE_COMPARATOR|Oral health education|"Participants will attend a 90-min oral care education session in the first week by a trained research staff (the same frequency and duration as the intervention group). The content includes the causes of xerostomia, consequences, current preventative measures, dietary advice and oral hygiene advice.~Participants in the control group will receive a booklet documenting the content of the oral care education sessions. Throughout the 12-week period, participants will receive reminders of oral care for xerostomia twice weekly"
62618402|NCT01267422|EXPERIMENTAL|rAAV2-ND4|injection
62618403|NCT00060372|EXPERIMENTAL|Treatment (ipilmumab and donor lymphocyte infusion)|Patients receive ipilimumab IV over 90 minutes. Cohorts of 3-6 patients receive escalating doses of ipilimumab until the MTD is determined. The MTD is the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients with persistent or progressive disease at 60 days after ipilimumab administration and no evidence of graft-versus-host disease receive donor lymphocyte infusions every 60 days for a total of 3 infusions.
62618404|NCT05413941|EXPERIMENTAL|Internet-based Cognitive Behavioral Therapy|
62618405|NCT01778751|NO_INTERVENTION|Control|Veterans will receive diabetes educational materials and management per their primary provider
62618406|NCT01778751|EXPERIMENTAL|Intervention|Veterans randomized to the intervention arm will be enrolled in the HT program, provided with standard telemonitoring equipment by HT nursing staff (current HT practice at DVAMC is use of the Health Buddy 3 device for patients with landline phones and the Cardiocom Interactive Voice Response System for patients with cell phones), and will receive the study intervention for 6 months. Veterans without depressive symptoms on baseline PHQ-9 assessment (PHQ-9 \< 10) will not initially be entered into the depressive symptom management component of the intervention, but will be monitored for new symptoms throughout the intervention.
62844070|NCT06117046|EXPERIMENTAL|Cardiopeptides|Cardiopeptide was administered intravenously once a day with 60mg of cardiopeptide for 3 days
62844071|NCT06117046|NO_INTERVENTION|Empety|
62844072|NCT02209532|ACTIVE_COMPARATOR|Blue - PINPOINT|The cervix will be injected 4 times with a 1ml solution of 1% Isosulfan blue followed by injection 4 times of 1 ml of 1.25 mg/ml solution of ICG. LN mapping with Blue dye will be performed until the investigator identifies all blue nodes or determines that blue nodes cannot be identified. Once complete, the Investigator will begin mapping with PINPOINT until all 'ICG' nodes are identified or the investigator determines that 'ICG' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.
62261889|NCT01419912|EXPERIMENTAL|soy milk|
62261890|NCT01419912|EXPERIMENTAL|cow's milk|
62261891|NCT00577785||cystectomy group|Subjects undergoing planned cystectomy who agree to provide bladder tissue from removed bladder post cystectomy and/or cystoscopic biopsy tissue prior to cystectomy
62261892|NCT00950664|EXPERIMENTAL|Dysport® to Botox®|Dysport® injection in first intervention period and Botox® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA)
62261893|NCT00950664|EXPERIMENTAL|Botox® to Dysport®|Botox® injection in first intervention period and Dysport® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA)
62261894|NCT04149015|EXPERIMENTAL|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles
62261895|NCT02184195|EXPERIMENTAL|Olaparib|Olaparib tablets po. 300 mg twice daily
62261896|NCT02184195|PLACEBO_COMPARATOR|Placebo|Placebo tablets twice daily
62446834|NCT02322047|ACTIVE_COMPARATOR|Praz/Pl|"Prazosin and Placebo (Naltrexone)~Prazosin will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone Placebo will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
62618407|NCT05979584|EXPERIMENTAL|Platelet Fibrin Plasma|Participants of intervention group will receive Platelet Fibrin Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
62618408|NCT05979584|PLACEBO_COMPARATOR|Platelet Rich Plasma|Participants of intervention group will receive Platelet Rich Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
62618409|NCT01125813|EXPERIMENTAL|human cl-rhFVIII|
62844073|NCT02209532|ACTIVE_COMPARATOR|PINPOINT - Blue|The cervix will be injected 4 times with 1 ml of a 1.25 mg/ml solution of ICG followed by injection 4 times of a 1 ml solution of 1% Isosulfan blue. LN mapping with PINPOINT will be performed until the investigator identifies all 'ICG' nodes or determines that 'ICG' nodes cannot be identified. Once complete, the Investigator will begin mapping with Blue dye until all 'blue' nodes are identified or the investigator determines that 'blue' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.
62844074|NCT00493051|OTHER|1|Standardized Wound Care
62058436|NCT06103214|OTHER|acute normovolemic hemodilution (ANH)|Before anesthesia induction, in the ANH Group, blood was withdrawn at a speed of 25-30ml/min from radial artery and stored in standard collection bags. The volume of blood to be removed during ANH was calculated using an established formula as follows: V = EBV (H0 - Ht) / H. During collection, a tilt rocker scale was used to rock, mix, and weigh the blood. To maintain euvolemia, half of the blood volume removed was replaced with 6% hydroxyethyl starch 130/0.4 with medium molecular weight at a 1:1 ratio and half was replaced with crystalloid at a 1:2 ratio. The autologous blood was returned to patients if the intraoperative transfusion trigger (Hb \<8.0g/dl) was reached or at the completion of the operation.
62058437|NCT06103214|OTHER|acute hypervolemic hemodilution (AHH)|In AHH group, 15ml/kg Voluven was transfused at a speed of 30 ml/min to make Hct to drop to medium. In control group, the regular transfusion and infusion were conducted. Allogenic blood was only given after all autologous blood had been returned to the patient. The transfusion triggers (Hb \<8.0g/dl) were used to determine the need for allogenic blood transfusions during the procedure in three groups.
62058438|NCT04563650|EXPERIMENTAL|COVID-19 positive resident|
62058439|NCT04563650|ACTIVE_COMPARATOR|COVID-19 negative resident|
62058440|NCT05185778||parasitic infected individuals received COVID-19 vaccine|parasitic infected individuals with helminthic or protozoan who received COVID-19 vaccines of any type
62058441|NCT05185778||parasitic infected individuals not received COVID-19 vaccine|parasitic infected individuals with helminthic or protozoan who don't receive COVID-19 vaccines of any type
62058442|NCT06194084|EXPERIMENTAL|Intervention - durian pulp.|Two-sequence of doses (100 g and 200 g) of durian pulp.
62058443|NCT01315730|EXPERIMENTAL|Device: Tactile Stimulation|"A new medical grade device (FDA - category exempt) has been newly designed and built at the University of Mississippi within the departments of Communication Sciences \& Disorders, Exercise Science, and Computer and Electrical Engineering. The device records either sound waves (via a small standard microphone) or three dimensional accelerometer data from the throat of a stuttering subject. This data is digitally signal processed, and fed back to the user in the form of a small vibrating disk/film that can be held between the fingers or mounted on the skin. This feedback data does not require the subject to attend to the incoming signal."
62058444|NCT03615781|EXPERIMENTAL|Two week's arm - surgery|The investigators perform a surgical drainage and removal of the infected orthopedic implant.
62058445|NCT03615781|ACTIVE_COMPARATOR|Four week's arm - surgery|The investigators surgically remove the infected implant.
62058446|NCT03615781|EXPERIMENTAL|Two week's arm - drugs|The investigators perform a surgical drainage and removal of the infected orthopedic implant. They start an empirical antibiotic treatment based on patient's history and co-morbidities, such as vancomycin or amoxicillin/clavulanic acid. The adapt later on the targeted antibiotic therapy according to the causative pathogens and their antibiotic susceptibility testing.
62844075|NCT00493051|PLACEBO_COMPARATOR|2|Placebo 1 dose
62261897|NCT05179447|EXPERIMENTAL|Molecular profile based treatment|Determination of the integrated genomic-pathologic profile to determine adjuvant treatment: observation for POLE-mutated profile; vaginal brachytherapy for intermediate profile; chemo-radiotherapy for p53-abnormal profile.
62446835|NCT02322047|ACTIVE_COMPARATOR|Nal/Pl|"Naltrexone and Placebo (Prazosin)~Prazosin Placebo will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
62618410|NCT02626923||Patients on once daily Maraviroc|Maraviroc tablet 600 mg once daily 48 weeks
62618411|NCT04727255|EXPERIMENTAL|Intervention|The intervention will be implemented through a group-based delivery format involving internal educated resilience trainers. The Engaged and Resilient training program consists of twenty weekly, short-term sessions to build resilience skills in leaders.
62618412|NCT04727255|NO_INTERVENTION|Control|Participants in the (waitlist) control group will be exposed to their usual activities in the organization and will not perceive any interventions from the resilience curriculum. After the final data is collected, the control participant will be offered the opportunity to be trained by the internal trainers, educated in the research study.
62058447|NCT03615781|ACTIVE_COMPARATOR|Four week's arm - drugs|The investigators surgically remove the infected implant and all soft tissue infection. Instead of a total of 2 week's of antibiotic therapy, they administer a total of 4 weeks of systemic antibiotic therapy targeted to the pathogen(s).
62058448|NCT04577807|EXPERIMENTAL|Arm 1: Lerapolturev Only|Lerapolturev (up to 1.6x10\^9 TCID50) administered via direct injection of up to 6 lesions given weekly for 7 weeks, followed by every 3 weeks thereafter.
62058449|NCT04577807|EXPERIMENTAL|Arm 2: Lerapolturev and anti-PD-1|Lerapolturev (up to 1.6x10\^9 TCID50) administered via direct injection of up to 6 lesions given weekly for 7 weeks, followed by every 3 or 4 weeks thereafter. Anti-PD-1 therapy given as per the anti-PD-1 approved package insert.
62058450|NCT04387864|EXPERIMENTAL|Whole-body Vibration Exercise Group|"The patients in the WBV exercise group underwent WBV exercise sessions 2 days a week (72 hours in between) for a total of 6 weeks. Each exercise session was performed under the supervision of a physician.~The patients received support from both hands on the WBV platform and both knees were positioned statically at 40-60 degree flexion (high squat position). All patients stood on the platform with sports socks (without shoes) to avoid the shoes absorbing vibration. Vibration was given by a Power Plate® device where a three-plane oscillation occurs (most vertical, Z axis). In all vibrations, 30 Hz frequency and 2 mm amplitude (low amplitude) were used. The vibration time was set to be 30 seconds in the first two weeks, 45 seconds in the next two weeks and 60 seconds in the last two weeks. The repetition of vibration was increased by 1 repetition every week, starting with 5, and 10 repetitions were given in the last week. A 1-minute rest period was given between each repetition."
62058451|NCT04387864|NO_INTERVENTION|Home Exercise Group|The home program, which included isometric and isotonic exercises, was followed at home for 6 weeks. Three sets of quadriceps setting as 5 repetitions, 5-second contractions, and three sets of isotonic quadriceps exercise in seating position with weights as 12 repetitions were administered to be performed two days a week. While the patients included in the study group came for TVT exercise two days a week, the patients in the control group performed quadriceps setting exercises also on those days. The patients were invited to the physician follow-up on Wednesday every week for motivation and follow-up. The patients were asked to write their complaints during and after the exercise, if any. In addition, they were asked to note the number of repetitions and sets of their exercises on exercise booklets prepared for the patient.
62261898|NCT05179447|ACTIVE_COMPARATOR|Radiotherapy|Adjuvant vaginal brachytherapy for intermediate risk (stage I A with G3 or stage I B with G1-2) and external beam pelvic radiotherapy for high-intermediate risk (stage I B with G3, or stage II) (standard treatment)
62261899|NCT04315675|EXPERIMENTAL|Guided Imagery Intervention|Participants randomly assigned to this group will be provided with a MP3 Player which will have three guided imagery programs The Guided Imagery Programs include: 1.) Relaxation and Wellness; 2.) Immune System Imagery; and 3.) Healing Trauma.
62261900|NCT04315675|EXPERIMENTAL|Cognitive Power Intervention|The participant who is randomly assigned to this group completes The Power as Knowing Participation in Change Version II (PKPCT) to determine 1.) Freedom to Act Intentionally, 2.) Involvement in Creating Change, 3.) Freedom to Act Intentionally and 4.) My Involvement in Creating Change.
62261901|NCT04315675|EXPERIMENTAL|Cognitive Power Intervention and Guided Imagery|The participant is randomly assigned to this group completes both the Guided Imagery Intervention and the Cognitive Power Intervention.
62261902|NCT04315675|NO_INTERVENTION|Control Group|The participant is randomized to the control group and completes all study measures twenty-one days after the baseline data are competed. .
62446836|NCT02322047|PLACEBO_COMPARATOR|Pl/Pl|"Placebo (Prazosin) and Placebo (Naltrexone)~Prazosin Placebo will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone Placebo will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
62618413|NCT01755806||aortic root dimension change|those without aortic valve calcification
62844076|NCT00493051|PLACEBO_COMPARATOR|3|Placebo 2 doses
62844077|NCT00493051|ACTIVE_COMPARATOR|4|Active 1 dose
62844078|NCT00493051|ACTIVE_COMPARATOR|5|Active 2 doses
62844079|NCT03882268|EXPERIMENTAL|MIYCN interventions|8 facilities run by 2 NGOs that will receive intensified MIYCN interventions.
62844080|NCT03882268|NO_INTERVENTION|Comparison facilities|8 facilities run by 2 other NGOs, which will not receive any standardized MIYCN interventions.
62844081|NCT02139592||brentuximab vedotin (recombinant) Intravenous infusion|Intravenous infusion of 1.8 mg/kg (body weight) of brentuximab vedotin (recombinant) administered once every three weeks
62844082|NCT02852616|ACTIVE_COMPARATOR|Narrative Exposure Therapy|Participants with a PTSD diagnosis
62844083|NCT02852616|NO_INTERVENTION|no / standard treatment|Participants with a PTSD diagnosis / other mental health problems / no mental health problems
62844084|NCT04276376|EXPERIMENTAL|Cohort 1A-D|"Molecularly selected cohorts that harbor DNA repair deficiency, defined as bi-allelic loss-of-function alteration (mutation and/or deletion) in at least one of the following genes: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK2, PALB2, RAD51C, RAD51D, FANCA, NBN, RAD51, RAD54L.~1.A - Non-Small Cell Lung Cancer~1.B - Urothelial Bladder Cancer~1.C - metastatic Castration Resistant Prostate Cancer~1.D - others: any histology, excepted breast cancer or serous ovarian cancer"
62844085|NCT04276376|EXPERIMENTAL|Cohort 2A-C|Platinum-sensitive disease 2.A - Non-Small Cell Lung Cancer 2.B - Urothelial Bladder Cancer 2.C - Gastric or gastro-esophageal junction adenocarcinoma
62844086|NCT04276376|EXPERIMENTAL|Cohort 3|Metastatic Castration Resistant Prostate Cancer (mCRPC)
62844087|NCT04276376|EXPERIMENTAL|Cohort 4|Clear Cell Renal Cell Carcinoma
62261903|NCT04017520||Mother-infant dyads|"221 mother-infant dyads enrolled at delivery and followed longitudinally at regularly scheduled well child checks (4, 16, 24, and 48- weeks) at a primary care outpatient pediatric clinic affiliated with an academic medical center. Eligible mothers will be those who plan to breast feed for 16 weeks and infants born at term (37-42 weeks). The cohort will be divided post-hoc into atopic and non-atopic groups based on the primary outcome measure (described below).~No intervention will be administered."
62058452|NCT00880308|EXPERIMENTAL|LDE225|
62261904|NCT06459154|EXPERIMENTAL|Mixed Reality interventional Group|
62261905|NCT06459154|EXPERIMENTAL|Traditional Physiotherapy Group|
62058453|NCT06395155|EXPERIMENTAL|Sequence A|DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period; then DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day, followed by 1 week of wash out period; then DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day
62261906|NCT06459154|PLACEBO_COMPARATOR|Placebo group|
62261907|NCT06353828|EXPERIMENTAL|IcBD-01|IcBD-01 is a novel Cannabidiol enema formulation
62844088|NCT03360318|ACTIVE_COMPARATOR|Elbow cast|Device: Elbow cast
62058454|NCT06395155|EXPERIMENTAL|Sequence B|DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period; then DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day, followed by 1 week of wash out period; then DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day
62261908|NCT06353828|PLACEBO_COMPARATOR|placebo|placebo enema formulation
62261909|NCT03435848|EXPERIMENTAL|BST-236|BST-236 Intravenous, 4.5 g/m2/d or 2.5 g/m2/d, for 6 days
62261910|NCT06272474|ACTIVE_COMPARATOR|Buccal interocclusal records|
62261911|NCT06272474|EXPERIMENTAL|Lateral interocclusal records|
62058455|NCT06395155|EXPERIMENTAL|Sequence C|DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day, followed by 1 week of wash out period; then DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period; then DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day
62261912|NCT04238975|EXPERIMENTAL|GC3111 Vaccine Group|Participants randomized to receive a single dose of GC3111 vaccine (Biological: GC3111 vaccine).
62261913|NCT04238975|ACTIVE_COMPARATOR|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine (Biological: Boostrix® vaccine).
62261914|NCT03312959|EXPERIMENTAL|hyperbaric bupvacaine group|Peribulbar block will be performed using a total volume of 7 ml 6ml hyperbaric bupivacaine 0.5% + hyaluronidase (50 IU) in 1ml saline
62058456|NCT06395155|EXPERIMENTAL|Sequence D|DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day, followed by 1 week of wash out period; then DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day; then DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period
62261915|NCT03312959|ACTIVE_COMPARATOR|isobaric bupvacaine group|Peribulbar block will be performed using a total volume of 7 ml 6ml isorbaric bupivacaine 0.5% + hyaluronidase (50 IU) in 1ml saline
62261916|NCT05503173|EXPERIMENTAL|Motivational and Cognitive-Behavioral Management for Alcohol and Pain Intervention (MCBMAP)|Participants randomized to this arm will receive MCBMAP which utilizes a self-regulation framework to integrate evidence-based approaches for chronic pain and unhealthy drinking.
62261917|NCT05503173|ACTIVE_COMPARATOR|Brief Advice and Information|Participants randomized to this arm will be provided treatment as usual for their conditions.
62261918|NCT01390272|EXPERIMENTAL|Titration Intervention|"The intervention arm includes three levels of resource intensity targeted to improve patients' systolic blood pressure (SBP) \[top number of blood pressure measurement\].~Medium/level 1 resource intensity: a registered nurse (RN) will provide monthly tailored behavioral support telephone calls + home BP monitoring.~High/level 2 resource intensity: a pharmacist will provide monthly tailored behavioral support telephone calls + home BP monitoring + pharmacist-directed medication management.~Booster (low) resource intensity: a licensed practical nurse (LPN) will provide non-tailored behavioral support telephone calls every two months to patients whose SBP comes under control."
62261919|NCT01390272|ACTIVE_COMPARATOR|LPN Control|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months (identical to booster (low) resource intensity component of the titrated intervention). The control arm will utilize the same procedures as the booster level for intervention patients for whom SBP comes under control.
62261920|NCT03803059|EXPERIMENTAL|Wrinkles of the Neck|Microneedle treatment neck areas.
62261921|NCT02064530|ACTIVE_COMPARATOR|bupivacaine|0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on TAP block
62446837|NCT05921058|EXPERIMENTAL|Messenchymal stem cell secretome|The hypoxic mesenchymal stem cell secretome has been developed up to chapter 7, stored at -196 C to -135 C in cryopreservation, and has passed quality tests.
62618414|NCT01755806||aortic root dimension change, aortic valve calcium score|those with aortic valve calcification
62261922|NCT02064530|ACTIVE_COMPARATOR|dexmedetomidine|100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on TAP block
62261923|NCT02064530|SHAM_COMPARATOR|serum phsyologic|0,9% 21 ml serum physiologic
62261924|NCT00807742|EXPERIMENTAL|Contingency Management (CM)|Condition provides contingent monetary reinforcement for smoking reductions (first 5 days) then for smoking abstinence (subsequent 14 days). Expired carbon monoxide (CO) levels will be the basis for determining reductions and abstinence.
62261925|NCT00807742|ACTIVE_COMPARATOR|Noncontingent Reinforcement (NR)|Controls for effects of receiving payments, providing daily breath samples for CO level, and degree of interaction between patient and research staff. NR will allow them to earn an amount which is matched in amount to the expected average earned in CM contingent only on providing breath samples independent of the CO level attained.
62446838|NCT05921058|PLACEBO_COMPARATOR|Placebo|Nacl 0,9% infusion
62844089|NCT03360318|EXPERIMENTAL|Removable elbow brace|Device: Removable elbow brace
62844090|NCT00388193|EXPERIMENTAL|1|
62844091|NCT02269267|OTHER|Discontinuation of TKI medication|Patients with CML on treatment with imatinib, dasatinib, nilotinib, or bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years.
62058457|NCT06395155|EXPERIMENTAL|Sequence E|DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day; then DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period; then DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day, followed by 1 week of wash out period
62446839|NCT04963348||convolutional neural network (CNN)|a classical deep convolutional neural network (CNN) called Inception-V3 was applied to the image sets and validated the classification performance of the trained models
62446840|NCT05896670|EXPERIMENTAL|licaminlimab (OCS-02)|60 mg/mL licaminlimab ophthalmic suspension
62446841|NCT05896670|PLACEBO_COMPARATOR|Vehicle|Vehicle of licaminlimab (OCS-02) ophthalmic suspension
62058458|NCT06395155|EXPERIMENTAL|Sequence F|DHP2306R1 100mg+ DHP2306R2 75mg twice a day for 4ayds and DHP2306R1 100mg+ DHP2306R2 75mg once for a day; then DHP2306R2 75mg twice a day for 4days, and DHP2306R2 75mg once for a day, followed by 1 week of wash out period ; then DHP2306R1 100mg twice a day for 4 days, and DHP2306R1 100mg once for a day, followed by 1week of wash out period
62261926|NCT00964743|EXPERIMENTAL|Intrathecal DepoCyt and Oral Sorafenib|This is a single arm pilot study. Investigators planned to enroll approximately 10 patients to receive concurrent intrathecal DepoCyt and oral Sorafenib. DepoCyt: through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses (a total of 10 DepoCyt treatments). Oral Sorafenib: at 400 mg twice a day throughout the treatment course until disease progression or death.
62261927|NCT02029859|EXPERIMENTAL|Prevalence of obstructive sleep apnea syndrome|"Determine the prevalence of obstructive sleep apnea syndrome (OSA) in late pregnancy in a population of obese patients .~Polygraphic examination between 30 and 36 weeks of amenorhea"
62261928|NCT02107638|EXPERIMENTAL|OMM treatment arm|Subject will receive osteopathic manipulative treatment protocol for Parkinson's disease (PARK-OMM), twice a week for 6 weeks.
62261929|NCT02107638|ACTIVE_COMPARATOR|Counseling|Subjects will receive counseling sessions weekly to match the face to face time with a physician during the OMM treatment arm. No OMM will be performed during this 6 week counseling study period.
62261930|NCT03710174|NO_INTERVENTION|Control group|Without bruxism and no intervention. They will be submitted to electromyographic assessment and evaluation of salivary cortisol and dopamine.
62261931|NCT03710174|EXPERIMENTAL|LED group|The volunteers in Group 2 will be submitted to the initial evaluation of the morphological and psychosocial variables. During the same appointment, red LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of 650 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2\~5 mW, with a dose of 2.675 J/cm2. Further analyses will be performed immediately after the photobiomodulation session and one week later. They will be submitted before and after LED to electromyographic assessment and evaluation of salivary cortisol and dopamine.
62261932|NCT03710174|EXPERIMENTAL|Occlusal splint group|They will be treated using the standard protocol of a rigid occlusal splint. After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later. Written and verbal instructions for use will be given. After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.
62261933|NCT03710174|PLACEBO_COMPARATOR|Placebo group|Subjects with bruxism. The same procedures as LED group, but the device will be turn off.
62261934|NCT00676676|ACTIVE_COMPARATOR|Testosterone|Testosterone patch delivering 300mcg daily for 8-weeks.
62261935|NCT02151474|EXPERIMENTAL|INCB047986 4 mg QD|INCB047986 4 mg will be orally self-administered once daily (QD) for 28 days.
62261936|NCT02151474|EXPERIMENTAL|INCB047986 8 mg QD|INCB047986 8 mg will be orally self-administered once daily (QD) for 28 days.
62261937|NCT02151474|EXPERIMENTAL|INCB047986 12 mg QD|INCB047986 12 mg will be orally self-administered once daily (QD) for 28 days.
62261938|NCT02151474|EXPERIMENTAL|INCB047986 placebo QD|INCB047986 placebo will be orally self-administered once daily (QD) for 28 days.
62261939|NCT02225080||Duragen Secure|Have undergone a neurosurgical procedure where DuraGen® Secure has been implanted
62844092|NCT03056508|EXPERIMENTAL|Exercise plus Nutrition|6 months of supervised group exercise plus education and strategy training to alter diet to be consistent with recommendations outlined in our brain health food guide (BHFG).
62261940|NCT01787682|EXPERIMENTAL|Boost High Protein|Boost high protein with added spirulina
62261941|NCT02994433|EXPERIMENTAL|Nitrous Oxide|One hour inhalation of nitrous oxide
62261942|NCT02994433|PLACEBO_COMPARATOR|Placebo Gas|One hour inhalation of placebo gas
62261943|NCT01305538|OTHER|Arm 1 BMS-954561 40mg or 80mg|"Arm description: BMS-954561 40mg or 80mg three times daily (TID) to Placebo OR Placebo to 40mg or 80mg TID.~Arm type: Active to Placebo or Placebo to Active (cross-over)"
62261944|NCT01305538|OTHER|Arm 2 BMS-954561 150mg or 300mg|"Arm description: BMS-954561 150mg or 300mg TID to Placebo OR Placebo to 150mg or 300mg TID~Arm type: Active to Placebo or Placebo to Active(cross-over)"
62261945|NCT03519763||Control group|Fifteen patients without isthmocele
62261946|NCT03519763||Study subgroup1|15 patients with 1 previous C-Section
62261947|NCT03519763||Study subgroup2|15 patients with 2 or more previous C-Section.
62261948|NCT06360263|EXPERIMENTAL|Sinus lifting using densah bur in combination with activated plasma albumin gel|
62446842|NCT03544320|ACTIVE_COMPARATOR|Activity Monitoring-Wrist worn wearable|Participants in the activity monitoring-wrist worn wearable group will be randomly assigned to track their activity using a Fitbit Charge 2 for 6 months.
62446843|NCT03544320|ACTIVE_COMPARATOR|Activity Monitoring-Waist-worn wearable|Participants in the activity monitoring-waist worn wearable group will be randomly assigned to track their activity using a Fitbit Zip for 6 months.
62261949|NCT01973712|EXPERIMENTAL|Locked Compression Plating|A direct lateral approach to the distal femur will be employed utilizing minimally invasive and indirect reduction techniques. After fracture reduction is achieved with the use of intra-operative fluoroscopy, a locking plate will be provisionally implanted. Following confirmation of placement, definitive fixation will follow with multiple locking screws in the distal fragment and bicortical screw fixation proximally. A standard layered closure will follow
62844093|NCT03056508|ACTIVE_COMPARATOR|Exercise|Identical exercise to the experimental plus education and passive discussion about brain health and healthy lifestyle to control for experimental group nutrition sessions.
62844094|NCT02940314|EXPERIMENTAL|sequence 1|HGP1103→HIP1503
62844095|NCT02940314|EXPERIMENTAL|Sequence 2|HIP1503→HGP1103
62844096|NCT01612806|EXPERIMENTAL|PriMatrix|PriMatrix Dermal Repair Scaffold
62844097|NCT01612806|EXPERIMENTAL|PriMatrix Ag|PriMatrix Ag Antimicrobial Dermal Repair Scaffold
62844098|NCT01612806|ACTIVE_COMPARATOR|Standard of Care|Standard of Care Moist Wound Therapy
62618415|NCT01158105|EXPERIMENTAL|Bortezomib|1.6 mg/m2 intravenous infusion will be administered on days 1, 8, 15, 22 of each 35 day cycle, for up to 6 cycles. Patients who continue to respond during the initial treatment phase with no ongoing significant adverse events will be eligible to receive up to 6 additional cycles. This maintenance dose will be administered on days 1 and 15.
62844099|NCT02453347|EXPERIMENTAL|CES Therapy|All participants will complete CES treatment over the course of four weeks. Assessments will take place at baseline and at post-test four weeks later.
62058459|NCT06452953|EXPERIMENTAL|suanzaoren decoction|The modified Suanzaoren decoction consists of 30.0g of jujube kernel, 15.0g of Chuanchang rhizome and poria, 3.0g of licorice, and 3.0g of amber. It is administered once in the morning and once in the evening.
62058460|NCT06452953|ACTIVE_COMPARATOR|eszopiclone|Eszopiclone: Take 1mg nightly before bedtime.
62058461|NCT01310309||EXecutive Registry|A prospective controlled registry to analyze the clinical efficacy and safety at mid and long-term follow-up in patients with MVD treated with the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS).
62058462|NCT00326586|EXPERIMENTAL|1|
62058463|NCT02950857|EXPERIMENTAL|EPEG (pegylated erythropoietin) - 0.9 µg/kg|Four weekly subcutaneous injections of 0.9 µg/kg EPEG
62058464|NCT02950857|EXPERIMENTAL|EPEG (pegylated erythropoietin) - 1.2 µg/kg|Four weekly subcutaneous injections of 1.2 µg/kg EPEG
62058465|NCT02950857|EXPERIMENTAL|EPEG (pegylated erythropoietin) - 1.5 µg/kg|Four weekly subcutaneous injections of 1.5 µg/kg EPEG
62058466|NCT00693576|EXPERIMENTAL|A|patients who will take simvastatin 20 mg daily
62058467|NCT03912493|ACTIVE_COMPARATOR|Control Group|Number of participants in this group is anticipated to be 20. Conventional physiotherapy and rehabilitation methods will be applied to this group. The conventional program includes the application of Transcutaneous Electrical Nerve Stimulation (TENS), cold pack, therapeutic ultrasound, Codman Exercises, Wand exercises, shoulder wheel exercises, finger ladder exercises, strengthening exercises with elastic band and capsule stretching.
62618416|NCT04725890|EXPERIMENTAL|Intervention|All eligible participants will receive the DyaMX procedure.
62261950|NCT01973712|EXPERIMENTAL|Retrograde Intramedullary Nailing (RIMN)|The previous midline knee incision will be employed to access to the knee joint, allowing exposure of the femoral start point via the open box in the femoral component. Following reaming of the canal, an appropriately sized retrograde nail will be inserted. Intra-operative fluoroscopy will be used to confirm reduction. Both proximal and distal locking screws will be used to transfix the nail. A standard layered closure will follow.
62261951|NCT00810056|ACTIVE_COMPARATOR|Assessment only|Cognitive, academic achievement and mental health screening assessment and report.
62446844|NCT04436692|OTHER|Improve dietary pattern|Nudging approach to test this methodological approach in persons with intellectual disabilitites with goal to improve dietary pattern and loss of weight
62844100|NCT06520644|ACTIVE_COMPARATOR|Traditional physical therapy program|Children in group A (control group N=15, Female =8, Male=7)received specially designed physical therapy program.Facilitation of balance reactions from standing position including; standing on balance board, standing on one leg, weights shifting from standing position and stoops and recover from standing,Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands,Gait training activities including: walking on balance board, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs,Facilitation of protective reaction from standing position by pushing the child in different directions.Facilitation of rising mechanism through changing position e.g.: from lying to standing and from sitting to standing,Strengthening exercises for back and abdominal muscles as well as upper and lower limbs,Jumping in place and jumping a board.
62844101|NCT06520644|ACTIVE_COMPARATOR|Traditional physical therapy program and Wii-based interactive training|"Children in group B (study group=15, Female =10, Male=5) received the same program given to (group A) in addition to Wii-based interactive training.Children in the study group received the same selected physical therapy program given to the control group in addition to 30 minutes Wii-based interactive training program. The frequency of the whole program will be three times per week, for three months.~Nintendo Wii video game consists of console, remote, nunchuck and balance board. The Wii gaming system is based on wireless controller.The games used in this study include step basic, hula hoop, table tilt, jogging, jumping, single limb extension."
62844102|NCT03314922|EXPERIMENTAL|Parsaclisib|
62844103|NCT04163172|ACTIVE_COMPARATOR|Elbow hemiarthroplasty|The Latitude anatomical hemiarthroplasty (WRIGHT -Memphis, Tennessee) for distal humeral fractures.
62058468|NCT03912493|ACTIVE_COMPARATOR|Study Group|Number of participants in this group is anticipated to be 20. Participants in this group will be receiving conventional physiotherapy and rehabilitation methods and 10 minutes of exercise with the game-based virtual reality system (USE-IT). In the USE-IT system two games will be played for 5 minutes each.
62058469|NCT03571737|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 800mg every 8 hours for 3 days
62058470|NCT03571737|EXPERIMENTAL|Ibuprofen & Lidocaine Patch 4%|Ibuprofen 800mg every 8 hours for 3 days and Lidocaine patch 4% 1 patch applied for 12 hours then removed for 12 hours, for 3 days
62058471|NCT03333915|EXPERIMENTAL|Phase 1: 20 milligram (mg) pamiparib|20 mg pamiparib twice a day for 21 days
62058472|NCT03333915|EXPERIMENTAL|Phase 1 : 40 mg pamiparib|40 mg pamiparib twice a day for 21 days
62058473|NCT03333915|EXPERIMENTAL|60 mg pamiparib|60 mg pamiparib twice a day for 21 days
62058474|NCT03333915|EXPERIMENTAL|60 mg pamiparib in platinum-sensitive ovarian cancer (PSOC)|60 mg pamiparib twice a day until occurrence of unacceptable toxicities, disease progression, withdrawal of consent or investigator discretion
62446845|NCT00783796|EXPERIMENTAL|2.25mm XIENCE V®|Patients receiving the 2.25 mm XIENCE V® stent
62844104|NCT04163172|ACTIVE_COMPARATOR|Open reduction and internal fixation|Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States) for distal humeral fractures.
62058475|NCT03333915|EXPERIMENTAL|60 mg pamiparib in platinum resistant ovarian cancer (PROC)|60 mg pamiparib twice a day until occurrence of unacceptable toxicities, disease progression, withdrawal of consent or investigator discretion
62261952|NCT00810056|EXPERIMENTAL|Assessment + FHF|Cognitive, academic achievement and mental health screening assessment and report. Fostering Healthy Futures program (FHF) including weekly therapeutic skill groups and mentoring over a 9-month period.
62261953|NCT05988658||Study cohort|Patients will be identified as high risk based on their AKI risk score (ESTOP- AKI 2.0) being in the top 10% of all hospitalized patients
62058476|NCT06625619||Group I (Patients)|Patients have their medical records reviewed on study.
62058477|NCT06625619||Group II (Nurses)|Nurses complete surveys on study.
62844105|NCT05543993||COVID-19 booster in pregnancy|Pregnant singletons who have received COVID-19 booster in pregnancy
62058478|NCT01808625|OTHER|HYPERBARIC OXYGEN STIMULATION|30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 atmospheres absolute(ATA).
62058479|NCT06282315|EXPERIMENTAL|Fixed Dose Combination (FDC) albendazole and Ivermectin (ALB/IVM )|"Single dose of a tablet of FDC 400 mg/18 mg IVM or 400 mg ALB/9 mg IVM, administered according to the following age criteria:~1. For children from 5-14 years old (included) at the time of screening visit: 1 tablet of FDC 400 mg ALB/9 mg IVM~2. For children from 15-17 years old (included) at the time of screening visit: 1 tablet of FDC 400 mg ALB/18 mg IVM"
62058480|NCT06282315|ACTIVE_COMPARATOR|Albendazole (ALB)|Single dose of a tablet of ALB 400 mg (active control arm).
62058481|NCT01423786|OTHER|Please help|"Dr. Kumar left Nationwide Children's Hospital in 2014 and efforts to get ahold of her to complete her ct.gov entries have been unsuccessful as we are not able to get ahold of her.~In July 2014, she wrote in her Continuing Review application to the NCH IRB: 34 patients have been recruited and data has mostly been collected. Follow up calls have been made and no adverse events occurred during the study period.~No other information is available."
62058482|NCT01859793|PLACEBO_COMPARATOR|Matching Placebo|Matching Placebo for Sitagliptin
62058483|NCT01859793|ACTIVE_COMPARATOR|Sitagliptin|100mg pill, PO administered once daily.
62058484|NCT04274959|ACTIVE_COMPARATOR|ceramic onlay with shoulder preparation design.|posterior ceramic onlay restoration with shoulder design with 1 mm shoulder thickness
62058485|NCT04274959|EXPERIMENTAL|ceramic onlay with butt joint preparation design|posterior ceramic onlay with butt joint preparation design with flat occlusal reduction with inclined surface
62446846|NCT05031728|EXPERIMENTAL|CPT Group|Cognitive Processing Therapy (CPT) is employed. Each patient will attend 12 individual sessions with the therapist. The sessions will be on the weekly basis. The standard manual of CPT (Resick et al., 2016) is going to be employed.
62446847|NCT05197907|EXPERIMENTAL|Diaphragm fascial release group.|Ten minutes lasting fascial release techinques performed on diaphragm.
62446848|NCT05197907|PLACEBO_COMPARATOR|Classic massage group|Ten minutes lasting classic massage performed on abdomen.
62446849|NCT01498484|EXPERIMENTAL|HCT EBV+ PTLD R/R Rituximab|Patients with Epstein-Barr virus positive (EBV+) posttransplant lymphoproliferative disorders (PTLD) hematopoietic cell transplant (HCT) who were relapse/refractory (R/R) to rituximab will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62844106|NCT05543993||COVID-19 booster in breastfeeding|Breastfeeding individuals who have received COVID-19 booster while breastfeeding
62844107|NCT00528450|EXPERIMENTAL|Tretinoin and Arsenic Trioxide With or Without Idarubicin|See Outline for details
62844108|NCT02665832|EXPERIMENTAL|AB|Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin) followed by DWJ1351
62844109|NCT02665832|EXPERIMENTAL|BA|DWJ1351 followed by Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)
62844110|NCT01904838||Patients in Pittsburgh, Pennsylvania|persons receiving treatment at integrative and conventional medicine clinics in Pittsburgh, Pennsylvania
62844111|NCT01904838||Internet sample|internet sample of persons reporting that they receive, or have received in the past year, integrative medicine or conventional medical treatments.
62058486|NCT04782934|EXPERIMENTAL|YANG system group|
62058487|NCT05750186|EXPERIMENTAL|Abdominal Massage Group|"At the first encounter with the patient; Patient Information Form, Gastrointestinal Symptom Rating Scale, General Comfort Scale and Functional Independence Scale will be applied.~* From the morning of the first day, abdominal massage will be applied to the patients 2 times a day, in the morning and in the evening, for 3 days (15 minutes).~* Then, applying abdominal massage to the patients in the experimental group. After each massage application, the patient's bowel sounds/movements will be listened to.~* Medicines such as laxatives, suppositories and enemas will not be given to the experimental group and Bristol Stool Scale will be filled in for patients who defecate within this period.~* In order to evaluate the abdominal massage and its effect on the comfort level of the patients, the Gastrointestinal Symptom Rating Scale, General Comfort Scale and Functional Independence Scale will be applied again at the end of the 3rd day after the application of abdominal massage."
62261954|NCT03868592|EXPERIMENTAL|Gastric sleeve surgery|before and after weight loss from bariatric surgery
62261955|NCT02774382|ACTIVE_COMPARATOR|Vancomycin|"Oral vancomycin according to number of recurrences (Danish guidelines):~First recurrence: Capsule vancomycin 125 mg x 4 p.o. times daily for 14 days~≥2 recurrences:~* capsule vancomycin 125 mg x 4 times daily p.o. for 14 days followed by~* capsule vancomycin 125 mg x 2 times daily p.o. for 7 days followed by~* capsule vancomycin 125 mg x 1 times daily p.o. for 7 days followed by~* capsule vancomycin 125 mg x 1 p.o. every second day for 7 days followed by~* capsule vancomycin 125 mg x 1 p.o. every third day for 14 days"
62261956|NCT02774382|EXPERIMENTAL|Vancomycin + fecal microbiota transplantation|Capsule vancomycin 125 mg x 4 times daily p.o. for 7-14 days followed by Fecal Microbiota Transplantation with 200 ml fecal suspension administrated with a rectal catheter.
62261957|NCT02774382|EXPERIMENTAL|Vancomycin + rectal bacteriotherapy|Capsule vancomycin 125 mg x 4 times daily p.o. for 7-14 days followed by Rectal bacteriotherapy with 200 ml suspension of a fixed mixture of bacterial strains administrated with a rectal catheter.
62058488|NCT05750186|NO_INTERVENTION|Control Group|"* Patients who did not defecate within the first 3 days after surgery will constitute the control group.~* At the first encounter with the patient; A Patient Information Form, Gastrointestinal Symptom Rating Scale (GSS), General Comfort Scale (GAS) and Functional Independence Scale (FIM) will be administered.~* From the first encounter, patients will be given medications that are in line with their clinical routine, such as laxatives, suppositories and enemas, according to the doctor's request.~* Intestinal sounds/movements of the patients will be listened to 6 times, 2 times a day for 3 days.~* Bristol Stool Scale will be filled in for patients who defecate within this period.~* At the end of the 3-day follow-up of the patients, Gastrointestinal Symptom Rating Scale, General Comfort Scale and Functional Independence Scale will be applied again and the first stool of the patients who defecate will be evaluated with the Bristol Stool Scale."
62058489|NCT01416233|EXPERIMENTAL|autologous fat grafting|There is one arm of this study. People with anophthalmic sockets and orbital atrophy are given a single session of autologous fat grafting by a closed cannula technique and are observed to measure, by MRI, the amount of fat retained at one year
62058490|NCT00838682|EXPERIMENTAL|rabeprazole sodium|Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
62058491|NCT00838682|ACTIVE_COMPARATOR|Omeprazole|Intravenous Omeprazole 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
62844112|NCT01349400|EXPERIMENTAL|watchful waiting|"After informed consent and randomization into the watchful waiting group patients will receive standardized verbal information and written instructions on symptoms of acute incarceration. In case of acute symptoms they will be told to visit a physician immediately. On follow-up visits at 1 month, 12 months and 24 months the hernia size will be determined by physical examination, and the pain/ discomfort and the functional status will be monitored.~Control intervention/ reference test:~Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided. Divergent types of repair are permitted but have to be documented."
62058492|NCT01021592||001|
62058493|NCT01498822|EXPERIMENTAL|Levetiracetam|Levetiracetam twice a day treatment group
62058494|NCT01498822|ACTIVE_COMPARATOR|Oxcarbazepine|Oxcarbazepine twice a day treatment group
62058495|NCT02823821|ACTIVE_COMPARATOR|137mmol/l|Participating dialysis sites will be randomised to a default dialysate sodium concentration of 137mmol/l
62058496|NCT02823821|ACTIVE_COMPARATOR|140mmol/l|Participating dialysis sites will be randomised to a default dialysate sodium concentration of 140mmol/l
62058497|NCT02143037|ACTIVE_COMPARATOR|Control Group|usual care
62058498|NCT02143037|EXPERIMENTAL|Experimental Group|usual care plus prize contingency management for attending treatment
62058499|NCT02171858||stroke|Patients admitted to hospital who are diagnosed with stroke will be treated as usually a our center by observation, venous or arterial thrombolysis depending on extension, condition, thrombolysis feasibility.
62058500|NCT05048849|EXPERIMENTAL|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
62058501|NCT06247202|EXPERIMENTAL|Intervention group|Participants in the intervention group will receive smart phone delivered health education in the form of text messages through WhatsApp.
62261958|NCT01538823||Group 1|Enrollment of surgical patients at Barnes Jewish Hospital (BJH) with a presumptive diagnosis of RCC and planned nephrectomy or partial nephrectomy.
62618417|NCT06300944|ACTIVE_COMPARATOR|Group C(Control Group)|At the beginning of the operation, intravenous infusion of reifentanil 0.1\~0.2 μg/kg·min, propofol 2\~4mg/kg·h, rocuronium 0.3mg/kg·h intermittently, inhalation of 1%\~2% sevoflurane were maintained, the fluctuation of blood pressure was not more than 20% of the basic level, and the heart rate was 50\~100 times /min. Pump proper amount of normal saline.The postoperative PCIA regimen was Sufentanil 2ug/kg, ondansetron 16mg, diluted with appropriate normal saline, a total of 100ml
62058502|NCT06247202|ACTIVE_COMPARATOR|Control group|Participants in the control group will receive paper delivered health education in the form of a one time handout.
62058503|NCT00509236|EXPERIMENTAL|Sitagliptin 25 mg|
62058504|NCT00509236|ACTIVE_COMPARATOR|Glipizide 2.5 mg - 20 mg|
62058505|NCT02524301|EXPERIMENTAL|anorexia nervosa patients|Cerebral \[11C\]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
62058506|NCT02524301|EXPERIMENTAL|Recovered anorexia nervosa patients|Cerebral \[11C\]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
62058507|NCT02524301|EXPERIMENTAL|Healthy Volonteers|Cerebral \[11C\]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
62261959|NCT01538823||Group 2|Surgical patients at BJH with non urological cancers
62261960|NCT01538823||Group 3|Surgical patients at BJH with a presumptive diagnosis of RCC and planned nephrectomy or partial nephrectomy
62058508|NCT01300325|PLACEBO_COMPARATOR|0.9% saline|patients receive every 6 hours the nebulized 0.9% saline (placebo comparator) (group I) or the 3% HS (group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
62058509|NCT01300325|NO_INTERVENTION|3% hypertonic saline|Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
62058510|NCT04671901|EXPERIMENTAL|Pediatric Participants|Male and female patients aged 1-21 years with a primary solid tumor undergoing treatment with the pre-defined chemotherapy regimens of EFT, MAP or D9803.
62058511|NCT05538962|EXPERIMENTAL|Healthy controls|Healthy controls will receive the sensors
62058512|NCT05538962|EXPERIMENTAL|Outpatients with cirrhosis|Outpatients with cirrhosis will receive the sensors
62058513|NCT05538962|EXPERIMENTAL|Inpatients with cirrhosis|Inpatients with cirrhosis will receive the sensors
62058514|NCT02579798|EXPERIMENTAL|PEEP 10 cmH20|In this group, a PEEP of 10 cmH20 is applied for the duration of the intervention and a recruitment maneuver is applied each time the SpO2 (oxygen pulsated saturation) drops below 95%.
62261961|NCT01538823||Group 4|Surgical patients at BJH with non urological cancers
62261962|NCT01538823||Group 5|Healthy volunteers with no history of cancer or renal disease
62261963|NCT01538823||Group 6|Patients at BJH/Washington University School of Medicine under post procedure surveillance for RCC recurrence and patients under treatment for metastatic disease.
62261964|NCT01538823||Group 7|Patients with a presumptive diagnosis of bladder cancer or prostate cancer
62261965|NCT03297736|ACTIVE_COMPARATOR|Control|Subjects receive the control device.
62261966|NCT03297736|EXPERIMENTAL|Investigational device|Subject receives the 3D CAD/CAM autograft prosthesis implant.
62261967|NCT03139812|OTHER|30-day SiH CW, No Daily Irrigation|Control group subjects wore SiH lenses for 30-day CW under normal clinical practice guidelines with no daily morning irrigation of the eyes with sterile saline solution
62261968|NCT03139812|OTHER|30-day SiH CW, Daily Irrigation|Treatment group subjects wore SiH lenses for 30-day CW under normal clinical practice guidelines, and also irrigated the eyes with sterile saline solution every morning upon awakening
62261969|NCT00622674|EXPERIMENTAL|Bortezomib and Cetuximab|The starting dose of bortezomib will be 1.3 mg/m2 with a 0.1 increment increase with each successive dose level to a maximum of 2.0 mg/m2. A loading dose of cetuximab will be given on day 1 (400 mg/m2) followed by a weekly dose of 250 mg/m2.
62261970|NCT03200327|ACTIVE_COMPARATOR|laparoscopic promontofixation|
62261971|NCT03200327|EXPERIMENTAL|Anterior vaginal sacrospinofixation|
62261972|NCT03040375|EXPERIMENTAL|Peer counselling|There were two types of intervention: one providing breast-feeding and complementary feeding counselling + psychosocial stimulation interventions.
62261973|NCT03040375|NO_INTERVENTION|Non peer counselling|Usual health messages
62261974|NCT06363721|EXPERIMENTAL|PerioPull™|Participants will swish 1 teaspoon (approx. 5 mL) of oil in the mouth for a minimum of 5 minutes after their normal brushing routine, as is suggested on the label of the bottle. They will spit out the oil and not rinse to allow for longer contact to the teeth and gums. This will be once a day for 12 weeks.
62261975|NCT00806936||A|
62261976|NCT00806936||B|
62261977|NCT05925296|EXPERIMENTAL|double-site high frequency rTMS over the bilateral M1 of the lower leg and SMA|Patients in the Experimental group underwent ten sessions of double-site high frequency rTMS over the bilateral M1 of the lower leg and SMA.
62261978|NCT05925296|ACTIVE_COMPARATOR|single-site high frequency rTMS over the bilateral primary motor cortex of the lower leg|Patients in the Active Comparator group underwent ten sessions of single-site active magnetic stimulation with high frequency rTMS over the bilateral M1 of the lower leg.
62261979|NCT05925296|SHAM_COMPARATOR|sham magnetic stimulation on motor cortex|Patients in the Sham Comparator group underwent 10 sessions of double sham rTMS on M1.
62058515|NCT02579798|ACTIVE_COMPARATOR|optimal PEEP|"In this group, 10 cmH20 PEEP is applied immediately. Then the optimal PEEP is sought at three key moments. It is determined by the best value of lung compliance found in the patient. It is sought by increasing or decreasing the value of the PEEP by increments or decrements of 2 cmH20. If after 6 respiratory cycles, the value of the compliance is increased, the investigator continues to increase the value of the PEEP. On the other hand, if the value of compliance is reduced, the investigator reduces the value of PEEP. The value of the PEEP selected shall in no event exceed the set pressure range (maximum pressure plate of 30 cmH20 and maximum inspiratory peak pressure 40cmH20). A recruitment maneuver is applied each time the SpO2 drops below 95%, as in the PEEP 10cmH2O group."
62058516|NCT05981664|EXPERIMENTAL|with adapter|All participants are in the experimental group baseline speed and accuracy using minecraft videogame will serve as baseline data and each subject will be their own control. participants will be given an adapter to support onehanded game play and an xbox system to use at home for a week. Follow-up data (speed and accuracy of minecraft) will be reevaluated one week later. Qualitative interview data will assist in understanding facilitators and barriers for use. On baseline and reassessment, the QUEST 2.0 and VAS will be administered as the primary outcome measures in addition to secondary outcome measures (speed and accuracy of minecraft).
62261980|NCT02124564|EXPERIMENTAL|Lacosamide|Open-label, single-arm
62261981|NCT06384209|ACTIVE_COMPARATOR|Friendship Bench alone|The treatment in the control arm consists of usual care being the Friendship Bench intervention as stand-alone.It consists of six sessions of problem-solving therapy delivered by Lay Health Workers (LHWs) on a bench in a discreet area on the premises of the PHC according to an established manual. Patients are encouraged to come up with a list of their problems, to select one problem they want to tackle, brainstorm for solutions, identify the best solution, and develop an action plan to implement it until the next session. The LHW help them recognize potentially dysfunctional problem-solving and develop a realistic plan for the successful resolution of the prioritized problem. The sessions will be delivered approximately one week apart.Patients from the control arm will be allowed to cross-over to the intervention arm after the four months follow-up in case of non-response defined as \<50% improvement in PHQ-9 as compared to baseline
62261982|NCT06384209|EXPERIMENTAL|Friendship Bench plus antidepressants|The treatment in the intervention arm consists of the Friendship Bench Plus Intervention (FB+) which combines six sessions of problem-solving therapy for depression delivered by trained Lay Health Workers and nurse-led prescription of antidepressants. The nurse will begin on the day of the first FB counselling session with 20mg Fluoxetine or 50mg Sertraline if breastfeeding. The nurse will then dispense the antidepressants for two weeks. As the study population comprises patients with more severe forms of depression, the investigators don't expect a relevant response to this starting dose. Therefore, after two weeks, which corresponds to the third FB counselling session, the nurse will increase to 40mg Fluoxetine or 100mg Sertraline if breastfeeding.If patients show \<30% improvement in PHQ-9 as compared to baseline on the sixth study vist, Fluoxetine will be increased to 60mg and Setraline to 150mg.
62261983|NCT06066827|EXPERIMENTAL|Minoxidil|The drug used is minoxidil 5% solutions for topical use, 1 cc, 2 times a day, every day for 12 weeks
62844113|NCT01349400|ACTIVE_COMPARATOR|Hernia repair|Intervention: Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided. Divergent types of repair are permitted but have to be documented.
62261984|NCT06066827|EXPERIMENTAL|Secretome from Adipose-Derived Stem Cells|Secretom concentrate of Adipose-Derived Stem Cells (ADSCs) 2cc, injected to the scalp on weeks 0, 4, and 8 of the study
62261985|NCT06066827|EXPERIMENTAL|Minoxidil + Secretome|The subject received both minoxidil and secretome from ADSCs, with the same dosage form, dosage, frequency, and duration
62261986|NCT06537713||Control Group|The control group consisted of healthy individuals without any disease who voluntarily participated in the study.
62261987|NCT06537713||Patients Group|The study specifically included patients over 18 years of age with moderate TBI (GCS: 9-13) who provided informed consent.
62261988|NCT04383860|EXPERIMENTAL|5-0 suture|5-0 suture administration during surgery
62261989|NCT04383860|ACTIVE_COMPARATOR|4-0 suture|4-0 suture administration during surgery
62261990|NCT04155255|NO_INTERVENTION|Control|Age-matched overweight and obese students were selected from control schools. The students participated in their usual health and physical education classes plus any other curriculum activities provided by the school.
62261991|NCT04155255|EXPERIMENTAL|Intervention|Overweight and obese students were recruited from intervention schools. Students underwent MyBFF@school intervention programme that consisted of physical activity, nutrition and psychological modules for the duration of 6 months. MyBFF@school intervention programme were conducted by trained personnel that were stationed full-time at each intervention school.
62261992|NCT03650842|EXPERIMENTAL|Laparoscopic pyloromyotomy|Infants undergoing laparoscopic pyloromyotomy.
62261993|NCT03332498|EXPERIMENTAL|Pembrolizumab and Ibrutinib|"Pembrolizumab intravenously (IV): 200 mg every 3 weeks (Q3W).~Ibrutinib by mouth (PO): Phase I Dose Escalation at doses of 420 mg daily (cohort 0) and 560 mg daily (cohort 1);. Phase II treatment at Recommended Phase II dose."
62261994|NCT06436651|EXPERIMENTAL|Experimental group|Children's group where digital storytelling method was applied and stories were created
62261995|NCT06436651|OTHER|Control group|Children's group where the stories of children in the initiative group will be watched
62261996|NCT03081520|EXPERIMENTAL|Affective response MIT|Moderate intensity continuous training 50 min with walking or running on approximately 75% of HRmax
62261997|NCT03081520|EXPERIMENTAL|Affective response HAIT|High-Intensity Aerobic Interval Training 4x4 min with walking or running on 85-95% of HRmax 3 min active recovery between sets, intensity of approximately 70% of HRmax
62261998|NCT03081520|EXPERIMENTAL|Affective response HIIT|High-Intensity Interval Training 4-6 x 30-sec sprints on tread mill, \>95% HRmax during sprints 4 min recovery between sprints, intensity of approximately 70% of HRmax
62844114|NCT03502356|ACTIVE_COMPARATOR|Control Group|This group will include 200women undergoing elective cs. In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
62261999|NCT06126302||Before 1930|the patients were divided into ten groups according to the decade of their birth: before 1930
62446850|NCT01498484|EXPERIMENTAL|SOT EBV+ PTLD R/R Rituximab|Patients with EBV+PTLD solid organ transplant (SOT) who were R/R to rituximab or R/R to rituximab and chemotherapy will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After 3 week observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62844115|NCT03502356|NO_INTERVENTION|Study Group|This group will include 200women undergoing elective cs. In this group, patients will receive only standard prophylaxis antibiotic(CEFAZOLIN)
62262000|NCT06126302||1930-1939|the patients were divided into ten groups according to the decade of their birth: 1930-1939
62262001|NCT06126302||1940-1949|the patients were divided into ten groups according to the decade of their birth: 1940-1949
62262002|NCT06126302||1950-1959|the patients were divided into ten groups according to the decade of their birth: 1950-1959
62844116|NCT00499083|EXPERIMENTAL|Vaccine|Patients with HER-2/neu negative tumors will receive IT DCs one week after the first three of four cycles of dose dense T therapy and then four cycles of dose dense AC therapy will be given (i.e. T-AC).
62262003|NCT06126302||1960-1969|the patients were divided into ten groups according to the decade of their birth: 1960-1969
62262004|NCT06126302||1970-1979|the patients were divided into ten groups according to the decade of their birth: 1970-1979
62262005|NCT06126302||1980-1989|the patients were divided into ten groups according to the decade of their birth: 1980-1989
62262006|NCT06126302||1990-1999|the patients were divided into ten groups according to the decade of their birth: 1990-1999
62262007|NCT06126302||2000-2009|the patients were divided into ten groups according to the decade of their birth: 2000-2009
62262008|NCT06126302||after 2009|the patients were divided into ten groups according to the decade of their birth: after 2009
62262009|NCT04179734|EXPERIMENTAL|Intervention|Bremelanotide 1.75 mg - prefilled subcutaneous autoinjector containing 1.75 mg Bremelanotide in a 0.3 mL solution volume.
62262010|NCT04179734|PLACEBO_COMPARATOR|Placebo|1.75 mg equivalent - prefilled subcutaneous autoinjector containing Bremelanotide formulation without the active ingredient in a 0.3 mL solution volume.
62262011|NCT05241990|EXPERIMENTAL|Alcohol Stepped Care|Based on severity of alcohol use, individuals receive brief alcohol intervention delivered in person or by computer, cognitive behavioral therapy by person or computer, or pharmacotherapy for alcohol use disorder
62058517|NCT04947254|ACTIVE_COMPARATOR|Group A (Apa, ADT, XRT)|"PART 1 NEOADJUVANT PHASE (CYCLES 1-3): Patients receive PO QD on days 1-28, and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~PART 2 RADIATION PHASE (CYCLES 4-6): Within 30 days of completing Part 1, patients undergo radiation therapy. Patients also receive apalutamide PO QD on days 1-28 and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~PART 3 ADJUVANT PHASE (CYCLES 7 AND BEYOND): Patients receive apalutamide PO QD on days 1-28 and physician's choice ADT. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
62058518|NCT04947254|EXPERIMENTAL|Group B (Apa, ADT, XRT, AAP, niraparib)|"PART 1 NEOADJUVANT PHASE (CYCLES 1-3): Patients receive PO QD on days 1-28, and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~PART 2 RADIATION PHASE (CYCLES 4-6): Within 30 days of completing Part 1, patients undergo radiation therapy. Patients also receive apalutamide PO QD on days 1-28 and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~PART 3 ADJUVANT PHASE (CYCLES 7 AND BEYOND): Patients receive abiraterone acetate PO QD, prednisone PO BID, physician's choice ADT, and niraparib PO QD. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
62058519|NCT02073916|EXPERIMENTAL|T-DM1 + Lapatinib + Abraxane|T-DM1 with Laptinib followed by Abraxane
62058520|NCT05878392|EXPERIMENTAL|group 1|immediate implant placement and the buccal jumping gap was packed using PRF
62058521|NCT05878392|EXPERIMENTAL|group 2|immediate implant placement and the buccal jumping gap was packed using xenograft
62058522|NCT05878392|EXPERIMENTAL|group 3|immediate implant placement and the buccal jumping gap was packed using alloplast
62058523|NCT05363319||Cohort 1|Cemiplimab monotherapy
62058524|NCT05363319||Cohort 2|Cemiplimab in combination with platinum-based chemotherapy
62058525|NCT06473844|EXPERIMENTAL|SGLT2 inhibitor empagliflozin|10mg daily from recruitment to hospital discharge
62058526|NCT06473844|PLACEBO_COMPARATOR|Placebo|1 tablet daily from recruitment to hospital discharge
62262012|NCT05995288||Children suffering from PFAPA|Children suffering from periodic fever, with at least one of the following symptoms: aphthous stomatitis, pharyngitis, cervical adenitis
62262013|NCT05418400|ACTIVE_COMPARATOR|bulkfill composites|sonic fill 3 \& PALFIQUE bulk flow bulk fill composite
62844117|NCT04211909|EXPERIMENTAL|SOF/VEL|Participants with chronic HCV infection (genotype 1 or 2), who are treatment-naive or treatment-experienced with interferon (IFN)-based treatments will receive SOF/VEL for 12 weeks.
62844118|NCT04211909|EXPERIMENTAL|SOF/VEL/VOX|Participants with chronic HCV infection (genotype 1), who are treatment-experienced with nonstructural protein 5A (NS5A) direct-acting antiviral (DAA)-based treatments of at least 4 weeks duration will receive SOF/VEL/VOX for 12 weeks.
62058527|NCT01889186|EXPERIMENTAL|Main Cohort|Participants received ABT-199 tablets once daily (QD) orally for up to 79 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
62058528|NCT01889186|EXPERIMENTAL|Safety Expansion Cohort|Participants received ABT-199 tablets once daily (QD) orally for up to 68 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
62262014|NCT05418400|ACTIVE_COMPARATOR|incremental composites|Neo spectra \& Clear fill AP-X incremental composites
62262015|NCT00522145|EXPERIMENTAL|Group 1|
62262016|NCT00540137|ACTIVE_COMPARATOR|NRTIs plus NNRTI arm|nevirapine 400 mg once daily (after 12 weeks induction)with a nucleoside backbone
62262017|NCT00540137|ACTIVE_COMPARATOR|NRTIs plus PI arm|atazanavir 300 mg once daily, ritonavir 100 mg once daily with a nucleoside backbone
62262018|NCT04832997|EXPERIMENTAL|mpMRI plus Micro-US|Patients with a clinical suspicion of csPCa will receive mpMRI and Micro-US in two different visits (randomized sequence). The results of the diagnostic procedures will determine how many and which type of prostate biopsies patients will undergo.
62262019|NCT02393638|EXPERIMENTAL|study group|Simulation and lecture
62262020|NCT02393638|ACTIVE_COMPARATOR|control group|Lecture only
62262021|NCT05063227||Study group|As this is a single-group, observational study all patients will be monitored with all three nociception monitoring systems (the Surgical Pleth Index (SPI), the Pupillary Pain Index (PPI) and the Nociception Level (NOL)) and data on heart rate changes as a variable used in current clinical practice to choose the opioid dosage during general anesthesia will be obtained additionally.
62844119|NCT05446818|ACTIVE_COMPARATOR|Flavanol first|Subjects will receive over 8 days both cocoa flavanols (CF) and placebo (P) capsules on alternating days. Sequence of this arm is: CF-P-CF-P-CF-P-CF-P
62844120|NCT05446818|ACTIVE_COMPARATOR|Placebo first|Subjects will receive over 8 days both cocoa flavanols (CF) and placebo (P) capsules on alternating days. Sequence of this arm is: P-CF-P-CF-P-CF-P-CF
62058529|NCT03390777|ACTIVE_COMPARATOR|surgery only|Surgery consisting in debridement/removal of affected tissue/s will be performed.
62844121|NCT00651729|EXPERIMENTAL|1|Botulinum Toxin Type A
62844122|NCT03588884|ACTIVE_COMPARATOR|CTAP101|CTAP101/Calcifediol Capsules 60 micrograms (mcg) once daily at bedtime, except on Days 1 and 29 when dosing will occur in the morning before breakfast
62262022|NCT04507685|EXPERIMENTAL|Low Glycaemic Diet (LG)|Low carbohydrate, low saturated fat diet
62262023|NCT04507685|ACTIVE_COMPARATOR|Control Diet|High unrefined carbohydrate, low fat diet
62618418|NCT06300944|EXPERIMENTAL|Group K(Esketamine Group)|Intraoperatively, remifentanil 0.1-0.2 μg/kg·min, propofol 2-4 mg/kg·h, intermittent rocuronium 0.3 mg/kg·h, inhalation of 1%-2% sevoflurane were given by continuous intravenous infusion, to maintain blood pressure fluctuation within 20% of the baseline level and heart rate within 50-100 beats/min. Esketamine 0.2mg/kg·h was pumped at the beginning of the procedure.The postoperative PCIA regimen was Sufentanil 2ug/kg, ondanseetron 16mg, esketamine 0.75mg/kg, diluted with appropriate normal saline, a total of 100ml.
62618419|NCT02697734|EXPERIMENTAL|osilodrostat Group|Participants in this arm were randomized to receive the study drug, osilodrostat followed after Week 12 by open-label osilodrostat at the starting dose (with a second dose titration)
62262024|NCT01388673|EXPERIMENTAL|ACE Stapler procedure|ACE Stapler procedure for the treatment of dilated post-surgical gastric anatomy
62262025|NCT06420778|EXPERIMENTAL|therapy group|Subjects in this group will be treated with Cluster needle shallow stabbing combined with electroacupuncture.The treatment time was 60 minutes each time, once every other day, and the treatment was carried out 3 times a week for 4 consecutive weeks, for a total of 12 treatments.
62618420|NCT02697734|PLACEBO_COMPARATOR|osilodrostat Placebo Group|Participants in this arm were randomized to receive osilodrostat placebo followed after Week 12 by open-label osilodrostat at the starting dose (with a dose titration)
62618421|NCT05867901||patients cohort|As an one-arm observational clinical trial, we have only one patients cohort.
62618422|NCT04404829|EXPERIMENTAL|Informational Manual Therapy|It is an integral no orthopedic and very soft manual therapy
62618423|NCT03519919|EXPERIMENTAL|Somofilcon A multifocal lens|Habitual wearers of multifocal contact lenses will be refit to somofilcon A multifocal lens and provide a subjective assessment.
62262026|NCT06420778|EXPERIMENTAL|Control group|Subjects in this group will be treated with oral pregabalin capsules only, 150 mg twice daily for 4 weeks.Pregabalin was administered with Lerica (specification: 75 mg\*8 capsules,manufactured by Pfizer Pharmaceuticals Ltd).
62262027|NCT00885274|EXPERIMENTAL|Split Dose|Doses of Pico-Salax split: one dose administered the night prior to colonoscopy and the other dose administered the day of the procedure.
62262028|NCT00885274|ACTIVE_COMPARATOR|Traditional Dose|Both doses of Pico-Salax taken the evening prior to colonoscopy.
62262029|NCT02431351|EXPERIMENTAL|Selinexor|60 mg once weekly
62262030|NCT03703102|PLACEBO_COMPARATOR|Arm A|Subcutaneous administration of placebo
62262031|NCT03703102|EXPERIMENTAL|Arm B|Subcutaneous administration of KHK4083 (dose level 1, dosing regimen 2)
62262032|NCT03703102|EXPERIMENTAL|Arm C|Subcutaneous administration of KHK4083 (dose level 2, dosing regimen 1)
62446851|NCT01498484|EXPERIMENTAL|EBV+ AID-LPD|Patients with EBV+ acquired immunodeficiency (AID) lymphoproliferative disorder (LPD) will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity
62446852|NCT01498484|EXPERIMENTAL|EBV+ PID-LPD|Patients with EBV+ primary immunodeficiency (PID) LPD will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62446853|NCT01498484|EXPERIMENTAL|EBV+ Viremia|Patients with EBV+ viremia will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62618424|NCT03246919|PLACEBO_COMPARATOR|Control (Group A)|One bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia. This amount of fluid is part of standard of care.
62618425|NCT03246919|ACTIVE_COMPARATOR|Intervention (Group B)|One bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia. This amount of fluid is part of standard of care.
62618426|NCT05358977|EXPERIMENTAL|Tisseel|Patients are undergoing bilateral blepharoplasty. In this arm (Tisseel), the patient with undergo blepharoplasty with topical Tisseel placed in the incision prior to standard closure. 1 minute of pressure will be exerted to both eyelids after closure to mask the patient as to which eyelid received the Tisseel.
62844123|NCT03588884|EXPERIMENTAL|Immediate-release (IR) calcifediol|Immediate-release (IR) calcifediol/266 micrograms (mcg) capsule before breakfast on the mornings of Day 1 and Day 29
62262033|NCT03703102|EXPERIMENTAL|Arm D|Subcutaneous administration of KHK4083 (dose level 3, dosing regimen 1)
62262034|NCT03703102|EXPERIMENTAL|Arm E|Subcutaneous administration of KHK4083 (dose level 3, dosing regimen 2)
62262035|NCT00514514|ACTIVE_COMPARATOR|CNI standard regimen|Myfortic, Sandimmun Optoral and corticosteroids
62262036|NCT00514514|EXPERIMENTAL|CNI free regimen|"CNI free regimen: comprising the following steps for switching treatment:~Step 1 at BL2 + 1 day: Myfortic, Certican 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, Certican 3 mg and corticosteroids"
62262037|NCT00514514|ACTIVE_COMPARATOR|CNI low regimen|"CNI low regimen: comprising the following steps for switching treatment:~Step 1 at BL2 + 1 day: Certican 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: Certican 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids"
62262038|NCT04080193|EXPERIMENTAL|Intervention Group|The study will be a Smartphone-based interventional trial. To assess the effectiveness of the intervention weight- and eating-related behavior and cognitive and emotional responding as well as body-weight will be assessed using questionnaires and ecological momentary assessment (EMA) for one week at a pre- (T0), post- (T1) and two follow-up-assessments after six (T2) and 12 months (T3).
62262039|NCT04080193|NO_INTERVENTION|Control Group|Members of the control group will participate at each assessment. During the intervention phase they will receive treatment as usual.
62262040|NCT04539561|EXPERIMENTAL|Pigmentation|Treatment of Hand Pigmentation Using PiQo4 Laser System
62058530|NCT03390777|ACTIVE_COMPARATOR|surgery and PRGF|Surgery consisting in debridement/removal of affected tissue/s will be performed. Platelet Rich Growth Factor (device) will be produced by a venous blood sampling of the patient and applied to the treated area
62058531|NCT00738101|EXPERIMENTAL|Fish Oil Emulsion Arm|"In infants who meet the eligibility criteria for Fish Oil Emulsion arm will receive Fish Oil Emulsion after enrollment under the study.~Therapy with Fish Oil Emulsion (Omegaven) will be provided at a dose of 1 gm/kg/day (by continuous infusion) and will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If previously on Intralipid, it will be stopped prior to initiation of Fish Oil Emulsion.Fish oil emulsion will be provided as a continuous intravenous emulsion over 24 hours."
62058532|NCT02645084|ACTIVE_COMPARATOR|Intervention|Intervention: offering an online risk assessment questionnaire to CRC patients, to facilitate the detection of colorectal cancer patients with hereditary or familial colorectal cancer
62058533|NCT02645084|NO_INTERVENTION|Control|Control: Hospital-based standard practice for the detection of colorectal cancer patients with hereditary or familial colorectal cancer, informed by the referral criteria that are being used in the intervention group
62058534|NCT05530590|EXPERIMENTAL|Training to Serve (TTS) in person training|Participants are provided access to the pretest one week before the training. On the day of training, when the trainers arrive, participants have a final opportunity to complete the baseline survey before the intervention. Tablets will be available to complete pre- and post- surveys. The training for management takes 3-4 hours, and for staff, one hour. For consistency and feasibility, both trainings are conducted by the same trainers at the same visit. Immediately after the intervention, participants complete the post-intervention seminar evaluation assessing knowledge and attitudes/comfort in serving SGM clients.
62262041|NCT06136377|EXPERIMENTAL|RIV treatment with 177Lu-PSMA-617.|
62262042|NCT05759754|EXPERIMENTAL|Traditional Chinese Medicine treatment group|"Patients will receive Gu Shen Juan Yu Formula, 3g or 6g or 12g each time based on weight (3g for W≤20kg, 6g for 20-30kg, or 12g for W\>30kg), 2 times a day for 12 weeks, orally, as an add-on to any ongoing treatment, including ACE inhibitors/ angiotensin II receptor blocker.~The GSJYF samples were made and packed by Shanghai Fangxin Pharmaceutical Technology Co., LTD. with lot number of 20230830.~Patients receiving a stable dose of ACEI/ARB will be continued."
62262043|NCT05759754|OTHER|Control group|Patients receive a stable dose of ACEI/ARB drug as a routine therapy.
62262044|NCT00582140|EXPERIMENTAL|Cohort Level 1|pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
62262045|NCT00582140|EXPERIMENTAL|Cohort Level 2|pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
62262046|NCT00582140|EXPERIMENTAL|Cohort Level 3|pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
62262047|NCT01763619|EXPERIMENTAL|Freedom Cervical Disc|
62618427|NCT05358977|NO_INTERVENTION|Control|Patients are undergoing bilateral blepharoplasty. In this arm (Control), the patient with undergo blepharoplasty with standard closure along. 1 minute of pressure will be exerted to both eyelids after closure to mask the patient as to which eyelid received the Tisseel.
62618428|NCT05868278|NO_INTERVENTION|Control|It is the group in which the traditional learning method will be used.
62618429|NCT05868278|EXPERIMENTAL|Experimental|It is the group in which the interactive learning method will be used.
62844124|NCT03588884|EXPERIMENTAL|Cholecalciferol|Cholecalciferol/Capsules 300,000 International Units (IU) (high-dose) before breakfast on the mornings of Day 1 and Day 29
62844125|NCT03588884|ACTIVE_COMPARATOR|Paricalcitol|Paricalcitol/Capsules 1 mcg plus cholecalciferol capsules 800 IU (low-dose) once daily in the morning before breakfast, except on Days 1 and29 when dosing will occur before breakfast
62446854|NCT01498484|EXPERIMENTAL|EBV+ Leiomyosarcoma|Patients with EBV+ leiomyosarcoma (LMS) will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62446855|NCT01498484|EXPERIMENTAL|EBV+ Lymphoma|Patients with EBV+ lymphoma will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62262048|NCT01473082|ACTIVE_COMPARATOR|PFNA|Proximal Femoral Nail Antirotation (PFNA Synthes)
62262049|NCT01473082|ACTIVE_COMPARATOR|PFNA Augmentation|Proximal Femoral Nail Antirotation PFNA Augmentation (Synthes) with Traumacem V+ Synthes
62446856|NCT01498484|EXPERIMENTAL|EBV+ NPC|Patients with EBV+ nasopharyngeal carcinoma (NPC) will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62446857|NCT01498484|EXPERIMENTAL|EBV+ Other Solid Tumor|Patients with EBV+ other solid tumors will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62446858|NCT02064426|EXPERIMENTAL|Molidustat (BAY85-3934)|
62446859|NCT02064426|ACTIVE_COMPARATOR|Epoetin alfa/beta|
62446860|NCT06375928|ACTIVE_COMPARATOR|ERCP with SEMS|"Endoscopic retrograde cholangiopancreatography (ERCP) with deployment of a self-expandable metallic stent (SEMS). Gold standard in malignant distal biliary obstruction (MDBO) in current practice.~ERCP technique: Cannulation with papillotome (advanced cannulation techniques are allowed). Sphincterotomy. Self-expandable metallic stent (SEMS) deployment."
62446861|NCT06375928|EXPERIMENTAL|EUS-CDS with LAMS-Pigtail|"Echoendoscopy-guided Choledochoduodenostomy (EUS-CDS) with deployment of a lumen-apposing metal stent (LAMS) and axis-orienting double-pigtail plastic stent throug LAMS.~EUS-CDS technique: Diagnostic EUS. Classic or free-hand with preloaded guidewire choledochoduodenostomy with LAMS. Pneumatic dilation whithin LAMS is allowed. In case of bile duct \< 15mm is mandatory the 'push' technique. Deployment of a pigtail coaxial to LAMS."
62446862|NCT01875575|ACTIVE_COMPARATOR|Glucose 10g|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)via nasogastric tube
62446863|NCT01875575|ACTIVE_COMPARATOR|Glucose 25g|25g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)via nasogastric tube
62618430|NCT05005767|PLACEBO_COMPARATOR|Placebo group|ten patients with sites suffering from mild chronic periodontitis sites will be treated with scaling and root planing (SRP) only
62618431|NCT05005767|ACTIVE_COMPARATOR|test group|Ten patients with sites suffering from mild chronic periodontitis. sites will be treated with scaling and root planing (SRP) and subgingival application of Frankincense extract gel
62618432|NCT02581033|EXPERIMENTAL|Nucleoside analogue therapy cessation|To determine if a sustained virological response can be achieved after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
62618433|NCT03202732|OTHER|DiabetesFlex|"In DiabetesFlex intervention, patients are offered 3 consultations/year. One mandatory consultations (30 minutes). The patient, an endocrinologist and a diabetes nurse attend.~Two optional consultations, patients can choose between face-to-face consultations, a telephone consultation or to cancel the consultation.~Ahead of the consultations, patients fill out the AmbuFlex Diabetes questionnaire and deliver a blood and urine sample.~Based on the patient's response to the AmbuFlex Diabetes questionnaire, the result of the blood sample and the urine sample, the diabetes nurse assign the patient to a face-to-face consultation, a telephone consultation or no consultation with an endocrinologist, a diabetes nurse or a dietician."
62618434|NCT03202732|NO_INTERVENTION|Standard care|"Standard diabetes care consists of 3 consultations (15 minutes)/year with a physician or a diabetes nurse by turns.~Ahead of the consultation patients send in a blood sample for measuring HgA1c, urine sample for measuring urin-albumin creatinin ratio and other blood samples depending of arrangements made in the last consultation.~Once a year in relation to a consultation, patients fill in the Problem Area In Diabetes (PAID) (20) scale together. Furthermore, based on the patients or healthcare professional judgement, patients see a dietician when needed."
62618435|NCT05635422|EXPERIMENTAL|isokinetism test in high level triathletes practicing an endurance sport|
62618436|NCT00629148|ACTIVE_COMPARATOR|combination chemotherapy|Simultaneous use of Vinorelbine and Capecitabine
62844126|NCT03031080|ACTIVE_COMPARATOR|Splinted|Patients will be given Thermoplastic Hand Splint to wear overnight for 12 weeks.
62058535|NCT05530590|EXPERIMENTAL|Training to Serve online training (eTTS)|Participants are provided a unique identifier to access the online website. The opening page welcomes them to the study, then directs them to the chunked consent materials and baseline survey. As soon as they have completed this, they receive access to the intervention, which for management is expected to take 1-2 hours and for staff, 30-45 minutes (i.e., the online equivalent of 3-4 and 1 hour, respectively). After completion of the required modules, participants receive access to the optional modules as well as the posttest survey to evaluate the training. Once the post-test is complete, they are thanked for their involvement and informed they will receive an e-mail to access a follow-up survey in six months' time.
62058536|NCT05530590|NO_INTERVENTION|Waitlist control|Participants complete the baseline survey, then they receive a note thanking them for completing all activities and informing them the intervention will be available in 6 months' time.
62262050|NCT00404690|ACTIVE_COMPARATOR|1|Operative attempt at closure
62618437|NCT00629148|EXPERIMENTAL|sequential chemotherapy|Sequential use of Vinorelbine and Capecitabine
62618438|NCT00012675||Group 1|
62618439|NCT00638261|OTHER|left/right|left or right body side
62618440|NCT04209907|ACTIVE_COMPARATOR|the group which retrolaminar block will be approved|the retrolaminar block will be made for postoperative analgesia
62618441|NCT04209907|NO_INTERVENTION|the group which retrolaminar block will not be approved|the retrolaminar block will not be made for postoperative analgesia
62618442|NCT05393687|EXPERIMENTAL|eccentric exercise group|8 weeks of progressive eccentric ankle muscle strengthening program with elastic bands. Regular swimming training program five times a week.
62618443|NCT05393687|NO_INTERVENTION|Control group|Regular swimming training program five times a week.
62618444|NCT03827551|EXPERIMENTAL|Parkinson's Patients|
62058537|NCT02093858||olanzapine|15-25mg/day for 24 weeks
62618445|NCT04850378|NO_INTERVENTION|Coagulation profile in Nephrotic syndrome|Investigation of the biochemical coagulation profile in patients with nephrotic syndrome.
62844127|NCT03031080|NO_INTERVENTION|Un-Splinted|Patients will not wear a night splint
62058538|NCT02835872|PLACEBO_COMPARATOR|Cellulose control|3 g Insoluble Fiber (Cellulose)/d contained within drinks and crackers
62262051|NCT00404690|EXPERIMENTAL|2|bedside silo
62262052|NCT04878003|EXPERIMENTAL|Arm 1|KRT-232 administered orally as 240 mg once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles
62262053|NCT04878003|EXPERIMENTAL|Arm 2|TL-895 administered orally as 150 mg twice daily continuously in 28-day cycles
62262054|NCT03325725|EXPERIMENTAL|NewBreez LD Intra-laryngeal implant|
62058539|NCT02835872|ACTIVE_COMPARATOR|Soluble fiber treatment|3 g soluble dietary fiber test ingredient contained within drinks and crackers
62618446|NCT04850378|EXPERIMENTAL|Nephrotic syndrome|Nephrotic patients without diabetes.
62618447|NCT04850378|EXPERIMENTAL|Membranous nephropathy and nephrotic syndrome|Membranous nephropathy and nephrotic syndrome.
62618448|NCT04850378|ACTIVE_COMPARATOR|Atrial fibrillation|Atrial fibrillation with no kidney disease.
62618449|NCT01470144|EXPERIMENTAL|Treatment|Single arm, open-label
62844128|NCT05852613|EXPERIMENTAL|Group (A)|this group will receive high power laser therapy (HPLT) for 15 minutes in addition to selected physical therapy program for 8 session two times weekly for 4 weeks.
62058540|NCT03490214|EXPERIMENTAL|Muscular Dystrophia|Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: Musculus brachioradialis
62262055|NCT03046485|EXPERIMENTAL|Self management program|Self management program 'Living with Vision Loss' 6 week course that met for 2 hours each week led by a trained leader.
62262056|NCT03046485|NO_INTERVENTION|Wait list control|Wait list control
62262057|NCT04687579|EXPERIMENTAL|Umbilical hernia repair|Patients with cirrhosis undergoing umbilical hernia repair with or without preoperative optimization. See the section about interventions.
62446864|NCT01875575|PLACEBO_COMPARATOR|Placebo|intragastric tap water
62618450|NCT02858232|EXPERIMENTAL|solid tumor|Multiple Target Antigen Stimulating Cell Therapy (MASCT-I)
62058541|NCT03490214|ACTIVE_COMPARATOR|Healthy Volunteer|Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: Musculus brachioradialis
62618451|NCT05920148||Elderly|
62618452|NCT02731547|EXPERIMENTAL|Intervention group|The intervention group receives a school-based module taking about two hours delivered by medical students in the schools.
62058542|NCT05877443||Respiratory support by an open system|
62058543|NCT05877443||Respiratory support by non-invasive mechanical ventilation|
62058544|NCT05877443||Respiratory support by invasive mechanical ventilation|
62058545|NCT05712902|EXPERIMENTAL|Daily dose of DZD9008|
62058546|NCT02872948||70 euploïdes foeti samples|"Patients with foetus euploïde (no sick)"
62058547|NCT02872948||30 trisomies 21 samples|"Patients with foetus reached(affected) by trisomy 21 (sick)"
62618453|NCT02731547|NO_INTERVENTION|Control group|
62618454|NCT03668522||children|age\<=17
62058548|NCT04659395|OTHER|Emergency nurses|Emergency nurses who are trained in an one-day course
62058549|NCT01453348|ACTIVE_COMPARATOR|Group 1|This group will receive Inactivated hepatitis A and recombinant hepatitis B or 'Combined inactivated hepatitis A \& recombinant hepatitis B vaccine' alone on the different visits.
62058550|NCT01453348|ACTIVE_COMPARATOR|Group 2|This group will receive Inactivated hepatitis A vaccine and recombinant hepatitis B Vaccine or 'Combined inactivated hepatitis A \& recombinant hepatitis B vaccine' concomitantly with MenACWY-CRM.
62058551|NCT01453348|ACTIVE_COMPARATOR|Group 3|This group will receive only MenACWY-CRM.
62262058|NCT04687579|OTHER|Watchful waiting|Patients who do not agree for operation but consent for follow-up. Patients will be followed in the whole inclusion period and can at any time change their preference if they wish to undergo surgery.
62262059|NCT04697459|EXPERIMENTAL|HD-EX (patient with intradialytic exercise)|will be enrolled in a 16 week intradilatytic exercise program.
62262060|NCT04697459|NO_INTERVENTION|HD (patients with standard HD)|patients with standard hemodialysis (e.g. without exercise).
62618455|NCT03668522||adult|age\>17
62618456|NCT00934232|EXPERIMENTAL|Busulfan|Busulfex given to patients who are either ≥65 years or have renal insufficiency
62618457|NCT00290693|EXPERIMENTAL|CapTere (Capecitabine + Docetaxel)|Capecitabine + Docetaxel (Taxotere)
62618458|NCT04032834|OTHER|Part 1, Arm A of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide.
62618459|NCT04032834|OTHER|Part 1, Arm B of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide.
62618460|NCT04032834|OTHER|Part 1, Arm C of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647.
62058552|NCT02620943||Exposed Group|Pregnant mothers reporting inadequate (\<4) dietary diversity during pregnancy
62262061|NCT06434415||HCM patients with low angio-IMR|This group patients have low angio-IMR value in LAD.
62446865|NCT01468051|EXPERIMENTAL|40 μg (2 ml) four doses of Euvax B vaccine|40 μg (2 ml) four doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
62844129|NCT05852613|ACTIVE_COMPARATOR|Group (B)|"this group will receive the same selected physical therapy program only for 8 session.~All patients will attended the physical therapy clinic two times weekly for 4 weeks ."
62844130|NCT03401619||Osteoporosis With Cognitive impairment|
62844131|NCT03401619||Osteoporosis With Arterial stiffness|
62844132|NCT03401619||Osteoporosis|
62844133|NCT03401619||Normal|
62844134|NCT01383148|EXPERIMENTAL|Arm 1 - TG4010 + first line therapy|First-line therapy and maintenance therapy
62844135|NCT01383148|ACTIVE_COMPARATOR|Arm 2 : Placebo + first line therapy|First-line therapy and maintenance therapy
62844136|NCT01237769|ACTIVE_COMPARATOR|Vitamin D|All patients will be instructed to exercise and lose weight according to the NCEP-ATP III diet. The participants will be randomized in an open manner into one of the following 2 treatment groups: a) cholecalciferol (VitD3) (2200 IU/day) plus lifestyle measures or b) only lifestyle measures. Recruitment will be completed within one year. The reassessment of the patients will be done 3 months after starting of treatment.
62844137|NCT01237769|ACTIVE_COMPARATOR|Lifestyle measures|
62844138|NCT02663401|NO_INTERVENTION|Control|Control situation in campus cafeterias where no labelling of food is proposed
62844139|NCT02663401|EXPERIMENTAL|Front-of-pack labelling (5-CNL)|Introduction of the 5-CNL front-of-pack nutrition label on shelf display tags for every food and beverage sold in the campus cafeteria. Communication campaigns accompanying the introduction of the label
62844140|NCT02403440|EXPERIMENTAL|Hetrombopag Olamine|Hetrombopag Olamine 2.5mg, 5mg and 7.5mg
62844141|NCT00436345|EXPERIMENTAL|Remifentanil|remifentanil
62844142|NCT00436345|ACTIVE_COMPARATOR|Propofol|Propofol infusion
62058553|NCT02620943||Unexposed group|Pregnant mothers reporting adequate (\>=4) dietary diversity during pregnancy
62058554|NCT06437093|EXPERIMENTAL|single-group pre-test post-test experimental study|"In our midwifery intervention, the mother was firstly educated about breastfeeding and relactation, using educational brochures prepared by the researchers. Afterwards, the mother was taught nipple stimulation, skin-to-skin contact and finger feeding method, and the first feeding of the baby was performed together with the mother. After this first intervention in the FHC, all interventions were performed at home. The follow-ups continued for 15 days with one day of telephone support and one day of home visit. Since the majority of mothers did not accept video calls (privacy, etc.), telephone support was provided only verbally."
62058555|NCT06437535||Group 1|will include 25 women with normal weight and normal blood pressure .
62262062|NCT06434415||HCM patients with high angio-IMR|This group patients have high angio-IMR value in LAD.
62262063|NCT01765920|EXPERIMENTAL|Ergoferon (5 ml 3 times a day)|"Oral use. Dose per administration: 1 dosing spoon (5ml) without food. For best effect, the solution should be held in the mouth before swallowing.~Dosing scheme. One dose every 30 minutes for the first 2 hours, followed by three more doses spaced regularly during the rest of the day. From day 2 to 5: 1 spoon taken 3 times daily."
62262064|NCT01765920|PLACEBO_COMPARATOR|Placebo (5 ml 3 times a day)|Oral use. Placebo using Ergoferon scheme.
62844143|NCT06230237|ACTIVE_COMPARATOR|Professional support|Participants randomly assigned to this groups will receive the self-administered psychotherapy via the Internet a with telephone psychotherapeutic support.
62844144|NCT06230237|ACTIVE_COMPARATOR|Non professional support|Participants randomly assigned to this group will receive the self-administered psychotherapy via the Internet without telephone psychotherapeutic support.
62844145|NCT00686114|EXPERIMENTAL|A|Enlarged field + Paclitaxel + Cisplatin + Tarceva
62058556|NCT06437535||Group2|:will include 25 obsese women with normal blood pressure.
62262065|NCT03458221|EXPERIMENTAL|A - ER active tumors|In case of an aberrantly active Estrogen Receptor (ER) pathway, patients will be treated with Letrozole 2.5mg daily orally until progression of disease.
62262066|NCT03458221|EXPERIMENTAL|B - AR active tumors|In case of an aberrantly active androgen receptor (AR) pathway, patients will be treated with Bicalutamide 150mg daily orally until progression of disease.
62844146|NCT00686114|EXPERIMENTAL|B|Enlarged field + Paclitaxel + Cisplatin
62844147|NCT00686114|ACTIVE_COMPARATOR|C|Conventional field + Paclitaxel + Cisplatin + Tarceva
62844148|NCT00686114|ACTIVE_COMPARATOR|D|Conventional field + Paclitaxel + Cisplatin
62844149|NCT01871740|EXPERIMENTAL|Enalapril maleate and folic acid tablets|A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
62844150|NCT01871740|ACTIVE_COMPARATOR|Enalapril maleate|Enalapril maleate 10 mg per day is given
62844151|NCT05023668||Chinese moderate to severe atopic dermatitis patients not controlled by topical therapy|Chinese moderate to severe atopic dermatitis patients not controlled by topical therapy
62844152|NCT01252225|ACTIVE_COMPARATOR|Nebulised Lidocaine followed by Placebo throat spray|
62844153|NCT01252225|ACTIVE_COMPARATOR|Nebulised Placebo followoed by Lidocaine Throat Spray|
62844154|NCT01252225|PLACEBO_COMPARATOR|Nebulised placebo followed by placebo throat spray|
62058557|NCT06437535||Group 3|: will include 25 obese women with confirmed diagnosis of severe preeclampsia .
62058558|NCT05485363|EXPERIMENTAL|optic nerve sheath diameter by using ocular sonography|
62058559|NCT00480792|ACTIVE_COMPARATOR|A|GenHevac-B 20 microgramme Intramuscular use at M0, M1, M6
62844155|NCT04105504|EXPERIMENTAL|Glutathione Group|Subjects were randomised to receive Glutathione capsules. The capsules were taken once daily for 12 weeks and evaluated every 4 weeks.
62844156|NCT04105504|PLACEBO_COMPARATOR|Placebo Group|Subjects were randomised to receive Placebo capsules, which were identical in appearance and packaged in identical-looking containers with the Glutathione capsules. The capsules were taken once daily for 12 weeks and evaluated every 4 weeks.
62262067|NCT03458221|EXPERIMENTAL|C - PI3K active tumors|In case of an aberrantly active phosphoinositide 3-kinase (PI3K) pathway, patients will be treated with Everolimus 10mg daily orally until progression of disease.
62844157|NCT06433492|EXPERIMENTAL|Study group|50 patients age 38-70 with OA confirmed by ACR criteria and radiologically verified OA (Kellgren-Lawrence grade 2 or 3) suffering from knee joint pain for at least 3 months and VAS pain score minimum 4 in one knee, and \< 2 in the contralateral knee were subjected to the administration of Lipotris™. The product was administered as a course of three injections weekly.
62262068|NCT03458221|EXPERIMENTAL|D - HH and/or PI3K active tumors|In case of an aberrantly active Hedgehog (HH) or PI3K pathway, patients will be treated with Itraconazole 300mg twice daily orally until progression of disease.
62262069|NCT01469338|EXPERIMENTAL|Supportive care (management of therapy complications)|Patients receive cabazitaxel IV over 1 hour on day 1, prednisone PO QD, and octreotide pamoate IM on day 1. Patients also receive octreotide acetate SC TID on days 1-14 of course 1 only. Treatment with cabazitaxel repeats every 21 days and treatment with prednisone and octreotide pamoate repeats every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
62262070|NCT01717209|EXPERIMENTAL|Combined nitric oxide and prostacyclin|iNO (20 ppm continuously) and iPGI2 (0.05 micrograms/kg/min continuously)
62262071|NCT01408992|EXPERIMENTAL|FMHT|All community people will be interviewed with Thai Five Minute Hearing Test questionnaire and will be tested with an audiometry.
62262072|NCT01527864|EXPERIMENTAL|pegylated endostatin|
62618461|NCT04032834|OTHER|Part 1, Arm D of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647.
62618462|NCT04032834|OTHER|Part 1, Arm E of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647.
62844158|NCT06522490|EXPERIMENTAL|Experimental group|Video Training was used for the experimental group
62844159|NCT06522490|ACTIVE_COMPARATOR|Controlled group|Face to face therapy was used for the control group
62262073|NCT01527864|PLACEBO_COMPARATOR|Control|
62262074|NCT01582425|EXPERIMENTAL|Isavuconazole and methadone|Single dose of methadone on Days 1 and 20, isavuconazole 3 times a day (TID) on Days 16-17 as a loading dose, isavuconazole once a day (QD) on Days 18-28
62262075|NCT05041751|ACTIVE_COMPARATOR|Arm I (trigger point injections)|Patients receive standard of care trigger point injections at baseline
62262076|NCT05041751|EXPERIMENTAL|Arm II (myofascial release)|Patients perform myofascial release for 10 minutes each day.
62262077|NCT04445675|EXPERIMENTAL|Experimental|The support for breastfeeding and the feeding of infants' with breast milk will be conducted in one stage for the experimental group. (1) breastfeeding support education. The content of the support for breastfeeding and the feeding of infants' with breast milk and the materials used were determined by the researchers in accordance with the literature. The content of the support for breastfeeding and the feeding of infants' with breast milk consists of the titles of the importance of breastfeeding and breast milk, the effect of breast milk on preventing jaundice, the importance of early start of breastfeeding, breastfeeding techniques and positions in infants, milking, storage and later use of milk, increasing the quantity and quality of milk, and nutrition of the mother during breastfeeding. Breastfeeding support will be provided in the postpartum service and lactation outpatient clinic of the relevant hospital.
62844160|NCT02928016|EXPERIMENTAL|Mixed meal 1|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) \<10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
62262078|NCT04445675|NO_INTERVENTION|Control Groups|The infants in the control group will be followed up in routine service. No intervention will be made.
62446866|NCT01468051|EXPERIMENTAL|20 μg (1 ml) three doses of Euvax B vaccine|20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
62058560|NCT00480792|EXPERIMENTAL|B|GenHevac-B 40 microgramme Intramuscular use at M0, M1, M2, M6
62058561|NCT00480792|EXPERIMENTAL|C|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
62058562|NCT04418934|EXPERIMENTAL|Investigational Product|Blood product from these donors will be processed and stored using the Hemanext One device.
62844161|NCT02928016|EXPERIMENTAL|Mixed meal 2|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) \<10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
62058563|NCT04418934|NO_INTERVENTION|Control Product|Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.
62058564|NCT03350100|EXPERIMENTAL|Birhi date cultivar|A 48.46 g of freeze dried powder of Birhi date Cultivar which is equivalent to a 115g of fresh dates, contains 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and a total phenolic content of 162.8 mg/100 g of GAE. and 0.80 g of fibres, will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
62262079|NCT00361270|EXPERIMENTAL|Arm 1 Hyp-8|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour hypnosis with hypnotherapist without audio recordings
62262080|NCT00361270|EXPERIMENTAL|Arm 2 Hyp-8 w recordings|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour hypnosis with hypnotherapist with audio recordings
62262081|NCT00361270|EXPERIMENTAL|Arm 3 Hyp-2 w recordings|Single-site study at MEDVA-Houston Behavioral: 2 weeks 1-hour hypnosis with hypnotherapist with audio recordings
62446867|NCT02184273|EXPERIMENTAL|Magnesium metamizol|
62446868|NCT02184273|PLACEBO_COMPARATOR|Placebo|
62446869|NCT05096325||Study pump|Subjects receive a CE-certified mylife™ YpsoPump® insulin pump system that allows detailed logging of pressure data.
62446870|NCT01276782|PLACEBO_COMPARATOR|Pregnant SLE|Pregnant SLE patients with autoimmune thyroid antibodies will be randomized to levothyroxine or Placebo
62058565|NCT03350100|EXPERIMENTAL|Khassab date cultivar|A 34.5 g of freeze dried powder of Khassab date Cultivar which is equivalent to A 115g of fresh dates, contains 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and a total phenolic content of 91.52 mg/100 g of GAE. and 0.80 g of fibres,will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
62058566|NCT03350100|PLACEBO_COMPARATOR|placebo|A 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and 0.80 g of fibres, will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
62446871|NCT05825300|EXPERIMENTAL|No-blood-type message|This group will receive a message that does not mention that the patient's blood type is in short supply.
62446872|NCT05825300|EXPERIMENTAL|Blood-type message|This group will receive a message that states their blood type is in short supply.
62446873|NCT00501761||1: Endometrial Cancer Survivors|
62446874|NCT00501761||2: Healthy Participants|Healthy participants that have no history of invasive cancer.
62058567|NCT01465828|ACTIVE_COMPARATOR|high clopidogrel dose|Patients will be randomized to this arm to receive before high clopidogrel dose and after crossover they will receive standard dose of prasugrel
62058568|NCT01465828|NO_INTERVENTION|prasugrel standard dose|Patients will be randomized to this arm to receive before standard dose of prasugrel and after crossover they will receive high clopidogrel dose.
62618463|NCT04032834|OTHER|Part 1, Arm F of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647.
62058569|NCT01960595|EXPERIMENTAL|IV fentanyl PCA|The patient receives post-OP IV fentanyl PCA
62058570|NCT01960595|ACTIVE_COMPARATOR|post-OP IV fentanyl PCA and local infiltration|pretreatment of local infiltration 0.25% bupivacaine 5 ml and post-OP IV fentanyl PCA
62058571|NCT01960595|ACTIVE_COMPARATOR|nerves block and post-OP IV fentanyl PCA|pretreatment of peroneal nerves 0.25% bupivacaine 10 ml and post-OP IV fentanyl PCA
62058572|NCT05124093|PLACEBO_COMPARATOR|Apnoea without apnoeic oxygenation|High-flow nasal oxygen administration ceases at the onset of apnoea.
62058573|NCT05124093|ACTIVE_COMPARATOR|Apnoeic oxygenation with high-flow nasal oxygen at 70 L/min (HFNO)|100% oxygen is administered via high-flow nasal cannulae at 70L/min from the onset of apnoea until four minutes of apnoea has completed.
62058574|NCT05124093|ACTIVE_COMPARATOR|Apnoeic oxygenation with high-flow nasal oxygen at 120 L/min (uHFNO)|100% oxygen is administered via high-flow nasal cannulae at 120L/min from the onset of apnoea until four minutes of apnoea has completed.
62058575|NCT02564679|EXPERIMENTAL|Sleeve gastrectomy|These patients are surgically treated with laparoscopic sleeve gastrectomy in association to lifestyle intervention (hypocaloric diet and physical activity)
62058576|NCT02564679|EXPERIMENTAL|Lifestyle Intervention|These patients are treated with lifestyle intervention (hypocaloric diet and physical activity)
62058577|NCT03994042|EXPERIMENTAL|Mental imagery neurofeedback training|Complete intervention with mental imagery neurofeedback training. Patients recruited by physioterapists who underwent baseline evaluations with clinical tests, fMRI and EEG measurements. Patients will after intervention perform clinical tests, fMRI, and EEG measurements to evaluate outcomes of intervention.
62058578|NCT05002205||COVID-19|exposed cohort with a diagnosis of COVID-19 in the last 6 months
62058579|NCT05002205||no history of COVID-19|non-exposed cohort without a diagnosis of COVID-19. Tested for COVID-19 because of symptoms at the same time (+/- 1 month) as the exposed cohort.
62262082|NCT00361270|ACTIVE_COMPARATOR|Arm 4 BIO|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour EMG biofeedback without audio recordings
62844162|NCT02928016|EXPERIMENTAL|Mixed meal 3|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) \<10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
62618464|NCT04032834|OTHER|Part 2, Arm A of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide.
62618465|NCT04032834|OTHER|Part 2, Arm B of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide.
62844163|NCT02928016|EXPERIMENTAL|Mixed meal 4|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) \<10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
62058580|NCT06610981|EXPERIMENTAL|Group A (Laser acupuncture group)|Participants will receive Laser acupuncture with energy of 4 J per point for 80 s, with a total dosage of 24 J in each session, 2 times /week for 4 weeks. Additionally, traditional physical therapy program will be conducted to participants in the study group.
62058581|NCT06610981|SHAM_COMPARATOR|Group B (Sham-laser acupuncture group)|Participants will receive the same intervention while the device turned off, in addition to the exercise program consisted of stretching for hamstring, gastrocnemius and iliotibial band, and strengthening exercises, which include isometric quadriceps exercises, straight leg raising, lateral straight leg raise, isometric hip adduction and squat to 30° knee flexion, 2 times /week for 4 weeks.
62058582|NCT03042962||Patients with dystonia|Patients with dystonia (spasmodic dysphonia, singer's dystonia, writer's cramp, musician's focal hand dystonia) will undergo MRI of the brain and blood draw.
62058583|NCT03042962||Healthy volunteers|Healthy subjects without any neurological, psychiatric or otolaryngological problems will undergo MRI of the brain and blood draw.
62058584|NCT05977894||Nurses and physicians|Nurses (registered, practitioner, and anesthetist) and physicians, employed at St. Elizabeth Youngstown Trauma Center, Mercy Health
62058585|NCT05470478|EXPERIMENTAL|Evaluation of an enhanced iBCI|Performance of new decoding algorithms and methods will be developed and embedded in a small, mobile neural processor. The utility of these will be assessed separately with participants in the BrainGate pilot clinical trial, IDE.
62058586|NCT02223884|EXPERIMENTAL|weekly docetaxel and carboplatin|
62058587|NCT00676130|ACTIVE_COMPARATOR|Standard therapy|cephalexin plus placebo
62058588|NCT00676130|EXPERIMENTAL|Standard plus anti-CA-MRSA|cephalexin plus trimethoprim-sulfamethoxazole
62058589|NCT03156634|EXPERIMENTAL|PALS|Participants will view materials about the antihypertensive, chlorthalidone on the Patient Activated Learning System (PALS).
62058590|NCT03156634|ACTIVE_COMPARATOR|WedMD|Participants will view materials about the antihypertensive, chlorthalidone on WebMD.
62058591|NCT03737201|EXPERIMENTAL|ozone|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with ozone. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The cavity was exposed to gaseous ozone for 60 seconds, with an ozone delivery system. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement to reopen 4 months later.
62058592|NCT03737201|ACTIVE_COMPARATOR|chlorhexidine digluconate|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with chlorhexidine digluconate. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. Following the excavation, 2% chlorhexidine digluconate was applied to the cavity for 60 seconds using a brush. According to the manufacturer instructions, puddled solution was removed with a new brush without dry to leave site moist. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
62058593|NCT03737201|ACTIVE_COMPARATOR|control|Thirty five molar teeth with deep caries lesion were selected to apply conventional two-visit indirect pulp therapy (control). The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
62058594|NCT01308606|EXPERIMENTAL|001|TMC435 gelatin capsule Single intake of one 150-mg capsule without food
62058595|NCT01308606|EXPERIMENTAL|002|TMC435 HPMC capsule Single intake of one 150-mg capsule without food
62058596|NCT01308606|EXPERIMENTAL|003|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule without food
62058597|NCT01308606|EXPERIMENTAL|004|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after standardized breakfast
62058598|NCT01308606|EXPERIMENTAL|005|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after high-fat breakfast
62058599|NCT01789697|EXPERIMENTAL|Receives text messages/emails|Will receive text messages and emails periodically from the surgeon from Day 1 (day after discharge) through day 21.
62058600|NCT01789697|NO_INTERVENTION|Does not receive text messages/emails|Will not receive text messages and emails periodically from the surgeon from Day 1 (day after discharge) through day 21.
62058601|NCT04885270|EXPERIMENTAL|Arm i.p|paclitaxel i.v. and cisplatin i.p.
62058602|NCT05921305|EXPERIMENTAL|MTX and corticosteroid|Methylprednisolone 2 mg/kg/day was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg/kg/day prednisone (or 0.2mg/kg/day methylprednisolone). MTX (5mg/m\^2/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR.
62058603|NCT05921305|ACTIVE_COMPARATOR|Corticosteroid|Methylprednisolone 2 mg/kg/day was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg/kg/day prednisone (or 0.2mg/kg/day methylprednisolone).
62058604|NCT02486679|ACTIVE_COMPARATOR|PGE2|Patients allocated to vaginal PGE2 (Prostin) for cervical ripening
62058605|NCT02486679|ACTIVE_COMPARATOR|Foley catheter|Patients allocated to foley catheter placement for cervical ripening
62262083|NCT01586884|EXPERIMENTAL|Intervention|"Ten patients undergoing LV lead placement for either initial CRT device implant or revision of an existing system at Lancaster General Hospital who meet the inclusion and exclusion criteria will be screened and approached for enrollment in this safety and feasibility study. Study participants may have ischemic or non-ischemic cardiomyopathy; results for ischemic and non-ischemic patients will be analyzed separately. Any device system from any manufacturer may be used; the choice of device and leads will be at the implanting physician's discretion.~Post implant procedures will be the same as those for any CRT implant. Outpatient follow-up other than the 1-month follow-up will be per the implanting physician's usual practice."
62262084|NCT05009771||IV-PCA group|Patients receiving intravenous patient-controlled analgesia (IV-PCA) will be allocated to IV-PCA group.
62618466|NCT04032834|OTHER|Part 2, Arm C of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647.
62058606|NCT05265455|EXPERIMENTAL|Plant sterol supplementation|2.5 g of phytosterols in pre-dosed sticks (oral supplementation)
62058607|NCT05265455|PLACEBO_COMPARATOR|Placebo|Placebo in pre-dosed sticks (the same matrix without plant sterols) (oral supplementation)
62618467|NCT04032834|OTHER|Part 2, Arm D of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647.
62618468|NCT04032834|OTHER|Part 2, Arm E of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647.
62844164|NCT02928016|EXPERIMENTAL|Mixed meal 5|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) \<10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
62058608|NCT00116272||Etanercept-Exposed|Pregnant women with a current diagnosis of rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis (AS), psoriatic arthritis (PsoA) or psoriasis (PsO) who used etanercept in the first trimester of pregnancy for any length of time.
62058609|NCT00116272||Diseased Controls|Pregnant women with a current diagnosis of RA, JRA, AS, PsA, or PsO who did not use etanercept or any tumor necrosis factor (TNF) antagonist during pregnancy.
62058610|NCT00116272||Non-Diseased Historical Comparison|Pregnant women not diagnosed with RA, JRA, AS, PsoA, or PsO who did not use etanercept or any TNF antagonist at any time in pregnancy and were not exposed to any known human teratogen during pregnancy. This cohort consists of historical controls enrolled in other pregnancy outcome studies selected to match pregnant women in the exposed cohort.
62058611|NCT05819996|OTHER|Martinsville Residents|Residents of Martinsville, Indiana, will receive educational campaign promoting participation in environmental testing
62058612|NCT03135535|EXPERIMENTAL|Avex Footbeat|Subjects will receive a new pair of diabetic shoes with BOA shoelace closure and a pair of AVEX Footbeat insoles, which include a micro-mobile compression pump. The entire system is named 'intervention shoes' for simplicity. They will be instructed to wear the intervention shoes on daily basis for 4 weeks for duration of at least 4 hours per day.
62618469|NCT04032834|OTHER|Part 2, Arm F of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647.
62844165|NCT02928016|EXPERIMENTAL|Mixed meal 6|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) \<10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
62844166|NCT05526963|EXPERIMENTAL|Intervention Group|Medication review (STOPP/START-criteria) + telephone-based adherence support measure (motivational interviewing)
62844167|NCT05526963|NO_INTERVENTION|Control Group|Usual care
62058613|NCT01373450|EXPERIMENTAL|OXM → Lg-0.6 → Pbo → Lg-1.2|Participants received Oxyntomodulin 3.0 pmol/kg/min in the first, Liraglutide 0.6 mg in the second, Placebo in the third, and Liraglutide 1.2 mg in the fourth period
62058614|NCT01373450|EXPERIMENTAL|Lg-0.6 → Pbo → OXM → Pbo|Participants received Liraglutide 0.6 mg in the first, Placebo in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Placebo in the fourth period
62262085|NCT05009771||IV-PCA + NALDEBAIN group|Patients treated with the combination of IV-PCA and intramuscular injection of dinalbuphine sebacate will be allocated to IV-PCA + NALDEBAIN group.
62844168|NCT02001636|EXPERIMENTAL|Protein group|"Patient group which takes daily protein supplements after bariatric surgery over 6 months.~Protein product: Resource Instant Protein 88, Nestlé Health Nutrition"
62844169|NCT02001636|PLACEBO_COMPARATOR|Control group|"Patient group which takes daily isocaloric placebo after bariatric surgery over 6 months and thus can be compared to the protein group.~Placebo product: Resource Maltodextrin, Nestlé Health Nutrition"
62844170|NCT02290678|EXPERIMENTAL|Intervention|Participate in a two day Adventure-based Programming retreat and team building exercises.
62844171|NCT06443567||adult cardiac arrest|blood pressure measurement pre and post impedance threshold device placement
62844172|NCT04956913||Mac Grath|Patients of this group were intubated using Mac Gath videolaryngoscope
62844173|NCT04956913||Machintosh|Patients of this group were intubated using the classic Macintosh laryngscoscope
62058615|NCT01373450|EXPERIMENTAL|Pbo → OXM → Lg-0.6 → Pbo|Participants received Placebo in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
62058616|NCT01373450|EXPERIMENTAL|Lg-0.6 → OXM → Pbo → Lg-1.2|Participants received Liraglutide 0.6 mg in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Placebo in the third and Liraglutide 1.2 mg in the fourth period
62058617|NCT01373450|EXPERIMENTAL|OXM → Pbo → Lg-0.6 → Pbo|Participants received Oxyntomodulin 3.0 pmol/kg/min in the first; Placebo in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
62262086|NCT05009771||NALDEBAIN group|Patients injected with dinalbuphine sebacate intramuscularly will be allocated to NALDEBAIN group.
62262087|NCT00885703|EXPERIMENTAL|Stage 1, Fluconazole 1200mg|Participants receive Fluconazole 1200mg induction dose in Stage 1
62262088|NCT00885703|EXPERIMENTAL|Stage 1, Fluconazole 1600mg|Participants receive Fluconazole 1600mg induction dose in Stage 1
62262089|NCT00885703|EXPERIMENTAL|Stage 1, Fluconazole 2000mg|Participants receive Fluconazole 2000mg induction dose in Stage 1
62262090|NCT00885703|ACTIVE_COMPARATOR|Stage 1, Ampho B|Participants receive Amphotericin B followed by Fluconazole in Stage 1
62262091|NCT00885703|EXPERIMENTAL|Stage 2, Fluconazole 1600mg|Participants receive Fluconazole 1600mg induction dose in Stage 2
62262092|NCT00885703|EXPERIMENTAL|Stage 2, Fluconazole 2000mg|Participants receive Fluconazole 2000mg induction dose in Stage 2
62262093|NCT00885703|ACTIVE_COMPARATOR|Stage 2, Ampho B|Participants receive Amphotericin B followed by Fluconazole in Stage 2
62262094|NCT01827670|EXPERIMENTAL|0.454% stannous fluoride dentifrice|Participants to brush whole mouth with 1-inch strip of the test dentifrice (0.454% SnF) for one timed minute, followed by rinsing with 5 milliliter (mL) of water.
62262095|NCT01827670|ACTIVE_COMPARATOR|0.76% sodium monofluorophosphate dentifrice|Participants to brush whole mouth with 1-inch strip of the control dentifrice (0.76% NaMFP) for one timed minute, followed by rinsing with 5 mL of water.
62844174|NCT04990804|ACTIVE_COMPARATOR|Standard Perioperative Pain Regimen|Patients will be provided a prescription for low dose opioids for 5 days postoperatively (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) to be taken every 6 hours as needed for pain. Refills may be provided (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) if requested by the patient at the providers discretion. In addition, patients will also be prescribed Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily and a muscle relaxer (Methocarbamol 750mg BID or Flexeril 5-10 mg TID) as needed for spasms. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
62844175|NCT04990804|EXPERIMENTAL|Opioid-Free Perioperative Pain Regimen|Patients will receive no opioids. Pain will be managed with Acetaminophen 1000mg q8 hours, Ketorolac 10mg every 6 hours (for 5 days), Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily, and a muscle relaxer (Methocarbamol 750mg BID or Cyclobenzaprine 5-10 mg TID) all to be taken as scheduled for the first 2 weeks (except Ketorolac - 5 days) postoperatively as side effects permit. Other NSAIDS (Naprosyn 500 mg BID or Ibuprofen 800 mg TID) may be utilized if contraindications to Ketorolac exist. Famotidine (20mg BID) or Omeprazole (20mg daily) will be prescribed along with NSAIDS for GI prophylaxis. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
62058618|NCT01373450|EXPERIMENTAL|Pbo → Lg-0.6 → OXM → Lg-1.2|Participants received Placebo in the first, Liraglutide 0.6 mg in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Liraglutide 1.2 mg in the fourth period
62058619|NCT00765284||Treatment|Ten subjects will be low HDL-C male volunteers who will receive aspirin and Niaspan
62844176|NCT04892849||Trial cohort|"The study cohort consist of patients suffering from HNSCC (palliative), NSCLC (separately palliative and adjuvant) and other solid tumors (including in particular esophageal carcinomas, urothelial and renal carcinomas, small cell bronchial carcinomas and squamous cell carcinomas of the skin \[depending on the current drug approval\]) which will be treated with ICI (PD-1/PD-L1) and potential radiation of metastases at Department of Radiation Oncology of Universitätsklinikum Erlangen."
62058620|NCT00765284||Placebo|Five subjects will be low HDL-C male volunteers who will receive only aspirin.
62058621|NCT05994391|EXPERIMENTAL|LasoperinTM|"Active ingredients:~Scutellaria baicalensis extract, 240 mg per capsule. Acacia catechu extract, 51 mg per capsule. With no less than 180 mg of baicalin, and no less than 30 mg of catechins from the above-mentioned extracts per capsule.~Inactive ingredients:~Maltodextrin~2 capsules per day~Take twice per day with food and water, once in the morning and once in the evening.~If a dose is missed the participant can consume it as soon as they remember within the day. This means that the participant may consume 2 capsules at once. If both capsules are missed for the day the participant should not consume 4 capsules the next day and should return to the normal dosage of one capsule in the morning and evening"
62844177|NCT00974480|EXPERIMENTAL|Redermic|Cream was applied twice a day every day, morning and evening for 24 weeks.
62844178|NCT00974480|ACTIVE_COMPARATOR|Rejuva-A|Week 1, Rejuva-A cream was applied to face in the evening twice a week. Weeks 2 \& 3, Rejuva-A cream was applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream was applied to the face in the evening every other day. In cases of intolerance, returned to the previous dosage and remained there until the end of study. Hydrating cream was applied to the face in the morning every day for 24 weeks.
62844179|NCT00974480|ACTIVE_COMPARATOR|Combination of Redermic and Rejuva-A|Week 1, Rejuva-A cream was applied to face in the evening twice a week. Weeks 2 \& 3, Rejuva-A cream was applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream was applied to the face in the evening every other day. In cases of intolerance, returned to the previous dosage and remained there until the end of study. Redermic was applied every evening when Rejuva-A™ was not applied, as well as every morning.
62262096|NCT00407095|EXPERIMENTAL|1|
62618470|NCT04032834|OTHER|Part 3, Arm A of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 15 breaths (120 µg) VR647 via mouthpiece, 15 breaths (120 µg) VR647 via facemask, 0.5 mg budesonide via mouthpiece, 0.5 mg budesonide via facemask.
62618471|NCT04032834|OTHER|Part 3, Arm B of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 15 breaths (120 µg) VR647 via facemask, 0.5 mg budesonide via mouthpiece, 0.5 mg budesonide via facemask, 15 breaths (120 µg) VR647 via mouthpiece.
62262097|NCT06470256|EXPERIMENTAL|Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy|Reduce tumor burden by over 90% through palliative hepatectomy . Starting two weeks post-surgery, patients began intravenous infusions of the PD-L1 monoclonal antibody, Durvalumab, at a dosage of 1500 mg every three weeks. Three weeks post-surgery, patients commenced oral administration of the targeted therapy, Lenvatinib, with a dosage based on body weight: 8 mg (≤60 kg) or 12 mg (\>60 kg), once daily. The use of Durvalumab and Lenvatinib continued until the primary endpoint or other criteria specified in the protocol for terminating the study treatment.
62262098|NCT03560856|OTHER|Fulvestrant 500mg + palbociclib 125 mg|Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
62262099|NCT00781911|EXPERIMENTAL|Carcinoid tumor|Participants with carcinoid tumor will receive cixutumumab 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
62618472|NCT04032834|OTHER|Part 3, Arm C of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 0.5 mg budesonide via mouthpiece, 0.5 mg budesonide via facemask, 15 breaths (120 µg) VR647 via mouthpiece, 15 breaths (120 µg) VR647 via facemask.
62618473|NCT04032834|OTHER|Part 3, Arm D of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 0.5 mg budesonide via facemask, 15 breaths (120 µg) VR647 via mouthpiece, 15 breaths (120 µg) VR647 via facemask, 0.5 mg budesonide via mouthpiece.
62058622|NCT05994391|PLACEBO_COMPARATOR|Placebo|"Active ingredients:~N/A~Inactive ingredients:~Microcrystalline cellulose~2 capsules per day~Take twice per day with food and water, once in the morning and once in the evening.~If a dose is missed the participant can consume it as soon as they remember within the day. This means that the participant may consume 2 capsules at once. If both capsules are missed for the day the participant should not consume 4 capsules the next day and should return to the normal dosage of one capsule in the morning and evening"
62058623|NCT00926510|EXPERIMENTAL|Language Toolkit|Language toolkit composed of simple tools that parents can use to interact with child and help language acquisition.
62618474|NCT01463358|OTHER|DDI30|Control group based only on backup pacing with lower rate 30 ppm
62618475|NCT01463358|ACTIVE_COMPARATOR|DDD60|Treatment arm based on full pacing support (60 Lower Rate)
62058624|NCT00926510|PLACEBO_COMPARATOR|2|Safety counseling and smoke detector
62058625|NCT01741454|ACTIVE_COMPARATOR|Tamsulosin plus placebo 7-day treatment|Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
62618476|NCT04457934||IBD patients|"Patients with IBD will undergo preparation for Standard endoscopy with PLENVU, since it is considered to be less affecting for patients. IBD patients have to undergo endoscopy often and mostly suffer from non-efficient preparation.~Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy and will follow the Guidelines for preparation of endoscopy.~The only Change from Standard care is that patients will receive Plenvu instead of Movicol."
62618477|NCT04457934||Screening patients|"Screening patients will undergo Standard endoscopy to prevent colon Cancer. Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy and nd will follow the Guidelines for preparation of endoscopy.~The only Change from Standard care is that patients will receive Plenvu instead of Movicol."
62618478|NCT02855177|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as an extemporaneously prepared suspension every 8 hours for 14 days
62618479|NCT02855177|EXPERIMENTAL|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared suspension every 8 hours for 14 days
62618480|NCT00670657|EXPERIMENTAL|1|AmBisome® 2 mg/kg/day in a unique daily IV administration
62618481|NCT03051347|OTHER|Itch Questionnaire and Interview|Up to 30 dyads of patients ages 8-17 and their parents/caregivers, as well as up to 20 parents of children ages 6mo-7 years, will participate in semi-structured interviews to evaluate the new and modified items (questions) written for the PIQ-C questionnaire
62446875|NCT05832255|EXPERIMENTAL|Psilocybin, 1.5 mg|Participants will take one capsule containing 1.5 mg psilocybin with a glass of water every other day for a period of 28 days. Dosing schedule will be same for all participants with the drug taken at days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, and no treatment taken on alternating days. No subject shall be provided with more than five capsules (7.5mg psilocybin) at any one time to prevent diversion to the illicit market. If a dose is missed, participants are instructed to skip that dose and continue with their regularly scheduled medications. Participants are not to take \>1 capsule per day.
62618482|NCT03051347|OTHER|Stigma Questionnaire and Interview|To assess stigma, up to 20 children ages 8-17 and 20 parents of children ages 5-12, will participate in semi-structured interviews to evaluate the modified Neuro-QoL stigma questionnaire. This questionnaire includes new skin-specific stigma items and existing items modified for use with children having a skin or other condition that may negatively affect their appearance
62844180|NCT01717924|ACTIVE_COMPARATOR|peri-operative chemotherapy|Neoadjuvant chemotherapy with 3 cycles of Epirubicin/Cisplatin/5 fluoro-uracil (oral or intra-veinous) Surgery within 3 and 6 weeks after the end of neoadjuvant chemotherapy Adjuvant chemotherapy with 3 cycles of the same chemotherapy within 6 and 12 weeks after surgery
62844181|NCT01717924|EXPERIMENTAL|surgery first with adjuvant chemotherapy|Surgery first Adjuvant chemotherapy with 3 cycles of Epirubicin/Cisplatin/5FU within 6 and 12 weeks after surgery No neoadjuvant chemotherapy
62058626|NCT01741454|EXPERIMENTAL|Tamsulosin plus Tolterodine ER 7-day treatment|"Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.~Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity."
62058627|NCT01741454|ACTIVE_COMPARATOR|Tamsulosin plus placebo 21-day treamtnet|Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
62844182|NCT02207426|EXPERIMENTAL|TobrAir® 6.0|Tobramycin 75mg inhalation solution
62844183|NCT02207426|EXPERIMENTAL|TOBI® / PARI LC® PLUS Nebulizer|Tobramycin 300mg nebulizer solution
62844184|NCT02207426|EXPERIMENTAL|TOBI® Podhaler™|Tobramycin 112mg (4x28mg) inhalation powder
62058628|NCT01741454|EXPERIMENTAL|Tamsulosin plus Tolterodine ER 21-day treatment|"Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.~Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity."
62058629|NCT02074046|PLACEBO_COMPARATOR|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62058630|NCT02074046|EXPERIMENTAL|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62058631|NCT02074046|EXPERIMENTAL|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62058632|NCT02074046|EXPERIMENTAL|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62058633|NCT01288339|EXPERIMENTAL|Panitumumab + FOLFOX (DP)|Panitumumab and FOLFOX will be administered to patients with DP (MMP7+/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
62262100|NCT00781911|EXPERIMENTAL|Islet cell carcinoma|Participants with islet cell carcinoma will receive cixutumumab 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
62262101|NCT02351505|EXPERIMENTAL|Treatment (selinexor)|Patients receive selinexor PO twice weekly. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62262102|NCT03949933|EXPERIMENTAL|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
62262103|NCT01796587||LoFric Origo|
62262104|NCT00113828|EXPERIMENTAL|Transplantation|T-cell depleted HLA-matched peripheral blood stem cell transplantation
62262105|NCT03695575|OTHER|Study sample|A repeated-measures model will be used. This means that participants in a single arm will be tested in all conditions. Speech recognition and listening effort outcomes will be measured in two conditions: with and without a bone-conduction headset.
62446876|NCT04118231|EXPERIMENTAL|Dry needling|
62446877|NCT04118231|NO_INTERVENTION|Control group|
62844185|NCT01670916||Probiotics|Capsule with 1 x 10\*\*9 Lactobacillus rhamnosus GG and 1 x 10\*\*8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
62844186|NCT01670916||Control|Probiotics never given
62844187|NCT04143464|EXPERIMENTAL|Intervention group|"The participants in this group will receive group kyphosis-specific exercise classes given by the certified physical trainer and kyphosis-specific exercise videos.~The intervention arrangement is:~1. Group learning and practice: a 1-hour kyphosis-specific exercise training session will be provided two times in the first week,~2. Weekly follow-up: a 1-hour kyphosis-specific exercise will be conducted with reinforcement of learning and remedial teaching by a certified physical trainer once a week for five consecutive weeks after the group learning and practice,~3. Self-practice: the participant will following the kyphosis-specific exercise videos doing self-practice every day for the whole intervention period lasting six weeks."
62844188|NCT04143464|NO_INTERVENTION|Control group|No special arrangement
62844189|NCT02873702|EXPERIMENTAL|Healing Period: Dexlansoprazole 60 mg|Dexlansoprazole 60 milligram (mg), delayed-release capsules, orally, once daily for up to 8 weeks in the Healing Period.
62262106|NCT05170906|EXPERIMENTAL|Experimental Group|"The subject will be placed on a stretcher with the torso uncovered. Once the spectroscopy helmet is in place, a recording of the resting activity will be started, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation on the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure on the pectoral area in the pattern of the reflex swing locomotion complex in its first phase. For this, the subject will be placed in supine decubitus aligned with respect to the axial axis, with the arms alongside the body, the lower extremities in extension and the head extended with a rotation of approximately 30º to one side of the stimulation. Manual stimulation pressure will be exerted in the space between the 6th-7th or 7th-8th ribs below the mammary line, with a force of about 2 kg."
62262107|NCT05170906|SHAM_COMPARATOR|Control Group|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The control group will receive an application in an area with low receptor density located on the thigh, with a force of about 2 kg"
62262108|NCT00350142|EXPERIMENTAL|Stereotactic Body Radiotherapy|Patients will have a 4D pancreatic protocol CT and a FDG PET scan scan, both for planning purposes. An SBRT treatment plan will be developed based on tumor geometry and location. All patients will receive a single fraction of 25 Gy dose of Stereotactic Body Radiotherapy on Trilogy Linear Accelerator, followed by weekly Gemcitabine.
62262109|NCT04343625|EXPERIMENTAL|Modified sitting, gentle yoga class|Participants attended a modified sitting gentle yoga class,10 weekly classes, each 60 minutes in duration.
62262110|NCT00715585|ACTIVE_COMPARATOR|Active Control|patients receive 3 individualized visits with a health educator for education on general diabetes and health promotion
62262111|NCT00715585|EXPERIMENTAL|Intervention 1|patients receive 3 individualized visits with an rd-cde for education focused on modified plate method
62262112|NCT00715585|EXPERIMENTAL|intervention 2|patients receive 3 individualized visits with an rd-cde for education focused on carb counting
62262113|NCT03446222|ACTIVE_COMPARATOR|Catheter Ablation|Catheter based radiofrequency ablation with wide antral circumferential PVI and isolation of posterior wall will be performed. Mitral and cavo-tricuspid isthmus ablation will be done only if such isthumus dependent flutters are documented prior to / during the procedure.
62446878|NCT05866146|EXPERIMENTAL|Interprofessional rehabilitation program|Participants of the intervention group will receive an interprofessional rehabilitation program, which involve a combination of physical, psychological, behavioral, and/or vocational components, for four weeks.
62262114|NCT03446222|ACTIVE_COMPARATOR|Mini-maze surgical procedure|Wolf Mini-maze surgical ablation along with left atrial appendage ligation will be performed.
62262115|NCT04086394|EXPERIMENTAL|PECS Block|Group who was randomly selected to receive the intraoperative nerve block.
62262116|NCT04086394|SHAM_COMPARATOR|Control|Patient who was randomly selected not to receive intraoperative nerve block
62618483|NCT03051347|OTHER|Validation Questionnaire and Interview-Moderate to Severe|For validation, up to 200 parent/child dyads ages 5-17 with a diagnosis of moderate to severe AD during the previous 6 months will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status.
62262117|NCT05123833|ACTIVE_COMPARATOR|Dartos Fascia|Dartos flap is used as a covering layer for urethra during repair of hypospadias
62262118|NCT05123833|ACTIVE_COMPARATOR|Tunica Vaginalis|Tunica Vaginalis Flap is used as a covering layer for urethra during repair of hypospadias
62262119|NCT04722575|EXPERIMENTAL|ARM A|"Arm A BRAF mutated patients. Over a period of 6 weeks (1) + (2):~1. Vemurafenib 960 mg bid p.o. from week 1 to week 6.~2. Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.~After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks"
62446879|NCT05866146|ACTIVE_COMPARATOR|Usual standard care|The control group participants will receive the usual standard care according to the current practices at the University of Gondar specialized hospital over the same four weeks.
62446880|NCT05850351|EXPERIMENTAL|Virtual reality|Children with cystic fibrosis will be given exercise in the form of a game in a virtual environment in groups of 4-6 children, accompanied by a physiotherapist, for 12 weeks, 3 days a week, between 30-45 minutes.
62446881|NCT05850351|EXPERIMENTAL|Online|Children with cystic fibrosis will be given online aerobic exercise for 12 weeks, 3 days a week, 30-45 minutes, in groups of 4-6 children, accompanied by a physiotherapist.
62446882|NCT00640978|EXPERIMENTAL|Erlotinib + RAD001|Erlotinib 150 mg orally daily for 28 Days + RAD001 (Everolimus) 30 mg orally weekly for 4 Weeks
62844190|NCT02873702|EXPERIMENTAL|Healing Period: Lansoprazole 30 mg|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks in the Healing Period.
62058634|NCT01288339|EXPERIMENTAL|Panitumumab + FOLFOX (no-DP)|Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
62058635|NCT00114361|ACTIVE_COMPARATOR|1|Ribavirin + Peg IFN
62058636|NCT00114361|ACTIVE_COMPARATOR|2|Peg IFN + Placebo
62058637|NCT02627508|EXPERIMENTAL|Pregnenolone (up to 500 mg per day)|"Twice daily intake of orally administered Pregnenolone will occur on a schedule as described below.~Weeks 1 and 2: 30mg twice daily (total 60mg per day)~Weeks 3 and 4: 60mg twice daily (total: 120mg per day)~Weeks 5 and 6: 90mg twice daily (total: 180mg per day)~Weeks 7 and 8: 150mg twice daily (total: 300mg per day)~Weeks 9 and 10: 210mg twice daily (total: 420mg per day)~Weeks 11 to 14: 250mg twice daily (total: 500mg per day)"
62058638|NCT02627508|PLACEBO_COMPARATOR|Placebo|Placebo
62058639|NCT00832195|EXPERIMENTAL|1|Footwear with motion controlling elements built into construction in order to reduce pronation of the foot and ankle during running.
62058640|NCT00832195|ACTIVE_COMPARATOR|2|Footwear with standard neutral stabilization elements for the foot and ankle during running.
62262120|NCT04722575|EXPERIMENTAL|ARM B|"Arm B BRAF mutated patients. Over a period of 6 weeks (1) + (2) + (3):~1. Vemurafenib 720 mg bid p.o. from week 1 to week 6.~2. Cobimetinib 60 mg qd p.o. from week 1 to week 3 and from week 5 to week 6. Week 4 off.~3. Atezolizumab 840 mg IV for 2 cycles (day 1 of week 4 and day 1 of week 7).~After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks"
62262121|NCT04722575|EXPERIMENTAL|ARM C|"Arm C BRAF WT patients. Over a period of six weeks (1) + (2):~1. Cobimetinib 60 mg qd p.o. from week 1 to week 3 and from week 5 to week 6,~2. Atezolizumab 840 mg IV for 2 cycles (day 1 of week 1 and day 1 of week 4).~After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks"
62844191|NCT02873702|EXPERIMENTAL|Maintenance Period: Dexlansprazole 30 mg|Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole 30 mg, delayed-release capsules, orally, once daily for up to 6 months in the Maintenance period.
62844192|NCT02873702|EXPERIMENTAL|Maintenance Period: Placebo|Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 6 months in the Maintenance period.
62844193|NCT03204240|EXPERIMENTAL|Intervention|This group will receive electrical stimulation induced exercises in addition to their standard care during in-patient rehabilitation (IPR). Standard care will include respiration therapy, bed mobility, transfers, wheelchair mobility skills, bowel and bladder management, tone and spasticity management, and skills for performing other activities of daily living. Exercises will include neuromuscular electrical stimulation (NMES) induced-resistance exercise (RE) (1x/day) and NMES-aerobic exercise (1x/day) for 3 days/week.
62058641|NCT05791448|EXPERIMENTAL|Treatment (AU409)|Patients receive AU409 PO on study. Patients also undergo CT or MRI and collection of blood samples throughout the trial.
62058642|NCT01575743|EXPERIMENTAL|Aerobic Exercise|
62058643|NCT01575743|OTHER|healthy controls|
62058644|NCT02145325|EXPERIMENTAL|Expanded Tregs|Immune cells in the blood will be removed by leukopheresis procedure and stored for later manufacture of subject's Expanded Tregs cellular product. Two months following subject's kidney transplantation, subject will be given an Expanded Tregs infusion intravenously in the Northwestern Clinical Research Unit.
62058645|NCT02202278||ovarian hyperstimulation patients|Moderate OHSS is defined as abdominal distension and discomfort, nausea with or without vomiting, ovarian enlargement (ovarian size of 8-12 cm) and ascites that revealed by ultrasonografic examination. Severe OHSS criteria is defined as ovarian enlargement, ascites with or without hydrothorax, haematocrit \>45%, weight gain \>2 kg, white blood cell count \>15.000, oliguria, creatinine of 1.0-1.5, creatinine clearance of \>50 ml/min, liver dysfunction.
62262122|NCT02853942|EXPERIMENTAL|Stem cell therapy group|Using the international standard 14G (diameter 1.54mm) needle inject autologous adipose derived mesenchymal stem cells 2ml to facial nerve, the effective release of the concentration is 100 million stem cells / ml.
62262123|NCT02853942|EXPERIMENTAL|Neurotrophic drugs treatment group|Patients were treated with routine drug therapy，do not inject stem cell to the facial nerve of patient
62262124|NCT03550482|EXPERIMENTAL|Oncoxin®|
62262125|NCT03550482|NO_INTERVENTION|Control|
62058646|NCT02202278||without ovarian hiperstimulation|Control group is composed of patients who underwent long luteal protocol but do not demonstrate symptoms of OHSS
62058647|NCT06578715|NO_INTERVENTION|Control Group|no intervention will be applied to the control group
62058648|NCT06578715|EXPERIMENTAL|Experimental Group|EFT will be applied to the women to be included in the experimental group in the study once a week, a total of four times in a month.
62058649|NCT01022086||early stage/adjuvant|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
62262126|NCT04426877|EXPERIMENTAL|Experimental group|The experimental group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.
62844194|NCT03204240|NO_INTERVENTION|Control|This group will receive standard care plus passive dynamic exercise of the lower legs (sham treatment for NMES-RE, 1x/day) and transcutaneous electrical nerve stimulation (TENS, sham treatment for NMES-aerobic exercise, 1x/day) during IPR.
62844195|NCT02288455|EXPERIMENTAL|RELIEF II - GTU AUS|Prospective, non-randomized multi-center study testing the safety and efficacy of the GTU Artificial Urinary Sphincter device in males with stress urinary incontinence.
62844196|NCT01284335|EXPERIMENTAL|Gemcitabine plus LY573636|
62844197|NCT01284335|EXPERIMENTAL|Docetaxel plus LY573636|
62058650|NCT01022086||locally advanced/neoadjuvant|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
62058651|NCT01022086||metastatic|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
62844198|NCT01284335|EXPERIMENTAL|Temozolomide plus LY573636|
62844199|NCT01284335|EXPERIMENTAL|Cisplatin plus LY573636|
62844200|NCT01284335|EXPERIMENTAL|Erlotinib plus LY573636|
62844201|NCT06204835|EXPERIMENTAL|RDCy7 Intraoperative Fluorescence|The patients will receive an injection of fluorophore (RDCy7) before the surgery. Then intraoperative fluorescence imaging will be performed to guide lesion resection.
62844202|NCT05244135|EXPERIMENTAL|Pulmonary rehabilitation in VR (VR group)|"The VR group will perform the endurance exercise training using the Virtual Park, developed by CNR-STIIMA. The system includes a COSMED cycle-ergometer, a virtual environment and a physiological sensor-either a HR band or a pulse-oximeter depending on the target patient's needs. The virtual environment represents a ride in a park, enriched with realistic elements and sound effects, in order to simulate a daily life situation.~In the VR group, the VR Tier One device (Stolgraf®) will be used as a VR source. Thanks to using a head mounted display and the phenomenon of total immersion, VR therapy provides an intense visual, auditory and kinaesthetic stimulation. The aim of the software was to calm and improve the mood, while motivating and cognitively activating the patient."
62844203|NCT05244135|ACTIVE_COMPARATOR|Traditional Pulmonary Rehabilitation (TPR)|"In the TPR group, exercise training will be performed on the bicycle. The training will be conducted on cycle ergometers with the use of the Peloton™ system, which ensures the monitoring of performance parameters.~In the TPR group, Schultz Autogenous Training will be performed. Schultz Autogenic Training has been shown to be effective in treating these pathologies. In both groups the relaxation training will be carried out once a day and will last about 20 minutes."
62262127|NCT04426877|EXPERIMENTAL|Control Group|The control group will receive the same web-based lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
62844204|NCT04901780|EXPERIMENTAL|PPCS|Novel intervention
62844205|NCT04901780|ACTIVE_COMPARATOR|CBS|Cross arm stretch gave to individuals
62844206|NCT01048632|EXPERIMENTAL|Oxandrolone|Following clinical evaluation, all patients will be receive oxandrolone in addition to their usual medications. Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
62058652|NCT01022086||anthracycline-containing|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
62058653|NCT01022086||non-anthracycline containing|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
62058654|NCT00357721|ACTIVE_COMPARATOR|A1|
62058655|NCT00357721|ACTIVE_COMPARATOR|A2|
62058656|NCT00357721|ACTIVE_COMPARATOR|A3|
62058657|NCT01296022|ACTIVE_COMPARATOR|Subcutaneous ICD|Subcutaneous Implantable Cardioverter Defibrillator
62058658|NCT01296022|ACTIVE_COMPARATOR|Transvenous ICD|Transvenous Implantable Cardioverter Defibrillator
62262128|NCT03734835|ACTIVE_COMPARATOR|hesperidin and flaxseed|1000 mg hesperidin as two capsules and 30 grams flaxseed
62262129|NCT03734835|PLACEBO_COMPARATOR|control|no supplementation
62844207|NCT00660634|NO_INTERVENTION|B|
62262130|NCT03734835|ACTIVE_COMPARATOR|flaxseed|30 grams flaxseed
62262131|NCT03734835|ACTIVE_COMPARATOR|hesperidin|1000 mg hesperidin as two capsules
62262132|NCT03103802|EXPERIMENTAL|Intra-oral scanning|
62262133|NCT03103802|EXPERIMENTAL|extra-oral scanning of the plaster model obtained via alginate|
62262134|NCT03103802|EXPERIMENTAL|extra-oral scanning of plaster model obtained via rubber base|
62262135|NCT03103802|EXPERIMENTAL|extra-oral scanning of the rubber base impression|
62262136|NCT03103802|EXPERIMENTAL|extra-oral scanning of the alginate impression|
62262137|NCT01888029|EXPERIMENTAL|transcranial direct current stimulation|
62446883|NCT04771000|EXPERIMENTAL|Ambrisentan|Ambrisentan, 125µg twice a day for up to 28 days
62446884|NCT04771000|PLACEBO_COMPARATOR|Placebo|Placebo
62446885|NCT04759495|EXPERIMENTAL|rtCGM|Patients with use of the DEXCOM G5 or G6 system (real time continuous glucose monitoring).
62844208|NCT00660634|EXPERIMENTAL|A|Endovascular angioplasty/stenting
62844209|NCT02618070|EXPERIMENTAL|Functional dyspepsia patient|Yogurt ingestion
62844210|NCT02618070|EXPERIMENTAL|Healthy|Yogurt ingestion
62844211|NCT00311129|EXPERIMENTAL|Arm 1|
62262138|NCT01888029|PLACEBO_COMPARATOR|sham stimulation|
62262139|NCT05182775|EXPERIMENTAL|experimental group|This trial is a prospective study without a control group. It is planned to recruit 15 patients with IgA nephropathy. The experimental group received fecal bacteria transplantation through FMT capsule. The researchers will judge the effectiveness and safety of fecal bacteria transplantation in the treatment of IgA nephropathy by observing the changes of monitoring indicators before and after fecal bacteria transplantation and during follow-up. Donor screening and FMT capsule preparation were completed by Dongyuan Yikang company (www.dongyuanyikang. com).The patients participating in the trial took 16 Enterobacteriaceae capsules on day 1, day 8 and day 15 respectively as a course of treatment. The researchers will collect stool samples from patients one day before taking the medicine, one week after the last taking the medicine and one month after the last taking the medicine, and analyze the intestinal flora by sequencing
62446886|NCT04759495|EXPERIMENTAL|FGM|Patients with use of the FreeStyle Libre Flash system (flash glucose monitoring).
62446887|NCT04552704|EXPERIMENTAL|Phase I (CD24Fc)|Patients receive CD24Fc IV over 60 minutes on days 1, 14, and 28 with standard of care (i.e., steroids per treating physician and best supportive care) in the absence of disease progression or unacceptable toxicity.
62446888|NCT04552704|EXPERIMENTAL|Phase II, Arm I (CD24Fc)|Patients receive CD24Fc IV over 60 minutes on days 1, 14, and 28 in addition to standard of care treatment for irAE in the absence of disease progression or unacceptable toxicity.
62844212|NCT00311129|ACTIVE_COMPARATOR|Arm 2|
62844213|NCT04483388|OTHER|Group AB|After randomization, 6 children composed the AB sequence were initially submitted to experimental training with virtual reality and after a week, a period considered washout, the conventional training.
62844214|NCT04483388|OTHER|Group BA|After randomization 6 children composed the BA sequence were initially submitted to conventional training and after a week, a period considered washout, the experimental training with virtual reality.
62844215|NCT00842322|EXPERIMENTAL|High fluid intake|fluid intake of 4 litres per day
62262140|NCT01594515|EXPERIMENTAL|BI 1015550 low dose A|Powder for oral solution
62262141|NCT01594515|EXPERIMENTAL|BI 1015550 low dose B|Powder for oral solution
62262142|NCT01594515|EXPERIMENTAL|BI 1015550 low dose C|Powder for oral solution
62262143|NCT01594515|EXPERIMENTAL|BI 1015550 low dose D|Powder for oral solution
62262144|NCT01594515|EXPERIMENTAL|BI 1015550 medium dose A|Powder for oral solution
62262145|NCT01594515|EXPERIMENTAL|BI 1015550 medium dose B|Powder for oral solution
62262146|NCT01594515|EXPERIMENTAL|BI 1015550 medium dose C|Powder for oral solution
62262147|NCT01594515|EXPERIMENTAL|BI 1015550 high dose A|Powder for oral solution
62262148|NCT01594515|EXPERIMENTAL|BI 1015550 high dose B|Powder for oral solution
62262149|NCT01594515|PLACEBO_COMPARATOR|Placebo|Solution for oral administration
62262150|NCT01088776|EXPERIMENTAL|Supplement|
62262151|NCT01088776|PLACEBO_COMPARATOR|Control|
62262152|NCT03151863|ACTIVE_COMPARATOR|Opioids, placebo|One single dose of subcutaneous opioids and intranasal placebo (NaCl0.9%).
62446889|NCT04552704|PLACEBO_COMPARATOR|Phase II, Arm II (placebo)|Patients receive placebo IV over 60 minutes on days 1, 14, and 28 in addition to standard of care treatment for irAE in the absence of disease progression or unacceptable toxicity.
62446890|NCT01348295||Mechanically ventilated children|All children under 16 years of age who are needing mechanical ventilation for any reason.
62844216|NCT00842322|EXPERIMENTAL|normal fluid intake|Fluid intake of 2 litres per day
62844217|NCT00433004|NO_INTERVENTION|1|No advance supply of emergency contraception
62844218|NCT00433004|ACTIVE_COMPARATOR|2|Advance supply of emergency contraception is given
62844219|NCT02028728||Orsiro|
62844220|NCT02465827|ACTIVE_COMPARATOR|Saphenous and obturator nerve block|"5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of ropivacaine 0,75% for the obturator nerve block.~Ropivacaine 0.75% for nerve blockades for both nerves mentioned."
62058659|NCT01488708|EXPERIMENTAL|LY 2127399 Q2W|If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
62058660|NCT01488708|EXPERIMENTAL|LY2127399 Q4W|If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
62058661|NCT03237273|EXPERIMENTAL|Single|All patients will undergo ultrasound scan using the HEAD-US Scoring System by a non-imaging specialist
62058662|NCT04256356|ACTIVE_COMPARATOR|Infants born by CS-fed fermented formula at double dosage|Infants born by CS-fed formula milk with fermented matrix at dosage of 4,6 g per 100g of powder (group fed with double dosage of fermented matrix compare trial FERCT15)
62058663|NCT04256356|ACTIVE_COMPARATOR|Infants born by CS-fed fermented formula at triple dosage|Infants born by CS-fed formula milk with fermented matrix at dosage of 6,9 g per 100g of powder (group fed with triple double dosage of fermented matrix compare trial FERCT15)
62058664|NCT04256356|PLACEBO_COMPARATOR|Infants born by CS-fed standard formula|Infants born by CS-fed formula milk without fermented matrix
62058665|NCT04256356|OTHER|Infants born by CS-breastfed|Infants born by cesarean section fed with mother milk during were the reference group
62058666|NCT00865943|EXPERIMENTAL|A|Citalopram HBr eq. 10 mg tablets, single dose
62058667|NCT00865943|ACTIVE_COMPARATOR|B|CELEXATM 10 mg tablets, single dose
62058668|NCT02294136|EXPERIMENTAL|Prep-C|Four session nurse administered behavioral intervention.
62058669|NCT02294136|ACTIVE_COMPARATOR|Educational Control|Attention Control
62058670|NCT05756608||Aortic stenosis|The investigators will recruit 70 patients with aortic stenosis (25 patients with asymptomatic moderate aortic stenosis and 25 patients with symptomatic severe aortic stenosis, 10 patients with mild aortic stenosis and 10 patients with aortic sclerosis) and 10 healthy volunteers, who will undergo baseline 68Ga-FAPI or 18F-AlF-FAPI PET/MR imaging to establish fibrosis activity in healthy myocardium and in context of chronic myocardial injury. All patients will have a follow up FAPI PET/ MR scan 1 year after their baseline scan to assess whether myocardial fibrosis activity reverses following aortic valve replacement and restoration of normal afterload in patients with severe aortic stenosis and if baseline myocardial fibrosis activity can predict progression in the fibrosis burden and clinical progression in patients with mild or moderate aortic stenosis or aortic sclerosis. Healthy volunteers will not undergo any repeat imaging.
62262153|NCT03151863|EXPERIMENTAL|Placebo, Dexmedetomidine|One single dose of subcutaneous placebo (NaCl0.9%) and intranasal Dexmedetomidine 1.25ug/Kg
62262154|NCT01166022|EXPERIMENTAL|Exercise|Muscle strengthening program using weights and resistance bands in combination with a home based cycle ergometry program. The home-based exercise program will be performed up to 5 times weekly.
62262155|NCT01166022|NO_INTERVENTION|Typical Activity|Subjects in this group will be asked to maintain their typical daily activity. Those assigned to this arm will be given the opportunity to join the intervention arm seven months after their screening visit.
62262156|NCT03455491|EXPERIMENTAL|XC221 100 mg|"XC221 100 mg orally.~1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period"
62262157|NCT03455491|EXPERIMENTAL|XC221 200 mg|XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
62618484|NCT03051347|OTHER|Validation Questionnaire and Interview-Mild|For validation, up to 90 parent/child dyads ages 0-17 with a diagnosis of mild AD will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status for mild patients.
62618485|NCT06033170|EXPERIMENTAL|Insertion of CELOX™ PPH trans-vaginally for bleeding control|There is only one group.
62844221|NCT02465827|ACTIVE_COMPARATOR|Saphenous nerve block|"5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.~Ropivacaine 0.75% for the saphenous nerve block and saline for the obturator nerve block"
62844222|NCT02465827|PLACEBO_COMPARATOR|Placebo nerve block|"5 ml of isotonic saline for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.~Saline for nerve blockades for both nerves mentioned."
62262158|NCT03455491|PLACEBO_COMPARATOR|Placebo|Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period
62262159|NCT04389762|EXPERIMENTAL|PS128|daily ingestion of Lactobacillus plantarum PS128 capsules
62262160|NCT04979442|EXPERIMENTAL|RAIN-32 (Milademetan)|260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle.
62262161|NCT04979442|ACTIVE_COMPARATOR|Trabectedin|1.5 mg/m2 body surface area as a 24-hour IV infusion, every 3 weeks.
62844223|NCT03230370|EXPERIMENTAL|enhanced upper-extremity program, EUEP|"Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.~The EUP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity.~The participants receive 20-day training over a 4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity.~Accordingly, one group can be used as the control group of the other one."
62262162|NCT02211729|ACTIVE_COMPARATOR|Seasonal malaria chemoprevention|Sulphadoxine-Pyrimethamine Amodiaquine Placebo Azithromycin
62262163|NCT02211729|EXPERIMENTAL|seasonal malaria chemoprevention plus AZ|Sulphadoxine-Pyrimethamine+ Amodiaquine + Azithromycin 4 rounds during malaria transmission season
62262164|NCT06443866||Thyroid Cancer patients, RAI-naive or refractory|
62262165|NCT06414811||Hypotension|Patients with a 30% decrease in SBP from baseline and a decrease in MAP below 65 mmHg in the first 10 minutes after anesthesia induction will be considered to have hypotension.
62262166|NCT06414811||none hypotension|Patients who do not have a 30% decrease from the baseline in SBP and a decrease in MAP below 65 mmHg in the first 10 minutes after anesthesia induction will be considered as not having hypotension.
62618486|NCT03574038|ACTIVE_COMPARATOR|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation
62618487|NCT03574038|SHAM_COMPARATOR|Sham Stimulation|Sham Stimulation
62618488|NCT05749497||NCRT+TME|Neoadjuvant chemoradiotherapy (NCRT) and total mesorectal excision (TME) Interventions
62618489|NCT04303468|EXPERIMENTAL|GABA|GABA is a nutrient commonly present in our diet in for example tomatoes and potatoes. It is also commercially sold as dietary supplement. A dose of 500 mg, 3 times daily is used
62058671|NCT05756608||Chemotherapy-induced cardiotoxicity|The investigators will recruit 60 patients who have undergone anthracycline treatment \>1 year from enrollment and 10 healthy volunteers as part of this cohort. This will include 50 patients who have either clear evidence of cardiotoxicity (Ejection fraction \<50% and a 10%point fall in ejection fraction) or a subclinical cardiac injury (elevated troponin, elevated T2, impaired global longitudinal strain) and 10 patients with no evidence of cardiotoxicity on their cardiac MRI scan (performed as part of the ongoing Cardiac CARE study). These patients will undergo baseline FAPI PET/MR imaging to establish the extent and pattern of myocardial fibrosis activity in context of delayed myocardial injury (chemotherapy-induced cardiotoxicity). All patients will have a follow up cardiac MRI scan 1-2 years after their baseline scan to assess whether baseline fibrosis activity is associated with a deterioration in cardiac function. Healthy volunteers will not undergo any repeat imaging.
62058672|NCT05756608||Carcinoid syndrome|In collaboration with the South East Scotland NET Service, the investigators will recruit 30 patients with carcinoid syndrome for this cohort. These patients will undergo a baseline echocardiogram and a FAPI PET/MR scan to investigate fibrosis activity within the cardiac chambers and valves. The investigators will recruit patients with established cardiac involvement as well as carcinoid syndrome patients with high circulating 5-HT concentrations who have no evidence of valve disease on echocardiography. All patients will have a follow up cardiac MRI scan and an echocardiogram, 6 months - 1 year after their baseline scan to assess whether baseline fibrosis activity is associated with subsequent deterioration in cardiac and valvular function.
62058673|NCT06352359|EXPERIMENTAL|ONC-841|ONC-841 will be given by IV infusion in designated dose, q4w.
62262167|NCT01833286|EXPERIMENTAL|TACE+RFA|TACE was performed according to the following protocol: All patients underwent a distal super-selective catheterization of the hepatic arteries using a coaxial technique and micro-catheters (2.9 Fr, Terumo Corporation, Tokyo, Japan). Then, the same three chemotherapeutic agents at the same dosages were used throughout this study, regardless of tumor number and size. Hepatic artery infusion chemotherapy was performed using carboplatin 300 mg. After that, chemolipiodolization was performed using epirubicin 50 mg, and mitomycin C 8 mg mixed with 5 mL of lipiodol. If the territory of the chemolipiodolized artery did not show stagnant flow, pure lipiodol was then injected. RFA was performed after TACE in 2 months by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).
62262168|NCT01833286|ACTIVE_COMPARATOR|re-resection|Re-resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. We performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
62262169|NCT03742180|EXPERIMENTAL|intranasal dexmedetomidine|this group is planned for intranasal dexmedetomidine
62262170|NCT03742180|ACTIVE_COMPARATOR|sublingual ketorolac|this group is planned for sublingual ketorolac
62618490|NCT04303468|PLACEBO_COMPARATOR|Placebo|The placebo consists of capsules containing powdered cellulose.
62058674|NCT02217280|EXPERIMENTAL|Injection with Gadolinium|This group of patients identified by the PI as having cervical radiculopathy will receive gadolinium (the intervention) in their epidural cervical injection along with steroid (DepoMedrol). There is no control group in this study.
62058675|NCT04555096|EXPERIMENTAL|Active GC4419|Arm A
62262171|NCT01178450|ACTIVE_COMPARATOR|Subtotal parathyroidectomy|The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland
62618491|NCT03648138|ACTIVE_COMPARATOR|Calorie label|"This arm will display a Calories per Bottle label on all beverages, not just sugary beverages. This label is identical to the American Beverage Association's current Clear on Calories labels (as of 2018)."
62844224|NCT03230370|EXPERIMENTAL|enhanced lower-extremity program,ELLP)|"Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.~The ELP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.~The participants receive 20-day training over a4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity.~Accordingly,one group can be used as the control group of the other one."
62262172|NCT01178450|EXPERIMENTAL|Cinacalcet|Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
62844225|NCT01918748|EXPERIMENTAL|MS & chronic stroke patients|"Intervention: 8 weeks of I-TRAVLE based training of proximal arm function, using the haptic master.~Each week participants will attend training sessions on 5 days per 2 weeks, during which they will train 2 times 30 minutes I-TRAVLE assisted therapy, of which 1x 30 minutes supervised self-training. The two times half an hour training sessions per day will be interspaced by at least half an hour to avoid (general) fatigue and overuse of the affected arm in the subjects."
62058676|NCT04555096|PLACEBO_COMPARATOR|Placebo|Arm B
62844226|NCT05436743|EXPERIMENTAL|K-Y jelly soaked packs|K-Y jelly soaked packs inserted for pretension of postoperative sore throat
62844227|NCT05436743|ACTIVE_COMPARATOR|Water soaked packs|Water soaked packs inserted for pretension of postoperative sore throat
62058677|NCT02102880|OTHER|Healthy Subjects|
62262173|NCT05377047|EXPERIMENTAL|Experimental SABR arm|Standard first line systemic therapy + SABR.
62262174|NCT05377047|NO_INTERVENTION|Control systemic therapy arm|Standard first line systemic therapy.
62262175|NCT01322464|EXPERIMENTAL|Group 1 Fasted-Fed|"4 sprays Sativex in fasted state, followed by wash-out followed by 4 sprays Sativex in fed state.~Followed by 4 sprays daily in fasted state."
62058678|NCT00705302|EXPERIMENTAL|patient education including self-help|Patients in the arm will participate in a three months patient education and exercise program including a self-help group in 3 months of time.
62058679|NCT00705302|ACTIVE_COMPARATOR|patient education|Patients in arm 2 will participate in the same patient education and exercise program as arm 1, but without an additional self-help group.
62262176|NCT01322464|EXPERIMENTAL|Group 1 Fed-Fasted|"4 sprays sativex in fed state followed by wash-out followed by 4 sprays Sativex in fasted state.~Followed by 4 sprays daily in fasted state."
62262177|NCT01322464|EXPERIMENTAL|Group 2|2 sprays Sativex daily in fasted state.
62262178|NCT01322464|EXPERIMENTAL|Group 3|8 sprays sativex daily in fasted state.
62262179|NCT03448068|EXPERIMENTAL|Ketamine Therapy|"1. Ketamine 0.3 mg/kg (IBW) bolus with induction.~2. Ketamine infusion 0.2 mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~3. Ketamine infusion will not be titrated.~4. Remaining care will be identical to standard therapy group."
62262180|NCT03448068|ACTIVE_COMPARATOR|Standard Therapy|"1. Calculation ideal body weight (IBW)~2. Pre-op dexamethasone~3. Pre-op midazolam at discretion of anesthesiologist~4. Anesthesia Induction - Propofol and fentanyl, anesthesiologist discretion. Neuromuscular block with succinylcholine and/or rocuronium at discretion of anesthesiologist. Orotracheal intubation.~5. Anesthesia Maintenance - Sevoflurane/rocuronium. Addl. doses of fentanyl, discretion of anesthesiologist.~6. Emergence from anesthesia - Acetaminophen, Ketorolac and Ondansetron unless contraindicated. Sugammadex depending on twitch response per drug manufacturer recommended protocol.~7. Post-Op Analgesia - Hydromorphone, acetaminophen and ketorolac~8. Other post-op care as per usual surgical routine"
62262181|NCT03359512|EXPERIMENTAL|qCON monitor|Simultaneous measurement of BIS and qCON
62262182|NCT02626897|OTHER|Sarcoidosis - GENEActiv device first|Six patients start with the GENEActiv wrist-worn accelerometer which is needed to be worn for a 7 day period. Participants then switch to the ActiGraph GT3X device for a 7 day period. At the end of this second period they complete a short exit questionnaire detailing their experience and their device preference.
62262183|NCT02626897|OTHER|Sarcoidosis - ActiGraph device first|Six patients start with the ActiGraph GT3X wrist-worn accelerometer which is needed to be worn for a 7 day period. Participants then switch to the GENEActiv device for a 7 day period. At the end of this second period they complete a short exit questionnaire detailing their experience and their device preference.
62262184|NCT01680822||NTM patient|confirmed NTM patient
62262185|NCT03652038|EXPERIMENTAL|TD-8236 for SAD (Part A)|6 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive TD-8236
62262186|NCT03652038|PLACEBO_COMPARATOR|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive placebo
62262187|NCT03652038|EXPERIMENTAL|TD-8236 for MAD (Part B)|6 out of 8 subjects per cohort (up to 6 cohorts) will be randomized to receive TD-8236.
62262188|NCT03652038|PLACEBO_COMPARATOR|Placebo for MAD (Part B)|2 out of 8 subjects per cohort (up to 6 cohorts) will be randomized to receive placebo.
62618492|NCT03648138|EXPERIMENTAL|Text warning label|This arm will display similar text proposed in a recent sugary drink warning label bill in California. Sample text: WARNING: Drinking beverages with added sugar(s) contributes to obesity, type 2 diabetes, and tooth decay. The calorie label will also appear on all beverages.
62844228|NCT04044001|EXPERIMENTAL|Stage 1 - Cohort 1 (BTZ 250)|Patients will receive 1 tablet of BTZ-043 orally once daily, containing 250mg BTZ-043 from Day 1 through to Day 14
62844229|NCT04044001|EXPERIMENTAL|Stage 1 - Cohort 2 (BTZ 500)|Patients will receive 2 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (500 mg in total) from Day 1 through to Day 14
62058680|NCT00876915|EXPERIMENTAL|High Risk for VTE recieving dalteparin|Patients assigned at random to receive prophylactic dalteparin injections
62262189|NCT03652038|EXPERIMENTAL|TD-8236 for Biomarker (Part C)|8 subjects in each of 2 biomarker cohorts will be randomized to receive TD-8236.
62262190|NCT03652038|PLACEBO_COMPARATOR|Placebo for Biomarker (Part C)|8 subjects in 1 biomarker cohort will be randomized to receive placebo.
62262191|NCT05650801|EXPERIMENTAL|Intervention Group 1|Participants who will be given music therapy 3 times a week for 4 weeks in a row. This group will get Maslach Burnout Inventory and Heart Rate Variability score evaluated before and after music therapy intervention.
62262192|NCT05650801|EXPERIMENTAL|Intervention Group 2|Participants with burnout syndrome who will be given music therapy 5 times a week for 2 weeks in a row. This group will get Maslach Burnout Inventory and Heart Rate Variability score evaluated before and after music therapy intervention.
62262193|NCT05650801|NO_INTERVENTION|Neutral Group|Participants in this group will not get any music intervention. The maslach burnout inventory and heart rate variability score will be evaluated before and after four weeks without any intervention
62262194|NCT04227262|NO_INTERVENTION|the control group|Group (a) control group received traditional physical therapy program.
62058681|NCT00876915|NO_INTERVENTION|High Risk for VTE No therapy|No prophylactic therapy for VTE prevention given (Subjects receiving standard of care)
62058682|NCT00876915|NO_INTERVENTION|Low Risk for VTE|Used as a control for the secondary outcome of evaluating tissue factor in collected blood samples
62262195|NCT04227262|EXPERIMENTAL|the study group|group (b) study group received the same traditional physical therapy program in addition to mirror therapy three times / weak for three successful months.
62262196|NCT05599542|EXPERIMENTAL|Solution-oriented approach group|A preliminary assessment of the pregnant woman's thoughts on breastfeeding was made and the EARS (Eliciting, Amplifying, Reinforcing and Start Over) process was applied. Eliciting, Amplifying, Reinforcing and Start Over process guides the second and subsequent sessions in a sequential order.
62262197|NCT05599542|EXPERIMENTAL|Hypno-breastfeeding group|A preliminary assessment was made about the pregnant woman's thoughts on breastfeeding. In the hypno-nursing philosophy, affirmation, relaxation, imagination and visualization techniques were used in order to positively affect the subconscious mind during the breastfeeding process.
62262198|NCT05599542|OTHER|control group|Data were collected with the Introductory Information Form at the first interview (admission to the postpartum service) with the women in the control group. Post-test data were collected with Primiparous Breastfeeding Motivation Scale and Insufficient Milk Perception Scale at 16-24 hours postpartum.
62262199|NCT00916188|EXPERIMENTAL|Black Tea-Four Doses|One, 2, 3 and 4 cups (150 ml/cup) of Black tea/day for week 1, 2, 3, and 4, respectively.
62618493|NCT03648138|EXPERIMENTAL|Sugar graphic warning label|"This arm will graphically display the amount of sugar in each sugary beverage along with the same text used in the text warning label arm. The calorie label will also appear on all beverages."
62618494|NCT03648138|EXPERIMENTAL|Health graphic warning label|"This arm will graphically display potential negative health effects of over consuming sugary drinks for each sugary beverage, along with the same text used in the text warning label arm. The calorie label will also appear on all beverages."
62618495|NCT06380972|EXPERIMENTAL|Polycaprolactone (PCL) Based Facial Injectable|
62844230|NCT04044001|EXPERIMENTAL|Stage 1 - Cohort 3 (BTZ 750)|Patients will receive 3 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (750 mg in total) from Day 1 through to Day 14
62058683|NCT00643123|EXPERIMENTAL|Allopurinol|Subjects will be randomized to allopurinol at a fixed dose of 300 mg/day for the first week and then 600mg/day while continuing their current medications during the 7-week study. A battery of assessments will be administered at baseline and weeks 1, 2, 4, 6 after baseline. At each assessment, subjects will also be asked about side effects including potential side effects of allopurinol. Side effects will be assessed by the Treatment Emergent Side Effects Scale. Serum levels of lithium, valproic acid, carbamazepine, atypical antipsychotics or atypical antipsychotic metabolite, uric acid blood levels will be drawn at screen and at week 6 after baseline. Subjects taking only lithium, valproic acid, and/or carbamazepine will also have their serum levels drawn at week 2.
62618496|NCT06380972|NO_INTERVENTION|no treatment control|
62618497|NCT00544908|EXPERIMENTAL|Dasatinib|Dasatinib 70 mg po bid (1 cycle=28 days)
62058684|NCT00643123|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to placebo and will follow the same protocol as the allopurinol group.
62058685|NCT03013946|EXPERIMENTAL|Arm A (Coaching)|Concomitant coaching (24 weeks) Pro-active TEAE (Treatment emergent adverse events) management Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15
62058686|NCT03013946|NO_INTERVENTION|Arm B (Control)|Re-activeTEAE management (SOC) Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15
62058687|NCT04495439|OTHER|Treatment with ISS Sleeve|The biocompatible, resorbable ISS sleeve is used for augmentation to enhance screw anchorage. It is melted into the trabecular bone structure of the osteoporotic vertebra using ultrasound. A standard pedicle screw is inserted into the sleeve.
62058688|NCT04495439|OTHER|Treatment with PMMA|The bone cement Polymethylmethacrylat (PMMA) that is injected into the osteoporotic vertebra.PMMA augmentation of pedicle screws is done using standard cannulated and perforated pedicle screws. The cancellous bone surrounding the screw is enhanced with PMMA bone cement to increase screw anchorage.
62058689|NCT00377780|EXPERIMENTAL|1|Myocet + docetaxel + trastuzumab
62058690|NCT01368445|ACTIVE_COMPARATOR|MP03-36 Nasal Spray|azelastine hydrochloride 0.15%
62058691|NCT01368445|ACTIVE_COMPARATOR|MP03-36 and Placebo Nasal Spray|azelastine hydrochloride 0.15% and Placebo
62058692|NCT01368445|ACTIVE_COMPARATOR|Azelastine 0.1%, Nasal Spray|Azelastine 0.1%, Nasal Spray
62058693|NCT01368445|PLACEBO_COMPARATOR|Placebo Nasal Sapray|0mg, 2 sprays per nostril twice daily AM \& PM)
62058694|NCT03034499|ACTIVE_COMPARATOR|Single-port sacrocolpopexy|Patients with vaginal apex prolapse randomized to undergo repair by single-port sacrocolpopexy.
62058695|NCT03034499|ACTIVE_COMPARATOR|Multi-port sacrocolpopexy|Patients with vaginal apex prolapse randomized to undergo repair by multi- port sacrocolpopexy.
62618498|NCT04110496|EXPERIMENTAL|RTX-134|Escalating doses of RTX-134 will be administered by intravenous infusion one time
62058696|NCT00959101|EXPERIMENTAL|A|
62058697|NCT00959101|EXPERIMENTAL|B|
62058698|NCT00959101|ACTIVE_COMPARATOR|C|
62618499|NCT00700050||CF Females|CF females, 14 - 28 years old, sexually mature, with regular menstrual cycles, not on contraceptive Pill. No intervention is being tested - subjects studied with normal menstrual variations in serum hormone levels. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
62058699|NCT05716984|ACTIVE_COMPARATOR|recombinant human brain natriuretic peptide|loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
62058700|NCT05716984|PLACEBO_COMPARATOR|placebo|loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
62058701|NCT02212444|EXPERIMENTAL|Dynamic elastomeric fabric orthoses (DEFO)|The DEFO will be provided after taking the baseline measures and orthoses measurements at the baseline session \~ 3 weeks later. The orthoses will be supplied via post and used for a period of 12 weeks.
62058702|NCT02212444|ACTIVE_COMPARATOR|Off-the-self orthotics|Off-the-shelf-Orthotics: Patients in the usual care group will be referred for off -the-shelf triplanar orthoses as indicated by a biomechanical assessment of foot posture while standing / walking on visit 1. The off the shelf orthotic will be provided after taking the baseline measures and orthoses measurements at the baseline session \~ 3 weeks later. The orthoses will be supplied via post and used for a period of 12 weeks.
62058703|NCT01201811|EXPERIMENTAL|Single-Arm|Azacitidine 75 mg/m\^2/day Subcutaneous for 7 days Day every 28 days for up to 6 cycles
62058704|NCT03728608|ACTIVE_COMPARATOR|Group 1--Short Dwell|Premature VLBW (very low birth weight) male and female infants will be randomly assigned to have their feeding tubes removed at 0-48 hours for the first 4 weeks of life.The feeding tube lumen, interluminal liquid and hub will be analyzed for level of contamination.
62058705|NCT03728608|ACTIVE_COMPARATOR|Group 2--Long Dwell|Premature VLBW (very low birth weight) male and female infants will be randomly assigned to have their feeding tubes removed at 7 days for the first 4 weeks of life.The feeding tube lumen, interluminal liquid and hub will be analyzed for level of contamination.
62058706|NCT05629663|EXPERIMENTAL|AR program group|participants in the AR group were guided by AR-based instructions and requested assistance with the head-mounted device.
62058707|NCT01013792|EXPERIMENTAL|Non-adherent Wound Dressing|The non-adherent dressing is the same as the Tegaderm Matrix dressing, with potassium chloride, rubidium chloride, calcium chloride, zinc chloride, potassium citrate and citric acid removed. This dressing is a Class I medical device (21 CFR Sec. 878.4020 Occlusive wound dressing) that is exempt from premarket notification procedures.
62058708|NCT01013792|ACTIVE_COMPARATOR|Tegaderm Matrix Dressing with PHI|A commercial wound dressing to be used per manufacturer's instructions for use.
62262200|NCT00916188|ACTIVE_COMPARATOR|Black Tea-One Dose|One cup (150 ml) of Black tea/day during study.
62262201|NCT04639973|EXPERIMENTAL|Group 1 (First trimester ultrasound)|
62262202|NCT04639973|ACTIVE_COMPARATOR|Group 2 (Second trimester anatomy ultrasound)|
62618500|NCT00700050||Non-CF Females|Non-CF control females, 14 - 28 years old, sexually mature, with regular menstrual cycles, not on contraceptive Pill. No intervention is being tested - subjects studied with normal menstrual variations in serum hormone levels. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
62618501|NCT00700050||CF Males|CF males, 14 - 28 years old. No intervention is being tested. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
62058709|NCT05917977|OTHER|Control group (Education Materials)|After completing the baseline screening, survey and randomization, the participants in the control group will receive educational materials regarding topics including: (1) what IGD is and its consequences, (2) how to communicate with parents about the gaming time, and (3) how to develop a healthy lifestyle, etc.
62262203|NCT03092102|EXPERIMENTAL|A single dose HEC585（A1）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
62262204|NCT03092102|EXPERIMENTAL|A single dose HEC585（A2）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
62262205|NCT03092102|EXPERIMENTAL|A single dose HEC585/FE（A3）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule~Treatment Period 1：No food prior to dosing；Treatment Period 2：High-fat meal prior to dosing"
62618502|NCT00700050||Non-CF males|Non-CF control males, 14 - 28 years old. No intervention is being tested. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
62618503|NCT06537050|ACTIVE_COMPARATOR|JX2105|JX2105 10mg；JX2105 30mg；JX2105 90mg；JX2105 180mg
62262206|NCT03092102|EXPERIMENTAL|A single dose HEC585（A4）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
62262207|NCT03092102|EXPERIMENTAL|A single dose HEC585（A5）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
62262208|NCT03092102|EXPERIMENTAL|A single dose HEC585（A6）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
62262209|NCT03092102|EXPERIMENTAL|A single dose HEC585（A7）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
62262210|NCT03092102|EXPERIMENTAL|A single dose HEC585（A8）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
62262211|NCT03092102|EXPERIMENTAL|Multiple doses HEC585（B1）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
62618504|NCT06537050|PLACEBO_COMPARATOR|Placebo|Placebo
62618505|NCT01077102|EXPERIMENTAL|Eccentric exercise training|
62618506|NCT01077102|ACTIVE_COMPARATOR|Concentric exercise training|
62618507|NCT02674126|PLACEBO_COMPARATOR|Control group|Control group
62618508|NCT02674126|ACTIVE_COMPARATOR|Maternal sound group|Maternal sound
62844231|NCT04044001|EXPERIMENTAL|Stage 1 - Cohort 4 (BTZ 1000)|Patients will receive 4 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1000 mg in total) from Day 1 through to Day 14
62844232|NCT04044001|EXPERIMENTAL|Stage 1 - Cohort 5 (BTZ 1250)|Patients will receive 5 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1250 mg in total) from Day 1 through to Day 14
62844233|NCT04044001|EXPERIMENTAL|Stage 1 - Cohort 6 (BTZ 1500)|Patients will receive 6 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1500 mg in total) from Day 1 through to Day 14
62844234|NCT04044001|EXPERIMENTAL|Stage 1 - Cohort 7 (BTZ 1750)|Patients will receive 7 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1750 mg in total) from Day 1 through to Day 14
62844235|NCT04044001|EXPERIMENTAL|Stage 1 - Cohort 8 (BTZ 2000)|Patients will receive 8 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (2000 total) from Day 1 through to Day 14
62844236|NCT04044001|EXPERIMENTAL|Stage 2 - Arm 1 (BTZ high)|Patients will receive a higher dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
62844237|NCT04044001|EXPERIMENTAL|Stage 2 - Arm 2 (BTZ medium)|Patients will receive a medium dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
62262212|NCT03092102|EXPERIMENTAL|Multiple doses HEC585（B2）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
62262213|NCT03092102|EXPERIMENTAL|Multiple doses HEC585（B3）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
62262214|NCT03092102|EXPERIMENTAL|Multiple doses HEC585（B4）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
62262215|NCT03092102|EXPERIMENTAL|Multiple doses HEC585（B5）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
62262216|NCT03092102|EXPERIMENTAL|Multiple doses HEC585（B6）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
62262217|NCT01903707|EXPERIMENTAL|Cognitive Remediation Therapy|Participants will undertake approximately 30 minutes of computerized CRT training for 8 weeks, 5 days per week. They will meet a therapist once per week to discuss any difficulties, help motivation.
62262218|NCT01903707|PLACEBO_COMPARATOR|Placebo Comparator|Participants will meet therapist once per week but will not undertake the Computerized Cognitive remediation training.
62262219|NCT04729673|ACTIVE_COMPARATOR|Patient's normal canine occlusal relationship.|Before full mouth rehabilitation with stainless steel crowns for primary molars , the vertical dimension of occlusion from gingival zenith of upper and lower primary canines shall be determined at the right and left sides. The distance shall be determined using a digital caliper.(Shenzhen Jiabaili Electronic Commerce Co., Ltd), and the reading will be photographed by a digital camera (iPhone 11 dual 12 MP Ultra-Wide and wide camera,Apple Inc.).
62262220|NCT04729673|SHAM_COMPARATOR|Canine occlusal relation after full mouth rehabilitation|After full mouth rehabilitation with stainless steel crowns for primary molars , the vertical dimension of occlusion from gingival zenith of upper and lower primary canines shall be determined at the right and left sides. The distance shall be determined using a digital caliper.(Shenzhen Jiabaili Electronic Commerce Co., Ltd), and the reading will be photographed by a digital camera (iPhone 11 dual 12 MP Ultra-Wide and wide camera,Apple Inc.).
62262221|NCT02970214||Heart Failure|Patients with chronic heart failure and with/without reduced left ventricular ejection fraction (EF) at baseline (HFrEF, HFmrEF, HFpEF)
62844238|NCT04044001|EXPERIMENTAL|Stage 2 - Arm 3 (BTZ low)|Patients will receive a lower dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
62844239|NCT04044001|ACTIVE_COMPARATOR|Stage 2 - Arm 4 (control)|"Patients will receive a standard dose of Rifafour e-275® orally once daily according to body weight from Day 1 through to Day 14. Each tablet of Rifafour e-275® contains 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide and 275mg ethambutol.~The daily doses will be given to fasting patients, in accordance with South African Guidelines for treatment of TB. The total number of tablets will be based on the body weight at screening:~* participants weighing 38 - 54 kg: 3 tablets~* participants weighing 55 - 70 kg: 4 tablets~* participants weighing \>70 kg: 5 tablets"
62844240|NCT01125696|ACTIVE_COMPARATOR|Standard of Care|
62844241|NCT01125696|EXPERIMENTAL|Tenofovir|
62844242|NCT04033393|EXPERIMENTAL|Game based dual-task training group|Participants in dual-task training group will execute game based dual-task training with treadmill, 3 times per week for 8 weeks
62844243|NCT04033393|ACTIVE_COMPARATOR|Treadmill training group|Participants in treadmill training group will do treadmill training, 3 times per week for 8 weeks
62058710|NCT05917977|EXPERIMENTAL|Intervention group (Collective Motivational Interviewing plus Education Materials)|Participants in the intervention group will be given the same Internet Gaming Disorder (IGD) education materials as those in the control group, thus, they will further participate in four counseling sessions with Collective Motivational Interviewing (CMI) (each session 60 mins). In the first session, adolescents with Internet Gaming Disorder will be implemented a standard MI session to elicit and strengthen the client's motivation to change. In the second session, a nominated CSO of the client will participate in a standard MI session to elicit their motivation to help the client toward change and prepare positive attitudes of CSO for the conjoint session. Afterward, the third and fourth sessions (75 mins) will be conjoint sessions. The Collective Motivational Interviewing practitioners will create a safe platform for both parties to share their perspectives with openness and trustfulness, in turn, to reach an agreed goal (e.g., develop a change plan on internet gaming behaviors).
62618509|NCT03754972|EXPERIMENTAL|Lumbar spinal stenosis surgery candidate|Patients with lumbar spinal stenosis and spondylolisthesis that have previously consented to surgical treatment. After recording the initial surgical plan, the Sagittal plane shear index (SPSI) will be provided to the surgeon. The surgeon may change the initial surgical plan based on the stability metric.
62618510|NCT02273765|ACTIVE_COMPARATOR|Raltegravir|Tenofovir 300mg QD + lamivudine 300mg QD + raltegravir 400mg BID
62618511|NCT02273765|EXPERIMENTAL|Efavirenz|Tenofovir 300mg QD + lamivudine 300mg QD + efavirenz 600mg QD
62058711|NCT03076541||patients with restless legs syndrome|
62618512|NCT05584878|EXPERIMENTAL|Group I|
62618513|NCT05584878|EXPERIMENTAL|Group II|
62618514|NCT05584878|ACTIVE_COMPARATOR|Group III|
62618515|NCT00057005|EXPERIMENTAL|1|
62618516|NCT00840697|ACTIVE_COMPARATOR|Work related rehabilitation|"work related rehabilitation and exercises~The workplace intervention includes two steps:~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks.~Exercises comprises of treatment in groups. The treatment includes exercises, both strength and fitness, in addition to cognitive intervention of how to manage pain and work."
62618517|NCT00840697|ACTIVE_COMPARATOR|Brief intervention|1 consultation at the physiotherapist, which give advise and a summary talk with the physician
62618518|NCT00840697|ACTIVE_COMPARATOR|Multidisciplinary exercise group|10 days of exercise and cognitive treatment group
62618519|NCT01651455||Cohort first decade|Patients born between 01/01/1979 and 12/31/1984
62618520|NCT01651455||Cohort second decade|Patients born between 01/01/1991 and 12/31/1996
62618521|NCT05843032|EXPERIMENTAL|Tongue tumor resection|
62618522|NCT06074627|PLACEBO_COMPARATOR|Placebo Control 1|Energy Product Form 1 - control
62618523|NCT06074627|EXPERIMENTAL|Active Product 1.1|Energy Product Form 1 - active product 1
62618524|NCT06074627|EXPERIMENTAL|Active Product 1.2|Energy Product Form 1 - active product 2
62618525|NCT06074627|EXPERIMENTAL|Active Product 1.3|Energy Product Form 1 - active product 3
62844244|NCT04072120||R1|"1. Norwegian citizens aged 45 and above 1.1.1994 - 31.12. 2009 registered in the FS-data during this period.~2. Sub-sample those attending a cardiovascular health survey who later developed stroke."
62844245|NCT04072120||R2|All Norwegians born in the period 1 January 1940 to 31 December 1959 who survived to 1991.
62844246|NCT04072120||R3|Norwegian citizens aged 45 and above 1.1.2016.
62844247|NCT05844488||Blood based biomarker group|Subjects who consent to having a blood based biomarker performed
62844248|NCT04802577||Primary Sjögren's syndrome|The patient's diagnosed with Primary Sjögren's according to 2016 ACR/EULAR classification criteria
62844249|NCT04802577||Healthy Controls|Healthy hospital workers without any chronic disease
62844250|NCT05006001||Case|Cases were defined as patients with an event of renal impairment during follow-up, such as acute kidney injury.
62844251|NCT05006001||Control|Cases were defined as patients without an event of renal impairment during follow-up, such as acute kidney injury.
62844252|NCT05006001||Exposure|Exposure was defined as patients with colchicine and NSAIDs combination therapy.
62844253|NCT05006001||Non-Exposure|Non-Exposure was defined as patients with other gout therapy.
62844254|NCT03378713|EXPERIMENTAL|GROUP 1: Long testosterone|Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application.
62844255|NCT03378713|ACTIVE_COMPARATOR|GROUP 2: Short testosterone|Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.
62844256|NCT03378713|ACTIVE_COMPARATOR|GROUP 3: Control|The COS starts directly on the second day of the cycle without prior medication.
62844257|NCT01094145|SHAM_COMPARATOR|Placebo|Stimulator setting is OFF
62844258|NCT01094145|ACTIVE_COMPARATOR|Deep Brain Stimulation|Stimulator setting is ON
62844259|NCT03005015|EXPERIMENTAL|Lenvatinib|Lenvatinib 24 mg orally every day. Treatment is continued until unacceptable toxicity, progressive disease or patient withdrawal
62844260|NCT03005015|ACTIVE_COMPARATOR|Doxorubicin|Doxorubicin 60 mg/m² iv bolus every 3 weeks. Treatment is continued for a maximum of 6 cycles or until unacceptable toxicity, progressive disease or patient withdrawal.
62844261|NCT02162043||Usability assessment|Patients without any experience with visual field testing will be recruited and tested with different versions of the developed self-test. This will help identify usability features that will make the test user-friendly.
62844262|NCT02162043||Hospital-based clinical trial|The new test will be evaluated on patients attending Manchester Royal Eye Hospital to provide an estimate of its diagnostic performance.
62844263|NCT02162043||Community-based trial|Patients attending Manchester Royal Eye Hospital's outpatient clinics will be recruited to trial the new test on their friends and family in order to evaluate the uptake and performance of the new test in a home environment without any researchers/clinicians presence.
62844264|NCT01989494||Attendings|Anesthesiology Attendings who will wear a pedometer for five days while at work
62844265|NCT01989494||CA1 Residents|Anesthesiology residents in their first year of anesthesiology residency who will wear a pedometer for five days while at work
62844266|NCT01989494||CA2 and CA3 Residents|Anesthesiology residents in their second year of anesthesiology residency who will wear a pedometer for five days while at work
62844267|NCT04631211|EXPERIMENTAL|Thrombosomes Low Dose|
62262222|NCT02970214||Cardiometabolic risk|Patients with cardiovascular diseases and metabolic risk factors at baseline
62844268|NCT04631211|EXPERIMENTAL|Thrombosomes Medium Dose|
62844269|NCT04631211|EXPERIMENTAL|Thrombosomes High Dose|
62844270|NCT04631211|ACTIVE_COMPARATOR|Liquid Stored Platelets (Control)|
62844271|NCT05915598|EXPERIMENTAL|Intervention group|"Right/left discrimination training: The training program will consist of tasks such as identifying the laterality of images (e.g., hands, feet, faces) and sounds (e.g., spatially localized sounds). The tasks will be designed with increasing levels of difficulty to challenge participants and promote skill development.~Training schedule: Participants will be instructed to engage in the right/left discrimination training for 20 minutes per day, 5 days per week, over a six-week period. They will be encouraged to complete the training sessions at consistent times to support habit formation.~Monitoring and feedback: The research team will remotely monitor participants' progress and provide personalized feedback on a weekly basis. This will include reviewing performance metrics within the app, discussing any challenges or barriers to adherence, and offering guidance to support continued engagement in the training program."
62844272|NCT05915598|ACTIVE_COMPARATOR|Control group|Usual care: Participants will continue their usual care management for fibromyalgia, including any prescribed medications and physician consultations. No specific right/left discrimination training will be provided to the control group.
62844273|NCT04252976|EXPERIMENTAL|Mantra Meditation|8 weeks of mantra meditation with weekly group sessions.
62262223|NCT01826110|EXPERIMENTAL|[11C]PIB|\[11C\]PIB
62618526|NCT02435056|NO_INTERVENTION|Classic Approach|Patient fills in a paper diary in order to quantify parameters of MOH (days with headache, acute drugs consumed, etc.)
62618527|NCT02435056|EXPERIMENTAL|IEPR Approach|Patient has to use the electronic diary to record days with headache, acute drugs consumed, etc.
62844274|NCT04252976|EXPERIMENTAL|Mantra Meditation plus Ethical Practice|8 weeks of mantra meditation plus ethical practice with weekly group sessions.
62058712|NCT04141735||patients from September 2016 to September 2018|all patients underwent allogeneic hematopoietic stem cell transplantation
62058713|NCT04269239|OTHER|Healthy Habits|This group will meet with a study therapist to discuss strategies to implement healthy habits that may enhance recovery from knee or hip surgery.
62262224|NCT03087630|EXPERIMENTAL|Reasoned-Based Intervention|Receives reason-based intervention.
62262225|NCT03087630|EXPERIMENTAL|Social-Based Intervention|Receives social-based intervention.
62844275|NCT04252976|EXPERIMENTAL|Mantra Meditation plus Yoga Exercises|8 weeks of mantra meditation plus Yoga Exercises with weekly group sessions.
62618528|NCT05491863|ACTIVE_COMPARATOR|conservative physiotherapy plan|Postural and Proprioceptive facilitation,walking ,jumping and staircase activity
62618529|NCT05491863|EXPERIMENTAL|Trunk stability exercise plan|Trunk stability exercises including proprioception,balance and stability.
62618530|NCT00611377||1|
62618531|NCT03935334|EXPERIMENTAL|Eptacog alfa, biosimilar (AryoSeven)|Patients will be randomized to receive, in a 2x2 crossover setting, either a single dose of biosimilar eptacog alfa, activated (AryoSeven) of 90 μg/kg or 270 μg/kg, or eptacog alfa, activated (Novoseven) of 90 μg/kg or 270 μg/kg, or vice-versa, separated by a washout period of 3 days.
62618532|NCT03935334|ACTIVE_COMPARATOR|Novoseven|Patients will be randomized to receive, in a 2x2 crossover setting, either a single dose of biosimilar eptacog alfa, activated (AryoSeven) of 90 μg/kg or 270 μg/kg, or eptacog alfa, activated (Novoseven) of 90 μg/kg or 270 μg/kg, or vice-versa, separated by a washout period of 3 days.
62844276|NCT04252976|EXPERIMENTAL|Mantra Meditation plus Yoga Exercises plus Ethical Practice|8 weeks of mantra meditation plus Yoga Exercises plus ethical practice with weekly group sessions.
62844277|NCT04893304|OTHER|1 group of 20 patients doing both types of lasers on 2 sites|comparing both types of laser
62844278|NCT02840604||patient with all types of solid malignant tumors not treatable|In the treatment or assessment of metastatic solid tumor malignancies not curable it can be offered to patients to establish the profile of their tumor by next generation sequencing (NGS). This technique permits the sequencing of millions of fragments in parallel in a short time and allows to identify rapidly somatic or constitutional mutations known or yet unknown. The establishment of the genetic profile of the tumor coupled to the available clinical data can help clinicians to predict patient outcome in terms of survival or progression to disease, but may also provide key clues to adapt the management and patient treatment.
62844279|NCT05417763||Pressure Microcatheter-First|Per the result of prior randomization, physiological assessment to the enrolled patient will be performed by the TruePhysio pressure microcatheter system ahead of the Pressure Wire system.
62844280|NCT05417763||Pressure Wire-First|Per the result of prior randomization, physiological assessment to the enrolled patient will be performed by the Pressure Wire system ahead of the TruePhysio pressure microcatheter system, per the result of prior randomization.
62844281|NCT02455830||Cell-treated|Infants with encephalopathy who receive autologous umbilical cord blood cell therapy along with therapeutic hypothermia.
62844282|NCT02455830||Cooled only|Infants with encephalopathy who receive therapeutic hypothermia only.
62262226|NCT03087630|EXPERIMENTAL|Integrated Intervention|Receives integrated intervention.
62262227|NCT03087630|EXPERIMENTAL|Attention Control|Receives attention control feedback.
62262228|NCT00279825|OTHER|Sequence 1|Subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR.
62844283|NCT04119791|EXPERIMENTAL|Wild rice|Participants will consume one serving of the test food containing wild rice every day over 28 days.
62844284|NCT05083585|EXPERIMENTAL|Group 1: Phase 3 Clinical Trial Material (CTM)|Participants will receive a single intramuscular (IM) injection of adenovirus serotype 26 (Ad26). respiratory syncytial virus (RSV). prefusion conformation-stabilized F protein (preF)-based vaccine on Day 1, which is a Phase 3 CTM.
62844285|NCT05083585|EXPERIMENTAL|Group 2: Phase 2b CTM|Participants will receive a single IM injection of Ad26.RSV.preF-based vaccine on Day 1, which is a Phase 2b CTM.
62618533|NCT02085226|EXPERIMENTAL|Creative Engagement Intervention|Creative Engagement Intervention participants will receive 4-8 art sessions over 3-5 weeks, depending on length of inpatient stay. Sessions will be delivered as 1:1 sessions with the artist lasting up to one hour (depending on patient fatigue levels) and group sessions, with up to 5 participants, lasting up to two hours (depending on patient fatigue levels). Participant with receive one group and one individual session per week of inpatient stay. The sessions will cover 5 activity stages of the intervention, taking the participant through a progressive artwork development process. Participants will explore basic visual art materials and processes and progress to creating artworks with a personal context that they have directed and controlled.
62844286|NCT04652219|EXPERIMENTAL|Patients with late malignant digestive tract tumor|Patients with late malignant digestive tract tumor, for example metastatic colorectal cancer, pancreatic cancer, gastric cancer and so on. because of this is a open, single arm trail, there is no control group.
62844287|NCT03208296|EXPERIMENTAL|Cohort A|Subjects with 4 or more lesions will receive 1.0 x 10\^11 vp/injection of ASN-002 into each of 4 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
62844288|NCT03208296|EXPERIMENTAL|Cohort B 1.5|Subjects with 4 or more lesions will receive 1.5 x 10\^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
62058714|NCT04269239|OTHER|Sleep Habits|This group will meet with a study therapist to discuss strategies to implement healthy sleep habits that may enhance recovery from knee or hip surgery.
62058715|NCT05114525|EXPERIMENTAL|Patients Who are Anticipated to Receive Definitive Treatment|
62844289|NCT03208296|EXPERIMENTAL|Cohort B 1.0|Subjects with 4 or more lesions will receive 1.0 x 10\^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
62844290|NCT05408546|PLACEBO_COMPARATOR|Placebo|Placebo + standard of care (SOC) anticoagulation
62262229|NCT00279825|OTHER|Sequence 2|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo.
62262230|NCT00279825|OTHER|Sequence 3|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Third treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo.
62446891|NCT04017013|ACTIVE_COMPARATOR|Epidural Analgesia|"The placement of the thoracic epidural catheter will be located depending on surgical incision as follows:~* Surgery of the upper abdomen: T7-T8.~* Surgery of lower abdomen: T8-T9. The epidural catheter placement technique will be determined by the treating anesthesiologist. However, once the epidural space is located and the respective catheter is inserted, the correct location of the catheter should be tested with lidocaine at 2% CE 5 cc and a sensitivity test with temperature should be performed on the target dermatomes. A negative test for an adequate location of the catheter indicates that the procedure should be repeated until the epidural space is correctly located. Once this is achieved, the catheter will be left 4 cm away from the skin. The catheter will be fixed according to the institutional protocol."
62844291|NCT05408546|EXPERIMENTAL|Low dose TS23|TS23 low dose + SOC anticoagulation
62844292|NCT05408546|EXPERIMENTAL|Intermediate dose TS23|TS23 medium dose + SOC anticoagulation
62844293|NCT05408546|EXPERIMENTAL|Higher dose TS23|TS23 highest dose + SOC anticoagulation
62844294|NCT02658617||patients|20 patients were enrolled. Subjects were investigated with magnetic resonance spectroscopy (MRS), functional magnetic resonance imaging (fMRI) and also underwent a psychodiagnostic assessment (evaluating the severity of depression: Hamilton Depression Rating Scale and Beck Depression Inventory; measuring hopelessness: Beck Hopelessness Scale; measuring Alexithymia: Toronto Alexithymia Scale; measuring self-perception: Body Perception Questionnaire). 1-2 days after the imaging patients started the treatment with duloxetine: 30mg for the first three days, then 60-90mg.
62844295|NCT02658617||healthy controls|Subjects were investigated with magnetic resonance spectroscopy (MRS), functional magnetic resonance imaging (fMRI) and also underwent a psychodiagnostic assessment (evaluating the severity of depression: Hamilton Depression Rating Scale and Beck Depression Inventory; measuring hopelessness: Beck Hopelessness Scale; measuring Alexithymia: Toronto Alexithymia Scale; measuring self-perception: Body Perception Questionnaire).
62844296|NCT00774267||1|
62844297|NCT00774267||2|
62844298|NCT00774267||3|
62844299|NCT00774267||4|
62844300|NCT05660018|OTHER|Active rTMS first and sham rTMS second|Participants in this arm will receive active rTMS in one visit first, then receive sham rTMS in another visit.
62844301|NCT05660018|OTHER|Sham rTMS first and active rTMS second|Participants in this arm will receive sham rTMS in one visit first, then receive active rTMS in another visit.
62844302|NCT06139770|ACTIVE_COMPARATOR|Active follow-up|The patients will recieve 3 sessions of MCT
62844303|NCT06139770|ACTIVE_COMPARATOR|Passive follow-up|The group receives no sessions during follow-up
62844304|NCT01455636|EXPERIMENTAL|Hand hygiene with Hand Sanitizer (HS)|"To obtain 480 low birth weight infants the entire area of Kaliganj and Norsinghdi will be divided into 48 clusters based on the list of pregnant women identified through a household survey.~24 clusters will be randomized to receive Hand Sanitizer plus nutrition and hygiene education and the remaining 24 will receive only nutrition and hygiene education."
62844305|NCT01455636|EXPERIMENTAL|Hand hygiene with no Hand Sanitizer|"To obtain 480 low birth weight infants the entire area of Kaliganj and Norsinghdi will be divided into 48 clusters based on the list of pregnant women identified through a household survey.~24 clusters will be randomized to receive Hand Sanitizer plus nutrition and hygiene education and the remaining 24 will receive only nutrition and hygiene education."
62446892|NCT04017013|EXPERIMENTAL|Lidocaine Infussion|Intravenous lidocaine
62446893|NCT05855915|EXPERIMENTAL|Kinesio taping|Kinesotaping will be applied with routine physical therapy
62262231|NCT00279825|OTHER|Sequence 4|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo.
62262232|NCT04808531|PLACEBO_COMPARATOR|Double Placebo Arm|"Spray Placebo + Tablet Placebo~Spray Placebo is a nanoparticle water soluble solution without cannabinoids containing a small amount of hemp seed oil (for fragrance purposes only) as defined by Australian Office of Drug Control (ODC) (https://www.odc.gov.au/hemp-products). One dose is equivalent to 2 actuations of the pump delivering 280 µL volume.~Tablet Placebo will be identical to the Oxycontin tablets."
62262233|NCT04808531|EXPERIMENTAL|Treatment NanaBis™ Arm|"NanaBis™ + Tablet Placebo~NanaBis™ is a nanoparticle water soluble equimolar solution of d9-THC and CBD. One dose is equivalent to 2 actuations of the pump delivering 280 µL volume containing 2.5 mg d9-THC and 2.5 mg CBD. The dose administered will be 1 - 3.5 doses (2 sprays to 7 sprays) per 4 hours unless asleep."
62262234|NCT04808531|ACTIVE_COMPARATOR|Comparator (Oxycodone) Arm|"Spray Placebo + Oxycodone CR~Spray Placebo is a nanoparticle water soluble solution without cannabinoids containing a small amount of hemp seed oil (for fragrance purposes only) as defined by Australian ODC (https://www.odc.gov.au/hemp-products). One dose is equivalent to 2 actuations of the pump delivering 280 µL volume.~Oxycodone controlled release (CR) used as a comparator will be Oxycontin tablets 10 mg - 70 mg po bd."
62618534|NCT02085226|PLACEBO_COMPARATOR|Portfolio Group|The Portfolio group will receive conventional rehabilitation activity at each site. In addition, to control for effects of art related attention received by the intervention group, after baseline assessment and randomisation, this group will receive from the research assistant, a portfolio of work produced by previous participants of the Tayside CEI, with details of community programmes that people with stroke can attend after hospital discharge. Participants will be invited to view the portfolio during their stay. Prior to outcome assessment, the research assistant will visit participants again to answer questions and to discuss options for community programmes, if the person is interested.
62618535|NCT01358240|EXPERIMENTAL|Econazole Nitrate Foam 1%|Study medication
62058716|NCT02653638|EXPERIMENTAL|Drug|"Control-Hypercapnic Trials: Three stepwise CO2 elevations will be applied to the patient by adding fractional concentration of inspired CO2 (FICO2) at 2%, 4%, and 6% each time, balanced with room air. The end tidal CO2 (PetCO2) will be elevated and maintained constant for three minutes at each target level. Breath-by-breath changes in minute ventilation (VE) and PetCO2 will be measured.~Drug-Indomethacin: Healthy volunteers, indomethacin suspension will be orally administered at 1.2 mg/kg. After drug administration, the patient will rest quietly for 90 minutes."
62262235|NCT05277545|EXPERIMENTAL|The effect of teknology addiction training on the experimental group|The arm explanations for which the analyzes of the research have not been completed yet cannot be made.
62262236|NCT05277545|ACTIVE_COMPARATOR|Comparison of the experimental group and control group on technology addiction|The arm explanations for which the analyzes of the research have not been completed yet cannot be made.
62262237|NCT03723707|EXPERIMENTAL|Intervention (INT)|(10 clinic sites and \~500 patients) which includes practice guidelines for clinicians, provider education, electronic health record support for quality DM-ADRD care, information about community/clinical resources, ongoing targeted provider feedback, and a panel manager (PM)
62262238|NCT03723707|PLACEBO_COMPARATOR|Control (CON)|During training the CON providers will be encouraged to do cognitive screening as well as follow the guidelines in general.
62618536|NCT01358240|PLACEBO_COMPARATOR|Vehicle Foam|Placebo medication
62618537|NCT01358240|ACTIVE_COMPARATOR|Econazole Nitrate Cream 1%|Econazole Nitrate Cream 1%
62618538|NCT01358240|SHAM_COMPARATOR|Placebo Cream|Placebo Cream
62618539|NCT05033977|EXPERIMENTAL|Center-based Exercise|"patients did exercises with a physical therapist in a clinic 3 days and 45 minute in a week for 6 weeks.~The exercise programe included strenghtening and streching exercises. Strenghtening exercises for lower extremity and streching exercises for hamstrings."
62618540|NCT05033977|EXPERIMENTAL|Home-based exercise|Patients did exercises at home every day and 3 times per day. The exercise programe included strenghtening and streching exercises. Strenghtening exercises for lower extremity and streching exercises for hamstrings.
62262239|NCT04851028|EXPERIMENTAL|One2One|1) Weekly individual (one2one) Music Therapy intervention lasting 5 months (n=20 sessions)
62262240|NCT04851028|EXPERIMENTAL|Small-group|2) Weekly small group (max 8 people per group) Music Therapy intervention lasting 5 months (n=20 sessions)
62262241|NCT04851028|NO_INTERVENTION|Control|Standard weekly music social listening in large group available in all care-homes. Lasting 5 months (n=20 sessions)
62446894|NCT05855915|EXPERIMENTAL|Sham taping|Sham taping will be applied with routine physical therapy
62446895|NCT00745095|NO_INTERVENTION|SCI MoviPrep® (without NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)\<=50ml/min and SCI, GFR\>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid \[MoviPrep®\] (without neostigmine plus glycopyrrolate \[NG\])
62618541|NCT06052644|NO_INTERVENTION|Control Group (CG)|The control group will not carry out any type of intervention. You will receive physical activity recommendations from the Pan American Health Organization, developed by sports science professionals.
62262242|NCT06466629||Cohort 1|Pregnant women vaccinated with Tdap vaccine between 16-18 weeks of gestation
62262243|NCT06466629||Cohort 2|Pregnant women vaccinated with Tdap vaccine between 25-27 weeks of gestation
62262244|NCT06466629||Cohort 3|Pregnant women vaccinated with Tdap vaccine between 34-36 weeks of gestation
62262245|NCT04136873|ACTIVE_COMPARATOR|Part A: 5 mg QD CVL-231|Oral Dose
62262246|NCT04136873|PLACEBO_COMPARATOR|Part A: 5 mg QD Placebo|Matching Placebo; Oral Dose
62262247|NCT04136873|ACTIVE_COMPARATOR|Part A: 10 mg QD CVL-231|Oral Dose
62262248|NCT04136873|PLACEBO_COMPARATOR|Part A: 10 mg QD Placebo|Matching Placebo; Oral Dose
62262249|NCT04136873|ACTIVE_COMPARATOR|Part A: 20 mg QD CVL-231|Oral Dose
62262250|NCT04136873|PLACEBO_COMPARATOR|Part A: 20 mg QD Placebo|Matching Placebo; Oral Dose
62262251|NCT04136873|ACTIVE_COMPARATOR|Part A: 5-10-20 mg BID CVL-231|Oral Dose
62262252|NCT04136873|PLACEBO_COMPARATOR|Part A: 5-10-20 mg BID Placebo|Matching Placebo; Oral Dose
62262253|NCT04136873|ACTIVE_COMPARATOR|Part A: 30 mg QD CVL-231|Oral Dose
62446896|NCT00745095|NO_INTERVENTION|SCI PIEE (without NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)\>=50ml/min) pulsed irrigation enhanced evacuation \[PIEE\] (without neostigmine plus glycopyrrolate \[NG\])
62446897|NCT00745095|NO_INTERVENTION|Control MoviPrep® only|(Control, glomerular filtration rate (GFR)\>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid (MoviPrep®) only (no NG)
62446898|NCT00745095|NO_INTERVENTION|Control PIEE only|(Control, glomerular filtration rate (GFR)\>=50ml/min), pulsed irrigation enhanced evacuation (PIEE) only (no NG)
62262254|NCT04136873|PLACEBO_COMPARATOR|Part A: 30 mg QD Placebo|Matching Placebo; Oral Dose
62262255|NCT04136873|ACTIVE_COMPARATOR|Part B 30 mg QD CVL-231|Oral Dose
62262256|NCT04136873|PLACEBO_COMPARATOR|Part B 30 mg QD Placebo|Matching Placebo; Oral Dose
62262257|NCT04136873|ACTIVE_COMPARATOR|Part B 20 mg BID CVL-231|Oral Dose
62262258|NCT04136873|PLACEBO_COMPARATOR|Part B 20 mg BID Placebo|
62262259|NCT02275078|OTHER|Interventional|The program consists of 3 components: 1) COPD self-management using an Action Plan; 2) Telesystem-Phone self-assessment/reporting system; and 3) Nurse case manager support.
62262260|NCT03621514|OTHER|painless indwelling catheter|This group of patients underwent catheterization after anesthesia. At the end of the operation, the patient was removed from the catheter before anesthesia was awakened.
62262261|NCT03621514|OTHER|indwelling catheter|This group of patients underwent catheterization after anesthesia,and the catheter was indwelled. The patient was routinely removed for 24 to 72 hours after surgery.
62262262|NCT02662621|OTHER|ill patient|Patient with a cancer disease
62262263|NCT02662621|OTHER|Healthy volunter|Subject without any cancer pathology
62262264|NCT06005727|ACTIVE_COMPARATOR|Transanal ice pack applied to hemorrhoidectomy wound for 1 minute|Transanal ice pack is applied to hemorrhoidectomy wound for 1 minute. After the surgery, standard postoperative analgesia and medications will be prescribed.
62058717|NCT06307184||Natural proliferative phase frozen embryo transfer (NPP-FET)|When the endometrial thickness is at least 7 mm, vaginal micronized progesterone will be initiated at 400mg every 12 hours, as per standard clinical practice, when the dominant follicle is at least 13 mm, serum estradiol (E2) levels are \>80 pg/ml, and serum progesterone levels are \<1.5ng/ml. One embryo will be transferred on the fifth day of progesterone supplementation under ultrasound guidance. Progesterone will be continued until the 11th week of pregnancy.
62262265|NCT06005727|NO_INTERVENTION|Standard postoperative care after hemorrhoidectomy|Standard postoperative analgesia and medications will be prescribed.
62262266|NCT06392568||eHDR+|Patients with Emergent Highly Resistant Bacteria healthcare associated infection
62262267|NCT06392568||eHDR-|Patients without Emergent Highly Resistant Bacteria healthcare associated infection
62262268|NCT03639870|EXPERIMENTAL|Implant Group|Qualified eyes with refractory glaucoma will be implanted unilaterally with the Glaukos® Trabecular Micro-Bypass System Model iS3 (three G2-W stents per study eye), and will be followed through 12 months postoperative.
62262269|NCT06288620|EXPERIMENTAL|Microwave Ablation|Preoperative US-guided microwave ablation of breast cancer
62262270|NCT03149081|EXPERIMENTAL|Boswellia|Boswellia will be given at 800mg by mouth three times a day, immediately after each meal. Boswellia will be given from the time surgical resection is scheduled until the night before surgical resection.
62262271|NCT02395926|ACTIVE_COMPARATOR|R|Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
62262272|NCT02395926|EXPERIMENTAL|T1|HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
62262273|NCT02395926|EXPERIMENTAL|T2|HT-003 600mg\*2tab, administration 1 times per 1 day 8:00 a.m.
62262274|NCT04170322|EXPERIMENTAL|thin pvc gasrtric calibration tube|thin pvc gastric calibration tube is inserted after intubation to release gas from the stomach, then moved in correct position to help surgeon construct a sleeve gastrectomy.
62262275|NCT04170322|ACTIVE_COMPARATOR|thick silicone gastric calibration tube|thick silicone gastrric calibration tube is inserted after intubation to release gas from the stomach, then moved in correct position to help surgeon construct a sleeve gastrectomy
62262276|NCT02512471|EXPERIMENTAL|middle aged group|brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB
62262277|NCT02512471|ACTIVE_COMPARATOR|young group|brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB
62262278|NCT03439202|OTHER|No arm used|No drug use for this study. No arm used in this study. Subjects are exposed to hypoxic conditions (clinical study).
62262279|NCT02866474|OTHER|- Puteaux or Paris for elderly persons|
62262280|NCT02866474|OTHER|-Two EHPAD in Lyon for elderly persons living|
62262281|NCT03568474|EXPERIMENTAL|Silver Diamine Fluoride|Silver Diamine fluoride will be applied after after minimal caries removal then glass ionomer over it followed by composite resin restoration.
62262282|NCT03568474|ACTIVE_COMPARATOR|Glass Ionomer|Glass ionomer will be applied after minimal caries removal followed by composite resin restoration.
62262283|NCT02347683||Benign pathology|We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days, 4, 6, and 12 weeks
62262284|NCT02347683||Malignant pathology|We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days ; 4, 6, and 12 weeks and 6 and 12 months
62262285|NCT00630656|EXPERIMENTAL|1|Talactoferrin alfa
62446899|NCT00745095|EXPERIMENTAL|SCI MoviPrep® (with NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)\<=50ml/min and SCI GFR\>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid \[MoviPrep®\] (with neostigmine plus glycopyrrolate \[NG\])
62446900|NCT00745095|EXPERIMENTAL|SCI PIEE (with NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)\>=50ml/min) pulsed irrigation enhanced evacuation (PIEE) (with neostigmine plus glycopyrrolate \[NG\])
62618542|NCT06052644|EXPERIMENTAL|EXPERIMENTAL GROUP 1 (EG1)|This group will engage in high-intensity physical exercise for 150 minutes per week, three days a week, with each session lasting 50 minutes. The session structure will include a 5-minute warm-up, 40 minutes of the core phase, and 5 minutes of cool down.
62618543|NCT06052644|EXPERIMENTAL|EXPERIMENTAL GROUP 2 (EG2)|Participants in this group will perform high-intensity exercise twice a week, with each session lasting 30 minutes. The session structure will include a 5-minute warm-up, 20 minutes of the core phase, and 5 minutes of cool down.
62618544|NCT06052644|EXPERIMENTAL|EXPERIMENTAL GROUP 3 (EG3)|This group will engage in high-intensity exercise four times a week, with each session lasting 50 minutes. The session structure will include a 5-minute warm-up, 40 minutes of the core phase, and 5 minutes of cool down.
62618545|NCT05962827|EXPERIMENTAL|Determine the prevalence of hyperlipoproteinemia (a) in a population of patients with lymphedema|The primary endpoint will be lipoprotein (a) \> 30 mg/dL, defining hyperlipoproteinemia (a).
62618546|NCT01111682|ACTIVE_COMPARATOR|Mannitol|0.9% normal saline infusion and boluses of mannitol
62262286|NCT00630656|PLACEBO_COMPARATOR|2|Placebo
62262287|NCT05329376|EXPERIMENTAL|Group A|12 weeks of daily interactions with Smart Speaker EchoDot 3rd Gen (Amazon Echo®).
62262288|NCT05329376|OTHER|Group B|12 weeks of maintenance of usual care.
62262289|NCT03978455||Patients Who Smoke|"This group will consist of up to 100 English-speaking adult smokers recruited from their primary care clinic who are willing to complete a brief phone-based interview about their experience in using the Learn, Connect, and Quit (LCQ) tablet-based mobile application. The LCQ app presents smoking and cessation-related educational and motivational content in an easily accessible manner (i.e., via videos) and provides avenues for smokers to connect to evidence-based treatment."
62262290|NCT03978455||Clinic Staff|"Rooming staff and physicians from the primary care clinic (where Patients Who Smoke group participants are recruited) will be asked to participate in interviews about the feasibility of implementing the LCQ app including implementation burden, impact on clinical workload, and clinical utility of the app (i.e., Did patients ask more questions about smoking treatment? How challenging was it to try to give all smokers the app to explore?)."
62262291|NCT00976222|OTHER|1 Arm Ranibizumab|
62262292|NCT03040440|ACTIVE_COMPARATOR|Cylindrical endotracheal tube|Cylindrical endotracheal tube was intubated in 32 participants
62262293|NCT03040440|EXPERIMENTAL|TaperGuard endotracheal tube|TaperGuard endotracheal tube was intubated in 32 participants
62262294|NCT06097117||one group undergoes multiplex PCR|treatment will be started according targeted antibiotics
62262295|NCT06097117||the other group undergoes simple culture and sensitivity|empirical antibiotics will be started until results appear and according results ,treatment will be completed or shifted to another treatment or be narrowed ,later on detect outcome of both groups.
62262296|NCT03381235|EXPERIMENTAL|Moderate exercise|Subjects in the moderate exercise group will participate in Spin exercise designed by Dr. Nocera.
62262297|NCT03381235|NO_INTERVENTION|Mild exercise|Sessions will be focused on balance and stretching.
62262298|NCT05309798|EXPERIMENTAL|Evening Fasting|Participants will undertake acute evening fasting (feeding between 8am-4pm)
62262299|NCT05309798|EXPERIMENTAL|Control|Participants will undertake an acute standard western feeding pattern (feeding between 8am-8pm).
62262300|NCT05309798|EXPERIMENTAL|Morning Fasting|Participants will undertake an acute morning fasting trial (feeding between 12pm-8pm).
62446901|NCT02462538|EXPERIMENTAL|Brentuximab vedotin and Imatinib|Brentuximab vedotin (every 3 weeks i.v., 1.8 mg/kg) and imatinib (200mg daily orally, escalated from 100mg daily) for up to 48 weeks
62446902|NCT04228341|OTHER|Glucose Reference 1|Glucose solution 1
62446903|NCT04228341|OTHER|Glucose Reference 2|Glucose solution 2
62446904|NCT04228341|OTHER|Glucose Reference 3|Glucose solution 3
62446905|NCT04228341|EXPERIMENTAL|Brown Rice|Cooked brown rice
62446906|NCT04228341|EXPERIMENTAL|3 % polished rice|Cooked 3 % polished rice
62446907|NCT04228341|EXPERIMENTAL|6 % polished rice|Cooked 6 % polished rice
62446908|NCT04228341|EXPERIMENTAL|9 % polished rice|9 % polished rice
62618547|NCT01111682|ACTIVE_COMPARATOR|Hypertonic Saline|3% hypertonic saline continuous infusion, with intermittent boluses as needed
62058718|NCT06307184||Natural cycle frozen embryo transfer (NC-FET)|When the mean dominant follicle diameter was at least 17 mm and the endometrial thickness was at least 7 mm, serum E2, progesterone and luteinizing hormone (LH) were evaluated. If a spontaneously LH peak was detected (E2\>80 pg/ml, LH peak \>18 mIU/mL with progesterone level \<1.5 ng/mL), vaginal micronized progesterone was started from the evening of ovulation at a dose of 200 mg every 12 hours. Conversely, whenever a LH peak was not detected (E2\>80 pg/ml, LH \<18mIU/ml and progesterone \<1,5 ng/ml), r-hCG 250µg (Ovitrelle®) was administered subcutaneously, followed, 48 hours later, by daily administration of 200 mg micronized vaginal progesterone every 12 hours. One embryo was transferred 7 days after r-hCG administration or 6 days after LH peak detection. Progesterone was continued until the 8th week of pregnancy.
62058719|NCT06472336|EXPERIMENTAL|Intervention group|In patients within the intervention group, the treating physician attempts to perform intracranial stenting (with or without balloon dilation).
62058720|NCT06472336|ACTIVE_COMPARATOR|Control group|In patients within the control group, the treating physician does not perform intracranial stenting and/or balloon dilation. Conventional endovascular therapy will be continued.
62058721|NCT05868915|EXPERIMENTAL|HV-101|"Participants with Advanced Solid Tumors~Interventions:~Biological: HV-101~Drug: IL-2~Drug: Fludarabine Drug: Cyclophosphamide"
62058722|NCT05362552|EXPERIMENTAL|Urban Afforestation Group|Participants will perform an afforestation activity with a duration of 90 minutes.
62058723|NCT02546414||Esophageal varices haemorrhage group|HBV hepatic cirrhosis with first esophageal varices haemorrhage were included and stratified using their Child-Pugh score. The platelet count were evaluated, and ultrasound was used to measure the longest diameter of the spleen. The platelet count(PC)/spleen diameter (SD)ratio was calculated and analyzed to determine whether it can predict the variceal haemorrhage. Upper gastrointestinal endoscopy was used as the gold standard.
62446909|NCT04228341|EXPERIMENTAL|20 % Polished rice|Cooked 20 % Polished rice (White Rice)
62618548|NCT04475770|EXPERIMENTAL|Real SNAGs|Real SNAGs group consists of 16 participants, where the Mulligan concept lumbal SNAGs is applied and evaluations are made before and after.
62618549|NCT04475770|SHAM_COMPARATOR|Sham SNAGs|The Sham SNAGs group consists of 16 participants who performed the same positioning as the Real SNAGs group and evaluated twice with a similar interval without any intervention to the spine.
62618550|NCT02462109|EXPERIMENTAL|Lorazepam|"Children with confirmed Nodding syndrome that had 2 or more of the symptoms on the 10-item Kampala Catatonia Panel (KCP) scale were recruited to undergo the catatonia test using oral Lorazepam EG® (n.v. Eurogenerics s.a. Brussels, Belgium) using the 1 mg formulation tablets. The amount of Lorazepam (LZP) drug given orally was based on the weight of the child. The lower dose (0.5 mg) was used as starting dose for patients with \<30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with \>30 kg body weight.~A positive response to a catatonia test consisted of a reduction in catatonic symptoms, 60 minutes later, by at least 50% assessed by the KCP (using all 10 items). If no response to the initial dose of LZP, was observed after one hour, a second administration of the same medication at double the dose was given. Catatonia was again assessed at 60 minutes thereafter. If no response was observed, the test was considered negative."
62844306|NCT01455636|EXPERIMENTAL|Micronutrient Powder|"From 6 months of age, children in randomized clusters will be assigned to receive one sachet of Improved Micronutrient Powder, I-MNP per day for six months with or without hand sanitizer.~Throughout the entire intervention period, mothers/caregivers of the children in all groups will receive simple, standardized, and age and culturally appropriate nutrition and health education that aims to improve feeding and health-seeking behavior and caring practices."
62844307|NCT01455636|PLACEBO_COMPARATOR|Control|"From 6 months of age, children in randomized clusters will be assigned to receive no hand sanitizer or no micronutrient powder~Throughout the entire intervention period, mothers/caregivers of the children in all groups will receive simple, standardized, and age and culturally appropriate nutrition and health education that aims to improve feeding and health-seeking behavior and caring practices."
62844308|NCT02474069|ACTIVE_COMPARATOR|Secukinumab Interval Shortening|
62844309|NCT02474069|ACTIVE_COMPARATOR|Secukinumab 4-weekly|
62844310|NCT01936441|EXPERIMENTAL|Cognitive Behavioral Therapy-Insomnia (CBT-I)|"Participants will have contact with a menopause counselor 6 times over 8 weeks. The first session will be in-person at a private research office. All other contacts will be by telephone. Women unable to attend the in-person session will receive a phone call. All in-person and telephone consultations will be 20-30 minutes.~Participants will receive reading materials before each phone call relating to menopausal changes, menopausal changes in sleep and strategies for lessening menopause related sleep disturbances. A daily sleep diary will be completed each week during the 8-week intervention period. The day before each telephone session, the participant will email that week's completed diary to a secure email address accessible only by the counselor; women who are unable to use email will provide their data by telephone directly to the counselor. During the weekly telephone calls, the reading and materials will be discussed and the sleep diary will be reviewed."
62618551|NCT03185494|EXPERIMENTAL|anti-CD19/22 CAR T cells|Patients receive anti-CD19/22-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
62844311|NCT01936441|PLACEBO_COMPARATOR|Menopause Education Control (MEC)|Participants will have contact with a menopause counselor 6 times over 8 weeks. The first session will be in-person at a private research office. All other contacts will be by telephone. Women who are unable to attend the in-person session will receive a phone call. All in-person and telephone consultations are designed to last 20-30 minutes. Participants will receive information about menopausal changes and ways to develop symptom management strategies. Women in the MEC will keep a daily sleep diary. The day before each telephone session, the participant will email that week's completed diary to a secure email address accessible only by the counselor; women who are unable to use email will provide their data by telephone directly to the counselor. During the weekly telephone calls, the reading material will be discussed and the sleep diary will be reviewed.
62844312|NCT01038999||A HIV1-infected naive patients|
62844313|NCT01038999||B HIV1-infected patients|in 1st line of ARV therapy for at least 12 months
62844314|NCT01038999||C= control Non infected HIV volunters|
62844315|NCT05955781|EXPERIMENTAL|Group A|Spinal Mobilization with Leg Movement (SMWLM) will be given as intervention to experimental group. Participants will be given Hot pack for 15 minutes, TENS for 10 minutes.
62844316|NCT05955781|ACTIVE_COMPARATOR|Group B|The patients will be given Spinal mobilization (transverse glide) on the effected spinous process. The total time duration will be 25-30 minutes. Participants will be given Hot pack for 15 minutes, TENS for 10 minutes.
62844317|NCT00776516|EXPERIMENTAL|1|mirabegron alone
62618552|NCT00926432|OTHER|Healthy volunteers|Small group of aged healthy volunteers
62618553|NCT00926432|OTHER|Patients|Patients consulting for spine disorders that may or may not have postural troubles
62844318|NCT00776516|EXPERIMENTAL|2|mirabegron and rifampin
62844319|NCT02182388|EXPERIMENTAL|BI 207127 NA|single rising dose part
62446910|NCT04164888|EXPERIMENTAL|CIVI 007, Dose A|Subcutaneous (SC) injection of a PCSK9 inhibitor- low dose given twice
62446911|NCT04164888|EXPERIMENTAL|CIVI 007, Dose B|SC injection of PCSK9 inhibitor- dose titration
62446912|NCT04164888|EXPERIMENTAL|CIVI 007, Dose C|SC injection of PCSK9 inhibitor- high dose given twice
62618554|NCT02578459|EXPERIMENTAL|Intrathecal Drug Delivery (ITDD)|These subjects will have a Prometra System implanted and managed with the appropriate drug regimen to treat their pain.
62844320|NCT02182388|PLACEBO_COMPARATOR|Placebo|
62844321|NCT02182388|EXPERIMENTAL|BI 207127 NA, fasted or fed|
62844322|NCT06167811|EXPERIMENTAL|whole-body electrical stimulation, Protocol 1|A whole body electrical stimulation session. Symmetrical biphasic current will be used, pulse width of 400µs, frequency of 75Hz, contraction time of five seconds, rest time of 10 seconds, for eight minutes, totaling 32 muscle contractions. During the first two minutes of stimulation, the patient will remain in isometry to become familiar with the electrical current. Then with the use of a stick (for proprioception), a series of biceps exercises and a series of triceps exercises, a series of sit-ups and a squat, a series of step ups and downs, and a series of plantings.
62844323|NCT06167811|EXPERIMENTAL|whole-body electrical stimulation, Protocol 2|A whole body electrical stimulation session. Symmetrical biphasic current will be used, pulse width of 400µs, frequency of 75Hz, contraction time of five seconds, rest time of 10 seconds, for 16 minutes, totaling 64 muscle contractions. During the first two minutes of stimulation, the patient will remain in isometry to become familiar with the electrical current. Then with the use of a stick (for proprioception), a series of biceps exercises and a series of triceps exercises, a series of sit-ups and a squat, a series of step ups and downs, and a series of plantings.
62844324|NCT06114667|EXPERIMENTAL|Nasal high flow|"Nasal high flow will be administered through a heated humidifier (Airvo 3, Fisher and Paykel healthcare) and applied through large bore binasal prongs.~Initial gas flow rate will be set at 60 l/min, FiO2 will be adjusted to maintain an SpO2 88-92% and Initial temperature will be set at 37° and reduced according to patient's tolerance.~Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment"
62844325|NCT06114667|ACTIVE_COMPARATOR|Non invasive ventilation|"NIV will be delivered through a face mask connected to a ventilator with pressure support applied in a noninvasive ventilation mode.~The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 88-92% and to patient's comfort.~Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment."
62844326|NCT02931773||Control|Probands having normal fasting glucose and having a head up tilt test with Task Force® Monitor.
62844327|NCT02931773||Pre-Diabetes|Patients having normal fasting glucose and abnormal Oral Glucose tolerance test and having a head up tilt test with Task Force® Monitor.
62844328|NCT02931773||Recently diagnosed Diabetic patients|Patients being diagnosed as Diabetics type in the recent five years and having a head up tilt test with Task Force® Monitor
62844329|NCT04113213|NO_INTERVENTION|Control|Standard care during consultations.
62844330|NCT04113213|EXPERIMENTAL|Intervention|Standard care during consultations with the addition of a physical lifestyle prescription.
62844331|NCT05523778|EXPERIMENTAL|Stented EN|Patients are placed the pancreatic duct stent by endoscopist 1day or several hours before the enucleation surgery.
62844332|NCT05523778|ACTIVE_COMPARATOR|Direct EN|Patients will receive enucleation surgery directly following normal procedure
62844333|NCT04320589|ACTIVE_COMPARATOR|General Anesthesia|Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ \& β-adrenergic blockers \[Prazosin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day \&/or Labetalol (Trandate)200-600 mg/day, Angiotensin Converting enzyme inhibitors ( ACE inhibitors ) \& Angiotensin II receptor blockers ARBs e.g. Tritace 2.5-10 mg/day \& Atacand 4-16 mg/day\]
62844334|NCT04320589|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine-Magnesium Sulfate (Dex-MgSo₄) group: in which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement \& a bolus of 40 mg/kg MgSo₄ is given I.V. \& may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached. Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient
62058724|NCT02546414||no haemorrhage but esophageal varice presence|HBV hepatic cirrhosis with no esophageal varices haemorrhage were included and upper gastrointestinal endoscopy were validate.They also stratified using their Child-Pugh score. The platelet count and longest diameter of the spleen were evaluated, The PC/SD ratio was calculated and analyzed to determine whether it can predict the variceal presence.
62844335|NCT06385782||outdoor groups|Outdoor work time is more than 2 hours
62844336|NCT06385782||indoor groups|Outdoor work time is less than 2 hours
62446913|NCT04164888|PLACEBO_COMPARATOR|Placebo|Placebo SC injection matching PCSK9 inhibitor given twice
62446914|NCT01813656|EXPERIMENTAL|Aripiprazole|Aripiprazole arm,5mg/pill,10mg/day.last12weeks.
62446915|NCT01813656|PLACEBO_COMPARATOR|Sugar pill|placebo arm,5mg/pill,10mg/day,last12weeks
62446916|NCT04043520|EXPERIMENTAL|Postmenopausal: GnRH antagonist + estradiol|"GnRH antagonist is degarelix acetate, 80 mg, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)~Estradiol is a transdermal patch 0.075 mg, applied weekly for 24 weeks"
62618555|NCT02578459|ACTIVE_COMPARATOR|Conventional Medical Management (CMM)|These subjects will be treated with conventional medical management to treat their pain.
62618556|NCT02191046|ACTIVE_COMPARATOR|syringe 20 ml|nasal irrigation with syringe by using buffer hypertonic saline about 100-240 ml until no nasal discharge
62618557|NCT02191046|EXPERIMENTAL|squeezable bottle|nasal irrigation with squeezable bottle by using buffer hypertonic saline about 100-240 ml until no nasal discharge
62618558|NCT03534739|EXPERIMENTAL|Pain Inducing Massage|Participants will receive manual pressure applied to one myofascial trigger point.
62618559|NCT03534739|ACTIVE_COMPARATOR|Light Touch Massage|Participants will receive light touch applied to one myofascial trigger point.
62618560|NCT03534739|PLACEBO_COMPARATOR|Coldpressor|Participants will place hand into water cooled to 6 degrees Celsius (males) or 8 degrees Celsius (females).
62058725|NCT02546414||no esophageal varice but cirrhotic|HBV hepatic cirrhosis with no esophageal varices were included and also validated by upper gastrointestinal endoscopy.They stratified using their Child-Pugh score. The platelet count and longest diameter of the spleen were evaluated,The PC/SD was calculated and analyzed to determine whether it can predict the variceal absence .
62058726|NCT02525003|PLACEBO_COMPARATOR|Group 1: placebo|Group 1: daily dose of regular bread (87 g/d) and placebo pill (0 µg of vitamin D/d) for 8 weeks
62058727|NCT02525003|EXPERIMENTAL|Group 2: Vitamin D2 supplement|Group 2: daily dose of regular bread (87 g/d) and D2 supplement (25 µg of vitamin D2/d.) for 8 weeks
62446917|NCT04043520|EXPERIMENTAL|Postmenopausal: GnRH antagonist + placebo|"GnRH antagonist is degarelix acetate, 80 mg, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)~Placebo is a transdermal patch, applied weekly for 24 weeks"
62446918|NCT04043520|PLACEBO_COMPARATOR|Postmenopausal: placebo + placebo|"Placebo (1) is normal saline, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)~Placebo (2) is a transdermal patch, applied weekly for 24 weeks"
62058728|NCT02525003|EXPERIMENTAL|Group 3: Vitamin D3 supplement|Group 3: daily dose of regular bread (87 g/d) and D3 supplement (25 µg of vitamin D3/d.) for 8 weeks
62058729|NCT02525003|EXPERIMENTAL|Group 4: Vitamin D2-fortified bread|Group 4: D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
62058730|NCT01121302|EXPERIMENTAL|1|dose escalating
62446919|NCT01341639|EXPERIMENTAL|PR5I|V419 + RotaTeq + Prevenar 13 + ProQuad
62446920|NCT01341639|ACTIVE_COMPARATOR|INFANRIX™ hexa|INFANRIX™ hexa + RotaTeq + Prevenar 13 + ProQuad
62446921|NCT05380856|ACTIVE_COMPARATOR|IPG turned ON|Continous neuromodulation
62446922|NCT05380856|PLACEBO_COMPARATOR|IPG turned OFF|No neuromodulation
62618561|NCT06279494|EXPERIMENTAL|Sirolimus+Abatacept+Mycophenolate mofetil (MMF)+anti-thymocyte globulin (ATG)|Patients receiving haplo-HSCT who are intolerant to calcineurin inhibitors would receive Sirolimus+Abatacept+MMF+ATG (SAMA) for prophylaxis of aGVHD
62844337|NCT03815266|EXPERIMENTAL|Patient with first ischemic or hemorrhagic stroke|"Patient with first ischemic or hemorrhagic stroke will be included. They will have the following program Computerized Mirror Therapy (CMT) associated at transcranial Direct Current Stimulation (tDCS). This program will consist of 5 sessions per week for 4 weeks (20 minutes).~In more, they will have the following tests: Tolerance Assessment Questionnaire, Ashworth's scale, Frenchay arm test, Abilhand questionnaire, Fugl-Meyer test, and Goal Attainment Scaling (GAS)."
62058731|NCT01121302|PLACEBO_COMPARATOR|2|placebo
62058732|NCT03730285|ACTIVE_COMPARATOR|Telemedicine|Discharge with telemedicine contact to emergency nurse, doctor, and municipality
62058733|NCT03730285|NO_INTERVENTION|Control|Standard care with 24-48 h observation at emergency unit
62058734|NCT02981901||Patient with ovarian epithelial cancer|Ovarian epithelial cancer diagnosed in 2012
62262301|NCT02573870|EXPERIMENTAL|Batefenterol + Fluticasone Furoate|Subjects will self-administer batefenterol/fluticasone furoate 300/100 micrograms inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.
62262302|NCT02573870|PLACEBO_COMPARATOR|Placebo|Subjects will self-administer matching placebo inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.
62262303|NCT03413111|EXPERIMENTAL|Modified double wire technique|A sphincterotome was used for standard wire-guided cannulation. If the difficult biliary cannulation occurred and guidewire inadvertently entered PD, a tiny cut of opening, with the length of 5mm, was performed with the sphincterotome. Then the guidewire was left in PD and the sphincterotome withdrew. The same sphincterotome was re-inserted in the working channel alongside the first guidewire, another wire is used for wire-guided selective cannulation of CBD. If the cannulation of CBD was not successful within 5 attempts, other cannulation techniques (e.g. transpancreatic precut, needle knife (NK) precut or over-the stent precut) would be tried at the discretion of endoscopists. A 5Fr, unflanged PD stent was placed before the ending of ERCP.
62058735|NCT05275439|EXPERIMENTAL|SL-172154|Patients will receive intravenous administration
62262304|NCT03413111|NO_INTERVENTION|Standard double wire technique|A sphincterotome was used for standard wire-guided cannulation. If the difficult biliary cannulation occurred and guidewire inadvertently entered PD, the guidewire was left in PD and the sphincterotome withdrew. The same sphincterotome was re-inserted in the working channel alongside the first guidewire, another wire is used for wire-guided selective cannulation of CBD. If the cannulation of CBD was not successful within 5 attempts, other cannulation techniques (e.g. transpancreatic precut, NK precut or over-the stent precut) would be tried at the discretion of endoscopists. A 5Fr, unflanged PD stent was placed before the ending of ERCP.
62262305|NCT04816929|EXPERIMENTAL|Bobath Method Group|The Bobath based exercises for 60 minutes will be formed according to the needs of the individual and will involve trunk exercises such as placing, stretching, functional reach, rotations, functional strengthening and, balance and walking exercises etc. It will be performed 3 days a week for 8 weeks.
62618562|NCT03872765|OTHER|Patients with chronic anal fissure|Use of laser in surgery of chronic anal fissure instead of the conventional surgical techniques.
62844338|NCT05817708|EXPERIMENTAL|CX-4945 200mg QD|CX-4945 will be administered at 200mg QD for continuously 5 days.
62844339|NCT05817708|EXPERIMENTAL|CX-4945 200mg BID|CX-4945 will be administered at 200mg BID for continuously 5 days.
62058736|NCT05275439|EXPERIMENTAL|SL-172154 + Azacitidine|Patients will receive intravenous administration of SL-172154 and Azacitidine.
62058737|NCT05275439|EXPERIMENTAL|SL-172154 + Azacitidine + Venetoclax|Patients will receive intravenous administration of SL-172154 and Azacitidine plus oral venetoclax.
62058738|NCT05275439|EXPERIMENTAL|Part D-Previously untreated HR-MDS 1:1:1 Randomization|"Previously untreated MDS patients with or without TP53 mutation will be randomized to receive the following:~* 3 mg/kg SL-172154 + Azacitidine~* 1 mg/kg SL-172154 + Azacitidine~* Azacitidine Monotherapy"
62058739|NCT02391636|EXPERIMENTAL|Carbetocin arm|100 μg intravenous injection at delivery of the anterior shoulder
62058740|NCT02391636|ACTIVE_COMPARATOR|oxytocin arm|5 IU intravenous injection at delivery of the anterior shoulder
62058741|NCT03756584|EXPERIMENTAL|Intermittent theta-burst stimulation|iTBS will be performed on the left lateral parietal cortex
62446923|NCT06077565|EXPERIMENTAL|Intervention group|The participants will be given a Practical Resource Hub for Healthy Life leaflet containing information on various applications. the research assistant will ask about the priority the participants place on engagement in desirable health-related lifestyle practices identified in the completed behavioural risk factor survey. The participants will also be asked to choose the goal that they consider easiest to achieve. The participants will be encouraged to quit health-risk behaviours (or adopt a healthy lifestyle) sequentially, but they will also be able to choose to quit them simultaneously if they are confident in doing so. For the first 6 months of the study period, the research assistant will deliver WhatsApp/WeChat messages about once per week. Follow-up assessment of behavioural changes at 3, 6, and 12 months
62446924|NCT06077565|PLACEBO_COMPARATOR|Control group|The participants will be given a Practical Resource Hub for Healthy Life leaflet containing information on various applications.The control group participants will receive a brief telephone intervention based on the AWARD model and delivered by the trained research assistant, similar to that delivered to the intervention group. However, the research assistant will simply advise the participants to change their health-risk behaviours and/or adopt a healthy lifestyle practice. The participants will also receive follow-up for outcome assessments with the same schedule as those in the intervention group.
62446925|NCT03785977||Air-Q 5-9kg|Participants weighing 5-9kg may be chosen to wear the Air-Q device.
62446926|NCT03785977||Air-Q 10-14kg|Participants weighing 10-14kg may be chosen to wear the Air-Q device.
62446927|NCT03785977||Air-Q 15-20kg|Participants weighing 15-20kg may be chosen to wear the Air-Q device.
62446928|NCT03785977||ETT 5-9kg|Participants weighing 5-9kg may be chosen to wear the ETT device.
62618563|NCT05167331|ACTIVE_COMPARATOR|Virtual Reality|"* (T1) after fitting the headset to the child's face, the assistant starts the VR program chosen by the child.~* (T2) Five minutes after induction, local anesthesia with the QUICKSLEEPER device is performed. The injection of a cartridge of anesthetic Articaïne SEPTANEST 1/200 000 is administered intraosseously.~* (T3) After placing the rubber dam, the investigator performs restorative +/- endodontic care of the selected temporary molar.~* (T4) Once the treatment is finished, the sedation is stopped and the patient rests in the chair for 5 minutes.~* (T5) As soon as the investigator considers that the child is back to normal state, he can leave the office with his parents."
62844340|NCT05817708|EXPERIMENTAL|CX-4945 400mg BID|CX-4945 will be administered at 400mg BID for continuously 5 days.
62844341|NCT01417494|EXPERIMENTAL|Chemotherapy associated with bevacizumab|Chemotherapy (FOLFIRI, FOLFOX, LV5FU2) associated with bevacizumab
62058742|NCT03756584|ACTIVE_COMPARATOR|Control stimulation|iTBS will be performed on the vertex
62058743|NCT02878174|ACTIVE_COMPARATOR|conventional ultrasound (US)-guided group|internal jugular vein catheterization using conventional US-guided internal jugular vein (IJV) cannulation
62058744|NCT02878174|EXPERIMENTAL|rotational Prelocation group|internal jugular vein catheterization using landmark approach based on the rotation-adjusted US screen
62058745|NCT02630095|OTHER|Control.|No anticoagulation，just routine follow up.
62058746|NCT02630095|EXPERIMENTAL|Anticoagulation|Nadroparin Calcium and Warfarin
62058747|NCT05685992||Infertile couples infected or not infected with COVID-19|Infertile couples infected or not infected with COVID-19 were included.This is an observational study with no interventions.
62446929|NCT03785977||ETT 10-14kg|Participants weighing 10-14kg may be chosen to wear the ETT device.
62446930|NCT03785977||ETT 15-20kg|Participants weighing 15-20kg may be chosen to wear the ETT device.
62446931|NCT05283239||Women with persistent HR-HPV infection|In the enrollment, women with persistent HR-HPV infection for more than 18 months will be included in this study. All participants will be followed up at 6th month, 12th month, 18th month and 24th month after baseline of recruitment.
62844342|NCT01417494|ACTIVE_COMPARATOR|Chemotherapy|Chemotherapy (FOLFIRI, FOLFOX, LV5FU2)
62844343|NCT04562818||Daunorrubicin|Patient treated with daunorrubicin
62844344|NCT04562818||Idarrubicin|Patient treated with idarrubicin
62844345|NCT04423341|ACTIVE_COMPARATOR|Group A - active medication followed by placebo|
62058748|NCT01988948|OTHER|student cohort|"Various biological sampling~* blood sampling,~* oral, vulvar, vaginal and anal sampling for women,~* oral and genital sampling for men"
62058749|NCT04095260||high school athletes|High school athletes, ages 14 to 18, who are participating in an organized sports training program.
62058750|NCT06539351|OTHER|All participants|
62058751|NCT03237858|ACTIVE_COMPARATOR|HeartLogic ON|ICD and CRT-D devices with HeartLogic alerts turned ON
62058752|NCT03237858|PLACEBO_COMPARATOR|HeartLogic OFF|ICD and CRT-D devices with HeartLogic alerts turned OFF
62844346|NCT04423341|ACTIVE_COMPARATOR|Group B - placebo followed by active medication|
62844347|NCT00384046|EXPERIMENTAL|1|300mcg/day testosterone
62844348|NCT00384046|PLACEBO_COMPARATOR|2|Placebo arm
62618564|NCT05167331|ACTIVE_COMPARATOR|Nitrous oxide sedation|"* (T1) With the nitrous oxide/oxygen inhalation system titrated to 50%/50% whose flow rate is adapted to the child's respiratory flow. The assistant is responsible for controlling the sedation. Verbal encouragement is always present to reassure the child.~* (T2) Five minutes after induction, local anesthesia with the QUICKSLEEPER device is performed. The injection of a cartridge of anesthetic Articaïne SEPTANEST 1/200 000 is administered intraosseously.~* (T3) After placing the rubber dam, the investigator performs restorative +/- endodontic care of the selected temporary molar.~* (T4) Once the treatment is finished, the sedation is stopped and the patient rests in the chair for 5 minutes.~* (T5) As soon as the investigator considers that the child is back to normal state, he can leave the office with his parents."
62446932|NCT05101928|EXPERIMENTAL|Intravitreal Dexamethasone Implant Group|Subjects randomized to the experimental group will receive a 0.7mg intravitreal dexamethasone (DEX) implant which will be injected in the vitreous cavity as one of the treatments of interest in this study.
62618565|NCT02774187|EXPERIMENTAL|Sorafenib combined with HAIC|Sorafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
62618566|NCT02774187|ACTIVE_COMPARATOR|Sorafenib alone|Sorafenib alone
62618567|NCT02958410|EXPERIMENTAL|Lymphocyte Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD30-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
62618568|NCT00560703|ACTIVE_COMPARATOR|COL-101 (doxycycline, USP) capsules|COL-101
62618569|NCT00560703|PLACEBO_COMPARATOR|Placebo|Sugar capsule
62446933|NCT05101928|ACTIVE_COMPARATOR|Prednisone Taper Group|Subjects randomized to the comparator group will receive oral prednisone. The initial dose is expected to range between 40 to 60mg of oral prednisone per day, with gradual tapering to the lowest dose that controls inflammation and eventually transitioning to a maintenance dose. Maintenance dose will be gradually lowered as per standard of care if remission is achieved for 6 to 12 months.
62446934|NCT00650156|EXPERIMENTAL|40 mg adalimumab|
62618570|NCT04468113||US-guided core biopsy and clip placement|Female patients with sonographically suspicious, intramammary foci, scheduled for ultrasound-guided core biopsy and marking of the lesion with the Tumark® Vision Clip
62618571|NCT05717205|ACTIVE_COMPARATOR|cases with gastroparesis|patients with a gastroparesis symptom score index (GCSI) of \> 1.9 will be considered as cases with gastroparesis and will be subjected to technetium-scintigraphy and gastroscopy with tissuesamples from antrum and fundus and bloodsamples of glucosemetabolism
62618572|NCT05717205|ACTIVE_COMPARATOR|Controls without gastroparesis|patients with a gastroparesis symptom score index (GCSI) of \< 1.9 will be considered as controls without gastroparesis and will be subjected to technetium-scintigraphy and gastroscopy with tissuesamples from antrum and fundus and bloodsamples of glucosemetabolism
62618573|NCT00275015|EXPERIMENTAL|High dose therapy + autologous PBSCT|"1. Cytoreductive treatment: (preferentially) FC (2-4 cycles)~2. Mobilization: Dexa-BEAM + G-CSF (1-2 cycles)~3. Myeloablation:~   fractionated TBI (e.g. 6x2Gy) + Cyclophosphamide (2 x 60 mg/kg; d -4 to -3)~4. autologous peripheral blood stem cell transplantation (PBSCT) (d 0)"
62618574|NCT01240395|EXPERIMENTAL|MBCT intervention|
62618575|NCT01240395|NO_INTERVENTION|Control group|
62618576|NCT01469598|EXPERIMENTAL|Gemcitabine/Docetaxel|Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
62058753|NCT06328582|EXPERIMENTAL|routine treatment+Acupuncture Technique for Restoring Consciousness Combined with Scalp Acupuncture|The experimental group was given routine treatment. Moreover, the experimental group will receive Acupuncture Technique for Restoring Consciousness.
62058754|NCT06328582|ACTIVE_COMPARATOR|routine treatment|The experimental group was given routine treatment.
62618577|NCT01609088|EXPERIMENTAL|Erythritol-containing beverage|
62618578|NCT00966901|EXPERIMENTAL|Three Treatment Sites UV Exposed|All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)
62618579|NCT03474146|EXPERIMENTAL|Ocimum sanctum extract as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
62618580|NCT03474146|ACTIVE_COMPARATOR|Chlorhexidine Gluconate as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
62618581|NCT03474146|PLACEBO_COMPARATOR|Propylene Glycol as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
62058755|NCT00674466|EXPERIMENTAL|1|Twice-a-week dose of 1.5 mg CJC-1134-PC
62618582|NCT00933985|EXPERIMENTAL|Treatment (obatoclax, vincristine, doxorubicin, dexrazoxane)|"STRATUM 1 (dose-escalation): Patients receive obatoclax mesylate IV over 3 hours on days 1 and 8 and vincristine sulfate IV, doxorubicin hydrochloride IV, and dexrazoxane hydrochloride IV on day 8 of course 1 (28 days). Drugs are administered on day 1 of subsequent courses and repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.~STRATUM 2: Patients receive obatoclax mesylate (at starting dose in stratum 1), vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride as in stratum 1.~STRATUM 3: Patients receive obatoclax mesylate (at the MTD determined in stratum 1), vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride as in stratum 1."
62618583|NCT02145637|EXPERIMENTAL|Afatinib plus Ruxolitinib combination (single arm)|
62844349|NCT01330108|EXPERIMENTAL|Ambrisentan|patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
62844350|NCT04096976||Hospital survival|
62058756|NCT00674466|EXPERIMENTAL|2|Twice-a-week dose of 1.5 mg CJC-1134-PC for 4 weeks, then once-a-week dose of 2.0 mg CJC-1134-PC plus mid-week dosing of placebo
62058757|NCT00674466|PLACEBO_COMPARATOR|3|Twice-a-week placebo for CJC-1134-PC
62058758|NCT00961025|PLACEBO_COMPARATOR|Placebo|
62058759|NCT00961025|EXPERIMENTAL|DA-1229|DA-1229
62446935|NCT00650156|EXPERIMENTAL|80 mg Adalimumab|
62446936|NCT02352883|EXPERIMENTAL|Arm A (MRI)|Patients undergo MRI prior to surgery. Patients undergo additional imaging and/or biopsies if indicated based on MRI.
62446937|NCT02352883|EXPERIMENTAL|Arm B (mastectomy)|Patients undergo a mastectomy. Patients do not register for Step 3.
62618584|NCT05433675|EXPERIMENTAL|Treatment Sequence AB|Participants will receive single oral dose of macitentan formulated as dispersible final market image (FMI) in fasted conditions (test) (Treatment A) in Intervention Period 1 followed by a single oral dose of film-coated opsumit tablet in fasted conditions (reference) (Treatment B) in Intervention Period 2 on Day 1. There will be washout period of at least 10 days between two period.
62618585|NCT05433675|EXPERIMENTAL|Treatment Sequence BA|Participants will receive Treatment B in Intervention Period 1 followed Treatment A in Intervention Period 2 on Day 1. There will be washout period of at least 10 days between two period.
62618586|NCT00183508|EXPERIMENTAL|1 Cognitive behavioral therapy|
62618587|NCT00183508|EXPERIMENTAL|2 Psychoeducation|
62618588|NCT00303472|EXPERIMENTAL|Part A: 300 µg romiplostim|Cohort 1 in Part A, participants received romiplostim 300 µg subcutaneously once weekly for 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
62618589|NCT00303472|EXPERIMENTAL|Part A: 700 µg romiplostim|Cohort 2 in Part A, participants received romiplostim 700 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
62618590|NCT00303472|EXPERIMENTAL|Part A: 1000 µg romiplostim|Cohort 3 in Part A, participants received romiplostim 1000 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
62058760|NCT04286126|ACTIVE_COMPARATOR|bilateral DMPFC|This arm will receive intermittent theta-burst stimulation to bilateral DMPFC site.
62058761|NCT04286126|ACTIVE_COMPARATOR|right OFC|This arm will receive continuous theta-burst stimulation to the right OFC site.
62058762|NCT01555164|EXPERIMENTAL|Ranolazine+metformin|"Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening).~Treatment Period: Participants will receive ranolazine 500 mg + metformin 500 mg + placebo to match metformin twice daily on Days 1 through 7, followed by ranolazine 1000 mg + metformin 500 mg + placebo to match metformin twice daily from Day 8 through Week 24.~Participants are required to maintain their diet and exercise regimen."
62262306|NCT04816929|ACTIVE_COMPARATOR|Task-Oriented Approach Group|The task-oriented approach for 60 minutes will be formed according to the needs of the individual and involve exercises targeting functional tasks determined. It will be performed 3 days a week for 8 weeks.
62262307|NCT04980482|EXPERIMENTAL|Cohort A, Group 1|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:~AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks."
62262308|NCT04980482|EXPERIMENTAL|Cohort A, Group 2|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:~NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks."
62262309|NCT04980482|EXPERIMENTAL|Cohort B, Group 1|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:~AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks."
62262310|NCT04980482|EXPERIMENTAL|Cohort B, Group 2|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:~NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks."
62446938|NCT02352883|EXPERIMENTAL|Arm C (wide local excision)|Patients undergo wide local excision +/- re-excision. Patients may cross-over to Arm B if mastectomy is indicated. Tissue samples collected during surgery are used to calculate the DCIS score using genetic analysis testing. Patients may then proceed to Step 3.
62446939|NCT02352883|EXPERIMENTAL|Arm D (endocrine therapy)|Patients undergo endocrine therapy as directed.
62446940|NCT02352883|EXPERIMENTAL|Arm E (radiation therapy, endocrine therapy)|Patients undergo radiation therapy and endocrine therapy as directed.
62618591|NCT00303472|EXPERIMENTAL|Part A: 1500 µg romiplostim|Cohort 4 in Part A, participants received romiplostim 1500 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
62618592|NCT00303472|EXPERIMENTAL|Part B: 750 µg romiplostim SC QW|Part B participants received romiplostim 750 µg subcutaneously (SC) once weekly (QW) for 8 weeks. Participants who complete Part B could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
62618593|NCT00303472|EXPERIMENTAL|Part B: 750 µg romiplostim SC Q2W|Part B participants received romiplostim 750 µg subcutaneously every two weeks (Q2W) for 8 weeks. Participants who complete Part B could continue to receive injections of romiplostim for up to 1 year in the extension treatment phase.
62618594|NCT00303472|EXPERIMENTAL|Part B: 750 µg romiplostim IV Q2W|Part B participants received romiplostim 750 µg intravenously (IV) once every two weeks for 8 weeks. Participants who complete Part B could continue to receive romiplostim for up to 1 year in the extension treatment phase.
62618595|NCT02304354|EXPERIMENTAL|Rituximab|two intravenous infusions of 1000 mg with a two-week interval between them
62844351|NCT04096976||No hospital survival|
62058763|NCT01555164|PLACEBO_COMPARATOR|Placebo+metformin|"Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening).~Treatment Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily through Week 24.~Participants are required to maintain their diet and exercise regimen."
62058764|NCT04524078|EXPERIMENTAL|Intensive integrated intervention care program|intensive integrated intervention care program \[ICP\] (lifestyle changes, patient education, adherence to practical guidelines) to transient ischemic attack or minor stroke patients would modify a variety of vascular risk factors and therefore should decrease the likelihood of recurrent stroke or vascular events
62262311|NCT04225130|EXPERIMENTAL|Written Exposure Therapy -for Suicide|Written Exposure Therapy-for Suicide (WET-S) consists of 5 treatment sessions. Each session includes a written exposure exercise. It also includes CRP. Participants assigned to WET-S will complete the CRP prior to beginning their writing in session 1. Patient use of the CRP since the previous session will be briefly reviewed at the start of each WET-S session to manage safety and problem solve fluctuations in risk during treatment.
62446941|NCT01640496|ACTIVE_COMPARATOR|Vitamin D|Subjects will take 1 pill per day for 8 weeks.
62446942|NCT01640496|PLACEBO_COMPARATOR|Placebo|Subjects will be asked to take 1 pill per day for 8 weeks.
62058765|NCT04524078|NO_INTERVENTION|Non intensive integrated intervention care program|
62618596|NCT02560623|EXPERIMENTAL|Phase 1: Sponge on a String 25 mm 10 pores/inch|In phase 1 of the study, subjects will be assigned to swallow a capsule sponge device 25 mm 10 pores/inch to collect cells and cellular material from the mucosa in the esophagus prior to scheduled for a clinically indicated upper endoscopy
62058766|NCT00509548|EXPERIMENTAL|1|Dose 1
62058767|NCT00509548|EXPERIMENTAL|2|Dose 2
62058768|NCT00632957|ACTIVE_COMPARATOR|Fish oil|
62058769|NCT00632957|PLACEBO_COMPARATOR|Placebo|
62618597|NCT02560623|EXPERIMENTAL|Phase 1: Sponge on a String 25 mm 20 pores/inch|In phase 1 of the study, subjects will be assigned to swallow a capsule sponge device 25 mm 20 pores/inch to collect cells and cellular material from the mucosa in the esophagus prior to scheduled for a clinically indicated upper endoscopy
62058770|NCT05698134|ACTIVE_COMPARATOR|Standard of care|Participants will receive blood products transfusion based on prevailing institution protocol, which is based on Platelet count and coagulation parameters (APTT, PT/INR)
62618598|NCT02560623|EXPERIMENTAL|Phase 2: Cases - Barrett's Esophagus|In phase 2 of the study, additional subjects will be assigned to swallow a capsule sponge device 25 mm 10 pores/inch to collect cells and cellular material from the mucosa in the esophagus prior to scheduled for a clinically indicated upper endoscopy
62618599|NCT02560623|EXPERIMENTAL|Phase 2: Controls - No Barrett's Esophagus|In phase 2 of the study, additional subjects will be assigned to swallow a capsule sponge device 25 mm 10 pores/inch to collect cells and cellular material from the mucosa in the esophagus prior to scheduled for a clinically indicated upper endoscopy
62618600|NCT03627715|EXPERIMENTAL|Propagermanium then Placebo|"Propagermanium one capsule orally twice daily for 12 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 12 weeks propagermanium and 12 weeks placebo separated by a 6 week washout period."
62262312|NCT04225130|ACTIVE_COMPARATOR|Treatment as Usual|The TAU condition consists of daily contact and patient centered care by the acute psychiatric inpatient unit provider team. TAU includes initial stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily.
62446943|NCT03537781|EXPERIMENTAL|Food label available, hungry state|foods will be displayed with food labels present and when participants had nothing to eat
62618601|NCT03627715|EXPERIMENTAL|Placebo then Propagermanium|"Propagermanium one capsule orally twice daily for 12 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 12 weeks placebo and 12 weeks propagermanium separated by a 6 week washout period."
62618602|NCT02400203|ACTIVE_COMPARATOR|Control|54 grams of hulled sesame seeds, consumed in 2 daily 27 gram portions, and 30 grams of soybean oil per day
62618603|NCT02400203|EXPERIMENTAL|Hemp foods|60 grams of hulled hemp seeds,consumed in 2 daily 30 gram portions, and 30 grams of hemp oil per day
62618604|NCT02387424|EXPERIMENTAL|MBCT-PD|Mindfulness-based cognitive therapy adapted for perinatal women (MBCT-PD)
62618605|NCT02387424|ACTIVE_COMPARATOR|OAR|Ongoing Assessment and Referral (OAR)
62618606|NCT02530697|ACTIVE_COMPARATOR|Group 1 - Mucosal Antimoniate and Pentoxifylline|20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days. Pentoxifylline 400mg 3x/daily for 28 days.
62618607|NCT02530697|EXPERIMENTAL|Group 2 - Mucosal Miltefosine and Pentoxifylline|Oral Miltefosine 2,5mg/kg/day up to 50mg 2x/daily. Oral Pentoxifylline 400mg 3x/daily for 28 days.
62844352|NCT01213199|EXPERIMENTAL|Differin 0.3%|"Differin® 0.3% Gel~Adapalene 0.3%~Topical to the face, once daily application in the evening for the first four weeks and twice daily application in the morning and in the evening for the following 20 weeks."
62844353|NCT01642784||Culprit lesion IRA revascularization|Culprit lesion IRA revascularization
62844354|NCT01642784||Complete IRA revascularization|Complete IRA revascularization
62058771|NCT05698134|EXPERIMENTAL|ROTEM guided Group|Participants will receive blood products transfusion based on ROTEM results
62058772|NCT06013943|EXPERIMENTAL|Envafolimab+Gemox|
62058773|NCT00464451|EXPERIMENTAL|1|Dexmedetomidine sedated pediatric patients undergoing EEG study.
62058774|NCT00464451|ACTIVE_COMPARATOR|2|Chloral hydrate sedated pediatric patients undergoing sedated EEG study.
62058775|NCT01394874|EXPERIMENTAL|Telephone-linked Communication (TLC)|This group will receive the computer-based telephone counseling.
62058776|NCT01394874|NO_INTERVENTION|Control|This is the control group. They will receive the exercise class, however, they will not receive the telephone counseling.
62058777|NCT03580590|EXPERIMENTAL|1st group|20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative
62058778|NCT03580590|EXPERIMENTAL|2nd group|20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative+ 10 mg/kg IV Tranexamic Acid slow infusion with saline half an hour before the induction of anesthesia
62058779|NCT03580590|PLACEBO_COMPARATOR|3rd group|20 patients will receive oral placebo tablet 3 hours pre-operative
62058780|NCT00927056|ACTIVE_COMPARATOR|Minimally Invasive Microdiscectomy|
62446944|NCT03537781|EXPERIMENTAL|food label available, satiated|foods will be displayed with food labels present and when participants had already eaten breaksfast
62446945|NCT03537781|EXPERIMENTAL|food label unavailable, hungry state|foods will be displayed without food labels present and when participants had nothing to eat
62446946|NCT03537781|EXPERIMENTAL|food label unavailable, satiated|foods will be displayed without food labels present and when participants had already eaten breakfast
62446947|NCT05200858|ACTIVE_COMPARATOR|Intervention Group at 4 weeks (blinded phase)|"The IG will be undergoing Transcutaneous Electrical Nerve Stimulation (TENS) therapy with a functional device during a blinded period of 4 weeks.~The functional device elicits 1 hour of TENS per session. Each session lasts 1 hour (100% of dose). To deliver TENS, a band strap with hydrogel pads will be placed around the calf muscle of one lower-extremity alternating to the other side in a weekly basis."
62058781|NCT00927056|ACTIVE_COMPARATOR|Conventional Open Microdiscectomy|
62058782|NCT03266822||Healthy control|
62058783|NCT03266822||RA patients on anti-TNF therapy|
62058784|NCT03266822||RA patients on anti-IL-6R therapy|
62058785|NCT00699088||Balance® Microplasty™ Hip System|
62058786|NCT04671238||Patient for SPECT/CT scan|Patients referred for SPECT/CT scan of the spine as part of a vertebroplasty workup and selected retrospectively.
62058787|NCT01154478|EXPERIMENTAL|B group|Diet rich in omega-3 fatty acids
62618608|NCT02530697|EXPERIMENTAL|Group 3 - Cutaneous Antimoniate and Pentoxifylline|20mgSb+5/kg/day meglumine antimoniate intravenous for 20 days Oral Pentoxifylline 400mg 3x/daily for 20 days.
62262313|NCT05240911|EXPERIMENTAL|Poisson regression model dosing scheme|daily levothyroxine dose=e\[2.02+0.01(W)-0.0037(A )-0.098(F)-0.01(B)+0.007(T)+0.108(I)-0.014(M), where W is the weight of the patient (Kg), A is the age of the patient (years), and F is the gender (for women 1, male is 0), B represents the patient's body mass index (BMI), T represents the preoperative TSH level, I represents whether the patient takes iron preparations (1, if not 0), M represents whether the patient takes multivitamins/minerals (1, if not 0).
62262314|NCT05240911|ACTIVE_COMPARATOR|weight-based dosing scheme|daily levothyroxine dose=1.6 μg /kg/d
62262315|NCT00507559|EXPERIMENTAL|AAA Repair System|
62844355|NCT02216604|EXPERIMENTAL|Intervention group|Multimodal Exercise intervention (console-based training, age-specific resistance training and body awareness)
62844356|NCT02216604|NO_INTERVENTION|Control|age, disease and gender matched
62262316|NCT04169360|EXPERIMENTAL|ANS-6637|ANS-6637 600mg once daily for 12 weeks
62262317|NCT04169360|PLACEBO_COMPARATOR|Placebo arm|Placebo 600 mg once daily for 12 weeks
62446948|NCT05200858|PLACEBO_COMPARATOR|Placebo Group at 4 weeks (blinded phase)|The PG will be undergoing Transcutaneous Electrical Nerve Stimulation (TENS) therapy with a placebo device during a blinded period of 4 weeks. The placebo device is identical to the functional device in all respects except that it delivers 6 minutes of TENS therapy per session (10% out of 60 minutes).
62618609|NCT02530697|EXPERIMENTAL|Group 4 - Cutaneous Miltefosine and Pentoxifylline|Oral Miltefosine 2,5mg/kg/day up to 50mg 2x/daily Oral Pentoxifylline 400mg 3x/daily for 20 days.
62618610|NCT01684124|PLACEBO_COMPARATOR|standard care|normal treatment
62618611|NCT01684124|ACTIVE_COMPARATOR|conservative O2 therapy|a value of 90-92% O2 saturation will be targeted
62618612|NCT04140084|NO_INTERVENTION|Translation, Redesign and Rapid prototyping with clinicians|This step includes a translation of the tools (English to French) and a redesign work of the original tools. Then, the study will include clinicians (at least 20) from two healthcare settings (CHU Sainte-Justine, and the CISSS-CA (Hotel-Dieu de Levis). After a presentation of the two tools during the Emergency Physicians' departmental meetings, the written comments about the prototype version will be collected. A revision of the prototypes is scheduled at the end of this step.
62844357|NCT06416579|EXPERIMENTAL|Group I-Schroth Exercise Group|Participants will be given individually structured scoliosis-specific three-dimensional exercises according to the Schroth method, 2 days a week for 12 weeks, 1 day a week for the next 12 weeks, under the supervision of a physiotherapist, for a total of 36 sessions. Participants will be given a home exercise program to do on the days they do not come to the session, and will be asked whether they have done it or not when they come to each session. The exercise program will be divided into 4 phases: 0-4, 5-8, 9-12, 12-24. Progress in the exercises will be made positionally by increasing the number of repetitions and the number of rotational breathing during the exercise.
62058788|NCT01154478|EXPERIMENTAL|C group|Diet rich in polyphenols
62058789|NCT01154478|EXPERIMENTAL|D group|Diet rich in polyphenols and in omega-3 fatty acids
62058790|NCT01154478|PLACEBO_COMPARATOR|A group (control group)|diet with low content of omega-3 fatty acids and polyphenols
62058791|NCT06228521|EXPERIMENTAL|Laser Group|LASEmaR MINI 980 nm
62262318|NCT03583151|ACTIVE_COMPARATOR|Steroid injection|1 mL Solu-medrol mixed with 0.5mL marcaine and 0.5 mL of lidocaine
62262319|NCT03583151|EXPERIMENTAL|Amniotic fluid injection|1 mL amniotic fluid mixed with 0.5mL marcaine and 0.5 mL of lidocaine
62262320|NCT05915572|EXPERIMENTAL|Mulligan Mobilization Technique Plus Traditional Physical Therapy Program|Mulligan Mobilization Technique plus traditional physical therapy program 3 sessions per week for 6 weeks.
62262321|NCT05915572|EXPERIMENTAL|Traditional Physical Therapy Program|Traditional physical therapy program 3 sessions per week for 6 weeks
62058792|NCT06228521|ACTIVE_COMPARATOR|Cryotherapy group:|CryoIQ
62058793|NCT03749577|EXPERIMENTAL|L-citrulline|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
62262322|NCT03594227|ACTIVE_COMPARATOR|400mg BID (Low dose)|ATI-501 low dose - oral administration
62262323|NCT03594227|ACTIVE_COMPARATOR|600mg BID (Mid dose)|ATI-501 mid dose - oral administration
62262324|NCT03594227|ACTIVE_COMPARATOR|800mg BID (High dose)|ATI-501 high dose - oral administration
62262325|NCT03594227|PLACEBO_COMPARATOR|Placebo|Placebo - oral administration
62262326|NCT03080298|EXPERIMENTAL|Treatment with BP101|
62844358|NCT06416579|EXPERIMENTAL|Group II-Schroth Method Based Virtual Reality Group|Participants will undergo a Schroth method-based virtual reality exercise program under the supervision of a physiotherapist, 2 days a week for 12 weeks, and 1 day a week for the next 12 weeks, for a total of 36 sessions. Participants will be given a home exercise program to do on the days they do not come to the session, and will be asked whether they have done it or not when they come to each session. Schroth method based virtual reality exercise program will be made on Nintendo Wii. Games within Nintendo Wii will be implemented in individually configured positions in accordance with the Schroth method.The virtual reality exercise program will be divided into 4 phases: 0-4, 5-8, 9-12, 12-24. Sessions will last 40 minutes in total, including 5 minutes of warm-up, 30 minutes of balance and sports games, and 5 minutes of cool-down. Progression will be made by difficulty level and positional in all games.
62844359|NCT06416579|OTHER|Group III-Control Group|Participants in the control group will be placed on a waiting list for 24 weeks. Participants will be given initial, intermediate and final evaluations. Participants will not receive any exercise intervention for 24 weeks and will be able to continue their routine physical activities.
62844360|NCT06085885||Cochlear implant recipients|This study involves no clinical interventions beyond cochlear implantation that will be already available to participants as part of their routine care pathway. Participants will undergo routine pre- and post-operative assessments as part of usual care.
62844361|NCT01897818|EXPERIMENTAL|ALS patients|
62844362|NCT01821560|PLACEBO_COMPARATOR|Sugar pill|Placebo-treated subjects will follow the identical schedule as Baclofen subjects.
62844363|NCT01821560|ACTIVE_COMPARATOR|Baclofen|Baclofen will be dispensed in pill form. Baclofen will be prescribed at 20 mg 4 times per day. Each baclofen pill will be 10 mg. Thus, 2 pills will be taken at each scheduled dose for a total of 8 pills a day over a period of 8 weeks. In this way, the titration schedule, taper and potential dose reductions can be managed.
62844364|NCT01628185||Pain Observations|Adult ICU patients who are not comatose with Richmond Agitation-Sedation Scale (RASS) score of -3 to 4 and unable to self-report pain. Patients will be excluded for neurological deficits (acute or chronic) that prevent observation of the muscle tonus or movement
62844365|NCT03807921|EXPERIMENTAL|Warfarin|"Warfarin will be started 48-72h after aortic valve replacement. Dose will be 5 mg daily in order to obtain an Internation normal ratio (INR) of 2-3. Warfarin treatment will continue for 3 months.~Aspirin will be administered 100 mg daily."
62844366|NCT03807921|ACTIVE_COMPARATOR|Aspirin only|Aspirin will be started 48-72h after aortic valve replacement. Dose will be 100 mg daily. Patients who undergo coronary artery revascularization will receive 325 mg daily.
62844367|NCT02810509||Short-term Warfarin-treated cohort|"1. admission due to AF-related ischemic stroke (known AF or newly detected AF)~2. for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment~3. TTR evaluable days \< 90 days"
62844368|NCT02810509||Long-term Warfarin-treated cohort|"1. admission due to AF-related ischemic stroke (known AF or newly detected AF)~2. long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period~3. for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment~4. TTR evaluable days ≥ 90 days"
62262327|NCT03080298|PLACEBO_COMPARATOR|Treatment with placebo|
62446949|NCT05200858|ACTIVE_COMPARATOR|Intervention Group at 8 weeks (unblinded phase)|"After 4 weeks, the IG will be unblinded, and will continue to receive high-dose TENS with a functional device for additional 4 weeks until completing 8 weeks.~The functional device elicits 1 hour of TENS per session. Each session lasts 1 hour (100% of dose). To deliver TENS, a band strap with hydrogel pads will be placed around the calf muscle of one lower-extremity alternating to the other side in a weekly basis."
62262328|NCT00736255|EXPERIMENTAL|Vyvanse and transdermal nicotine patch|The first group will receive LDX/SPD489 titrated up to 70 mg qd for 4 weeks after the identified quit date. Subjects will continue to receive NRT 21 mg at week 1 post quit date, then 14mg at week 2 post quit date and 7 at weeks 3 and 4 post quit date.
62262329|NCT00736255|PLACEBO_COMPARATOR|Placebo and transdermal nicotine patch|The second group will receive matching placebo and NRT after the quit date.
62262330|NCT02936583|EXPERIMENTAL|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62262331|NCT01155362|EXPERIMENTAL|1 unit Human Placenta-Derived Cells PDA001|1 unit PDA001 in 240 millilters (mL) infused intravenously in one arm on Day 0 and Day 7.
62618613|NCT04140084|NO_INTERVENTION|Rapid prototyping with patients|This step will include the assessment of the tools by patients (or parents of patients) that have had a previous mTBI at the CISSS-CA (Hotel-Dieu de Levis). The comments about the adult and pediatric prototypes (5 adult patients, 5 parents of pediatric patients) will be collected through interviews. A revision of the prototypes is scheduled at the end of this step.
62844369|NCT03675906||preoperative albumin levels <3.8|
62618614|NCT04140084|EXPERIMENTAL|Real-life clinical meetings|This step will include a presentation of the tools to 5 emergency physicians so that they can use the tools with patients (5 adults, 5 parents of pediatric patients) in a realistic setting to identify any problems of use. The clinicians and patients that had used the tools during the clinical encounters will be then met during cognitive interviews to collect their comments on the tools and to address any usability issues. A final revision of the prototypes is scheduled at the end of this step.
62618615|NCT04140084|NO_INTERVENTION|Training session developement|This step includes the development of a training session on how to perform SDM with patients facing the decision to undergo head CTs for mTBI and about how to use our newly developed decision aids in this clinical setting. The content of the training session will be adapted to the needs, goals, strengths and limitations observed during the focus groups (departmental meetings) exploring health professionals' barriers to using a decision aid about head CTs in mTBI. The expertise of SAVIE (www.savie.ca) in producing online and interactive elearning programs will be mobilized in order to produce a training program that will integrate the content the investigators will have identified as the main skills, knowledge and competencies needing development among our health professionals to stimulate the use of SDM and our decision aids. SAVIE will produce a virtual elearning program adaptable to all media (PC, mobile device, tablet) and different health professionals.
62446950|NCT05200858|ACTIVE_COMPARATOR|Placebo Group at 8 weeks (unblinded phase)|"After 4 weeks, the PG will be unblinded and will switch to a high-dose TENS with a functional device for additional 4 weeks until completing 8 weeks.~The functional device elicits 1 hour of TENS per session. Each session lasts 1 hour (100% of dose). To deliver TENS, a band strap with hydrogel pads will be placed around the calf muscle of one lower-extremity alternating to the other side in a weekly basis."
62446951|NCT04914715|EXPERIMENTAL|Non-invasive High Frequency Oscillatory Ventilation|"Preterm babies (26-28 weeks) born with respiratory distress will be initially started on nCPAP with setting of flow 6-8 liter, PEEP 5-6, FiO2 21-40%. If fio2 requirefment more than 40%, surfactant will be given in first 2 hours of birth. If baby fails on CPAP then will be switched to nHFOV with below mentioned settings.~Preterm born babies 28-34 weeks gestation with RDS, respiratory support will be started on Heated Humidified High Flow Oxygen therapy or nCPAP, if that fails then baby will be switched to NHFOV with frequency of 5-20 (300-1200 breathe/min), Amplitude of 1-10, flow1-17.5 liter/min, fiO2 21-100% and integrated pressure triggered sensitivity option."
62446952|NCT04914715|ACTIVE_COMPARATOR|Conventional Invasive Ventilation|"Preterm babies (26-28 weeks) born with respiratory distress will be initially started on nCPAP with setting of flow 6-8 liter, PEEP 5-6, FiO2 21-40%. If fio2 requirement more than 40%, surfactant will be given in first 2 hours of birth. If baby fails on CPAP then will be switched to nHFOV with below mentioned settings.~Preterm born babies 28-34 weeks gestation with RDS, respiratory support will be started on Heated Humidified High Flow Oxygen therapy or nCPAP, if that fails then baby will be switched to invasive ventilation through endotracheal tube, mode will be selected as Synchronized Intermittent Mandatory ventilation (SIMV) with rate of 25-60 breath/min, flow of 8 liter, positive inspiratory pressure (PIP) of 14-25, Positive end expiratory pressure (PEEP) 4-5, fio2 of 21-40."
62446953|NCT05393947|EXPERIMENTAL|patient aducation|It is planned to provide education to patients about the side effects of chemotherapy.
62446954|NCT05393947|NO_INTERVENTION|observation|While training the patients in the intervention group, observations will be made on the patients in the experimental group.
62446955|NCT03482713|EXPERIMENTAL|Gefapixant 45 mg|Participants will receive a gefapixant 45 mg film-coated tablet BID for 28 days.
62844370|NCT03675906||preoperative albumin level >3.8|
62844371|NCT03675906||postoperative Day 2 albumin level <2.9|
62844372|NCT03675906||postoperative Day 2 albumin level >2.9|
62844373|NCT04083768|PLACEBO_COMPARATOR|Supine group|After the patient completes the spinal anesthesia, the cesarean section is completed in the supine position.
62844374|NCT04083768|ACTIVE_COMPARATOR|15° group|After the patient completed the spinal anesthesia, the preoperative preparation (about 10 minutes) was completed with a left tilt of 15°, and the cesarean section was completed using the supine position after the skin was cut.
62844375|NCT04083768|ACTIVE_COMPARATOR|30° group|After the patient completed the spinal anesthesia, the preoperative preparation (about 10 minutes) was completed with a left tilt of 30°, and the cesarean section was completed using the supine position after the skin was cut.
62844376|NCT03924830|ACTIVE_COMPARATOR|Bulk without Surface Sealant|53 teeth will receive restorations using Bulk fill restoration without surface sealant
62844377|NCT03924830|EXPERIMENTAL|Bulk with Biscover|53 teeth will receive restorations using Bulk fill restoration with Biscover surface sealant
62844378|NCT03924830|EXPERIMENTAL|Bulk with Permaseal|53 teeth will receive restorations using Bulk fill restoration with Permaseal surface sealant
62058794|NCT03749577|EXPERIMENTAL|Beetroot juice|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
62446956|NCT03482713|PLACEBO_COMPARATOR|Placebo|Participants will receive a film-coated placebo tablet matching gefapixant BID for 28 days.
62844379|NCT01643096|OTHER|sumac|Thermic effect of food of Sumac and comparison between hot and cold temperament people
62844380|NCT01643096|OTHER|Zataria multiflora Boiss|Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
62844381|NCT05568303|EXPERIMENTAL|study ( interventional ) group|this group received 8 sessions of CBT
62844382|NCT05568303|NO_INTERVENTION|Control group|they will receive on intervention sessions or any education researchers makes meeting every month to answer any questions and to maintain continuity of relation with participants
62618616|NCT04140084|NO_INTERVENTION|Retrospective analysis|This step will retrospectively analyze the medical records of traumatic brain injury adult patients (adult, 350, Hotel-Dieu de Levis) and pediatric patients (406, CHU de Sainte-Justine and Hotel-Dieu de Levis)) randomly selected throughout the year preceding this study in each of the two centers to determine the rate of head CT ordering, the head CT result and the appropriateness of having ordered the head CT based on the CCHR and PECARN criteria. One reviewer will judge the appropriateness of having done a CT scan according to the CCHR and PECARN criteria based on a structured extraction form that will previously be approved by the study's steering committee. To ensure validity, 10% of the analysis will be reviewed by an expert. The reviewer will look at prehospital data collection, triage information, physician's notes, nursing notes and head CT requisition form information to determine if any of the clinical decision rule criteria are present.
62058795|NCT03749577|PLACEBO_COMPARATOR|L-citrulline placebo|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
62058796|NCT03749577|PLACEBO_COMPARATOR|Denitrated beetroot juice|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
62618617|NCT04442698||Diabetic MGB post op patients|Diabetic MGB post op patients
62618618|NCT00290654|EXPERIMENTAL|Lumpectomy with Brachytherapy|Patients with ductal carcinoma in situ (DCIS, a non-invasive form of breast cancer) treated with standard lumpectomy/brachytherapy following by radiation using the MammoSite (FDA approved a balloon-catheter device placed in the lumpectomy cavity through which high dose radiation is delivered). Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient.
62618619|NCT01690299|EXPERIMENTAL|Apremilast 30 mg plus placebo injection|Apremilast 30 mg tablets orally twice a day (BID) plus once weekly (QW) evaluator/subject-blinded subcutaneous (SC) saline (placebo) injections
62618620|NCT01690299|EXPERIMENTAL|Etanercept 50 mg plus placebo tablet|Etanercept 50 mg evaluator/subject-blinded SC QW injections plus placebo tablets orally BID
62618621|NCT01690299|PLACEBO_COMPARATOR|Oral placebo tablets plus SC placebo injections|Identically matching placebo tablets and evaluator/subject-blinded SC injections
62618622|NCT02373137|OTHER|DSAEK|Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
62844383|NCT03783624|EXPERIMENTAL|Hypnosis|"This represents 6 individual script-based sessions lasting 1h, distributed over 8 weeks, administered by a certified expert in therapeutic hypnosis. A set of standardized recordings are provided to use at home for self-hypnosis. Suggestions address deep relaxation, sensory substitution or transformation, pain intensity reduction, decreased pain unpleasantness and intensity, sense of control. A brief example of such suggestions: in this deeply relaxed state, you can imagine that your feet are covered in anesthetic... a deep layer of a powerful anesthetic medication, creating protective, soothing socks with which you can walk again...."
62058797|NCT03198286|EXPERIMENTAL|Supportive care (survivor care plan, survey)|Patients receive a customized treatment summary and survivor care plan via the Carevive Survivor Care Planning System and review it during their follow-up visit. Patients also complete a survey on a tablet computer over 10-20 minutes before and after their follow-up visit.
62446957|NCT00710203|ACTIVE_COMPARATOR|Pulsed dye laser|Four lesions are selected on each subject for study. One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
62446958|NCT00710203|ACTIVE_COMPARATOR|Curettage|Four lesions are selected on each subject for study. A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
62446959|NCT00710203|ACTIVE_COMPARATOR|Electrodesiccation|Four lesions are selected on each subject for study. A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
62058798|NCT02998814|ACTIVE_COMPARATOR|acid-etch only|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for acid-etch only will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
62058799|NCT02998814|ACTIVE_COMPARATOR|self-etch adhesive|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for self-etch adhesive will be treated with self-etch adhesive (AdperTM EasyBond, 3M ESPE) for 10 seconds followed by light curing for 20 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
62262332|NCT01155362|EXPERIMENTAL|4 units Human Placenta-Derived Cells PDA001|4 units PDA001 in 240 mL infused intravenously in one arm on Day 0 and Day 7.
62262333|NCT01155362|PLACEBO_COMPARATOR|vehicle control|4 units placebo in 240 mL infused intravenously in one arm on Day 0 and Day 7.
62446960|NCT00710203|ACTIVE_COMPARATOR|No treatment|Four lesions are selected on each subject for study. A fourth lesion will not be treated and will serve as a control.
62446961|NCT04032873|OTHER|Provider Cost|The subject will be given information about the cost of casting and splinting for treatment of the buckle fracture by the orthopaedic surgeon before the decision for immobilization has been made.
62446962|NCT04032873|OTHER|Research Team Cost|The subject will be given information about the cost of casting and splinting for treatment of the buckle fracture by a member of the study team after the decision for immobilization has been made.
62618623|NCT02373137|OTHER|DMEK|Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
62618624|NCT04171856|EXPERIMENTAL|Motor Skill Learning (CIRCUIT)|Intervention: training on the REAplan robot with a serious game based on motor skill learning (MSkL) serious game, the CIRCUIT.
62618625|NCT04171856|ACTIVE_COMPARATOR|Motor control recovery (EASY)|Training on the REAplan robot with a serious game that requires similar type and amount of movements but does not rely on motor skill learning (EASY), a brick buster game.
62618626|NCT04171856|ACTIVE_COMPARATOR|Conventional|Training sessions with classical exercices focused on the upper limb administered by occupation therapist.
62618627|NCT05693025|ACTIVE_COMPARATOR|Standard Implementation (SI)|Participants the Standard Implementation (SI) model complete a 6 week structured Walk with Ease group exercise program designed to build capacity and function in older adults. Sessions are held 3 days a week for an hour each session. Each session includes a 10 minute warmup including strength/flexibility exercises, a 30 minute bout of walking and a 10 minute cool-down including strength/flexibility exercises. Participants complete standard exercises recommended in the base program.
62618628|NCT05693025|EXPERIMENTAL|Enhanced Implementation (EI)|Participants the Enhanced Implementation (SI) model complete the 6 week structured Walk with Ease group exercise program designed to build capacity and function in older adults. Sessions are held 3 days a week for an hour each session. Each session includes a 10 minute warmup including strength/flexibility exercises, a 30 minute bout of walking and a 10 minute cool-down including strength/flexibility exercises. Participants complete personalized exercises prescribed by a licensed Physical Therapist to help reduce potential risks of falling.
62618629|NCT05693025|ACTIVE_COMPARATOR|Standard Training (ST)|Participants the Standard Training (ST) model receive access to on online portal with weekly tips and education content, goal setting options and a daily tracking system for logging walking and exercises performed. They receive instruction on how to use the portal and are encouraged to use the integrated eBook and resources to supplement the group exercise programming. Weekly video-based lessons provide standard knowledge-based training about how to become more physically active.
62262334|NCT01155362|EXPERIMENTAL|8 units Human Placenta-Derived Cells PDA001|4 units PDA-001 in 240 mL infused intravenously in each arm on Day 0 and Day 7 or 8 units PDA-001 in 240 mL infused intravenously in one arm on Day 0 and Day 7
62446963|NCT02133755|OTHER|Bromocriptine mesylate (Cycloset)|Cycloset 1.6 to 3.2 mg daily for 3 months
62446964|NCT02177955|PLACEBO_COMPARATOR|midazolan|7.5 mg midazolan 45 minutes before the surgery
62446965|NCT02177955|PLACEBO_COMPARATOR|diazepam|10 mg diazepam 45 minutes before the surgery
62446966|NCT04153253|ACTIVE_COMPARATOR|Group I|Intravitreal injection of Aflibercept followed by panretinal photocoagulation.
62446967|NCT04153253|ACTIVE_COMPARATOR|Group II: Early vitrectomy.|Early vitrectomy.
62446968|NCT02746263|EXPERIMENTAL|IV acetaminophen/Morphine|IV acetaminophen 1000 mg every 6 hours over 18 hours
62446969|NCT02746263|ACTIVE_COMPARATOR|Oral acetaminophen/Morphine|Oral acetaminophen two 500 mg tablets every 6 hours over 18 hours
62446970|NCT01557647|EXPERIMENTAL|inhaled treprostinil|
62446971|NCT01557647|PLACEBO_COMPARATOR|placebo|
62446972|NCT04145908|ACTIVE_COMPARATOR|preperitoneal mesh|patients underwent preperitoneal mesh mesh placement
62446973|NCT04145908|ACTIVE_COMPARATOR|onlay mesh|patients underwent preperitoneal mesh mesh placement
62446974|NCT04639934||Breast cancer patients|Breast cancer patients being seen at SingHealth
62446975|NCT00958581|PLACEBO_COMPARATOR|Normal Saline|Patients infused with normal saline before and during the surgical procedure as a placebo.
62446976|NCT00958581|EXPERIMENTAL|Tranexamic acid|Patients receive TXA before and during the surgical case.
62446977|NCT00958581|EXPERIMENTAL|Epsilon Aminocaproic Acid|Patients will receive EACA before and during the surgical case.
62446978|NCT04664842|EXPERIMENTAL|Manual Therapy Group|
62446979|NCT04664842|SHAM_COMPARATOR|Manual Control Group|
62446980|NCT04664842|EXPERIMENTAL|Breathing Training Group|
62446981|NCT04664842|SHAM_COMPARATOR|General Exercise Control Group|
62446982|NCT04664842|EXPERIMENTAL|Manual Therapy Combined Breathing Training Group|
62446983|NCT06339593||CF pts on MACT|Males and females from 12 to 21 years old who have been prescribed Mechanical Airway Clearance Therapy for CF.
62618630|NCT05693025|EXPERIMENTAL|Enhanced Training (ET)|Participants the Enhanced Training (ET) model receive access to on online portal with weekly tips and education content, goal setting options and a daily tracking system for logging walking and exercises performed. They receive instruction on how to use the portal and are encouraged to use the integrated eBook and resources to supplement the group exercise programming. Weekly video-based lessons provide habit-formation training about how to form regular habits for physical activity. Participants are paired with a student 'coach' trained in motivational interviewing skills to provide virtual assistance in maintaining motivation during the programming.
62618631|NCT01889732||ROTEM|
62618632|NCT01943955|EXPERIMENTAL|home-based computer gaming|computer gaming, balance exercises carried out at home for 20 minutes 5 days/week and monitored by a physical therapist.
62618633|NCT01717157|EXPERIMENTAL|Treatment sequence 1 (AEBD)|
62618634|NCT01717157|EXPERIMENTAL|Treatment sequence 2 (BACE)|
62618635|NCT01717157|EXPERIMENTAL|Treatment sequence 3 (CBDA)|
62618636|NCT01717157|EXPERIMENTAL|Treatment sequence 4 (EDAC)|
62618637|NCT01717157|EXPERIMENTAL|Treatment sequence 5 (DECA)|
62618638|NCT01717157|EXPERIMENTAL|Treatment sequence 6 (EADB)|
62446984|NCT00976235|EXPERIMENTAL|IMT|
62618639|NCT01717157|EXPERIMENTAL|Treatment sequence 7 (ABEC)|
62618640|NCT01717157|EXPERIMENTAL|Treatment sequence 8 (BCAD)|
62618641|NCT00003513|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62618642|NCT06054958||ME/CFS|"ME/CFS: adolescents aged 14-17 years, fulfilling diagnostic criteria for ME/CFS according to Rowe e 2017, Jason 2006, CCC 2003, and/ or IOM 2015 at the time of recruitment.~Methods: Semi-structured interview, questionnaires, passive 10-minute standing test (NASA lean test), blood sampling."
62618643|NCT06054958||Healthy Controls (HC)|"HC: adolescents aged 14-17, clinically healthy without any known underlying disease and with no prescription drugs (except contraception).~Methods: Semi-structured interview, questionnaires, passive 10-minute standing test (NASA lean test), blood sampling."
62618644|NCT05271097|EXPERIMENTAL|MyLink2Care app|Participants in the MyLink2Care group will be provided with full app access and will be encouraged to use all features of the app.
62618645|NCT05271097|ACTIVE_COMPARATOR|treatment-as-usual (TAU)|Participants in the TAU group will receive the MyLink2Care app with major intervention features inactivated.
62618646|NCT01471275|EXPERIMENTAL|Jiangtangtiaozhi decoction|
62618647|NCT01471275|ACTIVE_COMPARATOR|metformin|
62618648|NCT01254084|PLACEBO_COMPARATOR|Placebo tea|Dietary Supplement: Placebo tea 3 gram twice daily, orally
62262335|NCT04058340|ACTIVE_COMPARATOR|lactizole-placebo|A group of patients who will receive 3ml lactizole solution (150ppm) in nebulization twice a day for 4 weeks , and then for the next 4 weeks they will receive 2 times a day 3ml 0.9% NaCl solution in nebulization
62262336|NCT04058340|ACTIVE_COMPARATOR|placebo-lactizole|A group of patients who will receive 2 times a day for 4 weeks (0.9% NaCl solution in nebulization) for 4 weeks and will receive 3ml of lactizole solution (150ppm) in nebulization 2 times a day for 4 weeks
62262337|NCT04911036||Mothers and/or fathers with an antenatal diagnosis|
62262338|NCT04911036||Mothers and/or fathers with a postnatal diagnosis|
62844384|NCT03783624|PLACEBO_COMPARATOR|Open Label placebo|This consists in information provided with a placebo pill. Patients are asked to take the placebo pills as a self-healing ritual. The information relies on 4 points of explanation, i.e. (1) the placebo effect can be powerful, (2) the body automatically can respond to taking placebo pills like Pavlov dogs who salivated when they heard a bell, (3) a positive attitude can be helpful but is not necessary, and (4) taking the pills faithfully for the full duration of treatment is critical.
62844385|NCT03783624|NO_INTERVENTION|Usual care|Patients continue with their usual treatments
62844386|NCT03227640|ACTIVE_COMPARATOR|stripping|standardized laparoscopic stripping technique
62844387|NCT03227640|EXPERIMENTAL|CO2 laser vaporization|drainage of the cyst content and vaporization of the internal wall with CO2 laser
62844388|NCT05420259|EXPERIMENTAL|Combined Exercise and Dietary Intervention|Intervention aimed at conveying a supervised combined moderate aerobic and resistance training, once a week with a duration of 40-60 minutes plus daily home exercise, personalized according to patients' age and functional status. Dietary intervention aimed at a one-on-one nutritional counseling. In the first visit a dietary plan is designed and one daily oral nutritional supplement (Fortimel Compact®, Nutricia) is given to meet the European Society of Parenteral and Enteral Nutrition (ESPEN) recommended intake.
62844389|NCT05420259|OTHER|Control|Standard Care
62262339|NCT05145907|EXPERIMENTAL|TJ107+Pembrolizumab|TJ107 1200ug/Kg,Q12W + Pembrolizumab 200mg Q3W
62262340|NCT03394144|EXPERIMENTAL|C1:AZD9150, C2:AZD9150+Durvalumab|After confirmed safety with Cohort 1, Cohort 2 will open
62262341|NCT02434848|ACTIVE_COMPARATOR|Engerix B|15 subjects per group (n = 30 in total)
62262342|NCT02434848|ACTIVE_COMPARATOR|Fendrix|15 subjects per group (n = 30 in total)
62618649|NCT01254084|ACTIVE_COMPARATOR|Gynostemma pentaphyllum Tea|Gynostemma Pentaphyllum tea 3 grams twice daily, orally
62844390|NCT00861562|ACTIVE_COMPARATOR|Imescard pills/Placebo crossover|Patients received Imescard water smartweed composed pills during the first intervention period and placebo during the second, after a 10-day washout period.
62844391|NCT00861562|ACTIVE_COMPARATOR|Placebo/Imescard pills crossover|Patients received placebo during the first intervention period and Imescard water smartweed composed pills during the second, after a 10-day washout period.
62844392|NCT04176848|EXPERIMENTAL|CFI-400945 + Durvalumab|CFI-400945 32 mg orally on Days 1-7 and Days 15-21 of Cycle 1 (28 day cycle) and then daily from Cycle 2 on and Durvalumab 1500mg IV on Day 1 (28 day cycles) from Cycle 2 on.
62844393|NCT01646125|EXPERIMENTAL|AUY922 arm|"Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the investigational drug arm.~AUY922 was to be administered weekly."
62844394|NCT01646125|ACTIVE_COMPARATOR|chemotherapy arm|"Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the control arm drug arm.~Pemetrexed or docetaxel was to be was to be given once every three weeks."
62844395|NCT00853567|ACTIVE_COMPARATOR|25 g Proellex|25 mg oral daily dose of Proellex
62844396|NCT00853567|ACTIVE_COMPARATOR|50 mg Proellex|50 mg oral daily dose of Proellex
62844397|NCT00853567|PLACEBO_COMPARATOR|Placebo|Placebo treatment
62844398|NCT04518267||Civilian group|Participants with civilian status
62844399|NCT04518267||Military group|Participants with military status
62844400|NCT05491668||Coronary Physiology Assessment|Patients undergoing coronary angiogram who are found to have \>/= 70% coronary stenosis and planned for percutaneous coronary intervention (PCI)/stent placement, will undergo pre and post PCI invasive physiologic assessment with a coronary pressure-sensing wire (OpSens OptoWire III) using non-hyperemic pressure ratio (NHPR) indices (diastolic pressure ratio \[dPR\]). Both the patient and interventional cardiologist will be blinded to the results of the invasive physiologic assessment. Angiogram co-registration will be performed on pullback of coronary pressure-sensing wire.
62446985|NCT01388023|ACTIVE_COMPARATOR|smellx|test group- SmellX palatal patch with the herbal formula
62446986|NCT01388023|PLACEBO_COMPARATOR|smellx palatal patch|negative control group- SmellX palatal patch with out the herbal formula
62446987|NCT01388023|ACTIVE_COMPARATOR|chlorhexidine|poositive control group-mouth wash with chlorhexidine 0.125%
62446988|NCT01388023|ACTIVE_COMPARATOR|listerine|listerine mouth wash
62844401|NCT00936780|EXPERIMENTAL|Infinnium-Core™ Paclitaxel eluting Coronary Stent|
62844402|NCT05283772|EXPERIMENTAL|Experimental|
62844403|NCT05283772|NO_INTERVENTION|No intervention|
62844404|NCT05866809|EXPERIMENTAL|HK-660S|Oral administration of HK-660S 100 mg (1 tablet) twice daily before morning and evening meals
62446989|NCT04109911|EXPERIMENTAL|Fermented oyster extract group|This group takes fermented oyster extract for 12 weeks
62844405|NCT05866809|PLACEBO_COMPARATOR|Placebo|Oral administration of placebo 1 tablet twice daily before morning and evening meals
62844406|NCT06464822||Control Group|For patients decide not for bariatric surgery
62844407|NCT06464822||Intervention Group|For patient decided for Bariatric surgery
62844408|NCT03667092|EXPERIMENTAL|Non-drug intervention type|"Exploration of gene transcript variation on seriate blood samples before treatment, before and after the 2nd and the 4th Lu-Dotatate injection and before and after the 6 month post treatment follow-up.~Measures of stability and reproducibility of selected gene transcripts and miRNA as radio sensitivity genes or progressive metastatic midgut neuroendocrine tumors genetic signatures before and during Lu-177 Dotatate internal vectorized therapy, as well as on the 6-month follow-up."
62844409|NCT02984605|EXPERIMENTAL|Interventional group|"Arm：Hypoglycemic agents + Nutrition meal replacement \& exercise prescription~Hypoglycemic agents in combined with 1 times a day with bags of nutritional meal replacement and exercise"
62446990|NCT04109911|PLACEBO_COMPARATOR|Placebo group|This group takes placebo for 12 weeks
62844410|NCT02984605|NO_INTERVENTION|Control group|"Arm：Hypoglycemic agents~without take nutrition meal replacement \& exercise prescription"
62844411|NCT05292157||Reverse total shoulder arthroplasty|Patients who have received a reverse total shoulder arthroplasty with more than 2 years of follow-up in a temporal frame going from 2016 to 2022.
62446991|NCT02046291|EXPERIMENTAL|Romiplostim treatment|Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks (i.e. 6 doses) unless platelet count exceeds 100 x 10\^9/L and at least 4 doses of therapy were given.After the initial dose, subsequent doses will be administered within a window of +/- 3 days.
62446992|NCT02442479|ACTIVE_COMPARATOR|HHH3|High-resistance concentric-eccentric training (H) 3 d/wk (HHH3).
62446993|NCT02442479|EXPERIMENTAL|HLH3|3 d/wk mixed model consisting of high-resistance concentric-eccentric training 2 d/wk separated by 1 bout of low-resistance, high-velocity, concentric only training (L) (HLH3).
62446994|NCT02442479|EXPERIMENTAL|HH2|High-resistance concentric-eccentric training 2 d/wk (HH2).
62844412|NCT01775618|EXPERIMENTAL|Main study|Participants were treated and prophylaxis administered with BAY94-9027 at a dose of 25-60 international units/kilogram (IU/kg) twice per week or 45-60 IU/kg every 5 days or 60 IU/kg every 7 days as an intravenous (IV) infusion as per clinical needs of each subject up to at least 50 exposure days (EDs) and a minimum of at least 6 months.
62844413|NCT01775618|EXPERIMENTAL|Part 2 (Expansion group)|Participants were administered with BAY94-9027 at a dose of 25-60 IU/kg twice per week for prophylaxis for 12 weeks.
62262343|NCT03448250|EXPERIMENTAL|Optimune|Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
62262344|NCT03448250|ACTIVE_COMPARATOR|Care-as-Usual|As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).
62262345|NCT01356082||Arterial blood pressure line|Patients receiving an arterial blood pressure line
62262346|NCT04549870|ACTIVE_COMPARATOR|Roflumilast|Roflumilast 500 microgram daily (capsule)
62262347|NCT04549870|PLACEBO_COMPARATOR|Placebo|Placebo (capsule)
62618650|NCT06174545|NO_INTERVENTION|Group 1 (HQ group)|Group 1 is control group, getting SPF 30 sunscreen cream in the morning and only 2% Hydroquinone cream at night without a combination cream and facial soap that can be used in the morning and evening.
62618651|NCT06174545|EXPERIMENTAL|Group 2 (PSP Group)|Group 2, the treatment group, used PSP cleanser, PSP Day Cream and SPF 30 sunscreen in the morning and used Hydroquinone 2% and PSP Night Cream at night and PSP cleanser which was used in the morning and evening before using the cream.
62262348|NCT05776836|EXPERIMENTAL|FASY|Subjects will be consecutively included to receive FASY F in cheeks and nasolabial folds and FASY P in periorbital areas.
62262349|NCT02247895|SHAM_COMPARATOR|Sham Treatment|Sham stimulation twice daily
62618652|NCT05816460|EXPERIMENTAL|Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I)|Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I) will be provided on an online digital platform called Sleepio (BigHealth Ltd). Sleepio delivers fully automated CBT-I through 6 sessions, lasting an average of 20 minutes each, over the course of 6 weeks.
62844414|NCT01775618|EXPERIMENTAL|Extension study|Participants were treated and prophylaxis administered with BAY94-9027 at a dose of 25- 60 IU/kg twice per week or 45-60 IU/kg every 5 days or 60 IU/kg every 7 days as an IV infusion as per clinical needs of each subject for at least 50 EDs or until marketing authorization of the drug.
62844415|NCT05241093|EXPERIMENTAL|HYML-122 plus cytarabine|"The first three eligible enrolled patients will be treated with initial dosing of HYML-122 400mg bid daily and cytarabine 100mg/m2 intravenously by using 3+3 escalating design to explore RP2D. the Data Monitoring Committee (DMC) will evaluate the safety, efficacy and PK data of the phase 1 subjects and establish the combined regimen recommended dose. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgement of the investigator, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet 1 of the discontinuation criteria, whichever occurs first."
62844416|NCT06367738|EXPERIMENTAL|Psilocybin Level 1|The effects of different doses of psilocybin (1 - 30 mg) will be compared.
62844417|NCT06367738|ACTIVE_COMPARATOR|Psilocybin Level 2|The effects of different doses of psilocybin (1 - 30 mg) will be compared.
62844418|NCT03535298|EXPERIMENTAL|EHT: Early Highly-effective|"Participants randomized to the EHT: Early Highly-effective arm will receive one of the highly effective MS therapies (Ocrevus, Lemtrada, Tysabri, Rituximab, Kesimpta) as their initial disease modifying treatment.~Interventions: one of the highly effective MS therapies~The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group."
62618653|NCT05816460|ACTIVE_COMPARATOR|Sleep Hygiene Education (SHE)|The Sleep Hygiene Education (SHE) provided is based on recognised sleep hygiene advice and will consist of behavioural recommendations concerning lifestyle and environmental factors associated with sleep and insomnia. SHE will be delivered electronically.
62618654|NCT01309451|ACTIVE_COMPARATOR|Bevacizumab alone|
62618655|NCT01309451|ACTIVE_COMPARATOR|Combined group|Bevacizumab plus Ozurdex
62618656|NCT06232486||Herpes zoster patients|The patient was diagnosed with herpetic neuralgia and the course of disease was ≤3 months;
62618657|NCT06283407||Poland|People with musculoskeletal conditions from the general population in Poland
62618658|NCT06283407||Spain|People with musculoskeletal conditions from the general population in Spain
62262350|NCT02247895|ACTIVE_COMPARATOR|Active Treatment|The active treatment group will receive neuromuscular electrical stimulation to both quadriceps muscle for 30 minutes twice daily for a total of 14 treatments.
62446995|NCT02442479|EXPERIMENTAL|HL2|2 d/wk mixed model consisting of high-resistance concentric-eccentric training 1 d/wk and low-resistance, high-velocity, concentric only training 1 d/wk (HL2).
62446996|NCT01983020|EXPERIMENTAL|Ketamine|Ketamine infused at 0.25 mg/kg/hour.
62618659|NCT03522207|EXPERIMENTAL|Trazo1|After a baseline polysomnography (PSG), subject will receive 100 mg of trazodone 30 minutes prior to their 2nd PSG and will receive 100mg Placebo 30 minutes prior to their 3rd PSG.
62618660|NCT03522207|EXPERIMENTAL|Trazo2|After a baseline polysomnography (PSG), subject will receive 100 mg of placebo 30 minutes prior to their 2nd PSG and will receive 100mg trazodone 30 minutes prior to their 3rd PSG.
62844419|NCT03535298|EXPERIMENTAL|ESC: Escalation|"Participants randomized to the ESC: Escalation arm will receive any other approved MS therapy (not one of the EHT group) as their initial disease modifying treatment.~Interventions: one of the MS therapies NOT in the highly effective group~The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group."
62844420|NCT03535298|NO_INTERVENTION|OBS: Observational|"Participants will not be restricted to a group of MS therapies.~Participants enter this arm if they are not comfortable with randomization, are not eligible to receive any of the options in a randomized arm, or are not able to secure insurance coverage for any therapy in a randomized arm."
62844421|NCT04787536||Study cohort|Patients aged 65 years or greater; scheduled to perform noncardiac elective surgery expected to require at least an overnight stay in hospital after surgery; surgery deferred, with a known or probable surgery date in ≥6 weeks
62844422|NCT03327103|NO_INTERVENTION|Enhanced Usual Care|Receive standard care
62844423|NCT03327103|EXPERIMENTAL|Decision Intervention|Receives decision aid intervention that encompasses balance sheets, navigation, audio files, and interaction -- Cancer Health Aid to Manage Preferences and Improve Outcomes through Navigation (CHAMPION)
62844424|NCT00522899|EXPERIMENTAL|Aerobic exercise|Study-specific group exercise classes include 10' warm-up, 30' cardio, 5' cool down, 15' stretching/toning. Target heart rate is 60-75% of maximum. Study participants attend classes 60 min/day, 3 days/week for 12 weeks.
62844425|NCT00522899|ACTIVE_COMPARATOR|Stretching/toning|Study-specific stretching/toning exercise classes include 10' warm-up, 40' stretching/toning, 10' relaxation. Participants attend classes 60 minutes/day, 3 days/week for 12 weeks.
62844426|NCT00522899|EXPERIMENTAL|Computer-based mental activity training|Computer-based visual and auditory stimulation training programs developed by Posit Science corporation. Participants perform assigned mental activity on computers in their homes for 60 minutes/day, 3 days/week for 12 weeks.
62262351|NCT01087905|ACTIVE_COMPARATOR|2 Weeks of Nicotine Patch Only, No CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~2 Weeks of Nicotine patch dosed as follows:~If \> 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If \< or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks"
62844427|NCT00522899|ACTIVE_COMPARATOR|Educational DVD training|Watching and listening to in-depth, college-level lectures on art, history and science on the computer. Participants perform assigned mental activities 60 minutes/day, 3 days/week for 12 weeks.
62844428|NCT04492332|SHAM_COMPARATOR|normal controls with VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis \>2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were found.
62844429|NCT04492332|SHAM_COMPARATOR|normal controls without VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis \>2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were not found.
62844430|NCT04492332|ACTIVE_COMPARATOR|BTSS patients with VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis \>2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were found.
62844431|NCT04492332|ACTIVE_COMPARATOR|BTSS patients without VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis \>2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were not found.
62262352|NCT01087905|ACTIVE_COMPARATOR|2 Weeks of Nicotine Patch Only plus CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling~2 Weeks of Nicotine patch dosed as follows:~If \> 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If \< or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks"
62446997|NCT01983020|EXPERIMENTAL|Lidocaine|Lidocaine infused at 0.5 mg/kg/hour.
62618661|NCT04990765|EXPERIMENTAL|Virtual Reality Cognitive Behavioral Therapy (VRCBT)|The VR exposure is performed to induce alcohol craving during the therapy session, in order to trigger a lifelike response to alcohol, while the therapist is present and able to train the participant in applying CBT-based coping strategies to deal with the alcohol cravings.
62446998|NCT01983020|EXPERIMENTAL|Ketamine and Lidocaine|Ketamine infused at 0.25 mg/kg/hour along with lidocaine at 0.5 mg/kg/hour
62446999|NCT01983020|PLACEBO_COMPARATOR|Placebo|Placebo (saline) given to compare usual treatment against active agents in post operative pain management.
62447000|NCT04884581|EXPERIMENTAL|GI Genius CADx device|
62447001|NCT02025114|EXPERIMENTAL|Capsule|The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
62447002|NCT00171496|EXPERIMENTAL|Cyclosporine microemulsion|
62447003|NCT00171496|ACTIVE_COMPARATOR|Tacrolimus|
62844432|NCT04097964|EXPERIMENTAL|FaCES Intervention|Primary care providers will deliver anticipatory guidance for adolescents reporting no drug, alcohol or marijuana use in past year, an abbreviated brief intervention for adolescents who report using these substances one or twice in the past year, and a full brief intervention for adolescents who report using these substances monthly or weekly in the past year.
62844433|NCT04097964|ACTIVE_COMPARATOR|Treatment as usual|Usual care will be delivered by primary care providers during the clinic visit
62844434|NCT05550688||NAFLD and NAFLD-free cohort|The investigators diagnosed nonalcoholic fatty liver based on abdominal ultrasonography and ruled out excessive alcohol consumption and other etiologies of liver disease according to the Chinese Liver Disease Association.
62844435|NCT01908803|EXPERIMENTAL|AL-60371/AL-817|AL-60371/AL-817 otic suspension, 200 μL in affected ear(s) through tympanostomy tube on Day 1 (Visit 1)
62844436|NCT01908803|ACTIVE_COMPARATOR|CIPRODEX|Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension, 4 drops in affected ear(s) twice daily through tympanostomy tube for 7 days
62844437|NCT02791503|EXPERIMENTAL|IRE group|FOLFIRINOX + IRE For patients diagnosed with LAPC, a combination of chemotherapy plus local tumor destruction using irreversible electroporation (IRE), a novel tumor ablation technique, has recently shown great promise. IRE is based on permeabilization of the cell membrane through electrical pulses leading to apoptosis. Theoretically, IRE only affects viable tumor tissue, leaving surrounding vital structures relatively intact. It is therefore considered to cause less morbidity than thermal ablative strategies.
62844438|NCT02791503|ACTIVE_COMPARATOR|SABR group|FOLFIRINOX + SABR Focal therapy using external beam radiation therapy (EBRT) may further improve survival, but outcome remains poor. Stereotactic ablative radiotherapy (SABR) is a form of EBRT that has important advantages over conventional radiotherapy such as a more precise and greater biological dose delivery and hence less toxicity and presumably better outcome.
62844439|NCT03641404|EXPERIMENTAL|Ergothioneine|Subjects will consume 25mg ergothioneine (capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.
62844440|NCT03641404|PLACEBO_COMPARATOR|Placebo|Subjects will be given placebo (99% microcrystalline cellulose, 1% magnesium stearate; capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.
62844441|NCT01146717|EXPERIMENTAL|Exercise|
62844442|NCT01146717|PLACEBO_COMPARATOR|Control group|
62844443|NCT03111628|OTHER|Omalizumab|Omalizumab 300mg every month for 3 doses
62844444|NCT01765972|OTHER|Test 1/Spectacles/Test 2/Test 3|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 1 (etafilcon A with Lacreon), spectacles, TEST 2 (etafilcon A with Lacreon with print) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.
62844445|NCT01765972|OTHER|Test 2/Test 3/ Spectacles/Test 1|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 2 (etafilcon A with Lacreon with print), TEST 3 (etafilcon A with print), spectacles and TEST 1 (etafilcon A with Lacreon) in both eyes for 8 +/-1 hours.
62844446|NCT01765972|OTHER|Test 3/Test 1/ Test 2/ Spectacles|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 3 (etafilcon A with print), TEST 1 (etafilcon A with Lacreon), TEST 2 (etafilcon A with Lacreon with print) and spectacles in both eyes for 8 +/-1 hours.
62844447|NCT01765972|OTHER|Spectacles/Test 2/Test 1/Test 3|Subjects assigned randomly to this arm will wear the study lenses sequentially as spectacles, TEST 2 (etafilcon A with Lacreon with print), TEST 1 (etafilcon A with Lacreon) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.
62844448|NCT00538811|EXPERIMENTAL|1|Interferon alpha, ribavirin, interferon gamma
62844449|NCT00538811|ACTIVE_COMPARATOR|2|Interferon alpha, ribavirin, amantadine
62844450|NCT03643068|EXPERIMENTAL|KSP-QRH-E3-IRDye800 (Peptide 919288G) 0.6 mg subjects 1-3|The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.6 mg of KSP-QRH-E3-IRDye800 (Peptide 919288G) total. For the first three subjects, 3.34 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)will be discarded. The 1.66 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)remaining in the syringe will be administered by squirting it into the mouth of the subject.
62844451|NCT03643068|EXPERIMENTAL|KSP-QRH-E3-IRDye800 (Peptide 919288G) 1.8 mg subjects 4-25|Following a safety review of the first three subjects receiving 0.6 mg dose, the remaining 22 subjects will receive the full 1.8 mg dose of KSP-QRH-E3-IRDye800 (Peptide 919288G) reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
62844452|NCT00672503||1|Patients who acquired a CA-UTI in the PICU between 2004-2007.
62447004|NCT05657093|ACTIVE_COMPARATOR|Beetroot juice|The swimmers ingested a shot of Beet-It 70 ml beetroot juice (BJ)) 3 hours before undergoing a 2x6x100m crawl intermittent maximal speed performance test.
62844453|NCT00672503||2|Patients who did not acquire a CA-UTI while hospitalized in the PICU but had an indwelling urinary catheter between 2004-2007.
62844454|NCT00672503||A|Nurses currently employed in the PICU at Children's Mercy Hospital.
62844455|NCT00672503||a|Root Cause Analysis on all patients who acquired a CA-UTI during 2009.
62844456|NCT03550352|EXPERIMENTAL|1) THC and CBD combined|TN-TC11M2 oral capsules (THC 2.5 mg / CBD 2.5 mg)
62844457|NCT03550352|EXPERIMENTAL|2) CBD alone|TN-C200M2 oral capsules (CBD 200 mg)
62844458|NCT03742752|EXPERIMENTAL|Enteral Nutrition (EN)|"To demonstrate the superiority of EN versus TPN in the treatment of postoperative upper GI anastomotic leak (PUGIAL) after upper GI surgery (including esophageal, gastric, duodenal, pancreatic and obesity surgery).~Patients will be randomized to receive EN through jejunostomy or nasojejunal tube until oral diet covering at least 60% of their daily requirement"
62844459|NCT03742752|ACTIVE_COMPARATOR|Parenteral Nutrition (TPN)|Patients will be randomized to receive TPN through central venous access, piccline or totally implantable venous access port tube until oral diet covering at least 60% of their daily requirement
62844460|NCT00575640|ACTIVE_COMPARATOR|1|"The objective of this study is to determine the MTD for Hydralazine added to standard neoadjuvant chemotherapy for operable recta cancer. Four dose levels of hydralazine are planned:~Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID"
62618662|NCT04990765|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT)|CBT is made up of the following elements: i) recognition (ii) avoiding and (iii) overcoming drinking cravings in high-risk situations with the aim of preventing relapse.
62262353|NCT01087905|ACTIVE_COMPARATOR|2 Wks Nicotine Patch+Nic Gum, No CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~2 Weeks of Nicotine patch dosed as follows:~If \> 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If \< or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks~2 Weeks of Nicotine gum dosed as follows:~If \< 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
62262354|NCT01087905|ACTIVE_COMPARATOR|2 Wks Nicotine Patch+Nic Gum plus CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling~2 Weeks of Nicotine patch dosed as follows:~If \> 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If \< or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks~2 Weeks of Nicotine gum dosed as follows:~If \< 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
62262355|NCT01087905|ACTIVE_COMPARATOR|6 Weeks of Nicotine Patch Only, No CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~6 Weeks of Nicotine patch dosed as follows:~If \> 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If \< or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks"
62447005|NCT05657093|PLACEBO_COMPARATOR|Placebo|The swimmers ingested a shot of Beet-It (70 ml placebo (PL)) 3 hours before undergoing a 2x6x100m crawl intermittent maximal speed performance test.
62618663|NCT04242485|OTHER|AFTER MATCH + OMT|Players undertook a recording session the day after a rugby match and received osteopathic manipulative treatment
62618664|NCT04242485|OTHER|AFTER MATCH + sham treatment|Players undertook a recording session the day after a rugby match and received sham treatment
62618665|NCT04242485|OTHER|NO MATCH + OMT|Players undertook a recording session the day after a resting day and received osteopathic manipulative treatment
62844461|NCT03266016|EXPERIMENTAL|REDvent-acute|Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 \> 90%), and undergoes a Spontaneous Breathing Trial (SBT). Patients will be managed with pressure control plus pressure support ventilation using a computerized decision support tool that will recommend changes to ventilator settings approximately every 4 hr (with or without a new blood gas). If the patient is spontaneously breathing, it will incorporate real-time measures of effort of breathing (esophageal manometry) to keep it in a target range.
62262356|NCT01087905|ACTIVE_COMPARATOR|6 Weeks of Nicotine Patch Only plus CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling~6 Weeks of Nicotine patch dosed as follows:~If \> 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If \< or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks"
62447006|NCT04915807||Prospective population|The target group for the purpose of prospectively collecting the clinical data (RWD) of patients using ramucirumab/paclitaxel as 2nd-line chemotherapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
62447007|NCT04915807||Historical retrospective population|The target group for the purpose of retrospectively collecting the clinical data (RWD) of patients who have failed platinum-based palliative first-line therapy, and who started the following second-line therapy: taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy, before May 1, 2018, when health insurance coverage for the ramucirumab/paclitaxel combination therapy started in South Korea.
62447008|NCT06460974|EXPERIMENTAL|stress ball group|A stress ball was applied to the patients in the stress ball group during chemotherapy treatment
62447009|NCT06460974|NO_INTERVENTION|Control group|Standard care without any additional application
62447010|NCT05895370|EXPERIMENTAL|HPV-T|Participants in the 2 dose groups will receive HPV-T injections of 5×10\^9 and 1.5×10\^10 cells intravenously each time.
62447011|NCT03172637||Group A|50 female end stage renal disease patients
62447012|NCT03172637||Group B|50 normal female patients
62447013|NCT03833596|ACTIVE_COMPARATOR|Standard course CS with Regular Food|40 mg a day of oral Prednisone for 2 weeks with subsequent taper of daily dose by 5 mg per week.
62447014|NCT03833596|EXPERIMENTAL|Standard course CS with EEN|40 mg a day of oral Prednisone for 2 weeks and taper of daily dose by 5 mg per week and Exclusive Enteral Nutrition for 6 weeks.
62844462|NCT03266016|PLACEBO_COMPARATOR|Control-acute|Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 \> 90%), and undergoes a Spontaneous Breathing Trial (SBT). Ventilator management will be per usual care until the patient meets weaning criteria and passes the oxygenation test.
62844463|NCT03266016|EXPERIMENTAL|REDvent-weaning|Weaning Phase: The weaning phase is defined as the time from the first Spontaneous Breathing Trial (SBT) until the patient successfully passes an SBT or is extubated (whichever comes first). Patients who pass the initial SBT at the end of the acute phase will not undergo weaning phase randomization. Patients will be managed in a pressure support/CPAP mode of ventilation with assessments or changes to the level of pressure support every 4 hours, targeting maintaining effort of breathing (esophageal manometry) in a normal range. An SBT will be conducted daily, and the weaning phase will continue until the patient passes the SBT.
62618666|NCT04242485|OTHER|NO MATCH + sham treatment|Players undertook a recording session the day after a resting day and received sham treatment
62058800|NCT02998814|ACTIVE_COMPARATOR|etch-and-rinse adhesive|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch-and-rinse adhesive will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Then, etch-and-rinse adhesive (Single BondTM, 3M ESPE) will be treated with for 10 seconds followed by light curing for 20 seconds.Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
62058801|NCT02998814|ACTIVE_COMPARATOR|self-etch adhesive after acid-etch|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for acid etch + self-etch adhesive will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Then, self-etch adhesive (AdperTM EasyBond, 3M ESPE) will be treated with for 10 seconds followed by light curing for 20 seconds.Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
62618667|NCT00348335|ACTIVE_COMPARATOR|1: Restasis|
62618668|NCT00348335|ACTIVE_COMPARATOR|2: Refresh Endura|
62618669|NCT03795662||Community-acquired pneumonia|Adults over 18 years old admitted with confirmed community-acquired pneumonia.
62618670|NCT00744406|EXPERIMENTAL|1|
62618671|NCT00744406|EXPERIMENTAL|2|
62618672|NCT00744406|EXPERIMENTAL|3|
62618673|NCT03816007|EXPERIMENTAL|Yoga and Mantram Repetition|An existing yoga intervention designed for persons with chronic pain will be augmented with training in mantram repetition. The intervention meets 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
62618674|NCT03816007|ACTIVE_COMPARATOR|Relaxation/Health Education|A relaxation intervention used previously as a comparator intervention will be delivered by a health educator.
62618675|NCT02946021|EXPERIMENTAL|Pneumatic Compression-1 session per day|Head and neck garments for pneumatic compression device for treatment of lymphedema (1 session per day) with imaging using NIRFLI with ICG (Indocyanine green).
62618676|NCT02946021|EXPERIMENTAL|Pneumatic Compression-2 sessions per day|Head and neck garments for pneumatic compression device for treatment of lymphedema (2 sessions per day) with imaging using NIRFLI with ICG (Indocyanine green).
62618677|NCT06108583|EXPERIMENTAL|Experimental group|"The experimental group received intervention with TEAlimento program. The intervention combines parent training in both group and individual sessions, as well as group sessions with children.~The program is made up of 12 sessions, focuses on parent training and uses video-modeling. Additionally, a post-group individual session is conducted three months after the intervention. Sessions are held weekly, combining group (1.5 h) with individual (1 h) sessions. During group sessions, caregivers attend a parent training session, which is focused on teaching strategies based on the principles of behavior intervention and specific techniques related to eating. Simultaneously, children attend a group session in a separate room to target sensory issues and receive oral-facial stimulation. Individual sessions are held only with caregivers in order to individualize strategies to target the needs of each child. Each group includes from 3 to 5 participants."
62618678|NCT06108583|NO_INTERVENTION|Control group|"The control group included participants in a waiting list. These families completed questionnaires at baseline and three months later (same time points as the experimental group), but they did not receive intervention during this period.~Intervention was provided afterwards, but data after participating in the program was not included in this study."
62618679|NCT04725123|EXPERIMENTAL|Clostridioides difficile infection|Stool of patients with Clostridioides difficile infection that will be subject to microbiome analysis. Comparisons will be done between patients with favorable and unfavorable outcome
62618680|NCT04934982|EXPERIMENTAL|1|the group of LRH
62058802|NCT02437825|EXPERIMENTAL|octreotide treatment|The studied drug Octreotide 100 mcg will be administered I.V in the evening prior to surgery and for two weeks on a thrice daily basis.
62058803|NCT02437825|PLACEBO_COMPARATOR|placebo treatment|plasebo will be administrated I.V in the evening prior to surgery and two weeks on a thrice daily basis
62058804|NCT04731155|ACTIVE_COMPARATOR|standard group|
62058805|NCT04731155|EXPERIMENTAL|experiment group|
62058806|NCT03816995|ACTIVE_COMPARATOR|Alexis O Wound Protector|Participants will undergo standard surgical procedure using the Alexis O wound protector.
62262357|NCT01087905|ACTIVE_COMPARATOR|6 Wks Nicotine Patch+Nic Gum, No CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~6 Weeks of Nicotine patch dosed as follows:~If \> 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If \< or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks~6 Weeks of Nicotine gum dosed as follows:~If \< 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
62262358|NCT01087905|ACTIVE_COMPARATOR|6 Wks Nicotine Patch+Nic Gum plus CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling~6 Weeks of Nicotine patch dosed as follows:~If \> 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If \< or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks~6 Weeks of Nicotine gum dosed as follows:~If \< 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
62262359|NCT03058042|EXPERIMENTAL|Home pelvic floor muscle training|Patients will perform strength training of the pelvic floor muscles daily at home. The training protocol consists of three sets of 30 slow contractions (type I muscle fibers), with maintenance contraction according to the initial evaluation, followed by three rapid contractions (type II muscle fibers) after each slow contraction. The protocol will account for 90 contractions of the pelvic floor muscles per day. At the end of one month, the patients will return for consultation, in which the MAP evaluation and training progression will be performed.
62262360|NCT03058042|SHAM_COMPARATOR|Outpatient pelvic floor muscle training|The patients will perform 24 outpatient sessions of pelvic floor muscle strength training and home training. The training protocol consists of three sets of 30 slow contractions (type I muscle fibers), with maintenance contraction according to the initial evaluation, followed by three rapid contractions (type II muscle fibers) after each slow contraction. The protocol will account for 90 contractions of the pelvic floor muscles per day. At the end of one month, the patients will perform the evaluation of the MAP and progression of the training.
62262361|NCT03930719||PSD|Patients fulfilling DSM-5 criteria of PSD within 7 days of admission.
62262362|NCT03930719||No PSD|Patients NOT fulfilling DSM-5 criteria of PSD within 7 days of admission.
62262363|NCT02587650|EXPERIMENTAL|Arm A (capmatinib)|Patients with MET fusion receive capmatinib PO BID on day 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
62262364|NCT02587650|EXPERIMENTAL|Arm B (ceritinib)|Patients with ALK fusion receive ceritinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
62618681|NCT04934982|ACTIVE_COMPARATOR|2|the group of ARH
62618682|NCT05124483|EXPERIMENTAL|Pfizer [Comirnaty]|To determine the immunogenicity 4-6 weeks after subcutaneous injection of a booster dose of 90 µg AKS-452X vaccine given at \>=3 months post-initial vaccination with the registered Pfizer \[Comirnaty\] vaccine.
62618683|NCT05124483|EXPERIMENTAL|Moderna [Spikevax]|To determine the immunogenicity 4-6 weeks after subcutaneous injection of a booster dose of 90 µg AKS-452X vaccine given at \>=3 months post-initial vaccination with the registered Moderna \[Spikevax\] vaccine.
62618684|NCT05124483|EXPERIMENTAL|Janssen [Ad26.COV2.S]|To determine the immunogenicity 4-6 weeks after subcutaneous injection of a booster dose of 90 µg AKS-452X vaccine given at \>=3 months post-initial vaccination with the registered Janssen \[Ad26.COV2.S\] vaccine.
62618685|NCT05124483|EXPERIMENTAL|AstraZeneca [Vaxzevria])|To determine the immunogenicity 4-6 weeks after subcutaneous injection of a booster dose of 90 µg AKS-452X vaccine given at \>=3 months post-initial vaccination with the registered AstraZeneca \[Vaxzevria\]) vaccine.
62058807|NCT03816995|EXPERIMENTAL|CleanCision Wound Protector|Participants will undergo standard surgical procedure using the CleanCision Wound Retraction and Protection System
62058808|NCT05226858||Trauma patients with suspected blunt traumatic aortic injury (BTAI)|All trauma patients with suspected BTAI at the emergency department who require both transesophageal echocardiography (TEE) and computed tomography angiography (CTA).
62058809|NCT02422719|EXPERIMENTAL|Radotinib|Radotinib treatement single arm
62618686|NCT02259699|EXPERIMENTAL|Decision Aid (PCOA)|PCOA will be designed to accomplish 2 objectives: 1) it will educate patients and allow them to assimilate information about the differences in outcomes and survival between IP and IV therapies; and 2) it will help patients make the difficult trade-offs between these two treatment options.
62844464|NCT03266016|PLACEBO_COMPARATOR|Control-weaning|Weaning Phase: The weaning phase is defined as the time from the first Spontaneous Breathing Trial (SBT) until the patient successfully passes an SBT or is extubated (whichever comes first). Patients who pass the initial SBT at the end of the acute phase will not undergo weaning phase randomization. Ventilator management will be per usual care. An SBT will be conducted daily, and the weaning phase will continue until the patient passes the SBT.
62844465|NCT06328413|EXPERIMENTAL|Photobiomodulation group|Photobiomodulation application at different extra and intraoral points for 60 seconds with a wavelength of 940 nm in repeated sessions after the extraction of third molar
62844466|NCT06328413|ACTIVE_COMPARATOR|Leukocyte and platelet-rich fibrin group|Leukocyte and platelet rich fibrin ( blood product centrifuged for 12 minutes at 2700rpm) application after third molar extraction, single session.
62844467|NCT05301114|EXPERIMENTAL|Intervention participants|Among patients who completed the social needs screening as a part of standard of care, all stage I-IV Black cancer survivors will be invited to participate in a six-month community health worker intervention. The community health worker will assess social needs and provide six months of support.
62844468|NCT00241189|EXPERIMENTAL|Rapamycin|Patients take oral rapamycin 6 mg daily (and dose adjusted to keep a serum trough level of 5-15 ng/ml) for one year
62844469|NCT00241189|ACTIVE_COMPARATOR|Methotrexate|Methotrexate 20 mg taken orally weekly for one year
62844470|NCT04857632|EXPERIMENTAL|Statins group|
62618687|NCT02259699|NO_INTERVENTION|UC (Standard care)|Standard pamphlets will be given to patients to educate them about IV and IV/IP therapies.
62618688|NCT00910546|EXPERIMENTAL|Implantation of gold marker|CT guided implantation of gold marker into early stage lung tumors. Extra 4DCT scans and fluoroscopies during planning and the 3 fraction radiotherapy course.
62618689|NCT02642783|OTHER|Descriptive analysis|panelists were asked to rate different sensory attributes for different laxative bowel cleansing solutions on a 15 cm line scale.
62618690|NCT02642783|OTHER|Acceptability test|panelists were asked to rate the acceptability of different laxative bowel cleansing solutions using the 9-point hedonic scale.
62618691|NCT00833014|EXPERIMENTAL|I|
62618692|NCT01043484|EXPERIMENTAL|A|Bevacizumab + Capecitabine + Radiotherapy
62618693|NCT01043484|ACTIVE_COMPARATOR|B|Capecitabine + Radiotherapy
62618694|NCT01461473|ACTIVE_COMPARATOR|Positive Airway Pressure|Participants randomized to standard clinical Positive Airway Pressure (PAP) treatment for Obstructive Sleep Apnea (OSA).
62618695|NCT01461473|ACTIVE_COMPARATOR|Oral Appliance|Subjects randomized to standard Oral Appliance (OA) treatment for Obstructive Sleep Apnea (OSA).
62618696|NCT05964010|ACTIVE_COMPARATOR|SBIRT-A-Standard|Standard adolescent-only approach to screening, brief intervention, and referral to treatment for adolescent substance use.
62618697|NCT05964010|EXPERIMENTAL|SBIRT-A-Family|Family-based approach to screening, brief intervention, and referral to treatment for adolescent substance use in which caregivers are systematically included in screening, intervention, and referral activities.
62618698|NCT03029026||Those patients for TAVR|Those patients who are undergoing TAVR (clinical decision) who are recruited at the Barts Heart Centre will undergo clinical echocardiography, research DPD scintigraphy and clinical TAVR work-up CT (with research post contrast acquisitions at 3-5 minutes), unless already performed prior to recruitment. Those patients undergoing TAVR (clinical decision) who are recruited at the John Radcliffe Hospital will undergo clinical echocardiography and research DPD scintigraphy only. N=150.
62618699|NCT03029026||Those patients for sAVR|Those patients who are undergoing sAVR (clinical decision) will undergo clinical echocardiography, research DPD scintigraphy, research CMR and endomyocardial biopsy at the time of surgery. N=50.
62844471|NCT04857632|NO_INTERVENTION|Control group|
62618700|NCT03029026||Those patients for medical management|Those patients who are decided for medical management (clinical decision) will undergo clinical echocardiography, research DPD scintigraphy and any other imaging as per work-up/trial prior to no intervention decision. N=50.
62618701|NCT05704179||Patients who undergo cesarean section|Obstetric comorbidity index will be calculated for all patients, obstetric quality of recovery score will be evaluated in postpartum period( on the first and second day postpartum)
62618702|NCT03102008|NO_INTERVENTION|2 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
62844472|NCT03284307|EXPERIMENTAL|Drug Administrated|Sedatives will be administered to participants while their brain activity is measured.
62262365|NCT02587650|EXPERIMENTAL|Arm C (regorafenib)|Patients with RET or BRAF fusion receive regorafenib PO QD on day 1-21. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
62844473|NCT05097040|EXPERIMENTAL|Acceptance and commitment therapy (ACT) group|A total of 7 ACT sessions individually guided by a trained coach through Zoom videoconferencing
62844474|NCT05097040|NO_INTERVENTION|Control group|Care as usual
62844475|NCT04120519|EXPERIMENTAL|TCD|thalidomide 100mg qn cyclophosphamide 300mg/m2 d1,8,15 dexamethasone 40mg d1,8,15,22
62844476|NCT00793013|EXPERIMENTAL|ARDS Net Low Tidal Volume|
62844477|NCT00793013|EXPERIMENTAL|APRV Ventilation|
62844478|NCT02525770|ACTIVE_COMPARATOR|acetabular liner in X3 polyethylene|acetabular in X3 polyethylene
62844479|NCT02525770|ACTIVE_COMPARATOR|acetabular liner in N2VAC® conventional polyethylene|hip replacement with acetabular liner in N2VAC® conventional polyethylene
62844480|NCT04301505|NO_INTERVENTION|control|Usual care.
62844481|NCT04301505|OTHER|Intervention 1|COPD management checklist will be delivered at the beginning of the study.
62058810|NCT01301274|ACTIVE_COMPARATOR|Hypotonic|Subjects in this arm will receive 0.45% NaCl/5% dextrose intravenous maintenance fluids.
62844482|NCT04301505|OTHER|Intervention 2|COPD management checklist will be delivered at the beginning of the study and repeated after 6 months.
62058811|NCT01301274|EXPERIMENTAL|Isotonic|Subjects in this arm will receive 0.9% NaCl/5% dextrose intravenous maintenance fluids.
62262366|NCT02587650|EXPERIMENTAL|Arm D (entrectinib)|Patients with NTRK1, NTRK2, NTRK3, OR ROS1 fusion receive entrectinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
62262367|NCT02345954|EXPERIMENTAL|Supracervical Hysterectomy and Sacropexy|Laparoscopic Supracervical Hysterectomy and Sacropexy
62262368|NCT02345954|EXPERIMENTAL|Hysteropexy|Laparoscopic Hysteropexy
62262369|NCT01690078||Cross sectional|Cross sectional study where subjects with PRS, micrognathia, or SGS will have a single study visit that will be scheduled within 14 days of a clinically indicated upper airway endoscopy. CT scans of the neck or maxillofacial CT will be obtained in all subjects. During upper airway endoscopy, airway measurements will be conducted. Cohort may include subjects who have previously undergone medical or surgical intervention for their airway obstruction, or who are currently undergoing multidisciplinary team management. The following data will be collected: clinical parameters, Obstructive Sleep Apnea (OSA)OSA-18 (quality of life) questionnaire, and lung function tests (subjects \> 4 years of age). Clinically indicated swallowing studies and voice evaluations will be collected.
62262370|NCT01690078||Longitudinal|The prospective, longitudinal cohort arm of the study is designed to describe the effects of treatment on clinical and computational model endpoints. This is performed in a subset of subjects with PRS, micrognathia, or SGS who are scheduled for clinically indicated upper airway endoscopy and who are scheduled to complete a definitive treatment course which necessitates multiple endoscopic evaluations and follow-up imaging. Subjects will have an entry visit comparable to the cross-sectional entry visit. Longitudinal subjects will have up to 3 additional study visits over a 12 to 15-month period.
62262371|NCT01690078||Normal Control Data|Normal de-identified control data is retrospectively collected from clinically indicated CT scans of the neck and maxillofacial CT scans in children less than 18 years of age.
62262372|NCT00074321|EXPERIMENTAL|Arm I|Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO QD on days 2-15. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62618703|NCT03102008|NO_INTERVENTION|3 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
62618704|NCT03102008|NO_INTERVENTION|4 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
62262373|NCT03080844|EXPERIMENTAL|Practice|Participants will be asked to delay time to smoking first cigarette of the day for up to two weeks.
62262374|NCT03080844|ACTIVE_COMPARATOR|No Practice|Participants will continue with their normal smoking behavior.
62262375|NCT05916027|NO_INTERVENTION|Control|Each participating clinic serves as its own control and as control for active clinics, in the stepped-wedge design. All clinics are inactive (no intervention) during the baseline period of three months.
62844483|NCT05804617|PLACEBO_COMPARATOR|Surgeon group|Dome-type morcellation performed by one skillful surgeon
62844484|NCT05804617|ACTIVE_COMPARATOR|Trainee group|Dome-type morcellation performed by trainees (residents) under supervision
62262376|NCT05916027|ACTIVE_COMPARATOR|Active|Active clinics are trained in the intervention object (the 15-method) prior to switching to the active group. Clinics are enrolled as active clinics (intervention) in four steps (4-5 clinics in each step). The intervention is implemented into the clinic, and the staff are free to use the intervention in everyday work.
62262377|NCT05382832|EXPERIMENTAL|A1 Group SCS|Botox Injection and the SCS Internal Pulse Generator turned on in sham-mode. Starting two weeks after the SCS implant
62262378|NCT05382832|EXPERIMENTAL|A1 Group Botox|Botox Injection and the SCS Internal Pulse Generator turned on in sham-mode. Starting two weeks after the SCS implant
62447015|NCT03833596|EXPERIMENTAL|Short course CS with EEN|40 mg a day of oral Prednisone for 3 days and taper of daily dose by 5 mg every 3 days and Exclusive Enteral Nutrition for 6 weeks.
62844485|NCT06252324|EXPERIMENTAL|submerged implant placement with healing abtument|"the implant was placed flush to the bone crest after anaesthesia and with no flap elevation.~A healing screw was positioned to have a transmucosal healing. the healing was removed after 3 months and cement restoration technique was performed in all cases."
62058812|NCT02013336|EXPERIMENTAL|MM-398 + cyclophosphamide|MM-398+cyclophosphamide
62058813|NCT03300570|EXPERIMENTAL|Arm A (dolcanatide)|Participants receive dolcanatide PO QD for 7 days.
62058814|NCT03300570|PLACEBO_COMPARATOR|Arm B (placebo)|Participants receive placebo PO QD for 7 days.
62262379|NCT05382832|PLACEBO_COMPARATOR|B1 Group SCS|Placebo Injection and Internal Pulse Generator turned on in the high-frequency working mode. Starting two weeks after the SCS implant
62262380|NCT05382832|PLACEBO_COMPARATOR|B1 Group Saline|Placebo Injection and Internal Pulse Generator turned on in the high-frequency working mode. Starting two weeks after the SCS implant
62262381|NCT05382832|EXPERIMENTAL|A2 Group SCS|Botox Injection and the SCS Internal Pulse Generator turned on in sham-mode. Starting at the 28th week of clinical trial investigation
62447016|NCT04784117||Subgroup 2016-2018|Subgroup before change of dispatcher protocol
62447017|NCT04784117||Subgroup 2019-2021|Subgroup after change of dispatcher protocol
62447018|NCT01136707||Patients with rheumatoid arthritis new to Orencia|
62447019|NCT06102629|EXPERIMENTAL|100 women undergoing surgery (laparoscopy / laparotomy) with presumed diagnosis of PCOS (|"1. We will take both blood and ovarian tissue samples used to diagnosis.~2. We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~3. Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment."
62058815|NCT04211415|EXPERIMENTAL|Part 1: DS-2741a Cohort 1, 5 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 5 mg.
62844486|NCT06252324|OTHER|Tissue level implant placement cover screw|"the implant was placed above the bone crest after anaesthesia and with no flap elevation.~A cover screw was positioned to have a tissue level healing. the screw was removed after 3 months and cement restoration technique was performed in all cases."
62058816|NCT04211415|EXPERIMENTAL|Part 1: DS-2741a Cohort 2, 15 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 15 mg.
62058817|NCT04211415|EXPERIMENTAL|Part 1: DS-2741a Cohort 3, 50 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 50 mg.
62618705|NCT03102008|EXPERIMENTAL|16 Sessions of Therapeutic Intervention|Participants receive 50 minute sessions weekly of therapeutic intervention (Unified Protocol for the Treatment of Emotional Disorders in Adolescents). Symptom change assessed weekly on the internet or before each session (via self- and parent-report questionnaires). At the end of treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
62618706|NCT01304290|NO_INTERVENTION|Control|
62844487|NCT06441916|EXPERIMENTAL|Dabigatran Etexilate Capsules 150 mg|Each capsule contains Dabigatran Etexilate 150 mg
62844488|NCT06441916|ACTIVE_COMPARATOR|Pradaxa®|Dabigatran Etexilate
62844489|NCT02191865|EXPERIMENTAL|Mild liver impairment|Patients with mild hepatic impaired function (Child-Pugh A)
62058818|NCT04211415|EXPERIMENTAL|Part 1: DS-2741a Cohort 4, 150 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 150 mg.
62844490|NCT02191865|EXPERIMENTAL|Moderate liver impairment|Patients with moderate hepatic impaired function (Child-Pugh B)
62844491|NCT02191865|EXPERIMENTAL|Healthy volunteers|Healthy control subjects
62844492|NCT05987410|EXPERIMENTAL|Nordic Walking (NW)|Nordic walking is a form of physical activity that originated in Finland and has gained popularity worldwide. It involves walking with the use of specially designed poles that resemble ski poles. This activity engages both the upper and lower body, making it a full-body workout. In summary, Nordic walking offers several benefits for cardiovascular individuals with Type II diabetes and those who are obese or overweight. These benefits include improved heart and lung function, better blood glucose control, weight management, low joint impact, muscle strengthening, improved balance and posture, and social engagement. However, it is important to consult with a healthcare provider before starting any new exercise program to ensure it is safe and suitable for individual health conditions and goals. Regular monitoring and adjustments by healthcare professionals can help optimize the benefits and ensure ongoing progress.
62844493|NCT05987410|ACTIVE_COMPARATOR|Standard Rehabilitation (SR)|A standard rehabilitation program for cardiovascular individuals with Type II diabetes and obesity/overweight typically involves a combination of cardiovascular exercise, strength training, and education on lifestyle modifications. The program is prescribed by a cardiologist and supervised by physiotherapists or exercise specialists. It includes an initial assessment to determine exercise parameters, cardiovascular exercise to improve heart function and manage blood glucose levels, strength training to increase muscle mass and aid in weight management, education on nutrition and lifestyle modifications, and progress tracking and monitoring to optimize outcomes. These programs provide benefits such as improved cardiovascular fitness, better blood glucose control, weight management, enhanced muscle strength, and overall well-being.
62058819|NCT04211415|EXPERIMENTAL|Part 1: DS-2741a Cohort 5, 500 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 500 mg.
62058820|NCT04211415|EXPERIMENTAL|Part 1: DS-2741a Cohort 6, 1000 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 1000 mg.
62058821|NCT04211415|PLACEBO_COMPARATOR|Part 1: Placebo|Participants will be randomized to receive a single, subcutaneous injection of placebo.
62058822|NCT04211415|EXPERIMENTAL|Part 2: DS-2741a Cohort 1, X mg (based on results of Part 1)|Participants will receive a single, subcutaneous injection of DS-2741a X mg, where X mg will be based on the maximum tolerated dose identified in Part 1.
62058823|NCT04211415|EXPERIMENTAL|Part 2: DS-2741a Cohort 1, Y mg (based on results of Part 1)|Participants will receive a single, subcutaneous injection of DS-2741a Y mg, where Y mg will be based on the maximum tolerated dose identified in Part 1.
62058824|NCT04211415|EXPERIMENTAL|Part 3: DS-2741a Cohort 1, Z mg (based on results of Part 1)|Participants will be randomized to receive a receive a single, subcutaneous injection of DS-2741a Z mg, where Z mg will be based on the maximum tolerated dose identified in Part 1.
62618707|NCT01304290|EXPERIMENTAL|Glucose/Insulin Clamp|
62618708|NCT05259618||Patients with elevated alanine transaminase (ALT)|patients with alanine transaminase (ALT) \> 3x upper limit of normal (ULN).
62618709|NCT00695214|OTHER|1|OSA Patients considering surgical treatment
62618710|NCT00511654|EXPERIMENTAL|Subjects in Group 1 receiving GW823296|Subjects will receive single dose of GW823296 on Day 1 followed by a wash-out period of 1 week. The subjects will then be administered GW823296 for 28 days in the repeat dosing period.
62618711|NCT00511654|PLACEBO_COMPARATOR|Subjects in Group 1 receiving placebo|Subjects will receive single dose of placebo on Day 1 followed by a wash-out period of 1 week. The subjects will then be administered placebo for 28 days in the repeat dosing period.
62844494|NCT05987410|OTHER|Control Group (CG)|Cardiological counseling for cardiovascular individuals with Type II diabetes and obesity/overweight often includes recommendations for unsupervised aerobic physical activity. This type of counseling typically involves a cardiologist providing guidelines and recommendations for safe and effective exercise routines. In summary, it involves an initial assessment to determine exercise capacity and precautions. The cardiologist prescribes specific guidelines for unsupervised aerobic physical activity, including the type, frequency, intensity, and duration of exercise sessions. Safety considerations are provided. The benefits of unsupervised aerobic physical activity include improved cardiovascular health, enhanced blood glucose control, weight management, psychological well-being, and increased energy and stamina.
62844495|NCT04011358|OTHER|Patient|Patient with Retinal Vein Occlusion
62844496|NCT04011358|OTHER|Patient control|Patient with no Retinal Vein Occlusion
62844497|NCT06370429|EXPERIMENTAL|Progressive Relaxation Exercises|Progressive Relaxation Exercises, randomized pretest-posttest
62844498|NCT06370429|NO_INTERVENTION|control|Non-intervention
62447020|NCT06102629|NO_INTERVENTION|100 women undergoing surgery for gynaecological disorder|"1. We will take both blood and ovarian tissue samples used to diagnosis.~2. We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~3. Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment."
62844499|NCT00282308|EXPERIMENTAL|Rituximab + methotrexate (Group A)|Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.
62844500|NCT00282308|ACTIVE_COMPARATOR|Methotrexate (Group B)|Patients received methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.
62844501|NCT02705066|PLACEBO_COMPARATOR|Placebo (Cellulose)|
62844502|NCT02705066|EXPERIMENTAL|Cognizin 250 mg/day|
62844503|NCT02705066|EXPERIMENTAL|Cognizin 500 mg/day|
62844504|NCT05801341|EXPERIMENTAL|COVID-19 Positive Participants|Determined by NP PCR test
62058825|NCT04211415|PLACEBO_COMPARATOR|Part 3: Placebo|Participants will be randomized to receive a single, subcutaneous injection of placebo.
62262382|NCT05382832|EXPERIMENTAL|A2 Group Botox -after washout period|Botox Injection and the SCS Internal Pulse Generator turned on in sham-mode. Starting at the 28th week of clinical trial investigation
62618712|NCT00511654|EXPERIMENTAL|Subjects in Group 2 and 3 receiving GW823296|Subjects will receive single dose of midazolam on Day 1 followed by wash-out period of one day. Further the subjects will be administered GW823296 on Day 3 of single dose period followed by a wash-out period of 1 week. The subjects will then be administered a single dose of GW823296 for 28 days (Day 1 to Day 28 of repeat dosing period) and a single dose of midazolam on Day 29 of repeat dosing period.
62844505|NCT01802996|EXPERIMENTAL|Arm I|Magnesium Isoglycyrrhizinate Injection 200mg IV on days 1-5
62447021|NCT02534948|EXPERIMENTAL|Mindfulness and acceptance group therapy|The intervention group will consist of female participants who will be provided MABT in a group.The intervention will consist of 10 group therapy sessions. Each session will be conducted for 120 minutes.
62447022|NCT02534948|NO_INTERVENTION|wait list control group|The control group will be the waiting list control group will receive no interventions in the first stage.
62844506|NCT01802996|NO_INTERVENTION|Arm II|Only chemotherapy
62844507|NCT01350401|EXPERIMENTAL|NY-ESO-1/LAGE-1 and HLA-A*02 Positive Subjects|
62844508|NCT03565497|PLACEBO_COMPARATOR|Wellness Education Control Condition|The wellness education control condition (CC) is modeled after that used in our studies of exercise for smoking cessation, but delivered in an individual format. Content focuses on discussions of a variety of healthy lifestyle topics, such as healthy eating, time management, recommended health screenings, and cancer and cardiovascular prevention. Content is delivered using a combination of lectures, videos, handouts, and discussions while allowing participants to set their own realistic wellness goals, which they can gradually incorporate into their lives.
62844509|NCT03565497|EXPERIMENTAL|Mindfulness Training (MT)|Mindfulness training will be adapted for 6 individual sessions;elements include: (1) a body scan designed to teach participants to pay attention to specific parts of their bodies as a strategy to increase attentional capacities/reduce habitual mind-wandering; (2) non-judgmental awareness, and (3) 'awareness of breath' meditation, with an additional focus on helping participants become more aware of the present moment and refrain from habitually engaging in self-related pre-occupations concerning the future or the past.
62058826|NCT00158340|EXPERIMENTAL|1|Participants will receive guided self-help cognitive behavioral therapy
62058827|NCT00158340|ACTIVE_COMPARATOR|2|Participants will receive treatment as usual
62058828|NCT01758484|EXPERIMENTAL|Supportive care (palliative care support)|Patients undergo palliative care support before transplantation and at least once monthly while they remain at the transplant center.
62058829|NCT01840384|EXPERIMENTAL|Multi-micronutrients|Multi-micronutrients
62844510|NCT03565497|EXPERIMENTAL|Mindfulness Training Plus IE (MT+IE)|This condition will mirror the MT condition for the first 4 individual sessions, then for the final 2 individual sessions, MT will be rehearsed under conditions of sensations of anxiety/tension induced by interoceptive exposure procedures (IE).
62844511|NCT01753648|EXPERIMENTAL|hypertensive retinopathy|30 patients with hypertensive retinopathy stage 2 or 3
62844512|NCT01753648|EXPERIMENTAL|healthy controls|30 healthy age- and sex-matched controls
62262383|NCT05382832|PLACEBO_COMPARATOR|B2 Group SCS|Placebo Injection and Internal Pulse Generator turned on in the high-frequency working mode. Starting at the 28th week of clinical trial investigation
62844513|NCT06003348|ACTIVE_COMPARATOR|Potassium Citrate (Urocit®-K)|Potassium Citrate KCit 10 mEq 2 tabs, twice daily and Placebo 1 tab, twice daily Total Daily Dose: Citrate 40 mEq/d
62262384|NCT05382832|PLACEBO_COMPARATOR|B2 Group Saline -after washout period|Placebo Injection and Internal Pulse Generator turned on in the high-frequency working mode. Starting at the 28th week of clinical trial investigation
62262385|NCT03061175|EXPERIMENTAL|Arm I (Web-Based Contralateral Prophylactic Mastectomy CPM-DA)|Patients receive a website address, a secure username and password, and instructions for using the web-based Contralateral Prophylactic Mastectomy (CPM)- Decision Aid (DA).
62447023|NCT04409366|ACTIVE_COMPARATOR|Conventional Crown Lengthening; CCL|Using the surgical guide, submarginal internal bevel incisions were performed on the buccal aspect of the affected teeth. A full-thickness flap was raised up to the mucogingival junction (Dominguez et al., 2020). Ostectomy and osteoplasty were carried out by means of rotatory instruments and surgical chisels, as necessary, to achieve the necessary space between the bone crest and the restorative margin according to the presurgical plan. The CEJ was not the reference point since, in many cases, the position of the final margin of the restoration was planned apical to the actual position of the CEJ. Exposed root surfaces were carefully instrumented manually with curettes and, finally, vertical internal mattress sutures were placed to position the gingival margin at the level of the margin of the planned restoration. Sutures were removed after 7 days.
62618713|NCT00511654|PLACEBO_COMPARATOR|Subjects in Group 2 and 3 receiving placebo|Subjects will receive single dose of midazolam on Day 1 followed by wash-out period of one day. Further the subjects will be administered placebo on Day 3 of single dose period followed by a wash-out period of 1 week. The subjects will then be administered a single dose of placebo for 28 days (Day 1 to Day 28 of repeat dosing period) and a single dose of midazolam on Day 29 of repeat dosing period.
62618714|NCT03092791|EXPERIMENTAL|Adult Lead-in Cohort: sIPV High Dose|Sabin-based inactivated poliomyelitis vaccine (sIPV) containing 3, 100, and 100 D-Ag units (DU) of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
62844514|NCT06003348|EXPERIMENTAL|Super CitriMax; OHCit-standard dose|Super CitriMax 7 mEq 3 tabs, twice daily Total Daily Dose: OHCit 42 mEq/d
62844515|NCT06003348|EXPERIMENTAL|Super CitriMax; OHCit-low dose|Super CitriMax 7 mEq 2 tabs, twice daily And Placebo 1 tab, twice daily Total Daily Dose: OHCit 28 mEq/d
62844516|NCT06003348|PLACEBO_COMPARATOR|Placebo|Placebo 3 tablets twice daily Total Daily Dose: None
62844517|NCT04229537|EXPERIMENTAL|SCT-I10A combined SCT200 in ESCC|SCT-I10A: 200 mg intravenous (IV) on Day 1 of Q3W. SCT200: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W
62844518|NCT04229537|EXPERIMENTAL|SCT-I10A combined SCT200 in CRC|SCT-I10A: 200 mg intravenous (IV) on Day 1 of Q3W. SCT200: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W
62844519|NCT04229537|EXPERIMENTAL|SCT-I10A combined SCT200 plus Chemotherapy in CRC|"SCT-I10A: 200 mg intravenous (IV) on Day 1 of Q3W. SCT200: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W.~Chemotherapy: Capecitabine and Oxaliplatin."
62058830|NCT01840384|PLACEBO_COMPARATOR|Maltodextrin and Lactose|Placebo contained maltodextrin and lactose
62058831|NCT00691925||1|bilateral post refractive surgery subject
62447024|NCT04409366|EXPERIMENTAL|Two-stage Crown Lengthening (SCL)|In the first surgical intervention, intrasulcular incisions were performed and a full thickness flap was raised up to the mucogingival junction. Ostectomy and osteoplasty were performed to establish the space for supracrestal tissue attachment, following the restorative plan and using the presurgical blueprint as the reference to determine the final position of the restoration margin, instead of the CEJ (Lee, 2004). Then the flaps were repositioned and secured with internal mattress sutures, placing the gingival margin at the original level. Sutures were removed at 7 days. In the second stage, after 3-4 months, minor gingival recontouring was performed, if necessary, to attain the desired gingival margin position according to the presurgical plan
62618715|NCT03092791|PLACEBO_COMPARATOR|Adult Lead-in Cohort: Placebo|Placebo, intramuscular injection on Day 1.
62618716|NCT03092791|EXPERIMENTAL|Toddler Lead-in Cohort: sIPV High Dose|sIPV containing 3, 100, and 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
62618717|NCT03092791|ACTIVE_COMPARATOR|Toddler Lead-in Cohort: Reference IPV|Reference IPV, intramuscular injection on Day 1.
62618718|NCT03092791|EXPERIMENTAL|Infant Dose Ranging Cohort: sIPV Low Dose|sIPV containing 0.75, 25, 25 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29, 57 and 365.
62262386|NCT03061175|EXPERIMENTAL|Arm II (Usual Care)|Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM.
62262387|NCT03957772|ACTIVE_COMPARATOR|Extrafascial injection|"Extrafascial injection of local anesthetic~Ultrasound guided supraclavicular plexus block with extrafascial injection of local anesthetic"
62447025|NCT03035279|EXPERIMENTAL|Arm A|SC-006 Dose regimen finding
62447026|NCT03035279|EXPERIMENTAL|Arm B|SC-006 Dose expansion
62844520|NCT04860388|ACTIVE_COMPARATOR|unilateral labially impacted maxillary canines|Distalization of the maxillary molars and/or protrusion of the maxillary and mandibular incisors made for creating sufficient space for impacted maxillary canines. After sufficient space for impacted maxillary permanent canine was obtained combine surgical-orthodontic treatment was performed via closed eruption technique. When the crown of the maxillary impacted canine was fully visible in the mouth, its bracket was inserted, and aligned within the dental arch. Posttreatment plaque index, gingival index, gingival bleeding index, probing depth, keratinized and attached gingival width and gingival thickness measurements of the impacted canines and controls were performed. The periodontal health of labially impacted maxillary canines compared with the contralateral canines that served as control teeth.
62618719|NCT03092791|EXPERIMENTAL|Infant Dose Ranging Cohort: sIPV Medium Dose|sIPV containing 1.5, 50, 50 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
62262388|NCT03957772|EXPERIMENTAL|Intrafascial injection|"Intrafascial injection of local anesthetic~Ultrasound guided supraclavicular plexus block with intrafascial injection of local anesthetic"
62262389|NCT01471782|EXPERIMENTAL|Blinatumomab|Blinatumomab was administered as a continuous intravenous (cIV) infusion at a constant daily flow rate over 4 weeks followed by a treatment-free interval of 2 weeks. Doses ranged between 5 and 30 µg/m²/day. Each participant received up to five cycles of treatment.
62844521|NCT04860388|ACTIVE_COMPARATOR|unilateral palatally impacted maxillary canines|Distalization of the maxillary molars and/or protrusion of the maxillary and mandibular incisors made for creating sufficient space for impacted maxillary canines. After sufficient space for impacted maxillary permanent canine was obtained combine surgical-orthodontic treatment was performed via closed eruption technique. When the crown of the maxillary impacted canine was fully visible in the mouth, its bracket was inserted, and aligned within the dental arch. Posttreatment plaque index, gingival index, gingival bleeding index, probing depth, keratinized and attached gingival width and gingival thickness measurements of the impacted canines and controls were performed. The periodontal health of palatally impacted maxillary canines compared with the contralateral canines that served as control teeth.
62844522|NCT06333119||individuals with stroke|
62058832|NCT03499522||Observational group|"80 patients with congenital coagulopathies (hemophilia A and B, and von Willebrand's disease), of legal age, will be included in the study. Patients will be recruited in six centers, from different regions of Spain.~The inclusion criteria to participate in the present study are patients: with a medical diagnosis of congenital coagulopathies (hemophilia A and B, or von Willebrand's disease); adults; in a prophylactic or on demand regimen with FVIII / FIX concentrates; and that they have signed the informed consent document.~On the other hand, those patients with: neurological or cognitive alterations that impede the comprehension of the questionnaires will be excluded from the study; inability to walk autonomously or with an orthosis; and without access to digital media to complement the measuring instruments."
62058833|NCT04307459||Coronavirus Infection|All patients admitted to the Respiratory Unit with SARS-CoV-2 infection and respiratory failure
62262390|NCT06199609||AVF group and TCC group|AVF and TCC are two different hemodialysis pathways
62262391|NCT06199609||Before AVF establishment and After AVF establishment|Evaluate and analyze the changes in cardiac structure and function before and after the establishment of AVF;
62262392|NCT06199609||Left atrial enlargement group and Left atrial normal group|Patients in the AVF group are divided into a left atrial enlargement group and a left atrial normal group based on whether the left atrium has expanded after the establishment of AVF
62262393|NCT06199609||Atrial fibrillation group and Non atrial fibrillation group|Divide AVF group patients into atrial fibrillation group and non atrial fibrillation group based on whether new atrial fibrillation occurs after AVF establishment
62447027|NCT03035279|EXPERIMENTAL|Arm C|SC-006 and ABBV-181 Combination escalation and expansion
62447028|NCT01741857|EXPERIMENTAL|human umbilical cord derived MSC|human umbilical cord derived MSC transplantation for SLE
62447029|NCT00387712|EXPERIMENTAL|Velocity based treadmill training|6 month of progressive treadmill walking with treadmill speed gradually progressed to meet the training heart rate goals for moderate intensity aerobic exercise, when hemiparetic gait velocity can no longer be safely progressed, incline is added to achieve the heart rate training goals.
62844523|NCT05337839|EXPERIMENTAL|Community-dwelling older adults receiving supervision|Group I; supervised home exercise group
62262394|NCT02267694|OTHER|Black raspberry powder|Black raspberry powder 25 grams once daily for 4 weeks. If tolerated, will increase to 25 grams twice a day for another 20 weeks. Total length of active treatment 24 weeks.
62447030|NCT00387712|EXPERIMENTAL|Duration based treadmill training|6 month of progressive treadmill walking with duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress.
62447031|NCT05924256|EXPERIMENTAL|Arm 1|This arm for HER2-alteration salivray gland carcinoma.
62447032|NCT05924256|EXPERIMENTAL|Arm 2|This arm for AR-postive salivray gland carcinoma.
62447033|NCT05924256|EXPERIMENTAL|Arm 3|This arm for salivray gland carcinoma without HER-2 alteration or AR-postive.
62447034|NCT05924256|EXPERIMENTAL|Arm 4|This arm for low HER2 expression salivray gland carcinoma.
62447035|NCT06484309|EXPERIMENTAL|Reflexology Group|"* Participants will sign an informed voluntary consent form during the active phase of labor,~* Group assignment will be made,~* Participant Information Form will be filled in,~* The study will continue if episiotomy is performed at birth; If episiotomy is not performed at birth, it will not be included in the study.~* Episiotomy repair will be performed by CG after anesthesia (5 ml lidocaine 2%) is applied in the 3rd stage of labor,~* Reflexology application will be performed during episiotomy repair,~* Evaluation with VAS will be performed before repair, during perineal repair (internal), during skin repair and immediately after the repair is completed,~* The McGill Pain Questionnaire will be completed 20 minutes after episiotomy repair."
62618720|NCT03092791|EXPERIMENTAL|Infant Dose Ranging Cohort: sIPV High Dose|sIPV containing 3, 100, 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
62844524|NCT05337839|ACTIVE_COMPARATOR|Community-dwelling older adults not supervised|Group II; unsupervised home exercise group
62844525|NCT01520610||CTT|Patients with cardiopathy of tako TSUBO.
62262395|NCT03295162|EXPERIMENTAL|Sepsis A Group|neonates diagnosed with Sepsis and will receive melatonin. 10 mg product as a total dose of 20 mg .together with conventional treatment of Neonatal sepsis
62262396|NCT03295162|SHAM_COMPARATOR|Sepsis B Group|neonates diagnosed with Sepsis and willnot receive melatonin., they will recieve only the conventional treatment of Neonatal Sepsis
62262397|NCT03295162|NO_INTERVENTION|Control|healthy neonates, in whom sepsis will be ruled-out on the basis of absence of any clinical or laboratory evidence suggestive of infection.
62262398|NCT04227509|EXPERIMENTAL|Experimental|Patients will be treated with pembrolizumab after concurrent chemoradiotherapy with cisplatin. Patients will be treated with up to 12 months (17 cycles) of pembrolizumab until disease progression or recurrence.
62262399|NCT04227509|PLACEBO_COMPARATOR|Placebo|Patients will not be treated with pembrolizumab and will be treated with normal saline after concurrent chemoradiotherapy. Patients will be treated with up to 12 months (17 cycles) of pembrolizumab until disease progression or recurrence.
62262400|NCT01664559|PLACEBO_COMPARATOR|Placebo with 1cc normal saline IM|If the patient is randomized to the placebo arm, they will receive 1cc of normal saline via the intramuscular route.
62262401|NCT01664559|EXPERIMENTAL|Toradol, 30mg in 1cc IM|If the patient is randomized to the toradol (ketorolac) arm, they will receive 30mg of toradol in a 1cc volume via the intramuscular route.
62844526|NCT01520610||SCA|Patients with acute coronary syndrome but without Tako-TSUBO cardiomyopathy.
62844527|NCT01520610||Surgical stress|patients with stressful event (emergency postoperative patients) but without Tako-TSUBO cardiomyopathy.
62844528|NCT01917162|OTHER|Nelfilcon A/UltraFilcon B|Nelfilcon A contact lenses, followed by UltraFilcon B contact lenses. Each product worn bilaterally for one week in a daily wear, daily disposable modality.
62844529|NCT01917162|OTHER|UltraFilcon B/Nelfilcon A|UltraFilcon B contact lenses, followed by Nelfilcon A contact lenses. Each product worn bilaterally for one week in a daily wear, daily disposable modality.
62844530|NCT01814241|EXPERIMENTAL|Open label peanut OIT|Open label orally ingested peanut flour with maintenance dose of 1450mg
62844531|NCT01808105|OTHER|Human Milk|Reference group, breast feeding ad libitum
62844532|NCT01808105|ACTIVE_COMPARATOR|Control Formula|Ready to feed infant formula, feed ad libitum
62844533|NCT01808105|EXPERIMENTAL|Experimental Formula 1|Ready to feed infant formula with human milk oligosaccharides, feed ad libitum
62844534|NCT01808105|EXPERIMENTAL|Experimental Formula 2|Ready to feed infant formula with human milk oligosaccharides, feed ad libitum
62844535|NCT02804152|OTHER|CBT for Chronic Pain|single arm open-label design
62844536|NCT01017913|ACTIVE_COMPARATOR|Electrotherapy equipment|The TENS equipment was calibrated on 20 hertz frequency, and a pulse width of 330 ms with two channels.
62844537|NCT01017913|ACTIVE_COMPARATOR|electrotherapy equipment|The CI was adjusted with 4000 HZ bases frequency, modulation frequency range 20 HZ, ∆F10 HZ, slope 1/1 and quadripolar manner.
62262402|NCT06496282|EXPERIMENTAL|Lemborexant 5 mg|Lemborexant 5 mg 1 tab hs before bedtime
62262403|NCT06496282|PLACEBO_COMPARATOR|Placebo|Placebo of Lemborexant 5 mg 1 tab hs before bedtime
62262404|NCT01173224|EXPERIMENTAL|Cohort 2: 20 mg 10 days|Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg).
62844538|NCT01017913|NO_INTERVENTION|Control|The patients of the Control group stayed without any treatment in the same period
62844539|NCT05167643|EXPERIMENTAL|Trastuzumab injection+Piperacillil tablets+Letrozole tablets|Trastuzumab injection:Once in 21 days IVD；Piperacillil tablets:125mg qd (d1-21) PO；Letrozole tablets:2.5mg POqd；According to the current clinical guidelines combined with clinical practice, the treating physicians recommended the treatment plan to the subjects, and decided to enroll HR+/HER2+ advanced breast cancer patients treated with H combined with CDK4/6 inhibitor + AI±OFS into this study
62844540|NCT02501395||Patients with Kennedy disease|Men over 18 years old with confirmed Kennedy disease.
62262405|NCT01173224|EXPERIMENTAL|Cohort 3: 30 mg 1 day|Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
62262406|NCT01173224|EXPERIMENTAL|Cohort 1: 20 mg, 1 day|Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg).
62262407|NCT00823823|ACTIVE_COMPARATOR|Bivalved cast|Patients with a displaced distal radius or mid-diaphyseal forearm fracture requiring closed reduction will be immobilized in a bivalved cast
62262408|NCT00823823|ACTIVE_COMPARATOR|Circumferential cast|Patients with a displaced distal radius or mid-diaphyseal forearm fracture requiring closed reduction will be immobilized in a circumferential cast
62058834|NCT03790670|EXPERIMENTAL|Leukine Treatment|36 month regimen of Leukine administered as a weight-based dose at 3 µg/kg/day for 5 days (week), followed by a 2-day holiday (weekend)
62262409|NCT03527121|EXPERIMENTAL|R.I.C.E.+ (ESP physiotherapy)|Participants will receive a single session with advice and instructions from an ESP physiotherapist in rest, ice, compression and elevation AND pain guided early weight bearing plus a written home-based exercise program.
62262410|NCT03527121|ACTIVE_COMPARATOR|R.I.C.E.(Usual care)|A single session with advice and instructions from a physician in rest, ice, compression and elevation.
62262411|NCT04995055|EXPERIMENTAL|Period 1|Eligible subjects will be randomly assigned to contact lens wear sequence TEST/CONTROL in a bilateral fashion.
62262412|NCT04995055|EXPERIMENTAL|Period 2|Eligible subjects will be randomly assigned to contact lens wear sequence CONTROL/ TEST in a bilateral fashion.
62262413|NCT03479996|EXPERIMENTAL|Anesthetic|
62262414|NCT03479996|NO_INTERVENTION|Control|
62262415|NCT01810185|EXPERIMENTAL|Low dose naltrexone|Subjects in this arm will recieve low dose naltrexone (4.5 mg) daily for 12 weeks.
62262416|NCT01810185|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will recieve a placebo daily for 12 weeks.
62618721|NCT03092791|ACTIVE_COMPARATOR|Infant Dose Ranging Cohort: Reference IPV|Reference IPV, intramuscular injection on Days 1, 29 57 and 365.
62618722|NCT01569373||Post allogeneic SCT patients|Patients who have undergone an allogeneic stem cell transplant.
62618723|NCT04721639|EXPERIMENTAL|The experimental intervention (Sphinx Yoga Therapy)|In this group, participants will be intervened with Sphinx Yoga therapy which will take place in a conserved therapy center of Koohi Goth Hospital. This stretching exercise session will take place in the afternoon and for a duration of 10 minutes followed by 30 minutes therapy session five times per week (total 12 weeks).
62618724|NCT04721639|NO_INTERVENTION|The control intervention (Usual Care)|In this Group, participants won't be receiving any intervention and provided with the usual care.
62618725|NCT03376126||MI-ILP|
62618726|NCT02974803|EXPERIMENTAL|Dabrafenib and Trametinib|Dabrafenib, PO, 150mg BID Continuously Trameteinib, PO 2mg OD Continuously
62844541|NCT02501395||Healthy, voluntary controls|Gender and age matched healthy, voluntary controls.
62844542|NCT03146299|ACTIVE_COMPARATOR|Group A: TLH|
62844543|NCT03146299|ACTIVE_COMPARATOR|Group B: LAVH|
62844544|NCT05444491||MRD positive group|ColonAiQ polygene methylation test was performed on peripheral blood plasma samples from the enrolled patients 4 weeks after surgery. If gene methylation levels in the samples exceeded the threshold, the patients were enrolled in the MRD positive group. The 2-year total tumor recurrence rate of patients in the MRD positive group was calculated, and the positive prediction rate of postoperative plasma ctDNA methylation-MRD detection results for 2-year tumor recurrence rate after colorectal cancer radical resection was calculated.
62844545|NCT05444491||MRD negative group|ColonAiQ polygene methylation test was performed on peripheral blood plasma samples from the enrolled patients 4 weeks after surgery. If the gene methylation level detected in the samples did not exceed the threshold, the patients were enrolled in the MRD negative group. The 2-year total tumor recurrence rate of patients in the negative MRD group was calculated, and the negative prediction rate of postoperative plasma ctDNA methylation-MRD test results for 2-year tumor recurrence rate after radical resection of colorectal cancer was calculated.
62844546|NCT05709938|EXPERIMENTAL|Glargine|Glargine-regular insulin regimen
62262417|NCT02550184|EXPERIMENTAL|Ultrasonography findings unblinded|"Intervention group: Patients in this group will receive a focused ultrasonography examination of the heart and the lungs which will be performed by the investigator.~Intervention: The treating physician receives the results from the ultrasonographic examination (=unblinding of ultrasonography examination results)."
62844547|NCT05709938|ACTIVE_COMPARATOR|NPH|NPH- regular insulin regimen
62618727|NCT01554163|EXPERIMENTAL|Etoricoxib 30 mg|Etoricoxib, 30 mg tablet, orally, once daily for 12 weeks.
62618728|NCT01554163|ACTIVE_COMPARATOR|Celecoxib 200 mg|Celecoxib, 200 mg capsule, orally, once daily for 12 weeks.
62618729|NCT03170609|EXPERIMENTAL|Lowest dose formulation a|Multivalent group B streptococcus vaccine
62618730|NCT03170609|EXPERIMENTAL|Middle dose formulation a|Multivalent group B streptococcus vaccine
62618731|NCT03170609|EXPERIMENTAL|Highest dose formulation a|Multivalent group B streptococcus vaccine
62618732|NCT03170609|EXPERIMENTAL|Lowest dose formulation b|Multivalent group B streptococcus vaccine
62618733|NCT03170609|EXPERIMENTAL|Middle dose formulation b|Multivalent group B streptococcus vaccine
62618734|NCT03170609|EXPERIMENTAL|Highest dose formulation b|Multivalent group B streptococcus vaccine
62618735|NCT03170609|PLACEBO_COMPARATOR|Placebo|Saline control
62844548|NCT04066907|EXPERIMENTAL|Integrated Disease Management|Physicians randomized to intervention will attend a training session on the program standards and details of the IDM. Following the initial baseline interview a heart failure educator (HFE) will meet with subjects to obtain a detailed history of their HF, provide education, self-care management strategies (medication adherence, symptoms monitoring, dietary adherence, fluid restriction, exercise, weight management, smoking cessation) and review immunization status. A self-management action plan will be developed with the study physician and HFE to enable monitoring and management of HF by the participant.
62844549|NCT04066907|NO_INTERVENTION|Usual Care|Subjects will receive HF care as usually provided by their physician as advised or as needed. Study commitments for the control group include the initial interview, the expected time allotment for this initial visit is 1 hour. Telephone follow-up will occur at 3 months and 9 months to collect exacerbation data and maintain contact with participant. At 6 months and 12 months telephone follow-up will be conducted by the research assistant and the questionnaires will be completed.
62844550|NCT03344770|EXPERIMENTAL|Active rESWT|Application of 5,000 pulses of rESWT by a pneumatic generator, with 0.16mJ/mm2 (millijoule per squared millimeter) of energy at a frequency of 20Hz on the most painful spot of the knee. The applications will be given once a week for three weeks.
62844551|NCT03344770|SHAM_COMPARATOR|Sham rESWT|Application of 5,000 pulses of rESWT by a pneumatic generator, at a frequency of 20Hz on the most painful spot of the knee with 0 mJ/mm2 energy. The applications will also be given once a week for three weeks.
62618736|NCT02870764|ACTIVE_COMPARATOR|Dan-shen extract|Based on the standard medical care, 200mg of Danshenduofensuanyan, added into 250ml of 0.9% saline injection, given by continuous IV infusion at 2.5ml/min within 2 hours, once a day during the patients' hospitalization. Danshen drop spill (30 pill/day) taken orally for 60 days after discharge.
62618737|NCT02870764|PLACEBO_COMPARATOR|Placebo|Based on the standard medical care, placebo was 200mg of glucose, added into 250ml of 0.9% saline injection, given by continuous IV infusion at 2.5ml/min within 2 hours.
62618738|NCT00662987|PLACEBO_COMPARATOR|Group B|Received 3 days of amoxicillin followed by 4 days of placebo
62618739|NCT00662987|ACTIVE_COMPARATOR|Group A|Received 7 days of amoxicillin
62618740|NCT01482299|EXPERIMENTAL|RAD001 (everolimus)|
62618741|NCT02187029|EXPERIMENTAL|PF-06743649 dose level 1 (Cohort 1)|
62618742|NCT02187029|PLACEBO_COMPARATOR|Placebo for PF-06743649 (Cohort 1)|
62618743|NCT02187029|EXPERIMENTAL|PF-06743649 dose level 2 (Cohort 2)|
62618744|NCT02187029|PLACEBO_COMPARATOR|Placebo for PF-06743649 (Cohort 2)|
62618745|NCT02298036|EXPERIMENTAL|Remote Therapy Offered|Participants randomised to this arm receive 6-10 sessions of remote CBT
62844552|NCT02465099|ACTIVE_COMPARATOR|Electrocautery Dissection (ED)|Patients meeting the study criteria, scheduled to undergo posterior spinal fusion (PSF) using monopolar electrocautery and metal Cobb elevator (considered the current standard) for soft tissue dissection and removal from vertebral surfaces.
62844553|NCT02465099|EXPERIMENTAL|Ultrasonic Dissection (UD)|Patients meeting the study criteria, scheduled to undergo PSF using ultrasonic dissection and metal Cobb elevator for soft tissue dissection and removal from vertebral surfaces.
62844554|NCT00080236|PLACEBO_COMPARATOR|Donor organ placebo and Recipient placebo|
62844555|NCT00080236|ACTIVE_COMPARATOR|Donor organ: IDN-6556 (15μg/ml), Recipient: Placebo|
62844556|NCT00080236|ACTIVE_COMPARATOR|Donor organ: IDN-6556 (5 μg/ml), Recipient: IDN-6556 0.5 mg/kg|
62844557|NCT00080236|ACTIVE_COMPARATOR|Donor organ: IDN-6556(15 μg/ml), Recipient: IDN-6556 0.5 mg/kg|
62844558|NCT06518018||Study Group|HDR Brachytherapy + Immunotherapy + Chemotherapy Group
62844559|NCT06518018||Control Group|Immunotherapy + Chemotherapy Group
62844560|NCT04413682|EXPERIMENTAL|Supervised Exercise Group|One session per day, 3 days per week over a 12-weeks structured exercise program under supervision of a physical therapist.
62844561|NCT04413682|EXPERIMENTAL|Telerehabilitation Group|One session per day, 3 days per week over a 12-weeks structured exercise program through Telerehabilitation
62844562|NCT00098813|EXPERIMENTAL|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of unacceptable toxicity or disease progression.
62844563|NCT04140513|EXPERIMENTAL|Diagnostic (dPET)|Patients receive fludeoxyglucose F-18 via injection and undergo dPET over 20 minutes after standard of care computed tomography (CT) imaging (week -2), after receiving 20-26 Gy and 40-46 Gy of radiation (weeks 3 and 5), and 3 months after completion of treatment. Patients with concern for residual disease may receive an additional dPET 6 months after treatment.
62844564|NCT02462915|EXPERIMENTAL|i-gel, an brand of supraglottic airway device|a supraglottic airway devices with a gastric suction channel
62058835|NCT05670925|EXPERIMENTAL|Camrelizumab plus Famitinib with/without nab-palitaxel|
62844565|NCT02462915|EXPERIMENTAL|endotracheal tube|traditional use for protect airway during the surgery
62618746|NCT02298036|NO_INTERVENTION|Treatment as Usual|Participants do not receive remote therapy and remain in usual care
62844566|NCT05590858||non-diabetes|patients without diabetes
62844567|NCT05590858||well-regulated diabetes|patients with diabetes and HbA1c ≤ 7%
62844568|NCT05590858||poorly regulated diabetes|patients with diabetes and HbA1c \> 7%
62844569|NCT03983317|NO_INTERVENTION|Baseline|For the first week of the study, participants will not administer treatment with the Empower device. Participants will complete surveys to establish baseline values for each participant.
62844570|NCT03983317|EXPERIMENTAL|Active treatment|Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.
62058836|NCT05683717|EXPERIMENTAL|Dose Escalation for TT-01488|TT-01488 tablets will be administered once daily in a 28-day cycle in increasing strength in order to determine the recommended dose for dose expansion.
62844571|NCT01525225|EXPERIMENTAL|Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC|
62844572|NCT00299429|ACTIVE_COMPARATOR|MIDCAB Surgery|MIDCAB Surgery
62844573|NCT00299429|EXPERIMENTAL|PCI with drug-eluting stent|PCI with DES
62844574|NCT01812278|EXPERIMENTAL|ACT|Acceptance \& Commitment Therapy
62844575|NCT01812278|ACTIVE_COMPARATOR|CBT|Cognitive Behavioral Therapy
62844576|NCT06412614||"SSc patients without specific or associated autoantibodies (seronegative patients)"|
62844577|NCT06412614||SSc patients with specific or associated autoantibodies|
62844578|NCT06143137||Control group|Subjects in this group where randomized in the control group in the ReActiF-ICE study previously
62844579|NCT06143137||Therapy Group|Subjects in this group where randomized in the therapy group in the ReActiF-ICE study previously
62618747|NCT01793350|ACTIVE_COMPARATOR|BC-DN-01 topically applied cream, DPN|4g topically applied BC-DN-01 cream applied twice daily to each leg and foot, for 12 weeks
62844580|NCT02212184|SHAM_COMPARATOR|Control Group|Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
62844581|NCT02212184|EXPERIMENTAL|Intevention Group|"All patients will receive the Manual Diaphragm Release Technique, during 6 days of treatment. They will undertake four evaluations throughout treatment: before and immediately after the Day 1 (Baseline 1 and Post 1) and before and after Day 6 (Baseline 6 and Post 6).~In the other Days (2nd to 5th) patients will only receive the intervention and won't be evaluated."
62262418|NCT02550184|ACTIVE_COMPARATOR|Ultrasonography findings blinded|"Control group: Patients in this group will receive a focused ultrasonography examination of the heart and the lungs which will be performed by the investigator.~Active Comparator: The ultrasonographic examination results will remain blinded for the treating physician."
62262419|NCT01918007|ACTIVE_COMPARATOR|AT (adenotonsillectomy) Group|AT (adenotonsillectomy) immediately after the baseline study evaluation
62844582|NCT04630808|EXPERIMENTAL|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes
62844583|NCT04630808|ACTIVE_COMPARATOR|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes
62844584|NCT01761240|EXPERIMENTAL|MORAb-066 0.1 mg/kg|Participants will receive MORAb-066 0.1 milligram per kilogram (mg/kg), infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.
62844585|NCT01761240|EXPERIMENTAL|MORAb-066 0.3 mg/kg|Participants will receive MORAb-066 0.3 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.
62844586|NCT01761240|EXPERIMENTAL|MORAb-066 1 mg/kg|Participants will receive MORAb-066 1 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.
62844587|NCT01761240|EXPERIMENTAL|MORAb-066 2 mg/kg|Participants will receive MORAb-066 2 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.
62844588|NCT01761240|EXPERIMENTAL|MORAb-066 3 mg/kg|Participants will receive MORAb-066 3 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.
62844589|NCT05938699|ACTIVE_COMPARATOR|NCX 470 0.1%|NCX 470 0.1% - one drop in the randomized eye once a day for 8 days
62844590|NCT05938699|PLACEBO_COMPARATOR|Placebo|Artificial tears - one drop in the randomized eye once a day for 8 days
62618748|NCT01793350|PLACEBO_COMPARATOR|Placebo topically applied cream, DPN|4g topically applied cream applied twice daily to each leg and foot, for 12 weeks
62618749|NCT06494618|NO_INTERVENTION|Botulinum Toxin Injection and Conventional Therapy|The group received conventional therapy (such as stretching exercises) after Botulinum Toxin Type A Injection for spastic lower extremity muscle groups.
62618750|NCT06494618|ACTIVE_COMPARATOR|Botulinum Toxin Injection and Shockwave Therapy|The group received extracorporeal shockwave therapy conventional therapy (such as stretching exercises). Shockwave therapy is planned 3 sessions, starting first week after injection. It is planned to apply 1500 pulses, 4 hertz, 2 bars radial eswt to the injected spastic muscle groups in each session. The patients in this group will continue to their conventional therapy like the first group.
62618751|NCT00392756|NO_INTERVENTION|off treatment|Subjects undergo the baseline evaluation off treatment
62618752|NCT00392756|EXPERIMENTAL|GnRH Treatment|Subjects receive long term pulsatile GnRH therapy
62618753|NCT01048684|ACTIVE_COMPARATOR|20% Mannitol 0.7 g/kg (low-dose)|Study subjects will be randomized to receive an infusion of 20% mannitol 0.7g/kg over 30 minutes after induction of general anesthesia.
62618754|NCT01048684|EXPERIMENTAL|20% Mannitol 1.4 g/kg (high dose)|Study subjects will be randomized to receive an infusion of 20% mannitol 1.4 g/kg over 30 minutes after induction of general anesthesia.
62262420|NCT01918007|NO_INTERVENTION|Control Group|No AT (adenotonsillectomy) for 3 months after the baseline study evaluation
62262421|NCT06248281||Experimental group|The experimental group will attend a structured psychoeducational program developed to build and promote psychological flexibility. In combination with this, participants of this group will have to follow a head and neck cooling protocol. Also, participants of this group will be required to increase their habitual exercise levels and follow a video exercise program specifically designed for their needs and improve their nutrition based on the instructions of a nutritionist and videos specially designed for them.
62262422|NCT06248281||Control group|As per the study plan, the Control group has been designated as the control group. They will continue with their normal lifestyle without any participation in rehabilitation activities or programs.
62262423|NCT04509375||Study Group|Premature babies in the first 28 postnatal days of life, with less than 32 gestational weeks or less than 1500 grams of birth weight, with documented anemia by current accepted transfusion guidelines of Turkish Neonatal Society
62262424|NCT01589471|EXPERIMENTAL|Botox-A|Intra-rectal (or intra-colic) injection of 100 U of Botox-A
62262425|NCT02012985|EXPERIMENTAL|Oxabact OC5 capsules|The active study drug consists of Oxalobacter formigenes OC5 in enteric-coated size-4 capsules. The dose (not less than (NLT) 1E+09 colony forming units (CFU)) will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks.
62262426|NCT02012985|PLACEBO_COMPARATOR|Placebo capsules|The placebo study drug consists of microcrystalline cellulose in enteric-coated size-4 capsules. It has been manufactured to mimic the OC5 capsule. The dose will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks.
62262427|NCT04012554|EXPERIMENTAL|avoiding chest drainage tube placement after resection of lung|This group of patients underwent avoiding chest drainage tube placement after VATS of the lung.
62262428|NCT04012554|OTHER|indewlling chest drainage tube after resection of lung|This group of patients underwent indewlling chest drainage tube after VATS of the lung.
62618755|NCT04624607|EXPERIMENTAL|Transspinal-transcortical paired-associative stimiulation combined with robotic gait training|Robotic gait training will be administered along with paired non-invasive transspinal stimulation over the thoracolumbar region and non-invasive brain stimulation during assisted stepping.
62844591|NCT02380469|EXPERIMENTAL|Immediate intervention|Immediately after enrollment in the project, caregivers and patients receive the intervention
62618756|NCT04624607|EXPERIMENTAL|Transcortical-transspinal paired-associative stimiulation combined with robotic gait training|Robotic gait training will be administered along with paired non-invasive brain stimulation and non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping.
62058837|NCT05683717|EXPERIMENTAL|Dose Expansion for TT-01488|TT-01488 tablets will be administered once daily in 28-day cycles to verify the safety and preliminary efficacy as observed in the dose escalation cohorts.
62058838|NCT04345458|EXPERIMENTAL|group I|twice weekly 25 mg prefilled liquid etanercept
62058839|NCT04345458|EXPERIMENTAL|group II|once weekly 50 mg prefilled liquid etanercept
62058840|NCT04345458|ACTIVE_COMPARATOR|group III|25 mg twice weekly lyophilized etanercept powder
62058841|NCT04803578||Knee Arthroplasty Group|Subjects that received knee arthroplasty 2-3 days before admission to undergo a rehabilitation period in our rehabilitation hospital.
62058842|NCT04803578||Hip Arthroplasty Group|Subjects that received hip arthroplasty 2-3 days before admission to undergo a rehabilitation period in our rehabilitation hospital.
62618757|NCT03190785|EXPERIMENTAL|Benzoic acid washout and exposure|All subjects will be in this arm which employs a pre-post exposure design. Subjects will undergo a 2 week washout period where they avoid consumption of benzoate containing beverages. Then there is a 1 week exposure period comprising daily consumption of benzoate containing beverages to result in up to 5 mg/kg per day benzoic acid intake.
62058843|NCT04803578||Age-Matched healthy Group|Subjects age-matched with those included in the knee and hip group. Subjects are asked to walk at their self-selected speed and at low speed matchable with those of the knee and hip group
62058844|NCT03287414|EXPERIMENTAL|VAY736|Participants received 300 mg VAY736 administered subcutaneously every 4 weeks for 48 weeks on top of current standard-of-care therapy
62058845|NCT03287414|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered subcutaneously every 4 weeks for 48 weeks on top of current standard-of-care therapy
62618758|NCT05913596|EXPERIMENTAL|Patient with CaAMR|This is a multicenter, prospective, single arm clinical study. The study will enroll 15 renal transplant recipients with positive DSA and CaAMR confirmed by biopsy after renal transplantation. According to inclusion and exclusion criteria patients will be screened to participate in the trial.
62618759|NCT03545633|EXPERIMENTAL|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic System
62618760|NCT00968357|EXPERIMENTAL|SCV-07|Cohort 1: SCV-07 0.1 mg/kg. Cohort 2: 1.0 mg/kg per day administered SC
62618761|NCT01841801|ACTIVE_COMPARATOR|Marketed Thermal Adhesive Patch|Group of subjects wearing comparative predicate device for 8 hours daily for 7 days.
62618762|NCT01841801|EXPERIMENTAL|Thermal Adhesive Patch|Group of subjects wearing the experimental patch for 8 hours daily for 7 days.
62618763|NCT01841801|PLACEBO_COMPARATOR|Placebo Patch|Group of subjects wearing the placebo patch for 8 hours daily for 7 days.
62618764|NCT01924104|ACTIVE_COMPARATOR|Low Molecular Weight Heparin|Low molecular weight heparin, 2500 milli-International unit/day, subcutaneously
62058846|NCT01329354|EXPERIMENTAL|Autologous effector lymphocytes|
62058847|NCT02085681|EXPERIMENTAL|Tele-medicine|Tele-medicine aided retinal imaging and referral to eye hospital
62058848|NCT02085681|OTHER|Conventional Referral|Patients will be counselled on the importance of eye examination and will be referred to the eye hospital in the conventional manner.
62058849|NCT04394247||Breast Cancer Patients|HR + /HER2- Advanced/Metastatic Breast Cancer patients in U.S.A
62058850|NCT02628132|EXPERIMENTAL|Durvalumab and Paclitaxel|After one cycle of paclitaxel, durvalumab will be given concurrently with paclitaxel. Once paclitaxel cycles are completed, durvalumab will be continued alone until disease progression or unacceptable toxicity.
62058851|NCT02677025|EXPERIMENTAL|Young Women's Health CoOp (YWHC)|This is an adapted behavioral intervention for young women in Cape Town South Africa who dropped out of school, who use alcohol and other drugs and are at risk for HIV.
62058852|NCT02677025|ACTIVE_COMPARATOR|HIV Counseling/Testing|Provide age and gender appropriate standard HIV counseling and testing.
62058853|NCT05163613|EXPERIMENTAL|Patients with COVID - 19, who we were treated with magnetic stimulation.|"The study group included patients hospitalized due to PCR-confirmed SARS-Cov-2 infection, who were treated with magnetic stimulation in addition to a standard therapy.~Standard therapy used in all patients consisted of the use of pharmacological agents necessary to treat the viral infection (antiviral drugs, antibiotics, dexamethasone) and the inclusion of proper care, education, occupational therapy, self-service learning, breathing exercises and motor mobilization."
62058854|NCT05163613|EXPERIMENTAL|Patients with COVID - 19, who we were treated without magnetic stimulation.|The control group included patients receiving a comprehensive treatment without magnetic stimulation. The patients were in a moderately severe condition.
62058855|NCT00570024|ACTIVE_COMPARATOR|TA|Active TA
62262429|NCT02971462|EXPERIMENTAL|RIC group|Experimental: RIC group The upper limb ischemic conditioning is composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 1 month after stroke. In addition, all participants receive a standard clinical therapy.
62262430|NCT02971462|NO_INTERVENTION|Control group|The participants receive a standard clinical therapy after diagnosed ischemic stroke.
62618765|NCT01924104|ACTIVE_COMPARATOR|Low dose aspirin|Low dose aspirin, 75mg/day, orally
62618766|NCT01924104|ACTIVE_COMPARATOR|Heparin & Aspirin|Heparin (40 mg/day, subcutaneously) and aspirin (70 mg/day, orally)
62058856|NCT00570024|OTHER|AA|
62058857|NCT00570024|NO_INTERVENTION|Waiting Group|
62058858|NCT05199610|EXPERIMENTAL|Aumolertinib|single dose oral 55mg of aumolertinib
62058859|NCT06249763|EXPERIMENTAL|High gluten|Participants complete both study arms in a crossover design separated by a washout period.
62618767|NCT01924104|PLACEBO_COMPARATOR|Sodium chloride (NaCl)|Equivalent volume of NaCl 0.9%, subcutaneously
62618768|NCT00521885|ACTIVE_COMPARATOR|Arixtra (Fondaparinox) 2.5 mg SC Daily|Arixtra (Fondaparinox) 2.5 mg SC Daily
62618769|NCT00521885|ACTIVE_COMPARATOR|Lovenox 40mg SC Daily|Lovenox 40mg SC Daily
62844592|NCT02380469|OTHER|Delayed intervention (3 weeks later)|This group receives the same intervention as in the experimental group, but after the outcome assessment at 2 weeks
62262431|NCT04081636|ACTIVE_COMPARATOR|Systematic Transrectal biopsy (TR-Bx)|Ultrasound guided; needle inserted through the rectum to reach the prostate
62618770|NCT01520519|EXPERIMENTAL|Rituximab + PCI-32765|Rituximab (375 mg/m2) given intravenously (IV) on Day 1, Day 8, Day 15, and Day 22, then continued once every 4 weeks only on Days 1 during cycles 2 - 6. PCI-32765 started on Day 2 of cycle 1 at a dose of 420 mg (3 \* 140-mg capsules) orally daily and will be continued daily.
62618771|NCT03778060|EXPERIMENTAL|Transcutaneous stimulation|Participants in the clinical study will consist of subjects with essential tremor who are scheduled more than 3 months in advance to undergo deep brain stimulation surgery for treatment of essential tremor at Mayo Clinic. Subjects will wear a Cala TWO stimulator to reduce hand tremors.
62618772|NCT01982799|EXPERIMENTAL|Endododontic Tx + Long acting local anesthetic|long acting local anesthetic
62618773|NCT01982799|EXPERIMENTAL|Endodontic Tx plus local anesthetic|local anesthetic
62618774|NCT00039481|EXPERIMENTAL|Treatment (Oblimersen sodium, cytotoxic chemotherapy)|See detailed description.
62618775|NCT03337048|EXPERIMENTAL|Measurement of endpoints|"In healthy volunteers the endpoint are measured while spontaneous voiding of the bladder and while emptying the bladder using a standard intermittent catheter.~In subjects with spinal cord injury or enlarged prostata the endpoint are measured while emptying the bladder using a standard intermittent catheter."
62618776|NCT06172790|EXPERIMENTAL|Training Group|"The training group will undergo the Otago Exercise Program (OEP) in a hospital setting, supervised by a physiotherapist, with sessions lasting 60 minutes each, three days a week for a duration of 8 weeks.~Following the initial assessment, a patient education session will be conducted to provide information about the pathophysiology of the disease and the benefits of physical activity."
62058860|NCT06249763|PLACEBO_COMPARATOR|Gluten free|Participants complete both study arms in a crossover design separated by a washout period.
62058861|NCT03122054|OTHER|Group L (n:88)|patients treated surgically with laparoscopic cholecystectomy immediately
62058862|NCT03122054|OTHER|Group D (n:88)|patients first treated medically and than treated surgically with delayed (4-8 weeks later) laparoscopic cholecystectomy
62058863|NCT04230057||Healthy volunteer|"* In good general health and feeling well (no diagnosed disorders/illnesses)~* At least 18 years old~* BMI in the range of 18-29.9 kg/m²~* No known history of substance abuse~* No known allergies to food/drug"
62058864|NCT02891343|EXPERIMENTAL|Healthy volunteers|
62262432|NCT04081636|ACTIVE_COMPARATOR|Targeted Transrectal biopsy (TR-Bx)|MRI-guided; needle inserted through the rectum to reach the prostate
62262433|NCT04081636|EXPERIMENTAL|Systematic Transperineal biopsy (TP-Bx)|Ultrasound guided; needle inserted directly through the skin to reach the prostate
62618777|NCT06172790|NO_INTERVENTION|Control Group|Any intervention will not be performed. After the initial assessment, a patient education session will be conducted to provide information on the pathophysiology of the disease and the benefits of physical activity.
62618778|NCT04939844|EXPERIMENTAL|NDMM ineligible for transplant|"All participants will receive isatuximab in combination with bortezomib, lenalidomide and dexamethasone for 2 cycles, followed by isatuximab in combination with bortezomib and lenalidomide for 6 cycles, followed by isatuximab in combination with lenalidomide for 10 cycles, followed by continuous lenalidomide until disease progression. The cycle duration is 28 days.~* Isatuximab will be administered IV at a dose of 10 mg/kg~  * on D1, D8, D15 and D22 during Cycle 1~ * on D1 and D15 during Cycles 2-18~* Bortezomib will be administered SC at a dose of 1,3mg/m2~  -on D1, D8 and D15 during Cycles 1-8~* Lenalidomide will be administered PO at a dose of 25mg/day (15 mg/day in participants with GFR \<30mL/minute/1.73m2)~  -on D1 to D21 during all Cycles.~* Dexamethasone will be administered PO at a dose of 20 mg -on D1, D8, D15 and D22 during Cycles 1 and 2"
62618779|NCT01713296|EXPERIMENTAL|Pazopanib|
62058865|NCT01015976|EXPERIMENTAL|Post bariatric surgery|Roux en Y bariatric surgery
62058866|NCT01015976|OTHER|Control|No surgery
62058867|NCT06625073|EXPERIMENTAL|Empagliflozin|A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
62058868|NCT06625073|PLACEBO_COMPARATOR|Placebo|A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
62058869|NCT06347484|EXPERIMENTAL|Educational Text-Messages and Connection to Cardiovascular Research Opportunities|All participants who enroll in CONNECT, regardless of method of contact, will receive educational text messages and connection to cardiovascular research opportunities.
62262434|NCT04081636|EXPERIMENTAL|Targeted Transperineal biopsy (TP-Bx)|MRI-guided; needle inserted directly through the skin to reach the prostate
62844593|NCT01166880||Laser Speckle Imaging|Laser Speckle Imaging Infant Head Blood flow
62844594|NCT04130269||Patients with MCI|Patients with myocardial infarction (STEMI/NSTEMI) aged 19-90
62844595|NCT01391052|ACTIVE_COMPARATOR|Norethindrone acetate pretreatment|This arm will receive two cycles of norethindrone acetate before LVN IUS insertion.
62844596|NCT01391052|OTHER|No pretreatment|LVN IUS is placed without norethindrone acetate pretreatment.
62844597|NCT04550598|EXPERIMENTAL|HD-tCES|The experiment group will receive active HD-tCES.
62844598|NCT04550598|SHAM_COMPARATOR|Sham HD-tCES|The sham control group will receive sham HD-tCES.
62844599|NCT00093704|EXPERIMENTAL|Bortezomib + ganciclovir|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
62844600|NCT01133249||Total hip|all consented patients receiving total hip arthroplasty
62844601|NCT02640196|PLACEBO_COMPARATOR|Macintosh|The participants intubated the easy airway simulator with a double lumen tube using the Macintosh laryngoscope followed with intubating the difficult airway simulator
62844602|NCT02640196|PLACEBO_COMPARATOR|GlideScope|The participants intubated the easy airway simulator with a double lumen tube using the GlideScope laryngoscope followed with intubating the difficult airway simulator
62844603|NCT02640196|ACTIVE_COMPARATOR|Airtraq|The participants intubated the easy airway simulator with a double lumen tube using the Airtraq laryngoscope followed with intubating the difficult airway simulator
62844604|NCT02640196|ACTIVE_COMPARATOR|King Vision|The participants intubated the easy airway simulator with a double lumen tube using the King Vision followed with intubating the difficult airway simulator
62844605|NCT04653597|EXPERIMENTAL|Conservative airway management|decision to intubate will be withheld as long as the patient's state allows it. The patient will be closely monitored and decision of intubation will be made upon presence of regurgitation, seizure, shock, or sign of respiratory distress.
62844606|NCT04653597|OTHER|Routine practice|decision of intubation left at the discretion of the emergency physician
62844607|NCT05895019||Patients with Parkinson's disease|Patients with Parkinson's disease
62844608|NCT05895019||Non-Parkinson's patients|Non-Parkinson's patients
62844609|NCT04408781|EXPERIMENTAL|Ridge expansion by osseodensifcation|Ridge expansion and osteotomy drilling by osseodensifcation in conjunction with simultaneous implant placement in narrow ridges
62844610|NCT04408781|ACTIVE_COMPARATOR|Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
62844611|NCT05490550|ACTIVE_COMPARATOR|COAST-enhanced CBTI|Patients randomized to COAST will receive CBTI via the COAST platform, with the assistance of a licensed clinician via NOCTEM's digital sleep hub. Participants will utilize the COAST patient app on their smartphone for engagement in insomnia treatment and receipt of clinician's recommendations. COAST clinicians will utilize the COAST web-based portal for adherence monitoring, progress review, and for providing personalized insomnia treatment recommendations.
62844612|NCT05490550|ACTIVE_COMPARATOR|Military Treatment Facility Insomnia Care As Usual|Patients randomized to the ICAU arm will receive insomnia care as usual by a certified clinician at their respective site, according to current referral and treatment practices.
62844613|NCT02437708|EXPERIMENTAL|REP with L-PRF|The first REP session will be performed as described by Diogenes et al. (2013). For the second REP-session a venipunction will be performed before the endodontic treatment. 2 to 4 tubes of blood will be collected per tooth. These blood samples will be put into a centrifuge for 12 minutes at 2700 rpm. Fibrin clots will be collected after centrifugation and inserted in the root canal with endodontic pluggers. Medcem Portlandcement (GmbH, Swiss) will be used instead of mineral trioxide aggregate in the second session, to prevent tooth discoloration.
62844614|NCT02437708|ACTIVE_COMPARATOR|REP|A REP will be performed on immature infected permanent teeth, as described in the protocol of Diogenes et al. (2013). Medcem Portlandcement (GmbH, Swiss) will be used instead of mineral trioxide aggregate in the second session, to prevent tooth discoloration.
62844615|NCT04910841|EXPERIMENTAL|Connect|
62844616|NCT04344561|EXPERIMENTAL|Postural Positioning|Participants in the group will have hospital beds placed in 15 degree (reverse Trendelenburg).
62844617|NCT04344561|NO_INTERVENTION|Standard Care|Participants in this group will have beds managed per standard nursing protocol.
62844618|NCT03016000|EXPERIMENTAL|Thalidomide|Thalidomide 50mg daily by mouth( increase 50mg after 2 weeks if tolerated until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if the patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/day, thalidomide discontinuation was allowed.
62844619|NCT03016000|OTHER|Observation|Observation
62844620|NCT06516523|EXPERIMENTAL|PEMF and Bone Formation|Use of activated miniaturized device with PEMF
62844621|NCT06516523|PLACEBO_COMPARATOR|Control SHAM PEMF|Use of SHAM miniaturized device with PEMF (without Pulse)
62844622|NCT06516523|ACTIVE_COMPARATOR|Non-surgical treament of peri-implantitis with PEMF|USE of PEMF on the microbiome modulation and bone formation under inflammatory conditions
62058870|NCT06347484|ACTIVE_COMPARATOR|EHR-Informed Recruitment Sub-Study #1, Arm #1: Contact Method, Patient Portal Message|Potential participants will be identified using an EHR query and will be randomized to receive a recruitment message via the patient portal message. This message will invite the participant to join CONNECT.
62058871|NCT06347484|ACTIVE_COMPARATOR|EHR-Informed Recruitment Sub-Study #1, Arm #2: Contact Method, Email|Potential participants will be identified using an EHR query and will be randomized to receive a recruitment message via email. This message will invite the participant to join CONNECT.
62844623|NCT06516523|PLACEBO_COMPARATOR|Non-surgical treatment of peri-implantitis without PEMF|USE of SHAM (no PEMF) on the microbiome modulation and bone formation under inflammatory conditions
62844624|NCT00567398|ACTIVE_COMPARATOR|non glucose sparing|Dianeal only
62844625|NCT00567398|EXPERIMENTAL|Glucose sparing|Physioneal, Extraneal, Nutrineal
62844626|NCT04069897|EXPERIMENTAL|Botox injections towards SPG|Botulinum Toxin type A injections
62844627|NCT04069897|PLACEBO_COMPARATOR|Controls|Placebo injections
62618780|NCT03601156|EXPERIMENTAL|NATACE-RT|Patients receive Oxaliplatin 130mg/m2 intraarterial chemoembolization on day1, and then radiation ( 44 Gy/20 fractions/4 weeks, from day 7 to day 11, day14 to day 18, day 21 to day 25, day 28 to day 32) plus oral S-1 (BSA \< 1.25 mm2 receive 80 mg/day; 1.25 mm2 \< BSA \< 1.5mm2 recive 100 mg/day, BSA\>1.5mm2 receive120 mg/day, twice daily, from day 1 to day 28, every 4 weeks)
62618781|NCT03601156|ACTIVE_COMPARATOR|NACT-RT|Patients receive Oxaliplatin 130mg/m2 intravenous chemotherapy on day1, and then radiation ( 44 Gy/20 fractions/4 weeks, from day 7 to day 11, day14 to day 18, day 21 to day 25, day 28 to day 32) plus oral S-1 (BSA \< 1.25 mm2 receive 80 mg/day; 1.25 mm2 \< BSA \< 1.5mm2 recive 100 mg/day, BSA\>1.5mm2 receive120 mg/day, twice daily, from day 1 to day 28, every 4 weeks)
62844628|NCT03629496|EXPERIMENTAL|Arts-based intervention|Participants will participate in 6x1 hourly art sessions over a period of 3 weeks while they receive their haemodialysis treatment. This will involve 1:1 facilitation with a student and will involve visual arts including sketching, water colour painting and pen and ink, and creative writing activities. Participants will be provided with their own art supplies for infection control purposes and these will be kept on the unit in between sessions. Participants will have an option of displaying completed work in the reception area of the unit during their sessions.
62844629|NCT03629496|NO_INTERVENTION|Control|Participants will receive usual care during their haemodialysis sessions and will be asked not to engage in any creative writing or visual arts during their haemodialysis sessions for the duration of the study. Once data collection has been completed the participants in the control group will receive art supplies and a single facilitated session on haemodialysis for the purpose of equity.
62618782|NCT01556230||Group I|The first group of subjects, Group I, will be followed in Protocol I and are a group of subjects with an apparent clinically nonfunctioning pituitary lesion who will be studied in a prospective study of conservative non-surgical management.
62844630|NCT01585857|EXPERIMENTAL|Group 1|2 x 10E6 ASC intra-articular injection (5 ml)
62844631|NCT01585857|EXPERIMENTAL|Group 2|10 x 10E6 ASC intra-articular injection (5 ml)
62844632|NCT01585857|EXPERIMENTAL|Group 3|50 x 10E6 ASC intra-articular injection (5 ml)
62618783|NCT01556230||Group II|A second group of subjects, Group II, are subjects who are undergoing surgical intervention for CNFA or radiotherapy for CNFA and these subjects will be studied in a prospectively follow up as part of Protocol II.
62618784|NCT03102749||Normal weight|Included patients with a BMI \< 25 will be part of this group.
62618785|NCT03102749||Overweight|Included patients with a BMI \>= 25 and \<30 will be part of this group.
62618786|NCT03102749||Obese|Included patients with a BMI \>= 30 will be part of this group.
62844633|NCT01146743|ACTIVE_COMPARATOR|EUS-guided|EUS-guided gallbladder drainage in acute cholecystitis with high risk patients
62844634|NCT01146743|ACTIVE_COMPARATOR|percutaneous transhepatic|percutaneous transhepatic gallbladder drainage in acute cholecystitis with high risk patients
62844635|NCT04846413||Patients|Patients affected by neurologic disorders showing a prominent voice impairment.
62618787|NCT01588405|EXPERIMENTAL|UT-15C SR|
62618788|NCT01153789|EXPERIMENTAL|Patients orthoptic rehabilitation|Children with vertigo-headache and vergence disorders
62618789|NCT01153789|OTHER|Control Orthoptic diagnostic|Healthy controls
62618790|NCT04864145|ACTIVE_COMPARATOR|Medical therapy|Patients in medical therapy will receive conservative care, mainly including angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.
62618791|NCT04864145|EXPERIMENTAL|Transcatheter Aortic Valve Implantation|Patients in TAVR group will receive transcatheter aortic valve replacement.
62618792|NCT06311071||patient group|patient suspected to have coronary artery disease in noninvasive tests
62262435|NCT00089362|EXPERIMENTAL|Treatment (alvespimycin hydrochloride)|"Patients receive alvespimycin hydrochloride IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-2 patients receive accelerated escalating doses of alvespimycin hydrochloride until at least 1 of 2 patients experience DLT. Cohorts are then expanded to 3-6 patients who receive escalating doses (in a standard manner) of alvespimycin hydrochloride until MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. Once the MTD is determined, 10 additional patients are treated at that dose."
62262436|NCT02642445|EXPERIMENTAL|Renal Sympathetic Denervation|Renal sympathetic Denervation are conducted from the adventitia of renal artery
62618793|NCT03077100||Newborns with positive cultures|Positive cultures of newborns hospitalized in the NICU in the past 5 years will undergo laboratory examination and identification
62262437|NCT02642445|NO_INTERVENTION|Control Group|Renal Sympathetic Denervation are not conducted in control group.
62262438|NCT05195294|EXPERIMENTAL|LioCyx-M monotherapy|Patients will receive up to 8 biweekly infusions of HBV antigen specific TCR redirected T cells (LioCyx-M).
62618794|NCT06122467|EXPERIMENTAL|Test group: EQ Product Line|"The following regimen should be completed in both the morning and the evening. The order of use is:~Cleanser Gel Moisturizer."
62844636|NCT01345357|EXPERIMENTAL|CEP-9722 in combination with Gemcitabine and Cisplatin|Study drugs will be administered in cycles of 21 days for up to 6 cycles. CEP-9722 treatment will be initiated at cycle 2. After cycle 3, patients may discontinue gemcitabine and/or cisplatin for reasons of tolerability, at the discretion of the investigator.
62262439|NCT05195294|EXPERIMENTAL|LioCyx-M + lenvatinib combinational therapy|Patients will receive up to 8 biweekly infusions of HBV antigen specific TCR redirected T cells (LioCyx-M) with daily intake of lenvatinib.
62262440|NCT04507555|EXPERIMENTAL|Intervention|
62262441|NCT04507555|ACTIVE_COMPARATOR|Standard Care|
62618795|NCT04121767|EXPERIMENTAL|Edoxaban group|patients prescribed edoxaban after thoracoscopic ablation during window period to prevent stroke
62618796|NCT04121767|ACTIVE_COMPARATOR|Warfarin group|patients prescribed warfarin after thoracoscopic ablation during window period to prevent stroke
62618797|NCT04460963|OTHER|Biological evaluation|Adrenomedullin evaluation at diagnosis at first CR and 1 year of follow-up
62618798|NCT04054674|EXPERIMENTAL|flat occlusal scheme restored by lithium disilicate crown|flat occlusal preparation of endodontically treated teeth is performed clinically and then the final restorations will be lithium disilicate (e.max) crowns.
62618799|NCT04054674|NO_INTERVENTION|planar occlusal scheme restored by lithium disilcate crown|planar occlusal preparation of endodontically treated teeth is performed clinically and then the final restorations will be lithium disilicate (e.max) crowns.
62618800|NCT00265408|EXPERIMENTAL|aspirin|
62618801|NCT00265408|EXPERIMENTAL|warfarin|
62618802|NCT06210815|EXPERIMENTAL|HLX42|Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
62618803|NCT03275935||Training Arm|Patients that were given training in regards to proper inhalation technique of Rotahalers
62618804|NCT02455973|EXPERIMENTAL|Transtheoretical model of change|In this type of intervention, the focus will be the development of skills through educational activities on health based on interdisciplinary motivational strategies.
62618805|NCT02455973|PLACEBO_COMPARATOR|Health information|In this type of intervention, the focus will be the development of skills through educational activities on health using the pedagogy of transmission.
62618806|NCT00999700|EXPERIMENTAL|ARM A|Induction chemotherapy: TCF (Vermorken, N Eng J Med 2007) Definitive treatment: RT + C-mab (Bonner, N Eng J Med 2006)
62262442|NCT04507555|NO_INTERVENTION|Observational|
62618807|NCT00999700|ACTIVE_COMPARATOR|ARM B|RT + Cddp (RTOG, Adelstein, J Clin Oncol 2003)
62844637|NCT03866876||Hôpital Femme Mère Enfants births|
62844638|NCT01879358|ACTIVE_COMPARATOR|ORSIRO stent|ORSIRO stent group
62844639|NCT01879358|ACTIVE_COMPARATOR|NOBORI stent|NOBORI stent group
62844640|NCT02983929||BMI <30 kg.m-2|Patients with a BMI inferior to the obesity limit defined by the World Health Organization.
62844641|NCT02983929||BMI >30 kg.m-2|Patients with a BMI superior to the obesity limit defined by the World Health Organization.
62844642|NCT05679895|EXPERIMENTAL|Experimental: CD1a-CAR T|CD1a CAR T cells transduced with a lentiviral vector to express CD1a chimeric receptor domain on T cells administered with a dose-escalation approach.
62844643|NCT04551872|EXPERIMENTAL|Obese High Risk|200 participants with BMI ≥30 and 10-year ASCVD risk ≥20%
62844644|NCT04551872|EXPERIMENTAL|Obese Low Risk|200 participants with BMI ≥30 and 10-year ASCVD risk \<7.5%
62262443|NCT05088486||Experimental group:|Patients with arterial hypertension
62262444|NCT05088486||Control group|Patients without arterial hypertension
62262445|NCT02886143|EXPERIMENTAL|Active Voiding Trial (instillation of sterile saline)|Patients randomized to receive an active voiding trial will have the bladder filled with 250-400 cc of sterile saline (or until the bladder was full) via the lumen of the urinary catheter before the urinary catheter is removed. The patient will then be immediately assisted to void. Physician teams will follow a standardized algorithm for the management of urinary retention arising during the study.
62262446|NCT02886143|ACTIVE_COMPARATOR|Passive Voiding Trial|For patients randomized to receive a passive voiding trial, the urinary catheter will be removed, the bladder will fill with urine naturally, and the patient will be assisted to void when he or she reports the urge. To ensure uniformity in the intervention, all voiding trials in the study will be supervised by an experienced nurse who will ensure that the protocol is followed.
62844645|NCT04551872|NO_INTERVENTION|Non-Obese High Risk|100 participants with BMI 18-25 and 10-year ASCVD risk ≥20%
62844646|NCT04551872|NO_INTERVENTION|Non-Obese Low Risk|100 participants with BMI 18-25 and 10-year ASCVD risk \<7.5%
62844647|NCT05802121|EXPERIMENTAL|Apple Cider Vinegar|Webbers Natural apple cider vinegar pills (NPN: 80021269), enteric coated. Each patient will be instructed to take 6 enteric slow-release acetate capsules (equivalent of 500 mg/ capsule containing 25 mg acetate x 6 capsules) per day for 3 months.
62058872|NCT06347484|ACTIVE_COMPARATOR|EHR-Informed Recruitment Sub-Study #1, Arm #3: Contact Method, Postal Mail|Potential participants will be identified using an EHR query and will be randomized to receive a recruitment message via postal mail. This message will invite the participant to join CONNECT.
62262447|NCT03672019||Patients Undergoing Percutaneous Biliary Drainage|Following Percutaneous Biliary Drainage (PBD), participants will complete Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
62262448|NCT00005832|EXPERIMENTAL|R115777|300mg/dose BID, PO, Days 1-21, q 28days
62262449|NCT05079945|EXPERIMENTAL|Spinal cord Tractography|Healthy volunteer having the tractography exam
62844648|NCT05802121|PLACEBO_COMPARATOR|Placebo|Placebo pills will be provided by our hospital pharmacy, and patients will be given the same instructions as in the treatment arm.
62844649|NCT01233557||Bone Metastases|
62058873|NCT01802437|EXPERIMENTAL|Talk Therapy 4-Week Decision Point|Interpersonal psychotherapy that focuses on an adolescents relationship and communication skills in the context of of their depression. After 4 weeks of therapy, participants with at less than a 20% reduction in Hamilton Rating Scale for Depression (HRSD) score will be further randomized into 2 groups, increased dose of interpersonal psychotherapy frequency or introduction of fluoxetine therapy starting with 10 mg per day for the first week and 20 mg per day in the following 5 weeks. If HRSD scores meet target, patients continue to receive initial dose of interpersonal psychotherapy
62262450|NCT00579371|EXPERIMENTAL|Transplantation of Islets of Langerhans|Subjects will receive islets isolated from one donor pancreas per transplantation event. Subjects will receive a cumulative dose of 8,000 International Units/kg. Islets will be infused intraportally. If necessary, additional transplantation events will be performed.
62262451|NCT00793637||Surgical|Patients with proximal and/or distal tibial, femoral and/or humeral fractures treated with intramedullary nails and the Angular Stable Locking System(ASLS)
62262452|NCT03711578|EXPERIMENTAL|Tenalisib|Participants receive Tenalisib 800 mg BID in 28-Days Cycle for 8 Cycles
62262453|NCT05374252|EXPERIMENTAL|Experimental Group|Concurrent PD-1 antibody sintilimab combined with mytomicin C, 5-fluorouracil, and IMRT, followed by adjuvant sintilimab
62262454|NCT05374252|ACTIVE_COMPARATOR|Control Group|Concurrent mytomicin C and 5-fluorouracil combined with IMRT
62262455|NCT01372384|EXPERIMENTAL|Single Arm|
62262456|NCT04966377|EXPERIMENTAL|Intervention Group|Intervention Group First, pre-tests were applied to the women in the experimental group. A 4-week training program created by taking into account the cultural characteristics of Syrian women; Explaining breast health, Explaining breast structure, Cancer, Breast cancer, Early diagnosis and its importance, BSE application, CBE and mammography, Barriers on breast cancer, Cancer Early Diagnosis, Screening and Education Center. A 'Nurse-directed screening counseling telephone support line' will be established for the women in the experimental group. Then, motivational interviews will be applied to the women in the experimental group by the researcher, who emphasizes the importance of early diagnosis in line with the health belief model. Reminders will be made by phone every week in the 3rd month. The final tests will be held 4 months after the end of the training.
62262457|NCT04966377|NO_INTERVENTION|Control Group|Pre-tests will be applied to the women in the control group. No intervention will be applied to the women in this group and post-tests will be performed 4 months after the pre-test.
62844650|NCT01041755|EXPERIMENTAL|Intravenous infusion of L- Ornithine L- Aspartate|a) 20 g L-ornithine-L-aspartate
62844651|NCT01041755|ACTIVE_COMPARATOR|Lactose enemas|b) 20% Lactose enemas
62844652|NCT00033267|EXPERIMENTAL|Treatment|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with stable disease receive a maximum of 6 courses. Patients with partial response receive a maximum of 12 courses. Patients with CR receive 2 additional courses beyond CR.
62844653|NCT02030236|EXPERIMENTAL|Cooling|
62844654|NCT02326857||Women with breast cancer|Observational study of women with Stage II/III locally advanced breast cancer in Latin America
62844655|NCT02010450|EXPERIMENTAL|Wearable Blanket|subjects randomized to this group will receive a wearable blanket (sleep sack) that contains a safe sleep message.
62618808|NCT01954199|EXPERIMENTAL|Neurodynamic group|Patients allocated to this group will receive three different neurodynamic techniques: a lumbar foramen dynamic opener; a side-lying slider and a slider in the slump position. Patients will be asked to perform home exercises (a slider and a tensioner technique). Treatment will receive four treatments during two weeks (two sessions/week).
62618809|NCT01954199|NO_INTERVENTION|Control Group|"Patients allocated to Control Group (CG) will receive no intervention and will be advised according to the best evidence available; i.e, advice to remain active and to resume activities of daily living~Upon trial completion, treatment will be offered."
62618810|NCT06033677|OTHER|Grup 1-Forearm radial artery cannulation (FRA)|The patients who were to undergo forearm radial artery catheterization were positioned with wrist dorsifection up to 30° and forearm supination. Intervention was planned after ultrasonographic measurements were taken.
62618811|NCT06033677|ACTIVE_COMPARATOR|Grup 2-Distal radial artery cannulation (DRA)|The patients who will undergo distal radial artery catheterization were placed in the pronation position of the forearm with the anatomical snuffbox facing upwards. Intervention was planned after ultrasonographic measurements were taken.
62618812|NCT05200845|EXPERIMENTAL|Conditioned Stimulus+ (CS+) and High Fat Test Meal First|Participants will undergo exposure sessions with flavored beverage solutions containing sucrose first. They will also undergo the high fat meal test session inside the metabolic chamber first. Then, they will undergo exposure sessions with flavored beverages containing sucralose and the high carbohydrate test meal session.
62618813|NCT05200845|EXPERIMENTAL|Conditioned Stimulus+ (CS+) and High Carbohydrate Test Meal First|Participants will undergo exposure sessions with flavored beverage solutions containing sucrose first. They will also undergo the high carbohydrate meal test session inside the metabolic chamber first. Then, they will undergo exposure sessions with flavored beverages containing sucralose and the high fat test meal session.
62618814|NCT05200845|EXPERIMENTAL|Conditioned Stimulus- (CS-) and High Fat Test Meal First|Participants will undergo exposure sessions with flavored beverage solutions containing sucralose first. They will also undergo the high fat meal test session inside the metabolic chamber first. Then, they will undergo exposure sessions with flavored beverages containing sucrose and the high carbohydrate test meal session.
62618815|NCT05200845|EXPERIMENTAL|Conditioned Stimulus- (CS-) and High Carbohydrate Test Meal First|Participants will undergo exposure sessions with flavored beverage solutions containing sucralose first. They will also undergo the high carbohydrate meal test session inside the metabolic chamber first. Then, they will undergo exposure sessions with flavored beverages containing sucrose and the high fat test meal session.
62618816|NCT00823758||1|Parents of children under 8 years of age who have ever given their children an over- the-counter medication.
62618817|NCT00823758||2|Adolescents who are 13 to 20 years of age who have ever heard of over-the-counter medication.
62618818|NCT00823758||3|Adults (21 years of age or older) who have used over-the-counter medication in the past 2 years.
62618819|NCT00823758||4|Primary care physicians will be Family Practitioners or General Internist, with an active Texas license, who devote at least 50% of their time to clinical practice.
62618820|NCT00823758||5|Pharmacists holding a PharmD degree and licensure in the state of Texas and work at least half-time in a community pharmacy setting.
62618821|NCT02050750||TAILORx ICORG 06-31|Patients must have participated in TAILORx ICORG 06-31, participated in trial arms, and have adequate tumour tissue available
62618822|NCT03832673|EXPERIMENTAL|Pembrolizumab + Epacadostat|Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles) Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
62618823|NCT05284903|OTHER|Experimental: Phonak device with activated feature|The clinical investigation is designed to evaluate clinical performances in terms of speech intelligibility and listening effort. The expected benefit is based on clinical relevant differences. This clinical investigation is divided in three parts including Beamformer benefit, Speech Enhancer benefit and Hearing aid benefit (this part will be performed aided).
62618824|NCT05284903|OTHER|Comparator: Phonak device with deactivated feature|The comparative testings should be used as reference. The measures will be performed by the same participant group and the same three parts will be evaluated including Beamformer (BF) benefit, Speech Enhancer benefit and Hearing aid benefit. The reference will be performed without these features or with different settings of these features. In case of the Hearing aid benefit, the reference is an unaided fitting.
62618825|NCT00596063|EXPERIMENTAL|Wosulin R|Regular insulin for subcutaneous injection (recombinant human insulin), 600nmol, 100 IU
62618826|NCT00596063|ACTIVE_COMPARATOR|Novolin R|Regular insulin for injection (recombinant human insulin)
62262458|NCT02230059||Metastatic Castration-resistant Prostate Cancer|Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
62618827|NCT03052348|ACTIVE_COMPARATOR|Group R|Polyethylene glycol hexadecyl ether \& betamethasone valerate cream 0.1% . ( 4 applications per day for 14 days treatment to taper fortnightly)
62618828|NCT03052348|EXPERIMENTAL|Group A|Fusidic acid \& Polyethylene glycol hexadecyl ether,\& betamethasone valerate cream 0.1%). ( 4 applications per day for 14 days treatment to taper fortnightly)
62844656|NCT02010450|ACTIVE_COMPARATOR|Control Group|subjects randomized to this group will receive an incentive item (such as a University of Kansas Pediatrics water Bottle) that does not contain the safe sleep message.
62618829|NCT05790668|EXPERIMENTAL|Evaluation of PIA-Informed Schedule Thinning|The goal of Arm 1 will be to will extend pilot work on the utility of individualizing the starting point for reinforcement schedule thinning based on the results of a progressive-interval assessement (PIA). The investigators will do so by conducting reinforcement schedule thinning using a multielement design in two separate contexts, one informed by the results of a PIA and another not so informed. The criteria for schedule thinning will be identical across both conditions but will be applied to each condition independently. Investigators will determine the efficiency of schedule thinning, reductions of destructive behavior, and durability of functional communication responses across the two conditions.
62618830|NCT05790668|EXPERIMENTAL|Evaluation of Competing Items|The goal of Arm 2 will be to evaluate the utility of competing items (e.g., alternative reinforcement or activities) during schedule thinning. Both conditions will be informed by the PIA, similar to the experimental condition in Arm 1. PIA-informed schedule thinning with competing stimuli will be identical to that of PIA-informed schedule thinning, except (a) the therapist will provide continuous access to the highly competing stimulus identified by that participant's competing stimulus assessment (e.g., providing attention while an iPad is unavailable, playing music while working), and (b) it will occur in the other context (e.g., the yellow context). Investigators will determine the efficiency of schedule thinning, reductions of destructive behavior, the durability of functional communication responses across the two conditions, and resurgence of destructive behavior during prolonged periods of extinction.
62618831|NCT05790668|EXPERIMENTAL|Effects of Competing Items on PIA Outcomes|The goal of Arm 3 will be to examine potential interaction effects between the above two experimental arms by conducting PIAs with no, low, moderate, and high competing stimuli to determine the schedule duration at which schedule thinning should commence with each competing stimulus. All participants will complete this arm prior to enrollment in Arms 1 or 2. The investigators will randomize the sequence of each of the four PIAs (PIA with no competing stimuli, PIA with low competing stimuli, PIA with moderately competing stimuli, PIA with highly competing stimuli) across participants.
62618832|NCT00868751|EXPERIMENTAL|Tocilizumab|Single arm study - treatment only
62618833|NCT01967979|EXPERIMENTAL|Cohort 1 (Itraconazole DDI)|
62618834|NCT01967979|EXPERIMENTAL|Cohort 2 (Fluoxetine DDI)|
62618835|NCT03280745|ACTIVE_COMPARATOR|7.3% NaCl (intervention)|At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl NaCl by infusion pump over 60 minutes.
62262459|NCT03321136|PLACEBO_COMPARATOR|Placebo, LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
62844657|NCT00884741|ACTIVE_COMPARATOR|Arm I (radiation therapy, temozolomide, placebo)|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks and receive temozolomide PO QD for up to 7 weeks. Beginning 4 weeks after completion of chemotherapy and radiation therapy, patients receive temozolomide PO QD on days 1-5. Treatment with temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients also receive placebo IV over 30-90 minutes once every 2 weeks beginning in week 4 of chemotherapy and radiation therapy and continuing until the completion of temozolomide.
62844658|NCT00884741|EXPERIMENTAL|Arm II (radiation therapy, temozolomide, bevacizumab)|Patients undergo radiation therapy and receive temozolomide as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes once every 2 weeks beginning in week 4 of chemoradiotherapy and continuing until the completion of adjuvant temozolomide.
62844659|NCT05591209||Alive and Dead|Following ICU admission patients are followed until discharge with the outcome of alive or dead
62844660|NCT04587609|NO_INTERVENTION|Control - Standard UBI|Participants will continue to be monitored as a part of their standard UBI and receive educational material about distracted driving in the enrollment period
62262460|NCT03321136|PLACEBO_COMPARATOR|LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
62262461|NCT03321136|PLACEBO_COMPARATOR|LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
62262462|NCT03321136|PLACEBO_COMPARATOR|LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
62447036|NCT06484309|NO_INTERVENTION|Control group|"* Participants will sign an informed voluntary consent form during the active phase of labor,~* Group assignment will be made,~* Participant Information Form will be filled in,~* The study will continue if episiotomy is performed at birth; If episiotomy is not performed at birth, it will not be included in the study.~* Episiotomy repair will be performed by CG after anesthesia (5 ml lidocaine 2%) is applied in the 3rd stage of labor,~* Evaluation with VAS will be performed before repair, during perineal repair (internal), during skin repair and immediately after the repair is completed,~* The McGill Pain Questionnaire will be completed 20 minutes after episiotomy repair."
62262463|NCT03321136|PLACEBO_COMPARATOR|LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
62262464|NCT03321136|PLACEBO_COMPARATOR|LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100, LSD-200|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
62618836|NCT03280745|ACTIVE_COMPARATOR|0.9% NaCl (comparator)|At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
62618837|NCT04691167|ACTIVE_COMPARATOR|group 1, Active intervention group|
62618838|NCT04691167|SHAM_COMPARATOR|group 2, sham controlled group|
62618839|NCT00084877|EXPERIMENTAL|Treatment (triapine, irinotecan hydrochloride)|"Patients receive irinotecan IV over 1 hour on day 1 and 3-AP (Triapine®) IV over 2 hours on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of irinotecan and 3-AP (Triapine®) until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 6 additional patients are treated at that dose."
62618840|NCT04012346|ACTIVE_COMPARATOR|Active Comparator: MCI patients with real iTBS|Patients will receive real iTBS in a week-long sessions.
62618841|NCT04012346|SHAM_COMPARATOR|Sham Comparator: MCI patients with sham iTBS|Patients will receive sham iTBS in a week-long sessions.
62618842|NCT05719025||HIV + COVID+|
62618843|NCT05719025||HIV + COVID -|
62618844|NCT05719025||HIV - COVID +|
62618845|NCT05719025||HIV- COVID-|
62618846|NCT06485011|EXPERIMENTAL|With Platysma suturing|platysma muscle was sutured in this group
62058874|NCT01802437|EXPERIMENTAL|Talk Therapy 8-Week Decision Point|Interpersonal psychotherapy that focuses on an adolescents relationship and communication skills in the context of of their depression. After 8 weeks of therapy, participants with at less than a 40% reduction in Hamilton Rating Scale for Depression (HRSD) score will be further randomized into 2 groups, increased dose of interpersonal psychotherapy or introduction of fluoxetine therapy starting with 10 mg per day for the first week and 20 mg per day in the following 5 weeks. If HRSD scores meet target, patients continue to receive initial dose of interpersonal psychotherapy.
62058875|NCT01949103|EXPERIMENTAL|TD-1607 or placebo (Dose1)|TD-1607 or placebo administered intravenously
62618847|NCT06485011|EXPERIMENTAL|Without Platysma suturing|platysma muscle was not sutured in this group
62618848|NCT05172401|EXPERIMENTAL|Active Treatment - Oxulumis® - Triesence®|"The Oxulumis® device will be used for the administration of Triesence® (Triamcinolone acetonide) via suprachoroidal microcatheterization~Interventions:~* Device: Oxulumis® suprachoroidal microcatheterization device~* Drug: Triesence® (Triamcinolone acetonide)"
62618849|NCT01313013|EXPERIMENTAL|intervention|question prompt sheet
62618850|NCT01313013|NO_INTERVENTION|control|no question prompt sheet
62618851|NCT03797131|EXPERIMENTAL|KB195 Arm|
62618852|NCT01268189|EXPERIMENTAL|Burn wound patients with donor sites|Oxygen diffusing dressing applied to wound vs standard of care dressing (Xeroform) applied to wound (patient serves as own control as s/he receives 1 dressing on 1 donor site and the other on a 2nd donor site)
62618853|NCT00860132||2|a group of consecutive hip fracture patients admitted to a dedicated comprehensive orthogeriatric ward and a group of similar patients admitted to an orthopedic ward and later on transferred to geriatric rehab center
62618854|NCT00842777|EXPERIMENTAL|Parent group treatment|Manualized group treatment of parents. Allocation of 4-6 parental couples of children with similar age.
62058876|NCT01949103|EXPERIMENTAL|TD-1607 or placebo (Dose 2)|TD-1607 or placebo administered intravenously
62058877|NCT01949103|EXPERIMENTAL|TD-1607 or placebo (Dose 3)|TD-1607 or placebo administered intravenously
62058878|NCT01949103|EXPERIMENTAL|TD-1607 or placebo (Dose 4)|TD-1607 or placebo administered intravenously
62058879|NCT01949103|EXPERIMENTAL|TD-1607 or placebo (Dose 5) [Optional]|TD-1607 or placebo administered intravenously
62058880|NCT01949103|EXPERIMENTAL|TD-1607 or placebo (Dose 6) [Optional]|TD-1607 or placebo administered intravenously
62262465|NCT00492752|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006)|Sorafenib was administered orally at a dose of 400 mg (2 x 200 mg tablets) bid (twice daily); 2 dose reductions to predefined levels of 400 mg (2 x 200 mg tablets) once daily (od) and 400 mg (2 x 200 mg tablets) every 2 days were permitted for treatment-emergent adverse events related to study treatment.
62262466|NCT00492752|PLACEBO_COMPARATOR|Placebo|Placebo tablets matching in appearance were orally administered bid (twice daily).
62618855|NCT00842777|ACTIVE_COMPARATOR|Parent self-help groups|Professionals initiate and organize the self-help groups initially. The groups will not receive any teaching or counseling concerning eating and physical activity.
62447037|NCT06546241|EXPERIMENTAL|Intervention Group|Hispanic/Latinx youth between the ages of 11 to 16 will participate in a 60 minute workshop aimed and increasing body image satisfaction and self esteem. Participants randomized to the intervention group are scheduled immediately to receive the intervention. The intervention is delivered in a group format with groups consisting of no more than 20 youth.
62618856|NCT00994214|EXPERIMENTAL|BIM 23A760 1 mg|
62618857|NCT00994214|EXPERIMENTAL|BIM 23A760 2 mg|
62618858|NCT00994214|EXPERIMENTAL|BIM 23A760 4 mg|
62618859|NCT00994214|EXPERIMENTAL|BIM 23A760 6 mg|
62618860|NCT00828269|NO_INTERVENTION|1|Liver tissue biopsy
62844661|NCT04587609|OTHER|Free Phone mount|Participants in this arm will be monitored through standard UBI, receive educational material about distracted driving in the enrollment period, and free phone mounts
62058881|NCT06484829|EXPERIMENTAL|A group|Cohort A was designed as a 3-week (21-day) one-cycle regimen Puesta mesylate for injection (PM): intravenous infusion, administered on days 1, 4, 8, and 11 of each cycle, 3 weeks (21 days) as a one-cycle regimen; Pomalidomide capsules (Pod): oral, 4 mg/dose once daily, 14 consecutive days off 7 days, 3-week (21-day) one-cycle regimen; Dexamethasone acetate tablets (DEX): oral, 20 mg/day on days 1, 2, 8, and 9 of each dosing cycle, a one-cycle regimen for 3 weeks (21 days).
62618861|NCT01270321|EXPERIMENTAL|Arm A (Everolimus alone)|CURRENTLY CLOSED TO ACCRUAL--Everolimus alone followed by Everolimus + Pasireotide at the time of progression
62618862|NCT01270321|EXPERIMENTAL|Arm B (Pasireotide alone)|CURRENTLY CLOSED TO ACCRUAL--Pasireotide alone followed by Everolimus + Pasireotide at the time of progression
62618863|NCT01270321|EXPERIMENTAL|Arm C (Everolimus + Pasireotide)|CURRENTLY CLOSED TO ACCRUAL
62618864|NCT02891486||Incidence of surgical site infection|The number of spinal surgery patients with surgical site infections.
62618865|NCT01903759|OTHER|Patients with spontaneous rupture of the fetal membranes|
62618866|NCT02142205|EXPERIMENTAL|BG00002 (natalizumab)|300 mg IV infusion every 4 weeks
62618867|NCT01017601|EXPERIMENTAL|Arm I|Patients receive a single dose of Seneca Valley virus-001 (NTX-010) IV over 1 hour on day 1.
62618868|NCT01017601|PLACEBO_COMPARATOR|Arm II|Patients receive a single dose of placebo IV over 1 hour on day 1.
62618869|NCT03840408|EXPERIMENTAL|Mitochondrial therapy with radiofrequency ablation|
62618870|NCT03840408|ACTIVE_COMPARATOR|Surgery|
62618871|NCT01390428|EXPERIMENTAL|Part 1-Mild Hepatic Impairment (HI)|Participants with mild hepatic impairment will receive 200 mg of Grazoprevir once a day for 10 consecutive days during Part 1 of the study.
62618872|NCT01390428|EXPERIMENTAL|Part 1-Healthy Matched to Mild HI|Healthy participants will receive 200 mg of Grazoprevir once a day for 10 consecutive days during Part 1 of the study.
62618873|NCT01390428|EXPERIMENTAL|Part 2-Moderate HI|Participants with moderate hepatic impairment will receive 100 mg of Grazoprevir once a day for 10 consecutive days during Part 2 of the study.
62618874|NCT01390428|EXPERIMENTAL|Part 2-Healthy Matched to Moderate HI|Healthy participants will receive 100 mg of Grazoprevir once a day for 10 consecutive days during Part 2 of the study.
62618875|NCT01390428|EXPERIMENTAL|Part 3-Severe HI|Participants with severe hepatic impairment will receive 50 mg of Grazoprevir once a day for 10 consecutive days during Part 3 of the study.
62262467|NCT05326945|NO_INTERVENTION|Measurement without sheath|"Sample A: Investigator will take culture from the inside of the BPC, which will contact the patient's right upper arm, wearing sterile gloves, and will remove the gloves.~B:Investigator will wipe the right upper arm area of the patient with (70% alcohol+2% chlorhexidine) solution in accordance after wearing sterile gloves, wait for 30 seconds and after the alcohol dries investigator will take culture from the patient's right upper arm, wearing a new sterile glove.~C:investigator will measure ABP on the right upper arm of the patient with the same sterile glove, and after the measurement, the first investigator will take culture from the patient's right upper arm by wearing a new sterile glove, both researchers will remove the gloves.~D:investigator wore a new sterile glove after ABP measurement and wiped the inside and outside of the BPC with solution, the first investigator would wear a new sterile glove to take culture, both researchers will remove the gloves."
62618876|NCT01390428|EXPERIMENTAL|Part 3-Healthy Matched to Severe HI|Healthy participants will receive 50 mg of Grazoprevir once a day for 10 consecutive days during Part 3 of the study.
62618877|NCT00913770|NO_INTERVENTION|SC|Standard Care
62618878|NCT00913770|EXPERIMENTAL|SBIRT|Screening, Brief Intervention and Facilitated Referral to Treatment
62618879|NCT00913770|EXPERIMENTAL|SBI+Bup|Screening, Brief Intervention and Buprenorphine initiation
62618880|NCT04437797|EXPERIMENTAL|Surgical Extrusion|The next step will be atraumatic extraction which will be initiated by using straight periotome until it is sufficiently luxated and gently pulled out to the amount of sufficient ferrule effect without encroaching the biological width. 90- or 180-degrees rotation of the tooth will be done if needed. The tooth will be supported from palatal side, etching will be done using 37% phosphoric acid, rinsing, drying, bonding agent and then application of 3M Filtek flowable composite on rounded 16mm stainless steel wire for splinting in the middle of the tooth without extension of flowable composite neither to the mesial nor to the distal. This procedure should be followed by occlusal adjustment if needed. Splint will be removed after 2 weeks.
62618881|NCT04437797|ACTIVE_COMPARATOR|Immediate Implant Placement|The patient is anaesthetized. Atraumatic extraction of the badly broken-down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, 11 to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed. Jumping gap occurring subsequent to atraumatic extraction and immediate implant placement more than 2 mm will be grafted using Xenograft.
62262468|NCT05326945|EXPERIMENTAL|Sheathed Measurement|"Sample E: DCC sterile package will be opened the investigator will hold the sphygmomanometer, after investigator wears sterile gloves, DCC will put it cuff of the same cuff. Culture will be taken investigator from the inside of the DCC that will contact the patient's left upper arm, before the ABP measurement, the first investigator will remove the gloves.~F:Sterile gloves will be worn by the investigator and the left upper arm area of the patient will be wiped with solution before the ABP measurement wait 30 seconds, and after the solution dries, the first investigator will use a new sterile After wearing gloves, he will take a swab culture from the left upper arm region.~G:The investigator will measure ABP from the patient's left upper arm with the same glove, and after the measurement, the first investigator will take culture from the patient's left upper arm after wearing a new sterile glove.~Culture results taken from the patients will be compared statistically."
62262469|NCT00492167|EXPERIMENTAL|Beta-Glucan and Monoclonal Antibody 3F8|"This is a dose-escalation study of beta-glucan. Patients receive oral beta-glucan once daily on days -4 to 12 and monoclonal antibody 3F8 IV over 30-90 minutes on days 1-5 and 8-12. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity and with a human antimouse antibody (HAMA) titer \< 1,000 U/mL.~Cohorts of 3-6 patients receive escalating doses of beta-glucan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Patients undergo urine, bone marrow, and blood sample collection periodically for biological studies. Samples are analyzed for antibody-dependent cellular cytotoxicity, complement-mediated cytotoxicity, and serum HAMA response via immunohistochemistry.~After completion of study treatment, patients are followed periodica"
62447038|NCT06546241|NO_INTERVENTION|Wait-List Control Group|The control group is a waitlist control group. Participants in the control group complete a survey, wait for 2 to 3 weeks, then are eligible to sign up for the workshop. During the wait-list period they complete 2 surveys.
62262470|NCT03992508|OTHER|complex decongestive treatment|In group 1, the patients were received standard complex decongestive therapy including skin care, manual lymphatic drainage, multi-layer compression bandaging and exercises. During the treatment, written and verbal information was given to the patients about skin care. Manual lymphatic drainage and compressive bandages were applied by a certified physical therapist. The patients received 30-minutes manual lymphatic drainage involving stationary circular, pumping, scooping, and rotary movements. Multi-layer compression bandaging was applied to the affected limb to promote the flow of excess interstitial fluid out of the extremity using a graded pressure for 22-23 hours in a day. The patients strictly followed a lymphoedema exercise program structured with breathing exercise, neck and shoulder range of motion, and stretching exercise to facilitating lymph resorption.
62844662|NCT04587609|OTHER|Commitment + Habit tips|Participants in this arm will receive educational material about distracted driving during the enrollment period, be sent a free phone mount with installation instructions, sign a personalized commitment contract to reduce their phone use, set personal phone use reduction goals, and be sent personalized habit tips framed to help them reduce their handheld phone use while driving;
62844663|NCT04587609|OTHER|Habit Formation + Social Gamification|Participants in this arm will will receive all treatments assigned to arm 3, plus social gamification feedback, where each week participants are told if they've reach their weekly handheld phone use while driving reduction goal, and receive or lose points based on whether or not they met their goal. Based on their points participants can either move up or down a level. Each week the participants will also be sent a leader board of their ranking within their group.
62447039|NCT02598271||Low SCr|Patients with a serum creatinine below or equal to 1.3mg/dL
62447040|NCT02598271||High SCr|Patients with a serum creatinine above to 1.3mg/dL
62447041|NCT03890250|SHAM_COMPARATOR|Sham group|Following the assessments, sham group will participate in a 20-30 minute low-medium intensity aerobic exercise training with cycling ergometer. In Sham training group, NMES will be applied to the same region after aerobic exercise, current frequency is 5 Hz, current transit time is 300 μs, 10 seconds warning, 30 seconds electrical stimulation in 20 seconds rest period. The rehabilitation program will be administered two days a week for 8 weeks under the supervision of a physiotherapist.
62844664|NCT04587609|OTHER|All + Contest Financial Incentive|Participants in this arm will receive all of the treatments of arm 4 plus be entered into a financial incentive contest where they can either finish in the highest level and split the prize money amongst all participants that reached that level, and the safest driver (driver ranked #1 on the leader board of their group) will receive a small weekly financial prize.
62447042|NCT03890250|EXPERIMENTAL|NMES group|"Following the assessments, both groups will participate in a 20-30 minute low-medium intensity aerobic exercise training with cycling ergometer.~After the aerobic exercise in NMES group, bilateral NMES application on Quadriceps femoris muscle will be applied as symmetrical biphasic square wave current with a wave frequency of 35-60 Hz, phase transition time of 8 seconds and active resting time of 15 seconds."
62447043|NCT02153307|EXPERIMENTAL|Implantable loop recorders Reveal ICM LINQ®,|
62844665|NCT05040503|ACTIVE_COMPARATOR|Patients without sepsis|patient without sepsis admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital
62844666|NCT05040503|EXPERIMENTAL|Patients with sepsis|Patients with sepsis admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital
62058882|NCT06484829|EXPERIMENTAL|B group|Cohort B is designed as a 4-week (28-day) cycle program Puesta mesylate for injection (PM): intravenous infusion, administered on days 1, 4, 15, and 18 of each cycle, 4 weeks (28 days) as a one-cycle regimen; Pomalidomide capsules (Pod): oral, 4 mg/dose once daily, 21 consecutive days off 7 days, 4-week (28-day) one-cycle regimen; Dexamethasone acetate tablets (DEX): oral, 20 mg/day on days 1, 2, 8, 9, 15, and 16 of each dosing cycle, a one-cycle regimen for 4 weeks (28 days).
62058883|NCT05944055||Overdose|Preterm born before 31 weeks of gestation with at least a 25OH-D measure above 120nmol/L before 36 weeks corrected age and no determination below 50nmol/L. Of note, 25OH-D determinations are routinely performed each month from the first month of life during the NICU hospitalization
62058884|NCT05944055||Control|"Preterm infants born before 31 weeks of gestation, who presented with a 25OH-D between 50 and 120nmol/L for all the 25OH-D measures during their hospitalization in the NICU setting.~Of note, 25OH-D determinations are routinely performed each month from the first month of life during the NICU hospitalization"
62058885|NCT04693676|EXPERIMENTAL|Prizloncabtagene autoleucel|Prizlon-cel will be intravenously administered as a single infusion after lymphodepletion
62058886|NCT01542060||BIAsp 30 users|
62058887|NCT06231823|EXPERIMENTAL|extraction of the compromised first permanent molars at 8-10 years children|extraction of badly decayed FPM at the E,F developmental stages of the second permanent molar.
62058888|NCT00901888|EXPERIMENTAL|Angiotensin II infusion|Using forearm venous occlusion plethysmography angiotensin II will be infused to cause reduction in forearm blood flow. Infusion of apelin and sodium nitroprusside will given and vasodilatation will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
62058889|NCT00901888|ACTIVE_COMPARATOR|Noradrenaline|Using forearm venous occlusion plethysmography noradrenaline will be infused to cause reduction in forearm blood flow. Infusion of apelin and sodium nitroprusside will given and vasodilatation will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
62058890|NCT04754672|EXPERIMENTAL|Continuous aerobic and resistance exercise (AE+RE)|"Two 60 min moderate-to-high intensity exercise sessions per week supervised by a physiotherapist.~Continuous aerobic exercise: 15-20 min continuous aerobic exercise (e.g. walking) of moderate intensity (Borg 13-14 'somewhat hard').~Resistance exercise (25 min): 6 exercises targeting large muscle groups vertical row, squat, bench press, pull over, abdominal crunch, and lunge. 2 sets of 10 repetitions at 70-80% of 1 RM. To ensure adequate training load over time, tests are repeated every 3/4 weeks aligned with the chemotherapy cycle.~One additional (third) session from home at moderate intensity for at least 30 min.~A brochure with exercise guidelines is provided."
62058891|NCT04754672|EXPERIMENTAL|Continuous aerobic and aerobic interval exercise (AE+AI)|"Continuous aerobic exercise: 15-20 min continuous aerobic exercise (e.g. walking) of moderate intensity (Borg 13-14 'somewhat hard').~Aerobic interval (25 min): cycling with high intensity intervals alternated with recovery intervals. Intensity of the interval: between 85% and 95% of estimated maximum heart rate, adjusted to Borg 16-18 'hard - very hard'. In between the intervals, light intensity cycling will be performed for active recovery at 30% of Wmax estimated from Steep ramp test and adjusted to Borg \< 12.~One additional (third) session from home at moderate intensity for at least 30 min.~A brochure with exercise guidelines is provided."
62447044|NCT01762358|ACTIVE_COMPARATOR|Standard Therapy|Standardized physiotherapy for 12 times (15 patients)
62844667|NCT05040503|EXPERIMENTAL|Patients with septic shock|Patients with septic shock admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital
62844668|NCT05040503|ACTIVE_COMPARATOR|Healthy volunteers|
62844669|NCT01754727||Participants with Ankylosing Spondylitis (AS)|Participants with ankylosing spondylitis treated with adalimumab in routine clinical practice.
62844670|NCT03777748|EXPERIMENTAL|Two dental implants in the edentulous maxilla and mandible|Edentulous maxilla und mandible are treated with two diameter-reduced tissue level implants (Straumann, Basel) and anchored with CM LOC® and CM LOC Flex® attachments (Cendres+Métaux SA, Bienne).
62844671|NCT05945719||Adult chronic pain patients|Adult chronic pain patients who sexually harass pain clinic staff
62844672|NCT01495806|EXPERIMENTAL|Glucomannan|5 g 2x 10 day
62844673|NCT01495806|PLACEBO_COMPARATOR|Placebo|
62844674|NCT00652106|EXPERIMENTAL|1|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution
62844675|NCT00652106|ACTIVE_COMPARATOR|2|Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution
62844676|NCT00652106|ACTIVE_COMPARATOR|3|0.2% brimonidine ophthalmic solution
62844677|NCT05335421|EXPERIMENTAL|Mindfulness Intervention plus Standard of Care|The Foundations and Awareness modules of the HMP app require a minimum of 133 and 253 minutes, equating to less than 5 and less than 10 minutes per day on average, respectively. Date, duration, and content of usage will be recorded for each participant through the app. Participants will have access to the entire contents of the app for the full duration of the study.
62844678|NCT05335421|NO_INTERVENTION|Standard of Care|Control group receives standard of care only
62844679|NCT05949164||Group 1: Children able to answer questionnaires independently|Children who are deemed by a healthcare professional to be able to answer questionnaires independently (group 1) will be asked to complete self-reported questionnaires. Caregivers will also be asked to complete proxy-reported questionnaires.
62618882|NCT03652688|EXPERIMENTAL|Three 0's|Observed indicators that a group member may be in trouble due identified risks were provided and if detected, they were given practical skills on implementing the 3 0's: Outreach, Options, and Out. Outreach consisted of techniques for approaching your friend and acquiring more information whether there was a problem. Options were to be employed if problems were confirmed and were designed to provide easy, simple steps to reduce risks and decrease probability of escalation of problems. Out refers to the plans the group made before entering the club that they would leave as a group to keep the group members safe. Group commitment to implement these safety steps was emphasized. Interactive and visually attractive scenes were drawn as graphic images to avoid didactic delivery.
62058892|NCT04754672|NO_INTERVENTION|Usual care control group|Patients in the usual care group receive care as usual. In addition, a brochure with exercise guidelines for cancer survivors is provided
62618883|NCT03652688|SHAM_COMPARATOR|Fire Safety|Groups in the control condition were also given information on safety and the focus of this safety message was regarding fires in nightclubs. Groups were given didactic materials to read with some still images. There were a few questions for the group to address.
62058893|NCT04137614|PLACEBO_COMPARATOR|Digital substraction angiography|
62058894|NCT04137614|EXPERIMENTAL|Drug-coated balloon|
62844680|NCT05949164||Group 2: Children unable to answer questionnaires|The caregivers of children who are deemed by a healthcare professional to be unable to answer questionnaires (group 2) will be invited to complete proxy-reported questionnaires only. There are no self-reported questionnaires for this group.
62058895|NCT02093663|EXPERIMENTAL|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (\<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (\>) 23 kg to \<= 35 kg; 1800 mg/day for participants weighing \> 35 kg to \<= 50 kg; 2400 mg/day for participants weighing \> 50 kg to \<= 90 kg.
62058896|NCT02093663|EXPERIMENTAL|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to \<= 23 kg; 2400 mg/day for participants weighing \> 23 kg to \<= 35 kg; 3600 mg/day for participants weighing \> 35 kg to \<= 50 kg; 4800 mg/day for participants weighing \> 50 kg to \<= 90 kg.
62058897|NCT06427122|EXPERIMENTAL|EMD-U|The EMD-U treatment lasts eight weeks, in which two EMD-U sessions of 60 minutes and two phone calls take place in the first three weeks. In the five following weeks, patients are phoned twice to ask for their experiences with the practicing at home. An important part of EMD-U consists of homework exercises. These homework exercises comprise to practice/apply the intervention as learned during the sessions with the therapist, in those situations wherein the urge to scratch their skin is present. In the text below, we will explain in more detail what the treatment protocol entails. Patients in this condition receive the EMD-U treatment in addition to the care as usual.
62058898|NCT06427122|ACTIVE_COMPARATOR|Care as Usual|Patients in the control group receive care as usual (CAU), which is the standard care of the dermatologist. In addition to completing the questionnaires at T0, 1, 2, 3, and 4 these patients are not offered any additional treatment or support aimed at their scratching behaviour.
62058899|NCT01125722|ACTIVE_COMPARATOR|Investigator Placement Group|
62058900|NCT01125722|ACTIVE_COMPARATOR|Subject Placement Group|
62058901|NCT02313909|EXPERIMENTAL|Rivaroxaban|Rivaroxaban 15 mg orally once daily
62058902|NCT02313909|ACTIVE_COMPARATOR|Aspirin|Aspirin 100 mg orally once daily
62058903|NCT04575363|EXPERIMENTAL|pancreatic adenocarcinoma patient|patient with pancreatic ductal adenocarcinoma
62058904|NCT04839029|EXPERIMENTAL|Bipolar En bloc TURBT|patient subjected to bipolar Needlescopic En bloc resection of NMIBC
62058905|NCT04839029|ACTIVE_COMPARATOR|Monopolar En bloc TURBT|patient subjected to Monopolar Needlescopic En bloc resection of NMIBC
62058906|NCT03590600|EXPERIMENTAL|Cohort 1: 125 mg BTZ-043 fasting|N=8, 125 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
62058907|NCT03590600|PLACEBO_COMPARATOR|Cohort 1: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
62058908|NCT03590600|EXPERIMENTAL|Cohort 2: 250 mg BTZ-043 fasting|N=8, 250 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
62058909|NCT03590600|PLACEBO_COMPARATOR|Cohort 2: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
62058910|NCT03590600|EXPERIMENTAL|Cohort 3: 500 mg BTZ-043 fasting|N=8, 500 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
62844681|NCT04606446|EXPERIMENTAL|1A Monotherapy Dose Escalation|PF-07248144 Monotherapy Escalation
62058911|NCT03590600|PLACEBO_COMPARATOR|Cohort 3: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
62058912|NCT03590600|EXPERIMENTAL|Cohort 4: 1000 mg BTZ-043 fasting|N=8, 1000 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
62058913|NCT03590600|PLACEBO_COMPARATOR|Cohort 4: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
62262471|NCT03992508|EXPERIMENTAL|intermittent pneumatic compression|In group 2, the patients received experimental intermittent pneumatic compression in addition to the standard complex decongestive therapy. The complex decongestive therapy procedure was the same as above, but additionally, 30 minutes of intermittent pneumatic compression was instituted using a pump (Pulse Press Multi 6 Pro; MJS Healthcare Ltd. UK) operating at 30-40 mmHg of pressure. All groups were given a total of 20 treatment sessions, including daily 5 times a week for 4 weeks.
62844682|NCT04606446|EXPERIMENTAL|1B Combination Dose Escalation|PF-07248144 with Fulvestrant Combination Dose Escalation
62058914|NCT03590600|EXPERIMENTAL|Cohort 5: 2000mg BTZ-043 fasting|N=8, 2000 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
62844683|NCT04606446|EXPERIMENTAL|1C Combination Dose Escalation|PF-07248144 with Letrozole + Palbociclib Combination Dose Escalation
62844684|NCT04606446|EXPERIMENTAL|2A Monotherapy Dose Expansion Arm|PF-07248144 Monotherapy Dose Expansion
62058915|NCT03590600|PLACEBO_COMPARATOR|Cohort 5: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
62262472|NCT00766532|EXPERIMENTAL|aromatase inhibitor therapy|aromatase inhibitor therapy for six weeks
62262473|NCT01867281|ACTIVE_COMPARATOR|Intervention: Aspirin|Participants will undergo aspirin desensitization over a 2-day period with increasing doses of aspirin (60, 125, 325 and 625 mg). Thereafter,they will be followed with 625 mg aspirin bid.
62262474|NCT01867281|PLACEBO_COMPARATOR|Control: placebo|Participants will receive placebo
62262475|NCT01238016|OTHER|device|Device implant and EEG recording
62262476|NCT03861754|EXPERIMENTAL|Lifestyle modification|intensified Behavioural Modification (iBM) group receiving lifestyle counselling
62262477|NCT03861754|EXPERIMENTAL|Lifestyle modification and exercise 1|"Intensified Behavioural Modification and exercise from 0 to 3 months (CWT1) group:~Lifestyle counselling 3 months Exercise intervention from 0 to 3 months"
62058916|NCT05164302|EXPERIMENTAL|Group A: LO1 point (Tooth)|Participant received auricular acupuncture and sham acupuncture at LO1 point in each side of the ear. In each session, temperature of skin surface at the pinna and lower jaw will be recorded.
62058917|NCT05164302|EXPERIMENTAL|Group B: LO3 point (Jaw)|Participant received auricular acupuncture and sham acupuncture at LO3 point in each side of the ear. In each session, temperature of skin surface at the pinna and lower jaw will be recorded.
62058918|NCT03482505|EXPERIMENTAL|INVSENSOR00004|All enrolled subjects will receive the INVSENSOR00004 sensor. The INVSENSOR00004 rainbow acoustic monitoring (RAM) acoustic respiration sensor is designed to noninvasively convert acoustical airflow patterns into respiratory rate (RRa).
62058919|NCT01905930|EXPERIMENTAL|PCM Cervical Disc|Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
62262478|NCT03861754|EXPERIMENTAL|Lifestyle modification and exercise 2|"Intensified Behavioural Modification and exercise from 6 to 9 months (CWT2) group:~Lifestyle counselling 3 months Exercise intervention from 6 to 9 months"
62262479|NCT03861754|NO_INTERVENTION|Control Group|Control group, no intervention, only measurements and questionnaires
62447045|NCT01762358|EXPERIMENTAL|Standard + Khalifa|Initial one hour Khalifa therapy followed by twelve times standardized Physiotherapy (15 patients)
62447046|NCT02776007|EXPERIMENTAL|Libre Flash CGMS (Continuous Monitoring System)|Patients will use the Libre Flash Continuous Glucose Monitoring System for 12 weeks for their glucose Management
62262480|NCT04905121|EXPERIMENTAL|Psilocybin|
62447047|NCT02776007|ACTIVE_COMPARATOR|SMBG|Patients will use Self-Monitoring of Blood Glucose for 12 weeks for their glucose management
62447048|NCT03845946||Hereditary angioedema type I/II|Hereditary angioedema with C1Inh deficiency
62447049|NCT03845946||Acquired angioedema|Angioedema with acquired C1Inh deficiency
62447050|NCT03845946||Drug induced angioedema|Angioedema associated with ACEi used
62447051|NCT03845946||Mast cell induced angioedema|Spontaneous mast cell induced isolated angioedema
62447052|NCT03845946||Hereditary angioedema with nC1Inh|Hereditary angioedema with normal C1Inh and with F12, PLG, ANGPT2 mutations
62844685|NCT04606446|EXPERIMENTAL|2B Combination Dose Expansion Arm|PF-07248144 with Fulvestrant Dose Expansion
62844686|NCT04606446|EXPERIMENTAL|1D Combination Dose Escalation|PF-07248144 with PF-07220060 +Fulvestrant
62844687|NCT04606446|EXPERIMENTAL|2D Combination Dose Expansion Arm|PF-07248144 with PF-07220060 +Fulvestrant Dose Expansion
62844688|NCT04606446|EXPERIMENTAL|China Monotherapy Dose Expansion|PF-07248144 Monotherapy Dose Expansion
62844689|NCT06390306||3G-TKI + AZA + Ven group|Adult CML-MBP
62844690|NCT04483648|EXPERIMENTAL|Exercise Group|A progressive home-based cervical stabilization exercise program was delivered by sending messages and video instructions via a freeware and cross-platform messaging service (WhatsApp Messenger) in a weekly basis.
62618884|NCT02913105|EXPERIMENTAL|LMB763|Oral dose once daily for 12 weeks (84 days)
62844691|NCT04483648|NO_INTERVENTION|Control Group|Patients in control group did not receive any exercise intervention.
62058920|NCT01905930|ACTIVE_COMPARATOR|Ant. Cervical Discectomy & Fusion(ACDF)|Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
62844692|NCT05261698|ACTIVE_COMPARATOR|Arms|Control group: in control group moist heating pads along with TENS shall be applied on neck for 10 minutes and then neck isometrics and strengthening exercises shall be performed.
62844693|NCT05261698|EXPERIMENTAL|Assigned Interventions|Experimental group: in the experimental group we will provide moist heating pads along with TENS on the neck for 10 minutes and then neck isometrics and strengthening exercises shall be performed. Patients in the experimental group will also receive a home-based exercise manual.
62844694|NCT02605122|EXPERIMENTAL|Solithromycin|Solithromycin will be administered orally, as capsules or as a suspension, or intravenously. Patients may receive intravenous therapy initially and switch to an oral formulation. Dosage is weight based and age based.
62844695|NCT02605122|ACTIVE_COMPARATOR|Standard of Care|Comparators will be selected according to subject age and are consistent with current recommendations for treatment of CABP in children. These include intravenous ceftriaxone, ampicillin, and amoxicillin and oral amoxicillin and amoxicillin-clavulanic acid. Azithromycin or erythromycin may be added as well.
62844696|NCT01955629|EXPERIMENTAL|Aflibercept + XELOX (Oxaliplatin and Capecitabine)|Aflibercept 6 mg/kg every 3 weeks (q3w) in combination with Oxaliplatin 100 mg/m\^2 q3w and Capecitabine 850 mg/m\^2 twice daily orally (from Day 1 to Day 14 of each cycle), up to 6 cycles as induction therapy, followed by aflibercept 6 mg/kg q3w as maintenance therapy up to disease progression or unacceptable toxicity or participant's refusal of further treatment.
62844697|NCT05083832|ACTIVE_COMPARATOR|Continuous erector spinae plane block|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine was injected into the area. A catheter will be placed in this area. Then, 5 ml/hour 0.125% bupivacaine will be infused via erector spinae plane block catheter.
62844698|NCT05083832|ACTIVE_COMPARATOR|Continuous serratus anterior plane block|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the serratus anterior muscles until the fourth rib area. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine was injected into the area. A catheter will be placed in this area. Then, 5 ml/hour 0.125% bupivacaine will be infused via serratus anterior plane block catheter.
62262481|NCT03930654|EXPERIMENTAL|iPrEP Intervention|"iPrEP Intervention:~* Women will receive the iPrEP intervention on an iPAD Air tablet device~* iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument~* iPrEP uses qualitative themes~* iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence~* Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument~* Scales were modified (in some cases) for cultural competency and tailoring to women"
62262482|NCT03930654|ACTIVE_COMPARATOR|Usual Care|"Control Intervention:~* Women will receive usual care~* Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use~* Social worker will offer a list of substance abuse treatment referral agencies"
62447053|NCT04105790|EXPERIMENTAL|Participants|Participants in class-based mental health intervention.
62844699|NCT05633316|EXPERIMENTAL|ICSIA|Intracytoplasmic sperm injection will be performed using the automated system named ICSIA (investigational device)
62844700|NCT05633316|EXPERIMENTAL|Control|In this control group oocytes will undergo manual ICSI as is routinely performed.
62844701|NCT05870943|EXPERIMENTAL|Hybrid Argon Plasma Coagulation and Endoscopic Sleeve Gastroplasty|Hybrid APC will be utilized to first ablate the gastric mucosa along the greater curve of the stomach, followed immediately by endoscopic full-thickness tissue acquisition and plication using 2-0 Prolene synthetic sutures via the Apollo ESG platform.
62262483|NCT00894556|EXPERIMENTAL|Treatment Sequence A|Rizatriptan - Rizatriptan - Placebo
62262484|NCT00894556|EXPERIMENTAL|Treatment Sequence B|Rizatriptan - Placebo - Rizatriptan
62262485|NCT00894556|EXPERIMENTAL|Treatment Sequence C|Placebo - Rizatriptan - Rizatriptan
62447054|NCT04951050|EXPERIMENTAL|Drug eluting stent|
62844702|NCT05870943|ACTIVE_COMPARATOR|Endoscopic Sleeve Gastroplasty|Endoscopic full-thickness tissue acquisition and plication using 2-0 Prolene synthetic sutures via the Apollo ESG platform.
62618885|NCT02913105|PLACEBO_COMPARATOR|Placebo|Oral dose once daily for 12 weeks (84 days)
62058921|NCT02809144|OTHER|Nerve block|One novel nerve block combination
62262486|NCT00894556|OTHER|Baseline Phase|Sumatriptan
62844703|NCT04595890|EXPERIMENTAL|Intervention Group|Injection of Bone Marrow Concentrate (BMC)
62844704|NCT04595890|PLACEBO_COMPARATOR|Control Group|Injection of saline
62844705|NCT05882708|NO_INTERVENTION|standard treatment group|"Standard treatment refers to that patients received active anti-infection and treatment of primary diseases according to the 2016 International Guidelines for the Management of Sepsis and septic shock. In addition, adequate volume resuscitation and vasoactive drug support can be given to maintain MAP≥65mmHg, and life support technologies such as ventilators and CRRT were given as needed.~The target of heart rate control not mentioned in the above guidelines, was not mandatory for this group of patients with sinus tachycardia, so pharmacologic intervention was not administered."
62844706|NCT05882708|EXPERIMENTAL|Ivabradine group|Standard treatment for sepsis plus enteral ivabradine.
62844707|NCT03284658||Observation|Patients with a Tyrosinemia type 1 or high-grade suspi-cion for Tyrosinemia type 1
62844708|NCT00167219|EXPERIMENTAL|Intent-to-Treat|Patients receiving study regimen.
62844709|NCT05932212|EXPERIMENTAL|AK104|AK104 15mg/kg intravenously(IV) every 3 weeks (Q3W), until progressive disease, unacceptable toxicity, completion of 2 years treatment or withdrawal of consent.
62844710|NCT02453204|EXPERIMENTAL|Sitting|Participants will remain sitting throughout the test period whilst undertaking typical sedentary behaviours such as watching TV, using a computer, reading and writing. Walking and standing will be restricted.
62844711|NCT02453204|EXPERIMENTAL|Standing|Participants will be asked to break their sitting time by standing for five minutes every 30 minutes. Participants will be asked to stand in the same position with no further instructions provided. In total, individuals will accumulate 12 bouts (60 minutes) of standing throughout the test period.
62844712|NCT02453204|EXPERIMENTAL|Walking|The walking condition will be identical to standing, but the breaks in sitting time will be punctuated with five minute bouts of self-paced walking rather than standing.
62844713|NCT02703337|EXPERIMENTAL|LY900014 (Part A)|Individualized doses of LY900014 administered by injection under the skin once in each of 3 periods
62844714|NCT02703337|ACTIVE_COMPARATOR|Insulin Lispro - Reference (Part A)|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
62844715|NCT02703337|EXPERIMENTAL|LY900014 (Part B)|Individualized doses of LY900014 administered by injection under the skin with each meal for 14 days
62844716|NCT02703337|ACTIVE_COMPARATOR|Insulin Lispro - Reference (Part B)|Individualized doses of insulin lispro reference formulation administered by injection under the skin with each meal for 14 days
62447055|NCT03212196|ACTIVE_COMPARATOR|Pancreaticogastrostomy|Pancreaticogastrostomy with external drain
62447056|NCT03212196|ACTIVE_COMPARATOR|Pancreaticojejunostomy|Pancreaticojejunostomy with transanastomotic drain
62447057|NCT04764500||travellers to Southeast Asia|Clients planning to travel to Southeast Asia will be recruited
62447058|NCT03101943|EXPERIMENTAL|Family Spirit Nurture (FSN)|The intervention group (n=68) will receive the Family Spirit Nurture (FSN) home-visiting module, consisting of six 45-minute lessons delivered biweekly by trained local American Indian Family Health Coaches (FHCs), from 3 to 6 months postpartum. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices. Lessons are highly visual and interactive, and will incorporate cultural teachings related to infant feeding and nutrition that support aims. All families will receive water delivery of drinking water from 6 to 9 months postpartum.
62844717|NCT04950621|EXPERIMENTAL|Remimazolam|In remimazolam group, a 0.1 mg/kg dose of intravenous remimazolam was administered for induction, and 0.3-0.7 mg/kg/h infusion for maintenance after intubation.
62844718|NCT04950621|ACTIVE_COMPARATOR|Propofol|In propofol group, a 2 mg/kg dose of intravenous propofol was administered for induction, and 4-12 mg/kg/h infusion for maintenance after intubation.
62844719|NCT04884178|EXPERIMENTAL|Trifocal Preloaded IOL Delivery System|Bilateral trifocal IOLs implanted through preloaded IOL Delivery System in the capsular bag in the posterior chamber of the eye during cataract surgery
62058922|NCT04976803||Group A|Deceased patients with archival tissue
62058923|NCT04976803||Group B|Living patients with archival tissue
62058924|NCT04976803||Group C|Living patients without archival tissue
62058925|NCT02740322|OTHER|Hum Test|To examine and compare the Hum Test, Weber Test, and audiogram in their ability to detect and identify hearing loss, hearing loss will be simulated with the use of ear plugs (mimicking conductive hearing loss). Subjects will serve as their own control as these tests will be conducted with and without ear plugs.
62058926|NCT01592162|ACTIVE_COMPARATOR|propofol 1% (Astra-Zeneca) - remi 0|propofol 1% (Astra-Zeneca)plus remifentanil 0 ng/ml
62058927|NCT01592162|ACTIVE_COMPARATOR|propofol 1% (Astra-Zeneca) - remi 2|propofol 1% (Astra-Zeneca)plus remifentanil 2 ng/ml
62058928|NCT01592162|ACTIVE_COMPARATOR|propofol 1% (Astra-Zeneca) - remi 4|propofol 1% (Astra-Zeneca)plus remifentanil 4 ng/ml
62058929|NCT01592162|ACTIVE_COMPARATOR|propofol 1% (Fresenius) - remi 0|propofol 1% (Fresenius) plus remifentanil 0 ng/ml
62058930|NCT01592162|ACTIVE_COMPARATOR|propofol 1% (Fresenius) - remi 2|propofol 1% (Fresenius) plus remifentanil 2 ng/ml
62058931|NCT01592162|ACTIVE_COMPARATOR|propofol 1% (Fresenius) - remi 4|propofol 1% (Fresenius) plus remifentanil 4 ng/ml
62058932|NCT01592162|ACTIVE_COMPARATOR|propofol 1% (B-Braun) - remi 0|propofol 1% (B-Braun) plus remifentanil 0 ng/ml
62058933|NCT01592162|ACTIVE_COMPARATOR|propofol 1% (B-Braun) - remi 2|propofol 1% (B-Braun) plus remifentanil 2 ng/ml
62058934|NCT01592162|ACTIVE_COMPARATOR|propofol 1% (B-Braun) - remi 4|propofol 1% (B-Braun) plus remifentanil 4 ng/ml
62262487|NCT04511247|EXPERIMENTAL|MagicTouch PTA sirolimus drug coated balloon (DCB)|MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
62618886|NCT05537285|EXPERIMENTAL|Individualized Accelerated Intermittent Theta Burst Stimulation (Ind-aiTBS)|Patients will receive individualized unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions. The target for stimulation will be individualized using the participant's fMRI scans by finding the region of the DLPFC most anti-correlated with the subgenual anterior cingulate cortex (sgACC). This target will be determined using e-field modeling and theta-gamma coupling.
62618887|NCT05537285|ACTIVE_COMPARATOR|Standard Accelerated Intermittent Theta Burst Stimulation (Std-aiTBS)|Patients will receive unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions.
62844720|NCT03284541|EXPERIMENTAL|2GETHER|2GETHER is an HIV prevention and relationship education program designed for young male couples. 2GETHER consists of 4 sessions (2 group sessions, 2 individualized couple session) administered over the course of 1 month (1 session per week). Group sessions focus on developing skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
62618888|NCT05537285|SHAM_COMPARATOR|Sham Accelerated Intermittent Theta Burst Stimulation (sham)|Patients will receive sham unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions.
62618889|NCT05035849|ACTIVE_COMPARATOR|Group A|Patients in group A were given sitagliptin and metformin for the first two weeks, and then were treated with acarbose and metformin for the second two weeks. FGM was used to monitor glycemic variations during the whole four weeks.
62058935|NCT05917704|ACTIVE_COMPARATOR|Guitar then physical therapy|Subjects will learn classical guitar then have physical therapy sessions.
62058936|NCT05917704|ACTIVE_COMPARATOR|Physical therapy then guitar|Subjects will have physical therapy sessions then learn classical guitar
62262488|NCT04511247|ACTIVE_COMPARATOR|Placebo balloon angioplasty|Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
62262489|NCT00782951|EXPERIMENTAL|Org 28611|
62262490|NCT00782951|ACTIVE_COMPARATOR|morphine sulfate|
62262491|NCT00782951|PLACEBO_COMPARATOR|Placebo|
62844721|NCT03284541|ACTIVE_COMPARATOR|Existing Public Health Practice|The control condition consists of the single-session Couples-Based HIV Counseling and Testing protocol for HIV-negative couples, the single-session Life-Steps medication adherence protocol for HIV-positive couples, or both intervention delivered jointly to serodiscordant couples
62058937|NCT03626090|EXPERIMENTAL|Treatment Arm|A single dose of 0.5 to 1 x 10\^6/kg autologous BM MSCs (Total volume: 30 - 50 ml) will be infused via peripheral venous access.
62058938|NCT03324438|ACTIVE_COMPARATOR|Home Telehealth T1D (CoYoT1-HR)|Home Telehealth T1D (C2oYoT1-HR), standard of care delivered via Telehealth for high-risk youth
62262492|NCT06012370|OTHER|Stress incontinence patients|PRP injection
62058939|NCT03324438|EXPERIMENTAL|Personalized Adherence Feedback|C2oYoT1-HR+Personalized Adherence Intervention
62058940|NCT03324438|EXPERIMENTAL|Personalized Behavioral Health|C2oYoT1-HR+Personalized Behavioral Health
62262493|NCT05140538|ACTIVE_COMPARATOR|Group 1|SRP + Biorepair Total Protective Repair toothpaste for home oral hygiene twice a day
62262494|NCT05140538|EXPERIMENTAL|Group 2|SRP + Biorepair Total Protective Repair toothpaste + Biorepair mouthwash (3 in 1) for home oral hygiene twice a day
62262495|NCT01834274|EXPERIMENTAL|Fasiglifam 50 mg|Fasiglifam (TAK-875) 50 mg tablets, orally, once daily, Sitagliptin placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum-tolerated dose), tablets, orally, daily for up to 24 weeks.
62262496|NCT01834274|ACTIVE_COMPARATOR|Sitagliptin 100 mg|Sitagliptin 100 mg, tablets, once daily, TAK-875 placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum-tolerated dose), tablets, orally, daily for up to 24 weeks.
62262497|NCT01708642|EXPERIMENTAL|Adrenaline|Intraoperative low-dose adrenaline infusion
62262498|NCT01708642|PLACEBO_COMPARATOR|Placebo|Placebo: Isotonic Saline
62262499|NCT06252064|ACTIVE_COMPARATOR|Combo Group|Rehabilitation treatment combined with drug therapy
62262500|NCT06252064|ACTIVE_COMPARATOR|Reha Group|Rehabilitation treatment
62262501|NCT06252064|ACTIVE_COMPARATOR|Drug Group|Drug therapy with Pridinol Mesylate
62262502|NCT00769184|EXPERIMENTAL|Corticosteroid + LCD|corticosteroid and LCD treatment (2 weeks), LCD alone treatment (4 weeks)
62262503|NCT00769184|PLACEBO_COMPARATOR|Corticosteroid + Placebo|corticosteroid and placebo treatment (2 weeks), placebo alone treatment (4 weeks)
62447059|NCT03101943|OTHER|Control Program|The control group (n=68) will receive three home-based lessons with home safety information (injury prevention is a priority identified by Navajo leadership that does not interfere with study questions). Mothers randomized to the control group will receive 3 educational lessons on home safety and child safety proofing. These meaningful topics were selected so as not to dilute measurement on key FSN outcomes and to provide benefit to all study participants. Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing. All families will receive water delivery of drinking water from 6 to 9 months postpartum.
62447060|NCT03902275|EXPERIMENTAL|Quantra|Evaluation of bloodsamples using the Quantra and Multiplate device
62058941|NCT03324438|EXPERIMENTAL|C2oYoT1-HR + Adherence + Behavioral|C2oYoT1-HR + both Personalized Adherence Feedback + Personalized Behavioral Health (C2oYoT1-HR + Adherence + Behavioral)
62262504|NCT02956603|EXPERIMENTAL|Neuroma Graft|In this arm, participants have already had partial muscle grafts placed on the amputated nerves to control neuroma growth. The investigators will place small electrodes percutaneously into the muscle grafts to record EMG signals and electrically stimulate the implanted nerves.
62262505|NCT02956603|EXPERIMENTAL|Prosthetic Control Graft|In this arm, participants will have an initial surgery to place partial muscle grafts on the amputated nerves. After a healing period, the investigators will place small electrodes percutaneously into the muscle grafts to record EMG signals and electrically stimulate the implanted nerves.
62447061|NCT03902275|ACTIVE_COMPARATOR|Control|Evaluation of bloodsamples using the ROTEM and Multiplate device
62447062|NCT04955379|OTHER|Measurements|Subjects will be tested with the Autorefractor and the EQ103 device
62618890|NCT05035849|ACTIVE_COMPARATOR|Group B|Patients in group B were given acarbose and metformin for the first two weeks, and then were treated with sitagliptin and metformin for the second two weeks.FGM was used to monitor glycemic variations during the whole four weeks.
62618891|NCT03873311|EXPERIMENTAL|Azacytidine + HAG Regimen|Azacytidine（75mg/m2 ）+ HAG Regimen（Homoharringtonine(HHT) 1mg/(m2.d) , Cytarabine 10mg/(m2.d), G-CSF 200ug/(m2.d) )
62618892|NCT03873311|ACTIVE_COMPARATOR|Azacytidine|75mg/m2
62618893|NCT01879202|ACTIVE_COMPARATOR|Methylphenidate modified release|The active agents is racemic methylphenidate hydrochloride, modified release, a mild central nervous system stimulant (pharmacotherapeutic group: psychostimulants). Study medication will be taken once daily. Initially patients will be provided with 20mg and 30mg capsules of study medication. They are instructed to take 20mg within the first week and within the second week 30mg capsules. Visit 2 is scheduled two weeks after baseline and at Visit 2 patients will be provided with 40mg capsules and instructed to take them for the rest of the study.
62844722|NCT03276091|EXPERIMENTAL|COLOFIT+ Study|Personnalized motivational phone call, done by a medical physician
62844723|NCT05862662||Children in MOVE Program|Children 5-12 years old who participated in the MOVE program for at least 12 continuous months prior to March 1, 2020 and again for at least 12 continuous months after August 2021.
62844724|NCT05862662||Adults in MOVE Program|Adults 22-65 years old who participated in the MOVE program for at least 12 continuous months prior to March 1, 2020 and again for at least 12 continuous months after August 2021.
62844725|NCT02140593|PLACEBO_COMPARATOR|Standard neuromuscular blockade|Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment decided by the attending anesthetist combined with saline infusion (placebo).
62844726|NCT02140593|ACTIVE_COMPARATOR|Deep neuromuscular blockade|Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level post tetanic count (PTC) of 0-1 combined with bolus saline (placebo) mimicking standard treatment.
62844727|NCT00921518|PLACEBO_COMPARATOR|Normal Saline|This group will receive isotonic saline at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
62844728|NCT00921518|ACTIVE_COMPARATOR|Sodium Bicarbonate|This arm two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
62844729|NCT02561468|EXPERIMENTAL|Nefopam|20 mg nefopam in 100 ml normal saline is infused before starting operation.
62844730|NCT02561468|PLACEBO_COMPARATOR|Control|100 ml normal saline is infused before starting operation.
62844731|NCT01999517|ACTIVE_COMPARATOR|Intravenous Nitroglycerin|IV Nitroglycerin with IV Fluids
62844732|NCT01999517|PLACEBO_COMPARATOR|Placebo|IV Fluids
62844733|NCT05550493|EXPERIMENTAL|Digital Therapeutics|The DTx group was asked to download and install a smartphone application (WonderLab Harbor) that incorporated Internet-based Cognitive Behavioral Therapy (ICBT), Approach Bias Modification (ApBM), cognitive function training, and Contingency Management (CM). During the 8-week treatment program, the participants in the DTx group were instructed to complete ICBT, cognitive trainings, and ApBM trainings. Reward points (which can be redeemed for cellphone plan credit) were rewarded following completing each task as part of the positive reinforcement following CM principles.
62058942|NCT03113123|OTHER|PrEP with Truvada®|"On demand PrEP (only for MSM - with the possibility of dosing schedule switching): 2 pills of Truvada within 24 to 2 hours prior first sexual intercourse, then 1 pill every 24 hours during the period of sexual activity with one pill after the last sexual intercourse, and one last pill 24 hours later~Continuous PrEP: 1 pill every 24 hours, at least 7 days before the first sexual intercourse. When PrEP is to be discontinued, 2 pills 24 hours apart after the last sexual intercourse then stop PrEP. If PrEP is to be resumed, 1 pill every 24 hours, started at least 7 days before the first sexual intercourse or 2 pills at least 2 hours before the first sexual intercourse and then 1 pill every 24 hours."
62058943|NCT05115344|EXPERIMENTAL|flonoltinib 25mg|1 case，The starting dose，Take the medicine once on D1 ，D 5 through 21.
62262506|NCT02956603|EXPERIMENTAL|Able Bodied|The investigators will place small electrodes percutaneously into intact muscles in the arm to record EMG signals and electrically stimulate the intact nerves nearby.
62058944|NCT05115344|EXPERIMENTAL|flonoltinib 50mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
62058945|NCT05115344|EXPERIMENTAL|flonoltinib 100mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
62058946|NCT05115344|EXPERIMENTAL|flonoltinib 150mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
62058947|NCT05115344|EXPERIMENTAL|flonoltinib 225mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
62262507|NCT02381639|OTHER|Patients|patients followed in the addiction service of the University Hospital of Nantes (consultations and / or hospitalizations) for restrictive anorexia nervosa
62262508|NCT02381639|OTHER|Healthy volunteers|control subjects matched for age and sex with the patients
62447063|NCT02490423|ACTIVE_COMPARATOR|Nudges Intervention|The intervention arm will employ standard cardiovascular clinical care plus the combination of the MoBe Maps Patient Activation Platform with the Intermountain Risk Score to personalize and deliver motivational nudges to each participant.
62618894|NCT01879202|PLACEBO_COMPARATOR|Maltodextrin|Study medication has to be taken once daily. Initially patients will be provided with 20mg and 30mg capsules of study medication. They are instructed to take 20mg within the first week and within the second week 30mg capsules. Visit 2 is scheduled two weeks after baseline and at Visit 2 patients will be provided with 40mg capsules and instructed to take them for the rest of the study.
62447064|NCT02490423|NO_INTERVENTION|Standard of Care|The standard of care arm will utilize Intermountain cardiovascular clinical program care processes as they are in place today for treatment of the study subjects.
62447065|NCT02089490|EXPERIMENTAL|NEVELIA®|NEVELIA® implantation according to the intended use in the leaflet, prior to autologous skin grafting planned 3 weeks after its application.
62447066|NCT04272775|EXPERIMENTAL|Cohort 1: Ixazomib 4.0 mg|Ixazomib 4.0 milligram (mg), capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87.
62447067|NCT04272775|EXPERIMENTAL|Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone|Ixazomib 4.0 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 milligram per day (mg/day), capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in 28-day treatment cycle for up to Cycle 62.
62618895|NCT03913871|EXPERIMENTAL|Telephone (text messages) support for healthy eating|Participants will receive average of 1-2 text messages per day for 4 weeks focused on health eating with the aim increasing consumption of fruits, vegetables and water; and a reduce intake of sugar sweetened beverages.
62618896|NCT03913871|ACTIVE_COMPARATOR|Telephone (text messages) support for physical activity|Participants will receive an average of 1-2 text messages per day for 4 weeks that offer physical activity and general health/wellbeing advice.
62618897|NCT06154421||Rheumatoid Arthritis finger joint destruction|Patients with rheumatoid arthritis who received a metacarpophalangeal joint prostheses system after 01.01.2014
62618898|NCT06154421||Osteoarthritis finger joint destruction|Patients with post-traumatic wrist osteoarthritis who received a metacarpophalangeal joint prostheses system after 01.01.2014
62618899|NCT01038752|EXPERIMENTAL|Suramin|This group will receive the combination of non-cytotoxic suramin with docetaxel and carboplatin.
62618900|NCT01038752|PLACEBO_COMPARATOR|Standard of care|This group will receive placebo with docetaxel and carboplatin.
62618901|NCT00135356|ACTIVE_COMPARATOR|Switch arm|
62618902|NCT00135356|ACTIVE_COMPARATOR|Control Arm|
62618903|NCT05732077|OTHER|Not stenting|Hyperemic FFR induced by 50μg/kg of dopamine via renal artery will be measured. If FFR is ≥0.80, randomization will be applied, and no stenting will be implanted. If FFR is \<0.80, randomization will be ignored, and stenting will be performed.
62058948|NCT05115344|EXPERIMENTAL|flonoltinib 325mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
62058949|NCT05094167|EXPERIMENTAL|probiotics group|"The oral probiotic (Lactobacillus Bifidobacterium V9,one times a day during the whole treatment) was isolated from healthy women's breast milk samples in 2017 and was identified as Lactobacillus rhamnosus by physiological and biochemical and 16S rRNA. It is listed as the List of Probiotics for Health Food in my country's List of Bacteria Available for Food, which can be directly applied to food production."
62058950|NCT05094167|PLACEBO_COMPARATOR|placebo group|Immunotherapy with placebo alone
62058951|NCT05094167|NO_INTERVENTION|healthy control group|healthy control group
62058952|NCT04219852||"bariatric surgery group"|Women between 18 and 50 years, who undergone bariatric surgery at the University Hospital of Reims.
62058953|NCT05539703|EXPERIMENTAL|Intervention groups: Invitation to get 2nd booster|Participants in the intervention group will receive an invitation to get a 2nd COVID-19 booster dose. Those who accept the invitation to be vaccinated will receive the vaccine through their municipality's vaccination service.
62058954|NCT05539703|NO_INTERVENTION|Control group: No invitation to get 2nd booster|The control group will receive no intervention.
62058955|NCT03976466|EXPERIMENTAL|Calcium sulfate Group|Group of members that will be submitted to prophylaxis with medicated calcium sulfate beads for hip or knee joint replacement
62058956|NCT03976466|ACTIVE_COMPARATOR|Control Group|Group of members that will be submitted to classic prophylaxis for hip or knee joint replacement
62058957|NCT06223503|EXPERIMENTAL|Telehealth Transitional Pain Service + Standard Postoperative Follow-Up Care|Telehealth Transitional Pain Service + Standard Postoperative Follow-Up Care
62058958|NCT06223503|ACTIVE_COMPARATOR|Standard Follow Up Care|Standard Follow Up Care
62058959|NCT06054230|EXPERIMENTAL|Genomic Sequencing|
62844734|NCT05550493|ACTIVE_COMPARATOR|Treatment as Usual|Upon enrollment, TAU participants were informed that they would receive weekly counseling sessions from a social worker for eight weeks. The counseling covered topics including work, family, stress management, and drug craving suppression.
62844735|NCT02955043|EXPERIMENTAL|Behavioral intervention|Participants will learn behavioral techniques to improve sleep and increase daytime activity with the goal of alleviating insomnia, fatigue, and depression. The intervention will be delivered in three 45-60 minute face-to-face sessions at approximately 3-4, 8, and 12 weeks post-HSCT with brief telephone coaching calls scheduled between sessions. Participants will be encouraged to use the behavioral strategies from hospital discharge through 18 weeks post-HSCT. Participants will be asked to complete a daily checklist indicating which intervention strategies they used. Participants will also receive standard medical care following HSCT.
62844736|NCT02955043|NO_INTERVENTION|Usual care|Participants will receive standard medical care following HSCT.
62058960|NCT01680393|EXPERIMENTAL|Sequential compression device|During arthroscopic shoulder surgery, an SCD device will be applied to the patients legs during surgery. Cerebral oxygenation and circulatory parameters will be recorded continuously throughout the surgery. Recordings will be hidden to the primary caregiver.
62844737|NCT00790140|ACTIVE_COMPARATOR|Immunonutrition Prosure|This group of patients are to be given a tube feed enriched with 2.2 g Eicosapentaenoic Acid (EPA) per day for 5 days pre surgery and 21 days post surgery
62844738|NCT00790140|PLACEBO_COMPARATOR|Standard enteral nutrition Ensure Plus|This group are to be given a standard enteral tube feed without EPA for 5 days pre op and 21 days post surgery
62844739|NCT02871752|EXPERIMENTAL|MBSR (Mindfulness condition)|MBSR (mindfulness-based stress reduction) is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations. Lesson activities include the following: (1) mindful meditation (e.g., awareness of breathing, body scan, sitting, walking); (2) yoga; and (3) group discussion.
62844740|NCT02871752|ACTIVE_COMPARATOR|HealthPro (Control Matched Condition)|HealthPro is a health promotion program designed by Dr. David Victorson of Northwestern University Medical Social Sciences Department and his research team to function as a matched control for the MBSR intervention in this research study. The program teaches and promotes healthy behaviors, skills, and lifestyles. Major learning themes include: (1) health behavioral change readiness and self-assessment; (2) physical activity, movement, and non-sedentary lifestyles; (3) dietary and nutritional considerations for optimal health; (4) emotional wellness and coping with difficulties; (5) social engagement, relationships intimacy, and health; (6) managing bodily pain; (7) weight management and weight loss strategies; (8) health behavior maintenance over the long-term.
62844741|NCT00758199|ACTIVE_COMPARATOR|2|Moxifloxacin
62844742|NCT00758199|PLACEBO_COMPARATOR|3|Prednisolone Acetate
62844743|NCT00758199|ACTIVE_COMPARATOR|1|Bromfenac
62844744|NCT02695420|PLACEBO_COMPARATOR|Placebo BID|Participants will receive placebo BID.
62844745|NCT02695420|EXPERIMENTAL|25 mg Omecamtiv Mecarbil BID|Participants will receive 25 mg omecamtiv mecarbil BID.
62058961|NCT01680393|EXPERIMENTAL|TED stockings|During arthroscopic shoulder surgery, TED stockings will be applied to the patients legs during surgery. Cerebral oxygenation and circulatory parameters will be recorded continuously throughout the surgery. Recordings will be hidden to the primary caregiver.
62058962|NCT01680393|NO_INTERVENTION|Control|no stockings will be applied to the patients legs
62447068|NCT04272775|EXPERIMENTAL|Cohort 3: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87.
62262509|NCT00712699|EXPERIMENTAL|Sequence 1: XR-MAS then placebo|Depending on whether 1) child has had previous medication trial or 2) is on psychotropic medication at time of screening, children will either enter the washout period of 3 days before extended release mixed amphetamine salts (XR-MAS) or placebo (PBO) is initiated or proceed directly to the active treatment sequence they were randomized to. Participants randomized to Sequence 1 first receive treatment with XR-MAR for 3 weeks and then placebo for 3 weeks. Flexible, forced dosing will start at 5 mg/day for the first week, increase to 10 mg/day for the second week and continue to 15 mg/day on the third week. No washout period otherwise occurs (XR-MAS is not clinically suspected to have lingering effects beyond initial dosing/day of administration), including the crossover week to PBO.
62844746|NCT02695420|EXPERIMENTAL|37.5 mg Omecamtiv Mecarbil BID Target Dose|Participants will receive omecamtiv mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 37.5 mg BID after Week 4 or Week 8, based on Week 2 PK.
62844747|NCT02695420|EXPERIMENTAL|50 mg Omecamtiv Mecarbil BID Target Dose|Participants will receive Omecamtiv Mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 50 mg BID after Week 4 or Week 8, based on Week 2 PK.
62618904|NCT05732077|OTHER|Stenting|Hyperemic FFR induced by 50μg/kg of dopamine via renal artery will be measured. No matter FFR is, stenting will be performed as planned.
62618905|NCT03013790|ACTIVE_COMPARATOR|Melatonin 5mg|This arm will be given 5mg tablets of Melatonin nightly for the duration of their hospital stay
62447069|NCT04272775|EXPERIMENTAL|Cohort 4: Ixazomib 5.5 mg + Lenalidomide and Dexamethasone|Ixazomib 5.5 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 mg/day, capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in 28-day treatment cycle for up to Cycle 87.
62447070|NCT05865509|EXPERIMENTAL|Escape room|This group received training on stress response using the escape room method.
62618906|NCT03013790|ACTIVE_COMPARATOR|Melatonin 3mg|This arm will be given 3mg tablets of Melatonin nightly for the duration of their hospital stay
62618907|NCT03013790|PLACEBO_COMPARATOR|Placebo|This arm will be given a Sucrose tablet nightly for the duration of their hospital stay
62618908|NCT01298349||schizophrenic patients|
62618909|NCT01298349||normal population|
62447071|NCT05865509|EXPERIMENTAL|Storytelling|This group received training on stress response using the storytelling method.
62447072|NCT00841256|EXPERIMENTAL|Immunotherapy|Grass pollen allergens in a water/glycerol solution
62447073|NCT00841256|PLACEBO_COMPARATOR|Placebo|Water/glycerol solution with phosphate buffered saline
62447074|NCT04689477||COVID-19|Hospitalized patients diagnosed with COVID-19, presenting with arterial hypoxemia.
62447075|NCT04689477||Control|Healthy subjects
62447076|NCT04689477||Non-COVID critically ill patients|Non-COVID critically ill patients admitted to the ICU.
62447077|NCT04453566||Elite Athletes|Elite Athletes
62618910|NCT04086381|ACTIVE_COMPARATOR|Intervention|Oral injestion of 20 grams of creatine monohydrate daily
62618911|NCT04086381|PLACEBO_COMPARATOR|Placebo|Oral injestion of 20 grams of cellulose daily
62618912|NCT00552890|EXPERIMENTAL|ATK|modified Atkins diet
62618913|NCT00552890|EXPERIMENTAL|ADA|subjects assigned to follow ADA recommended diet for 1 year
62618914|NCT06485570|OTHER|control group|"In the control group, the trainings prepared by the researcher in line with the literature information on the Environmental Theory, Self-Care Disability Theory and Adaptation Model will be carried out in 3 sessions with the lecture method, respectively. The trainings will be planned in the classroom environment for 4 weeks and 2 lesson hours (100 minutes) for each session. At the end of the trainings, Knowledge Measurement Questionnaire and Perception of Nursing Profession Scale will be applied to the participants as a post-test to measure their level of knowledge about nursing theories. In the third stage of the study, semi-structured interviews will be conducted with the students from the experimental group after the applications in order to reveal the participants' views on teaching methods."
62844748|NCT02672293|EXPERIMENTAL|Phosphate|500 mg of oral phosphate is administered after an overnight fast.
62844749|NCT06211959|EXPERIMENTAL|Classical Approach Bias Modification|The 3 arms will follow a similar procedure, except that they will receive 3 different experimental interventions, dependly on their conditions.
62844750|NCT06211959|EXPERIMENTAL|Approach Bias Modification with Implementation Intentions|The 3 arms will follow a similar procedure, except that they will receive 3 different experimental interventions, dependly on their conditions.
62618915|NCT06485570|EXPERIMENTAL|Experimental|"The trainings prepared by the researcher in line with the literature information on Environmental Theory, Self-Care Disability Theory and Adaptation Model will be carried out in 3 sessions with creative drama teaching method to the experimental group. The trainings will be planned in the classroom environment for 4 weeks and 2 lesson hours (100 minutes) for each session. At the end of the trainings, Knowledge Measurement Questionnaire and Perception of Nursing Profession Scale will be applied to the participants as a post-test to measure their level of knowledge about nursing theories. In the third stage of the study, semi-structured interviews will be conducted with the students from the experimental group after the applications in order to reveal the participants' views on teaching methods."
62262510|NCT00712699|EXPERIMENTAL|Sequence 2 Placebo then XR-MAS|Depending on whether 1) child has had previous medication trial or 2) is on psychotropic medication at time of screening, children will either enter the washout period of 3 days before extended release mixed amphetamine salts (XR-MAS) or placebo (PBO) is initiated or proceed directly to the active treatment sequence they were randomized to. Participants randomized to Sequence 2 will first receive treatment with PBO for 3 weeks and then XR-MAS for 3 weeks. Flexible, forced dosing will start at 5 mg/day for the first week, increase to 10 mg/day for the second week and continue to 15 mg/day on the third week. No washout period (stimulants are not clinically suspected to have lingering effects beyond initial dosing/day of administration)otherwise occurs, including the crossover week to XR-MAS.
62262511|NCT05486559|EXPERIMENTAL|The ECMO-free Protocol group|For patients assigned to the ECMO-free protocol group, the study personnel will perform the ECMO-free protocol daily from enrollment until the first of death or ECMO decannulation; results will be recorded and shared with the treatment team. Final decisions regarding decannulation will be made by treating clinicians who are aware of the results of daily ECMO-free protocolized assessments.
62618916|NCT02593955|ACTIVE_COMPARATOR|PD exercise group|Supervised exercise training, 3x per week for 16 weeks
62447078|NCT05469282|EXPERIMENTAL|blood circulation treatment|Blood circulation treatment for the risk group for Deep Vein Thrombosis (DVT) and the ordinary person
62447079|NCT04530786||Vaccine, Post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
62447080|NCT04530786||Vaccine, Healthy Control|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
62618917|NCT02593955|ACTIVE_COMPARATOR|PD sleep hygeine group|Tips for improved sleep hygiene, reading materials
62262512|NCT05486559|ACTIVE_COMPARATOR|The Usual Care Group|For patients assigned to the usual care group, ECMO weaning and assessments of readiness for ECMO decannulation will be at the discretion of treating clinicians.
62618918|NCT02593955|NO_INTERVENTION|Healthy control|MRI sub-study only
62618919|NCT01961167|EXPERIMENTAL|Gore VIABAHN BX|Balloon expandable stenting of iliac occlusive disease
62618920|NCT05614583|EXPERIMENTAL|MORT-PFPS|Participants randomly assigned to this arm will use the app, MORT-PFPS.
62618921|NCT05614583|ACTIVE_COMPARATOR|treatment as usual (TAU)|Participants randomly assigned to this arm will receive their TAU only (no use of the app, MORT-PFPS).
62618922|NCT06543420|EXPERIMENTAL|lateral reconstruction group|After RARP surgery, lateral reconstruction is performed
62618923|NCT06543420|EXPERIMENTAL|posterior reconstruction group|After RARP surgery, posterior reconstruction is performed
62618924|NCT06543420|NO_INTERVENTION|control group|No lateral or posterior reconstruction is performed after RARP surgery
62844751|NCT06211959|PLACEBO_COMPARATOR|Sham-training|The 3 arms will follow a similar procedure, except that they will receive 3 different experimental interventions, dependly on their conditions.
62618925|NCT04413383|ACTIVE_COMPARATOR|Traditional Curved Iris Scissors|The traditional curved Iris scissors are used to during the dermatologic surgery. Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure.
62618926|NCT04413383|EXPERIMENTAL|Modified Curved Iris Scissors|"The Wuennenberg modified curved Iris scissors are used during the dermatologic surgery.~Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure."
62618927|NCT04413383|OTHER|Comparative Experience|Both the traditional and modified curved Iris scissors are used and patients are asked which they prefer. Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure.
62618928|NCT02499510|EXPERIMENTAL|GoldenFlow stent|Titanium nitrite coated woven nitinol stent
62618929|NCT04720625|EXPERIMENTAL|Adapt2Quit|These participants will receive Adapt2Quit motivational messaging and quitline facilitation messaging for 6 months.
62618930|NCT04720625|ACTIVE_COMPARATOR|Control|These participants will receive quitline facilitation-only messaging for 6 months.
62262513|NCT03943875|ACTIVE_COMPARATOR|Females, 3 dose standard|Three doses of the 9-valent HPV vaccine to be administered to the comparison group (15-26 years of age) at 0, 2, and 6 months.
62618931|NCT02624128|EXPERIMENTAL|valproic acid plus cisplatin and cetuximab|
62618932|NCT00523809|EXPERIMENTAL|Bevacizumab + Fludarabine + Melphalan|Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m\^2 IV Daily over 5 Days; Melphalan 70 mg/m\^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.
62618933|NCT05635500|EXPERIMENTAL|Middle Insertion|Videolaryngoscope is inserted from the middle for endotracheal intubation.
62618934|NCT05635500|NO_INTERVENTION|Right Insertion|Videolaryngoscope is inserted from the right for endotracheal intubation.
62844752|NCT01281332|ACTIVE_COMPARATOR|Menopod device|Menopod®
62844753|NCT01281332|SHAM_COMPARATOR|Sham device|Inactive device.
62844754|NCT05526404|EXPERIMENTAL|Mobile application-based Bristol stool scale|Subjects with cirrhosis who are taking lactulose for the treatment of hepatic encephalopathy will download the Dieta mobile application on their mobile device and take a photo of each bowel movement using the Dieta application
62262514|NCT03943875|EXPERIMENTAL|Females, 2 dose with delayed 3rd dose|Two doses of the 9-valent HPV vaccine to be administered to the experimental group (15-26 years of age) at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
62262515|NCT03943875|ACTIVE_COMPARATOR|Males, 3 dose standard|Three doses of the 9-valent HPV vaccine to be administered to the comparison group (15-26 years of age) at 0, 2, and 6 months.
62844755|NCT05860972|ACTIVE_COMPARATOR|Active group|Active group that will receive 2 treatments with the InMode RF Pro System with the Morpheus8 Applicator (with the 24 pin tip)
62844756|NCT05860972|SHAM_COMPARATOR|Sham group|Sham group that will receive 2 sham treatments with the same InMode RF Pro System and Morpheus8 Applicator (with a sham 24 pin tip).
62844757|NCT00870519|EXPERIMENTAL|I 123-MNI-168|
62844758|NCT00870519|EXPERIMENTAL|I123 MNI168|brain imaging using I123MNI168
62844759|NCT06413082|EXPERIMENTAL|Torasemide|The study involves the administration of Torasemide 2.5 mg.
62844760|NCT06413082|EXPERIMENTAL|Spironolactone|The study involves the administration of Spironolactone 50 mg orally every day.
62844761|NCT04056832|EXPERIMENTAL|Single Strip Pericardium|Aortic Valve Replacement using single strip of patient's autologous pericardium
62262516|NCT03943875|EXPERIMENTAL|Males, 2 dose with delayed 3rd dose|Two doses of the 9-valent HPV vaccine to be administered to the experimental group (15-26 years of age) at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
62447081|NCT02807142|EXPERIMENTAL|NC 1 cell therapy|All patients will be treated with the same treatment: NC1 cell therapy
62844762|NCT04056832|ACTIVE_COMPARATOR|Mechanical Prosthetic Valve|Aortic Valve Replacement using mechanical prosthetic valve
62447082|NCT04168476|EXPERIMENTAL|Treatment group|"Participants of this group were assessed by the examiner twice, pre and post intervention, having recorded two values for each of the following variables:~* Visual Analogue Scale~* Range of movement~* Hand grip strength. After a first assessment, scapula mobilization techniques were performed and participants reassessed."
62447083|NCT04168476|PLACEBO_COMPARATOR|Control group|"Participants of this group were assessed by the examiner twice, pre and post intervention, having recorded two values for each of the following variables:~* Visual Analogue Scale~* Range of movement~* Hand grip strength. The procedure was a contralateral calcaneus abduction and adduction mobilization technique was carried out."
62844763|NCT02752581|OTHER|Drain Group|Suction drain was applied to these patients after arthroscopic knee surgery.
62844764|NCT02752581|OTHER|Control Group|No suction drain was applied to this group, therefore used as a control group.
62844765|NCT00569517|EXPERIMENTAL|1|6-CBT-sessions for weight loss
62844766|NCT00569517|EXPERIMENTAL|2|Single educational intervention for weight
62844767|NCT03227419|EXPERIMENTAL|Tocilizumab Prefilled Syringe|"Market approval recommendations will be respected. Treatment should be started within 7 days of randomization.~The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below."
62844768|NCT03227419|EXPERIMENTAL|Abatacept Prefilled Syringe|"Market approval recommendations will be respected. Treatment should be started within 7 days of randomization.~The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below."
62844769|NCT02174822|EXPERIMENTAL|Paroxetine + AVP-786|Paroxetine once daily orally Days 1-20. AVP-786 twice daily orally for Days 13 - 20.
62262517|NCT01920880||ACNES patients|Patients being treated in past for anterior cutaneous nerve entrapment syndrome
62262518|NCT01920880||Healthy controls|Healthy controls
62844770|NCT02174822|EXPERIMENTAL|AVP-786 + paroxetine|AVP-786 twice daily orally Days 1-20. Paroxetine once daily orally for Days 9 - 20
62844771|NCT02174822|EXPERIMENTAL|Duloxetine + AVP-786|Duloxetine twice daily orally Days 1 - 13. AVP-786 twice daily orally Days 6 - 13.
62844772|NCT02174822|EXPERIMENTAL|AVP-786 + duloxetine|AVP-786 twice daily orally Days 1 - 13. Duloxetine twice daily Days 9 - 13.
62844773|NCT03279640|EXPERIMENTAL|Dual-mode stimulation|"rTMS on ipsilesional M1 + tDCS on contralesional M1~10 Hz of rTMS was applied over the ipsilesional M1 for 20 minutes with simultaneous application of cathodal tDCS on the contralesional M1.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
62844774|NCT03279640|EXPERIMENTAL|Single stimulation|"rTMS on ipsilesional M1~10 Hz of rTMS over the ipsilesional M1 was applied for 20 minutes.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
62844775|NCT05658315|NO_INTERVENTION|Baseline|Participants will be randomly assigned to either a 5-, 6-, or 7-week baseline phase.
62262519|NCT06216639||Individuals between 30 and 34 years of age registered at HCM|Random sample of participants representing the eligible cohort is drawn.
62262520|NCT02541279|EXPERIMENTAL|Intervention|The intervention group received 6 sessions of shoulder exercises controlled by a physiotherapist.
62262521|NCT02541279|ACTIVE_COMPARATOR|Control|The control group received a paper explaining the same exercises which were performed by the intervention group. This group made the exercises at home.
62262522|NCT00356928|EXPERIMENTAL|Cyclophosphamide + T cells|Conditioning regimen with cyclophosphamide followed by donor T cells on Day 0.
62447084|NCT03363581||Gastric bypass|Obese patients due to undergo gastric bypass surgery
62447085|NCT03363581||Control|Healthy free-living individuals
62447086|NCT01953497|PLACEBO_COMPARATOR|Placebo|Placebo
62618935|NCT01044589|EXPERIMENTAL|Biodesign Tissue Repair Graft|Biodesign Tissue Repair Graft
62618936|NCT01044589|ACTIVE_COMPARATOR|Overlapping Sphincter Repair|Control
62618937|NCT01523327||A|40 pregnant Women with hypertension who have uric acid level more than 6 mg per dL.
62618938|NCT01523327||B|40 pregnant women with hypertension who have uric acid level less than 6 mg per dl.
62844776|NCT05658315|EXPERIMENTAL|ApplTree intervention|Following baseline, participants will complete training in the use of ApplTree and a 5-week intervention phase, where they will utilise ApplTree to set reminders about weekly prospective memory tasks.
62618939|NCT06408350|EXPERIMENTAL|Peer Health Navigation (PHN)|PHN is a peer navigation intervention to advance trans women through the HIV Care Continuum by identifying their individual needs and barriers to HIV care, including: substance use and behavioral health needs; adherence goal(s); and methods to achieve adherence. Participants receive unlimited navigation sessions over 3 months; PHN sessions are delivered in a private room similar to a one-on-one peer counseling session.
62618940|NCT06408350|EXPERIMENTAL|Simple Message System (SMS [text messaging])|Text messages are scripted across: 1) HIV Care Continuum (HIV Positivity/Physical and Emotional Health, Linkage/Retention in HIV Care, and ART Adherence/Viral Load Suppression); and, 2) theoretical foundation (Social Support Theory, Social Cognitive Theory, or Health Belief Model). Participants receive three daily, theory-based text messages for 90 days (270 unique scripted messages), evenly arrayed across the HIV Care Continuum. Text messages are delivered and transmitted to either a cell phone or an email inbox.
62618941|NCT06408350|EXPERIMENTAL|PHN and SMS|"PHN + SMS is the combined intervention.~PHN is a peer navigation intervention to advance trans women through the HIV Care Continuum by identifying their individual needs and barriers to HIV care, including: substance use and behavioral health needs; adherence goal(s); and methods to achieve adherence. Participants receive unlimited navigation sessions over 3 months; PHN sessions are delivered in a private room similar to a one-on-one peer counseling session.~Text messages are scripted across: 1) HIV Care Continuum (HIV Positivity/Physical and Emotional Health, Linkage/Retention in HIV Care, and ART Adherence/Viral Load Suppression); and, 2) theoretical foundation (Social Support Theory, Social Cognitive Theory, or Health Belief Model). Participants receive three daily, theory-based text messages for 90 days (270 unique scripted messages), evenly arrayed across the HIV Care Continuum. Text messages are delivered and transmitted to either a cell phone or an email inbox."
62618942|NCT04857853|EXPERIMENTAL|Exercise Without Rest Breaks|Exercise Without Rest Breaks
62618943|NCT04857853|EXPERIMENTAL|Exercise With Rest Break|Exercise With Rest Break
62618944|NCT04857853|EXPERIMENTAL|Rest Break|Rest Break
62618945|NCT03701685|OTHER|nerve grafting|The stumps of digital nerve are connected with nerve graft
62618946|NCT04037852|EXPERIMENTAL|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM.
62618947|NCT04037852|ACTIVE_COMPARATOR|Conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy.
62262523|NCT02681172|EXPERIMENTAL|Neuraceq (florbetaben 18F) PET scan|"A single dose of 300 Megabecquerels (8.1 millicuries) Neuraceq will be administered per subject.~The applied florbetaben radioactive dose will be ± 20%."
62262524|NCT02404259|OTHER|non-nucleoside reverse transcriptase inhibitor (NNRTI)|Efavirenz
62447087|NCT01953497|ACTIVE_COMPARATOR|URC102|URC102
62262525|NCT02404259|OTHER|ritonavir-boosted protease inhibitor|lopinavir/ritonavir atazanavir/ritonavir
62262526|NCT05137548|EXPERIMENTAL|ATI-2173.|ATI-2173
62844777|NCT04768608|EXPERIMENTAL|PD1-PSMA-CART|Patients undergo leukapheresis by receiving cyclophosphamide and fludarabine on days -6 to -4, and then receive PD1-PSMA-CART intravenous injection (IV) at split doses from day 0 on.
62262527|NCT05137548|EXPERIMENTAL|Tenofovir Disoproxil Fumarate|Tenofovir disoproxil fumarate
62262528|NCT00982865|EXPERIMENTAL|MSC1936369B Regimen 1|Subjects will be administered MSC1936369B (pimasertib) capsules 1 to 120 milligram (mg) orally, once daily (QD) on Days 1 to 5, 8 to 12, 15 to 19 of each 21-day treatment cycle until progressive disease (PD) or intolerable toxicity or investigator/subject decision.
62447088|NCT04967313|EXPERIMENTAL|Behavioral Change Techniques to Increase Walking|Individuals will receive daily text messages with the goal of increasing daily walking by 2,000 more steps five days per week. Participants will be enrolled for a baseline period lasting two weeks where their average daily activity level will be assessed using a Fitbit device to generate an average daily step counts. Following completion of baseline, participants will receive daily text messages of behavior change techniques (BCTs) for eight weeks. The four BCTs utilized in this study are: goal setting, action planning, self-monitoring of behavior, and feedback on behavior. Each BCT will be delivered to participants daily for a two-week block. Four blocks (one BCT per block) will be delivered to the participant. The order in which the BCT interventions are presented to participants will be randomized by the study statistician. The goal of the BCT text messages will be to encourage walking behavior.
62447089|NCT05180006|ACTIVE_COMPARATOR|Arm 1A: Atezolizumab, in TNBC patients (cohort 1)|atezolizumab alone, administered as one single IV infusion on day -15 +/- 48 h (D1) prior to the date of surgery or the start of standard of care neoadjuvant systemic treatment.
62447090|NCT05180006|EXPERIMENTAL|Arm 1B: Atezolizumab + Bevacizumab, in TNBC patients (cohort 1)|atezolizumab and bevacizumab as one single IV infusion on day -15 +/- 48 h (D1) prior to the date of surgery or the start of standard of care neoadjuvant systemic treatment.
62262529|NCT00982865|EXPERIMENTAL|MSC1936369B Regimen 2|"MSC1936369B Regimen 2 (Without Food Effect): Subjects will be administered MSC1936369B capsules 1 to 255 mg orally QD on Days 1 to 15 of each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.~MSC1936369B Regimen 2 (With Food Effect): : Subjects will be administered MSC1936369B capsules 90 or 150 mg orally QD on Day 1 to 15 of each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision. Subjects in the Regimen 2 FE cohort were assigned in a 1:1 ratio to either the fed/fasted sequence or fasted/fed sequence for Day 1 of Cycle 1 and Day 1 of Cycle 2."
62262530|NCT00982865|EXPERIMENTAL|MSC1936369B Regimen 3 once daily|Subjects will be administered MSC1936369B capsules 60 to 90 mg orally QD in each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.
62618948|NCT04037852|ACTIVE_COMPARATOR|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, with endoscopic instruments to performed nipple sparing mastectomy.
62618949|NCT02529098|SHAM_COMPARATOR|asymptomatic patients|fMRI Asymptomatic patients
62618950|NCT02529098|EXPERIMENTAL|symptomatic patients|fMRI patients with visual difficulties
62618951|NCT02222116|EXPERIMENTAL|MGuard Prime|MGuard Prime
62844778|NCT01279785||Prostate Cancer Patients|Male participants who are scheduled to undergo standard of care prostatectomy for presumed localized prostate cancer at the NIH Clinical Center and have evidence of a recent (within 12 months of study entry) trans-rectal biopsy documenting adenocarcinoma of the prostate.
62844779|NCT03110770|EXPERIMENTAL|Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 injections|Zika virus wildtype (ZIKVwt) DNA vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered intramuscularly (IM) by a needle-free injection device
62262531|NCT00982865|EXPERIMENTAL|MSC1936369B Regimen 3 twice daily (BID)|Subjects will be administered MSC1936369B capsules 45 to 75 mg orally BID in each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.
62262532|NCT00554502|ACTIVE_COMPARATOR|A|
62262533|NCT00554502|ACTIVE_COMPARATOR|B|
62262534|NCT01332357||Fluticasone propionate/salmeterol combination ED MD|Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the ED physician
62844780|NCT03110770|EXPERIMENTAL|Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered IM by a needle-free injection device
62844781|NCT03110770|EXPERIMENTAL|Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 8 mg of vaccine administered IM by a needle-free injection device
62844782|NCT03110770|EXPERIMENTAL|Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered IM by a needle-free injection device
62844783|NCT03110770|PLACEBO_COMPARATOR|Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 injections|Sterile phosphate-buffered saline (PBS) (VRC-PBSPLA043-00-VP), the placebo, in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 1 mL of placebo administered IM by a needle-free injection device
62262535|NCT01332357||Fluticasone propionate/salmeterol combination OP MD|Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the OP physician
62447091|NCT05180006|ACTIVE_COMPARATOR|Arm 2A: Trastuzumab + Pertuzumab, in HER2+ patients (cohort 2)|trastuzumab + pertuzumab for one IV infusion on day -15 +/- 48 h (D1) prior to the date of surgery or the start of standard of care neoadjuvant systemic treatment.
62447092|NCT05180006|EXPERIMENTAL|Arm 2B: Atezolizumab + Trastuzumab + Pertuzumab, in HER2+ patients (cohort 2)|atezolizumab as one single IV infusion in combination with trastuzumab + pertuzumab for one IV infusion on day -15 +/- 48 h (D1) prior to the date of surgery or the start of standard of care neoadjuvant systemic treatment.
62262536|NCT05815407||NSCLC patients|Patients were diagnosed with NSCLC at any stage, then will be subdivided into Early stage, Lympho-node involvement stage and Distant metastatic stage
62262537|NCT05815407||Control subjects|Appearantly healthy age-matched individuals
62262538|NCT02124239|EXPERIMENTAL|Scalp|Treatment of scalp with 0.027% ingenol mebutate once daily for 3 days
62618952|NCT02222116|ACTIVE_COMPARATOR|Control|BMS or DES
62618953|NCT02155322|EXPERIMENTAL|PEG-IFN|6.0 μg/kg/week subcutaneous administration during the Induction Phase of 8 weeks followed by a dose of 3.0 μg/kg/week subcutaneous administration in the Maintenance Period (Week 8 to Month 12)
62262539|NCT02124239|EXPERIMENTAL|Arm|Treatment of arm with 0.06% ingenol mebutate once daily for 4 days
62262540|NCT02124239|EXPERIMENTAL|Face|Treatment of face with 0.027% ingenol mebutate once daily for 3 days
62262541|NCT03910907||Standard of care|Men treated for mycoplasma according to standard of care
62618954|NCT01108237|OTHER|TruMatch™ Personalized Solutions|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using TruMatch™ Personalized Solutions
62618955|NCT01108237|OTHER|Historical Control|Total Knee Arthroplasty (PFC Sigma System) implanted using conventional and CAS surgical techniques without TruMatch™ instrumentation.
62618956|NCT06549881||ICG fluorescence guided group|Patients with acute cholecystitis underwent emergent laparscopic cholecystectomy guided by indocyanine green (ICG) fluorescence.
62618957|NCT05390723|EXPERIMENTAL|video 1|The investigators cannot yet reveal the specific communication that will be manipulate, as this might influence participant outcomes.
62618958|NCT05390723|EXPERIMENTAL|video 2|The investigators cannot yet reveal the specific communication that will be manipulate, as this might influence participant outcomes.
62844784|NCT01466582||HIV-negative controls|A group of HIV-negative controls, aged 45 years and above, that is recruited at the STD-clinic of the Public Health Service Amsterdam or at the existing Amsterdam Cohort Studies.
62844785|NCT01466582||HIV-positive patients|A group of HIV-1-infected patients, aged 45 years and above, that is recruited at the HIV outpatient clinic of the Academic Medical Center.
62844786|NCT04287296|EXPERIMENTAL|App users|The app users who are at least 18 years old.
62844787|NCT04309097|EXPERIMENTAL|Digital intervention|Participants will have access to a live-streaming App that offers Recess and Exercise Advocate Program (REAP).
62618959|NCT05390723|EXPERIMENTAL|video 3|the investigators cannot yet reveal the specific communication that will be manipulate, as this might influence participant outcomes.
62058963|NCT05248321|EXPERIMENTAL|Extra treatment (ET) group|In the extra treatment (ET) group, standard endoscopic therapy will be performed to the bleeding peptic ulcer by local injection of diluted epinephrine 1:10 000 in combination with either heater probe coagulation, hemoclipping and/or rubber band ligation. Afterwards, we will apply 1.25g tranexamic acid powder via the endoscopy to the peptic ulcer before the end of endoscopic exam. After the first endoscopy, the patient will receive a 3-day continuous high-dose (8 mg/h) PPI infusion and Rockall score assessment as current guideline's recommendation. In patients with Rockall scores ≥6, after 3-day intravenous PPI infusion, we will apply oral twice-daily PPI for 11 days followed by once-daily PPI after then. In patients with Rockall scores \<6, we will apply once-daily PPI after 3-day intravenous PPI infusion. A second-look esophagogastroduodenoscopy (EGD) will be performed 2-3 days after the initial endoscopy, aiming to survey if major SRH of peptic ulcer persists.
62262542|NCT03910907||Standard of care plus|Men treated for mycoplasma according to standard of care with regimen selected based on laboratory detection of resistance markers
62262543|NCT02081534|EXPERIMENTAL|1 mg bid|1 mg AZD1722 bid
62262544|NCT02081534|EXPERIMENTAL|3 mg bid|3 mg AZD1722 bid
62618960|NCT05390723|EXPERIMENTAL|video 4|the investigators cannot yet reveal the specific communication that will be manipulate, as this might influence participant outcomes.
62618961|NCT02411981|OTHER|Autogenic drainage|"The autogenic drainage will be the chest physiotherapy technique used for this study.~Autogenic drainage is an airway clearance technique that attempts to obtain the optimal airflow to evacuate the secretions. This technique uses modulation of inspiratory and expiratory airflow at different breathing level within the vital capacity."
62618962|NCT06139705|EXPERIMENTAL|Walking outdoors group (OUT group)|The OUT group will walk in natural environment.
62618963|NCT06139705|EXPERIMENTAL|Walking indoors group (IN group)|The IN group will walk indoors.
62618964|NCT03307460|EXPERIMENTAL|uPAR PET/MRI|68Ga-NOTA-AE105 is injected once for performing a PET/MRI scan
62618965|NCT04765670|EXPERIMENTAL|Instrument Assisted Soft Tissue Mobilization|"The instruments will be applied to the soft tissue at 30º-60º angles, with multi-directional stroking movements. Instrument Assisted Soft Tissue Mobilization will be applied to the trapezius and sternocleidomastoideus muscles of the participants for 90 seconds."
62623737|NCT04613440|OTHER|Intervention - Facilitated cascade testing|In the intervention group, a patient navigator will provide facilitated support, including an initial genetic counseling call, an email with a link to an educational video, and, for individuals who are interested in completing testing - a link to create an account for a free saliva kit and a follow-up call to discuss the results and ensure participants are connected with their primary care provider or other clinician, as appropriate.
62844788|NCT04309097|ACTIVE_COMPARATOR|Information-only intervention|Participants will have access to health information only.
62844789|NCT04936087|OTHER|WHO 8-steps|Single group intervention and described in the Intervention section.
62844790|NCT04464018|EXPERIMENTAL|Working group|Working group (hybrid simulation method) after the theoretical lecture, the application with hybrid simulation method is made by videotaping. Repeat the same practice after 1 Week
62844791|NCT04464018|NO_INTERVENTION|Control group|Control group (Low reality simulation method) after the theoretical lecture, the application with low reality simulation method is made. Repeat the same practice after 1 Week Control group received only general care
62844792|NCT02642315|OTHER|open-label|"open-label single arm study~Horizant, 600 mg oral once daily at 5 pm for 360 days."
62844793|NCT05063773|EXPERIMENTAL|Group 1|
62844794|NCT05063773|NO_INTERVENTION|Group 2|
62844795|NCT05054387|EXPERIMENTAL|Agalsidase beta|Agalsidase beta treatment at approved dose and regimen, administered once every 2 weeks as an IV infusion
62844796|NCT03727724|EXPERIMENTAL|Afatinib plus cetuximab|"Afatinib, 40 mg once daily, orally.~Cetuximab, 500 mg/m² intravenously, every 2 weeks.~Treatment will be continued until tumor progression (according RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs."
62618966|NCT04765670|EXPERIMENTAL|Kinesiotape Application|The application will be made from the insertion of the upper trapezoidal muscle to its origo . During taping, the patient will be allowed to sit in an upright position in a chair with a back, with the scapula fixed, without supporting the arms. Before taping, the patient will be positioned with the shoulder in adduction and the head in lateral flexion towards the contralateral side. The patient will be asked to perform shoulder abduction against resistance, and the insertion area of the upper trapezius fibers will be palpated. The initial 2-3 cm part of the band will be glued to the lateral of the acromion without stretching, after full (100%) stretching is applied to the 2-3 cm part of the band from the insertion area of the upper trapezoid fibers, the patient's head is rotated to the affected side and the arm part of the band is stretched along the muscle fibers. it will be glued up to the hairline without doing it.
62262545|NCT02081534|EXPERIMENTAL|10 mg bid|10 mg AZD1722 bid
62262546|NCT02081534|EXPERIMENTAL|30 mg bid|30 mg AZD1722 bid
62262547|NCT02081534|EXPERIMENTAL|3 mg od|3 mg AZD1722 od
62618967|NCT03642444|ACTIVE_COMPARATOR|Phase A cane walking (assistive walking-device a cane)|9-12 weeks usual cane-walking to establish baseline values. Patients walk with their usual assistive-walking device - a cane.
62844797|NCT06327880|EXPERIMENTAL|PF-07054894|
62262548|NCT02081534|EXPERIMENTAL|30 mg od|30 mg AZD1722 od
62262549|NCT02081534|PLACEBO_COMPARATOR|Placebo|Placebo (double dummy technique)
62262550|NCT05012956|ACTIVE_COMPARATOR|POP group|Pelvic organ prolapse patients enrolled for sacrocolpopexy surgery at UZ Leuven.
62844798|NCT06327880|PLACEBO_COMPARATOR|Placebo|
62262551|NCT05012956|ACTIVE_COMPARATOR|Control group|Patients assigned to gynecologic laparoscopic surgery, other than sacrocolpopexy, at UZ Leuven.
62262552|NCT02807480|EXPERIMENTAL|Exposure-based therapy|Participants will complete 10, 90-minute sessions of Exposure-based therapy, conducted using a group format. Each group will include 8-12 participants. Exposure-based therapy seeks to increase abilities to manage anxiety through repeated practice in facing the situations or thoughts that are the focus of worry or fear. All participants will complete computer-based behavioral assessments, surveys and interviews, functional magnetic resonance imaging (fMRI), and electroencephalography (EEG).
62262553|NCT02807480|EXPERIMENTAL|Behavioral Activation therapy|Participants will complete 10, 90-minute sessions of Behavioral Activation therapy, conducted using a group format. Each group will include 8-12 participants. Behavioral Activation therapy seeks to target behaviors that might maintain or worsen negative mood. All participants will complete computer-based behavioral assessments, surveys and interviews, functional magnetic resonance imaging (fMRI), and electroencephalography (EEG).
62262554|NCT02829307|EXPERIMENTAL|89Zr-GSK3128349|Subjects will receive a single dose of 89Zr-GSK3128349 as an intravenous (IV) infusion over 20 minutes to deliver a dose of 1 mg
62262555|NCT00518037||1|nonmelanoma skin cancer patients
62262556|NCT00379652|ACTIVE_COMPARATOR|A|Patient-based intervention
62844799|NCT06520085|EXPERIMENTAL|Personalized rehabilitation program|The intervention group receives an interactive app that is different from the control is different from the control group in that it provides interactive and personalized information and a personalized rehabilitation program. Both the timing and the amount and nature of the exercises are personalized.
62618968|NCT03642444|ACTIVE_COMPARATOR|Phase B elasticated orthotic-garment - TheraTogs|9-19 weeks : assistive walking-device which is an elasticated orthotic-garment worn throughout the day (product name TheraTogs). Cane use maximally reduced during his period.
62618969|NCT03642444|NO_INTERVENTION|Phase C follow-Up|9-10 weeks individually determined follow-up: subjects determine whether they walk independently (without assistive device) or with the elasticated orthotic-garment (TheraTogs) or with a cane.
62618970|NCT05456854|EXPERIMENTAL|Kisspeptin|Intravenous administration of kisspeptin 112-121 x 16 hours
62844800|NCT06520085|ACTIVE_COMPARATOR|Standard care|The control group will receive postoperative information and a rehabilitation program via the non-interactive application, which is current standard care
62844801|NCT04980144|EXPERIMENTAL|DQS group|Participants in DQS group will be administered one drop of 3% DQS (Diquas, Santen Pharmaceutical Co., Ltd., Osaka, Japan) six times per day for 8 weeks.
62844802|NCT04980144|ACTIVE_COMPARATOR|HA group|Participants in HA group will be administered one drop of 0.1% Sodium hyaluronate artificial tears (preservative free) six times per day for 8 weeks.
62844803|NCT05585606|PLACEBO_COMPARATOR|Placebo|Volume Matched Placebo (normal saline)
62262557|NCT00379652|ACTIVE_COMPARATOR|B|Health center-based intervention
62262558|NCT00379652|ACTIVE_COMPARATOR|C|Combination of patient and health center-based intervention
62262559|NCT00379652|NO_INTERVENTION|D|Control group: Neither patient-based nor center-based intervention
62262560|NCT01675635|EXPERIMENTAL|OxyNorm Capsules|To determine the efficacy and safety of OxyNorm Capsules.
62262561|NCT01675635|ACTIVE_COMPARATOR|Morphine tablet|To determine the efficacy and safety of Morphine tablet.
62618971|NCT05456854|PLACEBO_COMPARATOR|Placebo|Intravenous administration of placebo x 16 hours
62844804|NCT05585606|EXPERIMENTAL|scp776 (1.9 mg/kg)|"Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~- 1.9 mg/kg"
62844805|NCT05585606|EXPERIMENTAL|scp776 (3.8 mg/kg)|"Cohort 2 dose regimen:~Intravenous (IV) injection(s) over 2 minutes~- 3.8 mg/kg"
62844806|NCT00687375|OTHER|1|Laparoscopic Inguinal Hernia Repair- Transabdominal preperitoneal (TAPP) approach
62844807|NCT00687375|OTHER|2|Laparoscopic Inguinal Hernia Repair- Totally extra peritoneal (TEP) Approach
62844808|NCT00505401|OTHER|A|Subjects were immunized subcutaneously with Tat, 3 dosage groups (7.5, 15 or 30 microgrammi), in association with Alum as adjuvant, or with Saline + Alum, as placebo.
62844809|NCT00505401|OTHER|B|Subjects were immunized intradermally with Tat, 3 dosage groups (7.5, 15 or 30 microgrammi), or with Saline, as placebo.
62844810|NCT01278212|EXPERIMENTAL|AHF-RT|"accelerated hypofractionated radiotherapy (AHF-RT)~30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy"
62262562|NCT03724071|EXPERIMENTAL|Phase 1, Arm A - Dose escalation and safety of TG6002 and flucytosine combination|Dose escalation with repeated administrations of TG6002 in combination with flucytosine in patients with advanced gastro-intestinal (GI) tumors.
62262563|NCT03724071|EXPERIMENTAL|Phase 1, Arm B - Dose escalation and safety of TG6002 and flucytosine combination|Dose escalation with closer administrations of TG6002 in combination with flucytosine in patients with advanced gastro-intestinal (GI) tumors.
62618972|NCT01955577|EXPERIMENTAL|Vitamin D3 cholecalciferol|1000IU x3 daily in a period of 14 days. After 14 days 1000IU x 1 daily.
62618973|NCT01955577|PLACEBO_COMPARATOR|Placebo orally everyday|One placebo pill x3 daily in a period of 14 days. After 14 days x1 placebo pill daily.
62618974|NCT03628716|EXPERIMENTAL|CV301 + Atezolizumab|Subject receiving combination treatment with CV301 + Atezolizumab
62844811|NCT04043156|EXPERIMENTAL|High-precision RT|Study Arm: 18 x 2.33 Gy of high-precision RT in 3.5 weeks.
62844812|NCT06176911|EXPERIMENTAL|Teriflunomide plus danazol|Oral teriflunomide was given at a starting dose of 7 mg once daily and danazol was given at a dose of 200mg twice daily for 24 weeks. Treatment was discontinued if very severe or life-threatening adverse events developed or at the patient's request.
62844813|NCT06176911|ACTIVE_COMPARATOR|Danazol|Danazol was given at a dose of 200 mg twice a day for 24 weeks. Treatment was discontinued if very severe or life-threatening adverse events developed or at the patient's request.
62618975|NCT02041780|EXPERIMENTAL|Shearwave electrography|"Two experimental interventions will be realized in each patient in this population : Shearwave electrography (new diagnostic test of fibrosis) and Fibrotest .~Moreover, liver biopsies, the gold standard for the fibrosis diagnosis is also realized in each patient within usual cares."
62618976|NCT03313310|EXPERIMENTAL|Employment Intervention|An employment intervention (iFOUR) that has been adapted from previous piloting work of focus groups, key informant interviews and a community advisory board.
62618977|NCT02030886|OTHER|Ocular hypertension subjects|All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
62618978|NCT01602679|EXPERIMENTAL|micronized progesterone, then placebo|Participants first received oral micronized progesterone (100 mg p.o.) suspension. After a washout period of approximately 20 days, they then received placebo (matching oral micronized progesterone suspension).
62618979|NCT01602679|PLACEBO_COMPARATOR|Placebo, then micronized progesterone|Participants first received placebo. After a washout period of approximately 20 days, they then received oral micronized progesterone syrup (100 mg p.o.)Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
62618980|NCT02588092|EXPERIMENTAL|Part 1: ADCT-301 (dose escalation)|"Weekly administration - Participants will receive an IV infusion of ADCT-301, on Days 1, 8, and 15 of each 3-week (21-day) cycle.~3-week administration - Participants will receive an IV infusion of ADCT-301, on Day 1 of each 3-week (21-day) cycle.~The dose escalation will be conducted according to a 3+3 design."
62618981|NCT02588092|EXPERIMENTAL|Part 2: ADCT-301 (dose expansion)|Participants will be assigned to receive the recommended dose and/or schedule of ADCT-301 as determined by the Dose Escalation Steering Committee.
62618982|NCT03034135|EXPERIMENTAL|DSF-Cu|Disulfiram/copper (oral capsules) dosed 80 mg/1.5 mg three times a day for approximately 6 months.
62618983|NCT00487097|EXPERIMENTAL|Study Group|Enteral Nutrition with Omega 3 (Eicosapentanoic acid, docosahexaenoic acid)
62618984|NCT00487097|NO_INTERVENTION|Control Group|Patients in control group will receive nutritional support composed of a standard formula
62618985|NCT04365673||Readmitted|Patients that were readmitted within 30 days post hospital discharge
62618986|NCT04365673||Not readmitted|Patients that were not readmitted within 30 days post hospital discharge
62618987|NCT04886752|SHAM_COMPARATOR|vitamin C without liposome|vitamin C without liposome
62844814|NCT00925925||Normal Birth Weight (NBW)|Term, healthy infants born at normal birth weights
62844815|NCT00925925||Low Birth Weight (LBW)|Infants born at \> or equal to 34 0/7 weeks with a birth weight at \< or equal to 10% for gestational age at birth (Small for Gestational Age, SGA)
62844816|NCT01996761|EXPERIMENTAL|Study Group 1|Study Group 1: 30ml Cerebrolysin
62844817|NCT01996761|PLACEBO_COMPARATOR|Study Group 2|Study Group 2: Placebo (0.9% NaCl)
62262564|NCT03724071|EXPERIMENTAL|Phase IIa - Efficacy of TG6002 and flucytosine combination|Repeated administrations of TG6002 in combination with flucytosine in patients with colorectal cancer and liver metastases
62262565|NCT05809414|EXPERIMENTAL|Amantadine|
62262566|NCT05809414|PLACEBO_COMPARATOR|Placebo|
62262567|NCT05809414|EXPERIMENTAL|TMS|
62262568|NCT05809414|SHAM_COMPARATOR|TMS sham|
62447093|NCT02789007|OTHER|parabolic flight|To evaluate Structural and functional changes, Cognitive performance, and specifically spatial cognition, Key neurotrophins...
62618988|NCT04886752|PLACEBO_COMPARATOR|liposomal process A vitamin C|liposomal process A vitamin C
62618989|NCT04886752|EXPERIMENTAL|liposomal process B vitamin C (Double Nutri™)|liposomal process B vitamin C (Double Nutri™)
62618990|NCT02769312|SHAM_COMPARATOR|Sham Stimulation|A sham coil is being used to compare against active coil.
62618991|NCT02769312|ACTIVE_COMPARATOR|Active Stimulation|An active coil is being used to compare against sham coil.
62844818|NCT02966444|EXPERIMENTAL|MUFA-rich HF Meal|High-fat meal rich in monounsaturated fatty acids
62844819|NCT02966444|EXPERIMENTAL|PUFA-rich HF Meal|High-fat meal rich in polyunsaturated fatty acids
62262569|NCT02031770|OTHER|A: Treatment/Control|Patients will start with sodium bicarbonate treatment then switch to control (no treatment)
62262570|NCT02031770|OTHER|B: Control/Treatment|Patients will start with control (no treatment) then switch to sodium bicarbonate treatment
62447094|NCT04366479|EXPERIMENTAL|intervention group|The study lasted for 5 weeks (1 month 7 days). During the research process, we monitor closely, especially the training schedule, implementation, and evaluation, directly and indirectly. Directly assisting participants to do endurance training activities, not directly monitoring via telephone or WhatsApp.
62447095|NCT05214742||Silver-Russell Syndrome|
62447096|NCT05214742||Beckwith-Wiedemann Syndrome|
62447097|NCT05214742||Temple Syndrome|
62844820|NCT02966444|EXPERIMENTAL|SFA-rich HF Meal|High-fat meal rich in saturated fatty acids
62844821|NCT06464783|EXPERIMENTAL|Comprehensive Corrective Exercise Program|"Comprehensive Corrective Exercise Program includes following exercises.~Corrective Exercises+ Core strengthening exercises include Chin tuck Supine bridging on stable surface supine bridging with knee flexed on unstable surface unilateral lifting of arms and legs in crawling position Activation of transverse abdominous muscle. Unilateral arms and legs movements in siting position on unstable surface (ball) Cat and camel exercises Contralateral arms and legs movements in siting position on unstable surface (ball)~Stretching include Stretching of neck extensor muscle Stretching of pectoral muscle group in standing and supine position"
62618992|NCT03089853|EXPERIMENTAL|Intervention Arm|Subjects randomized to intervention arm will have a device applied to their thigh on either side, and subject to neuromuscular electrical stimulation for 30 minutes daily for 2 weeks, followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
62618993|NCT03089853|NO_INTERVENTION|Usual Care Arm|Usual care will consist of a protocolized regimen of 5 days of systemic steroids, unless the treating physician determines a different regimen, in which case the change will be documented.
62618994|NCT04513899|EXPERIMENTAL|Community Health Worker/Registered Nurse (CHW/RN)|Nurse-led Community Health Worker (CHW/RN) program delivered DOT for HCV treatment.
62618995|NCT04513899|ACTIVE_COMPARATOR|Clinic-based Standard of Care (cbSOC)|Standard of care for HCV treatment delivered by a clinic-based MD or clinic-based NP at the clinic site
62058964|NCT05248321|NO_INTERVENTION|standard treatment (ST) group|In the standard treatment (ST) group, the endoscopic exam ends after standard endoscopic therapy. After the first endoscopy, the patient will receive a 3-day continuous high-dose (8 mg/h) PPI infusion and Rockall score assessment as current guideline's recommendation. In patients with Rockall scores ≥6, after 3-day intravenous PPI infusion, we will apply oral twice-daily PPI for 11 days followed by once-daily PPI after then. In patients with Rockall scores \<6, we will apply once-daily PPI after 3-day intravenous PPI infusion. A second-look esophagogastroduodenoscopy (EGD) will be performed 2-3 days after the initial endoscopy, aiming to survey if major SRH of peptic ulcer persists.
62058965|NCT00855595|EXPERIMENTAL|Azelaic acid (Finacea, BAY39-6251) plus Doxycycline (Oracea)|Participants received topical azelaic acid gel 15% twice daily and doxycycline 40 mg once daily for 12 weeks
62058966|NCT00855595|ACTIVE_COMPARATOR|Metronidazole (Metrogel) plus Doxycycline (Oracea)|Participants received topical metronidazole 1% gel once daily and doxycycline 40 mg once daily for 12 weeks
62262571|NCT04346589|EXPERIMENTAL|Antibodies (immunoglobulins) infusion|Anti-coronavirus antibodies obtained with double-filtration plasmapheresis (DFPP )from convalescent patients.
62058967|NCT02816086|NO_INTERVENTION|Standard care|The study participants receives standard care in the ward, this does not include a pharmacist.
62262572|NCT05254184|EXPERIMENTAL|Patients With NSCLC|All participants will receive the intervention.
62262573|NCT04350775|EXPERIMENTAL|RE-IADL group|Reablement
62262574|NCT04350775|PLACEBO_COMPARATOR|Control group|General community rehabilitation
62262575|NCT02176473|EXPERIMENTAL|Computerized Cognitive Behavioral Therapy|A computerized version of CBT has been developed in an effort to more widely disseminate the powerful effects of this psychotherapy modality, with studies showing efficacy comparable to that of traditional CBT.8 The present study aims to further investigate the feasibility of combining ECT and computerized CBT (c-CBT).
62262576|NCT02757599|OTHER|Top-down (TD)|The group having the transvaginal ultrasound image top-down. During training and transfer test.
62058968|NCT02816086|EXPERIMENTAL|Intervention|Interdisciplinary collaboration structure
62058969|NCT04131595|EXPERIMENTAL|MVA-BN-WEV Dose 1|Subjects in treatment Group 1 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 1 x 107 Inf.U in 0.5 mL.
62058970|NCT04131595|EXPERIMENTAL|MVA-BN-WEV Dose 2|Subjects in treatment Group 2 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 1 x 108 Inf.U in 0.5 mL
62058971|NCT04131595|EXPERIMENTAL|MVA-BN-WEV Dose 3|Subjects in treatment Group 3 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 2 x 108 Inf.U in 2 x 0.5 mL
62058972|NCT00615381|ACTIVE_COMPARATOR|Normal insulin|Maintenance of intraoperative euglycemia (blood glucose 80--110 mg/dL) using normal intensive insulin infusion rates (0-10 U/hr).
62262577|NCT02757599|OTHER|Bottom-up (BU)|The group having the transvaginal ultrasound image bottom-up. During training and transfer test.
62262578|NCT05347186|EXPERIMENTAL|Systematic corrective exercises and non-biomechanical functional exercises|
62262579|NCT05347186|OTHER|Non biomechanical functional exercises.|
62262580|NCT04116385||Cancer surgery patients|Adult subjects (18 years or older) undergoing an oncologic surgical procedure.
62262581|NCT05049096|EXPERIMENTAL|intervention group|In intervention group, participants will receive the whole peri-renal fat modification therapy (including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting and initiating)
62262582|NCT05049096|SHAM_COMPARATOR|sham-control group|In sham control group, participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
62618996|NCT01514890||Telaprevir|
62618997|NCT01514890||Boceprevir|
62618998|NCT03747913|EXPERIMENTAL|Antioxidative Supplementation|Each participant conducts two identical cycling tests, first without and a week later with antioxidative supplementation
62618999|NCT04386161|EXPERIMENTAL|Children with dyslexia|Children, aged between 8 and 11 years, with clinical dyslexia diagnosed by a child and adolescent psychiatrist
62619000|NCT06330675|EXPERIMENTAL|Mobilization 4-h after procedure|Short-term bed-rest (4-h) after CIED implantation
62619001|NCT06330675|ACTIVE_COMPARATOR|Mobilization day-after procedure|Standard of care with prolungate bed-rest after CIED implantation
62619002|NCT04321941|EXPERIMENTAL|CTE (Computerised Tomography Enterography)|CTE examination performed with experimental contrast agent, Lumentin.
62619003|NCT04321941|ACTIVE_COMPARATOR|MRE (Magnetic Resonance Enterography)|Comparative diagnostic method performed with the contrast agent Movprep®
62619004|NCT04052516|PLACEBO_COMPARATOR|Placebo|Placebo oral capsules taken one daily for 52 weeks
62619005|NCT04052516|EXPERIMENTAL|Icosabutate 300mg|Icosabutate 300mg oral capsule taken once daily for 52 weeks
62262583|NCT00777101|EXPERIMENTAL|Neratinib|
62262584|NCT00777101|ACTIVE_COMPARATOR|Lapatinib plus Capecitabine|
62619006|NCT04052516|EXPERIMENTAL|Icosabutate 600mg|Icosabutate 600mg oral capsules taken once daily for 52 weeks
62619007|NCT01204918|EXPERIMENTAL|Riluzole addition to SSRI antidepressant|Riluzole 100mg added to ongoing SSRI or SNRI antidepressant for 8 weeks
62619008|NCT01204918|PLACEBO_COMPARATOR|Placebo addition to standard SSRI antidepressant|Placebo will be added to ongoing SSRI or SNRI antidepressant treatment for 8 weeks
62619009|NCT01204918|EXPERIMENTAL|Riluzole/Placebo addition to SSRI antidepressant|Riluzole 100mg added to ongoing SSRI or SNRI antidepressant for 4 weeks and placebo will added to ongoing SSRI or SNRI antidepressant treatment for 4 weeks
62619010|NCT01343966|EXPERIMENTAL|Part 1: Subcutaneous cohort exp|
62619011|NCT01343966|EXPERIMENTAL|Part 2: Intravenous cohort exp|
62619012|NCT01343966|PLACEBO_COMPARATOR|Part 1: Subcutaneous cohort|Repeating subcutaneous injection
62619013|NCT01343966|PLACEBO_COMPARATOR|Part 2: Intravenous cohort|Repeating intravenous infusion
62619014|NCT03610321|ACTIVE_COMPARATOR|Statin group|Receiving statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) only for 1 month.
62619015|NCT03610321|EXPERIMENTAL|Gefarnate group|Combined treatment with statins (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) and gefarnate (100 mg, three times daily, oral) for 1 month.
62844822|NCT06464783|ACTIVE_COMPARATOR|Thoracic Exercise Program|"Thoracic Exercise Program includes following exercises.~Extension exercises include Thoracic extension in kneeling position T W Y I thoracic exercise in prone position.~Mobilization includes Self-mobilization~Stretching includes Stretching of pectoral muscle group in standing and supine position"
62844823|NCT04312646||patients with thyroid nodules|
62844824|NCT01296672|EXPERIMENTAL|Finasteride|Finasteride 5mg tablets every day by mouth for 3 months
62262585|NCT03068442|EXPERIMENTAL|Carotid atherosclerosis group|This group includes all enrolled subjects (those with carotid disease and plans to undergo surgery).
62262586|NCT02149940|EXPERIMENTAL|clinical pharmacy intervention|
62262587|NCT00961220|EXPERIMENTAL|Treatment (O6-benzylguanine, carmustine)|Patients receive O6-benzylguanine IV over 1 hour and apply topical carmustine to the total skin surface (excluding the lips, eyelids, and ulcerated lesions) 1 hour after completing O6-benzylguanine infusion on days 1-2. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62262588|NCT06365203|ACTIVE_COMPARATOR|Through knee amputation|Through knee amputation
62262589|NCT06365203|ACTIVE_COMPARATOR|Above knee Amputation|Above knee Amputation
62262590|NCT04893642|ACTIVE_COMPARATOR|Abdominal suture rectopexy|Patients were randomized first into either an abdominal or a perineal approach. The abdominal group was then further randomized to suture rectopexy or resection rectopexy.
62447098|NCT02655627|EXPERIMENTAL|Group A|Usual Care Group: A brochure which emphasis the importance of physical activity and exercise in Type 2 DM will be given to the patients in this group after the evaluation.
62262591|NCT04893642|ACTIVE_COMPARATOR|Abdominal resection rectopexy|Patients were randomized first into either an abdominal or a perineal approach. The abdominal group was then further randomized to suture rectopexy or resection rectopexy.
62447099|NCT02655627|EXPERIMENTAL|Group B|Supervised Clinical Exercise Training Group: Patients in this group will continue group exercise training includes aerobic and resistance training, 1 hour in a day, 3 times in a week for 8 weeks with the supervision of a researcher physiotherapist.
62619016|NCT05810610||Adult with stenosis ≥40% on CCTA|Adult patient,- with no diagnosed coronary status or history of stenting or bypass surgery- whose CCTA evaluation by the local radiologist results in at least an intermediate stenosis ≥40% on at least one vessel with indication for FFR measurement.- Who has not expressed opposition to the use of their data.
62619017|NCT03072251||Anyone|Any individual may complete this survey
62844825|NCT01296672|PLACEBO_COMPARATOR|Placebo|Placebo 5mg tablet every day by mouth for 3 months
62619018|NCT00974038|EXPERIMENTAL|CBT, SP|cognitive behavioral therapy, supportive psychotherapy
62619019|NCT01905774||Deferasirox|The patients will be treated by the primary physician according to clinical status. The Deferasirox dose range is between 20 to 40 mg/kg/day once daily dose. The treatment is a continuous treatment and not a single course.
62619020|NCT06043492|EXPERIMENTAL|High Intensity Interval Training|The participants will perform an acute bout of high intensity interval training
62619021|NCT06043492|EXPERIMENTAL|Coninuous Running|The participants will perform an acute bout of continuous running
62619022|NCT06043492|OTHER|Control Trial|The participants will not perform any endurance exercise protocol
62619023|NCT04234594|EXPERIMENTAL|QL1203|Participants only receive QL1203, 6mg/kg on Day 1.
62619024|NCT04234594|ACTIVE_COMPARATOR|Vectibix®|Participants only received Vectibix®，6 mg/kg on Day 1.
62619025|NCT04377841||Facial Demodicosis|"1. Clinical presentation of facial skin matches any of the followings:~   1. Pityriasis folliculorum.~  2. Papulopustular lesion.~  3. Rosacea.~2. Demodex infestation detected by direct microscopic examination ≥ 5 mites/cm2."
62619026|NCT04377841||Ocular Demodicosis|"1. Clinical presentation of ocular region matches any of the followings:~   1. Chronic blepharitis.~  2. Eyelash abnormalities: trichiasis, distichiasis, madarosis.~  3. Meibomian gland dysfunction.~  4. Recurrent chalazion.~  5. Ocular rosacea.~2. Demodex infestation detected by cilia epilation test ≥ 1 mite/eyelid."
62619027|NCT00909220||Current Major Depressive Disorder|Forty-one participants with a primary diagnosis of major depression using the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV) and scores \> 24 on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-C; Rush et al., 1986) were enrolled into a treatment study at Northwestern University's Feinberg School of Medicine in Chicago, Illinois. This group will receive Behavioral Activation psychotherapy.
62844826|NCT02717806|EXPERIMENTAL|PATHway|"Patients allocated to the PATHway intervention will be given a 4 week run-in period as an outpatient to get acquainted with the system. During this run-in period, the PATHway system will also be installed in each participant's home. They will be provided with a training manual and a quick set up guide for getting started with PATHway in the home.~After this 4 week run-in period, the PATHway system will be set up for each individual patient including a patient specific exercise prescription. The patient will then exercise with the PATHway platform for 6 months."
62619028|NCT00909220||Healthy Participants|Another 36 participants with no lifetime psychiatric symptoms and scores \< 11 on the IDS-C were tracked prospectively, naturalistically, for 16 weeks.
62844827|NCT02717806|NO_INTERVENTION|Usual care|Patients randomized to the control group will receive usual care.
62844828|NCT03743857|EXPERIMENTAL|Manual Therapy|6 sessions of ankle manual therapy
62844829|NCT03743857|NO_INTERVENTION|Control|No intervention
62844830|NCT02538913|EXPERIMENTAL|Exercise training|Patients randomized to the exercise training group will be individually instructed in correct pelvic floor muscle contractions and intensive pelvic floor muscle training to perform daily. In addition they will be encouraged to exercise regularly ≥3 days/week. The exercise program will be individualized and consisting of both aerobic and strength exercise training.
62844831|NCT02538913|ACTIVE_COMPARATOR|Usual care|Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
62844832|NCT02471599|EXPERIMENTAL|tonsillectomy group|The case group will receive tonsillectomy.
62619029|NCT03409484|ACTIVE_COMPARATOR|Concord Grape Juice|100% Concord Grape Juice
62619030|NCT03409484|SHAM_COMPARATOR|Low flavonoid low essence beverage|Low flavonoid low essence beverage
62619031|NCT03409484|SHAM_COMPARATOR|Low flavonoid beverage|Low flavonoid beverage
62844833|NCT02471599|ACTIVE_COMPARATOR|non-tonsillectomy group|The controlled group will not receive tonsillectomy.
62844834|NCT06383312|ACTIVE_COMPARATOR|Reflexologic Magnetic Insoles Group|Participants will place the insoles inside their shoes and use them for at least 7 hours a day, every day, for 12 weeks.
62262592|NCT04893642|ACTIVE_COMPARATOR|Perineal Delorme|Patients were randomized first into either an abdominal or a perineal approach. The perineal group was then further randomized to Delorme's operation or Altemeier's operation.
62619032|NCT02671617|NO_INTERVENTION|Control|Control: This group of patients will receive 'current best practice' as per UK NHS recommendations for their specific cancer management prior to surgery.
62619033|NCT02671617|EXPERIMENTAL|High intensity interval training|"Exercise: Participants in this group will attend 3-4 times per week to complete HIIT training during the period from diagnosis to surgery.~High intensity interval training (HIIT)"
62844835|NCT06383312|SHAM_COMPARATOR|Orthopedic Insoles Group|Participants will place the insoles inside their shoes and use them for at least 7 hours a day, every day, for 12 weeks.
62844836|NCT06159426|EXPERIMENTAL|Expert group|The stimulation will be applied by an expert therapist.
62447100|NCT02655627|EXPERIMENTAL|Group C|Internet Based Exercise Training Group. the patients to this group will be a member of the web site named www.diyabetvehareket.com. The participation of the patients will be provided with the videos directing them to 1 hour in a day, 3 times in a week for 8 week both aerobic and resistance exercise training from the researcher physiotherapist.
62619034|NCT00485186||1|
62844837|NCT06159426|ACTIVE_COMPARATOR|Non-expert group|This group will receive the same stimulation as the expert group but in this case it will be applied by a therapist not specialized in therapy.
62844838|NCT04179292|EXPERIMENTAL|Physiotherapy Program|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients by physiotherapist for 3 sessions per week. On the other days, it will be implemented as an 8-week home program with 5 sessions per week.
62262593|NCT04893642|ACTIVE_COMPARATOR|Perineal Altemeier|Patients were randomized first into either an abdominal or a perineal approach. The perineal group was then further randomized to Delorme's operation or Altemeier's operation.
62262594|NCT02257372|EXPERIMENTAL|UMEC (62.5 mcg)|Participants will self-administer blinded UMEC (62.5 mcg) each morning (once daily) as one inhalation from the double-blind DPI over a treatment period of 12 weeks. Participants will receive open labeled ICS/LABA medication through out duration of the treatment period as background treatment.
62447101|NCT02518230|OTHER|Neurally Adjusted Ventilatory Assist|Subject will be randomized to NAVA ventilation. Intervention is mechanical ventilation with Neurally Adjusted Ventilatory Assist for 12 hours.
62844839|NCT04179292|EXPERIMENTAL|Home Program|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients as home program. Motivation will be provided by contacting by phone / call once a week for follow-up.
62844840|NCT00492128|EXPERIMENTAL|Losartan/hydrochlorothiazide|Combination drug with losartan 50mg and hydrochlorothiazide 12.5mg
62619035|NCT00485186||2|
62619036|NCT04424914|OTHER|ATTR-CM positive|Participants diagnosed with ATTR-CM by scintigraphy
62619037|NCT04424914|OTHER|ATTR-CM negative|Participants who are scintigraphy negative for ATTR-CM
62619038|NCT03605472|EXPERIMENTAL|Patients|
62619039|NCT03489122|EXPERIMENTAL|Iyengar yoga and coherent breathing|The yoga intervention consists of Iyengar yoga method and coherent breathing sessions for 90 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
62619040|NCT03489122|ACTIVE_COMPARATOR|Walking|The walking intervention consists of walking sessions at 2.5 miles an hour on a flat surface for 60 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
62619041|NCT04064255|ACTIVE_COMPARATOR|Case: Practical Body Image + Treatment as Usual|"The Case arm involves Practical Body Image + treatment as usual.~Practical Body Image is based on a cognitive behavioural model of body image addressing thoughts, feelings, behaviours and misperceptions. PBI is designed to be administered over 10 weeks (6 weekly sessions over 6 weeks, followed by 8 twice weekly sessions over 4 weeks).~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist."
62844841|NCT00492128|ACTIVE_COMPARATOR|Losartan/amlodipine|Combination therapy with losartan 50mg and amlodopine 5mg
62844842|NCT00703248|EXPERIMENTAL|1|
62844843|NCT00703248|NO_INTERVENTION|2|
62058973|NCT00615381|EXPERIMENTAL|Supraphysiologic insulin|Maintenance of intraoperative euglycemia (blood glucose 80--110 mg/dL) using supraphysiologic insulin infusion doses (0.3 U/kg/hr) and exogenous dextrose to provide stable blood glucose levels .
62058974|NCT00953134|EXPERIMENTAL|1|IFA - Iron and Folic Acid (60 mg of ferrous fumarate and 400 mcg folic acid)
62262595|NCT02257372|EXPERIMENTAL|Placebo|Participants will self-administer blinded placebo each morning (once daily) as one inhalation from the double-blind DPI over a treatment period of 12 weeks. Participants will receive open labeled ICS/LABA medication through out duration of the treatment period as background treatment
62262596|NCT02522702||Routine colonoscopy Cohort|
62262597|NCT02534402|EXPERIMENTAL|Prednisone Group|30mg of prednisone PO (orally) everyday for 5 days.
62619042|NCT04064255|NO_INTERVENTION|Control: Treatment as Usual Only|"Control arm involves treatment as usual only.~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist."
62619043|NCT02156063|EXPERIMENTAL|NT100|NT100 Dose 1
62058975|NCT00953134|ACTIVE_COMPARATOR|2|FA - Folic Acid (400 mcg folic acid)
62619044|NCT02156063|PLACEBO_COMPARATOR|Placebo|Placebo
62619045|NCT02343432|EXPERIMENTAL|Epidural Volume 10mL|Epidural Volume 10mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 10mL Intervention: Drug: Bupivacaine 12.5mg
62844844|NCT04950478|EXPERIMENTAL|Virtual Reality|The children wore the virtual reality headset and game was started one minute before the venipuncture. The children took off the virtual reality headset after the venipuncture ended.
62844845|NCT04950478|NO_INTERVENTION|Control Group|No intervention was performed to reduce pain in the control group
62844846|NCT06237478|EXPERIMENTAL|Group L|The HR at 10 minutes after the start of surgery was considered as the baseline HR. Patients were divided into two groups based on their baseline HR: Group L: Baseline HR 40-60 beats/min.
62844847|NCT06237478|EXPERIMENTAL|Group H|The HR at 10 minutes after the start of surgery was considered as the baseline HR. Patients were divided into two groups based on their baseline HR: Group H: Baseline HR 60-100 beats/min.
62844848|NCT00707941|EXPERIMENTAL|1|Oseltamivir for 5 days for patients with illness duration \< 48 hours
62844849|NCT00707941|PLACEBO_COMPARATOR|2|Placebo for 5 days for patients with illness duration \< 48 hours
62844850|NCT00707941|EXPERIMENTAL|3|Oseltamivir for 5 days for patients with illness duration ≥ 48 hours
62058976|NCT01852058|EXPERIMENTAL|OnabotulinumtoxinA 50 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 50 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
62058977|NCT01852058|EXPERIMENTAL|OnabotulinumtoxinA 100 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 100 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
62619046|NCT02343432|EXPERIMENTAL|Epidural Volume 15mL|Epidural Volume 15mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 15 mL Intervention: Drug: Bupivacaine 12.5mg
62619047|NCT02343432|EXPERIMENTAL|Epidural Volume 20mL|Epidural Volume 20mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 20 mL Intervention: Drug: Bupivacaine 12.5mg
62619048|NCT06004323|EXPERIMENTAL|Digital health literacy intervention|The interventions will be developed based on the Best Practices for Digital Health Literacy, WHO health literacy toolkits and the findings of the interviews. The content to be covered in the intervention will include news about vaccines; alerts about COVID-19 preventive measures; guidelines on social distancing, COVID-19 screening test arrangements, vaccination and compulsory quarantines; COVID-19-related law enforcement; and self-monitoring of COVID-19 symptoms
62058978|NCT01852058|EXPERIMENTAL|OnabotulinumtoxinA 200 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 200 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
62262598|NCT02534402|NO_INTERVENTION|Control Group|no treatment
62262599|NCT04445571|ACTIVE_COMPARATOR|INSURE|Surfactant administration by Intubation-surfactant-extubation to CPAP according to standard protocol including premedication with analgesia and sedation.
62262600|NCT04445571|ACTIVE_COMPARATOR|LISA|Surfactant administration by thin catheter during spontaneous breathing and continued CPAP according to set protocol including premedication with analgesia.
62262601|NCT04812132|ACTIVE_COMPARATOR|Women|
62262602|NCT04812132|ACTIVE_COMPARATOR|Men|
62262603|NCT01245582|EXPERIMENTAL|SECOX regimen|Oxaliplatin (Eloxatin) 85mg/m2 , 2 hour infusion, day 1 Capecitabine (Xeloda) 850 mg/m2 BID orally daily, from day 1 to 7 Sorafenib (Nexavar) 400 mg BID orally daily, from day 1 to 14 (continuously)
62619049|NCT06004323|NO_INTERVENTION|Control|No intervention will be provided to the control group
62844851|NCT00707941|PLACEBO_COMPARATOR|4|Placebo for 5 days for patients with illness duration ≥ 48 hours
62844852|NCT04251026|EXPERIMENTAL|Cohort A|Dose escalation followed by a consistent dose level in participants with neuronopathic MPS II
62262604|NCT01245582|ACTIVE_COMPARATOR|Sorafenib alone|Sorafenib (Nexavar) 400 mg BID orally daily, from day 1 to 14 (continuously)
62619050|NCT02553798|EXPERIMENTAL|Glycopyrronium|Glycopyrronium Topical Wipes
62844853|NCT04251026|EXPERIMENTAL|Cohort B|A consistent dose level in participants with non-neuronopathic MPS II, neuronopathic MPS II, or unknown phenotype followed by dose escalation in some participants.
62844854|NCT04251026|EXPERIMENTAL|Cohort C|A consistent dose level in participants with neuronopathic MPS II
62619051|NCT02313805|EXPERIMENTAL|With checklist|Students will simulate insulin initiation with the aid of a checklist
62619052|NCT02313805|NO_INTERVENTION|Without checklist|Students will simulate insulin initiation without the aid of a checklist
62262605|NCT01263821|EXPERIMENTAL|Arm I|Patients undergo magnetic resonance spectroscopic imaging, functional magnetic resonance imaging (MRI), diffusion-weighted MRI, and perfusion-weighted MRI. Patients then undergo maximum surgical resection followed by intensity-modulated radiation therapy (IMRT) 5 days a week for 6 weeks.
62058979|NCT04508179|EXPERIMENTAL|7HP349 Capsules|Part A: 7HP349 Capsules (5 cohorts); Part B: 7HP349 Capsules (2 cohorts); Part C: 7HP349 Capsules (3-period cross-over)
62058980|NCT04508179|PLACEBO_COMPARATOR|Placebo Capsules|Part A: Placebo Capsules (5 cohorts); Part B: Placebo Capsules (2 cohorts)
62058981|NCT05374044||rectal cancer with NAT|The patients are planned to receive neoadjvant therapy, and then receive radical surgery.
62262606|NCT05500209|EXPERIMENTAL|Coping Self-Efficacy|Experimental condition enhancing coping self-efficacy
62447102|NCT02518230|OTHER|Synchronized Interm. Mandatory Assist|Subject will be randomized to SIMV(PC)PS ventilation. Intervention is mechanical ventilation with Synchronized Intermittent Mandatory Assist with Pressure Support for 12 hours.
62058982|NCT05838001|EXPERIMENTAL|patients after neoadjuvant therapy-combined localization|
62262607|NCT05500209|NO_INTERVENTION|Waitlist control|Waitlist control condition
62262608|NCT05973929||Multiple sclerosis patients with movement disorders.|"A randomized cross-sectional study will be conducted on diagnosed multiple sclerosis patients who were diagnosed according to McDonald criteria of MS 2017 (Thompson et al. 2018).~We will study the prevalence of movement disorders in M.S patients, clinical type of movement disorder and the MRI findings. Data collected from patients admitted or following at Al-Azhar university hospitals at Al-Hussein and El-Sayed Galal hospitals. The included eligible patients should fulfil the following inclusion criteria:~i. Full clinical history and neurological assessment. ii. Detailed multiple sclerosis history according to MS unit history sheet. iii. Detailed history of movement disorder which include clinical type of movement disorder and medication taken (or not).~iv. MRI Brain and spine of the included patient will be photographed."
62447103|NCT05622955|EXPERIMENTAL|Endometriosis group care|Groups of 6-10 patients with endometriosis and chronic pelvic pain will attend eight weekly two-hour sessions.
62844855|NCT04251026|EXPERIMENTAL|Cohort D|A consistent dose level in participants with non-neuronopathic MPS II or neuronopathic MPS II
62844856|NCT04251026|EXPERIMENTAL|Cohort E|A consistent dose level in participants with non-neuronopathic MPS II or neuronopathic MPS II
62058983|NCT05838001|ACTIVE_COMPARATOR|patients after neoadjuvant therapy-single localization|
62447104|NCT03386097||Type 2 diabetes patients|
62058984|NCT01461382|EXPERIMENTAL|Phase I|Entered Study May 2008.
62058985|NCT01461382|EXPERIMENTAL|Phase II|Phase II entered 6 months after Phase I. Phase II was a no intervention control for 6 months, then followed an identical intervention protocol to Phase I.
62058986|NCT03502616|EXPERIMENTAL|Tofacitinib|
62058987|NCT03502616|PLACEBO_COMPARATOR|Placebo|
62447105|NCT03386097||Healthy controls|
62447106|NCT01051609||Intervention Group|There is only one arm in this trial. Please see interventions for more detailed descriptions.
62447107|NCT01689480||FSHD training|Only the patients who have participated to the FSHD1 study (NCT01116570) can be included in this study.
62844857|NCT00538668|EXPERIMENTAL|1|20 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
62058988|NCT04498325|EXPERIMENTAL|NT-I7 (Phase I)|"* In the phase I study, 3 dose levels of NT-I7 are planned. Dosing will be staggered such that there will be a minimum of 72 hours between the dosing of one participant and the dosing of the next participant~* NT-I7 will be given by intramuscular injection on Day 0~* Participants will also be given standard of care treatment for COVID-19"
62058989|NCT04498325|EXPERIMENTAL|NT-I7 (Pilot)|"* NT-I7 (dose determined by Phase I portion of study) will be given by intramuscular injection on Day 0~* Participants will also be given standard of care treatment for COVID-19"
62058990|NCT04498325|PLACEBO_COMPARATOR|Placebo (Pilot)|"* Placebo will be given by intramuscular injection on Day 0~* Participants will also be given standard of care treatment for COVID-19"
62058991|NCT04176341|OTHER|Intervention group|chronic pain patient consulting in Grenoble Alps University Hospital, and Hospital Mutualist Group who will one non pharmacological intervention between slackline, mindfulness, adapted physical activity, self-hypnosis, Qi Gong during 6 to 8 weeks.
62058992|NCT04176341|NO_INTERVENTION|Control group|chronic pain patient consulting in Lyon University Hospital who will receive usual care.
62262609|NCT02662257|ACTIVE_COMPARATOR|Sevoflurane group|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
62447108|NCT01399723|EXPERIMENTAL|Amoxicillin 45mg/kg 12 hourly|
62619053|NCT00555776|ACTIVE_COMPARATOR|1|Randomly,half of the subjects are given Gabapentin.
62619054|NCT00555776|PLACEBO_COMPARATOR|2|Randomly,half of the subjects receive placebo.
62844858|NCT00538668|EXPERIMENTAL|2|25 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
62844859|NCT00538668|EXPERIMENTAL|3|30 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
62844860|NCT00538668|EXPERIMENTAL|4|35 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
62844861|NCT00538668|EXPERIMENTAL|5|40 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
62844862|NCT00538668|EXPERIMENTAL|6|45 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
62844863|NCT00538668|EXPERIMENTAL|7|50 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
62844864|NCT00538668|EXPERIMENTAL|8|55 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
62844865|NCT00538668|EXPERIMENTAL|9|25 mCi/m2 of 177Lu-J591 will be given every 2 weeks.
62447109|NCT01399723|ACTIVE_COMPARATOR|Benzyl Penicillin 50,000IU/kg 6 hourly|
62447110|NCT05933304||Vaccinated Cohort|Participants who receive Moderna COVID-19 vaccine during a pre-specified time frame and meet eligibility criteria will be included in this cohort. Participants will be followed up through Electronic Health Record (EHR) for occurrence of COVID-19 outcomes until the end of the study period, or censoring events (termination of KPSC membership allowing for a 31-day gap, death, receipt of a COVID-19 vaccine).
62844866|NCT00479687|ACTIVE_COMPARATOR|Supartz|SUPARTZ® 3 injections over 2 weeks
62844867|NCT00479687|PLACEBO_COMPARATOR|Phosphate Buffered Saline|Phosphate Buffered Saline 3 injections over 2 weeks
62844868|NCT03651024|OTHER|Treating Patients with ED|Treatment of patients with ED
62844869|NCT06326333|OTHER|Combined parasternal block and serratus anterior plane block|"In the parasternal block application, the needle will be advanced under the pectoralis major muscle and above the intercostal muscle with the ultrasound-guided in-plane technique. 7.5 ml of 0.25% bupivacaine will be injected into this area per each level, at the level of the second and fourth intercostal space.~Then, in the serratus anterior plane block application, in the anterior axillary line, the needle will be advanced under the serratus anterior muscle, above the sixth rib, with the in-plane technique under ultrasound guidance. 10 ml of 0.25% bupivacaine will be injected into this area.~The application will be applied bilaterally."
62844870|NCT05721599|EXPERIMENTAL|Intervention group|Structured integrated care model
62844871|NCT05721599|NO_INTERVENTION|Control group|General outpatient care
62844872|NCT02653417|EXPERIMENTAL|Regimen 1|RAD1901 5 mg/day
62844873|NCT02653417|EXPERIMENTAL|Regimen 2|RAD1901 10 mg/day
62844874|NCT02653417|EXPERIMENTAL|Regimen 3|RAD1901 20 mg/day
62058993|NCT04513522|EXPERIMENTAL|Nivolumab + ipilimumab|
62447111|NCT05933304||Unvaccinated Cohort|Participants who have not received Moderna COVID-19 vaccine or any other COVID-19 vaccine as of the index date of their matched vaccinated participant and who meet eligibility criteria will be included in this cohort. Participants will be followed up through EHR for occurrence of COVID-19 outcomes until the end of the study period, or censoring events (termination of KPSC membership allowing for a 31-day gap, death, receipt of a COVID-19 vaccine).
62447112|NCT03752671|EXPERIMENTAL|the IntraSPINE® device associated with discectomy|
62447113|NCT03752671|ACTIVE_COMPARATOR|discectomy alone|
62447114|NCT00993057|ACTIVE_COMPARATOR|Q1 hour protocol|change of insulin infusion every hour
62447115|NCT00993057|ACTIVE_COMPARATOR|Q30min protocol|change of insulin infusion every 30 minutes
62619055|NCT01777139|EXPERIMENTAL|Retigabine IR|All subjects will initially receive a starting dose of retigabine IR at 900 mg/day and after the first week of the OLE study, the dose of retigabine IR may be increased or decreased in increments or decrements of decrements of 150 mg/day on weekly basis based on efficacy and tolerability. The overall daily dose of retigabine IR must be maintained between a minimum dose of 600 mg/day and a maximum dose of 1200 mg/day.
62619056|NCT02570230|PLACEBO_COMPARATOR|Control|NSS infusion
62619057|NCT02570230|EXPERIMENTAL|Ketamine|Ketamine 0.2 mg/kg/hr intravenous infusion
62844875|NCT02653417|PLACEBO_COMPARATOR|Regimen 4|Placebo
62844876|NCT03652285|EXPERIMENTAL|Esophageal stent implantation (UAS-RBS implantation)|Esophageal stent implantation (UAS-RBS implantation) at J0, removal after 6 months and follow-up for 6 months
62262610|NCT02662257|EXPERIMENTAL|Propofol group|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
62262611|NCT01157975|EXPERIMENTAL|Pioglitazone|
62262612|NCT01157975|EXPERIMENTAL|Prednisone|
62619058|NCT04839432||Crystalloids group|Patients had only a balanced crystalloid solution in the priming of the cardiopulmonary bypass (pre interventional group)
62619059|NCT04839432||albumin group|Patients had only a 4% albumin solution in addtion to a very low volume of a balanced crystalloid solution in the priming of the cardiopulmonary bypass (post interventional group)
62844877|NCT05033704|EXPERIMENTAL|(Group A)|"Twenty-four of the 48 patients will receive an intraoperative intravenous infusion of 5% human plasma protein fraction PPF, (A group). PPF 5% Octapharma 5 % is a colloid solution containing (47.6-52.5% proteins, of which 45.6-52.5 gm/L albumin and 142.5-157.5 mmol/L sodium).~Fluids will be given targeting euvolemic state which is defined as central venous pressure (CVP) 5-10 mmHg or Stroke volume variation (SVV) of ≤ 13%. Central venous pressure (CVP) CVP of -1 to 1 mmHg or Stroke volume variation (SVV) of 18-21% (12) will be targeted during transaction times. The transfusion trigger will be Hemoglobin of ≤8 gm/dl."
62844878|NCT05033704|NO_INTERVENTION|(Group RS)|24 patients will receive an intraoperative intravenous infusion of crystalloids (0.9 % normal saline and/ or Lactated Ringer's solution) (RS group). Fluids will be given targeting euvolemic state which is defined as central venous pressure (CVP) 5-10 mmHg or Stroke volume variation (SVV) of ≤ 13%. Central venous pressure (CVP) CVP of -1 to 1 mmHg or Stroke volume variation (SVV) of 18-21% (12) will be targeted during transaction times. The transfusion trigger will be Hemoglobin of ≤8 gm/dl.
62844879|NCT02246413|EXPERIMENTAL|RAINBOW Intervention Program|An integrated intervention program for helping to improve mood and weight in adults who may be at risk for diabetes and heart disease.
62844880|NCT02246413|NO_INTERVENTION|Usual Care|Usual Care.
62262613|NCT05017207||Patient with periampullary cancer and pancreaticoduodenectomy|Only one group of patient with periampullary cancer
62619060|NCT01905592|ACTIVE_COMPARATOR|Physician's choice|Physician may select from 4 active comparators
62262614|NCT02641145|EXPERIMENTAL|Active AL cardiac amyloidosis|75 individuals with light chain systemic amyloidosis with active plasma cell dyscrasia and cardiac involvement will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of blood of the heart, as well as the heavy metal analysis of the blood at baseline, 6 months and 12 months after initiation of chemotherapy. 25 of these individuals will also undergo a N-13 ammonia PET scan of the heart following supine bicycle stress at baseline and at 6 months after initiation of chemotherapy.
62447116|NCT05074082||Flap reconstruction|Patients who had a flap formation as part of a multi-visceral extended resection for advanced pelvic (rectal, urological, gynaecological, sarcomatous origin) malignancy
62447117|NCT02289768|EXPERIMENTAL|5-fluorouracil/salicylic acid|Actikerall® solution (5-fluorouracil 0.5%, salicylic acid 10.0%) applied to the affected area once-daily for 12 weeks
62619061|NCT01905592|EXPERIMENTAL|niraparib|Patients will be randomized 2:1 to receive niraparib 300 mg (3x100 mg capsules) once daily for 21 continuous days
62619062|NCT04951713|EXPERIMENTAL|XZP-3287 combined with clarithromycin|XZP-3287 combined with clarithromycin
62447118|NCT02289768|PLACEBO_COMPARATOR|Vehicle|Vehicle solution applied to the affected area once-daily for 12 weeks
62447119|NCT04757415|EXPERIMENTAL|Traction straight leg raise technique for hamstring.|Experimental group underwent conventional physiotherapy treatment (hot pack) followed by five main gluteal activation exercises three in first five sessions and rest two in remaining five sessions along with traction straight leg raise technique. Each session took 30 minutes . Participants were treated 10 times over a 5 week period with 2 treatment sessions per week. Pre and Post treatment readings were taken in 1st and 10th session over a 5 week period respectively. Assessment was done via Numeric pain rating scale and sphygmomanometer for assessing pain intensity and muscle strength of gluteus maximus.
62619063|NCT04951713|EXPERIMENTAL|XZP-3287 combined with rifampicin|XZP-3287 combined with rifampicin
62619064|NCT06039605|NO_INTERVENTION|Control|This group will only receive motor training, which consists of 10 trials of motor training per day across 3 days, followed by a one-week follow-up of 2 trials.
62619065|NCT06039605|EXPERIMENTAL|tDCS1|This group will receive motor training concurrent with 20 minutes of either sham or active tDCS. Sham tDCS will be a 30-second ramp up from 0 to 2 milliamps (MA), then a 30-second ramp-down from 2 mA to 0 mA. The next 18 minutes will have no stimulation (0 mA), starting at minute 19 with 30-second ramp up from 0 to 2 milliamps (MA), then a 30-second ramp-down from 2 mA to 0 mA. Active tDCS will ramp up to 2 mA in the first 30 seconds, then stay at 2 mA for 19 minutes, then ramp down to 0 mA.
62619066|NCT06039605|EXPERIMENTAL|tDCS2|This group will first read some information about tDCS based on cited studies. They will then receive the same motor training and tDCS as the tDCS1 arm.
62619067|NCT06039605|EXPERIMENTAL|tDCS3|This group will first read some information about tDCS based on cited studies, but different cited studies than the tDCS2 arm. They will then receive the same motor training and tDCS as the tDCS1 and 2 arms.
62844881|NCT04082819|OTHER|Low Blood Pressure|Low blood pressure (systolic: 0-129, diastolic: 0-79)
62844882|NCT04082819|OTHER|Medium Blood Pressure|Medium blood pressure (systolic: 130-160, diastolic: 80-100)
62844883|NCT04082819|OTHER|High Blood Pressure|High blood pressure (systolic: 161 or higher, diastolic: 101 or higher)
62058994|NCT04379193|EXPERIMENTAL|Motor program activating therapy|MPAT is method developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centered. Somatosensory (manual and verbal) stimuli are then applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when laying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to automatically use the acquired motor skills in daily life. Therapy was realized within the ambulatory area of the Department of Neurology at Kralovske Vinohrady University Hospital in Prague.
62619068|NCT02324699|EXPERIMENTAL|Prednisone co-inductive therapy|Prednisone 40 mg/day starting at week 0 for 2 weeks, tapered by 10 mg weekly to achieve 0 mg by end of week 5
62619069|NCT02324699|PLACEBO_COMPARATOR|Placebo|Identical placebo taper
62262615|NCT02641145|ACTIVE_COMPARATOR|Remission AL cardiac amyloidosis|25 individuals with light chain systemic amyloidosis with cardiac involvement and plasma cell dyscrasia in hematological remission (complete hematological remission or very good partial response-differential free light chain (dFLC)\<40 mg/dL for \> 1 year prior to enrollment) will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI scan of the heart as well as a heavy metal analysis of the blood at baseline.
62262616|NCT02641145|EXPERIMENTAL|Active AL Pre-CMP|36 individuals with light chain systemic amyloidosis with active plasma cell dyscrasia and without cardiac involvement will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of the heart, as well as a heavy metal analysis of the blood at baseline. At 6 months they will undergo a research MRI of the heart and at 12 months they will have a clinical follow up. Subjects with contraindications to Cardiac MRI or gadolinium contrast may still be eligible for study participation.
62447120|NCT04757415|EXPERIMENTAL|Gluteal activation exercises|Experimental group underwent conventional physiotherapy treatment (hot pack) followed by five main gluteal activation exercises three in first five sessions and rest two in remaining five sessions. Each session took 30 minutes . Participants were treated 10 times over a 5 week period with 2 treatment sessions per week. Pre and Post treatment readings were taken in 1st and 10th session over a 5 week period respectively. Assessment was done via Numeric pain rating scale and sphygmomanometer for assessing pain intensity and muscle strength of gluteus maximus.
62447121|NCT01110681|EXPERIMENTAL|Solesta|"Open label. Solesta (Dextranomer in gel of stabilized non-animal hyaluronate) The study treatment consisted of 4 submucosal injections, 1 mL Solesta each, in the proximal part of the high pressure zone in the anal canal.~Re-treatment is allowed one month after initial treatment if the subject is still incontinent."
62619070|NCT05205629||Donafenib + TACE|
62262617|NCT02641145|NO_INTERVENTION|Multiple Myeloma Controls|25 individuals with diagnosis of multiple myeloma without concomitant amyloidosis by standard criteria will undergo urine and blood testing only.
62447122|NCT00982410|EXPERIMENTAL|Arm 1|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
62447123|NCT00982410|PLACEBO_COMPARATOR|Arm 2|educational supportive group
62844884|NCT03714581|EXPERIMENTAL|Laser|Microablative Fractional CO2 Laser Therapy (The parameters that will be used are the following: 1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode.)
62844885|NCT03714581|PLACEBO_COMPARATOR|Placebo|Placebo therapy (The parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode.
62844886|NCT01041963|ACTIVE_COMPARATOR|Enalapril|
62447124|NCT03842371||Sepsis with type 2 diabetes|Sepsis patients with type 2 diabetes
62619071|NCT00594074|EXPERIMENTAL|1|This group will receive 3.25 ounces of white wine with lunch and dinner
62844887|NCT01041963|ACTIVE_COMPARATOR|Enalapril plus Losartan|
62262618|NCT02641145|EXPERIMENTAL|Heart Failure|10 individuals with diagnosis of heart failure without amyloidosis by standard criteria will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of the heart, as well as a heavy metal analysis of the blood at baseline..
62262619|NCT03048903|EXPERIMENTAL|Rheum Palmatum Root|Rheum Palmatum Root is commercially certified rhubarb(Rheum palmatum ,Sichuan origin, provided by the pharmacy of my hospital)
62619072|NCT00594074|NO_INTERVENTION|2|This group receives the same amount of calories as the experimental group
62262620|NCT03048903|PLACEBO_COMPARATOR|Starch Corn|Medical Starch is harmless to people
62619073|NCT02126124|ACTIVE_COMPARATOR|Active dTMS Treatment|Brainsway Deep TMS Treatment
62619074|NCT02126124|SHAM_COMPARATOR|Sham Treatment|Brainsway Sham Treatment
62619075|NCT03704506|EXPERIMENTAL|treatment group 1|Reyanning mixture+amoxil capsule simulator
62619076|NCT03704506|EXPERIMENTAL|treatment group 2|Reyanning mixture +amoxil capsule
62619077|NCT03704506|ACTIVE_COMPARATOR|control group|Reyanning mixture simulator +amoxil capsule
62619078|NCT00312052|EXPERIMENTAL|E5555 50 mg|Participants received one 50 mg E5555 and two 100 mg placebo tablets, once orally daily for 24 weeks.
62844888|NCT01041963|PLACEBO_COMPARATOR|Control|Drug: antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Administration of antihypertensive agents will select as follows : CCB→β-blocker→α-blocker--\>hydralazine
62844889|NCT00580528|EXPERIMENTAL|1 Tailored internet newsletters|Tailored newsletters delivered via the Internet with content for improving eating and activity to reduce blood pressure.
62844890|NCT00580528|EXPERIMENTAL|2 Tailored print newsletters|Tailored print newsletters delivered via the mail with content for improving eating and activity to reduce blood pressure.
62844891|NCT00580528|NO_INTERVENTION|3 No newsletters|Participants receive no newsletters
62844892|NCT01396070|EXPERIMENTAL|Brentuximab vedotin|Novel antibody-drug conjugate, 1.8 mg/kg intravenously every 3 weeks
62844893|NCT00256672|ACTIVE_COMPARATOR|1|High-dose Thoraco-Lumbar-Sacral Orthoses wear (\>23hrs/day) will be compared to low-dose Thoraco-Lumbar-Sacral Orthoses wear (12hrs/day)
62844894|NCT00256672|ACTIVE_COMPARATOR|2|Low-dose Thoraco-Lumbar-Sacral-Orthoses wear (12hrs/day)
62844895|NCT01929811|EXPERIMENTAL|Metformin arm|Docetaxel: 75mg/m2, d1, q3w\*6 Epirubicin: 75mg/m2, d1, q3w\*6 Cyclophosphamide: 500mg/m2, d1, q3w\*6 Metformin: 500mg tid, orally (500mg daily in first cycle)
62844896|NCT01929811|OTHER|TEC|Docetaxel: 75mg/m2, d1, q3w\*6 Epirubicin: 75mg/m2, d1, q3w\*6 Cyclophosphamide: 500mg/m2, d1, q3w\*6
62262621|NCT01565733||NovoMix® 30 users|
62262622|NCT01382992||Early Stage|
62058995|NCT04379193|EXPERIMENTAL|Vojta's reflex locomotion|VRL is a standard approach for patients with MS in the Czech Republic. In the therapy, global patterns of the reflex locomotion are activated by stimulation of specific zones, with the individual placed in a precisely determined initial position (supine, prone and side laying, low kneeling position). These movement patterns have the qualities of the forward movement (locomotion) and the movement responses are precisely defined. Reflex locomotion (reflex turning and reflex creeping) is used in therapy to activate involuntarily responses of muscle function, which are necessary for spontaneous movements. Therapy was realized at the Department of Rehabilitation and Sport Medicine at Motol University Hospital.
62619079|NCT00312052|EXPERIMENTAL|E5555 100 mg|Participants received one 50 mg placebo, one 100 mg E5555 and one 100 mg placebo tablets, once orally daily for 24 weeks.
62619080|NCT00312052|ACTIVE_COMPARATOR|E5555 200 mg|Participants received one 50 mg placebo and two 100 mg E5555 tablets were taken orally once daily for 24 weeks.
62262623|NCT01382992||Late Stage|
62262624|NCT03858673||Ligations group|VTH via the Tsuzi method with residual uterine ligament ligation (ligations group)
62262625|NCT03858673||Without ligations group|Traditional VTH without residual uterine ligament ligation (without ligations group)
62262626|NCT02701868||Phase 1|Up to 40 individuals will be recruited to participate in focus groups at Pennington Biomedical Research Center. Approximately six focus groups (each with 5-10 participants) will be conducted at the Pennington Biomedical Demonstration Kitchen over the course of approximately 3 months.
62262627|NCT02701868||Phase 2|Up to 150 individuals who did not participate in Whoa Baby Phase 1 will be recruited to test the efficacy of the revised instructions on infant overfeeding in comparison with the instructions currently provided on the packaging.
62262628|NCT01901575|EXPERIMENTAL|Remifentanil IV PCA|patients with PVC's prior to administration of remifentanil
62619081|NCT00312052|PLACEBO_COMPARATOR|Placebo|Participants received one 50 mg placebo and two 100 mg placebo tablets, once orally daily for 24 weeks.
62262629|NCT04481984|EXPERIMENTAL|Exercise group|The training including isometric and stretching hand exercise was applied once by a physiatrist. A hand exercise ball was used for isometric exercise. Patients performed both stretching exercises and isometric exercises according to the training and printed materials. The home-based exercise program was implemented 7 days per week during an 8-week period. In addition, patients received recommendations such as avoiding cold exposure and trauma.
62262630|NCT04481984|OTHER|Control group|Patients received care advice including avoiding cold exposure and trauma.
62262631|NCT02651168|OTHER|aflibercept|aflibercept treatment aflibercept, 40 mg/mL Solution for Intravitreal Injection
62262632|NCT04085679||MMU active group|Subjects residing in nursing homes where the MMU care model has already been implemented
62447125|NCT03842371||Sepsis without type 2 diabetes|Sepsis patients without type 2 diabetes
62447126|NCT03842371||Volunteers|Healthy volunteers
62619082|NCT02653898|ACTIVE_COMPARATOR|Focused Screening and Treatment + ITU|Approved antimalarial based on the malaria species identified on the monthly follow ups, following national treatment guidelines in Cambodia AND Insecticide Treated Uniform with 40% Permethrin; DHA-PIP or Artesunate + Mefloquine based on the malaria species, single dose Primaquine 15 mg in subjects with P.f uncomplicated malaria or Primaquine 45 mg weekly x 8 weeks in G6PD-deficient volunteers, or Primaquine 15 mg daily for 14 days in G6PD-normal volunteers.
62262633|NCT04085679||MMU control group|Subjects residing in nursing homes where the MMU care model has not yet been implemented (ED visits performed in case of urgent clinical situations)
62447127|NCT01680679|EXPERIMENTAL|Inactivated Trivalent Influenza Vaccine|Inactivated trivalent influenza vaccine (TIV), split virion
62447128|NCT01680679|PLACEBO_COMPARATOR|Inactivated Polio Vaccine|Inactivated poliovirus vaccine (IPV), trivalent
62447129|NCT01680679|NO_INTERVENTION|Surveillance arm|Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members.
62619083|NCT02653898|ACTIVE_COMPARATOR|Focused Screening and Treatment + sITU|Approved antimalarial based on the malaria species identified at the monthly follow up and following national treatment guidelines in Cambodia AND sham treated uniform. DHA-PIP or Artesunate + Mefloquine based on the malaria species, single dose Primaquine 15 mg in subjects with P.f uncomplicated malaria or Primaquine 45 mg weekly x 8 weeks in G6PD-deficient volunteers, or Primaquine 15 mg daily for 14 days in G6PD-normal volunteers.
62619084|NCT02653898|ACTIVE_COMPARATOR|Monthly Malaria Prophylaxis + ITU|Monthly DHA-PIP + weekly Primaquine 22.5 mg for 3 months; All subjects will also receive insecticide treated uniforms with 40% Permethrin
62262634|NCT05120479|EXPERIMENTAL|Experimental arm|"The intervention will be the application of a Kinesiotape (KT) strip on the anterior side of the forearm.~The day of the intervention will proceed as follows:~* Warm-up: The total warm-up time will be 5 minutes. After warm-up, a 1 minute rest will be carried out.~* Skin cleansing with 96% alcohol.~* Kinesiotape (KT): KT will be placed without any extra tension (in the scientific literature it is called paper off tension)."
62447130|NCT01485913|EXPERIMENTAL|Lifestyle counseling|"The group subjected to educations will follow the whole process of peer education described in Part 1 of this Protocol.~The control group will perform these classic individual consultations but will not follow the whole process of peer education.~The classical management in diabetes consultations consists of:~* A counselling session~* A measure of blood glucose~* A measurement of blood pressure~* A measure of weight and size~* A complete clinical examination~* A prescription or a renewal of treatment (diabetes pills, insulin, IEC, statins etc ...)"
62619085|NCT02653898|ACTIVE_COMPARATOR|Monthly Malaria Prophylaxis + sITU|Monthly DHA-PIP + weekly Primaquine 22.5 mg for 3 months; All subjects will also receive sham treated uniforms
62619086|NCT05270278||1. Eosinophilic AB - initiated biological treatment against IL-5 or IL-5R|"* initiated biological treatment - mepolizumab or benralizumab~* judged by the treating physician, the patient cannot indicated treatment of type anti IgE or anti IL-4R"
62619087|NCT05270278||2. Eosinophilic AB - initiated biological treatment against IgE or IL-4R|"* initiated biological treatment - omalizumab or dupilumab~* judged by the treating physician, patient cannot indicated treatment type anti IL-5 or anti IL-5R"
62844897|NCT04310371|EXPERIMENTAL|Obese adolescents|BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention
62262635|NCT05120479|SHAM_COMPARATOR|Control arm|"The intervention will be the application of a tape strip on the anterior side of the forearm. Sham tape appears to be kinesiotape but is an inelastic tape.~The day of the intervention will proceed as follows:~* Warm-up: The total warm-up time will be 5 minutes. After warm-up, a 1 minute rest will be carried out.~* Skin cleansing with 96% alcohol.~* Sham tape: exactly the same procedure is followed as experimental arm, but an adhesive inelastic tape is used. Material: Omnifix elastic (Laboratorios Hartmann S.A .; Spain)."
62844898|NCT04310371|NO_INTERVENTION|Control group|to be normal-weighted (no obesity if overweight, \<85th percentile of national curves).
62844899|NCT03783715||Ketoprofen|Participants will take ketoprofen for six months. They will have evaluations at baseline and month 6.
62262636|NCT02679898|NO_INTERVENTION|Lean Control|This arm involves not making any changes to the subject's lifestyle at the moment of the start of the intervention and for 6 weeks.
62262637|NCT02679898|NO_INTERVENTION|Overweight/Obese Control|This arm involves not making any changes to the subject's lifestyle at the moment of the start of the intervention and for 6 weeks.
62262638|NCT02679898|EXPERIMENTAL|Unloaded-Whole Body Vibration (WBVT)|Lower-body exercise training on a vibration platform
62262639|NCT02679898|EXPERIMENTAL|Loaded-Whole Body Vibration (WBVT)|Externally loaded lower-body exercise training on a vibration platform
62619088|NCT05270278||3. Eosinophilic AB - initiated biological treatment against IgE or IL-4R, or against IL-5 or IL-5R|"* initiated biological treatment - omalizumab or dupilumab, or mepolizumab or benralizumab~* judged by the treating physician, the patient could be potentially indicated to treatment with all 4 alternatives"
62844900|NCT02472067|NO_INTERVENTION|Physical Therapy|Usual care of physical therapy and rehabilitation for a musculoskeletal injury. Patients complete self-rated standardized surveys before and following treatment.
62844901|NCT02472067|EXPERIMENTAL|Psychologically-Based Physical Therapy|Psychologically-Based Physical Therapy includes the early identification and management of psychological obstacles to recovery in order to modify maladaptive responses previously found to be associated with chronicity and disability. This is accomplished through patient education, an emphasis on functional goals and encouraging self-care techniques. Patients complete self-rated standardized surveys before and following treatment.
62262640|NCT02270619|PLACEBO_COMPARATOR|Uninterrupted sleep & placebo|Uninterrupted sleep followed by placebo
62262641|NCT02270619|EXPERIMENTAL|Uninterrupted sleep & endotoxin|Uninterrupted sleep followed by endotoxin 0.8 ng/kg of body weight IV bolus
62844902|NCT04875143|PLACEBO_COMPARATOR|PLACEBO|From a pre-established randomization, on the first day of collection, volunteers will be allocated to group I (Placebo) or group II (Citrus aurantium L.). In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention. Conversely, the volunteers allocated to group II will ingest a capsule containing 500mg of Citrus aurantium L. in the first intervention, and at the end of the experiment, another capsule containing 500mg of starch will be provided.
62262642|NCT02270619|EXPERIMENTAL|Partial sleep deprivation & placebo|Partial sleep deprivation followed by placebo
62262643|NCT02270619|EXPERIMENTAL|Partial sleep deprivation & endotoxin|Partial sleep deprivation followed by endotoxin 0.8 ng/kg of body weight IV bolus
62262644|NCT01251653||Afatinib and docetaxel|
62262645|NCT01251653||Afatinib and gemcitabine|
62058996|NCT05565807|EXPERIMENTAL|STI-6129|Nine dosing cohorts will be evaluated: 0.25 mg/kg，0.50 mg/kg，0.67 mg/kg, 0.88 mg/kg, 1.18 mg/kg, 1.56 mg/kg, 2.08 mg/kg, 2.77 mg/kg, 3.68 mg/kg where STI-6129 will be intravenously administered once as part of a 4-week treatment cycle.
62058997|NCT03115333|EXPERIMENTAL|Diagnostic (DSC-MRI)|Patients undergo DSC-MRI within 3 days before bevacizumab initiation and at day 15.
62058998|NCT04773210||Mini tube system|Mini tube system (FLOW-JAC System, Bogotá, Colombia) orthodontic treatment.
62058999|NCT04773210||Conventional ligating brackets|Conventional ligating brackets (Gemini 3M Unitek Orthodontic Products bracket, Calif, USA) with Nitinol Classic or superelastic (SE) archwires 0.014 and 0.016 orthodontic treatment.
62059000|NCT03810534|EXPERIMENTAL|Connect-Home|Connect-Home intervention at the skilled nursing facility and at the subject's home.
62059001|NCT03810534|NO_INTERVENTION|Control|Standard discharge planning at the skilled nursing facility only.
62262646|NCT04933175|EXPERIMENTAL|fluzopali combined with anlotinib|Patients 18 years of age or older, 75 years of age or younger with histologically proven small cell carcinoma of the lung were assessed by radiography as having an extensive stage (according to the American Veteran Lung Cancer Association). Patients received first-line two-drug chemotherapy with standard cisplatin, carboplatin, or lobaplatin, combined with or without immunotherapy, and developed radiologically evaluated disease progression during treatment or within 6 months of completion of treatment.
62262647|NCT05349929|EXPERIMENTAL|Ibuprofen|Ibuprofen(Gelofen) 400mg capsules, Dana pharma company, every 6hours
62844903|NCT04875143|EXPERIMENTAL|Citrus aurantium L.|From a pre-established randomization, on the first day of collection, volunteers will be allocated to group I (Placebo) or group II (Citrus aurantium L.). In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention. Conversely, the volunteers allocated to group II will ingest a capsule containing 500mg of Citrus aurantium L. in the first intervention, and at the end of the experiment, another capsule containing 500mg of starch will be provided.
62844904|NCT02334540|OTHER|purses or a calorie/protein matched smoothie|
62844905|NCT03458195|EXPERIMENTAL|Crohn's disease patients|Patients aged 18 or more, for whom Crohn's disease diagnosis is confirmed and ileum or ileocecal Crohn's disease require surgical resection. in addition to usual practice, a bio-banking (blood samples, biopsies and surgical specimens) is collected.
62844906|NCT01464060|ACTIVE_COMPARATOR|"Hybrid therapy"|Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
62059002|NCT04794426|ACTIVE_COMPARATOR|control group|The group that have caries in primary molars and treat them with Hall Technique
62059003|NCT04794426|EXPERIMENTAL|experimental group|The group that have caries in primary molars and treat them with Silver diamine fluoride (SDF) solution would exert a preventive result in managing early childhood caries ECC.
62059004|NCT06426017|EXPERIMENTAL|High Protein Low Calorie Diet|3 meals/day consumed by the participants with daily caloric intake of 800 kcal. 40-60% of the total calories added from both animal and plant proteins. 30% of the total calories added from fats. 20% of the total calories added from carbohydrates.
62059005|NCT02790008||Aortic valve disease|Patients with aortic stenosis referred to surgery. Exclusion criteria are concomitant heart valve disease, congenital heart disease, hemodynamic instability, previous cardiac surgery, history of myocardial infarction and coronary artery disease.
62059006|NCT03052114||Stroke|Electrical Impedance Tomography with scalp electrodes
62059007|NCT03052114||Head Injury|Electrical Impedance Tomography with scalp electrodes
62059008|NCT02622204||Corrective osteotomy|patients with knee osteoarthritis undergoing corrective osteotomy
62059009|NCT03873818|EXPERIMENTAL|Treatment (ipilimumab, pembrolizumab)|Patients receive ipilimumab IV over 90 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 4 cycles for ipilimumab and up to 35 cycles for pembrolizumab in the absence of disease progression or unacceptable toxicity.
62059010|NCT06194409||IE in IV drug abusers|Infective endocarditis in intravenous drug abusers
62262648|NCT05349929|EXPERIMENTAL|Anahil|Bromelain(Anahil) 200 mg capsules, Permon Amin Health Company,every 6hours
62262649|NCT01324258|EXPERIMENTAL|GSK1120212|Part 1-Dose escalation will be conducted to assess PK after single dosing and safety, tolerability, PK and efficacy of GSK1120212 in Japanese subjects with solid tumors using a continuous daily dosing schedule.
62059011|NCT06194409||IE in non- IV drug abusers|Infective endocarditis in non - intravenous drug abusers
62059012|NCT01460082||Exacerbation|The study sample will consist of patients admitted to the hospital because of an acute exacerbation of COPD
62059013|NCT01529008|EXPERIMENTAL|Core decompression/PREOB® implantation|
62262650|NCT01324258|EXPERIMENTAL|GSK1120212+Gemcitabine|Part 2-Further evaluate the safety, tolerability, PK, and efficacy of GSK1120212 in combination with gemcitabine in subjects with non-small cell lung cancer, pancreatic cancer, biliary cancer, urothelial cancer or other tumor types for which 4-week schedule of gemcitabine has been approved using the recommended dose from Part 1 (single agent).
62844907|NCT01464060|EXPERIMENTAL|"Concomitant therapy"|Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
62844908|NCT04484220|EXPERIMENTAL|Ellipsys Vascular Access System|The Ellipsys System is indicated for the creation of a proximal radial artery to perforating vein anastomosis via a retrograde venous access approach in patients who have chronic kidney disease requiring dialysis.
62059014|NCT01529008|PLACEBO_COMPARATOR|Core decompression/placebo implantation|
62059015|NCT04271943|ACTIVE_COMPARATOR|COMPUTER BASED EXERCISES|
62059016|NCT04271943|ACTIVE_COMPARATOR|AEROBIC EXERCISES|
62059017|NCT05742425|EXPERIMENTAL|One-arm research group|
62059018|NCT01769170|PLACEBO_COMPARATOR|Placebo|Matching placebo administered orally twice weekly
62059019|NCT01769170|ACTIVE_COMPARATOR|Brincidofovir|100 mg brincidofovir administered orally twice weekly
62844909|NCT02063191||Atrial Fibrillation|Patients with atrial fibrillation during the EP study
62844910|NCT02063191||Bundle Branch Block|Patient with bundle branch block during the course of the EP study
62844911|NCT05214261|EXPERIMENTAL|TAP block group|Patiens undergo laparoscopic-guided TAP block installation for laparoscopic clolorectal surgery
62844912|NCT05214261|ACTIVE_COMPARATOR|Epidural analgesia group|Patients undergo epidural catheters placement for laparoscopic colorectal surgery
62844913|NCT02291458|EXPERIMENTAL|L-arginine|Subjects will receive 9 gram of L-arginine per day in three gifts (3dd 3 gram) during 6 weeks.
62844914|NCT02291458|PLACEBO_COMPARATOR|Placebo|Subjects will receive 9 gram of placebo per day in three gifts (3 dd 3 gram) during 6 weeks.
62844915|NCT02802267|EXPERIMENTAL|inecalcitol|Two tablets of Inecalcitol 2mg each (total 4mg) taken orally every other day.
62844916|NCT02802267|PLACEBO_COMPARATOR|placebo|Two tablets of placebo 2mg each (total 4mg) taken orally every other day
62059020|NCT06342986|EXPERIMENTAL|Dose Cohort -1: IP FT536 monotherapy 3 x 10^6 cells/dose|FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master human induced pluripotent stem cell (iPSC) line with the following engineered elements: a) deletion of the gene encoding CD38 (i.e., CD38 knockout) and expression of the MICA and MICB (MICA/B) chimeric antigen receptor (CAR); b) high-affinity, non-cleavable CD16 receptor; and c) interleukin (IL)-15/IL-15 receptor alpha fusion protein. Participants will receive doses on Day 1, Day 4 and day 8.
62059021|NCT06342986|EXPERIMENTAL|Dose Cohort 1: IP FT536 monotherapy 1 x 10^8 cells/dose|FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master human induced pluripotent stem cell (iPSC) line with the following engineered elements: a) deletion of the gene encoding CD38 (i.e., CD38 knockout) and expression of the MICA and MICB (MICA/B) chimeric antigen receptor (CAR); b) high-affinity, non-cleavable CD16 receptor; and c) interleukin (IL)-15/IL-15 receptor alpha fusion protein. Participants will receive doses on Day 1, Day 4 and day 8.
62059022|NCT06342986|EXPERIMENTAL|Dose Cohort 2: IP FT536 monotherapy 3 x 10^8 cells/dose|FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master human induced pluripotent stem cell (iPSC) line with the following engineered elements: a) deletion of the gene encoding CD38 (i.e., CD38 knockout) and expression of the MICA and MICB (MICA/B) chimeric antigen receptor (CAR); b) high-affinity, non-cleavable CD16 receptor; and c) interleukin (IL)-15/IL-15 receptor alpha fusion protein. Participants will receive doses on Day 1, Day 4 and day 8.
62059023|NCT06342986|EXPERIMENTAL|Dose Cohort 3: IP FT536 monotherapy 1 x 10^9 cells/dose|FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master human induced pluripotent stem cell (iPSC) line with the following engineered elements: a) deletion of the gene encoding CD38 (i.e., CD38 knockout) and expression of the MICA and MICB (MICA/B) chimeric antigen receptor (CAR); b) high-affinity, non-cleavable CD16 receptor; and c) interleukin (IL)-15/IL-15 receptor alpha fusion protein. Participants will receive doses on Day 1, Day 4 and day 8.
62262651|NCT04233697|EXPERIMENTAL|Copanlisib and Romidepsin|"Copanlisib and romidepsin will be both administered via IV (through a vein in arm) on days 1, 8, and 15 every 28 days, also called a cycle."
62619089|NCT05270278||4. Non-eosinophilic AB - without indication for biological treatment|"* no biological treatment initiated~* judged by the treating physician, the patient cannot be indicated to biological treatment"
62844917|NCT05857488|EXPERIMENTAL|Trans Nasal Endomicroscopy Imaging|The subject will have the transnasal introduction tube inserted, and OCT images will be acquired using the OCT compact imaging system. The subject may also undergo a microbiome brushing and/or intestinal potential difference measurement procedure during the study visit.
62844918|NCT00857688|EXPERIMENTAL|1 - Test|Patients will recieve the association.
62844919|NCT00857688|PLACEBO_COMPARATOR|2|Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
62844920|NCT02306902|EXPERIMENTAL|Test|Fenofibrate Capsules, USP 130 mg
62844921|NCT02306902|ACTIVE_COMPARATOR|Reference|ANTARA® (fenofibrate) Capsules 130 mg
62844922|NCT04941287|EXPERIMENTAL|Arm A (cobimetinib, atezolizumab, varlilumab)|Patients receive cobimetinib PO QD on days 1-21 of each cycle, atezolizumab IV over 30-60 minutes on days 1 and 15 of each cycle, and varlilumab IV over 90 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI at baseline, every 8 weeks while on treatment, and at end of treatment or progression. Patients also undergo a tumor biopsy at baseline and on day 21 of cycle 1. Patients also undergo blood sample collection on study.
62844923|NCT04941287|EXPERIMENTAL|Arm B (atezolizumab, varlilumab)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15 of each cycle and varlilumab IV over 90 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI at baseline, every 8 weeks while on treatment, and at end of treatment or progression. Patients also undergo a tumor biopsy at baseline and on day 21 of cycle 1. Patients also undergo blood sample collection on study.
62844924|NCT03482596|EXPERIMENTAL|Intervention|All participants will follow the personalised multifaceted intervention to reducing/breaking prolonged sitting.
62844925|NCT00287378|EXPERIMENTAL|1|
62844926|NCT05239780|EXPERIMENTAL|Participants with depression|Participants with depression to undergo brain stimulation
62844927|NCT06095713||Standard of Care|Patient treated with Pegunigalsidase-alfa according to standard of care
62844928|NCT06522542||Test group|Gastirc cancer with bleeding at first diagnosis
62844929|NCT06522542||Control group|Gastirc cancer without bleeding at first diagnosis
62844930|NCT05867498|EXPERIMENTAL|Concurrent exercise|"Strength component (circuit-based exercise) 7 exercises:~* General (2 sets of 15-18 Rep, OMNI-Resistance Exercise Scale 4-5, x 10 s) 180 s~* Block (3 sets of 12-15 Rep, OMNI-Resistance Exercise Scale 5-6, x 10 s) 70 s~* Concentrated (3 sets of 10-12 Rep, OMNI-Resistance Exercise Scale 7-8, x 15 s) 110 s~Aerobic component~* Low-to-moderate-intensity continuous training: 16 min to 18 min (\< VT 1)~* Interval training: in a block (\> VT 2)~  * 5 bouts of 30 s loads. Work:rest ratio: 1:1~ * 4 bouts of 45 s loads. Work:rest ratio: 1:1~ * 5 bouts of 50 s loads. Work:rest ratio: 2:1~ * 4 bouts of 60 s loads. Work:rest ratio: 2:1~ * 3 bouts of 70 s loads. Work:rest ratio: 2:1~ * 4 bouts of 80 s loads. Work:rest ratio: 2:1"
62619090|NCT05366114||New patients at the GoodHope EDS clinic at Toronto General Hospital|All patients seen in the EDS clinic are eligible for inclusion, regardless of their presenting diagnosis or the results of their assessments.
62059024|NCT04905277|EXPERIMENTAL|Atenolol|Study subjects will take Atenolol 50 mg daily over 2 years
62059025|NCT04905277|PLACEBO_COMPARATOR|Placebo|Study subjects will take a placebo daily over 2 years
62262652|NCT03666832|EXPERIMENTAL|Arm1|TEW-7197 100mg will be administered orally once a day 5days and rest 2days. Study treatment will be continued until objective disease progression.
62619091|NCT05440721|ACTIVE_COMPARATOR|Treatment A (device Clickotine®)|User will open and use Treatment A (Clickotine® device) several times a day up to their quit date to complete a program of 21 Missions.
62844931|NCT05867498|ACTIVE_COMPARATOR|Aerobic exercise|"* Low-to-moderate-intensity continuous training: 36 min (\< VT 1)~* Interval training: in two blocks (\> VT 2) 5 bouts of 35 s loads. Work:rest ratio: 1:1 4 bouts of 45 s loads. Work:rest ratio: 1:1 4 bouts of 60 s loads. Work:rest ratio: 2:1 3 bouts of 75 s loads. Work:rest ratio: 2:1 4 bouts of 80 s loads. Work:rest ratio: 2:1"
62844932|NCT00499590|ACTIVE_COMPARATOR|A|Lucentis® (0.5mg) every 4 weeks.
62844933|NCT00499590|EXPERIMENTAL|B|Bevasiranib (2.5mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 \& 6.
62844934|NCT00499590|EXPERIMENTAL|C|Bevasiranib (2.5mg) every 12 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 \& 6.
62059026|NCT02323984||Hypoactive Delirium - Delirious|Hypoactive delirious patients presenting with lethargy and sedation and are slow to respond to questions and demonstrate little spontaneous movement. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
62059027|NCT02323984||Hyperactive Delirium - Delirious|Hyperactive delirious patients presenting with restlessness, agitation, hyper vigilance, and occaionally hallucinations. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
62059028|NCT02323984||No Delirium - Nondelirious|Patients not presenting any symptoms of hypoactive or hyperactive postoperative delirium. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
62059029|NCT02628392|EXPERIMENTAL|DS-8500a 25 mg QD|DS-8500a 25 mg tablet once daily (QD), orally, for up to 12 weeks, and matching sitagliptin placebo capsule
62059030|NCT02628392|EXPERIMENTAL|DS-8500a 50 mg QD|DS-8500a 50 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule
62059031|NCT02628392|EXPERIMENTAL|DS-8500a 75 mg QD|DS-8500a 75 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule
62059032|NCT02628392|PLACEBO_COMPARATOR|placebo|placebo tablet and placebo capsule, orally, once daily for up to 12 weeks to match DS-8500a and sitagliptin, respectively.
62059033|NCT02628392|ACTIVE_COMPARATOR|Sitagliptin|capsule, orally, once daily for up to 12 weeks and matching DS-8500 placebo tablet
62059034|NCT03263832||Exposed|"Patients with a monomicrobial S. aureus orhtopaedic device-related infection who have received antibiotherapy able to prevent biofilm formation following surgical intervention (from day 0 to day 7).~Upon inclusion, antibiograms were performed on the S. aureus isolated as part of routine procedure. S. aureus isolates was further analysed via an Antibiofilmogramme, which is an experimental element added by this research."
62844935|NCT02656693|EXPERIMENTAL|Online Program Only|Patients will use an online weight management program called BMIQ, with minimal additional support.
62844936|NCT02656693|EXPERIMENTAL|Combined Intervention|Patients will use an online weight management program called BMIQ, but will also receive additional monitoring and support from a population health manager who works with their primary care practices.
62844937|NCT02656693|NO_INTERVENTION|Usual Care|Patients will continue receiving usual care but will also be mailed some general written information about weight management (very minimal intervention.)
62059035|NCT03263832||Not Exposed|"Patients with a monomicrobial S. aureus orhtopaedic device-related infection who not have received antibiotherapy able to prevent biofilm formation following surgical intervention (from day 0 to day 7).~Upon inclusion, antibiograms were performed on the S. aureus isolated as part of routine procedure. S. aureus isolates was further analysed via an Antibiofilmogramme, which is an experimental element added by this research."
62059036|NCT06624891|EXPERIMENTAL|pleth variability index (PVI)|Participants will be monitored during the intervention using a Radical-7 Pulse CO-Oximeter to instantly determine the pleth variability index (PVI). If the PVI is more than 14% for at least 5 minutes, 250 ml of gelofusine solution will be given over 10 minutes.
62059037|NCT06624891|ACTIVE_COMPARATOR|delta PP|Participants will be monitored during the intervention using arterial catheter to instantly determine delta PP. If Delta PP is more than 13% for at least 5 minutes, 250 ml of gelofusine solution will be given over 10 minutes.
62262653|NCT06281860|EXPERIMENTAL|Cohorte 1 _ 7.5 mg/m2|cohorte 1: 7.5 mg/m2 of cisplatin (once)
62619092|NCT05440721|SHAM_COMPARATOR|Treatment B (smoking education)|Treatment B app provides education and support to smokers seeking to quit. When a user has a craving or wants support or education, they can log into the app.
62619093|NCT06435078|EXPERIMENTAL|AR-mPETS|subjects will be instructed to execute simulated piano playing tasks with Augmented Reality.
62844938|NCT04129281|OTHER|Surgery|Surgery
62844939|NCT04129281|NO_INTERVENTION|Active surveillance|Follow up
62844940|NCT03196362|ACTIVE_COMPARATOR|PIO/MET|one fixed dose pioglitazone/metformin (15mg/500mg) tablet will be orally administrated twice daily
62844941|NCT03196362|PLACEBO_COMPARATOR|placebo|one tablet of placebo will be given twice daily
62059038|NCT02512679|OTHER|Cyclophosphamide Dose Level 1|"Cyclophosphamide given by Intravenous (IV) at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level.~Drug to be given in combination of Busulfan, Campath and Fludarabine"
62059039|NCT02512679|OTHER|Cyclophosphamide Dose Level 2|Cyclophosphamide given by intravenous (IV) at a total dose of 70 mg/kg (divided in two doses) given once a day for two days in combination with Busulfan, Campath and Fludarabine.
62262654|NCT06281860|EXPERIMENTAL|Cohorte 2 _ 12.5 mg/m2|cohorte 2: 12.5 mg/m2 of cisplatin (once)
62262655|NCT06281860|EXPERIMENTAL|cohorte 3: 35 mg/m2 of cisplatin|cohorte 3: 35 mg/m2 of cisplatin (once)
62262656|NCT06281860|EXPERIMENTAL|cohorte 4: 70 mg/m2 of cisplatin|cohorte 4: 70 mg/m2 of cisplatin (once)
62844942|NCT02353845||aMCI|aMCI means a group of patients who do not qualify for a diagnosis of dementia but do display memory impairment beyond what is expected for their age and with regards to the educational history and with positive β-amyloid PET
62059040|NCT02512679|OTHER|Cyclophosphamide Dose Level 3|Cyclophosphamide given by intravenous (IV) at total does of 35 mg/kg as a one time dose in combination with Busulfan, Fludarabine and Campath
62844943|NCT02353845||normal control|
62844944|NCT02353845||aMCIp|progressive aMCI：aMCI subjects who will convert to AD during the follow-up period
62844945|NCT02353845||aMCIs|stable aMCI：aMCI subjects who will not convert to AD during the follow-up period
62844946|NCT01849731|EXPERIMENTAL|Intervention A|Face-to face intervention
62844947|NCT01849731|EXPERIMENTAL|Intervention B|Face-to-face intervention plus telephone reinforcement
62844948|NCT01849731|NO_INTERVENTION|Control Group|
62262657|NCT01500278|ACTIVE_COMPARATOR|Certolizumab Pegol + Methotrexate (CZP + MTX)|
62844949|NCT04024813|PLACEBO_COMPARATOR|Placebo (N=25)|Placebo for the remainder of the study
62844950|NCT04024813|EXPERIMENTAL|Seladelpar 5 mg (N=25)|5 mg seladelpar daily for the remainder of the study
62844951|NCT04024813|EXPERIMENTAL|Seladelpar 10 mg (N=25)|10 mg seladelpar for the remainder of the study
62059041|NCT02512679|OTHER|Cyclophosphamide Dose Level 4|No cyclophosphamide given with Busulfan, Fludarabine and Campath
62059042|NCT01163643|EXPERIMENTAL|0.3% BOL-303242-X ophthalmic suspension|0.3% BOL-303242-X ophthalmic suspension
62059043|NCT01163643|EXPERIMENTAL|2% BOL-303242-X ophthalmic suspension|2% BOL-303242-X ophthalmic suspension
62619094|NCT06435078|ACTIVE_COMPARATOR|VR-mPETS|subjects will be instructed to execute simulated piano playing tasks with Virtual Reality.
62844952|NCT04024813|EXPERIMENTAL|Seladepar 25 mg (N=25)|25 mg seladelpar for the remainder of the study
62844953|NCT06120790||Patients with Tracheostomies|Patients with openings in their airways (i.e. tracheostomies)
62844954|NCT04735484||Case|Participants will attend one data collection appointment wearing form-fitting sports clothing and trainers. Participants will wear infrared markers and wearable devices whilst walking over level ground and on a treadmill. Data will be collected using a motion capture system and the wearable devices themselves. Data collection will take approximately 90 minutes
62059044|NCT01163643|PLACEBO_COMPARATOR|Vehicle|Vehicle twice daily (BID)
62059045|NCT01163643|EXPERIMENTAL|1% BOL-303242-X ophthalmic suspension|1% BOL-303242-X ophthalmic suspension
62059046|NCT01163643|EXPERIMENTAL|2% BOL-303242-X ophthalmic suspension in the morning|2% BOL-303242-X ophthalmic suspension in the morning (AM) and vehicle in the afternoon (PM)
62059047|NCT01163643|EXPERIMENTAL|2% BOL-303242-X ophthalmic suspension PM|Vehicle in the AM and 2% BOL-303242-X ophthalmic suspension in the PM.
62059048|NCT02309112|EXPERIMENTAL|Yoga Group A: Minimum Exposure|The minimum-exposure yoga package, this intervention included 45-minutes of contact time with a trained yoga professional. In Week 1, this session included a 30-minute introductory session focussing on pranayama (breathing techniques), as well as a brief introduction to available community-based and online yoga to encourage a safe home-based practice (15-minutes). Financial subsidy, compensation or special promotion of any particular yoga was not provided. Participants were invited to stay for a social discussion following the yoga class.
62619095|NCT03173495|EXPERIMENTAL|FRUCTOSE|Day 0, 45 min in rest position. Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a fructose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
62619096|NCT03173495|PLACEBO_COMPARATOR|DEXTROSE|Day 0, 45 min in rest position. Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
62844955|NCT04735484||Control|Participants will attend one data collection appointment wearing form-fitting sports clothing and trainers. Participants will wear infrared markers and wearable devices whilst walking over level ground and on a treadmill. Data will be collected using a motion capture system and the wearable devices themselves. Data collection will take approximately 90 minutes
62059049|NCT02309112|EXPERIMENTAL|Yoga Group B: Medium Exposure|The medium-exposure yoga package, this intervention included the components of Group A, with an additional 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were then invited to stay and ask questions following the yoga class. A pre-paid online yoga membership to http://www.myyogaonline.com was offered for the duration of the study (Weeks 1 to 4). In addition to this, one 120-minute workshop to further develop yoga pranayama, dhyana and asana training was administered by an expert instructor during Week 2 or 3.
62059050|NCT02309112|EXPERIMENTAL|Yoga Group C: Maximum Exposure|The maximum-dose yoga package, this intervention includes the components of Group A, with the same 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were invited to stay and ask questions following the yoga class. As in Group B, a pre-paid online yoga membership to http://www.myyogaonline.com was also provided for the duration of the study (Weeks 1 to 4). Participants were then invited to attend three 60-minute yoga group classes led by an expert yoga instructor per week (Weeks 1 to 4). These yoga sessions were held in a clinical setting in proximity to their treatment location and delivered at no cost to the patient.
62262658|NCT01500278|ACTIVE_COMPARATOR|Adalimumab + Methotrexate (ADA + MTX)|
62262659|NCT01500278|ACTIVE_COMPARATOR|CZP + MTX followed by ADA + MTX|Those subjects who received Certolizumab Pegol (400 mg at Weeks 0, 2, 4 followed by 200 mg every two weeks) + Methotrexate (CZP+ MTX) at Baseline and are Non-Responders at Week 12, switch to Adalimumab (40 mg) + Methotrexate (ADA + MTX) after Week 12.
62844956|NCT02439502|EXPERIMENTAL|open label|Upper and Lower digestive tract diagnostic. The Fuse® system is intended for diagnostic visualization of the digestive tract. The system also provides access for therapeutic interventions using standard endoscopy tools. Fuse Colonoscopies are indicated for use within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) for adult subjects and for the upper digestive tract (including the esophagus, stomach, and duodenum).
62844957|NCT04241055|ACTIVE_COMPARATOR|Control|"The control condition of a standard values affirmation intervention"
62262660|NCT01500278|ACTIVE_COMPARATOR|ADA + MTX followed by CZP + MTX|Those subjects who received Adalimumab (40 mg + Placebo at Weeks 0, 2, 4 followed by 40 mg ADA every two weeks) + Methotrexate (ADA+ MTX) at Baseline and are Non-Responders at Week 12, switch to Certolizumab Pegol (400 mg at Weeks 12, 14, 16 followed by 200 mg every two weeks) + Methotrexate (CZP+ MTX) after Week 12.
62262661|NCT05818592|EXPERIMENTAL|Self-Pulse Monitoring Intervention Group|Participants view an educational video instructing them on how to manually check their pulse for irregularities. Participants will be instructed to check their pulse for 30 seconds twice daily for 2 weeks.
62262662|NCT05818592|NO_INTERVENTION|Control Group Standard of Care|The control group will continue with usual care.
62844958|NCT04241055|EXPERIMENTAL|Values affirmation|"The treatment condition of a standard values affirmation intervention"
62844959|NCT04392180||Caregivers|"Caregivers who care for a child that is both under 3 years of age and has experienced acute pain.~This cohort will participate in a qualitative interview about pain assessment, treatment, and response to treatment in their child."
62844960|NCT05812560|EXPERIMENTAL|Intervetion|The intervention of the experimental group: application of a protocol of postural changes every 30-60 min or at least two postural changes in one hour during labor.
62844961|NCT05812560|NO_INTERVENTION|Control|In the control group, each midwife will apply postural changes according to their usual practice. Differences with the experimental group: the choice of postural changes according to the stage of labor, its cadence and posture during the expulsive.
62844962|NCT02121119|ACTIVE_COMPARATOR|Lidocaine|0.5% lidocaine infusion hour to 5 ml Baxter Infusor elastomeric pump 5 ml / hr.
62844963|NCT02121119|PLACEBO_COMPARATOR|Bupivacaine|Infusion of 0.1% bupivacaine hour to 5 ml Baxter Infusor elastomeric pump 5 ml / hr.
62844964|NCT03993652|EXPERIMENTAL|Screen-time and Snacking|Aim: to reduce both screen-time and unhealthy snacking
62844965|NCT03993652|EXPERIMENTAL|Screen-time only|Aim: to reduce screen-time only
62844966|NCT03993652|EXPERIMENTAL|Snacking only|Aim: to reduce unhealthy snacking only
62844967|NCT03993652|NO_INTERVENTION|Control|Control
62844968|NCT00452361|EXPERIMENTAL|1|Sirolimus therapy
62844969|NCT00452361|ACTIVE_COMPARATOR|2|Calcineurin Inhibitor therapy (either cyclosporine or tacrolimus)
62844970|NCT04528966|EXPERIMENTAL|Treatment Group|Group that have received whole-body vibration treatment in addition to conventional physiotherapy
62844971|NCT04528966|ACTIVE_COMPARATOR|Control group|Group that have received conventional physiotherapy only
62059051|NCT01190046|OTHER|Resistance exercise training|Exercise is being used as an experimental tool to determine if remediation of muscle disuse counteracts cellular/molecular defects in muscle structure/function.
62262663|NCT06152445|PLACEBO_COMPARATOR|Gluten free bread|Bread will be eaten by the participants for 7 consecutive days
62844972|NCT01798849|EXPERIMENTAL|Panel A-Healthy|Within each of the 5 rising dose treatment periods, 6 participants received a single dose of MK-8892 0.5 mg, 2.0 mg, 6.0 mg, 14 mg or 2.0 mg fed, and 2 participants received placebo. Dosing periods will alternate with Panel B.
62844973|NCT01798849|EXPERIMENTAL|Panel B-Healthy|Within each of the 4 rising dose treatment periods, 6 participants received a single dose of MK-8892 1.0 mg, 4.0 mg, 9.0 mg or 12 mg, and 2 participants received placebo. Dosing periods will alternate with Panel A.
62844974|NCT01798849|EXPERIMENTAL|Panel C-Mild/Moderate Hypertension|Within each of the 5 single dose treatment periods, 6 participants with mild to moderate hypertension received a single dose of MK-8892 0.5 mg, 1.0 mg, 2.0 mg or 6.0 mg, and 2 participants received placebo. Dosages will be determined by the results of Panels A and B.
62844975|NCT06081933|EXPERIMENTAL|intranasal dexmedetomidine|Patients will receive 1.5 micro g/kg intranasal dexmedetomidine diluted with saline + infusion saline
62059052|NCT00954954|ACTIVE_COMPARATOR|Standard|Knees that will be implanted with standard posterior stabilized RP-MB knee prostheses
62262664|NCT06152445|ACTIVE_COMPARATOR|Gluten free bread with added wheat flour|Bread will be eaten by the participants for 7 consecutive days
62262665|NCT06152445|EXPERIMENTAL|Wheat bread with Yeast, short fermentation + bread improver|Bread will be eaten by the participants for 7 consecutive days
62262666|NCT06152445|EXPERIMENTAL|Wheat bread with Yeast, long fermentation|Bread will be eaten by the participants for 7 consecutive days
62844976|NCT06081933|EXPERIMENTAL|intravenous dexmedetomidine|patients will receive 0.1- 0.4 micro g/kg intravenous infusion dexmedetomidine + intranasal saline.
62844977|NCT02657408|EXPERIMENTAL|BI 1026706|
62844978|NCT02657408|EXPERIMENTAL|Placebo|
62844979|NCT01839669|ACTIVE_COMPARATOR|Foot Orthoses Only|including Patient Education; Abbreviation: FOO
62844980|NCT01839669|EXPERIMENTAL|Foot Orthoses and Eccentric Exercise|including Patient Education; Abbreviation: FOE
62844981|NCT01839669|SHAM_COMPARATOR|Sham Foot Orthoses|including Patient Education; Abbreviation: FOS
62844982|NCT03444636|EXPERIMENTAL|Ropivacaine/Fentanyl|
62844983|NCT03444636|ACTIVE_COMPARATOR|Bupivacaine/Fentanyl|
62844984|NCT04162691||Malignant thymoma|
62844985|NCT04162691||Benign thymoma|
62844986|NCT04856813|EXPERIMENTAL|active|this is the group that does a treatment with active movement, a program of pain education and a program of home exercise.
62844987|NCT04856813|ACTIVE_COMPARATOR|non active|this is the group that does a treatment without active movement, a program of pain education and a program of home exercise.
62844988|NCT06178601|EXPERIMENTAL|RC48-ADC plus cadonilimab（AK104）|RC48-ADC plus cadonilimab（AK104）
62844989|NCT02152956|EXPERIMENTAL|Cohort 0-a|
62844990|NCT02152956|EXPERIMENTAL|Cohort 0-b|
62844991|NCT02152956|EXPERIMENTAL|Cohort 0-c|
62844992|NCT02152956|EXPERIMENTAL|Cohort 0-d|
62844993|NCT02152956|EXPERIMENTAL|Cohort 1|
62059053|NCT00954954|ACTIVE_COMPARATOR|High-flexion|Knees that will be implanted with high-flexion posterior stabilized RP-MB knee prostheses
62059054|NCT03809364|EXPERIMENTAL|START Together|Couples randomized to START Together will receive the manualized treatment to enhance women's medication adherence. The treatment is 5 sessions in length and conducted weekly. Sessions are 60 - 75 minutes. Couples have the option of completing up to 3 additional booster sessions. Total treatment therefore ranges between 5 to 8 sessions.
62262667|NCT06152445|EXPERIMENTAL|Wheat bread with Sourdough, long fermentation|Bread will be eaten by the participants for 7 consecutive days
62262668|NCT05791500|EXPERIMENTAL|lifestyle intervention group|People in intervention group are required to have a daily work and rest time of 7-8 hours, adjusted according to their original work and rest, but no later than 9:00 to get up and 23:00 to fall asleep; change their intimate clothes every day and clean themselves at least twice a day（mainly including brushing their teeth and washing their faces at least twice in the morning and evening, and showering once）The bed is guaranteed to sun/wash the quilt once a month, the sheets are changed twice a week in spring and autumn, and once a month in winter. The desk in the dorm is arranged neatly and orderly, the study and daily necessities are sorted and placed, at least there is place for office and study, the bed is clean and tidy, no garbage, no dirt. It is required to upload the hygiene situation of the bedroom (including the desk and the bed) once a week, and take a photo every time the bedding is changed.
62262669|NCT05791500|NO_INTERVENTION|lifestyle control group|This group doesn't conclude any intervention measures.But the data of participants is obtained at the same time as the intervention group.
62262670|NCT05791500|EXPERIMENTAL|dietary habits intervention group|Before the interventions,data such as dietary health scores which includes Dietary Quality Index(DQI) ,score based on dietary health questionaire and so on are collected.Then people in the intervention group are gathered to participate in dietary health education lectures,after which the data such as DQI will be obtained again.
62262671|NCT05791500|NO_INTERVENTION|dietary habits control group|This group doesn't conclude any intervention measures.But the data of participants is obtained at the same time as the intervention group.
62447131|NCT01485913|NO_INTERVENTION|No Lifestyle counseling|"The group subjected to educations will follow the whole process of peer education described in Part 1 of this Protocol.~The control group will perform these classic individual consultations but will not follow the whole process of peer education.~The classical management in diabetes consultations consists of:~* A counselling session~* A measure of blood glucose~* A measurement of blood pressure~* A measure of weight and size~* A complete clinical examination~* A prescription or a renewal of treatment (diabetes pills, insulin, IEC, statins etc ...)"
62844994|NCT02152956|EXPERIMENTAL|Cohort 2|
62844995|NCT02152956|EXPERIMENTAL|Cohort 2a|
62844996|NCT02152956|EXPERIMENTAL|Cohort 3|
62844997|NCT02152956|EXPERIMENTAL|Cohort 6|
62844998|NCT02152956|EXPERIMENTAL|Cohort 7|
62844999|NCT02152956|EXPERIMENTAL|Cohort 8|
62845000|NCT02152956|EXPERIMENTAL|MTD Expansion|
62845001|NCT02152956|EXPERIMENTAL|MTD expansion with Ruxolitinib|
62845002|NCT05161013|EXPERIMENTAL|The LINFU™ test|LINFU™ to increase sensitivity of pancreatic juice cytology LINFU™ consists of analysis of pancreatic fluid collected with the help of low intensity non-focused ultrasound excitation of the pancreas. Lumason, will be used to create bubbles and possibly increase the number of pancreatic cell we collect for the study. Secretin is also used to increase the number of pancreatic cell excretion to maximize the number of cells collected.
62845003|NCT03512938|ACTIVE_COMPARATOR|Non-smoker Group|This group included non-smoker generalized aggressive periodontitis patients.
62059055|NCT03809364|NO_INTERVENTION|Standard of Care (SOC)|Couples randomized to SOC will receive referrals to local HIV clinics to support medication adherence (for women) or other HIV-related issues (for men).
62059056|NCT05964855|EXPERIMENTAL|Unilateral Subject Group|Foot-ankle devices will be given to this group to evaluate and compare the devices.
62447132|NCT02848430|EXPERIMENTAL|Humulus lupulus|Spent hop extract; 2 gelatin capsules (59.5 mg extract) per day for 14 days
62447133|NCT03149588|EXPERIMENTAL|propofol|
62447134|NCT03149588|EXPERIMENTAL|sevoflurane|
62447135|NCT03176225|EXPERIMENTAL|Test Arm|In Test Arm, the subjects will be implanted with test article - XenoSure patch. The interventions include: Open heart surgery to address the heart disease; Close the defects with XenoSure Patch
62845004|NCT03512938|EXPERIMENTAL|Smoker Group|This group included smoker generalized aggressive periodontitis patients.
62845005|NCT00862082|EXPERIMENTAL|PR104 + Sorafenib|PR104 will be administered IV once every four weeks, in addition to 400mg sorafenib PO twice daily
62845006|NCT03202615|EXPERIMENTAL|L (lactoferrin in IDA with pregnancy)|Pregnant women with IDA, in the 2nd trimester are enrolled and treated for 2 months regularly with oral administration of 100 mg bLf granules (Pravotin sachets , Hygint, Egypt) in 1/4 glass of water twice a day before meals in addition to placebo tablets three time per day on an empty stomach.
62845007|NCT03202615|ACTIVE_COMPARATOR|F (ferrous sulphate with pregnancy)|Pregnant women with IDA, in the 2nd trimester are enrolled and treated for 2 months regularly with oral administration of 150 mg of dried ferrous sulphate capsules (Ferrofol capsules, Eipico, Egypt), one capsule three times daily on an empty stomach, at least 1 hour before or 2 hours after meals, in addition to placebo sachets (starch) twice a day.
62845008|NCT02180776|ACTIVE_COMPARATOR|Group A|Patients assigned to group A wore the Summit 456 TLSO (intervention) for four weeks in phase 1 of the study, followed by four weeks of observation (control) in phase 2.
62845009|NCT02180776|PLACEBO_COMPARATOR|Group B|Patients assigned to group B started four weeks of observation (control) in phase 1, followed by four weeks of summit 456 TLSO (intervention) in phase 2 of the study.
62845010|NCT04570319|EXPERIMENTAL|Probiotic Bths-08|a capsule containing the probiotic blend (nutritional complement)
62845011|NCT04570319|PLACEBO_COMPARATOR|Placebo|a capsule containing placebo comparator
62845012|NCT05768607|OTHER|Patients undergone Laparoscopic Extraperitoneal Burch Colposuspension|
62845013|NCT05125588|EXPERIMENTAL|Treatment A|"Reumoxicam® 15 mg tablets (PJSC Farmak, Ukraine)"
62845014|NCT05125588|ACTIVE_COMPARATOR|Treatment B|"Movalis 15 mg tablets (Boehringer Ingelheim Ellas A.E., Greece)"
62262672|NCT05791500|EXPERIMENTAL|physical activity intervention Group A-jogging|People in the Group A-jogging need to training at least 4 times a week, each time at least 50 minutes for boys and at least 40 minutes for girls, for 4 months. Before the experiment, students in the Group A-jogging learned the basic movements and complete sets of movements of this exercise prescriptions.
62262673|NCT05791500|EXPERIMENTAL|physical activity intervention Group B-rope skipping|People in the Group B-rope skipping need to training at least 4 times a week, each time at least 50 minutes for boys and at least 40 minutes for girls, for 4 months. Before the experiment, people in the Group B-rope skipping learned the basic movements and complete sets of movements of this exercise prescriptions.
62262674|NCT05791500|NO_INTERVENTION|physical activity Control Group|This group doesn't conclude any intervention measures.But the data of participants is obtained at the same time as the intervention group.
62619097|NCT03173495|ACTIVE_COMPARATOR|FRUCTEX|Day 0, 45 min of 60%VO2peak aerobic exercise . Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a fructose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
62619098|NCT02788318||diagnostic of SUDEP|patient with epilepsy in whom anamnestic and post-mortem evidence does not identify a particular cause (diagnosis of SUDEP). Brain samples and skin samples are collected.
62619099|NCT02788318||Control 1|Subjects with a known epilepsy, whose death is linked to a specific cause. Brain samples and skin samples are collected.
62619100|NCT02788318||Control 2|Subjects without known pathological history, remained victims of unexplained sudden unexpected death (SUDEP) after all investigations and for which a heart rhythm disorder is suspected in first intention. Brain samples and skin samples are collected.
62845015|NCT06435897|EXPERIMENTAL|MSC combined with 4SCAR T-cell therapy for autoimmune diseases|nfusion of 4SCAR T cells at 10\^6 cells/kg body weight and MSCs at 3x10\^6 cells via IV
62262675|NCT03173833|NO_INTERVENTION|Control group|Participants will not receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) after the first time they fill in the questionnaire. And they will be able to discuss their care needs with their health care practitioners.
62262676|NCT03173833|EXPERIMENTAL|Experimental group|"Participants will receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) every time after the first time they fill in the questionnaire.~And they will be able to discuss their care needs with their health care practitioners."
62262677|NCT03363321|EXPERIMENTAL|PF-06741086 (Cohort 1)|
62262678|NCT03363321|EXPERIMENTAL|PF-06741086 (Cohort 2)|
62262679|NCT03363321|EXPERIMENTAL|PF-06741086 (Cohort 3)|
62262680|NCT03363321|EXPERIMENTAL|PF-06741086 (Cohort 4)|
62262681|NCT03363321|EXPERIMENTAL|PF-06741086 (Cohort 5)|
62262682|NCT03363321|EXPERIMENTAL|PF-06741086 (Cohort 6)|
62262683|NCT06489444||IBS-D|
62262684|NCT06489444||IBS-C|
62262685|NCT06489444||Health control|
62262686|NCT06489444||UC(ulcerative colitis)|
62262687|NCT04940104|EXPERIMENTAL|Botox|
62262688|NCT04940104|NO_INTERVENTION|Control No Botox|
62262689|NCT02120014|EXPERIMENTAL|Heart Failure Reduced EF|"Patient prior to clinically ordered right heart catheterization identified patients will have a blood volume measurement completed in the nuclear medicine laboratory. Patients will receive an intravenous administration of low dose iodinated I-131 labeled albumin. Blood specimens (6 cc each) will be drawn at 6 minute intervals times 6. The analysis will be completed following the testing.~Venous plethysmography will be completed on eligible patients prior to the clinically indicated right heart catheterization. Calf and forearm venous compliance will be measured.~Measurements form the right heart catheterization will be recorded for analysis."
62262690|NCT02120014|EXPERIMENTAL|Heart Failure Preserved EF|"Patient prior to clinically ordered right heart catheterization identified patients will have a blood volume measurement completed in the nuclear medicine laboratory. Patients will receive an intravenous administration of low dose iodinated I-131 labeled albumin. Blood specimens (6 cc each) will be drawn at 6 minute intervals times 6. The analysis will be completed following the testing.~Venous plethysmography will be completed on eligible patients prior to the clinically indicated right heart catheterization. Calf and forearm venous compliance will be measured.~Measurements form the right heart catheterization will be recorded for analysis."
62262691|NCT05894590||Cohort 1|Participants received 2 doses of mRNA-1273 vaccine approximately 4 weeks apart.
62262692|NCT05428891|OTHER|Only pleural effusion|The patients with only pleural effusion on their CT scans.
62262693|NCT05428891|OTHER|Pleural effusion associated with pleural thickening or any other lesion like mass or nodules.|The patients with pleural effusion associated with pleural thickening or any other lesion-like mass or nodules on their CT scans.
62262694|NCT00427076|EXPERIMENTAL|A|Cotrimoxazole
62619101|NCT03165084|EXPERIMENTAL|Intervention arm|Participants in the intervention group will receive usual care, and also use a diabetesapp and a homepage and advice personally tailored according to the personal needs to provide support for them to manage e.g. food choices, exercise, medicine, blood sugars and emotional adaptation.
62619102|NCT03165084|OTHER|Control arm|Participants in the control group will receive usual care and also take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
62619103|NCT03165084|OTHER|External comparison group|An external comparison group will be recruited from two other primary health care centers in order to analyse possible Hawthorne effects.
62619104|NCT01194193|EXPERIMENTAL|1|
62619105|NCT01607346|EXPERIMENTAL|ezogabine/retigabine|Open-label
62619106|NCT02509793|EXPERIMENTAL|Tetrabenazine|Xenazine (tetrabenazine), pill, dosage titrated to effect, three times a day, 12 weeks
62845016|NCT01619969|EXPERIMENTAL|Celgosivir|
62262695|NCT00427076|ACTIVE_COMPARATOR|B|Vancomycin
62447136|NCT03176225|ACTIVE_COMPARATOR|Control Arm|In Control Arm, the subjects will be implanted with comparator device - Polyester patch by Shanghai Chest Medical Technology Co. The interventions include: Open heart surgery to address the heart disease; Close the defects with Chest Polyester Patch
62447137|NCT02246842|EXPERIMENTAL|D-Gam®|D-Gam® (human anti-D immunoglobulin)
62447138|NCT02246842|ACTIVE_COMPARATOR|Rhophylac®|Human Anti-D Immunoglobulin
62059057|NCT05316584|EXPERIMENTAL|Remote Monitoring|At the time of a medication dose, participants scan the smart label by tapping it with their mobile device. Participants receive a notification on their device indicating that their medication adherence was updated. Each day a medication is due, patients receive a morning reminder through SMS message notifying them on their medications schedule. If patients fail to scan the label at a given time (as expected by their specific medication regimen), they will receive an end of day text message. Participants will also complete a patient reported outcome (PRO) 2 assessment at baseline, and then monthly for the entire 12 months of the study through an HTML link sent to patients by SMS message. If nonadherence is present and/or moderate to severe symptoms, an alert will be triggered to the research team. The research team can send the PRO2 survey to patients at any given time, at their discretion, if patients are experiencing a flare or at the time of a change in medication dose.
62059058|NCT05316584|NO_INTERVENTION|Control|The standard of care for participants in this study is modeled after the standard of care at all five study sites. Standard of care is based on current evidence-based guidelines including a comprehensive assessment, a guideline-concordant therapy plan, scheduled and as needed clinic visits, scheduled and as needed telephone calls, and administration of educational fact sheets about disease-specific topics when appropriate. Personnel used to provide standard of care at each site will vary and may include nurse coordinators, advanced practice providers, social workers, psychologists, dieticians, pharmacists, and other ancillary staff.
62059059|NCT01480596|EXPERIMENTAL|Belimumab|10mg/kg
62447139|NCT03141489|EXPERIMENTAL|NICE guidelines for refeeding syndrome|High protein enteral tubefeeding solution. NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
62447140|NCT03141489|EXPERIMENTAL|Diakonhjemmet Hospital Protocol(DS)|High protein enteral tubefeeding solution. The intervention group, Diakonhjemmets feeding protocol, will start at 20 calories a kg a day, and increasing until estimated needs are met within 3days
62447141|NCT01188707|EXPERIMENTAL|Belinostat, Erlotinib, NSCLC|
62447142|NCT06528717||ECA flow preserved group|Patients with carotid graft interposition after endarterectomy of the common carotid artery and external carotid artery with preserved flow through the external carotid artery by side-to-end proximal anastomosis.
62619107|NCT02252926|ACTIVE_COMPARATOR|Bupivacaine lozenge|The patients can take up to eight 25 mg bupivacaine lozenges (max. every second hour in the awake hours) a day for seven days. The patients can use concomitant systemic pain treatment (e.g. morphine).
62619108|NCT02252926|OTHER|Standard treatment|The patients will be treated with the currently used standard pain treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin). The anesthetics are being administered at the physician's discretion.
62619109|NCT05668572|EXPERIMENTAL|The Group of Investigational Vaccine|
62619110|NCT05668572|ACTIVE_COMPARATOR|The Group of Active Control Vaccine|
62845017|NCT01619969|PLACEBO_COMPARATOR|Placebo|
62447143|NCT06528717||Ligated ECA group|Patients with carotid graft interposition and end-to-end anastomoses on the undiseased segments of the common (proximally) and internal (distally) carotid artery, with ligation of the external carotid artery.
62619111|NCT03029845|ACTIVE_COMPARATOR|propranolol 1|20 mg propranolol twice a day
62619112|NCT03029845|ACTIVE_COMPARATOR|propranolol 2|10 mg propranolol twice a day
62619113|NCT03029845|PLACEBO_COMPARATOR|Placebo|Placebo twice a day
62619114|NCT06543082|EXPERIMENTAL|MACT|Mono Antiplatelet and Colchicine Therapy
62619115|NCT00802958||Cohort Group 1|Subjects number 1 to 30
62845018|NCT03200886||Sinovial H-L Group|The patients treated have received one cycle of two injections (at baseline and 15 days apart) of 1 ml of Sinovial H-L® (3.2% - 16mg + 16mg, Ibsa).
62845019|NCT03200886||Control Group|The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl).
62447144|NCT03803709|PLACEBO_COMPARATOR|placebo|"* maltodextrin received at 4g/day on day 3 and 4~* maltodextrin received at 8g/day from day 5 to 14~* maltodextrin received at 16g/day from day 15 to 20"
62447145|NCT03803709|EXPERIMENTAL|inulin|"* inulin received at 4g/day on day 3 and 4~* inulin received at 8g/day from day 5 to 14~* inulin received at 16g/day from day 15 to 20"
62619116|NCT00802958||Cohort Group 2|Subjects number 31 to 56
62845020|NCT02234895|EXPERIMENTAL|Lateral wedge plus medial arch support|The lateral wedge plus medial support orthotic will be custom-made and designed using a 3D volumetric cast of the foot with the participant's foot in a subtalar joint neutral position. The cast will be balanced so that it rests in a neutral position then smoothed to address any irregularities and to allow for soft tissue splay. Polypropylene sheets of 3mm or 4mm thickness will be vacuum formed or milled directly to produce a ¾ length shell. An ethyl-vinyl-acetone (EVA) lateral post in the heel and forefoot of 5 degrees will be incorporated into the orthotic. The orthotic will be finished with a neoprene cover for improved comfort and patient compliance.
62059060|NCT01480596|PLACEBO_COMPARATOR|Placebo|placebo IV infusion
62619117|NCT00802958||Cohort Group 3|Subject Numbers 57 to 76
62619118|NCT00581061|EXPERIMENTAL|Vesicare Treatment|
62619119|NCT04324515|OTHER|Study Arm without cholecystectomy|Study Arm: Patients with gastric bypass without concomitant cholecystectomy
62619120|NCT04324515|OTHER|Control Arm with cholecystectomy|Control Arm: Patients with gastric bypass with concomitant cholecystectomy
62619121|NCT04165135||Haemophilia A Without FVIII Inhibitors|
62619122|NCT03495115|ACTIVE_COMPARATOR|SCREENING MRI|Standard MRI procedure will be used.
62619123|NCT03495115|EXPERIMENTAL|SCREENING MG BI-RADS 4/5|"* RSI is a DWI sequence with a built in distortion-correction technique that can be applied to any diffusion technique using echo planar imaging acquisition.~* RSI will be performed using pulsed-field gradient, spin-echo, echo planar imaging with multi-shell diffusion data .~* The b0 images will be collected in both the forward and reverse phase encoding directions to allow for post-processing correction of spatial distortion from magnetic field."
62619124|NCT02374619|EXPERIMENTAL|Iron supplement|Oral supplementation
62619125|NCT02374619|PLACEBO_COMPARATOR|Control|Oral supplementation
62619126|NCT01360047||Cases|Cases with nonfatal MI or coronary death
62059061|NCT06624761|EXPERIMENTAL|ShotBlocker|ShotBlocker will be applied to the experimental group.
62059062|NCT06624761|NO_INTERVENTION|Control group|no intervention will be made
62059063|NCT04792125|EXPERIMENTAL|External electrical stimulation (EES) added to pelvic floor muscle training (PFMT) group|This arm is going to include the patients who are performed external electrical stimulation (EES) added to pelvic floor muscle training (PFMT).
62059064|NCT04792125|OTHER|External electrical stimulation (EES) group|This arm is going to include the patients who are performed external electrical stimulation (EES).
62059065|NCT04792125|ACTIVE_COMPARATOR|Pelvic floor muscle training (PFMT) group|This arm is going to include the patients who are performed pelvic floor muscle training (PFMT).
62059066|NCT05893680|EXPERIMENTAL|Group to play online games|The child's pain was evaluated 4 hours after the surgery, and then he/she was allowed to play an online game that he/she knew, loved, and wanted to play for 20 minutes.
62059067|NCT05893680|EXPERIMENTAL|Group that received cold application|The child's pain was evaluated 4 hours after the surgery, and then a clean gauze wrapped cold gel pack was applied to the surgical site for 20 minutes.
62059068|NCT05893680|PLACEBO_COMPARATOR|Group that received placebo|The child in the relevant group had their pain evaluated 4 hours after the surgery, and then was given 2 cc of 0.9% saline (isotonic) solution intravenously, while being told that it was a painkiller administered to both the child and the parent.
62059069|NCT05893680|ACTIVE_COMPARATOR|"Group that played an online game and received cold application at the same time"|Pain assessment was performed on the child in the relevant group 4 hours after surgery, and then while playing an online game that the child knew, liked, and wanted to play, a clean gauze-wrapped cold gel pack was applied to the surgical site for cold therapy. The interventions lasted for 20 minutes.
62059070|NCT01152775|PLACEBO_COMPARATOR|No Media|Sixty participants will be randomized into one of two cohorts: 1. No media 2. Yes media
62059071|NCT01152775|EXPERIMENTAL|Yes Media Newly Diagnosed Breast Cancer Pts|Sixty participants will be randomized into one of two cohorts: 1. No media 2. Yes media
62447146|NCT00555009|EXPERIMENTAL|Genotropin treatment arm|
62447147|NCT00555009|PLACEBO_COMPARATOR|Placebo|
62059072|NCT03258424|ACTIVE_COMPARATOR|PTI-428|Subjects will receive once daily dosing of PTI-428 or placebo for 14 days.
62447148|NCT04528095|EXPERIMENTAL|Clozapine|Clozapine 400 \~ 600mg/d or plasma concentration \>350ng/ml
62447149|NCT04528095|EXPERIMENTAL|Clozapine+Amisulpride|Clozapine 400 \~ 600mg/d or plasma concentration \>350ng/ml Amisulpride 200-800mg/d
62059073|NCT03258424|PLACEBO_COMPARATOR|Placebo|Subjects will receive once daily dosing of PTI-428 or placebo for 14 days.
62845021|NCT02234895|EXPERIMENTAL|Lateral wedge|The lateral wedge only orthotic will be constructed of EVA, made to full length of the subject's footwear and incorporate a 5 degree posting. The wedge will be finished with a neoprene cover for improved comfort and patient compliance.
62059074|NCT04309825|EXPERIMENTAL|G-tube endoscopies patients|patients who will undergo an endoscopy through g-tube port
62059075|NCT06624774|NO_INTERVENTION|Standard care|This group will receive NHS standard care. This includes the 'your heart surgery' - a new beginning booklet at the pre-op assessment 2-4 weeks, before surgery as part of routine care. The leaflet will include information regarding heart procedures, recovery, post-surgery rehabilitation, cardiovascular risk factors, lifestyle advice and support
62059076|NCT06624774|ACTIVE_COMPARATOR|Prehabilitation|Participants randomised to the exercise and education intervention will follow an individualised structured exercise programme and receive group education sessions.
62059077|NCT05616741|EXPERIMENTAL|Treatment group|Cerebri biofeedback and Cerebri headache diary
62447150|NCT04528095|EXPERIMENTAL|Clozapine+Gingke biloba|Clozapine 400 \~ 600mg/d or plasma concentration \>350ng/ml Gingke biloba 120-360mg/d
62619127|NCT01360047||Controls|Age, sex, and calendar-year matched controls sampled from the original study cohort to be a round number of at least four times the number of cases
62619128|NCT02083302|EXPERIMENTAL|Treatment1|The Treatment1 group received SCREAM Theater Dose 1, SCREAM Theater Dose 2 and SCREAM Theater Dose 3.
62619129|NCT02083302|EXPERIMENTAL|Treatment2|The Treatment2 group received SCREAM Theater Dose 1, SCREAM Theater Dose 2, SCREAM Theater Dose 3 and SCREAM Theater Dose 4.
62619130|NCT02083302|OTHER|Control|The control group received SCREAM Theater Dose 1.
62619131|NCT02840227|EXPERIMENTAL|Combined general/epidural anesthesia|Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
62619132|NCT02840227|EXPERIMENTAL|General anesthesia with opioid analgesia|General anesthesia with routine drugs and intravenous PCA opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
62619133|NCT06320353|EXPERIMENTAL|RPH-075|"Pembrolizumab will be administered as an intravenous infusion every 3 weeks, at a fixed dose of 200 mg, for 30 minutes (it is permissible, but not desirable, to carry out an infusion in the range from 25 to 40 minutes).~Premedication before administration of pembrolizumab is not mandatory."
62619134|NCT06320353|ACTIVE_COMPARATOR|Keytruda®|"Pembrolizumab will be administered as an intravenous infusion every 3 weeks, at a fixed dose of 200 mg, for 30 minutes (it is permissible, but not desirable, to carry out an infusion in the range from 25 to 40 minutes).~Premedication before administration of pembrolizumab is not mandatory."
62845022|NCT01731418|OTHER|Treamtent-as-usual|Treatment-as-usual can be defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive psychotherapy.
62447151|NCT04528095|EXPERIMENTAL|MECT|MECT:The treatment lasted for 4 months,16 times in total
62619135|NCT05753540|EXPERIMENTAL|Laser therapy|Multiwave locked system laser therapy
62619136|NCT05753540|PLACEBO_COMPARATOR|Sham laser therapy|Sham laser therapy
62619137|NCT01508390|EXPERIMENTAL|Boost|CyberKnife Boost 21 Gy in 7 Gy per day, 3 fractions, Every other day
62619138|NCT02530918|EXPERIMENTAL|Part 1 DS-7080a dose escalation|3 sequential ascending dose levels (1.0, 2.0, 4.0 mg), every 4 weeks for 12 weeks
62845023|NCT01731418|EXPERIMENTAL|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a standardized short-term approach based on the principles of cognitive behavioral exposure therapy and testimony therapy for the treatment of PTSD resulting from organized violence.
62845024|NCT01750749|EXPERIMENTAL|Autologous BMDC implantation at the venous ulcer|Autologous BMDC implantation at the venous ulcer in conjunction with SOC treatment (advanced wound management plus pressure therapy)
62845025|NCT03016494|EXPERIMENTAL|Test/Reference Drug|DWJ1386 Tab. followed by co-administration of DWC20155 and DWC20156 Tab.
62447152|NCT04528095|EXPERIMENTAL|MST|MST:The treatment lasted for 4 months,16 times in total
62447153|NCT04528095|EXPERIMENTAL|DBS|Two electrode emplacement groups (target nucleus accumbens and hippocampus respectively)
62447154|NCT03150251|EXPERIMENTAL|Overnight Oats|40 g of overnight oats
62447155|NCT03150251|PLACEBO_COMPARATOR|Soaked Cream of Rice|28.8 cream of rice
62619139|NCT02530918|EXPERIMENTAL|Part 2 DS-7080a|Specific dose (either the maximum tolerated dose or 4.0 mg) of DS-7080a determined in Part 1, every 4 weeks for 12 weeks
62619140|NCT02530918|ACTIVE_COMPARATOR|Part 2 ranibizumab|Ranibizumab 0.5 mg, every 4 weeks for 12 weeks
62619141|NCT02530918|EXPERIMENTAL|Part 2 DS-7080a and ranibizumab|Specific dose of DS-7080a determined in Part 1 and ranibizumab 0.5 mg, every 4 weeks for 12 weeks
62059078|NCT05616741|OTHER|Waitlist control group|Only Cerebri headache diary
62059079|NCT04402437|ACTIVE_COMPARATOR|Receives LP Block|Subjects randomized to the lumbar plexus block group will receive a subcutaneous lidocaine skin wheal 3-4 cm lateral to midline on the operative side along the intercristal line. A nerve stimulator will be sent to 1-1.5mA and a stimulating needle inserted perpendicular to the skin. The needle will be advanced slowly until the quadriceps muscle is stimulated and maintained at less than 0.6mAs. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement.
62059080|NCT04402437|ACTIVE_COMPARATOR|Receives QL Block|Subjects randomized to the quadratus plexus block group will receive a subcutaneous lidocaine skin wheal that will be placed after ultrasound identification of external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A needle will then be advanced under ultrasound guidance below the internal oblique aponeurosis and lateral to the quadratus lumborum muscle. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement. Local anesthetic injection will also be observed with real time ultrasound guidance.
62059081|NCT03439189|EXPERIMENTAL|Emricasan 5mg|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (5 mg) twice a day. The MBT will be performed at screening, at week 24/week 48/at early termination.
62059082|NCT03439189|EXPERIMENTAL|Emricasan 25mg|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (25 mg) twice a day. The MBT will be performed at screening, at week 24/ week 48/ at early termination.
62059083|NCT03439189|EXPERIMENTAL|Emricasan 50mg|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (50 mg) twice a day. The MBT will be performed at screening, at week 24/ week 48/ at early termination.
62059084|NCT03439189|PLACEBO_COMPARATOR|Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with a matching placebo twice a day. The MBT will be performed at screening, at week 24/week 48/at early termination.
62059085|NCT05915962|EXPERIMENTAL|volunteer for an autograft|Collecting and preparing a Nanofat-type autograft using a special kit.
62059086|NCT05108168||infiltrative cardiomyopathy|infiltrative cardiomyopathy
62059087|NCT00944723|EXPERIMENTAL|Zinc-fortified bread (10 mg zinc/d)|Daily consumption of zinc fortified bread for 1 month
62059088|NCT00944723|EXPERIMENTAL|Zinc fortified bread (20 mg zinc/d)|Daily consumption of zinc fortified bread for 1 month.
62059089|NCT00944723|EXPERIMENTAL|Zinc supplemented group|Daily consumption of non-fortified bread and daily intake of zinc supplement (10 mg zinc/d)
62059090|NCT00944723|PLACEBO_COMPARATOR|Non-fortified group|Daily consumption of non-fortified bread and a placebo supplement for 1 month.
62059091|NCT06089122|EXPERIMENTAL|IVIG|Patients with primary immunodeficiency will switch to Shu Yang IVIG and optimize the posology to IgG 300 to 600 mg every 21 or 28 days in a run-in period of 2 to 6 administrations, aiming at keeping the IgG trough levels above 5 g/L. In the one-year test period, the patients will receive the test IVIG at the same dose/intervals of the optimization. However, the IgG trough levels will be monitored every visit, and new adjustments/dose optimization will be performed whenever needed to keep the IgG trough levels above 5g/L.
62059092|NCT03205540|EXPERIMENTAL|Epidural analgesia|Lumbar continuous epidural block
62059093|NCT03205540|EXPERIMENTAL|Bilateral ACB|Ultrasound-guided bilateral adductor canal blocks
62059094|NCT00615186|EXPERIMENTAL|A|"Prior Surgery~Rickham Catheter placement 99mTc-DTPA Flow Study~Neuradiab Dosimetry Study~Neuradiab Therapeutic Dose Administration~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
62059095|NCT00615186|ACTIVE_COMPARATOR|B|"Prior Surgery: Gross total resection (\< 1 cm. enhancing rim)~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
62059096|NCT03340948|EXPERIMENTAL|MBSR participation|Participation in the 8 week Mindfulness Based Stress Reduction (MBSR) course.
62447156|NCT03150251|PLACEBO_COMPARATOR|Cooked Cream of Rice|28.8 cooked cream of rice
62447157|NCT05984537|EXPERIMENTAL|bivalirudin group|participants using bivalirudin during PCI
62845026|NCT03016494|EXPERIMENTAL|Reference/Test Drug|co-administration of DWC20155 and DWC20156 Tab. followed by DWJ1386 Tab.
62845027|NCT06098742|EXPERIMENTAL|TR-sequence (T-test drug, R-reference drug)|Group 1 (25 volunteers, TR sequence) will take 2 sachets of Antareit 800 mg/10 ml oral suspension 2 h prior to food intake in Period 1 and 2 tablets of Riopan 800 mg chewable tablets 2 h prior to food intake in Period 2
62447158|NCT05984537|ACTIVE_COMPARATOR|standard heparin group|participants using standard heparin during PCI
62447159|NCT03341273|EXPERIMENTAL|Azithromycin|500 mg of Azithromycin (2 capsules of 250 mg) administered orally as a single dose on Day 1, followed by 250 mg capsule of Azithromycin administered orally once daily for 4 days (Day 2 through Day 5). N=337
62845028|NCT06098742|EXPERIMENTAL|RT-sequence|Group 2 (25 volunteers, RT sequence) will take 2 tablets of Riopan 800 mg chewable tablets 2 h prior to food intake in Period 1 and 2 sachets of Antareit 800 mg/10 ml oral suspension 2 h prior to food intake in Period 2
62845029|NCT04205383||pregnancy|pregnant women with normal pregnancy
62447160|NCT03341273|PLACEBO_COMPARATOR|Placebo|2 capsules of Azithromycin placebo administered orally as a single dose on Day 1, followed by 1 capsule of Azithromycin placebo administered orally once daily for 4 days (Day 2 through Day 5). N=337
62845030|NCT04205383||pregnancy with complications|pregnant women with placental-mediated complications of pregnancy type complications
62845031|NCT04205383||healthy volunteer|healthy, non-pregnant women volunteers
62845032|NCT01942733|EXPERIMENTAL|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant treatment (ADT)
62845033|NCT04944264|ACTIVE_COMPARATOR|Immediate start|Behavioral: Stress Management and Resiliency Training (SMART) program
62845034|NCT04944264|ACTIVE_COMPARATOR|Delayed start|Wait time control
62845035|NCT04011215|EXPERIMENTAL|wool-first (wool X standard)|superfine merino wool clothing to be worn for 6 weeks followed by 6 weeks of standard clothing
62845036|NCT04011215|ACTIVE_COMPARATOR|standard-first (standard X wool)|standard clothing to be worn for 6 weeks followed by 6 weeks of superfine merino wool clothing
62845037|NCT00612248|EXPERIMENTAL|SG|Study group
62845038|NCT00612248|NO_INTERVENTION|CG|Control group
62845039|NCT00482066|ACTIVE_COMPARATOR|1|Abatacept (Orencia)
62845040|NCT00482066|PLACEBO_COMPARATOR|2|saline placebo
62845041|NCT01745549|EXPERIMENTAL|needle 4 mm gauge 33|Needle for insulin pen, 4 mm long and with a diameter of 33 gauge (the smaller needle)
62845042|NCT01745549|ACTIVE_COMPARATOR|needle 4 mm gauge 32|Needle for insulin pen, 4 mm long and with a diameter of 32 gauge
62845043|NCT05250063|EXPERIMENTAL|LUM-201 (3.2 mg/kg/day)|
62845044|NCT02703441|EXPERIMENTAL|Intervention: Tablet computer|Patients from the local municipality, planned to be discharged to a rehabilitation stay at the municipality training centre receive a tablet computer. The patient will be introduced to the tablet and informed about the nutritional and mobilisation intervention based on his/her individual needs and preferences. The patient and the research assistant will jointly prepare an individual plan for nutrition and physical activity The patient uses the tablet for ordering meals, registering dietary intake, viewing his/her instruction videos for the activity programme and registering physical activity during hospital admission and at the training centre up to 6 weeks after discharge from hospital.
62059097|NCT03312153|EXPERIMENTAL|Neem (Azadirachta indica)|Neem (Azadirachta indica) (alcoholic solution) used as an anti inflammatory , antibacterial irrigant
62059098|NCT03312153|ACTIVE_COMPARATOR|2.5%sodium hypochlorite|2.5% sodium hypochlorite, anti-bacterial root canal irrigant solution
62059099|NCT03688152|EXPERIMENTAL|INCB053914 + INCB050465|INCB053914 in combination with INCB050465.
62059100|NCT02731664|EXPERIMENTAL|GLP-1|Intravenous infusion of GLP-1 at 0.7 and 1.2 mol/kg per minute
62447161|NCT04690270|EXPERIMENTAL|Sumatriptan 100 mg|Given the cross-over design all participants will receive both sumatriptan (100 mg, single dose) and placebo in a random order.
62845045|NCT02703441|NO_INTERVENTION|Control group|Patients in the control group receive usual care during their hospital stay and after discharge at the municipality training centre. Data are recorded at baseline and 6 and 12 weeks after discharge.
62845046|NCT04932408|EXPERIMENTAL|Hip Region|"Pre selected exercises (8) will be performed by the participant using an elastic resistance band anchored from ground level and placed around the hip region.~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold.~Cool down. Post intervention- Semi-structured Interview schedule"
62845047|NCT04932408|EXPERIMENTAL|Chest Region|"Pre selected exercises (8) will be performed by the participant using an elastic resistance band anchored from ground level and placed the chest region (using velcro on a chest harness/training vest).~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold.~Cool down. Post intervention- Semi-structured Interview schedule"
62845048|NCT02206971|ACTIVE_COMPARATOR|Feedback Group|receive a Smoking Cessation Manual, the opportunity for smoking cessation counseling on the phone, and urine analyses feedback via the mail plus a phone call to discuss the information
62845049|NCT02206971|NO_INTERVENTION|Standard Care|receive a Smoking Cessation Manual and the opportunity for smoking cessation counseling on the phone
62262696|NCT06080828|EXPERIMENTAL|study group (SG)|they will receive treatment with 20 minutes of neuromodulation of the posterior tibial nerve of both lower limbs using Physio Go-lite electrical stimulation device (made by ASTAR, ver 1.0.2 in Poland). Using TENS current in the device, the positive electrode will be placed posterior to the medial ankle malleolus, and the negative electrode will placed ten centimeters away on the leg along the tibial nerve path. The TENS current parameters will be 200 micro second pulse width, 10 Hz frequency, and intensity according to participant tolerance ranging between (10 - 50 mA) that increased gradually until visible movement in the big toe or fanning of toes will be noticed. The therapy sessions will be given three times a week, every other day, for a total of twelve sessions. Alos, they will receive leaflet with information for home instructions on how to properly walk, sleep, maintain good posture, and deal with activities of daily living.
62262697|NCT06080828|PLACEBO_COMPARATOR|control group (CG)|They will receive placebo neuromodulation of the posterior tibial nerve in both lower limbs, much as those in the research group. Alos, they will receive leaflet with information for home instructions on how to properly walk, sleep, maintain good posture, and deal with activities of daily living.
62619142|NCT02530918|EXPERIMENTAL|Part 3 DS-7080a|Specific dose of DS-7080a determined in Part 1, every 4 weeks for 12 weeks
62262698|NCT03866135||patients with osteoporosis|Osteoporosis has been operationally defined on the basis of bone mineral density (BMD) assessment. According to the WHO criteria, osteoporosis is defined as a BMD that lies 2.5 standard deviations or more below the average value for young healthy women (a T-score of \<-2.5 SD)
62262699|NCT03866135||patients without osteoporosis|Bone mineral densities of patients were based on the World Health Organization (WHO) classification of a T score between -1 and -2.5 for osteopenia
62262700|NCT05513248||patients who recovered from COVID-19|patients with previous COVID-19 infection who underwent anatomic lung resection (segmentectomy, lobectomy, bilobectomy or pneumonectomy)
62447162|NCT04690270|PLACEBO_COMPARATOR|Placebo|Given the cross-over design all participants will receive both sumatriptan (100 mg, single dose) and placebo in a random order.
62447163|NCT01877707|OTHER|Cystic Fibrosis patients|Patients with a diagnosis of cystic fibrosis, who are able to produce daily sputum samples. With a history of at least two pulmonary infective exacerbations within the past 12 months.
62447164|NCT04409665|EXPERIMENTAL|Ketamine sedated group|30 randomized patients will receive Ketamine 1 mg/kg , I.V. 2 minutes before LISA
62619143|NCT02530918|EXPERIMENTAL|Part 3 ranibizumab|Ranibizumab 0.3 mg, every 4 weeks for 12 weeks
62619144|NCT06020248|EXPERIMENTAL|Low melanin|Individuals with skin reflectance scores below 150 using the Mexameter 18 instrument.
62059101|NCT02731664|PLACEBO_COMPARATOR|Control|Intravenous saline
62059102|NCT02012062|ACTIVE_COMPARATOR|Arm Cisplatin|Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by cisplatin 40 mg/m2/week in concurrent with IMRT
62262701|NCT01783080|EXPERIMENTAL|Behavioral Activation for Return to Work|BA is a manualized psychotherapy with comparable efficacy to cognitive behavioral treatment and antidepressant medication for acute treatment of depression. In this study, BA's focus was shifted to target work dysfunction by activating the patient into employment-related goals. BA-W consisted of 12 50-minute weekly sessions. Conceptualizing work dysfunction as a product of avoidance patterns and low levels of positive reinforcement, the treatment addressed maladaptive coping strategies such as avoidance as maintaining work dysfunction beyond remission of symptoms. Rather than broadly activating patients, activity scheduling focused on tasks such as sending out resumes, calling for job interviews, and networking to meet potential employers.
62262702|NCT05470127|EXPERIMENTAL|SUREcore biopsy needle|The SUREcore needle will be used to collect up to 10 tissue samples
62262703|NCT05470127|ACTIVE_COMPARATOR|Standard of Care biopsy needle|The urologist will use his/her standard biopsy needle to collect up to 15 tissue samples
62059103|NCT02012062|EXPERIMENTAL|Arm Nimotuzumab|Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by weekly nimotuzumab 200mg in concurrent with IMRT
62262704|NCT02514616|ACTIVE_COMPARATOR|Active Electric Stimulation Therapy|The subject receives Active Electric Stimulation Therapy for 12 weeks, 2 weeks after laparoscopic IPG and lead implant procedure. The subject and physician will be blinded to the randomization group assignment. The subject continues on stimulation treatment after 14 weeks and an extended open-label follow-up phase includes annual visits through 5 years.
62619145|NCT06020248|EXPERIMENTAL|High melanin|Individuals with skin reflectance scores above 249 using the Mexameter 18 instrument
62059104|NCT03158363|EXPERIMENTAL|"LPS, 36 hour immobilization and fast"|"Interventions:~Test subjects undergo 48 hour exercise restriction and overnight fast.~Study day 1:~- LPS (1 ng/kg) will be administered. Test subjects will fast and bedrest for the rest of the study period.~Study day 2:~* 3 hour Basal period: Continued fast and bedrest. Phenylalanine, tyrosine, carbamide, glucose and palmitate tracers are infused. Muscle and fat biopsies are taken from m. vastus lateralis and stomach.~* 3 hour hyperinsulinemic euglycemic clamp period with muscle and fat biopsies.~Study day 3:~- Blood sample."
62262705|NCT02514616|SHAM_COMPARATOR|Delayed Electric Stimulation Therapy|The subject receives no active Electric Stimulation Therapy for 12 weeks, 2 weeks after laparoscopic IPG and lead implant procedure. The subject and physician will be blinded to the randomization group assignment. The subject will receive Active Electric Stimulation Therapy at week 14 visit, and an extended open-label follow-up phase includes annual visits through 5 years.
62447165|NCT04409665|ACTIVE_COMPARATOR|Glucose sedated group|30 patients will receive Glucose 30% 1 mL, sublingually, 2 minutes before LISA
62447166|NCT01963364|EXPERIMENTAL|Intervention group|All healthy volunteers
62619146|NCT05956405|EXPERIMENTAL|Amygdala & Insula Retraining + Mindfulness|
62262706|NCT05348174|ACTIVE_COMPARATOR|Virtual Reality Assisted Guided Imagery (VRAGI )|20 participants will be randomized to this arm. Participants in this arm will experience the immersive VR guided imagery on VR Head Mounted Displays (Meta Quest 2). They will experience video content and the accompanying guided imagery and nature soundscapes.
62262707|NCT05348174|SHAM_COMPARATOR|Virtual Reality No Guided Imagery or other audio ( VR No GI or other audio)|20 participants will be randomized to this arm. Participants in this arm will experience the immersive VR visual content on VR Head Mounted Displays (Meta Quest 2) but will not experience the accompanying guided imagery narration or nature soundscapes.
62262708|NCT05348174|ACTIVE_COMPARATOR|Laptop Assisted Guided Imagery (Laptop AGI)|20 participants will be randomized to this arm. Participants in this arm will experience the VR content on laptops. They will not receive the VRHMDs. They will experience video content and the accompanying guided imagery and nature soundscapes on a laptop.
62447167|NCT06264947|EXPERIMENTAL|laser acupuncture group|3 minutes for each time, and 3 times per week, with duration of 4 weeks
62447168|NCT06264947|SHAM_COMPARATOR|sham laser acupuncture group|3 minutes for each time, and 3 times per week, with duration of 4 weeks
62059105|NCT03158363|NO_INTERVENTION|"Control"|"Test subjects undergo overnight fast. No exercise restrictions.~* 3 hour Basal period: Continued fast and bedrest. Phenylalanine, tyrosine, carbamide, glucose and palmitate tracers are infused. Muscle and fat biopsies are taken from m. vastus lateralis and stomach.~* 3 hour hyperinsulinemic euglycemic clamp period with muscle and fat biopsies."
62059106|NCT03993509|EXPERIMENTAL|1 Hz Arm|Subjects will receive a continuous train of 1 Hz stimulation until all 3000 pulses are delivered. Consistent with the 10 Hz condition, TMS will occur during the Sternberg WM paradigm.
62059107|NCT03993509|EXPERIMENTAL|10 Hz Arm|Subjects will receive 75, 4 second trains at 10 Hz, separated by a 36 second ITI. Stimulation will occur while subjects are doing the Sternberg WM paradigm. The timing of the Sternberg task will be jittered so that each rTMS train will be administered during the maintenance interval of a WM trial.
62059108|NCT00871650||Combat Veterans with PTSD|Male Veterans of Operation Iraqi Freedom (OIF) and/or Operation Enduring Freedom (OEF), ages 18-50, with Combat Exposure Scale score \> 17, who are not on medication and do not have trauma history before age 18.
62059109|NCT00871650||Combat Veterans without PTSD|Male Veterans of Operation Iraqi Freedom (OIF) and/or Operation Enduring Freedom (OEF), ages 18-50, with combat experience, who are not suffering from PTSD, and who are not on medication.
62059110|NCT04585659|EXPERIMENTAL|Qigong Intervention|60-90 minute community qigong classes, once per week plus at least 10 minutes of home practice
62059111|NCT04585659|NO_INTERVENTION|Wait-List Control|Participants asked not to do any qigong, yoga or taichi for 10 weeks. Participants have the option to cross-over to the experimental arm after 10 weeks of no intervention.
62262709|NCT05348174|SHAM_COMPARATOR|Laptop no Guided Imagery or other audio (Laptop no GI or other audio)|20 participants will be randomized to this arm. Participants in this arm will experience the VR content on laptops. They will not receive the VRHMDs. They will experience only the video content on a laptop and will no experience the accompanying guided imagery or nature soundscapes.
62447169|NCT00026104|EXPERIMENTAL|Arm I (radiation therapy, paclitaxel, gemcitabine)|Patients receive radiotherapy once daily, 5 days a week, for 5.5 weeks, beginning on day 1. Patients also receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, and 36.
62262710|NCT04535349|OTHER|No cardiac ATTR amyloidosis|"Cardiac echocardiography at baseline and whole-body \& CZT bone tracer imaging (SPECT).~day 3 - day 10 : second whole-body \& CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging Perugini 0 : no cardiac TTR amyloidosis No further follow-up."
62262711|NCT04535349|OTHER|Cardiac ATTR amyloidosis, no treatment with tafamidis planned|"Cardiac echocardiography at baseline and whole-body \& CZT bone tracer imaging (SPECT).~day 3 - day 10 : second whole-body \& CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging demonstrating cardiac ATTR amyloidosis but no treament with tafamidis planned.~Cardiac echocardiography at 3 months and whole-body \& CZT bone tracer SPECT and cardiac echocardiography at 6 months"
62447170|NCT00026104|EXPERIMENTAL|Arm II (radiation therapy, tipifarnib)|Patients receive chemoradiotherapy as in arm I. Within 3-8 weeks after completion of chemoradiotherapy, patients without disease progression receive oral tipifarnib twice daily for 21 days.
62619147|NCT05956405|ACTIVE_COMPARATOR|Relaxation condition|
62845050|NCT06103188|PLACEBO_COMPARATOR|Placebo|A 5mg vitamin B12 pill
62845051|NCT06103188|ACTIVE_COMPARATOR|Diazepam|A 5mg diazepam pill
62262712|NCT04535349|OTHER|Cardiac ATTR amyloidosis, treatment with tafamidis planned|"Cardiac echocardiography at baseline and whole-body \& CZT bone tracer imaging (SPECT).~day 3 - day 10 : second whole-body \& CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging demonstrating cardiac ATTR amyloidosis. Start of the treament with tafamidis.~Cardiac echocardiography at 3 months and whole-body \& CZT bone tracer SPECT and cardiac echocardiography at 6 months"
62262713|NCT01531309|EXPERIMENTAL|Mild Hepatic Impaired Participants|Mild hepatic impaired participants will receive a single sublingual dose of AGO178, 1 milligram (mg) on Day 1.
62262714|NCT01531309|EXPERIMENTAL|Moderate Hepatic Impaired Participants|Moderate hepatic impaired participants will receive a single sublingual dose of AGO178, 1 mg on Day 1.
62059112|NCT05265663|NO_INTERVENTION|best supportive care|Standard of care or best supportive care (or palliative care) is care that focuses on relieving symptoms caused by serious illnesses like cancer, in this case PDAC. It can be given at any point during a person's illness to help them feel more comfortable. For instance, prescription of medicines to help control or prevent nausea and vomiting or to help relieve pain. All patients will be treated with pancreatic enzymes like Creon and a proton pomp inhibitor. Current guidelines for best supportive care include follow-up visits at three-monthly intervals in order to optimize symptom relief.
62059113|NCT05265663|EXPERIMENTAL|stereotactic ablative radiotherapy|SABR will be delivered in an image-guided hypofractionated scheme of 5 fractions of 8 Gy (total 40 Gy), prescribed to 95% of the planning target volume (PTV). Treatment is delivered on alternate days within a maximum overall treatment duration of 14 days.
62059114|NCT02636257|EXPERIMENTAL|Recessive Spherical Headed Silicone Intubation|The silicone nasolacrimal intubation under nasal endoscopy can restore natural drainage pathway in tears and as an out-patient surgery, it is more simple,cheap and mini-invasive.Recessive Spherical Headed Silicone Intubation is safe,convenient and almost unpainful for no trauma.It has no facial scar and no damage for structure and function of lacrimal duct.Besides,silica gel is non-toxic and nonirritating.Nasal endoscopy handed by otorhinolaryngologist helps intraoperative visualization about anatomy of the nasal cavity,understanding and management of congenital nasolacrimal duct obstruction and is the only method that confirms the correct anatomic position of the catheterization and in real time,avoiding traditionally the blind raking-out wire by the ophthalmologist alone.Compare to the classic DCR,its short therapeutic effects are equal but more convenient and fewer time and money-cost.
62059115|NCT02636257|OTHER|Dacryocystorhinostomy|Nasolacrimal duct obstruction is common among patients with epiphora,which is seriously affect the quality of life. The treatment principle is to restore or rebuild the lacrimal duct drainage channel. The classic operation type is dacryocystorhinostomy(DCR), which is complex for face-section particularly.After surgery the lacrimal passage can't siphon the tear out physically any more so that it will effect the patients' life.Besides,the operating time,bleeding volume,hospitalization time and total cost for the surgery is higher.
62059116|NCT01599923|EXPERIMENTAL|Alacramyn|
62262715|NCT01531309|EXPERIMENTAL|Healthy Participants Matched by Aged, Gender and Body Mass Index (BMI)|Healthy participants matched by aged, gender and BMI will receive a single sublingual dose of AGO178, 1 mg on Day 1.
62262716|NCT06466226|ACTIVE_COMPARATOR|Group 1|Multiple central venous lines in two sites separately
62262717|NCT06466226|EXPERIMENTAL|Group 2|Multiple central venous lines in a single internal jugular vein
62262718|NCT01505634|EXPERIMENTAL|Relebactam 250 mg with imipenem/cilastatin|Relebactam 250 mg IV co-administered with 500 mg of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
62262719|NCT01505634|EXPERIMENTAL|Relebactam 125 mg with imipenem/cilastatin|Relebactam 125 mg IV co-administered with 500 mg of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
62845052|NCT06103188|EXPERIMENTAL|Melatonin|A 5mg melatonin pill
62845053|NCT02116205|EXPERIMENTAL|Vaccine + Placebo at 1.0 mg|1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 56 and 168. 1.0 mg placebo administration on Study Day 28.
62059117|NCT01295658||Cancer Survivors|"This is a broad observational study conducted online at www.cancerexperienceregistry.org, or via pen and paper survey obtained by calling the cancer support helpline at 888-793-9355~Any individual who has ever received a cancer diagnosis, regardless of disease type, stage, treatment, and time since diagnosis, can take part in this study."
62059118|NCT04269915|EXPERIMENTAL|Intervention|Volunteers will be exposed to escalating doses of female Schistosoma mansoni cercariae
62059119|NCT00231907|ACTIVE_COMPARATOR|Vaccine 1: TIV. Vaccine 2: TIV.|Vaccine 1: TIV. Vaccine 2: TIV.
62059120|NCT00231907|EXPERIMENTAL|Vaccine 1: LAIV. Vaccine 2: TIV.|Vaccine 1: LAIV. Vaccine 2: TIV.
62059121|NCT00231907|EXPERIMENTAL|Vaccine 1: LAIV. Vaccine 2: LAIV.|Vaccine 1: LAIV. Vaccine 2: LAIV.
62262720|NCT01505634|PLACEBO_COMPARATOR|Relebactam placebo with imipenem/cilastatin|Matching placebo for relebactam (0.9% normal saline) IV co-administered with 500 mg dose of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
62262721|NCT05113875||COVID-19 Patients|Completed Sample of all patients admitted to the Mitchells Plain Hospital of Hope COVID-19 Field Hospital between January 1st and February 29th 2021. All patients were diagnosed with COVID-19 prior to admission to the hospital and were transferred directly from a referring hospital.
62447171|NCT01584661||Compliance with nutritional care|"The Inclusion criteria comprise patients who were treated nutritionally with food enrichment supplements during their hospitalization in Bait Balev and were discharged to their homes with dietary recommendations. Participants who are willing to participate will sign an informed consent form. For patients with cognitive impairment or dementia, as reported in their medical records, their formal primary caregiver or proxy will sign the informed consent form."
62447172|NCT06371599|EXPERIMENTAL|Playing game|The children will be asked which game they want to play before the procedure. They will start to play the game 3 minutes before the procedure.
62845054|NCT02116205|EXPERIMENTAL|Vaccine at 1.0 mg|1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 28, 56 and 168.
62059122|NCT00231907|EXPERIMENTAL|Vaccine 1: TIV. Vaccine 2: LAIV.|Vaccine 1: TIV. Vaccine 2: LAIV.
62059123|NCT01578863|ACTIVE_COMPARATOR|Intervention program|6 months intervention program to lose weight in obese children. Behavioral, emotional, physical, familial and demographic questioners will be fulfilled at the beginning and at the end of the program.
62059124|NCT01578863|NO_INTERVENTION|Untreated obese children|Behavioral, emotional, physical, familial and demographic questioners will be fulfilled twice in a 6 month program.
62059125|NCT01578863|NO_INTERVENTION|Normal weight children|Behavioral, emotional, physical, familial and demographic questioners will fulfill twice in the 6 month period.
62059126|NCT03213990|OTHER|Continuous Infusion|The prescribed Beta-lactam is administered by a continuous infusion.
62262722|NCT01897285|EXPERIMENTAL|All study participants: AQUACEL® foam adhesive dressings|Original adhesive + test adhesive
62262723|NCT04314921|EXPERIMENTAL|10-week Yoga|Eighteen healthy elderly people, who were classified into two age groups, participated in this study. All participants had not practiced yoga before and were asked not to perform any sports activities while the research was ongoing. In the experimental group, participants (n = 18) had to participate in 10 weeks of yoga classes. In the control group, participants (n = 15) did not perform any exercises or other changes in their daily living life. All experimental group subjects participated in Himalayan yoga classes, which lasted 10 weeks: 2 times per week, 90 min per session. Yoga classes were conducted by 16-year-old qualified yoga instructor from Yoga Academy, Kaunas.
62447173|NCT06371599|ACTIVE_COMPARATOR|Watching cartoon|The children will be asked which cartoon they want to watch before the procedure. They will start to watch the cartoon 3 minutes before the procedure.
62845055|NCT02116205|EXPERIMENTAL|Vaccine + Placebo at 2.0 mg|2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 56 and 168. 2.0 mg placebo administration on Study Day 28.
62845056|NCT02116205|EXPERIMENTAL|Vaccine at 2.0 mg|2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 28, 56 and 168.
62845057|NCT01757249|EXPERIMENTAL|Group 1 OCP|Combined oral contraceptive pill (OCP) (Microgynon 30) containing Levonorgestrel/Ethinylestradiol 150/30mcg. Taken orally on a continuous regime for 8 weeks, once a day.
62059127|NCT03213990|OTHER|Intermittent infusion|the prescribed Beta-lactam is administered by intermittent infusion over 30 minutes
62059128|NCT02107794|ACTIVE_COMPARATOR|Decision Aid|Observation of clinical encounter using the decision aid, via video, audio or written notes.
62059129|NCT02107794|NO_INTERVENTION|Usual Care|Observations in clinical encounters, either video, audio, or observational notes.
62059130|NCT03929562|ACTIVE_COMPARATOR|Brief advice|One brief advice session, resource brochure, standard of care, and an infographic about alcohol and surgical health at patient's pre-existing pre-operative clinical visit.
62059131|NCT03929562|EXPERIMENTAL|Health coaching|Two health coaching sessions, resource brochure, standard of care
62059132|NCT01099514|EXPERIMENTAL|Nilotinib|Nilotinib 400 mg (2 capsules) PO BID q 28 days
62059133|NCT03663764|EXPERIMENTAL|Expeiment|"HRT using the IMRT technique was administered. For patients with limited pulmonary or pleural metastases (≤3 lesions), stereotactic body radiation therapy (SBRT) could be used.~All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy .~Meanwhile they received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy."
62262724|NCT04314921|NO_INTERVENTION|Control|In the control group, participants (n = 15) did not perform any exercises or other changes in their daily living life.
62619148|NCT01633970|EXPERIMENTAL|A: Atezolizumab + Bevacizumab|Participants will receive atezolizumab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion (or a selected dose level not to exceed the single agent MTD or MAD determined in Study PCD4989g) with bevacizumab 15 mg/kg every 3 weeks (q3w). After establishment of MTD or MAD, participants will receive bevacizumab 15 mg/kg IV infusion on Day 1 of Cycle 1 followed by atezolizumab 1200 mg IV infusion q3w after Days 5-7 and then atezolizumab 1200 mg q3w and bevacizumab 15 mg/kg q3w on Day 1 of all subsequent cycles until disease progression or unacceptable toxicity.
62262725|NCT01199042|OTHER|BiPAP autoSV Advanced Device|Positive airway pressure device
62619149|NCT01633970|EXPERIMENTAL|B: Atezolizumab + Bevacizumab + FOLFOX|Participants will receive FOLFOX IV infusion (oxaliplatin \[85 milligrams per square meter {mg/m\^2}\], leucovorin \[400 mg/m\^2\], 5-FU \[400 mg/m\^2\]) on Day 1 of Cycle 1 and then atezolizumab 800 mg IV infusion every 2 weeks (q2w), bevacizumab 10 mg/kg IV infusion q3w and FOLFOX q2w on Day 1 of all subsequent cycles as per institutional guidelines until disease progression or unacceptable toxicity.
62619150|NCT01633970|EXPERIMENTAL|C: Atezolizumab + Carboplatin + Paclitaxel|Participants will receive atezolizumab 1200 mg IV infusion q3w in combination with paclitaxel 200 mg/m\^2 IV infusion q3w and then carboplatin IV q3w (on Day 1 of every 3-week cycle) to achieve an initial target area under the curve (AUC) of 6 milligrams per milliliter\*minute (mg/mL\*min) until disease progression or unacceptable toxicity.
62619151|NCT01633970|EXPERIMENTAL|D: Atezolizumab + Carboplatin + Pemetrexed|Participants will receive atezolizumab 1200 mg IV infusion q3w in combination with premetrexed 500 mg/m\^2 IV infusion q3w and then carboplatin IV q3w (on Day 1 of every 3-week cycle) to achieve an initial target AUC of 6 mg/mL\*min until disease progression or unacceptable toxicity.
62619152|NCT01633970|EXPERIMENTAL|E: Atezolizumab + Carboplatin + Nab-paclitaxel|Participants will receive atezolizumab 1200 mg IV infusion q3w (on Day 1 of every 3-week cycle) in combination with nab-paclitaxel 100 mg/m\^2 IV infusion once weekly (qw) (on Days 1, 8 and 15 of every 3-week cycle) and then carboplatin IV infusion q3w (on Day 1 of every 3-week cycle) to achieve an initial target AUC of 6 mg/mL\*min until disease progression or unacceptable toxicity.
62619153|NCT01633970|EXPERIMENTAL|F: Atezolizumab + Nab-paclitaxel|Participants will receive atezolizumab 800 mg IV infusion q2w (Days 1 and 15) in combination with nab-paclitaxel 125 mg/m\^2 IV infusion qw (on Days 1, 8 and 15 of every 3-week cycle) until disease progression or unacceptable toxicity.
62262726|NCT00914927|EXPERIMENTAL|1|
62262727|NCT00914927|EXPERIMENTAL|2|
62619154|NCT01897519|EXPERIMENTAL|Arm 1 lower dose ABT-719|
62619155|NCT01897519|EXPERIMENTAL|Arm 2 intermediate dose ABT-719|
62262728|NCT00914927|PLACEBO_COMPARATOR|3|
62262729|NCT04759976|EXPERIMENTAL|Robotic motor training|Participants will perform motor tasks (i.e. movements) with upper limb robotic devices applying different strategies (e.g. supporting or challenging the subject, or being fully compliant).
62262730|NCT05073497|EXPERIMENTAL|Experimental Group|One minute before the procedure the children in the experimental group will start to play with finger puppets under the direction of the researcher. The researcher will continue to distract the child's attention during the procedure with finger puppets.
62262731|NCT05073497|NO_INTERVENTION|Control Group|No intervention will perform to reduce pain in the control group.
62262732|NCT01748279|ACTIVE_COMPARATOR|Atorvastatin|40 mg of Atorvastatin once daily as add-on to Formoterol only 12 weeks therapy.
62262733|NCT01748279|PLACEBO_COMPARATOR|Lactose tablet|One tablet taken once a day as add-on treatment to Formoterol baseline 12 weeks therapy.
62262734|NCT04066582||Experimental|Suspected skin inflammations or skin tumors
62262735|NCT00982085||Soldiers|Soldiers: The soldiers who respond the questionnaires
62619156|NCT01897519|EXPERIMENTAL|Arm 3 high dose ABT-719|
62059134|NCT06111339|EXPERIMENTAL|Ketamine|This arm will receive ketamine (n=25)
62845058|NCT01757249|NO_INTERVENTION|Group 2 Control|Control Group - no intervention
62447174|NCT03395821|ACTIVE_COMPARATOR|Conventional training|Residents will receive the traditional training for laparoscopic surgery according to their residency program.
62059135|NCT06111339|PLACEBO_COMPARATOR|Saline Placebo|This arm will receive the saline placebo (n=25)
62059136|NCT01822938|EXPERIMENTAL|effects of a incentive program for physical activity|The aim of the study is the assessment of the effects of a incentive program for physical activity on people following/with stroke
62059137|NCT01822938|NO_INTERVENTION|control group|No intervention
62059138|NCT01960725|ACTIVE_COMPARATOR|Standard Dosing Group|Group will receive RV5 vaccine at 2, 4, and 6 months of age
62059139|NCT01960725|EXPERIMENTAL|Alternate Dosing Group|Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
62059140|NCT01975155||Celiac|patients with celiac disease filling the questionnaire and undergoing urinary test
62059141|NCT01975155||healthy controls|healthy patients filling the questionnaire and undergoing urinary test
62059142|NCT03319511|ACTIVE_COMPARATOR|paravertebral group|ultrasound guided, in sitting position, or lateral position, at T2 and T4 levels, using 22 G spinal needle, in plane technique, traversing the costo-transverse ligament
62059143|NCT03319511|EXPERIMENTAL|spinal group|Ultrasound guided, In the lateral decubitus or sitting position, the puncture performed via para-median approach, at the T4-T5 or T5-T6 interspace, with a 27G spinal needle. After piercing the ligamentum flavum, the needle's stylet removed and the hub observed for free flow of CSF; injection when there is a flow of clear CSF.
62059144|NCT05347901||Health Control|Health children with age and sex paired with experimental group
62059145|NCT05347901||Kawasaki Disease|KD patients, with no congenital heart disease, metabolic disease or Immune deficiency disease.
62059146|NCT01036022|EXPERIMENTAL|Group 2|ASACOL 800mg t.i.d.
62059147|NCT01036022|EXPERIMENTAL|Group 1|GSK1399686 at 3-4 dose levels
62619157|NCT01897519|PLACEBO_COMPARATOR|Arm 4 Placebo|
62619158|NCT01842906|EXPERIMENTAL|Theravent|A singe use, disposable, positive end expiratory pressure device worn over the nostrils while sleeping.
62845059|NCT04030117|EXPERIMENTAL|ACTIVA Test arm|Treatment of decay in Class II second primary molars using ACTIVA restorative material.
62619159|NCT01842906|SHAM_COMPARATOR|Control|A visibly identical sham device that does not provide positive end expiratory pressure.
62619160|NCT05435560|EXPERIMENTAL|Dexmedetomidine|During the imaging scan subjects will receive an initial 1µg/kg bolus of dexmedetomidine up to a maximum dose of 80 µg, infused through IV over 10 minutes. After the bolus has been administered, a constant infusion of up to 0.6 µg/kg/hr (0.01 µg/kg/min) of dexmedetomidine will be maintained for the remainder of the scan (about 60 minutes).
62619161|NCT05435560|PLACEBO_COMPARATOR|Saline|A saline infusion will be used as a placebo comparator for the dexmedetomidine infusion. It will be administered in the same manner and dosages as the dexmedetomidine.
62619162|NCT06344117||Controls|patients without evidence of Aspergillus colonization or Aspergillus related disease
62619163|NCT06344117||Colonised Aspergillus|patients with Aspergillus colonization
62845060|NCT04030117|ACTIVE_COMPARATOR|Compomer Comparator arm|Treatment of decay in Class II second primary molars using compomer restorative material.
62845061|NCT03198507|EXPERIMENTAL|RHB-105|RHB-105 is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin, Omeprazole and Rifabutin; as well as separate Riboflavin
62845062|NCT03198507|ACTIVE_COMPARATOR|Active Comparator|Active comparator is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin and Omeprazole; as well as separate Riboflavin
62845063|NCT05349799|EXPERIMENTAL|TEOSYAL RHA® 1|"Subjects injected with TEOSYAL RHA® 1 during the skin beautification phase, not further treated with TEOSYAL® PureSense Redensity 1 during the skin redensification phase."
62059148|NCT01036022|EXPERIMENTAL|Group 3|Placebo
62059149|NCT02949921|EXPERIMENTAL|"Grade 4 Hands group"|"Grade 4 Hands group will be subjects with hand grading of grade 4 (very severe loss of fatty tissue, marked visibility of veins and tendons in the dorsal hand). Grade 4 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 4 Hands group can have up to three retreatments over an 18 month period."
62059150|NCT02949921|EXPERIMENTAL|"Grade 2 or 3 Hands group"|"Grade 2 or 3 Hands group will be subjects with hand grading of grade 2 or grade 3 (moderate to severe loss of fatty tissue, mild to moderate visibility of veins and tendons in the dorsal hand). Grade 2 or 3 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 2 or 3 Hands group can have up to three retreatments over an 18 month period."
62059151|NCT03536364|EXPERIMENTAL|Prediabetes|manipulation of food order during a meal on postprandial in subjects with prediabetes
62059152|NCT05149092|PLACEBO_COMPARATOR|Placebo (casein protein supplement)|
62059153|NCT05149092|ACTIVE_COMPARATOR|Chicken protein hydrolysate supplement|
62059154|NCT02125448||Resectable esophageal cancer|Neoadjuvant chemoradiotherapy. MRI and PET-CT.
62059155|NCT04334239||Intervention|Cancer patients who have undergone substantial parts of inpatient treatment in a certified cancer centre.
62059156|NCT04334239||Control|Cancer patients who have not undergone inpatient treatment in a certified cancer centre.
62059157|NCT00160420|EXPERIMENTAL|1|
62059158|NCT00175344|EXPERIMENTAL|A|Arm A: Self-administered massage of the postoperative scar after breast cancer surgery.
62262736|NCT02965521|EXPERIMENTAL|Intervention|Participants will be given print material on diet for cancer survivors and access to a web-based dietary intervention with text messaging for 12 weeks.
62619164|NCT06344117||Invasive Aspergillus|patients with proven or probably IA
62845064|NCT05349799|EXPERIMENTAL|TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 with a needle|"Subjects injected with TEOSYAL RHA® 1 during the skin beautification phase, further treated with TEOSYAL® PureSense Redensity 1 using a needle during the skin redensification phase."
62262737|NCT02965521|NO_INTERVENTION|Control|Participants randomized to the control arm will receive print materials on diet for cancer survivors. After completion of their 12-week follow-up assessments, control participants will be given access to the web-based dietary intervention with text messaging for 12 weeks.
62619165|NCT05326256|EXPERIMENTAL|PSSE Group|Physiotherapy Scoliosis Specific Exercises (PSSE), 45-minute exercise session with the supervisor, twice a week for 12 weeks
62619166|NCT05326256|EXPERIMENTAL|Vestibular Exercise Group|Vestibular exercises to be added to PSSE exercises, 45-minute exercise session with the supervisor, twice a week for 12 weeks
62619167|NCT03340467|EXPERIMENTAL|CGM patch|Patient receives four models of CGM patches. Adhesion sites are randomly allocated (1 on each upper arm, 2 on the abdomen).
62619168|NCT00815503|ACTIVE_COMPARATOR|Ropivacaine|
62619169|NCT00815503|PLACEBO_COMPARATOR|Saline|
62845065|NCT05349799|EXPERIMENTAL|TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 with a cannula|"Subjects injected with TEOSYAL RHA® 1 during the skin beautification phase, further treated with TEOSYAL® PureSense Redensity 1 using a cannula (optional for perioral lines) during the skin redensification phase."
62845066|NCT03565094|EXPERIMENTAL|Lu AF28996|"Lu AF28996 solution, cohort depending dose~Part A:~Cohort 1: single oral dose of Lu AF28996~Cohorts 2-6: two single ascending oral doses of Lu AF28996 with a washout in between~Possibility of 4 additional cohorts (Cohorts 7 to 10), allowing for the investigation of a potential 13 additional subjects~Part B: 8 subjects (randomised to one of four treatment sequences)"
62262738|NCT03341962|EXPERIMENTAL|10 mg IMU-838 (Induction)|"Two 5 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.~Patients will receive only half of their assigned full dose during the first week of treatment."
62262739|NCT03341962|EXPERIMENTAL|30 mg IMU-838 (Induction)|"Two 15 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.~Patients will receive only half of their assigned full dose during the first week of treatment."
62447175|NCT03395821|EXPERIMENTAL|Virtual Reality+conventional training|Residents will receive 12 weeks of virtual training for laparoscopy and their traditional training for laparoscopic surgery according to their residency program.
62619170|NCT05682729|EXPERIMENTAL|Size to Number|
62619171|NCT05682729|EXPERIMENTAL|Mixed|
62845067|NCT05350397|EXPERIMENTAL|Acupressure group|The patients in the intervention group were informed about what acupressure was and why it was applied. An acupressure wristband was correctly worn on both wrists to provide patients with adequate pressure on the HT7 point for 5 minutes
62262740|NCT03341962|EXPERIMENTAL|45 mg IMU-838 (Induction)|"Two 22.5 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.~Patients will receive only half of their assigned full dose during the first week of treatment."
62262741|NCT03341962|PLACEBO_COMPARATOR|placebo (Induction)|The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging.
62262742|NCT03341962|EXPERIMENTAL|10 mg IMU-838 (Maintenance)|Two 5 mg tablets once daily of IMU-838 until Week 50 or ulcerative colitis relapse.
62262743|NCT03341962|EXPERIMENTAL|30 mg IMU-838 (Maintenance)|Two 15 mg tablets once daily of IMU-838 until Week 50 or ulcerative colitis relapse.
62262744|NCT03341962|PLACEBO_COMPARATOR|placebo (Maintenance)|The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. Patients who have received placebo during the induction phase will be 're-randomized' to continue to receive placebo (in a blinded fashion).
62262745|NCT03341962|EXPERIMENTAL|30 mg IMU-838 (Open-label)|Two 15 mg tablets once daily of IMU-838 or one 30 mg tablet IMU-838 once daily for up to 10 years and up to 3 years in UK sites
62262746|NCT00911352|EXPERIMENTAL|Frozen gel glove (Elasto-Gel Mitten)|Cryotherapy hand
62262747|NCT00911352|NO_INTERVENTION|No frozen glove therapy|Usual care
62262748|NCT05530265|EXPERIMENTAL|Smart watch group|The user of the smart watch and Samsung Health app
62447176|NCT00208949|ACTIVE_COMPARATOR|G-CSF(Granulocyte Colony-Stimulating Factor )|Single use of G-CSF(Granulocyte Colony-Stimulating Factor ) G-CSF 7.5 µg/kg twice a day
62447177|NCT00208949|ACTIVE_COMPARATOR|Granulocyte CSF+Granulocyte Macrophage CSF|Combined use of G-CSF(Granulocyte Colony-Stimulating Factor ) and GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) (G-CSF 7.5 µg/kg / GM-CSF 7.5 µg/kg.)
62447178|NCT03996603|EXPERIMENTAL|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
62447179|NCT03996603|NO_INTERVENTION|Control Cohort|No intervention will be given.
62447180|NCT00679523|EXPERIMENTAL|Group 1|AN2690 Solution, 5.0%
62619172|NCT05682729|ACTIVE_COMPARATOR|Traditional Counting|
62619173|NCT05682729|PLACEBO_COMPARATOR|Non-Numerical Control|
62619174|NCT03187717||TIVA (Total intravenous anesthesia)|Group TIVA; patients who used intravenous anesthesia procedure
62845068|NCT05350397|PLACEBO_COMPARATOR|Placebo Group|Patients in the placebo group were informed about what acupressure was and why it was applied. In order not to apply pressure to the Shenmen (HT7) pressure point in the patients in this group, the acupressure wristband was placed on both wrists in an inverted and loose manner and the wristband was worn for 5 minutes, the procedure was completed.
62845069|NCT05350397|NO_INTERVENTION|Control group|No procedure was applied to the patients in the control group. The patients received routine treatment and care.
62262749|NCT05530265|NO_INTERVENTION|Usual care|No use of both the smart watch and Samsung Health app
62262750|NCT05530603|EXPERIMENTAL|Intervention|Participants are randomized to interventional arm which is seven-day intervention that requires them to download mobile app to complete educational courses each day. There are pre and post tests to complete and a follow up focus group six month after intervention. The intervention encourages education on mammogram needs.
62619175|NCT03187717||IA (Inhalation anesthesia)|Group IA; patients who used inhalation anesthesia procedure
62059159|NCT06625424|EXPERIMENTAL|Interventional group|"Participants in this group will perform short sprint interval training on a flat running track in field. Each lane will be materialized by placing cones 5 m from each other for a total of 30 m on which Subject will perform Short Sprint Interval Training.~The instructions will be to travel the greatest distance possible in 10 seconds, making trips of 5, 10, 15 m, etc.~Participants of this group will opt for 1 minute of active recovery i.e. they will perform brisk walk between 6 bouts of 10 sec sprint.~The duration of the training will be of 2 weeks."
62059160|NCT06625424|ACTIVE_COMPARATOR|Control group|"Patients will Participants in this group will perform short sprint interval training on a flat running track in field. Each lane will be materialized by placing cones 5 m from each other for a total of 30 m on which Subject will perform Short Sprint Interval Training.~The instructions will be to travel the greatest distance possible in 10 seconds, making trips of 5, 10, 15 m, etc.~Participants of this group will opt for 1 minute of passive recovery i.e. they will stay stationary between 6 bouts of 10 sec sprint.~The duration of the training will be of 2 weeks."
62059161|NCT03075592||ERCP candidates|ERCP candidates
62059162|NCT02162680|ACTIVE_COMPARATOR|lidocaine|1% lidocaine intradermal injection
62059163|NCT02162680|ACTIVE_COMPARATOR|bacteriostatic normal saline (BNS)|bacteriostatic normal saline (BNS) injection
62059164|NCT02162680|NO_INTERVENTION|no local anesthetic|usual care practice of no local anesthetic administration
62059165|NCT04557839|ACTIVE_COMPARATOR|Traditional physical therapy balance exercise|Traditional physical therapy including balance exercise on mate and swiss ball.
62059166|NCT04557839|EXPERIMENTAL|proprioception based balance training|proprioception based balance training with eye open and close on soft , firm and foam surface.
62059167|NCT01257464|ACTIVE_COMPARATOR|Sitagliptin|
62059168|NCT01257464|PLACEBO_COMPARATOR|Placebo|
62059169|NCT02799186|EXPERIMENTAL|SCAD (spontaneous coronary artery dissection)|Every patient included with a SCAD or hematoma, will systematic benefit a tomographic or MRI angiography of renal, cerebrovascular and iliac arteries, to look for the presence of a fibromuscular displasia. A blood sample will be collected for the genetic analysis which will be realized by the Team 3 of the INSERM UMR970, Paris Cardiovascular research Center, France.
62059170|NCT05282290|EXPERIMENTAL|Experimental group|"1. Lower systolic blood pressure to 90-110 mm Hg.~2. Blood pressure not lower than 90/60 mm Hg~3. Hypotensive maintenance treatment for 48 hours."
62059171|NCT05282290|ACTIVE_COMPARATOR|The control group|"1. Subjects with basic blood pressure(BBP) \> 140/90 mm Hg should have BBP lowered to about 140/90 mm Hg.~2. Subjects whose BBP was less than 140/90mm Hg were kept BBP."
62059172|NCT00697190|ACTIVE_COMPARATOR|senofilcon A/galyfilcon A|senofilcon A silicone hydrogel toric contact lenses will be worn first. galyfilcon A silicone hydrogel toric contact lenses will be worn second.
62059173|NCT00697190|ACTIVE_COMPARATOR|galyfilcon A/senofilcon A|galyfilcon A silicone hydrogel toric contact lenses worn first. senofilcon A silicone hydrogel toric contact lenses worn second.
62059174|NCT01471132|EXPERIMENTAL|HIPEC|
62262751|NCT05530603|NO_INTERVENTION|Control|Participants are randomized to control arm where they are give an education brochure. There are pre and post tests to complete.
62262752|NCT02845570|EXPERIMENTAL|68Ga-DOTANOC PET/MRI|Comparison between 68Ga-DOTANOC PET/MRI and 18F-FDG PET/MRI scans
62262753|NCT00650702|EXPERIMENTAL|1|Low Latanoprost-PPDS
62262754|NCT00650702|EXPERIMENTAL|2|Medium Latanoprost-PPDS
62262755|NCT00650702|EXPERIMENTAL|3|High Latanoprost-PPDS
62262756|NCT04788121|ACTIVE_COMPARATOR|Treatment/Tranexamic Acid Group|The treatment group will receive Injection TXA 1gm intravenous (IV) over 15 minutes infusion dissolved in 100 ml normal saline (NS- 0.9% NaCl), followed by injection TXA 2 g IV over 12 hours infusion dissolved in a 500 ml NS.
62059175|NCT01933035||Immune Thrombocytopenics|The study shall be a single institution prospective cohort study. Comparison will be made among individuals with known ITP . Those with known hypo-proliferative forms of thrombocytopenia \[aplastic anaemia, chemotherapy induced thrombocytopenia, and myelodysplastic thrombocytopenia, and a control population.
62059176|NCT01933035||Hypo-proliferative thrombocytopenics|The study shall be a single institution prospective cohort study. Comparison will be made between individuals with known ITP versus those with known hypo-proliferative forms of thrombocytopenia \[aplastic anaemia, chemotherapy--induced thrombocytopenia, and myelodysplastic thrombocytopenia\], and a control population.
62059177|NCT01933035||Control Pupulation|comprised of healthy individuals with normal platelet counts, to confirm normal values for MPC and MPM
62059178|NCT05747339|EXPERIMENTAL|Tumor treatment vaccine for patients with advanced solid tumors|Tumor treatment vaccine(TTV) would be given deep subcutaneously in the arm or near the tumor.The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62059179|NCT06625970|OTHER|Arm A (Standard arm)|ADT + conventional fractionated or moderately hypo-fractionated prostate radiotherapy including pelvic nodal radiotherapy
62059180|NCT06625970|EXPERIMENTAL|Arm B (Experimental arm):|ADT + conventional fractionated or moderately hypo-fractionated prostate radiotherapy including pelvic nodal radiotherapy + darolutamide
62059181|NCT06625970|EXPERIMENTAL|Arm C (Experimental arm):|ADT + conventional fractionated or moderately hypo-fractionated pelvic nodal radiotherapy + Prostate SBRT
62059182|NCT06625970|EXPERIMENTAL|Arm D (Experimental arm):|ADT + conventional fractionated or moderately hypo-fractionated pelvic nodal radiotherapy + Prostate SBRT + darolutamide
62059183|NCT06029894|EXPERIMENTAL|Treatment Group|Participants with MCI will receive dietary citicoline supplements.
62059184|NCT06029894|PLACEBO_COMPARATOR|Placebo|Participants with MCI will receive a placebo supplement.
62059185|NCT04034394|EXPERIMENTAL|Electromoxibustion|Participants in this group will receive electromoxibustion using a knee-brace-like device which produces thermal stimulation with a moxa pad inside (Fort Mayer, Guangzhou, China).
62059186|NCT04034394|ACTIVE_COMPARATOR|Knee health education|Participants in this group will attend 2 sessions (120 minutes each, 1-week apart) of health education related to knee OA symptom management.
62059187|NCT05613114|EXPERIMENTAL|Medication|Dalfampridine plus physiotherapy
62059188|NCT05613114|PLACEBO_COMPARATOR|No Medication|Placebo plus physiotherapy
62059189|NCT00800280|EXPERIMENTAL|Single dose PD 0332334|
62059190|NCT00800280|EXPERIMENTAL|Single dose PD 0332334 with steady-state cimetidine|
62059191|NCT02357004|EXPERIMENTAL|Carvedilol|Carvedilol CR 40 mg daily in addition to their normal BP medications. Subjects will be seen in follow-up at 2-week intervals for the duration of the 8-week intervention period. If the clinic BP remains elevated (\>140/90 mmHg) at any of the follow-up visits, the study medication will be titrated up to carvedilol CR 80 mg daily (subjects will take 2 of the study pills).
62059192|NCT02357004|EXPERIMENTAL|Chlorthalidone|Chlorthalidone 12.5 mg daily in addition to their normal BP medications. Subjects will be seen in follow-up at 2-week intervals for the duration of the 8-week intervention period. If the clinic BP remains elevated (\>140/90 mmHg) at any of the follow-up visits, the study medication will be titrated up to chlorthalidone 25 mg daily (subjects will take 2 of the study pills).
62059193|NCT03113084|EXPERIMENTAL|Group Sodium Heparin UQ First|The participants will receive the Sodium heparin UQ subcutaneous drug administration at first period and the Sodium heparin FK subcutaneous drug administration at second period
62059194|NCT03113084|EXPERIMENTAL|Group Sodium Heparin FK First|The participants will receive the Sodium heparin FK subcutaneous drug administration at first period and the Sodium heparin UQ subcutaneous drug administration at second period
62262757|NCT04788121|PLACEBO_COMPARATOR|Control Group|The control group will receive injection 100 ml NS over 15 minutes infusion, followed by injection 500 ml NS over 12 hours infusion.
62262758|NCT04618159|OTHER|Helipyl|helipyl wil be given to 10 children with asymptomatical helicobacter pylori infection
62262759|NCT00075400|EXPERIMENTAL|Treatment (imatinib mesylate)|Patients receive imatinib mesylate PO QD or BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62262760|NCT00542256|ACTIVE_COMPARATOR|1|Each subject will receive 14 days (2 week period: 10 weekdays and 2 weekends) of constraint induced movement therapy. In addition, on the 10 weekdays during the treatment period, the subjects will come into the laboratory and receive up to 6 hours per day of training of the affected arm in a variety of tasks. At the beginning of each of the 10 weekday training sessions, participants will receive 40 minutes of active tDCS over the primary motor cortex.
62447181|NCT00679523|EXPERIMENTAL|Group 2|AN2690 Solution, 7.5%
62447182|NCT00182091|ACTIVE_COMPARATOR|AcroGHD Randomized to Growth Hormone|Subjects with a history of acromegaly who are now growth hormone deficient, randomized to growth hormone. This is an interventional arm.
62447183|NCT00182091|PLACEBO_COMPARATOR|AcroGHD Randomized to Placebo|Subjects with a history of acromegaly who are now growth hormone deficient, randomized to placebo. This is an interventional arm.
62262761|NCT00542256|SHAM_COMPARATOR|2|Each subject will receive 14 days (2 week period: 10 weekdays and 2 weekends) of constraint induced movement therapy. In addition, on the 10 weekdays during the treatment period, the subjects will come into the laboratory and receive up to 6 hours per day of training of the affected arm in a variety of tasks. At the beginning of each training day tDCS will be applied for 40 minutes with the current active for only 30 seconds over the primary motor cortex.
62262762|NCT05432882|EXPERIMENTAL|bi-4SCAR-CD19/22 T Cell Therapy for CD19 and/or CD22 positive B cell malignancies|
62262763|NCT01250600|EXPERIMENTAL|Remote-care|Home exercise monitored by the remote care system
62262764|NCT01250600|ACTIVE_COMPARATOR|Control|Home exercise under expert's instruction
62262765|NCT01610180|OTHER|Eltrombopag Olamine|Eltrombopag Olamine Initial dose 50 mg/day for 14 days. Then adjusted according to platelet count
62262766|NCT00821080|EXPERIMENTAL|Vandetanib and Sirolimus|Single arm study
62262767|NCT05775471|EXPERIMENTAL|Treatment (pembrolizumab, enfortumab vedotin)|Patients receive pembrolizumab IV and enfortumab vedotin IV on study. Patients undergo radical nephroureterectomy and receive pembrolizumab IV on study Patients also undergo MRU imaging and undergo blood, urine and tissue sample collection throughout the study.
62262768|NCT03284671|EXPERIMENTAL|bifocal stimulation|Transcranial direct current Bifocal stimulation
62262769|NCT02263898|EXPERIMENTAL|Treatment (LGX818, MEK162)|Patients receive LGX818 PO QD and MEK162 PO BID continuously for 8 weeks followed by intermittent dosing in subsequent cycles (3 weeks off therapy, 5 weeks on therapy). Cycles repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
62262770|NCT03615196|EXPERIMENTAL|USB005 0.03%|USB005 (aclerastide) Ophthalmic Solution 0.03%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
62262771|NCT03615196|EXPERIMENTAL|USB005 0.1%|USB005 (aclerastide) Ophthalmic Solution 0.1%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
62262772|NCT03615196|EXPERIMENTAL|USB005 0.3%|USB005 (aclerastide) Ophthalmic Solution 0.3%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
62262773|NCT03615196|EXPERIMENTAL|USB005 0.45%|USB005 (aclerastide) Ophthalmic Solution 0.45%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
62262774|NCT03615196|PLACEBO_COMPARATOR|USB005 Placebo|USB005 Ophthalmic Solution Placebo; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
62262775|NCT01278745|EXPERIMENTAL|Rituximab|Rituximab induction/conventional immunosuppression
62262776|NCT01278745|PLACEBO_COMPARATOR|Rituximab Placebo|Rituximab Placebo / conventional immunosuppression
62262777|NCT04458298|EXPERIMENTAL|Stage I: Cohort A: OP-101 2 mg/kg|Participants will receive a single intravenous (IV) infusion of OP-101 2 milligram per kilogram (mg/kg) on Day 1.
62262778|NCT04458298|EXPERIMENTAL|Stage I: Cohort B: OP-101 4 mg/kg|Participants will receive a single IV infusion of OP-101 4 mg/kg on Day 1.
62262779|NCT04458298|EXPERIMENTAL|Stage I: Cohort C: OP-101 8 mg/kg|Participants will receive a single IV infusion of OP-101 8 mg/kg on Day 1.
62262780|NCT04458298|PLACEBO_COMPARATOR|Stage I: Cohort D: Placebo|Participants will receive a single IV infusion of matching placebo on Day 1.
62262781|NCT04458298|EXPERIMENTAL|Stage II: Cohort E: OP-101 8 mg/kg|Participants will receive a single IV infusion of OP-101 8 mg/kg on Days 1 and 4.
62619176|NCT05415514|OTHER|Instrumented assessment of muscle function|During the instrumented evaluations, the investigators will evaluate the possibility of measuring the passive and active function of the muscle using: - an isokinetic dynamometer, an ultrasound and elastography device, an electrical stimulation of the calf nerve
62262782|NCT04458298|PLACEBO_COMPARATOR|Stage II: Cohort F: Placebo|Participants will receive a single IV infusion of matching placebo on Days 1 and 4.
62262783|NCT05412056|ACTIVE_COMPARATOR|Metformin|Metformin will be prescribed before 20 weeks to 33+6 weeks, started at a daily dose of 500mg in the first week, and the daily dose is increased by 500mg per week to a maximum of 2000mg in week 4 (1000mg twice per day). Women will be asked to take the maximum tolerated dose if they experience side effects from the medication.
62262784|NCT05412056|PLACEBO_COMPARATOR|Placebo|Placebo will be prescribed before 20 weeks to 33+6 weeks, started at a daily dose of 1 tablet in the first week, and the daily dose is increased by 1 tablet per week to a maximum of 4 tablets in week 4 (2 tablets twice per day). Women will be asked to take the maximum tolerated dose if they experience side effects from the medication.
62262785|NCT00381342|EXPERIMENTAL|Exenatide 5 mcg/exenatide 5 mcg|Exenatide 5 mcg; then exenatide 5 mcg
62262786|NCT00381342|EXPERIMENTAL|Exenatide 5 mcg/exenatide 10 mcg|Exenatide 5 mcg, then exenatide 10 mcg
62262787|NCT00381342|PLACEBO_COMPARATOR|Placebo|Placebo in volumes equivalent to exenatide
62262788|NCT03007056||Period 1|year 2011 nCPAP
62262789|NCT03007056||Period 2|year 2014 nCPAP and high flow nasal cannula
62262790|NCT05020873||Crizanlizumab|Patients initiated on treatment with commercially available crizanlizumab
62262791|NCT01803984||Patient with migraine with aura|Patients with a clearly defined migraine (as per IHS criteria) with aura, who are aged 30 and older and are able to fluently speak French.
62447184|NCT00182091|NO_INTERVENTION|AcroGHS|
62619177|NCT00415324|EXPERIMENTAL|Arm 1|Patients receive eribulin mesylate IV over 5 minutes on days 1, 8, and 15 and cisplatin IV over 30-60 minutes on day 1.
62619178|NCT06337227||atherosclerosis and calcific aortic stenosis with diabetes patients|
62619179|NCT06337227||atherosclerosis and calcific aortic stenosis without diabetes patients|
62059195|NCT04410289|EXPERIMENTAL|Intervention Group|After induction of general anesthesia, and prior to direct laryngoscopy, patients in the intervention group were positioned using props horizontally aligning the external auditory meatus (EAM) with the sternal notch (SN) and the chin with the sinciput. A lateral side-profile photograph was taken for latter analysis and an Intubation Difficulty Scale (IDS) score card completed.
62262792|NCT01803984||Patient with migraine without aura|patients with a clearly defined migraine (as per IHS criteria) without aura who are aged 30 and older, are able to fluently speak French, and who are willing to participate
62059196|NCT04410289|ACTIVE_COMPARATOR|Control Group|After induction of general anesthesia, and prior to direct laryngoscopy, patients in the control group were positioned freely according to the provider's preference. A lateral side-profile photograph was taken for latter analysis and an Intubation Difficulty Scale (IDS) score card completed.
62262793|NCT01602770||Group 1|Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
62262794|NCT03799250|EXPERIMENTAL|Goal Directed Hemodynamic Therapy|"The GDT (Goal Directed Therapy) group will not receive any maintenance fluid. Fluid boluses will be given according to the flowchart attached.~Baseline MAP and HR will be measured in the pre-anesthetic clinic or if not available will be recorded according to community medical record.~Measurements of hemodynamic variables including heart rate and automatic non-invasive blood pressure measurements as well pulse oximetry as routine procedures will be recorded and stored by Metavision system (iMDsoft company) at regular intervals, all according to standard clinical practice.~Blood gases measurement will be performed upon admission and at discharge. Urine output will be measured and recorded every hour.~Other laboratory exams will be taken based on the physician discretion unrelated to the participation in the study."
62262795|NCT03799250|ACTIVE_COMPARATOR|Control Group|The control group will receive standard care which includes fluid maintenance program as dictated by the operating room anesthesiologist and as needed boluses through the PACU (Post Anesthesia Care Unit) stay.
62262796|NCT04670614|OTHER|Nerve Block Procedure|Supra-orbital and Infra-orbital peripheral nerve blocks with 0.5% ropivicaine
62059197|NCT03893201||Venaseal|Patients that have undergone venaseal
62059198|NCT03983122|EXPERIMENTAL|Study group|Patients who undergo laparoscopic sleeve gastrectomy
62059199|NCT03629652|EXPERIMENTAL|Head down position|head-down position treatment combined with conventional rehabilitation.
62059200|NCT03629652|SHAM_COMPARATOR|Conventional Rehabilitation|Conventional rehabilitation treatment
62059201|NCT05673876|EXPERIMENTAL|GDC-8264, 35 mg|Participants will receive oral GDC-8264, 35 milligrams (mg), once daily (QD) for 28 days.
62059202|NCT05673876|EXPERIMENTAL|GDC-8264, 75 mg|Participants will receive oral GDC-8264, 75 mg, PO, QD for 28 days.
62059203|NCT03874845|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy|Participants will have 8 weeks of group therapy and will be asked to do MBCT exercises for approximately 20-30 minutes on 5 or more days/week.
62059204|NCT03874845|ACTIVE_COMPARATOR|Muscle Relaxation Therapy (MRG)|Participants will have 8 weeks of group therapy participants and will be asked to do MRG exercises for approximately 20-30 minutes on 5 or more days/week.
62262797|NCT04670614|SHAM_COMPARATOR|Placebo sham control|sham control 0.9% Normal Saline
62059205|NCT05599802|EXPERIMENTAL|1A: 50μg SARS-CoV-2 variant mRNA vaccine|Participants who have not received any COVID-19 vaccines will vaccinate two doses of study vaccine with 28 days apart.
62059206|NCT05599802|EXPERIMENTAL|1B: 100μg SARS-CoV-2 variant mRNA vaccine|Participants who have not received any COVID-19 vaccines will vaccinate two doses of study vaccine with 28 days apart.
62059207|NCT05599802|EXPERIMENTAL|2A: 50μg SARS-CoV-2 variant mRNA vaccine|Participants who have received 2 dose of COVID-19 inactivated vaccines will vaccinate 1 doses of study vaccine.
62059208|NCT05599802|EXPERIMENTAL|2B: 100μg SARS-CoV-2 variant mRNA vaccine|Participants who have received 2 dose of COVID-19 inactivated vaccines will vaccinate 1 doses of study vaccine.
62059209|NCT05599802|EXPERIMENTAL|3A: 50μg SARS-CoV-2 variant mRNA vaccine|Participants who have received 2 dose of COVID-19 mRNA vaccines will vaccinate 1 doses of study vaccine.
62619180|NCT06337227||Patients without atherosclerosis undergoing surgical procedure for endocarditis|
62059210|NCT05599802|EXPERIMENTAL|3B: 100μg SARS-CoV-2 variant mRNA vaccine|Participants who have received 2 dose of COVID-19 mRNA vaccines will vaccinate 1 doses of study vaccine.
62059211|NCT04587128|EXPERIMENTAL|Cohort A: No Previous EGFR|"Participant who have not be previously exposed to anti-EGFR therapies and are in the first or second-line metastatic treatment setting.~Panitumumab (6mg/kg) or Cetuximab 500mg (per treating physician) on day 1 and 15 of a 28-day cycle"
62059212|NCT04587128|EXPERIMENTAL|Cohort B: Retreatment|"Participants with treatment refractory disease who have previously benefitted (greater than or equal to 4 months ago) from anti-EGFR therapy.~Panitumumab (6mg/kg) or Cetuximab 500mg (per treating physician) on day 1 and 15 of a 28-day cycle, +/- Irinotecan (180mg/m\^2) every 2 two weeks per standard of care"
62059213|NCT04587128|EXPERIMENTAL|Cohort C: Rechallenge|"Participants with prior FOLFOX and either no prior EGFR inhibitor or treated on Cohort A.~Alternating Panitumumab (6mg/kg) or Cetuximab 500mg (per treating physician) and 4 cycles of FOLFIRI +/- bevacizumab"
62059214|NCT03083535|ACTIVE_COMPARATOR|Tooth Brushing|Tooth brushing with dentifrice and standardized tooth brush
62059215|NCT03083535|EXPERIMENTAL|Aloe vera massaging|Tooth brushing with dentifrice and standardized tooth brush followed by massaging with aloe vera gel
62059216|NCT03083535|EXPERIMENTAL|SRP with aloe vera massaging|Scaling and root planning was done with ultrasonic scalar. It was followed by aloe vera massaging on half arch for 3 minutes daily
62059217|NCT00738686|EXPERIMENTAL|1|Single-arm study, no placebo or control group
62059218|NCT02246335|ACTIVE_COMPARATOR|Control group|Hemiarthroplasty
62262798|NCT02676492||Tic Disorder|Boys with a diagnosis of Tourette Syndrome (TS) or chronic tic disorder (CTD) aged 11-14 years
62059219|NCT02246335|ACTIVE_COMPARATOR|Treatment group|Total hip arthroplasty
62059220|NCT01622244|EXPERIMENTAL|Intervention arm|Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
62059221|NCT01622244|ACTIVE_COMPARATOR|Counseling and Resource Education (CARE)|Participants will receive care as usual in the community. In addition, participants in this arm will receive an educational session and resource guide outlining available community-based services
62059222|NCT05239988||COVID-19 patients treated with Remdesivir|Patients suffering from SARS-CoV-2 and treated with Remdesivir admitted to Internal Medicine Unit
62059223|NCT05313386|EXPERIMENTAL|Cohort 1- 120 Micrograms|"120 Micrograms film or Placebo film are given to patients in 3:1 ratio respectively.~Repeat doses may be administered in increments of 120 μg every 3 to 6 hours post first dose (StartD) only if the RASS score remains ≥ +1. For subjects 65 years and older, repeat doses may start in increments of 60 μg every 3 to 6 hours post first dose only if RASS is still ≥+1."
62059224|NCT05313386|EXPERIMENTAL|Cohort 2- 180 Micrograms|"180 Micrograms film or Placebo film are given to patients in 3:1 ratio respectively.~Repeat doses may be administered in increments of 120 μg every 3 to 6 hours post first dose (StartD) only if the RASS score remains ≥ +1. For subjects 65 years and older, repeat doses may start in increments of 60 μg every 3 to 6 hours post first dose only if RASS is still ≥+1."
62059225|NCT05313386|EXPERIMENTAL|Cohort 3- 240 Micrograms|"Two 120 Micrograms films or two Placebo films are given to patients in 3:1 ratio respectively.~Repeat doses may be administered in increments of 120 μg every 3 to 6 hours post first dose (StartD) only if the RASS score remains ≥ +1. For subjects 65 years and older, repeat doses may start in increments of 60 μg every 3 to 6 hours post first dose only if RASS is still ≥+1."
62262799|NCT02676492||Control|Boys aged 11-14 years without a diagnosis of TS/CTD (i.e. typically developing)
62262800|NCT01568398|EXPERIMENTAL|TAK-438 20 mg QD|
62262801|NCT04398875|EXPERIMENTAL|ASC|Traditional manual acupuncture with standard care (ASC) will be provided. Subjects in the ASC group will receive 9 sessions of acupuncture and standard care for 3 weeks. A semi-standardized acupuncture treatment protocol (combined fixed acupoints with additional acupoints by symptom differentiation) will be employed. The fixed acupuncture points including, Guanyuan (CV4), Xuanzhong(GB39), Sanyinjiao (SP6), Yinlingquan (SP9), Zusanli (ST36), Yingtang (EX-HN3), Baihui (GV20), and Qihai (CV6) will be used in every session.
62262802|NCT04398875|SHAM_COMPARATOR|SSC|Sham acupuncture plus standard care (SSC) will be provided. Subjects in the SSC group will receive 9 sessions of sham acupuncture and standard care for 3 weeks. The Streitberger sham acupuncture will be employed. The selection of acupoints is the same as ASC.
62262803|NCT04398875|PLACEBO_COMPARATOR|SC|Standard care alone (SC) will be provided. Subjects in the SC group will standard care for 3 weeks.
62262804|NCT06439212|EXPERIMENTAL|Ginger|"Choosing ginger as a pain analgesic is significant due to its anti-inflammatory properties. The presence of active compounds, like shogaols, suggests ginger could provide a clinically effective and safer alternative in managing intra-operative and post-endodontic pain.~Patient will receive one capsule of 500mg ginger powder capsule thrice daily for two days. First dose will be administered 1 hour before starting endodontic treatment."
62619181|NCT00548249|PLACEBO_COMPARATOR|0 µg iron/dL of dialysate|Placebo 0 micrograms (µg) of iron/ deciliter (dL) of dialysate
62619182|NCT00548249|EXPERIMENTAL|5 µg iron/dL of dialysate|5 micrograms (µg) of iron/ deciliter (dL) of dialysate
62619183|NCT00548249|EXPERIMENTAL|10 µg iron/dL of dialysate|10 micrograms (µg) of iron/ deciliter (dL) of dialysate
62619184|NCT00548249|EXPERIMENTAL|12 µg iron/dL of dialysate|12 micrograms (µg) of iron/ deciliter (dL) of dialysate
62845070|NCT00588497||Study Group|Twenty-five subjects for this study will be recruited from patients who have requested a form of permanent sterilization, and who, after considering all the options, choose the trans-cervical hysteroscopic sterilization for this end. Any subject who is deemed suitable for the micro-insert hysteroscopic sterilization system (Essure micro-insert system, Conceptus Incorporated, Mountain View, California) placement will be offered the opportunity to participate in the study.
62845071|NCT02413151|EXPERIMENTAL|Exercise Training Program|The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods.
62845072|NCT02413151|ACTIVE_COMPARATOR|Control|Regular lifestyle
62845073|NCT00635297|ACTIVE_COMPARATOR|1|50 osteoporotic patients with a vertebral insufficiency fracture will receive treatment of the vertebrae with standard vertebroplasty
62845074|NCT00635297|EXPERIMENTAL|2|50 osteoporotic patients with a vertebral insufficiency fracture will receive treatment of the vertebrae with standard vertebroplasty. The adjacent vertebrae will be treated with 3-5 ml of PMMA
62845075|NCT01994824|EXPERIMENTAL|Intervention arm|"Transplant recipients will have IL15 and IL2Ra measured on day 7. If at risk for significant GVHD, the patient will get rabbit antithymocyte globulin, 3 mg/kg on day 8.~Patients from this intervention/experimental arm will be compared to historical and concurrent controls (no ATG on day 8)."
62845076|NCT06140810||Right ventricular End diastolic pressure|Measurement of pre and post recruitment right ventricular end diastolic pressure
62845077|NCT03668301||Group CPB-T2DM|Patients with diabetes mellitus undergoing cardiac surgery with cardiopulmonary bypass
62262805|NCT06439212|PLACEBO_COMPARATOR|Placebo|Patient will receive one capsule of placebo thrice daily for two days. First dose will be administered 1 hour before starting endodontic treatment.
62447185|NCT00182091|NO_INTERVENTION|Active Acromegaly|
62845078|NCT03668301||Group OPCAB-T2DM|Patients with diabetes mellitus undergoing cardiac surgery without cardiopulmonary bypass
62845079|NCT03668301||Group CPB-C|Control patients undergoing cardiac surgery with cardiopulmonary bypass
62845080|NCT03668301||Group OPCAB-C|Control patients undergoing cardiac surgery without cardiopulmonary bypass
62845081|NCT01271296|ACTIVE_COMPARATOR|Liquorice|Liquorice eq to 150 mg glycyrrhizinic acid. Results are compared to a baseline assessment without liquorice/grapefruit juice ingestion.
62619185|NCT00548249|EXPERIMENTAL|15 µg iron/dL of dialysate|15 micrograms (µg) of iron/ deciliter (dL) of dialysate
62845082|NCT01271296|ACTIVE_COMPARATOR|Grapefruit juice|200 ml pink grapefruit juice three times a day. Results are compared to a baseline assessment without liquorice/grapefruit juice ingestion.
62845083|NCT01271296|NO_INTERVENTION|Baseline|Baseline assessment without intake of liquorice or grapefruit juice
62845084|NCT01439828|EXPERIMENTAL|Experimental : N-acetylcystein|N-acetylcystein and placebo doses will be increased if craving decreases \<25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h
62845085|NCT01439828|PLACEBO_COMPARATOR|Placebo Comparator|N-acetylcystein and placebo doses will be increased if craving decreases \<25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h
62845086|NCT00251043|EXPERIMENTAL|1|Participants will Psychotherapy weekly for 12 weeks
62845087|NCT00251043|ACTIVE_COMPARATOR|2|Parenting Education will include 45-minute weekly sessions for 12 week
62845088|NCT04110288||Uncoated Balloon Treatment|Patients treated for PAD with balloon angioplasty, without use of stent.
62845089|NCT04110288||Bare Metal Stent Treatment|Patients treated for PAD with implantation of bare metal stent.
62845090|NCT04110288||Paclitaxel Coated Balloon|Patients treated for PAD with drug coated balloon angioplasty, without use of stent.
62845091|NCT04110288||Paclitaxel Eluting Stent|Patients treated for PAD with implantation of Paclitaxel DES.
62059226|NCT05313386|EXPERIMENTAL|Cohort 4- 300 Micrograms|"One 120 Micrograms film and one 180 Micrograms film or two Placebo films are given to patients in 3:1 ratio respectively.~Repeat doses may be administered in increments of 120 μg every 3 to 6 hours post first dose (StartD) only if the RASS score remains ≥ +1. For subjects 65 years and older, repeat doses may start in increments of 60 μg every 3 to 6 hours post first dose only if RASS is still ≥+1."
62262806|NCT04031742|EXPERIMENTAL|Part 1: IBI306|Participants receive open-label IBI306 150 mg subcutaneously Q2W or 450 mg Q4W for 12 weeks.
62619186|NCT00564291||1|Healthy volunteers
62619187|NCT00564291||2|CSME secondary to diabetic retinopathy
62619188|NCT00564291||3|ARMD with CNV before and after therapy
62619189|NCT00564291||4|ARMD atrophic
62619190|NCT00564291||5|Retinal vein occlusion
62845092|NCT02250703|ACTIVE_COMPARATOR|Midazolam|In M group, patients will be given oral midazolam 0.5mg/kg upto maximum dose of 15mg (5mg/ml parenteral preparation) mixed with flavored syrup as premedication
62845093|NCT02250703|EXPERIMENTAL|Dexmedetomidine|In D group, patients will be given intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg prepared from 100mcg/ml parenteral preparation (Hospira R) . The drug will be administered using a intranasal mucosal administration device (LMA MAD NasalTM).
62845094|NCT02876536|EXPERIMENTAL|TNES with sending electrical impulses|The MS patients will receive electrical impulses by TENS device for 30 minutes a day, for 5 days a week and in 6 weeks
62845095|NCT02876536|SHAM_COMPARATOR|TENS without sending electrical impulses|The MS patients will use the TENS device for 30 minutes a day, for 5 days a week and in 6 weeks without receiving any electrical impulses
62845096|NCT02037308|PLACEBO_COMPARATOR|Control white bread|
62845097|NCT02037308|EXPERIMENTAL|Beetroot bread|
62845098|NCT03747666|EXPERIMENTAL|Locking miniplate|The fractured segments in the parasymphyseal region will be fixed using 2.0 single locking miniplates and the fractured segments of the angle will be fixed conventionally using 2.0 single non-locking miniplate placed on the external oblique ridge.
62845099|NCT03747666|EXPERIMENTAL|Non-locking miniplates|The fractured segments in the parasymphyseal region will be fixed using 2.0 two non-locking miniplates and the fractured segments of the angle will be fixed conventionally using 2.0 single non-locking miniplate placed on the external oblique ridge.
62845100|NCT04232293|EXPERIMENTAL|Blood tests|Two diagnostic tests (eLift and FibroMeter) will be performed to evaluate liver fibrosis
62845101|NCT00586417|EXPERIMENTAL|1|This is a basic research study. There are no treatments with drugs or devices. Wound healing is being studied in healthy volunteers.
62845102|NCT03353506|ACTIVE_COMPARATOR|LFMT|Lyophilized fecal microbiota transplant capsules
62845103|NCT03353506|EXPERIMENTAL|LSFF|Lyophilized sterile fecal filtrate capsules
62845104|NCT06329895|EXPERIMENTAL|Healthy volunteers|"The healthy volunteers will be confined to the clinic throughout the Intervention Period of the study.~The study includes visits during Screening, Intervention, and Follow-up."
62845105|NCT04254913|EXPERIMENTAL|MT-1186|Patients receive the edaravone oral suspension.
62845106|NCT01421355|EXPERIMENTAL|Atazanavir 300 mg BID|Atazanavir 300 mg BID for 4 days.
62845107|NCT01380821||SPECT|Patients clinically indicated to undergo myocardial SPECT in our institution.
62059227|NCT03033459|EXPERIMENTAL|Motivational Interviewing|Participants assigned to the Motivational Interviewing condition will receive an approximately 45 (± 5) minute intervention provided by a female masters-level supervised psychologist with training in Motivational Interviewing.
62845108|NCT01567709|EXPERIMENTAL|Treatment (alisertib, vorinostat)|Patients receive alisertib PO BID on days 1-7 or days 1-3 and 8-10, and vorinostat PO BID on days 1-14 or days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62845109|NCT04663659||diabetic group|Patients over the age of 18 with diabetes mellitus in intensive care unit
62845110|NCT04663659||non-diabetic group|Patients over the age of 18 without diabetes mellitus in intensive care unit
62262807|NCT04031742|EXPERIMENTAL|Part 2: IBI306|Participants receive open-label 450 mg Q4W subcutaneously for 12 weeks.
62845111|NCT04468152|EXPERIMENTAL|Case|
62845112|NCT04468152|NO_INTERVENTION|Control|
62845113|NCT03980691|EXPERIMENTAL|Chidamide combined with CAR-T or TCR-T cell therapy|Receiving chidamide combined with CAR-T or TCR-T cell therapy based on based on cART after attaining plasma HIV suppression (plasma HIV RNA \<50 cp/ ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections.
62262808|NCT04413253|ACTIVE_COMPARATOR|Xiidra Only Group|Patients with dry eye disease Xiidra only
62262809|NCT04413253|EXPERIMENTAL|Xiidra + Dextenza Group|Patients with dry eye disease Xiidra + Dextenza
62447186|NCT01661413||Acute Leukemia|Children diagnosed with acute leukemia, undergoing chemotherapy. Patients with acute leukemia will receive intrathecal methotrexate on day 1 plus intravenous vincristine on day 1 plus oral steroid on days 1-5 plus their regularly scheduled and ongoing daily oral 6-mercaptopurine at the start of a maintenance therapy cycle.
62447187|NCT02247700||Mechanical Ventilation|Infants and Children requiring mechanical ventilation
62845114|NCT03980691|NO_INTERVENTION|without intervention|Not receiving chidamide combined with CAR-T or TCR-T cell therapy but continuing cART after attaining plasma HIV suppression (plasma HIV RNA \<50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
62845115|NCT01012089|EXPERIMENTAL|Daptomycin|Pediatric patients on hemodialysis or peritoneal dialysis with suspected or confirmed infection and who were receiving standard of care antibiotics were also eligible to receive a single dose of daptomycin 5mg/kg IV. Serial blood draws were obtained to assess daptomycin pharmacokinetics
62845116|NCT04749056|EXPERIMENTAL|EPAS screening (intervention)|"Patients undergo EPAS (electronic psycho-oncological adaptive screening), a tablet-based screening application consisting of three adaptive tests and one supportive care checklist. EPAS provides immediate feedback via a printed results page, which presents and interprets the level of distress and contains individualized recommendations for psychosocial services.~The results pages are printed by research assistants immediately after the screening on a mobile printer and given to the participants together with a brochure containing information about all psychosocial services available at the health care institution.~The treating physicians also receive a slightly modified results page, but are not expected to discuss these with the patient unless they are highly distressed.~Before and during the screening, patients are explained how to use the program by the research assistance and supported if needed.~The whole screening process takes about 30 minutes."
62845117|NCT04749056|NO_INTERVENTION|Care as usual (control)|"Patients complete the assessment paper pencil. The same instruments as in the intervention condition are used except for the 3 adaptive tests (i.e., the supportive care checklist and the outcomes).~Neither patients nor physicians receive any feedback of the results. Psychosocial services are recommended by the physicians on their own discretion only, and patients are not handed out the information brochure."
62059228|NCT03033459|ACTIVE_COMPARATOR|Psychoeducation Control|Participants who have been randomly assigned to participate in the attention-control group session will receive approximately 45 (± 5) minutes of psychoeducation on typical developmental stages and infant feeding methods. The psychoeducation will be provided by a female masters-level supervised psychologist.
62262810|NCT00947180|ACTIVE_COMPARATOR|Electrogalvanic stimulation|High voltage electrical stimulation was delivered through an anal plug to induce relaxation of pelvic floor muscles.
62262811|NCT00947180|ACTIVE_COMPARATOR|Digital massage|The therapist massaged the levator ani muscles by applying firm pressure with a gloved finger and rotating from left to right.
62262812|NCT00947180|EXPERIMENTAL|Biofeedback|Electromyographic (EMG) activity was recorded from a probe in the anal canal, averaged and displayed to patients to help them learn to relax pelvic floor muscles during straining.
62262813|NCT04425187|ACTIVE_COMPARATOR|gefitinib|
62262814|NCT04425187|EXPERIMENTAL|gefitinib&bevacizumab|
62262815|NCT02019576|OTHER|Stereotactic radiotherapy (SRT)|Stereotactic radiotherapy will be administered for up to five areas of metastatic sites showing oligo-progression within the same time period. During the Sunitinib break period, stereotactic radiotherapy will be delivered in a single fraction or up to a maximum of eight fractions. The number of fractions will depend on how many sites are being irradiated.
62262816|NCT01367535|EXPERIMENTAL|Arm 1|
62262817|NCT01367535|EXPERIMENTAL|Arm 2|
62447188|NCT05955352|EXPERIMENTAL|Procedural intervention and Control group with standard care|There will be two groups. Interventional group will receive perineal warm compression and control group will receive standard care
62619191|NCT00564291||6|retinitis pigmentosa
62262818|NCT01367535|ACTIVE_COMPARATOR|Arm 3|
62262819|NCT01367535|PLACEBO_COMPARATOR|Arm 4|
62262820|NCT01811875|EXPERIMENTAL|Optivate 500IU|Optivate 500IU
62447189|NCT01990547||Healthy Veterans|Healthy veterans, who have been deployed in support of OIF/OEF who do not have blast exposure or PTSD
62447190|NCT01990547||Veterans with history of blast exposure|OIF/OEF veterans with a history of blast exposure who do not meet criteria for PTSD
62447191|NCT01990547||Veterans with PTSD receiving usual care|OIF/OEF veterans with PTSD (with or without blast exposure) only who receive usual care (i.e., pharmacotherapy and/or supportive or psychodynamic individual or group therapy, not involving exposure therapy)
62619192|NCT00564291||7|vitreoretinal proliferation
62619193|NCT00857467|EXPERIMENTAL|1 g suppository|Subjects receive 5 mg NRL001, 10 mg NRL001 and placebo in a 1g rectal suppository
62619194|NCT00857467|EXPERIMENTAL|2 g suppository|Subjects receive 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository.
62845118|NCT01136083|EXPERIMENTAL|Exercise training|Subjects in exercise group will undergo individualized high aerobic interval training on treadmill for 30 minutes under the supervision of an experienced physical therapist 3 times a week and home exercise twice a week with accelerometer.
62845119|NCT01136083|ACTIVE_COMPARATOR|Control group|Subjects in control group will not undergo individualized high aerobic interval training on treadmill. They will receive usual care as normally does in hospital.
62845120|NCT04900727||Current smokers|Individuals who, at the time of the survey, smoke any forms of tobacco product either daily or occasionally.
62845121|NCT04900727||Ex-smokers|Individuals who were formerly smokers but, at the time of the survey, do not smoke at all.
62845122|NCT04900727||Never Smokers|Individuals who, at the time of the survey, have never smoked at all.
62845123|NCT02165098|EXPERIMENTAL|Cariprazine PR tablet B|Cariprazine prolonged release tablet B - fed
62845124|NCT02165098|EXPERIMENTAL|Cariprazine PR tablet A|Cariprazine prolonged release tablet A - fed
62845125|NCT02165098|EXPERIMENTAL|Cariprazine capsule|Cariprazine capsule - fasted
62845126|NCT02165098|EXPERIMENTAL|Cariprazine prolonged release tablet B|Cariprazine prolonged release tablet B - fasted
62845127|NCT02165098|EXPERIMENTAL|Cariprazine prolonged release tablet A|Cariprazine prolonged release tablet A - fasted
62845128|NCT03967613|EXPERIMENTAL|FES|Functional Eletrical Stimulation
62845129|NCT06137495|EXPERIMENTAL|Allergic Rhinitis Patients|House dust mites (HDMs) IgE in sera of allergic rhinitis patients (AR) who were monosensitized to mixed HDMs, identified by SPT, is assayed using immunoblotting, chemiluminescence, and ImmunoCAP assays to compare between the accuracy of both immunoblotting and chemiluminescence assays, and ImmunoCAP as gold standard
62845130|NCT05809297|EXPERIMENTAL|Diode laser combined with photodynamic-red laser therapy by RapidoPodia Laser Diodo® (MEDENCY)|According to the manufacturer's recommendations, the treatment will be carried out in consultation in 8 sessions by a specialised podiatrist.
62262821|NCT00531752|EXPERIMENTAL|Flexible Dose|
62262822|NCT00531752|PLACEBO_COMPARATOR|Placebo|
62262823|NCT00531752|EXPERIMENTAL|Fixed Dose|
62262824|NCT02145286|EXPERIMENTAL|Radiation Therapy|Stereotactic Body Radiation Therapy
62619195|NCT05445388|EXPERIMENTAL|OCT imaging|OCT imaging
62845131|NCT05809297|ACTIVE_COMPARATOR|Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer|The application of Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer will be performed at home by the patient once a day.
62845132|NCT03519191|OTHER|Healthy Relationships Education (HRE)|Social-behavioral intervention Participants will receive employment support services and Healthy Relationships Education interventions.
62262825|NCT05928195|EXPERIMENTAL|Moderate-Dose Guayusa Extract|Acute, single dose of 600 mg Organic Guayusa Extract
62619196|NCT02107313|OTHER|Fed Cohort|PBT2 250 mg is administered orally following a high fat breakfast
62619197|NCT02107313|OTHER|Fasted Cohort|PBT2 250 mg is administered orally following a 10 hour period of fasting
62619198|NCT02535377||High cryoresistance|High resistance to sperm cryopreservation (decreased sperm motility \<20%)
62619199|NCT02535377||Low cryoresistance|Low resistance to sperm cryopreservation (decreased sperm motility \>20%)
62619200|NCT02182830|EXPERIMENTAL|Empagliflozin|starting dose 10mg; forced titration after 4 weeks 25mg dose
62845133|NCT03519191|OTHER|HRE+Technology Bootcamp|Social-behavioral intervention + technology bootcamp (associated economic pathways for participants) Participants will receive employment support services, Healthy Relationships Education, and Technology Bootcamp interventions.
62845134|NCT04245683||Operative Group|Patients who select operative treatment and follow up after successful neoadjuvant treatment.
62845135|NCT04245683||Non-operative Group|Patients who select non-operative follow up after successful neoadjuvant treatment
62845136|NCT00755638|EXPERIMENTAL|single|8 subjects (6 active and 2 placebo)
62845137|NCT03260751|EXPERIMENTAL|Zingiber officinale Roscoe extract 200 mg|2 cap/day, 800 mg/cap for 12 weeks
62845138|NCT03260751|PLACEBO_COMPARATOR|Placebo|Placebo for 12 weeks
62262826|NCT05928195|EXPERIMENTAL|High-Dose Guayusa Extract|Acute, single dose of 1200 mg Organic Guayusa Extract
62262827|NCT05928195|PLACEBO_COMPARATOR|Placebo|Acute, single dose of Placebo (dextrose)
62262828|NCT05617976|ACTIVE_COMPARATOR|Group L (levobupivacaine only group)|Caudal block was done in this group using levobupivacaine 0.25% with the dose of 1 ml /kg plus one ml normal saline after induction of general anesthesia.
62619201|NCT02182830|PLACEBO_COMPARATOR|Placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
62619202|NCT03996122||resistant patients with schizophrenia|Age 18 - 60 years No MRI contraindication
62619203|NCT03014141|ACTIVE_COMPARATOR|Oat bran (Oatwell 28)|A beverage containing 11 gram (3 gram of oat beta-glucan) of Oat bran (Oatwell 28) will be consumed before breakfast
62619204|NCT03014141|PLACEBO_COMPARATOR|Maltodextrin|A beverage containing 11 gram of maltodextrin will be consumed before breakfast.
62619205|NCT01241331|EXPERIMENTAL|BLI1100|BLI1100 topical cream
62845139|NCT01227018|EXPERIMENTAL|STA-9090|Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62845140|NCT04112212|OTHER|No administration of vedolizumab-800CW|Patients did not receive vedolizumab-800CW but underwent a Fluorescence molecular imaging procedure to serve as a control group and compare results with patients receiving the tracer
62262829|NCT05617976|ACTIVE_COMPARATOR|Group L+N(levobupivacaine plus nalbuphen group)|Caudal block was done in this group using levobupivacaine 0.25% with the dose of 1 ml /kg and nalbuphine 0.1 mg /kg in one ml normal saline after induction of general anesthesia.
62262830|NCT00530894|EXPERIMENTAL|1|Cohort A: Sapien Valve
62845141|NCT04112212|EXPERIMENTAL|4.5 mg vedolizumab-800CW group|Patients received 4.5 mg vedolizumab-800CW and subsequently underwent a Fluorescence molecular imaging procedure
62059229|NCT05856214|EXPERIMENTAL|Couple-based violence prevention education(CBVPE)|Couples in the intervention group will receive trainings on gender based violence, intimate partner violence, Consequences of violence during pregnancy, common triggers of intimate partner violence, a healthy relationship in marriage ,couples communication and conflict management
62059230|NCT06434792|EXPERIMENTAL|Bronpass Tab.|Twice daily for 12 weeks
62059231|NCT06434792|PLACEBO_COMPARATOR|Placebo|Twice daily for 12 weeks
62059232|NCT00735501||A|
62262831|NCT00530894|ACTIVE_COMPARATOR|2|Cohort A: other surgical valve
62262832|NCT00530894|EXPERIMENTAL|3|Cohort B: Sapien Valve
62262833|NCT00530894|ACTIVE_COMPARATOR|4|Cohort B: Medical therapy
62262834|NCT03010124|OTHER|Patients with ovarian cancer|
62262835|NCT01290380|EXPERIMENTAL|ASA 404 + standard chemotherapy|ASA 404 in combination with in combination with standard chemotherapy (paclitaxel + carboplatin or docetaxel) and a cocktail of caffeine, diclofenac, simvastatin and omeprazole
62262836|NCT01445821|ACTIVE_COMPARATOR|Cyclophosphamide rATG/HSCT|The control arm will have the same conditioning regimen used in ASSIST study. The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. Peripheral blood stem cells (PBSC) will be infused intravenously on day 0. Filgrastim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
62262837|NCT01445821|EXPERIMENTAL|Cyclophosphamide rATG/Fludarabine/HSCT|The conditioning regimen will be 120 mg/kg of intravenous cyclophosphamide given in 2 equal fractions on days -3 and -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Fludarabine 30 mg/m2 will be given IV on days -5, -4, and -3. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. PBSC will be infused intravenously on day 0. Filgrastim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
62619206|NCT01241331|PLACEBO_COMPARATOR|Vehicle cream|Vehicle topical cream
62845142|NCT04112212|EXPERIMENTAL|15 mg vedolizumab-800CW group|Patients received 15 mg vedolizumab-800CW and subsequently underwent a Fluorescence molecular imaging procedure
62845143|NCT04112212|EXPERIMENTAL|75 mg vedolizumab + 15 mg vedolizumab-800CW group|Patients received 75mg vedolizumab + 15 mg vedolizumab-800CW and subsequently underwent a Fluorescence molecular imaging procedure
62845144|NCT04112212|EXPERIMENTAL|300mg vedolizumab + 15mg vedolizumab-800CW group|Patients received 300mg vedolizumab + 15 mg vedolizumab-800CW and subsequently underwent a Fluorescence molecular imaging procedure
62845145|NCT04112212|EXPERIMENTAL|> 14 weeks of vedolizumab therapy + 15 mg vedolizumab-800CW group|Patients received 300mg vedolizumab + 15 mg vedolizumab-800CW after \>14 weeks vedolizumab therapy and subsequently underwent a Fluorescence molecular imaging procedure
62845146|NCT02773576|EXPERIMENTAL|2x360 mg risperidone implant|2, 360 mg risperidone implants
62845147|NCT02773576|EXPERIMENTAL|3x300 mg risperidone implant|3, 300 mg risperidone implants
62845148|NCT01229293|EXPERIMENTAL|Resurfacing Total Hip Arthroplasty|A hip replacement that leaves most of the underlying bone intact and mimics the natural biomechanical features of the hip joint. Articular surface replacement ASR, DePuy posterolateral approach used (RTHA)
62845149|NCT01229293|ACTIVE_COMPARATOR|Standard Total Hip Arthroplasty (THA)|A standard 28 mm head uncemented THA
62845150|NCT06353555|EXPERIMENTAL|Thyroid hormone replacement therapy|Upon discovering low T3 or low T4 levels, administer oral levothyroxine sodium tablets daily. If accompanied by a decrease in TSH, the regimen is 100μg qd (for individuals weighing \<75kg) or 150μg qd (for individuals weighing \>75kg). If not accompanied by a decrease in TSH, the regimen is 50μg qd. However, if thyroid function does not significantly improve within 3 days of medication, the regimen is adjusted to 100μg qd. Treatment should continue until transfer out of the NICU or discharge, with a minimum duration of 7 days.
62845151|NCT06353555|SHAM_COMPARATOR|Non-thyroid hormone replacement therapy|Patients will not receive the oral levothyroxine sodium tablets.
62059233|NCT00840801|EXPERIMENTAL|1|Subjects receive three vaccinations with a paediatric TBE vaccine according to the conventional vaccination schedule.
62059234|NCT00840801|EXPERIMENTAL|2|Subjects receive three vaccinations with a paediatric TBE vaccine according to the conventional vaccination schedule.
62059235|NCT03540875|EXPERIMENTAL|Full automation group|Full automation control of propofol and remifentanil
62059236|NCT03540875|OTHER|Control group|Manual control of of propofol and remifentanil using TCI system
62059237|NCT05762848||Researcher|Patients will have their Head circumference measured with a tape and with the mobile phone app.
62059238|NCT05762848||Parent|Patients will have their Head circumference measured with a tape and with the mobile phone app.
62262838|NCT02775396|EXPERIMENTAL|Adult computer user|Wearing each of the two spectacle lens designs for one month in random sequence
62262839|NCT05069181|EXPERIMENTAL|Pilates mat exercises|one hour Pilates exercises with 10 min warm up and 5-10 min cooling down
62262840|NCT05069181|EXPERIMENTAL|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit
62845152|NCT02433951||healthy individuals|Age, gender and BMI matched healthy subjects without any chronic disease or physical disability, and being sedentary.
62845153|NCT02433951||CABG patients|Age, gender and BMI matched CABG patients, without neurologic, nephrologic, respiratory disease.
62059239|NCT03262558||Patients with ECC|No intervention
62059240|NCT01487876|EXPERIMENTAL|LAM+DNA vaccine|lamivudine (LAM) chemotherapy and DNA vaccine
62059241|NCT01487876|PLACEBO_COMPARATOR|LAM+Placebo|"Each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.~lamivudine (LAM) chemotherapy and Placebo"
62845154|NCT02433951||endo-ACAB patients|Age, gender and BMI matched endo-ACAB patients without neurologic, nephrologic, respiratory disease.
62845155|NCT03398083|ACTIVE_COMPARATOR|CBD (500 mg)|CBD (500 mg) capsule by mouth one time during the 18 day treatment period
62845156|NCT03398083|ACTIVE_COMPARATOR|CBD (1000 mg)|CBD (1000 mg) capsule by mouth one time during the 18 day treatment period
62845157|NCT03398083|ACTIVE_COMPARATOR|THC (2.5 mg)|THC 2.5 mg capsule by mouth one time during the 18 day treatment period
62845158|NCT03398083|ACTIVE_COMPARATOR|THC (30 mg)|THC 30 mg capsule by mouth one time during the 18 day treatment period
62845159|NCT03398083|ACTIVE_COMPARATOR|Alprazolam|Alpraxolam 1.5 mg capsule by mouth one time during the 18 day treatment period
62845160|NCT03398083|PLACEBO_COMPARATOR|Placebo Oral Capsule|Placebo capsule by mouth one time during the 18 day treatment period
62262841|NCT05069181|ACTIVE_COMPARATOR|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program
62262842|NCT01497639|ACTIVE_COMPARATOR|Process 1|"* Visit 1: Baseline evaluation (maximum 1 week before operation)~* Visit 2: Testing of electrodes and subsequent initiation of interleaving stimulation mode (4th postoperative week).~* Visit 3 Evaluation and cross-over to double-monopolar stimulation mode (16th postoperative week).~* Visit 4 Final evaluation. (28th postoperative week)."
62262843|NCT01497639|ACTIVE_COMPARATOR|Process 2|"* Visit 1: Baseline evaluation (maximum 1 week before operation)~* Visit 2: Testing of electrodes and subsequent initiation of double-monopolar stimulation mode (4th postoperative week).~* Visit 3 Evaluation and cross-over to interleaving stimulation mode (16th postoperative week).~* Visit 4 Final evaluation. (28th postoperative week)."
62262844|NCT02509806|EXPERIMENTAL|Apatinib Maintenance Therapy After First-line Chemotherapy|Apatinib Mesylate Tablets 500 mg qd p.o. after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）
62262845|NCT02509806|NO_INTERVENTION|No Intervention After First-line Chemotherapy|No Intervention after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）
62262846|NCT02734160|EXPERIMENTAL|Galunisertib + Durvalumab|(Dose Escalation and Cohort Expansion) Galunisertib administered orally in combination with durvalumab administered intravenously (IV).
62845161|NCT04077788||Study group (group A):|It consisted of fifteen subjects who received muscle energy technique (Mitchell relaxation osteopathic technique). Two sessions per cycle for three cycles before menstruation by one week and after the end of menstruation by one week. In addition to their medical treatment non-steroidal anti-inflammatory drugs (NIAIDS).
62845162|NCT04077788||control group (group B):|It consisted of fifteen subjects who took their medical treatment only (non-steroidal anti-inflammatory drugs (NIAIDS)).
62845163|NCT02805829|EXPERIMENTAL|Trastuzumab + NK cells|"On Cycle 1,day -2, patients will receive IV loading dose 8mg/Kg trastuzumab, followed by collection blood on day 0. After NK expansion and verification that the resulting NK cells meet release criteria, NK cells were washed and resuspended in isotonic sodium chloride for intravenous transfusion on day 14.~NK cellular therapy conduct 2 cycles per year. The maintenance dose of trastuzumab monotherapy is 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks till to disease progress."
62262847|NCT05464303||Postoperative cholangitis|Patients who had conducted kasai procedure and suffered from postoperative cholangitis after surgery
62845164|NCT00740857|PLACEBO_COMPARATOR|1|
62262848|NCT05464303||None postoperative cholangitis|Patients who had conducted kasai procedure and followed up in a clinic，at which time they didn't present signs of cholangitis
62845165|NCT00740857|ACTIVE_COMPARATOR|2|
62845166|NCT00740857|ACTIVE_COMPARATOR|3|
62845167|NCT01367990|EXPERIMENTAL|Norepinephrine|
62262849|NCT01462435|EXPERIMENTAL|Diclofenac Test (lower dose)|
62059242|NCT04822844|EXPERIMENTAL|Aromatherapy with Essential Oil|Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
62845168|NCT03133416|ACTIVE_COMPARATOR|PRP preparation|PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. Then about 2ml PRP will be extracted, and will be infiltrated to the lesion site under ultrasound guidance. The injection technique is similar to that described by Kesikburun .21 Patients in group 1 or group 3 will receive 2 injections of PRP, with 1 month interval.
62845169|NCT03133416|ACTIVE_COMPARATOR|Physiotherapy|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretch, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, 3 times a week, and will continue for 1.5 months. After 1.5 months' supervised training, home program exercise follows and will be continued for another 1.5 months.
62845170|NCT03133416|ACTIVE_COMPARATOR|PRP and physiotherapy|PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. Then about 2ml PRP will be extracted, and will be infiltrated to the lesion site under ultrasound guidance. The injection technique is similar to that described by Kesikburun .21 Patients in group 1 or group 3 will receive 2 injections of PRP, with 1 month interval;Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretch, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, 3 times a week, and will continue for 1.5 months. After 1.5 months' supervised training, home program exercise follows and will be continued for another 1.5 months.
62845171|NCT05838482||Subject's Scanned with Investigational Device|Eligible and consented subjects will be scanned using the investigational Pluto Photon-Counting CT system.
62845172|NCT00959985|NO_INTERVENTION|Group 1A|Mild Lymphedema: Only required to meet with the lymphedema physical therapist
62845173|NCT00959985|ACTIVE_COMPARATOR|Group 1B|Mild Lymphedema: Fitted for compression sleeve
62845174|NCT00959985|ACTIVE_COMPARATOR|Group 2A|Moderate lymphedema: Fitted with a compression sleeve
62059243|NCT02666287|EXPERIMENTAL|Sequence 1|"Each subject will receive all the 9 treatment regimens in the following order: A,G/B/F/C,H/E/D,I with a washout period of 7 days between each treatment period administered via the ELLIPTA inhaler. Where Treatment A= BAT/FF 900/300 microgram (mcg) (3 inhalations of 300/100 mcg).~Treatment B= BAT 900 mcg (3 inhalations of 300 mcg) concurrently with FF (lactose) 300 mcg (3 inhalations of 100 mcg) from separate inhalers.~Treatment C= BAT 900 mcg (3 inhalations of 300 mcg). Treatment D= FF (lactose) 300 mcg (3 inhalations of 100 mcg). Treatment E= FF (magnesium stearate \[MgSt\]) 300 mcg (3 inhalations of 100 mcg). Treatment F= FF/VI 300/75 mcg (3 inhalations of 100 mcg/25 mcg). Treatment G= 7-day repeat doses: BAT/FF 300/100 mcg (1 inhalation). Treatment H= 7-day repeat doses: BAT 300 mcg (1 inhalation). Treatment I= 7-day repeat doses: FF (lactose) 100 mcg (1 inhalation)."
62059244|NCT02666287|EXPERIMENTAL|Sequence 2|Each subject will receive all the 9 treatment regimens in the following order: B/C,H/A,G/D,I/F/E with a washout period of 7 days between each treatment period.
62059245|NCT02666287|EXPERIMENTAL|Sequence 3|Each subject will receive all the 9 treatment regimens in the following order: C,H/D,I/B/E/A,G/F with a washout period of 7 days between each treatment period.
62059246|NCT02666287|EXPERIMENTAL|Sequence 4|Each subject will receive all the 9 treatment regimens in the following order: D,I/E/C,H/F/B/A,G with a washout period of 7 days between each treatment period.
62059247|NCT02666287|EXPERIMENTAL|Sequence 5|Each subject will receive all the 9 treatment regimens in the following order: E/F/D,I/A,G/C,H/B with a washout period of 7 days between each treatment period.
62059248|NCT02666287|EXPERIMENTAL|Sequence 6|Each subject will receive all the 9 treatment regimens in the following order: F/A,G/E/B/D,I/C,H with a washout period of 7 days between each treatment period.
62059249|NCT01879592||Asthma + sickle cell disease|African American children affected with both sickle cell disease and asthma
62059250|NCT01879592||Sickle cell disease|African American children affected with sickle cell disease but who do not have asthma
62262850|NCT01462435|EXPERIMENTAL|Diclofenac Test (upper dose)|
62059251|NCT01879592||Asthma|African American children affected with asthma but without sickle cell disease
62059252|NCT01879592||Healthy control|African American children who are healthy with no chronic disease
62059253|NCT02087436|ACTIVE_COMPARATOR|Taperloc Complete Standard|Group one will receive a total hip replacement with Taperloc Complete Standard. Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
62262851|NCT01462435|ACTIVE_COMPARATOR|Celecoxib|
62262852|NCT01462435|PLACEBO_COMPARATOR|Placebo|
62262853|NCT03578471|ACTIVE_COMPARATOR|Hearing Aid without NR and BF|Hearing Aid without Noise Reduction (NR) or beam forming (BF) enabled serves as reference condition.
62262854|NCT03578471|EXPERIMENTAL|Hearing Aid with NR|Hearing Aid with Noise Reduction (NR) enabled.
62262855|NCT03578471|EXPERIMENTAL|Hearing Aid with BF|Hearing Aid with beam forming (BF) enabled.
62845175|NCT00959985|ACTIVE_COMPARATOR|Group 2B|Moderate Lymphedema: Fitted with compression sleeve and instructed to wear a short-stretch compression bandage
62059254|NCT02087436|ACTIVE_COMPARATOR|Taperloc Complete Microplasty|Group one will receive a total hip replacement with Taperloc Complete Microplasty.Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.
62845176|NCT00601393|ACTIVE_COMPARATOR|1|Participants will receive treatment as usual followed by 8 weeks of Internet-based cognitive behavioral therapy treatment
62845177|NCT00601393|EXPERIMENTAL|2|Participants will receive 8 weeks of Internet-based cognitive behavioral therapy treatment
62845178|NCT06291818|OTHER|Assess the performance of this novel eyelid closure device in vivo|The primary goal of this study is to determine the feasibility and success of a temporary magnetic system for tarsorrhaphy (MST) to provide adequate closure of the eyes for ultimate use in conditions causing lagophthalmos (a disorder in eyelid closure). In this disorder, people are unable to sufficiently cover their cornea (the front of the eye), which can lead to dryness, infection, scarring and even blindness. Current therapies are invasive, involving local anesthesia and surgeries, and have a negative cosmetic impact.
62845179|NCT04753151|EXPERIMENTAL|Tranexamic acid|Patients scheduled for liver transplantation and allocated for treatment with tranexamic acid (Group 1).
62845180|NCT04753151|PLACEBO_COMPARATOR|Placebo|Patients scheduled for liver transplantation and allocated for treatment with placebo (Group 2).
62845181|NCT04354649|EXPERIMENTAL|Hydroxychloroquine, plus prednisone|Hydroxychloroquine 5mg/kg PO daily, plus prednisone starting at 20 mg PO daily for 8 weeks tapering dose.
62845182|NCT04354649|PLACEBO_COMPARATOR|Hydroxychloroquine-matching placebo, plus prednisone|Matching placebo daily, plus prednisone starting at 20 mg PO daily for 8 weeks tapering dose.
62845183|NCT04133142|NO_INTERVENTION|Medical treatment|"Patients receive the standard medical medication for herpes pain~* Oral administration of Gabapentin~  * 300 mg/d on day 1 and 2~ * 600 mg/d on day 3 and 4 if pain persists~ * 900 mg/d on day 5 and 6 if pain persists~* Oral administration of Paracetamol up to 3 g per day prescription for 7 day and continue for 3 weeks after evaluation"
62845184|NCT04133142|EXPERIMENTAL|Early block Single|the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ration benefit risks. Choice of Block by an anesthesiologist expert in regional anaesthesia techniques. After the block performance if the pain comes back patient will receive the standard medical treatment as in the group medical treatment
62845185|NCT04133142|EXPERIMENTAL|Early Repeated block|the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. The block will be repeated every 48h until the pain will reach VAS \< 3 6 h after block recovery.
62845186|NCT04133142|EXPERIMENTAL|Late block single|"Patients receive the standard medical medication for herpes pain~* Oral administration of Gabapentin~  * 300 mg/d on day 1 and 2~ * 600 mg/d on day 3 and 4 if pain persists~ * 900 mg/d on day 5 and 6 if pain persists~* Oral administration of Paracetamol up to 3 g per day at day 7 if pain more than VAS 4 the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block . Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ration benefit risks. Choice of Block by an anesthesiologist expert in regional anaesthesia techniques. After the block performance if the pain comes back patient will receive the standard medical treatment as in the group medical treatment"
62845187|NCT04133142|EXPERIMENTAL|late block repeated|"Patients receive the standard medical medication for herpes pain~* Oral administration of Gabapentin~  * 300 mg/d on day 1 and 2~ * 600 mg/d on day 3 and 4 if pain persists~ * 900 mg/d on day 5 and 6 if pain persists~* Oral administration of Paracetamol up to 3 g per day prescription for 7 day and continue for 3 weeks after evaluation At day 7 if pain more than VAS 4 the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. The block will be repeated every 48h until the pain will reach VAS \< 3 6 h after block recovery."
62845188|NCT02254954|EXPERIMENTAL|Macitentan in combination with RT & TMZ|Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
62059255|NCT06009601||Patients aged 3-18 years who were diagnosed with pectus deformity|Pectus study forms consisting of clinical and radiological measurements of patients aged 3-18 years who applied to the outpatient clinic with chest deformity will be filled in in detail.
62059256|NCT02042079|EXPERIMENTAL|EFTR with LA|(Endoscopic full-thickness resection with laparoscopic assistance)
62262856|NCT01950000|PLACEBO_COMPARATOR|Placebo|Placebo Treatment: A sterile sodium chloride injection 0.9% 10 ml
62619207|NCT05282589|EXPERIMENTAL|Lumbopelvic manipulation and conventiontional therapy|Group A an experimental group was given conventional therapy and lumbopelvic manipulation. conventional therapy include TENS and Hot pack for 20 minutes , hamstrings stretching, calf stretching,transversus abdominis strengthening and lumber multipedes muscle strengthening. while lumbopelvic manipulation include high velocity thrust given in posterior direction to ASIS.
62845189|NCT02230319|EXPERIMENTAL|Cryotherapy|Each patient will receive cryotherapy administered during weekly paclitaxel treatments by Elasto gel™ Hypothermia mitts and slippers. Patients will wear the mitts and slippers for 15 minutes prior to treatment start, for 60 minutes during treatment, and for 15 minutes following treatment completion, for a total of 90 minutes.
62845190|NCT00476229|EXPERIMENTAL|Radiation + Chemotherapy + BSCT|Total Lymphoid Irradiation (2 times) at 80 cGy daily for five days + Thymoglobulin 1.5 mg/kg intravenous 5 days + Rituximab 375 mg/m\^2 intravenous on 4 different days + Blood stem cell transplant (BSCT)
62447192|NCT01990547||Veterans with PTSD receiving Virtual Reality Exposure Therapy|"OIF/OEF veterans with PTSD (with or without blast exposure) that will receive Virtual Reality Exposure Therapy through the WRNMMC IRB approved protocol entitled Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure with Cognitive Enhancer ClinicalTrials.gov Identifier: NCT01352637, which is also open to new enrollment"
62447193|NCT02215174|EXPERIMENTAL|Asians|Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
62447194|NCT02215174|EXPERIMENTAL|Caucasians|Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
62447195|NCT04810819|EXPERIMENTAL|Experimental group|
62447196|NCT04810819|PLACEBO_COMPARATOR|control group|
62447197|NCT00226720|EXPERIMENTAL|1|at the hospital
62447198|NCT00226720|ACTIVE_COMPARATOR|2|out of the hospital
62447199|NCT02841306|ACTIVE_COMPARATOR|3-5 hours|Duration between oral UDCA intake and surgery of 3-5 hours.
62447200|NCT02841306|ACTIVE_COMPARATOR|6-8 hours|Duration between oral UDCA intake and surgery of 6-8 hours.
62447201|NCT02841306|ACTIVE_COMPARATOR|9-12 hours|Duration between oral UDCA intake and surgery of 9-12 hours.
62845191|NCT03543228||MyoStrain|During standard chemotherapy and/or targeted treatment for breast cancer or lymphoma, MyoStrain will be used during standard cardiac magnetic resonance imaging to evaluate the change in myocardial contraction regionally and globally to detect cardiotoxicity and management of myocardial dysfunction.
62845192|NCT04495608|EXPERIMENTAL|fluconazole|Fluconazole 50mg capsule (1, 2, 3 or 4 pills to take daily during 18 weeks, corresponding respectively to 50, 100, 150 or 200 mg of fluconazole).
62845193|NCT04495608|PLACEBO_COMPARATOR|placebo|Placebo (1, 2, 3 or 4 pills to take daily during 18 weeks), same appearance to experimental drug
62845194|NCT03832049|ACTIVE_COMPARATOR|15 to 26 years - 3 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses
62447202|NCT02841306|ACTIVE_COMPARATOR|> 12 hours|Duration between oral UDCA intake and surgery of \>12 hours.
62059257|NCT04975633|EXPERIMENTAL|BodyPort Cardiac Scale|Patient will receive the Bodyport scale with access to Bodyport care services, such as remote monitoring, educational materials, different biomarkers detected by the scale, and online access to their data
62447203|NCT02841306|NO_INTERVENTION|Control|No medication
62447204|NCT00999609|EXPERIMENTAL|AAV2-hRPE65v2,voretigene neparvovec-rzyl|voretigene neparvovec rzyl, 1.5 E11 vector genomes, per eye, administered by subretinal injection in a volume of 0.3mL, 6-18 days apart
62447205|NCT00999609|NO_INTERVENTION|Control|No intervention
62447206|NCT02591784|EXPERIMENTAL|Nimotuzumab group|Nimotuzumab+radiotherapy
62447207|NCT02929693|EXPERIMENTAL|combination|YYJD plus gefitinib
62447208|NCT02929693|PLACEBO_COMPARATOR|controll|placebo plus gefitinib
62447209|NCT06546410||Epilepsy|
62447210|NCT06546410||Non-epilepsy|
62262857|NCT01950000|EXPERIMENTAL|Fentanest|"For this study Fentanest doses were adjusted based on published guidelines from the values recommended media to a whole number and differentiating two groups of patients (multiple trauma / surgical or medical) The maximum dose is 100 mcg Fentanest. The multiple trauma patients / surgical 1.5 mcg / kg and in medical patients 1.0 mcg / kg were given a single bolus Fentanest / Placebo by type of patient (surgical / multiple trauma or physician) 5 'before turning mobilization with personal hygiene.~The bolus is given slowly (30'') intravenously, to be preferred by a peripheral without vasoactive drugs (only with fluid therapy).~Pharmaceutical form:~Sterile solution for injection. Each mL of injectable solution contains the equivalent of 0.05 mg of Fentanest; Excipients: sodium chloride and water for injection."
62262858|NCT05677555|EXPERIMENTAL|colchicine group|Treatment with colchicine 0.5 mg
62262859|NCT05677555|PLACEBO_COMPARATOR|placebo group|Treatment with matched placebo
62262860|NCT05872750|EXPERIMENTAL|Active arm|The intervention group will receive repetitive transcranial magnetic stimulation at the left dorsolateral prefrontal cortex and pre-supplementary motor area
62262861|NCT05872750|SHAM_COMPARATOR|Sham arm|the control group will receive sham stimulation
62262862|NCT03328650||Proximal Humerus Fracture Patients|As part of their routine care, patients who have experienced a proximal humerus fracture that requires operative fixation will receive the A.L.P.S® Proximal Humerus Plating System. This study is an observational, prospective study that monitors the patient's pain, functional ability, and patient-reported outcomes.
62262863|NCT03308838||Cases|Cases consisted of Costa Rican adults who were diagnosed as survivors of a first acute myocardial infarction.
62619208|NCT05282589|ACTIVE_COMPARATOR|conventional therapy|Group B, control group was given only conventional therapy which include TENS and Hot pack for 20 minutes , hamstrings stretching, calf stretching,transversus abdominis strengthening and lumber multipedes muscle strengthening . 1 set of 10 repetitions, 3 sessions per week with a total of 12 sessions.
62845195|NCT03832049|EXPERIMENTAL|9 to 14 years - 2 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
62845196|NCT03832049|EXPERIMENTAL|4 to 8 years - 2 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
62845197|NCT03832049|EXPERIMENTAL|9 to 14 years - 1 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
62845198|NCT03832049|EXPERIMENTAL|4 to 8 years - 1 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
62059258|NCT04975633|NO_INTERVENTION|Control|Patients will receive usual care and a Bodyport scale that only displays weight and weight change. No other access to care services, features, or materials will be provided during this 90 day period
62059259|NCT03140501|EXPERIMENTAL|Immediate Intervention|"Participants randomized to this group will receive the intervention, the mobile application (app), immediately after baseline data are collected."
62059260|NCT03140501|OTHER|Delayed intervention|"Participants randomized to this group will receive the intervention, the mobile application (app), after a three month delay."
62059261|NCT03547492|EXPERIMENTAL|Language Intervention|"1. Baseline LENA recording 2. Review language curriculum and motor curriculum with study personnel 2. Direct linguistic feedback of baseline LENA recording 4. 2nd LENA recording completed and analyzed 5. Direct or mailed linguistic feedback of 2nd LENA recording 6. 16- Weekly text messages 7. 4 month LENA recording with mailed linguistic feedback 8. 12 month LENA recording with mailed linguistic feedback~Assessments:~1. Ages and Stages Questionnaire at 4 and 12 months~2. Maternal Peabody Picture Vocabulary test at 4 months~3. Edinburgh Post-partum Depression Scale at 4 months~4. MacArthur Bates Communicative Developmental Inventory: Words and Gestures at 12~Participants receive a book at each interaction."
62262864|NCT03308838||Controls|Controls consisted of healthy individuals randomly identified from the underlying source population in Costa Rica and matched to each case by age, sex, and area of residence.
62845199|NCT05302336|ACTIVE_COMPARATOR|Liposomal doxorubicin + Cyclophosphamide|Liposomal doxorubicin + cyclophosphamide A 35mg(per r square meter of body surface)+C 600mg(per r square meter of body surface) every 3 weeks for 4 cycles
62845200|NCT05302336|ACTIVE_COMPARATOR|Docetaxel + Cyclophosphamide|Docetaxel + Cyclophosphamide T 75mg(per r square meter of body surface)+C 600mg(per r square meter of body surface) every 3 weeks for 4 cycles
62262865|NCT03255707|EXPERIMENTAL|Group A|50 patients will receive the gold standard occlusion therapy
62262866|NCT03255707|EXPERIMENTAL|Group B|50 patients will receive dichoptic treatment in the form of playing a video game (Lazy Eye Blocks ®) while wearing a red/green goggle.
62845201|NCT01716403||HCV tritherapy and anemia|HCV-genotype 1 infected patients
62845202|NCT02479308|ACTIVE_COMPARATOR|Moxifloxacin|Oral tablet
62262867|NCT00003535|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62619209|NCT01586702|NO_INTERVENTION|Regular care|Consisting of structured information given at hospital discharge regarding stroke etiology and recommended secondary prevention plus regular outpatient care by general practitioners or family doctors.
62619210|NCT01586702|ACTIVE_COMPARATOR|Support program|In addition to regular care: Up to 8 appointments in outpatient clinics. Results of risk factor measurements and assessed adherence to medical recommendations are shared with the patients. In case that a patients fails to meet target values, preventive measures will be modified directly or via recommendation to GPs / family doctors. Patients are also offered assistance in finding appropriate physical activities or smoking cessation programs.
62619211|NCT01154205||Patients post implantation of ICD or CRTD|
62619212|NCT00623857|ACTIVE_COMPARATOR|1|Zinc
62845203|NCT02479308|EXPERIMENTAL|ALKS 5461|Sublingual tablet
62619213|NCT00623857|ACTIVE_COMPARATOR|2|Vitamins and minerals other than zinc
62619214|NCT00623857|ACTIVE_COMPARATOR|3|Vitamins plus zinc and other minerals
62619215|NCT00623857|PLACEBO_COMPARATOR|4|Placebo for all vitamins and minerals
62845204|NCT02479308|PLACEBO_COMPARATOR|Placebo|
62845205|NCT00145158|EXPERIMENTAL|Cohort 1: 8 HLA-A2-restricted peptides and CpG 7909|Patients were immunized with a combination of 8 peptides corresponding to defined tumor antigens (MAGE-1.A2, MAGE-3.A2, MAGE-4.A2, MAGE-10.A2, MAGE-C2.A2, NY-ESO-1.A2, NA17.A2 and Tyrosinase.A2), mixed with CpG 7909. Patients received six sequential injections at 2-week intervals.
62619216|NCT03240185||Hemroidectomy patients|Patients undergoing hemorrhoid surgery who receive education regarding deep breathing exercises for pain control as part of their preoperative appointment
62619217|NCT03264534|ACTIVE_COMPARATOR|limbal relaxing incisions|Manually performed limbal relaxing incisions
62262868|NCT02758340|EXPERIMENTAL|M=misoprostol|Patients who would receive Only oral misoprostol{(50 micrograms) tab cytotec ¼ tablets (Searle)}. All patients in this group will be given oral misoprostol 50 μg per dose. The dose will be repeated at 4 hours interval up to a maximum of 4 doses till labor is induced (3 contractions per 10 minutes). If labor is not established within 4 hours of the administration of the fourth dose, induction will be considered to be failed
62059262|NCT03547492|ACTIVE_COMPARATOR|Motor Control|"1. Baseline LENA recording~2. Review motor curriculum with study personnel~3. 2nd LENA recording completed and analyzed~4. 4- monthly text messages~5. 4 month LENA recording~6. 12 month LENA recording with mailed linguistic feedback of all recordings~Assessments:~1. Ages and Stages Questionnaire at 4 and 12 months~2. Maternal Peabody Picture Vocabulary test at 4 months~3. Edinburgh Post-partum Depression Scale at 4 months~4. MacArthur Bates Communicative Developmental Inventory: Words and Gestures at 12~Participants receive a toy at each interaction."
62619218|NCT03264534|ACTIVE_COMPARATOR|astigmatic keratotomy|femtosecond laser-guided astigmatic keratotomy
62619219|NCT05057858|EXPERIMENTAL|Perfect Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC once daily (7 doses per week).
62619220|NCT05057858|EXPERIMENTAL|Moderate Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC tablet 4 times per week (Monday, Tuesday, Thursday, Friday)
62619221|NCT05057858|EXPERIMENTAL|Poor Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC tablet twice per week(Monday and Tuesday)
62845206|NCT00145158|EXPERIMENTAL|Cohort 2: 8 HLA-A2-Restricted Peptides and Montanide ISA51|Patients were immunized with a combination of 8 peptides corresponding to defined tumor antigens (MAGE-1.A2, MAGE-3.A2, MAGE-4.A2, MAGE-10.A2, MAGE-C2.A2, NY-ESO-1.A2, and NA17.A2), mixed with Montanide ISA 51. Tyrosinase.A2 was administered without Montanide ISA51. Patients received six sequential injections at 2-week intervals.
62845207|NCT04963985|EXPERIMENTAL|Tafamidis group|During the treatment period, each participant will receive 20 mg tafamidis meglumine once daily for 24 weeks.
62059263|NCT02340923||Healthy Subjects|Healthy subjects aged 0-18 years old. Subjects cannot have a presence or past history of a neurological disorder or other disease that would be expected to substantially impact health.
62059264|NCT02340923||Duchenne Muscular Dystrophy Subjects|Male subjects aged 0-18 years old with genetic or histopathologic diagnosis of duchenne muscular dystrophy, or signs and symptoms of DMD and genetic or histopathologic diagnosis in a family member. Additionally, subjects cannot have the presence of a superimposed neuromuscular or other medical condition that substantially impacts the individual's health or ability to cooperate.
62059265|NCT02503683|ACTIVE_COMPARATOR|ALN-AAT|
62059266|NCT02503683|PLACEBO_COMPARATOR|Sterile Normal Saline (0.9% NaCl)|
62262869|NCT02758340|EXPERIMENTAL|M+F=MISOPROSTOL+FOLEY'S BALLOON CATHETER|All patients in this group will be explained the technique of foley's catheter ballooning and informed consent will be taken. The cervix will be visualized with the help of Cusco's speculum. The balloon will be inflated with about 30 cc of sterile water. The catheter will be pulled down to bring the balloon into the cervical canal and will be tapped around the thigh. Patients will also be given oral misoprostol 50 μg per dose. The dose will be repeated at 4 hours interval up to a maximum of 4 doses till labor is induced (3 contractions per 10 minutes).
62262870|NCT06320587|EXPERIMENTAL|Experimental group|Newborns in this group will be given kangaroo care by both their mother and father.
62262871|NCT06320587|PLACEBO_COMPARATOR|Control group|Newborns in this group will be given kangaroo care by only the mother.
62619222|NCT03244267|ACTIVE_COMPARATOR|Standard Education|Participants randomized to this arm will receive the standard education provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery.
62845208|NCT03767790|EXPERIMENTAL|Automated Insulin Delivery|Participants will use the Automated Insulin Delivery (AID) iAPS system for 2 weeks in the outpatient setting. During AID use, subjects will consume 6 study meals (3 meals of each meal type in assigned random order, 1-2 portions per meal,) at dinner time over the 2-week period in a pre-assigned random order, and document on the study meal forms when they consume each numbered meal.
62619223|NCT03244267|EXPERIMENTAL|Medication Reminder App + Standard Education|Participants randomized to this arm will use a smartphone app with preset reminders to take aspirin to prevent thromboembolic events after orthopedic surgery in addition to usual postoperative discharge teaching.
62619224|NCT04049305|EXPERIMENTAL|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM.
62619225|NCT04049305|ACTIVE_COMPARATOR|Conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy.
62619226|NCT04049305|ACTIVE_COMPARATOR|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, with endoscopic instruments to performed nipple sparing mastectomy.
62619227|NCT02540161|EXPERIMENTAL|non-bevacizumab failures - 18 mg/kg|Non-bevacizumab failure (either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen) will receive Sym004 intravenously every two weeks.
62619228|NCT02540161|EXPERIMENTAL|bevacizumab failures - 18 mg/kg|Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment) will receive Sym004 intravenously every two weeks.
62619229|NCT02540161|EXPERIMENTAL|non-bevacizumab failures - 24 mg/kg|Non-bevacizumab failure (either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen) will receive Sym004 intravenously every two weeks.
62619230|NCT02540161|EXPERIMENTAL|bevacizumab failures - 24 mg/kg|Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment) will receive Sym004 intravenously every two weeks.
62262872|NCT02838498|EXPERIMENTAL|Intensive EMS training group|"Device: ERCP mechanical simulator training EMS group was coached (by JWL) on how to use the EMS, and then practiced with supervision by a senior surgeon biliary endoscopist (WBM). Trainees practiced for a total of 20 hours performing basic maneuvers including scope insertion 2 hours, scope positioning 6 hours, selective guide wire cannulation of common bile duct (CBD) stricture or pancreatic duct (PD) 10 hours and placement of a biliary stent 2 hours.~All trainees received hands-on supervised clinical ERCP practice on patients. Time taken to perform ERCP procedures was documented. Trainees received verbal instructions, hands-on assistance from the trainer in performing the clinical procedure. If the trainee still failed after 20 minutes, the trainer took over."
62262873|NCT02838498|NO_INTERVENTION|Routine ERCP training group|Other: Routine ERCP training group All trainees received hands-on supervised clinical ERCP practice on patients. Time taken to perform ERCP procedures was documented. Trainees received verbal instructions, hands-on assistance from the trainer in performing the clinical procedure. If the trainee still failed after 20 minutes, the trainer took over.
62262874|NCT02289950|EXPERIMENTAL|Farletuzumab|All participants will receive a loading dose for the first 2 weeks of 10 milligram per kilogram (mg/kg) farletuzumab, followed by 5 mg/kg weekly farletuzumab administered intravenously (IV).
62619231|NCT03544281|EXPERIMENTAL|Arm A: Belantamab mafodotin+lenalidomide +dexamethasone|"Participants will receive SINGLE full dose of belantamab mafodotin as 2.5 mg/kg and 1.9 mg/kg on Day 1 of every 28-day cycle as a 30-60 min infusion.~SPLIT: belantamab mafodotin will be administered in two equal divided doses, 2.5 mg/kg SPLIT dose of a 1.25 mg/kg dose on Day 1 and a 1.25 mg/kg dose on Day 8 of each 28-day cycle.~STRETCH: belantamab mafodotin will be administered as 1.9 mg/kg dose on Day 1 of every alternate 28-day cycles (C1, C3, C5, C7 and so on.) Participants will also receive Lenalidomide 25 mg or 10 mg orally daily, on Days 1-21 of each 28 day cycle with Dexamethasone, 40 mg weekly per oral (PO)/intravenously (IV) on Days 1,8,15, \& 22 of each cycle."
62623738|NCT04613440|EXPERIMENTAL|Exploratory Arm|Probands at WCM only who do not meet eligibility criteria for randomization to the intervention and control arms will be offered enrollment in a third arm, in which they will receive the intervention in addition to the option for referral to patient advocacy/support groups including FORCE: Facing Hereditary Cancer EMPOWERED, Sharsheret, SHARE, LatinaSHARE, Oneinforty, Susan G. Komen, Any Mountain, and Genetic Support Foundation, for additional guidance. Probands enrolled in this third arm only will be asked to share the names and contact information for all first, second, and third-degree relatives with whom they have shared their genetic testing results. We estimate enrolling up to 200 subjects into this exploratory third arm (50 probands and 150 Relatives including first, second, and third-degree relatives).
62845209|NCT03767790|NO_INTERVENTION|SAP/PLGS|Participants will use their home pump with a CGM sensor (sensor augmented pump) or in Predictive Low Glucose Suspend (PLGS) mode if their home pump supports this mode, for 2 weeks in the outpatient setting. During these 2 weeks, subjects will consume 6 study meals (3 meals of each meal type in assigned random order, 1-2 portions per meal,) at dinner time over the 2-week period in a pre-assigned random order, and document on the study meal forms when they consume each numbered meal.
62845210|NCT00031278|EXPERIMENTAL|Cohort 1|0.01 mg/kg CPG 7909 plus Herceptin®
62262875|NCT02289950|PLACEBO_COMPARATOR|Placebo|All subjects will receive placebo weekly, administered intravenously (IV).
62262876|NCT01053390|ACTIVE_COMPARATOR|epirubicin,cisplatin,LV（Leucovorin）、5-FU (5-Fluorouracil)|conventional regimen
62262877|NCT01053390|EXPERIMENTAL|Somatotatin|Conventional chemotherapy regimen plus somatostatin
62845211|NCT00031278|EXPERIMENTAL|Cohort 2|0.04 mg/kg CPG 7909 plus Herceptin®
62845212|NCT00031278|EXPERIMENTAL|Cohort 3|0.16 mg/kg CPG 7909 plus Herceptin®
62845213|NCT00031278|EXPERIMENTAL|Cohort 4|0.32 mg/kg CPG 7909 plus Herceptin®
62059267|NCT03692338|EXPERIMENTAL|12 week supervised exercise program|"Patients will be asked to complete 3 30-minute supervised exercise sessions/week under the guidance of the study exercise physiologist. The preferred mode will be treadmill walking, however, alternatives such as cycling or stair climbing machines will be used. For these sessions, patients will be asked to wear a heart rate monitor. Following a 5 minute warm-up, the exercise physiologist will increase speed to correspond with an intensity of approximately 80% VO2peak for 1-minute before returning to a lower speed for 1-minute (50% VO2peak). Patients will complete up to 20 of each 1-minute interval, then cool-down for 5 minutes. At the end of each higher intensity interval patients will be asked to rate their perceived exertion (RPE).~Additionally, patients will receive standard of care nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks."
62262878|NCT04162574||BEGIN Case|Enrolled participants with BN/BED will participate in a 30-day observational study.
62262879|NCT05909982|EXPERIMENTAL|Ischemic post-conditioning group|Mechanical thrombectomy combined with ischemic post-conditioning
62619232|NCT03544281|EXPERIMENTAL|Arm B: Belantamab mafodotin+bortezomib+dexamethasone|Participants will receive SINGLE full dose of belantamab mafodotin as 3.4 mg/kg; 2.5 mg/kg; 1.9 mg/kg on Day 1 of each 21-day cycle. SPLIT: belantamab mafodotin will be administered in two equal divided doses: 3.4 mg/kg SPLIT as 1.7 mg/kg dose on Day 1 \& 1.7 mg/kg dose on Day 8; 2.5 mg/kg SPLIT dosing as 1.25 mg/kg dose on Day 1 \& 1.25 mg/kg dose on Day 8 of each 21-day cycle. STRETCH: belantamab mafodotin will be administered as single dose of 2.5 mg/kg on Day 1 of every alternate 21-day cycles (C1,C3,C5,C7 \& so on), 1.9 mg/kg administered on Day 1 of every alternate 21-day cycles (C1,C3,C5,C7 and so on). Step Down(S/D) STRETCH=belantamab mafodotin 2.5 mg/kg dose will be administered on Day 1 C1 followed by 1.9 mg/kg starting dose on Day1 of alternate 21-day cycles C3 onwards (C3,C5,C7, \& so on). Bortezomib will be administered at 1.3 mg/m\^2 SC/IV on Days 1,4,8, \& 11 of every 21-day cycle. Dex will be administered at 20 mg PO or IV on Days 1,2,4,5,8,9,11, \& 12 of every 21-day cycle.
62619233|NCT04998383|EXPERIMENTAL|HVNI|High velocity nasal insufflation (Fisher \&Paykel, Auckland, New Zealan High-velocity nasal insufflation (Precision Flow;Vapotherm, Inc, Exeter, NH) (Figure 2) using a smallborenasal cannula was initiated with a flow rate set to 35 L/min, with a starting temperature between 35C and 37C and FiO2 at 1.0. Adjustments in flow (up to 40 L/min) and temperature (typically between 35C and 37C) were made to alleviate respiratory distress and optimize comfort
62619234|NCT04998383|EXPERIMENTAL|Noninvasive ventilation|Respiratory assistance is provided by a NIV either Puritan Bennet 840 (Covidien, U.S.A.), EngströmCarestation (GE Healthcare, Finland) or Hamilton-G5 (Hamilton Medical, Germany), will be used for conventional non-invasive ventilation via an oronasal mask that helps patients to cope with their Breathlessness. Settings will be adjusted based on the clinical assessment of the respiratory therapist as per standard practice.
62845214|NCT03446196|EXPERIMENTAL|MOSTCARE UP|Clinician will be able to read MOSTCARE parameters and to choose the best treatment to adequate hemodynamics considering that current literature suggests a fluid IV expansion only if PPV \> 12%
62845215|NCT03446196|NO_INTERVENTION|CLINICIAN EXPERIENCE|Fluid replacement will be made based on clinician experience
62845216|NCT05733767|ACTIVE_COMPARATOR|Enhanced usual care (EUC)|The investigators will administer the enhanced usual care intervention to randomized patients.
62845217|NCT05733767|EXPERIMENTAL|Personalized Care: Nurse Practitioner led Tobacco Treatment Team (NPT3)|The investigators will administer the personalized care NPT3 intervention to randomized patients.
62845218|NCT01440192|EXPERIMENTAL|Cohort A: 1 Unit PDA001 (cenplacel-L)|
62845219|NCT01440192|EXPERIMENTAL|Cohort B: 1 Unit PDA001 (cenplacel-L)|1 unit PDA001(cenplacel-L)
62845220|NCT01782248|OTHER|Alzheimer disease|Patients with Alzheimer disease
62845221|NCT01782248|OTHER|Fronto-temporal lobar dementia|Patients with Fronto-temporal lobar dementia
62845222|NCT01782248|OTHER|Control|Control group
62845223|NCT01986699||Standard Therapy|Patients are treated as per current standard of care
62845224|NCT01986699||Laparoscopic Assisted Polypectomy|Patients treated with Laparoscopic Assisted Colonoscopic Polypectomy
62845225|NCT05300763|EXPERIMENTAL|TEST LENS|Eligible subjects who are habitual soft contact lens wearers will be randomly assigned the TEST Lens for the duration of the study.
62845226|NCT05300763|EXPERIMENTAL|CONTROL LENS|Eligible subjects who are habitual soft contact lens wearers will be randomly assigned the CONTROL Lens for the duration of the study.
62845227|NCT01594528|EXPERIMENTAL|SC|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects with schizophrenia
62845228|NCT01594528|EXPERIMENTAL|controls|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects without any psychiatric trouble
62845229|NCT01594528|EXPERIMENTAL|MD|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects with major depression
62845230|NCT06245096|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Over 8 sessions, clients learn techniques to challenge and change maladaptive thought and behavioral patterns
62845231|NCT06245096|ACTIVE_COMPARATOR|Acceptance and Commitment Therapy|Over 8 sessions, clients learn techniques to accept their negative internal experiences and commit to action in line with their values
62845232|NCT01118000|EXPERIMENTAL|limb ischemia preconditioning|limb ischemic preconditioning consists of three 5-min cycles of left upper limb ischemia induced by a blood pressure cuff placed on the left upper arm and inflated to 200 mmHg,with an intervention 5-min of reperfusion during which the cuff was deflated.
62845233|NCT03815318|EXPERIMENTAL|Recombinant Human Coagulation FVIII|Participant receivedSCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
62262880|NCT06011148||Subject implanted with Perceval S sutureless prosthetic heart valve|Subjects who have been implanted with Perceval S sutureless prosthetic heart valve from 2022 onward and subjects that will be implanted up to study closure.
62262881|NCT04777487|EXPERIMENTAL|Healthy Periodontium|Full-mouth clinical periodontal measurements recorded and GCF obtained.
62262882|NCT04777487|EXPERIMENTAL|Gingivitis|Full-mouth clinical periodontal measurements recorded and GCF obtained.
62619235|NCT05912985||nasal cannula group|Nasal cannula will be used in bronchoscopy procedures in which sedation is applied in this group.
62619236|NCT05912985||modified nasopharyngeal cannula group|In this group, modified nasopharyngeal cannula will be used in bronchoscopy procedures with sedation.
62845234|NCT04279613|EXPERIMENTAL|NNC0361-0041|Dosage form: 9 mg/ml Solution for injection Route of administration: Subcutaneous Initial dose/Unit dose strength(s)/Dosage level(s) in cohort 1: 1mg Additional doses in cohorts 2, 3, and 4: 5mg, 12.5mg and 25mg Dosing instructions: Once weekly on site
62845235|NCT04279613|PLACEBO_COMPARATOR|Placebo|Dosage form: Solution for injection Route of administration: Subcutaneous Dosing instructions: Once weekly on site
62845236|NCT01783704|EXPERIMENTAL|PUSH and Nutrition|PUSH is a specific multi-component intervention based on improving specific precursors to community ambulation. The intervention addresses endurance with continuous upright exercise for 20 min.; function by improving fast walking, standing from a chair, and stair negotiation; muscle performance by exercising to enhance lower extremity strength; and balance by performing unilateral activities and activities with decreased base of support. Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive up to three visits a week, on non-consecutive days, for 16 weeks. Visits take place in the participant's place of residence. Participants also receive the nutritional intervention for the duration of the 16-week study.
62845237|NCT01783704|EXPERIMENTAL|PULSE and Nutrition|PULSE is a non-specific multi-component intervention in which participants will receive flexibility exercises, active range of motion (AROM) for the upper and lower extremities, breathing exercises, and transcutaneous electrical nerve stimulation (TENS). Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive up to three visits a week, on non-consecutive days, for 16 weeks. Visits will take place in the participant's place of residence. Participants will also receive the nutritional intervention for the duration of the 16-week study.
62059268|NCT03692338|EXPERIMENTAL|12 week semi-supervised exercise program|"This cohort will complete 12 weeks of a semi-supervised exercise program independently. Patients will be scheduled for an exercise session with a study exercise physiologist during clinical appointments to complete a sample intensity and time specific exercise session. The preferred mode will be walking, however cycling is also permitted. For each session the patient will wear a heart rate monitor. Following a 5 minute warm-up, patients will increase the intensity of exercise to reach a heart rate corresponding to approximately 60% VO2peak, and will continuously maintain this intensity for their individualized duration to elicit the desired energy expenditure. Each week, the exercise physiologist will call the patient and discuss how to approach the next set of exercise sessions.~Additionally, patients will receive standard of care nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks."
62059269|NCT03692338|NO_INTERVENTION|Control cohort|Participants will have routine care for 12 weeks. This will consist of nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks.
62059270|NCT05968768|EXPERIMENTAL|Experimental - Naxitamab Arm|Treatment with naxitamab will be continued no longer than 6 cycles a year or until disease progression, patient consent, unacceptable toxicities, or study closure
62059271|NCT05968768|NO_INTERVENTION|Control Group - standard treatment|The control group - will receive only standard treatment.
62059272|NCT06267456|OTHER|handball players|Handball players aged between 18 and 35 who have been playing for a minimum of 3 years.
62059273|NCT06267456|OTHER|volleyball players|volleyball players aged between 18 and 35 who have been playing for a minimum of 3 years.
62059274|NCT06267456|OTHER|basketball players|Basketball aged between 18 and 35 who have been playing for a minimum of 3 years.
62845238|NCT04551534|EXPERIMENTAL|DNL201|Part 1: Single-ascending dose cohorts; Part 2: Multiple-ascending dose cohorts (10 days); Part 3: Additional multiple-dose cohort (10 days)
62262883|NCT04777487|EXPERIMENTAL|Periodontitis|Full-mouth clinical periodontal measurements recorded and GCF obtained.
62619237|NCT05912985||HFNO group|HFNO will be used in bronchoscopy procedures in which sedation is applied in this group.
62059275|NCT01885728|ACTIVE_COMPARATOR|Arginine rich nutritional supplement|237 ml of an arginine rich nutritional supplement 4 times a day for the five days preceding surgery.
62059276|NCT01885728|NO_INTERVENTION|No nutritional supplement|No specific nutritional requirements have to be met in this group.
62059277|NCT03315130|EXPERIMENTAL|0.1 mg/kg zilucoplan (RA101495)|
62059278|NCT03315130|EXPERIMENTAL|0.3 mg/kg zilucoplan (RA101495)|
62059279|NCT03315130|PLACEBO_COMPARATOR|Placebo|
62059280|NCT06161311|ACTIVE_COMPARATOR|Myopic RPR group|Patients with myopic relative peripheral refraction
62059281|NCT06161311|ACTIVE_COMPARATOR|Hyperopic RPR group|Patients with hyperopic relative peripheral refraction
62262884|NCT06024642|EXPERIMENTAL|V117957|
62262885|NCT06024642|PLACEBO_COMPARATOR|Placebo|
62262886|NCT05827939||SARS-CoV-2 Infection|Participants from individuals with SARS-CoV-2 Infection .
62262887|NCT05827939||SARS-CoV-2 non-infection with vaccination|Participants after the second dose covid19 vaccination from individuals without SARS-CoV-2 infection.
62619238|NCT00759655|OTHER|open label|
62619239|NCT03585972|EXPERIMENTAL|Frailty Prevention Program|4 face-to-face sessions, with a licensed and registered occupational therapist over 4 months
62619240|NCT03585972|NO_INTERVENTION|Educational materials|Participants receive publicly available educational materials
62619241|NCT01741350|EXPERIMENTAL|CHRP Group|Patients assigned to Community-friendly Health Recovery Program (CHRP) will receive a weekly HIV risk reduction group level intervention led by two facilitators trained and supervised by the PI, a licensed clinical psychologist. The CHRP intervention is a substantially shortened version of the comprehensive Holistic Health Recovery Program (HHRP)-based interventions that have been identified as demonstrating evidence of effectiveness in two randomized clinical trials. The CHRP, which includes four 50-minute groups (1 group per week), will contain only content that relates explicitly to drug- or sex-related HIV risk reduction. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
62619242|NCT01741350|ACTIVE_COMPARATOR|Control Condition|The time-and-attention-matched control condition for the proposed research will be a time and contact-matched, non-contaminating support group for individuals in recovery modeled after similar groups offered in the community. There will be no overlap between the content of the comparison intervention and experimental intervention although the basic structure will be the same. Thus, each participant will be asked to attend four 50-minute weekly group sessions led by two trained facilitators. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
62619243|NCT02368275||prospective cohort of patients undergoing mastectomy|Prospective cohort
62619244|NCT02368275||cross sectional cohort of patients|Cross sectional cohort
62619245|NCT05461989||primary hypertension|adolesence primary hypertension patients
62845239|NCT04551534|PLACEBO_COMPARATOR|Placebo|Part 1: Single-ascending dose cohorts; Part 2: Multiple-ascending dose cohorts (10 days); Part 3: Additional multiple-dose cohort (10 days)
62845240|NCT04518579|ACTIVE_COMPARATOR|Group (EP)|Group (EP) received epidural (fentanyl and bupivacaine) - propofol based anesthetic technique and postoperative analgesia through patient controlled analgesia device (PCA)
62845241|NCT04518579|ACTIVE_COMPARATOR|Group (EH)|Group (EH) received epidural (fentanyl and bupivacaine)- inhalational based anesthetic technique and postoperative analgesia through patient controlled analgesia device (PCA)
62845242|NCT02550405|EXPERIMENTAL|Craving behavioral intervention|The craving behavioral intervention (CBI) was developed based on the framework of craving, combining with behavior intervention (Dong and Potenza, 2014), and conducted among individuals with IGD.
62059282|NCT00671957||Patients undergoing gastric bypass|"Patients undergoing gastric bypass surgery and who are participants in Longitudinal Assessment of Bariatric Surgery (LABS-2).~Inclusion Criteria:~* No acute illnesses~* Weight less than 227 kg (limit of Bod Pod and Treadmill)~* Able to walk at 2.4 mph for 15 minutes (needed for the energy expenditure testing)~* No tobacco use~* Ability to stop alcohol consumption during test phases~* For female subjects; no plans for pregnancy in 24 months and menstrual cycles of 21-35 days~* No history of eating disorder~* No history of current substance abuse~* No history of chest pain or shortness of breath at rest or on exertion.~* Negative pregnancy in women."
62262888|NCT05827939||SARS-CoV-2 non-infection without vaccination|Participants get covid19 vaccination below 2 dose from individuals without SARS-CoV-2 infection.
62262889|NCT02846532|EXPERIMENTAL|Rivaroxaban|
62262890|NCT02846532|EXPERIMENTAL|Acetylsalicylic Acid|
62262891|NCT05121480|EXPERIMENTAL|Cohort 1|100 participants with mild, moderate or severe Atopic Dermatitis 75 participants on EDP1815 and 25 participants on matching placebo administered as 2 capsules (1.6 x 10\^11 total cells) once daily for 16 weeks
62262892|NCT05121480|EXPERIMENTAL|Cohort 2|100 participants with mild, moderate or severe Atopic Dermatitis 75 participants on EDP1815 and 25 participants on matching placebo administered as 2 capsules (6.4 x 10\^11 total cells) once daily for 16 weeks
62619246|NCT05461989||secondary hypertension|adolesence secondary hypertension patients
62619247|NCT02651688|EXPERIMENTAL|Enclomiphene 12.5 mg|Enclomiphene 12.5 milligram (mg) capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
62619248|NCT02651688|EXPERIMENTAL|Enclomiphene 25 mg|Enclomiphene 25 mg capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
62619249|NCT02651688|PLACEBO_COMPARATOR|Placebo|One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
62845243|NCT02550405|NO_INTERVENTION|Control|The control group were individuals with Internet gaming disorder who did not receive any intervention but were scanned twice with the similar interval period as experimental group.
62845244|NCT03825861|EXPERIMENTAL|FOLFIRINOX|Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
62845245|NCT06159218|ACTIVE_COMPARATOR|Omeprazole|Patients with active EoE who have been started on omeprazole as treatment
62845246|NCT06159218|ACTIVE_COMPARATOR|Budesonide|Patients with active EoE who have been started on budesonide as treatment
62845247|NCT02049593|EXPERIMENTAL|Arm A (PARP inhibitor BMN-673, temozolomide)|Patients receive PARP inhibitor BMN-673 PO QD on days 1-28 and temozolomide PO daily on days1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62845248|NCT02049593|EXPERIMENTAL|Arm B (PARP inhibitor BMN-673, irinotecan hydrochloride)|Patients receive PARP inhibitor BNM-673 as in Arm A and irinotecan hydrochloride IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62059283|NCT03842839|EXPERIMENTAL|Tiotropium (0-12 month) + SABA as needed|"* During the 2 years treatment phase patients will be administered with tiotropium bromide (Spiriva) capsule 18μg once daily from baseline to the 12th months.~* Any long acting bronchodilator will not be used from the 12 to 24 months.~* Salbutamol sulphate aerosol (Ventolin) will be administered as concomitant medication treatment when exacerbation occurs."
62845249|NCT02039024|EXPERIMENTAL|18F- DTBZ for Parkinson's Disease|"This study will compare the amyloid deposition of brain by florbetapir F-18 PET imaging and monoaminergic function by18F- DTBZ PET in 10 NC group, 30 PD group, 30 PDD group, 20 AD group. We will also analyze monoaminergic function by18F- DTBZ PET in 30 PDI group.~Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, healthy subjects, PD, PDD, and AD patients will have 4 visits in this study. PDI patients will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
62059284|NCT03842839|EXPERIMENTAL|Tiotropium (0-24 month) + SABA as needed|"* During the 2 years treatment phase patients will be administered with tiotropium bromide (Spiriva) capsule 18μg once daily from baseline to the 24th months.~* Salbutamol sulphate aerosol (Ventolin) will be administered as concomitant medication treatment when exacerbation occurs."
62619250|NCT03876496|EXPERIMENTAL|SensableCareCare System|The Sensable®Care System uses pressure sensors and computer software to sense how patients are positioned on the bed in order to reduce bed falls. The Sensable®Care System Mattress has sensors embedded in them, which will be monitored by the nurses in the unit.
62845250|NCT04494997||Dentists|Practicing Dental Health Professionals who are either General Dentists \&/or Specialists Dentists are part of the Cohort. They should have held or currently hold Social Media account for their Professional purpose. They should have used or currently using their Social Media account for Professional purpose. The Google form questionnaire survey link will be shared with the Dentists in internet via Social Media \&/Or email to seek responses. The link will be available for single response for a single respondent.
62845251|NCT02004041|EXPERIMENTAL|VLY-686|
62845252|NCT02004041|PLACEBO_COMPARATOR|Placebo|
62845253|NCT00283335|ACTIVE_COMPARATOR|Gemfibrozil|1200 mg slow-release gemfibrozil (Lopid-SR) once per day
62059285|NCT03842839|OTHER|SABA as needed only|"* During the 2 years treatment phase patients will be administered with salbutamol sulphate aerosol (Ventolin) when exacerbation occurs.~* Any long acting bronchodilator will not be used during the 2 years treatment phase."
62619251|NCT04622202|ACTIVE_COMPARATOR|pregabalin|oral capsule pregabalin 150 mg.
62262893|NCT05121480|EXPERIMENTAL|Cohort 3|100 participants with mild, moderate or severe Atopic Dermatitis 75 participants on EDP1815 and 25 participants on matching placebo administered as 1 capsule (3.2 x 10\^11 cells) twice daily (6.4 x 10\^11 total cells) for 16 weeks
62619252|NCT04622202|PLACEBO_COMPARATOR|multivitamin|oral multivitamin capsule.
62619253|NCT01768923|ACTIVE_COMPARATOR|SDAI remission group|SDAI remission
62619254|NCT01768923|ACTIVE_COMPARATOR|Minimal disease activity group|Minimal disease activity remission
62619255|NCT03079973|EXPERIMENTAL|P-3073|
62619256|NCT03079973|PLACEBO_COMPARATOR|Vehicle|
62619257|NCT00591019|ACTIVE_COMPARATOR|modafinil|
62619258|NCT00591019|PLACEBO_COMPARATOR|Placebo|
62619259|NCT01950156|EXPERIMENTAL|Vaccine|HLA-A\*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant
62262894|NCT05121480|EXPERIMENTAL|Cohort 4|105 participants with mild, moderate or severe Atopic Dermatitis 70 participants on EDP1815 and 35 participants on matching placebo administered at 1 capsule (8.0x10\^10 total cells) once daily for 16 weeks
62447211|NCT03057262||Study group|Study group consisted of 56 subjects of both genders with unilateral or bilateral disc displacement(s) with reduction and pain in the area of temporomandibular joint. Patients were recruited from the Consulting Room of Temporomandibular Joint Dysfunction at the Jagiellonian University in Krakow during the years 2014-2016. In the study group was used the typical acrylic anterior repositioning splint fabricated in tete-a-tete (incisal) jaws position, covered the lower teeth arch to recapture a displaced disc(s) and decrease the intensity of pain. The anterior repositioning splint was recommended to 20 - hour use for a period of four months.
62447212|NCT03057262||Control group|Control group consisted of 56 subjects of both genders with unilateral or bilateral disc displacement(s) with reduction and pain in the area of temporomandibular joint. Patients were recruited from the Consulting Room of Temporomandibular Joint Dysfunction at the Jagiellonian University in Krakow during the years 2014-2016. In the control group the investigators used the biostymulation laser (Terapus 2, Accuro, Poland), wave length 808 nm, power 32 J in the form of 12 session (duration of a single session was 3 min 45 s), performed every second day, on the area of the both temporomandibular joints (distance to the skin was 1 cm) with opened mouth and systematic performing of muscles self-exercises with a dominant protrusive position of mandible.
62447213|NCT02942303|ACTIVE_COMPARATOR|Technique 1: Lateral orbicularis injections|5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim.
62447214|NCT02942303|ACTIVE_COMPARATOR|2. Technique 2: Lateral orbicularis and Corrugator injections|5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed into the corrugator at the medial brow
62447215|NCT00798551|OTHER|Risk counseling|Risk counseling regarding elevated blood pressure
62447216|NCT05812105|EXPERIMENTAL|Health Buddy Program|This intergenerational program targets Spanish speaking older adults who lack reliable and/or safe transportation and are managing at least one chronic illness. The program goal is to improve older adults' awareness of existing community resources, with an emphasis on transportation and health assets. Trained college students acted as facilitators for the program and helped older adults with relevant community resources.
62447217|NCT06484712|EXPERIMENTAL|Stochastic Resonance (SR)|During this condition, participants will walk on the treadmill while receiving SR stimulation at their individual optimal intensity (SR) with and without visual perturbations.
62619260|NCT00284154|EXPERIMENTAL|Intervention|Patients received vinflunine 320 mg/m2 every 21 days as a 15- to 20-minute infusion.
62619261|NCT02528617|OTHER|Gaucher Type 1 or 3|Velaglucerase alfa IV 60 units/kg every other week for duration of the study.
62619262|NCT01331135|EXPERIMENTAL|sirolimus treatment|Dose escalation of sirolimus with starting dose at 1 mg/m2 and increasing to a possible 3 mg/m2.
62619263|NCT01227239|EXPERIMENTAL|1|
62619264|NCT05215353|EXPERIMENTAL|Music Therapy (MT)|MT is a non-pharmacological, evidence-based intervention, in which board-certified music therapists engage patients in personally tailored experiences with music to achieve therapeutic goals. Patients will receive a workbook with materials for each session These experiences range from music-guided relaxation to more active forms of musical engagement, including singing and improvising music.
62619265|NCT05215353|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT) is an evidence-based, nonpharmacological intervention delivered by licensed mental health providers. Informed by the cognitive behavior model of anxiety, CBT focuses on the relationship between thoughts, behaviors, and emotions and how thoughts and behaviors can exacerbate or reduce anxiety.
62619266|NCT05308849|OTHER|Pediatric Peritonitis|Patient (from 3 to 17 years-old) treated for appendicular peritonitis. It includes surgical treatment (appendicectomy, peritoneal toilet) and antibiotherapy according to French recommendation.
62619267|NCT03909698||Hemodialysis patients on amoxicillin-clavulanic acid|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.~All blood and urine samples are analyzed for amoxicillin-clavulanic acid."
62845254|NCT00283335|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets taken once per day
62262895|NCT06268743|EXPERIMENTAL|High intensity|Participants will perform high-intensity aerobic and strength training exercises.
62262896|NCT06268743|ACTIVE_COMPARATOR|Moderate Intensity|Participants will perform moderate-intensity aerobic and strength training exercises.
62845255|NCT00332722|ACTIVE_COMPARATOR|Group 1- without steroid|Cervical Facet Joint Nerve block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin)
62262897|NCT01651715|EXPERIMENTAL|TAO1, oral homeopathic antibodies|TAO1 is an investigational medicinal product containing homeopathic dilutions (\<10-24M) of antibodies purified from the serum of rabbit immunised against a synthetic peptide with an amino acid sequence selected in the human toll-like receptor type 3 sequence (anti-TLR3). It is intended for the treatment of viral Upper Respiratory Tract Infections (URTIs) such as common cold, influenza or influenza-like illnesses.
62059286|NCT06407076||Observacional group|18 people (6 doctors, 6 nurses and 6 physiotherapists) will be included in the study. The 18 health professionals will participate in personal interviews and focus groups (3 focus groups with 6 participants each). Participants will be recruited from the Intensive Care Unit of the Hospital Universitario Central de Asturias.
62262898|NCT01651715|PLACEBO_COMPARATOR|Placebo|Same characteristics as investigational medicinal Product except for homeopathic dilutions of oral antibodies to the TLR3 FYW peptide
62262899|NCT00718276|ACTIVE_COMPARATOR|1|25(OH)D
62619268|NCT03909698||Hemodialysis patients on ceftazidim|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.~All blood and urine samples are analyzed for ceftazidim."
62845256|NCT00332722|ACTIVE_COMPARATOR|Group 2 - with steroid|Cervical Facet Joint nerve block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin) and 0.15 mg of non-particulate betamethasone)
62845257|NCT05355883|EXPERIMENTAL|Remote Ischemic Conditioning (RIC)|"RIC is achieved via blood pressure cuff inflation to at least 20 mmHg above systolic blood pressure to 250 mmHg on the more involved arm. RIC involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. RIC is performed on visits 2-6.~Intervention~* Hand Arm Bimanual Intensive Therapy (HABIT)~* Bimanual cup stacking training~* Balance training"
62845258|NCT05355883|SHAM_COMPARATOR|Sham Conditioning|"Sham conditioning is achieved via blood pressure cuff inflation to 25 mmHg on the more involved arm. RIC involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. RIC is performed on visits 2-6.~Intervention~* Hand Arm Bimanual Intensive Therapy (HABIT)~* Bimanual cup stacking training~* Balance training"
62845259|NCT01747395|NO_INTERVENTION|Control Group|No exercise group (sedentary)
62262900|NCT00718276|ACTIVE_COMPARATOR|2|vitamin D3
62059287|NCT06624553|NO_INTERVENTION|Control group. Capilary glucose monitoring|The patient randomized to the control group, capillary glucose monitoring, will be provided with the necessary material for six weeks (Free Style Optium glucometer, puncturer, Free Style Optium strips, lancets and record book) and the objectives, technique of analysis, recording and interpretation. The patient/carer will be asked to practice before leaving the office to ensure that they perform the technique correctly and effectively.
62262901|NCT03344744||SAH with DCI|Aneurysmal subarachnoid haemorrhage patients with delayed cerebral infarction
62262902|NCT03344744||SAH nonDCI|Aneurysmal subarachnoid haemorrhage patients without delayed cerebral infarction
62262903|NCT03344744||Control|Healthy volunteers
62262904|NCT00336453|EXPERIMENTAL|FluBlok-22.5 μg, 6-35 months old|6-35 months old, FluBlok-22.5 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
62262905|NCT00336453|EXPERIMENTAL|FluBlok-45 μg, 6-35 months old|6-35 months old, FluBlok-45 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
62262906|NCT00336453|ACTIVE_COMPARATOR|TIV-7.5 μg, 6-35 months old|6-35 months old, 2006-2007 formulation of Fluzone, (sanofi-pasteur, Swiftwater, PA)-7.5 μg of each hemagglutinin antigen: A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Malaysia/2506/2004 like viruses
62262907|NCT00336453|ACTIVE_COMPARATOR|TIV-15 μg, 36-59 months old|36-59 months old, 2006-2007 formulation of Fluzone (sanofi-pasteur, Swiftwater, PA)-15 μg of each hemagglutinin antigen: A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Malaysia/2506/2004 like viruses
62845260|NCT01747395|EXPERIMENTAL|Aerobic Exercise Training|Group undergoing isolate aerobic exercise training 3 times/week, during 40 minutes, for 04 mouths
62845261|NCT01747395|EXPERIMENTAL|Inspiratory Muscle Training|Group undergoing isolate inspiratory muscle training 7 times/week, during 30 minutes, for 04 mouths
62845262|NCT01747395|EXPERIMENTAL|Aerobic+Inspiratory Muscle Training|Group undergoing aerobic exercise training (3 times/week during 40 minutes) associate inspiratory muscle training (7 times/week during 30 minutes) for 04 mounths
62262908|NCT00336453|EXPERIMENTAL|FluBlok-45 μg, 36-59 months old|36-59 months old, FluBlok-45 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
62262909|NCT05671432|EXPERIMENTAL|Group A|Group A: CM326, subcutaneous (SC)
62262910|NCT05671432|EXPERIMENTAL|Group B|Group A: CM326, subcutaneous (SC)
62262911|NCT05671432|PLACEBO_COMPARATOR|Group C|Group C: placebo, subcutaneous (SC)
62262912|NCT02244216||Chronic Obstructive Respiratory Tract Disease|
62262913|NCT02854423||biodegradable polymer|
62262914|NCT02854423||durable-polymer|
62262915|NCT02109900||Serum Progesteron Levels|
62262916|NCT04451421|EXPERIMENTAL|Standing Angle|Assist the electric hospital bed to conduct different Angle standing training, starting from 20 degrees, every five minutes to rise 5 degrees, the maximum rise to 80 degrees
62619269|NCT03909698||Hemodialysis patients on piperacillin-tazobactam|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.~All blood and urine samples are analyzed for piperacillin-tazobactam."
62845263|NCT00946153|EXPERIMENTAL|Lenvatinib|
62845264|NCT05522348|EXPERIMENTAL|Stability of a two piece PSI deign in splintless maxillary orthognathic surgery|A two piece fixation device will be used connecting the nasomaxillary and the zygomaticomaxillary buttresses on both sides
62262917|NCT03051360|ACTIVE_COMPARATOR|PCSK9 inhibitor|Patients will receive bi-weekly PCSK9 inhibitor .
62262918|NCT03051360|PLACEBO_COMPARATOR|Placebo|Patients will receive bi-weekly placebo.
62059288|NCT06624553|EXPERIMENTAL|Intervention group. FreeStyle Libre 2|The patient randomized to the intervention group (FSL2) will be provided with the necessary material for six weeks (sensor, applicator and reader or mobile application (App)) and the objectives, analysis, recording and interpretation technique will be explained. The patient will be helped to register in the application and share the data with the hospital. The patient will carry out the first readings before leaving the consultation to ensure that they are carried out correctly.
62262919|NCT00675922|EXPERIMENTAL|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon 5% Solution and Silver Nitrate soaked dressings to two different burned area. Sites were then monitored for infections during hospitalization.
62262920|NCT03669458|EXPERIMENTAL|Arm 1: BTK intervention with SPUR/DCB|Below the knee peripheral intervention using SPUR/DCB.
62262921|NCT03669458|EXPERIMENTAL|Arm 2: BTK intervention using SPUR Only|Below the knee peripheral intervention using SPUR only.
62262922|NCT03669458|EXPERIMENTAL|ARM 3: BTK intervention using DCB Only|Below the knee peripheral intervention using DCB only.
62447218|NCT06484712|NO_INTERVENTION|No Stochastic Resonance (no-SR)|During this condition, participants will walk on the treadmill while receiving no SR stimulation (no-SR) with and without visual perturbations.
62447219|NCT02638831|EXPERIMENTAL|Ketorolac Tromethamine|Ketorolac 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
62845265|NCT05522348|ACTIVE_COMPARATOR|Stability of a one piece PSI deign in splintless maxillary orthognathic surgery|A one piece fixation device will be used extending from one zygomaticomaxillary buttress to the nasomaxillary area then just below the anterior nasal spine then to the same buttresses on the other side
62447220|NCT02638831|ACTIVE_COMPARATOR|Ketoprofen|Ketoprofen gel 2.5% for external application. Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
62845266|NCT02549924|EXPERIMENTAL|Resveratrol|Individuals with T2DM inadequately controlled with metformin 2000 mg/day and A1C ≥7%.
62845267|NCT02549924|PLACEBO_COMPARATOR|Placebo|Individuals with T2DM inadequately controlled with metformin 2000 mg/day and A1C ≥7%.
62059289|NCT04709432||ECMO group|children supported by ECMO in the past 10 years
62262923|NCT01783275|EXPERIMENTAL|Aerobic Exercise|12 weeks of aerobic exercise
62262924|NCT01783275|NO_INTERVENTION|Control|12 weeks with no change in diet or exercise habits (weight maintenance).
62447221|NCT01140074|EXPERIMENTAL|Zinc sulfate|Children in active treatment group will be given zinc sulfate 10-20 mg per day orally plus probiotics
62447222|NCT01140074|PLACEBO_COMPARATOR|Placebo|Children will be given placebo plus probiotics
62845268|NCT01048034|EXPERIMENTAL|Azacitidine +/- erythropoetin|
62845269|NCT02871908|EXPERIMENTAL|L reuteri DSM 17938|L reuteri DSM 17938 2 x 10\^8 twice daily
62059290|NCT04945421|EXPERIMENTAL|Sintilimab and IBI310 (single arm)|The test group will be treated with either (IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
62845270|NCT02871908|PLACEBO_COMPARATOR|Controls|Identically appearing placebo twice daily
62845271|NCT00133068|OTHER|1|Control
62845272|NCT00133068|EXPERIMENTAL|2|Reduction of financial barrier
62845273|NCT00133068|EXPERIMENTAL|3|Computer Intervention
62845274|NCT00133068|EXPERIMENTAL|4|Reduction of financial barrier and Computer Intervention
62262925|NCT06076421|EXPERIMENTAL|Evidence-based fact box on COVID-19 or influenza (intervention)|"Health educators (HE) will receive a flyer with a brief description of the study, a Quick Response-code (QR-code) and a link to an online survey, including either a fact box as tabular format or a visualization on the reverse side about COVID-19 or the flu vaccine to distribute to potential study participants. HE are free to decide if and how to use the fact boxes: whether during, before or after vaccination education, and who to target.~Participants who receive the flyer from their HE can decide on their own to participate in the study by using the QR-code or link on the flyer."
62262926|NCT06076421|NO_INTERVENTION|Usual education/care|Study participants whose HE will be randomised to the control will receive the same flyer but without a fact box on the reverse side.
62845275|NCT02201264||Primary PCI for STEMI patients|Primary PCI for patients presenting with ST elevation MIs
62059291|NCT03244150||School sample|Conducted in 1983 and included 1260 students in high school or trade school.
62262927|NCT04512040|EXPERIMENTAL|Yoga Dyads AD patients and Caregivers|Initially Yoga will be delivered in 1-on-1 format between the yoga therapist and the AD/caregiver dyad. Five outpatient adults, with chronic musculoskeletal pain and a diagnosis of mild AD and their Caregiver, will receive at-home teleyoga classes via video conferencing. Later, yoga will be delivered in a group format. Ten outpatient adults with chronic musculoskeletal pain and a diagnosis of mild AD and their Caregiver will receive group at-home teleyoga classes via video conferencing.
62619270|NCT03909698||Hemodialysis patients on vancomycin|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.~All blood and urine samples are analyzed for vancomycin."
62845276|NCT03204864|ACTIVE_COMPARATOR|Conventional CS lead placement|Patients will be implanted with a CRT device with or without defibrillator (P/D) as per standard clinical practice, without CS lead pacing specific optimization.
62845277|NCT03204864|EXPERIMENTAL|RLD Group|Patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.
62845278|NCT01721837||Atrial fibrillation and mild to moderate renal impairment|
62845279|NCT00243438||1|Patients who have received a Vision stent and who have diabetes and/or complex lesions.
62845280|NCT01274689||cohort|cohort of consecutively enrolled patients with lagophthalmos
62059292|NCT03244150||Nationwide sample|Conducted in 1985 and included a representative sample of 2498 teenagers drawn from the Danish Civil Registration (CPR)
62262928|NCT02411539|EXPERIMENTAL|Arm A: VRC01 followed by placebo|Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo (normal saline) at Weeks 6 and 9.
62845281|NCT03163797||Oropharyngeal cancer|A total of 160 patients with histologically proven oropharyngeal SCC subjected to chemoradiation will be enrolled. Exclusion criteria include previous head or neck malignant tumor, a second malignant tumor, distant metastasis, contraindications to MRI (renal insufficiency, cochlear implant, cardiac pacemaker placement or intracranial aneurysmal ferromagnetic clips), and serum glucose level \>200 mg/dl. Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test.
62845282|NCT05765513|EXPERIMENTAL|35kDa hyaluronan fragment HA35 injection|The investigator injected 35kDa hyaluronan fragment HA35 into the periodontal pocket in a single dose of 100 mg.The distribution of injection amount was determined by the location of gingival inflammation.
62845283|NCT00928993||Main group|pediatric patients receiving overnight sleep study
62845284|NCT01039272||oral cancer|patients with oral squamous cell carcinoma
62845285|NCT01039272||control group|healthy patients without any oral pathology
62845286|NCT03801044||PD patients|All PD patients treated in out unit were enrolled.
62845287|NCT02249832|EXPERIMENTAL|seated robot-assisted ankle therapy|All participants received eighteen 1 hour sessions (3x/week for 6 weeks) of seated robot-assisted ankle training with the MIT anklebot. Upon analysis, subjects were stratified based on average admission gait speed on the 10 Meter Walk Test at comfortable pace according to clinically established gait speed performance groups: low (\<0.4m/sec), moderate (0.4m/sec-0.8m/sec) and high (\>0.8m/sec) functioning.
62059293|NCT04556994|ACTIVE_COMPARATOR|Phase 1 Cardiac Rehabilitation|Phase 1 Cardiac Rehabilitation
62059294|NCT04556994|EXPERIMENTAL|Phase 1 Cardiac Rehabilitation with Lower Limb Paddling|Phase 1 Cardiac Rehabilitation with lower limb paddling
62059295|NCT03566459||Veterans with opioid use disorder (OUD)|Veterans with opioid use disorder (OUD) in VA Maine Healthcare System catchment area
62845288|NCT03311698|EXPERIMENTAL|Intervention|Households receiving the intervention will receive (1) Interventions to promote homestead food production, increase agricultural production and food diversity, (2) nutritional counselling, including locally adapted instructions on the mix and quantity of food suitable for children of ages 6-24 months, and (3) a health-focused intervention, including information on micronutrient supplementation, integrated management of child illnesses, and prevention and management of child malnutrition with a focus on the first 1,000 days.
62845289|NCT03311698|NO_INTERVENTION|Control|Households receive the standard of care in the area for agricultural and health services.
62447223|NCT05133128|OTHER|PATIENTS with cancer and HEALTHY VOLUNTEERS|"* Cohort 1: Patients with Non-Small Cell Lung cancer (25 patients)~* Cohort 2: Patients with Colorectal cancer (25 patients)~* Cohort 3: Patients with Pancreatic cancer (25 patients)~* Cohort 4: Patients with Liver cancer (25 patients)~* Cohort 5: Patients with Gastric cancer/cholangiocarcinoma (25 patients)~* Cohort 6: Healthy volunteers (25 subjects)"
62619271|NCT03909698||Hemodialysis patients on teicoplanin|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.~All blood and urine samples are analyzed for teicoplanin."
62619272|NCT05497817|EXPERIMENTAL|Algorithmically Matched|Individuals that identify as a current and/or former Care Partner for a person with dementia will be matched to other care partners using an algorithm based on personal preferences.
62619273|NCT05497817|ACTIVE_COMPARATOR|Randomly Matched|Individuals that identify as a current and/or former Care Partner for a person with dementia will be randomly matched to other care partners.
62619274|NCT01639924||Study Cohort|Patients with known or suspected gastrointestinal disease
62619275|NCT00332306|EXPERIMENTAL|2|Didanosine + Lamivudine + Nevirapine
62619276|NCT00332306|ACTIVE_COMPARATOR|1|Didanosine + Lamivudine + Efavirenz
62619277|NCT03126123|OTHER|acetic acid test|Patients will receive surgical treatment for anal condylomatosis and acetic acid on the mucosa of the anal canal before the surgical procedure
62059296|NCT05302505|EXPERIMENTAL|Simulation|"Theoretical training in e-learning for nurses on :~* arteriovenous fistula puncture~* use of ultrasound with echoreferencing and ultrasound guidance~* therapeutic communication~And simulation-based training (procedural) on :~* arteriovenous fistula puncture~* use of ultrasound with echoreferencing and ultrasound guidance~* therapeutic communication"
62059297|NCT05302505|NO_INTERVENTION|Control|"Theoretical training for nurses in e-learning on :~* arteriovenous fistula puncture~* use of ultrasound with echoreferencing and ultrasound guidance~* therapeutic communication"
62059298|NCT01475695|EXPERIMENTAL|Single cohort|14C GSK2251052
62059299|NCT02098018|ACTIVE_COMPARATOR|Program 1|Program 1
62059300|NCT02098018|ACTIVE_COMPARATOR|Program 2|Program 2
62059301|NCT04598035||Primary Group|Patients with chronic low back pain that candidates them for surgical implant of a SCS device, and received a permanent SCS device.
62059302|NCT04598035||Control Group|Patients with chronic low back pain that are candidates for a surgical implant of a SCS device and do not receive a permanent SCS device after trial leads are placed.
62059303|NCT02939300|EXPERIMENTAL|Combination Of Nivolumab with Ipilimumab|"All patients will be treated based on their primary tumor diagnosis with a combination regimen of Nivolumab and Ipilimumab. Each treatment cycle is 6 weeks; exceptions below.~* Melanoma:~  * Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg, every 3 weeks for 4 doses.~ * Followed by Nivolumab 480 mg every 4 weeks until disease progression. Each cycle of monotherapy is defined as 8 weeks.~* Non-small Cell Lung Cancer / Head and Neck Cancer:~  - Nivolumab 3 mg/kg every 2 weeks, and Ipilimumab 1 mg/kg every 6 weeks.~* Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~  * Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg, every 3 weeks for 4 doses.~ * Followed by Nivolumab 240 mg every 2 weeks until disease progression.~* Renal Cell Carcinoma / Other Solid Tumors (not listed above):~  * Nivolumab 3 mg/kg and Ipilimumab 3 mg/kg, every 3 weeks for 4 doses.~ * Followed by Nivolumab 480 mg every 4 weeks until disease progression. Each cycle of monotherapy is defined as 8 weeks."
62262929|NCT02411539|EXPERIMENTAL|Arm B: placebo followed by VRC01|Participants received an infusion of placebo (normal saline) at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
62619278|NCT01066702|EXPERIMENTAL|NeoCart|Autologous cartilagenous tissue implant
62619279|NCT01066702|ACTIVE_COMPARATOR|Microfracture|surgical intervention
62619280|NCT01612078|EXPERIMENTAL|Droxidopa, antihypotensive drug, tablet|
62619281|NCT01612078|PLACEBO_COMPARATOR|placebo, tablet|
62619282|NCT03579121|EXPERIMENTAL|Pharmacogenomic (PGx) guided|Subjects will have Pharmacogenomic (PGx) testing preoperatively. The pharmacists will review results and make recommendations to the anesthesia and orthopedic teams for perioperative anesthesia and analgesia. The teams will use this information to drive clinical decisions as they see fit.
62619283|NCT03579121|ACTIVE_COMPARATOR|Control|Subjects will undergo Pharmacogenomic (PGx) preoperatively but the results will be sealed until completion of treatment and clinicians will not have access to this information. These patients will undergo standard treatment dosing and medication selection.
62619284|NCT00791700|EXPERIMENTAL|Maraviroc|"Subjects will be stratified by age and formulation into one of the following cohorts:~Cohort 1: ≥2-\<6 years of age, maraviroc liquid formulation; Cohort 2: ≥6-\<12 years of age, maraviroc tablet formulation; Cohort 3: ≥6-\<12 years of age, maraviroc liquid formulation and Cohort 4: ≥12-\<18 years of age, maraviroc tablet formulation."
62619285|NCT05717621|EXPERIMENTAL|Test Arm|VTD-101 ointment
62619286|NCT06154720||Study Group|women who received co-amoxiclav 625gm (Megamox® film-coated tablet formed of clavulanic acid 125 mg + amoxicillin 500 mg) tab twice daily for 3 days after delivery
62619287|NCT06154720||Control Group|women who did not receive antibiotics.
62447224|NCT02267096|EXPERIMENTAL|Telephone Counseling (TC)|The TC arm will receive the list of minimal treatment interventions plus 3-6 sessions of stepped-care, proactive, telephone counseling.
62623739|NCT05826340|EXPERIMENTAL|Tailored loading|Participants will be provided with a 5-stage return to sport tool, which gradually increases sports intensity and knee loading. In addition, they are to perform a progressive exercise program at home to increase lower extremity strength and prepare them for the demands of sport. Participants will begin at a starting point in the five stages based on their current symptoms and self reported sports related disability, and given guidance on how to progress / regress their loading within the five stage framework
62619288|NCT02851212|EXPERIMENTAL|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 100 milligram (mg) and 1 canagliflozin tablet 50 mg along with two Extended Release (XR) tablets of metformin of each 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 Extended Release (XR) fixed dose combination \[FDC\] tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg and metformin XR two tablets of each 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62619289|NCT02851212|EXPERIMENTAL|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62619290|NCT02851212|EXPERIMENTAL|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62619291|NCT02851212|EXPERIMENTAL|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62619292|NCT02610530||Non-Surgery|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2 who have been on medical treatment for glycemic control.
62619293|NCT02610530||Surgery-A|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2. who underwent sleeve gastrectomy with ileal transposition
62619294|NCT02610530||Surgery-B|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2. who underwent sleeve gastrectomy with transit bipartition
62619295|NCT01515735||pseudoexfoliation|The study group composted of the patients with pseudoexfoliation syndrome
62619296|NCT02502695||Cohort 1-VATS-associated best practices|"* Data to be collected will include demographic data and information about the pre-operative workup, surgical procedure, postoperative course and early discharge course for these patients.~* After the last patient completes the 30-day post surgery follow-up, the investigators will determine a set of best practices to implement at each of the sites for the quality improvement initiative. During the assessment period, no patients will be enrolled into the study."
62845290|NCT00463567|EXPERIMENTAL|Indacaterol 150 µg (Continued Into Stage 2)|"In the morning, Indacaterol 150 µg once daily orally inhaled via a single dose dry powder inhaler (SDDPI) + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily Inhaled Corticosteroid (ICS) monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
62845291|NCT00463567|EXPERIMENTAL|Indacaterol 300 µg (Continued Into Stage 2)|"In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
62845292|NCT00463567|ACTIVE_COMPARATOR|Tiotropium 18 µg (Continued Into Stage 2)|"Tiotropium 18 µg dry powder capsules delivered (open label) via manufacturer's proprietary SDDPI, (Handihaler®). Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
62619297|NCT02502695||Cohort 2-VATS-associated best practices|-Once the set of VATS-associated best practices, an additional cohort of approximately 200 patients will be enrolled and followed in a manner identical to the first cohort.
62619298|NCT02751619|EXPERIMENTAL|Lidocaine Group|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, PA, USA) measuring 10 x 14 cm and containing 700 mg of Lidocaine, was applied to cover the planned skin incision, marked with a pen by surgeon. Patch was applied for 12 hours during the night, removed for the subsequent 12 hours during the day, and then a new patch was applied at the same level the night after. This process was continued for 3 days before thoracotomy
62619299|NCT02751619|ACTIVE_COMPARATOR|Placebo Patch|A patch, that was identical in appearance to the active patch but did not contain Lidocaine, was applied to cover the planned skin incision, marked with a pen by surgeon. Patch was applied for 12 hours during the night, removed for the subsequent 12 hours during the day, and then a new patch was applied at the same level the night after. This process was continued for 3 days before thoracotomy
62619300|NCT01958398|EXPERIMENTAL|Promillekoll|Smartphone app monitoring alcohol use with feedback.
62059304|NCT04323982|EXPERIMENTAL|New Cataract Surgery|Traditional surgery combined triamcinolone staining of the anterior vitreous (TA)
62262930|NCT01576549|EXPERIMENTAL|LY2127399|LY2127399 given subcutaneously (SC) at 240 milligrams (mg) as a loading dose in the first week followed by 120 mg SC every 4 weeks for up to 52 weeks.
62262931|NCT05497596|EXPERIMENTAL|Treatment group|Vitamin D (2000IU/day) for 6 months
62619301|NCT01958398|EXPERIMENTAL|PartyPlanner|Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
62619302|NCT01958398|NO_INTERVENTION|Control|Untreated control group
62619303|NCT01908582|EXPERIMENTAL|Evacetrapib|"Period 1:~130 milligram (mg) evacetrapib administered orally, once on Day 1"
62262932|NCT05497596|PLACEBO_COMPARATOR|Control group|placebo
62845293|NCT00463567|PLACEBO_COMPARATOR|Placebo (Continued Into Stage 2)|"In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
62262933|NCT05931887|ACTIVE_COMPARATOR|SILQ ClearTract 100% Silicone 2-Way Foley Catheter|Subjects in this arm will receive the SILQ ClearTract 100% Silicone 2-Way Foley Catheter for approximately the first 3 month period of enrollment. In a subsequent period of approximately 3 months subjects in this arm will receive their current standard of care catheter.
62262934|NCT05931887|ACTIVE_COMPARATOR|Standard of Care Catheter|Subjects in this arm will receive their current Standard of Care Catheter for the first 3 month period of enrollment. In a subsequent period of approximately 3 months subjects in this arm will receive the SILQ ClearTract 100% Silicone 2-Way Foley Catheter
62262935|NCT03496220|EXPERIMENTAL|Feedback|The ICU with feedback will be equipped with display device corresponding to each Angulus device with an interactive software interface which displays the patient's elevation.
62619304|NCT01908582|EXPERIMENTAL|Evacetrapib + Rifampin|"Period 2:~Rifampin: 600 mg administered orally, once daily (QD) for 14 days (Days 9 to 22)~Evacetrapib: 130 mg administered orally once on Day 16"
62619305|NCT04825925|EXPERIMENTAL|DEB-BACE|
62619306|NCT01282905||Healthy controls|
62262936|NCT03496220|OTHER|No Feedback|The Angulus device will be on the patient but will NOT have the corresponding display data on patient elevation available to nurses.
62262937|NCT02300701|EXPERIMENTAL|Xolair/Omalizumab|
62262938|NCT02300701|PLACEBO_COMPARATOR|Placebo|
62262939|NCT02055820|EXPERIMENTAL|Venetoclax + G-CHOP Arm|Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + obinutuzumab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
62262940|NCT02055820|EXPERIMENTAL|Venetoclax + R-CHOP Arm|Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + rituximab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
62262941|NCT02037295|EXPERIMENTAL|OF_UF Vancomycin|Healthy volunteers assigned overfeeding diet, underfeeding diet, and then vancomycin
62845294|NCT00463567|EXPERIMENTAL|Indacaterol 75 µg (Not Continued into Stage 2)|"In the morning, Indacaterol 75 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
62262942|NCT02037295|PLACEBO_COMPARATOR|OF_UF Placebo|Healthy volunteers assigned overfeeding diet, underfeeding diet, and then placebo
62447225|NCT02267096|ACTIVE_COMPARATOR|Minimal Treatment|The minimal treatment intervention includes a list of print, online, national telephone quitline phone number, and in-person cessation resources that is sent to participants.
62619307|NCT01282905||Ulcerative colitis|
62845295|NCT00463567|EXPERIMENTAL|Indacaterol 600 µg (Not Continued Into Stage 2)|"In the morning, 2 capsules of Indacaterol 300 µg once daily orally inhaled via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
62845296|NCT00463567|ACTIVE_COMPARATOR|Formoterol 12 µg (Not Continued Into Stage 2)|"In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Formoterol 12 µg delivered via Aerolizer. In evening, Formoterol 12 µg delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
62845297|NCT04949321|EXPERIMENTAL|Gadovist (gadobutrol) / two MRI|60 Meniere's Disease patients and 20 healthy volunteers (sample of 5 volunteers per MRI machine)
62262943|NCT02037295|EXPERIMENTAL|UF_OF Vancomycin|Healthy volunteers assigned underfeeding diet, overfeeding diet, and then vancomycin
62447226|NCT04428671|EXPERIMENTAL|Treatment (cemiplimab)|"NEOADJUVANT PHASE: Prior to standard of care surgery, patients receive cemiplimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~ADJUVANT PHASE: Within 2-6 weeks after standard of care radiation therapy (or surgery if no radiation therapy), patients receive cemiplimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity."
62262944|NCT02037295|PLACEBO_COMPARATOR|UF_OF Placebo|Healthy volunteers assigned underfeeding diet, overfeeding diet, and then placebo
62262945|NCT04141384|OTHER|General rehabilitation+Modular Interactive Tiles System, MITS|Subjects were randomly assigned to the experimental or control group after completing the Berg scale test before the experiment. In the experimental group, external stimulation (MITS) was added, and the training time was 65 minutes. Before the start of the experiment and after the training every 4 weeks, each group must carry out the Berg scale and balance assessment.
62262946|NCT04141384|NO_INTERVENTION|General rehabilitation|Subjects were randomly assigned to the experimental or control group after completing the Berg scale test before the experiment.In the control group, each training time was 45 minutes.Before the start of the experiment and after the training every 4 weeks, each group must carry out the Berg scale and balance assessment.
62262947|NCT03915015|OTHER|the study|Patients with a PPM or ICD getting a clinically indicated MRI
62447227|NCT02675543|EXPERIMENTAL|Standard silicone oil|after vitreous removal, the vitreous chamber was filled with standard silicone oil (PDMS)
62447228|NCT02675543|EXPERIMENTAL|Heavy silicone oil|after vitreous removal, the vitreous chamber was filled with heavy silicone oil (Densiron 68)
62619308|NCT03349489|ACTIVE_COMPARATOR|Reduction of insulin basal rate 40 minutes prior to exercise|
62619309|NCT03349489|ACTIVE_COMPARATOR|Reduction of insulin basal rate 90 minutes prior to exercise|
62619310|NCT05460637|EXPERIMENTAL|Intervention Group|Participants receive a Fitbit and access to a 10 week educational course that accessible through the web or app. While participants can complete the program at their own pace, there is a suggested schedule with 1-2 modules/lessons completed per week. Each module has a different topic related to promoting adoption and maintenance of physical activity.
62619311|NCT05050422|PLACEBO_COMPARATOR|Control|
62619312|NCT05050422|ACTIVE_COMPARATOR|Study|
62447229|NCT04843163|EXPERIMENTAL|Wave A (Immediate NAMI Basics)|Once a participant has completed the questionnaires, that participant will be randomly assigned to either an immediate NAMI Basics class (Wave A), or an 8-week delay (Wave B) condition. Those in the immediate condition will be assigned to take the next available NAMI Basics class. Participants in both groups will be assessed at three time points. Participants in the immediate Basics group (Wave A) condition will be assessed pre-class, post-class, and 6 months after class has ended.
62447230|NCT04843163|NO_INTERVENTION|Wave B (Waitlist Control)|Participants in the 8-week delay condition will be able to participate in a NAMI Basics class immediately following the 8-week time frame. Participants in the 8-week delay group (Wave B) will be assessed before the 8-week delay, after the 8-week delay (prior to their Basics course), and after the Basics course.
62619313|NCT03013192|NO_INTERVENTION|Control|No text message reminders, usual patient protocol
62619314|NCT03013192|EXPERIMENTAL|Intervention (text messaging)|Text message reminders for PT
62845298|NCT02469870|EXPERIMENTAL|Autism Parent Trainer (APT)|Practiced Routines was a facilitated program. It was organized into four modules that included a total of seven videos ranging from 3-13 minutes each. The topics overlapped with those in the TR program, but included more explicit information on function-based strategies, as well as mindfulness practice. Participants were assigned six fillable forms, and provided supplemental data collection tools. Additional resources focused on mindfulness and PBS within family routines. Eighteen brief guided audio meditations were available to participants via the Practiced MindTM mobile application. The meditations focused on bringing the parents' awareness to both internal and external experiences and helping them act intentionally.
62845299|NCT02469870|ACTIVE_COMPARATOR|Teaching Routines (Control|Teaching Routines was entirely self-directed. The program included eight modules with videos for each ranging 3 - 5 minutes in duration. The topics were antecedent-behavior-consequence method, creating task analyses, antecedent-based strategies, communication, reinforcement, teaching methods, and overcoming obstacles. Participants were assigned six activities using fillable forms and provided additional resources including examples, a glossary of terms, and a list of websites. No feedback was given to the parents apart from the automated completion responses. The participants were given access to the TR LMS for the duration of the study, but post and follow-up assessments were completed at 6 and 10 weeks (i.e., same as the PR condition).
62845300|NCT03241511|EXPERIMENTAL|Test|Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic and repeated supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene). Outcomes will be assessed at 2-, 4-, and 6-months. Throughout the course of the study, additional dental needs will be addressed with immediate referral to the subject's general dentist or clinics at the University of Connecticut.
62262948|NCT05865236|EXPERIMENTAL|physical therapy Dry air heat group along with kegel exercise|Woman should lie on the bed without panties or the sanitary Pad. Place towels under buttocks to absorb any vaginal discharge. She should lie on her back with the knees bent and feet flat. Let the vagina dry by holding a hair dryer 10 to 12 inches away from episiotomy. The dry heat will gives a soothing effect on the wound
62447231|NCT06484101|EXPERIMENTAL|Exercise|Healthy human subjects performing 3 x 30 seconds of supramaximal exercise with blood obtained before and up to 60 minutes after the exercise bout
62447232|NCT04686136|EXPERIMENTAL|Atogepant 60 mg|Taken once daily
62447233|NCT02948322|EXPERIMENTAL|OGTT, CMRI with gadolinium in patients|Patients with acromegaly will be investigated
62447234|NCT02948322|ACTIVE_COMPARATOR|OGTT, CMRI with gadolinium in volunteers|Age-, sex- and BMI-matched healthy volunteers will be investigated
62447235|NCT01621490|EXPERIMENTAL|Part 1-Cohort 1 and 2: Nivolumab|Nivolumab 3 mg/kg solution intravenously Every 2 weeks, Up to 2 years depending on response
62447236|NCT01621490|EXPERIMENTAL|Part 2-Arm A: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
62447237|NCT01621490|EXPERIMENTAL|Part 3-Arm A: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
62447238|NCT01621490|EXPERIMENTAL|Part 3-Arm B: Nivolumab|Nivolumab 3 mg/kg solution intravenously as specified
62447239|NCT01621490|EXPERIMENTAL|Part 4-Arm D: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
62447240|NCT01621490|EXPERIMENTAL|Part 4-Arm E: Nivolumab|Nivolumab 3 mg/kg solution intravenously as specified
62447241|NCT05666843|EXPERIMENTAL|Intervention group|Personalized dietary guidance to increase the intake of fibre-rich foods on top of usual care. The dietary guidance is implemented by dieticians and is personalized based on current adherence to the dietary guidelines, usual dietary intake, gender and personal goals and preferences.
62447242|NCT05666843|NO_INTERVENTION|Usual care group|Participants in the control group receive usual health care as provided by general practitioners and nurse practitioners or other health care professionals involved in diabetes care.
62447243|NCT00907842|EXPERIMENTAL|mesh placement|
62619315|NCT03370185|EXPERIMENTAL|Duvelisib|Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles
62619316|NCT00109941|EXPERIMENTAL|metenkephalin, OGF-opioid growth factor|DRUG All subjects treated with met-enkephalin (also called OGF) 250 ug/kg iv weekly over 45 minutes
62619317|NCT04283110|ACTIVE_COMPARATOR|Midazolam group|Midazolam group will receive 1 mg intrathecal midazolam once during induction for anethesia
62619318|NCT04283110|NO_INTERVENTION|control group|control group will receive placebo ( 0.5cm of sterile saline
62619319|NCT03274752|EXPERIMENTAL|Paroxetine|Paroxetine 20mg QD per os for 12 weeks followed by 10mg for one additional week
62619320|NCT03274752|PLACEBO_COMPARATOR|Placebo|Placebo oral capsule QD per os for 13 weeks
62623740|NCT05826340|EXPERIMENTAL|Pain within acitvity limits|Participants will be advised to participate in sport/exercise to the extent that pain allows. They will not be restriced full from sport but will be instructed how to use a pain moritoring tool to help monitor pain and balance the amount of activities in which they can participate.
62059305|NCT04323982|ACTIVE_COMPARATOR|Traditional Cataract Surgery|For patients younger than 2 years of age: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + A-vit) For patients older than 2years of age: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + primary intraocular lens implantation + anterior vitrectomy (ACCC+ I/A + PCCC + IOL + A-vit)
62619321|NCT05263297|OTHER|video group|During the bloodletting process, children in the video game group will be played with audio and visual video games that they can play with one hand. Thus, children will be provided with both visual and auditory stimuli. It will be preferred that children play the video game that they have knowledge about and know how to play the game. For this reason, children in the video game group will be given the chance to choose video games suitable for their age and development level on their parents' smartphones. These video games within the scope of the research will not be named and will not be promoted/advertised.
62623741|NCT05826340|NO_INTERVENTION|Rest until pain subsides|Participants will be provided advice on rest for a minimum of four weeks or until pain subsides
62262949|NCT05865236|ACTIVE_COMPARATOR|therapeutics execise Infra-red lamp therapy along with kegel execise|The infrared the infrared lamp will be placed at distance of 45 cm away from the perineum with the heat emitted with 220 volts used for 10-15 minutes IRR is beneficial for promoting wound healing, tissue repair, and skin rejuvenation.
62262950|NCT02142777|EXPERIMENTAL|Investigational|All study subjects will take a 10mg pill by mouth twice daily over a 6 week period. Subjects will receive either placebo or S -Equol. They will not know which they are receiving.
62262951|NCT01756131|EXPERIMENTAL|Cohort 1|100 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
62447244|NCT01466803|ACTIVE_COMPARATOR|Vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
62447245|NCT01466803|PLACEBO_COMPARATOR|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
62447246|NCT04571723|ACTIVE_COMPARATOR|Established Diabetes Prevention Program|This arm will receive the established diabetes prevention program curriculum.
62845301|NCT03241511|NO_INTERVENTION|Control|The Control arm will receive only a single treatment session without maintenance sessions (see visit Table in Human Subject Protection section). Outcomes will be assessed at 2-, 4-, and 6-months.
62845302|NCT01155518|EXPERIMENTAL|testosterone|intramuscular injections every 2 weeks
62845303|NCT01155518|EXPERIMENTAL|clomiphene|oral drug thrice a week
62845304|NCT01155518|PLACEBO_COMPARATOR|placebo for testosterone|placebo for testosterone arm
62845305|NCT01155518|PLACEBO_COMPARATOR|placebo for clomiphene|oral placebo for clomiphene arm
62845306|NCT01155518|NO_INTERVENTION|eugonadal obese|obese men with normal testosterone level
62845307|NCT01155518|NO_INTERVENTION|lean|healthy lean men (control)
62845308|NCT00361777||Possible Cushing's|Patients with possible cushion's syndrome
62845309|NCT01818752|EXPERIMENTAL|Carfilzomib, Melphalan, Prednisone|Participants received carfilzomib administered in combination with melphalan and prednisone for nine 42-day cycles. Carfilzomib was administered as an intravenous (IV) infusion on days 1, 2, 8, 9, 22, 23, 29, and 30 of each 42-day cycle. The carfilzomib dose was at 20 mg/m² on cycle 1, days 1 and 2 followed by 36 mg/m² thereafter. On days 1 to 4, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².
62262952|NCT01756131|EXPERIMENTAL|Cohort 2|200 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
62447247|NCT04571723|ACTIVE_COMPARATOR|Health Mindset modified Diabetes Prevention Program|This arm will receive the modified curriculum with the added health mindset information.
62845310|NCT01818752|ACTIVE_COMPARATOR|Bortezomib, Melphalan, Prednisone|Participants received bortezomib in combination with melphalan and prednisone for nine 42-day cycles. Bortezomib was administered either IV or subcutaneously at 1.3 mg/m² during cycles 1 to 4 on days 1, 4, 8, 11, 22, 25, 29, and 32 followed by 1.3 mg/m² during cycles 5 to 9 on days 1, 8, 22, and 29. On days 1 to 4 of each cycle, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².
62845311|NCT02619162|EXPERIMENTAL|Letrozole+Nintedanib|Letrozole+Nintedanib
62845312|NCT01145599||Type-2 diabetes, NPDR|Type-2 diabetic patients with NPDR.
62623742|NCT00805129|EXPERIMENTAL|Everolimus|Everolimus will be administered at a dose of 10 mg orally once daily continuously.
62059306|NCT02788630|EXPERIMENTAL|Intervention group|Arm: Experimental: Intervention group Field workers trained in sleep hygiene counseling will advice the mothers randomly allocated to the intervention group. The intervention will be delivered at the child household and will include information on: Normal sleep behaviors during the first year of life; ideal conditions to promote sleep onset like environmental improvements that ensure restful sleep (no screen media, low noise and light); calming naptime routines and avoiding stimulating or stressing children just before naptime; practices that promote child self-regulation of sleep, including putting infants to sleep drowsy but awake; and how to handle nighttime awakenings. A booklet with the intervention content to aid the mother in implementing the intervention will be used.
62262953|NCT01756131|EXPERIMENTAL|Cohort 3|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
62262954|NCT01756131|EXPERIMENTAL|Cohort 4|800 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
62262955|NCT01756131|EXPERIMENTAL|Cohort 5|100 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
62447248|NCT05209646|EXPERIMENTAL|Trial (Intervention) group|Patients will receive honey for 8 weeks in a dose of 30 ml undiluted honey per day divided as 5 ml honey 30 minutes before each meal six times daily. The honey will be kept in a closed glass container and away from light until the time of use. Each patient will be provided with a well-sealed container containing 210 ml honey each week. The honey used in the study will be a raw, unprocessed Clover honey collected from AL Mahala-Gharbia governorate, Egypt. The honey will be supplied directly from a beekeeper without heating or gamma irradiation
62447249|NCT05209646|NO_INTERVENTION|Control (Non-intervention) group|No honey will be given to this group
62059307|NCT02788630|NO_INTERVENTION|Control group|Mothers randomly allocated to the control group will be visited at home following the same schedule as the intervention group. The control group will receive a written material describing the advantages of breastfeeding over maternal and child health. No advice in relation to child sleep hygiene will be delivered to the mothers from the control group.
62262956|NCT01756131|EXPERIMENTAL|Cohort 6|200 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
62262957|NCT01756131|EXPERIMENTAL|Cohort 7|400 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
62262958|NCT01756131|EXPERIMENTAL|Cohort 8|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
62262959|NCT01756131|EXPERIMENTAL|Cohort 9|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
62262960|NCT05752253|OTHER|Patients with Hereditary Hemorragic Teleangectasia|Patients with Hereditary Hemorragic Teleangectasia
62447250|NCT06465823|EXPERIMENTAL|Bumetanide|Patients in the experimental group will receive the pharmacological treatment with Bumetanide
62447251|NCT06465823|PLACEBO_COMPARATOR|Placebo|Patients in the control group will receive the placebo
62447252|NCT01127542|EXPERIMENTAL|Lenalidomide for early stage poor prognosis CLL|
62447253|NCT00356746||1|elective CABG only patients
62447254|NCT00356746||2|elective ICD replacement surgical patients requiring general anesthesia
62623743|NCT04875572|EXPERIMENTAL|Study group|Since this is a single group study, all patients enrolled will receive the same care, as described in the study description above.
62262961|NCT03373097|EXPERIMENTAL|GD2-CART01|After a lymphodepleting regimen the patients will receive 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells.
62262962|NCT06183840|ACTIVE_COMPARATOR|Conventional|Patients with a traumatic fixation of the mesh
62447255|NCT02750761|EXPERIMENTAL|Group 1 Cohort 1: Tedizolid IV 5 mg/kg (6 to <12 years)|Participants 6 to \<12 years of age received a single intravenous infusion of tedizolid phosphate dosed at 5 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
62447256|NCT02750761|EXPERIMENTAL|Group 1 Cohort 2: Tedizolid IV 4 mg/kg (6 to <12 years)|Participants 6 to \<12 years of age received a single intravenous infusion of tedizolid phosphate dosed at 4 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
62845313|NCT05457439|EXPERIMENTAL|Experimental Group|Will be evaluated at baseline and will be intervened for 7 weeks, receiving educational workshops twice a week, addressing the target behaviors. They will also be prescribed a personalized food plan, will receive daily messages through the mobile application, and will have a doubt resolution chat. They will have a digital forum to post photos and comments about their food intake, and physical activity performance, and to like and comment on other participants' photos. They will be asked to enter food records and photos of their food intake into the mobile application, for which they will receive points for performing the expected behavior in a token economy. They will have access to their data for auto-monitoring. In week 8, the experimental group will be evaluated and divided into two sub-groups. One will be completely stopped intervening (n = 25) and one will continue receiving messages through the mobile app, but will no longer have workshops and food plan prescriptions (n = 25).
62845314|NCT05457439|NO_INTERVENTION|Control Group|The control group will be evaluated at baseline and will not be intervened. Anyway, they will be evaluated at weeks 8 (as monitoring) and 15, at the end of the intervention.
62845315|NCT00850421|OTHER|Botulinum Toxin Type A|
62845316|NCT06233513|EXPERIMENTAL|Healthy Adult Speakers|healthy adult participants across the lifespan in three groups:18-35, 36-55, and 56+
62845317|NCT03563118||Group OSAS|We included 56 with OSAS \[13 subjects 23.2% mild, 19 subjects 33.9% moderate, 24 subjects 42.8% severe
62845318|NCT03563118||control group|simple snoring
62845319|NCT03773796|OTHER|Treatment Group|Assessment of long-term efficacy and safety of nabilone 0.25 mg - 2 mg
62845320|NCT00951977||Subjects who have formerly donated a kidney|
62845321|NCT00951977||Matched community control Subjects|
62262963|NCT06183840|EXPERIMENTAL|Glutack|Patient with Glutack mesh fixation
62262964|NCT00746980|EXPERIMENTAL|Treatment|Subjects receiving drug
62262965|NCT00784654|EXPERIMENTAL|Lisdexamfetamine dimesylate (LDX)|Open-label 30, 50, or 70mg
62262966|NCT00784654|PLACEBO_COMPARATOR|Placebo|
62262967|NCT05352815|EXPERIMENTAL|IcoSema|
62262968|NCT05352815|ACTIVE_COMPARATOR|Insulin icodec|
62262969|NCT00884273|EXPERIMENTAL|Degarelix 240 mg/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
62845322|NCT02448641|EXPERIMENTAL|SB623 Implant (2.5M)|2.5 million SB623 cells
62845323|NCT02448641|EXPERIMENTAL|SB623 Implant (5.0M)|5 million SB623 cells
62845324|NCT02448641|SHAM_COMPARATOR|Sham Control|Sham surgery
62845325|NCT05983315||CONECCT's classification assessment|Every patient who needs diagnostic colonoscopy because of digestive symptoms, medical or family history of colorectal cancer/polyps, positive colorectal screening test, acromegaly or referred by another gastroenterologist upon discovery of colorectal polyp after colonoscopy can join the cohort of this study and can get CONECCT's classification histological assessment of their neoplastic lesion by experienced endoscopist.
62262970|NCT00884273|ACTIVE_COMPARATOR|Goserelin (3.6 mg) + bicalutamide (50 mg)|"Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.~On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin."
62447257|NCT02750761|EXPERIMENTAL|Group 2 Cohort 1: Tedizolid IV 6 mg/kg (2 to <6 years)|Participants 2 to \<6 years of age received a single intravenous infusion of tedizolid phosphate dosed at 6 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
62619322|NCT05263297|OTHER|kaleidoscope group|In this study, a kaleidoscope with colorful patterns that can be used by children with one hand will be used. In the research, the kaleidoscope will be introduced to children and how to use it will be explained. After the procedure, the kaleidoscope will be disinfected using appropriate disinfectant materials.
62619323|NCT01385956|EXPERIMENTAL|SOM 230 LAR and Gemcitabine|"Combination Therapy: Dose escalation of SOM 230 LAR and standard treatment with gemcitabine. Treatment will be administered on an outpatient basis. Gemcitabine is administered by IV infusion. The dose should be based on the patient's actual baseline body weight; the dose will be recalculated if there is a weight change of \> 10% from baseline. The dose of gemcitabine will be given over 30 minutes, weekly every 3 weeks followed by 1 week rest period.~SOM 230 LAR will be administered as an intramuscular dose determined by the dosing schema, every month."
62619324|NCT00508157|EXPERIMENTAL|A|
62619325|NCT00508157|ACTIVE_COMPARATOR|B|
62619326|NCT02324621|EXPERIMENTAL|Treatment (oral ONC201)|Patients receive oral ONC201 PO on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62447258|NCT02750761|EXPERIMENTAL|Group 2 Cohort 2: Tedizolid IV 3 mg/kg (2 to <6 years)|Participants 2 to \<6 years of age received a single intravenous infusion of tedizolid phosphate dosed at 3 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
62619327|NCT04183569||Primary diffuse cutaneous B-cell lymphoma, leg type|Cohort of 32 patients LBC-TJ treated with R-chemotherapy for which data collection was carried out in homogeneous and prospectively followed according to international standards through RCP monthly cutaneous lymphomas managed by Professor Beylot-Barry and inclusion of cases in the national database of rare cancer network French Study Group of Cutaneous Lymphomas in Bordeaux managed by Prof. Beatrice Vergier.
62619328|NCT02945696|NO_INTERVENTION|Local port site injection|
62619329|NCT02945696|NO_INTERVENTION|Ultrasound-guided nerve blocks|
62619330|NCT02945696|EXPERIMENTAL|Laparoscopic guided nerve blocks|These patients will receive the same volume of local anesthetic as those in the ultrasound-guided arm, but the delivery of the local anesthetic will be guided by laparoscopy.
62619331|NCT03251482|EXPERIMENTAL|Part 1: Cohort 1 (0.3 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenously (IV) or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
62845326|NCT01971086||acute rhinitis|
62845327|NCT04159311|ACTIVE_COMPARATOR|Treated group|"The treated group will have 3 sessions of osteopathy testing followed by osteopathy treatment (M0, M1, M2) and a final testing session at M3."
62845328|NCT04159311|SHAM_COMPARATOR|Untreated group|"The untreated group will have 4 sessions of only testing osteopathy (M0, M1, M2, M3)."
62447259|NCT02750761|EXPERIMENTAL|Group 3: Tedizolid oral 4 mg/kg (6 to <12 years)|Participants 6 to \<12 years of age received a single dose of tedizolid phosphate oral suspension dosed at 4 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
62447260|NCT02750761|EXPERIMENTAL|Group 4: Tedizolid oral 3 mg/kg (2 to <6 years)|Participants 2 to \<6 years of age received a single dose of tedizolid phosphate oral suspension dosed at 3 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
62447261|NCT01409850|ACTIVE_COMPARATOR|Aqualizer|
62447262|NCT01409850|ACTIVE_COMPARATOR|Soft splint|elastic splint made of copolyester foil
62845329|NCT01509053|EXPERIMENTAL|Aripiprazole IM depot injection|Patients who had no history of tolerability to oral aripiprazole received 10-15 mg/day (up to 30 mg/day) oral aripiprazole for 1 to 4 weeks to determine tolerability in the Tolerability Assessment Phase prior to receiving treatment with aripiprazole IM Depot. In the Open-label Aripiprazole IM Depot Phase, participants received aripiprazole intramuscular (IM) Depot 400 mg injection (dosage could be adjusted to 300 mg at the investigator's discretion) monthly in the clinic for a total of 6 injections + concomitant oral aripiprazole 10-15 mg/day for the first 14 days. Participants at the investigator's discretion were eligible to continue to receive aripiprazole IM depot (400 or 300 mg) injection monthly in the Open-label Aripiprazole IM Depot Extension phase. Oral aripiprazole was available as rescue medication if necessary.
62059308|NCT01539876|OTHER|Fine Needle aspiration will be done X5:|Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
62262971|NCT02228291|PLACEBO_COMPARATOR|Placebo|Cellulose
62262972|NCT02228291|EXPERIMENTAL|Citric flavonoid|Citric flavonoid
62262973|NCT01032915|EXPERIMENTAL|AIN457 300mg s.c weekly for 3 weeks|AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
62619332|NCT03251482|EXPERIMENTAL|Part 1: Cohort 2 (0.6 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 0.6 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
62845330|NCT00441064|EXPERIMENTAL|Diet Sequence Low/High Sodium|Patients on low sodium diet ( \<= 100 mmol/day) for the first 4 weeks and high sodium (\>= 200 mmol/day) diet for the next 4 weeks. \[with Aliskiren 300 mg\]
62059309|NCT04490564||HNSCC, NSCLC, melanoma Patients|The study population are subjects with a confirmed diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), who are going to receive PD-1 inhibitor nivolumab or ii) metastatic Non-Small Cell Lung Cancer (NSCLC), who are going to receive PD-1 inhibitor, e.g. nivolumab, pembrolizumab or iii) metastatic melanoma, who are going to receive PD-1 inhibitor, e.g. nivolumab, embrolizumab. The selected inclusion/exclusion criteria have been set to include in the performance study appropriate population of interest, as broad as possible, but to exclude these subjects that have another current malignancy or any history of recent malignancy within 3 years.
62845331|NCT00441064|EXPERIMENTAL|Diet Sequence High/Low Sodium|Patients on high sodium (\>= 200 mmol/day) diet for the first 4 weeks and on low sodium diet ( \<= 100 mmol/day) for the next 4 weeks. \[with Aliskiren 300 mg\]
62845332|NCT03719196|EXPERIMENTAL|Reading glass provided|"Randomization took place after conducting the census survey. Participants were selected based on the inclusion criteria.~423 random households were surveyed at the baseline. These households have been given reading glasses free of cost."
62845333|NCT03719196|NO_INTERVENTION|Non-reading glass|A total of 824 households were surveyed at the baseline survey. Among them, 423 households have been provided reading glasses. The 401 remaining households were not given reading glasses during the baseline survey. The endline survey will be conducted in March 2018. Upon completing the endline survey, the non-reading glasses group will be provided reading glasses.
62059310|NCT04490564||Healthy volunteers|In case of healhty volunteers, only peripheral blood samples will be collected.
62447263|NCT01409850|NO_INTERVENTION|Counselling|
62845334|NCT00333762|EXPERIMENTAL|SPAM and SWCS|Smart Power Assistance Module (SPAM) Smart Wheelchair Component System (SWCS)
62845335|NCT02672527|EXPERIMENTAL|TRA|"At Day 1 (D1), premedication with dexamethasone (20 mg) and a 5-HT3 receptor antagonist anti-emetic agent will be intravenously administered 30 minutes prior to trabectedin administration. Trabectedin will be administered through a central venous catheter at a starting dose of 1.5 mg/m² over 24 hours, diluted in at least 500 mL of normal saline solution or of glucose 5% injectable solution.~Each treatment cycle will last 21 days. Treatment duration: the treatment might be pursued until disease progression according to RECIST 1.1, or patient refusal, or toxicities.~In case of disease progression, the further treatments will be based on investigator's judgement."
62845336|NCT02672527|NO_INTERVENTION|BSC|"Treatment:~Patients will receive the best supportive care (BSC) in order to alleviate their symptoms and improve their Quality of Life (QoL).~Antineoplastic agents (including surgery, radiotherapy, thermotherapy, chemotherapy, immunotherapy, hormonal treatment or antibodies-based treatments) are prohibited.~Treatment duration: the treatment might be pursued until disease progression according to RECIST 1.1, or patient refusal.~In case of disease progression, a treatment with trabectedin will be proposed (cross-over). In case of patient refusal, the further treatments will be based on investigator's judgement."
62059311|NCT05889884|EXPERIMENTAL|Fixed retainer group|test group who undergoes retention using extended maxillary fixed retainer
62059312|NCT05341986|OTHER|Link-Out|Clinicians will be trained on the web-based portal of the CDS tool and shown where the Link to the tool will be available in the EHR.
62059313|NCT05341986|OTHER|BPA + Link-out|Clinicians will be trained on how a BPA is triggered when a patient is diagnosed with AF. The alert will pop up within the EHR with the Link-out to the web portal.
62619333|NCT03251482|EXPERIMENTAL|Part 1: Cohort 3 (1.2 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 1.2 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
62623744|NCT03442088|EXPERIMENTAL|Apremilast for Treatment of Psoriasis with the AM-endotype|Psoriasis patients with the AM-endotype will be followed during treatment over 16 weeks with 5 monthly individual blood draws will be enrolled.
62262974|NCT01032915|EXPERIMENTAL|AIN457 300mg s.c at baseline and Week 2|AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
62262975|NCT01032915|EXPERIMENTAL|AIN457 150mg s.c at baseline and Week 2|AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
62262976|NCT01032915|PLACEBO_COMPARATOR|Placebo s.c weekly for 3 weeks|Placebo s.c weekly for 3 weeks then every 2 weeks
62262977|NCT00625833|PLACEBO_COMPARATOR|Placebo|
62262978|NCT00625833|EXPERIMENTAL|2|
62262979|NCT05606367|EXPERIMENTAL|Non-slip Balloon Catheter|Subjects in experimental arm will be treated with the Non-slip Balloon Catheter manufactured by Shanghai Microport Rhythm Co. Ltd.
62262980|NCT05606367|ACTIVE_COMPARATOR|NSE Coronary Dilatation Catheter|Subjects in control arm will be treated with Lacrosse® NSE manufactured by Goodman Medical Co. Ltd.
62262981|NCT01157312|EXPERIMENTAL|minimal stimulation protocol|5 days of CC (100mg/day) from day 3 followed by 150 IU of highly purified uFSH on cycle day 9 for three treatment cycles
62845337|NCT04162860|EXPERIMENTAL|minimally invasive esophagectomy with preemptive ENP|Patients will undergo a standard total minimally invasive transthoracic Ivor Lewis esophagectomy with preemptive ENP. After completion of the esophago-gastric anastomosis, an Eso-SPONGE® system will be inserted via an intraoperative gastroscopy. ENP will be carried out upon completion of the esophago-gastrostomy, but no later than 12 hours after the surgical intervention. Postoperatively, secretions are then continuously evacuated using a suction pump generating a negative pressure between 75 and 100 mmHg. ENP will remain for 4 days and will be monitored with clinical parameters.
62262982|NCT01157312|ACTIVE_COMPARATOR|clomiphene citrate(CC)|5 days of CC (100mg/day) from cycle day 3 for three treatment cycles.
62447264|NCT06211426|EXPERIMENTAL|the experimental group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.The experimental group was given Stellate Ganglion Block.
62845338|NCT04162860|NO_INTERVENTION|Standard minimally invasive esophagectomy|Patients in the control group will undergo a standard minimally invasive transthoracic Ivor Lewis esophagectomy without preemptive ENP.
62447265|NCT06211426|ACTIVE_COMPARATOR|the control group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.
62447266|NCT04954131|EXPERIMENTAL|SCB-2019 vaccine|Investigational SCB-2019 vaccine contains 30 μg of SCB-2019 antigen, and 1.5 mg CpG 1018 and 0.75 mg Alhydrogel as adjuvants, in each 0.5 mL dose
62447267|NCT04954131|PLACEBO_COMPARATOR|Placebo|Saline solution (0.9%)
62447268|NCT00284297|EXPERIMENTAL|knee arthrodesis|
62845339|NCT02103673|EXPERIMENTAL|DAOIB|Drug: DAOIB 250-1500 mg/day by mouth for 6 weeks
62845340|NCT02103673|PLACEBO_COMPARATOR|Placebo|Placebo by mouth per day for 6 weeks
62845341|NCT00646269|ACTIVE_COMPARATOR|1|
62262983|NCT00708500|PLACEBO_COMPARATOR|Placebo+PEG2b+RBV, x 44 weeks|Participants in Arm 1 (control) received pegylated interferon alfa 2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing \[WBD\]) for 4 weeks followed by boceprevir placebo + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
62262984|NCT00708500|EXPERIMENTAL|Boceprevir+PEG2b+RBV, Response Guided Therapy|"Participants in Arm 2 (experimental) were assigned either a 36-week or 48-week course of therapy based on their HCV-RNA status at Treatment Week 8.~PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 32 weeks, then:~* 36-week regimen: Participants who have undetectable HCV-RNA at Treatment Week 8 discontinue treatment and enter 36 weeks of post treatment follow-up.~* 48-week regimen: Participants who have detectable HCV-RNA at Treatment Week 8 are assigned an additional 12 weeks of therapy, followed by 24 weeks of post treatment follow-up. Placebo replaces boceprevir for the remaining 12 weeks of therapy, and this switch will occur in a blinded fashion."
62447269|NCT02033265||Patients with BMI less than 30 kg/m2|Patients with BMI less than 30 kg/m2 undergoing surgical procedures on upper limb (elbow, forearm and hand) scheduled to receive ultrasound-guided axillary brachial plexus block as their primary anesthetic modality at SJHC.
62845342|NCT00646269|EXPERIMENTAL|2|
62845343|NCT00646269|EXPERIMENTAL|3|
62845344|NCT00646269|EXPERIMENTAL|4|
62845345|NCT04917341||preoperative endometrial sampling result (secondary hospital)/1|Endometrial biopsy samples taken at the stage 2 state hospital
62845346|NCT04917341||preoperative endometrial sampling result (tertiary hospital)/2|Endometrial biopsy samples taken at the stage (tertiary hospital)
62845347|NCT04917341||final postoperative pathology/3|final postoperative pathology results with grade (endometrium cancer)
62845348|NCT03144934|EXPERIMENTAL|Administraion of investigational product|"* 0.25mg, 1mg, 3mg, 6mg, or 9mg (optional) of GX-I7~* 6 subjects per each cohort~* twice administration with 4-week intervals"
62619334|NCT03251482|EXPERIMENTAL|Part 1: Optional Cohort 4 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose to be determined (TBD) based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
62845349|NCT03144934|PLACEBO_COMPARATOR|Administraion of placebo|"* GX-I7 vehicle (formulation buffer)~* 2 subjects per each cohort~* twice administration with 4-week intervals"
62845350|NCT05231096|EXPERIMENTAL|Group A: SRD & Gingival massage with Aloe-vera gel.|Group A: Scaling and Root Debridement \& Gingival massage with Aloe-vera gel.
62845351|NCT05231096|EXPERIMENTAL|Group B: SRD & Gingival massage with Sidr honey|Group B: Scaling and Root Debridement \& Gingival massage with Sidr honey
62262985|NCT00708500|EXPERIMENTAL|Boceprevir+PEG2b+RBV, x 44 weeks|Participants in Arm 3 (experimental) received PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
62845352|NCT05231096|OTHER|Group C SRD only.|Group C Scaling and Root Debridement only.
62845353|NCT00097604|EXPERIMENTAL|Valerian|This study used a cross-over design with valerian compared to placebo. Group 1 received valerian first followed by placebo after washout and cross-over; group 2 received placebo first followed by placebo after wash-out and cross-over.
62845354|NCT00097604|PLACEBO_COMPARATOR|Placebo|This study used a cross-over design with valerian compared to placebo. Group 1 received valerian first followed by placebo after washout and cross-over; group 2 received placebo first followed by placebo after wash-out and cross-over.
62845355|NCT02274909|NO_INTERVENTION|control group|The subjects received no intervention and continued with their daily activities.
62845356|NCT02274909|ACTIVE_COMPARATOR|Pilates group|The exercise protocol of Pilates method consisted of muscle stretching of the upper limbs, trunk and lower limbs before the exercises. Then, exercises involving range of motion and strength of upper limbs, trunk and lower limbs were performed, always associated with breathing in different positions and with increasing repetitions and resistance along the weeks of training.
62845357|NCT02274909|ACTIVE_COMPARATOR|PNF group|The exercises from the PNF method were performed with stretching, associated to hold-relax technique, for upper and lower limbs. Then, subjects carried out exercises with the upper limbs, in a bilaterally symmetrical pattern, and with the lower limbs, in the asymmetric bilateral pattern. Additionally, scapular and pelvic girdle exercises were done with symmetrical and reciprocal combination.
62845358|NCT03710083|EXPERIMENTAL|Study arm|Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-5, or 7).
62262986|NCT01097278|EXPERIMENTAL|Arm I|Participants receive oral cholecalciferol once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
62262987|NCT01097278|ACTIVE_COMPARATOR|Arm II|Participants receive oral placebo once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
62262988|NCT02684604||unexplained infertility patients|44 patients diagnosed to have unexplained infertility
62845359|NCT01516086|EXPERIMENTAL|Fluticasone Propionate (FP) - arm 1|FP BID (twice daily)
62845360|NCT01516086|EXPERIMENTAL|Fluticasone propionate (FP) - arm 2|FP BID
62845361|NCT01516086|EXPERIMENTAL|Fluticasone Propionate (FP) - arm 3|FP BID
62845362|NCT01516086|EXPERIMENTAL|FLuticasone Propionate (FP) - Arm 4|FP BID
62845363|NCT01516086|EXPERIMENTAL|Fluticasone Propionate (FP) - Arm 5|FP BID
62845364|NCT01516086|PLACEBO_COMPARATOR|Placebo - Arm 6|Placebo inhalation solution
62845365|NCT04007757||1|Participants who have had a hemorrhagic stroke and have been enrolled into the Genetic and Environmental Risk Factors for Hemorrhagic Stroke Study who live in the area of University of Cincinnati, Massachusetts General Hospital, University of Maryland, Duke University, Columbia University and University of Chicago Illinois, age 18 years or greater. Ability of participant or legal representative to provide informed consent. Racial/ethnic category of Caucasian, African American or Hispanic.
62845366|NCT05131724|ACTIVE_COMPARATOR|Treadmill training|The treadmill training would be 10 sessions over 2 weeks with 30 minutes for each session (5-min warm-up; 20 min gait training; 5-min cool-down). During the sessions, treadmill speed will be maintained at 60 to 80% of the maximum speed established on an exertion test. The child will walk at 60% maximum speed in the first and final five minutes and 80% in the middle 20 minutes.
62262989|NCT02684604||Fertile women|44 fertile women
62262990|NCT05348057|EXPERIMENTAL|Ivabradine group|The starting dose is 5 mg twice a day. After 2 weeks of treatment, if the patient's resting heart rate continues to be higher than 70 beats per minute, increase the dose to 7.5 mg twice a day. If the patient's resting heart rate continues to be less than 50 beats per minute or symptoms related to bradycardia occur, reduce the dose to 2.5 mg
62845367|NCT05131724|EXPERIMENTAL|Virtual reality|Infants in the TTVR group will perform gait training on the treadmill simultaneously with virtual reality.
62845368|NCT04346719|EXPERIMENTAL|10 kHz stimulation|"Transcutaneous application of high frequency electrical current at 10 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
62447270|NCT02033265||Patients with BMI 30 or above|Patients with BMI 30 kg/m2 undergoing surgical procedures on upper limb (elbow, forearm and hand) scheduled to receive ultrasound-guided axillary brachial plexus block as their primary anesthetic modality at SJHC
62447271|NCT01443806|EXPERIMENTAL|Oseltamivir, genetic testing|
62619335|NCT03251482|EXPERIMENTAL|Part 1: Optional Cohort 5 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
62845369|NCT04346719|EXPERIMENTAL|20 kHz stimulation|"Transcutaneous application of high frequency electrical current at 20 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
62845370|NCT04346719|SHAM_COMPARATOR|Sham stimulation|Electrodes are placed over the median nerve for 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity during the first 30 seconds.
62845371|NCT04001959|ACTIVE_COMPARATOR|Silver Diamine Fluoride|Initially a prophylaxis will be done on the tooth to be treated with Robinson brush and prophylactic paste and then the relative isolation (with mouth openers and cotton rollers) and protection of the soft tissues with vaseline in the region to be treated to protect the surrounding tissues will be carried out. Next, dry the tooth for 30 seconds with air jet followed by a drop of 30% Diamino Fluoride Silver with a disposable applicator brush for 3 minutes and after that time washing for 1 minute.
62845372|NCT04001959|EXPERIMENTAL|Silver Diamine Fluoride with Potassium Iodide|Initially a prophylaxis will be done on the tooth to be treated with Robinson brush and prophylactic paste and then the relative isolation (with mouth openers and cotton rollers) and protection of the soft tissues with vaseline in the region to be treated to protect the surrounding tissues will be carried out. Then the tooth is dried for 30 seconds with an air jet and applied one drop of the Diamino 30% Silver Fluoride with a disposable applicator brush for 3 minutes and one drop of potassium iodide solution immediately on the surface treated with Diamino , until the formed creamy white color becomes transparent. After these steps have been completed, rinse with water for 1 minute.
62447272|NCT06209788|EXPERIMENTAL|Experimental group|The music intervention consists of two parts. The first part occurs during the surgical procedure, starting from the induction of anesthesia and continuing until the surgery over. The second part spans from the first day post-surgery to the fifth day (or until discharge), with the patient listening to music twice a day, each session lasting for 30 minutes. The planned times for the music sessions are expected to be at 11 a.m. and 8 p.m. Each day post-surgery, the music intervention must be completed, and measurements of respiratory rate, pulse rate, blood pressure, and pain score should be taken both before and after listening to the music. Other are routine post-operative care.
62845373|NCT01209702|PLACEBO_COMPARATOR|Part 1: Placebo|Participants received intravenous infusions of placebo once every 4 weeks until Week 12. Following the Week 12 visit, participants who completed Part 1 of the study received open-label 8 mg/kg tocilizumab through Week 208.
62845374|NCT01209702|EXPERIMENTAL|Part 1: Tocilizumab|Participants received intravenous infusions of 8 mg/kg tocilizumab once every 4 weeks until Week 12. Following the Week 12 visit, participants who completed Part 1 of the study received open-label 8 mg/kg tocilizumab through Week 208.
62845375|NCT01209702|PLACEBO_COMPARATOR|Part 2: Placebo|Participants received intravenous infusions of placebo once every 4 weeks until Week 24. Participants who did not attain an ASsessment in Ankylosing Spondylitis-20 (ASAS20) response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
62845376|NCT01209702|EXPERIMENTAL|Part 2: Tocilizumab 4 mg/kg|Participants received intravenous infusions of 4 mg/kg tocilizumab once every 4 weeks until Week 24. Participants who did not attain an ASAS20 response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
62447273|NCT06209788|NO_INTERVENTION|Control group|Routine post-operative care.
62059314|NCT05341986|OTHER|BPA + FHIR|Instead of a link to the web-based portal, the BPA will contain a link to the FHIR-integrated CDS tool portal. FHIR will automatically pull EHR data about the patient into the CDS tool portal. Data include demographic information, comorbidities in the active problem list, past medical and surgical history, and social history. Clinicians will also receive training before the implementation of this step.
62059315|NCT04504695||Thrombectomy group|Major patients requiring management for endovascular thrombosis
62262991|NCT05348057|NO_INTERVENTION|The control group|
62447274|NCT01338428|ACTIVE_COMPARATOR|Brochure|
62447275|NCT01338428|EXPERIMENTAL|Enhanced AAA Sexual Assault Education|
62619336|NCT03251482|EXPERIMENTAL|Part 1: Optional Cohort 6 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
62623745|NCT01104714||All patients|As the trial progresses, patients will be classified as either chemotherapy responders or non-responders.
62619337|NCT03251482|EXPERIMENTAL|Part 2: Group A: JNJ-64179375 A mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose A mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
62619338|NCT03251482|EXPERIMENTAL|Part 2: Group B: JNJ-64179375 B mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose B mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
62619339|NCT03251482|EXPERIMENTAL|Part 2: Group C: JNJ-64179375 C mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose C mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
62845377|NCT01209702|EXPERIMENTAL|Part 2: Tocilizumab 8 mg/kg|Participants received intravenous infusions of 8 mg/kg tocilizumab once every 4 weeks until Week 24. Participants who did not attain an ASAS20 response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
62845378|NCT00846963|EXPERIMENTAL|Ursodiol|Participants assigned in this arm receive an ursodiol suspension at 20mg/ml.
62845379|NCT00846963|PLACEBO_COMPARATOR|placebo|A placebo suspension that looks like the ursodiol suspension used.
62262992|NCT04360551|EXPERIMENTAL|Telmisartan|Telmisartan 40 mg po daily x 21 days
62447276|NCT06379009|EXPERIMENTAL|Home-based training|Structured home-based training program over 12 week period (in addition to standard care). The program has been prepared by physiotherapists and starts 4 weeks after kidney transplantation. It consists of 2 sessions of strength training and 1 session of cardio training each week. In addition, optional training sessions on the other days of the week. The patients will be followed up by phone every week, heart rate monitor and patients logs. A physiotherapist will guide the patients in the beginning of the intervention period
62845380|NCT03204734|EXPERIMENTAL|Capecitabine|Capecitabine by mouth twice per day for 14 days, per 21 days as a cycle, until disease progress or toxicity can not be tolerated.Capecitabine starting dose was the dose used at the end of the combined chemotherapy regimen,eg:1000mg per BSA.
62447277|NCT06379009|NO_INTERVENTION|Standard of care|This group will undergo standard physical training program in addition to standard care. They will be informed about the importance of regular exercise after discharge from hospital.
62447278|NCT03407859|EXPERIMENTAL|Sequential therapy with different CART|Sequential therapy With different CART including one kind of CD20/CD22/CD10-CART After CD19-CART therapy in CD19-negative relapse ALL patients, subjects will receive 1-5 x 10\^6/Kg transduced CAR T cells at one time.
62619340|NCT03251482|EXPERIMENTAL|Part 2: Group D: JNJ-64179375 D mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose D mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
62619341|NCT03251482|EXPERIMENTAL|Part 2: Group E: JNJ-64179375 placebo IV and apixaban 2.5 mg|Participants will receive JNJ-64179375 placebo (saline) IV as a single dose on Day 1 and apixaban 2.5 mg orally twice a day for 10 to 14 days.
62619342|NCT02163317|EXPERIMENTAL|Treatment (MRI-guided focal SRS)|Patients undergo 3 fractions of MRI-guided focal SRS every other day for 1 week. Patients undergo additional MRI scans between the 2nd and 3rd fractionated treatments, at 6 months following the end of radiation therapy, and at 12 and 24 months.
62619343|NCT06380933|EXPERIMENTAL|experimental group|foot bath with lavender essential oil for 3 days, and then received routine care for 3 days
62619344|NCT06380933|NO_INTERVENTION|control group|first received routine care for 3 days, and then received lavender essential oil with foot bath for 3 days
62619345|NCT05642416|ACTIVE_COMPARATOR|Continuous Infusion|Will receive a continuous infusion of pain medication (0.2% ropivacaine at a rate of 10mL per hour- 5mL per side per hour) via erector spinae plane (ESP) catheter for their postoperative pain following median sternotomy incision.
62619346|NCT05642416|EXPERIMENTAL|Intermittent Bolus|Will receive intermittent boluses of pain medication (30mL bolus of 0.2% ropivacaine every three hours) via erector spinae plane (ESP) catheter for their postoperative pain following median sternotomy incision.
62619347|NCT00080483|EXPERIMENTAL|1|Testosterone transdermally 5 g a day and somatropin subcutaneously 2 µg/kg body weight a day
62845381|NCT03204734|EXPERIMENTAL|endocrine therapy|endocrine therapy will been given as a sequential treatment in Metastatic breast cancer patients who are got benefit in capecitabine-base chemotherapy.The medicine will be confirmed by the patient's past-treatment.
62845382|NCT01696604|EXPERIMENTAL|Part A: Cohort 1-GSK2849466|The subjects will receive single planned dose of GSK284946 in ascending order (0.01, 0.03, 0.1, and 0.3 mg) in ratio of 3:1.with placebo within each of 4 treatment periods. The dose will not be allowed to exceed 30 mg over a 24-hour period.
62059316|NCT04504695||Aneurysm group|Major patients requiring management for an intracranial aneurysm
62262993|NCT04360551|PLACEBO_COMPARATOR|Placebo|Placebo
62262994|NCT02085382|OTHER|Kangaroo Mother Care Group|"Mothers in the KMC group were oriented in detail about KMC procedure. The mothers provided skin to skin contact using a specially tailored kangaroo tube made of soft flannel cloth. The mothers were encouraged to keep the baby in KMC as long as possible during the day and night for an accumulated time of at least 6 hours per day. The duration of the kangaroo care by each of the mother were recorded and tallied accordingly."
62262995|NCT02085382|OTHER|Conventional Mother Care|Conventional method of care was the routine care offered in the neonatal unit to low birth weight infants.
62619348|NCT00080483|ACTIVE_COMPARATOR|2|AndroGel transdermally 5 g a day for two years
62845383|NCT01696604|EXPERIMENTAL|Part A: Cohort 1-Placebo|The subjects will receive single dose of matching placebo in one of the 4 treatment periods.
62845384|NCT01696604|EXPERIMENTAL|Part A: Cohort 2-GSK2849466|The subjects will receive single planned dose of GSK284946 in ascending order (0.3, 1, 3, and 10 mg) in ratio of 3:1.with placebo within each of 4 treatment periods. The dose will not be allowed to exceed 30 mg over a 24-hour period in one of the 4 treatment periods.
62845385|NCT01696604|EXPERIMENTAL|Part A: Cohort 2-Placebo|The subjects will receive single dose of matching placebo in one of the 4 treatment periods.
62845386|NCT01696604|EXPERIMENTAL|Part B: Cohort 3-GSK2849466 (Repeat dose 1)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo.
62845387|NCT01696604|EXPERIMENTAL|Part B: Cohort 3-Placebo (Repeat dose 1)|The subjects will receive repeat dose of matching placebo.
62059317|NCT06101251|NO_INTERVENTION|Control|"Participants will have the Way to Drive app monitoring in the background throughout the intervention period for overall driving score, handheld phone use, speeding, hard braking, and fast acceleration. They will not receive feedback, driving tips or UBI-like behavioral incentives.~Participants will also receive payment or non-adherence messages as needed for having the app functioning."
62262996|NCT03992976||Teenagers with chronic pain|Semi-structured interviews followed by 'think-aloud' procedure in part two. Semi-structured interviews may last up to 1 hour and are audio-recorded. A pre-piloted interview schedule has been developed and will guide the conversation. 'Think-aloud' procedure involves showing participants some of the online content that has been developed on a computer screen, and asking them to say aloud their commentary on any aspects. Participants will be audio-recorded during the task, and it is not anticipated the task will take longer than 1 hour to complete. Each participant may only take part in one interview and one think-aloud procedure.
62845388|NCT01696604|EXPERIMENTAL|Part B: Cohort 4-GSK2849466 (Repeat dose 2)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo. In Cohort 4 subjects will be dosed in the fasted state on Days 1 and 14 and in the fed state on Day 7.
62845389|NCT01696604|EXPERIMENTAL|Part B: Cohort 4-Placebo (Repeat dose 2)|The subjects will receive repeat doses of matching placebo.
62262997|NCT03992976||Parents of teenagers with chronic pain|Semi-structured interviews followed by 'think-aloud' procedure in part two. Semi-structured interviews may last up to 1 hour and are audio-recorded. A pre-piloted interview schedule has been developed and will guide the conversation. 'Think-aloud' procedure involves showing participants some of the online content that has been developed on a computer screen, and asking them to say aloud their commentary on any aspects. Participants will be audio-recorded during the task, and it is not anticipated the task will take longer than 1 hour to complete. Each participant may only take part in one interview and one think-aloud procedure.
62262998|NCT02148965|EXPERIMENTAL|Lifestyle intervention|Physical Exercise / Physical Activity. Exercise intervention, three weekly sessions. Each session will last around 60 minutes and will include aerobic exercises (treadmill or stationary cycling) and strength training (with focus on major muscle groups and pregnancy-specific exercises to help alleviate low back pain and work abdominal and pelvic floor muscles to prevent urinary incontinence).
62262999|NCT02148965|NO_INTERVENTION|Control Group|A group of eligible women, twice as large as the intervention group, will not receive the exercise intervention but will be followed-up equally to compare outcomes in the future.
62619349|NCT04384198|EXPERIMENTAL|Sonolysis group|Cerebral hemisphere with sonolysis during MitraClip implantation.
62619350|NCT04384198|NO_INTERVENTION|Control group|Cerebral hemisphere without sonolysis during MitraClip implantation.
62619351|NCT03142256|ACTIVE_COMPARATOR|Incentivised - Conditional Cash Transfer|Cash incentive for good drug levels assed by Dried Blood Spot
62059318|NCT06101251|ACTIVE_COMPARATOR|Standard Feedback + UBI-like Behavioral Incentive|Participants will have the Way to Drive app monitoring in the background, and will receive payment or non-adherence messages as needed, but will also receive, Standard Feedback, Study Dashboard, Driving Tips, and UBI-like Behavioral Incentive
62619352|NCT03142256|NO_INTERVENTION|No incentive|Truvada 200Mg-300Mg Tablet
62619353|NCT01644760|EXPERIMENTAL|Study population|Healthy subjects with spontaneous ventilation, 18 to 50 years of age.
62619354|NCT00618852|EXPERIMENTAL|1|Furosemide
62845390|NCT01696604|EXPERIMENTAL|Part B: Cohort 5-GSK2849466 (Repeat dose 3)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo
62845391|NCT01696604|EXPERIMENTAL|Part B: Cohort 5-Placebo (Repeat dose 3)|The subjects will receive repeat doses of matching placebo.
62845392|NCT02064582|OTHER|Enzalutamide, Leuprolide, radiation|Single arm Enzalutamide 160 mg daily for 6 months Leuprolide acetate 22.5mg every 3 months or 45mg every 6 months Radiation therapy as standard of care
62059319|NCT06101251|ACTIVE_COMPARATOR|Assigned Goal with UBI-like Behavioral Incentive|Participants will have the Way to Drive app monitoring in the background, and will receive payment or non-adherence messages as needed, but will also receive Assigned Focus Area Feedback, Driving Tips, a Study Dashboard, and UBI-like Behavioral Incentive
62845393|NCT00876551|EXPERIMENTAL|E-V.A.C.|Patients that are treated with E-V.A.C.
62447279|NCT02855190|EXPERIMENTAL|68Ga-citrate and 18F-FDG PET scans|The recruited subject with surgery/pathology proved periprosthetic joint infection will undergo total four PET scans at two different stages. At first stage, subsequent FDG PET/CT and Ga68 citrate PET/CT scans on different two days will be arranged before infective prosthesis is removed. Eight to twelve weeks after the 1st stage operation, patient will receive two subsequent PET/MR scans using Ga-68 Citrate and FDG on different two days, respectively. For the subject without surgery/pathology proved infection, PET/MR scans will NOT be applied.
62447280|NCT04700995|EXPERIMENTAL|ProTaper rotary NiTi instruments|The ProTaper Universal Retreatment rotary system and ProTaper Gold rotary system were used.
62447281|NCT04700995|EXPERIMENTAL|Hyflex EDM rotary NiTi instruments|Hyflex EDM rotary system was used.
62447282|NCT04700995|EXPERIMENTAL|Reciproc Blue reciprocating NiTi instruments|Reciproc Blue reciprocating system was used.
62845394|NCT03205449|EXPERIMENTAL|MaPa Programme|Masayang Pamilya Parenting Program: A 12-session, a group-based parenting programme focused on reducing violence against children and improving child wellbeing in low-income families with young children
62845395|NCT03205449|ACTIVE_COMPARATOR|Treatment-as-usual|Parenting Effectiveness Service programme: A family strengthening programme delivered by trained service providers on a monthly basis.
62845396|NCT03231878|ACTIVE_COMPARATOR|Active|
62845397|NCT03231878|PLACEBO_COMPARATOR|Placebo|
62447283|NCT04700995|EXPERIMENTAL|Waveone Gold reciprocating NiTi instruments|WaveOne Gold reciprocating system was used.
62845398|NCT00796419|EXPERIMENTAL|1|Intravenous 5% human albumin
62845399|NCT00796419|EXPERIMENTAL|2|Intravenous 6% hetastarch
62845400|NCT01441362|ACTIVE_COMPARATOR|90 degrees rotation|Double-lumen tube intubation with 90 degrees rotation
62059320|NCT06101251|ACTIVE_COMPARATOR|Self-Chosen Goal with UBI-like Behavioral Incentive|Participants will have the Way to Drive app monitoring in the background, and will receive payment or non-adherence messages as needed, but will also receive Self-Chosen Focus Area Feedback, Driving Tips, Study Dashboard, and UBI-like Behavioral Incentive.
62059321|NCT05962983|EXPERIMENTAL|SSBC participants|Participants will attend a 6-week diet and exercise changes program (SSBC).
62447284|NCT01909466|OTHER|Gluteal Injection|
62447285|NCT01909466|OTHER|Deltoid Injection|
62059322|NCT01632943|EXPERIMENTAL|Symplicity renal denervation system|
62263000|NCT00635037|EXPERIMENTAL|A|"G1 (n=15)received trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.~G2(n=15) was submitted to classical and trigger point acupuncture twice a week."
62447286|NCT04107493|ACTIVE_COMPARATOR|Portable oxygen cylinder|Continuous flow oxygen cylinders will be used as a comparison.
62447287|NCT04107493|EXPERIMENTAL|Mobi™ Portable Oxygen Concentrator|Mobi™ is indicated for patients who require supplemental oxygen, including COPD patients. It provides supplemental, high oxygen concentration to these patients. It is available via prescription only and may be used in the home, institution, and hospital settings, as well as travel environments
62447288|NCT01395953|ACTIVE_COMPARATOR|Buspirone|
62447289|NCT01395953|PLACEBO_COMPARATOR|Placebo|
62447290|NCT03937466|EXPERIMENTAL|Experimental Cooling Mattress Pad|Subjects will use a cooling mattress pad nightly for approximately 8 weeks
62447291|NCT01589536|EXPERIMENTAL|Interventiongroup|A Stationary psychocardiological interval-rehabilitation.
62447292|NCT01589536|NO_INTERVENTION|controlgroup|The Patients in the control group receive a personal recommendation concerning psychotherapy outpatient counseling and therapy services at home and take therapeutic help.
62447293|NCT02076477|EXPERIMENTAL|Arm A|"Patients receive concurrent chemoradiotherapy at first。Patients also receive chemotherapy every 3-4 weeks for two cycles after concurrent chemoradiotherapy.~chemotherapy：（1） squamous cell carcinoma：Docetaxel 60mg/m2 d1+Cisplatin 25mg/m2 d1-3.（2）non squamous cell carcinoma： pemetrexed 500mg/m2 d1+Cisplatin 25mg/m2 d1-3."
62845401|NCT01441362|EXPERIMENTAL|180 degrees rotation|Double-lumen tube intubation with 180 degrees rotation
62845402|NCT05130515|EXPERIMENTAL|Treatment group|Niraparib 200mg po QD day1\~21, Anlotinib 10mg po QD day1\~14
62845403|NCT02504216|EXPERIMENTAL|Rivaroxaban|Rivaroxaban 2.5 mg orally twice daily (5 mg cumulative daily dose)
62845404|NCT02504216|PLACEBO_COMPARATOR|Placebo|Rivaroxaban-placebo orally twice daily
62845405|NCT03515668|EXPERIMENTAL|Ritalin|20 mg Ritalin, 90 min before testing
62845406|NCT03515668|PLACEBO_COMPARATOR|Control|Identical size/taste placebo pill, 90 min before testing
62263001|NCT03816930|ACTIVE_COMPARATOR|Mechanical cord usage|Mechanical retraction
62263002|NCT03816930|ACTIVE_COMPARATOR|Chemical contained retraction usage|Chemical retraction
62845407|NCT03351283|EXPERIMENTAL|Severe sodium restriction|"Patients will be assigned to a diet with two grams of sodium. The nutritionist will be responsible for calculating diets appropriate to the needs of each patient. The diet will not have the intention to modify the weight of the patient but only to indicate the menus that the patients will follow. All the patients will be explained the diet. Patients will be allowed a maximum intake of 1.5 liters of water per day, including the liquid of soups, juices and drinks; This will be explained in detail to the patients.~The diets will be identical in calories according to the weight of the patient. The only difference in diets will be the sodium content, which will be 2 grams of sodium vs. 3 grams of sodium."
62845408|NCT03351283|ACTIVE_COMPARATOR|Moderate sodium restriction.|Patients will be assigned to a diet with three grams of sodium.
62845409|NCT02125019||Breast cancer patients|This is a single arm study evaluating feasibility of evaluating gait and parameter changes in patients with early stage breast cancer undergoing adjuvant taxane chemotherapy.
62845410|NCT03296319|ACTIVE_COMPARATOR|echocardiography guided fluid resuscitation|
62263003|NCT03816930|ACTIVE_COMPARATOR|MZ-6 laser tip used throughing|Laser retraction
62447294|NCT02076477|ACTIVE_COMPARATOR|Arm B|"Patients receive neoadjuvant chemotherapy every 3-4 weeks for two cycles at first.Patients then receive concurrent chemoradiotherapy after neoadjuvant chemotherapy.~chemotherapy：（1） squamous cell carcinoma：Docetaxel 60mg/m2 d1+Cisplatin 25mg/m2 d1-3.（2）non squamous cell carcinoma： pemetrexed 500mg/m2 d1+Cisplatin 25mg/m2 d1-3."
62447295|NCT04760067||Turf|After obtaining the demographic information of the athletes participating in our study, information about injury anxiety and injury anxiety will be collected with the Sports Injury Anxiety Scale.
62447296|NCT04760067||Artificial Turf|After obtaining the demographic information of the athletes participating in our study, information about injury anxiety and injury anxiety will be collected with the Sports Injury Anxiety Scale.
62447297|NCT04760067||Wood Parquet|After obtaining the demographic information of the athletes participating in our study, information about injury anxiety and injury anxiety will be collected with the Sports Injury Anxiety Scale.
62447298|NCT02971046|EXPERIMENTAL|Protein intake|Varying protein intakes.
62447299|NCT02231190|EXPERIMENTAL|GSK1278863|Subjects will be given five oral doses of GSK1278863 100 mg (5mg if a low dose is elected for subjects enrolled after interim analysis). The first dose will be administered immediately after completion of eccentric exercise, and then at 4, 8, 24, and 48 hours
62447300|NCT02231190|PLACEBO_COMPARATOR|Placebo|Subjects will be given five oral doses of Placebo. The first dose will be administered immediately after completion of eccentric exercise, and then at 4, 8, 24, and 48 hours
62845411|NCT03296319|EXPERIMENTAL|clinically guided fluid resuscitation|
62845412|NCT06181344|EXPERIMENTAL|implementation condition|Under implementation condition, a fear of cancer recurrence screening program will be implemented in routine oncological clinics using 5 implementation strategies including training, audit and feedback, facilitation and adaptable workflow.
62263004|NCT02907385|EXPERIMENTAL|LifeSeal™ Kit|Stapled Anastomosis is performed according to Standard of Care (SoC) with the addition of LifeSeal™ Kit application during surgery.
62263005|NCT02907385|NO_INTERVENTION|Standard of Care|Stapled Anastomosis is performed according to SoC without LifeSeal™ reinforcement.
62263006|NCT04522089|EXPERIMENTAL|AdimrSC-2f Group 1|low dose mcg
62263007|NCT04522089|EXPERIMENTAL|AdimrSC-2f Group 2|low dose mcg+AL
62263008|NCT04522089|EXPERIMENTAL|AdimrSC-2f Group 3|medium dose mcg
62263009|NCT04522089|EXPERIMENTAL|AdimrSC-2f Group 4|high dose mcg
62263010|NCT01888640|ACTIVE_COMPARATOR|ActiveTENS|Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
62263011|NCT01888640|PLACEBO_COMPARATOR|Placebo TENS|This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
62263012|NCT01888640|NO_INTERVENTION|No TENS (Standard Care)|Participants will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.
62447301|NCT03841097|ACTIVE_COMPARATOR|Extended Release Tacrolimus Tablets|Dosed once daily in the morning and started at a dose of 0.14 mg/kg/day by the first day after kidney transplant (post-operative day 1). This medication will be given with rabbit antithymocyte globulin (rATG) induction, oral mycophenolate mofetil (MMF) and oral steroids to help prevent rejection. These medications will be ordered per standard of care both inpatient and outpatient.
62619355|NCT00618852|PLACEBO_COMPARATOR|2|
62263013|NCT06356961|NO_INTERVENTION|Treatment as usual (TAU)|TAU: therapists and patients proceed with psychotherapy as they normally would without receiving any initial training and using only Mindy as a simplified digital folder.
62263014|NCT06356961|ACTIVE_COMPARATOR|OPM|"Process and outcome monitoring (OPM) in which patients will complete process and outcome measures with baseline feedback related to each psychotherapy session, but therapists will not receive support with clinical support tools on these measures, will not have specific training on Feedback Informed Therapy (FIT), and will not receive monthly supervision, but rather will use the Mindy platform as a medical record"
62845413|NCT06181344|NO_INTERVENTION|Control condition|In the control condition, the clinical outpatient operation is performed as usual. The FCR screening tool and referral forms will be provided to the study sites and nursing staff are encouraged to adopt fear of cancer recurrence screening. Patients referred to JCICC will be managed following the predefined clinical pathway triage system. A briefing session about the purpose of the implementation program and the introduction of the FCR screening tool will be given to the staff at each study unit before the start of the first 4-months control condition. The briefing session will be recorded for the purpose of fidelity assessment.
62059323|NCT01702441|EXPERIMENTAL|AKB-9778|Up to 4 dose levels of subcutaneous AKB-9778 will be evaluated. Doses will be administered daily for 28 days.
62845414|NCT00756262|ACTIVE_COMPARATOR|1|Lactobacillus rhamnosus LGG
62845415|NCT00756262|PLACEBO_COMPARATOR|2|Microcrystalline cellulose capsules
62845416|NCT00661427|ACTIVE_COMPARATOR|Cetuximab 500 mg/m^2|Cetuximab 500 mg/m\^2 IV over 2 hours every other week
62845417|NCT00661427|ACTIVE_COMPARATOR|Cetuximab 750 mg/m^2|Cetuximab 750 mg/m\^2 IV over 3 hours every other week
62845418|NCT03398499|EXPERIMENTAL|Magnetoledotherapy|Active ELF EMF Participants will receive active transcranial low frequency elec-tromagnetic field and magnetic induction (ELF EMF) and high energy LED light were used stimulation,Using the Viofor JPS device (Med \& Live)
62845419|NCT04521725|NO_INTERVENTION|Group1: ECG+SpO2 only|Traditional ECG (heart rate) and SpO2 (pulse oximetry) monitoring for resuscitation only.
62845420|NCT04521725|ACTIVE_COMPARATOR|Group 2: ECG+SpO2+RFM|Addition of Respiratory Function Monitor to ECG and SpO2 during resuscitation.
62845421|NCT04521725|ACTIVE_COMPARATOR|Group 3: ECG+SpO2+RFM+NIRS|Addition of cerebral NIRS and Respiratory Function Monitor to ECG and SpO2 during resuscitation.
62059324|NCT01786486||Delivery system entry|
62059325|NCT00382824|ACTIVE_COMPARATOR|CoQ10|Half of the enrolled patients will be randomized into the the CoQ10 arm and will receive a dosage of 2400mg/day of Coenzyme Q10
62059326|NCT00382824|PLACEBO_COMPARATOR|Placebo|Half of the enrolled patients will be randomized into the the Placebo arm and will receive a matching dose of placebo that resembles the 2400mg/day dose of the CoQ10 arm.
62059327|NCT02993887|PLACEBO_COMPARATOR|Mindfulness|Mindfulness (Decentering) only using the Stop, Breathe, Think Smart Phone application
62059328|NCT02993887|EXPERIMENTAL|Resourcefulness and Mindfulness|Resourcefulness Training (a cognitive behavioral intervention that teaches self-help and help-seeking skills) and Mindfulness using the Stop, Think, Breathe app.
62263015|NCT06356961|EXPERIMENTAL|OPM-F|Process and outcome monitoring with feedback (OPM-F) in which patients will complete process and outcome measures related to each session, and therapists will receive feedback on patient progress and patient experiences of the therapeutic alliance with specific training on feedback informed therapy (FIT) and use the Mindy platform with all information inherent to feedback and Clinical Support Tools, they will also receive monthly supervision/coaching (for three months) designed to complete on-going training on FIT and ROM, with practical discussion of the most difficult clinical cases and possible solutions to be implemented in therapy.
62845422|NCT01712399|EXPERIMENTAL|Mavrilimumab 100 mg|Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years.
62263016|NCT03853603|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62059329|NCT00881491|EXPERIMENTAL|Group A|Group A - Double antibiotic paste: intracanal medicament consisting of ciprofloxacin and metronidazole
62059330|NCT00881491|EXPERIMENTAL|Group B|Group B - Triple Antibiotic Paste: intracanal medicament consisting of ciprofloxacin, metronidazole, minocycline
62059331|NCT00881491|ACTIVE_COMPARATOR|Group C|Group C - Mineral trioxide aggregate: used as an apical barrier
62059332|NCT00185640|EXPERIMENTAL|Non-myeloablative transplantation|Pre-transplant total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) infusion with Day 0 allogeneic hematopoietic cell transplant (HCT), followed by post-transplant immunosuppression by cyclosporine and mycophenolate mofetil.
62263017|NCT03853603|ACTIVE_COMPARATOR|Santa herba extract|Santa herba extract
62263018|NCT05078294||Cases|Patients treated as monotherapy with phototherapy, cyclosporine, methotrexate, azathioprine, mycophenolate, dupilumab, baricitinib, upadacitinib, or tralokilumab for the treatment of moderate to severe atopic dermatitis.
62263019|NCT01422122|EXPERIMENTAL|Vitamin D|Oral vitamin D3 in syrup form
62059333|NCT03911427|EXPERIMENTAL|Powder Mix 1|Oat powder product, mixed with water
62059334|NCT03911427|PLACEBO_COMPARATOR|Powder Mix 2|Brown rice milk powder product, mixed with water
62845423|NCT05834829|EXPERIMENTAL|dPI|LIFU to the dPI
62845424|NCT05834829|EXPERIMENTAL|ACC|LIFU to the ACC
62845425|NCT05834829|SHAM_COMPARATOR|Sham|Sham LIFU application
62845426|NCT04222010|EXPERIMENTAL|serratus loco-regional anesthesia|patient who underwent thoracoscopic surgery will be assigned to serratus plane bloc (Ropivacaine 2 mg/mL, 40 mL) and paravertebral placebo bloc (saline, 20 mL)
62845427|NCT04222010|EXPERIMENTAL|paravertebral bloc Loco-regional anesthesia|patient who underwent thoracoscopic surgery will be assigned to paravertebral bloc (Ropivacaine 4 mg/mL, 20 mL) and serratus plane placebo bloc (saline, 40 mL)
62845428|NCT04222010|EXPERIMENTAL|serratus and paravertebral bloc Loco-regional anesthesia|patient who underwent thoracoscopic surgery will be assigned to serratus plane bloc (Ropivacaine 1,3 mg/mL, 40 mL) and paravertebral bloc (Ropivacaine 1,3 mg/mL, 20 mL)
62845429|NCT05966688|EXPERIMENTAL|SPR720 1000 mg|Healthy participants will receive SPR720 1000 milligrams (mg), orally, once daily (QD) for 7 days.
62263020|NCT01422122|PLACEBO_COMPARATOR|placebo|Placebo syrup identical in colour and taste to that of intervention
62619356|NCT05739175|EXPERIMENTAL|Intervention group receiving interactive nurse support based on mobile application|Experimental: Intervention Group The mobile application containing an interactive nurse support program will be uploaded to the telephone of the intervention group patients. Patients will be informed on how to use the mobile application. Data will be collected face-to-face before chemotherapy begins and by telephone one week after every four chemotherapy. Demographic/Clinical Information Form, Eastern Cooperative Oncology Group Performance Scale, Multidimensional scale of perceived social support, Memorial Symptom Rating Scale, European Organization for Research and Treatment of Cancer- Quality of Life, QLQ-BR23, Beck Anxiety Scale and Mobile Application evaluation form will be used to collect data.
62619357|NCT05739175|NO_INTERVENTION|Control group receiving standard care and no intervention|No Intervention: Control Group The patients received routine care and training in the polyclinic, and no additional intervention was applied. Data will be collected face-to-face before chemotherapy begins and by telephone one week after every four chemotherapy.Demographic/Clinical Information Form, Eastern Cooperative Oncology Group Performance Scale, Multidimensional scale of perceived social support, Memorial Symptom Rating Scale, European Organization for Research and Treatment of Cancer- Quality of Life, QLQ-BR23,Beck Anxiety will be used to collect data.
62619358|NCT01214460||All MET calls|We make an Utstein type analyze to all MET calls
62263021|NCT03084536|ACTIVE_COMPARATOR|Preoperative PECS blocks|"* PECS I \& II block will be administered preoperatively~* For unilateral surgeries, a PECS I block will be performed with 0.15mL/kg of 0.375% bupivacaine (maximum 10mL). The PECS II block will be performed with 0.3 mL/kg of the same solution (maximum 20mL). If there is a contralateral surgery (simple mastectomy) a PECS II block will also be performed on the other side with 0.2mL/kg of 0.375% bupivacaine (maximum 20mL)~* To ensure blind integrity, study drug syringes will be marked only study drug and subject number~* Perioperative analgesic will be encouraged.. Gabapentin 300mg, celecoxib 200mg and acetaminophen 1000mg will be administered to all patients following arrival to the preoperative area. All patients will receive premedication of 1-2 mg midazolam IV (age \< 65) and 50-100 μg fentanyl IV prior to the block placement or entry to the operating room at the discretion of the regional team or operating room anesthesiologist"
62447302|NCT03841097|ACTIVE_COMPARATOR|Immediate Release Tacrolimus Capsules|Dosed twice daily 12 hours apart and started at a dose of 0.1mg/kg/day by the first day after kidney transplant (post-operative day 1). This medication will be given with rabbit antithymocyte globulin (rATG) induction, oral mycophenolate mofetil (MMF) and oral steroids to help prevent rejection. These medications will be ordered per standard of care both inpatient and outpatient.
62447303|NCT02259712|ACTIVE_COMPARATOR|Pelvic-perineal physiotherapy|"The treatment duration is 2 days per week during 8 weks (two months). The aproximate duration of the season is 45 minutes. The protocol consists in:~1. Anatomical and physiological explanation of the pelvic girdle (perineal organs bony, ligaments and muscular structures of the entire abdominal and pelvic cavity).~2. Hygienic and behavioral advises preventing pelvic floor dysfunctions.~3. Awareness of the pelvic floor muscles.~4. Strengthening the pelvic floor muscles and the entire abdominal pelvic cavity. Use of electrostimulation and biofeedback in different positions if deemed necessary.~5. Treatment the abdominal-pelvic cavity pain if it requires."
62619359|NCT01214460||All EMS calls|We make an Utstein type analyze to all EMS calls during June 2015
62447304|NCT02259712|EXPERIMENTAL|Hyporessive and Pelvic-perineal PT|The treatment duration is 2 days per week, 8 weeks (two months). The session is about 45 minutes. All women are instructed on hygienic and behavioral advises preventing pelvic floor dysfunctions. They are teach basic anatomy and physiology to understand the importance of these advises and anatomical and physiological explanation of the pelvic girdle. The participants are also treated by doing Hypopressive exercises and by specific physiotherapy for the strengthening the pelvic floor muscles.
62619360|NCT01214460||All patient in the emergency department|We make an Utstein type analyze to all Emergency visits during June 2015
62619361|NCT03713996|EXPERIMENTAL|CBT-I intervention|The intervention includes several face-to-face interview techniques: sleep restriction therapy, stimulus control procedures, sleep hygiene, relaxation training and cognitive components.
62619362|NCT03713996|ACTIVE_COMPARATOR|Diabetes Education|Sleep hygiene, foot care, causes and diagnosis of diabetes, healthy diet, and physical activity will be delivered for the Health Education group. During all sessions, subjects will be encouraged to engage in the discussion through open questions about their experience in diabetes, lifestyle, and understanding about provided materials.
62619363|NCT02192853|EXPERIMENTAL|Sitagliptin|Patients with Type 2 Diabetes Mellitus and healthy control subjects are given tablets of sitagliptin in either a dosage of 25, 100 or 200 mg tablet in 3 different days.
62619364|NCT02192853|PLACEBO_COMPARATOR|placebo|
62619365|NCT05239546|EXPERIMENTAL|Neoadjuvant Dostarlimab|Participants will receive Dostarlimab 500 mg IV every 3 weeks for 9 cycles followed by 1000 mg every 6 weeks for 12 cycles until 2 years
62447305|NCT02259712|EXPERIMENTAL|Hypopressive exercises|The treatment is done 2 times per week for 8 weeks (2 months). The session duration is about 45 minutes. All participants are instructed on hygienic and behavioral advises preventing pelvic floor dysfunctions. They are teach basic anatomy and physiology to understand the importance of these advises and anatomical and physiological explanation of the pelvic girdle (perineal organs bony, ligaments and muscular structures of the entire abdominal and pelvic cavity). The participants are also treated by doing Hypopressive exercises in standing, sitting, and supine fours.
62447306|NCT05050786|ACTIVE_COMPARATOR|Standard wound dressing|
62619366|NCT06405802|EXPERIMENTAL|Tele-evulation|Face-to-face tests will be recorded by video and re-evaluation will be made over the video by another person who has not performed the tests. During technology-based remote evaluations, the evaluator will monitor the tests simultaneously via video. During technology-based remote evaluations, video recording will be made and a re-evaluation will be made over the video by another person who has not performed the tests.
62619367|NCT06405802|EXPERIMENTAL|Face-to face evulation|Face-to-face applications were carried out with individuals with low back pain who came to Bozyaka Training and Research Hospital and volunteered to participate in the study.
62845430|NCT05966688|EXPERIMENTAL|Azithromycin 500 mg|Healthy participants will receive azithromycin 500 mg, orally, QD for 7 days.
62447307|NCT05050786|EXPERIMENTAL|Negative Pressure Wound Therapy (NPWT)|
62619368|NCT05943184|NO_INTERVENTION|Control group|
62619369|NCT05943184|EXPERIMENTAL|Observation group|
62619370|NCT02242370|EXPERIMENTAL|Telmisartan low dose|
62619371|NCT02242370|EXPERIMENTAL|Telmisartan high dose|
62619372|NCT02318654|ACTIVE_COMPARATOR|Ice Pack|
62619373|NCT02318654|ACTIVE_COMPARATOR|Topical EMLA cream|
62619374|NCT04321551|EXPERIMENTAL|Provocative Hormonal Testing|TGN subjects will undergo baseline endocrine and menstrual cycle evaluation, followed by intramuscular (i.m.) administration of testosterone cypionate (TC) 50 mg (standard dose) every 7 d for 32 wks (Fig. 8). After 24 wks, an aromatase inhibitor, letrozole (LET, 2.5 mg/d oral), will be co-administered with TC for 8 wks to block estrogen synthesis and examine whether T's effects are independent of E2 signaling.
62619375|NCT04611282|EXPERIMENTAL|Microsurgery group|All defects were treated with a CPF plus an SCTG by the same investigator using microsurgery technique.
62619376|NCT04611282|ACTIVE_COMPARATOR|Macrosurgery group|All defects were treated with a CPF plus an SCTG by the same investigator using macrosurgery technique.
62619377|NCT03331705||Use of new cystoscope|Patients in which the cystoscope is used.
62619378|NCT04242407|ACTIVE_COMPARATOR|DMTS|DMTS applied to the upper arm
62619379|NCT04242407|PLACEBO_COMPARATOR|Placebo|Placebo system (with no drug) to match DMTS applied to the upper arm
62619380|NCT04636671|EXPERIMENTAL|Methylprednisolone|"A. On day 1, loading dose of methylprednisolone (MP) 80 mg IV in 30 minutes, promptly followed by continuous infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h.~B. From day 2 to day 8: infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h.~C. From day 9 and beyond:~1. If not intubated patient and PaO2/FiO2 \> 200, taper to MP 20 mg IV in 30 minutes three times a day for 3 days, then MP 20 mg IV twice daily for 3 days, then MP 20 mg IV once daily for 2 days, then switch to MP 16 mg/day PO for 2 days, then MP 8mg/day PO for 2 days, then MP 4mg/day PO for 2 days;~2. If intubated patient or PaO2/FiO2 \<= 200 with at least 5 cmH2O CPAP, continue infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h until PaO2/FiO2 \> 200 then taper as in a)"
62845431|NCT05966688|EXPERIMENTAL|Ethambutol 800 mg|Healthy participants will receive ethambutol 800 mg, orally, QD for 7 days.
62845432|NCT05966688|EXPERIMENTAL|SPR720 1000 mg + Azithromycin 500 mg + Ethambutol 800 mg|Healthy participants will be co-administered SPR720 1000 mg, azithromycin 500 mg, and ethambutol 800 mg, orally, QD for 7 days.
62619381|NCT04636671|ACTIVE_COMPARATOR|Dexamethasone|"A. Dexamethasone (DM) 6 mg IV in 30 minutes or PO from day 1 to day 10 or until hospital discharge (if sooner).~B. After day 10 study treatment is interrupted."
62845433|NCT05966688|EXPERIMENTAL|Azithromycin 500 mg + Ethambutol 800 mg|Healthy participants will be co-administered azithromycin 500 mg, and ethambutol 800 mg, orally, QD for 7 days.
62447308|NCT06338709|EXPERIMENTAL|BariClip® Device Treatment|Subjects allocated to the Treatment Arm of this study will have a BariClip® device implanted.
62619382|NCT02547701|EXPERIMENTAL|P-3058|
62619383|NCT01358578|EXPERIMENTAL|AIN457 150mg|AIN457 150mg
62619384|NCT01358578|EXPERIMENTAL|AIN457 300mg|AIN457 300mg
62619385|NCT01358578|PLACEBO_COMPARATOR|Placebo|Placebo
62845434|NCT04458090|EXPERIMENTAL|Intervention|Receive hospice patient decision aid
62845435|NCT04458090|NO_INTERVENTION|Control|Does not receive hospice decision aid
62845436|NCT03353519|EXPERIMENTAL|Primary care model|The new model of care incorporates a multi-factorial package of service aimed at providing a review of patient needs, facilitated self-management of longer-term stroke care needs for survivors and their carers, optimised communication between patients and health and social care services, optimised communication between the different care services, and increased awareness of and access to national and local community and charity provided services.
62447309|NCT06338709|NO_INTERVENTION|Control|The implantation of a BariClip® device will not be performed on subjects allocated to the Control Arm of this study.
62447310|NCT05134064||PCa patients underwent 1 h p.i. PSMA PET/CT imaging and 3 h p.i. PSMA imaging|
62447311|NCT04371978|EXPERIMENTAL|DPP-4 inhibition|Participants in the Dipeptidyl Peptidase-4 (DPP-4) inhibition group will receive linagliptin in addition to standard of care insulin regimen as per hospital protocol during their entire hospitalization.
62619386|NCT01358578|ACTIVE_COMPARATOR|Etanercept|Etanercept
62619387|NCT01358578|EXPERIMENTAL|AIN457 150mg from Placebo|Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase
62619388|NCT01358578|EXPERIMENTAL|AIN457 300mg from Placebo|Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase
62619389|NCT03141034|EXPERIMENTAL|Irinotecan plus ramucirumab|-Patients will receive ramucirumab intravenously on an outpatient basis at a dose of 8 mg/kg over the course of 60 minutes on Day 1 of each 14-day cycle. They will then receive irinotecan intravenously at a dose of 180 mg/m2 over the course of 90 minutes on Day 1 of each 14-day cycle.
62619390|NCT00560898|EXPERIMENTAL|2|contact lenses disinfected in multipurpose solution
62619391|NCT00560898|EXPERIMENTAL|3|contact lenses disinfected in multipurpose solution
62619392|NCT00560898|EXPERIMENTAL|4|contact lenses disinfected in multipurpose solution
62619393|NCT00560898|EXPERIMENTAL|1|contact lenses disinfected in multipurpose solution
62263022|NCT03084536|PLACEBO_COMPARATOR|Placebo PECS blocks|"* A sham block (normal saline) will be placed preoperatively~* To ensure blind integrity, study drug syringes will be marked only study drug and subject number.~* Perioperative analgesic regimen will be encouraged. Gabapentin 300mg, celecoxib 200mg and acetaminophen 1000mg will be administered to all patients following arrival to the preoperative holding area. On the day of surgery all patients will receive premedication of 1-2 mg midazolam IV (age \< 65) and 50-100 μg fentanyl IV prior to the block placement or entry to the operating room at the discretion of the regional team or operating room anesthesiologist."
62845437|NCT03353519|NO_INTERVENTION|Usual care|The control arm will consist of the usual care currently provided for stroke survivors registered with each general practice.
62845438|NCT03306316|EXPERIMENTAL|Experimental|Experimental Arm
62619394|NCT05211908|EXPERIMENTAL|D-SE|Absence of dentinal sclerosis and self-etching adhesive protocol
62619395|NCT05211908|ACTIVE_COMPARATOR|D-SELETIVE|Absence of dentinal sclerosis and selective enamel etching adhesive protocol
62619396|NCT05211908|EXPERIMENTAL|SD-SE|Sclerotic dentin and self-etching adhesive protocol
62619397|NCT05211908|EXPERIMENTAL|SD-SELETIVE|Sclerotic dentin and selective enamel etching adhesive protocol
62619398|NCT01768221|OTHER|Caregiver intervention|
62845439|NCT03306316|PLACEBO_COMPARATOR|Control|Placebo Control Arm
62845440|NCT03703193|EXPERIMENTAL|Dry needling|The experimental group will receive a single session of modulatory interventions combined with a single session of dry needling into the shoulder muscles which active trigger points will reproduce the shoulder pain symptoms.
62845441|NCT03703193|ACTIVE_COMPARATOR|Physical Therapy|This group will receive a single session of modulatory interventions targeting modulation of central nervous system.
62263023|NCT02831413|PLACEBO_COMPARATOR|Control|Control group members will receive an alternate curriculum that is not related to relationship education. Family Bridges has identified a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
62619399|NCT00802672|EXPERIMENTAL|Test Product|Ciclopirox Olamine Cream 0.77%
62619400|NCT00802672|ACTIVE_COMPARATOR|Reference Product|Loprox Cream 0.77%
62619401|NCT00802672|PLACEBO_COMPARATOR|Vehicle Product|placebo of test product
62845442|NCT05584319|EXPERIMENTAL|Empagliflozin group|Subjects in Empagliflozin group take in 10Mg Empagliflozin per day.
62845443|NCT05584319|NO_INTERVENTION|Blank control group|Subjects in Blank control group will not receive Empagliflozin or other sglt-2 inhibitors.
62845444|NCT03383016||Men at high-rik of prostate cancer|Lifestyle questionnaires such as diet questionnaire, physical activities questionnaires, quality of life , Follows up 1 year and 2 years after the enrollment, Anthropometric measures during the first visit , Blood withdrawal for laboratory biomarkers analysis After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.
62845445|NCT01914341|EXPERIMENTAL|Music|pentatonic live music
62447312|NCT04371978|NO_INTERVENTION|Control|Participants in the control group will receive only the standard of care insulin regimen as per hospital protocol during their entire hospitalization.
62447313|NCT00908752|ACTIVE_COMPARATOR|Brivanib|Adjuvant treatment with TACE Therapy
62447314|NCT00908752|PLACEBO_COMPARATOR|Brivanib Placebo|Placebo adjuvant treatment with TACE Therapy
62447315|NCT03686709|EXPERIMENTAL|SIR-Spheres Therapy Selection|Patient selected for SIR-spheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET/CT. A final blood draw will take place in conjunction with PET/CT imaging.
62447316|NCT03686709|EXPERIMENTAL|TheraSpheres Therapy Selection|Patient selected for TheraSpheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET/CT. A final blood draw will take place in conjunction with PET/CT imaging.
62845446|NCT01914341|NO_INTERVENTION|control|no intervention
62059335|NCT00328614|EXPERIMENTAL|Samarium-153 (0.25 mCi/kg)|Cohort 1: Patients receive 0.25 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
62447317|NCT06543641|OTHER|Study population|All patients included in the study.
62619402|NCT06196697|EXPERIMENTAL|AK104+AK112+SOX/XELOX|Biological: Cadonilimab (AK104) 10mg/kg or 15mg/kg or 6mg/kg Q6W iv D8 (dose choosing depends on the outcome of the dose climb stage) Biological: Ivonescimab (AK112): 20mg/kg Q3W iv D1 Drug:SOX or XELOX SOX: Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Tegafur (40 mg/m2, p.o., Bid, Q3W, for day 1 to day 14 per cycle) XELOX: Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+Capecitabine(1000 mg/m2, p.o., Bid, Q3W, for day 1 to day 14 per cycle)
62619403|NCT03406624||Spinal fusion with modic changes|Patients scheduled for surgery with lumbar spinal fusion with procedures involving moderate to extensive removal of the disc, and with modic changes seen on MRI at the actual level for surgery
62619404|NCT03406624||Spinal fusion without modic changes|Patients scheduled for surgery with lumbar spinal fusion with procedures involving moderate to extensive removal of the disc, but with no modic changes seen on MRI at the actual level for surgery
62619405|NCT03406624||Disc herniation surgery with modic changes|Patients scheduled for disc herniation surgery, and with modic changes seen on MRI at the actual level for surgery
62619406|NCT03406624||Disc herniation surgery without modic changes|Patients scheduled for disc herniation surgery, but with no modic changes seen on MRI at the actual level for surgery
62619407|NCT02643706||CIN|CIN was defined as an absolute increase in serum creatinine concentration of at least 0.5 mg/dL (44.2umol/l) or a relative rise of at least 25% from baseline on the follow-up blood sample drawn 24 to 72 hours after the operation.
62619408|NCT02643706||Control|The enrolled patients without CIN.
62845447|NCT03091348|EXPERIMENTAL|SQ - IM|Subcutaneous testosterone injection followed by intramuscular testosterone injection
62845448|NCT03091348|EXPERIMENTAL|IM - SQ|Intramuscular testosterone injection followed by subcutaneous testosterone injection
62845449|NCT04121585||SL-PLUS™ hydroxylapatite coated cement free hip stem|Total Hip Arthroplasty using the SL-PLUS™ hydroxylapatite coated cement free hip stem
62845450|NCT05681143|ACTIVE_COMPARATOR|Crisis Prevention Arm|
62845451|NCT05681143|PLACEBO_COMPARATOR|Control|
62447318|NCT02452645|EXPERIMENTAL|Intervention|The intervention will integrate: a) support from peer counselors with child care experience who will serve as team leaders for groups of FCCPs; b) tailored print and video materials; and c) a set of portable active toys to elicit changes to the nutrition and physical activity environments of family child care homes.
62447319|NCT02452645|ACTIVE_COMPARATOR|Comparison|The comparison intervention will provide print materials and videos on literacy and school readiness to children and books in both English and Spanish. Participants will also receive support from peer counselors with child care experience.
62447320|NCT02375126||Ages 18-35, no antidepressant use|Ages 18-35, up to 15 males and 15 females, no antidepressant use
62447321|NCT02375126||Ages 36-55, no antidepressant use|Ages 36-55, up to 15 males and 15 females, no antidepressant use
62447322|NCT02375126||Ages 18-55, with antidepressant use|Ages 18-55, up to 10 males and 10 females, taking antidepressants
62447323|NCT04583579|EXPERIMENTAL|New Scleral Lens Wearers|All patients will be asked to wear scleral lenses for the duration of this study.
62447324|NCT00886665|PLACEBO_COMPARATOR|Placebo|
62447325|NCT00886665|EXPERIMENTAL|JWHGWT|
62447326|NCT01820871|EXPERIMENTAL|application arm|"The patients of application arm have the smartphone application (android) for management of type 2 DM.~The application contains action plans and alarm system for each situation of serum fasting glucose, blood pressure, body weight, exercise amount, calori intake, medication, etc."
62447327|NCT01820871|ACTIVE_COMPARATOR|conventional arm|The patients of conventional arm have the booklet for management of type 2 DM. The application contains general medical guideline and knowledge for management of type 2 DM such as,exercise amount, calori intake, medication, etc.
62845452|NCT05094388||Critically ill patients|Patients admitted to intensive care units
62845453|NCT04927624|ACTIVE_COMPARATOR|transversus abdominis plane|In the group in which Transversus Abdominis Plan Block was applied, the patient was placed in the supine position. After skin antisepsis was achieved with 10% povidone iodine, the USG probe was placed transversely between the iliac crest and the anterolateral abdominal wall. After visualizing the external-internal obliq and transversus abdominis muscles, 0.5 ml/kg of 0.25% bupivacaine was injected after negative aspiration by advancing the needle into the fascia between the internal obliq muscle and the transversus abdominis muscle with the in-plane technique.
62447328|NCT06067711|EXPERIMENTAL|Study group:|This group includes 30 burned patients who will receive resistance training program for 12 weeks (3times/week) using resistance band in addition to their traditional physical therapy program and medical treatment.
62447329|NCT06067711|NO_INTERVENTION|Control group:|This group includes 30 burned patients who will receive only their traditional physical therapy program and medical treatment.
62447330|NCT02510716|EXPERIMENTAL|Scheduled Gradual Reduction (SGR)|Four week SGR program plus support text messages.
62447331|NCT02510716|ACTIVE_COMPARATOR|Support Message Only|Support text messages only.
62447332|NCT03263481|EXPERIMENTAL|ERCP with inadvertent pancreatic cannulation|Subjects undergoing ERCP for a biliary indication in which inadvertent pancreatic cannulation occurs will undergo intraductal secretin testing per the study protocol.
62619409|NCT04897035|EXPERIMENTAL|Subjects with Lower Extremity Lymphedema and phlebolymphedema|Lower Extremity Lymphedema and phlebolymphedema
62619410|NCT02004314|OTHER|Chloroquine|This will be a single arm, pilot study with each subject as his/her own control. The study will last 44 weeks, with 8 weeks observation period on ART alone to assess stability of activated CD8CD38 T cells, followed by 24 weeks chloroquine treatment with ART and a 12-week follow-up period on ART alone. Twenty ART treated patients will be recruited. To maximize chances of demonstrating a treatment effect, the chloroquine will be administrated for 24 weeks.
62619411|NCT06288542|NO_INTERVENTION|group c|control group . this group will not receive any iv fluids
62619412|NCT06288542|EXPERIMENTAL|group d|Group D will receive 1 mL/kg/h 5% Dextrose infusion, applied preoperatively during fasting until induction of anesthesia
62619413|NCT06288542|ACTIVE_COMPARATOR|group r|this group will receive 1 mL/kg/h ringer infusion, applied preoperatively during fasting until induction of anesthesia
62619414|NCT02692131||Speckle strain|All adult patients undergoing on pump CABG Surgery.
62619415|NCT02692131||Tissue doppler strain|All adult patients undergoing on pump CABG Surgery
62619416|NCT02770846|EXPERIMENTAL|Immediate loading|Immediate loading of single dental implant in the anterior maxilla with temporary crown in central occlusion
62619417|NCT02770846|ACTIVE_COMPARATOR|Delayed loading|Delayed loading. 2-stage procedure with a 4 months healing period before fabrication of temporary crown.
62845454|NCT04927624|ACTIVE_COMPARATOR|quoadratus lumborum block|In the Quadratus Lumborum Block (Lateral approach) group, the patient was placed in the lateral position with the side to be blocked on top. After skin antisepsis was achieved with 10% povidone iodine, the USG probe was placed transversely between the iliac crest and costa edge. After visualizing the extarnal-internal obliq and transversus abdominis muscles, the probe was advanced posteriorly. Quadratus lumborum muscle and thoracolumbar fascia were visualized. The needle was advanced to the anterolateral border of the quadratus lumborum muscle with the in-plane technique and 0.5 ml/kg of 0.25% bupivacaine was injected after negative aspiration.
62447333|NCT03752541|EXPERIMENTAL|BCMA-UCART|Each subject will accept one of the following dosages of BCMA-UCART cells intravenously (IV) on day 0: 0.5-1\*10\~6/KgBW, 1-2\*10\~6/KgBW,2-3\*10\~6/KgBW.
62447334|NCT03513497|EXPERIMENTAL|Periodontal Profile Class (PPC-A)|Periodontally healthy participants (PPC-A) and participants with mild disease (PPC-B) will wear customized acrylic mouthguard only during tooth brushing for 21 days.
62447335|NCT03513497|EXPERIMENTAL|Periodontal Profile Class (PPC-G)|Participants with severe periodontal disease (PPC-G) and participants with posterior disease (PPC-E) will wear customized acrylic mouthguard only during tooth brushing for 21 days.
62447336|NCT06544005||Non-metastatic HCC group|"129 HCC patients attending the Faculty of Medicine, Ain Shams University Hospital, males and females (according to availability), diagnosed with primary HCC receiving any type of therapy (neoadjuvant or radiotherapy).~Criteria for HCC diagnosis following the ASU hospital role relying on AFP level and CT scan or the fine needle biopsy.~Groups to be matched socioeconomically, in age range, residence."
62447337|NCT06544005||Metastatic HCC group|"69 HCC patients attending the Faculty of Medicine, Ain Shams University Hospital, males and females (according to availability), diagnosed with primary HCC receiving any type of therapy (neoadjuvant or radiotherapy).~Criteria for HCC diagnosis following the ASU hospital role relying on AFP level and CT scan or the fine needle biopsy.~Groups to be matched socioeconomically, in age range, residence."
62447338|NCT05822596|EXPERIMENTAL|Tablet-based interactive games experimental group|The experimental group will take part in a 12-week cognitive training program using tablet-based interactive games.
62447339|NCT05822596|NO_INTERVENTION|Control group|The control group will receive treatment as usual during the 12-week trial.
62619418|NCT02322333|ACTIVE_COMPARATOR|MLD10|Subjects randomized to MLD10 will be dispensed a 28 day supply of magnesium L-lactate dehydrate for daily treatment. A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window. Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day. Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
62619419|NCT02322333|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo will be dispensed a 28 day supply of matching placebo for daily treatment. A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window. Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day. Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
62619420|NCT04677387|PLACEBO_COMPARATOR|Prescribe to Prevent Naloxone Training Module|This a 55-minute online module that covers basic information about naloxone that is relevant to community pharmacists.
62619421|NCT04677387|EXPERIMENTAL|Nalox-Comm|This is a newly developed 30-60 minute online module focused on teaching pharmacists how to overcome naloxone communication barriers.
62619422|NCT05050500|EXPERIMENTAL|Intervention Group|Dapagliflozin 10 mg every 24 hours for 6 months
62619423|NCT05050500|PLACEBO_COMPARATOR|Control Group|1 placebo tablet every 24 hours for 6 months
62623746|NCT05236855||Intervention|Women seen at the colposcopy clinic at Nova Scotia Health in Gynaecology-Oncology because of an abnormal cervical screen lab report
62619424|NCT05012774|EXPERIMENTAL|Aim 1, Sentence Training: Sentence Feedback|"In Aim 1, which is sentence lipreading training, the intervention compares the provision of three different types of feedback for lipreading.~This arm gives printed whole sentence feedback following an attempt to lipread each sentence.~Participants receive pre- and post-training tests."
62619425|NCT05012774|EXPERIMENTAL|Aim 1, Sentence Training: Word Feedback|"In Aim 1, which is sentence lipreading training, the intervention compares the provision of three different types of feedback for lipreading.~This arm gives printed whole word feedback following an attempt to lipread each sentence. Word feedback is for correct words and words that are perceptually similar but incorrect responses.~Participants receive pre- and post-training tests."
62619426|NCT05012774|EXPERIMENTAL|Aim 1, Sentence Training: Consonant Feedback|"In Aim 1, which is sentence lipreading training, the intervention compares the provision of three different types of feedback for lipreading.~This arm gives printed consonant word feedback following an attempt to lipread each sentence. Word feedback is for correct words, but only the consonants are given as feedback for words that are perceptually similar but incorrect responses.~Participants receive pre- and post-training tests."
62619427|NCT05012774|NO_INTERVENTION|Aim 1, Sentence Training: No Training Control|Participants receive only the pre- and post-training tests.
62619428|NCT05012774|EXPERIMENTAL|Aim 2, Nonsense Word Training|Participants train to lipread nonsense words that name nonsense pictures. Participants receive pre- and post-training tests.
62619429|NCT05012774|EXPERIMENTAL|Aim 3, Audiovisual Nonsense Word Training|"Participants train to recognize audiovisual spoken nonsense words that name nonsense pictures and are presented in speech-shaped noise. The paradigm is the same as in Aim 2.~Participants receive pre- and post-training tests."
62619430|NCT05012774|EXPERIMENTAL|Aim 3, Audiovisual Sentence Training|"Participants receive the same training paradigm from Aim 1 with the most effective feedback type from Aim 1. But the sentences are audiovisual and in speech-shaped noise.~Participants receive pre- and post-training tests."
62623747|NCT05236855||Control|Women seen at the General Gynaecology Clinic and the Izaak Walton Killam (IWK) Health Centre with a normal cervical screen lab report
62447340|NCT04263870|EXPERIMENTAL|Sintilimab plus capecitabine and oxaliplatin|Subjects enrolled are treated with oral capecitabine 1000mg per m2 bid for two weeks（every 3 weeks）and intravenous oxaliplatin 130mg per m2（every 3 weeks）in combination with sintilimab 200mg (every 3 weeks)
62447341|NCT01099384|ACTIVE_COMPARATOR|Behavioral: written self-help materials|Behavioral: written self-help materials
62447342|NCT01099384|EXPERIMENTAL|Group behavioral counseling|Group behavioral counseling, weekend program
62447343|NCT06318858|EXPERIMENTAL|Group 1 daily iron supplementation|"12.5 mg daily iron syrup supplementation from 6-9 months old, followed by 12.5 mg weekly iron syrup supplementation from 9-12 months old.~Infants aged 6-9 months will receive two iron syrup bottles. One bottle aims for ingestion every Monday of the week, and one bottle aims for ingestion on other days of the week.~At ages 9-12 months, infants will receive an iron syrup bottle that aims for ingestion every Monday of the week."
62447344|NCT06318858|OTHER|Group 2 weekly iron supplementation|"12.5 mg weekly iron syrup supplementation from 6-12 months old. Infants aged 6-9 months will receive an iron syrup bottle that aims for ingestion every Monday of the week and a placebo bottle that aims for ingestion on other days of the week.~At ages 9-12 months, infants will receive an iron syrup bottle that aims for ingestion every Monday of the week."
62447345|NCT06350721|EXPERIMENTAL|Intervention group|Each patient will receive a total of 8 sessions of vestibular rehabilitation with the DizzyVR system. Each session will last for 50 minutes, with a frequency of one session per week. The total duration of the intervention will be 10 weeks, with the initial assessment/T0 taking place in the first week and the final assessment/T2 in the tenth week. Similarly, the total expected participation time for each participant is set at 12 weeks (T3).
62447346|NCT03465371|EXPERIMENTAL|OnDemand Training Intervention|Participants receiving the OnDemand Training Intervention
62447347|NCT03465371|ACTIVE_COMPARATOR|InPerson Intervention|Participants receiving the InPerson Intervention
62447348|NCT03465371|ACTIVE_COMPARATOR|Virtual InPerson Intervention|Participants receiving the Virtual InPerson Intervention (the InPerson training via Zoom)
62447349|NCT03108365|EXPERIMENTAL|Axiostat|"Size: 1 x 1 cm~Chitosan based haemostatic dressing"
62447350|NCT03108365|ACTIVE_COMPARATOR|Cotton Gauze|Size: 1 x 1 cm
62447351|NCT03109366|OTHER|Online self-management support|Access to online self-management support tool for six months
62447352|NCT02422290|EXPERIMENTAL|Adolescents and young adults with OCD|All participants will be receive the intravenous ketamine infusion.
62447353|NCT03182608|EXPERIMENTAL|Group 1|In the lateral decubitus position, an investigator evaluate the L4-5 interspinous level using an anatomic landmark (Tuffier's line), and then evaluate the L4-5 interspinous level using another anatomic landmark (Tenth rib line). Another investigator evaluate the actual L4-5 interspinous level by noninvasive ultrasonography.
62447354|NCT03182608|EXPERIMENTAL|Group 2|In the lateral decubitus position, an investigator evaluate the L4-5 interspinous level using an anatomic landmark (Tenth rib line), and then evaluate the L4-5 interspinous level using another anatomic landmark (Tuffier's line). Another investigator evaluate the actual L4-5 interspinous level by noninvasive ultrasonography.
62447355|NCT02958215|PLACEBO_COMPARATOR|Group A|This group will include patients with orthostatic hypotension and will be managed with routine spinal anesthesia Ephedrine will be used for management of intraoperative hypotension
62447356|NCT02958215|ACTIVE_COMPARATOR|Group B|This group will include patients with orthostatic hypotension and will be managed with prophylaxis single dose of phenylephrine, 50 ug IV, will be administered immediately before the spinal block then the patients will be managed with routine spinal anesthesia Ephedrine will be used for management of intraoperative hypotension
62447357|NCT01414465|NO_INTERVENTION|low caloric diet|10 health obese women (BMI 30 to 40 kg/m2)
62447358|NCT01414465|EXPERIMENTAL|Orlistat|10 obese women treated with Orlistat 120mg 3 times per day
62619431|NCT01379105|OTHER|electromyography|The electrical activity of the femoral bicep muscle of the right thigh was recorded by a four channel EMG system with using superficial bipolar active electrodes (pre-amplified) with acquisition software and signal processing. The sampling frequency was 2,000 Hz, and the amplifier had a high-pass filter at 20 Hz and a low-pass filter at 500 Hz; a 12-bit analogical converter and computer completed the system
62619432|NCT03630029|OTHER|Administer a dose 12mgFeS/9mg SnPP|12 healthy volunteers will be administered a single dose of 12 mg Iron Sucrose and 9 mg of Stannous Protoporphyrin and followed for seven days.
62619433|NCT03630029|OTHER|Administer a dose 60mgFeS/45 mg SnPP|12 healthy volunteers will be administered a single dose of 60 mg of Iron Sucrose and 45 mg of Stannous Protoporphyrin and followed for seven days.
62619434|NCT03630029|OTHER|Administer a dose 120mgFeS/90mg SnPP|12 healthy volunteers will be administered a single dose of 120 mg of Iron Sucrose and 90 mg of Stannous Protoporphyrin and followed for seven days.
62619435|NCT03630029|OTHER|Administer a dose 180mgFeS/135mg SnPP|12 healthy volunteers will be administered a single dose of 180 mg and 135 mg of Stannous Protoporphyrin and followed for seven days.
62447359|NCT01414465|SHAM_COMPARATOR|lifestyle counseling|Women with BMI \< 30 kg/m2, no taking drug in study
62447360|NCT06347497|EXPERIMENTAL|zonisamide and Acetaminophen arm|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive zonisamide 50 mg twice daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
62619436|NCT03630029|OTHER|Administer a dose of FeS/SnPP CKD Arm|12 subjects with stage 3 or 4 CKD will be administered a single dose of Iron Sucrose and Stannous Protoporphyrin selected from the highest dose from the prior arm that evidences the best safety profile. The subjects will be followed for seven days.
62619437|NCT04876313|EXPERIMENTAL|Combined Drugs|Participants received 4x3 weekly cycles of 360 mg Nivolumab + 125 mg/m\^2 Nab-paclitaxel IV on days 1 and 8, then they had cystectomy after that partecipants received adjuvant nivolumab 360 mg IV Q3W X13 cycles
62619438|NCT02226120|EXPERIMENTAL|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
62619439|NCT02702232||Parkinson's disease|Patients with PD will be recruited consecutively from a neurology clinic. A group of sex- and age-matched normal subjects with be recruited from the public. These patients will be evaluated by ultrasonography for shoulder.
62619440|NCT02702232||Normal|Normal controls who will be evaluated by ultrasonography for shoulder
62619441|NCT05045404|EXPERIMENTAL|Treatment (poziotinib hydrochloride, ramucirumab)|Patients receive poziotinib hydrochloride PO BID on day 1 and ramucirumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62619442|NCT02932605|EXPERIMENTAL|Cannabidiol|Patients will be treated with 600mg CBD daily for 4 weeks (28 days)
62447361|NCT06347497|EXPERIMENTAL|topiramate and Acetaminophen group|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive topiramate100 mg once daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
62447362|NCT00917033|EXPERIMENTAL|GlideScope|Orotracheal intubation using the GlideScope videolaryngoscope
62447363|NCT00917033|ACTIVE_COMPARATOR|Macintosh|Orotracheal intubation using the Macintosh direct laryngoscope
62447364|NCT00959959|EXPERIMENTAL|650 mg TOK-001|
62447365|NCT00959959|EXPERIMENTAL|1300 mg TOK-001|
62447366|NCT00959959|EXPERIMENTAL|1950 mg TOK-001|
62447367|NCT00959959|EXPERIMENTAL|975 mg TOK-001|
62447368|NCT00959959|EXPERIMENTAL|975 mg TOK-001, supplement|
62447369|NCT00959959|EXPERIMENTAL|1950 mg TOK-001, split dose|
62447370|NCT00959959|EXPERIMENTAL|2600 mg TOK-001|
62619443|NCT02932605|PLACEBO_COMPARATOR|Placebo|Patients will be treated with placebo daily for 4 weeks (28 days)
62447371|NCT00959959|EXPERIMENTAL|2600 mg TOK-001, split dose|
62447372|NCT06087913|EXPERIMENTAL|Active|TAF/EVG (20/16mg) vaginal insert
62447373|NCT06087913|PLACEBO_COMPARATOR|Placebo|Matching placebo insert
62447374|NCT05312125|ACTIVE_COMPARATOR|control group|Children in this group will take routine physiotherapy (stretching, strengthening) program during 6 weeks. 3 days/week.
62447375|NCT05312125|ACTIVE_COMPARATOR|intervention group|Children in this group will take routine physiotherapy (stretching, strengthening) program + backward downhill walking (10 minutes in a day) during 6 weeks. 3 days/week.
62447376|NCT04392089||COVID-19|Mechanically ventilated COVID-19 patients with severe ARDS included within 3 days from time of intubation
62447377|NCT05658367|ACTIVE_COMPARATOR|Group 1|- Group I: The group applied arm massage with sesame oil
62447378|NCT05658367|EXPERIMENTAL|Group 2|- Group II: The group applied arm massage with a mixture of sesame-lavender oil
62619444|NCT01467193||1|Endurance trained athletes: minimal \>50 mlO2/KG body weight
62619445|NCT01467193||2|Sedentary healthy control subjects: age, BMI, Gender and waist matched (to the growth hormone deficient patients)
62619446|NCT01467193||3|GHD patients without a GH substitution therapy in the last 6 months
62619447|NCT03469999|EXPERIMENTAL|Dysport Injectable Product|All participants will participate in baseline data collection of energy expenditure, gait analysis, and lower limb spasticity assessment. All participants will receive single event multi level chemoneurolysis with Dysport and will have repeat data collection at 4 weeks and 12 weeks post injection.
62619448|NCT00300846|ACTIVE_COMPARATOR|A1|
62619449|NCT00300846|PLACEBO_COMPARATOR|A2|
62059336|NCT00328614|EXPERIMENTAL|Samarium-153 (0.5 mCi/kg)|Cohort 2: Patients receive 0.5 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
62263024|NCT02831413|EXPERIMENTAL|RS+|The RS+ curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.
62263025|NCT02831413|EXPERIMENTAL|RS+ with enhanced facilitator support|The RS+ curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making. Affiliates assigned to this enhanced treatment group will participate in enhanced facilitator training and support activities.
62263026|NCT05234970|ACTIVE_COMPARATOR|Active Comparator: App 1 Study group (Wysa)|"Wysa App~Wysa provides free, 24/7, emotional support to users through an app-based AI chatbot system. All Wysa chats are anonymous. The AI-based bot responds to the users' emotions and uses CBT, DBT, meditation, breathing, yoga, motivational interviewing, and micro-actions to help the user manage their emotions and encourage mental well-being. In addition, there are over a hundred AI-guided self-care exercises which are backed by science and handpicked by therapists."
62447379|NCT05658367|PLACEBO_COMPARATOR|Group 3|- Group III (Control): The group applied arm massage with paraffin oil
62447380|NCT02354378||Children undergoing sedation with Dexmedetomidine|Children who will undergo sedation for MRI will be given a memory encoding task during dexmedetomidine bolus induction to measure the effects of sedation. The mere task of naming a picture will encode that picture into memory. When the anesthesia has worn off (at approximately 1 hour later), children will be given a memory recognition task to measure the amnesic effects of dexmedetomidine.
62619450|NCT01265004||Stitches, rupture of achilles tendon|Patients, in who the achilles tendon rupture was treated with tendon surgery including a special way of stitching to preserve the sliding ability of the tendon.
62619451|NCT01265004||Fibrin-glue, rupture of achilles tendon|Patients, who received a surgical treatment including a fixing of the tendon with fibrin-glue.
62619452|NCT01265004||Stiches and Fibrin-glue|Patients, in who the achilles rupture was treated with stitches and fibrin-glue.
62619453|NCT02437188|EXPERIMENTAL|ACT plus TAU|"Participants randomized to receive ACT will be scheduled to attend a 1-day training session before their preoperative clinic visit. The intervention will incorporate both experiential learning and didactic content, will include a summary of the main concepts at the end of the day, and a manual of the main concepts will be sent home with participants so they can practice the exercises prior to and after surgery. Participants will also receive an individualized phone call booster intervention 2 weeks after surgery to address any issues and reinforce the information that was given during the workshop. This will be done to facilitate the participant's use of the skills during the postoperative period."
62623748|NCT02497404|EXPERIMENTAL|5 Azacytidine|Patients will be given a five day course of subcutaneous 5-azacytidine, followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irradiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor.
62623749|NCT06553482|EXPERIMENTAL|FatMax group|low-intensity exercise training sessions (FatMax zone)
62623750|NCT06553482|EXPERIMENTAL|FatMAx and musuclar endurance exercise group|FatMax zone exercises as well as muscular resistance exercises
62059337|NCT00328614|EXPERIMENTAL|Samarium-153 (0.75 mCi/kg)|Cohort 3: Patients receive 0.75 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
62059338|NCT00328614|EXPERIMENTAL|Samarium-153 (1.0 mCi/kg)|Cohort 4: Patients receive 1.0 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
62059339|NCT00328614|EXPERIMENTAL|Samarium-153 (1.5 mCi/kg)|Cohort 5: Patients receive 1.5 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
62263027|NCT05234970|PLACEBO_COMPARATOR|Placebo Comparator: App 2 Study Group (Harvard College Mobile)|"Harvard College Mobile App~Harvard College Mobile is an informational app developed by the Harvard University, and is designed to help students navigate resources on campus including professional and peer support groups, but does not allow direct messaging through the app. All Harvard students have full access to the contents of this application."
62263028|NCT01997736|EXPERIMENTAL|Ablation|
62263029|NCT03473574|EXPERIMENTAL|Arm A|Durvalumab in combination with Tremelimumab (Regimen 1) and Gemcitabine
62263030|NCT03473574|EXPERIMENTAL|Arm B|Durvalumab in combination with Tremelimumab (Regimen 1), Gemcitabine and Cisplatin
62059340|NCT00328614|EXPERIMENTAL|Samarium-153 (2.0 mCi/kg)|Cohort 6: Patients receive 2.0 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
62263031|NCT03473574|OTHER|Arm C|Gemcitabine in combination with Cisplatin
62263032|NCT03473574|EXPERIMENTAL|Arm D|Durvalumab in combination with Tremelimumab (Regimen 2), Gemcitabine and Cisplatin
62263033|NCT03473574|EXPERIMENTAL|Arm E|Durvalumab in combination with Gemcitabine and Cisplatin
62263034|NCT03168880|ACTIVE_COMPARATOR|A|weekly Paclitaxel chemotherapy at the dose of 100 mg/m2/week for 8 weeks as a 1-hour infusion and AC/EC (60/600 or 90/600) / 3 weekly.
62447381|NCT02354378||Children not undergoing sedation|A control group of children of similar age scheduled for MRI will be recruited to perform memory recognition testing.
62447382|NCT01669109|EXPERIMENTAL|Hatha yoga|"* 10 weeks of Hatha yoga, designed for patients with colorectal cancer, as a group intervention~* 1 weekly class (90 minutes)"
62263035|NCT03168880|EXPERIMENTAL|B|weekly Paclitaxel at 100mg /m2/week + weekly Carboplatin AUC-2 as an infusion over 60 minutes and AC/EC (60/600 or 90/600)/ 3 weekly.
62263036|NCT05591664||GROUP 1|There will be 38 patients diagnosed with gestational diabetes in the study group.
62263037|NCT05591664||GROUP 2|There will be 80 normal pregnant women in the control group
62263038|NCT02936427|NO_INTERVENTION|Control|Control group will receive normal post operative care including intercostal wound catheters however will not receive dexamethasone
62263039|NCT02936427|EXPERIMENTAL|Dexamethasone 4mg|Participants will receive 4mg of dexamethasone into the intercostal space surrounding the intercostal nerve prior to the first incision. They will then receive routine post operative care including intercostal wound catheters.
62263040|NCT02936427|EXPERIMENTAL|Dexamethasone 8mg|Participants will receive 8mg of dexamethasone into the intercostal space surrounding the intercostal nerve prior to the first incision. They will then receive routine post operative care including intercostal wound catheters.
62263041|NCT03570931|EXPERIMENTAL|RT001|RT001, oral, 3.84 g/day
62263042|NCT02848378||Chronic periodontitis group|Subjects who have moderate to severe alveolar bone loss and clinical attachment level (CAL) ≥5 mm and probing depth (PD) ≥6mm in multiple sites of all four quadrants of the mouth but with no evidence of rapid progression
62263043|NCT02848378||Gingivitis group|Subjects who show gingival inflammation that is based on the presence of bleeding on probing (BOP) at \>50% of sites in the whole mouth, no clinical and radiographic signs of periodontitis
62845455|NCT05448885|EXPERIMENTAL|Experimental: GP combined with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (25mg per square meter on day 1-3) and tislelizumab(200mg) every three weeks for 2 cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy ,then followed by adjuvant therapy with tislelizumab(200mg) every three weeks for 13 cycles after radiotherapy
62845456|NCT01034748|EXPERIMENTAL|1|Single 45 mg oral dose of \[14C\]PF-00299804
62845457|NCT00929396|EXPERIMENTAL|Latent TB infection group|The latent TB group will receive two injections of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart.
62845458|NCT00929396|EXPERIMENTAL|BCG vaccinated group|The BCG vaccinated group will receive two vaccinations of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart
62845459|NCT01468116||RYGB patients with type 2 diabetes|Morbidly obese patients with type 2 diabetes undergoing gastric bypass surgery
62845460|NCT01468116||RYGB patients without type 2 diabetes|Morbidly obese patients with normal glucose tolerance undergoing gastric bypass surgery
62845461|NCT01468116||Cholecystectomy patients without type 2 diabetes|Patients with normal glucose tolerance undergoing laparoscopically cholecystectomy
62263044|NCT02848378||Periodontally healthy group|Subjects who have no sites with PD \>3mm and CAL \>0 mm, a BOP score of \<15% at the examination and no alveolar bone loss.
62845462|NCT05250388||Patient group|"Patients aged 18-40 years with symptomatic unilateral traumatic anterior shoulder instability, following radiographically confirmed or manually reduced dislocation (first-time or recurrent), scheduled for arthroscopic Bankart repair, and with no pathology in the contralateral shoulder.~The study is not interventional but observational, examining biomechanical and proprioceptive conditions in patients' unstable shoulders before and after the surgical procedure."
62845463|NCT04522830|EXPERIMENTAL|BTL-TML-COVID|BTL-TML-COVID
62845464|NCT04522830|PLACEBO_COMPARATOR|Placebo|Placebo
62263045|NCT01479179|EXPERIMENTAL|AMG 479 + Trastuzumab|AMG 479 18 mg/kg or 12 mg/kg intravenously (IV) 30 minutes after trastuzumab. Trastuzumab loading dose (Week 1) 8 mg/kg IV over 90 minutes; maintenance dose 6 mg/kg IV over 30 minutes every 3 weeks.
62845465|NCT01858935|EXPERIMENTAL|ND-L02-s0201 Injection 0.03 mg/kg|
62263046|NCT03057106|ACTIVE_COMPARATOR|Durvalumab and Tremelimumab|Durvalumab q4 weeks until PD + Tremelimumab q 4 wk x 4 doses
62263047|NCT03057106|ACTIVE_COMPARATOR|Platinum based chemotherapy + Durvalumab + Tremelimumab|"4 cycles platinum plus gem or pem + Durva + Treme (q 3 wk x 4 cycles)~Followed by:~Squamous Cell: Maintenance Durva q 4 wk until PD Non-Squamous Cell: Pemetrexed + Durva q 4 wk until PD"
62263048|NCT00123006|ACTIVE_COMPARATOR|1|Dietary Approaches to Stop Hypertension (DASH)
62263049|NCT00123006|PLACEBO_COMPARATOR|2|Control diet
62263050|NCT00450723|EXPERIMENTAL|Sentinel Lymph Node Biopsy|
62845466|NCT01858935|EXPERIMENTAL|ND-L02-s0201 Injection 0.1 mg/kg|
62845467|NCT01858935|EXPERIMENTAL|ND-L02-s0201 Injection 0.2 mg/kg|
62263051|NCT01745770|EXPERIMENTAL|A|
62263052|NCT01745770|ACTIVE_COMPARATOR|B|
62263053|NCT02590120|ACTIVE_COMPARATOR|Enteral nutrition product : product A|Administration during 16 hours.
62263054|NCT02590120|ACTIVE_COMPARATOR|Enteral nutrition product : product B|Administration during 16 hours.
62447383|NCT01669109|NO_INTERVENTION|Usual care|Patients continue their self-directed usual care
62447384|NCT04170166|ACTIVE_COMPARATOR|Anterolateral Approach|The randomised group of patients receiving the subacromial steroid injection via an anterolateral approach
62447385|NCT04170166|ACTIVE_COMPARATOR|Posterior Approach|The randomised group of patients receiving the subacromial steroid injection via a posterior approach
62447386|NCT02892877||Complete Hydatidiform mole and Partial Hydatidiform mole|
62447387|NCT02892877||Invasive mole|
62447388|NCT02892877||Choriocarcinoma|
62447389|NCT02892877||Post-molar neoplasia|
62845468|NCT01858935|EXPERIMENTAL|ND-L02-s0201 Injection 0.4 mg/kg|
62845469|NCT01858935|EXPERIMENTAL|ND-L02-s0201 Injection 0.5 mg/kg|
62845470|NCT01858935|EXPERIMENTAL|ND-L02-s0201 Injection 0.6 mg/kg|
62845471|NCT01858935|EXPERIMENTAL|ND-L02-s0201 Injection 0.8 mg/kg|
62845472|NCT01858935|PLACEBO_COMPARATOR|Placebo|
62845473|NCT03382340|EXPERIMENTAL|Imx-110|
62845474|NCT02197078||Glitazones|
62845475|NCT02197078||Linagliptin|
62845476|NCT02197078||Sulfonylurea|
62263055|NCT03412656|EXPERIMENTAL|Patient|Testing will include assessments of activities of daily living (ADLs) by a physical therapist, biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks, and surveys assessing user preference regarding the force feedback feature, all while using the SoftHand Pro myoelectric lower arm prosthetic and the CUFF force feedback devices in tandem, utilizing the subjects' own prosthetic sockets. Grip force will be recorded using sensors attached to the CUFF device. During each session, videos will be obtained of the subjects performing tasks for kinematics analysis. The experimental sessions are organized into one to two sessions, comprising up to 16 hours, as determined by subject availability.
62263056|NCT03412656|OTHER|Control|Testing will include assessments of activities of daily living (ADLs) by a physical therapist, biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks, and surveys assessing user preference regarding the force feedback feature, all while using the SoftHand Pro myoelectric lower arm prosthetic and the CUFF force feedback devices in tandem, utilizing an adapter simulating a prosthetic socket. Grip force will be recorded using sensors attached to the CUFF device. During each session, videos will be obtained of the subjects performing tasks for kinematics analysis. The experimental sessions are organized into one to two sessions, comprising up to 16 hours, as determined by subject availability.
62263057|NCT00363948|PLACEBO_COMPARATOR|P|
62263058|NCT00363948|EXPERIMENTAL|E|
62263059|NCT03518788|EXPERIMENTAL|Pleur-X|Placement of a permanent drainage under local anesthesia
62619454|NCT02437188|NO_INTERVENTION|TAU|Current pre-surgery treatment includes a nurse-led patient education class covering the post-operative course and what to expect for pain control and recovery. Patients may be taking analgesia (i.e. opioids and/or non-opioids) preoperatively for a chronic pain condition and are prescribed analgesics, sedatives and/ or anxiolytics immediately prior to surgery. Intraoperatively, regional (i.e., spinal and femoral) anesthesia and analgesia is given and patients receive opioids, non-opioids, anticonvulsants and/or anxiolytics during the immediate postoperative period. Other pain treatments may be used, such as cryotherapy, music therapy, relaxation, imagery, etc. Patients are sent home with analgesia (often a combination medication of an opioid and acetaminophen) for breakthrough pain.
62619455|NCT06188676|ACTIVE_COMPARATOR|A|Active Comparator: Arm A (DA-EPOCH-R) Patients receive prednisone or prednisolone on days 1-5 and rituximab IV or rituximab and hyaluronidase human SC over 5 minutes on day 1 or 5. Patients also receive etoposide phosphate, doxorubicin hydrochloride, and vincristine sulfate IV over 96 hours on days 1-4 and cyclophosphamide IV over 30-60 minutes on day 5. Beginning 24-72 hours after completing cyclophosphamide, patients receive filgrastim or pegylated filgrastim SC daily until ANC is \>= 500/uL after the expected nadir. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET/CT on study. When СR is achieved according to PET / CT after 4 cycles of chemotherapy, 2 randomization is performed, a total of 4 or 6 chemotherapy courses
62623751|NCT06553482|ACTIVE_COMPARATOR|Control|Group without physical activity intervention
62845477|NCT02197078||Within-class comparators|
62059341|NCT00816933|EXPERIMENTAL|one port|Patients undergo one port appectomy. Skin incision about 2cm size is made upon umbilicus and dissection is performed to make opening. Then, wound retractcor(Alexis) is iserted on opening site and wound is extended. Rubber glove built-in three 5mm trocars is applied over wound retractor. Pneumoperitoneum is achieved via trocar and appendectomy is performed. After appendectomy, wound is repaired.
62059342|NCT00816933|ACTIVE_COMPARATOR|Three ports|"Paitents will undergo three port appendectomy. 10 mm trocar is inserted on umbilicus, and two 5mm trocas is inserted low abdomen, left flank respectively.~Appendectomy is performed vis these trocas. After operation, wounds are repaired."
62059343|NCT06475001|EXPERIMENTAL|VER-01|VER-01 is administered orally (b.i.d.) using a dosing syringe. One unit corresponds to 2.5 mg THC. The patient is assigned a fixed dose according to their cohort.
62059344|NCT06475001|PLACEBO_COMPARATOR|Placebo|Placebo is administered orally (b.i.d.) using a dosing syringe. The patient is assigned a fixed dose according to their cohort.
62263060|NCT03518788|EXPERIMENTAL|pleurodesis|Pleurodesis with talc in VATS
62447390|NCT02892877||Placental Site Trophoblastic and Epithelioid Tumor|
62845478|NCT03616301|EXPERIMENTAL|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml is the test product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) will be given single oral dose (5 ml containing 400 mg of amoxicillin and 57 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
62447391|NCT02626793||Patients with ≤ 1 conventional, systemic pre-treatment|After failure (inadequate response/intolerance) to or contraindication for ≤ 1 conventional, systemic pre-treatment
62447392|NCT02626793||Patients with > 1 conventional, systemic pre-treatment|After failure (inadequate response/intolerance) to or contraindication for \> 1 conventional, systemic pre-treatment
62845479|NCT03616301|ACTIVE_COMPARATOR|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml is the reference product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) will be given single oral dose (5 ml containing 400 mg of amoxicillin and 57 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
62263061|NCT02636582|EXPERIMENTAL|Arm I (nelipepimut-S plus GM-CSF vaccine)|Patients receive nelipepimut-S plus GM-CSF vaccine ID on days 0 and 14 and then undergo surgery on day 28.
62447393|NCT02497781|EXPERIMENTAL|ceftazidime-avibactam (CAZ-AVI)|CAZ-AVI to be administered every 8 hours as a 2-hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function)
62263062|NCT02636582|ACTIVE_COMPARATOR|Arm II (sargramostim)|Patients receive sargramostim ID on days 0 and 14 and then undergo surgery on day 28.
62619456|NCT06188676|EXPERIMENTAL|B|(DA-EPOCH-R, nivolumab) Patients receive treatment as in Arm A. Patients also receive nivolumab 40 mg IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET/CT on study. When СR is achieved according to PET / CT after 4 cycles of chemotherapy, 2 randomization is performed, a total of 4 or 6 chemotherapy courses.
62447394|NCT02497781|ACTIVE_COMPARATOR|Cefepime|Patients randomised to receive cefepime should receive the dose, schedule and infusion duration as recommended in the local prescribing information or as prescribed by the investigator. The maximum dose of cefepime in any single infusion should not exceed 2000 mg
62619457|NCT02356107|EXPERIMENTAL|Open label treatment with 5-HTP and Creatine|
62619458|NCT03850990|EXPERIMENTAL|Placebo group|In the first visit, this group will learn about placebo pills from a video and will be placebo pills to take twice a day for 8 weeks. They will be asked to take the pills in conjunction with following the weight-loss protocol.
62619459|NCT03850990|EXPERIMENTAL|No placebo group|In the first visit, this group will learn about placebo pills from a video but will not be given placebo pills. They will follow the weight-loss protocol without placebo pills.
62619460|NCT03853291|EXPERIMENTAL|PICT Workbook|PICT Workbook components includes: a) training using an observational assessment tool to detect pain in PWD, b) coaching and feedback by a research nurse in effective strategies for communicating with providers about PWD's pain, c) future planning for what steps to take when a pain symptom is detected, and d) updating the caregiver's skill set through routine practice.
62845480|NCT05533580|EXPERIMENTAL|Remimazolam group|"1. Induction of anesthesia Slowly injects remimazolam 0.4-0.6 mg/kg (about 1 minute) until loss of consciousness (LoC), if the degree of sedation is insufficient, additional remimazolam (0.05 mg/kg each time) is allowed. After the LoC, intravenous sufentanil 0.3 \~0.5ug/kg and cisatracurium besylate 0.1 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.~2. Maintenance of anesthesia remimazolam 0.4\~1.2 mg/kg/h and remifentanil 0.1\~0.3 ug/kg/min are injected intravenously to maintain sedation and assistant analgesia, and cisatracurium besylate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 10 %."
62845481|NCT05533580|ACTIVE_COMPARATOR|Propofol group|"1. Induction of anesthesia Slowly injects propofol 2-4 mg/kg (about 1 min) until loss of consciousness (LoC), allowing additional propofol (0.5 mg/kg each time) if sedation is insufficient. after LoC, intravenous sufentanil 0.3 \~0.5ug/kg and cisatracurium besylate 0.1 mg/kg. after sufficient muscle relaxation and blood circulation stabilization, the tracheal tube was inserted under the sliding scope.~2. Maintenance of anesthesia propofol 4\~10mg/kg/h and remifentanil 0.1\~0.3 ug/kg/min are injected intravenously to maintain sedation and assistant analgesia, and cisatracurium besylate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 10 %."
62845482|NCT00486291|EXPERIMENTAL|1|Phentermine 15mg/topiramate 100mg
62845483|NCT00486291|PLACEBO_COMPARATOR|2|Matched placebo
62845484|NCT01522937|EXPERIMENTAL|Liver cancer patients|The aim of this study is to determine the safety and effectiveness of individualized Stereotactic Body Radiation Therapy (SBRT) in patients who either (1) have had previous liver treatments, and/or (2) have primary hepatocellular carcinoma (HCC).
62845485|NCT02832362|EXPERIMENTAL|Carbomer 980|Participants will be administered test product (nasal spray) containing 0.5% carbomer 980, 4 times per day (i.e. 3 actuations per nostril per dose; each actuation will be 140 mcL, equivalent to 140 mg).
62059345|NCT04469647||High-risk|Employees at high-risk of Coronavirus exposure areas (physicians, nurses, respiratory therapists, radiology technologists, lab technologists, housekeepers)
62263063|NCT05335460|EXPERIMENTAL|Envafolimab combined with XELOX regimen|Envafolimab:300mg,sc,d1,Q3W XELOX( Oxaliplatin 130mg/m2,ivgtt, Q3w capecitabine 1000mg/m2, p.o Q3w)
62447395|NCT01584336|EXPERIMENTAL|LATG group|It means the patients who will be enrolled in our study.
62619461|NCT03853291|ACTIVE_COMPARATOR|Information Pamphlet|Informational pamphlet about pain in dementia and a link to the Alzheimer's Association website.
62623752|NCT05446142|EXPERIMENTAL|Four Period Treatment Sequence: PPI Effect|Participants will receive a single encorafenib dose formulation, a single encorafenib dose of the formulated capsule (CAP), and a single encorafenib dose of the formulation after administration of 20 mg rabeprazole every evening for 5 days.
62059346|NCT04469647||Low-risk|Employees working at lower risk areas such as (administration, HR, Public relations)
62059347|NCT01092403|EXPERIMENTAL|ASM-024|ASM-024 once daily by inhalation
62059348|NCT01092403|PLACEBO_COMPARATOR|Placebo|Placebo once daily by inhalation
62263064|NCT03138434||Optimization phase|The first five patients will be included for the optimization of the MRI sequences. This is to ensure that a standard protocol will work for different sizes of AAA. These patients will only be scanned once.
62447396|NCT00815490|EXPERIMENTAL|Desaturation|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
62447397|NCT03992287|EXPERIMENTAL|Hydrolysed Red Ginseng Extract|10 ml/day, 2.4g/day for 12 weeks
62447398|NCT03992287|PLACEBO_COMPARATOR|Placebo|Placebo for 12 weeks
62845486|NCT02832362|PLACEBO_COMPARATOR|Placebo|Participants will be administered reference product (nasal spray) containing vehicle without carbomer 980, 4 times per day (i.e. 3 actuations per nostril per dose; each actuation will be 140 mcL, equivalent to 140 mg).
62447399|NCT05117099|EXPERIMENTAL|FCU Online + Coach|Parents in this arm will receive access to the FCU Online website and telehealth coaching/ support provided by a trained mental health provider. The FCU Online website includes a brief 5-minute assessment, feedback on parents' responses, and online tools to support parenting in areas that were identified as challenges by the assessment. These tools include videos, animated videos, parenting tips, and interactives to help practice parenting skills.Telehealth coaching sessions will focus on Healthy Behaviors, Positive Parenting, Rules and Consequences, School Support, and Communication.
62845487|NCT05344378|NO_INTERVENTION|1 Month Baseline Period|Initial baseline period for rollout at 6 different clinics throughout the year-long intervention period using a step-wedge design.
62845488|NCT05344378|EXPERIMENTAL|Stage 1 Enrollment|Enrollment of 2 clinics over 4 months including 5 PCPs per clinic (2 total clinics).
62845489|NCT05344378|EXPERIMENTAL|Stage 2 Enrollment|Addition of 2 clinics with modifications over 4 months including 5 PCPs per clinic (4 total clinics).
62845490|NCT05344378|EXPERIMENTAL|Stage 3 Enrollment|Addition of 2 clinics with modifications over 4 months including 5 PCPs per clinic (4 total clinics).
62845491|NCT01315561|EXPERIMENTAL|acupuncture|MSAT is a treatment method in which the patient is exposed to active or passive movement and exercise during acupuncture, as opposed to conventional acupuncture.
62845492|NCT01315561|ACTIVE_COMPARATOR|injections of diclofenac|the control group was treated with intramuscular injections of diclofenac(NSAID). All administrations were limited to 1 session
62845493|NCT02983201|ACTIVE_COMPARATOR|filiform needle|Patients will receive filiform needle treatment only.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
62845494|NCT02983201|EXPERIMENTAL|thumbtack needle+filiform needle|Thumbtack intra-dermal needle will be applied to selected acupuncture points after filiform needle treatment. The thumbtack needle will remain embedded in the patient's dermal part for 2-3 days as per instruction.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
62845495|NCT05541796|OTHER|Contralateral implantation of Tecnis Synergy and Tecnis Symfony IOLs|Non-comparative study involving contralateral implantation of Tecnis Synergy and Tecnis Symfony IOLs.
62447400|NCT05117099|NO_INTERVENTION|Waitlist Control|Parents in this arm will initially serve as the control group but will receive access to the FCU Online website and telehealth coaching after completing three waves of data collection (baseline, 2-mo, and 4-mo follow-up).
62619462|NCT03853291|NO_INTERVENTION|Family Caregivers - Interview Phase|Interviews will be conducted with family caregivers and health care providers in-person in private offices at WCMC/NYP or over the telephone. The primary objectives of the qualitative interviews are to: a) adapt the PAINAD for use with caregivers by asking them to comment on its format and content; and b) generate an initial question pool for the Question Prompt List. After reviewing the PICT workbook, caregivers will complete a brief qualitative questionnaire about the content, format, and perceived utility of PICT, as well as ways to enhance its cultural relevance. They will also complete a semi-structured interview to clarify their perspectives. Health care providers will answer a similar set of questions. Results from this first field-test will inform the next version of PICT and address key issues, such as the feasibility of using research nurses to administer the intervention, anticipation of participant burden for caregivers, and adequacy of PICT format and instructions.
62845496|NCT05014867||Arm 1|Poor responders women undergoing frozen sequential embryo transfer on Day 3 and Day 5
62845497|NCT05014867||Arm 2|Poor responders women undergoing sequential fresh embryo transfer on Day 3 and Day 5
62845498|NCT05014867||Arm 3|Poor responders women undergoing sequential embryo transfer on Day 3 and Day 5 after performing PGS
62845499|NCT05014867||Arm 4|Poor responders women undergoing conventional frozen embryo transfer on Day 5
62845500|NCT01608932|NO_INTERVENTION|Control Group|Treatment as usual
62845501|NCT01608932|EXPERIMENTAL|Telemonitoring for frail patients with chronic diseases|Telemonitoring for frail patients with chronic diseases
62845502|NCT04040933|ACTIVE_COMPARATOR|Marketed Adhesive Bandage #1|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
62263065|NCT03138434||Study phase|"This phase will commence after the optimization phase. This phase is where we want to assess the feasibility, reproducibility and association with disease severity between MRI parameters and AAA.~These twenty patients will be scanned twice, with an interval of 1 week ± 5 days.~The study will be completed when we have 20 patients with 2 scans for each sequence, or when a maximum number of 30 patients in the study phase have been scanned."
62619463|NCT03853291|NO_INTERVENTION|Healthcare Providers - Interview Phase|Interviews will be conducted with family caregivers and health care providers in-person in private offices at WCMC/NYP or over the telephone. The primary objectives of the qualitative interviews are to: a) adapt the PAINAD for use with caregivers by asking them to comment on its format and content; and b) generate an initial question pool for the Question Prompt List. After reviewing the PICT workbook, caregivers will complete a brief qualitative questionnaire about the content, format, and perceived utility of PICT, as well as ways to enhance its cultural relevance. They will also complete a semi-structured interview to clarify their perspectives. Health care providers will answer a similar set of questions. Results from this first field-test will inform the next version of PICT and address key issues, such as the feasibility of using research nurses to administer the intervention, anticipation of participant burden for caregivers, and adequacy of PICT format and instructions.
62619464|NCT03853291|NO_INTERVENTION|Family Caregivers - Field Test Phase|Once initial versions of the PICT manual and workbook are developed, they will be iteratively field-tested and vetted by family caregivers and health care providers. After reviewing the PICT workbook, caregivers will complete a brief qualitative questionnaire about the content, format, and perceived utility of PICT, as well as ways to enhance its cultural relevance. They will also complete a brief (15-20 minute) semi-structured interview to clarify their perspectives. Health care providers will answer a similar set of questions. Results from this first field-test will inform the modified version of PICT and will address key issues, such as the feasibility of using research nurses (and other practice staff) to administer the intervention, anticipation of participant burden for caregivers, and adequacy of PICT format and instructions.
62619465|NCT03853291|NO_INTERVENTION|Healthcare Providers - Field Test Phase|Once initial versions of the PICT manual and workbook are developed, they will be iteratively field-tested and vetted by family caregivers and health care providers. After reviewing the PICT workbook, caregivers will complete a brief qualitative questionnaire about the content, format, and perceived utility of PICT, as well as ways to enhance its cultural relevance. They will also complete a brief (15-20 minute) semi-structured interview to clarify their perspectives. Health care providers will answer a similar set of questions. Results from this first field-test will inform the modified version of PICT and will address key issues, such as the feasibility of using research nurses (and other practice staff) to administer the intervention, anticipation of participant burden for caregivers, and adequacy of PICT format and instructions.
62619466|NCT03577314||miscarriage|Patients were aged from 18 to 35 years, 50 females who have history of at least two unexplained recurrent miscarriage below 20th week of pregnancy
62619467|NCT03577314||healthy|50 systemically healthy females with at least two normal births and no poor obstetric history such as preeclampsia and premature birth
62619468|NCT04884971|EXPERIMENTAL|Microbiota Treatment Arm|Participants will receive the encapsulated microbiota intervention daily for seven days and will be subsequently monitored for six months.
62619469|NCT06004830|EXPERIMENTAL|Spironolactone|Participants will receive a prescription for spironolactone
62619470|NCT00460356||Ancillary-Correlative (glycoprotein and glycan profiling)|Primary and metastatic tumor specimens are collected during lymphadenectomy and used for tissue microarray analysis, mutational analysis of T-synthase and Cosmc, immunohistochemical staining of Tn antigen and sialyl Tn antigen, and customized gene expression array analysis of 400 genes associated with glycobiology. Pre-lymphadenectomy blood is collected from patients at baseline for customized glycan array analysis of 300 carbohydrates.
62619471|NCT03022487||ICD Patients with Ischaemic cardiomyopathy|A standard 30-minute electrophysiological (EP) cardiac stimulation protocol will be performed at the end of the ICD implant at baseline. Participants will be followed up for at least 12 months for endpoints.
62619472|NCT05388422|EXPERIMENTAL|Severe cerebral palsy (GMFCS IV and V)|This study included patients with severe cerebral palsy (GMFCS IV and V)
62619473|NCT00994799||ranibizumab group|patients receiving intravitreal ranibizumab for diabetic macular edema
62619474|NCT00994799||laser|patients receiving macular grid-pattern laser therapy
62619475|NCT06005090||FCL group|Plate fixation performed with the use of far cortical locking (2 point screw fixation into the plate and far cortex of the diaphysis)
62619476|NCT06005090||BL group|Traditional 3 point fixation of the screw into two cortices of the diaphysis and into the plate
62845503|NCT04040933|ACTIVE_COMPARATOR|Marketed Adhesive Bandage #2|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed only on Days 3, 5, 7, 9, 11, 13, 15, and 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
62845504|NCT04040933|ACTIVE_COMPARATOR|Non-marketed Adhesive Bandage #1|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
62263066|NCT03917823|EXPERIMENTAL|Cryoneurolysis (active)|The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation (active or sham) separated by 1-minute defrost periods.
62263067|NCT03917823|SHAM_COMPARATOR|Sham|For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
62263068|NCT02336490|NO_INTERVENTION|Usual Care|discharge medication prescriptions are printed or sent electronically to a patient's pharmacy of choice
62845505|NCT04040933|EXPERIMENTAL|Non-marketed Adhesive Bandage #2|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
62263069|NCT02336490|ACTIVE_COMPARATOR|Meds-in-Hand|discharge medication delivery service: discharge prescriptions are filled at the hospital pharmacy and delivered to patients before they leave the hospital
62059349|NCT01830595|ACTIVE_COMPARATOR|Recombinant Lactoferrin|Recombinant lactoferrin will be administered by mouth twice daily
62619477|NCT03157596|EXPERIMENTAL|intervention group|"selected randomly from a list of all the 105 special education centers registered at the State Ministry of Education, and randomly allocated into intervention group.~all the children with developmental disabilities in enrolled in the school who met the eligibility criteria were examined and all their parents were interviewed.~Caregivers' baseline knowledge and attitudes towards the oral healthcare of their children was assessed by an interview questionnaire.~examination for the children with developmental disabilities was carried out to assess caregivers' practice by assessing the oral hygiene level and amount of unmet treatment needs.~educational intervention by an Oral Health Education Program for Caregivers of Children with developmental disabilities about the oral health care of Children with DD, in the form of a short video, accompanied by demonstration \& followed by an interactive discussion .~the same evaluation was carried out again 3 months after the intervention."
62619478|NCT03157596|NO_INTERVENTION|control group|Evaluation of the knowledge, attitude and practice of caregivers of children with developmental disabilities towards the oral health of their children at baseline and 3 months after without any intervention.
62619479|NCT03492905|EXPERIMENTAL|Internet-based CBT|Internet-based Cognitive Behaviour Therapy (iCBT)
62845506|NCT04040933|EXPERIMENTAL|Non-marketed Adhesive Bandage #3|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
62845507|NCT04040933|EXPERIMENTAL|Non-marketed Adhesive Bandage #4|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
62845508|NCT04040933|EXPERIMENTAL|Non-marketed Adhesive Bandage #5|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
62845509|NCT04040933|NO_INTERVENTION|No Treatment (Uncovered, Negative Control)|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, no treatment will be applied as the wound will be kept uncovered as negative control.
62447401|NCT04616417|EXPERIMENTAL|Investigational Oocyte Cryopreservation|All subjects will undergo controlled ovarian hyperstimulation. They will be treated with variable dosages of injectable gonadotrophins over a period of 8 to 12 days. Response will be monitored using vaginal ultrasound and serum estradiol levels. When appropriate follicle maturation has been achieved, a single dose of human chorionic gonadotropin (hCG) will be administered to induce final oocyte maturation. Thirty-six hours after hCG administration, the subject will undergo standard transvaginal oocyte retrieval under ultrasound guidance. The procedure takes approximately 20 minutes and is carried out under conscious sedation with Fentanyl and Versed. The oocytes are immediately handed off to the embryology technicians in the IVF laboratory.
62845510|NCT00713167|EXPERIMENTAL|Grape Seed Extract|Enrolled patients who are randomly assigned to receive Grape Seed Extract capsules
62845511|NCT00713167|PLACEBO_COMPARATOR|Placebo|Placebo enrolled patients who are randomly assigned to receive placebo of Grape Seed Extract
62845512|NCT05349565|ACTIVE_COMPARATOR|CONVENTIONAL PHYSICAL THERAPY|TENS , Open chain knee flexion and extension, Calf stretch , Quad set
62263070|NCT03223480|EXPERIMENTAL|EUS-guided gastrojejunostomy|"The procedures would be performed under conscious sedation or monitored anesthesia by a therapeutic gastroscope. The endoscope would be used to reach the site of obstruction. The stricture would be cannulated with a 0.025 or 0.035 guide-wire. The double balloon occluder would then be inserted on guidewire beyond the duodenal-jejunal flexure and the two balloons of the occluder would be inflated. A segment of duodenum/jejunum would then be occluded and saline would be injected. A linear echoendoscope would then be inserted into the stomach to guide insertion of the gastrojejunostomy stent."
62845513|NCT05349565|EXPERIMENTAL|MUSCLE ENERGY TECHNIQUE|MET ( isometric contraction with 6-10 sec )
62845514|NCT06112106|NO_INTERVENTION|Control group|Surgeons assigned to the control group will be asked (to continue) to apply the ergonomic recommendations in the daily practice introduced three months ahead of trial start.
62059350|NCT01830595|PLACEBO_COMPARATOR|Placebo|Matched placebo will be administered by mouth twice daily
62059351|NCT01418014||Infected Cohort|Perinatally HIV-infected adolescents from 7 years of age (7th birthday) up to but not including the 16th birthday at enrollment, engaged in care with ART treatment history available.
62059352|NCT01418014||Uninfected Cohort|HIV-uninfected adolescents from 7 years of age (7th birthday) up to but not including the 16th birthday at enrollment born to HIV-infected mothers.
62619480|NCT06015919|EXPERIMENTAL|effect of dash diet and acupuncture on hypertention in post menopausal women|"* Group (A): It will include 15 post-menopausal women who will be treated by DASH diet and anti-hypertensive drugs.~* Group (B): It will include 15 post-menopausal women who will be treated by acupuncture and anti-hypertensive drugs.~* Group (C): It will include 15 post-menopausal women who will be treated by DASH diet, acupuncture and anti-hypertensive drugs."
62447402|NCT01494688|EXPERIMENTAL|Part 1 - Dose Escalation: RO5509554|Participants will receive a single, low dose of 100 milligrams (mg) RO5509554 in 7-day PK run-in period (Cycle 0), followed by dose escalation from Day 1 of Cycle 1. RO5509554 will be escalated as monotherapy in approximately 6 cohorts with dose increments between cohorts of up to 100 percent (%). The doses will be escalated further until MTD/OBD as single agent is reached.
62447403|NCT01494688|EXPERIMENTAL|Part 1 - Dose Escalation: RO5509554 + Paclitaxel|RO5509554 will be administered in combination with a fixed dose of weekly (QW) paclitaxel (80 milligrams per square meter \[mg/m\^2\]). The starting dose for RO5509554 in combination with paclitaxel will be 2 dose levels below to that of the highest dose of monotherapy RO5509554. Escalation of RO5509554 in combination with QW paclitaxel will start in a standard 3 + 3 design until MTD/OBD as combination dose is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of paclitaxel and lower dose of RO5509554. If insufficient safety, pharmacokinetic or pharmacodynamic data have been collected at the MTD/OBD, up to an additional 4 participants may be enrolled at that dose level.
62447404|NCT01494688|EXPERIMENTAL|Part 2 - Expansion Cohort: RO5509554|Participants will receive RO5509554 1000 mg Q2W, Q3W or initial biweekly followed by monthly maintenance.
62447405|NCT01494688|EXPERIMENTAL|Part 2 - Expansion Cohort: RO5509554 + Paclitaxel|Participants will receive RO5509554 1000 mg Q2W in combination with a fixed dose of QW paclitaxel (80 mg/m\^2).
62447406|NCT03533946|EXPERIMENTAL|Rucaparib, all participants|Single Arm study, all participants will get rucaparib
62447407|NCT04810923|EXPERIMENTAL|i-PRF group|arthrocentesis procedure plus four consecutive intra-articular injection of i-PRF.
62447408|NCT04810923|EXPERIMENTAL|Control group|arthrocentesis procedure alone.
62447409|NCT00468741|NO_INTERVENTION|1|subjects receive internet access and computer
62447410|NCT00468741|EXPERIMENTAL|2|CHESS informational services only
62447411|NCT00468741|EXPERIMENTAL|3|CHESS social support and informational services
62447412|NCT00468741|EXPERIMENTAL|4|Full CHESS
62447413|NCT03982966|EXPERIMENTAL|Omega 3|Group 1 will be 40 patients that will take Omega 3 fatty acids (fish oil)
62447414|NCT03982966|NO_INTERVENTION|Control|20 patients will not take omega 3 fatty acids.
62447415|NCT05411042|EXPERIMENTAL|Intervention group|The experimental group intervened a dance somatosensory game (DSG), DANZ BASE developed by International Games System Company, at the Xinzhuang health center, which is a local bureau with outpatient clinic. The participants in experimental group played twice a week, each time requiring at least lasting 30 minutes, for half of a year.
62447416|NCT05411042|NO_INTERVENTION|Control group|The control group only performed routine data collection; the research assistant asked the subjects about their usual activities by telephone every month to understand their physical activity in this half of the year.
62059353|NCT05837208||Treated Group|all subjects will apply the study product RV4369A
62059354|NCT04588935|NO_INTERVENTION|Group 1|women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy, untreated
62447417|NCT02359604|OTHER|Single Arm Study -microbiome|This is a single-arm study. The patients will serve as their own controls. The PPI administered for PPI-therapy is already FDA approved. A stool sample will be obtained for intestinal microbiome testing before PPI, under PPI and after PPI therapy.
62447418|NCT01599208|EXPERIMENTAL|Single-pulse online stimulation|Online single-pulse online stimulation at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
62447419|NCT01599208|EXPERIMENTAL|Repetitive online stim., 400ms, 10Hz|Repetitive online stimulation for 400ms at 10Hz at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
62619481|NCT01054313|EXPERIMENTAL|Docetaxel + Sirolimus|Starting doses of Docetaxel 30 mg/m\^2 IV every 3 weeks + Sirolimus 1 mg daily
62619482|NCT05872659|PLACEBO_COMPARATOR|Control group|Participants will receive continuous antiviral therapy and saline placebo (iv, 100 mL) treatment on Day 0，Day30，Day60 and followed up for 48 weeks.
62845515|NCT06112106|EXPERIMENTAL|Intervention group|Surgeons
62059355|NCT04588935|ACTIVE_COMPARATOR|Group 2|women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy, receiving treatment with a combination of bisoprolol and perindopril
62059356|NCT03585296|EXPERIMENTAL|ATI-502|ATI-502 topical solution applied daily for four weeks.
62059357|NCT00774384|ACTIVE_COMPARATOR|1|Immunisation with NZ MenB OMV vaccine (NZ98/254)
62059358|NCT00774384|NO_INTERVENTION|2|No vaccine
62263071|NCT02761304|EXPERIMENTAL|ultrasound results given to obstetrical practionnair|
62619483|NCT05872659|EXPERIMENTAL|Treatment group|Participants will receive continuous antiviral therapy and Mesenchymal stem cells (1\*10\^6/kg subject weight, iv, 100 mL) treatment on Day 0，Day30，Day60 and followed up for 48 weeks.
62619484|NCT06080165|EXPERIMENTAL|Sirolimus|Participants that are 5 to 12.99 years old will start at 1 mg/m2/dose. Participants that are 13 to 45.99 years old and \< 39.99 kg in weight will also start on 1 mg/day. Participants that are 13 to 45.99 years old and \> 40 kg in weight will start on 2 mg/day. The target blood level will be 5-15 ng/ml with dose adjustment based on sirolimus levels obtained every 2 to 3 weeks after every dose change.
62619485|NCT06080165|PLACEBO_COMPARATOR|Placebo|matching placebo
62619486|NCT05735405|EXPERIMENTAL|Experimental Group|The experimental group will first perform 30 minutes of pedaling as a moderate intensity aerobic activity. Subsequently it will carry out a daily cognitive training of 60 minutes to improve attentional, working memory and executive functions.
62619487|NCT05735405|EXPERIMENTAL|Control Group|The control group will first carry out a daily 60-minute cognitive training to improve attentional, working memory and executive functions. It will then perform 30 minutes of pedaling as a moderate intensity aerobic activity.
62619488|NCT01121536|EXPERIMENTAL|Armodafinil 150-200 mg/day|Participants began taking armodafinil at a dosage of 50 mg/day; the dosage was increased by 50 mg/day on days 2 and 4, up to a dosage of 150 mg/day. At the discretion of the investigator, the dosage of armodafinil may be increased to 200 mg/day on day 6 or thereafter, and reduced to 150mg/day if the higher dose is not well tolerated. Treatment was administered for six months.
62619489|NCT02315664|EXPERIMENTAL|Immediate Intervention Group|Education session, Fitbit Flex, and remote coaching by a PT: These three components of the intervention will be delivered to the participants in Month 1 and 2. At the end of the education session, the PT will help participants set personal activity goals. In Month 1 and 2, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will keep the Fitbit and continue to use it with access to a PT via email as needed. In addition, they will receive a monthly e-newsletter about arthritis research that is not related to physical activity.
62845516|NCT05792241||Women of reproductive age|Randomly selected women of reproductive age in study communities.
62845517|NCT00955201|NO_INTERVENTION|Arm 1|Sedentary Control Group
62845518|NCT00955201|EXPERIMENTAL|Arm 2|Aerobic Exercise Group
62447420|NCT01599208|EXPERIMENTAL|Repetitive online stim., 400ms, 20Hz|Repetitive online stimulation for 400ms at 20Hz at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
62845519|NCT00955201|EXPERIMENTAL|Arm 3|Isokinetic Strength Exercise Group
62845520|NCT00955201|EXPERIMENTAL|Arm 4|Combined Aerobic and Isokinetic Strength Exercise Group
62845521|NCT04947982|NO_INTERVENTION|Control|All laparoscopic surgical procedures were performed at 12 mmHg CO2 pressure throughout the surgery
62263072|NCT02761304|OTHER|ultrasound results shaded to obstetrical practionnair|
62263073|NCT04022915|EXPERIMENTAL|Acute pulmonary embolism|Subjects will receive 64Cu-FBP8 and undergo PET-CT imaging.
62447421|NCT01599208|EXPERIMENTAL|Repetitive offline stimulation at 10Hz|Repetitive offline stimulation at 10Hz for 4 min before study or for 8 min before test (in accordance with the phase length), comprising 2-second stimulation trains and 20-second breaks. Stimulation will be given at 120% of motor threshold to either the right or the left MTL in comparison to sham condition.
62619490|NCT02315664|EXPERIMENTAL|Delayed Intervention Group|Same intervention with a 2 month delay: The Delayed Intervention Group (control group) will receive the same monthly e-newsletter in Months 1-2. The full intervention will be initiated in Month 3 with a brief education session, use of Fitbit Flex, and counseling by a physiotherapist. In Month 4, they will continue the intervention without the PT phone calls. Participants will keep the Fitbit for Month 5-6, and have email access to PT as needed.
62619491|NCT03564132|EXPERIMENTAL|Yigansan|2.5g of Yigansan granules by mouth, three times a day for 4 weeks
62619492|NCT03564132|PLACEBO_COMPARATOR|Placebo|2.5g of Placebo(contained one-tenth Yigansan) granules by mouth, three times a day for 4 weeks
62619493|NCT03724019|EXPERIMENTAL|Group Q|20 milliliter of ketamine (0.5mg / kg ideal body weight) at induction of anesthesia.
62619494|NCT03724019|NO_INTERVENTION|Group S|
62845522|NCT04947982|EXPERIMENTAL|Study|All laparoscopic surgical procedures were performed at 8 mmHg CO2 pressure throughout the surgery
62845523|NCT03739021|EXPERIMENTAL|Group 1 (30 participants)|
62845524|NCT03739021|EXPERIMENTAL|Group 2 (30 participants)|
62845525|NCT02029898|ACTIVE_COMPARATOR|Remifentanil|injectable solution, 0.5 microgramme/Kg for 30 seconds following by a continuous dose of 0.1 microgramme/kg/minute
62845526|NCT02029898|PLACEBO_COMPARATOR|Placebo|injectable solution 0.9% for the end of surgery
62845527|NCT05159336|EXPERIMENTAL|schizophrenia patients with auditory hallucinations|For schizophrenia patients with auditory hallucinations, tACS for implementation intervention
62845528|NCT05733312|EXPERIMENTAL|Focused Ultrasound|Subjects with known or suspected glioma (≥3cm) undergoing routine planned neurosurgical resection will undergo a focused ultrasound prior to the surgery with the InSightec's ExAblate Neuro Model 4000 Type 2.0 (220 KHz) system
62845529|NCT01419197|EXPERIMENTAL|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.
62845530|NCT01419197|ACTIVE_COMPARATOR|Treatment of physician's choice|Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.
62263074|NCT01263483|ACTIVE_COMPARATOR|Voglibose 0.2 mg TID|
62263075|NCT01263483|EXPERIMENTAL|Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID|
62263076|NCT01263483|EXPERIMENTAL|Alogliptin 25 mg QD and Voglibose 0.2 mg TID|
62263077|NCT03219242|EXPERIMENTAL|Caiman device|Time sparing and post-operative outcome in ovarian cancer including bowel resection for cytoreductive surgery with Caiman device
62619495|NCT03464474|EXPERIMENTAL|Assessment of inflammation grade|Colonic biopsies will be acquired. Biopsies from all patients will be examined using digital holographic microscopy as well as performing a histopathological analysis using the Nancy-score (Goldstandard).
62619496|NCT02346214||Preterm and term neonates|A. Preterm and term neonates B. Singleton live births between 26 and 42 weeks gestation (determined by first of early-second trimester ultrasound dating) at three referral hospitals
62845531|NCT03912519|ACTIVE_COMPARATOR|Parallel placement of 16 gauge electrodes|Parallel Group will undergo radiofrequency ablation via the approach described in Spine Intervention Practice Guidelines via 16 gauge electrodes. Specifically, the target nerve will be targeted with a parallel approach so as the electrode lay parallel to the nerves location within the sulcus formed by the neck of superior articular process and transverse process (or sacral ala for L5) cephalad to the point it is covered by the mamillo-accessory ligament.
62619497|NCT02886013||Mexican adolescents|"Students without known disease, between 14 and 18 years from the Lic. Adolfo Lopez Mateos Preparatory school of the Autonomous University of the State of Mexico (UAEMex)."
62619498|NCT02118259|OTHER|The study population|"See inclusion and exclusion criteria.~Intervention: Before-after study"
62619499|NCT05131347|EXPERIMENTAL|motor intervention|Children in the motor intervention group will receive a 8-week motor intervention program. Each week will be of 1.5-hour duration.
62619500|NCT05131347|ACTIVE_COMPARATOR|cognitive intervention|Children in the cognitive intervention group will receive a 8-week cognitive training program. Each week will be of 1.5-hour duration.
62619501|NCT04721366||Standard of Care (SoC)|Neonatal and pediatric participants who has been on ERT (VPRIV) will be followed up for 36 months from the time of treatment initiation as per SOC.
62059359|NCT00246337|PLACEBO_COMPARATOR|Placebo|Placebo to match assigned treatment arm; one orally-administered dose, plus an optional second dose of active drug, per assigned treatment arm, to treat a single moderate-to-severe migraine headache.
62059360|NCT00246337|EXPERIMENTAL|MK0974 25 mg|MK0974 25 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
62447422|NCT01599208|EXPERIMENTAL|Repetitive offline stimulation at 20Hz|Repetitive offline stimulation at 20Hz for 4 min before study or for 8 min before test (in accordance with the phase length), comprising 2-second stimulation trains and 20-second breaks. Stimulation will be given at 120% of motor threshold to either the right or the left MTL in comparison to sham condition.
62059361|NCT00246337|EXPERIMENTAL|MK0974 50 mg|MK0974 50 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
62447423|NCT01599208|EXPERIMENTAL|Repetitive offline stimulation with iTBS|Repetitive offline stimulation with Intermittent Theta Burst Stimulation (iTBS) comprising 3 pulses at 50Hz, repeated at 5Hz for 2-second stimulation trains with 8-second breaks for 192 seconds. Stimulation will be given at 90% of motor threshold to either the right or the left MTL in comparison to sham condition.
62619502|NCT00421109|EXPERIMENTAL|1|Bilastine 20 mg
62619503|NCT00421109|ACTIVE_COMPARATOR|2|Levocetirizine 5 mg
62059362|NCT00246337|EXPERIMENTAL|MK0974 100 mg|MK0974 100 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
62059363|NCT00246337|EXPERIMENTAL|MK0974 200 mg|MK0974 200 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
62619504|NCT00421109|PLACEBO_COMPARATOR|3|Placebo
62619505|NCT04163926|EXPERIMENTAL|Intervention group - Post op follow up by trained optometrist|Intervention group will have cataract follow up conducted by a trained optometrist 4-6 weeks after surgery in community clinic
62619506|NCT04163926|ACTIVE_COMPARATOR|Usual care group - Consultant led post op follow up|Follow-up at 4-6 weeks after surgery led by consultant ophthalmologist
62619507|NCT02779270|EXPERIMENTAL|BAY987518|Subject will apply the test product to all sun exposed areas of face and body, wait for 15 minutes, then sunbathe for 30 minutes, exercise for 20 minutes, and then sunbathe for additional 30 minutes. Immediately after the second sunbathing, enter the pool and remain in the water for 20 minutes. Then repeat the sun and water exposure activities again.
62619508|NCT02779270|ACTIVE_COMPARATOR|Sunscreen control|Subject will apply the test product to all sun exposed areas of face and body, wait for 15 minutes, then sunbathe for 30 minutes, exercise for 20 minutes, and then sunbathe for additional 30 minutes. Immediately after the second sunbathing, enter the pool and remain in the water for 20 minutes. Then repeat the sun and water exposure activities again.
62619509|NCT04609449|EXPERIMENTAL|Long biliopancreatic limb|Patients submitted to long biliopancreatic limb Roux-en-Y gastric bypass.
62619510|NCT04609449|ACTIVE_COMPARATOR|Standard biliopancreatic limb|Patients submitted to standard Roux-en-Y gastric bypass.
62619511|NCT02535754|EXPERIMENTAL|ALIVE|Email program N=170
62619512|NCT02535754|EXPERIMENTAL|CCS BCY|Comprehensive program N=285
62619513|NCT02535754|EXPERIMENTAL|ALIVE + CCS BCY|Email + comprehensive program N=225
62619514|NCT04708496|EXPERIMENTAL|Standard dose of Artemether lumefantrine|Dose comparison-concurrent control In this arm, Participants receiving Efavirenz400mg based ART will be randomized to standard dose Artemether Lumefantrine when treating uncomplicated malaria in HIV-malaria co-infected participants
62845532|NCT03912519|ACTIVE_COMPARATOR|Perpendicular placement with 22 gauge electrodes|Perpendicular Group will undergo radiofrequency ablation via the approach described in Spine Intervention Society Practice Guidelines for medial branch blocks, using a 22 gauge electrode. Specifically, the target nerve will be targeted with a perpendicular approach so as the tip of electrode contact the nerve at some point of it course along the sulcus formed by the neck of superior articular process and transverse process (or sacral ala for L5) cephalad to the point it is covered by the mamillo-accessory ligament.
62845533|NCT03508908|NO_INTERVENTION|Observation Period|HIV testing will only be done if ordered by the primary care clinician. Individuals diagnosed with HIV who have not yet notified partners will be offered assisted partner notification at a 6-week visit.
62845534|NCT03508908|ACTIVE_COMPARATOR|Intervention Period|Combination intervention with HIV-1 RNA testing followed by rapid tests if positive for HIV diagnosis, immediate ART if diagnosed, assisted partner notification with HIV-1 RNA testing of partners, and PrEP for uninfected partners in discordant relationships.
62845535|NCT03282604||male|
62845536|NCT03282604||female|
62845537|NCT04441541|EXPERIMENTAL|Treadmill with auditory feedback group|
62845538|NCT04441541|EXPERIMENTAL|Treadmill with visual feedback group|
62845539|NCT04441541|EXPERIMENTAL|Treadmill with auditory and visual feedback group|
62845540|NCT04441541|ACTIVE_COMPARATOR|Treadmill training group|
62845541|NCT01474239|EXPERIMENTAL|Calibration Arm|
62059364|NCT00246337|EXPERIMENTAL|MK0974 300 mg|MK0974 300 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
62619515|NCT04708496|EXPERIMENTAL|Double dose Artemether lumefantrine|Dose comparison concurrent control In this arm, Participants receiving Efavirenz based ART will be randomized to double dose Artemether Lumefantrine when treating uncomplicated malaria in HIV-malaria co-infected participants
62619516|NCT04708496|EXPERIMENTAL|5 day course of Artemether lumefantrine|Dose comparison concurrent control In this arm, Participants receiving Efavirenz based ART will be randomized to 5 day course of Artemether Lumefantrine as opposed to the standard 3day course when treating uncomplicated malaria in HIV-malaria co-infected participants
62619517|NCT05223166|EXPERIMENTAL|Pitolisant|Histamine H3 receptor H3R antagonist/ inverse agonist
62619518|NCT05223166|PLACEBO_COMPARATOR|Placebo|Placebo
62619519|NCT01483599|EXPERIMENTAL|CNTO 1959 (5 mg)|CNTO 1959 5 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
62619520|NCT01483599|EXPERIMENTAL|CNTO 1959 (15 mg)|CNTO 1959 15 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
62059365|NCT00246337|EXPERIMENTAL|MK0974 400 mg|MK0974 400 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
62447424|NCT04142346|NO_INTERVENTION|Uninterrupted sitting|Participants remained seated throughout 7 hours. During the protocol, participants were allowed to go to the bathroom in a wheelchair and al-libitum water was granted.
62619521|NCT01483599|EXPERIMENTAL|CNTO 1959 (50 mg)|CNTO 1959 50 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
62619522|NCT01483599|EXPERIMENTAL|CNTO 1959 (100 mg)|CNTO 1959 100 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
62845542|NCT01474239|EXPERIMENTAL|Investigational Arm|
62845543|NCT02349217|EXPERIMENTAL|Mindfulness Based Stress Reduction Intervention (MBRE)|"Participant and partner take part in an 8-week Mindfulness-Based Relationship Enhancement (MBRE) intervention course. MBRE course consists of meditation and yoga techniques and handouts.~Pain assessment administered at baseline and at follow up visit. Questionnaires completed at baseline and at follow up visit. Neurocognitive tests administered at baseline and at follow up visit. Cortisol testing performed after baseline visit and at follow up visit. Interviews conducted after follow up visit. These interviews are audio-taped and transcribed."
62619523|NCT01483599|EXPERIMENTAL|CNTO 1959 (200 mg)|CNTO 1959 200 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
62619524|NCT01483599|ACTIVE_COMPARATOR|Adalimumab (approved psoriasis dosing)|Adalimumab 80 mg at week 0 followed by 40 mg at week 1 and every second week through Week 39 (i.e., Weeks 3, 5, 7, etc.)
62619525|NCT01483599|PLACEBO_COMPARATOR|Placebo to CNTO 1959 (100 mg)|Placebo at weeks 0, 4, and 8; then crossover to CNTO 1959 100 mg at Week 16, then every 8 weeks through Week 40
62619526|NCT05938322|EXPERIMENTAL|Ketogenic Diet|In the group of intervention is prescribed a ketogenic diet plan.
62845544|NCT02349217|ACTIVE_COMPARATOR|Standard of Care|"Participants receive self-help materials that have been previously developed by MD Anderson's Office of Public Education, the American Cancer Society, and the National Cancer Institute.~Pain assessment administered at baseline and at follow up visit. Questionnaires completed at baseline and at follow up visit. Neurocognitive tests administered at baseline and at follow up visit. Cortisol testing performed after baseline visit and at follow up visit. Interviews conducted after follow up visit. These interviews are audio-taped and transcribed."
62619527|NCT05938322|ACTIVE_COMPARATOR|Standard Diet|The control group (SD) will follow the Mediterranean diet pattern based on ESPEN (European Society of Parenteral and Enteral Nutrition) guidelines
62619528|NCT01796275|EXPERIMENTAL|Group A|Subjects will have a core session intervention and booster intervention; questionnaire evaluation is conducted at baseline, post-session, pre-booster and 3 month after core session.
62619529|NCT01796275|EXPERIMENTAL|Group B|Subjects will only have a core session intervention; Questionnaire evaluation are conducted at baseline (T1-baseline), post-session (T2), 4 weeks after core session (T3) and 3 month after core session (T4).
62619530|NCT01796275|OTHER|Group C|Group C is a waiting list control, only questionnaire evaluations can be conducted at T1-baseline, T3- tea gathering and T4- 3 month after baseline evaluation; when finish T4 evaluation, the core session and booster can be optionally conducted subsequently.
62619531|NCT03446209|EXPERIMENTAL|Tocilizumab|Tocilizumab Infusion RoAcemtra (EU) or Actemra (Rest of the world)
62619532|NCT03446209|PLACEBO_COMPARATOR|Placebo|0,9% physiological Saline
62619533|NCT03290183||Intrathoracic malignancy|Patients with (strong suspicion of) intrathoracic malignancy and an indication for tissue collection by CT-guided, transthoracic or thoracoscopic approach undergo additional imaging with confocal laser endomicroscopy (CLE).
62619534|NCT02985021|EXPERIMENTAL|Treatment (docetaxel, carboplatin)|"Docetaxel 60 mg/m2 will be administered on Day 1 of each 21-day cycle. Carboplatin Area Under the Curve (AUC) 5 will be administered on Day 1 of each 21-day cycle.~Docetaxel and carboplatin should be administered per institutional guidelines. Treatment will be repeated until disease progression or unacceptable toxicity."
62619535|NCT00983541|EXPERIMENTAL|All patients|All participants enrolled.
62619536|NCT04350164||treatment|romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.
62619537|NCT04394663|EXPERIMENTAL|High-dose oral PPI|Omeprazole 80 mg/day (40 mg twice a day) per oral route for 72 hours
62619538|NCT04394663|ACTIVE_COMPARATOR|Standard IV PPI|Pantoprazole 8 mg/hour IV continuous drip for 72 hours
62619539|NCT05919355|EXPERIMENTAL|Offered to try Komp|The intervention group consists of eligible service recipients in the three boroughs, who are given the offer to try Komp. Upon receiving the offer, the participant may take up to 14 days to decide. Participants who accept, receive a Komp and use it freely; participants who decline receive services as usual. Responses are documented. Participants who accepted the offer may at any point decide to stop and return the Komp to the municipality. The actual uses and effects of the technology, being a communication technology, depends on the actions of the app users (family and friends) and platform users (care services). The investigators record the types of use and the frequency of use, but not the actual content that is transferred (e.g., pictures are counted but not seen). The investigators can also distinguish between transfers originating from the app and the platform respectively, meaning that they can analyse the effects of private and professional use separately.
62263078|NCT04378530|EXPERIMENTAL|Personalized Cue|Participants in the intervention group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day. Participants will be asked to select a cue to use to remember to meditate.
62263079|NCT04378530|ACTIVE_COMPARATOR|Study control|Participants in the control group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive non-anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day.
62263080|NCT04378530|EXPERIMENTAL|Fixed Cue|Participants in the intervention group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day. Participants will be given a specific cue (i.e. leaving the bathroom in the morning) to use to remember to meditate.
62447425|NCT04142346|EXPERIMENTAL|Sitting + moderate intensity breaks|Participants were instructed to sit throughout 7 hours, while interrupting the sitting position every 30 minutes to perform 2 minutes of moderate-intensity physical activity. The breaks consisted of walk up and down stairs and squats. Each person performed these exercise alternately. During the protocol, participants were allowed to go to the bathroom in a wheelchair and al-libitum water was granted.
62447426|NCT00520507|EXPERIMENTAL|1|
62447427|NCT00520507|PLACEBO_COMPARATOR|2|
62447428|NCT01679821||Dental students|Seventy dental students of State University of West of Paraná - UNIOESTE. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. A questionnaire and a clinical examination were employed.
62447429|NCT01679821||Removable partial denture|Seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous). Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary were not included in the research. A questionnaire and a clinical examination were employed.
62447430|NCT01679821||Double complete denture|Seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Patients wearing just one complete denture were not included in the research. A questionnaire and a clinical examination were employed.
62845545|NCT02779556|OTHER|Enhanced Usual Care|ADA Living Well with Diabetes Workbook, 15 minute in-person counseling, follow-up every 3 months
62845546|NCT02779556|OTHER|Intervention|ACP Living with Diabetes Guide, 15 minute in-person counseling , 15 minute follow-up counseling (3, 6, and 9 months), monthly phone calls after 3 months
62845547|NCT01782716||ASA|
62845548|NCT01782716||ASA+Euroscore|
62845549|NCT04090801|ACTIVE_COMPARATOR|Topical minoxidil 5% in 90% ethanol and 5% propylene glycol|Group A applied topical minoxidil 5% in 90% ethanol and 5% propylene glycol
62845550|NCT04090801|ACTIVE_COMPARATOR|Topical minoxidil 5% in pure ethanol alone|Group B applied topical minoxidil 5% in pure ethanol alone
62845551|NCT04090801|PLACEBO_COMPARATOR|Placebo|Group C applied pure ethanol (placebo)
62845552|NCT03236662|EXPERIMENTAL|Treatment|(-)-epicatechin 50mg twice per day (100mg per day total dose)
62845553|NCT02893956|EXPERIMENTAL|echocardiography with postural support then standard condition|the first echocardiography (ultrasound) is performed with a postural support then the second echocardiography is performed with standard condition
62845554|NCT02893956|ACTIVE_COMPARATOR|echocardiography with standard condition then support postural|the first echocardiography (ultrasounds) is performed with standard condition (usual) and the second echocardiography is performed with a postural support
62845555|NCT04918043||HUCS, NKL|Newborns and their mothers at the Helsinki University Central Hospital maternity ward.
62845556|NCT01071798||Main Analysis Set|Participants who received at least one cycle of rituximab
62263081|NCT02868073|EXPERIMENTAL|H1N1 (high dose) Oral Vaccine Tablet|Singe dose of orally administered VXA-G1.1-NN (high dose) Oral Vaccine Tablet. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk.
62447431|NCT03267342|EXPERIMENTAL|All participants|low-income people with mental illness will be given one-on-one financial counseling, a weekly peer support group, supported access to mainstream banking services and access to a matched savings account for a 12-14 month period.
62263082|NCT02868073|EXPERIMENTAL|H1N1 (low dose) Oral Vaccine Tablet|Singe dose of orally administered VXA-G1.1-NN (low dose) Oral Vaccine Tablet. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk.
62447432|NCT01604681|PLACEBO_COMPARATOR|placebo group|3 g of powdered gelatin encapsulated in opaque capsules.
62447433|NCT01604681|EXPERIMENTAL|Flaxseed oil group|Oil extracted from linseed by pressing the cold and encapsulated, providing 3g per day containing 1.75 g of alpha linolenic acid.
62447434|NCT04380220||Relapsing MS patients|Patients diagnosed with relapsing-remitting multiple sclerosis and in relapse, untreated or treated with only immunomodulatory therapy.
62447435|NCT04380220||Remitting MS patients|Patients diagnosed with relapsing-remitting multiple sclerosis and in remission, untreated or treated with only immunomodulatory therapy.
62447436|NCT04380220||Healthy controls|Age- and sex-matched healthy control subjects.
62447437|NCT03516383||Experimental|"* ABI \< 0.6, confirmed PAD~* 50 - 90 years of age~* In-patients or out-patients~* Participants who understand the study and are able to give consent~* Participants who can be followed by the same investigating team for the whole period of their participation in the study"
62447438|NCT03516383||Control|"* ABI of 0.9 \< ABI \< 1.2~* 50 - 90 years of age~* Participants who understand the study and are able to give consent~* Participants who can be followed by the same investigating team for the whole period of their participation in the study"
62447439|NCT04018261|EXPERIMENTAL|Activated T-Lymphocytes|Allogeneic T-Lymphocytes obtained from apheresis activated against CMV.
62447440|NCT02789033|ACTIVE_COMPARATOR|Chitosan|Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
62447441|NCT02789033|ACTIVE_COMPARATOR|Isosorbide dinitrate spray|Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.
62447442|NCT02789033|PLACEBO_COMPARATOR|Placebo|Placebo in the same pharmacological presentation
62447443|NCT00523393|NO_INTERVENTION|1|
62447444|NCT00523393|EXPERIMENTAL|2|
62447445|NCT00523393|ACTIVE_COMPARATOR|3|
62447446|NCT00290121|ACTIVE_COMPARATOR|Olanzapine|
62447447|NCT03348215|OTHER|Enhanced Treadmill Training|Treadmill walking with an immersive environment and bio mechanical support (body weight, ankle-foot -orthosis and functional electrical stimulation)
62447448|NCT03431584|ACTIVE_COMPARATOR|Infiltration of corticosteroids|
62447449|NCT03431584|EXPERIMENTAL|Infiltration of corticosteroids and hyaluronic acid|
62447450|NCT04200508|EXPERIMENTAL|Intervention|Targeted gown and glove use for high risk care activities in high risk residents
62447451|NCT04200508|NO_INTERVENTION|Baseline|Standard of Care
62447452|NCT05977621||Intact anatomy|Patients with intact anatomy (uterus and cervix)
62447453|NCT05977621||Post-hysterectomy|Post-hysterectomy patients (vaginal cuff) who are planned to receive brachytherapy
62447454|NCT01290393||Exposed vaccinated cohort|Women with last menstrual period between 30 days before and 90 days after any CERVARIX dose. The target sample size of the Exposed vaccinated cohort is 150 subjects.
62447455|NCT01290393||Non-exposed vaccinated cohort|Women with last menstrual period between 120 days and 18 months after the last CERVARIX or GARDASIL dose. The target sample size of the Non-exposed vaccinated cohort is 300 subjects.
62447456|NCT03970772|EXPERIMENTAL|Glucagon injection|Dilute Glucagon (1 mg/ml)
62447457|NCT03970772|ACTIVE_COMPARATOR|Glucose tablets|Dextrose glucose tablets
62447458|NCT00650299|EXPERIMENTAL|1|Alprazolam Extended-release Tablets 3 mg
62447459|NCT00650299|ACTIVE_COMPARATOR|2|Xanax XR® Tablets 3 mg
62447460|NCT05064696|ACTIVE_COMPARATOR|Group 1 (Control group)|Surgical wound will be covered with the standard non-stick gauze dressing.
62447461|NCT05064696|EXPERIMENTAL|Group 2 (Treatment group)|Surgical wound will be covered with the PICO dressing.
62447462|NCT02962011|EXPERIMENTAL|Knotless barbed suture|
62447463|NCT02962011|ACTIVE_COMPARATOR|polyglactin 910|Vicryl
62447464|NCT00575757||Primary|HIV infected with abnormal liver enzymes in the absence of HCV or HBV coinfections.
62619540|NCT05919355|NO_INTERVENTION|Services as usual|"At a certain point, because the burrough runs out of Komp units to distribute or because they get halfway through the list, recruitment stops and no one else is offered to try Komp. All names on the burrough's list below this juncture are in the services as normal arm, which is the control group in this intention-to-treat trial. Services as normal means that the trial has no bearing on the participant (apart from having been informed about the project and being given the chance to opt out). They continue to receive needs-based services from their municipality, like they would have if there was no trial."
62619541|NCT03428399||Breast reconstruction patients|Self-reported psychosocial variables and a clinical interview assessing mental health history will be administered prior to participants' scheduled mastectomy and breast reconstruction surgery (which is part of their routine medical care for cancer treatment or prevention). Follow up self-report measures will be collected after the surgery as well.
62263083|NCT02868073|PLACEBO_COMPARATOR|Placebo Tablets|Singe dose of VXA Placebo tablets. The placebo tablets are small off-white tablets that are similar in size and number to the active vaccine dose being delivered.
62263084|NCT01081912|ACTIVE_COMPARATOR|Hydrocodone Bitartrate Capsules|Hydrocodone Bitartrate Controlled-Release Capsules
62263085|NCT01081912|PLACEBO_COMPARATOR|Placebo comparator|
62447465|NCT03229655|EXPERIMENTAL|Sequential stent addition|ERCP with sphincterotomy and stent placement is initially performed, then additional stents are placed across the stricture during sequential ERCPs, without stent removal/exchange or stricture dilation.
62447466|NCT03229655|ACTIVE_COMPARATOR|Incremental Dilation & Stent Exchange|ERCP with sphincterotomy and stent placement is initially performed, with subsequent ERCPs involving removal of previously placed stents, stricture dilation and balloon sweeps to extract stone debris/sludge.
62447467|NCT03356613||focus group of paramedical staff from Nancy|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
62619542|NCT03276845|OTHER|1|
62619543|NCT01993641|EXPERIMENTAL|Pracinostat added to HMA|Pracinostat in combination with HMA treatment (either azacitidine or decitabine) used in initial single agent treatment for that patient
62619544|NCT00568568|EXPERIMENTAL|Growth hormone|
62619545|NCT02756364|ACTIVE_COMPARATOR|Fulvestrant 500 mg|Fulvestrant 500 mg, intramuscularly (IM), once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 16.0 weeks).
62059366|NCT00246337|EXPERIMENTAL|MK0974 600 mg|MK0974 600 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
62447468|NCT03356613||focus group of paramedical staff from Metz|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
62619546|NCT02756364|EXPERIMENTAL|Fulvestrant 500 mg + Sapanisertib 4 mg|Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with the sapanisertib 4 mg, capsules, orally, once daily in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 20.1 and 20.3 weeks for fulvestrant and sapanisertib respectively).
62059367|NCT00246337|ACTIVE_COMPARATOR|Rizatriptan 10 mg|Rizatriptan 10 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
62059368|NCT03324880|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to rhPTH (1-84) as subcutaneous (SC) injection once daily (QD) with active vitamin D and calcium supplements up to 31.3 weeks.
62059369|NCT03324880|EXPERIMENTAL|rhPTH (1-84)|Participants received rhPTH (1-84) 50 microgram (mcg) SC injection QD, titrated within the dose range of 25-100 mcg QD as an adjunctive treatment with active vitamin D and calcium supplements based on metabolic response up to 32 weeks.
62263086|NCT01285115|PLACEBO_COMPARATOR|Placebo; corn flour,|"* raw material total contents(500㎎) cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)~* shape, type: extract(brown)~* usage, content: adults;three times a day each sack taken before or between meals~* dose, standard: for each sack 7.67g~* storage : airtight container, stored in room temperature~* expiration date : after manufacture 36 month~* macufacturing company: KyungBangnShinYak inc."
62447469|NCT03356613||focus group of paramedical staff from Dijon|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
62447470|NCT03356613||focus group of paramedical staff from Bar-le-Duc|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
62447471|NCT03356613||Test of the tool by paramedical staff center 1|Paramedical staff who didn't participate to the focus group, will test the GenI tool to generate research ideas.
62447472|NCT03356613||Test of the tool by paramedical staff center 2|Paramedical staff who didn't participate to the focus group, will test the GenI tool to generate research ideas.
62447473|NCT02084381|EXPERIMENTAL|MCO-Ci 400|MCO-Ci 400 is the investigational medical product applied in hemodialysis mode
62447474|NCT02084381|ACTIVE_COMPARATOR|Revaclear 400|the standard high flux dialyzer Revaclear 400 is used as an comparator in hemodialysis mode
62447475|NCT04787406|ACTIVE_COMPARATOR|Anodal tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
62845557|NCT02442804|EXPERIMENTAL|Stroke - POMx|Pomegranate supplement (1g) by mouth twice per day for 7 days
62263087|NCT01285115|ACTIVE_COMPARATOR|Gamisoyosan extract|"* name of product: KyungBangn-Gamisoyosan-x-gwarip~* standard code for item : 200005799~* shape, type: extract(grayish brown)~* usage, content : adults;three times a day , each sack taken before or between meals~* dose, standard: 7.67g for each sack~* storage : airtight container, stored in room temperature expiration date : after manufacture 36 month macufacturing company: KyungBangnShinYak inc."
62845558|NCT02442804|PLACEBO_COMPARATOR|Stroke - Placebo|Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
62845559|NCT03338127||Participants|all patients recruited in the trial will be investigated for renal function test
62845560|NCT00336648|EXPERIMENTAL|Gemcitabine + Avastin + Surgery|Gemcitabine plus Avastin-based chemoradiation followed by pancreaticoduodenectomy
62845561|NCT01678495|EXPERIMENTAL|Sonothrombolysis + microbubbles|"rtPA+ sonovue. SonoVue sulphur hexafluoride microbubbles 8 microlitres/ml Powder and solvent for dispersion for injection 1 vial containing 25 mg lyophilized powder to be reconstituted with 5 ml sodium chloride 9 mg/ml (0.9%) solution for injection~1 pre-filled syringe containing sodium chloride 9 mg/ml (0.9%) solution for injection~1 Mini-Spike Plus 6/8 (CE 0123) transfer system.~1 ml of the reconstituted dispersion contains 8 microlitres sulphur hexafluoride microbubbles."
62845562|NCT01678495|ACTIVE_COMPARATOR|Standard intravenous thrombolysis|Patients in thecontrol group will use thehelmetbut without U.S continuous U.S wave emission. Serial monitoring of the status ofrecanalizationaccording to theschedule set will be carried out according to theestablished schedule
62263088|NCT01285115|ACTIVE_COMPARATOR|Gamisoyosan extract powder|"* name of product: KyungBangn Gamisoyosan~* standard code for item: 200005591~* shape, type: powder(brown)~* usage, content: adults;three times a day each sack taken before or between meals~* dose, standard: 7.67g for each sack~* storage : airtight container, stored in room temperature~* expiration date : after manufacture 36 month~* macufacturing company: KyungBangnShinYak inc."
62845563|NCT01389843||All consecutive hospitalized adult patients|"All consecutive hospitalized adult patients who have 1 and (2 and/or 3)~1. Symptom and/or sign of heart failure~2. Lung congestion~3. Objective finding of LV systolic dysfunction (LVEF), or structural heart disease."
62059370|NCT04045093|EXPERIMENTAL|Dabigatran etexilate|Subjects randomized into this group will be prescribed with either Dabigatran 150mg or Dabigatran 110mg (twice daily) according to creatinine clearance level, twice daily) for stroke prevention.
62263089|NCT06518122|EXPERIMENTAL|[PART A] Sequence 1|Period1 : Treatment A (HCP1306) Period2 : Treatment B (RLD2302) Period3 : Treatment C (HCP1306+RLD2302)
62845564|NCT00706303|ACTIVE_COMPARATOR|1 Intervention group|Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
62845565|NCT00706303|NO_INTERVENTION|2|Usual care. The control group will receive usual care, as decided by their GP and or hospital consultant, and the patient themselves (e.g., NHS 24 helpline). They will be asked to complete diary cards and receive telephone follow up calls as an attention control, similar to the intervention group.
62845566|NCT01013103|OTHER|Atorvastatin, Ischemic Heart Disease|
62845567|NCT01013103|PLACEBO_COMPARATOR|Atorvastatin vs Placebo Cardiac Surgery|
62845568|NCT01257061|EXPERIMENTAL|Group 1|Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g
62845569|NCT01257061|ACTIVE_COMPARATOR|Group 2|Dexchlorpheniramine maleate 10 mg/g
62845570|NCT01590888|EXPERIMENTAL|PBT2 250mg|
62845571|NCT01590888|EXPERIMENTAL|PBT2 100mg|
62845572|NCT01590888|PLACEBO_COMPARATOR|Sugar pill|
62845573|NCT04491513||Overall cohort|Pateints that underwent both CTA and CAG in the work-up for TAVI
62845574|NCT05390619|EXPERIMENTAL|50% dose of PDT|Patients received 50% dose of verteporfin PDT therapy.
62845575|NCT05390619|EXPERIMENTAL|70% dose of PDT|Patients received 70% dose of verteporfin PDT therapy.
62845576|NCT04465838||Psoriasis|This is a non-interventional study (NIS). All the patients diagnosed as psoriasis by the dermatologists in the clinic are included in this study no matter what kind of treatment they adopt.
62845577|NCT03879005|OTHER|Renal scintigraphy|5 mci of 99mTc-DTPA or 99mTc-DMSA is injected once IV. Dose is adjusted according to age and weight.
62263090|NCT06518122|EXPERIMENTAL|[PART A] Sequence 2|Period1 : Treatment C (HCP1306+RLD2302) Period2 : Treatment A (HCP1306) Period3 : Treatment B (RLD2302)
62263091|NCT06518122|EXPERIMENTAL|[PART A] Sequence 3|Period1 : Treatment B (RLD2302) Period2 : Treatment C (HCP1306+RLD2302) Period3 : Treatment A (HCP1306)
62263092|NCT06518122|EXPERIMENTAL|[PART A] Sequence 4|Period1 : Treatment C (HCP1306+RLD2302) Period2 : Treatment B (RLD2302) Period3 : Treatment A (HCP1306)
62263093|NCT06518122|EXPERIMENTAL|[PART A] Sequence 5|Period1 : Treatment B (RLD2302) Period2 : Treatment A (HCP1306) Period3 : Treatment C (HCP1306+RLD2302)
62263094|NCT06518122|EXPERIMENTAL|[PART A] Sequence 6|Period1 : Treatment A (HCP1306) Period2 : Treatment C (HCP1306+RLD2302) Period3 : Treatment B (RLD2302)
62263095|NCT06518122|EXPERIMENTAL|[PART B] Single arm|Period1 : Treatment D (RLD2102) Period2 : Treatment C (HCP1306) Period3 : Treatment E (HCP1306, RLD2302, RLD2102)
62845578|NCT02861274|ACTIVE_COMPARATOR|electrophysiological testing|Patients will receive a pacemaker.
62263096|NCT04916509||Palbociclib plus an aromatase inhibitor|"Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor.~Data will be retrospectively abstracted over an observational look-back period from 01st January 2015 to 30th September 2019.~Aligned with Locally Approved Indication"
62263097|NCT04916509||palbociclib plus fulvestrant|"Adult metastatic breast cancer patients who initiated Palbociclib + fulvestrant. Data will be retrospectively abstracted over an observational look-back period from 01st January 2015 to 30th September 2019.~Aligned with Locally Approved Indication"
62263098|NCT04261075|EXPERIMENTAL|IPH5201 monotherapy dose escalation|IPH5201 monotherapy
62263099|NCT04261075|EXPERIMENTAL|IPH5201 dose escalation with durvalumab|IPH5201 plus durvalumab
62263100|NCT04261075|EXPERIMENTAL|IPH5201 dose escalation with durvalumab + oleclumab|IPH5201 plus durvalumab and oleclumab
62263101|NCT02327637|NO_INTERVENTION|Bedrest|"Bedrest is a standard recommendation for patients with PPROM. Subjects randomized to this arm of the study will undergo the following:~1. Receive recommendation for bedrest (standard of care).~2. Have maternal mood and muscle strength evaluated on enrollment and after delivery (observational study procedure).~3. Wear a pedometer to measure activity when out of bed (observational study procedure)."
62623753|NCT05446142|EXPERIMENTAL|Four Period Treatment Sequence: PPI Effect Second Formulation|Participants will receive a single encorafenib dose of the second formulation, a single encorafenib dose of the second formulation, a single encorafenib dose of the formulated capsule (CAP), and a single encorafenib dose of the second formulation after administration of 20 mg rabeprazole every evening for 5 days.
62845579|NCT02861274|NO_INTERVENTION|control group|These subjects will receive cardicor® (beta blockers).
62845580|NCT01888302|EXPERIMENTAL|Treatment (cisplatin, gemcitabine hydrochloride, sirolimus)|Patients receive cisplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and sirolimus PO daily or three times weekly. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.
62845581|NCT04117867||Intraoperative hypotension|
62845582|NCT03156699||STEMI patients treated with primary PCI|Database analysis only
62845583|NCT00768924||1|Spinal fusion patients
62845584|NCT04394637||PROSe-ICD|PROSe-ICD \[NCT00733590/ Institutional Review Board (IRB) NA_00045142\], a large prospective cohort study of patients who received an ICD for primary prevention.
62845585|NCT04394637||Reynolds study|Functional Energetics (Reynolds study, NA_00037404), a study with conventional contrast-enhanced 1H MRI to determine ventricular geometry, global and regional function, as well as infarct size characteristics following delayed contrast enhancement.
62845586|NCT05231512|EXPERIMENTAL|Individuals living with post-Covid-19 respiratory symptoms|Live virtual music therapy interventions for people experiencing difficulties breathing after having had COVID-19 (diagnosed or presumed).
62845587|NCT03128125|EXPERIMENTAL|High intellectual potential|Participation in the study involves the conduct of a clinical examination in neurology, the collection of anamnestic elements and a neuropsychological examination in children with high intellectual potential.
62845588|NCT03128125|OTHER|Control|Participation in the study involves the conduct of a clinical examination in neurology, the collection of anamnestic elements and a neuropsychological examination in control children with no particularities.
62263102|NCT02327637|EXPERIMENTAL|Moderate Activity|"Subjects randomized to this arm of the study will undergo the following:~1. Receive recommendation to ambulate 150 feet, twice per day (interventional study procedure). Prior to each session of ambulation, an ultrasound will be performed to ensure adequate amniotic fluid volume and appropriate fetal position, and a fetal heart rate tracing will be obtained to ensure that there is reassuring fetal status (observational study procedure). During each session of ambulation, the fetal heart rate tracing will be monitored continuously (observational study procedure).~2. Have maternal mood and muscle strength evaluated on enrollment and after delivery (observational study procedure).~3. Wear a pedometer to measure activity when out of bed (observational study procedure)."
62845589|NCT05306808|EXPERIMENTAL|center-based exercise|Participants in intervention group will attend a program combining 24 sessions of physiotherapy and 10 sessions of educational class over 12 weeks.
62845590|NCT05306808|NO_INTERVENTION|exercise on his/her own|Participants in control group will be asked to exercise on their own, they will only attend 10 sessions of educational class over 12 weeks.
62845591|NCT05432089|EXPERIMENTAL|Experimental Group|
62845592|NCT05432089|PLACEBO_COMPARATOR|Placebo Group|
62845593|NCT03206229|EXPERIMENTAL|TPI-120 (PEG-rhG-CSF)|PEG-rhG-CSF (recombinant granulocyte-colony stimulating factor conjugated with monomethoxypolyethylene glycol) Adello Biologics, LLC, Chicago, IL
62845594|NCT03206229|ACTIVE_COMPARATOR|Neulasta (PEG-rhG-CSF)|Neulasta®, (PEG-rhG-CSF) Amgen, Thousand Oaks, CA
62059371|NCT04045093|ACTIVE_COMPARATOR|Warfarin|Subjects randomized into this group will be prescribed with Warfarin with dosage adjustment according to INR level (targeting to INR 2-3) for stroke prevention.
62059372|NCT02890537|EXPERIMENTAL|Core decompression/PREOB® implantation|Core decompression/autologous osteoblastic cells (PREOB®) implantation
62059373|NCT02890537|ACTIVE_COMPARATOR|Core decompression/BMC implantation|Core decompression/bone marrow concentrate (BMC) implantation
62059374|NCT03518125|EXPERIMENTAL|Age ≥ 66, BioThrax (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL BioThrax.
62059375|NCT03518125|EXPERIMENTAL|Age ≥ 66, AV7909 (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL AV7909.
62059376|NCT03518125|EXPERIMENTAL|Age ≥ 66, AV7909 (Days 1 and 15)|Subjects dosed on Days 1 and 15 with 0.5 mL AV7909 and on Day 29 with 0.5 mL placebo.
62059377|NCT03518125|EXPERIMENTAL|Age ≥ 66, AV7909 (Days 1 and 29)|Subjects dosed on Days 1 and 29 with 0.5 mL AV7909 and on Day 15 with 0.5 mL placebo.
62059378|NCT03518125|ACTIVE_COMPARATOR|Age18-50, BioThrax (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL BioThrax.
62263103|NCT04327583|EXPERIMENTAL|Coordinated pharmaceutical path|Patients treated with anti-cancer oral therapy who benefit a specific pharmaceutical follow-up by the healthcare facilities pharmacist and by the dispensary pharmacist
62263104|NCT04327583|NO_INTERVENTION|Standard of care|Patients treated with anti-cancer oral therapy who who do not benefit from an additional pharmaceutical intervention
62845595|NCT02952443||Exercise|EX group will attend multi-component exercise sessions 3 times a week at 45-60 minutes a session for 16 weeks. Each session will include aerobic, flexibility, resistance and balance training but a strong emphasis will be placed on the latter two components.
62059379|NCT03518125|ACTIVE_COMPARATOR|Age 18-50, AV7909 (Days 1 and 15)|Subjects dosed on Days 1 and 15 with 0.5 mL AV7909 and on Day 29 with 0.5 mL placebo.
62059380|NCT02320643|EXPERIMENTAL|Seratom® PA mesh|Partially absorbable mesh
62059381|NCT05862467|EXPERIMENTAL|Written Exposure Therapy|Behavioral therapy: Written Exposure Therapy via telehealth
62447476|NCT04787406|ACTIVE_COMPARATOR|Cathodal tDCS|Cathodal electrode (35 cm2 sponge electrode) placed over C3. Anodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
62845596|NCT02952443||Control|CON group will be asked to just maintain their normal daily living habits for the duration of the study. The same exercise program will be made available to the CON group upon completion of the study.
62845597|NCT04762719|EXPERIMENTAL|Diabetic Gastroparesis Subjects|Type I or II diabetes subjects who also have a diagnosis of Gastroparesis (defined by gastric retention of Tc-99m \>20% at 4 hrs on scintigraphy). Subjects will receive PET/CT Scan with 11C-ER176 and a core biopsy of gastric muscle
62059382|NCT02848261|EXPERIMENTAL|Developmental Demands|Provide education on using diabetes technology in various settings and formats in this age group, and increase ability for real-time problem-solving.
62059383|NCT02848261|EXPERIMENTAL|Distress Reduction|Identify and reduce parent distress symptoms and worries. Provide strategies for obtaining social support.
62845598|NCT04762719|EXPERIMENTAL|Diabetic without gastroparesis subjects|Type I or II diabetes subjects who have not been clinically diagnosed with Gastroparesis. Subjects will receive PET/CT Scan with 11C-ER176
62845599|NCT04762719|PLACEBO_COMPARATOR|Healthy Subjects|Healthy subjects will be age-matched and receive a PET/CT Scan with 11C-ER176
62845600|NCT04506099|ACTIVE_COMPARATOR|TINS Active|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible. For example, a T7 level of injury will have TINS applied to the T8 level. A T2 level of injury will have TINS applied to the T6 level. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect, verified with contraction of the rectus abdominis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
62059384|NCT02848261|EXPERIMENTAL|Remote Monitoring|Optimize the use of remote monitoring by focusing on situational demands and problem solving.
62059385|NCT02848261|EXPERIMENTAL|Fear of Hypoglycemia|Decrease fear of hypoglycemia, particularly focusing on overnight glycemic control.
62059386|NCT02848261|PLACEBO_COMPARATOR|No Intervention|Serves as the control group comparator. No intervention provided.
62059387|NCT05338255||Patients who have undergone surgery at the MAZ hospital for knee/hip replacement.|
62059388|NCT00203060|EXPERIMENTAL|A|Rasagiline treatment
62059389|NCT00203060|PLACEBO_COMPARATOR|B|placebo arm
62059390|NCT03577158|EXPERIMENTAL|Closed-loop controller with exercise mitigation module|"Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with mitigation module.~Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFEAP with mitigation module) based on blood glucose estimations from CGM."
62263105|NCT01055600|EXPERIMENTAL|Study|Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
62619547|NCT02756364|EXPERIMENTAL|Fulvestrant 500 mg + Sapanisertib 30 mg|Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with sapanisertib 30 mg, capsule, orally, once weekly in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 17.0 weeks for fulvestrant and sapanisertib, each).
62619548|NCT04213833|PLACEBO_COMPARATOR|group I (control group)|patients will receive propofol 50 mg
62619549|NCT04213833|ACTIVE_COMPARATOR|group II|patients will receive propofol 50 mg + dexmedetomidine 0.5 mcg/ kg
62619550|NCT04213833|ACTIVE_COMPARATOR|group III|patients will receive propofol 50 mg +15 g palatable lidocaine gel
62619551|NCT00888290|ACTIVE_COMPARATOR|Sodium Bicarbonate|Sequential design. Participants will be getting different doses of sodium bicarbonate during the study.
62059391|NCT03577158|EXPERIMENTAL|Closed-loop controller without exercise mitigation module|Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFEAP without mitigation module) based on blood glucose estimations from CGM.
62619552|NCT00888290|PLACEBO_COMPARATOR|Placebos|Sequential design. Participants will be getting either placebo of different doses during the study.
62619553|NCT03549065|ACTIVE_COMPARATOR|20 min active tDCS, and 20 min active rTMS|Applying active tDCS AND active TMS will reduce cue induced craving and opioid use, more than sham TMS AND sham tDCS and also either active TMS OR active tDCS alone. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of 20 minutes active tDCS (anode on F3 EEG positioning and cathode on contra shoulder), followed by 4000 pulses of real rTMS (10Hz over left Dorsolateral Prefrontal Cortex(DLPFC) for 20 minutes at 120%MT). There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS and the groups with only active tDCS OR active TMS.
62059392|NCT03577158|ACTIVE_COMPARATOR|Open-loop insulin infusion system|Standard Open-loop intensive insulin treatment with continuous subcutaneous insulin infusion (CSII). Commercially available insulin infusion systems will be used.
62059393|NCT03035890|EXPERIMENTAL|Radiation Therapy + Immunotherapy|3-5 fraction course of radiation therapy to target lesion concurrent with an immuno-therapeutic agent
62619554|NCT03549065|ACTIVE_COMPARATOR|20 min sham tDCS, and 20 min active rTMS|Applying sham tDCS AND active TMS will reduce cue induced craving and opioid use, more than will sham TMS AND sham tDCS. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes sham tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of real rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
62059394|NCT00339690|EXPERIMENTAL|Test Kit Homes|Households assigned to use the in-home test kit.
62059395|NCT01208740|EXPERIMENTAL|Metformin|Metformin pre-treatment and co-administration
62263106|NCT04249687|EXPERIMENTAL|Treatment|QM1114-DP, a Botulinum Toxin Type A (BoNT-A); Mode of administration: intramuscular injection
62263107|NCT04249687|PLACEBO_COMPARATOR|Placebo|A buffered solution; Mode of administration: intramuscular injection
62619555|NCT03549065|ACTIVE_COMPARATOR|20 min active tDCS, and 20 min sham rTMS|Applying active tDCS AND sham TMS will reduce cue induced craving and opioid use, more than will sham TMS AND sham tDCS. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes active tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of sham rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
62619556|NCT03549065|SHAM_COMPARATOR|20 min sham tDCS, and 20 min sham rTMS|Applying sham tDCS AND sham TMS will not reduce cue induced craving and opioid use. We will apply 10 sessions of one hour of brain stimulation. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes sham tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of sham rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
62059396|NCT01208740|PLACEBO_COMPARATOR|Placebo|Placebo pre-treatment and co-administration
62059397|NCT02309437|EXPERIMENTAL|Mild group|Use oxycodone when pain is mild level. Start from 10 mg every 12 hours and titrate for appropriate dose.
62263108|NCT00983177|ACTIVE_COMPARATOR|colchicine|
62263109|NCT00983177|PLACEBO_COMPARATOR|Lactose capsule|
62263110|NCT06490016|EXPERIMENTAL|Intervention group that given face to face education|6 face-to-face meetings will be held with adolescent disabled girls. Training will be held collectively at school or in an association. The training modules will last 3 weeks and 5 modules will be used in the training. (1st Meeting and Survey collection, 2nd week: 1st and 2nd module, 3rd week: 3 modules and 4th week: 5 modules, 6th interview: after training). Training modules will be given every week at a determined place and time. Following the training, the effect of the training will be investigated by repeating the data collection forms twice at 1-month intervals during the menstrual periods of the participants.
62059398|NCT02309437|ACTIVE_COMPARATOR|Moderate group|Use oxycodone when pain is moderate or severe level. Start from 10 mg every 12 hours and titrate for appropriate dose.
62619557|NCT03167255|EXPERIMENTAL|NS-065/NCNP-01 40mg/kg|Patients receiving 40mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 192 weeks or until enrollment in a separate long-term follow up program of NS-065/NCNP-01, whichever is earlier.
62619558|NCT03167255|EXPERIMENTAL|NS-065/NCNP-01 80mg/kg|Patients receiving 80mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 192 weeks or until enrollment in a separate long-term follow up program of NS-065/NCNP-01, whichever is earlier.
62619559|NCT04652518|EXPERIMENTAL|LYT-100|LYT-100 taken orally twice a day (BID) for 91 days
62447477|NCT04787406|SHAM_COMPARATOR|Sham tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. Stimulation was phased in for 30 seconds up to 2 mA and then switched off. Stimulation was again phased in for 30 seconds following 20 minutes of no stimulation.
62619560|NCT04652518|PLACEBO_COMPARATOR|Placebo|Placebo matching LYT-100 taken orally BID for 91 days
62619561|NCT04652518|OTHER|Open Label Extension LYT-100|Open Label Extension: LYT-100 taken orally BID for 91 days The Open Label Extension (Part B) was terminated after results of the Double Blind Portion.
62619562|NCT01480817|ACTIVE_COMPARATOR|Sorafenib|Sorafenib 400mg po bid
62619563|NCT01480817|EXPERIMENTAL|TACE for HCC with portal vein invasion|Antineoplastic agents are directly injected into the hepatic artery, allowing high intratumoral concentrations of drugs and thereby reducing systemic side effects. The mixture of chemotherapeutic agents and iodized oil is almost completely retained in neoplastic nodules and can remain in HCC tissue for a long time. Subsequent mechanical embolization of the artery feeding the neoplasm causes ischemic damage to the tumor and prolongs the duration of the effects of chemotherapeutic agents.
62447478|NCT04897698|PLACEBO_COMPARATOR|Placebo|Four capsules containing rice flour will be given to the placebo group daily.
62447479|NCT04897698|EXPERIMENTAL|Single dose|"Two capsules of probiotics and two capsules of placebo daily. Probiotic capsules contains strains of pediococcus (Bacterial family of Lactobacillaceae) and saccharomycetes (kingdom of Fungi and the division Ascomycota) with a concentration of 13 millions cfu/g. Other ingredients (including stabilization) include rice bran, vegetable L-Cystein, magnesium salts from vegetable fatty acids. The capsule shell is made of vegetable HydroxyPropylMetylCellulosa (HPMC). Each capsule has a weight of 0.4 gram.~The placebo is made of rice flour."
62447480|NCT04897698|EXPERIMENTAL|Double dose|Four capsules of probiotics daily. Probiotic capsules contains strains of pediococcus (Bacterial family of Lactobacillaceae) and saccharomycetes (kingdom of Fungi and the division Ascomycota) with a concentration of 13 millions cfu/g. Other ingredients (including stabilization) include rice bran, vegetable L-Cystein, magnesium salts from vegetable fatty acids. The capsule shell is made of vegetable HydroxyPropylMetylCellulosa (HPMC). Each capsule has a weight of 0.4 gram.
62447481|NCT04302779|EXPERIMENTAL|Solid Model|Whey Permeate Lemon Cupcake and Protein Fortified Lemon Cupcake
62447482|NCT04302779|EXPERIMENTAL|Liquid Model|Whey Protein Beverage
62447483|NCT01081561|ACTIVE_COMPARATOR|Cross-linking|Corneal collagen cross-linking with riboflavin and UVA light
62447484|NCT01081561|ACTIVE_COMPARATOR|Cross-linking plus INTACS|Corneal collagen cross-linking with riboflavin and UVA light plus INTACS
62447485|NCT06134674||Early Enteral Nutrition|Patients who received enteral nutrition within the first 48 hours following intubation were included in the Early Enteral Nutrition (EEN) group.
62447486|NCT06134674||Late Enteral Nutrition|Patients who received enteral nutrition 48 hours or later following intubation were included in the late Enteral Nutrition (LEN) group.
62447487|NCT05412758|EXPERIMENTAL|Oesophageal/GOJ cancer|"AROMA 1: 216 treatment naive patients with oesophageal/GOJ cancer will be recruited to undertake an augmented breath test.~BIORESOURCE: 75 treatment naive patients with oesophageal/GOJ cancer will be recruited for biosample collection at the time of their staging laparoscopy procedure."
62447488|NCT05412758|EXPERIMENTAL|Gastric cancer|"AROMA 1: 216 treatment naive patients with gastric cancer will be recruited to undertake an augmented breath test.~BIORESOURCE: 75 treatment naive patients with gastric cancer will be recruited for biosample collection at the time of their staging laparoscopy procedure."
62447489|NCT05412758|EXPERIMENTAL|Control/ normal patients with upper gastrointestinal symptoms|"AROMA 1: 216 control subjects will be recruited to undertake an augmented breath test.~BIORESOURCE: 75 control subjects will be recruited for biosample collection at the time of their routine endoscopy procedure."
62447490|NCT03795103|EXPERIMENTAL|Patients achieving neuromuscular electrical stimulation|LEPAD patients achieving a 12-week program of neuromuscular electrical stimulation. Group of arteriopathic patients who will perform electrostimulation sessions at home and independently. These patients will also receive a study participation guide that will include an information leaflet outlining tips for active living and walking.
62619564|NCT02783313|EXPERIMENTAL|PR-plasma-PCs|Pooled buffy coat-derived pathogen reduced plasma-stored platelet concentrates (PR-plasma-PCs)
62619565|NCT02783313|ACTIVE_COMPARATOR|Plasma-PCs|Pooled buffy coat-derived plasma-stored platelet concentrates (plasma-PCs)
62845601|NCT04506099|SHAM_COMPARATOR|Sham protocol|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible until contraction is seen in the rectus abdominis. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect. The intensity level will be set to 1mA . If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable.
62619566|NCT04540731||NAFLD and diabetes/NASH and fibrosis|Patients with NAFLD and type 2 diabetes (or insulin-resistance) or with any stage of fibrosis in the inclusion visit will be followed over time in a prospective cohort study with scheduled visits. Patients without diabetes/insulin-resistance or any stage of fibrosis will participle in a single visit (inclusion) and will be part of a cross-sectional study.
62619567|NCT04540731||NAFLD without diabetes/NASH without fibrosis|Patients without diabetes (or insulin-resistance) or any stage of fibrosis will participle in a single visit (inclusion) and will be part of a cross-sectional study
62447491|NCT03795103|OTHER|Control|Group of artriopathic patients who will maintain their usual drug management. These patients will also receive a study participation guide that will include an information leaflet outlining tips for active living and walking.
62845602|NCT02383212|EXPERIMENTAL|Monotherapy Cohort|Cemiplimab will be administered alone
62845603|NCT02383212|EXPERIMENTAL|Dual Combination Cohorts|"Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy~Doses of cemiplimab will be administered in combination with Cyclophosphamide~Doses of cemiplimab will be administered in combination with Docetaxel"
62845604|NCT02383212|EXPERIMENTAL|Triple Combination Cohorts|"Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus Cyclophosphamide~Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus GM-CSF~Doses of cemiplimab will be administered in combination with Carboplatin plus Paclitaxel~Doses of cemiplimab will be administered in combination with Carboplatin plus Pemetrexed~Doses of cemiplimab will be administered in combination with Carboplatin plus Docetaxel"
62845605|NCT02383212|EXPERIMENTAL|Quadruple Combination Cohorts|Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus GM-CSF plus Cyclophosphamide
62845606|NCT04643652|NO_INTERVENTION|Control|Usual Care
62845607|NCT04643652|EXPERIMENTAL|Intervention|Implementation of a Noise Reduction Bundle
62845608|NCT01254162|EXPERIMENTAL|Placebo Gel|
62845609|NCT02641561|PLACEBO_COMPARATOR|A (NS+Placebo)|Normal Saline (intravenous during procedure) + Placebo (100mg suppository per rectum prior to procedure )
62845610|NCT02641561|ACTIVE_COMPARATOR|B (NS+IND)|Normal Saline (intravenous during procedure) + Indomethacin (100mg suppository per rectum prior to procedure )
62845611|NCT02641561|ACTIVE_COMPARATOR|C (LR+Placebo)|Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Placebo (100mg suppository per rectum prior to procedure)
62845612|NCT02641561|EXPERIMENTAL|D (LR+IND)|Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Indomethacin (100mg suppository per rectum prior to procedure)
62845613|NCT02912858|EXPERIMENTAL|geko plus R-2|neuromuscular electrostimulation
62845614|NCT06333899|EXPERIMENTAL|Lorlatinib Monotherapy|Lorlatinib administered as monotherapy by PO (per os) or NG (nasogastric) for two 28-day cycles at 115 mg/m2/day (or maximum 200mg/dose), after which disease evaluation by Magnetic Resonance Imaging (MRI) imaging will be performed.
62845615|NCT06333899|EXPERIMENTAL|Lorlatinib Combination with BABY POG chemotherapy|Lorlatinib monotherapy x2 cycles followed by maintenance therapy with lorlatinib (115 mg/m2/day) and BABY-POG chemotherapy backbone (vincristine, cyclophosphamide, cisplatin) The BABYPOG chemotherapy backbone regimen will consist of six 12-week courses. Each course will consist of cycles A, A2 and B, which will be administered consecutively, in 28-day cycles for a total of 72 weeks
62845616|NCT06333899|EXPERIMENTAL|Lorlatinib Combination with HIT-SKK chemotherapy|Lorlatinib monotherapy x2 cycles followed by maintenance therapy with lorlatinib (115 mg/m2/day) and HIT-SKK chemotherapy backbone (cyclophosphamide, vincristine, methotrexate, carboplatin, etposide) The recommended HIT-SKK chemotherapy backbone regimen consists of modular chemotherapy cycles, three courses of 4 blocks each (Element IIS, Element IIIS/1, Element IIIS/2, and Element IVS). Each element will be administered consecutively at 2-3-week intervals. Elements IIS and IVS cycles will be repeated twice thereafter. The entire length of treatment for HIT-SKK will be approximately 42 weeks.
62845617|NCT06333899|EXPERIMENTAL|Lorlatinib Maintenance Therapy post RT|Lorlatinib monotherapy x2 cycles followed by Radiation Therapy and continue lorlatnib maintenance monotherapy (115 mg/m2/day) 28 days post completion of RT for 12 cycles
62845618|NCT03402464|EXPERIMENTAL|Icotinib combined dihydroaremisinin|
62845619|NCT03202771|EXPERIMENTAL|Home Biofeedback Therapy|Patients will use home biofeedback device to practice their maneuvers taught by the nurse.
62845620|NCT03202771|ACTIVE_COMPARATOR|Office Biofeedback Therapy|Patients will get regular office biofeedback therapy with an anal probe inserted while a nurse runs through the exercise session together.
62845621|NCT05212870||Low back and neck pain group with experience of Covid-19|
62447492|NCT03795103|OTHER|Healthy volunteers|Ancillary study. Participants will perform a precise program of walking sessions performed outdoors and independently and the same biological parameters as those assessed in arteriopathic patients will be assessed
62845622|NCT05212870||Low back and neck pain group without experience of Covid-19|
62845623|NCT03357588|ACTIVE_COMPARATOR|Control|Standard of Care monitoring
62845624|NCT03357588|EXPERIMENTAL|Intervention|Intensified monitoring
62845625|NCT01295437|ACTIVE_COMPARATOR|Vypro II mesh|A partly absorbable polypropylene-polyglactin mesh (50g/m2).
62845626|NCT01295437|ACTIVE_COMPARATOR|Premilene LP|A lightweight polypropylene mesh (55 g/m2)
62845627|NCT01295437|PLACEBO_COMPARATOR|Premilene mesh|A conventional polypropylene mesh (82 g/m2)
62845628|NCT01322893||Blood sampling.|Blood samples will be taken before start of treatment, at month 1, month 3, month 4 and month 6.
62845629|NCT02722499|EXPERIMENTAL|High Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the high frequency incentive structure
62623754|NCT03130933|ACTIVE_COMPARATOR|The first tested subgroup|The tested subgroup from the main group without prior inflammation received a prophylactic single dose of 4 x Amoxicillin 500 Mg one hour prior the lower third molar surgery.
62623755|NCT03130933|PLACEBO_COMPARATOR|The first control subgroup|The control subgroup from the main group without prior inflammation received a placebo one hour prior the lower third molar surgery .
62845630|NCT02722499|EXPERIMENTAL|Moderate Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the moderate frequency incentive structure
62845631|NCT02722499|EXPERIMENTAL|Low Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the low frequency incentive structure
62845632|NCT02340637|EXPERIMENTAL|Coping Kids|"A Program for Managing Anxiety and Depression (P.C Kendall et al., 2013) is a newly developed group intervention targeting children aged 8 to 13 years who experience difficulty with symptoms of anxiety, depression, or both. The program is designed as an indicated prevention intervention to reduce the symptom levels and reduce the likelihood of the development of an anxiety disorder and/or depression.~The youth-focused sessions are designed for implementation in school settings, and the program includes parent group meetings.~All groupleaders participate in a three days training, followed by supervision. Manuals and workbooks are provided by the project. In addition is the same presentation as in TAU offered to the schools."
62845633|NCT02340637|ACTIVE_COMPARATOR|TAU|The teachers and school-nurses in the control schools will conduct treatment as usual (TAU).The project offers a 2,5 hours presentation to the schools, providing general information about the research study, the prevalence of emotional disorders and how to handle emotional disorders in treatment as usual. No materials are provided by the project.
62845634|NCT05620693|EXPERIMENTAL|Treatment group|TCR-T treatment group
62845635|NCT01006291|EXPERIMENTAL|IDeg OD FF|
62845636|NCT01006291|EXPERIMENTAL|IDeg OD|
62845637|NCT01006291|EXPERIMENTAL|IGlar OD|
62845638|NCT01766999||SpMetHb > 8%|hemoximetric MetHb measurements triggered
62845639|NCT05651685||TDApp2|This cohort will use TDApp2: an eHealth tool that formulates participatory, individualized, explainatory and automated treatment recommendations for patients with Attention Deficit Hyperactivity Disorder
62845640|NCT01490489|OTHER|Pregnent women with blood sample|
62845641|NCT04504552|EXPERIMENTAL|Single Arm Avelumab|Avelumab monotherapy on the Day 1 (± 2 days) of a 2-week treatment cycle for 4 administrations.
62845642|NCT00547443|ACTIVE_COMPARATOR|Arm I|Patients receive chemoradiotherapy comprising paclitaxel, carboplatin, and high-dose external beam radiotherapy (HDRT) as in phase I. Patients also receive consolidation therapy comprising paclitaxel and carboplatin as in phase I.
62845643|NCT00547443|EXPERIMENTAL|Arm II|Patients receive chemoradiotherapy comprising paclitaxel, carboplatin, and HDRT as in phase I. Patients also receive consolidation therapy comprising paclitaxel, carboplatin, and sorafenib tosylate at the MTD as in phase I, as well as maintenance therapy comprising sorafenib tosylate at the MTD as in phase I.
62619568|NCT01002248|EXPERIMENTAL|Perifosine added to combination|"Perifosine added to the combination of Bortezomib and Dexamethasone. Perifosine is is supplied as a film-coated tablet containing 50 mg of active ingredient. Perifosine will be administered orally on an outpatient basis throughout the study. Daily administration will be one 50 mg tablet.~The first dose of perifosine should be taken on the same day that bortezomib and dexamethasone are administered (Cycle 1 Day 1)."
62845644|NCT02860429|EXPERIMENTAL|Cinobufacini injection|"Capsule Dosage and frequency:This group receives cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.~Duration:6 chemotherapy cycles."
62845645|NCT02860429|OTHER|Control group|Only receive the same chemotherapy with the experimental groups.No Cinobufacini injection.And have the same adjuvant treatment with the experimental groups.
62845646|NCT04374942|EXPERIMENTAL|Study drug arm|50% of participants will be randomized to the study drug arm, and will take 400mg hydroxychloroquine orally once a day for three months (Day 1-90).
62845647|NCT04374942|PLACEBO_COMPARATOR|Placebo arm|50% of participants will be randomized to the placebo arm, and will take placebo orally once a day for three months (Day 1-90).
62845648|NCT05493800|EXPERIMENTAL|Part 1, MIT-001 5 mg group|"Part 1, MIT-001 5 mg, once a day IV administration for 30 minutes before conditioning regimen administration 0.5\~1 hr.~5 subject were enrolled sequentially."
62845649|NCT05493800|EXPERIMENTAL|Part 1, MIT-001 10 mg group|"Part 1, MIT-001 10 mg, once a day IV administration for 30 minutes before conditioning regimen administration 0.5\~1 hr.~6 subjects were enrolled sequentially."
62845650|NCT05493800|EXPERIMENTAL|Part 1, MIT-001 20 mg group|"Part 1, MIT-001 20 mg, once a day IV administration for 30 minutes before conditioning regimen administration 0.5\~1 hr.~5 subjects were enrolled sequentially."
62845651|NCT05493800|EXPERIMENTAL|Part 1, MIT-001 30 mg group|"Part 1, MIT-001 30 mg, once a day IV administration for 30 minutes before conditioning regimen administration 0.5\~1 hr.~It was optional but did not ptoceed according to Steering committee's decision because low level of MIT-001 is enough to show the efficacy and safety of MIT-001."
62845652|NCT05493800|EXPERIMENTAL|Part 2, 5mg of MIT-001 low dose group|"Part 2, MIT-001 low dose, once a day IV administration for 30 minutes before conditioning regimen administration 0.5\~1 hr.~15 subject will be enrolled parallelly."
62845653|NCT05493800|EXPERIMENTAL|Part 2, 20mg of MIT-001 high dose group|"Part 2, MIT-001 high dose, once a day IV administration for 30 minutes before conditioning regimen administration 0.5\~1 hr.~15 subject will be enrolled parallelly."
62845654|NCT05493800|PLACEBO_COMPARATOR|Part 2, placebo(normal saline) group|"Part 2, placebo(normal saline), once a day IV administration for 30 minutes before conditioning regimen administration 0.5\~1 hr.~15 subject will be enrolled parallelly."
62845655|NCT03485872|EXPERIMENTAL|Self-Screening and Referral Information|The intervention will include a combination of self-screening and UI specific information and resources. Older adults in the intervention group will complete a gender specific UI Self-Screening tool. Men will complete the International Consultation on Incontinence Modular Questionnaire (ICIQ) for Males and women will complete the ICIQ for Females. In addition, the intervention group will receive a fact sheet with UI specific information, contact information to the local incontinence clinic and a link to a website with patient incontinence resources and education.
62845656|NCT03485872|ACTIVE_COMPARATOR|Control Group|Older adults assigned to the control group will receive standard care from their physicians. Standard care may differ from general practitioner to general practitioner. Usual care for urinary incontinence (UI) from general practitioners is generally minimal. Most patients do not tell their physicians about UI, and most physicians do not ask about UI. If this topic does come up during a GP appointment, a patient may be offered no treatment, lifestyle advice (e.g., do not drink before bed), told to do Kegels (but likely not instructed how to do these properly) or in some cases, offered pharmacological therapies (which will be captured in our questionnaire with the participants). But standard of care is unfortunately very often no care.
62447493|NCT06545383|EXPERIMENTAL|Dynamic Neuromuscular Stabilization Exercises|Participants will be taught face-to-face the same home exercise program that was taught to the Exercise Group. In addition, Dynamic Neuromuscular Stabilization (DNS) exercises will be performed. Participants will be informed about DNS exercises and postures. Progress will be made in the exercises step by step. The exercises performed during the positions will be increased by performing 3 sets of 10 repetitions in the first 3 weeks and 3 sets of 15 repetitions in the last 3 weeks.
62447494|NCT06545383|ACTIVE_COMPARATOR|Exercise|Participants will be taught the home exercise program face to face. Exercises will start with diaphragmatic breathing. Breathing exercises will be done in 2 sets of 10 repetitions. Lower extremity joint range of motion exercises; It will consist of hip flexion in the supine position, hip abduction in the side lying position, hip extension and knee flexion in the prone position, knee extension and ankle dorsi-plantar flexion in the sitting position. Exercises will be increased to 3 sets of 10 repetitions for the first 3 weeks, and 3 sets of 15 repetitions after the 3rd week. After the exercises, they will be asked to walk for 20 minutes at moderate intensity on a flat surface. Additionally, the control group will be asked to walk at moderate intensity.
62845657|NCT00933777|EXPERIMENTAL|Therapy with everolimus and sorafenib|Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg
62845658|NCT03257319|EXPERIMENTAL|inhaled morphine + IV placebo|Arm A: inhaled titration of morphine chlorhydrate+ IV placebo
62059399|NCT04141631|EXPERIMENTAL|STOP Group|"EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if~* Hb \< 13g/dL the day before surgery~* Hb ≥ 7g/dL AND ScvO2 \> 65% in postoperative ICU stay~Postoperative Transfusion will be guided by ScvO2 values :~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb \< 7g/dL independently of ScVO2 value"
62447495|NCT03424291|EXPERIMENTAL|Apatinib plus chemoradiation|Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
62059400|NCT04141631|NO_INTERVENTION|Control Group|"Only postoperative anemia will be managed:~* RBC transfusion will be performed if Hb ≤ 8 g/dL (2017 EACTS/EACTA guidelines)~* Iron sucrose administration if Hb \> 8g/dL : 2 injections of 200 mg according to Height (+/- 70 Kg) in 250 mL of saline solution 0.9% over 1h30 into 48 h intervals without exceeding a total dose of 15mg/kg."
62447496|NCT00240682|EXPERIMENTAL|cetuximab|cetuximab
62447497|NCT01298856|ACTIVE_COMPARATOR|hydrotherapy|hydrotherapy and ankle taping and land based exercise
62623756|NCT03130933|ACTIVE_COMPARATOR|The second tested subgroup|The tested subgroup from the main group with prior inflammation received a prophylactic single dose of 4 x Amoxicillin 500 Mg one hour prior the lower third molar surgery .
62845659|NCT03257319|PLACEBO_COMPARATOR|IV morphine +inhaled placebo|Arm B:IV titration of morphine chlorhydrate + inhaled placebo
62845660|NCT00441116|PLACEBO_COMPARATOR|Dutasteride|Dutasteride
62845661|NCT04456855||Locoregional surgery|
62845662|NCT04456855||No surgery|
62059401|NCT05087914|EXPERIMENTAL|Carbidopa-Levodopa (100mg/25mg) + Naproxen (250mg)|"The study drug, Carbidopa-Levodopa, is an FDA-approved medicine traditionally used for the treatment of Parkinson's disease. The study drug will be used for an un-approved or un-labeled use: potentially managing pain in post-surgical patients. Carbidopa/Levodopa is an artificially made version of a naturally occurring hormone that helps regulate brain activity (Levodopa), combined with an artificially made version of a naturally occurring molecule that inhibits the breakdown of Levodopa (Carbidopa).~Naproxen (250mg): Participants will receive one capsule TID, throughout the 5 days of the treatment period. Naproxen will be prescribed for active and control group."
62447498|NCT01298856|ACTIVE_COMPARATOR|land-based|land-based and ankle taping program
62623757|NCT03130933|PLACEBO_COMPARATOR|The second control subgroup|The control subgroup from the main group with prior inflammation received a placebo one hour prior the lower third molar surgery .
62845663|NCT02105961|EXPERIMENTAL|Arm 1|Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
62845664|NCT02105961|EXPERIMENTAL|Arm 2|Each subject will receive 300 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
62845665|NCT02105961|EXPERIMENTAL|Arm 3|Each subject will receive placebo (0.9percent sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) their baseline standard of care COPD medication
62845666|NCT04285619|EXPERIMENTAL|Experimental group|Each session will last 10 minutes and a weekly intervention will take place over 3 weeks. The intervention by flossing will be carried out following the application protocol described by the manufacturer for the application of flossing on the ankle. Before the intervention, participants will perform a standard warm-up: 10 minutes of exercise bike at a moderate intensity
62059402|NCT05087914|PLACEBO_COMPARATOR|Placebo + Naproxen (250mg)|"Placebo:Participants will receive 1 the capsules on a three-times a day schedule for 5 days. A placebo looks like the study drug but is an inactive substance that has no medication. Researchers use a placebo to see if the study drug works better or is safer than not taking anything.~Naproxen (250mg): Participants will receive one capsule TID, throughout the 5 days of the treatment period. Naproxen will be prescribed for active and control group."
62447499|NCT03947580|EXPERIMENTAL|Use of the Dvectis Single pad|The Dvectis Single Dynamic-directional pad is a basic model of the Dvectis product range that provides full functionality based on the dynamic-directional seating principle. The Dvectis Single pad is designed to steer muscle tension during sitting in deep-seated muscles. The Dvectis Single pad is intended to eliminate chronic lumbar spine pain by strengthening the stabilizing muscles.
62059403|NCT03474549|EXPERIMENTAL|Tigertriever revascularization device|Mechanical thrombectomy with Tigertriever
62059404|NCT00981851|ACTIVE_COMPARATOR|beta 2 agonist + anticholinergic aerosol|
62447500|NCT03947580|EXPERIMENTAL|Use of the Dvectis Double pad|The Dvectis Double Dynamic-directional pad is based on the Dvectis Single model, but in addition to its dual-chamber design, it provides seating with a more balanced load and a higher dynamic-directional effect. The Dvectis Double pad is designed to create and route muscle tension during sitting in deep-seated muscles. The Dvectis Double is also suitable for soft substrates (sofa, soft chair, etc.). The Dvectis Double Pad is intended to remove chronic lumbar spine pain by strengthening the stabilizing muscles.
62447501|NCT03947580|NO_INTERVENTION|Use of no pad|Description is not needed
62623758|NCT02634801|EXPERIMENTAL|Ixekizumab|"160 milligrams (mg) ixekizumab given as two subcutaneous injections (SC) followed by 80 mg ixekizumab given SC every 2 weeks until week 12 and then 80 mg ixekizumab given SC every 4 weeks until week 24.~Extension Period: At week 24, participants have the option to continue ixekizumab treatment for up to 36 weeks."
62845667|NCT04285619|ACTIVE_COMPARATOR|Control group|Each session will last 10 minutes and a weekly intervention will take place over 3 weeks. The intervention by flossing will be carried out following the application protocol described by the manufacturer for the application of flossing on the ankle. Before the intervention, participants will perform a standard warm-up: 10 minutes of exercise bike at a moderate intensity
62059405|NCT00981851|PLACEBO_COMPARATOR|placebo inhalation|
62059406|NCT02483286|EXPERIMENTAL|ICG|Integrated Care Group
62059407|NCT02483286|EXPERIMENTAL|MTG|Muscle Training Group
62059408|NCT02483286|EXPERIMENTAL|XBG|X-box Group
62059409|NCT03395808|OTHER|AVE-901 50mg|IV Tramadol
62059410|NCT02028832|ACTIVE_COMPARATOR|Usual care|Usual care provided to pediatric inpatients
62447502|NCT02145975|EXPERIMENTAL|Fentanyl|"Procedure: Fentanyl for rescue of acute postoperative pain in the postanesthesia care unit~Intervention:~The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS \> 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized."
62447503|NCT02145975|ACTIVE_COMPARATOR|Morphine|"Procedure: Morphine for rescue of acute postoperative pain in the postanesthesia care unit~Intervention:~The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS \> 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized."
62447504|NCT03144856|EXPERIMENTAL|Apatinib group|Apatinib 500mg, po, QD, every 4 weeks.
62447505|NCT05733195||Women with GDM|All basic information was collected in the first trimester, and all subjects underwent OGTT (75g glucose) at 24-28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG. At four time points during pregnancy (6-13 weeks, 24-28 weeks, 36-weeks before delivery, and 6 weeks after delivery), blood samples of 5ml were collected from each subject at each time point without increasing the number of blood samples. In the GDM group, blood samples were collected at the same time during routine visit 6 weeks after delivery. The relevant broad metabolomics and targeted vitamin profiles were also detected.
62447506|NCT05733195||Women with no-GDM|All basic information was collected in the first trimester, and all subjects underwent OGTT (75g glucose) at 24-28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG. At three time points during pregnancy (6-13 weeks, 24-28 weeks, 36-weeks before delivery), blood samples of 5ml were collected from each subject at each time point without increasing the number of blood samples. The relevant broad metabolomics and targeted vitamin profiles were also detected.
62447507|NCT01614327||Retinal Screening; Diabetes 1 and 2|Patients diagnosed as either having Pre-Diabetes, Diabetes 1 or Diabetes 2
62447508|NCT04431271||Robot-assisted laparoscopy|Patients who underwent robot-assisted groin hernia repair
62447509|NCT04431271||Conventional laparoscopy|Patients who underwent conventional laparoscopic groin hernia repair
62447510|NCT00615784|EXPERIMENTAL|A|
62447511|NCT04152928|EXPERIMENTAL|Neuroendocrine Tumors Patients|Patients with confirmed NET
62447512|NCT02701478|OTHER|N2O exposure|"There is only one arm in this study. All patients under General Anesthesia are exposed to 4 different doses or concentrations of inhaled N2O that is combined with the anesthetic desflurane. Each patient will be submitted to the standard nociceptive stimulus when inhaled N2O is at 0, 50, 25, and finally back to 0%. ANI and NoL Indices variations between before stimulus and after stimulus at each N2O concentration will be assessed and compared. This will allow to demonstrate an analgesic effect (less variations of ANI and NoL) when inhaled N2O is high (50%) testifying for the analgesic effect of this gas N2O."
62447513|NCT00003145|EXPERIMENTAL|Treatment (chemotherapy, TBI, PBSCT, DLI)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV BID or TID on days -3 to 56 with taper to day 77 or 180, and mycophenolate mofetil PO or IV BID on days 0-27.~DLI: At least 2 weeks after completion of immunosuppression, patients with \> 5% donor CD3+ T cells and no evidence of GVHD receive donor lymphocytes IV over 30 minutes. Patients may receive up to 3 DLIs at increasing cell doses in the absence of GVHD."
62447514|NCT01474278|EXPERIMENTAL|1|
62447515|NCT01474278|PLACEBO_COMPARATOR|2|
62447516|NCT05060627|EXPERIMENTAL|Belantamab-Mafodotin + Carfilzomib+ dexametasona|"In the phase 1 of the study, aiming to establish the recommended phase 2 dose (RP2D), patients will be included following the classic 3 + 3 design.~Once the DLT assessment period is completed and the MTD is defined, the recruitment will continue in the expansion phase 2.~Combination treatment will be administered at the recommended Phase 2 dose (RP2D) based on the results of the phase 1 dose escalation part of the study:~* Belantamab mafodotin on day 1 at the RP2D, every 8 weeks, intravenously (IV).~* Carfilzomib will be given at the RP2D weekly IV on days: 1, 8, and 15 of every 4-week cycle (Q4W).~* Dexamethasone will be given at the dose of 40 mg (or 20 mg if patient \> 75 years old) on days: 1, 8, 15 and 22 Q4W.~From month 13 onwards carfilzomib treatment will be given on day 1 and 15 of every 4-weeks cycles. Belantamab will be given at the RP2D every 8 weeks and Dexamethasone 40mg on days 1, 8, and 15 of every 4-week cycle."
62447517|NCT01729936|EXPERIMENTAL|Sitting time Change Intervention|"Sitting time Change Intervention: recommendation to substitute Sitting time by doing the regular activities standing or walking.~Duration: 6 month. Frequency: 1 time each 15 days during the first 4 month and 1 time each month the last 2 months."
62447518|NCT01729936|NO_INTERVENTION|Active Control|Control visits to the Primary Health Care Center
62447519|NCT02893748|ACTIVE_COMPARATOR|1: HyGIeaCare Prep and Colonoscopy|"Patients will receive:~1. HyGIeaCare Prep~2. Colonoscopy"
62447520|NCT02893748|ACTIVE_COMPARATOR|2: Split-dose PEG Prep and Colonoscopy|"Patients will receive:~1. Split-dose PEG~2. Colonoscopy"
62845668|NCT02830685|ACTIVE_COMPARATOR|Direct-To-Implant A|DTI with Acellular Dermal Matrix (CELLIS® Breast), pre-pectoral, subcutaneous direct-to-implant breast reconstruction with the aid of an Acelluar Dermal Matrix (ADM)
62619569|NCT01002248|PLACEBO_COMPARATOR|Perifosine Placebo added to combination|Perifosine placebo added to the combination of Bortezomib and Dexamethasone. The placebo for perifosine is provided in 256 mg white to off-white, round, biconvex film-coated tablets to permit a blinded trial with perifosine 50 mg film coated tablets. Placebo will be administered orally on an outpatient basis throughout the study. Daily administration will be one perifosine placebo tablet. The first dose of placebo should be taken on the same day that bortezomib and dexamethasone are administered (Cycle 1 Day 1).
62619570|NCT01615159|NO_INTERVENTION|Self directed control|
62619571|NCT01615159|ACTIVE_COMPARATOR|Behavior and lifestyle counseling|
62845669|NCT02830685|EXPERIMENTAL|Direct-To-Implant B|DTI with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra), pre-pectoral, subcutaneous direct-to-implant breast reconstruction with the aid of a titanium coated polypropylene mesh
62619572|NCT03494049|ACTIVE_COMPARATOR|Veil sparring HoLEP|"Early mucosal incision lateral to the Veru followed by early separation of the adenoma from the sphincter ring after identification of the plane of enucleation, this minimizes sphincter stretch.~Furthermore, more proximal incision of the 12 O'clock mucosal strip sparring a veil of mucosa covering the sphincter ring."
62619573|NCT03494049|ACTIVE_COMPARATOR|Standard HoLEP|Standard HoLEP TECHNIQUE as described by Elhilali et al 2010
62619574|NCT03884270|EXPERIMENTAL|Hypnotherapy|7 sessions of on-line hypnotherapy treatment over the course of 12 weeks (1 new session every 2 weeks)
62619575|NCT02741115|EXPERIMENTAL|Drug|Udenafil. One tablet twice daily for 26 weeks
62619576|NCT02741115|EXPERIMENTAL|Placebo|Placebo. One tablet twice daily for 26 weeks
62619577|NCT00743847|PLACEBO_COMPARATOR|placebo|
62619578|NCT00743847|ACTIVE_COMPARATOR|varenicline 0.5 mg BID|
62619579|NCT00743847|ACTIVE_COMPARATOR|varenicline 1mg BID|
62619580|NCT01133496|EXPERIMENTAL|Alendronate Sodium|Alendronate Sodium Tablets, 70 mg of Dr. Reddy's
62619581|NCT01133496|ACTIVE_COMPARATOR|Fosamax|Fosamax Tablets 70 mg of Merck \& Company. Inc., USA.
62619582|NCT01181947||patients undergoing TEVAR|Those with a thoracic aortic aneurysm/dissection
62619583|NCT02662270||Cases|Patients with a fibromyalgia diagnosis established according to the American College of Rheumatology current criteria by a trained physician.
62619584|NCT02662270||Controls|Healthy subjects paired by age and gender to the subjects in the cases group.
62619585|NCT03116724|EXPERIMENTAL|CVC catheterization through Rt. IJV|"The depth of central venous catheter during central venous catheterization through Rt. IJV will be decided by using real-time TEE.~The position of tip of CVC will be guided by TEE to fit the tip at 2 cm away from the junction between right atrium and superior vena cava."
62619586|NCT05487820|EXPERIMENTAL|Patients with reconstructed flap monitored by tissue CO2|Patients scheduled for reconstructive flap surgery are monitored postoperatively with IscAlert biosensor measuring local tissue CO2 and temperature in the reconstructed flap
62619587|NCT03447964||Type 1 diabetes|dosing of sphingolipids
62619588|NCT03447964||Type 2 diabetes|Dosing of sphingolipids
62619589|NCT01498042||stroke, thrombolysis, over 80, outcome|To study the outcome of stroke patients over 80 years treated with thrombolysis.
62619590|NCT04685356|EXPERIMENTAL|IBAIP Group|Children benefiting from assessment and intervention providing by a healthcare professional (physiotherapist or psychomotor therapist) trained and certified for IBAIP. This care will take place upon discharge from the hospital at the rate of one session per month for 6 months. The sessions will take place in the presence of at least one of the parents and at home. These children will also benefit from standard follow-up (medical follow-up, paramedical or specialized medical support depending on the development and needs).
62619591|NCT04685356|ACTIVE_COMPARATOR|Control group|Children benefiting from standard care upon discharge from hospital with 1 medical consultation per month and, medical sepcialist and / or paramedical(physiotherapy, speech therapy, psychomotricity, etc.). consultations if indicated by the physician providing follow-up
62619592|NCT01756248||Group 1|
62619593|NCT00073008|OTHER|lapatinib|Randomized, open-label, parallel group, 2-stage study to evaluate and compare 2 dose schedules (1500 mg once daily and 500 mg twice daily) of oral lapatinib.
62845670|NCT03366519||patients with pulmonary embolism|patients with pulmonary embolism confirmed by tomography scan in emergency department
62845671|NCT03546452||malignant NSCLC hydrothorax|cell free DNA ,which is purified from malignant NSCLC hydrothorax, tested by in vitro NGS-panel
62447521|NCT02952248|EXPERIMENTAL|BI 754091|
62447522|NCT02424981|EXPERIMENTAL|inspiratory muscle training|Muscle training
62619594|NCT01711008|PLACEBO_COMPARATOR|No Breakfast|Water only
62619595|NCT01711008|ACTIVE_COMPARATOR|20g Cereal|20g Kelloggs Special K cereal with 83ml semi-skimmed milk
62619596|NCT01711008|ACTIVE_COMPARATOR|40g Cereal|40g Kelloggs Special K cereal with 166ml semi-skimmed milk
62619597|NCT02314312|EXPERIMENTAL|A: investigation arm|De novo kidney transplantation form ECD/AKI donor with Everolimus + low dose cyclosporinA + prednisolone as immunosuppressive regimen
62619598|NCT02314312|OTHER|B: control arm|De novo kidney transplantation form ECD/AKI donor with standard immunosuppressive regimen
62619599|NCT02491580||KTx Uppsala|Patients who have received a kidney transplant in Uppsala.
62619600|NCT02491580||KTx Europe|Patients who have received a kidney transplant in Uppsala.
62263111|NCT06490016|EXPERIMENTAL|Intervention group that given web-based education|This group will not be met face to face and communication will be provided via the website. A username and password will be defined for each user before entering the web page. Visually impaired adolescent girls will be able to individually enter the relevant modules without assistance, read the module they want, and listen to the depicted pictures and graphics. From the admin section of the website, it will be tracked who attended the training, how many minutes they stayed, and how many times a week they attended. The training modules will last 3 weeks and 5 modules will be used in the training. (1st Meeting and Survey collection, 2nd week: 1st and 2nd module, 3rd week: 3 modules and 4th week: 5 modules, 6th interview: after training). A reminder notification will be sent to the contact section on the website every week for them to attend the training.
62263112|NCT04322851||B-line positive|
62263113|NCT04322851||B-line negative|
62263114|NCT00947336|ACTIVE_COMPARATOR|Norfloxacin + Synbiotic|
62263115|NCT00947336|PLACEBO_COMPARATOR|Norfloxacin + Placebo|
62263116|NCT03152019|ACTIVE_COMPARATOR|Protopic® 0.1% (Tacrolimus) ointment|Protopic® 0.1% ointment, packed in blinded tube of 30g.
62263117|NCT03152019|PLACEBO_COMPARATOR|Placebo ointment|Same formulation as the Protopic® 0.1% ointment but without tacrolimus, packed in blinded tube of 30g.
62263118|NCT02919878|EXPERIMENTAL|pre-op Gemcitabine & XRT|"Pre-op chemo: Gemcitabine will be administered as continuous infusion IV over 24 hrs (100 mg/m2) weekly for 6 wks starting on day 1 of Radiotherapy (XRT).~XRT/ Intensity modulated radiotherapy(IMRT): 1.8 Gy/fx, 5 fractions/wk will be delivered. Pelvis will receive 45 Gy/25 fractions/5 wks with a boost dose of 5.4 Gy for T3 and 9 Gy for T4 to a cone down volume. The total tumor dose= 50.4 -54 Gy.~Post-op chemo: Standard 6 cycles of adjuvant Capecitabine (1250 mg/m2) PO twice per day on days 1-14 each cycle, (every 21 days) in patients who have a complete resection of rectal cancer and negative surgical margins."
62263119|NCT02244502|EXPERIMENTAL|TTFields in combination with weekly paclitaxel|Patients will be treated continuously with the NovoTTF-100L(O) device, in addition to weekly paclitaxel.
62263120|NCT00117598|EXPERIMENTAL|A|
62263121|NCT00117598|EXPERIMENTAL|B|
62263122|NCT00117598|ACTIVE_COMPARATOR|C|
62263123|NCT03217006|EXPERIMENTAL|Single Arterial Group|Patients in this group will receive a single arterial graft which will be the left internal thoracic artery. Additional grafts used in this group will all be venous grafts.
62263124|NCT03217006|EXPERIMENTAL|Multiple Arterial Group|Patients in the group will receive multiple arterial grafts. All patients will receive at least two arterial grafts, the left internal thoracic artery with the addition of either the right internal thoracic artery or the radial artery as the second conduit. Some patients may receive additional arterial grafts consisting of the radial artery, the right internal thoracic artery, or the right gastroepiploic artery.
62263125|NCT05793671|ACTIVE_COMPARATOR|immediate stenting in heavy thrombus STEMI burden patients|This group - heavy thrombus burden STEMI patients with thrombolysis in myocardial infarction ( TIMI ) 2-3 flow - will receive loading dose of GPIIbIIIa inhibitor intracoronary followed by immediate stenting .
62263126|NCT05793671|ACTIVE_COMPARATOR|Deferred stenting in heavy thrombus burden STEMI patients .|This group - heavy thrombus burden STEMI patients with TIMI 2-3 flow - will receive loading dose of GPIIbIIIa inhibitor intracoronary followed by GPIIbIIIa inhibitor infusion and LMWH administration for 48 -72 hours followed by stenting .
62845672|NCT00485134|EXPERIMENTAL|Stage 1: Group A, Dolphin 240 µg|240 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of lipopolysaccharides (LPS). 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
62263127|NCT04659265|ACTIVE_COMPARATOR|No suspected diagnosis (control group)|Participants receive the information that the pre-treating physician thought that the patient is suffering from a medical emergency (no diagnosis).
62263128|NCT04659265|ACTIVE_COMPARATOR|Correct suspected diagnosis|Participants receive the information that the pre-treating physician thought that the patient is suffering from an acute myocardial infarction (correct diagnosis).
62263129|NCT04659265|ACTIVE_COMPARATOR|Wrong suspected diagnosis|Participants receive the information that the pre-treating physician thought that the patient is suffering from a pulmonary embolism (wrong diagnosis).
62263130|NCT01059669||Patients|Patients with suspected Chronic Pancreatitis
62263131|NCT01059669||Control group|Healthy controls
62263132|NCT02089399|EXPERIMENTAL|Treatment AB|S-\>S+C
62263133|NCT02089399|EXPERIMENTAL|Treatment C|C
62263134|NCT02410304|OTHER|Arm C (Clinical)|No drug and no placebo were used in this arm. Patients were followed only by clinical évaluation.
62263135|NCT02410304|OTHER|Arm B (Clinical + Ultrasound)|No drug and no placebo were used in this arm. Patients were followed by Clinical evaluation in combination with ultrasound (in B mode).
62263136|NCT02410304|OTHER|Arm D (Ultrasound)|No drug and no placebo were used in this arm. Patients were followed by Ultrasound approach in D mode.
62263137|NCT04944160||Pre Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a reverse transcriptase - polymerase chain reaction (RT-PCR) positive for Respiratory Syncytial Virus (RSV) during the 2019-2020 winter epidemic"
62619601|NCT02727309|EXPERIMENTAL|apatinib|Patients with advanced hepatocellular carcinoma after been treated with TACE receive apatinib (750mg) daily, until disease progression or unacceptable toxicity.
62845673|NCT00485134|EXPERIMENTAL|Stage 1: Group B, Dolphin 480 µg|480 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
62263138|NCT04944160||Post Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a reverse transcriptase - polymerase chain reaction (RT-PCR) positive for Respiratory Syncytial Virus (RSV) during the 2020-2021 winter epidemic"
62263139|NCT03001089|ACTIVE_COMPARATOR|Fludrocortisone 10 µg tablets|Oral Fludrocortisone (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
62447523|NCT02424981|NO_INTERVENTION|control|Control group
62619602|NCT00943501|EXPERIMENTAL|I.a|
62845674|NCT00485134|EXPERIMENTAL|Stage 1: Group C, Dolphin 690 µg|690 Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
62845675|NCT00485134|OTHER|Stage 1: Group D, Pipette 240 µg|240 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. These subjects received 200 μL the vaccine via electronic pipette. This group is for lot bridging only, not included in dose-finding study.
62845676|NCT00485134|OTHER|Stage 2: Immunized / Challenge|The selected dose was to be administered with the Dolphin™ using the vaccination schedule from stage 1. Immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast.
62845677|NCT00485134|PLACEBO_COMPARATOR|Stage 2: Controls|A control was to be administered with the DolphinTM using the vaccination schedule from Stage 1. Non-immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast.
62447524|NCT06191367|EXPERIMENTAL|Group I (experimental) Aerobic Exercises and Traditional Chest Physiotherapy.|It was consisted of fifteen patients with positive covid-19 test from at least a month before trial. They received aerobic exercise techniques which consist of 3 levels of activity exercises and traditional program of chest physiotherapy. (Five times per week for two months).
62447525|NCT06191367|EXPERIMENTAL|Group II (experimental)Incentive Spirometer Device and Traditional Chest Physiotherapy.|It was consisted of fifteen patients with positive covid-19 test from at least a month before trial. They received incentive spirometer training techniques and traditional program of chest physiotherapy. (Five times per week for two months).
62845678|NCT00982423|EXPERIMENTAL|Furosemide|Subjects received their clinically prescribed dose of furosemide for a 3 week stabilization period, then were assessed for cardiorenal and humoral function. Subjects then had a 50% reduction of the furosemide dose for a 3 week stabilization period, and were assessed for cardiorenal and humoral function again.
62845679|NCT04800172|ACTIVE_COMPARATOR|Roflumilast arm|
62845680|NCT04800172|PLACEBO_COMPARATOR|Placebo arm|
62447526|NCT06191367|ACTIVE_COMPARATOR|Group III (control) will receive Traditional Chest Physiotherapy only.|"As a control group it was consisted of fifteen patients with positive covid-19 test from at least a month before trial. They received traditional program of chest physiotherapy only. (Five times per week for two months).~for example: - Breathing Exercises. - Postural Drainage. - Percussion. - Coughing - Vibration."
62447527|NCT00957983|ACTIVE_COMPARATOR|BGC20-1531 200mg|
62447528|NCT00957983|PLACEBO_COMPARATOR|sugar pill|
62447529|NCT00957983|ACTIVE_COMPARATOR|BGC20-1531 400mg|
62447530|NCT02989766|ACTIVE_COMPARATOR|A - Intervention|Education on Breast Feeding 3 activity sheets prenatally-study related. Complete a pre-questionnaire, a pre-delivery and a postpartum questionnaire
62447531|NCT02989766|NO_INTERVENTION|B - Standard of Care|Complete a pre-questionnaire, a pre-delivery and a postpartum questionnaire
62447532|NCT03287596|EXPERIMENTAL|HEALTHY VOLUNTEERS|"* 3D sequence ZTE2 DP without gadolinium~* 3D Sequence UTE without gadolinium"
62447533|NCT03287596|EXPERIMENTAL|SPA + NON-SYMPTOMATICS|"* 3D sequence ZTE2 DP without gadolinium~* 3D Sequence UTE without gadolinium~* 3D Sequence ZTE2 DP with gadolinium~* 3D sequence UTE with gadolinium"
62845681|NCT06184568|ACTIVE_COMPARATOR|Semaglutide|
62447534|NCT03287596|EXPERIMENTAL|SPA + SYMPTOMATICS|"* 3D sequence ZTE2 DP without gadolinium~* 3D Sequence UTE without gadolinium~* 3D Sequence ZTE2 DP with gadolinium~* 3D sequence UTE with gadolinium"
62447535|NCT03287596|EXPERIMENTAL|MECHANIC TENDINOPATHY|"* 3D sequence ZTE2 DP without gadolinium~* 3D Sequence UTE without gadolinium~* 3D Sequence ZTE2 DP with gadolinium~* 3D sequence UTE with gadolinium"
62447536|NCT00838318||Arm 1 Hispanic CRC Patients|
62447537|NCT00838318||Arm 2 FDRs of Hispancic CRC Patients|First-Degree Relatives (FDRs) of Hispanic CRC Patients
62447538|NCT00838318||Arm 3 Key Informants|Key informants from Houston Hispanic Health Coalition.
62447539|NCT01185288|EXPERIMENTAL|Adalimumab + Low Dose Methotrexate|Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, low dose methotrexate (7.5 mg orally once weekly).
62447540|NCT01185288|ACTIVE_COMPARATOR|Adalimumab + High Dose Methotrexate|Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, high dose methotrexate (20 mg orally once weekly).
62447541|NCT02327000|EXPERIMENTAL|GLA5PR GLARS-NF1 tablet 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day, after meal)
62447542|NCT02327000|EXPERIMENTAL|GLA5PR GLARS-NF1 tablet 300mg|GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day, after meal)
62845682|NCT06184568|EXPERIMENTAL|IBI362|
62845683|NCT03620786||HIFU Study Participants|Subjects who have biopsy-proven adenocarcinoma of the prostate, who have met all study inclusion and exclusion criteria, and have elected to receive or have already received the HIFU procedure as part of their routine prostate cancer treatment, will be invited to participate in this observational registry study. The HIFU device currently used in this standard-of-care procedure at UCLA is the Sonablate 450 HIFU System.
62447543|NCT02327000|EXPERIMENTAL|GLA5PR GLARS-NF1 tablet 450mg|GLA5PR GLARS-NF1 tablet 450mg/day(Pregabalin 150mg 1 tablet and Pregabalin 300mg 1 tablet, 1 times a day, after meal)
62619603|NCT00943501|PLACEBO_COMPARATOR|I.b|
62619604|NCT00943501|EXPERIMENTAL|II.a|
62619605|NCT00943501|PLACEBO_COMPARATOR|II.b|
62619606|NCT05987943|OTHER|healing.recurrence of oroanral fistula|A Pedicled Buccal Periosteal Flap for the Closure of Oro-antral Fistula
62619607|NCT05325723||Intervention group|"1. 30 second audio phonocardiogram (PCG) recordings at each of the five standard cardiac auscultatory positions using an Apple iPhone®.~2. the assessment of VHD by echocardiogram, as reported by the echocardiography laboratory."
62619608|NCT03293446|EXPERIMENTAL|Patients with chronic kidney disease|
62845684|NCT04088058|EXPERIMENTAL|GXHPC1|One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
62263140|NCT03001089|PLACEBO_COMPARATOR|placebo oral tablet|Oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
62263141|NCT02514915|OTHER|Stereotactic Radiosurgery|Subjects will receive stereotactic radiosurgery prior to resection
62263142|NCT04500535||Cohort 1|Immuno-oncology (IO)-naïve patients
62263143|NCT04500535||Cohort 2|IO-experienced patients for whom last IO discontinuation was not primarily related to IO-toxicity
62263144|NCT04500535||Cohort 3|IO-experienced patients for whom last IO discontinuation was primarily due to IO-toxicity
62263145|NCT05601648|EXPERIMENTAL|Psilocybin|Eligible adults to undergo a single drug session with psilocybin (25mg tablet) plus supportive psychotherapy
62263146|NCT02714920|OTHER|DNA Repair enzyme signature|Tumor biopsies and blood samples performed specifically to determine DNA Repair enzyme signature biomarkers profiles (CHEMRAD assay)
62619609|NCT03293446|ACTIVE_COMPARATOR|Healthy controls|
62619610|NCT03162328|PLACEBO_COMPARATOR|Powersleep Sham, PowerSleep Stim|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers. After 2 nights in the lab in the sham condition participants will cross-over to the other arm of the trial the following week. Week 2 - Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night.
62619611|NCT03162328|EXPERIMENTAL|Powersleep Stim, PowerSleep Sham|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night. After 2 nights in the lab in the stim condition participants will cross-over to the other arm of the trial the following week. Week 2 - Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers.
62619612|NCT00714155||1|Physical examination, questionnaires, retrospective chart review
62619613|NCT00714155||2|Questionnaires, retrospective chart review
62619614|NCT00714155||3|Retrospective chart review
62619615|NCT02278705||Weight-status improved|"Cases, termed, weight-status improved, are defined as children whose BMI percent relative to their age/sex-specific BMI at the 95th percentile decreases from one visit to the next; and from one well-child visit to the next well-child (or primary-care visit approximately 9-18 months later)."
62845685|NCT00634101|ACTIVE_COMPARATOR|nefilcon A|Subjects randomized to this arm received the nelfilcon A lens throughout the entire duration of the study.
62845686|NCT00634101|EXPERIMENTAL|narafilcon A|Subjects randomized to this arm received the narafilcon A lens throughout the entire duration of the study.
62845687|NCT05028244|EXPERIMENTAL|Intervention group|Selected patients undergo lower extremity ultrasound for diagnosis of deep vein thrombosis 2 times per week (Mondays and Thursdays) in a period of 3 weeks (21 days) of follow up
62263147|NCT04098770|EXPERIMENTAL|Conventional treatment plus Allogeneic Adoptive Immune Therapy|Participants will receive conventional treatment (anti-opportunistic infections, cART and other treatments) plus a dose (2-3 times) of Allogeneic Adoptive Immune Therapy
62619616|NCT02278705||Weight-status unchanged/worse|Controls are defined as children whose BMI percent relative to their age/sex-specific BMI at the 95th percentile remains unchanged or increases from one visit to the next; and from one well-child visit to the next well-child (or primary-care visit approximately 9-18 months later).
62619617|NCT03947502|EXPERIMENTAL|Intervention Group with|Educational intervention in neurobiology of pain
62845688|NCT05028244|NO_INTERVENTION|control group|This group only undergo the first ultrasound assessment to discard previous thrombosis not detected during hospitalisation or ambulatory
62619618|NCT03947502|NO_INTERVENTION|Control group|The control group is treated with usual medication for fibromyalgia, anxiolytics, antidepressants, analgesics, ... Depending on the medical needs and criteria of patients´s primary care physician.
62623759|NCT02634801|ACTIVE_COMPARATOR|Fumaric Acid Esters|"Starting dose of 105 mg FAE given orally followed by 215 mg FAE given orally 1 to 3 times per day until week 24.~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks."
62623760|NCT02634801|ACTIVE_COMPARATOR|Methotrexate|"7.5 mg starting dose up to 30 mg MTX given orally once a week until week 24.~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks."
62059411|NCT02028832|EXPERIMENTAL|PIM consult and service provision|Pediatric integrative medicine service (PIM) through which pediatric inpatients will have the option of supplementing their usual care with acupuncture/acupressure, massage, and/or reiki
62263148|NCT04098770|NO_INTERVENTION|Conventional treatment|Without Allogeneic Adoptive Immune Therapy but conventional treatment (anti-opportunistic infections , cART and other treatments) should be received
62263149|NCT04352959|ACTIVE_COMPARATOR|mouth rinse with antiviral|
62619619|NCT04888858|EXPERIMENTAL|Epidural Analgesia|All subjects will be given epidural analgesia to treat their labor pain. As part of standard protocol for all patients who receive a labor epidural, the epidural will then be tested using 3ml of 1.5% lidocaine and 1:200,000 epinephrine test solution, and the epidural catheter will then be loaded with 10ml of 0.125% bupivacaine solution. The epidural catheter will then be connected to a programmed intermittent epidural bolus pump which will administer 5ml of a 0.125% bupivacaine/2mcg fentanyl solution every 30minutes. The first dose will be given following 30minutes after the loading dose. 30 minutes after loading the loading dose and after the first pump dose has been given, we will assess the VAS pain scores and the level of the analgesic based on decreased sensation to ice.
62447544|NCT02327000|EXPERIMENTAL|GLA5PR GLARS-NF1 tablet 600mg|GLA5PR GLARS-NF1 tablet 600mg/day(Pregabalin 300mg, 2 tablets 1 times a day, after meal)
62619620|NCT00845676|EXPERIMENTAL|Pegylated interferon alfa-2a + Ribavirin|Pegylated interferon alfa-2a + Ribavirin
62845689|NCT00773318|EXPERIMENTAL|A|"Patients with histologically proven AJCC stages I - II - III prostate cancer including men with clinical T3N0M0 disease, men with PSA \> 10 mg/ml, and men with Gleason score of 8-10. Prostate cancer patients scheduled for prostatectomy and pelvic lymph node dissection (CLND).~Arm A = SPECT/CT guided LM/SL versus CLND"
62845690|NCT02657473|ACTIVE_COMPARATOR|TIS 300mg once daily|Tobramycin inhalation solution (TIS) 300mg once daily for at least 9 months and up to 12 months
62845691|NCT02657473|PLACEBO_COMPARATOR|Placebo once daily|Saline 0.9% inhalation solution 300mg once daily for at least 9 months and up to 12 months
62845692|NCT06517485|EXPERIMENTAL|Dose Expansion - Ovarian Cancer|"Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, new groups of patients will receive XMT-1536 (upifitamab rilsodotin) at this fixed-dose.~This cohort is closed to enrollment."
62845693|NCT06517485|EXPERIMENTAL|Dose Expansion - NSCLC adenocarcinoma|"Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, new groups of patients will receive XMT-1536 (upifitamab rilsodotin) at this fixed-dose.~This cohort is closed to enrollment."
62263150|NCT04352959|PLACEBO_COMPARATOR|mouth rinse without antiviral|
62447545|NCT04053842|EXPERIMENTAL|Multi-modality prostate cancer imaging|The study requires eligible patients to complete one imaging session at St. Joseph's Health Care to begin within 6 weeks of the scheduled Radical Prostatectomy. Imaging will consist of simultaneous multiparametric MRI (mpMRI), sodium MRI and positron emission tomography (PET) with a radio-labeled probe for prostate-specific membrane antigen (PSMA).
62845694|NCT01956916|EXPERIMENTAL|Probiotics|Capsules containing lyophilized 6x10\^9 Colony Forming Units (CFU)/die of Lactobacillus rhamnosus GG (LGG)
62263151|NCT02907294|EXPERIMENTAL|PBF-999|
62263152|NCT02907294|PLACEBO_COMPARATOR|Placebo|
62263153|NCT02318862|OTHER|GERD|Those who have abnormal pH and abnormal esophageal mucosa and those who have abnormal pH and normal esophageal mucosa and are scheduled for standard of care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
62263154|NCT02318862|OTHER|non-GERD|Those who have normal pH and normal esophageal mucosa and are scheduled for standard of care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
62263155|NCT01758939||Hepatitis C virus infected patients|
62263156|NCT03155581|OTHER|User intervention|Bilingual key women from Somalia and Pakistan trained as peer educators for their respective communities will meet the women to increase awareness regarding the importance of cervical cancer prevention and to help peers overcome detected barriers and increase attendance to screening during meetings with the women organised according to their practical needs, using videos and interactive material
62447546|NCT01193608|EXPERIMENTAL|0.5 mg/kg AAB-003|
62447547|NCT01193608|EXPERIMENTAL|1 mg/kg AAB-003|
62447548|NCT01193608|EXPERIMENTAL|2 mg/kg AAB-003|
62447549|NCT01193608|EXPERIMENTAL|4 mg/kg AAB-003|
62845695|NCT01956916|PLACEBO_COMPARATOR|Placebo|Capsules containing maltodextrin
62845696|NCT03238690|EXPERIMENTAL|Controlled Cardiac Reloading|Heart failure patients with recent LVAD implantation after an optimum unloading phase, will undergo controlled cardiac reloading through LVAD speed adjustment reductions in a controlled reloading phase
62447550|NCT01193608|EXPERIMENTAL|8 mg/kg AAB-003|
62447551|NCT01193608|PLACEBO_COMPARATOR|Placebo|
62619621|NCT06006637|EXPERIMENTAL|CognilumTM|During the study participants will be wear the transcranial photobiomodulation device Cognilum. The device will administer the stimulation of near infrared light (830nm) to specific areas of the child's brain.
62619622|NCT06006637|SHAM_COMPARATOR|Sham control|During the study participants will wear the transcranial photobiomodulation device. The device will not be turned on and therefore no brain stimulation with near infrared light (830nm) will be provided.
62619623|NCT01362023|NO_INTERVENTION|control|Control pupils follow their usual activities
62619624|NCT01362023|EXPERIMENTAL|lifestyle counseling|"In 3 academic years, the intervention program consisted of three components:~1. Classroom practice by HPA to highlight healthy lifestyle habits~2. Teaching practice by HPA using books designed to include the nutritional objectives~3. Parental activities included with their children~In each of 12 activities (1 h/activity), the classroom practice consisted of three components:~1. Experimental development of activities regarding each healthy lifestyle habit~2. Assessment of activity performed in classroom~3. An activity developed for use at home"
62619625|NCT00600314||High risk|Patients who are at high risk of developing acute or chronic GVHD
62619626|NCT00600314||GVHD|Patients who currently have either grade II or greater acute GVHD, or clinically extensive chronic GVHD
62619627|NCT01753414|OTHER|Surgery|Complete resection, i.e., removal of the primary tumor with at least a 2 cm margin together with nodal dissection/sampling
62059412|NCT01395823|OTHER|ergocalciferol supplementation|
62059413|NCT01395823|PLACEBO_COMPARATOR|placebo|
62059414|NCT00990340|ACTIVE_COMPARATOR|Tev-Tropin® needle-free|needle-free injection method (T-jet®)for 14 days before cross-over to other arm
62059415|NCT00990340|ACTIVE_COMPARATOR|Tev-Tropin® by Needle-syringe|needle-syringe injection method for 14 days before cross-over to other arm
62059416|NCT06205732||TACE+PD-(L)1+TKI|Application of TACE, TKI, and immunotherapy in patients with intermediate and advanced liver cancer.
62059417|NCT06205732||TACE alone|Application of TACE in patients with intermediate and advanced liver cancer.
62059418|NCT03177122|EXPERIMENTAL|Myo-Inositol|1g Myo-inositol per day, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) + 400 ug of Folic acid
62059419|NCT03177122|NO_INTERVENTION|No intervention|Standard care: 400 ug of Folic acid
62059420|NCT03551314|ACTIVE_COMPARATOR|Nasal Intermittent Positive Pressure|"In this group, soon after extubation, the newborns will be studied initially in NIPPV for one hour. Infants will be studied in supine while in their incubator.~NIPPV: Nasal Intermittent Positive Pressure Ventilation"
62263157|NCT03155581|OTHER|Health professional intervention|"General practitioners working in the intervention areas are contacted by letter and an appointment is made for a short meeting to increase awareness of the health professionals involved in screening working in the chosen areas. Material is given(posters and reminding objects) to remind practitioners of the intervention and invite women attending to the center to make an appointment with their GP. No change in screening as usual will be implemented for health professionals working in the control areas."
62263158|NCT01227486||Obese patients for planned surgery and endotracheal intubation|
62263159|NCT02709564|PLACEBO_COMPARATOR|Group A|400 mg placebo
62619628|NCT01753414|EXPERIMENTAL|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy (SBRT) given every other day 11 Gy in 5 fractions to a total dose of 55 Gy in 10-15 days with an inter-fraction interval of 2-3 days
62619629|NCT03541447|EXPERIMENTAL|Tolvaptan plus Octreotide LAR / Tolvaptan plus Placebo|Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of Octreotide LAR (two 20 mg i.m. injections). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of placebo (two i.m. injections of 0.9% NaCl solution)
62619630|NCT03541447|EXPERIMENTAL|Tolvaptan plus placebo/Tolvaptan plus Octreotide LAR|Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of placebo (two i.m. injections of 0.9% NaCl solution). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of Octreotide LAR (two 20 mg i.m. injections).
62619631|NCT00707642|EXPERIMENTAL|1|Low Dose WN-80E API (5 µg) + Alhydrogel (3.5 mg)
62059421|NCT03551314|ACTIVE_COMPARATOR|Continuous Positive Airway Pressure|"In this group, soon after extubation, the newborns will be studied initially in CPAP for one hour. Infants will be studied in supine while in their incubator.~CPAP: Continuous Positive Airway Pressure"
62059422|NCT01247428|EXPERIMENTAL|MiStent SES|The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
62059423|NCT00118092|EXPERIMENTAL|Treatment (tanespimycin)|Patients receive 17-N-allylamino 17-demethoxygeldanamycin (17-AAG) IV over 2-6 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses of treatment beyond documentation of CR.
62059424|NCT06058390|EXPERIMENTAL|Group 1|Participants will receive Bepirovirsen vial administered by Healthcare Professionals (HCP).
62059425|NCT06058390|EXPERIMENTAL|Group 2|Participants will receive Bepirovirsen PFS SSD administered by HCP.
62059426|NCT06058390|EXPERIMENTAL|Group 3|Participants will receive Bepirovirsen PFS SSD self- administered with training by HCP.
62059427|NCT06058390|EXPERIMENTAL|Group 4|Participants will receive Bepirovirsen PFS SSD self- administered with no training by HCP.
62059428|NCT05553639|EXPERIMENTAL|HB-302/HB-301 Alternating 2-Vector Therapy Intravenously (IV)|HB-302/HB-301 Alternating 2-Vector Therapy Intravenously (IV)
62059429|NCT00993239|EXPERIMENTAL|Birinapant (TL32711)|
62263160|NCT02709564|ACTIVE_COMPARATOR|Group B|400 microgram misoprostol
62619632|NCT00707642|EXPERIMENTAL|2|Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)
62619633|NCT00707642|EXPERIMENTAL|3|High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)
62619634|NCT00707642|EXPERIMENTAL|4|High Dose WN-80E API (50 µg), no adjuvant
62845697|NCT02452515|EXPERIMENTAL|BAY1142524 (5 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
62845698|NCT02452515|EXPERIMENTAL|BAY1142524 (10 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
62059430|NCT01056588|PLACEBO_COMPARATOR|Control Condition|In this condition, participants will receive reinforcement for timely breath samples with no contingency for a specific breath CO level.
62059431|NCT01056588|ACTIVE_COMPARATOR|CO-Contingent|In this condition, participants will receive reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking.
62845699|NCT02452515|EXPERIMENTAL|BAY1142524 (25 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
62845700|NCT02452515|EXPERIMENTAL|BAY1142524 (50 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
62059432|NCT02178644|EXPERIMENTAL|Chemo with concomitant Capecitabine and KD018|Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
62059433|NCT04338854|EXPERIMENTAL|Root canal treatment|It's one of the restorative groups with LA (Local Anesthesia). An aerator and micromotor were used as cavity preparation in this group. Only conventional root canal treatment and extirpation were planned for the children included in the root canal treatment group in the measurement session.
62845701|NCT01646229|ACTIVE_COMPARATOR|Polymyxin-B hemoperfusion|In the HEMOPERFUSION group, a veno-venous dialysis catheter type GamCath 12 F, 3 lumen will be inserted instead of a regular double or triple-lumen central venous catheter, and connected to the Toraymyxin® (PMX-20-R) device for endotoxin adsorption by hemoperfusion with the DECAPSMART pump. The length of the hemoperfusion will be a minimum of 120 min and started just before the beginning of the surgical intervention in the OR and stopped at the end of surgery.
62059434|NCT04338854|EXPERIMENTAL|Pulpotomy treatment|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group. it was noted that at least one of the approximal surfaces of the teeth had decay and iron sulfate (ViscoStat®, UltraDent, South Jordan, USA) was used as pulpotomy material
62059435|NCT04338854|EXPERIMENTAL|two-surface restoration with Local Anesthesia|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group. A Tofflemire matrix retainer and 0.05 mm thick matrix band (Hahnenkratt, Königsbach-Stein, Germany) were used in groups with a two-surface cavity.
62059436|NCT04338854|EXPERIMENTAL|one surface restoration with Local Anesthesia|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group.
62059437|NCT04338854|EXPERIMENTAL|two-surface restoration without Local Anesthesia|An aerator and micromotor were used as cavity preparation in this group. A Tofflemire matrix retainer and 0.05 mm thick matrix band (Hahnenkratt, Königsbach-Stein, Germany) were used in groups with a two-surface cavity.
62059438|NCT04338854|EXPERIMENTAL|one surface restoration without Local Anesthesia|An aerator and micromotor were used as cavity preparation in this group.
62059439|NCT04338854|EXPERIMENTAL|fluoride application by disposable arch tray|It's one of the protective groups.Only the micromotor was used for polishing purposes in the protective treatment groups. 2% NaF (Polimo® IMICRYL, Konya, Turkey) was preferred in groups who received fluoride application.
62619635|NCT05574829||Patients under pressure support ventilation|Patients under assisted mechanical ventilation monitored with esophageal manometry and electrical activity of the diaphragm
62059440|NCT04338854|EXPERIMENTAL|fluoride application by cotton roll|It's one of the protective groups. Only the micromotor was used for polishing purposes in the protective treatment groups 2% NaF (Polimo® IMICRYL, Konya, Turkey) was preferred in groups who received fluoride application.
62059441|NCT04338854|EXPERIMENTAL|Fissure Sealant group|It's one of the protective groups. Only the micromotor was used for polishing purposes in the protective treatment groups.
62059442|NCT05930301||single|Mode of administration：IV Administration dosage：10\^7/100ml Dosing frequency：Every three weeks
62263161|NCT00265538|NO_INTERVENTION|Arm 1 (Pure Control Group)|Pure control (no intervention letter);
62263162|NCT00265538|NO_INTERVENTION|Arm 2 (Contaminated Control Group)|Intervention control (patient does not receive intervention letter, but provider sees other patients who may bring in letter);
62263163|NCT00265538|EXPERIMENTAL|Arm 3 (Intervention Group A)|Intervention group A (the intervention is a letter only mailed to the subject); This intervention group receives an educational letter, which is the intervention. It is an educational intervention only.
62619636|NCT03016468|EXPERIMENTAL|Parenteral Remodulin then Oral Treprostinil|
62263164|NCT00265538|EXPERIMENTAL|Arm 4 (Intervention Group B)|Intervention group B (intervention letter A + financial incentive for discussion w/ provider and 6 month copay reimbursement); This group receives the same educational intervention as Group A, but also receives the Financial incentive, which is an added intervention.
62619637|NCT06454643|ACTIVE_COMPARATOR|Control|"Patients received flucloxacillin and ceftriaxone 60 minute before incision and then continued for 48 hours as follows:~* Flucloxacillin 2g given before surgery then 1g \* 4 for 48 hours after operation.~* Ceftriaxone 1g given before surgery then 1g \* 2 for 48 hours after operation."
62263165|NCT00265538|EXPERIMENTAL|Arm 5 (Intervention Group C)|Intervention group C (intervention letter A, financial incentive for discussion w/ provider + copay reimbursement, PLUS reminder phone call 1-3 days prior to primary care visit). This group receives the same intervention as Group B, but with the added intervention of a reminder phone call to test whether additional prompting is needed to make the intervention more effective.
62263166|NCT01918839|EXPERIMENTAL|VINCI Plus|One side has been treated with VINCI Plus
62263167|NCT01918839|ACTIVE_COMPARATOR|Restylane-L|One side has been treated with Restylane-L
62263168|NCT01487252|ACTIVE_COMPARATOR|Healthy Controls|
62263169|NCT01487252|ACTIVE_COMPARATOR|Delayed Sleep Phase Disorder|
62447552|NCT04291079|EXPERIMENTAL|Part A1: Dose Escalation|Part A1 will determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of SRK-181 as a single agent and will determine the recommended Phase 2 dose (RP2D) of SRK-181 as a single-agent.
62447553|NCT04291079|EXPERIMENTAL|Part A2: Dose Escalation|Part A2 will determine the MTD or MAD of SRK-181 in combination with anti-PD-(L)1 antibody therapy and will determine the RP2D of SRK-181 in combination with anti-PD-(L)1 antibody therapy for use in Part B.
62447554|NCT04291079|EXPERIMENTAL|Part B: Dose Expansion|In Part B, parallel cohorts of patients with Non-Small Cell Lung Cancer (NSCLC), Urothelial Carcinoma (UC), Cutaneous Melanoma (MEL), Clear Cell Renal Cell Carcinoma (ccRCC), Head and Neck Squamous Cell Carcinoma (HNSCC), or other advanced or metastatic solid tumor type that is not NSCLC, UC, MEL, or ccRCC will be enrolled to confirm the tolerability of the RP2D of SRK-181 (determined in Part A2) and to evaluate the anti-tumor activity of SRK-181 in combination with an anti-PD-(L)1 antibody therapy.
62447555|NCT04291079|EXPERIMENTAL|Long Term Extension Phase (LTEP)|"Patients may continue treatment in a LTEP:~* Part A1: Patients may continue treatment with SRK-181 as a single agent at the RP2D in the LTEP following 3 cycles of treatment with SRK-181 as a single agent in Part A1.~* Part A2: Patients may continue treatment with SRK-181 at the RP2D in combination with anti-PD-(L)1 antibody therapy in the LTEP following 3 cycles of treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy in Part A2.~* Part B: Patients may continue treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy following 9 cycles of treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy in Part B"
62447556|NCT04630197|EXPERIMENTAL|e-CBT|16 weekly sessions will be conducted through OPTT and consist of approximately 30 slides and interactive therapist videos. The content and format will mirror in-person CBT for OCD. The connection between thoughts, behaviours, emotions, physical reactions, and the environment will be a focus. Moreover, mindfulness, body scanning, self-care, goal setting, thinking errors, the 5-part model, thought records, and ERP will be incorporated. Slides will highlight different topics each week and include general information, an overview of skills, and homework on that topic. The homework will be submitted through OPTT and reviewed by therapists with personalized feedback provided within 3 days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. After each completion of the e-CBT program, participants will be interviewed to investigate their experience using OPTT and their perception of how the treatment went.
62447557|NCT05107440|EXPERIMENTAL|BREATHE|This is an eight-week intervention involving two sessions per week, hosted virtually on Zoom. The main session is scheduled to last 60 min and the session hosts remain online for an additional 15 minutes to answer individual questions on the management of symptoms and activities that have not been addressed during the main session. The content was developed based on clinical experience, best available evidence for the management of specific symptoms (chronic fatigue, post-exertional malaise, breathing discomfort) in other conditions, including post-viral syndromes, and the current understanding and recommendations for rehabilitation of people living with long COVID. Long COVID can be isolating, and challenges often interfere with everyday lifestyle and socialization. The investigators have incorporated breakout rooms (where the group is divided into two smaller groups based on current activity limitations) to include elements of peer support.
62447558|NCT04001608|EXPERIMENTAL|Seraprevir and sofosbuvir|Subjects will receive oral tablets of Seraprevir 100mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 12.
62447559|NCT02455700|ACTIVE_COMPARATOR|Hand driven enamel reduction|This group will have enamel reduction in the lower incisor region carried out using hand held devices
62447560|NCT02455700|ACTIVE_COMPARATOR|Rotary ( motor driven) device|This group will ahve enamel reduction in the lower incisor region carried out using a rotary (motor driven) device
62447561|NCT05791760|EXPERIMENTAL|Compassion-focused therapy (CFT)|
62447562|NCT02264951|ACTIVE_COMPARATOR|A meal containing carrot and tributyrin|A meal containing 200 g grated carrot and 0.0216 mol tributyrin; blood test taken from 0 - 2 hours postprandial
62447563|NCT02264951|ACTIVE_COMPARATOR|A meal containing carrot and C8-diet oil|A meal containing 200 g grated carrot and 0.0216 mol of C8-diet oil; blood test taken from 0 - 2 hours postprandial
62447564|NCT02264951|ACTIVE_COMPARATOR|A meal containing carrot and olive oil|A meal containing 200 g grated carrot and 0.0216 mol of olive oil; blood test taken from 0 - 2 hours postprandial
62447565|NCT02264951|PLACEBO_COMPARATOR|A meal containing carrot|A meal containing 200 g grated carrot; blood test taken from 0 - 2 hours postprandial
62447566|NCT03164148|EXPERIMENTAL|Case Evaluation by T-REX TRI00A|Case evaluation consists of confirmation of hospital visit dates, any side effects of device, T-REX TRI00A
62447567|NCT00619632|EXPERIMENTAL|1|LC- Primary-care based lactation consultant meeting women pre- and post-natally.
62447568|NCT00619632|EXPERIMENTAL|2|Provider Prompt
62447569|NCT00619632|EXPERIMENTAL|3|LC+Provider Prompt
62447570|NCT00619632|NO_INTERVENTION|Control|
62447571|NCT01548872|ACTIVE_COMPARATOR|crystalloid cardioplegia solution|After aortic cross clamp 30ml/kg will be administered
62447572|NCT01548872|ACTIVE_COMPARATOR|HTK solution|After aortic cross clamp 50ml/kg will be administered
62263170|NCT02575768||Severe AS: asymptomatic|Asymptomatic
62447573|NCT05505123|EXPERIMENTAL|sevoflurane|induction and maintenance with sevoflurane
62845702|NCT01646229|ACTIVE_COMPARATOR|Control|"In the CONTROL group, the administration of fluids (250 to 500ml crystalloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP \> 65mmHg, HR \< 90/min, CVP between \> 8 and 12 \< mmHg, urinary output \> 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° \> 35.5°C, Sp02 \> 95%, lactate \< 2.5 mMol/L, normalisation of the BE.~At the discretion of the attending anaesthesiologist with the FMH level, a PiCCO monitoring, a transoesophageal echography, or a pulmonary artery catheter, will be inserted to complement the standard hemodynamic monitoring if deemed necessary."
62845703|NCT01034670|EXPERIMENTAL|endoscopy arm|imaging performed in conjunction with the regularly scheduled endoscopy during which the newer imaging techniques will be used to detect premalignant conditions. includes wide field fluorescence, microscopy, Raman spectroscopy and/or ultrasound.
62845704|NCT02935439|ACTIVE_COMPARATOR|Cell-Phone Intervention Arm|A standard cell phone system sent web-browser messages daily to ask about their weight and symptoms of heart failure. Participants received up to 3 daily messages 15 minutes apart at a time of their choosing for 90 days. Participants were given a mobile phone for the 90 day period and a weight scale.
62447574|NCT05505123|EXPERIMENTAL|propofol|induction and maintenance with propofol
62845705|NCT02935439|NO_INTERVENTION|Usual Care|Usual Care participants continued to receive care in the Heart Failure Clinic. All subjects were enrolled in the study for 90 days. Participants were given a weight scale.
62845706|NCT04602871|EXPERIMENTAL|COVID 19 Positive patients|Patients with COVID-19, qPCR for SARS-CoV-2 confirmed
62845707|NCT04602871|OTHER|Healthy subjects|COVID-19 Negative subjects
62845708|NCT06275945|EXPERIMENTAL|Voro Urologic Scaffold Group|"Subjects undergo radical prostatectomy procedure as part of their stand of care treatment for their prostate cancer. The Voro Urologic Scaffold is placed during the prostatectomy procedure after prostate removal. The device is placed over the urethral stump in its compressed configuration. With the device compressed at the pelvic floor, the urethral stump is anastomosed with the bladder neck. The device is expanded and positioned over the anastomosed urethra and bladder neck. The distal end of the device is sutured in place and the proximal end of the device is sutured to the bladder.~The time of Voro Urologic Scaffold insertion and time of completion of device placement (i.e., final sutures placed) will be recorded.~Incision closure will proceed per institution standard of care for the radical prostatectomy procedure."
62447575|NCT01400113|EXPERIMENTAL|Asenapine|This group received 10mg asenapine sl x 1 dose
62845709|NCT01617746|EXPERIMENTAL|Ambrisentan|5mg od ambrisentan
62845710|NCT01617746|EXPERIMENTAL|Bosentan|62.5mg bosentan
62845711|NCT01617746|PLACEBO_COMPARATOR|Placebo|
62845712|NCT04797559|EXPERIMENTAL|SZMN Treatment Group|Patients randomized into the SZMN-treatment group will receive a bilateral single injection SZMN block under general anesthesia in the operating room. The injection will occur through the pterygomaxillary fissure into the pterygomaxillary fossa. Patients will receive 5 ml of local anesthestic per side.
62845713|NCT04797559|NO_INTERVENTION|Control Group|Patients in this group will receive the standard of care for T\&A procedures within the pediatric population.
62845714|NCT00785382|PLACEBO_COMPARATOR|1|
62845715|NCT00785382|EXPERIMENTAL|2|
62059443|NCT00691132|EXPERIMENTAL|PEITC - Placebo (short-term trial)|Participants are asked to smoke only deuterated NNK cigarettes (provided by the study) and record the exact number of cigarettes smoked and alcoholic drinks consumed each day for 1 month. Participants receive oral phenethyl isothiocyanate (PEITC) four times daily for 5 days in week 2 and oral placebo four times daily for 5 days in week 4. Participants keep a diary of all food and beverages consumed on the days that PEITC or placebo are taken.
62263171|NCT02575768||Severe AS: pure angina|Presence of exertional chest pain
62447576|NCT01400113|PLACEBO_COMPARATOR|Placebo|This group received placebo sl x 1 dose
62263172|NCT02575768||Normal controls|Healthy controls
62263173|NCT03972969|EXPERIMENTAL|In-person exercise group|facility-based structured exercise program
62447577|NCT01927757|EXPERIMENTAL|Etanercept|Participants received etanercept 50 mg administered subcutaneously once a week with methotrexate for 24 weeks
62447578|NCT01315145|ACTIVE_COMPARATOR|Percutaneous Lumbar Decompression|Patients receiving percutaneous decompression using the mild® Device Kit.
62447579|NCT01315145|ACTIVE_COMPARATOR|Lumbar Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
62263174|NCT03972969|EXPERIMENTAL|Remote exercise group|home-based structured exercise program
62263175|NCT03972969|ACTIVE_COMPARATOR|Control group|health education
62263176|NCT04678570|EXPERIMENTAL|Intervention Group-1|White Noise intervention and standard care, procedures will be applied.
62263177|NCT04678570|EXPERIMENTAL|Intervention Group- 2|The swaddling method and standard care, procedures will be applied.
62447580|NCT01568008||All participants|Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) eye drops at a dose and frequency as determined by the physician.
62447581|NCT03294538|EXPERIMENTAL|Generic Estradiol Vaginal Cream USP, 0.01%|Participants were to self-administer 2 grams (g) of generic Estradiol Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
62619638|NCT06454643|EXPERIMENTAL|Gentamicin|"Patients received flucloxacillin and gentamicin 60 minute before incision and then continued for 48 hours, as follows:~* Flucloxacillin 2g given before surgery then 1g \* 4 for 48 hours after operation.~* Gentamicin 2mg/kg of ideal body weight given before surgery, then 80 mg \*3 for 48 hours after surgery."
62619639|NCT02698709||Healthy corneas (C)|Corneas of normal candidates to refractive surgery who did not develop any sign of corneal ectasia after laser in situ keratomileusis during a two year follow-up period were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
62059444|NCT00691132|EXPERIMENTAL|Placebo - PEITC (short-term trial)|Participants receive oral placebo four times daily for 5 days in week 2 and oral PEITC four times daily for 5 days in week 4. Participants are also asked to smoke only deuterated NNK cigarettes, record the number of cigarettes smoked and alcoholic drinks consumed each day, and keep a food and beverage diary as in arm I.
62059445|NCT01023802||Neoadjuvant therapy for breast cancer|Women who present to the Internal Medicine Breast Cancer Clinic with breast cancer and who after discussion with the consulting surgeon and oncologist have agreed to undergo neoadjuvant chemotherapy or neoadjuvant hormone therapy.
62619640|NCT02698709||Overt keratoconus (Kc)|Whether both eyes manifested classic Kc-suggestive topographic features, such as corneal steepness higher than 47.20 diopters (D), superior-inferior asymmetry higher than 1.40 D and thinnest pachymetric reading lower than 500 micrometers. Such eyes were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
62619641|NCT02698709||Forme fruste keratoconus (FFKc)|Whether only one eye manifested classic Kc-suggestive topographic features, such as corneal steepness higher than 47.20 diopters (D), superior-inferior asymmetry higher than 1.40 D and thinnest pachymetric reading lower than 500 micrometers, and the fellow eye seemed unaffected. Such unaffected eyes were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
62263178|NCT04678570|EXPERIMENTAL|Intervention Group- 3|White Noise, swaddling method, and standard care, procedures will be applied.
62447582|NCT03294538|ACTIVE_COMPARATOR|Estrace Vaginal Cream USP, 0.01%|Participants were to self-administer 2 g of Estrace Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
62619642|NCT02488967|ACTIVE_COMPARATOR|Arm I (AC-->WP)|Patients receive doxorubicin hydrochloride IV over 15 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive paclitaxel IV over 60 minutes on day 1. Treatment repeats weekly for 12 courses in the absence of disease progression or unacceptable toxicity.
62845716|NCT03089905|EXPERIMENTAL|Sevoflurane/dexmedetomidine/remifentanil|"Dexmedetomidine: loading dose of 1mcg/kg over 10 minutes followed by an infusion of at 1 mcg/kg/hr.~Remifentanil: loading dose 1 mcg/kg over 2 minutes followed by an infusion starting at 0.1 mcg/kg/min or greater.~Sevoflurane: end tidal concentration of 0.6 -0.8% or less."
62845717|NCT03089905|ACTIVE_COMPARATOR|Sevoflurane|End tidal concentration of 2.5-3.0% or greater.
62845718|NCT04180124|EXPERIMENTAL|GaitRite|"Patients will walk on the GaitRite.~* forward walking at comfortable gait speed (6 x 10 meter)~* backward walking at comfortable gait speed (4 x 10 meter)"
62845719|NCT04180124|EXPERIMENTAL|Treadmill walking self-paced|"Patients will walk on the treadmill in self-paced mode. They can control walking speed by themselves.~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
62845720|NCT04180124|EXPERIMENTAL|Treadmill walking fixed speed - comfortable speed|"Patients will walk on the treadmill in fixed speed mode. They will walk at comfortable gait speed, which is determined in the familiarization period.~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
62845721|NCT04180124|EXPERIMENTAL|Treadmill walking fixed speed - fast speed|"Patients will walk on the treadmill in fixed speed mode. They will walk at a gait speed, which is 1 minimal clinical difference faster than their comfortable gait speed.~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
62447583|NCT03294538|PLACEBO_COMPARATOR|Vehicle Vaginal Cream|Participants were to self-administer 2 g of vehicle vaginal cream once daily at approximately the same time of the day for 7 consecutive days.
62619643|NCT02488967|EXPERIMENTAL|Arm II (AC-->WP + carboplatin)|Patients receive doxorubicin hydrochloride and cyclophosphamide as in Arm I. Patients then receive paclitaxel IV over 60 minutes on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
62619644|NCT04202536|EXPERIMENTAL|TDF switch to Besifovir Dipivoxil Maleate|Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Besifovir Dipivoxil Maleate 183mg daily
62619645|NCT04202536|ACTIVE_COMPARATOR|Maintaining on TDF|Maintaining on Tenofovir Disoproxil Fumarate(TDF) 300mg daily
62619646|NCT00419159|EXPERIMENTAL|Everolimus (RAD001) 70 mg/week|
62619647|NCT00419159|EXPERIMENTAL|Everolimus (RAD001) 10 mg/day|
62619648|NCT02710552|ACTIVE_COMPARATOR|Three antihypertensive Drugs|Patients will be treated with Tripliam, that is a commercially available fixed low-dose combination of three antihypertensive drugs, that is 5 mg/daily perindopril, 1,25 mg/daily indapamide and 5 mg/day amlodipine
62059446|NCT01403025||Liraglutide|
62059447|NCT01494155|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine with chemoradiation
62059448|NCT02583438|EXPERIMENTAL|Lifestyle intervention|
62263179|NCT04678570|NO_INTERVENTION|No Intervention Group|Standard care and procedures to be applied.
62263180|NCT01676675|EXPERIMENTAL|7.5μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml in 30 adolescents aged 12-17 years old on day 0, 21
62263181|NCT01676675|EXPERIMENTAL|15μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml in 30 adolescents aged 12-17 years old on day0,21
62263182|NCT01676675|EXPERIMENTAL|30μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml in 30 adolescents aged 12-17 years old on day0,21
62619649|NCT02710552|ACTIVE_COMPARATOR|Two antihypertensive drugs|Patients will be treated with Reaptan, that is a commercially available fixed high-dose combination of two antihypertensive drugs, that is 10 mg/daily perindopril and 5 mg/day amlodipine
62619650|NCT04649970||malignant uropathy|Antegrade double-J stent
62619651|NCT01198535|EXPERIMENTAL|Arm A (RO4929097, cetuximab)|Patients in Arm A will receive cetuximab at the standard dose: 400 mg/m2 IV loading dose on Day 1 followed by cetuximab 250 mg/m2 IV weekly. The RO4929097 will be dose escalated starting at 20 mg given daily 3 days on, 4 days off, weekly. The dose levels of RO4929097 to be explored will be 20 mg, 30 mg, 45 mg, 90 mg, 140 mg given days 1-3 weekly. No intrapatient dose escalation will be allowed.
62619652|NCT01198535|EXPERIMENTAL|Arm B (RO4929097, cetuximab)|Patients in Arm B will receive cetuximab 200 mg/m2 IV weekly without a loading dose. The RO4929097 will be dose escalated starting at 20 mg given daily 3 days on, 4 days off, weekly. The dose levels of RO4929097 to be explored will be 20 mg, 30 mg, 45 mg, 90 mg, 140 mg given days 1-3 weekly. No intrapatient dose escalation will be allowed.
62619653|NCT02102672|PLACEBO_COMPARATOR|Sugar pill|Placebo 1 pill bid, 3 months
62619654|NCT02102672|EXPERIMENTAL|Trimetazidine|Trimetazidine 35 mg bid for 3 months
62619655|NCT06468163|EXPERIMENTAL|Catheter group|Using catheter after knee DAIR surgery.
62619656|NCT06468163|ACTIVE_COMPARATOR|None-catheter group|Without using catheter after knee DAIR surgery.
62845722|NCT04180124|EXPERIMENTAL|Treadmill walking fixed speed - backward walking|"Patients will walk on the treadmill in fixed speed mode. Patient will walk backwards on the treadmill if they are able to.~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
62845723|NCT06035419|EXPERIMENTAL|education|A specially prepared training program for immigrant mothers was applied to the mothers in the experimental group.
62845724|NCT06035419|NO_INTERVENTION|control|No interventions were made to the control group other than the routine interventions of the clinic (unstructured training practices given by the individual effort of the nurse).
62845725|NCT05886348|EXPERIMENTAL|Model-A Novel Spectacle lens|
62845726|NCT05886348|EXPERIMENTAL|Model-B Novel Spectacle lens|
62619657|NCT01742715|EXPERIMENTAL|PEEP by Best oxygenation|"Set Positive End Expiratory Pressure (PEEP) at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg Ideal Body Weight (IBW). fraction of inspired oxygen (FiO2) is set to 60%.~Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with arterial blood gas (ABGs), and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% Partial Oxygen tension (PaO2) PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected."
62059449|NCT05222464|OTHER|Standard of Care Intervention|Standard of care intervention - The intervention will consist of 4 classes of standard of care treatments, namely, lifestyle modifications, complementary and alternative medicine (CAM) therapies, prescription medications, or adjustment of anti-cancer therapy.
62059450|NCT04067401|EXPERIMENTAL|Wingman Connect|Wingman-Connect total training time is 5 hours, typically spread over three consecutive training 'blocks'(or days), plus 1-hour of booster training (one month later).
62263183|NCT01676675|EXPERIMENTAL|7.5μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
62619658|NCT01742715|EXPERIMENTAL|PEEP by Best Compliance|"In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.~Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed."
62845727|NCT05886348|OTHER|Single Vision Spectacle lens|
62845728|NCT01715012|EXPERIMENTAL|ST266|ST266 sprayed to the skin graft and donor site
62845729|NCT01715012|PLACEBO_COMPARATOR|Saline|Saline (placebo)sprayed to the skin graft and donor site
62845730|NCT03292172|EXPERIMENTAL|Group 1 - Escalation Dose: RO6870810 + Atezolizumab|Participants will be administered escalating doses of RO6870810 (0.3 milligram per kilogram \[mg/kg\], 0.45 mg/kg, and 0.65 mg/kg) subcutaneously (SC) once daily (QD) along with fixed dose of atezolizumab 1200 mg intravenously (IV) on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
62263184|NCT01676675|EXPERIMENTAL|15μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
62263185|NCT01676675|EXPERIMENTAL|30μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
62845731|NCT03292172|EXPERIMENTAL|Group 2 - Sequential Dose: RO6870810 + Atezolizumab|Participants will be administered RO6870810 monotherapy (starting dose 0.30 mg/kg) during the first 14 days of 21-day Run-in period. Following the Run-in period, participants will continue to receive RO6870810 at the same dose in combination with fixed dose of atezolizumab 1200 mg IV every 3 weeks in 21-day cycles.
62263186|NCT01676675|PLACEBO_COMPARATOR|0/0.5ml in adolescents (12-17 years old)|0/0.5ml placebo in 30 adolescents aged 12-17 years old on day 0, 21
62263187|NCT01676675|PLACEBO_COMPARATOR|0/0.5ml in adults(18-60 years old)|0/0.5ml placebo in 30 adults aged 18-60 years old on day 0, 21
62845732|NCT03292172|EXPERIMENTAL|Group 3 - Expansion in TNBC Group: RO6870810 + Atezolizumab|Participants will be administered dose of RO6870810 established in Group 1 (either 0.3 mg/kg, 0.45 mg/kg, or 0.65 mg/kg) SC QD along with fixed dose of atezolizumab 1200 mg IV on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
62845733|NCT03292172|EXPERIMENTAL|Group 4 - Expansion in OC Group: RO6870810 + Atezolizumab|Participants will be administered dose of RO6870810 established in Group 1 (either 0.3 mg/kg, 0.45 mg/kg, or 0.65 mg/kg) SC QD along with fixed dose of atezolizumab 1200 mg IV on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
62845734|NCT03507387|EXPERIMENTAL|Intramuscular phenylephrine group|Patients in intramuscular phenylephrine group will receive spinal anesthesia with bupivacaine. 5 mg (1ml) phenylephrine intramuscular injection will be given into the gluteus maximus muscle before anesthesia.1ml of 0.9% normal saline intravenous injection will be given after the subarachnoid injection is completed.
62263188|NCT02840695||AS patients|Patients registered in the Swedish Patient Registry with active AS treated with or without biological DMARD according to the Swedish Prescribed Drugs Registry, with or without spinal fractures
62845735|NCT03507387|ACTIVE_COMPARATOR|Intravenous phenylephrine group|Patients in intravenous phenylephrine group will receive spinal anesthesia with bupivacaine. 1ml of 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia.100ug (1ml) phenylephrine intravenous injection will be given after the subarachnoid injection is completed.
62263189|NCT01339806|OTHER|Standard of Care for mTBI Provider Arm|Arm 1: Psychoeducational Control Group. Individuals assigned to arm 1 will receive psychoeducational materials specifically adapted for persistent management of symptoms and routine follow-up with medical providers (every three weeks). Additionally, subjects assigned to this group will receive medical care (e.g., psychopharmacological management of depression) and/or referral for symptom management (e.g., vestibular rehabilitation) of non-cognitive complaints, consistent with the current standard of care treatment model for managing post-concussive symptoms (see Figure below adapted with permission from authors; Brenner et al., 2009).
62845736|NCT03507387|PLACEBO_COMPARATOR|Placebo group|Patients in intravenous phenylephrine group will receive spinal anesthesia with bupivacaine. 1ml of 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia. 1ml of 0.9% normal saline intravenous injection will be given after the subarachnoid injection is completed.
62845737|NCT04139993|EXPERIMENTAL|Treatment (RBX7455)|Prior to standard of care surgery, patients receive RBX7455 orally (PO) 4 days a week for 2-4 weeks in the absence of disease progression or unacceptable toxicity.
62845738|NCT01613898||CTX Group|
62845739|NCT03346642|EXPERIMENTAL|GVD and SHR-1210 with or without Decitabine|This is a two stage study. For the first stage, the participants will receive the combination of GVD chemotherapy and PD-1 antibody SHR-1210. The patients enrolled into the second stage will received the combination of GVD and SHR-1210 with low-dose decitabine primed.
62845740|NCT04603027|EXPERIMENTAL|Cohort 1|75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 0.8 x 10\^11 cells, capsule, once daily, 16 weeks
62845741|NCT04603027|EXPERIMENTAL|Cohort 2|75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 3.2 x 10\^11 cells, capsule, once daily, 16 weeks
62845742|NCT04603027|EXPERIMENTAL|Cohort 3|75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 8.0 x 10\^11 cells, capsule, once daily, 16 weeks
62845743|NCT06109961|EXPERIMENTAL|Active Hyperbaric Oxygen Therapy|The active Hyperbaric Oxygen Therapy (HBOT) arm will receive 100% oxygen at 2.0-2.5 atmospheres (ATM).
62845744|NCT06109961|OTHER|Standard of care treatment|The standard of care for perianal Crohn's disease (PCD) involves conventional therapies such as immunosuppressive agents and biologics, which can be used to induce and maintain fistula remission. Tumor necrosis factor (TNF) antagonists are considered the first-line therapy for PCD, and clinical trial evidence supports their efficacy in achieving short-term fistula remission.
62845745|NCT02609113|ACTIVE_COMPARATOR|Strong Magnetic Wristband|Magnetic wristband of 1,795 Gauss strength
62845746|NCT02609113|PLACEBO_COMPARATOR|Weaker Magnetic Wristband|Magnetic wristband of 5 Gauss strength.
62059451|NCT04067401|ACTIVE_COMPARATOR|Stress Management|The control training condition will consist of a 2 hr. informational training that provides an overview of the human stress response system and strategies to manage stress. The training will be delivered through lecture format using PowerPoint, supplemented by brief videos and interactive discussion.
62263190|NCT01339806|EXPERIMENTAL|Computer Based Therapy Group|"Arm 2: Non-therapist directed computerized cognitive rehabilitation. Individuals assigned to treatment arm 2 will receive ten hours of in-clinic, computerized treatment per week throughout the 6-week treatment trial. Participants will be scheduled for 2 hours per day, proctored by clinic staff (certified recreation therapist or neuropsychology technician) who will be responsible for recording daily performance, providing positive reinforcement of participation, and effort. Computer programs selected for this treatment trial include both skill-specific training (e.g., attention processes) and general cognitive activation. These computer programs are commercially available and advertised as brain fitness or brain training."
62447584|NCT02271555|ACTIVE_COMPARATOR|sevoflurane-remifentanil (Group SR)|Sevoflurane will be initiated, at 8% for anesthesia induction until loss of consciousness will achieve, at which point it will be discontinued. After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
62263191|NCT01339806|EXPERIMENTAL|Cognitive Rehab Group|"Arm 3: Therapist-directed individualized cognitive rehabilitation. Individuals assigned to treatment arm 3 will receive 10 hours of individual and group cognitive rehabilitation treatment (including homework assignments) per week conducted by credentialed speech therapists and occupational therapists. The treatment components will include five hours of weekly individual therapy (one-hour sessions; two hours focused on compensatory strategies and three hours focused on restorative strategies), two hours of weekly group therapy (one hour sessions focused on compensatory strategies), and three hours of weekly computer-based homework proctored by clinic staff who will be responsible for recording performance, and providing positive reinforcement of participation and effort."
62845747|NCT04314713|PLACEBO_COMPARATOR|Scopolamine HBT 0.005 mg/kg|Dose of Scopolamine 0.005mg/kg verses Placebo
62845748|NCT04314713|PLACEBO_COMPARATOR|Scopolamine HBT 0.007 mg/kg|Dose of Scopolamine 0.007mg/kg verses Placebo
62845749|NCT04314713|PLACEBO_COMPARATOR|Scopolamine HBT 0.011 mg/kg|Dose of Scopolamine 0.011mg/kg verses Placebo
62845750|NCT04314713|PLACEBO_COMPARATOR|Scopolamine HBT 0.014 mg/kg|Dose of Scopolamine 0.014mg/kg verses Placebo
62845751|NCT04314713|PLACEBO_COMPARATOR|Scopolamine HBT 0.021 mg/kg|Dose of Scopolamine 0.021mg/kg verses Placebo
62845752|NCT04314713|NO_INTERVENTION|Placebo|Placebo controlled
62845753|NCT00340873||Cases|Individuals exposed to digoxin
62845754|NCT00340873||Controls|Individuals not exposed to digoxin
62059452|NCT02560662|EXPERIMENTAL|Physical activity|Individual consultation with a physiotherapist in order to increase the participants existing level of physical activity by adding 30minutes of physical activity daily, preoperatively and 4 weeks postoperatively.
62845755|NCT02697474|EXPERIMENTAL|Hexaxim® Group|Subjects that received Hexaxim® in Study A3L12
62845756|NCT02697474|EXPERIMENTAL|Infanrix® hexa Group|Subjects that received Infanrix® hexa in Study A3L12
62845757|NCT03261427|EXPERIMENTAL|YNP-1807 Tablet(Pregabalin 330mg)|YNP-1807(Pregabalin 330mg), QD
62845758|NCT03261427|ACTIVE_COMPARATOR|Lyrica Capsule(Pregabalin 150mg)|Lyrica Capsule(Pregabalin 150mg), BID
62845759|NCT02496052|EXPERIMENTAL|dried biological amnion graft|patients, who are with IUA, treated by uterine application of amnion membrane + Foley balloon+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
62845760|NCT02496052|SHAM_COMPARATOR|Foley catheter balloon only|patients, who are with IUA, treated by uterine application of Foley balloon only+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
62845761|NCT05861167|EXPERIMENTAL|SIIT group|
62845762|NCT05861167|NO_INTERVENTION|Non-intensive induction therapy group|
62845763|NCT01081964|ACTIVE_COMPARATOR|Levofloxacin 500mg|Levofloxacin 500mg once daily for 7 days
62845764|NCT01081964|EXPERIMENTAL|Zabofloxacin 5 days|Zabofloxacin 400mg for 5 days
62845765|NCT01081964|EXPERIMENTAL|Zabofloxacin 3 days|Zabofloxacin 400mg for 3 days
62845766|NCT02934100|ACTIVE_COMPARATOR|Group 1 - ESWT Treatment|Patients treated with Extracorporeal Shock Wave Therapy once a week for 10 weeks
62845767|NCT02934100|ACTIVE_COMPARATOR|Group 2 - Body Wave|Patients treated with electric field diathermy three times a week for 5 weeks
62845768|NCT02934100|ACTIVE_COMPARATOR|Group 3 - Ultrasound|Patients treated with ultrasound therapy three times a week for 5 weeks
62845769|NCT02934100|SHAM_COMPARATOR|Group 4 - Control group|Patients treated with sham laser therapy three times a week for 5 weeks
62845770|NCT04626167|EXPERIMENTAL|Intervention group|Patients will undergo a cadaveric donor bladder transplant in addition to or after their kidney transplant rather than using intestinal segments for bladder reconstruction or construction.
62447585|NCT02271555|PLACEBO_COMPARATOR|sevoflurane-saline (Group SS)|Sevoflurane will be initiated, at 8% for anesthesia induction until loss of consciousness will achieve, at which point it will be discontinued. Placebo is 0.9% saline. After the loss of consciousness saline will be administered to Group sevoflurane-saline in the form of intravenous bolus.
62447586|NCT05131126|EXPERIMENTAL|Patient requiring anterior abutment surgery by Latarjet method|
62447587|NCT05131126|ACTIVE_COMPARATOR|Healthy volunteers|
62619659|NCT01742715|EXPERIMENTAL|PEEP by Esophageal pressure|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
62619660|NCT00729300|PLACEBO_COMPARATOR|1|Placebo
62619661|NCT00729300|EXPERIMENTAL|2|disulfiram
62845771|NCT06153797|EXPERIMENTAL|PATH-C|"Participants will be recruited from the Dana-Farber Cancer Institute and randomized in a 1:1 fashion, stratified by transplant type (autologous versus allogeneic), to PATH-C versus usual care.~Caregivers of patients undergoing HSCT will receive the PATH-C intervention to learn to reflect on their positive emotions and consistently use and incorporate positive psychology exercises in their daily routine, as well as learn how to set goals and track their physical activity (i.e., with an activity tracker) daily while caring for a loved one undergoing HSCT.~Participants will complete questionnaires (in person, over the computer or telephone, or by mail) at predetermined days per protocol."
62447588|NCT04755881||All anaphylaxis reactions seen during the phase 2 period of the SHARED study.|All patients presenting to the 3 sites emergency departments (Chicoutimi, Alma, Jonquière) diagnosed with an anaphylactic reaction or a severe allergic reaction that is rapidly evolving towards anaphylaxis in the opinion of the treating physician.
62447589|NCT04561128|EXPERIMENTAL|SHR-1819|Experimental: SHR-1819
62447590|NCT04561128|PLACEBO_COMPARATOR|Placebo|Placebo comparator: placebo
62447591|NCT02027779|EXPERIMENTAL|Prophylaxis safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over ≥ 50 additional exposure days.
62447592|NCT02027779|EXPERIMENTAL|On-demand safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during additional 50 exposure days.
62447593|NCT02505854|ACTIVE_COMPARATOR|Probiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache with 5 g of maltodextrin
62619662|NCT04013152||clinical database|
62623761|NCT01829997|EXPERIMENTAL|nanOss Bioactive 3D BVF|Bilateral, instrumented posterolateral fusion surgery where nanOss Bioactive 3D will be hydrated with autologous BMA and placed bilaterally on a bed of local autograft bone spanning the transverse processes of the treated segment. If an interbody fusion is performed, only a PLIF or TLIF with PEEK IBF devices may be performed.
62619663|NCT03040349|EXPERIMENTAL|TiTAN Intervention|The TiTAN Crete program has adapted the existing curricula and resources originally developed at the University of Ottawa Heart Institute and which are specific to primary practice settings. To facilitate maximum uptake the intervention program was adapted to reflect: language; cultural appropriateness; local patient beliefs and attitudes regarding tobacco-use and cessation; local social and clinical norms; provider perceptions surrounding 5As delivery; and, practice characteristics. The TiTAN multi-component training includes: 1) a 1-day foundational tobacco treatment training program for general practitioners, 2) the dissemination of provider and patient tools, and 3) E-blasts and webinars to supplement skills development and continuing medical education through e-learning.
62619664|NCT03573570|EXPERIMENTAL|Treatment|110 Fair Price Shops (FPS) in Chidambaram, Tamil Nadu, India will be assigned randomly to receive rice fortified. Rice will be fortified using Fortified Rice Kernels (FRKs) containing iron, zinc, vitamin A and vitamins B1, B3, B6, B9 and B12. All households receiving rice from the PDS will receive fortified rice instead of conventional PDS rice, and members of households sampled for baseline will have blood samples and demographic surveys taken at a baseline visit, and another visit at 12-15 months after the baseline visit. Because a given FPS only receives rice from a single upstream distributor (godown) it should be straightforward to ensure that fortified rice reaches the appropriate treatment FPS and only those FPS.
62845772|NCT06153797|NO_INTERVENTION|Usual Care|"Participants will be recruited from the Dana-Farber Cancer Institute and randomized in a 1:1 fashion, stratified by transplant type (autologous versus allogeneic), to PATH-C versus usual care.~Participants will complete questionnaires (in person, over the computer or telephone, or by mail) at predetermined days per protocol.~Participants in the usual care arm will receive their usual support from the HSCT team as caregivers of patients undergoing HSCT, including all routine supportive care resources (e.g., support from social work) offered by the HSCT team.~Patients in the usual care and PATH-C groups will be permitted to use all supportive care services per standard care. The investigators will track referrals to supportive care services in both groups by reviewing the Electronic Health Record (EHR)."
62845773|NCT00771953|EXPERIMENTAL|Apricoxib|Apricoxib 400mg once a day
62845774|NCT00771953|PLACEBO_COMPARATOR|Placebo|Placebo once a day
62059453|NCT02560662|NO_INTERVENTION|Control|Participants randomized to the control group will not be advised to change their current level of physical activity.
62059454|NCT01667913|NO_INTERVENTION|6 minutes walking test|
62059455|NCT02259517|EXPERIMENTAL|Guanfacine|Participants will be administered extended-release guanfacine, which is in tablet form, and will be instructed to take the medication once daily for 6 weeks. The daily dose will range between 1 and 4 mg.
62059456|NCT02259517|EXPERIMENTAL|Lisdexamfetamine|Participants will be administered lisdexamfetamine, which is in tablet form, and will be instructed to take the medication daily for 6 weeks. The daily dose will range between 30 and 70mg.
62447594|NCT02505854|ACTIVE_COMPARATOR|Symbiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache with 5 g of fructooligosaccharide
62059457|NCT02544464|EXPERIMENTAL|Experimental group|ferric carboxymaltose 1000 mg
62059458|NCT02544464|PLACEBO_COMPARATOR|Control group|placebo
62059459|NCT02293395|ACTIVE_COMPARATOR|Stratum 1/ASA|Acetylsalicylic acid (ASA) 100 milligram (mg) enteric-coated tablet once daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
62059460|NCT02293395|EXPERIMENTAL|Stratum 1/Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
62059461|NCT02293395|ACTIVE_COMPARATOR|Stratum 2/ASA|ASA 100 mg enteric-coated tablet once daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
62447595|NCT02505854|PLACEBO_COMPARATOR|Placebo|Hypocaloric diet associated with capsule containing 50g of gelatin and sache with 5 g of maltodextrin
62447596|NCT04414215|EXPERIMENTAL|Cognitive training|Emotional working memory training
62447597|NCT04414215|PLACEBO_COMPARATOR|Placebo training|Placebo working memory training
62619665|NCT03573570|NO_INTERVENTION|Control|The control arm, i.e. FPS not a part of the treatment shops, will continue to receive the regular rice supplied by the Public Distribution System (PDS), and members of households sampled for baseline will have blood samples and demographic surveys taken at a baseline visit, and another visit at 12-15 months after the baseline visit. It therefore represents the status quo and serves as a control group against which any improvements observed in the treatment group will be gauged.
62845775|NCT02869659|ACTIVE_COMPARATOR|Control/Delayed Weight Loss Group|"Control/Delayed Weight Loss Group: (18 weeks) Participants randomized to the delayed weight loss intervention (n=100) will serve as a no-weight loss control to the weight loss group during the first 18 weeks of the study. During the control (18 weeks) phase these participants will receive a monthly phone call visit from staff to maintain contact and interest in the study. At the end of the initial 18 weeks participants will complete all follow up assessments prior to being offered the opportunity to participate in a weight loss program.~No outcome data will be collected at the end of the delayed weight loss phase."
62845776|NCT02869659|EXPERIMENTAL|Weight Loss Group|"Weight Loss group: Phase 1 (18 wks): Participants assigned to this group will undergo a dietary intervention for the first 18 weeks of the study.~This level of weight loss will be achieved through the combination of a partial meal replacement (MR) program and individual and group nutrition/behavioral counseling. Participants will be provided with and asked to consume 4 Medifast® MR per day.~Phase 2 (8 wks): After completion of the active weight loss phase, participants in this group will attend bimonthly group meetings to discuss increasing their activity.~Phase 3 (26 wks): After completion of phase 2, participants will be called monthly for 26 weeks and then asked to return for a maintenance visit at the end of the 52 weeks from study start."
62845777|NCT00531791|ACTIVE_COMPARATOR|1|
62263192|NCT01339806|EXPERIMENTAL|Cognitive and Psychological Based Rehab|"Arm 4: Integrated interdisciplinary cognitive rehabilitation combined with cognitive-behavioral psychotherapy. Individuals assigned to treatment arm 4 will receive 10 hours of individual and group treatment per week conducted by credentialed therapists and doctoral-level psychologists. The treatment components will include four hours of weekly 1 hr individual therapy sessions; 2 hrs of cognitive rehabilitation, 1 hr of cognitive rehab \& 1 hr of individual psychotherapy targeting anxiety/combat stress symptoms including relaxation training \& exposure therapy and cognitive-behavioral principles, 3 hrs of weekly group therapy \& three hours of weekly homework including 30-mins relaxation training, 30-mins cognitive-behavioral psychotherapy homework, and 2 hrs of computerized cognitive rehabilitation exercises proctored by clinic staff."
62845778|NCT00531791|EXPERIMENTAL|2|
62845779|NCT05284526|EXPERIMENTAL|parkinsonian patients with and without dopaminergic drug treatment|Electroencephalogram (EEG) of 10 parkinsonian subjects with and without dopaminergic drug treatment during the preparation and execution of movements
62845780|NCT05284526|EXPERIMENTAL|parkinsonian patients with and without High-frequency stimulation of the subthalamic nucleus|Electroencephalogram (EEG) of 10 parkinsonian subjects with and without High-frequency stimulation (HFS) of the subthalamic nucleus (STN) during the preparation and execution of movements
62845781|NCT05284526|ACTIVE_COMPARATOR|control subjects|Electroencephalogram (EEG) of control subjects during the preparation and execution of movements
62263193|NCT01525784||Rt-CGMS|Using Rt-CGMS, approved by ministry of health as part f clinical care
62263194|NCT01525784||Control|Not approved or suggested for RtCGMS. Other acceptabl means of therapy
62447598|NCT05053893|EXPERIMENTAL|New treatment group(Roxadustat combined with Sacubitril Valsartan Sodium Tablets)|Roxadustat(FibroGen, China), 100mg (45-60kg) or 120mg (≥ 60kg) each time, three times a week, orally on an empty stomach in the morning. The initial dose of Sacubitril Valsartan Sodium Tablets(Novartis, China) is 50mg, once a day, taken on an empty stomach in the morning, and gradually titrated from the minimum dose to the maximum tolerated dose.
62447599|NCT05053893|EXPERIMENTAL|Traditional treatment group(EPO combined with ACEI or ARB )|Recombinant human erythropoietin (SEBOR, 10000 units / Branch) was injected subcutaneously once a week; Perindopril tablets (Servier, China), taken on an empty stomach, gradually titrated from the minimum dose to the maximum tolerated dose.
62447600|NCT03081715|EXPERIMENTAL|Experimental Group|"Peripheral blood lymphocytes will be collected and Programmed cell death 1(PD-1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and reinfused back into patients. To avoid allergic reactions, 50 mg hydrocortisone was intravenously injected into the patient 30 min before cells infusion every time. Best supportive care was also provided for patients.~A total of 1 to 10 x 10\^9 PD-1 Knockout T cells will be infused each cycle. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT or they withdrew consent."
62447601|NCT01919879|EXPERIMENTAL|Arm A: Cetuximab + Afatinib|Afatinib 40 mg daily Cetuximab 500 mg/m2 every 2 weeks until progression
62447602|NCT01919879|ACTIVE_COMPARATOR|Arm B : Cetuximab alone|Cetuximab 500mg/m2 every 2 weeks until progression After progression: Cetuximab 500mg/m2 + Afatinib 40 mg per day until progression
62447603|NCT04893148|ACTIVE_COMPARATOR|iGlar/Lixi|"Switching to IGlarLixi from insulin glargine iGlar/Lixi starts with the following doses depending on the existing insulin glargine dose: 1) insulin glargine \<20 unit/day = iGlar/Lixi 10 unit/day, 2) insulin glargine \>=20 unit/day = iGlar/Lixi 20 unit/day.~Training to increase the iGlar/Lixi dosage every 3 days to meet the target fasting blood glucose level to 80\~130 mg/day"
62619666|NCT03369873|EXPERIMENTAL|Nursing Orientation with guidance manual|The patients received the nursing orientation with validated guidance manual of cardiac catheterization.
62619667|NCT03369873|NO_INTERVENTION|Routine Nursing Orientation|The patients received the routine nursing orientation about cardiac catheterization.
62263195|NCT06548256|EXPERIMENTAL|Miyarisan-BM (Clostridium Butyricum Miyairi) first|Miyarisan-BM (Clostridium Butyricum Miyairi) for 1 year, then stopped for 1 year
62263196|NCT06548256|EXPERIMENTAL|Miyarisan-BM (Clostridium Butyricum Miyairi) later|observation for 1 year and then Miyarisan-BM (Clostridium Butyricum Miyairi) for 1 year.
62263197|NCT05462847|EXPERIMENTAL|Volume loading|
62263198|NCT05462847|ACTIVE_COMPARATOR|Control|
62263199|NCT04200729|EXPERIMENTAL|Irrigation with PVI|
62263200|NCT04200729|ACTIVE_COMPARATOR|Usual care|
62619668|NCT03470623|EXPERIMENTAL|bioabsorbable screws|hallux valgus treated with chevron osteotomy using bioabsorbable screws
62845782|NCT03828019|ACTIVE_COMPARATOR|Adalimumab (ADA)|"Adalimumab administered by subcutaneous injection at dosage and frequency specified below; total duration of treatment is 12 months.~Adults (≥ 18 years of age) and adolescents ≥30 kg: 80 mg as initial dose; one week later by 40 mg then 40 mg every two weeks. Adolescents \<30 kg: 40 mg as initial dose; one week later 20 mg then 20 mg every 2 weeks."
62263201|NCT03581227||Participants without a diagnosis of COPD|Men and women aged 45 to 80, who have not been diagnosed with Chronic Obstructive Pulmonary Disease (COPD)
62845783|NCT03828019|ACTIVE_COMPARATOR|Conventional immunosuppression (CON)|"Conventional immunosuppressive agent selected by study ophthalmologist at dose and frequency specified below;12 month treatment duration.~Azathioprine: initially 2 mg/kg/day; max dose 200 mg/day. Methotrexate initially 15mg/wk; max dose 25 mg/wk. Mycophenolate initially 1 gm BID; max dose1.5 gm BID. Cyclosporine (Sandimmune - dose 2.5 mg/kg BID and Neoral dose 2 mg/kg BID. Tacrolimus initially 1 mg BID; max dose 3 mg BID."
62447604|NCT04893148|ACTIVE_COMPARATOR|Dulaglutide plus insulin glargine|Adding Dulaglutide to insulin glargine. Keep insulin glargine and dulaglutide start at 0.75 mg per week and increase to 1.5 mg per week after 1 month with evaluating compliance and tolerability.
62447605|NCT00772564|EXPERIMENTAL|Atorvastatin 80 mg|
62845784|NCT02744040|OTHER|Early ART initiation|Immediate ART initiation at the time of HIV diagnosis; daily dose of combination ART (one pill/day)
62845785|NCT02744040|OTHER|Deferred ART initiation|ART initiation at 24 weeks after HIV diagnosis; daily dose of combination ART (one pill/day)
62845786|NCT02420015|EXPERIMENTAL|iCOMMIT|The components of the intervention include 1) behavioral therapy in the form of mobile contingency management (mCM) designed to increase early abstinent rates; 2) pharmacotherapy for smoking cessation \[including nicotine replacement therapy (NRT) and bupropion\]; 3) four sessions of guideline based cognitive-behavioral smoking cessation counseling designed to increased coping skills specific to smoking cessation; 4) a smart-phone based relapse prevention application (the Stay Quit Coach) that is populated during the counseling sessions; and 5) SMS text messaging reminders to increase medication adherence.
62845787|NCT02420015|ACTIVE_COMPARATOR|Control Group|The components of the intervention include 1) pharmacotherapy for smoking cessation \[including nicotine replacement therapy (NRT) and bupropion\]; and 2) four sessions of guideline based cognitive-behavioral smoking cessation counseling designed to increased coping skills specific to smoking cessation.
62059462|NCT02293395|EXPERIMENTAL|Stratum 2/Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
62447606|NCT00772564|EXPERIMENTAL|Atorvastatin 10 mg|
62447607|NCT02236533|PLACEBO_COMPARATOR|Control pasta|Volunteers were fed with control pasta, without B-glucans and spores of B. coagulans once a day for 12 weeks.
62447608|NCT02236533|EXPERIMENTAL|Probiotic Whole Grain Pasta|Volunteers were fed with probiotic fortified pasta, including B-glucans and spores of B. coagulans once a day for 12 weeks.
62447609|NCT04511559||chronic gastritis|This group will include 80 patients with chronic gastritis and the diagnoses will be based on the British Society of Gastroenterology guidelines.
62447610|NCT04511559||Moderate to severe atrophy/intestinal metaplasia/|This group will include 80 patients with Moderate to severe atrophy/intestinal metaplasia/ and the diagnoses will be based on British Society of Gastroenterology guidelines.
62447611|NCT04511559||gastric cancer|This group will include 380 patients with gastric cancer and the diagnoses will be based on British Society of Gastroenterology guidelines.
62619669|NCT03470623|EXPERIMENTAL|steel screws|hallux valgus treated with chevron osteotomy using steel screws
62619670|NCT05683951|EXPERIMENTAL|DWKH|
62619671|NCT05683951|ACTIVE_COMPARATOR|DWKH-R|
62263202|NCT00001788||1|patients with primary immunodeficiency disorders
62263203|NCT02410135||Patients with symptomatic LUTS and disordered sleep|Patients exhibiting symptoms of LUTS and disordered sleep and who meet all inclusion/exclusion criteria will be prescribed Mirabegron for 12 weeks.
62263204|NCT00971451|EXPERIMENTAL|knee joint cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
62263205|NCT00971451|EXPERIMENTAL|TENS|continuous TENS for duration of the 1 hour exercise session
62263206|NCT00971451|NO_INTERVENTION|No intervention|no modality intervention; just exercise
62263207|NCT02849561|ACTIVE_COMPARATOR|Favourable neurological evolution after cardiac arrest|MGOS 4-5
62619672|NCT05683951|PLACEBO_COMPARATOR|PLACEBO|
62263208|NCT02849561|ACTIVE_COMPARATOR|Unfavourable neurological evolution after cardiac arrest|MGOS 1-3
62619673|NCT00621517|EXPERIMENTAL|1|Participants will receive 150MG Bupropion nightly.
62619674|NCT00621517|PLACEBO_COMPARATOR|2|Participants will receive matching placebo capsule nightly.
62619675|NCT03983434|EXPERIMENTAL|Healthy volunteers|Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
62263209|NCT02205203|ACTIVE_COMPARATOR|Face-to-Face w/ Anxiety Coach (FTF-AC)|In this condition therapists will provide 6 to 12 50-minute, face-to-face therapy sessions using Mayo Clinic Anxiety Coach. The sessions are expected to initially occur weekly and be within the office although the therapist can leave the office to conduct exposure. The therapist is expected to utilize Anxiety Coach within the session, encourage the patient to use the application to complete homework, and review progress in-session via the web-based portal.
62263210|NCT02205203|EXPERIMENTAL|Treatment as Usual (TAU)|In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure). Therapists can communicate with patients between sessions (e.g., phone calls), as long as this medium is not the primary mode of treatment.
62263211|NCT03175900|EXPERIMENTAL|Naoan dripping pills for migraine|Drug: Naoan dripping pills, Chinese patent medicine，pill. Patients will receive treatment with Naoan dripping pills for 12 weeks, Fenbid can be taken if headache is unbearable Procedure: MRI scanning（fMRI and DTI）
62845788|NCT03428035|EXPERIMENTAL|Modified Package Insert|Simplified and focused on neutral risk perception. The representations and formulations are based on the findings from research on evidence-based patient information and risk communication. The package insert contains the same information as the statutory package insert to ensure that it complies with the legal requirements.
62845789|NCT03428035|NO_INTERVENTION|Verbal Information|The patient is informed verbally about side effects and does not receive any package insert.
62059463|NCT04445857|ACTIVE_COMPARATOR|Group 1|injection of 15 mg (3 ml) hyperbaric bupivacaine 0.5% and 100 IU salmon calcitonin(1ml) intrathecally and injection of 10 ml normal saline (NS) slowly intravenously (IV) over 5 min.
62059464|NCT04445857|ACTIVE_COMPARATOR|Group 2|injection of 15 mg (3 ml) hyperbaric bupivacaine 0.5% and 1ml NS intrathecally and injection of 100 IU salmon calcitonin (1ml) diluted in 9 ml NS slowly IV over 5 min.
62059465|NCT04445857|PLACEBO_COMPARATOR|Group 3 (control group)|injection of 15 mg (3 ml) hyperbaric bupivacaine 0.5% and 1ml NS intrathecally and injection of 10 ml NS slowly IV over 5 min.
62059466|NCT03748511||fatty liver disease 0-1F|20 patients with uncomplicated liver disease, with fibrosis stage 0-1F.
62845790|NCT03428035|ACTIVE_COMPARATOR|Control|Package insert according to EU Directive 2001/83 / EC (usual package insert)
62845791|NCT06445205||Sample collection|Sample collection via standard phlebotomy as well as point-or-care Mitra device.
62059467|NCT03748511||fatty liver disease 2F|20 patients with liver disease, fibrosis stage 2F.
62059468|NCT03748511||fatty liver disease 3-4F|20 patients with advanced liver disease, fibrosis stage 3-4F.
62845792|NCT02829190|EXPERIMENTAL|Healthy volunteers|Magnetic Resonance Imaging (MRI)
62845793|NCT02829190|EXPERIMENTAL|Patients treated by radiotherapy|Magnetic Resonance Imaging (MRI)
62059469|NCT05647863|EXPERIMENTAL|F-CaST|The experimental group who will receive the Functional Cognitive and Sensory Treatment (F-CaST)- in which therapy is individually tailored for successful task performance and where the focus is on strategies for improving sensory and EF deficits.
62059470|NCT05647863|NO_INTERVENTION|Standard Care|Standard care at the therapeutic community for SUD.
62059471|NCT00722501|ACTIVE_COMPARATOR|ERB-257|7 IV single doses of ERB-257 will be given to 6 healthy subjects per group - 1,4, 15, 45, 90, 180, and 300 mg
62059472|NCT00722501|PLACEBO_COMPARATOR|placebo|2 placebo subjects per group
62059473|NCT05614414|EXPERIMENTAL|VL Group|Patients who were intubated by videolaryngoscope.
62059474|NCT05614414|ACTIVE_COMPARATOR|LD Group|Patients who were intubated by direct laryngoscope
62059475|NCT03762343|EXPERIMENTAL|Greater occipital nerve block group (group GONB)|Patient in this group will receive 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.
62059476|NCT03762343|PLACEBO_COMPARATOR|Control group (group C):|Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)
62059477|NCT02355613|ACTIVE_COMPARATOR|Radiosurgery with Gamma Knife Perfexion|A single dose of 24 Gy at 50% isodose will be prescribed at metastases with diameter ≤ 20 mm, while a dose of 20 Gy at 50% isodose will be prescribed for metastases with diameter 21-30 mm
62059478|NCT02355613|ACTIVE_COMPARATOR|Linac-based Radiosurgery with EDGE|A single dose of 24 Gy will be prescribed at mean dose to PTV at metastases with diameter ≤ 20 mm, while a dose of 20 Gy will be prescribed for metastases with diameter 21-30 mm
62263212|NCT03175900|PLACEBO_COMPARATOR|Placebo|Drug: Placebo, pill. Patients will receive treatment with placebo for 12 weeks, Fenbid can be taken if headache is unbearable Procedure: MRI scanning （fMRI and DTI）
62263213|NCT00350051|EXPERIMENTAL|Arm 1|
62263214|NCT02389803|EXPERIMENTAL|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
62263215|NCT02389803|PLACEBO_COMPARATOR|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and mineral
62263216|NCT06534450|ACTIVE_COMPARATOR|TPE Monthly|will receive 6 monthly TPE procedures (TOTAL 6 treatments)
62263217|NCT06534450|ACTIVE_COMPARATOR|TPE Bimonthly|will receive 2 TPE procedures in one week. The same treatment will be repeated on a monthly basis two more times (Two treatments per month for three months to total 6 treatments)
62845794|NCT02829190|EXPERIMENTAL|Patients treated by embolization|Magnetic Resonance Imaging (MRI)
62059479|NCT01782872|ACTIVE_COMPARATOR|Interscalene Block (ISB) - 0.375% Ropivacaine + additives|
62619676|NCT03983434|EXPERIMENTAL|Irritable Bowel Syndrome Patients with Diarrhea|Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
62619677|NCT03983434|EXPERIMENTAL|Irritable Bowel Syndrome Patients with Constipation|Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
62845795|NCT02829190|EXPERIMENTAL|Patient operated on with free flap|Magnetic Resonance Imaging (MRI)
62845796|NCT02313961|EXPERIMENTAL|RIC patients|Subjects submitted to remote ischaemic conditioning (RIC)
62845797|NCT02313961|NO_INTERVENTION|No RIC patients|Subjects not submitted to remote ischaemic conditioning (RIC)
62447612|NCT04126057|EXPERIMENTAL|DOT Spectacle Lenses using Manufacturing Method A|Single vision, impact-resistant spectacles using SightGlass Vision DOT spectacle lenses, manufacturing method A
62447613|NCT04126057|EXPERIMENTAL|DOT Spectacle Lenses using Manufacturing Method B|Single vision, impact-resistant spectacles using SightGlass Vision DOT spectacle lenses, manufacturing method B
62447614|NCT04125628|EXPERIMENTAL|Exercise with cooling|Assigned Interventions 10 MS patients (aged 25----50 years) with Expanded Disability Status Scale between 2 to 6.5 have agreed to participate in this study. The exercise training session involved head cooling and neck wraps. The exercise training session consisted of 40 min continuous cycling where the participants performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
62619678|NCT05249621|EXPERIMENTAL|MZE001|MZE001 is a small molecule inhibitor of muscle glycogen synthase for the potential treatment of Pompe disease.
62619679|NCT05249621|PLACEBO_COMPARATOR|Placebo|Excipients containing no active ingredients.
62845798|NCT04875000|ACTIVE_COMPARATOR|UltraEZ|"Group of patients randomly assigned to receive the the application of the commercial fluoride remineralizing and desensitizing agent UltraEZ (Ultradent Products, Inc, South Jordan, UT, USA) after teeth bleaching"
62845799|NCT04875000|EXPERIMENTAL|Arginine|Group of patients randomly assigned to receive the the application of the 2.5% arginine solution after teeth bleaching
62845800|NCT04875000|EXPERIMENTAL|Nano-hydroxyapatite|Group of patients randomly assigned to receive the application of the 2.5% nano-hydroxyapatite solution after teeth bleaching
62845801|NCT06164990|EXPERIMENTAL|PEKK (Pekkton) framework|PEKK (Pekkton) framework in mandibular implant-supported complete fixed dental prostheses with All-on-four treatment concept and evaluated regarding peri-implant tissue health
62845802|NCT00838084|EXPERIMENTAL|LY2811376 Part 1|LY2811376 (5 mg up to 500 mg); once a day or twice a day for 1 day in up to 3 periods.
62619680|NCT02446847|EXPERIMENTAL|Group A: 3BNC117 IV + ART Interruption|Two intravenous infusions of 3BNC117 (30 mg/kg) at day 0 and day 21, with interruption of antiretroviral treatment (ART) at day 2.
62845803|NCT00838084|PLACEBO_COMPARATOR|Placebo Part 1|once a day or twice a day for 1 day in up to 3 periods.
62845804|NCT00838084|EXPERIMENTAL|LY2811376 - Part 2 low dose|Single dose of LY2811376, dose determined by part 1
62845805|NCT00838084|EXPERIMENTAL|LY2811376 - Part 2 high dose|Single dose of LY2811376, dose determined by part 1
62845806|NCT00838084|PLACEBO_COMPARATOR|Placebo Part 2|single dose
62845807|NCT04708314|OTHER|30 mg/kg|Golodirsen 30 mg/kg will be administered as an intravenous (IV) infusion over approximately 35 to 60 minutes once a week during the treatment period (up to 96 weeks). After the treatment period, patients can go into a safety extension period (not to exceed 48 weeks) until the patient is able to transition to commercially available drug or a separate golodirsen study.
62845808|NCT05884541|EXPERIMENTAL|Intervention|Children and parents receiving Early Math Texts (TipsbyText)
62845809|NCT05884541|NO_INTERVENTION|Control|Children and parents not receiving Early Math Texts (TipsbyText)
62845810|NCT02569099|EXPERIMENTAL|Intervention using standardised care|"Caregiver training /standardised care: where the participants (caregivers)s are trained on caring for relative who has survived a stroke once only for one hour using a developed curriculum.~Plus Conventional care: where the participants continue to receive the usual care as offered in protocols for treatment of stroke in Zimbabwe."
62619681|NCT02446847|EXPERIMENTAL|Group B: 3BNC117 IV + ART interruption|Four intravenous infusions of 3BNC117 (30 mg/kg) at day 0, day 14, day 28, and day 42 with interruption of antiretroviral treatment (ART) at day 2.
62619682|NCT00755261|EXPERIMENTAL|Avastin and Doxorubicin|Patients will be treated with Avastin 15 mg/kg IV infusion plus doxorubicin 60 mg/M2 (body surface area) IV 6-hour infusion on Day 1 of each 21-day treatment cycle. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
62619683|NCT01125085|OTHER|131I-L19SIP RIT in Combination with WBRT|131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)
62619684|NCT01810744|OTHER|metastatic colorectal cancer|Patients treated by bevacizumab will be follow up by capillaroscopy and blood pressure measurements.
62619685|NCT01810744|OTHER|glioblastoma|Patients treated by bevacizumab will be follow up by capillaroscopy and blood pressure measurements.
62619686|NCT03894761|OTHER|Patients with Rotator Cuff Syndrome|The patients diagnosed with rotator cuff syndrome by clinical and magnetic resonance imaging.
62059480|NCT01782872|ACTIVE_COMPARATOR|Interscalene Block (ISB) - 0.2% Ropivacaine + additives|
62619687|NCT01759394|EXPERIMENTAL|Avatrombopag maleate 40 mg|
62619688|NCT00538512|ACTIVE_COMPARATOR|TIV|the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur
62619689|NCT00538512|ACTIVE_COMPARATOR|LAIV|live-attenuated influenza vaccine Flumist, manufactured by MedImmune
62845811|NCT02569099|NO_INTERVENTION|Control|No training offered to caregivers but conventional care only where the people who have survived a stroke receive the usual care as offered in protocols for treatment of stroke in Zimbabwe.
62845812|NCT01460043|PLACEBO_COMPARATOR|placebo|
62059481|NCT01782872|ACTIVE_COMPARATOR|Interscalene Block (ISB) - 0.1% Ropivacaine + additives|
62059482|NCT01782872|ACTIVE_COMPARATOR|Interscalene Block (ISB) - Systemic Control|
62059483|NCT00511979|EXPERIMENTAL|Technosphere insulin inhalation system, 25 units|
62059484|NCT00511979|EXPERIMENTAL|Technosphere insulin inhalation system, 50 units|
62059485|NCT00511979|EXPERIMENTAL|Technosphere insulin inhalation system, 100 units|
62059486|NCT00511979|ACTIVE_COMPARATOR|Subcutaneous regular human insulin|
62845813|NCT01460043|EXPERIMENTAL|Homeopathy|Individualized symptom based therapy
62059487|NCT01965782|EXPERIMENTAL|[^14C]-LY3023703|Single oral dose of 15 mg LY3023703, containing approximately 100 µCi \[\^14C\] labeled drug, administered as an oral solution.
62263218|NCT06534450|ACTIVE_COMPARATOR|TPE Bimonthly with IVIG|will receive 2 TPE procedures followed by 2 gm of IVIG in one week. The same treatment will be repeated on a monthly basis twice more. (Two TPE procedures per month for three months - total of 6 treatments)
62447615|NCT04125628|ACTIVE_COMPARATOR|Exercise without cooling|10 MS patients (aged 25----50 years) with Expanded Disability Status Scale between 2 to 6.5 have agreed to participate in this study. The exercise session performed without cooling. The exercise training session consisted of 40 min continuous cycling where the participants performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
62447616|NCT04497428|EXPERIMENTAL|Adaptation to Altered Sensory Feedback + cTBS to S1|Adaptation to Altered Sensory Feedback + cTBS to S1
62447617|NCT04497428|EXPERIMENTAL|Adaptation to Altered Sensory Feedback + cTBS to A1|Adaptation to Altered Sensory Feedback + cTBS to A1
62447618|NCT04497428|EXPERIMENTAL|Adaptation to Altered Sensory Feedback + cTBS to M1|Adaptation to Altered Sensory Feedback + cTBS to M1
62619690|NCT00538512|PLACEBO_COMPARATOR|Placebo|Physiologic saline administered as a nasal spray or intramuscular injection
62059488|NCT04728178|ACTIVE_COMPARATOR|study group|In the control group, fluid management was set as MAP (Mean arterial pressure) 65 mmHg and above and diuresis 0.5ml/kg/hour and above. Crystalloid infusion at 7ml/kg/hour was started. When SVV value increased to 13% and over in the study group, 250 ml of crystalloid was given in the first stage, and if it continued to be 13% and over, 250 ml of colloid bolus was given. Vasoconstrictor agent was used when SVV was below 13% and MAP was below 65 mmHg.
62059489|NCT04728178|PLACEBO_COMPARATOR|control group|In the control group, fluid management was set as MAP (Mean arterial pressure) 65 mmHg and above and diuresis 0.5ml/kg/hour and above. Crystalloid infusion at 7ml/kg/hour was started. They were given 250 ml of crystalloid in the first stage if the MAP was below 65 mmHg, and 250 ml of colloid bolus if the hypotensive episode continued. If hypotension persisted despite these fluid boluses, a vasoconstrictor agent was used. In addition, when the diuresis of the patients was detected at 0.5mg/kg/hr or less, 250 ml of colloid bolus was administered.
62059490|NCT02126683|EXPERIMENTAL|Plaquenil first|Start Plaquenil 200mg BID orally since enrollment Duration: 6 months
62059491|NCT02126683|EXPERIMENTAL|Plaquenil later|Start Plaquenil 200mg BID orally since the 25th week after enrollment Duration: 6 months
62059492|NCT03458767|EXPERIMENTAL|Intervention group|Eight weekly 90-minute group educational sessions attended via a computer, tablet, or smart phone using a web-based video conference platform.
62059493|NCT03458767|NO_INTERVENTION|Control group|Enhanced usual care control group will receive an illustrated instructional booklet on Physical Activity for persons with MS developed by the National Center on Health, Physical Activity and Disability (NCHPAD).
62263219|NCT06534450|SHAM_COMPARATOR|Sham|Sham TPE PROCEDURE once a month for 6 months (total of 6 treatments)
62263220|NCT06154369|EXPERIMENTAL|JoyPop|Participants will receive access to the Joypop app for 8 weeks.
62263221|NCT06154369|NO_INTERVENTION|No Intervention|No intervention will be offered. After 8 weeks in the control condition, participants will be offered access to the JoyPop app.
62263222|NCT01441531|EXPERIMENTAL|Gabapentin|Gabapentin 600 mg po given 1 hour before surgery
62263223|NCT01441531|PLACEBO_COMPARATOR|Placebo sugar pill|
62263224|NCT03893968|EXPERIMENTAL|Informed by a doctor|Information by a doctor
62263225|NCT03893968|EXPERIMENTAL|Informed by an assistant nurse|Information by an assistant nurse
62447619|NCT04497428|EXPERIMENTAL|Adaptation to Altered Sensory Feedback + Sham cTBS|Adaptation to Altered Sensory Feedback + Sham cTBS
62619691|NCT02097771|ACTIVE_COMPARATOR|LMA SupremeTM|
62619692|NCT02097771|SHAM_COMPARATOR|Ambu AuraOnce|
62619693|NCT01383252|EXPERIMENTAL|Water method|Water infusion in lieu of air insufflation for screening and surveillance colonoscopy
62845814|NCT03114852||CKD patients|"'blood collection'~Patients with chronic kidney disease in renal replacement therapy living in the sanitary administrative region of Niteroi/Rio de Janeiro. They will be interviewed about past history of familiar renal disease. They will have blood functional renal biochemistry analysed."
62845815|NCT03114852||Renal Familiar Disease|'blood collection' They will have blood tested to renal genetic diseases
62845816|NCT03904992|NO_INTERVENTION|Non-exposed|Subjects with access to nutritional counseling sessions every 30 days
62845817|NCT03904992|EXPERIMENTAL|Exposed|Subjects with access to the progressive web app in their smartphones.
62619694|NCT01383252|ACTIVE_COMPARATOR|Air method|Air insufflation for screening and surveillance colonoscopy
62845818|NCT06014398|EXPERIMENTAL|Study investigation|All enrolled patients will undergo standardised pituitary hormone assessments.
62845819|NCT04684238|ACTIVE_COMPARATOR|Drug: Midazolam|Midazolam for sedation in the ICU
62845820|NCT04684238|EXPERIMENTAL|Drug: Isoflurane|Volatile for sedation in the ICU
62845821|NCT02057081|EXPERIMENTAL|Treatment|Intensive 14-session psychoeducational rehabilitation and skills-building intervention for couples.
62845822|NCT02057081|ACTIVE_COMPARATOR|Control|Didactic 14-session educational group intervention for families.
62845823|NCT02800629|ACTIVE_COMPARATOR|Intervention|Patients will be given Modified Citrus Pectin twice daily for 12 weeks, and have their change in knee pain as measured by survey instruments assessed
62845824|NCT02800629|PLACEBO_COMPARATOR|Control|Patients will be given placebo twice daily for 12 weeks, and have their change in knee pain as measured by survey instruments assessed
62845825|NCT01686542|EXPERIMENTAL|CPVI+RSM group|Circumferential pulmonary vein isolation (CPVI) plus renal sympathetic modification for atrial fibrillation ablation.
62845826|NCT01686542|ACTIVE_COMPARATOR|CPVI group|Circumferential pulmonary vein isolation is done alone for atrial fibrillation.
62845827|NCT05113069|EXPERIMENTAL|Treatment group|SHR-A1912
62845828|NCT01864603|EXPERIMENTAL|1st: universal test and treat; 2nd: targeted PrEP and cascade|"Intervention arm first phase: annual universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery~Intervention arm second phase: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery + targeted PrEP, and targeted HIV testing interventions"
62845829|NCT01864603|ACTIVE_COMPARATOR|1st: baseline community testing; 2nd: None|Comparator arm first phase: baseline community-based HIV and multi-disease testing; ART by country standard of care
62845830|NCT04945057|EXPERIMENTAL|Intervention group|"All participants will use the Mindpax mobile application, wear the wrist accelerometer and fill in weekly self-assessments. All participants will obtain weekly health tips (general psychoeducation) and additional individualized targeted tips when the system detects deviation from individual mood, activity and sleep patterns.~Participants, who did not participate in the previous AKTIBIPO study (DeNovo) will complete additional 3 months of actigraphy and self-evaluation monitoring with research version of the Mindpax application, providing limited feedback and no health tips."
62845831|NCT02791763|EXPERIMENTAL|Daprodustat in ND participants|Eligible ND participants will receive oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 milligrams \[mg\] as recommended) dose once daily for 52 weeks.
62263226|NCT02026895|EXPERIMENTAL|Patient with infection by Staphylococcus lugdunensis|
62447620|NCT06241898|EXPERIMENTAL|dose escalation|BB-1709 will be administered as an intravenous infusion by Q3W or Q2W as long as they continue to show clinical benefit as judged by the investigator, until disease progression or intolerable toxicity, withdrawal of consent, death, or termination of the study.
62447621|NCT06241898|EXPERIMENTAL|dose expansion|BB-1709 will be administered as an intravenous infusion by Q3W or Q2W as long as they continue to show clinical benefit as judged by the investigator, until disease progression or intolerable toxicity, withdrawal of consent, death, or termination of the study.
62447622|NCT01573065|EXPERIMENTAL|Single arm|
62447623|NCT05881148|EXPERIMENTAL|Carbon sprinting Super-spikes|Trademarked Carbon Spiked-Shoes, from one Trademark only to ensure generalization concerns, is used alternatively with standard carbon-free spiked-shoes, for 8 repetitions of 30m-sprint each, separated by 10 minutes rest each.
62059494|NCT03062202|EXPERIMENTAL|Depression group|SilverCloud iCBT for depression.
62619695|NCT06525974|ACTIVE_COMPARATOR|Control group (Mesalamine group)|Control group (Mesalamine group, n =23) who will receive 1 g mesalamine three times daily for 3 months.
62619696|NCT06525974|EXPERIMENTAL|Experimental group (Febuxostat group)|Experimental group (Febuxostat group, n = 23) which will receive the standard treatment for UC plus 40 mg febuxostat once daily for 3 months.
62623762|NCT01050322|ACTIVE_COMPARATOR|Capecitabine Lapatinib|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
62845832|NCT02791763|ACTIVE_COMPARATOR|Epoetin beta pegol in ND participants|Eligible ND participants will receive subcutaneous (SC) epoetin beta pegol (25, 50, 75, 100, 150, 200 or 250 microgram \[µg\] as recommended) dose once every 2 or 4 weeks for 52 weeks.
62059495|NCT03062202|EXPERIMENTAL|Anxiety group|SilverCloud iCBT anxiety disorders.
62263227|NCT02189213|ACTIVE_COMPARATOR|Sertraline|Sertraline will be administered PO to treat anxiety disorders in children and adolescents. he following dosing schedules will be used: Sertraline will be titrated from 25mg once a day orally up to 200mg once a day orally, for 12 weeks. The titration will stop at the dose in which the participant shows a full response to the medication or experiences side effects that will inhibit titration.
62263228|NCT02189213|NO_INTERVENTION|Control|There will be no intervention in this arm.
62263229|NCT00071071|EXPERIMENTAL|HuMax-CD4 280 milligrams (mg)|
62845833|NCT02791763|EXPERIMENTAL|Daprodustat in PD participants|Eligible PD participants will receive oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 mg as recommended) dose once daily for 52 weeks.
62263230|NCT00071071|EXPERIMENTAL|HuMax-CD4 560 mg|
62845834|NCT05190926|EXPERIMENTAL|Smart Treatment for Anorexia Nervosa Recovery (STAR) app|STAR incorporates elements from the Unified Protocol and Acceptance and Commitment Therapy to reduce emotion avoidance and improve disordered-eating behaviors and negative emotions. Participants will complete 1-2 weekly modules in STAR for 12 weeks. During this time, participants will continue working with their outpatient therapist. Outcome and target engagement measures will be assessed daily or weekly within the STAR app. Participants will complete additional measures of outcome and target engagement at 3-months and 6-months after treatment. Parents will be asked to complete outcome measures at baseline, 12 weeks, 3-months, and 6-months.
62619697|NCT01119846|EXPERIMENTAL|Part A|Part A (Cohort 1) is a single-blind, randomized, placebo-controlled, 5-period crossover in which drug naïve T2DM subjects will receive escalating doses of GSK1292263 in each of 3 periods and placebo and open-label sitagliptin in the other 2 periods. The sequence will be randomized, but will maintain the low, medium and high dose order for GSK1292263.
62619698|NCT01119846|EXPERIMENTAL|Part B|Part B (Cohort 2) is a single-blind, randomized, 2-period study in which T2DM subjects will receive a single dose of GSK1292263, fasted or fed.
62619699|NCT01119846|EXPERIMENTAL|Part C|Part C (Cohort 3, optional Cohort 4) is a single-blind, randomized, placebo-controlled, 5-arm study of 14 days of dosing with GSK1292263, placebo or open-label sitagliptin. An optional Cohort 4 may be enrolled to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1292263 when dosed in a BID regimen.
62619700|NCT05008445|EXPERIMENTAL|LM-102 Dose Escalation Level 1, 3mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~first dose: 3mg/kg, Q3W;"
62619701|NCT05008445|EXPERIMENTAL|LM-102 Dose Escalation Level 2, 10mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~Second dose: 10mg/kg, Q3W;"
62619702|NCT05008445|EXPERIMENTAL|LM-102 Dose Escalation Level 3, 20mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~Third dose: 20mg/kg, Q3W;"
62619703|NCT05008445|EXPERIMENTAL|LM-102 Dose Escalation Level 4, 30mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~Four dose: 30mg/kg, Q3W;"
62619704|NCT05008445|EXPERIMENTAL|LM-102 Dose Escalation Level 5, 40mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~Five dose: 40mg/kg, Q3W;"
62619705|NCT05008445|EXPERIMENTAL|LM-102 (RP2D-1) combined with SOC Dose Escalation|During the dose escalation of LM-102 combined with SOC,the next lower dose groups (RP2D-1) of LM-102 monotherapy's RP2D will be adopted as the starting dose.
62619706|NCT05008445|EXPERIMENTAL|LM-102 (RP2D) combined with SOC Dose Escalation|During the dose escalation of LM-102 combined with SOC,(If applicable) LM-102 monotherapy's RP2D will be adopted as the starting dose.
62619707|NCT06307171|OTHER|Leishmaniasis cases|Archived, cryo-preserved or prospectively collected samples from patients with clinically or laboratory confirmed leishmaniasis
62619708|NCT06307171|OTHER|Community Controls|Sera from uninfected subject archived, cryo-preserved serum sample,stored at the Tropica Biobank at the DITM, IRCCS Sacro Cuore Don Calabria Hospital, Negrar (Vr), from subjects from Italy and from Africa with negative results to two serological test for leishmaniasis. Archived, cryo-preserved serum sample from subjects with a confirmed diagnosis of Chagas' diseases, TB, leprosy, and malaria stored at the Tropica Biobank at the DITM, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona.
62619709|NCT06307171|OTHER|Validation CONTROLS (VC)|Serum samples stored in Tropica Biobank at the DITM from subjects that have been clinically diagnosed with Chagas's disease (n=15), or TB (n=15), or malaria (n=15) or leprosy (n=5).
62619710|NCT06450093|OTHER|Group I Stainless steel crowns (control group)|It will include 17 molars that will be restored by a stainless steel crown.
62619711|NCT06450093|OTHER|Group II: Preformed zirconia crown (study group)|It will include 17 molars that will be restored by Zirconia crowns.
62619712|NCT06450093|OTHER|Group III: Preformed BioFlx crown (study group)|It will include 17 molars that will be restored by BioFlx crowns.
62619713|NCT01601067|EXPERIMENTAL|Arm 1: Integrated Prolonged Exposure Therapy|Integrated Prolonged exposure Psychotherapy (I-PE; PE integrated with elements of Integrated Cognitive Behavioral Therapy for alcohol use disorder)
62619714|NCT01601067|ACTIVE_COMPARATOR|Arm 2: Seeking Safety|Seeking Safety
62619715|NCT05827588|EXPERIMENTAL|AWAK PD|Wearable/Ultra-portable peritoneal dialysis device for home-use
62845835|NCT05190926|PLACEBO_COMPARATOR|Present-focused Anorexia Nervosa Coping Treatment (PACT) app|PACT is an adapted form of Present-Centered Therapy and focuses on daily life stressors, problems, and concerns that may impact AN. Participants will complete 1 weekly module in Weeks 1, 2, and 12 and complete a Daily Diary of life stressors thereafter for 9 weeks. During this time, participants will continue working with their outpatient therapist. Outcome and target engagement measures will be assessed daily or weekly within the PACT app. Participants will complete additional measures of outcome and target engagement at 3-months and 6-months after treatment. Parents will be asked to complete outcome measures at baseline, 12 weeks, 3-months, and 6-months.
62059496|NCT03062202|EXPERIMENTAL|Comorbid Depression and Anxiety group|SilverCloud iCBT for comorbid depression and anxiety.
62619716|NCT05911698|OTHER|Patients with all types of melasma|"Fractional ablative CO2 laser : For each patient, Right side of the face : Fractional ablative CO2 laser will be followed by immediate topical application of vitamin c 3% .~Left side of the face: Fractional ablative CO2 laser will be followed by immediate topical application of tranexamic acid.~* Fractional ablative CO2 laser sessions will be performed using the following parameters: power 8-10 W(according to the skin type), spacing 1000 μm (5.3% density), dwell time 400 μs, and stack .~* During the session, protective goggles will be used both by the patient and by the physician."
62619717|NCT03461302|EXPERIMENTAL|Topical Coal Tar treatment|
62619718|NCT03461302|ACTIVE_COMPARATOR|Topical Corticosteroids treatment|
62619719|NCT00560911|OTHER|1Self-management|
62619720|NCT00560911|OTHER|2 Routine control|
62619721|NCT04017117|EXPERIMENTAL|Custom Made Poly Ether Ether Ketone Mesh|Applying Poly Ether Ether Ketone mesh with mix of autogenous bone graft and bone substitute in posterior atrophic mandible for augmentation
62619722|NCT04017117|ACTIVE_COMPARATOR|Conventional Titanium mesh|Applying Titanium mesh with mix of autogenous bone graft and bone substitute in posterior atrophic mandible for augmentation
62619723|NCT02415231|EXPERIMENTAL|humor|humor group will watch humor video for 20 minutes
62619724|NCT02415231|NO_INTERVENTION|control non humor|control group did not watch humor, they sat quietly for 20 minutes.
62845836|NCT00001213|EXPERIMENTAL|Cysteamine topical solution|Cysteamine topical solution administered hourly while awake in both eyes
62845837|NCT04721301|EXPERIMENTAL|Combination immunotherapy|Treatment arm with Nivolumab, Ipilimumab and Maraviroc combination treatment
62059497|NCT04763811||Older 65 people|Older 65 people who live alone in their house will be included. They will have focus groups and Individual interviews.
62845838|NCT00594243|EXPERIMENTAL|Intervention|8-week mindfulness based stress reduction program
62845839|NCT00594243|ACTIVE_COMPARATOR|Wait-list control|Wait-list received no intervention during the time the treatment group received the 8-week program
62845840|NCT02476266|NO_INTERVENTION|Control|Participants randomized to this group will come in for testing at pre-intervention, post-intervention, three month wash out and six month wash out. Participants will be asked to continue their activities of daily living. To account for any physical activity changes over the length of the study the Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire will be administered to all individuals. A control group is necessary to compare to show normal disease progression over the length of the study as well as to demonstrate that improvements in outcome measures are due to the interventions and not practice effects.
62845841|NCT02476266|ACTIVE_COMPARATOR|Strength Training|Individuals randomized to this program will complete three sets of eight to ten repetitions at 70% of their predicted 1-RM for each of the exercises mentioned above. The speed of the movements in this program will be two to three seconds each for the concentric and eccentric components. When participants are able to complete ten repetitions in their third set for two consecutive days, weight will be increased for the following session by 5% of the current weight that they are at in accordance with Canadian Society for Exercise Physiology (CSEP) and American College of Sports Medicine (ACSM) guidelines. Participants will complete a total of 24 sessions over the course of 12 weeks, two times per week for an hour each session.
62845842|NCT02476266|EXPERIMENTAL|Power Training|Participants randomized to this program will complete three sets of 12 to 15 repetitions completed at 40% of predicted 1-RM for each exercises. The concentric part of the movement will be completed as fast as possible, whereas the eccentric component will be accomplished in two to three seconds. The load in this group is lower as it has been shown that by performing power training at lighter loads, the muscles are able to be activated, throughout the entire concentric component, while maintaining a consistent level of force. The progression will be determined through the same means as the conventional strength training group. Participants will complete a total of 24 sessions over 12 weeks, twice per week for an hour each session
62845843|NCT01039662|EXPERIMENTAL|Oolong tea containing L-arabinose and indigestible dextrin|
62845844|NCT01039662|PLACEBO_COMPARATOR|Oolong tea|
62845845|NCT01050517|ACTIVE_COMPARATOR|1|albendazole + ivermectin + praziquantel
62059498|NCT01511796|EXPERIMENTAL|upper limb rehabilitation for total of 6 months|upper limb rehabiliation
62059499|NCT04897425|EXPERIMENTAL|Mindful SensoriMotor Therapy Enhanced with Brain Modulation|"The participant can choose between one, two, or five interventions per week depending on their availability.~Steps of each intervention:~1. Pain Evaluation: Numeric Rating Scale (NRS)~2. Functional Assessments (1st, 5th, 10th, and last sessions)~3. Preparation:~   1. Locate participant in a comfortable position for training (comfortable chair, about a meter distance to the screen, pleasant arm position)~  2. Placement of the surface electrodes~  3. Positioning of the feedback wearable device over the affected body part~  4. Placement of the brain modulation cap~4. Treatment modalities:~   1. Motor training~  2. Sensory training~  3. Sensorimotor training~5. Assessments~Step 4 is repeated for different phantom movements, initially one at a time, progressing to several joints simultaneously. A treatment session lasts 2 hours."
62059500|NCT00270361|EXPERIMENTAL|001|nesiritide
62059501|NCT00270361|EXPERIMENTAL|002|nesiritide
62059502|NCT00270361|ACTIVE_COMPARATOR|003|usual long term cardiac medications
62059503|NCT04934722|EXPERIMENTAL|Pembrolizumab + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive 200 mg pembrolizumab intravenously (IV) every 3 weeks (Q3W) for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a luteinizing-hormone releasing hormone (LHRH) agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
62059504|NCT04934722|PLACEBO_COMPARATOR|Placebo + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive placebo IV Q3W for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a LHRH agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
62059505|NCT01222143|EXPERIMENTAL|NOVE-HiDAC and Nilotinib|All patients will be receiving nilotinib combined with mitoxantrone, etoposide and high-dose cytarabine reinduction therapy. Patients achieving complete remission will receive consolidation therapy with nilotinib combined with high-dose cytarabine and mitoxantrone.
62059506|NCT01038115|ACTIVE_COMPARATOR|Cryoballoon|
62059507|NCT01038115|ACTIVE_COMPARATOR|Radiofrequency|
62059508|NCT01038115|ACTIVE_COMPARATOR|Cryoballoon + Radiofrequency together|
62845846|NCT01050517|PLACEBO_COMPARATOR|2|albendazole + ivermectin + (1 week later) praziquantel
62845847|NCT03198325|EXPERIMENTAL|Interruption of antiretroviral therapy|Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values \>50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
62845848|NCT04669626|OTHER|Group 2|Wound cleansing with NaCl (natrium chlorid) solution 0.9%
62845849|NCT04669626|EXPERIMENTAL|Group 1|Wound cleansing with Octenilin®
62845850|NCT00194532|EXPERIMENTAL|Cefpodoxime|Cefpodoxime 100mg twice a day(BID)for 3 days
62619725|NCT05450406|ACTIVE_COMPARATOR|Intervention group|Participants in the intervention group will receive 12-week follow-up from the Healthy Life Center
62845851|NCT00194532|ACTIVE_COMPARATOR|Ciprofloxacin|Ciprofloxacin 250mg twice a day (BID)for 3 days
62619726|NCT05450406|NO_INTERVENTION|Control group|Participants in the intervention group will not receive follow-up from the Healthy Life Center
62845852|NCT02659046||FH30|Patients treated by Pirkanmaa physician-staffed emergency medical service (EMS) unit
62263231|NCT03415295||Gestational diabetes mellitus|"Gestational diabetes mellitus (GDM) was diagnosed according to the American Diabetes Association criteria, which is based on the one-step approach recommended by the International Association of Diabetes and Pregnancy Study Groups. All women underwent a 75g OGTT in the morning after an overnight fast, with plasma glucose measurement fasting and at 1 and 2 hours. The criteria for GDM diagnosis was to have at least one abnormal value: Fasting glucose ≥ 5.1 mmol/L (92 mg/dL), 1 h glucose ≥ 10.0 mmol/L (180 mg/dL), 2 h glucose ≥ 8.5 mmol/L (153 mg/dL)."
62263232|NCT03415295||Healthy pregnant control|Pregnant women with fasting glucose \< 5.1 mmol/L (92 mg/dL), 1 h glucose \< 10.0 mmol/L (180 mg/dL) and 2 h glucose \< 8.5 mmol/L (153 mg/dL) were considered as healthy controls.
62263233|NCT00346073|EXPERIMENTAL|Boostrix Group|Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Boostrix® vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
62263234|NCT00346073|EXPERIMENTAL|Adacel Group|Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Adacel™ vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
62447624|NCT05881148|ACTIVE_COMPARATOR|Standard sprinting carbon-free spiked-shoe|
62447625|NCT01433835|PLACEBO_COMPARATOR|Placebo|
62619727|NCT00048165|EXPERIMENTAL|Daclizumab|Daclizumab will be administered as a intravenous dose of 1 milligrams per kilogram \[mg/kg\] on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily \[BID\], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg, and 500-1000 mg IV methylprednisolone peri operative switch to oral at 0.5-1 mg/kg/day followed by tapering.
62619728|NCT00048165|PLACEBO_COMPARATOR|Placebo|Matching placebo will be administered on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily \[BID\], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg orally, and 500-1000 mg IV methylprednisolone peri-op switch to oral at 0.5-1 mg/kg/day followed by tapering.
62845853|NCT02659046||FH10|Patients treated by Helsinki and Uusimaa physician-staffed emergency medical service (EMS) unit
62845854|NCT03658590|ACTIVE_COMPARATOR|Group D|including 51 women who will receive a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously.
62845855|NCT03658590|PLACEBO_COMPARATOR|Group P|including 51 women who will receive a prefilled syringe with two milliliters of distilled water intravenously.
62845856|NCT02538354|EXPERIMENTAL|Riboflavin supplementation in quiescent disease|Group 1 (n=42) will consist of patients with disease in remission (quiescent disease).
62845857|NCT02538354|EXPERIMENTAL|Riboflavin supplementation in active disease|Group 2 (n=42) will consist of patients with active disease.
62845858|NCT03237286|EXPERIMENTAL|Ketamine + Cognitive Training|
62845859|NCT03237286|SHAM_COMPARATOR|Ketamine + Sham Training|
62845860|NCT03237286|PLACEBO_COMPARATOR|Saline + Cognitive Training|
62845861|NCT04593264|ACTIVE_COMPARATOR|Traditional Supervised Prehabilitation with a Physical Therapist|
62845862|NCT04593264|EXPERIMENTAL|Self-guided Home-based Prehabilitation|
62059509|NCT00805090|ACTIVE_COMPARATOR|Sporanox|Active arm approved as an anti-fungal being used to compare HPβCD when administered in DIC075V compared to Sporanox.
62059510|NCT00805090|EXPERIMENTAL|Dyloject|Diclofenac Sodium
62059511|NCT03188120||Spiriva Respimat group|
62263235|NCT01097746|EXPERIMENTAL|Treatment (paclitaxel, carboplatin, bevacizumab)|Participants receive paclitaxel IV over 3 hours on days 1, 8 and 15 and carboplatin IV over 1 hour on day 1. Beginning course 2, participants also receive bevacizumab IV over 1.5 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62263236|NCT03269045|OTHER|Treatment with ORL-1B.|Pediatric patients with biotinidase deficiency.
62263237|NCT03574090|EXPERIMENTAL|amoxicillin clavulanate|1000 mg amoxicillin and potassium clavulanate equivalent to 200mg of clavulanic acid. administered topically and dissolved in 500 ml 0.9% Physiological Serum.
62263238|NCT03574090|ACTIVE_COMPARATOR|Physiological Saline|500 milliliters of 0.9% Physiological Serum.
62447626|NCT01433835|EXPERIMENTAL|MBX-400|
62619729|NCT03627650|EXPERIMENTAL|1 group of 15 patients|procedure/surgery: fat grafting injection of scar
62619730|NCT03627650|EXPERIMENTAL|Same group of 15 patients|procedure/surgery: placebo injection of scar
62845863|NCT04860778|EXPERIMENTAL|BDNF Essentials|A proprietary blend of botanical extracts and isolates.
62845864|NCT02409277|EXPERIMENTAL|Standard e-AT Intervention|Patients in Standard e-AT or standard intervention group will receive a daily (if a participant forgets to complete his/her weekly assessment) email and text reminders with a link to the e-AT website to help patient/parent participants to comply with their weekly assessment of patient's level of asthma control. Note: patient/parent participants are required to complete their asthma control assessment 1x/week. The e-AT is now set up to send a weekly reminder to participants with a link to the website. If a participant does not complete an assessment within a week of the last assessment, the reminder will be sent daily until the patient/parent complies and the system resets to weekly.
62845865|NCT02409277|EXPERIMENTAL|Intensive e-AT Intervention|Participants in the intensive e-AT or adherence support intervention will receive everything as those in Standard Intervention. In addition, they will see a progress bar display, which adds 25 points each time they complete an assessment. When this bar reaches 100 points, a pop-up message with fireworks will appear to congratulate them about the milestone. The progress bar resets to zero after it reaches 100 points. Participants will also see a leader board allowing them to compare themselves with the 5 best users to increase compliance.
62845866|NCT02409277|NO_INTERVENTION|Usual Care (Non-Randomized Cohort)|Both arms (Intensive and standard e-AT interventions) will be compared to each other as well as to a non-randomized cohort who did not receive the e-AT interventions. These non-randomized cohort will be matched 2:1 to each randomized individuals.
62623763|NCT01050322|EXPERIMENTAL|Vinorelbine Lapatinib|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
62059512|NCT02796430||Mechanically ventilated patients|Ease of use will be assessed by analysing the time needed to start indirect calorimetry measurement, and results of indirect calorimetry measurements by both the new indirect calorimeter and the currently used calorimeters at each study center.
62059513|NCT02913066|EXPERIMENTAL|Single drug|S-1 concurrent Radiotherapy
62059514|NCT02913066|ACTIVE_COMPARATOR|Double drug|S-1 plus cisplatin concurrent Radiotherapy
62059515|NCT02923739|ACTIVE_COMPARATOR|Arm I (paclitaxel, bevacizumab)|Patients receive paclitaxel IV over 60 minutes on days 1, 8, 15, and 22 and bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62059516|NCT02923739|EXPERIMENTAL|Arm II (paclitaxel, bevacizumab, emactuzumab)|Patients receive paclitaxel and bevacizumab as in Arm I. Patients also receive emactuzumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62059517|NCT00735111|EXPERIMENTAL|Karnofsky Performance Status Score|
62263239|NCT05433571|EXPERIMENTAL|Myopes - Against the Rule Sequence 1|Eligible subjects that are habitual contact lens wearers will be randomized to the Myope, against-the-rule-astigmatism, (LOW/HIGH DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
62263240|NCT05433571|EXPERIMENTAL|Myopes - Against the Rule Sequence 2|Eligible subjects that are habitual contact lens wearers will be randomized to the Myope, against-the-rule-astigmatism, (HIGH/LOW DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
62447627|NCT05016349|EXPERIMENTAL|All trans-retinoic acid, Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral All trans-retinoic acid and Mifepristone daily for 2 weeks ,after which daily oral Cannabidiol (Epidiolex) is added to the regimen for 2 weeks , after which daily oral tamoxifen is added to the regimen. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
62059518|NCT04774523|ACTIVE_COMPARATOR|Control group|This group will be made up of patients implanted with CRT-D devices without the CRT AutoAdapt feature, or with the CRT AutoAdapt feature deactivated.
62059519|NCT04774523|EXPERIMENTAL|AutoAdapt group|This group will be made up of patients implanted with CRT-D devices that have the CRT AutoAdapt feature available. It is mandatory that all patients within this group have the feature activated, independently of other characteristics.
62263241|NCT05433571|EXPERIMENTAL|Myopes - With the Rule Sequence 1|Eligible subjects that are habitual contact lens wearers will be randomized to the Myope, with-the-rule-astigmatism, (LOW/HIGH DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
62263242|NCT05433571|EXPERIMENTAL|Myopes - With the Rule Sequence 2|Eligible subjects that are habitual contact lens wearers will be randomized to the Myope, with-the-rule-astigmatism, (HIGH/LOW DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
62447628|NCT05016349|EXPERIMENTAL|Mifepristone, Cannabidiol (Epidiolex) , All trans-retinoic acid and tamoxifen|Patients will receive oral Mifepristone daily for 4 weeks ,after which daily oral All trans-retinoic acid, tamoxifen and Cannabidiol (Epidiolex) is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
62619731|NCT02918097|EXPERIMENTAL|Lithium Carbonate|"Group Started: Lithium Carbonate (900mg-1500mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Lithium (LSL 0.6-0.8). Non responsive patients: 2nd step.~Second step: Monotherapy with lithium (LSL 1.0-1.2). Non responsive patients: 3rd step.~Third step: Lithium + Sertraline (50mg-200mg). Non responsive patients: 4th step.~Fourth step: Lithium + Nortriptyline 100mg. Non responsive patients: 5th step.~Fifth step: Lithium + Nortriptyline 100mg + Sertraline (100mg-200mg). Non responsive patients: 6th step~Sixth step: Lithium + Nortriptyline 100mg + Sertraline 200mg + Risperidone (1mg-6mg)."
62263243|NCT05433571|EXPERIMENTAL|Hyperopes - Against the Rule Sequence 1|Eligible subjects that are habitual contact lens wearers will be randomized to the Hyperope, against-the-rule-astigmatism, (LOW/HIGH DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
62263244|NCT05433571|EXPERIMENTAL|Hyperopes - Against the Rule Sequence 2|Eligible subjects that are habitual contact lens wearers will be randomized to the Hyperope, against-the-rule-astigmatism, (HIGH/LOW DC) sequence and wear two different study lens designs one at time bilaterally over 2 wear periods.
62263245|NCT05433571|EXPERIMENTAL|Hyperope - With the Rule Sequence 1|Eligible subjects that are habitual contact lens wearers will be randomized to the Hyperope, with-the-rule-astigmatism, (LOW/HIGH DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
62263246|NCT05433571|EXPERIMENTAL|Hyperope - With the Rule Sequence 2|Eligible subjects that are habitual contact lens wearers will be randomized to the Hyperope, with-the-rule-astigmatism, (HIGH/LOW DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
62263247|NCT06361732||Liver Transplant|Liver Transplant
62263248|NCT04867473|EXPERIMENTAL|Teleyoga|Lyme disease participants will attend home-based yoga sessions using HIPAA-compliant telehealth software and devices and complete pain inventory questionnaires pre and post-treatment
62263249|NCT00997100|OTHER|ABR-215757|
62263250|NCT05590286|EXPERIMENTAL|vonoprazan 20mg QD|Vonoprazan 20 mg, tablets, orally, qd given in combination with amoxicillin 750mg capsules, orally, qid for up to 2 weeks.
62447629|NCT05016349|EXPERIMENTAL|Mifepristone , All trans-retinoic acid, Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, All trans-retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
62447630|NCT05016349|EXPERIMENTAL|9 cis retinoic acid, Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, 9 cis retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
62845867|NCT04856839||syringomyelia group|
62845868|NCT04856839||Other neurodegenerative diseases|such as hydrocephalus
62845869|NCT04856839||Normal group|
62059520|NCT02243202|EXPERIMENTAL|Canagliflozin + Phentermine|300 mg capsule of Canagliflozin along with 15 mg capsule of Phentermine, taken once daily, orally for 26 weeks.
62059521|NCT02243202|EXPERIMENTAL|Canagliflozin + Placebo (Phentermine)|300 mg capsule of Canagliflozin along with matching placebo to Phentermine, taken once daily, orally for 26 weeks.
62059522|NCT02243202|EXPERIMENTAL|Phentermine + Placebo (Canagliflozin)|15 mg capsule of Phentermine along with matching placebo to Canagliflozin, taken once daily, orally for 26 weeks.
62845870|NCT05071768|EXPERIMENTAL|ACT|Focused ACT Group Treatment
62059523|NCT02243202|PLACEBO_COMPARATOR|Placebo|Matching placebo to Canagliflozin and Phentermine, taken once daily, orally for 26 weeks.
62059524|NCT03732625|EXPERIMENTAL|Raltegravir|Raltegravir (RAL) x 2 600mg QD (Total 1200mg QD)
62263251|NCT05590286|ACTIVE_COMPARATOR|esomeprazole 20 mg BID|"esomeprazole 20 mg, tablets, orally, bid given in combination with amoxicillin 1000mg，clarithromycin 500mg bid，colloidal bismuth pectin 200mg bid for up to 2 weeks.~OR esomeprazole 20 mg, tablets, orally, bis in die given in combination with amoxicillin 750mg capsules, orally, quarter die for up to 2 weeks."
62845871|NCT05466617|EXPERIMENTAL|PuzzleWalk|"PuzzleWalk incorporates behavior change techniques (BCTs), a theory-based method of promoting healthy behavior change by leveraging psychological determinants. The example techniques included in PuzzleWalk are a comprehensive, visualized user guide, self-monitoring of target performance, contingent rewards, and goal setting.~It is a spot the difference puzzle game comprising 660 major city images around the world. This format was chosen because it is easy to understand the purpose of the game, and it can quickly capture the user's interests without a complex comprehension process. Moreover, this visual image-based game facilitates visual interaction, which is a unique strength of individuals with ASD. The most unique design element of PuzzleWalk is the conversion algorithm between steps and game-solving time. Specifically, the user's accumulated steps are directly converted to game-solving time to motivate PA participation."
62059525|NCT02669095|EXPERIMENTAL|Arm 1 (Test Lens)|Subjects will be dispensed the Investigational Contact Lenses (Test) to be worn as daily wear.
62447631|NCT05016349|EXPERIMENTAL|Mifepristone, 13 cis retinoic acid , Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, 13 cis retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
62845872|NCT05466617|EXPERIMENTAL|Google Fit|Google Fit (Google LLC) is a PA-tracking platform developed by Google for Android and Apple iOS. The app uses a sensor built into a smartphone device to automatically track PA, including steps and active minutes. It also allows users to journal and record a variety of forms of PA (eg, cycling, weightlifting, and yoga) by manually setting the activity tracking mode. Google Fit uses a heart point-based reward system as a gamification strategy to provide users with individualized exercise tips incorporated with PA recommendations outlined by the American Heart Association. The number of heart points received based on active minutes is the app's primary gamification strategy.
62845873|NCT03871218|ACTIVE_COMPARATOR|Test Group|Hyaluronic acid application group. After FGG was taken from the donor region in the TG, sterile gauze was applied with moderate pressure for 2 minutes, and HA was applied topically after the bleeding stopped. The cross-linked HA package containing 20 mg/ml Na-hyaluronate, stored at room temperature, was opened, and the protective cap of the syringe was removed.
62845874|NCT03871218|NO_INTERVENTION|Control Group|In the control group (CG), HA was not applied to the recipient or the donor site.
62845875|NCT02936921||Pergravidic maternal infections|proven maternal infections: true seroconversions of profiles of recent infections
62845876|NCT02936921||Subjects free of congenital infection|children who whom all tests performed before birth, at birth and after birth confirmed the absence of congenital toxoplasmosis.
62845877|NCT02936921||Congenitally infected subjects|children for whom at least one test performed before birth, at birth or after birth demonstrated a congenital infection.
62845878|NCT04609644|NO_INTERVENTION|Passive|"Passive arm participants will be sent two devices, at no cost-an Apple Watch and a Beddit Sleep Monitor. These are commercially available and have not been modified for this study. Participants will be asked to use these devices regularly throughout study Year 1. Participants can optionally continue to use devices during Year 2, if they have met requirements during Year 1 to keep study devices. To be eligible to keep devices, participants must meet pre-specified levels of adherence to study procedures.~Access to the Study App will be provided to all participants. It will be used to administer informed consent and electronic patient reported outcome (ePRO) measures, and for other study purposes. However, passive participants will not have access to the Study App features designed to support asthma self-management."
62845879|NCT04609644|EXPERIMENTAL|Active|"Active arm participants will be sent the same devices, also at no cost, and asked to use them in the same manner.~Only the active arm will have access to Study App features for asthma self-management, including:~* Smart nudges that may promote proactive asthma self-management~* Asthma symptom and trigger tracking~* Evidence-based asthma education~* The ability to photograph and easily reference an asthma action plan from a healthcare provider.~* A 90-day summary of self-reported asthma symptoms/triggers and device-recorded heart rate and respiratory rate. This summary can be shared with providers.~* In-app viewing of active asthma medications, refills available, and phone numbers to call for refills (subject to prescription benefits).~Active participants can, but are not required to, use the Study App in Year 2. Those who choose to may keep using study devices in Year 2, provided they meet requirements to keep devices. These requirements are the same for both arms."
62845880|NCT04412785|EXPERIMENTAL|Single Arm|Cyclosporine; oral or IV route of administration, per investigator discretion. Duration of administration up to 14 days, as tolerated.
62845881|NCT01043289|EXPERIMENTAL|Bright light therapy|Early morning white light @ 7,000 lux for 60 minutes daily (4.2 x 10\^5 lux-min) for 5 weeks
62845882|NCT01043289|PLACEBO_COMPARATOR|Dim red light|Early morning dim red light @ 70 lux for 60 minutes daily (3.0 x 10\^3 lux-min) for 5 weeks
62845883|NCT03540836|EXPERIMENTAL|Relacorilant 3x100mg softgel capsules|Relacorilant (3x100 mg softgel capsules)
62845884|NCT03540836|EXPERIMENTAL|Relacorilant 3x100mg hard-shell capsules|Relacorilant (3x100 mg hard-shell capsules)
62845885|NCT03540836|EXPERIMENTAL|Relacorilant 6x50mg hard-shell capsules|Relacorilant (6x50mg hard-shell capsules)
62845886|NCT02823067||Nursing home patients|Nursing home patients aged 65 years or above. One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
62845887|NCT03746119|ACTIVE_COMPARATOR|Nicotine-free e-cigarette|Subjects will undergo baseline assessments, then actively inhale nicotine-free vapor from an e-cigarette prior to blood samples and various cardiovascular testing.
62845888|NCT03746119|ACTIVE_COMPARATOR|Nicotine e-cigarette|Subjects will undergo baseline assessments, then actively inhale nicotine containing vapor from an e-cigarette prior to blood samples and various cardiovascular testing.
62845889|NCT05909657||Sickle Cell Disease patients = or > 18 years in Jamaica|surveys, interviews
62845890|NCT05909657||Adult Caregivers of Sickle Cell Disease Children/Adolescents under 18 years|surveys, interviews
62059526|NCT02669095|ACTIVE_COMPARATOR|Arm 2 (Control Lens)|Subjects will be dispensed the Marketed Contact Lenses (Control) to be worn as daily wear.
62845891|NCT05909657||Healthcare Providers: SCD Physicians, Nurses and Pharmacists|surveys and interviews
62263252|NCT03115567|NO_INTERVENTION|Control|Patients in Control group will be instructed to follow a daily moisturizer and sunscreen regimen. Erlotinib, cetuximab, panitumumab, or afatinib will be administered as standard of care treatment.
62263253|NCT03115567|EXPERIMENTAL|Triamcinolone|Patients in the Triamcinolone group will be applying Triamcinolone 0.1% cream daily to their face, chest, and upper back, in addition to adhering to the same daily moisturizer and sunscreen regimen of the Control group. Erlotinib, cetuximab, panitumumab, or afatinib will be administered concomitantly as standard of care treatment.
62263254|NCT05972200|EXPERIMENTAL|HD-tDCS V5/MT, HD-tDCS V1, Sham|"1. Active HD-tDCS over V5/MT~2. Active HD-tDCS over V1~3. Sham HD-tDCS over V5/MT or V1"
62263255|NCT05972200|EXPERIMENTAL|HD-tDCS V5/MT, Sham, HD-tDCS V1|"1. Active HD-tDCS over V5/MT~2. Sham HD-tDCS over V5/MT or V1~3. Active HD-tDCS over V1"
62263256|NCT05972200|EXPERIMENTAL|HD-tDCS V1, HD-tDCS V5/MT, Sham|"1. Active HD-tDCS over V1~2. Active HD-tDCS over V5/MT~3. Sham HD-tDCS over V5/MT or V1"
62263257|NCT05972200|EXPERIMENTAL|HD-tDCS V1, Sham, HD-tDCS V5/MT|"1. Active HD-tDCS over V1~2. Sham HD-tDCS over V5/MT or V1~3. Active HD-tDCS over V5/MT"
62263258|NCT05972200|EXPERIMENTAL|Sham, HD-tDCS V5/MT, HD-tDCS V1|"1. Sham HD-tDCS over V5/MT or V1~2. Active HD-tDCS over V5/MT~3. Active HD-tDCS over V1"
62263259|NCT05972200|EXPERIMENTAL|Sham, HD-tDCS V1, HD-tDCS V5/MT|"1. Sham HD-tDCS over V5/MT or V1~2. Active HD-tDCS over V1~3. Active HD-tDCS over V5/MT"
62263260|NCT03027531|EXPERIMENTAL|Control|Control group entered sexual history via computer assisted self-interview and provided specimens for chlamydia, gonorrhea and pregnancy(females) testing. The do not receive the feedback intervention of eKISS: electronic KIOSK for safer-sex
62447632|NCT05016349|EXPERIMENTAL|9 cis retinoic acid , Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral 9 cis retinoic acid and Mifepristone daily for 2 weeks ,after which daily oral Cannabidiol (Epidiolex) is added to the regimen for 2 weeks , after which daily oral tamoxifen is added to the regimen. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
62619732|NCT02724566|OTHER|Apelin then Placebo|First clamp during which an apelin infusion will be administered followed by a wash-out period and then, a second clamp in which a placebo infusion will be administered
62263261|NCT03027531|EXPERIMENTAL|Intervention|Intervention group entered sexual history via computer assisted self-interview and received the interactive computer-based intervention with individualized feedback eKISS: electronic KIOSK for safer-sex. They provided specimens for chlamydia, gonorrhea and pregnancy(females) testing.
62263262|NCT01394042|NO_INTERVENTION|No intervention|All consenting patients will be imaged with the Proxiscan and data compared with MRI, ProstaScint and biopsy data
62845892|NCT06424314||weaning success|Patient passed SBT test with no need to receive invasive mechanical ventilation 48 hours after extubation
62845893|NCT06424314||weaning failure|Patient failed SBT test or need to receive invasive mechanical ventilation 48 hours after extubation
62845894|NCT06208475|EXPERIMENTAL|The exercise in the follicular phase (EF)|Resistance exercise during the early-follicular phase (approximately during days 1-7 of the menstrual cycle).
62845895|NCT06208475|EXPERIMENTAL|The exercise in the luteal phase (EL)|Resistance exercise during the mid-luteal phase (approximately during days 18-25 of the menstrual cycle).
62845896|NCT06208475|NO_INTERVENTION|The control in the follicular phase (CF)|Sit and rest during the early-follicular phase (approximately during days 1-7 of the menstrual cycle).
62845897|NCT06208475|NO_INTERVENTION|The control in the luteal phase (CL)|Sit and rest during the mid-luteal phase (approximately during days 18-25 of the menstrual cycle).
62845898|NCT00742235|EXPERIMENTAL|1|Vitamin D insufficient (treated with ergocalciferol 50,000 IU every other day x 5 doses)
62845899|NCT00742235|NO_INTERVENTION|Vitamin D sufficient|Subjects who did not receive ergocalciferol and had a 25-OH vitamin D level \>32 ng/ml
62845900|NCT04738461|EXPERIMENTAL|Telerehabilitation|Telerehabilitation program will be applied 5 days a week for 3 weeks to patients in the telerehabilitation group. A physiatrist will meet with patients via videoconferencing over the internet and guide the program.
62845901|NCT04738461|ACTIVE_COMPARATOR|Standard Physiotherapy|Patients in the standard physiotherapy group will receive one-to-one physiotherapy sessions in the hospital 5 days a week for 3 weeks. In these sessions, active-passive exercises accompanied by a physiotherapist and physical therapy methods (electrotherapy and thermotherapy) will be applied in accordance with the standard procedure according to the patient's needs.
62263263|NCT03536871|ACTIVE_COMPARATOR|Multinutrient Supplement|Participants will be allocated in a randomized double-masked manner to receive a multi-nutrient supplement (protein and creatine sachet and omega-3 oil) or placebo during a 12 week home-based exercise program and we will assess the influence on the primary and secondary outcomes.
62263264|NCT03536871|NO_INTERVENTION|Age biological and chronological|The primary and secondary outcomes will be compared between the younger and older age groups as a function of both exercise and nutritional supplementation.
62263265|NCT03536871|NO_INTERVENTION|Sarcopenia grades|The baseline primary and secondary outcomes will be compared for each of the 3 older adults males groups as a function of muscle mass (healthy active, mild sarcopenia and moderate sarcopenia).
62263266|NCT03536871|EXPERIMENTAL|Exercise - home based programme|Each of the older participants will undergo a 12 week home-based exercise program (endurance = increased steps; resistance = body weight and elastic band exercise) to determine the effects on the primary and secondary outcomes.
62263267|NCT05219942|PLACEBO_COMPARATOR|low dose insulin infusion +Subcutaneous saline|low dose insulin infusion +Subcutaneous saline
62263268|NCT05219942|ACTIVE_COMPARATOR|low dose insulin infusion +subcutaneous Glargine insulin|low dose insulin infusion +subcutaneous Glargine insulin
62263269|NCT04500977|EXPERIMENTAL|Training community health promotion leaderss|Community women are trained in leadership and community-based health promotion skills
62263270|NCT01114503|EXPERIMENTAL|Part A|Up to 4 cohorts of 5 patients receive dose rising treatments of otelixizumab
62447633|NCT05016349|EXPERIMENTAL|13 cis retinoic acid , Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, 13 cis retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
62447634|NCT05016349|SHAM_COMPARATOR|Standard therapy|Patients will receive the approved standard therapy
62447635|NCT03337178|NO_INTERVENTION|Control|Standard of care
62447636|NCT03337178|EXPERIMENTAL|Blinded Fitbit|Blinded Fitbit, no step goal, and no activity feedback
62447637|NCT03337178|EXPERIMENTAL|Fitbit|Fitbit plus step goal and activity feedback
62059527|NCT05412888|PLACEBO_COMPARATOR|Supplemented population 300mg|Supplemented population 300mg/24h CoQ10 - 25 participants
62059528|NCT05412888|EXPERIMENTAL|Training and IPC preconditioning|Group subjected to training and preconditioning by ischemia (IPC training) - 25 participants,
62059529|NCT05412888|PLACEBO_COMPARATOR|Control group (placebo)|Control group to CoQ10 supplementation (placebo)- 25 participants
62059530|NCT05412888|SHAM_COMPARATOR|IPC control group|IPC control group - 25 participants
62059531|NCT05664932|EXPERIMENTAL|LYB001 Booster Group|Subjects 18 years of age or older who has completed two or three-dose inactivated COVID-19 will receive 30μg LYB001 at day 0 as a booster vaccination.
62059532|NCT05664932|ACTIVE_COMPARATOR|ZF2001 Booster Group|Subjects 18 years of age or older who has completed two or three-dose inactivated COVID-19 will receive ZF2001 at day 0 as a booster vaccination.
62059533|NCT04655885|EXPERIMENTAL|Optimization of cardiac flow by base water-electrolyte supply|Optimization of cardiac flow by base water-electrolyte supply of 1 ml / kg / h by Ringer Lactate® and faced with any decrease of more than 10% of the VES compared to the reference VES, achievement of an optimization of the preload by administration of 250 ml of Ringer Lactate® with renewal until correction of the VES.
62059534|NCT04655885|OTHER|Control arm|Increase basic hydro-electrolyte supply of 6 ml / kg / h by Ringer Lactate® and 1: 1 blood loss compensation by crystalloids of the same nature.
62263271|NCT01114503|EXPERIMENTAL|Part B - Otelixizumab|Parallel dosing group in Part B receive otelixizumab over 8 days at a dose decided upon results from Part A
62263272|NCT01114503|ACTIVE_COMPARATOR|Part B - Methylprednisolone|Parallel dosing group in Part B of weekly doses of methylprednisolone for 12 weeks
62263273|NCT01028092|ACTIVE_COMPARATOR|Control|anti R-IL2 induction + Mycophenolate Mofetil + cyclosporine A + corticosteroids
62263274|NCT01028092|EXPERIMENTAL|CNI-free|Thymoglobulin + Mycophenolate Mofetil + everolimus + corticosteroids
62447638|NCT05681624|OTHER|Oxygen|
62447639|NCT05681624|ACTIVE_COMPARATOR|Room air|
62447640|NCT06130956|EXPERIMENTAL|Vegan group|Subjects in the vegan group will receive a vegan diet during the 2-week preoperative period.
62447641|NCT06130956|ACTIVE_COMPARATOR|Omnivorous group|Subjects in the omnivorous group will receive an omnivorous diet during the 2-week preoperative period.
62447642|NCT02605109||RiskMERS|Exposed to case-patients
62447643|NCT06544551|EXPERIMENTAL|Peginterferon Alfacon-2 treated patients|
62263275|NCT01028092|EXPERIMENTAL|Switch|anti R-IL2 + Mycophenolate Mofetil + (Cyclosporine then Everolimus) + corticosteroids
62447644|NCT06544551|PLACEBO_COMPARATOR|Peginterferon Alfacon-2 placebo treated patients|
62263276|NCT05989906|ACTIVE_COMPARATOR|Usual Care|Participant will take part in the usual care during inpatient rehabilitation
62263277|NCT05989906|EXPERIMENTAL|Spring Interval Training (SIT)|Participant will take part in SIT approximately three times per week during inpatient rehabilitation.
62263278|NCT05989906|EXPERIMENTAL|SIT + ERGO|Participant will take part in SIT approximately three times per week during inpatient rehabilitation. In addition, participant will be provided with an consumer grade ergometer for home use.
62263279|NCT05989906|EXPERIMENTAL|SIT + ERGO + MI|Participant will take part in SIT approximately three times per week during inpatient rehabilitation. In addition, participant will be provided with an consumer grade ergometer for home use. The participant will receive Motivational Interviewing sessions with a rehab psychologist one time per week (approximately 4 sessions) during inpatient rehabilitation and one time per month for six months after discharge from the hospital
62447645|NCT05503004|EXPERIMENTAL|Intervention group|comprehensive prehabilitation program including supervised exercise., mindfulness and nutrition assessment.
62059535|NCT06446076|NO_INTERVENTION|Control group|"Participants in this group will not receive goal-setting or gamification interventions during the 6-week intervention period and the additional 6-week follow-up period. As an active control during the 12-week trial period, participants will be able to check their daily step counts using an application with the same specifications."
62059536|NCT06446076|EXPERIMENTAL|Gamification (Loss framing)|This group will receive a gamification intervention with loss framing.
62263280|NCT04706676|EXPERIMENTAL|Integrative neuromuscular training + motivational counseling + usual care|General and specific strength and conditioning elements such as strength, power, motor skill training, dynamic stability, core-focused strength, plyometric and agility.
62263281|NCT04706676|ACTIVE_COMPARATOR|Active control group + motivational counseling + usual care|home-based training program
62447646|NCT05503004|ACTIVE_COMPARATOR|Standard care|Standard care before surgery
62447647|NCT05654779|EXPERIMENTAL|LCAR-AMDR Cells Product|Each subject will be treated with LCAR-AMDR Cells
62447648|NCT06484036|EXPERIMENTAL|Group with periodontal treatment strategy|Group with periodontal treatment strategy, in addition to routine care and secondary prevention of ischemic stroke
62447649|NCT06484036|NO_INTERVENTION|Group without periodontal treatment|Group without periodontal treatment, with routine care and secondary prevention of ischemic stroke
62447650|NCT01933295|ACTIVE_COMPARATOR|Sleep Education|Weekly educational emails sent to participants with information about sleep science and tips for better sleep.
62447651|NCT01933295|EXPERIMENTAL|Cognitive Behavioral Therapy for Insomnia|Behavioral treatment (5 component)
62447652|NCT01933295|EXPERIMENTAL|Sleep Restriction Therapy|Brief sleep restriction therapy.
62447653|NCT03267056||DCB arm|drug eluting balloon catheter
62619733|NCT02724566|OTHER|Placebo then Apelin|First clamp during which a placebo infusion will be administered followed by a wash-out period and then, a second clamp in which an apelin infusion will be administered
62845902|NCT04738461|ACTIVE_COMPARATOR|Home exercise group|The home exercise program was explained to the patients in the control group by the physiotherapist and the relevant brochures were delivered to the patients. Home exercise program will consist of telerehabilitation group exercises. However, patients will be not under any supervision and exercise themselves at home.
62059537|NCT06446076|EXPERIMENTAL|Gamification (Gain framing)|This group will receive a gamification intervention with gain framing.
62845903|NCT01950013|NO_INTERVENTION|Passive Control|Hearing aid alone
62845904|NCT01950013|EXPERIMENTAL|Training|Auditory Training Program. Hearing aid plus auditory training
62845905|NCT01950013|SHAM_COMPARATOR|Active control|Sham comparator: Active control. Hearing aid plus audio-book use
62845906|NCT05805319|NO_INTERVENTION|Control Group|Patients in the control arm will complete the dietary survey without dietary intervention or counselling from a dietician. Control group will have dietary survey and 24-hour recall survey at baseline, at 6 weeks, and at 12 weeks relative to ICI initiation.
62263282|NCT03065907|ACTIVE_COMPARATOR|Vision Rehabilitation Group 1|Vision rehabilitation assessment will be scheduled within 1 months of randomization; interventions will be scheduled and vision rehabilitation appointments will be scheduled accordingly.
62263283|NCT03065907|ACTIVE_COMPARATOR|Vision Rehabilitation Group 2|Vision rehabilitation assessment will be scheduled within 7 months of randomization; interventions will be scheduled and vision rehabilitation appointments will be scheduled accordingly.
62845907|NCT05805319|EXPERIMENTAL|Intervention Group|Patients in the intervention arm will complete a dietary survey and be counselled on increasing their total fiber intake. Intervention group will have dietary survey and 24-hour recall survey at baseline, at 6 weeks, and at 12 weeks relative to ICI initiation.
62845908|NCT03404752|EXPERIMENTAL|Peg-Neutropine®|Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
62845909|NCT03404752|ACTIVE_COMPARATOR|Neulastim®|Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
62845910|NCT04335734|ACTIVE_COMPARATOR|Nissen fundoplication with fixation of the wrap|In this arm, which included 87 patients we performed the following manipulations: NF was supplemented with suturing wrap to the diaphragmatic crura (52 patients) on each side using two non-absorbable stitches. In case of weak conditions of crura or short esophagus (35 patients) fundoplication wrap was sutured to the body of stomach using two non-absorbable stitches on each side. .
62845911|NCT04335734|ACTIVE_COMPARATOR|Nissen fundoplication without fixation of the wrap|Arm included 51 patients, who underwent classic Nissen fundoplication without wrap fixation.
62845912|NCT05261529|NO_INTERVENTION|Control Group|Control Group with 30 patients diagnosed with SLE following their normal lifestyle in terms of dietary intake and physical exercise.
62845913|NCT05261529|EXPERIMENTAL|Oil Group|Group with 30 patients diagnosed with SLE that add to their normal dietary intake a supplementation with 40ml of EVOO daily during 24 weeks, without changing their lifestyle in terms of physical exercise.
62059538|NCT06446076|EXPERIMENTAL|Gamification (Loss framing) + Social support|This group will receive a gamification intervention with loss framing and a social support intervention.
62059539|NCT06446076|EXPERIMENTAL|Gamification (Gain framing) + Social support|This group will receive a gamification intervention with gain framing and a social support intervention.
62059540|NCT04358172|EXPERIMENTAL|Mobile app|Participants in this group is educated using the mobile application
62059541|NCT04358172|NO_INTERVENTION|Control|Participants in this group is educated using the conventional method practised in the Faculty of Dentistry, National University of Malaysia (verbal instructions accompanied by demonstrations on dental models)
62263284|NCT02445807|EXPERIMENTAL|DFD-06 cream|DFD-06 Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
62263285|NCT02445807|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
62263286|NCT00226109|ACTIVE_COMPARATOR|A|
62263287|NCT00271596|EXPERIMENTAL|Citalopram|20mg daily citalopram
62263288|NCT00271596|PLACEBO_COMPARATOR|Placebo|Matching daily placebo
62447654|NCT00743067|EXPERIMENTAL|Cohort 1|Cohort 1 will include 60 milligram (mg) of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
62619734|NCT01908309|ACTIVE_COMPARATOR|Iodixanol|Patients randomized to coronary angiography/angioplasty with Iodixanol 320
62619735|NCT01908309|ACTIVE_COMPARATOR|Iobitridol|Patients randomized to coronary angiography/angioplasty with Iobitridol 350
62845914|NCT05261529|EXPERIMENTAL|Oil + Exercise Group|Group with 30 patients diagnosed with SLE that besides adding to their normal dietary intake a supplementation with 40ml of EVOO daily during 24 weeks, will follow a physical exercise multimodal program the 12 last weeks.
62845915|NCT01282619|EXPERIMENTAL|Huperzine A Sustained-Release Tablet|
62059542|NCT04958356||Children with increased risk for T1D and/or CeD|The participants carrying HLA-conferred susceptibility to type 1 diabetes will be screened annually for four diabetes predictive autoantibodies and followed up to 1-3 years of age. The participants carrying HLA-conferred susceptibility to celiac disease are screened for tissue transglutaminase antibodies (tTGA) at the age of 1 and 3 years. If a child tests positive for such autoantibodies, endomysial antibodies will be analyzed.
62059543|NCT04129814|EXPERIMENTAL|test group|Non-surgical periodontal treatment consisted of oral hygiene instructions (OHI), single session full-mouth scaling and root planing (SRP)
62059544|NCT04129814|NO_INTERVENTION|control group|no periodontal treatment was performed during the follow-up period in the control group.
62059545|NCT01945905|EXPERIMENTAL|Extramural|Extramural medication delivery and supervision
62263289|NCT01599403|ACTIVE_COMPARATOR|Paravertebral Block|Patients will receive 1 or 2 paravertebral catheters for ongoing infusion of local anesthestic
62059546|NCT01945905|ACTIVE_COMPARATOR|Intramural|Intramural medication delivery and supervision
62263290|NCT01599403|NO_INTERVENTION|Patient Controlled Anesthesia|Standard usual care
62447655|NCT00743067|EXPERIMENTAL|Cohort 2|Cohort 2 will include 120 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
62263291|NCT01599403|EXPERIMENTAL|Epidural Block|"Intervention:~Patients will have epidural catheters placed for the infusion of local anesthetic solution to control pain (if qualified for this approach and randomized here)"
62263292|NCT01599403|ACTIVE_COMPARATOR|Intercostal Nerve Block|Patients will receive intercostal catheters for the infusion of local anesthetic solution to control pain(if qualified for this arm and randomized here)
62447656|NCT00743067|EXPERIMENTAL|Cohort 3|Cohort 3 will include 240 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
62845916|NCT01282619|ACTIVE_COMPARATOR|Huperzine A Tablet|
62845917|NCT01282619|PLACEBO_COMPARATOR|Placebo|
62845918|NCT02894736|EXPERIMENTAL|Active tDCS|Soterix tDCS machine is used to administer active stimulation
62845919|NCT02397629||Patients Undergoing Prostate Biopsy|Men referred for biopsy because of an abnormal or suspicious PSA digital rectal exam, or both.
62845920|NCT04629066|NO_INTERVENTION|Usual care|Usual care will include regularly scheduled visits with the clinical heart failure care team and medical therapy as prescribed by that team.
62845921|NCT04629066|EXPERIMENTAL|Remote prescription for aerobic exercise|The exercise prescription will be created by an exercise physiologist after incorporating remotely collected data from a patient directed smartphone app assessing HF symptom severity, vital signs, weight, and blood sugar, and cardiac implant measures of physical activity, heart rate, heart failure volume status and heart rhythm, and Fitbit measures of physical activity.
62447657|NCT00743067|EXPERIMENTAL|Cohort 4|Cohort 4 will include 480 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
62619736|NCT00674895|EXPERIMENTAL|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
62845922|NCT06072456|EXPERIMENTAL|lateral suspension|Suspending the cervix to the bilateral abdominal wall through subperitoneal tunnels may properly mimic cardinal ligament and restore the normal vaginal axis. Preoperative and postoperative MRI results were evaluated
62845923|NCT06072456|EXPERIMENTAL|pectopexy|The cervix or vaginal cuff was suspended by the Cooper ligament.Preoperative and postoperative MRI results were evaluated
62845924|NCT06072456|EXPERIMENTAL|sacrospinous ligament fixation|vaginal cuff/uterus was sutured to the unilateral sacrospinous ligament.Preoperative and postoperative MRI results were evaluated
62845925|NCT06072456|NO_INTERVENTION|hysterectomized patients|Vaginal axis MRI of women who have previously been hysterectomized and who do not have apical prolapse
62059547|NCT00751764|EXPERIMENTAL|1|
62059548|NCT04203043|ACTIVE_COMPARATOR|Pycnogenol oral product to prevent Hyperpigmentation|Evaluate hyperpigmentation post foam sclerotherapy with placebo versus pycnogenol use
62263293|NCT06156982||Evusheld administered group|
62263294|NCT05927051|EXPERIMENTAL|Stabilization exercises|Core stability exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
62263295|NCT05927051|EXPERIMENTAL|McKenzie exercises|McKenzie exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
62263296|NCT05927051|EXPERIMENTAL|Home exercises|Home exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
62059549|NCT04203043|PLACEBO_COMPARATOR|Placebo to prevent hyperpigmentation|Evaluate hyperpigmentation post foam sclerotherapy with placebo versus pycnogenol use
62263297|NCT05745220|OTHER|Daily contact lens wear|Participant wear silicone hydrogel contact lenses daily for 6 weeks ±2 days for a minimum wearing time of 5 days per week and 8 hours per day - corneal sensitivity will be measured and compared at baseline versus after 7±2 days and 5 weeks ±2 days daily contact lens wear.
62263298|NCT03314974|EXPERIMENTAL|TBI Regimen|
62263299|NCT03314974|EXPERIMENTAL|Non-TBI Regimen|
62263300|NCT05176119|ACTIVE_COMPARATOR|Nalbuphine arm|0.1 mg /kg nalbuphine was given to 30 patients
62263301|NCT05176119|ACTIVE_COMPARATOR|Ketamine arm|0.25 mg /kg ketamine was given to 30 patients
62263302|NCT05176119|PLACEBO_COMPARATOR|Saline arm|an equivalent volume of normal saline was given to 30 patients
62263303|NCT02744443|EXPERIMENTAL|Leucine|Leucine supplementation (10 g/d)
62845926|NCT06072456|NO_INTERVENTION|Nulliparous women|MRI of nulliparous women was evaluated for vaginal axis.
62263304|NCT02744443|PLACEBO_COMPARATOR|Placebo|Placebo supplementation (alanine, 10 g/d)
62263305|NCT04739085||Defocus curve group|The monocular distance visual acuity of each participant' eye is evaluated using trial lenses of -3.00 sph, -2.50 sph, -1.75 sph, and -1.25 sph (added to the best correction for distance), which correspond to the distances of 30 cm, 40 cm, 60 cm, and 80 cm, respectively.
62263306|NCT04739085||wDDART group|The same participants undergo visual acuity test via the web-based digital near vision reading test wDDART at 30 cm, 40 cm, 60 cm and 80 cm, having their best correction for distance.
62263307|NCT01734577|ACTIVE_COMPARATOR|Dry needling|Monofilament needles will be inserted into each subject's left multifidus muscle and stimulated mechanically for a local twitch response
62263308|NCT01734577|SHAM_COMPARATOR|Sham needling|Monofilament tubes will be pressed into the left multifidus muscle and mechanically manipulated to give the sensation that needling is occuring.
62845927|NCT01206088|EXPERIMENTAL|nilotinib|
62845928|NCT04952935|EXPERIMENTAL|True Acupuncture|
62845929|NCT04952935|SHAM_COMPARATOR|Sham Acupuncture|
62059550|NCT00624611|ACTIVE_COMPARATOR|1|Residual pump blood management post aortic cannula removal
62059551|NCT00624611|EXPERIMENTAL|2|Residual pump blood management post aortic cannula removal
62263309|NCT03754075||CME group|The CME group consisted of patients, who underwent elective CME for right-sided colon adenocarcinoma at Nordsjaellands Hospital Hillerød from 1 June 2008 to 31 December 2013.
62263310|NCT03754075||Non-CME group|The non-CME group comprised patients having a elective conventional colon cancer resection for right-sided adenocarcinoma at the other three colorectal centers in the Capital Region of Denmark from 1 June 2008 to 31 December 2013.
62263311|NCT03379272|ACTIVE_COMPARATOR|GOLD STANDARD|RECORDING WITH EEG GOLD STANDARD
62263312|NCT03379272|EXPERIMENTAL|NEURONAUTE|RECORDING WITH THE NEURONAUTE
62263313|NCT05722119|EXPERIMENTAL|Multiplex test|Multiplex Polymerase Chain Reaction (PCR) assay on stool samples, within 2 hours, in patients with acute diarrhea
62263314|NCT05722119|NO_INTERVENTION|Standard of care tests|Coproculture with direct examination and Clostridium difficile and A-B toxins search, parasitological examination of the stool and search for enteric viruses (rotavirus, adenovirus, norovirus, astrovirus) in patients with acute diarrhea
62263315|NCT05722119|EXPERIMENTAL|Control group without diarrhea|Multiplex Polymerase Chain Reaction (PCR) assay on stool samples in asymptomatic patients
62263316|NCT04752709|EXPERIMENTAL|Active Group A|Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region, with stimulation group A.
62263317|NCT04752709|ACTIVE_COMPARATOR|Active Group B|Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region with stimulation group B.
62263318|NCT05261958|EXPERIMENTAL|Interventional Group|"1. Warm up and cool down (10 minutes before physical activity)~2. Players will be given the SAQ training which includes~   * High Knees with Mini Hurdles.~  * 30 Yard Sprint.~  * Agility Ring Hops.~  * Ladder 2 in 2 out.~  * Depth Jumps.~  * Overhead Ball Drop Reaction Drill"
62263319|NCT05261958|NO_INTERVENTION|Control Group|"Players in this group did not undergo any interventional Programme rather than their daily routine work which includes:~* Dumbbell squat~* Dumbbell bicep arm curl~* Burpee pull up~* Medicine ball pushups~* Sprints~* HIIT on treadmill"
62263320|NCT03471039|ACTIVE_COMPARATOR|Active|PACAP-27
62263321|NCT03471039|PLACEBO_COMPARATOR|Placebo|Saline
62263322|NCT03820622|EXPERIMENTAL|DIOR group|in this group, patients will be treated with Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)
62845930|NCT04711161|EXPERIMENTAL|Part 1 (Phase 1a): Single Arm, Open Label (GRN-300 single-agent)|Part 1 of the study will determine the safety of continuous twice a day oral dosing of GRN-300, with each cycle consisting of 28 days of treatment. The number of administered cycles will depend on the tolerability of each dose level and the severity and occurrence of side effects and DLTs. The maximal tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of GRN-300 as a single agent will be determined. The overall duration of Part 1 will be approximately 24-36 months, depending on the rate of enrollment and the number of subjects enrolled.
62845931|NCT04711161|EXPERIMENTAL|Part 2 (Phase 1b): Single Arm, Open Label (GRN-300 plus paclitaxel)|"The study will determine the safety of continuous twice a day oral dosing of GRN-300, with each cycle consisting of 28 days of treatment, in combination with intravenously administered paclitaxel weekly x 3 during each 28-day cycle. The number of administered cycles will depend on the tolerability of each dose level and the severity and occurrence of side effects and DLTs. The maximal tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of GRN-300 in combination with paclitaxel will be determined. The overall duration of Part 2 will be approximately 12-18 months, depending on the rate of enrollment and the number of subjects enrolled. Part 2 will commence following determination of the MTD and RP2D of single-agent GRN-300 in Part 1.~Overall duration of the study will be approximately 36-48 months, depending on the rate of enrollment and number of subjects enrolled."
62845932|NCT01763996|EXPERIMENTAL|Sequence 1: Febuxostat 80 mg + Placebo|Febuxostat 80 mg, capsules, orally, once daily for 6 weeks in Period 1, followed by febuxostat placebo-matching capsules, orally, once daily for up to 6 weeks in Period 2.
62845933|NCT01763996|EXPERIMENTAL|Sequence 2: Placebo + Febuxostat 80 mg|Febuxostat placebo-matching capsules, orally, once daily for 6 weeks in Period 1, followed by febuxostat 80 mg, capsules, orally, once daily for up to 6 weeks in Period 2.
62263323|NCT03820622|ACTIVE_COMPARATOR|Bingo group|in this group, patients will be treated with Paclitaxel-Eluting Balloon (Bingo)
62845934|NCT06201806|EXPERIMENTAL|Test food breakfast with NCS|"Experimental: Participants with type 1 diabetes will consume Breakfast I with a mixed sweetener of stevia and sucralose, equivalent to 30 drops (36 mg stevia + 34.8 mg sucralose). Total non-nutritive sweeteners (NNS) amount to 70.8 mg.~Intervention: Breakfast I includes whole wheat pita bread (43 g), turkey ham (40 g), gouda cheese (18 g), semi-skimmed milk 200 cc (enhanced with 15 drops of sweetener), and natural orange juice 200 cc (with an additional 15 drops of sweetener). 15 drops for each preparation, making a total of 30 drops, providing 50 grams of available carbohydrates. Subjects administer rapid-acting insulin before breakfast based on their ratio and sensitivity."
62845935|NCT06201806|EXPERIMENTAL|Test food breakfast without NCS|"Experimental: Intervention involves the consumption of a breakfast without non-nutritive sweeteners (NNS).~Intervention: Subjects with type 1 diabetes who ingest Breakfast II (without sweetener): Whole wheat pita bread (43 g), turkey ham (40 g), gouda cheese (18 g), semi-skimmed milk 200 cc, and natural orange juice 200 cc.~Intervention includes the ingestion of 50 grams of available carbohydrates in the breakfast without NNS. Subjects will administer rapid-acting insulin before breakfast based on their ratio and sensitivity."
62845936|NCT06201806|ACTIVE_COMPARATOR|Reference food|Intervention involves the consumption of White Bread (standard food): 86g of crustless white sandwich bread as the standard food to reach the 50g of available CHO. Subjects administer rapid-acting insulin before consumption based on their ratio and sensitivity.
62845937|NCT04695717|PLACEBO_COMPARATOR|Vaccine|Received two doses of IVACFLU-S vaccine intramuscularly in children aged 6 months to under 9 years old and one dose of IVACFLU-S vaccine in children from 9 years old to under 18 years old adult over 60 years old
62263324|NCT00897663||Single group|Tissue samples from patients enrolled on clinical trials NCCTG-N0177 or NCCTG-N0074 are analyzed by microarray analysis and immunohistochemistry for biological markers predicting progression-free survival and overall survival. Biological markers include epidermal growth factor expression, vIII mutant p53 gene, P-AKT, p7056k, S6, 4EBP1, STAT-3, PLC-g, Erk, ErbB2, ErbB3, ErbB4, platelet-derived growth factor receptor, IGF1R, interleukin-6, FADD, and MGMT.
62845938|NCT04695717|OTHER|Placebo|Received two doses of placebo intramuscularly in children aged 6 months to under 9 years old and one dose placebo in children from 9 years old to under 18 years old adult over 60 years old
62845939|NCT01508806|EXPERIMENTAL|Normal renal function|
62845940|NCT01508806|EXPERIMENTAL|Mild renal impairment|
62059552|NCT02675478|EXPERIMENTAL|AC220|This study will follow a mCRM (modified continual reassessment method) + EWOC (Escalation with Overdose Control) design.
62845941|NCT01508806|EXPERIMENTAL|Moderate renal impairment|
62845942|NCT01508806|EXPERIMENTAL|Severe renal impairment|
62845943|NCT01508806|EXPERIMENTAL|End-stage renal disease|
62059553|NCT04842214||Oncologic disorders|"All patients assigned for oncological rehabilitation with the diagnosis Cancer are included to this cohort."
62263325|NCT02682628|EXPERIMENTAL|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62263326|NCT01570504|EXPERIMENTAL|ivermectin multiple doses|A dose of 200 mcg/kg of ivermectin given on days 1,2, 15 and 16
62263327|NCT01570504|ACTIVE_COMPARATOR|1 dose ivermectin|A single 200 mcg/kg dose of ivermectin
62263328|NCT01255527|ACTIVE_COMPARATOR|Busulfan|
62263329|NCT01255527|ACTIVE_COMPARATOR|Melphalan|
62263330|NCT03357679|ACTIVE_COMPARATOR|Bed up head elevated intubation|Patients positioned in the bed up head elevated position, followed by tracheal intubation
62263331|NCT03357679|ACTIVE_COMPARATOR|Glidescope assisted intubation|Glidescope is used for laryngoscopy, followed by intubation
62263332|NCT02634853|ACTIVE_COMPARATOR|Tavilermide Ophthalmic Solution|1% Tavilermide Ophthalmic Solution
62263333|NCT02634853|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution|Placebo Ophthalmic Solution
62059554|NCT01715610|ACTIVE_COMPARATOR|Antibiotic Clavulin or Clindamycin|Patient's in this arm are randomized by random-number generator to receive antibiotics. This is for a 7 day course of antibiotics. Those that are allergic to penicillin will receive clindamycin. Randomization occurs after knowledge of the patient's allergy status.
62059555|NCT01715610|PLACEBO_COMPARATOR|Placebo|Patient's randomized to this arm post-drainage will receive placebo and not receive antibiotics
62059556|NCT06311084|EXPERIMENTAL|Imaginator - Functional Imagery Training|3 weekly face to face sessions of Functional Imagery Training, followed by 5 fortnightly phone support calls, and the Imaginator app
62059557|NCT01105286|EXPERIMENTAL|Calcipotriol ointment|
62059558|NCT03010839|ACTIVE_COMPARATOR|Modified Remote Ischemic Preconditioning(mRIPC)|modified RIPC was induced at 24 h, 12 h and 1 h before surgery to reinforce the protective effects of RIPC. The single RIPC protocol was induced by three cycles of upper-limb ischemia, a standard blood-pressure cuff was placed on the ringt upper arm, then inflated the cuff to 200 mm Hg for 5 minutes, followed by 5 min of cuff deflation.
62059559|NCT03010839|PLACEBO_COMPARATOR|Control|Control group without remote ischemic preconditioning
62059560|NCT06626152|EXPERIMENTAL|L-DOPA Challenge|Participants will be administered a levodopa-carbidopa challenge, at a dosage of 150mg/37.5mg once daily for one week, followed by twice daily for one week. Psychomotor speed will be assessed before and after the challenge.
62059561|NCT04741516|EXPERIMENTAL|Medication arm|
62059562|NCT00224770|NO_INTERVENTION|Medical Management|Standard of care medical management as per American Heart Association (AHA) guidelines.
62263334|NCT01803321|EXPERIMENTAL|Cohort 1|Dose 1
62263335|NCT01803321|EXPERIMENTAL|Cohort 2|Dose 2
62263336|NCT04551937|PLACEBO_COMPARATOR|Control|4-5 week period where participant will consume control beverage
62263337|NCT04551937|EXPERIMENTAL|Prebiotic|4-5 week period where participant will consume the intervention beverage
62263338|NCT03852251|EXPERIMENTAL|AK104|AK104 IV every 2 weeks (q2w)
62263339|NCT03852251|EXPERIMENTAL|AK104 and chemotherapy|AK104 IV Q2W or Q3W，oxaliplatin IV 85 mg/m2 Q2W or 130mg/m2 Q3W，capecitabine 1000 mg/m2#twice a day (bid) for day 1to day 10 or day 1 to day 14 per cycle
62263340|NCT00658476|EXPERIMENTAL|Omega-3 Fatty Acids|Adolescents receive cognitive behavior therapy in combination with Omega-3 fatty acid supplements.
62263341|NCT00658476|PLACEBO_COMPARATOR|Placebo|Adolescents receive cognitive behavior therapy in combination with placebo.
62447658|NCT00743067|EXPERIMENTAL|Cohort 5|Cohort 5 will include 960 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
62263342|NCT04919642|EXPERIMENTAL|Cohort A1|FGFR2 fusions who have failed at least one previous treatment with an FGFR inhibitor
62059563|NCT00224770|ACTIVE_COMPARATOR|MISTIE Surgical Management|"Minimally invasive surgery (MIS) with clot lysis with recombinant tissue plasminogen activator (rt-PA).~MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo®) through the catheter once every eight hours for up to 72 hours, in addition to best medical care.~This includes 54 intent-to-treat patients, and excludes 27 pilots."
62059564|NCT00224770|ACTIVE_COMPARATOR|ICES Surgical Management|"Intraoperative stereotactic CT-Guided Endoscopic Surgery~Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative-targeting arm as MISTIE arm. Best medical care was provided, but no rt-PA was administered.~This includes 14 intent-to-treat patients, and excludes 4 pilots."
62059565|NCT02572947|EXPERIMENTAL|Dolutegravir monotherapy|10 patients will be simplified to monotherapy of dolutegravir tablet 50mg once daily for 24 weeks
62263343|NCT04919642|EXPERIMENTAL|Cohort A2|FGFR2 fusions who have previously responded on at least one previous treatment with an FGFR inhibitor and discontinued due to disease progression
62263344|NCT04919642|EXPERIMENTAL|Cohort B|Other FGFR alterations, including FGFR2 mutations and FGFR1/3 alterations, including fusions
62263345|NCT04919642|EXPERIMENTAL|Cohort C|Negative for FGFR alterations (FGFR wild-type)
62263346|NCT04161430|EXPERIMENTAL|DRBP108|Phase A (Weeks 1-24): DBPR108 100mg + placebo matching Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
62263347|NCT04161430|ACTIVE_COMPARATOR|Sitagliptin|Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg + Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
62263348|NCT04161430|PLACEBO_COMPARATOR|Placebo|Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg + placebo matching Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
62263349|NCT02581202||HIV-1 infected participants|HIV-1-infected participants on any triple highly active antiretroviral therapy (HAART) with plasma HIV-1 ribonucleic acid (RNA) level \< 50 copies/mL for at least 6 months (two consequently plasma HIV-1 RNA levels) transferred as medically appropriate to lopinavir with ritonavir plus lamivudine (LPV/r+3TC) as decided by the physician in the routine clinical settings. Or HIV-1 infected participants who were switched on the dual therapy (LPV/r+3TC) no more than 60 days prior to enrollment.
62263350|NCT03581786|PLACEBO_COMPARATOR|placebo combine with chemotherapy|Gemcitabine 1000 mg/m² IV are given on Days 1 \& 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，placebo will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and placebo for up to 2 years
62263351|NCT03581786|EXPERIMENTAL|TORIPALIMAB INJECTION(JS001 )combine with chemotherapy|Gemcitabine 1000 mg/m² IV are given on Days 1 \& 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，JS001 will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and JS001 for up to2years
62447659|NCT02507375|EXPERIMENTAL|Cohort 1|Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 100 mg orally (PO).
62447660|NCT02507375|EXPERIMENTAL|Cohort 2|Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 150 mg orally (PO).
62263352|NCT00872651|EXPERIMENTAL|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
62845944|NCT01423747|OTHER|MSD - matched sibling donor|patients with a MSD receive a conditioning of total body irradiation (TBI) (12 Gy, 6 fractions) and VP16 60mg/kg for one day (-3)
62845945|NCT01423747|OTHER|MD - matched donor|patients with a HLA (Human Leukocyte Antigen) matched unrelated Donor (9/10 oder 10/10) receive total body irradiation (TBI) (12Gy in 6 fractions), VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
62845946|NCT01423747|OTHER|MMD - mismatched Donor|Patients with a mismatched donor receive stem cells either from cord blood, a haploidentical donor (parent) or from a non-related donor with a match less or equal 8/10
62845947|NCT04563897||HBV/HCV|
62845948|NCT04563897||Fatty liver disease|
62845949|NCT04563897||Liver background after systematic treatment|
62845950|NCT04563897||normal hepatic background|
62059566|NCT05591248|EXPERIMENTAL|Intervention Group Virtual Reality Rehabilitation|All included patients will receive 3 - 9 sessions (3x/w) of VR rehabilitation during their stay at the intensive care unit. The games will stimulate them to move the arm(s). How long they play the game(s) is not decided in advance (patient-therapist-decision at the time of playing).
62059567|NCT00717314|EXPERIMENTAL|MMF, 50% CNI Reduction|Participants received mycophenolate mofetil (MMF), 1.5 to 2.0 grams (g) daily, orally (PO), twice per day (BID) from baseline (BL) to Week 52. Participants also received a 50 percent (%) reduced dose of calcineurin inhibitor (CNI) from BL to Week 52.
62059568|NCT00717314|EXPERIMENTAL|MMF, ≥75% CNI Reduction|Participants received MMF, 1.5 to 2.0 g daily, PO, BID from BL to Week 52. Participants also received a 75% reduced dose of CNI from BL to Week 52.
62059569|NCT01682993|ACTIVE_COMPARATOR|Corneal Cross Linking|Patients will receive a standard corneal cross linking treatment
62263353|NCT00872651|ACTIVE_COMPARATOR|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
62263354|NCT00370279|ACTIVE_COMPARATOR|1|scleral buckling
62263355|NCT00370279|ACTIVE_COMPARATOR|2|Primary vitrectomy without encircling band
62263356|NCT00370279|ACTIVE_COMPARATOR|3|Primary vitrectomy with encircling band
62263357|NCT00370279|ACTIVE_COMPARATOR|4|Triamcinolone assisted vitrectomy
62263358|NCT04916457||group ND|control group without DM non-intervention
62263359|NCT04916457||group VD|"very low-risk group: diabetic patient with no loss of protective sensation(LOPS) and no peripheral artery disease(PAD).~non-intervention"
62263360|NCT04916457||group LD|low-risk group: diabetic patient with LOPS or PAD non-intervention
62263361|NCT04916457||group MD|moderate-risk group: diabetic patient with LOPS + PAD non-intervention
62263362|NCT04916457||group HD|"high-risk group: diabetic patient with LOPS or PAD, and one or more of the following:~* history of a foot ulcer~* a lower-extremity amputation (minor or major)~* end-stage renal disease~non-intervention"
62845951|NCT01088048|EXPERIMENTAL|Idelalisib + Rituximab|"Participants with chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL) will receive treatments as follows:~Cohort 1a: Idelalisib (IDELA) 100 mg orally twice daily (BID) on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m\^2 intravenously (IV) on Days 1, 8, 15 \& 22, Cycles 1 \& 2~Cohort 2a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m\^2 IV on Days 1, 8, 15, \& 22, Cycles 1 \& 2~Cohort 3e: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m\^2 IV on Days 1, 8, 15, \& 22, Cycles 1 \& 2~Cohort 4a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle, starting Cycle 2 Day 1 with the 5th dose of rituximab + rituximab 375 mg/m\^2 IV on Days 1, 8, 15, \& 22, Cycles 1 \& 2"
62059570|NCT01682993|EXPERIMENTAL|Corneal Cross Linking and Topo Laser|Patients will receive a topography guided laser treatment in combination with a standard corneal cross linking treatment in the same session.
62263363|NCT03445871|ACTIVE_COMPARATOR|Patients with active rheumatoid arthritis|Patients with active rheumatoid arthritis will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
62263364|NCT03445871|ACTIVE_COMPARATOR|Patients with rheumatoid arthritis into remission|Patients with rheumatoid arthritis into remission will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
62447661|NCT04820608|EXPERIMENTAL|Customized, transepithelial cross-linking|All study patients will be treated according to the customized remodeled vision protocol
62447662|NCT01701284|EXPERIMENTAL|Right-Sided Low-Frequency rTMS|Participants will have rTMS administered at 1Hz to the right dorsolateral Prefrontal Cortex (dlPFC) once a day for 40 minutes, 5 days a week, for a total of six weeks.
62059571|NCT03010462|ACTIVE_COMPARATOR|Active|Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation
62619737|NCT02696174|EXPERIMENTAL|Health Microinsurance Scheme|Households owning the HMI package, entitling them to visit and receive treatment from the selected primary care clinic
62619738|NCT02696174|NO_INTERVENTION|Out-Of-Pocket|Households who visit the selected primary care clinic, but pay by Out-Of-Pocket
62619739|NCT02009423|EXPERIMENTAL|Masitinib|masitinib-treatment arm
62845952|NCT01088048|EXPERIMENTAL|Idelalisib + Rituximab + Bendamustine|"Participants with CLL, iNHL and mantle cell lymphoma (MCL) will receive treatments as follows:~Cohort 3a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m\^2 IV on Day 1 of each 28-day cycle, Cycles 1 - 6 + bendamustine 90 mg/m\^2 IV on Days 1 \& 2 of each 28-day cycle, Cycles 1 - 6~Cohort 3b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m\^2 IV on Day 1 of each 28-day cycle, Cycles 1 - 6 + bendamustine 70 mg/m\^2 IV on Days 1 \& 2 of each 28-day cycle from Cycles 1 - 6~Cohort 5c: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m\^2 IV on Day 1 of each 28-day cycle, Cycles 1 - 6 + bendamustine 90 mg/m\^2 IV on Days 1 \& 2 of each 28-day cycle, Cycles 1 - 6"
62845953|NCT01088048|EXPERIMENTAL|Idelalisib + Bendamustine|"Participants with CLL and iNHL will receive treatments as follows:~Cohort 1b: IDELA 100 mg orally BID on Days 1 - 28 of each 28-day cycle + bendamustine 90 mg/m\^2 IV on Days 1 \& 2 of each 28-day cycle, Cycles 1 - 6~Cohort 2b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + bendamustine 90 mg/m\^2 IV on Days 1 \& 2 of each 28-day cycle, Cycles 1 - 6~Cohort 3f: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + bendamustine 90 mg/m\^2 IV on Days 1 \& 2 of each 28-day cycle, Cycles 1 - 6~Cohort 3g: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + bendamustine 70 mg/m\^2 IV on Days 1 \& 2 of each 28-day cycle, Cycles 1 - 6~Cohort 4b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle starting Cycle 2, Day 3 (after the Cycle 2 bendamustine dosing) + bendamustine 90 mg/m\^2 IV on Days 1 \& 2 of each 28-day cycle, Cycles 1 - 6"
62263365|NCT04290832|EXPERIMENTAL|CO intervention|"South Africa: All health facility staff working in facilities assigned to the intervention arm receive standard Ipas support (including monitoring of abortion service provision and support to Ipas-trained abortion providers) plus the CO intervention.~Mexico: Doctors/anyone eligible to be an abortion provider working in facilities assigned to the intervention arm receive the CO intervention."
62263366|NCT04290832|NO_INTERVENTION|Control|"South Africa: All health facility staff working in facilities assigned to the control arm receive standard Ipas support (including monitoring of abortion service provision and support to Ipas-trained abortion providers).~Mexico: No intervention"
62263367|NCT00930761|NO_INTERVENTION|Control|
62263368|NCT00930761|EXPERIMENTAL|Music therapy|
62059572|NCT03010462|SHAM_COMPARATOR|Control|Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation
62059573|NCT04359771|ACTIVE_COMPARATOR|Yellow MPL|
62059574|NCT04359771|ACTIVE_COMPARATOR|Diode MPL|
62263369|NCT03709654|EXPERIMENTAL|Treatment Arm|Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.
62263370|NCT03709654|PLACEBO_COMPARATOR|Vehicle Control|Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.
62263371|NCT04158622|EXPERIMENTAL|Pneumatic Retinopexy|Patients with retinal detachment allocated to pneumatic retinopexy + laser/cryotherapy
62263372|NCT04158622|EXPERIMENTAL|Pars Plana Vitrectomy|Patients with retinal detachment allocated to pars plana vitrectomy + laser/cryotherapy
62263373|NCT02122328|ACTIVE_COMPARATOR|Selective procedure|Selective laser photocoagulation of communicating vessels.
62263374|NCT02122328|EXPERIMENTAL|Sequential procedure|Sequential laser photocoagulation of communicating vessels
62619740|NCT02009423|PLACEBO_COMPARATOR|Placebo|placebo-treatment arm
62619741|NCT03727516||patients undergone elbow surgery|Patients undergone elbow surgery at routine follow up at 2 or 6 months
62619742|NCT02741466|EXPERIMENTAL|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application
62619743|NCT02010541||insulin pump group|20 children below the age of 7 years who use an insulin pump for at least 6 months, more than 6 months of duration of type 1 diabetes, complete remission, no associated disease (normal blood pressure for age, only therapy insulin).
62619744|NCT02010541||RT (real time) -CGMS group|20 children below the age of 7 years who use an insulin pump and RT-CGMS on regular basis for at least 6 months, more than 6 months of duration of type 1 diabetes, complete remission, no associated disease (normal blood pressure for age, only therapy insulin). pump for at least 6 months, and children below the age of 7 years who use RT-CGMS on regular
62263375|NCT01307215|EXPERIMENTAL|20mLs of 0.5% ropivacaine per side|
62263376|NCT01307215|EXPERIMENTAL|30mLs of 0.33% ropivacaine per side|
62263377|NCT01307215|EXPERIMENTAL|40mLs of 0.25% ropivacaine per side|
62263378|NCT01986413|ACTIVE_COMPARATOR|BIPAP ST|one night, NIV with pressure controlled ventilation (BIPAP ST) with individually titrated pressure parameters.
62263379|NCT01986413|EXPERIMENTAL|IVAPS|one night, NIV with volume assured pressure support (IVAPS).The pressure parameters will be adjusted according to the BIPAP pressure levels.
62263380|NCT00317109|EXPERIMENTAL|AC primed Group|
62263381|NCT00317109|ACTIVE_COMPARATOR|AC unprimed Group|
62263382|NCT05114200||patient|erector spinae plane block applied patients
62263383|NCT00925015|EXPERIMENTAL|Cetux/Irin - Dmab 10 mg/kg|After treatment with Cetuximab (Cetux) and Irinotecan (Irin), Dalotuzumab (Dmab) was administered as an intravenous infusion at 10 mg/kg in Cycle 1 on Days 22, 29 and 36; followed in subsequent cycles by treatment with 10 mg/kg on Days 1, 8, 15, 22, 29 and 36. Each cycle was 6 weeks long.
62263384|NCT00925015|EXPERIMENTAL|Cetux/Irin - Dmab 15/7.5 mg/kg|After treatment with Cetux/Irin, Dmab was administered as an intravenous infusion at 15 mg/kg in Cycle 1 on Days 8, 22 and 36; followed in subsequent cycles by treatment with 7.5 mg/kg on Days 8, 22 and 36. Each cycle was 6 weeks long.
62845954|NCT01088048|EXPERIMENTAL|Idelalisib + Ofatumumab|"Participants with CLL will receive treatments as follows:~Cohort 3c: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + ofatumumab 12 doses (300 mg (Day 1 or Day 2, Dose 1), followed 1 week later by 1,000 mg weekly for 7 doses (Doses 2 - 8), followed 5 weeks later by 1,000 mg every 4 weeks for 4 doses (Doses 9 - 12))"
62619745|NCT01811290||Gilenya Subjects|Gilenya therapy group subjects must have been treated with Gilenya a minimum of 3 months uninterrupted prior to screening visit, and approved by the principal investigator to continue on this agent.
62845955|NCT01088048|EXPERIMENTAL|Idelalisib + Fludarabine|"Participants with CLL will receive treatments as follows:~Cohort 3d: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + fludarabine 40 mg/m\^2 orally on Days 1 - 5 of each 28-day cycle, Cycles 1 - 6"
62447663|NCT01701284|EXPERIMENTAL|Left-Sided High-Frequency rTMS|Participants will have rTMS administered at 10Hz to the left dorsolateral Prefrontal Cortex (dlPFC) once a day for 40 minutes, 5 days a week, for a total of six weeks.
62447664|NCT05263232|EXPERIMENTAL|Natural office light|Over 4.5 days, participants will stay inside in an office room from 8:00 to 17:00h with wide transparent windows under natural daylight.
62619746|NCT01811290||Controlled Therapy Group|Control therapy group subjects must have been consistently on an FDA approved disease modifying therapy other than Gilenya or off such therapy a minimum of 6 months prior to screening visit.
62619747|NCT02353221||Subjects|Entry criteria include being at least 18 years old at screening visit, being able to understand the information given to them and to give written informed consent, willingness to comply with the requirements of the data collection, absence of a diagnose of autoimmune disease or inflammatory arthritis, and absence of a previous treatment with any disease modifying anti-rheumatic drug (DMARD). We will exclude patients that are pregnant or intend to become pregnant during the time of follow up.
62059575|NCT06365307|EXPERIMENTAL|Clinical group|Group of patients, who is treated with usage of Histograft bone substitute (gene-activated matrix based on octacalcium phosphate and plasmid DNA encoding VEGFA gene) in spinal fusion of cervical or lumbal spine
62059576|NCT06365307|ACTIVE_COMPARATOR|Control group|Group of patients, who get standard treatment with usage of synthetic osteoplastic material based on β-TCP for spinal fusion of the cervical spine or use of bone autograft for spinal fusion of the lumbar spine
62263385|NCT00925015|EXPERIMENTAL|Dmab 10 mg/kg - Cetux/Irin (DDI)|Dmab was administered in each cycle as an intravenous infusion at 10 mg/kg once weekly on Days 1, 22 and 29; followed by treatment with Cetux/Irin. For Drug-Drug Interaction (DDI). Each cycle was 6 weeks long.
62263386|NCT02770547|ACTIVE_COMPARATOR|Low Heat Thermotherapy|Low heat thermotherapy will be applied to subject's leg. Subject will wear a garment through which heated water is circulated which in turn supplies low heat to the subject's leg.
62263387|NCT02770547|EXPERIMENTAL|High Heat Thermotherapy|High heat thermotherapy will be applied to subject's leg. Subject will wear a garment through which heated water is circulated which in turn supplies high heat to the subject's leg.
62263388|NCT05597085||Adult relapsed or refractory B Cell ALL|Adult patients whose B Cell ALL has occurred again after the last treatment or patients who never responded to prior treatment
62447665|NCT05263232|EXPERIMENTAL|Artificial office light|Over 4.5 days, participants will stay inside in an office room from 8:00 to 17:00h with shielded windows under artificial light.
62447666|NCT02663596|EXPERIMENTAL|Vancomycin|Patients with vancomycin mixed in the CRRT solution(s)
62447667|NCT03199248||the participant accepted needle assisted capsulotomy for DMC|
62447668|NCT03199248||the participant accepted aspiration for DMC only|
62447669|NCT01055249|OTHER|Group A|Ibuprofen 600 mg (active comparator); Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)
62447670|NCT01055249|OTHER|Group B|Oral Placebo (placebo comparator), Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)
62059577|NCT02974881|EXPERIMENTAL|transcatheter mitral valve replacement|HighLife TMVR System is a novel and innovative approach developed as an alternative treatment for severe MR when medical treatment is maximal and surgical interventions not possible or at high risk. The HighLife TMVR system is composed of a Transcatheter Mitral Valve (TMV), a sub-annular implant (SAI), and their delivery systems and loading tools. The HighLife Valve is a 31 mm mitral bioprosthesis made of a self-expanding Nitinol frame covered with polyester graft and supporting bovine pericardium leaflets. The bioprosthesis is used in conjunction with the Sub-Annular Implant (SAI).
62059578|NCT00949715|ACTIVE_COMPARATOR|RV Mid-Septal Pacing|Pacing lead located in the right ventricle at the middle of the muscle separating the right and left sides of the heart
62263389|NCT00706251||Primary|All the patients in our medical center who underwent nasolacrimal intubation, due to mild epiphora, during the years 2000-2007.
62263390|NCT01042015|ACTIVE_COMPARATOR|Concurrent controls|These subjects would undergo standard resuscitative efforts.
62263391|NCT01042015|EXPERIMENTAL|Emergency preservation and resuscitation|These subjects would undergo the complete EPR protocol, including rapid induction of hypothermia, resuscitative surgery, and resuscitation with cardiopulmonary bypass.
62263392|NCT01732497|EXPERIMENTAL|Single Group miraDry Treatment|This is a single group study where each enrolled subject will receive active miraDry treatment in each axilla.
62263393|NCT04749823|EXPERIMENTAL|Blended treatment program|The blended treatment program will consist of a combination of specific active exercises of the neck and general aerobic exercises. This contains a program of 12 weeks, including 9 supervised online sessions supplemented with 1 to 3 individual home exercises sessions without supervision per week, with a total of 3 sessions/week.
62263394|NCT04749823|ACTIVE_COMPARATOR|Specific strength exercise program|This group will receive an exercise program with specific strength exercises of the neck muscles. Within a 12-week period, patients will receive 9 online treatment sessions under supervision and 1 to 3 additional home exercise sessions without supervision, with a total of 3 sessions/week..
62263395|NCT04749823|ACTIVE_COMPARATOR|General aerobic exercise program|This control group will perform general aerobic exercises. Within a 12-week period, patients will be instructed to perform a general aerobic exercise session 3 times a week.
62263396|NCT03096964|EXPERIMENTAL|Nordic walking|Experimental: Nordic walking Training The total period of training was composed by 8-week of walking with poles, three sessions per week. The cycles were divided into eight microcycles composed by three training sessions. Each training session took 60 min. Nordic walking aerobics training were used during the training period. These exercises were performed alternating volume and intensity. Exercise intensities were controlled using the cardiac monitor, and the zone was since 70% to 105% of the heart rate at the second ventilatory threshold. And volume was controlled using the time of the session.
62263397|NCT03096964|EXPERIMENTAL|Free Walking|Experimental: Free walking Training The total period of training was composed by a 8-week cycles of walking without poles, with three sessions per week. The cycles were divided into eight microcycles composed by three training sessions. Each training session took 60 min. Free walking aerobics training were used during the training period. These exercises were performed alternating volume and intensity. Exercise intensities were controlled using the cardiac monitor, and the zone was since 70% to 105% of the heart rate at the second ventilatory threshold. And volume was controlled using the time of the session.
62263398|NCT04691193||study and control group|The study group included patients with low back pain for less than 3 months. The control group consists of healthy volunteers.
62447671|NCT03757962|EXPERIMENTAL|Dietary intervention|
62447672|NCT05893550|EXPERIMENTAL|Both Parent and child|Smartfish Omega Both parent and child receive Omega-3 drink
62447673|NCT05893550|EXPERIMENTAL|Parent Only|Smartfish Omega Only the parent receives Omega-3 drink, child receives Placebo.
62623764|NCT01050322|EXPERIMENTAL|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
62623765|NCT00103662|EXPERIMENTAL|G-CSF plus plerixafor|
62059579|NCT00949715|ACTIVE_COMPARATOR|RV Apical Pacing|Pacing lead located at the bottom of the right ventricle of the heart, in the right ventricular apex
62059580|NCT05709990|EXPERIMENTAL|High dose vitamin D supplementation (combined with standard urotherapy)|These patients will receive high dose vitamin D supplementation (more than 2000IU daily) and behavioral therapy for 8 weeks
62059581|NCT05709990|ACTIVE_COMPARATOR|Solifenacin succinate group (combined with standard urotherapy)|These patients will receive solifenacin (5-10 mg daily) and behavioral therapy for 8 weeks
62059582|NCT05709990|ACTIVE_COMPARATOR|standard urotherapy group|These patients will receive behavioral therapy alone for 8 weeks.
62447674|NCT05893550|EXPERIMENTAL|Child Only|Smartfish Omega Only the child receives Omega-3 drink, the parent receives placebo
62623766|NCT00103662|PLACEBO_COMPARATOR|G-CSF plus placebo|
62263399|NCT01179464|ACTIVE_COMPARATOR|Aminobiphosphonates|Aminobiphosphonates
62447675|NCT05893550|PLACEBO_COMPARATOR|Neither|Smartfish Fruit Juice Only Neither parent nor child receives omega-3; both receive placebo (fruit juice).
62447676|NCT01197963|OTHER|Surgical treatment|Surgical treatment of one arm of the patient population.
62447677|NCT01197963|OTHER|Medically controlled group|Managed by endocrinologists using current medical therapy such as pills, injections and life style medication.
62447678|NCT00765700|ACTIVE_COMPARATOR|Ketoprofen 10% Cream|"Topical Ketoprofen 10% Cream~1gram three times daily for 7 days"
62619748|NCT02353221||Controls|Healthy control subjects will be recruited based on similar criteria as study subjects. Our effort will be to include age and gender matched control subjects in the registry. We will be also aiming to match environmental characteristics (i.e. partners living in same location as registry subject or in a radius of 10 miles for at least one year previous to the date of evaluation) or genetic background (i.e. by asking the participation of first-degree relatives)
62845956|NCT01088048|EXPERIMENTAL|Idelalisib + Everolimus|"Participants with MCL will receive treatments as follows:~Cohort 5a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + everolimus 10 mg orally once daily on Days 1 - 28 of each 28-day cycle"
62263400|NCT01179464|EXPERIMENTAL|Aminobiphosphonates and Statin|Aminobiphosphonates and Statin
62263401|NCT04038788|ACTIVE_COMPARATOR|Active tRNS|In active tRNS condition, random noise was delivered by a battery-operated device (Eldith DC stimulator Plus, neuroConn, Ilmenau, Germany) via 5 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration with a gel layer of 2.0 mm), with 2 mA amplitude, offset at 1 mA, frequency 100-640 Hz, for 20 min with 15 s ramp-in/ramp-out. The combined impedance of all electrodes was kept below 15 kΩ, as measured by NeuroConn DC stimulator Plus device, using electrolyte gel. The anode was placed over International 10-10 electrode position AF3 (a point midway between F3 and Fp1), with cathodes (reference electrodes) at AF4, F2, F6 and FC4. Stimulation was applied at an intensity of 2 milliampere (mA) for 20 min, twice-daily on 5 consecutive weekdays. All patients in the active stimulation group were maintained on their antipsychotic medications throughout the study period.
62447679|NCT00765700|PLACEBO_COMPARATOR|Placebo|"Topical placebo cream~1gram three times daily for 7 days"
62447680|NCT01633827|PLACEBO_COMPARATOR|Placebo|Subjects will receive both a sugar pill and room air during their overnight sleep studies
62447681|NCT01633827|ACTIVE_COMPARATOR|Treatment|Subjects will receive both Lunesta (eszopiclone) and medical grade oxygen during their overnight sleep studies
62447682|NCT04879420||Teriparatide|Reference Group
62447683|NCT04879420||Risedronate|Exposure Group
62619749|NCT01608191|NO_INTERVENTION|Ordinary primary care follow up|Ordinary follow up after 24 weeks of LCD diet + reintroduction of food.
62845957|NCT01088048|EXPERIMENTAL|Idelalisib + Bortezomib|"Participants with MCL will receive treatments as follows:~Cohort 5b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + bortezomib 1.3 mg/m\^2 subcutaneously on Days 1, 8 \& 15 of each 28-day cycle"
62447684|NCT00901628|EXPERIMENTAL|Periarticular Injection group|Periarticular injection with ropivacaine, morphine, ketorolac, epinephrine, cefuroxime
62447685|NCT00901628|NO_INTERVENTION|No Injection group|usual postoperative care without periarticular injection
62447686|NCT06227975|EXPERIMENTAL|[14C]-BMS-986368|
62845958|NCT01088048|EXPERIMENTAL|Idelalisib + Chlorambucil|"Participants with CLL will receive treatments as follows:~Cohort 6a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + chlorambucil 10 mg/m\^2 orally once daily for 7 days every 28 days, Cycles 1 - 12"
62845959|NCT01088048|EXPERIMENTAL|Idelalisib + Rituximab + Chlorambucil|"Participants with CLL will receive treatments as follows:~Cohort 6b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m\^2 IV on Day 1 of each 28-day cycle, Cycles 1 - 6 + chlorambucil 10 mg/m\^2 orally once daily for 7 days every 28 days, Cycles 1 - 12"
62059583|NCT00979823|EXPERIMENTAL|Early SimCare Diabetes Group|This group will receive an email web-link to 3 simulated learning cases each month for 6 months. After 6 months (18 total learning cases), they will then complete 4 simulated assessment cases, a diabetes knowledge survey, and a satisfaction survey.
62263402|NCT04038788|SHAM_COMPARATOR|Sham treatment|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham group were maintained on their antipsychotic medications throughout the study period.
62263403|NCT04368728|EXPERIMENTAL|10 µg dose, 18-55 years of age (2 doses)|
62263404|NCT04368728|EXPERIMENTAL|20 µg dose, 18-55 years of age (2 doses)|
62263405|NCT04368728|EXPERIMENTAL|30 µg dose, 18-55 years of age (2 doses)|
62447687|NCT01807871|EXPERIMENTAL|nicotine patch, experimental use|Participants will continue to use nicotine patch after they lapse and resume smoking as long as smoking is less than 75% of pre study levels.
62447688|NCT01807871|ACTIVE_COMPARATOR|nicotine patch, labeled use|Participants will discontinue using the nicotine patch when they resume smoking. This is the current FDA approved use of the nicotine patches.
62447689|NCT04381884|EXPERIMENTAL|IVERMECTIN (IVER P®)|Patients in this group will receive Ivermectin (IVER P®) 600 µg / kg / once daily plus standard care.
62447690|NCT04381884|NO_INTERVENTION|CONTROL|Patients in this group will receive standard care.
62447691|NCT05313204||Pregnant with Multiple Sclerosis|Pregnant individuals (\> 13 weeks) with a Multiple Sclerosis diagnosis.
62447692|NCT05313204||Pregnant without Multiple Sclerosis|Pregnant individuals (\> 13 weeks) without Multiple Sclerosis.
62619750|NCT01608191|ACTIVE_COMPARATOR|CBT follow up|11 weeks intervention programme with CBT conducted via internet.
62845960|NCT01088048|EXPERIMENTAL|Idelalisib + Rituximab + Lenalidomide|"Participants with CLL and iNHL will receive treatments as follows:~Cohort 7a: IDELA 150 mg orally BID on Days 1 - 35 of Cycle 1 (35 days) \& Days 1 - 28 of all subsequent 28-day cycles + rituximab 375 mg/m\^2 IV on Days 1 \& 8 of Cycle 1 \& Day 1 of Cycles 2 - 6 + lenalidomide 5 mg orally once daily on Days 8 - 28 of Cycle 1 (35 days) \& Days 1 - 21 of next five 28-day cycles~Cohort 7b: IDELA 150 mg orally BID on Days 1 - 35 of Cycle 1 (35 days) \& Days 1 - 28 of all subsequent 28-day cycles + rituximab 375 mg/m\^2 IV on Days 1 \& 8 of Cycle 1 \& Day 1 of Cycles 2 - 6 + lenalidomide 10 mg orally once daily on Days 8 - 28 of Cycle 1 (35 days) \& Days 1 - 21 of next five 28-day cycles~Cohort 7c: IDELA 150 mg orally BID on Days 1 - 35 of Cycle 1 (35 days) \& Days 1 - 28 of all subsequent 28-day cycles + rituximab 375 mg/m\^2 IV on Days 1 \& 8 of Cycle 1 \& Day 1 of Cycles 2 - 6 + lenalidomide 20 mg orally once daily on Days 8 - 28 of Cycle 1 (35 days) \& Days 1 - 21 of next five 28-day cycles"
62059584|NCT00979823|ACTIVE_COMPARATOR|Delayed SimCare Diabetes Group|Beginning in the spring of 2011, residents in this group will receive an email web-link to complete 4 simulated assessment cases and a diabetes knowledge survey. They will subsequently be sent 3 learning cases a month for 6 months and a satisfaction survey to complete.
62059585|NCT05474521|EXPERIMENTAL|Participant 1|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059586|NCT05474521|EXPERIMENTAL|Participant 2|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059587|NCT05474521|EXPERIMENTAL|Participant 3|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059588|NCT05474521|EXPERIMENTAL|Participant 4|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059589|NCT05474521|EXPERIMENTAL|Participant 5|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059590|NCT05474521|EXPERIMENTAL|Participant 6|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059591|NCT05474521|EXPERIMENTAL|Participant 7|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059592|NCT05474521|EXPERIMENTAL|Participant 8|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62845961|NCT00935922|PLACEBO_COMPARATOR|Soybean oil bar|A nutrition bar enriched with soybean oil
62059593|NCT05474521|EXPERIMENTAL|Participant 9|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059594|NCT05474521|EXPERIMENTAL|Participant 10|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059595|NCT05474521|EXPERIMENTAL|Participant 11|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059596|NCT05474521|EXPERIMENTAL|Participant 12|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059597|NCT05474521|EXPERIMENTAL|Participant 13|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059598|NCT05474521|EXPERIMENTAL|Participant 14|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059599|NCT05474521|EXPERIMENTAL|Participant 15|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059600|NCT05474521|EXPERIMENTAL|Participant 16|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62263406|NCT04368728|EXPERIMENTAL|10 µg dose, 65-85 years of age (2 doses)|
62263407|NCT04368728|EXPERIMENTAL|20 µg dose, 65-85 years of age (2 doses)|
62845962|NCT00935922|EXPERIMENTAL|Flaxseed bar with low lignans|A nutrition bar enriched with flaxseed oil
62845963|NCT00935922|EXPERIMENTAL|Flaxseed bars with high lignans|A nutrition bar enriched with flaxseed oil and high lignans
62845964|NCT00637988|EXPERIMENTAL|1|Nexium 40mg
62263408|NCT04368728|EXPERIMENTAL|30 µg dose, 65-85 years of age (2 doses)|
62263409|NCT04368728|EXPERIMENTAL|30 µg dose, ≥12 years of age (2 doses)|
62845965|NCT00637988|EXPERIMENTAL|2|Nexium 40mg + aspirin
62845966|NCT00637988|EXPERIMENTAL|3|Nexium 40mg + Rofecoxib 25 mg
62845967|NCT00637988|ACTIVE_COMPARATOR|4|Rofecoxib 25mg
62263410|NCT04368728|PLACEBO_COMPARATOR|Placebo, 18-55 years of age|
62263411|NCT04368728|PLACEBO_COMPARATOR|Placebo, 65-85 years of age|
62263412|NCT04368728|PLACEBO_COMPARATOR|Placebo, ≥12 years of age|
62263413|NCT04368728|EXPERIMENTAL|100 µg dose, 18-55 years of age (2 doses)|
62623767|NCT02538406||non segmental withdrawal|A standard of care colonoscopy will be done on the patient without extra time on the right side of the colon.
62845968|NCT00947687|EXPERIMENTAL|PUR003|
62059601|NCT05474521|EXPERIMENTAL|Participant 17|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62845969|NCT00947687|PLACEBO_COMPARATOR|Placebo|
62845970|NCT04463069|EXPERIMENTAL|intervention group|Participants in the intervention group participated in the APA intervention consisting of simple and fun endurance and strength-building exercise at a frequency of two sessions per week.
62845971|NCT04463069|NO_INTERVENTION|control group|Participants in the control group received no intervention in the study time period.
62845972|NCT05191914|EXPERIMENTAL|chidamide + fulvestrant|
62845973|NCT06060327|ACTIVE_COMPARATOR|Oxytocin Group|o In Oxytocin group (n=111), patients will receive 10 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) given as infusion in 500 ml lactated ringer/s solution at a rate of 125ml/hour after delivery of the placenta.
62059602|NCT05474521|EXPERIMENTAL|Participant 18|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62845974|NCT06060327|ACTIVE_COMPARATOR|Tranexamic acid|"o In Tranexamic group (n=111), patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision).~Oxytocin 5 IU will be given slowly intravenous following delivery of the baby."
62059603|NCT05474521|EXPERIMENTAL|Participant 19|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059604|NCT05474521|EXPERIMENTAL|Participant 20|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059605|NCT05474521|EXPERIMENTAL|Participant 21|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059606|NCT05474521|EXPERIMENTAL|Participant 22|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059607|NCT05474521|EXPERIMENTAL|Participant 23|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059608|NCT05474521|EXPERIMENTAL|Participant 24|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059609|NCT05474521|EXPERIMENTAL|Participant 25|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059610|NCT05474521|EXPERIMENTAL|Participant 26|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62263414|NCT04368728|OTHER|Vaccination of Placebo recipients with BNT162b2 - Stage 1|Participants ≥16 years of age who originally received placebo and are eligible for COVID-19 vaccination following any local or national recommendations will be offered the opportunity to receive BNT162b2 as part of the study.
62263415|NCT04368728|OTHER|Vaccination of placebo recipients with BNT162b2 - Stage 2|Participants ≥16 years of age who originally received placebo will be offered the opportunity to receive BNT162b2 at defined points as part of the study.
62263416|NCT04368728|EXPERIMENTAL|Booster vaccination of Phase 1 participants with BNT162b2 at a dose of 30 µg|
62263417|NCT04368728|EXPERIMENTAL|Booster vaccination of Phase 3 participants with BNT162b2 at a dose of 30 µg|
62845975|NCT06060327|ACTIVE_COMPARATOR|Misoprostol|o In Misoprostol group (n=111), 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) will be inserted intraoperative inside the uterus after delivery of the placenta Oxytocin 5 IU will be given slowly intravenous following delivery of the baby.
62845976|NCT06060327|ACTIVE_COMPARATOR|Carbetocin|"o In carbetocin group (n=111) 100 microgram carbetocin (Pabal, Ferring, Kiel, Germany) will be given as an intravenous bolus dose following the delivery of the placenta.~Oxytocin 5 IU will be given slowly intravenous following delivery of the baby."
62447693|NCT05313204||Postpartum with Multiple Sclerosis|Postpartum individuals (\< 1 year since delivery) with a Multiple Sclerosis diagnosis.
62447694|NCT05313204||Postpartum without Multiple Sclerosis|Postpartum individuals (\< 1 year since delivery) without Multiple Sclerosis.
62447695|NCT00135707|EXPERIMENTAL|Dietary Supplement/Vitamins|1000mg of Vitamin C and 400IU of Vitamin E per capsule, twice daily between randomization (at 9 to 16 weeks) up to delivery.
62447696|NCT00135707|PLACEBO_COMPARATOR|Placebo for Vitamin C and Vitamin E|Placebo capsules consisting of Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell, twice daily between randomization (at 9 to 16 weks) up to delivery.
62447697|NCT01727245|OTHER|Obese|Obese patients undergoing gastric by-pass surgery
62447698|NCT01727245|OTHER|Control group|Cholecystectomy and anti-reflux surgery
62059611|NCT05474521|EXPERIMENTAL|Participant 27|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059612|NCT05474521|EXPERIMENTAL|Participant 28|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62059613|NCT05474521|EXPERIMENTAL|Participant 29|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62447699|NCT04447274|EXPERIMENTAL|Camrelizumab and Apatinib|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62447700|NCT03654456||Sepsis patients with OSA|Sepsis patients who received a prior polysomnography showing an apnea-hypopnea index at least 5/hr with compatible symptoms
62447701|NCT03654456||Sepsis patients without OSA|Sepsis patients who received a prior polysomnography showing an apnea-hypopnea index less than 5/hr
62447702|NCT03538236|ACTIVE_COMPARATOR|Lifestyle intervention alone|All patients included in the study will undergo an evaluation by a nutritionist and will undergo diet and lifestyle intervention.
62845977|NCT04846933||HGSOC patients treated with Neoadjuvant chemotherapy (NACT)|"Diagnostic laparoscopy followed with 3-4 cycles of platinum-taxane NACT and interval debulking surgery (IDS). Treatment response is monitored with FDG PET/CT. IDS is followed by standard adjuvant therapy (ESGO/ESMO + local guidelines).~Digital H\&E slides and WGS, RNAseq are obtained from performed surgeries including relapse operations/ascites drainages. Patients are followed with longitudinal ctDNA sampling."
62845978|NCT04846933||HGSOC patients treated with primary debulking surgery (PDS)|PDS is followed by standard adjuvant therapy (ESGO/ESMO + local guidelines). Digital H\&E slides and WGS, RNAseq obtained from PDS and possible relapse operations/ascites drainages when performed. Patients are followed with longitudinal ctDNA sampling.
62845979|NCT05163626|EXPERIMENTAL|Combined aerobic exercise and cognitive training program|
62059614|NCT05474521|EXPERIMENTAL|Participant 30|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
62263418|NCT04368728|EXPERIMENTAL|Booster vaccination of Phase 3 participants with BNT162b2SA at a dose of 30 µg|
62263419|NCT04368728|EXPERIMENTAL|Vaccination of BNT162b2-naive participants with BNT162b2SA at a dose of 30 µg|
62263420|NCT04368728|EXPERIMENTAL|Booster and further vaccination of Phase 3 participants with BNT162b2SA at a dose of 30 µg|
62263421|NCT04368728|EXPERIMENTAL|Booster vaccination of Phase 3 participants with BNT162b2 at a dose of 5 µg|
62263422|NCT04368728|EXPERIMENTAL|Booster vaccination of Phase 3 participants with BNT162b2 at a dose of 10 µg|
62263423|NCT01012791|EXPERIMENTAL|Zumba exercise group|
62263424|NCT01012791|NO_INTERVENTION|Non-Zumba exercise group|
62447703|NCT03538236|EXPERIMENTAL|Intragastric balloon with lifestyle|Patients who do not reach the 10% weight loss with lifestyle intervention alone after 6 months will be offered to have intragastric balloon insertion for 6 months. Regardless of whether an intragastric balloon is inserted, all patients will continue with the same lifestyle changes described above for another 6 months.
62263425|NCT01102647|EXPERIMENTAL|Phytosterol ester|Plant sterol compared with placebo
62447704|NCT03742531|ACTIVE_COMPARATOR|low dose group|oxytocin therapy starting with 2mU/min increased by 2 mU/min every 15 minutes. oxytocin will be stopped at the beginning of the active phase of labor.
62263426|NCT03478111|EXPERIMENTAL|CMAB008+MTX|"Drug: CMAB008 (recombinant chimeric anti-TNF-α monoclonal antibody injection) infusion of 3mg/kg in Week 0, 2, 6, 14, 22, 30.~Drug: MIX (methotrexate) will be oral administered at a dose of 7.5mg\~15mg weekly from Week 0 to 38."
62263427|NCT03478111|ACTIVE_COMPARATOR|Remicade+MTX|"Drug: Remicade (recombinant chimeric anti-TNF-α monoclonal antibody injection) infusion of 3mg/kg in Week 0, 2, 6, 14, 22, 30.~Drug: MIX (methotrexate) will be oral administered at a dose of 7.5mg\~15mg weekly from Week 0 to 38."
62263428|NCT01485627|EXPERIMENTAL|Intervention|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
62263429|NCT01485627|NO_INTERVENTION|Control|Patients will receive usual care
62263430|NCT05909956|EXPERIMENTAL|KT Group|This group will receive Abdominal KT tape (From initial 4 h to 72 h of menstruation). General physio session will also be given to this group.
62263431|NCT05909956|SHAM_COMPARATOR|ST Group|This group will receive Abdominal KT tape (without strech) from initial 4 h to 72 h of menstruation. General physio session will also be given to this group.
62263432|NCT05909956|OTHER|CT Group|this group will receive General physical therapy session including Hot pack (3-5min) and General body stretching(stretching of neck \& upper trapezius, arm \& shoulder girdle, triceps brachii, teres major \& minor, quadriceps muscle iliopsoas muscle, adductors muscle, hamstrings muscle) 30-45 sec each, for 7-10 min, (0-4 week) ,45-60sec each, for 10-15 min(4-8week), 15-20 min(8-12week) will be repeated 2 times/day.
62263433|NCT03978195|EXPERIMENTAL|Treatment|
62263434|NCT03978195|NO_INTERVENTION|Control|
62263435|NCT04817644|EXPERIMENTAL|Oral semaglutide|All participants will receive oral semaglutide once daily for a total of 10 days: 3 mg for 5 days followed by 7 mg for 5 days.
62263436|NCT02872740|EXPERIMENTAL|Embolization of Left Gastric Artery|These patients will have their left gastric artery embolized
62263437|NCT02872740|EXPERIMENTAL|Embolization of Gastroepiploic Artery|These patients will have their gastroepiploic artery embolized
62263438|NCT04354714|EXPERIMENTAL|Ruxolitinib|-Ruxolitinib is an oral medication that will be given twice daily (BID). Dosing on Days 1 through 3 will be 5 mg BID; dosing on Days 4 through 10 will be 10 mg BID.
62263439|NCT05876052|EXPERIMENTAL|Hypothermic oxygenated Perfusion - HOPE|"Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion, 3000 ml for livers, 1-3 hours.~Liver perfusion will be performed through the portal vein at a 5 mmHg pressure. Flow, pressure and temperature will be monitored and registered on REDCap software during organ perfusion. Gas analysis of the effluent perfusate (partial pressure O2 and CO2, pH, lactate and glutamate production) will be accomplished every 15 minutes."
62263440|NCT05876052|NO_INTERVENTION|Static Cold Storage - SCS|Livers undergoing SCS will be stored in sterile organ bags with Belzer or Celsior solution and cooled in ice until transplant.
62263441|NCT06424938|EXPERIMENTAL|The group in which epidural block|The group in which epidural block is applied for postoperative analgesia (Group Epidural)
62263442|NCT06424938|EXPERIMENTAL|The group in which erector spinae plane block|The group in which erector spinae plane block is applied (Group ESP)
62619751|NCT05712837|ACTIVE_COMPARATOR|Group A 25% TCA|25% TCA peel Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment.
62263443|NCT05569707|OTHER|MelaDiff|Patients with melanoma of the extremities included in the protocol. Preoperative, patients will receive two MRI-scans and a magnetic tracer injection at the primary tumor site. During surgery, SLNs will be detected using two types of magnetometers (SentiMag® \& DiffMag) in combination with Magtrace®, in addition to the standard procedure.
62845980|NCT05163626|NO_INTERVENTION|Standard health counseling at baseline|
62447705|NCT03742531|ACTIVE_COMPARATOR|high dose group|oxytocin therapy starting with 4mU/min increased by 4 mU/min every 15 minutes. oxytocin will be stopped at the beginning of the active phase of labor.
62263444|NCT02471495|EXPERIMENTAL|Synergo® RITE + MMC|"Induction~Patients will receive 8 weekly treatments of Synergo® RITE + MMC, using the Synergo® System. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. These 8 treatments will be followed by a pause (see Table 1), after which a follow-up cystoscopy (first follow-up control) will be conducted during Weeks 12-13 (from the first treatment).~Maintenance~Patients will receive one Synergo® RITE + MMC treatment every 6 weeks. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. Maintenance treatments will be given until the end of 12 months after the patient's first induction treatment."
62263445|NCT04347707|EXPERIMENTAL|BRIDGE Clinical Group|This group of mother-child dyads will have mothers who have been screened for and met diagnostic criteria for depression. Mothers in this group will participate in the 20-week group therapy and parent skills training intervention.
62263446|NCT04347707|NO_INTERVENTION|Baseline Comparison Group|This group of mother-child dyads will not meet diagnostic criteria for depression and will serve as a comparison group for baseline measures. Dyads will be matched to the BRIDGE clinical group based on household income and child age.
62619752|NCT05712837|ACTIVE_COMPARATOR|Group B 30% SALICYLIC ACID|30% SA peels Patients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment
62263447|NCT02055105|OTHER|miRNA|
62619753|NCT00528372|EXPERIMENTAL|Group 1: Dapagliflozin, 2.5 mg AM|Participants with hemoglobin A1c (HbA1c) ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each morning for up to 102 weeks.
62845981|NCT01553370|ACTIVE_COMPARATOR|Alternate Intake-time|
62845982|NCT01553370|EXPERIMENTAL|Immediately post-exercise|
62845983|NCT03903224|ACTIVE_COMPARATOR|Combined PECS II and TTP blocks (PT)|"Modified Pectoralis block (PECS II) : Using ultrasound we proceed to inject 10 ml of bupivacaine 0.25% between the pectoral muscles and 10 ml under Pmm above the serratus muscle.~Transversus Thoracic Plane block : 10 mL bupivacaine (0.25%) is injected between the transversus thoracic muscle and the internal intercostal muscle between the third and fourth left ribs connecting at the sternum."
62059615|NCT04308902||Children previously enrolled in the OptiMoM Fortifier Study|This is an observational study of children who were previously enrolled in a trial (Bovine vs. Human Milk-Based Fortifier Study) between 2014 and 2016 during which time they were randomized to have their feeds (mother's own milk or pasteurized donor breastmilk) nutrient enriched with a human milk-based fortifier or a bovine protein-based fortifier.
62059616|NCT04308902||Term-born Comparison|This is an observational study of children born at full term (\>= 37 weeks gestation) and weighing more than 2500g. These children will be recruited from the communities in which the OptiMoM participants live.
62059617|NCT03494569|EXPERIMENTAL|Treatment (TMLI, fludarabine, melphalan)|Participants undergo TMLI BID on days -8 to -5, and receive fludarabine IV on days -4 to -2 and melphalan on day -2. Participants then undergo alloHCT on day 0.
62059618|NCT04961866|ACTIVE_COMPARATOR|Group A|patients received 1 g/ kg of protein
62059619|NCT04961866|ACTIVE_COMPARATOR|Group B|patients received 2 g/ kg of protein
62059620|NCT03145766|EXPERIMENTAL|Group 1: VRVg-2 Formulation 1|VRVg-2 formulation 1, intramuscular (IM) injection on Days 0, 3, 7, 14 and 28. Concomitant administration of human rabies immunoglobulins (HRIG) on Day 0.
62059621|NCT03145766|EXPERIMENTAL|Group 2: VRVg-2 Formulation 2|VRVg-2 formulation 2, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
62059622|NCT03145766|EXPERIMENTAL|Group 3: VRVg-2 Formulation 3|VRVg-2 formulation 3, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
62059623|NCT03145766|EXPERIMENTAL|Group 4: VRVg-1|VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
62059624|NCT03145766|ACTIVE_COMPARATOR|Group 5: Imovax Rabies|Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
62059625|NCT02929355||diabetic patients with carotid assessment|Patients with diabetes and a carotid assessment by duplex ultrasonography in 2012 in a monocentric diabetic unit
62059626|NCT04946929|EXPERIMENTAL|Ticagrelor, 2-3mg/kg, 12h|2-3mg/kg, q12h, p.o. for 2w
62059627|NCT04946929|ACTIVE_COMPARATOR|low molecular weight heparin|half amount low molecular weight heparin
62059628|NCT01802255|EXPERIMENTAL|Inhalatory sedation|Sevoflurane given via AnaConDa for sedation minimum 48 hours
62059629|NCT01802255|ACTIVE_COMPARATOR|Intravenous sedation|Midazolam given intravenously for sedation minimum 48 hours
62059630|NCT03129048|EXPERIMENTAL|MedDiet-WL|MedDiet-WL group, advice and exchange lists will be designed to promote a 1-2 lb. per week weight loss (approximately 30% caloric restriction or a reduction of about 600 calories per day) for an end goal of a 7% weight loss from baseline.
62263448|NCT05365503|EXPERIMENTAL|Shamiri Intervention|The Shamiri intervention group will recieve a brief character strength intervention that will be delivered over the span of 4 weeks. There will be four sessions each lasting one hour each.
62263449|NCT05427552|EXPERIMENTAL|Prefrontal hemodynamic response to 50% rMT iTBS|Participants will receive 50% rMT iTBS over left DLPFC in this arm. The prefrontal hemodynamic response will be observed simultaneously before, during, and after iTBS using fNIRS.
62263450|NCT05427552|EXPERIMENTAL|Prefrontal hemodynamic response to 70% rMT iTBS|Participants will receive 70% rMT iTBS over left DLPFC in this arm. The prefrontal hemodynamic response will be observed simultaneously before, during, and after iTBS using fNIRS.
62263451|NCT05427552|EXPERIMENTAL|Prefrontal hemodynamic response to 90% rMT iTBS|Participants will receive 90% rMT iTBS over left DLPFC in this arm. The prefrontal hemodynamic response will be observed simultaneously before, during, and after iTBS using fNIRS.
62263452|NCT01221220|ACTIVE_COMPARATOR|Behavioral Treatment|Six-month, family-based, group, behavioral weight control program
62263453|NCT01221220|EXPERIMENTAL|Behavioral Treatment plus Environmental Strategies|Six-month, family-based, group, behavioral weight control program plus home-based environmental intervention
62263454|NCT01972867|EXPERIMENTAL|NanoKnife Procedure|The NanoKnife procedure will be performed on focal prostate tumors, under ultrasound guidance.
62059631|NCT03129048|EXPERIMENTAL|MedDiet-A|For the MedDiet-A group, dietary advice and corresponding exchange lists will be given within the context of promoting weight stability.
62263455|NCT02237521||End-stage renal disease|Patients with normal glucose tolerance and end-stage renal disease
62263456|NCT02237521||Controls|Healthy controls with normal kidney function and normal glucose tolerance
62447706|NCT02524379|EXPERIMENTAL|Glyburide Treatment Arm|Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of SCI. The dosing regimen involves an initial dose of 1.25 mg followed by eleven consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2 and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.
62447707|NCT00265759|EXPERIMENTAL|Arm I|Patients receive oral exemestane once daily for up to 16-18 weeks.
62447708|NCT00265759|EXPERIMENTAL|Arm II|Patients receive oral letrozole once daily for up to 16-18 weeks.
62059632|NCT03129048|OTHER|Typical Diet Control (TDC)|Typical Diet Control (TDC) will maintain current eating and activity patterns and weight over 14 months.
62059633|NCT05211271|EXPERIMENTAL|Intervention Arm|Treatment of cervical neoplasia by thermal ablation
62059634|NCT00985985|EXPERIMENTAL|2mg nicotine lozenge|2 mg nicotine lozenge
62059635|NCT00985985|PLACEBO_COMPARATOR|2 mg placebo|2 mg placebo
62059636|NCT00985985|EXPERIMENTAL|4 mg nicotine lozenge|4 mg nicotine lozenge
62059637|NCT00985985|PLACEBO_COMPARATOR|4 mg placebo|4 mg placebo
62059638|NCT00953303|EXPERIMENTAL|glucocorticoid|
62059639|NCT00953303|ACTIVE_COMPARATOR|Standard care|
62059640|NCT05186337|EXPERIMENTAL|Experimental|Functional Remediation for Older-Age Patients With Bipolar Disorder (FROA-BD)
62059641|NCT05186337|NO_INTERVENTION|Control|The control group (42 patients) will not receive any type of add-on psychotherapy.
62059642|NCT04105335|EXPERIMENTAL|Cohort 1 MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA 70mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
62059643|NCT04105335|EXPERIMENTAL|Cohort 2 MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA 98mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
62059644|NCT04105335|EXPERIMENTAL|Cohort 3 MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA 130mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
62263457|NCT06264700|EXPERIMENTAL|Video Directly Observed Therapy (VDOT)|Participants randomized to this arm will be connected with Scene Health by a study staff member (not the PI or Co-I's). After submitting and receiving approval of a test video submission, the participants' hydroxyurea dosing schedule will be entered into the VDOT app by the research staff and will be updated by these staff after their routine hematology visits and/or hospitalizations. Participants will receive VDOT for 180 days, beginning the day after randomization. After that time, they will start a 180-day ongoing monitoring period, during which VDOT participants will receive monthly telephone calls and intermittent text messages from Scene Health staff to encourage ongoing adherence. The Scene Health staff will access the electronic adherence platform and use this data to inform their communications during the ongoing monitoring period. Participants in both arms will be offered a smartphone with a data plan at enrollment to ensure equal opportunity for participation.
62845984|NCT03903224|ACTIVE_COMPARATOR|Erector Spinae Block (E)|Using ultrasound an echogenic 22-G block needle is inserted in-plane in a cranial-to-caudal direction until contact is made with the T5 transverse process. A total of 30 bupivacaine 0.25% is then injected while seeing the fluid lifting the erector spinae muscle off.
62059645|NCT04105335|EXPERIMENTAL|Expansion Cohort MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA RP2D administered once every 3 weeks on Day 1 of every 3 week cycle. Pembrolizumab 200mg administered once 3 weeks on Day 8 of every 3 week cycle.
62059646|NCT04900350|EXPERIMENTAL|AK117+ azacitidine|"Phase 1: Subjects will receive escalating doses of A117 in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28 day cycle;~Phase 2: Subjects will receive AK117 at the recommended Phase 2 dose in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28-day cycle."
62059647|NCT01683162|EXPERIMENTAL|Olive oil lipid emulsion|the olive oil lipid emulsion is ClinOleic
62059648|NCT01683162|EXPERIMENTAL|MCT/LCT lipid emulsion|the MCT/LCT lipid emulsion is Lipofundin
62263458|NCT06264700|OTHER|Attention Control|Participants randomized to this arm will receive an automated, daily, short health or safety tip alert.
62263459|NCT02268903|ACTIVE_COMPARATOR|Diuretics|
62263460|NCT02268903|PLACEBO_COMPARATOR|Placebo|
62619754|NCT00528372|EXPERIMENTAL|Group 1: Dapagliflozin, 10 mg AM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each morning for up to 102 weeks.
62619755|NCT00528372|EXPERIMENTAL|Group 1: Dapagliflozin 2.5 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each evening for up to 102 weeks.
62059649|NCT01683162|EXPERIMENTAL|LCT lipid emulsion|the LCT lipid emulsion is Intralipid
62059650|NCT02965222|EXPERIMENTAL|Intervention arm|After injecting HCG 38- 40 hours , the patient's oocytes will be taken with ICSI , then placed in the Time-Lapse. The oocytes will be IVF after 4 hours and will be stripped surrounding cumulus cell ,then will be placed in the Time-Lapse.The third day the top-grade embryo will be selected by time-lapse imaging (TLI) . The cleavage pattern and time parameters for marker embryo development were recorded daily after insemination.
62059651|NCT02965222|EXPERIMENTAL|Control arm|The development of the embryos at time-lapse was recorded directly and was not disturbed by temperature changes.
62059652|NCT06274814|ACTIVE_COMPARATOR|Type 2 Pectoral Nerve Block|23 patients Type 2 Pectoral Nerve Block pecs2 Group A
62447709|NCT00265759|EXPERIMENTAL|Arm III|Patients receive oral anastrozole once daily for up to 16-18 weeks.
62447710|NCT04459481|EXPERIMENTAL|70-degree bending angle group|intubation with a 70-degree bending angle
62447711|NCT04459481|EXPERIMENTAL|90-degree bending angle group|intubation with a 90-degree bending angle
62619756|NCT00528372|EXPERIMENTAL|Group 1: Dapagliflozin, 5 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 5 mg, once each evening for up to 102 weeks.
62619757|NCT00528372|EXPERIMENTAL|Group 1: Dapagliflozin, 10 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each evening for up to 102 weeks.
62845985|NCT00620529|EXPERIMENTAL|1|20/50 fish oil, 1000mg capsules, Ocean Nutrition 2050,4g/day.
62845986|NCT00620529|PLACEBO_COMPARATOR|2|olive oil capsules
62845987|NCT05181189|EXPERIMENTAL|DAOIB+Omega-3|
62845988|NCT05181189|PLACEBO_COMPARATOR|DAOIB+Placebo|
62845989|NCT02164487||B1 blood levels|
62263461|NCT01865409|ACTIVE_COMPARATOR|Kangoroo care|"While performing Kangaroo care the infant should be held skin-to-skin contact with her mother for 30-60 minutes. The baby, who is naked except for a diaper and a piece of cloth covering his or her back (either a receiving blanket or the parent's clothing), is placed in an upright position against a parent's bare chest. The values of heart rate variability will be measured during and also without Kangaroo Care in the same infants but different times."
62263462|NCT01735487|ACTIVE_COMPARATOR|Own Brand cigarette|Smoke Own Brand cigarette, 15 puff of cigarette.
62447712|NCT01994603|EXPERIMENTAL|Opt-in testing|"Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group. Opt-in: Common barriers to HIV screening testing will be removed as much as possible (i.e., providing rapid testing, results shortly available, testing on-site, confidentiality). There is voluntary HIV testing available to all study participants if you wish to do it. "
62447713|NCT01994603|EXPERIMENTAL|Opt-out testing|Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group. Opt-out multicomponent testing. Participants will be informed that a bundled routine health test is available on a voluntary basis to study participants, and the participant may elect to decline all or part of the testing.
62619758|NCT00528372|EXPERIMENTAL|Group 2: Dapagliflozin, 5 mg AM|Participants with HbA1c ≥10.1% and ≤12% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
62619759|NCT00528372|EXPERIMENTAL|Group 2: Dapagliflozin, 10 mg AM|Participants with HbA1c ≥10.1% and ≤12% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
62447714|NCT02326428|EXPERIMENTAL|Thrombectomy|Thrombectomy arm consists of patients undergoing thrombectomy according to accepted critera in the judgement of investigator. Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reasons.
62447715|NCT02326428|ACTIVE_COMPARATOR|Control|Control arm patients are treated with standard stroke care including IVT but do not receive Thrombectomy. Control arm consists of patients fulfilling criteria for thrombectomy according to accepted critera in the judgement of investigator. Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reason.
62447716|NCT04130256|EXPERIMENTAL|Active Reminders|43 patients, each assigned to use the electronic pill bottle for 90 days. Participants will use the bottle to house their multiple sclerosis medication. The electronic pill bottle will provide daily medication reminders for participants to take their pill.
62059653|NCT06274814|ACTIVE_COMPARATOR|RISS Rhomboid intercostal block combined with the sub-serratus plane block|23 patients the RIB combined with the sub-serratus plane block (RISS) Group B
62619760|NCT00528372|EXPERIMENTAL|Group 1: Dapagliflozin placebo AM & PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin placebo once each morning and evening for up to 102 weeks.
62619761|NCT00528372|EXPERIMENTAL|Group 1: Dapaglifozon, 5 mg AM|Participants with (HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
62619762|NCT02102594|EXPERIMENTAL|Bortezomib (Velcade)|
62619763|NCT01758042|OTHER|Haploidentical Bone Marrow/Kidney|Single Arm Study
62619764|NCT02928601|EXPERIMENTAL|Ondansetron|
62845990|NCT03859362|EXPERIMENTAL|Ertapenem in urosepsis|Ertapenem PK studies were carried out on the 3rd dose of ertapenem administration. Blood samples (3 mL) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h after the start of ertapenem administration. All blood samples were added to a heparinized tube and centrifuged at 1,000 g for 10 min at 4°C within 5 min.
62059654|NCT06274814|NO_INTERVENTION|No block intervention|"routine IV analgesia 23 patients no block intervention was performed. The anesthetic dose was adjusted to maintain blood pressure within 20% of the baseline value. An additional dose of intravenous fentanyl (0.1 µg kg-1 min-1) was injected as needed.~Group C"
62059655|NCT06142825|EXPERIMENTAL|CFTC|Community-Facility Transfusion Committees (CFTCs) will be established at the facilities randomized to this arm.
62059656|NCT06142825|NO_INTERVENTION|Control|
62263463|NCT01735487|EXPERIMENTAL|One High 2,4% nicotine|Smoke electronic cigarette One High 2,4% nicotine for a day, 15 puff of e-cigarette.
62263464|NCT01735487|EXPERIMENTAL|Original 7,4 mg nicotine|Smoke electronic cigarette Original 7,4 mg nicotine for a day. 15 puff of e-cigarette.
62263465|NCT01735487|PLACEBO_COMPARATOR|Nicotine Free|Smoke electronic cigarette nicotine free (15 puff)
62619765|NCT02928601|ACTIVE_COMPARATOR|Saline|
62619766|NCT04872738||Vaccinated Breast Cancer Patients|Patients who enroll in the trial and decided to get the COVID-19 vaccine will complete surveys to indicate their experiences, side effects, location of vaccination (i.e. right arm, left arm, or leg). This information will be analyzed in conjunction with their breast cancer treatment history and lymphedema measurements.
62623768|NCT02538406||Segmental withdrawal|A standard of care colonoscopy will be done on the patient , however the time spent in the right side of the colon will be more than half of the normal colonoscopy procedure (i.e. more than 3 minutes)
62845991|NCT00122980|ACTIVE_COMPARATOR|1|Hydroxyurea and phlebotomy
62845992|NCT00122980|ACTIVE_COMPARATOR|2|Transfusion and chelation
62845993|NCT02831101|EXPERIMENTAL|Sufentanil|Sufentanil intravenously, continuously with effect-site concentration of 0.3 ng/ml until the end of the study
62845994|NCT02831101|OTHER|Placebo|Saline intravenously, continuously with the same effect-site concentration as sufentanil (recorded on administration device) until the end of the study
62447717|NCT04130256|EXPERIMENTAL|Passive Adherence Monitoring|42 patients, each assigned to use the electronic pill bottle for 90 days. Participants will use the bottle to house their multiple sclerosis medication. The electronic pill bottle will not provide medication reminders and will only track medication use.
62059657|NCT01673893||ST elevation myocardial infarction|"The registry will record the use of the ClearWay™ Rx catheter during the index procedure, and assess whether or not the patient was readmitted within 30 days, related to the index procedure.~1st Group/Cohort - ST elevation myocardial infarction"
62845995|NCT02831101|NO_INTERVENTION|Propofol|Open administration using a separate target controlled infusion system and the PK/PD model by Schnider. Initial effect-site concentration 0.5 mcg/ml increased by 0.5 mcg/ml until LOC
62845996|NCT04006275|EXPERIMENTAL|Sonovue and Sonazoid Group|"Subjects were randomized to receive SonoVue firstly and Sonazid secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at observing room for at least 30min.~Contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
62059658|NCT01673893||Non-ST elevation myocardial infarction/ACS/UNSTABLE ANGINA|"The registry will record the use of the ClearWay™ Rx catheter during the index procedure, and assess whether or not the patient was readmitted within 30 days, related to the index procedure.~2nd Group/Cohort - Non-ST elevation myocardial infarction/ACS/Unstable Angina"
62845997|NCT04006275|EXPERIMENTAL|Sonazoid and Sonovue Group|"Subjects were randomized to receive Sonazoid firstly and SonoVue secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at observing room for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
62619767|NCT04872738||Unvaccinated Breast Cancer Patients|Patients who enroll in the trial and did not choose to receive the COVID-19 vaccine once it was available to them with complete a survey to indicate why they chose not to receive the vaccine. This information will be analyzed in conjunction with their breast cancer treatment history and lymphedema measurements.
62619768|NCT02609373|OTHER|Sleep intervention|Sleep intervention
62845998|NCT03173183|EXPERIMENTAL|genuine regional Rhizoma Atractylodis|"Granules of genuine regional Rhizoma Atractylodis:~Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day."
62059659|NCT06623396|EXPERIMENTAL|Participants with Mesothelin-Positive Esophagogastric Adenocarcinoma with Peritoneal Carcinomatosis|Participants will be diagnoses with Mesothelin-Positive Esophagogastric Adenocarcinoma with Peritoneal Carcinomatosis
62059660|NCT04766632|EXPERIMENTAL|one group|patients with high grade glioma
62059661|NCT03862287|ACTIVE_COMPARATOR|Intrathecal Lidocaine|Patients will receive spinal anesthesia in the sitting position under strict sterile conditions in the operating room. Using a median or paramedian approach, the spinal needle will be inserted into the L2-3 or L3-4 interspace to reach the subarachnoid space. After confirming the space by free flow of CSF, 60 mg of isobaric preservative-free Lidocaine 2% will be injected. Sedation using propofol infusion (50-100 mcg/kg/min) and fentanyl (0.5-1 mcg/kg) will be given throughout the procedure as required.
62263466|NCT01735487|EXPERIMENTAL|EGO 9mg|Smoke electronic cigarette EGO for a day (15 puff)
62263467|NCT00960661|EXPERIMENTAL|Exenatide (BET)|Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET)
62263468|NCT00960661|ACTIVE_COMPARATOR|Insulin Lispro (BBT)|Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT)
62263469|NCT05331521|ACTIVE_COMPARATOR|RT PCV|"Radiotherapy (RT) for over approximately 5-6 weeks:~* at 50.4/54 Gy in 1.8 Gy fractions for grade II and~* at 59.4 Gy in 1.8 Gy fractions for grade III gliomas~PCV cycles are 6 weeks long and given as:~* Day 1: Lomustine (CCNU) at 110 mg/m2 body surface orally,~* Days 8/29: Vincristine 1.4 mg/m2 i.v. (capped at 2 mg),~* Days 8-21: Procarbazine 60 mg/m2 orally (capped at 100 mg)."
62263470|NCT05331521|EXPERIMENTAL|CETEG|"Six 42-day cycles of lomustine plus temozolomide according to the commonly used regimen:~* Day 1: Lomustine (CCNU) at 100 mg/m2~* Days 2-6: Temozolomide at 100 mg/m2 (cycles 1) and in 50 mg/m2 steps to 200 mg/m2 from cycle 2 on dependent on hematological toxicity"
62447718|NCT05463861|ACTIVE_COMPARATOR|Lemborexant|Patients receive Lemborexant 5mg for 7 days and may be dose adjusted to 10mg. Patients continue to take Lemborexant 5mg or 10 mg for an additional 7 days.
62447719|NCT05463861|PLACEBO_COMPARATOR|Placebo|Patients receive placebo to match Lemborexant for 14 days.
62447720|NCT01630200|ACTIVE_COMPARATOR|Roflumilast|Active arm including patients who receive the study drug (500µg Roflumilast once daily)
62447721|NCT01630200|PLACEBO_COMPARATOR|Placebo|Control arm including patients who receive the placebo tablet (once daily)
62619769|NCT05957185|ACTIVE_COMPARATOR|P3 - WHEY|OPTIZIOME® P3 HYDROLYZER® - WHEY (P3 - WHEY) is a mixture of 3 microbial protease preparations with 50,000 HUT fungal proteolytic activity units per 250 mg dose.
62619770|NCT05957185|PLACEBO_COMPARATOR|Placebo|Maltodextrin from waxy maize at 265 mg per dose.
62619771|NCT03430856|EXPERIMENTAL|Insulin Tregopil (IN-105) - 45mg|Strength of each tablet is 15mg
62845999|NCT03173183|ACTIVE_COMPARATOR|non-genuine regional Rhizoma Atractylodis|"Granules of non-genuine regional Rhizoma Atractylodis (Luotian, Hubei province) :~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day."
62447722|NCT04468919|EXPERIMENTAL|BCI-FIT multi-modal configuration|For this single case research design with alternating treatments without baseline, 5 participants with severe speech and physical impairment will complete copy spelling tasks with a standard P300 matrix speller layout and with the multi-modal configurations optimized from the BCI-FIT algorithms. Outcome measures are typing accuracy, typing speed and user experience.
62846000|NCT03173183|PLACEBO_COMPARATOR|placebo|placebo granules: Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd., orally administration, 9g per time, 3 times a day.
62846001|NCT06335004||Patients with white matter disease/healthy subjects|Patients with white matter disease due to genetic or acquired causes. MRI with or without intravenous gadolinium will be performed
62846002|NCT06335004||Patients with no white matter disease|Patients undergoing MRI with or without gadolinium for clinical diagnostic purposes, with no known white matter disease.
62846003|NCT05032924|EXPERIMENTAL|PPR group|Receive PRP injection only (PRP form Regen Kit BCT 1)
62846004|NCT05032924|PLACEBO_COMPARATOR|HA group|Receive HA injection only (HYAJOINT Synovial Fluid Supplement, active ingredient: Sodium Hyaluronate 25 mg, package: 2.5 mL per syringe)
62846005|NCT01227174|EXPERIMENTAL|Propofol sedation|Patients will be undergo procedural sedation using propofol.
62846006|NCT03791099|EXPERIMENTAL|Metronidazole|19,8 mg of metronidazole in one polymer matrix
62846007|NCT03791099|NO_INTERVENTION|Only SRP|standard non-surgical treatment- scaling/root planing
62846008|NCT03554486|EXPERIMENTAL|Fiasp then Novolog|Following a 2-week run-in period for pump-setting adjustments and monitoring, participants 1 will use Fiasp insulin for 2 weeks, followed by Novolog insulin for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
62846009|NCT03554486|EXPERIMENTAL|Novolog then Fiasp|Following a 2-week run-in period for pump-setting adjustments and monitoring, participants 1 will use Novolog insulin for 2 weeks, followed by Fiasp insulin for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
62846010|NCT03755128||Pregnant women and their offspring from current pregnancy|
62846011|NCT03795272|EXPERIMENTAL|Rucaparib|Patients will be treated with active oral drug, Rucaparib twice daily for 24 months
62846012|NCT03795272|PLACEBO_COMPARATOR|Placebo|Patients will be treated with oral placebo twice daily for 24 months
62846013|NCT03783078|EXPERIMENTAL|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W) intravenous (IV), for up to 35 administrations (approximately 2 years)
62263471|NCT00971178|ACTIVE_COMPARATOR|Local Dexmedetomidine|
62263472|NCT00971178|PLACEBO_COMPARATOR|Normal Saline|
62263473|NCT00971178|ACTIVE_COMPARATOR|IV dexmedetomidine|
62263474|NCT01337856|OTHER|WHO alcohol handrub protocol|handrubbing with alcohol using the standard 7-step technique (WHO alcohol handrub protocol)
62263475|NCT01337856|OTHER|CDC alcohol handrub protocol|Handrubbing with alcohol covering all hand surfaces in no particular order (CDC alcohol handrub protocol)
62263476|NCT01337856|OTHER|Chlorhexidine handwashing|chlorhexidine handwashing using the standard 7-step technique (WHO handwashing protocol)
62263477|NCT01239602||Normal control|
62263478|NCT01239602||with Stem cell therapy plus G-CSF|
62619772|NCT03430856|EXPERIMENTAL|Insulin Tregopil (IN-105) - 30mg|Strength of each tablet is 15mg
62846014|NCT04541459|SHAM_COMPARATOR|Sham Qi-Shield user group|
62846015|NCT04541459|ACTIVE_COMPARATOR|Qi-Shield user group|
62846016|NCT01516541|EXPERIMENTAL|Dalcetrapib|Dalcetrapib 600 mg orally daily on a background of contemporary, guidelines-based medical care.
62846017|NCT01516541|PLACEBO_COMPARATOR|Placebo|Placebo orally daily, on a background of contemporary, guidelines-based medical care.
62846018|NCT01697618|EXPERIMENTAL|BIAsp 30|
62846019|NCT01697618|ACTIVE_COMPARATOR|BHI 30|
62846020|NCT02841514|EXPERIMENTAL|treatment group|the operator will administer the Y10 whitening toothpaste in to the attachable mouthpiece and place it in the subject's mouth and turn on the device RF. After treating the patients for 30 minutes the operator will turn off the device and retrieve the mouthpiece from the mouth.
62846021|NCT02841514|PLACEBO_COMPARATOR|placebo group|the operator will administer an off the shelf regular toothpaste in to the attachable mouthpiece and place it in the subject's mouth. At this point the operator will switch on the device but the RF will not be activated. After 30 minutes the operator will turn off the device and retrieve the mouthpiece from the mouth.
62846022|NCT05241613|EXPERIMENTAL|AC176 Dose Escalation as Single Agent|Single agent dose escalation of AC176. AC176 will be given orally (PO) on a 28-day cycle.
62846023|NCT05859191||LUPUS PATIENTS|Three extra tubes of blood will be taken at each consultation or inpatient visit when routine blood samples are taken as part of lupus monitoring.
62846024|NCT05454072|EXPERIMENTAL|Sinonasal Microbiota Transfer|The transfer site for patients will be prepared by endoscopically removing any visible crusting, mucin, and purulent discharge from the sinuses and via manual high-volume (\>60 ml), high-pressure saline wash on day 0. The donor mucus sample will be homogenized using sterile, disposable rotor-stator homogenizer tips for 30 seconds and 5 ml of donor mucus will be instilled into the affected sinus cavity(ies) using a masked syringe under endoscopic visualization, with the recipient's head in a dependent position. Patients will remain in this position for 15 minutes to facilitate transfer.
62846025|NCT05454072|SHAM_COMPARATOR|Sham Sinonasal Microbiota Transfer|Sterile saline will replace the SNMT donor mucus in the masked syringe and will be delivered in an identical manner to the SNMT intervention.
62263479|NCT01239602||G-CSF along|
62059662|NCT03862287|ACTIVE_COMPARATOR|Intrathecal Bupivacaine|Patients will receive spinal anesthesia in the sitting position under strict sterile conditions in the operating room. Using a median/paramedian approach, the spinal needle will be inserted into the L2-3 or L3-4 interspace to reach the subarachnoid space. After confirming the space by free flow of CSF, 6 mg of 0.5% isobaric bupivacaine will be injected. Sedation using propofol infusion (50-100 mcg/kg/min) and fentanyl (0.5-1 mcg/kg) will be given throughout the procedure as required.
62447723|NCT04468919|EXPERIMENTAL|Adaptive signal modeling|For this single case research design with alternating treatments without baseline, 5 participants with severe speech and physical impairment will complete copy spelling tasks with 3 signal adaptive modeling configurations. Outcome measures are typing accuracy, typing speed and user experience.
62619773|NCT03430856|ACTIVE_COMPARATOR|Insulin Aspart|Pre-filled pen: 100 U/L
62619774|NCT01914965|ACTIVE_COMPARATOR|Bupropion|First treatment group: 150 mg bupropion or placebo once daily for 2 weeks, followed by 300 mg bupropion or placebo once daily for subsequent 8 weeks (until week 10; visit 4) First tapering and washout: 150 mg bupropion or placebo once daily for 7 days followed by a washout phase of 1 week on placebo
62059663|NCT05674591|EXPERIMENTAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a manual-guided therapy that incorporates cognitive processing techniques to relieve PTSD symptoms (Resick et al., 2016). Each group session will be 90 to 120 minutes long and will be occur once each week for 12 weeks.
62059664|NCT03757143|ACTIVE_COMPARATOR|PVI et Insyte|Groupe A: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) InsyteTM AutoguardTM BC Winged, BD
62059665|NCT03757143|EXPERIMENTAL|CHG et Insyte|Groupe B: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) InsyteTM AutoguardTM BC Winged, BD
62059666|NCT03757143|EXPERIMENTAL|PVI et Nexiva|Groupe C: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, , PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD
62263480|NCT04255446||Dysfunctional Breathing|Patients with Dysfunctional breathing age between 16 to 75 will be included.
62263481|NCT04255446||Healthy Volunteers|Healthy Volunteers without any respiratory problems age between 16 to 75 will be included.
62263482|NCT06240832|EXPERIMENTAL|Aerobic and strength training in children with CLD|AEROBIC AND STRENGTHENING EXERCISE USING TREADMILL AND WEIGHT TO IMPROVE FUNCTIONAL OUTCOMES IN CHILDREN WITH CHRONIC LIVER DISEASE
62263483|NCT03548935|EXPERIMENTAL|Semaglutide s.c. 2.4 mg once weekly|Participants will receive semaglutide for 68 weeks.
62263484|NCT03548935|PLACEBO_COMPARATOR|Semaglutide placebo|Participants will receive semaglutide matching placebo for 68 weeks.
62263485|NCT05345964|ACTIVE_COMPARATOR|Single-dose experimental group|5mg,15mg,30mg,60mg,90mg,120mg,150mg and 180mg need to complete a single-dose clinical study. The first two dose groups had 4 subjects in each group (3 received GST-HG151 and 1 received placebo，randomly assigned), and the rest are 10 ubjects in each group (8 received GST-HG151 and 2 received placebo， randomly assigned)
62263486|NCT05345964|PLACEBO_COMPARATOR|Single-dose control group|5mg,15mg,30mg,60mg,90mg,120mg,150mg and 180mg need to complete a single-dose clinical study. The first two dose groups had 4 subjects in each group (3 received GST-HG151 and 1 received placebo，randomly assigned), and the rest are 10 ubjects in each group (8 received GST-HG151 and 2 received placebo， randomly assigned)
62447724|NCT04468919|EXPERIMENTAL|Active querying techniques|For this single case research design with alternating treatments without baseline, 5 control volunteers and 5 participants with severe speech and physical impairment who have AUC scores between 70-80% will complete copy spelling tasks with BCI-FIT active querying technique on and with BCI-FIT active querying technique off. Outcome measures are typing accuracy, typing speed and user experience.
62619775|NCT01914965|PLACEBO_COMPARATOR|Placebo|Second treatment group (crossover): placebo or 150 mg bupropion once daily for 2 weeks, followed by placebo or 300 mg bupropion once daily for subsequent 8 weeks (until week 22; visit 6) Second tapering placebo or 150 mg bupropion once daily for 7 days
62619776|NCT04728984|EXPERIMENTAL|Nalfurafine Hydrochloride 5μg|Oral administration after dinner, once daily for 14 consecutive days
62059667|NCT03757143|EXPERIMENTAL|CHG et Nexiva|Groupe D: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD
62059668|NCT03830203|EXPERIMENTAL|BAT1806|BAT1806 injection: 8 mg/kg, intravenous infusion by 60 min
62263487|NCT05345964|ACTIVE_COMPARATOR|Multi-dose experimental group|According to the results of the SAD, it is planned to carry out multiple-dose studies in 2 to 3 dose groups. Continuous administration, 12 subjects in each group(10 received GST-HG151 and 2 received placebo， randomly assigned)
62263488|NCT05345964|PLACEBO_COMPARATOR|Multi-dose control group|According to the results of the SAD, it is planned to carry out multiple-dose studies in 2 to 3 dose groups. Continuous administration, 12 subjects in each group(10 received GST-HG151 and 2 received placebo， randomly assigned)
62263489|NCT05345964|ACTIVE_COMPARATOR|Food Impact Study Group A|According to the results of the SAD, it is planned to select 1 dose group，10 subjects(8 received GST-HG151 and 2 received placebo， randomly assigned)，two cycles, crossover
62263490|NCT05345964|ACTIVE_COMPARATOR|Food Impact Study Group B|According to the results of the SAD, it is planned to select 1 dose group，8 subjects，two cycles, crossover
62263491|NCT04276714|EXPERIMENTAL|Adjustable socket|First week of the study is with adjustable socket
62263492|NCT04276714|EXPERIMENTAL|Classical socket|First week of the study is with classical socket
62619777|NCT04728984|EXPERIMENTAL|Nalfurafine Hydrochloride 2.5μg|Oral administration after dinner, once daily for 14 consecutive days
62619778|NCT04728984|PLACEBO_COMPARATOR|Placebo|Oral administration after dinner, once daily for 14 consecutive days
62059669|NCT03830203|ACTIVE_COMPARATOR|Actemra(EU-licensed)|Actemra(EU-licensed): 8 mg/kg, intravenous infusion by 60 min
62619779|NCT05593328|EXPERIMENTAL|Onvansertib 20 mg + Standard of Care (SOC)|Participants will receive 20 mg of onvansertib on Days 1 to 5 and 15 to 19 of a 28-day treatment cycle and SOC (FOLFIRI + bevacizumab) on Days 1 and 15 of each 28-day cycle.
62623769|NCT04787614||Home-based providers|Individuals who provided paid care for children under the age of 13 in a residential setting as of 2019
62059670|NCT05608096||Hemoperfusion|ICU septic patients treated with hemoperfusion
62059671|NCT05608096||non-hemoperfusion|ICU septic patients non treated with hemoperfusion
62059672|NCT03839732||Vascular Calcification Group|Patients with prevalent vascular calcifications will be analysed to verify the intra- and inter-observer reliability of the score of abdominal aorta calcifications
62059673|NCT00732602|ACTIVE_COMPARATOR|B|GLP-2 infusion
62059674|NCT00732602|PLACEBO_COMPARATOR|C|Sodium-chloride infusion
62059675|NCT00732602|ACTIVE_COMPARATOR|A|GIP-infusion
62059676|NCT05999084||Anti-amyloid Monoclonal Antibodies (mAbs)|Patients with Mild Cognitive Impairment (MCI) or mild AD dementia who are receiving treatment with anti-amyloid mAbs, per standard of care. Patients seen in the Emory and GMN MACs are evaluated with standard instruments for cognitive and functional abilities.
62059677|NCT05999084||Historical Comparator Group|Available historical data from biomarker-confirmed patients with MCI or mild dementia due to AD who have been followed in the Emory Cognitive Neurology Clinic will serve as a comparator group. Patients seen in the Emory and GMN MACs are evaluated with standard instruments for cognitive and functional abilities.
62059678|NCT05999084||Caregivers of Patients Receiving Anti-amyloid Monoclonal Antibodies (mAbs)|Caregivers of patients with Mild Cognitive Impairment (MCI) or mild AD dementia who are receiving treatment with anti-amyloid mAbs, per standard of care. Caregivers of patients seen in the Emory and GMN MACs are evaluated with standard instruments for cognitive and functional abilities.
62059679|NCT01546792|NO_INTERVENTION|Usual care control|Leaflet on exercise and diet
62059680|NCT01546792|EXPERIMENTAL|Lifestyle intervention|Exercise training (mixture of supervised and non-supervised) Dietary advice Behaviour change counselling (physical activity, diet)
62263493|NCT03399877|ACTIVE_COMPARATOR|Combining electromygraphy with uroflowmetry|Children who assigned group A perform uroflowmetry-electromyography for the first and subsequently perform uroflowmetry-electromyography
62263494|NCT03399877|ACTIVE_COMPARATOR|Uroflowmetry|Children who assigned Group B perform uroflowmetry-electromyography for the first, and subsequently perform uroflowmetry solely.
62263495|NCT03399877|EXPERIMENTAL|Uroflowmetry-Combining electromygraphy with uroflowmetry|Children who assigned Group C firstly perform uroflowmetry solely. and subsequently perform uroflowmetry-electromyography.
62059681|NCT05318469|EXPERIMENTAL|Treatment (ivermectin, balstilimab)|Patients receive ivermectin PO QD on days 1-3, 8-10, and 15-17. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also receive balstilimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
62059682|NCT02282397|NO_INTERVENTION|Phase 1: SMBG|Type 1 or Type 2 diabetes mellitus subjects using SMBG testing and usual care for diabetes management. No intervention to be administered
62263496|NCT03569709|ACTIVE_COMPARATOR|Aerobic Exercise|Sub-threshold aerobic exercise.
62263497|NCT03569709|PLACEBO_COMPARATOR|Stretching|Stretching program that will not raise heart rate.
62263498|NCT03569709|PLACEBO_COMPARATOR|Rest|Relative rest. Avoid all structured exercise.
62263499|NCT01170403||NGT/IFG/DM, MeS/no-MeS|NGT: normal glucose tolerance IFG: impaired glucose tolerance DM : diabetes mellitus MeS: metabolic syndrome no-MeS: no metabolic syndrome
62263500|NCT04746352|EXPERIMENTAL|BES-SMFR group|Using the same Vishee neuro-muscle stimulator as the sEMG assessment with a vaginal probe was inserted into the vagina and placed close to the PFMs. Three standardized programs were used in our study: (1) Tens electricity (first program): 5 min of 50-280 Hz frequency and a pulse duration of 50 µs. (b) Endorphin electricity (second program): 5 min of 1-10 Hz frequency and a pulse duration of 200 µs. (c) Spasmolysis electricity (third program): 5 min of 1-2 Hz frequency and a pulse duration of 300 µs. At the same time, patients could learn about their neuromuscular activity through the biofeedback instrument, abdominal breathing for 5 sec was necessary when PFMs were overactive.
62447725|NCT04468919|EXPERIMENTAL|Language modeling|For this single case research design with alternating treatments, 5 control volunteers and 5 participants with severe speech and physical impairment, each with a control partner for partner input will complete a story retell task with BCI-FIT language modeling features on and with BCI-FIT language modeling features off. Outcome measures are information transfer rate and user experience.
62447726|NCT00719784|EXPERIMENTAL|1|All patients recruited will have VRI recordings done. There is no comparative arm.
62447727|NCT03019393|OTHER|Beef|Beef topside fully cooked, 200g
62447728|NCT05973227|EXPERIMENTAL|interventional arm (use of TRIDENT system)|
62447729|NCT04002921||Right colectomy|Patient with scheduled right colectomy and with a documented preoperative scan.
62447730|NCT02577159|EXPERIMENTAL|Dapagliflozin|Diabetic patients who met the inclusion/exclusion criteria. Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
62447731|NCT03664856|EXPERIMENTAL|experimental group|Subject suffering from a locally advanced or metastatic cancer therefore falling under palliative care as defined by the definition of the French Society of Support and Palliative Care An interview will be performed
62447732|NCT01698996|ACTIVE_COMPARATOR|No Packing|No Packing
62447733|NCT01698996|EXPERIMENTAL|Packing|Packing
62447734|NCT04921033|EXPERIMENTAL|Exclusive Enteral Nutrition|35kcal/kg/day EEN (Nestle Modulen®) - Subjects will take medicine and EEN solution orally themselves.
62447735|NCT04921033|ACTIVE_COMPARATOR|Standard of care|"* Budesonide 9mg/day for mild disease~* Prednisolone 1mg/kg, maximum 40mg/day in decreasing doses (40mg for 4 weeks followed by a fixed taper for 6 weeks) for moderate-to-severe disease for 12 weeks.~* Patients with moderate-to-severe disease in the steroid group will also receive 2mg/kg azathioprine. The dose of azathioprine will be adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine."
62619780|NCT05593328|EXPERIMENTAL|Onvansertib 30 mg + Standard of Care (SOC)|Participants will receive 30 mg of onvansertib on Days 1 to 5 and 15 to 19 of a 28-day treatment cycle and SOC (FOLFIRI + bevacizumab) on Days 1 and 15 of each 28-day cycle.
62619781|NCT05593328|ACTIVE_COMPARATOR|Standard of Care (SOC)|Participants will receive SOC (FOLFIRI + bevacizumab) on Days 1 and 15 of each 28-day cycle.
62447736|NCT06349720||severe vs non-severe|
62619782|NCT02546596|EXPERIMENTAL|Electro-hyperthermia plus radiation|External beam radiation 40 Gy with 20 fractions (4 weeks) Electro-hyperthermia twice a week, one hour for each session
62846026|NCT05294289||PROS patients treated with alpelisib|Patients with PROS who receive treatment with alpelisb
62846027|NCT05294289||PROS patients not treated with alpelisib|Patients with PROS who don't receive treatment with apelisib
62846028|NCT05024110|EXPERIMENTAL|Group I|GI received high-intensity exercise training.
62447737|NCT06349720||COVID-19 patients vs healthy volunteers|
62447738|NCT06349720||emote respiratory rehabilitation vs outpatient respiratory rehabilitation|
62619783|NCT03090503|ACTIVE_COMPARATOR|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
62619784|NCT03090503|ACTIVE_COMPARATOR|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
62619785|NCT05674409|EXPERIMENTAL|Cognitive Behavioral Therapy + Brief Family-Involved Treatment|"Approximately half of enrolled veterans and their treatment companion will be randomly assigned to the experimental group. The identified veteran participant wil receive 12 sessions of Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD). In addition, both the identified veteran and their treatment companion will receive an additional 3 sessions of Brief Family-Involved Treatment (B-FIT).~B-FIT is a manualized, 3-session AUD intervention, designed to be implemented in combination with any existing alcohol treatment program."
62846029|NCT05024110|EXPERIMENTAL|Group II|GII received moderate-intensity exercise training.
62846030|NCT04030273||Open (laparotomic) myomectomy|Women undergoing uterine myomectomy by open surgery (laparotomy).
62846031|NCT04030273||Laparoscopic myomectomy|Women undergoing uterine myomectomy by laparoscopy.
62846032|NCT04030273||Robotic myomectomy|Women undergoing uterine myomectomy by robotic surgery.
62846033|NCT02440841|EXPERIMENTAL|fedovapagon and itraconazole|Two daily doses of fedovapagon and once daily doses of itraconazole
62846034|NCT02440841|EXPERIMENTAL|fedovapagon and rifampicin|Two daily doses of fedovapagon and once daily doses of rifampicin
62846035|NCT00540852|OTHER|Diagnostic Tool|Diffuse Optical Spectroscopy Imaging
62846036|NCT01625741|EXPERIMENTAL|rituximab|4 monthly administrations of rituximab
62846037|NCT01358721|EXPERIMENTAL|Arm 1: BMS-936558|
62059683|NCT02282397|OTHER|Phase 1: CGM|Type 1 or Type 2 diabetes mellitus subjects using RT-CGM and SMBG testing for diabetes management. RT-CGM (Continuous Glucose Monitoring) is the intervention.
62059684|NCT02282397|NO_INTERVENTION|Phase 2: CGM/MDI|Type 1 Diabetes Mellitus subjects using RT-CGM and injections for diabetes management.
62059685|NCT02282397|NO_INTERVENTION|Phase 2: CGM/CSII|Type 1 Diabetes Mellitus subjects using RT-CGM and CSII for diabetes management.
62059686|NCT01957501||Major Depressive Disorder Participants|
62059687|NCT01957501||Bipolar Disorder Participants:|
62059688|NCT01957501||Healthy Control Participants|
62059689|NCT01959347|SHAM_COMPARATOR|Miduretheral Sling (Control)|Miduretheral Sling (Control)
62447739|NCT01604421|SHAM_COMPARATOR|Thermoregulation-standard care|Standard thermoregulation without a plastic bag from one hour after birth until discharge or 24 hours after birth, whichever comes first.
62447740|NCT01604421|ACTIVE_COMPARATOR|Thermoregulation-with plastic bag|Thermoregulation with plastic bag covering torso and lower extremities from one hour after birth until discharge or 24 hours after birth to assist with thermoregulation. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.
62447741|NCT05697809|EXPERIMENTAL|A1: OXU-001 / Mid dose|The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 1 (mid dose) will be applied.
62447742|NCT05697809|EXPERIMENTAL|A2: OXU-001 / High Dose|The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 2 (high dose) will be applied.
62619786|NCT05674409|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Approximately half of enrolled veterans and their treatment companion will be randomly assigned to the active comparator group. The identified veteran participant wil receive 12 sessions of Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD).
62619787|NCT02350088|ACTIVE_COMPARATOR|Fast-track Surgery|probiotics,oral,b.i.d.
62619788|NCT02350088|ACTIVE_COMPARATOR|Traditional Group|placebo,oral,b.i.d.
62846038|NCT01358721|EXPERIMENTAL|Arm 2: BMS-936558|
62846039|NCT01358721|EXPERIMENTAL|Arm 3: BMS-936558|
62846040|NCT01358721|EXPERIMENTAL|Arm 4: BMS-936558|(treatment naive)
62846041|NCT02269579|EXPERIMENTAL|CPX-351|Study Drug CPX-351 will be given intravenously at 100u/m2 on days 1, 3 and 5 by approximately 90 minute infusion.
62846042|NCT00272025|ACTIVE_COMPARATOR|1|There is a 50% chance of being randomized to Escitalopram in addition to current atypical antipsychotic (minimum dose risperidone 3mg, olanzapine 10mg or seroquel 400mg) or mood stabilizer (lithium, epival or lamotrigine)
62846043|NCT00272025|PLACEBO_COMPARATOR|2|to be filled in
62846044|NCT02507700|ACTIVE_COMPARATOR|popliteal block|Popliteal block will be performed with a single dose of 0.3 ml·kg(-1) of 0.25% bupivacaine.
62059690|NCT01959347|EXPERIMENTAL|MUS+BPTx|Miduretheral Sling with behavioral/pelvic floor therapy
62059691|NCT02269514|ACTIVE_COMPARATOR|Own Brand Cigarette|Own Brand Cigarette
62059692|NCT02269514|EXPERIMENTAL|Electronic Cigarette #1|VUSE® (original flavor, 14mg nicotine)
62059693|NCT02269514|EXPERIMENTAL|Electronic Cigarette #2|VUSE® (original flavor, 29mg nicotine)
62059694|NCT02269514|EXPERIMENTAL|Electronic Cigarette #3|VUSE® (original flavor, 36mg nicotine)
62059695|NCT02269514|ACTIVE_COMPARATOR|Leading U.S. Nicotine Gum|Leading U.S. Nicotine Gum
62059696|NCT03767270|EXPERIMENTAL|MRT5201|Single Ascending Low, Mid, and High doses of MRT5201
62059697|NCT03767270|PLACEBO_COMPARATOR|Placebo|Placebo comparator using 5% dextrose in water at the same administration rate as study drug.
62059698|NCT05671640|EXPERIMENTAL|DragonFly-T Transcatheter Tricuspid Valve Repair System|The experimental group is allocated to use a novel tricuspid valve repair system for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd.
62059699|NCT00229957|EXPERIMENTAL|Intervention|Intervention
62059700|NCT00229957|NO_INTERVENTION|Control|Control group received usual care in primary care.
62059701|NCT02552238|EXPERIMENTAL|Lumason|Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection
62059702|NCT01227603|EXPERIMENTAL|Nifedipine-candesartan FDC|Each subject received single fixed dose combination of 60 mg nifedipine and 32 mg candesartan orally.
62846045|NCT02507700|SHAM_COMPARATOR|Plaster cover|Only plaster cover will be applied without nerve block for sham procedure.
62846046|NCT04010604||SMA type I|
62846047|NCT04010604||SMA type II|
62846048|NCT04010604||SMA type III|
62846049|NCT04010604||Asymptomatic carriers of SMA|
62846050|NCT04010604||Relatives of SMA patients and carriers|
62846051|NCT04010604||Unrelated healthy controls|
62447743|NCT05697809|EXPERIMENTAL|B1: OXU-001 / Mid Dose|The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 1 (mid dose) will be applied.
62619789|NCT01138527||Biopsy-proven prostate cancer|Patients with biopsy-proven prostate cancer, planned for radical prostatectomy
62619790|NCT06224296|EXPERIMENTAL|Group A: Inflammatory cytokine group|Self-control
62619791|NCT06224296|EXPERIMENTAL|Group B: Lipid group|Self-control
62619792|NCT06224296|EXPERIMENTAL|Group C: Toxic metal ions group|Self-control
62059703|NCT01227603|ACTIVE_COMPARATOR|Nifedipine and candesartan|Each subject received one dose of nifedipine GITS 60 mg and candesartan 32 mg (2 x 16 mg tablet) as loose combination, orally.
62059704|NCT01227603|ACTIVE_COMPARATOR|Nifedipine|Each subject received one dose of nifedipine GITS 60 mg orally.
62059705|NCT01227603|ACTIVE_COMPARATOR|Candesartan|Each subject received one dose of candesartan 32 mg (2 x 16 mg tablet), orally.
62059706|NCT00830622|EXPERIMENTAL|1|Cell Phone Intervention: participant receives weekly SMS text message from the health care worker.
62059707|NCT00830622|NO_INTERVENTION|2|SOC: Participant receives standard of care support but not weekly SMS text messages from the health care worker.
62059708|NCT01257711|OTHER|Billroth II reconstruction|Following Radical Distal Subtotal Gastrectomy, patient will be randomised to restore the continuity of the intestine with the stomach using Billroth II reconstruction.
62059709|NCT01257711|OTHER|Roux-en-Y reconstruction|Following Radical Distal Subtotal Gastrectomy, patient will be randomised to restore the continuity of the intestine with the stomach using Roux-en-Y reconstruction.
62059710|NCT03161366|EXPERIMENTAL|Single arm|Vaccination of contacts and contacts of contacts of a confirmed Ebola Zaire case with one dose of rVSVΔG-ZEBOV-GP (≥ 2x10\^7 PFU)
62059711|NCT01120158|EXPERIMENTAL|1|Paclitaxel/Bevacizumab
62059712|NCT05124106|EXPERIMENTAL|Diagnostic ability of Raman spectrometry|Endoscopic Raman spectrometry during endoscopic bladder cancer surgery
62059713|NCT00849004|ACTIVE_COMPARATOR|Gel vs. Sheet|One group will act to compare the effectiveness between silicone gel and silicone sheet.
62447744|NCT05697809|EXPERIMENTAL|B2: OXU-001 / High Dose|The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 2 (high dose) will be applied. This dose may be adpated based on the outcome of a Week 6 data review of Part A
62447745|NCT05697809|ACTIVE_COMPARATOR|B3: Ozurdex®|A single treatment with intravitreal Ozurdex®
62619793|NCT03975725|EXPERIMENTAL|witcard|
62619794|NCT02780960|EXPERIMENTAL|HPV self-testing|Patients will perform HPV self-testing at home, prior to their follow-up visit. At the colposcopy visit, the doctor or nurse will also perform HPV testing. This procedure will be repeated at 6 and 12 months following LEEP.
62619795|NCT06389383|OTHER|Nasal swab|"* Nasal swab once a week for the duration of the stay in intensive care unit/intensive care (procedure already carried out routinely to detect nasal staphylococcus once a week).~* Nasal swab every 14 days when the newborn is hospitalized in routine care/kangaroo unit/hospitalization at home"
62619796|NCT02963272|OTHER|Conventional strategy|Conventional strategy to manage the patients with HF, following the international guidelines
62059714|NCT00849004|ACTIVE_COMPARATOR|sheet vs. paper tape|The second group between silicone sheet and paper tape.
62059715|NCT00849004|ACTIVE_COMPARATOR|gel vs. paper tape|One group will act to compare the effectiveness between silicone gel and paper tape.
62619797|NCT02963272|OTHER|ST2-guided strategy|Management of patients follow the international guidelines but are also guided by the ST2, to adapt the drugs indicated in patients with HF.
62619798|NCT02552953|EXPERIMENTAL|CYC065 - 4 hour infusion (Part 1 completed)|CYC065 will be administered by 4 -hour infusion every 3 weeks.
62619799|NCT02552953|EXPERIMENTAL|CYC065 - 1 hour infusion (Part 2 - ongoing)|CYC065 will be administered by 1 - hour infusion on Days 1, 2, 8, and 9 every 3 weeks
62619800|NCT02552953|EXPERIMENTAL|CYC065 - Oral (Part 3 - ongoing)|CYC065 will be administered orally on Days 1, 2, 8 and 9 every 3 weeks
62059716|NCT03034018|EXPERIMENTAL|suvorexant|suvorexant 10-20 mg taken at bedtime for four weeks
62059717|NCT03034018|PLACEBO_COMPARATOR|placebo|placebo taken at bedtime for four weeks
62059718|NCT02530814||Lake Apopka Farmworkers|This group will have a onetime blood collection and questionnaires regarding health status and health concerns.
62059719|NCT02530814||Existing Data Group|The investigators will collect existing data from the National Health and Nutrition Examination Survey (NHANES) for the range of concentrations of these chemicals in the blood of Americans.
62059720|NCT01874314|EXPERIMENTAL|SQ109 450 mg|Single daily dose of oral 450mg SQ109 for 7 days.
62059721|NCT01874314|ACTIVE_COMPARATOR|Moxifloxacin|Single daily dose of oral 400mg moxifloxacin for 7 days followed by 7 days washout period.
62059722|NCT01874314|PLACEBO_COMPARATOR|SQ109 Placebo|Single daily dose of oral SQ109 placebo for 7 days followed by 7 days washout period.
62059723|NCT01874314|EXPERIMENTAL|SQ109 300 mg|Single daily dose of oral 300mg SQ109 for 7 days followed by 7 days washout period.
62059724|NCT03877965||Children with single ventricle congenital heart disease|Receiving digoxin per standard of care during the interstage period
62447746|NCT00796510|EXPERIMENTAL|Sitaxsentan|Monotherapy arm
62447747|NCT00796510|EXPERIMENTAL|Sitaxsentan and Sildenafil|Combination treatment
62447748|NCT04469608|EXPERIMENTAL|TCM clinical daycare model for depression patients|Tai Chi and Acupuncture and Yoga and Mindfulness
62619801|NCT05808270|ACTIVE_COMPARATOR|Nutrition care process|
62619802|NCT05808270|PLACEBO_COMPARATOR|Conventional nutritional intervention|
62619803|NCT05194241|EXPERIMENTAL|One MORE|
62619804|NCT05194241|NO_INTERVENTION|Waitlist Control|
62619805|NCT00886964|ACTIVE_COMPARATOR|1|HBV ID
62619806|NCT00886964|ACTIVE_COMPARATOR|2|HBV IM
62619807|NCT05326126|EXPERIMENTAL|Coronary physiology evaluation|Patient will undergo TAVI and then Myocardial fibrosis will be evaluated on images acquired at the time of the cardiac CT obtained for TAVI planning. Briefly, an extra late post-contrast acquisition image will be acquired. The delayed post-contrast scan will be reconstructed with a soft convolution kernel and will be reformatted in the short- and long-axis planes (slice thickness 8 mm; gap 0 mm) in average mode.
62263501|NCT04746352|ACTIVE_COMPARATOR|BES group|"1. A standardized and structured vaginal examination was performed by digital palpation to identify pelvic floor active MTrPs, and then pain mapping was developed for the patient's use.~2. Patients were required to participate in intensive training regarding myofascial release techniques. (I) Pressing: press directly on a specific MTrP with gentle, slow pressures (2kg/cm2) using a flat palpation, the pressure was sustained until the participant perceived the pain decreased and taut band released, and then gradually increased to previous level of MTrPs tension and maintained until a reduction of pain again. The process was usually 3 to 5 repetitions for 90 sec. (II) Stretching: stretch in parallel to the direction of the myofascial to facilitate elongation of a contracted muscle. (III) Strumming: stroking and strumming the affected muscles region with the fingertips to aid in MTrPs tension release, the initial pressure was small and increased gradually until the patients adapted."
62263502|NCT05941975|EXPERIMENTAL|PIRA|From the MS functional outcome database, identification of a cohort of patients with RMS experiencing progression independent of relapse (PIRA)
62263503|NCT05941975|ACTIVE_COMPARATOR|N-PIRA|From the MS functional outcome database, identification of a cohort of patients with RMS not experiencing progression independent of relapse (N-PIRA)
62263504|NCT03401515|ACTIVE_COMPARATOR|Intervention|Adminstration of propranolol hydrochloride ( 1 MG /ml) 1 mg every 6 hrs .
62263505|NCT03401515|PLACEBO_COMPARATOR|Control|Adminstration of normal saline 1 mg every 6 hrs
62619808|NCT01775683||Group A - chronically homeless|Men and women, greater than or equal to age 18 years, English-speaking, who are currently homeless and/or housed in an emergency shelter or housing facility for chronically homeless individuals ≥ 6 months.
62619809|NCT01775683||Group B - control/formerly homeless|Men and women, greater than or equal to 18 years, English-speaking who are not homeless ≥4 times in the last 3 years and currently living in stable housing ≥ 6 months and in the last 3 years, has been homeless ≤ 1 month
62619810|NCT00055497|PLACEBO_COMPARATOR|Double-blind (DB) adalimumab placebo|Double-blind nonactive matching subcutaneous injection
62619811|NCT00055497|EXPERIMENTAL|Double-blind adalimumab 40 mg every other week (eow)|Double-blind adalimumab 40 mg eow by subcutaneous injection
62059725|NCT01618890|EXPERIMENTAL|HVPG-propranolol arm|"A baseline hepatic venous pressure gradient measurement (HVPG measurement) is performed in day-care setting. After this procedure propranolol is started at 20 mg BID. with dose escalation as described in the propranolol arm.~A second HVPG measurement is performed at 4 weeks after adequate propranolol therapy. In patients who reach target HVPG reduction (responders), propranolol is continued at the same dose without routine control endoscopy. In patients who do not reach target HVPG reduction (nonresponders), endoscopic band ligation is performed in day-care setting with intervals of 2-4 weeks until complete obliteration of varices. Follow-up endoscopy with 6 months interval is performed to detect and treat recurrent large varices."
62059726|NCT01618890|NO_INTERVENTION|Propranolol arm|Propranolol start 20 mg BID. orally with dose escalation based on heart frequency (HF) with 3-days interval to the maximum tolerated dose. No routine control endoscopy is required.
62059727|NCT00231673|EXPERIMENTAL|001|Topiramate Increasing dosing of topiramate gradually to 200 mg daily by mouth dose maintenance for 12 weeks then decreasing dose until stopped over 12 weeks
62059728|NCT02891538|EXPERIMENTAL|epigallocatechin gallate (EGCG)|Patients randomized to the EGCG arm, will start EGCG within 4-12 weeks of surgery and take EGCG 450 mg PO twice a day.
62059729|NCT02891538|NO_INTERVENTION|Observation Only|Standard of care surgical resection followed by standard of care colonoscopy at year.
62059730|NCT05250622|EXPERIMENTAL|Japanese group|Participants who will receive Japanese-translated version of evidence summaries
62059731|NCT05250622|ACTIVE_COMPARATOR|English group|Participants who will receive English version of evidence summaries
62059732|NCT00661661|EXPERIMENTAL|CP-690,550|
62059733|NCT01076283|ACTIVE_COMPARATOR|Baclofen|Baclofen 10 mg three times a day (t.i.d.) for 8-10 days
62619812|NCT00055497|EXPERIMENTAL|Double-blind adalimumab 40 mg every week (ew)|Double-blind adalimumab 40 mg every week by subcutaneous injection
62263506|NCT04200261|EXPERIMENTAL|Banapenem|2000 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 3000 mg group is then performed
62263507|NCT04200261|PLACEBO_COMPARATOR|placebo|sodium chloride injection Once daily for 7 days
62619813|NCT00055497|EXPERIMENTAL|Open-label adalimumab 40 mg|Open-label adalimumab 40 mg eow or ew by subcutaneous injection
62619814|NCT00516490|EXPERIMENTAL|1|GnRH agonist administration
62619815|NCT00516490|PLACEBO_COMPARATOR|2|Sterile saline injection
62619816|NCT05393297|EXPERIMENTAL|HNSCC receiving (chemo)radiotherapy|Radiation: Intra-treatment FDG-PET-CT and MRI will be used to identify tumours and patients for dose-escalation. Patients identified for dose-escalation (boost) will undergo adaptive radiotherapy replanning, with the primary tumour (GTVp) receiving 76.9Gy in 35 fractions.
62619817|NCT00966355|ACTIVE_COMPARATOR|Terlipressin|treat with terlipressin IV for 5 days and endoscopic treatment
62619818|NCT00966355|ACTIVE_COMPARATOR|Somatostatin|treat with somatostatin IV for 5 days and endoscopic treatment
62059734|NCT01076283|PLACEBO_COMPARATOR|Cyproheptadine|Cyproheptadine 2 mg t.i.d. for 8-10 days
62619819|NCT00966355|ACTIVE_COMPARATOR|Octreotide|treat with octreotide IV for 5 days and endoscopic treatment
62619820|NCT01090297|ACTIVE_COMPARATOR|Fixed pressure|
62619821|NCT01090297|ACTIVE_COMPARATOR|Auto-adjusting pressure|
62059735|NCT00846443|EXPERIMENTAL|1|pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
62447749|NCT04469608|NO_INTERVENTION|Depression patients|Tai Chi and acupuncture and yoga and mindfulness are not added
62059736|NCT00846443|EXPERIMENTAL|2|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
62059737|NCT00846443|EXPERIMENTAL|3|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions
62059738|NCT00846443|EXPERIMENTAL|4|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
62059739|NCT03585101|EXPERIMENTAL|All participants|Intervention: Elbasvir/grazoprevir
62059740|NCT00650195|EXPERIMENTAL|1|Metolazone Tablets 10 mg
62447750|NCT02901899|EXPERIMENTAL|Treatment (guadecitabine, pembrolizumab)|Patients receive guadecitabine SC on days 1-4 and pembrolizumab IV over 30 minutes on day 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62059741|NCT00650195|ACTIVE_COMPARATOR|2|Zaroloxyn® Tablets 10 mg
62059742|NCT04667975|EXPERIMENTAL|Part 1(Dose escalation)|"Part 1: 3 or 6 subjects are enrolled, per each dose group in a traditional 3+3 design.~Begin with the starting dose determined by the non-clinical study and increase the dose according to the dose levels. If DLT does not occur in the 3 subjects when they have completed the 1st cycle at each dose level, increase the dose to the next level. Dose escalation proceeds until the maximum tolerated dose (MTD) is reached.~Dose-limiting toxicity (DLT) is evaluated following the completion of dosing for the 1st cycle of all subjects enrolled in each dose group in order to determine whether to proceed to the next level. Following completion of the DLT evaluation of the planned dose level in this study, the SRC reviews the outcome of the evaluation and determines whether to set additional dosing or proceed to PART 2 (Dose expansion)."
62059743|NCT04667975|EXPERIMENTAL|Part 2(Dose expansion)|"Part 2: The primary objective of Part 2 is to evaluate the efficacy of CKD-702 by identifying the ORR after administering the RP2D of CKD-702 determined in Part 1. Along with this, to determine the CKD-702 effective patient group, the patient groups were classified into several cohorts based on non-clinical study results.~Therefore, in Part 2, the RP2D determined in Part 1 is administered until the occurrence of an adverse event causing PD occurrence, death or treatment discontinuation, and tumor response is evaluated based on RECIST version 1.1."
62059744|NCT01889173|EXPERIMENTAL|TNX-102 SL Tablets at 2.8 mg|1 x TNX-102 SL Tablets (with potassium phosphate) at 2.8 mg
62447751|NCT00719381|ACTIVE_COMPARATOR|1|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
62447752|NCT00719381|NO_INTERVENTION|2|Patients in this arm will receive no intervention
62059745|NCT01889173|EXPERIMENTAL|TNX-102-B SL Tablets at 2.8 mg|1 x TNX-102-B SL Tablets (with sodium phosphate) at 2.8 mg
62059746|NCT01889173|EXPERIMENTAL|TNX-102-C SL Tablets at 2.8 mg|1 x TNX-102-C SL Tablets (with trisodium citrate) at 2.8 mg
62059747|NCT01889173|ACTIVE_COMPARATOR|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine oral tablet
62059748|NCT03473223|EXPERIMENTAL|CSL112|Apolipoprotein A-I \[human\]
62059749|NCT03473223|PLACEBO_COMPARATOR|Placebo|25% albumin solution diluted to 4.4%
62263508|NCT02828553||Control Group - Usual Care|At the start of the study, subjects will be enrolled in usual care when admitted to the heart failure unit following standard protocols.
62447753|NCT02180308||PET/MRI|Patient receives PET/MRI
62447754|NCT01809613||Deep Brain Stimulation|Functional Magnetic Resonance Imaging (fMRI) will be performed to determine the areas of BOLD signal modulation with DBS.
62447755|NCT02139514|ACTIVE_COMPARATOR|Virtual Reality Social Cognition Training|Virtual Reality Social Cognition Training
62619822|NCT05589220|EXPERIMENTAL|Music intervention and NRT|The rhythm of the music sessions will be 2 per week in the first month, 1 per week in the second month and 1 every 15 days in the third month. In this group, music intervention will be associated to NRT.
62263509|NCT02828553||Intervention Group - Aggressive Ambulation|After a washout period and transition to a new aggressive ambulation protocol, subjects will be enrolled to usual care + aggressive planned ambulation with a trained mobility aide.
62447756|NCT02139514|NO_INTERVENTION|Control|Participants in the Control condition will be offered treatment following the Control condition.
62619823|NCT05589220|ACTIVE_COMPARATOR|NRT group|Nicotine Patch, Nicotine Gum As in the intervention group, the physician will adapt the type of NRT according to the patient's smoking profile.
62619824|NCT05438758|OTHER|Intranasal Esketamine with Addition of Almond TherapyTM|Intranasal Esketamine - Dose of 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks.
62619825|NCT05438758|OTHER|Intranasal Esketamine with Treatment as Usual|Intranasal Esketamine - Dose of 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks.
62619826|NCT04089501||Inflammatory Bowel Disease (IBD)|Subjects will be asked to provide a stool sample (if no colonoscopy is to be performed) or if clinically indicated, a colonoscopy will be performed per standard medical routine. During colonoscopy, stool will be collected for analysis and 3 additional biopsies will be taken each from the ileum and colon for research purposes. Alternatively, subjects who are undergoing intestinal and/or colonic resection will provide stool prior to surgery and a portion of their pathology specimens will be used for research purposes following complete pathologic evaluation.
62619827|NCT04089501||Subjects not affected by IBD (Control Group)|Results of subjects with IBD will be compared to subjects in the control group.
62619828|NCT00977691|EXPERIMENTAL|Cohort 1|PBSC transplant with no post-transplant cyclophosphamide (PT-Cy)
62619829|NCT00977691|EXPERIMENTAL|Cohort 2|PBSC transplant with 50 mg/kg post-transplant cyclophosphamide (PT-Cy)
62619830|NCT00977691|EXPERIMENTAL|Cohort 3|PBSC transplant with 100 mg/kg post-transplant cyclophosphamide (PT-Cy)
62619831|NCT02187861|EXPERIMENTAL|Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)|Participants will receive venetoclax no more than 600 milligrams (mg) orally once daily continuously along with rituximab 375 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Day 1 of 28-day cycle and bendamustine 90 mg/m\^2 IV infusion on Days 1 and 2 of the 28-day cycle. Safety run-in will continue until first 9 participants complete the safety observation window of 28 days. Participants will continue receiving the same treatment as decided for Arm B.
62619832|NCT02187861|EXPERIMENTAL|Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)|Participants will receive venetoclax 800 mg orally once daily for 1 year along with rituximab 375 mg/m\^2 IV infusion on Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, 10, and 12. Each cycle will be of 28 days.
62263510|NCT02912572|EXPERIMENTAL|Pole Mutated Endometrial Cancer|Participants with Pole mutated endometrial cancer Avelumab will be administered intravenously twice per cycle
62263511|NCT02912572|EXPERIMENTAL|MSS Endometrial Cancer|Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle
62447757|NCT02922218||Enzalutamide|Enzalutamide 160 mg/day c/24h
62623770|NCT04787614||Center-based providers|Providers who cared to children ages 0 through 5 years of age (not yet in kindergarten) in a non-residential setting as of 2019
62619833|NCT02187861|EXPERIMENTAL|Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)|Participants will receive venetoclax at doses decided from safety run-in orally once daily continuously for 1 year along with rituximab 375 mg/m\^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m\^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
62619834|NCT02187861|ACTIVE_COMPARATOR|Chemotherapy-Containing Cohort: Arm C (BR)|Participants will receive rituximab 375 mg/m\^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m\^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
62619835|NCT04748393||Study cohort|Consecutive female patients between the ages of 18 and 50 with child bearing potential and objectivated, symptomatic VTE, who fulfil all the inclusion criteria and meet none of the exclusion criteria, are eligible for inclusion.
62846052|NCT01014351|EXPERIMENTAL|Paclitaxel/Carboplatin/Everolimus|Systemic Therapy using everolimus, paclitaxel and carboplatin given during a 21-day treatment cycle
62846053|NCT05603234|EXPERIMENTAL|Symptom Monitoring Intervention|This group reported their symptoms every day for 14 days.
62846054|NCT05603234|NO_INTERVENTION|Control|This group did not monitor their symptoms every day for the 14 day period, however they did report their symptoms at the beginning and end of the 14 day period
62846055|NCT04986761|EXPERIMENTAL|Workflows|Digital and conventional workflows for treatment of implant single crowns
62846056|NCT04986761|EXPERIMENTAL|Materials|Materials for treatment of implant single crowns (polymer-infiltrated ceramic networks, PICNs and lithium disilicate, LS2).
62846057|NCT05435443|EXPERIMENTAL|the PowerBreathe and PEP Therosold tools group|
62846058|NCT05435443|ACTIVE_COMPARATOR|perform diaphragmatic breathing, series of abdominal crunches and expiratory exercises group.|
62846059|NCT01215097|EXPERIMENTAL|Linagliptin|once a day
62846060|NCT01215097|PLACEBO_COMPARATOR|placebo|once a day
62263512|NCT02912572|EXPERIMENTAL|MSS Avelumab/Talazoparib Combination Arm|Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle Talazoparib will be administered one time per day by mouth
62263513|NCT02912572|EXPERIMENTAL|MSS Avelumab/Axitinib Combination Arm|Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle Axitinib will be administered twice per day by mouth
62263514|NCT02194751|EXPERIMENTAL|Oncoquest-L vaccine|Patients will receive a total of 5 single injections of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration.
62619836|NCT00632632|EXPERIMENTAL|D-Cycloserine (DCS)|
62619837|NCT00632632|PLACEBO_COMPARATOR|Placebo|
62619838|NCT01872806|EXPERIMENTAL|Experimental: Mobile phone radiation|Dialing mobile phone placed against the ear/chest for a duration of 15 minutes, before and after 15 minutes sham phone will be placed against the ear/chest.
62846061|NCT01521312|EXPERIMENTAL|Saxagliptin|Saxagliptin 5 mg (tablet) at BREAKFEAST
62059750|NCT01581723|ACTIVE_COMPARATOR|Monopolar TUR|Monopolar diathermy is used to perform tranurethral resection of bladder tumor
62059751|NCT01581723|EXPERIMENTAL|Biploar TUR|Bipolar diathermy is used to perform transurethral resection of bladder tumor
62623771|NCT04787614||Center-based workforce|Individuals employed in center-based child care programs working directly with children in classrooms as of 2019
62623772|NCT04508647|EXPERIMENTAL|Ublituximab Only|Treatment-Naive Stage II (non-contiguous), Stage III, Stage IV FL + MZL will receive Ublituximab 900mg IV weekly x 4 doses. End of treatment assessment 8 weeks post last dose of single agent ublituximab will be performed.
62846062|NCT01521312|PLACEBO_COMPARATOR|placebo pill|at BREAKFEAST
62846063|NCT03455231|EXPERIMENTAL|Short course radiotherapy|The radiotherapy is delivered over two days with accelerated hypo-fractionation
62846064|NCT05522491|EXPERIMENTAL|Olapalib|Olaparib Oral 300mg 2/day; 4 weeks (28 days) as a treatment cycle.
62846065|NCT01749189|PLACEBO_COMPARATOR|Placebo|Placebo dry blended beverage (carbohydrate)
62846066|NCT01749189|EXPERIMENTAL|Blend|A dry blended beverage containing a protein blend of soy, whey and casein
62846067|NCT01749189|ACTIVE_COMPARATOR|Whey|A dry blended beverage containing Whey protein
62846068|NCT03680326||OCT|only optical coherence tomography and visual acuity testing at each visit, patients were recruited retrospectively, only data analysis
62846069|NCT05724511|EXPERIMENTAL|Intervention|
62846070|NCT05724511|NO_INTERVENTION|Control|
62263515|NCT04971291|EXPERIMENTAL|AXS-05|45 mg dextromethorphan-105 mg bupropion
62447758|NCT05158777|EXPERIMENTAL|Experimental Group with the immunization course of 0,28 days or 0,56 days|1240 subjects (including 620 children aged 13-17 years and 620 adults aged 18 years and older) will receive two doses of experimental vaccine with the immunization course of 0,28 days or 0,56 days.
62263516|NCT04971291|ACTIVE_COMPARATOR|Bupropion SR|150 mg bupropion
62447759|NCT05158777|ACTIVE_COMPARATOR|Control Group|1240 subjects (including 620 children aged 13-17 years and 620 adults aged 18 years and older) will receive two doses of control vaccine with the immunization course of 0,28 days or 0,56 days.
62447760|NCT01797120|ACTIVE_COMPARATOR|Fulvestrant & Everolimus|Fulvestrant Day 1 \& 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus everolimus daily x 12 cycles.
62619839|NCT06386159|NO_INTERVENTION|Control Group|During routine medical care and nursing, the responsible nurse provides daily oral care and delivers health education to patients and their caregivers regarding diet and swallowing safety. Within 8 hours after the removal of the endotracheal tube, the Standardized Swallowing Assessment (SSA) is used to screen for swallowing function. Patients are guided in food selection based on the severity of their swallowing difficulties and personal preferences, and are supplemented with enteral or parenteral nutrition or prescribed specific diets as directed by their doctor.
62619840|NCT06386159|ACTIVE_COMPARATOR|Comprehensive Intervention Group|On the basis of the control group, a comprehensive intervention plan determined through Delphi expert consultation is implemented for PED patients. This plan includes multidisciplinary collaboration, screening and assessment, oral sensory training, oral motor training, respiratory training, and feeding management. The duration and frequency of the exercises are tailored to the patient's actual condition.
62619841|NCT06386159|EXPERIMENTAL|Comprehensive Intervention Combined with Vagus Nerve Stimulation Group|On the basis of the control group, a comprehensive intervention is implemented in combination with vagus nerve electrical stimulation.
62619842|NCT06040671|EXPERIMENTAL|Lateral canthal hinge surgery patients|Patients undergoing lateral canthal hinge surgery will be enrolled in this group.
62846071|NCT05126251|EXPERIMENTAL|Tangningtongluo group|"1. Tangningtongluo tablet will be used in this arm. Patients should take medicine with warm water about 30min after meal. (1.6g/time, twice a day) According to the above usage and dosage, take 12 weeks continuously. After 12 weeks, the researcher decided whether the subjects entered the extended trial according to the wishes of the subjects, and continued to use the drug until 24 weeks.~2. Lifestyle intervention"
62846072|NCT05126251|PLACEBO_COMPARATOR|Placebo group|"Placebo of Tangningtongluo tablet will be used in this arm. Patients should take medicine with warm water about 30min after meal. (2.0g/time, twice a day) According to the above usage and dosage, take 12 weeks continuously. After 12 weeks, the researcher decided whether the subjects entered the extended trial according to the wishes of the subjects, and continued to use the drug until 24 weeks.~2） Lifestyle intervention"
62263517|NCT06003114||First-line patients on Palbociclib|Participants taking oral palbociclib as prescribed in first-line treatment
62447761|NCT01797120|PLACEBO_COMPARATOR|Fulvestrant & Placebo|Fulvestrant Day 1 \& 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus placebo daily x 12 cycles.
62447762|NCT02473978||Participants undergoing cesarean sections|The participants preoperative data will be compared to intraoperative data and analyzed in order to evaluate the dynamic cerebral oxygen and blood perfusion changes in participants undergoing cesarean sections.
62447763|NCT02473978||Participants throughout cesarean sections|The participants intraoperative data will be compared to preoperative data and analyzed in order to evaluate the dynamic cerebral oxygen and blood perfusion changes in participants undergoing cesarean sections.
62447764|NCT05177757|EXPERIMENTAL|Yoga Intervention|The yoga exercise program will be conducted at the Marquette campus and will consist of one session per week for 12 weeks. The duration of each session will be approximately one hour. The program the investigators will use is the Mindful Resilience for Trauma Recovery Program (https://www.veteransyogaproject.org/), an evidence-informed practice adapted for veterans with PTSD based on clinical and neuroscientific knowledge. This program is a 12-week protocol developed by a licensed clinical psychologist and is publicly available. All yoga sessions will be standardized based on the resilience program guidelines.
62059752|NCT01664520|EXPERIMENTAL|Dexmedetomine infusion|
62263518|NCT01611974|EXPERIMENTAL|Maribavir 400 mg twice daily|
62263519|NCT01611974|EXPERIMENTAL|Maribavir 800 mg twice daily|
62263520|NCT01611974|EXPERIMENTAL|Maribavir 1200 mg twice daily|
62447765|NCT03243539|EXPERIMENTAL|Lung Protective Ventilation|Subjects with acute brain injury (traumatic brain injury and non-traumatic brain injury) will receive neuro lung protective ventilation which targets a normal arterial partial pressure of carbon dioxide with the lowest tidal volume possible (6 to 8 ml/kg predicted body weight). Protocols for oxygenation and weaning from the ventilator will also be followed.
62447766|NCT04043845|EXPERIMENTAL|LY3214996+Ibrutinib|"* LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle~* Ibrutinib will be administered by mouth once daily continuously throughout each treatment cycle."
62846073|NCT05796206|EXPERIMENTAL|MIL62(Part A and B)|
62846074|NCT05796206|PLACEBO_COMPARATOR|Placebo (Part A and B)|
62846075|NCT01302249|EXPERIMENTAL|AR-12286|AR-12286 Ophthalmic Solution 0.5%
62846076|NCT01302249|ACTIVE_COMPARATOR|Timolol|Timolol maleate ophthalmic solution 0.5%
62263521|NCT01483391|ACTIVE_COMPARATOR|Enhanced Care|Three sessions of family education and three sessions of individual support over 4 months.
62263522|NCT01483391|EXPERIMENTAL|Family-Focused Treatment|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training.
62447767|NCT05721144|EXPERIMENTAL|Experimental: Treatment Group|Inspired NO/N2 will be delivered at 80 parts per million (ppm) after anesthesia induction and intubation and lasted until the end of surgery and leave the operating room. The physician will follow their own institutional weaning protocols.
62846077|NCT02978599|EXPERIMENTAL|AVL-3288 10 mg|AVL-3288 10 mg daily for 5 days
62846078|NCT02978599|EXPERIMENTAL|AVL-3288 30 mg|AVL-3288 30 mg daily for 5 days
62846079|NCT02978599|PLACEBO_COMPARATOR|Placebo|Placebo daily for 5 days
62447768|NCT05721144|NO_INTERVENTION|Sham Comparator: Control Group|The delivery system will be set up anyway without studying gas administration
62447769|NCT05659550|EXPERIMENTAL|Fan-to-face|The participants will complete a 4-minute constant work rate treadmill test with a basic, portable fan placed in front of the face. The fan will be placed at a location to target the second and third branches of the trigeminal nerve and will be placed a distance chosen by the participant so that the airflow speed is comfortable.
62619843|NCT06040671|EXPERIMENTAL|Ptosis surgery patients|Patients undergoing ptosis surgery will be enrolled in this group.
62846080|NCT05063656|EXPERIMENTAL|Gabapentin Open-label treatment|8-week treatment with gabapentin
62846081|NCT02644109|EXPERIMENTAL|Phytosterols|"1. Milk powder: subjects will be instructed to consume 22 g/day of the product, with 0.65 g of esterified phytosterols (0.39 g of free equivalent sterols). The product will be reconstituted with 200 ml of water at time of consumption, preferably at breakfast or tea time. The total amount of product will be provided at the beginning of the study (day 1), together with instructions, material for preparation, and storage.~2. Drinking yoghurt: the daily volume consumed will be 90 ml/day with 1.3 grs of esterified phytosterols (0.78 g of free equivalent phytosterols). Subjects will be instructed to consume this beverage with main meal (not later than 15 min after it. The product should be kept refrigerated. Products will be distributed to subjects on a weekly basis."
62846082|NCT02644109|PLACEBO_COMPARATOR|Placebo|"1. Milk powder: subjects will be instructed to consume 22 g/day of the product, without phytosterols. The product will be reconstituted with 200 ml of water at time of consumption, preferably at breakfast or tea time. The total amount of product will be provided at the beginning of the study (day 1), together with instructions, material for preparation, and storage.~2. Drinking yoghurt: the daily volume consumed will be 90 ml/day without phytosterols. Subjects will be instructed to consume this beverage with main meal (not later than 15 min after it. The product should be kept refrigerated. Products will be distributed to subjects on a weekly basis."
62846083|NCT04727372||Islamabad Group|Individuals residing and surveyed in Islamabad
62846084|NCT04727372||Lahore Group|Individuals residing and surveyed in Lahore
62846085|NCT04727372||Faisalabad Group|Individuals residing and surveyed in Faisalabad
62846086|NCT04727372||Bahawalpur Group|Individuals residing and surveyed in Bahawalpur
62846087|NCT00778661|EXPERIMENTAL|1|amoxicillin 400mg + clovalunic acid 57.5mg tablets of Ranbaxy
62619844|NCT00575471|EXPERIMENTAL|1|rivoglitazone HCl 0.5 mg tablets once daily for 12 weeks
62619845|NCT00575471|EXPERIMENTAL|2|rivoglitazone HCl 1 mg tablets once daily for 12 weeks
62619846|NCT00575471|EXPERIMENTAL|3|rivoglitazone HCl 1.5 mg tablets once daily for 12 weeks
62619847|NCT00575471|PLACEBO_COMPARATOR|4|Matching placebo tablets once daily for 12 weeks
62619848|NCT03876847||Spontaneous Coronary Artery Disection|The spontaneous coronary artery disection (SCAD) diagnosis will be based on independent review of clinical presentation, cardiac imaging, and angiography findings by three cardiologists. The determination will be evidence of linear luminal defect (intimal flap) detection, luminal narrowing or occlusion confirmed to be a dissection on further imaging, or by clinical judgment classifying it as definite SCAD.
62846088|NCT00778661|ACTIVE_COMPARATOR|2|Augmentin® tablets of glaxosmithkline
62846089|NCT00275548|OTHER|The Preventative (Prophylaxis) Group:|This group of patients will receive study drugs for the treatment of recurring (or returning) hepatitis C before they actually develop clinical symptoms of hepatitis C.
62619849|NCT03876847||Control|A set of controls will be used for genetic analysis. These controls will pulled from subjects in the INSPIRE registry that had coronary angiography at Intermountain Medical Center for stable angina and meet inclusion/exclusion criteria.
62619850|NCT03057717|OTHER|Ultrasound|All participants in the study will have fetal thymus size measured using ultrasound.
62619851|NCT01687855||OSAHS group|Subjects that underwent night Ultrafast Magnetic Resonance Imaging with obtaining a series of midline sagittal images of the upper airway .
62619852|NCT01687855||normal group|Subjects that underwent night Ultrafast Magnetic Resonance Imaging with obtaining a series of midline sagittal images of the upper airway .
62263523|NCT04911803|EXPERIMENTAL|Anxiety Group|Participants will download the anxiety application to their own handphones, and will complete the programme subsequently in their own time over the course of 2 weeks. The expected duration participants will spend on the anxiety application daily is estimated to be around 5 to 10 minutes, amounting to a total of around 140 minutes (2 hours and 10 minutes) during the 2 weeks intervention. Participants in the anxiety group are asked to complete daily brief exercises. For example, they will practice noticing worry thoughts and journal them down.
62447770|NCT05659550|SHAM_COMPARATOR|Fan-to-leg|The participants will complete a 4-minute constant work rate treadmill test with a basic, portable fan placed in front of the face. The fan will be placed at a location to target the second and third branches of the trigeminal nerve and will be placed a distance chosen by the participant so that the airflow speed is comfortable.
62447771|NCT05659550|NO_INTERVENTION|No fan|The participants will complete a 4-minute constant work rate treadmill test with no fan.
62447772|NCT05699356||Surgical treatment of Poly cystic ovary for infertility by laparoscopic drilling|laparoscopic drilling response in Poly Cystic Ovary case
62619853|NCT01047111|ACTIVE_COMPARATOR|Ivor-Lewis Procedure|Arm A: Esophagectomy was conducted through right side thoracotomy plus midline laparotomy approach:Ivor-Lewis Procedure.
62263524|NCT04911803|ACTIVE_COMPARATOR|Procrastination Group|Participants will download the procrastination application to their own handphones, and will complete the programme subsequently in their own time over the course of 2 weeks. The expected duration participants will spend on the procrastination application daily is estimated to be around 5 to 10 minutes, amounting to a total of around 140 minutes (2 hours and 10 minutes) during the 2 weeks intervention. Participants in the procrastination group are asked to complete daily brief exercises. For example, they will practice to reduce procrastination-related thoughts.
62263525|NCT04643912|EXPERIMENTAL|Injured wrist or ankle|"Child with trauma needing wrist or ankle x-ray:~Will receive vibration analysis blinded to x-ray findings."
62263526|NCT00798850|ACTIVE_COMPARATOR|PTA|
62619854|NCT01047111|ACTIVE_COMPARATOR|Sweet Procedure|Arm B: Esophagectomy was conducted through left side thoracotomy or thoracoabdominal incision: Sweet Procedure
62619855|NCT03153683||Cerebrovascular procedure patients|This is a registry. No above standard of care interventions will take place. Participants must be undergoing a clinically routine cerebrovascular procedure.
62263527|NCT00798850|ACTIVE_COMPARATOR|SEP|
62263528|NCT00798850|ACTIVE_COMPARATOR|PTA+SEP|
62263529|NCT04133467||Group SB|Scalp block performed with Levobupivacaine 0.125% (total dose 2 mg/kg) in combination with intraoperative intravenous acetaminophen (15 mg/kg if body weight \>10Kg, 7 mg/kg if body weight \< 10 kg).
62447773|NCT05699356||Non-surgical treatment of Poly cystic ovary for infertility|induction,Anti estrogen,Insulin sensitizing agent, Aromatase Inhibitor,Gonadotropin
62447774|NCT05699356||Treatment of Poly cystic ovary for infertility by Life style modification|Life style modification response in Poly Cystic Ovary case for treatment of infertility
62447775|NCT05699356||Treatment of Poly cystic ovary for infertility by Assisted reproductive technique|Assisted reproductive technique response in Poly Cystic Ovary case for treatment of infertility
62447776|NCT05699356||Treatment of Poly cystic ovary for infertility by controlling menstrual disorders|Controlling menstrual disorders response in Poly Cystic Ovary case for treatment of infertility
62263530|NCT04133467||Group ST|intravenous acetaminophen according to the body weight, plus intravenous tramadol 1 mg/kg
62263531|NCT00426257|EXPERIMENTAL|1|Secondary debulking surgery with hyperthermic intraperitoneal chemotherapy
62447777|NCT05699356||Treatment of Poly cystic ovary for infertility by Cutaneous manifestation|Cutaneous manifestation response in Poly Cystic Ovary case for treatment of infertility
62447778|NCT03301675|EXPERIMENTAL|Orange juice|Orange Juice: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) plus 100% orange juice (500 mL/d) during 12 weeks.
62447779|NCT03301675|NO_INTERVENTION|Control|Control: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) during 12 weeks.
62447780|NCT00194103|NO_INTERVENTION|TAU|
62447781|NCT00194103|ACTIVE_COMPARATOR|Telephone Monitoring|
62447782|NCT00194103|EXPERIMENTAL|Telephone Monitoring and Counseling|
62619856|NCT00671099|EXPERIMENTAL|1|Dietary Supplement: Omega-3 Polyunsaturated Fatty Acid
62619857|NCT00671099|PLACEBO_COMPARATOR|2|Placebo
62846090|NCT00275548|OTHER|The Observational Group:|This group of patients will receive the study drugs for the treatment of recurring hepatitis C only if they develop the clinical symptoms of hepatitis C infection.
62846091|NCT02592057||SOF-based regimens|Adults with chronic HCV infection in India who are being treated with a SOF-based treatment regimen as per the approved prescribing information.
62059753|NCT06300138|EXPERIMENTAL|Drug combined with infrared hyperthermia group|oral itraconazole (children less than 15 years old 6 mg/kg/d; adult patients: 200 mg/d) for a total course of 3-6 months, while infrared hyperthermia device for 3 consecutive days (times / day), each treatment for 30 minutes After two weeks (14 days), the lesions of the same target were treated continuously for 2 days (times per day), and then once a week for 2 consecutive times, the method was the same as before. After 7 times of treatment, the study physician decided whether to continue treatment n times after 1-2 weeks (n ≥ 0) according to the recovery of the subjects.
62059754|NCT06300138|EXPERIMENTAL|Drug group|Itraconazole (6 mg/kg/d; for children less than 15 years old, 200 mg/d for adults) was taken orally for 3-6 months. The specific course of treatment was determined by the research physician according to the recovery of the subjects.
62059755|NCT06300138|EXPERIMENTAL|Infrared hyperthermia group|Infrared hyperthermia device for 3 consecutive days (times / day), each treatment for 30 minutes After two weeks (14 days), the lesions of the same target were treated continuously for 2 days (times per day), and then once a week for 2 consecutive times, the method was the same as before. After 7 times of treatment, the study physician decided whether to continue treatment n times after 1-2 weeks (n ≥ 0) according to the recovery of the subjects.
62059756|NCT03226964|EXPERIMENTAL|High flow nasal oxygen|(Optiflow; Fisher \& Paykel, Auckland, New Zealand)
62059757|NCT03226964|ACTIVE_COMPARATOR|Nasal prongs|
62619858|NCT00647036|ACTIVE_COMPARATOR|1|Dipeptiven (L-glutamine- Lalanine)
62059758|NCT06075797|EXPERIMENTAL|PQ-ResPOND (Intervention)|"Participants in the intervention arm will (i) answer weekly PQ-ResPOND Surveys over 12 weeks, (ii) receive feedback reports (generated by the PediQUEST system to summarize parents answers), and (iii) engage with the pediatric palliative care (PPC) team.~The interprofessional PPC team will focus on child's recurrent pain and related symptoms using a standardized approach and work on family activation strategies."
62263532|NCT00426257|ACTIVE_COMPARATOR|2|Secondary debulking surgery
62263533|NCT01956903|EXPERIMENTAL|Allogenic Mesenchymal Stem Cell|Sequential Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell (MSC). Dosage 0,7 x 10e6 MSC/Kg/dose (cumulative minimum dose: 2,8 x 10e6 CSM/Kg.
62263534|NCT05007951|EXPERIMENTAL|Test group (GBP510) - Cohort 1|Immunogenicity Cohort
62619859|NCT00647036|PLACEBO_COMPARATOR|2|Isonitrogenous Vaminolact
62619860|NCT03488602|EXPERIMENTAL|F-SPS Intervention|This group will receive the F-SPS intervention.
62619861|NCT03488602|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|This group will receive Enhanced Usual Care (EUC)
62619862|NCT00600158|EXPERIMENTAL|2|lidocaine intravenously
62619863|NCT00600158|ACTIVE_COMPARATOR|1|epidural local anesthetic
62619864|NCT03604705|EXPERIMENTAL|APX001 Treatment|
62846092|NCT02369744|ACTIVE_COMPARATOR|Silodosin|Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks.
62846093|NCT02369744|ACTIVE_COMPARATOR|Tamsulosin|Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks.
62846094|NCT01171560|ACTIVE_COMPARATOR|EZ Blocker|Patients assigned to the EZ group will be intubated using a conventional tube in an adequate size as it is standard of care and single lung ventilation will be provided using the EZ-Blocker.
62846095|NCT01171560|ACTIVE_COMPARATOR|Double lumen tube|"The patients assigned to the double lume tube group will be intubated using the double lume tube in an adequate size as it is standard of care."
62263535|NCT05007951|ACTIVE_COMPARATOR|Control group (ChAdOx1-S) - Cohort 1|Immunogenicity Cohort
62263536|NCT05007951|EXPERIMENTAL|Test group (GBP510) - Cohort 2|Safety Cohort
62263537|NCT05007951|ACTIVE_COMPARATOR|Control group (ChAdOx1-S) - Cohort 2|Safety Cohort
62263538|NCT05007951|EXPERIMENTAL|Test group (GBP510) - Cohort 3|Booster Subcohort
62619865|NCT04124328|ACTIVE_COMPARATOR|ALINE only group|Patients in this arm are scheduled for an extended AF ablation, including the mitral isthmus line, according to the ALINE criteria
62619866|NCT04124328|ACTIVE_COMPARATOR|VoM group|Patients in this arm are scheduled for an extended AF ablation, including the mitral isthmus line, according to the ALINE criteria and vein of Marshall (VoM) ethanol infusion
62619867|NCT03051438|OTHER|Subxiphoid uniportal VATS|retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
62846096|NCT02796261|EXPERIMENTAL|Eflornithine + Lomustine|Eflornithine dosed on a 2 weeks on, 1 week off schedule + Lomustine dosed every 6 weeks
62846097|NCT02796261|ACTIVE_COMPARATOR|Lomustine|Lomustine dosed every 6 weeks
62846098|NCT00202878|EXPERIMENTAL|ezetimibe/simvastatin|One Ezetimibe 10 mg/simvastatin 40 mg combination tablet and two simvastatin 40 mg placebo tablets once per day.
62846099|NCT00202878|ACTIVE_COMPARATOR|simvastatin|One simvastatin 40 mg tablet, one ezetimibe/simvastatin combination 10/40 placebo tablet and one simvastatin 40 mg placebo tablet once per day.
62846100|NCT02049606|EXPERIMENTAL|LAYLA|Drug : LAYLA tablet/bid
62846101|NCT02049606|ACTIVE_COMPARATOR|CENATONE|Drug : CENATONE tablet/qd
62846102|NCT03202602||Telemedicine|Patients randomized to receive telemonitoring in combination with telephone calls after CPAP start.
62059759|NCT06075797|NO_INTERVENTION|Usual care (Control)|"Participants randomized to the control arm will be assigned weekly PQ-ResPOND Surveys up to week 12. Participants in this arm will not have access to the full PediQUEST system, i.e. no reports will be generated. They will not meet the PPC team but can receive regular palliative care consultations following the site's usual referral procedures.~Children in the usual care arm will receive standard care, which at Boston Children's Hospital usually involves several primary clinicians (primarily neurologists or Complex Care Service attending physicians) and access to psychosocial clinician care throughout the illness course. PPC referrals are typically made at the discretion of the primary clinician, often for decision making reasons and/or closer to end-of-life. If a child presents persistent distress, they will be cared through the usual mechanisms. The rationale for collecting weekly surveys is to minimize reporting bias and may increase adherence and retention."
62059760|NCT04665011||Clinically stable adults, including heart failure patients visiting an outpatient clinic|Observational to compare simultaneous pulse tracings from PPG and non-invasive blood pressure monitors in capturing the pulse responses to a Valsalva maneuver.
62059761|NCT03489096|EXPERIMENTAL|Cryoballoon Ablation|Cryoballoon Ablation: PVI + substrate modification. Left atrial fibrosis ablation in addition to standard pulmonary vein isolation in patients with paroxysmal and persistent atrial fibrillation. Ablation will be performed utilizing the Medtronic Arctic Front Advance Cryoballoon catheter.
62059762|NCT03389139|ACTIVE_COMPARATOR|spinal anesthesia|Patients in this group were randomized to receive spinal anesthesia. (Near infrared spectroscopy (spinal anesthesia))
62059763|NCT03389139|ACTIVE_COMPARATOR|general anesthesia|Patients in this group were randomized to receive general anesthesia. (Near infrared spectroscopy (general anesthesia)).
62619868|NCT03051438|OTHER|Three-port VATS|retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
62619869|NCT00718016||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
62059764|NCT05426564||ECMO Patients|Patients undergoing an ECMO procedure
62059765|NCT05628805|EXPERIMENTAL|iTBS|Each participant will have two separate study days in the TMS lab. On one day, the participant will receive active pre-SMA iTBS. On the other day, the patricipant will receive sham pre-SMA iTBS. The order that active versus sham is given will be randomized and the participant will be blinded. After each iTBS session, blinding assessment will be performed. To avoid contamination of results, a minimum of 5 days between study days will be required.
62059766|NCT05628805|SHAM_COMPARATOR|Sham iTBS|Each participant will have two separate study days in the TMS lab. On one day, the participant will receive active pre-SMA iTBS. On the other day, the patricipant will receive sham pre-SMA iTBS. The order that active versus sham is given will be randomized and the participant will be blinded. After each iTBS session, blinding assessment will be performed. To avoid contamination of results, a minimum of 5 days between study days will be required.
62059767|NCT01722162|EXPERIMENTAL|Arm A: (start levocetirizine after bevacizumab/capecitabine)|"Bevacizumab IV 5 mg/kg on Days 1 each 2-week cycle.~Capecitabine PO 850 mg/m2 twice a day on Days 1-7 of each 2 week cycle.~Levocetirizine PO 5 mg daily before bed starting on Day 8 of Cycle 1. 5 mg daily before bed Days 1-4 of each cycle starting with cycle 2."
62059768|NCT01722162|EXPERIMENTAL|Arm B: (start levocetirizine before bevacizumab/capecitabine)|"Bevacizumab IV 5 mg/kg on Days 1 each 2-week cycle.~Capecitabine PO 850 mg/m2 twice a day on Days 1-7 of each 2 week cycle.~Levocetirizine PO 5 mg daily starting 7 days prior to initiation of bevacizumab and capecitabine therapy. 5 mg daily Days 1-14 starting with cycle 2."
62059769|NCT05588609|EXPERIMENTAL|Part 1: NSCLC harboring NRG1+ fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab once every 2 weeks in combination with afatinib 40 mg orally once daily.
62059770|NCT05588609|EXPERIMENTAL|Part 1: mCRPC|"Participants will receive intravenous infusion of 750 mg of zenocutuzumab once every 2 weeks in combination with the AR targeting agent they experienced disease progression on prior to study entry:~enzalutamide 160 mg orally once daily or abiraterone 1000 mg orally once daily with prednisone 5 mg orally twice daily."
62619870|NCT06075043|EXPERIMENTAL|AND017 Dose A three times weekly|
62059771|NCT05588609|EXPERIMENTAL|Part 2: NSCLC harboring NRG1+ fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab once every 2 weeks in combination with afatinib 40 mg orally once daily.
62263539|NCT05007951|ACTIVE_COMPARATOR|Control group (ChAdOx1-S) - Cohort 3|Booster Subcohort
62846103|NCT03202602||Standard care|Patients randomized to receive usual office visits after CPAP start.
62846104|NCT02874703||HIV-positive|
62263540|NCT03698435||Prophylaxis|Patients who receive (val)ganciclovir for prophylaxis of cytomegalovirus
62619871|NCT06075043|EXPERIMENTAL|AND017 Dose B three times weekly|
62619872|NCT06075043|EXPERIMENTAL|AND017 Dose C three times weekly|
62846105|NCT02874703||HIV-negative|
62846106|NCT05770323||Patients with normal uric acid levels|Patient with uric acid level (2.5_6)for femal and (3_7)for males
62846107|NCT05770323||Patients with elevated uric acid level (hyperurecemia)|Uric acid level more than 7 for males and more than 6 for female
62846108|NCT01833156|EXPERIMENTAL|patient with local edema by histamin|Measuring at 3 locations (on the histmin spot, at 5 cm and 10 cm border (is the control) at 7 times: T0 - T10 minutes - T20 - T30 - T45 - T60 - T75
62263541|NCT03698435||Treatment|Patients who receive (val)ganciclovir for treatment of cytomegalovirus
62263542|NCT00530114|PLACEBO_COMPARATOR|Placebo|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
62263543|NCT00530114|EXPERIMENTAL|AMG 223|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
62263544|NCT02543463|OTHER|With Navigation system|Large diameter head with Trident X3 insert with Navigation system
62263545|NCT02543463|OTHER|Without Navigation system|Large diameter head with Trident X3 insert with conventional instrumentation
62263546|NCT02954367|EXPERIMENTAL|PROTEIN (MEAT + WHEY)|Post workout (training days) or breakfast (non training days) 20g of meat protein (10g meat + 10g whey) mixed with 200ml of orange juice and water
62263547|NCT02954367|PLACEBO_COMPARATOR|CARBOHYDRATE (CHO)|Post workout (training days) or breakfast (non training days) 20g of maltodextrin mixed with 200ml orange juice and water
62619873|NCT05068479|EXPERIMENTAL|Natural Emmetropic Presbyopes|Patients that did not undergo any vision correcting surgery or implantation of an intraocular lens but suffering from presbyopia will receive bilateral Laser Scleral Microporation procedure.
62619874|NCT05068479|EXPERIMENTAL|Post Laser Vision Correction (LVC) Emmetropic Presbyopes|Patients that underwent laser vision correction procedure (e.g. LASIK) in the past and suffering from presbyopia will receive bilateral Laser Scleral Microporation procedure.
62619875|NCT06034132|EXPERIMENTAL|Test group|
62619876|NCT06034132|ACTIVE_COMPARATOR|Control group|
62619877|NCT01459835|EXPERIMENTAL|media diet|advice tips and tools to reduce exposure to violent programming
62447783|NCT05215899|EXPERIMENTAL|MINDFULNESS-BASED YOGA AND MEDITATION INTERVENTION|MINDFULNESS-BASED YOGA AND MEDITATION INTERVENTION
62619878|NCT01459835|ACTIVE_COMPARATOR|Nutrition intervention|diet advice
62619879|NCT01957839|NO_INTERVENTION|pretreatment group|doppler evaluation at pretreatment period
62619880|NCT01957839|EXPERIMENTAL|posttreatment group|doppler evaluatıon in normoprolactinemia women who given cabergoline treatment
62619881|NCT00076999|EXPERIMENTAL|TPV/r 290/115 mg/m^2|TPV and RTV oral solution low dose
62619882|NCT00076999|EXPERIMENTAL|TPV/r 375/150 mg/m^2|TPV and RTV oral solution high dose
62263548|NCT00535132|EXPERIMENTAL|002|Oral Risperidone 4 or 6 mg MG once daily for 0-2 weeks
62263549|NCT00535132|EXPERIMENTAL|001|Paliperidone ER 6, 9 or 12 MG once daily for 4-6 weeks
62619883|NCT05683925|NO_INTERVENTION|baseline|Participants will receive no stimulation, the electrode will be placed in the ear in a random position and turned off. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.
62619884|NCT05683925|ACTIVE_COMPARATOR|taVNS100|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 100Hz. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.
62619885|NCT05683925|ACTIVE_COMPARATOR|taVNS25|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 25Hz. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.
62619886|NCT05683925|SHAM_COMPARATOR|sVNS|Noninvasive electrostimulation will be applied to the left earlobe through the Nemos® electrode at 25Hz. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.
62619887|NCT05742113|EXPERIMENTAL|Triage status red|the relationship between the perfusion index and the emergency triage classification in patients admitted to the emergency department with dyspnea.
62619888|NCT00678964|EXPERIMENTAL|A|
62619889|NCT00678964|ACTIVE_COMPARATOR|B|
62619890|NCT02425423|EXPERIMENTAL|New thickened infant formula|
62619891|NCT05294809|EXPERIMENTAL|PsyPills|"The participants randomized in this condition will receive the mobile health application PsyPills."
62619892|NCT05294809|EXPERIMENTAL|OCAT|"The participants randomized in this condition will receive the mobile health application OCAT."
62619893|NCT05294809|PLACEBO_COMPARATOR|OCAT sham|"The active control group, which consists of the fake version of the OCAT intervention, by offering the same attentional training, without training and feedback on performance."
62619894|NCT04918472|EXPERIMENTAL|MCCE|Magnetically controlled capsule endoscopy will be performed before UGI endoscopy.
62619895|NCT06028386|ACTIVE_COMPARATOR|Arm 1-AC5® Advanced Wound System|The intervention in this arm is the application of a synthetic self assembling peptide matrix (AC5) to UT Grade 1A diabetic foot ulcers
62263550|NCT03951675||Individuals Living with DMD|90 patients/parents
62263551|NCT03951675||Healthcare Providers to Patients with DMD|40 healthcare providers
62263552|NCT01157364|OTHER|bimatoprost 20 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 20 µg generation 2 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
62263553|NCT01157364|OTHER|bimatoprost 15 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 15 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
62263554|NCT01157364|OTHER|bimatoprost 10 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
62619896|NCT06028386|PLACEBO_COMPARATOR|Arm2- Fibracol Plus Collagen dressing|The intervention in this arm is the application of collagen dressings to UT Grade 1A diabetic foot ulcers
62619897|NCT02940236||Multimodal analgesia|Patients scheduled for general surgery and requiring multimodal analgesia in preoperative period.
62619898|NCT04949204||Migraine patients|Wearable wrist sensor + headache application on smartphone
62619899|NCT04949204||Cluster Headache Patients|Wearable wrist sensor + headache application on smartphone
62619900|NCT04633291|EXPERIMENTAL|Novel swelling media|Participants underwent catheterization with the SpeediCath standard male catheter containing the novel swelling media. The catheterization was performed by a trained nurse.
62263555|NCT01157364|OTHER|bimatoprost 6 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
62263556|NCT01157364|OTHER|bimatoprost 15 µg generation 1, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
62263557|NCT01157364|OTHER|bimatoprost 10 µg generation 1, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
62619901|NCT04633291|ACTIVE_COMPARATOR|Comparator swelling media|Participants underwent catheterization with CE-marked SpeediCath® standard male containing the original swelling media. The catheterization was performed by a trained nurse.
62059772|NCT05588609|EXPERIMENTAL|Part 2: mCRPC|"Participants will receive intravenous infusion of 750 mg of zenocutuzumab once every 2 weeks in combination with the AR targeting agent they experienced disease progression on prior to study entry:~enzalutamide 160 mg orally once daily or abiraterone 1000 mg orally once daily with prednisone 5 mg orally twice daily"
62059773|NCT04391465|EXPERIMENTAL|Patients Scheduled for Elective Electrophysiological Study|"High right atrial pacing will occur at the following rates for 60 seconds each, with a rest period of at least 60 seconds between pacing runs:~* 600 msec (100 bpm)~* 500 msec (120 bpm)~* 400 msec (150 bpm)~* 350 msec (171 bpm)"
62059774|NCT01495884|EXPERIMENTAL|Lapatinib (Tyverb™) and (Myocet™)|
62059775|NCT04713267|OTHER|ISABel Bed 1 or ISABel Bed 2|The study has a within-subject repeated measures-design. After a baseline measurement, participants will be allocated to either a first experimental night in automated bed 1 (ISABel Bed 1) and a second one in automated bed 2 (ISABel Bed 2) or a first experimental night in bed 2 and a second one in bed 1. Afterwards, the results of each polysomnographic measurement carried out during the intervention will be compared to the off-treatment baseline measurement.
62059776|NCT02227316|EXPERIMENTAL|Intravenous Ibuprofen|Ibuprofen 800mg IV piggyback and Saline IVP q 6 hours x 4 during uterine fibroid embolization
62059777|NCT02227316|EXPERIMENTAL|Intravenous acetaminophen|Acetaminophen 1 gram IV piggyback and Saline IVP q6 hours x 4 during uterine fibroid embolization
62059778|NCT02227316|EXPERIMENTAL|IV ibuprofen/IV acetaminophen|Ibuprofen 800 mg/ Acetaminophen 1 gram IV piggyback and Saline IVP 6 hours x 4 during uterine fibroid embolization
62059779|NCT02227316|ACTIVE_COMPARATOR|Intravenous placebo/Intravenous placebo|Saline/Saline IV piggyback and IVP Ketorolac 30 mg q6 hours x 4 during uterine fibroid embolization
62059780|NCT03575338|ACTIVE_COMPARATOR|Open Scarf Osteotomy|This group of patients will undergo surgery performing an open scarf osteotomy
62059781|NCT03575338|EXPERIMENTAL|Minimally invasive scarf Osteotomy|This group of patients will undergo surgery performing a Minimally invasive scarf osteotomy
62059782|NCT00070811||Revision|Patients with repaired cleft lip who receive lip revision surgery
62059783|NCT00070811||Non-Revision|Patients with repaired cleft lip who do not have lip revision surgery
62059784|NCT00070811||Non-cleft|Non-cleft 'control' subjects.
62059785|NCT03790332|EXPERIMENTAL|Phase 1/2|"Part A: Subjects ≥1 to \<12 years of age with moderate or severe cGVHD after failure of 1 or more lines of systemic therapy, will receive oral ibrutinib once daily to determine Recommended Pediatric Equivalent Dose (RPED).~Part A Continuation: Subjects participating in Part A may continue receiving daily ibrutinib until the RPED is determined, at which time their dose may be adjusted to the RPED.~Part B: Subjects ≥1 to \<12 years of age( upper age limit is \< 22 years) with moderate or severe cGVHD after failure of 1 or more lines of systemic therapy or with newly diagnosed moderate or severe cGVHD will be dosed at the RPED. Subjects ≥12 will be given 420mg orally ibrutinib once daily."
62059786|NCT00003084|EXPERIMENTAL|Arm I (Estramustine + Etoposide)|Arm I: Oral Estramustine 3 x day + oral Etoposide 2 x day on days 1-14 + Paclitaxel IV over 1 hour Day 2, repeats every 21 days.
62263558|NCT01509196|EXPERIMENTAL|HIP0901|Fenofibric acid
62263559|NCT01509196|ACTIVE_COMPARATOR|Lipidilsupra|Fenofibrate
62263560|NCT05339295|EXPERIMENTAL|Test Group|Levomerc (Levofloxacin) tablets 500 mg
62263561|NCT05339295|ACTIVE_COMPARATOR|Reference Group|Tavanic (Levofloxacin) tablets 500 mg
62263562|NCT02180555||ICU patients|
62263563|NCT04818684||Physician|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
62059787|NCT00003084|EXPERIMENTAL|Arm II (Chemotherapy + Ketoconazole)|Arm II: Doxorubicin IV Days 1, 15, and 29, Vinblastine IV Days 8, 22, and 36, Oral Ketoconazole 3 x day on Days 1-7, 15-21, + 29-35, and Oral Estramustine 3 x day on Days 8-14, 22-28, and 36-42; 6 weeks of alternating chemotherapy and 2 weeks rest, for 8 week course.
62619902|NCT05118763|EXPERIMENTAL|INNA-051 arm 1|INNA-051 intranasal spray low dose administered once on each of Days 1, 4, 7 and 10
62619903|NCT05118763|EXPERIMENTAL|INNA-051 arm 2|INNA-051 intranasal spray high dose administered once on each of Days 1, 4, 7 and 10
62619904|NCT05118763|PLACEBO_COMPARATOR|Placebo|Placebo intranasal spray high dose administered once on each of Days 1, 4, 7 and 10
62059788|NCT00069784|EXPERIMENTAL|Insulin glargine + omega-3 polyunsaturated fatty acids|"* Insulin glargine once daily by subcutaneous injection in a titrated regimen targeting a fasting plasma glucose (FPG) level of ≤95 mg/dL (5.3 mmol/L)~* One capsule of omega-3 polyunsaturated fatty acids once daily"
62059789|NCT00069784|EXPERIMENTAL|Insulin glargine + placebo|"* Insulin glargine once daily by subcutaneous injection in a titrated regimen targeting a fasting plasma glucose (FPG) level of ≤95 mg/dL (5.3 mmol/L)~* One capsule of placebo once daily"
62059790|NCT00069784|EXPERIMENTAL|Standard care + omega-3 polyunsaturated fatty acids|• One capsule of omega-3 polyunsaturated fatty acids once daily
62059791|NCT00069784|PLACEBO_COMPARATOR|Standard care + placebo|• One capsule of placebo once daily
62059792|NCT00621608|EXPERIMENTAL|1|Hyperbaric Oxygen Therapy
62059793|NCT00621608|SHAM_COMPARATOR|2|Placebo Hyperbaric Oxygen Chamber
62059794|NCT01164462|OTHER|A 2|During the normal opening hours of five testing centers, clients with a rapid finger-stick blood specimen test
62263564|NCT04818684||Psychologists|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
62447784|NCT05215899|EXPERIMENTAL|Comparison group|Patients in the comparison group will not be subjected to any intervention other than the tests specified in the method. Comparison group patients will continue their standard treatment and care. Questionnaires and scales will be applied to this group again before the application starts and after the application is finished.
62447785|NCT05137080|ACTIVE_COMPARATOR|Treatment A|24mg dexamethasone i.v. perioperatively and 24mg dexamethasone i.v. on the first postoperative day
62619905|NCT03048071||Homograft in pulmonary position replacement|All patients having had the replacement of an homograft in pulmonary position between January 1999 and October 2016, within the Queen Fabiola Children Hospital of Brussels, Belgium.
62846109|NCT00829192|EXPERIMENTAL|1|Afamelanotide (CUV1647) implant administered subcutaneously every 60 days for 24 months
62059795|NCT01164462|OTHER|B group|During evenings and week-ends (i.e. when the centers are closed) only community based with rapid HIV testing
62059796|NCT01164462|OTHER|A1 group|During the normal opening hours of five testing centers, clients with a conventional test.
62059797|NCT02467517|EXPERIMENTAL|INTRAVENOUS KETAMINE|
62059798|NCT03677011|OTHER|category 1|Low responder
62263565|NCT04818684||Caregivers|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
62263566|NCT04818684||Nurses|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
62447786|NCT05137080|ACTIVE_COMPARATOR|Treatment B|24mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
62447787|NCT05137080|PLACEBO_COMPARATOR|Treatment C|Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
62263567|NCT04818684||Social and Educational Assistants|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
62059799|NCT03677011|OTHER|category 2|Medium Responder and High Responder
62059800|NCT04836858|EXPERIMENTAL|CMK389 10mg/kg i.v.|Active
62059801|NCT04836858|PLACEBO_COMPARATOR|Placebo i.v.|Placebo
62263568|NCT04818684||Volunteers|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit. The representative participating in the study will preferably be the volunteer coordinator.
62447788|NCT05306379|EXPERIMENTAL|Voclosporin/Simvastatin|"Subjects will receive a single oral dose of 40 mg simvastatin (given as two 20 mg tablets) in the morning of Day 1 and Day 8.~Subjects will receive voclosporin administered as an oral 23.7 mg dose (three 7.9 mg capsules) twice-daily for 7 days from the morning of Day 2 until the evening of Day 8."
62447789|NCT01817556|EXPERIMENTAL|Stillen Tab.|administered three times daily for four weeks
62619906|NCT03048071||Contegra conduct replacement|All patients having had the replacement of a Contegra conduct between January 1999 and October 2016, within the Queen Fabiola Children Hospital of Brussels, Belgium.
62619907|NCT04608890||Long-standing T1D patients|Patients with long-standing type 1 diabetes
62619908|NCT04608890||Healthy volunteers|Healthy volunteers
62619909|NCT00693485|EXPERIMENTAL|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
62059802|NCT04836858|EXPERIMENTAL|CMK389 300mg s.c.|Active
62059803|NCT04836858|PLACEBO_COMPARATOR|Placebo s.c.|Placebo
62059804|NCT00103961||1|Treatment-naive and treatment-experienced HIV-infected adults
62059805|NCT05596084|EXPERIMENTAL|Bio-oss bovine bone graft with maxillary sinus augmentation and implant placement|A 2 cc Bio-oss bovine bone graft will be used for maxillary sinus augmentation before placing an implant on one side of the bilateral atrophic maxillary posterior regions. Then, 6 months after the surgery, the implant will be placed in accordance with the standard protocol
62619910|NCT00693485|EXPERIMENTAL|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
62619911|NCT00693485|SHAM_COMPARATOR|Sham (no implant)|Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
62619912|NCT00500253|ACTIVE_COMPARATOR|1|children with asthma with FeNO monitored treatment (study group)
62846110|NCT00829192|PLACEBO_COMPARATOR|2|Placebo implant administered subcutaneously every 60 days for 24 months
62846111|NCT01286909|EXPERIMENTAL|LaFlavon|
62846112|NCT01286909|NO_INTERVENTION|Placebo|
62846113|NCT05874193|EXPERIMENTAL|Treatment every 6 weeks|Treatment every 6 weeks
62846114|NCT03820687|ACTIVE_COMPARATOR|Intervention Group|Participants in the intervention group will receive 3 components: 1) a bilingual, culturally tailored clinical trial educational video, 2) a low literacy booklet, and 3) support from a patient navigator to empower cancer patients to make informed decisions about cancer clinical trial participation by increasing awareness of clinical trials and MCC services, positive attitudes and intentions to consider clinical trials as an appropriate treatment option for cancer.
62846115|NCT03820687|ACTIVE_COMPARATOR|Usual Care Control Group|Participants in the usual care control group will receive a general clinical trial fact sheet.
62846116|NCT04086329|OTHER|Affected MM Cases|Key eligibility criteria for MM cases includes physically-capable adults (male and females, ages 18 to 65 years, inclusive) with genetically-confirmed MM with predominant symptoms of myopathy as expressed by exercise intolerance and muscle weakness and fatigue.
62846117|NCT04086329|OTHER|Healthy Controls|Adult healthy volunteers will be individually matched with corresponding MM cases based on age, biological sex, and body mass index.
62846118|NCT00379301|ACTIVE_COMPARATOR|Group 1|Pulmonary vein isolation (PVI) combined with ablation of documented non-PV triggers of atrial fibrillation --- (sites away from the pulmonary veins where consistent abnormal impulses that can trigger AF are identified during the procedure)
62447790|NCT01817556|ACTIVE_COMPARATOR|Mucosta Tab.|administered three times daily for four weeks
62447791|NCT03761433||SPI group|All patients who received the liver resection surgery will receive surgical pleth index
62447792|NCT04122105|EXPERIMENTAL|intervention|sildenafil administration perioperative to renal transplant
62447793|NCT04122105|ACTIVE_COMPARATOR|control|renal transplant recipients
62447794|NCT06357026|EXPERIMENTAL|percutaneous left ventricular assist system|Subjects with coronary artery disease receiving high-risk PCI will be supported by Percutaneous Ventricular Assist System during the procedure.
62447795|NCT06357026|ACTIVE_COMPARATOR|intra-aortic balloon pump (IABP)|Subjects with coronary artery disease receiving high-risk PCI will be supported by IABP during the procedure.
62619913|NCT00500253|OTHER|2|group of children with treatment monitored by GINA's grade of disease clinical control (control group)
62846119|NCT00379301|ACTIVE_COMPARATOR|Group 2|PVI combined with ablation at documented sites of non-PV triggers, PLUS ablation at sites where non-PV triggers are commonly found
62846120|NCT00379301|ACTIVE_COMPARATOR|Group 3|PVI combined with ablation at documented sites of non-PV triggers and ablation at sites in the left atrium that demonstrate disorganized electrical impulses called complex fractionated electrograms (CFE).
62846121|NCT05158764|EXPERIMENTAL|URGO BD001|Treatment with URGO DB001 during 12-week treament period (5 medical visits are planned: D0, W2, W4, W8, W12)
62846122|NCT05158764|ACTIVE_COMPARATOR|Kit Biflex|Treatment with Kit Biflex during 12-week treament period (5 medical visits are planned: D0, W2, W4, W8, W12
62846123|NCT04606329|EXPERIMENTAL|LuminoMark inj.|Injection LuminoMark inj. 0.2mL once in this study.
62846124|NCT04606329|ACTIVE_COMPARATOR|Charcotrace Inj.|Charcotrace Inj. about 0.3\~1mL
62619914|NCT04648839||Benralizumab|Patients that received at least one dose of benralizumab according to routine clinical practice
62619915|NCT05266859|ACTIVE_COMPARATOR|Group I- Calcium hydroxide (Control)|"Group I will receive Calcium hydroxide . Calcium hydroxide is a gold standard medicament for the pulpotomy in deciduous teeth. It has antibacterial effects and widely used to disinfect the root canals.~This group will act as a control"
62619916|NCT05266859|EXPERIMENTAL|Group II- MTA (Experimental)|Group II will receive MTA (Mineral Trioxide Aggregate). MTA is a calcium silicate based highly biocompatible material that is commonly used for pulpotomies in deciduous teeth along with the regenerative procedures in permanent and deciduous teeth
62619917|NCT05266859|EXPERIMENTAL|Group III- PRF (Experimental)|Group III will receive PRF. PRF is platelet-rich fibrin that is a biocompatible product derived from patient's own blood. It is formed by centrifugation of the blood of the patient. It provides the growth factors and promotes regeneration of the pulp
62619918|NCT01863719|EXPERIMENTAL|Cohort 1|9 Subjects
62619919|NCT01863719|EXPERIMENTAL|Cohort 2|9 Subjects
62619920|NCT01863719|EXPERIMENTAL|Cohort 3|9 Subjects
62619921|NCT01863719|EXPERIMENTAL|Cohort 4|12 Subjects
62619922|NCT01754766|EXPERIMENTAL|AGN-229666 Dose A|One drop of AGN-229666 Dose A into each eye on Day 1 and Day 15.
62619923|NCT01754766|EXPERIMENTAL|AGN-229666 Dose B|One drop of AGN-229666 Dose B into each eye on Day 1 and Day 15.
62619924|NCT01754766|PLACEBO_COMPARATOR|vehicle of AGN-229666|One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
62619925|NCT05682274|ACTIVE_COMPARATOR|Group I|Partial restoration with the apical border at the level of CEJ in combination with CAF+CTG
62619926|NCT05682274|ACTIVE_COMPARATOR|Group II|Partial restoration with the apical border within 1 mm apical to the CEJ.
62846125|NCT02895789||spinal muscular atrophy|ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with laboratory documentation of homozygous deletion of SMN1 exon 7
62619927|NCT06041282|EXPERIMENTAL|manipulation under anesthesia group|The patient underwent manipulation under anesthesia
62619928|NCT06041282|ACTIVE_COMPARATOR|Supervised home rehabilitation group|The patient underwent supervised home rehabilitation
62619929|NCT02734225|EXPERIMENTAL|EXPERIMENTAL|Functional recovery Balance training
62619930|NCT02734225|ACTIVE_COMPARATOR|CONTROL|Functional recovery Balance training Dynamometric Platform training
62619931|NCT02137226|EXPERIMENTAL|BI 695501|one injection every 2 weeks for 48 weeks (25 injections in total)
62846126|NCT02895789||mitochondrial myopathy|ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with genetic confirmation or evidence from muscle biopsy confirming the diagnosis
62846127|NCT02895789||control|The healthy control group will be age and gender-matched to the SMA and mitochondrial myopathy groups as best as possible.
62846128|NCT04604769||Daily routine, control group|ICU medical staff were asked about their stress and causes of stress during their daily professional life.
62846129|NCT04604769||During Covid-19|ICU medical staff were asked about their stress and causes of stress in their daily professional life during COVID-19 crisis.
62846130|NCT00950859|EXPERIMENTAL|GSK1349572 Cohort I|Single Arm, Cohort I
62619932|NCT02137226|ACTIVE_COMPARATOR|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
62619933|NCT02439788|EXPERIMENTAL|GINAKIT Cells plus chemotherapy|Patients receive chemotherapy with Fludarabine and Cyclophosphamide and then an infusion of the GINAKIT cells (iC9-GD2.CD28.OX40.zeta Natural Killer T cells)
62619934|NCT03887156|OTHER|Arm 1|One arm
62619935|NCT01578499|EXPERIMENTAL|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).
62619936|NCT01578499|ACTIVE_COMPARATOR|Methotrexate or Bexarotene|Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m\^2, tablets, orally, once daily with meals for up to 48 weeks.
62619937|NCT01627795|EXPERIMENTAL|Oshadi D and Oshadi R|anti cancer agents
62619938|NCT02614508|EXPERIMENTAL|Cohort A (buparlisib, ofatumumab)|Patients receive buparlisib PO QD on days 1-28 and ofatumumab IV on days 1, 8, 15, and 22 during of courses 1-2; and day 1 of courses 4-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62619939|NCT02614508|EXPERIMENTAL|Cohort B (buparlisib, ibrutinib)|Patients receive buparlisib as in Cohort A and ibrutinib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62619940|NCT02301845|EXPERIMENTAL|Suspended Diatoms|Suspended diatom shells (10 mg/ 10 ml of saline) will be instilled in the oral cavity of the study subject every 12 hours for the first three study days. The total amount of amorphous silica administered will be 20 mg/day, which is the average daily intake of amorphous silica in normal human diet (0.3 mg/kg body weight/day)
62619941|NCT03140865||Cognitively Normal|This group will include 300 healthy volunteers with no apparent memory problems. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend the visits or be available via telephone to complete study interviews.
62619942|NCT03140865||Mild Cognitive Impairment|This group will include 400 volunteers who have mild memory problems that are observed during cognitive testing. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend the visits or be available via telephone to complete study interviews.
62846131|NCT00950859|EXPERIMENTAL|GSK1349572 Cohort II|Single Arm, Cohort II
62059806|NCT05596084|EXPERIMENTAL|Titanium-Platelet Rich Fibrin with maxillary sinus augmentation and implant placement|A Titanium-Platelet Rich Fibrin will be used for maxillary sinus augmentation before placing an implant on other side of the bilateral atrophic maxillary posterior regions. Titanium platelet-rich fibrin was prepared by centrifugation at 2700 rpm for 14 minutes in accordance with standard protocols. Then, 6 months after the surgery, the implant will be placed in accordance with the standard protocol
62263569|NCT04818684||Relatives|"Relative of a patient who died in the palliative care unit at least 6 months ago Person to trust or to prevent if not designated Relative understanding and speaking sufficient French Relative not a health professional~Relative who visited the palliative care unit during the last 3 days of the patient's life and who met the care team:~* Traceability of the arrival of the loved one in the last 2/3 days of the patient's hospitalization~* Traceability of a meeting of the loved one with a member of the team over the last 3 days of his hospitalization or verification during telephone contact with the loved one after drawing lots Relative with an email address (to be verified during telephone contact with the loved one after drawing lots)"
62263570|NCT02401828|EXPERIMENTAL|Group A - Direct Switch|Direct switch from cART to Dolutegravir mono-therapy at baseline. Dolutegravir single tablet 50mg QD, once a day. Duration = 48 weeks
62263571|NCT02401828|EXPERIMENTAL|Group B - Delayed Switch|Delayed switch from cART to Dolutegravir mono-therapy at week 24 from baseline. Dolutegravir single tablet 50mg QD, once a day. Duration = 48 weeks
62263572|NCT05376865|EXPERIMENTAL|Intervention|Vitamin D3 supplement every week
62263573|NCT05376865|PLACEBO_COMPARATOR|Control|Placebo every week
62263574|NCT00845650|EXPERIMENTAL|AIGIV 3.5 mg/kg (Cohort A)|AIGIV containing 3.5 mg/kg anti-PA IgG as a single intravenous infusion.
62263575|NCT00845650|OTHER|Gamunex 90 mg/kg (Cohort A)|Gamunex 90 mg/kg total IgG as a single intravenous infusion.
62263576|NCT00845650|EXPERIMENTAL|AIGIV 7.0 mg/kg (Cohort B)|AIGIV containing 7.0 mg/kg anti-PA IgG as a single intravenous infusion.
62263577|NCT00845650|OTHER|Gamunex 180 mg/kg (Cohort B)|Gamunex 180 mg/kg total IgG as a single intravenous infusion.
62263578|NCT00845650|EXPERIMENTAL|AIGIV 14.0 mg/kg (Cohort C)|AIGIV containing 14.0 mg/kg anti-PA IgG as a single intravenous infusion.
62263579|NCT00845650|OTHER|Gamunex 360 mg/kg (Cohort C)|Gamunex 360 mg/kg total IgG as a single intravenous infusion.
62263580|NCT02755311|EXPERIMENTAL|liver resection|Resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. The investigators performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
62263581|NCT02755311|ACTIVE_COMPARATOR|transarterial chemoembolization|A microcatheter was inserted into the feeding arteries as selectively as possible through the lobar, segmental, or subsegmental arteries, dependent on the tumor distribution and hepatic functional reserve. Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin. Subsequently, chemolipiodolization was performed mixed with 5 ml of lipiodol. According to the number and size of the lesions, and liver and kidney function of the patient, the chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team. If residual flow remained after infusion of these agents, additional lipiodol was injected. Embolization was performed with absorbable gelatin sponge particles 350-560 μm in diameter.
62447796|NCT03034083||Couples Elevate Weekly Series|Participants in a couple relationship receive needs assessment and 8 hours of classes over a 4-week period in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
62619943|NCT03140865||Alzheimer's disease|This group will include 150 volunteers with mild stage Alzheimer's disease dementia. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend visits to complete study interviews.
62619944|NCT02411344|EXPERIMENTAL|Pertuzumab, Trastuzumab, Letrozole|
62619945|NCT01399281||Biologics alone or methotrexate alone|This group mainly refer to children with polyarticular course JIA treated with methotrexate ± biologics,
62619946|NCT01399281||Biologics and MTX|JIA treated with a combination of biologic and MTX (including any other add on therapy e.g. cyclosporine, leflunomide etc). This group mainly refer to children with polyarticular course JIA treated with MTX ± biologics
62846132|NCT01462253|EXPERIMENTAL|Clofarabine, Cyclophosphamide|"Clofarabine concentrate for solution for infusion should be filtered using a 0.2 micron filter and diluted to a final concentration between 0.15 mg/mL and 0.4 mg/mL with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS), or 5% dextrose injection (D5W) USP or EP prior to infusion.~Cyclophosphamide should be prepared for parenteral use by adding 0.9% sterile sodium chloride solution. Solutions of cyclophosphamide may be injected intravenously without further dilution or may be infused following further dilution: Dextrose Injection, USP (5% dextrose), Dextrose and Sodium Chloride Injection, USP (5% dextrose and 0.9% sterile sodium chloride), 5% Dextrose and Ringer's Injection."
62059807|NCT03642860|EXPERIMENTAL|Active treatment|Triheptanoin oil
62059808|NCT03642860|PLACEBO_COMPARATOR|Placebo treatment|Safflower oil
62447797|NCT03034083||Foster Parents Elevate Weekend Intensive|Foster parent participants receive 8 hours of classes over a weekend in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
62447798|NCT01752348|PLACEBO_COMPARATOR|Placebo (isotonic saline)|Endotoxin + isotonic saline. Reference for model of acute inflammatory illness
62846133|NCT02294799|OTHER|Intervention Group|TMD diagnosed sujects that will receive the mobilization treatment
62846134|NCT02294799|PLACEBO_COMPARATOR|Placebo Group|TMD diagnosed sujects that will receive the placebo treatment
62846135|NCT00194493|EXPERIMENTAL|1|Patient's clinician receives graphical report of patient-reported symptoms and quality of life issues.
62059809|NCT06499623||Oncological patients|The inclusion criteria for the cohort of oncological patients are age 18+, an oncological diagnosis and a survival prognosis of at least 3 months.
62059810|NCT06499623||Patients older than 65 years|The inclusion criteria for this cohort are age 65 and older and hospitalization at least 14 days or longer.
62263582|NCT04918199||Paris Transplant Group cohort|400 (10%) of the patients were randomly selected from 4,000 consecutive patients over 18 years of age prospectively enrolled at the time of kidney transplantation from a living or deceased donor at Necker Hospital, Saint-Louis Hospital, Foch Hospital, and Toulouse Hospital between January 1, 2005, and January 1, 2014, in France.
62263583|NCT00067028|EXPERIMENTAL|Clofarabine + Ara-C|"Clofarabine 40 mg/m\^2 by vein over 1 hour daily for 5 days.~Ara-C Starting dose: 1 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle."
62263584|NCT00067028|EXPERIMENTAL|Clofarabine + Idarubicin|"Clofarabine 22.5 mg/m\^2 by vein over 1 hour daily for 5 days.~Idarubicin 10 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle."
62263585|NCT00067028|EXPERIMENTAL|Clofarabine + Idarubicin + Ara-C|"Clofarabine 22.5 mg/m\^2 by vein over 1 hour daily for 5 days.~Idarubicin 6 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.~Ara-C Starting dose: 0.75 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle."
62263586|NCT03900403|NO_INTERVENTION|Habitual Intake|This will be the comparative arm, of 6 weeks before and after the study participant is on their habitual diet
62846136|NCT00194493|NO_INTERVENTION|2|
62846137|NCT02803983||Pediatric hip plate|The children were treated with pediatric hip plate.
62263587|NCT03900403|EXPERIMENTAL|Walnut Intake|Experimental Arm of 12 weeks of Walnut Intake, with study visits at baseline (prior to walnut intake) and after 6 and 12 weeks of 40g of Walnut Intake.
62263588|NCT06156956|EXPERIMENTAL|Fecal Microbiota Transplantation|Antibiotics pre-treatment on days 1-5 and a bowel cleansing on day 6. Days 7-14 are dedicated to active eradication treatment with FMT. First dose on day 7 and second dose in days 9-14 (1/6 of full dose every day).
62263589|NCT00409084|ACTIVE_COMPARATOR|1|endoscopic variceal band ligation
62619947|NCT01399281||NSAIDs and/or steroid injections alone|This group refers to children with mostly oligoarticular persistent course who are usually NOT treated with second line agents and have a more benign course.
62619948|NCT05431114||Shoulder patients|Participants who presents with glenohumeral instability.
62619949|NCT05041777||Prospective data collection, retrospective OCT image evaluation|From February 2017-June 2017 patients were included prospectively. OCT images were evaluated retrospectively in conjunction with clinical images. A deep learning algorithm is developed with use of this dataset including 676 OCT images.
62846138|NCT02803983||Cannulated screw|The children were treated with cannulated screw.
62846139|NCT02637492||ICCMI|Patient hospitalized for lower limb arterial disease and suspected to have critical ischaemia
62846140|NCT01037777||presymptomatic carriers|
62846141|NCT01037777||non carrier relatives|
62059811|NCT03711630|EXPERIMENTAL|Meditation|The study cohort will participate in self-guided meditation practice over the course of eight weeks.
62059812|NCT01450722|ACTIVE_COMPARATOR|drug eluting stent|Paclitaxel eluting stent for long superficial femoral artery obstruction
62059813|NCT01450722|ACTIVE_COMPARATOR|bypass operation|femoropopliteal artery bypass operation by using synthetic PTFE graft
62059814|NCT05467579|ACTIVE_COMPARATOR|Healthy subjects|Healthy patients that will serve as controls will recruited having the same demographic characteristics of the experimental group i.e., age, sex, vertebral maturation stage and the same cranio-facial features, skeletal class II, class II division 1 malocclusion, mandibular retrognathia, normal/hyperdivergent growth pattern.
62059815|NCT05467579|EXPERIMENTAL|JIA subjects|Young people aged from 10 to 14 years old with skeletal class II, class II division 1 malocclusion, mandibular retrognathia, normal/hyperdivergent growth pattern, and affected by juvenile idiopathic arthritis
62846142|NCT01305798|EXPERIMENTAL|Control Arm|The control arm will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment.
62619950|NCT05041777||Prospective data collection and OCT image evaluation|From January 2021-April 2021 patients were included prospectively. OCT images were evaluated prospectively in a clinical setting. The deep learning algorithm will be prospectively validated with use of this dataset including 287 OCT images.
62619951|NCT02336009|EXPERIMENTAL|total wrist arthroplasty, Trimed|This is a pilot study where all patients will be operated with the Trimed total wrist arthroplasty.
62619952|NCT05692804||Group with Sevoflurane|The Sevoflurane used for maintenance of general anesthesia
62619953|NCT05692804||Group with Propofol|The Propofol (IV) used for maintenance of general anesthesia
62619954|NCT00162097|EXPERIMENTAL|EFV600mg Participants With Mild Hepatic Impairment|
62619955|NCT00162097|EXPERIMENTAL|EFV600mg Participants With Moderate Hepatic Impairment|
62846143|NCT01305798|EXPERIMENTAL|Active Choice and Default Option Arm|The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email.
62846144|NCT01305798|EXPERIMENTAL|Active Choice Only Arm|The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
62846145|NCT01956721|EXPERIMENTAL|Patients with heart failure (FEVG ≥ 50%)|Patients with heart failure (FEVG ≥ 50%)
62846146|NCT01956721|EXPERIMENTAL|Patients with heart failure (FEVG ≤ 35%),|Patients with heart failure (FEVG ≤ 35%),
62619956|NCT00162097|EXPERIMENTAL|EFV600mg Participants With Severe Hepatic Impairment|
62846147|NCT01956721|OTHER|Healthy Volunteers|Healthy Volunteers with no heart failure
62846148|NCT05861349||Patients with CTS|Patients referred to the Electromyographic Laboratory of the Department of Neurology at the Jagiellonian University Medical College, Cracow, Poland with symptoms suggestive of CTS (numbness of the hand, present or accentuated in the night, reduced hand dexterity) with CTS confirmed in NCS or US.
62846149|NCT05861349||Healthy controls|Subjects referred to the Electromyographic Laboratory of the Department of Neurology at the Jagiellonian University Medical College, Cracow, Poland for investigation towards tetany, with no or only weak signs of tetany in electromyography.
62846150|NCT03867318|EXPERIMENTAL|Atorvastatin Monotherapy|Participants receive double-blind atorvastatin 10 mg once daily (QD) via oral tablet PLUS open-label atorvastatin 10 mg QD via oral tablet for the entire duration of the study. Double-blind atorvastatin is to be added to the regimen for participants not achieving LDL-C target (≤100 mg/dL; 2.59 mmol/L). The maximum possible total daily dose of atorvastatin received in this group is 80 mg (10 mg open label plus 70 mg double blind).
62846151|NCT03867318|EXPERIMENTAL|Ezetimibe + Atorvastatin|Participants receive double-blind ezetimibe 10 mg QD via oral tablet PLUS open-label atorvastatin 10 mg QD via oral tablet for the entire duration of the study. Double-blind atorvastatin is to be added to the regimen for participants not achieving LDL-C target (≤100 mg/dL; 2.59 mmol/L). The maximum possible total daily dose of atorvastatin received in this group is 40 mg (10 mg open label plus 30 mg double blind).
62846152|NCT01680042|ACTIVE_COMPARATOR|phenytoin paste|this group receives phenytoin paste after oral biopsy
62846153|NCT01680042|PLACEBO_COMPARATOR|usual mucoadhesive paste|this group receives the usual mucoadhesive paste without phenytoin after oral biopsy
62846154|NCT00923611|PLACEBO_COMPARATOR|Placebo|3 tablets of placebo will be taken 30minutes after breakfast for 8 weeks
62263590|NCT00409084|ACTIVE_COMPARATOR|2|subjects will receive nadolol (beta blocker) at 20mg/day with dose titration
62619957|NCT00162097|ACTIVE_COMPARATOR|EFV600mg Participants With Normal Hepatic Function|
62619958|NCT02708030|ACTIVE_COMPARATOR|Ketogenic Diet|Ketogenic diet (KD) will be administered by the non-fasting protocol. The child will be admitted to the hospital, and KD will be started in 1:1 ratio. The ratio will increased every 48hours to a maximum of 4:1 or ketosis (urinary ketones 40-80mg/dL) is attained. The child will thereafter be discharged and followed up on Out patient basis.
62619959|NCT02708030|EXPERIMENTAL|Modified Atkins Diet|Modified Atkins Diet (MAD) will be administered on out patient basis. Parents of children will be advised to monitor for seizure frequency and ketosis at home.
62619960|NCT02708030|EXPERIMENTAL|Low Glycemic Index Therapy|Low Glycemic Index Therapy (LGIT) will be administered on out patient basis. Parents of children will be advised to monitor for seizure frequency and ketosis at home.
62619961|NCT04726774|EXPERIMENTAL|Hypnosis group|The intervention consisted of two hypnosis sessions by a physician trained in medical hypnosis. The hypnosis group received also the usual rehabilitation program.
62619962|NCT04726774|ACTIVE_COMPARATOR|Control group|The control group follow the usual rehabilitation program which includes intensive physiotherapy for 2 weeks (i.e., focused on walking and enhancing balance exercises in group or individual and group) and patient education on the risk of falling and on prevention of falls.
62619963|NCT06613308||Arm1(Neoadjuvant immunotherapy combined with chemotherapy)|
62619964|NCT06613308||Arm2(Neoadjuvant chemotherapy)|
62619965|NCT00413933|EXPERIMENTAL|Intrevention group|each subject in intervention group will get 15 weekly sessions (each session - 45 minutes) of specified exercise from a physical therapist that specializes in fall prevention and walking device recommendations. All subjects will get brochure for home exercise. It will be expected for intervention group to exercise twice daily, each time for 20 minutes in addition to the PT sessions
62263591|NCT06082986||Bio-naive Participants With Crohn's Disease (CD)|Participants with CD from inflammatory bowel disease (IBD) database who received ustekinumab from 20 May 2020 to 16 September 2022 in the real-world setting in China will be observed in the study. Only data available per routine clinical practice will be collected within this study.
62263592|NCT05429827|PLACEBO_COMPARATOR|Normal saline|Injection of 2 ml normal saline into a myofascial trigger point.
62263593|NCT05429827|EXPERIMENTAL|hypo-osmolar dextrose solution|Injection of 2 ml 5% dextrose into a myofascial trigger point.
62263594|NCT05429827|EXPERIMENTAL|hyper-osmolar dextrose solution|Injection of 2 ml 15% dextrose into a myofascial trigger point.
62263595|NCT06470139|ACTIVE_COMPARATOR|Ropivacaine|Ultrasound-guided PENG block - 20ml 0,2% ropivacaine + 2ml 0.9% NaCl
62447799|NCT01752348|EXPERIMENTAL|Acipimox + Placebo (isotonic saline)|Endotoxin + Acipimox + Placebo (isotonic saline). Intervention: blockage of endogenous lipolysis.
62447800|NCT01752348|EXPERIMENTAL|Acipimox + free fatty acids|Endotoxin + Acipimox + free fatty acids. Intervention: free fatty acids
62619966|NCT00413933|NO_INTERVENTION|Control group|"Those who agree to participate in the study will fill in questionnaire about falls (causes, circumstance, results). All will pass through: cognitive assessment by the Mini-Mental State Examination (MMSE), affective assessment by the 15-item Geriatric Depression Scale (GDS), functional assessment by Barthel Index (BI), visual assessment by Snellen charts and basic gait assessment by a Timed get Up and Go test (TU\&G).~Participants that fulfill inclusion criteria will be randomly assigned to the intervention group or the control group"
62619967|NCT04854941|EXPERIMENTAL|Probiotics group (PRO)|99 patients with COVID-19 infection who have been supplemented with a Lactobacillus and Bifidobacterium containing probiotic in addition to standard regimen (oxygen support, antiviral, antibacterial, anticoagulant, anticytokine (tocilizumab and olokizumab) drugs and dexamethasone treatment according to indications and contraindications)
62619968|NCT04854941|NO_INTERVENTION|Control group (CON)|101 patients with COVID-19 infection who have been treated with standard regimen only (oxygen support, antiviral, antibacterial, anticoagulant, anticytokine (tocilizumab and olokizumab) drugs and dexamethasone treatment according to indications and contraindications)
62619969|NCT06344689||Patients with ectropion underwent surgical treatment.|
62059816|NCT02542644|OTHER|Patients with Fuchs endothelial dystrophy scheduled for DMEK|
62846155|NCT00923611|ACTIVE_COMPARATOR|Fimasartan 20mg|2 tablets of placebo and 1 tablets of fimasartan 20mg will be taken 30minutes after breakfast for 8 weeks
62846156|NCT00923611|ACTIVE_COMPARATOR|Fimasartan 60mg|3 tablets of fimasartan 20mg will be taken 30minutes after breakfast for 8 weeks
62263596|NCT06470139|ACTIVE_COMPARATOR|Ropivacaine+Dexamethasone|Ultrasound-guided PENG block - 20ml 0,2% ropivacaine + 4mg Dexamethasone
62447801|NCT01752348|EXPERIMENTAL|Acipimox + 3-hydroxybutyrate|Endotoxin + Acipimox + 3-hydroxybutyrate. Intervention: 3-hydroxybutyrate
62447802|NCT02390622|OTHER|FMT treatment|Treat the patients by fecal microbiota transplantation
62447803|NCT03028662|EXPERIMENTAL|Immediate exposure|Exposure to video on alcohol (update phase) followed (10 minutes) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
62447804|NCT03028662|ACTIVE_COMPARATOR|Delayed exposure|Exposure to a video of alcohol consumption (update phase) followed (6 hours) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
62447805|NCT03028662|ACTIVE_COMPARATOR|No exposure|Exposure to a video of neutral situations (update phase) followed (10 minutes) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
62619970|NCT05977556|EXPERIMENTAL|Experimental|"Neuromuscular strength training: The experimental group will receive up to 24 sessions of neuromuscular strength training led by a physical therapist with expertise in geriatrics and movement behaviors. The program includes exercises such as pelvic lifts, lunges, step-ups, squats, and sit-stands. The difficulty level will progressively increase using techniques like manual resistance, dumbbells, and unstable surfaces.~Sedentary behavior intervention: The experimental group will also undergo a sedentary behavior intervention based on social cognitive theory. It involves weekly coaching sessions to enhance self-efficacy in reducing sedentary time and increasing light-intensity activity throughout the day. Participants will be provided with a wrist-worn Fitbit activity monitor for daily feedback and to track adherence to the intervention. The aim is to encourage participants to sit less and move more throughout their waking hours."
62619971|NCT05977556|NO_INTERVENTION|Standard of care|The control group will receive standard of care that is provided as part of the perioperative surgical procedure and subsequent rehabilitation.
62846157|NCT00923611|ACTIVE_COMPARATOR|Fimasartan 120mg|3 tablets of fimasartan 40mg will be taken 30minutes after breakfast
62059817|NCT04215016|EXPERIMENTAL|Humanized anti-CD19 and anti-CD20 dual specific CAR-T cells|
62059818|NCT04858802|EXPERIMENTAL|PROPEL Contour Sinus Implant|Following successful in-office bilateral balloon dilation, placement of PROPEL Contour Sinus Implant in the randomized side.
62059819|NCT04858802|ACTIVE_COMPARATOR|Balloon Sinus Dilation Alone|Following successful in-office bilateral balloon dilation, placement of no implant on the contralateral side.
62059820|NCT04146246||Adult|Adults aged 18 years or older. Collect whole blood sample via venous/arterial puncture and, where possible, finger stick.
62059821|NCT04146246||Neonate|Neonates gestational age \>35 weeks or older. Collect whole blood sample via heel prick or, where an in dwelling line already exists, via arterial/umbilical draw.
62619972|NCT00849290|EXPERIMENTAL|APC8015F|
62619973|NCT05591534|EXPERIMENTAL|Endorectal brachytherapy|Endorectal brachytherapy
62619974|NCT03592849|EXPERIMENTAL|UC-MSCs therapy|transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by thin endometrium or endometrial scarring
62619975|NCT00423358|ACTIVE_COMPARATOR|vitamin D|ergocalciferol 50,000 IU Twice monthly
62846158|NCT00923611|ACTIVE_COMPARATOR|Fimasartan 240mg|3 tablets of fimasartan 80mg will be taken 30minutes after breakfast for 8 weeks
62059822|NCT04806646|EXPERIMENTAL|Single Arm Treatment|"One cycle of therapy is defined as 28 days of sonidegib. The patient will start with TS1 schedule.~* TS1: assumption 14 days on and 14 days off. TS1 may be temporary interrupted for any grade 2 or 3 toxicity (excluding alopecia) until return to grade 1. If the patient experiences any grade 3 or 2 side effects lasting for more than 28 days, at treatment resumption they will start the TS2 schedule.~* TS2: assumption 7 days on and 21 days off. TS2 may be temporary interrupted for any grade 2 or 3 toxicity (excluding alopecia) until return to grade 1. If the patient experiences any grade 3 or 2 side effects lasting for more than 28 days, he/she is discontinued from the study.~If progression of disease is observed (during TS1 or TS2) the patient is discontinued from the study."
62059823|NCT04981691|EXPERIMENTAL|anti-MESO CAR-T cells|"The subjects in this arm will receive Cyclophosphamide 300mg/m2/d and Fludarabine 30mg/m2/d from day-4 to day-2. Subjects will be treated with six administrations of anti-MESO CAR-T cells three times weekly (Monday-Wednesday-Friday) for two weeks. In the first week, total 1×109 or 3×109 will be infused, the second week is to plan three times consecutive infusions of 1x109 or 3×109 anti-MESO CAR-T cells each time.~Subjects will be enrolled serially. For subject safety, the preceding subject must have completed therapy and be 28 days from their last infusion before the next subject can be treated.~Interventions:~* Drug: anti-MESO CAR-T cells~* Drug: Fludarabine~* Drug: Cyclophosphamide"
62059824|NCT00891865||Pediatric lung transplantation|
62059825|NCT01058538|EXPERIMENTAL|L19IL2|
62059826|NCT02292264||Surgical treatment of ventral hernia|Adult patients who underwent a ventral hernia Repair at Zealand University hospital
62059827|NCT01800201|NO_INTERVENTION|Control|The control group will have their claims data analyzed for a 12 month period. We will be examining these data for hospital admissions, new vascular events (AMI, stroke, acute coronary syndrome admission), or repeat or new cardiovascular procedures.
62059828|NCT01800201|EXPERIMENTAL|Intervention|The intervention group (1) will use GlowCaps, a remote monitoring and reminder pill bottle; (2) assigned an engagement advisor from the study team; (3) asked to provide study team with names and contact information of up to 3 family members or friends as support partners for med adherence. The study team will contact these people in order listed until 1 agrees to this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on med adherence; and (5) will determine preferences for Way to Health platform communication methods.The group receiving the program intervention will also have their claims data analyzed for the 12 months post-enrollment.
62447806|NCT04210895|EXPERIMENTAL|Warm footbath with ginger powder|Participants receive a daily warm water footbath with added ginger powder over a two-week period
62619976|NCT00423358|PLACEBO_COMPARATOR|placebo|matching placebo tablet
62619977|NCT02169297|EXPERIMENTAL|Ultrasound-Guided Sub-Paraspinal Block|Patients allocated to the treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location and an intravenous PCA post-operatively
62619978|NCT02169297|PLACEBO_COMPARATOR|PCA only|Patients allocated to the control group had two sham multi-perforated soaker catheters taped to their back and received intravenous PCA post-operatively
62619979|NCT01474161|PLACEBO_COMPARATOR|Matching placebo|
62619980|NCT01474161|ACTIVE_COMPARATOR|GFT505 20mg - old formulation|Study Part I : dose level = 120mg
62846159|NCT04343235|EXPERIMENTAL|labetalol + furosemide|labetalol + furosemide
62846160|NCT04343235|ACTIVE_COMPARATOR|labetalol only|labetalol only
62846161|NCT03367078||tDCS cohort|DOC patients treated according to usual care, plus anodal tDCS (prospective cohort)
62846162|NCT03367078||Historical control cohort|DOC patients treated according to usual care only (retrospective cohort of patients matched for demographic and clinical characteristics, admitted at the Montecatone Rehabilitation Institute no more than 3 years before the introduction of tDCS)
62846163|NCT00467753|EXPERIMENTAL|Oxcarbazepine|Oxcarbazepine is the active drug to be given to subjects in the experimental arm
62846164|NCT00467753|PLACEBO_COMPARATOR|Sugar Pill|Patients are given either active or inactive intervention.
62619981|NCT01474161|EXPERIMENTAL|GFT505 60mg - new formulation|Study Part I : dose level = 120mg ; Study Part II : dose level = 180mg, 240mg and 300mg ; Study Part III : dose level = 120mg, 180mg and 240mg ; Study Part IV : dose level = 120mg or 180mg.
62619982|NCT00621998|EXPERIMENTAL|1|Flexible dose of olanzapine
62846165|NCT04755686|EXPERIMENTAL|Fast-tracking at geriatric medicine ward|Fast-tracking hip fracture patients at geriatric medicine ward. The goal is to optimize the medical care of older hip fracture patients at a geriatric ward and to shorten the time to operation.
62059829|NCT04069780|ACTIVE_COMPARATOR|Study group I : Intravitreal injection|A single intravitreal injection of 0.1 ml triamcinolone acetonide in a concentration of 4 mg / 0.1 ml.
62059830|NCT04069780|ACTIVE_COMPARATOR|Study group II: Suprachoroidal injection of full dose|A single suprachoroidal injection of 0.1 ml triamcinolone acetonide in a concentration of 4 mg / 0.1 ml.
62263597|NCT03906097|EXPERIMENTAL|intervention|SPSS 24.00 was randomized with the program and the control group was divided into 2 equal groups (intervention group n = 40; control group n = 40). The intervention group was received cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program (Figure 3.1). Both groups were evaluated three times at baseline, at the end of the 10th week and at the end of the third month (follow up).
62263598|NCT03906097|NO_INTERVENTION|control|SPSS 24.00 was randomized with the program and the control group was divided into 2 equal groups (intervention group n = 40; control group n = 40). The intervention group was received cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program (Figure 3.1). Both groups were evaluated three times at baseline, at the end of the 10th week and at the end of the third month (follow up).
62059831|NCT04069780|ACTIVE_COMPARATOR|Study group III : Suprachoroidal injection of half dose|They will receive a single suprachoroidal injection of 0.1 ml triamcinolone acetonide in a concentration of 2 mg / 0.1 ml.
62059832|NCT04002804|EXPERIMENTAL|Immunotherapy|Autologous DC loaded with a autologous tumor lysate, in order to stimulate the immune response of the patient.
62059833|NCT01819025|EXPERIMENTAL|4 face-to-face and smartphone-app|Four face-to-face therapy sessions and smartphone app as a complement and support to the four sessions.
62059834|NCT01819025|ACTIVE_COMPARATOR|TAU|10 sessions of face-to-face therapy, full behavioral activation
62059835|NCT05566808|OTHER|Autologous Costal Cartilage Graft|Patients undergoing rhinoplasty will receive autologous rib graft.
62059836|NCT05566808|OTHER|Costal Cartilage Allograft|Patients undergoing rhinoplasty will receive costal cartilage allograft.
62059837|NCT03319082||CXL Group|Patients with corneal ectasia following refractive surgery who had corneal collagen cross-linking in one or both eyes according to the Photrexa Viscous and Photrexa prescribing information
62059838|NCT05176977|EXPERIMENTAL|Peer Specialist - Whole Health Coaching (PS-WHC)|Participants will meet with a Peer Specialist for 18 sessions over 24 weeks. The essential elements of this intervention include 1) general support provided via the core functions of a Peer Specialist, and 2) a structured Whole Health Coaching curriculum.
62263599|NCT02595151||gastric intestinal metaplasia|Those fulfilling the criteria of GIM by CLE according to the study by Yuting Guo et al were included.
62263600|NCT02595151||normal gastric|diagnosed during routine colonoscopy procedures.
62447807|NCT04210895|ACTIVE_COMPARATOR|Warm water only footbath|Participants receive a daily warm water footbath over a two-week period
62447808|NCT05636878|EXPERIMENTAL|With EMPPer|All children (0 to 3 years old) in the areas Meurthe-et-Moselle South will benefit from the intervention of the Mobile Perinatal Psychiatry Team (EMPPer)
62447809|NCT05636878|NO_INTERVENTION|without EMPPer|All children (0 to 3 years) from Strasbourg and Reims will not benefit from the Mobile Intervention Team in Perinatal Psychiatry
62619983|NCT00621998|ACTIVE_COMPARATOR|2|Flexible dose of risperidone
62619984|NCT04137341|EXPERIMENTAL|Tablet A|A single oral 300-mg dose of GLPG1972 in fasted state
62619985|NCT04137341|EXPERIMENTAL|Tablet B|A single oral 300-mg dose of GLPG1972 in fasted state
62846166|NCT04755686|NO_INTERVENTION|Regular admission|Regular admission and care of hip fracture patients at the emergency room prior to surgery.
62846167|NCT03542786|EXPERIMENTAL|i3.1|This group will have their habitual antiretroviral therapy (integrase inhibitor (INI), protease inhibitor (IP), reverse transcriptase inhibitor (ITINAN)) combined with the research product (probiotic i3.1). The prebiotic will be taken once a day during 6 months.
62619986|NCT04137341|EXPERIMENTAL|Tablet C|A single oral 300-mg dose of GLPG1972 in fasted state
62846168|NCT03542786|EXPERIMENTAL|i3.1 + ProSeed|This group will have their habitual antiretroviral therapy combined with the probiotic (i3.1) and the prebiotic (ProSheed). The prebiotic and probiotic will be taken once a day during 6 months.
62846169|NCT03542786|PLACEBO_COMPARATOR|Placebo|This group will only have their habitual antiretroviral therapy. The placebo will be taken once a day during 6 months.
62846170|NCT04820140||muscle strengthening program|All patients will be receiving a muscle strengthening program consisting in both a training against resistance and an endurance training by elliptical bike during an observational period of 12 weeks for each treatment. Each training program will be preceded by a 4-week period of lymphatic drainage in order to improve neuromuscular sensitivity.
62846171|NCT04293822|EXPERIMENTAL|Study group|Group of 30 patients randomly selected will use topical Cetirizine 1% gel twice daily over a period of 6 months, where the treatment will be given in identical non-labeled bottles with a code and neither the patients, healthcare provider nor the investigator will know which treatment is given and what the code referred to.
62846172|NCT04293822|ACTIVE_COMPARATOR|Control group|Group of 30 patients randomly selected will use topical Minoxil 5% gel twice daily over a period of 6 months, where the treatment will be given in identical non-labeled bottles with a code and neither the patients, healthcare provider nor the investigator will know which treatment is given and what the code referred to.
62846173|NCT01452932|EXPERIMENTAL|Physiotherapy|Group of participants who recive physiotherapy treatment using Kabat technique for the upper limbs resistance training during 12 weeks
62846174|NCT01452932|OTHER|Yoga|Group of participants who recive Yoga sessions during 12 weeks
62846175|NCT00590772|ACTIVE_COMPARATOR|montelukast|montelukast 10 mg daily
62846176|NCT00590772|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62263601|NCT03966742|EXPERIMENTAL|Treatment|Doxorubin-eluting particle embolization for treatment of Desmoid Fibromatosis.
62263602|NCT02184078|EXPERIMENTAL|single group|"Nevirapine:~Study days 15-28 dose given once a day (q.d.) Study days 29-42 dose given twice a day (b.i.d.)~Rifabutin:~Study Days 0 to 42"
62619987|NCT04137341|EXPERIMENTAL|Food effect|selected tablet B or C under fed conditions
62059839|NCT05176977|NO_INTERVENTION|Enhanced Usual Care (EUC)|Usual PACT care plus Hot Spotter Analytics (consists of access to field-based dashboard that allows PACTS to identify homeless Veterans on their panels who were super-utilizers, and the hot spotter manual).
62263603|NCT00259883|EXPERIMENTAL|paroxetine|paroxetine 20 to 40mg/day
62263604|NCT06537960|OTHER|18FDG PET-CT|"18FDG PET-CT will be performed in 2 phases:~1. st standard phase: Standard acquisition (vertex to mid-thigh) at 1 hour post-injection of radiotracer~2. nd phase: Complementary abdomino-pelvic acquisition at 2.5 hours post radiotracer injection."
62263605|NCT04553120|EXPERIMENTAL|Alternating treatments condition - 10 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
62263606|NCT04553120|EXPERIMENTAL|Alternating treatments condition - 9 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
62263607|NCT04553120|EXPERIMENTAL|Alternating treatments condition - 13 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
62619988|NCT02088398|EXPERIMENTAL|160 mg ACY-1215 CLF (20 mg/mL) fed|• Treatment A: a single dose of 160 mg ACY-1215 CLF (20 mg/mL) in the fed state
62059840|NCT03138733|EXPERIMENTAL|Ceftobiprole medocaril|Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril)
62263608|NCT04553120|EXPERIMENTAL|Alternating treatments condition - 12 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
62059841|NCT03138733|ACTIVE_COMPARATOR|Daptomycin|Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards), with or without aztreonam
62059842|NCT04879199|EXPERIMENTAL|Typically Developing (TD) children|Static stability and Dynamic stability measurement in children with: 1) between the age of 7 and 18 years, 2) who are typically developing, 3) able to stand and walk alone without using assistance or assistive devices, 4) able to place their feet flat on the force platforms, and 5) with enough German language skills to follow the instructions.
62447810|NCT01479452|OTHER|Bariatric surgery|Bariatric surgery
62447811|NCT01479452|OTHER|Controls|Usual care
62447812|NCT04605510|EXPERIMENTAL|Intervention Group|24 female participants with non-specific neck pain included in the mobilization group will undergo detailed manual cervical examination. In the evaluation, the most painful segment with dysfunction will be selected and mobilization application and algometric measurements will be performed on this segment. Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization with Maitland method will be applied in 3 sets, 30 seconds, to the segment with the detected dysfunction.
62447813|NCT04605510|NO_INTERVENTION|Healthy Control Group|Healthy volunteer participants included in the control group will only be applied an evaluation protocol and blood samples will be taken without any application.
62447814|NCT06386497|EXPERIMENTAL|Parkinson's disease patients|All included Parkinson's disease patients
62447815|NCT05210023|EXPERIMENTAL|Nutrigenetic Diet Group|Participants randomly included in this group will receive nutrigenetic menus, i.e., considering the genotypes of the 11 variants analyzed.
62447816|NCT05210023|EXPERIMENTAL|Conventional Diet Group|Participants randomly included in this group will receive menus prepared following the international conventional guidelines set out by the WHO, AHA and Official Mexican Standards (NOM) for the treatment of obesity and dyslipidemia.
62619989|NCT02088398|EXPERIMENTAL|120 mg ACY-1215 ALF (10 mg/mL) fed|• Treatment B: a single dose of 120 mg ACY-1215 ALF (10 mg/mL) in the fed state
62619990|NCT02088398|EXPERIMENTAL|120 mg ACY-1215 ALF (10 mg/mL) fasted|• Treatment C: a single dose of 120 mg ACY-1215 ALF (10 mg/mL)
62619991|NCT03323970||Physicians|
62619992|NCT01500655|EXPERIMENTAL|Catheter|An ultrasound guided block of the LFCN is performed, followed by the placement of a catheter underneath the fascia iliaca.
62619993|NCT01500655|EXPERIMENTAL|Ultrasound guided LFCN block|An ultrasound guided regional nerve block --using ropivacaine 0.2%-- will be performed around the lateral femoral cutaneous nerve (LFCN).
62846177|NCT00892216|EXPERIMENTAL|Acupressure Band|A band with bead attachment will be used to produce Acupressure and applied to the P6 (three fingers breath from the wrist crease on th ventral surface of the upper limb). The application will be done 20 minutes prior to anesthesia and explanation as to usage after surgery will be given. The patient of caregiver will apply pressure on the bead for three minutes and repeat this four times a day for the next five days. None of the protocol for prevention of PONV in this group of patients will be changed. The postoperative therapy for nausea and vomiting will be on a PRN (as required) basis. Nausea and vomiting scores and VAS scores for pain estimation will be carried out according to hospital protocol in the PACU amd twice a day thereafter for their period of stay in the hospital. The amount of analgesics and antiemetics used and the number of days spent in the hospital will be registered.
62846178|NCT00892216|SHAM_COMPARATOR|Sham Acupressure|The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
62846179|NCT01374503|EXPERIMENTAL|ALX-0651|
62846180|NCT01374503|PLACEBO_COMPARATOR|Placebo|
62846181|NCT04349800|EXPERIMENTAL|Single Ascending Dose - 5 mg|
62846182|NCT04349800|EXPERIMENTAL|Single Ascending Dose - 10 mg|
62846183|NCT04349800|EXPERIMENTAL|Single Ascending Dose - 20 mg|
62846184|NCT04349800|EXPERIMENTAL|Single Ascending Dose - 40 mg|
62846185|NCT04349800|EXPERIMENTAL|Single Ascending Dose - 80 mg|
62619994|NCT01500655|NO_INTERVENTION|Control|This group gets the current standard of care--the donor site is infiltrated with 0.25% bupivacaine.
62619995|NCT06356324|EXPERIMENTAL|Music intervention|Participants instructed to listen to 20 minutes of relaxing classical music (e.g., Chopin, Mozart)
62846186|NCT04349800|EXPERIMENTAL|Single Ascending Dose - 160 mg|
62846187|NCT04349800|EXPERIMENTAL|Single Ascending Dose - 300 mg|
62846188|NCT04349800|EXPERIMENTAL|Single Ascending Dose - 600 mg|
62846189|NCT04349800|EXPERIMENTAL|Formulation Screen|
62846190|NCT04349800|EXPERIMENTAL|Food Effect|
62846191|NCT05591235|ACTIVE_COMPARATOR|Metformin|
62846192|NCT05591235|ACTIVE_COMPARATOR|Fixed-dose combination of metformin and pioglitazone (500mg metformin plus 15mg pioglitazone)|
62846193|NCT05591235|ACTIVE_COMPARATOR|Dapagliflozin|
62846194|NCT06354816|EXPERIMENTAL|A: dominant/ Saline solution isotonic 0.9% NaCl - non-dominant/Xylocaine 10% pump spray|"Vessel at the dorsum manus: dominant/ placebo - non-dominant/ LA (Local anaesthesia)~Forearm/cubita: dominant/ placebo - non dominant/ LA (Local anaesthesia)"
62846195|NCT06354816|EXPERIMENTAL|B: non-dominant/ Saline solution isotonic 0.9% NaCl - dominant/ Xylocaine 10% pump spray|"Vessel at the dorsum manus: non-dominant/ placebo - dominant/ LA (Local anaesthesia)~Forearm/cubita: non-dominant/ placebo - dominant/ LA (Local anaesthesia)"
62846196|NCT06354816|EXPERIMENTAL|C: non-dominant/ Xylocaine 10% pump spray - dominant/ Saline solution isotonic 0.9% NaCl|"Vessel at the dorsum manus: non-dominant/ LA (Local anaesthesia)- dominant/ placebo~Forearm/cubita: non-dominant/ LA (Local anaesthesia) - dominant/ placebo"
62846197|NCT06354816|EXPERIMENTAL|D: dominant/ Xylocaine 10% pump spray - non-dominant/ Saline solution isotonic 0.9% NaCl|"Vessel at the dorsum manus: dominant/ LA (Local anaesthesia) - non-dominant/ placebo~Forearm/cubita: dominant/ LA (Local anaesthesia) - non-dominant/ placebo"
62447817|NCT03279679|EXPERIMENTAL|costoclavicular group|patients in this group are assigned to receive ultrasound-guided costoclavicular infraclavicular block with 0.5% ropivacaine for upper limb surgery at elbow joint and below
62447818|NCT03279679|OTHER|paracoracoid group|patients in this group are assigned to receive ultrasound-guided paracoracoid infraclavicular block with 0.5% ropivacaine for upper limb surgery at elbow joint and below
62619996|NCT06356324|EXPERIMENTAL|Television intervention|Participants instructed to watch a 20 minute segment of a relaxing home improvement show (e.g., House Hunters)
62619997|NCT06356324|NO_INTERVENTION|Control|Participants instructed to wait in their preoperative room with no added stimulus intervention (i.e., music or television)
62619998|NCT01439490|EXPERIMENTAL|FES-PET|Patients undergo FES-PET prior to obtaining histology
62619999|NCT01990768|EXPERIMENTAL|1 gram Tranexamic Acid (TXA)|Loading dose of 1 gram TXA given prior to hospital arrival followed by a 1 gram TXA infusion over 8 hours after hospital arrival
62620000|NCT01990768|EXPERIMENTAL|2 grams TXA|Loading dose of 2 gram TXA given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival
62846198|NCT04058132|OTHER|Group 1: acute/subacute Traumatic Brain Injury|Any gender, age 18-55 years who have had a traumatic brain injury within 30 days
62846199|NCT04058132|OTHER|Group 2: Non-TBI healthy control (HC)|Any gender, age 18-55 years with no history of traumatic brain injury
62846200|NCT06030570||Subjects with low back pain|Patients of University Hospitals Leuven participating in the interdisciplinary spine rehabilitation program (REVITA)
62846201|NCT06520293|EXPERIMENTAL|Beverage containing Serendipity Berry Sweet Protein|Single dose of 400 ml beverage containing Serendipity Berry Sweet Protein to be consumed in less than 15 minutes. The beverage will be at a similar sweet potency as 75 grams glucose.
62846202|NCT06520293|OTHER|Beverage containing glucose|Single dose of 400 ml beverage containing 75 grams glucose to be consumed in less than 15 minutes.
62846203|NCT06520293|OTHER|Beverage containing Stevia|Single dose of 400 ml beverage containing Stevia to be consumed in less than 15 minutes. The beverage will be at a similar sweet potency as 75 grams glucose.
62846204|NCT01900717|ACTIVE_COMPARATOR|chimiotherapy alone|"* LV5FU2 simplified,~* 5-fluorouracil/leucovorin with oxaliplatin 4 (FOLFOX) simplified,~* fluorouracil, leucovorin, and irinotecan(FOLFIRI) modified."
62846205|NCT01900717|EXPERIMENTAL|chemiotherapy + bevacizumab 5 mg/kg/ 2 weeks|"* LV5FU2 simplified,~* FOLFOX 4 simplified,~* FOLFIRI modified.~* Bevacizumab 5 mg/kg/ 2 weeks"
62846206|NCT00960570|ACTIVE_COMPARATOR|Efavirenz Alone|Baseline Efavirenz pharmacokinetics.
62846207|NCT00960570|EXPERIMENTAL|Efavirenz with Steady State Fenofibric Acid|Efavirenz pharmacokinetics in the presence of steady state Fenofibric Acid.
62846208|NCT02865707|EXPERIMENTAL|Prebiotic|Prebiotic group will take 15 grams of prebiotic product Synergy-1 per day for 6 months. Synergy-1 is chicory-derived β-fructans inulin plus FOS (1:1). During the first two weeks the patient is advised to take 7.5 g of the product at breakfast only. Starting in week 3 until the end of the treatment the participant will take 7.5 g at breakfast and 7.5 g at dinner for a total of 6 months, or until you experience a flare.
62059843|NCT04879199|EXPERIMENTAL|Spastic Cerebral Palsy (sCP) children|Static stability and Dynamic stability measurement in children with: 1) between the age of 7 and 18 years, 2) with the diagnosis of spastic CP or CP similar (both unilateral and bilateral), functionally classified level I or II according to the Gross Motor Function Classification System (GMFCS) \[98\], 3) being able to stand and walk alone without assistance or assistive devices, 4) able to place their feet flat on the force platforms, and 5) with enough German language skills to follow the instructions.
62059844|NCT06621966|EXPERIMENTAL|experimental|
62263609|NCT05778058|EXPERIMENTAL|Unilateral Stimulation|"After evaluating with 7 different parameters on the first, second, third and fourth days of the protocol, the participants in all groups will be asked to do cycling exercise with maximum performance for 30 minutes under the same wattage load.~It will be re-evaluated after the cycling exercise application. After the assessment is complete, stimulation will be given with Vagustim non-invasively for 30 minutes. After vagus nerve stimulation, a re-evaluation will be made and the protocol for that day will be terminated.~With the Vagustim device, vagus nerve stimulation will be applied in one ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably."
62263610|NCT05778058|EXPERIMENTAL|Bilateral Stimulation|"After evaluating with 7 different parameters on the first, second, third and fourth days of the protocol, the participants in all groups will be asked to do cycling exercise with maximum performance for 30 minutes under the same wattage load.~It will be re-evaluated after the cycling exercise application. After the assessment is complete, stimulation will be given with Vagustim non-invasively for 20minutes. After vagus nerve stimulation, a re-evaluation will be made and the protocol for that day will be terminated.~With the Vagustim device, vagus nerve stimulation will be applied in bilateral ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably."
62263611|NCT05778058|SHAM_COMPARATOR|Bilateral Sham Stimulation|"After evaluating with 7 different parameters on the first, second, third and fourth days of the protocol, the participants in all groups will be asked to do cycling exercise with maximum performance for 30 minutes under the same wattage load. Bisiklet egzersiz uygulaması sonrasında tekrar değerlendirilecektir.~It will be re-evaluated after the cycling exercise. After the assessment is complete, sham stimulation with Vagustim for 20 minutes will be given non-invasively. After vagus nerve stimulation, a re-evaluation will be made and the protocol for that day will be terminated."
62263612|NCT02376270|EXPERIMENTAL|Pectin|This group will receive 7.5 grams of pectin supplements twice daily for four weeks.
62263613|NCT02376270|PLACEBO_COMPARATOR|Maltodextrin|This group group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
62263614|NCT04070742|EXPERIMENTAL|FMX-101|
62620001|NCT01990768|PLACEBO_COMPARATOR|0.9% Sodium Chloride injectable|Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival
62620002|NCT01893268||Cohort|
62620003|NCT03038776|EXPERIMENTAL|1|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen)
62620004|NCT03038776|EXPERIMENTAL|2|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-1 adjuvant
62620005|NCT03038776|EXPERIMENTAL|3|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-2 adjuvant
62620006|NCT03038776|EXPERIMENTAL|4|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) antigen
62846209|NCT02865707|PLACEBO_COMPARATOR|Placebo|Placebo group will take 15 grams of maltodextrin per day for 6 months. Maltodextrin is a sugar adsorbed in the small bowel with no effect on the colonic intestinal microbiota. During the first two weeks the patient is advised to take 7.5 g of the product at breakfast only. Starting in week 3 until the end of the treatment the participant will take 7.5 g at breakfast and 7.5 g at dinner for a total of 6 months, or until you experience a flare.
62059845|NCT01231139|EXPERIMENTAL|Paracetamol|Paracetamol dissolved in 0.9% Sodium Chloride
62059846|NCT01231139|PLACEBO_COMPARATOR|0.9% Sodium Chloride|0.9% Sodium Chloride
62059847|NCT05770830||Esophageal temperature|Esophageal temperature
62059848|NCT05770830||Skin core temperature|Skin core temperature
62059849|NCT01003665||Intensive Care treatement|ASA status 3 or 4 patients with invasive blood pressure measurement on the intensive care unit
62263615|NCT01536600||BIAsp 30 users|
62263616|NCT06402708|ACTIVE_COMPARATOR|Radiotherapy Arm|Radiotherapy (50Gy/25f), IMRT
62263617|NCT06402708|EXPERIMENTAL|Chemoradiotherapy Arm|2 cycle of chemotherapy, and then radiotherapy of 50Gy/25f，and then another 2 cycle of chemotherapy
62263618|NCT02960828|EXPERIMENTAL|"Intervention-Device:_Laser"|"* Subthreshold focal photocoagulation~* Intravitreal Anti-vascular endothelial growth factor (Anti-VEGF) injection"
62263619|NCT02960828|NO_INTERVENTION|Control|Contralateral eye
62263620|NCT02526342|ACTIVE_COMPARATOR|Negative Pressure Wound Therapy|Patients receive a Negative Pressure Wound Therapy-Dressing (V.A.C. Ultra (KCI®,San Antonio, Texas, USA) with a subatmospheric pressure of 125mmHg to cover the muscle flap for five days following surgery.
62620007|NCT03038776|EXPERIMENTAL|5|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-1 adjuvant
62620008|NCT03038776|EXPERIMENTAL|6|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-2 adjuvant
62263621|NCT02526342|NO_INTERVENTION|Conventional Dressing|Patients receive a conventional dressing for the muscle flap including fatty gauze and cotton gauze.
62263622|NCT03580252||Preterm Infant Neurological Follow-Up|"Preterm infants \<37 weeks' gestational age (GA) at birth admitted to the neonatal nurseries at the Abha Private Hospital in Kingdom of Saudi Arabia. This project aims to recruit 50 infants \<37weeks at birth over a 1-year stating from march 2018.~A Correlation analyses for the outcomes with initial regular medical practice of MRI/Ultrasound and Hammersmith assessment."
62263623|NCT04255264||Study patients|Obese subjects scheduled to undergo abdominoplasty surgery are included. These are later classified according to metabolic status.
62263624|NCT01747642|ACTIVE_COMPARATOR|Oncoxin|Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
62263625|NCT01747642|ACTIVE_COMPARATOR|Oncoxin & Suranix|Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
62263626|NCT01747642|NO_INTERVENTION|Supportive treatment|Only supportive treatment. No chemotherapy, radoiotherapy, ablation or surgical intervention will be carried out.
62263627|NCT00868777|EXPERIMENTAL|Sinus grafting using allogenic bone|
62620009|NCT05203679|EXPERIMENTAL|Arm of BBM-H901|1×10\^13 vg/kg, Single-dose treatment
62620010|NCT05152199|OTHER|Cystoscopy with use of obturator sheath|This intervention arm will include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy.
62620011|NCT05152199|ACTIVE_COMPARATOR|Cystoscopy without use of obturator sheath|This intervention arm will not include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy, but will consist of using the telescope under direct visualization.
62059850|NCT03837808|EXPERIMENTAL|Nimotuzumab|nimotuzumab 200mg/week in concurrent with IMRT
62059851|NCT03837808|ACTIVE_COMPARATOR|Cisplatin|cisplatin 40mg/m2/week in concurrent with IMRT
62620012|NCT04187716|EXPERIMENTAL|Ferinject|"For patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.~Patients using targeted therapies can be dosed at any time after recognizing Hb 8.0-10.5g / dL and injecting 1000 mg of ferinject."
62620013|NCT04187716|OTHER|remedies|Treatment for anemia will include remedies such as iron (oral or intravenous), hematopoietic accelerators, and blood transfusions, and will be determined by researchers at each institution to provide optimal treatment for patients.
62620014|NCT00963846|PLACEBO_COMPARATOR|placebo|
62846210|NCT04726969|EXPERIMENTAL|Arm A: moxidectin and albendazole|Combination therapy of moxidectin (8 mg, i.e. 4 tablets of 2 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
62263628|NCT04523311|EXPERIMENTAL|Hypnosis + usual care|An online, group-based, single session hypnosis workshop followed by 2 weeks of self hypnosis. Participants will continue with whatever usual care they receive/undertake.
62263629|NCT04523311|OTHER|Waitlist control + usual care|The control group will receive no intervention beyond whatever usual care they receive/undertake. After the study is complete, they will be offered the option of participating in the hypnosis intervention.
62620015|NCT00963846|EXPERIMENTAL|huperzine 0.2 mg BID|
62263630|NCT05294055|EXPERIMENTAL|lymphoma, chemotherapy plus Mecapegfilgrastim SC on day 2|
62620016|NCT00963846|EXPERIMENTAL|huperzine 0.4 mg BID|
62620017|NCT00963846|EXPERIMENTAL|huperzine 0.8 mg BID|
62620018|NCT06323213|EXPERIMENTAL|610 group|Subjects will receive 610 for 52 weeks.
62620019|NCT06323213|PLACEBO_COMPARATOR|placebo group|Subjects will receive placebo for 52 weeks.
62263631|NCT05294055|EXPERIMENTAL|lymphoma, chemotherapy plus Mecapegfilgrastim SC on day 5|
62263632|NCT05294055|EXPERIMENTAL|myltiple myeloma, chemotherapy plus Mecapegfilgrastim SC on day 2|
62263633|NCT05294055|EXPERIMENTAL|myltiple myeloma, chemotherapy plus Mecapegfilgrastim SC on day 5|
62263634|NCT01438580|EXPERIMENTAL|standard intensity warfarin group|Eligible 80 patients(83.14±4.05,33.0%)with chronic NVAF were randomly assigned to this group and the target international normalised ratio(INR) was 2.1-3.0
62263635|NCT01438580|EXPERIMENTAL|low intensity warfarin group|Eligible 81 patients(84.0±4.71,33.5%)with chronic NVAF were randomly assigned to this group and the target international normalised ratio(INR) was 1.5-2.0
62263636|NCT01438580|ACTIVE_COMPARATOR|aspirin group|Eligible 81 patients(83.4±5.13,33.5%)with chronic NVAF were randomly assigned to this group and 100mg aspirin was administrated every day
62263637|NCT04945070|EXPERIMENTAL|iGlarLixi|Subjects switched from MDI to iGlarLixi
62263638|NCT04945070|ACTIVE_COMPARATOR|Control|Patients continuing with previous MDI
62263639|NCT04081350|ACTIVE_COMPARATOR|10 µg/kg LY3471851|Participants received subcutaneous (SC) injection of 10 microgram per kilogram (μg/kg) LY3471851 every 2 weeks for a treatment period of 12 weeks.
62263640|NCT04081350|ACTIVE_COMPARATOR|12 µg/kg LY3471851|Participants received subcutaneous injection of 12 μg/kg LY3471851 every 2 weeks for a treatment period of 12 weeks.
62620020|NCT00631163|EXPERIMENTAL|Deferasirox|Participants received initial dose of 20 milligrams per kilogram (mg/kg) Deferasirox tablets was administered orally once daily (OD) based on the Participants body weight. The dose of Deferasirox was adjusted to either 10 mg/kg or 30 mg/kg based on the volumes of blood transfusions being administered.
62620021|NCT03006263|EXPERIMENTAL|Totally Laparoscopic Total Gastrectomy|Totally Laparoscopic Total Gastrectomy will be performed for the treatment of patients assigned to this group.
62620022|NCT03006263|EXPERIMENTAL|Laparoscopy Assisted Total Gastrectomy|Laparoscopy Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
62620023|NCT06150729||OnabotulinumtoxinA|Participants will receive OnabotulinumtoxinA as prescribed by their physician.
62620024|NCT03633916|EXPERIMENTAL|Intervention|Classroom sensitization session (plus school-level sensitization activities)
62620025|NCT03633916|ACTIVE_COMPARATOR|Control|School-level sensitization activities only
62620026|NCT06002256|ACTIVE_COMPARATOR|Group 1 : Mostafa Maged maneuver|The first step in the Mostafa Maged maneuveur step is placing the right hand to the posterior fornix of vaginal canal trying to put pressure on the cervix and the lower part of uterus compressing the anterior and posterior walls of the lower uterine segment. The second point is placing the left hand over the fundus of the uterus and the posterior wall of the uterus from the abdominal part of the pregnant mother (the side of the abdominal skin). The third step is trying to grasp the whole uterus by the two hands abdominally and vaginally against the symphysis pubis as if the uterus is containing or surrounding the symphysis pubis bone, and in this way, getting the anterior and posterior walls of the uterus against each other (compression achieved)
62620027|NCT06002256|OTHER|Group 2 : bimanual uterine compression|"Both maneuver s are performed immediately after the delivery of the placenta and foetus, with no uterotonics administered at the onset of these maneuver s. In the event of atony after hand release due to fatigue, 5 IU of oxytocin is administered intravenously as uterotonics.~the clinician places one hand on the abdomen and the other hand inside the vagina then compresses the uterus between the two hands."
62620028|NCT01392456|ACTIVE_COMPARATOR|Retentive Anchor Group|23 fully edentulous patients will receive Retentive Anchors (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
62620029|NCT01392456|ACTIVE_COMPARATOR|Magnet Group|23 fully edentulous patients will receive Magnets (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
62620030|NCT01392456|ACTIVE_COMPARATOR|Locator Group|23 fully edentulous patients will receive Locator (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
62620031|NCT01543737|ACTIVE_COMPARATOR|Single injection hyaluronic acid|3ml hyaluronic acid (DUROLANE)
62620032|NCT01543737|ACTIVE_COMPARATOR|Three injection hyaluronic acid|2ml hyaluronic acid (HYALGAN)
62620033|NCT01065298||Group 1:Stem cell Recipient|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of \>0.4U/Kg for blood glucose control. They will undergo stem cell therapy initialy and G-CSF therapy at 2 months
62620034|NCT01065298||Group-2: Controls|Type 2 Diabetes mellitus patients on full doses of vildagliptin+metformin+pioglitazone and on Insulin \>0.4U/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1.
62620035|NCT02951793||AUDIT-C > 4|Significant alcohol use within 1 year prior to ICU admission (AUDIT-C\>4)
62059852|NCT06215001|EXPERIMENTAL|EFL Positive - intervention|Patients with Expiratory flow limitation will undergo a positive end-expiratory pressure trial to assess the level of positive end-expiratory pressure that eliminates the Expiratory Flow limitation. Positive end-expiratory pressure will be therefore set according to this value.
62059853|NCT06215001|ACTIVE_COMPARATOR|EFL Positive - control group|Patients with Expiratory flow limitation will undergo a positive end-expiratory pressure trial to assess the level of positive end-expiratory pressure that eliminates the Expiratory Flow limitation. Positive end-expiratory pressure will be set at a fixed level of 4 cmH2O.
62620036|NCT02951793||AUDIT-C <=4|No significant alcohol use within 1 year prior to ICU admission (AUDIT-C: equal or less than 4)
62620037|NCT02951793||Smoking history positive last year|Who smoke cigarette within 1-year prior to ICU admission
62620038|NCT02951793||Smoking history negative last year|Who did not smoke cigarette within 1-year prior to ICU admission
62620039|NCT02951793||Prior psychotropic medication use - yes|Who used psychotropic medication within 1-year prior to ICU admission
62620040|NCT02951793||Prior psychotropic medication use - no|Who did not use psychotropic medication within 1-year prior to ICU admission
62620041|NCT05401487||Adult patient with a severe trauma requiring SMUR activation|Trauma defined by appearance of lesions following a fall, a road accident, a burn or the penetration of a foreign body and regulated by one of the SAMU PACA region centres (84, 83, 13, 04)
62846211|NCT04726969|PLACEBO_COMPARATOR|Arm B: albendazole|Placebo (for moxidectin, 4 tablets) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
62263641|NCT04081350|ACTIVE_COMPARATOR|24 µg/kg LY3471851|Participants received subcutaneous injection of 24 μg/kg LY3471851 every 2 weeks for a treatment period of 12 weeks.
62263642|NCT04081350|PLACEBO_COMPARATOR|Placebo|Participants received subcutaneous injection of placebo every 2 weeks for a treatment period of 12 weeks.
62263643|NCT06282042|EXPERIMENTAL|TEER + OMT|Early transcatheter edge-to-edge mitral valve repair (TEER) plus optimal medical treatment
62263644|NCT06282042|OTHER|OMT|Optimal medical treatment
62620042|NCT05309330||Participants with CeD|Participants diagnosed with CeD will be observed prospectively for CeD symptom patterns over a 3-month period.
62620043|NCT05034835|EXPERIMENTAL|With compression garments|Usual care in day hospitals, i.e. 3 occupational therapy sessions / week for 3 months, with the usual protocol of desensitization by Aquaroll (hydro-massage ball device) and by Vibralgic (device generating electronic transcutaneous vibrations) + wearing a compression garment for 3 months.
62620044|NCT05034835|OTHER|Without compression garments|Usual care in day hospitals, i.e. 3 occupational therapy sessions / week for 3 months, with the usual protocol of desensitization by Aquaroll (hydro-massage ball device) and by Vibralgic (device generating electronic transcutaneous vibrations).
62059854|NCT06215001|NO_INTERVENTION|EFL negative patients|Patients with negative positive end-expiratory pressure test (no expiratory flow limitation) will be treated according to the current evidence and followed up for 7 days after surgery to evaluate the incidence of pulmonary postoperative complications.
62059855|NCT06492161|EXPERIMENTAL|GT3X ActiGraph's activity monitor|Patients who have undergone thoracic surgery wearing an ActiGraph GT3X-BT device that measures and records physical movement associated with daily activity.
62059856|NCT05375955|EXPERIMENTAL|Atopic Dermatitis PF-07038124 0.01% ointment|Atopic Dermatitis
62059857|NCT05375955|PLACEBO_COMPARATOR|Atopic Dermatitis Vehicle ointment|Atopic Dermatitis
62059858|NCT05375955|EXPERIMENTAL|Atopic Dermatitis PF-07038124 0.03% ointment|Atopic Dermatitis
62059859|NCT05375955|EXPERIMENTAL|Plaque Psoriasis PF-07038124 0.01% ointment|Plaque Psoriasis
62059860|NCT05375955|EXPERIMENTAL|Plaque Psoriasis PF-07038124 0.03% ointment|Plaque Psoriasis
62263645|NCT06262958|ACTIVE_COMPARATOR|Treatment as usual|Clients are receiving normal adolescent psychiatric care, mostly psychotherapy, medications, or both.
62846212|NCT04726969|EXPERIMENTAL|Arm C: ivermectin and albendazole|Combination therapy of ivermectin (Stromectol®, 200 µg/kg using tablets of 3 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
62059861|NCT05375955|EXPERIMENTAL|Plaque Psoriasis PF-07038124 0.06% ointment|Plaque Psoriasis
62059862|NCT05375955|PLACEBO_COMPARATOR|Plaque Psoriasis Vehicle ointment|Plaque Psoriasis
62059863|NCT05254444|NO_INTERVENTION|Group 1: Control|No activities will take place in group 1.
62059864|NCT05254444|EXPERIMENTAL|Group 2: Social Marketing|Households in this arm will receive a multi-tiered social marketing campaign focusing on sustainable fish nutrition, dietary diversity and food safety.
62059865|NCT05254444|EXPERIMENTAL|Group 3: Social Marketing + Gear Modification|Households in this arm will receive a bundled intervention of the social marketing campaign as well as modified fishing gear (basket traps with fish escape gaps) and training on proper utilization and management.
62059866|NCT06210906||Sips of water|Patients taking sips of water within 1 hour in preoperative fasting
62620045|NCT06371937||study controls|Healthy control participants (n=50) aged 80 and older enrolled in the study with no known CVD or history of significant medical problems.
62620046|NCT06371937||cardiovascular disease|Participants with cardiovascular disease (n=150)
62846213|NCT01892839|EXPERIMENTAL|high dialysate flow, larger dialyzer|high dialysate flow, larger dialyzer
62059867|NCT06210906||No sips of water|Patients not taking sips of water within 1 hour in preoperative fasting
62059868|NCT04366726|EXPERIMENTAL|abaloparatide-sMTS|Abaloparatide-sMTS 300 micrograms (μg) was applied to the thigh for 5 minutes once daily for 29 days.
62059869|NCT05842785|EXPERIMENTAL|Phase I Dose escalation|100 microgram (μg), 200 μg, 400 μg, 800 μg, 1600 μg, and 3200 μg of TSN222 as a single agent in subjects with advanced solid tumors or lymphomas.
62059870|NCT05842785|EXPERIMENTAL|Phase II-HNSCC|Patients with advanced squamous cell carcinoma of head and neck (HNSCC).
62059871|NCT05842785|EXPERIMENTAL|Phase II-Advanced melanoma|patients with the advanced melanoma.
62059872|NCT05842785|EXPERIMENTAL|Phase II-solid tumors or lymphomas.|patients with advanced other types of solid tumors or lymphomas.
62620047|NCT05624216|EXPERIMENTAL|BTL-084 Treatment|Radiofrequency and targeted pressure energy devices for the treatment of cellulite
62620048|NCT02495818|EXPERIMENTAL|Lidocaine|Suprascapular nerve block with infusion of 5ml lidocaine at 2%, guided by Ultrasound combined with homemade exercises (Codman and Hughston exercises).
62620049|NCT02495818|SHAM_COMPARATOR|Saline solution|Intervention with suprascapular nerve block with 5ml saline solution guided by Ultrasound combined with homemade exercises (Codman and Hughston exercises).
62620050|NCT00988819||No treatment|
62059873|NCT05787613|EXPERIMENTAL|HLX26 MTD + serplulimab 300 mg + chemotherapy intravenous infusion Q3W|In this group, HLX26 (MTD) in combination with HLX10 (300 mg) and chemotherapy will be intravenously administered every 3 weeks. About 40 subjects will be enrolled in this cohort. Patients will be treated with until disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first). The efficacy of HLX26 (MTD) in combination with Serplulimab and chemotherapy will be evaluated in this group.
62059874|NCT05787613|EXPERIMENTAL|HLX26 MTD-1 + serplulimab 300 mg + chemotherapy intravenous infusion Q3W|In this group, HLX26 (MTD-1) in combination with HLX10 (300 mg) and chemotherapy will be intravenously administered every 3 weeks. About 40 subjects will be enrolled in this cohort. Patients will be treated with until disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first). The efficacy of HLX26 (MTD-1) in combination with Serplulimab and chemotherapy will be evaluated in this group.
62263646|NCT06262958|EXPERIMENTAL|e-form of ASSIST alcohol and substance use mini-intervention|Clients are receiving normal adolescent psychiatric care, mostly psychotherapy, medications, or both. In addition to that, they will receive a mini-intervention for substance and alcohol use.
62620051|NCT01033708|ACTIVE_COMPARATOR|treatment as usual|Treatment as usual
62620052|NCT01033708|EXPERIMENTAL|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
62059875|NCT05787613|PLACEBO_COMPARATOR|placebo + serplulimab 300 mg + chemotherapy intravenous infusion Q3W|In this group, placebo in combination with HLX10 (300 mg) and chemotherapy will be intravenously administered every 3 weeks. About 40 subjects will be enrolled in this cohort. Patients will be treated with until disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first). The efficacy of Serplulimab and chemotherapy will be evaluated in this group.
62620053|NCT00978341|EXPERIMENTAL|Pregabalin|
62620054|NCT00978341|OTHER|Placebo|
62620055|NCT02540122|ACTIVE_COMPARATOR|Subject A (Neophytes)|Subjects will wear the Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, and Marketed Contact Lens 4 for a 6-hour period in a bilateral and random fashion, with a washout period of one week between lenses. Each subject will randomly be assigned to one of four unique sequences of a 4 x 4 crossover design. A block size of two sequences will be used.
62620056|NCT02540122|ACTIVE_COMPARATOR|Subject B (Habitual Lens Wearers)|Subjects will wear the Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, and Marketed Contact Lens 4 for a 6-hour period in a bilateral and random fashion, with a washout period of one week between lenses. Each subject will randomly be assigned to one of four unique sequences of a 4 x 4 crossover design. A block size of two sequences will be used.
62620057|NCT05262855|EXPERIMENTAL|68Ga-FAPI-46 PET/CT|Patients receive \[68Ga\]FAPI-46 intravenously followed by PET/CT 15-25 minutes later
62620058|NCT01146015|EXPERIMENTAL|1|
62620059|NCT02801981|EXPERIMENTAL|Sequence 1: GSK2230672 10mg, 30mg, 90mg, and Placebo|Subjects will receive GSK2230672 10 mg in period 1, GSK2230672 30 mg in Period 2, GSK2230672 90 mg in Period 3 and placebo in period 4.
62620060|NCT02801981|EXPERIMENTAL|Sequence 2:GSK2230672 10mg, 30mg, Placebo, and GSK2230672 90mg|Subjects will receive GSK2230672 10 mg in period 1, GSK2230672 30 mg in Period 2, placebo in period 3, and GSK2230672 90 mg in period 4.
62059876|NCT05958498|ACTIVE_COMPARATOR|Group I|who will receive intrusive arches after leveling and alignment assisted with i-PRF according to standardized protocol
62059877|NCT05958498|ACTIVE_COMPARATOR|Group II|Will includes 9 patients who will receive intrusive utility arches after leveling and alignment assisted with (MOPs) according to standardized protocol.
62059878|NCT06439056|EXPERIMENTAL|Single dose of NEX-22-01|The trial is single ascending dose study where the dose is escalated depending on previous cohorts PK data.
62620061|NCT02801981|EXPERIMENTAL|Sequence 3:GSK2230672 10mg, Placebo, GSK2230672 90mg and 180mg|Subjects will receive GSK2230672 10 mg in period 1, placebo in Period 2, GSK2230672 90 mg in Period 3 and GSK2230672 180 mg in period 4.
62620062|NCT02801981|EXPERIMENTAL|Sequence 4: Placebo, GSK2230672 30mg, 90mg and 180mg|Subjects will receive placebo in period 1, GSK2230672 30 mg in Period 2, GSK2230672 90 mg in Period 3 and GSK2230672 180 mg in period 4.
62059879|NCT04422613|EXPERIMENTAL|characterization of pulmonary damage|This clinical trial will be characterized the pulmonary damage after COVID-19 pneumonia
62059880|NCT03819582|EXPERIMENTAL|Intraocular lens|Subjects implanted with the EyeCee One Intraocular lens
62059881|NCT02295566|ACTIVE_COMPARATOR|Nitric Oxide Group|Inhaled Nitric Oxide delivered via nasal canulae at 10ppm for 8 hours a night for 7 nights.
62059882|NCT02295566|PLACEBO_COMPARATOR|Control Group|Air/oxygen mix (according to clinical need) delivered via nasal canulae for 8 hours a night for 7 nights.
62059883|NCT01005303|PLACEBO_COMPARATOR|Placebo|
62059884|NCT01005303|ACTIVE_COMPARATOR|Micronutrient|
62059885|NCT04465825|ACTIVE_COMPARATOR|Interspersing HITT in exercise|We will test whether introducing HITT into an acute exercise bout will increase overall energy expenditure or time to fatigue.
62059886|NCT04465825|NO_INTERVENTION|Acute exercise bout with no HITT|Exercise will occur at 50% peak without introducing HITT.
62620063|NCT00652808|ACTIVE_COMPARATOR|Arm 1|
62620064|NCT00652808|ACTIVE_COMPARATOR|Arm 2|
62620065|NCT04351477|EXPERIMENTAL|Massage chair group|Use mechanical massage chair for 20 minutes/1 session, 3 sessions/week, for 3 weeks
62620066|NCT04351477|NO_INTERVENTION|Control|No use of mechanical massage chair for 3 weeks
62620067|NCT02427243|EXPERIMENTAL|Crenezumab Formulation 2|A single dose given as two subcutaneous injections on Day 1
62620068|NCT02427243|EXPERIMENTAL|Crenezumab Formulation 3|A single dose given as two subcutaneous injections on Day 1
62620069|NCT03947593||Households with children under 13|Interviews conducted with the parent or guardian of a child or children under age 13.
62620070|NCT03947593||Home-based providers|Individuals who provide care in a home-based setting to children under age 13 who are not their own for five or more hours a week.
62620071|NCT03947593||Center-based providers|Directors of early care and education programs that provide care to children not yet in kindergarten.
62059887|NCT00993824|PLACEBO_COMPARATOR|Welchol then Placebo|3.75 grams of colesevelam HCl (Welchol) at evening meal for 12 weeks, and then crossover to placebo at evening meal for 12 weeks.
62059888|NCT00993824|PLACEBO_COMPARATOR|Placebo then Welchol|Placebo taken for 12 weeks at evening meal, and then crossover to 3.75 grams of colesevelam HCl taken at evening meal fro 12 weeks.
62059889|NCT05941325|EXPERIMENTAL|fruquintinib combined with envafolimab|
62059890|NCT04112225|ACTIVE_COMPARATOR|Positive affect condition|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
62059891|NCT04112225|SHAM_COMPARATOR|Psychoeducation condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
62059892|NCT03070717||All patients|Patients with diagnosis of high myopia secondary to an anterior-posterior elongation of the bulbus confirmed by ocular examination in either eye using specific criteria.
62059893|NCT03557086|EXPERIMENTAL|Advanced Care Planning Video Decision Support Tool|We designed a 3-minute advance care planning video to provide patients with advanced liver disease general understanding of the types of medical care patients may receive at the end of life (EOL) and a description of medical interventions such as hospitalizations, intensive care unit (ICU) admission, cardiopulmonary resuscitation (CPR), and intubation. The video begins by addressing the importance of the patient's personal goals and perspectives by asking the viewer to reflect on their concerns about getting sick and their overall goals for their EOL care. The physician narrator then introduces a framework for choices of medical care at the EOL including: 1) life-prolonging care; 2) limited medical care; and 3) comfort care followed by visual images illustrating each of these EOL care choices. All three sequences of video images accompanying the narration attempt to help the viewer imagine the experience and likely outcomes of receiving these medical interventions at the EOL.
62059894|NCT03557086|ACTIVE_COMPARATOR|Verbal Narrative Control|Immediately after completing baseline assessments and randomization, patients assigned to the verbal narrative control arm will listen to the same description of the 3 goals of care used in the video arm read out by a research assistant
62059895|NCT04850404|EXPERIMENTAL|the group of abdominal nerve block combined with moderate NMB|The patients of group N-M received the rectus abdominis block combined with transverse plane block.
62059896|NCT04850404|NO_INTERVENTION|moderate NMB group|The patients of group M received moderate NMB through the surgery.
62059897|NCT04384822|EXPERIMENTAL|Tai Chi Group|Subjects will participate in a tai chi program conducted in small groups (10 subjects per group) delivered by qualified instructors, who have experience in teaching tai chi to older adults. The tai chi intervention will be prescribed as a 3-month program with two 1-hour sessions weekly. Tai chi forms will be taught for 2 months followed by 1 month of consolidation. The 24-form simplified Yang-style tai chi will be adopted, as it is the most popular form of tai chi and older adults can manage to learn this simplified form of tai chi within 2-3 months. The instructors will introduce the safety issues, proper training principles, and skills to the subjects in their first class to minimize any avoidable adverse events due to improper skill/practice. The appropriate intensity will be individually determined for each subject by the attending instructors to achieve the training principle of progressive adaptation regarding the exercise intensity.
62059898|NCT04384822|ACTIVE_COMPARATOR|CBT-I Group|Subjects will participate in a conventional CBT-I program conducted in small groups (10 subjects per group) delivered by trained personnel. The CBT-I will be prescribed as a 3-month program with two 1-hour sessions weekly. The CBT-I components will be delivered for 2 months, which is consistent with the duration of the majority of CBT-I treatments, followed by 1 month of consolidation.
62620072|NCT03947593||Center-based workforce|Classroom-assigned instructional staff sampled from each center-based provider who completed an interview.
62059899|NCT01689584|OTHER|Covar|
62263647|NCT02111161|ACTIVE_COMPARATOR|IVIG (Privigen)|Intravenous polyspecific immunoglobulin G (Privigen). Dosage: 25 g/day (250 ml) for three consecutive days
62263648|NCT02111161|PLACEBO_COMPARATOR|Saline 0.9%|0.9% saline for Intravenous administration. Dosage: 250 ml for three consecutive days.
62263649|NCT04071821|EXPERIMENTAL|A: Test under Fasted Condition|Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fasted conditions
62263650|NCT04071821|ACTIVE_COMPARATOR|B: Reference under Fasted Condition|Reference: Single oral dose of cetirizine HCl oral tablets 10 mg, administered with approximately 240 mL of room temperature water, under fasted conditions
62620073|NCT05624736||Glioblastoma Group|Patients with the diagnosis of Glioblastoma based on 2021 WHO central nervous system tumor guideline.
62846214|NCT01892839|ACTIVE_COMPARATOR|low dialysate flow, smaller dialyzer|low dialysate flow, smaller dialyzer
62263651|NCT04071821|EXPERIMENTAL|C: Test under Fed Condition|Test: Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fed conditions
62263652|NCT04071821|EXPERIMENTAL|D: Test under Fasted Condition with No Water|Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with no water, under fasted conditions
62846215|NCT01085994||Procalcitonin-guided group|
62263653|NCT04071821|EXPERIMENTAL|E: Test Swallowed Whole with Water, under Fasted Condition|Single oral dose of cetirizine HCl Gummy 10 mg, swallowed whole, administered with approximately 240 mL of room temperature water, under fasted conditions
62263654|NCT02821507|EXPERIMENTAL|sirolimus and cyclophosphamide|combining sirolimus 4mg daily orally and cyclophosphamide 200mg day 1 to 7 and 15 to 21 orally in a 4 week schedule
62620074|NCT05624736||Astrocytoma Group|Patients with the diagnosis of Astrocytoma based on 2021 WHO central nervous system tumor guideline.
62620075|NCT05624736||Oligodendroglioma Group|Patients with the diagnosis of Oligodengroglioma based on 2021 WHO central nervous system tumor guideline.
62846216|NCT01085994||Routine practice group|
62620076|NCT05274087|EXPERIMENTAL|Group 1|Participants will receive Regimen A (15-minute autoinjector (AI) warm-up time) in Period 1, Regimen B (30-minute AI warm-up time) in Period 2 followed by Regimen C (45-minute AI warm-up time) in Period 3.
62620077|NCT05274087|EXPERIMENTAL|Group 2|Participants will receive Regimen B in Period 1, Regimen C in Period 2 followed by Regimen A in Period 3.
62620078|NCT05274087|EXPERIMENTAL|Group 3|Participants will receive Regimen C in Period 1, Regimen A in Period 2 followed by Regimen B in Period 3.
62620079|NCT03285165|ACTIVE_COMPARATOR|DEX I|Trauma Patients without TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
62620080|NCT03285165|ACTIVE_COMPARATOR|DEX II|Trauma Patients with TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
62620081|NCT03285165|ACTIVE_COMPARATOR|Propofol I|Trauma Patients without TBI received 10-70 mcg/kg/h propofol infusion.
62620082|NCT03285165|ACTIVE_COMPARATOR|Propofol II|Trauma Patients with TBI received 10-70 mcg/kg/h propofol infusion.
62620083|NCT03949738||Adult patients with ARDS|Adults patients fulfilling the Berlin criteria for ARDS
62620084|NCT04668872||Participants with colorectal cancer liver metastases|The study population is represented by patients with colorectal cancer liver metastases that have been deemed clinically appropriate/eligible to receive Y90 TARE for the management of their liver metastases.
62620085|NCT03556397|EXPERIMENTAL|cN0 before and after neoadjuvant th., SLNB - negative, no AD|Patients with cN0 before and after neoadjuvant therapy, SLNB - negative, without AD
62620086|NCT03556397|EXPERIMENTAL|cN0 before and after neoadjuvant th., SLNB - posit., AD|Patients with cN0 before and after neoadjuvant therapy, SLNB - positive, AD (separated histological examination of lymph nodes in levels I and II)
62620087|NCT03556397|EXPERIMENTAL|cN1 before neoadj. th., cN0 after neoadj. th., SLNB, AD|Patients with cN1 before neoadjuvant th., cN0 after neoadjuvant therapy, SLNB, AD (separated histological examination of lymph nodes in levels I and II)
62620088|NCT03556397|EXPERIMENTAL|cN1 after neoadjuvant therapy, SLNB, AD|Patients with cN1 after neoadjuvant therapy, SLNB, AD.
62620089|NCT04309487||ShuntCheck|Participants will be administered the ShuntCheck diagnostic test.
62620090|NCT01343784|ACTIVE_COMPARATOR|Standard Voiding Trial|Subjects in this group will undergo backfill-assisted voiding trial that involves infusing 300ml of fluid in the bladder, removing the catheter and allowing the patient to void. All subjects will be asked to use visual analog scale (VAS) to assess their force of stream (FOS) and the voided amount as well as post-void residual (PVR) (measured by the bladder ultrasound) will be measured and recorded. Subjects will be discharged without a catheter if the voided amount is more than 200ml, or 2/3rds of the infused volume (300ml).
62620091|NCT01343784|EXPERIMENTAL|Force of Stream Voiding Trial|Subjects in this group will undergo backfill-assisted voiding trial that involves infusing 300ml of fluid in the bladder, removing the catheter and allowing the patient to void. All subjects will be asked to use visual analog scale (VAS) to assess their force of stream (FOS) and the voided amount as well as post-void residual (PVR) (measured by the bladder ultrasound) will be measured and recorded. Subjects in the FOS group will be discharged home without a catheter if they are able to void any amount and report an FOS of at least 50% their typical FOS based on a visual analog scale
62620092|NCT02940015||Anonymous Sample Collection - Adults (ASCA)|Healthy Volunteers ages 18 and older
62620093|NCT03402425|EXPERIMENTAL|All included patients|A 18F-FET PET scan is performed
62620094|NCT02437643|PLACEBO_COMPARATOR|WL-LoEX|10% Weight loss diet plus low intensity exercise (protein \~0.8g/kg). Participants will be provided one serving of dairy protein daily.
62620095|NCT02437643|ACTIVE_COMPARATOR|Pro-WL-LoEX|Protein-enhanced 10% Weight loss diet plus low intensity exercise (protein \~1.2 g/kg with \> 30g per meal and \>60% as dairy). Participants will be provided at least 8 servings of dairy protein daily.
62620096|NCT00030966|EXPERIMENTAL|Group 1|Adding natalizumab monthly infusion to Avonex weekly injection for up to 116 weeks.
62620097|NCT00030966|PLACEBO_COMPARATOR|Group 2|Adding placebo monthly infusion to Avonex weekly injection for up to 116 weeks.
62620098|NCT00332774|EXPERIMENTAL|Nevanac|
62620099|NCT00332774|ACTIVE_COMPARATOR|Acular|
62620100|NCT00332774|PLACEBO_COMPARATOR|Vehicle|
62620101|NCT04350931|ACTIVE_COMPARATOR|BCG Vaccine|0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds (In Egypt, the available BCG vaccine is the Copenhagen BCG vaccine - The Danish Strain 1331 of Mycobacterium Bovis). Each 0.10 mL vaccine contains 200000-800000 colony forming units.
62620102|NCT04350931|PLACEBO_COMPARATOR|intradermal normal saline|placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds.
62620103|NCT06197477|EXPERIMENTAL|Air purification|The intervention will consist of air purification placed in the classrooms.
62620104|NCT06197477|SHAM_COMPARATOR|Control|Filtration will be turned off in the air purifier placed in the classrooms in the control part of the study.
62620105|NCT01085240|OTHER|Start Later|The participants receive the Mission Possible intervention but it is delayed by 3 months.
62620106|NCT01085240|EXPERIMENTAL|Start Now|The participants start the Mission Possible program right away.
62620107|NCT04858867|OTHER|Cohort 1|"Study procedures~* Lenvatinib during week 1-12~* rhTSH-stimulated I-124 dosimetry at week 0, 6 and 12~* rhTSH-stimulated I-131 therapy at week 13 (if eligible)~* Intra-therapeutic I-131 dosimetry at week 13 (if eligible)~* Biopsy at week 0 and 6~* F-18 FDG PET/CT at week 0, 6, 12, 24 and 36~* Tg levels at week 0, 6, 12, 24 and 36~* QoL assessment at week 0, 6, 12, 24 and 36"
62620108|NCT04858867|OTHER|Cohort 2|"Study procedures (in case of 12-wk lenvatinib):~* Lenvatinib during week 1-12~* rhTSH-stimulated I-124 dosimetry at week 0 and 12~* rhTSH-stimulated I-131 therapy at week 13 (if eligible)~* Intra-therapeutic I-131 dosimetry at week 13 (if eligible)~* Biopsy at week 0 and 6~* F-18 FDG PET/CT at week 0, 12, 24 and 36~* Tg levels at week 0, 6, 12, 24 and 36~* QoL assessment at week 0, 6, 12, 24 and 36~Study procedures (in case of 6-wk lenvatinib)~* Lenvatinib during week 1-6~* rhTSH-stimulated I-124 dosimetry at week 0 and 6~* rhTSH-stimulated I-131 therapy at week 13 (if eligible)~* Intra-therapeutic I-131 dosimetry at week 13 (if eligible)~* Biopsy at week 0 and 6~* F-18 FDG PET/CT at week 0, 6, 12, 24, 30 and 36~* Tg levels at week 0, 6, 12, 24, 30 and 36~* QoL assessment at week 0, 6, 12, 24, 30 and 36"
62620109|NCT03323697|EXPERIMENTAL|Herbal|SZ-05 (2.5 gr; 3 capsules twice a day)
62620110|NCT03323697|ACTIVE_COMPARATOR|Selective serotonin reuptake inhibitor|Escitalopram (10 mg capsule plus 5 placebo capsules)
62846217|NCT03788772|EXPERIMENTAL|Adults patients hospitalized in ICU|Adult patients hospitalized in the intensive care unit (ICU) for severe infections (sepsis and septic shock) or or non-septic shock (cardiogenic or hemorrhagic shock)
62846218|NCT04110535|EXPERIMENTAL|Remimazolam 5 mg|IV administration of remimazolam 5 mg
62846219|NCT04110535|EXPERIMENTAL|Remimazolam 10 mg|IV administration of remimazolam 10 mg
62620111|NCT00154375|EXPERIMENTAL|Imatinib mesylate + hydroxyurea (HU)|Imatinib was supplied as 100 mg and 400 mg tablets. Patients in the combination arm were instructed to take a daily oral imatinib dose of 600 mg (600 mg at lunch time) and a daily oral hydroxyurea (HU) dose of 1000 mg (500 mg twice daily; in the morning and at bed time). Every 6 weeks after randomization based on assessment of therapeutic response, either patients continued with above mentioned dosing regimen or switched to receive a daily dose of 800 mg imatinib with 1000 mg HU. Patients were instructed to split the intake, taking 400 mg imatinib with 500 mg HU in the morning, then the same in the evening.
62620112|NCT00154375|ACTIVE_COMPARATOR|Hydroxyurea alone|1500 mg/day of HU given as 500 mg 3 times daily. Every 6 weeks after randomization and based on assessment of therapeutic response, the patients were either switched to combination arm or continued in monotherapy arm of hydroxyurea.
62620113|NCT05430113|EXPERIMENTAL|Spinal Cord Stimulation|All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
62620114|NCT02869893|OTHER|Healthy Participants|MRCP with Secretin and MR elastography will be performed on all participants.
62620115|NCT01109134|EXPERIMENTAL|Tirofiban intracoronary bolus-only|Tirofiban bolus administered via intracoronary route at the time of primary PCI with no additional peri/postprocedural maintenance infusion
62846220|NCT04110535|ACTIVE_COMPARATOR|Midazolam 2.5 mg|IV administration of midazolam 2.5 mg
62846221|NCT04110535|ACTIVE_COMPARATOR|Midazolam 5 mg|IV administration of midazolam 5 mg
62846222|NCT04110535|PLACEBO_COMPARATOR|Placebo|Saline injection
62846223|NCT01563133|OTHER|Lymph nodes, pancreatic masses & cysts|
62846224|NCT06332417|EXPERIMENTAL|Intervention group|Ba-Duan-Jin Exercise + FET (Forced Expiratory Technique)
62846225|NCT06332417|ACTIVE_COMPARATOR|Control Group|FET (Forced Expiratory Technique) only
62846226|NCT04677413|EXPERIMENTAL|Phase I Dose Cohorts|"DOSE LEVEL 1 : 30 Gy (tumor)/ 25 Gy (pelvis)~DOSE LEVEL 2 : 35 Gy (tumor)/ 25 Gy (pelvis)~DOSE LEVEL 3 : 40 Gy (tumor)/ 25 Gy (pelvis)"
62846227|NCT02098122||Tetraplegia|
62846228|NCT02098122||Paraplegia|
62846229|NCT05515497|EXPERIMENTAL|BMT4me 2.0 Intervention Group|The intervention group will be receiving the BMT4me 2.0 app at discharge as the primary intervention.
62620116|NCT01109134|ACTIVE_COMPARATOR|Tirofiban intravenous bolus+infusion|Tirofiban bolus administered intravenously before PCI, followed by periprocedural maintenance infusion
62620117|NCT03616392|EXPERIMENTAL|Part 1: Group 1(Treatment A/Treatment B)|Period 1: Treatment A (D308 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO
62846230|NCT05515497|NO_INTERVENTION|BMT4me 2.0 Control Group|The control group will be receiving usual care at discharge. These participants will not be receiving the BMT4me 2.0 app.
62846231|NCT02784067|EXPERIMENTAL|Treatment|Subjects randomized to the active treatment arm will take Sucraid, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
62846232|NCT02784067|PLACEBO_COMPARATOR|Placebo|Subjects randomized to the placebo treatment arm will take Sucraid placebo, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
62846233|NCT01032889|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
62846234|NCT01032889|EXPERIMENTAL|Deoxycholic acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
62846235|NCT01032889|EXPERIMENTAL|Deoxycholic acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
62846236|NCT03883165|EXPERIMENTAL|high-intensity neck strengthening group|
62846237|NCT03883165|OTHER|Control group|
62846238|NCT01517425||Cases|Subjects previously enrolled in the Scripps Genebank Study
62846239|NCT01517425||Controls|Subjects previously enrolled in the Scripps Healthy Elderly Active Longevity (HEAL) Cohort
62846240|NCT00684060|EXPERIMENTAL|1|Participants will receive active stem cell infusion 2 to 3 weeks after a percutaneous coronary intervention (PCI).
62846241|NCT00684060|PLACEBO_COMPARATOR|2|Participants will receive placebo infusion (5% human serum albumin \[HSA\]) 2 to 3 weeks after a PCI.
62846242|NCT05170997|ACTIVE_COMPARATOR|Iodine Control|Participants taking an iodine-containing multivitamin or supplement and randomly allocated not to receive milk supply.
62846243|NCT05170997|ACTIVE_COMPARATOR|No Iodine Control|Participants not taking an iodine-containing multivitamin or supplement and randomly allocated not to receive milk supply.
62846244|NCT05170997|EXPERIMENTAL|Iodine Intervention|Participants taking an iodine-containing multivitamin or supplement and randomly allocated to receive milk supply.
62846245|NCT05170997|EXPERIMENTAL|No Iodine Intervention|Participants not taking an iodine-containing multivitamin or supplement and randomly allocated to receive milk supply.
62263655|NCT04254068|EXPERIMENTAL|Parent based prevention|Parent-Based Prevention (PBP; Sadeh-Sharvit \& Lock, 2018) is a manualized preventive intervention, focused on increasing parental awareness and competence to facilitate healthy eating habits, body image, and self-regulation in children whose parent has an eating disorder history. PBP is comprised of three phases that focus on unique goals. The strategies in each session include psycho-education, behavioral experiment planning, and skill practicing to augment parents' insight into how the context of the parental cognitions and behaviors may impact child outcomes, with the goal of creating a longstanding effect.
62263656|NCT04254068|NO_INTERVENTION|Usual care|Families randomized to usual care will be permitted to utilize any medical, psychological, or nutritional services they desire for the waitlist period of 16 weeks.
62620118|NCT03616392|EXPERIMENTAL|Part 1: Group 2(Treatment B/Treatment A)|Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment A (D308 1T)/day for 5days, QD, PO
62620119|NCT03616392|EXPERIMENTAL|Part 2: Group 1(Treatment C/Treatment B)|Period 1: Treatment C (CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO
62620120|NCT03616392|EXPERIMENTAL|Part 2: Group 2(Treatment B/Treatment C)|Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment C (CKD-501 1T)/day for 5days, QD, PO
62620121|NCT03838029|ACTIVE_COMPARATOR|Propranolol and etodolac|Both study medications will be given orally for an intervention phase of 35 days as follows. Etodolac:400mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery and the following morning, 40 mg PO bid for following 6.5 days, and 20 mg PO bid for next 22 days.
62620122|NCT03838029|PLACEBO_COMPARATOR|Placebo|Same schedule as in the active comparator arm
62620123|NCT03685500|ACTIVE_COMPARATOR|Arm 1|Patients who postpone switching from ABC/3TC/DTG to Symtuza® (TAF/FTC/DRV/c) four weeks
62620124|NCT03685500|EXPERIMENTAL|Arm 2|Patients who switch from ABC/3TC/DTG to Symtuza® (TAF/FTC/DRV/c) during the baseline visit
62620125|NCT03326115|EXPERIMENTAL|Peer Visitation Program (PVP)|Participants in this group will begin participation in the Peer Visitation Program (PVP) beginning at amputation date with the initiation window ranging from immediately pre-operative to 7 days post operative.
62620126|NCT03326115|NO_INTERVENTION|Delayed Peer Visitation (NoPVP)|Not participating in a Peer Visitation Program for 60 days post-operatively, followed by participation and completion in a PVP 60 days later than the PVP group for a total of 120 days.
62620127|NCT03488563|EXPERIMENTAL|B244 Dose 1|B244 1X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
62620128|NCT03488563|EXPERIMENTAL|B244 Dose 2|B244 4X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
62620129|NCT03488563|PLACEBO_COMPARATOR|Vehicle|Vehicle, 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
62263657|NCT02260115|EXPERIMENTAL|LABS™|hydrogel sprayed laparoscopically over all pelvic areas of surgical trauma
62059900|NCT01834443|EXPERIMENTAL|GVS CL|Transmastoid galvanic vestibular stimulation is applied, with the cathode placed on the left mastoid
62620130|NCT03992677||Brugada VF|Confirmed Brugada Syndrome by either Spontaneous or drug induced Type 1 ECG, confirmed cardiac arrest or appropriate ICD therapy for potentially lethal arrhythmia.
62620131|NCT03992677||Brugada relative|Relatives of Brugada syndrome patients with proven no pathology by Ajmaline challenge
62620132|NCT03992677||Ventricular ectopy|Patients undergoing ablation with ECGi system for other arrhythmias -these patients will be similar to our original controls and provide a repeat set of controls.
62620133|NCT03992677||Ischaemic VF|Out-of-hospital cardiac arrest primary PCI with full recovery of left ventricular function and full revascularisation (n=10) - the purpose of this group is to confirm that the changes detected in our SCD group are not secondary to the SCD event. These are patients who have had a cardiac arrest secondary to coronary occlusion, but have made a full recovery with normal LGE-MRI and no indication for ICD.
62620134|NCT00559663|ACTIVE_COMPARATOR|GT|The green tea group is given initially green tea treatment and then after a washout period of four weeks switched to the dark chocolate treatment.
62846246|NCT02451384|EXPERIMENTAL|routine surgery|In this arm the patients will be performed routine surgery to remove the tumors. And then we compare their circulating tumor cell countings in the pre and post-operation.
62059901|NCT01834443|EXPERIMENTAL|GVS CR|Transmastoid galvanic vestibular stimulation is applied, with the cathode placed on the right mastoid
62059902|NCT01834443|SHAM_COMPARATOR|GVS Sham|Transmastoid galvanic stimulation set-up is applied, with only 30s of stimulation
62059903|NCT02302131||pulmonary valve replacement|SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection
62059904|NCT06339580|EXPERIMENTAL|VT-NMD arm|all patients will be trialed on volume targeted non invasive ventilation
62620135|NCT00559663|ACTIVE_COMPARATOR|DC|The dark chocolate group is given initially dark chocolate treatment and then after a washout period of four weeks switched to the green tea treatment.
62620136|NCT01607853|EXPERIMENTAL|Daivobet® gel|
62846247|NCT02451384|EXPERIMENTAL|no-touch surgery|In this arm the patients will be performed no-touch surgery to remove the tumors. And then we compare their circulating tumor cells countings in the pre and post-operation.
62059905|NCT03501329||Outpatients in Community Psychiatry|"Treatment with consultations, social support, psychological and psychopharmacological treatment. This is routine psychiatric care.~Treatment was not changed as a result of the investigation in itself."
62059906|NCT02234063|EXPERIMENTAL|Immediate Genetic Testing|Participants randomized to intervention will receive the APOL1 genetic test upon study enrollment.
62620137|NCT02849171|EXPERIMENTAL|high-grade glioma|Eligible patients must have undergone standard radiation (typically 60Gy in 30 fractions), with or without concurrent drug therapy, and have MRI findings consistent with tumor progression and/or pseudoprogression within 24 weeks after completion of radiation. Eligible patients will undergo an 11C-CH PET study within 2 weeks of the standard of care MRI that shows changes concerning for tumor progression vs. pseudoprogression. All patients will then be followed with surveillance brain MRI with and without contrast as per standard of care for a period of 11 months, to assess further progression or stabilization of the lesion. Initial MRI changes are considered to represent pseudoprogression/treatment related changes if the lesion stabilizes or becomes smaller without a change in tumor-related therapy. Otherwise, it will be considered a recurrence should there be progessive radiographic changes.
62620138|NCT01209247|ACTIVE_COMPARATOR|patient treated by fluoroquinolone|patient treated by fluoroquinolone. Nasal, rectal and pharyngeal swabs
62620139|NCT01209247|PLACEBO_COMPARATOR|patient not receiving FQ treatment|reference group of patients not receiving FQ treatment, but hospitalized in the same wards at the same time
62620140|NCT02360748|EXPERIMENTAL|single|Pilot Study in which patients will be adding food items to improve their nutritional status
62620141|NCT04247451|EXPERIMENTAL|Interventional group|"Nutritional intake: these data will be evaluated daily during preoperative hospitalization, at home, and during the actual hospitalization, from surgical intervention to discharge. Before the follow-up consultation, patients will keep a food diary. The dieticians will calculate intake and need.~Metabolic data: body composition using BIA (Nutrilab Akern) and REE using indirect calorimetry (Cosmed Q NRG) will be analyzed in three timepoints: preoperative, postoperative and at follow-up consultation. This measurements take maximum ten minutes and do not cause discomfort to the participants."
62846248|NCT02451384|EXPERIMENTAL|laparoscopy surgery|In this arm the patients will be performed laparoscopy surgery to remove the tumors. And then we compare their circulating tumor cells countings in the pre and post-operation.
62846249|NCT05820906|EXPERIMENTAL|Cadonilimab+rego+Gem/Cis|
62846250|NCT05008900|EXPERIMENTAL|Surveillance|Patients with early biochemical relapse of prostate cancer following radical prostatectomy who have a PSA greater than or equal to 0.1 to less than 0.3 ng/mL with negative PSMA PET/CT will go on surveillance. Routine PSA will be conducted and a repeat PSMA PET/CT imaging will be conducted when the PSA rises to greater than 0.5 to less than 1.0 ng/mL.
62846251|NCT05008900|NO_INTERVENTION|Salvage radiotherapy|Patients with early biochemical relapse of prostate cancer following radical prostatectomy who have a PSA of greater than or equal to 0.1 to less than 0.3 ng/mL with negative PSMA PET/CT will receive salvage radiotherapy to the prostate bed. This radiotherapy may or may not include the pelvic lymph nodes.
62846252|NCT01119079|PLACEBO_COMPARATOR|Standard labor epidural protocol|Standard labor epidural protocol
62059907|NCT02234063|NO_INTERVENTION|Control- Delayed Testing|Participants randomized to control will not receive the APOL1 genetic test upon study enrollment. They will be offered the option to take the test during their final follow-up study visit (12 months post enrollment).
62059908|NCT00959062|EXPERIMENTAL|clonidine|
62059909|NCT00959062|PLACEBO_COMPARATOR|placebo|
62059910|NCT01406704|NO_INTERVENTION|Control|
62059911|NCT01406704|EXPERIMENTAL|Rosiglitazone|Rosiglitazone (8 mg/day)
62059912|NCT01406704|EXPERIMENTAL|alpha-lipoic acid|alpha-lipoic acid (1800 mg/day)
62620142|NCT04144868|EXPERIMENTAL|Experimental: NBO group|"For eligible patients into the group of cerebral hemorrhage,Low-flow oxygen is delivered through the facemask at a rate of 8 L/min, once a hour, every 4 hours.~Regular treatment is based on associated guidelines for ICH ."
62846253|NCT01119079|EXPERIMENTAL|10ml Normal Saline prior to lidocaine|
62846254|NCT00003496|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62846255|NCT03722277|EXPERIMENTAL|Variable load training|"The participants will be training two times per week in 10 weeks. Training will consist of variable load training in knee flexion- and extension.~Training will be based on symptoms in isometric strength at five different angles of flexion- and extension."
62846256|NCT03722277|ACTIVE_COMPARATOR|Conventional strength training|The participants will be training two times per week in 10 weeks. Training will consist of a training programme consisting of strength training with rubber bands for hip and knee.
62059913|NCT01406704|EXPERIMENTAL|Rosiglitazone/alpha-lipoic acid|combination of Rosiglitazone (8 mg/day) and alpha-lipoic acid (1800 mg/day)
62059914|NCT02055560||PK-Guided Cohort|CRC patients who were treated with 5-FU containing therapy regimen where 5-FU dosing was monitored and optimized using PK-guided dose adjustment.
62059915|NCT02055560||BSA Cohort|CRC patients who were treated with 5-FU containing therapy regimen where 5-FU dosing was done according to body surface area (BSA) and no PK monitoring was performed.
62059916|NCT01785563|EXPERIMENTAL|Nasal NIV-NAVA|Infants will be transitioned from their current mode of ventilation to nasal NIV-NAVA. If patients are currently on nasal NIV-NAVA an increase in the NAVA level will be utilized for the intervention.
62059917|NCT05705999|ACTIVE_COMPARATOR|Active rTMS|Patients receiving active rTMS
62059918|NCT05705999|SHAM_COMPARATOR|Sham rTMS|Patients receiving sham rTMS
62059919|NCT01927679|OTHER|Antioxidant (LB) + control (UB)|Antioxidant will be weighed and applied to an area on the lower back (LB) to be exposed with visible light at a concentration of 2 mg/cm\^2. Control will also be weighed and applied to an area of the upper back (UB) to be exposed with visible light at a concentration of 2 mg/cm\^2. These will be applied according to the randomization scheme.
62263658|NCT02260115|SHAM_COMPARATOR|Surgical Control|Laproscopic Surgery Only
62059920|NCT01927679|OTHER|Antioxidant (UB) and Control (LB)|Antioxidant will be weighed and applied to an area on the upper back (UB) to be exposed with visible light at a concentration of 2 mg/cm\^2. Control will also be weighed and applied to an area of the lower back (LB) to be exposed with visible light at a concentration of 2 mg/cm\^2. These will be applied according to the randomization scheme.
62620143|NCT04144868|NO_INTERVENTION|Control group|"Low-flow oxygen is delivered through the facemask at a rate of 2 L/min, once a hour, every 4 hours.~Regular treatment is based on associated guidelines for ICH ."
62620144|NCT00921206|ACTIVE_COMPARATOR|VAX102 given i.m.|Universal influenza candidate vaccine
62263659|NCT00338039|EXPERIMENTAL|Chemotherapy + Chemoradation|Systemic chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. Cetuximab 500 mg/m\^2 intravenous (IV)/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy. Induction Therapy Gemcitabine 1 gm/m\^2 over 100 minutes every 2 weeks +/-1 day for 4 doses; Induction Chemotherapy Oxaliplatin 100 mg/m\^2 over 120 minutes every 2 weeks +/-1 day for 4 doses. Capecitabine Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m\^2 by mouth (PO) twice daily Monday-Friday throughout radiation. Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.
62263660|NCT02005809|ACTIVE_COMPARATOR|Second look endoscopy|This group is performed second look endoscopy about 24 hours later from endoscopic submucosal dissection.
62620145|NCT00921206|ACTIVE_COMPARATOR|VAX102 given s.c.|Universal influenza candidate vaccine
62846257|NCT03536416|EXPERIMENTAL|Asthma workshop and theatre group|My Asthma in School. This group will receive the self-management workshops for asthmatic children and the theatre performance for the whole year group.
62263661|NCT02005809|NO_INTERVENTION|without second look endoscopy|This group is not performed second look endoscopy after ESD
62846258|NCT03536416|ACTIVE_COMPARATOR|Theatre only group|My Asthma in School. This group will receive the theatre performance only.
62846259|NCT03536416|NO_INTERVENTION|Control group|My Asthma in School. The control group will receive usual care for the duration of the intervention.
62846260|NCT05750771|EXPERIMENTAL|DCB Group|Implantation of drug-coated balloons in patients with satisfactory pretreatment
62059921|NCT04191109||1|Subacute stroke patients admitted to an inpatient rehabilitation facility.
62263662|NCT04451980||HIV+ non-diabetics|HIV-infected participants with hemoglobin A1c (HbA1c) \<5.7% or fasting glucose \<100 mg/dl.
62263663|NCT04451980||HIV+ pre-diabetics|HIV-infected participants with HbA1c 5.7-6.4% or fasting glucose 100-125 mg/dl.
62263664|NCT04451980||HIV+ diabetics|HIV-infected participants with HbA1c \>=6.5% or fasting glucose \>=126 mg/dl or on anti-diabetic medications.
62263665|NCT04451980||HIV-negative diabetics|HIV-negative participants with HbA1c \>=6.5% or fasting glucose \>=126 mg/dl or on anti-diabetic medications.
62263666|NCT03767023||Stable AAA|"= patients with a small abdominal aortic aneursym diameter \< 55 mm "
62263667|NCT03767023||instable AAA|"=patients with a large abdominal aortic aneursym diameter \> 55 mm and/or AAA with rapid growth who needs open surgery or EndoVascular Aneurysm Repair EVAR"
62059922|NCT05548439|EXPERIMENTAL|Group G1|33 participants aged 18-64 years to receive two doses of VBI-2901a at 5 µg per dose at Day 1 and Day 56.
62263668|NCT05378256|OTHER|Clinical scales of CIPN|Patients with lymphoma will be evaluated before chemotherapy (T1), after 4 cycles (T2), at the end of the chemotherapy treatment (If more than 4 cycles) (T3) and 6 month after the end of chemotherapy (T4).
62263669|NCT01358864|ACTIVE_COMPARATOR|Placebo/PegIFN/RBV|patient to receive two capsules identical to those containing BI201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks
62263670|NCT01358864|EXPERIMENTAL|BI201335 12 weeks|patient to receive two capsules containing BI 201335 once a day for 12 weeks and PegIFN/RBV for 48 weeks
62059923|NCT05548439|EXPERIMENTAL|Group G2|33 participants aged 18-64 years to receive two doses of VBI-2901a at 10 µg per dose at Day 1 and Day 56.
62059924|NCT05548439|EXPERIMENTAL|Group G3|33 participants aged 18-64 years to receive one dose of VBI-2901a at 10 µg per dose at Day 1.
62059925|NCT02458001|EXPERIMENTAL|SAFFRON stepped care|3 level intervention: level 1:Self help booklet level 2: CNS delivered intervention level 3: psychologist delivered intervention
62620146|NCT04605718|EXPERIMENTAL|Part 1 (SAD)|Due to mandatory sentinel dosing, participants will be divided into two groups: 2 participants will be dosed on one day (sentinel group with 1 on active treatment and 1 on placebo) and remaining participants of the dose cohort (randomized as 5 on active treatment and 1 on placebo) at the earliest 24 hours after the first dosing occasion.
62620147|NCT04605718|EXPERIMENTAL|Part 2 (MAD)|In each dose cohort, a minimum of 4 participants and a maximum of 12 participants will receive either multiple IV doses of RO72232809 or placebo once-daily for 10 days (3:1 ratio of active:placebo treatment).
62620148|NCT04605718|EXPERIMENTAL|Part 3 (Elderly)|In this cohort, a minimum of 4 participants and a maximum of 12 participants will receive a single IV dose of RO7223280 or placebo (3:1 ratio of active:placebo treatment).
62846261|NCT05750771|EXPERIMENTAL|DES Group|Implantation of drug-eluting stents in patients with satisfactory pretreatment
62846262|NCT00006205|EXPERIMENTAL|Ondansetron|Ondansetron + cognitive behavioral therapy
62846263|NCT00006205|EXPERIMENTAL|Topiramate|Topiramate + cognitive behavioral therapy
62846264|NCT00006205|PLACEBO_COMPARATOR|Placebo|Placebo + cognitive behavioral therapy
62846265|NCT00006205|EXPERIMENTAL|Ondansetron + Topiramate|Ondansetron + Topiramate + cognitive behavioral therapy
62059926|NCT02458001|NO_INTERVENTION|enhanced treatment as usual (ETU)|level 1 intervention: self help booklet Non study trained CNS will offer assessment, advice, vaginal dilator training where appropriate, arrange topical oestrogens or other creams
62059927|NCT01648621|EXPERIMENTAL|Case Management|In addition to usual care, the intervention group will receive case management that includes: 40 minute standardized education session, an individualized action plan, an individualized care plan for management of COPD and comorbidities, standardized reinforcement/motivational interviewing and action plan teach-back sessions and assessment of symptoms, progress and problems, and problem solving by phone weekly for 12 weeks, then monthly for 9 months (21 sessions), tele-home monitoring, coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and CCAC facilitated by the case manager, priority access to ambulatory clinics.
62059928|NCT01648621|ACTIVE_COMPARATOR|Usual care|Usual care for these patients comprises: Dictated patient summary, referral to an 8 week in-hospital rehabilitation and self-management education program, referral to a smoking cessation program (as applicable), individualized action plan developed with treating respirologist at the discretion of the attending respirologist, Referral to web based educational materials and resources.
62620149|NCT05792137|EXPERIMENTAL|High saturated fat challenge meal followed by high mono-unsaturated fat challenge meal|High saturated fat mixed macronutrient challenge meal with palm oil followed by high mono-unsaturated fat mixed macronutrient challenge meal with olive oil two weeks later
62263671|NCT01358864|EXPERIMENTAL|BI201335 24 weeks|patient to receive two capsules containing BI 201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks
62263672|NCT01620242|EXPERIMENTAL|Cabazitaxel|All patients are treated with Cabazitaxel.
62620150|NCT05792137|EXPERIMENTAL|High mono-unsaturated fat challenge meal followed by high saturated fat challenge meal|High mono-unsaturated fat mixed macronutrient challenge meal with olive oil followed by high saturated fat mixed macronutrient challenge meal with palm oil two weeks later
62620151|NCT00571753|EXPERIMENTAL|Test|Isoniazid dose adapted according to NAT2 status i.e. appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively
62620152|NCT00571753|ACTIVE_COMPARATOR|Control|Treatment with standard isoniazid dose (appr. 5 mg/kg b.w.)
62620153|NCT00287521|EXPERIMENTAL|AL-37807 Suspension|
62620154|NCT00287521|ACTIVE_COMPARATOR|Xalatan|
62846266|NCT03869008|SHAM_COMPARATOR|Sham Device Group|"15 patients will be randomized to the Sham device for the first half of the treatment window then switch to the gammaCore Sapphire device (study device) for the rest of the study.~The Sham device will look exactly like the gammaCore Sapphire device but will not deliver non invasive vagus nerve stimulation."
62846267|NCT03869008|EXPERIMENTAL|gammaCore Sapphire (Study Device) Group|15 patients will be randomized to the gammaCore Sapphire device for the full length of the treatment window.
62846268|NCT04988503|EXPERIMENTAL|Second-generation hydrogel coil group|Treatment using second-generation hydrogel coils (had to constitute \> 50% of the total coil length) for ruptured cerebral aneurysms
62846269|NCT04988503|ACTIVE_COMPARATOR|Bare platinum coil group|Treatment using bare metal coil only for ruptured cerebral aneurysms
62846270|NCT05236088|EXPERIMENTAL|NMES group|Neuromuscular electrical stimulation (NMES) will be applied with INNOVO brand (Atlantic Therapeutics, Galway, Ireland) device for 30 minutes 3 days a week during 4 weeks
62846271|NCT05236088|SHAM_COMPARATOR|Sham group|Sham group will be applied from the same device (INNOVO brand (Atlantic Therapeutics, Galway, Ireland)), for 3 days a week for 30 minutes during 4 weeks, but no current will be given from the device.
62846272|NCT03193827|EXPERIMENTAL|study group|In this group in-line filters (Pall, Dreieich, Germany) are connected to peripheral vascular access and used during anaesthesia and the following 96 postoperative hours.
62846273|NCT03193827|ACTIVE_COMPARATOR|control group|Patients randomised to standard care are managed without an in-line filter and according to local routine practice for intravenous drug administration in the adult patient.
62846274|NCT01173289|EXPERIMENTAL|External Beam Radiotherapy|"Definition of target volume:~* Gross tumor volume (GTV) = gross tumor defined with intravenous bolus contrast administration given CT scan~* Clinical target volume (CTV) = GTV + included volumes of clinical and suspected subclinical involvement (draining lymph nodes)~* Planning target volume (PTV) = CTV + 5-10 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning :~* Total dose 65 Gy for gross tumor, 62.4 Gy for microscopic involved area, 58.5 Gy for high risk lymph node area and 52 Gy for elective lymph node area in 26 fractions during 6 weeks~* Dose prescription: 90% isodose volume of prescribed dose encompassed PTV~* The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the esophagus, lung, contralateral normal thyroid, arytenoids, vocal cord and spinal cord, etc., was calculated."
62846275|NCT01666795||IVIG therapy in ITP|IVIG therapy in untreated adults with severe ITP
62846276|NCT03412240|EXPERIMENTAL|Anti tachycardia pacing|
62846277|NCT00888043|OTHER|I|CNTO 95 and avastin
62846278|NCT02956200|EXPERIMENTAL|fingolimod with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with fingolimod.
62846279|NCT02956200|NO_INTERVENTION|standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy.
62846280|NCT05687669|EXPERIMENTAL|Group GTN|Glyceryl trinitrates (GTN) is infused to patients with severe hypertensive preeclampsia till oral anti-hypertensives and Magnesium sulfate loadings lower blood pressure
62846281|NCT05687669|EXPERIMENTAL|Group Phentolamine|Phentolamine is infused to patients with severe hypertensive preeclampsia till oral anti-hypertensives and Magnesium sulfate loadings lower blood pressure
62846282|NCT02648256|EXPERIMENTAL|Oropharyngeal rinse|"Polymerase Chain Reaction on Oropharyngeal rinse:~Dosage of Pneumocystis jiroveci will be performed on the broncho-alveolar lavage following the usual routine diagnosis.~Polymerase Chain Reaction will be performed on the broncho-alveolar lavage and the oropharyngeal rinse (not communicated to the clinician result) in the same series, in order to compare the results of the fungal quantification."
62263673|NCT00000421|ACTIVE_COMPARATOR|Prednisone arm|Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.
62263674|NCT00000421|PLACEBO_COMPARATOR|Placebo|Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.
62263675|NCT02191254|EXPERIMENTAL|Antistax®|1 tablet per day for 12 weeks
62263676|NCT02191254|PLACEBO_COMPARATOR|Placebo|
62263677|NCT02383732|EXPERIMENTAL|Treatment|Pediatric subjects between the age of 4-12 years with autistic spectrum disorder and elopement will begin the Elopement Prevention and Safety Training (EPST) program. EPST includes up to 12 120-minute weekly sessions delivered over approximately 12-14 weeks. EPST is a modular treatment, with three components: 1) Universal Safety Measures (USM), 2) Proximity training, and 3) Check-in training. All participants receive the USM module in the first two sessions. They then receive either the Proximity training or Check-in training module depending on the type of elopement exhibited by the child (i.e., bolting vs. wandering).
62263678|NCT02383732|ACTIVE_COMPARATOR|Waitlist Control|Pediatric subjects between the age of 4-12 years with autistic spectrum disorder and elopement will be assigned to the Waitlist Control group. The subjects will be offered the intervention after completion of the 12-week waiting period. The subjects will then begin the Elopement Prevention and Safety Training (EPST) program. EPST includes up to 12 120-minute weekly sessions delivered over approximately 12-14 weeks. EPST is a modular treatment, with three components: 1) Universal Safety Measures (USM), 2) Proximity training, and 3) Check-in training. All participants receive the USM module in the first two sessions. They then receive either the Proximity training or Check-in training module depending on the type of elopement exhibited by the child (i.e., bolting vs. wandering).
62263679|NCT01880931|EXPERIMENTAL|Normotensive patients|To find out the effect site concentration of remifentanil for preventing QTc prolongation \< 15 sec during intubation : Dixon's up-and-down method
62263680|NCT01880931|EXPERIMENTAL|Hypertensive patients|To find out the effect site concentration of remifentanil for preventing QTc prolongation \< 15 sec during intubation : Dixon's up-and-down method
62263681|NCT04195152||Difficult intubation group|An intubation is called difficult if a normally trained anesthesiologist needs more than 3 attempts or more than 10 min for a successful endotracheal intubation.
62263682|NCT04195152||Non difficult intubation group|An intubation is called non difficult if a normally trained anesthesiologist needs only one attempt for a successful endotracheal intubation.
62263683|NCT02069405|EXPERIMENTAL|Music Group plus normal standard of care|Patients will listen to music prior and during the scan
62263684|NCT02069405|NO_INTERVENTION|Control Group - Normal standard of care|
62263685|NCT00116350|EXPERIMENTAL|Misoprostol|800 mcg sublingual misoprostol
62447819|NCT00829413|OTHER|Patients who received SonoVue|"Patients with at least one target lesions requiring work-up for characterization to undergo~* Unenhanced ultrasound of the target lesion (UE-US): gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion using commercially available ultrasound equipment and standard techniques (B-mode or Harmonic imaging) to study the anatomy of the target lesion and surrounding parenchyma;~* SonoVue-enhanced ultrasound of the target lesion (CE-US):procedures described in protocol Section 7.5.1.2, to study the lesion vascularity in comparison to the surrounding parenchyma; and~* Truth standard~2.4 mL of sulfur hexafluoride microbubbles (SonoVue®) will be administered as a bolus injection in a peripheral vein."
62447820|NCT04936971|EXPERIMENTAL|Everolimus|"Kidney transplant induction with Rabbit Anti-Thymocyte globulin (rATG) as per local practice.~Kidney transplant manteinance treatment with Tacrolimus (TAC) to achieve 4-6 ng/mL trough levels, Everolimus (EVL) to achieve 3-8 ng/mL trough levels and Corticosteroids (CS) as per local practice."
62620155|NCT00287521|PLACEBO_COMPARATOR|AL-37807 Vehicle|
62059929|NCT04280523|EXPERIMENTAL|ESR-specific PET Scan|"Specific Aim: To test the hypothesis that among PAH patients, higher lung ESR density associates with a more severe hemodynamic profile and worse 1 year outcomes.~Study Design: Enroll 20 randomly selected subjects from each group (PAH vs. control)"
62059930|NCT05240430||stem cell application; Group I disease 0-7. days,|In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group I disease 0-7. days,
62620156|NCT00287521|EXPERIMENTAL|Timolol Maleate|
62059931|NCT05240430||stem cell application; Group II; 8-14 days of the disease. days|In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group II; 8-14 days of the disease. days
62059932|NCT05240430||stem cell application; Group III; those applied on the 15th day and after.|In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group III; It will be divided into 3 groups as those applied on the 15th day and after.
62263686|NCT00116350|ACTIVE_COMPARATOR|Oxytocin|40 IU Oxytocin IV
62263687|NCT05908682||Study Cohort|Subjects who have been treated with Brexafemme (Ibrexafungerp) at any time during pregnancy or whose conception is estimated to have occurred within four days after receiving the last dose of Brexafemme.
62263688|NCT03617991|EXPERIMENTAL|Exercise Group|Participants will be provided an 8-week home exercise program that they will complete. The participants will also be provided all of the equipment. An investigator will contact them weekly to ensure compliance and send You Tube videos with new Phases.
62620157|NCT02598778|ACTIVE_COMPARATOR|Chlorhexidine gluconate (0.12%)|An oral rinse given to pediatric patients in routine practice within the standard of care.
62620158|NCT02598778|ACTIVE_COMPARATOR|Sodium Fluoride (0.05%)|An oral rinse given to pediatric patients in routine practice within the standard of care.
62620159|NCT02598778|PLACEBO_COMPARATOR|Paraffin wax chewing gum (sugar-free)|A food product. Minimum of 2 minutes of chew time prior to salivary sample being obtained.
62620160|NCT02598778|PLACEBO_COMPARATOR|Deionized water|Water that has had the majority of its ions removed.
62846283|NCT02405442|EXPERIMENTAL|Andecaliximab 150 mg Every 2 Weeks|Double-Blind Phase: Participants will receive 1 single-use prefilled syringe (PFS) of andecaliximab 150 mg and matching placebo coadministered at Weeks 0, 2, 4, and 6 and 2 single-use PFS of placebo coadministered at Weeks 1, 3, 5, and 7. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
62846284|NCT02405442|EXPERIMENTAL|Andecaliximab 150 mg Weekly|Double-Blind Phase: Participants will receive 1 single-use PFS of andecaliximab 150 mg and matching placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
62846285|NCT02405442|EXPERIMENTAL|Andecaliximab 300 mg Weekly|Double-Blind Phase: Participants will receive 2 single-use PFS of andecaliximab 150 mg coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
62846286|NCT02405442|PLACEBO_COMPARATOR|Placebo|Double-Blind Phase: Participants will receive 2 single-use PFS of placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
62059933|NCT05914402|EXPERIMENTAL|Observation group( Axillary surgical evaluation is spared)|Breast cancer patients with initial axillary metastasis（T1-3N1-3M0） who are preparing for neoadjuvant therapy(NAT)，including neoadjuvant chemotherapy, targeted therapy, immunotherapy, etc. will received imaging examination（MRI、mammography、ultrasonography）at baseline and after every two cycles of NAT before surgery, dedicated breast/lymph positron emission tomography(DB/L-PET) at baseline and after first 1-2 cycle of NAT. We have developed a prediction model, which includes clinical parameters, pathological parameters, imaging examination parameters and DB/L-PET to predict the probability of complete pathological remission of axillary lymph nodes after receiving NAT. If the probability is more than 90%, the process of axillary surgical evaluation will be spared. If the probability is 50% -90%, Sentinel lymph node biopsy will be performed. If the probability is less than 50%, standard axillary lymph node dissection will be performed.
62059934|NCT05083325|EXPERIMENTAL|Oseltamivir Phosphate Test Product|Participants will receive one capsule of the test formulation containing Oseltamivir 75 mg. The capsules will be taken with water and in a fasting condition.
62059935|NCT05083325|ACTIVE_COMPARATOR|Oseltamivir Phosphate Referent Product|Participants will receive one capsule of the marketed reference containing Oseltamivir 75 mg. The capsules will be taken with water and in a fasting condition.
62059936|NCT02456701|EXPERIMENTAL|Combination of Vemurafenib and KTN3379|Vemurafenib 960 mg po bid KTN3379 1000 mg IV q2weeks
62263689|NCT03617991|NO_INTERVENTION|Control Group|The control group will be contacted weekly to check on health status.
62620161|NCT03250247|EXPERIMENTAL|Endovascular Therapy - Intervention|"All subjects (EVT and No-EVT Arms) will receive optimal PTS care. At each Clinical Center, this will be supervised by a physician experienced in managing PTS.~Subjects randomized to EVT will receive the following:~1. imaging-guided iliac vein stent placement, and~2. endovenous ablation of refluxing saphenous vein(s), if the patient has truncal reflux and is still symptomatic.~3. optimal PTS therapy: medical and compression, lifestyle interventions and venous ulcer care"
62620162|NCT03250247|NO_INTERVENTION|Non-Endovascular Therapy - Control|All subjects will receive optimal PTS care as noted above.
62620163|NCT05527899|PLACEBO_COMPARATOR|Placebo|½ RDA of micronutrients including 5 mg/d Zn
62059937|NCT05061537|EXPERIMENTAL|Monotherapy dose escalation (Part 1A)|Participants will receive PF-07263689 once a week for 4 doses
62263690|NCT02463409|EXPERIMENTAL|Theophylline|Patients will receive a 24 hour continuous infusion of intravenous theophylline.
62447821|NCT04936971|ACTIVE_COMPARATOR|Mycophenolate Mofetil|"Kidney transplant induction with Rabbit Anti-Thymocyte globulin (rATG) as per local practice.~Kidney transplant manteinance treatment with Tacrolimus (TAC) to achieve 4-6 ng/mL trough levels, Mycofenolate Mofetil (MMF) 500mg/bid and Corticosteroids (CS) as per local practice."
62620164|NCT05527899|EXPERIMENTAL|Zinc 30 mg|½ RDA of micronutrients including 30 mg/d Zn
62620165|NCT05527899|EXPERIMENTAL|Zinc 60 mg|½ RDA of micronutrients including 60 mg/d Zn
62620166|NCT03992898||Chronic hepatitis cohort|In this cohort, patients were defined as type A acute-on-chronic liver failure (ACLF) patients who have chronic liver disease but without cirrhosis.
62620167|NCT03992898||Cirrhosis cohort|In this cohort, patients were defined as type B and type C ACLF patients with cirrhosis.
62620168|NCT00441038|ACTIVE_COMPARATOR|1|Education on postural hygiene and handout of The Back Guide
62620169|NCT00441038|ACTIVE_COMPARATOR|2|Education on active management and handout of The Back Book
62620170|NCT00441038|ACTIVE_COMPARATOR|3|Education on cardiovascular and general health
62620171|NCT04511000|EXPERIMENTAL|Experimental group|
62620172|NCT04511000|ACTIVE_COMPARATOR|Comparator group|
62620173|NCT05395533|EXPERIMENTAL|Recombinant CD20 monoclonal antibody-MMAE conjugte for injection (TRS005)|To evaluate the safety and tolerability of TRS005 in patients with recurrent or refractory CD20-positive B-cell non-Hodgkin's lymphoma with treatment at one or more times, and to recommend the dose for phase II clinical trials (RP2D).
62620174|NCT05987592|EXPERIMENTAL|Brain Education and WELLness with Migraine Group A|8 weekly virtual sessions plus online platform
62846287|NCT04401683|EXPERIMENTAL|Digital Rehabilitation|Standard medical treatment + Fully remote rehabilitation program with a digital therapist
62059938|NCT05061537|EXPERIMENTAL|Combination dose escalation (Part 1B)|Participants will receive PF-07263689 intravenous (IV) once week for 4 doses in combination with sasanlimab subcutaneous (SC) once every 4 weeks
62263691|NCT02216032|EXPERIMENTAL|Treatment Group|We will deliver the TMW Curriculum to 106 Treatment families. The TMW Curriculum is comprised of 1) 12 educational modules, 2) animations and videos of real parent-child interactions to teach parents about the science behind child brain development, and model strategies for improving parents' child-directed speech, 3) video modeling and collaborative goal setting, and 4) quantitative linguistic feedback from Language ENvironment Analysis (LENA) recordings.
62263692|NCT02216032|OTHER|Control Group|We will deliver a Nutrition Curriculum to 100 Control families. The Nutrition Curriculum provides information about the importance of healthy nutrition for child development, strategies for healthy eating, and meal preparation.
62263693|NCT01870102|ACTIVE_COMPARATOR|Pelubiprofen IR (Pelubiprofen 30 mg)|
62447822|NCT06169098|EXPERIMENTAL|AA-SA|"Order: auricular acupressure on the left ear, auricular acupressure on the right ear, sham auricular acupressure on the left ear.~There will be a 30-minute break between each stage."
62263694|NCT01870102|EXPERIMENTAL|Pelubiprofen SR (Pelubiprofen 45 mg)|
62263695|NCT01870102|OTHER|Pelubiprofen SR (Pelubiprofen 45 mg) fasting condition|
62263696|NCT01870102|OTHER|Pelubiprofen SR (Pelubiprofen 45 mg) fed condition|
62447823|NCT06169098|EXPERIMENTAL|SA-AA|"Order: sham auricular acupressure on the left ear, auricular acupressure on the right ear, auricular acupressure on the left ear.~There will be a 30-minute break between each stage."
62447824|NCT02103088|EXPERIMENTAL|Sexual and urological intervention|Standard care and the PROCAN intervention consisting of i) DVD instruction in pelvic floor muscle training ii) group instructions in pelvic floor muscle training by physiotherapist including three individually follow-up and ii) up to six couple sessions performed by a sexual nurse counselor.
62447825|NCT02103088|NO_INTERVENTION|Control|Standard care consists of:systematic offer of medical treatment for erectile dysfunction, if not contra indicated. The medical treatment will consist of either daily treatment with Cialis 5 mg or phosphodiesterase type 5 inhibitor on demand before sexual activity. Alternatively use of alprostadil as either urethral pin or penile injection. Furthermore standard treatments include preoperative instruction in pelvic floor muscle training, regular outpatient visits and possible referral to rehabilitation in accordance with the rules that apply to the Danish Health legislations. In case of prolonged incontinence the patients may on request be referred to a private practicing physiotherapist.
62447826|NCT00805909|EXPERIMENTAL|NI-0401|5 daily infusions of escalating doses of NI-0401
62447827|NCT05650788|EXPERIMENTAL|Bipolar disorder group|Patients with a diagnosis of bipolar II mood disorder stabilized in remission, according to DSM 5 criteria, with mood stabilizer treatment (lithium, anticonvulsant or antipsychotic) at an effective dose, with possible antidepressant treatment (SSRI, SNRI, tricyclics )
62620175|NCT05987592|EXPERIMENTAL|Brain Education and WELLness with Migraine Group B|8 weekly virtual sessions plus online platform
62620176|NCT02851316|EXPERIMENTAL|Whole Body Vibration|The WBV intervention consists of 6 bouts of 60 seconds vibration with 2 minutes of rest in between (30Hz, 2g acceleration) while participants stand on a vibrating platform with their knees bent.
62620177|NCT02851316|NO_INTERVENTION|Control|The control intervention consists of 6 bouts of 60 seconds with 2 minutes of rest in between while participants stand with their knees bent (no vibration applied).
62620178|NCT02612545|ACTIVE_COMPARATOR|ACT|Patients randomized to ACT will receive DHA-PPQ only
62620179|NCT02612545|EXPERIMENTAL|TACT|Patients randomized to TACT will receive DHA-PPQ plus MQ
62620180|NCT05037890|ACTIVE_COMPARATOR|Plant sterol enriched margarine|20 grams plant sterol enriched margarine on a daily basis for a period of 6 months.
62846288|NCT04401683|ACTIVE_COMPARATOR|Conventional Rehabilitation|Standard medical treatment + Home-based rehabilitation program
62846289|NCT04380246||Clinicians|"Clinicians who care for pediatric patients \>50% of their time, who treat pediatric patients who are in acute pain and between 0 and 3 years of age. May include physicians, clinical pharmacists, nurse practitioners, physician assistants, and/or nurses.~This cohort will complete a qualitative interview about pain and distress in infants and young children."
62846290|NCT00620503|EXPERIMENTAL|Formulation A Fed|Single dose of Proellex 25 mg formulation A, fed
62059939|NCT05061537|EXPERIMENTAL|Dose expansion (Part 2) - Tumor specific Arm A|Participants will receive PF-07263689 IV once week for 4 doses in combination with sasanlimab SC once every 4 weeks
62059940|NCT05061537|EXPERIMENTAL|Dose expansion (Part 2) - Tumor specific Arm B|Participants will receive PF-07263689 IV once week for 4 doses in combination with sasanlimab SC once every 4 weeks
62059941|NCT05061537|EXPERIMENTAL|Dose expansion (Part 2) - Tumor specific Arm C|Participants will receive PF-07263689 IV once week for 4 doses in combination with sasanlimab SC once every 4 weeks
62846291|NCT00620503|EXPERIMENTAL|Formulation B Fed|Single dose of Proellex 25 mg formulation B, fed
62846292|NCT00620503|EXPERIMENTAL|Formulation B Fasted|Single dose of Proellex 25 mg formulation B, fasted
62846293|NCT04802668||Circulatory failure patients|Circulatory failure patients requiring fluid responsiveness evaluation
62846294|NCT03899467|EXPERIMENTAL|Arm 1: 400 mg /day of GT0918|"Group 1: Post enzalutamide failure~Group 2: Post abiraterone failure"
62059942|NCT02681575|EXPERIMENTAL|Cog-Fun A|Metacognitive-Functional occupational therapy intervention (Cog-Fun - A) includes enhancing self awareness in occupational context, acquiring executive strategies and skills and implementation across multiple occupational domains.
62059943|NCT02536014|EXPERIMENTAL|Dexmedetomidine|
62620181|NCT05037890|ACTIVE_COMPARATOR|Plant stanol enriched margarine|20 grams plant stanol enriched margarine on a daily basis for a period of 6 months.
62620182|NCT05037890|PLACEBO_COMPARATOR|Control margarine|20 grams control margarine on a daily basis for a period of 6 months.
62620183|NCT00826150|EXPERIMENTAL|BC-819|BC-819 60, 120 and 240 mg IP administration
62846295|NCT03899467|EXPERIMENTAL|Arm 2: 500 mg/day of GT0918|"Group 1: Post enzalutamide failure~Group 2: Post abiraterone failure"
62059944|NCT02536014|ACTIVE_COMPARATOR|Saline|
62263697|NCT01535170|EXPERIMENTAL|bovine Lactoferrin|"Lactoferrin and placebo will be masked as drug A and B in the factory. Randomization will be stratified by center and patients will be randomized into A or B groups by a random-number table sequence after informed consents are obtained. No patients, research nurses, investigators, or other medical staffs in RCC will be aware of the assignment during the study period.~Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) \[16\] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori \[17\]. Drug administration will begin within 24 hours after RCC admission and will last for 6 weeks or until discharge. Medication and nutritional support will be prescribed as the medical routine."
62263698|NCT01535170|PLACEBO_COMPARATOR|Placebo|Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control.
62059945|NCT06510530|EXPERIMENTAL|Astragalus|
62059946|NCT06510530|PLACEBO_COMPARATOR|Placebo|
62263699|NCT03914794|EXPERIMENTAL|Treatment: Pemigatinib|Patients will receive pemigatinib for 4 to 6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).
62447828|NCT05650788|EXPERIMENTAL|Mood depressive disorder group|Patients with a diagnosis of unipolar mood disorder stabilized in remission, according to DSM 5 criteria, with or without antidepressant treatment (SSRI, SNRI, tricyclics)
62059947|NCT03042598|EXPERIMENTAL|Biphasic Cuirass Ventilation|Patients requiring emergent intubation in the Emergency Department will be provided ventilation during the apnic phase of intubation via the use of BCV.
62447829|NCT05650788|EXPERIMENTAL|Healthy volunteer|People for whom no psychiatric diagnosis can be retained, according to DSM 5 criteria and naïve to psychotropic treatments
62447830|NCT01474226|EXPERIMENTAL|Lysine Amino Acid|
62447831|NCT01844583|EXPERIMENTAL|Esomeprazole 40 mg + Alisertib 50 mg|"Alisertib 50 mg, tablets, orally, once on Day 1, followed by twice daily on Days 4 to 10, followed by a 14-day rest period in Cycle 1.~Esomeprazole, 40 mg, delayed-release capsules, orally, once daily on Days 1 to 10 plus alisertib, 50 mg, tablets, orally, once on Day 8, followed by twice daily on Days 11 to 17, followed by a 14-day rest period in Cycle 2.~Alisertib 50 mg, tablets, orally, twice daily on Days 1 to 7 beginning with Cycle 3 (21-day cycles) to the end of study (Up to 15 Cycles)."
62620184|NCT00565890|NO_INTERVENTION|2|No replacement therapy
62620185|NCT04501016|EXPERIMENTAL|Tailored Intervention|Tailored behavioral counseling combined with tobacco cessation pharmacotherapy.
62846296|NCT03159039|EXPERIMENTAL|Conventional Physiotherapy (PT)|Postural drainage + manual vibration
62846297|NCT03159039|ACTIVE_COMPARATOR|Prolonged slow exhalation technique|Prolonged exhalation + Conventional PT
62059948|NCT02049125||No AKI|Patients with cirrhosis admitted to hospital with bacterial infection with initial serum creatinine below 1.5mg/dL.
62059949|NCT02049125||AKI and Infection|Patients with cirrhosis admitted to hospital with bacterial infection and initial serum creatinine above 1.5mg/dL.
62059950|NCT02049125||AKI with No Infection|Patients with cirrhosis admitted to hospital with initial serum creatinine above 1.5mg/dL without bacterial infection.
62846298|NCT05756075||Parkinson's Disease|
62846299|NCT05756075||COPD|
62846300|NCT03373396|OTHER|Case group with Metavir score between F1 and F4|Patient with Metavir score between F1 and F4 will be assigned to the case group. Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage.
62846301|NCT03373396|OTHER|Control group with Metavir score of between F0|Patient with Metavir score of F0 will be assigned to the control group. Collected data will contain epidemiological and biological data. Blood samples with chlordecone dosage will be performed.
62846302|NCT01623713|ACTIVE_COMPARATOR|Risperidone|
62846303|NCT01623713|EXPERIMENTAL|iloperidone|
62846304|NCT05453669|EXPERIMENTAL|CD19-CAR-DNT cells|9 patientsare planned to be enrolled in the dose-escalation trial (1×10\^6 CD19-CAR-DNT cells/kg, 3×10\^6 CD19-CAR-DNT cells/kg, 9×10\^6 CD19-CAR-DNT cells/kg) and 3 patients in the dose-expansion trial.
62846305|NCT02465424||questionnaire order|the order of presentation of the 4 quality of life questionnaires to the patients will be randomised to reduce the impact of boredom and habituation on responses
62263700|NCT01709149|EXPERIMENTAL|CK-2017357|125 mg tablets
62263701|NCT01709149|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62620186|NCT02483325|OTHER|Busulfan with adapted doses|Conditioning regimen for allogeneic transplant (Busulfan, Thymoglobuline and Fludarabine)
62620187|NCT00255840|ACTIVE_COMPARATOR|A|Study-specified Antiretroviral regimen under care of HIV-trained medical doctor
62620188|NCT00255840|ACTIVE_COMPARATOR|B|Study-specified Antiretroviral regimen under care of HIV-trained primary care nurse
62620189|NCT02121353|EXPERIMENTAL|PF582|PF582 is provided as single use vials and will be administered by intra-vitreal injection on Day 1, 28 and 56.
62620190|NCT02121353|ACTIVE_COMPARATOR|Lucentis|Lucentis® is provided as single use vials and will be administered by intra-vitreal injection on Day 1, 28 and 56.
62846306|NCT05495269|EXPERIMENTAL|QLS-101, 2.0%|Qlaris' investigational product, QLS-101, 2.0% concentration, ocular administration (eye drop), given once daily in the morning to both eyes
62263702|NCT05479942|EXPERIMENTAL|Group A|Study group
62263703|NCT05479942|EXPERIMENTAL|Group B|Control group
62620191|NCT04848246|EXPERIMENTAL|Bupropion|
62620192|NCT04848246|EXPERIMENTAL|Behavioural Change Communication|
62620193|NCT04848246|NO_INTERVENTION|Control|
62620194|NCT00683761|EXPERIMENTAL|1|
62620195|NCT04844983|EXPERIMENTAL|Part 1: Arm A|STP705 30 μg dose, intralesional injection, given once a week for 6 weeks.
62620196|NCT04844983|EXPERIMENTAL|Part 1: Arm B|STP705 60 μg dose, intralesional injection, given once a week for 6 weeks.
62620197|NCT04844983|EXPERIMENTAL|Part 1: Arm C|STP705 90 μg dose, intralesional injection, given once a week for 6 weeks.
62620198|NCT04844983|OTHER|Part 1: Arm D|Placebo (normal saline), intralesional injection, given once a week for 6 weeks.
62620199|NCT04844983|EXPERIMENTAL|Part 2: Arm A, B or C|STP705 selected dose 1, intralesional injection, given once a week for 6 weeks.
62846307|NCT02310204|EXPERIMENTAL|multidisciplinary education program|individual and group education sessions over a 6-month period
62263704|NCT00081159|EXPERIMENTAL|HAT, Doxorubicin, Zoledronate + Strontium chloride|Arm I: Hormonal ablative therapy (HAT) comprising luteinizing hormone-releasing hormone agonist (e.g., leuprolide or goserelin) continuously during study treatment OR bilateral orchiectomy; doxorubicin IV on days 1, 8, and 15 every 28 days for 2 courses; zoledronate IV over 15 minutes on day 1 every 28 days for 6 courses; and a single dose of strontium chloride Sr 89 IV over 1-2 minutes on day 1.
62263705|NCT00081159|EXPERIMENTAL|HAT, Doxorubicin + Zoledronate|Arm II: HAT, doxorubicin, and zoledronate as in arm I. HAT comprising luteinizing hormone-releasing hormone agonist (e.g., leuprolide or goserelin) continuously during study treatment OR bilateral orchiectomy; doxorubicin IV on days 1, 8, and 15 every 28 days for 2 courses; zoledronate IV over 15 minutes on day 1 every 28 days for 6 courses.
62263706|NCT06182982|EXPERIMENTAL|Auricolotherapy|Preoperative positioning of magnetic ball plasters for auricolotherpy.
62263707|NCT06182982|SHAM_COMPARATOR|Control|Ears will be covered by a band-aid (after a simulation of auricolotherapy)
62620200|NCT04844983|EXPERIMENTAL|Part 2: Arm A or B or C|STP705 selected dose 2, intralesional injection, given once a week for 6 weeks.
62846308|NCT02310204|ACTIVE_COMPARATOR|Standard psoriasis care alone|Standard psoriasis care alone
62846309|NCT01600170|ACTIVE_COMPARATOR|Atorvastatin|Participants were given atorvastatin for 12 weeks at various doses based on their specific HAART treatment.
62620201|NCT04844983|OTHER|Part 2: Arm D|Placebo (normal saline), intralesional injection, given once a week for 6 weeks.
62620202|NCT04498039|EXPERIMENTAL|Active|Electrical stimulation to the tongue is delivered via the Portable Neuromodulation Stimulator (PoNS™) device . The PoNS™ device is held in place lightly by the lips and teeth around a rectangular tab that goes into the mouth and rests on the anterior, superior part of the tongue. Active subjects will be able to feel the sensation.
62620203|NCT04498039|SHAM_COMPARATOR|Control|Electrical stimulation to the tongue will be delivered via the Portable Neuromodulation Stimulator (PoNS™) device . The PoNS™ device is held in place lightly by the lips and teeth around a rectangular tab that goes into the mouth and rests on the anterior, superior part of the tongue. Control subjects will be informed that while they may not feel the electrotactile stimulation, they are in-fact receiving a low level signal.
62620204|NCT02550080|EXPERIMENTAL|The prospective genetic screening arm|Prospective HLA-B\*1301 screen before administrated treatment included dapsone
62620205|NCT02550080|ACTIVE_COMPARATOR|The control arm|No HLA-B\*1301 screen before administrated treatment included dapsone
62620206|NCT05446220|EXPERIMENTAL|Diet + physical activity|Dietary advise and advise on physical activity monitored by pedometer
62620207|NCT05446220|EXPERIMENTAL|Physical activity|Advise on physical activity monitored by pedometer
62620208|NCT05446220|NO_INTERVENTION|Control|No intervention
62620209|NCT01197209|EXPERIMENTAL|Ad-REIC/Dkk-3 Arm|Active arm on Ad-REIC/Dkk-3
62623773|NCT04508647|EXPERIMENTAL|Ublituximab first, then Ublituximab and Umbralisib|Patients who achieve less than a complete response will receive a combination of ublituximab AND umbralisib for a total of 12 cycles. (In the combination arm ublituximab will be administered on day 1,8 and 15 on cycle 1 and on day 1 on each cycle thereafter. Umbralisib will be administered at 800 mg daily for 12 cycles)
62846310|NCT01600170|PLACEBO_COMPARATOR|Placebo|Participants were given Placebo tablets for 12 weeks.
62846311|NCT02840591|EXPERIMENTAL|Drug Treatment|"* First 5 consecutive subjects: Ramelteon 8 mg daily at 8 pm for 5 days~* Next 5 consecutive subjects: Citicoline 250 mg daily at 8 pm for 2 days, followed by citicoline 500 mg daily at 8 pm for 3 days~* All subjects: Standard medical care"
62846312|NCT02840591|NO_INTERVENTION|Observation-Only|Standard medical care
62263708|NCT02250820|EXPERIMENTAL|Nasal Dexmedetomidine and oral placebo|If the patient is assigned to the dexmedetomidine arm, they will receive dexmedetomidine through the nose. In order to keep the assignment blinded, the patient will also receive an oral placebo.
62846313|NCT03482960|EXPERIMENTAL|129Xe MRI|Participants will self-administer hyperpolarized xenon gas via inhalation prior to the investigators acquiring MRI images. MRI imaging will be taken during approximately 15-second breath-holds. After the MRI is complete, participant performs spirometry maneuvers in a room outside the magnet. Once a minimum of 15 minutes has elapsed since leaving the MRI scanner, the participant will return to the MRI scanner, where the second phase of the study will occur. PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath.
62263709|NCT02250820|EXPERIMENTAL|Nasal placebo and oral pentobarbital|If the patient is assigned to the pentobarbital arm, they will receive pentobarbital through the mouth. In order to keep the assignment blinded, the patient will also receive an nasal placebo.
62620210|NCT00459368|EXPERIMENTAL|I|In this cluster-randomized trial physicians practicing at intervention clinic sites will receive adherence information on their patients with asthma who are currently taking an inhaled corticosteroid medication. This information will be available to them via our electronic prescribing software to discuss with patients at the time of the visit. Physicians at these sites also receive standardized training in how to interpret and intervene when poor adherence is identified.
62620211|NCT00459368|ACTIVE_COMPARATOR|II|Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
62620212|NCT04641533|EXPERIMENTAL|L-PRF + DPSC|Mandibular third molars were extracted and DPSC with L-PRF placed into the socket.
62263710|NCT05744089|EXPERIMENTAL|Cancer patients suffering severe or critically painful|
62263711|NCT04967937|EXPERIMENTAL|Single-Group|The neuromuscular training program will consist of three 90-minute training sessions per week for 6 weeks. The 3 components of the dynamic neuromuscular training protocol utilized in this study include: (1) balance training and hip/pelvis/trunk strengthening, (2) plyometrics and dynamic movement training, and (3) resistance training. Following the completion of the training program, each subject will be re-evaluated to determine change in total, anterior-posterior, and medial-lateral single-limb stability. Two-way analysis of variance models will be used to determine differences between pre-training and post-training and between limbs.
62447832|NCT01844583|EXPERIMENTAL|Rifampin 600 mg + Alisertib 50 mg|"Alisertib 50 mg, tablets, orally, once on Day 1, followed by twice daily on Days 4 to 10, followed by a 14-day rest period in Cycle 1.~Rifampin 600 mg, capsules, orally, once daily on Days 1 to 10 in Cycle 2 plus alisertib, 50 mg, tablets, orally, once on Day 8, followed by twice daily on Days 11 to 17, followed by a 14-day rest period in Cycle 2.~Alisertib 50 mg, tablets, orally, twice daily on Days 1 to 7 beginning with Cycle 3 (21-day cycles) to the end of study (Up to 15 Cycles)."
62447833|NCT01578174|PLACEBO_COMPARATOR|Control|
62447834|NCT01578174|ACTIVE_COMPARATOR|Dexmedetomidine|
62447835|NCT04165720||Psychiatrists in Germany|Psychiatrists in Germany currently working with patients with mental disorders
62447836|NCT03185897||Hemophilia A|Participants with hemophilia A
62447837|NCT03185897||Hemophilia B|Participants with hemophilia B
62447838|NCT04060823|EXPERIMENTAL|Easy Breathing|Easy Breathing will be implemented in participating clinics. Asthma-related sick visits will be monitored for changes.
62447839|NCT03347695|EXPERIMENTAL|A new operation|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
62447840|NCT03347695|OTHER|A new operation (Selected pilot study)|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
62447841|NCT03249181|EXPERIMENTAL|Dolutegravir|"Dolutegravir group (DTG+2 NRTIs) - to make best comparison with standard of care, these NRTIs should be those recommended by national policy.~Participants randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs"
62620213|NCT04641533|ACTIVE_COMPARATOR|L-PRF|Mandibular third molars were extracted and L-PRF placed into the socket
62623774|NCT01963091|EXPERIMENTAL|oxytocin|
62623775|NCT01963091|PLACEBO_COMPARATOR|placebo|
62623776|NCT06222177||GERD group|Patients with AET\>6% at pH-study
62623777|NCT06222177||Non GERD group|Patients with AET\<6% at pH-study
62620214|NCT06186596|EXPERIMENTAL|intervention|All subjects will receive standard-of-care intralesional injection with triamcinolone using an Injection Assistance Device (i.e., for self-administered intralesional injections) at Visit 1 (Day 1). Subjects will then submit photos via secure photographic app for asynchronous follow up on Day 2 (24-hours post-injection), Day 3 (48-hours post-injection), Day 4 (72-hours post-injection), Day 7, and Day 14.
62620215|NCT02113007|EXPERIMENTAL|Rituximab plus Temozolomide|Rituximab: 375 mg/m2 IV, days 1, 3, and 5 Temozolomide: 150 mg/m2 PO, days 1-5
62620216|NCT03792542|EXPERIMENTAL|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
62620217|NCT01378715|ACTIVE_COMPARATOR|Rosuvastatin|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
62620218|NCT01378715|NO_INTERVENTION|Control|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to no-pretreatment with rosuvastatin.
62620219|NCT00903578||Kidney transplant recipients|
62620220|NCT05208268||Pariet|Participants with gastric and duodenal ulcer being administered with Pariet 5 mg, tablet within the scope of the approved label for Korea under the medical judgment of the investigator will be observed up to maximum of 24 weeks.
62620221|NCT05472571|EXPERIMENTAL|Forest bathing|
62846314|NCT03482960|EXPERIMENTAL|19F MRI with PFP|PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. After the MRI is complete, participant performs spirometry maneuvers in a room outside the magnet. Once a minimum of 15 minutes has elapsed since leaving the MRI scanner, the participant returns to the MRI scanner, where he/she will self-administer hyperpolarized xenon gas prior to acquiring MRI images. MRI imaging will be taken during approximately 15-second breath-holds.
62263712|NCT01505842|EXPERIMENTAL|Colonoscopy with chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
62447842|NCT03249181|ACTIVE_COMPARATOR|Standard of Care (EFV + 2 NRTI backbone)|Participants randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy (EFV + 2NRTIs at both study sites).
62447843|NCT02497833|PLACEBO_COMPARATOR|control|the participants in this arm are instruted to consume placebo capsules
62846315|NCT03304249|EXPERIMENTAL|iAmHealthy|Participants randomized to this arm receive the iAmHealthy Healthy Lifestyles Program.
62620222|NCT03581955|EXPERIMENTAL|Banana Cavendish|240g of fruit plus 150ml of Fresubin ® 2kcal fiber neutral flavor
62620223|NCT03581955|EXPERIMENTAL|Control drink|250ml of Fresubin ® 2kcal fiber neutral flavor
62447844|NCT02497833|EXPERIMENTAL|treatment|the participants in this arm are instruted to consume retinoic acid capsules
62447845|NCT01572766|ACTIVE_COMPARATOR|FRAX Assessment|FRAX Assessment Tool administered by a pharmacist. This group also receives a heel ultrasound and pharmacist counseling.
62620224|NCT03581955|EXPERIMENTAL|Tomato|300g of tomato plus of Fresubin ® 2kcal fiber neutral flavor plus 12g of refined sunflower oil.
62620225|NCT00329745|EXPERIMENTAL|Rotarix Group|During the primary study (NCT00197210) subjects received two oral doses of Rotarix™ vaccine.
62620226|NCT00329745|PLACEBO_COMPARATOR|Placebo Group|During the primary study (NCT00197210) subjects received two oral doses of placebo.
62620227|NCT01137656|OTHER|Acetylcholine and Blood|This is single arm study. Acetylcholine and blood is infused in brachial artery of non-dominant arm. Blood flow
62846316|NCT03304249|ACTIVE_COMPARATOR|Control|Participants randomized to this group receive comparable content delivered via a newsletter.
62846317|NCT00327197|EXPERIMENTAL|Intermittent mild steroid-naïve asthmatic group|Asymptomatic subjects receiving only beta-agonist inhaler with predicted FEV1 \>=80% and normal peak expiratory flow between attacks will be included.
62846318|NCT00327197|EXPERIMENTAL|Mild to moderate persistent asthmatic group|Subjects with mild to moderate persistent asthma on low to moderate dose of inhaled corticosteroid (200-500 microgram fluticasone propionate daily or equivalent), an FEV1 \>= 80% predicted (post-bronchodilator), and less than 20% variability in peak expiratory flow.
62263713|NCT01505842|ACTIVE_COMPARATOR|Conventional colonoscopy|White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
62620228|NCT04805164|EXPERIMENTAL|Innovative strategy|usual medical and surgical care with corticotomy and use of a bone substitute (Cerament-G) delivering gentamicin locally (± skin and soft-tissue/muscle flap) and antibiotic therapy.
62620229|NCT04805164|ACTIVE_COMPARATOR|Reference strategy|Medico-surgical usual care with corticotomy (± skin and soft-tissue/muscle flap), and antibiotic therapy.
62620230|NCT02703376|OTHER|Patients after esophageal surgery|Oral Prednisone for 12 weeks
62620231|NCT00061750|EXPERIMENTAL|ICL670|
62620232|NCT00061750|ACTIVE_COMPARATOR|Deferoxamine|
62263714|NCT04584528|OTHER|EHR-embedded Individualized Pain Plan (IPP)|The EHR embedded IPP will be made accessible to patients and ED providers at each study site.
62263715|NCT01859728|EXPERIMENTAL|IP (irinotecan and cisplatin)|Irinotecan 65mg/m² D1 and D8 q21 days plus Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.
62447846|NCT01572766|NO_INTERVENTION|Control group|Control group receives heel ultrasound and pharmacist counseling
62447847|NCT05789277|ACTIVE_COMPARATOR|Conventional training program group|The control group will perform conventional training program
62447848|NCT05789277|EXPERIMENTAL|Eccentric hamstring training group|The interventional group will perform eccentric hamstring training
62447849|NCT02010411|ACTIVE_COMPARATOR|Prolastin|Prolastin 250 mg nebulized BID, 10 days
62620233|NCT06262022|EXPERIMENTAL|experimental arm|A cold ice pack will be applied to the patient's knee for 20 minutes every hour for three days, starting after total knee arthroplasty.
62620234|NCT06262022|NO_INTERVENTION|control arm|Only unit-specific routine treatment and care interventions will be applied to the patients in the control arm by the team in the unit, and no intervention will be applied by the researcher.
62620235|NCT03538691|EXPERIMENTAL|Phase A: Brexpiprazole + ADT|Participants received brexpiprazole 2 or 3 milligrams per day (mg/day) along with protocol-specified antidepressant therapy (ADT), orally, for 6 to 8 weeks during Phase A. Participants were initially titrated to a target dose of brexpiprazole 2 mg over a 2 to 4-week period. Thereafter, participants who had not met response criteria as defined in the blinded addendum, did not have potentially dose-related adverse events (AEs), and had not achieved the maximum dose of medication had their dose increased up to 3 mg.
62620236|NCT03538691|EXPERIMENTAL|Phase B: Brexpiprazole + ADT|Eligible participants completing Phase A were enrolled in Phase B to receive brexpiprazole 2 or 3 mg/day along with protocol-specified ADT, orally, for 12 weeks.
62620237|NCT03538691|EXPERIMENTAL|Phase C: Brexpiprazole + ADT|Eligible participants completing Phase B received brexpiprazole 2 or 3 mg/day (dose of brexpiprazole that they were receiving at Week 20 of the Stabilization Phase) along with protocol-specified ADT, orally, for up to 26 weeks during Phase C.
62620238|NCT03538691|EXPERIMENTAL|Phase C: Placebo + ADT|Eligible participants completing Phase B received brexpiprazole-matching placebo along with protocol-specified ADT, orally, for up to 26 weeks during Phase C.
62620239|NCT03718234|EXPERIMENTAL|Subcutaneous Hydrocortisone via Infusion Pump|Patients will receive a subcutaneous injection of hydrocortisone (HC). Each patient's total daily dose (TDD) of oral tablet hydrocortisone to determine the doses to be delivered of the study drug. The 24-hr schedule and percentage of the TDD of HC will be as follows: approximately 60% of the TDD of HC will be delivered in 3 equal pulses at 0300, 0600 and 0900. Another 35% will be delivered in 3 equal pulses at 1200, 1500 and 1800 and the remaining 5% at 2100 and 2400.
62620240|NCT03718234|ACTIVE_COMPARATOR|Standard glucocorticoid therapy|Subjects in this arm will continue on standard oral hydrocortisone therapy
62620241|NCT02018770|EXPERIMENTAL|Phototherapy|Three groups will receive different fototerapia of light sources, and group 1 will not receive dose: Group A (0, 65Joules), Group B (1.30 Joules) and Group C (1.95 Joules) .
62620242|NCT02018770|PLACEBO_COMPARATOR|Placebo phototherapy|The volunteers will be subjected to the same Groups intervention Phototherapy . The but researcher will receive placebo pen. It is the caveat that, after completed the voluntary participation, will be held with the active pen treatment.
62620243|NCT04281628|PLACEBO_COMPARATOR|Control group|control group: where normal saline will be administered as a loading dose then infused with same rate of another group, throughout the whole surgery.
62263716|NCT01859728|ACTIVE_COMPARATOR|GC (gemcitabine and cisplatin)|Gemcitabine 1000mg/m² D1 and D8 every 21 days plus cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.
62620244|NCT04281628|ACTIVE_COMPARATOR|ketamine group|Ketamine group: will be administered ketamine in a loading dose of 0.2 mg/kg over 5 min pre incision followed-by an infusion at 0.2 mg/kg/h until the end of surgery.
62620245|NCT02740335|EXPERIMENTAL|Octaplex|Participants to receive1 Octaplex infusion intravenously
62263717|NCT04527302|ACTIVE_COMPARATOR|active tDCS+exposure based CBT|The exposure and response prevention (ERP) treatment concurrently with an anode transcranial direct current stimulation over the mPFC will be applied 8 times (tDCS+ERP, 8sessions) in the whole treatment.
62620246|NCT02740335|ACTIVE_COMPARATOR|Beriplex P/N (Kcentra)|Participants to receive1 Kcentra infusions intravenously
62620247|NCT03780972|ACTIVE_COMPARATOR|Cohort 1 Dose A|Intravitreal injection of 50 μl of ONL1204 liquid formulation to deliver dose 1
62620248|NCT03780972|ACTIVE_COMPARATOR|Cohort 2 Dose B|Intravitreal injection of 100 μl of ONL1204 liquid formulation to deliver dose 2
62620249|NCT03780972|ACTIVE_COMPARATOR|Cohort 3 Dose C|Intravitreal injection of 50 μl of ONL1204 liquid formulation to deliver dose 3
62620250|NCT03780972|ACTIVE_COMPARATOR|Cohort 4 Dose D|Intravitreal injection of 100 μl of ONL1204 liquid formulation to deliver dose 4
62620251|NCT03735745|EXPERIMENTAL|Caucasian, HPV positive, Non Smoking patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
62620252|NCT03735745|EXPERIMENTAL|Caucasian, HPV positive, Smoking patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
62263718|NCT04527302|SHAM_COMPARATOR|sham tDCS +exposure based CBT|the exposure and response prevention (ERP) treatment concurrently with an sham transcranial direct current stimulation over the mPFC will be applied 8 times (sham tDCS+ERP, 8 sessions) in the whole treatment.
62263719|NCT05260619|EXPERIMENTAL|Single arm|lenalidomide will be given as maintenance treatment to 28 PCNSL patients after achieving response to high-dose methotrexate-based immunochemotherapy
62263720|NCT05029635|ACTIVE_COMPARATOR|treatment arm|Eligible subjects will be treated with planned dose of 300 mg HMPL-523 once daily for 24 weeks
62263721|NCT05029635|PLACEBO_COMPARATOR|placebo arm|Drug: Placebo HMPL-523 matching placebo will be oral administrated once daily for 24 weeks.
62620253|NCT03735745|EXPERIMENTAL|Newly diagnosed, African American/Black, HPV negative, Smoking|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
62620254|NCT03735745|EXPERIMENTAL|Young (<40 years old), Oral Cavity (Tongue) patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
62263722|NCT01692964||InflammaDry|Patients suspected of having dry eye will be tested with the InflammaDry.
62620255|NCT03735745|EXPERIMENTAL|Neoadjuvant PD-1 Blockade patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
62620256|NCT04933864|EXPERIMENTAL|Methylene Blue and Photodynamic Therapy|Methylene Blue 1 mg/kg water solution. Participants have orally received Methylene Blue solution of 1 mg/kg concentration one time in addition to the current therapy of the participant (e.g., azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.), if any. After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm\^2 energy dose was performed.
62620257|NCT04933864|NO_INTERVENTION|Control group|COVID-19 positive participants treated with standard medical supportive therapy (e.g. azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.).
62059951|NCT02481375|EXPERIMENTAL|Multiple micronutrients with iron|"Multiple micronutrient formulations were based on the UNICEF/WHO/UNU standard formulation for pregnant and lactating women (UNIMMAP) with increased iron (from 30 mg to 60 mg elemental iron) for comparability to the iron only group (60 mg). This formulation has 15 micronutrients including iron.~Women will receive the multiple micronutrient with iron for 12 weeks."
62263723|NCT04534478|ACTIVE_COMPARATOR|Control Group|Prednisone 0.75mg / Kg / d 4 weeks; 0.5mg / Kg / d 4 weeks; 20mg / d 4 weeks; 10mg / d 6 weeks; 5mg / d 6 weeks (6m)
62263724|NCT04534478|ACTIVE_COMPARATOR|Experimental group|Prednisone 0.5mg / Kg / d 3 weeks, 20mg / day 3 weeks; 15mg / day 2 weeks; 10mg / day 2 weeks, 5mg / day 2 weeks and discontinue.
62263725|NCT06500351||denovo postpartum hypertension|females with new onset hypertension after delivary
62263726|NCT06500351||persitant postpartum hypertension|females with preexisting hypertension or preeclampsia that persist after delivery
62263727|NCT06500351||control|females with normal postpartum blood pressure
62263728|NCT03446950|ACTIVE_COMPARATOR|Candy Cane|Participants in this arm will be positioned with their legs in candy cane stirrups. Patients will then undergo scheduled vaginal surgery and be asked to complete PROMIS questionnaires before and after surgery.
62620258|NCT03734809|EXPERIMENTAL|pembrolizumab|"Total 51 weeks for 17 doses of pembrolizumab:~* Neoadjuvant pembrolizumab-chemotherapy: 6 weeks (2 doses of pembrolizumab)~* Concurrent pembrolizumab-chemoradiation: 9 weeks (3 doses of pembrolizumab~* Maintenance pembrolizumab: 36 weeks (12 doses of pembrolizumab)"
62846319|NCT00327197|EXPERIMENTAL|Severe asthma group|Subjects with severe persistent asthma. They will be on either: high inhaled corticosteroid (CS \>=1000 microgram fluticasone daily or equivalent) or on high dose inhaled CS plus oral CS (no more than 20 milligrams predisolone a day). The subjects should have at least one ( if on oral steroids) or two (if only on inhaled steroids) of the following: 1) FEV1\<80% and FEV1/FVC ratio \<70% 2) more than 25% variability in peak expiratory flow 3) daily symptoms ± nocturnal symptoms 4) severe exacerbations of \>= twice a year in at least one of the last two years.
62846320|NCT00327197|PLACEBO_COMPARATOR|Healthy subjects group|Non-asthmatic and non-smokers with FEV1 \> 85% predicted, on no regular medication.
62846321|NCT02310867|EXPERIMENTAL|Hand transplant with Belatacept|
62263729|NCT03446950|ACTIVE_COMPARATOR|Boot Stirrups|Participants in this arm will have their feet placed in boot stirrups. Patients will then undergo scheduled vaginal surgery and be asked to complete PROMIS questionnaires before and after surgery.
62263730|NCT01053871|EXPERIMENTAL|1|sedation using propofol
62620259|NCT02523404|EXPERIMENTAL|HepaSphere|lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
62846322|NCT01437904|EXPERIMENTAL|Outpatient|Outpatient recovery following Percutaneous nephrolithotomy
62846323|NCT01437904|SHAM_COMPARATOR|In hospital|Inpatient recovery following Percutaneous nephrolithotomy
62846324|NCT01668862|OTHER|Study arm A|Subjects will receive one injection of Autologous Human Platelet lysate in the lateral epicondyle space
62059952|NCT02481375|ACTIVE_COMPARATOR|Multiple micronutrients without iron|"This formulation has the 14 micronutrients included in the UNIMMAP formulation, but does not include iron.~Women will receive the multiple micronutrient without iron for 12 weeks."
62059953|NCT02481375|ACTIVE_COMPARATOR|Iron only|"This formulation only has 60 mg elemental iron.~Women will receive iron for 12 weeks."
62263731|NCT01053871|EXPERIMENTAL|2|sedation using midazolam with fentanyl
62263732|NCT01791348|OTHER|d2 test of attention|
62263733|NCT02136030|EXPERIMENTAL|Lipo-AB|
62263734|NCT02136030|ACTIVE_COMPARATOR|Amphotericin B|
62846325|NCT01668862|OTHER|Control Arm B|Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
62846326|NCT01384149|ACTIVE_COMPARATOR|standart slt|gonioscopic selective laser trabeculoplasty
62846327|NCT01384149|EXPERIMENTAL|external slt|perilimbal ,above trabecular meshwork 180 degrees ,100 laser dots
62620260|NCT02523404|PLACEBO_COMPARATOR|control|lung cancer patients received traditional therapy
62620261|NCT02984644|ACTIVE_COMPARATOR|Dapagliflozin|32 subjects will receive dapagliflozin 10mg
62620262|NCT02984644|PLACEBO_COMPARATOR|Placebo|16 subjects will receive placebo
62447850|NCT04388891|EXPERIMENTAL|Minimally supervised therapy|This group will undergo minimally supervised therapy with the robot ReHapticKnob.
62620263|NCT03942003|EXPERIMENTAL|Rhomboid|When applying the Rhomboid nerve block, the patient is tilted to the side position so that the corresponding breast is at the top. After T7 up to T10 sterile preparation of the C7 spinous projection, the convex probe shows a rhomboid muscle at the level of T5 and block is applied with 0.25% bupivacaine (20 cc), 2% lidocaine (10 cc) and 10 cc SF mixture.
62620264|NCT03942003|EXPERIMENTAL|Pectoral|The PEC I field block is performed by administering 10 cc of local anesthetic between the pectoralis minor and the major at the 2nd costal position. PEC II field block is performed using linear USG probe visibly in 3rd and 4th ribs while the patient is in supine position. In this block, a total of 20 cc 0.25% bupivacaine (10 cc), 2% lidocaine (5 cc) and 5 cc SF mixture were used to block the area between the pectoralis minor muscle and the serratus muscle
62620265|NCT03942003|SHAM_COMPARATOR|Control|Infiltration analgesia was performed.
62620266|NCT04592796||Nursing-home residents|Older adults in a nursing-home who report a self-perception of poor sleep quality
62620267|NCT01859871|NO_INTERVENTION|Control Arm|Study participants will take the self-administered pre-test and receive the standard of care. After taking the pre-test, control arm participants will be done with study participation for that day and will attend the transplant center's education sessions. All participants will receive a letter and follow-up call at about two weeks later to schedule the final survey. They will take a final survey via telephone about 3 weeks later. The final survey includes the same topics as the pre-test. They will receive a thank you letter and gift card by mail after completing the final survey.
62620268|NCT01859871|EXPERIMENTAL|Website Intervention|Navigate website plus standard of care
62620269|NCT03615820|EXPERIMENTAL|Niosomal PPE oromucoadhesive film|Niosomal PPE oromucoadhesive film in which PPE entrapped in niosomes then incorporated in oromucoadhesive films
62263735|NCT01794572|EXPERIMENTAL|Total BM irradiation dose|"Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are determined according to a 3x3 modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.~For Every patients:~Drug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.~Autologous Peripheral Stem Cell Rescue : are re-infused in the central line on day 0 after adequate premedication."
62447851|NCT04969614||kidney transplant recipients|kidney transplant recipients receiving inactivated SARS-CoV-2 vaccine
62447852|NCT00810732|EXPERIMENTAL|Sitaxsentan|Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
62620270|NCT03615820|PLACEBO_COMPARATOR|Oromucoadhesive film|Oromucoadhesive film that has no niosomal PPE in its content
62620271|NCT03743844|EXPERIMENTAL|Compassion-focused psychoeducation group|Receiving 2-hours of group-based in-person psychoeducational sessions weekly for 6-weeks.
62620272|NCT03743844|NO_INTERVENTION|Control group|Weight management treatment as usual
62447853|NCT00810732|ACTIVE_COMPARATOR|Nifedipine|Nifedipine 30 mg extended release tablets, orally administered once daily (open label arm)
62447854|NCT00810732|PLACEBO_COMPARATOR|Placebo|Placebo for sitaxsentan, orally administered once daily (double blind arm)
62620273|NCT02036541|EXPERIMENTAL|AqueSys XEN 45 Glaucoma Implant|
62059954|NCT02481375|PLACEBO_COMPARATOR|Placebo|"This formulation is a placebo.~Women will receive a placebo for 12 weeks."
62447855|NCT01455753||Employees|A total of 1,801 employees of a health benefits administrator that held a free workplace influenza vaccination clinic.
62447856|NCT04656977|ACTIVE_COMPARATOR|VR+TAU|Participants will participate first to a VR-based intervention and then to the TAU condition. The TAU condition is a homogenous standard program proposed by the Centre d'études et de recherché en intervention familiale (CERIF) at Université du Québec en Outaouais (UQO) based on group counseling offered to women and men who experienced a perinatal loss.
62620274|NCT00497341|EXPERIMENTAL|1|antibiotic is given before tourniquet inflation and before tourniquet release
62620275|NCT00497341|PLACEBO_COMPARATOR|2|antibiotic is given before tourniquet inflation
62620276|NCT01888250|EXPERIMENTAL|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
62620277|NCT01888250|ACTIVE_COMPARATOR|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC
62620278|NCT05294965|EXPERIMENTAL|Normal weight|"1. A bolus of 25µg fenoterol will be slowly injected intravenously during 2-3 minutes followed by a continuous infusion of fenoterol 1µg/min over 120 minutes. The total dose of fenoterol per subject will thus be 145µg.~2. Mild cold exposure: During 120 minutes the water temperature in cooling sleeves, covering the participant's waist, is gradually decreased to 10 degrees or to the lowest tolerable temperature without shivering."
62620279|NCT05294965|EXPERIMENTAL|Overweight|"1. A bolus of 25µg fenoterol will be slowly injected intravenously during 2-3 minutes followed by a continuous infusion of fenoterol 1µg/min over 120 minutes. The total dose of fenoterol per subject will thus be 145µg.~2. Mild cold exposure: During 120 minutes the water temperature in cooling sleeves, covering the participant's waist, is gradually decreased to 10 degrees or to the lowest tolerable temperature without shivering."
62620280|NCT02258906|EXPERIMENTAL|Ulinastatin group|Patients in the ulinastatin group are given ulinastatin during operation.
62846328|NCT01780064|PLACEBO_COMPARATOR|Standard group|routine monitoring with questionnaires
62263736|NCT03844165|EXPERIMENTAL|Diet change (red rice) with yoga|Following randomisation, participants are given a schedule of group and personal meetings and details of each session. Food for the diet (red rice and lentils) will be provided for those randomised to the diet arm. The study will last 16 weeks following start of the diet/yoga programme. There will be further visits to measure outcomes at week 8 and week 16. All participants in both arms will complete the same programme of Yoga sessions, organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute.
62263737|NCT03844165|ACTIVE_COMPARATOR|Yoga|Following randomisation, participants are given a schedule of group and personal meetings and details of each session. The study will last 16 weeks following start of the diet/yoga programme. There will be further visits to measure outcomes at week 8 and week 16. All participants in both arms will complete the same programme of Yoga sessions, organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute.
62263738|NCT06186960|EXPERIMENTAL|Tandem Virtual Reality Experience|Tandem VR Intervention After the surveys are completed, the researchers will share a personalized library of immersive, nature-based, 360-degree VR experiences for the participant-caregiver dyads to choose from based on their VR Intake Form. Once the dyad has determined their desired Tandem VR experience from the library, the researchers will assist the dyads in donning the VR head mounted display (HMD). The researchers will ensure the safety of both dyads while using the HMDs. The researchers will then initiate the Tandem VR experience. The duration of the Tandem VR experience will be 5-15 minutes.
62263739|NCT03243383|NO_INTERVENTION|Low-risk Group|Low-risk as determined by the predicted risk of readmission by the DERRI. The low-risk group will be followed in a prospective, observational arm of the study.
62263740|NCT03243383|EXPERIMENTAL|High-risk Group - Intervention|High-risk as determined by the predicted risk of readmission by the DERRI. Subjects in the high-risk group will be randomly assigned to receive either the intervention (DiaTOHC Program) or usual care (control).
62263741|NCT03243383|NO_INTERVENTION|High-risk Group - Usual Care|Patients in the high-risk usual care group will receive the standard hospital discharge process and post-discharge followup.
62263742|NCT04257825|OTHER|Initial Off|Individuals were asked to not use their device on weeks 1 and 3 of the study. They were asked to use their device on weeks 2 and 4.
62263743|NCT04257825|OTHER|Initial On|Individuals were asked to not use their device on weeks 2 and 4 of the study. They were asked to use their device on weeks 1 and 3.
62263744|NCT05939024|ACTIVE_COMPARATOR|Conventional Physical Therapy (CPT) Group|Patients in this group will receive Conventional Physical therapy only, which includes hot pack, TENS, Ultrasonic, stretching and strengthening exercises.
62846329|NCT01780064|ACTIVE_COMPARATOR|Interviews with psychologist|Patients have interviews with a psychologist (at cure one of chemotherapy treatment,at cure six of chemotherapy treatment, at last radiotherapy session, and three months after the end of radiotherapy) and questionnaires
62846330|NCT03961009|EXPERIMENTAL|Kedrion IVIG 10%|Participants received intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligrams per kilogram (mg/kg) body weight on every 21 or 28 days for period of 48 weeks.
62263745|NCT05939024|EXPERIMENTAL|Muscle Energy Technique plus Conventional Physical Therapy Group|In this group, Post Isometric Relaxation of the Muscle Energy Techniques will be applied to the Spinal Stabilizers and Mechanoreceptors in addition to Conventional Physical Therapy.
62620281|NCT02258906|PLACEBO_COMPARATOR|control group|Patients in the control group receive the same volume of normal saline during operation.
62846331|NCT05688124|OTHER|IBI351|This cohort investigated the effect of food on the pharmacokinetics of IBI351 in healthy subjects. In a double-crossover design, subjects were enrolled and randomly divided into two test groups A and B. Group A: IBI351 was orally administered to subjects in this group on an empty stomach on Day 1, followed by a high-fat meal on Day 4. Group B: IBI351 was orally administered to subjects in this group after a high-fat meal on Day 1 followed by an empty stomach on Day 4.
62846332|NCT05688124|OTHER|IBI351+Esomeprazole|Enrolled subjects were orally administered IBI351 with recommended dose on an empty stomach. Esomeprazole were administered orally.
62263746|NCT00639483|EXPERIMENTAL|A|
62846333|NCT04675008|EXPERIMENTAL|Study arm|Dacomitinib
62846334|NCT03805113|EXPERIMENTAL|Intervention group|Treatment with magnetotherapy device 15 20-minute-sesions every consecutive working day.
62846335|NCT03805113|PLACEBO_COMPARATOR|Control group placebo|Treatment with misconnected magnetotherapy device 15 20-minute-sesions every consecutive working day.
62846336|NCT00286598|EXPERIMENTAL|Feet First|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
62846337|NCT00286598|NO_INTERVENTION|Control|Usual care
62846338|NCT02989428|EXPERIMENTAL|Early parathyroidectomy group|Parathyroidectomy (surgery), is performed as soon as possible in the experimental group after randomization.
62846339|NCT02989428|NO_INTERVENTION|Late parathyroidectomy group|Parathyroidectomy (surgery), is performed three months after study inclusion.
62846340|NCT04437121||Parents of children aged 2-18 years|Parents of children aged 2-18 years during the lockdown due to the COVID-19 pandemic, following their informed consent form prior to their participation to the study.
62263747|NCT00639483|PLACEBO_COMPARATOR|B|
62447857|NCT04656977|ACTIVE_COMPARATOR|TAU+VR|Participants will be invited first to participate to the TAU condition and then to the VR-based intervention.
62263748|NCT01964014|EXPERIMENTAL|advagraf|The same capacity advagaf + sirolimus
62263749|NCT04052451|EXPERIMENTAL|Major Depression Disorder|MET-2 will be given to subjects with major depression disorder and its effect on mood will be measured
62263750|NCT04052451|EXPERIMENTAL|Generalized Anxiety Disorder|MET-2 will be given to subjects with generalized anxiety disorder and its effect on mood will be measured
62447858|NCT05783583||Enrolled participants|Adult human subjects showing either healthy eyes or specific ocular pathologies.
62447859|NCT02453425|ACTIVE_COMPARATOR|60 mmHg|Norepinephrine adjusted to reach MAP 60 mmHg
62263751|NCT02898259|EXPERIMENTAL|Lenalidomide + Ixazomib + Rituximab|Ixazomib will be orally administered with a starting dose of 2.0mg. Lenalidomide will be administered orally with a starting dose of 20mg. Rituximab will be administered intravenously at the standard dose of 375mg/m2. The study will use a standard 3 + 3 design for determination of MTD during cycle 1. There will be three dose levels for escalation, followed by two expansion cohorts of 12 patients each at the MTD, one cohort with follicular lymphoma and one cohort with non-follicular low-grade lymphoma (SLL, marginal zone, lymphoplasmacytic). Patients will be treated for 12 cycles of 4 week duration.
62263752|NCT01411436||Group 1|
62263753|NCT04185688||Multiple Sclerosis|"Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.~Biodex Balance System: Biodex Balance System is used to evaluate limits of stability. The limits of stability test consists of standing on the platform and leaning in eight directions to make a cursor displayed on the system's screen hit a target.~Berg Balance Scale: It has 14 items, each of which is scored from 0 (i.e, severely impaired balance) to 4 (i.e., no balance impairment).~Timed Up and Go test: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.~Four square step test: It requires an individual to step over obstacles in various directions including forward, backward, and sideways."
62263754|NCT04185688||Healthy People|Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.
62620282|NCT05992688|ACTIVE_COMPARATOR|Sucrose sweetened beverage|Sucrose (i.e. sugar): 25 g sugar (100 Kcal per serving). Participants will be asked to consume the study product once a day for 8 to 14 weeks if they have normal weight or excessive weight, respectively.
62846341|NCT05002751||Cohort 1|1. Patients with histologically confirmed newly diagnosed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma): FIGO 2009 clinical stages IB2/IIA with positive para-aortic nodes, or FIGO 2009 clinical stages IIB/IIIB/IVA with positive pelvic or para-aortic lymph nodes (PALN). Pelvic or PALN nodal status confirmed by PET/CT scan or fine needle biopsy or extra peritoneal biopsy or laparoscopic biopsy. The PALN must be inferior to the T12/L1 interspace.
62846342|NCT01709669||Enrolling by invitation|
62263755|NCT03775954||1) Fetal Congenital Heart Disease|Pregnancy with major fetal congenital heart disease, after 20 weeks gestation, and as neonate following delivery. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
62263756|NCT03775954||2) History of fetal demise (Stillbirth)|Pregnancy with a history of an unexplained fetal demise (stillbirth at 20 -40 weeks gestation) during any prior pregnancy. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
62263757|NCT03775954||3) Fetal hydrops, immune or non-immune|Pregnancy with fetal hydrops, immune or non-immune, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
62263758|NCT03775954||4) Fetal gastroschisis|Pregnancy with fetal gastroschisis, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
62263759|NCT03775954||5) Twin pregnancy, monochorionic|Twin pregnancy, monochorionic, with or without twin-twin transfusion syndrome, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (fMCG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
62263760|NCT00047060|EXPERIMENTAL|Stem Cell Transplant Therapy With Campath-1H|Recipients received a nonmyeloablative preparative regimen of alemtuzumab 30mg iv three times a week for two weeks followed by fludarabine 25mg/m2/day for five days followed by a PBPC graft targeted to deliver ≥ 5x106 CD34+ cells/kg. Cyclosporine A (CSA) for GVHD prophylaxis used initially with target CSA levels in the therapeutic range (200 -400 ng/ml).
62263761|NCT03205462|EXPERIMENTAL|Group 1|Fluorothyazinone in a dosage of 300 mg (1 tablet) will be administrated to 5 volunteers
62846343|NCT00690144|EXPERIMENTAL|simulation group|the trainees in the simulation group receive simulation-based training
62620283|NCT05992688|EXPERIMENTAL|Stevia sweetened beverage|The stevia-sweetened beverage contains 30.1 mg of steviol equivalents. Participants will be asked to consume the study product once a day for 8 to 14 weeks if they have normal weight or excessive weight, respectively.
62846344|NCT04132271|EXPERIMENTAL|Personalized diet|Personalized diet during the swallowing rehabilitation
62846345|NCT04132271|ACTIVE_COMPARATOR|Control|Nutritional recommendations during the swallowing rehabilitation
62059955|NCT05067439|OTHER|Period 1|In Period 1, all the participants will receive single doses of the probe drugs, including caffeine 100 mg, efavirenz 50 mg and omeprazole 10 mg, together on Day 1.
62447860|NCT02453425|ACTIVE_COMPARATOR|75 mmHg|Norepinephrine adjusted to reach MAP 75 mmHg
62846346|NCT06126198|EXPERIMENTAL|Active treatment|Active treatment with Repetitive Transcranial Magnetic Stimulation (rTMS) according to clinical protocol.
62447861|NCT02453425|ACTIVE_COMPARATOR|90 mmHg|Norepinephrine adjusted to reach MAP 90 mmHg
62846347|NCT02216240|ACTIVE_COMPARATOR|Accident and emergency|Patients randomised to A\&E were treated as per standard care and given no information other than that pertaining to the study.
62846348|NCT02216240|EXPERIMENTAL|Paramedic|Treatment at the scene by a paramedic. Valsalva manoeuvre with subsequent administration of 6mg and 12mg of adenosine unless the supraventricular tachycardia terminated. Patients were taken to accident and emergency if the tachycardia did not terminate, restarted, or the patient had continuing symptoms, a persistently abnormal ECG (other than T wave inversion) or was heamodynamically unstable. Prior to discharge from the ambulance patients received an information pack and a referral letter for their GP to refer them to an arrhythmia clinic.
62846349|NCT04078256|EXPERIMENTAL|Experimental group|Group will carry out the proprioceptive exercise program during 8 weeks at the begining of the season
62846350|NCT04078256|PLACEBO_COMPARATOR|Control group|Control group will continue with their usual training routine
62846351|NCT02812017|EXPERIMENTAL|1 - Intervention|The treatment group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will then view the Thirty Million Words-Well Baby intervention, which consists of educational, multimedia modules at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
62846352|NCT02812017|PLACEBO_COMPARATOR|2 - Neutral|The Neutral Video group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will then view the neutral videos about car safety at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
62846353|NCT02812017|NO_INTERVENTION|3 - Usual care|The treatment group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will receive care as usual at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
62846354|NCT00592800||1|children between 11 and 13 years of age
62846355|NCT00592800||2|children between 14 to 15 years of age
62846356|NCT00592800||3|children between 16 and 18 years of age
62846357|NCT06058000|EXPERIMENTAL|QLM3003 Low Dose|2% cream applied once daily (QD)
62846358|NCT06058000|EXPERIMENTAL|QLM3003 Middle Dose|1.5% cream applied twice daily (BID)
62846359|NCT06058000|EXPERIMENTAL|QLM3003 High Dose|2% cream applied twice daily (BID)
62263762|NCT03205462|EXPERIMENTAL|Group 2|Fluorothyazinone in a dosage of 600 mg (2 tablets) will be received per os (oral administration) as a single dose
62447862|NCT05017181||BioVal|BioVal is a single site validation study to determine the histological correlates underpinning signals derived from 13C-pyruvate HYP-MRI in men with known prostate cancer scheduled for prostatectomy.
62447863|NCT05017181||ProVal|ProVal is a single site, prospective, longitudinal observational cohort study to determine the prognostic value of signals derived from VERDICT, Luminal Index MRI and 13C-pyruvate HYP-MRI in men with known early prostate cancer on active surveillance.
62447864|NCT05017181||TecVal|TecVal is a multi-site validation study to determine the inter-site repeatability and intra-site reproducibility of signals derived from VERDICT, Luminal Index MRI and 13C-pyruvate HYP-MRI in men with known prostate cancer.
62846360|NCT06058000|PLACEBO_COMPARATOR|Placebo Comparator: Vehicle|Vehicle cream applied twice daily (BID)
62846361|NCT06058000|PLACEBO_COMPARATOR|High Placebo Comparator: Vehicle|Vehicle cream applied twice daily (BID)
62846362|NCT04849559|EXPERIMENTAL|Tradipitant|Oral Capsule
62846363|NCT04849559|PLACEBO_COMPARATOR|Placebo|Oral Capsule
62846364|NCT00837317|EXPERIMENTAL|1|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
62846365|NCT02467634|EXPERIMENTAL|HuCNS-SC|HuCNS-SC sub-retinal transplantation
62846366|NCT05366868|EXPERIMENTAL|Imeglimin|Imeglimin 1000 mg orally twice daily in the morning and evening (2000 mg daily).
62846367|NCT05366868|ACTIVE_COMPARATOR|Metformin|Metformin 500 mg orally twice daily in the morning and evening (1000 mg daily). However, until 2 weeks after the start of treatment, 250 mg should be administered orally twice daily in the morning and evening. Thereafter, after 4, 8, or 12 weeks, the dose may be increased up to 750 mg twice daily (1500 mg daily) if the physician determines that the hypoglycemic effect is inadequate.
62846368|NCT05366868|ACTIVE_COMPARATOR|Vildagliptin|Vildagliptin 50 mg orally twice daily in the morning and evening (100 mg daily).
62846369|NCT05201664||Surgical Extrusion|Patients who receive surgical extrusion treatment in maxillary premolars.
62846370|NCT03565952|EXPERIMENTAL|Cranial massage|Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.
62846371|NCT03565952|ACTIVE_COMPARATOR|Control Group|The control group does not receive treatment.
62263763|NCT03205462|EXPERIMENTAL|Group 3|on the first day of administration, the product is received according to the following regimen: the first dosage of 60 mg (2 tablets) should be taken orally 30 minutes after meals and swallowed with room-temperature water; the second dosage - 1 tablet (300 mg) - 12 hours later, and then for 5 days the subjects will receive 2 tablets per day. The duration of antibacterial therapy is 6 days. The total dose of Fluorothyazinone per treatment course is 3900 mg.
62620284|NCT05992688|ACTIVE_COMPARATOR|Calorie free flavored water beverage|Flavored water. Participants will be asked to consume the study product once a day for 8 to 14 weeks if they have normal weight or excessive weight, respectively.
62620285|NCT02849210|EXPERIMENTAL|Allergovac depot|Allergovac depot with Olea europaea pollen extract
62846372|NCT04058184||Contact sports players|Athletes who engage in contact sports, football for example. Participation in this study will involve listening to sudden, very brief bursts of noise (startle blocks) and tones, and responding with a keypress to certain tones. Electromyogram (EMG) will measure the electrical activity generated from movement of the orbicularis oculi muscle during the startle blocks.
62846373|NCT04058184||Non-contact sports players|Athletes who engage in non-contact sports, swimming for example.Participation in this study will involve listening to sudden, very brief bursts of noise (startle blocks) and tones, and responding with a keypress to certain tones. Electromyogram (EMG) will measure the electrical activity generated from movement of the orbicularis oculi muscle during the startle blocks.
62846374|NCT04716296|EXPERIMENTAL|Ketamine arm|Treatment arm consisting of patients randomized to receive a low dose of ketamine for the second stage of DBS surgery.
62059956|NCT05067439|OTHER|Period 2|In Period 2, participants will receive abrocitinib 200 mg once daily (QD) on Day 1-10, single dose of omeprazole on Day 2 and single dose of probe drugs together on Day 8.
62059957|NCT03056625|EXPERIMENTAL|Fortified rice|Participant will be given vitamin A fortified rice 1 meal/day
62059958|NCT03056625|PLACEBO_COMPARATOR|Control|Participant will be given normal rice 1 meal/day
62059959|NCT05140291|EXPERIMENTAL|Dry needling|Experimental Group
62059960|NCT05140291|SHAM_COMPARATOR|Sham Needling|Sham Group
62263764|NCT06001060||women of reproductive age with elevated homocysteine levels|
62263765|NCT01489007||Vegetarian Children|"Self-described lacto-ovo vegetarians for the past 6 months (Subjects who include a small amount of fish or chicken in the diet (not more than 2 servings total/week of both combined) will be allowed to participate in this study as these are not major iron contributors to the diet. Subjects must not have eaten any red meat however for 6 months.) Control subjects will be non-vegetarians."
62447865|NCT06341088|ACTIVE_COMPARATOR|unilateral suture sacro-hysteropexy|patients in this group will undergo unilateral sacrouterine ligament plication with nonabsorbable suture and unilaterally suspended to the anterior longitudinal ligament.
62447866|NCT06341088|ACTIVE_COMPARATOR|bilateral suture sacro-hysteropexy|patients in this group will undergo bilateral sacrouterine ligament plication with nonabsorbable sutures and bilaterally suspended to the anterior longitudinal ligament.
62447867|NCT05593198|ACTIVE_COMPARATOR|Guided bone regeneration|Patients will be treated with guided bone regeneration.
62447868|NCT05593198|EXPERIMENTAL|Bone block|Patients will be treated with bone blocks using the Khoury technique.
62447869|NCT04309409|EXPERIMENTAL|Nivolumab (Arm A)|"Patients with a risk score of \> 0.0 corresponding to high risk of relapse (randomized):~Nivolumab will be applied at a flat dose of 480 mg given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year. Afterwards these patients will receive intense clinical follow up according German Follow up guidelines."
62447870|NCT04309409|NO_INTERVENTION|Observation, High Risk (Arm B)|"Patients with a risk score of \> 0.0 corresponding to high risk of relapse (randomized):~Control group (observation only). These patients will receive intense clinical follow up but no further specific therapy according German Follow up guidelines."
62447871|NCT04309409|NO_INTERVENTION|Observation, Low Risk (Arm C)|"Patients with a risk score of ≤ 0.0 corresponding to low risk of relapse who are not eligible for randomization:~These patients will receive intense clinical follow up but no further specific therapy according German Follow up guidelines. Documentation of clinical outcome of these patients."
62447872|NCT05420506|EXPERIMENTAL|NROT1|Intestinal device placement in subjects and their follow up
62447873|NCT02946164|NO_INTERVENTION|Comparison: Standard of Care|Standard services available to all men at AHF Wellness Centers.
62447874|NCT02946164|ACTIVE_COMPARATOR|Intervention: 'Stick To It' Intervention|Behavioral intervention.
62447875|NCT01323348|EXPERIMENTAL|Diabetes Educational Intervention|Study participants in the intervention group will receive a diabetes management educational intervention at baseline and at follow-up visits. For those on an annual follow-up schedule, educational intervention will take place at baseline and 12 months. For those whose standard care involves more frequent, than annual, visits the educational intervention will take place no more than once every 12 weeks.
62447876|NCT01323348|NO_INTERVENTION|Standard Care|Usual care
62447877|NCT01539109|EXPERIMENTAL|Rehab and tDCS|Patients in this group will receive Noninvasive brain stimulation: tDCS, during rehabilitation exercises of the weak upper limbs for 2 hours per day, 5 times a week, for 2 weeks. tDCS is Transcranial Direct Current Stimulation. Prior to this 2-week intervention phase, all patients will be monitored over a 2-week control phase.
62059961|NCT06253949|ACTIVE_COMPARATOR|high tie ligation of inferior mesenteric artery|Group A patients of elective operable colorectal cancer : high tie group
62059962|NCT06253949|ACTIVE_COMPARATOR|low tie ligation of inferior mesenteric artery|Group B patients of elective operable colorectal cancer : low tie group
62447878|NCT01539109|SHAM_COMPARATOR|Rehab and sham tDCS|Patients in this group will receive Sham tDCS: placebo noninvasive brain stimulation, during rehabilitation exercises of the weak upper limbs for 2 hours per day, 5 times a week, for 2 weeks. tDCS is Transcranial Direct Current Stimulation. Prior to this 2-week intervention phase, all patients will be monitored over a 2-week control phase
62263766|NCT01437852|EXPERIMENTAL|StrataGraft skin tissue|"All subjects enrolled in this study will receive StrataGraft tissue. Will randomly assign treatment regimens to the two comparable study treatment sites pre-identified as A or B. A sealed randomization envelope will be supplied to the clinical site along with the shipment of clinical tissue. Neither the surgeon nor scrubbed operating room personnel will be informed of the randomization until completion of surgical excision. The treatment sites A or B will be randomized to receive either StrataGraft skin tissue or autograft using a 1:1 ratio.~Two comparable areas of healthy skin will be pre-identified by the clinical staff as donor sites A or B. The randomization assignment will be identical as that above for the treatment sites. For example, if treatment site A is randomized to receive an autograft, donor site A will be designated the donor site for autografting"
62620286|NCT00973284|EXPERIMENTAL|Norwalk VLP Vaccine 100 µg|Norwalk Virus-like Particle (VLP) Vaccine 100 µg, dry powder, intranasally using a delivery device with a puff of air, 50 µg in each nostril, on Days 0 and 21 in the Vaccination Stage. Norwalk Virus, 48 Reverse Transcription Polymerase Chain Reaction (RT-PCR) units, solution, orally, on Day 42 in the Challenge Stage.
62846375|NCT04716296|ACTIVE_COMPARATOR|Control arm|Control arm consisting of patients randomized to receive sham control of saline during the second stage of DBS surgery.
62846376|NCT01536067|EXPERIMENTAL|Treatment (monoclonal antibody therapy)|"INDUCTION PHASE: Patients receive ofatumumab IV on days 1, 8, and 15 and bortezomib SC on days 8 and 15. Beginning on course 2, patients receive ofatumumab IV on days 1 and 15 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Beginning 8 weeks after course 4 of induction phase, patients receive ofatumumab IV on day 1 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
62846377|NCT03387878|OTHER|Single Arm Study|This is a single arm study with no comparator
62846378|NCT05838118|OTHER|Washed Microbiota Transplantation to treat Chronic Kidney Disease|
62846379|NCT05838118|OTHER|Standard of Care for Chronic Kidney Disease|
62846380|NCT00310661|PLACEBO_COMPARATOR|Placebo|Placebo hard gelatin capsules matching the investigational medication
62846381|NCT00310661|EXPERIMENTAL|Sarizotan HCI|Sarizotan HCI is administered at various doses ranging from 2-7mg.
62846382|NCT04202172|ACTIVE_COMPARATOR|BIOFREEDOM|Implantation of Drug-eluting coronary stent without polymer in patients with myocardial infarction.
62846383|NCT04202172|EXPERIMENTAL|COMBO|Implantation of Bioactive coronary stent in patients with myocardial infarction.
62263767|NCT02316535|ACTIVE_COMPARATOR|standard-dose|capecitabine, oral administration, 1,250 mg/m2 twice daily on days 1-14, and repeated on day 22; 8 circles in total.
62263768|NCT02316535|EXPERIMENTAL|reduced-dose|capecitabine, oral administration, 1,000 mg/m2 twice daily on days 1-14, and repeated on day 22; 8 circles in total.
62447879|NCT02123056|ACTIVE_COMPARATOR|Metoprolol|Metoprolol 50 mg po tablets will be provided for final dosing range (25 mg po BID to 100 mg po BID) for study duration (1 year). Patients will be started at 50 mg po BID and titrated over 2 weeks to target of 100 mg po BID.
62447880|NCT02123056|PLACEBO_COMPARATOR|Placebo|Matching placebo will be identical in appearance to the active treatment pill. Patients will be started at 50 mg po BID and titrated over 2 weeks to target of 100 mg po BID.
62620287|NCT00973284|PLACEBO_COMPARATOR|Placebo|Norwalk VLP placebo-matching vaccine, dry powder, intranasally using a delivery device with a puff of air, 50 µg in each nostril, on Days 0 and 21 in the Vaccination Stage. Norwalk Virus, 48 RT-PCR units, solution, orally, on Day 42 in the Challenge Stage.
62620288|NCT00758329||1|
62620289|NCT05061381|EXPERIMENTAL|A Lust for Life Schools Programme Group|A Lust for Life programme will be delivered to primary school pupils by their school teachers in six weekly lessons. Well-being and resilience will be promoted in each lesson through classroom discussions, videos, classroom activities and homework assignments.
62846384|NCT03894228||Biologics exposed cohort|Children born from mothers treated with biologic drugs (with or without immunomodulators) at any time during pregnancy or the three months before conception. Biologic drugs are IgG monoclonal antibodies able to cross the placenta.
62846385|NCT03894228||Immunomodulators exposed cohort|Children born from mothers treated with immunomodulators (without biologics) during pregnancy or the three months before conception.
62846386|NCT03894228||Non-exposed cohort|Children born from mothers treated neither with biologic drugs nor with immunomodulators at any time during pregnancy or the three months before conception.
62846387|NCT00627276|EXPERIMENTAL|Arm I|Patients receive oral omega-3 fatty acid capsules 3 times daily for up to 8 weeks.
62846388|NCT00627276|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo olive oil capsules 3 times daily for up to 8 weeks.
62846389|NCT01994889|EXPERIMENTAL|Tafamidis - 20 mg|Active Treatment-Low dose
62620290|NCT05061381|NO_INTERVENTION|Waiting list control group|Participants will be placed on a sixteen-week waiting list for the programme.
62620291|NCT04303234|ACTIVE_COMPARATOR|Artinibsa|"Powerful local anesthetic with short time for patients who can not tolerate normal doses of vasoconstrictor latency.~High lipid solubility gives a better diffusion through the soft tissue and bone being very effective in infiltrative techniques.~Duration:~Latency time: 2 minutes~Each mL contains:~4%Articaine 1:100000. Hydrochloride 40.00 mg, Epinephrine (D.C.I) 0.005 mg tartrate"
62846390|NCT01994889|EXPERIMENTAL|Tafamidis - 80 mg|Active Treatment-High Dose
62846391|NCT01994889|PLACEBO_COMPARATOR|Placebo|Placebo control
62620292|NCT04303234|EXPERIMENTAL|Artpharma|Its a special amide local anesthetic contain 4% articaine with epinephrine 1/200000 as a vasoconstrictor ,Contains only sulfite as a stabilizer (max 0.31 mg)
62620293|NCT03695328||physical activity level|Children categorized either in the group with moderate to vigorous physical activity or in the group with low physical activity according the accelerometer's measures
62620294|NCT03695328||dietary intake|Childrens' 24th dietary recalls for 7 days analyzed for protein, calcium, vitamin D and phosphorus intake and they categorized according the RDAs above or below them.
62447881|NCT02486796|ACTIVE_COMPARATOR|Immediate and Continuous Dosing|Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 1 Day 1 of their prescribed neoadjuvant chemotherapy.
62447882|NCT02486796|ACTIVE_COMPARATOR|Delayed Dosing|Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 3 Day 1 of their prescribed neoadjuvant chemotherapy.
62447883|NCT06283862|EXPERIMENTAL|Immediate Education|Education sessions starting \~ week 4 of trial
62620295|NCT03439891|EXPERIMENTAL|Part 1: Dose Escalation|Participants receive sorafenib PO on days 1-28, and nivolumab IV over 30 minutes beginning on day 15 of course 1, then on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course will continue until 1 dose-limiting toxicity occurs to establish maximum tolerated dose.
62620296|NCT03439891|EXPERIMENTAL|Part 2: Child Pugh B Expansion (sorafenib, nivolumab)|Participants receive sorafenib on days 1-28, and nivolumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62846392|NCT03595995|EXPERIMENTAL|Cohort 1|"1. Placebo (volume equivalent to 2.5 mg/kg UB-621)~2. 2.5 mg/kg UB-621"
62846393|NCT03595995|EXPERIMENTAL|Cohort 2|"1. Placebo (volume equivalent to 5 mg/kg UB-621)~2. 5 mg/kg UB-621"
62846394|NCT02439489|EXPERIMENTAL|BKM120-CIS|BKM120 (60, 80 100 mg po continuously) and Cisplatin (iv 75 mg/m2)
62846395|NCT02439489|EXPERIMENTAL|BKM120-CARBO|BKM120 and (60, 80 100 mg po continuously) and Carboplatin (iv AUC 5)
62846396|NCT05613218|ACTIVE_COMPARATOR|Liberal oxygenation group|SpO2 target of 96%
62447884|NCT06283862|OTHER|Waitlist Control - delayed education|Education sessions starting \~ week 12 of trial
62447885|NCT01908114|NO_INTERVENTION|Group A|Routine Polio Program activities will be carried out with out any active intervention
62447886|NCT01908114|EXPERIMENTAL|Group B|"Expanded intervention with following components~1. Community support groups for both male and female at village/community level~2. Enhanced communication package and involvement of local social networks for group counseling on promotion of nutrition, hygiene and Expanded Program of Immunization (EPI) vaccinations~3. Involvement of Private sector (General Physicians,health care providers etc.) through advocacy and inclusion in Supplementary Immunization activities (SIAs)~4. Delivery of interventions \& commodities through low cost health camps during National Immunization days (NIDs) and SIAs (will also assist in mop-up campaigns)"
62846397|NCT05613218|ACTIVE_COMPARATOR|Restrictive oxygenation group|SpO2 target of 90%.
62846398|NCT02942459|EXPERIMENTAL|Music Therapy|"25 Weekly Hours of Music Therapy adapted to the Needs of the Participants. Interventions can be Active (playing Music, singing, improvising, Song-writing) or Receptive (Listening to selected Play-lists, or to the Participants´ favored Music).~A Manual is created and trained with the Music Therapists, which distinguishes between~1. Unique and Essential Principles for Music Therapy with people suffering from Schizophrenia with negative Symptoms,~2. Essential but not Unique Principles,~3. Acceptable but not necessary Principles,~4. Not acceptable and Proscribed Principles. These Principles concern Attitude and Listening Perspectives by the Music Therapist, how to conduct the Musical Interventions and Questions of Frames for the Music Therapy Work."
62846399|NCT02942459|ACTIVE_COMPARATOR|Music Listening|"25 Weekly Hours of Being together with an unknown Care Staff Member listening to Music from selected Play-Lists. Music Therapists at the Music Therapy Research Clinic at Aalborg University Hospital, Psychiatry have developed Play-Lists in a Taxonomy from very Supportive to less Supportive Music including around 100 Hours of Music all together on the Lists.~A Manual is created and trained with the Care Staff Members. Here the Activities are much more limited (only Music Listening to the Play-Lists are allowed). No Therapeutical Conversation is allowed."
62846400|NCT01420211|EXPERIMENTAL|Primovist|
62620297|NCT05334459||Intervention|"Operable, postmenopausal ER/PR positive and Her2 neu (-), oligometastatic dnMBC patients~* Primary tumor biopsy, Metastatic site biopsy (Bone, liver, etc)~  o ER / PR /Her2 /Ki67 study~* Collection of CTC.~* Radiotherapy (RT) to the primary breast tumor (Hypo fractionated)~* All patients will receive the standard of care treatment with CDK4/6 inhibitor + AI for 6 months (at least 26 weeks).~  o Denosumab, Biphosphonate for bone metastasis~* RT to metastatic side (if visible). Continue Systemic therapy~* 12 months, patients will have LRT surgery (BCS/mastectomy + LN evaluation; SLNB+ALND) + RT (based on the institutional practice). Collect CTC and ER/PR/Her 2 in the final specimen~* ST will be continued until progression and/or unmanageable toxicity.~* Radiologic evaluation every 3-6-month based on institutional practice."
62620298|NCT00488137|ACTIVE_COMPARATOR|1|Prucalopride 2 mg
62059963|NCT05796180|EXPERIMENTAL|Behavioral: sexual health counseling based on the BETTER model|"Sexual health counseling based on the BETTER model~The content of the research will be discussed by face-to-face interviews with women who gave birth vaginally and applied to the hospital for birth control 8-10 weeks after delivery. Pre-evaluation forms will be applied to women who have agreed to participate in the study to evaluate the inclusion criteria. Women who meet the inclusion criteria will be divided into experimental-control groups using the block randomization method.~An appointment will be made for interviews with the women in the experimental group. It is planned that these meetings will be held in the form of online video calls and will last an average of 45 minutes. The final tests will be held 8 weeks after the online meetings are over."
62620299|NCT00488137|PLACEBO_COMPARATOR|3|Placebo
62846401|NCT06164340||Case group - Mother-child dyads|Case group: mother-child dyads (including children with overweight or obesity and early adiposity rebound).
62846402|NCT06164340||Control group - Mother-child dyads|Control group: mother-child dyads (including children with healthy weight).
62846403|NCT02888938||Patients suspected of SpA|
62846404|NCT06120829|ACTIVE_COMPARATOR|Control Arm|FNA followed by Core Needle biopsy
62059964|NCT05796180|NO_INTERVENTION|Control group: Routine postpartum care|"Routine postpartum care~Women who gave birth vaginally and applied to the hospital for postpartum controls 8-10 weeks after delivery will be interviewed face-to-face with the women and the content of the research will be mentioned. Pre-evaluation forms will be applied to the women who accepted to participate in the study to evaluate the inclusion criteria. Women who meet the inclusion criteria will be divided into experimental-control groups using the block randomization method. Women in the control group will receive routine postpartum care administered in the hospital. Women in the control group will receive routine postpartum care administered in the hospital. Post-tests will be administered 8 weeks after the first interview."
62059965|NCT04228640|EXPERIMENTAL|Investigational Product|Ingredient: NMN Dosage form: Capsule, 150 mg/capsule Frequency: 2 capsules per day Duration: 60 days
62059966|NCT04228640|PLACEBO_COMPARATOR|Placebo|Ingredient: Starch powder Dosage form: Capsule, 150 mg/capsule Frequency: 2 capsules per day Duration: 60 days
62059967|NCT04269018|EXPERIMENTAL|Cancer specific Mobile text message|This arm will receive daily mobile text message related with cancer risks and prevention
62059968|NCT04269018|ACTIVE_COMPARATOR|general health messages|This arm will receive general health message once a week
62059969|NCT01908322||Group 1|
62059970|NCT01483937|ACTIVE_COMPARATOR|Usual care physical therapy only|Subjects will receive usual care physical therapy intervention provided by vestibular and balance specialists. Usual care physical therapy, in general, includes but is not limited to static and dynamic balance activities with or without head movements on firm floor or compliant surfaces.
62263769|NCT04671277|EXPERIMENTAL|Chewing of breads|"6 samples (2x3 full factorial design with 2 white sandwich bread types (a regular gluten-containing (GC) and a gluten-free version (GF)) and 3 spread conditions (no spread, butter and mayonnaise)) were evaluated in two sessions of 30 min each. The first session was designed for video recording and the second session for the evaluation of texture attributes and collection of food bolus.~Bread samples were served as two stacked cylinders resembling the consumption of a sandwich (diameter: 3.5 cm, approximate total height: 2.4 cm) (Figure 1). Due to differences in bread density, the average weight of two stacked cylinders was 5.1 ± 0.2 and 5.7 ± 0.4 for GC and GF breads, respectively. Butter and mayonnaise were added to breads at approximately 12% w/w."
62263770|NCT04608227||Third trimester pregnant women undergoing ceasarean section|
62263771|NCT04064502||volunteers|273 adult volunteers ranging from 18-78 years old
62263772|NCT01761084|EXPERIMENTAL|Exercise and behaviour change strategies|The exercise program will include strength training, balance training and cardiovascular exercise that is individually tailored to the participants' abilities. The physical therapist will also implement strategies to assist with behaviour change, such as documenting progress in a log, participating in action planning and coping planning, and using techniques in the spirit of motivational interviewing.
62263773|NCT01761084|NO_INTERVENTION|General health or social discussion|Participants in the control group will receive equal attention, but will not be prescribed exercise, or participate in counselling about exercise. The physical therapist will discuss topics related to general health.
62620300|NCT00488137|ACTIVE_COMPARATOR|2|Prucalopride 4 mg
62846405|NCT06120829|EXPERIMENTAL|Experimental Arm|FNA followed by cryobiopsy through a introducer sheath
62846406|NCT01074593|EXPERIMENTAL|Test|Bergamo - Interferon beta-1a
62846407|NCT01074593|ACTIVE_COMPARATOR|Comparator - Merck Serono|Merck Serono - Interferon beta-1a
62846408|NCT00554710|EXPERIMENTAL|1|Patients received three infusions of infliximab 5 milligrams per kilogram (weeks 0, 2 and 6) in combination with azathioprine 2-2.5 milligrams per kilogram per day from day 0 onwards. If the patients responded and tolerated both drugs, azathioprine was continued for the duration of the trial. Patients who were intolerant to azathioprine received methotrexate at an initial dose of 25 milligrams administered subcutaneously each week for 12 weeks with dose reduction to 15 milligrams per week thereafter. Following initial therapy, patients who developed worsening symptoms were retreated with additional infusions of infliximab. If symptoms persisted methylprednisolone was initiated and azathioprine or methotrexate was continued.
62620301|NCT00284011|ACTIVE_COMPARATOR|SAMe|Two 400 mg pills.
62620302|NCT00284011|PLACEBO_COMPARATOR|Placebo|Two placebo pills (identical in appearance to SAMe).
62620303|NCT01575002|EXPERIMENTAL|Active tDCS|Subjects will undergo 20 minutes of active tDCS stimulation.
62846409|NCT00554710|ACTIVE_COMPARATOR|2|Induction with methylprednisolone (MP) or budesonide (BUD): MP 32 mg/day for 3 weeks was followed by tapering by 4 mg per week to 0; BUD 9 mg per day for 8 weeks with tapering to 0 by 3 mg per week thereafter.Patients who worsened during the tapering had the dose increased to the initial dose and tapered again. If patients worsened, azathioprine (2-2.5 mg per day) was introduced. Patients who relapsed following withdrawal of steroids received a second course in combination with azathioprine. For patients who failed 4 weeks of steroids, MP dose was given at 64 mg/day for 2 weeks, tapered by 8 mg per week; azathioprine was added. Patients who remained symptomatic despite 16 weeks of azathioprine received infliximab (5 mg/kg IV at weeks 0, 2 and 6). Patients who relapsed despite methotrexate or those intolerant to both azathioprine and methotrexate also received infliximab, without antimetabolite therapy. Infliximab was repeated upon relapse of symptoms in these patients.
62846410|NCT04985552|EXPERIMENTAL|ciNPT|
62846411|NCT04985552|ACTIVE_COMPARATOR|Conventional tape dressings|
62846412|NCT01805791|PLACEBO_COMPARATOR|Placebo|Placebo, oral tablets, three times a day
62263774|NCT05373654|EXPERIMENTAL|Patients that have at least one year of follow-up since the procedure.|
62263775|NCT05030870|EXPERIMENTAL|Capnographic monitoring group|In this group, in addition to the standard monitoring including observation, pulse oxygen saturation, non-invasive blood pressure, electrocardiogram in selected patients, the capnographic is also monitored. The capnographic data of the patients are available for additional noninvasive assessment of ventilation.
62263776|NCT05030870|ACTIVE_COMPARATOR|Standard monitoring group|In this group, standard monitoring including observation, pulse oxygen saturation, non-invasive blood pressure, electrocardiogram in selected patients. Capnographic data are not visible by closing the CO2 sampling line till the endoscopy end.
62263777|NCT05032612|EXPERIMENTAL|PBM Therapy|
62263778|NCT05032612|SHAM_COMPARATOR|PBM Sham|
62263779|NCT01819051|EXPERIMENTAL|Plasma|Apply plasma to great toenail for up to 20 minutes, 1X/week for 3 weeks
62263780|NCT01379274|EXPERIMENTAL|lenalidomide and azacitidine combination|Lenalidomide and azacitidine combination to be utilized in patients who did not respond to 3 months of lenalidomide monotherapy.
62263781|NCT04963556|EXPERIMENTAL|Red Bull|Drinking of 355 ml Red Bull
62263782|NCT04963556|PLACEBO_COMPARATOR|Placebo|Drinking of 355 ml sweetened water
62263783|NCT04687787|EXPERIMENTAL|Group I|This group will receive Core Stability Exercises with Application of TENS
62263784|NCT04687787|ACTIVE_COMPARATOR|Group II|This group will receive Routinely prescribed Exercises with application of TENS
62447887|NCT01908114|EXPERIMENTAL|Group C|All Interventions of Group A and B Plus combined bOPV/IPV strategy in the SIAs during the project
62620304|NCT01575002|SHAM_COMPARATOR|Sham tDCS|Subjects will undergo 20 minutes of sham tDCS stimulation.
62620305|NCT05989971||Extracorporeal carbon dioxide removal combined with continuous renal replacement therapy|extracorporeal carbon dioxide removal combined with continuous veno-venous hemofiltration or continuous veno-venous hemodialysis.CVVH and CVVHD set-up: predilution 30 ml/kg/h, dialysate dose 30 ml/kg/h, ultrafiltration rate was equal to the total rate of substitution fluid infusion.
62846413|NCT01805791|EXPERIMENTAL|HMPL-004 1800 mg/day|1 600 mg HMPL-004 tablet, 2x400 mg placebo tablets taken 3 times a day
62846414|NCT01805791|EXPERIMENTAL|HMPL-004 2400 mg/day|2 x 400 mg HMPL tablets, 1 x 600 mg placebo tablet, taken 3 times per day
62846415|NCT02059291|EXPERIMENTAL|crFMF: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing \<= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing \<= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration.
62447888|NCT02318498|ACTIVE_COMPARATOR|Prospective MINCA patients|Patients with MINCA prospectively investigated with an early CMR with latest technique
62447889|NCT02318498|PLACEBO_COMPARATOR|Historical MINCA patients|Patients with MINCA investigated earlier with a late CMR (median 12 days)
62620306|NCT03411902|ACTIVE_COMPARATOR|Risedronate|Experimental: Risedronate sodium,150 mg capsule once every 4 weeks for 24 weeks.
62846416|NCT02059291|PLACEBO_COMPARATOR|crCMF: placebo|"During epoch 2, participants received matching placebo to canakinumab 150 mg Participants who required blinded escape,they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing \<= 40kg) between day 8 and day 28, and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab.~150mg, participants were uptitrated to open-label canakinumab 300 mg."
62447890|NCT02958956||Ever User of Pioglitazone|Ever user of pioglitazone was defined as having filled 2 prescriptions for the drug within a 6-month period.
62620307|NCT03411902|PLACEBO_COMPARATOR|Placebo|Active comparator: Identical 150 mg placebo capsules once every 4 weeks for 24 weeks.
62620308|NCT02393235||unexplained infertility(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
62620309|NCT02393235||tubal infertility(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
62263785|NCT01187953|EXPERIMENTAL|LCP-Tacro|The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
62447891|NCT02958956||Never User of Pioglitazone|Never user of pioglitazone, which included participants receiving no diabetes medications, with fewer than 2 pioglitazone prescription fills in a 6-month period, and with use of diabetes medications other than pioglitazone.
62263786|NCT01187953|EXPERIMENTAL|Prograf (tacrolimus)|Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Doses will be adjusted according to whole blood tacrolimus trough levels. In the initial post-transplant period, plasma trough levels will be measured at 24 and 48 hours. Study drugs will be adjusted to maintain the whole blood pre-dose (trough) concentration of tacrolimus in the target range of 6 - 11 ng/mL for the first 30 days, then 4 - 11 ng/mL for the remainder of the study.
62263787|NCT03923972||Patients with chronic kidney disease|Patients with non dialysis dependent chronic kidney disease stages 4-5, patients on renal replacement therapy treated with peritoneal dialysis or hemodialysis, patients after renal transplantation
62263788|NCT03923972||Nephrologists|physicians treating patients with chronic kidney disease
62263789|NCT03923972||Nephrology nurses|nurses caring for patients with chronic kidney disease
62263790|NCT03923972||heads of Nephrology departments|Medical and/or administrative directors of e nephrology department with knowledge of the healthcare system in their country
62263791|NCT02534701||ERIC® and SOFIA™|ERIC® device in combination with SOFIA™ Distal Access Catheter
62263792|NCT00003625|EXPERIMENTAL|Stratum 1|Concomitant irradiation and vincristine sulfate in esc dose beginning with 0.8 mg/m2, etoposide and Cyclosporine A given over 6 weeks, then monthly maint courses over 6 mths, with no clinical and radiologic progression. Stable disease indicates continuation of therapy. Clinical deterioration within 4 months of completion of radiation therapy must be confirmed to be PD by imaging. Clinical progression even in the absence of imaging changes will be accepted as reflecting disease progression. Steroids dexamethasone (Decadron) given as clinically indicated and tapered as tolerated. Steroids may decrease capillary permeability to chemotherapeutic agents and antagonise the effect of cyclosporin A. Also contributes to the syndrome of seizures and white matter changes seen with cyclosporine in the post BMT period. If steroid use is required, the recommended schedule of Decadron dosing during the 6 week induction course is 8 mg/m2 divided q 6-8 hours.
62263793|NCT01761292|EXPERIMENTAL|Givinostat|Givinostat will be administered as 2 oral doses daily while the child is in fed state.
62846417|NCT02059291|EXPERIMENTAL|HIDS/MKD: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing \<= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing \<= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration.
62846418|NCT02059291|PLACEBO_COMPARATOR|HIDS/MKD: placebo|During epoch 2, participants received matching placebo to canakinumab 150 mg qw4. Participants who required blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing \<= 40kg) between day 8 and day 28 and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab 150mg, participants were uptitrated to open-label canakinumab 300 mg.
62263794|NCT02396134|EXPERIMENTAL|Arm I (CMVpp65-A*0201 peptide vaccine)|Patients receive CMVpp65-A\*0201 peptide vaccine SC on days 28 and 56 after HCT.
62263795|NCT02396134|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo SC on days 28 and 56 after HCT.
62263796|NCT03100045|EXPERIMENTAL|ART 200 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 200 mg/day
62263797|NCT03100045|EXPERIMENTAL|ART 200 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 200 mg/day
62263798|NCT03100045|EXPERIMENTAL|ART 400 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 400 mg/day
62620310|NCT02393235||fertile group(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
62620311|NCT02072070|EXPERIMENTAL|TissueGene-C|Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10\^7 cells
62620312|NCT02072070|PLACEBO_COMPARATOR|Placebo|Single intra-articular injection to the damaged knee joint
62263799|NCT03100045|EXPERIMENTAL|ART 400 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 400 mg/day
62263800|NCT03100045|EXPERIMENTAL|ART 600 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 600 mg/day
62263801|NCT03100045|EXPERIMENTAL|ART 600 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 600 mg/day
62263802|NCT00575627|NO_INTERVENTION|2|
62263803|NCT00575627|EXPERIMENTAL|1|Drug: peginterferon α-2a (40 kDa) plus ribavirin for 24-48 weeks
62263804|NCT06171321|NO_INTERVENTION|Group 1: Patients testing negative for ctDNA treated using standard of care treatment|Postoperative ctDNA-negative patients receive oral Teysuno (S-1) for adjuvant therapy。
62263805|NCT06171321|EXPERIMENTAL|Group 2: Patients with a positive ctDNA test are treated with an escalation strategy|Postoperative ctDNA-positive patients receive intravenous combined oral Teysuno (S-1) for adjuvant therapy。
62263806|NCT05654389|EXPERIMENTAL|Application of teleconsultation using WhatsApp to refer patient with with myocardial infarction|Application of teleconsultation using WhatsApp for a patient with myocardial infarction with a provisional diagnosis of myocardial infarction during referral from a district hospital to a cardiac centre.
62620313|NCT02875873|EXPERIMENTAL|Plasma-Lyte, Slow Infusion|Plasma-Lyte will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h.
62059971|NCT01483937|EXPERIMENTAL|Usual care physical therapy plus SEMD|"Subjects will receive usual care physical therapy intervention provided by vestibular balance specialists while using the Sensory Enrichment Multimodal Device (SEMD). SEMD protocols use visual, vibrotactile, and auditory cueing referenced to subject's Center of Gravity (COG) and/or Sum of Pressure (SOP) data collected from a force platform upon which the subject is placed. Static and dynamic balance activities with or without head movement are preformed while watching a computer screen; paced with an auditory metronome; and cued by touch vibration via coin tactors imbedded in a belt worn around the waist matching the COG/SOP data display."
62059972|NCT00909428|EXPERIMENTAL|Solifenacin Succinate|The intervention for this study is 10mg daily solifenacin. Patients with overactive bladder syndrome will take this study drug for 30 days.
62059973|NCT06138249|EXPERIMENTAL|Calcifediol each month|Calcifediol 0,266 mg each month
62059974|NCT06138249|EXPERIMENTAL|Cholecalciferol 25.000 UI|Cholecalciferol 25000UI each 15 days
62059975|NCT06138249|EXPERIMENTAL|Calcifediol 4 drops each day|Calcifediol 4 drops each day
62059976|NCT04011579|EXPERIMENTAL|MSFIT|The MSFIT group will self-manage Pilates exercises at-home through a tool based on XBox Kinect for 12 weeks, performing at least 3 sessions/week for a total of 30 minutes of exercises for each session(also distributed during the day with a minimum slot of 10 minutes). No rehabilitative interventions except sphincter and speech rehabilitation and psychological support, are admitted for the 12 weeks of participation to the project and the following 6 weeks before Follow-up evaluations (a total of 18 weeks). The execution of unspecific physical activities, if not already practiced, will be suggested to the participants.
62059977|NCT04011579|NO_INTERVENTION|CTRL|No rehabilitative interventions except sphincter and speech rehabilitation and psychological support, are admitted for the 12 weeks of participation to the project and the following 6 weeks before Follow-up evaluations (a total of 18 weeks). The execution of unspecific physical activities, if not already practiced, will be suggested to the participants.
62059978|NCT01023243|PLACEBO_COMPARATOR|1 CAre of the Feet for Those at Risk|secular trends for physician documentation in the medical record for care of the feet for high risk patients
62059979|NCT01023243|ACTIVE_COMPARATOR|Care of the feet for those at risk|the impact of 1) patient survey regarding last foot exam, tobacco and aspirin use on documentation of foot exam and 2) patient education material: Care of the Foot For Those at Risk, on documentation of foot examination in the medical record
62059980|NCT01023243|ACTIVE_COMPARATOR|Impact of Quality Survey|Impact of patient survey regarding last foot exam, tobacco and aspirin use on documentation of foot exam in the medical record
62059981|NCT06063122|SHAM_COMPARATOR|Control Group: Non-contingent exposure to recorded mother's voice|Participants will receive 20 minutes of non-contingent recorded mother' voice during two 20-minute sessions, with a maximum of 2 sessions per day. Recordings are played through the smallTalk speaker device in passive mode, which limits play time to 20-minute exactly and volume to 45 dB in the A-weighted scale as per American Academy of Pediatrics recommendations. For these sessions, the therapist will remain at bedside with the infant and the device, as if they were administering the intervention. Nurses do not typically remain at bedside for the procedure due to workload issues and the low risk of the intervention.
62263807|NCT05654389|NO_INTERVENTION|Routine care and handling of a patient with mycardial infarction at peripheral hospital|Routine care and consultation received by a patient with a provisional diagnosis of myocardial infarction during referral from the district hospital to the cardiac centre
62620314|NCT02875873|EXPERIMENTAL|Plasma-Lyte, Fast Infusion|Plasma-Lyte will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h.
62620315|NCT02875873|EXPERIMENTAL|Saline 0.9%, Slow Infusion|Saline 0.9% will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h.
62846419|NCT02059291|EXPERIMENTAL|TRAPS: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing \<= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing \<= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration
62059982|NCT06063122|EXPERIMENTAL|Intervention Group: Contingent exposure to recorded mother's voice|Participants will receive 20 minutes of contingent recorded mother' voice also at 45 dBA, during two 20-minute sessions, with a maximum of 2 sessions per day. The smallTalk Active system integrates a wireless, lightweight and sealed sensor unit that securely fits into a Philips NICU Soothie pacifier. The speaker device is factory set to communicate constantly with the sensor unit, and to only deliver a predetermined 10 seconds of recorded parent's voice upon detection of a suck that meets a pressure threshold, which is automatically set by the speaker device.
62059983|NCT02661802|EXPERIMENTAL|Oxygen Supplementation|Two six-minute walk tests, one with oxygen supplementation and another without were performed on different days. During the test with oxygen supplementation the delivery was continuous by mask at 40% and technician walked behind the patient with the oxygen source.
62059984|NCT02258048||Patients with cirrhosis|
62059985|NCT00978965||All patients|
62447892|NCT02984436||ED Patients with Acute Chest Pain|Emergency Department (ED) Patients with Acute Chest Pain will have blood samples collected for High sensitivity cardiac troponin T (hs-CTnT) analysis. Results from this analysis will be integrated into the HEART Score/Pathway. It will later be seen if integration of the hs-cTnT outperforms the use of HEART Score/Pathway alone.
62447893|NCT01626859|EXPERIMENTAL|MP-214 3mg|
62620316|NCT02875873|EXPERIMENTAL|Saline 0.9%, Fast Infusion|Saline 0.9% will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h.
62620317|NCT05889208|ACTIVE_COMPARATOR|Prophylactic pacemaker implantation|Brady-pacemaker implantation prior the TAVI-procedure. Pacemaker modus is according to local conditions.
62620318|NCT05889208|NO_INTERVENTION|Usual care|Pacemaker implantation after TAVI if atrioventricular block occurs.
62620319|NCT04755738|EXPERIMENTAL|Almonertinib plus Microwave ablation group|Patients in the group were treated with both targeted therapy and microwave ablation. Patients were treated with Almonertinib with the dose of 110mg once daily firstly. When the best response achieved, microwave ablation was conducted in the primary tumors, and then followed by Almonertinib treatments.
62620320|NCT04755738|ACTIVE_COMPARATOR|Almonertinib group|Patients in the group were treated with Almonertinib with the dose of 110mg once daily until disease progression, death or intolerable adverse events.
62059986|NCT02425748|EXPERIMENTAL|Group A|DC-CIK cells will be used against tumor cells.
62447894|NCT01626859|EXPERIMENTAL|MP-214 6mg|
62447895|NCT01626859|EXPERIMENTAL|MP-214 9mg|
62447896|NCT03513354|NO_INTERVENTION|Control group|The control group did not perform any of the interventions.
62447897|NCT03513354|EXPERIMENTAL|Soil group|(2) Stretching from the lateral flexors of the cervical spine, elbow flexors and extensors, trunk lateral flexors, flexors and extensors of hip with support of 30 seconds (1x30), (3) aerobic workout through front and lateral gait walking for 20 minutes, (4) resisted exercise for upper limbs (anterior, middle and posterior deltoid, biceps, triceps) and to the lower limbs (abductors, flexors and extensors of hip and flexors and extensors knee, calf), using dumbbells and shin guards for the resistance (20 minutes), (5) balance and proprioception training through front and backward walking on mattresses, march in a straight line with one foot in front of the other, one-feet support orthostatism, touching some points marked on the ground with the toe (15 minutes)
62620321|NCT02128334||Patients with advanced prostate carcinoma|
62620322|NCT01234064|ACTIVE_COMPARATOR|Graduated Compression Stockings|
62620323|NCT01234064|OTHER|No Graduated Compression Stockings|
62620324|NCT04040465|ACTIVE_COMPARATOR|Normal Weight/Low Dose Aspirin|BMI 22-25 kg/m\^2 \& receiving 81mg Aspirin daily for 2 weeks
62620325|NCT04040465|ACTIVE_COMPARATOR|Normal Weight/Normal Dose Aspirin|BMI 25-30 kg/m\^2 \& receiving 325mg Aspirin daily for 2 weeks
62620326|NCT04040465|ACTIVE_COMPARATOR|Normal Weight/High Dose Aspirin|BMI \> 30 kg/m\^2 \& receiving 500mg Aspirin daily for 2 weeks
62620327|NCT04040465|ACTIVE_COMPARATOR|Overweight/Low Dose Aspirin|BMI 22-25 kg/m\^2 \& receiving 81mg Aspirin daily for 2 weeks
62620328|NCT04040465|ACTIVE_COMPARATOR|Overweight/Normal Dose Aspirin|BMI 25-30 kg/m\^2 \& receiving 325mg Aspirin daily for 2 weeks
62620329|NCT04040465|ACTIVE_COMPARATOR|Overweight/High Dose Aspirin|BMI \> 30 kg/m\^2 \& receiving 500mg Aspirin daily for 2 weeks
62620330|NCT04040465|ACTIVE_COMPARATOR|Obese/Low Dose Aspirin|BMI 22-25 kg/m\^2 \& receiving 81mg Aspirin daily for 2 weeks
62620331|NCT04040465|ACTIVE_COMPARATOR|Obese/Normal Dose Aspirin|BMI 25-30 kg/m\^2 \& receiving 325mg Aspirin daily for 2 weeks
62620332|NCT04040465|ACTIVE_COMPARATOR|Obese/High Dose Aspirin|BMI \> 30 kg/m\^2 \& receiving 500mg Aspirin daily for 2 weeks
62620333|NCT04154839||Atopic dermatitis group|Number of subjects in atopic dermatitis group 0 - \< 6 years : 50 subjects 6 - \<12 years : 50 subjects 12 - \<18 years : 50 subjects Adult (\>= 18 years) : 150 subjects Total no. of cases: 300 cases
62620334|NCT04154839||Control group|\>= 40 yrs : 150 subjects
62620335|NCT03158610|EXPERIMENTAL|Capecitabine metronomic chemotherapy|Capecitabine 500mg/m2 bid po qd
62620336|NCT03158610|ACTIVE_COMPARATOR|Capecitabine standard dosage chemotherapy|Capecitabine 1000mg/m2 bid po d1-d14,q3w
62620337|NCT01675388|EXPERIMENTAL|Hypothermia|Hypothermia to 33.5 deg Centigrade
62059987|NCT02425748|EXPERIMENTAL|Group B|γδ T cells will be used against tumor cells.
62059988|NCT02425748|EXPERIMENTAL|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
62059989|NCT02320747|EXPERIMENTAL|Tai Chi Group|Experienced instructor at teaching tai chi delivered in a group setting in the community lasted approximately 40 minutes. Participants in the program served as an active control group that matched to the program and delivered.The class comprised mainly seated exercises including stretching, low-level strength, and low-level cardiovascular exercise. Participants walked (warm-up and cool-down) for 7 min in class, remaining seated or standing with arm support the rest of the time.
62059990|NCT02320747|NO_INTERVENTION|Control Group|
62059991|NCT03221088|EXPERIMENTAL|Jintrolong® low dose group|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
62059992|NCT03221088|EXPERIMENTAL|Jintrolong® high dose group|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
62059993|NCT03221088|NO_INTERVENTION|Negative control group|Untreated Control Group
62263808|NCT00466466|EXPERIMENTAL|Daily dosing RAD001|
62263809|NCT00466466|EXPERIMENTAL|Weekly dosing RAD001|
62263810|NCT05168800|EXPERIMENTAL|Dialogue-Based Webinar|
62263811|NCT05168800|EXPERIMENTAL|Social Media Website|
62263812|NCT05168800|ACTIVE_COMPARATOR|Enhanced Usual Practice|
62263813|NCT04899700|PLACEBO_COMPARATOR|WLE-LCI|First endoscopist will perform an optical diagnosis of recurrence of post-polypectomy scar with WLE. Then a second diagnosis will be performed by the same endoscopist with blue light imaging (BLI)
62263814|NCT04899700|ACTIVE_COMPARATOR|LCI-WLE|First endoscopist will perform an optical diagnosis of recurrence of post-polypectomy scar with Linked Color Imaging (LCI). Then a second diagnosis will be performed by the same endoscopist with blue light imaging (BLI)
62263815|NCT06490835|EXPERIMENTAL|Critically ill patients requiring ICU admission and their surrogates|Participants receive high-quality palliative care through consultation-based palliative care services in addition to standard critical care.
62263816|NCT01227187|EXPERIMENTAL|Xigris|Drotrecogin alfa activated (Xigris) used as anticoagulant in patients treated with hemodialysis.
62263817|NCT02499679||Patients diagnosed with CAD by cCTA|All clinically stable, symptomatic patients diagnosed with CAD by coronary computed tomography angiography (cCTA), that meet eligibility criteria, and are able and willing to participate are candidates for the ADVANCE Registry. Those patients that meet all inclusion/exclusion criteria and who sign the ethics committee (EC)/institutional review board (IRB) approved informed consent will be enrolled in the registry. FFRCT shall be used in accordance with the current Instructions for Use (IFU) document.
62263818|NCT00553709|EXPERIMENTAL|Nicotine patch|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
62059994|NCT03322371|OTHER|Health Subjects in Sleep Lab|Adult patients (\> 18yrs old) scheduled for a standard of care PSG (sleep study) lasting at least 8 hours for any condition. Patients will undergo simultaneous 2-lead limited EEG recording with experimental device. 2-lead limited electroencephalography recording
62059995|NCT03322371|OTHER|ICU patients, not sedated or ventilated|Adult ICU patients (\> 18yrs old) anticipated to stay in the ICU overnight (minimum 8 hours) with a Glasgow Coma Scale of 13 or greater, not intubated and not sedated. Patients will undergo simultaneous 2-lead limited electroencephalography recording
62059996|NCT03322371|OTHER|ICU patients, sedated and ventilated|Adult ICU patients (\> 18yrs old) who are intubated, sedated, ventilated, and anticipated to stay in the ICU overnight (minimum 8 hours). Patients will undergo simultaneous 2-lead limited electroencephalography recording
62263819|NCT00553709|PLACEBO_COMPARATOR|Placebo patch|Placebo patch 10 cm2
62263820|NCT04539340|OTHER|Cohort 1 GNR-055 (0.3 mg/kg)|GNR-055 (0.3 mg/kg) Single intravenous administration GNR-055
62263821|NCT04539340|OTHER|Cohort 2 GNR-055 (0.5 mg/kg)|GNR-055 (0.5 mg/kg) Single intravenous administration GNR-055
62447898|NCT03513354|EXPERIMENTAL|Pool group|(2) Stretching from the lateral flexors of the cervical spine, elbow flexors and extensors, trunk lateral flexors, flexors and extensors of hip with support of 30 seconds (1x30), (3) aerobic workout through front and lateral gait walking for 20 minutes, (4) resisted exercise for upper limbs (anterior, middle and posterior deltoid, biceps, triceps) and to the lower limbs (abductors, flexors and extensors of hip and flexors and extensors knee, calf), using dumbbells and shin guards for the resistance (20 minutes), (5) balance and proprioception training through front and backward walking on mattresses, march in a straight line with one foot in front of the other, one-feet support orthostatism, touching some points marked on the ground with the toe (15 minutes)
62059997|NCT06386003|EXPERIMENTAL|Experimental|Single dose of psilocybin 25mg Massed cognitive processing therapy
62059998|NCT05931627|NO_INTERVENTION|Control|Patients undergoing patellar bone-tendon-bone autograft ACL reconstruction with a tourniquet used for the duration of the case.
62263822|NCT04539340|OTHER|Cohort 3 GNR-055 (1 mg/kg)|GNR-055 (1 mg/kg) Single intravenous administration GNR-055
62263823|NCT04539340|OTHER|Cohort 4 GNR-055 ( 2 mg/kg)|GNR-055 ( 2 mg/kg) Single intravenous administration GNR-055
62263824|NCT04539340|OTHER|Cohort 5 GNR-055 (3 mg/kg)|GNR-055 (3 mg/kg) Single intravenous administration GNR-055
62263825|NCT03476499|EXPERIMENTAL|Planned skin flap procedure|"Inclusion Criteria: i. Planned skin flap procedure, ii. SpO2 above 96% and iii: Written informed consent.~Exclusion criteria: Use of epinephrine, patent blue V or methelyne blue during procedure.~The near infrared imaging NIR device is experimental. Experimental means that the NIR imaging is not used routinely in patients' care.~The research will require no extra study visits. Images will be taken at 3 - 4 time points and a separate photo consent will be obtained prior to imaging.~* One set of pre-procedure images, NIR images will be taken prior to the start of the breast surgery.~* One set of intra-operative Images that will be taken intra-operatively following the mastectomy.~* One to two follow-up sets of NIR images will be taken at the standard post-op follow-up visits at 1 to 2 weeks post-op for up to 30 days post-op. Follow-up visits will be scheduled as per the standard of care."
62263826|NCT00978211|EXPERIMENTAL|DOTA-TOC|Treatment arm
62263827|NCT03746704|EXPERIMENTAL|89Zr˗DFO˗REGN3504|Part A: Cohorts 1-3 Part B
62263828|NCT04486092|EXPERIMENTAL|Valproic Acid|
62447899|NCT05259033|EXPERIMENTAL|IcoSema|Participants will get once weekly dose
62447900|NCT05259033|EXPERIMENTAL|Semaglutide|Participants will get once weekly dose
62447901|NCT05253560||Carriers of Gaucher disease|Family of patients with Gaucher disease, sequenced for the GBA1 gene.
62263829|NCT02544711|EXPERIMENTAL|Prospective group :Innovation|Surgical treatment using a patient specific instrument (PSI)
62263830|NCT02544711|OTHER|Retrospective group: Reference|Conventional surgical treatment without PSI, using 2D imaging planification
62263831|NCT05998421|ACTIVE_COMPARATOR|the drug group (control group)|The patients in the control group accepted routine aspirin and heparin treatment. Two months before pregnancy, 50 mg of aspirin (Chenxin Pharmaceutical, China) was taken orally once a day.
62263832|NCT05998421|EXPERIMENTAL|the drug-accompanied-by-acupuncture group (acupuncture group)|The patients in the acupuncture group accepted acupuncture treatment weekly from the second day of menstruation and three times in one cycle.
62263833|NCT04989283|EXPERIMENTAL|Arm I (atezolizumab, chemotherapy, RT, surgery)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Patients also receive one of the chemotherapy combinations below depending on their previous therapy and disease. Between the first day of chemotherapy and the first day of cycle 2 of chemotherapy, patients undergo external beam radiation therapy 5 days per week. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning 21 and 90 days after treatment, patients undergo surgery. Within 42 days after completion of surgery, patients then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients may undergo a PET scan, CT scan, and MRI on study. Patients also undergo tumor biopsies and blood sample collection throughout the trial.
62263834|NCT04989283|ACTIVE_COMPARATOR|Arm II (chemotherapy, RT, surgery)|Patients receive one of the chemotherapy combinations below depending on their previous therapy and disease. Between the first day of chemotherapy and the first day of cycle 2 of chemotherapy, patients also undergo external beam radiation therapy 5 days per week. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning 21 and 90 days after treatment, patients undergo surgery. Patients may undergo a PET scan, CT scan, and MRI on study. Patients also undergo tumor biopsies and blood sample collection throughout the trial.
62263835|NCT02263157||BSI group with thrombocytopenia|BSI patients with thrombocytopenia
62263836|NCT02263157||Non-BSI group with thrombocytopenia|Non-BSI patients with thrombocytopenia
62263837|NCT02263157||BSI group without thrombocytopenia|BSI patients without thrombocytopenia
62263838|NCT02263157||Non-BSI group without thrombocytopenia|Non-BSI patients without thrombocytopenia
62263839|NCT05790122||Group PN|The patients undergoing partial nephrectomy.
62263840|NCT05790122||Group TE|The patients undergoing renal tumor enucleation.
62263841|NCT05956951|EXPERIMENTAL|Experimental: Night three- sham, night four - active|"This arm will receive sham auditory stimulation for the first 3 nights and active auditory stimulation for the fourth night.~Night one - sham auditory stimulation, night 2 - sham auditory stimulation, night 3 - sham auditory stimulation, night 4 - active auditory stimulation"
62447902|NCT05253560||Gaucher patients|Patients from the Gaucher clinic in Shaare Zedek Medical Center, Jerusalem, Israel
62620338|NCT04456400||Derivation cohort|"The derivation sub-cohort will be used to derive optimum reconstruction algorithm parameters of MSOT images.~Primary objective of the derivation cohort is to derive Multispectral Optoacoustic Tomography (MSOT) thresholds maximizing receiver operating characteristic (ROC) to distinguish endoscopic remission from active disease.~As secondary objective, performance of the Multispectral Optoacoustic Tomography (MSOT) device will be analyzed."
62059999|NCT05931627|ACTIVE_COMPARATOR|Treatment/Intervention|Patients undergoing ACL reconstruction with a tourniquet used only during patellar bone-tendon-bone autograft harvest, for a maximum of 20 minutes.
62060000|NCT05545891|PLACEBO_COMPARATOR|Placebo|5mg once daily of placebo for three weeks, then 10mg once daily for the remaining three weeks.
62060001|NCT05545891|EXPERIMENTAL|Aripiprazole|5mg once daily of aripiprazole for three weeks, then 10mg once daily for the remaining three weeks.
62060002|NCT03271476|EXPERIMENTAL|Arms|Experimental: EMDR psychotherapy All the women will be in this arm and thus will receive the same intervention which is : 8 sessions (1 per week). The first session is an inclusion visit at Metz-Thionville Hospital, then 6 EMDR psychotherapy sessions and finally a last visit one month after for data recovery (questionnaire and semi-directive interview)
62060003|NCT02995850|EXPERIMENTAL|anti-cancer drug|
62263842|NCT05956951|EXPERIMENTAL|Experimental: Night three - active, night four - sham|"This arm will receive sham auditory stimulation for the first two nights, active auditory stimulation for the third night, and sham auditory stimulation for the fourth night.~Night one - sham auditory stimulation, night two - sham auditory stimulation, night three - active auditory stimulation, night four - sham auditory stimulation"
62060004|NCT00925535|ACTIVE_COMPARATOR|Treatment A|Lersivirine
62060005|NCT00925535|ACTIVE_COMPARATOR|Treatment B|Rifabutin
62060006|NCT00925535|EXPERIMENTAL|Treatment C|Lersivirine and Rifabutin
62447903|NCT05253560||Healthy controls|Family members of Gaucher patients who are not carriers of Gaucher disease
62060007|NCT00618696|EXPERIMENTAL|AHN-12|2.0, 5.0, 7.5, 10.0 or 12.5 mCi/m\^2 of \^90Y-AHN-12 at Day 7/8
62060008|NCT04503096|EXPERIMENTAL|High-dose accelerated rTMS|
62060009|NCT01984801|EXPERIMENTAL|Part 1|Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.5% SLS in sterile distilled water, Each treatment will be applied using individual patches, daily for 2 days
62263843|NCT03490643|OTHER|TMD Group|people who has TMD
62263844|NCT03490643|OTHER|Control Group|individuals who dont have healthy temporomandibular joint
62263845|NCT01399788|ACTIVE_COMPARATOR|1.0|Test Myrin P Forte Contains 150mg Rifampicin, 75mg Isoniazid, 275mg Ethambutol, 400mg Pyrazinamide
62447904|NCT04156269|EXPERIMENTAL|BCMA-CD33 cCAR T cells|BCMA-CS1 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-BCMA and CS1 CARs
62447905|NCT03305055|EXPERIMENTAL|Fentanyl Plus Ketamine|"Study drug group~1. Ketamine Loading Dose (Low Dose, Slow Infusion) =~   • 0.3 mg/kg; Initiated approximately 10 minutes before wound care start, pump set to deliver slowly over approximately 5 minutes, ... Then,~2. Fentanyl Loading Dose (UC, injection) =~   • 1 mcg / kg. This is given to participants in both Group 1 and Group 2 initiated \< 1 minute prior to wound care.~3. Ketamine (Study Drug, Infusion) = • 2.5 mcg/kg/min, Pump initiates infusion immediately after the fentanyl Loading Dose and continued for session duration. The nurse determines session end, then turns off infusion.~Fentanyl PRN dose\* = 1 mcg / kg. Provided when participant requires additional pain medication."
62620339|NCT04456400||Validation cohort|Objective of the validation cohort is to confirm the performance of Multispectral Optoacoustic Tomography (MSOT) using prescribed thresholds from the derivation cohort.
62620340|NCT00305565|OTHER|Low Dose|
62620341|NCT00305565|OTHER|Medium Dose|
62263846|NCT01399788|ACTIVE_COMPARATOR|2.0|Reference Single drug reference preparations contain Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
62060010|NCT01984801|EXPERIMENTAL|Part 2|Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.1% SLS in sterile distilled water. Each treatment will be applied using individual patches, daily for 21 days
62060011|NCT01984801|EXPERIMENTAL|Part 3|Each acne patient will apply a thin coat of one or two concentration of GSK1940029 gel or vehicle to acne affected facial/neck skin by hand, once daily for 28 days
62060012|NCT05564741|ACTIVE_COMPARATOR|15 s injection time|Patients in group A will be given the spinal anesthesia with an injection time of 15 s
62060013|NCT05564741|ACTIVE_COMPARATOR|90 s injection time|Patients in group B will be given the spinal anesthesia with an injection time of 90 s
62060014|NCT01228422||1|test interferon - blausiegel
62263847|NCT00091806|EXPERIMENTAL|Cohort 1|6mg/kg of panitumumab administered once every 2 weeks until subjects develop disease progression or are unable to tolerate the study drug
62263848|NCT00091806|EXPERIMENTAL|Cohort 2|Panitumumab 9 mg/kg administered once every 3 weeks until subjects develop disease progression or are unable to tolerate the study drug.
62263849|NCT02170402|EXPERIMENTAL|Previously Treated Patients (PTPs)|"PTPs will participate sequentially with:~Part 1: Pharmacokinetic parameters of ADVATE measured in subset of 24 participants, consisting of:~* 12 adults (\>12 years of age)~* 12 children (≤12 years of age)~Part 2: On-demand treatment with ADVATE for 6 months~Part 3: Prophylaxis regimen with ADVATE for 6 months"
62263850|NCT01166737|NO_INTERVENTION|Control Arm - Chemotherapy only|Chemotherapy for platinum-sensitive Ovarian Cancer can be selected on investigators choice
62620342|NCT00305565|OTHER|High Dose|
62620343|NCT04150536|EXPERIMENTAL|Lidocaine Topical System with Moderate Exercise (Treatment A)|Three lidocaine topical systems 1.8% are applied to mid-lower back for 12 hours. Subjects are instructed to exercise 30 minutes on an exercise bicycle, achieving at heart rate of approximately 108 bpm. Exercise is performed after 2.5 hours, 5.5 hours, and 8.5 hours after topical system application.
62620344|NCT04150536|EXPERIMENTAL|Lidocaine Topical System with Heat Applied (Treatment B)|Three lidocaine topical systems 1.8% are applied to mid-lower back for 12 hours. A heating pad is applied for 20 minutes at 2.5, 5.5, and 8.5 hours after the product is applied.
62060015|NCT01228422||2|reference interferon - Roferon A (Roche)
62060016|NCT05313750|EXPERIMENTAL|sitafloxacin group|Oral sitafloxacin (0.1g one time daily) for 10 days
62060017|NCT05313750|ACTIVE_COMPARATOR|levofloxacin group|Oral levofloxacin (0.4g one time daily) for 10 days
62060018|NCT01897831|EXPERIMENTAL|xin te mie|1.5-3.0g,iv,bid or tid for 7-14 days
62060019|NCT04302831|ACTIVE_COMPARATOR|Standard|The standard arm consists of strength, endurance and flexibility exercises 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
62263851|NCT01166737|EXPERIMENTAL|Procedure/Surgery|Maximum effort cytoreductive surgery
62263852|NCT03380260|EXPERIMENTAL|Paranoia Induction|Behavioral procedure involving social exclusion and negative feedback to induce paranoia
62263853|NCT03380260|NO_INTERVENTION|Control Condition|No manipulation of paranoid ideation
62263854|NCT05873998||Adults anesthetized patients undergoing mediastinoscopy|Determination of the lung's closing pressure by pressure-CO2 and volume-CO2 curves using a slow pressure-volume curve after anesthesia induction. Later on, a standard lung recruitment maneuver followed by a positive end-expiratory pressure trial was done to detect the lung's closing pressure.
62263855|NCT02076789||ICD generator replacement|Patients with standard indications to ICD generator replacement
62263856|NCT05415995|EXPERIMENTAL|101 Patients with Below The Knee Artery stenosis or occlusion in Experimental Group|Patients in this group use Drug eluting Balloon (Zylox-tonbridge), this is the product to be test in this clinical trail. The drug we coated is paclitaxel.
62263857|NCT05415995|ACTIVE_COMPARATOR|101 Patients with Below The Knee Artery stenosis or occlusion in Controlled Group|Patients in this group use Drug eluting Balloon(Acotec), this is a product that has got approved by NMPA in 2016.
62263858|NCT04100889||Alzheimer's disease patients|Patients who have been diagnosed with Alzheimer's disease
62263859|NCT03537027|EXPERIMENTAL|Vitamin D3|2000 micrograms of vitamin D3 in two doses during one day
62263860|NCT03116074|NO_INTERVENTION|Study 1: Pre-intervention 1|"Usual care.~Patients/caregivers do not have access to patient portal. Providers have access to safety dashboard without discharge preparation indicator. Providers do not have access to secure patient-provider messaging tools."
62263861|NCT03116074|EXPERIMENTAL|Study 1: Post-intervention|"Patient-Centered Discharge Toolkit: patient portal and provider safety dashboard PLUS patient pre-discharge checklist, provider discharge preparation indicator, secure patient-provider messaging~Patients/caregivers have access to patient portal with discharge module (pre-discharge preparation checklist) and secure patient-provider messaging tools activated. Providers have access to discharge preparation indicator on safety dashboard and secure patient-provider messaging tools."
62263862|NCT03116074|NO_INTERVENTION|Study 1: Pre-intervention 2|"Usual care PLUS patient portal and provider safety dashboard.~Patients/caregivers have access to patient portal but not discharge module or secure patient-provider messaging tools. Providers have access to safety dashboard without discharge preparation indicator. Providers do not have access to secure patient-provider messaging tools."
62263863|NCT03116074|NO_INTERVENTION|Study 2: Pre-intervention|"Usual care on three general medicine units.~Patients/caregivers do not have access to the discharge preparation checklist. Providers do not have access to the safety dashboard."
62620345|NCT04150536|EXPERIMENTAL|Lidocaine Topical System under normal conditions (Treatment C)|Three lidocaine topical systems 1.8% are applied to mid-lower back for 12 hours. No heat application or exercise is performed during this period.
62846420|NCT02059291|PLACEBO_COMPARATOR|TRAPS: placebo|During epoch 2, participants received matching placebo to canakinumab 150 mg qw4. Participants who required blinded escape,they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing \<= 40kg) between Day 8 and 28 and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab 150mg, participants were uptitrated to open-label canakinumab 300 mg.
62060020|NCT04302831|EXPERIMENTAL|Standard-plus|The standard-plus arm consists of strength, endurance and flexibility exercises plus task specific timing and coordination exercises to improve gait 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
62060021|NCT03960229|EXPERIMENTAL|MicroFluidic Sperm Sorting Chips|Sperm Sorting microfluidic chips (for ICSI) will be used when preparing sperm of male partner and microinjection (ICSI) will be made with separated sperm
62060022|NCT03960229|ACTIVE_COMPARATOR|gradient-density centrifugation|gradient-density centrifugation technique will be used when preparing sperm of male partner and microinjection (ICSI) will be made with separated sperm
62060023|NCT03020563|ACTIVE_COMPARATOR|Liposomal Bupivacaine|Time release Bupivacaine
62263864|NCT03116074|EXPERIMENTAL|Study 2: Post-intervention|Patients/caregivers have access to the discharge preparation checklist. Providers have access to safety dashboard.
62263865|NCT02528903|EXPERIMENTAL|Cohort A|
62263866|NCT02528903|EXPERIMENTAL|Cohort B|
62263867|NCT02528903|EXPERIMENTAL|Cohort C|
62263868|NCT02528903|EXPERIMENTAL|Cohort D|
62060024|NCT03020563|PLACEBO_COMPARATOR|Bupivacaine|Immediate Acting Bupivacaine
62060025|NCT00518635|EXPERIMENTAL|A|Growth hormone or Placebo 0.1 mg/day self-administrated once a day.
62060026|NCT00641719|EXPERIMENTAL|Duloxetine 40 mg|Duloxetine 40 milligrams (mg) once daily (QD), orally (PO), 1 year
62060027|NCT00641719|EXPERIMENTAL|Duloxetine 60 mg|Duloxetine 60 mg QD, PO, 1 year
62060028|NCT00578721|EXPERIMENTAL|325 mg Aspirin|325 mg aspirin po qd with arginine-restricted diet
62263869|NCT02528903|EXPERIMENTAL|Cohort E|
62620346|NCT06330571|ACTIVE_COMPARATOR|Molar distalization by aligners without attachment|
62620347|NCT06330571|EXPERIMENTAL|Molar distalization by aligners with attachments|
62620348|NCT00895934|EXPERIMENTAL|Phase 1 - Dose Finding|Varying schedules and dose levels of vorinostat, azacitidine and gemtuzumab ozogamicin. Includes cohorts 1-3.
62263870|NCT03458208|EXPERIMENTAL|Metformin|"First aIntervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition~Third Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
62620349|NCT00895934|EXPERIMENTAL|Phase 2 - Treatment at Selected Dose|Vorinostat 400 mg/day on days 1-9, azacitidine 75 mg/m2/day on days 1-7, gemtuzumab ozogamicin 3 mg/m2/day on days 4 and 8.
62263871|NCT03458208|ACTIVE_COMPARATOR|Glucophage®|"Second Intervention Period:~Single administered dose of Glucophage® ( 1 000 mg tablet immediate release) in a fasting condition~Fourth Intervention Period:~Single administered dose of Glucophage® ( 1 000 mg tablet immediate release) in a fed condition"
62263872|NCT01553630|ACTIVE_COMPARATOR|RIA bone graft|Surgery: open reduction and internal fixation (ORIF) of high energy metaphyseal fractures with Reamed Irrigator Aspirator (RIA) bone graft at the time of fixation.
62263873|NCT01553630|ACTIVE_COMPARATOR|Surgery without bone graft|Surgery:open reduction and internal fixation (ORIF) of high energy metaphyseal fractures without Reamed Irrigator Aspirator (RIA) bone graft at the time of fixation.
62263874|NCT01685463|EXPERIMENTAL|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive brain stimulation technology that can focally stimulate the brain of an awake individual. The brain stimulation techniques could theoretically improve the efficacy of smoking cessation.
62263875|NCT01685463|PLACEBO_COMPARATOR|Sham Transcranial Magnetic Stimulation|Sham-TMS procedures: After rTMS determination, participants were fitted with two electrodes on the scalp just below the hairline. Electrodes will be connected to an Epix VT Transcutaneous Electrical nerve stimulation device.
62263876|NCT00710476|EXPERIMENTAL|1|Insemination of the oocytes with a lower concentration of spermatozoa.
62263877|NCT00710476|NO_INTERVENTION|2|Insemination with a normal concentration of spermatozoa.
62447906|NCT03305055|ACTIVE_COMPARATOR|Fentanyl Plus Saline|"Usual care group~1. Saline Loading Dose (Low Dose, Slow Infusion) =~   • An identical volume of saline as that in 0.3 mg/kg of ketamine. Initiated approximately 10 minutes before wound care start, pump set to deliver slowly over approximately 5 minutes, (i.e., same time/rate as STUDY DRUG GROUP receives ketamine loading dose), ... Then, ...~2. Fentanyl Loading Dose (UC, injection) =~   • 1 mcg / kg: This is given to participants in both Group 1 and Group 2 initiated \<1 minute prior to wound care.~3. Saline (Placebo, Infusion) = • Identical volume of fluid as that in 2.5 mcg/kg/min of ketamine; Pump initiates infusion immediately after the fentanyl Loading Dose and continued for session duration. The nurse determines session end, then turns off infusion.~FENTANYL PRN DOSE = 1 mcg / kg. Provided when participant requires additional pain medication."
62620350|NCT05119686|EXPERIMENTAL|Group 1|AR882 Dose 1 x 12 weeks
62620351|NCT05119686|EXPERIMENTAL|Group 2|AR882 Dose 1 x 2 weeks, then Dose 2 x 10 weeks
62620352|NCT05119686|PLACEBO_COMPARATOR|Group 3|AR882 matching placebo x 12 weeks
62060029|NCT04425018|EXPERIMENTAL|Paclitaxel + Pertuzumab + Margetuximab|"The research study procedures include screening for eligibility and study treatment including laboratory evaluations, two mandatory research biopsies and follow up visits.Cycle=21 days~* Paclitaxel- via IV, Day 1,8,15 of each cycle~* Margetuximab via IV, Day 1 of each cycle~* Pertuzumab via IV, Day 1 of each cycle"
62060030|NCT04425018|EXPERIMENTAL|Paclitaxel + Pertuzumab + Trastuzumab|"The research study procedures include screening for eligibility and study treatment including laboratory evaluations, two mandatory research biopsies and follow up visits.Cycle=21 days~* Paclitaxel- via IV, Day 1,8,15 of each cycle~* Pertuzumab via IV, Day 1 of each cycle~* Trastuzumab via IV, Day 1 of each cycle"
62060031|NCT03427554|EXPERIMENTAL|Tretinoin cream 0.1%|Once daily at home, to apply the entire affected areas of the face.
62060032|NCT03427554|ACTIVE_COMPARATOR|RETIN-A® Cream|Once daily at home, to apply the entire affected areas of the face.
62060033|NCT03427554|PLACEBO_COMPARATOR|Vehicle of the test product|Once daily at home, to apply the entire affected areas of the face.
62060034|NCT01108393|EXPERIMENTAL|Agomelatine A|
62263878|NCT03655808|EXPERIMENTAL|Cell treatment group|Patients receive both autologous BBCs transplantation and B-ACT therapy.
62263879|NCT03655808|SHAM_COMPARATOR|Control group|Patients only receive B-ACT therapy.
62263880|NCT03529266|EXPERIMENTAL|A(Surgery+PFS)|Arm A consists of the concurrent application of Porcine Fibrin Sealant (PFS) on the gastroesophageal or coloesophageal anastomosis during Mckeown surgery .
62263881|NCT01513421||Active vacuum pressure drainage|
62263882|NCT01513421||Free drainage|
62263883|NCT04265183|EXPERIMENTAL|patients treated with preformed metal crowns|All patients included received a preformed metal crown on their HSPM affected teeth.
62263884|NCT04459182|ACTIVE_COMPARATOR|Endothelial dysfunction (DE+)|obsese patient with OSA (AHI\>15) and endothelial dysfunction
62263885|NCT04459182|SHAM_COMPARATOR|No endothelial dysfunction (DE-)|obsese patient with OSA (AHI\>15) and no endothelial dysfunction
62263886|NCT04572477|OTHER|[18F]THK-5351|"1. Primary endpoint A. To compare the distribution of cerebral amyloid plaques and tau protein between stroke patients and normal controls.~2. Secondary endpoints A. To compare tau distribution on \[18F\]THK5351 PET at acute, subacute and chronic stroke stages.~B. To correlate the \[18F\]THK5351 PET findings with \[18F\]AV45 PET, brain MRI, and functional and cognitive performance.~C. To compare the \[18F\]THK5351PET, \[18F\]AV45 PET, and brain MRI findings among stroke patients with no cognitive impairment (NCI), storke patients with VaMCI and stroke patients with PSD."
62620353|NCT04163315|EXPERIMENTAL|dMRI, fMRI and electrocorticography|With this exploratory pilot study, the investigator propose a multimodal evaluation of the structural and functional connectivity of patients with brain tumours, in order to better understand the tumor-induced lesion mechanisms on brain connectivity as well as the brain plasticity mechanisms that the brain develops to maintain a level of overall function neurological. The investigator hope to obtain multimodal brain mapping of locally brain-damaged patients, with a view to improving onco-functional neurosurgical practices.
62620354|NCT01759719||PtCr stent PCI treated patients|patients treated with PCI in whichat least 1 PtCr stent was used
62620355|NCT04174365|EXPERIMENTAL|Brexpiprazole|"Participants received flexible doses of brexpiprazole 0.25 to 3 milligram per day (mg/day), orally, once daily (QD) up to Week 8. For participants with body weight \< 50 kilograms (kg) the dose was titrated up from 0.25 mg/day on Days 1 to 3, followed by 0.5 mg on Days 4 to 7, and to 1 mg on Days 8 to 14. Based on the investigator's judgment the dose was increased to 1.5 mg/day after Day 15. The dose was fixed after Week 6 and administration continued for another 2 weeks until Week 8.~For participants with body weight ≥ 50 kg the dose was titrated up from 0.5 mg/day on Days 1 to 3, followed by 1.5 mg on Days 4 to 7, and to 2 mg on Days 8 to 14. Based on the investigator's judgment the dose was increased to 3 mg/day after Day 15. The dose was fixed after Week 6 and administration continued for another 2 weeks until Week 8."
62620356|NCT04174365|PLACEBO_COMPARATOR|Placebo|Participants received brexpiprazole matching placebo orally, QD, in the same way as brexpiprazole up to Week 8.
62263887|NCT04572477|OTHER|[18F]AV-45|"1. Primary endpoint A. To compare the distribution of cerebral amyloid plaques and tau protein between stroke patients and normal controls.~2. Secondary endpoints A. To compare tau distribution on \[18F\]THK5351 PET at acute, subacute and chronic stroke stages.~B. To correlate the \[18F\]THK5351 PET findings with \[18F\]AV45 PET, brain MRI, and functional and cognitive performance.~C. To compare the \[18F\]THK5351PET, \[18F\]AV45 PET, and brain MRI findings among stroke patients with no cognitive impairment (NCI), storke patients with VaMCI and stroke patients with PSD."
62620357|NCT03940443||Ground Emergency Medical Services|Patients suffering TBI or acute MI and has been treated by GEMS dispatched by an emergency dispatch centre.
62263888|NCT03854864||Oncologists|French oncologists
62263889|NCT02043535|OTHER|Myocardial blood flow quantification|"The RA-MR™ Virtual Sequential Gas Delivery System. : delivery of CO2 in increasing levels.~Rubidium Elution System: delivery of Rb-82 through an automated pump system for myocardial PET perfusion imaging.~Persantine stress myocardial PET perfusion imaging: as a standard for comparison."
62263890|NCT03241953|EXPERIMENTAL|debridement made by ultrasonic tips|mechanical debridement made by ultrasonic polyetheretherketone coated tips developed for implant surface and combined air-flow debridement
62263891|NCT03241953|ACTIVE_COMPARATOR|implants were debrided with standard plastic curettes|dental implants were debrided with standard plastic curettes, debridement made by combined klorhegsidin rinse
62263892|NCT04111211||Individuals at high risk of developing Alzheimer's dementia|
62263893|NCT02854644|EXPERIMENTAL|glioma|1 additional blood sample for patients with glioma and without treatment
62620358|NCT03013712|EXPERIMENTAL|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen by infusion.
62620359|NCT05727150|EXPERIMENTAL|Patient operated by Supraclavicular Artery flap for Reconstruction|Supraclavicular artery flap will be used for reconstruction
62263894|NCT02854644|EXPERIMENTAL|breast cancer|2 additional blood samples for patients with localized brest cancer, metastatic breast cancer in 1st line of treatment and breast cancer in second line of treatment.
62447907|NCT01618799|ACTIVE_COMPARATOR|LAMICTAL®|Lamictal® (Lamotrigine) Tablets 25 mg of GlaxoSmithkline, USA
62447908|NCT01618799|EXPERIMENTAL|Lamotrigine Tablets 25 mg|Lamotrigine Tablets 25 mg of M/s Ipca Laboratories Limited, India
62447909|NCT02729896|EXPERIMENTAL|Dose-Escalation Phase|During the induction treatment Cycle 1 (21-day cycles): participants will receive obinutuzumab on Days 1, 8, and 15 and Pola on Day 1; Cycles 2-6: participants will receive obinutuzumab on Day 1, Atezo on Day 1, and Pola on Day 1. This is followed by obinutuzumab on Day 1 of every other month starting with Month 1 for 24 months, during maintenance treatment for FL participants.
62447910|NCT02729896|EXPERIMENTAL|Expansion Phase|For FL during the induction treatment Cycle 1 (21-day cycles): participants will receive obinutuzumab on Days 1, 8, and 15 and Pola at identified RP2D (decided from dose-escalation phase) on Day 1; Cycles 2-6: participants will receive obinutuzumab on Day 1 and Pola at RP2D on Day 1. This is followed by obinutuzumab on Day 1 of every other month starting with Month 1 for 24 months (during maintenance treatment for FL participants).
62060035|NCT01108393|PLACEBO_COMPARATOR|Placebo|
62263895|NCT02854644|EXPERIMENTAL|breast cancer HER2+|1 additional blood sample for patients with metastatic breast cancer with HER2 surexpression
62263896|NCT02854644|EXPERIMENTAL|Breast Cancer HER 2+ or HER2 triple -|1 additional blood sample for patients with breast cancer HER2 + or HER2 triple negative treated by neo adjuvant
62263897|NCT02324075|EXPERIMENTAL|Behavior change|Behavior change messaging with facilitating hardware
62263898|NCT02324075|NO_INTERVENTION|Control Arm|Standard habits and practices
62263899|NCT01881464||endothelial dysfunction assessment|This study is a one arm study . In this arm we will assess endothelial function (with Endopath device) in patients with Crohn's disease, before and after treatment of anti TNF α and other medication, and evaluate the possible role of tumor necrosis factor (TNF)-α in the pathophysiology of this abnormality.
62263900|NCT05965349|EXPERIMENTAL|Group-based MBCT|A telephone-based, 8-week MBCT session including: (1) learning mindfulness skills; (2) practicing mindfulness skills in class and at home; and (3) dialogue and inquiry.
62263901|NCT02599701|PLACEBO_COMPARATOR|Placebo|A single dose of placebo with exactly the same characteristics of the active drug at bedtime.
62263902|NCT02599701|EXPERIMENTAL|Gabapentin|A single dose of Gabapentin 300mg at bedtime.
62263903|NCT04153864|EXPERIMENTAL|Non-specialist|Trained non-mental health providers (e.g., nurses or midwives) with general healthcare professional skills (as assessed during recruitment) with no previous experience delivering psychological treatments implementing a brief, manualized behavioral activation treatment
62263904|NCT04153864|ACTIVE_COMPARATOR|Specialist|Psychiatrists, psychologists and social workers with experience in treating perinatal mental illness and a minimum of 5 years of experience delivering psychological treatments delivering a brief, manualized behavioral activation treatment
62447911|NCT02729896|EXPERIMENTAL|Safety Run-In Phase|For DLBCL, during the induction treatment Cycles 1-6 (21-day cycles): participants will receive rituximab on Day 1 and Pola on Day 1.
62620360|NCT03110081|EXPERIMENTAL|Quadratus lumborum block|Quadratus lumborum (QL) block group will receive a single shot injection of 25 ml 0.25% bupivacaine pre-operatively, followed post-operatively by infusion of ropivacaine 0.2% continuously administered via the QL catheter for at least 48 hours.
62620361|NCT03110081|ACTIVE_COMPARATOR|Epidural analgesia|Midthoracic catheters will be inserted preoperatively. A bupivacaine 0.1% infusion will be started before the surgical incision, and continuously administered for at least 48 hr at an infusion rate of 5 ml/hr.
62263905|NCT04153864|EXPERIMENTAL|Telemedicine|A brief, manualized behavioral activation treatment delivered over Zoom™ in Toronto, via Webex™ in Chapel Hill, and via Zoom™ in NorthShore
62263906|NCT04153864|ACTIVE_COMPARATOR|In-Person|A brief, manualized behavioral activation treatment delivered in-person held at participating clinical care sites within UToronto, UNC and NorthShore
62263907|NCT03027986|EXPERIMENTAL|postural rehabilitation program based on sensory-motor control|
62263908|NCT03027986|NO_INTERVENTION|Standard physiotherapy|
62263909|NCT00343889|EXPERIMENTAL|Group 1: DTaP-Hep B-PRP-T + Oral Polio Vaccine (OPV) vaccine|Participants received 3 doses of the DTaP-Hep B-PRP\~T concomitantly with Oral Polio Vaccine (OPV), 1 dose each at 6, 10, and 14 weeks of age.
62263910|NCT00343889|ACTIVE_COMPARATOR|Group 2: Tritanrix-HepB/Hib™ + OPV vaccine|Participants received 3 doses of Tritanrix-Hep B/Hib™ concomitantly with Oral Polio Vaccine (OPV) at 6, 10, and 14 weeks of age.
62263911|NCT04084574|EXPERIMENTAL|Behavioral Diet Counseling|Groups of 4-6 participants will attend 12 weekly dietitian-led counseling sessions and receive coaching on practical strategies to enhance DASH diet adherence and reduce daily sodium intake.
62263912|NCT04084574|OTHER|Standard of Care|Participants will meet one-on-one with the study dietitian for a single 30- minute encounter and be advised to limit daily sodium intake per current clinical practice guidelines for hypertension in patients with CKD. Educational handouts and tip sheets about practical strategies to reduce dietary sodium will be distributed.
62263913|NCT03551223||Women undergoing cesarean delivery with general anesthesia|Preeclamptic parturients undergoing cesarean delivery under general anesthesia
62620362|NCT06070675|OTHER|Paper bladder diary (pBD)|Patients will complete the paper bladder diary at home for at least 2 consecutive days.
62846421|NCT00632788||intervention group|patients presented with acute ST-elevation myocardial infarction and received emergency cardiac catheterization between March 1, 2007 and Oct. 31, 2007
62060036|NCT01960075|ACTIVE_COMPARATOR|Fosphenytoin (FOS)|Administer 20 mg/Kg fosphenytoin intravenously up to a maximum dose of 1500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 1500 fosphenytoin over 10 minutes.
62263914|NCT03551223||Women undergoing cesarean delivery with spinal anesth|Preeclamptic parturients undergoing cesarean delivery under regional-spinal anesthesia
62263915|NCT01302951|EXPERIMENTAL|Moxifloxacin|Moxifloxacin 400 mg i.v.
62263916|NCT01302951|NO_INTERVENTION|No drug|2 Patients were included as controls- no MXF given
62263917|NCT01155804|OTHER|Exercice|
62263918|NCT01155804|OTHER|non-exercice|
62263919|NCT01838109|EXPERIMENTAL|ONS group|oral administration of Encover 2 package for day starting at the time of discharge (200ml/package x 2, total 400Kcal/day) total 87 patients
62263920|NCT01838109|NO_INTERVENTION|Control group|no intervention total 87 patients
62263921|NCT04296370|EXPERIMENTAL|Safety Lead-in, Doublet Arm|Fluzoparib+Apatinib
62263922|NCT04296370|EXPERIMENTAL|Single Arm|Fluzoparib
62447912|NCT01892579|EXPERIMENTAL|Tailored Activity Program|"The Tailored Activity Program unfolds over 3 phases: Phase I (sessions 1-2) involves assessment of Person with Dementia (PwD)capacity and interests, caregiver (CG) interactions and the physical environment and CG education. Phase II (sessions 3-6) involves identifying and implementing 3 Activity Prescriptions tailored to PwD's cognitive and interest profile using an algorithmic guide. The prescription summarizes PwD capabilities in lay language, identifies the activity and a specific activity goal, and provides specific instructions for introducing the activity. CGs are trained to integrate activities in daily care. Also provided are simple deep breathing stress reduction techniques to address CG upset. Phase III (sessions 7-8) involves instructing CGs in simplifying activities for future cognitive declines and applying simplification principles to other care challenges."
62846422|NCT00632788||control group|patients presented with acute ST-elevation myocardial infarction and received emergency cardiac catheterization between April 1, 2006 and Feb. 28, 2007
62060037|NCT01960075|ACTIVE_COMPARATOR|Valproic acid|Administer 40 mg/Kg valproic acid intravenously up to a maximum dose of 3000 mg (75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 3000 valproic acidover 10 minutes.
62263923|NCT04296370|ACTIVE_COMPARATOR|Physician's choice chemotherapy|Capecitabine or Vinorelbine
62263924|NCT05209503|EXPERIMENTAL|AccuFFRangio Group|STEMI patients with multiple lesions who met the requirements of the study were enrolled and received coronary angiography. First, the revascularization of the criminal vessel (PCI) was completed. The patients were randomly grouped and divided into AccuFFRangio Group and Angiography Group if the treatment results were good. The AccuFFRangio Group was defined as non-IRA of these patients who were treated with PCI after angio-FFR measurement with FFR≤0.8.
62620363|NCT06070675|OTHER|Automated bladder diary (autoBD)|Patients will complete the automated bladder diary (Minze Diary Pod) at home for at least 2 consecutive days.
62620364|NCT04657575|NO_INTERVENTION|ASTI|ECT guided with ASTi 2-4 min
62620365|NCT04657575|ACTIVE_COMPARATOR|Narcotrend|ECT guided with ECT
62620366|NCT01911793|EXPERIMENTAL|Stoma tube|Stoma tube (18 French) red robinson catheter inserted into stoma at the time of surgery
62620367|NCT01911793|NO_INTERVENTION|Standard Stoma|Patients will have standard stoma created without insertion of stoma tube. Stoma tube will only be inserted postoperative if the patient is felt to have postoperative ileus, nausea, vomiting, and decreased stoma output as per standard protocol.
62620368|NCT05979207|EXPERIMENTAL|MMV367|IBSM challenge and MMV367
62620369|NCT02954588|ACTIVE_COMPARATOR|Pyridoxamine (1)|Subjects will be asked to consume dietary supplements containing pyridoxamine (dosage 1), three times daily during 8 weeks.
62620370|NCT02954588|ACTIVE_COMPARATOR|Pyridoxamine (2)|Subjects will be asked to consume dietary supplements containing pyridoxamine (dosage 2), three times daily during 8 weeks
62263925|NCT05209503|ACTIVE_COMPARATOR|Angiography Group|The Angiography Group was defined as PCI treatment for non-IRA when diameter stenosis \> 70% based on angiographic results.
62263926|NCT05437120|EXPERIMENTAL|Cohort 1: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive single dose of VX-121/TEZ/D-IVA .
62263927|NCT05437120|EXPERIMENTAL|Cohort 2: Matched Healthy Participants|Healthy participants will receive single dose of VX-121/TEZ/D-IVA.
62263928|NCT04897464|EXPERIMENTAL|Treatment|
62060038|NCT01960075|ACTIVE_COMPARATOR|Levetiracetam|Administer 60 mg/Kg levetiracetam intravenously up to a maximum dose of 4500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 4500 levetiracetam over 10 minutes.
62060039|NCT01829984||control injection teaching|The first 25 subjects recruited into the study will be that control group. Subjects accrued during the control phase will receive the control injection teaching, which at MSKCC is verbal instruction. To minimize practice variation, the teaching will be provided by the office-practice nurse guided by a verbal script. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
62060040|NCT01829984||intervention group|The subsequent 25 subjects enrolled into the study will be in the intervention group. Subjects accrued during the intervention phase will receive the verbal and written injection teaching, plus demonstration and return demonstration using an injection model. It is anticipated that the intervention teaching will take no longer then 5 additional minutes, however time will be evaluated as a secondary objective as well in both groups. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
62060041|NCT04990284|EXPERIMENTAL|50 mg opicapone once-daily|
62060042|NCT04990284|EXPERIMENTAL|100 mg of L-DOPA|
62060043|NCT01605214||Bilateral Lung Transplant|All patients undergoing bilateral lung transplant for any indication will be considered for enrollment in the study. The characteristics of measurements of extravascular lung water will be compared following surgery in those who develop primary graft dysfunction compared to those who do not.
62060044|NCT04863989|EXPERIMENTAL|Small sized chest tube|Insertion of small sized chest tube in patients with traumatic hemothorax, pneumothorax or hemopneumothorax.
62620371|NCT02954588|PLACEBO_COMPARATOR|Placebo|Subjects will be asked to consume dietary supplements containing placebo (amylum solani), three times daily during 8 weeks
62060045|NCT04863989|ACTIVE_COMPARATOR|Large sized chest tube|insertion of large sized chest tube in patients with traumatic hemothorax, pneumothorax or hemopneumothorax.
62060046|NCT04444284|EXPERIMENTAL|Dosage Group 1: RSV Vaccine Dosage 1|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 1.
62060047|NCT04444284|PLACEBO_COMPARATOR|Dosage Group 1: Placebo|Participants in this arm will receive a single intranasal dose of placebo.
62060048|NCT04444284|EXPERIMENTAL|Dosage Group 2: RSV Vaccine Dosage 2|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 2.
62060049|NCT04444284|PLACEBO_COMPARATOR|Dosage Group 2: Placebo|Participants in this arm will receive a single intranasal dose of placebo.
62620372|NCT00357890|EXPERIMENTAL|Pump therapy (CSII)|Use of pump therapy
62620373|NCT00357890|ACTIVE_COMPARATOR|Multiple daily injections (MDI)|Use of MDI (basal bolus therapy with glargine)
62620374|NCT01583283|EXPERIMENTAL|ACY-1215, Lenalidomide and Dexamethasone|Open label dosing cohorts will evaluate oral ACY-1215 (doses ranging from 40 - 480 mg days 1-5, 8-12, 15-19) in combination with oral Lenalidomide (doses ranging from 15 - 25 mg days 1-21) and oral Dexamethasone (40 mg once weekly).
62060050|NCT04444284|EXPERIMENTAL|Dosage Group 3: RSV Vaccine Dosage 3|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3.
62060051|NCT00201500||preeclampsia|women with preeclampsia
62060052|NCT00201500||controls|healthy pregnant women
62060053|NCT04499716|ACTIVE_COMPARATOR|Arm 1: ITO group|Arm 1: IPACK combined with femoral triangle and obturator nerve blocks
62060054|NCT04499716|EXPERIMENTAL|Arm 2 : Quadri-block group|Arm 2 : Femoral, sciatic, obturator and lateral femoral cutaneous nerve blocks
62060055|NCT04581148||M6|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M6) with residual blood samples.
62060056|NCT04581148||M12|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M12) with residual blood samples.
62060057|NCT04581148||M15|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M15) with residual blood samples.
62060058|NCT04581148||M19|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M19) with residual blood samples.
62060059|NCT04581148||M21|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M21) with residual blood samples.
62620375|NCT03818009||women undergoing elective CS under general anesthesia|Early postoperative assessment of the cognitive function of patients through evaluation document which will be filled by the anesthesiologist.
62620376|NCT03818009||women undergoing emergency CS under general anesthesia|Early postoperative assessment of the cognitive function of patients through evaluation document which will be filled by the anesthesiologist.
62620377|NCT04593355||HCV|
62060060|NCT04581148||M22|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M22) with residual blood samples.
62060061|NCT04581148||M23|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M23) with residual blood samples.
62060062|NCT04581148||M24|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M24) with residual blood samples.
62060063|NCT04581148||M25|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M25) with residual blood samples.
62060064|NCT04581148||M26|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M26) with residual blood samples.
62060065|NCT04658823|EXPERIMENTAL|HOV-12020|Palm tocotrienols complex Oral softgel capsule (containing 285mg mixed tocotrienols and tocopherol)
62620378|NCT00939744||EAU2|Women who will have a c-section at the CHUS
62846423|NCT01324401|NO_INTERVENTION|Control|The subjects randomized to the observational control group will have follow-up visits every 6 months. Each visit will involve a medical history and physical examination. These subjects are then offered to cross-over to active treatment.
62620379|NCT03974529|EXPERIMENTAL|Intensive running arm|20 patients will be assigned randomly to intensive running arm (intervention arm). They will be required to complete a designed training protocol.
62620380|NCT03974529|ACTIVE_COMPARATOR|Physiotherapy arm|10 patients will be assigned randomly to physiotherapy arm. They will be required to complete a designed training protocol.
62620381|NCT00985933|EXPERIMENTAL|1|180 mg of AZD8529
62620382|NCT00985933|EXPERIMENTAL|2|50 mg AD8529
62620383|NCT00985933|PLACEBO_COMPARATOR|3|Placebo
62620384|NCT03270033|ACTIVE_COMPARATOR|Dexamethasone|4 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
62620385|NCT03270033|ACTIVE_COMPARATOR|Dexmedetomidine|50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
62620386|NCT03270033|ACTIVE_COMPARATOR|Dexamethasone and Dexmedetomidine|4 milligrams dexamethasone and 50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
62620387|NCT05351593|EXPERIMENTAL|Phase 1 (Tafasitamab, Lenalidomide)|Participants will be given 12mg of Tafasitamab on days 1, 4, 8, 15, and 22 of cycle 1, days 1, 8, 15, and 22 of cycles 2 \& 3, and days 1 and 15 for any cycle thereafter. Participants will also be given daily Lenalidomide on days 1-21 of each cycle.
62620388|NCT05351593|EXPERIMENTAL|Phase 2 (Tafasitamab, Lenalidomide)|Participants will be given 12mg of Tafasitamab on days 1, 4, 8, 15, and 22 of cycle 1, days 1, 8, 15, and 22 of cycles 2 \& 3, and days 1 and 15 for any cycle thereafter. Participants will also be given daily Lenalidomide on days 1-21 of each cycle at the recommended phase 2 dose.
62620389|NCT01427543|EXPERIMENTAL|MILE group sessions|Participants will attend 6 - 2 hour long, interactive, culturally congruent, group sessions that address knowledge, beliefs, attitudes, and skills related to reducing HIV risk behaviors.
62620390|NCT01427543|NO_INTERVENTION|Control|These subjects will be provided with access to post-incarcerations services that will be provided by the Center for Health Justice.
62620391|NCT01671098||Control|Healthy adults
62620392|NCT01671098||Balloon Sinuplasty|Patients who had balloon sinuplasty
62846424|NCT01324401|EXPERIMENTAL|Peanut OIT|The subjects randomized to the active treatment group will receive defatted peanut flour per protocol.
62620393|NCT01671098||FESS-Uncinectomy|Patients who had FESS-Uncinectomy
62620394|NCT04869852|EXPERIMENTAL|Mango|85g mango, 4x/week
62846425|NCT00333099|PLACEBO_COMPARATOR|nutrition|study of immuno-modulating enteral nutrition
62846426|NCT03937999|EXPERIMENTAL|Bezlotoxumab Arm|Single dose of Bezlotoxumab 10mg/kg iv over 60 minutes on Day 0
62620395|NCT04869852|NO_INTERVENTION|No Mango|No mango intake
62620396|NCT02021110|NO_INTERVENTION|Control group|This group will receive standard care (no treatment)
62620397|NCT02021110|EXPERIMENTAL|Ursodeoxycholic Acid|The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
62620398|NCT04792060|EXPERIMENTAL|adult patients with distal ulna fractures|adult patients with distal ulna fractures
62620399|NCT00264290|EXPERIMENTAL|Valganciclovir|900mg PO qd
62620400|NCT00264290|PLACEBO_COMPARATOR|Placebo|900mg PO qd
62620401|NCT01971515|EXPERIMENTAL|MSC2363318A|
62620402|NCT01971515|EXPERIMENTAL|MSC2363318A plus Trastuzumab|
62620403|NCT01971515|EXPERIMENTAL|MSC2363318A plus Tamoxifen|
62846427|NCT03937999|NO_INTERVENTION|No Bezlotoxumab|Control group who are eligible as per the inclusion/exclusion criteria to the Bezlotoxumab arm, but not given Bezlotoxumab (Day 0) .
62846428|NCT01449799|EXPERIMENTAL|Sequence 1|In period 1, subjects will be administered GSK961081/fluticasone propionate blend via Diskus inhaler followed by the administration of GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers in period 2. In period 3 and period 4, the subjects will receive fluticasone propionate and GSK961081 respectively.
62620404|NCT03896178||Firefighters|
62263929|NCT03782376|EXPERIMENTAL|Group 1: Ustekinumab (IV re-induction)|Participants who experience a secondary loss of response (LoR) to 90 mg ustekinumab maintenance treatment, administered subcutaneously every 8 weeks (q8w) will receive a weight-tiered based ustekinumab IV re-induction dose of approximately 6 mg/kg and matching placebo subcutaneously at Week 0. At Weeks 8 and 16, all participants will receive SC maintenance injections of 90 mg ustekinumab. Participants will resume their standard-of-care therapy at Week 24 at the discretion of the treating physician.
62620405|NCT03896178||Pilots|
62620406|NCT03896178||Police|
62620407|NCT03896178||Military personnel|
62620408|NCT03896178||Controls|Control group matched for geographic location (county), and year of diagnosis. Consisting of all other workers than the four specified groups.
62620409|NCT06274242|EXPERIMENTAL|Prebiotic arm|
62620410|NCT06274242|PLACEBO_COMPARATOR|Placebo arm|
62620411|NCT05313646|EXPERIMENTAL|batch 1 of Ad5-nCoV|Eligible subjects in both cohort were vaccinated with one injection of Ad5-nCoV, lot NCOV202101001.
62620412|NCT05313646|EXPERIMENTAL|batch 2 of Ad5-nCoV|Eligible subjects in both cohort were vaccinated with one injection of Ad5-nCoV, lot NCOV202101002.
62620413|NCT05313646|EXPERIMENTAL|batch 3 of Ad5-nCoV|Eligible subjects in both cohort were vaccinated with one injection of Ad5-nCoV, lot NCOV202102003.
62620414|NCT04966819|EXPERIMENTAL|Survivorship Care|"Survivorship care will consist of:~1. Regular meetings with the rectal cancer oncology pivot nurse~2. Identification of a primary care physician~3. Development of an individualized survivorship plan~4. Educational resources for patients"
62620415|NCT04966819|NO_INTERVENTION|Standard Care|The control arm will consist of patients treated at the same institution who are receiving standard of care. Standard of care consists of meeting with colorectal oncology pivot nurse as needed (i.e. by referral from specialist based on patient needs).
62620416|NCT02669043|EXPERIMENTAL|Ketamine|All participants receive open-label ketamine
62263930|NCT03782376|ACTIVE_COMPARATOR|Group 2: Ustekinumab (Continuous q8w SC maintenance)|Participants who experience a secondary LoR to 90 mg ustekinumab maintenance treatment, administered subcutaneously q8w will receive ustekinumab 90 mg subcutaneously and matching placebo intravenously at Week 0. At Weeks 8 and 16, all participants will receive SC maintenance injections of 90 mg ustekinumab. Participants will resume their standard-of-care therapy at Week 24 at the discretion of the treating physician.
62263931|NCT04966546|EXPERIMENTAL|Memantine|Subjects will be given memantine 10mg PO/ NG BID for 7 days
62263932|NCT04966546|PLACEBO_COMPARATOR|Placebo|Subjects will be given identical placebo syrup PO/NG BID for 7 days
62263933|NCT04342871|EXPERIMENTAL|FACT|Patients will receive access to intervention materials.
62263934|NCT03889314|EXPERIMENTAL|Rosuvastatin 20mg|Each participant will receive a 3 month randomly allocated supply of this medication preceded by a 7 day wash-out period.
62263935|NCT03889314|PLACEBO_COMPARATOR|Placebo|
62263936|NCT03889314|NO_INTERVENTION|No Treatment|7 day wash-out period between months
62263937|NCT00500019||1.|Elective Cesarean sections
62263938|NCT00500019||2.|Non-elective cesarean section
62263939|NCT00595998||1|newly onset CNV secondary to AMD
62263940|NCT00595998||2|Intermediate AMD
62620417|NCT04885790||Bronchiectasis|Children with bronchiectasis
62846429|NCT01449799|EXPERIMENTAL|Sequence 2|In period 1, subjects will be administered GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers followed by administration of GSK961081 in period 2. In period 3 and period 4, the subjects will receive GSK961081/fluticasone propionate blend via Diskus inhaler followed by the administration of fluticasone propionate respectively.
62846430|NCT01449799|EXPERIMENTAL|Sequence 3|In period 1, subjects will be administered GSK961081 followed by administration of fluticasone propionate in period 2. In period 3, subjects will be administered GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers followed by GSK961081/fluticasone propionate blend via Diskus inhaler in period 4.
62846431|NCT01449799|EXPERIMENTAL|Sequence 4|In period 1, subjects will be administered fluticasone propionate followed by the administration of GSK961081/fluticasone propionate blend via Diskus inhaler in period 2. The subjects will receive GSK961081 in period 3 and concurrent administration of GSK961081 and fluticasone propionate in period 4.
62846432|NCT02983812||Activity Monitoring - Smartphone|Patients in the activity monitoring - smartphone group will be randomly assigned to track their data using a smartphone app (which collects step counts) for 6 months. There will be no intervention for either group, both are being passively monitored.
62846433|NCT02983812||Activity Monitoring - Wearable|Patients in the activity monitoring - wearable device group will be randomly assigned to track their data using a wearable activity tracker (which collects step counts and sleep patterns/duration). There will be no intervention for either group, both are being passively monitored.
62263941|NCT02589444|EXPERIMENTAL|Participants with vitamin D deficiency - treatment group|Participants with 25-hydroxyvitamin D (25(OH)D) ≤30 ng/mL taking oral high-dose vitamin D3 (50,000 IU) once a week and providing stool and sputum sample at screening and 3 months after screening.
62263942|NCT02589444|SHAM_COMPARATOR|Participants with vitamin D deficiency - placebo group|Participants with 25-hydroxyvitamin D (25(OH)D) concentrations ≤30 ng/mL taking a sham comparator (placebo) once a week and providing stool sample and sputum sample at screening and 3 months after screening.
62263943|NCT02589444|OTHER|Participants without vitamin D deficiency|Participants with 25-hydroxyvitamin D (25(OH)D) concentrations \> 30 ng/mL with no intervention and providing stool sample and sputum sample at screening and 3 months after screening.
62263944|NCT01428284|EXPERIMENTAL|001|Canagliflozin/Probenecid
62263945|NCT00750737|EXPERIMENTAL|Posaconazole|Posaconazole 200 mg three times daily by mouth up to 6 weeks (Days 1-42)
62846434|NCT06516926|EXPERIMENTAL|Dose 1|
62846435|NCT06516926|EXPERIMENTAL|Dose 2|
62846436|NCT06516926|EXPERIMENTAL|Dose 3|
62846437|NCT04793022|EXPERIMENTAL|TIVA-Propofol|Intravenous anesthesia with Propofol
62846438|NCT04793022|ACTIVE_COMPARATOR|Inhaled Anesthesia|General Inhaled Anesthesia
62846439|NCT00578292|EXPERIMENTAL|Bone Marrow or Stem Cell Infusion|"Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H~Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.~Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor."
62846440|NCT02786420||Observational|Pregnant women
62263946|NCT00750737|EXPERIMENTAL|Amphotericin B Lipid Complex (ABLC)|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
62263947|NCT03141736|ACTIVE_COMPARATOR|KMC & WHO protocol (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
62263948|NCT03141736|ACTIVE_COMPARATOR|KMC & WHO protocol (1-24 hours)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
62263949|NCT03141736|EXPERIMENTAL|KMC, WHO protocol & bag (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
62620418|NCT02557685|NO_INTERVENTION|Fecal Microbiota Translantation|After completing at least 10 days course of antibiotic treatment for C. difficile infection, subjects will receive Fecal Microbiota transplantation with a 300 mL fecal suspension delivered via sigmoidoscopy.
62620419|NCT01613079|PLACEBO_COMPARATOR|Methotrexate|Patients were treated with methotrexate alone.
62620420|NCT01613079|EXPERIMENTAL|T2|Patients were treated with oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).
62620421|NCT01613079|EXPERIMENTAL|MTX+T2|The patients were treated with methotrexate and T2.
62620422|NCT05299762||Patients treated with the INFUSE™ Bone Graft|Patients intended to be treated with the INFUSE™ Bone Graft are eligible for enrollment. The investigator screen candidate patients against inclusion/exclusion criteria and enroll a patient only when all inclusion/exclusion criteria meet, and the patient provide written informed consent.
62620423|NCT02574936|OTHER|modified Karydakis,surgical technique|a new surgical technique(modified Karydakis) to be compared with standard Karydakis
62620424|NCT00548483|ACTIVE_COMPARATOR|1|dexamethasone 5mg was administered every 6 hour for 1 day
62620425|NCT00548483|ACTIVE_COMPARATOR|2|dexamethasone 10mg was administered every 6 hour for 1 day
62620426|NCT03739801|EXPERIMENTAL|Treatment (ramucirumab, liposomal irinotecan[MM-398])|Patients receive ramucirumab IV over 30 minutes and MM-398 IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62620427|NCT04063605|EXPERIMENTAL|Clinical Pilates|Participants in this group will receive twice a week, total 8 weeks of clinical pilates exercise program. Each session will take 45 minutes.
62620428|NCT04063605|ACTIVE_COMPARATOR|Classic Physiotherapy|Participants in this group will receive twice a week, total 8 weeks of classic physiotherapy exercise program. Each session will take 45 minutes.
62620429|NCT06114771|ACTIVE_COMPARATOR|orthognathic surgery patients / lozange|Throat lozenge (strepsilis) was given to 30 patients,30 minutes before the operation (the dissolution rate of the lozenge was proven to be 6-9 minutes).
62620430|NCT06114771|PLACEBO_COMPARATOR|orthognathic surgery patients / candy|Sugar dragee in the same size and shape was given to 30 patients 30 minutes before the operation. In order not to cause any complications, sugar patients were sucked and told not to chew.
62263950|NCT03141736|EXPERIMENTAL|KMC, WHO protocol & bag (1-24 hours|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
62263951|NCT06232070||Standard Pathway Arm|All participating patients will have their mammograms reported using the standard of care. The mammograms randomised to the Standard Pathway arm will be reported using the current standard of care, which involves two human readers; The readers will be blind to Lunit INSIGHT MMG report
62620431|NCT02842008|EXPERIMENTAL|Exercise group|Wheelchair basketball players participating in home therapeutic exercise program that use the protocol of postural hygiene.
62620432|NCT02842008|NO_INTERVENTION|Control group|Wheelchair basketball players that not participate in home therapeutic exercise program and use a protocol of postural hygiene provided.
62620433|NCT05202535|EXPERIMENTAL|Aerobic exercise training|hospital-based aerobic exercise training on treadmill/cycle ergometer with the intensity of 40-70% of HR max, for 15-30 mints for 8 weeks
62620434|NCT05202535|ACTIVE_COMPARATOR|Conventional therapy|Patient education and counseling with diet plan.Walking 3 days15min/day for 8 weeks
62620435|NCT04653155|EXPERIMENTAL|Treatment arm|Participants in the treatment group will show significant improvement on insomnia symptoms after intervention compared to those in the waitlist control group.
62447913|NCT01892579|ACTIVE_COMPARATOR|Home Safety and Education Program|This arm receives 6 in-home and 2 brief telephone education sessions. Each contact is structured to provide helpful education. Sessions include information on home safety, fall risk assessment, talking to your doctor, advanced planning, identifying resources, and caring for the caregiver (CG). Each session is prescriptive and designed to maximize attention; yet, sessions will not involve any component of the intervention group. To engage the person with dementia (PwD), the interventionist will socially engage the person briefly in select sessions. Time spent with CG and PwD in the control group is comparable to that for intervention dyads.
62447914|NCT01911585|ACTIVE_COMPARATOR|90 minute Prolonged Exposure Sessions|Prolonged Exposure Therapy for PTSD consists of 10 to 15 weekly or twice-weekly sessions, each lasting about 90 minutes, with 40 to 60 minutes imaginal exposure.
62447915|NCT01911585|EXPERIMENTAL|60 minute Prolonged Exposure Sessions|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of 10 to 15 weekly or twice-weekly sessions, each lasting about 60 minutes, with 20 minutes imaginal exposure.
62447916|NCT01924390|ACTIVE_COMPARATOR|mineralized FDBA alone|Socket grafting with mineralized freeze-dried bone allograft alone
62447917|NCT01924390|EXPERIMENTAL|Combination of mineralized and deminieralized FDBA|Socket grafting with a combination of mineralized and demineralized freeze-dried bone allograft alone
62447918|NCT03156166|EXPERIMENTAL|Ambu AuraGain|Ambu AuraGain is inserted in children undergoing general anesthesia. The size of AuraGain is as follows: size 1 for children \<5 kg, size 1.5 for 5-10kg, size 2 for 10-20kg, size 2.5 for 20-30kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
62447919|NCT03156166|EXPERIMENTAL|I-gel|I-gel is inserted in children undergoing general anesthesia. The size of I-gel is as follows: size 1 for children weighing 2-5kg, size 1.5 for 5-12kg, size 2 for 10-25kg, size 2.5 for 25-35kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
62447920|NCT03156166|EXPERIMENTAL|Air-Q intubating laryngeal airway (ILA)|Air-Q ILA is inserted in children undergoing general anesthesia. The size of Air-Q ILA is as follows: size 1 for children between 4-7 kg, size 1.5 for 7-17kg, size 2 for 17-30kg, size 2.5 for 30-50kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
62447921|NCT06045481|EXPERIMENTAL|Single Dose of 200mg doxycycline|Treatment of a single dose of 200mg doxycycline
62447922|NCT06045481|NO_INTERVENTION|Standard treatment of 5 days doxycycline (200mg at 1st day followed by 4 days of 100mg)|Treatment of 5 days doxycycline (200mg at 1st day followed by 4 days of 100mg)
62620436|NCT04653155|NO_INTERVENTION|Waitlist control|Participants in the waitlist control group will show little improvement on insomnia symptoms after the treatment period of the treatment group.
62620437|NCT02759835|EXPERIMENTAL|Tyrosine Kinase Inhibitor Naïve Epidermal Growth Factor Receptor *mutated Non Small Cell Lung Cancer|"Cohort 1 - Osimertinib followed by LAT followed by osimertinib. Single daily dose of osimertinib until progression. The starting dose of osimertinib will be 80 mg per day for participants without leptomeningeal disease and 160 mg per day for those with leptomeningeal disease at baseline.~\*including germline T790M mutation"
62846441|NCT04343105|SHAM_COMPARATOR|sham group|will receive sham bilateral ultrasounded guided single shot pecto-intercostal plane block between 3rd and 4th rib 2 cm lateral to sternal border for each side after induction of anaesthesia in supine position
62060066|NCT04658823|PLACEBO_COMPARATOR|PLACEBO|Placebo Oral Softgel capsule (each capsule containing vitamin E stripped soybean oil)
62060067|NCT05050578|OTHER|LID018869, then AOHP|Lehfilcon A contact lenses worn in Period 1, followed by senofilcon A contact lenses worn in Period 2, as randomized. Each product will be worn in both eyes during waking hours only for at least 10 hours per day for 30 days. CLEAR CARE will be used for daily contact lens cleaning and disinfection.
62060068|NCT05050578|OTHER|AOHP, then LID018869|Senofilcon A contact lenses worn in Period 1, followed by lehfilcon A contact lenses worn in Period 2, as randomized. Each product will be worn in both eyes during waking hours only for at least 10 hours per day for 30 days. CLEAR CARE will be used for daily contact lens cleaning and disinfection.
62060069|NCT06626022|ACTIVE_COMPARATOR|MRI|
62060070|NCT06626022|EXPERIMENTAL|microUltransound|
62060071|NCT01743794|EXPERIMENTAL|ropivacaine 0.2%, wound infusion|
62060072|NCT01743794|PLACEBO_COMPARATOR|saline solution 0.9%, wound infusion|
62060073|NCT04148339||Patients|Patients with Elevated Cholesterol
62060074|NCT04687735|EXPERIMENTAL|Intervention arm|Patients with frozen shoulders at any stage
62060075|NCT00978354|ACTIVE_COMPARATOR|Furosemide|Furosemide intravenous continuous infusion
62060076|NCT00978354|PLACEBO_COMPARATOR|Normal Saline|Normal saline titrated continuous intravenous infusion
62846442|NCT04343105|EXPERIMENTAL|real group|will receive real bilateral ultrasounded guided single shot pecto-intercostal plane block between 3rd and 4th rib 2 cm lateral to sternal border for each side after induction of anaesthesia in supine position with 10 ml bupivacaine 0.5% + 10 ml lidocaine 2% in total volume 20 ml for each side.
62846443|NCT00711477|EXPERIMENTAL|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/day
62060077|NCT00577018|ACTIVE_COMPARATOR|1|
62060078|NCT00577018|ACTIVE_COMPARATOR|2|
62060079|NCT00577018|PLACEBO_COMPARATOR|3|
62060080|NCT00768508|EXPERIMENTAL|Ondansetron|Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy
62060081|NCT00768508|EXPERIMENTAL|Naltrexone|Naltrexone 50 mg/day + Cognitive Behavioral Therapy
62060082|NCT00768508|EXPERIMENTAL|Ondansetron + Naltrexone|Ondansetron 4 ug/kg b.i.d. + Naltrexone 50 mg/day + Cognitive Behavioral Therapy
62263952|NCT06232070||Lunit Assisted Arm|All participating patients will have their mammograms reported using the standard of care. Those randomised to the Lunit assisted arm will also undergo double reader process , ensuring the current standard of clinical care is provided. In addition to that, the Lunit INSIGHT MMG report will also be available to the readers. Within this arm, each reader will be presented with a Likert scale to rank their level of agreement with the Lunit INSIGHT MMG report
62263953|NCT04696432|EXPERIMENTAL|Prizloncabtagene autoleucel|Prizlon-cel will be intravenously administered as a single infusion after lymphodepletion.
62846444|NCT00711477|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62846445|NCT06316024|NO_INTERVENTION|Nothing Per Os group|The participants do not drink anything approximately 6-8 hours after surgery.
62846446|NCT06316024|EXPERIMENTAL|water group|The participants drink 240 ml water approximately 6-8 hours after surgery.
62846447|NCT06316024|EXPERIMENTAL|juice/sport drink group|The participants drink 240 ml juice/sport drink approximately 6-8 hours after surgery.
62060083|NCT00768508|PLACEBO_COMPARATOR|Placebo|Placebo + Cognitive Behavioral Therapy
62060084|NCT04555902|ACTIVE_COMPARATOR|Standard Mailer and Small Gift|A postcard encourages mammograms and includes a small gift.
62060085|NCT04555902|EXPERIMENTAL|Mailer with Loss Frame, Risks, and Small Gift|The postcard is enhanced with language that further emphasizes the risks but also clearly describes how early detection with a test can reduce those risks; a small gift is included.
62060086|NCT04555902|EXPERIMENTAL|Mailer with Loss Frame, Risks, and No Gift|The postcard is enhanced with language that further emphasizes the risks but also clearly describes how early detection with a test can reduce those risks; the small gift is not included.
62060087|NCT01691183||Study Subjects|Subjects with or without orbital disease that present to clinic for scheduled appointments.
62060088|NCT03186482|ACTIVE_COMPARATOR|Descovy® (TAF/FTC)|"ATC Code J05AR17. Pharmaceutical form (use standard terms): Film-Coated Tablet Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol: 56 days.~Maximum dose allowed 200mg/25mg per day. Total dose 200/25mg. Oral Use."
62060089|NCT03186482|ACTIVE_COMPARATOR|Viread® (TDF)|"ATC Code J05AF07. Pharmaceutical form (use standard terms): Film-Coated Tablet. Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol 28 days.~Maximum dose allowed: 245mg per day. Total dose: 245mg. Oral Use."
62060090|NCT03186482|ACTIVE_COMPARATOR|Rifadin® (Rifampicin)|"ATC Code J0AB02 Pharmaceutical form (use standard terms): Capsule, Hard. Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol 28 days.~Maximum dose allowed: 600mg per day. Total dose: 600mg. Oral Use."
62060091|NCT00581373|EXPERIMENTAL|1|water 16 oz
62060092|NCT00295763|OTHER|1|
62060093|NCT03561337|EXPERIMENTAL|PROTEIN-CARBOHYDRATE|Intervention group receiving protein and carbohydrate supplement
62060094|NCT03561337|PLACEBO_COMPARATOR|CARBOHYDRATE|Intervention groups receiving carbohydrate supplement
62060095|NCT05233202|EXPERIMENTAL|LEVOSIMEDAN|Levosimendan administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin 24H to 48H before anesthetic induction.
62060096|NCT05233202|PLACEBO_COMPARATOR|PLACEBO|Placebo (isotonic sodium) administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin \<48H before anesthetic induction.
62060097|NCT04075617|EXPERIMENTAL|intervention group|electronic habit reminder will fabricated to treat thumb/finger sucking habit containing two parts: acrylic part specially fabricated for the child finger/thumb connected to the reminder in the shape of wrist watch.
62060098|NCT04075617|ACTIVE_COMPARATOR|control group|palatal crib will be cemented after impression taking and fabrication
62060099|NCT01053260|ACTIVE_COMPARATOR|LEARN Program|Participants will receive weekly weight loss counseling based on the LEARN Program for Weight Management.
62263954|NCT04294875|OTHER|MPT0B640|There is Single Arm in this Clinical Trials.
62263955|NCT00751595|EXPERIMENTAL|ARM A (Tat Protein 7.5 or 30 microg 5X)|Group I: Subjects receiving 5 intradermal immunization with Tat (7.5 microg); Group II: Subjects receiving 5 intradermal immunization with Tat (30 microg).
62263956|NCT00751595|EXPERIMENTAL|ARM B (Tat Protein 7.5 or 30 microg, 3X)|Group I: Subjects receiving 3 intradermal immunization with Tat (7.5 microg); Group II: Subjects receiving 3 intradermal immunization with Tat (30 microg)
62263957|NCT01217671|EXPERIMENTAL|Alpha-1 Antitrypsin|
62263958|NCT01217671|PLACEBO_COMPARATOR|Placebo|
62263959|NCT02816307|EXPERIMENTAL|Infective endocarditis|
62263960|NCT01301339||failed and passed physical fitness test|520 subjects who have failed their Air Force physical fitness test and 520 volunteers who have passed their physical fitness test both within the last 6 months
62263961|NCT04600245|EXPERIMENTAL|M-FAM|Will undergo the procedure with assistance from the M-FAM syetem Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months
62263962|NCT04600245|EXPERIMENTAL|CARTOSOUND-FAM|Will undergo the procedure with assistance from the CARTOSOUND-FAM syetem Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months
62263963|NCT04649476|EXPERIMENTAL|Neoadjuvant PD-1 blockade alone|The participants will receive 3 doses of neoadjuvant PD-1 blockade. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.
62447923|NCT04251611|NO_INTERVENTION|Control group|The usual care in patients with myocardial ischemia without other cardiovascular risk factors (CVFR) will be to attend one visit per year with doctor and nurse of the local health center. In this visit, it will be done a blood test and an electrocardiogram. Blood pressure, weight, body mass index, abdominal circumference will be measured and, in case of detecting enolic habit, smoking or sedentary lifestyle, generic advice will be done. If the patient, apart from myocardial ischemia, presents diabetes mellitus type 2, 3-4 follow-up visits per year will be recommended and will be increased according to specific needs. In case of presenting hypertension, will be recommended 2 visits with the nurse and one visit with the doctor per year and will be increased according to specific needs. In addition, in this case the blood pressure is checked every 6 months. During all visits, professionals will reinforce the control of CVRF and the maintenance of a long-term cardio-healthy lifestyle.
62846448|NCT06316024|EXPERIMENTAL|chewing gum group|The participants start chewing gum approximately 6-8 hours after surgery.
62846449|NCT05518578|EXPERIMENTAL|Open-Label Treatment|0.25 mg to 4 mg SPN-817 taken orally twice daily
62263964|NCT04649476|EXPERIMENTAL|Neoadjuvant PD-1 blockade plus TPF induction chemotherapy|The participants will receive 3 doses of PD-1 blockade and 2 courses of TPF induction chemotherapy. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.
62263965|NCT04891042||Latent Phase of Labour|
62263966|NCT04891042||Active Phase of Labour|
62263967|NCT02053168|OTHER|Resorbable Mesh|Phasix Mesh
62263968|NCT04499443|EXPERIMENTAL|Single-dose experimental group|10mg, 30mg, 60mg, 100mg, 150mg, 200mg, 250mg and 300mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo. Each group was administered once, under the fasting condition of Day1, and the tolerance was evaluated on Day2，Day4 and Day6. Subjects in different dose groups were enrolled in turn, and the next set of trials was conducted on the premise that the previous set of tolerability assessments were tolerated. The actual completion of the final dose, depending on the test results.
62263969|NCT04499443|PLACEBO_COMPARATOR|Single-dose control group|10mg, 30mg, 60mg, 100mg, 150mg, 200mg, 250mg and 300mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo.
62263970|NCT04499443|EXPERIMENTAL|Multi-dose experimental group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo. It is necessary to decide the multiple administration method and dosage according to the result of single administration, which is initially determined to be once a day. After the first dose, Day3, Day6, Day8 and Day12 were evaluated for tolerance, and the next group of tests was conducted under the premise that the previous group of Day12 tolerance evaluation was tolerated.
62263971|NCT04499443|PLACEBO_COMPARATOR|Multi-dose control group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo.
62620438|NCT02759835|EXPERIMENTAL|EGFR mutated NSCLC Progressed on prior 1st/2nd Generation EGFR TKI therapy &acquired T790M Mutation|Cohort 2 - Osimertinib followed by LAT followed by osimertinib. Participants may undergo 1 of 3 local ablative procedures after initial progression on osimertinib: surgery, radiotherapy, or radiofrequency ablation.
62846450|NCT00759538||1|lung transplant patients performing a three week lasting rehabilitation program
62846451|NCT00527241|EXPERIMENTAL|1: A|
62846452|NCT00527241|NO_INTERVENTION|2 B|wait-listed for intervention to begin in 6 months
62846453|NCT04984837|EXPERIMENTAL|Lacutamab|Lacutamab 750 mg/IV + GEmOx (1000 mg/m² / 100 mg/m²) 6 cycles of 3 weeks (4,5 months) during the induction phase Lacutamab 750 mg/IV for a maximum of 20 additional cycles of 4 weeks during the maintenance phase
62060100|NCT01053260|EXPERIMENTAL|LEARN Plus Contingency Management|Participants will receive weekly counseling based on the LEARN Program for Weight Management plus contingency management. Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
62060101|NCT02189902|ACTIVE_COMPARATOR|4000 IU/d of D3 by mouth for 12 weeks|4000 IU/d of D3 by mouth for 12 weeks
62846454|NCT04984837|ACTIVE_COMPARATOR|Standard of care|GemOx (1000 mg/m² / 100 mg/m²) 6 cycles of 3 weeks (4,5 months) during the induction phase
62846455|NCT05407662||Survey on users of sMRA therapies|sMRA stands for steroidal mineralocorticoid receptor antagonist.
62263972|NCT04499443|EXPERIMENTAL|Food Impact Study Group A|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 \~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day2, Day4 and Day6 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
62263973|NCT04499443|EXPERIMENTAL|Food Impact Study Group B|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 \~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day2, Day4 and Day6 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
62846456|NCT04296448|NO_INTERVENTION|Traditional Otoscope|Pediatric trainees use a traditional otoscope to evaluate pediatric patient ears. Trainees' supervisors will also evaluate patients with the traditional otoscope. The study evaluates concordance of the exams.
62846457|NCT04296448|EXPERIMENTAL|Cellscope|Pediatric trainees use a cellphone otoscope (Cellscope) to evaluate pediatric patient ears. Trainees' supervisors will evaluate patients remotely with the video on the cellphone otoscope. The study evaluates concordance of the exams.
62846458|NCT04508088||Crohn Disease|"This group will be 46 adolescents, ages 13-20, who have been recently (within 3 months) diagnosed with Crohn Disease.~All participants will have a two study visits approximately one year apart during which the listed diagnostic testing will be performed."
62846459|NCT04508088||Control|"Controls will be matched for age, Tanner staging, and BMI percentile.~All participants will have a two study visits approximately one year apart during which the listed diagnostic testing will be performed."
62846460|NCT02614599|EXPERIMENTAL|BP22042013|This group of patients receive 2.000 kilocalories diet(60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
62846461|NCT02614599|EXPERIMENTAL|Low carbohydrate Diet|the second group of patients receive diet of 2.000 Kilo calories without rapidly absorbed carbohydrates and without proteins supplements
62846462|NCT04103788|ACTIVE_COMPARATOR|95% Curcuminoid Powder|Curcumin powder standardized to \>95% curcuminoids, single dose, used to determine standard absorptivity of unformulated powder.
62846463|NCT04103788|EXPERIMENTAL|CurQ+|Highly absorbed curcumin coconut oil emulsion, single dose, used to produce serum samples for analytical comparison of sample preparation methodologies.
62846464|NCT02004444||Natalizumab 18 months|10 patients on continuous natalizumab monotherapy for 18 months
62846465|NCT02004444||Natalizumab 24 months|10 patients on continuous natalizumab monotherapy for 24 months
62846466|NCT02004444||Natalizumab 36 months|10 patients on continuous natalizumab monotherapy for 36 months
62846467|NCT02004444||IFN-beta 36 months|10 patients on continuous interferon-beta monotherapy for 36 months
62846468|NCT02004444||Untreated|10 untreated patients
62060102|NCT02189902|EXPERIMENTAL|7000IU/d of D3 by mouth for 12 weeks|7000IU/d of D3 by mouth for 12 weeks
62620439|NCT02759835|EXPERIMENTAL|Epidermal Growth Factor Receptor mutated Non Small Cell Lung Cancer Progressed on Osimertinib|Cohort 3 - LAT followed by Osimertinib. Participants may undergo 1 of 3 local ablative procedures after initial progression on Osimertinib: surgery, radiotherapy, radiofrequency ablation. The starting dose of Osimertinib will be 80 mg per day for participants without leptomeningeal disease and 160 mg per day for those with leptomeningeal disease at baseline. Single daily dose of Osimertinib until progression.
62620440|NCT04794673||Left damage|Have the brain damage and the location of the damage in the left brain
62620441|NCT04794673||Right damage|Have the brain damage and the location of the damage in the right brain
62846469|NCT01712724|ACTIVE_COMPARATOR|Aerobic Training|Walking, elliptical, stationary recumbent or upright cycling will be the modes of AT prescribed depending on individual ability and access to equipment when away from the Centre. Treadmill or overground walking will be considered for those who can sustain high enough speeds and durations to achieve aerobic benefit. Cycle ergometer exercise (upright or recumbent) will be prescribed to patients in addition to walking when stroke-related deficits preclude a sufficient walking speed. The AT group will complete AT 5 d∙wk-1.
62846470|NCT01712724|EXPERIMENTAL|Combined Resistance and Aerobic Training|The AT+RT group will complete AT 3 d∙wk-1 + RT 2 d∙wk-1.The RT exercises will be task specific, incorporating muscle actions that are performed during daily activities. Resistance will be provided by hand-held dumbbells, exercise bands (wrist/ankle attachments), or patients' body weight. A weight load equivalent to 50-60% of 1 repetition maximum will be prescribed on the non-affected limb. On the hemiparetic limb ≥50% of 1 repetition maximum and/or a resistance rated as 13-14 on the Rating of Perceived Exertion scale on the last repetition of the set will be prescribed
62060103|NCT03697525|EXPERIMENTAL|Vibration Group (VG)|VG participants undergo rMV treatment, carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (for each treated limb), interspersed with a 5-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle
62263974|NCT05922462|EXPERIMENTAL|Greek yogurt intervention group (GY)|Participants in the GY group will be instructed by a registered dietician to consume 2 servings/day (preferably morning and night) of 175 g GY (0% MF, flavoured, 130 calories, 17 g protein, 225 g calcium; e.g., OIKOS High Protein GY) for a total of 16 weeks. For their convenience, the athletes will be provided with appropriate scoops to measure out 175 g of GY per serving of the larger 650 g commercially available, pre-packaged containers. Although it is recommended to consume the two servings morning and night, to increase ecological validity and strengthen the feasibility of the intervention, the timing of the servings will be flexible to facilitate the training and competition routines. For the same reasons, the athletes will be able to choose the flavour of their GY.
62447924|NCT04251611|EXPERIMENTAL|Intervention group|"Patient will go to health center to visit the cardiac rehabilitation (CR) reference team, which is composed for a doctor and a nurse. This team will establish the guideline of action in the maintenance and/or increase in the physical exercise practice, in function of the resources of each zone and the preferences and motivations of the patient. They also reinforce the control of CVRF and the maintenance of a long-term cardio-healthy lifestyle.~At the end of the visit, control visit will be given with the CR reference team at 3, 6 and 12 months after completing the supervised physical exercise program of phase II of the CRP. In case of detecting specific needs for the patient and/or relapses, the team will consult with the appropriate professional (cardiologist, cardiology nurse, physiotherapist, rehabilitator, nutritionist and/or psychologist). At the same time, the patient will be informed of the possibility of re-evaluating the CR reference team."
62060104|NCT03697525|SHAM_COMPARATOR|Control Group (CG)|CG participants undergo the sham rMV by positioning the vibrator close to the tendon but without touching the skin. In this condition, patients were only subject to the faint buzzing sound of the vibrator. Sham rMV treatment is carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (for each treated limb), interspersed with a 5-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle
62060105|NCT01489644|EXPERIMENTAL|Treatment period 1|
62060106|NCT01489644|EXPERIMENTAL|Treatment period 2|
62060107|NCT01489644|EXPERIMENTAL|Treatment period 3|
62060108|NCT01489644|ACTIVE_COMPARATOR|Treatment period 4|
62447925|NCT03081767|OTHER|Patients undergoing digital PET/CT|Single arm prospective study of paired imaging studies. Patients who are referred to Nuclear Medicine and are scheduled to undergo imaging on the standard PET/CT will also have imaging performed on the digital PET/CT.
62447926|NCT00449072|PLACEBO_COMPARATOR|Placebo|"3 to 9 year old participants with Perennial Allergic Rhinitis (PAR) administered~* Placebo in the baseline/screening period to demonstrate administration of investigational product (IP) with the nasal spray bottle~* Placebo in the double-blind treatment period~All participants were provided Children's Claritin® Syrup as a rescue medication."
62060109|NCT04013412|EXPERIMENTAL|Protein-Calorie Restriction|Four day dietary intervention immediately before surgery of ScandiShake \[any of 4 flavors\] mixed with almond milk, calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on body weight and activity level.
62060110|NCT04013412|NO_INTERVENTION|Control|Ad libitum diet for four days immediately before surgery
62060111|NCT06425848||Retrospective arm|Patients who underwent PA pressure implantation from January 1, 2019 will be identified for registry participation. Patients who were implanted before November 8, 2022 will be considered enrolled in the retrospective arm of the registry and may not need to consent if consent waiver is granted by the institutional IRB (Institutional Review Board).
62060112|NCT06425848||Prospective arm|Patients will be identified as eligible for PA pressure sensor implant by a heart failure cardiologist. Patients will consent for device implant and procedure (right heart catheterization) as per standard of care. Patients may also consent to registry participation as per local institutional guidelines and requirements.
62060113|NCT02544828|EXPERIMENTAL|Experimental group|Iron Sucrose 200mg
62060114|NCT02544828|PLACEBO_COMPARATOR|Control Group|placebo
62060115|NCT00784433|EXPERIMENTAL|alcohol 1|
62060116|NCT00784433|EXPERIMENTAL|alcohol 2|
62060117|NCT00784433|PLACEBO_COMPARATOR|control|
62060118|NCT04573725|EXPERIMENTAL|5 mg|Period in which participants received single-dose of 5 mg TS-142 prior to bedtime
62060119|NCT04573725|EXPERIMENTAL|10 mg|Period in which participants received single-dose of 10 mg TS-142 prior to bedtime
62060120|NCT04573725|EXPERIMENTAL|30 mg|Period in which participants received single-dose of 30 mg TS-142 prior to bedtime
62060121|NCT04573725|PLACEBO_COMPARATOR|Placebo|Period in which participants received single placebo prior to bedtime
62263975|NCT05922462|EXPERIMENTAL|Whey protein intervention group (WP)|Participants in the WP group will follow a similar consumption schedule but will be instructed by the RD to consume two servings/day (preferably morning and night) each of 2/3 of a scoop of commercially available WP powder (flavoured, \~29 g, 120 calories, 19 g protein, 112.5 g calcium; e.g., PURE Whey Protein, Walmart) for a total of 16 weeks. The WP scoop will be dissolved in water (e.g., 1 g of WP isolate to 10 mL of water, as recommended by the manufacturer). This protein dose is similar to the previous dose in young swimmers and comparable to other studies in adults. Athletes will be provided with appropriately marked scoops (corresponding to 2/3 of the manufacturer scoop) to measure their single servings. Each athlete will receive two large containers (2 x 907 g = 1814 g per week) at the beginning of each week, which will be enough to cover the two daily servings of 29 g (i.e., 58 g/day).
62263976|NCT02839980||orthopedics (gr1) surgery|parient admitted to the orthopedics (gr1) surgery ward for an elective or semi-emergent surgical procedure.
62263977|NCT02839980||thoracic (gr2) surgery|parient admitted to the thoracic (gr2) surgery ward for an elective or semi-emergent surgical procedure.
62447927|NCT00449072|ACTIVE_COMPARATOR|TAA-AQ|"3 to 9 year old participants with Perennial Allergic Rhinitis (PAR) administered~* Placebo in the baseline/screening period to demonstrate administration of IP with the nasal spray bottle~* Triamcinolone acetonide (TAA-AQ) in the double-blind treatment period~All participants were provided Children's Claritin® Syrup as a rescue medication."
62620442|NCT04794673||Nomal control|Not have the brain damage
62447928|NCT01704391||Aortic aneurysm patients|10 patients with a CT verified diagnosis of aortic aneurysm demanding open elective surgical correction with insertion of vascular prosthesis
62447929|NCT01704391||Aortic occlusive disease patients|10 patients with CT verified aortic occlusive disease demanding open elective surgical correction with insertion of vascular prosthesis
62060122|NCT03217435|EXPERIMENTAL|Cornea epithelial allograft|Femtosecond laser assisted corneal epithelial allograft from live relatives in the treatment of limbal stem cell deficiency (LSCD)
62060123|NCT03217435|ACTIVE_COMPARATOR|Limbal conjunctival allograft|Diamond knife assisted limbus conjunctival allograft from live relatives in the treatment of limbal stem cell deficiency (LSCD)
62060124|NCT03519243|EXPERIMENTAL|BCD-131 1,05 mcg/kg * conversion ratio|subcutaneously monthly
62060125|NCT03519243|EXPERIMENTAL|BCD-131 1,7 mcg/kg * conversion ratio|subcutaneously monthly
62060126|NCT03519243|EXPERIMENTAL|BCD-131 2,75 mcg/kg * conversion ratio|Subcutaneously monthly
62060127|NCT03519243|ACTIVE_COMPARATOR|Mircera|subcutaneously monthly
62060128|NCT05739383|EXPERIMENTAL|Inclisiran sodium 300mg|"Inclisiran sodium 300 mg in 1.5 mL solution for injection (subcutaneous) in pre-filled syringe.~Randomized in a 1:1 ratio with matching placebo"
62846471|NCT01497366|EXPERIMENTAL|Sofosbuvir+RBV|Participants were randomized to receive sofosbuvir+RBV for 12 weeks.
62846472|NCT01497366|ACTIVE_COMPARATOR|PEG+RBV|Participants were randomized to receive PEG+RBV for 24 weeks.
62846473|NCT00201513|EXPERIMENTAL|TrA exercise|Isolated Transversus abdominis (TrA) exercises (low load)
62060129|NCT05739383|PLACEBO_COMPARATOR|Placebo|Matching placebo in 1.5ml pre-filled syringe. Randomized in a 1:1 ratio with Inclisiran.
62060130|NCT06525363|EXPERIMENTAL|treatment group|chitosan nanoparticles spray 1% w/w twice daily
62060131|NCT06525363|NO_INTERVENTION|control group|normal healthy hygiene of mouth
62060132|NCT01674348|ACTIVE_COMPARATOR|P2202|"Two treatment arms in Stage I- P2202 (1000 mg) and placebo~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo"
62060133|NCT01674348|PLACEBO_COMPARATOR|Placebo|"Two treatment arms in Stage I- P2202 (1000 mg) and placebo~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo"
62060134|NCT00755222|EXPERIMENTAL|AA4500|Clostridial collagenase for injection
62263978|NCT02839980||abdominal (gr3) surgery|parient admitted to the abdominal (gr3) surgery ward for an elective or semi-emergent surgical procedure.
62263979|NCT02839980||ICU (gr4)|patients admitted to the ICU with an antcipated length of stay of 3 days or more
62447930|NCT01687309|OTHER|Cohort A fed session|GSK2586184 800mg single dose with food
62447931|NCT01687309|OTHER|Cohort A fasted session|GSK2586184 single dose without food
62447932|NCT01687309|ACTIVE_COMPARATOR|Cohort B active study medication|GSK2586184 800mg single and twice daily dose for 13 days
62447933|NCT01687309|PLACEBO_COMPARATOR|Cohort B placebo|Placebo-to-match single and twice daily dose for 13 days
62447934|NCT01781065|EXPERIMENTAL|transcranial direct current stimulation|Anodal stimulation on motor cortex
62447935|NCT01781065|SHAM_COMPARATOR|Sham transcranial direct current stimulation|Turn off after 10 s of stimulation
62447936|NCT04330248|EXPERIMENTAL|Erdafitinib and Carbamazepine|Participants will receive single oral dose of erdafitinib dose 1 on Day 1 30 minutes after the start of a standardized breakfast in Period 1 followed by repeated doses of carbamazepine orally every 12 hours from Days 15 to 35 (carbamazepine Dose 1 from Days 15 to 17, Dose 2 from Days 18 to 20, and then Dose 3 from Days 21 to 35) 30 minutes after the start of standardized meal (breakfast and dinner) in Period 2. After 8 Days of Dose 3 carbamazepine treatment, on Day 28, participants will receive a single oral dose of erdafitinib dose 1 with that day's carbamazepine dose.
62447937|NCT02281942|EXPERIMENTAL|Yoga|Sequential movements in coordination to the breath cycle followed by seated and supine postures to release muscle tension.
62447938|NCT02281942|PLACEBO_COMPARATOR|Education|A series of 30-minute recordings focused on different aspects of healthy living (e.g. diet, stress).
62620443|NCT06239181|EXPERIMENTAL|EBECA|The patients in the intervention group scheduled for angiography were administered the Beck Anxiety Scale, and then they underwent conscious, deep breathing exercises along with synchronized breathing training. The face-to-face teaching and application of the breathing exercises took an average of 15-20 minutes.
62620444|NCT06239181|ACTIVE_COMPARATOR|control group|For the patients in the control group who were scheduled for angiography, the Beck Anxiety Scale was administered face-to-face before the procedure, and they were then sent for the procedure after receiving routine treatment without any additional intervention.
62846474|NCT00201513|EXPERIMENTAL|sling exercise|Sling exercises (high load)
62846475|NCT00201513|ACTIVE_COMPARATOR|group exercise|Non-specific group exercises
62060135|NCT00755222|PLACEBO_COMPARATOR|Placebo|
62060136|NCT03114371|EXPERIMENTAL|Oxytocin|Daily intranasal administrations of oxytocin for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be 8 International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.
62060137|NCT03114371|PLACEBO_COMPARATOR|Placebo|Daily intranasal administrations of placebo for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.
62060138|NCT00925405||Breast MRI Screening|
62060139|NCT03754205|EXPERIMENTAL|Laser Group|"Microablative Fractional CO2 laser therapy at monthly intervals.~The laser parameters that will be used are the following: (1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode."
62060140|NCT03754205|PLACEBO_COMPARATOR|Placebo Group|"Placebo CO2 laser therapies at monthly intervals.~The laser parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode."
62060141|NCT02290002|ACTIVE_COMPARATOR|group A|In group A, (Calcium Dobesilate group), 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given from at day of HCG injection and for 21 days.
62060142|NCT02290002|ACTIVE_COMPARATOR|group B|In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
62060143|NCT00547287|ACTIVE_COMPARATOR|1|Currently prescribed dosage of sildenafil is continued until wash-out period.
62060144|NCT00547287|ACTIVE_COMPARATOR|2|20 mg tadalafil given after one week sildenafil wash-out period.
62060145|NCT02874651|EXPERIMENTAL|Apatinib|In the phase IIb part of this trial, patients in this arm will take oral apatinib until disease progression, intolerable toxicity, death or to a maximum of 2 years.
62263980|NCT04086823|ACTIVE_COMPARATOR|RZL-012|"A single-treatment injection, multiple subcutaneous injections of RZL-012 administered into 48 sites in the submental fat (0.05/0.1mL per site):~1. Up to 120mg administered at 48 sites in a volume of 0.05 ml at each injection site (total injected volume 2.4mL)~2. Up to 240 mg administered at 48 sites in a volume of 1 ml at each injection site (total volume injected 4.8mL)"
62263981|NCT04086823|PLACEBO_COMPARATOR|Vehicle|"Subject receive a single-treatment injection. Multiple injections of the Placebo are administered at 48 sites (0.05/0.1mL per site) into the submental fat.~Up to a total of 2.4 mL will be injected for placebo subjects enrolled during cohort 1.~Up to a total of 4.8 mL will be injected for placebo subjects enrolled during cohort 2."
62263982|NCT01624662|ACTIVE_COMPARATOR|OPN-375 100 mcg|Double-Blind Treatment Phase: OPN-375 100 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
62263983|NCT01624662|ACTIVE_COMPARATOR|OPN-375 200 mcg|Double-Blind Treatment Phase: OPN-375 200 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
62263984|NCT01624662|ACTIVE_COMPARATOR|OPN-375 400 mcg|Double-Blind Treatment Phase: OPN-375 400 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
62263985|NCT01624662|PLACEBO_COMPARATOR|Placebo|Double-Blind Treatment Phase: Matched Placebo BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
62263986|NCT02097914|NO_INTERVENTION|Control|Participant receives usual care.
62263987|NCT02097914|EXPERIMENTAL|Intervention|Educational print materials and coaching call: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and once coaching call.
62447939|NCT06542159|EXPERIMENTAL|The study group|Patients in the study group will receive online adaptive stereotactic body radiotherapy (without PTV expansion margin). The total dose will be 45-50Gy/3-4 fractions, administered once daily. Both FBCT and 4DCT will be acquired before initiating treatment at each fraction.
62447940|NCT06542159|ACTIVE_COMPARATOR|The control group|Patients in the control group will receive conventional standard stereotactic body radiotherapy. The total dose will be 45-50Gy/3-4 fractions, administered once daily. CBCT will be acquired before initiating treatment at each fraction.
62447941|NCT06205719|EXPERIMENTAL|Remazolam combined with Remifentanil anesthesia|0.2mg/kg Remazolam and 2ug/kg Remifentanil for induction of anesthesia, remifentanil 0.1 μg/kg/min and 0.2mg/kg Remazolam were continuously pumped intravenously.
62060146|NCT02874651|PLACEBO_COMPARATOR|Placebo|In the phase IIb part of this trial, patients in this arm will take oral placebo until disease progression, intolerable toxicity, death or to a maximum of 2 years.
62060147|NCT02492555|EXPERIMENTAL|Scheduled (SI)|"Scheduled means screening every 3rd month ( home FC and DA) plus when needed and upgrade of ususal treatment"
62060148|NCT02492555|ACTIVE_COMPARATOR|On Demand (OD)|"On Demand means screening of home FC and DA when the patients feel for it and upgrade of usual treatment"
62060149|NCT02932592|EXPERIMENTAL|Dysglycemic group|"Patients with dysglycemia (not diabetic patients) will be undergone a monitoring of blood glucose with a device till the discharge of the patient.~Then, an oral glucose tolerance test (OGTT) will be done to categorize the patient as having impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), or diabetes mellitus."
62060150|NCT04489693|ACTIVE_COMPARATOR|Ambulatory Care Coordinator Team (ACCT)|Patients randomized to ACCT receive care from different doctors in clinic and in the hospital. ACCT patients who have been hospitalized twice, had 4 emergency department (ED) visits in the last year or are referred by their primary care physician are offered ACCT care coordination services (ACCT-CC) from nurses and social workers who manage their care with the larger clinical team. Patients are graduated from ACCT if the ACCT team thinks they are no longer high risk.
62620445|NCT05319262|NO_INTERVENTION|Control|Single study night with no noise exposure, to determine normal baseline sleep
62620446|NCT05319262|EXPERIMENTAL|Traffic noise|Single study night with traffic noise events, to determine consequences of sleep disturbance by traffic noise
62620447|NCT05319262|EXPERIMENTAL|Pink noise|Single study night to measure the effects of a non-pharmacological intervention to promote sleep, pink noise.
62620448|NCT05319262|EXPERIMENTAL|Traffic noise + pink noise|Single study night with concurrent traffic noise events and continuous pink noise sound exposure. Night is used to determine attenuation of sleep disturbance by traffic noise due to introduction of pink noise.
62620449|NCT01882803|EXPERIMENTAL|Duvelisib|
62620450|NCT04671056|EXPERIMENTAL|MGL-3196 100 mg tablet plus Pioglitazone 15 mg tablet|MGL-3196 administered orally plus Pioglitazone administered orally on 2 separate days
62620451|NCT00565097|PLACEBO_COMPARATOR|2|Placebo
62620452|NCT00565097|EXPERIMENTAL|1|Lanreotide
62060151|NCT04489693|ACTIVE_COMPARATOR|Comprehensive Care Physician (CCP)|Patients randomized to the CCP group are assigned to a Comprehensive Care Physician and are asked to see their assigned CCP for their primary care. The patients receive their care from the same CCP in the outpatient clinic and also if they were to be hospitalized.
62620453|NCT04063995|EXPERIMENTAL|Excitatory repetitive transcranial magnetic stimulation group|One session of repetitive transcranial magnetic stimulation (rTMS) treatment with 10 Hz frequency will be applied to the contralesional dorsal premotor cortex. Application will be performed with Neurosoft-Neuro MS / D device. 90% of the motor threshold will be used in the stimulation. Stimulation is planned for a total of 15 minutes and a total of 1500 beats in the form of a 5 seconds 10 Hz stimulation followed by a 25 seconds interval.
62620454|NCT04063995|EXPERIMENTAL|Inhibitory repetitive transcranial magnetic stimulation group|One session of repetitive transcranial magnetic stimulation (rTMS) treatment at 1 Hz frequency will be applied to the contralesional dorsal premotor cortex. Application will be performed with Neurosoft-Neuro MS / D device. 90% of the motor threshold will be used in the stimulation. Stimulation is planned for a total of 25 minutes and a total of 1500 beats in the form of 1 Hz stimulation.
62620455|NCT04063995|SHAM_COMPARATOR|Sham repetitive transcranial magnetic stimulation group|Single session of sham application for a total of 25 minutes. Sham application will be performed by holding the probe of the device vertically to the vertex. The device will be operated at the lowest operating power of 1 to produce the same stimulation sounds like the active application. The device operating at this power is not likely to give any stimulation due to the probe being held upright.
62620456|NCT05411601||C1|Subjects with socket-type attachment of their prostheses
62620457|NCT05411601||C2|Subjects with direct skeletal attachment
62620458|NCT01370616|EXPERIMENTAL|Ertapenem sodium|Participants received 1.0 g intravenous (IV) ertapenem sodium as a single daily dose at Hour 0 infused over a 30-minute interval , and IV piperacillin/tazobactam-matching placebo at Hours 8 and 16 infused over a 30-minute interval, for 5 to 28 days. Participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
62620459|NCT01370616|ACTIVE_COMPARATOR|Piperacillin/tazobactam sodium|Participants received 4.5 g IV piperacillin/tazobactam at Hours 0, 8, and 16 infused over a 30-minute interval, for 5 to 28 days. Participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
62620460|NCT04525326|EXPERIMENTAL|standard chemotherapy plus Cetuximab|
62620461|NCT04525326|EXPERIMENTAL|standard chemotherapy plus Bevacizumab|
62447942|NCT06205719|ACTIVE_COMPARATOR|ciprofol combined with Remifentanil anesthesia|0.4mg/kg ciprpfol and 2ug/kg Remifentanil for induction of anesthesia,remifentanil 0.1 μg/kg/min and 0.4-2.4mg/kg/h ciprpfol were continuously pumped intravenously.
62620462|NCT06138717|ACTIVE_COMPARATOR|only aerobic exercise|Aerobic exercises will be performed with a lower extremity ergometer for 30 minutes and 12 sessions.
62447943|NCT06205719|ACTIVE_COMPARATOR|The flumazenil was injected at the end of the surgery|0.2mg/kg Remazolam and 2ug/kg Remifentanil for induction of anesthesia, remifentanil 0.1 μg/kg/min and 0.2mg/kg Remazolam were continuously pumped intravenously. The 0.5mg flumazenil was injected at the end of the surgery
62447944|NCT03882164||Rejection|Patient undergone liver transplant with diagnosis of rejection within 10 days
62620463|NCT06138717|ACTIVE_COMPARATOR|combine aerobic exercise and yoga exercises|Aerobic exercises will be performed with a lower extremity ergometer for 30 minutes and 12 sessions.A yoga-based exercise programme consisting of exercises will be applied for 40 minutes and 12 session
62620464|NCT05694273||Ischemic stroke group|"1. Ischemic stroke secondary to patients receiving catheter ablation.~2. Ischemic stroke met the diagnostic criteria of the 2018 edition of the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke, and was confirmed by cranial CT/MRI scan."
62620465|NCT05694273||Transient ischemic attack group|"1. Transient ischemic attack secondary to patients receiving catheter ablation.~2. Ischemic stroke met the diagnostic criteria of the 2018 edition of the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke, and was confirmed negative of new onset of infarction by cranial CT/MRI scan."
62620466|NCT05694273||Cerebral hemorrhage group|"1. Cerebral hemorrhage secondary to patients receiving catheter ablation.~2. Cerebral hemorrhage met the diagnostic criteria of the 2021 Chinese Guidelines for the Diagnosis and Treatment of cerebral hemorrhage and was confirmed by head CT/MRI."
62620467|NCT05694273||Contral group|Patients who did not experience acute cerebrovascular events in the hospital.
62620468|NCT04030637||CRC cases|samples will be collected from subjects with known diagnosis of colorectal cancer
62620469|NCT04030637||Healthy cases|samples will be collected from healthy subjects with normal colonoscopy findings
62620470|NCT04030637||Cases with pathologies|samples will be collected from subjects whose colonoscopies showed other pathologies (e.g. inflammatory polyps, adenomas, diverticular diseases)
62447945|NCT03882164||No-Rejection|Patient undergone liver transplant wothout diagnosis of rejection within 10 days
62060152|NCT04489693|ACTIVE_COMPARATOR|Comprehensive Care, Community & Culture Program (C4P)|Patients randomized to C4P receive care from a CCP in both the hospital and the clinic as well as the following: 1) systematic screening of 17 domains of unmet social needs, 2) access to a community health worker and 3) access to community-based arts and culture programming.
62060153|NCT05046496|NO_INTERVENTION|Observational arm|Patients recruited to this arm will undergo no intervention.
62060154|NCT05046496|ACTIVE_COMPARATOR|Interventional arm|Patients recruited to this arm will undergo intra-arterial digital subtraction angiography, with or without intra-arterial stent placement
62060155|NCT05839223|EXPERIMENTAL|Intervention|received the educational process (recommendations) about isotretinoin by a clinical pharmacist in addition to the routine education about isotretinoin provided by the physician
62060156|NCT05839223|NO_INTERVENTION|Control|received only the routine education about isotretinoin provided by the physician
62060157|NCT01846000|EXPERIMENTAL|Muscles of mastication|This group with TMD will receive low-level laser treatment at masseter and temporal muscles - three points on the masseter (upper, middle and lower) and one point on the anterior temporal
62620471|NCT03658642|EXPERIMENTAL|Clinical Decision Support for BUP|The Clinical Decision Support (CDS) will be available for clinician use for Emergency Department (ED)-initiated buprenorphine/naloxone (BUP) with referral for ongoing medication assisted treatment (MAT) if: ED chief complaint or urine drug screen indicate opioid use. The clinician will then be prompted to complete DSM-5 checklist for OUD. If DSM-5 OUD Score\>5 and urine drug screen is positive for opioids, then the clinician is prompted to complete COWS scale. If COWS score \>12, then the clinician is prompted to order BUP. Regardless of COWS score, the clinician will be prompted to schedule an MAT appointment with BUP provider. The CDS will interface with outside MAT facilities so that making an appointment is easy and to capture data on whether an appointment has been scheduled.
62620472|NCT03658642|NO_INTERVENTION|Usual Care|The CDS will not be activated and patients will receive care as usual.
62620473|NCT01797588|ACTIVE_COMPARATOR|adductor-canal block and periarticular infiltration|Adductor-canal block,performed prior to surgery using ultra sound guidance by an anesthetist, with a total of 30mL of 0.33% ropivacaine injected into the area surrounding the saphenous nerve. Periarticular infiltration, performed intra-operatively by the surgeon, involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee.
62620474|NCT01797588|ACTIVE_COMPARATOR|adductor-canal block|The adductor-canal block only group will receive an adductor-canal block prior to surgery in the block room using ultra sound guidance by an anesthetist. After the adductor-canal is located a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve. Participants will also receive 110mL of normal saline administered as follows: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (\~60mL) is used to infiltrate the muscle, subcutaneous tissues.
62060158|NCT01846000|EXPERIMENTAL|TMJ and muscles|This group with TMD will receive a mixed application of low-level laser treatment- TMJ and muscles of mastication.
62060159|NCT01846000|PLACEBO_COMPARATOR|Placebo|This group with TMD will receive a low-level laser placebo treatment at TMJ and muscles of mastication. The same equipment will be used with a pen that emits a red guide light and a warning sound, but without the emission of laser
62263988|NCT03002584||IBS & general population|"The participants will be given the IGQ questionnaire to complete as well as other self-reported questionnaires.~Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).~Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale."
62263989|NCT05288400|EXPERIMENTAL|Group A|single-capsule of fixed dosed combination (FDC) of amlodipine 5 mg / bisoprolol fumarate 5 mg / perindopril arginine 5 mg
62263990|NCT05288400|ACTIVE_COMPARATOR|Group B|Free triple therapy of amlodipine 5 mg + bisoprolol fumarate 5 mg + perindopril arginine 5 mg, given concomitantly
62263991|NCT04875546|ACTIVE_COMPARATOR|Standard treatment|"* A 5'A' and '5'R' models~* STAR method for quitting"
62263992|NCT04875546|ACTIVE_COMPARATOR|Integrated Intervention|"* A 5'A' and '5'R' models~* Receive brief advice on alcohol use based on the FRAMES model~* Complete the Alcohol Use Disorders Identification Test"
62447946|NCT04954456|EXPERIMENTAL|QLS31901|"Part 1 (Dose escalation): QLS31901will be administered in sequential cohorts each receiving 1 of 6 doses of QLS31901 on day 1 of every 21-day cycle (3 weeks) via IV infusion. Dose escalation will continue until an MTD is reached.~Part 2 (Dose Expansion): The PK parameters of QLS31901 will be tested at 2-3 doses determined during the dose-escalation phase in subjects with advanced malignant tumor cohorts."
62447947|NCT04807114||NSCLC st.IV (PD-L1 > 50%)|Anti-PD-1 monotherapy
62447948|NCT04807114||NSCLC st.IV (PD-L1 < 50%)|Combination anti-PD-1 + chemotherapy
62447949|NCT01776346||Barrett's Esophagus/Esophageal Adenocarcinoma|Patients who have Barrett's esophagus or esophageal adenocarcinoma.
62060160|NCT01846000|EXPERIMENTAL|Tempormandibular Joint|This group with TMD will receive low-level laser treatment in TMJ region - five points around the TMJ.
62060161|NCT01846000|NO_INTERVENTION|Withou TMD|This will be a follow up group, with volunteers without TMD.
62263993|NCT04875546|SHAM_COMPARATOR|Control|Participants will receive two leaflets.
62447950|NCT01776346||Healthy control|
62447951|NCT03651674|ACTIVE_COMPARATOR|ECT treatment|Patients received bilateral temporal modified ECT (MECT) for three weeks,four times a week. Meanwhile, they also had antipsychotic drugs.
62060162|NCT03710525|EXPERIMENTAL|Own-Price Elasticity|"The price of vegetables will vary (own-price elasticity) while the price of all other foods in the mock grocery store will remain constant."
62060163|NCT03710525|EXPERIMENTAL|Cross-Price Elasticity|"The price of vegetables will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
62447952|NCT03651674|SHAM_COMPARATOR|Drug treatment|Patients only received antipsychotic drugs during observation period.
62447953|NCT01899963||Tele-ophthalmology Referral Group|This group includes patients referred to a retinal specialist via a teleophthalmology referral system.
62447954|NCT01899963||Conventional Referral Group|This group includes patients referred to a retinal specialist via a conventional fax system.
62263994|NCT02620696|EXPERIMENTAL|Treatment 1|"* esomeprazole 40 mg daily for 28 days (Days 1-28)~* netazepide placebo daily from Days 1-42"
62263995|NCT02620696|EXPERIMENTAL|Treatment 2|"* esomeprazole 40 mg daily for 28 days (Days 1-28)~* netazepide 25 mg daily for 14 days (Days 15-28)~* netazepide placebo daily from Days 1-14, and from Days 29-42"
62447955|NCT01842048|EXPERIMENTAL|External-beam radiotherapy combine hyperthermia|Hyperthermia 42℃ ± 0.5℃ for 40min, 2 times/week within 2hr after irradiation. Radiation protocol are 3Gy 5 times a week for a total of 30Gy/10fx/2 weeks
62447956|NCT01842048|ACTIVE_COMPARATOR|External-beam radiotherapy alone|External-beam radiotherapy alone comprising 30Gy/10 fractions, 5 times a week, administered with 2 weeks.
62447957|NCT05561114|EXPERIMENTAL|GIE Medical ProTractX3 TTS DCB|"The ProTractX3 Drug-coated balloon is a 0.035 guidewire compatible over-the-wire catheter."
62620475|NCT01797588|ACTIVE_COMPARATOR|periarticular infusion group|Periarticular infiltration,performed intra-operatively,involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. It will be administered as follows: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (\~60mL) is used to infiltrate the muscle, subcutaneous tissues.
62263996|NCT02620696|EXPERIMENTAL|Treatment 3|"* esomeprazole 40 mg daily for 28 days (Days 1-28)~* netazepide 25 mg daily for 14 days (Days 29-42)~* netazepide placebo daily from Days 1-28"
62263997|NCT02620696|EXPERIMENTAL|Treatment 4|"* esomeprazole 40 mg daily for 28 days (Days 1-28)~* netazepide placebo daily from Days 1-28"
62263998|NCT02620696|EXPERIMENTAL|Treatment 5|"* esomeprazole 40 mg daily for 28 days (Days 1-28)~* netazepide 1 mg daily for 14 days (Days 15-28)~* netazepide placebo daily from Days 1-14"
62263999|NCT02620696|EXPERIMENTAL|Treatment 6|"* esomeprazole 40 mg daily for 28 days (Days 1-28)~* netazepide 5 mg daily for 14 days (Days 15-28)~* netazepide placebo daily from Days 1-14"
62447958|NCT05561114|ACTIVE_COMPARATOR|Control|Standard of Care Endoscopic Dilation
62447959|NCT01411995|EXPERIMENTAL|2% Lidocaine gel|Women randomized to the Lidocaine arm will receive a total of 3-5cc of 2% gel at the tenaculum site and within the endocervical canal
62447960|NCT01411995|PLACEBO_COMPARATOR|Water based lubricant|Women randomized to the placebo arm will receive a total of 3-5cc of water based lubricant at the tenaculum site and within the the endocervical canal
62447961|NCT03811379|EXPERIMENTAL|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
62447962|NCT05780437|EXPERIMENTAL|AZD7442 plus SOC|"* AZD7442 600 mg solution (4 separate vials, 2 containing 150 mg each of AZD88995 and 2 containing 150 mg each of AZD1061); administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
62447963|NCT05780437|PLACEBO_COMPARATOR|Placebo plus SOC|"* Placebo administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
62447964|NCT00622908|EXPERIMENTAL|ISV-403|ISV-403 0.6%
62447965|NCT00622908|PLACEBO_COMPARATOR|Vehicle|Vehicle of ISV-403
62447966|NCT03841383||Healthy controls|
62447967|NCT03841383||Hypertensive patients|
62620476|NCT06321185|ACTIVE_COMPARATOR|Subcostal TAP block|Subcostal TAP block will be applied bilaterally with 20 ml 0.25% bupivacaine for each side.
62447968|NCT05316675|ACTIVE_COMPARATOR|Group 1|:(25)patients will be treated by oral isotretinoin; 0.5 -1 mg/kg/day in two divided doses for 6 months.
62447969|NCT05316675|ACTIVE_COMPARATOR|Group 2|:(25) Patients will be treated by oral isotretinoin; 0.5 -1 mg/kg/day for seven days each month for 6 pulses.
62447970|NCT05316675|ACTIVE_COMPARATOR|Group 3|:(25) Patients will be treated by oral isotretinoin; 0.1-0.2 mg/kg/day for 6months
62447971|NCT05316675|ACTIVE_COMPARATOR|Group 4:|(25) Patients will be treated by oral isotretinoin;20mg /day for one month then the dose increased in monthly steps to reach the standard dosing for 6 months
62447972|NCT05392621|EXPERIMENTAL|Yoga+Progressive Muscle Relaxation+Deep Breathing|Participants engage in a single session combining yoga, progressive muscle relaxation, and deep breathing.
62264000|NCT06383273|EXPERIMENTAL|MELT-300 sublingual tablet|Participants will receive a single dose of MELT-300 sublingual, tablet containing 3 mg of midazolam and 50 mg of ketamine.
62264001|NCT06383273|ACTIVE_COMPARATOR|Midalozam sublingual tablet|Participants will receive a single dose of midazolam 3 mg sublingual tablet.
62264002|NCT06383273|PLACEBO_COMPARATOR|Placebo sublingual tablet|Participants will receive a single dose of a matching placebo sublingual tablet.
62264003|NCT06548919||Chemotherapy|
62264004|NCT06548919||Endocrine therapy|
62264005|NCT01418183|EXPERIMENTAL|5ml 5% levobupivacaine|5ml 5% levobupivacaine to both maxillary and mandibular branches of trigeminal nerve on experimental side. (total 10ml)
62264006|NCT01418183|PLACEBO_COMPARATOR|5ml normal saline|5ml for maxillary and mandibular branches of trigeminal nerve (total 10ml on controlled side)
62264007|NCT01418183|EXPERIMENTAL|2.5ml 5% levobupivacaine|2.5ml 5% levobupivacaine to both maxillary and mandibular branches of trigeminal nerve on experimental side. (total 10ml)
62447973|NCT05392621|EXPERIMENTAL|Yoga+Progressive Muscle Relaxation|Participants engage in a single session combining yoga and progressive muscle relaxation
62447974|NCT05392621|EXPERIMENTAL|Yoga+Deep Breathing|Participants engage in a single session combining yoga and deep breathing.
62447975|NCT05392621|EXPERIMENTAL|Yoga|Participants engage in a single session of yoga.
62447976|NCT05392621|EXPERIMENTAL|Progressive Muscle Relaxation+Deep Breathing|Participants engage in a single session combining progressive muscle relaxation and deep breathing.
62447977|NCT05392621|EXPERIMENTAL|Progressive Muscle Relaxation|Participants engage in a single session of progressive muscle relaxation.
62060164|NCT01567332|EXPERIMENTAL|rTMS active|
62264008|NCT04639583|EXPERIMENTAL|Observational Arm|Any infant consented to participate in the study will have the NIRS applied for the first 96 hours of life. It will be the goal to apply the NIRS sensors in the first 12 hours of life. All infants will have the same treatment if in the study, but clinicians will not be able to see the data obtained so that there is no clinical interpretation during this time.
62060165|NCT01567332|PLACEBO_COMPARATOR|rTMS inactive (sham)|
62264009|NCT00953368|ACTIVE_COMPARATOR|Remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
62620477|NCT06321185|ACTIVE_COMPARATOR|Port site local anesthetic infiltration|A total solution of 20 ml 0.25% bupivacaine will be infiltrated into the port sites before port placements.
62060166|NCT05525936||Critically-ill patients|"Patients admitted to intensive care unit~* inserted with a central venous catheter in the superior vena cava territory or a pulmonary arterial catheter for their management, and requiring one or both of the following:~* invasive ventilation, and/or~* catecholamine infusion."
62264010|NCT00953368|PLACEBO_COMPARATOR|control|sham placement of a blood-pressure cuff around the upper limb without inflation
62264011|NCT05133011|EXPERIMENTAL|Low muscle strength|The participants underwent before tongue base reduction surgery used Iowa Oral Performance Instrument (IOPI) system test upper tongue muscle strength were the last 5%
62447978|NCT05392621|EXPERIMENTAL|Deep Breathing|Participants engage in a single session of deep breathing.
62620478|NCT06321185|OTHER|Standard multimodal IV analgesia|There will not be an intervention or local anesthetic administration.
62060167|NCT01756521|EXPERIMENTAL|Moxifloxacin 400mg|moxifloxacin 400mg
62060168|NCT01756521|EXPERIMENTAL|Moxifloxacin 800mg|moxifloxacin 800mg
62060169|NCT01756521|PLACEBO_COMPARATOR|Placebo(No treatment)|Only drink water
62060170|NCT01238224|PLACEBO_COMPARATOR|Placebo|A single dose of placebo is administered 30 min before a mixed meal.
62060171|NCT01238224|ACTIVE_COMPARATOR|Tadalafil|A single dose of tadalafil 20 mg is administered 30 min before a mixed meal.
62060172|NCT00575497|EXPERIMENTAL|A|Six Day per week short daily hemodialysis
62060173|NCT00575497|EXPERIMENTAL|B|Six nights per week nocturnal hemodialysis
62060174|NCT00575497|EXPERIMENTAL|C|Every other day short daily hemodialysis
62060175|NCT00575497|EXPERIMENTAL|D|Every other night hemodialysis
62060176|NCT00575497|EXPERIMENTAL|E|5 days per week short daily hemodialysis
62060177|NCT00575497|EXPERIMENTAL|F|5 nights per week hemodialysis
62060178|NCT00575497|ACTIVE_COMPARATOR|G|Conventional three time per week short daily hemodialysis
62264012|NCT05133011|EXPERIMENTAL|Normal groups|The participants underwent before tongue base reduction surgery used Iowa Oral Performance Instrument (IOPI) system test upper tongue muscle strength were greater than 5%
62264013|NCT02995486|NO_INTERVENTION|Control|Standard care with only an educational pamphlet.
62447979|NCT05392621|SHAM_COMPARATOR|Quiet sitting|Participants engage in a low-touch relaxation condition.
62447980|NCT03076177|EXPERIMENTAL|Kinesio taping group|Participants receiving kinesio taping application
62447981|NCT03076177|SHAM_COMPARATOR|Non specific taping|Participants receiving non specific taping application
62620479|NCT00696995||A|
62447982|NCT05188521|EXPERIMENTAL|Cutaneous LP|Subjects with a diagnosis of cutaneous LP will receive Baricitinib (LY3009104) for a 16 weeks treatment period
62620480|NCT00946062|ACTIVE_COMPARATOR|regular O&M-training|orientation and mobility training in use of the identification cane as provided by mobility trainers
62060179|NCT02850432|ACTIVE_COMPARATOR|Invasive treatment|Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol
62447983|NCT05188521|EXPERIMENTAL|Dose Escalation Extension Group|Subject that demonstrate a response to the 16 weeks of treatment with 2 mg of Baricitinib (LY3009104), but have not achieved a PGA 0 will receive 4 mg of Baricitinib (LY3009104) for 12 weeks
62447984|NCT06090656|ACTIVE_COMPARATOR|Bevacizumab combined with Sintilimab|Bevacizumab combined with sintilimab, sindilizumab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
62447985|NCT06090656|SHAM_COMPARATOR|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization, patients were treated with cTACE, and the efficacy was assessed by repeat CT/MRI 1 month after the initial treatment, and if the tumor still had arterial phase enhancement, TACE treatment could be supplemented until treatment failure and withdrawal of consent.
62447986|NCT06244979|EXPERIMENTAL|Intervention|Patients will undergo a PET/CT scan at t=60 min after a single intravenous injection of a fixed dose of 100 MBq +/- 10% \[68Ga\]Ga-DFO-B (gallium-68-deferoxamine) which contains 100 µg deferoxamine (DFO-B).
62447987|NCT00794079|EXPERIMENTAL|A|omega-3 fatty acids
62447988|NCT00794079|PLACEBO_COMPARATOR|B|corn oil
62620481|NCT00946062|EXPERIMENTAL|standardised O&M-training|standardised orientation and mobility training in use of the identification cane as provided by mobility trainers who received instruction in using the standardised protocol
62620482|NCT03189069||Patients prescribed apixaban|
62620483|NCT03189069||Patients prescribed dabigatran|
62620484|NCT03189069||Patients prescribed rivaroxaban|
62447989|NCT01400321||Distal region|Patients with loss of tooth in the premolar and molar region of the atrophied mandible
62620485|NCT03189069||Patients prescribed warfarin|
62620486|NCT04993703|EXPERIMENTAL|Kinesiotaping|"A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3sets of ten repetitions) will be applied.~Additionally for this group, kinesiotaping will be applied by using carpal tunnel technique including button hole and I band technique of space correction; and with 25-50% tension in center of tape over dorsal carpal tunnel at the end of the each session. Patients will request to keep kinesiotaping at nights throughout the study."
62060180|NCT02850432|ACTIVE_COMPARATOR|Conservative treatment|rehabilitation with medical therapy
62060181|NCT01515462|EXPERIMENTAL|OTL-103 gene therapy|Eligible subjects will receive intravenous (IV) infusion of OTL-103 gene therapy. Subjects affected by WAS who don't have a suitable matched donor for allogenic hematopoietic stem cell transplantation will be included
62060182|NCT05389111|EXPERIMENTAL|Internal discourses|Introduction to internal discourses with a brief definition and key elements for implementation.
62060183|NCT05389111|SHAM_COMPARATOR|Non-internal discourses|Introduction to the risks associated with the practice of activity in the mountain environment and practical tips to prevent the risks
62060184|NCT02623114|EXPERIMENTAL|Methylphenidate|ADHD patients with methylphenidate administration Generic names include concerta, metadata and penid. The initial dosage was fixed for 2 weeks and then adjusted according to the clinician's judgement. The patients visited the hospital at week 2,4,6,8,16,24, 9months, 12,15,18,21,24 months.
62447990|NCT01400321||aesthetic zone|Patients with loss of tooth within the aesthetic zone (canine to canine)
62447991|NCT04623736|EXPERIMENTAL|quitSTART|
62447992|NCT01107236|EXPERIMENTAL|IW-6118|
62447993|NCT01107236|PLACEBO_COMPARATOR|Placebo|
62447994|NCT01107236|ACTIVE_COMPARATOR|Naproxen Sodium|
62447995|NCT03763110|EXPERIMENTAL|Photo Activated Disinfection|Photoactivated disinfection (PAD) is based on the interaction of a photosensitive antibacterial agent and a light source. It uses a nontoxic dye \[named photosensitizer PS\] and low-intensity visible light. In oxygen presentation, these combine to produce some cytotoxic species. The PS molecules attach to bacteria membrane
62447996|NCT03763110|ACTIVE_COMPARATOR|Antibiotic paste|Hoshino et al. recommended a ratio of 1:1:1 of metronidazole (500 mg), minocycline (100 mg) and ciprofloxacin (200 mg) for the 3Mix formulation
62447997|NCT02254148|EXPERIMENTAL|Treatment|single dose of CYP 450 substrates and a P-gp substrate + multiple doses of BI 187004
62447998|NCT01339910|EXPERIMENTAL|Reduced Intensity Conditioning (RIC)|One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
62447999|NCT01339910|ACTIVE_COMPARATOR|Myeloablative Conditioning Regimen (MAC)|One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
62846476|NCT06291519|EXPERIMENTAL|Experimental Group 1|In this group, the mother applied multiple sensory stimuli. In this group, the mothers of the babies to be vaccinated applied multiple sensory stimuli such as breastfeeding, mother's voice, touch-light massage, and eye contact. The mother breastfed her baby for a total of 20 minutes. Breastfeeding was terminated before vaccination. Other applications were applied for 5 minutes before vaccination and 5 minutes after vaccination. FLACC pain scale, SPO2, and pulse oximetry were evaluated and recorded 5 min before and 2 min after vaccination, immediately before vaccination, immediately after vaccination (pain during the procedure), and 2 and 5 min after the procedure.
62060185|NCT02623114|EXPERIMENTAL|Atomoxetine|ADHD patients with atomoxetine administration Generic names include strattera. The initial dosage was fixed for 2 weeks and then adjusted according to the clinician's judgement. The patients visited the hospital at week 2,4,6,8,16,24, 9months, 12,15,18,21,24 months.
62448000|NCT04972656|EXPERIMENTAL|Ambrisentan|Monotherapy using ambrisentan will start at a dose of 5 mg (once daily) and will be up-titrated to 10 mg (once daily) after 4 weeks apart if patients are tolerable.
62448001|NCT04972656|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62060186|NCT00819364|EXPERIMENTAL|1|Participants with autism will receive BCRI intervention program.
62060187|NCT00819364|ACTIVE_COMPARATOR|2|Participants with autism will receive standard care available in the community.
62448002|NCT05869942|ACTIVE_COMPARATOR|groupA (Diseased group)|patients with Vitiligo
62060188|NCT02317055|OTHER|Patient|Imaging
62060189|NCT02317055|OTHER|healthy subject|Imaging
62264014|NCT02995486|EXPERIMENTAL|Intervention|Post-discharge exercise group
62264015|NCT02302508|EXPERIMENTAL|T2D patients with A1C ≤7.0|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
62448003|NCT05869942|ACTIVE_COMPARATOR|group B(Control group)|Normal control group not diseased
62448004|NCT01555619||CRT-D System|St. Jude Medical (SJM) Promote® Q/Promote® Quadra/Unify Quadra™ CRT-D system.
62448005|NCT03043378||Chronic Non-Malignant Pain - Cancer Patients|Chronic non-malignant pain among cancer patients undergoing a consultation at the outpatient Supportive Care Clinic at MD Anderson Cancer Center.
62620487|NCT04993703|EXPERIMENTAL|Night splinting|"A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3sets of ten repetitions) will be applied.~Additionally, night splinting will be advised. Patients will request to keep their splints at nights throughout the study."
62620488|NCT04993703|EXPERIMENTAL|Control group|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3sets of ten repetitions) will be applied.
62846477|NCT06291519|EXPERIMENTAL|Experimental Group 2|In this group, the nurse applied multiple sensory stimuli. In this group, the mothers of the babies to be vaccinated breastfed the baby for 20 minutes. The mother stopped breastfeeding before the vaccination procedure. The nurse started to give multisensory stimuli. The nurse administered multisensory stimuli including soft tone of voice, touch-light massage, and eye contact 5 minutes before the vaccination. Other applications were applied 5 minutes before and 5 minutes after vaccination. FLACC pain scale, SPO2, and pulse oximetry were evaluated and recorded 5 min before and 2 min after vaccination, immediately before vaccination, immediately after vaccination (pain during the procedure), and 2 and 5 min after the procedure.
62846478|NCT06291519|EXPERIMENTAL|Experimental Group 3|In this group, the mother breastfed her baby for 20 minutes before vaccination. Breastfeeding was terminated before vaccination. FLACC pain scale, SPO2, and pulse oximetry were evaluated and recorded 5 min before and 2 min after vaccination, immediately before vaccination, immediately after vaccination (pain during the procedure), and 2 and 5 min after the procedure.
62060190|NCT04141449|EXPERIMENTAL|Potlako intervention|"* Provider oncology training focused on detection of cancer symptoms/signs and performance of appropriate diagnostic evaluation~* Community-led cancer symptom awareness campaign to educate residents on methods and importance of early detection of cancer~* Support/counselling call after initial clinician recognition that patient requires evaluation for possible cancer.~* Cross-sectional community-facing activities partnered with longitudinal clinic-based targeted educational program~* Remote phone/SMS-based cancer suspect navigation program to support and expedite evaluation for symptoms/signs of possible cancer."
62846479|NCT06291519|NO_INTERVENTION|Control Group|Babies in this group did not receive any treatment. A light touch was applied for ethical reasons. FLACC pain scale, SPO2, and pulse oximetry were evaluated and recorded 5 min before and 2 min after vaccination, immediately before vaccination, immediately after vaccination (pain during the procedure), and 2 and 5 min after the procedure.
62846480|NCT04422678|EXPERIMENTAL|Imatinib Standard Dose|"Imatinib 400 mg oral tablet once daily for 21 days~In addition for the treatment for COVID-19 pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH)."
62846481|NCT04422678|EXPERIMENTAL|Imatinib Low Dose|"Imatinib 200 mg oral tablet once daily for 21 days.~In addition to the treatment for COVID-19 Pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH)."
62846482|NCT04422678|ACTIVE_COMPARATOR|Control|Treatment for COVID-19 pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH).
62846483|NCT02512835||Clinic patients|Aims 1a and 1b: The participants include all unique patients seen at the 12 study practices (approximately 170,000 patients over the past two years).
62060191|NCT04141449|ACTIVE_COMPARATOR|Enhanced Care|"* Provider oncology training focused on detection of cancer symptoms/signs and performance of appropriate diagnostic evaluation.~* Support/counselling call after initial clinician recognition that patient requires evaluation for possible cancer."
62846484|NCT02512835||Clinicians|Aims 2 and 3: The clinicians in this analysis will include 15 participants recruited from the approximately 100 clinicians at the 12 practices
62448006|NCT03852199||Case Group|Our study was performed with 30 healthy individuals at Hacettepe University, Faculty of Physical Therapy and Rehabilitation. The FS of the knee joint was measured with a Pressure Biofeedback Device (Stabilizer ™, Chattanooga Group Inc., Chattanooga, TN), a device similar to a sphygmomanometer. To correlate the outcomes of biofeedback device, simultaneously, a surface electromyography (EMG) data of M. Quadriceps femoris muscle activation levels from the individuals were recorded.
62448007|NCT02829671|OTHER|Patients with major depressive disorders|
62448008|NCT03327896||OCHIN EHR|"Patients who were established patients at OCHIN Primary Care Clinics in 2015 and had a face to face visit at the clinic in 2015.~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
62620489|NCT01570842|OTHER|Anthropometric Measurements; Tissue Samples|All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity. Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
62846485|NCT06248190|OTHER|Intervention|"1. Treatment literacy in chronic condition waiting rooms/pick-up points (posters, health promotion talks)~2. 1-2 longer consultations with ENHANCE guide trained clinician~3. Treatment literacy event - a contact between a CHW and a person with MLTC in their home (hopefully with carer), at 2 weeks and 4 weeks, using Health Diary~4. Referrals to additional adherence counselling if necessary"
62448009|NCT03327896||OneFlorida EHR|"Patients who were established patients at OneFlorida Primary Care clinics in 2015 and had a face to fact visit at the clinic in 2015.~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
62620490|NCT00280696|EXPERIMENTAL|Lev 0.5 g|Levetiracetam 0.5 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
62846486|NCT06248190|NO_INTERVENTION|Control|Usual care at primary health care clinic, which includes consultation with a clinician using the PACK/APC guide. No additional support is usually provided for care of MLTCs.
62846487|NCT02489305||Participants With Major Depressive Disorder|Participants with major depressive disorder who have responded to oral antidepressant treatment will be observed over time.
62846488|NCT00836121||tumor|
62846489|NCT00498290|EXPERIMENTAL|A|received enhanced recovery after surgery (ERAS) protocol in colorectal surgery
62846490|NCT00498290|NO_INTERVENTION|B|normal recovery protocol in colorectal surgery
62846491|NCT04625517|EXPERIMENTAL|Breast cancer patients|Patients with ipsilateral intact biopsy-proven breast cancer
62846492|NCT06436599|ACTIVE_COMPARATOR|Patients with serratus posterior superior intercostal plan block|Serratus posterior superior intercostal plane block was applied to a certain group of patients for postoperative anaesthesia.
62620491|NCT00280696|EXPERIMENTAL|Lev 1 g|Levetiracetam 1 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
62620492|NCT00280696|EXPERIMENTAL|Lev 2 g|Levetiracetam 2 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
62620493|NCT00280696|EXPERIMENTAL|Lev 3 g|Levetiracetam 3 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
62846493|NCT06436599|ACTIVE_COMPARATOR|Patients with serratus anterior plan block|Serratus anterior plane block was applied to a certain group of patients for postoperative anaesthesia.
62448010|NCT03327896||Oregon Medicaid|"Clients who were continuously insured through Oregon Medicaid in 2015 and had a claim with an Evaluation and Management Current Procedure Terminology (CPT) code indicating an office visit listing a Primary Care provider as the performing provider.~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
62620494|NCT00280696|PLACEBO_COMPARATOR|Placebo|Placebo tablets as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
62620495|NCT05597449|EXPERIMENTAL|Video group|Access to YouTube videos and written postoperative instructions
62620496|NCT05597449|NO_INTERVENTION|Control group|Access to written instructions only
62846494|NCT05069272|ACTIVE_COMPARATOR|Intervention|Synergistic combination of Bakuchiol and Ethyl Linoleate
62060192|NCT02789384|EXPERIMENTAL|Procedure/Surgery|Newly obtained biopsy if applicable and blood samples collection according to the usual medical practices.
62620497|NCT02496741|EXPERIMENTAL|Metformin and chloroquine combination|"Metformin will be administered in a 3+3 dose-escalation schedule.~Chloroquine will be administered in a fixed dose."
62620498|NCT01173900|OTHER|Class-based delivery|All girls attending standard 6 in schools selected for class-based vaccine delivery
62620499|NCT01173900|OTHER|Age-based delivery|All girls born in 1998 attending schools selected for age-based delivery
62620500|NCT03457844|EXPERIMENTAL|Anlotinib|
62620501|NCT00585325|EXPERIMENTAL|Instilled 1% Lidocaine|5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
62620502|NCT00585325|PLACEBO_COMPARATOR|Instilled Placebo (0.9% Normal Saline)|receive .9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
62620503|NCT00657995|EXPERIMENTAL|2|Thirty patients who underwent pancreatic resection for pancreatic neoplasm were prospectively randomized. Perioperative blood glucose levels were continuously monitored using an artificial endocrine pancreas (STG-22). Glucose levels were controlled using either the sliding scale method or the artificial pancreas.
62846495|NCT05069272|PLACEBO_COMPARATOR|Vehicle|No active ingredients
62846496|NCT00715910|EXPERIMENTAL|Nimenrix 1 Group|Subjects 11-25 years of age who were previously vaccinated with 1 dose of Nimenrix vaccine at the time of vaccination
62846497|NCT00715910|ACTIVE_COMPARATOR|Menactra Group|Subjects 11-25 years of age who were previously vaccinated with 1 dose of Menactra vaccine at the time of vaccination
62846498|NCT00715910|EXPERIMENTAL|Nimenrix 2 Group|Subjects 10\<11 years of age who were previously vaccinated with 1 dose of Nimenrix vaccine at the time of vaccination
62846499|NCT00715910|EXPERIMENTAL|Nimenrix Naive Group|Subjects 15 to \<31 years of age at the time of primary vaccination with 1 dose of Nimenrix vaccine at year 5 of the current study
62846500|NCT00715910|EXPERIMENTAL|Nimenrix Pooled Group|Pooled group of subjects 10-25 years of age from Nimenrix 1 and Nimenrix 2 groups in the primary study (NCT00454909) who had received 1 dose of Nimenrix vaccine in that study and will receive a booster dose in this current study.
62846501|NCT00715910|ACTIVE_COMPARATOR|Menactra Booster Group|Subjects 11-25 years of age who had received 1 dose of Menactra vaccine in primary study (NCT00454909) and will receive 1 dose of Nimenrix vaccine in this current study.
62846502|NCT03012048|EXPERIMENTAL|MadiDrop (ceramic tablet)|"Households receive a MadiDrop (silver-impregnated ceramic tablet) in a safe-storage water container to use for all drinking water needs in the household. MadiDrops are replaced every 6 months over the 2-year intervention study period.~In July 2017, all households in the MadiDrop arm were crossed over to the ceramic water filter arm due to inconsistent silver release from the ceramic tablets."
62448011|NCT03327896||Florida Medicaid|"Clients who were continuously insured through Florida Medicaid in 2015 and had a claim with an Evaluation and Management Current Procedure Terminology (CPT) code indicating an office visit listing a Primary Care provider as the performing provider. Florida Medicaid data is limited to clients who were 22 years or younger.~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
62846503|NCT03012048|ACTIVE_COMPARATOR|Silver-impregnated ceramic water filter|"Households receive a silver-impregnated ceramic filter in a safe-storage water container to use for all drinking water needs in the household. Filters are replaced at the end of the 2-year intervention study period.~In December 2017, all silver-impregnated ceramic water filters were replaced with the same ceramic filters without silver due to continued inconsistencies with silver release."
62846504|NCT03012048|ACTIVE_COMPARATOR|Safe-storage water container|Households receive a safe-storage water container alone to use for all drinking water needs in the household.
62264016|NCT02302508|EXPERIMENTAL|T2D patients with A1C>7.5|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
62846505|NCT03012048|NO_INTERVENTION|No intervention|Households are encouraged to continue their usual water treatment practices.
62264017|NCT02302508|EXPERIMENTAL|Insulino-treated|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
62264018|NCT02302508|ACTIVE_COMPARATOR|Non-diabetic healthy subjects|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
62264019|NCT01784770||Azithromycin IV|Subjects who are treated with Azithromycin IV for Legionnaires' disease
62846506|NCT05118880|EXPERIMENTAL|İntervention group|the children enrolled in the Peer Bullying Counseling Program based on the Interpersonal Relationship Model
62264020|NCT01739985|ACTIVE_COMPARATOR|Dexamethasone + ondansetron + Placebo|dexamethasone + ondansetron + Placebo
62264021|NCT01739985|EXPERIMENTAL|Dexamethasone + ondansetron + Droperidol|dexamethasone + ondansetron + Droperidol
62264022|NCT03005795|EXPERIMENTAL|Music and colposcopy|Women will hear Mozarts symphony Nr. 40 during the colposcopic examination
62264023|NCT03005795|ACTIVE_COMPARATOR|Colposcopy without music|During the colposcopic examination women will not hear music
62448012|NCT03743428|EXPERIMENTAL|Apatinib-FOLFIRI|Apatinib Mesylate Tablets 250mg po qd Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks.
62448013|NCT03743428|ACTIVE_COMPARATOR|Bevacizumab-FOLFIRI|Bevacizumab Injection 5mg/kg IV,day 1 Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks.
62448014|NCT03430375|ACTIVE_COMPARATOR|Alternating air then static air cushion|The participants in all three populations or groups (healthy adults, adults with stroke, and adults with spinal cord injury) will first sit on the alternating air wheelchair cushion for 32 minutes and then the static air cushion for 32 minutes under two conditions (static: sitting without intentional moving) and (active: reaching with their upper extremity) while pressure mapping and skin responses are recorded. The Ease alternating air wheelchair cushion inflates/deflates which shifts the points of pressure \[every 3 minutes\] and allows fresh blood to flow where the pressure has been lifted. The Roho static air cushion is a common wheelchair cushion currently used for pressure relief purposes.
62264024|NCT01003275|ACTIVE_COMPARATOR|Paricalcitol followed by placebo|Participants will receive paricalcitol for 8 weeks, then an 8-week wash-out, then placebo for 8 weeks.
62264025|NCT01003275|ACTIVE_COMPARATOR|Placebo followed by paricalcitol|Participants will receive placebo for 8 weeks, then an 8-week wash-out, then paricalcitol for 8 weeks.
62264026|NCT02366611|EXPERIMENTAL|Transcranial Direct Current Stimulation (tDCS)|tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
62264027|NCT02366611|NO_INTERVENTION|Chemoradiotherapy Standard of Care|The control group will consist of patients receiving the Standard of care and no neuromodulation.
62448015|NCT03430375|ACTIVE_COMPARATOR|Static air then alternating air cushion|The participants in all three populations or groups (healthy adults, adults with stroke, and adults with spinal cord injury) will first sit on the static air wheelchair cushion for 32 minutes and then the alternating air cushion for 32 minutes under two conditions (static: sitting without intentional moving) and (active: reaching with their upper extremity) while pressure mapping and skin responses are recorded. The Roho static air cushion is a common wheelchair cushion currently used for pressure relief purposes. The Ease alternating air wheelchair cushion inflates/deflates which shifts the points of pressure \[every 3 minutes\] and allows fresh blood to flow where the pressure has been lifted.
62448016|NCT04708795|EXPERIMENTAL|Verum|AP701 single dose oromucosal application
62448017|NCT06009523|EXPERIMENTAL|Active tDCS|Participants received an active tdcs: transcranial direct current with an intensity of 2 mA for 30 minutes
62448018|NCT05432843|ACTIVE_COMPARATOR|Pregabalin|Treatment with pregabalin in the treatment of globus sensation
62448019|NCT05432843|PLACEBO_COMPARATOR|Placebo|Treatment with placebo in the treatment of globus sensation
62448020|NCT02158936|EXPERIMENTAL|Eltrombopag|Eligible subject will receive a starting dose of eltrombopag of 200 milligrams (mg) (100 mg for subjects of East Asian heritage). Dose modifications of eltrombopag will be permitted by 100 mg increments (50 mg increments for East Asians) to a lowest dose of 100 mg (50 mg for East Asian heritage) or a maximum dose of 300 mg (150 mg for East Asian heritage) in order to maintain platelet counts at a safe and effective level (i.e. a level sufficient to avoid platelet transfusions and bleeding events). Subjects will receive azacitidine 75 mg/meter\^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
62448021|NCT02158936|PLACEBO_COMPARATOR|Placebo|Eligible subject will receive eltrombopag matching placebo. Subjects will receive azacitidine 75 mg/meter\^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
62620504|NCT05787743|ACTIVE_COMPARATOR|Facial cream with 2% palm tocotrienols extract|Facial cream with 2% palm tocotrienols extract
62448022|NCT02417090||Metformin therapy|9-year-old children whose mothers used metformin for gestational diabetes
62620505|NCT05787743|PLACEBO_COMPARATOR|Base cream (no active)|Base cream (no active)
62846507|NCT05118880|NO_INTERVENTION|control group|
62448023|NCT02417090||Insulin therapy|9-year-old children whose mothers used insulin for gestational diabetes
62620506|NCT03952026||isolated pelvic fracture|Patients with an isolated pelvic fracture
62620507|NCT03952026||combined abodominal/pelvic injury|Patients with a combined injury of a pelvic fracture and an abdominal injury.
62620508|NCT02824562|OTHER|Intervention|The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain. The participants will complete an outcome assessment within 30 days of the last group session.
62620509|NCT02824562|OTHER|Control|"The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group. The participants will complete an outcome assessment within 30 days of the last group session."
62620510|NCT05300659|NO_INTERVENTION|Standard Care|
62846508|NCT00625430|EXPERIMENTAL|1|Six Cohorts with escalating vector dose
62846509|NCT01170247|EXPERIMENTAL|Intranasal Ketamine|
62846510|NCT01170247|ACTIVE_COMPARATOR|Intramuscular Ketamine|
62264028|NCT05462015|EXPERIMENTAL|Elastic band|The experimental group received a 35-minute training course for 2 weeks, 3 times a week, each time during the hospitalization. A total of 4 assessments were performed: baseline (pre-intervention), after third-time intervention, post-intervention, and one week after the intervention.
62264029|NCT05462015|ACTIVE_COMPARATOR|Control|The control group was given routine rehabilitation exercise
62264030|NCT05807360|EXPERIMENTAL|Eyedrops treatment arm|
62264031|NCT01195727|EXPERIMENTAL|Group 5A - Apixaban (Low Dose)|"Group 5: 12 years to \<18 years;~0.66 mg/m² Oral solution, Oral, Twice A Day (BID), 10 days"
62620511|NCT05300659|EXPERIMENTAL|ARNI care|
62448024|NCT05976971|OTHER|Patients with REM Sleep Behaviour Disorder|
62846511|NCT06425042|EXPERIMENTAL|NR+EXTR|This arm will ingest NR orally and perform exercise training
62846512|NCT06425042|PLACEBO_COMPARATOR|PLA+EXTR|This arm will ingest placebo orally and perform exercise training
62846513|NCT01111578||New enteral feeding tube|
62846514|NCT02497742|ACTIVE_COMPARATOR|Once daily BMP|Patient in this arm will receive once daily basic metabolic panel to monitor electrolytes
62060193|NCT00939601|ACTIVE_COMPARATOR|Motivational Enhancement Therapy|MET will involve counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
62060194|NCT00939601|ACTIVE_COMPARATOR|Educational Counseling|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
62448025|NCT05976971|OTHER|Healthy volunteers|
62448026|NCT06544083||Hepatocellular carcinoma group|Patients with histologically or cytological, imaging confirmed untreated hepatocellular carcinoma.
62448027|NCT06544083||Benign liver lesions group|Untreated patients with confirmed or suspected benign liver lesions by histopathology, or with high suspicion of benign liver lesions by imaging evaluation or other routine clinical diagnosis
62846515|NCT02497742|ACTIVE_COMPARATOR|Twice daily BMP|Patient in this arm will receive twice daily basic metabolic panel to monitor electrolytes
62846516|NCT02807584|EXPERIMENTAL|ELECT|Adhesive Foam Dressing
62846517|NCT03707704||SCI patients in primary rehabilitation|
62846518|NCT05766878|ACTIVE_COMPARATOR|machined collar|"The arm will be constituted by healthy people, that need to be rehabilitated by dental implant placement.~A short implant (length 6mm; diameter 4.3) will be inserted in an edentulous site. The implant will present a surface treated with double acid etching and traditional machined collar. A definitive transgingival standard machined abutment will be immediately screwed. Four months later, prosthetic procedures will start."
62060195|NCT00939601|NO_INTERVENTION|Standard Care|
62060196|NCT00239564|EXPERIMENTAL|Experimental: carbidopa and levodopa|Subjects receive IPX054 100 mg, IPX054 150 mg, IPX054 200 mg, IPX054 250 mg, or IPX054 300 mg to achieve optimum dosage and dosing frequency as directed by the Investigator for 5 weeks.
62060197|NCT01452646|EXPERIMENTAL|MRD-directed therapy|
62060198|NCT02563002|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years). Participants that have stopped the initial course of pembrolizumab and have stable disease but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 year additional).
62448028|NCT06544083||Healthy people group|People without any liver disease
62448029|NCT06358378|EXPERIMENTAL|Single Arm|Enrolled patients will be asked to wear both the cuff-based ambulatory blood pressure monitor (ABPM) and the Aktiia bracelet at the same time during daytime hours (9am - 9pm) for a 72-hour period after calibration of the bracelet at the site. The ABPM will provide reference blood pressure measures to compare the Aktiia-derived measures against
62448030|NCT00697775|EXPERIMENTAL|Group A|HBV-MPL Formulation A at months 0 and 6
62448031|NCT00697775|EXPERIMENTAL|Group B|HBV-MPL Formulation B at months 0 and 6
62448032|NCT00697775|EXPERIMENTAL|Group C|HBV-MPL Formulation A at month 0 and Engerix™-B at month 6
62448033|NCT00697775|ACTIVE_COMPARATOR|Group D|Engerix™-B at months 0, 1, 6
62448034|NCT05602090|EXPERIMENTAL|Growth Hormone adjuvant treatment|Growth hormone in this trial will use 4 IU of recombinant GH (Somatotropin, ) by day after day subcutaneous injection for 6 weeks before starting cycle. And on start day of induction ( Day 2 to 3) until the day of the human chorionic gonadotropin (hCG) trigger.
62448035|NCT05602090|NO_INTERVENTION|control|standard controlled ovarian stimulation
62448036|NCT00132002|EXPERIMENTAL|Treatment (vorinostat)|Patients receive oral suberoylanilide hydroxamic acid twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62448037|NCT02899130|EXPERIMENTAL|Polyherbal|Combination of 3 whole herbs in a capsule
62448038|NCT02899130|PLACEBO_COMPARATOR|Matching placebo|Similar looking inert capsules
62448039|NCT02863302|EXPERIMENTAL|Reflexology treatment|All patients will receive reflexology (a specialized foot therapy) from a certified reflexologist twice weekly from the beginning of chemotherapy treatment until the end of hospitalization.
62620512|NCT01608672||All participants|Botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
62620513|NCT05137002|EXPERIMENTAL|CIN-107 0.5 mg|Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks
62846519|NCT05766878|EXPERIMENTAL|anodized collar|"The arm will be constituted by healthy people, that need to be rehabilitated by dental implant placement.~A short implant (length 6mm; diameter 4.3) will be inserted in an edentulous site. The implant will present a surface treated with double acid etching and anodized collar. A definitive transgingival anodized abutment will be immediately screwed. Four months later, prosthetic procedures will start."
62846520|NCT00650676||A|
62846521|NCT02904213|EXPERIMENTAL|Pentavalent vaccine|3 Dose, interval for each dose is 4 weeks. The first dose will be received at 8-10 weeks of age
62620514|NCT05137002|EXPERIMENTAL|CIN-107 1 mg|Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks
62846522|NCT01794143|ACTIVE_COMPARATOR|Sulfonylurea (glimepiride)|Sulfonylurea
62846523|NCT01794143|ACTIVE_COMPARATOR|DPP-4 inhibitor|DPP-4 inhibitor (sitagliptin)
62620515|NCT05137002|EXPERIMENTAL|CIN-107 2 mg|Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient may remain on CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks or withdraw study participation depending on BP control
62846524|NCT01794143|ACTIVE_COMPARATOR|GLP-1 receptor agonist|GLP-1 receptor agonist (liraglutide)
62846525|NCT01794143|ACTIVE_COMPARATOR|Insulin (glargine)|Insulin (glargine), Lantus
62846526|NCT02415036|EXPERIMENTAL|Melphalan/HDS treatment of patients with HCC|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System on patients with Hepatocellular carcinoma (HCC).~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 2 cycles of treatment."
62846527|NCT02415036|EXPERIMENTAL|Melphalan/HDS treatment of patients with ICC|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System on patients with Intrahepatic cholangiocarcinoma (ICC).~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 2 cycles of treatment."
62846528|NCT05207800||healthy pregnant woman|healthy pregnant woman
62846529|NCT05207800||pregnant women with TPROM|pregnant women with term premature rupture of membranes
62264032|NCT01195727|EXPERIMENTAL|Group 5B - Apixaban (High Dose)|"Group 5: 12 years to \<18 years;~1.32 mg/m² Oral solution, Oral, Twice A Day (BID), 10 days"
62264033|NCT04219345|ACTIVE_COMPARATOR|Active group|In the group A will be administered anodic tDCS and instructed in mindfulness practices.
62264034|NCT04219345|SHAM_COMPARATOR|Sham group|In the group B will be administered sham tDCS and instructed in mindfulness practices.
62846530|NCT05207800||pregnant women with PPROM|pregnant women with preterm premature rupture of membranes
62846531|NCT04728516|EXPERIMENTAL|Vonoprazan-based dual eradication therapy|H. pylori eradication using a dual eradication regimen, a course of 14 days, followed up to 6 months after randomization; the treatment regimen is as follows: routine use of Vonoprazan 20mg bid + amoxicillin 1g tid, a course of 14 days .
62846532|NCT04728516|ACTIVE_COMPARATOR|Pantoprazole|To take pantoprazole 40 mg daily, followed up to 6 months after randomization.
62846533|NCT01028196||1 - schizophrenia|Psychiatrists will enrol patients meeting inclusion/exclusion criteria with schizophrenia as they routinely attend the clinic or are examined in hospital in a consecutively manner.
62846534|NCT01028196||2 - recurrent depression|Psychiatrists will enrol patients meeting inclusion/exclusion criteria with recurrent depression as they routinely attend the clinic or are examined in hospital in a consecutively manner.
62846535|NCT02604160|EXPERIMENTAL|LY3113593|Escalating doses of LY3113593 administered by intravenous (IV) infusion once every 4 weeks (Q4W) on (Day 1 and 29) in part A.
62846536|NCT02604160|PLACEBO_COMPARATOR|Placebo|0.9% saline, administered by intravenous (IV) infusion once Q4W (Day 1 and 29) in part A.
62846537|NCT03966430|EXPERIMENTAL|damage control surgery group|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the damage control surgery group.
62264035|NCT01630473|EXPERIMENTAL|Corticotomy-assisted orthodontics|This group of patients will receive corticotomy surgical procedure at day 0. Orthodontic activation will start immediately after surgery.
62264036|NCT01630473|ACTIVE_COMPARATOR|Conventional orthodontics|This group of patients will receive conventional orthodontics starting at day 0.
62264037|NCT01407705||Control Group|"* No diagnosis of cervical degenerative or traumatic disease~* 30 to 80 years of age~* Ability of volunteers to tolerate 1 hr examination"
62264038|NCT01407705||Disease (Non-healthy) Group|"Cervical Spinal Cord:~* Clinical and Radiographic evidence of cervical spondylotic myelopathy~* 18 to 80 years of age~* Safe and stable clinical scenario to undergo imaging~* Awake, alert patient able to cooperate with physical examination~* Give written informed consent prior to any testing under this protocol~Degenerative Disease Group:~* Have signs or symptoms consistent with spinal cord injury.~* Be diagnosed with cervical spondylosis (degenerative disease).~Traumatic Group:~• A spinal cord injury associated with a traumatic event."
62264039|NCT06077604||Patients with a diagnosis of Axial Spondyloarthritis|Patients with a diagnosis of Axial Spondyloarthritis, received in rheumatology consultation/hospitalization over the period 2019-2022 and living in Franche-Comté over the same period
62264040|NCT00643266|EXPERIMENTAL|1|Recollection training via graduated increases in task difficulty, carried out over 36 sessions over 9 training days
62264041|NCT00643266|ACTIVE_COMPARATOR|2|Computer-delivered information sessions about memory and aging with Jeopardy-like games to engage participants
62264042|NCT00877812|EXPERIMENTAL|Arm 1 glycine and leucine infusion|Determine in healthy, adequately pyridoxine nourished humans using a protocol based on amino acid glycine tracer methods: (a) the postprandial rates of in vivo glycine turnover, glycine-based generation of one-carbon units, thymidylate and purine synthesis, and the impact of vitamin B6 deficiency on the rates of these processes and (b) the effect of vitamin B6 deficiency on the postprandial rate of glutathione synthesis. 14 subjects will be chosen after screening is complete and will begin a B6 deficient diet for 30 days. At the beginning and end of the 30 days they will receive an infusion of leucine and glycine then they will begin the four week diet. At the end of four weeks the infusion will be repeated.
62846538|NCT03966430|SHAM_COMPARATOR|non-damage control surgery group|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the non-damage control surgery group.
62264043|NCT00877812|EXPERIMENTAL|Arm 2 Intervention of Serine and methionine infusion|This arm will allow investigation of total Hcy remethylation and remethylation from serine-derived 1C units, kinetics of serine and the methionine cycle and kinetics of transsulfuration reactions. 14 healthy subjects will be selected and screened. Prior to starting a B6 deficient diet for four weeks an infusion of serine and methionine will commence. Following the first infusion the diet will begin and after four weeks another infusion will be done.
62846539|NCT03795246|EXPERIMENTAL|Study Process|Consultation, Biological Test, Pelvic Ultrasound
62846540|NCT04696614|EXPERIMENTAL|aerobic exercise to aerobic exercise|first 8-week: aerobic exercise second 8-week: aerobic exercise
62846541|NCT04696614|EXPERIMENTAL|aerobic exercise to interval training|first 8-week: aerobic exercise second 8-week: interval training
62846542|NCT04696614|EXPERIMENTAL|aerobic exercise to aerobic exercise +resistance exercise|first 8-week: aerobic exercise second 8-week: aerobic exercise +resistance exercise
62264044|NCT05554848|NO_INTERVENTION|control group|patients will receive normal saline instead of dexmedetomidine and MgSo4 .
62264045|NCT05554848|ACTIVE_COMPARATOR|dexmedetomidine group|patients will receive the same of dexmedetomidine as MD group in addition to normal saline instead of Magnesium Sulfate .
62264046|NCT05554848|ACTIVE_COMPARATOR|Dexmedetomidine Mgso4 group|patients will receive dexmedetomidine 0.5 µg/kg diluted in 50 mL of normal saline intravenously over 20 minutes, After induction followed by 0.5 µg/kg per hour infusion for 72 hours postoperatively or ready for extubation prior to 72 hour time period (Precedex ; Hospira Worldwide ,Lake Forest, IL).(20) and receiving Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release. with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day
62264047|NCT05313451|EXPERIMENTAL|Soluble fiber|Participants ingest 15 g daily of the experimental product for 2 months and receive the influenza vaccine at the end of the first month.
62264048|NCT05313451|PLACEBO_COMPARATOR|Placebo|Participants ingest 15 g daily of the placebo product for 2 months and receive the influenza vaccine at the end of the first month.
62264049|NCT02691442|ACTIVE_COMPARATOR|Ropivacaine 0.75%|The investigators administer 5 milliliters of Ropivacaine 0.75% in the inter scalene space
62620516|NCT05137002|PLACEBO_COMPARATOR|Placebo|Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2mg) and discontinue their background antihypertensive agent(s) for 4 weeks
62846543|NCT04696614|EXPERIMENTAL|interval training to interval training|first 8-week: interval training second 8-week: interval training
62264050|NCT02691442|ACTIVE_COMPARATOR|Levobupivacaine 0.5%|The investigators administer 5ml of Levobupivacaine 0.5% in the inter scalene space
62264051|NCT02691442|ACTIVE_COMPARATOR|Levobupivacaine 0.5% + epinephrin|The investigators administer 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in the inter scalene space
62264052|NCT02364089|EXPERIMENTAL|Surgery followed by intensive medical care|Laparoscopic surgical removal of the adrenal tumor
62264053|NCT02364089|ACTIVE_COMPARATOR|Intensive medical treatment only|Standardized medical treatment of hypertension by SAHR.
62264054|NCT01826279|EXPERIMENTAL|Resveratrol|Resveratrol 500mg 3 times daily for 1 month
62264055|NCT01826279|PLACEBO_COMPARATOR|Placebo|Placebo 1 tablet 3 times daily for 1 month
62620517|NCT00351936|ACTIVE_COMPARATOR|Aripiprazole|aripiprazole 15mg/day
62620518|NCT00351936|PLACEBO_COMPARATOR|placebo|matched placebo for aripiprazole 15mg/day
62620519|NCT06168747|EXPERIMENTAL|İntervention|In the study group, wrist mediolateral glide, 1st MCP joint anteroposterior glide, CMC joint mediolateral, and anteroposterior glide were applied to the individuals by an experienced physiotherapist. Applications were made 6 times with 3 repetitions
62620520|NCT06168747|SHAM_COMPARATOR|Sham Mobilization|In the sham mobilization group, individuals were placed in the same position, but no mobilization application was performed.
62620521|NCT02227368|EXPERIMENTAL|Ticagrelor|26 Weeks of ticagrelor 90mg twice a day plus aspirin placebo once daily
62846544|NCT04696614|EXPERIMENTAL|interval training to aerobic exercise|first 8-week: interval training second 8-week: aerobic exercise
62846545|NCT04696614|EXPERIMENTAL|interval training to aerobic exercise+resistance exercise|first 8-week: interval training second 8-week: aerobic exercise +resistance exercise
62846546|NCT00792168|ACTIVE_COMPARATOR|1. Venlafaxine|
62846547|NCT00792168|PLACEBO_COMPARATOR|2. Placebo|
62846548|NCT04074161|EXPERIMENTAL|Semaglutide|Semaglutide administered s.c. (subcutaneously, under the skin) adjunct to a reduced-calorie diet and increased physical activity
62846549|NCT04074161|PLACEBO_COMPARATOR|Placebo (semaglutide)|Placebo (semaglutide) administered s.c. adjunct to a reduced-calorie diet and increased physical activity
62846550|NCT04074161|ACTIVE_COMPARATOR|Liraglutide|Liraglutide administered s.c. adjunct to a reduced-calorie diet and increased physical activity
62846551|NCT04074161|PLACEBO_COMPARATOR|Placebo (liraglutide)|Placebo (liraglutide) administered s.c. adjunct to a reduced-calorie diet and increased physical activity
62620522|NCT02227368|ACTIVE_COMPARATOR|Aspirin|26 Weeks of aspirin 100mg once daily plus ticagrelor placebo twice a day
62620523|NCT02374437|ACTIVE_COMPARATOR|PART A (single dose)-200 mg|200 mg ARAMCHOL
62620524|NCT02374437|ACTIVE_COMPARATOR|PART A (single dose)-400 mg|400 mg ARAMCHOL
62620525|NCT02374437|ACTIVE_COMPARATOR|Part B ( food effect)- -Fasting|600 mg Aramchol tablets under fasting conditions (fasting for at least 10 hours before and 4 hours after dosing)
62060199|NCT02563002|ACTIVE_COMPARATOR|Standard of Care (SOC)|Participants receive 1 of 6 possible standard chemotherapy regimens: mFOLFOX6, or mFOLFOX6+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or mFOLFOX6+cetuximab 400 mg/m\^2 IV over 2 hours then 250 mg/m\^2 over 1 hour weekly in each 2-week cycle, or FOLFIRI, or FOLFIRI+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or FOLFIRI+cetuximab 400 mg/m\^2 IV over 2 hours then 250 mg/m\^2 over 1 hour weekly in each 2-week cycle. Participants with documented disease progression following chemotherapy can crossover to receive pembrolizumab for up to 35 cycles (approximately 2 years). Participants that have stopped pembrolizumab and have stable disease but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 year additional).
62060200|NCT06284863|OTHER|nutrition|The study aims to improve the health status of chronic renal failure patients on hemodialysis using nutritional education program on quality of life anserum d electrolytes level by application of physical and clinical evaluation and some biochemical analysis before and after a specified nutritional program
62060201|NCT04761276||Lucidis Intra-ocular lens (IOL)|Adult patients with significant reduction in visual acuity and/or visual comfort from cataract who will receive Lucidis Intra-ocular lens
62264056|NCT03050242|EXPERIMENTAL|Glycopyrrolate|Glycopyrrolate 0.005mg/kg is administered intramuscularly, one hour before the surgery.
62620526|NCT02374437|ACTIVE_COMPARATOR|Part B ( food effect)- -Fed|600 mg Aramchol tablets under fed conditions (fasting for at least 10 hours before dosing, consumption of a high calorie high fat meal within 30 minutes prior to drug administration and no food for additional 4 hours after dosing)
62846552|NCT03518255|NO_INTERVENTION|Control group|This control group will not receive an intervention.
62846553|NCT03518255|EXPERIMENTAL|Nature video|A pre-validated nature images video will be shown to the patient during their chemotherapy session. After thirty minutes of the start of the chemotherapy session, the patient you will receive a notebook (specific to the study and blocked for other functions) that he can watch a presentation of nature images. It will be four videos with fifteen minutes each one.
62846554|NCT04815148|EXPERIMENTAL|Phase Ia: MH004 (0.1%) in healthy volunteers|SAD and MAD
62846555|NCT04815148|EXPERIMENTAL|Phase Ia: MH004 (0.3%) in healthy volunteers|SAD and MAD
62846556|NCT04815148|EXPERIMENTAL|Phase Ia: MH004 (1%) in healthy volunteers|SAD and MAD
62846557|NCT04815148|EXPERIMENTAL|Phase Ia: MH004 (3%) in healthy volunteers|SAD and MAD
62264057|NCT03050242|NO_INTERVENTION|Control|No injection is conducted in this group.
62620527|NCT02374437|ACTIVE_COMPARATOR|Part C ( multiple doses)- 200 mg|200 mg Aramchol tablets for ten consecutive days.
62846558|NCT04815148|EXPERIMENTAL|Phase Ib-1: MH004 (0.1%) in Atopic Dermatitis|28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis
62846559|NCT04815148|EXPERIMENTAL|Phase Ib-1: MH004 (0.3%) in Atopic Dermatitis|28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis
62846560|NCT04815148|EXPERIMENTAL|Phase Ib-1: MH004 (1%) in Atopic Dermatitis|28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis
62060202|NCT05537480|OTHER|Normal GCT|Women with GCT \<140mg/dl
62060203|NCT05537480|OTHER|Abnormal GCT|Women with GCT \>=140mg/dl
62264058|NCT04338035||Patients with rectosigmoid endometriosis|
62264059|NCT04135430||Survey|Practice of an updated questionnaire at D0, D2 and D7
62264060|NCT05455853|EXPERIMENTAL|bilateral transcutaneous tibial nerve stimulation,exercise and advices|•They will receive bilateral transcutaneous tibial nerve stimulation three times per week for 4 weeks, in addition to abdominal muscle training and breathing exercise and bowel care advices.
62264061|NCT05455853|EXPERIMENTAL|Exercises and advices|They will perform abdominal muscle training and breathing exercise three times per week, for 4 weeks in addition to bowel care advices.
62620528|NCT02374437|ACTIVE_COMPARATOR|Part C ( multiple doses)- 400 mg|400 mg Aramchol tablets for ten consecutive days.
62620529|NCT02374437|ACTIVE_COMPARATOR|Part C ( multiple doses)- 600 mg|600 mg Aramchol tablets for ten consecutive days.
62620530|NCT02374437|PLACEBO_COMPARATOR|Part C ( multiple doses)- Placebo|Placebo tablets for ten consecutive days.
62846561|NCT04815148|EXPERIMENTAL|Phase Ib-2: MH004 (0.3%) in Rheumatoid Arthritis|28-Day Repeated Dosing in Participants with Mild to Moderate Rheumatoid Arthritis
62846562|NCT04815148|EXPERIMENTAL|Phase Ib-2: MH004 (1%) in Rheumatoid Arthritis|28-Day Repeated Dosing in Participants with Mild to Moderate Rheumatoid Arthritis
62846563|NCT04815148|EXPERIMENTAL|Phase Ib-2: MH004 (3%) in Rheumatoid Arthritis|28-Day Repeated Dosing in Participants with Mild to Moderate Rheumatoid Arthritis
62846564|NCT05070351|EXPERIMENTAL|PPI deprescribing arm|Patients taking a PPI (at least 20 mg omeprazole equivalent daily) will be instructed to stop taking their PPI.
62448040|NCT03303638|OTHER|Multi-sensory Environment during bathing|The MSE intervention will be provided by an interactive waterproof fiber optic kit that includes: a light-emitting diode (LED) wall-washer light, a waterproof fiber optic cable that can be controlled by a waterproof switch held by the participant while bathing, showering, and or tub bathing, and a mobile MSE cart. The wall-washer LED light creates the illusion that the room is painted a variety of bright colors that can be changed by the veteran being bathed. The mobile MSE cart includes an LED solar projector providing visual sensory stimulation by projecting scenes on the wall, an aroma therapy diffuser and a portable bubble tube to create positive distraction during the bathing process.
62448041|NCT01974895|EXPERIMENTAL|FluLaval Quadrivalent Group|Subjects received 1 or 2 doses of FluLaval® Quadrivalent vaccine at Day 0 or Days 0 and 28, depending on age and vaccine priming status.
62448042|NCT01974895|ACTIVE_COMPARATOR|Fluzone Group|Subjects received 1 or 2 doses of Fluzone® vaccine at Day 0 or Days 0 and 28, depending on age and priming status.
62060204|NCT03911453|EXPERIMENTAL|Treatment (rucaparib)|"Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of programmed cell death-1 with ligand (PD-L1) by immunohistochemistry (IHC)~. Starting Dose 600 mg twice daily Dose Level -1 500 mg twice daily Dose Level -2 400 mg twice daily Dose Level -3 300 mg twice daily"
62060205|NCT03850080|EXPERIMENTAL|Autologous Conditioned Serum|Patients that were deemed admissible to the trial received 1 intra-articular injection of autologous conditioned serum (Orthokine®) for 4 consecutive weeks at the site of OA. These patients were then followed at 1 month and 6 months for clinical and functional evaluation using VAS for pain, WOMAC, and KSS.
62060206|NCT05432908|EXPERIMENTAL|Orofacial exercises and oropharyngeal functions|Orofacial exercises and oropharyngeal functions.
62060207|NCT06214858|EXPERIMENTAL|（Trial group）-SHEN211 tablets|"part 1：Four dose groups were set up: 110mg,330mg, 550mg and 770mg, each group was intended to include 2 subjects and was administered orally. SHEN211 tablets in the corresponding dose group were given on fasting in the morning of D1. PK blood collection and related tests were completed on day 8 (D8), PK and safety tests were completed on day 10 (D10), and telephone follow-up was performed on day 14 (D14±1).~part 2：Two dose groups were set up with 8 subjects in each group. In the first dose group, 330mg SHEN211 tablets D1 and 110mgSHEN211 tablets D2 \~ D5 were taken orally once a day (QD). The second dose group was taken orally 660mg SHEN211 tablets on D1 and 220mg SHEN211 tablets from D2 to D5, once a day (QD). PK samples were collected before and after administration, and safety observation was performed up to 8 days after the last administration."
62448043|NCT00866242|EXPERIMENTAL|Challenge-recipients|
62620531|NCT00747253|EXPERIMENTAL|Single Active Arm|Only Arm. Patients treated using AutoLITT System.
62448044|NCT02255513|EXPERIMENTAL|HLD200|"HLD200 (methylphenidate hydrochloride) 20, 40, 60, 80, or 100 mg capsules~Subjects were allowed to titrate to their optimal HLD200 dose during a 6 week open-label, treatment optimization phase before being randomized to continue their HLD200 treatment over an one week double-blind, placebo-controlled phase. HLD200 was administered orally, once daily each evening."
62448045|NCT02255513|PLACEBO_COMPARATOR|Placebo|"Placebo capsules (dose matched to HLD200 capsules)~Subjects were allowed to titrate to their optimal HLD200 dose during a 6 week open-label, treatment optimization phase before being randomized to receive placebo treatment over a one week double-blind, placebo-controlled phase. Treatments were administered orally, once daily each evening."
62620532|NCT04677452|EXPERIMENTAL|JWCAR129|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by a single dose of JWCAR129
62620533|NCT01171469|EXPERIMENTAL|Dose Level 3|15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
62620534|NCT01171469|EXPERIMENTAL|Dose Level 2|10 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
62846565|NCT05070351|NO_INTERVENTION|PPI continuation arm|Patients will be instructed to continue taking their PPI (at least 20 mg omeprazole equivalent daily) as usual.
62620535|NCT01171469|EXPERIMENTAL|Dose Level 1|5 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
62264062|NCT02501265|ACTIVE_COMPARATOR|Varenicline Standard Protocol|Participant choses Varenicline-based treatment and is then randomized to Standard Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts placebo Varenicline. Consistent with Varenicline Standard Treatment, 1 week prior to the TQD the participant will switch to active Varenicline and placebo Bupropion. Participant will continue active Varenicline and placebo Bupropion to 12 weeks post-TQD.
62264063|NCT02501265|ACTIVE_COMPARATOR|Nicotine Patch Standard Protocol|Participant choses Nicotine patch-based treatment and is then randomized to Standard Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts placebo Nicotine Patch. One week prior to TQD, participant will start placebo Bupropion. Consistent with Nicotine Patch Standard Treatment, participant will start active Nicotine Patch on TQD. Participant will continue active Nicotine Patch and placebo Bupropion to 12 weeks post-TQD.
62846566|NCT02101424||Overdose|
62846567|NCT04239378|EXPERIMENTAL|Test group -Autogenous dentin matrix and collagen membrane|Test group - After atraumatic tooth extraction , socket will be augmented with autogenous dentin matrix and covered with collagen membrane and sutures are placed.
62846568|NCT04239378|ACTIVE_COMPARATOR|Control group-bovine derived xenograft and collagen membrane|control group- After atraumatic tooth extraction, socket will be augmented with bovine derived xenograft and covered with collagen membrane and sutures are placed.
62846569|NCT02093195|EXPERIMENTAL|Bosentan|Bosentan,125mg,po,bid combined with inhaled Symbicort turbuhaler, 320/9μg, bid.
62846570|NCT02093195|ACTIVE_COMPARATOR|Control|Inhaled Symbicort turbuhaler, 320/9μg, bid.
62846571|NCT01110148|EXPERIMENTAL|Video-based informed consent|patients receiving informed consent through video format
62846572|NCT01110148|ACTIVE_COMPARATOR|traditional informed consent|patients receiving traditional informed consent from the physicians.
62846573|NCT00555061|EXPERIMENTAL|Arm 1|Single Arm Retapamulin 1% Ointment
62264064|NCT02501265|EXPERIMENTAL|Varenicline Adaptive Protocol|Participant chooses Varenicline treatment and is randomized to Adaptive Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts active Varenicline. Two weeks prior to TQD, cigarettes smoked per day is assessed. If the number of cigarettes smoked per day is reduced by \>50%, the participant is considered a Varenicline responder, and starts placebo Bupropion 1 week prior to the TQD. If the participant DOES NOT reduce cigarettes smoked per day by \>50%, the participant is considered a Varenicline non-responder and starts active Bupropion 1 week prior to TQD. Varenicline responders will continue active Varenicline and placebo Bupropion to 12 weeks post TQD. Varenicline non-responders will continue active Varenicline and active Bupropion to 12 weeks post TQD.
62620536|NCT03890978|EXPERIMENTAL|intervention|The intervention group will receive EBF promotional messages from the time of discharge until 6 months post delivery.
62620537|NCT03890978|OTHER|control|the control group will receive child health care-related messages (except breastfeeding messages) from the time of discharge until 6 months post delivery.
62620538|NCT05582759|ACTIVE_COMPARATOR|SH/ReadiWatchTM|Participants receive real-time feedback on sleep metrics and sleep hygiene education
62620539|NCT05582759|EXPERIMENTAL|teleCBT-I + SH/ReadiWatchTM|Participants receive real-time feedback on sleep metrics and sleep hygiene education plus cognitive cognitive behavioral therapy for insomnia
62620540|NCT02008032|EXPERIMENTAL|All patients|Stationary Breast Tomosynthesis
62620541|NCT02247271|OTHER|Diabetes health coach support|The intervention is that subjects will receive coach support once a week for 30 minutes for six months. Support is provided by a Diabetes Coach who uses self-management support strategies to assist subjects to achieve their personal health goals.
62620542|NCT03510897|ACTIVE_COMPARATOR|QPI-1002|QPI-1002 Injection, Single dose
62620543|NCT03510897|PLACEBO_COMPARATOR|Placebo|isotonic saline
62846574|NCT01191762|ACTIVE_COMPARATOR|sevelamer carbonate|2400 mg (3 pills) with each meal
62846575|NCT01191762|PLACEBO_COMPARATOR|placebo control|3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.
62846576|NCT04059536||Roxwood Anchoring Catheters|Participants will be treated for an index procedure using Roxwood Medical device(s) as prescribed by the Investigator SOC on Day 0. All devices will be used in accordance with the Instructions for Use (IFU). Participants are to be administered SOC acetylsalicylic acid (ASA) and/or anti-platelet medications orally per physician discretion prior to the index procedure. Administration of an intravenous injection of heparin during the index procedure will also be at the discretion of the Investigator per Institutional SOC.
62846577|NCT04909918|EXPERIMENTAL|(Group D )Dexamethasone|Intravenous dexamethasone 8 mg/day given for 7 days
62846578|NCT04909918|EXPERIMENTAL|(Group M) methylprednisolone|Intravenous methylprednisolone 1 mg/kg/day in 2 divided doses per day given for 7 days
62846579|NCT05423743|ACTIVE_COMPARATOR|Arm 1: Routine Care|Continuation of routine antibiotic stewardship strategies.
62846580|NCT05423743|ACTIVE_COMPARATOR|Arm 2: INSPIRE Stewardship Bundle|Use of computerized physician order entry (CPOE) smart prompts, clinician feedback, and activities to support CPOE adoption (including education and alignment of CPOE workflows) to guide empiric choice of antibiotics for abdominal infection in the first 3 days of hospitalization.
62846581|NCT04527900|EXPERIMENTAL|Concurrent chemoradiation|Concurrent carboplatin and paclitaxel and IMPT (Intensity Modulated Proton Therapy)
62846582|NCT04944290|EXPERIMENTAL|Perrigo active|
62846583|NCT04944290|ACTIVE_COMPARATOR|Reference active|
62264065|NCT02501265|EXPERIMENTAL|Nicotine Patch Adaptive Protocol|Participant choses Nicotine treatment and is randomized to Adaptive Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts active Nicotine Patches. Two weeks prior to TQD, cigarettes smoked per day is assessed. If cigarettes smoked per day is reduced by \>50%, the participant is considered a Nicotine Patch responder and starts placebo Bupropion 1 week prior to the TQD. If the participant DOES NOT reduce cigarettes smoked per day by \>50%, the participant is considered a Nicotine Patch non-responder and starts active Bupropion 1 week prior to the TQD. Nicotine Patch responders will continue active Nicotine Patches and placebo Bupropion to 12 weeks post TQD. Nicotine Patch non-responders will continue active Nicotine Patches and Bupropion to 12 weeks post TQD.
62264066|NCT04272684|EXPERIMENTAL|Interventional|Driving Assessment
62264067|NCT00254748|PLACEBO_COMPARATOR|1|Placebo
62264068|NCT00254748|EXPERIMENTAL|2|Flexible doses of 200 mg/day to 600 mg/day quetiapine fumarate
62620544|NCT02641405|EXPERIMENTAL|Equistasi|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.
62620545|NCT02641405|PLACEBO_COMPARATOR|Placebo|Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
62264069|NCT01628588||POAG or OHT|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
62620546|NCT01575730|ACTIVE_COMPARATOR|Oxaliplatin 37°C, high dose, 30 minutes|
62846584|NCT02039843|ACTIVE_COMPARATOR|Emotional Support Dogs|"Participants paired with Emotional Support Dogs~Emotional Support Dogs were required to pass the American Kennel Club Canine Good Citizen and the American Kennel Club Community Canine tests and be well-behaved and well-socialized."
62264070|NCT05904977||Type B resection|The patients reviced type B resection of the antierior leaf of vesicouterine ligament
62620547|NCT01575730|PLACEBO_COMPARATOR|Oxaliplatin 41 °C, high dose, 30 minutes|
62620548|NCT01575730|ACTIVE_COMPARATOR|Oxaliplatin 37°C, low dose, 90 minutes|
62846585|NCT02039843|ACTIVE_COMPARATOR|Service Dogs|"Participants paired with Service Dogs~Service Dogs were required to pass the American Kennel Club Canine Good Citizen and the Assistance Dogs International Public Access tests and trained to complete five PTSD-specific tasks (lights, sweep, bring, block, \& behind)."
62846586|NCT02563067|EXPERIMENTAL|QAW039 150 mg|QAW039 150 mg once daily
62846587|NCT02563067|EXPERIMENTAL|QAW039 450 mg|QAW039 450 mg once daily
62846588|NCT02563067|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62846589|NCT00922948|EXPERIMENTAL|Cryoablation|
62846590|NCT00922948|ACTIVE_COMPARATOR|Radiofrequency ablation|Radiofrequency ablation
62846591|NCT01402102|EXPERIMENTAL|Aged garlic powder|
62846592|NCT01402102|PLACEBO_COMPARATOR|Placebo|
62264071|NCT05904977||Type C resection|The patients reviced type C resection of the antierior leaf of vesicouterine ligament
62264072|NCT05087290||Cases|SARS-CoV-2 +ve cases
62264073|NCT05087290||Control|SARS-CoV-2 -ve cases
62264074|NCT03452592|EXPERIMENTAL|The way patients take Alflutinib|patients take Alflutinib orally once per day at dose of 80mg or160mg
62264075|NCT03719274|EXPERIMENTAL|non-surgical vitamin c depigmentation|locally injected vitamin c is used to depigment the hyperpigmented gingival tissues
62264076|NCT03719274|ACTIVE_COMPARATOR|surgical depigmentation|the conventional scalpel surgical technique is used to depigment the hyperpigmented gingival tissues
62264077|NCT06051682|EXPERIMENTAL|Patient with emergency physician and AI for diagnosis|Patient benefiting from imaging submitted to radiological reading by the emergency physician and the AI for diagnosis and treatment decision
62264078|NCT06051682|PLACEBO_COMPARATOR|Patient with emergency physician only for diagnosis|
62620549|NCT03816111|EXPERIMENTAL|TEACH-PD Training Curriculum|All patients at sites randomized to this arm will receive the TEACH-PD Training Curriculum
62620550|NCT03816111|ACTIVE_COMPARATOR|Current Standard PD Training|All patients at sites randomized to this arm will receive the unit's current PD training materials and plan
62620551|NCT03247881|OTHER|Nut Free Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet with 0 g/d of mixed nuts.
62620552|NCT03247881|ACTIVE_COMPARATOR|Added Mixed Nuts Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet which will include 2 servings (2 ounces) of mixed nuts per day (1 serving just prior to breakfast and 1 serving as an afternoon snack).
62620553|NCT06277713|ACTIVE_COMPARATOR|Exercise after prolonged sitting (SIT)|All participants will be instructed to complete two working days (8h) where they perform seated desk-work throughout the day. At the end of the second day, they will perform a supervised exercise bout at the research facility.
62620554|NCT06277713|EXPERIMENTAL|Exercise after sitting with standing breaks (WBR)|All participants will be instructed to complete two working days (8h) where they alternate seated desk-work with standing desk-work hourly throughout the day. At the end of the second day, they will perform a supervised exercise bout at the research facility.
62620555|NCT06277713|OTHER|Non-exercise control (NEX)|In this control group all participants will be instructed to complete two working days (8h) where they perform seated desk-work throughout the day.
62620556|NCT03178851|EXPERIMENTAL|Cohort A|Participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib and atezolizumab treatment during 28-day cycles.
62846593|NCT00277654|ACTIVE_COMPARATOR|Risperidone|
62846594|NCT00277654|PLACEBO_COMPARATOR|Sugar pill|
62846595|NCT05647603||"group Parents of adolescents"|Parents of adolescents aged 12 to 18
62846596|NCT02606201|EXPERIMENTAL|IPSMA|Injection Peri Sphincter Myofibers Autologous
62620557|NCT03178851|EXPERIMENTAL|Cohort B|Participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib prior to initiating atezolizumab treatment during Cycle 1. During subsequent 28-day cycles participants will initiate both atezolizumab and cobimetinib on Day 1 of each cycle. Participants in this cohort will undergo tumor biopsies before and during treatment.
62846597|NCT04201808|EXPERIMENTAL|Single Arm Intervention Group|All approximately 100 patients experienced previous suboptimal response to other direct acting antivirals. Patients must have received nucleos(t)ide therapy consisting of LAM/LdT/ADV and its combinations with other second-line antivirals for 24 weeks, or with the first-line antiviral ETV or any antiviral combinations containing ETV for 48 weeks with medication adherence. All patients in this study are in the same arm.
62264079|NCT05216042|EXPERIMENTAL|Experimental: Low NP Genotype Group|150 healthy adult participants with low NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours.
62264080|NCT05216042|EXPERIMENTAL|Active Comparator: High NP Genotype Group|50 healthy adult participants with high NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours.
62264081|NCT05196126|ACTIVE_COMPARATOR|Group A - PACEMAKER|According with ESC indications for elective pacemaker implantation due to SND will referred for PM implantation.
62264082|NCT05196126|EXPERIMENTAL|Group B - CARDIONEUROABLATION|According with ESC indications for elective PM implantation due to SND will referred for ICM/ILR implantation or prolonged ECG monitoring. Within 4 weeks patient will be screened by interdisciplinary team and autonomic tests (including atropine tests) will be performed. Than, based on atropine tests, electrophysiologic study and extracardiac vagal nerve stimulation, final indication for cardioneuroablation will be established. Biatrial, binodal cardioneuroablation will be performed with anatomical approach with bilateral extra cardiac vagal nerve stimulation during general anesthesia. Than, patient will be closely monitored and indication for PM implantation will be verified.
62620558|NCT03178851|EXPERIMENTAL|Cohort C|Participants with advanced melanoma, who have not received previous treatment, will receive atezolizumab monotherapy during 21-day cycles.
62620559|NCT03147976|EXPERIMENTAL|AMG 337|AMG 337 in subjects with advanced or metastatic solid tumors that overexpress MET or harbor METex14del mutations
62620560|NCT03364621||Metastatic Colorectal Cancer with Isolated Liver Metastasis|Patients with advanced colorectal cancer with isolated liver metastasis. Primary cancer must be resectable (if no archival exists) and patient must be planned for liver resection with at least 3 cycles of chemotherapy prior to liver surgery.
62620561|NCT06000553|OTHER|collection of blood and tumor samples|
62846598|NCT04890041|EXPERIMENTAL|Treatment group|100 subjects will be enrolled with the indicated treatment dose of TPO-RA
62264083|NCT02241759|EXPERIMENTAL|TA-8995|Single oral dose of 150mg TA-8995
62448046|NCT02202174||Supraglottic Airway Device|Patients will receive a supraglottic airway device as a primary means of ventilation. The following devices may be used: LMA Unique, LMA ProSeal, LMA Supreme, LMA Flexible, Ambu Aura-I, Ambu Aura Once, Air-Q, I-Gel, or other supraglottic airway device. Choice of the device will be clinician dependent and based on the patients body weight per manufacturer guidelines
62448047|NCT00661505|EXPERIMENTAL|C.E.R.A. 120, 200, or 360 mcg|Eligible participants were administered Continuous Erythropoietin Receptor Activator (C.E.R.A.) at a dose of 120, 200, or 360 microgram (mcg), intravenously (IV), every 4 weeks i.e. Weeks 4, 8, 12, 16 and 20 but not on Weeks 24 and 28. The initial dose of C.E.R.A.was based on the last dose of the previous Erythropoiesis Stimulating Agent (ESA). The ESA therapy was administered from enrollment to the 4 weeks stability verification period (SVP), weekly, either as epoetin (\<8000 IU, 8000-16000 IU, or \>16000 IU) or darbepoetin alpha (\<40 mcg, 40-80 mcg, or \>80 mcg). A telephone follow-up visit took place 4 weeks after the end of C.E.R.A. treatment (Week 28).
62448048|NCT04758936|EXPERIMENTAL|Clonidine|Given that agitated delirium requires rapid medical intervention, α-2 agonist therapy (clonidine) will be administered as soon as possible, The sedative and analgesic treatments will be administered and titrated according to the scales on the usual protocol of the service (evaluation of sedation (NICS) and analgesia (VAS, BPS, BPS-NI). In case of excessive sedation assessed by the scores and administration of combined treatments (α-2 agonist and other sedatives), the reduction of the doses of other sedatives will be preferred over the α-2 agonist treatment. In case of insufficient sedation despite maximal doses of α-2 agonist, other sedatives (choosen by the attending physician) will administered and titrated according to the scales for pain and sedation evaluation.
62448049|NCT04758936|EXPERIMENTAL|Dexmedetomidine|Given that agitated delirium requires rapid medical intervention, α-2 agonist therapy (dexmedetomidine) will be administered as soon as possible. The α-2 agonist treatment that will be started will depend on the allocation of the previously randomized unit. The sedative and analgesic treatments will be administered and titrated according to the scales on the usual protocol of the service (evaluation of sedation (NICS) and analgesia (VAS, BPS, BPS-NI). In case of excessive sedation assessed by the scores and administration of combined treatments (α-2 agonist and other sedatives), the reduction of the doses of other sedatives will be preferred over the α-2 agonist treatment. In case of insufficient sedation despite maximal doses of α-2 agonist, other sedatives (choosen by the attending physician) will administered and titrated according to the scales for pain and sedation evaluation.
62620562|NCT06609031|EXPERIMENTAL|EMR in treating SSLs less than 10mm in size|The EMR procedure included the following: (1) needle injection of normal saline into the submucosa; (2) entrapment of the mucosal protrusion with a snare; and (3) resection using electrocautery
62620563|NCT06609031|ACTIVE_COMPARATOR|CSP in treating SSLs less than 10mm in size|The CSP procedure included the following: (1) entrapment and resection of the polyp with a snare without electrocautery.
62846599|NCT00552188|EXPERIMENTAL|VIA-2291|VIA-2291 100mg
62846600|NCT00552188|PLACEBO_COMPARATOR|Placebo|Matching placebo
62620564|NCT01796301|EXPERIMENTAL|Romosozumab|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
62620565|NCT01796301|ACTIVE_COMPARATOR|Teriparatide|Participants received 20 μg/day teriparatide administered by subcutaneous injection for 12 months.
62620566|NCT05524727|EXPERIMENTAL|Intervention Group|Usual care + concept-guided, personalized, motor-cognitive training by means of an exergame
62620567|NCT05524727|NO_INTERVENTION|Control Group|Usual care only
62620568|NCT04819477|OTHER|Cate Plots|after being asked about current referral practices and assessment of benefits and risks of lung cancer screening, all respondents will receive the Fact box after which they will be randomized into two equal groups. The first group (Arm 1) receives a Cates plot and then another survey about assessment of benefits and risks of lung cancer screening and potential change in referral behavior.
62264084|NCT02241759|EXPERIMENTAL|Placebo|Single oral dose of placebo to TA-8995
62264085|NCT02241759|ACTIVE_COMPARATOR|Moxifloxacin|Single open-label oral dose of 400mg moxifloxacin
62264086|NCT02199938||musculoskeletal tumors|Patients with suspected or confirmed bone or soft tissue tumors undergoing biopsy or surgery
62620569|NCT04819477|OTHER|Fact box only|after being asked about current referral practices and assessment of benefits and risks of lung cancer screening, all respondents will receive the Fact box after which they will be randomized into two equal groups. The second group (Arm 2) receives then a survey about assessment of benefits and risks of lung cancer screening and potential change in referral behavior
62620570|NCT00619125||A|20 patients with IBS C
62620571|NCT00619125||D|20 Subjects without IBS
62620572|NCT00619125||B|20 patients with IBS D
62620573|NCT00619125||C|20 patients with IBS M
62620574|NCT02726984|EXPERIMENTAL|case|Patients with carotid plaque ≥ 50% symptomatic (ischemic stroke on CT or MR) during the last 15 days
62620575|NCT02726984|EXPERIMENTAL|control|Patients with asymptomatic carotid plaque ≥ 50%
62620576|NCT00099177|EXPERIMENTAL|1|
62620577|NCT00099177|ACTIVE_COMPARATOR|2|
62620578|NCT04295369|EXPERIMENTAL|Lifestyle Medicine Group|
62620579|NCT04295369|NO_INTERVENTION|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment.
62620580|NCT03250338|EXPERIMENTAL|Crenolanib|Crenolanib following salvage chemotherapy
62620581|NCT03250338|PLACEBO_COMPARATOR|Placebo|Placebo following salvage chemotherapy
62264087|NCT06095661|EXPERIMENTAL|Virtual Reality|Each enrolled participant in a single arm will be offered a virtual reality headset with a menu of virtual reality environments and experiences such as nature scenes, mindful meditation, travel, and various games. Enrolled participants be offered the virtual reality as early as the first day after their inpatient surgery in their hospital room. Each virtual reality session will last 5-30 minutes, depending on the participant's selection of the virtual reality environment/experience. Participants will have the option to use the virtual reality as often as twice daily up through the third day after their surgery during their hospitalization, for a total of six sessions.
62264088|NCT03275194|NO_INTERVENTION|Control group|After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm does not receive additional treatment and the procedure will be finished.
62620582|NCT01398358|NO_INTERVENTION|Usual Head Start Exposure|Children will attend their usual Head Start classroom and receive the usual educational interventions provided in that classroom.
62620583|NCT01398358|EXPERIMENTAL|Parents of Preschoolers Series (POPS)|Children attend Head Start preschool. Within the classroom, they receive a series of lessons about nutrition and obesity prevention delivered by an Extension Educator in collaboration with the classroom teacher. Parents are invited to attend a series of classes about nutrition and obesity prevention.
62264089|NCT03275194|EXPERIMENTAL|HIPEC group|After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm receive a HIPEC procedure with cisplatin and doxorubicin.
62448050|NCT00365261|ACTIVE_COMPARATOR|eszopiclone|active drug
62448051|NCT00365261|PLACEBO_COMPARATOR|placebo|placebo
62620584|NCT01398358|EXPERIMENTAL|POPS + Incredible Years Series (IYS)|Children attend Head Start preschool. Within the classroom, they receive a series of lessons about nutrition and obesity prevention delivered by an Extension Educator in collaboration with the classroom teacher. Parents are invited to attend a series of classes about nutrition and obesity prevention. In the classroom, children also receive a series of lessons about emotional and behavioral self-regulation delivered by a trained mental health specialist. The parents also are invited to classes about child behavioral and emotional self-regulation delivered by a mental health specialist.
62620585|NCT02005237|EXPERIMENTAL|Aerobic Exercise (12 Weeks)|Aerobic exercise on a bicycle ergometer, tailored to the individual's level of fitness. Duration: 12 weeks with 2-3 sessions per week.
62620586|NCT02005237|NO_INTERVENTION|Waitlist Control Group|No intervention (patients randomized to this group will be offered access to the training program after completion of the trial)
62620587|NCT04389307|OTHER|Group 1: Bladder Training - Control group|Specific goals are to correct faulty habit patterns of frequent urination, improve control over bladder urgency, prolong voiding intervals, increase bladder capacity, reduce incontinence episodes and restore patient confidence in controlling bladder function
62620588|NCT04389307|ACTIVE_COMPARATOR|Group 2: Bladder Training+Intra Vaginal Electrical Stimulation|IVES was performed in lithotomy position via Enraf Nonius Myomed 632 device with a vaginal probe. IVES sessions were performed three times in a week, for 8 weeks. Every session lasted 20 minutes. The intervention comprised a 24-session treatment program of ES. The stimulation parameters were frequency at 10 Hz, a 5-10s work-rest cycle and 100 ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 0-100 mA. The intensity was controlled according to patients' discomfort level feedback
62620589|NCT00815477|ACTIVE_COMPARATOR|1|Waitlist control with generic Information about lifestyle and hypertension
62620590|NCT00815477|EXPERIMENTAL|2|Web-based intervention of lifestyle counseling messages based on the transtheoretical model of readiness for change.
62620591|NCT03042910|EXPERIMENTAL|Patients with advanced solid tumors|Talazoparib 1 mg daily
62264090|NCT04876170|ACTIVE_COMPARATOR|VS-EFP Neurofeedback|Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop; in this condition, participants will receive musical feedback driven by their own VS-EFP
62264091|NCT04876170|SHAM_COMPARATOR|Yoked sham Neurofeedback|"Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop; in this condition, the musical feedback will be provided based on another participant's VS-EFP signal. Hence, each participant from the sham group is paired with a participant from the test group, thus receiving feedback based on the paired test participant. This way, both groups are exposed to the exact proportion of sound manipulation that indicates their success level. To account for a possible contribution of the temporal order of feedback presentation, in half of the control participants, the feedback pattern will be replayed forward (maintaining the original temporal pattern of VS-EFP that the paired participant has received), and in half - backward (flipping the original temporal pattern right-to-left)."
62264092|NCT03383445|OTHER|TAVR|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local abesthesia, Imaging guidance during the TAVR procedure, and post-procedural TAVR management.
62264093|NCT03383445|OTHER|SAVR|SAVR procedure will be performed using standard techniques, with no limitation in terms of type and size of the valve prosthesis or surgical procedure (e.g. enlargement of the aortic root).
62264094|NCT03263962||With canrenone|Patients with canrenone
62264095|NCT03263962||Without canrenone|Patients without canrenone
62620592|NCT04250428|NO_INTERVENTION|Control|Women in the control arm will have (standard) access to antenatal care.
62620593|NCT04250428|EXPERIMENTAL|Demand intervention|Women in this arm will receive a home visit by a study nurse at the beginning of their pregnancy that will inform them regarding the importance of iron and folic acid supplementation as well as malaria prophylaxis.
62620594|NCT04250428|EXPERIMENTAL|Supply intervention|Women in this arm will get a monthly visit by study nurses. Women who did not obtain supplements or malaria prophyllaxis through routine antenatal care services will be directly provided with the supplements and malaria drugs by the study nurse.
62620595|NCT04455737||Patients with indigo carmine stained specimen|Specimen which underwent pathologic work-up after ex vivo indigo carmine injection into the inferior mesenteric artery after transanal total mesorectal excision.
62620596|NCT04455737||Patients with unstained specimen|Specimen which underwent pathologic work-up after transanal total mesorectal excision without indigo carmine dyeing.
62620597|NCT03395847|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
62846601|NCT02571335|EXPERIMENTAL|Intensive Training|Treatment consists of endurance training in both groups of physiologically defined heart rate controlled cycling at 50-60 rounds per minutes (rpm) and progressive resistance training. Training groups differ in the applied intensities and frequencies.The IT will train less frequent but training sessions will be more intensive in its effects. Training will be performed daily in six sessions (three morning and three afternoon sessions), synchronized and individually matched to a ratio of active versus passive sessions of 2:1.
62846602|NCT02571335|ACTIVE_COMPARATOR|Normal Training|The NT is the normal training performed out of the daily routine and outlines the usual care of the Valens clinic. Training will be performed in up to eight training sessions that will not be synchronized and not individually matched to a ratio of active versus passive sessions.
62846603|NCT01640314|EXPERIMENTAL|Cell derived subunit trivalent nonadjuvanted vaccine|
62264096|NCT04506008|EXPERIMENTAL|Group I (UH HRT)|Patients undergo HRT daily for a total of 5 fractions followed by surgery.
62264097|NCT04506008|EXPERIMENTAL|Group II (MH HRT)|Patients undergo HRT daily for a total of 15 fractions followed by surgery.
62846604|NCT00324259|ACTIVE_COMPARATOR|Arm 1 (6 mg estradiol)|6 mg of estradiol daily (2 mg tid).
62846605|NCT00324259|ACTIVE_COMPARATOR|Arm 2 (30 mg estradiol)|30 mg of estradiol. (10 mg tid)
62846606|NCT04135287|EXPERIMENTAL|Arm 1|Treatment with GLP-1 RA
62846607|NCT03145688|NO_INTERVENTION|Control|The control group package will consist of the Canadian 24 Hour Movement Guidelines recommending 60 minutes of moderate to vigorous physical activity per day for children. The guide also contains arguments \& information about the benefits of physical activity.
62264098|NCT05040594|EXPERIMENTAL|Treatment A (right) B (left)|Subjects will receive PavéDerm J-Fill Soft Dermal Filler and Restylane® Lyft Lidocaine. One product will be randomized, per NLF.
62264099|NCT05040594|EXPERIMENTAL|Treatment B (right) A (left)|Subjects will receive Restylane® Lyft Lidocaine and PavéDerm J-Fill Soft Dermal Filler. One product will be randomized, per NLF.
62264100|NCT05076383|EXPERIMENTAL|Motor relearning program (MRP)|
62620598|NCT03574688|EXPERIMENTAL|Water intervention|The participants increase their habitual daily water intake with 1.5 Liters of tap water per day during 6 weeks.
62620599|NCT04769492|OTHER|Pilot Intervention|Tailored violence prevention intervention (#ChopViolence/#ChopHIV) for B-YGBMSM and B-TW in the Chicago HBC.
62846608|NCT03145688|EXPERIMENTAL|Family physical activity Planning|Behavoural: Family Physical Activity Planning. The physical activity planning intervention condition will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include workbook on how to plan for family physical activity; brainstorming exercises for parents \& children where they list physical activities that they have found fun in the past, as well as some new activities they would like to try \& skill training content to help with goal setting \& tracking of physical activity.
62060208|NCT06214858|PLACEBO_COMPARATOR|（Placebo group）-placebo tablets|"part 1：Four dose groups were set up: 110mg,330mg, 550mg and 770mg, each group was intended to include 2 subjects and was administered orally. placebo tablets in the corresponding dose group were given on fasting in the morning of D1. PK blood collection and related tests were completed on day 8 (D8), PK and safety tests were completed on day 10 (D10), and telephone follow-up was performed on day 14 (D14±1).~part 2：Two dose groups were set up with 8 subjects in each group. In the first dose group, 330mg placebo tablets D1 and 110mg placebo tablets D2 \~ D5 were taken orally once a day (QD). The second dose group was taken orally 660mg placebo tablets on D1 and 220mg placebo tablets from D2 to D5, once a day (QD). PK samples were collected before and after administration, and safety observation was performed up to 8 days after the last administration."
62060209|NCT06214858|EXPERIMENTAL|（Food influence group）-SHEN211 tablets|The dose of SHEN211 tablets 330mg was intended to be selected in this experiment. Subjects in group A took SHEN211 tablets 330mg orally on an empty stomach in the morning of the first day of the experiment (the first cycle). On the morning of the 12th day of the trial (the second cycle), SHEN211 tablets 330mg were taken orally once, 30min after starting to eat a high-fat high-calorie meal; Subjects in group B took SHEN211 tablets 330mg orally once in the morning of the first day of the trial (the first cycle) when they started to eat A high-fat and high-calorie meal for 30min, and took SHEN211 tablets 330mg orally in the morning of the 12th day of the trial (the second cycle) on an empty stomach.
62060210|NCT02393521|EXPERIMENTAL|Vibration group|Patients in the vibration therapy group received 10 self-administered sessions of vibration therapy (45-50 Hz), one session per day, remaining on their Shindo® vibration mattress at home in supine for 15 min.
62060211|NCT02393521|NO_INTERVENTION|Control group|Subjects in the control group did not receive vibration therapy
62060212|NCT06315296|EXPERIMENTAL|Arm I (txt4fasting)|Patients follow a time-restricted diet, receive interactive positive reinforcement messages, and record food intake using the txt4fasting platform daily for 30 days. Patients receive counseling calls twice weekly in weeks 1 and 2 then once weekly in weeks 3 and 4. Patients then undergo SRS on study. Patients also undergo blood sample collection and brain MRI throughout study.
62060213|NCT06315296|ACTIVE_COMPARATOR|Arm II (attention control)|Patients receive text messages about healthy eating habits and food suggestions twice daily and record food intake using txt4fasting program for 30 days. Patients then undergo SRS on study. Patients also undergo blood sample collection and brain MRI throughout study.
62060214|NCT04325113|PLACEBO_COMPARATOR|NaCl 0,9%|patients receive 5ml of NaCl 0,9% at the level of the tonsils lodge
62060215|NCT04325113|ACTIVE_COMPARATOR|Xylocaine 2%|patients receive 5ml of Xylocaïne 2% at the level of the tonsils lodge
62060216|NCT04325113|ACTIVE_COMPARATOR|Levobupivacaine 0,5%|patients receive 5ml of Levobupivacaine 0,5% at the level of the tonsils lodge
62060217|NCT04492319|ACTIVE_COMPARATOR|control group|
62060218|NCT04492319|ACTIVE_COMPARATOR|neostigmine group|
62060219|NCT04167995|ACTIVE_COMPARATOR|Patient with attention deficit hyperactive disorser|patients (n=40) will receive probiotic preparation twice daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks added to standard treatment
62060220|NCT04167995|NO_INTERVENTION|ADHD not receiving probiotics|ADHD patient (40) on standard treatment
62264101|NCT05076383|ACTIVE_COMPARATOR|Conventional physical therapy program (CPT)|
62448052|NCT06421844||Real-Time Scleral Jaundice Evaluation in Gastroenterology Cohort|The cohort consists of at least 270 subjects consecutively enrolled from the Department of Gastroenterology at Xijing Hospital. The subjects will be followed prospectively over a period of time to collect data on their age, medical information, scleral images, and liver function test results. The cohort includes patients with various liver diseases and varying degrees of jaundice severity.
62448053|NCT06485895|EXPERIMENTAL|TUBERCULOSIS (LATENTE OR ACTIVE) ARM|
62264102|NCT04474756|EXPERIMENTAL|Mandibular Advancement Devices Narval™|The tested device Narval™ will be a custom-made adjustable bi-block mandibular advancement device, that is made with semi-rigid plastic materials (bio-compatible polymer) and customized using a high-precision computer-aided design (CAD)/computer-aided manufacturing (CAM) ) (ResMed, Narval CC™). The Mandibular Advancement Devices will be gradually adjusted to provide mandibular advancement over a 15-mm range. Each Mandibular Advancement Device will be ﬁtted by a dental specialist with an initial advancement of about 60 % of maximal jaw protrusion. During titration, mandibular advancement will be adjusted at the discretion of the dental specialist.
62846609|NCT03145688|EXPERIMENTAL|Family Physical Activity Habit Formation|Behavioural: Family Physical Activity Habit formation. The Habit formation intervention condition will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. The material includes a brief discussion of what habits are with some very straightforward examples such as preparing for sleep routines or initiating to drive a car to work. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms.
62060221|NCT01105013|EXPERIMENTAL|tonaftato|Apply the product in sufficient quantity to cover the affected area 2 times daily (every 12 hours) for 60 days.
62448054|NCT01841320|EXPERIMENTAL|Intervention|Participants who are assigned to intervention arm will receive ART and methadone maintenance at an integrated methadone and antiretroviral therapy (iMART) clinic and ART adherence support through the use of mobile phone technologies.
62448055|NCT01841320|NO_INTERVENTION|Standard of Care|Participants will be referred to standard HIV outpatient clinics and methadone maintenance clinics.
62846610|NCT06140030|EXPERIMENTAL|Mindfulness training mobile health application|Use of a mindfulness training mobile health application
62846611|NCT05262049|EXPERIMENTAL|intermittent compression-decompression with glides|Patients in this group will be given only intermittent compression and decompression with glides. Traction (decompression applied at knee joint with anteroposterior glide followed by compression for about 6 minutes (30 glides, 10 seconds compression and vice versa), for the duration of 4 weeks (3 days a week, alternate days)
62846612|NCT05262049|EXPERIMENTAL|Conventional Physical Therapy|"In this group conventional therapy will be given according to below mentioned protocol for 4 weeks (3 days a week, alternate days).~* Hot pack /TENS for 10 minutes~* Stretching: Hamstring(10x) and calf (10x)~* Strengthening of periarticular muscles especially the quadriceps (straight leg raising, pillow squeeze-isometric and dynamic)"
62846613|NCT05262049|EXPERIMENTAL|conventional physical therapy and intermittent compression-decompression with glides|Patients in this group will receive the combination of conventional physical therapy andintermittent compression and decompression with glides, for 4 weeks (3 days a week, alternate days).
62846614|NCT05944484|ACTIVE_COMPARATOR|kegel exercises|"Kegel exercise program performed for 12 weeks( 3 sessions /week )~.• The first step is external observation, with the patient in the lithotomy position.And describe for each woman how to feel her muscle when she stops mid-stream urine.~* The second step is vaginal examination, performed gently with one finger. - The digital exam served a double purpose: first to assess the development of the puboccocygeus muscle and second to verify that the patient was able to identify the correct muscle~* The third stage main exercises quick flick : contract muscle as quickly as possible 10-20 times then relax then count 10 for relax then reapeat .( 50 repetitions) slow contraction: tighten the muscle as hard as you can for account of 10 -20 .relax for acount 10 then repeat ( 50 repetitions) sustained contraction: tighten the muscle halfway and hold 60 seconds .relax for account 20 then repeat (10 repetitions)"
62846615|NCT05944484|ACTIVE_COMPARATOR|low caloric diet|low caloric diet (800-1200) calories/day . According to each patient, diet should contain (carbohydrate protein, fats, minerals, vitamins),1200 calories in the first month, 1000 calories in the second month, and 800 calories in the third month. Every week, each woman will be allowed to change the types of food to avoid boarding.
62846616|NCT05944484|ACTIVE_COMPARATOR|ultrasound cavitation|ultrasound cavitation, for 30 minutes on abdomen with continuous emission and frequency of 40 KHz, 3-6 W/cm2, 60W with 10cm2 active surface, twice/ week with 3 days apart for 12 weeks.
62846617|NCT05233241|EXPERIMENTAL|Patients with acute drug-induced interstitial nephritis|Patients with acute drug-induced interstitial nephritis
62846618|NCT02296983|EXPERIMENTAL|Low dose arm|The low dose cohort will receive an intramuscular (deltoid) injection of 3x106 pfu of VSV-ZEBOV vaccine.
62060222|NCT06622785||Group 1|People aged 18-29 years
62060223|NCT06622785||Group 2|People aged 30-44 years
62060224|NCT06622785||Group 3|People aged 45-60 years
62060225|NCT05279222|EXPERIMENTAL|gait training|
62060226|NCT02531763|NO_INTERVENTION|Control|FHS participants who enrolled with family member will not receive the social incentive intervention and will participate individually but will set a daily step goal and receive daily feedback on whether he or she achieved the goal or not.
62060227|NCT02531763|ACTIVE_COMPARATOR|Intervention|FHS participants who enrolled with a family member will be placed on a team as connected individuals (both in the same family) who will set a daily step goal, receive daily feedback on whether they achieved their goal, and receive the social incentive intervention.
62060228|NCT01287884|NO_INTERVENTION|Venous Blood Gas|All subjects have an ABG and VBG drawn. No intervention.
62060229|NCT03327584|ACTIVE_COMPARATOR|Ultrasound Guided Arthrocentesis|The patients in this group will have ultrasound guided arthrocentesis.
62060230|NCT03327584|ACTIVE_COMPARATOR|Landmark Guided Arthrocentesis|The patients in this group will have landmark guided arthrocentesis.
62060231|NCT03030937|EXPERIMENTAL|Irinotecan plus apatinib|"Irinotecan:160mg/m2, ivgtt,given on the eighth day; Apatinib:initial dose:250mg,oral,once a day, after meal ( try to take the medicine at the same time of the dauntoy ).~Repeat the therapeutic schedule every 2 weeks till progressive disease or intolerable toxicities."
62060232|NCT03030937|ACTIVE_COMPARATOR|Irinotecan|Irinotecan:180mg/m2, ivgtt,given on the eighth day. Repeat the therapeutic schedule every 2 weeks till progressive disease or intolerable toxicities.
62264103|NCT04474756|ACTIVE_COMPARATOR|Mandibular Advancement Devices TALI ™|"The control device TALI ™ is a mandibular advancement orthesis, customized and manufactured by the laboratoire TALI, of the bi-bloc type consisting of rigid gutters thermo-formed on the plaster dental arches and articulated by two links of variable size allowing to adjust the advance in steps of 1 millimeter. This orthesis is manufactured on molding from bio-compatible plastic materials. The different sizes of rods proposed allow mandibular advances of 4 mm to 16 mm. Two clinical studies evaluated the effectiveness of the AMC / AMO orthosis (initial version of the TALI orthesis, with non-curved links) in patients with OSA. They have already demonstrated the effectiveness of the TALI orthesis by decreasing AHI and drowsiness; most patients preferred to use the orthesis (76.4% vs. 9.1%)11."
62060233|NCT04601441|OTHER|Apalutamide|Apalutamide 240 mg administered orally once a day as four 60 mg tablets
62060234|NCT03733561|EXPERIMENTAL|LY03003|LY03003
62060235|NCT03733561|ACTIVE_COMPARATOR|Neupro transdermal patch|Neupro transdermal 4 mg patch
62060236|NCT03249610|EXPERIMENTAL|Jindal Steel Pvt Ltd|Lifestyle intervention given
62264104|NCT00597480|ACTIVE_COMPARATOR|1|the recommended dose in the EU of rhGH (Norditropine SimpleXx®)
62264105|NCT00597480|ACTIVE_COMPARATOR|2|"the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)"
62264106|NCT04845100|EXPERIMENTAL|Intervention|"The Effect Of Animal Assisted Activities On The Stress And Social Anxiety Levels Of Disabled Children~Animal Assisted Activity Program (HayDAP)"
62264107|NCT04845100|OTHER|Control group|No intervention
62264108|NCT01068171|ACTIVE_COMPARATOR|shoe, plain dressing|post-op shoe with plain occlusive dressing
62264109|NCT01068171|ACTIVE_COMPARATOR|shoe, collagen|post-op shoe with collagen dressing
62060237|NCT03249610|EXPERIMENTAL|Maruti Udyog Ltd|Lifestyle intervention given
62060238|NCT03249610|NO_INTERVENTION|Tata Capital|Control arm so no intervention given
62060239|NCT03249610|NO_INTERVENTION|Powergrid Corporation|Control arm so no intervention given
62060240|NCT01606696|EXPERIMENTAL|HIIT|Higher intensity interval training.
62264110|NCT01068171|ACTIVE_COMPARATOR|boot, plain dressing|air boot with occlusive dressing
62060241|NCT01606696|ACTIVE_COMPARATOR|Standard intensity non-interval training|Standard intensity non-interval training
62060242|NCT06537011|EXPERIMENTAL|AK112 combined with AP neoadjuvant therapy|Three cycles of AK112 were given before operation every 3 weeks on D 1, D 22 and D 43, while AP regimen was given every 3 weeks on D 1, D 22 and D 43, respectively.
62060243|NCT04144803||Cerebral desaturation group|absolute drop of forehead cerebral oxygen saturation ≥ 10% from baseline for ≥ 5 minutes during prehospital anesthesia
62060244|NCT04144803||Control group|no absolute drop of forehead cerebral oxygen saturation ≥ 10% from baseline for ≥ 5 minutes during prehospital anesthesia
62060245|NCT03116464|EXPERIMENTAL|Intervention Group|Caregiver and patient with dementia dyads who receive the family intervention.
62264111|NCT01068171|ACTIVE_COMPARATOR|boot, collagen|air boot with collagen dressing
62264112|NCT01068171|ACTIVE_COMPARATOR|monitored air boot, plain dressing|air boot with retention strap to monitor whether boot is removed with occlusive dressing
62264113|NCT01068171|ACTIVE_COMPARATOR|monitored boot with collagen|air boot with retention strap to monitor whether boot is removed with collagen dressing
62264114|NCT03829319|EXPERIMENTAL|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib|Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years.
62264115|NCT03829319|PLACEBO_COMPARATOR|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo|In Parts 1 and 2: Participants receive carboplatin AUC5 or cisplatin 75 mg/m\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily for up to 2 years.
62846619|NCT02296983|EXPERIMENTAL|Full dose arm|The full dose cohort will receive an intramuscular (deltoid) injection1x107 pfu of VSV-ZEBOV vaccine.
62060246|NCT06019195|EXPERIMENTAL|Time restricted eating|not more than 10 hrs. eating window daily goal for 6 months
62060247|NCT06626256|EXPERIMENTAL|Treatment (STIL101 for injection)|Patients undergo excisional biopsy and continue receiving standard of care therapy for 3-4 months prior to the start of study therapy. Patients with successful generation of STIL101 for injection receive cyclophosphamide IV over 2 hours on days -5 to -4, fludarabine IV over 30 minutes on days -5 to -1 and STIL101 for injection IV on day 0 in the absence of disease progression or unacceptable toxicity. Patients also receive aldesleukin SC QD on day 0 for up to 6-10 days. Additionally, patients undergo blood sample collection, biopsy, CT and optional MRI throughout the study.
62264116|NCT01652183|PLACEBO_COMPARATOR|Group Control (n=32):iv 1.5 ml/kg 0.9% NaCl|
62060248|NCT05773014|ACTIVE_COMPARATOR|Speculum Exams|If a patient requires cervical evaluation after PPROM, their cervix will be evaluated with a sterile speculum exam. A sterile speculum with lubricating jelly will be inserted into the patient's vagina to visualize the cervix and visually estimate cervical dilation and effacement.
62060249|NCT05773014|ACTIVE_COMPARATOR|Digital Exams|If a patient requires cervical evaluation after PPROM, their cervix will be evaluated with a digital exam. The provider will wear sterile gloves with lubricating jelly and will palpate the cervix to assess cervical dilation, effacement, and station.
62060250|NCT05686772||First-episode psychosis patients|
62060251|NCT00548132|NO_INTERVENTION|1|Patients in this arm will continue to get routine care
62060252|NCT00548132|EXPERIMENTAL|Chlorhexidine-impregnated foam dressing|Patient's catheters were cleaned with chlorhexidine-alcohol solution at least weekly before application of the Biopatch. These were evaluated daily and if the dressing was bloody, soiled or damaged, the dressing and the Biopatch were replaced prior to the 7-day period.
62060253|NCT01756261||Group 1|
62060254|NCT04095143||New onset of stage ≥2 acute kidney injury|"Either:~1. A ≥ 2-fold increase in serum creatinine OR~2. A serum creatinine ≥ 354 μmol/L with evidence of a minimum increase of 27 μmol/L OR~3. Urine output \< 6.0 mL/kg over the preceding 12 hours OR~4. Initiation of RRT for severe acute kidney injury less than 72 hours before recruitment"
62846620|NCT04279418|EXPERIMENTAL|Mixed functional foods group with SCD|Thirty participants in this group will take mixed functional foods for three months.
62060255|NCT02319070||Cohort 1|Adult patients with severe Hemophilia A.(25 patients on Secondary Prophylaxis treatment)
62448056|NCT04277611|ACTIVE_COMPARATOR|QLB|The patient is in the prone position, an ultrasound probe is placed in a transverse, oblique, and paramedian orientation approximately lateral to the posterior axillary line. The needle is then inserted in-plane from the medial side of the transducer and advanced laterally to enter the interfascial plane between the Quadratus Lumborum muscle and the kidney. We confirmed that the local anesthetic appeared to press down the kidney in the ultrasound image
62448057|NCT04277611|ACTIVE_COMPARATOR|ESPB|Using aseptic technique, an ultrasound probe is placed at the T9 vertebral level. After identifying the ribs and sliding towards the midline in a longitudinal parasagittal orientation, the overlying Erector Spinae is identified by visualization of the transition between the rib and transverse apophysis a block needle is inserted in plane with ultrasound beam and is advanced in a cephalo-caudal direction until the tip contacted the transverse process.
62846621|NCT04279418|PLACEBO_COMPARATOR|Placebo group with SCD|Thirty participants in this group will take placebo for three months.
62846622|NCT06363942|EXPERIMENTAL|SAFE program|Participants will be asked to carry out the SAFE program with the help of a caregiver. Our healthcare professionals will visit them during the first week to explain to them and their caregivers how to perform the exercises correctly while using our website. All exercises will be performed using video capsules available on our website (https://safe-seniors.com/fr). The exercises are divided into 4 levels of difficulty: level 1 (light); level 2 (moderate); level 3 (moderate to vigorous); and level 4 (vigorous). Each level lasts 25 to 30 minutes and includes 5 exercise categories split into 5 videos: warm-up, strength, balance, flexibility, and endurance. The exercise intervention will include 3 sessions per week over 12 weeks.
62846623|NCT06363942|NO_INTERVENTION|Control group|Participants will be asked to continue their activities of daily living without making any changes.
62060256|NCT02319070||Cohort 2|Adult patients with severe Hemophilia A.(50 patients on On Demand treatment)
62060257|NCT04538365|ACTIVE_COMPARATOR|Hand antisepsis with propanolol-1 60%|Effectiveness of pre-surgical hand washing in reducing bacterial load using propanolol-1 60% as control
62060258|NCT04538365|EXPERIMENTAL|Hand antisepsis with triclosan solution|Effectiveness of pre-surgical hand washing in reducing bacterial load using triclosan 0.5% solution
62060259|NCT00278538|EXPERIMENTAL|Hematopoietic Stem Cell Transplant Regimen 2|Autologous Hematopoietic Stem Cell Transplantation: Rituximab, rATG and Cyclophosphamide regimen
62060260|NCT01710163|EXPERIMENTAL|Lithium|Potentiation of previous treatment (Quetiapine monotherapy) with Lithium (0.5 - 0.8 mEq/L)
62060261|NCT01710163|EXPERIMENTAL|Aripiprazole|Potentiation of previous treatment (Quetiapine monotherapy) with Aripiprazole (10 - 15 mg)
62060262|NCT00651235|EXPERIMENTAL|B|In combination therapy,the maximal dose of Losartan is 100 mg/day for adult and 50 mg/day for children. 50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children
62060263|NCT00651235|ACTIVE_COMPARATOR|A|The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
62060264|NCT05582694|EXPERIMENTAL|1|10 adults (\>18 years of age) with human immunodeficiency virus (HIV) who demonstrate evidence of HIV-1 replication despite ongoing ART with documented genotypic and/or phenotypic resistance to multiple classes of HIV drugs (3 classes or more)
62060265|NCT03254160|EXPERIMENTAL|DNS-3379 (0.5mg)|
62060266|NCT03254160|EXPERIMENTAL|DNS-3379 (2.5mg)|
62060267|NCT03254160|PLACEBO_COMPARATOR|Placebo|
62060268|NCT03354650||complete blood count|blood sample is collected from infant to detect presence of sepsis
62846624|NCT02973438|EXPERIMENTAL|Spinal Cord Injury (SCI) Intermittent Hypoxia then SHAM|This arm of individuals with SCI will receive Intermittent Hypoxia (IH) and following a 3 week washout, SHAM treatment interventions.
62846625|NCT02973438|EXPERIMENTAL|Control (CON) Intermittent Hypoxia then SHAM|This arm of non injured control subjects will receive Intermittent Hypoxia (IH) and following a 3 week washout, SHAM treatment interventions.
62846626|NCT02973438|EXPERIMENTAL|Spinal Cord Injury (SCI) SHAM then Intermittent Hypoxia|This arm of individuals with SCI will receive SHAM and following a 3 week washout, Intermittent Hypoxia (IH) treatment interventions.
62448058|NCT03529955|EXPERIMENTAL|Dermatomyositis patients with refractory cutaneous disease|Patients with dermatomyositis and refractory skin disease on steroids and one steroid-sparing agent.
62448059|NCT03925220|EXPERIMENTAL|Substance Use Prevention Intervention|Parents will be given a handbook specific to the gender of their child that provides information and advice communication and substance use prevention. Parents will then participate in a one-hour session with an interventionist where the main points in the handbook will be reviewed and they will fill out an action plan on how to make changes in communication about substances with their child. The interventionist will also provide parents with a referral packet. Two weeks after the live session, participants will have a half-hour follow-up phone call with the same study interventionist. For the home-based component, parents will receive two messages each week with reminders and tips that reinforce the information covered in the handbook. Finally, participants will receive a magnet about the importance of family meals that they will be instructed to put on their refrigerators.
62620600|NCT02306421|ACTIVE_COMPARATOR|RPH with the simplified Milligan-Morgan|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation. The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer, anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids. Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
62060269|NCT03354650||c reactive protein|measuring c reactive protein in blood sample to determine neonatal sepsis
62060270|NCT01042509|EXPERIMENTAL|Alemtuzumab and rituximab|Patients with chronic GVHD after first-line therapy failure will receive Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25. THE STUDY HAVE ONLY ONE ARM.
62620601|NCT02306421|ACTIVE_COMPARATOR|PPH with the simplified Milligan-Morgan|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position.Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
62620602|NCT02306421|ACTIVE_COMPARATOR|R P H|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation.The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer , anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids , making hemorrhoidal lump shrink, thus eliminating bleeding and prolapse symptoms of hemorrhoid.It is suitable for internal hemorrhoids in every period and internal hemorrhoids part of mixed hemorrhoid.
62846627|NCT02973438|EXPERIMENTAL|Control (CON) SHAM then Intermittent Hypoxia|This arm of non injured control subjects will receive SHAM and following a 3 week washout, Intermittent Hypoxia (IH) treatment interventions.
62846628|NCT05178719|EXPERIMENTAL|PMA-zeolite|All subjects receive the substance 3 times per day in a measuring spoon as powder
62060271|NCT04620629||control group|Late premature and term babies without any disease
62060272|NCT04620629||probiotic group|Babies whose probiotic support is started and continues because they cannot receive breast milk, and whose antibiotic treatment is started in the neonatal period.
62060273|NCT04620629||antibiotic group|Babies who receives antibiotic treatment in the neonatal period and does not receive probiotic support before.
62060274|NCT00601003|EXPERIMENTAL|Nifurtimox|
62060275|NCT06095557|EXPERIMENTAL|Sponsor MCG device|All participants will receive a scan from the Sponsor MCG device
62060276|NCT03966053|EXPERIMENTAL|Cohort A|"Cohort A: Three subjects will receive Trifluoperazine (TFP) 1 mg PO daily.~* If there is no non-neurologic toxicity Grade 3 at the end of the 21 days, Cohort B will start.~* If 1/3 subjects in Cohort A demonstrates toxicity Grade 3, an additional 3 subjects will be enrolled in Cohort A.~* If 2 or more of the 6 subjects in Cohort A demonstrate toxicity Grade 3, the trial will be stopped; no MTD will be declared.~* If less than 2 of the 6 subjects in Cohort A demonstrate toxicity Grade 3 within 21 days of starting therapy, Cohort B will start."
62846629|NCT00104520|PLACEBO_COMPARATOR|Placebo (pooled two times a day [BID]/three times a day [TID])|
62264117|NCT01652183|ACTIVE_COMPARATOR|Group Paracetamol(n=32):iv 15mg/kg paracetamol|The patients were randomly divided into two groups: Group P (Paracetamol group, n=32) received intravenous 15mg/kg paracetamol during the surgery and Group C (Control Group, n=32) received intravenous 1.5 ml/kg 0.9% NaCl solution 30 minutes before the of surgery.At the end of the surgery, all patients had an nephrostomy catheter and the insertion site was infiltrated with 20 ml 0.25% bupivacaine infiltration for postoperative analgesia. Each patient received patient-controlled intravenous analgesia by meperidine (10 mg bolus, 20-minute lock-out, no infusion dose and 4 hour limit) for postoperative analgesia. All patients were planned to receive tenoxicam 20 mg intravenously as a rescue analgesic when visual analogue scale (VAS) was \>3.
62264118|NCT05522075|EXPERIMENTAL|Exercise Group|Binge drinkers who have been assigned to exercise group will receive baseline assessment, 8-week exercise training plus alcohol abstinence intervention, and post-intervention assessment.
62846630|NCT00104520|EXPERIMENTAL|AZLI (pooled two times a day [BID]/three times a day [TID])|
62264119|NCT05522075|ACTIVE_COMPARATOR|Non-exercise Group|Binge drinkers who have been assigned to non-exercise group will receive baseline assessment, 8-week alcohol abstinence intervention, and post-intervention assessment.
62264120|NCT05522075|NO_INTERVENTION|Alcohol abstainer/moderate drinker group|Alcohol abstainer/moderate drinker will complete baseline assessment only and will not receive any intervention.
62264121|NCT06053255|EXPERIMENTAL|HIFU for Sacroiliitis|High-intensity focused ultrasound delivered to the lateral sacral branch nerve for neurolysis.
62846631|NCT01910935|EXPERIMENTAL|Physical activity prescription|24 weeks physical activity program. 1 hour, 3 times a week, moderate to vigorous intensity.
62846632|NCT01910935|NO_INTERVENTION|No physical activity prescription|Provide information to patients about the benefits of physical activity and how to increase it safely.
62846633|NCT05343728||Thromboelastographic Methods|Patients whose coagulation profile were done by using a thromboelastography in addition to standard coagulation profile laboratory examination (thrombocyte count, PT, APTT, D-dimer, Fibrinogen)
62846634|NCT05343728||Standard coagulation profile laboratory examination|Patients whose coagulation profile were done by using a standard coagulation profile laboratory examination (thrombocyte count, PT, APTT, D-dimer, Fibrinogen)
62846635|NCT06290648|EXPERIMENTAL|Experimental: Forging New Paths + Usual Care|The experimental condition receives Forging New Paths in addition to community based mental health services as determined by their treatment providers.
62846636|NCT06290648|NO_INTERVENTION|Control: Usual Care Alone|The control condition receives community based mental health services as determined by their treatment providers.
62264122|NCT01776879||early & advanced PD 1st degree relatives|no intervention is performed in the study
62264123|NCT01776879||recording speech and voice|no intervention(s) will be administered
62264124|NCT01776879||speech intelligibility|no intervention(s) will be administered
62264125|NCT03461328|EXPERIMENTAL|Mg-group|10% MgSO4 solution will be used, a loading dose of 30mg/kg over 20 min (equivalent to infusion rate of 0.9 ml/kg/hr for 20 min) will be given followed by continuous infusion of 10mg/kg/hr (equivalent to infusion rate of 0.1ml/kg/hr).
62264126|NCT03461328|NO_INTERVENTION|Control group|In control group, same rates of infusion for loading and maintenance will be applied using 0.9 normal saline.
62264127|NCT03326076||Primary donor-derived cell-free DNA|300 patients with planned renal surveillance biopsies at 12 months post-transplantation
62264128|NCT03326076||Control|A matched control cohort of 1000 patients with planned renal surveillance biopsies at 12 months post-transplantation but were not managed with donor-derived cell-free DNA (AlloSure®) or KidneyCare will be retrospectively selected
62846637|NCT04588467|ACTIVE_COMPARATOR|Conservative group|Conservative treatment included dietary modification (intake of at lest 3 liters of water), stool-softeners (a 25 ml solution containing: Macrogol 3350: 13.125 g Sodium chloride: 0.3508 g Sodium hydrogen carbonate: 0.1786 g Potassium chloride: 0.0502 g) and local anesthetics application (Lidocaine 2.5%+Prilocaine 2.5%, 2g twice a day) for 10 days
62846638|NCT04588467|EXPERIMENTAL|Surgical group|Thrombectomy and local excision of external hemorrhoids were performed with the patient in the lithotomy position under local infiltrative anesthesia with UltracainDS 1:200000 1.7ml
62846639|NCT01120717|EXPERIMENTAL|QVA149|110µg/50µg capsule for oral inhalation, once daily, delivered by a single dose dry powder inhaler (SDDPI)
62846640|NCT01120717|PLACEBO_COMPARATOR|Placebo|Placebo to match QVA149, capsules for inhalation once daily, delivered by an SDDPI
62846641|NCT02512848||endometrial neoplasms|patients with risk of endometrial cancer in the postmenopausal period
62846642|NCT03913338|OTHER|Study group|LASIK followed by intraoperative application of riboflavin under the flap and crosslinking after reposition of the flap.
62846643|NCT03913338|OTHER|Control group|LASIK only
62846644|NCT00752804|EXPERIMENTAL|1|Dialysis during 4 hours
62846645|NCT00752804|ACTIVE_COMPARATOR|2|Dialysis during 6 hours
62846646|NCT00752804|ACTIVE_COMPARATOR|3|Dialysis during 8 hours
62846647|NCT00886678|EXPERIMENTAL|1|patients receiving pemetrexed, carboplatin and radiation therapy.
62846648|NCT01367951|EXPERIMENTAL|Surgical fixation|"* The fractures will be reduced and stabilized by use of plates and screws~* Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.~* Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.~* Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted."
62846649|NCT01367951|NO_INTERVENTION|non-operative|"1. Mechanical ventilation: Patients in respiratory distress will receive endotracheal intubation, and placed on mechanical ventilation. PEEP will be utilized as needed, at the discretion of the ICU and respiratory therapy team.~2. Other conservative means/Pulmonary toilet:Patients will receive aggressive pulmonary toilet (suctioning of ET tube as needed), chest physiotherapy (as per standard local protocol), and will have the head of the bed elevated to 30° unless contraindicated (ie unstable C-spine injury).~3. Pain control:Epidural catheters, intercostal nerve block, PCA, IV/PO pain medication"
62846650|NCT04198051|EXPERIMENTAL|treatment group|
62264129|NCT03326076||Secondary donor-derived cell-free DNA|1200 patients without planned renal surveillance biopsies at 12 months post-transplantation
62264130|NCT03326076||Primary KidneyCare®|300 patients with planned renal surveillance biopsies at 12 months post-transplantation
62264131|NCT03326076||Secondary KidneyCare®|1200 patients without planned renal surveillance biopsies at 12 months post-transplantation
62264132|NCT01685827|ACTIVE_COMPARATOR|NECT (Nifurtimox Eflornithine Combination Therapy)|"* Nifurtimox tablets will be given orally three times a day, at the daily dose of 15 mg/kg/day, for 10 days.~* Eflornithine (400 mg/kg/day) will be given twice daily for 7 days, as a 2-hour IV infusion."
62264133|NCT01685827|EXPERIMENTAL|Fexinidazole|"Fexinidazole, 600 mg tablets given by oral route, after the main daily meal (within 30 minutes from the start of the meal), at the daily dose of:~* 1 800 mg (3 tablets) once a day for 4 days,~* Followed by 1 200 mg (2 tablets) once a day for 6 days. Total duration of treatment will be 10 days."
62846651|NCT00862641|PLACEBO_COMPARATOR|Placebo - Asthma|Matching intravenous (IV) bolus injection, subjects with Asthma
62264134|NCT00684255|EXPERIMENTAL|Reduced Intensity Regimen for Refractory SLE|RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with medically refractory Systemic Lupus Erythematosus (SLE).
62264135|NCT00684255|EXPERIMENTAL|Reduced Intensity Regimen for SSc|RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with Systemic Sclerosis (SSc).
62264136|NCT01579188|EXPERIMENTAL|GV1001|The adjuvant GM-CSF is administered first as an intradermal injection followed in 10-15 minutes by the GV1001 peptide injected into the same site.
62264137|NCT01579188|PLACEBO_COMPARATOR|Placebo|Placebo
62264138|NCT03201458|EXPERIMENTAL|Arm A (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and collection of blood samples throughout the trial and undergo tumor biopsy on study.
62264139|NCT03201458|EXPERIMENTAL|Arm B (atezolizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15 and cobimetinib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and collection of blood samples throughout the trial and undergo tumor biopsy on study.
62264140|NCT02361502|PLACEBO_COMPARATOR|placebo|mirabegron placebo qd
62264141|NCT02361502|EXPERIMENTAL|mirabegron|mirabegron 50mg qd
62264142|NCT00841802|EXPERIMENTAL|Prednisone|Steroid medication
62264143|NCT00841802|NO_INTERVENTION|No Intervention|No Intervention
62264144|NCT03997435|EXPERIMENTAL|Control arm|neoadjuvant concurrent capecitabine-radiotherapy followed by surgery and postoperative chemotherapy
62264145|NCT03997435|EXPERIMENTAL|Experimental arm|Neoadjuvant FOLFOXIRI x4 cycles, then capecitabine-radiotherapy and postoperative chemotherapy
62264146|NCT03611192|EXPERIMENTAL|Multicomponent exercise group|
62264147|NCT03611192|ACTIVE_COMPARATOR|Home-program exercise group|
62264148|NCT02198703|EXPERIMENTAL|AB-Life|1 capsule of AB-Life daily during 12 weeks consumed immediately before, after or during the breakfast. The daily dose corresponds to the intake of 1.8E+10 CFU. According to the product's stability and the duration of the experiment, all participants receive at least 1.2E+09 CFU/capsule/day by the end of the study.
62264149|NCT02198703|PLACEBO_COMPARATOR|Placebo|1 capsule of placebo daily during 12 weeks consumed immediately before, after or during the breakfast.
62620603|NCT02306421|ACTIVE_COMPARATOR|P P H|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids-PPH.In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position
62620604|NCT02306421|ACTIVE_COMPARATOR|Milligan-Morgan|Milligan-Morgan surgery ,created in 1937 by Milligan etc,whose essence is to excise hemorrhoids of increasing prolapse in anatomy has good curative effect, low recurrence.It is currently the most common clinical surgery.
62620605|NCT03711136||Frozen elephant trunk surgery|
62620606|NCT03711136||Standart surgery|
62264150|NCT03094234|ACTIVE_COMPARATOR|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
62620607|NCT01129271|EXPERIMENTAL|Group clopidogrel fed - fasting|"Period 1:~* Day 1: clopidogrel 300 mg loading dose with high fat breakfast~* Day 2 to Day 5: clopidogrel 75 mg/day with standard breakfast, once daily~Period 2:~* Day 1: clopidogrel 300 mg loading dose under fasted conditions~* Day 2 to Day 5: clopidogrel 75 mg/day under fasted conditions, once daily"
62846652|NCT00862641|EXPERIMENTAL|Regadenoson - Asthma|0.4mg / 5mL intravenous bolus injection, subjects with Asthma
62264151|NCT03094234|ACTIVE_COMPARATOR|EVL plus propranolol|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
62264152|NCT02577614|EXPERIMENTAL|FEIBA|Single dose of commercially available FEIBA
62264153|NCT02577614|PLACEBO_COMPARATOR|Normal Saline|Single dose of NaCl 0.9%
62264154|NCT05143892|EXPERIMENTAL|Avatrombopag|In the 4-weeks'study,the initial dose of avatrombopag is 20 mg/d. If the patient's PLT count remains less than 20\*10\^9/L after one week, the maximum dose was increased to 40 mg/d. Avatrombopag will be taken orally with food.
62264155|NCT05143892|OTHER|Supportive care|Patients in this arm receive same treatment as in the avatrombopag group,except any TPO-RAs or recombinant human thrombopoietin.
62264156|NCT06334289||Frailty group|
62264157|NCT06334289||Non-frailty group|
62264158|NCT05227521|EXPERIMENTAL|AH-GRASP feedback intervention group|All study participants will receive the AH-GRASP feedback intervention.
62620608|NCT01129271|PLACEBO_COMPARATOR|Group placebo fed - fasting|"Period 1:~* Day 1: placebo loading dose with high fat breakfast~* Day 2 to Day 5: placebo with standard breakfast, once daily~Period 2:~* Day 1: placebo loading dose under fasted conditions~* Day 2 to Day 5: placebo under fasted conditions, once daily"
62846653|NCT00862641|PLACEBO_COMPARATOR|Placebo - COPD|Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)
62846654|NCT00862641|EXPERIMENTAL|Regadenoson - COPD|0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)
62264159|NCT03587220|EXPERIMENTAL|Capsaicin+UVB group|All subjects will be treated with capsaicin, placebo + UVB, or Capsaicin+UVB.
62264160|NCT03587220|EXPERIMENTAL|Capsaicin + EMLA group|All subjects will be pre-treated with lidocain cream before capsaicin application
62264161|NCT02249143|ACTIVE_COMPARATOR|CPAP and room air|Stable premature infants on CPAP and room air will be randomized to stay on CPAP for an additional two weeks.
62264162|NCT02249143|NO_INTERVENTION|Room air|Premature stable infants on CPAP and room air will be randomized to transition to room air alone.
62264163|NCT02707120|EXPERIMENTAL|PRGF-Endoret eye-drops|
62620609|NCT01129271|EXPERIMENTAL|Group clopidogrel fasting - fed|"Period 1:~* Day 1: clopidogrel 300 mg loading dose under fasted conditions~* Day 2 to Day 5: clopidogrel 75 mg/day under fasted conditions, once daily~Period 2:~* Day 1: clopidogrel 300 mg loading dose with high fat breakfast~* Day 2 to Day 5: clopidogrel 75 mg/day with standard breakfast, once daily"
62846655|NCT00811486|NO_INTERVENTION|Usual care|Group II
62846656|NCT00811486|EXPERIMENTAL|Spironolactone and conivaptan|Group I
62846657|NCT00796991|ACTIVE_COMPARATOR|Arm A|
62846658|NCT00796991|ACTIVE_COMPARATOR|Arm B|
62264164|NCT02707120|ACTIVE_COMPARATOR|Artificial tears eye-drops|
62264165|NCT04159220|NO_INTERVENTION|Control group|The transport will be released without a clamping of endotracheal tube before each disconnection from ventilator.
62264166|NCT04159220|EXPERIMENTAL|Clamping group|The transport will be released with a clamping of endotracheal tube before each disconnection from ventilator.
62264167|NCT05464888|EXPERIMENTAL|+Short AAT|Children aged 4-8 y.o. willing to receive an oral exam, a toothbrush cleaning, simulated radiographs and be a study participant - 75 experimental patients who will be interacting with the dog prior to their oral exam.
62060277|NCT03966053|EXPERIMENTAL|Cohort B|"Cohort B: Three subjects will receive TFP 2 mg PO daily.~* If there is no non-neurologic toxicity Grade 3 at the end of the 21 days, Cohort C will start.~* If 1/3 subjects in Cohort B demonstrates toxicity Grade 3, an additional 3 subjects will be enrolled in Cohort B:~* If 2 or more of the 6 subjects in Cohort B demonstrate toxicity Grade 3, the study will be stopped, and 1 mg/day will be declared the MTD.~* If \< 2 of the 6 subjects in Cohort B demonstrate toxicity Grade 3 within 21 days of starting therapy, Cohort C will start."
62060278|NCT03966053|EXPERIMENTAL|Cohort C|"Cohort C: Three subjects will receive TFP 5 mg PO daily.~* If there is no non-neurologic toxicity ≥ Grade 3 at the end of the 21 days, Cohort D will start.~* If 1/3 subjects in Cohort C demonstrates toxicity Grade 3, an additional 3 subjects will be enrolled in Cohort C:~* If 2 or more of the 6 subjects in Cohort C demonstrate toxicity Grade 3, the study will be stopped, and 2 mg/day will be declared the MTD.~* If \< 2 of the 6 subjects in Cohort C demonstrate toxicity Grade 3 within 21 days of starting therapy, cohort D will start."
62060279|NCT03966053|EXPERIMENTAL|Cohort D|"Cohort D: Three subjects will receive TFP 10 mg PO daily.~* If 0/3 subjects in Cohort D demonstrates toxicity Grade 3, the study will be stopped, and 10 mg/day will be declared the MTD.~* If 1/3 subjects in Cohort D demonstrates toxicity Grade 3, an additional 3 subjects will be enrolled in Cohort D.~* If 2 or more of the 6 subjects in Cohort D demonstrate toxicity Grade 3, the study will be stopped, and 5 mg/day will be declared the MTD.~* If \<2 of the 6 subjects in Cohort D demonstrate toxicity \> Grade 3 within 21 days of starting therapy, 10mg/day will be declared the MTD."
62060280|NCT02283489|EXPERIMENTAL|Combination therapy A|Recombinant human endostatin adenovirus (EDS01), 5.0 × 1011 VP intratumorally on days 0 and 7; paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
62620610|NCT01129271|PLACEBO_COMPARATOR|group placebo fasting -fed|"Period 1:~* Day 1: placebo loading dose under fasted conditions~* Day 2 to Day 5: placebo in fasted conditions, once daily~Period 2:~* Day 1: placebo loading dose with high fat breakfast~* Day 2 to Day 5: placebo with standard breakfast, once daily"
62620611|NCT05287854|EXPERIMENTAL|Local anesthesia + Virtual Reality|In addition to local standard anaesthesia, patients benefit from a virtual reality session during the operation using a virtual reality headset
62060281|NCT02283489|EXPERIMENTAL|Combination therapy B|Recombinant human endostatin adenovirus (EDS01), 1.0 × 1012 VP intratumorally on days 0 and 7; paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
62060282|NCT02283489|EXPERIMENTAL|Chemotherapy|Paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
62060283|NCT00265330|EXPERIMENTAL|Open|
62060284|NCT01073670|ACTIVE_COMPARATOR|Acetaminophen|Participants received a loading dose of acetaminophen (2600 mg) at induction followed by 1300 mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
62846659|NCT00796991|ACTIVE_COMPARATOR|Arm C|
62846660|NCT05048576|EXPERIMENTAL|Positive auditory cues|Participants will listen to the following auditory cues \~30 seconds apart Good job, you're doing awesome! Keep up the good work! You've got this! You're almost done, just a few more minutes! That's a great pace! You're going strong! Keep it up! Nice work. Great job! Good stuff. Keep it up. You're doing an amazing job.
62846661|NCT05048576|EXPERIMENTAL|Negative auditory cues|Participants will listen to the following auditory cues \~30 seconds apart You've got to walk faster than that. You're so slow! Why do you walk like that? Did you learn how to walk yesterday? You're doing terrible. Who walks like that? You have potential but you don't use it. You'll never amount to anything. You're not putting very much effort into this. This is the worst pace you've had yet.
62846662|NCT05048576|EXPERIMENTAL|Music|Participants will be allowed to select a streaming music station of their choice.
62846663|NCT05048576|ACTIVE_COMPARATOR|Silence|Participants will walk in silence while wearing noise cancelling headphones.
62846664|NCT03136848|EXPERIMENTAL|Normothermic perfusion|Kidneys retrieved from deceased donors will undergo the study intervention consisting of 4-10 hours of Normothermic ex-vivo perfusion using a blood-based solution, prior to implantation in the transplant recipient
62846665|NCT02487017|SHAM_COMPARATOR|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization treatment according to NCCN guidelines，patients will receive 5-FU Hepatic arterial infusion,3 cycles at least.
62846666|NCT02487017|EXPERIMENTAL|DC-CIK|After accepting concurrent TACE according to NCCN guidelines,patients will receive 3 cycles of DC-CIK treatment at least.
62846667|NCT01895556|EXPERIMENTAL|Information|Information about male circumcision and HIV risk
62846668|NCT01895556|PLACEBO_COMPARATOR|Control|Control
62846669|NCT02199210|EXPERIMENTAL|Prompting forethought|"A demographic questionnaire will be filled out by each participant. After randomization, participants will be presented with the background information of the simulated scenario.Subsequently:~* participants forethought will be prompted and each participant will be asked to report his/her forethought,~* participants then will be asked to manage a simulated massive transfusion scenario,~* at completion of the scenario, each participant will undergo individualized debriefing and a syllabus on massive transfusion will be briefly discussed with them and also provided as a reading material for learning."
62846670|NCT02199210|NO_INTERVENTION|No prompting|"A demographic questionnaire will be filled out by each participants. After randomization, participants will be presented with the background information of the simulated scenario.Subsequently:~* participants will sit and wait for a predetermined time before entering into the simulator,~* participants then will be asked to manage a simulated massive transfusion scenario,~* at completion of the scenario, each participant will be interviewed about their thought process before entering to the simulation room,~* each participant will undergo individualized debriefing and a syllabus on massive transfusion will be briefly discussed with them and also provided as a reading material for learning."
62846671|NCT05274893|EXPERIMENTAL|SYHX2011(T)-Abraxane®(R)|Patients will be administrated with SYHX2011 followed by Abraxane®
62060285|NCT01073670|EXPERIMENTAL|Indomethacin|Participants were given 100 mg of indomethacin at induction and then 50 mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
62060286|NCT01073670|EXPERIMENTAL|Combination|Participants were given a loading dose of 1300 mg of acetaminophen and 50 mg of Indomethacin followed by 650mg of acetaminophen and 25 mg of indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
62060287|NCT01237184||biocortical fixation|Bi-cortically fixed implants intentionally engaging sinus floor beyond up to 1-2mm without graft but using stopper drill and self-threading concept
62620612|NCT05287854|NO_INTERVENTION|Local anesthesia alone|Patients benefit only from a local anaesthesia is provided according to the standard procedure
62620613|NCT00211432|EXPERIMENTAL|Title: Treatment of Pseudovitellium Detachment|Open-Label Anecortave Acetate Sterile Suspension(15mg)
62060288|NCT01237184||unicortical fixation|Short implants placed in proximity of the sinus without sinus floor involvement
62264168|NCT05464888|EXPERIMENTAL|+Long AAT|Children aged 4-8 y.o. willing to receive an oral exam, a toothbrush cleaning, simulated radiographs and be a study participant - 75 experimental patients who will be interacting with the dog throughout their entire visit.
62264169|NCT05464888|ACTIVE_COMPARATOR|Active control; NO dog|Children aged 4-8 y.o. willing to receive an oral exam, a toothbrush cleaning, simulated radiographs and be a study participant - 75 control patients who will not be interacting with the dog during their visit and will color a dog picture for 3 minutes instead.
62264170|NCT00952497|EXPERIMENTAL|Cisplatin, Capecitabine, Telatinib|
62264171|NCT03717909|EXPERIMENTAL|Experimental Group|Sodium Valproate 200Mg E/C Tablet (active treatment)
62264172|NCT03717909|PLACEBO_COMPARATOR|Control Group|Sodium Valproate matched placebo (inactive treatment)
62264173|NCT04558866|EXPERIMENTAL|ExBAT Arm|Testosterone Cypionate 400 mg IM on Day 1 and Darolutamide 1,200mg/day (two 300 tablets every 12 hours) p.o. for 28 days, from day 29 to day 56 followed by a washout period of 7 days (63-day cycles), until loss of benefit (disease progression and/or limiting toxicity).
62264174|NCT02864368|EXPERIMENTAL|5-day TMZ: Components A and B|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m\^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
62620614|NCT04217642||Delay surgery|Patients who have passed more than 48 hours from admission to surgery
62620615|NCT01979601|EXPERIMENTAL|Patient: LGT209 0.3 mg/kg|0.3 mg/kg LGT209 intravenous administration in patients on stable doses of statins
62620616|NCT01979601|EXPERIMENTAL|Patient: LGT209 1 mg/kg|1 mg/kg LGT209 intravenous administration in patients on stable doses of statins
62620617|NCT01979601|EXPERIMENTAL|Patient: LGT209 3 mg/kg|3 mg/kg LGT209 intravenous administration in patients on stable doses of statins
62620618|NCT01979601|EXPERIMENTAL|Patient: LGT209 10 mg/kg|10 mg/kg LGT209 intravenous administration in patients on stable doses of statins
62060289|NCT01237184||indirect sinus lift|implants engaging both crest and sinus floor but with green stick fracture
62620619|NCT01979601|EXPERIMENTAL|Patient: LGT209 20 mg/kg|20 mg/kg LGT209 intravenous administration in patients on stable doses of statins
62620620|NCT01979601|EXPERIMENTAL|Healthy Volunteers: LGT209 0.3 mg/kg|0.3 mg/kg LGT209 intravenous administration in healthy volunteers
62620621|NCT01979601|EXPERIMENTAL|Healthy Volunteers: LGT209 1 mg/kg|1 mg/kg LGT209 intravenous administration in healthy volunteers
62060290|NCT04952584|EXPERIMENTAL|Treatment Phase|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level The dose is based on the number of CD.30 CAR-EBVT-expressing cells administered. The total number of dose levels evaluated will depend upon toxicities experienced. Dose level cohorts will be numbered sequentially.~Dose Level 1: 1 × 10\^8 CD30.CAR-EBVST cells~Dose Level 2: 4 × 10\^8 CD30.CAR-EBVST cells~Dose Level 3: 1 × 10\^9 CD30.CAR-EBVST cells"
62060291|NCT04164602||elderly patients with newly diagnosed diabetes|"1. Group with exposure: patients over 60 years of age with diabetes diagnosed within six months (newly diagnosed)~2. Control Group: without exposure; patients over 60 years, without diabetes."
62060292|NCT01106430|EXPERIMENTAL|Lisdexamfetamine Dimesylate|
62060293|NCT01106430|ACTIVE_COMPARATOR|Atomoxetine Hydrochloride|
62264175|NCT02864368|EXPERIMENTAL|21-day TMZ: Components A and B|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of dose-intensified TMZ (75-100 mg/m\^2/day on days 1-21 of each 28 day cycle) with PEP-CMV vaccination on day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
62264176|NCT02864368|EXPERIMENTAL|5-day TMZ: Safety Cohort|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m\^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine. Vaccine components A and B were administered separately, with a delay between them, to determine if it was an individual component or a combination of the components that resulted in adverse reactions.
62620622|NCT01979601|EXPERIMENTAL|Healthy Volunteers: LGT209 3 mg/kg|3 mg/kg LGT209 intravenous administration in healthy volunteers
62620623|NCT01979601|EXPERIMENTAL|Healthy Volunteers: LGT209 10 mg/kg|10 mg/kg LGT209 intravenous administration in healthy volunteers
62620624|NCT01979601|EXPERIMENTAL|Healthy Volunteers: 20 mg/kg|20 mg/kg LGT209 intravenous administration in healthy volunteers
62620625|NCT01979601|PLACEBO_COMPARATOR|Patient: Placebo|Matching intravenous placebo in patients on stable doses of statins
62620626|NCT01979601|PLACEBO_COMPARATOR|Healthy Volunteers: Placebo|Matching intravenous placebo in healthy volunteers
62846672|NCT05274893|EXPERIMENTAL|Abraxane®(R)-SYHX2011(T)|Patients will be administrated with Abraxane® followed by SYHX2011
62060294|NCT05287308|EXPERIMENTAL|AC followed by albumin-bound paclitaxel|A (doxorubicin, epirubicin or pirarubicin) and C (cyclophosphamide) for 4 cycles followed by albumin-bound paclitaxel for 4 cycles.
62060295|NCT05287308|ACTIVE_COMPARATOR|AC followed by taxanes|A (doxorubicin, epirubicin or pirarubicin) and C (cyclophosphamide) for 4 cycles followed by paclitaxel or docetaxel for 4 cycles.
62060296|NCT04711356|EXPERIMENTAL|Study Intervention|All study participants will receive an Ad26.ZEBOV vaccine at a dose of 5x10\^10 vp given via IM injection
62060297|NCT05964088||Group1|These critically ill patients were directly admitted to the intensive care unit from the emergency department
62060298|NCT05964088||Group 2|These critically ill patients were were initially managed on the medical floor and later transferred to the intensive care unit for worsening respiratory status
62060299|NCT04266639|ACTIVE_COMPARATOR|Remote Ischemic Conditioning|"Remote Ischemic Conditioning (RIC) is applied during the in-hospital phase using an automated RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes of cuff deflation. The cuff pressure will be 200 mmHg; if initial systolic blood pressure is above 175 mmHg, the cuff is automatically inflated to 35 mmHg above the systolic blood pressure.~* Initial Remote Ischemic Conditioning: \< 2 hours from inclusion~* Remote Ischemic Postconditioning: twice daily for 7 days~Usual care with or without acute reperfusion therapy"
62060300|NCT04266639|SHAM_COMPARATOR|Sham - Remote Ischemic Conditioning|"Sham Remote Ischemic Conditioning (Sham-RIC) is applied during the in-hospital phase using an automated Sham-RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes of cuff deflation. The cuff pressure will be always be 20 mmHg.~* Initial Sham Remote Ischemic Conditioning: \< 2 hours from inclusion~* Sham Remote ischemic Postconditioning: twice daily for 7 days~Usual care with or without acute reperfusion therapy."
62060301|NCT04266639|NO_INTERVENTION|Controls|The control group will not receive treatment with Remote Ischemic Conditioning.
62264177|NCT02864368|EXPERIMENTAL|5-day TMZ: Component A Alone|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m\^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
62264178|NCT02864368|EXPERIMENTAL|21-day TMZ: Component A Alone|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of dose-intensified TMZ (75-100 mg/m\^2/day on days 1-21 of each 28 day cycle) with PEP-CMV vaccination on day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
62264179|NCT00400673|OTHER|Chemotherapy|Risk-oriented chemotherapy for remission induction (application of sequential high-dose cytarabine course to patients unresponsive to standard chemotherapy course 1) and postremission consiolidation(standard risk: blood stem cell supported high-dose cytarabine course \[x3\]; high risk: allogeneic SCT)
62264180|NCT03703882|EXPERIMENTAL|Dose 1|Edasalonexent 100 mg/kg/day. Capsules taken by mouth three times per day.
62264181|NCT03703882|PLACEBO_COMPARATOR|Placebo|Matching placebo
62264182|NCT00271817|ACTIVE_COMPARATOR|Part 1 - Arm 1|ezetimibe/simvastatin combination tablet + niacin (ER)
62264183|NCT00271817|ACTIVE_COMPARATOR|Part 1 -Arm 2|ezetimibe/simvastatin
62264184|NCT00271817|ACTIVE_COMPARATOR|Part 1 - Arm 3|Niacin (ER)
62846673|NCT02428725|EXPERIMENTAL|Acute coronary syndrome patient|Acute coronary syndrome patient undergoing PCI and eligible for ticagrelor therapy according to the guidelines accepting blood samples measuring platelets reactivity
62060302|NCT04860817|EXPERIMENTAL|Target CD7 CAR-T cells|Three dose levels will be evaluated. The CAR-T cells will be administered with Cytoxan and fludarabine.
62060303|NCT01583101|EXPERIMENTAL|Receiving Highlighted Prompts|Prompts received by physicians were highlighted.
62060304|NCT01583101|ACTIVE_COMPARATOR|Receiving Non-highlighted Prompts|Prompts received by physicians were not highlighted.
62264185|NCT00271817|ACTIVE_COMPARATOR|Part 2 - Arm 1|ezetimibe/simvastatin combination tablet + niacin (ER)
62264186|NCT00271817|PLACEBO_COMPARATOR|Part 2 - Arm 2|ezetimibe/simvastatin combination tablet + niacin (Pbo)
62264187|NCT03632733|ACTIVE_COMPARATOR|Tetracycline group|Tetracycline cream twice daily for three months
62264188|NCT03632733|ACTIVE_COMPARATOR|Clotrimazole group|Clotrimazole cream twice daily for three months
62264189|NCT03632733|ACTIVE_COMPARATOR|Combination drug group|Tetracycline and Clotrimazole combination cream twice daily for three months
62264190|NCT03632733|PLACEBO_COMPARATOR|Placebo group|participants will be provided a cream containing no active drug ingredients
62264191|NCT02688595|EXPERIMENTAL|Seldinger|Use a 23 gauge introducer needle for ultrasound-guided central venous catheterization
62264192|NCT02688595|EXPERIMENTAL|Modified Seldinger|Use a 22 gauge Angiocath Plus catheter for ultrasound-guided central venous catheterization
62264193|NCT03440814|EXPERIMENTAL|DCCR|75 - 450 mg DCCR
62264194|NCT03440814|PLACEBO_COMPARATOR|Placebo|75 - 450 mg placebo for DCCR
62264195|NCT01890642|SHAM_COMPARATOR|J tip Noise|This group will have a J tip deployed without medication to create the noise that the device makes. They will also receive Pain Ease spray if \> age 1 yr or sucrose if \< 1 yr
62264196|NCT01890642|OTHER|Pain Ease|This group will receive Pain Ease Spray only if \> 1 yr or sucrose only if child \< 1 yr
62264197|NCT01890642|EXPERIMENTAL|J tip|This group will receive 1% buffered lidocaine via Jet Injection. They will receive placebo cooling spray (normal saline spray) to maintain blinding if \> 1 yr and will receive sucrose is \< 1 yr
62264198|NCT04879043|EXPERIMENTAL|HDP-101|"Participants will receive HDP-101 intravenously in a 21 day cycle until disease progression, intolerable toxicity, Investigator's discretion or patient withdrawal.~During the phase 1 tolerability of different dose levels will be evaluated. During the phase 2a dose expansion part the recommended phase 2 dose (RP2D) of HDP-101 will be administered."
62264199|NCT03983577|EXPERIMENTAL|Point of service delivery model|After the informed consent is signed, the participant will watch a standardized video on the principles of genetic testing. At the end of the video, the provider will return to answer any remaining questions. The participant will receive pre- and post- surveys for evaluation of the delivery model.
62060305|NCT02628002|EXPERIMENTAL|Test arm|The subjects randomized to the anti-gravity treadmill arm will be instructed on the safe use of the Alter-G treadmill by the study staff. After this instruction, subjects will be exercised on the Alter-G anti-gravity treadmill using the conventional Bruce protocol with unweighting to 75% of their body weight to reach target heart rate. If the subject is unable to reach the target heart rate, they will be further unweighted to 50% of their body weight to enable the subject to reach target heart rate on the Bruce protocol. If the subject is still unable to reach target heart rate with 50% unweighting, the patient's subsequent SPECT images will be excluded from use in the research comparison to control subject images.
62060306|NCT02628002|ACTIVE_COMPARATOR|Control arm|The control arm subjects will undergo the conventional treadmill/regadenoson pharmacological stress SPECT. Consistent with standard practice, these patients will perform adjunctive low-intensity walk on a conventional treadmill prior to regadenoson and Tc-99m injection if tolerated.
62264200|NCT02603874|EXPERIMENTAL|Target Tape|Including target tape in the procedure
62264201|NCT02603874|NO_INTERVENTION|Control|Without target tape in the procedure
62264202|NCT03836391|EXPERIMENTAL|Nudge Intervention|"Each of 7 intervention message options has specific decision rules (including weighed/not weighed and progress toward daily dietary and activity goals) that make a participant eligible to receive a specific intervention type at a specific time (decision points).~At each decision point (early morning, morning, midday, and evening), the system evaluates which intervention options a participant is eligible to receive, and randomly chooses one intervention option from that list. Then the participant is randomly assigned to either receive or not receive that intervention message (with a 50-50 probability)."
62264203|NCT05112536|EXPERIMENTAL|Trilaciclib plus chemotherapy|"Trilaciclib lead-in, followed by trilaciclib plus anthracycline/cyclophosphamide, then trilaciclib plus taxane chemotherapy:~* Lead-in trilaciclib (240mg/m2) single dose monotherapy~* Trilaciclib (240mg/m2) + doxorubicin (60 mg/m2) + cyclophosphamide (600 mg/m2) + pembrolizumab (per Investigator discretion; 400mg)~* Trilaciclib (240mg/m2) + paclitaxel (80 mg/m2) + carboplatin (per Investigator discretion; AUC 1.5)"
62264204|NCT04945603||Poor Grade Subarachnoid Hemorrhage|"All patients (prospective and retrospective) included will have to present a subarachnoid hemorrhage defined poor grade according to the WFNS scale due to the rupture of an intracranial aneurysm.~The patients are managed according to both most recent international guidelines on the specific disease (Stroke, May 2012) and according to national and institutional guidelines/protocols."
62264205|NCT03496246|ACTIVE_COMPARATOR|Group A|patients with vitamin D deficiency are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
62264206|NCT03496246|ACTIVE_COMPARATOR|Group B|patients with vitamin D insufficiency are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
62264207|NCT03496246|ACTIVE_COMPARATOR|Group C|patients with normal vitamin D level normal are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
62264208|NCT02705651|EXPERIMENTAL|Somatostatin-Analog|A long acting somatostatin analog will be applied.
62620627|NCT05388084|ACTIVE_COMPARATOR|Male peer led intervention|Male partners of women randomized to the intervention arm will receive a phone call from the male peer to encourage them to test for HIV at the clinic. Male peer fathers will offer to meet men at the clinic and guide them through the process of HIV testing. Men who are not willing/able to attend the clinic for HIV testing will be offered testing in a private and confidential location in the community; the peer male counselor meet men and offer to assist them through the process of using and interpreting an oral HIVST. Men who are not interested in testing with the peer father will be offered the HIVST kit to take home. Peer fathers will obtain men's consent to participate in the study.
62620628|NCT05388084|ACTIVE_COMPARATOR|Standard of care and delayed intervention|Standard of care standard of care invitation letter to provide to their partner for fast-track HIV testing and male peer father phone calls after a 3 month delay.
62620629|NCT02328937|ACTIVE_COMPARATOR|etafilcon A/lotrafilcon B/comfilcon A|Subjects that were randomized to receive the etafilcon A lens 1st, the lotrafilcon B lens 2nd and the comfilcon A lens 3rd.
62620630|NCT02328937|ACTIVE_COMPARATOR|etafilcon A/comfilcon A/lotrafilcon B|Subjects that were randomized to receive the etafilcon A lens 1st, the comfilcon A lens 2nd and the lotrafilcon B lens 3rd.
62620631|NCT02328937|ACTIVE_COMPARATOR|comfilcon A/etafilcon A/lotrafilcon B|Subjects that were randomized to receive the comfilcon A lens 1st, the etafilcon A lens 2nd and the lotrafilcon B lens 3rd.
62620632|NCT02328937|ACTIVE_COMPARATOR|comfilcon A/lotrafilcon B/etafilcon A|Subjects that were randomized to receive the comfilcon A lens 1st, the lotrafilcon B lens 2nd and the etafilcon A lens 3rd.
62620633|NCT02328937|ACTIVE_COMPARATOR|lotrafilcon B/etafilcon A/comfilcon A|Subjects that were randomized to receive the lotrafilcon B lens 1st, the etafilcon A lens 2nd and the comfilcon A lens 3rd.
62620634|NCT02328937|ACTIVE_COMPARATOR|lotrafilcon B/comfilcon A/etafilcon A|Subjects that were randomized to receive the lotrafilcon B lens 1st, the comfilcon A lens 2nd and the etafilcon A lens 3rd.
62620635|NCT05578677|OTHER|A|Single-biopsy advance-and-close
62620636|NCT05578677|OTHER|B|Single-biopsy turn-and-suction
62620637|NCT05578677|OTHER|C|Double-biopsy advance-and-close
62620638|NCT05578677|OTHER|D|Double-biopsy turn-and-suction
62620639|NCT03928379|EXPERIMENTAL|LY3305677|LY3305677 administered SC
62620640|NCT03928379|PLACEBO_COMPARATOR|Placebo|Placebo administered SC
62620641|NCT04592679|EXPERIMENTAL|FES-C|
62620642|NCT04592679|ACTIVE_COMPARATOR|Standard|
62060307|NCT05929443|EXPERIMENTAL|END-IT intervention for nursing homes|This complex intervention, implemented at the level of the nursing home, encompasses process and goals setting, education for healthcare providers, environmental adaptations, audit and feedback on benzodiazepine use, use of an educational leaflet for residents and relatives, and multidisciplinary work.
62264209|NCT02705651|NO_INTERVENTION|No treatment|This arm will be be the observational control according to the endpoints of the study. No intervention will be made.
62264210|NCT01026831|EXPERIMENTAL|Tafluprost|Preservative-free tafluprost
62264211|NCT01026831|ACTIVE_COMPARATOR|timolol maleate|Preservative-free timolol maleate
62264212|NCT05980624|NO_INTERVENTION|Group A|nutrition counselling plus Standard chemotherapy only. Patients will undergo only standard chemotherapy for 3 months
62264213|NCT05980624|EXPERIMENTAL|Group B|nutrition counselling plus standard chemotherapy adding oral nutrition supplements as described in manufacturer label daily for 3 month and
62620643|NCT05180981|EXPERIMENTAL|Breath task|Participants will breathe in specific patterns.
62620644|NCT05180981|EXPERIMENTAL|Transcutaneous vagal nerve stimulation|Participants will receive transcutaneous vagal nerve stimulation in specific patterns.
62620645|NCT05719298|EXPERIMENTAL|Respiratory interface|Use of the new respiratory interface and accessories to deliver non-invasive therapy
62620646|NCT01216917||Fitness|
62620647|NCT01216917||Whole-body vibration|
62620648|NCT01216917||Control|
62620649|NCT01456143|EXPERIMENTAL|HRME with proflavine|High Resolution Microendoscopy (HRME) imaging device that operates as a fluorescence microscope with a fiber optic imaging probe. The probe is placed against the mucosa to obtain images relayed to a tablet computer. 0.01% Proflavine hemisulfate used as a fluorescent contrast agent applied topically to mucosa. HRME is used to capture images of suspicious areas sprayed with proflavine hemisulfate.
62620650|NCT04019886|EXPERIMENTAL|Experimental Group|"It consists following techniques-~1. Peri-oral stimulation~2. Vertebral pressure~3. Anterior stretch -lifting posterior basal area~4. Co-contraction -abdomen~5. Intercoastal stretch~6. Moderate manual pressure"
62620651|NCT04019886|NO_INTERVENTION|Control Group|Outcome measure will be measured at baseline on first day prior to the intervention and on 5th day after the treatment.
62620652|NCT01782352|ACTIVE_COMPARATOR|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
62620653|NCT01782352|ACTIVE_COMPARATOR|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])"
62620654|NCT01782352|PLACEBO_COMPARATOR|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~fish oil placebo"
62060308|NCT05929443|NO_INTERVENTION|Control|Usual care. Nursing homes allocated to this study arm will access intervention material at the end of the study.
62060309|NCT03694314|EXPERIMENTAL|Omega-3 fatty acids|Both the mother and child will receive omega-3 supplements in the form of a 200 mL drink to be taken once daily. The intervention will last 45 days. Assessments will take place at 0 months (baseline), 45 days (end of treatment), and 3 months (1 and a half months post-treatment).
62264214|NCT00170287|EXPERIMENTAL|1|ICD Therapy plus VT-Ablation
62264215|NCT00170287|ACTIVE_COMPARATOR|2|ICD Therapy only
62264216|NCT01452763|EXPERIMENTAL|TAK-438 10 mg QD|
62264217|NCT01452763|EXPERIMENTAL|TAK-438 20 mg QD|
62060310|NCT03694314|PLACEBO_COMPARATOR|Placebo|The mother and child will both receive a placebo drink to take daily, with no known effect on the brain. The intervention will last 45 days. Assessments will take place at 0 months (baseline), 45 days (end of treatment), and 3 months (1 and a half months post-treatment).
62264218|NCT01452763|ACTIVE_COMPARATOR|Lansoprazole 15 mg QD|
62264219|NCT06493773|NO_INTERVENTION|Standard care group|Patients randomized to standard care will receive standard supporting care by their care providers, entailing education on the nature of alcohol-related liver disease and encouragement to abstain from alcohol use.
62060311|NCT05982301|EXPERIMENTAL|Nab-POF|Sintilimab 200mg d1 ivgtt+paclitaxel-albumin 125mg/m2 d1 ivgtt+oxaliplatin 85mg/m2 d1 ivgtt+5-FU 2.4g/m2 civ46h, q2w.
62264220|NCT06493773|EXPERIMENTAL|Intervention group|Patients randomized to the intervention group.
62264221|NCT02526706|EXPERIMENTAL|Glaucoma Study Group|Glaucoma patients scheduled for trabeculectomy were recruited for this study and VisionBlue dye is injected prior to the surgery.
62264222|NCT05389163|EXPERIMENTAL|Giomer based injectable resin composite|Beautifil Flow plus X F03, SHOFU, USA
62264223|NCT05389163|ACTIVE_COMPARATOR|Resin modified glass ionomer|Fuji II LC, GC
62264224|NCT02286700|ACTIVE_COMPARATOR|Desonide Group|Group randomly receiving desonide cream as the treatment cream for 3 weeks. Fifteen (15) gram tubes are dispensed at the beginning of each week and will be applied twice daily, by the subject, during the 3 week treatment phase.
62620655|NCT01782352|ACTIVE_COMPARATOR|Vitamin D + fish oil|"Vitamin D (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])"
62620656|NCT06073509||Breast cancer patients treated with RT 5 years ago|Retrospective and cross-sectional data collection based on a medical questionnaire and screening for atrial fibrillation and other cardiac arrhythmias and diseases.
62060312|NCT03682705|PLACEBO_COMPARATOR|ELS placebo/UPA placebo|Placebo capsule for elsubrutinib once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
62264225|NCT02286700|EXPERIMENTAL|Amino Acid Group|Group randomly receiving amino acid moisturizing cream as the treatment cream for 3 weeks. Fifteen (15) gram tubes are dispensed at the beginning of each week and will be applied twice daily, by the subject, during the 3 week treatment phase.
62060313|NCT03682705|EXPERIMENTAL|UPA 15 mg/ELS 60 mg|15 mg film-coated upadacitinib tablet once a day by mouth for 12 weeks; 60 mg elsubrutinib capsule once a day by mouth for 12 weeks
62060314|NCT03682705|EXPERIMENTAL|ELS 60 mg/UPA placebo|60 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
62060315|NCT03682705|EXPERIMENTAL|ELS 20 mg/UPA placebo|20 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
62264226|NCT06494631|EXPERIMENTAL|aXess graft|
62264227|NCT02353156|EXPERIMENTAL|Electronic bidet|Electronic bidet for 3min at early morning for 4 weeks after hemorrhoidectomy
62264228|NCT02353156|ACTIVE_COMPARATOR|Sitz bath|Wamr sitz bath for 3min at early morning for 4 weeks after hemorrhoidectomy
62264229|NCT00385502|EXPERIMENTAL|EcoNail™|econazole 5%/SEPA® 18% nail lacquer
62264230|NCT03209102|EXPERIMENTAL|BPD adolescents|Adolescents suffering from Borderline Personality Disorder. Clinical assessment, Stress Elicitation Experiment, Structural and Functional MRI, salivary collections of amylase and cortisol
62264231|NCT03209102|EXPERIMENTAL|Healthy controls adolescents|Healthy controls adolescents. Clinical assessment, Stress Elicitation Experiment, Structural and Functional MRI, salivary collections of amylase and cortisol
62264232|NCT03009214|EXPERIMENTAL|AMC303|"cohorts will receive ascending doses of AMC303 as intravenous infusion~Planned doses are:~0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg, 4 mg/kg, 10 mg/kg and 20 mg/kg"
62264233|NCT01191073|EXPERIMENTAL|CAD/CAM fabricated dentures|group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)
62264234|NCT01191073|ACTIVE_COMPARATOR|traditional fabricated dentures|group receiving traditional fabricated dentures (double blind)
62620657|NCT01694901||SmartPilot® system|50 patients scheduled for elective surgery (general/abdominal surgery; traumatological/orthopedic surgery, gynecology, urology) in general anesthesia using the SmartPilot® system
62620658|NCT01694901||Standard arm|50 patients scheduled for elective surgery (general/abdominal surgery; traumatological/orthopedic surgery, gynecology, urology) in general anesthesia according to the standard operating procedures of the department, i.e. manually controlled clinical anesthesia and EEG-derived parameters of anesthetic depth
62620659|NCT05969587|EXPERIMENTAL|patients treated with 5% cysteamine cream|
62620660|NCT05969587|ACTIVE_COMPARATOR|patients treated with a combination of 4% hydroquinone cream and 0.06% betamethasone valerate|
62264235|NCT04971876|EXPERIMENTAL|Group 1 - Lips Enhancement|Participants treated with HLR-1 for lip enhancement, with optional Touch-Up (TU) 4 weeks afterwards
62264236|NCT04971876|EXPERIMENTAL|Group 2 - Nasolabial Fold Correction|Participants treated with HLR-2 for nasolabial folds (NLFs) correction, with optional Touch-Up (TU) 4 weeks afterwards
62264237|NCT04971876|EXPERIMENTAL|Group 3 - Treatment of Midface Volume Deficit|Participants treated with HLR-3 for treatment of midface volume deficit, with optional Touch-Up (TU) 4 weeks afterwards
62264238|NCT03480100||Xylometazoline Nasal spray|1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day
62264239|NCT03480100||Xylometazoline + Ectoin Nasal Douche|Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Douche (END01): 1 spray per nostril 2-6 times per day or as often as required
62264240|NCT05566951|EXPERIMENTAL|Experimental group|-The experimental group that applied the technology-based psychosocial program
62264241|NCT05566951|OTHER|Control group|Control group receiving standard care
62620661|NCT03440970|EXPERIMENTAL|Lysine Chloride|Patients will be randomized to receive either lysine chloride or placebo. Patients will receive the study drug twice a day for 5 days of randomized therapy, starting after the completion of a blood volume assessment.
62620662|NCT03440970|PLACEBO_COMPARATOR|Placebo|Patients will be randomized to receive either lysine chloride or placebo. Patients will receive the study drug twice a day for 5 days of randomized therapy, starting after the completion of a blood volume assessment.
62620663|NCT04763616|EXPERIMENTAL|Isatuximab and Cemiplimab combined therapy|"Drug : Isatuximab~1 cycle : 10mg/kg IV every week. It is administered on Day 2, Day 9, Day 16, Day 23.~2\~6 cycle : 10mg/kg every 2 weeks . It is administered on Day 2, Day 16.~7th cycle and beyond : 10mg/kg IV every 3 weeks. It is administered on Day 2.~Drug : Cemiplimab~1st - 6th cycle : 250mg IV every 2 weeks. It is administered on Day 1, Day 15.~7th cycle and beyond : 350mg every 3 weeks. It is administered on Day 1."
62264242|NCT02604277|EXPERIMENTAL|Group Intervention Program|Patients diagnosed with Bipolar Disorder will receive therapy in a group setting of 4 to 12 male and female participants.
62264243|NCT00820677|EXPERIMENTAL|DVD/Video|Parents of newborns in the experimental group attending their first baby visit will be shown a video about newborn care.
62264244|NCT00563186|EXPERIMENTAL|A|Admission to a novel hospital ward (e.g. abundance of sinks, predominance (80%) of private rooms, absence of shared bathrooms, absence of curtains)
62264245|NCT00563186|NO_INTERVENTION|B|Hospital admission to a ward with traditional design features (eg. lack of sinks, predominance of 4-bed rooms \[80%\], shared bathrooms, curtains present)
62264246|NCT02954497|EXPERIMENTAL|Jarvik 2015 Device VAD|New, experimental continuous flow VAD
62264247|NCT05663762||Pre-pandemic pregnancy and birth|Live hospital births that occurred Jan 1 - Mar 31 2019
62264248|NCT05663762||Pregnant and gave birth during the pandemic but before widespread COVID-19 vaccine availability|Live hospital births that occurred Jan 1 - Mar 31 2021
62264249|NCT05663762||Pregnant and gave birth during the pandemic and after widespread COVID-19 vaccine availability|Live hospital births that occurred Jan 1 - Mar 31 2022
62264250|NCT04772495||Study group|with Multiple sclerosis
62264251|NCT04772495||Control group|not Multiple sclerosis
62264252|NCT01303094|OTHER|Continuation of Trabectedin|patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle, every 3 weeks until progression/ toxicity
62620664|NCT00936676||Rasagiline mesylate|Enrollment by invitation to participates from the ADAGIO trial
62846674|NCT04562051||stratified prophylaxis group|The process of stratified prophylaxis was as follows. 1) If the recipient's HBsAb level is more than 100 IU/L and the donor is HBV DNA-, the recipient will not receive any preventive measures; 2) If the recipient's HBsAb is more than 100 IU/L and the donor is HBV DNA+, the recipient receives antiviral treatment for 1 month; 3) If the recipient's HBsAb is between 10 and 100 IU/L, the recipient is treated with single dose HBIG and antiviral treatment for 1 month regardless of the donor's HBV DNA status; 4) If the recipient's HBsAb is less than 10 IU/L, the recipient will receive single dose HBIG and antiviral treatment for 1 month regardless of the donor's HBV DNA status.
62846675|NCT04562051||Routine prophylaxis group|Transplant centers adopted routine prophylaxis based on clinical experience
62264253|NCT01303094|OTHER|"Drug holiday therapy"|patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle and he stops the drug until progression and re-challenge
62264254|NCT00671021||1|Patients suffering from stable CAD, on chronic ASA therapy
62264255|NCT02375230|PLACEBO_COMPARATOR|Control|"Control group~Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise."
62264256|NCT02375230|ACTIVE_COMPARATOR|MR SOPA|"Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. Each participant will receive five minutes of training at the start of each shift.~The educator will teach mask adjustment, and airway reposition. If either of these first steps is unsuccessful the participant will learn about mouth and nose suction, open mouth and increase of airway pressure. All participants will also learn and practice alternative airways placement including intubation and laryngeal mask airway placement."
62264257|NCT01999803|EXPERIMENTAL|sNN0029 (VEGF)|4 µg/d of sNN0029 administered by continuous intracerebral infusion during12 weeks
62846676|NCT01397903||Group 1|"Inpatients and outpatients diagnosed with major depressive disorder as per the DSM-IV criteria who had poor disease control during antidepressant treatment and have completed 4 weeks of add-on drug therapy at enrolment in the study.~The percentage of patients with CGI-I score ≤ 2 at study Visit (4 weeks after the commencement of add-on treatment)."
62846677|NCT03328208|EXPERIMENTAL|Comfort Talk® App Group|Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.
62846678|NCT03328208|ACTIVE_COMPARATOR|White Noise Group|Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
62846679|NCT02032238|EXPERIMENTAL|laser photocoagulation with bevacizumab|Combining laser photocoagulation and Anti-VEGF Injections in a pre-defined manner
62264258|NCT01999803|PLACEBO_COMPARATOR|Placebo|Placebo administered by continuous intracerebral infusion during12 weeks
62264259|NCT01141504|PLACEBO_COMPARATOR|Placebo|Oral placebo capsules similar in color and size to the intervention
62846680|NCT02032238|NO_INTERVENTION|Bevacizumab, no laser photocoagulation|patients receive Anti-VEGF injections (Bevacizumab) only
62846681|NCT02739971|ACTIVE_COMPARATOR|Low AGEs diet|Participants randomized to this arm will receive active instruction on reducing dietary AGEs intake, in addition to standard of care dietary guidance for type 2 diabetes.
62264260|NCT01141504|ACTIVE_COMPARATOR|PeakATP 250|Oral supplement capsules containing 250 mg/day of PeakATP
62264261|NCT01141504|ACTIVE_COMPARATOR|PeakATP 400|Oral supplement capsules containing 400 mg/day of PeakATP
62264262|NCT01141504|ACTIVE_COMPARATOR|PeakATP 400 plus proprietary blend|Oral supplement capsules containing 400 mg/day of PeakATP plus a proprietary blend
62264263|NCT04705194||One stage resection|Patients that are selected for a single hepatectomy of 2 segments or more.
62620665|NCT01763203|EXPERIMENTAL|Care Management+Community Health Worker|Care management
62620666|NCT01763203|ACTIVE_COMPARATOR|Usual Care|Written materials
62846682|NCT02739971|PLACEBO_COMPARATOR|Standard of care dietary guidance|Participants randomized to this arm will only recieve standard of care dietary guidance for type 2 diabetes.
62846683|NCT03672890||Pre-Telestroke|Retrospective collection of defined metrics for all ischemic stroke patients admitted to the participating ASRH 2 years prior to implementation of an inpatient telestroke service.
62846684|NCT03672890||Post-Telestroke|Prospective collection of defined metrics for all ischemic stroke patients admitted to the participating ASRH after implementation of an inpatient telestroke service.
62264264|NCT04705194||Two stage resection|Patients that are selected for a two-stage resection, where the first stage consists of either PVE or ALPPS and the second stage is a hepatectomy of 2 or more segments.
62264265|NCT03869528|ACTIVE_COMPARATOR|5 sprays|5 sprays of 10% lignocaine administered for topical anaesthesia during flexible bronchoscopy
62264266|NCT03869528|EXPERIMENTAL|10 sprays|10 sprays of 10% lignocaine administered for topical anaesthesia during flexible bronchoscopy
62620667|NCT01981070|OTHER|Mindfulness Intervention for Parents|"The mindfulness intervention program incorporates the same structure as the Support and Information for Parents intervention (orientation session, six 2-hour sessions over 6 weeks, co-facilitated by two leaders) but different content. Instead of presentations by experts and open-ended discussions and peer support, sessions will offer experiential training in meditation practice (sitting meditation, gentle yoga, and walking meditation), as outlined in the MBCT Program (Segal et al., 2012). Each week, parents will be required to practice a mindfulness skill, and also participate in a mindful parenting exercise as homework, such as joining their child in an activity of the child's choice."
62846685|NCT00687778||1|100 patients with newly diagnosed tumors, which are often non-FDG avid or show only low intensity uptake: Soft tissue sarcomas, well-differentiated thyroid cancer, well-differentiated and bronchoalveolar lung cancer, indolent lymphomas, neuroendocrine tumors, GIST, uterine malignancies, mucin-producing cancer, teratoma, hepatoma, HCC and lobular breast carcinoma.
62846686|NCT01984658|EXPERIMENTAL|Alecsat|The ALECSAT CBMP will be administered as single dose at week 4, 7 and week 10 which is considered an appropriate time for ALECSAT CBMP to strengthen the immune system and thus have the ability to kill tumour cells. It is the aim that the patients will receive three doses during the study period however, if the patient wish and it is recommended by the investigator, patients may receive more than three doses, continuing until progression or as judged by the Investigator. Continued treatment after the 24 week study period is only possible under the condition that no safety issues have been discovered. The interval between injections for continued treatment will be decided based on e.g. tumour response and clinical examinations.
62846687|NCT02049541|EXPERIMENTAL|Treatment (PI3K inhibitor BKM120, rituximab)|Patients receive BKM120 PO daily and rituximab IV. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with asymptomatic progression may continue treatment for up to 12 months. Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline. Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission.
62846688|NCT00732446|ACTIVE_COMPARATOR|2|antibiotic /steroid combination compared with individual administration of steroid and antibiotic
62846689|NCT00732446|EXPERIMENTAL|1|combination antibiotic steroid compared with individual administration of steroid and antibiotic - new therapeutic indication
62846690|NCT00908843|EXPERIMENTAL|(I) BICARBONATE INTRAVENOUS INFUSION|Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
62846691|NCT00908843|ACTIVE_COMPARATOR|(II) ORAL SODIUM SOLUTION|Oral hydration with Sodium solution (Casen solution of rehydratation) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
62846692|NCT05744804|ACTIVE_COMPARATOR|-group of patients(75 patients) will receive low dose rivaroxaban|-group of patients(75 patients) will receive low dose rivaroxaban (rivaroxaban 2.5 mg twice daily orally) for 1 month after anterior ST-segment myocardial infarction plus dual antiplatelet therapy (acetylsalicylic acid 75 mg once daily orally and cloppe
62846693|NCT05744804|ACTIVE_COMPARATOR|control group of patients:|control group of patients: 75 Patients of anterior ST-segment myocardial infarction on dual antiplatelet therapy only
62846694|NCT01264705|EXPERIMENTAL|Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 1: Participants were administered Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily
62846695|NCT01264705|EXPERIMENTAL|Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 2: Participants were administered Bavituximab:1.0 mg/kg weekly Sorafenib: 400mg PO twice daily
62846696|NCT01264705|EXPERIMENTAL|Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 3: Participants were administered Bavituximab:3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
62846697|NCT02561338|EXPERIMENTAL|HMS5552 dose 1|75mgQD oral administration
62846698|NCT02561338|EXPERIMENTAL|HMS5552 dose 2|100mgQD oral administration
62846699|NCT02561338|EXPERIMENTAL|HMS5552 dose 3|50mgBID oral administration
62846700|NCT02561338|EXPERIMENTAL|HMS5552 dose 4|75mgBID oral administration
62846701|NCT02561338|PLACEBO_COMPARATOR|Placebo|Placebo, BID/QD oral administration
62846702|NCT03544333|EXPERIMENTAL|real transcranial magnetic stimulation|In the treatment arm, patients will receive 1Hz of repetitive transcranial magnetic stimulation (rTMS) over the left Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al.,1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
62264267|NCT03075527|EXPERIMENTAL|Tremelimumab + Durvalumab|Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression.
62264268|NCT01750385|ACTIVE_COMPARATOR|no antibiotic prophylaxis|These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
62264269|NCT01750385|ACTIVE_COMPARATOR|second-generation cephalosporin|These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
62264270|NCT03114176|EXPERIMENTAL|Divers group|Throughout each dive, subjects performed a 20-minute long mild exercise on an underwater bike. The depth of dive was set at 15 meters, where the subjects performed an activity guided by Borg CR-10 scale at intensity level 3 (25 rpm). The ascent rate was set at 10 m/min, with a decompression stop at 5 meters for 3 min, according to the US Navy Manual Diving Table. 48 h prior to the immersions, none of the participants consumed medications or dived or flew. In the first part of the experiment, all subjects performed a dive breathing Enriched Air Nitrox (EAN, 32% ppO2). Baseline clinical measurements were collected before and after this first dive in order to have a reference \[CTRL\] and to measure physiological modifications due to immersion \[NTRX\]. After twenty days of no diving activity, subjects were engaged in a KD for seven days. At the end of this period, subjects performed a single immersion breathing EAN. The measures were performed after this single dive \[KETO-NTRX\]
62264271|NCT02855528|EXPERIMENTAL|Reduction of radiation dose and diagnostic accuracy|Reduction of radiation dose during coronary artery calcium scoring with the use of a tin filter system.
62264272|NCT00558870|ACTIVE_COMPARATOR|Morphine Only|"Morphine - Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain."
62264273|NCT00558870|ACTIVE_COMPARATOR|Morphine + Methadone|"Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain.~1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)"
62846703|NCT03544333|PLACEBO_COMPARATOR|sham transcranial magnetic stimulation|In the comparator arm, patients will receive no stimulation. The TMS coil adjusted to the patients head will not be plugged into the TMS machine and can thus not have an effect on the brain. Yet, patients will hear the same noises from a coil that is plugged in, see the TMS machine running, and area Spt localized via baseline structural imaging and our Localite TMS navigation system.
62846704|NCT01259232||schizophrenia patients,untreated|
62846705|NCT01259232||schizophrenia relatives|
62846706|NCT01259232||controls|
62846707|NCT02640339||Parkinson Disease|Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually, with alpha-synuclein deposits in neurons which aggregate into Lewy bodies.
62846708|NCT02640339||Mutiple system atrophy|is a degenerative neurological disorder. MSA is associated with the degeneration of nerve cells in specific areas of the brain. This cell degeneration causes problems with movement, balance, and autonomic functions of the body such as bladder control or blood-pressure regulation. Neuronal death probably occurs as a consequence of alpha-synuclein aggregation in oligodendroglia.
62846709|NCT02640339||REM sleep behavior disorder|a sleep disorder in which you physically act out vivid, often unpleasant dreams with vocal sounds and sudden, often violent arm and leg movements
62264274|NCT01423409|ACTIVE_COMPARATOR|pictorial VAS|VAS with colours and 6 expressive faces
62264275|NCT01423409|SHAM_COMPARATOR|usual VAS|VAS
62846710|NCT02640339||dementia with Lewy bodies|"causes a progressive decline in mental abilities.~It may also cause visual hallucinations, which generally take the form of objects, people or animals that aren't there. This can lead to unusual behavior such as having conversations with deceased loved ones.~Another indicator of Lewy body dementia may be significant fluctuations in alertness and attention, which may include daytime drowsiness or periods of staring into space. And, like Parkinson's disease, Lewy body dementia can result in rigid muscles, slowed movement and tremors."
62846711|NCT02640339||Pure autonomic failure|Pure autonomic failure is dysfunction of many of the processes controlled by the autonomic nervous system, such as control of blood pressure•Blood pressure may decrease when people stand, and they may sweat less and may have eye problems, retain urine, become constipated, or lose control of bowel movements
62264276|NCT05142527|EXPERIMENTAL|High Dose IM injection of active drug or Placebo (Phase 2)|"Subjects will receive a high dose IM injection of either active drug or placebo.~Approximately 300 subjects will receive active drug and approximately 150 subjects will receive placebo in the Phase 2 segment."
62846712|NCT02640339||Healthy controls|Healthy normals with no neurological involvement
62060316|NCT03682705|EXPERIMENTAL|ELS 5 mg/UPA placebo|5 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
62060317|NCT03682705|EXPERIMENTAL|UPA 15 mg/ELS placebo|15 mg film-coated upadacitinib tablet once a day by mouth for 12 weeks; placebo capsule for elsubrutinib once a day by mouth for 12 weeks
62060318|NCT05412810||Oxygen exposures|mechanically ventilated patients with atleast 1.5 hours of FiO2 exposure of 50% or more
62264277|NCT05142527|EXPERIMENTAL|High Dose IM injection of active drug or Placebo (Phase 3)|"Subjects will receive a high dose IM injection of either active drug or placebo.~Approximately 3000 subjects will receive active drug and approximately 1000 subjects will receive placebo in the Phase 3 segment"
62264278|NCT04199637|EXPERIMENTAL|Experimental group|Experimental group is provided therapeutic video games
62264279|NCT04199637|NO_INTERVENTION|Control group|Control group is provided regular care
62846713|NCT06186193||Mindful Interoceptive Exposure|Mindful Interoceptive Exposure Phone-based interoceptive exposure task as attention exercise with chronic low back pain
62846714|NCT00442364|EXPERIMENTAL|1|Polidocanol (1%) Microfoam (Varisolve)
62060319|NCT02352441|EXPERIMENTAL|Implementation Intentions|This group will receive training in Implementation Intentions during 3 sessions, 1 day/week, over 3 weeks. They will receive usual care through the standard program, 1 day/week during these 3 weeks.
62448060|NCT03925220|ACTIVE_COMPARATOR|Nutrition, Physical Activity, and Weight Talk Comparison|"For the comparison condition, after the baseline assessment, parents will receive a handbook on nutrition and physical activity entitled: Healthy Eating \& Physical Activity Across Your Lifespan: Helping your Child - Tips for Parents. This handbook, which is adapted from the handbook developed by the National Institute of Diabetes and Digestive and Kidney Diseases and the Weight Control Information Network, is approximately the same length as the intervention handbook and is available in English and Spanish. It is given with an insert on reducing weight talk and weight teasing in the family. Parents will also receive a magnet with a message about nutrition and exercise. To control for contact time, these participants will meet live with a study staff member two weeks after receiving the handbook, complete an action plan, and have the 30-minute call, as well as receive two text messages twice per week for 13 weeks with tips and reminders from the comparison handbook and insert."
62264280|NCT02888093|EXPERIMENTAL|Absorbable|Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)
62846715|NCT01374230|EXPERIMENTAL|E1 Tibial bearing|All patients undergoing primary total knee replacement surgery will receive a tibial bearing made of E1 polyethylene, which is the material being monitored in this study.
62264281|NCT02888093|EXPERIMENTAL|Permanent|Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)
62264282|NCT02810756|EXPERIMENTAL|Treated patients|
62264283|NCT02572752|EXPERIMENTAL|Treatment T (Test)|Nintedanib, 1 capsule, oral with 240 mL of water
62846716|NCT03865381|OTHER|Virtual Diabetes Clinic|The Onduo Virtual Diabetes Clinic (VDC) is the suite of diabetes management services including remote monitoring, diet/lifestyle coaching, medication management accessed via Onduo App and partner apps. Subjects will engage with a Care Lead through the App and will have a medical consultation via telemedicine with an Onduo VDC Physician.
62846717|NCT03807375|OTHER|CPAP|During preoxygenation, the ventilator device will be placed in spontaneous mode and set as CPAP: 5 cmH2O. The process will continue until the end-tidal O2 concentration ≥ 90% is removed.
62846718|NCT03807375|NO_INTERVENTION|standard preoxygenation|During the preoxygenation, the ventilator device will be put in spontaneous mode and the procedure will continue until the End-tidal O2 concentration ≥90% is removed without additional pressure.
62846719|NCT01900418|ACTIVE_COMPARATOR|Walking|Walk with Ease
62060320|NCT02352441|NO_INTERVENTION|Usual Care|This group will participate in the usual group intervention provided to Service members experiencing executive dysfunction associated with mild traumatic brain injury, 2 days / week during 3 weeks.
62846720|NCT01900418|NO_INTERVENTION|Wait list control|Wait list control receiving the active intervention 6 weeks later.
62846721|NCT01284036|OTHER|PF-05230905|9 subjects will participate in each dose cohort. 6 subjects will receive investigational product (PF-05230905) and 3 subjects will receive placebo
62846722|NCT01819532|ACTIVE_COMPARATOR|Immediate umbilical cord clamping|The umbilical cord will be clamped immediately after delivery.
62846723|NCT01819532|EXPERIMENTAL|Cord milking group|"The umbilical cord will be milked in direction towards neonate 4 times over the course of 10 minutes."
62060321|NCT02081235||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease during 2012 in Samsung Medical Center
62060322|NCT03685396|EXPERIMENTAL|Test Group|In the Test Group venous blood sampling was done in order to prepare PRF membranes used to cover the donor site of the connective tissue graft.
62264284|NCT02572752|EXPERIMENTAL|Treatment R - 1 (Reference)|Nintedanib, 2 capsules, oral with 240 mL of water
62264285|NCT02572752|EXPERIMENTAL|Treatment R - 2 (Reference)|Nintedanib, 2 capsules, oral with 240 mL of water
62264286|NCT04012047|ACTIVE_COMPARATOR|Levcromakalim|
62264287|NCT04012047|PLACEBO_COMPARATOR|Saline|
62264288|NCT06450652|EXPERIMENTAL|Chinese Herbal Medicine granules|
62264289|NCT03825874||amikacin IV|Febrile urinary tract infection treated with amikacin IV
62060323|NCT03685396|ACTIVE_COMPARATOR|Control Group|In Control Group hemostatic agents with oxidized and regenerated cellulosa were used to cover the donor site.
62060324|NCT01100255|ACTIVE_COMPARATOR|Group A|0.5mg/kg IV ketamine infusion over 40 minutes then IV saline infusion over 40 minutes
62060325|NCT01100255|ACTIVE_COMPARATOR|Group B|IV saline infusion over 40 minutes then 0.5mg/kg IV ketamine infusion over 40 minutes
62060326|NCT00886067|EXPERIMENTAL|2-[18F]-F-A85380|Single microdose
62060327|NCT00886067|EXPERIMENTAL|AZD1446|Single oral administration
62264290|NCT03825874||Other antibiotics|Febrile urinary tract infection treated with other antibiotic, according to the recommendations: ceftriaxone or cefixime
62264291|NCT03572985|OTHER|Blood alcohol concentration (BAC) level 0.025 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.025%
62264292|NCT03572985|OTHER|BAC level 0.05 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.05%
62264293|NCT03572985|OTHER|BAC level 0.09 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.09%
62264294|NCT03572985|OTHER|BAC level 0 %|Drink beverages containing non alcohol
62264295|NCT04718974|EXPERIMENTAL|"intervention  Call for life- mHealth tool with standard of care for PLHIV"|"The system has options to either use interactive voice response or short message service and the user has to make a choice, get a secret pin code which ensures privacy to end user.~The mHealth tool/system offers personalised pill reminder calls, health tip messages, clinic appointment reminders and remote symptom reporting"
62264296|NCT04718974|NO_INTERVENTION|"Standard of care usual care"|"Standard~• Care and support for people living with HIV, and the first line ART regimen is based on the Apr 2018, consolidated guidelines for prevention and treatment of HIV in Uganda (MoH, 2018), and will also follow the healthcare services package for PLHIV including the Adult Care and Treatment Package."
62264297|NCT05284942|EXPERIMENTAL|Mycophenolate mofetil|Mycophenolate mofetil oral 500mg twice a day from baseline to week 108
62448061|NCT04043013|ACTIVE_COMPARATOR|Mini-Taurus® (Rocky Mountain©) Brackets|"Brackets Mini-Taurus® (Rocky Mountain©) with:~ORTHODONTIC BRACKET PRESCRIPTION Canines 0º First Premolar 0º Second Premolar 0º First Molar 0º"
62448062|NCT04043013|ACTIVE_COMPARATOR|Smart Clip® SL3 High Torque (3M Unitek©)|"Brackets Smart Clip® SL3 High Torque (3M Unitek©) with:~ORTHODONTIC BRACKET PRESCRIPTION~Canines +6º First Premolar -4º Second Premolar -4º First Molar -14º"
62448063|NCT04043013|ACTIVE_COMPARATOR|Tip-Edge Plus® (TP Orthodontics©)|"Brackets Tip-Edge Plus® (TP Orthodontics©) with:~ORTHODONTIC BRACKET PRESCRIPTION~Canines -4º First Premolar -7º Second Premolar -7º First Molar 0º -14º -11º -14º"
62846724|NCT05749432|EXPERIMENTAL|Hemay181|"Part one: Dose Escalation Group Hemay181 will be injected in doses of 4.5 mg/m\^2, 9.0 mg/m\^2, and 18 mg/m\^2 until any drug-related toxicity of grade 2 or higher is observed in any dose group. Next, Hemay181 will be injected in doses of 36mg/m\^2, 60mg/m\^2, 90mg/m\^2, 120mg/m\^2, 150mg/m\^2, 180mg/m\^2, 210mg/m\^2 until there are two cases of dose-limiting toxicity in a dose group.~Part two: Extension Group Hemay181 will be injected in the highest three dose groups that had been assessed until disease progression."
62060328|NCT00076791|ACTIVE_COMPARATOR|1|Each participant in Cohort 1 received a single 600 mg oral dose of TDF at the start of active labor or 4 hours prior to C-section, with concurrent administration of standard intravenous zidovudine (ZDV) prophylaxis and/or other antiretrovirals prescribed by her physician. The infants from Cohort 1 received only the standard 6 weeks of oral ZDV prophylaxis postpartum.
62264298|NCT01858077|ACTIVE_COMPARATOR|ABSORB BVS™|Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
62264299|NCT01858077|ACTIVE_COMPARATOR|XIENCE™|XIENCE PRIME everolimus eluting coronary stent system and the XIENCE Xpedition everolimus eluting coronary stent system
62264300|NCT02970890|PLACEBO_COMPARATOR|Placebo group|Subjects received placebo therapy. The placebo Portable Pain Away™ device was identical to the active device, displayed the same settings and emitted the same sound regardless of the comparator.
62264301|NCT02970890|ACTIVE_COMPARATOR|PBMT group|Subjects received active photobiomodulation therapy (PBMT). The active Portable Pain Away™ device was identical to the placebo device, displayed the same settings and emitted the same sound.
62264302|NCT04827784|EXPERIMENTAL|Auriculotemporal Nerve Block Administration|A total of 3 doses of Auriculotemporal Nerve Block (ATNB) were administered to involved participants. Local anesthetic solutions containing Articaine Hydrochloride (80 mg / 2 ml) and epinephrine bitartrate (0.02 mg / 2 ml) were used for ATNB application. The injections were repeated on follow-up visits in the first and fourth weeks. The maximal mouth opening amounts, pain intensity values (via VAS scale), and self-reported outcomes were evaluated at the pre-injection, first week, fourth week, and sixth-month follow-up controls.
62264303|NCT01577186|EXPERIMENTAL|Paliperidone Extended Release (ER)|
62264304|NCT05435651|EXPERIMENTAL|Multitask game-based digital therapy|Multitask game-based digital therapy group will be asked to practice multitask-game on the system for approximately 25 minutes/day at least 5 days a week. Compliance will be monitored electronically.
62264305|NCT05435651|ACTIVE_COMPARATOR|Schulte Grid digital game|Schulte Grid digital game group will be asked to practice Schulte Grid digital game on the system for approximately 25 minutes/day at least 5 days a week. Compliance will be monitored electronically.
62264306|NCT03685266||Pediatric Residents|Participating pediatric residents from first postgraduate year (PGY-1) through third postgraduate year (PGY-3) will be observed over a 12 month timeframe.
62264307|NCT01698164|ACTIVE_COMPARATOR|estradiol plus MPA|"1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 4mg medroxyprogesterone acetate, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.~estradiol valerate, 1mg\*21/box medroxyprogesterone acetate, 2mg\*100/bottle"
62264308|NCT01698164|EXPERIMENTAL|estradiol plus progesterone|"1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 200mg progesterone capsule, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.~estradiol valerate, 1mg\*21/box progesterone capsule, 100mg\*6/box"
62264309|NCT01698164|EXPERIMENTAL|Ximingting tablet|1 tablet of cimicifuga rhizoma extract, tid 100mg\*15\*2/box The anticipated duration is 2 years.
62264310|NCT05347160|EXPERIMENTAL|calcium hydroxide : group 1|Immature permanent molars with immature root filled by ca(oh)2
62264311|NCT05347160|EXPERIMENTAL|biodentine : group 2|clinically and radiographically evaluate BIODENTINE effect on permanent molars with immature root
62264312|NCT05347160|EXPERIMENTAL|platelet rich fibrin : group 3|filling of permanent molars with immature root by platelet rich fibrin
62448064|NCT04043013|ACTIVE_COMPARATOR|Victory® (3M Unitek©)|"Brackets Victory® (3M Unitek©) with:~ORTHODONTIC BRACKET PRESCRIPTION~Canines 0º First Premolar -7º Second Premolar -7º First Molar -14º"
62448065|NCT04350567|EXPERIMENTAL|Intervention|
62448066|NCT04389879|EXPERIMENTAL|CAD/CAM|CAD/CAM custom-cut Nickel Titanium (NiTi) FR
62448067|NCT04389879|ACTIVE_COMPARATOR|Conventional multistranded|Conventional multistranded Stainless Steel (SS) FR
62448068|NCT02565420|ACTIVE_COMPARATOR|Lactated Ringer's solution|During the perioperative period of the colorectal, orthopedic or similar surgery the patient will receive an intervention of Lactated Ringer's solution fluids.
62060329|NCT00076791|ACTIVE_COMPARATOR|2|Mothers in Cohort 2 will receive a single dose of 900 mg of TDF combined with 600 mg emtricitabine, along with standard ZDV prophylaxis and/or other antiretrovirals prescribed by her physician. Infants will receive a single dose of TDF at 4 mg/kg combined with 3 mg/kg emtricitabine as soon as possible after delivery and within 6 hours of age as well as the standard 6 weeks of oral ZDV prophylaxis after birth.
62060330|NCT02701335|EXPERIMENTAL|Experimental group|Neural mobilization and standardized exercise . 12 sessions over 4 weeks (3 sessions per week).
62060331|NCT02701335|ACTIVE_COMPARATOR|Control group|Gloreha device and standardized exercise. 12 sessions over 4 weeks (3 sessions per week).
62060332|NCT04871035||Immunoadsorption|
62060333|NCT04871035||Plasma Exchange|
62060334|NCT04889235||Sarcopenia|Sarcopenia will be defined as either low estimated muscle mass measured by CT-muscle volumetry or reduced muscle function measured by handgrip strength, or reduced physical condition as defined by the European Working Group on Sarcopenia in Older People (EWGSOP)
62060335|NCT04889235||No Sarcopenia|Sarcopenia will be defined as either low estimated muscle mass measured by CT-muscle volumetry or reduced muscle function measured by handgrip strength, or reduced physical condition as defined by the European Working Group on Sarcopenia in Older People (EWGSOP)
62060336|NCT02635074|EXPERIMENTAL|Treatment (ibrutinib, idarubicin, cytarabine)|"INDUCTION: Ibrutinib daily on days 1 to 21, idarubicin intravenously (IV) over 15 minutes on days 1 to 3 and cytarabine IV continuously on days 1 to 4.~CONSOLIDATION: Patients achieving CR or CRi may receive ibrutinib daily on days 1 to 21, idarubicin IV over 15 minutes on days 1 to 2 and cytarabine IV continuously on days 1 to 3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients maintaining a CR/CRi may receive ibrutinib daily on days 1 to 28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
62060337|NCT05300802|PLACEBO_COMPARATOR|Group A|Ringer acetate
62060338|NCT05300802|EXPERIMENTAL|Group B|Priming Dexmedetomidine 1 mcg/kg, Intravenous Ringer acetate
62060339|NCT05300802|EXPERIMENTAL|Group C|Priming Dexmedetomidine 0.5 mcg/kg, Intravenous Dexmedetomidine 0.25 mcg/kg/hour
62060340|NCT06431438|PLACEBO_COMPARATOR|0.5mg single-dose|Ten subjects were enrolled, of whom 8 received the trial drug and 2 received placebo.
62060341|NCT06431438|PLACEBO_COMPARATOR|1.0mg single-dose|Ten subjects were enrolled, of whom 8 received the trial drug and 2 received placebo.
62264313|NCT02115204|EXPERIMENTAL|EC-Doc|4 cycles epirubicin + docetaxel (90/600) i.v., q = 3 weeks, followed by 4 cycles docetaxel (100) i.v., q = 3 weeks
62264314|NCT02115204|ACTIVE_COMPARATOR|CMF/CEF|6 cycles cyclophosphamide, methotrexate, 5-fluorouracil (CMF) (600/40/600) i.v., day 1 + 8, q = 4 weeks or 6 cycles cyclophosphamide, epirubicin, 5-fluorouracil (CEF) (500/100/500) i.v., day 1, q = 3 weeks
62264315|NCT02323269||Treatment naive to dimethyl fumarate|Participants who are prescribed dimethyl fumarate as their initial therapy will receive 120 mg tablet administered orally twice a day for 7 days, then switch to maintenance dose of 240 mg tablet twice daily.
62264316|NCT02323269||Switch to dimethyl fumarate|Participants who are prescribed dimethyl fumarate after suboptimal response to IFN or GA will receive 120 mg tablet administered orally twice a day for 7 days, then switch to maintenance dose of 240 mg tablet twice daily.
62264317|NCT03609697|EXPERIMENTAL|Community-based lifestyle intervention|Participants will attend 7 community-based group intervention sessions plus 2 individual face-to-face dietician consultation sessions during the first 6 months, followed by a 6-month maintenance phase which they will receive monthly phone support from the research team.
62264318|NCT03609697|OTHER|Minimal intervention (SMS intervention)|Participants will receive one SMS per month during the first 6 months, followed by a 6-month maintenance phase which participants will receive one SMS every 2 months.
62264319|NCT04762537|ACTIVE_COMPARATOR|Standard Induction Method|The Standard Method (13-day long) includes 5-days of buprenorphine taper followed by 7-day washout period
62448069|NCT02565420|PLACEBO_COMPARATOR|normal saline|During the perioperative period of the colorectal, orthopedic or similar surgery the patient will receive an intervention of normal saline solution.
62448070|NCT00475020|EXPERIMENTAL|Fludarabine + Busulfan + Thymoglobulin|Fludarabine 40 mg/m\^2 by vein daily over 1 hour x 4 days. Busulfan test dose = 32 mg/m\^2 by vein x 1 day; 100 mg/m\^2 by vein daily over 3 hours x 4 days. Thymoglobulin 2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor.
62846725|NCT04978103|EXPERIMENTAL|Single Arm|Hundred postmenopausal women were enrolled and received therapeutic dose of Gum Arabic (0.5 gm/kg/day) and followed for 12 weeks then the intended outcomes will be compared before and after completion of the study
62846726|NCT03578952|EXPERIMENTAL|Pure AR|Patients with symptomatic severe aortic valve regurgitation without severe aortic stenosis requiring aortic valve replacement.
62060342|NCT06431438|OTHER|Food impact group|Sixteen subjects were enrolled and all received the trial drug.
62060343|NCT06431438|PLACEBO_COMPARATOR|0.1mg single-dose|Ten subjects were enrolled, of whom 8 received the trial drug and 2 received placebo.
62060344|NCT06431438|PLACEBO_COMPARATOR|0.3mg single-dose|Ten subjects were enrolled, of whom 8 received the trial drug and 2 received placebo.
62060345|NCT06431438|ACTIVE_COMPARATOR|Drug interaction group|Sixteen subjects were enrolled and all received the trial drug.
62060346|NCT06431438|PLACEBO_COMPARATOR|0.1mg multiple dosing|Ten subjects were enrolled, of whom 8 received the trial drug and 2 received placebo.
62060347|NCT06431438|PLACEBO_COMPARATOR|0.3mg multiple dosing|Ten subjects were enrolled, of whom 8 received the trial drug and 2 received placebo.
62060348|NCT06431438|PLACEBO_COMPARATOR|0.5mg multiple dosing|Ten subjects were enrolled, of whom 8 received the trial drug and 2 received placebo.
62060349|NCT06431438|PLACEBO_COMPARATOR|0.2mg multiple dosing|Ten subjects were enrolled, of whom 8 received the trial drug and 2 received placebo.
62060350|NCT06214078|EXPERIMENTAL|NMN group|Patients in this group will take nicotinamide mononucleotide capsules orally twice daily for 8 weeks, one capsule per time, each actually containing 250mg of nicotinamide mononucleotide.
62060351|NCT06214078|PLACEBO_COMPARATOR|placebo group|Patients in this group will receive 1 placebo capsule orally twice daily for 8 weeks.
62060352|NCT01450202|PLACEBO_COMPARATOR|Air insufflation, colonoscopy, esophagogastroduodenoscopy|
62060353|NCT01450202|ACTIVE_COMPARATOR|CO2 insufflation, colonoscopy, esophagogastroduodenoscopy|
62264320|NCT04762537|EXPERIMENTAL|Rapid Induction Method|The Rapid Method includes one day of buprenorphine followed by a day of washout and 3-4 days of oral naltrexone titration with adjunctive medications
62264321|NCT03854708|EXPERIMENTAL|3 pmol/kg*min pancreatic polypeptide|3 pmol/kg\*min of pancreatic polypeptide was intravenously infused.
62264322|NCT03854708|EXPERIMENTAL|10 pmol/kg*min pancreatic polypeptide|10 pmol/kg\*min of pancreatic polypeptide was intravenously infused.
62264323|NCT03854708|PLACEBO_COMPARATOR|Placebo|0.9 % saline solution was intravenously infused.
62264324|NCT06073600|EXPERIMENTAL|First group of healthy volunteers|The first group of healthy volunteers, defined by randomization
62264325|NCT06073600|ACTIVE_COMPARATOR|Second group of healthy volunteers|The second group of healthy volunteers, defined by randomization
62060354|NCT02634840|EXPERIMENTAL|Surgical intervention|"Patients receiving our modified bilateral sagittal split osteotomy procedure during orthognathic surgery, intervention arm in prospective cohort study"
62060355|NCT01379027|NO_INTERVENTION|a treatment as usual (TAU) control condition|Participants will receive recruitment information, go on the study website to enroll and complete assessments over the study web site but will not receive the study intervention.
62060356|NCT01379027|EXPERIMENTAL|Pure self-help Internet CBT for depression|Participants will receive TAU plus access to the study website for the self-help Internet CBT for depression, consisting of access to the Internet site without any contact with therapist
62060357|NCT01379027|EXPERIMENTAL|Guided self-help Internet CBT|Participants will receive TAU plus Guided self-help Internet CBT, consisting of access to the Internet site plus brief, periodic telephone contacts with therapists
62060358|NCT01379027|EXPERIMENTAL|Stepped-Care Internet CBT condition|This consists of a Stepped-Care Internet CBT condition, starting with TAU + Pure self-help CBT and progressing to Guided self-help CBT if adequate progress is not observed early on
62060359|NCT02376621|ACTIVE_COMPARATOR|PronovaPure 150:500 triglycerides|3 × PronovaPure 150:500 triglycerides (TG) European Union (EU)
62060360|NCT02376621|ACTIVE_COMPARATOR|Pronovum PRF-048|3 × Pronovum PRF-048
62060361|NCT02376621|ACTIVE_COMPARATOR|Pronovum PRF-037|3 × Pronovum PRF-037
62060362|NCT02376621|ACTIVE_COMPARATOR|PronovaPure 500:200 TG|3 × PronovaPure 500:200 TG EU
62060363|NCT02376621|ACTIVE_COMPARATOR|Pronovum PRF-047|3 × Pronovum PRF-047
62060364|NCT06624982||Non-molar sites with immediate post-extraction ridge expansion|Non-molar sites with an increase of buccolingual bone width immediately after tooth extraction compared to pre-extraction.
62264326|NCT01346033||Those with Type 2 diabetes|All subjects have been diagnosed with type 2 diabetes.
62264327|NCT04004637|EXPERIMENTAL|CD7 CAR-T cells Infusion|
62448071|NCT03881813|EXPERIMENTAL|Fiber reinforced composite retainers|Fiber reinforced composite retainers were inserted in group 1 and were evaluated after every 3 months for a follow up period of 3 months.
62060365|NCT06624982||Non-molar sites with no immediate post-extraction ridge width change|Non-molar sites without a change in buccolingual bone width immediately after tooth extraction compared to pre-extraction.
62060366|NCT06624982||Molar sites with immediate post-extraction ridge expansion|Molar sites with an increase of buccolingual bone width immediately after tooth extraction compared to pre-extraction.
62060367|NCT06624982||Molar sites with no immediate post-extraction ridge width change|Molar sites without a change in buccolingual bone width immediately after tooth extraction compared to pre-extraction.
62264328|NCT04307992|EXPERIMENTAL|Intervention|Device: ANEUFIX
62264329|NCT00892385|EXPERIMENTAL|Non-CNS Disease|A traditional 3 + 3 dose escalation design will be implemented. Successive cohorts of participants (3 participants/cohort) will be entered sequentially to each dose level. If 0/3 participants at a dose level experience dose limiting toxicity (DLT) new participants may be entered at the next higher dose level. If 1 participant has a DLT, 3 more will be enrolled at the same dose level. If the 1st participant in the expanded cohort (4th at the given DL), experiences no DLT, the remaining 2 participants can start treatment. If 2 or more experience DLT in the first cycle, no further participants are started at that dose and the MTD is the highest dose level in which \<2 (of 6) participants develop DLT. If the final dose level is deemed the MTD, 6 participants will be treated at this dose level even if a DLT has not been observed.
62448072|NCT03881813|EXPERIMENTAL|Multistranded stainless steel retainers|Multistranded stainless steel retainers were inserted in group 2 and were evaluated after every 3 months for a follow up period of 3 months.
62448073|NCT06327295|EXPERIMENTAL|ATB1651-102 Cohort 1|The planned ATB1651 dose of 3% solution to each infected toenail once daily for 12 weeks (follow up for 24 weeks) Twenty-five participants are expected to enroll per cohort.
62448074|NCT06327295|EXPERIMENTAL|ATB1651-102 Cohort 2|The planned ATB1651 dose of 3% solution to each infected toenail once daily for 20 weeks follow up for 16 weeks) Twenty-five participants are expected to enroll per cohort.
62846727|NCT00539942|ACTIVE_COMPARATOR|Intermittent compression devices (ICD)|All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
62448075|NCT06327295|EXPERIMENTAL|ATB1651-102 Cohort 3|"The planned ATB1651 dose of 3% solution to each infected toenail twice daily for 12weeks follow up for 24 weeks).~Twenty-five participants are expected to enroll per cohort."
62846728|NCT00539942|EXPERIMENTAL|Arixtra (fondaparinux sodium)|Patients randomized to treatment arm will initiate Arixtra (fondaparinux sodium) treatment on post-operative day 1 and continue treatment until post-operative day 22 (21 consecutive days). Subjects randomized to this arm are to receive the standard prophylactic dose for major abdominal surgery of 2.5 mg/day for a total of 21 consecutive days (including hospitalization time and after hospital discharge).
62846729|NCT02067676|EXPERIMENTAL|CJCV1 2 μg / Alum 0 μg (1A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 2 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
62846730|NCT02067676|EXPERIMENTAL|CJCV1 2 μg / Alum 125 μg (1B)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 2 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
62846731|NCT02067676|EXPERIMENTAL|CJCV1 5 μg / Alum 0 μg (2A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 5 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
62846732|NCT02067676|EXPERIMENTAL|CJCV1 5 μg / Alum 125 μg (2B)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 5 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
62264330|NCT00892385|EXPERIMENTAL|CNS Disease|A traditional 3 + 3 dose escalation design with successive cohorts of 3 participants will be entered sequentially to each dose level. If 0/3 participants experience DLT, new participants may be entered at the next higher dose level. If 1 participant has a DLT, 3 more will be enrolled at the same dose level. If the 1st participant in the expanded cohort (4th at the given DL), experiences no DLT, the remaining 2 participants can start treatment. If 1/3 participants experience a non-CNS DLT in Cohort B dose level 6, dose escalation will continue to dose level 7, as 3 subjects have already been treated in Cohort A dose level 6 and 7 subjects in Cohort A dose level 7, none of whom experienced non-CNS toxicities. If 2 or more experience DLT in cycle 1, no more participants are started at that dose and the MTD is the highest dose where \<2/6 participants develop DLT. If the final dose level is deemed the MTD, 6 participants will be treated at this dose level even if no DLT has been observed.
62264331|NCT02536989|EXPERIMENTAL|1|receive high dose PPI treament with intravenous omeprazole 80 mg stat and then 8mg/hr infusion for 3 days
62264332|NCT02536989|ACTIVE_COMPARATOR|2|receive usual dose PPI treatment with ntravenous omeprazole 40 mg stat and then 40 mg q12h for 3 days
62264333|NCT04192487|EXPERIMENTAL|Healthy Volunteers (HIV-negative)|Drug: crofelemer delayed-release tablets, 125 mg BID x 30 days
62846733|NCT02067676|EXPERIMENTAL|CJCV1 10 μg / Alum 0 μg (3A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 10 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
62846734|NCT02067676|EXPERIMENTAL|CJCV1 10 μg / Alum 125 μg (1A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 10 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
62264334|NCT04192487|EXPERIMENTAL|HIV+ Patients (Fully Suppressed, Viral Load < 50c/mL)|Drug: crofelemer delayed-release tablets, 125mg BID x 30 Days
62264335|NCT04192487|EXPERIMENTAL|HIV+ Patients (Not fully suppressed viral load > 1000c/mL|Drug: crofelemer delayed-release tablets, 125mg BID x 30 Days
62264336|NCT01383577|EXPERIMENTAL|Single hemorrhoidal ligation|Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each session of treatment.
62264337|NCT01383577|EXPERIMENTAL|Triple hemorrhoidal ligation|The three major hemorrhoidal groups are ligated in the first session of ligation. The three following monthly appointments of patients of this arm are for sham hemorrhoidal ligations and final revision.
62264338|NCT00916266|EXPERIMENTAL|stem cell transplantation|Patients with refractory temporal lobe epilepsy that are transplanted with autologous bone marrow stem cells in order to provide seizure control.
62448076|NCT06327295|EXPERIMENTAL|ATB1651-102 Cohort 4|"The planned ATB1651 dose of 5% solution to each infected toenail once daily for 12weeks follow up for 24 weeks).~Twenty-five participants are expected to enroll per cohort."
62448077|NCT06327295|PLACEBO_COMPARATOR|Placebo|"Matching placebo to the IP per cohort.~Five participants are expected to be enrolled per cohort."
62448078|NCT04076358|EXPERIMENTAL|Tab-CBI|The Tab-CBI group receives a tablet preloaded with the Tab-CBI application and an accelerometer. During the study period, the participants have four weekly educational sessions plus one booster session by the research assistant through a videoconferencing tool. The educational modules were developed based on the principles of cognitive behavioral therapy. The key elements of the modules include activity-pacing, adjustment of goal-setting to the current physical condition, setting priorities and structured planning of a simple walking activity and time off, and cognitive restructuring of activity demands (see attached, outline of education modules).
62620668|NCT01981070|ACTIVE_COMPARATOR|Support and Information for Parents|This 6-week program includes orientation session, six 2-hour sessions, held weekly. Parents will be provided with information on existing services in the region, and strategies to be strong advocates and plan and access services for their child. Each session will include a presentation by an expert, with a question answer period, a break, and facilitated discussion with other parents. The sessions will be co-facilitated by clinicians from the Disability Services Ontario (DSO) and Centre for Addiction and Mental Health (CAMH).
62060368|NCT00723099|EXPERIMENTAL|Treatment (chemotherapy, transplant)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1-2 hours on day -6. Patients undergo a lower dose of TBI on day -1.~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo donor umbilical cord blood infusion on day 0.~IMMUNOSUPRESSIVE THERAPIES: Patients receive cyclosporine IV over 1 hour every 8-12 hours on days 0 to +180 and mycophenolate mofetil IV or PO every 8 hours on days -3 to +96."
62060369|NCT00884754|EXPERIMENTAL|rigid GlideScope Specific Stylet|
62620669|NCT02301819|ACTIVE_COMPARATOR|Invasive|Immediate veno-arterial extracorporeal membrane oxygenation (ECMO)
62060370|NCT00884754|ACTIVE_COMPARATOR|90º curvature, malleable stylet|
62060371|NCT05464381|EXPERIMENTAL|Verum|
62060372|NCT05464381|PLACEBO_COMPARATOR|Placebo|
62060373|NCT02782884||Outpatient general surgery operation|Patients undergoing outpatient general surgical operations They will be given a specified number of narcotic pills based on our retrospective analysis of patient post-operative opioid use
62060374|NCT02782884||Inpatient general surgical patients|Inpatients who are being discharged They will be given a specified number of narcotic pills based on the number of pills they took in the 24 hrs prior to discharge
62060375|NCT04130139||residents|obstetrics and gynecology residents from France with or without previous experience in oocyte pick up
62060376|NCT04376801||Tension-band Fixation Group|Patients with distal humerus fractures admitted to our hospital in 2012-2017 who had been performed open reduction and internal fixation through olecranon osteotomy approach were selected. All patients were devided into two groups by different fixation method. Patients who had been performed tension-band fixation after olecranon osteotomy were classified into Tension-band Fixation Group.
62264339|NCT02783703|EXPERIMENTAL|MCT|Medium chain triglyceride (MCT) oil ingested daily for 6 weeks
62264340|NCT04870242||pediatric surgery patients|all pediatric surgery patients, aged from 6 months up to 18 years, underwent surgery between January 2017 to December 2018
62448079|NCT04076358|NO_INTERVENTION|Usual Care|The usual care group receives Arthritis related fatigue management which are currently offered to the participants at the recruitment sites. Participant are also instructed to maintain usual activity during the study period. The control group participants also receive an accelerometer to count steps, but without a tablet.
62264341|NCT01851681|ACTIVE_COMPARATOR|Amoxicillin taken 2 g preoperatively|2 g amoxicillin 1h preop then placebo tid x 7 days
62448080|NCT02442856|EXPERIMENTAL|Intervention|We will measure dCA with both TCD and DCS during acute changes in mean arterial pressure using thigh cuff deflation techniques in vascular risk factor subjects. Measurements will be compared between TCD and DCS in order to validate DCS as a tool to measure dCA in this population.
62620670|NCT02301819|ACTIVE_COMPARATOR|Conservative|Early conservative therapy according to standard practice
62448081|NCT02563522|ACTIVE_COMPARATOR|Active|Engensis (VM202) + standard of care
62448082|NCT02563522|PLACEBO_COMPARATOR|Control|Placebo (VM202 Vehicle) + standard of care
62620671|NCT02130700|EXPERIMENTAL|Chemotherapy-Naive Patients|VT-464: given orally twice daily in 28-day cycles
62620672|NCT02130700|EXPERIMENTAL|Previous Chemotherapy Patients|VT-464: given orally twice daily in 28-day cycles
62620673|NCT02130700|EXPERIMENTAL|AR Positive 1 - 9% TNBC|VT-464: given orally once daily in 28-day cycles
62620674|NCT02130700|EXPERIMENTAL|Male ER Positive|VT-464: given orally once daily in 28-day cycles
62620675|NCT02130700|EXPERIMENTAL|AR Positive >10% TNBC|VT-464: given orally once daily in 28-day cycles
62620676|NCT00799799|EXPERIMENTAL|NK|patient treated as per protocol
62060377|NCT04376801||Plate Fixation Group|Patients with distal humerus fractures admitted to our hospital in 2012-2017 who had been performed open reduction and internal fixation through olecranon osteotomy approach were selected. All patients were devided into two groups by different fixation method. Patients who had been performed plate fixation after olecranon osteotomy were classified into Plate Fixation Group.
62060378|NCT01896284|EXPERIMENTAL|0.5mg AFLIBERCEPT injection|Patients will receive intravitreal injection of aflibercept 0.5mg at baseline, week 4,8,16,24 and 32. Optionally, if intra or subretinal fluid persists at week 12, patients will receive an additional injection.
62060379|NCT03493763||serum AFP negative HCC patients|"1. Patients who received liver resection within 3 months;~2. Hepatocellular carcinoma confirmed pathologically;~3. Serum alpha-fetoprotein level lower than 20ng/ml before hepatectomy."
62060380|NCT00421213|EXPERIMENTAL|Single Arm|
62264342|NCT01851681|ACTIVE_COMPARATOR|Amoxicillin 2g taken preoperatively and 500mg tid x 7 days|2g amoxicillin 1h preop then tid x 7 days
62264343|NCT01265550|OTHER|Medical Treatment Group|Omeprazole or Omeprazole + baclofen or Omeprazole + desipramine
62264344|NCT01265550|OTHER|Surgical Treatment Group|Laparoscopic nissen fundoplications
62264345|NCT01265550|OTHER|Placebo Medical Treatment Group|Omeprazole + placebo
62264346|NCT04755361|EXPERIMENTAL|Housing Outreach Project - Collaboration (HOP-C) + Treatment as Usual|The treatment condition is HOP-C plus treatment as usual (TAU).
62620677|NCT04521842|PLACEBO_COMPARATOR|Standard size femoral head implant|Participants qualified to undergo total hip replacement who will receive standard femoral head size implant
62620678|NCT04521842|ACTIVE_COMPARATOR|Large size femoral head|Participants qualified to undergo total hip replacement who will receive large femoral head size implant
62620679|NCT01651754|OTHER|Seasonal influenza vaccination|
62264347|NCT04755361|NO_INTERVENTION|Treatment As Usual|TAU for this population reflects the standard array of services accessed by transitional youth populations. Most will have some contact with a youth worker with ranging focus and intensity (none likely to receive case management at HOP-C intensity), and very few will have any routine contact with other professionals or peer support. They may have some sporadic access to skills development programs and primary healthcare providers with mental health and addictions needs addressed primarily through emergency services at times of crisis.
62060381|NCT05827458||I A|INTENSIVE 3 MONTHS Appropriate local imaging including ultrasound for soft-tissue sarcomas at three-month follow-up A CT scan of the chest was done on a six-monthly basis. CXR at the intervening three-month follow-up.
62264348|NCT03268044||Weekend admission|Adults admitted to hospital at the weekend (Saturday or Sunday) and who underwent surgery
62264349|NCT03268044||Weekday admission|Adults admitted to hospital on a weekday (Tuesday to Thursday) and who underwent surgery
62264350|NCT03666455|EXPERIMENTAL|Acceptance and Commitment Therapy|The intervention consists of eight individual (one-on-one) acceptance and commitment therapy sessions approximately one week apart over a 12-week period.
62264351|NCT06250803|EXPERIMENTAL|early pancreatic stent placement (EPSP)|a pancreatic stent will be placed immediately after endoscopic retrograde cholangiography (ERC) or endoscopic sphincterotomy (EST)
62264352|NCT06250803|OTHER|late pancreatic stent placement (LPSP)|a pancreatic stent will be placed after all completion of therapeutic biliary procedures, e.g. biliary stone removal or drainage
62264353|NCT03129659|EXPERIMENTAL|CT-group|Coronary CT angiography
62264354|NCT04289337|EXPERIMENTAL|Combined probiotics (1)|Combined Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9 and Lactobacillus paracasei ET-66.
62264355|NCT04289337|EXPERIMENTAL|Combined probiotics (2)|Combined Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus plantarum LPL28 and Lactobacillus paracasei ET-66.
62060382|NCT05827458||I B|"INTENSIVE 6 MONTHS~Appropriate local imaging including ultrasound for soft-tissue sarcomas at six month follow-up A CT scan of the chest was done on a six-monthly basis"
62620680|NCT01648998|EXPERIMENTAL|Fludrocortisone|Fludrocortisone 500 mg in capsule
62620681|NCT01648998|PLACEBO_COMPARATOR|Placebo|Placebo capsule, single dose, main ingredient lactose
62060383|NCT05827458||II A|COST EFFECTIVE 3 MONTHS Appropriate local imaging including ultrasound for soft-tissue sarcomas at three-month follow-up with CXR
62060384|NCT05827458||II B|COST EFFECTIVE 6 MONTHS Appropriate local imaging including ultrasound for soft-tissue sarcomas at six month follow-up with CXR
62060385|NCT00977756||Group G|Participants will receive a medication regimen including RAL + ATV + RTV.
62264356|NCT04289337|EXPERIMENTAL|Combined heat-killed probiotics (1)|Combined heat-killed Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9 and Lactobacillus paracasei ET-66.
62264357|NCT04289337|EXPERIMENTAL|Combined heat-killed probiotics (2)|Combined heat-killed Lactobacillus salivarius subsp. salicinius AP-32 and Lactobacillus paracasei ET-66.
62264358|NCT04289337|EXPERIMENTAL|Probiotic metabolites|Combined Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus plantarum LPL28 and Lactobacillus paracasei ET-66 metabolites.
62264359|NCT04289337|PLACEBO_COMPARATOR|Placebo|Does not contain probiotics, heat-killed probiotics and related metabolites.
62060386|NCT00977756||Group H|Participants will receive a medication regimen including RAL + TDF.
62060387|NCT00977756||Group I|Participants will receive a medication regimen including ETV + DRV + RTV.
62060388|NCT00977756||Group J|Participants will receive a medication regimen including MVC + ATV + RTV.
62060389|NCT00977756||Group K|Participants will receive a medication regimen including MVC + LPV + RTV.
62264360|NCT03254420|ACTIVE_COMPARATOR|Image-guided radiation therapy (IGRT) with standard margins|moderate hypofractionation during 4 weeks
62264361|NCT03254420|EXPERIMENTAL|Calypso tracking system with margin reduction|moderate hypofractionation during 4 weeks after calypso beacon implant 10 days before
62264362|NCT03838302||Transvaginal retrieval|Transvaginal retrieval via a posterior colpotomy for removing tissue by laparoscopic surgery with uterus preservation
62264363|NCT03838302||Transabdominal retrieval|Transabdominal retrieval via trocar for removing tissue by laparoscopic surgery with uterus preservation
62264364|NCT03317938|EXPERIMENTAL|Fecobionics studies|
62264365|NCT02785250|EXPERIMENTAL|Arm 1|DPX-Survivac, Cyclophosphamide, Epacadostat (Phase 1 and initially Phase 2)
62264366|NCT02785250|EXPERIMENTAL|Arm 2|DPX-Survivac, Cyclophosphamide (in Phase 2 only)
62264367|NCT02424253|EXPERIMENTAL|ZPL-3893787|30 mg ZPL-3893787 orally once daily for 8 weeks.
62264368|NCT02424253|PLACEBO_COMPARATOR|Placebo|1 capsule orally once daily for 8 weeks.
62264369|NCT05574595|EXPERIMENTAL|The Mean of the Hemodialysis Comfort Scale scores of the experimental and group patients|To the Experimental Group; The information form and the short form of the comfort scale will be applied to the patient who is taken to the dialysis unit to start HD treatment.
62264370|NCT05574595|NO_INTERVENTION|The mean of the Hemodialysis Comfort Scale scores of the control group patients|No procedure was performed on the patients in the control group.
62264371|NCT01136655|EXPERIMENTAL|BUD 160/FM 2.25|2.25 μg formoterol (as 80/2.25 μg Symbicort pMDI × 1 inhalation) + 40 μg budesonide HFA pMDI × 2 inhalations
62620682|NCT05887960||1|healthy persons to see normal ratio of of neutrophil lymphocyte and monocyte lymphocyte
62620683|NCT05887960||2|CKD patients stage (4-5) not on dialysis to see impact of (NLR) and (MLR) as regard inflamation and cardiovascular complications
62620684|NCT05887960||3|patients ESRD on maintenance hemodialysis compared with CKD pre dialysis patents and see if hemodialysis is better for removal toxic granules and inflamatory markers caused by CKD
62060390|NCT00977756||Group L|Participants will receive a medication regimen including MVC + RAL + ETV.
62060391|NCT00977756||Arm M|Participants will receive a medication regimen of DRV
62060392|NCT00977756||Arm N|Participants will receive a medication regimen of DRV
62060393|NCT00977756||Arm O|Participants will receive a medication regimen of unboosted ATV
62060394|NCT00977756||Arm P|Participants will receive a medication regimen of RPV
62060395|NCT00977756||Arm Q|Participants will receive a medication regimen of RPV
62264372|NCT01136655|EXPERIMENTAL|BUD 160/FM 4.5|placebo HFA pMDI × 1 inhalation + 4.5 μg formoterol (as 80/2.25 μg Symbicort pMDI × 2 inhalations)
62264373|NCT01136655|EXPERIMENTAL|BUD 160/FM 9.0|placebo HFA pMDI × 1 inhalation + 9 μg formoterol (as 80/4.5 μg Symbicort pMDI × 2 inhalations)
62620685|NCT02632370||Gliolan®|Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials. The formulation contains 1.5 g 5-aminolevulinic acid hydrochloride corresponding to 1.17 g of 5-aminolevulinic acid. The oral solution is intended for single (partial) use.
62620686|NCT03231397|OTHER|Control Group|"Six control subjects (three males and three females) with known atherosclerosis by standard clinical criteria without aneurysmal disease.~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
62264374|NCT01136655|PLACEBO_COMPARATOR|BUD 160|placebo HFA pMDI × 1 inhalation + 80 μg budesonide HFA pMDI × 2 inhalations
62264375|NCT01136655|ACTIVE_COMPARATOR|BUD 160/Foradil 12.0|Foradil Aerolizer 12 μg × 1 inhalation + 80 μg budesonide HFA pMDI × 2 inhalations
62060396|NCT01960530|NO_INTERVENTION|Endogenous Cortisol|No Study medication will be given during this study period, however various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
62264376|NCT02560376|EXPERIMENTAL|68Ga-NOTA-exendin-4 PET/CT|The patients were injected with 55.5-111 MBq of 68Ga-NOTA-exendin-4 PET/CT in one dose intravenously and underwent PET/CT scan 30-60 min later.
62060397|NCT01960530|OTHER|Dexamethasone|1mg Dexamethasone will be administered at 22:00 on Day 1 and at 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. Dexamethasone is considered a challenge agent and therefore a non-IMP
62264377|NCT01321710|ACTIVE_COMPARATOR|Dietary information & standard care|"Mothers in this arm receive dietary information aimed at reducing postpartum sleep disturbance.~Infants in this arm receive no intervention beyond standard immunization care."
62264378|NCT01321710|EXPERIMENTAL|Sleep hygiene & standard care|"Mothers in this arm receive a sleep hygiene intervention aimed at improving their postpartum sleep.~Infants in this arm receive standard immunization care."
62264379|NCT01321710|EXPERIMENTAL|Sleep hygiene & acetaminophen|"Mothers in this arm receive a sleep hygiene intervention aimed at improving postpartum sleep.~Infants in this arm receive an acetaminophen intervention (12.5mg per kg infant weight, 1 dose 30 minutes prior to immunization and q4-6h thereafter, for a total of 5 doses) to minimize sleep disturbance following immunization."
62620687|NCT03231397|OTHER|Small AAA's|"Six subjects (three males and three females) with small AAAs (diameter 3.0-4.5cm).~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
62264380|NCT00475683|SHAM_COMPARATOR|regular measurments|Mouth wash with chlorexidin
62264381|NCT00475683|EXPERIMENTAL|Curucmol|mouth wash with curcumol and mouth wash with chlorexidin
62264382|NCT03413501|NO_INTERVENTION|Treatment as usual|Receives treatment as usual at the clinic
62264383|NCT03413501|EXPERIMENTAL|MUD-PI|Receives multi-disciplinary pain intervention, agroup-based, multi-disciplinary treatment
62264384|NCT04001023|EXPERIMENTAL|PDS|18F-EF5 PET/CT and 18F-FDG PET/CT scan prior to primary cytoreductive surgery and targeted sample collection during primary cytoreductive surgery
62060398|NCT01960530|EXPERIMENTAL|Infacort®|20mg Infacort® will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous adrenocorticotropic Hormone (ACTH) and cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
62620688|NCT03231397|OTHER|Rapidly expanding AAA's|"Six subjects (three males and three females) with rapidly expanding AAAs (\>0.5cm over 6 months and/or \>1.0cm over 12 months).~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
62620689|NCT03231397|OTHER|AAA's undergoing treatment|"Six subjects (three males, AAA \>5.5cm and three females, AAA \>5.0cm) with AAAs that are indicated for treatment.~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
62620690|NCT04282616|EXPERIMENTAL|Home-based unstructured physical activity program|According to each patient's baseline physical activity level, the facilitator will advise patients to start or to increase their spontaneous activity by giving counselling on total exercise time, mode, intensity and frequency as suggested by the American College of Sport Medicine guidelines. Every patient will be provided with a log-book and a wearable physical activity monitor, which has to be returned in the subsequent controls, to favor adherence and objectively measure the exercise activities
62620691|NCT04282616|EXPERIMENTAL|Home-based structured low-intensity physical activity program|According to each patient's baseline physical activity level, a semi-personalized walking program, will be provided. This program, derived from previous experience on renal patients, includes a 10-min session/day of intermittent walking (1- or 2-min work and 1-min seated rest) to be performed at home at prescribed speed. The speed, converted into walking cadence and followed by a metronome, is weekly increased. Patients will be provided with a daily log containing the detailed exercise prescription and spaces to give a feedback on training execution and related symptoms.
62620692|NCT04282616|EXPERIMENTAL|In-hospital structured supervised physical activity program|"Patients will join the room properly equipped for the exercise program in groups of maximum four subjects for a 2-time/week thirty minutes training sessions, to be performed for dialysis patients immediately before or after the dialysis treatment, or in non-dialysis according to their preferences.~Each sessions will include low-intensity walking exercises (similar to the structured home-based training), resistance and power exercises with elastic bands and light weights. Each sessions will begin and end with a warm-up and cool-down period of stretching. The total duration of the session will be about 30 minutes. Rate of perceived exertion will be collected and the training intensity will be set according to the patient's baseline capacity and weekly increased."
62620693|NCT04282616|NO_INTERVENTION|No-training|Patients choosing this option will not start any physical activity program, but they will perform the outcome measures, acting as a control group.
62620694|NCT02900664|EXPERIMENTAL|PDR + ACZ 100mg Q8W|PDR + ACZ 100mg Q8W
62620695|NCT02900664|EXPERIMENTAL|PDR + ACZ 300mg Q8W|PDR + ACZ 300mg Q8W
62264385|NCT04001023|EXPERIMENTAL|IDS|"18F-EF5 PET/CT and 18F-FDG PET/CT scans prior to diagnostic laparoscopy and after neoadjuvant chemotherapy before interval cytoreductive surgery .~Targeted sample collection during diagnostic laparoscopy and interval cytoreductive surgery"
62620696|NCT02900664|EXPERIMENTAL|PDR + ACZ RDE TNBC|PDR + ACZ Recommended Dose for Expansion (RDE) Triple Negative Breast Cancer (TNBC)
62620697|NCT02900664|EXPERIMENTAL|PDR + ACZ RDE NSCLC|PDR + ACZ Recommended Dose for Expansion (RDE) Non-Small Cell Lung Cancer (NSCLC)
62620698|NCT02900664|EXPERIMENTAL|PDR + ACZ RDE CRC|PDR + ACZ Recommended Dose for Expansion (RDE) Colorectal Cancer (CRC)
62620699|NCT02900664|EXPERIMENTAL|PDR + CJM 25mg Q4W|PDR + CJM 25mg Q4W
62620700|NCT02900664|EXPERIMENTAL|PDR + CJM 75mg Q4W|PDR + CJM 75mg Q4W
62620701|NCT02900664|EXPERIMENTAL|PDR + CJM 225mg Q4W|PDR + CJM 225mg Q4W
62620702|NCT02900664|EXPERIMENTAL|PDR + CJM 450mg Q4W|PDR + CJM 450mg Q4W
62620703|NCT02900664|EXPERIMENTAL|PDR + CJM 450mg Q2W|PDR + CJM 450mg Q2W
62620704|NCT02900664|EXPERIMENTAL|PDR + CJM 900mg Q4W|PDR + CJM 900mg Q4W
62620705|NCT02900664|EXPERIMENTAL|PDR + CJM 900mg Q2W|PDR + CJM 900mg Q2W
62846735|NCT04522284|EXPERIMENTAL|CURATE.AI|"- Cohort 1: Capecitabine in solid tumours. In this cohort, participants will receive the treatment in three-week cycles. Only the dose of capecitabine will be modulated with CURATE.AI, based on measurements of the tumour marker (CEA/CA19-9). CT scans for radiological assessment will be performed according to standard of care, usually after every 2 to 3 cycles of chemotherapy for Cohort 1 only.~Cohort 2: Ibrutinib in Waldenström macroglobulinaemia In this cohort, participants will receive the treatment in four-week cycles. The total cumulative dose of Ibrutinib will be modulated with CURATE.AI, based on measurements of the tumour marker (IgM paraprotein)."
62060399|NCT01960530|ACTIVE_COMPARATOR|Hydrocortisone Tablet|20mg Hydrocortisone Tablet will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
62060400|NCT01960530|ACTIVE_COMPARATOR|i.v Hydrocortisone Injection|20mg i.v. Hydrocortisone Injection will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
62060401|NCT02507778|OTHER|biopsy|needle will be inserted before and after biopsy and will measure circulating tumor cells.
62846736|NCT02734641||intravenous (IV) iron therapy|"Patients register to intravenous (IV) iron therapy due to iron deficiency anemia that wasn't responded to oral treatment or wasn't tolerable due to side effects.~20 mL of blood will be draw for complete blood count, renal function, electrolytes and ghrelin. In addition, the patient will fill a structured questionnaire that examines the appetite of the patient before and after treatment. At the end of Iron administration Ghrelin will be retested."
62620706|NCT02900664|EXPERIMENTAL|PDR + CJM 1200mg Q4W|PDR + CJM 1200mg Q4W
62620707|NCT02900664|EXPERIMENTAL|PDR + TMT 0.5mg QD|PDR + TMT 0.5mg QD
62620708|NCT02900664|EXPERIMENTAL|PDR + TMT 1mg QD|PDR + TMT 1mg QD
62620709|NCT02900664|EXPERIMENTAL|PDR + TMT 1mg QD, 3 Weeks on/1 Week off|PDR + TMT 1mg QD, 3 Weeks on/1 Week off
62620710|NCT02900664|EXPERIMENTAL|PDR + TMT 1.5 mg QD, 2 Weeks on/2 Weeks off|PDR + TMT 1.5 mg QD, 2 Weeks on/2 Weeks off
62620711|NCT02900664|EXPERIMENTAL|PDR + TMT 1.5 mg QD, 3 Weeks on/1 Week off|PDR + TMT 1.5 mg QD, 3 Weeks on/1 Week off
62620712|NCT02900664|EXPERIMENTAL|PDR + EGF816 25mg QD|PDR + EGF816 25mg QD
62620713|NCT02900664|EXPERIMENTAL|PDR + EGF816 50mg QD|PDR + EGF816 50mg QD
62264386|NCT01056627|EXPERIMENTAL|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
62620714|NCT02900664|EXPERIMENTAL|s.a. ACZ RDE TNBC|Single agent (s.a.) ACZ Recommended Dose for Expansion (RDE) Triple Negative Breast Cancer (TNBC)
62620715|NCT02900664|EXPERIMENTAL|s.a. ACZ RDE NSCLC|Single agent (s.a.) ACZ Recommended Dose for Expansion (RDE) Non-Small Cell Lung Cancer (NSCLC)
62620716|NCT02900664|EXPERIMENTAL|s.a. ACZ RDE CRC|Single agent (s.a.) ACZ Recommended Dose for Expansion (RDE) Colorectal Cancer (CRC)
62620717|NCT01549340||Participants with Allergic Rhinitis (AR)|Patients in a private allergy practice who were diagnosed with AR, with or without asthma, and advised to consider AIT between January 2005 and June 2011 and whose medical records were retrospectively reviewed.
62620718|NCT00645671|EXPERIMENTAL|Loteprednol Etabonate|Loteprednol etabonate 0.5% ophthalmic ointment
62620719|NCT00645671|PLACEBO_COMPARATOR|Vehicle|Vehicle of loteprednol etabonate ointment
62620720|NCT01894971|EXPERIMENTAL|twice coagulated side of fallopian tube|twice coagulated side of fallopian tube once coagulated sied of fallopian tube
62620721|NCT05091996|EXPERIMENTAL|Post-isometric muscle relaxation group|The post-isometric relaxation techniques were administered to the mandibular adductors and muscles responsible for lateral movements of the mandible.
62620722|NCT05091996|EXPERIMENTAL|Myofascial release group|The myofascial release procedure was performed successively in the area of the anterior parts of the temporal muscles, the superficial parts of the masseter muscles and the sternocleidomastoid muscles.
62620723|NCT01765816|EXPERIMENTAL|high intensity interval training|one interval training session with 1 x 4 and 4 x 4 minutes interval training at 90-95% of peak heart rate
62620724|NCT01765816|ACTIVE_COMPARATOR|moderate intensity training|45 minutes of moderate continuous training at 75% of maximal heart rate
62620725|NCT02186899|ACTIVE_COMPARATOR|General Anesthesia Femoral continuous|General anesthesia plus continuous femoral nerve block
62620726|NCT02186899|ACTIVE_COMPARATOR|General anesthesia Femoral bolus|General anesthesia plus single shot femoral nerve block
62620727|NCT02186899|ACTIVE_COMPARATOR|Femoral Sciatic Obturator Nerve block|Ultrasound guided femoral plus sciatic plus obturator nerve block
62620728|NCT04536298|ACTIVE_COMPARATOR|Vitamin D|Daily vitamin D3 (9600 IU/day on days 1 and 2; 3200 IU/day on days 3 through 28)
62620729|NCT04536298|PLACEBO_COMPARATOR|Placebo|Placebo
62620730|NCT05597878|ACTIVE_COMPARATOR|Opioid Control Cohort|Participants will receive standard general anesthesia and receive local anesthesia medication (bupivacaine) during surgery per the investigator's surgical protocol. AFTER surgery participants will be administered oxycodone and acetaminophen.
62846737|NCT02734641||healthy volunteer|healthy volunteer, will be asked 20 mL of blood will be draw for complete blood count, renal function, electrolytes and ghrelin. In addition, the patient will fill a structured questionnaire that examines his appetite. Ghrelin will be retested after 6 weeks.
62620731|NCT05597878|ACTIVE_COMPARATOR|Experimental Non-Opioid Cohort|Participants will receive standard general anesthesia and receive local anesthesia medication (bupivacaine) during surgery per the investigator's surgical protocol. BEFORE and AFTER surgery participants will be administered Ketamine; DURING surgery Ketorolac and acetaminophen.
62620732|NCT05887362|EXPERIMENTAL|STUDY GROUP|Each patient in the study group received 8 sessions of hand reflexology after CA in a room separating them from the patients in the control group.Using pleasant odourless almond oil to lubricate the patients' hands, the researcher used Ingham's approach to hand reflexology for 10 minutes, applying pressure for 5 minutes on the right hand and then the left.
62060402|NCT01357330|EXPERIMENTAL|Dose Escalation|Dose escalation phase The starting dose of SAR245408 will be 25-mg once daily (up to 200-mg). The starting dose of MSC1936369B will be 15- mg once daily (up to 90-mg)
62620733|NCT05887362|NO_INTERVENTION|Group 2|The control group was selected first and received the routine care delivered by the hospital, such as assessment of vital signs, supine position, complete bed rest, and hygienic care. They didn't receive the hand reflexology intervention.
62264387|NCT01056627|ACTIVE_COMPARATOR|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
62264388|NCT01412476||case group|Subjects with metabolic syndrome
62620734|NCT04318262||Patient with Staphylococcus lugdunensis infection|All consecutive patients with S. lugdunensis infection (microbiological and clinical data)
62620735|NCT04318262||Patient with Staphylococcus aureus infection|Patients with S. aureus infection (microbiological and clinical data), matched to the hospital sector for S. lugdunensis infections
62620736|NCT04318262||Patient with other coagulase negative Staphylococcus infection|Patients with CoNS infection (microbiological and clinical data),matched to the hospital sector for S. lugdunensis infections
62620737|NCT03548350|EXPERIMENTAL|Intervention|"The experimental group will participate in a 24 week multi-component programme that includes four strands:~* A physical literacy programme focusing on core elements of strength, agility, speed, balance and flexibility. Delivered by external facilitators for one hour per week over 16 weeks of the programme (2 x8week blocks).~* 'Golden Mile' - pupils and teachers participate 15min walk/run a min of 2 times per week~* After schools club (not compulsory) featuring mind-set component delivered by external facilitators~* Healthy kidz app with reward system"
62264389|NCT01412476||control group|Healthy individuals
62620738|NCT03548350|NO_INTERVENTION|Control|The control group will continue doing physical activity including physical education as is normal for their school
62620739|NCT04750941|EXPERIMENTAL|Follicular Lymphoma (FL)|"The lymphoma study group will enroll 23 patients with FL.~In cycle 1, patients will first start ketogenic diet for 7 days (Day -6 to Day 0). Only patients who demonstrate compliance and tolerance with the ketogenic diet for all 7 days, as confirmed by pertinent blood and urine tests, will be allowed to continue the study and treatment using copanlisib and the ketogenic diet starting on Day 1. In cycle 2 and beyond, patients will start the ketogenic diet and copanlisib on day 1."
62846738|NCT04208607|EXPERIMENTAL|Study group|Patients with bronchiectasis
62846739|NCT03867370|EXPERIMENTAL|Group A|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg. After the operation, the patients will receive JS001 240 mg Q3W for up to 48 weeks.
62060403|NCT06550349||Volunteer Participants|Volunteer participants being scanned by a qualified clinician using various ultrasound machines
62846740|NCT03867370|EXPERIMENTAL|Group B (Toripalimab, Lenvatinib)|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg in combination with oral lenvatinib at a starting dose of 8 or 12 mg once a day. After the operation, the patients will receive JS001 240 mg Q3W and lenvatinib for up to 48 weeks.
62846741|NCT03867370|ACTIVE_COMPARATOR|Group C (Toripalimab, Lenvatinib)|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg in combination with oral lenvatinib at a starting dose of 8 or 12 mg once a day. After the operation, the patients will receive JS001 240 mg Q3W for up to 48 weeks.
62846742|NCT00314795|EXPERIMENTAL|Peginesatide|"Peginesatide 0.05 mg/kg injection, subcutaneously as a starting dose followed by peginesatide 0.1 mg/kg injection, subcutaneously once every 4 weeks for up to 6 months.~Individual dose of peginesatide injection was modified based on hemoglobin levels. Dose adjustments were made in order to achieve and maintain hemoglobin in the target range of 10.0-12.0 g/dL."
62846743|NCT03672097|EXPERIMENTAL|Prasugrel|Participants with ACS who underwent PCI, and were previously taking clopidogrel, receive a maintenance dose (MD) of prasugrel for a total of 28 weeks (optionally up to a maximum 12 months of P2Y12 inhibitor treatment after ACS underwent PCI)
62846744|NCT02978781|EXPERIMENTAL|Part A: SAGE-217 Oral Solution|Participants received SAGE-217 10 mg oral solution on Day 1, 20 mg on Day 2 and 30 mg on Days 3 to 7 with food in the morning.
62846745|NCT02978781|EXPERIMENTAL|Part A: SAGE-217 Capsules|Participants received SAGE-217 10 mg capsules on Day 1, 20 mg on Day 2 and 30 mg on Days 3 to 7, orally, with food in the morning.
62060404|NCT00650143|ACTIVE_COMPARATOR|1|"Application G-CSF (10µg/kg/d divided in two doses subcutaneously) over a period of 5 days and Sitagliptin 100 mg each day for 28 days.~n=74"
62264390|NCT02728830|EXPERIMENTAL|Pembrolizumab|"Subjects will receive one dose of 200mg pembrolizumab by IV 14-21 days prior to surgery. Subjects will undergo standard surgical cytoreductive surgery as deemed appropriate by their gynecologic oncologist, followed by standard adjuvant chemotherapy for their cancer as deemed appropriate by their treating physician.~If subject's disease does not get worse following standard of care chemotherapy, they will receive pembrolizumab in the maintenance setting every three weeks for up to a year.~If subject's disease returns after completing a year of pembrolizumab and they have not had adverse reactions to pembrolizumab they may be eligible to continue receiving pembrolizumab for an additional year in the second course phase."
62264391|NCT02389127||Group A|"* Cirrhosis, either clinically- or biopsy-proven~* Child-Pugh-Turcotte (CTP) A, B, and C (only biopsy-proven in the case of CTP-A)~* Random glucose \<200 mg/dL on at least 3 occasions~* No use of insulin or any hypoglycemic agent~(Group A) patients with cirrhosis and varying degrees of liver dysfunction but no prior diagnosis of T2DM will have an OGTT performed after overnight fasting (8-12-hours). HbA1c will be obtained before OGTT along with the following tests: HbA1c, fructosamine, insulin, CBC, HFP, GGT, OP Chem 7, INR, and prealbumin."
62060405|NCT00650143|PLACEBO_COMPARATOR|2|"NaCl 0.9% applied twice daily over a period of 5 days and oral Placebo given once a day for 28 days.~n=74"
62060406|NCT01583686|EXPERIMENTAL|1/Phase I|Non-myeloablative but lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL) plus low dose aldesleukin.
62264392|NCT02389127||Group B|"* Cirrhosis, either clinically- or biopsy-proven~* Child-Pugh-Turcotte (CTP) A, B, and C (only biopsy-proven in the case of CTP-A)~* Prior diagnosis of T2DM as based on any of ADA criteria~* Use of insulin or any hypoglycemic agent~(Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (?Dexcom, ?Medtronic) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks. On the day the continuous monitor is retrieved by the investigators, patients will have the following blood tests performed after overnight fasting (8-12-hours): HbA1c, fructosamine, CBC, HFP, GGT, BMP, INR, and prealbumin."
62264393|NCT02389127||Control|"* Age 18 to 75~* No known chronic liver disease~* Prior diagnosis of T2DM as based on any of ADA criteria~* Use of insulin or any hypoglycemic agent"
62264394|NCT05535348|EXPERIMENTAL|Open Pilot|An adapted version of the Relaxation Response Resiliency Program (3RP) for fathers of CYSHCN. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
62264395|NCT03358719|EXPERIMENTAL|Treatment (CDX-1401, poly ICLC, decitabine, nivolumab)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 intracutaneously and poly ICLC SC on day -14, on day 15 of courses 1-4, and then on day 1 of every 4 courses thereafter. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 and decitabine IV over 1 hour on days 1-5. Courses with nivolumab and decitabine repeat every 4 weeks in the absence of disease progression or unaccepted toxicity.
62264396|NCT03227263|EXPERIMENTAL|Bevacizumab|Intravenous infusion of Bevacizumab at a dose of 5 mg/kg
62264397|NCT03227263|PLACEBO_COMPARATOR|Placebo|0.9% of sodium chloride is infused every 14 days for 6 consecutive administrations
62264398|NCT04105374|ACTIVE_COMPARATOR|Arm I (surgery, radiation therapy, temozolomide)|Beginning on week 5 following standard of care surgery, patients undergo radiation therapy over 30 fractions 5 days per week for up to 6 weeks, and receive temozolomide PO QD for up to 49 days. At the discretion of treating physician, patients may also receive novoTTF-100A (Optune) device 0-7 weeks following radiation and temozolomide treatment. One month following completion of radiation therapy, patients continue to receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62264399|NCT04105374|EXPERIMENTAL|Arm II (Toca 511, Toca FC, radiation therapy, temozolomide)|Patients receive vocimagene amiretrorepvec via intracranial injection during surgery on day 1. Beginning on week 5 following surgery, patients receive extended release flucytosine PO TID for 7 consecutive days every 7 weeks. Patients also undergo radiation therapy and receive temozolomide as in arm I. After completion of radiation therapy and at the discretion of the treating physician, patients may continue to receive extended release flucytosine PO TID for 7 consecutive days every 8 weeks in the absence of disease progression or unacceptable toxicity.
62264400|NCT03276000|ACTIVE_COMPARATOR|Group A|50 patients receive 200 mg oral misoprostol (Misotac; Sigma Pharm) 3h before office hysteroscopy
62264401|NCT03276000|ACTIVE_COMPARATOR|group B|50 patients receive 200 mg misoprostol (Misotac; Sigma Pharm) 3h before office hysteroscopy moistened with saline solution will be inserted in posterior fornix of vagina.
62264402|NCT04990089||VIVO|Patients in which VIVO is used.
62264403|NCT06475859||Women with chronic widespread pain|Women who received the diagnosis of fibromyalgia from a doctor.
62620740|NCT04750941|EXPERIMENTAL|Endometrial Cancer (EC)|"The solid tumor group will enroll 19 patients with EC.~In cycle 1, patients will first start ketogenic diet for 7 days (Day -6 to Day 0). Only patients who demonstrate compliance and tolerance with the ketogenic diet for all 7 days, as confirmed by pertinent blood and urine tests, will be allowed to continue the study and treatment using copanlisib and the ketogenic diet starting on Day 1. In cycle 2 and beyond, patients will start the ketogenic diet and copanlisib on day 1."
62060407|NCT01583686|EXPERIMENTAL|2/Phase II|Non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine + anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL) + low-dose aldesleukin
62060408|NCT03928145|EXPERIMENTAL|Chlorthalidone 25 mg + amiloride 20 mg|Chlorthalidone 25 mg plus amiloride 20 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
62846746|NCT02978781|PLACEBO_COMPARATOR|Part B: Placebo|Participants who received maximum tolerated dose of SAGE-217 in Part A and achieved response on Day 8 were randomized to receive to SAGE-217 matching placebo for 7 days beginning on Day 8 with food in the morning.
62846747|NCT02978781|EXPERIMENTAL|Part B: SAGE-217 Capsules|Participants who received maximum tolerated dose of SAGE-217 in Part A and achieved response on Day 8 were randomized to receive to SAGE-217 for 7 days beginning on Day 8 with food in the morning.
62060409|NCT03928145|ACTIVE_COMPARATOR|Chlorthalidone 25 mg + amiloride 10 mg|Chlorthalidone 25 mg plus amiloride 10 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
62060410|NCT03928145|ACTIVE_COMPARATOR|Hydrochlorothiazide 50 mg + amiloride 20 mg|Hydrochlorothiazide 50 mg plus amiloride 20 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
62060411|NCT03928145|ACTIVE_COMPARATOR|Hydrochlorothiazide 50 mg + amiloride 10 mg|Hydrochlorothiazide 50 mg plus amiloride 10 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
62060412|NCT04846764|ACTIVE_COMPARATOR|Healthy volunteers|"60 healthy volunteers (aged 18-40 and 60-80) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Visit 1~* Neuropsychological tests~* A cranial MRI~Visit 2~• Neuropsychological tests"
62060413|NCT04846764|EXPERIMENTAL|Patients with neurological diseases of the central nervous system|"36 patients will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Visit 1~* Neuropsychological tests~* A cranial MRI~Visit 2~• Neuropsychological tests"
62060414|NCT04143984|ACTIVE_COMPARATOR|Arm-C|Patients will receive induction chemotherapy followed by carbon-ion radiotherapy with a dose of 63 GyE in 21 fractions (the fraction size is 3 GyE).
62060415|NCT04143984|EXPERIMENTAL|Arm-CC|Patients will receive induction chemotherapy followed by carbon-ion radiotherapy and camrelizumab. In details, patients will receive carbon-ion radiotherapy with a dose of 63 GyE in 21 fractions (the fraction size is 3 GyE); in addition, patients will also receive camrelizumab of 200 mg (IV.), every 2 weeks, started with carbon-ion radiotherapy for a maximal period of 1 year.
62060416|NCT04567264|EXPERIMENTAL|With stimulation|Implantation of device electrodes subcutaneous in lower tibia area; stimulation of posterior tibial nerves.
62060417|NCT02857439|OTHER|MD as first examiner|Patients will be examined according to a standardized physical examination item list
62060418|NCT02857439|OTHER|Triage nurse as first examiner|Patients will be examined according to a standardized physical examination item list
62620741|NCT03234920|PLACEBO_COMPARATOR|Group 1- Control Group|Placebo The placebo will be 200 ml of fruit juice twice a day. Placebo will be provided for 12 weeks
62264404|NCT06475859||Healthy women|Healthy women without any chronic diseases or pain in daily life.
62264405|NCT01316861|EXPERIMENTAL|EMS Acarbose|
62264406|NCT01316861|ACTIVE_COMPARATOR|Bayer Acarbose|
62846748|NCT02978781|EXPERIMENTAL|Part C: SAGE-217 Capsules|Participants received SAGE-217 10 mg capsules on Day 1, 20 mg on Day 2, 30 mg on Day 3, orally, with food in the evening. Beginning on Day 4 through Day 14, participants received a 40-mg total daily dose (administered as 10 mg with food in the morning and 30 mg with food in the evening).
62264407|NCT01179009|EXPERIMENTAL|ketamine 100-hour infusion|100-hour infusion of ketamine plus a safener (clonidine)
62264408|NCT01179009|ACTIVE_COMPARATOR|ketamine 40-minute infusion|40-minute ketamine infusion following a 100-hours +/- placebo (saline) infusion. Participants will also receive a safener (clonidine)
62264409|NCT03222791|EXPERIMENTAL|Algorithm-based diet|Subjects randomized to this arm will receive personally tailored dietary recommendations based on their predicted glycemic responses according to the study algorithm.
62846749|NCT03492918|EXPERIMENTAL|pembrolizumab group|Drug:Pembrolizumab Dose/Potency:200 mg Dose Frequency:Q3W Route of Administration:IV infusion Regimen/Treatment Period:Day 1 of each 3 week cycle Use:Experimental
62846750|NCT02666625||Patients treated for cancer in childhood|
62846751|NCT03122951|OTHER|ovulation test use|All voluteers will receive device for use according to instructions
62846752|NCT03435783|EXPERIMENTAL|Intervention|
62846753|NCT03435783|ACTIVE_COMPARATOR|Attention-matched control|
62846754|NCT00166413|EXPERIMENTAL|CC5013|Assess the proportion of confirmed hematologic responses (HCR, HPR) resulting from treatment with CC5013 after 3 months in patients with primary systemic amyloidosis.
62846755|NCT02184624|EXPERIMENTAL|Sub-Study 1|Subjects will be randomized to either use ELLIPTA inhaler first and then DISKUS/ACCUHALER inhaler or use DISKUS/ACCUHALER inhaler first and then ELLIPTA inhaler.
62846756|NCT02184624|EXPERIMENTAL|Sub-Study 2|Subjects will be randomized to either use ELLIPTA inhaler first and then MDI inhaler or use MDI inhaler first and then ELLIPTA inhaler.
62264410|NCT03222791|OTHER|Mediterranean-style low-fat diet|Subjects randomized to this arm will receive nutritional recommendations according to the standard Israeli dietary approach for treating pre-diabetes: Mediterranean-style low-fat diet.
62846757|NCT02184624|EXPERIMENTAL|Sub-Study 3|Subjects will be randomized to either use ELLIPTA inhaler first and then TURBUHALER inhaler or use TURBUHALER inhaler first and then ELLIPTA.
62846758|NCT02184624|EXPERIMENTAL|Sub-Study 4|Subjects will be randomized to either use ELLIPTA inhaler first and then HANDIHALER inhaler or use HANDIHALER inhaler first and then ELLIPTA inhaler.
62846759|NCT02184624|EXPERIMENTAL|Sub-Study 5|Subjects will be randomized to either use ELLIPTA inhaler first and then BREEZEHALER inhaler or use BREEZEHALER inhaler first and then ELLIPTA inhaler.
62846760|NCT00725062|EXPERIMENTAL|Patients Receiving CD4+/CD25+ cells|CD4+/CD25+ cells given intravenously over 15-60 minutes on Day -2 (prior to peripheral blood progenitor cell transplant)
62846761|NCT02314637|EXPERIMENTAL|Teneligliptin|Teneligliptin for 52 weeks
62846762|NCT02314637|EXPERIMENTAL|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
62846763|NCT03264729|EXPERIMENTAL|Isometric exercise|
62846764|NCT03264729|ACTIVE_COMPARATOR|Isotonic exercise|
62846765|NCT03264729|ACTIVE_COMPARATOR|Walking|
62846766|NCT04937465||Elderly|Elderly (\> 70 yrs) eligible for a short term rehabilitation
62846767|NCT05065411|EXPERIMENTAL|Enobosarm Combination Group|"Enobosarm Combination Group will receive enobosarm 9 mg each day by mouth (QD), and abemaciclib will administered by mouth at a dose of 150 mg BID.~Stage 2 Subjects in the Enobosarm Combination Group will receive enobosarm 9 mg QD each day by mouth and abemaciclib 150 mg BID by mouth until disease progression is observed and confirmed by BICR."
62060419|NCT01446796|PLACEBO_COMPARATOR|Native Conduction|Devices will be programmed to continuous atrial pacing at an AAI (atrial inhibited pacing) setting with base rate 90 bpm. Patients will not receive ventricular pacing.
62060420|NCT01446796|EXPERIMENTAL|Continuous RV Pacing|Devices will be programmed to continuous dual chamber pacing at a DDD (dual chamber dual pacing) setting with base rate ≥ 90 bpm (not to exceed 100 bpm) to achieve a majority (\>80%) of paced right ventricular beats
62620742|NCT03234920|EXPERIMENTAL|Group 2 - Treatment group|HMB Supplementation with 1.5 g of HMB dissolved in 200 ml of fruit juice and taken twice daily. Supplementation will be provided for 12 weeks
62846768|NCT05065411|ACTIVE_COMPARATOR|Control Treatment Group|Control Treatment Group will receive a non-steroidal AI, a non-steroidal or steroidal (exemestane with or without everolimus), AI OR fulvestrant approved for the treatment of metastatic breast cancer and is part of the standard of care at the clinical study site until disease progression is observed and confirmed by BICR. The decision of which comparator treatment will be used will be made prior to randomization.
62846769|NCT03180840|EXPERIMENTAL|Pegunigalsidase alfa|Pegunigalsidase alfa 2 mg/kg intravenous infusion every 4 weeks
62846770|NCT03122834||Cohort A|Newly diagnosed Heart Failure patients who will be treated with beta blockers (BB) and Angiotensin converting enzyme inhibitors (ACEIs)/or Angiotensin receptor blockers (ARBs) for the first time.
62846771|NCT03122834||Cohort B|Heart Failure patients who are candidate for add-on treatment with Spironolactone / Eplerenone.
62846772|NCT02396472|PLACEBO_COMPARATOR|Order by time and topic|"Volunteers from the American Cancer Society's Cancer Survivors' Network (CSN) will see some of their messages delivered using CSN's default ordering, which shows messages within a conversational thread ordered by time stamp. Conversational threads are nested within a broad topic-based forum, like breast cancer or colorectal cancer survivors.~Note that this is a within-participant trial, so that all participants participate in all arms of the trial. Messages, not people, are randomly assigned to condition."
62846773|NCT02396472|ACTIVE_COMPARATOR|Order by information relevance|In this condition some messages will be highlighted if they match the type of content the user has previously shown interest in, by previously contributing or reading semantically similar material.
62846774|NCT02396472|ACTIVE_COMPARATOR|Order by social relationship|In this condition some messages will be highlighted because they come from people the user has previously shown interest in, by previously reading their posts or communicating with them.
62846775|NCT02396472|ACTIVE_COMPARATOR|Order by help giving|In this condition some messages will be highlighted because they seek help and therefore provide an opportunity for participants to provide social support to others.
62846776|NCT02396472|ACTIVE_COMPARATOR|Order by self-disclosure|In this condition some messages will be highlighted because in them the writer is self-disclosing, and they provide provide an opportunity for participants to self-disclose in return.
62846777|NCT02945709|EXPERIMENTAL|Personalized ACT|The personalized attention control training (ACT), comprised of six computerized sessions, in purpose of modulate biases in attention for personalized threat stimuli.
62846778|NCT02945709|ACTIVE_COMPARATOR|Non personalized ACT|The Non-personalized attention control training (ACT), comprised of six sessions, in purpose of modulate biases in attention for non-personalized threat stimuli.
62264411|NCT01020864|EXPERIMENTAL|Chemotherapy|"Patients will be treated with Cetuximab, Carboplatin and Vinorelbine i.v. day 1, every 2nd week.~Patients will be treated until progression and/or in case of unacceptable toxicity or if the patient wishes to stop treatment."
62264412|NCT06493968|EXPERIMENTAL|Group (A)|Patients will be given uterotonics
62264413|NCT06493968|PLACEBO_COMPARATOR|Group (B)|Patients will not be given uterotonics
62264414|NCT03177421|EXPERIMENTAL|Bedtime media use and sleep problems|This arm will receive screening for and associated clinical decision support on sleep problems and bedtime media use.
62264415|NCT03177421|OTHER|Sleep problems only|This arm will receive screening for and associated clinical decision support on sleep problems only.
62060421|NCT01492686|EXPERIMENTAL|Arm 1|
62264416|NCT00578305|EXPERIMENTAL|Rituximab 500 mg|Participants received rituximab 500 mg iv on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants received further treatment courses on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
62264417|NCT00578305|EXPERIMENTAL|Rituximab 1000 mg|Participants received rituximab 1000 mg iv on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants received further treatment courses on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
62264418|NCT00578305|PLACEBO_COMPARATOR|Placebo|Participants received placebo intravenously (iv) on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants were switched to receive rituximab 1000 mg iv on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
62264419|NCT03051555|EXPERIMENTAL|18F-FDG PET/CT-based prognostic model of NK/T-cell lymphoma|The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
62846779|NCT02945709|PLACEBO_COMPARATOR|Control training|Computerized control training, comprised of six sessions with a variation of the dot-probe task with neutral stimuli
62846780|NCT01046838|PLACEBO_COMPARATOR|Placebo|placebo 3 x daily
62846781|NCT01046838|ACTIVE_COMPARATOR|sildenafil|40 mg sildenafil 3 x daily
62846782|NCT05540587|EXPERIMENTAL|Edoxaban|"Patients in the Edoxaban group take Edoxaban 60mg once daily. If any of the following conditions are present, take 30mg once daily.~* CrCl 15-50mL/min~* Body weight ≤ 60kg~* Concomitant use of P-glycoprotein inhibitor (Dronearone, Ciclosporine, Erythromycin or Ketoconazole)"
62060422|NCT01492686|PLACEBO_COMPARATOR|Arm 2|
62060423|NCT02974816|NO_INTERVENTION|Standard of Care|Subjects in this arm will visit their physician once every 3 months and will receive usual care.
62060424|NCT02974816|EXPERIMENTAL|Remote Monitoring|Subjects in this arm will visit their physician once every 3 months and will receive usual care. In addition, in between clinic visits, subjects will measure their blood glucose (BG) readings at least once a day and share their BG readings with their CDE using Glooko's mobile application. Once a week, the CDE will review the subject's BG readings on Glooko's population tracker and reach out to the subjects if he/she experienced clinical incident(s). During the conversation, the CDE will either recommend medication or lifestyle modification to address the clinical incident.
62060425|NCT00286208|ACTIVE_COMPARATOR|Sublingual Misoprostol|400 mcg of sublingual misoprostol
62060426|NCT00286208|ACTIVE_COMPARATOR|Oral Misoprostol|Misoprostol administered orally
62264420|NCT03586128||HIV serodiscordant couples|
62264421|NCT05656677|NO_INTERVENTION|Two nurses executing facilitated tucking (FT)|Usual care
62264422|NCT05656677|ACTIVE_COMPARATOR|One parent watching passively|One parent watching passively the 2 nurses executing FT
62264423|NCT05656677|ACTIVE_COMPARATOR|One parent actively involved|One parent actively executing FT
62264424|NCT00066703|ACTIVE_COMPARATOR|T+OFS|Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.
62264425|NCT00066703|EXPERIMENTAL|E+OFS|Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.
62264426|NCT05632887||Control|The population who do not use eyeliner.
62264427|NCT05632887||Eyeliner|The population who using eyeliner and the duration and frequency are appropriate。
62846783|NCT05540587|ACTIVE_COMPARATOR|Warfarin|Patients in the Warfarin group take Warfarin 2-10mg once daily, dose adjusted with the target INR 2-3. In the elderly or frail patients, a lower dose administration is allowed at the discretion of the investigator.
62846784|NCT04346355|EXPERIMENTAL|Experimental Arm|Tocilizumab within 8 hours from entering the study + standard of care; 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
62846785|NCT04346355|OTHER|Control Arm|Standard of care; In the event of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
62060427|NCT01667367|PLACEBO_COMPARATOR|Placebo|
62060428|NCT01667367|EXPERIMENTAL|RG1662|
62264428|NCT04132362||People living with dementia, their families and carers|The cohort consists of people living with dementia. Each of them will be accompanied, throughout the study, by a family member or friend. They will take part together in a one hour music listening session, to discover their personalised playlist. Where possible, a care home staff member will join in, in order to witness the benefits of the music to the dementia resident and learn how to provide the music, as part of their care in the care home.
62264429|NCT04577235|EXPERIMENTAL|Survivors group|Lung ultrasound score and computed tomography score were evaluated in the surviving group
62846786|NCT03479164|EXPERIMENTAL|Ultra Low-Dose CT|One non-contrast gated aortic (NCGA) computer tomography scan, a low radiation, non-contrast, low cost CT based study
62620743|NCT03747783||Survival Group|status from radical operation to follow-up
62846787|NCT04455152|EXPERIMENTAL|Self-control|two-week period of practicing self-control (attempting to avoid eating sweet foods) and self-monitoring success in doing so
62846788|NCT04455152|NO_INTERVENTION|wait list|waiting 2 weeks after baseline assessment before gaining access to web-based self-help
62846789|NCT04981535|EXPERIMENTAL|Patients undergoing upper gastrointestinal endoscopy with head box|experimental group
62846790|NCT04981535|NO_INTERVENTION|Patients undergoing upper gastrointestinal endoscopy without head box|standard of care group
62264430|NCT04577235|EXPERIMENTAL|Non survivors group|Lung ultrasound score and computed tomography score were evaluated in the non surviving group
62620744|NCT03747783||Non-Survival Group|status from radical operation to follow-up
62846791|NCT04452110||Group I|In volunteers in Group 1, values obtained using a linear probe will be compared.
62846792|NCT04452110||Group II|In volunteers in Group 2, values obtained using a hockey stick probe will be compared.
62846793|NCT01656655||PTSD group|Patients with PTSD
62846794|NCT01656655||Control Group|non PTSD group
62846795|NCT03340324|EXPERIMENTAL|One arm open label V-Endo recepients|This is single arm open label trial wherein active drug is V-Endo
62846796|NCT01601652|EXPERIMENTAL|Omeagven|
62264431|NCT02690155||Rivaroxaban|NVAF patients who were initiated on rivaroxaban for stroke prevention
62264432|NCT02690155||VKA (Vitamin K antagonist)|NVAF patients who were initiated on VKA for stroke prevention
62620745|NCT02022735|EXPERIMENTAL|Bilateral stimulation|Participants will receive Deep Brain Stimulation Bilaterally.
62620746|NCT02022735|EXPERIMENTAL|Left stimulation|Participants will receive Deep Brain Stimulation on the left side only
62620747|NCT02022735|EXPERIMENTAL|Right stimulation|Participants will receive Deep Brain Stimulation on the right side only
62620748|NCT02022735|NO_INTERVENTION|Off stimulation|Participants will receive no brain stimulation
62620749|NCT03142776|PLACEBO_COMPARATOR|Periodontal debridement|Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
62620750|NCT03142776|ACTIVE_COMPARATOR|Periodontal debridement + CLM|Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours) for 3 days.
62620751|NCT03142776|ACTIVE_COMPARATOR|Periodontal debridement + PDT|Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days) and a single application of PDT (Photodynamic Therapy).
62846797|NCT01146327|EXPERIMENTAL|PF-04620110|
62846798|NCT01146327|PLACEBO_COMPARATOR|Placebo Comparator|
62846799|NCT03458013|EXPERIMENTAL|Mindfulness Meditation plus Hand Therapy|Participants will be recruited from patients suffering from a traumatic injury who are entering hand therapy at a community based clinic in the Los Angeles area.
62846800|NCT03458013|NO_INTERVENTION|Standard Care in Hand Therapy|Participants will be recruited from patients suffering from a traumatic injury who are entering hand therapy at a community based clinic in the Los Angeles area.
62264433|NCT02237300|EXPERIMENTAL|VR based cue-exposure therapy|Throughout the six sessions, participants (n=30) will be exposed to different VR environments related to binge behavior, according to a previously constructed hierarchy. During exposure, patients will face high risk situations to diminish or to extinguish the conditioned response of anxiety when exposed to food related cues. In each session, the patient will be exposed to the corresponding step of the hierarchy. During the exposure session, the patient can handle the virtual foods using the laptop's mouse but cannot eat the foods (exposure with response prevention). Exposure will end when the anxiety level decreased by 40% in relation to the level registered at the initiation of the exposure session or after 60 minutes of exposure.
62264434|NCT02237300|ACTIVE_COMPARATOR|Additional Cognitive-behavioral treatment|Participants (n=30) in this condition will receive six CBT booster sessions (two sessions per week) over the course of three weeks to improve the output of treatment. CBT sessions are based on the approach described by by Eldredge and colleagues (Eldredge et al.,1997). In this treatment program, patients are trained to self-monitor their food patterns and to identify and manage thoughts, emotions, and environmental factors related to disrupted eating behaviors.
62264435|NCT06223282|EXPERIMENTAL|short inter-set rest|3 multi-joints resistance exercise with short (60s) inter-set rest
62264436|NCT06223282|EXPERIMENTAL|medium inter-set rest|3 multi-joints resistance exercise with medium(120s) inter-set rest
62264437|NCT06223282|EXPERIMENTAL|long inter-set rest|3 multi-joints resistance exercise with long (180s) inter-set rest
62264438|NCT06223282|EXPERIMENTAL|medium inter-set rest with failure|3 multi-joints resistance exercise with medium (120s) inter-set rest repeated to failure each set
62060429|NCT02975635||Oral patient information only|Patients are given oral information only (information as usual). After patients have made their decisions (repair or replacement), a questionnaire survey is conducted.
62060430|NCT02975635||Written patient education before oral patient information|Patients are given a flow chart in advance of oral information. After patients have made their decisions (repair or replacement), a questionnaire survey is conducted.
62060431|NCT03804775||case group|patients presenting with gallstone disease
62060432|NCT03804775||control group|inpatients with no history of gallstones
62264439|NCT06223282|NO_INTERVENTION|control|stayed sedentary during the period.
62448083|NCT06131021|EXPERIMENTAL|Test Arm|Patient participants in this arm will receive a combination of Amoxicillin 500mg \& Metronidazole 500mg orally (AMXM) as adjuncts along with their scheduled non-surgical periodontal treatment as the study intervention. A loading dose of 1g of Amoxicillin and 1g of Metronidazole will be given 30-60 minutes prior to periodontal treatment. After the loading dose, each patient participant will be instructed to take Amoxicillin 500mg \& Metronidazole 500mg every 8 hours for 10 days.
62620752|NCT03142776|ACTIVE_COMPARATOR|Periodontal debridement + CLM + PDT|Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours for 3 days) and single application of PDT.
62620753|NCT00593606|EXPERIMENTAL|Rotigotine|Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.
62060433|NCT05153460||Single Arm Study (Cohort)|"All participants will be on standard telemetry monitoring for Heart Rate and Respiration Rate using the gold standard (Electrocardiography and Capnography respectively).~In addition, two contactless monitoring devices will be placed on the patient bed to measure data simulataneously. These devices include EarlySense (USFDA approved ballistocardiography device) and Dozee VS (Investigational Device)."
62060434|NCT00519701|EXPERIMENTAL|1|hydroxyurea
62264440|NCT02079103|EXPERIMENTAL|Virtual reality|Virtual reality training using the YouGrabber® for patients with impaired arm motor function after stroke. The YouGrabber exercises focus on intensity, repetitions and motivating tasks and are adapted to the patient's motor abilities.
62620754|NCT00547417|ACTIVE_COMPARATOR|1|tadalafil
62060435|NCT04570241|ACTIVE_COMPARATOR|Group A-Malaria toolkit|School children shall be trained on key malaria messages with a malaria toolkit. From the training received, the pupils will carry out awareness-raising in communities with key messages learnt.
62060436|NCT04570241|NO_INTERVENTION|Group B-No malaria toolkit|"School children shall not be trained on key malaria messages with a malaria toolkit. Pupils will not carry out awareness-raising in communities with key messages.~."
62060437|NCT05806944|EXPERIMENTAL|Group A|Patients with BED not undergoing symptom provocation
62060438|NCT05806944|EXPERIMENTAL|Group B|Patients with BED not undergoing symptom provocation
62060439|NCT05806944|EXPERIMENTAL|Group C|Patients with BED undergoing symptom provocation
62060440|NCT05806944|EXPERIMENTAL|Group D|Patients with BED undergoing symptom provocation
62060441|NCT03379623|EXPERIMENTAL|Intervention group|
62264441|NCT02079103|ACTIVE_COMPARATOR|Conventional arm training|The patients receive supervised self-training exercises with focus on functional tasks adapted to their motor abilities.
62060442|NCT03379623|NO_INTERVENTION|Usual care group|
62448084|NCT06131021|PLACEBO_COMPARATOR|Control Arm|Patient participants in this arm will receive a placebo capsules identical to the study drug capsules along with their scheduled non-surgical periodontal treatment as the placebo comparator in an identical frequency and duration fashion as the active drug group.
62620755|NCT03425994||Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide|Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) tablet by mouth, once daily for 48 weeks
62620756|NCT02992756|EXPERIMENTAL|Instillation of growth factors|Patients candidates to an IVF/ICSI cycle with low follicular reserve: after at least one cycle of stimulation obtaining 0-3 oocytes.
62620757|NCT05158842|OTHER|Bubble CPAP Oxygen Therapy|Feasibility of Device
62620758|NCT05546320|ACTIVE_COMPARATOR|Migraine Medication Group|Patients randomized into migraine medication group will be given Metoprolol 25mg twice a day as the control group.
62620759|NCT05546320|EXPERIMENTAL|Anticoagulation or anti-platelet medication Group 1|Patients randomized into anticoagulation or anti-platelet medication group will be given aspirin.
62264442|NCT05021107|EXPERIMENTAL|Group A|Fascial Distortion Model with neck isometrics
62448085|NCT02354300||TCD Ultrasound|Transcranial doppler ultrasound monitoring during flow diverter placement.
62846801|NCT01236976|EXPERIMENTAL|Intervention Group|Participants in Group A will receive a triad of interventions comprising body weight supported treadmill training (BWSTT) using the Therastride Treadmill System, functional electrical stimulation (FES)-assisted cycling, and trunk and upper and lower limb exercise. These interventions will be provided at the spinal unit.
62264443|NCT05021107|ACTIVE_COMPARATOR|Group B|Fascial Distortion Model with neck isometrics
62846802|NCT01236976|OTHER|Control Group|Participants in Group B will receive an upper body strength and fitness program. This program may be provided at the spinal unit, or an appropriately equipped gymnasium as approved by the SCIPA Full-On Project Committee. It will be based on the Burn Rubber Burn (BRB) exercise program already established in Sydney. BRB is a circuit-based exercise program incorporating resistance and cardiovascular training. For this protocol, the circuit will comprise several stations using different pieces of equipment.
62846803|NCT03563183||Overall Group|Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
62264444|NCT03448237|ACTIVE_COMPARATOR|Speech therapy|Speech therapy adapted to the child,
62264445|NCT03448237|EXPERIMENTAL|Combined Treatment|Association of speech therapy and proprioceptive treatment, adapted to the child.
62620760|NCT05546320|EXPERIMENTAL|Anticoagulation or anti-platelet medication Group 2|Patients randomized into anticoagulation or anti-platelet medication group will be given clopidogrel.
62620761|NCT05546320|EXPERIMENTAL|Anticoagulation or anti-platelet medication Group 3|Patients randomized into anticoagulation or anti-platelet medication group will be given Rivaroxaban.
62846804|NCT03771170|EXPERIMENTAL|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
62846805|NCT03771170|ACTIVE_COMPARATOR|Ringer lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
62846806|NCT03407716|EXPERIMENTAL|Group I (North American ginseng extract AFX-2)|Patients receive North American ginseng extract AFX-2 PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62846807|NCT03407716|PLACEBO_COMPARATOR|GROUP II (placebo)|Patients receive placebo PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. At the end of course 2, patients may optionally crossover to Group I to receive ginseng for an additional 28 days.
62846808|NCT02176252|EXPERIMENTAL|AZD1722|Dose escalation from 5 mg to 90 mg BID
62060443|NCT05680454|EXPERIMENTAL|The Group of Investigational Vaccine|"For Low-dosage group, 0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 20μg、40μg、40μg、20μg、20μg、20μg、20μg、20μg, and 20μg respectively, totaling 220μg of antigens.~For High-dosage group, 0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30μg、40μg、80μg、60μg、30μg、30μg、30μg、30μg and 30μg respectively, totaling 360μg of antigens.~For Mid-dosage group, 0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30μg、40μg、60μg、40μg、20μg、20μg、20μg、20μg and 20μg respectively, totaling 270μg of antigens."
62264446|NCT04304716|ACTIVE_COMPARATOR|Fibular free flap-Block performed|For subjects in the experimental/regional anesthesia group for anterolateral thigh or radial forearm free flap, during the procedure a catheter will be placed into the donor site (leg or arm), wound bed
62264447|NCT04304716|ACTIVE_COMPARATOR|Anterolateral thigh free flap-Block performed|Description: For subjects in the experimental/regional anesthesia group for anterolateral thigh or radial forearm free flap, during the procedure a catheter will be placed into the donor site (leg or arm), wound bed
62264448|NCT04304716|ACTIVE_COMPARATOR|Radial forearm free flap-Block performed|Description: For subjects in the experimental/regional anesthesia group for anterolateral thigh or radial forearm free flap, during the procedure a catheter will be placed into the donor site (leg or arm), wound bed
62264449|NCT04304716|NO_INTERVENTION|Fibular free flap -Control|No additional procedures beyond the normal standard of care will be performed
62264450|NCT04304716|NO_INTERVENTION|Anterolateral thigh free flap-Control|No additional procedures beyond the normal standard of care will be performed
62448086|NCT01223807|NO_INTERVENTION|Control Group|The control group will receive only usual care.
62448087|NCT01223807|EXPERIMENTAL|Diaphragmatic breathing training|The training group will be submitted to a diaphragmatic breathing training program of 4 weeks.
62620762|NCT02178358|EXPERIMENTAL|150 milligram (mg) Galunisertib Monotherapy|150 mg galunisertib administered orally, twice daily (BID) for 14 days followed by 14 days with no study drug (28 days cycle).
62620763|NCT02178358|EXPERIMENTAL|150 mg Galunisertib + 400 mg Sorafenib Therapy|"150 mg galunisertib administered orally, BID for 14 days followed by 14 days with no study drug (28 days cycle).~400 mg sorafenib administered orally BID for 28 days."
62264451|NCT04304716|NO_INTERVENTION|Radial forearm free flap-Control|No additional procedures beyond the normal standard of care will be performed
62448088|NCT06201273|EXPERIMENTAL|High-Intensity Interval Training|This High-Intensity Interval Training (HIIT) program, structured to span 12 weeks, incorporates three sessions per week. Each session comprises 8 to 10 exercise intervals on a cycle ergometer. During these intervals, participants are required to reach an intensity level between 8 and 10 points, based on the modified Borg scale, which ranges from 1 to 10 points. A typical interval involves 1 minute of intensive pedaling, followed by a 2-minute rest period without any activity. To facilitate progressive development, the resistance of the cycle ergometer will be adjusted biweekly to increase the pedaling challenge. Despite these adjustments, participants should consistently maintain their effort intensity within the 8 to 10 point range on the modified Borg scale for each interval.
62620764|NCT02178358|PLACEBO_COMPARATOR|400 mg Sorafenib + Placebo Therapy|"Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 days cycle).~400 mg sorafenib administered orally BID for 28 days."
62620765|NCT00565227|EXPERIMENTAL|docetaxel plus vorinostat|
62846809|NCT05266833|NO_INTERVENTION|Control|Students in the control class received regular class instruction during the 5 weeks. This instruction did not deviate from regular instruction that was provided to all classes, including the intervention classes. During the intervention period, control group students completed the assessments once per week. The control class is considered a treatment-as-usual active control.
62060444|NCT05680454|ACTIVE_COMPARATOR|The Group of Active Control Vaccine|Each 0.5-mL single-dose vial of GARDASIL9 contains approximately 30 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 60 mcg of HPV Type 16 L1 protein, 40 mcg of HPV Type 18 L1 protein, 20 mcg of HPV Type 31 L1 protein, 20 mcg of HPV Type 33 L1 protein, 20 mcg of HPV Type 45 L1 protein, 20 mcg of HPV Type 52 L1 protein, and 20 mcg of HPV Type 58 L1 protein, totaling 270 mcg of antigens.
62060445|NCT02832622||MPP Programming|This post-market study was designed to characterize the real-world use of MPP technology in patients indicated for CRT device implant. Therefore in order to adequately characterize MPP, data from subjects with MPP programmed continuously or for at least 3 months prior to the final follow-up are reported as the MPP programming group.
62060446|NCT05760976|EXPERIMENTAL|Age range of 18 to 44 years olds|The initial dose of cisatracurium for pre-injection was set at 0.015mg/kg according to previous literature and preliminary test results. The dose of cisatracurium was according to the patients' fasciculation level. If there is no fasciculation (negative reaction), the dose of cisatracurium in the next patient will be reduced until the patient has fasciculation. If there is fasciculation (positive reaction), the dose of cisatracurium will be increased in the next patient until the patient has no fasciculation.
62060447|NCT05760976|EXPERIMENTAL|Age range of 45 to 59 years olds|The initial dose of cisatracurium for pre-injection was set at 0.015mg/kg according to previous literature and preliminary test results. The dose of cisatracurium was according to the patients' fasciculation level. If there is no fasciculation (negative reaction), the dose of cisatracurium in the next patient will be reduced until the patient has fasciculation. If there is fasciculation (positive reaction), the dose of cisatracurium will be increased in the next patient until the patient has no fasciculation.
62060448|NCT05760976|EXPERIMENTAL|Age range of 60 to 80 years olds|The initial dose of cisatracurium for pre-injection was set at 0.015mg/kg according to previous literature and preliminary test results. The dose of cisatracurium was according to the patients' fasciculation level. If there is no fasciculation (negative reaction), the dose of cisatracurium in the next patient will be reduced until the patient has fasciculation. If there is fasciculation (positive reaction), the dose of cisatracurium will be increased in the next patient until the patient has no fasciculation.
62620766|NCT00006244|EXPERIMENTAL|Treatment (immunotherapy)|Patients receive melphalan IV over 2-3 hours on day -2 and an infusion of IL-2-treated autologous or syngeneic peripheral blood stem cells on day 0. Beginning on day 0, patients also receive IL-2 IV continuously over 5 days followed by 2 days off. Treatment with IL-2 repeats weekly for 4 weeks. Beginning 1 month later, patients undergo maintenance therapy comprising interferon alfa SC 3 times a week in the absence of disease progression or unacceptable toxicity.
62620767|NCT00845273||Pegaptanib sodium|Patients administered Pegaptanib sodium.
62620768|NCT00639392|PLACEBO_COMPARATOR|2|Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive placebo are 1 out of 3.
62264452|NCT01375842|EXPERIMENTAL|Dose Escalation Cohort: Atezolizumab 0.01 mg/kg|Participants will receive intravenous (IV) infusion of atezolizumab 0.01 milligrams per kilogram (mg/kg) every 3 weeks (q3w) until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
62264453|NCT01375842|EXPERIMENTAL|Dose Escalation Cohort: Atezolizumab 0.03 mg/kg|Participants will receive IV infusion of atezolizumab 0.03 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
62264454|NCT01375842|EXPERIMENTAL|Dose Escalation Cohort: Atezolizumab 0.1 mg/kg|Participants will receive IV infusion of atezolizumab 0.1 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
62264455|NCT01375842|EXPERIMENTAL|Dose Escalation Cohort: Atezolizumab 0.3 mg/kg|Participants will receive IV infusion of atezolizumab 0.3 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
62264456|NCT01375842|EXPERIMENTAL|Dose Escalation Cohort: Atezolizumab 1 mg/kg|Participants will receive IV infusion of atezolizumab 1 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
62264457|NCT01375842|EXPERIMENTAL|Dose Escalation Cohort: Atezolizumab 3 mg/kg|Participants will receive IV infusion of atezolizumab 3 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
62264458|NCT01375842|EXPERIMENTAL|Dose Escalation Cohort: Atezolizumab 10 mg/kg|Participants will receive IV infusion of atezolizumab 10 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
62264459|NCT01375842|EXPERIMENTAL|Dose Escalation Cohort: Atezolizumab 20 mg/kg|Participants will receive IV infusion of atezolizumab 20 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
62264460|NCT01375842|EXPERIMENTAL|Expansion Cohort (Atezolizumab)|Participants will receive IV infusion of atezolizumab q3w up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first. The dose which result in total drug exposure less than or equal to (\</=) exposures achieved at the MTD or maximum administered dose (MAD), will be selected for expansion cohort.
62264461|NCT05618600||Paxlovid Cohort|Participants will be separated into 2 arms that are self-selected through the decision to opt in or out of Paxlovid. After patients are offered a 5-day course of Paxlovid and have made a treatment decision they will be eligible to join the study. Arm 1 will include 400 participants that opt to take the 5-day course of Paxlovid. Participation will look identical in this study.
62264462|NCT05618600||Control Cohort|Participants will be separated into 2 arms that are self-selected through the decision to opt in or out of Paxlovid. After patients are offered a 5-day course of Paxlovid and have made a treatment decision they will be eligible to join the study. Arm 2, control, will include 400 participants that opt out of taking the 5-day course of Paxlovid. Participation will look identical in this study.
62264463|NCT02835183|EXPERIMENTAL|Insulin pump followed by iDECIDE|Participants will be randomly assigned to 4 weeks of using their insulin pump to decide insulin boluses and then 4 weeks of using iDECIDE to receive recommendations for insulin dosing.
62264464|NCT02835183|EXPERIMENTAL|iDECIDE followed by insulin pump|Participants will be randomly assigned to 4 weeks of using iDECIDE to receive recommendations for insulin dosing and then 4 weeks of using their insulin pump to decide insulin boluses.
62264465|NCT06023160||Dutch National anti-NMDAR Encephalitis Cohort|Dutch National anti-NMDAR Encephalitis Cohort
62264466|NCT06023160||German anti-NMDAR Encephalitis Cohort (GENERATE)|German anti-NMDAR Encephalitis Cohort (GENERATE)
62264467|NCT06023160||Spanish anti-NMDAR Encephalitis Cohort|Spanish anti-NMDAR Encephalitis Cohort
62264468|NCT06023160||French anti-NMDAR Encephalitis Cohort|French anti-NMDAR Encephalitis Cohort
62264469|NCT06023160||Japanese anti-NMDAR Encephalitis Cohort|Japanese anti-NMDAR Encephalitis Cohort
62264470|NCT01248351|EXPERIMENTAL|autologous stored platelets|
62264471|NCT03138538|EXPERIMENTAL|M8891 7 mg|Participant received M8891 at dose of 7 milligrams (mg) orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
62264472|NCT03138538|EXPERIMENTAL|M8891 12 mg|Participant received M8891 at dose of 12 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
62264473|NCT03138538|EXPERIMENTAL|M8891 20 mg|Participant received M8891 at dose of 20 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
62264474|NCT03138538|EXPERIMENTAL|M8891 35 mg|Participant received M8891 at dose of 35 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
62264475|NCT03138538|EXPERIMENTAL|M8891 60 mg|Participant received M8891 at dose of 60 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
62264476|NCT03138538|EXPERIMENTAL|M8891 80 mg|Participant received M8891 at dose of 80 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
62264477|NCT02006342|EXPERIMENTAL|Insulin Glargine plus Regular Insulin|Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring, with the addition of subcutaneous Insulin Glargine within 2 hours of diagnosis.
62264478|NCT02006342|ACTIVE_COMPARATOR|Control - Regular Insulin|Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring.
62264479|NCT03114514|EXPERIMENTAL|PRP injection|A PRP-injection will be performed three times during the course of treatment
62264480|NCT03896516|EXPERIMENTAL|Active Drug|GOAT Inhibitor
62620769|NCT00639392|EXPERIMENTAL|1|Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive Zolendronic Acid are 2 out of 3.
62620770|NCT04672876|EXPERIMENTAL|Telotristat Ethyl (Xermelo®)|After the surgery is performed, study participants will stop taking telotristat ethyl (Xermelo®) as part of this study and there will be no follow-up visits or calls required outside of the usual postoperative care. The research team will collect clinical data on the participants' outcomes up to 30 days after surgery by accessing medical records.
62846810|NCT05266833|EXPERIMENTAL|Self-Paced Breathing|The self-paced slow diaphragmatic breathing intervention provided guidance for participants to breathe at a slower pace than normal with brief, organic pauses after each inhale and exhale, and with exhales longer than inhales. Participants were guided to breathe at their own pace while following these principles of longer exhales and brief pauses after each inhale/exhale. They were invited to slow their pace when ready, both during each 5-minute session and over the course of the 5 weeks.
62060449|NCT01852331|ACTIVE_COMPARATOR|PGD granules|While continuing current antipsychotic medications, subjects will receive adjunctive Peony-Glycyrrhiza Decoction (PGD) granules (equivalent to 45 g raw materials in total per day). They need to take the granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
62060450|NCT01852331|PLACEBO_COMPARATOR|Placebo|While continuing current antipsychotic medications, subjects will receive adjunctive treatment with placebo granules. They need to take the placebo granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
62060451|NCT05175599|NO_INTERVENTION|Land Birth|Women in the land birth group will labor and give birth according to standard of care procedures.
62264481|NCT03896516|PLACEBO_COMPARATOR|Placebo|Placebo Participants will take GLWL-01 450 mg b.i.d. or matched placebo for up to 16 days
62264482|NCT02132481|EXPERIMENTAL|EMA Only|See intervention
62060452|NCT05175599|EXPERIMENTAL|Water Birth|Women in the water birth group will give birth in the water. During the first stage of labor, women may enter or leave the water at any point.
62060453|NCT02592330|EXPERIMENTAL|Cultivated Autologous Limbal Epithelial Cell (CALEC) graft|Participants will have a corneal biopsy in their non-diseased eye, which will provide cells for the creation of the CALEC graft. The CALEC will be made at the Good Manufacturing Practice (GMP) Laboratory, Dana Farber Cancer Institute and transported to Mass. Eye and Ear Infirmary for application to the participant's diseased eye during their standard corneal reconstruction procedure.
62264483|NCT02132481|EXPERIMENTAL|EMI Only|See intervention
62264484|NCT02132481|EXPERIMENTAL|EMA+EMI|See intervention
62264485|NCT02132481|ACTIVE_COMPARATOR|Neither - RSAU|See intervention
62264486|NCT03861559|EXPERIMENTAL|mometasone furoate nasal spray|Participants administered mometasone furoate nasal spray 200 mcg once daily (QD), as two 50 mcg sprays per nostril, for 14 consecutive days.
62620771|NCT04363138||bacterial infection|Patients with bacterial infection
62264487|NCT03861559|PLACEBO_COMPARATOR|placebo nasal spray|Participants administered placebo nasal spray QD, as two placebo sprays per nostril, for 14 consecutive days.
62264488|NCT02579070|EXPERIMENTAL|DFUPS (visual and thermal images)|Visual and thermal imaging with DFUPS and standard foot care. The study investigator will have access to the thermal and visual images captured with DFUPS.
62264489|NCT02579070|PLACEBO_COMPARATOR|DFUPS ( visual images)|Visual and blinded thermal imaging with DFUPS and standard foot care. The study investigator will have access only to the visual images and will be blinded to the thermal images which will be captured at each visit but accessed only at the end of the study.
62264490|NCT05075070|EXPERIMENTAL|Experimental Group|A total 400 HIV-infected subjects receive two doses inactivated COVID-19 vaccine with the interval of 21 days.
62264491|NCT00881400|EXPERIMENTAL|1|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)
62264492|NCT00881400|ACTIVE_COMPARATOR|2|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)
62264493|NCT04807907|EXPERIMENTAL|Infant Directed Speech (IDS) Video + IDS Calendar|The participant will be shown a 3-minute video describing the value of IDS and how the participant can use IDS with their child. The participant will receive an IDS-themed wall calendar.
62264494|NCT04807907|NO_INTERVENTION|Control|No intervention. The participant will receive a regular wall calendar with an image of Stanford.
62264495|NCT03866044||Parkinson's Disease (PD)|"Patients with Parkinson's Disease meeting the following criteria:~Inclusion criteria:~* Aged 18 or more.~* Clinically established or probable PD according to the MDS Clinical Diagnostic Criteria for Parkinson's Disease~* Signed informed consent~Exclusion criteria:~* Pregnancy or breastfeeding~* History of other neurologic or psychiatric disease~* Pacemaker or other implanted electronic devices~* Claustrophobia"
62620772|NCT04363138||No bacterial infection|Patients without bacterial infection
62620773|NCT00691652|EXPERIMENTAL|Oral Clofarabine + Rituximab in Relapsed B Cell NHL|"Phase I: Oral Clofarabine x 14 days for up to 8 cycles at assigned dose level below (1 cycle equals 14 days on drug, 14 days off).~Rituximab weekly for 4 weeks than monthly for up to 8 cycles on day 1 of cycle 375 mg/m2 IV~Dose Level 1: 2 mg Dose Level 2: 4 mg Dose Level 3: 6 mg~Phase II:~Oral Clofarabine x 14 days for up to 8 cycles (Dose determined from phase I) AND Rituximab weekly for 4 weeks than monthly for up to 8 cycles on day 1 of cycle 375 mg/m2 IV"
62846811|NCT05266833|EXPERIMENTAL|Guide-Paced Breathing|The guide-paced slow diaphragmatic breathing intervention comprised slow breathing with all exhales twice as long as the inhales; e.g., a 3-second inhale was followed by a 6-second exhale. Participants were instructed to breathe in sync with the guided pace. The breathing pace slowed over the 5 weeks: for weeks 1-2, the breath pattern comprised a 3-second inhale followed by a 6-second exhale; for weeks 3-4, the timing was 4 and 8, respectively; and was 5 and 10 for the last week.
62846812|NCT03333772|EXPERIMENTAL|REAL-T Intervention|The current feasibility study will evaluate the feasibility of implementing the REAL-T RCT by enrolling 10 participants who are 18-30 years of age, conducting the REAL-T intervention with all participants over a 3-month period, evaluating pre-to-post changes in their health and quality of life, and assessing the process of implementing the study (feasibility and participant satisfaction).
62846813|NCT01658644|NO_INTERVENTION|Group A|Patients participating in group A, will not be exposed to any interventions, they will partake in the typical hospital and communication experience.
62846814|NCT01658644|EXPERIMENTAL|Group B (text handout)|Patients assigned to group B will be provided with a paper or electronic version displaying a list of the names and roles of their clinical care staff; each name will NOT be accompanied by the respective photograph of each clinician. This document will be presented to the patient at the earliest possible time after admission to the hospital.
62846815|NCT01658644|EXPERIMENTAL|Group C (text & image handout)|Patients assigned to group C will be provided with a paper or electronic version displaying a list of the names and roles of their clinical care staff; each name will also be accompanied by the respective photograph of each clinician. This document will be presented to the patient at the earliest possible time after admission to the hospital.
62060454|NCT01437150|EXPERIMENTAL|Simple posterior wall fracture|Simple posterior wall fracture means the fracture was only occurred in the posterior wall of acetabular.
62060455|NCT01437150|EXPERIMENTAL|Complex posterior wall fracture|Complex posterior wall fracture means the fracture was not only occurred in the posterior wall of acetabular, but also occurred in other part of acetabular.
62620774|NCT03087383||Prospective Cohort|In adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm, investigator will collect data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions. Data collection will be established with just observing and recording values displayed in screens of monitoring devices, and reviewing patient charts.
62620775|NCT03087383||Retrospective Cohort|In previous study performed in adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm (NCT02700126, 4-2015-1195), investigator enrolled patients and collected data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions.
62620776|NCT02079441||Infants, IBD, anti TNF, pregnancy|Infants of mothers with anti-TNF in pregnancy
62620777|NCT02079441||infants, IBD, pregnancy, medications|Infants of mothers with non anti TNFin pregnancy
62264496|NCT03866044||Healthy participants|"Healthy participants age- and sex-matched to the PD group.~Inclusion criteria:~* Age- and sex-matched to PD group (aged 18 or more)~* Signed informed consent~Exclusion criteria:~* Pregnancy or breastfeeding~* History of neurologic or psychiatric disease~* Pacemaker or other implanted electronic devices~* Claustrophobia"
62620778|NCT03824366|EXPERIMENTAL|Volumetric MR imaging planning|"* All patients will undergo volumetric MR imaging on treatment days in positioning appropriate for the specific treatment site.~* Patients will receive standard of care palliative radiation therapy"
62620779|NCT06010628|EXPERIMENTAL|Tenecteplase group|intravenous thrombolysis with tenecteplase
62620780|NCT06010628|OTHER|Control group|standard stroke care based on national guideline
62620781|NCT03701152|EXPERIMENTAL|Negative pressure therapy|Negative pressure therapy topical application using negative pressure therapy sub atmospheric pressure Continuous course
62846816|NCT06205550|ACTIVE_COMPARATOR|Flecainide + beta-blocker|
62846817|NCT06205550|EXPERIMENTAL|Flecainide monotherapy|
62846818|NCT05927337|EXPERIMENTAL|Cognitive Behavioral Therapy for managing Obesity|"Participants will be enrolled in a 4-month programme of cognitive behavioural therapy for obesity management. The programme is described in more detail in the annex. The programme will consist of 12 individual sessions, with weekly sessions for the first eight weeks and bi-monthly sessions for the following eight weeks.~Treatment as usual: participants will receive three sessions with a dietician to receive basic information on appropriate diet, energy deficit and nutrition plan and three sessions with a kinesiologist to receive advice on physical activity."
62060456|NCT03040921|EXPERIMENTAL|Uterine Transposition|Patients submitted to uterine transposition.
62060457|NCT01437124||Ceramic on metal THA|Those who have received a ceramic on metal total hip replacement
62060458|NCT04142502|ACTIVE_COMPARATOR|Propofol group|Using propofol as a sedation drug Infusion rate control Effect site concentration 0.3\~1.0 mg/ml using target concentration infusion Bispectral index 60\~80
62060459|NCT04142502|ACTIVE_COMPARATOR|Dexmedetomidine group|Using dexmedetomidine as a sedation drug First 10 minutes 1.0 mcg/kg loading After 10 minutes 0.3-1.0 mcg/kg/hr maintenance Bispectral index 60\~80
62264497|NCT00129766|ACTIVE_COMPARATOR|palivizumab|15 mg/kg administered intramuscularly for 5 monthly doses
62264498|NCT00129766|EXPERIMENTAL|motavizumab (MEDI-524)|15 mg/kg of motavizumab was administered intramuscularly for 5 monthly doses
62264499|NCT04027400|ACTIVE_COMPARATOR|Primarily visual computer exercises|Participant performs visual computer exercises 30 minutes a day, five days a week for one month.
62620782|NCT03701152|EXPERIMENTAL|Investigator|Negative pressure therapy topical application using negative pressure therapy sub atmospheric pressure Splitted course
62620783|NCT00888498|PLACEBO_COMPARATOR|Hands-On Control|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the experimental groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
62620784|NCT00888498|EXPERIMENTAL|Fast Stretching|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
62620785|NCT00888498|EXPERIMENTAL|Slow Stretching|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
62620786|NCT04969588||Children and adult|Participants aged 6-65 years old are recruited for the measurements of depth camera, bioelectrical impedance analysis and dual energy X-ray absorptiometry.
62620787|NCT02156440|PLACEBO_COMPARATOR|Placebo|Placebo capsules: one capsule taken 3 times per day with water. Subjects are to drink 6 to 8 glasses of water daily.
62620788|NCT02156440|EXPERIMENTAL|SierraSil Joint Formula 14|SierraSil Joint Formula 14 capsules: one capsule taken 3 times per day with water. Subjects are to drink 6 to 8 glasses of water daily.
62620789|NCT05633589|EXPERIMENTAL|Experimental: Sc610 cell injection|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention: Sc610 cell injection.
62620790|NCT00621725|EXPERIMENTAL|1|
62620791|NCT00313586|EXPERIMENTAL|Arm A (azacitidine)|Patients receive azacitidine SC QD on days 1-10. Treatment repeats every 28 days for 6-24 courses in the absence of disease progression or unacceptable toxicity.
62620792|NCT00313586|EXPERIMENTAL|Arm B (azacitidine, entinostat)|Patients receive azacitidine as in Arm A and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 6-24 courses in the absence of disease progression or unacceptable toxicity.
62620793|NCT06012526||OSA group|The group of patients who had sleep disordered breathing
62620794|NCT06012526||No OSA group|The group of patients who had not sleep disordered breathing
62620795|NCT04965337|EXPERIMENTAL|ASC42 Dose A|ASC42 tablet Dose A, once daily
62620796|NCT04965337|PLACEBO_COMPARATOR|Placebo Dose A|Placebo Comparator: Single dose of matched placebo to ASC42 tablet Dose A, once daily
62620797|NCT04965337|EXPERIMENTAL|ASC42 Dose B|ASC42 tablet Dose B, once daily
62620798|NCT04965337|PLACEBO_COMPARATOR|Placebo Dose B|Placebo Comparator: Single dose of matched placebo to ASC42 tablet Dose A, once daily
62620799|NCT02993965|NO_INTERVENTION|Control 11-17|No additional intervention done aside from usual care for 11-17 year olds
62264500|NCT04027400|EXPERIMENTAL|Visual+Audio|Participant performs audio computer exercises and some visual computer exercises 30 minutes a day, five days a week for one month
62264501|NCT01231100|EXPERIMENTAL|HCUE-guided care|Hand-carried ultrasound echocardiography
62264502|NCT01231100|NO_INTERVENTION|Standard care|
62264503|NCT02372474|EXPERIMENTAL|Stem Cell therapy in POF|POF cases were evaluated hormonally, HP and IH using ESS. Autologous MSC were prepared and laparoscopically transplanted.
62620800|NCT02993965|EXPERIMENTAL|1 R/R per Dose 11-17|Sending up to one recall notice per dose of HPV vaccine needed for 11-17 year olds
62620801|NCT02993965|EXPERIMENTAL|2 R/R per Dose 11-17|Sending up to two recall notices per dose of HPV vaccine needed for 11-17 year olds
62620802|NCT02993965|EXPERIMENTAL|3 R/R per Dose 11-17|Sending up to three recall notices per dose of HPV vaccine needed for 11-17 year olds
62620803|NCT02993965|NO_INTERVENTION|Control 11-14|No additional intervention done aside from usual care for 11-14 year olds
62620804|NCT02993965|EXPERIMENTAL|Phone R/R 11-14|Sending up to two recall notices per dose of HPV vaccine needed via autodialer for 11-14 year olds
62060460|NCT04021186|EXPERIMENTAL|Intervention|Insulin treatment using standard measurements.
62060461|NCT04021186|NO_INTERVENTION|Control|Standard care.
62060462|NCT06155305||Breast cancer patients|Patients diagnosed with breast cancer undergo biopsy before initiating neoadjuvant therapy.
62060463|NCT05762835|EXPERIMENTAL|Intervention (Virtual Family-Centered Rounds [FCR])|"Virtual FCR-arm parents/guardians (referred to as parents hereafter) will have the option use have the option to use telehealth for virtual rounds. Parents can participate in virtual FCR as much, or as little, as they choose. Parents also will have the option to attend FCR in person or to not attend FCR."
62060464|NCT05762835|NO_INTERVENTION|Control (Usual Care)|Usual care-arm parents will receive usual care. Usual care-arm parents will have the option to attend FCR in person or to not attend FCR.
62264504|NCT01886365|ACTIVE_COMPARATOR|Group A|With start of the cardiopulmonary bypass, computerized algorithmic application of insulin was performed with a dedicated computerized syringe pump system (Space GlucoseControl System, B. Braun, Germany). The targeted corridor for blood glucose was determined with 80 - 150 mg/dl. During surgery, blood glucose was measured every 30 min, and on the ICU every 2 hours. TGC management was continued until ICU discharge.
62264505|NCT01886365|ACTIVE_COMPARATOR|Group B|Corresponding computerized algorithmic application of insulin management was used as for group A. However, only the interval of blood glucose measurement during surgery was adjusted to 15 minutes.
62264506|NCT01886365|OTHER|Group C|With start of the cardiopulmonary bypass conventional therapy with a fixed insulin dosing scheme was initiated. If blood glucose was \> 150 mg/dl, manual insulin therapy was started following a fixed insulin dosing scheme. Measurements of blood glucose were performed during surgery every 30 minutes, and on the ICU every 2 hours until discharge (Routine Care).
62264507|NCT05639907|EXPERIMENTAL|K21 Cavity cleanser-coated TAD|A TAD to be placed is coated with K21 solution. The solution is allowed to evaporate to dryness, leaving a K21-rich film. The TAD is placed following the University TAD placement protocol.
62620805|NCT02993965|EXPERIMENTAL|Mail R/R 11-14|Sending up to two recall notices per dose of HPV vaccine needed via mailed postcards for 11-14 year olds
62846819|NCT05927337|NO_INTERVENTION|Control group|Treatment as usual: participants will receive three sessions with a dietician to receive basic information on appropriate diet, energy deficit and nutrition plan and three sessions with a kinesiologist to receive advice on physical activity.
62060465|NCT00649363|EXPERIMENTAL|1|Ondansetron Orally Disintegrating Tablets 8 mg
62620806|NCT05390385|PLACEBO_COMPARATOR|Control placebo|
62620807|NCT05390385|EXPERIMENTAL|KE1 5g|
62620808|NCT05390385|EXPERIMENTAL|KE1 10g|
62620809|NCT05390385|EXPERIMENTAL|KE4 5g|
62060466|NCT00649363|ACTIVE_COMPARATOR|2|Zofran ODT® Tablets 8 mg
62620810|NCT05390385|EXPERIMENTAL|KE4 10g|
62060467|NCT00405457|OTHER|A|
62060468|NCT01933880|EXPERIMENTAL|OROS-MPH Group|Participants with ADHD will receive OROS -MPH starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
62620811|NCT04591392|EXPERIMENTAL|Device|ASD closure with the reSept ASD Occluder
62060469|NCT01933880|ACTIVE_COMPARATOR|Normal Group|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
62620812|NCT04414423|EXPERIMENTAL|Bone marrow concentrate|Bone marrow concentrate combined with Autogenous bone graft
62620813|NCT04414423|ACTIVE_COMPARATOR|autogenous bone graft|grafting with autogenous bone graft
62620814|NCT06133959|ACTIVE_COMPARATOR|e-Lymph Control|e-Lymph (Control). e-Lymph includes training sessions on the lymphatic system, lymphedema, lymphedema diagnosis and measurement, risk of lymphedema.
62620815|NCT06133959|EXPERIMENTAL|The-Optimal-Lymph Flow (TOLF) Program|TOLF includes training sessions on the lymphatic system, lymphedema, lymphedema diagnosis and measurement, risk of lymphedema, healthy diet, sleep hygiene, and daily lymphatic exercises. It has 8 avatar videos with step-by-step instructions for TOLF lymphatic exercises to promote lymph flow.
62620816|NCT05643209|OTHER|consecutive patients|20 patients clinically indicated for a endo-epicardial catheter-based mapping procedure for the treatment of ventricular tachycardia/ ventricular fibrillation substrate
62620817|NCT00708474|EXPERIMENTAL|OsseoFit™|Treatment of bone graft site with OsseoFit™ Porous Tissue Matrix™.
62620818|NCT00708474|NO_INTERVENTION|Open|Treatment of bone graft site without OsseoFit™ Porous Tissue Matrix™.
62620819|NCT01872650|NO_INTERVENTION|Control|No placement of an adhesion barrier
62620820|NCT01872650|EXPERIMENTAL|C-Qur|C-Qur film placement beneath the incision. Possibly placement of C-Qur film at other sites considered to be adhesiogenic (but not around the anastomosis)
62846820|NCT04390204|EXPERIMENTAL|Experimental|Motor control exercises are performed on foam mats. The physiotherapist instructs them, and gives a description on paper, as well as a USB key allowing to view the exercises on video. A supervised home self-rehabilitation program on foam mats is implemented.
62846821|NCT04390204|NO_INTERVENTION|control|According to the recommendations of learned societies, patients are offered voluntary MPP contraction work, in strength and endurance, in increasing complexity, under manual endocavitary control and under biofeedback. A supervised program of self-rehabilitation at home by voluntary contraction of MPP is set up.
62846822|NCT06457906|EXPERIMENTAL|SRS/SRT/Hypo-RT group|The patients in this group will receive local treatment for BM.
62846823|NCT06457906|ACTIVE_COMPARATOR|HA-WBRT group|The patients in this group will receive HA-WBRT.
62846824|NCT01358955|ACTIVE_COMPARATOR|Group cognitive intervention|The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
62846825|NCT01358955|ACTIVE_COMPARATOR|Home-based cognitive intervention|The participants will do their homework for 30 minutes every business days for 12 weeks.
62846826|NCT01358955|NO_INTERVENTION|Wait list Control|They will participate in cognitive intervention after ending this study.
62264508|NCT05639907|PLACEBO_COMPARATOR|Ethanol Control|A TAD to be placed is coated with ethanol solution. The solution is allowed to evaporate to dryness (no residue is expected). The TAD is placed following the University TAD placement protocol.
62620821|NCT03859648|EXPERIMENTAL|Bone Conduction Implant|All subjects will be implanted with the bone conduction implant.
62846827|NCT04820881||Case Group|Measurement of cerebrovascular reactivity and oxygen metabolism before and after a single dose of 50mg sildenafil citrate. Diffusion tensor imaging, other structural imaging and cognitive testing will also be completed.
62846828|NCT04820881||Control Group|Measurement of cerebrovascular reactivity and oxygen metabolism before and after a single dose of 50mg sildenafil citrate. Diffusion tensor imaging, other structural imaging and cognitive testing will also be completed.
62846829|NCT06273696||Circumcision clients|Participants who underwent the ShangRing circumcision procedure
62846830|NCT05431270|EXPERIMENTAL|Part A: Monotherapy Dose Escalation|A standard 3+3 dose escalation design will be employed, and 3 patients will be enrolled initially at each dose level. The starting dose of PT199 to be evaluated in the dose escalation study is 10 mg/kg weekly (QW). Additional provisional dose levels include: 20 mg/kg QW, and 30 mg/kg QW.
62846831|NCT05431270|EXPERIMENTAL|Part B: Combination Therapy Dose Escalation|A standard 3+3 dose escalation design will be employed, and 3 patients will be enrolled initially at each dose level. The starting dose of PT199 to be evaluated in the dose escalation study is 10 mg/kg weekly (QW). The dose level of PD-1 inhibitor, Tislelizumab in all provisional dose levels will be 200 mg once every 3 weeks (Q3W).
62846832|NCT05431270|EXPERIMENTAL|Part C: Combination Therapy Dose Expansion|"Approximately 8 additional patients will be treated in a dose expansion cohort at the MTD/DRDE.~A minimum of 14 evaluable patients should be treated at DRDE before it can be declared as Recommend Phase II dose (RP2D). These can include the evaluable patients who were treated at DRDE in the dose escalation cohort(s). The RP2D may be declared based on the totality of safety, pharmacokinetics, and efficacy data from the dose escalation and dose expansion cohort, and upon the consensus of the Investigator(s), medical monitor, and Sponsor."
62846833|NCT02384434|OTHER|Low Level Laser Therapy|Non-invasive, cold laser output treatment.
62846834|NCT03308721|EXPERIMENTAL|NNC9204-1177|Dose trial with a sequential trial design
62846835|NCT03308721|PLACEBO_COMPARATOR|Placebo|
62846836|NCT04215497|EXPERIMENTAL|Physiotherapeutic Scoliosis-Specific Exercises|PSSE group will receive corrective exercise for scoliosis
62060470|NCT03569696|EXPERIMENTAL|Nivolumab|Nivolumab will be administered intravenously every 2 weeks in a dose of 240mg over 30 minutes for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
62264509|NCT05644028|EXPERIMENTAL|Emotion regulation Intervention|An 8-week blended intervention targeting emotion dysregulation in ADHD
62264510|NCT02024542||Weight Loss Surgery - Healthy|Patients consented to participate have met the NIH criteria for Bariatric Surgery and have completed the normal pre-operative work up including nutritional counseling, psychological evaluation, and all necessary studies to rule out other co-morbid conditions prior to surgery. Patients do not have metabolic syndrome.
62264511|NCT02024542||Weight Loss Surgery - Metabolic Syndrome|Patients consented to participate have met the NIH criteria for Bariatric Surgery and have completed the normal pre-operative work up including nutritional counseling, psychological evaluation, and all necessary studies to rule out other co-morbid conditions prior to surgery. Patients have metabolic syndrome.
62264512|NCT05504733|EXPERIMENTAL|Layperson Audiovisual Assist Tourniquet (LAVA TQ)|For participants in the experimental arm, the Layperson Audiovisual Assist Tourniquet (LAVA TQ) is the first tourniquet applied to their leg as the intervention.
62264513|NCT05504733|ACTIVE_COMPARATOR|Combat Application Tourniquet (CAT)|For participants in the control/active comparator arm, the Combat Application Tourniquet (CAT) is the first tourniquet applied to their leg as the intervention.
62264514|NCT05269485|EXPERIMENTAL|High-dose hypofraction Arm|Irradiation of 60-68Gy/15-17f is administered followed by one-year immunotherapy maintenance.
62620822|NCT00564395|EXPERIMENTAL|Insulin Detemir+RAI, then Insulin Detemir and RAI separately|Participants first received, Insulin Detemir mixed with RAI, twice daily as subcutaneous injection for 10 days. Then they received Insulin Detemir and RAI as separate subcutaneous injections, twice daily for the next 10 days.
62620823|NCT00564395|ACTIVE_COMPARATOR|Insulin Detemir and RAI separately, then Insulin Detemir+RAI|Participants first received Insulin Detemir and RAI as separate subcutaneous injections, twice daily for 10 days. Then they received Insulin Detemir mixed with RAI, twice daily as subcutaneous injection for the next 10 days.
62264515|NCT05269485|EXPERIMENTAL|Low-dose hypofraction Arm|Irradiation of 48Gy/12f is administered followed by one-year immunotherapy maintenance.
62264516|NCT01121133|EXPERIMENTAL|Arm A (navitoclax and rifampin)|
62264517|NCT02701543|ACTIVE_COMPARATOR|Ranger Drug Eluting Balloon|Intervention with Over the Wire (OTW) Percutaneous transluminal angioplasty (PTA )balloon catheter with a semi-compliant balloon coated with a formulation of 2μg/mm2 paclitaxel and acetyl tri-n-butyl citrate (ATBC) as carrier substance
62264518|NCT02701543|ACTIVE_COMPARATOR|In Pact Drug Eluting Balloon|Intervention with Over the Wire (OTW) peripheral balloon catheter. The balloon surface is coated with a formulation of 3μg/mm2 paclitaxel and urea as carrier substance.
62448089|NCT06201273|EXPERIMENTAL|Resistance Training|"This training protocol, spanning a duration of 12 weeks, consists of three weekly sessions. In each session, participants will engage in Elastic Resistance Exercises (ERE) using Theraband elastic bands (CLX). The focus will be on both concentric and eccentric contractions, maintaining an intensity level of 8 to 10 as per the Resistance Exercise Scale (OMNI-RES). Each exercise will be conducted for 1 minute, followed by a 2-minute rest period. Each exercise will be repeated three times within the session.~The specific exercises include bicep curls, seated horizontal rows, and wide squats. To ensure proper progression and adaptation, the exercise load will be adjusted biweekly. This adjustment will be based on the physiological adaptations of the subjects to the training, aiming to recalibrate the loads to new resistance thresholds and maintain a consistent intensity of 8 to 10 on the OMNI-RES scale for each exercise."
62448090|NCT06201273|NO_INTERVENTION|Control|Participants in the control group will be instructed to maintain their current lifestyle and exercise habits throughout the duration of the study. This includes adhering to their prescribed medication regimen as usual.
62620824|NCT02829385|EXPERIMENTAL|Apatinib combined treatment group|"Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs."
62620825|NCT06304298|ACTIVE_COMPARATOR|Sham blocks|iPACK block with 20ml of 0.9% sodium chloride
62620826|NCT06304298|ACTIVE_COMPARATOR|iPACK block|iPACK block with 20ml 0f 0.2% ropivacaine
62620827|NCT06054945||SIFIB|Patients who underwent SIFIB in knee arthroplasty patients under spinal anesthesia will be evaluated retrospectively in terms of opioid consumption and NRS scores.
62620828|NCT06054945||SIFIB+IPACK|Patients who underwent SIFIB+IPACK blocks in knee arthroplasty patients under spinal anesthesia will be evaluated retrospectively in terms of opioid consumption and NRS scores.
62620829|NCT03482908|EXPERIMENTAL|Responsive parenting treatment|Early Healthy Lifestyles (EHL) screening tool reported by participants to identify potentially obesogenic parenting practices and child behaviors; data sharing/coordination into electronic health records to inform counseling by trained providers; responsive parenting curriculum delivered by trained WIC nutritionists.
62620830|NCT03482908|NO_INTERVENTION|Standard Care Control|Standard of pediatric and WIC care
62620831|NCT00048997|EXPERIMENTAL|Prophylactic cranial irradiation (PCI)|Radiation therapy
62620832|NCT00048997|OTHER|Observation|Observation
62620833|NCT01247389|ACTIVE_COMPARATOR|midline incision|
62620834|NCT01247389|ACTIVE_COMPARATOR|transverse incision|
62620835|NCT00222014|EXPERIMENTAL|1|TIPS réalisé avec prothèse couverte de PTFE
62620836|NCT00222014|ACTIVE_COMPARATOR|2|Paracenthese and albumine perfusion
62620837|NCT03732222|EXPERIMENTAL|Stretching the diaphragm muscle|The interventor places his hands on the last costal cartilages and the subject makes an inspiration and keeps his hands resisted in the expiration.
62620838|NCT03732222|EXPERIMENTAL|Impulse technique in rotation of cervical level 3 and 4|The thumbs position the head in a double chin and then place it with neutral flexion-extension until focusing on the level of manipulation, ipsilateral lateral flexion and contralateral rotation approximately 45 degrees.
62620839|NCT03732222|EXPERIMENTAL|Combined technique of diaphragm muscle stretch and cervical ro|combine both previous techniques.
62846837|NCT04215497|NO_INTERVENTION|Control|Control group will be taken to the queue list.
62448091|NCT01649141|EXPERIMENTAL|Treatment Group|Trauma-Focused Cognitive Behavioral Therapy
62620840|NCT05823974|EXPERIMENTAL|Flu mRNA_1_1 Group|Eligible Younger Adults (YA) participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 1 administered in Phase 1, at Day 1.
62448092|NCT00071552|EXPERIMENTAL|Qvar|Qvar 160 mcg twice daily
62448093|NCT00071552|ACTIVE_COMPARATOR|Flovent Diskus|Flovent Diskus 200 mcg twice daily
62620841|NCT05823974|EXPERIMENTAL|Flu mRNA_1_2 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 2 administered in Phase 1, at Day 1.
62620842|NCT05823974|EXPERIMENTAL|Flu mRNA_1_3 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 3 administered in Phase 1, at Day 1.
62620843|NCT05823974|EXPERIMENTAL|Flu mRNA_1_4 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 4 administered in Phase 1, at Day 1.
62620844|NCT05823974|EXPERIMENTAL|Flu mRNA_1_5 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 5 administered in Phase 1, at Day 1.
62620845|NCT05823974|EXPERIMENTAL|Flu mRNA_1_6 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 6 administered in Phase 1, at Day 1.
62620846|NCT05823974|EXPERIMENTAL|Flu mRNA_1_7 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 7 administered in Phase 1, at Day 1.
62620847|NCT05823974|EXPERIMENTAL|Flu mRNA_1_8 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 8 administered in Phase 1, at Day 1.
62620848|NCT05823974|EXPERIMENTAL|Flu mRNA_1_9 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 9 administered in Phase 1, at Day 1.
62846838|NCT04103580|NO_INTERVENTION|Control|Will receive usual hospice care plus measures
62846839|NCT04103580|EXPERIMENTAL|Intervention|Will receive photo elicitation intervention and will join a secret Facebook group to share photos with other caregivers
62620849|NCT05823974|EXPERIMENTAL|Flu mRNA_1_10 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 10 administered in Phase 1, at Day 1.
62620850|NCT05823974|EXPERIMENTAL|Flu mRNA_1_11 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 11 administered in Phase 1, at Day 1.
62620851|NCT05823974|EXPERIMENTAL|Flu mRNA_1_12 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 12 administered in Phase 1, at Day 1.
62620852|NCT05823974|ACTIVE_COMPARATOR|Control Group|Eligible YA participants receive a single dose of Control 1 administered in Phase 1, at Day 1.
62620853|NCT05823974|EXPERIMENTAL|Flu mRNA_Ph2_1_YA Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 1 administered in Phase 2, at Day 1.
62846840|NCT01837823|EXPERIMENTAL|rosuvastatin|All subjects will receive rosuvastatin 40mg/day
62264519|NCT02895464|EXPERIMENTAL|Exercise group|The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
62846841|NCT01293656||CD and UC participants|All participants with CD or UC visiting their physician over a period of one year, newly and already diagnosed, regardless of treatment pattern.
62846842|NCT02706262|NO_INTERVENTION|Metabolically normal lean - Baseline testing only|"Metabolically normal lean - Lean individuals that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.~Dietary intervention - None."
62060471|NCT02981381|EXPERIMENTAL|Active sTMS (NEST-1)|"Subjects randomized to this group will receive 20 active synchronized Transcranial Magnetic Stimulation (sTMS) treatments (30 minutes each) over a period of 40 calendar days. Treatment windows will be 10 calendar days to complete 5 active sTMS sessions. Serial assessments will be completed every 5 sessions. Post-treatment (PT1) endpoint assessments will take place on the last day of active sTMS.~Participants that elect to participate in the open-label continuation phase, will receive an additional 20 sTMS treatments (using the NEST-2 device), following the same administration structure as the sham-control series.~Participants will return to complete post-treatment follow-up assessments (PT2) 1 month after their last treatment session (either PT1 or OL PT1)."
62060472|NCT02981381|SHAM_COMPARATOR|Sham sTMS (SHAM)|"Subjects randomized to this group will receive 20 sham synchronized Transcranial Magnetic Stimulation (sTMS) treatments (30 minutes each) over a period of 40 calendar days. Treatment windows will be 10 calendar days to complete 5 sham sessions. Serial assessments will be completed every 5 sessions. Post-treatment (PT1) endpoint assessments will take place immediately after the final sham session.~Participants that elect to participate in the open-label continuation phase, will receive 20 sTMS treatments (using the NEST-2 device), following the same administration structure as the sham-control series.~Participants will return to complete post-treatment follow-up assessments (PT2) 1 month after their last treatment session (either PT1 or OL PT1)."
62620854|NCT05823974|EXPERIMENTAL|Flu mRNA_Ph2_2_YA Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 2 administered in Phase 2, at Day 1.
62620855|NCT05823974|EXPERIMENTAL|Flu mRNA_Ph2_3_YA Group|Eligible YA participants receive single dose of Flu mRNA (GSK4382276A) study intervention formulation 3 administered in Phase 2, at Day 1.
62060473|NCT03712735|ACTIVE_COMPARATOR|Group A|"Bupivacaine 0.08% - fentanyl 2mcg on the following pump settings:~PIEB flow rate = high; interval = 60 min"
62264520|NCT02895464|OTHER|Control group|The participants will receive ordinary preoperative information, but will also be encouraged to follow the recommendation of 150 minutes/week of moderate physical activity.
62264521|NCT03651284|EXPERIMENTAL|Aim2Be Live Coach|Aim2Be app with Live Coach + Fitbit + BMI tracking tools
62448094|NCT03765073|EXPERIMENTAL|Stage 1 - Highest dose formulation a|Multivalent group B streptococcus vaccine - Stage 1 Nonpregnant women
62846843|NCT02706262|NO_INTERVENTION|Metabolically normal obese - Baseline testing only|"Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.~Dietary intervention - None."
62846844|NCT02706262|EXPERIMENTAL|Metabolically abnormal obese - Mediterranean diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.~Dietary intervention - A nutritionally balanced diet that includes fruits, vegetables, fish, beans, whole grains, and olive oil with approximately 50% of daily calories coming from complex carbohydrates, 30% of calories from fat, and 20% of calories from protein."
62846845|NCT02706262|EXPERIMENTAL|Metabolically abnormal obese - Low carbohydrate ketogenic diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.~Dietary intervention - A very-low-carbohydrate, adequate protein, high-fat diet containing 20 grams of carbohydrate or less per day (about 5% of calories), derived mainly from vegetables."
62264522|NCT03651284|OTHER|Aim2Be Waitlist|Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools for three months, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools
62448095|NCT03765073|EXPERIMENTAL|Stage 1 - Highest dose formulation b|Multivalent group B streptococcus vaccine - Stage 1 Nonpregnant women
62448096|NCT03765073|EXPERIMENTAL|Stage 2 - Lowest dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
62448097|NCT03765073|EXPERIMENTAL|Stage 2 - Lowest dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
62448098|NCT03765073|EXPERIMENTAL|Stage 2 - Middle dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
62846846|NCT02706262|EXPERIMENTAL|Metabolically abnormal obese - Plant-based very-low-fat diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.~Dietary intervention - A plant-based diet high in complex carbohydrates and low in fat, protein, and sodium, with approximately 70% of daily calories from carbohydrates, 15% from fat, and 15% from protein."
62846847|NCT03859297|EXPERIMENTAL|Rumination-Focused CBT|RF-CBT is a manual-based treatment for prevention of depression, includes focus on ruminations, mental habits, concreteness training, and mindfulness.
62846848|NCT03859297|NO_INTERVENTION|Treatment as Usual|Participants are allowed to continue any therapy outside of the treatment study.
62060474|NCT03712735|EXPERIMENTAL|Group B|Bupivacaine 0.08% - fentanyl 2mcg on the following pump settin PIEB flow rate = high; interval = 45 min
62060475|NCT03712735|EXPERIMENTAL|Group C|Bupivacaine 0.08% - fentanyl 2mcg on the following pump settin PIEB flow rate = low; interval = 45 min
62060476|NCT04450186|EXPERIMENTAL|EEG/fMRI neurofeedback|Healthy volunteers
62264523|NCT05171257||repeat group|patients receiving empiric therapy with the same IV antibiotics from prior
62264524|NCT05171257||change group|patients receiving differing IV antibiotics from prior
62264525|NCT01803243|EXPERIMENTAL|Leg length correction|The shorter leg in a sample of 15 patients with structural leg length inequality will be corrected by either a shoe insole or a modified shoe with sole lift.
62264526|NCT01803243|EXPERIMENTAL|Control of foot position 1|The foot position in in a sample of 15 patients with hemiplegic cerebral palsy will be controlled by an ankle foot orthosis.
62448099|NCT03765073|EXPERIMENTAL|Stage 2 - Middle dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
62846849|NCT03859297|ACTIVE_COMPARATOR|Relaxation-based therapy|RelaxT includes an active comparison treatment that can be used to monitor and modify physiological responses to stress
62846850|NCT02173509|EXPERIMENTAL|Educational multifaceted intervention|Multidisciplinary and multifaceted educational intervention about antibiotic prescription and dispense, in physicians and pharmacists.
62846851|NCT02173509|NO_INTERVENTION|Control|Physicians and pharmacists that not received the multidisciplinary and multifaceted educational intervention about antibiotic prescription and dispense.
62264527|NCT01803243|EXPERIMENTAL|Control of foot position 2|The foot position in in a sample of 15 patients with diplegic cerebral palsy will be controlled by an ankle foot orthosis.
62448100|NCT03765073|EXPERIMENTAL|Stage 2 - Highest dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
62448101|NCT03765073|EXPERIMENTAL|Stage 2 - Highest dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
62846852|NCT02129088|EXPERIMENTAL|Cohort 1|Participants will receive esketamine 14 milligram (mg) as intranasal spray into each nostril on Day 1.
62846853|NCT02129088|EXPERIMENTAL|Cohort 2|All participants will receive esketamine 14 mg as intranasal spray into each nostril on Day 1 of Period 1 as Treatment A and esketamine 14 mg as intranasal spray followed by intranasal administration of placebo solution after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Period 2 as Treatment B in a fixed sequence.
62264528|NCT01803243|NO_INTERVENTION|Control|A sample of 15 healthy controls from a simultaneously conducted study (UKBB-Spine-1315-1) will be used for comparative purposes.
62264529|NCT00390754|EXPERIMENTAL|Pregnancy Test Group|Group got free home pregnancy test kits
62264530|NCT00390754|NO_INTERVENTION|2|Group did not receive free home pregnancy test kits
62264531|NCT02199080|OTHER|Atrial fibrillation|D-dimer assay before ablation of atrial fibrillation
62060477|NCT04871984||Holmium laser lithotripsy|Stone fragmentation are performed with Holmium laser in ureteroscopy
62060478|NCT04871984||Thulium laser lithotripsy|Stone fragmentation are performed with Thulium laser in ureteroscopy
62060479|NCT05807659|EXPERIMENTAL|fractionated busulfan|fractionated busulfan-based ChiFAB conditioning regimen: busulfan 3.2mg/kg d-13, -12, 1.6mg/kg d-6\~-3, fludarabine 35mg/m2 d-6\~-2 cytarabine 1g/m2,d-6\~-2 chidamide 30mg d-13,-10,-6,-3
62060480|NCT02929225|EXPERIMENTAL|Bifid Triple Viable Capsules|BIFICO(Shanghai Sine Pharmaceutical Laboratories Co.Ltd,S10950032), A biological preparation composed of triple viable microbe(Live combined Bifidobacterium, Lactobacillus and enterococcus capsules)
62060481|NCT02929225|PLACEBO_COMPARATOR|placebo|placebo is also manufactured by Sine Pharmaceutical Laboratories,but only contains starch.And placebo is the same as probiotics in appearance,odor,flavor and color.
62060482|NCT02785874|EXPERIMENTAL|Statin(Crestor) taken|Subjects take Statin(Crestor) 10mg per day for a- year
62060483|NCT02785874|NO_INTERVENTION|non Statin(Crestor) taken|non Statin(Crestor) taken as a reference for experimental group.
62060484|NCT03008525|EXPERIMENTAL|obese patients (group OB)|patients with body mass index ≥ 35 kg/m²
62448102|NCT03765073|EXPERIMENTAL|Stage 3 - Selected dose and formulation|Multivalent group B streptococcus vaccine - Stage 3 Pregnant women
62448103|NCT03765073|PLACEBO_COMPARATOR|Stage 1 Placebo|Saline control
62448104|NCT03765073|PLACEBO_COMPARATOR|Stage 2 Placebo|Saline control
62264532|NCT04938583|EXPERIMENTAL|oregovomab, bevacizumab, paclitaxel and carboplatin|Combination of anti-angiogenesis and Chemo-immunotherapy
62448105|NCT03765073|PLACEBO_COMPARATOR|Stage 3 Placebo|Saline control
62448106|NCT06374030||patients who underwent the intervention of endotracheal intubation|"Inclusion criteria:~All patients who underwent endotracheal intubation between 01-01-2019 and 31-12-2023 in the participating ED's.~Exclusion criteria:~Patients for which no information about the intubation can be found in the electronic patient chart will be excluded from the study."
62846854|NCT05338424||Sprint Interval Training (SIT)|"The 1-session SIT protocol will include Work bouts performed at maximal intensity targets. Three Work bouts will be performed at 20-second intervals separated by 2 recovery bouts consisting of 2 minutes of low-intensity cycling. The SIT session will employ a standardized warm up and cool down of 3 minutes at a self-selected light intensity, per current guidelines. SIT sessions will take 15 minutes to complete."
62620856|NCT05823974|ACTIVE_COMPARATOR|Control_Ph2_YA Group|Eligible YA participants receive single dose of Control 1 vaccine administered in Phase 2, at Day 1.
62846855|NCT05338424||Stretching|Stretching will include a low-intensity range of motion and stretching exercises with session duration (15 minutes) being matched to SIT.
62060485|NCT03008525|ACTIVE_COMPARATOR|non-obese patients (group NO)|patients with body mass index \< 30 kg/m²
62060486|NCT05360030|EXPERIMENTAL|active stimulation of M1|pcTBS was administered to the left M1 at 80% resting motor threshold (RMT), consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline.
62060487|NCT05360030|EXPERIMENTAL|active stimulation of DLPFC|pcTBS was administered to the left DLPFC at 80% resting motor threshold (RMT), consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline.
62264533|NCT04319133|EXPERIMENTAL|intervention|Participants will ask to do 5:2 intermittent fasting (2 non-consecutive days a week) within 8 weeks
62264534|NCT04319133|NO_INTERVENTION|control|Participants will not doing fasting or intake restriction within 8 weeks
62264535|NCT01353027|PLACEBO_COMPARATOR|Placebo|
62264536|NCT01353027|EXPERIMENTAL|AVI-6002|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
62620857|NCT05823974|EXPERIMENTAL|Flu mRNA_Ph2_1_OA Group|Eligible OA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 4 administered in Phase 2, at Day 1.
62846856|NCT06103253|PLACEBO_COMPARATOR|Placebo group|a placebo 27 group (maltodextrin)
62846857|NCT06103253|ACTIVE_COMPARATOR|Probiotic group|a Bla80 group (maltodextrin + strain BLa80 in 10B /day)
62846858|NCT03159793|ACTIVE_COMPARATOR|Group A|Live Modelling
62846859|NCT03159793|ACTIVE_COMPARATOR|Group B|Filmed Modelling
62264537|NCT03709173||Premanifest HDGEC participants|
62264538|NCT03709173||Early-manifest HDGEC participants|
62264539|NCT03709173||Companions of Premanifest HDGEC|
62448107|NCT04905342|EXPERIMENTAL|NVP-1805|NVP-1805 (80/10/20.8mg)
62448108|NCT04905342|ACTIVE_COMPARATOR|NVP-1805-R1 and NVP-1805-R2|coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10/20.8mg)
62448109|NCT02407379|ACTIVE_COMPARATOR|PAPD+SRP Quadrant|This quadrant, randomly selected in each patients, undergoes treatment with PAPD+ SRP
62448110|NCT02407379|SHAM_COMPARATOR|Sham-laser + SRP|This quadrant, randomly selected in each patients, undergoes treatment with sham-laser + SRP
62448111|NCT02894775||included in a clinical trial|
62448112|NCT02894775||not included in a clinical trial|
62620858|NCT05823974|EXPERIMENTAL|Flu mRNA_Ph2_2_OA Group|Eligible OA participants receive single dose of Flu mRNA (GSK4382276A) study intervention formulation 5 administered in Phase 2, at Day 1.
62620859|NCT05823974|EXPERIMENTAL|Flu mRNA_Ph2_3_OA Group|Eligible OA participants receive single dose of Flu mRNA (GSK4382276A) study intervention formulation 6 administered in Phase 2, at Day 1.
62620860|NCT05823974|ACTIVE_COMPARATOR|Control_Ph2_OA Group|Eligible OA participants receive a single dose of Control 2 vaccine administered in Phase 2, at Day 1.
62620861|NCT01041677|EXPERIMENTAL|001|R256918 10 mg capsule twice daily
62846860|NCT03159793|NO_INTERVENTION|Group C|No Modelling
62846861|NCT00794313|EXPERIMENTAL|Amantadine|
62846862|NCT00794313|EXPERIMENTAL|Amantadine plus Topiramate|
62846863|NCT00794313|PLACEBO_COMPARATOR|Sugar Pill|
62846864|NCT01475617|EXPERIMENTAL|Novel Multivitamin/Mineral Supplement|These subjects will be given a novel multivitamin/mineral supplement post RYGB bariatric surgery for 6 months duration.
62264540|NCT03709173||Companions of Early-manifest|
62264541|NCT05382637|EXPERIMENTAL|Growth hormone|The participant will receive escalating dose of growth hormone until an IGF-1 level is maintained between the mean and +2 standard deviations.
62264542|NCT04686721||Patients at risk of developing tracheal stenosis after prolonged intubation or tracheostomy|Patients older than 18 years of age who underwent either prolonged intubation or tracheostomy will be enrolled. A minimum of 2 months follow-up from hospital discharge is required. Patients tested negative for SARS-CoV-2 will be used as a control group
62264543|NCT03512600|EXPERIMENTAL|Study group|"All patients will follow four different dietary interventions (with or without cacao) for 1 day prior to the taking of a urine sample.~After the sample is taken the patient will follow a washout period of 6 days before following a different diet and this process will be repeated for each patient until they have followed the four diets.~."
62264544|NCT05359120||cohort A|new brain metastases directly treated with pyrotinib combined with capecitabine
62846865|NCT01475617|ACTIVE_COMPARATOR|Standard of care supplement|These subjects will be given the standard recommended regimen at Johns Hopkins Bayview Medical Center post RYGB bariatric surgery for 6 months duration.
62264545|NCT05359120||cohort B|whole brain radiotherapy or stereotactic radiotherapy concurrently (≤3 months before and after radiotherapy) with pyrotinib combined with capecitabine
62846866|NCT01802073|EXPERIMENTAL|Oral Vancomycin|1) For children who weight \< or = 30 kg, the vancomycin dose will be 50 mg/kg/day given orally 3 times per day for the 1st month and continue with the same dose for subsequent months if the clinical laboratory studies improved and are normal. If the laboratory studies are not normal the dose will be increased to 75 mg/kg/day given orally 3 times per day for the 2nd month and 100mg/kg/day given orally 3 times per day the 3rd month. If the laboratory studies do not improve by the end of the 3rd month since starting the vancomycin, the vancomycin will be stopped and the child will not continue the study. 2) For adults and children who weigh \>30 kg, the vancomycin dose will be 500 mg given orally 3 times per day for the 1st month and continue with this dose if the clinical laboratory studies improve and are normal. If the laboratory studies are not normal the dose will be increased to 750 mg 3 times per day for the 2nd month and 1000 mg 3 times per day the 3rd month.
62264546|NCT05359120||cohort C|after whole brain radiotherapy or stereotactic radiotherapy (more than 3 months after radiotherapy) treated with pyrotinib combined with capecitabine
62264547|NCT01530984|EXPERIMENTAL|Ipilimumab alone|Ipilimumab 3 mg/kg (IV) will be given every 28 days for six cycles (induction) followed by administration once every three months for patients who are not progressing (maintenance).
62264548|NCT01530984|EXPERIMENTAL|Ipilimumab with GM-CSF|Ipilimumab 3 mg/kg (IV) will be given every 28 days for six cycles (induction) followed by administration once every three months for patients who are not progressing (maintenance). GM-CSF 250 mcg/m2 SQ will be administered on days 1-14 in Cycles 1-6 and then every 3 months for 14 days beginning on the day of ipilimumab administration during the maintenance therapy phase
62264549|NCT01226550|EXPERIMENTAL|cytoreductive surgery and HIPEC|
62264550|NCT05802719|EXPERIMENTAL|rheumatoid arthritis patient|patient with an active Rheumatoid arthritis and an indication to start an anti-TNFa treatment
62264551|NCT01040455|EXPERIMENTAL|lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
62264552|NCT01040455|PLACEBO_COMPARATOR|placebo|placebo once daily for eight weeks
62264553|NCT03443908||CPAP therapy|CPAP therapy (minimum of 3-4 weeks)
62264554|NCT04431570|EXPERIMENTAL|rTMS over M1 region|The stimulus intensity was set to 100% of the resting motor threshold. Ten sessions of rTMS were delivered over 2 weeks, one session per day for 5 consecutive days per week. Each session consisted of 10 trains of 100 pulses at 10Hz with an inter-train interval of 40 seconds. In this group, the target of rTMS is M1 region.
62264555|NCT04431570|EXPERIMENTAL|rTMS over supplementary motor area (SMA)|The stimulus intensity was set to 100% of the resting motor threshold. Ten sessions of rTMS were delivered over 2 weeks, one session per day for 5 consecutive days per week. Each session consisted of 10 trains of 100 pulses at 10Hz with an inter-train interval of 40 seconds. In this group, the target of rTMS is SMA region.
62264556|NCT04431570|SHAM_COMPARATOR|sham stimulation|
62264557|NCT03171207|EXPERIMENTAL|Start with Lite Run Gait Trainer|Patients start therapy with the Lite Run Gait Trainer device, followed by a Current Harness System in an ABAB design.
62264558|NCT03171207|EXPERIMENTAL|Start with Current Harness System|Patients start therapy with a Current Harness System, followed by the Lite Run Gait Trainer in an ABAB design.
62264559|NCT02202876|ACTIVE_COMPARATOR|Aim 1: Children with Cystic Fibrosis|Cystic Fibrosis children aged 1 to 9 years with normal glucose tolerance receiving Oral Glucose Tolerance Test
62264560|NCT02202876|ACTIVE_COMPARATOR|Aim 1: Control Children|Children with out Cystic Fibrosis aged 1 to 9 years controls with normal glucose tolerance receiving Oral Glucose Tolerance Test
62264561|NCT02202876|ACTIVE_COMPARATOR|Aim 2a: Teens with Cystic Fibrosis - High Glycemic Meal|Cystic Fibrosis subjects 12 years of age or older with normal glucose tolerance eating High Glycemic Index Meal
62620862|NCT01041677|EXPERIMENTAL|002|R256918 15 mg capsule twice daily
62846867|NCT00778843|EXPERIMENTAL|Viusid|
62846868|NCT00778843|PLACEBO_COMPARATOR|Placebo|Placebo three oral sachets daily during 24 weeks
62846869|NCT05211583||subfertile women|Subfertile women with regular menses (menstrual cycle length range from 21 to 35 days) will be examined by transvaginal ultrasonography at menstruation, before the anticipated date of ovulation and after ovulation. Serum hormone levels will be measured at menstruation, before ovulation and after ovulation with a serial manner.
62846870|NCT02230514|EXPERIMENTAL|XCEL-MT-OSTEO-ALPHA and surgery|"ex-vivo expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue"
62846871|NCT02230514|OTHER|Autologous iliac crest and surgery|Standard treatment
62846872|NCT00936312||Females with Hemophilia|Females with severe or moderate Hemophilia A or B
62846873|NCT00936312||Control group|Male subjects with severe Hemophilia A or B and female subjects with mild (20-60%) Hemophilia A or B.
62448113|NCT02775890||Eating lead-shot wild game|Hunters that have eaten lead-shot in the past week will have blood lead levels measured.
62264562|NCT02202876|ACTIVE_COMPARATOR|Aim 2a: Teens with Cystic Fibrosis - Low Glycemic Meal|Cystic Fibrosis subjects 12 years of age or older with normal glucose tolerance eating Low Glycemic Index Meal
62264563|NCT02202876|ACTIVE_COMPARATOR|Aim 2b: Cystic Fibrosis Consuming Test Soda|Participants with Cystic Fibrosis 12 years of age or older with normal glucose tolerance or impaired glucose tolerance consuming a test beverage of a test soda. A week later these participants will have an Oral Glucose Tolerance Test.
62264564|NCT02202876|ACTIVE_COMPARATOR|Aim 2b: Cystic Fibrosis Consuming Fruit Juice|Participants with Cystic Fibrosis 12 years of age or older with normal glucose tolerance or impaired glucose tolerance consuming a test beverage of fruit juice. A week later these participants will have an Oral Glucose Tolerance Test.
62264565|NCT05572047|EXPERIMENTAL|Coherent Sine-Burst Electroporation for AF|"Patients with paroxysmal AF will receive treatment using the Arga Medtech Coherent Sine-Burst Electroporation ablation system to achieve pulmonary vein isolation (plus cavo-tricuspid isthmus ablation as necessary)~Patients with persistent AF will receive treatment using the Arga Medtech Coherent Sine-Burst Electroporation ablation system to achieve pulmonary vein isolation and posterior wall ablation (and cavo-tricuspid isthmus ablation as necessary)"
62448114|NCT02775890||Not eating lead-shot wild game|Hunters that have not eaten lead-shot in the past week will have blood lead levels measured.
62620863|NCT01041677|PLACEBO_COMPARATOR|003|placebo placebo capsule twice daily
62620864|NCT03041467|EXPERIMENTAL|IN.PACT AV DCB|"PTA will be performed using the IN.PACT AV Access Drug Coated Balloon. IN.PACT AV Access DCB was the device name used during the clinical study. Medtronic has changed the name of the device to IN.PACT™ AV Paclitaxel-Coated Balloon Catheter (also referred as IN.PACT AV DCB). Hence, throughout posting, the study device will be referred to as the IN.PACT AV DCB."
62620865|NCT03041467|ACTIVE_COMPARATOR|Standard Balloon Angioplasty|PTA will be performed using a commercially available uncoated PTA balloon.
62620866|NCT02800915|EXPERIMENTAL|Intervention, telemedicine and multidisciplinary cooperation|The intervention group will be offered regular multidisciplinary outpatient follow-up via telemedicine.
62846874|NCT01316068|EXPERIMENTAL|sequencial use of sulodexide|Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks. Then patients will receive 1000 LSU per day orally for 50 weeks.
62846875|NCT01316068|ACTIVE_COMPARATOR|oral use of sulodexide|Patients allocated to oral group will received 1000 LSU per day orally for 52 weeks
62264566|NCT03238859|EXPERIMENTAL|Real cTBS|10 days of real cTBS treatment will be given (3600 pulses to the left frontal pole as defined by EEG coordinate: FP1; 60 second pause after 1800 pulses; 110% RMT including a 30 second initial ramp period 80%-110% RMT; Magventure MagPro X100 Cool Coil).
62448115|NCT05571527|EXPERIMENTAL|Menopause patients having genitourinary syndrome (PRP)|Preparation of PRP sample from the patient's own blood and then the volume immediately above the erythrocyte layer was collected. Calcium gluconate in conc. 1:9 will be used as an activator. After activation, in a period of less than 2 min, approximately 4 ml of the PRP will be injected into the vaginal wall. ( at 3,6 and 9 o clock)It will be repeated once a month for 3 times.
62264567|NCT03238859|SHAM_COMPARATOR|Sham cTBS|10 days of sham cTBS treatment will be given (3600 pulses to the left frontal pole as defined by EEG coordinate: FP1; 60 second pause after 1800 pulses; 110% RMT including a 30 second initial ramp period 80%-110% RMT; Magventure MagPro X100 Cool Coil).
62264568|NCT02915523|ACTIVE_COMPARATOR|Entinostat plus Avelumab|Avelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with Entinostat administration on Day 1 and Day 8 of each cycle at the Maximum tolerated Dose (MTD)/RP2D as determined in the Phase Ib (Dose Determination) part of the study.
62264569|NCT02915523|PLACEBO_COMPARATOR|Placebo plus Avelumab|Avelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with placebo administered on Day 1 and Day 8 of each cycle.
62264570|NCT01118351|EXPERIMENTAL|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
62620867|NCT02800915|ACTIVE_COMPARATOR|Control, multidisciplinary guidance on request.|The control group will receive guidance based on existing routines (on-site consultations at the wound clinic and telephone consultations), and based on initiative taken by the local healthcare service/ patient/ next of kin.
62448116|NCT05571527|ACTIVE_COMPARATOR|vaginal hyluronic acid supplement for GSM|Patients receive Vaginal Hyaluronic Acid supplement for 10 days, then once a week for 3 months.
62448117|NCT00830674|EXPERIMENTAL|KRN23|Single IV or SC administration on day 1
62448118|NCT00830674|PLACEBO_COMPARATOR|Placebo|Single IV or SC administration on day 1
62620868|NCT04235816|ACTIVE_COMPARATOR|Group 1|AZi at DTP-1 visit at 6 weeks of age, AZi (plus IPTi) at measles visit at 9 months of age and AZi (plus IPTi) at measles booster visit at 15 months of age.
62620869|NCT04235816|PLACEBO_COMPARATOR|Group 2|Placebo at DTP-1 visit at 6 weeks of age, placebo (plus IPTi) at measles visit at 9 months of age and placebo (plus IPTi) at measles booster visit at 15 months of age.
62620870|NCT01709864|EXPERIMENTAL|NVA237|NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
62620871|NCT01709864|PLACEBO_COMPARATOR|Placebo|Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks.
62620872|NCT06439472|EXPERIMENTAL|Suboccipital Inhibition Technique|Experimental: Suboccipital Inhibition Technique
62620873|NCT06439472|PLACEBO_COMPARATOR|Sham Technique|Placebo Comparator: Sham Technique
62846876|NCT00481091|EXPERIMENTAL|Navitoclax 14/21 Day Cycle: 10 mg|Navitoclax 10 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.
62846877|NCT00481091|EXPERIMENTAL|Navitoclax 14/21 Day Cycle: 110 mg|Navitoclax 110 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.
62846878|NCT00481091|EXPERIMENTAL|Navitoclax 14/21 Day Cycle: 200 mg|Navitoclax 200 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.
62846879|NCT00481091|EXPERIMENTAL|Navitoclax 14/21 Day Cycle: 250 mg|Navitoclax 250 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.
62620874|NCT06228495|EXPERIMENTAL|Social Support|This version of the intervention prompted users to engage in social support which is thought to buffer against the negative effects of stress. This effect is present in occupational settings, with several studies indicating that social support plays an important role in preventing burnout among nurses. Furthermore, interventions targeting social support in the workplace suggest that these have positive effects on mental health. Sample strategies included asking for help from co-workers, listening with compassion, and sharing authentic emotions.
62620875|NCT06228495|ACTIVE_COMPARATOR|Physical Activity|This version of the interventions promoted an increase of physical activity in daily life. Physical activity is well-known to improve various health outcomes similar to our outcomes of interest, for instance reducing stress and burnout symptoms. Additionally, physical activity interventions in the workplace are widely used and have been found effective in many studies. Sample strategies included taking walks, going to the gym, and using the stairs instead of the elevator.
62620876|NCT06228495|ACTIVE_COMPARATOR|Psychological Strategies|This version of the intervention promoted a variety of psychological strategies for stress reduction. Sample strategies included sleep quality improvement tips, mindfulness, and work detachment - evidence-based strategies that have a positive effect on outcomes of interest. Workplace interventions targeting these kinds of strategies have been found to be effective.
62620877|NCT01281956|EXPERIMENTAL|Placebo Then PRX|Subjects are administered Placebo x3 months followed by PRX (selective 5HT1A agonist) x3 months
62620878|NCT01281956|EXPERIMENTAL|PRX Then Placebo|Subjects are administered PRX (selective 5HT1A agonist) x3 months followed by Placebo x3 months
62620879|NCT03958942|ACTIVE_COMPARATOR|quadratus lumborum block|received pre-emptive ultrasound-guided quadratus lumborum block with 25 mL of 0.25% bupivacaine on each side of the abdominal wall before induction of GA.
62620880|NCT03958942|ACTIVE_COMPARATOR|lumbar epideural block|received pre-emptive lumbar epidural block with 15 mL of 0.25% bupivacaine before induction of GA.
62620881|NCT03585712|OTHER|Arm A: Delayed then Missed Pill|Treatment period 2, Day 42 +/- 3 days: 6 hour delayed intake of Norgestrel 75 mcg Treatment period 3, Day 70 +/- 3 days: missed pill of Norgestrel 75 mcg
62620882|NCT03585712|OTHER|Arm B: Missed then Delayed Pill|Treatment period 2, Day 42 +/- 3 days: missed pill of Norgestrel 75 mcg Treatment period 3, Day 70 +/- 3 days: 6 hour delayed intake of the pill of Norgestrel 75 mcg
62448119|NCT05679765|EXPERIMENTAL|Group G|Greater occipital nerve block (GONB) under ultrasound guidance with lidocaine and dexamethasone on the side of headache
62620883|NCT02732015|EXPERIMENTAL|Arm I (rolapitant hydrochloride)|"Patients receive treatment as in part I. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities."
62620884|NCT02732015|ACTIVE_COMPARATOR|Arm II (fosaprepitant dimeglumine)|"Patients receive dexamethasone IV and ondansetron IV on days 1-5, and fosaprepitant dimeglumine IV over 30 minutes on days 1 of cycle 2. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities."
62620885|NCT05483465|EXPERIMENTAL|NR|Treatment with oral NR (1g/day per os for 8 weeks)
62846880|NCT00481091|EXPERIMENTAL|Navitoclax 21/21 Day Cycle: 125 mg|Navitoclax 125 mg administered for 21 consecutive days to complete a 21-day cycle.
62846881|NCT00481091|EXPERIMENTAL|Navitoclax 21/21 Day Cycle: 200 mg|Navitoclax 200 mg administered for 21 consecutive days to complete a 21-day cycle.
62846882|NCT00481091|EXPERIMENTAL|Navitoclax 21/21 Day Cycle: 250 mg|Navitoclax 250 mg administered for 21 consecutive days to complete a 21-day cycle.
62846883|NCT00481091|EXPERIMENTAL|Navitoclax 21/21 Day Cycle: 300 mg|Navitoclax 300 mg administered for 21 consecutive days to complete a 21-day cycle.
62846884|NCT00481091|EXPERIMENTAL|Phase 2: Navitoclax 100 mg|Navitoclax 100 mg in participants with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).
62846885|NCT00481091|EXPERIMENTAL|Phase 2: Navitoclax 250 mg|Navitoclax 250 mg in participants with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).
62846886|NCT03799042|EXPERIMENTAL|Vitural Reality|Virtual Reality 3D glass
62846887|NCT03799042|ACTIVE_COMPARATOR|Inter-generation interaction|Elders-teenager interaction
62448120|NCT05679765|ACTIVE_COMPARATOR|Group S|Greater occipital nerve block (GONB) under ultrasound guidance on the side of headache with 0.9% Saline (Placebo)
62448121|NCT01127581|EXPERIMENTAL|MVI 200|MVI 200 mcg vaginal insert
62448122|NCT01127581|ACTIVE_COMPARATOR|Dinoprostone Vaginal Insert (DVI)|10 mg Dinoprostone vaginal insert
62448123|NCT05343156|EXPERIMENTAL|DexNP Eye Drop|The study eye received 1 DexNP eye drop 3 times a day (every 8 hours) for 12 weeks.
62448124|NCT05343156|PLACEBO_COMPARATOR|Vehicle Eye Drop|The study eye received 1 vehicle eye drop 3 times a day (every 8 hours) for 12 weeks.
62448125|NCT00279448|EXPERIMENTAL|A|
62448126|NCT00279448|ACTIVE_COMPARATOR|B|
62448127|NCT01176448|EXPERIMENTAL|Fractionated laser|This Arm is the section of scar that will be treated with Fractionated Laser
62448128|NCT01176448|ACTIVE_COMPARATOR|Dermabrasion|Dermabrasion is the gold standard for scar resurfacing and will be used as the control against which Fractionated Laser is compared.
62448129|NCT01105650|EXPERIMENTAL|Arm 1: CsA|Patients receiving Cyclosporine (CsA) and Natural Killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
62448130|NCT01105650|EXPERIMENTAL|Arm 2: CsA plus Methylprednisolone (10mg)|Patients receiving Cyclosporine (CsA), methylprednisolone and natural killer cells (NK) infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
62620886|NCT05483465|PLACEBO_COMPARATOR|Control|Visually identical placebo (daily, per os, for 8 weeks)
62620887|NCT02007655||Eliquis on Nonvalvular Atrial Fibrilliation patients|Patients who are beginning to receive the treatment with Eliquis under the approved indications, dosage, and administration will be included in this study
62620888|NCT01522131|OTHER|Bioresorbable membrane will be used as the control|Bioresorbable membrane alone (control)
62620889|NCT01522131|EXPERIMENTAL|laser with bioresorabable membrane (test)|
62060488|NCT05360030|SHAM_COMPARATOR|SHAM stimulation|The Sham stimulation was delivered using the same protocol, with the coil being orientated at 90° to the scalp so that the magnetic field would be delivered away from the scal
62060489|NCT03068325|EXPERIMENTAL|TF-EAT|
62060490|NCT00353613|OTHER|1|LBJ Hospital
62060491|NCT00353613|OTHER|2|Ben Taub Hospital
62448131|NCT01105650|EXPERIMENTAL|Arm 3: CsA plus Methylprednisolone (1 mg)|Patients receiving Cyclosporine (CsA), methylprednisolone and natural killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
62448132|NCT01105650|EXPERIMENTAL|Arm 4: CsA minus Methylprednisolone|Patients receiving Cyclosporine (CsA), no methylprednisolone, eliminating IL-2 doses 4-6 and receiving Natural Killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 3 doses given post NK cell infusion.
62060492|NCT01980615|EXPERIMENTAL|BGF MDI (PT010) Dose 1|BGF MDI Dose 1 taken as 2 inhalations
62060493|NCT01980615|EXPERIMENTAL|BGF MDI (PT010) Dose 2|BGF MDI Dose 2 taken as 2 inhalations
62060494|NCT01980615|EXPERIMENTAL|BGF MDI (PT010) Dose 3|BGF MDI Dose 3 taken as 2 inhalations
62264571|NCT00644787|EXPERIMENTAL|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14. Participants who met the predefined criteria at the end of Titration Phase enter the Double Blind Phase.
62264572|NCT00644787|EXPERIMENTAL|Fentanyl 1-day transdermal patch (Double Blind Phase)|Participants who meet the predefined criteria at the end of Titration Phase and enter the Double Blind Phase receive fentanyl 1-day application transdermal patch and placebo matched to fentanyl 3-day application (JNS005) transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
62448133|NCT01490281|EXPERIMENTAL|water-based exercise intervention|
62448134|NCT01490281|EXPERIMENTAL|land-based exercise intervention|
62448135|NCT01490281|NO_INTERVENTION|Control group|
62448136|NCT01524042|EXPERIMENTAL|group 2|study group:double pants group
62448137|NCT02456909|EXPERIMENTAL|Cues|The PCA pump will be programmed to provide a cue to the end of the lockout period.
62448138|NCT02456909|PLACEBO_COMPARATOR|No Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period (current standard of care).
62448139|NCT03420066||Retrospective data collection|Group includes subjects that were implanted with the Nexus device as part of compassionate use procedure before joining the CIP008 study. Only intervention foreseen by CIP008 study is retrospective collection of data previously recorded as standard of care in medical charts (refer to Intervention/treatment section)
62448140|NCT01997554|EXPERIMENTAL|less than 60 years old with clinical symptom of hypothyroidism|Group of patients less than 60 years old, with at least one clinical symptom of hypothyroidism
62448141|NCT01997554|EXPERIMENTAL|less than 60 years old without clinical symptoms|Group of patients less than 60 years old, without clinical symptoms of hypothyroidism
62448142|NCT01997554|EXPERIMENTAL|more than 60 years old|Group of patients more than 60 years old at recruitment.
62448143|NCT04736264|ACTIVE_COMPARATOR|Rehabilitation group|"This is the phase 3 of the entire research protocol. Phase 3 will be initiated once the phase 2 (development of rehabilitation module) is completed. A user friendly and inexpensive device and program with minimal usage of low vision aid will be designed and piloted. There are 3 different rehabilitation modules.~A total of 300 primary glaucoma patients will be recruited and randomized using SNOSE: 150 intervention group and 150 non-intervention group. The intervention group will comprised of 150 primary glaucoma patients who will be assigned to different rehabilitation program:~1. navigation and mobility (50 patients)~2. physical activities including special exercise (50 patients)~3. reading (50 patients) There will be no patient who will be involved in more than one rehabilitation program at anytime."
62448144|NCT04736264|NO_INTERVENTION|Non-rehabilititation group|Group of primary glaucoma patients who are not taught and practiced the new rehabilitation module for navigation, physical activity (exercise) and reading. They will be asked to continue their regular activities and provided with the similar reading material (book) to read daily.
62448145|NCT01326026|EXPERIMENTAL|IDeg Simple|
62448146|NCT01326026|EXPERIMENTAL|IDeg Step wise|
62448147|NCT02362919||A cohort of elderly individuals|A cohort of elderly individuals between 65 and 80 years of age were vaccinated with Fluad, a seasonal inactivated trivalent adjuvanted influenza vaccine. Blood samples before (day 0) and at days 1/3, 7,21 and 70 after vaccination were collected.
62060495|NCT01980615|ACTIVE_COMPARATOR|GFF MDI (PT003)|GFF MDI (PT003) taken as 2 inhalations
62060496|NCT01980615|ACTIVE_COMPARATOR|Symbicort MDI Dose 1|Symbicort MDI taken as 2 inhalations
62060497|NCT01980615|ACTIVE_COMPARATOR|Symbicort MDI Dose 2|Symbicort MDI Dose 2 taken as 2 inhalations
62620890|NCT04046822|ACTIVE_COMPARATOR|Active drug|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
62060498|NCT00780650|EXPERIMENTAL|1|
62060499|NCT00780650|PLACEBO_COMPARATOR|2|
62060500|NCT05296395|EXPERIMENTAL|Lp299v|Subjects will consume 20 billion colony forming units of Lp299v (1 serving of GoodBelly fermented oat drink) once daily for 6 weeks
62060501|NCT05296395|PLACEBO_COMPARATOR|Heat-killed placebo control|Subjects will consume 1 serving of GoodBelly fermented oat drink that has been treated to heat kill all Lp299v once daily for 6 weeks
62060502|NCT00668135|EXPERIMENTAL|Arm 1|
62060503|NCT00668135|PLACEBO_COMPARATOR|Arm 2|
62264573|NCT00644787|ACTIVE_COMPARATOR|Fentanyl 3-day transdermal patch (Double Blind Phase)|Participants who meet the predefined criteria at the end of Titration Phase and enter the Double Blind Phase receive fentanyl 3-day application transdermal patch and placebo matched to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
62264574|NCT06355765||Citicoline blackcurrant|The treated group received a unique combination of oral dietary supplements, formulated in a soluble liquid sachet format for optimal absorption and convenience. This formulation included the following key components: citicoline (500 mg), vitamins A (300 μm), B group (4.415 mg), C (115 μm), and E (5 μm), and blackcurrant extract (50 mg). The participants in the treated group were instructed to take one sachet daily for 20 days each month, followed by a 10-day pause, and this therapy cycle was repeated throughout the 12-month follow-up period
62264575|NCT06355765||Placebo|The treated group received a unique combination of oral placebo. The participants in the treated group were instructed to take one sachet daily for 20 days each month, followed by a 10-day pause, and this therapy cycle was repeated throughout the 12-month follow-up period
62264576|NCT01279577|EXPERIMENTAL|Low dose TSO|Low dose suspension of TSO
62264577|NCT01279577|EXPERIMENTAL|Medium dose TSO|Medium dose suspension of TSO
62264578|NCT01279577|EXPERIMENTAL|High dose TSO|High dose suspension of TSO
62264579|NCT01279577|PLACEBO_COMPARATOR|Placebo|Placebo solution
62264580|NCT06227299||Glaucoma patients|Patients with glaucoma
62264581|NCT01862042|OTHER|Supportive and Palliative care|A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
62448148|NCT04317573|ACTIVE_COMPARATOR|Personalised card|The personalised card was printed by the attending ophthalmologist for the patient via a web accessible software we have developed. The software allowed the reviewing physician to select the medications the patient was prescribed and auto-generate a personalised card that will be sent to the network printer. The card illustrated the patient's eye drop regime in a simple pictorial format using coloured pictures of the eye drop bottles and universally recognised symbols. It can be folded to a compact size of 11cm x 7.5cm to allow patients to carry around in their wallets. This card will be given to patients at the end of their consult and explanation will be provided by the attending physician who will manually tick in the corresponding boxes depending on the frequency of administration
62448149|NCT04317573|ACTIVE_COMPARATOR|Personalised card and telereminder|Patients who were recruited into the group receiving tele-monitoring were contacted via text messages daily by a programmed software at the scheduled time of eye drop administration. They were required to acknowledge the reminder by replying a 'Yes' if they had administered the eyedrop and 'No' if they had not. A nil reply was taken as a 'No'.
62448150|NCT04317573|NO_INTERVENTION|No intervention|No intervention
62448151|NCT03316937|EXPERIMENTAL|Teflon Scaler|The buccal and lingual surface of the 23 participants' crowns will be randomly assigned to receive scaling and root planing with either Teflon scalers, or non-Teflon scalers after implant crown delivery. Each patient will act as their own control.
62448152|NCT03316937|EXPERIMENTAL|Non Teflon Scaler|The buccal and lingual surface of the 23 participants' crowns will be randomly assigned to receive scaling and root planing with either Teflon scalers, or non-Teflon scalers after implant crown delivery. Each patient will act as their own control.
62448153|NCT05116228|ACTIVE_COMPARATOR|500mg RTX Group|Patients in this group will receive 1x500mg (500mg RTX group) RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
62448154|NCT05116228|ACTIVE_COMPARATOR|1000mg RTX group|Patients in this group will receive 1x1000mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
62448155|NCT05709509|EXPERIMENTAL|Late PCI + Colchicine|Subjects that undergo late PCI (12-48 hours after STEMI), received optimal medical treatment (statin, aspirin, P2Y12 inhibitor, and nitrate), and colchicine
62448156|NCT05709509|EXPERIMENTAL|Late PCI + Optimal Medical Treatment|Subjects that undergo late PCI (12-48 hours after STEMI) and received optimal medical treatment (statin, aspirin, P2Y12 inhibitor, and nitrate)
62264582|NCT05289635|EXPERIMENTAL|test group|vertical mattress suture
62060504|NCT02565901|EXPERIMENTAL|Arm I (sirolimus, docetaxel, carboplatin)|Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30 minutes on day 1. Beginning in cycle 2 and continuing in subsequent cycles, patients also receive sirolimus PO on day -2. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.
62264583|NCT05289635|OTHER|control group|horizontal mattress suture
62264584|NCT06244758|ACTIVE_COMPARATOR|Treatment|Renal hemodynamic parameters and oxidative stress will be obtained and the patient will be given finerenone orally
62264585|NCT06244758|PLACEBO_COMPARATOR|Placebo|Renal hemodynamic parameters and oxidative stress will be obtained and the patient will be given placebo orally
62620891|NCT04046822|PLACEBO_COMPARATOR|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
62620892|NCT03899402|ACTIVE_COMPARATOR|Control|Standard of care insulin will be used as an active comparator arm for 1/3 of patients (38 patients) for the entire duration of the study.
62264586|NCT04071184|EXPERIMENTAL|Dose cohorts|"Part 1 (dose escalation): 3+3 design will be used. Alofanib (dose levels of 50, 100, 165, 250, 350 mg/m2) will be given i.v. daily (1-5 days on, 6-7 days off, every week) till progression or unacceptable toxicity.~Part 2 (dose expansion): Afterwards the dosing regimen identified in Part 1 will be evaluated in a single-arm study focused on clinical efficacy."
62846888|NCT03135691||Patients at High Risk for OSA|Patients at High Risk for Obstructive Sleep Apnea Undergoing Laparoscopic Bariatric Surgery; retrospective study, no intervention administered.
62846889|NCT03548181|EXPERIMENTAL|"Intervention group tele-rehabilitation"|"Each patient will have the opportunity to have minimum one Video Consultation (VC) per week the first month, one VC each second week the second month one VC a month the rest of the trial.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Instead of ergometer bike training, the patient will receive some easy training tools such as elastics, weights and a fitness-step that can be used in the different exercises showed by the VPA to reach the same intensity of workout. The VPA will then be animated to motivate and encourage the patient to exercises at home. A digital diary will automatically register the data obtained by the system on patient's performance."
62264587|NCT04737655|ACTIVE_COMPARATOR|TRIMBOW + Standard of care|"1. Inclusion~   * Maintenance therapy (LAMA or LABA) for COPD~  * Age \>18~  * Admission for AE of COPD~  * Signed Inform consent (see protocol attached)~  * Admitted in ICU \>24h and less than 72h~2. Exclusion~   * No CI for studied medication~  * Not treated with studied medication for at least 3 months~  * Admitted in ICU for AE of COPD within the past 3 months~  * Intolerance to studied medication~  * Hospitalized since \>6 days~  * ARDS condition (PAFI \<200)~  * Admitted in ICU \>72H~  * Patient with severe asthma~  * The use of high dose of ICS as baseline therapy~  * Right/left heart failure~  * Immunocompromized~  * Acute myocardial infaction~  * Left heart insufficiency (LVEF\<35%)~  * Stroke \<6 months prior to hospital admission~Patients will be separated in 2 randomized groups (Trimbow + SOC versus SOC) 1:1."
62264588|NCT04737655|NO_INTERVENTION|standard of care|
62264589|NCT00360594|EXPERIMENTAL|1|Acamprosate
62448157|NCT05709509|EXPERIMENTAL|Optimal Medical Treatment + Colchicine|Subjects that received optimal medical treatment (statin, aspirin, P2Y12 inhibitor, and nitrate) and colchicine
62620893|NCT03899402|EXPERIMENTAL|Dual Therapy|Once a week injection of Semaglutide (a GLP-1 receptor agonist) in addition to standard of care insulin for the first six months in 2/3 of patients (76 patients). Semaglutide is a clear, colorless solution that contains 2 mg of semaglutide in a 1.5 mL (1.34 mg/mL) pre-filled, disposable, single-patient-use pen injector. Semaglutide will be started at the 0.25 mg dose for the first two weeks, then increased to 0.5 mg at week 2, and then yet again increased to 1.0 mg at week 4.
62620894|NCT03899402|EXPERIMENTAL|Triple therapy|Once a day oral pill (green, plain, diamond shaped film coated 5 mg tablet) of Dapagliflozin (an SGLT-2 inhibitor) added to once a week injection of semaglutide and standard of care insulin in the second 6 months of 1/2 of the dual therapy arm (1/3 of total patients (38 patients)). Dapagliflozin will be started at 5 mg for one week, and then increased to 10 mg for the remainder of the study
62846890|NCT03548181|ACTIVE_COMPARATOR|Control|Patients will be followed, but they do not get any other kind of treatment comparable to the intervention group treatment.
62846891|NCT04119518|OTHER|Healthy and hypertensive subjects|Subjects will be enrolled to be monitored for 24 hours via: the non-occlusive CSEM Pulse Watch, and a gold standard oscillometric device (Spacelabs OnTrak Ambulatory Blood Pressure monitor, Spacelabs Healthcare, Washington, USA) internationally validated for the 24h ABPM.
62264590|NCT00360594|PLACEBO_COMPARATOR|2|Placebo
62264591|NCT04061421|EXPERIMENTAL|ASTX727 + itacitinib|ASTX727 and itacitinib will be taken by mouth
62264592|NCT02980224|EXPERIMENTAL|OmegaD|OmegaD Softgels
62264593|NCT02980224|PLACEBO_COMPARATOR|Placebo|Placebo Softgels
62448158|NCT05709509|PLACEBO_COMPARATOR|Optimal Medical Treatment|Subjects that received optimal medical treatment (statin, aspirin, P2Y12 inhibitor, and nitrate)
62448159|NCT05163509|EXPERIMENTAL|MR-Linac Guided Adaptive Radiotherapy|Patients will receive Adaptive Radiotherapy on the MR-Linac treatment machine.
62448160|NCT02354586|EXPERIMENTAL|Niraparib|
62846892|NCT04240132|EXPERIMENTAL|Adherence to hand hygene|The face-to-face interview will be held in an appropriate empty room in the intensive care unit (ICU) in a time schedule suitable for the healthcare workers. The researchers will provide training to healthcare workers working in the ICU in accordance with the World Helath Organization (WHO) Hand Hygiene Guidelines. One day training on nursing interventions related to enteral feeding treatment will be provided to nurses and their questions will be answered. At the end of the each training, trainees will be given a data collection form to assess the effectiveness of the training.
62846893|NCT06315790|PLACEBO_COMPARATOR|Isotonic saline|
62846894|NCT06315790|ACTIVE_COMPARATOR|Botulinum toxin A|
62846895|NCT02172417|EXPERIMENTAL|Cimetidine + Tiotropium followed by Tiotropium|
62264594|NCT05595824|EXPERIMENTAL|JCBC00101 (Molnupiravir, Esperavir)|Group 1 (n=120) received the study drug JCBC00101, capsules 800 mg, 2 times a day with 12 ±2 hours interval for 5 days in the setting of pathogenetic and symptomatic therapy provided by Interim Guidelines for the prevention, diagnosis and treatment of COVID-19 approved by the Russian Ministry of Health (version 14, December 27, 2021) or valid as of the time of the study
62264595|NCT05595824|ACTIVE_COMPARATOR|Standard of care|Group 2 (n=120) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of COVID-19 approved by the Russian Ministry of Health (version 14, December 27, 2021) or valid as of the time of the study by decision of the investigator and taking into accountthe availability of drugs at the study site (Favipiravir, Umifenovir, IFN α, used incombination with each other).
62264596|NCT00258674|ACTIVE_COMPARATOR|Medicare Claims Feedback|Practices randomised to the Medicare Claims Feedback arm received period feedback on their performance on selected diabetes quality of care measures as reflected in the claims data for their diabetes patients.
62264597|NCT00258674|EXPERIMENTAL|Medicare Claims+Medical Record Feedback|Practices randomised to the Medicare Claims + Medical Record Review Feedback arm received periodic feedback on their performance on selected diabetes quality of care measures as reflected in both the Medicare claims for the diabetes patients AND review/audit of their diabetes patients' medical records.
62060505|NCT02565901|EXPERIMENTAL|Arm II (sirolimus, docetaxel, carboplatin)|Patients receive sirolimus PO on day -2. Patients also receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.
62448161|NCT06412393|PLACEBO_COMPARATOR|Placebo powder|Dietary Supplement: Placebo powder
62448162|NCT06412393|EXPERIMENTAL|Black tomato extract powder|Dietary Supplement: Black tomato extract powder
62448163|NCT05520281|EXPERIMENTAL|Patients|Adult patients across all phases of advanced disease (UICC stage IV solid tumor) from diagnosis to terminal stages
62846896|NCT02172417|EXPERIMENTAL|Ranitidine + Tiotropium followed by Tiotropium|
62620895|NCT03899402|PLACEBO_COMPARATOR|Triple therapy control|Once a day oral pill (green, plain, diamond shaped film coated 5 mg tablet) of the Placebo form of Dapagliflozin added to once a week injection of semaglutide and standard of care insulin in the second 6 months of 1/2 of the dual therapy arm (1/3 of total patients (38 patients)).
62846897|NCT01783756|EXPERIMENTAL|Treatment (lapatinib ditosylate, everolimus, capecitabine)|Patients receive lapatinib ditosylate PO QD and everolimus PO QD on days 1-21, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.
62846898|NCT02174484||Pacemaker recipients|Patients implanted with a single or dual pacemaker and with Home-Monitoring system activated and periodic IEGM activated
62846899|NCT05433285|EXPERIMENTAL|COVID-19 Protein Subunit Recombinant Vaccine|2 doses of COVID-19 Protein Subunit Recombinant Vaccine administered with 28 days interval (0.5 mL per dose)
62846900|NCT05433285|ACTIVE_COMPARATOR|Active Comparator|2 doses of Covovax® - recombinant spike protein Nanoparticle Vaccine, administered with 28 days interval (0.5 mL per dose)
62846901|NCT03198624|ACTIVE_COMPARATOR|HTL0018318 Low dose, Part A.|Part A. 1 single dose on day 1. Discharged on day 4 of Period 1 (following 10 day washout).
62060506|NCT00002760|OTHER|Antiandrogen withdrawal|"antiandrogen therapy withdrawn; patient who progress will be crossed over to Arm 1A: 400 mg ketoconazole PO tid and hydrocortisone 30 mgs PO q am and 10 mgs PO qhs until treatment is no longer effective"
62060507|NCT00002760|ACTIVE_COMPARATOR|Antiandrogen withdrawal + therapy|Ketoconazole and hydrocortisone
62448164|NCT05140161|EXPERIMENTAL|Collagen 1|Medium porosity collagen sponge is used in the operated nail grooves. The hallux is covered with a non-stick dressing, five gauze surrounding it and a cohesive bandage
62620896|NCT05745233|EXPERIMENTAL|Checkpoint inhibitor (nivolumab or pembrolizumab)|Patients with malignant ascites will received either nivolumab or pembrolizumab intraperitoneally.
62846902|NCT03198624|ACTIVE_COMPARATOR|HTL0018318 High dose, Part A|1 single dose on day 1. Discharged on day 4 of period 2 (following 10 day washout).
62846903|NCT03198624|ACTIVE_COMPARATOR|HTL0018318 Low dose, Part B|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.
62846904|NCT03198624|PLACEBO_COMPARATOR|Placebo oral capsule, Part B|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.
62846905|NCT03198624|ACTIVE_COMPARATOR|HTL0018318 High dose, Part B.|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.
62846906|NCT03198624|PLACEBO_COMPARATOR|Placebo oral capsule, Part B.|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.
62846907|NCT04909073||Afatinib 30 mg daily|Oral afatinib 30 mg tablet once daily, continuously
62264598|NCT00258674|EXPERIMENTAL|Medicare Claims+Medical Chart Review+DRN|In addition to the performance data from both Medicare Claims data and from review of patients' medical records, practices randomised to the Medicare Claims + Medical Record review + Diabetes Resource Nurse (DRN) had a diabetes resource nurse assigned to them, who was available to provide diabetes education and care-coordination type services for their diabetes patients.
62264599|NCT00137111|OTHER|1|
62264600|NCT00137111|OTHER|2|
62264601|NCT00549172|ACTIVE_COMPARATOR|Operative (O)|Partial resection of degenerative tear of medial meniscus
62264602|NCT00549172|SHAM_COMPARATOR|Conservative (K)|Arthroscopy (diagnostic)
62264603|NCT02544685|ACTIVE_COMPARATOR|Synbiotics group|"Interventions: administration of Probio-Fix Inum + Beneo Synergy 1~Start of prophylaxis: 5 days before or 2 days after starting chemotherapy~Prophylaxis duration: 3 months"
62264604|NCT02544685|PLACEBO_COMPARATOR|Placebo group|"Interventions: administration of placebo~Start: 5 days before or 2 days after starting chemotherapy~Duration: 3 months"
62264605|NCT05297942|EXPERIMENTAL|Intervention (Expansion) Arm|Expansion of abbreviations and acronyms
62264606|NCT05297942|NO_INTERVENTION|Control (Abbreviation) Arm|No expansion of abbreviations and acronyms
62264607|NCT00083031|EXPERIMENTAL|Arm A-Bevacizumab|"* Methotrexate- twice daily on predetermined days per each week per cycle~* Cyclophosphamide- oral, daily, predetermined dose~* Bevacizumab- Via IV on predetermined days per cycle"
62264608|NCT00083031|EXPERIMENTAL|Arm B- Without Bevacizumab|"* Methotrexate- twice daily on predetermined days per each week per cycle~* Cyclophosphamide- oral, daily, predetermined dose"
62264609|NCT03061981|ACTIVE_COMPARATOR|DA-1241:8 subjects in each cohort(Cohort 1-6)|Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
62264610|NCT03061981|PLACEBO_COMPARATOR|Placebo: 2 subjects in each cohort(Cohort 1-6)|Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
62264611|NCT03061981|OTHER|DA-1241 in IE Cohort: 8 subjects in choosen cohort|One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
62264612|NCT03061981|OTHER|Placebo in IE Cohort: 2 subjects in choosen cohort|One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
62448165|NCT05140161|EXPERIMENTAL|Collagen 2|High porosity collagen sponge is used in the operated nail grooves. The hallux is covered with a non-stick dressing, five gauze surrounding it and a cohesive bandage
62448166|NCT05140161|NO_INTERVENTION|Control group|No hemostatic device is used in the nail grooves. No hemostatic device is used in the nail grooves. Only non-stick dressing, five gauze pads and cohesive bandage are used
62448167|NCT04429451|EXPERIMENTAL|4SCAR-PSMA Cell Therapy for PSMA positive tumor|Infusion of 4SCAR-PSMA T cells at 10\^6 cells/kg body weight via IV
62620897|NCT00774072|ACTIVE_COMPARATOR|Tobramycin 80 mg|applied once daily via Pari Sinus nebulizer
62620898|NCT00774072|PLACEBO_COMPARATOR|isotonic saline|applied once daily via Pari Sinus nebulizer
62620899|NCT00615810|ACTIVE_COMPARATOR|2|Open label Kivexa (abacavir (as sulfate) 600 mg/lamivudine 300 mg) once daily for oral administration plus Sustiva (efavirenz 600 mg) once daily for oral administration
62620900|NCT00615810|EXPERIMENTAL|1|Open label Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir DF 300 mg) once daily for oral administration to be taken on an empty stomach
62620901|NCT04964583|EXPERIMENTAL|Hydroxychloroquine with Azithromycin|Fixed combination of Hydroxychloroquine with Azithromycin 200 mg / 250 mg one tablet every 12 hours for five days and continue with Hydroxychloroquine 200 mg one tablet every 12 hours for 5 more days.
62620902|NCT04964583|ACTIVE_COMPARATOR|Hydroxychloroquine|Hydroxychloroquine 200 mg, one tablet every 12 hours for ten days.
62620903|NCT04964583|PLACEBO_COMPARATOR|Placebo|Placebo one tablet every 12 hours for ten days.
62620904|NCT01858220||Video capsule examinee|Every subject having capsule endoscopy for any indication
62620905|NCT03990779||Children with congenital cardiac disease|Children with congenital cardiac disease who undergoing surgery
62620906|NCT05950165|EXPERIMENTAL|CHO-H01|"Dose escalation phase~Phase 1:~Five to six cohorts of escalating dose levels of CHO-H01 from 0.5mg/kg to 12 mg/kg."
62620907|NCT05950165|EXPERIMENTAL|CHO-H01+Lenalidomide|"Expansion phase with lenalidomide combination.~Phase2a:~Single cohort at Recommended Phase 2 Dose (RP2D) of CHO-H01."
62620908|NCT05041660|EXPERIMENTAL|VR ICT|Virtual-reality-based inhibitory control training done daily at home for 6 weeks.
62264613|NCT00619073|ACTIVE_COMPARATOR|Clopidogrel + aspirin|The subjects will be randomized to clopidogrel 75 mg plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., clopidogrel) will then be discontinued and aspirin continued for another 43 days.
62264614|NCT00619073|PLACEBO_COMPARATOR|Placebo + aspirin|The subjects will be randomized to placebo plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., placebo) will then be discontinued and aspirin continued for another 43 days.
62620909|NCT05041660|SHAM_COMPARATOR|VR Sham ICT|"Virtual-reality-based sham inhibitory control training (i.e., one that does not include a stop signal and that thus does not truly train inhibitory control) done daily at home for 6 weeks."
62620910|NCT05041660|ACTIVE_COMPARATOR|Non-VR ICT|Computerized inhibitory control training done daily at home for 6 weeks.
62620911|NCT05041660|SHAM_COMPARATOR|Non-VR Sham ICT|"Computerized sham inhibitory control training (i.e., one that does not include a stop signal and that thus does not truly train inhibitory control) done daily at home for 6 weeks."
62620912|NCT00940186||pikamilone|
62620913|NCT00940186||dosage|low dosage group: administrate pikamilone tablet 50 mg; middle dosage group: administrate pikamilone tablet 100 mg; hige dosage group: administrate pikamilone tablet 200 mg.
62620914|NCT00940186||tablet|
62620915|NCT04202965|EXPERIMENTAL|PTG-300|PTG-300 Subcutaneous
62620916|NCT06397209|EXPERIMENTAL|proprioceptive neuromuscular facilitation|Propioceptive neuromascular facilitation alongwith routine therapy
62620917|NCT06397209|ACTIVE_COMPARATOR|Neural flossing|Neural flossing alongwith routine therapy
62620918|NCT00633490|EXPERIMENTAL|A|
62448168|NCT01673009|EXPERIMENTAL|Administration of Gleevec|Gleevec® will be dosed orally 440 mg/m\^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
62448169|NCT01095003|EXPERIMENTAL|Vinflunine plus Capecitabine|"Patients received (in combination with capecitabine)~• Vinflunine at the dose of 280 mg/m² and as a 20-minute IV. infusion on day 1 of each cycle repeated every 3 weeks."
62448170|NCT01095003|ACTIVE_COMPARATOR|Capecitabine single-agent|Capecitabine at the dose of 825mg/m² per os twice per day each morning and each evening for 14 consecutive days beginning on day 1 of each cycle repeated every 3 weeks (self-administered).
62448171|NCT03504852|EXPERIMENTAL|Secukinumab 300 mg every 2 weeks (Q2W)|2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter every 2 weeks. Subjects remained on secukinumab 300 mg every 2 weeks until the end of treatment.
62448172|NCT03504852|ACTIVE_COMPARATOR|Secukinumab 300 mg every 4 weeks (Q4W)|2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter Q4W. Includes both subjects randomized to remain on Q4W the entire treatment period, and subjects that were Psoriasis Area and Severity Index (PASI) 90 responders at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group.
62448173|NCT03504852|ACTIVE_COMPARATOR|Secukinumab 300 mg every 4 weeks non-responders up-titration (Q4W NR up)|2 injections of secukinumab 150 mg once weekly up to week 4, then Q4W up to Week 16 and thereafter Q2W. Includes Psoriasis Area and Severity Index (PASI) 90 non-responders (NR) at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group (subjects randomized to switch to Q2W if PASI 90 non-responder at Week 16).
62448174|NCT05977257||Non Interventional long term safety follow up|Non Interventional long term safety follow up
62448175|NCT06096623|EXPERIMENTAL|electronic patient-reported outcome (ePRO) questionnaires.|Subjects with colon or breast carcinoma will respond to weekly electronic patient-reported outcome (ePRO) questionnaires.
62448176|NCT04052867|EXPERIMENTAL|Lignocaine group|20 patients undergoing elective laparoscopic donor nephrectomy will be given lignocaine infusion as part of the perioperative pain management.
62448177|NCT04052867|ACTIVE_COMPARATOR|Control group|20 patients undergoing elective laparoscopic donor nephrectomy will be receiving an equivalent volume of normal saline.
62448178|NCT03519256|EXPERIMENTAL|Nivolumab monotherapy|
62448179|NCT03519256|EXPERIMENTAL|Nivolumab + BCG|
62448180|NCT03519256|EXPERIMENTAL|Nivolumab + BMS-986205|
62448181|NCT03519256|EXPERIMENTAL|Nivolumab + BMS-986205 + BCG|
62448182|NCT03246230|NO_INTERVENTION|NO VACCINES AT BIRTH|These will be newborns who will not receive any vaccines at birth and will have delayed immunization with catch-up (i.e., HBV, BCG and polio vaccine) by Day of Life 7.
62448183|NCT03246230|OTHER|HBV VACCINE AT BIRTH|Participants in this arm will receive licensed hepatitis B vaccine (HBV) at birth (Day of Life (DOL)-0) with catch up immunization (i.e., BCG and polio vaccine) at DOL-1, -3, or -7.
62448184|NCT03246230|OTHER|BCG VACCINE AT BIRTH|Participants in this arm will receive licensed Bacillus Calmette-Guérin (BCG) vaccine at birth (Day of Life(DOL)-0) with catch up immunization (i.e., HBV and polio vaccine) at DOL-1, -3 or- 7.
62620919|NCT06217445|EXPERIMENTAL|HIFU plus exercises|"1. A physician or technician first cleans the target area.~2. They may apply a topical anesthetic cream before starting.~3. The physician or technician then applies an ultrasound gel.~4. The HIFU device is placed against the skin.~5. Using an ultrasound viewer, the physician or technician adjusts the device to the right setting.~6. Ultrasound energy is then delivered to the target area in short pulses for roughly 30 to 90 minutes.~7. The device is removed."
62620920|NCT06217445|EXPERIMENTAL|doubled chin exercises|"1. Straight jaw jut~2. Ball exercise~3. Pucker up~   .~4. Tongue stretch~5. Neck stretch~6. Bottom jaw jut"
62620921|NCT00781924||biopsy|
62620922|NCT02758197|EXPERIMENTAL|Interdisciplinary program including MBSR|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
62620923|NCT02758197|NO_INTERVENTION|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
62620924|NCT02431104|EXPERIMENTAL|Laser Treatment|Treatment to unwanted tattoo using a 532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser
62620925|NCT01084538||End stage chronic kidney disease|Secondary hyperparathyroidism defined as intact PTH \> 300 pg/mL
62620926|NCT04747665||Patients|Patients who have undergone or refused to undergo colonoscopy
62060508|NCT02366897|OTHER|Tolerability and sensitivity|Stage 1: tolerability as per study design Stage 2: sensitivity as per study design - either quetiapine or risperidone. The intervention is the use of the Manus sensor pen
62620927|NCT04747665||Endoscopists|Endoscopists who perform or are training to perform colonoscopy
62620928|NCT03582319|EXPERIMENTAL|Biodentine|Regenerative material for pulp therapy
62620929|NCT03582319|ACTIVE_COMPARATOR|Formocresol|Fixative agent for pulp therapy
62620930|NCT04926506|EXPERIMENTAL|Xiyanping injection combined with routine treatment|
62620931|NCT04926506|NO_INTERVENTION|routine treatment|
62620932|NCT02634632|EXPERIMENTAL|Subjects with cancer|choose to write advance directives
62620933|NCT04856059|OTHER|Cardiac MRI, ECG and Blood Biomarkers|Additional sequences will be performed during routine clinical cardiac MRI and additional blood samples will be collected during routine blood work.
62620934|NCT00627926|PLACEBO_COMPARATOR|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 48 weeks.
62846908|NCT02897570|ACTIVE_COMPARATOR|Glucose|EEG_pre + Oral glucose tolerance test (50-g OGTT) + EEG_post
62060509|NCT02181686||Sentus QP group|Patients with standard indication for CRT-D therapy who will be implanted with Sentus QP LV lead and the BIOTRONIK HF-T QP device.
62060510|NCT02181686||VR-T/DR-T group|Patients with standard indication for ICD therapy who will be implanted with either single chamber ICD or dual chamber ICD of the Iperia ICD family
62060511|NCT04140253|ACTIVE_COMPARATOR|Standard Duloxetine treatment|Peroral treatment with duloxetine at a dose of 40 mg twice a day
62620935|NCT00627926|EXPERIMENTAL|Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week|Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.
62620936|NCT00627926|EXPERIMENTAL|Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.
62620937|NCT05565885||patients with vascularitis|Two additional 7ml EDTA tubes of blood are taken from the same blood puncture as during routine follow-up at several points in the follow-up
62620938|NCT02751164||Weekday daytime|Admitted to the critical care unit Monday-Friday 08:00-17:59
62620939|NCT02751164||Weekend daytime|Admitted to the critical care unit Saturday-Sunday 08:00-17:59
62620940|NCT02751164||Weekday night|Admitted to the critical care unit Monday-Friday 18:00-07:59 the next day
62620941|NCT02751164||Weekend night|Admitted to the critical care unit Saturday-Sunday 18:00-07:59 the next day
62620942|NCT05762809|EXPERIMENTAL|Kinesiophobia tests|Patients were assessed using the Tampa Scale of Kinesiophobia (TSK-17), Knee injury and Osteoarthritis Outcome Score (KOOS), and Oxford Knee score (OKS). Ten minutes cycling with light resistance on a stationary bike was used for warm up before the physical tests. Quadriceps and hamstring muscle isokinetic strength was assessed at 60°/sec and 180°/sec using a Humac Norm Isokinetic dynamometer (Stoughton, United States). Functional performance was tested with the single-leg hop test for distance and the Y-balance test for anterior reach. The non-operated leg was tested first. All physical tests were supervised by the same specialized physiotherapists.
62846909|NCT02897570|EXPERIMENTAL|Milk + Cereals|EEG_pre + B1: milk (125ml) and cereals (30g) + EEG_post
62846910|NCT02897570|EXPERIMENTAL|Milk + Apple + Snack|EEG_pre + B2: milk (220ml), apple (200g) and cream chocolate filled sponge cake (30g) + EEG_post
62846911|NCT02897570|EXPERIMENTAL|Milk + Apple + Bread w/ cream|EEG_pre + B3: milk (125ml), apple (150g), and bread (50g) with hazelnut chocolate cream (15g) + EEG_post
62846912|NCT05376332|EXPERIMENTAL|Sonomyographic control|Sonomyographic control involves the use of ultrasound signals from muscle deformation to control a prosthetic hand.
62846913|NCT05376332|ACTIVE_COMPARATOR|Myoelectric control|Myoelectric control involves the use of surface electromyography signals from muscle activation to control a prosthetic hand.
62060512|NCT04140253|EXPERIMENTAL|Standard Duloxetine treatment with PFMT|Peroral treatment with duloxetine at a dose of 40 mg twice a day. Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.
62264615|NCT02284126|EXPERIMENTAL|Topical Vancomycin|Treatment group, receive 2 g topical vancomycin hydrochloride (1 g applied as powder, 1 g mixed with sterile solution and applied as paste) at the time of closure, in addition to the standard of care for wound prophylaxis
62264616|NCT02284126|NO_INTERVENTION|Standard of Care|Control group, receive standard of care only
62846914|NCT01186172|EXPERIMENTAL|Ethanol-lock|Treatment with a combination of ethanol-lock and parenteral therapy
62846915|NCT01186172|ACTIVE_COMPARATOR|Antibiotic lock|Treatment with a combination of antibiotic-lock and parenteral therapy
62264617|NCT05860075|EXPERIMENTAL|IMM01 in subjects with hematologic malignancy|"The escalation dosing were 3µg/kg, 10µg/kg, 50µg/kg, 150µg/kg, 500µg/kg, 1.0mg/kg, 1.5mg/kg and 2.0mg/kg.~The extend cohorts were Hodgkin's lymphoma, B-cell lymphoma,NK/T-cell lymphoma,AML,MDS and MM cohorts"
62264618|NCT01824277|NO_INTERVENTION|Group 1|Group 1 - Standard Pre-operative Diabetes Care
62846916|NCT01698034|EXPERIMENTAL|Volunteering|Weekly volunteering with elementary school children in after school programs
62846917|NCT01698034|NO_INTERVENTION|Control|Wait-list control
62846918|NCT02608801||Patients from NoFRACT|Patients from NoFRACT who consent to participate in this sub-study, will be offered examination and treatment with anti-osteoporotic drugs cf. treatment algorithm in the main-study. I.e. if osteoporosis is present clinically or at DXA scan, treatment is started.
62264619|NCT01824277|EXPERIMENTAL|Group 2|Group 2 - Structured Pre-operative Diabetes Optimization
62846919|NCT05649319|EXPERIMENTAL|ERAS group|Perioperative care for laparoscopic distal gastrectomy is managed according to ERAS protocol.
62846920|NCT05649319|NO_INTERVENTION|Conventional group|Perioperative care for laparoscopic distal gastrectomy is managed according to our current perioperative practice.
62846921|NCT02879201|ACTIVE_COMPARATOR|Slow efficiency dialysis|SLED is a kind of hemodialysis technique performed using Fresenius 4008B dialysis machine with FDX 120 GW (NIKKISO Japan) dialyzer. SLED sessions were 6-8 hour duration, three times per week (except Sunday), In case of severe volume overload, the session could be increased to meet clinical situation. Blood flow was maintained between 150-200 mL/hr and the dialysate flow of 300 mL/hr. Both the groups use unfractionated heparin as anticoagulant to prevent clotting of the extracorporeal circuit .the target partial thromboplastin time( PTT) was not more than twice the control level.
62846922|NCT02879201|NO_INTERVENTION|Continuous renal replacement therapy|CRRT is a kind of therapy involved continuos dialysis throughout 24 hours by using Edward Delivery system (Edward Life Science) as continuous venovenous hemodiafiltration (CVVHDF) mode using Aquamax HF 12 dialyzer. Blood flow rate was kept from 100-200 mL/hr and target effluent rates of 20 mL/hr . The substitution fluid was infused at a rate of 1,000 ml/hr with ultrafiltration rate at 100-300 mL/hr.Intervention here is the different mode of dialysis
62060513|NCT01776021|ACTIVE_COMPARATOR|cranberry juice|cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
62060514|NCT01776021|PLACEBO_COMPARATOR|Placebo|placebo beverage at a dose of one 8 oz. beverage per day for six months
62060515|NCT04086784||3D-printed Cage|Patients undergoing posterior lumbar interbody fusion with 3D-printed Porous Titanium Alloy Cages at the lowest fusion segment
62060516|NCT04086784||Peek Cage|Patients undergoing posterior lumbar interbody fusion with PEEK Cages at the lowest fusion segment
62060517|NCT04532658|EXPERIMENTAL|Intervention arm|Surgeons randomly assigned to the intervention arm
62060518|NCT04532658|NO_INTERVENTION|Control arm|Surgeons randomly assigned to the control arm
62060519|NCT00883038|ACTIVE_COMPARATOR|Active Comparator|Diabetic diet following the DNSG guidelines
62060520|NCT00883038|EXPERIMENTAL|Experimental|Low-fat vegetarian diet
62264620|NCT03073980|EXPERIMENTAL|Group 1: Intravenous (IV) acetaminophen/oral (PO) placebo|In the pre-operative suite, these patients will receive 1000mg IV acetaminophen and PO placebo, followed by standard protocol anesthesia and pain control as needed.
62264621|NCT03073980|ACTIVE_COMPARATOR|Group 2: Intravenous (IV) placebo/oral (PO) acetaminophen|In the pre-op suite, these patients will receive 1000mg PO acetaminophen and IV placebo, followed by standard protocol anesthesia and pain control as needed.
62264622|NCT03073980|PLACEBO_COMPARATOR|Group 3: Oral and intravenous Placebo / Standard of care|In the pre-op suite, these patients will receive PO and IV placebo, followed by standard protocol anesthesia and pain control as needed.
62448185|NCT03246230|OTHER|(HBV + BCG) VACCINES AT BIRTH|Participants in this arm will receive licensed hepatitis B vaccine (HBV) and licensed Bacillus Calmette-Guérin (BCG) vaccine at birth (Day of Life (DOL- 0) with catch up immunization (i.e., polio vaccine) at DOL-1, -3, or -7.
62846923|NCT03290924|EXPERIMENTAL|Intervention|Low-dose high-frequency health worker training approach to update skilled birth attendants in key evidence-based intrapartum and immediate newborn care practices
62846924|NCT03290924|ACTIVE_COMPARATOR|Comparison|Training on data collection and reporting
62448186|NCT01821625|EXPERIMENTAL|Thrombocytopenic (Low Platelet) Patients|"All study patients will undergo intervention in this study.~The intervention will be a lead-in with eltrombopag and antiviral triple therapy (interferon, ribavirin and boceprevir)."
62846925|NCT00930072|EXPERIMENTAL|Block|
62846926|NCT00930072|NO_INTERVENTION|Standard Care|
62060521|NCT02100150|EXPERIMENTAL|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
62060522|NCT02100150|PLACEBO_COMPARATOR|Placebo (strawberry flavored solution)|Strawberry flavored solution and water
62060523|NCT03021486|EXPERIMENTAL|Group I (haloperidol)|Patients receive haloperidol IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
62060524|NCT03021486|EXPERIMENTAL|Group II (chlorpromazine)|Patients receive chlorpromazine IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
62448187|NCT04082962|EXPERIMENTAL|Treatment Group|Participants receiving dexamethasone implant.
62060525|NCT03021486|EXPERIMENTAL|Group III (haloperidol, chlorpromazine)|Patients receive haloperidol and chlorpromazine IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
62060526|NCT05356390|EXPERIMENTAL|Stabilization exercises|Group A performed stabilization exercises for 4 weeks. In stabilization exercises, floor bridging, heel prop and alternate arm and leg exercises were administered in iliopsoas, gluteal and hamstring groups.
62264623|NCT05288283|EXPERIMENTAL|GWP42003-P|Participants will be initiated on a dose of GWP42003-P 2.5 milligrams per kilogram (mg/kg) twice a day (BID) (5 mg/kg/day); after 1 week, the dose will be increased to 5 mg/kg BID (10 mg/kg/day). Dose escalation up to a maximum daily dosage of 20 mg/kg/day (in increments of 5 mg/kg/day \[2.5 mg/kg BID\] no more rapidly than every 7 days) may occur after Day 15 based on the investigator's assessment of efficacy, safety and tolerability.
62264624|NCT05288283|PLACEBO_COMPARATOR|Placebo|Participants will receive the matching placebo.
62448188|NCT04082962|NO_INTERVENTION|Non-treatment group (control)|Participants not receiving dexamethasone implant.
62448189|NCT04543136|ACTIVE_COMPARATOR|Intermittent catheter; SpeediCath® Standard male|Participants underwent two catheterizations with standard of care intermittent catheter: The first was performed by a trained nurse, the second by the participant later the same day.
62448190|NCT04543136|EXPERIMENTAL|New intermittent catheter Variant 1 for males|Participants underwent two catheterizations with the new intermittent catheter Variant 1 for males: The first was performed by a trained nurse, the second by the participant later the same day.
62846927|NCT00845767|EXPERIMENTAL|Diesel Exposure|1 hour exposure to dilute diesel exhaust at a concentration of 300 µg/m3 with intermittent exercise
62846928|NCT00845767|EXPERIMENTAL|Air Exposure|1 hour exposure to filtered air during intermittent exercise
62846929|NCT00373113|ACTIVE_COMPARATOR|A|1250 mg/m\^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
62846930|NCT00373113|EXPERIMENTAL|B|37.5 mg daily, continuous dosing
62060527|NCT05356390|ACTIVE_COMPARATOR|Muscle energy techniques|Muscle energy techniques were given to group B. These techniques are active form of manual therapy in which patient uses its own energy on request to aid in treatment.
62060528|NCT05839353||simulated training by Serious Game (SG)|Simulated training (by SG) for the use of the SBAR tool associated with the usual instructions issued in routine care, on the management of dyspnea
62060529|NCT05839353||usual instructions issued in routine care|Usual instructions issued in routine care, on the management of dyspnea
62060530|NCT02304965|EXPERIMENTAL|Daily physical activity|Eligible subjects will be included in the feasibility study to conduct an individualized and structured training program with defined walking and cycling on a bicycle ergometer for 2 months.
62060531|NCT02421666|EXPERIMENTAL|behavioral PNMI|eligible patients received patient navigator led plus mobile phone text messaging intervention(PNMI) or standard care.
62060532|NCT02421666|NO_INTERVENTION|control|eligible chronic HBV patients received standard care
62060533|NCT01711957||Liver disease and liver transplantation|Patient with end stage liver disease and/or primary liver tumor undergoing liver transplantation
62448191|NCT04543136|EXPERIMENTAL|New intermittent catheter Variant 2 for males|Participants underwent two catheterizations with the new intermittent catheter Variant 2 for males: The first was performed by a trained nurse, the second by the participant later the same day.
62448192|NCT04787757||Percutaneous cardiac procedures|Patients undergoing percutaneous cardiac procedures
62448193|NCT03966170|EXPERIMENTAL|Citicoline|Citicoline as neuroprotector
62448194|NCT03966170|PLACEBO_COMPARATOR|Placebo drug|Placebo
62448195|NCT02494726||Ischemic Stroke|Ischemic stroke patients who have had blood analyzed using thromboelastography (TEG)
62448196|NCT02494726||Healthy Controls|Healthy controls who have had their blood analyzed using thromboelastography (TEG)
62846931|NCT04133129|EXPERIMENTAL|LV-High Intensity Interval Training|2 x 4 minutes at 85%-95% of Heart rate max.
62846932|NCT04133129|EXPERIMENTAL|Moderate Intensity Continuous Training|1 x 45 minutes at 65%-75% of Heart rate max.
62846933|NCT04133129|NO_INTERVENTION|Control Group|They will not be prescribed any training and will be asked to continue with their normal lifestyle.
62620943|NCT00359177|EXPERIMENTAL|Healthy subjects receiving GW679769|Healthy Subjects will receive single 100 milligram (mg) oral doses of GW679769 for five consecutive days.
62620944|NCT00359177|EXPERIMENTAL|Subjects with hepatic impairment receiving GW679769|Subjects with hepatic impairment will receive single 100 mg oral doses of GW679769 for five consecutive days.
62620945|NCT01519973|OTHER|Evaluation of technology in SPECT|Evaluation of the accuracy of SPECT with new technologies for attenuation correction (AC), scatter correction (SC) and resolution recovery (RR) for assessment of myocardial perfusion using Rb-82 PET as the gold standard.
62620946|NCT05208580|EXPERIMENTAL|On-line education|Virtual educational activities
62620947|NCT05208580|EXPERIMENTAL|Contact education|Live educational classes
62620948|NCT05208580|NO_INTERVENTION|Control group|Regular perioperative care without additional educational activities
62620949|NCT03419143||Cohort 1|naïve of abatacept, other biologic agents and Targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs)
62060534|NCT03798600||Critically ill patients|"20 patients consecutively admitted in the ICU with severe sepsis or septic shock requiring caspofungin therapy will be considered for this observational study.~Inclusion Criteria:~Adult ICU patients (\>18 yrs) with severe sepsis or septic shock undergoing caspofungin therapy based on clinical judgement (empiric therapy) or microbiological result (targeted therapy).~Exclusion criteria:~Concomitant ciclosporin or rifampicin therapy. Pregnancy Continuous renal replacement therapy Severe Liver failure (Child Pugh score \> 6)"
62846934|NCT02202083|EXPERIMENTAL|oxytocin|"There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon.~This group is term gestaion,with bishop score less than 6."
62846935|NCT00865540|EXPERIMENTAL|prednisolone acetate 1%|one drop every 8h two days before surgery
62060535|NCT04096612|EXPERIMENTAL|Orbital decompression combined MPT|Orbital decompression was performed by the same doctor with rich clinical experience. MPT should be implemented in the patients with obvious thyroid disorder before orbital decompression surgery which should only be performed when thyroid function was stabilized. The surgery was performed under general anesthesia. An arcuate incision was made in the skin 2 mm below the lower eyelid margin, and the tissue under the incision were separated to the periorbita and orbital septum. Part of the medial orbital wall, inferior orbital wall and partial tissue of ethmoidal sinus were removed, and an appropriate amount of adipose tissue was excised. MPT was conducted after the surgery, at a dose of 1g methylprednisolone per day through intravenous injection for 3 consecutive days with a total amount of 3g methylprednisolone. After 3 days of intravenous injection of methylprednisolone, prednisone was orally taken by the patients at a dose of 30 mg/day which was gradually reduced.
62060536|NCT04096612|EXPERIMENTAL|Separate MPT|MPT was conducted after the surgery, at a dose of 1g methylprednisolone per day through intravenous injection for 3 consecutive days with a total amount of 3g methylprednisolone. After 3 days of intravenous injection of methylprednisolone, prednisone was orally taken by the patients at a dose of 30 mg/day which was gradually reduced.
62060537|NCT05030896|EXPERIMENTAL|Experimental group|Participants will receive EPM and they will perform exercise program during 1 month.
62060538|NCT05030896|EXPERIMENTAL|Control group|Participants will receive needling puncture and they will perform exercise program during 1 month.
62060539|NCT02401074|EXPERIMENTAL|Segmental bronchoprovocation with Allergen (SBP-Ag)|Following nasopharyngeal anesthesia, the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During SBP-Ag challenge, 15% of the Ag-PD20 allergenic extract will be instilled into the segment.
62264625|NCT02882633|ACTIVE_COMPARATOR|Lumbar Plexus Block|Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain
62264626|NCT02882633|ACTIVE_COMPARATOR|Fascia Iliac Block|Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain
62264627|NCT03362424|EXPERIMENTAL|Mesenchymal stem cell group|rotator cuff repair stem cells
62264628|NCT03362424|ACTIVE_COMPARATOR|Control group|rotator cuff repair
62264629|NCT04185090|ACTIVE_COMPARATOR|ID1801|qd daily for 6days Intervention: Drug: administration of ID1801 for 6days.
62620950|NCT03419143||Cohort 2|"naïve of abatacept, who previously failed one tumor necrosis factor inhibitor (TNFi), but are naïve of any other biologic agent and tsDMARDs"
62620951|NCT03419143||Cohort 3|naïve of abatacept, who previously failed treatment with tsDMARDs and/or biologic agents\*\* other than a single TNFi
62620952|NCT02834832||Control|The patients will be given removable dentures with no coatings. These dentures are part of the standard of care to treat their edentulism.
62846936|NCT00865540|EXPERIMENTAL|ketorolac tromethamine 0.4%|one drop every 8h two days before surgery
62846937|NCT00865540|EXPERIMENTAL|nepafenac 0.1%|one drop every 8h two days before surgery
62846938|NCT00865540|PLACEBO_COMPARATOR|placebo|one drop every 8h two days before surgery
62264630|NCT04185090|ACTIVE_COMPARATOR|ID1803|qd daily for 10days Intervention: Drug: administration of ID1803 for 10days.
62620953|NCT02834832||PECVD Coatings|The patients will be given removable partial dentures with PECVD coatings on both the tissue surface of the dentures and the acrylic denture teeth.
62620954|NCT06345391||Children living beyond cancer|Children between 8-12 years with a history of any cancer diagnosis that are currently in the early survivorship phase (\<2y post-treatment).
62620955|NCT06345391||Parents of children living beyond cancer|Parents of children (8-12 years) living beyond cancer.
62620956|NCT06345391||Pediatric oncology clinicians|Clinicians (e.g. physician, nurse, physical therapist, occupational therapist, psychologist, child life specialist) currently employed in pediatric oncology.
62620957|NCT05376072|EXPERIMENTAL|Experimental data|
62620958|NCT03745248|EXPERIMENTAL|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
62846939|NCT02934503|EXPERIMENTAL|Cisplatin or carboplatin, Etoposide, Pembrolizumab & Radiation|"Cohort A: cisplatin (75 mg/m\^2) + carboplatin (AUC 6) + etoposide (100mg/m\^2) for four to six, 3-week cycles + pembrolizumab (200 mg) followed by radiation. Pembrolizumab will be started with first cycle of chemotherapy and continued for up to 2 years.~Cohort B: Pembrolizumab (200 mg) will be added to standard therapy with cisplatin (75 mg/m2) or carboplatin (AUC 6) and etoposide (100 mg/m2) (and radiation, if appropriate), after one 3- week cycle of standard therapy and continued for up to 2 years.~Cohort C: 200 mg IV infusion of Pembrolizumab every 3 weeks over about 30 minutes after completion of standard chemotherapy with cisplatin (75 mg/ m2) and etoposide (100 mg/m2). Treatment with pembrolizumab will continue for up to 2 years.~Cohort D: Pembrolizumab 200 mg IV infusion every 3 weeks in vein after completion of standard chemotherapy and radiation. Pembrolizumab will start within 6 weeks of completing radiation therapy and continue for up to 2 years."
62846940|NCT01309282||Rituximab|Sero-positive \[Rheumatoid Factor (RF) and/or anti-Cyclic Citrullinated Peptide (CCP+)\] rheumatoid arthritis (RA) patients, who had initiated therapy with Rituximab (MabThera) following lack of response or intolerance to a single tumour necrosis factor (TNF)-inhibitor will be included in this arm
62846941|NCT06257589||Intrathoracic Approach|"Patients who have undergone the intrathoracic approach of phrenic nerve reconstruction for the treatment of diaphragmatic paralysis.~NO INTERVENTION."
62846942|NCT06257589||Cervical Approach|"Patients who have undergone the cervical approach of phrenic nerve reconstruction for the treatment of diaphragmatic paralysis.~NO INTERVENTION."
62846943|NCT03891238|EXPERIMENTAL|Avelumab Arm|Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
62846944|NCT05217316|NO_INTERVENTION|Control Group|Control group will receive a videos five times a week that illustrate a unified toothbrushing technique and remind the child to brush their teeth.
62060540|NCT00717821|EXPERIMENTAL|Methoxy Polyethylene Glycol-epoetin Beta|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will receive monthly injections of methoxy polyethylene glycol-epoetin beta, with the starting dose of 120 or 200 micrograms calculated from the last weekly dose of epoetin beta or darbepoetin alfa previously administered, using the same route of administration (SC or IV). Thereafter, when the hemoglobin concentration will increase or decrease in a clinically significant amount, a dose adjustment will be performed according to specific provided guidance. Total duration of treatment will be up to 48 weeks.
62846945|NCT05217316|EXPERIMENTAL|Intervention Group|Both groups will receive a videos five times a week that illustrate a unified toothbrushing technique and remind the child to brush their teeth. The intervention lies in which the intervention group will receive a supervised virtual toothbrushing performed once a week for all students by dental hygienist that will be performed through a prescheduled virtual appointment for each child.
62060541|NCT00717821|ACTIVE_COMPARATOR|Epoetin Beta or Darbepoetin Alfa|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will continue to receive the same treatment (epoetin beta or darbepoetin alfa at the same dose, same administration intervals, and the same route of administration). When necessary, dose adjustments will be performed according to Summary of Product Characteristics (SmPC). Total duration of treatment will be up to 48 weeks.
62846946|NCT01291082||Breast cancer patients|Breast cancer patients
62060542|NCT01669590||old (60-75yr)|
62060543|NCT01669590||young (18-35y)|
62060544|NCT05811039|EXPERIMENTAL|Treatment|Treatment with RemoWax Oil
62060545|NCT02378740|PLACEBO_COMPARATOR|Placebo|Placebo (.9 sterile normal saline) administered IV
62264631|NCT04185090|EXPERIMENTAL|ID1801 and ID1803|qd daily for 7days Intervention: Drug: administration of ID1801 and ID1803.
62264632|NCT01841944|ACTIVE_COMPARATOR|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
62620959|NCT03745248|ACTIVE_COMPARATOR|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre-training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge. Individuals will be instructed to perform more difficult exercises if balance challenge scores are low.
62620960|NCT04692272|NO_INTERVENTION|CONTROL group|The CONTROL group did not exercise.
62620961|NCT04692272|EXPERIMENTAL|XBOX group|"The XBOX group performed exercise for 60 min, three times/week, for 6 weeks, using the Xbox Kinect game Your Shape Fitness evolved. This game was chosen because it simulates an environment with a variety of physical activities, in which the majority can be practiced by older adults. The activities were carried out individually. The game activities selected for the physical activity sessions were: 1) Zen-Develop it (stretching, balance and flexibility activities, similar to Yoga); 2) Pump it (to fill balls until they burst); 3) Wall Breaker (to break blocks, similar to boxing); 4) Kick it (soccer activity); 5) Hurricane (to lift the balls off the floor and not let them fall); 6) Stack in Up (balance activity)."
62620962|NCT01404897|EXPERIMENTAL|Dietary Intervention: Control Diet|
62620963|NCT01404897|EXPERIMENTAL|Dietary Intervention: DASH-based diet|
62620964|NCT01404897|EXPERIMENTAL|Dietary Intervention: Modified DASH diet|
62620965|NCT04476498|NO_INTERVENTION|Standard pull-PEG|"Standard pull-PEG~In this group the participants receive a conventional pull-PEG as firstly described by Ponsky and Gauderer."
62846947|NCT03945604|EXPERIMENTAL|SHR-1210 + Apatinib +Fluzoparib|SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity
62846948|NCT01533350||group1|women with a ultrasonographic homogeneous echo endometrium in the late follicle phase
62846949|NCT01533350||group2|"women with a ultrasonographic  triple-line endometrium in the late follicle phase"
62060546|NCT02378740|ACTIVE_COMPARATOR|Ketamine|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
62264633|NCT01841944|PLACEBO_COMPARATOR|Corn oil|3x capsules of corn oil pr day
62846950|NCT05101304||HEAR(Healthcare European Amyloidosis Registry)-Retrospective Cohort|Retrospective collection of deceased patients data with inclusion criteria
62060547|NCT00703040||Component 1|Existing linkage to care protocols will be obtained from the 15 sites. This component does not involve study subjects.
62060548|NCT00703040||Component 2|Person-to-person or telephone interviews with ATN clinical site staff and staff from their community partners will be audio-taped.
62060549|NCT00703040||Component 3|Notes from direct observation of the linkage to medical care process within sites will be taken.
62060550|NCT03072238|ACTIVE_COMPARATOR|Placebo + Abiraterone|Participants received Placebo plus Abiraterone (along with Prednisone/Prednisolone), administered orally in 28-day cycles.
62846951|NCT05101304||HEAR(Healthcare European Amyloidosis Registry)-Retrospective-Prospective Cohort|Retrospective and prospective collection of patient data and real-life follow-up of patients from the date of inclusion Living patients who met the inclusion criteria
62060551|NCT03072238|EXPERIMENTAL|Ipatasertib + Abiraterone|Participants received Ipatasertib plus Abiraterone (along with Prednisone/Prednisolone), administered orally in 28-day cycles.
62060552|NCT00904891|EXPERIMENTAL|1|Participants will receive a cognitive-behavioral group intervention.
62060553|NCT00904891|ACTIVE_COMPARATOR|2|Participants will receive cognitive-behavioral bibliotherapy.
62264634|NCT01539590|EXPERIMENTAL|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
62264635|NCT01539590|PLACEBO_COMPARATOR|Normal Saline|Daily intravenous administration for four (4) days
62264636|NCT02106052|ACTIVE_COMPARATOR|Aerobic exercise|
62264637|NCT02106052|OTHER|Stretching and toning exercise|
62060554|NCT00904891|NO_INTERVENTION|3|Participants will only complete study assessments.
62448197|NCT02494726||Hemorrhagic Stroke|Intracerebral hemorrhage patients who have had their blood analyzed by thromboelastography (TEG)
62448198|NCT00017563|EXPERIMENTAL|Docetaxel, Mitoxantrone, Conventional Surgery|"Drug: Docetaxel-35 mg/m2 i.v. over 15 - 30 minutes will be administered immediately after the mitoxantrone on the same schedule.~Drug: Mitoxantrone-Initial dose will be 2 mg/m2 weekly for 3 of every 4 weeks. The dose will then be escalated as described in the dose escalation section up to a maximum dose of 6 mg/m2 weekly for 3 of every 4 weeks.~Procedure/Surgery: Conventional Surgery- Prostatectomy will be scheduled 2-4 weeks after the last dose of chemotherapy"
62448199|NCT03580343|EXPERIMENTAL|Tofacitinib Treatment|11mg extended-release tofacitinib, once daily, oral
62448200|NCT00698685|EXPERIMENTAL|Preparative Regimen|"Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)~Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)~Followed by Allogeneic hematopoietic stem cell transplantation, related or unrelated donor, on day 0. Patients also receive cyclosporine intravenous (IV) continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper."
62620966|NCT04476498|ACTIVE_COMPARATOR|Pull-PEG with gastropexy|"Pull-PEG with gastropexy~In this group the participants firstly receive a gastropexy with the Funada style gastropexy device. Afterwards a conventional pull-PEG will be inserted."
62620967|NCT05693324|ACTIVE_COMPARATOR|1 Minority stress|"Intervention starts with the minority stress module, followed by worry and then compassion.~Modules are given with a trans-affirmative stance, based on the minority stress model. The minority stress module contains psychoeducation on minority stress and minority joy as well as behavioral interventions. The worry module contains cognitive interventions. The compassion module targets internalized transphobia and is based on compassion-focused therapy."
62620968|NCT05693324|ACTIVE_COMPARATOR|2 Minority stress|"Intervention starts with minority stress module, followed by compassion and then worry.~Modules are given with a trans-affirmative stance, based on the minority stress model. The minority stress module contains psychoeducation on minority stress and minority joy as well as behavioral interventions. The worry module contains cognitive interventions. The compassion module targets internalized transphobia and is based on compassion-focused therapy."
62620969|NCT05693324|ACTIVE_COMPARATOR|3 Worry|"Intervention starts with worry module, followed by minority stress and then compassion.~Modules are given with a trans-affirmative stance, based on the minority stress model. The minority stress module contains psychoeducation on minority stress and minority joy as well as behavioral interventions. The worry module contains cognitive interventions. The compassion module targets internalized transphobia and is based on compassion-focused therapy."
62620970|NCT05693324|ACTIVE_COMPARATOR|4 Worry|"Intervention starts with worry module, followed by compassion and then minority stress.~Modules are given with a trans-affirmative stance, based on the minority stress model. The minority stress module contains psychoeducation on minority stress and minority joy as well as behavioral interventions. The worry module contains cognitive interventions. The compassion module targets internalized transphobia and is based on compassion-focused therapy."
62620971|NCT05693324|ACTIVE_COMPARATOR|5 Compassion|"Intervention starts with compassion module, followed by minority stress and then worry.~Modules are given with a trans-affirmative stance, based on the minority stress model. The minority stress module contains psychoeducation on minority stress and minority joy as well as behavioral interventions. The worry module contains cognitive interventions. The compassion module targets internalized transphobia and is based on compassion-focused therapy."
62620972|NCT05693324|ACTIVE_COMPARATOR|6 Compassion|"Intervention starts with compassion, followed by worry and then minority stress.~Modules are given with a trans-affirmative stance, based on the minority stress model. The minority stress module contains psychoeducation on minority stress and minority joy as well as behavioral interventions. The worry module contains cognitive interventions. The compassion module targets internalized transphobia and is based on compassion-focused therapy."
62620973|NCT02328794|ACTIVE_COMPARATOR|Control|Participants randomized to this arm will receive a standardized Vitality program aimed at promoting tobacco cessation. This program includes existing employee benefits for quitting and the use of text/email messages to encourage tobacco cessation. No incentives will be given to participants randomized to this arm. Free cessation aids will not be available to participants in this arm. They will receive compensation for completing study related activities (sample submissions).
62620974|NCT02328794|EXPERIMENTAL|E-cigarette free access|Participants randomized to this experimental arm will receive the standardized program including text/email messaging and will have access to free e-cigarettes only. These products can be ordered directly, free of charge, through the web-based interface. No incentives will be given to participants randomized to this arm. They will receive compensation for completing study related activities (sample submissions).
62846952|NCT05101304||HEAR(Healthcare European Amyloidosis Registry)-Prospective Cohort|Prospective data collection and real-life follow-up of patients from the date of inclusion These patients are either newly followed in the centre with the inclusion criteria
62846953|NCT04976907||Perioperative patients|Patients undergoing perioperative assessment of vital signs.
62846954|NCT03156296|ACTIVE_COMPARATOR|BUPIVACAINE|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
62846955|NCT03156296|ACTIVE_COMPARATOR|DEXMEDETOMIDINE|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
62264638|NCT06145555|EXPERIMENTAL|Acute psychological sleep stabilization|The basis of the treatment is CBT-I adapted to a short version performed by trained staff (nurses or mental health care assistants), with support from a psychologist. The manuals are designed to be read by patients and staff together and each treatment manual covers a specific topic. The focus of the treatment is behavioral changes and central manuals are stimulus control and scheduled sleep and sleep compression (if needed). Systematic work with light / darkness based on mapping of the patient's circadian rhythm is included.
62846956|NCT06096571|OTHER|Experimental: RT-sequence|Group 1 (18 volunteers, RT sequence) will take 1 tablet of Aterixen,100 mg as a single dose in the fasting state in Period 1 and 1 tablet of Aterixen,100 mg film-coated tablet as a single dose in the fasting conditions in Period 2
62846957|NCT06096571|OTHER|Experimental: TR-sequence|Group 2 (18 volunteers, TR sequence) will take 1 tablet of Aterixen,100 mg film-coated tablet as a single dose in the fasting state in Period 1 and 1 tablet of Aterixen,100 mg as a single dose in the fasting conditions in Period 2
62846958|NCT01040234||Active pain treatment|Bilateral dual TAP block
62264639|NCT06145555|ACTIVE_COMPARATOR|Sleep hygiene education|The control treatment is delivered through structured manuals which patients work through together with the staff. The manuals cover sleep hindering factors (eg coffee, nicotine), sleep promoting factors (eg physical activity during the day, relaxation, blinds), sleep aids (for example, weight blanket, calm music).
62264640|NCT01201161|EXPERIMENTAL|RANI/PPV|Preoperative intravitreal ranibizumab and pars plana vitrectomy
62264641|NCT01201161|PLACEBO_COMPARATOR|PPV|Sham injection and pars plana vitrectomy
62846959|NCT01675167|PLACEBO_COMPARATOR|Placebo Buccal Film|Twice Daily Dosing
62846960|NCT01675167|EXPERIMENTAL|Buprenorphine HCl Buccal Film|Twice Daily Dosing
62448201|NCT04936997|EXPERIMENTAL|3rd COVID-19 vaccine (2nd booster)|Patients who were a part of the non-interventional portion of the study are eligible to receive a third COVID-19 Pfizer vaccine.
62620975|NCT02328794|EXPERIMENTAL|E-cigarette/NRT/Zyban/Chantix Choice|Participants randomized to this experimental arm will receive the standardized program including text/email messaging and will have access to free e-cigarettes, conventional Nicotine Replacement Therapy (NRT), Zyban, or Chantix. Each of these can be ordered directly, free of charge, through the web-based interface. No incentives will be given to participants randomized to this arm. They will receive compensation for completing study related activities (sample submissions).
62620976|NCT02328794|EXPERIMENTAL|Outcome Incentive arm|Participants randomized to this experimental arm will receive the standardized program and access to free e-cigarettes, NRT, Zyban, or Chantix. In addition, they will also be able to earn incentives across six months for testing negative for tobacco use (see Incentive payout, below). They will also receive compensation for completing study related activities (sample submissions).
62846961|NCT04367623|ACTIVE_COMPARATOR|Control|Patients receiving conventional hand therapy, time matched to the duration of total intervention in the Active group
62846962|NCT04367623|ACTIVE_COMPARATOR|Active|Patients receiving BCI FES prior to the conventional therapy
62846963|NCT00528697|EXPERIMENTAL|1|Lowest ABT-089 dose
62846964|NCT00528697|EXPERIMENTAL|2|Low-medium ABT-089 dose
62060555|NCT02307591|ACTIVE_COMPARATOR|Best Supportive Care|Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is \>7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
62060556|NCT02307591|EXPERIMENTAL|Best Supportive Care + Amiodarone|"This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .~During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).~Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.~Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.~Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).~Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:~* Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)~* Children \< 29 kg: 5 mg/kg 3 times a day"
62060557|NCT02869919||Patients with AKI|critically ill patients with acute kidney injury
62060558|NCT02869919||Patients without AKI|critically ill patients without acute kidney injury
62060559|NCT05428514|EXPERIMENTAL|Maternity Home Bed|Receives a bed in the maternity home, wrap-around services, etc.
62060560|NCT05428514|NO_INTERVENTION|Control|Referred to other services available in the community
62060561|NCT01163890|EXPERIMENTAL|WHI|
62448202|NCT03784261|ACTIVE_COMPARATOR|SAR, usually subucutaneous injection every 2 weeks|
62448203|NCT03784261|ACTIVE_COMPARATOR|TCZ, usually subucutaneous injection every 2 weeks|
62448204|NCT03784261|ACTIVE_COMPARATOR|ABT, usually subucutaneous injection every week|
62846965|NCT00528697|EXPERIMENTAL|3|Medium-high ABT-089 dose
62846966|NCT00528697|EXPERIMENTAL|4|Highest ABT-089 dose
62846967|NCT00528697|ACTIVE_COMPARATOR|5|atomoxetine
62846968|NCT00528697|PLACEBO_COMPARATOR|6|placebo
62846969|NCT01275807|EXPERIMENTAL|acupuncture|10 acupuncture sessions
62846970|NCT01275807|ACTIVE_COMPARATOR|self care|psychological support, phisical exercice, diet, self care groups
62846971|NCT04865900||Covid19 Vaccinated Patients|Patients who are planning to receive Pfizer-BioNTech BNT162b2 vaccines against Covid19
62846972|NCT03877328|EXPERIMENTAL|Virtual Coach|BiotechCoachForAll
62060562|NCT01163890|ACTIVE_COMPARATOR|Usual Care|
62060563|NCT06419244|OTHER|Surgical patients|Patients undergoing surgery
62060564|NCT06419244|OTHER|Non surgical patients|Patients not undergoing surgery
62060565|NCT01598298|EXPERIMENTAL|Arm I|Patients receive duloxetine hydrochloride orally (PO) once daily (QD) on days 1-7, twice daily (BID) on days 8-84, and then QD on days 85-91.
62060566|NCT01598298|PLACEBO_COMPARATOR|Arm II|Patients receive placebo PO QD on days 1-7, BID on days 8-84, and then QD on days 85-91.
62060567|NCT01398423|ACTIVE_COMPARATOR|Active control|Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
62060568|NCT01398423|EXPERIMENTAL|INV-144|INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
62060569|NCT04504643|EXPERIMENTAL|Technology-assisted circuit training|Multicomponent circuit training using FItLight Trainer™ as an embodied tool to perform motor task. The circuit training is composed by aerobic, muscular, coordination and balance exercises.
62448205|NCT01657539|EXPERIMENTAL|Probiotics|Group of patients using yogurt containing probiotics during the experimental phase of the study.
62846973|NCT03391245||Cirrhotic patients with or without infection|"We will include admitted patients with liver cirrhosis irrespective of the underlying etiology during 6 months in Al Rajhi Tertiary Liver Hospital, Assiut, Egypt. They will be divided into 2 Groups. Group I: Cirrhotic patients with evidence of infections at any site and Group II: Cirrhotic patients without evidence of infections.~Diagnosis of infection will based on related clinical symptoms and signs with laboratory and radiological findings."
62846974|NCT04872140|EXPERIMENTAL|Pea power with high iron bio-availability|Pea powder with low phytate levels to increase iron bio-availability (7mg iron per day)
62846975|NCT04872140|ACTIVE_COMPARATOR|Pea powder|Pea powder with normal phytate levels (7mg iron per day)
62846976|NCT04872140|PLACEBO_COMPARATOR|Placebo|Placebo (maltodextrin) powder (0g iron per day)
62448206|NCT01657539|PLACEBO_COMPARATOR|Control Yogurt|Group of patients that will use a placebo yogurt for providing comparison with the experimental group.
62846977|NCT01882608|NO_INTERVENTION|Treatment-as-usual|Treatment-as-usual, with no active intervention or follow-up. TAU patients will have readmission events monitored over the six-month interval by the study RA via periodic chart reviews and updates from their clinicians
62846978|NCT01882608|EXPERIMENTAL|Mental Health Telemetry (MHT)|Patients in the MHT group will be encouraged to provide daily symptom self-reports using MHT. MHT patients will also have readmission events monitored over the six-month interval by the study RA via periodic chart reviews and updates from their clinicians
62846979|NCT03337490|EXPERIMENTAL|Ivermectin 0.5% Lotion|Ivermectin 0.5% lotion, topical, 117g, single dose
62846980|NCT03337490|ACTIVE_COMPARATOR|Ivermectin 0.5% Lotion [SKLICE]|Sklice 0.5% Lotion, topical, 117g, single dose
62620977|NCT02328794|EXPERIMENTAL|Loss framing incentive arm|Participants randomized to this experimental arm will receive the standardized program and access to free e-cigarettes, NRT, Zyban, or Chantix. In addition they will also be able to earnincentives across six months through a pre-funded deposit or precommitment account. They will be notified that money has been placed into an account for them. At each time point they will lose a portion (see below) of this initial funding if they do not provide biochemical evidence of abstinence. They will also receive compensation for completing study related activities (sample submissions).
62846981|NCT03337490|PLACEBO_COMPARATOR|Placebo 0% Lotion|0% lotion, 117g, single dose
62846982|NCT06046170|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Participants will receive cognitive behavioral therapy that has been adapted for autistic youth with anxiety. These sessions will also include components of exposure. Participants will receive therapy around once a week for 14 weeks.
62846983|NCT06046170|PLACEBO_COMPARATOR|Treatment as Usual|Participants will complete treatment as usual. They will be referred to other community resources, including skills training. Additionally, participants may begin or end therapy and/or medication.
62846984|NCT06099080|EXPERIMENTAL|SM-020 gel 1.0%|Subjects will apply the investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12 weeks post final application for a total of approximately 16 weeks of required participation in the study.
62846985|NCT04161703|EXPERIMENTAL|focused ultrasound, diet and exercises|
62846986|NCT04161703|EXPERIMENTAL|diet and exercises|
62846987|NCT01962363|EXPERIMENTAL|EPI-743|EPI-743, oral, 400mg three times daily for 3 months
62846988|NCT05354362|EXPERIMENTAL|ATG-010 and ATG-008|ATG-010 and ATG-008 should be taken 6 hours apart on a PK sampling day
62846989|NCT02427997|EXPERIMENTAL|Treadmill training with virtual reality|The TT+VR patients (i.e., the experimental arm) will receive 18 sessions (3 times per week x 6 weeks) of training that will consist of walking on a treadmill while wearing a safety harness (without body weight support, recall Figure 1), and while being provided with feedback from the system.
62060570|NCT04504643|EXPERIMENTAL|Conventional circuit training|Multicomponent circuit training composed by aerobic, muscular, balance and coordination exercises. Coordination exercises wll be charged of simple dual task cognitive exercises (counting backwards, or making some easy math calculations, repeating words backward, finding words of the same family).
62620978|NCT04959292||Meniscus regeneration|Reconstruction of the anterior cruciate ligament, total or partial meniscus resection was performed in our hospital, and two years after the operation, the meniscus regeneration was found under secondary arthroscopy.
62846990|NCT02427997|ACTIVE_COMPARATOR|Treadmill training alone|TT alone will receive conventional treadmill training with no feedback from the system. They will train with a safety harness 18 sessions (3 times per week x 6 weeks).
62846991|NCT02529228|EXPERIMENTAL|CON-2|Consuming 2 Low Protein, High Carbohydrate Meals i.e. changing Meal Frequency and Protein Composition.
62846992|NCT02529228|EXPERIMENTAL|CON-6|Dividing meal intake into 6 smaller Low Protein, High Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
62846993|NCT02529228|EXPERIMENTAL|PRO-2|Consuming 2 High Protein, Low Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
62846994|NCT02529228|EXPERIMENTAL|PRO-6|Dividing meal intake into 6 smaller High Protein, Low Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
62448207|NCT02015091|EXPERIMENTAL|1, 4, 5, 6, 7|Vaccination schedules with 3 to 4 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
62448208|NCT02015091|EXPERIMENTAL|2|Vaccination schedules 4 IM vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
62448209|NCT02015091|EXPERIMENTAL|3|Vaccination schedules 5 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
62448210|NCT02015091|NO_INTERVENTION|8|Participation in controlled human malari infection (CHMI) without prior vaccinations to serve as controls.
62060571|NCT04504643|EXPERIMENTAL|Nordic Walking|The training sessions are performed in a natural parc, which offers pathways of different lengths and levels of difficulty that will increase over the weeks.
62060572|NCT01003522|OTHER|Treatment Arm A|Stenting of central lesion and subsequent standard palliative treatment and dyspnoea symptom control
62060573|NCT01003522|OTHER|Treatment Arm B|Standard palliative treatment and standard dyspnoea symptom control.
62060574|NCT01896635|ACTIVE_COMPARATOR|FMT infusions|FMT infusions constituted from stool provided by healthy, screened donors
62264642|NCT00867373|EXPERIMENTAL|Education Intervention|"The intervention used in the randomized controlled trial consists of 1) measuring the parents' height and weight and 2) providing the parents with feedback on their calculated BMI on an educational handout (included in Appendix V). The purpose of the handout is to convey the following 5 messages:~1. Definition of BMI~2. How BMI is calculated~3. What the parent's BMI is based on the measurements taken~4. What weight category the parent is in (underweight, normal weight, overweight, or obese)~5. Children with overweight or obese parents are at higher risk of becoming overweight themselves.~The Research Assistant will verbally review the educational handout with the parent. The handout will be available in both English and Spanish."
62448211|NCT01800565|OTHER|pubertal progression|A collection of first voided urine sample for the measurement of LH.
62448212|NCT00922779|EXPERIMENTAL|1|
62620979|NCT04959292||Meniscus without regeneration|Anterior cruciate ligament reconstruction, total or partial meniscus resection was performed in our hospital, and two years after the operation, no meniscus regeneration was found under secondary arthroscopy.
62620980|NCT00939237|EXPERIMENTAL|Active Ateronon|7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
62060575|NCT01896635|PLACEBO_COMPARATOR|Placebo arm|Placebo infusions
62620981|NCT00939237|PLACEBO_COMPARATOR|Placebo|placebo dietary supplement supplied as one capsule taken daily
62620982|NCT02383355|EXPERIMENTAL|Switch group|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy for 10 weeks
62620983|NCT02383355|ACTIVE_COMPARATOR|Continuation group|Individuals in the continuation group will continue the regimen, which consists of antiretroviral therapy as indicated in the inclusion criteria
62620984|NCT00316914|EXPERIMENTAL|Ca/Mg|Patients receive calcium gluconate (Ca) and magnesium sulfate (Mg) IV over 30 minutes immediately before and after each oxaliplatin administration (once every 2 weeks) of their assigned chemotherapy regimen.
62264643|NCT00867373|NO_INTERVENTION|Control Group|Parents assigned to the control group will proceed to their child's well child visit after their baseline data are collected.
62264644|NCT03506035||Rheumatoid arthritis|Patients who meet the criteria of the 1987 ACR
62264645|NCT03506035||Arthritis not Rheumatoid arthritis|Patients with psoriatic arthritis, peripheric spondyloarthropathies and connective tissue diseases.
62264646|NCT03506035||Healthy controls|From health blood donors
62264647|NCT01323426|EXPERIMENTAL|periurethral injection|Periurethral injection of autologous muscle fibers
62060576|NCT01925027|EXPERIMENTAL|NANO+ DES|The Nano+ Polymer-free Sirolimus-Eluting Coronary Stent System is device/drug combination products consisting of a drug-coated stent and a balloon expandable delivery system. The stent is coated with a formulation containing rapamycin, the active ingredient, adhered to 316L stainless bare stent scaffold with submicron micropores, and is approved by State Food and Drug Administration of China in 2011(No. 3460037).
62060577|NCT04983758||PHP|
62060578|NCT04983758||Moderate PCP|
62060579|NCT04983758||Severe PCP|
62264648|NCT04772937|OTHER|LLETZ group|LLETZ (large loop excision of the transformation zone) is one of several possible surgical interventions for treating cervical dysplasia.
62264649|NCT04772937|OTHER|LEEP group|LEEP (loop electrosurgical excision procedure) is one of several possible surgical interventions for treating cervical dysplasia.
62448213|NCT01164943|ACTIVE_COMPARATOR|Human FSH|
62448214|NCT01164943|ACTIVE_COMPARATOR|Recombinant FSH|
62448215|NCT00885690|ACTIVE_COMPARATOR|Sertindole|Sertindole 16-24 mg
62448216|NCT00885690|ACTIVE_COMPARATOR|Olanzapine|Olanzapine 10-20 mg
62448217|NCT00228904|PLACEBO_COMPARATOR|1|Control patients with diagnosed diabetic neuropathy will receive baseline testing and testing every six months thereafter to compare and analyze results with patients treated with pulsatile intravenous insulin therapy.
62448218|NCT00228904|ACTIVE_COMPARATOR|2|Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after the start of pulsatile intravenous insulin therapy.
62448219|NCT02367495|EXPERIMENTAL|PCB|Paclitacel-coated balloon (Agent, Boston Scientific)
62448220|NCT06192251||Cohort 1|Weekly classes of pillars of lifestyle medicine, monthly sessions with dietician, Lifestyle Medicine physician,kinesiologist and health coach
62448221|NCT01174056|EXPERIMENTAL|Pioglitazone+zileuton placebo|Pioglitazone 45 mg qD for 2 weeks plus Sugar pill q6hr for 5 days
62448222|NCT01174056|EXPERIMENTAL|Zileuton+pioglitazone placebo|Sugar pill qD for 2 weeks plus Zileuton 600 mg q6hr for 5 days
62448223|NCT01174056|SHAM_COMPARATOR|Pioglitazone placebo+zileuton placebo|Sugar pill qD for 2 weeks plus Sugar pill q6hr for 5 days
62448224|NCT02856256|EXPERIMENTAL|RedBull® energy drink|
62448225|NCT00624156||1|emotional disclosure writing intervention
62448226|NCT00624156||2|control writing
62448227|NCT00364403|EXPERIMENTAL|1|Low glycemic load diet
62448228|NCT00364403|ACTIVE_COMPARATOR|2|Low fat diet
62846995|NCT00459186|EXPERIMENTAL|RAD001 Followed by RAD001 + Docetaxel|RAD001 10 mg daily for 2 weeks, followed by RAD001 + Docetaxel at one of three doses: 5 mg RAD001 and docetaxel at 60 mg/m2, 10 mg RAD001 and docetaxel at 60 mg/m2, and 10 mg RAD001 and docetaxel at 70 mg/m2. RAD001 was given daily. Docetaxel was given every 3 weeks by intravenous infusion. Patients also received prednisone 5 mg by mouth twice daily.
62846996|NCT02273804|EXPERIMENTAL|topiramate|pill
62846997|NCT02273804|PLACEBO_COMPARATOR|placebo|Sugar pill
62846998|NCT04145219|EXPERIMENTAL|Active treatment|HDM SLIT-tablet plus allergy and asthma rescue medication
62846999|NCT04145219|PLACEBO_COMPARATOR|Placebo|Placebo oral tablet plus allergy and asthma rescue medication
62847000|NCT05549752|ACTIVE_COMPARATOR|Flecainide|
62264650|NCT05183607|EXPERIMENTAL|Virtual nutritional Intervention|This arm will receive the virtual nutritional intervention consisting of 4 - 30 minute sessions to educate cardiac surgery patients before their date of surgery. Each session will provide a different theme such as: 1) nutritional assessment, 2) protein intake education, 3) nutritional adequacy prior to surgery, and 4) protein and nutrition intake post surgery
62847001|NCT05549752|ACTIVE_COMPARATOR|Amiodarone|
62847002|NCT01864382|OTHER|Standard Physiotherapy Exercises|Standard Physiotherapy Exercises 5 days a week during 5 weeks
62847003|NCT01864382|EXPERIMENTAL|Core stability|Core stability.5 days a week during 5 weeks
62264651|NCT01365260|EXPERIMENTAL|MM-II|
62847004|NCT00947193|EXPERIMENTAL|Ataluren Overall Study|Ataluren was provided as a vanilla-flavored powder to be mixed with water or milk. Ataluren was taken 3 times per day, with dosing based on the participant's body weight. The dose level for ataluren was 5 mg/kg in the morning, 5 mg/kg at midday, and 10 mg/kg in the evening or 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 14 days, followed by an interval of 14 days without treatment.
62847005|NCT02014701|OTHER|Echocardiogram|Patients presenting with NSTEMI who are scheduled to undergo elective cardiac catheterization and coronary angiography with primary PCI will be selected for participation in the study. The patients will undergo a clinically indicated resting non-contrast echocardiogram to assess LV function and regional wall motion. They will then undergo contrast echocardiography with bolus injection of Optison™ contrast to reassess LV ejection fraction, improve LV opacification and assess regional wall motion abnormalities. Finally, they will be given a continuous infusion of Optison™ and will have assessment of myocardial perfusion of each of the 17 myocardial segments using low mechanical index continuous imaging of the myocardium and blood pool.
62847006|NCT04541771|EXPERIMENTAL|drug group|The trial group will receive their usual feeds plus daily probiotic (Lactobacillus Reuteri DSM 17938) addition 1 drop/kg/dose(. minimum of 20 million live Lactobacillus Reuteri are present in One drop) twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds
62847007|NCT04541771|PLACEBO_COMPARATOR|control group|this group is control group and will receive normal saline drops as 1 drop/kg/ dose mixed in enteral feed
62847008|NCT06523101|EXPERIMENTAL|PJ009 group|Participants will receive a single dose of PJ009 on day1, and then multiple doses of PJ009 once daily for 7 days (day5-11). Three dose levels will be evaluated. subcutaneous injection
62448229|NCT05435222|EXPERIMENTAL|male-specific psychotherapeutic program (MSPP)|In this treatment group, eugonadal depressed men will receive the male-specific adjusted psychotherapy for depressive disorders (MSPP) based on cognitive behavioral principles in a single setting.
62448230|NCT05435222|ACTIVE_COMPARATOR|cognitive behavioral therapy (CBT)|In this treatment group, depressed men will receive standard cognitive behavioral psychotherapy for depressive disorders (CBT) in a single setting.
62847009|NCT06523101|PLACEBO_COMPARATOR|PJ009 Placebo group|Participants will receive a single dose of PJ009 placebo on day1, and then once daily for 7 days (day5-11). subcutaneous injection
62847010|NCT05078762|EXPERIMENTAL|iVR|The intervention group will train on a bronchoscopy simulator in an iVR environment with Virtual Reality Goggles (HTC IVE Pro Eye, HTC corporation, Taiwan) while using the bronchoscopy simulator.
62847011|NCT05078762|NO_INTERVENTION|Non iVR|The control group will train on a bronchoscopy simulator without VR goggles.
62847012|NCT00865410|EXPERIMENTAL|A|Abrika Bupropion 150 mg Extended-Released Tablet, single dose
62847013|NCT00865410|ACTIVE_COMPARATOR|B|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
62847014|NCT01588392|EXPERIMENTAL|Short bouts of structured activity|
62264652|NCT01365260|ACTIVE_COMPARATOR|DurolaneTM|hyaluronic acid
62620985|NCT00316914|PLACEBO_COMPARATOR|Placebo|Patients receive a placebo IV over 30 minutes immediately before and after each oxaliplatin administration (once every 2 weeks) of their assigned chemotherapy regimen.
62620986|NCT01937884|EXPERIMENTAL|Early Parenteral Nutrition|Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
62847015|NCT01588392|ACTIVE_COMPARATOR|Unstructured physical activity|
62847016|NCT02238080||Methoxy Polyethylene Glycol-Epoetin Beta|Participants with anemia and CKD who are on dialysis therapy, and who initiate erythropoiesis-stimulating agent (ESA) treatment with methoxy polyethylene glycol-epoetin beta or who are on stable methoxy polyethylene glycol-epoetin beta maintenance therapy, will be treated according to the usual standard of care and current best practice guidelines, and will be observed during the study period.
62847017|NCT05430633||Pregnant patients who underwent laparoscopic appendectomy|Pregnant patients who underwent laparoscopic appendectomy
62847018|NCT05430633||Pregnant patients who underwent open appendectomy|Pregnant patients who underwent open appendectomy
62847019|NCT02470000|EXPERIMENTAL|Experimental Group|Intravascular laser irradiation of blood (ILIB, output power 0.3mW), Transcutaneous electrical nerve stimulation (TENS), stretching exercise.
62847020|NCT02470000|SHAM_COMPARATOR|Control Group|Intravascular laser irradiation of blood (ILIB, output power 0mW), Transcutaneous electrical nerve stimulation (TENS), stretching exercise.
62847021|NCT01214096|PLACEBO_COMPARATOR|placebo|
62847022|NCT01214096|EXPERIMENTAL|rhNRG-1|recombinant human neuregulin-1
62620987|NCT01937884|ACTIVE_COMPARATOR|Late Parenteral Nutrition|Patients receive supplemental parenteral nutrition 96 hours after enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
62620988|NCT06307834|EXPERIMENTAL|Neurofeedback - based therapy group|In this arm/group, each participant will undergo a series of ten sessions (2-3 sessions per week) over a period of 3-5 weeks. Participants will be trained in modulating their brain activation patterns by using Mental Imagery (MI) involving various hand movements. EEG will be used to record brain responses. A visual feedback will be provided during the training to help achieve specific changes in brain responses. Once an appropriate brain response is achieved, an EMG-controlled hand exoskeleton will aid in opening and closing the hand.
62847023|NCT02937324|ACTIVE_COMPARATOR|Clinical Assessment|Motor assessment will be performed by a clinician using the Unified Parkinson's Disease Rating Scale.
62264653|NCT00949546||placebo controlled|A randomized, double-blind trial of 3 months duration comparing etanercept 50 mg sc twice weekly to placebo in 20 patients with HS. Patients will be randomized with equal allocation to the two treatment groups.
62448231|NCT05435222|NO_INTERVENTION|Waitlist|"The participants in the Waitlist group are required to complete a waiting period of 36 weeks prior receiving the MSPP.~As an additional safety measure, participants will be monitored by means of three appointments at week 6, 10 and 14 with a study psychologist. Subsequently, monthly telephone calls at week 18, 22, 26, and 30 are conducted. During these appointments no intervention will occur, while a treatment relationship is to be established so that the patient can describe his specific life circumstances and report possible symptom exacerbations or suicidality."
62448232|NCT05435222|EXPERIMENTAL|male-specific psychotherapeutic program (MSPP) + testosterone treatment (TT)|In this treatment group, hypogonadal depressed men will receive the male-specific adjusted psychotherapy for depressive disorders (MSPP) based on cognitive behavioral principles in a single setting. Further participants receive a standard testosterone replacement therapy consisting of testosterone undecanoate administered via deep intramuscular injection.
62847024|NCT02937324|EXPERIMENTAL|Smartphone assessment|CloudUPDRS smartphone software assessment will be performed.
62847025|NCT02064413|EXPERIMENTAL|ESS310|All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.
62847026|NCT02228837|PLACEBO_COMPARATOR|Placebo|12 weeks of consuming 50 g pear-flavored placebo powder mixed with 480 ml per day (1/2 in the morning and 1/2 in the evening at least 6-8 hours apart).
62847027|NCT02228837|EXPERIMENTAL|Pear|12 weeks of consuming 2 medium-sized pears per day (1 in the morning and 1 in the evening at least 6-8 hours apart).
62847028|NCT03038828|EXPERIMENTAL|Arm A|Cohort A - 200IU Leukocyte Interleukin, Injection 5 days/week x 2 weeks, off two weeks, then repeat 200IU 5 days/week x 2 weeks.
62847029|NCT03038828|EXPERIMENTAL|Arm B|Arm B - 400IU Leukocyte Interleukin, Injection 5 days/week x 2 weeks, off 2 weeks, 400IU 5 days/week x 2 weeks.
62264654|NCT03036137|ACTIVE_COMPARATOR|Active tDCS|Subjects will receive 20 minutes of active tDCS for five consecutive days, current of 2 mA, in the temporoparietal left area, and right prefrontal cortex.
62448233|NCT05435222|ACTIVE_COMPARATOR|cognitive behavioral therapy (CBT) + testosterone treatment (TT)|In this treatment group, hypogonadal depressed men (blood testosterone ≤ 12.1 nmol/l) will receive standard cognitive behavioral psychotherapy for depressive disorders (CBT) in a single setting. Further participants receive a standard testosterone replacement therapy consisting of testosterone undecanoate administered via deep intramuscular injection.
62847030|NCT05311813|PLACEBO_COMPARATOR|Control group|The control group including 50 patients (n=50) receiving the conventional therapy of Covid-19 adopted by the Egyptian ministry of health for 15 days.
62847031|NCT05311813|ACTIVE_COMPARATOR|Enaxoprin group|The enoxaparin group (n=50) which received 40mg/day SC for 14 days (for patients with normal renal function and body weight between 50 and 100kg) plus the conventional therapy of Covid-19 adopted by the Egyptian ministry of health for 15 days.
62847032|NCT05311813|ACTIVE_COMPARATOR|Hydroxychloroquine group|The HCQ group which received 400 mg/day HCQ for five days plus the conventional therapy of Covid-19 adopted by the Egyptian ministry of health for 15 days(n=50).
62847033|NCT05311813|ACTIVE_COMPARATOR|Enoxaparin plus Hydroxychloroquine group|The HCQ plus Enoxaparin combination group including 50 patients receiving combined therapy of 400 mg/day HCQ for five days and 40mg/day enoxaparin for 14 days plus the conventional therapy of COVID-19 adopted by the Egyptian ministry of health for 15 days
62847034|NCT05737199|EXPERIMENTAL|MK-3475 (Pembrolizumab)|Treatment with MK-3475 (pembrolizumab) 200 mg.
62847035|NCT01172717|EXPERIMENTAL|Panitumumab|Single arm study
62847036|NCT03763097||participants|Patients who are scheduled for single-incision needleless (Contasure-needleless®) mini-sling for their stress urinary incontinence. They will be assessed by Pelvic floor ultrasound
62264655|NCT03036137|SHAM_COMPARATOR|Sham tDCS|Subjects will receive 20 minutes of Sham tDCS for five consecutive days in the temporoparietal left area, and right prefrontal cortex.
62264656|NCT01208350|EXPERIMENTAL|1|
62264657|NCT01208350|EXPERIMENTAL|2|
62264658|NCT01208350|ACTIVE_COMPARATOR|3|
62264659|NCT01501305|PLACEBO_COMPARATOR|Placebo|Mineral rehydration solution
62620989|NCT06307834|ACTIVE_COMPARATOR|Standard Hand exercises therapy group|In this arm/group, each participant will undergo a series of ten sessions (2-3 sessions per week) over a period of 3-5 weeks. At each session, participants will practice a particular set of hand exercises. In this intervention, a variety of games, tasks, and movements will be used to improve grasping abilities. These exercises will be personalized according to each participant's interests, which will be identified through the Canadian Occupational Performance Measure and will be guided by study personnel.
62448234|NCT05435222|NO_INTERVENTION|Waitlist + testosterone treatment (TT)|"The participants in the Waitlist group are required to complete a waiting period of 36 weeks prior receiving the MSPP. As an additional safety measure, participants will be monitored by means of three appointments at week 6, 10 and 14 with a study psychologist. Subsequently, monthly telephone calls at week 18, 22, 26, and 30 are conducted. During these appointments no intervention will occur, while a treatment relationship is to be established so that the patient can describe his specific life circumstances and report possible symptom exacerbations or suicidality.~Further participants receive a standard testosterone replacement therapy consisting of testosterone undecanoate administered via deep intramuscular injection."
62620990|NCT02625246|EXPERIMENTAL|Group 1|3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion
62620991|NCT02625246|EXPERIMENTAL|Group 2|3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion
62620992|NCT05867680|EXPERIMENTAL|Treatment|Treatment group participants received the eMB intervention during the 8-week trial period.
62620993|NCT05867680|NO_INTERVENTION|Control|The control group received a PDF community resources informational sheet, also available to the intervention group via the eMB program.
62620994|NCT06414876|EXPERIMENTAL|The children played with the hospital dog and then by themselves.|
62264660|NCT01501305|ACTIVE_COMPARATOR|Carob powder|Carob powder and probiotics
62448235|NCT04956549|EXPERIMENTAL|Physical Activity|150 minutes of physical activity weekly
62620995|NCT06414876|EXPERIMENTAL|The children played by themselves and then with the hospital dog.|
62620996|NCT05644990||T2Bacteria Panel positive|Patients with spondylodiscitis and endocarditis who had positive T2Bacteria Panel test.
62620997|NCT02843165|EXPERIMENTAL|Checkpoint blockade immunotherapy plus SBRT|Checkpoint blockade immunotherapy (CBI) plus stereotactic body radiation therapy (SBRT)
62847037|NCT05282134|EXPERIMENTAL|Wet cupping therapy|The intervention group will undergo 3 successive wet cupping therapy (WCT) sessions once in a month throughout 3 months (On 0, 30, and 60 days. Cups will be held for 5 minutes on the 5 regions of the C7 cervical spine (DU14 acupuncture point), bilateral T2-4 lateral spine (BL41-42 acupoint) and bilateral T6-8 lateral spine (BL44-46) points, which are recommended areas for headache, Then, these areas where the blood supply has increased will be drawn with a sterile lancet and the cup will be applied again and left for 10 minutes, and then the cups will be removed and the accumulated blood will be cleaned.
62847038|NCT05282134|EXPERIMENTAL|Acupuncture|Acupuncture application will be done by manually needling selected acupuncture points specific to the disease twice a week for 4 weeks. After the needles are placed, they will be manipulated to create a feeling of de-qi and left for 20 minutes.
62620998|NCT02843165|ACTIVE_COMPARATOR|Checkpoint blockade immunotherapy|Checkpoint blockade immunotherapy (CBI) alone
62620999|NCT01584700|OTHER|Renal Artery Denervation|Ontervention
62847039|NCT05282134|NO_INTERVENTION|Control|Control group will not receive any intervention
62847040|NCT00892983|NO_INTERVENTION|Standard well child care|Standard Well Child Care (SWCC) - 8 Core visits at 2-4 weeks, 6 weeks, 3, 5, 8-10 and 15 months, 2 and 3 years.
62847041|NCT00892983|EXPERIMENTAL|Food Activity Breast feeding support|FAB (Food Activity Breast feeding support) 8 extra parent contacts for augmented education and support around breast feeding, food and activity
62264661|NCT00859378|ACTIVE_COMPARATOR|1 - cemented|Patients are treated with a cemented semiendoprosthesis
62264662|NCT00859378|ACTIVE_COMPARATOR|2 - non-cemented|Patients are treated with a non-cemented semiendoprosthesis
62264663|NCT01677533|ACTIVE_COMPARATOR|PM-Data|Team will receive data only.
62264664|NCT01677533|EXPERIMENTAL|PM-Support|Team will receive data and panel management support
62448236|NCT04956549|EXPERIMENTAL|Successful Aging|Low intensity activity program and a healthy aging educational component
62264665|NCT01677533|EXPERIMENTAL|PM-Education|Team will receive data, panel management support, and educational interventions.
62448237|NCT01134653|EXPERIMENTAL|Jump stretch|Distraction with early mobilization
62621000|NCT00456781|EXPERIMENTAL|Augmentation|Rotator Cuff Repair augmented with the Graft Jacket Device
62621001|NCT00456781|ACTIVE_COMPARATOR|No Augmentation|Rotator Cuff RFepair
62847042|NCT00892983|EXPERIMENTAL|Sleep|Prevention of sleep problems in first 6 months and then active early intervention for sleep problems from 6 months to 24 months
62264666|NCT04833088|OTHER|Healthcare professionals|
62264667|NCT04833088|OTHER|Patients who suffer from spatial neglect|
62264668|NCT04833088|OTHER|Patients who have walking difficulties|
62621002|NCT01004432|EXPERIMENTAL|Open-label (OL) Overall Group: Golimumab 50 mg SC + MTX|All enrolled and dosed participants receive golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks + Methotrexate (MTX) from Week 0 to Week 12.
62621003|NCT01004432|EXPERIMENTAL|Double blind (DB) Group 2a: Golimumab 50mg SC & Placebo IV+MTX|Participants, who do not achieve Disease Activity Score in 28 joints (DAS28) good response at Week 16, will be randomly assigned to receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 16 to Week 48, along with placebo matched to golimumab intravenous infusion (IV) at Week 16, 20, 28, 36, and 44.
62621004|NCT01004432|EXPERIMENTAL|DB Group 2b: Golimumab 2mg/kg IV & Placebo SC + MTX|Participants, who do not achieve DAS28 good response at Week 16, will be randomly assigned to receive golimumab 2 milligram per kilogram (mg/kg) intravenous infusion (IV) + MTX, at Week 16, 20, 28, 36 and 44, along with placebo matched to golimumab SC injection every 4 weeks from Week 16 to Week 48.
62621005|NCT01004432|EXPERIMENTAL|OL Group 1: Golimumab 50 mg SC + MTX|Participants, who achieve DAS28 good response at Week 16, will receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 16 to Week 48.
62621006|NCT01004432|EXPERIMENTAL|OL Study Extension Group: Golimumab 50 mg SC + MTX|Participants who complete the main study (Week 0 to Week 52), do not meet lack of efficacy criteria, and participate in the OL study extension, will receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 52 to Week 72.
62621007|NCT03280706|EXPERIMENTAL|Maltodextrin|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of maltodextrin 200kcal, no protein or fat, 49,5g of carbohydrate.
62621008|NCT03280706|ACTIVE_COMPARATOR|Orange Juice|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of orange juice, 200kcal, 2,82g of protein, 0,67g of fat, 47,08g of carbohydrate.
62621009|NCT03280706|ACTIVE_COMPARATOR|Coffee with milk|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of coffee with milk, 200kcal, 10,6g of protein, 10,73g of fat, 14,9g of carbohydrate.
62621010|NCT03414398||Experimental|Qualitative interview
62621011|NCT05761457|EXPERIMENTAL|Treatment group|Patients receive cryopreserved autologous platelet transfusion
62621012|NCT00624832|EXPERIMENTAL|Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 30-300 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.
62847043|NCT00892983|EXPERIMENTAL|FAB + Sleep|combination of interventions used in arms 2 and 3
62847044|NCT06214091|EXPERIMENTAL|Gastrointestinal decompression group|
62060580|NCT02541032|ACTIVE_COMPARATOR|Intensive Dental Treatment|Patients will undergo up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm. All patients will be reexamined at 3, 6 and 9 months for safety checks. Patients will be given instructions in basic oral hygiene and treated for stroke risk factors in accordance to the current guidelines for secondary stroke prevention.
62060581|NCT02541032|ACTIVE_COMPARATOR|Standard Dental Treatment|Patients will undergo supragingival mechanical scaling and polishing. They will be informed of the presence and severity of their periodontal disease and will be advised to be seen by their dentist if their condition requires immediate attention. If they have no dental provider they will be referred for care. All patients will be reexamined at 3, 6 and 9 months for safety checks. Among the group the periodontal condition will be monitored to assure there is no progression of disease. If any site demonstrates an increase in periodontal pockets \>3mm, they will receive site-directed scaling and root planing. Patients will be given instructions in basic oral hygiene and treated for stroke risk factors in accordance to the current guidelines for secondary stroke prevention. At the completion of the study, the control treatment patients will be offered to receive the same dental care as provided to the intensive treatment group as needed.
62060582|NCT02532179|EXPERIMENTAL|Mouse Allergenic Extract|Participants will receive escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol.
62060583|NCT05667766|OTHER|Standard of Care|Standard of Care prescribing for period of 12 months. Participants will receive pharmacogenomic test results according to the current standard of care. The participants will be followed up for a minimum of 12 weeks, with maximal time-period being 12 months depending on time of enrolment.
62621013|NCT00624832|EXPERIMENTAL|Xolair (Immunoglobulin E (IgE) = 700-2000 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 700- 2000 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.
62621014|NCT00624832|EXPERIMENTAL|Xolair (Immunoglobulin E (IgE) = 301-699 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 301- 699 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.
62847045|NCT06214091|PLACEBO_COMPARATOR|Control group|
62847046|NCT02441296|EXPERIMENTAL|Formula with lactose|Carbohydrate-free formula with added lactose
62847047|NCT02441296|EXPERIMENTAL|Formula with maltodextrins|Carbohydrate-free formula with added maltodextrins
62847048|NCT02441296|NO_INTERVENTION|Breastfeeding|Breastfed reference group
62847049|NCT00823615|OTHER|Lotrafilcon B / Senofilcon A|Lotrafilcon B, followed by Senofilcon A
62847050|NCT00823615|OTHER|Senofilcon A / Lotrafilcon B|Senofilcon A, followed by Lotrafilcon B
62847051|NCT05519722|EXPERIMENTAL|Intervention group|
62847052|NCT05519722|NO_INTERVENTION|Control group|
62847053|NCT03734640|PLACEBO_COMPARATOR|Guideline recommended standard monitoring|vital signs (HR, BP) and neurological assessment (GCS and NIHSS) 15-30mins x 2 hours, 30mins x 6 hours, 1hourly x 16 hours in usual care monitoring environment
62621015|NCT00624832|PLACEBO_COMPARATOR|Placebo|By subcutaneous injection of a solution with a concentration of 125 mg/mL placebo in a supine position: Patients in Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL) group received doses of 150 mg to 375 mg of placebo every 2 or 4 weeks for 12 or 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL) group received doses of 450 mg, 525 mg, or 600 mg of placebo every 2 weeks for 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 301- 699 IU/mL) group received doses of 225 mg to 375 mg of placebo every 2 weeks for 6 weeks.
62060584|NCT05667766|EXPERIMENTAL|Experimental Arm|Extended Pharmacogenomic prescribing for a period of 12 months. Participants will receive pharmacogenomic testing across a range of clinically relevant variants, to guide the dose and drug selection of 27 drugs commonly used in supportive care. The participants will be followed up for a minimum of 12 weeks, with maximal time-period being 12 months depending on time of enrolment.
62060585|NCT01112228||Obese patients|Obese patients for Bariatric surgery
62060586|NCT00909480|EXPERIMENTAL|IDet|Individually adjusted insulin detemir once daily + metformin at least 1500 mg/day
62621016|NCT00892814|EXPERIMENTAL|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
62621017|NCT00892814|ACTIVE_COMPARATOR|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
62621018|NCT04088539|EXPERIMENTAL|Group A|"CSD participants will receive a combined intervention:~1. Brief intervention using AWARD advice at baseline,~2. Video-based health education"
62621019|NCT05491681|EXPERIMENTAL|Low dose|Experimental: Cohort 1 Low dose, 20M cells, 3 patients
62621020|NCT05491681|EXPERIMENTAL|Medium dose|Experimental: Cohort 2 Med dose, 100M cells, 3 patients
62847054|NCT03734640|ACTIVE_COMPARATOR|Low-intensity monitoring strategy|vital signs (HR, BP) and neurological assessment (GCS and/or NIHSS) 15-30mins x 2 hours, 2hourly x 8 hours, 4hourly x 14 hours in a non-ICU ward
62060587|NCT00909480|ACTIVE_COMPARATOR|IGlar|Individually adjusted insulin glargine once daily + metformin at least 1500 mg/day
62621021|NCT05491681|EXPERIMENTAL|High dose|Experimental: Cohort 3 High dose, 200M cells, 3 patients
62621022|NCT00913302|EXPERIMENTAL|Training|cardiovascular training
62060588|NCT02098408|EXPERIMENTAL|Standard treatment + cognitive remediation|The cognitive remediation therapy targets neurocognition as well as social cognition.
62621023|NCT02291003||Healthy controls|Healthy controls -observational, no intervention administered.
62621024|NCT02670421|ACTIVE_COMPARATOR|Face to face Heart SMART program|Stress management program presented in a face to face meeting of 90-100 minutes with daily printed program instructions to follow over the next 12 weeks, accompanied by reading from a book entitled The Mayo Clinic Guide to Stress Free Living.
62621025|NCT02670421|ACTIVE_COMPARATOR|Online Heart SMART program|Stress management program in the form of 10- minute videos completed weekly by participant on-line for 12 weeks, accompanied by reading from a book entitled The Mayo Clinic Guide to Stress Free Living.
62621026|NCT05437614|ACTIVE_COMPARATOR|Treatment of refractory glaucoma using Micropulse diode laser cyclophotocoagulation|
62621027|NCT05437614|ACTIVE_COMPARATOR|Treatment of refractory glaucoma using cyclocryoablation|
62264669|NCT04833088|OTHER|Patients who require long term use of an IV-stand|
62264670|NCT03257007|NO_INTERVENTION|Usual Care|Participants assigned to Usual Care will continue to receive standard care from their oncology team, including access to supportive care from oncology social workers. At the end of the study, usual care dyads will receive a packet of informational materials on mindfulness meditation, receive a CD with 5 mindfulness meditation practices, and meet with the study interventionist for guidance on how to use the materials and mindfulness recordings to their advantage in coping with cancer-related challenges.
62448238|NCT01134653|ACTIVE_COMPARATOR|RICE|Subject receive standard ankle sprain treatment of Rest Ice compression and elevation for one week. This is followed by traditional strength and range of motion therapy. The subject does not receive distraction treatments.
62621028|NCT02741232|ACTIVE_COMPARATOR|Pectoral nerve block|After induction of general anesthesia and under ultrasound visual guidance, pectoral block is performed with 30 mL total of local anesthetic (1% lidocaine + 1/400000 epinephrine). 10 mL of local anesthetic between pectoralis major muscle and pectoralis minor muscle and 20 mL between pectoralis minor muscle and serratus anterior muscle at the third rib.
62621029|NCT02741232|SHAM_COMPARATOR|Sham block|No needle or injection will be used
62621030|NCT00456261|EXPERIMENTAL|Cohort A|Cohort A, will receive bevacizumab 10mg/kg by vein over 30-90 minutes followed by pemetrexed 500 mg/m2 by vein over 10 minutes followed by gemcitabine 1500 mg/m2 by vein over 30-60 minutes. This regimen will be given on day 1 and day 15 of each treatment cycle. Each cycle is 28 days long. As long as their disease does not worsen patients can receive up to a maximum of 6 cycles of this combination chemotherapy. Following that they can receive bevacizumab alone once every 2 weeks as long as their disease does not worsen.
62847055|NCT02121821|NO_INTERVENTION|Control|A control group of pregnant women receiving no intervention (i.e. no SMS reminders).
62847056|NCT02121821|EXPERIMENTAL|SMS reminder messages|The intervention group will be composed of pregnant women receiving SMS reminder messages via the SMS Mother Reminder system.
62847057|NCT05302648|EXPERIMENTAL|Human Derived anti-BCMA CAR-T Injection|Single administration：1.0×10\^6 CAR+T, 3.0×10\^6 CAR+T, 6.0×10\^6 CAR+T
62847058|NCT03536117|EXPERIMENTAL|MTBVAC Group 1|MTBVAC intermediate dose 2.5 x 10E+04 CFU/0.05 mL
62847059|NCT03536117|EXPERIMENTAL|MTBVAC Group 2|MTBVAC high dose 2.5 x 10E+05 CFU/0.05 mL
62847060|NCT03536117|EXPERIMENTAL|MTBVAC Group 3|MTBVAC highest dose 2.5 x 10E+06 CFU/0.05 mL
62847061|NCT03536117|ACTIVE_COMPARATOR|BCG Group 4|BCG control 2.5 x 10E+05 CFU/0.05 mL
62264671|NCT03257007|ACTIVE_COMPARATOR|Mindfulness|The Mindfulness intervention will consist of six 2-hour sessions that will include guided mindfulness practices, didactics, and group discussion. The course curriculum is modeled on the Mindfulness-Based Stress Reduction program which involves intensive experiential training of participants in secular mindfulness meditation practices (i.e., body scan, sitting meditation, gentle hatha yoga with chair adaptations, compassion meditation), with an emphasis on embodying interpersonal mindfulness in dialogue.
62264672|NCT02725723|EXPERIMENTAL|Subject after epidural injection|Subjects are patients from the clinic who have been diagnosed with Lumbar spinal stenosis and determined eligible for receiving steroidal epidural injection for pain management
62264673|NCT02413112|EXPERIMENTAL|Training once per week|Subjects train once per week in the University gym. All training sessions are supervised by the researchers.
62264674|NCT02413112|EXPERIMENTAL|Training twice per week|Subjects train twice per week in the University gym. All training sessions are supervised by the researchers.
62448239|NCT00953979|ACTIVE_COMPARATOR|Sulfasalazine|Sulfasalazine is a drug in treatment RA, AS and ulcerative colonitis. In this study, Sulfasalazine is used to act as an active comparator to access the efficacy of kunxian capsule.
62448240|NCT00953979|PLACEBO_COMPARATOR|placebo|The placebo capsule was used to be a comparator of kunxian capsule
62448241|NCT02192905|EXPERIMENTAL|Behavioral Weight Loss + Habit|Participants will receive 8 week of an online-delivered weight loss intervention adapted from the Diabetes Prevention Program Lifestyle Intervention and will use the Habit mobile app during the study.
62847062|NCT05367089|ACTIVE_COMPARATOR|Fluconazole|"Way of administration: oral capsules. One capsule at the same day of the week.~Dosage:~As treatment for active RVVC- in the first week on day 1 one capsule 150 mg Fluconazole, on day 4 one capsule 150 mg Fluconazole and on day 7 one capsule 150 mg Fluconazole.~As prophylaxis to prevent a new RVVC episode: one capsule Fluconazol 150 mg per week for a duration of 6 months."
62448242|NCT02739542|ACTIVE_COMPARATOR|Tecfidera|Tecfidera (120mg by mouth twice daily for 7 days with dose escalation to 240mg by mouth twice daily)
62621031|NCT00456261|EXPERIMENTAL|Cohort B|Cohort B, will receive bevacizumab 15mg/kg by vein over 30-90 minutes followed by pemetrexed 500 mg/m2 by vein over approximately 10 minutes followed by carboplatin AUC=5 by vein over 30-60 minutes. This regimen will be given on day 1 of each treatment cycle. Each cycle is 21 days long. As long as their disease does not worsen patients can receive up to a maximum of 6 cycles of this combination chemotherapy. Following that they can receive bevacizumab alone once every 3 weeks as long as their disease does not worsen.
62621032|NCT04261647|EXPERIMENTAL|Experimental group 1|kinesio- taping technique plus traditional physical therapy program.
62847063|NCT05367089|EXPERIMENTAL|L-Mesitran|"Way of administration: intra-vaginal application using an applicator.~Dosage:~As treatment for active RVVC - Single daily application (5 grams) for 1 month. As prophylaxis to prevent a new RVVC episode: Single weekly (5 grams) application for 5 months."
62847064|NCT02551549|EXPERIMENTAL|CD101 IV|multiple ascending dose intravenous infusion
62847065|NCT02551549|PLACEBO_COMPARATOR|Placebo|normal saline
62847066|NCT03120195|EXPERIMENTAL|EndoRotor® ablation|Prospective pilot study, to be performed in 30 patients with Barrett's esophagus that have an indication for ablation treatment. Barrett's ablation will be performed using the EndoRotor®.
62847067|NCT04299932|EXPERIMENTAL|Electroacupuncture(EA) group|Participants in EA group will receive treatment at bilateral Bladder Meridian (BL) 33 \[Zhongliao\], BL35 \[Huiyang\] and Spleen Meridian (SP) 6 \[Sanyinjiao\]. The EA treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 8 weeks.
62264675|NCT02413112|EXPERIMENTAL|Thrice per week|Subjects train three times per week in the University gym. All training sessions are supervised by the researchers.
62264676|NCT02413112|NO_INTERVENTION|Non-training Control group|Subjects continue with their normal daily lives, just performing measurements
62448243|NCT02739542|PLACEBO_COMPARATOR|Placebo|Placebo by mouth twice daily.
62847068|NCT04299932|SHAM_COMPARATOR|Sham Electroacupuncture (SA) group|Participants in SA group will receive treatment at bilateral sham BL33 \[Zhongliao\], sham BL35 \[Huiyang\] and sham SP6 \[Sanyinjiao\]. The SA treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 8 weeks.
62847069|NCT04299932|NO_INTERVENTION|Waiting List (WL) group|Participants in WL group will be followed up for 20 weeks. Participants only receive healthcare education and advice on lifestyle modification, which will be received by all the participants in the three groups.
62847070|NCT03745599|EXPERIMENTAL|Diclofenac|Diclofenac group, which received diclofenac 50 mg capsules (Cataflam) and placebo sprays. Placebo sprays have consisted of a normal saline solution and peppermint flavor.
62847071|NCT03745599|EXPERIMENTAL|Flurbiprofen|Flurbiprofen group, which received flurbiprofen 100 mg capsules and placebo sprays. Placebo sprays have consisted of a normal saline solution and peppermint flavor.
62847072|NCT03745599|EXPERIMENTAL|Benzydamine|Benzydamine group, which received benzydamine 0.045 g, 30 mL oral sprays (Tantum Verde) and placebo capsules. Placebo capsules contained starch.
62847073|NCT00244140|EXPERIMENTAL|Iopromide 370 mg I/mL|Iopromide (Ultravist 370 mg I/mL) administered intravenously
62847074|NCT00244140|EXPERIMENTAL|Iopromide 300 mg I/mL|Iopromide (Ultravist 300 mg I/mL) administered intravenously
62621033|NCT04261647|EXPERIMENTAL|Experimental group 2|Pelvic floor exercise plus traditional physical therapy program.
62847075|NCT03605628|OTHER|abdominal wall length|Measurement of abdominal wall length during neuromuscular block with a measuring tape
62264677|NCT05780307|EXPERIMENTAL|IMM2520 in subjects with advanced solid tumors|Dose-escalation phase: the dosing schedule of IMM2520 is 0.1 mg/kg, 0.4 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 4.0 mg/kg and 6.0 mg/kg sequentially.
62264678|NCT03179332|EXPERIMENTAL|BioChaperone® insulin lispro|Single subcutaneous administration of BioChaperone® insulin lispro
62264679|NCT03179332|ACTIVE_COMPARATOR|Fiasp®|Single subcutaneous administration of Fiasp® (insulin aspart)
62264680|NCT03179332|ACTIVE_COMPARATOR|Novorapid®|Single subcutaneous administration of Novorapid® (insulin aspart)
62264681|NCT01661907|EXPERIMENTAL|Combined Epi-GA/PCEA|"Patients assigned to this group (experimental group) will receive combined epidural-general anesthesia (combined Epi-GA) and patient-controlled epidural analgesia (PCEA).~An epidural catheter will be placed before anesthesia induction. General anesthesia will be induced and maintained in the same manner as in the control group, with the addition of a continuous infusion or intermittent boluses of 0.375%-0.5% ropivacaine given through the epidural catheter for analgesia maintenance. Patient-controlled epidural analgesia will be provided for postoperative analgesia (established with 0.12% ropivacaine and 0.5 μg/mL sufentanil in 250 mL normal saline, programmed to deliver a 2-mL bolus with a lockout interval of 20 minutes and a background infusion of 4 mL/hr)."
62264682|NCT01661907|ACTIVE_COMPARATOR|GA/PCIA|"Patients assigned to this group (control group) will receive general anesthesia (GA) and patient-controlled intravenous analgesia (PCIA).~General anesthesia will be induced with midazolam, sufentanil, propofol and rocuronium. Anesthesia will then be maintained by inhalation of sevoflurane with or without nitrous oxide, and/or continuous intravenous infusion of propofol. Sufentanil and rocuronium will be given when needed. Patient-controlled intravenous analgesia will be provided for postoperative analgesia (established with 50 mg morphine in 100 mL normal saline, programmed to deliver a 2-mL bolus with a 6-10 minutes lockout interval and a 1 mL/hr background infusion)."
62264683|NCT02287623|EXPERIMENTAL|liposomal bupivacaine TAP|Patients will receive a TAP block with liposomal bupivacaine
62264684|NCT02287623|ACTIVE_COMPARATOR|bupivacaine TAP|Patients will receive a TAP block with bupivacaine
62264685|NCT03391271|EXPERIMENTAL|photobiomodulation therapy (PBMT)|During photobiomodulation therapy (PBMT) or low-level laser therapy, visible and/or (near)-infrared laser light is used at the affected area to improve tissue repair and thereby promote functional recovery of peripheral nerves
62264686|NCT03391271|PLACEBO_COMPARATOR|Placebo group|No PBMT
62264687|NCT06033742|EXPERIMENTAL|HS-10374|Single and multiple ascending doses of HS-10374 orally
62264688|NCT06033742|PLACEBO_COMPARATOR|Placebo|Single and multiple ascending doses of HS-10374-matched placebo orally
62264689|NCT05743452|EXPERIMENTAL|CS@Mg|The patient was treated by GBR with magnesium calcium silicate scaffold for alveolar bone defect.
62264690|NCT01308970|EXPERIMENTAL|Stress Management Group 1|
62264691|NCT01308970|EXPERIMENTAL|Stress Management Group 2|
62264692|NCT01308970|EXPERIMENTAL|Stress Management Group 3|
62264693|NCT03641066|EXPERIMENTAL|Ankle Brace|Each participant will complete a baseline analysis of 1 minute of walking and 2 minutes of running, repeated 4 more times wearing 4 different braces. The analysis will be completed on the Walker View Treadmill, which used 3D camera technology to capture lower body kinematics. The treadmill also has load cells built in to capture gait characteristics
62264694|NCT03553043|EXPERIMENTAL|Energy Label 1|Alcoholic beverage displayed with Energy label 1
62264695|NCT03553043|EXPERIMENTAL|Energy Label 2|Alcoholic beverage displayed with Energy Label 2
62621034|NCT04261647|ACTIVE_COMPARATOR|Control group|traditional physical therapy program in the form of stretching of piriformis, stretching of iliopsoas and clam shell exercise, seat cushioning and seat kitz.
62621035|NCT03323645||Patients with penile prostheses|
62264696|NCT03553043|EXPERIMENTAL|Energy Label 3|Alcoholic beverage displayed with Energy Label 3
62264697|NCT03553043|PLACEBO_COMPARATOR|Unlabelled|Alcohol beverage displayed unlabelled.
62621036|NCT03191825|ACTIVE_COMPARATOR|Standard web-application|Endre: a digital smoking cessation counsellor
62621037|NCT03191825|EXPERIMENTAL|Web-based lapse management system|Endre: a digital smoking cessation counsellor + Lapse management system triggered from web-page
62264698|NCT01774578|ACTIVE_COMPARATOR|Arm 1: Docetaxel|"Arm 1: Docetaxel 75 mg/m\^2 IV given every 3 weeks x 4 doses. If response or stable: Observe until disease progression.~First Progression: Gemcitabine 1250 mg/m\^2/week for 2 weeks with 1 week rest or Pemetrexed 500 mg/m\^2 every 3 weeks until disease progression or significant toxicity."
62621038|NCT03191825|EXPERIMENTAL|SMS & web-based lapse management system|Endre: a digital smoking cessation counsellor + Lapse management system triggered by SMS-textmessage
62621039|NCT04436653|EXPERIMENTAL|Tricuspid Valve Replacement System|Subjects who received transcatheter tricuspid valve replacement with LuX-Valve and delivery system will be included in this arm.
62621040|NCT02151214|EXPERIMENTAL|Parenteral nutrition|Parenteral nutrition will be administered to the patients
62621041|NCT02151214|NO_INTERVENTION|Normal per os nutrition|The patients will eat orally
62621042|NCT04818723|EXPERIMENTAL|Montelukast Group|53 in Case Group (given montelukast 5mg at bed time). All patients were induced with prednisolone 2mg/kg single morning dose with breakfast for total 4 weeks. Patients who did not achieve remission after 4 weeks' full dose were labeled steroid resistant nephrotic syndrome (SRNS). Children with steroid sensitive nephrotic syndrome SSNS were further treated by prednisolone 1.5 mg/kg single morning dose with breakfast every other day for the next 4 weeks. Prednisolone was then tapered by reducing 25% dose fortnightly and completely stopped in 8 weeks. Patients in the Case Group continued taking montelukast after stopping steroids. All patients were followed up every 4-8 weeks for a minimum of 12 months to look for response to treatment, side effects of medications, other co-morbidities, and the number of relapses. Relapses were treated with repeat prednisolone doses according to the protocol of treatment for relapse.
62621043|NCT04818723|PLACEBO_COMPARATOR|Placebo Group|Patients in this groups were induced with prednisolone 2mg/kg single morning dose with breakfast for total 4 weeks. Patients who did not achieve remission after 4 weeks' full dose were labeled steroid resistant nephrotic syndrome (SRNS). Children with steroid sensitive nephrotic syndrome SSNS were further treated by prednisolone 1.5 mg/kg single morning dose with breakfast every other day for the next 4 weeks. Prednisolone was then tapered by reducing 25% dose fortnightly and completely stopped in 8 weeks. Patients in the Case Group continued taking montelukast after stopping steroids. All patients were followed up every 4-8 weeks for a minimum of 12 months to look for response to treatment, side effects of medications, other co-morbidities, and the number of relapses. Relapses were treated with repeat prednisolone doses according to the protocol of treatment for relapse.
62847076|NCT03536793||Pancreatic cysts|Samples (urine, serum, whole blood and cystic fluid) will be taken from 50 patients with pancreatic cysts on follow-up. These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM). Some of the cystic fluid and the whole blood sample will either be analysed at the University of Hull or a commercial laboratory for proteomic and genomic data. Collection will occur on the same day of the participants' routinely indicated procedure.
62847077|NCT03536793||Pancreatic cancers|Samples (urine and serum) will be taken from 50 patients diagnosed with pancreatic cancer (resectable and non-resectable). These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM).
62621044|NCT03691506|ACTIVE_COMPARATOR|Classic CIMT group|Total session of 6 hours a day, 5 days per week for 3 weeks to Classic CIMT groups will be given.
62621045|NCT03691506|EXPERIMENTAL|mCIMT group|Session of 6 hours a day, 5 session per week for first 2 weeks (CIMT), session of 2 hours a day, 5 days per week for last 1 week (BIT) to modified CIMT group will be given.
62621046|NCT03387657|EXPERIMENTAL|Sotagliflozin + Hydrochlorothiazide (HCTZ)|Sotagliflozin to be administered alone in Period 1. HCTZ to be given in Period 2 for 4 days followed immediately by HCTZ and sotagliflozin for 5 days.
62621047|NCT04305860|ACTIVE_COMPARATOR|Modified starch without flavoring|Patients thicken water with modified starch during 3 days of hospitalization. They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake.
62621048|NCT04305860|ACTIVE_COMPARATOR|Modified starch with flavoring|"Patients thicken water with modified starch adding any of 5 kinds of flavorings Bi1 aromas during 3 days of hospitalization. They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake."
62621049|NCT04305860|ACTIVE_COMPARATOR|Xanthan gum without flavoring|Patients thicken water with xanthan gum during 3 days of hospitalization. They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake.
62621050|NCT04305860|ACTIVE_COMPARATOR|Xanthan gum with flavoring|"Patients thicken water with xanthan gum adding any of 5 kinds of flavorings Bi1 aromas during 3 days of hospitalization.They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake."
62847078|NCT03536793||Benign hepatopancreatobiliary conditions|Samples (urine and serum) will be taken from 80 age- and gender-matched control patients - 20 patients with acute pancreatitis and a non-resolving pseudocyst, 20 undergoing cholecystectomy for stones, 20 undergoing cholecystectomy for inflammation and 20 patients undergoing investigations for dyspepsia (normal control subgroup). These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM).
62621051|NCT03454386|ACTIVE_COMPARATOR|Active Treatment|"Stress Management and Resilience Training Program~This group will be initially enrolled in the program."
62621052|NCT03454386|OTHER|Control|"Self-Management Stress Reduction Program~This group will be placed in a self-management stress reduction program. During this time these participants will be given a popular stress reduction book to read over 12 weeks. They will complete questionnaires at weeks 4 and 12. After the 12 weeks, this group will be enrolled in the online SMART program and complete assessments at week 24 (upon completion of the program."
62621053|NCT04243226|EXPERIMENTAL|this study is to develop exercise prescription of TBI patients|The aim of this study is to develop exercise prescription of TBI patients and then to evaluate the effectiveness of programmed aerobic exercise to improve psysical-psycho-social health such as cognitive status, 6 minutes walk test, depression relief, motivation, symptom, resilience and quality of life. This will be a randomized-controlled clinical trial, by using a mixed method to explore the feasibility and validity of such a safety exercise prescription. In the next stage, a randomized clinical control trial will be applied in TBI patients to evaluate the effectiveness of programmed aerobic exercise to promote psysical-psycho-social health such as cognitive status, 6 minutes walk test, depression relief, motivation, symptom, resilience and quality of life.
62621054|NCT04243226|NO_INTERVENTION|No exercise prescription in TBI patients|Routine Care of TBI Patients
62621055|NCT04860024||ADHD|"Blood sample for miRNA qRT-PCR~Behavioral and neuropsychological assessments"
62621056|NCT04860024||Healthy|"Blood sample for miRNA qRT-PCR~Behavioral and neuropsychological assessments"
62621057|NCT02800395|OTHER|Nutritional evaluation|
62621058|NCT02524626|SHAM_COMPARATOR|Sham stimulation|no stimulation of vagus nerve
62621059|NCT02524626|ACTIVE_COMPARATOR|Vagus stimulation|Stimulation of the vagus nerve at the beginning and the end of the surgery
62621060|NCT04348500|ACTIVE_COMPARATOR|Clazakizumab|25 mg in 50 mL of 0.9% saline given by IV infusion x 1 dose over 30 minutes
62621061|NCT04348500|PLACEBO_COMPARATOR|Placebo|50 mL of 0.9% saline given by IV infusion x 1 dose over 30 minutes
62847079|NCT02498171|EXPERIMENTAL|Intrathecal morphine with fentanyl|Single shot of intrathecal morphine 100mcg mixed with 25mcg of fentanyl and filled up to make a 2ml solution. This would then be injected into the subarachnoid space through L2-3 or L3-4 following standard procedures.
62847080|NCT02498171|ACTIVE_COMPARATOR|Intrathecal morphine with bupivacaine|Single shot of intrathecal morphine 100mcg mixed with 2.5mg of spinal bupivacaine and filled up to make a 2ml solution.This would then be injected into the subarachnoid space through L2-3 or L3-4 following standard procedures.
62847081|NCT01563653|EXPERIMENTAL|Patients|Women with stress urinary incontinence schelduled for TVT or TOT procedures. See inclusion/exclusion criteria.
62847082|NCT05219916|EXPERIMENTAL|Adult patients infected by HIV, controlled under treatment.|Blood sample collection from HIV controlled patients during their scheduled consultation, after obtaining their non-opposition by an investigator.
62847083|NCT01297491|EXPERIMENTAL|Squamous BKM120 100mg qd|Diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease.
62847084|NCT01297491|EXPERIMENTAL|Non-Squamous BKM120 100mg qd|Diagnosed patients with non-squamous NSCLC that progressed after one or two prior antineoplastic therapy lines for metastatic disease.
62847085|NCT03309176|ACTIVE_COMPARATOR|Standard group|Intervention:Medroxyprogesterone acetate (Provera) 10 mg daily for 10 days will be used prior to starting ovulation induction with clomiphene citrate (CC) and between anovulatory cycles. On cycle day (CD) 3 CC 50 mg is administered daily for 5 days. Follicle growth will be monitored by ultrasound, starting from CD11. Anovulatory patients (defined as no follicle ≥ 14 mm) on CD20, will receive Provera 10mg daily for 10 days. The CC dosage will be increased in the next cycle. On CD3 patients will receive CC 100 mg daily for 5 days with ultrasounds performed from CD11 onwards. Anovulatory patients will receive Provera 10mg daily for 10 days. In the next cycle the CC dose will be increased to 150 mg, starting from CD3, daily for 5 days with ultrasounds starting from CD11-20.
62621062|NCT04554381|EXPERIMENTAL|JL1|JL1 on acute leukemia
62621063|NCT04554381|EXPERIMENTAL|JL1 and acute leukemia|Assesment of JL1 expression on acute leukemia
62621064|NCT04852211|ACTIVE_COMPARATOR|Open major hepatectomy|Resection of the tumor together with 3 or more liver segments using open standard techniques of hepatectomy
62621065|NCT04852211|ACTIVE_COMPARATOR|Laparoscopic major hepatectomy|Resection of the tumor together with 3 or more liver segments using minimally invasive techniques of hepatectomy
62621066|NCT03756597||Cases Pathway A|"Case pathway A - Intention to diagnose population~Only patients with a very high clinical suspicion based on imaging are scheduled for surgical procedures.Subjects with a confirmed diagnosis of cancer after clinical work-up will be labelled cases. of the study.~Patients with Gastric or Oesophageal cancer will be recruited after confirmation of their diagnosis but prior to initiation of therapy."
62621067|NCT03756597||Clinical Controls|"Clinical controls represent subjects that:~* Are suspected of the same cancer or part of an at risk-group~* Have undergone full per-guideline diagnostic work-up, resulting in confirmation the subject does not have cancer (see section 6)~* Is matched to the case for age, gender and known risk-factors specific to that tumour type (section 5.4)"
62621068|NCT03756597||Healthy volunteers|Healthy volunteers will be recruited from the clinical research facility at Addenbrooke's Hospital (Cambridge) or from the Cambridge BioResource. These subjects will be selected to have a similar age and sex distribution as the overall PAN-study cases.
62621069|NCT03756597||Substudy Cases|Patients with a confirmed diagnosis of cirrhosis and providing up to 6 samples will be labelled as the washout substudy cases
62621070|NCT03756597||Cases Pathway B|"Case pathway B - Confirmed malignancy population~Patients with a Gastric, Liver or Oesophageal cancer will be recruited after confirmation of their diagnosis but prior to initiation of therapy. Patients will be recruited by research staff at the clinic they are referred to for diagnosis and/or treatment"
62621071|NCT02025270|OTHER|Laboratory and Clinical|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into rete testis.
62264699|NCT01774578|EXPERIMENTAL|Arm 2a: HyperAcute®-Lung Immunotherapy (weekly)|"Arm 2a: 300 Million HAL cells given by intradermal injection weekly for 11 weeks and then every 2 months for 5 additional doses.~Up to 16 total immunizations of 300 million immunotherapy cells until disease progression or toxicity.~First Progression: Docetaxel 75 mg/m\^2 IV given every 3 weeks or Gemcitabine 1250 mg/m\^2 for 2 weeks with 1 week rest or Pemetrexed 500 mg/m\^2 every 3 weeks until disease progression or significant toxicity and continue with HAL administration given every 2 weeks (not to exceed 16 total immunizations)."
62621072|NCT04208672|EXPERIMENTAL|Patient attending for PSG in Sleep Assessment Unit|Subjects referred to the SAU will be invited to participate into this study
62621073|NCT04160637||Patients with post-thyroidectomy hypocalcemia|Patients with postoperative hypocalcemia defined as serum calcium levels \< 2.00 mmol/L regardless of clinical symptoms present. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
62264700|NCT01774578|EXPERIMENTAL|Arm 2b: HyperAcute®-Lung Immunotherapy (biweekly)|"Arm 2b: 300 Million HAL cells given by intradermal injection biweekly for 6 doses and then every month for 10 additional doses.~Up to 16 total immunizations of 300 million immunotherapy cells until disease progression or toxicity.~First Progression: Docetaxel 75 mg/m\^2 IV given every 3 weeks or Gemcitabine 1250 mg/m\^2 for 2 weeks with 1 week rest or Pemetrexed 500 mg/m\^2 every 3 weeks until disease progression or significant toxicity and continue with HAL administration given every 2 weeks (not to exceed 16 total immunizations)."
62264701|NCT05394064|EXPERIMENTAL|Active Treatment|Patients treated with SBT101
62264702|NCT05394064|SHAM_COMPARATOR|Imitation Procedure|Procedure that mimics treatment with SBT101, but does not infuse anything into the spinal cord
62448244|NCT06469879|EXPERIMENTAL|TQB2450+Anlotinib|TQB2450 injection: 1200 mg/time, intravenous infusion, day 1, every 3 weeks (Q3W); Anlotinib hydrochloride capsules: 8 mg/time, once a day (QD), for 2 weeks, stop for 1 week, oral before breakfast; (The starting dose of anlotinib hydrochloride is 8 mg, and an upward adjustment to 10 mg is allowed after two cycles.)
62448245|NCT06469879|PLACEBO_COMPARATOR|TQB2450 placebo + anlotinib placebo|TQB2450 injection placebo: 0 mg/time, intravenous drip, day 1; anlotinib hydrochloride capsule placebo: 0 mg/time, once a day (QD), for 2 consecutive weeks, stop for 1 week, oral administration before breakfast.
62621074|NCT04160637||Patients without post-thyroidectomy hypocalcemia|Patients without postoperative hypocalcemia defined as serum calcium levels \> 2.00 mmol/L regardless of clinical symptoms present. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
62621075|NCT05007171|EXPERIMENTAL|Very low calorie diet|Use of very low calorie diet in hospital for 3 weeks
62621076|NCT03717649|ACTIVE_COMPARATOR|Conventional 2-stage venous cannulation|The two-stage venous cannula 36Fr and 51Fr (size) for each of the two stages (91251C, Medtronic)
62448246|NCT01503723||Patients with acute lung injury|Patients who are admitted to ICU with the diagnosis of acute hypoxemic respiratory failure
62621077|NCT03717649|ACTIVE_COMPARATOR|Conventional 3-stage venous cannula|The standard three-stage cannula (91437C, Medtronic) is 29Fr, 46Fr and 37Fr for each of the three stages.
62621078|NCT03717649|EXPERIMENTAL|Fenestrated 3-stage venous cannula|The fenestrated three-stage cannula (MC2X, Medtronic) is 29Fr, 29Fr and 29Fr for each of the three stages.
62621079|NCT06055153|EXPERIMENTAL|RC48+PD-1+platinum-based|"Dose 1: RC48 2.5mg/kg intravenous infusion, d1 once every 3 weeks;~Camrelizumab dose: 200mg, intravenous infusion 30-60min, d1 once every 3 weeks;~Platinum (cisplatin or nedaplatin) : Cisplatin 75mg/m2, added into 500ml 0.9% sodium chloride injection for infusion, hydration and alkalization of -1d, d1, d2, once every 3 weeks; Nedaplatin 75mg/m2 was added to 500ml 0.9% sodium chloride injection, once every 3 weeks.~Dose 2: rc48 2.0mg/kg, d1, once every 3 weeks; Camrelizumab 200mg, d1 once every 3 weeks; Platinum: Cisplatin 75mg/m2(or nedaplatin 75mg/m2), d1, once every 3 weeks"
62621080|NCT02547909|EXPERIMENTAL|Study group|a probe-based Confocal Laser Endomicroscopy examination will be done using a standard recto-sigmoidoscopy, in women suffering from endometriosis who are referred for a TRUS examination as part of a suspected deep endometriosis diagnostic workup. pCLE images will be compared to normal bowel mucosa.
62621081|NCT03188523|EXPERIMENTAL|MK-8504 100 mg (Panel A)|Participants receive a single oral dose of MK-8504 100 mg.
62621082|NCT03188523|EXPERIMENTAL|MK-8504 240 mg (Panel B)|Participants receive a single oral dose of MK-8504 240 mg.
62621083|NCT03188523|EXPERIMENTAL|MK-8504 ≤240 mg (Panel C)|Participants receive a single oral dose of MK-8504 ≤240 mg.
62621084|NCT03188523|EXPERIMENTAL|MK-8504 ≤240 mg (Panel D)|Participants receive a single oral dose of MK-8504 ≤240 mg.
62621085|NCT05689788|EXPERIMENTAL|HILT + stretching exercise|High-intensity laser therapy (HILT) will be applied with the punctual technique on the 6 bilateral points of the cervical region and shoulder girdle, to be followed by a sweep technique on both trapezius muscles (upper portions). The parameters proposed by Dundar et al. will be used: an average power of 3 W, 60 J per point (360 J), and 500 J for manual scanning (1000 J). For the application of laser therapy, the 12 W BTL-6000 equipment that emits at 1064 nm wavelengths will be used. Laser therapy will be applied with the participant in the prone position.The treatment will be complemented with passive static stretching for the upper trapezius, levator scapulae, and scalene muscles (bilaterally) in three series. Each series will last 30 seconds, followed by a 30-second rest interval. The exercises will be carried out with the participant in a seated position in a chair with a backrest.
62621086|NCT05689788|SHAM_COMPARATOR|Sham HILT + stretching exercise|The group will receive a sham treatment of high-intensity laser therapy (HILT). The treatment will be complemented with passive static stretching for the upper trapezius, levator scapulae, and scalene muscles (bilaterally) in three series. Each series will last 30 seconds, followed by a 30-second rest interval. The exercises will be carried out with the participant in a seated position in a chair with a backrest.
62621087|NCT00877539|EXPERIMENTAL|PF-03526299|
62621088|NCT00877539|PLACEBO_COMPARATOR|Placebo|
62621089|NCT00877539|ACTIVE_COMPARATOR|Fluticasone propionate|
62847086|NCT03309176|EXPERIMENTAL|Stair Step group|Intervention: Stair step protocol without medroxyprogesterone acetate 10 mg prior to ovulation induction with clomiphene citrate (CC), nor in between anovulatory cycles. After performing an ultrasound to check for the presence of cysts or any other abnormalities and a negative pregnancy test, patients will receive CC 50 mg daily for 5 days. Ultrasounds will be performed on CD11-14. If there is no response on CD14 (no follicle ≥ 14 mm), the dose of CC is immediately increased to 100 mg CC daily for 5 days and an ultrasound is performed 1 week following the last ultrasound. If there is no response, 150 mg CC daily is initiated immediately for 5 days and the ultrasound is repeated 1 week after the previous ultrasound.
62448247|NCT00727285||A|CF patients followed by the Adult CF Program at National Jewish Health meeting criteria for an acute pulmonary exacerbation.
62847087|NCT00541619||A|hypertensives with proteinuria
62847088|NCT03872778|EXPERIMENTAL|Phase I: Cohort I|"\[68 Ga\]-NeoB: 50 micrograms/dose at screening~\[177Lu\]-NeoB: 50 mCi (1.85 GBq) cycle 1, 60% Estimated Cumulative Dose (ECD) for cycles 2-4, q6w"
62621090|NCT05042986|EXPERIMENTAL|Single Dose Capsule|Single oral dose of 200 mg (100 μCi in 200 mg salt \[0.5 μCi/mg as salt\], equivalent to 100 μCi in 142 mg active \[0.7 μCi/mg as active\]) of \[14C\]-SKI-O-703 containing approximately 100 μCi of \[14C\]-SKI-O-703 per capsule after an overnight fast.
62621091|NCT04217824|ACTIVE_COMPARATOR|karydakis flap|An asymmetric elliptical excision is performed, defective tissues between the lower and upper ends are removed until they reach healthy borders. The wound edge is then mobilized and the flap is slid over the corresponding wound edge by suturing to the fascia and the skin to the appropriate wound layers. Thus, the gluteal groove is lateralized. Subcutaneous tissue and skin are closed.
62847089|NCT03872778|EXPERIMENTAL|Phase I: Cohort II|"\[68 Ga\]-NeoB: 50 micrograms/dose at screening~\[177Lu\]-NeoB: 60% ECD for 3 cycles (q6w)"
62847090|NCT03872778|EXPERIMENTAL|Phase I: Cohort III|"\[68 Ga\]-NeoB: 50 micrograms/dose at screening~\[177Lu\]-NeoB: 80% ECD for 3 cycles (q6w)"
62847091|NCT03872778|EXPERIMENTAL|Phase I: Cohort IV|"\[68 Ga\]-NeoB: 50 micrograms/dose at screening~\[177Lu\]-NeoB: 100% ECD for 3 cycles (q6w)"
62847092|NCT03872778|EXPERIMENTAL|Phase I: Cohort V|"\[68 Ga\]-NeoB: 50 micrograms/dose at screening~\[177Lu\]-NeoB: 120% ECD for 3 cycles (q6w)"
62847093|NCT03872778|EXPERIMENTAL|Phase IIa: Cohort A|"\[68 Ga\]-NeoB: 50 micrograms/dose at screening~\[177Lu\]-NeoB: dose TBD based on Cohorts I-VI, 3 cycles q6w"
62847094|NCT03872778|EXPERIMENTAL|Phase IIa: Cohort B|"\[68 Ga\]-NeoB: 50 micrograms/dose at screening~\[177Lu\]-NeoB: dose TBD based on Cohorts I-VI, 3 cycles q6w"
62448248|NCT00929409|ACTIVE_COMPARATOR|Peroral iron - ferrous sulfate tablets|Peroral iron given as one tablet of ferrous sulfate 100 mg two times daily
62847095|NCT03872778|EXPERIMENTAL|Phase IIa: Cohort C|"\[68 Ga\]-NeoB: 50 micrograms/dose at screening~\[177Lu\]-NeoB: dose TBD based on Cohorts I-VI, 3 cycles q6w"
62847096|NCT03872778|EXPERIMENTAL|Phase IIa: Cohort D|"\[68 Ga\]-NeoB: 50 micrograms/dose at screening~\[177Lu\]-NeoB: dose TBD based on Cohorts I-VI, 3 cycles q6w"
62448249|NCT00929409|ACTIVE_COMPARATOR|Ferric carboxymaltose|Intravenous infusion of Ferric Carboxymaltose (Ferinject), the given dose is adapted according to the individual patient's requirement. No other form of iron supplementation is given.
62621092|NCT04217824|ACTIVE_COMPARATOR|limberg flap|Rhomboid excision and pilonidal sinuses together with damaged tissue. On the right side of the patient, the intact skin is shifted to the medial area where the tissues are removed without tension. Thus, the defective part and gluteal groove are corrected.
62621093|NCT05700331|EXPERIMENTAL|Chronic Widespread Pain patients|3 FMT infusions, 2 weeks apart Procedures for Infusion: 100-200 ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via oesophago-gastro-duodenoscopy (OGD). After infusion, subjects will be monitored for 1 hour before discharged.
62621094|NCT02065518|ACTIVE_COMPARATOR|Standard Rehabilitation Protocol (SRP)|All participants will receive the current standard of care, the physical therapy rehabilitation protocol for knee injuries at the WRNMMC and MGMCSC sites. This program includes treatment supervised by a physical therapist at the physical therapy clinics.
62621095|NCT02065518|EXPERIMENTAL|NMES w/ SRP|In addition to the standard rehabilitation protocol, two treatment groups will receive a portable lightweight device (300PV unit) that provides clearly defined electrical stimuli. NMES training will consist of performing four 30-minute stimulation sessions per week for 12 weeks; each 30-minute session will entail 15 minutes/leg with 15 contractions per leg. Each contraction will be elicited by an electrical impulse (300PV) generated by a battery-operated device (EMPI, St. Paul, MN).
62621096|NCT02065518|EXPERIMENTAL|Strength Walking w/ SRP|The Strength Walking groups will participate in a Home-Based Pedometer-Driven Walking Program. All participants in this group will be given a pedometer to monitor their daily steps and, at week 7, a weighted exercise vest to begin the strengthening component. In addition to the standard WRNMMC rehabilitation protocol, a series of 10-minute lessons focused on increasing physical activity through lifestyle education and the use of a pedometer as a motivational tool and personal fitness tracker will be incorporated into their testing sessions for the first 6 weeks. At week 7, participants will be given a weighted vest to begin the strengthening component.
62621097|NCT02065518|EXPERIMENTAL|NMES/Strength Walking w/ SRP|In addition to the standard rehabilitation protocol, one group will receive NMES training and will participate in a Home-Based Pedometer-Driven Walking Program. This group will follow the protocol for both the NMES training and Strength Walking.
62621098|NCT03105856|ACTIVE_COMPARATOR|CERVARIX|hrHPV-based screening and HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 months)
62847097|NCT03872778|EXPERIMENTAL|Phase IIa:Cohort E|"\[68 Ga\]-NeoB: 50 micrograms/dose at screening~\[177Lu\]-NeoB: dose TBD based on Cohorts I-VI, 3 cycles q6w~LCZ696: co-administered with \[177Lu\]-NeoB"
62621099|NCT03105856|ACTIVE_COMPARATOR|GARDASIL|hrHPV-based screening and Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) vaccine group according to a two-dose schedule (0-12 months)
62621100|NCT03105856|NO_INTERVENTION|CONTROL GROUP|Control group who will receive only hrHPV-based screening.
62847098|NCT02584556|EXPERIMENTAL|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks within 4-6 weeks after hepatic resection(a total of 4 cycles).
62847099|NCT02584556|ACTIVE_COMPARATOR|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization (Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou)) within 4-6 weeks after hepatic resection(a total of 1 cycle).
62847100|NCT03894397|EXPERIMENTAL|Stimulation of left BNST|
62448250|NCT06398769|EXPERIMENTAL|SecuFix UM|SecuFix UM arm: patients undergoing total laparoscopic hysterectomy
62847101|NCT03894397|EXPERIMENTAL|Stimulation of right BNST|
62847102|NCT03894397|EXPERIMENTAL|Stimulation of bilateral BNST|
62847103|NCT03894397|PLACEBO_COMPARATOR|Stimulation OFF|
62847104|NCT03005405|ACTIVE_COMPARATOR|restoration - control|Restoration
62621101|NCT05459558|EXPERIMENTAL|Experimental Dentifrice 1|Randomized participants will brush their teeth with the experimental dentifrice (covering the entire length of the toothbrush), twice daily (morning and evening) for 2 minutes for 8 weeks.
62621102|NCT05459558|EXPERIMENTAL|Experimental Dentifrice 2|Randomized participants will brush their teeth with the experimental dentifrice (covering the entire length of the toothbrush), twice daily (morning and evening) for 2 minutes for 8 weeks.
62847105|NCT03005405|EXPERIMENTAL|sealant - test|Sealant
62847106|NCT05689580|EXPERIMENTAL|Patients received ketogenic diet then Balanced diet|subjects will be educated by dietitian and receive two months of ketogenic diet. Then, followed by three months of washout period. Finally, they will receive dietary education and follow balanced diet for two months.
62847107|NCT05689580|EXPERIMENTAL|Patients received Balanced diet then ketogenic diet|subjects will receive dietary education and follow balanced diet for two months first, then followed by three months of washout period. At last, they will receive dietary education of ketogenic diet and need to follow the ketogenic diet for two months.
62847108|NCT03742466|ACTIVE_COMPARATOR|Ozone|After prepping and draping the area, intracarpal injection of ozone/oxygen mixture (20 ml, 25μg/ml) will be performed under sonographic guidance
62847109|NCT03742466|ACTIVE_COMPARATOR|methylprednisolone acetate|After prepping and draping the area, intracarpal injection of methylprednisolone acetate 40mg, and 40 mg lidocaine (20 ml, volume) will be performed under sonographic guidance
62847110|NCT01055067|EXPERIMENTAL|Tivantinib (ARQ 197)|3 capsules of 120 mg each, administered twice a day (once in the morning and once in the evening - total daily dose of 720 mg) in continuous 4-week cycles
62448251|NCT06398769|ACTIVE_COMPARATOR|VCare UM|VCare UM arm: patients undergoing total laparoscopic hysterectomy
62448252|NCT03711955|EXPERIMENTAL|Aerobic training group (AET)|Each AET sessions are to last one hour, with 40 minutes being allocated to the aerobic exercise training component, 10 minutes allocated to warm-ups, 5 minutes allocated to cool-downs, and one 5 minute rest period between the 20 minutes spent on each machine (20 minutes of cycling, 5 minute rest, 20 minutes seated row). The AET program consists of 20 minutes of cycling on the stationary bicycle and 20 minutes of seated row on the kinesis Technogym machine. This is to be preceded by 10 minutes of static stretching during warm up, and 5 minutes of post-exercise recovery (dynamic stretches).
62621103|NCT05459558|ACTIVE_COMPARATOR|Reference Dentifrice|Randomized participants will brush their teeth with the Reference dentifrice (covering the entire length of the toothbrush), twice daily (morning and evening) for 2 minutes for 8 weeks.
62621104|NCT06145113|ACTIVE_COMPARATOR|Continuous Positive Airway Pressure - 10cmH2O|This arm will consist of positive airway pressure at an FiO2 of 21% (ambient air), supplied by CPAP device set to 10cmH2O of pressure, for a total of 2 hours.
62621105|NCT06145113|PLACEBO_COMPARATOR|Placebo Continuous Positive Airway Pressure - 1cmH2O|This arm will consist of positive airway pressure at an FiO2 of 21% (ambient air), supplied by CPAP device set to 1cmH2O of pressure, for a total of 2 hours. This 1cmH2O is necessary to maintain blinding and will provide minimal therapeutic effect.
62621106|NCT06145113|OTHER|Continuous Positive Airway Pressure - 10cmH2O, with supplemental oxygen|This arm will only be enrolled into once the other two arms have been completed. Additional subjects will receive CPAP at 10cmH2O with in-line oxygen (estimated 2-4 liters per minute). This is done to determine if adding supplemental oxygen can further improve symptoms.
62847111|NCT02834793|EXPERIMENTAL|Perampanel up to 8 mg/day|"During the Randomization Phase, participants will receive perampanel at a starting dose of 2 milligrams per day (mg/day). Thereafter, the dose will be increased to a maximum target dose of 8 mg/day according to individual tolerability and efficacy for up to 18 weeks. Participants who enter into Extension A will continue to receive perampanel at the dose last received during randomization phase. Participants can be titrated up to 12 mg/day (at 2-week intervals) per the investigator's discretion.~Participants who continue in Extension B will continue to receive perampanel at the dose last received at the end of Extension A."
62847112|NCT02834793|PLACEBO_COMPARATOR|Matching placebo|"During the Randomization Phase, participants will receive matching placebo for up to 18 weeks.~During the Extension A, participants who received placebo during the Randomization Phase will begin treatment with perampanel in a blinded manner in double-blind Conversion Period, starting at 2 mg/day and then up-titrated to a maximum target dose of 8 mg/day according to individual tolerability and efficacy. After the Conversion Period, participants can be titrated up to 12 mg/day (at 2-week intervals) per the investigator's discretion."
62847113|NCT05891574||healthy older adults|"* Age between 65 and 90 years~* No frailty indicated by Fried frailty criteria~* Mini-mental state examination score equals to or more than 24, and Montreal Cognitive Assessment score equals to or more than 26~* Ability to walk independently for 1 min"
62847114|NCT00348881|EXPERIMENTAL|Group 1: DTaP-Hep B-PRP-T + OPV vaccine|Participants received 3 doses of the DTaP-Hep B-PRP-T concomitantly with OPV vaccine, 1 dose each at 6, 10, and 14 weeks of age.
62847115|NCT00348881|ACTIVE_COMPARATOR|Group 2: Tritanrix-HepB/Hib™ + OPV vaccine|Participants received 3 doses of the Tritanrix-HepB/Hib™ concomitantly with OPV vaccine, 1 dose each at 6, 10, and 14 weeks of age.
62847116|NCT05518747|EXPERIMENTAL|Probiotic|In this group participants will receive non-surgical periodontal treatment at baseline, which will for 12 weeks
62847117|NCT05518747|PLACEBO_COMPARATOR|Placebo|In this group participants will receive non-surgical periodontal treatment at baseline, which will for 12 weeks
62621107|NCT04660786|ACTIVE_COMPARATOR|intralesional injection of triamcinolone acetonide|5mg/ml) using sterile saline for dilution every 4 weeks for 3 sessions
62621108|NCT04660786|ACTIVE_COMPARATOR|intralesional injection of vitamin D|(2.5 mg/mL) every 4 weeks for 3 sessions
62621109|NCT06265571||GROUP I|Interscalene block (group I)15 ml of 0.5% bupivacaine was applied with a single injection to 12 of 18 patients,
62621110|NCT06265571||GROUP II|7.5 ml of interscalene and 7.5 ml of suprascapular block (GROUP II) were applied to 6 patients with posterior approach.
62621111|NCT01687283|EXPERIMENTAL|fluticasone propionate|1 mg BID inhalation via nebulizer
62847118|NCT04215965|EXPERIMENTAL|Experimental Standard citrate protocol|CVVHDF will be performed using Regiocit solution in the predilution mode, Biphozyl in the dialysate and postdilution mode. CRRT will be started at a dose of 35 ml/kg/h.
62621112|NCT01687283|ACTIVE_COMPARATOR|budesonide suspension|2 mg BID inhalation via nebulizer
62621113|NCT02626000|EXPERIMENTAL|Talimogene Laherparepvec + Pembrolizumab|Talimogene laherparepvec is administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL on day 1 followed by a dose of 10⁸ PFU/mL 3 weeks after the initial dose and every 3 weeks (Q3W) thereafter. Pembrolizumab is administered by intravenous infusion at a dose of 200 mg Q3W after the initial dose. Participants are treated until complete response, no injectable lesions, confirmed disease progression, intolerance of study treatment, 24 months from the date of the first dose of talimogene laherparepvec, or end of study, whichever occurred first.
62847119|NCT04215965|ACTIVE_COMPARATOR|Conventionnal citrate protocol|CVVHDF will be performed using Regiocit solution in the predilution mode, Prismocal B22 (calcium and phosphate free) in the dialysate mode, and Phoxilium in the postdilution mode. CRRT will be started at a dose of 35 ml/kg/h.
62847120|NCT04254770|ACTIVE_COMPARATOR|ADA (American Dental Association) approved Manual Toothbrush|
62847121|NCT04254770|EXPERIMENTAL|Marketed Power Toothbrush|
62847122|NCT00838513|EXPERIMENTAL|eculizumab|
62847123|NCT02352285|EXPERIMENTAL|Tolvaptan|Tovaptan tablet 15mg, 30mg, 60mg, once a day, oral
62847124|NCT02352285|PLACEBO_COMPARATOR|placebo|placebo tablet 15mg, 30mg, 60mg, once a day, oral
62847125|NCT01338454|ACTIVE_COMPARATOR|tranexamic acid|TA administered intravenously over a 5 min period at delivery of the anterior shoulder
62847126|NCT01338454|NO_INTERVENTION|saline|10 mL of saline was administered intravenously over a 5 min period at delivery of the anterior shoulder
62847127|NCT00552747|ACTIVE_COMPARATOR|1|fenofibrate 160 mg capsules (QD) Taken once daily with the largest meal of the day
62847128|NCT00552747|PLACEBO_COMPARATOR|2|placebo (capsules identical to those of fenofibrate) taken once daily (QD)with the largest meal of the day
62621114|NCT03060291|EXPERIMENTAL|Web/ Mobile-only|Participants will complete the FCU online independently, without the help of a coach.
62847129|NCT02804841|EXPERIMENTAL|Intervention|Healthy, Community Dwelling; Aged 60-80 years; Cholecalciferol -Vitamin D3, 4000 international units (IU) on alternating days.
62847130|NCT02804841|PLACEBO_COMPARATOR|Placebo|Healthy, Community Dwelling; Aged 60-80 years; Placebo -gel capsule containing no vitamin D on alternating days.
62847131|NCT03013309|EXPERIMENTAL|Intervention|Receives the Family Check-Up 4 Health
62847132|NCT03013309|EXPERIMENTAL|Control|Receives Treatment as Usual
62060589|NCT02098408|ACTIVE_COMPARATOR|Standard treatment|Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling
62060590|NCT04566302|EXPERIMENTAL|SECM Skin Imaging|The SECM skin imaging procedure will be very similar to that by the FDA approved RCM devices. First, the skin lesion (such as a mole) will be identified on a forearm of the subject. The lesion will be imaged first with a dermatoscope, and then with the SECM device. A dermatoscope is a hand-held device used for the visual observation of the epidermis. It is a superior surface contact microscope used to examine skin lesions.
62060591|NCT04959630|OTHER|Group A|Group A received first five patient cases and 3D models via DI and another five cases in the VR environment
62060592|NCT04959630|OTHER|Group B|Group B received first five patient cases and 3D models via VR and another five cases in the DI.
62060593|NCT05550363|EXPERIMENTAL|DEXYCU|DEXYCU, 103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
62060594|NCT05550363|PLACEBO_COMPARATOR|Placebo|Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
62621115|NCT03060291|ACTIVE_COMPARATOR|Web/mobile + coach|Participants will complete the FCU online and will be contacted by a family coach. The coach will conduct motivational interviewing and provide support to parents via phone. Participants in this condition will have contact with a coach at least 2 times.
62621116|NCT03060291|NO_INTERVENTION|Wait list control|"Participants in this condition will receive middle school as usual, meaning that they will continue to receive whatever services are normally provided by the middle school during the year of their participation in the study. Once their research participation is completed (i.e., after they complete their final follow-up survey), participants in this condition will be offered the opportunity to use the FCU-Online website if they wish, without the support of a coach. No additional data will be collected."
62621117|NCT04722536||Cervico-isthmic cerclage|Are included in this group the women who underwent cervico-isthmic cerclage between January 1, 2010 and April 1, 2019, in 3 hospitals of the Hospices Civils de Lyon, respecting the inclusion and exclusion criteria, to assess the primary and secondary outcomes before and after performing the cerclage.
62847133|NCT04249349|EXPERIMENTAL|Robot-assisted Gait|Participants will receive assisted gait with a motorized ankle foot orthosis. Patient´s gait will be analyzed by a photogrammetry system during device assistance. Session will involve 1 hour of supervised training.
62847134|NCT04254991||Infectious disease group|
62847135|NCT04254991||Non-infectious disease group|
62847136|NCT05950386||The control group|The invited non-lead-exposed workers live in Yangzhou, Jiangsu, China
62847137|NCT05950386||The lead exposure group|The invited chronic-lead exposed workers live in Yangzhou, Jiangsu, China
62847138|NCT00824304||Fe, Zn, Fe+Zn, Placebo|placebo comparator
62060595|NCT06359236|EXPERIMENTAL|Treatment Group|Participants in the treatment group will be involved in a process that includes three phases of the study: preparation phase, implementation phase and follow-up phase.
62847139|NCT03073837|OTHER|Rhinovirus Challenge|Challenge with HRV-16
62847140|NCT00849095|EXPERIMENTAL|as needed medication|patients assigned to this arm will take bid inhaled placebo plus prn inhaled 160/4.5 mcg budesonide/formoterol combination
62847141|NCT00849095|ACTIVE_COMPARATOR|guideline treatment|bid inhaled 160/4.5 mcg budesonide/formoterol combination plus prn 500 mcg terbutaline
62060596|NCT06359236|NO_INTERVENTION|Control Group|The control group will not be able to access the entire treatment program content. However, they will be able to access animation contents such as energy balance training, eating change, planning where and when and what to eat, healthy weight loss targets, three main and three snacks, determining weight loss targets and informational content titled diet types specified in the nutrition education module for a period of 6 weeks.
62060597|NCT05502614|EXPERIMENTAL|Treatment|
62060598|NCT03659604|EXPERIMENTAL|Experimental with tailored feedback|'SmartLife' with tailored feedback: School classes will receive the developed 'SmartLife' intervention with tailored feedback, that is based on data from a sensors that is integrated in a T-shirt.
62847142|NCT01742819||Advanced glaucoma|Patients with MD \< -6 or visual field loss within the central 10 degrees of the visual field.
62621118|NCT01044368|EXPERIMENTAL|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
62621119|NCT01044368|NO_INTERVENTION|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
62060599|NCT03659604|ACTIVE_COMPARATOR|Active control without tailored feedback|'SmartLife' without tailored feedback: School classes will receive the developed 'SmartLife' intervention without tailored feedback.
62847143|NCT03848182|EXPERIMENTAL|Gemcitabine with TT vaccine booster|Gemcitabine will be delivered as is standard of care. Patients diagnosed with pancreatic ductal carcinoma (PCD) will be treated with Gemcitabine and boosted once with the human childhood vaccine to TT
62847144|NCT04724824|EXPERIMENTAL|Brain-Computer Interface controlled robotic feedback|
62847145|NCT04724824|SHAM_COMPARATOR|Sham Brain-Computer Interface controlled robotic feedback|
62847146|NCT00397917|ACTIVE_COMPARATOR|400 micrograms of folic acid|Blinded study with two arms one of 400ug in arm 1
62847147|NCT00397917|ACTIVE_COMPARATOR|4mg of folic acid|Second arm is 4mg of folic acid in arm 2
62847148|NCT00929643||1|
62847149|NCT00539188|EXPERIMENTAL|N-Acetylcysteine|Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose (3000 mg daily), in addition to the medication regimen they are on at enrollment
62847150|NCT00539188|PLACEBO_COMPARATOR|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
62847151|NCT03368690|EXPERIMENTAL|Oligopin®|"Dietary supplement, Polyphenolic extract from pine bark. This group receives a nutritional supplement for a period of 10 weeks.~Children and adolescent 20-50 kg body weight: 25 mg Oligopin®/day; \> 50 kg body weight: 50 mg Oligopin®/day Adults 40-60 kg body weight: 100 mg Oligopin®/day; \> 60 kg body weight: 150 mg Oligopin®/day"
62621120|NCT02570035||Mirabegron group|Subjects with overactive bladder and cardiovascular disease prescribed mirabegron
62621121|NCT04646811|EXPERIMENTAL|Tricuspid valve|tricuspid valve percutaneous repair strategy with clip for the tricuspid valve
62847152|NCT03368690|PLACEBO_COMPARATOR|Placebo|Placebo treatment ( identical capsules containing maltodextrin and magnesium stearate )
62621122|NCT04646811|OTHER|Best medical treatment|
62847153|NCT04107025|EXPERIMENTAL|Intervention|As part of the intervention, along with legal opinions, advise and support, participants were provided counselling support during their time to help survivors with trauma of legal proceedings.
62847154|NCT04107025|NO_INTERVENTION|Usual Care|Participants were scheduled for legal consultancy only.
62847155|NCT02088138|EXPERIMENTAL|Functional Electrical Stimulation|"Functional Electrical Stimulation~In the intervention group the FES was applied in the medial and lateral vastus of both thighs targeting the movement of knee extension. The application frequency was 15 Hz, lasting 40 minutes, pulse width of 0.5 ms, time ON 5s, time OFF 10s, ramp-up of 0 or 1s, descent ramp 2s and intensity as tolerance patient."
62847156|NCT02088138|EXPERIMENTAL|FES placebo|"Functional Electrical Stimulation placebo~The placebo group received functional electrical stimulation with the same parameters in the intervention group, except that the intensity of stimulation did not lead to visible or palpable contraction."
62847157|NCT02505828|OTHER|Septic arthritis|with bacteriological identification
62847158|NCT02505828|OTHER|Juvenile idiopathic arthritis|beyond the ILAR (International League of Associations for Rheumatology) definition
62847159|NCT03023813|EXPERIMENTAL|Intervention|Individualized preventive care recommendations will be distributed to subjects.
62847160|NCT03023813|NO_INTERVENTION|Control|Usual care
62060600|NCT03659604|OTHER|Passive control|School classes will not receive any intervention, thus no game.
62060601|NCT01913106|EXPERIMENTAL|HSV-tk + Valacyclovir and Brachytherapy|You will be given an antibiotic (Ciproflaxin) to take twice a day beginning the day before the procedure, and continuing for a total of 3 - 5 days. You will also be given 4 pills called (Valtrex) valacyclovir to take three times a day for 14 days, beginning the day before the procedure. You will be given a pill diary in which you will record each dose of valacyclovir that you take. You will receive brachytherapy (radioactive seed placement) the day after you begin taking your pills. After the radioactive seeds are placed, while you are still in the operating room, you will receive an injection into your prostate of 1 or 2 ml (one-fifth or two-fifths of a teaspoon) of a solution of the vector carrying the gene.
62621123|NCT02112877|EXPERIMENTAL|VICI Stent Implantation - Feasibility|Percutaneous stent placement in the common femoral vein, external iliac vein and/or common iliac vein Veniti Vici™ Venous Stent System
62621124|NCT02112877|EXPERIMENTAL|VICI Stent Implantation - Pivotal|Percutaneous stent placement in the common femoral vein, external iliac vein and/or common iliac vein Veniti Vici™ Venous Stent System
62621125|NCT03315494|EXPERIMENTAL|SKI-O-703 200 mg (once daily)|SKI-O-703 capsule (1 x 200 mg)
62621126|NCT03315494|EXPERIMENTAL|SKI-O-703 400 mg (once daily)|SKI-O-703 capsule (2 x 200 mg, once daily)
62621127|NCT03315494|EXPERIMENTAL|SKI-O-703 200 mg (twice daily)|SKI-O-703 capsule (1 x 200 mg twice daily)
62621128|NCT03315494|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62847161|NCT03023813|EXPERIMENTAL|Development Phase|Non-randomized receipt of individualized preventive care recommendations
62847162|NCT04013828||Patients|Patients with recurrent high-grade glioma
62847163|NCT04013828||Relatives|Close relatives of patients with recurrent high-grade glioma
62847164|NCT05818969|EXPERIMENTAL|Hypnosis Therapy Group|"Experimental: Hypnosis Therapy Group~Patients will receive questionnaires to establish their attitudes/beliefs toward hypnosis, baseline pain, anxiety, \& knee function. 7 days prior to surgery, they will receive a pre-recorded video (-19 min) of guided hypnosis to be watched at least 1x/day, until surgery. Postoperative course will be otherwise completely standard of care, including a clinic visit at 10 days after surgery, where they will be given these same questionnaires. Patients will answer them again on postoperative day 49, constituting a study endpoint. Access to pain medication \& study doctor will be the same as any total knee arthroplasty regardless of study participation."
62060602|NCT01087996|EXPERIMENTAL|Auto-hMSCs|Participants will receive an injection of 20 million, 100 million or 200 million autologous human mesenchymal stem cells.
62847165|NCT05818969|NO_INTERVENTION|Control Care Group|"No Intervention: Control Care Group~Patients will receive questionnaires to establish their attitudes/beliefs toward hypnosis, baseline pain, anxiety, \& knee function. 7 days prior to surgery, they will receive a pre-recorded video (-19 min) of guided information to be watched at least 1x/day, until surgery. Postoperative course will be otherwise completely standard of care, including a clinic visit at 10 days after surgery, where they will be given these same questionnaires. Patients will answer them again on postoperative day 49, constituting a study endpoint. Access to pain medication \& study doctor will be the same as any total knee arthroplasty regardless of study participation."
62847166|NCT03667456|EXPERIMENTAL|Self-rehabilitation by digital support|"Provision to patients selected by doctors or physiotherapists of an interactive digital tool (tablet + inertial sensor) to support self-rehabilitation home Parkinson's patients.~Monitoring and regulation of remote self-reeducation by tele-reeducation. Evaluation of the acceptance of the tool and the quality of life of the patients by questionnaire at day 0, and two and twelve months after."
62847167|NCT03719924|EXPERIMENTAL|arm A: ONIVYDE|ONIVYDE ONIVYDE will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14 ONIVYDE: 80 mg/m² intravenous over 90 minutes Folinic acid: 400 mg/m² intravenous over 30 minutes or L-folinic acid (racemic form L) 200 mg/m² over 30 minutes 5-FU: 2400 mg/m² over 46 hours
62847168|NCT03719924|ACTIVE_COMPARATOR|Arm B: TAXOL|TAXOL Premedication consists of corticosteroids, H1 antihistamines and H2 antagonists during 30 minutes at time 1 hour before chemotherapy One cycle every 28 days (D1=D28) 80 mg/m2 IV over 60 minutes at D1, D8 and D15
62847169|NCT01697514|EXPERIMENTAL|Part A: LY2940680 (Dose Escalation)|LY2940680 administered orally once daily at escalating doses (92.5 milligrams per square meter \[mg/m\^2\] up to 370 mg/m\^2) for two 28 day cycles. Lower dose levels (23 mg/m\^2 and 46 mg/m\^2) may also be explored, if necessary. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
62847170|NCT01697514|EXPERIMENTAL|Part B: LY2940680 (Dose Confirmation)|LY2940680 administered orally once daily for two 28 day cycles. Dose based on Part A. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
62847171|NCT01519193|EXPERIMENTAL|Narrative Exposure Therapy|
62847172|NCT01519193|NO_INTERVENTION|No treatment control|
62847173|NCT01701232|ACTIVE_COMPARATOR|MabThera|Reference rituximab at a dose of 375 mg/m2 intravenously once a week for four weeks (on days 1, 8, 15 and 22)
62847174|NCT01701232|EXPERIMENTAL|BCD-020|Proposed rituximab biosimilar at a dose of 375 mg/m2 intravenously once a week for four weeks (on days 1, 8, 15 and 22)
62847175|NCT01040117|EXPERIMENTAL|Sensory-motor Integration Training|
62847176|NCT01040117|ACTIVE_COMPARATOR|Conventional neurorehabilitation|
62847177|NCT04137445|EXPERIMENTAL|Study Provided Diet|A group of complementary foods provided to participants by researchers.
62264703|NCT04065555|EXPERIMENTAL|CIVO Microdose Injection of TAK-981, Cetuximab, and Avelumab|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected one day (Cohort 1) or three days (Cohort 2) prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of TAK-981, cetuximab, avelumab, TAK-981 combined with cetuximab, or TAK-981 combined with avelumab. Each microdose is simultaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node. Approximately six patients will be assigned to each time point cohort. Cohort assignment is not sequential and will be selected by the Investigator based on clinic logistics and patient scheduling. Should one cohort fill in advance of the other, sites will be directed by Presage to enroll patients into the second cohort only.
62264704|NCT05214729|EXPERIMENTAL|Fast to Slow Group|The Fast to Slow Group corresponds to enrolled patients randomized, following the sequential crossover design, to first perform the fast UF challenge immediately after inclusion, followed by the slow UF challenge after a washout period of 24 hours.
62847178|NCT04137445|PLACEBO_COMPARATOR|Traditional Diet|No study foods provided to participants by researchers. Participants will eat a typical diet provided by caregivers.
62847179|NCT01616693|EXPERIMENTAL|Zinc and probiotic|Received daily zinc and probiotic supplements, in addition to rotavirus vaccine and trivalent oral polio vaccines.
62264705|NCT05214729|EXPERIMENTAL|Slow to Fast Group|The Slow to Fast Group corresponds to enrolled patients randomized, following the sequential crossover design, to first perform the slow UF challenge immediately after inclusion, followed by the fast UF challenge after a washout period of 24 hours.
62847180|NCT01616693|ACTIVE_COMPARATOR|Zinc alone|Received daily zinc and probiotic placebo supplement, in addition to rotavirus vaccine and trivalent oral polio vaccine.
62847181|NCT01616693|ACTIVE_COMPARATOR|Probiotic alone|Received daily zinc placebo and probiotic supplement, in addition to rotavirus vaccine and trivalent oral polio vaccine.
62847182|NCT01616693|PLACEBO_COMPARATOR|Placebo|Received daily zinc placebo and probiotic placebo, in addition to rotavirus vaccine and trivalent oral polio vaccine.
62847183|NCT02246465|EXPERIMENTAL|RXI-109|RXI-109 dosed at the site of the revised hypertrophic scar
62847184|NCT02451215|EXPERIMENTAL|Laser interstitial thermotherapy (LITT) treated patients|All patients enrolled on the trial will undergo LITT therapy per protocol. Side-effects and outcomes will be monitored and compared with disease matched historical controls.
62847185|NCT06131060|EXPERIMENTAL|Progressive eccentric exercises|"Group A will perform progressive eccentric exercises that includes eccentric squats, Nordic hamstring curls and reverse Nordic hamstring curls.~Three sessions per week for 6 weeks."
62847186|NCT06131060|EXPERIMENTAL|Bodyweight exercises|"Group B will perform bodyweight exercises that includes Bulgarian split squat, Glut-Ham bridge, sliding leg curl.~Three sessions per week for 6 weeks."
62060603|NCT01087996|EXPERIMENTAL|Allo-hMSCs|Participants will receive an injection of 20 million, 100 million or 200 million allogeneic human mesenchymal stem cells.
62060604|NCT06251986||ofatumumab|Subcutaneous ofatumumab in a real-world setting
62847187|NCT05670938||Non-seminomatous germ cell tumours, stage I low risk|No lymphadenopathy or metastases on the postoperative scan. Three consecutive blood drawings with normal tumour markers. Patients undergoing lymph node dissection as a second curative operation after an orchiectomy, can also be included in case that the postoperative scan shows no residual disease or metastases.
62847188|NCT05670938||Non-seminomatous germ cell tumours, stage I high risk|"After completion of one cycle of Bleomycin, etoposide and platinum (BEP). Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers.~No lymphadenopathy or metastases on the CT scan after completion of chemotherapy."
62847189|NCT05670938||Seminomatous germ cell tumours (after chemotherapy) with complete remission.|"Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers.~No lymphadenopathy or metastases on the CT scan after completion of chemotherapy."
62847190|NCT05670938||Non-seminomatous germ cell tumours (after chemotherapy) with complete remission.|"Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers.~No lymphadenopathy or metastases on the CT scan after completion of chemotherapy."
62847191|NCT02837107|ACTIVE_COMPARATOR|Supplement|The supplement (Mind Master) were custom prepared and donated by LR Healthy and Beauty Systems LTD. The supplement contained per 80ml, aloe barbadensis miller gel (USA/Mexico 36%), grape juice, Polygonum cuspidatum extract (that contain 10% resveratrol), green tea extract, 1.1 mg vitamin B1 (100% RDA), 2.5 µg vitamin B12 (100% RDA), 12 mg vitamin E (α - ΤΕ) (100% RDA), coenzyme Q10, 200 µg folic acid (100% RDA), ascorbic acid, 27.5 µg selenium (100% RDA), 4.2 mg iron (100% RDA).
62847192|NCT02837107|PLACEBO_COMPARATOR|Placebo|A look-alike placebo were prepared and donated by LR Healthy and Beauty Systems LTD. The placebo contained Aloe barbadensis Miller Gel (USA/Mexico 3.6%), ascorbic acid, and some excipients.
62847193|NCT05907213|EXPERIMENTAL|Loading dose Ketamine|Loading dose of ketamine in 3+3 MTD for 1 hour followed by maintenance 0.05mg/kg/hr ketamine 11-hour infusion.
62847194|NCT05526040|EXPERIMENTAL|Intervention|Standard medical nutrition therapy with Immunonutrition
62264706|NCT06444139|ACTIVE_COMPARATOR|Probiotics|
62264707|NCT06444139|PLACEBO_COMPARATOR|Placebo|
62264708|NCT03175666|EXPERIMENTAL|Nant TNBC|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
62448253|NCT03711955|EXPERIMENTAL|Instability training group (IRT)|Each IRT sessions are to last one hour, with time being allocated to a 10 minute warm up, consisting of static stretches, a 5 minute cool down, consisting of dynamic stretches, and a series of IRT exercises performed in a circuit setting over the duration of 40 minutes. In the sessions, five resistance exercises will be performed. A linear periodization will occur, in which the training load will progress from high-volume low-intensity to low-volume high-intensity loads over the duration of eight weeks to maximize training adaptations. Additionally, there will be a progressive increase in load/resistance by 1-2 lbs and the degree of instability of each exercise during the course of the eight week program. Unstable devices will be changed from the least unstable to the most unstable device throughout the program, but only when participants showed a considerable decrease in body sway/movement and force production increased when performing exercises.
62448254|NCT01384695|EXPERIMENTAL|Fluorescein|Confocal imaging using contrast agent fluorescein
62264709|NCT02517164||Fallers|patients aged 50 years and over who already fell
62264710|NCT02517164||At risk of falls|patients aged 50 years and over at risk of falls
62264711|NCT02656485|EXPERIMENTAL|Dose I|B244 Dose 1 (dose level \[cells/mL\] 20,000,000,000)
62264712|NCT02656485|EXPERIMENTAL|Dose II|B244 Dose 2 (dose level \[cells/mL\] 40,000,000,000)
62264713|NCT02656485|EXPERIMENTAL|Dose III|B244 Dose 3 (dose level \[cells/mL\] 80,000,000,000)
62264714|NCT02656485|PLACEBO_COMPARATOR|Placebo|Placebo to Match B244
62264715|NCT02011321|EXPERIMENTAL|clevidipine|Four-hour infusion of low-dose intravenous clevidipine in patients with moderate vasospasm after aneurysmal subarachnoid hemorrhage
62264716|NCT04778046|EXPERIMENTAL|PAH:|Clinical diagnosis of PAH (Group 1 PH) in the absence of severe chronic lung disease, left heart disease, chronic thromboembolism, sarcoidosis, sickle cell disease or other causes of non-Group 1 PH.
62264717|NCT04778046|EXPERIMENTAL|COPD-noPH|Clinical diagnosis of COPD in the absence of precapillary PH.
62264718|NCT04778046|EXPERIMENTAL|COPD-PH|Clinical diagnosis of COPD with precapillary PH
62264719|NCT04778046|EXPERIMENTAL|IPF-noPH|Clinical diagnosis of IPF in the absence of precapillary PH
62264720|NCT04778046|EXPERIMENTAL|IPF-PH|Clinical diagnosis of IPF with precapillary PH
62264721|NCT05284123|EXPERIMENTAL|Self-compassion intervention|Brief (20-minute) workshop with a self-compassion writing exercise and information about mental health resources available to students.
62264722|NCT05284123|EXPERIMENTAL|Mental health literacy intervention|Brief (20-minute) workshop with information and a written reflection about common mental disorders, and information about mental health resources available to students.
62448255|NCT01384695|EXPERIMENTAL|Proflavine hemisulfate|confocal imaging using contrast agent proflavine
62448256|NCT01693783|EXPERIMENTAL|Treatment (ipilimumab)|Patients receive ipilimumab IV over 90 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving objective response or stable disease continue to receive maintenance therapy comprising ipilimumab IV over 90 minutes once every 12 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
62448257|NCT02224456|EXPERIMENTAL|Tenofovir|Subjects will receive TDF 300 milligrams (mg) tablet once daily for 240 weeks in the study. Subjects who receive add-on rescue treatment may take LAM 100 mg, ETV 0.5 mg or LdT 600 mg per day upon investigator's decision in addition to TDF tablet.
62847195|NCT05526040|ACTIVE_COMPARATOR|Control|Standard medical nutrition therapy
62847196|NCT01510769|EXPERIMENTAL|lesinurad 400 mg + febuxostat 80 mg|
62847197|NCT01510769|EXPERIMENTAL|lesinurad 200 mg + febuxostat 80 mg|
62847198|NCT01510769|PLACEBO_COMPARATOR|placebo + febuxostat 80 mg|
62264723|NCT05284123|ACTIVE_COMPARATOR|Control|Brief (7-minute) workshop with information about mental health resources available to students.
62847199|NCT02428283|EXPERIMENTAL|Nerve block|Scalp nerve block was performed with 0.25% ropivacaine.
62621129|NCT05897827|EXPERIMENTAL|PLANTS|Schools will receive the online-delivered PLANTS intervention, which includes 3 asynchronous training modules and 3 synchronous group events.
62847200|NCT02428283|ACTIVE_COMPARATOR|Control|Remifentanil was administered intravenously.
62847201|NCT04974632|OTHER|localization|small, deep or ground-glass opacity (GGO) lung tumor, Mobile 3D C-arm CT assisted pre-operative localization, video-assisted thoracic surgery(VATS)
62847202|NCT04375462|EXPERIMENTAL|AspireAssist|"Gastrostomy tubes will be placed 1-2 days after enrollment. Questionnaires will be completed at 7 and 30 days, and the AspireAssist group will have a clinic visit at 7 days to have the skin-port placed.~All participants will be placed on a diet consisting of liquids and soft foods to prevent clogging of the gastrostomy tube"
62060605|NCT04045730|EXPERIMENTAL|Patients with metastatic pancreatic ductal adenocarcinoma|Patients must have histologically or cytologically confirmed pancreatic ductal adenocarcinoma, and all patients must have at least 15 unstained slides of formalin fixed paraffin embedded (FFPE) tumor tissue available or a pre-treatment core needle biopsy will be required as outlined in section 7.1.2.7. All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab in 4-week cycles.
62060606|NCT06065384|EXPERIMENTAL|intensive upper limb training|The intervention group receives 12 hours of motor training each week upon usual care during 10 weeks. This involves active and targeted motor training of all affected muscles below the injury level in the context of functional activities.
62060607|NCT06065384|OTHER|usual care|The control group receives only standard rehabilitation and care
62621130|NCT05897827|ACTIVE_COMPARATOR|EMAILS|Comparison schools will receive emails with publicly available resources for supporting LGBTQ+ students as a control intervention.
62621131|NCT05861206|ACTIVE_COMPARATOR|GT-MW group (5% Green tea), WT-MW group (5% White tea), EO-MW group (Listerine mouthrinse)|"Chronic gingivitis patients whose mechanical plaque control was supported with 5% Green tea. Each patient was instructed to use 15 mL of the mouthwash delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for 4 weeks.~Chronic gingivitis patients whose mechanical plaque control was supported with 5% White tea. Each patient was instructed to use 15 mL of the mouthwash delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for 4 weeks.~Chronic gingivitis patients whose mechanical plaque control was supported with Listerine mouthrinse. Each patient was instructed to use 15 mL of the mouthwash delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for 4 weeks."
62847203|NCT04375462|ACTIVE_COMPARATOR|Standard PEG|Gastrostomy tubes will be placed 1-2 days after enrollment. Questionnaires will be completed at 7 and 30 days All participants will be placed on a diet consisting of liquids and soft foods to prevent clogging of the gastrostomy tube
62847204|NCT00963118|PLACEBO_COMPARATOR|placebo|Rice powder based nutrition bar
62847205|NCT00963118|EXPERIMENTAL|Angelica keiskei|Angelica keiskei (green leafy vegetable) based nutrition bar
62847206|NCT00963118|EXPERIMENTAL|Glycine max|Glycine max (black soybeans) based nutrition bar
62847207|NCT00963118|EXPERIMENTAL|Angelica keiskei + Glycine max|Angelica keiskei (green leafy vegetable) and glycine max (black soybeans) based nutrition bar
62847208|NCT03133741|PLACEBO_COMPARATOR|Placebo|Saline
62847209|NCT03133741|OTHER|GIP-A|Infusion of GIP-A alone as study tool.
62847210|NCT03133741|OTHER|GLP-1 receptor antagonist Exendin[9-39]|Infusion of GLP-1 receptor antagonist Exendin\[9-39\] alone as study tool.
62060608|NCT01949233|EXPERIMENTAL|Irbesartan 150-300mg (and doxycycline placebo)|Irbesartan 150-300mg capsules daily for 6 months Doxycycline placebo capsules daily for 6 months
62060609|NCT01949233|EXPERIMENTAL|Doxycycline 100-200mg (and irbesartan placebo)|Doxycycline 100-200mg capsules daily for 6 months Irbesartan placebo capsules daily for 6 months
62060610|NCT01949233|EXPERIMENTAL|Irbesartan 150-300mg and doxycycline 100-200mg|Irbesartan 150-300mg capsules daily for 6 months Doxycycline 100-200mg capsules daily for 6 months
62847211|NCT03133741|OTHER|GIP-A + Exendin[9-39]|Infusion of GIP-A + GLP-1 receptor antagonist Exendin\[9-39\] together as study tools.
62060611|NCT01949233|PLACEBO_COMPARATOR|irbesartan and doxycycline placebo|Irbesartan placebo capsules daily for 6 months Doxycycline placebo capsules daily for 6 months
62847212|NCT03936790|OTHER|Ropi_dosing|The dose of ropivacaine for each parturient is determined by the response of the previous participant to a higher or lower dose according to the sequential distribution algorithm (up-down sequential allocation).
62847213|NCT05349006|EXPERIMENTAL|Azathioprine|"Azathioprine, dose related to weight (100 mg for \<50 kg, 150 mg 50-100 kg, 200 mg for \>100 kg), oral, daily~Associated to oral corticosteroid, prednisone : 40 mg per day during three months, and progressively tapered during three months until stop (- 30 mg during 15 days, 20mg during 15 days, 15 mg during 15 days, 10 mg during 15 days, 5 mg during 15 days and introduction of hydrocortisone 20 mg + Stop prednisone; hydrocortisone 20mg during 15 days, Stop hydrocortisone)"
62847214|NCT05349006|PLACEBO_COMPARATOR|Placebo|"Placebo, once a day, oral, number of caps related to weight~Associated to oral corticosteroid: prednisone 40 mg per day during three months and progressively tapered during three months until stop (- 30 mg during 15 days, 20mg during 15 days, 15 mg during 15 days, 10 mg during 15 days, 5 mg during 15 days and introduction of hydrocortisone 20 mg + Stop prednisone; hydrocortisone 20mg during 15 days, Stop hydrocortisone)"
62264724|NCT03472157|EXPERIMENTAL|Bariatric surgery|"Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy.~Decision of the surgery type will be made according to surgical expertise, habits of investigation centers and the patient's desire. All patients receive nutritional support and therapeutic education adapted to recommendations bariatric surgery care."
62264725|NCT03472157|ACTIVE_COMPARATOR|Lifestyle therapy|The group will received the medical standard treatment defined as lifestyle therapy combining diet with increased physical activity (standard treatment, control) (figure 1, design of study).
62264726|NCT04585464|EXPERIMENTAL|Healthy Volunteer: Single Ascending Dose|"Single oral ascending dose in healthy volunteers~Interventions:~Drug: EDG-5506 Drug: Placebo"
62264727|NCT04585464|EXPERIMENTAL|Healthy Volunteer: Multiple Ascending Dose|"Multiple oral ascending doses in healthy volunteers~Interventions:~Drug: EDG-5506 Drug: Placebo"
62847215|NCT01856218|EXPERIMENTAL|UX003|"During the initial 14-week treatment period of the study, participants receive 2 mg/kg UX003 every other week (QOW) for 12 weeks. At Week 14, participants continue on UX003 therapy and begin a forced dose titration period for an additional 24 weeks at the dose sequence of 1, 4, and 2 mg/kg UX003 QOW as follows: 1 mg/kg UX003 for 8 weeks beginning on Week 14; then 4 mg/kg UX003 for 8 weeks beginning on Week 22; then 2 mg/kg UX003 for 8 weeks beginning on Week 30. Following the 24 week forced dose titration period, participants who continue on treatment (continuation period) received 2 mg/kg UX003 QOW beginning at Week 38 for up to an additional 36 weeks.~After the first phase of the study, participants who elect to continue drug treatment are transitioned to the long-term extension phase, where they are treated with UX003 at 4 mg/kg beginning at Week 74, for up to an additional 168 weeks."
62847216|NCT06164639||Reflux aspiration group|Reflux aspiration group
62060612|NCT00954226|EXPERIMENTAL|Arm I (standard-dose erlotinib hydrochloride)|Patients receive standard-dose erlotinib hydrochloride PO QD for 2-3 weeks (up to 8 weeks if surgery is delayed).
62060613|NCT00954226|EXPERIMENTAL|Arm II (high-dose erlotinib hydrochloride)|Patients receive high-dose erlotinib hydrochloride PO QD for 2-3 weeks (2-8 weeks for current smokers or up to 8 weeks if surgery is delayed).
62264728|NCT04585464|EXPERIMENTAL|Becker Muscular Dystrophy: Multiple Ascending Dose|"Multiple oral ascending doses in adults with Becker muscular dystrophy~Interventions:~Drug: EDG-5506 Drug: Placebo"
62847217|NCT06164639||Non-reflux aspiration group|Non-reflux aspiration group
62060614|NCT05741099|EXPERIMENTAL|MSCs group|Patient in Mscs group will receive MSCs implantation by intravenous injection Within 10-15 days of infection
62060615|NCT05741099|PLACEBO_COMPARATOR|comparator|Patients in comparator group will receive placebo treatment Within 10-15 days of infection
62060616|NCT03841955|EXPERIMENTAL|Experimental group|Peripheral implantation of central venous catheters and accessories with high pressure tolerance
62448258|NCT02925273|OTHER|Standard|Prospective, grasp techniques will be compared in each patient from the experimental group using a palmar grasp without dorsal stimulation and a standard palmar grasp test with dorsal stimulation on the same patient as the control group
62448259|NCT00800059|EXPERIMENTAL|Treatment|Treatment with TMI and autologous Stem Cell transplant
62448260|NCT03756909||adenoidectomy group|Operations of adenoidectomy
62448261|NCT03756909||adenotonsillectomy group|Operations of adenotonsillectomy
62448262|NCT03405285|EXPERIMENTAL|Connected Catheter Feasibility Study|Clinical Feasibility Evaluation of Connected Catheter Wireless Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
62448263|NCT05166330|ACTIVE_COMPARATOR|ketofol 1:1|0.15-0.2 mL/kg from of 5 mg/mL propofol and 5 mg/mL ketamine mixture
62448264|NCT05166330|ACTIVE_COMPARATOR|ketofol 1:3|0.15-0.2 mL/kg from of 7.5 mg/mL propofol and 2.5 mg/mL ketamine mixture
62448265|NCT01691859|EXPERIMENTAL|Mepolizumab|Subjects will receive 100 mg of mepolizumab (in 1ml polypropylene syringe) injected subcutaneously (SC) approximately every 4 weeks.
62448266|NCT01989507|EXPERIMENTAL|Very low nicotine content cigarettes|Cigarettes with Nicotine Yield 0.07 ± 0.02
62448267|NCT01989507|ACTIVE_COMPARATOR|Conventional nicotine content cigarettes|Cigarettes with Nicotine Yield 0.8 ± 0.15
62621132|NCT05861206|ACTIVE_COMPARATOR|CHX-MW group (0.12% CHX, as a positive control group)|Chronic gingivitis patients whose mechanical plaque control was supported with 0.12% CHX. Each patient was instructed to use 15 mL of the mouthwash delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for 4 weeks.
62621133|NCT05231070|EXPERIMENTAL|TeleSPC|"Patients will be offered regular multidisciplinary video consultations with the SPC team and these patients and their informal caregiver will also be offered a dyadic psychological intervention.~Regular multidisciplinary video consultations with multidisciplinary team, involvering cooperation between the section og Palliative medicine and the Department of Oncology, District nurse and the general practitioner.~Operationel definition of informal caregiver: Patients will designated the closest person involved in their care (e.g., spouse, son/daughter, other relatives, and friends)."
62264729|NCT01042860|ACTIVE_COMPARATOR|supplement|lutein supplement
62448268|NCT01364870|ACTIVE_COMPARATOR|Active TENS|High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
62448269|NCT01364870|PLACEBO_COMPARATOR|Placebo TENS|"Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working."
62448270|NCT01364870|NO_INTERVENTION|Standard Care|"Subjects randomized to Standard Care will be given no TENS unit."
62448271|NCT03987152|OTHER|Sirolimus|Sirolimus administration: during Challenge and Rechallenge phase. Compared with the period 2 months before start of Sirolimus.
62448272|NCT02051803|EXPERIMENTAL|Distress Tolerance Treatment for Weight Concern (DT-W)|DT-W is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes distress tolerance intervention for weight concern plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
62448273|NCT02051803|ACTIVE_COMPARATOR|Health Education (HE)|HE is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes smoking health education program plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
62448274|NCT01508936|PLACEBO_COMPARATOR|Placebo|Placebo intravenous injection every 4 weeks for a total of 4 doses.
62448275|NCT01508936|EXPERIMENTAL|Reslizumab 3.0 mg/kg|Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses.
62847218|NCT05012384|EXPERIMENTAL|Vergence exercises|Orthoptic vergence exercises
62847219|NCT05012384|PLACEBO_COMPARATOR|Generic treatment|
62060617|NCT03841955|EXPERIMENTAL|Control group|Peripheral intubation of central venous catheter
62264730|NCT01042860|PLACEBO_COMPARATOR|placebo|Placebo
62264731|NCT00584155|PLACEBO_COMPARATOR|1|Each patient will receive a bottle containing normal saline and 0.03% ofloxacin.
62448276|NCT03295643|OTHER|Mobile smoking cessation program|Mobile smoking cessation program delivered through an app with access to a breath sensor device and coaching support.
62448277|NCT02989142|NO_INTERVENTION|Control arm|No intervention
62448278|NCT02989142|EXPERIMENTAL|INTER-ACT arm|"Four pre-conception coaching sessions : postpartum week 6, week 8, week 12, 6 months.~Three pregnancy coaching sessions: at the time of the planned ultrasound scans."
62448279|NCT00506753|EXPERIMENTAL|MI/CBT|Motivational Interviewing followed by Cognitive Behavior Therapy
62448280|NCT00506753|EXPERIMENTAL|RT/TU|Relaxation Training followed by Treatment as Usual
62448281|NCT03581474|OTHER|aScope 3 Large|Bronchoscopic procedure
62448282|NCT02240758|EXPERIMENTAL|surgical removal of the tumors+stereotaxic biopsy|
62621134|NCT05231070|NO_INTERVENTION|Control|Patients will follow the current practice in the healthcare system (standard care). Control patients will be offered information to clarify the options available in case of unmet palliative needs. Patients' informal caregiver will be invited to participate in the study, but no intervention will be offered.
62060618|NCT03997513|EXPERIMENTAL|Pulmonary Telerehabilitation Intervention Group|The intervention will consist of an eight-week, three sessions per week, home-based pulmonary telerehabilitation program that will incorporate both lower extremity endurance exercise and upper and lower extremity resistance training. Subjects randomized to the study intervention will also participate in a one hour, twice-monthly support group via group video conferencing consisting of an educational topic (i.e. inhaler use, understanding COPD) and group discussion.
62060619|NCT03997513|NO_INTERVENTION|Usual Care Group|Participants randomized to the usual care arm will also be enrolled in our institution's telehealth program, will receive an automatic blood pressure monitor, portable pulse oximeter, and scale and will be in regular contact with a telehealth provider. A study team member will meet with participants randomized to the usual care arm to discuss the importance of exercise and will encourage exercise (strength training, light aerobic activity such as walking or cycling) a minimum of 20-40 minutes three times per week at discharge.
62060620|NCT02017080||Hyperthyroid pregnant women|Autoimmune hyperthyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound clinical examination
62264732|NCT00584155|EXPERIMENTAL|2|Each patient will receive a bottle containing Lactated Ringer's solution and 0.03% ofloxacin.
62060621|NCT02017080||Hypothyroid pregnant women|Autoimmune hypothyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination
62264733|NCT03646851|EXPERIMENTAL|COPD|COPD patients GOLD stage III and IV
62847220|NCT03928977|OTHER|Confirmed TIA|Confirmed TIA at 3 months with standardized neurological expertise
62847221|NCT03928977|OTHER|Confirmed non-TIA|Not-confirmed TIA at 3 months with standardized neurological expertise
62060622|NCT02017080||Healthy pregnant women|Euthyroid women with uncomplicated pregnancies, with antithyroid antibodies within reference ranges
62060623|NCT03857568|EXPERIMENTAL|SHR0410 group|SHR0410 will be dosed
62060624|NCT03857568|EXPERIMENTAL|Placebo|Placebo will be dosed
62060625|NCT00886028|EXPERIMENTAL|Liposomal doxorubicin|Thirty patients with MPM who received liposomal doxorubicin 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles.
62264734|NCT01950871|OTHER|single arm study|Prostate HistoScanning (HS) analysis with HS-guided biopsy will be used to sample two cores per suspicious area (displayed as red on an imaging monitor), up to a maximum of 3 suspicious areas per subject. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero (if no suspicious area is identified) up to a maximum of 6 cores.
62264735|NCT03101228|EXPERIMENTAL|Reduced sitting|Objectively measured daily inactive time will be reduced by one hour compared to the baseline.
62264736|NCT03101228|NO_INTERVENTION|Control|Subjects will be guided to maintain their normal sedentary behaviour and physical activity habits.
62264737|NCT06388655|EXPERIMENTAL|MNF active group|In this study, neurofeedback headsets developed by OmniCNS were utilized, employing a dry EEG method to measure EEG signals at a rate of 250Hz. Signals were then transformed into the frequency domain through Fourier transform, allowing assessment of power across a wide range of frequencies. Feedback activities, like levitation or running, were based on attention levels determined by the Low beta + Middle beta / Theta Power ratio. Participants received training and engaged in neurofeedback games through the Omnifit Brain app using the provided headsets and personal smartphones for 12 weeks, three times a week for 10-20 minutes per session. Four game types based on the theta/beta ratio were offered, allowing participants to choose freely.
62264738|NCT06388655|SHAM_COMPARATOR|sham control group|The sham neurofeedback was implemented through presenting randomized game outcomes, independent of real measurements. The scoring distribution was meticulously adjusted to achieve a realistic spectrum of results, prioritizing median scores to uphold uniformity in user experience.
62621135|NCT01917695|ACTIVE_COMPARATOR|Concurrent Radical Chemoradiation|Paclitaxel(175 mg/sq.m) + Cisplatin (75 mg/sq.m) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT + Brachytherapy (7Gy HDR x 3 doses) All to be completed within 8-10 weeks
62847222|NCT05570461|EXPERIMENTAL|Experimental Group|Experimental group will receive Modified Constraint-Induced Movement Therapy and traditional physical therapy to the impaired upper limb based on the repetitive training of functional activities and behavioral shaping and a task-oriented approach, while the unaffected arm of subjects in the Modified Constraint-Induced Movement Therapy group will be constrained by wearing a mitten during the treatment session
62847223|NCT05570461|ACTIVE_COMPARATOR|Control Group|Control group therapy will consist of increasing upper limb function with the use of both hands. The session include active or active assistive range of motion exercises, unilateral and bimanual activities, balance and strength training or coordination exercises depending on the severity of motor impairment. Similar to group A, daily therapy will be conducted for 40 min/day, 6 days/ week for upto 2 weeks.
62847224|NCT00015834|EXPERIMENTAL|Treatment (imatinib mesylate, cytarabine)|Patients who have not previously received imatinib mesylate receive oral imatinib mesylate daily on days 1-35. Patients who have previously received imatinib mesylate for at least 28 days receive oral imatinib mesylate on days 22-35. All patients receive cytarabine IV over 2 hours every 12 hours on days 29-32. Patients with more than 5% residual blasts in bone marrow on day 28 receive a second course in the absence of disease progression or unacceptable toxicity.
62847225|NCT03488264||United States|50 participants will be recruited from the United States.
62847226|NCT03488264||Jamaica|50 participants will be recruited from Jamaica.
62060626|NCT02331719||MiSPACE Eligible Cohort|This will be a prospective record review of patients where the MiSPACE technique is being/was used for the treatment of their ICH.
62264739|NCT05627063|EXPERIMENTAL|ABSK121-NX|"Dose escalation of oral ABSK121-NX will be guided by the Bayesian optimal interval (BOIN) design based on safety data collected until a maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified. Patients will receive a single dose of ABSK121-NX on Day -7 followed by a 7-day washout, as a run-in period to access the safety and PK of ABSK121-NX. Then, patients will continuously receive ABSK121-NX once daily (QD).~The dose escalation will start at 3 mg QD followed by dose escalation of a total of 8 potential dose levels. Once RDE is determined, an RDE-confirmation group of up to 24 more patients may be enrolled at the selected dose levels to further evaluate safety and efficacy (up to 12 per dose level/regimen), if approved by the sponsor. In addition, a preliminary food-effect (FE) may be evaluated in at least 6 patients from the RDE- confirmation part.~After the RDE is confirmed in the dose Escalation part, the dose Expansion phase will be conducted."
62621136|NCT01917695|EXPERIMENTAL|Neoadjuvant Chemoradiation + Radical Hysterectomy|Paclitaxel(175 mg/m2) + Cisplatin(75 mg/m2) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT - completed within 5 weeks Radical Hysterectomy - 3 weeks after completion of RT All to be completed within 8-10 weeks
62621137|NCT01917695|EXPERIMENTAL|Neoadjuvant Chemotherapy + Radical Hysterectomy|Paclitaxel(175 mg/m2) + Cisplatin (75 mg/m2) chemotherapy - 3 cycles of 3 weekly cycle Radical Hysterectomy - 3 weeks after completion of chemotherapy All to be completed within 8-10 weeks
62448283|NCT00766584||PROOF cohort|This cohort is the same than the PROOF study (NCT00759304). Subjects were recruited amongst the inhabitants of the city of Saint-Etienne, France, and were eligible if aged 65 at the inclusion date in the PROOF study
62448284|NCT05152641|EXPERIMENTAL|BGE-117 4mg|BGE-117 4mg, Capsules, Oral-administered Once Per Day up to 12 weeks Ferrous sulfate 325mg, Tablets, Oral-administered 3 Times Per Week up to 12 weeks
62448285|NCT05152641|EXPERIMENTAL|BGE-117 8mg|BGE-117 8mg, Capsules, Oral-administered Once Per Day up to 12 weeks Ferrous sulfate 325mg, Tablets, Oral-administered 3 Times Per Week up to 12 weeks
62448286|NCT05152641|EXPERIMENTAL|BGE-117 16mg|BGE-117 16mg, Capsules, Oral-administered Once Per Day up to 12 weeks Ferrous sulfate 325mg, Tablets, Oral-administered 3 Times Per Week up to 12 weeks
62448287|NCT05152641|PLACEBO_COMPARATOR|Placebo|Matching Placebo Capsules, Oral-administered Once Per Day up to 12 weeks Ferrous sulfate 325mg, Tablets, Oral-administered 3 Times Per Week up to 12 weeks
62448288|NCT05775913|EXPERIMENTAL|Tubal Selective Delivery System|The same intervention will be used for all study subjects.
62448289|NCT02625948|ACTIVE_COMPARATOR|tranexamic acid|tranexamic acid
62448290|NCT02625948|PLACEBO_COMPARATOR|Placebo|0.9% NaCl
62448291|NCT02625948|NO_INTERVENTION|observation(spot sign -)|regular clinical treatment
62060627|NCT02331719||Historical Cohort|This is a retrospective records review of patients who received either medical intervention or conventional surgical intervention for the treatment of their ICH.
62448292|NCT04223050|ACTIVE_COMPARATOR|High oxygen saturation|Peripheral oxygen saturation level \>94%
62448293|NCT04223050|ACTIVE_COMPARATOR|Low oxygen saturation|Peripheral oxygen saturation level 88-92%
62448294|NCT03496870|EXPERIMENTAL|Opicapone once daily with Carbidopa/Levodopa|Opicapone administered once daily for 14 days; carbidopa/levodopa administered at set frequency on Study Days 1, 2 \& 15
62448295|NCT04604665|EXPERIMENTAL|High frequency postural change|"Repositioning or rotation of patients hospitalized in bed in intensive care units will be carried out with a frequency interval that we call high-frequency. It has to be performed on each patient between an interval less than or equal to every 2 hours in a full day (24 hours) (minimum goal of 8-10 in 24 hours subtracting 2 or 4 at night and not alter the circadian cycle). The position must be modified in each postural change to the right lateral, supine, left lateral, supine, or prone position to supine position. The repositioning will be provided until a patient is discharged from ICU, die or begin ambulation. When providing each repositioning, avoid dragging the patient, the shear, and the friction to increase UPP risk. This must be applied to avoiding massage. Patients in any position should use pressure-reducing items such as pillows."
62621138|NCT01215435|EXPERIMENTAL|Pre-breakfast BIAsp 30|
62621139|NCT01215435|EXPERIMENTAL|Pre-dinner BIAsp 30|
62847227|NCT04834622|EXPERIMENTAL|Melodies for Mums|Mothers will start a block of 10-week classes and continue with their group for the duration of the course. Classes will take place in Children's Centres (or online). Mothers will attend with their babies and will sit in a socially-distanced circle on the floor surrounded by soft play cushions and mats. Classes will start with welcome songs, introducing everyone to one another, and involve a range of singing and music activities. Mothers will be required to respect social distancing guidelines. Music activities will include learning songs from around the world and will be accompanied by instruments that the mothers and babies can play together. Instruments will not be shared and will be disinfected before and after the singing sessions. Mothers will also work to write some of their own songs over the weeks. Recordings of the group singing the songs together will be made for the mothers to listen to at home. Classes will be led by professional workshop leaders trained by Breathe.
62060628|NCT02491021|ACTIVE_COMPARATOR|Treatment Group|Treatment Group (TG) The TG underwent a 7-week outpatient rehabilitation programme comprising both exercise and education sessions under the direct supervision of the physiotherapy team. The exercise intervention was 20 minutes, 3x/week (1 supervised, 2 self directed) titrated to a specific intensity based on risk stratification - highvs low risk). The intervention also included 6 x 1 hour education sessions.
62264740|NCT00956670|EXPERIMENTAL|Supportive care (lymphedema assessment)|"Patients with vulvar cancer undergo a radical vulvectomy or hemi-vulvectomy followed immediately by an ipsilateral or bilateral inguinal-femoral lymphadenectomy. (Closed to accrual as of June 9, 2014)~Patients with cervical cancer undergo a radical hysterectomy or trachelectomy and bilateral pelvic lymphadenectomy +/- para-aortic nodal sampling via vaginal, laparoscopic, or open route.~Patients with endometrial cancer undergo a laparoscopic-assisted vaginal hysterectomy, a total laparoscopic hysterectomy, or total abdominal hysterectomy with pelvic lymphadenectomy +/- para-aortic node sampling.~Patients undergo limb measurements at baseline, weeks 4-6, and at 3, 6, 9, 12, 18, and 24 months."
62621140|NCT02707172|EXPERIMENTAL|Intervention|"Subject was first exposed to 1000 microgram of diethylhexyl phthalate on both hands, and was asked to perform the intervention, handwashing with soap, by a standardized hand washing technique.~Then the subjects in this arms are crossover to receive placebo, handwashing with water only."
62621141|NCT02707172|PLACEBO_COMPARATOR|Placebo|"Subject was exposed to 1000 microgram of diethylhexyl phthalate on both hands, and was asked to perform the placebo, handwashing with water, by a standardized hand washing technique.~Then the subjects in this arms are crossover to perform the intervention, handwashing with soap."
62847228|NCT04834622|ACTIVE_COMPARATOR|Control (mother-baby community sessions)|Our control group will be a 'active' control. During the first 10 weeks (during the study period), mothers in the control group will receive details of other non-music classes available to them in the community (or online if necessary, depending on the programs available at the time and government guidelines) and will receive the same schedule of texts and phone calls to encourage them to join these activities. They will still be seen by the researchers to collect clinical measures and biological samples (including the pre-post saliva samples) and to monitor engagement in other activities. Following the first 10 weeks, the mothers in the control group will be offered a place on the singing programme, but these data will not be part of the study, and they will not join groups with women who are in the study
62847229|NCT03855826|EXPERIMENTAL|Nifekalant Hydrochloride|Nifekalant hydrochloride (50mg) should be dissolved into a 50ml dilution solution (0.9% sodium chloride injection or 5% glucose injection), and configured as 1mg/ml solution of nificaine hydrochloride. The dosage should be taken as needed. The diluted solution should be used within 24 hours. The amount of fluid per hour should not exceed 50ml when intravenously infused. It is recommended to use intravenous pump.
62847230|NCT03855826|ACTIVE_COMPARATOR|Amiodarone|The concentration of more than 2 ampoule amiodarone injection in 500 ml (only isotonic grape solution) is suitable. Amiodarone should be administered as far as possible via the central venous route (administered separately).
62847231|NCT04748367|EXPERIMENTAL|Intervention group|Children wear VR headset during immunisation
62847232|NCT04748367|NO_INTERVENTION|Control group|Children did not wear VR headset during immunisation( usual care)
62060629|NCT02491021|NO_INTERVENTION|Control Group|Control Group (CG) The CG received physiotherapy, exercises and education as per current standards of practice in our institution up until hospital discharge. Following discharge no further specific input or education was provided. Participants were contacted at least once during the study period to check on their general well being and to encourage attendance at the second assessment by the physiotherapy team. In line with the ethical requirements for the study, all control subjects were offered the chance to participate in the rehabilitation programme once their trial participation was completed following second assessment.
62264741|NCT04155749|EXPERIMENTAL|ARM 1|Phase I study of BCMA-specific CAR-modified T-cell therapy using alternative binding domain, for the treatment of patients with relapsed and refractory multiple myeloma
62264742|NCT04891315||Pregnant women|Women aged 16+ in early pregnancy (before 20 weeks of gestation).
62621142|NCT02935296|NO_INTERVENTION|Control|Standard of Care
62621143|NCT02935296|EXPERIMENTAL|Integrated Intervention|Standard of care plus an integrated system of psychosocial counseling and systems navigation for HIV treatment and Substance Use treatment
62621144|NCT02057432|EXPERIMENTAL|Intra-operative MRI|Images will be obtained both before and after intravenous bolus injection with subsequent dynamic imaging. Dynamic contrast enhancement maps will be created for evaluation of residual tumor. Images will be reformatted into three orthogonal planes as well as into a 3D model for surgical orientation. All imaging protocols using contrast, contrast enhancement maps and reformatting, as described above, which will be applied to the intra-operative MRI performed in the AMIGO suite are consistent with the standard MRI breast imaging at Brigham and Women's Hospital.
62621145|NCT03148067||Patients|Patients with closed or open diaphyseal femoral and tibial fractures treated through intramedullary nailing for fracture fixation
62621146|NCT00561535|EXPERIMENTAL|A|Lactobacillus FARCIMINIS
62621147|NCT00561535|PLACEBO_COMPARATOR|B|Placebo
62621148|NCT06612918|EXPERIMENTAL|high-intensity laser acupuncture and the exercise program|The patients will receive high-intensity laser acupuncture and the exercise program three times a week for four weeks.
62847233|NCT01931371|ACTIVE_COMPARATOR|Recurrent anal fistula|Patients with a complex anal fistula that recurred after surgery with an Anal Fistula Plug or and Endorectal Advancement Flap
62847234|NCT01931371|ACTIVE_COMPARATOR|No recurrence of anal fistula|Patients with a complex anal fistula that did not develop recurrence after surgery with an Anal Fistula Plug or and Endorectal Advancement Flap
62847235|NCT01433380|EXPERIMENTAL|600 mg PF-05175157|Subjects will receive one dose of PF-05175157. The sequence of receiving 600 mg PF-05175157 or placebo will be randomized.
62847236|NCT01433380|PLACEBO_COMPARATOR|Placebo|Subjects will receive one dose of placebo. The sequence of receiving placebo or 600 mg PF-05175157 will be randomized.
62847237|NCT01696513|EXPERIMENTAL|Subcision & Suction|Standard treatment for acne scars followed by suction.
62847238|NCT01696513|ACTIVE_COMPARATOR|Subcision|Standard treatment for acne scars only
62060630|NCT01551004|EXPERIMENTAL|Cohort A|8 subjects (6 active, 2 placebo) receive a single oral dose of 100 mg CRS3123 or placebo
62621149|NCT06612918|SHAM_COMPARATOR|sham laser acupuncture and exercises program.|The patients will receive sham acupuncture laser and the exercise program three times a week for four weeks.
62621150|NCT03039465|EXPERIMENTAL|Modified Trans-Esophageal Prosthesis|Patients satisfying the selection criteria would be subjected to the insertion of the TEP and evaluated at subsequent time points for the success of the procedure.
62621151|NCT06222814|ACTIVE_COMPARATOR|Reconstruction group|Patients with ACL injury and antero-lateral knee instability undergo ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft
62621152|NCT06222814|ACTIVE_COMPARATOR|Tenodesis group|Patients with ACL injury and antero-lateral knee instability undergo ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire).
62621153|NCT03662035|EXPERIMENTAL|single-arm|Apatinib and S-1 Patients will be offered with Apatinib (500mg/d) and S-1 (60mg/d for BSA\<1.25m2, 80mg/d for 1.25\<BSA\<1.5m2, and 100mg for BSA \>1.5m2) until their disease have progressed.
62621154|NCT03635008|EXPERIMENTAL|Anodal tDCS|"This group will receive the 25 mins of the tDCS (Yrain, Korea) over the contralesional premotor area simultaneously with 25 mins of the robotic arm training using Armeo Power (Hocoma, Switzerland), per day. Additional 30 mins of occupational therapy focusing on the arm motor recovery will be provided per day. These interventions will be provided for 10 weekdays. Other conventional rehabilitation (e.g. gait training, speech therapy) will be permitted.~Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA."
62621155|NCT03635008|PLACEBO_COMPARATOR|sham tDCS|"This group will receive the 25 mins of the tDCS (Yrain, Korea) over the contralesional premotor area simultaneously with 25 mins of the robotic arm training using Armeo Power (Hocoma, Switzerland), per day. Additional 30 mins of occupational therapy focusing on the arm motor recovery will be provided per day. These interventions will be provided for 10 weekdays. Other conventional rehabilitation (e.g. gait training, speech therapy) will be permitted.~Regard to the sham tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be started but the intensity will decrease and stop in 30 seconds."
62264743|NCT03958162|EXPERIMENTAL|uniportal and tubeless video assisted thoracic surgery|lung biospy by the uniportal and tubeless video assisted thoracic surgery
62621156|NCT04755894|EXPERIMENTAL|group A|
62621157|NCT04755894|ACTIVE_COMPARATOR|group B|
62060631|NCT01551004|EXPERIMENTAL|Cohort B|8 subjects (6 active, 2 placebo) receive a single oral dose of 200 mg CRS3123 or placebo
62060632|NCT01551004|EXPERIMENTAL|Cohort C|8 subjects (6 active, 2 placebo) receive a single oral dose of 400 mg CRS3123 or placebo
62264744|NCT03958162|EXPERIMENTAL|transbronchial lung cryobiopsy|transbronchial lung cryobiopsy
62621158|NCT04198142|EXPERIMENTAL|Imagery Rehearsal Therapy Intervention|This group receives one to two sessions of Imagery Rehearsal Therapy.
62621159|NCT04198142|ACTIVE_COMPARATOR|Treatment as Usual with dream diaries|This group receives the usual inpatient care without additional Imagery Rehearsal Therapy sessions, but also keeps dream diaries.
62621160|NCT05522946|EXPERIMENTAL|Parent and child without disability|Parent and child will play the game on the iPad using the sensors provided.
62621161|NCT05522946|EXPERIMENTAL|Parent and adolescent with mild to moderate cognitive or physical disability|Parent and adolescent will play the game on the iPad using the sensors provided.
62621162|NCT05522946|EXPERIMENTAL|Parent and adolescent with moderate to severe cognitive and/or physical disability|Parent and adolescent will play the game on the iPad using the sensors provided.
62621163|NCT05774002|NO_INTERVENTION|standard of care control groups no psychological intervention|standard of care control groups no psychological intervention
62060633|NCT01551004|EXPERIMENTAL|Cohort D|8 subjects (6 active, 2 placebo) receive a single oral dose of 800 mg CRS3123 or placebo
62060634|NCT01551004|EXPERIMENTAL|Cohort E|8 subjects (6 active, 2 placebo) receive a single oral dose of 1200 mg CRS3123 or placebo
62621164|NCT05774002|EXPERIMENTAL|psychological intervention ADAPT|The psychological intervention plan is based on the Aim to Decrease Anxiety and Pain Treatment (ADAPT) model.
62060635|NCT05999786|ACTIVE_COMPARATOR|patients receiving early rehabiliation swallowing program|the early rehabilitation program beginning from before to after surgery
62060636|NCT05999786|PLACEBO_COMPARATOR|patients not receiving early rehabilitation swallowing program|the Taiwan Dysphagia Society's publicly shared swallowing exercises for dysphagia, which is started from before to after surgery
62060637|NCT06197555|ACTIVE_COMPARATOR|Group A (Sodium Monofluorophosphate)|Dentifrice containing Sodium Monofluorophosphate, daily homecare usage Colgate®, Cavity Protection
62264745|NCT00714220||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
62264746|NCT00714220||Neurological Control|Subjects having been diagnosed with a non-ALS neurological condition
62264747|NCT00714220||Healthy Control|Subjects in good health without any neurological conditions
62060638|NCT06197555|ACTIVE_COMPARATOR|Group B (Stannous Fluoride)|Dentifrice containing Stannous Fluoride, daily homecare usage Oral B®, Gum Calm \& Sensitivity
62060639|NCT06197555|ACTIVE_COMPARATOR|Group C (Nano-Hydroxyapatite)|Dentifrice containing Nano-Hydroxyapatite, daily homecare usage ApaCare®
62060640|NCT06197555|ACTIVE_COMPARATOR|Group D (8% Arginine & Calcium Carbonate)|Dentifrice containing 8% Arginine \& Calcium Carbonate, daily homecare usage Colgate®, Sensitive Pro-Relief
62060641|NCT06426784||Low Perfusion index|Pregnant patients having baseline perfusion index less than 3.5 will be enrolled into this group.
62264748|NCT03917173|EXPERIMENTAL|Experimental|Prophylactic surgery plus HIPEC CO2 performed with mitomycin and cisplatin
62264749|NCT03917173|ACTIVE_COMPARATOR|Comparator|Standard surgery
62264750|NCT05785663||I|Subjects received Lysine hydrochloride 26 g ± 5% Arginine hydrochlordie 26 g ± 5% Amifostine trihydrate 0.65 g ± 5%
62060642|NCT06426784||High Perfusion index|Pregnant patients having baseline perfusion index ≥ 3.5 will be enrolled into this group.
62621165|NCT01548768|EXPERIMENTAL|Patients - DMARDs + TNF Inhibitors|Patients will receive a TNF inhibitor in addition to their current treatment in an open label protocol for increased disease activity and in the context of standard of care.
62621166|NCT01548768|ACTIVE_COMPARATOR|Patients - DMARDs only|Patients will receive their current treatment in an open label protocol in the context of standard of care.
62621167|NCT01548768|NO_INTERVENTION|Healthy Volunteers|Subjects without RA who will function as controls.
62621168|NCT04544839|EXPERIMENTAL|ADLC attachment in first phase|Each patient will receive 2 implants in the canine region. Three months later, each patient will be randomized and half of the patients will receive first the ADLC (test) device (first phase). In the second phase of the crossover trial (6 months after the start of the first phase), the attachments will be replaced. Patients previously allocated to the ADLC group will receive the LOC attachments.
62621169|NCT04544839|ACTIVE_COMPARATOR|LOC attachment in first phase|Each patient will receive 2 implants in the canine region. Three months later, each patient will be randomized and half of the patients will receive first the LOC (control) device (first phase). In the second phase of the crossover trial (6 months after the start of the first phase), the attachments will be replaced. Patients previously allocated to the LOC group will receive the ADLC attachments.
62621170|NCT04161105|EXPERIMENTAL|Rectus femoris dry needling group|The rectus femoris dry needling group will have their strength assessed. They will then receive one treatment of dry needling to a trigger point in their rectus femoris muscle. They will have their strength re-assessed 24, 48 \& 72 hours after dry needling.
62621171|NCT04161105|EXPERIMENTAL|Gluteus maximus dry needling group|The gluteus maximus dry needling group will have their strength assessed. They will then receive one treatment of dry needling to trigger points in their gluteus maximus muscle only. They will have their strength re-assessed 24, 48 \& 72 hours after dry needling.
62621172|NCT04161105|NO_INTERVENTION|Control|This group will receive no intervention. They will have their strength assessed at baseline and 24, 48 \& 72 hour follow-up
62621173|NCT00031772|NO_INTERVENTION|Control|Standard level of support after recurrence diagnosis
62621174|NCT00031772|EXPERIMENTAL|Intervention|Phone intervention for patients experiencing first recurrence with quality of life questionnaires, psychosocial assessment and care.
62621175|NCT02591030|PLACEBO_COMPARATOR|GEMCIS|
62621176|NCT02591030|EXPERIMENTAL|mFOLFIRINOX|
62847239|NCT06339268|EXPERIMENTAL|Intervention group|Patients included in the first group will be subjected to psychological testing and preoperative training with the aim of receiving tasks to improve cognitive functions. This technique involves several standardized tests of cognitive stimulation through the Cognifit application on a phone or tablet that patients use three times a week for 20 minutes for a month (from inclusion in the study to scheduled surgery). Also, after consultation with a physiatrist and testing for the presence of weakness syndrome as well as other tests related to the mobility and physical condition of patients, preoperative physical therapy (breathing exercises, walking, climbing stairs) will be carried out in this group of patients. Patients from this group, receive preoperative education on techniques and exercises that they will do immediately postoperatively in bed. Patients will keep a diary of preoperative activities that will be controlled by researchers.
62060643|NCT06619782|EXPERIMENTAL|Practice Facilitation|Practice facilitation is added to training in the suicide prevention pathway in primary care to provide implementation support for integrating the pathway into routine care
62264751|NCT05785663||II|Subjects received Lysine hydrochloride 39 g ± 5% Arginine hydrochlordie 39 g ± 5% Amifostine trihydrate 0.98 g ± 5%
62264752|NCT05785663||III|Subjects received Lysine hydrochloride 52 g ± 5% Arginine hydrochlordie 52 g ± 5% Amifostine trihydrate 1.3 ± 5%
62264753|NCT05785663||IV|Subjects received Lysine hydrochloride 60 g ± 5% Arginine hydrochlordie 60 g ± 5% Amifostine trihydrate 1.5 ± 5%
62621177|NCT04131582|EXPERIMENTAL|Empagliflozin + linagliptin + metformin plus lifestyle|Patients are randomized to receive for 12 months Linagliptin 2.5 mg + metformin 850 mg every 12 hours and empagliflozin 12.5 mg + metformin 850 mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90/150 min/week
62621178|NCT04131582|ACTIVE_COMPARATOR|Metformin plus lifestyle|Patients are randomized to receive for 12 months Metformin 850 mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the complete dose. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90/150 min/week
62621179|NCT02494648|EXPERIMENTAL|Inspiratory muscles strengthening|"The device used is : POWERbreathe Fitness Plus, (POWERbreathe International Ltd, UK).~Class I, CE labelled. POWERbreathe fitness Plus uses the technique of training against resistance to increase the strength, the power and the endurance of the respiratory muscles (diaphragm and rib cage)."
62621180|NCT02494648|PLACEBO_COMPARATOR|Control|No intervention
62621181|NCT02883621|ACTIVE_COMPARATOR|Group A|subjects receive standard upper endoscopy
62621182|NCT02883621|EXPERIMENTAL|Group B|subjects receive cap assisted upper endoscopy
62621183|NCT01386944||Neupro® Treatment|Routine treatment (1,2,3 mg/24 h) as per approved label in the European Union (EU).
62060644|NCT06619782|ACTIVE_COMPARATOR|Training Only|Primary care practices are trained in the National Institute of Mental Health (NIMH) youth suicide prevention pathway without practice facilitation
62264754|NCT06423573||Patients with dystrophic or junctional EB being treated with Filsuvez|Patients in this cohort will be receiving treatment with Filsuvez for their EB.
62264755|NCT06423573||Patients with dystrophic or junctional EB not being treated with Filsuvez|Patients in this cohort will be receiving treatment other than Filsuvez or no treatment at all for their EB.
62621184|NCT04186221|EXPERIMENTAL|Treatment arm|
62847240|NCT06339268|NO_INTERVENTION|Control group|Patients from the second group will be tested perioperatively with cognitive and weakness syndrome tests and other physiatry tests, but without cognitive intervention and physical therapy, they will be referred for surgery
62847241|NCT06148454|EXPERIMENTAL|Positive Psychology A & B|Module A and B
62060645|NCT05995301|EXPERIMENTAL|Group I|Transversus Abdominis Plane block
62060646|NCT05995301|EXPERIMENTAL|Group II|Local infiltration
62060647|NCT03379701||CRSwPolyps with no Eosonophilia|CRS patients with nasal polyposis, and no eosonophilia.
62060648|NCT03379701||CRSwPolyps with Eosonopholia|CRS patients with nasal polyposis and eosonophilia.
62060649|NCT03379701||CRS without Polyps|Patients with chronic rhinosinusitis and no nasalpolyposis.
62060650|NCT03379701||PCD|Patients with Primrary ciliary dyskinesia .
62060651|NCT03379701||AFRS|Patients with allergic fungal rhinosinusitis.
62448296|NCT04604665|ACTIVE_COMPARATOR|Conventional care|Repositioning or rotation of patients hospitalized will be the conventional or usual care. Units in this group are not going to receive any intervention. Will be only observed in their current intervention of repositioning.
62448297|NCT05830006|EXPERIMENTAL|main group|
62060652|NCT03379701||allergic rhinitis|Patients with allergic rhinitis
62060653|NCT03379701||Control|Healthy subjects.
62448298|NCT03583333|EXPERIMENTAL|IMI/REL FDC|Imipenem/cilastatin/relebactam (IMI/REL) administered intravenously (IV) as a fixed-dose combination (FDC) at a dosage of 500 mg IMI/250 mg REL, once every 6 hours for a minimum 7 days, up to 14 days. At the start of IMI/REL treatment, participants will be treated empirically with 600 mg open-label linezolid administered IV every 12 hours until methicillin-resistant Staphylococcus aureus (MRSA) is ruled out. Participants with confirmed MRSA infection will continue to receive 600 mg linezolid every 12 hours for a minimum of 7 days, up to 14 days total.
62448299|NCT03583333|ACTIVE_COMPARATOR|PIP/TAZ FDC|Piperacillin/tazobactam (PIP/TAZ ) administered IV as a FDC at a dosage of 4000 mg PIP/500 mg TAZ once every 6 hours for a minimum 7 days, up to 14 days. At the start of PIP/TAZ treatment, participants will be treated empirically with 600 mg open-label linezolid administered IV every 12 hours until methicillin-resistant Staphylococcus aureus (MRSA) is ruled out. Participants with confirmed MRSA infection will continue to receive 600 mg linezolid every 12 hours for a minimum of 7 days, up to 14 days total.
62621185|NCT00998205|OTHER|Dobutamine stress echo (DSE)|Dobutamine intravenous infusion would be undertaken starting at 10 micrograms/kg per minute in three minute intervals increased to 20, 30, 40 or 50 micrograms/kg per minute or to a peak heart rate response of at least 85% age predicted maximum heart rate. If at the end of the Dobutamine protocol, there is inadequate heart rate response, intravenous atropine boluses of 0.5 milligrams (maximum 1.0 mg) would be used as needed to achieve a heart rate of at least 85% of age predicted maximum heart rate.
62060654|NCT03857230|EXPERIMENTAL|Sequence A: Primapur - Gonal-F|Subjects were randomly assigned to receive treatment sequence A: single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Gonal-F.
62060655|NCT03857230|ACTIVE_COMPARATOR|Sequence B: Gonal-F - Primapur|Subjects were randomly assigned to receive treatment sequence B: single subcutaneous injection of 300 IU Gonal-F on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Primapur.
62060656|NCT05882175||OHI+ patients|Adult patients with hematologic malignancies that have sCD25\>3,900 U/mL and ferritin \>1,000 ng/mL
62060657|NCT05882175||OHI- patients|Adult patients with hematologic malignancies, with sCD25\>3,900 U/mL and/or ferritin \< 1,000 ng/mL
62060658|NCT01397994|ACTIVE_COMPARATOR|Nicorandil test arm|Nicorandil is given with atenolol therapy.
62060659|NCT01397994|ACTIVE_COMPARATOR|Atenolol control arm|Atenolol 50 mg OD is given.
62847242|NCT06148454|EXPERIMENTAL|Positive Psychology C & D|Module C and D
62060660|NCT05448547|EXPERIMENTAL|immediate curative therapy|Patients randomized to the intervention arm will receive immediate curative therapy in the form of either radiotherapy to the prostate in combination with hormone therapy (ADT or monotherapy) or surgery (radical prostatectomy). Standard treatment in this arm is radiotherapy + hormone therapy. Surgery is reserved for patients with strong preferences against radiotherapy.
62264756|NCT00732511|EXPERIMENTAL|1|Coreg Cr will be up-titrated as needed to achieve blood pressure \<130/80
62264757|NCT00732511|ACTIVE_COMPARATOR|2|Toprol XL will be up-titrated at weekly intervals to achieve a blood pressure \<130/80 mm Hg
62847243|NCT06148454|NO_INTERVENTION|Control Group with no intervention|
62060661|NCT05448547|ACTIVE_COMPARATOR|initial observation/ hormone therapy|Patients in this arm will either be observed (with localized high-risk prostate cancer) or receive hormone therapy (locally advanced prostate cancer; ADT or monotherapy). Further local or systemic therapy is given at doctor's discretion triggered by local or/ and systemic progression.
62060662|NCT01303120|ACTIVE_COMPARATOR|Femoral Nerve Block|
62847244|NCT03052400|EXPERIMENTAL|Mifepristone 600 mg daily|Mifepristone 300 mg po daily x 2 weeks, followed by mifepristone 600 mg po daily x 10 weeks
62847245|NCT03052400|PLACEBO_COMPARATOR|Placebo|Matching, blinded placebo 1 tablet po daily x 2 weeks, followed by matching, blinded placebo 2 tablets po daily x 10 weeks
62847246|NCT04851405|ACTIVE_COMPARATOR|Otago Exercise Programme+ Intervention Group (OEP+)|"Physiotherapists receive OEP training, a 2 hour workshop on the coaching protocol using the OEP app, and online training on the Brief Action Plan Approach with 2 telephone practice sessions with an experienced Brief Action Plan counsellor.~Each PT will deliver exercise program to 8 older adults. PTs will help older adults to set-up OEP app and Fitbit. PT will return bi-weekly over the course of two months (four visits total) for follow-up. During months 3-5, PTs will call participants three times times to review the exercise plan. The last visit will be an at-home visit which will occur 6 months after the initial visit. Between Months 7-12, PTs will continue to a phone call follow-up once a month to review the exercise routine.~Older Adults will receive an OEP manual and cuff weights to be used with the strength training. They will also have access to the OEP app which allows the PT to prescribe exercises and record the participant's exercise goal."
62060663|NCT01303120|ACTIVE_COMPARATOR|Combined Nerve Blocks|
62264758|NCT04096274|EXPERIMENTAL|LOCI (Intervention)|In clinics assigned to the LOCI condition, executives and first-level leaders will receive leadership training and coaching to support implementation of the OQ-A system. In addition, leaders and clinicians in this condition will receive training and technical assistance to implement the OQ-A measurement-based care system.
62264759|NCT04096274|ACTIVE_COMPARATOR|Training and Technical Assistance only (Control)|In clinics assigned to the control group, leaders and clinicians will receive training and technical assistance to implement the OQ-A measurement-based care system. In addition, to support enrollment in this condition, leaders in this condition will be offered access to general web-based leadership seminars.
62621186|NCT03011437||cases|Patients who undergo esophagogastroduodenoscopy during 01/12/2016 and 31/12/2016 in the First People's Hospital of Kashgar Region.
62847247|NCT04851405|PLACEBO_COMPARATOR|Otago Exercise Programme Group (OEP)|"Physiotherapists receive OEP Training and a 2 hour workshop on just the counselling protocol.~Each PT will deliver exercise program to 8 older adults. PTs will help older adults to set-up the Fitbit. For the first two months, PTs will provide bi-weekly home visits. During months 3-5, PTs will call participants three times times to review the exercise plan. The last visit will be an at-home visit which will occur 6 months after the initial visit.~Older Adults will receive an OEP manual and cuff weights to be used with the strength training. They will also receive a Fitbit. Between Months 7-12, older adults will receive follow-up phone calls from the research staff."
62060664|NCT01303120|ACTIVE_COMPARATOR|Patient-controlled analgesia|
62621187|NCT00272844|EXPERIMENTAL|Cholesterol supplementation|
62621188|NCT05216640|ACTIVE_COMPARATOR|High Flow Nasal Cannula|Standard operating procedures represented by high flow nasal cannula oxygen therapy
62621189|NCT05216640|ACTIVE_COMPARATOR|High Velocity Nasal Insufflation|Standard operating procedures represented by high velocity nasal insufflation therapy
62264760|NCT00457015|EXPERIMENTAL|DX-88 (ecallantide)|DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections.
62264761|NCT00457015|PLACEBO_COMPARATOR|Placebo|Placebo, Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.
62264762|NCT01553981|ACTIVE_COMPARATOR|Tadalafil|Tablet Tadalafil 20 mg every alternate day
62264763|NCT01553981|PLACEBO_COMPARATOR|Placebo|Tablet Placebo every alternate day
62264764|NCT05303545||All subjects with poliomyelitis sequelae|
62264765|NCT03991130|EXPERIMENTAL|High Dose IL-2 and Nivolumab|
62264766|NCT00678873|EXPERIMENTAL|Surgical group|Patients with ultrasound proven symptomatic cholelithiasis (gallstones).
62264767|NCT02125227|EXPERIMENTAL|Group 1 of Study A|single dosing of Rosuvastatin and Metformin 14 days later, single dosing of YH14755
62264768|NCT02125227|EXPERIMENTAL|Group 2 of Study A|single dosing of YH14755 14 days later, single dosing of Rosuvastatin and Metformin
62264769|NCT02125227|EXPERIMENTAL|Group 1 of Study B|single dosing of YH14755 with fasting state 14 days later, single dosing of YH14755 after having breakfast
62621190|NCT00534105||Gestational Diabetics|Patients with Gestational Diabetes
62621191|NCT00534105||2|Normal pregnant women without gestational diabetes
62621192|NCT05061901|OTHER|Sequence TR|19 subjects assigned to the sequence TR will receive a single 20 mg dose of the test product Lisinopril (1 x 20 mg tablet), marked as T in the sequence, in Period 1 and a single 20 mg dose of the reference product Zestril® (1 x 20 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62621193|NCT05061901|OTHER|Sequence RT|19 subjects assigned to the sequence RT will receive a single 20 mg dose of the reference product Zestril® (1 x 20 mg tablet), marked as R in the sequence, in Period 1 and a single 20 mg dose of the test product Lisinopril (1 x 20 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62621194|NCT04235842|NO_INTERVENTION|Control Group (CG)|The CG will receive the standard indications routinely provided by the hospital which consists in information about practice of regular physical activity according to World Health Organization. A leaflet with illustrations and indications will be provided and will be explained by the principal investigator.
62621195|NCT04235842|EXPERIMENTAL|Moderate-intensity continuous exercise training group (GMICT)|The GMICT will be submitted to a physical exercise program in which the aerobic component will be a moderate-intensity continuous exercise training, performed at 60% of the heart rate reserve, two days a week, for 30 minutes.
62621196|NCT04235842|EXPERIMENTAL|High-intensity interval training exercise group (GHIIT)|The GHIIT will be will be submitted to a physical exercise program in which the aerobic component will be a high-intensity interval exercise training, performed in a protocol consisted of four one-min sprint at 90% of the heart rate reserve, alternated with one-min rest (at week 1) and progressing until reach 10 bouts of one-min sprint alternated with one-min rest.
62264770|NCT02125227|EXPERIMENTAL|Group 2 of Study B|single dosing of YH14755 after having breakfast 14 days later, single dosing of YH14755 with fasting state
62264771|NCT03099187|EXPERIMENTAL|Pirfenidone|Participants will receive pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
62264772|NCT03099187|EXPERIMENTAL|Placebo|Participants will receive matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
62264773|NCT01468584|EXPERIMENTAL|MP-424|
62264774|NCT04536688|EXPERIMENTAL|RGLS4326 1 mg/kg Q2W|Eligible participants will receive subcutaneous injection of 1 mg/kg of RGLS4326 every other week for 4 doses
62264775|NCT04536688|EXPERIMENTAL|RGLS4326 0.3 mg/kg Q2W|Eligible participants will receive subcutaneous injection of 0.3 mg/kg of RGLS4326 every other week for 4 doses
62621197|NCT01664507|ACTIVE_COMPARATOR|conventional dose epinephrine|L-epinephrine (1:1000) 0.5 mL/kg (maximum 5mL) + normal saline : total 5mL
62621198|NCT01664507|EXPERIMENTAL|low dose epinephrine|L-epinephrine (1:1000) 0.1 mL/kg (maximum 1mL) + normal saline : total 5mL
62847248|NCT02185924|EXPERIMENTAL|CONTINUOUS FEMORAL BLOCK AND PARECOXIB|Continuous infusion of0,2% of ropivacaine at 10 ml/h and 2 mls (40 mg) of iv parecoxib
62264776|NCT04536688|EXPERIMENTAL|RGLS4326 0.1 or 0.5 mg/kg Q2W|Eligible participants will receive subcutaneous injection of 0.1 or 0.5 mg/kg of RGLS4326 every other week for 4 doses
62621199|NCT05979480||Growth Hormone Treatment Continuation Group|Adult patients with GHD who have been on GH treatment for at least 5 years and will be continuing their treatment whilst on the study.
62621200|NCT05979480||Growth Hormone Treatment Discontinuation Group|Adult patients with GHD who have been on GH treatment for at least 5 years and will be discontinuing their treatment whilst on the study for 2 years.
62621201|NCT02937636|EXPERIMENTAL|Test Product|Participants will apply a full strip of dentifrice to cover the head of the toothbrush provided and brush their teeth with the assigned dentifrice twice daily (morning and evening) for one timed minute following their normal routine.
62621202|NCT02937636|ACTIVE_COMPARATOR|Reference Product|Participants will apply a full strip of dentifrice to cover the head of the toothbrush provided and brush their teeth with the assigned dentifrice twice daily (morning and evening) for one timed minute following their normal routine.
62621203|NCT01891240||First time, low risk mothers|The study population will consist of first time, low risk mothers attending for antenatal care in one of the participating clinical centres.
62621204|NCT00619372|EXPERIMENTAL|B|Low dose OKT3 with GC
62621205|NCT00619372|EXPERIMENTAL|C|Mid dose OKT3
62621206|NCT00619372|EXPERIMENTAL|D|Mid OKT3 dose with GC
62060665|NCT05438186||Liraglutide|Participants with obesity who received initial prescription of Saxenda® (liragltuide 3.0 milligrams (mg) once daily) and maintained treatment with Saxenda® for at least 16 weeks, without treatment break, following the initial prescription for weight management.
62264777|NCT02385630|EXPERIMENTAL|Esophagectomy|"Serial assessment:~Fasting gut hormones, post-prandial gut hormone response to a standardized 400kcal meal"
62264778|NCT02385630|EXPERIMENTAL|Gastrectomy|"Serial assessment:~Fasting gut hormones, post-prandial gut hormone response to a standardized 400kcal meal"
62264779|NCT00655031|EXPERIMENTAL|1|Pomegranate concentrate (POMx)
62264780|NCT00655031|PLACEBO_COMPARATOR|2|Fruit flavored juice low in antioxidants
62621207|NCT00619372|EXPERIMENTAL|E|High dose OKT3
62060666|NCT03962296|EXPERIMENTAL|Entelon|Three daily oral doses of 50mg tablets were administered to patients
62448300|NCT05731713|EXPERIMENTAL|Immediate group|Study participants in the immediate group will be randomly assigned to start the intervention immediately at the beginning of the fall trimester.
62448301|NCT05731713|EXPERIMENTAL|Waitlist group|Study participants in the waitlist group will be randomly assigned to start the intervention at the beginning of the winter trimester.
62448302|NCT02314377|EXPERIMENTAL|AVM treatment with Bevacizumab|Bevacizumab infusion dose of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
62448303|NCT01555320|PLACEBO_COMPARATOR|Qishen Yiqi dripping pills dummy|
62448304|NCT01555320|EXPERIMENTAL|Qishen Yiqi Dripping Pills|
62448305|NCT06544668||Breast cancer patients with bone metastasis|
62448306|NCT06544668||Breast cancer patients without bone metastasis|
62448307|NCT04023279|EXPERIMENTAL|TENS|Conventional TENS of 100 Hz and 100 usec for 20 minutes
62448308|NCT04023279|EXPERIMENTAL|Myofascial Therapy|Conventional TENS of 100 Hz and 100 usec for 20 minutes plus myofascial release therapy in the brachial biceps; Seven to fifteen transverse sliding repetitions and three repetitions of longitudinal sliding
62448309|NCT03807687||Patient with pancreatic disease|Patients diagnosed with pancreatic disease evaluated at this institution.
62448310|NCT05191446|EXPERIMENTAL|Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use|For participants randomized to SAT, consistent with stepped care, treatment will begin with lower intensity services that are stepped up, if necessary, at a predefined time point. Step 1 consists of three motivational interviewing (MI)sessions delivered every 2 weeks. At the 3-month assessment, those with non-response to MI, defined as continued unhealthy alcohol use in the prior 14 days, will be referred to on site physician managed addiction specialty services (Step 2) for higher intensity services.
62448311|NCT05191446|ACTIVE_COMPARATOR|Usual Care (UC)|UC participants will receive their usual services in hepatology. They will also be given publicly available patient education materials regarding risk associated with unhealthy drinking (mail/email or in-person if desired) and will be asked to follow up with their physician should they have questions about information provided in the handouts. UC participants' hepatology provider will be notified if AUDIT-C scores are greater than 3 at baseline. All UC participants will have access to alcohol and other substance use treatment available to patients at their respective sites.
62448312|NCT01946347|EXPERIMENTAL|Patients with type 2 diabetes|30 individuals with type 2 diabetes Intervention: mixed meal, acute in vivo induced hyperinsulinemia
62448313|NCT01946347|ACTIVE_COMPARATOR|Healthy subjects|30 healthy men and women with no metabolic syndrome Intervention: mixed meal, acute in vivo induced hyperinsulinemia
62448314|NCT02676154|OTHER|Fesoterodine|Open-Label
62448315|NCT06297889|EXPERIMENTAL|Core strength training interventions for 1-6 weeks|Core strength training: Experiment: Experimental Group: Core Strength Training for 1-6 Weeks.Participants undergo a one-hour training session three times a week for 1- 6 weeks, incorporating a 15-minute warm-up followed by 45 minutes of targeted core strength training.
62448316|NCT06297889|EXPERIMENTAL|Core strength training interventions for 7-12 weeks|Core strength training: Experiment: Experimental Group: Core Strength Training for 7-12 Weeks.Participants undergo a one-hour training session three times a week for 7-12 weeks, incorporating a 10-minute warm-up followed by 50 minutes of targeted core strength training.
62448317|NCT01326403|EXPERIMENTAL|Group A|Patients will receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.
62448318|NCT01326403|EXPERIMENTAL|GROUP B|Patients will receive IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.
62448319|NCT01326403|PLACEBO_COMPARATOR|GROUP C|A control group will only receive placebo in the emergency room and in the OR.
62448320|NCT02568384|EXPERIMENTAL|Users of Onyx BG Meter / App System|"Subjects with diabetes used the Onyx Blood Glucose (BG) Meter / App System at home. The enrollment goal for the intended use population:~1. 40 to 70% of subjects will have type 1 diabetes~2. Not more than 30% of subjects will use an insulin pump"
62448321|NCT00722254||PPH|Subjects diagnosed with primary pulmonary hypertension (PPH)
62621208|NCT00619372|EXPERIMENTAL|F|GC only
62060667|NCT03962296|ACTIVE_COMPARATOR|Doxium|Three daily oral doses of 250mg tablets were administered to patients
62060668|NCT03962296|PLACEBO_COMPARATOR|Placebo|Three masking tablets were administered to patients
62060669|NCT03680664|EXPERIMENTAL|Active tDCS + MBSR|"Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 milliamps (mA) (current density = 0.57 A/m2) for 30 min per day.~After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with Compact Discs-Read Only Memory (CD-ROMs) of meditative practice."
62621209|NCT00619372|EXPERIMENTAL|A|Low dose OKT3
62847249|NCT02185924|PLACEBO_COMPARATOR|CONTINUOUS FEMORAL BLOCK AND PLACEBO|Continuous infusion of 0.2% ropivacaine at 10 ml/h and 2 mls of iv N/S0.9%
62847250|NCT06342193|EXPERIMENTAL|intervention group|This group will use virtual reality glasses during cystoscopy.
62060670|NCT03680664|SHAM_COMPARATOR|sham tDCS + MBSR|"The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.~After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice."
62060671|NCT03915184|EXPERIMENTAL|CAR-BCMA T Cells|Phase 1b will include a dose escalation followed by an expansion cohort to determine the recommended dose for the expansion part. After recommended Phase 2 is determined, patients in Phase 2 will be treated.
62060672|NCT00749125|EXPERIMENTAL|1 Lexapro|The depressed participants in this arm will be given Lexapro.
62060673|NCT00749125|NO_INTERVENTION|2 Control|The nondepressed participants in this arm will not be given any intervention for depression.
62060674|NCT02655601|EXPERIMENTAL|Radiation Therapy, TMZ and BMX-001|Patients will receive standard of care radiation therapy plus temozolomide (TMZ). BMX-001 will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks. A total of 80 subjects will receive BMX-001 in this phase.
62264781|NCT03080246|ACTIVE_COMPARATOR|Strength Training Group|This group will begin coming to the Clinical Research Center (near the undergraduate campus of Wake Forest University) for exercise classes 2-3 days per week for about an hour each day. The investigators also have a site on High Point University's campus. The class will consist of a 10-minute warm-up, a 20-minute strength training period, 15-minutes of neuromuscular (balance/coordination) training, and a 15-minute cool down. These regular exercise classes at Wake Forest and High Point University will go on for 9 months, followed by another 9 months of option to continue at facility, plus follow-up via email and 2 group meetings/runs at Fleet Feet (at around months 12 and 15).
62448322|NCT00722254||Myelofibrosis|Subjects diagnosed with Primary or Secondary Myelofibrosis
62847251|NCT06342193|NO_INTERVENTION|controlled group|No intervention
62621210|NCT05054205|EXPERIMENTAL|Experimental group|To the experimental group; motivational interview based self-management education was given for 30-45 minutes with groups of 5-8 people, COPD education guide was given, questions were shared with the question-answer method and group interaction was provided. After the self-management education, 3 motivational interviews were conducted 3 days apart with 30-45 minutes.The data were collected in three stages as pre-test, post-test and follow-up (after 30 day).
62621211|NCT05054205|NO_INTERVENTION|Control group|Normal care was continued in the control group.
62621212|NCT02143934|ACTIVE_COMPARATOR|Primaquine|Primaquine, 0.5mg/kg/day, 20 days directly observed treatment Chloroquine, 25mg/kg total dose, divided over 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD
62621213|NCT02143934|PLACEBO_COMPARATOR|Placebo|Placebo, 20 days directly observed treatment Chloroquine, mg/kg, 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD
62847252|NCT01182090|ACTIVE_COMPARATOR|Prolapse repair by open approach|Correction of urogenital prolapse by open surgery approach
62847253|NCT01182090|ACTIVE_COMPARATOR|Prolapse repair by laparoscopic approach|Correction of urogenital prolapse by laparoscopic approach
62847254|NCT03387527|EXPERIMENTAL|Prostate Cancer Decision Aid|The research intervention will be exposure to the screening decision aid. Patients will receive standardized counseling including population based risks and benefits of prostate cancer screening. Then, patients will be given opportunity to review the screening decision aid prior to offering a decision on whether or not to undergo prostate cancer screening. The patient decision aid will be a computer application that generates predicted risks associated with prostate cancer.
62847255|NCT02236117|EXPERIMENTAL|Intervention: Aerobic Training|The children included in the experimental group will make 10 weeks of aerobic training. The intensity of the race will be based on individual speed obtained in the last stage completed the progressive test, known as the maximal aerobic speed (MAV) in km/h. The running speed of the exercise protocol will be minimum 80% of the MAV in the protocol of continuous training. The intermittent progressive training is n \* (10\*15 s) to 100% MAV, and n from 2 to 6 series between the first and tenth week. The training protocol was adapted from previously described (Mandigout et al, 2002, Gamelin et al, 2009.). Acceptance of the exercise in a pediatric population has been previously observed by pilot study.
62847256|NCT02236117|NO_INTERVENTION|physical education classes|
62847257|NCT05306119|ACTIVE_COMPARATOR|Main group|Patients with low back pain who had undergone myocardial revascularization surgery within a year prior to admission to a sanatorium organization, admitted for a course of sanatorium treatment with an individual program of medical rehabilitation with the use of means, affecting both diseases lasting up to 21 days
62847258|NCT05306119|NO_INTERVENTION|Comparison group|Patients with low back pain who had undergone myocardial revascularization surgery within a year prior to admission to a sanatorium organization, admitted for a course of sanatorium treatment lasting up to 21 days
62621214|NCT03714776|PLACEBO_COMPARATOR|Placebo|Placebo matching solution injected subcutaneously (SC) once weekly for up to 6 weeks and an additional loading dose on Day 3.
62621215|NCT03714776|EXPERIMENTAL|ISIS 757456 80 mg|ISIS 757456 80 mg injected SC once weekly for up to 6 weeks and an additional loading dose of 80 mg on Day 3.
62621216|NCT03788980||carotid endarterectomy group|patients undergoing carotid endarterectomy
62621217|NCT03729791|EXPERIMENTAL|actual tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
62621218|NCT03729791|ACTIVE_COMPARATOR|sham tDCS|sham direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
62621219|NCT00964405|EXPERIMENTAL|LAMA|After randomization subject will inhale either GSK233705 50, 100 or 200 microgram once daily for 7 days.
62621220|NCT00964405|PLACEBO_COMPARATOR|Placebo|After randomization subjects will inhale placebo once daily for 7 days.
62621221|NCT03072823|ACTIVE_COMPARATOR|n-3 polyunsaturated fatty acids|n-3 polyunsaturated fatty acids dosage of 2 g of Eicosapentaenoic acid(EPA) and 1 g of Docosahexaenoic acid (DHA).
62621222|NCT03072823|PLACEBO_COMPARATOR|placebo|olive oil ethyl esters
62621223|NCT00994227|EXPERIMENTAL|surgery|
62621224|NCT01812616|EXPERIMENTAL|Sativex and Dose-Intense Temozolomide|Patients will received Sativex and Dose-Intense Temozolomide in a double-blind manner
62621225|NCT01812616|PLACEBO_COMPARATOR|Placebo and Dose-Intense Temozolomide|Patients will received placebo and Dose-Intense Temozolomide and in double-blind manner
62621226|NCT06232746|EXPERIMENTAL|Magnet System, DI Biofragmentable|GT Metabolic Solutions DI Biofragmentable Magnetic Anastomosis System (Magnet System, DI Biofragmentable)
62847259|NCT05306119|NO_INTERVENTION|Control group|Healthy people aged 40-60 y.o.
62847260|NCT01145677|EXPERIMENTAL|Topiramate|
62621227|NCT01637883|NO_INTERVENTION|nothing|nothing will be dripped on the cuff of the endotracheal tube in the control group
62621228|NCT01637883|EXPERIMENTAL|benzydamine HCl|benzydamine HCl will be dripped on the cuff of the endotracheal tube 5 minutes before induction of general anesthesia
62847261|NCT00763698|EXPERIMENTAL|QuickFlex micro 1258T left heart lead|
62847262|NCT03647852|EXPERIMENTAL|Methylprednisolone group|In this group patients will be given Methylprednisolone pulse(15-30mg/kg/d) and continued with oral prednisolone (2mg/kg/d)
62847263|NCT03647852|ACTIVE_COMPARATOR|IVIG group|In this group patients will be given IVIG (2g/kg) and at the same time oral prednisolone (2mg/kg/d)
62847264|NCT01280877|EXPERIMENTAL|Verum stimulation|Complete treatment with transorbital alternating current stimulation (tACS)
62847265|NCT01280877|SHAM_COMPARATOR|Sham stimulation|Same electrode montage set-up is used during tACS- and placebo-stimulation. Sham stimulation condition consists of minimal treatment with low intensity/few impulses tACS.
62847266|NCT04319692|EXPERIMENTAL|Fermented Prunus Mume Vinegar group|This group takes Fermented Prunus Mume Vinegar for 8 weeks.
62847267|NCT04319692|PLACEBO_COMPARATOR|Placebo group|This group takes placebo for 8 weeks.
62448323|NCT05628675|EXPERIMENTAL|Intervention|"Single-session 90-minute psychoeducational group (Baby CHAT) delivered antenatally."
62847268|NCT02558413|ACTIVE_COMPARATOR|BTA-C585 oral capsules|25 or 100 mg oral capsules; Single ascending doses (SAD) from 50 mg to 800 mg
62621229|NCT00741598|EXPERIMENTAL|Galantamine-ER|Participants will receive treatment with extended release galantamine
62621230|NCT00741598|PLACEBO_COMPARATOR|Galantamine placebo|Participants will receive treatment with placebo.
62621231|NCT00673374||1|All consecutive emergency department patients undergoing abdominal CT for non-traumatic abdominal pain and tenderness will be prospectively enrolled, except for those meeting pre-specified exclusion criteria.
62621232|NCT02394184||patients with bicuspid aortic valve stenosis|
62621233|NCT05206383|EXPERIMENTAL|Positive message|Group A - 30 subjects who will be told that positive message.
62621234|NCT05206383|EXPERIMENTAL|Negative message|Group B - 30 subjects who will be told negative message.
62621235|NCT05206383|EXPERIMENTAL|Neutral message|Group C - 30 people who will be told neutral message.
62621236|NCT01640886||Standard of Care|"1. Comparison of S. aureus to the reference methods for S. aureus (tube coagulase and Staphaurex.)~2. Comparison to the reference method (30 ug cefoxitin disc diffusion)."
62621237|NCT01640886||KeyPath Test Group|All specimens collected that meet the inclusion criteria will be tested using the KeyPath BTA Test.
62621238|NCT03354052|EXPERIMENTAL|Real-rTMS + Gloreha device|
62621239|NCT03354052|ACTIVE_COMPARATOR|Sham-rTMS + Gloreha device|
62621240|NCT06387446|EXPERIMENTAL|Valve transplantation group|This arm undergoes Allogeneic Valve transplantation
62621241|NCT01592123||The participants with septal deviation|
62621242|NCT00869583|EXPERIMENTAL|1|Participants will immediately take part in the physical activity program.
62621243|NCT00869583|NO_INTERVENTION|2|
62847269|NCT02558413|PLACEBO_COMPARATOR|BTA-C585 matching placebo|BTA-C585 Matching placebo capsules; single doses
62847270|NCT00885209||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases.
62621244|NCT02857036|EXPERIMENTAL|responder|responder to antidepressant treatment
62621245|NCT02857036|EXPERIMENTAL|non responder|non responder to antidepressant treatment
62621246|NCT01692522|EXPERIMENTAL|Ambu Aura-i|intubation
62621247|NCT01692522|ACTIVE_COMPARATOR|AirQ|intubation
62621248|NCT04238338||high MLR group|"Divided into high MLR group and low MLR group according to the median of monocyte / lymphocyte ratio(MLR).~Patients undergo peritoneal dialysis 3, 4 or 5 times per day, with a daily peritoneal dialysate dose of approximately 6000-10000 ml. The glucose concentration of peritoneal dialysate varies depending on the specific requirements of the individual patient for ultrafiltration volume. Three concentrations of glucose peritoneal dialysis solution are available for peritoneal dialysis patients. The low concentration is 1.5% or 2.5% and the high concentration is 4.25%. In principle, a 1.5% glucose peritoneal dialysis solution is first applied, or a high concentration of 4.25% glucose peritoneal dialysis solution can be appropriately applied according to the actual situation. Other drugs continued to be used in patients with other diseases."
62621249|NCT04238338||low MLR group|"Divided into high MLR group and low MLR group according to the median of monocyte / lymphocyte ratio(MLR).~Patients undergo peritoneal dialysis 3, 4 or 5 times per day, with a daily peritoneal dialysate dose of approximately 6000-10000 ml. The glucose concentration of peritoneal dialysate varies depending on the specific requirements of the individual patient for ultrafiltration volume. Three concentrations of glucose peritoneal dialysis solution are available for peritoneal dialysis patients. The low concentration is 1.5% or 2.5% and the high concentration is 4.25%. In principle, a 1.5% glucose peritoneal dialysis solution is first applied, or a high concentration of 4.25% glucose peritoneal dialysis solution can be appropriately applied according to the actual situation. Other drugs continued to be used in patients with other diseases."
62621250|NCT05513768||women who gave birth prematurely|women who had serum taken in the first trimester and gave birth earlier than 37 weeks according to the time of delivery
62847271|NCT04466202|EXPERIMENTAL|Music Group with Structured Verbal Training|Music with structured verbal training was applied during transrectal ultrasound guided prostate biopsy.
62847272|NCT04466202|NO_INTERVENTION|Control Group|The control group did not listen to music during the procedure, and they received routine training.
62847273|NCT01541683|EXPERIMENTAL|Halls|every patient will drink 4 Liters of PEG solution (FORTRANS®) split into 2 days with sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy with Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure with Halls®).
62847274|NCT01541683|OTHER|no Halls|Every patient will drink 4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
62847275|NCT05788016|EXPERIMENTAL|Pharmacist-led opioid taper intervention|The participant will attempt to taper their opioid dose by \~50% during the 4-6 week preoperative period. Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.
62847276|NCT04105491||Aligner Patients|Patients who decided to be treated with Invisalign® aligners
62264782|NCT03080246|NO_INTERVENTION|Running Group|This group will be observed as they follow their usual run-training routine over the course of 18 months. Emails will be sent biweekly for 18 months to update the research team on injury/training status. The group will attend 5 group meetings/runs at Fleet Feet (at around months 1, 3, 6, 12, and 15). After the 18 months, the participants will be offered a free 8-week strength training program at the Clinical Research Center or High Point University.
62264783|NCT00827021|EXPERIMENTAL|ESAs 1 low dose|
62264784|NCT00827021|ACTIVE_COMPARATOR|ESAs 2 high dose|
62847277|NCT01598129|EXPERIMENTAL|CGTG-102|CGTG-102 dose escalation
62847278|NCT00000400|EXPERIMENTAL|PTH|Human parathyroid hormone \[hPTH-(1-34)\]
62847279|NCT00000400|ACTIVE_COMPARATOR|ALN|Alendronate
62621251|NCT05513768||those who gave birth on time|women who have had serum taken in the first trimester, stored and delivered on time
62847280|NCT00000400|EXPERIMENTAL|PTH+ALN|Human parathyroid hormone \[hPTH-(1-34)\] plus alendronate
62847281|NCT00709865|EXPERIMENTAL|1|.03 mg/kg
62847282|NCT00709865|EXPERIMENTAL|2|.15 mg/kg
62847283|NCT00709865|EXPERIMENTAL|3|.3 mg/kg
62847284|NCT00709865|PLACEBO_COMPARATOR|4|Placebo
62847285|NCT02762370|EXPERIMENTAL|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release Formulation
62448324|NCT05435001|EXPERIMENTAL|OSAS disease status|The dependent variable was diseased status (OSAS +/-). The independent variables analyzed were age, sex, body mass index (BMI), and for HRV variables, their day and night values and the differences between their night and day values (D\[D/N\]), as night mean HR, D\[D/N\] mean HR, night r-MSSD, D\[D/N\] r-MSSD, night SDNN, D\[D/N\] SDNN, night SDNN index, D\[D/N\] SDNN index, night SDANN, and D\[D/N\] SDANN.
62448325|NCT02385526||Group A|Vagus Nerve Stimulation Therapy Standard Titration
62448326|NCT02385526||Group B|Vagus Nerve Stimulation Therapy Alternate Titration 1
62847286|NCT02762370|ACTIVE_COMPARATOR|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-release Formulation
62847287|NCT02280018|EXPERIMENTAL|JNJ-49122944, 5 milligram (mg)|Single dose of 5 mg JNJ-49122944, administered as a 22.2 milliliter (mL) intravenous (IV) infusion over 45 minutes in the morning following an overnight fast.
62847288|NCT02280018|PLACEBO_COMPARATOR|Placebo|Placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes in the morning following an overnight fast.
62847289|NCT02954172|EXPERIMENTAL|Bevacizumab in Combination With Paclitaxel/Carboplatin|Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
62448327|NCT02385526||Group C|Vagus Nerve Stimulation Therapy Alternate Titration 2
62621252|NCT02923401|EXPERIMENTAL|High-Intensity Interval Training (HIIT) Group|"Participants come to the Energy Balance Center to exercise 3 times a week for 12 weeks.~Participants receive written materials and instructions on how to perform their exercises.~Participants walk uphill on a treadmill for a total of 33 minutes 3 times a week for 12 weeks.~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.~One (1) time each month, participant attends a motivational session."
62621253|NCT02923401|EXPERIMENTAL|Moderate-Intensity Continuous Training (MICT) Group|"Participants come to the Energy Balance Center to exercise 3 times a week for 12 weeks.~Participants receive written materials and instructions on how to perform their exercises.~Participants walk uphill on a treadmill or use a stationary bicycle continuously for 41 minutes 3 times a week for 12 weeks.~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.~One (1) time each month, participant attends a motivational session."
62621254|NCT02923401|ACTIVE_COMPARATOR|Control Group|"Participants receive written materials and counseling by an exercise physiologist.~Participants called by a member of the study staff 1 time each week for 12 weeks and asked about any exercise they have done and their weight loss goals.~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.~One (1) time each month, participant attends a motivational session."
62621255|NCT04829617|EXPERIMENTAL|PP-MI Intervention|Participants will receive a 12-week, Positive Psychology-Motivational Interviewing (PP-MI) intervention. Each week, participants will complete a PP activity and work towards one or more health behavior goals, then complete a phone session with a study trainer. Each weekly session will include PP and goal setting portions. In the PP portion, a study trainer will (a) review the week's PP exercise, (b) discuss the rationale of the next week's PP exercise through a guided review of the PP-MI manual, and (c) assign the next week's PP exercise. Additionally for the goal-setting portion, the trainer will (a) review their goals and health behaviors from the prior week, (b) discuss techniques for improving health behavior adherence (e.g., monitoring physical activity, reading nutrition labels), and (c) set goals for the next week. Finally, participants will receive supplemental text messages throughout the 12 weeks of the intervention and during the initial follow-up period (Week 13-24).
62621256|NCT04829617|ACTIVE_COMPARATOR|MI-alone Intervention|This condition will mirror the MI component of the PP-MI intervention. During the first three sessions, participants will learn about the causes and types of HF, risk factors for cardiovascular disease, and methods for monitoring risk factors and symptoms. Then participants will complete nine sessions related to physical activity, a low sodium diet, and medication adherence. Weekly tasks (e.g., brainstorming barriers) will be assigned, completed between calls, and reviewed at the following call. Finally, participants will receive supplemental text messages throughout the 12 weeks of the intervention and during the initial follow-up period (Week 13-24).
62621257|NCT00408551|EXPERIMENTAL|FOLFOX6|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continously over 46 hours beginning on day 1.
62621258|NCT00408551|EXPERIMENTAL|FOLFIRI|Patients receive irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1.
62621259|NCT00408551|EXPERIMENTAL|FUDR|Patients receive floxuridine IV continuously on days 1-14.
62621260|NCT02688764|EXPERIMENTAL|PA21 (Velphoro®)|"PA21 (Velphoro®), chewable tablets 500 mg iron~PA21 (Velphoro®), chewable tablets 250 mg iron~PA21 (Velphoro®), powder for oral suspension 500 mg iron~PA21 (Velphoro®), powder for oral suspension 250 mg iron~PA21 (Velphoro®), powder for oral suspension 125 mg iron"
62847290|NCT02954172|ACTIVE_COMPARATOR|IBI305 in Combination with Paclitaxel/Carboplatin|Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
62621261|NCT02688764|ACTIVE_COMPARATOR|Calcium Acetate (Phoslyra®)|Calcium Acetate (Phoslyra®) - Oral Solution: 667 mg calcium acetate per 5 mL.
62621262|NCT01168609||patients with acute myocardial infarction|Acute myocardial infarction (AMI) was defined using the European Society of Cardiology / American College of Cardiology guidelines. Myocardial infarction was detected by the presence of at least two of the following criteria: chest pain lasting more than 30 minutes, typical electrocardiographic changes, and elevated creatinine kinase-MB fraction. Consecutive patients 18 years of age or older who presented within 12 hours after the onset of symptoms were considered for enrollment. Patients who had ST-segment elevation of 1 mm or more in two or more contiguous leads were classified as ST-segment elevation MI.
62621263|NCT02452255|ACTIVE_COMPARATOR|Fenofibrate|Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
62621264|NCT02452255|ACTIVE_COMPARATOR|Fenofibrate and Propranolol|Fenofibrate and Propranolol by mouth given throughout hospitalization for up to 12 months
62621265|NCT02452255|PLACEBO_COMPARATOR|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months.
62621266|NCT02452255|ACTIVE_COMPARATOR|Propranolol|Propranolol by mouth given throughout hospitalization for up to 12 months
62621267|NCT03237052|EXPERIMENTAL|model|model aided decision
62621268|NCT03237052|ACTIVE_COMPARATOR|non-model|real-world psychiatrist decision
62621269|NCT05000736||palbociclib + aromatase inhibitor|Adult patients with HR+/HER2- advanced breast cancer who received the initial endocrine therapy of palbociclib plus aromatase inhibitor at the Cancer Hospital Chinese Academy of Medical Sciences from August 1, 2018 to December 31, 2020.
62847291|NCT01092117|OTHER|Ovation™ Abdominal Stent Graft System|Implant of Ovation™ Abdominal Stent Graft System
62847292|NCT05625555|EXPERIMENTAL|Ketamine|Participants will be randomly assigned to receive Ketamine or Midazolam
62448328|NCT05368896||Elderly patients with postoperative complications after major surger|Patients \>80 years that will undergo major visceral or orthopedic surgery
62847293|NCT05625555|ACTIVE_COMPARATOR|Midazolam|Participants will receive either Ketamine or Midazolam based on what they initially received
62448329|NCT01025856|ACTIVE_COMPARATOR|high fibre/low glycemic index diet - P A|patients will follow for two months a diet high fibre/low glycemic index without physical activity program
62448330|NCT01025856|ACTIVE_COMPARATOR|Rich in MUFA diet - PA|Patients will follow for two months a rich in MUFA diet without a physical activity program.
62847294|NCT01883076|EXPERIMENTAL|autologous cell-based delivery|autologous cell-based delivery a target dose of 3 million cells / kg of body weight will be delivered into the right heart muscle at the time of surgery. Cells are derived from autologous (self) umbilical cord blood.
62847295|NCT03338738|EXPERIMENTAL|Patients with ESBL, antibiotic pressure|Patients with ESBL, antibiotic pressure will be included. On the day of inclusion, a stool culture is performed on the first stool issued after the start of antibiotic therapy in order to evaluate the initial flora and the relative initial faecal abundance of multidrug-resistant bacteria. In the absence of stool emission by the patient, a rectal swab will be performed. 72 hours after initiation of antibiotic therapy, a blood sample (5 ml) will be taken to determine plasma concentrations of antibiotics. In addition, a stool sample will be taken at 72 hours after the start of antibiotic therapy, at the end of antibiotic therapy and 60 days after this end to evaluate the change in initial flora and relative faecal abundance of ESBL-producing enterobacteria.
62847296|NCT01320137|OTHER|Allergy Group|Subjects with ages ranging from 18-45 years and inclusive, presenting symptomatic allergy to birch pollen.
62847297|NCT01320137|OTHER|Control Group|Subjects with ages ranging from 18-45 years and inclusive, with no known allergies.
62847298|NCT06175949|EXPERIMENTAL|HRS-7085|
62264785|NCT02757560|EXPERIMENTAL|SFA versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour saturated fatty acids enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the SFA diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (SFA or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
62448331|NCT01025856|ACTIVE_COMPARATOR|high fibre/low glycemic index diet+PA|Patients will follow for two months a high fibre and low glycemic index diet associated with a physical activity program.
62621270|NCT05000736||fulvestrant|Adult patients with HR+/HER2- advanced breast cancer who received the initial endocrine therapy of fulvestrant monotherapy at the Cancer Hospital Chinese Academy of Medical Sciences from August 1, 2018 to December 31, 2020.
62621271|NCT00504543|ACTIVE_COMPARATOR|Neoral|
62847299|NCT06175949|PLACEBO_COMPARATOR|HRS-7085 simulant|
62847300|NCT02704143|EXPERIMENTAL|Combination of Cyberknife with S-1|Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.
62847301|NCT02361632|EXPERIMENTAL|Group 1|"Dietary Supplement. Participants drink coffee with or without milk in following order:~1. Black coffee~2. Coffee with 20% milk added~3. Coffee with 50% milk added"
62448332|NCT01025856|ACTIVE_COMPARATOR|Rich in MUFA diet+PA|Patients will follow for 2 months a rich in MUFA diet with a physical activity program.
62448333|NCT01791283||Healthy volunteers|Healthy volounteers with no previous medical history, age between 20-40. Both male and female. Subjects are provided extensive information about the study and the obligations and expectations included. All subjects sign a witnessed informed consent before inclusion.
62621272|NCT00504543|ACTIVE_COMPARATOR|AEB071 high dose with Cetican reduced dose|
62621273|NCT00504543|ACTIVE_COMPARATOR|AEB071 low dose with Cetican standard dose|
62060675|NCT02655601|ACTIVE_COMPARATOR|Radiation Therapy and TMZ|In this arm, one-half of the study subjects will not receive BMX-001 but will undergo all components of standard therapy (radiation therapy plus temozolomide \[TMZ\]). A total of 80 subjects will be in this study arm.
62621274|NCT05509101|ACTIVE_COMPARATOR|Clinically Available Control Algorithm (MyoPro)|Binary control of the orthosis is based on a clinically available control algorithm. This condition serves as a control. Participants will use a commercially available device, the MyoPro.
62621275|NCT05509101|EXPERIMENTAL|High-Density EMG Control Algorithm|Control of the orthosis is based on residual muscle activity mapped to intended movement using advanced predicted algorithms. This condition is a novel algorithm and serves as the experimental condition.
62621276|NCT05834478|EXPERIMENTAL|Transcutaneous Cervical Vagal Nerve Stimulation Device|Stimulation with the tcVNS
62621277|NCT05834478|SHAM_COMPARATOR|Sham Stimulation Device|Stimulation with the sham device.
62060676|NCT00595270|OTHER|IC51|In study IC51-305, subjects who had received IC51 in study IC51-304 were tested for seroconversion 6 months after the first vaccination. Subjects who had protective titers were again tested for persistence of immunity at 12 months after the first immunization,whereas subjects who had titers below the seroconversion threshold by Month 6 received a booster dose of 1x6 mcg IC51 at Month 11. Their immune response was also assessed at Month 12. Thereafter, subjects who had no protective titer by Month 12 received a booster dose of 1x6 mcg IC51 at Month 23, regardless of prior treatment; and neutralizing antibody titers were reassessed at Month 24. Subjects who had protective titers at month 12 did not receive a booster at Month 23, and their neutralizing antibody titer was also assessed at Month 24.
62621278|NCT06129097|EXPERIMENTAL|Thyme honey mouthwash|"* Thyme honey will be applied as oral rinse.~* Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day.~* Patients will be instructed to perform thyme honey rinses in the oral mucosa.~* Patients will be instructed not to swallow the thyme honey oral rinse."
62060677|NCT01203930|EXPERIMENTAL|Idelalisib|This arm consists of 2 cohorts. Participants in Cohort 1 will receive idelalisib for up to twelve 28-day cycles (or development of unacceptable toxicity) plus rituximab (8 doses through the end of Cycle 2). Upon completion of twelve 28-cycles, participants are eligible to remain on idelalisib in a continuation protocol. Participants in Cohort 2 will receive idelalisib until disease progression or development of unacceptable toxicity.
62060678|NCT02710305|ACTIVE_COMPARATOR|Group A|oral hyoscine butyl bromide tablets plus lidocaine cream
62621279|NCT06129097|PLACEBO_COMPARATOR|Saline mouthwash|Patients in the control arm followed the same protocol with normal saline rinses.
62621280|NCT05905081|EXPERIMENTAL|Exercise Group|30-minutes moderate-intensity aerobic exercise will be performed according to ACSM guidelines
62621281|NCT05905081|NO_INTERVENTION|Control Group|30-minutes video screening while sitting
62847302|NCT02361632|EXPERIMENTAL|Group 2|"Dietary supplement. Participants drink coffee with or without milk in following order:~1. Coffee with 20% milk added~2. Black coffee~3. Coffee with 50% milk added"
62847303|NCT02361632|EXPERIMENTAL|Group 3|"Dietary supplement. Participants drink coffee with or without milk in following order:~1. Black coffee~2. Coffee with 50% milk added~3. Coffee with 20% milk added"
62264786|NCT02757560|EXPERIMENTAL|MUFA versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour monounsaturated fatty acids (MUFA) enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the MUFA diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (MUFA or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
62448334|NCT06203275|PLACEBO_COMPARATOR|group 1 (control group)|which will receive metformin based combined oral hypoglycemic plus placebo tablets
62060679|NCT02710305|PLACEBO_COMPARATOR|Group B|oral placebo tablets plus placebo cream
62060680|NCT03831984|ACTIVE_COMPARATOR|0,09% Bromfenac|Topical 0,09% Bromfenac twice daily 3 days before surgery
62060681|NCT03831984|PLACEBO_COMPARATOR|0,1% sodium hyaluronate|Topical 0,1% sodium hyaluronate twice daily 3 days before surgery
62060682|NCT01824615|EXPERIMENTAL|Sunitinib|Use Sutent for treatment of recurrent / persisted OCCA
62060683|NCT05971901||BV use cases|cases in whom BV was ordered
62060684|NCT05971901||BV non-use cases|cases in whom BV was not ordered
62621282|NCT00255164|EXPERIMENTAL|Dexlansoprazole MR 60 mg QD|
62448335|NCT06203275|ACTIVE_COMPARATOR|group II (intervention group)|which will receive metformin based combined oral hypoglycemic plus 12.5 mg paroxetine daily at morning.
62448336|NCT03617484|EXPERIMENTAL|Bortezomib + Ibrutinib|"Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.~Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m\^2 on days 1, 4, 8, and 11 of each 21-day cycle."
62621283|NCT00255164|EXPERIMENTAL|Dexlansoprazole MR 90 mg QD|
62621284|NCT00255164|PLACEBO_COMPARATOR|Placebo|
62621285|NCT01960062|NO_INTERVENTION|Control|Diabetes care with primary care practitioner supplemented with clinical pharmacy specialist
62621286|NCT01960062|EXPERIMENTAL|Intervention|Diabetes care with primary care practitioner and clinical pharmacy specialist, with the aid of a diabetes software and device to upload glucometer results from home
62621287|NCT04229771|EXPERIMENTAL|Participants who received proparacaine hydrochloride solution in left eye and placebo in right eye|Participants receiving a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in left eye and a drop of basic salt solution (BSS, placebo) in the right eye prior to probing and irrigation.
62621288|NCT04229771|EXPERIMENTAL|Participants who received proparacaine hydrochloride solution in right eye and placebo in left eye|Participants receiving a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in right eye and a drop of basic salt solution (BSS, placebo) in the left prior to probing and irrigation.
62060685|NCT02378558|EXPERIMENTAL|Investigational Device|All patients will undergo breast localization and excision of a lesion using the MagneMark system. The radiologist will insert the MagneMarker clip into the area of concern using the MagneJector device. The surgeon will then locate the MagneMaker clip using the MagneProbe. The clip and breast tissue of concern will then be removed.
62060686|NCT06212466||CMD Positive|Patients who have confirmed presence of CMD via invasive angiography/CFR
62448337|NCT04155164|EXPERIMENTAL|Metformin|Participants will receive Metformin for 12 months.
62621289|NCT01090050|ACTIVE_COMPARATOR|Sumatriptan/Naproxen Sodium|In Treatment Period Month 1: Subjects randomized to Sumatriptan/Naproxen Sodium will treat daily with 1 tablet Sumatriptan 85mg / Naproxen Sodium 500mg per day x 30 days. Subjects will be provided with 30 tablets of Sumatriptan/Naproxen Sodium for rescue. In Treatment Period Months 2 and 3: Subjects randomized to Sumatriptan/Naproxen Sodium will be provided with 14 tablets of Sumatriptan/Naproxen Sodium to treat on 14 or fewer days per month. Subjects will be provided with 14 tablets of Sumatriptan/Naproxen Sodium per month for rescue.
62621290|NCT01090050|ACTIVE_COMPARATOR|Naproxen Sodium|In Treatment Period Month 1: Subjects randomized to Naproxen Sodium will treat daily with 1 tablet Naproxen Sodium 500mg per day x 30 days. Subjects will be provided with 30 tablets of Naproxen Sodium for rescue. In Treatment Period Months 2 and 3: Subjects randomized to Naproxen Sodium will be provided with 14 tablets of Naproxen Sodium to treat on 14 or fewer days per month. Subjects will be provided with 14 tablets of Naproxen Sodium per month for rescue.
62847304|NCT02433080|ACTIVE_COMPARATOR|Shape-Up following cancer treatment|"In addition to usual care, cancer survivors in the intervention group will participate in a behaviour change programme, called Shape-Up following cancer treatment: a self-help programme on eating well and being active. Participants will be allocated to groups of eight to ten. These groups will meet every week for eight weeks and each session will last approximately 90 minutes. The programme focuses on strategies for improving diet and physical activity in a self-help and peer education format. Each week, one participant will volunteer to present a new concept (e.g. regular eating, being active, eating a balanced diet, keep an eye on portion sizes, and manage internal and external triggers, and understanding food labeling) to the rest of the group."
62847305|NCT02433080|NO_INTERVENTION|Control intervention|"Participants in the control group will be offered usual care until the 24-week follow-up. Quantifying usual care is challenging, but preliminary qualitative work suggested that most survivors do not received any unsolicited advice about healthy eating and physical activity from their health care professionals after treatment.~During the course of their participation in the trial, participants will be contacted only for the assessments. After the completion of the 24-week follow-up, participants will receive the booklet Healthy living after cancer; a brief self-help manual produced by the World Cancer Research Fund. Providing only this information aims to match the currently offered usual care as accurately as possible but also meet ethical standards."
62847306|NCT01335737|EXPERIMENTAL|aerobic training|12 weeks of aerobic training, 4 times/week
62847307|NCT01335737|PLACEBO_COMPARATOR|wait list control|wait list control condition, 12 weeks + 4 to parallel the deconditioning protocol in active intervention group
62264787|NCT02757560|EXPERIMENTAL|CARB versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour carbohydrate (CARB) enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the CARB diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (CARB or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
62264788|NCT02601339||GM-IVH|Premature infants who developed germinal matrix-intraventricular hemorrhage. FDNIRS-DCS measures will be performed up to once a day if clinically feasible.
62264789|NCT02601339||Posthemorrhagic hydrocephalus (PHH)|"Premature infants with complications of hydrocephalus secondary to intraventricular hemorrhage and have the potential to receive endoscopic third ventriculostomy (ETV) with choroid plexus cauterization (CPC) and/or ventriculoperitoneal (VP) shunting for clinical treatment.~FDNIRS-DCS measures will be performed up to once a day if clinically feasible. Additional FDNIRS-DCS measures will be performed on the day of hydrocephalus treatment to monitor the treatment response if clinically feasible. These additional measures are limited to up to four times a day."
62621291|NCT00160342|ACTIVE_COMPARATOR|1|
62621292|NCT00160342|EXPERIMENTAL|2|
62847308|NCT01526824|NO_INTERVENTION|Control arm, clopidogrel without Lovaza|These patients will be receiving standard of care therapy with either standard dose (75mg daily) or high dose (150mg daily) clopidogrel +/- aspirin based on physician discretion.
62847309|NCT01526824|EXPERIMENTAL|Clopidogrel plus Lovaza|This is the study arm of the trial, in which patients will be receiving either a standard dose (75mg daily) or high dose (150mg daily) clopidogrel with or without aspirin as well as therapy with daily Lovaza.
62847310|NCT03194737|EXPERIMENTAL|UroLift System procedure|All eligible,enroled subjects will undergo a UroLift procedure.
62847311|NCT03194737|NO_INTERVENTION|Retrospective Arm|Chart review will be performed on all invasive BPH surgeries (TURP, Holmium Laser Enucleation of the prostate (HoLEP), etc) performed by the site from June 1, 2015 to December 31, 2015
62847312|NCT01765218|PLACEBO_COMPARATOR|Placebo|Subjects will receive the standard of care intervention for HIE at our institution (whole body cooling for 72h followed by gradual rewarming)
62847313|NCT01765218|ACTIVE_COMPARATOR|Topiramate|In addition to whole body cooling, infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
62264790|NCT02601339||Healthy Control (HC)|Premature infants without diagnosed brain injuries. FDNIRS-DCS measures will be performed up to once a day if clinically feasible.
62264791|NCT02601339||Ventriculomegaly Control (VC)|"Infants who have symptomatic hydrocephalus of any etiology except post-hemorrhagic etiology and have the potential to receive ETV/CPC and/or VP shunting for clinical treatment.~FDNIRS-DCS measures will be performed up to once a day if clinically feasible. Additional FDNIRS-DCS measures will be performed on the day of hydrocephalus treatment to monitor the treatment response if clinically feasible. These additional measures are limited to up to four times a day."
62621293|NCT00160342|EXPERIMENTAL|3|
62060687|NCT06212466||CMD Negative|Patients who have confirmed absence of CMD via invasive angiography/CFR
62621294|NCT00160342|ACTIVE_COMPARATOR|4|
62621295|NCT00160342|EXPERIMENTAL|5|
62621296|NCT00160342|EXPERIMENTAL|6|
62621297|NCT00160342|ACTIVE_COMPARATOR|7|
62621298|NCT00160342|ACTIVE_COMPARATOR|8|
62621299|NCT00160342|PLACEBO_COMPARATOR|9|
62621300|NCT01247675|EXPERIMENTAL|ACP-001, 0.02 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.02 mg hGH/kg/week for 4 weeks
62060688|NCT03264885|NO_INTERVENTION|Usual Care|The usual stand of care (UC) after community eye screening was to provide a GP referral letter and advice to attend a tertiary eye care facility most accessible to them
62264792|NCT00670319|EXPERIMENTAL|1|Raloxifene HCL 60 mg orally once a day
62847314|NCT01920685|EXPERIMENTAL|Immediate therapy|6 sessions of talking therapy, targeting anxiety processes associated with paranoia, will be delivered for a period of 8 weeks immediately after randomisation.
62060689|NCT03264885|OTHER|Incentive Care|In addition to the UC, those assigned to the ICS also received social and financial support to incentivise and improve compliance. All ICS participants were assisted with scheduling their tertiary care appointments, given telephone reminders, provided once-off transportation allowance and subsidy for their first tertiary eye-care consultation - while participants with mobility issues were assisted by volunteers.
62060690|NCT03326310|EXPERIMENTAL|Azacitidine and selumetinib|Subjects will receive azacitidine subcutaneously on days 1-7. Selumetinib will be administered on days 8-21. Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression.
62060691|NCT03114917|EXPERIMENTAL|CARMS therapy + TAU|Participants allocated to the CARMS therapy + TAU arm will receive their usual care and treatment from mental health services along with CARMS (Cognitive AppRoaches to coMbatting Suicidality) therapy. The CARMS therapy comprises of 24 sessions, each up to 50 minutes long over a 6 month period.
62060692|NCT03114917|NO_INTERVENTION|TAU|Participants allocated to treatment as usual (TAU) will receive their usual care and treatment from mental health services.
62060693|NCT05156502|EXPERIMENTAL|Fractionated Laser|
62264793|NCT00670319|EXPERIMENTAL|2|Raloxifene HCL 120 mg orally once a day
62264794|NCT00670319|PLACEBO_COMPARATOR|3|
62264795|NCT00371865|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|8 group-administered sessions of Cognitive-Behavioral Therapy
62264796|NCT00371865|EXPERIMENTAL|Acceptance-Based Therapy|8 group-administered sessions of Acceptance-based therapy
62448338|NCT04155164|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo for 12 months.
62448339|NCT06483659|ACTIVE_COMPARATOR|Medication|one group will receive Oxytocin infusion: 30 IU in 500 ml of 0.9% normal saline .
62448340|NCT06483659|PLACEBO_COMPARATOR|Placebo|one group will receive 500 ml of 0.9% normal saline
62060694|NCT05156502|ACTIVE_COMPARATOR|Fractionated.Laser|
62264797|NCT03553342|EXPERIMENTAL|Corticoids|
62264798|NCT03553342|PLACEBO_COMPARATOR|Placebo|
62264799|NCT02466152|EXPERIMENTAL|GSK2894512 2.0% Cohort|Subjects will apply a thin layer of GSK2894512 2.0% topical cream twice daily (morning and evening) for 20 days and only in morning on day 21, to all affected skin areas (15-35% BSA) identified at baseline, excluding the scalp and around the eyes
62264800|NCT02466152|EXPERIMENTAL|GSK2894512 1.0% Cohort|Subjects will apply a thin layer of GSK2894512 1.0% topical cream twice daily (morning and evening) for 20 days and only in morning on day 21, to all affected skin areas (15-35% BSA) identified at baseline, excluding the scalp and around the eyes
62264801|NCT03043248|EXPERIMENTAL|Cohort A|TRK-700 + Digoxin
62264802|NCT03043248|EXPERIMENTAL|Cohort B|TRK-700 + Midazolam
62264803|NCT02611856||monochorial-biamniotic pregnancies|
62264804|NCT04452981|ACTIVE_COMPARATOR|Active|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
62448341|NCT02974972||Pith Moromo 2 Cohort|
62060695|NCT04598854|EXPERIMENTAL|Treatment group|The treatment groupreceive an intravenous helium-neon laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The power is set between 2.5 \~ 3.0Mw, 60 minutes each time, once a day for five consecutive days. The steps for the control group are the same, except that the output power is adjusted to zero intensity.
62060696|NCT04598854|SHAM_COMPARATOR|Control group|The steps for the control group are the same as the treatment group, except that the output power is adjusted to zero intensity.
62060697|NCT04358276|EXPERIMENTAL|Group I (PAE)|Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months.
62060698|NCT04358276|EXPERIMENTAL|Group II (PAE, physician)|Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit.
62060699|NCT04358276|EXPERIMENTAL|Group III (PAE, physician, dermatoscope)|"Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit. Physicians also receive a free dermatoscope with instructions for uploading images of suspect lesions and attend a 30-minute online course comprising additional descriptions of dermoscopic images for skin cancers and mimickers common in hematopoietic stem cell transplantation patients, along with clear instructions for using a dermatoscope and steps to integrate dermoscopy into their practice."
62060700|NCT01821417|EXPERIMENTAL|Microtextured dental implant|Randomized for microtextured dental implant treatment
62060701|NCT01821417|ACTIVE_COMPARATOR|Dental implant|Randomized dental implant treatment with machined-collar implants
62060702|NCT04465461|EXPERIMENTAL|Treatment|Patients exhibiting baseline collateral ventilation by Chartis® balloon catheter assessment who undergo video-assisted thoracoscopic surgery (VATS) fissure completion surgery, confirmation of fissure completion by computerized tomography (CT) scan and confirmation of conversion to collateral ventilation negative by Chartis® balloon catheter assessment post VATS surgery and subsequent Zephyr Valve insertion.
62264805|NCT04452981|SHAM_COMPARATOR|Sham|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
62264806|NCT04914208|ACTIVE_COMPARATOR|Wearing a face mask for 4 hours|Participants are wearing different kinds of face masks for 4 hours each. Masks are worn on different days and the order is randomly assigned.
62264807|NCT04914208|OTHER|4 hours without wearing a face mask|Participants do not wear any face mask for 4 hours.
62621301|NCT01247675|EXPERIMENTAL|ACP-001, 0.04 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.04 mg hGH/kg/week for 4 weeks
62847315|NCT01920685|OTHER|Delayed intervention|Therapy will be delayed until 12 weeks following randomisation, and then 6 sessions of talking therapy, targeting anxiety processes associated with paranoia, will be delivered over a period of 8 weeks.
62264808|NCT03853785|ACTIVE_COMPARATOR|Intralesional MMR vaccine|Intralesional Mumps, measles and rubella (MMR) vaccine in genital warts
62847316|NCT02267317|ACTIVE_COMPARATOR|Obese Group-D5W|Obese subjects receive IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours
62264809|NCT03853785|ACTIVE_COMPARATOR|intralesional candida antigen|intralesional candida antigen in genital warts
62264810|NCT03853785|ACTIVE_COMPARATOR|Topical Podophyllin|Topical Podophyllin in genital warts
62264811|NCT01006265|EXPERIMENTAL|ACT-128800 Dose 1|ACT-128800 Dose 1
62264812|NCT01006265|EXPERIMENTAL|ACT-128800 Dose 2|ACT-128800 Dose 2
62264813|NCT01006265|EXPERIMENTAL|ACT-128800 Dose 3|ACT-128800 Dose 3
62448342|NCT04132661|EXPERIMENTAL|bisacodyl|5 mg bisacodyl, one tablet once
62448343|NCT04132661|PLACEBO_COMPARATOR|placebo|placebo, one tablet once
62847317|NCT02267317|ACTIVE_COMPARATOR|Obese Group - Eritoran|Obese subjects receive IV administration of Eritoran 12 mg every 12 hours
62448344|NCT03650582|EXPERIMENTAL|Glucagon|Glucagon, 0.7mg, intranasal, single dose
62264814|NCT01006265|PLACEBO_COMPARATOR|Placebo|Matching placebo
62621302|NCT01247675|EXPERIMENTAL|ACP-001, 0.08 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.08 mg hGH/kg/week for 4 weeks
62621303|NCT01247675|ACTIVE_COMPARATOR|Omnitrope, 0.04 mg hGH/kg/wk|Once daily subcutaneous injection of human Growth Hormone (Omnitrope) equivalent to 0.04 mg hGH/kg/week for 4 weeks
62264815|NCT03410173|EXPERIMENTAL|Taurine|2.4mg/d for 12 weeks
62264816|NCT03410173|PLACEBO_COMPARATOR|Placebo|2.4mg/d for 12 weeks
62264817|NCT03489382|NO_INTERVENTION|Control|Emergency Departments providing usual care, which includes assessment in hospital followed by placement on a wait list for psychiatric services and access to regional community resources for suicide prevention.
62264818|NCT03489382|EXPERIMENTAL|Smartphone Assisted PST|Emergency Departments providing the option to refer men who self-harm to a service that will deliver smartphone-assisted problem solving therapy.
62448345|NCT03650582|PLACEBO_COMPARATOR|Placebo|Placebo, intranasal, single dose
62621304|NCT02650492|EXPERIMENTAL|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
62621305|NCT01482234|EXPERIMENTAL|pedometers only|Participants randomized to this arm will receive pedometers only. They will participate in baseline and 3 months data collection.
62847318|NCT02267317|ACTIVE_COMPARATOR|Diabetes (T2DM) Group - D5W|T2DM subjects receive IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours
62847319|NCT02267317|ACTIVE_COMPARATOR|Diabetes (T2DM) Group - Eritoran|T2DM subjects receive IV administration of Eritoran 12 mg every 12 hours
62060703|NCT03118102||anesthetist group|anesthetist doctor who subjected to noise in operating rooms
62060704|NCT03118102||control group|doctors in the same hospital who are not subjected to noise in operating rooms
62264819|NCT03203239|EXPERIMENTAL|Red Light treatment|This is a single arm design. All subjects will be enrolled to have peripheral blood flow measured before, during, and after red light exposure.
62847320|NCT01387542|EXPERIMENTAL|Paliperidone Extended Release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
62847321|NCT02084290|EXPERIMENTAL|Shared Decision Making Program|Patients will have access to an educational decision making program and a risk prediction model, this web based program will be sent subjects in the intervention arm upon enrollment, they can access the program as many times as they wish.
62847322|NCT02084290|NO_INTERVENTION|Control|Subjects enrolled at sites participating as control arms will access the same web-based surveys as the intervention group, and receive the same contacts from the study coordinator as the subjects enrolled at intervention sites.
62847323|NCT04520438|EXPERIMENTAL|NSPT + L-PRF|Scaling and root planing associated to Leucocyte and Platelet rich Fibrin Membrane and irrigation with exudate of L-PRF.
62264820|NCT04288154|EXPERIMENTAL|EMS Group - Experimental|EMS device will be turned on during exercise for this group.
62847324|NCT04520438|OTHER|NSPT alone|Only Scaling and root planing
62060705|NCT00594191|PLACEBO_COMPARATOR|A|Placebo treatment
62060706|NCT00594191|EXPERIMENTAL|B|
62060707|NCT00288301|EXPERIMENTAL|1|Special Intervention
62060708|NCT00288301|EXPERIMENTAL|2|Delayed intervention
62060709|NCT03998683|EXPERIMENTAL|Guselkumab Group|Participants will receive guselkumab 100 mg SC injections at Weeks 0, 4, 12 and placebo subcutaneous (SC) injection at Week 16 in double-blind phase followed by guselkumab 100 mg SC injections at Weeks 20, 28, 36, and 44 in open-label phase.
62060710|NCT03998683|PLACEBO_COMPARATOR|Placebo Group|Participants will receive placebo SC injection at Weeks 0, 4, 12 and guselkumab 100 mg SC injection at Week 16 in double-blind phase followed by guselkumab 100 mg SC injection at Week 20, 28, 36, and 44 in open-label phase.
62847325|NCT02980913|EXPERIMENTAL|Experimental: Patients with dry eye syndrome 1|20 patients with dry eye syndrome, they will receive intervention 1 for one week and then cross over to intervention 2
62847326|NCT02980913|EXPERIMENTAL|Experimental: Patients with dry eye syndrome 2|20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1
62060711|NCT05205317|EXPERIMENTAL|vaginal repair + metformin|CSD patients were treated with vaginal repair of CSD in combination with metformin (Boke, 500 mg, Wanhui Shuanghe, Beijing, China) as an oral medicine (abbreviated as VR + metformin). In the group of VR + metformin, the patients start oral metformin from one month before the operation to 6 months after the operation. The dose is 500mg twice a day. The detailed procedure of VR has been described in investigators' previous study.
62060712|NCT05205317|ACTIVE_COMPARATOR|vaginal repair|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
62060713|NCT05889806||Healthy|Healthy subjects with no history of chronic disease
62264821|NCT04288154|PLACEBO_COMPARATOR|EMS Group - Control|EMS device will be turned off during exercise for this group.
62264822|NCT01277549||Non-mobilized donors|In this arm the collection efficiency of mononuclear cells from non-mobilized donors will be studied.
62264823|NCT01277549||G-CSF mobilized donors|In this arm the collection efficiency of CD34+ cells will be studied.
62264824|NCT02279459||Patient|Patients head and neck CT scans performed as standard of care done prior to radiation treatment and approximately 12 weeks following treatment, will be acquired in the dual-energy computed tomography (DECT) mode. Participants will have one additional scan, also in the DECT mode, 2 to 3 weeks after the start of their radiation treatment.
62621306|NCT01482234|EXPERIMENTAL|pedometers + prompts|Participants randomized to this arm will receive pedometers plus a weekly prompt to set a step goal. They will participate in baseline and 3 months data collection.
62847327|NCT03791944|EXPERIMENTAL|3DV+TPS/VARIAN|Use 3DV+TPS to map targets and develop treatment plans. The intervention is 3DV+TPS and VARIAN.
62621307|NCT01482234|EXPERIMENTAL|pedometer + prompt + messages|Participants randomized to this arm will receive pedometers, weekly prompts, and 6 motivational text messages a week. They will participate in baseline and 3 months data collection.
62621308|NCT01482234|NO_INTERVENTION|Control|Participants randomized to this group will participate in data collection only; they will not receive an intervention.
62621309|NCT04282837||NW|normal weight control
62621310|NCT04282837||MHO|metabolic healthy obesity
62621311|NCT04282837||LMO|hypometabolic obesity
62621312|NCT04282837||HMO-U|hypermetabolic obesity with hyperuricemia
62621313|NCT04282837||HMO-I|hypermetabolic obesity with hyperinsulinemia
62621314|NCT05857800||Lung cancer patients|Patients in LungMate clinical trial series.
62621315|NCT01875263|EXPERIMENTAL|Experimental|Cloxacillin 2g / 4 hours iv, 5 days followed levofloxacin 500 mg po / 24, 9 days.
62621316|NCT01875263|ACTIVE_COMPARATOR|Control|Cloxacillin 2g / 4 hrs iv 14 days
62621317|NCT05034289|EXPERIMENTAL|PINPOINT Digital Educational Tool|Newly diagnosed Black cancer patients will be asked to access and engage with the educational website/intervention prototype before their clinic visit or in the clinic immediately before their appointment with their treating oncologist.
62621318|NCT01680952|ACTIVE_COMPARATOR|A) TEST|
62621319|NCT01680952|EXPERIMENTAL|B) CONTROL|
62264825|NCT00711984|ACTIVE_COMPARATOR|1|Renal artery stenting and Best medical treatment
62448346|NCT01543100|EXPERIMENTAL|monoclonal gamopathy|"Patients with monoclonal gammopathy either MGUS or myeloma at diagnosis or more than 3 months after a first myeloma treatment with chemotherapy and/or antiangiogenic drugs.~* Patient's age ≥18 yo,~* Patients having signed the specific consent of the study."
62621320|NCT06378203|EXPERIMENTAL|Limb GIrdle Muscular Dystrophy|Open label study one arm
62621321|NCT05011578|EXPERIMENTAL|clinical and radiographic findings after surgical treatment for radiocapitellar fracture|30 patients will be included in a interventional study for an evaluation of the clinical and radiographic finding after at least 10 years after radiocapitellar surgery
62621322|NCT02915250|EXPERIMENTAL|BioChaperone® Combo|Individualised single subcutaneous of BioChaperone® Combo + injection of placebo (0.9% NaCl) to ensure the double dummy
62621323|NCT02915250|ACTIVE_COMPARATOR|Humalog® Mix25|Individualised single subcutaneous of Humalog® Mix25 + injection of placebo (0.9% NaCl) to ensure the double dummy
62621324|NCT02915250|ACTIVE_COMPARATOR|Humalog® and Lantus®|Individualised simultaneous subcutaneous injections
62621325|NCT03099226|EXPERIMENTAL|Group 1 - BIA 5-453 50 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.~The patients were administered between 7:00 and 9:00 o'clock a.m"
62621326|NCT03099226|EXPERIMENTAL|Group 2 - BIA 5-453 100 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.~The patients were administered between 7:00 and 9:00 o'clock a.m"
62448347|NCT02934750|EXPERIMENTAL|Pursed lip breathing|In this arm, patients will be asked to perform a six-minute walking test while continuously using the pursed lip breathing technique.
62448348|NCT02934750|NO_INTERVENTION|Usual breathing|In this control arm, patients will be asked to perform a six-minute walking test while breathing normally.
62621327|NCT03099226|EXPERIMENTAL|Group 3 - BIA 5-453 200 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.~The patients were administered between 7:00 and 9:00 o'clock a.m"
62621328|NCT04826835|EXPERIMENTAL|Prehabilitation intervention|Participants in the intervention group will follow a 2-week prehabilitation program before lung resection.
62621329|NCT04826835|ACTIVE_COMPARATOR|Health education control|Participants in the control group will receive health education classes during 2 weeks before lung resection.
62621330|NCT06063161|EXPERIMENTAL|Music Therapy|Music therapy intervention will be administered for 30 minutes 3 times per week between Day 0 and Day 15 of inpatient hospitalization. Daily passive music listening will be required for 30 minutes twice a day, at least 4 days per week. This daily listening experience will consist of personalized playlists developed by the music therapist with specific purpose and goal.
62847328|NCT03791944|ACTIVE_COMPARATOR|TPS/VARIAN|Use imported Varian TPS to map targets and develop treatment plans.
62847329|NCT03791944|EXPERIMENTAL|3DV+TPS/ Domestic accelerator|Use 3DV+TPS to map targets and develop treatment plans.
62060714|NCT05889806||Subjects with various conditions|Subjects that have been diagnosed with a condition of interest such as Diabetes, NASH, Breast Cancer, Endometriosis, or other designated condition.
62264826|NCT00711984|ACTIVE_COMPARATOR|2|Best medical treatment alone
62264827|NCT01627899|OTHER|VerioIQ|Subjects replaced own Blood Glucose Monitoring system with VerioIQ.
62448349|NCT02984306|EXPERIMENTAL|Dietary supplement|
62621331|NCT06063161|ACTIVE_COMPARATOR|Active Control|Daily passive music listening will be required for 30 minutes twice a day, at least 4 days per week. This daily listening experience will consist of non-personalized, auto-generated playlists based on popular genres. No interaction with a music therapist will occur.
62621332|NCT06063161|PLACEBO_COMPARATOR|Standard of care|Usual standard of care.
62621333|NCT01912053|EXPERIMENTAL|Therasphere®|Therasphere® in association with Gemcitabine and Cisplatin
62621334|NCT05343299|EXPERIMENTAL|Patients undergoing hand surgery with a combination of lidocaine and ropivacaine|Patients undergoing Wide Awake Local Anesthesia No Tourniquet -type hand surgery with lidocaine
62621335|NCT05343299|ACTIVE_COMPARATOR|Patients undergoing hand surgery with lidocaine alone|Patients undergoing Wide Awake Local Anesthesia No Tourniquet -type hand surgery with lidocaine
62060715|NCT03390530|ACTIVE_COMPARATOR|Thyroxine treatment|Intravenous thyroxine in a dose of 8 µg/kg/day divided into two doses (every 12 hours)
62264828|NCT05386355|EXPERIMENTAL|Vaccine Uptake App|24-week (8 weeks with weekly push notifications; 2 monthly push notifications for 2 months \[1 notification per month\]; 8 weeks without) exposure to a mobile phone application (app) designed to improve parental knowledge, attitudes, and self-efficacy regarding pediatric COVID-19 vaccination. The app will address logistical and motivational barriers to pediatric COVID-19 vaccination. Participants will also receive eight weekly nudges and 1 monthly nudge for 2 months (cues to action) regarding vaccinating their child that will be sent to participants via push notifications to their mobile devices. Through branching logic, users will access content tailored to their COVID-19 vaccine knowledge and confidence gaps, locality, degree of rural-urban primary residence, primary language (English/Spanish), race/ethnicity, and child's age.
62264829|NCT05386355|ACTIVE_COMPARATOR|General Health App|24-week (8 with weekly push notifications; 2 monthly push notifications for 2 months \[1 notification per month\]; 8 weeks without) exposure to a mobile phone app designed to provide information on general pediatric health and infection prevention and mitigation strategies based on recommendations from the American Academy of Pediatrics (AAP) and the Centers for Disease Control and Prevention (CDC). Eight weekly nudges and 1 monthly nudge for 2 months regarding these topics will be sent to participants via push notifications to their mobile devices.
62264830|NCT00315744|EXPERIMENTAL|Subjects receiving salmeterol/fluticasone|Eligible subjects will receive 60 individual doses of the salmeterol 50 microgram/ fluticasone 100 microgram combination. Subjects will also receive placebo.
62264831|NCT00315744|ACTIVE_COMPARATOR|Subjects receiving fluticasone|Eligible subjects will receive 60 individual fluticasone 100 microgram doses each.
62264832|NCT05639127|EXPERIMENTAL|Low dose, wash out, high dose|
62264833|NCT01211600|ACTIVE_COMPARATOR|Staples|Interrupted Ethicon Staples
62264834|NCT01211600|ACTIVE_COMPARATOR|Suture|Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
62264835|NCT02989064|EXPERIMENTAL|Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells|
62264836|NCT04342221|EXPERIMENTAL|Hydroxychloroquine Sulfate|First dose: 800 mg. From 2nd day on, each patient will get 600 mg (3 capsules) once a day until day 7 (6 more does of 600 mg).
62621336|NCT01891682||Critically Ill Pediatric Patients|Critically ill septic pediatric patients, Age 1 month-3 years, Age 4-12 years and Age 13-19 years, males and females
62621337|NCT03993977|EXPERIMENTAL|ROTEM-arm|Treatment of significant blood loss using point-of-care testing of whole blood viscoelasticity (ROTEM) monitoring coagulopathy or hyperfibrinolysis.
62060716|NCT03390530|PLACEBO_COMPARATOR|Placebo treatment|Intravenous placebo treatment every 12 hours.
62621338|NCT03993977|ACTIVE_COMPARATOR|Control-arm|Treatment of significant blood loss conventionally, ie. using massive transfusion protocol if necessary, clinical judgement and conventional coagulation tests, such as prothrombin time (as international normalized ratio, INR), activated partial thrombin time (APTT), fibrinogen in plasma (Clauss method).
62621339|NCT05761119|EXPERIMENTAL|Early Initiated Physiotherapy Intervention|All participants will recieve the intervention (see Intervention for description) to investigate the feasibility.
62621340|NCT05096611|ACTIVE_COMPARATOR|ABC|Attachment and Biobehavioral Catch-up, 10 weekly sessions that provide parenting support
62621341|NCT05096611|EXPERIMENTAL|ABC+D|Attachment and Biobehavioral Catch-up plus weekly 5-10 minute videos that additional provide support for mothers' mood, stress, and coping
62621342|NCT03286660|OTHER|COPD patients|"All convenient COPD patients admitted in real life for a rehabilitation program were included.~Exercises consist on a Chair Rise Tests and short questionnaire were added to the usual tools for the evaluation."
62621343|NCT02629042|ACTIVE_COMPARATOR|Control|
62621344|NCT02629042|EXPERIMENTAL|Experimental|
62621345|NCT05665426|OTHER|AW group|(1) AW group: acupuncture at Weizhong point,
62060717|NCT01417052|EXPERIMENTAL|50 mg LX3305 QD|
62060718|NCT01417052|EXPERIMENTAL|100 mg LX3305 QD|
62060719|NCT01417052|EXPERIMENTAL|150 mg LX3305 QD|
62847330|NCT03791944|ACTIVE_COMPARATOR|TPS/ Domestic accelerator|Adopt domestic TPS hook target and develop treatment plan.
62060720|NCT01417052|EXPERIMENTAL|200 mg LX3305 QD|
62060721|NCT01417052|EXPERIMENTAL|250 mg LX3305 QD|
62060722|NCT01417052|EXPERIMENTAL|300 mg LX3305 QD|
62060723|NCT01417052|EXPERIMENTAL|400 mg LX3305 QD|
62621346|NCT05665426|OTHER|AC group|(2) AC group: acupuncture at Chize point,
62060724|NCT01417052|EXPERIMENTAL|250 mg LX3305 BID|
62060725|NCT01417052|EXPERIMENTAL|500 mg LX3305 QD|
62060726|NCT01417052|PLACEBO_COMPARATOR|Placebo|
62060727|NCT02311816||Infection|"Based on the microbiological results and clinical picture patients were grouped post hoc into infection and no infection groups by two independent experts (intensivist, infectologist) who were blinded for procalcitonin."
62060728|NCT02311816||No infection|"Based on the microbiological results and clinical picture patients were grouped post hoc into infection and no infection groups by two independent experts (intensivist, infectologist) who were blinded for procalcitonin."
62060729|NCT05981222||Osteo Match cage|Patients undergoing posterior lumbar interbody fusion with Osteo Match Cages
62060730|NCT05981222||Peek Cage|Patients undergoing posterior lumbar interbody fusion with PEEK Cages
62264837|NCT04342221|PLACEBO_COMPARATOR|Placebo|Equivalent number of placebo capsules at the day of inclusion (4 capsules) and the following days (3 capsules)
62847331|NCT04102163||All Participants|Participants diagnosed with CD and CPF from approximately 20 Spanish hospitals, who will initiate medical or surgical treatment for their CPF within the eligibility period from Sep 2020 to Sep 2021, will be observed prospectively for approximately 31 months.
62264838|NCT02194127|EXPERIMENTAL|Anthocyan capsules|capsules containing 160 mg standardised bilberry extract (25% anthocyanidines)
62847332|NCT01702493|ACTIVE_COMPARATOR|Part 1: Cap SRT2104|500 mg SRT2104 (in the form of two, 250 mg capsules) will be administered as a single oral dose in the fasting state
62847333|NCT01702493|EXPERIMENTAL|Part 1: Tab SRT2104 (slow release)|500 mg SRT2104 (in the form of two, 250 mg slow release tablets) will be administered as a single oral dose in the fasting state.
62621347|NCT05665426|OTHER|MW group|(3) MW group: moxibustion at Weizhong point,
62264839|NCT02194127|PLACEBO_COMPARATOR|Placebo|
62264840|NCT00535561|ACTIVE_COMPARATOR|1|Oral iron treatment only- for iron deficiency anemia and subclinical hypothyroidism coexisting patients
62264841|NCT00535561|ACTIVE_COMPARATOR|2|Oral iron plus levothyroxine treatment- for iron deficiency anemia and subclinical hypothyroidism coexisting patients
62264842|NCT01262690|EXPERIMENTAL|Dose|6 treated, 3 placebos
62264843|NCT00841594|ACTIVE_COMPARATOR|1|"MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.~Applied to the hand."
62847334|NCT01702493|EXPERIMENTAL|Part 1: Tab SRT2104 (intermediate release)|500 mg SRT2104 (in the form of two, 250 mg intermediate release tablets) will be administered as a single oral dose in the fasting state.
62847335|NCT01702493|EXPERIMENTAL|Part 1: Tab SRT2104 (fast release)|500 mg SRT2104 (in the form of two, 250 mg fast release tablets) will be administered as a single oral dose in the fasting state.
62847336|NCT01702493|EXPERIMENTAL|Part 2A: SRT2104 500 mg single-dose|500 mg SRT2104 (formulation selected from Part 1) will be administered as a single oral dose in the fed state.
62060731|NCT02612480|EXPERIMENTAL|Ticagrelor and acetylsalicylic acid|7 day treatment with ticagrelor 2x90mg after a loading dose of 180 mg and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg.
62264844|NCT00841594|ACTIVE_COMPARATOR|2|"MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.~Applied to the chest."
62264845|NCT06169475|EXPERIMENTAL|dexmedetomidine group|
62264846|NCT06169475|EXPERIMENTAL|esmolol group|
62847337|NCT01702493|EXPERIMENTAL|Part 2B: SRT2104 single alternative dose|An alternative dose (other than 500 mg, but not to exceed 2000 mg) of SRT2104 (formulation selected from Part 1) will be administered as a single oral dose.
62847338|NCT01702493|EXPERIMENTAL|Part 2C: SRT2104 500 mg daily for 7 days|500 mg SRT2104 (formulation selected from Part 1) will be administered daily for 7 days.
62264847|NCT06169475|NO_INTERVENTION|control group|
62847339|NCT02759718|EXPERIMENTAL|pancreatic neuroendocrine tumor|chromogranin A
62847340|NCT05266885||Male and Female|(37 male, 63 female)
62847341|NCT05989451|NO_INTERVENTION|Treatment as Usual (TAU)|Treatment-as-usual (TAU) is a naturalistic treatment condition as delivered in current daily practice by psychiatrists in the medical services in Taiwan. TAU typically includes prescription and monitoring of antidepressant and/or anxiolytic medication, psychological treatment (this may include empathic listening and/or supportive counselling, psychoeducation, etc), or a combination of both. Patients in the TAU condition already receiving any of the aforementioned treatments are informed they will continue to receive as usual the services received before enrollment in the study.
62060732|NCT02612480|ACTIVE_COMPARATOR|Clopidogrel and acetylsalicylic acid|7 day treatment with clopidogrel x75 mg after a loading dose of 300 mg and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg
62264848|NCT00283075|EXPERIMENTAL|Cancer macrobeads|Cancer Macrobead placement in abdominal cavity
62264849|NCT04186741||HBO Group|Patients already recieving hyperbaric oxygen therapy for treatment of other medical conditions requiring it as in diabetic foot , cerebral infarctions
62264850|NCT01448460||Fertility Patients|IVF patients with extra eggs or other subjects who desire egg vitrification for fertility preservation
62847342|NCT05989451|EXPERIMENTAL|Transdiagnostic Adapted DBT plus TAU|The modified DBT protocol, developed by the principal investigator and co-investigators, which will be offered in an individual therapy format. It consists of 12 weekly individual sessions, each lasting 50-60 minutes. It is made based on the manual (Linehan 2015), retaining the essence of DBT (Linehan 1993), and remain dialectically focused. Each session focuses on specific skills within that content of modules.
62847343|NCT01278472|EXPERIMENTAL|Single Port Cholecystectomy|Laparoscopic Cholecystectomy with single port transumbilical access
62847344|NCT01278472|ACTIVE_COMPARATOR|4 Port Cholecystectomy|Laparoscopic Cholecystectomy using 4 separate conventional trocars
62847345|NCT02036853|EXPERIMENTAL|Schedule A|Subjects previously treated with triheptanoin
62847346|NCT02036853|EXPERIMENTAL|Schedule B|Naïve to triheptanoin
62847347|NCT04497623|EXPERIMENTAL|Intervention arm|Patients with indication for volume-controlled mechanical ventilation
62264851|NCT00677274|ACTIVE_COMPARATOR|1|Epidural analgesia initiated at the cervix 0cm
62264852|NCT00677274|ACTIVE_COMPARATOR|2|Epidural analgesia initiated at the cervix 0.5cm
62264853|NCT00677274|ACTIVE_COMPARATOR|3|Epidural analgesia initiated at the cervix 1.0cm
62264854|NCT00677274|ACTIVE_COMPARATOR|4|Epidural analgesia initiated at the cervix 1.5cm
62264855|NCT00677274|ACTIVE_COMPARATOR|5|Epidural analgesia initiated at the cervix 2.0cm
62264856|NCT00677274|ACTIVE_COMPARATOR|6|Epidural analgesia initiated at the cervix 3.0cm
62264857|NCT00677274|ACTIVE_COMPARATOR|7|Epidural analgesia initiated at the cervix 4.0cm
62264858|NCT00677274|ACTIVE_COMPARATOR|8|Epidural analgesia initiated at the cervix 5.0cm
62264859|NCT02326454|ACTIVE_COMPARATOR|Talaporfin sodium/Light dose 100 J/cm|Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
62264860|NCT02326454|ACTIVE_COMPARATOR|Talaporfin sodium/Light dose 200 J/cm|Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours
62264861|NCT02326454|PLACEBO_COMPARATOR|Saline/Light dose 100 J/cm|0.9% Sodium Chloride is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
62264862|NCT02326454|PLACEBO_COMPARATOR|Saline/Light dose 200 J/cm|0.9% Sodium Chloride is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours.
62264863|NCT04923659|EXPERIMENTAL|LIFUS|Low Intensity Focussed ultrasound.
62621348|NCT05665426|OTHER|MC group|(4) MC group: moxibustion at Chize point.
62621349|NCT01114295|EXPERIMENTAL|Overt Obscure Gastrointestinal Bleeders|The only cohort in this study are those patients identified as having overt, obscure gastrointestinal bleeding who will then undergo CE or CTE.
62621350|NCT04482608||pMMR/MSS mCRC patients|The metastatic colorectal cancer patients with proficient mismatch repair or microsatellite stable status.
62621351|NCT04482608||dMMR/MSI-H mCRC patients|The metastatic colorectal cancer patients with deficient mismatch repair or microsatellite instability high status.
62621352|NCT05882383||Control Group|unifected with SARS-CoV-2 during follow-up
62621353|NCT05882383||Group A|uninfected at the first visit, have been infected at the second visit
62621354|NCT05882383||group B|have been infected at twice visit
62621355|NCT00568217|ACTIVE_COMPARATOR|1 drug|diclofenac 15 mg/kg suppository once
62621356|NCT00568217|PLACEBO_COMPARATOR|2 drug|Placebo suppository once
62847348|NCT04336501|EXPERIMENTAL|IM19 CAR-T group|Subject will be treated with IM19 car-t cells
62847349|NCT03114540|EXPERIMENTAL|GBT440 Dose 1:Mild hepatic impairment|Child Pugh A
62847350|NCT03114540|EXPERIMENTAL|GBT440 Dose 1:Moderate hep. impairment|Child Pugh B
62847351|NCT03114540|EXPERIMENTAL|GBT440 Dose 1:Severe hepatic impairment|Child Pugh C
62847352|NCT03114540|EXPERIMENTAL|GBT440 Dose 1:Normal hepatic function|Healthy subjects
62060733|NCT02612480|PLACEBO_COMPARATOR|Placebo and acetylsalicylic acid|7 day treatment with placebo and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg
62264864|NCT02874807|ACTIVE_COMPARATOR|Empagliflozin|Treatment with empagliflozin 25mg once daily for four days
62264865|NCT02874807|PLACEBO_COMPARATOR|Placebo|Treatment with Placebo once daily for four days
62264866|NCT03116698|EXPERIMENTAL|Low dose DFD07 once daily|
62621357|NCT00568217|ACTIVE_COMPARATOR|3 drug|acetaminophen mixture 15 mg/kg up to four times a day
62621358|NCT00568217|ACTIVE_COMPARATOR|4 drug|ibuprofen mixture 10 mg/kg up to four times a day
62621359|NCT00568217|PLACEBO_COMPARATOR|5 drug|oral placebo mixture up to four times a day
62847353|NCT04812262|EXPERIMENTAL|Group A1 - Single Ascending Dose|DD01 Dose 1 (N=6) Placebo (N=2) Subcutaneous injection
62847354|NCT04812262|EXPERIMENTAL|Group A2, Single Ascending Dose|DD01 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection
62847355|NCT04812262|EXPERIMENTAL|Group A3, Single Ascending Dose|DD01 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection
62847356|NCT04812262|EXPERIMENTAL|Group A4, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
62621360|NCT04452552|EXPERIMENTAL|ultra-sound cavitation|cavitation40 KHz applied for 30 min, once time weekly for 8 weeks.
62847357|NCT04812262|EXPERIMENTAL|Group B2 - Multiple Ascending Dose|DD01 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
62621361|NCT04452552|EXPERIMENTAL|radiofrequency|radiofrequency multi-polar 5MHZ applied for 30 min, once time weekly for 8 weeks
62621362|NCT01760213|EXPERIMENTAL|Treatment|intervention delivered via internet
62621363|NCT01760213|NO_INTERVENTION|Control|
62621364|NCT03485703|EXPERIMENTAL|azithromycin group|A control group composed of 40 newborns receiving azithromycin
62060734|NCT02612480|PLACEBO_COMPARATOR|Placebo|7 day treatment with 2 placebos
62264867|NCT03116698|EXPERIMENTAL|High dose DFD07 once daily|
62264868|NCT03116698|EXPERIMENTAL|High dose DFD07 twice daily|
62264869|NCT03116698|PLACEBO_COMPARATOR|Placebo twice daily|
62264870|NCT03740971|EXPERIMENTAL|Guideline-based therapy+RIC|RIC is given twice a day with 200mmHg pressure.
62264871|NCT03740971|ACTIVE_COMPARATOR|Guideline-based therapy|
62264872|NCT03801850|EXPERIMENTAL|observational cohort|
62621365|NCT03485703|PLACEBO_COMPARATOR|placebo group|comparative group composed of 40 newborns who would receive saline 0.9%
62621366|NCT02086955|NO_INTERVENTION|Standard care|All participants receive three specially-developed brochures with information regarding the diabetic foot condition. The brochures containes explanations to a) the cause and warning signs of diabetic foot ulcers, b) the precautions patients can take in their daily life, and c) helpful foot gymnastics to be practiced at home.
62621367|NCT02086955|EXPERIMENTAL|Nursing counseling|The participants who are randomized in the intervention group receive standardized education regarding diabetic foot care. The nurse-led outpatient intervention go on for five weeks. During a period of five weeks, the participants are provided with weekly education, skill training, and counseling sessions on foot care.
62621368|NCT01207011|EXPERIMENTAL|1 AMR|
62621369|NCT01207011|ACTIVE_COMPARATOR|2 DOC|
62847358|NCT04812262|EXPERIMENTAL|Group B3 - Multiple Ascending Dose|DD01 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
62847359|NCT04812262|EXPERIMENTAL|Group B4 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
62621370|NCT04264754||Cases Group|Subjects who have already been diagnosed with liver cancer, however did not yet undergo any surgery, ablation, embolization or any other treatment for this cancerous lesion (including, but not limited to systemic therapies)
62621371|NCT04264754||Control Group|"Cancer free subjects with high risk to development HCC. High risk subjects include the following:~1. Subjects with HCV (hepatitis C virus) and cirrhosis~2. Subjects with HBV (hepatitis B virus) and cirrhosis~3. Non-cirrhotic chronic HBV subjects at intermediate or high risk of HCC, according to EASL (European Association for the Study of the Liver) Clinical Practice Guidelines for the management of hepatocellular carcinoma~4. Subjects with NAFLD (Non-Alcoholic Fatty Liver Disease) with cirrhosis~5. Cirrhotic patients due to any other reasons, including alcohol disease"
62621372|NCT01359020|EXPERIMENTAL|Ibuprofen|10 milligram per kilo, oral administration
62847360|NCT04812262|EXPERIMENTAL|Group B5 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
62847361|NCT04812262|EXPERIMENTAL|Group B6 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
62847362|NCT04812262|EXPERIMENTAL|Group A5, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
62621373|NCT01359020|ACTIVE_COMPARATOR|Acetaminophen|10 milligram per kilo, oral administration
62621374|NCT01359020|ACTIVE_COMPARATOR|Dipyrone|10 milligram per kilo, oral administration
62847363|NCT04812262|EXPERIMENTAL|Group A6, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
62264873|NCT02448030|EXPERIMENTAL|Functional electric stimulation|Other: The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively.
62264874|NCT02448030|PLACEBO_COMPARATOR|Isometric exercise|For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test.
62264875|NCT01997411|EXPERIMENTAL|Nasal Glucagon (NG)|Nasal glucagon (NG) doses of 2.0 mg and 3.0 mg for participants 4 to less than 12 years of age and 3.0 mg for those 12 to less than 17 years of age were administered in a nostril with a prefilled delivery device that delivered a single dose upon activation.
62264876|NCT01997411|ACTIVE_COMPARATOR|Intramuscular (IM) Glucagon|Participants who weighed at least 25 kilograms (kg)/55 pounds (lbs) were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 lbs, IM glucagon dosed with 0.5 mg
62621375|NCT00634296|ACTIVE_COMPARATOR|G2|Inspiratory muscle training added by aerobic training to aerobic training alone
62621376|NCT02273128||CTR Gene in Osteoporosis and Periodontitis|Patients aged between 35 - 60 yrs with Osteoporosis (BMD\>-2.5) and Chronic Periodontitis (\>3mm Pocket Probing Depth)
62264877|NCT04182373|EXPERIMENTAL|KW-3357|72 IU/kg
62264878|NCT04182373|PLACEBO_COMPARATOR|placebo|
62621377|NCT05054816|EXPERIMENTAL|Investigational adaptive directional microphone strategy|Receiver-in-canal hearing aid with an investigational adaptive directional microphone strategy.
62621378|NCT05054816|ACTIVE_COMPARATOR|Comparator omnidirectional microphone strategy|Receiver-in-canal hearing aid with a comparator omnidirectional microphone strategy.
62621379|NCT05054816|ACTIVE_COMPARATOR|Comparator fixed directional microphone strategy|Receiver-in-canal hearing aid with a comparator fixed directional microphone strategy.
62621380|NCT05307003||Quetiapine|"Patients diagnosed with delirium who received quetiapine for treatment.~* Start study medication at 25 mg daily PO ; may increase to BID (twice a day) or TID (three times a day) if RASS\>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS\>=2 and/or \>1 dose of rescue medication is given within 24 hours \[max dose 200 mg/day\]~* dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE (adverse effects) likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~* dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
62621381|NCT05307003||Trazodone|"Patients diagnosed with delirium who received trazodone for treatment.~* Start study medication at 25 mg daily PO ; may increase to BID or TID if RASS\>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS\>=2 and/or \>1 dose of rescue medication is given within 24 hours \[max dose 200 mg/day\]~* dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~* dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
62621382|NCT01515696|ACTIVE_COMPARATOR|Gastrografin|infants receive 3ml/kg Gastrografin + 6ml/kg sterile water
62621383|NCT01515696|PLACEBO_COMPARATOR|Sterile water|infants receive 9ml/kg sterile water
62621384|NCT02657824||measuring ejection fraction|ejection fraction in an acute dyspneic patients
62621385|NCT01643486|EXPERIMENTAL|iTouch phosphate counting program|All patients will have an iTouch that will help them to calculate the required number of phosphate binders to be taken with each meal
62847364|NCT04812262|EXPERIMENTAL|Group A7, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
62847365|NCT04812262|EXPERIMENTAL|Group A8, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
62847366|NCT04812262|EXPERIMENTAL|Group B7 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
62847367|NCT04812262|EXPERIMENTAL|Group B8 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
62847368|NCT00084136|EXPERIMENTAL|ZDV/3TC+EFV|ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz
62847369|NCT00084136|EXPERIMENTAL|ddI+FTC+ATV|ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine
62847370|NCT00084136|EXPERIMENTAL|TDF/FTC+EFV|TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz
62847371|NCT06033755|OTHER|Participants with EILO were recruited and given treatment (i.e. one arm?)|Only participants with EILO were recruited and given treatment as usual.
62264879|NCT04697680|ACTIVE_COMPARATOR|Group 1|Subjects randomized into Group 1 will be provided with a sleep schedule each week based on an algorithm (Algorithm 1) calculated from sleep diaries and fitbit data. Subjects will complete questionnaires at an initial clinic visit. Subjects will then complete a sleep diary upon waking each day and wear a Fitbit Charge 2 device for sleep monitoring each day for 8 weeks. At the end of the study, subjects will complete follow-up questionnaires at a final clinic visit.
62621386|NCT01643486|ACTIVE_COMPARATOR|Usual Care|Participants in the active comparator group will document their meals in the iTouch but continue to take their phosphate binders as prescribed by their MD/dietician
62621387|NCT02840773|ACTIVE_COMPARATOR|Test group-baseline|Press-fit implant connection was monitored at baseline
62621388|NCT02840773|ACTIVE_COMPARATOR|Test group-12 month|Press-fit implant connection was monitored at 12 month after prosthesis delivered.
62621389|NCT02840773|ACTIVE_COMPARATOR|Control group-baseline|Screw-retained connection was monitored at baseline
62621390|NCT02840773|ACTIVE_COMPARATOR|Control group-12 month|Screw-retained connection was monitored at 12 month after prosthesis delivered.
62621391|NCT00860080|EXPERIMENTAL|PXL01|Four Subjects per cohort will receive 10, 20, or 40 mg PXL01 respectively.
62621392|NCT00860080|PLACEBO_COMPARATOR|Placebo|One subject per cohort will receive 10, 20, or 40 mg Placebo respectively.
62621393|NCT01394341|ACTIVE_COMPARATOR|T2D, Dialysis, Liraglutide|Daily liraglutide treatment Chronic dialysis treatment
62621394|NCT01394341|PLACEBO_COMPARATOR|T2D, Dialysis, Placebo|Daily placebo Chronic dialysis treatment
62621395|NCT01394341|ACTIVE_COMPARATOR|T2D, Normal kidney function, Liraglutide|Daily Liraglutide treatment Normal kidney function
62621396|NCT01394341|PLACEBO_COMPARATOR|T2D, Normal kidney function, Placebo|Daily placebo treatment Normal kidney function
62847372|NCT05273671|EXPERIMENTAL|nalbuphine|0.1 mg/kg nalbuphine diluted in 10 ml I.V 10 minutes before the end of surgery
62847373|NCT05273671|EXPERIMENTAL|dexmedetomedine|receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery
62264880|NCT04697680|ACTIVE_COMPARATOR|Group 2|Subjects randomized into Group 2 will be provided with a sleep schedule each week based on an algorithm (Algorithm 2) calculated from sleep diaries and fitbit data. Subjects will complete questionnaires at an initial clinic visit. Subjects will then complete a sleep diary upon waking each day and wear a Fitbit Charge 2 device for sleep monitoring each day for 8 weeks. At the end of the study, subjects will complete follow-up questionnaires at a final clinic visit.
62621397|NCT04656184|EXPERIMENTAL|KINERET|The patients will receive anakinra, an analogue of the IL-1 receptor antagonist, at a starting dose of 4 mg/kg. If patients are still febrile with 12 hours (H12) of treatment, they will receive a supplementary dose of 2 mg/Kg; otherwise, they will remain at a starting dose of 4 mg/kg. If they are still febrile at H24, they will receive a dose of 8mg/kg; otherwise, they will maintain their dose of 6 mg/kg. Patients with temperature \<38°C at any point between initiation and day 14, but who develop secondary fever due to KD could have further escalation dose of anakinra until a maximum dose of 8mg/Kg. Patients will receive anakinra during 14 days independently of the period of escalation dose if any. After the last escalation dose, if any necessary, the primary criteria will be measured. Patients not responding to anakinra will follow usual standard care and will complete information related to all the study visits
62060735|NCT03485677|EXPERIMENTAL|Cohort 1: Eliglustat monotherapy|"Eliglustat for at least two years. Cohort 1 patients that experience significant clinical decline will receive rescue treatment.~Rescue Treatment Step 1: Switch from eliglustat to imiglucerase monotherapy.~Rescue Treatment Step 2: Patients who after 6 months of rescue therapy with imiglucerase monotherapy do not show improvement in the parameter(s) that led to the switch from eliglustat to imiglucerase, will then receive combination therapy with eliglustat + imiglucerase."
62621398|NCT04656184|ACTIVE_COMPARATOR|Intravenous Immunoglobulin|The patients will receive a standard therapy, IVIG infusion of 2g/kg, and their treatment will follow usual standard care. Patients in the IVIG treatment will complete information related to the study visits.
62621399|NCT02131116|EXPERIMENTAL|IMT|Integrated Metacognitive Therapy
62621400|NCT02131116|NO_INTERVENTION|TAU|No intervention group/Treatment as Usual
62621401|NCT01883661|OTHER|BMMNC|Administration of of Bone Marrow derived Mono Nuclear Stem Cell (MNCs)
62621402|NCT00323076|EXPERIMENTAL|1|18F-FAZA PET Imaging
62621403|NCT00479115|EXPERIMENTAL|AMD3100|
62621404|NCT02283580|EXPERIMENTAL|Single limb resistance training|"Low load, high-repetitive resistance training.~* single limb at a time (e.g., one arm or one leg)~* elastic bands"
62621405|NCT02283580|ACTIVE_COMPARATOR|Two limb resistance training|"Low load, high-repetitive resistance training.~* two limbs at a time (e.g., both arms or both legs)~* elastic bands"
62621406|NCT02253381|ACTIVE_COMPARATOR|Right lateral decubitus position|Right lateral decubitus position during spinal anesthesia
62847374|NCT05273671|PLACEBO_COMPARATOR|saline|receive a saline solution 10 min before the end of surgery
62847375|NCT04286906||One group (cohort)|Asthmatic patients
62847376|NCT02920099||Nutrition Literacy|Participants will be asked to completed the Nutrition Literacy Assessment Instrument (NLAI).
62847377|NCT01961726|PLACEBO_COMPARATOR|Placebo|
62847378|NCT01961726|EXPERIMENTAL|30 mg dose of JVS-100|
62847379|NCT01961726|EXPERIMENTAL|45 mg dose of JVS-100|
62847380|NCT02230917|EXPERIMENTAL|Sotatercept|Sotatercept 0.2 mg/kg will be administered every 21 days for 12 doses subcutaneously into the upper arm, abdomen or thigh.
62847381|NCT02230917|PLACEBO_COMPARATOR|Placebo|0.2 mg/kg of normal saline will be administered subcutaneously in the upper arm, abdomen or thigh for 21 days for 12 doses.
62847382|NCT02761902||Preschool group|3-6 years old
62847383|NCT02761902||school age group|7-12 years old
62847384|NCT02761902||Adolescence group|13-15 years old
62847385|NCT00192634|ACTIVE_COMPARATOR|1|Abacavir 600mg/Lamivudine 300mg
62621407|NCT02253381|ACTIVE_COMPARATOR|Left lateral decubitus position|Left lateral decubitus position during spinal anesthesia
62621408|NCT00839748||asthmatics|asthmatics registry for those interested in future asthma studies
62847386|NCT00192634|ACTIVE_COMPARATOR|2|Tenofovir 300mg/emtricitabine 200mg
62847387|NCT04901689|EXPERIMENTAL|Leronlimab (700 mg)|Leronlimab 700 mg intravenously once a week (up to 4 doses) until hospital discharge
62847388|NCT04901689|PLACEBO_COMPARATOR|Placebo|Placebo intravenously once a week (up to 4 doses) until hospital discharge
62847389|NCT04527393|EXPERIMENTAL|individualized opioid analgesia regimen group|The dose of oral morphine for patients in the individualized group is determined according to the results of fentanyl test.
62847390|NCT04527393|ACTIVE_COMPARATOR|conventional opioid analgesia regimen group|Patients in the conventional group are given routine dose of oral morphine.
62264881|NCT04697680|ACTIVE_COMPARATOR|Group 3|Subjects randomized into Group 1 will be provided with a sleep schedule each week based on an algorithm (Algorithm 3) calculated from sleep diaries and fitbit data. Subjects will complete questionnaires at an initial clinic visit. Subjects will then complete a sleep diary upon waking each day and wear a Fitbit Charge 2 device for sleep monitoring each day for 8 weeks. At the end of the study, subjects will complete follow-up questionnaires at a final clinic visit.
62264882|NCT03169985|ACTIVE_COMPARATOR|Rosuvastatin plus ezetimibe arm|In patients who have moderate stenosis(30-70%) in coronary artery and deferred to medical treatment by intracoronary physiologic or radiologic test, this arm will be received rosuvastatin 10 mg plus ezetimibe 10 mg qd during 12 months after randomization.
62060736|NCT03485677|EXPERIMENTAL|Cohort 2: Eliglustat plus imiglucerase|Eliglustat plus imiglucerase for three years, at the dose of enzyme replacement therapy received before enrollment. After Week 52, Cohort 2 patients will switch to eliglustat monotherapy for the remainder of the study if the desired clinical response has been achieved.
62060737|NCT02110745|EXPERIMENTAL|Sevofluorane|Sevofluorane 8% in induction
62847391|NCT02787629|EXPERIMENTAL|Simultaneous|Simultaneous Intubation with GlideScope and ETT inserted simultaneously
62847392|NCT02787629|ACTIVE_COMPARATOR|Control Standard|Standard Intubation with GlideScope inserted first and ETT inserted after the GlideScope view is obtained
62847393|NCT05416710||Solid tumor cancers|Adult participants with a diagnosis of a solid tumor cancer who are able to consent to the study and who are interested in undergoing germline genetic testing will receive testing using Invitae's 84 gene Multi-Cancer panel.
62847394|NCT06371001||prevalence of helicobacter pylori in chronic kidney diseased patient|prevalence of helicobacter pylori in chronic kidney diseased patient
62060738|NCT02110745|EXPERIMENTAL|Propofol|Propofol 2.5 mg/kg intravenous in induction
62060739|NCT01630720|ACTIVE_COMPARATOR|vitamin C|vitamin C 500 mg twice daily
62060740|NCT01630720|ACTIVE_COMPARATOR|vitamin D|vitamin D 5000 IU daily
62264883|NCT03169985|ACTIVE_COMPARATOR|High-dose rosuvastatin monotherapy arm|In patients who have moderate stenosis(30-70%) in coronary artery and deferred to medical treatment by intracoronary physiologic or radiologic test, this arm will be received rosuvastatin 20 mg qd during 12 months after randomization.
62264884|NCT00794677|PLACEBO_COMPARATOR|Sugar Pill|Placebo medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
62264885|NCT00794677|EXPERIMENTAL|ezetimibe|10 mg medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
62264886|NCT00664833|EXPERIMENTAL|Arm 2|
62264887|NCT00664833|OTHER|Arm 4|
62264888|NCT00664833|EXPERIMENTAL|Arm 3|
62264889|NCT00664833|EXPERIMENTAL|Arm 1|
62264890|NCT04414800|PLACEBO_COMPARATOR|Control (Placebo+ Standard of Care))|
62264891|NCT04414800|ACTIVE_COMPARATOR|Ketamine + Standard of Care|
62264892|NCT04414800|ACTIVE_COMPARATOR|Fentanyl + Standard of Care|
62264893|NCT01834092|ACTIVE_COMPARATOR|Fresh frozen plasma|2 portions of FFP will be transfused prior to reperfusion
62264894|NCT01834092|EXPERIMENTAL|Fresh non-frozen plasma|2 portions of non-frozen plasma will be transfused prior to reperfusion
62847395|NCT06371001||prevalence of helicobacter pylori in non chronic kidney diseased patient|prevalence of helicobacter pylori in non chronic kidney diseased patient
62847396|NCT03059680|EXPERIMENTAL|High potassium diet group|Individuals in this arm were asked to increase dietary potassium intake over a 4 week period. This was achieved through an increase in consumption of fruits and vegetables.
62847397|NCT03059680|NO_INTERVENTION|Usual diet group|Individuals in this group were asked to continue habitual dietary intake
62264895|NCT02210065|EXPERIMENTAL|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
62264896|NCT04077996|ACTIVE_COMPARATOR|Peritonitis treatment with one exchange in CAPD|This group will receive peritonitis treatment with one exchange on Continuous Ambulatory Peritoneal Dialysis per day. The initial antibiotic scheme will be with ceftazidime (1500mg/day) and vancomycin (20mg/kg every 3 days) according to current management guidelines; adjusting the management according to the result of the culture, completing the antibiotic scheme for 14 to 21 days.
62621409|NCT04891926|EXPERIMENTAL|Hormonal therapy|Patients choosing to start hormoanl treatment using ural or transdermal estrogen.
62621410|NCT05964829|EXPERIMENTAL|Control|Participants will follow the walking program.
62621411|NCT05964829|EXPERIMENTAL|Functional electrical stimulation|Participants will follow the walking program and receive stimulation assistance during the walking sessions.
62621412|NCT04736095||3D ultrasound for diagnosis of submucous myomas|
62621413|NCT04736095||Hysteroscopy for diagnosis of submucous myoma|
62621414|NCT02076815|EXPERIMENTAL|Anagrelide retard|Anagrelide Retard prolonged-release formulation
62621415|NCT02076815|ACTIVE_COMPARATOR|Thromboreductin|Anagrelide immediate release formulation
62621416|NCT01593449|ACTIVE_COMPARATOR|American Heart Association|Participants will receive handouts on increasing physical activity derived from the American Heart Association materials on increasing physical activity.
62621417|NCT01593449|EXPERIMENTAL|Dog Walking|The 6-month dog walking intervention involves 5 components to address the individual, interpersonal and community levels of the socio-ecological model: newsletters, pedometers, social networking website, neighborhood dog walks, and invitations to community events.
62621418|NCT02890563|NO_INTERVENTION|No Compression|Patients in this group will not receive any compression after treatment.
62621419|NCT02890563|ACTIVE_COMPARATOR|Compression|Patients in this group will use compression stockings for seven days after treatment (2 days continuously and 5 days during daytime).
62621420|NCT04406116|EXPERIMENTAL|patients receiving microwave therapy using the HS1 Instrument|
62621421|NCT04779281|EXPERIMENTAL|Oral Rehydration Salts supplemented with L. Rhamnosus GG|a supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, Lactobacillus Rhamnosus GG ATC53103 HN019 strain and fructooligosaccharides
62621422|NCT04779281|EXPERIMENTAL|Oral Rehydration Salts only|A supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, microcrystalline cellulose
62621423|NCT01724944|EXPERIMENTAL|Systematic Lymphadenectomy|
62621424|NCT02148081||Critically ill children|
62621425|NCT02644447|EXPERIMENTAL|HUC-MSCs Transplantation|
62621426|NCT02644447|EXPERIMENTAL|HUC-MSCs with Injectable Collagen Scaffold Transplantation|
62621427|NCT05180890|PLACEBO_COMPARATOR|Placebo|Placebo infusion, intravenously, administered overnight for approximately 10-hours on Days 1 to 2 in each Treatment Period 1, 2, or 3.
62621428|NCT05180890|EXPERIMENTAL|Danavorexton LD|Danavorexton LD regimen, infusion, intravenously, administered overnight for approximately 10-hours on Days 1 to 2 in each Treatment Period 1, 2, or 3.
62621429|NCT05180890|EXPERIMENTAL|Danavorexton HD|Danavorexton HD regimen, infusion, intravenously, administered overnight for approximately 10-hours on Days 1 to 2 in each Treatment Period 1, 2, or 3.
62060741|NCT01547988|EXPERIMENTAL|Balance Training Intervention|The Balance Training Intervention group received 24 training sessions over three months that included perturbation as well as dual-task exercises.
62060742|NCT01547988|NO_INTERVENTION|Reference Group|
62621430|NCT02889146|ACTIVE_COMPARATOR|Control group|Conventional Physical Therapy: motor physical therapy delivered by the intensive care unit physical therapists, according to his own criteria, without following any protocol. Respiratory therapy.
62621431|NCT02889146|EXPERIMENTAL|Protocol group|Early and progressive mobilization program: motor physical therapy delivered by a trained physical therapist according to the mobilization protocol, in which patient progress according to his performance. Respiratory therapy.
62621432|NCT06342856|ACTIVE_COMPARATOR|Group 1|will receive a daily dose of 200 mg of CoQ10 for 3 months
62621433|NCT06342856|ACTIVE_COMPARATOR|Group 2|will receive L-carnitine 1 tablet per day orally for 3 months
62621434|NCT06342856|ACTIVE_COMPARATOR|Group 3|will receive combination of a daily dose of 200 mg of CoQ10 and 1 tablet of L-carnitine for 3 months
62621435|NCT06342856|PLACEBO_COMPARATOR|Group 4|will receive a placebo for 3 months
62621436|NCT02868736||Suspected Periprosthetic Joint Infection|Individuals who are suspected of having Periprosthetic Joint Infection (PJI)
62621437|NCT00640406|EXPERIMENTAL|STN|Device: Dynamic Renal Stent plus Best Medical Treatment
62621438|NCT00640406|ACTIVE_COMPARATOR|BMT|Drug: Best Medical Treatment
62621439|NCT05972642|EXPERIMENTAL|HIFU treatment|Eligible patients will be treated with HIFU instrument.
62621440|NCT06331975|OTHER|Radiomic signature|Assessment of radiomic signature and tumor genetic profile at baseline
62621441|NCT05495529||Patients|Patients with single liver tumor traited by thermoablation with high iatrogenic risk, with biliary or digestive protection by ambiant air interposition
62621442|NCT04385979|ACTIVE_COMPARATOR|Curcumin|%2 Curcumin gel
62621443|NCT04385979|ACTIVE_COMPARATOR|Nanocurcumin|%1 NanoCurcumin gel
62621444|NCT00986323|ACTIVE_COMPARATOR|Temeperature controlled Laminar Airflow|Active treatment with Temperature controlled Laminar Airflow (TLA)
62621445|NCT00986323|PLACEBO_COMPARATOR|Placebo TLA|Placebo TLA treatment
62621446|NCT04561986|ACTIVE_COMPARATOR|Arm A: Standard of care (SOC) + tocilizumab (TCZ)|SOC, as below + TCZ (162 mg every week, subcuataneous administration)
62621447|NCT04561986|NO_INTERVENTION|Arm B: SOC|Tacrolimus (target concentration 6 ±1 µg/L) + MPA (1.5-2 g/day as tolerated) + prednisolone (not less than 5 mg/day), all oral administration
62621448|NCT04625413|EXPERIMENTAL|Experimental: Experimental Arm: single|The UR-GOAL tool will incorporate conjoint analysis to elicit patient preferences as well as assessments of fitness and prognostic awareness.
62621449|NCT02517021|EXPERIMENTAL|Pro-netupitant/Palonosetron plus Dexamethasone|Intravenous Pro-netupitant/Palonosetron (260 mg/0.25 mg) powder for solution for infusion (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
62847398|NCT04165421|EXPERIMENTAL|Family intervention group|The intervention starts with a two hour group session for AF-patients and family members designed by the PhD student and the project nurses based on clinical guidelines of AF-management and theory from multifamily group intervention. Project nurses who are also Nurse specialists will facilitate knowledge to patients and family members about AF and how to support self-management in their daily living. Furthermore the (Family focused nursing) FFN intervention will consist of 3 -5 Family Strength Orientated Therapeutic Conversations (FAM-SOTC) accordingly to the needs of patient and the family. The FAM-SOTC conversations will be used as health promoting conversations and a way to enhance family health and psychological resilense
62847399|NCT04165421|NO_INTERVENTION|Control group|"The control group will receive conventional care and treatment according to guidelines.~Conventional care is characterized by ad hoc management as per usual standards of clinical care (with access to routine medical care, hospital care, and pharmacotherapy)."
62847400|NCT05525806|NO_INTERVENTION|Control Group|Control group treats their simulated patients using standard practice and have no introduction to the new LynxDx test.
62847401|NCT05525806|EXPERIMENTAL|Intervention Group 1|Intervention Group 1 will receive information regarding the LynxDx rest and will be given the test results, whether selected or not, in Round 2 of CPV administration.
62847402|NCT05525806|EXPERIMENTAL|Intervention Group 2|Intervention Group 2 will receive information regarding the LynxDx test and will be given the test results if selected in Round 2 of CPV administration.
62847403|NCT01148992|ACTIVE_COMPARATOR|Lofexidine|
62847404|NCT01148992|PLACEBO_COMPARATOR|Placebo|
62847405|NCT03897517|EXPERIMENTAL|Proprietary Botanical Blend|Proprietary Botanical Blend - Dietary supplement with alpha amylase and sucrase inhibitory activity. 2 capsules
62847406|NCT03897517|PLACEBO_COMPARATOR|Placebo|Non/minimally nutritive nonactive material: rice flour. 2 capsules
62847407|NCT01396447|PLACEBO_COMPARATOR|Placebo|Participants received placebo orally once a day for 8 weeks.
62264897|NCT04077996|EXPERIMENTAL|Peritonitis treatment placed in APD|This group will receive peritonitis treatment placed in Automated Peritoneal Dialysis. The initial antibiotic scheme will be with ceftazidime (1500mg/day) and vancomycin (20mg/kg every 3 days); adjusting the management according to the result of the culture, completing the antibiotic scheme for 14 to 21 days.
62264898|NCT06091215|ACTIVE_COMPARATOR|Single Treatment Arm|Subjects will receive a single treatment of BBL/MOXI/HALO
62264899|NCT06091215|ACTIVE_COMPARATOR|Double Treatment Arm|Subjects will receive double treatment of BBL/MOXI/HALO 4-6 weeks apart.
62448350|NCT03389386||Congestive Heart Failure (NYHA II-IV)|"N=90~Patients with a clinically documented diagnosis of congestive heart failure (CHF), as assessed per New York Heart Association (NYHA) functional classification will be prospectively and consecutively enrolled in this group. Patients will be of both sexes, enrolled in 1:1 ratio.~All subjects in this group will undergo blood withdrawal for laboratory analysis, transthoracic echocardiography (TTE) examination and will be treated with the Standard-of-care treatment according to their current clinical condition at admission."
62448351|NCT03389386||Healthy Control Group|"N=30~Healthy volunteers (both sexes, enrolled in 1:1 ratio) with a negative history of cardiovascular diseases will be enrolled in this group that will serve as a study control.~All subjects in this group will undergo blood withdrawal for laboratory analysis and transthoracic echocardiography (TTE) examination."
62448352|NCT01197313|EXPERIMENTAL|Exercise|
62448353|NCT00322400|EXPERIMENTAL|B1|AMG 706 50 mg daily + Docetaxel (100 mg/m2 D1 every 21 days)
62847408|NCT01396447|EXPERIMENTAL|Cariprazine 0.75 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2 and cariprazine 0.75 mg orally once a day starting on Day 3 for the remainder of the 8 week treatment period.
62847409|NCT01396447|EXPERIMENTAL|Cariprazine 1.5 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, and cariprazine 1.5 mg orally once a day starting on Day 8 for the remainder of the 8 week treatment period.
62264900|NCT03593252|EXPERIMENTAL|Combination bowel prep|"Patients will received mechanical bowel preparation (age appropriate dose, starting 2 days before surgery) and prophylactic oral antibiotics (3 doses, 1 day before surgery).~Clear fluids (or breast milk if applicable) will be given starting day before surgery.~The standard care will also be delivered (NPO for anesthesia and intravenous antibiotics on induction) Patients/parents will be provided with stool diary to document the adequacy of preparation. This will include frequency and character of stool according to Bristol grade. The treating surgeon will rate the adequacy of the preparation intra-operatively."
62847410|NCT01396447|EXPERIMENTAL|Cariprazine 3.0 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, cariprazine 1.5 mg orally on Days 8-14, and cariprazine 3.0 mg orally once a day starting on Day 15 for the remainder of the 8 week treatment period.
62264901|NCT03593252|ACTIVE_COMPARATOR|Oral antibiotics|The patients will receive prophylactic oral antibiotics (3 doses, 1 day before surgery)as well as standard care (NPO for anesthesia and intravenous antibiotics on induction).
62448354|NCT00322400|EXPERIMENTAL|A4|75 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8 and D15 every 28 days)
62448355|NCT00322400|EXPERIMENTAL|A1|AMG 706 50 mg daily + Paclitaxel (90 mg/m2 D1, D8, D15 every 28 days)
62448356|NCT00322400|EXPERIMENTAL|B4|75 mg AMG 706 daily + Docetaxel (100 mg/m2, D1 every 21 days)
62847411|NCT02377739|EXPERIMENTAL|non-invasive ventilation|patients will undergo about 14 nights of non-invasive ventilation during pulmonary rehabilitation
62847412|NCT02897661|EXPERIMENTAL|Early WMT and EEN|WMT (day1), EEN (day1-15)
62847413|NCT02897661|EXPERIMENTAL|Late WMT and EEN|WMT (day8), EEN (day1-15)
62847414|NCT04779788|EXPERIMENTAL|I-125 seeds loaded stent group|Patients who receive the I-125 seeds loaded stent insertion
62847415|NCT04779788|ACTIVE_COMPARATOR|Normal stent group|Patients who receive the normal stent insertion
62847416|NCT04651504|EXPERIMENTAL|Primary Care Clinics|"* Southern Illinois Healthcare System will contact the site management and ask for participation in the study~* Eligible providers and staff will be identified by clinic management. The research coordinator will work with the clinic to schedule a virtual site visit(s). The study team will interview providers and staff at the beginning and/or end of each active intervention period to assess knowledge and attitudes about CRC screening and follow-up processes, the Consolidated Framework for Implementation Research (CFIR) constructs such as role clarity within the clinical team, and satisfaction with the intervention and implementation. Post-implementation surveys will also ask about work-arounds and adaptations of the intervention tools and perceived efficacy."
62847417|NCT00888186|ACTIVE_COMPARATOR|1. Duodopa optimal dose|
62847418|NCT00888186|EXPERIMENTAL|2. Duodopa 20% too high dose|
62847419|NCT00888186|EXPERIMENTAL|3. Duodopa 10% too low dose|
62847420|NCT00888186|EXPERIMENTAL|4. Duodopa 20% too low dose|
62448357|NCT00322400|EXPERIMENTAL|B5|MTD of AMG 706 + Docetaxel (75mg/m2 D1 every 21 days)
62448358|NCT00322400|EXPERIMENTAL|B3|100 mg AMG 706 daily + Docetaxel (100 mg/m2 on D1 every 21 days)
62847421|NCT00888186|EXPERIMENTAL|5. Duodopa 10% too high dose|
62847422|NCT05574413|PLACEBO_COMPARATOR|Resting (no exercise) control|Resting (no exercise) control condition
62847423|NCT05574413|EXPERIMENTAL|Moderate intensity continuous exercise (MICE)|Experimental session involving an acute bout of moderate intensity continuous exercise (MICE; continous cycling expending 350 kcal at 70% of lactate threshold)
62847424|NCT05574413|EXPERIMENTAL|High intensity continuous exercise (HICE)|Experimental session involving an acute bout of high intensity continuous exercise (HICE; continuous cycling expending 350 kcal at 10% of the difference between lactate threshold and VO2peak)
62847425|NCT05574413|EXPERIMENTAL|High intensity interval exercise (HIIT)|Experimental session involving an acute bout of high intensity interval exercise (HIIT; cycling intervals expending 350 kcal at 10% of the difference between lactate threshold and VO2peak)
62264902|NCT03593252|PLACEBO_COMPARATOR|No prep|Patients will receive no pre-operative bowel prep. The will receive the standard care only.
62264903|NCT05341960|EXPERIMENTAL|Food Delivery|Food box delivered to participant home every 2 weeks until 6 weeks post delivery
62264904|NCT05341960|EXPERIMENTAL|Financial Support and Navigation|$30 provide on gift card every two weeks until 6 weeks post delivery + neighborhood food retail navigation support.
62264905|NCT05341960|NO_INTERVENTION|Control Group|Selected from claims data, matched.
62448359|NCT00322400|EXPERIMENTAL|B2|AMG 706 125 mg daily + Docetaxel (100 mg/m2 D1 every 21 days)
62448360|NCT00322400|EXPERIMENTAL|A2|AMG 706 125 mg daily + paclitaxel 90 mg/m2 D1, D8, D15 every 28 days
62448361|NCT00322400|EXPERIMENTAL|A3|100 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8, and D15 every 28 days)
62448362|NCT04805684|ACTIVE_COMPARATOR|lung ultrasound 12|12 zone lung ultrasonography protocol
62448363|NCT04805684|ACTIVE_COMPARATOR|lung ultrasound 14|14 zone lung ultrasonography protocol
62448364|NCT00231868|EXPERIMENTAL|A|Drug:Carboplatin and Paclitaxel and Radiation: Pelvic Radiation Therapy
62448365|NCT03997747||comprehensive genomic analysis group|Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray. The therapy patients received would not be based on the results of the genomic analysis.
62448366|NCT01055964|EXPERIMENTAL|Tacrobell|
62448367|NCT01055964|ACTIVE_COMPARATOR|Prograf|
62448368|NCT05787756||Parkinson disease|Participants with newly diagnosed Parkinson's disease
62448369|NCT05787756||Control Subjects|Control subjects - will be selected from household/spousal contacts of the participants with Parkinson's disease
62448370|NCT05299268|EXPERIMENTAL|Pain (hypertonic saline)|Injection (1 ml) of painful hypertonic saline (5.8%) prior to performance of the 1x3 min Seated Isometric Knee Extension
62847426|NCT01656265|EXPERIMENTAL|ARQ 197|
62847427|NCT05546203|EXPERIMENTAL|Ischemic compression (IC) group|Ischemic compression group received ischemic compression and standardized exercise program twice a week for 6 weeks. Each session takes 50 minutes.
62847428|NCT05546203|EXPERIMENTAL|Low-level laser therapy (LLLT) group|Low-level laser therapy group received Low-level laser therapy and standardized exercise program twice a week for 6 weeks. Each session takes 50 minutes.
62847429|NCT02767349|EXPERIMENTAL|MNK-155|MNK-155, initial dose of two or three tablets followed by 2 tablets every 12 hours up to a maximum of five doses.
62621450|NCT02517021|ACTIVE_COMPARATOR|Netupitant/Palonosetron plus Dexamethasone|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
62847430|NCT02879006|ACTIVE_COMPARATOR|Chinese Herbal Medication|
62060743|NCT04959487|NO_INTERVENTION|Standard of care|Control participants will receive standard of care as offered by clinical partners to all T2DM patients, including referral to nutritional counseling, T2DM support groups, and participation in local diabetes self-management programs. Control participants are also often provided referral information for locally available food support services in the region that provide diabetes-appropriate foods. At the end of follow up, the control arm will receive similar services from POH to what the intervention arm received during the intervention, regardless POH eligibility criteria (6 months of DM-tailored food support to meet 67% of their daily requirements, video recording of the 4 CHEFS-DM education classes, and access to a POH dietitian at their request).
62060744|NCT04959487|EXPERIMENTAL|Food support and nutrition education|The intervention entails two components: 1) food support that consists of weekly medically tailored meals and healthy groceries that on average covers 75% of daily energy requirements from baseline to six months and 2) diabetes-tailored nutritional education that consists of two individual counseling sessions with a Registered dietitian and four group education sessions.
62448371|NCT05299268|PLACEBO_COMPARATOR|No pain (isotonic saline)|Injection (1 ml) of non-painful isotonic saline (0.9%) prior to performance of the 1x3 min Seated Isometric Knee Extension
62847431|NCT02879006|PLACEBO_COMPARATOR|Placebo|
62847432|NCT02460237|EXPERIMENTAL|Arm I (intervention)|Participants receive a study kit that includes culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing. Participants are asked to complete the HPV self-test and return the test for HPV testing.
62264906|NCT05558280|EXPERIMENTAL|Dinutuximab beta|The treatment phase foresees 5 cycles of Dinutuximab Beta. Dinutuximab Beta administration is restricted to hospital-use only and must be administered under the supervision of a physician experienced in the use of oncological therapies. It must be administered by a healthcare professional prepared to manage severe allergic reactions including anaphylaxis in an environment where full resuscitation services are immediately available. The study treatment will be administered with a continuous intravenous infusion at a dose of 14 mg/mq/day, days 1-5, a total of 60 hours (cumulative dose/cycle: 70 mg/mq). Each cycle lasts 28 days.
62847433|NCT02460237|ACTIVE_COMPARATOR|Arm II (control)|Participants receive a study kit that includes standard instructions for using and returning the HPV self-test device and a standard information sheet about HPV and cervical cancer. Participants are asked to complete the HPV self-test and return the test for HPV testing.
62847434|NCT03315962|EXPERIMENTAL|Aim 1: DHO Intervention Arm|A selection of DHO or TB district supervisors that are randomized to the multicomponent SPIRIT intervention.
62847435|NCT03315962|NO_INTERVENTION|Aim 1: DHO Control Arm|A selection of DHO or TB district supervisors that are randomized to the country standard of care, but not to receive the study intervention.
62847436|NCT01589991|PLACEBO_COMPARATOR|Non-fluoride toothpaste|
62060745|NCT00658502||1|
62060746|NCT00658502||2|
62060747|NCT00602914|EXPERIMENTAL|1|10 healthy volunteers will receive 0.1 U/kg. Once administered with a conventional needle (SQ) and then with MicronJet needle (ID) in a randomized order
62621451|NCT00560482|ACTIVE_COMPARATOR|A|
62621452|NCT00560482|PLACEBO_COMPARATOR|B|
62847437|NCT01589991|EXPERIMENTAL|Toothpaste 550 µg F/g (NaF/SiO2)|
62847438|NCT01589991|EXPERIMENTAL|Toothpaste 1100 µg F/g (NaF/SiO2)|
62847439|NCT01589991|EXPERIMENTAL|Toothpaste 1450 µg F/g (MFP/CaCO3)|
62847440|NCT03966339|EXPERIMENTAL|GH group|Growth Hormone adding to controlled ovarian hyperstimulation
62060748|NCT00602914|EXPERIMENTAL|2|10 Type II DM subject will receive 0.2 U/kg. Once administered with a conventional needle (SQ) and then with MicronJet needle (ID) in a randomized order
62060749|NCT04062123|EXPERIMENTAL|Dexmedetomidine|Subjects in this group will receive dexmedetomidine during the drug portion of the experiment.
62264907|NCT02474433|ACTIVE_COMPARATOR|PO Misoprostol|Patients assigned to PO Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
62448372|NCT02022007|ACTIVE_COMPARATOR|Metformin XR|Metformin 2000 mg daily (QD) for 16 weeks
62448373|NCT02022007|ACTIVE_COMPARATOR|Saxagliptin|Saxagliptin 5 mg QD for 16 weeks
62621453|NCT04393857||Oocyte donors|Healthy Oocyte donors fulfilling the criteria for oocyte donation are eligible. Patients may not have received any antibiotics or vaginal products (other than for menstrual hygiene - such as tampons) for the last 1 month. Informed consent is mandatory.
62621454|NCT03802734|EXPERIMENTAL|Mindful Meditation App|Group A will be given a free subscription to a mindful meditation phone app for six months. They will also be given an actigraph and a general pregnancy and sleep information leaflet.
62847441|NCT03966339|NO_INTERVENTION|control group|regular controlled ovarian hyperstimulation
62847442|NCT01590758|PLACEBO_COMPARATOR|Topical placebo control|
62847443|NCT01590758|EXPERIMENTAL|Topical pexiganan cream 0.8%|
62847444|NCT03961438|ACTIVE_COMPARATOR|Group A|HIV-uninfected participants
62847445|NCT03961438|ACTIVE_COMPARATOR|Group B|HIV-uninfected participants
62847446|NCT04841642|EXPERIMENTAL|Manual therapy and a telerehabilitation program|"In the experimental group, an intervention based on manual therapy and a telerehabilitation program based on exercises will be carried out.~The investigators will apply manual therapy for ten minutes a week based on cervical mobilizations and suboccipital inhibitions.~The access to telerehabilitation will be through a web page, through which patients could see explanatory videos of the exercises as many times as they need."
62847447|NCT04841642|ACTIVE_COMPARATOR|Manual therapy and recommendations for home exercises|"In the control group, the same manual therapy intervention and recommendations for home exercises will be applied.~This exercises recommendations will be based on a simulation of the exercise in the same session of the manual therapy of each week."
62847448|NCT04357223|EXPERIMENTAL|Experimental|
62847449|NCT04357223|PLACEBO_COMPARATOR|Placebo|
62847450|NCT01940172|EXPERIMENTAL|Birinapant with Conatumumab|
62847451|NCT01705509|OTHER|Ranolazine Treatment Arm|All patients who meet the criteria of ischemia will receive ranolazine after enrollment. The initial CPET will serve as the control. The second CPET after 30-days of therapy will serve as the therapy arm. CPET parameters will be assessed and compared both on and off therapy.
62847452|NCT06240416|EXPERIMENTAL|Control group|High speed drilling (800 rpm) with irrigation
62264908|NCT02474433|ACTIVE_COMPARATOR|PV Misoprostol|Patients assigned to PV Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
62264909|NCT02474433|ACTIVE_COMPARATOR|Buccal Misoprostol|Patients assigned to buccal Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
62448374|NCT02022007|EXPERIMENTAL|Saxagliptin-Metformin XR|"Saxagliptin-Metformin XR (combination pill)~5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks"
62621455|NCT03802734|NO_INTERVENTION|No Meditation App|Group B will be given an actigraph and a general pregnancy and sleep information leaflet only.
62621456|NCT03860766|SHAM_COMPARATOR|Sham Group (G-S)|The LED will be positioned across the quadriceps and hamstring bilaterally, however, there will be no light emission. However, the volunteer will perform the strength training protocol.
62621457|NCT03860766|EXPERIMENTAL|50J Infrared LED Group (G-50J)|The LED with a wavelength of 940nm, 50J power, will be applied throughout the quadriceps and hamstrings bilaterally, just before the strength training protocol.
62847453|NCT06240416|EXPERIMENTAL|Test group|Low speed drilling (50 rpm) without irrigation
62847454|NCT02164461|EXPERIMENTAL|Axalimogene filolisbac 1x10^9 cfu|Participants with persistent, metastatic, or recurrent carcinoma of the cervix who failed conventional therapy received axalimogene filolisbac at dose of 1x10\^9 colony forming units (cfu) by intravenous infusion, over 60 minutes duration, every 3 weeks (Q3W) in repeating 12-week treatment cycles (Day 1 of Weeks 1, 4, 7, and 10 of each cycle) until a discontinuation criterion was met. Participants received a 7-day course of oral antibiotic therapy starting approximately 72 hours (Day 4) after each administration of axalimogene filolisbac. Antibiotic therapy consisted of trimethoprim (80 mg)/sulfamethoxazole (400 mg) tablets (Bactrim) or trimethoprim (160 mg)/ sulfamethoxazole (800 mg) tablets (Bactrim DS), administered 3 times during the 7 consecutive days or ampicillin 500 mg 4 times daily for 7 consecutive days for participants with sulfa allergy.
62847455|NCT02164461|EXPERIMENTAL|Axalimogene filolisbac 5x10^9 cfu|Participants with persistent, metastatic, or recurrent carcinoma of the cervix who failed conventional therapy received axalimogene filolisbac at dose of 5x10\^9 cfu by intravenous infusion, over 60 minutes duration, Q3W in repeating 12-week treatment cycles (Day 1 of Weeks 1, 4, 7, and 10 of each cycle) until a discontinuation criterion was met. Participants received a 7-day course of oral antibiotic therapy starting approximately 72 hours (Day 4) after each administration of axalimogene filolisbac. Antibiotic therapy consisted of trimethoprim (80 mg)/sulfamethoxazole (400 mg) tablets (Bactrim) or trimethoprim (160 mg)/ sulfamethoxazole (800 mg) tablets (Bactrim DS), administered 3 times during the 7 consecutive days or ampicillin 500 mg 4 times daily for 7 consecutive days for participants with sulfa allergy.
62060750|NCT04062123|EXPERIMENTAL|Propofol|Subjects in this group will receive propofol during the drug portion of the experiment.
62060751|NCT04062123|EXPERIMENTAL|Fentanyl|Subjects in this group will receive fentanyl during the drug portion of the experiment.
62060752|NCT06129240||Cohort A|PH-ILD
62060753|NCT05555160|EXPERIMENTAL|Single-chamber valve tip conductive PICC catheter|
62060754|NCT05555160|EXPERIMENTAL|Single - chamber valve non - tip conductive PICC catheter|
62060755|NCT04340128|ACTIVE_COMPARATOR|1|Intra-lesional injection of Glucantime once a week
62060756|NCT04340128|EXPERIMENTAL|2|Intra-lesional injection twice a week, 0.1/cm2
62060757|NCT03211299||IHL <5%|overweight and obese humans with a liver fat percentage \<5%
62060758|NCT03211299||IHL 5-10%|overweight and obese humans with a liver fat percentage 5-15%
62060759|NCT03211299||IHL >15%|overweight and obese humans with a liver fat percentage \>15%
62060760|NCT05159323|EXPERIMENTAL|Diffusion Spectrum Imaging|All participants accept diffusion spectrum imaging, the quantitative parameters of the diffusion spectrum imaging are obtained. The quantitative parameters are compared in different subgroups based on the pathologic examination results.
62060761|NCT06614049|NO_INTERVENTION|Standard care|Receive usual standard of care for lipid management
62060762|NCT06614049|EXPERIMENTAL|Standard care + Human Coach-supported Digital/AI Personal Health Assistant|The intervention group will receive personalised feedback through the digital mobile health app coupled with human coaching (i.e., support from a human coach-supported digital/AI personal health assistant) on top of usual clinical care for cholesterol management.
62060763|NCT00641914|EXPERIMENTAL|1|
62060764|NCT00641914|PLACEBO_COMPARATOR|2|
62060765|NCT03771014|EXPERIMENTAL|Early mobility|Patients will receive standard physiotherapy regimen plus 2 x 30 minute rehabilitation sessions 5 days per week.
62060766|NCT03771014|NO_INTERVENTION|Standard care|Patients will receive standard physiotherapy regimen
62060767|NCT04299516|EXPERIMENTAL|Two-team SBA|Two-team simultaneous bilateral total knee arthroplasty
62060768|NCT04299516|ACTIVE_COMPARATOR|Single-team SBA|Single-team simultaneous bilateral total knee arthroplasty
62060769|NCT05166538|EXPERIMENTAL|Ticagrelor|
62060770|NCT05166538|ACTIVE_COMPARATOR|Clopidogrel|
62060771|NCT02856425|EXPERIMENTAL|Colorectal adenocarcinoma (not mismatch repair deficient by either PCR and/or IHC)|
62060772|NCT02856425|EXPERIMENTAL|Gastric or gastroesophageal adenocarcinoma (not mismatch repair deficient by either PCR and/or IHC|
62060773|NCT02856425|EXPERIMENTAL|Urothelial cancer|
62060774|NCT02856425|EXPERIMENTAL|Renal Cell cancer (RCC)|
62060775|NCT02856425|EXPERIMENTAL|Mesothelioma (MPM)|
62060776|NCT02856425|EXPERIMENTAL|Cervical Cancer (CC)|
62621458|NCT03860766|EXPERIMENTAL|240J Infrared LED Group (G-240J)|The LED with a wavelength of 940nm, 240J power, will be applied across the quadriceps and hamstrings bilaterally, just before the strength training protocol.
62847456|NCT02164461|EXPERIMENTAL|Axalimogene filolisbac 1x10^10 cfu|Participants with persistent, metastatic, or recurrent carcinoma of the cervix who failed conventional therapy received axalimogene filolisbac at dose of 1x10\^10 cfu by intravenous infusion, over 60 minutes duration, Q3W in repeating 12-week treatment cycles (Day 1 of Weeks 1, 4, 7, and 10 of each cycle) until a discontinuation criterion was met. Participants received a 7-day course of oral antibiotic therapy starting approximately 72 hours (Day 4) after each administration of axalimogene filolisbac. Antibiotic therapy consisted of trimethoprim (80 mg)/sulfamethoxazole (400 mg) tablets (Bactrim) or trimethoprim (160 mg)/ sulfamethoxazole (800 mg) tablets (Bactrim DS), administered 3 times during the 7 consecutive days or ampicillin 500 mg 4 times daily for 7 consecutive days for participants with sulfa allergy.
62847457|NCT05906290|EXPERIMENTAL|Multigenerational eHealth Intervention for Grandparents and Grandchildren Group|Participants in this group will have access to eHealth intervention for 2 weeks.
62847458|NCT02780011|EXPERIMENTAL|Alsertib and Brentuximab Vedotin|Brentuximab vedotin at a fixed dose of 1.8 mg/kg will be administered by intravenous infusion on day 1 of every 21-day cycle. MLN8237 at a dose of 60 mg will be orally administered daily in 2 divided doses (30 mg qAM, 30 mg qPM) from days 1 to 7 of each 21-day cycle. MLN8237 dose will be escalated in 20-mg increments to the maximum dose of 100 mg (Level 2) or de-escalated in a 20-mg decrement to the minimum dose of 40 mg (Level -1).
62847459|NCT01708785|ACTIVE_COMPARATOR|Single context|Subjects will be exposed to food cues in a single context.
62847460|NCT01708785|EXPERIMENTAL|Multiple contexts|Subjects will be exposed to food cues in multiple contexts.
62847461|NCT01708785|ACTIVE_COMPARATOR|8 treatment sessions|Subjects receive 8 treatment sessions.
62847462|NCT01708785|EXPERIMENTAL|16 treatment sessions|Subjects receive 16 treatment sessions
62264910|NCT02732769|ACTIVE_COMPARATOR|Group treated by radiosurgery with stereotaxic frame|Subjects will receive a radiosurgery during a brief hospitalization by LeksellGammaKnifePerfexion® (LGKP)
62448375|NCT06227065|EXPERIMENTAL|Epirubicin|Patients in that PDOs show highest response to this drug in-vitro will be treated with Epirubicin.
62847463|NCT02506803|EXPERIMENTAL|NAC-GEMABR|Neoadjuvant chemotherapy 2 courses of NAC-GEMABR for subsequent 10 patients.
62847464|NCT02865876|EXPERIMENTAL|Accelerated Corneal Cross-linking|Cross-linking in the management of microbial keratitis is an adjunctive therapy.This procedure is conducted under sterile conditions in the operating room. Tetracaine hydrochloride 0.5% (Ponti Ofteno, Sophia, Mexico) eye drops is apply for topical anesthesia. The corneal epithelium on the edge of the ulcer is cautiously removed using a microsponge. As photosensitizer, riboflavin 0.1% (Vibex, Avedro Inc, Waltham, USA) is used for 10 minutes. After impregnation, the participant´s cornea is irradiaded with UVA-light (370 nm) using 30 mW/cm2 for 3 minutes (which corresponds to a total dose of 5.4J/cm2) with accelerated cross-linking (Avedro Inc., Waltham, USA). After procedure, conventional treatment for keratitis remains unchanged.
62847465|NCT02865876|SHAM_COMPARATOR|Sham Accelerated Corneal Cross-linking|"Placebo surgery. This procedure is conducted under sterile conditions in the operating room. Tetracaine hydrochloride 0.5% (Ponti Ofteno, Sophia, Mexico) eye drops is apply for topical anesthesia. Investigators do not perform removal of the corneal epithelium in edge of the ulcer. The researchers conducted the impregnation phase applying drops of saline solution for 10 minutes. After impregnation fase, a device is placed in Avedro equipment off (Avedro Inc, Waltham, USA) this device emits white light for 3 minutes. After procedure, conventional treatment for keratitis remains unchanged."
62060777|NCT02856425|EXPERIMENTAL|Hepatocellular (HCC)|
62060778|NCT02856425|EXPERIMENTAL|Thymic Carcinoma (TC)|
62264911|NCT02732769|EXPERIMENTAL|Group treated by radiosurgery with the thermoformed mask|Subjects will receive a radiosurgery with thermoformed mask during a brief hospitalization by GammaKnifeICON® (GKI) with Efficast®
62264912|NCT01366547|EXPERIMENTAL|Single Arm|Subjects will be randomized in a three-way crossover design to receive a single dose of each of two different tablet formulations of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg or dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg). There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
62847466|NCT02685982|EXPERIMENTAL|Rhythmic Sensory Stimulation|Participants in this group will undertake 30 minutes of daily Rhythmic Sensory Stimulation, for 5 day per week, for a total of 5 weeks. The stimulation consists of specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range. The intervention is conducted at the participant's home using a portable device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit. This device is a low-voltage consumer product device that has built in low frequency (subwoofer-type) speakers. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration that is synchronized with the relaxing musical track.
62264913|NCT04284202|EXPERIMENTAL|PD-1 plus Dasatinib|
62264914|NCT03699176|EXPERIMENTAL|Vilaprisan|2 treatment periods of 12 weeks without a break
62264915|NCT03699176|PLACEBO_COMPARATOR|Placebo|2 treatment periods of 12 weeks without a break
62264916|NCT03992040||Reinforced SSIAD (SSIADR arm )|"Reinforced Home Nursing Care Services: Patients with a score between 11 and 21 on the regional public health authorities (ARS) score.~This arm will benefit from better coordination and delivery of care, which can reduce hospitalizations and visits to emergency departments"
62448376|NCT06227065|EXPERIMENTAL|Mitomycin|Patients in that PDOs show highest response to this drug in-vitro will be treated with Mitomycin.
62847467|NCT02664948|EXPERIMENTAL|Intervention group|Early geriatric follow-up after discharge from hospital in the patient's home
62847468|NCT02664948|NO_INTERVENTION|Control group|Usual care with follow-up home-visits conducted by home care and the GP after discharge, if they consider it as necessary
62847469|NCT05910190|EXPERIMENTAL|Intervention|Receiving buprenorphine with short acting full agonist opioid with CPM Rx app to document medication use.
62847470|NCT04971317|EXPERIMENTAL|Sugar-Sweetened Beverage (SSB) Video|
62847471|NCT04971317|EXPERIMENTAL|Water Video|
62847472|NCT04971317|ACTIVE_COMPARATOR|Control|
62847473|NCT01707784||Women with gestational diabetes|Women with gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
62847474|NCT01707784||Women without gestational diabetes|Women without gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
62847475|NCT04335136|ACTIVE_COMPARATOR|Group A (active) APN01|Recombinant human angiotensin-converting enzyme 2 (rhACE2) - APN01
62847476|NCT04335136|PLACEBO_COMPARATOR|Group B (placebo control)|
62847477|NCT06078943|ACTIVE_COMPARATOR|Investigational Device|The test device in this clinical study is the ABL90 FLEX PLUS running SW3.5 MR2 manufactured by Radiometer Medical ApS The analyzer provides results for 17 parameters in 35 seconds using 65 µL heparinized whole blood. However, in this investigation only the data concerning the parameters ctBil and FHbF will be evaluated.
62060779|NCT02856425|EXPERIMENTAL|Patients with advanced cancers and high tumor mutational burden (TMB-High)|High tumor mutational burden (TMB-High) on their circulating tumor DNA (ctDNA) as defined by more than twenty mutations per megabase (≥20Mut/Mb) on FoundationOne Liquid CDx assay
62264917|NCT03992040||Classic SSIAD (Control arm)|Classic Home Nursing Care Services. For this arm, no direct benefit is expected since taking care, even for the heaviest patients, corresponds to current practice.
62448377|NCT06227065|EXPERIMENTAL|Gemcitabine|Patients in that PDOs show highest response to this drug in-vitro will be treated with Gemcitabine.
62847478|NCT06078943|SHAM_COMPARATOR|Predicate device|"The predicate device for this study is the unmodified device ABL90 FLEX PLUS (k160153) running software SW 3.1 MR7 including sensor casettes and solution packs versions corresponding to 2016.~ABL90 FLEX PLUS SW 3.1 MR7, has been selected as the predicate device because it has the appropriate 510(k) clearance, and the intended use matches the ABL90 FLEX PLUS SW. SW3.5 MR2 device."
62448378|NCT06227065|EXPERIMENTAL|Docetaxel|Patients in that PDOs show highest response to this drug in-vitro will be treated with Docetaxel.
62448379|NCT01104519|EXPERIMENTAL|1|Niaspan - Placebo
62847479|NCT04611399|EXPERIMENTAL|Virtual Reality (VR) Group|"The treatment for the participants allocated to the VR Group consists of three home-sessions of approximately 30 minutes each, conducted over one week. In each session, participants will be asked to try for about 15 minutes MIND-VR. Subsequently, they will try the virtual relaxation content The Secret Garden."
62060780|NCT04370054|EXPERIMENTAL|PF-07055480 (giroctocogene fitelparvovec)|Single administration of PF-07055480
62060781|NCT02104362|OTHER|exclusive single-fraction irradiation|
62060782|NCT02276924|EXPERIMENTAL|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will follow a laser confocal microscopy procedure.
62060783|NCT00617695|EXPERIMENTAL|1|
62060784|NCT00617695|PLACEBO_COMPARATOR|2|
62060785|NCT05006677||non-vitamin K antagonist oral anticoagulants (NOACs)|
62060786|NCT05006677||vitamin K antagonists (VKAs)|
62060787|NCT05006677||antiplatelet agents|
62448380|NCT01104519|EXPERIMENTAL|2|Placebo - Niaspan
62060788|NCT05006677||non-antithrombotic therapy|
62264918|NCT06464250|EXPERIMENTAL|Bundle care group|"Before the intervention, both the Control and Intervention groups underwent face-to-face interviews and completed forms such as the 'Patient Identification Form,' 'Nottingham Functional Foot Care Diagnosis Form,' and 'Diabetic Foot Evaluation Form.' Subsequently, both groups received one-on-one training covering various aspects related to diabetic foot. This training, conducted by the researcher, involved interactive question-answer sessions and practical demonstrations of foot care techniques.~Following the training, the Intervention group received a care package comprising foot examination, guidance on correct foot care practices, and a request for regular blood glucose monitoring. These patients were then monitored at the 1st, 2nd, and 3rd months."
62621459|NCT03860766|EXPERIMENTAL|Progressive dose infrared LED group (G-50-240J)|The LED with a wavelength of 940nm, initial energy of 50J with an increment of 38J each week to the final energy of 240J, will be applied throughout extension of the quadriceps and hamstrings bilaterally, immediately prior to the performance of the strength training protocol
62621460|NCT00193739|ACTIVE_COMPARATOR|NACT followed by surgery|3 cycles of neoadjuvant chemotherapy (NACT) (Inj.Paclitaxel +Inj.Carboplatin) followed by surgery (radical abdominal hysterectomy Class III , bilateral pelvic lymphadenectomy \& lower para aortic lymph node sampling)
62621461|NCT00193739|ACTIVE_COMPARATOR|Concurrent chemoradiotherapy|Radiation therapy will be administered to whole pelvis followed by intracavitary brachytherapy. Patients will be given chemotherapy (Inj.Cisplatin) concurrently with external beam radiotherapy.
62060789|NCT03484676|OTHER|Unilateral Non comminuted zygomatic complex fracture|Patient undergo treatment no control group
62448381|NCT06543706||the Metabolic Related Diseases in Medical Workers (MRDMW) cohort|The cohort includes all hospital employees who receive annual check-ups.
62847480|NCT04611399|ACTIVE_COMPARATOR|Control (CR) Group|The CR Group will undergo pre- and post-protocol tests without undergoing any treatment.
62847481|NCT00753246|PLACEBO_COMPARATOR|Arm B|adults with TMZ, RT
62847482|NCT00753246|EXPERIMENTAL|Arm A|adults with TMZ, RT, nimotuzumab
62847483|NCT01913496|PLACEBO_COMPARATOR|Standard care|standard care ,without the web application ebalance
62847484|NCT01913496|ACTIVE_COMPARATOR|ebalance|using the ebalance application for 14 weeks
62847485|NCT02121080|EXPERIMENTAL|Cohort 1|Dosing regimen 1
62847486|NCT02121080|EXPERIMENTAL|Cohort 2|Dosing regimen 2
62847487|NCT02121080|EXPERIMENTAL|Cohort 3|Dosing regimen 3
62847488|NCT02121080|EXPERIMENTAL|Cohort 4|Dosing regimen 4
62060790|NCT05640414|EXPERIMENTAL|Weekly Family Food Packages|
62060791|NCT05640414|EXPERIMENTAL|Family Health Group Sessions|
62060792|NCT01874145|ACTIVE_COMPARATOR|GA 20 mg/mL every day|Glatiramer acetate (GA) 20 mg in 1 mL SC injection administered every day (QD) for the 4 months of the core study.
62060793|NCT01874145|EXPERIMENTAL|GA 40 mg/mL 3 times a week|"Glatiramer acetate (GA) 40 mg in 1 mL SC injection administered three times a week (TIW) for the 4 months of the core study.~During the Extension period, all participants to continue treatment with GA 40 mg/mL TIW until this dose regimen is commercially available for the treatment of RRMS patients."
62060794|NCT03160287|EXPERIMENTAL|Motivational interview and text messages|Multidimensional, tailored intervention for sleep deficiency in for older adults with OA
62847489|NCT02121080|EXPERIMENTAL|Cohort 5|Dosing regimen 5
62847490|NCT06022523|EXPERIMENTAL|Acquisition|Subjects will undergo profound hypoxia with stable plateaus.
62847491|NCT03074552|EXPERIMENTAL|Probiotics|The probiotic preparation \[ LactoLevure\] will consist a combination of four probiotics.
62847492|NCT03074552|PLACEBO_COMPARATOR|Placebo|Placebo will consist of identical capsules of powdered glucose polymer, and they will be constructed by the same industry that manufactures the probiotics capsules.
62060795|NCT01728792|EXPERIMENTAL|Group 1: TDV SC_2 Doses Day 0|Takeda's Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous (SC) injection, one dose in each arm, Day 0 using a needle/syringe.
62448382|NCT02033525|EXPERIMENTAL|XCEL-M-ALPHA and standard rehabilitation|Intraarticular administration of XCEL-M-ALPHA followed by standard rehabilitation program
62847493|NCT04380272||Brodsky tonsil staging system|An oropharynx examination of all participants will be performed and tonsil size will be evaluated according to the Brodsky staging system. According to this staging system, tonsil sizes will be classified as stage I when the tonsils fill less than 25% of the transverse oropharyngeal space measured between the anterior tonsillar pillars; stage II when they fill between 25% and 50%, stage III when they fill between 50% and 75%, and stage IV when they fill more than 75%.
62060796|NCT01728792|EXPERIMENTAL|Group 2: TDV IM_2 Doses Day 0|TDV, 0.5 mL, intramuscular (IM) injection, one dose in each arm, Day 0 using a needle/syringe.
62264919|NCT06464250|NO_INTERVENTION|Control Group|For the Control group, after receiving education and brochures, the 'Nottingham Functional Foot Care Diagnostic Form' and 'Diabetic Foot Evaluation Form' were completed at the 1st, 2nd, and 3rd months. Similar to the Intervention group, new wound formation, wound classification, and healing status of existing ulcers were monitored for this group as well.
62264920|NCT00822965||Patient Knowledge Assessments|Questionnaires + Phone Interview
62847494|NCT04380272||The ultrasonographic data|The submental ultrasonography will be performed on all participants. Ultrasonographic examinations will be performed blinded to the physical examination results. All measurements will be performed by the same radiologist with experience in the field of ultrasonography. A GE LOGIQ E9 (GE Healthcare, Milwaukee, WI, USA) device will be used in the ultrasonography examination. The participants will be viewed using a 2-9 MHz linear probe from the submental region. The examination will be performed while the patient was lying in a supine position with a support placed under the neck.
62847495|NCT05857696|OTHER|neurostimulation|3 months of tonic stimutaltion + 3 weeks with random stimulation mode between microburst, High frequency, stopped stimulation (Off) then stimulation with the more efficient mode (according the patient) until 6 monthe after implantation.
62060797|NCT01728792|EXPERIMENTAL|Group 3: TDV IM_2 Doses Days 0 and 90|TDV, 0.5 mL, IM injection, one dose on Day 0 and one dose on Day 90 using a needle/syringe.
62264921|NCT01230307|ACTIVE_COMPARATOR|Vitamin D|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
62264922|NCT01230307|PLACEBO_COMPARATOR|Placebo|A placebo loading dose will be given followed by two placebo tablets daily for 6 months.
62847496|NCT03372902||normal mammograms (BI-RADS 1 or 2)|
62264923|NCT05800548||postpartum women|The sample of the research is; puerperant women who applied to the hospital for delivery within the research dates and gave birth in a healthy way, did not have any risk for the mother and the baby, had no communication barriers and met the research criteria.
62448383|NCT02033525|ACTIVE_COMPARATOR|standard rehabilitation|Standard rehabilitation program
62448384|NCT03632174|EXPERIMENTAL|Topical Ointment with L. reuteri|Adult subjects presenting with mild-moderate Atopic Dermatitis
62448385|NCT03632174|EXPERIMENTAL|Topical Ointment without L. reuteri|Adult subjects presenting with mild-moderate Atopic Dermatitis
62847497|NCT03372902||suspicious lesion group (BI-RADS 4)|
62847498|NCT03956238|EXPERIMENTAL|Males and Alcohol Intoxication|Men assigned to alcohol intoxication arm (target BAC .08%)
62847499|NCT03956238|PLACEBO_COMPARATOR|Males and Placebo Control|Men assigned to placebo control arm
62847500|NCT03956238|EXPERIMENTAL|Females and Alcohol Intoxication and Objectifying Gazes|Women assigned to alcohol intoxication arm (target BAC .08%) and objectifying gazes arm
62847501|NCT03956238|EXPERIMENTAL|Females and Alcohol Intoxication and Eye Gazes|Women assigned to alcohol intoxication arm (target BAC .08%) and eye gazes arm
62847502|NCT03956238|EXPERIMENTAL|Females and Placebo Control and Objectifying Gazes|Women assigned to placebo control arm and objectifying gazes arm
62847503|NCT03956238|PLACEBO_COMPARATOR|Females and Placebo Control and Eye Gazes|Women assigned to placebo control arm and eye gazes arm
62448386|NCT03631524|NO_INTERVENTION|Conventional therapy|The control arm will be subject to the same assessments as the treatment arm at the start and end of the two week period. They will receive standard care in the ward including physiotherapy as prescribed by the managing team
62264924|NCT04776382|EXPERIMENTAL|Study Group|Trainees of this group will watch an EMME (Eye Movement Modeling Examples) pre-recorded video, on where to focus their gaze while performing the epidural procedure in accordance with expert eye-tracking
62264925|NCT04776382|NO_INTERVENTION|Control Group|Trainees of this group will not watch the pre-recorded video
62621462|NCT01167725|ACTIVE_COMPARATOR|Arm I|Patients receive standard systemic therapy, at the discretion of patients' oncologist, comprising combinations of fluorouracil, leucovorin calcium, irinotecan hydrochloride, oxaliplatin, and/or capecitabine (including FOLFOX4, mFOLFOX6, CapeOx, or FOLFIRI), bevacizumab, or cetuximab. Treatment repeats in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may crossover to arm II.
62621463|NCT01167725|EXPERIMENTAL|Arm II|Patients undergo cytoreduction surgery and hyperthermic intraperitoneal mitomycin C over 45-90 minutes. Beginning 8 weeks after surgery, patients receive standard systemic therapy as in arm I. Treatment with systemic therapy repeats for 6 courses in the absence of disease progression or unacceptable toxicity.
62621464|NCT03534999|EXPERIMENTAL|TENS|This is intervention Group. Patients in this group received Transcutaneous Electrical Nerve Stimulation (TENS). The VAS and Oxford hip score was administered prior to the treatment to ascertain their pain intensity and hip disability level. The site of intervention (5cm away from incision site) was cleaned properly with cotton wool soaked in methylated spirit in an outward motion. Before the self-adhesive, pre gelled electrodes was placed on the cleansed sites.The TENS unit was switched on and the parameters was adjusted to the required level. For this study, parameters used are: 100µs pulse duration, 100Hz frequency and an intensity comfortable for the patient for a duration of 15 minutes.
62621465|NCT03534999|NO_INTERVENTION|Control|This was the group with no intervention. Subjects were on their normal analgesic and antibiotic medication for the period of research. The VAS and Oxford hip score were administered on the first day to ascertain pain intensity and hip disability level. The subject continued on the normal analgesics only till the third day and VAS and Oxford hip score was re-administered to assess any change in the pain intensity and hip disability level.
62621466|NCT04769973||Work Packages 1 - 3|"Work Package 1: Interviews with 15-20 people with Parkinson's and 15-20 caregivers.~Work Package 2: National Survey with up to 2000 participants~Work Package 3: Two to four Focus Groups with key stakeholders (6-10 participants per focus group)"
62621467|NCT05505695|EXPERIMENTAL|"Brace&Exercise Group"|The patients who were the rigid brace and performed the SSE therapy in the specified constituted the Brace \& Exercise. Experimental group patients wore full-time rigid brace and Schroth exercises for 60 minutes 5 days a week by the physician.
62621468|NCT05505695|ACTIVE_COMPARATOR|"Brace Group"|The patients who wore full-time rigid braces but did not perform exercise constituted the Brace group. Comparator group patients wore full-time brace only, did not perform Schroth exercises.
62621469|NCT02858024|ACTIVE_COMPARATOR|Cohort I|In Cohort I, eligible participants will be randomly assigned to one of two treatment sequences (ABE or BAE). During two consecutive 28-day treatment periods (treatment periods 1 and 2), separated by a washout period of 28 days, the participants will receive each of the following treatments according to their assigned treatment sequence
62621470|NCT02858024|ACTIVE_COMPARATOR|Cohort II|In Cohort II, eligible participants will be randomly assigned to one of two treatment sequences (CDE or DCE). During two consecutive 28-day treatment periods (treatment periods 1 and 2), separated by a washout period of 28 days, the participants will receive each of the following treatments according to their assigned treatment sequence
62621471|NCT01911702|ACTIVE_COMPARATOR|Conventional Group|In this group patients receive volemic standard treatment (conventional)
62621472|NCT01911702|ACTIVE_COMPARATOR|Restrictive Group|In this group patients receive volemic small treatment (restrictive)
62847504|NCT01137604|EXPERIMENTAL|Cohort 1|"Cohort 1 assessed participants with recurrent Grade 4 malignant glioma (ie, glioblastoma \[GBM\]) who were bevacizumab-naive. Participants were planned to be accrued in Cohort 1 and randomized in a 1:1 ratio to receive lenvatinib (experimental) or bevacizumab (active comparator).~Cohort 1 - Bevacizumab~Cohort 1 - Lenvatinib"
62847505|NCT01137604|EXPERIMENTAL|Cohort 2|Cohort 2 assessed participants with recurrent Grade 3 malignant glioma who were bevacizumab-naive. Participants in Cohort 2 were planned to be treated with lenvatinib.
62847506|NCT01137604|EXPERIMENTAL|Cohort 3|Cohort 3 assessed participants with recurrent GBM who had disease progression following prior bevacizumab treatment. Participants in Cohort 3 were planned to be treated with lenvatinib.
62847507|NCT02935283||OTCD participants|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD who can undergo MRI and behavioral testing
62847508|NCT02935283||Normal controls|Healthy males or females without known medical or metabolic disorder (control group) who can undergo MRI and behavioral testing
62264926|NCT01480336|PLACEBO_COMPARATOR|Amiodarone with Placebo|
62264927|NCT01480336|ACTIVE_COMPARATOR|Amiodarone with Ranolazine|
62264928|NCT04271436|EXPERIMENTAL|PET/CT + PET/MR|-Eligible patients will have imaging assessments (as part of the study) performed at three time-points: pre-treatment, following cycle 1 of treatment, and following cycle 2 of treatment. Baseline FDG PET/CT will be a standard-of-care procedure. If possible, PET/CT imaging will be performed, followed immediately by PET/MR imaging during each imaging session. At minimum, PET/MR should be obtained at least once during each time-point (i.e. either during the FDG or FLT procedure). FDG imaging and FLT imaging should be performed at least 24 hours apart and no more than 7 days apart.
62621473|NCT02652559|EXPERIMENTAL|Home initiation|Home initiation of long-term NIV will be compared with standard in-hospital initiation. NIV at home will be titrated by a specialised nurse of our home mechanical ventilation centre (HMV) on transcutaneously measured gas exchange and respiratory electromyography and will be adjusted with the use of telemedicine.
62448387|NCT03631524|EXPERIMENTAL|Intervention arm|The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period. They will be evaluated for motor strength, activity of daily living performance, mood and perceived level of health.
62060798|NCT01728792|EXPERIMENTAL|Group 4: TDV SC_2 Doses Day 0|TDV, 0.5 mL, SC injection, one dose in each arm, Day 0 using the PharmaJet Stratis™ device.
62060799|NCT01728792|EXPERIMENTAL|Group 5: TDV IM_2 Doses Day 0|TDV, 0.5 mL, IM injection, one dose in each arm, Day 0 using the PharmaJet Stratis™ device.
62060800|NCT01519388|EXPERIMENTAL|neuromuscular patients|Neuromuscular non invasively ventilated patients in stable at the time of the study
62060801|NCT03207906|ACTIVE_COMPARATOR|Lower concentration VBP-926|VBP-926 solution applied to affected area BID
62060802|NCT03207906|ACTIVE_COMPARATOR|Higher concentration VBP-926|VBP-926 solution applied to affected area BID
62060803|NCT03207906|PLACEBO_COMPARATOR|Vehicle|Vehicle solution applied to affected area BID
62060804|NCT01101360|ACTIVE_COMPARATOR|Matrix RF followed by Pulse Dye Laser|
62060805|NCT02944656|EXPERIMENTAL|Gabapentin group|This group will receive local anesthesia per clinic protocol plus Gabapentin 600mg 1-2 hours preoperatively.
62060806|NCT02944656|PLACEBO_COMPARATOR|Placebo group|This group will receive local anesthesia per clinic protocol plus placebo 1-2 hours preoperatively.
62264929|NCT01152021|ACTIVE_COMPARATOR|Dexmedetomidine Group|Dexmedetomidine given as 2mcg/kg bolus over 10 minutes followed by 1.5mcg/kg/hr infusion for duration of scan. The bolus may be repeated up to 2 times at any time during the sedation in the event that adequate sedation conditions (minimum Ramsay Sedation Score of 4) are not achieved. In the event that dexmedetomidine is unable to achieve motionless conditions, after a total of 3 boluses, 0.5 mg/kg IV pentobarbital may be administered at q1 minute intervals up to a maximum of 2 mg/kg, per established protocol.
62448388|NCT04044430|EXPERIMENTAL|Treatment (encorafenib, binimetinib, nivolumab)|"Participants in Phase 1 receive encorafenib PO QD on days 1-28, binimetinib PO BID on days 1-28, and nivolumab IV on day 1. Cycles repeat every 28 days for a maximum of 24 cycles of treatment in the absence of disease progression or unacceptable toxicity.~The study was terminated before Phase II was initiated. The study did not open Phase II for enrollment."
62448389|NCT04670913|EXPERIMENTAL|Camrelizumab plus Apatinib|Camrelizumab, 200mg, q3w, iv and Apatinib, 250mg, qd, po
62448390|NCT00999869|EXPERIMENTAL|Botulinum toxin A|At first visit, patients will be randomized by blocked randomization into 2 sides of scalp. Experimental side will be injected with botulinum toxin A ( Botox) 2 units per 6.05 cm2 of lesion ( Concentration 2 units of Botox per 0.1 ml of normal saline ).
62448391|NCT00999869|ACTIVE_COMPARATOR|Triamcinolone acetonide|At visit0, patients will be injection with triamcinolone acetonide concentration at 10 mg/ml on the comparison side
62448392|NCT04049331|EXPERIMENTAL|Testosterone|Testosterone undecanoate injection 750 MG/3 ML
62448393|NCT04049331|PLACEBO_COMPARATOR|Placebo|clinical grade saline 0.9% sodium chloride injection
62448394|NCT00203879|EXPERIMENTAL|1|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
62448395|NCT00203879|EXPERIMENTAL|2|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 without IL-2
62264930|NCT01152021|ACTIVE_COMPARATOR|Propofol Group|Propofol bolus at an initial dose of 1 mg/kg over 1 minute then up to two additional 1 mg/kg boluses may be administered (total 3 mg/kg) - each over a one (1) minute interval, waiting 30 seconds after completion of each bolus to reassess sedation level. Once a minimum Ramsey Sedation Score 4 is achieved, an infusion at 125 mcg/kg/min is initiated. It may be titrated to 300 mcg/kg/min. If there is movement or awakening the patient may be rebolused with no more than 2 doses of Propofol at 1 mg/kg over 1 minute, in the same dosing manner as described above, waiting 30 seconds between doses. If adequate sedation is not achieved, 0.5 mg/kg IV pentobarbital may be administered at q1 minute intervals up to a maximum of 2 mg/kg.
62264931|NCT03688932|EXPERIMENTAL|WBV + IMT|Whole body vibration training associated with respiratory muscle training (WBV + IMT)
62264932|NCT03688932|ACTIVE_COMPARATOR|WBV + IMTsham|Whole body vibration training associated with respiratory muscle training sham (WBV + IMTsham)
62264933|NCT03688932|SHAM_COMPARATOR|WBVsham + IMTsham|Whole body vibration training sham associated with respiratory muscle training sham (WBVsham + IMTsham)
62264934|NCT04401176|ACTIVE_COMPARATOR|Heparin & Alkalinized Lidocaine Bladder Instillation|Six weekly bladder instillations, each instillation consisting of 40,000 IU Heparin, 200mg lidocaine, 2ml 8.4% sodium bicarbonate, sterile water for a total volume 50 milliliters (mL).
62264935|NCT04401176|ACTIVE_COMPARATOR|Intradetrusor Onabotulinumtoxin A Injection|100 units onabotulinumtoxinA reconstituted in 10mL of injectable saline, injected in 20 sites with 0.5mL per injection along the posterior wall of the bladder above the trigone.
62264936|NCT05710471|EXPERIMENTAL|Brolucizumab|new drug (brolocizumab) and novel treatment protocol
62264937|NCT05710471|ACTIVE_COMPARATOR|Aflibercept|aflibercept and continuing on the traditional T\&E protocol. There will also be a rescue option for those in the aflibercept arm who are not responding well to also switch to brolocizumab
62264938|NCT02833974|EXPERIMENTAL|GSK2245035 20 ng|Participants will receive 20 ng of GSK2245035 Nasal spray solution (1 spray=10 ng GSK2245035 per actuation per nostril) every week for the duration of 8 weeks administered using a metered Valois VP7 pump
62264939|NCT02833974|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo Nasal spray solution (1 spray per nostril) every week for the duration of 8 weeks administered using a metered Valois VP7 pump
62264940|NCT03870542||Deceased donor kidney transplantation|Patients receiving kidney transplants from deceased donor in the participating centers during the study period
62264941|NCT02422212|ACTIVE_COMPARATOR|healthy weight group|Postop RYGBP patients who underwent surgery at least 2 years previously and have healthy weight (at least 50% loss of excess weight) (HW group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
62448396|NCT00645489|OTHER|1|Control condition is wait-list control.
62448397|NCT00645489|EXPERIMENTAL|2|Active treatment condition: psychoeducational intervention for patients with HF
62448398|NCT04871737|EXPERIMENTAL|Low Dose, IM-IM|Group 1. Dose: 10 7.0-7.49 EID 50/dose. Both first and second administration by the intramuscular route, separated by 21 days.
62448399|NCT04871737|EXPERIMENTAL|Intermediate dose, IM-IM|Group 2. Dose: 10 7.5-7.99 EID 50/dose. Both first and second administration by the intramuscular route, separated by 21 days
62448400|NCT04871737|EXPERIMENTAL|High dose, IM-IM|Group 3. Dose: 10 8.0-8.49 EID 50/dose. Both first and second administration by the intramuscular route, separated by 21 days.
62448401|NCT04871737|EXPERIMENTAL|Low dose, IN-IN|Group 4. Dose: 10 7.0-7.49 EID 50/dose. Both first and second administration by the intranasal route, separated by 21 days
62448402|NCT04871737|EXPERIMENTAL|Intermediate dose, IN-IN|Group 5. Dose: 10 7.5-7.99 EID 50/dose. Both first and second administration by the intranasal route, separated by 21 days
62448403|NCT04871737|EXPERIMENTAL|High dose, IN-IN|Group 6. Dose: 10 8.0-8.49 EID 50/dose. Both first and second administration by the intranasal route, separated by 21 days
62448404|NCT04871737|EXPERIMENTAL|Low dose, IN-IM|Group 7. Dose: 10 7.0-7.49 EID 50/dose. First administration by the intranasal route and second administration by the intramuscular route, separated by 21 days
62448405|NCT04871737|EXPERIMENTAL|Intermediate dose, IN-IM|Group 8. Dose: 10 7.5-7.99 EID 50/dose. First administration by the intranasal route and second administration by the intramuscular route, separated by 21 days
62448406|NCT04871737|EXPERIMENTAL|High dose, IN-IM|Group 9. Dose: 10 8.0-8.49 EID 50/dose. First administration by the intranasal route and second administration by the intramuscular route, separated by 21 days
62448407|NCT04871737|EXPERIMENTAL|High dose, IM|Group 10. Dose: 10 8.0-8.49 EID 50/dose. 3rd administration by the intramuscular route to all the volunteers who agree to participate
62448408|NCT01604213|EXPERIMENTAL|Vildagliptin+metformin|Oral Vildagliptin+metformin combination
62448409|NCT01604213|ACTIVE_COMPARATOR|Metformin only|Oral metformin only
62448410|NCT04546607|EXPERIMENTAL|Nuvastatic TM|Nuvastatic TM (C5OSEW5050ESA) capsule 1000 mg administered orally 3 times a day for 9 weeks.
62448411|NCT04546607|PLACEBO_COMPARATOR|Placebo|Excipient, without Nuvastatic TM (C5OSEW5050ESA) capsule administered orally 3 times a day for 9 weeks.
62448412|NCT01684410|EXPERIMENTAL|Alpha-1 HC 100 mg|100 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.
62448413|NCT01684410|EXPERIMENTAL|Alpha-1 HC 200 mg|200 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.
62448414|NCT01684410|PLACEBO_COMPARATOR|Placebo|Placebo inhaled daily via nebulizer for 3 weeks. Placebo (phosphate buffer saline with polysorbate).
62448415|NCT05496075|EXPERIMENTAL|Orlistat group|Orlistat was administered orally on the basis of lifestyle guidance.
62448416|NCT05496075|PLACEBO_COMPARATOR|control group|Orlistat placebo was administered orally on the basis of lifestyle guidance.
62448417|NCT04236765|EXPERIMENTAL|TB infection-screening benefiting group|children VFRs under 15 years of age (which are children of immigrants and born or not in Spain) who travel to countries with an elevated incidence of TB will be screened for LTBI after their return.
62448418|NCT03791450||pancreaticoduodenectomy|patients underwent pancreaticoduodenectomy in recent ten years.
62448419|NCT00788190|OTHER|Surgery|Surgical intervention to reduce Distal Radius Fracture
62448420|NCT00788190|OTHER|Conservative Treatment|Conservative treatment of Distal Radius Fractures
62448421|NCT02867904|PLACEBO_COMPARATOR|Group A|After arthroscopic surgery the control group (Group A) will undergo a subacromial marcaine injection (standard of care).
62621474|NCT02652559|ACTIVE_COMPARATOR|Inhospital initiation|Inhospital initiation of NIV is standard care and in the study will be set as the control arm.
62621475|NCT02044562|EXPERIMENTAL|nitrate supplementation|Patients will receive 7-day nitrate supplementation at the end of the radiotherapy.
62621476|NCT02044562|PLACEBO_COMPARATOR|Placebo|Patients will receive 7-day placebo supplementation at the end of the radiotherapy
62621477|NCT01043094|EXPERIMENTAL|Pitavastatin 4mg renal impaired|Subjects with severe renal impairment (glomerular filtration rate \[GFR\] of 15 to 29 mL/min/1.73 m2, inclusive) who are not being treated with hemodialysis
62448422|NCT02867904|EXPERIMENTAL|Group B|After arthroscopic surgery the experimental group (Group B) will undergo a subacromial corticosteroid injection+marcaine.
62448423|NCT05783479|ACTIVE_COMPARATOR|1 (estradiol)|estradiol 0.5 mg in vaginal cream twice daily for 10 days pre-procedure
62448424|NCT05783479|ACTIVE_COMPARATOR|2 (hyaluronic acid)|hyaluronic acid 5 mg in vaginal gel twice daily for 10 days pre-procedure
62448425|NCT05783479|NO_INTERVENTION|3 (control)|no preparation of the cervix - arm without medication
62448426|NCT05751070|ACTIVE_COMPARATOR|Bowen Technique|BOWEN TECHNIQUE Hot pack TENS Cervical isometrics
62448427|NCT05751070|EXPERIMENTAL|Graston technique|GRASTON TECHNIQUE Hot pack TENS Cervical isometrics
62448428|NCT03093454|NO_INTERVENTION|Control|No intervention patient will receive current standard of care treatment and will answer surveys to collect data.
62448429|NCT03093454|EXPERIMENTAL|Lavender Group|Patient will receive lavender essential oil topically and by inhalation during their hospital stay while at the same time receiving regular standard of care.
62448430|NCT03734237|ACTIVE_COMPARATOR|Egg based influenza vaccines|Quadrivalent egg-based vaccines, which contain an inactivated form of the virus. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. All egg-based vaccines are FDA licensed for use in the United States.
62448431|NCT03734237|ACTIVE_COMPARATOR|Recombinant influenza vaccines|FluBlok, recombinant HA influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flublok Quadrivalent is a quadrivalent recombinant influenza vaccine that has been licensed by the FDA for use in the United States.
62448432|NCT03734237|ACTIVE_COMPARATOR|Cell-culture based influenza vaccines|Flucelvax, Madin-Darby canine kidney (MDCK)-cell-culture based inactivated influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flucelvax quadrivalent, the only cell-based flu vaccine FDA licensed for use in the United States.
62448433|NCT01398579|ACTIVE_COMPARATOR|Group A|Group A: WLE followed by AFI followed by NBI followed by pCLE.
62448434|NCT01398579|ACTIVE_COMPARATOR|Group B|Group B: WLE followed by NBI followed by AFI followed by pCLE.
62448435|NCT00257296|EXPERIMENTAL|Screening and Intervention|Use a computer-based screening tool for intimate partner violence and provide a multi-faceted intervention based on the needs of the woman and services should would like to utilize.
62448436|NCT00257296|ACTIVE_COMPARATOR|Usual Care|Use a computer-based screening tool for intimate partner violence and provide list of resources available. Also, all physicians were trained on intimate partner violence and were told they could help anyone regardless of randomization.
62448437|NCT01948505|ACTIVE_COMPARATOR|Intervention group|IV acetaminophen: 1000mg IV q 8 hrs (scheduled) until: a) tolerating PO and IV saline-locked or b) 48 hours reached on medication
62448438|NCT01948505|PLACEBO_COMPARATOR|Placebo Group|IV Normal Saline: 100ml IV q 8 hrs (scheduled) until: a) tolerating PO and IV saline-locked or b) 48 hours reached on medication
62448439|NCT01455558|EXPERIMENTAL|Cilostazol|
62448440|NCT03316313||Date of birth|Those people born within the years 1945-1965
62448441|NCT05549284|EXPERIMENTAL|Orelabrutinib,Rituximab and Methotrexate|Rituximab 375 mg/m2 d1; MTX 3.5mg/m2,d2; Orelabrutinib 150g/day; every three week/cycle.
62448442|NCT05265195||Semi-structured Interviews|"Interviews will be conducted with parents and clinicians regarding their experiences of periviable counselling conversations. The interviews aim to identify key priorities and topic themes for the pre-delivery conversation for both parents and the clinicians, as these are hypothesised to differ between the groups.~* Thematic analysis of transcribed semi-structured interviews with 20 parents and 20 clinicians.~* The recruited parents will encompass a mixture of parent experiences: those with a surviving periviable child, parents whose baby died in delivery room and parents whose baby died in the neonatal unit."
62448443|NCT05265195||National evaluation of current periviable management practices across the UK.|Review of periviable deliveries and antenatal management practices in the United Kingdom for infants where the decision is for active care at delivery.
62448444|NCT05265195||Recording and thematic analysis of periviable decision-making conversations|"* Recruiting parents who have presented in periviable labour to Manchester Foundation Trust sites.~* Aiming to audio record 20 conversations discussing management options and potential outcomes between healthcare professionals and parents.~* Thematic analysis will be undertake to determine key topics and priorities for parents and clinicians (these may well differ), time taken to discuss each topic, order topics presented, management options offered or requested, and discussion of comfort care."
62621478|NCT01043094|ACTIVE_COMPARATOR|Pitavastatin 4mg healthy subjects|Healthy subjects (GFR greater than or equal to 90 mL/min/1.73 m2)
62621479|NCT02736708||PSC|Male or female \> 18 years of age Clinically Indicated for ERCP and/or cholangioscopy for dominant PSC stricture Inclusion of patients either previously stented or not
62621480|NCT00124722|EXPERIMENTAL|0.45 mg/kg Zemuron|0.45 mg/kg Zemuron
62621481|NCT00124722|ACTIVE_COMPARATOR|0.6 mg/kg Zemuron|0.6 mg/kg Zemuron
62847509|NCT02935283||HA recovery group|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD or participants with CPS-1 who have had a recent hyperammonemic episode who can undergo MRI and behavioral testing
62621482|NCT00124722|EXPERIMENTAL|1.0 mg/kg Zemuron|1.0 mg/kg Zemuron
62621483|NCT00768287|EXPERIMENTAL|IB1001|
62621484|NCT00768287|ACTIVE_COMPARATOR|nonacog alfa|
62621485|NCT01641471|EXPERIMENTAL|Active TENS|Active TENS (EMPI Select TENS) in combination with a femoral nerve catheter. Patients will begin using the TENS unit immediately following surgery and continuing throughout the 6 weeks postoperatively.
62847510|NCT02935283||Distal UCD|Males and females with ASSD and ASLD who can undergo MRI and behavioral testing
62847511|NCT01380626|EXPERIMENTAL|exercise training|
62847512|NCT04021693|EXPERIMENTAL|Handheld Ultrasound Devices|
62847513|NCT04021693|NO_INTERVENTION|No Handheld Ultrasound Devices|
62847514|NCT01786772|EXPERIMENTAL|Cryotherapy and compression|Cryotherapy and intermittent pneumatic compression will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. Circumferential intermittent pneumatic compression to the knee joint (5 to 50 mm Hg) will be applied in conjunction with cryotherapy. The duration of intervention will be 20 minutes.
62847515|NCT01786772|ACTIVE_COMPARATOR|Cryotherapy|Cryotherapy will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. The duration of intervention will be 20 minutes.
62847516|NCT03780296|EXPERIMENTAL|Real-Time Action Observation with augmented Kinect|Participants will receive 30 minutes of the augmented kinect software in real-time undergoing an exercise protocol involving seated upper extremity exercises, seated lower extremity exercises and standing upper extremity exercises.
62847517|NCT01745822|EXPERIMENTAL|Tenofovir disoproxil fumarate|tenofovir disoproxil fumarate, 300 mg tablets
62060807|NCT02347514|EXPERIMENTAL|Diabetes Group Visit|"Subjects in this arm will be asked to attend one group visit at their health center each month for six months. The group visits will involve various staff and providers at the health center who will teach them how to take care of their diabetes. Subjects will be scheduled to attend the same group visit appointments as the other subjects, and health center staff will encourage the group to share their own experiences about living with diabetes with the rest of the group.~If subjects at the health center additionally implementing the text-messaging intervention consent to enroll in the study, their phone number will also be entered into a secure system that will allow the group visit healthcare team to send them text messages during the course of the six months they are in the program. These text messages are intended to offer the subjects additional support in taking care of their diabetes."
62264942|NCT02422212|OTHER|Obese group|Clinically severe obese patients (Body Mass Index greater than 40 kg/m2, without co-morbidities and greater than 35 kg/m2 with co-morbidities) (OB group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
62264943|NCT02422212|ACTIVE_COMPARATOR|weight regain group|Patients who suffered weight regain after RYGBP (at least 10% above the minimum weight after surgery and less than 50% loss of preop excess weight) (WR group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
62264944|NCT05885100|EXPERIMENTAL|Obesity class 1|
62264945|NCT05885100|EXPERIMENTAL|Obesity class 2|
62448445|NCT05265195||Comparison of recorded and simulated periviable decision-making conversations|"* Recruit 20 senior clinicians from mixture of obstetric and neonatal specialities.~* Clinician will participate in a standardised simulated discussion with two parents (played by actors) who have presented in periviable labour.~* Simulated conversations will be audio recorded and transcribed.~* Analysis will be performed for structure and topics included in this simulated conversation. Comparison will be undertaken comparing the conversational architecture of the simulated conversations with the recorded real conversations (recorded in the above phase of this study)."
62448446|NCT05265195||Focus Groups with parents and clinicians|"* Parent focus groups to consolidate and stratify key priority themes for periviable counselling and development of parent resources.~* Clinician focus groups to discuss experiences with training in this area and preferences for future training methods/resources.~* Parents will be recruited from parental advisory groups and local baby groups.~* Aiming to run 5x focus groups with maximum 8 participants in each group."
62621486|NCT01641471|PLACEBO_COMPARATOR|Placebo TENS|Placebo TENS (Placebo EMPI Select TENS) in combination with a femoral nerve catheter. Patients will begin using a sham TENS unit (appears identical to Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation) immediately following surgery and continuing throughout the 6 weeks postoperatively.
62621487|NCT04901234|ACTIVE_COMPARATOR|Standard radiotherapy|Radiotherapy as planned at baseline, with replanning allowed only if significant weight loss or change in anatomy due to unforeseen circumstances (eg that would affect dosimetry and treatment delivery of baseline treatment plan). No adaptation to shrinking tumour is allowed.
62847518|NCT01745822|PLACEBO_COMPARATOR|Placebo|matching placebo (of tenofovir disoproxil fumarate)
62847519|NCT02697149||intervention|patients undergoing nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography
62264946|NCT05885100|EXPERIMENTAL|Obesity class 3|
62264947|NCT02503228||MOPS|Transplanted tissue preserved using the MOPS method and obtained from one AATB-approved tissue bank
62264948|NCT02503228||Standard Preservation|Transplanted tissue preserved using standard preservation methods and obtained from one of three AATB-approved tissue banks
62264949|NCT03008850|ACTIVE_COMPARATOR|Group M|2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally
62448447|NCT05265195||Parental survey of long-term outcomes|"* Survey will be distributed to all parents of surviving periviable deliveries at St Mary's Manchester over the last 2 - 10 years.~* Parents will be asked to complete the survey at home giving their views on their child's strengths, difficulties, development and social interactions.~* The survey also asks parents for their views on what they remember they were told before they delivered and, in light of their experiences, what would they recommend clinicians include in pre-delivery periviable conversations with future parents.~* The survey will be sent to all eligible parents, which equates to 220 surviving infants. All returned surveys will be analysed."
62621488|NCT04901234|EXPERIMENTAL|Adaptive radiotherapy|Systematic radiation treatment plan adaptation according to the shrinking tumour on mid-treatment MRI.
62621489|NCT02039323|EXPERIMENTAL|All Participants|Maraviroc 600 mg + Tenofovir 600 mg
62847520|NCT02697149||control|patients undergoing standard endoscopic retrograde cholangiopancreatography
62847521|NCT03590964|ACTIVE_COMPARATOR|Open sinus lift using chin bone graft|Patients with atrophied posterior maxilla will undergo open sinus lift with chin bone graft according to standardized surgical approach.
62264950|NCT03008850|ACTIVE_COMPARATOR|Group P|2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally
62264951|NCT03729674||Biosimilar|Exposed group
62264952|NCT03729674||Originator (legacy) drug|Reference group
62448448|NCT05289622|EXPERIMENTAL|Polyurethane expandable valve stent implant surgery|Valve stent implantation will be performed under general anesthesia with transesophageal echocardiography monitoring, with thoracotomy approach median and circulation aid extracorporeal.
62448449|NCT04954950||sports injuries|Patients were classified according to self-reported years of participation in skiing and snowboarding: beginner (first season), medium (1-5 years), advanced (5-10 years) and expert (≥10 years). Date of injury was divided into weekdays and weekends/ holidays according to the Chinese government holiday arrangement.
62621490|NCT02782377||Pelvic Floor Dysfunction|"Observational study where patients with pelvic floor dysfunction undergo three AAR measurements. One at baseline, one with the catheter alongside and a third with the rectal balloon inflated. No intervention is performed~Note, that initial inclusion of Squeeze parameters was detailed in error, these were not compared in this study and were compared in previous study"
62847522|NCT03590964|EXPERIMENTAL|Sinus lift using bone ring containing the implant|Patients with atrophied posterior maxilla will undergo sinus lift using bone ring containing the implant.
62847523|NCT06327841|EXPERIMENTAL|sesame oil|8 weeks oil pulling with sesame oil 15ml 15min every morning
62847524|NCT06327841|OTHER|distilled water|8 weeks rinsing with distilled water 15ml 15min every morning
62847525|NCT06039865|EXPERIMENTAL|Immediate Intervention|Participants will be provided with a consumer wearable immediately after randomization to wear for 4 weeks.
62847526|NCT06039865|OTHER|Waitlist control|Participants will receive usual care from the sleep center for 6 weeks and then be provided with a consumer wearable to wear for 4 weeks.
62847527|NCT04509349|ACTIVE_COMPARATOR|Real tACS|For transcranial stimulation, a stimulation method called high-definition tACS (HD-tACS) will be applied to target the primary motor cortex (M1), an area of the brain that is involved in controlling movement, using gel electrodes placed on the scalp. Participant will wear an electrode cap with 5 gel-filled cup HD electrodes arranged in a 4 x 1 montage, to create focused stimulation over the M1 region. A stimulator will be connected to the electrodes to deliver a low-intensity stimulating current to the scalp.
62847528|NCT04509349|PLACEBO_COMPARATOR|Sham tACS|For the transcutaneous ACS, the procedure for real and sham stimulation will be identical to HD-tDCS, but ACS will be delivered to the upper arm contralateral to hand attached to the accelerometer.
62847529|NCT04075734|EXPERIMENTAL|Intervention|The intervention consists of (1) online self-management educational modules and (2) weekly peer mentor calls to facilitate engagement with the modules and offer specialized support over approximately six weeks.
62847530|NCT04075734|NO_INTERVENTION|Usual Care|Participants are not receiving the tested intervention. They continue to receive standard or routine psychosocial or transition care available to them as part of the normal practice
62847531|NCT02906176|EXPERIMENTAL|SLCO2B1 wild type|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)
62847532|NCT02906176|EXPERIMENTAL|SLCO2B1 variant|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)
62847533|NCT03510741|ACTIVE_COMPARATOR|Sodium Benzoate|Sodium Benzoate added to TAU will be administered at 1000mg daily
62060808|NCT02347514|NO_INTERVENTION|Usual care|Patients in the control arm will be selected after the follow-up period is over for the intervention arm. They will receive the care they normally receive at their health center.
62264953|NCT01586351||Patch and ACP Treatment|Patents who get an patch augmentation and ACP injection following an arthroscopic repair of the rotator cuff.
62264954|NCT01486927|EXPERIMENTAL|Recombinant Factor VIII (rFVIII)|
62264955|NCT00870051||AAA patients|Subjects diagnosed with an AAA who are considered candidates for endovascular repair with Endurant Stent Graft, and who meet the inclusion/exclusion criteria are intended to participate in this registry
62264956|NCT05417724|OTHER|Battlefield Acupuncture|All subjects will receive BFA treatment weekly for 12 weeks.
62448450|NCT05575375|EXPERIMENTAL|Values Affirmation + Usual Care|
62448451|NCT05575375|OTHER|Usual Care|
62847534|NCT03510741|ACTIVE_COMPARATOR|N-Acetylcysteine|N-Acetylcysteine added to TAU 1000 mgs twice daily dose
62847535|NCT03510741|ACTIVE_COMPARATOR|Placebo|Placebo added to TAU
62448452|NCT02363309||Healthy Volunteers|Subjects without liver disease or metabolic syndrome
62448453|NCT02363309||NAFLD subjects|Subjects with Non-Alcoholic Fatty Liver Disease
62448454|NCT02363309||non-NAFLD metabolic syndrome|Subjects who have metabolic syndrome but do not have Non-Alcoholic Fatty Liver Disease
62448455|NCT04812106||Participants with LC-FAOD|
62847536|NCT03510741|ACTIVE_COMPARATOR|Sodium Benzoate Plus N-Acetylcysteine|Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
62847537|NCT03226197|EXPERIMENTAL|Study group|Ketone ester drink to be administered by nasogastric tube. Initial bolus dose of 25 ml on enrollment. After 1 hour, begin 47 hr infusion at 6 ml per hour.
62448456|NCT04621409|EXPERIMENTAL|liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, approximately 5 hours
62847538|NCT05310175|EXPERIMENTAL|Experimental group|Participants will receive electroacupuncture at Yamen(DU15), bilateral Tianzhu(BL10), Fengchi(GB20), Wangu(GB12), and Yifeng(SJ17) for 30minutes, 3 times a week for 4 weeks.
62847539|NCT05310175|PLACEBO_COMPARATOR|Control group|Participants will receive shallow needle insertion of 2-3 mm at sham acupoints without manipulation for 30minutes, 3 times a week for 4 weeks.
62060809|NCT02440984|OTHER|Enteric nervous system dysfunction|colonic biopsies and usual care
62847540|NCT04415671|EXPERIMENTAL|Part A- AD-214 SAD in Healthy Volunteers|
62060810|NCT01623648|EXPERIMENTAL|Arm 1 Whey Breakfast|The arm 1 will be assigned to eating Whey protein in the breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 42 g protein namely from whey at breakfast
62060811|NCT01623648|ACTIVE_COMPARATOR|Arm 2: No Whey Breakfast|The arm 2 will be assigned to intake other proteins (No Whey) in the breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 42 g protein from other sources at breakfast
62060812|NCT01623648|PLACEBO_COMPARATOR|Arm 3: Low Protein Breakfast|The arm 3 will be assigned to intake low protein and high carbohydrate breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 22 g protein from other sources at breakfast
62847541|NCT04415671|PLACEBO_COMPARATOR|Part A-Placebo SAD in Healthy Volunteers|
62847542|NCT04415671|EXPERIMENTAL|Part B-AD-214 MAD in Healthy Volunteers|
62847543|NCT04415671|PLACEBO_COMPARATOR|Part B-Placebo MAD in Healthy Volunteers|
62847544|NCT01627288|EXPERIMENTAL|Boost Radiation: Dose Level 1|2.4 Gy X 25 fractions = 60 Gy
62847545|NCT01627288|EXPERIMENTAL|Boost Radiation: Dose level 2|2.6 Gy X 25 fractions = 65 Gy
62847546|NCT01627288|EXPERIMENTAL|Boost Radiation: Dose level 3|2.8 Gy x 25 fractions = 70 Gy
62060813|NCT00003137|EXPERIMENTAL|irinotecan|"Patients receive irinotecan (CPT-11) by IV over 90 minutes every 3 weeks. Dosage modifications are made based on toxicity. Retreatment may be delayed another 3 weeks (for a total of 6 weeks) to allow for recovery from toxic effects. Patient is taken off study if they do not recover from toxic effects, unless cause is documented to be unrelated to CPT-11. Patients with stable disease or partial response continue on treatment until disease progression or intolerable toxicity. Patients with complete response continue on treatment for another 2 courses and then are observed.~Patients are followed every 3 months for 3 years or until disease progression."
62060814|NCT01364597|EXPERIMENTAL|Brivaracetam|
62060815|NCT04191447|EXPERIMENTAL|FLAMBOYANT 200/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:~1 Flamboyant 200/12 capsule~1 Budesonide/formoterol Placebo capsule."
62847547|NCT01627288|EXPERIMENTAL|Experimental: Boost Radiation Dose Level 0|"If the 2 dose limiting toxicities are documented at dose level 1, therapy will be de-escalated to Dose level 0 defined below.~Dose level 0: 2.2 Gy X 25 fractions = 55 Gy"
62847548|NCT01454817|OTHER|Patients with ICDs|
62847549|NCT01454817|OTHER|Caregivers of Patients with ICDs|
62060816|NCT04191447|ACTIVE_COMPARATOR|Budesonide/formoterol 400/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:~1 Budesonide/formoterol 400/12 capsule~1 Flamboyant 200/12 Placebo capsule."
62060817|NCT00402701|EXPERIMENTAL|1|Students in school with active walk-to-school promotion programs.
62060818|NCT00402701|NO_INTERVENTION|2|Students in schools with access to standard school district transportation resources.
62448457|NCT04621409|PLACEBO_COMPARATOR|Placebo|IV infusion of saline, approximately 5 hours
62448458|NCT01968798|ACTIVE_COMPARATOR|Aspirin|100 mg enteric-coated aspirin
62448459|NCT01968798|PLACEBO_COMPARATOR|Placebo|Placebo
62448460|NCT01189825|EXPERIMENTAL|Exercise|
62448461|NCT03376594|ACTIVE_COMPARATOR|Benjakul Extract|Benjakul Extract 100 mg capsule by mouth 3 times a day for 42 days
62448462|NCT03376594|PLACEBO_COMPARATOR|Loratadine|Loratadine 10 mg capsule by mouth 3 times a day for 42 days
62448463|NCT06424847|ACTIVE_COMPARATOR|Lifestyle intervention (physical activity and diet)|
62448464|NCT06424847|ACTIVE_COMPARATOR|Lifestyle (physical activity and diet) and Sleep intervention|
62448465|NCT06424847|SHAM_COMPARATOR|Health education intervention|
62448466|NCT03400306|EXPERIMENTAL|Part 1, Bioequivalence Sequence Group 1|Veliparib 400-mg doses administered orally on Day 1 of each 2-3 day period in Part 1 with the following sequence for the 3 dosing days: four 100 mg capsules under fasting conditions, followed by one 400-mg tablet under fasting conditions, then one 400 mg tablet under non-fasting conditions.
62847550|NCT00800254|EXPERIMENTAL|Neuromuscular Electrical Stimulation (NMES)|
62847551|NCT00800254|ACTIVE_COMPARATOR|Standard Rehabilitation Protocol|
62847552|NCT02042872|EXPERIMENTAL|Zoledronic acid|At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
62847553|NCT02042872|NO_INTERVENTION|No Intervention|Participants will receive no therapy and serve as a control group and have the same outcome measures completed at parallel time points.
62847554|NCT03253861||control patients|patients without an infected pancreatic necrosis
62847555|NCT03253861||Case patients|patients with an infected pancreatic necrosis
62847556|NCT01727024|EXPERIMENTAL|Indacaterol (QAB149) Breezhaler®|In period 1, participants received Indacaterol 150 mcg once daily via Breezhaler® device for 7 days, followed by a 7-day washout. In period 2, participants received Tiotropium 2.5 mcg, in 2 consecutive puffs, once daily via Respimat® device for 7 days.
62847557|NCT01727024|ACTIVE_COMPARATOR|Tiotropium Respimat®|In period 1, participants received Tiotropium 2.5 mcg, in 2 consecutive puffs, once daily via Respimat® device for 7 days, followed by a 7-day washout. In period 2, participants received Indacaterol 150 mcg once daily via Breezhaler® device for 7 days.
62847558|NCT00843284||Patients with neuropathic pain|
62847559|NCT01396057|EXPERIMENTAL|Ranibizumab|Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally
62847560|NCT01396057|SHAM_COMPARATOR|Dexamethasone|Intravitreal implant as per commercial label (700 μg Dexamethasone; long acting release (LAR) over 6 months
62847561|NCT02824406||Patients|CVR assessment consists of CBF measurement with arterial spin labelling (ASL)-MRI before and after intravenous administration of 16mg/kg acetazolamide (Diamox)
62847562|NCT02824406||Controls|CVR assessment consists of CBF measurement with arterial spin labelling (ASL)-MRI before and after intravenous administration of 16mg/kg acetazolamide (Diamox)
62847563|NCT00750152|PLACEBO_COMPARATOR|2|placebo
62847564|NCT00750152|EXPERIMENTAL|1|NAFT-500
62847565|NCT06110637|EXPERIMENTAL|Hard shoes runners|Half-marathon runners with hard shoes preceded and followed by assessment of neuromuscular fatigue.
62060819|NCT06626438|EXPERIMENTAL|Treatable Traits model of care|Embedded multidisciplinary clinic. This involves multidimensional assessment of patients with MDT review to determine presence of treatable traits and their specific management.
62060820|NCT06626438|NO_INTERVENTION|Standard of Care|Standard of care where physician-led ILD clinic. All referrals and comorbidity management as guided by physician.
62060821|NCT00864708|EXPERIMENTAL|Arm 1|radio frequency-controlled (RF) Microstimulator (RFM) Gait System
62060822|NCT06181032|EXPERIMENTAL|Single arm|Neoadjuvant treatment with adebrelimab in combination with apatinib gemcitabine and cisplatin
62060823|NCT02607371||Cohort 1 / VKA treatment|A sample of about 200 patients with nonvalvular atrial fibrillation who are treated with VKAs for at least three months at date of study inclusion
62060824|NCT02607371||Cohort 2 / NOAC treatment|A sample of about 200 patients with nonvalvular atrial fibrillation who are treated with NOACs for at least three months at date of study inclusion
62060825|NCT02466646|ACTIVE_COMPARATOR|Full-mouth Disinfection IPT|Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).
62060826|NCT02466646|EXPERIMENTAL|Conventional IPT|Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
62448467|NCT03400306|EXPERIMENTAL|Part 2, Extension|Veliparib as monotherapy or in combination with carboplatin and paclitaxel, per investigators' discretion.
62448468|NCT03400306|EXPERIMENTAL|Part 1, Bioequivalence Sequence Group 2|Veliparib 400-mg doses administered orally on Day 1 of each 2-3 day period in Part 1 with the following sequence for the 3 dosing days: one 400-mg tablet under fasting conditions, followed by four 100 mg capsules under fasting conditions, then one 400 mg tablet under non-fasting conditions.
62060827|NCT02466646|EXPERIMENTAL|Full-mouth IPT|Initial periodontal treatment was performed in 2 sessions within 24 hours.
62060828|NCT04018248|EXPERIMENTAL|Treatment (BR101801): Phase Ia (dose escalation)|Patients will receive BR101801 capsules orally, QD in 28-day cycles. The regimen may be changed to BID dosing based on emerging data.
62060829|NCT04018248|EXPERIMENTAL|Treatment (BR101801):Phase Ib (dose expansion)|• Subjects with PTCL NOS, PTCL AITL, Nodal PTCL with TFH and PTCL FTCL
62448469|NCT01482624|ACTIVE_COMPARATOR|VISCOSEAL® SYRINGE|
62448470|NCT01482624|OTHER|Standard arthroscopic meniscal surgery|
62448471|NCT00729859|EXPERIMENTAL|Group 1|Acyline 300 µg/kg injections every two weeks (2 doses) + placebo (no active ingredients) gel daily for 28 days + oral placebo pill daily for 28 days
62448472|NCT00729859|EXPERIMENTAL|Group 2|Acyline 300 µg/kg injections every two weeks (2 doses) + Testosterone gel 100 mg daily for 28 days + oral placebo pill daily for 28 days
62448473|NCT00729859|EXPERIMENTAL|Group 3|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
62448474|NCT05006937|ACTIVE_COMPARATOR|laser dusting|"In the dusting arm, the ureteroscope will be advanced into the kidney or ureter over an access wire without an access sheath in place. The identified stone will be dusted using a 200 micron Moses laser fiber at a setting of 0.3-0.6 J and 50-120 Hz using the Moses 2.0 laser system. Stone dusting will continue until the surgeon feels the fragments are all negligible in size and would be able to pass. One small piece will be extracted for analysis and the remainder will be left to pass spontaneously. If there is no evidence of injury or swelling of the ureter at the conclusion of the case a stent will be omitted."
62847566|NCT06110637|ACTIVE_COMPARATOR|Soft shoes runners|Half-marathon runners with soft shoes preceded and followed by assessment of neuromuscular fatigue.
62847567|NCT02522663|NO_INTERVENTION|Usual Care|Today, no post-discharge telephone support is offered as standard care from the hospital.
62847568|NCT02522663|EXPERIMENTAL|Intervention group|Experimental group is offered 24/7-telephone support during the first 1 month post-discharge, and patients are actively called at day 2 and day 9 day after discharge.
62847569|NCT03005899|EXPERIMENTAL|SyB P-1501 group|One patch of SyB P-1501 contains 10.8 mg of fentanyl hydrochloride (fentanyl 9.7 mg) and produces an electric current to deliver the drug iontophoretically after the system is activated. 40 µg fentanyl per on-demand dose, each delivered over 10 minutes for a maximum of 6 doses/hr for 24 hours or maximum of 80 doses. Each system will inactivate at 80 doses or 24 hours, whichever occurs first.
62847570|NCT03005899|PLACEBO_COMPARATOR|SyB P-1501 placebo group|Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
62621491|NCT02697591|EXPERIMENTAL|Phase 1: 20.0 Milligram Per Kilograms (mg/kg) Every 2 Weeks (Q2W)|Participants received IV infusion of study drug at a dose of 20.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
62621492|NCT02697591|EXPERIMENTAL|Phase 1: 0.03 mg/kg Q2W|Participants received intravenous (IV) infusion of study drug at a dose of 0.03 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
62448475|NCT05006937|ACTIVE_COMPARATOR|basketing|In the Basketing arm, a ureteral access sheath (UAS) will be placed per standard fashion. The ureteroscope will be introduced into the kidney and the stone fragmented at a setting of 0.8-1.0 J and 6-15 Hz. The resultant fragments will be basket extracted through the sheath for analysis. All fragments will be removed until no residual stone remains. At the time of UAS removal the ureter will be inspected. If there is no evidence of ureteral injury or swelling then a stent will be omitted.
62621493|NCT02697591|EXPERIMENTAL|Phase 1: 0.1 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 0.1 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
62621494|NCT02697591|EXPERIMENTAL|Phase 1: 0.3 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 0.3 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
62621495|NCT02697591|EXPERIMENTAL|Phase 1: 1.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 1.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
62621496|NCT02697591|EXPERIMENTAL|Phase 1: 3.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 3.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
62621497|NCT02697591|EXPERIMENTAL|Phase 1: 5.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 5.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
62060830|NCT04077255|EXPERIMENTAL|anti-EGFR|Participants will receive GC-1118 in combination with weekly paclitaxel.
62060831|NCT04061226||Central obesity group|Normal weight central obesity patients (by BMI and WHR).
62060832|NCT04061226||Without central obesity group|Normal weight patients without central obesity (by BMI and WHR).
62060833|NCT01339286|EXPERIMENTAL|atomoxetine|
62060834|NCT02753348||Newborns|Newborns (within 14 days from birth)
62621498|NCT02697591|EXPERIMENTAL|Phase 1: 10.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 10.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
62621499|NCT02697591|EXPERIMENTAL|Phase 1: 400 mg/kg Every 4 Weeks (Q4W)|Participants received IV infusion of study drug at a dose of 400 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
62621500|NCT02697591|EXPERIMENTAL|Phase 2: 300 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 300 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
62621501|NCT05421806||Treatment naive|
62621502|NCT05421806||Treatment switched|Virologically suppressed (VL \< 50 copies for more than 6 months)
62621503|NCT01134393|EXPERIMENTAL|telmisartan/amlodipine|start low dose and uptitrate to high dose on the basis of blood pressure goal
62847571|NCT00984997|EXPERIMENTAL|Surgery + Radiotherapy + Chemotherapy|"Surgery followed by radiotherapy and chemotherapy started at the beginning of radiotherapy. Segmentectomy or lobectomy with en bloc resection of the involved chest. Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week. Cisplatin 50 mg/M\^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.~Etoposide given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29. Prophylactic Cranial Irradiation 25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional."
62847572|NCT04824651||Solid cancer|objective : 800 participants for adult cohort, 100 for pediatric cohort (solid cancer and malignant hemopathy)
62847573|NCT04824651||Solid organ transplantation|objective : 700 participants for adult cohort, 50 for pediatric cohort
62847574|NCT04824651||Allogeneic hematopoietic stem cell transplantation|objective : 350 participants for adult cohort, 50 for pediatric cohort
62448476|NCT04262596|EXPERIMENTAL|Interactive Consulting System|The AI system adheres to the AHRQ SHARE approach (https://www.ahrq.gov/health-literacy/professional-training/shared-decision/tools/factsheet.html) for shared decision-making, which involves evaluating healthcare options, weighing pros and cons, and assessing potential risks while allowing patients to express their preferences.
62448477|NCT04262596|ACTIVE_COMPARATOR|Traditional decision aid brochure|A traditional patient decision aid brochure that includes provide standard general information, quantitative risk information on the possible outcomes of cataract surgery and value clarification exercise.
62448478|NCT06483607|NO_INTERVENTION|CONTROL|Control group patients are not going to be subjected to any block or local infiltration anesthesia. Their postoperative pain will be relieved with ibuprofen and tramadol (intravenous) administrations.
62448479|NCT06483607|ACTIVE_COMPARATOR|M-TAPA|Patients will have bilateral M-TAPA block with 0.25% bupivacaine (total volume of 40 ml) at the end of the surgery for postoperative pain control.
62621504|NCT04663854|EXPERIMENTAL|Trehalose|Trehalose Participants will be received intravenous trehalose infusion weekly (15 g/week) for a period of 12 weeks.
62621505|NCT04663854|PLACEBO_COMPARATOR|Placebo|Participants will be received equal volume of normal saline weekly for a period of 12 weeks.
62847575|NCT04824651||Chronic renal failure|Patients with chronic renal failure stage 4, 5 who receive dialysis or not. objective : 350 participants for adult cohort, 30 for pediatric cohort
62847576|NCT04824651||Autoimmune and autoinflammatory systemic diseases|Systemic lupus erythematosus ,Systemic Vasculitides,... objective : 750 participants for adult cohort, 130 for pediatric cohort
62621506|NCT01041339||acute chest pain ST elevation|patients admitted with acute chest pain sharing ST elevation in ER-ECG and elevated troponin
62847577|NCT04824651||Multiple sclerosis/ Neuromyelitis optica diseases|MS defined by Mac Donald et al. 2017 and Neuromyelitis optica defined by Wingerchuk et al. 2015 ; objective : 600 participants for adult cohort
62847578|NCT04824651||Chronic inflammatory rheumatism|Ankylosing spondylitis and rheumatoid polyarthritis objective : 600 participants for adult cohort
62847579|NCT04824651||Hypogammaglobulinemia|objective : 300 participants for adult cohort
62448480|NCT06483607|ACTIVE_COMPARATOR|TAP|Patients will have bilateral lateral-TAP block with 0.25% bupivacaine (total volume of 40 ml) at the end of the surgery for postoperative pain control.
62847580|NCT04824651||Obese non diabetic|BMI ≥ 30 objective : 1400 participants for adult cohort, 100 for pediatric cohort
62448481|NCT01927536||Night Vision|White LED Flashlight, Red/Green Green Dominant LED Flashlight
62621507|NCT01041339||controls|asymptomatic patients
62060835|NCT05907486|EXPERIMENTAL|Arm A|Modified BUCY conditioning regimen: busulfan (3.2mg/kg, day-7 to day -5), cytarabine (2g/m2, day -8), cyclophosphamide (1.8g/m2, day -4 to day -3), followed by stem cells infusion; N-acetyl-cysteine (Zambon Pharma, Hainan, China) : 8g/d (\>=45kg); 200mg/kg.d (\<45kg), intravenously for at least 4 hours, day -9 to day +45.
62621508|NCT04175041|OTHER|ADHD|Patients with ADHD.
62847581|NCT04824651||Diabetic (type I and II) obese or not|objective : 1400 participants for adult cohort, 100 for pediatric cohort
62847582|NCT04824651||People living with HIV-1|objective : 1400 participants for adult cohort
62847583|NCT04824651||Senior group (free from chronic conditions of interest listed above)|≥75 years objective : 450 participants for adult cohort
62448482|NCT02275923|EXPERIMENTAL|Diagnostic|'Reveal LINQ™ Insertable Cardiac Monitor' will be used to measure changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions.
62448483|NCT05625256||Accuracy of Continuous Noninvasive Blood Pressure at Various Stages of Anesthesia|To compare noninvasive continuous arterial pressures obtained from the SentiCor-300 with direct intra-arterial blood pressure measurements at various stages of anesthesia (such as induction, laryngoscopy, maintenance, emergence, and recovery) and after emergence in various positions.
62448484|NCT01843283|EXPERIMENTAL|Daily Enhancement Meaningful Activity (DEMA)|The group member will receive Self-management Toolkit and 6 bi-weekly individualized sessions, 2 face-to-face and 4 via telephone delivered by a trained intervener. DEMA will provide autonomy support by helping patients to identify and prioritize activities, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed.
62448485|NCT01843283|ACTIVE_COMPARATOR|Information Support (IS)|The IS group will receive 2 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer Association, educational brochure. Then they will receive 4 biweekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials.
62448486|NCT01054599|EXPERIMENTAL|Memantine|Subjects will randomly assigned to take either a placebo or memantine for 13 weeks. The assignment will be double-blind, neither the study members nor the subject will know if he/she is taking memantine or a placebo.
62448487|NCT01054599|PLACEBO_COMPARATOR|Sugar Pill|Subjects will be randomly assigned to take either memantine or a placebo. The study is double-blind, and neither the study members nor the subject will know if he/she is taking memantine or a placebo.
62448488|NCT04185558|EXPERIMENTAL|ActiGraft|Whole blood clot (WBC) gel
62448489|NCT04185558|ACTIVE_COMPARATOR|Standard of Care|Alginate dressing, a non-adherent foam dressing, and an outer gauze wrap
62621509|NCT04175041|OTHER|Healthy Control|Volunteers without Neuropsychiatric Disorders.
62060836|NCT05907486|ACTIVE_COMPARATOR|Arm B|Modified BUCY conditioning regimen: busulfan (3.2mg/kg, day-7 to day -5), cytarabine (2g/m2, day -8), cyclophosphamide (1.8g/m2, day -4 to day -3), followed by stem cells infusion.
62448490|NCT04954014|EXPERIMENTAL|BEVACIZUMAB|Patients will receive best available treatment (BAT) for COVID-19 plus single dose bevacizumab calculated as 7,5 mg/kg diluted in 250cc of saline solution during 90 minutes.
62448491|NCT04954014|ACTIVE_COMPARATOR|BEST AVAILABLE TREATMENT|Patients will receive best available treatment for COVID-19.
62448492|NCT02197533|EXPERIMENTAL|Written list|Patients in the intervention group will receive both verbal information and a written supplement (Appendix 1), produced during the discussion by CM or a fellow (not the individual who obtained consent), on treatment recommendations for OAB. They will leave clinic with this written list of recommendations and will be able to take it home with them.
62448493|NCT02197533|NO_INTERVENTION|Control|Patients in the control group will receive the same verbal information on the treatment recommendations for OAB, however, these patients will not receive the written list of management strategies for their condition.
62448494|NCT00521456|EXPERIMENTAL|1|
62448495|NCT00521456|PLACEBO_COMPARATOR|2|
62448496|NCT04395365|EXPERIMENTAL|Co-trimoxazole|Co-trimoxazole, 960mg capsule oral tablet, to be taken daily for 18 months
62448497|NCT04395365|PLACEBO_COMPARATOR|Placebo|Placebo, 960mg capsule oral tablet, to be taken daily for 18 months
62621510|NCT00797940|EXPERIMENTAL|Single Arm|Up to 42 subjects with first recurrence or progression of GBM
62621511|NCT03450408|ACTIVE_COMPARATOR|Placement with gloved hand|The Foley bulb transcervical dilator will be placed blindly with a gloved hand.
62621512|NCT03450408|ACTIVE_COMPARATOR|Placement with sterile speculum|The cervix will be directly visualized using a sterile speculum, and an instrument will be used to advance the Foley bulb transcervical dilator into the cervical os.
62847584|NCT04824651||Control group (free from chronic conditions of interest listed above)|18 to 74 years objective : 1400 participants for adult cohort, 100 for pediatric cohort (from 5 to 17 years old)
62847585|NCT04824651||Control AZ-PF group (free from chronic conditions of interest listed above)|Participants with first dose of Astra-Zeneca vaccine AZD1222 and second dose of Pfizer ARNm vaccine BNT162b2 objective : 200 participants for adult cohort
62847586|NCT04824651||Major sickle cell syndrome|100 for pediatric cohort (from 5 to 17 years old)
62847587|NCT01145586|EXPERIMENTAL|Lactase EUF|1 oral tablet of the test drug before breakfast, lunch and dinner for 42 consecutive days
62847588|NCT01145586|ACTIVE_COMPARATOR|Lactase Ref|1 oral tablet of the comparative drug before breakfast, lunch and dinner for 42 consecutive days
62621513|NCT02956707||No pre-operative steroids|"This is a prospectively enrolling group of 40 subjects.~Our current clinical practice has changed. We no longer administer pre-oeprative steroids to neonates undergoing surgery with cardiopulmonary bypass. These patients still receive their post-operative steroid infusion that starts after termination from bypass. This is their standard of care and does not change due to study enrollment.~Subject's enrolled in this trial have a ACTH stimulation test performed: pre-operative, immediately post-cardiopulmonary bypass prior to the initiation of their clinical steroids, and prior to leaving the cardiac intensive care unit."
62621514|NCT02956707||Pre-operative steroids|This is a retrospective group of 40 subjects who were previously administered pre-operative steroids. These subjects also had ACTH testing performed pre-operative and immediately post-separation from cardiopulmonary bypass.
62847589|NCT06170411|EXPERIMENTAL|Experimental Group|1-hour trigeminal nerve stimulation with the Elexir (program1), as acute treatment of an early stage migraine attack
62847590|NCT06170411|SHAM_COMPARATOR|Control Group|1-hour trigeminal nerve stimulation with the sham device, as acute treatment of an early stage migraine attack
62847591|NCT03277339|EXPERIMENTAL|Paroxetine|Paroxetine (Deroxat®) Posology : 20 mg per day for 3 weeks. After 2 weeks of treatments, if indicated, physicians will prescribe until 50 mg.
62847592|NCT03277339|OTHER|Thermal cure|This study is controlled with a comparator which is the Thermal cure. Thermal cure is realized for 3 weeks.
62847593|NCT02711709||Intra-abdominal sepsis|Frailty measurements. Modified Minnesota Leisure Time Activities. Computed tomography morphometrics. Mobility Monitors.
62847594|NCT06436677||Prospective study group|The group included patients with confirmed cutaneous T-cell lymphoma (CTCL) based on clinical features and histopathology from three research units: Peking University First Hospital, Peking University Third Hospital, and Beijing Institute of Cancer Prevention and Treatment. According to the immunohistochemistry algorithm established previously, the formalin-fixed and paraffin-embedded skin lesions of the patients will be stained. Patients will be assigned to different molecular subtypes, and the treatment strategy will be selected based on the classification.
62847595|NCT06436677||Retrospective control group|The control group included patients with complete baseline information and previous follow-up data in the TACTICAL database, established by Peking University First Hospital in 2009 for cutaneous lymphoma cases.
62847596|NCT00496938|OTHER|1|Observational cohort using an all-comers design
62847597|NCT02917642|EXPERIMENTAL|Passive Ultrasonic Irrigation Protocol|ultrasonic activation of antimicrobial solutions
62847598|NCT02917642|ACTIVE_COMPARATOR|Non-Ultrasonic Irrigation Protocol|no-activation of antimicrobial solutions
62847599|NCT04229407|EXPERIMENTAL|Dietary supplement|"subject will be evaluated for the eligibility of MRI assessment to assign subjects in randomization strata (MRI or non-MRI).~After 32 subjects in MRI strata is reached. subjects will be randomized to intake Dietary supplement twice daily (every morning and night, 30 minutes after exercise if do exercise) for 12 weeks"
62847600|NCT04229407|PLACEBO_COMPARATOR|vitamin B|"subject will be evaluated for the eligibility of MRI assessment to assign subjects in randomization strata (MRI or non-MRI).~After 32 subjects in MRI strata is reached. subjects will be randomized to intake placebo vitamin B twice daily (every morning and night, 30 minutes after exercise if do exercise) for 12 weeks."
62621515|NCT05499871|EXPERIMENTAL|Minimalist footwear|Transition toward a minimalist footwear.
62060837|NCT01576367|EXPERIMENTAL|canakinumab|Patients will receive a standard dose at an equivalent of 2 mg/kg s.c. of canakinumab (ACZ885) every 8 weeks. Possible dose and/or dosing regimen adjustments that can be administered include: 4 mg/kg s.c. (every 4 to 8 weeks) 6 mg/kg s.c. (every 4 to 8 weeks) 8 mg/kg s.c. (every 4 to 8 weeks)
62060838|NCT05933265|EXPERIMENTAL|Phase 1 Single Arm Multicenter Study to Assess the Safety and Tolerability of LP-184|Phase 1 Single Arm Multicenter Study to Assess the Safety and Tolerability of LP-184 in Patients with Advanced Solid Tumors
62060839|NCT01581385||Carotid endarterectomy|Adult patient volunteers, male and female, undergoing clinically indicated carotid endarterectomy surgery.
62847601|NCT04137939|NO_INTERVENTION|Control group|Ctrl group is instructed to maintain their original daily life
62847602|NCT04137939|EXPERIMENTAL|Smart Exercise group|SE group are instructed to perform one session of upper extremity ergometer and one session of lower extremity ergometer in a week, 30 minute per session, lasting for 12 weeks.
62448498|NCT05073653|OTHER|68Ga-PSMA PET/CT Imaging|Injection of the radioligand 68Ga-PSMA; Device: PET/CT; Following injection of 68Ga-PSMA, the participants will be subjected to whole body PET/CT.
62448499|NCT05073653|OTHER|68Ga-GRP PET/CT Imaging|Injection of the radioligand 68Ga-GRP; Device: PET/CT; Following injection of 68Ga-GRP, the participants will be subjected to whole body PET/CT.
62448500|NCT04538963|EXPERIMENTAL|Banded Tooth|This tooth will have an orthodontic band and glass ionomer cement placed as an intervention for interproximal incipient caries.
62847603|NCT04079309|NO_INTERVENTION|No Intervention|No mist will be diffused into the environment.
62847604|NCT04079309|ACTIVE_COMPARATOR|Lavender|0,3 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
62847605|NCT04079309|ACTIVE_COMPARATOR|Orange|0,3 ml orange oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
62847606|NCT05106699|EXPERIMENTAL|Carbon ion followed by Proton radiotherapy|All patients received whole pelvis and prostate region radiotherapy. The dose to metastatic LN was escalated using simultaneous integrated boost (SIB) technique.
62847607|NCT00942097|PLACEBO_COMPARATOR|Nutritional plus Placebo (homeopathy)|Nutritional oriented diet for pregnancy period add homeopathic preparation from inert substance.
62060840|NCT06281353|EXPERIMENTAL|Capsules with active ingredient /Nanocurcumin|Participants received a dosage of 200mg capsules with active ingredient /Nanocurcumin per day after breakfast, for 8 weeks.
62621516|NCT05499871|EXPERIMENTAL|Footstrike pattern|Transition toward a forefootstrike pattern.
62621517|NCT05499871|NO_INTERVENTION|Control|No intervention
62621518|NCT02134392|EXPERIMENTAL|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline given by colonoscopy or enema.
62847608|NCT00942097|ACTIVE_COMPARATOR|Nutr and Homeop Sulph Puls Lyc Lackt Con Sep Nuxv Calcc Phos|Nutrition oriented diet for pregnancy period add active homeopathic medication (Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos)
62847609|NCT01962961|EXPERIMENTAL|PharmaNAC 1800 mg|PharmaNAC 900 mg orally twice daily for 8 weeks
62847610|NCT01962961|EXPERIMENTAL|PharmaNAC 3600 mg|PharmaNAC 1800 mg orally twice daily for 8 weeks
62847611|NCT01962961|PLACEBO_COMPARATOR|Placebo|Matching placebo pills given twice daily for 8 weeks
62847612|NCT05696093|EXPERIMENTAL|cotrimoxazole|Use of cotrimoxazole for enterobacterial VAP. Posology and modalities of antibiotic administration will be optimized based on most recent recommendations for ICU patient. They will receive the treatment for 28 days or until death or until ICU discharge if its before 28days.
62847613|NCT05696093|ACTIVE_COMPARATOR|standard antibiotic therapy|Use of standard antibiotic therapy enterobacterial VAP. Posology and modalities of antibiotic administration will be optimized based on most recent recommendations for ICU patient. They will receive the treatment for 28 days or until death or until ICU discharge if its before 28days.
62847614|NCT06110169|EXPERIMENTAL|Group A (anodal tDCS)|Participants will receive 20 minutes of anodal tDCS
62847615|NCT06110169|SHAM_COMPARATOR|Group B (sham tDCS)|Participants will receive 20 minutes of sham anodal tDCS
62847616|NCT03263702|EXPERIMENTAL|Computational Mapping Algorithm|AF mapping (utilizing CMA) will be performed and used to point the operator to regions within a heart chamber that should be interrogated further for suspicious electrogram activity, as measured by the St. Jude Ensite System, and ablated if the suspicious electrogram activity persists.
62847617|NCT01158599|OTHER|IXIARO 0,5 ml|IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28
62847618|NCT00635219|PLACEBO_COMPARATOR|Placebo|
62847619|NCT00635219|EXPERIMENTAL|Vortioxetine: 2.5 mg|
62060841|NCT06281353|PLACEBO_COMPARATOR|Placebo|Participants received a dosage of 200mg capsules without Nanocurcumin per day after breakfast, for 8 weeks
62847620|NCT00635219|EXPERIMENTAL|Vortioxetine: 5 mg|
62847621|NCT00635219|EXPERIMENTAL|Vortioxetine: 10 mg|
62847622|NCT00635219|OTHER|Duloxetine: 60 mg|Active reference
62847623|NCT05295667||Fetal Growth Retardation Group|
62847624|NCT00229385|ACTIVE_COMPARATOR|1|
62847625|NCT00229385|ACTIVE_COMPARATOR|2|
62847626|NCT02922686|ACTIVE_COMPARATOR|flucloxacillin + phenoxymethylpenicillin|Flucloxacillin 500 mg four times daily + Phenoxymethylpenicillin 500 mg four times daily for 7 days.
62847627|NCT02922686|PLACEBO_COMPARATOR|flucloxacillin + placebo|Flucloxacillin 500 mg four times daily + Placebo four times daily for 7 days.
62847628|NCT01430052|OTHER|Gemcitabine , S-1|Gemcitabine 1000mg/m2 on Day 1 and 8, every 3 weeks. S-1 60-100mg/day on Day 1 to 14, every 3 weeks
62847629|NCT01430052|EXPERIMENTAL|Gemcitabine, S-1, radiotherapy|Gemcitabine 600mg/m2 on Day 1 and 8, every 3 weeks. S-1 60-100mg/day on Day 1 to 14, every 3 weeks with radiotherapy 50.4Gy in 28 fractions
62847630|NCT03849118|EXPERIMENTAL|89Zr-girentuximab|A single administration of 37 Megabecquerel (MBq) (±10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab, followed by a diagnostic scan on Day 5 ± 2 days after administration.
62847631|NCT01532492||Rotator cuff repair group|Patients undergoing an arthroscopic rotator cuff repair
62060842|NCT06319703|EXPERIMENTAL|DSMES+CHW (IDEAL)|Participants in this group will receive brief pre-recorded DSMES videos, which include both educational and Social Cognitive Theory-based behavioral content. Participants will receive 1 DSMES video via text message each week for a total of 24 weeks with each video lasting about 5 minutes in duration. In addition, they will also receive brief phone calls from CHWs every 2 weeks during the 24 weeks video program. During these calls, CHWs will assess whether participants need assistance on social determinants of health (SDOH) barriers. If needed, CHWs will link participants to available services within the community. CHWs will also provide assistance on navigating the complex health care systems and serve as an advocate for patients during doctor visits if needed.
62060843|NCT06319703|NO_INTERVENTION|Wait-list control group (CONTROL)|Participants in this group will continue to receive the standard of usual care for their T2D at their doctor's office during the course of our study.
62060844|NCT00727324|EXPERIMENTAL|1|BIAP
62060845|NCT04083716|EXPERIMENTAL|Group 1|ABI-H2158 Reference Formulation in a fasting state on Day 1 (Period 1), then ABI-H2158 Test Formulation in a fasting state on Day 8 (Period 2), then ABI-H2158 Test Formulation after a high-fat meal on Day 15 (Period 3)
62847632|NCT01532492||DRC without rupture|Disorders of the rotator cuff without rupture
62264957|NCT04560595|EXPERIMENTAL|Caffeine Reduction Manual, Immediate Treatment Group|"Weekly caffeine consumption is to be measured before and after using the caffeine reduction program, which has been summarized in a Guide to Caffeine Reduction and Cessation manual to help people reduce their caffeine use. Those in the immediate treatment group will receive the guide immediately after screening."
62847633|NCT01532492||Shoulder instability|Shoulder instability
62060846|NCT04083716|EXPERIMENTAL|Group 2|ABI-H2158 Test Formulation in a fasting state on Day 1 (Period 1), then ABI-H2158 Test Formulation after a high-fat meal on Day 8 (Period 2), then ABI-H2158 Reference Formulation in a fasting state on Day 15 (Period 3)
62060847|NCT04083716|EXPERIMENTAL|Group 3|ABI-H2158 Test Formulation after a high-fat meal on Day 1 (Period 1), then ABI-H2158 Reference Formulation in a fasting state on Day 8 (Period 2), then ABI-H2158 Test Formulation in a fasting state on Day 15 (Period 3)
62060848|NCT03120689|ACTIVE_COMPARATOR|Live Surgery with VITOM|Learner will not assist during the surgery, but watch the live surgery that is projected on a screen via the VITOM camera followed by a short questionnaire.
62060849|NCT03120689|ACTIVE_COMPARATOR|Live Surgery without VITOM|Learner will assist in the traditional manner without the use of the VITOM camera followed by a short questionnaire.
62060850|NCT03120689|ACTIVE_COMPARATOR|Video viewing with VITOM|Learner will watch a video taped using the VITOM camera followed by a short questionnaire.
62060851|NCT03120689|ACTIVE_COMPARATOR|Video viewing with standard camera|Learner will watch a video taped using the standard hand-held high definition camera followed by a short questionnaire.
62060852|NCT03007654|EXPERIMENTAL|Mediclore|adhesion barrier Mediclore 5cc, to apply medical device fully around surgery area
62621519|NCT05436171||All deliveries conducted from 2011 to 2021 in Prince of Wales Hospital|"All deliveries conducted from 2011 to 2021 in Prince of Wales Hospital~The target sample size will be about 67,000 women who had delivered in our unit from 2011 to 2021. Among them, it is expected that 75-80% had vaginal deliveries, either normal vaginal delivery or instrumental delivery. 53,600 will be recruited in study site."
62847634|NCT03994653||Cases|Participants diagnosed with ovarian cancer
62060853|NCT03007654|NO_INTERVENTION|No treatment|standard treatment for surgery
62060854|NCT03007654|ACTIVE_COMPARATOR|Adept|adhesion barrier, Adept, to apply medical device fully around surgery area
62264958|NCT04560595|EXPERIMENTAL|Caffeine Reduction Manual, Delayed Treatment Group|"Weekly caffeine consumption is to be measured before and after using the caffeine reduction program, which has been summarized in a Guide to Caffeine Reduction and Cessation manual to help people reduce their caffeine use. Those in the delayed treatment group will receive the guide seven weeks after screening."
62264959|NCT03916211|NO_INTERVENTION|routine treatment|Diabetic foot routine treatment without intervention
62847635|NCT03994653||Controls|Participants without ovarian cancer
62847636|NCT04552249||Group 1|
62847637|NCT04552249||Group 2|
62847638|NCT04552249||Group 3|
62847639|NCT04552249||Group 4|
62847640|NCT04552249||Group 5|
62847641|NCT04552249||Group 6|
62847642|NCT05552417|NO_INTERVENTION|control group|Conventional control group(C) (n=--) where --- children will not receive any intervention.
62847643|NCT05552417|ACTIVE_COMPARATOR|Pectointercostal|Pectointercostal facial group (PI) (n=--) where --children will have bilateral Pectointercostal Block.
62847644|NCT03790033|EXPERIMENTAL|UCHA group|2.5g, three times a day, each taken before or between meals for 8 weeks. Manufacturing company: Shinhwa Pharmaceutical company
62847645|NCT03790033|PLACEBO_COMPARATOR|Placebo group|2.5g, three times a day, each taken before or between meals for 8 weeks. Manufacturing company: Tsumura Co., Tokyo, Japan
62060855|NCT05922839|EXPERIMENTAL|Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA|Zanubrutinib 160mg, orally, twice daily, for a minimum of 3 months For effective patients, continue to use for 2 years after achieving optimal therapeutic effect.
62060856|NCT00765310|ACTIVE_COMPARATOR|Lipoic Acid|600 mg R-alpha lipoic acid in morning on empty stomach (two 300 mg capsules)
62060857|NCT00765310|PLACEBO_COMPARATOR|Placebo|Placebo two caps every morning on empty stomach
62060858|NCT01768546|EXPERIMENTAL|Video on Demand (VOD)|Virtual Diabetes Prevention Program: All participants will view the 16 Comcast on Demand episodes, weigh themselves, and track their progress weekly. Participants in the VOD arm of the study received access to a paper tracker to track food and activity during the program.
62060859|NCT01768546|EXPERIMENTAL|Video on Demand Plus (VOD+)|Virtual Diabetes Prevention Program: All participants will view the 16 Comcast on Demand episodes, weigh themselves, and track their progress weekly. Participants in the VOD+ arm of the trial received access an interactive tracking and problem solving web portal offered by SparkPeople™ (Cincinnati, Ohio).
62060860|NCT05340751||Anesthesia|hemoglobin
62060861|NCT04835714|EXPERIMENTAL|Part A with Monotherapy dose escalation|
62060862|NCT04835714|EXPERIMENTAL|Part B with Combination therapy dose escalation|
62060863|NCT04835714|EXPERIMENTAL|Part C with Combination therapy dose confirmation|
62847646|NCT03493217|EXPERIMENTAL|ICP-022|Two regimens of ICP-022 (High and low dose QD) are designed for study Part I to determine RP2D. The RP2D determined will be used in Part II to further evaluate the preliminary efficacy of ICP-022 in Chinese subjects with R/R CLL/SLL.
62847647|NCT06373133|EXPERIMENTAL|SHR-8068+Adebrelimab+BP102|The first 9 subjects will be treated with low dose SHR-8068 (1mg/kg, q6w), and the subsequent subjects will be treated with high dose SHR-8068 (4mg/kg, q12w) if the toxicity of DLT is tolerable during the observation period.
62847648|NCT01599988|ACTIVE_COMPARATOR|Milk protein isolate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
62847649|NCT01599988|ACTIVE_COMPARATOR|Caseinate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate.
62847650|NCT00547833||Experimental|Children with language-learning disabilities reading at approximately a 6th grade level
62847651|NCT00547833||Age-Matched|Typical language learners each of whom is pair match to an experimental participant by age and gender.
62847652|NCT00547833||Language-Matched|Typical language learners, each of whom is pair-matched to an experimental participant by reading comprehension skills and gender.
62847653|NCT05561556|EXPERIMENTAL|MitoQ|8-week MitoQ supplementation (20 mg daily capsule).
62847654|NCT05561556|PLACEBO_COMPARATOR|Placebo|8-week placebo matched in appearance to MitoQ supplementation (20 mg daily capsule).
62060864|NCT04835714|EXPERIMENTAL|Part D with Combination therapy dose expansion|
62847655|NCT06136585|EXPERIMENTAL|2 mg/kg sugammadex|All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 2 mg/kg sugammadex.
62847656|NCT06136585|ACTIVE_COMPARATOR|0.07 mg/kg neostigmine|All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 0.07 mg/kg neostigmine (to a maximum of 5 mg).
62847657|NCT05688722|PLACEBO_COMPARATOR|Control|Patient positioned in supine conventional position
62847658|NCT05688722|ACTIVE_COMPARATOR|20 degree head elevation|Patient positioned in 20 degree head elevation position
62847659|NCT05688722|ACTIVE_COMPARATOR|30 degree head elevation|Patient positioned in 30 degree head elevation position
62847660|NCT05688722|ACTIVE_COMPARATOR|45 degree head elevation|Patient positioned in 45 degree head elevation position
62847661|NCT03265652|EXPERIMENTAL|Intense Pulsed Light (IPL) therapy|Subjects with receive 10-15 intense pulsed light (IPL) pulses on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and up to 3 mm from the lid margin of the lower eyelid. Following the administration of IPL pulses, subjects will undergo meibomian gland expression.
62060865|NCT01438463|PLACEBO_COMPARATOR|placebo|
62060866|NCT01438463|EXPERIMENTAL|PURETHAL Mites, 6,667 AU/ml|
62060867|NCT01438463|EXPERIMENTAL|PURETHAL Mites, 20,000 AU/ml|
62060868|NCT01438463|EXPERIMENTAL|PURETHAL Mites, 50,000 AU/ml|
62060869|NCT01438463|EXPERIMENTAL|PURETHAL Mites, 100,000 AU/ml|
62060870|NCT03391960|OTHER|Disinfecting barrier cap|"In the participating wards, disinfecting barrier cap was used on every needless connector used for accessing CVC IV lines.~Compliance with disinfecting barrier cap was observed weekly."
62060871|NCT05232032|EXPERIMENTAL|Participants with MDD or an anxiety disorder receiving the nociceptin receptor antagonist|After a diagnostic interview (determining the presence of MDD or an anxiety disorder) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive the nociceptin receptor antagonist. Participants will then complete an approach/avoidance task. Functional magnetic resonance imagining (fMRI) will begin 2 hours after the nociceptin receptor antagonist is administered.
62060872|NCT05232032|PLACEBO_COMPARATOR|Participants with MDD or an anxiety disorder receiving the placebo|After a diagnostic interview (determining the presence of MDD or an anxiety disorder) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive the placebo. Participants will then complete an approach/avoidance task. fMRI will begin 2 hours after the placebo is administered.
62060873|NCT05232032|EXPERIMENTAL|Healthy controls receiving the nociceptin receptor antagonist|After a diagnostic interview (determining healthy control status) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive a nociceptin receptor antagonist. Participants will then complete an approach/avoidance task. fMRI will begin 2 hours after the nociceptin receptor antagonist is administered.
62060874|NCT05232032|PLACEBO_COMPARATOR|Healthy controls receiving the placebo|After a diagnostic interview (determining healthy control status) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive the placebo. Participants will then complete an approach/avoidance task. fMRI will begin 2 hours after the placebo is administered.
62060875|NCT05882201|PLACEBO_COMPARATOR|Control group|Control group
62060876|NCT05882201|EXPERIMENTAL|Group FICB|✓ Group FICB; (30 patients) Fascia Iliaca compartment block group.
62060877|NCT05882201|EXPERIMENTAL|Group FNB|✓ Group FNB; (30 patients) Femoral nerve block group.
62060878|NCT05590988|EXPERIMENTAL|Tablet|The intervention group trained bimanual coordination once a day for about 31 minutes on a total of ten days using a tablet game. A ball is to be moved on a circular line.
62060879|NCT05590988|ACTIVE_COMPARATOR|Aximo|"The patients in the control group receive an ergotherapeutic therapy unit once a day for the same length of time (approx. 31 minutes) for a total of ten days, in which they train unilaterally. In this therapy unit, the control group uses the Aximo. This is a comb stand and so-called rolls with which plugging tasks can be practiced. The patients should push the rolls into the stand fields with the affected hand. With the plug-in game, the patients can complete different tasks that challenge and train their hand-eye coordination, their fine motor skills and their ability to grasp things (e.g. following a specific pattern based on a template or putting colors in a specific order)."
62060880|NCT02475135|EXPERIMENTAL|Panel 1: Group 1|Subject will receive a single oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI)/emtricitabine (FTC) /tenofovir alafenamide (TAF) (D/C/F/TAF) under fed conditions (standardized regular breakfast, test Panel 1) on Day 1 of treatment period 1 and by FDC of elvitegravir (EVG)/cobicistat (COBI)/emtricitabine (FTC)/ tenofovir alafenamide (TAF) (E/C/F/TAF) under fed conditions (standardized regular breakfast, reference Panel 1) on Day 1 of treatment period 2.
62060881|NCT02475135|EXPERIMENTAL|Panel 1: Group 2|Subject will receive a single oral tablet of FDC containing E/C/F/TAF under fed conditions (standardized regular breakfast, reference Panel 1) on Day 1 of treatment period 1 and a single oral tablet of FDC containing D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 1) on Day 1 of treatment period 2.
62060882|NCT02475135|EXPERIMENTAL|Panel 2: Group 1|Subject will receive a single oral tablet of D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 2) on Day 1 of treatment period 1 and a single oral tablet of DRV, a tablet of emtricitabine/ tenofovir alafenamide (FTC/TAF) and a tablet of COBI under fed conditions (standardized regular breakfast, reference Panel 2) on Day 1 of treatment period 2.
62060883|NCT02475135|EXPERIMENTAL|Panel 2: Group 2|Subject will receive a single oral tablet of DRV, a tablet of FTC/TAF and a tablet of COBI under fed conditions (standardized regular breakfast, reference Panel 2) on Day 1 of treatment period 2 and a single oral tablet of D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 2) on Day 1 of treatment period 2.
62060884|NCT02475135|EXPERIMENTAL|Panel 3: Group 1|Subject will receive a single oral tablet of D/C/F/TAF under fasted conditions (test Panel 3) on Day 1 of treatment period 1 and a single oral tablet of D/C/F/TAF with a standardized high-fat breakfast (reference Panel 3) on Day 1 of treatment period 2.
62621520|NCT06526325|EXPERIMENTAL|Application of enhanced Golgi tendon organ stimulation to patients|The effect of golgi tendon organ stimulation on the symptoms will be examined after applying the improved golgi tendon organ stimulation to patients diagnosed with cervical disc herniation and having pain, limitation of movement, spasm and tenderness in the neck region.
62847662|NCT03265652|PLACEBO_COMPARATOR|Sham therapy|Participants will undergo a sham treatment that will mimic the intense pulsed light (IPL) therapy. The tip of the IPL lightguide will be placed in 10-15 locations on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and up to 3 mm from the lid margin of the lower eyelid, but IPL pulses will not be actually delivered. Following this sham procedure, subjects will undergo meibomian gland expression.
62847663|NCT03220906||Arterial line|Children undergoing surgical procedure with planned arterial cannula placement.
62847664|NCT05933239|OTHER|Patients diagnosed with non-small cell lung cancer (NSCLC), planned for standard-of-care surgery|
62847665|NCT01475149||aPL positive - group 1|aPL positive with APS, receiving HCQ
62847666|NCT01475149||aPL positive - group 2|aPL positive with APS and SLE, receiving HCQ
62847667|NCT01475149||aPL positive - group 3|aPL positive without APS but with SLE, receiving HCQ
62060885|NCT02475135|EXPERIMENTAL|Panel 3: Group 2|Subject will receive a single oral tablet of D/C/F/TAF with a standardized high-fat breakfast (reference Panel 3) on Day 1 of treatment period 1 followed by a single oral tablet of D/C/F/TAF under fasted conditions (test Panel 3) on Day 1 of treatment period 2.
62060886|NCT04500496|EXPERIMENTAL|INH|3 tablet of INH 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.
62264960|NCT03916211|EXPERIMENTAL|MSCs treatment|On the basis of routine treatment of diabetic foot, adipose stem cells will be added to treat diabetic foot
62264961|NCT03487575|EXPERIMENTAL|Open trial|
62264962|NCT04071743|ACTIVE_COMPARATOR|Treatment|Treatment and Prevention with active gammacore device(vagus nerve stimulator)
62448501|NCT04538963|NO_INTERVENTION|Non-banded Tooth|This tooth will be monitored per standard of care; encourage good dental hygiene at home.
62448502|NCT00815451|PLACEBO_COMPARATOR|placebo dark chocolate|polyphenol-poor dark chocolate
62847668|NCT01475149||aPL positive - group 4|aPL positive without APS or SLE, receiving HCQ
62264963|NCT04071743|SHAM_COMPARATOR|Sham|Treatment and Prevention with sham gammacore device(vagus nerve stimulator)
62448503|NCT00815451|EXPERIMENTAL|polyphenol-rich dark chocolate|
62847669|NCT01475149||aPL negative - group 1|aPL negative with SLE, receiving HCQ
62847670|NCT01475149||aPL negative - group 2|aPL negative with SLE, not receiving HCQ
62847671|NCT01388985|ACTIVE_COMPARATOR|Standard vaccination schedule|One injection will be given on three different days (day 0, day 7 and day 21 or 28)
62847672|NCT01388985|EXPERIMENTAL|Accelerated vaccination schedule|Two injections will be given on the same day (day 0 and day 7): one on each forearm.
62847673|NCT03085797|EXPERIMENTAL|Mepolizumab 100 mg SC + MF|Participants will receive total thirteen doses of 100 mg SC of mepolizumab in thigh, abdomen or upper arm every 4 weeks for 52 weeks on top of SoC which includes daily nasal spray of mometasone furoate.
62847674|NCT03085797|PLACEBO_COMPARATOR|Placebo SC + MF|Participants will receive total thirteen doses of SC matching placebo in thigh, abdomen or upper arm every 4 weeks for 52 weeks on top of SoC which includes daily nasal spray of mometasone furoate.
62847675|NCT02481453|EXPERIMENTAL|Rapamycin|rapamycin 1 mg/ml oral solution, 2 mg/day (2 ml/day), once a day, during one year
62060887|NCT04500496|ACTIVE_COMPARATOR|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
62060888|NCT01731743|OTHER|implantation of a trifocal IOL (AT LISA tri 839MP)|
62060889|NCT05155995|EXPERIMENTAL|Sequence 1|"Period 1: Fasted state + RLD2007 +RLD2008 + RLD2102~Period 2: Fasted state + HCP2001"
62060890|NCT05155995|EXPERIMENTAL|Sequence 2|"Period 1: Fasted state + HCP2001~Period 2: Fasted state + RLD2007 +RLD2008 + RLD2102"
62060891|NCT05155995|EXPERIMENTAL|Sequence 3|"Period 1: High fat diet + RLD2007 +RLD2008 + RLD2102~Period 2: High fat diet + HCP2001"
62060892|NCT05155995|EXPERIMENTAL|Sequence 4|"Period 1: High fat diet + HCP2001~Period 2: High fat diet + RLD2007 +RLD2008 + RLD2102"
62847676|NCT02481453|PLACEBO_COMPARATOR|Placebo|Placebo oral solution, 2 ml/day, once a day, during one year
62264964|NCT00772954|PLACEBO_COMPARATOR|Placebo vaccine group|Participants scheduled to receive a dose of placebo vaccine on Day 0, Day 28, and Day 56, respectively.
62264965|NCT00772954|EXPERIMENTAL|Clostridium Difficile Vaccine Group 1|Participants scheduled to receive a dose of 50 μg Clostridium Difficile vaccine on Day 0, Day 28, and Day 56, respectively.
62264966|NCT00772954|EXPERIMENTAL|Clostridium Difficile Vaccine Group 2|Participants scheduled to receive a dose of 100 μg Clostridium Difficile vaccine on Day 0, Day 28, and Day 56, respectively.
62264967|NCT04404387|EXPERIMENTAL|Experimental arm|vitamin C 50 mg/kg every 6 hours for 96 hours.
62264968|NCT04404387|PLACEBO_COMPARATOR|Control arm|Placebo administration
62060893|NCT01457235|ACTIVE_COMPARATOR|Active Group|This group receives cognitive remediation in groups (each group consisting of 6-8 subjects)
62060894|NCT01457235|NO_INTERVENTION|Waiting List|Patients randomized to the waiting list group continues standard treatment and will be offered a course of cognitive remediation upon completion of participation provided that they still meet the inclusion criteria.
62060895|NCT04943263|EXPERIMENTAL|Tracheal Temperature|Intubation done with a temperature sensor located on the cuff surface of the endotracheal tube
62060896|NCT05256095|EXPERIMENTAL|Immediate Assignment to Intervention Group|This group will begin to receive the intervention immediately upon entering the study. Thinking in Speech is a novel cognitive therapy that helps children with autism independently cope with everyday events that cause stress, by developing their ability to use inner speech. Participants will complete two sessions per week for eight week, for a total of sixteen sessions. Sessions will be conducted by speech-language pathologists who are trained in Thinking in Speech. Sessions will be conducted via a secure Zoom platform.
62060897|NCT05256095|EXPERIMENTAL|Waitlist Assignment to Intervention Group|The Waitlist group will begin to receive the intervention 10 weeks after entering the study. Thinking in Speech is a novel cognitive therapy that helps children with autism independently cope with everyday events that cause stress, by developing their ability to use inner speech. Participants will complete two sessions per week for eight week, for a total of sixteen sessions. Sessions will be conducted by speech-language pathologists who are trained in Thinking in Speech. Sessions will be conducted via a secure Zoom platform.
62060898|NCT00954733|EXPERIMENTAL|All participants|All participants, one arterial blood draw
62060899|NCT01117701|EXPERIMENTAL|A - with SGW|Measurement of the forces needed to passage the ureteroscope in the ureter with a SGW in place.
62264969|NCT03511963|EXPERIMENTAL|HLX04|
62264970|NCT03511963|ACTIVE_COMPARATOR|Bevacizumab|
62264971|NCT05093400||Normal Saliva|"saliva from normal healthy adults."
62264972|NCT03134352|EXPERIMENTAL|ZL-3101(Fugan) bid group|Fugan AM + Fugan PM
62264973|NCT03134352|EXPERIMENTAL|ZL-3101(Fugan) qd group|Fugan AM + Placebo PM
62264974|NCT03134352|PLACEBO_COMPARATOR|placebo group|Placebo AM + Placebo PM
62448504|NCT01325675|EXPERIMENTAL|Interval training|Interval training
62448505|NCT01325675|NO_INTERVENTION|Control|Live as usual
62448506|NCT04258670||Cross-reactive loiasis|This cohort will prospectively enroll 50 adults (age 18+) with cross-reactive antigenemia based on a positive filariasis test strip (FTS) and L. loa Mf counts \>20,000 Mf/mL.
62847677|NCT03036215|NO_INTERVENTION|Traditional Self-Care Control Arm|Traditional self-care includes focusing on rest and healing through changes in chewing, diet, heat/cold, over the counter analgesics, and reducing strain from oral and sleeping habits. Participants will also participate in usual care from the dentist such as a splint or anti-inflammatory medications. Participants will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end). .
62264975|NCT01701570|ACTIVE_COMPARATOR|An Active Comparator exercise training intervention|The Active Comparator Groupwill participate in an exercise training intervention to distinguish the relative roles of objective factors (lactate level) and subjective factors (self-efficacy) in mediating pre-post change in RPE during low, moderate, and vigorous exercise.
62264976|NCT01701570|PLACEBO_COMPARATOR|A Placebo Attention Control|The placebo attention control group will receive monthly diabetes education and phone calls phone calls to monitor their blood glucose levels. Participants will receive an accelerometer to wear for one week.
62448507|NCT04258670||non-cross-reactive loiasis|This cohort will prospectively enroll 10 adults (age 18+) with a negative filariasis test strip (FTS) and L. loa Mf counts \>20,000 Mf/mL.
62264977|NCT02250352||Cohort I (newly diagnosed, surgery before systemic therapy)|Patients undergo baseline and, if applicable, follow-up core needle biopsies of breast cancer in the breast, regional nodes, and distant metastases. Patients who experience a recurrence or progression after therapy undergo additional core biopsies at the time of recurrence. Clinical and blood specimens will also be gathered.
62847678|NCT03036215|EXPERIMENTAL|PACT Experimental Arm|If selected for the PACT care arm, participant will be prompted to complete a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. Participant will also participate in usual care from the dentist such as a splint or anti- inflammatory medications.Participant will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end).
62847679|NCT05433844|OTHER|Group 1|Test Drug for Period I Reference Drug for Period II
62448508|NCT03996486|EXPERIMENTAL|Hemophilia|Dose escalation starting with 200 mg of BAY1093884
62847680|NCT05433844|OTHER|Group 2|Reference Drug for Period I Test Drug for Period II
62847681|NCT02054104|EXPERIMENTAL|1/Vaccine Plus Chemotherapy|H1299 cell lysates with iscomatrix vaccine with metronomic chemotherapy
62847682|NCT02054104|EXPERIMENTAL|2/Vaccine Alone|H1299 cell lysates with iscomatrix adjuvant vaccine
62847683|NCT04845711|PLACEBO_COMPARATOR|Control group|patients will receive general anesthesia only.
62847684|NCT04845711|EXPERIMENTAL|Erector spinae plane block group|patients will receive general anesthesia and bilateral ultrasound guided erector spinae plane block (20ml Bupivacaine 0.25%)
62847685|NCT04845711|EXPERIMENTAL|Quadratus lumborum block group|patients will receive general anesthesia and bilateral ultrasound guided quadratus lumborum block (20 ml Bupivacaine 0.25%)
62847686|NCT02543060|EXPERIMENTAL|stannous fluoride toothpaste|brush twice a day for 8 weeks
62448509|NCT00544765|EXPERIMENTAL|resp: 4xTAC|Patients sufficiently responding (iPR, iCR) will recieve 4 further cycles of TAC
62448510|NCT00544765|EXPERIMENTAL|resp: 6xTAC|Patients sufficiently responding (iPR, iCR) will recieve 6 further cycles of TAC
62847687|NCT02543060|SHAM_COMPARATOR|cavity protection toothpaste|brush twice a day for 8 weeks
62847688|NCT04269798|ACTIVE_COMPARATOR|Traditional Treatment Arm|Will receive conventional rehabilitation program for the lower limbs, balance and gait training. Two hours of conventional physical therapy program /session - 3 sessions/week/ three successive months.
62847689|NCT04269798|EXPERIMENTAL|Functional Electrical Stimulation Group|Will receive 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
62847690|NCT03161444|OTHER|Elective patient|Patient who has patricipated to the study CHIKVIH (NCT02553369) will have a blood collection during a follow up visit for HIV infection.
62264978|NCT02250352||Cohort II (newly diagnosed, systemic therapy before surgery)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients also undergo biopsies at a specific time point following the initiation of standard systemic therapy.
62448511|NCT00544765|EXPERIMENTAL|nonResp: 4xTAC|Patients non-sufficiently responding (iNC) will recieve 4 further cycles of TAC
62448512|NCT00544765|EXPERIMENTAL|nonResp: 4xNX|Patients non-sufficiently responding (iNC) will recieve 4 further cycles of NX
62448513|NCT01689259|EXPERIMENTAL|SL TNX-102 at 2.4 mg|1 x TNX-102 SL Tablets at 2.4 mg
62448514|NCT01689259|EXPERIMENTAL|SL TNX-102 at 4.8 mg|2 x TNX-102 SL Tablets at 2.4 mg
62448515|NCT01689259|EXPERIMENTAL|SL TNX-102-A at 2.4 mg|1 x TNX-102-A (without phosphate) SL Tablet at 2.4 mg
62448516|NCT01689259|ACTIVE_COMPARATOR|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine oral tablet
62847691|NCT03126318|ACTIVE_COMPARATOR|COR-001|COR-001 5, 15, 50, or 100 mg dose (depending on dose cohort assigned to patient) given by subcutaneous injection one time only
62847692|NCT03126318|PLACEBO_COMPARATOR|Placebo|Placebo at pH 6.0will be given in a volume to match the volume of COR-001 being given for the dose cohort by subcutaneous injection one time only
62847693|NCT06226220|EXPERIMENTAL|3-day trial|Patients randomized to the 3-day trial arm will undergo a 3-day PNE trial phase for sacral neuromodulation. Participants will have the PNE placed in the office and return on day 3 for PNE removal.
62847694|NCT06226220|ACTIVE_COMPARATOR|7-day trial|Patients randomized to the73-day trial arm will undergo a 7-day PNE trial time for sacral neuromodulation. Participants will have the PNE placed in the office and return on day 7 for PNE removal.
62847695|NCT04702919||Healthy volunteers|
62847696|NCT03170180|EXPERIMENTAL|sunitinib|
62847697|NCT03170180|EXPERIMENTAL|gefitinib|
62847698|NCT03170180|EXPERIMENTAL|imatinib|
62847699|NCT06325592||group 1|patients underwent laparoscopic hysterectomy within 3 days after LEEP
62847700|NCT06325592||group 2|patients underwent abdominal hysterectomy within 3 days after LEEP
62847701|NCT06325592||group 3|patients underwent laparoscopic hysterectomy 4 weeks after LEEP
62847702|NCT06325592||group 4|underwent abdominal hysterectomy 4 weeks after LEEP
62847703|NCT06325592||control group|Patients who underwent laparoscopic hysterectomy (LH) due to benign gynecological diseases were included in the control group.
62847704|NCT02883218||Comunity-acquired severe sepsis patients|Patients with new-onset community-acquired severe sepsis within 24h without confounding factors in immune status
62847705|NCT02883218||Non-severe sepsis patients|Patients between 18 and 90 years of age and be admitted to the ICU without a diagnosis of severe sepsis.
62060900|NCT01117701|EXPERIMENTAL|B - without SGW|Measurement of the forces needed to passage the ureteroscope in the ureter without a SGW in place.
62060901|NCT05782010|EXPERIMENTAL|PexyEazy procedure|PexyEazy procedure on patients with hemorrhoidal disease grade II and III. The study is descriptive and non-comparable to evaluate the safety and performance of PexyEazy.
62448517|NCT01717378||Potential research participants|UCSF Registry represents a single recruitment pool of individuals who have consented to be contacted about future studies for which they may be eligible based on self-reported health information.
62060902|NCT01141023|EXPERIMENTAL|Datscan SPECT Imaging|Subjects will b injected with 3-5 mCi of dopamine transporter. Within a 4 hour (+/- 30 minutes) window following the injection, subjects will undergo SPECT imaging on the camera.
62060903|NCT00061113|ACTIVE_COMPARATOR|1|fluoxetine + CBT
62060904|NCT00061113|PLACEBO_COMPARATOR|2|placebo + CBT
62060905|NCT00255346|EXPERIMENTAL|Acute myeloid leukemia (AML)|Dasatinib 70 mg orally twice daily.
62060906|NCT00255346|EXPERIMENTAL|MDS/CMML|Dasatinib 70 mg orally twice daily.
62264979|NCT02250352||Cohort III (patients with suspicious breast mass)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients who have BIRADS 4b, 4c, and 5 lesions may undergo up to 6 additional 6 core biopsies.
62264980|NCT02250352||Cohort IV (breast cancer recurrence or progression)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients may also undergo 1-3 extra core biopsies.
62448518|NCT00049036|EXPERIMENTAL|Arm I|Patients receive rituximab intravenously (IV) over 2-4 hours prior to each course of chemotherapy. Treatment repeats every 3 weeks for 4-6 courses. Patients who achieve a complete response after 4 courses of chemotherapy and rituximab receive additional rituximab alone weekly for 2 weeks.
62448519|NCT00049036|EXPERIMENTAL|Arm II|Patients do not receive rituximab concurrently with chemotherapy. Beginning 4 weeks after completion of chemotherapy, patients receive rituximab IV over 2-4 hours weekly for 6 weeks.
62060907|NCT00255346|EXPERIMENTAL|HES/CEL|Dasatinib 70 mg orally twice daily.
62060908|NCT00255346|EXPERIMENTAL|Primary myelofibrosis (PMF)|Dasatinib 70 mg orally twice daily.
62060909|NCT00255346|EXPERIMENTAL|Systemic Mastocytosis (SM)|Dasatinib 70 mg orally twice daily.
62060910|NCT02459158|EXPERIMENTAL|Low dose of ME1100|
62060911|NCT02459158|EXPERIMENTAL|High dose of ME1100|
62060912|NCT05958160|EXPERIMENTAL|Modified Atkins Diet Arm|Modified Atkins diet will be added to the ongoing anti-seizure medication regimen
62264981|NCT06367257|EXPERIMENTAL|App Usage|Patients receive the daily reminder message via app (Emento) that they should pay attention to sufficient calorie intake. In addition, these patients receive 3 screening questions about their current health and nutritional status twice a week.
62264982|NCT06367257|OTHER|Standard|Patients in the control arm receive supportive care during and after radio(chemo)therapy according to hospital standards.
62448520|NCT03680170|EXPERIMENTAL|Working memory updating training|"Training with web-based program on the internet for 30 sessions (4-5 times a week). The result of the training is registered.~Intervention Device: web-based cognitive training"
62448521|NCT03680170|PLACEBO_COMPARATOR|Placebo training|"Low dose, short term memory training. Intervention: Training with computer based program on the internet for 30 sessions (4-5 times a week).~Intervention Device: Web-based cognitive training"
62847706|NCT02883218||Healthy controls|Heathy vonlunteers between 18 and 90 years of age.
62847707|NCT02375334||Observational (medical chart review)|Patient lab and visit dates are monitored by the Cancer Center ORIS and EPIC based systems during the 42 days of the concurrent temozolomide and radiation therapy.
62060913|NCT05958160|ACTIVE_COMPARATOR|Topiramate arm|Topiramate will be added to the ongoing anti-seizure medication regimen
62060914|NCT04568954|EXPERIMENTAL|TB testing using the Truenat platform/TB assays|TB testing using the Truenat platform/TB assays placed at primary health care clinics combined with rapid communication of results and same day TB treatment initiation
62060915|NCT04568954|NO_INTERVENTION|Standard of care Arm|Standard of care for TB testing using a combination of smear microscopy and laboratory (off-site) Xpert testing, may vary by clinic depending on availability of transport and stock of Xpert MTB/RIF or Xpert MTB/RIF Ultra cartridges (Xpert).
62060916|NCT01637701|ACTIVE_COMPARATOR|PkEP|Patients in this group undergo PkEP using the Gyrus plasmakinetic tissue management system (Gyrus Medical Ltd,Bucks,UK).
62060917|NCT01637701|ACTIVE_COMPARATOR|B-TURP|Patients in this group undergo B-TURP using the Gyrus plasmakinetic tissue management system (Gyrus Medical Ltd,Bucks,UK).
62060918|NCT00457639|EXPERIMENTAL|Cholic Acid active capsules|Cholic Acid weight based dose for 6 months double-blind
62060919|NCT00457639|PLACEBO_COMPARATOR|Placebo for Cholic Acid|Placebo for Cholic Acid for 6 months double-blind
62060920|NCT03204058|PLACEBO_COMPARATOR|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
62060921|NCT03204058|ACTIVE_COMPARATOR|group 2|SRP followed by 1.2% rosuvastatin (RSV) gel
62060922|NCT03204058|ACTIVE_COMPARATOR|group 3|SRP followed by 1% Metformin ( MF) gel
62060923|NCT04146896|EXPERIMENTAL|NYX-2925|NYX-2925 50 mg
62060924|NCT04146896|PLACEBO_COMPARATOR|Placebo|Placebo
62060925|NCT05923229|EXPERIMENTAL|Mindfulness-Based Walking Therapy (MBWT)|Participants will receive the MBWT intervention.
62060926|NCT05923229|PLACEBO_COMPARATOR|Freezing of Gait (FOG) Education|Participants will receive educational materials about FOG and track their usual care.
62060927|NCT06623071||Infected patients|Patients infected with hepatitis B virus
62060928|NCT03489057|EXPERIMENTAL|PERC Program|Prostate Cancer Education and Resources for Couples (PERC) program. Participants assigned to experimental condition will receive access to the PERC website.
62060929|NCT03489057|ACTIVE_COMPARATOR|usual care plus NCI website|Participants in this usual care plus NCI website group will be automatically directed to the NCI prostate cancer website after logging in to the study website homepage.
62060930|NCT02239497|EXPERIMENTAL|femoral block by US and NE and intravenous analgesia|preincisional femoral block by ultrasound and neurostimulation, with 20 ml bupivacaine 0,5% and epinephrine. ketoprofen, dipyrone and dexamethasone IV. Morphine IV to rescue analgesia
62264983|NCT02567149|EXPERIMENTAL|Cidofovir|Cidofovir clinical resolution of treated warts as evaluated by the investigators
62448522|NCT04523649|EXPERIMENTAL|Home-based atrial fibrillation screening group|Patients in this group will be given a handheld single lead ECG recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China) and a patient-facing smartphone application specially designed for the study, and they will be requested to record daily ECG and certain vital measurement.
62448523|NCT04523649|NO_INTERVENTION|Control group|Conventional medical care
62448524|NCT05918523||CKD patients previously treated with REACT|Participants Exposed to Renal Autologous Cell Therapy from studies RMCL-002, REGEN-003, REGEN-004 (REGEN-008S1).
62621521|NCT04039425||cancer patient|"* Recently diagnosed cancer stage 1, 2, or 3~* Assigned to receive immunosuppressive chemotherapy treatment~* Natural hair that has not been dyed or permed in the past 3 months"
62621522|NCT06212570|EXPERIMENTAL|KeySuite|The KeyLoop and KeyScope devices will be used to perform intra-abdominal biopsies.
62621523|NCT01065571|EXPERIMENTAL|carrageenan-free diet with placebo|This is the experimental arm in which subjects will be on a no-carrageenan diet and receive placebo capsules. This will test whether the no carrageenan diet leads to longer relapse-free interval for patients with ulcerative colitis.
62621524|NCT01065571|ACTIVE_COMPARATOR|carrageenan-free diet w/ carrageenan|The carrageenan-free diet with carrageenan supplement will mimic the carrageenan normally consumed in the diet. The study will permit blinded comparison of carrageenan-free vs. carrageenan consumption.
62847708|NCT05764447|EXPERIMENTAL|Combined Qigong Baduanjin and Self-administered Acupressure Intervention|The intervention will last 16 weeks, including twice-weekly supervised group sessions. The first 8 weeks will focus on training of qigong Baduanjin and self-administered acupressure. The duration of each group session will be 90 min. From week 9 onwards, the group sessions will be shortened to 60 min twice a week led by the BQ master. For self-practice prescription, participants will be instructed to practice the combined BQ and acupressure intervention three times a week (30 min each time) on the days without group sessions.
62847709|NCT05764447|ACTIVE_COMPARATOR|Wait-list Control Group|The control group will be offered a free modality of their choice after the last follow-up. The participants will receive usual care alone during the study period.
62847710|NCT03584880|EXPERIMENTAL|Diode Laser disinfection|Diode laser disinfection Laser type: 940 nm diode laser Power: 1 Watt Tip: 200 micrometer fibre tip
62847711|NCT03584880|PLACEBO_COMPARATOR|Pseudo Diode Laser Disinfection|Inactivated Diode laser application in root canal
62060931|NCT02239497|EXPERIMENTAL|Intravenous analgesia|Intravenous analgesia with ketoprofen, dipyrone and morphine. IV morphine to rescue analgesia
62060932|NCT06465277||Lung resection|12 patients undergoing lobectomy. Pre and post-operative dobutamine stress CMR testing and cardiac biomarker testing.
62264984|NCT02140814|EXPERIMENTAL|Niacinamide|All subjects in this study will take niacinamide at a dose of 30 mg per kilogram of body weight by mouth daily, in two divided daily doses, for 12 months.
62264985|NCT02756728|ACTIVE_COMPARATOR|HDM+ASCT|Standard of care; High dose Melphalan + Autologous Stem Cell Transplantation
62264986|NCT02756728|EXPERIMENTAL|BI-505|Biweekly infusions of BI-505 in addition to High dose Melphalan + Autologous Stem Cell Transplantation
62448525|NCT01768728|ACTIVE_COMPARATOR|Laparoscopic left hemihepatectomy group|Group of patients that are operated with laparoscopic left hemihepatectomy
62448526|NCT01768728|ACTIVE_COMPARATOR|Open left hemihepatectomy|Group of patients operated with open left hemihepatectomy
62448527|NCT03777670||Cases|Infants with suspected sepsis
62847712|NCT05299632||Patients with biochemical and clinical evidence of primary hyperparathyroidism|Patients who have biochemical and clinical evidence of primary hyperparathyroidism and who are scheduled for routine surgery and preoperative imaging including 99mTc-MIBI planar imaging and SPECT/CT. Subjects who enroll in the study will receive one additional F-18PSMA PET/CT imaging study. F-18 PSMA imaging study will be scheduled on the same day as of the Tc-99m MIBI scan. Since F-18 PSMA PET/CT employs 511kEv annihilation photon, the lower energy if (140 KeV) of Tc-99m MIBI will not interfere.
62060933|NCT06465277||Oesophagectomy|15 patients Peri-operative cardiac biomarker testing.
62264987|NCT01647451|EXPERIMENTAL|Active|
62060934|NCT06465277||Gastrectomy|15 patients Peri-operative cardiac biomarker testing.
62060935|NCT04529265|EXPERIMENTAL|Methylene Blue group|The first dosage: 2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour; The second dosage: 1mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration before the end of surgery within 30 minutes.
62264988|NCT01647451|PLACEBO_COMPARATOR|Placebo|
62448528|NCT03777670||Controls|Infants with no suspicion of sepsis
62448529|NCT01027442|PLACEBO_COMPARATOR|Conventional implant placement method|"The patients in ths group will be treated by conventional, free-hand implant placement"
62448530|NCT01027442|ACTIVE_COMPARATOR|Computer-guidedimplant placement|In this group, the patients will be treated by implants placed via computer generated SLA guides
62448531|NCT06544837|NO_INTERVENTION|Control Group|Embryo implantation according to standard procedures
62448532|NCT06544837|EXPERIMENTAL|Study Group|Embryo implantation according to test recommendations
62621525|NCT00639925|EXPERIMENTAL|Phase I study|
62621526|NCT00761371|EXPERIMENTAL|Imiquimod|Imiquimod 5% cream
62621527|NCT06294158||Observation Cohort|Adult patients (age ≥ 18 years) admitted to to participating Intensive Care Units with an expected (further) stay in participating Intensive Care Unit ≥ 48 hours who are not (currently) deeply sedated (RASS ≥ -3) and are not already in delirium (CAM-ICU positive), do not require environmental modification due to treatment necessities (e.g., burns care), and do not have advanced directives or treatment limitation orders in place, in whom environmental light and noise are measured.
62621528|NCT01179932||Anesthesia Record|The nursing and anesthesia records will be examined for accuracy and completeness
62621529|NCT01326013||Blinded, Prospective Arm|Diagnostic accuracy for higher prevalence targets will be evaluated in prospectively collected, anonymized, leftover, stool specimens.
62621530|NCT01326013||Blinded, Pre-selected Arm|For targets that exhibit lower prevalence rates in the intended use population, banked, pre-selected, positive clinical specimens will be tested.
62847713|NCT02364635|EXPERIMENTAL|Icosabutate dose 1|Dose 1
62847714|NCT02364635|EXPERIMENTAL|Icosabutate dose 2|Dose 2
62621531|NCT05573178|EXPERIMENTAL|Ablation of left atrial ganglion plexus|In this arm, ablation of GPs will only performed in the left atrium, including ablation of right anterior ganglion plexus (RAGP)，left superior ganglion plexus (LSGP)，left ganglion plexus (LLGP), left interior ganglion plexus (LIGP) and right interior ganglion plexus（RIGP).
62621532|NCT05573178|EXPERIMENTAL|combined ablation of left and right atrial ganglion plexus|In the arm the, ablation of GPs will perform in both atrium, including ablation of right anterior ganglion plexus (RAGP)，left superior ganglion plexus (LSGP)，left ganglion plexus (LLGP), left interior ganglion plexus (LIGP), right interior ganglion plexus (RIGP), and superior vena cava ganglion plexus (SVCGP). SVCGP were ablated in the right atrium，the left GPs were ablated through the left atrium
62621533|NCT02794506|EXPERIMENTAL|Propolis|400 mg oral proplois (capsule) was given to participants once daily for 6 months after performing scaling and root planing.
62621534|NCT02794506|PLACEBO_COMPARATOR|Placebo|Placebo capsule was given to participants once daily for 6 months after performing scaling and root planing.
62621535|NCT01027377|EXPERIMENTAL|A|Cohort to receive a single low dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single low dose intravenous injection of rFVIIIFc with safety and PK assessments
62621536|NCT01027377|EXPERIMENTAL|B|Cohort to receive a single high dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single high dose intravenous injection of rFVIIIFc with safety and PK assessments
62060936|NCT04529265|PLACEBO_COMPARATOR|Control group|The first dosage: normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour; The second dosage: normal saline in total 50 ml volume intravenous administration before the end of surgery within 30 minutes.
62264989|NCT02700490|ACTIVE_COMPARATOR|Specialist|Assessment and treatment of common mental disorders by a clinical psychologist in primary care facilities.
62621537|NCT02217670|EXPERIMENTAL|Metformin (test)|single oral dose of Metformin 1000 mg granules
62847715|NCT02364635|EXPERIMENTAL|Icosabutate dose 3|Dose 3
62847716|NCT02364635|PLACEBO_COMPARATOR|Placebo|Placebo (medium chain triglycerides)
62847717|NCT02364635|EXPERIMENTAL|Icosabutate dose 4|Dose 4
62847718|NCT06122311|EXPERIMENTAL|N-acetylcysteine|amphotericin b (0.5-1.25 mg/kg )over 6-8 hours +NAC 600mg twice daily throughout amphotericin b treatment
62847719|NCT06122311|NO_INTERVENTION|amphotericin b|amphotericin b (0.5-1.25mg/kg)over 6-8 hours infusion
62847720|NCT02894268|EXPERIMENTAL|Regimen A|esomeprazole (E) 20 mg, doxycycline (D) 100mg, furazolidone (F) 100 mg, and colloidal bismuth subcitrate (B) 100 mg
62847721|NCT02894268|ACTIVE_COMPARATOR|Regimen B|two sensitivity antibiotics based on antibiotic sensitivity of helicobacter pylori culture, colloidal bismuth subcitrate (B) 100 mg, esomeprazole (E) 20 mg
62847722|NCT05928546|PLACEBO_COMPARATOR|Group(I):scaling and root planing only|10 sites will receive non-surgical periodontal therapy (scaling and root planing) .
62060937|NCT01167686|EXPERIMENTAL|Food supplement|Half of the subjects participating in the trial (91) will recieve four tablets of the food supplement (Gardemont Goldrain Plus) three times a day for seven consecutive days from inclusion.
62060938|NCT02596763|OTHER|Baclofen|Patient with current alcohol use disorder included by any baclofen prescriber located in the French region of Nord - Pas-de-Calais - Picardie.
62264990|NCT02700490|EXPERIMENTAL|Enhanced Usual Care|Assessment and treatment of common mental disorders by a general practitioner and nurse practitioner, who have been trained in the WHO mhGap manual, in primary care facilities.
62847723|NCT05928546|ACTIVE_COMPARATOR|Group(Ⅱ):scaling and root planing with application of quercetin nanoemulgel|10 sites will receive non-surgical periodontal therapy followed by the application of quercetin nanoemulgel local delivery 2 times one at the day of non-surgical periodontal therapy and after 2 weeks.
62847724|NCT05863208|ACTIVE_COMPARATOR|Artificial Intelligence-assisted Colonoscopy with Endocuff Vision|Use artificial intelligence-assisted colonoscopy with Endocuff Vision
62847725|NCT05863208|ACTIVE_COMPARATOR|Artificial Intelligence-assisted Colonoscopy|Use artificial intelligence-assisted colonoscopy alone
62847726|NCT05863208|SHAM_COMPARATOR|Standard colonoscopy|Use standard colonoscopy without artificial intelligence-assisted colonoscopy or Endocuff Vision
62264991|NCT01008683||Stem cell and and heart transplant patients|Stem cell and and heart transplant patients
62264992|NCT05200078||Radiotherapy at free-breathing|breast/chest wall+-RNI 43.5Gy/15f/3w（tumor bed 49.5Gy/15f/3w) delivered at free-breathing
62264993|NCT05200078||Radiotherapy at deep inspiration breath-hold|breast/chest wall+-RNI 43.5Gy/15f/3w（tumor bed 49.5Gy/15f/3w) delivered at deep inspiration breath-hold
62448533|NCT02201498|ACTIVE_COMPARATOR|Formocresol/OZE|Conventional pulpotomy technique, with formocresol and zinc oxide eugenol
62621538|NCT02217670|ACTIVE_COMPARATOR|Metformin (reference)|Single dose of Glucophage 1000 mg film-coated tablet
62621539|NCT05557617||Memory clinic cohort|A cohort of 120 individuals that has been investigated for cognitive impairment at the Memory Clinic, Department of Geriatric Medicine, Örebro University Hospital and from which a sample of cerebrospinal fluid has been stored in biobank.
62621540|NCT01210014|PLACEBO_COMPARATOR|A|Patients with Recurrent aphthous stomatitis
62621541|NCT01210014|ACTIVE_COMPARATOR|B|Patients with Recurrent aphthous stomatitis
62621542|NCT05205200|EXPERIMENTAL|Cohort 1A|In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with SHR1316 (anti-PD-L1) and endocrine therapy.
62621543|NCT05205200|ACTIVE_COMPARATOR|Cohort 1B|In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with endocrine therapy.
62621544|NCT05205200|EXPERIMENTAL|Cohort 2A|In this cohort, a patient would receive SHR1316 (anti-PD-L1) combined with nab-paclitaxel.
62621545|NCT05205200|ACTIVE_COMPARATOR|Cohort 2B|In this cohort, a patient would single nab-paclitaxel.
62847727|NCT04091607|ACTIVE_COMPARATOR|Music Therapy Intervention Group|listen to preferred choice of music during the Lumbar Medial Branch Block procedure.
62847728|NCT04091607|NO_INTERVENTION|Control Group|No music will be provided but will be provided earbuds. The sound environment will be standard for procedures by closing procedure room door and minimizing extraneous sounds.
62847729|NCT02709538|EXPERIMENTAL|GSP 301 NS|
62847730|NCT02709538|PLACEBO_COMPARATOR|GSP 301 Placebo NS pH 3.7|
62847731|NCT02709538|PLACEBO_COMPARATOR|GSP 301 Placebo NS pH 7.0|
62621546|NCT05205200|OTHER|Cohort 2C|In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with fulvestrant.
62621547|NCT05163938|EXPERIMENTAL|REThink therapeutic game|"Game based Cognitive-Behavioral Therapy: REThink therapeutic game is an online therapeutic game developed by David and collaborators (2018).~The seven levels of the game were developed based on the REBT model and each level trains an ability:~Level 1: identify the emotional reactions, and differentiating between basic emotions, complex emotions, and functional and dysfunctional emotions; Level 2: identify cognitive processes.~Level 3: identify the relation between cognitive processes, emotions, and behavioral reactions; Level 4: change irrational cognitions into rational cognitions; Level 5: build problem-solving skills; Level 6: build relaxation skills; Level 7: consolidate of the previous skills and building happiness skills. A new level will be unlocked once every three days. In order for a level to be unlocked, the previous one must have been completed.~Duration of the intervention: 21 days (a total of seven levels unlocked every three days)"
62621548|NCT05163938|ACTIVE_COMPARATOR|Treatment as usual|In the treatment as usual group the child/adolescent benefits from a free trial version of the REThink game which means a shorter version of each level of the game.
62621549|NCT00703326|EXPERIMENTAL|ramucirumab (IMC-1121B) + docetaxel|
62621550|NCT00703326|PLACEBO_COMPARATOR|placebo + docetaxel|
62621551|NCT05633628|EXPERIMENTAL|Periodic CGM- Intervention group|The participants in the intervention group will be provided with FreeStyle Libre (Abbott Diabetes Care). Participants wear the sensor and check their glucose level for a period of 28 days (14 days X 2) during week 0-4 and week 10-13.Patient's measurement data from the FreeStyle Libre system will be transferred to the OneTwo Analytics (DDA) analysis tool for an automated analysis and this Insight report will be presented to the participants at visit week 4 (digital) and at visit week 16 (clinical). The diabetes nurse and the patient reviews and discuss trends, patterns, and challenges to support the person's self-management care of their type 2 diabetes. This approach is intended to facilitate communication and patient participation and create the conditions for shared informed decisions and health planning.
62621552|NCT05633628|NO_INTERVENTION|Self-monitoring of blood glucose, SMBG and usual care - Control Group|The participants in the control group perform SMBG testing as usual including fasting, pre- or post-prandial measurements. They also receive usual care which comprises consultation with physician diabetes specialist or diabetes nurse depending on individual health care needs.
62621553|NCT01100632|EXPERIMENTAL|Treatment|Treatment with the combination of Panax ginseng, vitamins and minerals
62621554|NCT01100632|PLACEBO_COMPARATOR|Placebo|Placebo.
62621555|NCT00920413|ACTIVE_COMPARATOR|vitamin C|vitamin C 500mg orally once a day
62621556|NCT00920413|PLACEBO_COMPARATOR|placebo|
62264994|NCT02261194|EXPERIMENTAL|Self-Care Tools|The tool binder includes 3 core tools and 4 supplemental tools. The tools that will be provided include a variety of self-care approaches to manage depression including audio-visual, internet, and paper-based tools that might appeal to individuals with different learning styles. The 3 core tools consist of the Antidepressant Skills Workbook, a Mood Monitoring Tool, and a DVD on depression.
62621557|NCT04193553|EXPERIMENTAL|Lenvatinib + Best Supportive Care|
62621558|NCT04193553|PLACEBO_COMPARATOR|Placebo + Best Supportive Care|
62621559|NCT00694356|EXPERIMENTAL|Dalotuzumab 5 mg/kg|Participants receive dalotuzumab 5 mg/kg by intravenous (IV) infusion once each week for up to 1 year or until participant withdraws consent, experiences an adverse event (AE), progressive disease or major protocol violation, has moved or is lost to follow up.
62621560|NCT00694356|EXPERIMENTAL|Dalotuzumab 10 mg/kg|Participants receive dalotuzumab 10 mg/kg by IV infusion once each week for up to 1 year or until participant withdraws consent, experiences an AE, progressive disease or major protocol violation, has moved or is lost to follow up.
62621561|NCT00694356|EXPERIMENTAL|Dalotuzumab 15 mg/kg/7.5 mg/kg|Participants receive an initial dose of dalotuzumab 15 mg/kg by IV infusion followed by a maintenance dose of dalotuzumab 7.5 mg/kg by IV infusion once every 2 weeks for up to 1 year or until participant withdraws consent, experiences an AE, progressive disease or major protocol violation, has moved or is lost to follow up.
62621562|NCT03579823|EXPERIMENTAL|AVT02 100 MG/ML|Single subcutaneous injection of 40 mg of AVT02 (100MG/ML)
62060939|NCT03978910|EXPERIMENTAL|Weigthlessness|during a flight
62060940|NCT03041844|EXPERIMENTAL|Low Frequency, Low Intensity Ultrasound|Low Frequency, Low Intensity therapeutic ultrasound applied weekly for up to 16 weeks.
62060941|NCT03041844|SHAM_COMPARATOR|Sham Ultrasound|Sham ultrasound applied weekly for up to 16 weeks.
62621563|NCT03579823|ACTIVE_COMPARATOR|Adalimumab 100 MG/ML [HUMIRA]|Single subcutaneous injection of 40 mg of Adalimumab (100MG/ML) \[HUMIRA\]
62621564|NCT05461352|EXPERIMENTAL|5 mg|Period in which participants received repeated doses of 5 mg TS-142 prior to bedtime
62060942|NCT06611683|EXPERIMENTAL|Inspiratory Muscle Training|Subjects received inspiratory muscle training twice daily over five consecutive days, followed by a two-day rest period. This regimen was continued for three consecutive weeks or until the subject no longer required ventilator support.
62621565|NCT05461352|EXPERIMENTAL|10 mg|Period in which participants received repeated doses of 10 mg TS-142 prior to bedtime
62621566|NCT01089452|ACTIVE_COMPARATOR|Perindopril monotherapy|Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks
62621567|NCT01089452|ACTIVE_COMPARATOR|Perindopril/amlodipine|Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.
62621568|NCT01089452|EXPERIMENTAL|Olmesartan/amlodipine FDC|Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
62621569|NCT05249387|EXPERIMENTAL|A-967079 Injections + BAM8-22|
62060943|NCT06611683|SHAM_COMPARATOR|Non-inspiratory muscle training|Subjects received routine care.
62264995|NCT02261194|NO_INTERVENTION|Delayed Self-Care Tools|This group will receive the self-care tools at the conclusion of the study.
62621570|NCT05249387|EXPERIMENTAL|A-967079 Injections and vehicle|
62621571|NCT02290925|EXPERIMENTAL|Kothala Himbutu biscuit|A biscuit containing Kothala Himbutu (Salacia reticulata) extract. This biscuit is available in the supermarkets. Four biscuits twice a day for 3 months.
62621572|NCT02290925|PLACEBO_COMPARATOR|placebo biscuit|An identical biscuit without the herbal extract from Kothala Himbutu (Salacia reticulate)
62621573|NCT00878579|EXPERIMENTAL|PDS System|
62448534|NCT02201498|ACTIVE_COMPARATOR|Biodentine|New technique, with biodentine
62448535|NCT04891588|EXPERIMENTAL|Switching the preserved to preservative free prostaglandin analog-timolol FC|To switch preserved prostaglandin analog- timolol FC (Fixapost 50 micrograms/ml + 5 mg/ml eye drops, solution in single-dose container) in the period of three months in patients with ocular hypertension and open angle glaucoma who exhibit ocular surface disease (OSD) signs and symptoms to an equally effective and safe preservative - free (PF) latanoprost - timolol FC in order to investigate whether that can result in alleviation or elimination of OSD and improvement of local tolerability.
62621574|NCT00878579|ACTIVE_COMPARATOR|Fusion|
62621575|NCT01830907|ACTIVE_COMPARATOR|Enteral|Enteral nutrition composed of carbohydrates and vitamins
62621576|NCT01830907|ACTIVE_COMPARATOR|Parenteral|
62621577|NCT02707900|EXPERIMENTAL|Vorinostat + AGS-004|"Vorinostat (VOR) 400 mg PO - two paired doses at Step 2 (Enrollment) - Only participants demonstrating an in vivo response to the 2nd of the paired VOR doses will proceed to the AGS-004 manufacturing and treatment in Steps 3 through 7.~Step 4 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal (ID) injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 10-7 viable cells. AGS-004 will be administered every 3 weeks for 4 doses."
62621578|NCT06106672|EXPERIMENTAL|CNP-106|200 mL intravenous infusion on Day 1 and Day 8: CNP-106
62621579|NCT06106672|PLACEBO_COMPARATOR|Placebo|CNP-106 Placebo
62621580|NCT01720485|EXPERIMENTAL|Desloratadine + Prednisolone|"The patients will take 2 tablets three times a day, as follows:~Morning: 1 tablet of the test medication(Desloratadine 5 mg + Prednisolone 20 mg) + 1 tablet of placebo control medication.~Afternoon: 1 tablet of placebo test medication + 1 tablet of placebo control medication.~Night: 1 tablet of placebo test medication + 1 tablet of placebo control medication."
62847732|NCT03611257|EXPERIMENTAL|dRAST|"Hematologic patients with bacteremia will receive antibiotics based on dRAST results."
62621581|NCT01720485|ACTIVE_COMPARATOR|Dexchlorpheniramine + Betamethasone|"The patients will take 2 tablets three times a day, as follows:~Morning: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.~Afternoon: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.~Night: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication."
62847733|NCT03611257|ACTIVE_COMPARATOR|Current standard method|Hematologic patients with bacteremia will receive antibiotics based on current standard method results.
62847734|NCT02361840||Exposed cohort: TI>0.05ng/ml|We call Exposed group to increased TI \> or = 0.05ng/ml We call Event to the onset of ARDS
62847735|NCT02361840||No Exposed cohort: TI<0.05ng/ml|We cal no Exposed group to increased TI (\<0.05ng/ml) We call Event to the onset of ARDS
62621582|NCT02118350|EXPERIMENTAL|Mat Pilates training|Mat Pilates training performed two times at week for 16 weeks.
62621583|NCT02118350|NO_INTERVENTION|Control|
62621584|NCT05742191||Established Clinic Patients at OSF INI with Episodic Migraine diagnosis.|Study subjects will be established clinic patients at OSF HealthCare INI neurological institute with a diagnosis of Episodic Migraine.
62847736|NCT02024789|PLACEBO_COMPARATOR|Placebo|
62847737|NCT02024789|EXPERIMENTAL|RG1662 120 mg bid|
62847738|NCT02024789|EXPERIMENTAL|RG1662 240 mg bid|
62847739|NCT04521049|ACTIVE_COMPARATOR|saxagliptin|patients received 5 mg daily ( 2.5 mg daily dose was given to patients with an eGFR of \<50 mL/min/1.73 m2
62448536|NCT00897897|OTHER|Treated leiomyomas|Pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure receive a treatment with the Philips MRI-guided HIFU system. Patients must have completed child bearing prior to enrolling in this study.
62847740|NCT04521049|NO_INTERVENTION|control|patients received the antihyperglycemic medication(s) such as metformin and/or sulphonyl ureas or insulin with no added gliptins,
62847741|NCT02975557|ACTIVE_COMPARATOR|Brimonidine 0.15%|Brimonidine 0.15% eye drops 2 times a day for 12 weeks
62847742|NCT02975557|ACTIVE_COMPARATOR|Brimonidine 0.075%|Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
62847743|NCT02975557|PLACEBO_COMPARATOR|Placebo|Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
62847744|NCT00737945||2|
62847745|NCT02385643|EXPERIMENTAL|Intervention group|This group of subjects receives mobile support system and conventional treatment
62847746|NCT02385643|NO_INTERVENTION|Control group|This group of patients receive conventional treatment only
62847747|NCT00666016|EXPERIMENTAL|1|TRO19622 500 mg
62448537|NCT03248479|EXPERIMENTAL|R/R Safety Cohort|Participants will receive 1 mg/kg magrolimab twice weekly for Cycle 1 Week 1 (Day 1 and 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11 and 15; and 30 mg/kg weekly thereafter starting Cycle 3 up to end of the study.
62448538|NCT03248479|EXPERIMENTAL|R/R Expansion Cohort:|Participants will receive 1 mg/kg magrolimab twice weekly for Cycle 1 Week 1 (Day 1 and Day 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11 and 15; 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, then 30 mg/kg every 2 weeks starting Cycle 3 up to end of the study + azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle.
62621585|NCT03333486|EXPERIMENTAL|Treatment (fludarabine, cyclophosphamide, TBI, PBSCT)|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 2 hours on days -6 and -5. Patients undergo TBI on days -1 and PBSCT on day 0.
62621586|NCT04276077|EXPERIMENTAL|High-frequency electrical muscle stimulation|
62847748|NCT00419445|ACTIVE_COMPARATOR|GTS21 25 mg tid/Placebo 25 mg tid|
62621587|NCT04276077|EXPERIMENTAL|Low-frequency electrical muscle stimulation|
62621588|NCT04276077|NO_INTERVENTION|Control|
62621589|NCT06323395|EXPERIMENTAL|Vizol S LIPID BALANCE|topical administration of 1 drop of Vizol S LIPID BALANCE in each eye 4 times a day for 30 days
62621590|NCT06323395|PLACEBO_COMPARATOR|ophthalmic saline eyedrops|topical administration of 1 drop of ophthalmic saline eye drops matching Vizol S LIPID BALANCE in each eye 4 times a day for 30 days
62621591|NCT06485622||Bypass group|open bypass group
62847749|NCT00419445|ACTIVE_COMPARATOR|GTS21 75 mg tid/Placebo 75 mg tid|
62847750|NCT00419445|ACTIVE_COMPARATOR|GTS21 150 mg tid/Placebo 150 mg tid|
62847751|NCT00775008|EXPERIMENTAL|podcast|
62847752|NCT00775008|ACTIVE_COMPARATOR|Web group|
62060944|NCT02442843|EXPERIMENTAL|active tDCS|Investigators will use cathodal tDCS to inhibit the brain regions that may be associated with symptoms of PTSD (temporal cortex). Active tDCS will be provided at 2 miliamps (mA) for 20 minutes (with gradual increase and withdraw of stimulation during the first and last minute).
62847753|NCT02001753|EXPERIMENTAL|CMR group|Endothelial function, oxidative stress and inflammation were measured before and after CMR.
62847754|NCT02001753|PLACEBO_COMPARATOR|Placebo group|"The subjects keep supine position the MR machine as same time as experimental group when the MR machine is power off. The endothelial function, oxidative stress and inflammation were measured before and after this procedure. This group is called the non-CMR group or sham CMR group."
62847755|NCT02001753|NO_INTERVENTION|health subject group|Healthy subjects (30) will be enrolled as controls at baseline.
62847756|NCT04583098||carbapenem-resistant Enterobacteriaceae|FMT using frozen or capsulized stool
62847757|NCT04583098||vancomycin-resistant Enterococci|FMT using frozen or capsulized stool
62847758|NCT06520410|EXPERIMENTAL|Short vitrector group|All enrolled patients will receive vitrectomy with the 18 mm short vitrectomy probe (25+ Short TOTALPLUS Vit Pak, 7500 CPM, Str Endoillum. w/ RFID, Alcon Laboratories Inc., Fort Worth, TX, USA.) for various vitreoretinopathies.
62847759|NCT04098484|ACTIVE_COMPARATOR|Normal-weight|Subjects with a BMI of 18-25 kg/m2
62847760|NCT04098484|EXPERIMENTAL|Obese|Subjects with a BMI of \> 30 kg/m2
62847761|NCT00482989|EXPERIMENTAL|1|MEDI-545
62847762|NCT00482989|OTHER|2|Placebo
62847763|NCT05246267||Study group|Patients with physician-diagnosed CRSwNP, with or without comorbid asthma that meet indication criteria for FDA-approved use of Dupilumab.
62847764|NCT02185859|EXPERIMENTAL|Perioperative lidocaine infusion|
62847765|NCT02185859|EXPERIMENTAL|Perioperative magnesium infusion|
62847766|NCT02185859|ACTIVE_COMPARATOR|Noraml saline infusion|
62847767|NCT01757353|ACTIVE_COMPARATOR|Self-directed: Information only|Participants in this arm will complete a baseline assessment, followed by a 50-minute brief motivational interview (the Brief Alcohol Screening and Intervention for College Students; BASICS) 10-14 days after the initial assessment. Participants in this arm will complete follow-up assessments at approximately 3 and 9 months.
62448539|NCT03248479|EXPERIMENTAL|R/R MDS Magrolimab Monotherapy Cohort|Participants will receive 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Day 11, 15, 22, weekly on Cycle 2, and then biweekly starting Cycle 3 up to end of the study.
62847768|NCT01757353|ACTIVE_COMPARATOR|BASICS motivational interview|Participants in this arm will complete a baseline assessment, immediately after which they will be administered alcohol-related informational sheets. These participants will participate in follow-up assessment sessions at approximately 3 and 9 months.
62847769|NCT01757353|EXPERIMENTAL|BASICS plus normative enhancement motivational interview|Participants in this arm will complete a baseline assessment, followed by a 60-minute brief motivational interview (the Brief Alcohol Screening and Intervention for College Students, with a normative enhancement module) 10-14 days after the initial assessment. Participants in this arm will complete follow-up assessments at approximately 3 and 9 months.
62847770|NCT03456310|EXPERIMENTAL|Trans-perineal ultrasound|Transperineal ultrasonography is done by 2D ultrasound machine, curved probe is placed in the perineum, mid sagittal and axial views are obtained Then it's accuracy is assessed according to findings on dynamic pelvic MRI .
62847771|NCT00942994|EXPERIMENTAL|Triple Therapy (Aliskiren/Amlodipine/HCTZ)|At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg.
62847772|NCT00942994|ACTIVE_COMPARATOR|Dual Therapy (Aliskiren/Amlodipine)|At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg.
62847773|NCT05977244|EXPERIMENTAL|HGI+palm olein|1 portion of HGI(high glycemic index) fried rice, fried with palm olein will be served together with 250 milliliter of plain water.
62448540|NCT03248479|EXPERIMENTAL|Treatment-naive Unfit (TNU) Dose Evaluation Cohort|Participants will receive 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Day 11, 15, 22, and then weekly starting Cycle 2 up to end of the study + azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle.
62847774|NCT05977244|EXPERIMENTAL|HGI+soy bean oil|1 portion of HGI (high glycemic index) fried rice, fried with soybean oil will be served together with 250 milliliter of plain water.
62448541|NCT03248479|EXPERIMENTAL|Treatment-naive Unfit (TNU) Dose Expansion Cohort|Participants will receive 1 mg/kg magrolimab twice weekly for Cycle 1; 15 mg/kg weekly for Cycle 1 Day 8; 30 mg/kg weekly through end of cycle 2; and then 30 mg/kg every 2 weeks starting Cycle 3 up to end of the study + azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle.
62847775|NCT05977244|EXPERIMENTAL|LGI+palm olein|1 portion of LGI (low glycemic index) fried rice, fried with palm olein will be served together with 250 milliliter of plain water.
62847776|NCT05977244|EXPERIMENTAL|LGI+soy bean oil|1 portion of LGI (low glycemic index) fried rice, fried with soybean oil will be served together with 250 milliliter of plain water.
62847777|NCT02932371|EXPERIMENTAL|Cardiac Surgery|
62847778|NCT06099730|OTHER|Pulsed Field Ablation|This is a non-randomized one arm study.
62847779|NCT00438568|PLACEBO_COMPARATOR|1|saline
62847780|NCT00438568|EXPERIMENTAL|2|10 Units
62847781|NCT00438568|EXPERIMENTAL|3|20 Units
62847782|NCT04052256||Patients with intermediate coronary lesions|Patients (age ≥ 18 years) who have undergone invasive coronary angiography and have a minimum of one non-treated coronary artery with a measured invasive FFR of 0.81-0.90.
62847783|NCT00959725|EXPERIMENTAL|Intravitreal infliximab.|
62847784|NCT01550848|EXPERIMENTAL|Abraxane and Gemcitabine|Abraxane and Gemcitabine
62448542|NCT03248479|EXPERIMENTAL|RBC transfusion-dependent low-risk MDS, Safety Run-in Phase|Participants will receive 1 mg/kg magrolimab on Cycle 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15, and 22; and 60 mg/kg every 4 weeks starting on Cycle 2 Day 1 and thereafter up to end of the study. For participants who do not respond after Cycle 2, azacitidine 75 mg/m\^2 may be added on subsequent cycles (ie starting at Cycle 3) on Days 1 to 5 of each cycle.
62621592|NCT06485622||BMS group|BMS (bare metal stent) group
62621593|NCT06485622||POBA group|POBA (plain old balloon angioplasty) group
62621594|NCT06485622||DCB group|drug-coated balloon group
62621595|NCT06485622||DA group|DA (directional atherectomy) group
62621596|NCT06485622||HR group|HR (hybrid repair) group
62621597|NCT03184779|EXPERIMENTAL|Intervention|The intervention group will receive an educational video containing safety messages and an injury prevention component with the intent of reducing behaviours and actions on the hill than can potentially lead to injury.
62847785|NCT05478525|EXPERIMENTAL|0.5 g GLY-200|
62847786|NCT05478525|EXPERIMENTAL|1.0 g GLY-200|
62847787|NCT05478525|EXPERIMENTAL|2.0 g GLY-200|
62448543|NCT03248479|EXPERIMENTAL|RBC transfusion-dependent low-risk MDS, Expansion Phase|Participants will receive 1 mg/kg magrolimab on Cycle 1 Day 1; at 30 mg/kg on Cycle 1 Days 8, 15, and 22; and 60 mg/kg every 4 starting on Cycle 2 Day 1 and thereafter up to end of the study + azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle.
62448544|NCT03248479|EXPERIMENTAL|Rollover|Participants on a previous AML Phase 1 trial (SCI-CD47-002; NCT02678338) with clinical benefit on magrolimab treatment will receive the same dose level (0.1 mg/kg up to 30.0mg/kg based on the cohort to which the participant was assigned) twice weekly or may transition to once weekly dosing at the discretion of the Investigator and approval from Gilead.
62448545|NCT04713696|EXPERIMENTAL|Functional training|Participants received functional training
62448546|NCT04713696|ACTIVE_COMPARATOR|Routine training|Participants received routine training
62448547|NCT05819008||Patients with neurological disorders or injuries and Healthy Controls|
62621598|NCT03184779|NO_INTERVENTION|Control|The control group will receive the usual procedures associated with school outings where students have the opportunity to watch the standard welcome video (\~8 minutes) with information on how their day will go and how to use and put on safety equipment. The information given in the control procedure emphasizes preparation and how to use and put on equipment rather than safety messages oriented towards preventing injury and collisions. Students in the control group will watch the video prior to participating in the ski area school program.
62621599|NCT02504047|EXPERIMENTAL|T-Cell replete haplo-transplant|Infusion of peripheral blood stem cells from a haploidentical related donor following myeloablative conditioning. Cyclophosphamide, mycophenolate mofetil and tacrolimus will be given for GVHD prophylaxis.
62621600|NCT04325165|EXPERIMENTAL|1: Chronic SCI subjects|"These subjects will undergo:~1. Bilateral implantation of PPN DBS electrodes;~2. Electrical stimulation of the DBS electrodes and~3. Intensive locomotor training"
62847788|NCT05478525|PLACEBO_COMPARATOR|Placebo for 0.5 g GLY-200 arm|
62847789|NCT05478525|PLACEBO_COMPARATOR|Placebo for 1.0 g GLY-200 arm|
62847790|NCT05478525|PLACEBO_COMPARATOR|Placebo for 2.0 GLY-200 arm|
62847791|NCT00324961|EXPERIMENTAL|Single arm open label adefovir dipivoxil|adefovir dipivoxil once daily 10 mg orally
62847792|NCT00947167|EXPERIMENTAL|Pertuzumab and Erlotinib|
62847793|NCT06382376||Group 1: Intrathecal morphine administered group|Group 1: Intrathecal morphine administered group
62847794|NCT06382376||Group 2: Four quadrant transversus abdominis plane block applied group|Group 2: Four quadrant transversus abdominis plane block applied group
62847795|NCT04064216||Robot assisted laparoscopic surgery|This group will be consisted of patients that will undergo robot assisted laparoscopic surgery for benign gynecologic disorders
62847796|NCT04064216||Conventional laparoscopic surgery|This group will be consisted of patients that will undergo conventional laparoscopic surgery for benign gynecologic disorders
62847797|NCT05507112|EXPERIMENTAL|Neoadjuvant chemoradiotherapy plus PD-1 inhibitor|"Capecitabine 1650mg/m2 is given 5 days a week in parallel with radiotherapy 45 to 50 Gy during 5 consecutive weeks.~Tislelizumab is given on day 1 of week 2, 5 and 8 at 200 mg i.v. 8-12 weeks after completion of radiation therapy, patients undergo total mesorectal excision (TME)."
62847798|NCT05507112|ACTIVE_COMPARATOR|Neoadjuvant chemoradiotherapy|"Capecitabine 1650mg/m2 is given 5 days a week in parallel with radiotherapy 45 to 50 Gy during 5 consecutive weeks.~8-12 weeks after completion of radiation therapy, patients undergo total mesorectal excision (TME)."
62621601|NCT02727179|EXPERIMENTAL|Laparoscopic group|Liver resection performed by laparoscopic approach
62847799|NCT01383343|EXPERIMENTAL|Treatment (FOLFIRI and bevacizumab)|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1, leucovorin calcium IV over 2 hours on day 1, fluorouracil IV continuously over 46 hours on days 1-2, bevacizumab IV over 30-90 minutes on day 1, and sorafenib tosylate PO QD or BID on days 3-6 and 10-13\*. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62847800|NCT01874340|EXPERIMENTAL|AIN457 low dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 low dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis.
62621602|NCT02727179|ACTIVE_COMPARATOR|Open group|Liver resection performed by open approach
62621603|NCT05143606|EXPERIMENTAL|3D printed simulator|"The participants in this arm will undergo two self-directed training sessions on a custom-made 3D-printed airway simulator. The participants will use a standard intubating fiberoptic bronchoscope to practice fiberoptic-assisted nasal intubation.~The sessions will be one week apart. Each session is 30 minutes per participant."
62621604|NCT05143606|EXPERIMENTAL|Virtual reality software|"The participants in this arm will practice fiberoptic-assisted nasal intubation using the free virtual reality software (AirwayEX) on their mobile phones or computer tablets. Two practice sessions are required by the investigators. The sessions will be one week apart. Each session is 30 minutes per participant.~The participants in this arm will have the opportunity to practice on the software as often as they feel necessary. All the additional practice data will be recorded."
62621605|NCT02002871|EXPERIMENTAL|Blue light|Irradiation with PSOCT02 device emitting blue light at a wavelength of 453nm
62264996|NCT03077347|OTHER|Sham Followed by Experimental Stimulation|"Sham stimulation administered followed by 24-48 hour washout, then experimental stimulation.~Experimental Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex Placebo Comparator. 1 minute of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19 minutes of sham stimulation."
62621606|NCT02002871|NO_INTERVENTION|Control|contralateral untreated control plaque on the same patient.
62621607|NCT01031004|EXPERIMENTAL|narafilcon B|contact lens
62621608|NCT01031004|ACTIVE_COMPARATOR|etafilcon A|contact lens
62847801|NCT01874340|PLACEBO_COMPARATOR|Placebo|Matching placebo will be administered intravenously. Approximately 105 patients will be randomized to placebo (65 in Stage 1 and 40 in Stage 2).
62060945|NCT02442843|SHAM_COMPARATOR|sham tDCS|Participants randomized to the sham condition will receive stimulation during the first and final minutes of the 20 minute period (with gradual increase and removal of current during that time).
62621609|NCT05331105|EXPERIMENTAL|HL-085|HL-085 9mg BID
62621610|NCT05056441||Cohort 1: Vedolizumab|Biologic-naïve participants diagnosed with CD, who have initiated vedolizumab treatment will be observed from the data of diagnosis of CD until the date of index when vedolizumab treatment was initiated during the eligibility period until the earliest of chart abstraction initiation, death or last contact with the site. Index date is defined as the date when vedolizumab treatment was initiated.
62621611|NCT05056441||Cohort 2: Ustekinumab|Biologic-naïve participants diagnosed with CD, who have initiated ustekinumab treatment will be observed from the data of diagnosis of CD until the date of index when ustekinumab treatment was initiated during the eligibility period until the earliest of chart abstraction initiation, death or last contact with the site. Index date is defined as the date when ustekinumab treatment was initiated.
62621612|NCT06178718|EXPERIMENTAL|TNP-2092 capsules 100mg|
62621613|NCT06178718|EXPERIMENTAL|TNP-2092 capsules 200mg|
62621614|NCT06178718|EXPERIMENTAL|TNP-2092 capsules 400mg (Food effect study Group A)|After completed the single ascending dose study, the participant will convert to the food effect study. The drugs will be administered in the fasting state and in the fed state for two cycles, with a wash-out period of 4 days.
62847802|NCT01874340|EXPERIMENTAL|AIN457 middle dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 middle dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis
62060946|NCT02442843|NO_INTERVENTION|Combat Controls|Participants without PTSD will undergo neuropsychological testing and a single fMRI scan.
62060947|NCT01069835||1|Non-small cell lung cancer patients
62060948|NCT04535622|EXPERIMENTAL|Exercise group|A structured exercise instruction for facedown posture-related pain will be provided to the patients, and patients will go through three times of self-exercise sessions everyday according to the training provided.
62060949|NCT04535622|NO_INTERVENTION|Control group|Patients are going to maintain face-down posture but no specific exercise instruction will be provided.
62847803|NCT01874340|EXPERIMENTAL|AIN457 high dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 high dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis.
62847804|NCT01744535|ACTIVE_COMPARATOR|Paper food diary|
62847805|NCT01744535|ACTIVE_COMPARATOR|Online food diary|
62060950|NCT06470074|ACTIVE_COMPARATOR|active stimulus group|Patients were assigned into active stimulus group according to random number table
62264997|NCT03077347|OTHER|Experimental Stimulation Followed by Sham|"Experimental stimulation administered followed by 24-48 hour washout, then sham stimulation.~Experimental Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex Placebo Comparator. 1 minute of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19 minutes of sham stimulation."
62264998|NCT01743755|ACTIVE_COMPARATOR|Dexamethasone|
62060951|NCT06470074|SHAM_COMPARATOR|sham stimulus control group|Patients were assigned into sham stimulus control group according to random number table
62621615|NCT06178718|EXPERIMENTAL|TNP-2092 capsules 800mg|
62621616|NCT06178718|EXPERIMENTAL|TNP-2092 capsules 1200mg|
62621617|NCT06178718|EXPERIMENTAL|Food effect study Group B (TNP-2092 capsules 400 mg)|The drugs will be administered in the fasting state and in the fed state for two cycles, with a wash-out period of 4 days.
62060952|NCT05578625||Myeloma|This study includes a total of 60 multiple myeloma patients, and peripheral blood will be collected at newly diagnosed, remission after 4 cycles of therapy, and, relapse stage.
62060953|NCT00804492|EXPERIMENTAL|1|To establish an integrated intervention model for prevention of elderly fall
62060954|NCT00804492|EXPERIMENTAL|2|To perform a RCT to investigate the effectiveness of the multicenter, multifaceted intervention program
62264999|NCT01743755|PLACEBO_COMPARATOR|Placebo|Placebo tablet, once daily for four consecutive days
62060955|NCT05995080|EXPERIMENTAL|chlorhexidine bathing group|Patients aged between 2 months and 18 years with temporary central venous catheter in the pediatric intensive care unit were recruited. Patients younger than 2 months of age, patients with a catheter use of less than 48 hours, patients with a history of allergic reaction with chlorhexidine, patients with a skin condition that interferes with skin cleansing with chlorhexidine, and immunocompromised patients were excluded from the study. Participants of the study were randomized with a ratio of 1:1. In study group, standard bathing will be applied on the first day of insertion of the central venous catheter, and in addition to that it is planned to clean the skin of the patient daily with cleaning pads impregnated with 2% Chlorhexidine gluconate.
62060956|NCT05995080|NO_INTERVENTION|standart bathing group|Patients who are included in the study but not intervention group will be treated with standard bathing, which applied in every 72 hours in our facility.
62060957|NCT04645784|EXPERIMENTAL|Intervention|Receives the supporting student-athlete mental wellness module
62847806|NCT01744535|EXPERIMENTAL|"My Meal Mate (smartphone application)"|"A smartphone application called My Meal Mate (MMM) designed to facilitate weight loss. The app allows system users to set a goal for weight loss and self monitor diet and activity in an electronic diary. Users can select foods from the large Weight Loss Resources food database. Instant nutritional feedback is provided along with weekly feedback by text message."
62847807|NCT00260962|PLACEBO_COMPARATOR|Placebo|Placebo and Treatment as usual (Day Hospital Program). After a 2-week baseline period, placebo was administered for 10 weeks (weeks 3-12 of the study). Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
62847808|NCT00260962|EXPERIMENTAL|Olanzapine Plus Day Hospital|After a 2-week baseline period, Olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of 10 mg/day. Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
62847809|NCT01543633|EXPERIMENTAL|Active Study Arm|Subjects recruited into this study will be required to undergo a base MRI scan of the brain. On a separate day propofol will be administered with concurrent EEG while subjects respond to stimuli.
62060958|NCT04645784|NO_INTERVENTION|Waitlist|Receives no intervention
62060959|NCT03123289|EXPERIMENTAL|68Gallium-citrate|"This arm, undergoing the 68-Gallium citrate PET/CT scan intervention, includes the PET/CT scans performed with 68Gallium-citrate radiotracer. Note that same patients scanned with different radiotracers serve in both arms."
62060960|NCT03123289|EXPERIMENTAL|18F-FDG|"This arm, undergoing the 18F FDG PET/CT scan intervention, includes the PET/CT scans performed with 18F-FDG tracer.~Note that same patients scanned with different radiotracers serve in both arms."
62060961|NCT04959474|ACTIVE_COMPARATOR|Arm I (standard dietary recommendations, SABR, surgery)|Patients receive standard dietary recommendations. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
62060962|NCT04959474|EXPERIMENTAL|Arm II (caloric restriction diet, SABR, surgery)|Beginning 1 week before the start of SABR, patients undergo a caloric restriction diet for 6-12 weeks (for the duration of radiation treatment, until post radiation follow-up appointment) consisting of reducing calorie intake by 25%. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
62621618|NCT06178718|PLACEBO_COMPARATOR|Placebo|
62621619|NCT02139774||Active Survelliance|Men age 65 and older who are undergoing active surveillance as primary treatment for their prostate cancer.
62621620|NCT02139774||Radiation|Men age 65 and older who are undergoing radiation only as primary treatment for their prostate cancer.
62847810|NCT01991613|EXPERIMENTAL|liquid protein supplement|Study subjects will receive standard of care nutrition with the addition of a liquid protein supplement when the baby is able to tolerate an enteral feeding volume of 40mL/kg/day.
62847811|NCT01991613|NO_INTERVENTION|Control group|Study subjects will receive standard of care nutrition
62847812|NCT02117622||Patients with diabetes mellitus requiring insulin therapy|
62847813|NCT01710813||pompe safety sub-registry|patients are selected from those who are enrolled in the Pompe Registry, and will be followed for safety evaluation in this sub-registry
62847814|NCT01132781|PLACEBO_COMPARATOR|Placebo|200mg twice daily of placebo drug
62060963|NCT01602081||LIFT+Biodesign|
62060964|NCT03018002|NO_INTERVENTION|Control group|HIV-infected participants identified from the churches randomized to CG will be referred to PEPFAR-supported HIV clinics that provide comprehensive care including counseling, laboratory testing, ART and ongoing support during treatment as the standard of care. The study team will not be involved in their care beyond data collection.
62060965|NCT03018002|EXPERIMENTAL|iSTAR|HIV-infected participants identified from the churches clustered within the randomized health facilities will receive interventions from the study team.
62265000|NCT02829138|PLACEBO_COMPARATOR|Non-genetic Group|General Nutrition related to Omega-3 fats: Individuals in this group will be provided with only general nutrition information related to omega-3 fats and health.
62265001|NCT02829138|EXPERIMENTAL|Genetic Group|Genetic information and Omega-3 fat intake: Individuals in this group will be provided with general nutrition information related to omega-3 fats and health, as well as their personal genetic information for a common gene variant related to omega-3 fatty acid metabolism.
62265002|NCT05411159|EXPERIMENTAL|Opioid-Free Anesthesia (OFA froup)|Opioid-free anesthesia group, avoid patients receive any kind of opioid during VATs.
62265003|NCT05411159|ACTIVE_COMPARATOR|Standard general anesthesia (OA)|Standard general anesthesia. Opioids allowed, including sufentanil, remifentanil, tramadol during VATs.
62621621|NCT02139774||Endocrine Therapy|Men age 65 and older who are undergoing endocrine therapy as primary treatment for their prostate cancer.
62847815|NCT01132781|ACTIVE_COMPARATOR|200mg theophylline|200mg twice daily of slow release theophylline
62265004|NCT06399627||Iron replete|Patient who did not meet the criteria for iron deficiency (see below)
62621622|NCT02139774||Surgery|Men age 65 and older who are undergoing surgery as primary treatment for their prostate cancer.
62060966|NCT03775226|EXPERIMENTAL|Single are|This study is designed as an early feasibility, prospective, open label, single arm study. 30 patients with infra-inguinal peripheral arterial disease appropriate for treatment with a femoro-popliteal stent will be treated with ChampioNIR® SFA stent implantation.
62621623|NCT05985330||Patients|Patients with metastatic non-small-cell lung cancer
62621624|NCT04186858||Symptomatic|Based on the score of the questionnaire, eligible subjects will be placed in the Symptomatic group where cell samples will be collected from the front surface of the subject's eyes.
62621625|NCT04186858||Asymptomatic|Based on the score of the questionnaire, eligible subjects will be placed in the Asymptomatic group where cell samples will be collected from the front surface of the subject's eyes.
62621626|NCT00082186|EXPERIMENTAL|1|Oral bosentan tablets
62621627|NCT01603199|EXPERIMENTAL|Primary biliary cirrhosis (Non-cirrhotic)|
62847816|NCT00831493|EXPERIMENTAL|Vorinostat + Radiation Therapy|Vorinostat starting dose 200 mg orally once daily, Monday to Friday, Weeks 1 to 6; Radiation Therapy Dose of 50.4 Gray (Gy) in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.
62060967|NCT00660335|EXPERIMENTAL|1|
62060968|NCT02374411||HIPEC surgeons|
62060969|NCT04452448|EXPERIMENTAL|Laser in situ keratomileusis|A prospective clinical study including 20 eyes of 10 cases undergoing laser in situ keratomileusis (LASIK)
62621628|NCT01603199|EXPERIMENTAL|Primary biliary cirrhosis (Cirrhotic)|
62621629|NCT03700918|EXPERIMENTAL|DaVingiTR System Single Arm|single-arm, open label, multi-center study.
62847817|NCT05276440||General Anesthesia|
62847818|NCT05276440||Erector Spinae Plane Block|
62060970|NCT01659892|ACTIVE_COMPARATOR|Montelukast|5 mg Chewable Tablet
62060971|NCT01659892|ACTIVE_COMPARATOR|Singulair|5 mg Chewable Tablet
62060972|NCT00433615|EXPERIMENTAL|1|
62060973|NCT00433615|EXPERIMENTAL|2|
62060974|NCT06056921|EXPERIMENTAL|CD19-targeted CAR-T|CD19 targeted CAR-T cells treat
62621630|NCT04184596||Stated-Preferences Observational Group|A discrete choice experiment will be conducted with participants with peripheral neuropathic pain in the stated-preferences observational group. The instrument will measure patient preferences for topical versus systemic pain treatment.
62621631|NCT04274075|EXPERIMENTAL|GDC-9545 Treatment Sequence A, B, and C|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence A, B, and C (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
62621632|NCT04274075|EXPERIMENTAL|GDC-9545 Treatment Sequence B, C, and A|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence B, C, and A (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
62621633|NCT04274075|EXPERIMENTAL|GDC-9545 Treatment Sequence C, A, and B|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence C, A, and B (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
62621634|NCT04274075|EXPERIMENTAL|GDC-9545 Treatment Sequence A, C, and B|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence A, C, and B (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
62847819|NCT05276440||Rhomboid Block|
62060975|NCT00927355|ACTIVE_COMPARATOR|Pioglitazone|half of the diabetic patients will be randomized to pioglitazone treatment for 6 months starting out with 15mg qd for 4 weeks and dose increased to 30mg (2 tablets) qday if no adverse effects noted at the four week mark by study physician.
62060976|NCT00927355|PLACEBO_COMPARATOR|Placebo|"The other half will be randomized to placebo for 6 months. The placebo pills also start out with one 15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician."
62060977|NCT06494969||Group P|Propofol-based total intravenous anesthesia
62060978|NCT06494969||Group S|Sevoflurane-based anesthesia
62060979|NCT04735016||Treatment Arm|Patients enrolled and treated with the DiamondTemp™ Ablation System
62060980|NCT05845775||percutaneous dilatational tracheostomy|Patients assigned to percutaneous dilatational tracheostomy
62060981|NCT03448159|EXPERIMENTAL|Fluoxetine Hydrochloride|Fluoxetine (Prozac) will be administered to this group. A ramp up period of 3-5 weeks will take place where the patient takes 10mg of Prozac per day. After that, the participant will take the regular dose of 20mg for the duration of the exercise intervention (12 weeks).
62060982|NCT03448159|PLACEBO_COMPARATOR|Placebo|"An over-encapsulated placebo, or sugar pill (so it appears identical to the trial drug) will be administered to this group. During the 3-5 week ramp up period for the experimental group, these participants will take a placebo identical to the 10mg Prozac capsule. After that, the participant will take a placebo identical to the 20mg Prozac capsule for the duration of the exercise intervention (12 weeks)."
62847820|NCT01057589|EXPERIMENTAL|Pemetrexed + Cisplatin + Cetuximab|"Participants will receive pemetrexed,cisplatin and cetuximab for up to 6 cycles (21 days per cycle) followed by optional maintenance of pemetrexed and cetuximab until disease progression. Optional maintenance therapy is permitted after at least 4 cycles of triplet combination therapy have been given. Cetuximab will be administered as an initial dose of 400 milligram per meter squared (mg/m\^2) intravenous (IV) infusion and as a 250 mg/m\^2 IV weekly dose thereafter.~As Standard of care dietary supplements included: 350 to 1000 micrograms (µg) oral Folic Acid 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed and 1000 µg vitamin B12 intramuscular injection (IM) during the week preceding the first dose of pemetrexed and every 9 weeks thereafter."
62847821|NCT01030926|EXPERIMENTAL|A1, first period|
62847822|NCT01030926|ACTIVE_COMPARATOR|A2, second period|
62847823|NCT01030926|ACTIVE_COMPARATOR|B1, first period|
62847824|NCT01030926|EXPERIMENTAL|B2, second period|
62265005|NCT06399627||Iron deficient|"patients with preoperative iron profile of either of the following were defined as iron deficient:~1. serum ferritin \<100mcg/L~2. 100mcg/L \< serum ferritin \<300mcg/L and~   * transferrin saturation \< 20% or~  * C reactive protein ≥ 5mg/L"
62265006|NCT04029974|EXPERIMENTAL|Treatment|Progressive elevation (0 degrees, 25 degrees, 50 degrees, 75 degrees; x2 minutes in each position) while on robotic tilt-stepper at the cadence of 0, 40, and 80 steps/minute.
62448548|NCT04852536||HD-tDCS4x1|All data will be acquired from patients of the triple-blind clinical trial that will investigate the effectiveness of treatment for neuropathic pain after brachial plexus injury with HD-tDCS. There will be collection and analysis of EEG data before the clinical trial protocol, to later assess the prediction of response to the technique employed. At the end, they will be grouped into responders and non-responders to HD-tDCS, according to the numerical scale of pain, with assignments serving as targets for the analyzes with machine learning. The labels for clinical improvement used to classify machine learning will be determined based on the data obtained in the baseline and post-treatment assessments, according to similar studies. Thus, the EEG data of these patients will be retrospectively examined, identifying possible neurophysiological characteristics and biomarkers related to the frequency bands that allow predicting which patients are most likely to improve with this treatment.
62448549|NCT05698381|EXPERIMENTAL|Liquid vinegar|4 tablespoons BID per day (3000 mg acetic acid)
62448550|NCT05698381|PLACEBO_COMPARATOR|Vinegar pill|2 vinegar pills per day (30 mg acetic acid)
62448551|NCT01519609|ACTIVE_COMPARATOR|Moviprep|Moviprep bowel preb
62448552|NCT01519609|ACTIVE_COMPARATOR|Phosphoral|Bowel prep
62448553|NCT02564913||control group|
62621635|NCT04274075|EXPERIMENTAL|GDC-9545 Treatment Sequence B, A, and C|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence B, A, and C (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
62448554|NCT02564913||pre-DM group|
62448555|NCT02564913||DM group|
62621636|NCT04274075|EXPERIMENTAL|GDC-9545 Treatment Sequence C, B, and A|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence C, B, and A (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
62621637|NCT04396145||Surgery group|Subjects who will have chronic otitis media surgery will be included in the study.
62621638|NCT04708899|ACTIVE_COMPARATOR|Cases|cases will receive the proposed program(the arabic version of differential processing training program)
62621639|NCT04708899|ACTIVE_COMPARATOR|control|controls will receive the computer based auditory training program (CBAT)
62621640|NCT01119820|EXPERIMENTAL|Tissue Donation|This study will involve females over 18 who are scheduled to undergo elective surgery. These patients will be screened for participation in this study, which will only involve the collection of discarded tissue.
62621641|NCT01206023||Multiple Sclerosis|Multiple Sclerosis patients
62621642|NCT01206023||Healthy controls|healthy individuals
62621643|NCT00042653|EXPERIMENTAL|AMG 073|AMG 073
62265007|NCT01526161|EXPERIMENTAL|Inhaled Fluticasone propionate and salmeterol|inhaled fluticasone propionate 100 micrograms and salmeterol 50 m
62448556|NCT06075654||Athletic Group|athletic females complaining of primary dysmenorrhea, they participated in the exercise for the last ≥ 6 months, did exercises for ≥ 3 days/ week, and practiced (swimming, basketball, volleyball, gymnastics, judo, wrestling, karate, and boxing.
62448557|NCT06075654||Non-Athletic Group|Non-athletic females complaining form primary dysmenorrhea who are have not participated in any physical activity before
62448558|NCT04055363|EXPERIMENTAL|Formula-fed infants|Infants fed exclusively with experimental formula
62621644|NCT00042653|PLACEBO_COMPARATOR|Placebo|Placebo
62621645|NCT04475627||Participants randomised to 1.5T then 3T|Participants randomized to be scanned at 1.5T first followed by 3T
62621646|NCT04475627||Participants randomised to 3T then 1.5T|Participants randomized to be scanned at 3T first followed by 1.5T
62265008|NCT01526161|ACTIVE_COMPARATOR|Inhaled Fluticasone propionate and placebo|inhaled fluticasone propionate 100micrograms twice daily + placebo
62265009|NCT01526161|ACTIVE_COMPARATOR|Inhaled Fluticasone propionate and Montelukast|inhaled fluticasone propionate 100micrograms twice daily + Montelukast
62448559|NCT04055363|EXPERIMENTAL|Mixed-fed infants|Infants receiving breastmilk and experimental formula
62448560|NCT04055363|NO_INTERVENTION|Breast-fed infants|Reference group of exclusively breastfed
62448561|NCT01820377|EXPERIMENTAL|Aboriginal Youth Mentorship Program|High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4 students, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s act as the intervention group.
62448562|NCT01820377|NO_INTERVENTION|Control Group|This group acts as a control, and are not apart of the Aboriginal Youth Mentorship Program
62621647|NCT01760447|EXPERIMENTAL|Sitagliptin/Metformin|Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.
62621648|NCT01760447|PLACEBO_COMPARATOR|Metformin|Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.
62621649|NCT01760447|EXPERIMENTAL|Sitagliptin/Metformin XR|Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.
62621650|NCT01760447|PLACEBO_COMPARATOR|Metformin XR|Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.
62621651|NCT03420001||VBAC|secundiparous women after one vaginal birth after caesarean section
62621652|NCT03420001||controls|women after one vaginal delivery
62621653|NCT03445403|EXPERIMENTAL|Chronic pain disorders|Administration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm.
62847825|NCT06083064|ACTIVE_COMPARATOR|Routine imaging|Patients will have first abdominal ultrasound, and if findings are negative or inconclusive for appendicitis abdominal CT scan is made. If ultrasound is not available, CT scan can be the first imaging study. If appendicitis is found in the imaging study patient is scheduled for urgent laparoscopic appendectomy. Other patients are discharged or treated according to possible alternative diagnosis.
62060983|NCT02696564|ACTIVE_COMPARATOR|Losartan|At randomization participants will start with a dose of 50mg (one capsule) once a day for 2 weeks. If this dose is well tolerated and systolic BP is \>90 mm Hg and diastolic BP is \> 60 mm Hg, the dose will be increased to 100 mg (2 capsules) once a day for the remaining 46 weeks.
62060984|NCT02696564|PLACEBO_COMPARATOR|placebo|At randomization participants will start with a dose of one capsule (inactive) once a day for 2 weeks. After two weeks, if systolic BP is \>90 mm Hg and diastolic BP is \> 60 mm Hg, the dose will be increased to 2 capsules once a day for the remaining 46 weeks.
62060985|NCT04748042|EXPERIMENTAL|Abiraterone, ADT, Radiation and Olaparib|Abiraterone, ADT, radiation to all metastases and Olaparib.
62265010|NCT03957564|EXPERIMENTAL|Patients receiving neoadjuvant chemotherapy.|"1. Compare the monitoring of CTC, ctDNA and cfDNA with the results of CT scan and the blood level of CEA ,CA19-9 and CA72-4 tumor markers to explore the clinical value of dynamic detection of CTC, ctDNA and cfDNA in neoadjuvant chemotherapy and operation for locally advanced or resectable gastric or gastro-oesophageal junction cancer.~2. Explore the clinical value of different types of CTC in neoadjuvant chemotherapy and Operation for locally advanced or resectable gastric or gastro-oesophageal junction cancer. CTC can be classified into three types: epithelial CTC, mesenchymal CTC, hybrids CTC.~3. Explore the consistency between plasma ctDNA and tumor related DNA in pathological tissues after operation.~4. To explore the relationship between the dynamic changes of plasma CTC, ctDNA and cfDNA levels and the prognosis of patients after operation."
62621654|NCT03445403|ACTIVE_COMPARATOR|Healthy controls|Administration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm.
62621655|NCT03216369||carotid artery stenting and carotid endarterectomy|Symptomatic patients with unilateral ICA severe stenosis by magnetic resonance angiography were performed 3D pseudo-Continuous Arterial Spin Labeling MRI before and after CAS and CEA.
62621656|NCT02006433|EXPERIMENTAL|Deep Brain Stimulation|"Deep brain stimulation (DBS) for the alleviation of chronic neuropathic pain in patients with spinal cord injury (SCI). The stimulation will be applied bilaterally or unilaterally in the midbrain periaqueductal/periventricular gray region (PAG/PVG).~Extended participation in the study, which will last approximately 2 more years, precisely 104 weeks.The purpose of this extended portion of the study is to obtain long-term follow-up information on safety and efficacy, in subjects that have opted to receive continuing brain stimulation. Investigators label weeks in terms of original enrollment. Thus the surgery occurs in weeks 7 and 8 and the original study finishes in week 52, with the extension lasting from week 53 to week 156."
62621657|NCT02445742|EXPERIMENTAL|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
62621658|NCT03365518|EXPERIMENTAL|Cognitive Behavioural Therapy (CBT)|Treatment will consist of a 4-week group lead by a trained clinician. Sessions are 2 hours in length and take place in consecutive weeks, with daily homework recommended between sessions.
62621659|NCT03365518|EXPERIMENTAL|Mindfulness-Based Therapy|Treatment will consist of a 4-week group lead by a trained clinician. Sessions are 2 hours in length and take place in consecutive weeks, with daily homework recommended between sessions.
62621660|NCT03365518|NO_INTERVENTION|Control - Usual Care|"Participants who are randomized to the control group will not receive mindfulness or CBT treatment. They will proceed with the course of treatment they were receiving prior to enrollment in the study. As resources for couples dealing with changes to their sexual lives after prostate cancer are limited, it is anticipated that the majority of these patients will have no treatment targeting sexual intimacy during the 6-week period between completing the first and second questionnaire.~Those randomized to the control group will have the opportunity to be randomized to one of the treatment groups following their third and final questionnaire if they wish. In this case, they will be issued an additional participant ID within one of the treatment groups."
62621661|NCT00493311|EXPERIMENTAL|IV Acetaminophen|1 g of acetaminophen in 100 mL of intravenous solution
62621662|NCT00493311|PLACEBO_COMPARATOR|IV Placebo|100 mL of intravenous placebo solution
62621663|NCT01319487|EXPERIMENTAL|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
62621664|NCT01319487|EXPERIMENTAL|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
62621665|NCT01319487|PLACEBO_COMPARATOR|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
62621666|NCT00298363|EXPERIMENTAL|Tenofovir DF|TDF 300 mg + FTC/TDF placebo + ETV placebo once daily (QD)
62621667|NCT00298363|EXPERIMENTAL|FTC/TDF|FTC 200 mg/TDF 300 mg + TDF placebo + ETV placebo QD
62621668|NCT00298363|EXPERIMENTAL|Entecavir|ETV 0.5 mg or 1 mg + TDF placebo + FTC/TDF placebo QD
62621669|NCT05647720|EXPERIMENTAL|Third molar extraction group|After surgical extraction of unerupted upper third molars, the maxillary first molars were distalized using the infra-zygomatic gear distalizer, which is anchored to infra-zygomatic mini-implants inserted in the infra-zygomatic crest.
62621670|NCT05647720|EXPERIMENTAL|Third molar presence group|Without extraction of unerupted upper third molars, the maxillary first molars were distalized using the infra-zygomatic gear distalizer, which is anchored to infra-zygomatic mini-implants inserted in the infra-zygomatic crest.
62060986|NCT01985620|ACTIVE_COMPARATOR|study group|Educational intervention with the parents
62060987|NCT01985620|NO_INTERVENTION|control group|
62060988|NCT00058201|ACTIVE_COMPARATOR|Arm I|Patients receive leucovorin calcium IV and fluorouracil IV on days 1-5.
62621671|NCT03066583|PLACEBO_COMPARATOR|trephination with placebo|meniscal repair with trephination and placebo
62265011|NCT00518154|EXPERIMENTAL|A|Patients will be taking oral Pyridostigmine 30mg tid, as well as their usual antiretroviral treatment
62265012|NCT06065852||Alport Syndrome Rare Disease Group|"The evidence base in Alport Syndrome is small, but there is a very important education gap which it is the group's priority.~Our first priorities are to assemble and make available clear information for clinicians caring for patients, as well as for patients themselves including making it clear for Commissioners 'Who should be tested' establish contact details for advice on specific issues make it clear how to approach the group for clinical advice and how to enrol patients in the group.~In time this may lead to specialised regional clinics, made possible by recruiting more interested clinicians as the project develops."
62265013|NCT06065852||APRT Deficiency Rare Disease Group|"Aims:~1. To collect clinical data on patients with APRT Deficiency in a Registry. This will allow us to:~   study the causes, natural history and outcome of the condition develop patient cohorts for future studies~2. To collect biological samples for future studies in a Biobank. This will allow us to:~   identify factors influencing the course of APRT Deficiency determine the role of various genes~3. To develop new methods to measure urinary purine excretion. This will improve tools that allow us to:~   study the effectiveness of pharmacological and dietary interventions identify factors influencing the course of the condition~4. To work with patient organisations, health care professionals and researchers:~to enhance the education and training aspect of this project to develop strategies to increase the awareness and early detection of APRT Deficiency and improve patient outcomes."
62448563|NCT05655936|ACTIVE_COMPARATOR|Usual Care Group|The usual care group will receive remote blood pressure monitoring for approximately 6 weeks via the clinical home blood pressure monitoring program at Magee Women's Hospital of UPMC and be discharged after delivery as usual. This monitoring is standardly offered to women post-delivery with hypertensive disorders of pregnancy. Participants will text in their blood pressures to the medical record systems and be monitored by clinical staff.
62621672|NCT03066583|EXPERIMENTAL|trephination with platelet rich plasma|meniscal repair with trephination and platelet rich plasma
62621673|NCT02425462||Cohort 1|Asian patients at least 18 years of age with clinical or surgical diagnosis of endometriosis, and patients with endometriosis associated pelvic pain.
62621674|NCT02259686|EXPERIMENTAL|Protocol 1. Apelin 1mg doses|5 Healthy volunteers
62621675|NCT02259686|EXPERIMENTAL|Protocol 2. Apelin 5mg doses|5 Healthy volunteers
62621676|NCT02259686|EXPERIMENTAL|Protocol 3. Apelin 10mg single dose|5 Healthy volunteers
62847826|NCT06083064|EXPERIMENTAL|Adult Appendicitis Score based selective imaging|Adult Appendicitis Score (AAS) is calculated as soon as possible. Patients with AAS 16 or higher are scheduled for urgent laparoscopic appendectomy. Patients with AAS 11- 15 will have abdominal imaging as in the group 1. If appendicitis is found in the imaging study patient is scheduled for urgent laparoscopic appendectomy. Patients with AAS 10 or less are discharged without imaging studies.
62847827|NCT06083064|EXPERIMENTAL|Appendicitis Severity Score based observation with selective imaging using Adult Appendicitis Score|Patients with Adult Appendicitis Score (AAS) 10 or less are discharged without imaging studies. Patients with AAS 11 or more are managed based on Appendicitis Severity Score (ASS). ASS is used to identify patients with low risk of complicated disease. Patients with high ASS (\>4) are managed as patients in arm 2. Patients with low ASS (\<=4) begin observation protocol where patients can leave hospital and they are re-evaluated with repeated scoring after 12-24 hours from randomization. After re-scoring patients may be discharged if AAS is below 16 and decreasing and ASS is below 5 or if AAS is below 11. If AAS is 16 or higher or increasing, patients are scheduled for urgent laparoscopic appendectomy. After observation period, patients with decreasing AAS between 11-15 and ASS higher than 4 or patients with stable AAS between 11-15 are send for imaging study.
62847828|NCT03521778|EXPERIMENTAL|Fascial Distortion Model group|Patients will receive manual treatment complies with Fascial Distortion Model method.
62847829|NCT03521778|EXPERIMENTAL|Mulligan Concept group|Patients will receive manual treatment complies with Mulligan Concept method.
62847830|NCT03521778|EXPERIMENTAL|Traditional physiotherapy group|Patients will receive traditional physiotherapy.
62847831|NCT00295880|EXPERIMENTAL|Transplant Patients|Patients receiving umbilical cord blood transplantation.
62847832|NCT04161248|EXPERIMENTAL|Venetoclax + R-GDP|
62847833|NCT04161248|EXPERIMENTAL|Glofitamab + R-GDP|
62847834|NCT04161248|EXPERIMENTAL|Tafasitamab + R-GDP|
62847835|NCT01318005|ACTIVE_COMPARATOR|Ortho-Novum® 1/35|Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.
62847836|NCT01318005|ACTIVE_COMPARATOR|Ovcon® 35|Ovcon® 35 is an oral contraceptive that contains less progestin.
62847837|NCT01318005|ACTIVE_COMPARATOR|Microgestin Fe® 1/20|is an oral contraceptive that contains less estrogen.
62621677|NCT03679819||HR-TRUS|HR-TRUS for the detection of prostate cancer in men scheduled for radical prostatectomy for localized prostate cancer
62621678|NCT04956939||Group 1|PD patients receiving low frequency dose of levodopa.
62621679|NCT04956939||Group 2|PD patients receiving high frequency dose of levodopa.
62621680|NCT04956939||Control Group|Spouses of PD patients without PD diagnosis
62847838|NCT02949895|EXPERIMENTAL|Dose Escalation Dose 1|BMS-986012 Dose Escalation Dose 1
62847839|NCT02949895|EXPERIMENTAL|Dose Escalation Dose 2|BMS-986012 Dose Escalation Dose 2
62847840|NCT02949895|EXPERIMENTAL|Chemotherapy Combination|BMS-986012 + Cisplatin + Etoposide
62621681|NCT05541913|NO_INTERVENTION|Control Grup|After acceptance of the child's admission to the ward, parents will be asked to complete the Beck Anxiety Scale. Beck Anxiety Scale and Health Care Satisfaction Scale will be applied to the parents again after the discharge training given routinely in the service. Control grup will be called on the postoperative 4th day after discharge and asked to fill in the Beck Anxiety Scale and Health Care Satisfaction Scale.
62847841|NCT05575323|EXPERIMENTAL|Intervention|Patients will receive high dose, single fraction stereotactic body radiotherapy (SBRT) using differential dosing: 18 or 21 Gy on the metastasis. Within 24 hours after SBRT, patients will have surgical stabilization with or without decompression.
62847842|NCT05575323|ACTIVE_COMPARATOR|Control|Patients will undergo the standard of care, which is surgical stabilization with or without decompression, followed by conventional radiotherapy (cRT) or SBRT as soon as the wound is healed sufficiently.
62847843|NCT04359901|ACTIVE_COMPARATOR|Standard of care plus subcutaneous sarilumab|Standard of care as directed by the treating clinicians, plus sarilumab 400 mg subcutaneous injection. Sarilumab is provided in prefilled syringes/pens containing 200 mg each as is used clinically, and both injections will be given as soon as is convenient after the patient has decided to enroll.
62847844|NCT04359901|NO_INTERVENTION|Standard of care|Standard of care as directed by the treating clinicians.
62847845|NCT05751564|EXPERIMENTAL|"Ready to inject MSC product"|"Cryopreserved ready to inject Umbilical Cord (UC) derived MSC"
62847846|NCT05751564|ACTIVE_COMPARATOR|Resuspended MSC product|Umbilical Cord (UC) derived MSC in suspension media
62847847|NCT00243269|SHAM_COMPARATOR|1|Expectancy neutral handout and expectancy neutral tape
62847848|NCT00243269|EXPERIMENTAL|2|Expectancy enhancing handout and expectancy neutral tape
62847849|NCT00243269|EXPERIMENTAL|3|Expectancy neutral handout and expectancy enhancing tape
62265014|NCT06065852||ARPKD & NPHP Rare Disease Group|"Aims:~The Autosomal Recessive Polycystic Kidney Disease (ARPKD)/Nephronophthisis (NPHP) Rare Disease Group (RDG) aims to:~Develop and advocate best practice guidelines for the treatment of ARPKD and NPHP Provide up-to-date, best practice patient information and group support Support research into basic science, genetic, translational, psychosocial and clinical aspects of ARPKD and NPHP Foster collaborations with European and international groups and partner"
62448564|NCT05655936|EXPERIMENTAL|Postpartum Doula Intervention Group|The intervention group will receive study devices (blood pressure cuff, scales, etc.) and instructions on 10-12 months of remote blood pressure, and weight monitoring. An electronic referral will be sent to the Healthy Start program to initiate postpartum Doula support for 8-12 weeks, and a Doula moderated social support group for 6 months. The postpartum Doula will deliver a heart health focused intervention aimed at reducing blood pressure by approximately 12 weeks postpartum.
62448565|NCT04481971|EXPERIMENTAL|40 mg|
62448566|NCT04481971|EXPERIMENTAL|20 mg|
62448567|NCT04481971|PLACEBO_COMPARATOR|Placebo|
62448568|NCT05518942|EXPERIMENTAL|sensorimotor rhythm neurofeedback training|Sensory motor rhythm neurofeedback: The subjects will perform 60 minutes per week for 10 weeks, with a total training time of 600 minutes. The intervention in this trial lasts for 10 weeks (1 time/week), with the goal of improving sensory motor rhythm. Since this training uses visual and auditory feedback, if patients are assigned to this group, they will be ask to wear an EEG cap with 19 electrodes. They can take a relaxed sitting posture and choose animations (e.g., puzzles, mazes, and other feedback content), and then focus on computer screen animation for training, each training time is approximately 60 minutes.
62847850|NCT00243269|EXPERIMENTAL|4|Expectancy enhancing handout and expectancy enhancing tape
62847851|NCT03803319|ACTIVE_COMPARATOR|Fibre 1 (combined fibres)|Ingestion of 150mls water with 7.5g fibre (two times a day)
62847852|NCT03803319|ACTIVE_COMPARATOR|Fibre 2 (natural fibres)|Ingestion of 150mls water with 15g fibre (two times a day)
62847853|NCT03803319|PLACEBO_COMPARATOR|Dietary Supplement (placebo)|Ingestion of 150mls water with 7.5g (two times a day)
62847854|NCT03475420||National Cancer Database|Use existing data to define surveillance strategy in use for patients in this cohort. We will use 10 randomly selected lung cancer resection patients from each accredited institution with stage I-III NSCLC (potentially curative resection) diagnosed in 2006-2007 and with 5 years of complete follow up or reported as deceased before 2012.
62847855|NCT05317117|OTHER|NxTek™ Malaria P.f plus Rapid Diagnostic Test (RDT) and NxTek™ Malaria P.f/P.v RDT|All participants will be tested with two investigational IVDs at the point of care, the NxTek™ Malaria P.f plus Rapid Diagnostic Test (RDT) and the NxTek™ Malaria P.f/P.v RDT, in addition to comparator tests and the standard of care (microscopy). The investigational tests will not be used to determine any treatment or case management.
62847856|NCT05132322|ACTIVE_COMPARATOR|Unlearning Only|Includes educational outreach and audit \& feedback.
62265015|NCT06065852||Atypical Haemolytic Uraemic Syndrome Rare Disease Group|"Aims:~To establish and maintain a registry of all individuals affected by aHUS in the UK To provide information to clinicians on the investigation and management of aHUS To provide information to affected individuals and their families on aHUS To facilitate collaborative research into all aspects of aHUS"
62847857|NCT05132322|EXPERIMENTAL|Unlearning + Substitution|Includes educational outreach, audit \& feedback, and an electronic health record-integrated clinical pathway to support appropriate use of pulse oximetry.
62847858|NCT04838080|EXPERIMENTAL|Low dose vaccine|Inactivated COVID-19 Vaccine 4 µg/0.5 ml
62847859|NCT04838080|EXPERIMENTAL|High Dose Vaccine|Inactivated COVID-19 Vaccine 6 µg/0.5 ml
62847860|NCT04838080|PLACEBO_COMPARATOR|Placebo|0.9 % NaCl
62847861|NCT02467686|ACTIVE_COMPARATOR|Cimicifuga racemosa|"The other group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal and will start with 2 tablets per day of dry extract of Cimicifuga racemosa.~Each tablet contains 20 mg of dry extract of Cimicifuga racemosa standardized between 1 mg and 1.25 mg of triterpene glycosides expressed in 26-deoxyactein. Will be guided 1 tablet 12/12 hours for 6 months.~WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.~FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up."
62060989|NCT00058201|EXPERIMENTAL|Arm II|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15.
62060990|NCT00058201|NO_INTERVENTION|Arm III|Patients undergo observation.
62621682|NCT05541913|EXPERIMENTAL|Intervention Grup|After the admission of the child in the service, the Beck Anxiety Scale will be applied to measure the anxiety levels of the parents at the first hospitalization. After the routine discharge training in the service, the Beck Anxiety Scale and Health Care Satisfaction Scale will be applied to the parents again. Then, the parents will be called on the 1st postoperative day and training will be provided. On the postoperative 2nd, 3rd and 4th days, counseling will be provided. on the postoperative 4th day Parents will be asked to fill in the Beck Anxiety sScale and Health Care Satisfaction scale.
62621683|NCT03801577|EXPERIMENTAL|Hepaxa|Subjects will receive Hepaxa according to standard use (4 capsules daily over a 6 month period)
62060991|NCT04557826|EXPERIMENTAL|RD19 Experimental Device|RD19 Experimental Device used twice/day for 3 minutes each use at least 4 hours, and preferably 8-12 hours, apart
62621684|NCT03438864|EXPERIMENTAL|10 Hz|Interferential current, entry frequency 4000 Hz and 4010 Hz, beat frequency 10 Hz, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
62265016|NCT06065852||Autosomal Dominant Polycystic Kidney Disease Rare Disease Group|"Aims:~To develop the ADPKD RaDaR registry To develop best practice guidelines in regards to the treatment of ADPKD To provide better patient information and support To develop international collaborations to enable the above aims To support research, in collaboration with international groups, into basic science, disease progression models and clinical trials"
62265017|NCT06065852||Autosomal Dominant Tubulointerstitial Kidney Disease Rare Disease Group|The group was established as part of the RaDaR initiative, in light of the increasing numbers of families being identified with this syndrome and following the pioneering work undertaken by Dr Anne Simmonds and others in the Purine Laboratory at Guy's Hospital, London.
62265018|NCT06065852||BK Nephropathy Rare Disease Group|"The BK Nephropathy (BKN) Rare Disease Group aims to:~collate contemporary information from UK kidney transplant recipients with BK Nephropathy use this information to develop current and relevant information for patients disseminate this information to the renal and transplant communities establish a national consensus to identify recipients at high risk of developing BK Nephropathy develop a recommendation for the optimal screening frequency for the presence of BK viraemia by PCR of peripheral blood produce guidance on the modification of immunosuppressive regimens and use of additional agents to treat BK Nephropathy develop a strategy for patient recruitment to observational and interventional clinical trials"
62448569|NCT05518942|NO_INTERVENTION|control group|Patient should maintain their usual activity and treatment. Research assistants will weekly contact them to confirm their compliance.
62621685|NCT03438864|EXPERIMENTAL|100 Hz|Interferential current, entry frequency 4000 Hz and 4100 Hz, beat frequency 100 Hz, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
62621686|NCT03438864|SHAM_COMPARATOR|Placebo-Sham Control|No current except for first 5 seconds, device open but does not appy electrotherapy.
62621687|NCT03825822|EXPERIMENTAL|ImPaC Resource Intervention (INT)|The INT arm will receive the 7-step web-based ImPaC intervention to use over 6 months. The intervention is divided into the Plan Stage and the Change Stage. The Plan Stage (steps 1-4) is expected to be completed in 1 month. The Change Stage (steps 5-7) is expected to be completed in 1-2 months. We anticipate that Change Teams will be able to complete 2 cycles of change over the 6-month intervention period.
62621688|NCT03825822|OTHER|Standard Practice (SP)|The SP arm will continue as usual with their unit or institutional standard pain practices and any strategies that they would normally use to improve them (e.g. new staff orientation).
62621689|NCT04835883|EXPERIMENTAL|Assigned interventions|Subjects enrolled into the CS20AT04 with corticosteroid taper regimen arm will receive two infusions of CS20AT04 (2.0×10\^6cell/kg), on 0 day and on 12 weeks post-enrollment.
62621690|NCT02173379|EXPERIMENTAL|Absorb BVS|Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
62265019|NCT06065852||Calciphylaxis rare Disease Group|"The Calciphylaxis Rare Disease Group aims to:~Develop a comprehensive clinical database of Calciphylaxis patients via the RaDaR Rare Disease Registry Collaborate with international registries, particularly the German registry Form an expert panel of interested clinicians to review future clinical trials and research programmes Develop diagnostic and treatment algorithms"
62847862|NCT02467686|PLACEBO_COMPARATOR|Control|"Control group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal . They will be followed for 6 months and answer Kupperman scale, WHOQOL questionnaire and FSFI questionnaire at the first visit, 3-month and 6-month follow-up.~WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.~FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up."
62448570|NCT04790305|EXPERIMENTAL|Huaier Granule + Conventional Treatment/visit|"Huaier Granule: oral administration, 20g each time, 3 times a day. The starting time of Huaier granule: from the beginning of adjuvant therapy to the end of adjuvant therapy, and within 60 days after the end of adjuvant therapy is also acceptable.~Conventional Treatment/visit：The postoperative adjuvant therapy and visit of TNBC are based on clinical routine."
62847863|NCT04765228|EXPERIMENTAL|Pegylated liposomal doxorubicin + Anlotinib|Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2\~4 cycles
62847864|NCT01988584|EXPERIMENTAL|umbilical cord blood (UCB) cells|Children who have banked UCB with CBR will receive an umbilical cord blood stem cell infusion at the baseline/treatment visit.
62847865|NCT01988584|EXPERIMENTAL|bone marrow-derived mononuclear cells (BMMNCs)|Children in the BMMNC group will undergo bone marrow harvest and stem cell infusion at the baseline/treatment visit.
62847866|NCT01988584|EXPERIMENTAL|saline infusion (placebo), then umbilical cord blood (UCB) cells|Five children in each group will be randomly assigned to receive an inactive substance (placebo) at the baseline/treatment visit. Parents will be given the opportunity to cross-over to either the umbilical cord blood or bone marrow harvest group at the one year visit.
62847867|NCT01988584|EXPERIMENTAL|saline infusion (placebo), then bone marrow-derived mononuclear cells (BMMNCs)|
62060992|NCT04436458|EXPERIMENTAL|Niclosamide|Continued SOC therapy together with Niclosamide tablets for 14 days
62060993|NCT04436458|PLACEBO_COMPARATOR|Placebo|Continued SOC therapy together with placebo tablets matching niclosamide
62060994|NCT02705781|EXPERIMENTAL|General|One arm study: smARTrack Feeding Tube System.
62265020|NCT06065852||CKD due to Genetic Factors in people of African ancestry Rare Disease Group|"People of African or Afro-Caribbean ancestry are five times more likely to have kidney disease. They also develop kidney failure when they are about ten years younger than white people. The connection between ethnicity and kidney disease is complex. There have been some new scientific discoveries which may help us to begin to understand the cause of this problem and develop treatments, but much more work is needed.~This group will allow us to find lots of people with African or Afro-Caribbean ancestry with CKD living in the UK that can take part in research."
62265021|NCT06065852||Cystinosis Rare Disease Group|"Aims:~To improve the care for all patients with cystinosis in the UK To collaborate with the National Designation Centres for Cystinosis To work together with Cystinosis Foundation UK and other patient groups To register every willing patient with cystinosis onto RaDaR To promote research for the benefit of patients with cystinosis, and their families To promote educational resources for patients with cystinosis, and their families"
62265022|NCT06065852||Cystinuria Rare Disease Group|To improve our understanding of kidney stone formation in Cystinuria, develop best practice in the care of patients with this condition and to develop new ways to prevent and treat Cystinuria.
62265023|NCT06065852||Dent Disease & Lowe Syndrome Rare Disease Group|"The group aims to advance our knowledge of Dent Disease and Lowe Syndrome by:~establishing a registry of patients developing clinical guidelines regarding diagnosis and treatment providing a platform for clinical and molecular research into these disorders empowering affected patients and their families by facilitating contacts between patient/families and by the development of educational material"
62265024|NCT06065852||Fabry Disease Rare Disease Group|"The main objectives of the Fabry Disease Rare Disease Group are to:~Provide reliable information for patients and relatives regarding the condition Provide referral information for clinicians, including details about where to send samples Improve referral pathways between the relevant specialties in each geographical area e.g. cardiology and nephrology Design and implement studies to determine the burden of undiagnosed disease and make testing for Fabry more accessible nationwide Organise patient information days to promote face-to-face contact between clinicians and patients/families"
62621691|NCT02173379|ACTIVE_COMPARATOR|XIENCE|Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) and XIENCE ProX (outside of the US only)
62847868|NCT00029146|EXPERIMENTAL|Surgical group|Assigned to undergo extracranial-intracranial arterial bypass in addition to best current practice medical therapy
62621692|NCT00000256|ACTIVE_COMPARATOR|Placebo + 20% N2O|0% N2O inhaled during psychomotor testing, 20% N2O inhaled during psycho motor testing, then subject's choice of the 2.
62847869|NCT00029146|ACTIVE_COMPARATOR|Non-surgical group|Receives best current practice medical therapy
62847870|NCT00977119||Capecitabine|Women with breast cancer receiving capecitabine as treatment for their breast cancer.
62847871|NCT02906605|EXPERIMENTAL|JNJ-809 plus Apalutamide (Group A)|JNJ-809 given as an infusion and Apalutamide 240 milligram (mg) daily.
62847872|NCT02906605|EXPERIMENTAL|Apalutamide (Group B)|Apalutamide 240 mg orally daily.
62847873|NCT03849625||NSAID sensitivity|Patients diagnosed with an immediate reaction to aspirin/NSAIDs/or paracetamol
62847874|NCT05756257||Acute Ischemic Stroke|Blood pressure variability will be measured in the patients with acute ischemic stroke.
62847875|NCT02974699|EXPERIMENTAL|Potato Starch (Bob's Red Mill)|Daily dietary supplementation with Potato Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.
62265025|NCT06065852||Fibromuscular Dysplasia Rare Disease Group|"The main objectives of the Fibromuscular Dysplasia Rare Disease Group are to:~Raise awareness and provide advice about the best strategy for the diagnosis and management of this still underdiagnosed disease.~Study the presentation of the disease and baseline patient demographics. Study the prevalence of different subtypes of Fibromuscular Dysplasia, the incidence and determinants of disease progression/extension and complications Develop a Register of long term impact of intervention, as part of RaDaR"
62621693|NCT00000256|ACTIVE_COMPARATOR|Placebo + 40% N2O|0% N2O inhaled during psychomotor testing, 40% N2O inhaled during psycho motor testing, then subject's choice of the 2.
62621694|NCT00000256|ACTIVE_COMPARATOR|Placebo + 60% N2O|0% N2O inhaled during psychomotor testing, 60% N2O inhaled during psycho motor testing, then subject's choice of the 2.
62847876|NCT02974699|PLACEBO_COMPARATOR|Resource ThickenUp Pregelatinized Starch|Daily dietary supplementation with Pregelatinized Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.
62621695|NCT00000256|ACTIVE_COMPARATOR|Placebo + 80% N2O|0% N2O inhaled during psychomotor testing, 80% N2O inhaled during psycho motor testing, then subject's choice of the 2.
62448571|NCT04790305|NO_INTERVENTION|Conventional Treatment/visit|Conventional Treatment/visit：The postoperative adjuvant therapy and visit of TNBC are based on clinical routine.
62448572|NCT02229890||Acute ischemic stroke within three hours after symptom onset|
62621696|NCT00551525|EXPERIMENTAL|Radiotherapy + Samarium 153|Samarium 153 infusion followed by radiotherapy 12 weeks later
62621697|NCT00664365|EXPERIMENTAL|Subjects receiving GSK958108 + placebo in cohort 1|Eligible subjects will receive GSK958108 with a starting dose of 1 milligram. The dose escalation will be continued up to 4 ascending doses. Subjects will also receive placebo. Each treatment period will be separated by at least 7 days washout period.
62621698|NCT00664365|EXPERIMENTAL|Subjects receiving GSK958108 + placebo in cohort 2|Eligible subjects will start dosing once the cohort 1 has completed the treatment phase and the initial dose will be the same as top dose in Cohort1.The dose escalation will be continued up to 4 ascending doses. Subjects will also receive placebo. Each treatment period will be separated by at least 7 days washout period.
62847877|NCT02636361|EXPERIMENTAL|LY900014 Test B|Test formulation B: Single dose of LY900014 formulation administered subcutaneously (SC) in one of five periods
62847878|NCT02636361|EXPERIMENTAL|LY900014 Test A|Test formulation B: Single dose of LY900014 formulation administered SC in one of five periods
62060995|NCT05346848|EXPERIMENTAL|Experimental Arm A: combination of radiotherapy and darolutamide|Patients with unfavorable intermediate risk prostate cancer will be treated with darolutamide for a maximum of 6 months combined with external beam radiotherapy
62621699|NCT02799121|EXPERIMENTAL|ReGenerCell™|Debridement and/or a sterile saline rinse of ulcer, as clinically indicated, followed by ReGenerCell™ treatment and appropriate dressing and off-loading
62621700|NCT04552171|EXPERIMENTAL|Access to Game Plan app and 24-hour helpline|Participants in this condition will be provided access to the Game Plan app and encouraged to use it after they complete their baseline assessments and STI testing has been completed. These participants will also be provided with access to a 24-hour helpline that provides free HIV/STI test counseling, which they can elect to use or not.
62621701|NCT04552171|NO_INTERVENTION|Access to a 24-hour helpline|"Participants in this condition will be provided access to a 24-hour helpline that provides free HIV/STI test counseling, which they can elect to use or not. Use of this comparison condition is intended to provide a real-world test of the added benefit of using Game Plan, above and beyond the current standard of care for HIV/STI self-testing, which involves providing users with access to a 24-hour helpline."
62060996|NCT05346848|OTHER|Standard Arm B: combination of radiotherapy and androgen deprivation therapy|Patients with unfavorable intermediate risk prostate cancer will be treated with androgen deprivation therapy (ADT) as per market authorization combined with external beam radiotherapy
62265026|NCT06065852||Haemolytic Uraemic Syndrome Rare Disease Group|"1. To identify key issues and challenges facing the field of Haemolytic Uraemic Syndrome, specifically in the development of an informatics framework within the UK~2. To stimulate and encourage industry partnerships.~3. To identify the needs and priorities for basic, clinical, translational and social research~4. To identify suitable funding opportunities and help support appropriate strategies for successful applications."
62265027|NCT06065852||Hepatic Nuclear Factor 1B Mutation Rare Disease Group|"The HNF1B rare disease group (RDG) covers all diseases associated with mutations and deletions in this gene. These include renal developmental disorders, most commonly renal cysts. The most common problem outside the kidneys is diabetes. When diabetes and renal cysts occur together this is known as the renal cysts and diabetes (RCAD) syndrome. Other clinical features may include hyperuricaemia and gout, hypomagnesaemia, abnormal liver function tests, pancreatic exocrine deficiency and genital tract malformations.~We aim to increase clincians' awareness of these presentations, improve recognition and streamline diagnosis, particularly at a genetic level. To do this we are studying genetic information on patients with well-defined clinical features. We hold open meetings to inform and support patients and their families."
62265028|NCT06065852||Hyperoxaluria Rare Disease Group|"The Hyperoxaluria Rare Disease Group aims to:~The Hyperoxaluria Rare Disease Group aims to:~Provide up to date support for patients and their families. Increase the knowledge and understanding of Primary Hyperoxaluria and Oxalosis to improve its clinical management.~Provide clinical information on dialysis and transplantation. Increase the knowledge of clinical presentation and outcome of Primary Hyperoxaluria.~Foster national and international partnerships to promote scientific innovation and research in Primary Hyperoxaluria and facilitate applications for funding for research collaboration.~Create a forum for UK clinical studies on Primary Hyperoxaluria, including trials with orphan drugs.~Foster genotype studies on Primary Hyperoxaluria. Co-operate in order to obtain funding for research activities through industrial or public partners in order to facilitate the dissemination of the results deriving from scientific research.'"
62265029|NCT06065852||IgA Nephropathy Rare Disease Group|"The IgA Nephropathy (IgAN) Rare Disease Group aims to:~collate avaliable information on IgAN and develop new information for both patients and carers implement a communications strategy for the wider renal community about all aspects of the RDG's work programme develop a strategy for patient recruitment to clinical trials in IgAN"
62265030|NCT06065852||Inherited Renal Cancer Syndromes Rare Disease Group|"The development of evidence based clinical care pathways in inherited RCC has been identified as a priority owing to the lack of fully commissioned screening programmes nationally. Several published expert led disease management guidelines are being evaluated. Therefore the familial RCC RDG will set as a priority the development and validation of evidence based care pathways that reflect both national and international opinion and can be adopted by NHS commissioning groups.~The familial RDG will work closely with other RDGs, the Renal Registry and the Renal Association to produce advice for commissioners that relate to specific aspects of these diseases as well as more general advice that relates to rare diseases, CKD and renal replacement therapy."
62265031|NCT06065852||Lupus Nephritis Rare Disease Group|
62448573|NCT01489722|EXPERIMENTAL|AZD1208|Single ascending dose escalation of 3 - 6 patient cohorts until maximum tolerated dose (MTD) is established. Up to 12 patients may be included at any dose not determined to be intolerable. Safety expansion using MTD in up to 44 Acute myelogenous leukemia (AML) patients.
62621702|NCT02738411||The study population|The study population corresponds to infants born at less than 33 weeks of gestation.
62060997|NCT01672853|EXPERIMENTAL|Treatment Arm A|Simtuzumab 75 mg for 96 weeks
62060998|NCT01672853|EXPERIMENTAL|Treatment Arm B|Simtuzumab 125 mg for 96 weeks
62060999|NCT01672853|PLACEBO_COMPARATOR|Treatment Arm C|Placebo for 96 weeks
62448574|NCT01566409|ACTIVE_COMPARATOR|Active maintenance treatment|
62448575|NCT01566409|PLACEBO_COMPARATOR|Placebo maintenance treatment|
62621703|NCT06427629|OTHER|Patients with ocular surface disease|Patients diagnosed with dry eye disease, sjogren syndrome, stevens-johnson syndrome, ocular graft versus host disease.
62621704|NCT06427629|OTHER|Patients scheduled for ocular surgery without ocular surface disease|Patients without ocular surface disease and scheduled for cataract surgery which requires moxifloxacin administration
62621705|NCT03990311|EXPERIMENTAL|Intervention|The experimental arm receives 2 months of sodium restricted prepared meals plus dietary counseling followed by 3 months of counseling alone.
62621706|NCT03990311|PLACEBO_COMPARATOR|Control|The control arm receives 5 months of usual care followed by 2 months of receipt of sodium restricted prepared meals.
62621707|NCT00004500|EXPERIMENTAL|Lucinactant|Lucinactant via bronchoaveolar lavage
62621708|NCT00004500|OTHER|Standard Care|Standard Care included the use of oxygen, CMV, sedation, paralysis, vasopressors, and/or alkalinization
62621709|NCT05363956|ACTIVE_COMPARATOR|miswak|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique. The technique will be demonstrated to the patient and an image of the technique provided to the participants.
62061000|NCT04912674||Operative|"Inclusion Criteria:~1. ≥18 years old at time of treatment~2. Patient undergoing a posterior cervical instrumented fusion using the DePuy Synthes SymphonyTM OCT System for the treatment of adult cervical deformity, defined as any of below criteria:~   1. Loss of cervical lordosis (≤ 0° cervical lordosis C2-7)~  2. ≥ 5° of kyphosis across any 1 or 2 cervical segments~  3. ≥ 10° of cervical scoliosis~  4. C2-C7 SVA ≥ 4cm~  5. T1 Slope minus Cervical Lordosis ≥ 20°~  6. Grade I or greater Spondylolisthesis at any segment C1-T1~  7. Horizontal Gaze ≤ 0 or ≥ 11~3. Plan for surgical correction of cervical deformity in the next 6 months~4. Willing to provide consent and complete study forms at baseline and follow-up intervals~Exclusion Criteria:~1. Active spine tumor or infection~2. Deformity due to acute trauma~3. Unwilling to provide consent or to complete study forms~4. Prisoner~5. Pregnant or immediate plans to get pregnant"
62847879|NCT02636361|EXPERIMENTAL|LY900014 Test C|Test formulation C: Single dose of LY900014 formulation administered SC in one of five periods
62847880|NCT02636361|EXPERIMENTAL|LY900014 Test D|Formulation D: Single dose of LY900014 formulation administered SC in one of five periods
62847881|NCT02636361|ACTIVE_COMPARATOR|Insulin Lispro|Reference formulation: Single dose of lispro administered SC in one of five periods
62448576|NCT04489407|EXPERIMENTAL|rPPG Vital Sign Monitor Readings|Oxygen saturation, heart rate and respiratory rate obtained with the rPPG app.
62061001|NCT01705535|EXPERIMENTAL|Pelvic floor muscle exercises|Individual supervised pelvic floor muscle exercises. Standard information and guidance
62448577|NCT04489407|OTHER|Conventional Vital Sign Monitor Readings|Oxygen saturation, heart rate and respiratory rate obtained with conventional vital sign monitors and manual respiratory rate counts.
62621710|NCT05363956|ACTIVE_COMPARATOR|eucalyptus oil|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique. The technique will be demonstrated to the patient and an image of the technique provided to the participants.
62621711|NCT02822833|EXPERIMENTAL|Sentinel lymph node mapping|Sentinel lymph node mapping with indocyanine green injection to cervix in endometrial cancer patients operated laparoscopically
62621712|NCT02917655|EXPERIMENTAL|Educational Program Associated (EPA)|"45 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital on months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; on month 4 for a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).~Answer WOMAC, Lequesne, Numerical Rating Scales (NRS), IPAQ, Tampa Scale for Kinesiophobia (TSK); perform the STS30, TUG, six-minute test have calculated BMI and body fat percentage at baseline evaluations, 6, 12 and 24 months."
62621713|NCT02917655|OTHER|Educational Program Isolated (EPI)|"45 patients will participate in two days of lectures two-months apart on the subject of knee OA.~Answer WOMAC, Lequesne, Numerical Rating Scales (NRS), IPAQ, Tampa Scale for Kinesiophobia (TSK); perform the STS30, TUG, six-minute test have calculated BMI and body fat percentage at baseline evaluations, 6, 12 and 24 months."
62621714|NCT00814593|EXPERIMENTAL|Arm I|Patients undergo intracranial placement of polifeprosan 20 with carmustine implant (Gliadel® wafer) at the time of therapeutic craniotomy.
62847882|NCT02961738|ACTIVE_COMPARATOR|Full-CAT|Participants in this arm receive an intervention of a full 8-session course of cognitive analytic therapy (CAT). This means that they are assessed then then receive a narrative reformulation, that then leads onto a sequential diagrammatic reformulation and then the change methods and completion.
62847883|NCT02961738|EXPERIMENTAL|An 8-session CAT without narrative reformulation (CAT-NR)|Participants in this arm receive an intervention of a full 8-session course of cognitive analytic therapy (as described above), but crucially with the narrative reformulation (NR) aspect removed. All other aspects of treatment remain the same.
62847884|NCT01776307|EXPERIMENTAL|BBI608 in combination with cetuximab|
62847885|NCT01776307|EXPERIMENTAL|BBI608 in combination with panitumumab|
62847886|NCT01776307|EXPERIMENTAL|BBI608 in combination with capecitabine|
62847887|NCT02377661|NO_INTERVENTION|Standard Care|Treatment of hypertension according to current guidelines
62847888|NCT02377661|EXPERIMENTAL|Experimental Care|Treatment of hypertension using a standardised and simplified titration regime with single pill combinations, comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide.
62847889|NCT01491984|EXPERIMENTAL|Laryngoscopy order: 1) MAC, 2) Levitan|Levitan FPS Intubation
62448578|NCT04840979|EXPERIMENTAL|Cognitive Impairment|Subjects diagnosed with Alzheimer's disease (AD) or mild cognitive impairment (MCI) will have one PET scan with 11C-ER176, with arterial sampling. If the subject lacks known AD-biomarkers, they may undergo a 18F-florbetaben PET scan prior to the 11C-ER176 PET scan. Genome-wide genetic analysis will be performed. Participants will undergo an annual clinical evaluation and blood sample collection for 5 years to establish the trajectory of AD-related serum biomarkers and syndromic diagnoses.
62265032|NCT06065852||Membranous Nephropathy Rare Disease Group|"Aims:~1. To develop evidence based clinical care pathways. Current treatment for Membranous Nephropathy (MN) is based on knowledge and drugs available in the 1990's.~2. To empower and inform patients and families.~3. To audit clinical outcomes:~   Establish a registry of biopsy proven prevalent cases and new incident cases of both primary and secondary MN starting from Jan 2013. In total we seek to capture data on 2000 patients during the next 5 years with a minimum of one complete data return per patient per year.~4. To promote and develop research."
62448579|NCT04840979|ACTIVE_COMPARATOR|No Cognitive Impairment|Healthy volunteers who are cognitively normal will have one PET scan with 11C-ER176, with arterial sampling. If the subject lacks known AD-biomarkers, they may undergo an 18F-florbetaben PET scan prior to the 11C-ER176 PET scan. Genome-wide genetic analysis will be performed. Participants will undergo an annual clinical evaluation and blood sample collection for 5 years to establish the trajectory of AD-related serum biomarkers and syndromic diagnoses.
62265033|NCT06065852||Mitochondrial disease affecting the kidney Rare Disease Group|This group is to promote the recognition of patients with mitochondrial disease affecting the kidney.
62448580|NCT01781039||low HIN difficulty- anesthetized|Subjects with normal OHC function and who will be undergoing an previously scheduled anesthetized procedure will be assigned into 2 groups based on their self-perceived HIN difficulty (high and low difficulty), and then undergo a test battery consisting of auditory threshold tests, objective HIN assays, OHC measurements, cognitive processing, and central auditory processing evaluations. Immediately after anesthetization, electrocochleography (ECochG) will be used to measure CAP amplitudes, which will be correlated with measurements obtained from unanesthetized subjects as described below. This aim will determine the optimal CAP recording method with the strongest correlation with HIN performance in humans
62448581|NCT01781039||high HIN difficulty- anesthetized|Subjects with normal OHC function and who will be undergoing an previously scheduled anesthetized procedure will be assigned into 2 groups based on their self-perceived HIN difficulty (high and low difficulty), and then undergo a test battery consisting of auditory threshold tests, objective HIN assays, OHC measurements, cognitive processing, and central auditory processing evaluations. Immediately after anesthetization, electrocochleography (ECochG) will be used to measure CAP amplitudes, which will be correlated with measurements obtained from unanesthetized subjects as described below. This aim will determine the optimal CAP recording method with the strongest correlation with HIN performance in humans
62621715|NCT00814593|EXPERIMENTAL|Arm II|Patients undergo leukapheresis to obtain autologous lymphokine-activated killer (LAK) cells, followed 3-7 days later by therapeutic craniotomy. The autologous LAK cells are then instilled into the tumor bed cavity at the time of therapeutic craniotomy.
62621716|NCT01118663|EXPERIMENTAL|Acetadote without EDTA|Acetadote EF \[Ethylenediaminetetraacetic Acid (EDTA) - Free\]
62847890|NCT01491984|EXPERIMENTAL|Laryngoscopy order: 1) Levitan, 2) MAC|Macintosh Intubation
62847891|NCT05331404|EXPERIMENTAL|Presbycusis|Patients with presbycusis who receive rehabilitation with hearing aids
62847892|NCT05331404|ACTIVE_COMPARATOR|Aged control group|Aged control group: 15 subjects with normal or near-normal hearing thresholds
62847893|NCT05331404|ACTIVE_COMPARATOR|Young control group|Young control group: 15 subjects with normal hearing thresholds
62847894|NCT01251341|EXPERIMENTAL|Compassion Meditation Group|
62847895|NCT01251341|ACTIVE_COMPARATOR|Health Education and Wellness Group|
62847896|NCT01251341|EXPERIMENTAL|Mindful Attention Training|
62847897|NCT03697915|EXPERIMENTAL|Experimental group|Experimental group, in which a physical therapy programme supplemented by the James lift system was applied
62847898|NCT03697915|PLACEBO_COMPARATOR|Control|Control group, in which a conventional physical therapy programme was applied.
62847899|NCT01330251||Patients with diabetes having Roux-en-Y gastric bypass|
62847900|NCT01330251||Patients without diabetes having Roux-en-Y gastric bypass|
62847901|NCT01330251||Control subjects (patients having gastroscopy, no surgery)|
62847902|NCT06043193||Major subjects, suffering from metastatic neuroendocrine tumours|Major subjects, suffering from metastatic neuroendocrine tumours, for whom the indication for treatment by vectorized internal radiotherapy is decided in a multidisciplinary consultation meeting (National Reference Network for the management of Neuro-Endocrine Tumors) and who will be treated in one of the 5 centers in the AURA region
62847903|NCT02056262||3 to 16 years of age|"Volunteers of 3 to 16 years of age, coming in to the hospital for a dental consultation. See inclusion/exclusion criteria.~Intervention: Dental cavity evaluation Intervention: Saliva sampling Intervention: Plaque sampling"
62621717|NCT01118663|ACTIVE_COMPARATOR|Acetadote|Acetadote \[Old formulation containing EDTA\]
62847904|NCT02056262||17 - 45 years of age|"Volunteers of 17 to 45 years of age, coming in to the hospital for a dental consultation. See inclusion/exclusion criteria.~Intervention: Dental cavity evaluation Intervention: Saliva sampling Intervention: Plaque sampling"
62847905|NCT06492863|EXPERIMENTAL|FT003 Dose 1|Low dose of FT-003
62847906|NCT06492863|EXPERIMENTAL|FT003 Dose 2|Mid dose of FT-003
62847907|NCT06492863|EXPERIMENTAL|FT003 Dose 3|High dose of FT-003
62847908|NCT06226389|EXPERIMENTAL|4 Different bulk-fill composite|Bulk-fill composite will be applied in different 4 posterior cavities with 3-4 ml in depth
62847909|NCT06226389|EXPERIMENTAL|Aging|For long term follow up
62847910|NCT04699136|EXPERIMENTAL|Cardiovascular disease|
62847911|NCT02905851|PLACEBO_COMPARATOR|Non Feedback|No feedback given to this group regarding their antibiotic use Subjects take images and answer questions during the study like the feedback group, but in this group no feedback re dosing is given.
62265034|NCT06065852||Monoclonal Gammopathy of Renal Significance Rare Disease Group|To promote the RaDaR registration of patients affected by Monoclonal Gammopathy of Renal Significance (MGRS) To develop standard operating procedures in regards to the treatment of Paraprotein Associated Kidney Diseases To provide better patient information and support To support research, in collaboration with international groups, into basic science, disease progression models and clinical trials
62265035|NCT06065852||MPGN, DDD & C3 Glomerulopathy Rare Disease Group|"To bring together clinicians, scientists and consumers for the purposes of:~Undertaking clinical research into the causes of and treatment for MPGN and C3 glomerulopathies Promoting best clinical practice for patients with MPGN and C3 glomerulopathies Facilitating support for patients and families affected by MPGN and C3 glomerulopathies"
62448582|NCT01781039||Hearing Aid fitting: MAD|Microphone adaptive directionality (MAD) feature will be activated, the WDC set to linear, and the DNR minimized
62448583|NCT01781039||Hearing Aid fitting: WDC|Wide dynamic compression (WDC) feature will be set to target levels, the MAD feature set to omnidirectional, and the DNR minimized.
62448584|NCT01781039||Hearing Aid fitting: DNR|Digital noise reduction (DNR) set to maximum, MAD set to omnidirectional, and WDC set to linear
62448585|NCT01781039||Hearing Aid fitting: Positive control|All hearing aid features enables
62448586|NCT01781039||Hearing Aid fitting: Negative control|All hearing aid features disabled
62448587|NCT05572411||Ponseti|Ponseti treated Clubfoot participants will be asked to walk across the GAITRite Electronic Walkway.
62448588|NCT03845933|ACTIVE_COMPARATOR|Water exchange (WE) colonoscopy|Water exchange will be used during colonoscopy insertion. Upon arriving at the cecum, CO2 will be opened. The scope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). The scope will be reinserted into the cecum by the first endoscopist. A tandem inspection of right colon will be performed by a second endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
62448589|NCT03845933|ACTIVE_COMPARATOR|CO2 insufflation colonoscopy|The colonoscopy is performed in the usual fashion, with minimal insufflation required to aid insertion. Cleaning will be performed entirely during withdrawal. Upon arriving at the cecum, CO2 insufflation will be used and the scope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). Then the scope will be reinserted into the cecum by the first endoscopist using CO2. A tandem inspection of the right colon will then be performed by a second endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the mark of distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
62621718|NCT02871284|EXPERIMENTAL|Sensorimotor training (EI)|The participants of the experimental intervention arm will take part in a 45 minutes sensorimotor training class two times a week for a maximum of 24 weeks at the NCT (National Center for Tumor Diseases). Highly qualified exercise therapists will guide the class. Class size will be no bigger than 8 patients to ensure adequate individual supervision and guidance. Additionally, participants will be asked to perform one weekly 15 minutes home-based sessions without supervision. Participants who are not able to come to the NCT Heidelberg 2x/week will be offered a home-based sensorimotor program including the same exercises. At the beginning, participants will receive an appointment for an individual face-to-face counseling session at the NCT. During this appointment, the patient will receive an exercise manual for individualized home-based sensorimotor training and a practical introduction by the exercise therapist.
62847912|NCT02905851|ACTIVE_COMPARATOR|Feedback group|"Feedback given to this group regarding their antibiotic use after baseline.~If the subject is in the feedback group, after this visit, a dermatologist will review all images and the survey results and give the patient information about whether they should:~1. Continue current dose~2. Reduce dose if there is at least a one point improvement in both the investigator acne global assessment AND the patient acne global assessment scores: A dose reduction will be such that the dose is halved from the previous dose. For example if the subject is on minocycline or doxycycline 100 mg twice daily, they will be reduced to minocycline or doxycycline 100 mg daily.~3. Increase dose if had been previously reduced, dose will not be increased beyond the initial starting dose."
62847913|NCT02639416|ACTIVE_COMPARATOR|Standard management|Standard management consists of F-100 and/or ready-to-use therapeutic food (RUTF) according to usual practice for 14 days
62847914|NCT02639416|EXPERIMENTAL|Polymeric formula|Exclusive polymeric formula supplemented with micronutrients in equivalent volume to F-100 for 14 days
62847915|NCT02639416|EXPERIMENTAL|Elemental formula|Exclusive elemental formula supplemented with micronutrients in equivalent volume to F-100 for 14 days
62847916|NCT02538393|EXPERIMENTAL|Treatment A-C-B-D|Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 \* 200 mg) in fasting state (Treatment A) in the first intervention period; followed by a single oral dose of 200 mg sorafenib tablets for oral suspension (2 \* 100 mg) in fasting state (Treatment C) in the second intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) in fasting state (Treatment B) in the third intervention period; and then a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
62847917|NCT02538393|EXPERIMENTAL|Treatment B-A-D-C|Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) in fasting state (Treatment B) in the first intervention period; followed by a single oral dose of 400 mg sorafenib marketed tablets (2 \* 200 mg) in fasting state (Treatment A) in the second intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the third intervention period; and then a single oral dose of 200 mg sorafenib tablets for oral suspension (2 \* 100 mg) in fasting state (Treatment C) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
62621719|NCT02871284|ACTIVE_COMPARATOR|machine-based resistance training (AC)|Participants of the active control arm will receive machine-based resistance training. The supervised resistance exercise program will be undertaken twice weekly in small groups (not more than 12 people per group) of participants and will be guided by an exercise physiotherapist over a maximum of 24 weeks. All sessions will start with a warm-up and finish with a cool-down (comprising exercise on a cycle ergometer or treadmill at a relatively low intensity and stretching activities) and will take approximately 45 minutes. Additionally, participants will be asked to perform a weekly 15 minutes home-based resistance training session without supervision
62621720|NCT02871284|NO_INTERVENTION|usual care|Participants will receive usual care with no additional exercise training or intervention
62621721|NCT06613321||Patients with increased lung distension|Defined by a residual volume over total lung capacity ratio (RV/TLC ratio) above the median value of all included patients.
62621722|NCT06613321||Patients without increased distension disorder|Defined by a residual volume over total lung capacity ratio (RV/TLC ratio) below the median value of all included patients.
62621723|NCT03934840|EXPERIMENTAL|Carboplatin, Cabazitaxel and Abiraterone|
62621724|NCT05963932|EXPERIMENTAL|Treatment A: BMS-986419 DR Capsule - Fasted|
62621725|NCT05963932|EXPERIMENTAL|Treatment B: BMS-986419 IR Tablet - Fasted|
62621726|NCT05963932|EXPERIMENTAL|Treatment C: BMS-986419 IR Tablet - Fed|
62621727|NCT05963932|EXPERIMENTAL|Treatment D: BMS-986419 Crushed IR Tablet - Fed|
62621728|NCT02838875|EXPERIMENTAL|Pregnant women at risk population|women who arrived to the delivery room at Lis hospital and which the newborn is about to undergo glucose levels follow-up after birth regardless the study, because of their affiliation to the at-risk population.
62621729|NCT02333994|EXPERIMENTAL|GROUP A|EDUCATION PROGRAMME AND BALANCE TRAINING EXERCISES
62621730|NCT02333994|ACTIVE_COMPARATOR|GROUP B|BALANCE EXERCISES
62621731|NCT02150252|EXPERIMENTAL|BY HWT，placebo-BY HWT ， Gait parameter|
62621732|NCT06435546|EXPERIMENTAL|Adherence oral anticancer therapies questionnaire|Blood samples
62621733|NCT03731208|EXPERIMENTAL|Intervention group|The patient assign to this arm receive the telerehabilitation program for 8-week after a knee operation
62621734|NCT02190123||ACS patients treated with OAP|Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets
62448590|NCT00362986|EXPERIMENTAL|sunscreen|"Patients apply sunscreen generously to the entire body twice daily for 4 weeks.~Patients complete self-reported questionnaires regarding their rash status at baseline and then weekly for 8 weeks.~After completion of study treatment, patients are followed for 8 weeks."
62448591|NCT00362986|PLACEBO_COMPARATOR|placebo|"Patients apply placebo generously to the entire body twice daily for 4 weeks.~Patients complete self-reported questionnaires regarding their rash status at baseline and then weekly for 8 weeks.~After completion of study treatment, patients are followed for 8 weeks."
62448592|NCT05067348|EXPERIMENTAL|Tocilizumab|Participants will receive tocilizumab administered intravenously (IV) on weeks 1,5,9 and 13 of the randomized controlled period.
62448593|NCT05067348|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo administered intravenously (IV) on weeks 1,5,9 and 13 of the randomized controlled period.
62448594|NCT00894907|EXPERIMENTAL|PiCCO-group|Insertion of an arterial PiCCO catheter. Resuscitation using crystalloids and/or colloids according to PiCCO-parameter-guided algorithm
62448595|NCT00894907|OTHER|2|Control: Haemodynamic management without ITBI and ELWI using any other haemodynamic monitoring tool, with the exception of the PiCCO-system.
62448596|NCT04511390|EXPERIMENTAL|Transparent, reusable respirator|Transparent, reusable elastomeric respirator that has been designed to fit multiple different face sizes and shapes.
62448597|NCT03864588|PLACEBO_COMPARATOR|Control|Anesthesiologist preforms ultrasound guided adductor canal block post-operatively
62448598|NCT03864588|EXPERIMENTAL|Intervention|Surgeon preforms inter-operative adductor canal block
62448599|NCT01058421|EXPERIMENTAL|Intensive physical therapy|four week intervention of daily intensive physical therapy
62448600|NCT01058421|ACTIVE_COMPARATOR|control group|
62448601|NCT04025619|EXPERIMENTAL|treatment group|the data is collected from the same participant after the intervention.
62448602|NCT04025619|NO_INTERVENTION|Control group|The Collect the data from the same participant before the intervention as control
62621735|NCT04331093|EXPERIMENTAL|resectable stage III-IV Acral melanoma|
62621736|NCT02583412|ACTIVE_COMPARATOR|Group 1: Accelerated Schedule|
62621737|NCT02583412|ACTIVE_COMPARATOR|Group 2: Standard Schedule|
62621738|NCT01080976||Primary Care Physicians|
62621739|NCT01080976||Diabetologists|
62621740|NCT00893529|EXPERIMENTAL|dietary intervention 1|
62621741|NCT00893529|EXPERIMENTAL|dietary intervention 2|
62621742|NCT05563623||progression group|
62621743|NCT05563623||non-progression group|
62623778|NCT02797509|EXPERIMENTAL|Psychosocial Skills-Based Intervention|Based on information from Phase I (semi-structured interviews), the investigators will develop a detailed psychosocial intervention manual. The intervention will be tailored consistent with American Heart Association (AHA) recommendations for stroke skills based interventions and will include 2 general and 4 specific modules (selected from 7 available). Generally, in the intervention, stroke patients and stroke caregivers will learn skills to cope and manage stroke-related stressors. It is anticipated that the intervention will have 6 sessions with 2 general sessions delivered within the NICU face to face and 4 tailored specific sessions to be delivered via live video using Vidyo. Participants in the intervention group will also receive treatment as usual.
62061002|NCT01705535|ACTIVE_COMPARATOR|Masage of the neck and back|Massage of the neck and back. Standard information and guidance
62448603|NCT04560764|EXPERIMENTAL|Virtual Reality + Action Observation Therapy|Participants will see a video demonstrating the exercise they will be later asked to perform. The same procedure is performed for each of the four different exercises.
62847918|NCT02538393|EXPERIMENTAL|Treatment C-D-A-B|Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 \* 100 mg) in fasting state (Treatment C) in the first intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the second intervention period; followed by a single oral dose of 400 mg sorafenib marketed tablets (2 \* 200 mg) in fasting state (Treatment A) in the third intervention period; and then a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) in fasting state (Treatment B) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
62448604|NCT04560764|SHAM_COMPARATOR|Virtual Reality + Landscape video|Participants will see a video demonstrating a natural landscape and later they will perform an exercise. The same procedure is performed for each of the four different exercises.
62621744|NCT06476938|EXPERIMENTAL|Gene PilotLX|"Gene PilotLX is an eHealth decision support tool that is designed to empower Latinx cancer patients to decide their preferences for learning about secondary genetic information, communicate those preferences to their doctors, and provide the opportunity to discuss information with their families or others to feel they have made an informed decision. The tool will be available in both English and Spanish. It is web-based, has a voice-over, and is easy to navigate, with simple forward and backward buttons. Each section includes a different aspect of tumor genomic profiling, from basic information about what the test is and what the pros and cons are of the test, to culturally specific potential barriers or benefits to learning hereditary results. At the end, the tool provides tailored potential questions for a doctor that users can choose, which are summarized in a score card that can be printed or emailed."
62621745|NCT06476938|NO_INTERVENTION|TGP brochure|Participants in the control arm will be provided a brochure about tumor genomic profiling (TGP) secondary hereditary risks, and what patients can decide about getting that information, including the pros and cons. It is literacy appropriate, incorporates visuals, and will also be offered in both English and Spanish.
62847919|NCT02538393|EXPERIMENTAL|Treatment D-B-C-A|Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the first intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) in fasting state (Treatment B) in the second intervention period; followed by a single oral dose of 200 mg sorafenib tablets for oral suspension (2 \* 100 mg) in fasting state (Treatment C) in the third intervention period; and then a single oral dose of 400 mg sorafenib marketed tablets (2 \* 200 mg) in fasting state (Treatment A) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
62847920|NCT04710472|EXPERIMENTAL|MH|Arm MH - mobile Mentora app to monitor and track treatment side-effects, vital signs, therapeutics and daily habits;
62448605|NCT02872649|EXPERIMENTAL|study medication|Dabigatran 110mg twice daily with normal renal function (glomerular filtration rate \>80 ml/min) Dabigatran 75mg twice daily with impaired renal function (glomerular filtration rate between 80 and 30 ml/min)
62448606|NCT02872649|ACTIVE_COMPARATOR|control group|Phenprocoumon dosage according to INR
62448607|NCT01936779|ACTIVE_COMPARATOR|Dietary supplement: fatty acid active|4g/day n-3 fatty acids for 8 weeks
62448608|NCT01936779|PLACEBO_COMPARATOR|Dietary supplement: fatty acid placebo|4g/day olive oil for 8 weeks
62448609|NCT03154658|EXPERIMENTAL|Sub-serratus regional block|A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site deep to the serratus anterior muscle.
62621746|NCT00914498|EXPERIMENTAL|Xylocaine|Participants will receive local injection of 20 ml 1% Xylocaine to the skin incision site
62621747|NCT00914498|PLACEBO_COMPARATOR|Controls|Participants will receive injection of 0.9% NaCl 20 ml to the incision site
62621748|NCT00134758|EXPERIMENTAL|1|"Ursodeoxycholic acid during 2 years :~* between 40 and 50 kg : 500 mg/day~* between 51 and 75 kg : 750 mg/day~* between 76 and 100 kg : 1000 mg/day"
62621749|NCT00134758|PLACEBO_COMPARATOR|2|
62621750|NCT05795972|EXPERIMENTAL|inulin supplementation|
62621751|NCT05795972|ACTIVE_COMPARATOR|standard therapy|
62621752|NCT03585517|EXPERIMENTAL|IM23 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD123 CAR will be infused 24-96 hours later.
62621753|NCT04745871|EXPERIMENTAL|Intervention|All patients with prostate cancer undergo PSMA PET/CT as part of the trial in addition to standard methods (abdo-pelvic MRI and a bone scan).
62621754|NCT00328445|NO_INTERVENTION|Control|Business as usual
62621755|NCT00328445|EXPERIMENTAL|Treatment|Positive Action
62847921|NCT04710472|NO_INTERVENTION|C|SOC
62847922|NCT03223519|EXPERIMENTAL|Comboprofen|Triple combination of Ibuprofen, Magnesium and Vitamin C.
62847923|NCT03223519|PLACEBO_COMPARATOR|Placebo|
62847924|NCT03223519|ACTIVE_COMPARATOR|Ibuprofen|
62847925|NCT03223519|ACTIVE_COMPARATOR|Magnesium|
62847926|NCT03223519|ACTIVE_COMPARATOR|Vitamin C|
62847927|NCT04838977|EXPERIMENTAL|RESET|Children will view 8 educational modules online and participate in 8 sessions with a therapist via telehealth.
62847928|NCT04838977|NO_INTERVENTION|Control|Children will receive usual post-trauma care.
62061003|NCT06263088|OTHER|EQUITY GI|"1. Data gathering~2. Program development and implementation~3. Health literacy"
62061004|NCT06000319||Lumbar Interbody Fusion with NMP|Subject has undergone lumbar interbody spine fusion at no more than 3 adjacent levels between L1 and S1 where NMP fibers have been used as a bone void filler
62621756|NCT03047564|EXPERIMENTAL|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
62621757|NCT03047564|ACTIVE_COMPARATOR|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
62061005|NCT06000319||Cervical Interbody Fusion with NMP|Subject has undergone cervical interbody spine fusion at no more than 3 adjacent levels between C2 and T1 where NMP fibers have been used as a bone void filler
62621758|NCT00932386|EXPERIMENTAL|dexmedetomidine Hcl infusion|Dexmedetomidine is a highly selective alpha-2 adrenoreceptor agonist, which possesses hypnotic, sedative, anxiolytic, sympatholytic and analgesic properties.
62621759|NCT00932386|PLACEBO_COMPARATOR|normal saline|
62621760|NCT02309723|EXPERIMENTAL|Positive beta amyloid findings|Beta amyloid imaging results indicated a positive finding.
62448610|NCT03154658|ACTIVE_COMPARATOR|Supra-serratus regional block|A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site superficial to the serratus anterior muscle.
62621761|NCT02309723|EXPERIMENTAL|Negative beta amyloid findings|Beta amyloid imaging results indicated a negative finding.
62621762|NCT02309723|NO_INTERVENTION|No beta amyloid information|
62621763|NCT02080338|EXPERIMENTAL|0.018 bracket slot system|Participants treated using 0.018-inch orthodontic bracket slot system
62621764|NCT02080338|ACTIVE_COMPARATOR|0.022 bracket slot system|Participants treated using 0.022-inch orthodontic bracket slot system
62621765|NCT05867225|EXPERIMENTAL|Biosynthetic absorbable mesh|Patients who have undergone hiatal surgery with use of a biosynthetic absorbable mesh
62847929|NCT03637439|EXPERIMENTAL|PNM group|Subjects were treated only once. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10 Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol (Valera \& Minaya). The subjects were lying prone in decubitus. The middle part of the sciatic nerve was located using an ultrasound machine (cross section), then an acupuncture needle (0.30 mm x 40 mm) was inserted in a short axis approach, perpendicular to the surface of the skin, to the perineurium of the sciatic nerve.
62847930|NCT03637439|SHAM_COMPARATOR|Control group|The subjects were lying prone in decubitus. The same puncture protocol was performed on the sciatic nerve for 1.5 minutes, but without the application of electricity.
62621766|NCT05867225|SHAM_COMPARATOR|No biosynthetic absorbable mesh|Patients who have undergone hiatal surgery without use of a biosynthetic absorbable mesh
62061006|NCT02739347|EXPERIMENTAL|Active Stimulation|Active stimulation group will receive 20 min of 2 mA direct current stimulation.
62448611|NCT02295709|EXPERIMENTAL|USNR steroid injection|the patient who are treated with steroid (dexamethasone) injection through selected cervical spinal nerve block approach guided by ultrasound and C arm.
62621767|NCT06395519|EXPERIMENTAL|Phase 1 Part 1: Monotherapy Dose Escalation|Participants will be assigned to a dose level.
62621768|NCT06395519|EXPERIMENTAL|Phase 1 Part 2: Monotherapy Dose Expansion|After a dose is decided in Part 1, participants entering part 2 will be assigned to a dose level.
62621769|NCT04089878|EXPERIMENTAL|PARTO/BRTO + SMT|PARTO/BRTO with SMT will be given.
62621770|NCT04089878|ACTIVE_COMPARATOR|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
62621771|NCT03139409|ACTIVE_COMPARATOR|conventonal adhesive|peak lc bond
62847931|NCT02923440|EXPERIMENTAL|Congenital heart defects|
62847932|NCT03601117|EXPERIMENTAL|Dorsolateral Prefrontal Cortex|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (L-DLPFC), for 10 sessions per day for up to 5 days.
62847933|NCT03601117|EXPERIMENTAL|Anterior Cingulate Cortex|The accelerated theta burst stimulation protocol will be applied to the left anterior cingulate cortex (ACC), for 10 sessions per day for up to 5 days.
62847934|NCT05037799||Group 1|body-weight \< 50kg
62847935|NCT05037799||Group 2|50 kg ≤ body-weight \< 100 kg
62847936|NCT05037799||Group 3|100 kg ≤ body-weight \< 150 kg
62061007|NCT02739347|SHAM_COMPARATOR|Sham Stimulation|This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
62061008|NCT03666936|EXPERIMENTAL|Intervention|Social-health care intervention
62448612|NCT02295709|EXPERIMENTAL|UCTF steroid injection|the patients who are treated with steroid (dexamethasone) injection through cervical transforaminal approach guided by ultrasound and C arm.
62448613|NCT02295709|EXPERIMENTAL|XCTF steroid injection|the patients who are treated with steroid (dexamethasone) injection through cervical transforaminal approach guided only by C arm.
62621772|NCT03139409|OTHER|Time variable|Diagnosis and follow up will be immediate ,6 months later and 1 year
62621773|NCT01916421|ACTIVE_COMPARATOR|EZ Shot|
62621774|NCT01916421|ACTIVE_COMPARATOR|Expect™|
62847937|NCT05037799||Group 4|150 kg ≤ body-weight \< 200 kg
62847938|NCT01221311|EXPERIMENTAL|Fully Covered Metallic Stent|Among patients randomized to the covered, self-expandable metallic stent (cSEMS) group, the endoscopist will deploy a cSEMS of sufficient length to traverse the papilla. Dilation will not be performed unless the cSEMS deployment catheter cannot be advanced over a guidewire beyond the stricture. A biliary sphincterotomy may be performed at the discretion of the treating endoscopist.
62621775|NCT01916421|ACTIVE_COMPARATOR|EchoTip® Ultra|
62621776|NCT01728441|EXPERIMENTAL|Paclitaxel Eluting Stent|Patients randomized to treatment with paclitaxel eluting stent will receive the Zilver® PTX® stent.Primary stenting should be performed covering the full lesion. Post-dilatation is at the investigator's discretion.
62621777|NCT01728441|ACTIVE_COMPARATOR|Paclitaxel Eluting Balloon|For patients randomized to treatment with drug eluting balloon (DEB), angioplasty (ballooning) should be performed covering the full lesion.
62847939|NCT01221311|ACTIVE_COMPARATOR|Plastic Stent|Patients randomized to the plastic stent (PS) group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and multiple (as many as technically feasible) PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing endoscopic retrograde cholangiopancreatography (ERCP), until the stricture has been obliterated using clinical and fluoroscopic criteria (details below).
62847940|NCT06373289|ACTIVE_COMPARATOR|Oxygen saturation target 92-95%|At UAB oxygen saturation targeting is achieved using systematic oxygen saturation histogram monitoring every 3-4 hours by nurse, respiratory therapists, and physicians. Upon randomization to this arm, infants oxygen saturation alarm limits will be adjusted to 92-95% after which an FiO2 modification algorithm will be employed to maintain targets. Daily compliance reports will be generated to ensure oxygen saturation achievement corresponds with oxygen saturation targets. Infants will be exposed for a 2 week period after which they will crossover to the alternative oxygen saturation target with a 1 week washout period in between targets.
62847941|NCT06373289|ACTIVE_COMPARATOR|Oxygen saturation target 95-98%|At UAB oxygen saturation targeting is achieved using systematic oxygen saturation histogram monitoring every 3-4 hours by nurse, respiratory therapists, and physicians. Upon randomization to this arm, infants oxygen saturation alarm limits will be adjusted to 95-98% after which an FiO2 modification algorithm will be employed to maintain targets. Daily compliance reports will be generated to ensure oxygen saturation achievement corresponds with oxygen saturation targets. Infants will be exposed for a 2 week period after which they will crossover to the alternative oxygen saturation target with a 1 week washout period in between targets.
62847942|NCT02513927|ACTIVE_COMPARATOR|A|To observe the effects of metoprolol (95 mg) on blood pressure variation after 12 weeks of treatment.Then to observe the effects of Nifedipine (30 mg) on blood pressure variation after 12 weeks of treatment.
62847943|NCT02513927|ACTIVE_COMPARATOR|B|To observe the effects of Nifedipine (30 mg) on blood pressure variation after 12 weeks of treatment. Then to observe the effects of metoprolol (95 mg) on blood pressure variation after 12 weeks of treatment.
62847944|NCT03725241|PLACEBO_COMPARATOR|Placebo|Intervention: Dietary Supplement: Placebo supplement
62061009|NCT03634618|EXPERIMENTAL|Mirror Therapy|Mirror Therapy program for 2 weeks and convantional physiotherapy for 4 weeks. Exercises Frequency: 5 days/week; 2 days with the physiotherapist, other days as home program; 2 weeks in total. Exercises Duration: 20 minutes. Exercises Repetation: 20 repetation for each exercise.
62061010|NCT03634618|EXPERIMENTAL|Convantional Physiotherapy|Convantional physiotherapy for 6 weeks. Exercises Frequency: 3 times a day, 4 weeks in total. Exercises Duration: 15-20 minutes. Exercises Repetation: 10 repetation for each exercise.
62061011|NCT04805749|EXPERIMENTAL|Osteopathic manipulation|Spinal Mobilisation / Cranial Osteopathy therapy / Circulatory Techniques / Visceral osteopathic therapy
62061012|NCT06153602|EXPERIMENTAL|Nalbuphine group|0.5% Hyperbaric Spinal Bupivacaine 5-15 mg (1-3 ml) + Nalbuphine(10mg/ml) 0.8 mg intrathecal
62061013|NCT06153602|PLACEBO_COMPARATOR|Control group|0.5% Hyperbaric Spinal Bupivacaine 5-15 mg (1-3 ml) + 0.9% Sodium chloride 0.08 ml intrathecal
62448614|NCT05906082|EXPERIMENTAL|Intervention (E-cigarette cessation text-messaging intervention)|
62448615|NCT05906082|ACTIVE_COMPARATOR|Standard care (Standard care control using standard national resources)|This standard care group will receive standard care resources from smokefree.gov.
62448616|NCT04837053|EXPERIMENTAL|Intervention cluster|EKIT tool
62448617|NCT04837053|ACTIVE_COMPARATOR|Control Cluster|routine care
62448618|NCT04524299|EXPERIMENTAL|Concurrent chemotherapy Twice a Week|During the period of radiotherapy, 30 mg / m2 albumin bound paclitaxel was intravenously infused twice a week for 0.5 hours, and nedaplatin 10 mg / m2 twice a week for 0.5 hours.
62448619|NCT04524299|ACTIVE_COMPARATOR|Concurrent chemotherapy Once a Week|During the same period of radiotherapy, albumin bound paclitaxel (50 mg / m2) was intravenously infused once a week for 0.5 hours; nedaplatin (25 mg / m2) was intravenously infused once a week for 0.5 hours.
62448620|NCT04879810|ACTIVE_COMPARATOR|Ginger exosomes|Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire
62448621|NCT04879810|ACTIVE_COMPARATOR|Curcumin|Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire
62448622|NCT04879810|ACTIVE_COMPARATOR|Ginger exosomes plus curcumin|Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire
62448623|NCT02471066|EXPERIMENTAL|active rTMS|12 patients will be enrolled in this arm.
62448624|NCT02471066|SHAM_COMPARATOR|sham rTMS|12 patients will be enrolled in this arm.
62448625|NCT06546189|ACTIVE_COMPARATOR|1|OMNi BiOTiC® 41167 sachet diluded in a glass of water twice daily oral intake for 6 months
62448626|NCT06546189|PLACEBO_COMPARATOR|2|Placebo sachet diluted in a glass of water twice daily oral intake for 6 months
62448627|NCT04127409|PLACEBO_COMPARATOR|Control Chicken-meat & Control Eggs|Participants will be provided with control chicken-meat and control eggs, and will be requested to eat at least three portions/week of the control chicken-meat, and to eat at least three control eggs/week, for 6 months.
62621778|NCT04945564|EXPERIMENTAL|Oxygen therapy and physical therapy|
62621779|NCT04945564|ACTIVE_COMPARATOR|Oxygen therapy|
62621780|NCT06179043|SHAM_COMPARATOR|Control labels|Individuals in this trial arm will see neutral control labels on sugar-sweetened beverages.
62621781|NCT06179043|EXPERIMENTAL|Nutrient warning labels|Individuals in this trial arm will see nutrient warning labels on sugar-sweetened beverages.
62621782|NCT06179043|EXPERIMENTAL|Text-only health warning labels|Individuals in this trial arm will see text-only health warning labels on sugar-sweetened beverages.
62847945|NCT03725241|EXPERIMENTAL|Experimental: Glutathione|Intervention: Dietary Supplement: Glutathione supplement
62061014|NCT01633801|OTHER|High flows|
62061015|NCT01633801|OTHER|oxygen therapy|
62061016|NCT01750762|EXPERIMENTAL|Lenalidomide|Dose escalation. Starting dose is 10 mg/day for 3 weeks followed by 1 week off (1 cycle). Subject will receive a total of 3 cycles.
62061017|NCT05542290|EXPERIMENTAL|With capsular tension ring implantation|We performed phacoemulsification lens extraction and intraocular lens implantation with capsular tension ring implantation combined with goniosynechialysis.
62847946|NCT03794830|EXPERIMENTAL|manipulation group (MG)|Patients were treated with sacroiliac joint osteopathic semidirect manipulation twice a week every 3 to 4 days over a period of time of 3 weeks
62448628|NCT04127409|EXPERIMENTAL|Control Chicken-meat & Omega-3 Eggs|Participants will be provided with control chicken-meat and omega-3-PUFA enriched eggs, and will be requested to eat at least three portions/week of the control chicken-meat, and to eat at least three omega-3-enriched eggs/week, for 6 months.
62847947|NCT03794830|ACTIVE_COMPARATOR|electrotherapy group (EG)|Patients were treated with micro-waves (circular antenna in lumbar area, pulsating-mode 120W for 12 minutes) and later conventional analgesic TENS (80Hz frequency, 30 minutes) 5 days per week over a period of time of 3 weeks (15 sessions of electrotherapy).
62847948|NCT02565784|EXPERIMENTAL|Intradermal injection|Restylane and/or Perlane
62847949|NCT03617328|EXPERIMENTAL|Arm A: 6MHP/Montanide ISA-51 + polyICLC + CDX-1127|200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously on days 1, 8, 15, and 36. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176. CDX-1127 (3mg/kg) will be administered intravenously on days 1, 36, and 78.
62847950|NCT03617328|EXPERIMENTAL|Arm B: 6MHP/Montanide ISA-51 + polyICLC|200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously on days 1, 8, 15, and 36. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176.
62847951|NCT04721080||COPD patients with tuberculous sequelae|COPD patients with tuberculous sequelae
62847952|NCT04721080||COPD patients without tuberculosis sequela|COPD patients with tuberculous sequelae
62847953|NCT03060980|EXPERIMENTAL|Experimental: Group 1|ITCA 650 20/60 mcg/day
62061018|NCT05542290|OTHER|Without capsular tension ring implantation|We performed phacoemulsification lens extraction and intraocular lens implantation without capsular tension ring implantation combined with goniosynechialysis.
62061019|NCT04121884|EXPERIMENTAL|ART Treatment|A broad patient representation of male and female adults; aged \> 18 years; English speaking; and significant clinical symptoms of any of the following conditions: PTSD, Depression, ASD, Complicated Grief, and Alcohol Abuse.
62061020|NCT04737109|EXPERIMENTAL|Phase I De-Escalation Cohort: ADT + Ipatasertib + Darolutamide|Cycle 0 Days 1-7: Ipatasertib Monotherapy + Androgen Deprivation Therapy (ADT) Cycle 1+: Ipatasertib + Darolutamid + ADT
62061021|NCT04737109|EXPERIMENTAL|Phase II: ADT + Ipatasertib + Darolutamide|All Cycles: Ipatasertib + Darolutamide + ADT
62061022|NCT03779178|EXPERIMENTAL|Landiolol group|Landiolol perfusion in incremental doses (range 0.5 to 10 µg/kg/min) over 2 hours
62448629|NCT04127409|EXPERIMENTAL|Omega-3 Chicken-meat & Control Eggs|Participants will be provided with omega-3-PUFA enriched chicken-meat and control eggs, and will be requested to eat at least three portions/week of the omega-3-PUFA enriched chicken-meat, and to eat at least three control eggs/week, for 6 months.
62448630|NCT04127409|EXPERIMENTAL|Omega-3 Chicken-meat & Omega-3 Eggs|Participants will be provided with omega-3-PUFA enriched chicken-meat and omega-3-PUFA enriched eggs, and will be requested to eat at least three portions/week of the omega-3-PUFA enriched chicken-meat, and to eat at least three omega-3-PUFA enriched eggs/week, for 6 months.
62847954|NCT03060980|EXPERIMENTAL|Experimental: Group 2|Empagliflozin 10 mg/day and 25 mg/day
62847955|NCT03060980|EXPERIMENTAL|Experimental: Group 3|Glimepiride 1-6 mg/day
62847956|NCT02011724|EXPERIMENTAL|Apligraf|
62847957|NCT00488683|EXPERIMENTAL|MenACWY-CRM and Routine Vaccines (Group 1)|Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 13 months), and 1 dose each of MMR and Hib (booster) at 13 months.
62847958|NCT00488683|EXPERIMENTAL|MenACWY-CRM and Routine Vaccines (Group 2)|"Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 12 months), and 1 dose each of MMR and Hib (booster) at 13 months.~This group had an additional blood draw at the time of enrollment."
62847959|NCT00488683|EXPERIMENTAL|MenACWY-CRM and Routine Vaccines (Group 3)|"Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 12 months), and 1 dose each of MMR and Hib (booster) at 13 months of age.~This group had an additional blood draw at 6-7 days after third dose of MenACWY-CRM."
62061023|NCT03779178|PLACEBO_COMPARATOR|Placebo group|Placebo perfusion in incremental doses (range 0.03 to 0.6 mL/kg/h) over 2 hours
62061024|NCT03351738|PLACEBO_COMPARATOR|Placebo|Participants will receive subcutaneous (SC) dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
62061025|NCT03351738|EXPERIMENTAL|MEDI5884 50 mg|Participants will receive SC dose of MEDI5884 50 mg on Days 1, 31, and 61.
62061026|NCT03351738|EXPERIMENTAL|MEDI5884 100 mg|Participants will receive SC dose of MEDI5884 100 mg on Days 1, 31, and 61.
62061027|NCT03351738|EXPERIMENTAL|MEDI5884 200 mg|Participants will receive SC dose of MEDI5884 200 mg on Days 1, 31, and 61.
62061028|NCT03351738|EXPERIMENTAL|MEDI5884 350 mg|Participants will receive SC dose of MEDI5884 350 mg on Days 1, 31, and 61.
62061029|NCT03351738|EXPERIMENTAL|MEDI5884 500 mg|Participants will receive SC dose of MEDI5884 500 mg on Days 1, 31, and 61.
62847960|NCT04140578|EXPERIMENTAL|Antibiotic|Participate will be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration
62847961|NCT04140578|NO_INTERVENTION|Control|Participate will not be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration
62061030|NCT01481545|EXPERIMENTAL|preoperative chemoradiotherapy|Preoperative radiation therapy and combination chemotherapy plus bevacizumab
62265036|NCT06065852||Nephrotic Syndrome Rare Disease Group|"To compile a comprehensive UK registry of childhood and adult Nephrotic Syndrome, which includes detailed clinical information, laboratory results and genetic testing information where available. The information will be available to the patients/parents, their clinicians, and, in an anonymised form, to the Nephrotic Syndrome Rare Disease Group for research purposes.~To investigate the underlying cause of Nephrotic Syndrome by comprehensive genetic testing of all patients (with full informed consent), and the study of patient plasma for biomarkers of disease To inform patients about the latest research and educational advances regarding the disease To put patients in touch with recognised support groups and charities To develop treatment and investigation guidelines for clinicians and patients To enable clinical trials to be designed and carried out to further management of the disease"
62448631|NCT06413537|ACTIVE_COMPARATOR|Experimental: Active SPG601 to be administered to participants with Fragile X Syndrome|Participants with Fragile X Syndrome will be randomized to receive SPG601 or placebo (8 capsules of 100 mg) one time on days 1 and 8 of the study.
62847962|NCT03812822|EXPERIMENTAL|Insole Group|Gait and foot posture analysis with and without the insole.
62847963|NCT03812822|NO_INTERVENTION|Control Group|Gait and foot posture analysis.
62847964|NCT01785992|OTHER|Irosustat (Single arm study)|Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or the development of unacceptable toxicities.
62448632|NCT06413537|PLACEBO_COMPARATOR|Placebo Comparator: Placebo comparator to be administered to participants with Fragile X Syndrome|Participants with Fragile X Syndrome will be randomized to receive SPG601 or placebo (8 capsules of 100 mg) one time on days 1 and 8 of the study.
62847965|NCT05301478|EXPERIMENTAL|Diabetic with elevated plantar pressure|Diabetic with elevated plantar pressure
62847966|NCT04713397||LLD group|Patients who have functional scoliosis due to structural LLD
62847967|NCT04713397||LLD concurrent with AIS|Patients who have structural LLD concurrent with AIS
62847968|NCT04158934||Haemophilia A Group|Participants with haemophilia A in the study will receive ADYNOVI/ADYNOVATE prescribed prophylactically by physicians based on their standard clinical practice and in accordance with the national summary of product characteristics (SmPC).
62847969|NCT02887118||Common arm|Children with sickle cell anemia will be included. Blood samples of all the included patients will be collected during a day-hospitalization for a planned chek-up. For all these patients the number of dense erythrocytes will be evaluated
62847970|NCT01192009|EXPERIMENTAL|Immobilization and Leucine|
62448633|NCT06163703|EXPERIMENTAL|Intervention|Participants in the intervention arm will receive a 12-session parent-based prevention program based on Family Life Skills Triple P.
62448634|NCT06163703|NO_INTERVENTION|Waitlist Control|Participants in the waitlist control arm will not receive any intervention during the clinical trial. They will be placed on a waitlist and then offered the intervention once post assessments are complete.
62448635|NCT02328781|EXPERIMENTAL|Experimental|Drug-eluting stent
62621783|NCT06179043|EXPERIMENTAL|Graphic warning labels|Individuals in this trial arm will see graphic health warning labels on sugar-sweetened beverages.
62061031|NCT03549884|EXPERIMENTAL|Delayed cord clamping (DCC)|Cord clamping will be performed after 60 seconds of life
62061032|NCT03549884|ACTIVE_COMPARATOR|Early cord clamping (ECC)|Cord clamping will be performed within 10 seconds of life
62061033|NCT03767725|EXPERIMENTAL|Treatment|Phase 1 Clinical Study of The patients undergo leukapheresis. The patients then receive fludarabine and cyclophosphamide on days-5 to-3. Subjects will receive (0.6-60)x10E8 transduced CART cells as a split dose over three days as follows: Day 0, 10% fraction: (0.06-6)x10E8 CART19 cells, Day 1, 30% fraction: (0.18-18)x10E8 CART19 cells, Day 2, 60% fraction: (0.36-36)x10E8 CART19 cells.
62621784|NCT00709527|EXPERIMENTAL|1|
62847971|NCT01192009|PLACEBO_COMPARATOR|Immobilization and Placebo|
62847972|NCT06341985||Exclusive Radiotherapy Treatment|Curative radiotherapy treatment using 3 Dimension (3D) conformal or Intensity Modulated Radiation Therapy (IMRT) techniques.
62847973|NCT03663621||Initial survey and interview (Aim 2)|Participants in Aim 2 will be asked to complete an initial 15-minute survey and 20-30 minute semi-structured interview. The purpose of this study is to learn the best ways to support healthful behaviors and weight loss prior to pregnancy. Researchers are also interested in what motivates or prevents women of reproductive age from engaging in a structured weight loss program.
62847974|NCT03663621||Formal weight loss program (Aim 3)|Participants in Aim 3 have expressed interest in referral to the Mass General Weight Center. The purpose of this study is to learn what motivates or prevents women of reproductive age from engaging in a structured weight loss program. Researchers will ask for no more than a half hour of participant's time to complete a 5- minute interview following Orientation at the Weight Center and another 10-minute interview after a participant has participated in a program offered at the Weight Center.
62847975|NCT01859520|EXPERIMENTAL|Swim up, density gradient|swim-up and density gradient sperm preparation techniques in male factor infertility and unexplained infertility groups
62847976|NCT00580671|EXPERIMENTAL|MET/CBT+CM/BPT|Integrated psychosocial counseling. 14 weekly session. Twice weekly urine testing. Abstinence-based incentives based on urine test results. 14 weekly behavioral parenting sessions.
62448636|NCT06412497|EXPERIMENTAL|Arm A: No clonal hematopoiesis|Participants 25 years of age and younger with no clonal hematopoiesis. Active study treatment includes the conditioning regimen followed by the stem cell infusion and GvHD prophylaxis through day +180. Supportive care and follow up activities continue through two years post HCT.
62847977|NCT00580671|EXPERIMENTAL|MET/CBT+CM|Integrated psychosocial counseling. 14 weekly sessions. Twice weekly urine testing. Abstinence-based incentives based on urine test results.
62847978|NCT00580671|ACTIVE_COMPARATOR|MET/CBT|Integrated psychosocial counseling. 14 weekly sessions.
62847979|NCT05025436|EXPERIMENTAL|Acupoint Laser Group|Each subject in the experimental group was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) interventional low-energy laser (Erger laser pen) acupoint stimulation, set wavelength 810nm +/- 10%, power 200mW, select Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module according to acupoints, treatment time is 30 seconds per acupoint, and the treatment dose is 3 joules per acupoint three times a week. After a period of 4 weeks, pause 2 After two weeks, the two groups crossed over and carried out 4 weeks of intervention.
62847980|NCT05025436|NO_INTERVENTION|Control Group|Each subject in the control group was given the same main acupoints (5 acupoints) and constitution matching acupoints (1-2 acupoints) without energy acupoint care (therapeutic dose is 0 joules per acupoint), three times a week, after 4 weeks After a two-week suspension, the two groups crossed over for another four-week intervention.
62448637|NCT06412497|EXPERIMENTAL|Arm B: Clonal hematopoiesis|Participants 25-75 years old and/or with clonal hematopoiesis. Active study treatment includes the conditioning regimen followed by the stem cell infusion and GvHD prophylaxis through day +180. Supportive care and follow up activities continue through two years post HCT.
62448638|NCT03493100|EXPERIMENTAL|oral nutritional supplementation|This group receives optimized nutritional support, by ONS for a period of four weeks.
62448639|NCT03493100|OTHER|Control|The control group will receive treatment according to usual care.
62448640|NCT03752593||Obese|Patients with a BMI of greater than 30 who are presenting to the hospital for any surgical procedure requiring general anesthesia
62448641|NCT03752593||Non-Obese|Patients with a BMI of less than 30 who are presenting to the hospital for any surgical procedure requiring general anesthesia
62448642|NCT05210348||HPV positive group|
62448643|NCT05210348||HPV negative group|
62448644|NCT05210348||Disease group (clinical diagnosis positive)|CIN2 and above disease cases, including HSIL or (CIN2, CIN2-3, CIN3) cervical cancer.
62448645|NCT05210348||Control group (clinical diagnosis is negative)|includes other benign lesions such as inflammation, polyps, and HPV-negative cases without pathological diagnosis and no abnormalities in TCT.
62448646|NCT04095299|ACTIVE_COMPARATOR|A: Standard chemoradiotherapy|50.4 Gy to the tumor and elective volume. The dose is given in 28 fractions on weekdays concomitantly with capecitabine 825 mg/m2 twice daily on weekdays.
62448647|NCT04095299|EXPERIMENTAL|B: High-dose radiotherapy|62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume. The dose is given in 28 fractions on weekdays concomitantly with capecitabine 825 mg/m2 twice daily on weekdays
62448648|NCT04501471|EXPERIMENTAL|SAAF-T|Participants received a 5 session, 10-hour family centered prevention program designed to prevent substance use, conduct problems, and risky sexual behavior
62621785|NCT06611488||Normal sleepiness group|Participants with normal daytime sleepiness
62847981|NCT01738646|EXPERIMENTAL|Vorinostat & Bevacizumab|Patients will be administered bevacizumab every 2 weeks and vorinostat will be taken on days 1-7 and 15-21 of each 28-day cycle at 400 mg per day.
62847982|NCT02606149|ACTIVE_COMPARATOR|Standard of information|Information on chemotherapy as done in routine practice following national and international guidelines
62847983|NCT02606149|EXPERIMENTAL|Truthful information on chemotherapy risks|Information on the potential role of anticancer chemotherapy in worsening life-threatening conditions
62847984|NCT00637780|EXPERIMENTAL|1|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 6 days
62847985|NCT02086396|EXPERIMENTAL|pumpkin seed flour|The pumpkin seed flour group received 20g/day of pumpkin seed flour during 12 weeks
62847986|NCT02086396|PLACEBO_COMPARATOR|Cassava flavored flour|The placebo group (cassava flour flavored) received 20g/day of cassava flour flavored during 12 weeks.
62448649|NCT04501471|PLACEBO_COMPARATOR|Fuel for Families|Participants received a 5 session, 10 hour family centered program that focused on healthy nutrition and exercise.
62448650|NCT03145532|EXPERIMENTAL|Real tDCS plus robotic training|Children will receive 20 min of real tDCS stimulation per session, followed by robotic training for 1 hr.
62448651|NCT03145532|SHAM_COMPARATOR|Sham tDCS plus robotic training|Children will receive 20 min of sham tDCS stimulation per session, followed by robotic training for 1 hr.
62061034|NCT05256030|EXPERIMENTAL|Control-Traditional Rehabilitation Group|"This group will receive a 6-week neurorehabilitation program that includes stretching for spasticity inhibition, strengthening of the antagonist muscle, autogenic inhibition methods, as well as conscious-unconscious balance training and gait training, which are routinely applied in physical therapy and rehabilitation units. The treatment will be applied 5 days a week.~In addition to the Bobath approach, the subjects in the study group received WBV for 20 minutes a day, 2 days a week. The frequency of the device was increased by 5 Hz every week, starting the treatment with 30 Hz. Whole body vibration application was performed on a platform (Power Plate Pro5®) that provides vertical vibration. Two different practice positions were chosen as standing and semi-squatting. In order to prevent muscle fatigue, the set consisting of 1 minute of application - 1 minute of rest in each position was applied for a total of 10 minutes with 5 repetitions"
62061035|NCT05256030|EXPERIMENTAL|Study-Neurodevelopmental Therapy Group|Function-oriented Neurodevelopmental Therapy will be applied to the subjects included in the study and randomly assigned to the study group in different positions such as supine, prone, sitting, standing for 6 weeks, 5 sessions per week, and the goal will be to achieve the task at different speeds. Spasticity, balance and gait exercises will be started at slow speeds, at muscle level, and in the following sessions, movement speed will be increased in relation to the patient's compliance, and global balance and gait exercises will be performed.
62061036|NCT03853460|ACTIVE_COMPARATOR|epidural group|ULTRASOUND GUIDED thoracic epidural at T 12 WILL BE INSERTED before anaesthesia induction
62061037|NCT03853460|ACTIVE_COMPARATOR|quadus lumborum group|bilateral ultrasound guided quadratus lumborum catheter will be inserted before anaesthesia induction
62448652|NCT01253720|EXPERIMENTAL|PACE CALL/Fit4Life|"Fit4Life intervention activities:~Website: Provides weekly nutrition, physical activity, and weight loss information.~Counseling Calls: Participants and their parents will get phone calls from their Health Coach to assess progress \& problems.~Health Coach Question \& Answer: Participants will be assigned a Health Coach that they can contact at any time to ask questions or express any concerns.~Text \& Picture Messages: Participants will receive daily text messages to help remind them of being healthy. Messages will relate to the weekly topics and general checking in questions.~Parent Materials: Parents will receive a packet of printed materials that relate to parenting skills regarding being a healthy role model for their child and healthy eating and exercise tips."
62448653|NCT01253720|NO_INTERVENTION|Control|The Control group will receive monthly mailings on basic nutrition and physical activity information.
62448654|NCT00883025||1|OSAS patients
62621786|NCT06611488||Excessive daytime sleepiness group|Participants with excessive daytime sleepiness group
62621787|NCT05977101|EXPERIMENTAL|MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray|Specifications: 5mg/mL, 5mL/ bottle; Provided by Chongqing Mingdao Haoyue Biotechnology Co., LTD
62448655|NCT00883025||2|no OSAS Patient
62448656|NCT02272868|EXPERIMENTAL|Fecal microbiome transplant|Pretransplant(Rifaximin 400mg tid x 10 days + omeprazole 20 mg night before transplant and day of transplant + miralax 17g tid x 2 days) + Fecal Microbial Transplant
62448657|NCT02272868|PLACEBO_COMPARATOR|Normal saline|Pretransplant(Rifaximin 400mg tid x 10 days + omeprazole 20 mg night before transplant and day of transplant + miralax 17g tid x 2 days) + Normal saline
62448658|NCT02052609|EXPERIMENTAL|KHK4827 140mg SC|
62448659|NCT02052609|EXPERIMENTAL|KHK4827 210mg SC|
62448660|NCT00424489|EXPERIMENTAL|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation will be performed after conditioning
62448661|NCT01000896|EXPERIMENTAL|AZD0530 + carboplatin and paclitaxel|AZD0530 in combination with carboplatin and paclitaxel
62621788|NCT05977101|PLACEBO_COMPARATOR|MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient|Specifications: 0mg/mL, 5mL/ bottle; Provided by Chongqing Mingdao Haoyue Biotechnology Co., LTD
62621789|NCT01693770|OTHER|MRgFUS|High intensity focused ultrasound energy, delivered under the guidance of the MR images (MgFUS) allows for a predefined amount of energy to be delivered in the desired target (Metastasis). Bone readily absorbs focused ultrasound energy resulting in a thermo-related neurolysis of the periostium with consequent pain palliation. The amount of energy delivered can be modulated with the objective to penetrate cortical space and obtain necrosis of the metastasis thus preventing local recurrence.
62847987|NCT02829801|EXPERIMENTAL|AAT arm|AAT and cognitive stimulation and rehabilitation of social tie.
62847988|NCT02829801|OTHER|control group|Cognitive stimulation and rehabilitation of social tie.
62621790|NCT01834664|OTHER|STEM CELL|Transfer of autologous stem cell \[MNCs \]intrathecally
62621791|NCT02731989||study group|The surgeon will estimate the size difference between the undescended and the normally located testis. Independently the ultrasonographer will measure the true size of both testes in the study group.
62621792|NCT02731989||Control group|The same measurments will be done by the surgeon and the ultrasonographer on boys without cryptorchism.
62847989|NCT02165267|EXPERIMENTAL|Arm 1: VRC01 (6 IV infusions)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Day 0, followed by IV infusions of 20 mg/kg of VRC01 administered in 100 mL of normal saline over at least 30 minutes to 1 hour at Days 28, 56, 84, 112, and 140.
62847990|NCT02165267|EXPERIMENTAL|Arm 2: VRC01 (3 IV infusions)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Day 0 and over at least 30 minutes to 1 hour at Days 56 and 112.
62847991|NCT02165267|EXPERIMENTAL|Arm 3a: VRC01 (1 IV infusion plus multiple SC injections)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Week 0, followed by SC injection of 5 mg/kg of VRC01 administered every 2 weeks for 20 weeks.
62448662|NCT00090038|EXPERIMENTAL|1|Rituximab
62448663|NCT00090038|NO_INTERVENTION|2|No drug
62621793|NCT05315648|EXPERIMENTAL|General anesthesia group|Patients in GA group will receive general anesthesia combined with FNB. All patients received routine anesthesia and surgical protocols. GA will be induced by intravenously administering propofol 2-4 mg/kg, cisatracurium 0.2mg/kg, sufentanil 0.2-0.3 μg/kg and maintained with remifentanil at 0.15-0.2 μg/kg/min and 2%-3% sevoflurane to keep bispectral index (BIS) values at 40 - 60. FNB will be performed under ultrasound-guieded and combined with nerve stimulation. Using an in-plane technique, a 10-cm long 18- gauge (G) Tuohy needle will be inserted in the lateral to medial direction towards the femoral nerve (FN). As the needle is being advanced toward the FN, the nerve stimulator is set at 1 mA, 0.1-millisecond pulse duration, and 2-Hz frequency. When the muscle contraction of the quadriceps muscle is identified, the current is reduced to 0.5 mA. After the negative aspiration, 20 mL of ropivacaine 0.375% is injected.
62621794|NCT05315648|EXPERIMENTAL|Non-general anesthesia group|"Patients in NGA group will receive combined spinal-epidural anesthesia（CSEA）at L3 to L4 interspace with 3.0 ml of 0.5% hyperbaric ropivacaine followed with FNB , and without sedation. The FNB will be performed under aseptic precautions using ultrasound guidance and nerve stimulation. A high frequency linear ultrasound transducer 5-12 MHz (Sonosite, Inc. Bothell WA 98021 USA) was placed on the inguinal crease to identify the femoral artery and nerve. Using an in-plane technique, a 10-cm long 18- gauge (G) Tuohy needle connected to the nerve stimulator will be inserted in the lateral to medial direction towards the femoral nerve. When the muscle contraction of the quadriceps muscle and negative aspiration are identified, 20 mL of ropivacaine 0.375% is injected.~If the CSEA analgesia is invalid (two times of epidural remedial analgesia) , change non-general anesthesia to general anesthesia, and the subjects withdrew from the trial."
62847992|NCT02165267|PLACEBO_COMPARATOR|Arm 3b: Placebo for VRC01 (infusion plus injections)|Participants will receive an IV infusion of sodium chloride placebo administered in 100 mL of normal saline over 1 hour at Week 0, followed by SC injection of placebo for VRC01 administered every 2 weeks for 20 weeks.
62847993|NCT02165267|EXPERIMENTAL|Arm 4: 10 mg/kg of VRC01 (3 IV infusions)|Participants will receive an IV infusion of 10 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Month 0 and over at least 30 minutes to 1 hour at Months 2 and 4.
62847994|NCT02165267|EXPERIMENTAL|Arm 5: 30 mg/kg of VRC01 (3 IV infusions)|Participants will receive an IV infusion of 30 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Month 0 and over at least 30 minutes to 1 hour at Months 2 and 4.
62847995|NCT06067620|EXPERIMENTAL|Robotic right hemicolectomy|Robotic right hemicolectomy with intracorporeal anastomosis and extraction through a C-section (fully minimally invasive right hemicolectomy)
62061038|NCT02124148|EXPERIMENTAL|Prexasertib + Cisplatin (Part A)|"Part A: Prexasertib and cisplatin administered intravenously (IV) once every 21 days.~Part A2: Prexasertib and cisplatin administered IV every 21 days; G-CSF administered subcutaneously (SC) starting approximately 24 hours after each prexasertib dose every 21 days.~Part A3: Cisplatin administered IV on day one and prexasertib administered IV on day two once every 21 days.~Part A Expansion: Part A, A2, and/or A3 may be expanded at the recommended dose.~Participants may remain on treatment until discontinuation criteria are met."
62265037|NCT06065852||Pregnancy and Chronic Kidney Disease Rare Disease Group|"Increasing numbers of women with chronic kidney disease (CKD) are thinking about pregnancy. It has been known for over 50 years that CKD can affect how a pregnancy progresses and that a pregnancy can have a negative effect on damaged kidneys. However, outcomes have been improving decade by decade.~The group will develop care pathways for women with CKD throughout pregnancy.~Specific areas of research interest include:~What is the best blood pressure target during pregnancy for women with CKD? Is preconception counselling for women with CKD useful? How should we prevent blood clots during pregnancy in women with CKD? What is the effect of protein loss in the urine on pregnancies? Which women with CKD are most likely to develop pre-eclampsia? What is the best way to measure kidney function in pregnant women with CKD? What happens to mothers with CKD and their babies after pregnancy?"
62448664|NCT01073995|ACTIVE_COMPARATOR|Kenalog and Sensorcaine|"The following drugs will be administered during a one time injection of the appropriate spinal level based off clinical and radiographic information:~Intervention:~Kenalog 40 mg/ml and Sensorcaine 0.25% 1cc"
62621795|NCT05709912|EXPERIMENTAL|CARE App|"Participants randomized to the CARE app + usual care will complete the following:~* Questionnaires at baseline, Day 10, Day 60, and Day 100 post-HCT~* use the CARE app from enrollment up to 60 days post-HCT: the CARE app includes 5 contains 5 modules and a 6th optional module~* receive usual care as per HCT practice which entails meeting with a transplant social worker prior to HCT and as needed for extra visits"
62621796|NCT05709912|ACTIVE_COMPARATOR|Usual Care|"Participants randomized to usual care will complete the following:~* Questionnaires at baseline, Day 10, Day 60, and Day 100.~* receive usual care as per HCT practice, which entails meeting with a transplant social worker prior to HCT and as needed for extra visits."
62621797|NCT03675529|EXPERIMENTAL|High Intensity Interval Training bout|Patients randomized to this group will perform a wattmax test immediately followed by 4 intervals of high and low intensity based on percentage of wattmax. Immediately after the exercise bout is finished patients will receive one dose of pimonidazole hydrochloride (500 mg per m2 body surface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate by radical prostatectomy the following day.
62847996|NCT06067620|ACTIVE_COMPARATOR|Laparoscopic right hemicolectomy|Laparoscopic right hemicolectomy with extracorporeal anastomosis and extraction through midline (standard of care)
62847997|NCT02456363|EXPERIMENTAL|NSAIDs(+) and sulfasalazine(+)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine
62061039|NCT02124148|EXPERIMENTAL|Prexasertib + Cetuximab (Part B)|"Part B: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days.~Part B2: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days; G-CSF administered SC starting approximately 24 hours after each prexasertib dose every 14 days.~Part B3: Cetuximab administered IV with prexasertib administered IV once every 14 days.~Part B Expansion: Part B, B2 and/or B3 may be expanded at the recommended dose.~Participants may remain on treatment until discontinuation criteria are met."
62265038|NCT06065852||Pure Red Cell Aplasia Rare Disease Group|To increase awareness of Pure Red Cell Aplasia (PRCA). To streamline the diagnostic process. To investigate and implement measures to reduce the incidence of the disease. To empower affected patients in seeking help and support. To establish international collaborations to promote research into the causes and management of the disease.
62265039|NCT06065852||Retroperitoneal Fibrosis Rare Disease Group|"The Retroperitoneal Fibrosis (RPF) Rare Disease Group aims to:~establish a registry of patient data and biological samples (plasma, urine, biopsy tissue) collate available information on RPF and develop new information for both patients and carers improve upon observational data in terms of the presentation, natural history and outcomes in RPF patients nationally develop multi-disciplinary consensus care pathways and clinical guidelines for RPF develop a strategy for patient recruitment to trials"
62265040|NCT06065852||Tuberous Sclerosis Rare Disease Group|"There are a number of unanswered questions relating to Tuberous Sclerosis Complex (TSC), which the RDG hopes to be able to address:~What is the frequency and severity of renal involvement in patients with TSC, particularly as they grow older? What is the frequency of multiple renal AMLs in individuals without other features of TSC? What is the frequency of renal impairment or renal haemorrhage in patients with renal AMLs, and how does this relate the lesion size, number and distribution? What is the frequency of bleeding or renal impairment in patients with multiple renal AMLS treated with mTOR inhibitors or other interventions? What is the frequency of impaired GFR (CKD stage 2 or higher), and what are the causes? What is the efficacy of treatment of renal AMLs in preventing bleeding and preserving GFR? What are the optional treatment regimes with mTOR inhibitors?"
62265041|NCT06065852||Tubulopathy Rare Disease Group|The newly renamed Tubulopathy Rare Disease Group, previously known as Hypokalaemic Alkaloses, has recently expanded it's inclusion criteria for RaDaR to include a large number of conditions.
62265042|NCT06065852||Vasculitis Rare Disease Group|"The Vasculitis Rare Disease Group has developed from the UK and Ireland Vasculitis registry initiative UKIVAS. The group members represent Vasculitis units across the UK and participate in Vasculitis research and care.~We have a number of aims:~To promote collaboration and sharing of expertise and resources in clinical research~To develop guidelines for the management of Vasculitis~To develop a nationwide registry of anonymized demographic, treatment and outcome data for patients with Vasculitis in the UK and Ireland~To develop high quality patient and clinician information via the Rare Renal and Vasculitis UK websites~To link with interested patient groups, research collaborations and industry."
62265043|NCT04795232|NO_INTERVENTION|Control|Participants in this arm will receive no intervention
62265044|NCT04795232|EXPERIMENTAL|COD45|Participants in this arm will participate in a COD training session consisted of 45 degrees changes of direction
62265045|NCT04795232|EXPERIMENTAL|COD90|Participants in this arm will participate in a COD training session consisted of 90 degrees changes of direction
62265046|NCT02318667|EXPERIMENTAL|Golimumab treatment|Golimumab 200 mg initially administered by subcutaneous (SC) injection at Week 0, followed by 100 mg at Week 2 and then 50 mg or 100 mg every 4 weeks (per prescribing information) up to 16 weeks.
62265047|NCT00000299|ACTIVE_COMPARATOR|buprenorphine|depot buprenorphine
62448665|NCT01073995|PLACEBO_COMPARATOR|Saline|Saline injections will be used to mimic the Steroid dose
62448666|NCT02584140|OTHER|AEGIS|All participants will be assigned to this arm of the study.
62448667|NCT00156949|EXPERIMENTAL|Epoetin alfa DT|
62448668|NCT04469738|EXPERIMENTAL|SCS off|
62448669|NCT04469738|EXPERIMENTAL|SCS on|
62621798|NCT03675529|NO_INTERVENTION|Controls (usual care)|Patients randomized to the control group will not be doing any exercise, but will after approximately 35 min from baseline blood sampling receive one dose of pimonidazole hydrochloride (500 mg per m2 bodysurface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate by radical prostatectomy the following day.
62621799|NCT05411991|EXPERIMENTAL|Intervention arm|"Application of a standardized diuretic schedule with following key components:~* UNa assessment in spot urine sample after every bolus of loop diuretics with continuation of intravenous diuretics until absence of clinical signs of fluid overload AND UNa \<80 mmol/L~* Loop diuretic dosing according to estimated glomerular filtration rate (eGFR) with higher dose for lower eGFR~* Upfront use of intravenous acetazolamide 500 mg OD unless hypernatremia or metabolic acidosis~* Upfront use of oral chlorthalidone 50 mg OD if eGFR \<30 mL/min/1.73m² OR hypernatremia~* Full nephron blockade with intravenous acetazolamide 500 mg OD, intravenous bumetanide 4 mg TID, oral chlorthalidone 100 mg OD, and intravenous canrenoate 200 mg OD in case of diuretic resistance, defined as UNa \<80 mmol/L and persistent clinical signs of fluid overload~* Provision of 500 mL intravenous Dextrose 5% with 3 g MgSO4 and 40 mmol KCl daily during intravenous diuretics"
62621800|NCT05411991|ACTIVE_COMPARATOR|Control arm|Usual care for AHF. It is recommended to administer an intravenous loop diuretic dose at least BID (or through continuous infusion), with the aim of achieving a urine output 3-5 L per day until the patient is considered in an optimal volume status as is recommended by current guidelines. Urine electrolyte assessment in the control arm is not allowed as it is a key component of the studied intervention.
62621801|NCT03956030|EXPERIMENTAL|Intervention|Intervention group will receive educational handout on contraception.
62621802|NCT03956030|EXPERIMENTAL|Control|Control group will receive educational handout on nutrition.
62621803|NCT02797860||transabdominal cervicoisthmic cerclage|Second Stage of Labor pregnant women who are scheduled for transabdominal cervicoisthmic cerclage due to incompetent internal os of cervix
62621804|NCT02797860||control|women of childbearing age between 20 and 45
62621805|NCT03332095|EXPERIMENTAL|Cohort 1: DOR|Participants received a single dose of DOR at study entry (Day 0).
62621806|NCT03332095|EXPERIMENTAL|Cohort 2: DOR/3TC/TDF|Participants received DOR/3TC/TDF from Day 0 through Week 96.
62621807|NCT06058273|EXPERIMENTAL|OPHL patients|
62621808|NCT06467539|EXPERIMENTAL|Experimental|DAOIB plus Antioxidant agent (AO)
62061040|NCT02124148|EXPERIMENTAL|Prexasertib + Pemetrexed (Part C)|"Part C: Pemetrexed administered IV on day one and prexasertib administered IV on day one and two every 21 days.~Participants may remain on treatment until discontinuation criteria are met."
62061041|NCT02124148|EXPERIMENTAL|Prexasertib + 5-FU (Part D)|"Part D: Leucovorin administered IV on day one, 5-FU administered IV bolus on day one and by continuous IV on days one to three (46 hours), and prexasertib administered IV on day three every 14 days.~Participants may remain on treatment until discontinuation criteria are met."
62448670|NCT02127996|PLACEBO_COMPARATOR|Normal Saline|Infusion of Normal Saline during Percutaneous Coronary Intervention
62621809|NCT06467539|PLACEBO_COMPARATOR|Placebo Comparator|DAOIB plus Placebo
62621810|NCT03181685|ACTIVE_COMPARATOR|Treatment S (Subcutaneous)|Progesterone 25 mg subcutaneous (a single administration per day) from the day of oocyte retrieval. Controlled ovarian stimulation (COS) will be performed with recombinant FSH and cetrorelix acetate.
62621811|NCT03181685|ACTIVE_COMPARATOR|Treatment V (Vaginal)|Micronized progesterone 200 mg (3 vaginal administrations per day) from the day of oocyte retrieval. Controlled ovarian stimulation (COS) will be performed with recombinant FSH and cetrorelix acetate.
62847998|NCT02456363|EXPERIMENTAL|NSAIDs(+) and sulfasalazine(-)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine
62061042|NCT02124148|EXPERIMENTAL|Prexasertib + LY3023414 (Part E)|"Part E: Prexasertib administered IV on day one and LY3023414 administered orally twice daily every 14 days.~Part E will be expanded at the recommended dose in participants with advanced or metastatic cancer, participants with PIK3CA mutations (E2 expansion), or with advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer (E3 expansion).~Participants may remain on treatment until discontinuation criteria are met."
62061043|NCT03761498||Normal Growth|Require less than or equal to 110 kcal/kg/day to maintain growth curve
62061044|NCT03761498||Slow Growth|Require more than 110 kcal/kg/day to maintain growth curve
62265048|NCT00000299|EXPERIMENTAL|buprenorphine and ultra-low dose naloxone|depot buprenorphine and naloxone
62265049|NCT03798964||Elective term cesarean|Low-risk women undergoing elective term cesarean section
62061045|NCT05965843||chronic liver disease|No additional interventions for this group.
62061046|NCT05965843||malignant tumor|No additional interventions for this group.
62265050|NCT03798964||Term vaginal delivery|Low-risk women undergoing term vaginal delivery
62265051|NCT03798964||Preterm vaginal delivery|Women undergoing preterm vaginal delivery
62265052|NCT02350556|OTHER|hemiplegic patients|Dynamic Avoidance Task
62265053|NCT02350556|OTHER|healthy volunteers|Dynamic Avoidance Task
62621812|NCT04041492|EXPERIMENTAL|Group 1|Vitamin D3 1000UI + Placebo (Calcined Magnesia).
62621813|NCT04041492|EXPERIMENTAL|Group 2|Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
62621814|NCT04041492|ACTIVE_COMPARATOR|Group 3|Vitamin D3 1000UI + Vitamin K2 100 mcg
62621815|NCT00121290|EXPERIMENTAL|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes once daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62621816|NCT03815435|EXPERIMENTAL|Controlled hypotension|Controlled hypotension will be administered according to the clarity of the surgical field evaluated according to the Boezaart scale (1995).
62621817|NCT05184387||Prospective epidemiological cohort|Urban and suburban population of healthy subjects aged 18-55 years, not vaccinated against influenza
62621818|NCT03058471|ACTIVE_COMPARATOR|methotrexate|mehotrexate 10 mg weekly, to be increased by 5 mg in each visit to a maximum of 25 mg
62621819|NCT03058471|ACTIVE_COMPARATOR|non steroidal anti inflammatory drugs|NSAID in full dose with Pantoprazole. If remission not achieved at 2 months, will be given methotrexate as in methotrexate arm
62847999|NCT02456363|EXPERIMENTAL|NSAIDs(-) and sulfasalazine(+)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of sulfasalazine and no NSAIDs
62265054|NCT03028571|PLACEBO_COMPARATOR|Intact Day|The rates of endogenous glucose appearance (Ra) and peripheral glucose uptake (Rd) will be measured during a regular insulin clamp with concomitant infusion of saline at 48 ml/hr IV
62265055|NCT03028571|EXPERIMENTAL|Blocked Day|The rates of endogenous glucose appearance (Ra) and peripheral glucose uptake (Rd) will be measured during a regular insulin clamp with concomitant infusion of trimethaphan (4mg/min) IV.
62265056|NCT04267874|EXPERIMENTAL|Arm I (BRB nectar, placebo, biospecimen collection)|Patients receive BRB nectar PO BID for weeks 0-4 and then receive placebo PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10.
62265057|NCT04267874|EXPERIMENTAL|Arm II (placebo, BRB nectar, biospecimen collection)|Patients receive placebo PO BID for weeks 0-4 and then receive BRB nectar PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10.
62265058|NCT05386992|EXPERIMENTAL|Anthropometric study of children's feet and healthy standard last design:|"An anthropometric study of the feet of the subjects included in the sample will be carried out. The variables of interest used in this work are collected by digitizing the foot and ankle of each person, as well as through an anonymous questionnaire, which the study volunteers and their parents or legal guardians fill out and deliver.~From the data collected, 5 models of healthy standard last will be produced that are adapted to the anthropometric characteristics of our study population: sports last, boot last, sandal last, ballerina last and moccasin last."
62061047|NCT05965843||autoimmune disease|No additional interventions for this group.
62265059|NCT01825707|EXPERIMENTAL|[14C]-YH4808 200 mg|\[14C\]-YH4808 200 mg
62265060|NCT03620227|EXPERIMENTAL|Beetroot juice|ingestion of beetroot juice before an exercise session.
62265061|NCT03620227|PLACEBO_COMPARATOR|Placebo|ingestion of placebo before an exercise session.
62265062|NCT05870267||Cohort 1 (arms 1-3)|"* Arm 1 will be designed as observational study providing the efficacy and safety of the load applied on osseointegrated fixation by transfemoral BAP fitted with the Power Knee for the whole cohort of 20 participants.~* Arm 2 will be designed as matched case-control study comparing the efficacy and safety the load applied on osseointegrated fixation by transfemoral BAP fitted with Power Knee and usual MPKs (e.g., C-Leg, Genium) for the whole cohort of 20 participants.~* Arm 3 will be designed as matched case-control study comparing the efficacy and safety the load applied on osseointegrated fixation by transfemoral BAP fitted with Power Knee and Rheo Knee XC for a subgroup of 5 participants."
62265063|NCT05870267||Cohort 2 (arm 4)|• Arm 4 will be designed as matched case-control study comparing the efficacy and safety the load applied on osseointegrated fixation by transfemoral BAP fitted with Power Knee for the whole cohort of 20 participants and non-MPKs for another cohort of 10 participants.
62265064|NCT03804294||vitamin D-ART|Infertile couples who undergo their ﬁrst IVF/ICSI and IUI cycle in Reproductive Medicin Center of Peking university Third Hosiptal.
62265065|NCT05139186|EXPERIMENTAL|WL+AI|Colonoscopy in white light and artificial intelligence
62265066|NCT05139186|EXPERIMENTAL|WL|Colonoscopy in white light
62265067|NCT03237104||acute spondylolysis|Athletes who meet the inclusion criteria and consent to participate in the pilot study will be referred directly to PT care for 2 times per week until cleared to return to sport.
62265068|NCT02229500|ACTIVE_COMPARATOR|Control|Inulin control, 10g/d for 7 days. Isotope and appetite measurements on day 7
62265069|NCT02229500|EXPERIMENTAL|Delivery system 1|Delivery system, 28.5% w/w propionate, 10g/d for 7 days. Isotope and appetite measurements on day 7.
62265070|NCT02229500|EXPERIMENTAL|Delivery system 2|Delivery system, 54% w/w propionate, 10g/d for 7 days. Isotope and appetite measurements on day 7.
62265071|NCT02598843|ACTIVE_COMPARATOR|Standard treatment protocol|Cast immobilisation with 4 weeks in equinus cast (non-weight bearing) followed by 4 weeks in semi-equinus cast (non-weightbearing) and 2 weeks in neutral cast (full weightbearing). At this point, the cast is removed and patients mobilise fully weightbearing for a further 2 weeks out of cast, with internal shoe insert heel raise. Commence physiotherapy at 10 weeks, when cast removed.
62621820|NCT01905332|EXPERIMENTAL|Literacy promoting home based program|Those 4 year old children who fall below the cutoff score on the literacy screening will be randomized to either receive standard of care (literacy toolkit) or will be given a referral to a home -based literacy promoting program through the Columbus Metropolitan Library.
62265072|NCT02598843|EXPERIMENTAL|Accelerated rehabilitation|4 weeks in Ossur rebound walking boot with 2 heel wedges (3cm), 2 weeks in Ossur rebound walking boot with 1 heel wedge (1.5cm) and 2 weeks in Ossur rebound walking boot with no heel wedges (neutral position). Fully weightbearing throughout. Commence physiotherapy at 8 weeks.
62265073|NCT04338750|EXPERIMENTAL|Telephone Acceptance and Commitment Therapy Intervention for Caregivers (TACTICs)|Participants in the ACT arm will learn new and more adaptive ways to respond to challenges, including anxiety and the irreversibility of dementia and its behavioral manifestations.
62448671|NCT02127996|EXPERIMENTAL|GLP-1|Infusion of GLP-1 (7-36) amide during elective percutaneous coronary intervention
62448672|NCT01369277|EXPERIMENTAL|Japanese cohort|A total of 12 Japanese healthy subjects will be allocated to receive 3 ascending single doses (100 mg, 300 mg and 750 mg) of PF-04991532 or placebo through 3 dosing periods in a randomization ratio of 3:1.
62621821|NCT01905332|ACTIVE_COMPARATOR|Literacy Toolkit|Children who fall below the cut off score on the GRTR-R will be randomized to either receive a literacy toolkit (current standard of care) or a referral to a home based literacy promoting program. The toolkit will contain age-appropriate books and games.
62621822|NCT04403165|EXPERIMENTAL|Cognitively Normal (CN) Older Adults|
62621823|NCT05347693|EXPERIMENTAL|Sodium Zirconium Cyclosilicate (SZC)|Participants discharged with SZC, as per local label, to manage HK until the end of the outpatient phase
62621824|NCT05347693|ACTIVE_COMPARATOR|Local standard of care (SoC)|Participants discharged with SoC, as per local practice, to manage HK until the end of study.
62848000|NCT02456363|EXPERIMENTAL|NSAIDs(-) and sulfasalazine(-)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) neither NSAIDs nor sulfasalazine
62848001|NCT05856136|EXPERIMENTAL|Ultrasound Shear Wave Elastography Examination - Lower|Subjects identified as being administered low dose opioids during an elective lower extremity orthopedic surgery per standard of care will undergo an ultrasound shear wave elastography examination while performing different breathing techniques.
62848002|NCT05856136|EXPERIMENTAL|Ultrasound Shear Wave Elastography Examination - Mid|Subjects identified as being administered mid dose opioids during an elective lower extremity orthopedic surgery per standard of care will undergo an ultrasound shear wave elastography examination while performing different breathing techniques.
62848003|NCT05856136|EXPERIMENTAL|Ultrasound Shear Wave Elastography Examination - Higher|Subjects identified as being administered higher dose opioids during an elective lower extremity orthopedic surgery per standard of care will undergo an ultrasound shear wave elastography examination while performing different breathing techniques.
62848004|NCT06222788|EXPERIMENTAL|NTP treatment|The patients will be treated with NTP intra-operatively.
62848005|NCT02641340|EXPERIMENTAL|Cycle 1, Cohort 1|Fentanyl Sublingual Spray (FSS) low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
62265074|NCT04338750|ACTIVE_COMPARATOR|minimally-Enhanced Usual Care (mEUC)|Participants randomized to mEUC will receive educational, science-based reading and resources, including a listing of Alzheimer's Association sponsored support groups closest to their home address.
62265075|NCT03044535||Group 1: Longitudinal assessment|Assessments will be performed pre-MCS, 3 months post-MCS and 6 months post-MCS. Participants in this group must be scheduled for MCS implant.
62448673|NCT01369277|EXPERIMENTAL|Weterner Cohort|9 western healthy subjects will be enrolled to receive 2 single ascending doses (300 mg and 750 mg) of PF-04991532 through 2 dosing periods.
62621825|NCT05937516|SHAM_COMPARATOR|Control Group|Nasotracheal intubation will be applied conventionally to patients in this group.
62621826|NCT05937516|ACTIVE_COMPARATOR|Study Group|In the study group (Group S), a guide wire will be inserted into the ETT before intubation and angled 100-120 degrees to the distal end (in the shape of a hockey stick). The angulation will not be sharp but slightly curved and the apex of the angulation will be 2.5-3 cm proximal from the distal end. The ETT will be positioned perpendicular to the face and inserted into the nostril. After the angled part of the ETT passes through the nostrils, it will be directed to caudally according to the angle given to the tip of the ETT. Meanwhile, the ETT will be moved as a whole to prevent the ETT tip from contacting the posterior wall of the nasopharynx. When the ETT tip reaches the oropharynx, the guidewire will be removed and the rest of the intubation will be completed as in the conventional method.
62621827|NCT06486051|EXPERIMENTAL|WZTL002 CAR T-cells|Target dose of 0.85×10\^6 CAR+ cells per kg body weight (target range 0.5 to 1.0×10\^6 CAR+ cells/kg; dose cap 1×10\^8 cells)
62621828|NCT06062095|EXPERIMENTAL|AI arm|AI will be used to diagnose polyps
62848006|NCT02641340|EXPERIMENTAL|Cycle 1, Cohort 2|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
62848007|NCT02641340|EXPERIMENTAL|Cycle 1, Cohort 3|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
62621829|NCT06062095|NO_INTERVENTION|Control arm|Conventional colonoscopy without AI will be perform to diagnose polyps
62848008|NCT02641340|EXPERIMENTAL|Cycle 1, Cohort 4|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
62848009|NCT02641340|EXPERIMENTAL|Cycle 2, Cohort 1|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
62848010|NCT02641340|EXPERIMENTAL|Cycle 2, Cohort 2|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
62848011|NCT02641340|EXPERIMENTAL|Cycle 2, Cohort 3|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
62848012|NCT02641340|EXPERIMENTAL|Cycle 2, Cohort 4|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
62061048|NCT05965843||medical staff|No additional interventions for this group.
62621830|NCT00045734|EXPERIMENTAL|Treatment (imatinib mesylate)|"Patients receive oral imatinib mesylate once or twice daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study/ laboratory biomarker analysis"
62621831|NCT01429441|EXPERIMENTAL|Ocriplasmin|
62848013|NCT02641340|EXPERIMENTAL|Cycle 3, Cohort 1|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
62848014|NCT02641340|EXPERIMENTAL|Cycle 3, Cohort 2|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
62848015|NCT02641340|EXPERIMENTAL|Cycle 3, Cohort 3|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
62061049|NCT02541214|EXPERIMENTAL|Trial Nasal Mask|The participant will use the Saturn nasal mask for 2 weeks in home
62061050|NCT03386032|EXPERIMENTAL|Investigational OTC Cream|Investigational Over the Counter (OTC) Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
62061051|NCT03386032|SHAM_COMPARATOR|Placebo Cream|Placebo Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
62061052|NCT03386032|ACTIVE_COMPARATOR|0.05% Desonide Cream|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions."
62621832|NCT01429441|SHAM_COMPARATOR|Sham injection|
62265076|NCT03044535||Group 2: Cross-sectional assessment|A one-time assessment will be performed on participants who are post-MCS implant (between 3 months and 10 years post-implant). Participants in this group must already have an MCS device in place.
62621833|NCT01756339|EXPERIMENTAL|Solithromycin|Solithromycin 800 mg orally (PO) on Day 1 followed by 400 mg PO daily on Days 2 through 5, followed by placebo on Days 6 and 7
62621834|NCT01756339|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin 400 mg PO daily on Day 1 through Day 7
62621835|NCT03577379|NO_INTERVENTION|Control|Patients in the control arm will receive standard of care for their rotator cuff tear, and will not receive the additional whole blood fibrin clot.
62848016|NCT02641340|EXPERIMENTAL|Cycle 3, Cohort 4|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
62848017|NCT02845167|NO_INTERVENTION|Usual-care only|Patients will receive usual-care only during the preoperative period.
62848018|NCT02845167|EXPERIMENTAL|Preoperative exercise|Patients will perform 3 consecutive days of 60 min submaximal cycling exercise at a moderate exercise intensity. During the 60 min of exercise, patients will be provided with three equally spaced 3min rest periods.
62848019|NCT04455464|EXPERIMENTAL|Midodrine|Midodrine will be given 10 mg for one time only. HVPG will be done at baseline and after 3 hours
62848020|NCT01652469|EXPERIMENTAL|A: Erlotinib|Erlotinib in standard dose. Until progression (clinical or radiological) or unacceptable toxicity.
62848021|NCT01652469|EXPERIMENTAL|B: Docetaxel|Docetaxel in standard dose. Until progression (clinical or radiological) or unacceptable toxicity.
62848022|NCT05369182||Deferred Population: Patients with CMD (CFR<2.0 and IMR≥25)|Among patients who did not undergo PCI at the discretion of the operator, patients diagnosed CMD (CFR\<2.0, IMR≥25) in physiologic assessment.
62848023|NCT05369182||Deferred Population: Patients with preserved microvascular function (CFR≥2.0 OR IMR<25)|Among patients who did not undergo PCI at the discretion of the operator, patients with preserved microvascular function (CFR≥2.0 OR IMR\<25) in physiologic assessment.
62848024|NCT05369182||Revascularized Population: Patients treated by intravascular imaging-guided PCI optimization|Among patients who received PCI, patients whose PCI was optimized through intravascular imaging device (IVUS or OCT).
62265077|NCT01178489||Patients undergoing arthroplasty|Patients undergoing primary, unilateral, total hip or knee arthroplasty under spinal anaesthesia
62848025|NCT05369182||Revascularized Population: Patients treated by angiography-only guided PCI|Among patients who received PCI, patients whose PCI was optimized through angiography-only.
62848026|NCT02046759|EXPERIMENTAL|Pharmacist-Intervention|
62061053|NCT02484079|ACTIVE_COMPARATOR|Cold polypectomy|"Patients in this arm will have their polyps removed by cold polypectomy, i.e. a metal sling that is closed around the basis of the polyp, and the polyp is cut off.~After removal there will be taken biopsies from the resection margins, and both the polyp and the biopsies will be examined by a histopathologist to see if the polyp is removed completely."
62621836|NCT03577379|EXPERIMENTAL|Treatment|Patients in the control arm will receive standard of care for their rotator cuff tear, in addition to, the whole blood fibrin clot.
62848027|NCT02046759|ACTIVE_COMPARATOR|Routine Care|
62848028|NCT00696917|ACTIVE_COMPARATOR|Group A|Three doses according to 0, 1, 6-month schedule
62848029|NCT00696917|EXPERIMENTAL|Group B|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
62265078|NCT00663988|EXPERIMENTAL|III|The effect of human partial facial allotransplantation
62265079|NCT00501787|ACTIVE_COMPARATOR|Group B|Non-tailoring
62265080|NCT00501787|ACTIVE_COMPARATOR|Group A|Tailoring
62265081|NCT01486836||ICD therapy|
62265082|NCT00750958|NO_INTERVENTION|1|ED patients that are not monitored with conventional therapy.
62848030|NCT00696917|EXPERIMENTAL|Group C|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
62848031|NCT00696917|EXPERIMENTAL|Group D|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
62848032|NCT01237899|EXPERIMENTAL|1 mg LY2623091|Daily by mouth for 7 days.
62848033|NCT01237899|EXPERIMENTAL|10 mg LY2623091|Daily by mouth for 7 days.
62848034|NCT01237899|EXPERIMENTAL|25 mg LY2623091|The anticipated dose of LY2623091 was revised down from the original proposed dose level of 100 mg based on safety and tolerability data. The 25 mg LY2623091 was administered daily by mouth for 7 days.
62848035|NCT01237899|EXPERIMENTAL|0.3 mg LY2623091|The anticipated dose of LY2623091 was revised down from the original proposed dose level of up to 200 mg. The 0.3 mg LY2623091 was determined based on an interim analysis after the third dose level and was administered daily by mouth for 7 days.
62848036|NCT01237899|PLACEBO_COMPARATOR|Placebo|Daily by mouth for 7 days.
62848037|NCT01237899|ACTIVE_COMPARATOR|50 mg Eplerenone|Daily by mouth for 7 days.
62265083|NCT01083303|EXPERIMENTAL|weaning at 1500 g|weaning infants from an incubator at 1500 g
62265084|NCT01083303|ACTIVE_COMPARATOR|weaning at 1600 g|weaning infants from an incubator at 1600 g
62265085|NCT01620931|EXPERIMENTAL|RO5469754|
62265086|NCT01620931|PLACEBO_COMPARATOR|Placebo|
62621837|NCT05903638|NO_INTERVENTION|Control|
62621838|NCT05903638|EXPERIMENTAL|Virtual Mindfulness-Based Stress Reduction (MBSR) program|
62621839|NCT03667443|ACTIVE_COMPARATOR|Myo-inositol plus folic|
62621840|NCT03667443|ACTIVE_COMPARATOR|Myo-inositol + folic a. + α-lactalbumin|
62621841|NCT06432907|EXPERIMENTAL|StereoEEG|Each patient will participate in one experimental session lasting no more than 60 minutes, recording brain signals associated with hand movement, motor imagery, and brain-computer interface (BCI) control.
62621842|NCT02380170||Urosepsis|Sepsis derived from the urinary tract infection
62621843|NCT02448745|NO_INTERVENTION|Control|21 clusters composed of one or more villages with a total number of 30 to 70 children under 5 years old. Routine distribution of long-lasting insecticidal nets is the only malaria control intervention.
62848038|NCT05539300|EXPERIMENTAL|PSMA response evaluation arm|PSMA-PET/CT response evaluation, 2 months after starting hormonal therapy, 2 months after starting upfront enzalutamide therapy
62621844|NCT02448745|EXPERIMENTAL|Intervention|21 clusters composed of one or more villages with a total of 30 to 70 children under 5 years old. Routine distribution of long-lasting insecticidal nets is available and in addition insecticide treated wall lining is installed in all sleeping areas with homeowner consent. All 4 walls and the ceiling are covered with lining.
62061054|NCT02484079|ACTIVE_COMPARATOR|Hot polypectomy|"Patients in this arm will have their polyps removed by hot polypectomy, i.e. a metal sling taht is closed around the basis of the polyp, electrical currents is applied, and the polyp is cut off.~After removal there will be taken biopsies from the resection margins, and both the polyp and the biopsies will be examined by a histopathologist to see if the polyp is removed completely."
62621845|NCT02963129|EXPERIMENTAL|Mupirocina|topical mupirocin nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days
62621846|NCT02963129|PLACEBO_COMPARATOR|Control|topical placebo nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days
62061055|NCT05207930|EXPERIMENTAL|Intervention Group|This arm will undertake a centre-based health education on nutrition and cognitive frailty for 4 weeks, followed by an 8-week homed based gamified cognitive-nutrition training (GAHOCON).
62621847|NCT02853071|EXPERIMENTAL|Estramustine|560 mg per day
62848039|NCT05622253|EXPERIMENTAL|Combined Low-Dose Isotretenion and Long-Pulsed 1064 ND-YAG Laser in the Treatment of Acne Erythema|Selected patients will be treated with low-dose oral isotretinoin (10mg/day) over a period of sessions and six sessions of 1064 ND- YAG laser (Deka motous AY) using 150 J/cm2, 20-25 milliseconds pulse duration, and 5 mm spot size, at 2 weeks' interval.
62848040|NCT06372236|EXPERIMENTAL|Targeted B7-H3 chimeric antigen receptor gdT cell injection|UTAA06 injection The subjects who sign the informed consent forms and been screened by inclusion/exclusion criteria,will be assigned into 1×10\^8CAR+gdT、3×10\^8CAR+gdT、5×10\^8CAR+gdT、8×10\^8CAR+gdT、1×10\^9CAR+gdT groups inder of sequence.And the subjects will be administered once.
62848041|NCT01901250|EXPERIMENTAL|Xylitol GB|Xylitol gummy bears 7.8g/day throughout the 9 month kindergarten year, oral health education, fluoride varnish, and dental sealant
62061056|NCT05207930|PLACEBO_COMPARATOR|Control Group|This arm will undertake the same centre-based health education on nutrition and cognitive frailty for 4 weeks but will be opened to undertake a remotely supervised online open-source cognitive games, with which the contents are unrelated to nutrition, at the elderly community centre.
62061057|NCT05164874|EXPERIMENTAL|Intervention|"Women will receive a proposition for an appointment at the MMU in complement to the current screening invitation, keeping the choice of their place of screening.~Women will also receive the timetable of prevention actions with the invitation to participate in screening."
62061058|NCT05164874|NO_INTERVENTION|Control|No change from the usual breast cancer screening organization
62061059|NCT04854005||Breast Cancer|Patients with cTx/cT1-2cN1 HR+/HER2- tumors who are scheduled to undergo upfront surgery will undergo AUS at the enrolling institution to characterize suspicious-appearing lymph nodes, as is part of routine practice.
62061060|NCT00718822|EXPERIMENTAL|I|5% oxygen concentration in the culture atmosphere
62061061|NCT00718822|EXPERIMENTAL|II|20% oxygen concentration in the culture atmosphere
62061062|NCT03857503||Coronary Lesion Assessment with iFR|Patients referred for cardiac catheterization for diagnostic and/or treatment purposes will undergo a screening angiogram to assess eligibility. Eligible patients will be those with at least one major epicardial vessel having a lesion of 40-90% diameter stenosis per visual assessment of angiogram.
62061063|NCT01255592|EXPERIMENTAL|1|Treatment arm AZD5069
62061064|NCT01255592|PLACEBO_COMPARATOR|2|Placebo dose.
62621848|NCT02853071|ACTIVE_COMPARATOR|Standard practice center|"Standard treatment center choice.~Excepted: anthracyclines, taxanes, capecitabine and eribulin"
62061065|NCT02743923|ACTIVE_COMPARATOR|carboplatin-paclitaxel- bevacizumab|carboplatin AUC 6, paclitaxel 200 mg/m2, bevacizumab 15 mg/kg all administered intravenously on day 1 every 3 weeks for 4-6 cycles, followed by bevacizumab maintenance every 3 weeks until progression
62061066|NCT02743923|ACTIVE_COMPARATOR|cisplatin-pemetrexed|pemetrexed 500 mg/m2 administered intravenously on day 1 and cisplatin 75 mg/m2 administered intravenously on day 1 every 3 weeks for 4-6 cycles, followed by maintenance pemetrexed every 3 weeks until progression.
62621849|NCT02865629|EXPERIMENTAL|N-acetyl cysteine|Following the screening and review of all laboratory studies, patients will be scheduled to receive N-acetylcysteine.
62621850|NCT02263729|ACTIVE_COMPARATOR|Losartan|Subjects will taken 50mg of losartan per day for 4 weeks
62621851|NCT02263729|PLACEBO_COMPARATOR|Placebo|Subjects will be given placebo to replicate appearance of losartan pills. Placebo pill will be taken once per day.
62621852|NCT05039125|ACTIVE_COMPARATOR|40000HZ ultrasound cavitation|group A (n=15) received 40000HZ ultrasound cavitation, Treatment time was 30 minutes /sessions, 3 times/ week for two months. Both groups (A and B) received a low caloric diet (1200 Kcal/day). All participants had their medical treatment as prescribed by the physician.
62621853|NCT05039125|ACTIVE_COMPARATOR|2600HZ ultrasound cavitation|group B (n=15) received 2600HZ ultrasound cavitation. Treatment time was 30 minutes /sessions, 3 times/ week for two months. Both groups (A and B) received a low caloric diet (1200 Kcal/day). All participants had their medical treatment as prescribed by the physician.
62621854|NCT00939588|EXPERIMENTAL|Aliskiren and Valsartan|
62621855|NCT00939588|ACTIVE_COMPARATOR|Telmisartan and Ramipril|
62621856|NCT01375452|ACTIVE_COMPARATOR|Femara|
62621857|NCT01375452|EXPERIMENTAL|Letrozole|
62621858|NCT01441245|EXPERIMENTAL|Continuous furosemide infusion|The group that received the continuous infusion of furosemide (cIV), consisted of 30 patients;
62621859|NCT01441245|EXPERIMENTAL|Intermittent furosemide infusion|The group that received the bolus infusion of furosemide (iIV), consisted of 27 patients
62621860|NCT03596515|EXPERIMENTAL|Received sensory integration therapy|Participants in the experimental group received 16 sessions (45 minutes each) of individualized Ayres Sensory Integration intervention.
62848042|NCT01901250|PLACEBO_COMPARATOR|Fiber GB|Sugar free fiber gummy bears 20g/day throughout the 9 month kindergarten year, oral health education, fluoride varnish, and dental sealant
62848043|NCT01330004||Hemodialysis patients|
62621861|NCT03596515|NO_INTERVENTION|Waitlist control group|Participants in the control group received Ayres Sensory Integration according to the usual clinical scheduling. It is after the post- assessment outcome at the same time of the experimental group.
62621862|NCT02102347|EXPERIMENTAL|exercise group|An exercise program will be performed to increase range of motion, improve motor learning and strengthen the muscles of the lower limb. The program will include exercises 2 times a week for four weeks. The first week the exercises will be performed with 2 sets of 15 repetitions and the remaining weeks 3 sets of 15 repetitions for each exercise. To exercise will be performed with the resistance of cinnamon, It will be recommended weight by 70% of one repetition maximum painless assigned individually per patient.
62848044|NCT03072004|SHAM_COMPARATOR|Control|"Leprosy patients with focal demyelinating neuropathy in compression sites of the ulnar and common peroneal nerves who will receive application sham LLLT. The laser will be turned off, but the procedure will be the same as with the Low Level Laser Therapy (LLLT) group"
62448674|NCT04665505|EXPERIMENTAL|ICU Staff|The study group is composed of ICU care providers at the Ottawa Hospital Civic campus and the Montfort Hospital, including intensivists, fellows, nurses and allied health professionals. The study site participant breakdown is approximately 58 TOH staff respondents and 15 Montfort respondents.
62448675|NCT03775681|EXPERIMENTAL|Device feasibility (Laryngeal Mask Airway, ERCP)|Patients wear Laryngeal Mask Airway after receiving general anesthesia and falling asleep. Patients then undergo standard of care endoscopic retrograde cholangiopancreatography. Patients also complete a 5-minute interview following ERCP procedure.
62448676|NCT00519337|ACTIVE_COMPARATOR|1|Ascorbic acid
62448677|NCT00519337|PLACEBO_COMPARATOR|2|Identical placebo
62448678|NCT01005836|EXPERIMENTAL|Cognitive-behavioral therapy: Anxiety|CBT for child anxiety. Coping Cat.
62448679|NCT01005836|OTHER|Usual care: Anxiety|Usual clinic care
62448680|NCT01005836|EXPERIMENTAL|Cognitive behavioral therapy: depression|CBT for youth depression. The Primary and Secondary Control Enhancement Training protocol.
62448681|NCT01005836|OTHER|Usual care: Depression|Usual clinic care for depression
62448682|NCT04689074||ADPKD|Patients with ADPKD
62448683|NCT04689074||advanced CKD|Patients with advanced CKD
62448684|NCT04689074||DKD|Patients with DKD
62448685|NCT04689074||IgAN|Patients with IgAN
62448686|NCT04689074||Healthy volunteers|Healthy volunteers
62448687|NCT01495377|ACTIVE_COMPARATOR|Remifentanil|
62448688|NCT01495377|PLACEBO_COMPARATOR|Placebo|
62448689|NCT01495377|EXPERIMENTAL|Technetium|
62448690|NCT01495377|EXPERIMENTAL|Dynamometer|
62448691|NCT00767507|EXPERIMENTAL|Cangrelor|Cangrelor was administered as a continuous IV infusion of 0.75µg/kg/min for a minimum of 48 hours and a maximum of 7 days.
62448692|NCT00767507|PLACEBO_COMPARATOR|Placebo|A placebo infusion was administered as a continuous IV infusion of 0.75µg/kg/min for a minimum of 48 hours and a maximum of 7 days, to maintain the blind.
62448693|NCT01904578|EXPERIMENTAL|true acupressure|Massage the effective pressure points as a self-care method at home \[ Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the centre line between the ends of the eyebrows\] for 10 minutes. It was done 1 to 2 hours before sleeping, each night (except Fridays) by circular massage with a 1 Cm circle diameter.
62448694|NCT01904578|SHAM_COMPARATOR|sham acupressure|Massage the sham pressure points as a self-care method at home for 10 minutes. It was done 1 to 2 hours before sleeping, each night (except Fridays) by circular massage with a 1 Cm circle diameter.
62448695|NCT01904578|NO_INTERVENTION|control|The control group only received the weekly control of blood pressure and speech communication .
62448696|NCT04000321|EXPERIMENTAL|Windmill group 30 Mins|In the Windmill Group, the Windmill technique is carried out after 30 minutes. The windmill technique of the umbilical cord for placental development is performed by a trained obstetrician or midwife with a doctor presence. In a frustrated attempt to develop placenta using the Windmill technique, a manual removal is performed according to the clinic standard.
62448697|NCT04000321|ACTIVE_COMPARATOR|Control Group|In the control group, after a total of 45 minutes of unsuccessful application of the traditional and customary measures, the Windmill technique is used. If unsuccessful, a manual placenta removal is performed according to hospital Standards.
62448698|NCT01523899|EXPERIMENTAL|Xpert MRSA/SA SSTI|use of the Xpert MRSA/SSTI diagnostic assay
62448699|NCT01523899|ACTIVE_COMPARATOR|Standard culture|performance of standard bacterial culture of abscess material
62448700|NCT03104322|OTHER|Observation sequence|Period 1: patientMpower platform+usual care for 8 weeks; Period 2: usual care alone for 8 weeks
62448701|NCT00708422|EXPERIMENTAL|Travoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
62448702|NCT00708422|ACTIVE_COMPARATOR|Latanoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
62448703|NCT01928277||ICU-patients|ICU-patients weaning form mechanical ventilation
62448704|NCT02507206|EXPERIMENTAL|DAR 0-100A then Placebo|15 mg is dissolved in 150 cc NS administered over 30 minutes x 3 consecutive days. Subjects will return a minimum of two weeks later for Visit 5 to receive drug (if randomized initially to placebo) or placebo (if randomized to drug).
62448705|NCT02507206|PLACEBO_COMPARATOR|Placebo then DAR 0-100A|15 mg dissolved in 150 cc NS saline is administered over 30 minutes x 3 consecutive days. Subjects will return a minimum of two weeks later for Visit 5 to receive drug (if randomized initially to placebo) or placebo (if randomized to drug).
62448706|NCT02507206|NO_INTERVENTION|Healthy Control|patients without diagnosis of SPD
62448707|NCT05008289|ACTIVE_COMPARATOR|ACTIVE|Magnetic transcutaneous spinal cord stimulation
62448708|NCT05008289|SHAM_COMPARATOR|PLACEBO|
62448709|NCT03830645|EXPERIMENTAL|Platelet rich plasma group|
62448710|NCT01691248|ACTIVE_COMPARATOR|Fidaxomicin|200 mg Fidaxomicin tablet once daily for no longer than 40 days
62448711|NCT01691248|PLACEBO_COMPARATOR|Placebo|Placebo tablet once daily for no longer than 40 days
62448712|NCT04813250|SHAM_COMPARATOR|Group R|IMV(intermittent mandatory ventilation) Regular Ventilation with Tidal volume with 7ml/ kg (Predicted body weight)
62621863|NCT02102347|EXPERIMENTAL|phototherapy group|And, Phototherapy will be administered with a portable nine-diode cluster. The portable nine-diode cluster will be used overlapping three quadrants of the knee in random sequence: medial quadrant, lateral quadrant and posterior quadrant.with one 905-nm diode (mean power: 1 milliwatt ; peak power: 10 megawatt; spot size: 0.44 cm2), four 875-nm diodes (mean power of each diode: 17.5 milliwatt; spot size: 1 cm2) and four 670-nm diodes (mean power of each diode: 15 mW; spot size: 1 cm2); frequency: 1000 Hz; 300-second irradiation time in each quadrant; total energy: 39.3 Joules per quadrant. Phototherapy will be included in the exercises group.
62061067|NCT05003050|EXPERIMENTAL|Meditation Based Group|8 sessions weekly for 8 weeks Each session for 1hour Sessions on line (virtual) Self-care tools and techniques, mindfulness and meditation
62061068|NCT05003050|EXPERIMENTAL|Energy Therapy (Pranic Healing)|8 Sessions Weekly sessions for 8 weeks Each session 1 hour Pranic Healing (Energy Therapy)
62061069|NCT05003050|NO_INTERVENTION|Stanrd of Care Group|Routine medical care and appointments
62848045|NCT03072004|EXPERIMENTAL|Low Level Laser Therapy|Leprosy patients with focal demyelinating neuropathy in compression sites of the ulnar and common peroneal nerves who will receive intervention with low-intensity laser therapy (LLLT).
62061070|NCT01423214|EXPERIMENTAL|Robotic LAR|Individuals who underwent robot-assisted surgery for primary rectal cancer
62061071|NCT01423214|ACTIVE_COMPARATOR|Lap LAR|Individuals who underwent laparoscopic surgery for primary rectal cancer
62265087|NCT01326546|EXPERIMENTAL|Therapeutic HBV vaccine+Entecavir|Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
62265088|NCT01326546|PLACEBO_COMPARATOR|placebo+Entecavir|Placebo comparator: Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
62848046|NCT01419652|ACTIVE_COMPARATOR|continue hypglycemic meds|
62848047|NCT01419652|NO_INTERVENTION|control - hold drug|
62848048|NCT02741973|EXPERIMENTAL|Yoga|Students have 10 weeks yoga instead of school sport.
62848049|NCT02741973|ACTIVE_COMPARATOR|School sport|Students have 10 weeks regular school sport.
62848050|NCT01787721|EXPERIMENTAL|Ankle manipulation|Treatment will consist of manipulation of the tibiotalar joint intended to produce anterior to posterior glide of the tibia on the talus
62848051|NCT01787721|SHAM_COMPARATOR|Sham manipulation|Sham manipulative procedure of the tibiotalar joint.
62848052|NCT01322841|ACTIVE_COMPARATOR|CHICA Diagnosis Module|This arm had the CHICA screening module turned on
62848053|NCT01322841|PLACEBO_COMPARATOR|CHICA Placebo|This arm had CHICA but no additional module
62061072|NCT01053377|ACTIVE_COMPARATOR|Tamiflu|
62061073|NCT01053377|PLACEBO_COMPARATOR|Placebo Tamiflu|
62061074|NCT00502034|EXPERIMENTAL|A-immunotherapy|Immunotherapy with interferon-alpha and interleukin
62061075|NCT00502034|NO_INTERVENTION|B-follow-up|Wait-and-see
62061076|NCT03763916|ACTIVE_COMPARATOR|Intra operative ureteric dissection|midline abdominal incision extending supraumbilical, incision of the SC tissue, dissection and splitting of the recti, classic midline incision of the uterus \[above the site of placental insertion\], delivery of the fetus , avoid traction of the placenta, quick closure of the uterus \[in presence of the placenta\] in one layer, clamping and cutting the round ligament, clamping and cutting the ovarian ligament with ovarian preservation, careful dissection and clamping of the broad ligament varicosities, careful dissection of the post leaflet of the broad ligament until ureter is reached, careful dissection and exposure of both ureter and proper identification of the iliac vessels
62061077|NCT03763916|ACTIVE_COMPARATOR|Preoperative ureteric stenting|preoperative insertion of ureteric catheters is performed by the urologist in our team just before the start of cesarean hysterectomy. Patient is positioned in lithotomy, cystoscopy \[Karl storz\] is done to identify the ureteric orifices. ureteric catheters \[Roche\] are inserted followed by the insertion of Foley's urethral catheter.
62061078|NCT02000830||Placebo|Participants received placebo during the earlier study
62061079|NCT02000830||Stannsoporfin 3.0 mg/kg|Participants received Stannsoporfin 3.0 mg/kg during the earlier study
62061080|NCT02000830||Stannsoporfin 4.5 mg/kg|Participants received Stannsoporfin 4.5 mg/kg during the earlier study
62061081|NCT01271998|EXPERIMENTAL|healthy volunteer|healthy volunteers
62265089|NCT00773812|EXPERIMENTAL|Active Mecamylamine|There will be 12 children in this arm. These children will receive the active medication (mecamylamine).
62265090|NCT00773812|PLACEBO_COMPARATOR|Placebo|There will be 8 children in this arm. These children will receive placebo instead of the active medication.
62265091|NCT05952245|EXPERIMENTAL|Intervention Group|Receiving CBT-I based EMI messages.
62848054|NCT03679832||Historical Group 1|Patients admitted at UMC between September 2015 and October 2016
62848055|NCT03679832||Historical Group 2|Patients admitted at UMC between November 2016 and up to the beginning of the QIP
62061082|NCT01407588|EXPERIMENTAL|Magnetic navigation|
62061083|NCT01407588|EXPERIMENTAL|Manual navigation|
62621864|NCT02102347|PLACEBO_COMPARATOR|Phototherapy placebo|Phototherapy will be administered with a portable nine-diode cluster. The portable nine-diode cluster will be used overlapping three quadrants of the knee in random sequence: medial quadrant, lateral quadrant and posterior quadrant), with one 905-nm diode (mean power: 0 milliwatt; peak power: 0 watt; spot size: 0.44 cm2), four 875-nm diodes (mean power of each diode: 0 milliwatt; spot size: 1 cm2) and four 670-nm diodes (mean power of each diode: 0 milliwatt; spot size: 1 cm2); frequency: 0 Hz; 300-second irradiation time in each quadrant; total energy: 0 Joules per quadrant. Phototherapy will be included in the exercises group.
62621865|NCT04279990||Functional dyspepsia patients with JHS|Patients with functional dyspepsia as defined by the Rome III criteria and joint hypermobility syndrome as defined by the Beighton Hypermobility criteria.
62848056|NCT03679832||Nutrition-Focused QIP|Patients admitted at UMC that meet eligibility criteria and prospectively enrolled into QIP including malnutrition screening, nutrition consultation, expedited provision of oral nutritional supplementation (ONS) and encouragement of ONS consumption 30-days post discharge
62061084|NCT05791890||Patients who receive or have received Gilteritinib|the retrospective part, clinical data will be collected on all patients with LMA FLT3+ (ITD or TKD mutation) treated with Gilteritinib from when the drug was approved and marketed in Italy (April 2, 2020) until April 30, 2022. Enrollment in the prospective cohort will have an estimated duration of 24 months from the time of study approval.
62621866|NCT04279990||Functional dyspepsia patients without JHS|Patients with functional dyspepsia as defined by the Rome III criteria and WITHOUT joint hypermobility syndrome as defined by the Beighton Hypermobility criteria.
62621867|NCT04279990||Healthy subjects|Healthy subjects with no gastrointestinal diseases including no functional dyspepsia
62621868|NCT06408779||coronary artery bypass grafting|
62621869|NCT06408779||coronary artery bypass grafting concomitant mitral valve repair|
62621870|NCT05492747|EXPERIMENTAL|Kangaroo Care Effects on Feeding|The researcher allocated the mothers blindly. Eligible mothers and their preterm babies were randomized to either the kangaroo care group or the standard care group (1:1) (Figure 1). The mothers' surnames were written and put in a bag. The surnames were drawn from the bag by lot. The lots were drawn by a neonatal nurse. Neonatal nurse is a research independent person. The first drawn surname was included in the kangaroo group, while the next one was included in the control group, respectively.
62621871|NCT02965508|EXPERIMENTAL|Home-based Primary Care Arm|Participants in this arm will be assigned a Mount Sinai Visiting Doctors primary care physician who makes a home based primary care visit.
62621872|NCT02965508|ACTIVE_COMPARATOR|Usual Care Arm|Participants in this arm will receive the usual care at office based visits
62621873|NCT00779987|OTHER|Autologous serum -Systane|Crossover arm starting with autologous serum for 2 weeks. After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using artificial tears (Systane)
62621874|NCT00779987|OTHER|Systane- Autologous serum|Crossover arm starting with artificial tears (Systane) for 2 weeks. After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using autologous serum.
62621875|NCT02496039|OTHER|NUEDEXTA®|NUEDEXTA capsules (20 mg dextromethorphan hydrobromide and 10 mg quinidine sulfate) administered orally, once a day from Days 1 to 7 and twice a day from Days 8 to 180
62621876|NCT03297021|PLACEBO_COMPARATOR|Ondansetron 4mg Pre-emergence|
62621877|NCT03297021|EXPERIMENTAL|Ondansetron 8mg Pre-emergence|
62621878|NCT03297021|EXPERIMENTAL|Ondansetron Pre-Incision and Pre-emergence|4mg Ondansetron Pre-Incision and 4mg Ondansetron Pre-emergence
62621879|NCT05273229|EXPERIMENTAL|Virtual Gait and Physical Exercise|"Virtual Gait and Physical Exercise Virtual Gait The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where a video of treadmill gait of a person will be projected.~Physical Exercise Specific gait exercise was conducted."
62621880|NCT05273229|SHAM_COMPARATOR|Documental projection and Physical Exercise|"Physical Exercise Specific gait exercise was conducted.~Documental projection The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where video without any type of animal or human movement was showed."
62621881|NCT05273229|EXPERIMENTAL|Virtual Gait|only the virtual gait program will be carried out, detailed in Arm I.
62621882|NCT05273229|SHAM_COMPARATOR|Virtual Gait Sham|Documental projection The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where video without any type of animal or human movement was showed.
62621883|NCT01284751||Breast cancer patients|Patients aged 30-70 years having a lumpectomy or mastectomy at the Department of Breast Surgery at Herlev Hospital, Copenhagen, Denmark.
62061085|NCT05791890||Case control|for each case of a patient receiving salvage monotherapy with Gilteritinib, a control patient with R/R AML FLT3+ on salvage chemotherapy should also be included.
62061086|NCT01993459|EXPERIMENTAL|Midazolam intravenous|3mg/ml midazolam given intravenously
62061087|NCT01993459|PLACEBO_COMPARATOR|NaCl (sodium chloride) 0,9%|NaCl (sodium chloride) 0,9% given intravenously 3ml.
62061088|NCT06625008|EXPERIMENTAL|3D-printed model arm|Surgeons in this arm will use a 3D-printed modular human torso model with a magnetically detachable colon and rectum to teach patients about the anatomy and proximity of colonic segments undergoing surgery, potential surgical complications, and operative procedures during the pre-operative consent.
62265092|NCT05952245|ACTIVE_COMPARATOR|Control Group|Receiving education-based EMI messages.
62448713|NCT04813250|EXPERIMENTAL|Group RP|Regular Ventilation with Tidal volume with 7ml/ kg (Predicted body weight) + PEEP : 6 cm H2O
62265093|NCT06087744|EXPERIMENTAL|NeuroN-QI|Randomized dyads in the experimental group will be asked to do at least one session weekly (ideally 3) skin-to-skin contact (SSC) lasting 2 hours until the age of 36 weeks. Auditory sensory stimulation by mothers or fathers (reading a book) will be carried out during the first 10 minutes during the SSC sessions. The SSC will be followed by a period of calm and rest of one hour during which the infants will rest in their incubator with breast milk's olfactory stimulation. Light and sound control will be done during the entire intervention.
62265094|NCT06087744|ACTIVE_COMPARATOR|SSC alone|Randomized dyads in the control group will be asked to do at least one session weekly (ideally 3) skin-to-skin contact (SPC) lasting 2 hours until the corrected age of 36 weeks. During these sessions, light and noise levels will not be controlled or accompanied of auditory stimulation. SSC periods will not be followed by a calm and rest period with a olfactory stimulation.
62448714|NCT04813250|EXPERIMENTAL|Group RI|Regular Ventilation with Tidal volume with 7ml/ kg (Predicted body weight) + Reverse IE ratio ventilation( I:E=1:1)
62448715|NCT04813250|EXPERIMENTAL|Group RPI|Regular Ventilation with Tidal volume with 7ml/ kg (Predicted body weight) + PEEP : 6 cm H2O + Reverse IE ratio ventilation( I:E=1:1)
62448716|NCT02031848|ACTIVE_COMPARATOR|Healthy Weight Control Group|Subjects will complete the Assessments, Diet Intake, and MRI portions of the study
62448717|NCT02031848|ACTIVE_COMPARATOR|Dieting Group|Subjects will complete the Assessments, Diet Intake, and MRI portions of the study and will be given the weight loss and weight maintenance diets, and will attend weekly behavioral meetings
62448718|NCT01508416||Patients with Multiple Myeloma|Patients with newly diagnosed Multiple Myeloma required chemotherapy
62448719|NCT04750005|ACTIVE_COMPARATOR|Brush only Group|Participants assigned to this group will brush their teeth using soft bristled toothbrush and colgate cavity protection toothpaste as directed under virtual supervision once daily during the week. Participants will brush second time unsupervised daily in the evening and twice daily over the weekend/holidays at home.
62621884|NCT05295199|EXPERIMENTAL|Experimental|Routine maintenance and Progressive relaxation exercise
62621885|NCT05295199|NO_INTERVENTION|Control|Routine maintenance
62448720|NCT04750005|EXPERIMENTAL|Brush/Rinse Group|Participants assigned to this group will perform their regimen (brushing \[soft bristled toothbrush and colgate cavity protection toothpaste\] and rinsing \[listerine cool mint antiseptic mouthwash\]) as directed under virtual supervision once daily during the week. Participants will brush and rinse a second time unsupervised daily in the evening at home. At home, participants will brush and rinse a second time unsupervised daily in the evening and twice daily over the weekend/holidays. First product use will occur at the site under supervision.
62448721|NCT04750005|EXPERIMENTAL|Brush/Floss Group|Participants assigned to this group will perform their regimen (brushing and flossing) as directed under virtual supervision once daily during the week. At home, participants will brush a second time unsupervised daily in the evening. Over the weekend and holidays, participants will brush and floss once daily. Only brushing will be performed a second time in the evening. First product use will occur at the site under supervision.
62448722|NCT04750005|EXPERIMENTAL|Brush/Floss/Rinse Group|Participants assigned to this group will perform their regimen (brushing \[soft bristled toothbrush and colgate cavity protection toothpaste\], flossing \[reach unflavored waxed dental floss\] and rinsing \[listerine cool mint antiseptic mouthwash\]) as directed under virtual supervision once daily during the week. Participants will brush and rinse a second time unsupervised daily in the evening. Over the weekend and holidays, participants will brush, floss and rinse once daily. Only brushing and rinsing will be performed a second time in the evening at home.
62448723|NCT01021436|EXPERIMENTAL|Amikacin inhalation solution|Subjects received 125 mg/mL of aerosolized amikacin via the PDDS clinical device at a nominal dose of 400 mg every 12 h for 7-14 days
62621886|NCT06351085|OTHER|Pre-Visit Planner (PVP)|A Licensed Vocational Nurse (LVN) will verify patient smoking history and calculate pack years with the patient over the phone.
62848057|NCT01454141|EXPERIMENTAL|Peripheral Vision Task|During this task participants viewed a circular array of 15 discs and were asked to move their attention, but not their eyes, clockwise around the array while auditory tones were presented. Following the presentation of a distinct target tone, the discs changed color and participants reported the color of the disc by pressing a designated button on the keyboard. This task was developed to be a non-active control condition, targeting visual and occipital areas of the brain, and therefore allows us to discriminate between the effects of completing a computer-based task from interventions that specifically target the PFC.
62265095|NCT03121404||Cirrhosis Patient|Patients will be identified from the transplant list. Inclusion criteria will be all subjects with cirrhosis of any etiology who will undergo liver transplantation. . Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery. For the cirrhotic patients this includes hand grip test and dual energy x-ray absorption (DEXA).
62265096|NCT03121404||Healthy Controls|Controls will be identified from the abdominal surgery operating room lists at Cleveland Clinic. Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery which will not include DEXA or hand grip test.
62061089|NCT06625008|NO_INTERVENTION|Standard care arm|Surgeons will employ the usual pre-operative counseling in this arm. This will include teaching patients about the anatomy, operative procedures, and potential surgical complications during the pre-operative consent using 2D images.
62061090|NCT04821128||Patients who improved surgical treatment for oral cavity cancer|T1 T2 and T3 OSCC tumor, patients who have a recent evaluation cervico thoracic scanner in their medical files.
62061091|NCT05019833|EXPERIMENTAL|Signals collection|Collection of sensors signals by the implanted device.
62061092|NCT03766841|EXPERIMENTAL|Facilitated Enrollment|Patients will be aided in the account creation and usage of a consumer informatics tool to collect and report patient-contextual data within the electronic health record
62265097|NCT01796327|EXPERIMENTAL|Treatment|Dacomitinib will be administered as a single oral dose and as an intravenous infusion
62061093|NCT03766841|NO_INTERVENTION|Usual Care|Patients will be invited to use the patient contextual data tool as per usual care, but will not receive additional assistance in account creation and usage.
62265098|NCT05884931|ACTIVE_COMPARATOR|Conventional Treatment|Conventional Treatment
62448724|NCT04308681|EXPERIMENTAL|IPF Dose 1 + Post Treatment Follow-up or OTE|IPF (Idiopathic Pulmonary Fibrosis) OTE (Optional Treatment Extension)
62448725|NCT04308681|EXPERIMENTAL|IPF Dose 2 + Post Treatment Follow-up or OTE|
62061094|NCT02334514||Adults with influenza|Patients diagnosed with influenza by PCR testing
62265099|NCT05884931|EXPERIMENTAL|Conventional Treatment + Nexpowder|Conventional Treatment + Nexpowder
62448726|NCT04308681|PLACEBO_COMPARATOR|IPF Placebo + Post Treatment Follow-up or OTE|
62448727|NCT04308681|EXPERIMENTAL|PF-ILD Dose 1 + Post Treatment Follow-up or OTE|PF-ILD (Progressive Fibrotic Interstitial Lung Disease)
62448728|NCT04308681|EXPERIMENTAL|PF-ILD Dose 2 + Post Treatment Follow-up or OTE|
62448729|NCT04308681|PLACEBO_COMPARATOR|PF-ILD Placebo + Post Treatment Follow-up or OTE|
62621887|NCT06351085|OTHER|Pre-Visit Planner (PVP) + MyChart|A Licensed Vocational Nurse (LVN) will verify patient smoking history and calculate pack years with the patient over the phone. In addition, the patient will receive educational video through MyChart prior to an LVN calling.
62621888|NCT06351085|NO_INTERVENTION|Usual Care|Patients will receive usual care.
62621889|NCT03336814|EXPERIMENTAL|terlipressin associated with norepinephrine|
62621890|NCT03336814|PLACEBO_COMPARATOR|placebo (physiologic serum) associated with norepinephrine|
62265100|NCT04103073||Study group|The patient with OSAS 35-70 years of age, clinically stabile, symptoms such as snoring, breathing cessations, and daytime sleepiness, and polysomnographic evidence consistent with mild (5\<apnea hypopnea index (AHI)\< 15) to moderate (16 \< AHI \< 30) OSAS.
62448730|NCT01266538||IBD patients|Patients diagnosed with Inflammatory Bowel Disease (IBD)
62448731|NCT01266538||patients after a Large Bowel Resection|Patients after a Large Bowel Resection, with or without a pouch.
62448732|NCT01266538||Control group|Family members of IBD patients, Patients with Irritable Bowel Syndrome (IBS), Fap (familial polyposis)patients after a large bowel resection, Patient performing screening endoscopy
62448733|NCT01937390||LAMA/LABA Patients|
62621891|NCT00702026|EXPERIMENTAL|1|
62621892|NCT00702026|PLACEBO_COMPARATOR|2|
62265101|NCT02185404|EXPERIMENTAL|wearing the iStride device|The training will consist of four weeks of training with three training sessions performed each week. The training sessions will consist of up to thirty minutes of training with the iStride on, with breaks between walking sessions and as needed if the subject requests an additional break. Subjects will place the device on their foot in which they have the shortest step length, as measured during the pre-training gait analysis. This is typically the healthy side foot. There will also be several follow up visits following the final testing session.
62448734|NCT00731159||A|"Sperm capacitation:~Sperm capacitation is measured in a sample of the same ejaculated sperm unit given for fertilizing human oocytes in an IVF treatment cycle"
62448735|NCT03665181||without modification of dose and without bismuth mask|The cranial CT imaging presrcibed in usual care will be performed without modification of dose and without bismuth mask
62448736|NCT03665181||with modification of dose and with bismuth mask|e cranial CT imaging presrcibed in usual care will be performed with modification of dose and with bismuth mask
62448737|NCT03665181||without modification of dose and with bismuth mask|e cranial CT imaging presrcibed in usual care will be performed without modification of dose and with bismuth mask
62621893|NCT05885061|ACTIVE_COMPARATOR|Spinal cord stimulation turned on|
62621894|NCT05885061|PLACEBO_COMPARATOR|Spinal cord stimulation turned off|
62621895|NCT05885061|ACTIVE_COMPARATOR|Spinal cord stimulation turned on and suggestions|
62621896|NCT05885061|NO_INTERVENTION|Control|
62848058|NCT01454141|EXPERIMENTAL|Cognitive Control Training|Cognitive Control Training (CCT) A modified version of the Paced Auditory Serial Addition Task (PASAT) and the Attention Control Intervention were used to train participants' attentional control in accordance with procedures used by Siegle and colleagues.
62848059|NCT04229134|OTHER|Pilot Arm: Project CONNECT|8-week home based reciprocal peer support pain self-management program for chronic musculoskeletal pain
62848060|NCT02668211|OTHER|PROFEMUR Preserve RSA|Single cohort of subjects prospectively implanted with PROFEMUR® Preserve Classic femoral components
62848061|NCT01050894||osteoarthritis patients|
62448738|NCT03665181||with modification of dose and without bismuth mask|e cranial CT imaging presrcibed in usual care will be performed with modification of dose and without bismuth mask
62448739|NCT00855283|EXPERIMENTAL|Arm 1|SCI
62448740|NCT02208141||lean and obese children and adolescents|study cohort may be stratified for lean (definded as BMI \<1.28 SDS) and overweight/obese (definded as BMI\>= 1.28 SDS) children for posthoc analyses no intervention
62448741|NCT01110265|PLACEBO_COMPARATOR|placebo training|
62448742|NCT01110265|EXPERIMENTAL|attention training|
62448743|NCT01412138||ARM 1|ENDOMETRIAL SAMPLE
62448744|NCT03820102||Vit D deficiency|Chronic HCV patients with vitamin D deficiency Sustained virological response after treatment
62448745|NCT03820102||Normal Vit D|Chronic HCV patients with normal vitamin D level Sustained virological response after treatment
62448746|NCT04641936||Cohort A|Training cohort will be recruited in the first 24 months of the study period to generate urine metabolomic and proteomic profiles as predictive and prognostic markers.
62448747|NCT04641936||Cohort B|Validation cohort will be recruited in the next 36 months of the study period.
62448748|NCT05033223|OTHER|Follow-up|
62448749|NCT03383393||adenosine|Intracoronary bolus of adenosine (adenocor)
62448750|NCT03383393||GP IIb/IIIa|Intracoronary bolus of Integrilin (eptifibatide)
62448751|NCT03383393||Nitroglycerine|Intracoronary bolus of nitroglycerine (nitronal)
62448752|NCT01606306|EXPERIMENTAL|Crossover sequence 1|daily fluticasone propionate, followed by daily montelukast, followed by as needed fluticasone propionate
62448753|NCT01606306|EXPERIMENTAL|Crossover sequence 2|daily fluticasone propionate, followed by as needed fluticasone propionate, followed by daily montelukast
62448754|NCT01606306|EXPERIMENTAL|Crossover sequence 3|daily montelukast, followed by as needed fluticasone propionate, followed by daily fluticasone propionate
62448755|NCT01606306|EXPERIMENTAL|Crossover sequence 4|daily montelukast, followed by daily fluticasone propionate, followed by as needed fluticasone propionate
62448756|NCT01606306|EXPERIMENTAL|Crossover sequence 5|as needed fluticasone propionate, followed by daily fluticasone propionate, followed by daily montelukast
62448757|NCT01606306|EXPERIMENTAL|Crossover sequence 6|as needed fluticasone propionate, followed by daily montelukast, followed by daily fluticasone propionate
62448758|NCT01623622|EXPERIMENTAL|HC-58 low dose|Low dose
62448759|NCT01623622|EXPERIMENTAL|HC-58 high dose|High dose
62448760|NCT01623622|PLACEBO_COMPARATOR|Placebo|
62448761|NCT06015633||Exudative AMD|Subjects that have at least one eye with a history of, or active, exudative age related macular degeneration
62448762|NCT06015633||Non-exudative AMD|Subjects that have at least one eye with late stage non-exudative age-related macular degeneration (presence of geographic atrophy)
62448763|NCT05670054|ACTIVE_COMPARATOR|palbociclib + fulvestrant|Arm A includes patients who receive palbociclib 125 mg tab/day for 3 weeks and 1 week rest+ Fulvestrant 500 mg IM injection d1, d15, d29 1st cycle then every month
62448764|NCT05670054|ACTIVE_COMPARATOR|Ribociclib + fulvestrant|Arm B includes patients who receive ribociclib 200 mg 3 tabs/day for 3 weeks and 1 week rest+ Fulvestrant 500 mg IM injection d1, d15, d29 1st cycle then every month
62448765|NCT03341507|EXPERIMENTAL|laryngoscopy and tracheal intubation|Tracheal intubation with the rigid tube for laryngoscopy for patients with difficult airway. Prior the use of rigid tube for laryngoscopy, a classical laryngoscopy with a McIntosh laryngoscope will be performed.
62448766|NCT03089528|EXPERIMENTAL|Videolaryngoscopy|the trachea will be intubated using a videolaringoscope
62448767|NCT03089528|ACTIVE_COMPARATOR|Direct laringoscopy|the trachea will be intubated using a laringoscope
62448768|NCT03049683||Normal subjects|Thirty healthy volunteers without a previous history of vertigo or neuro-otologic diseases will be enrolled in this study. The subjects will be also screened with a full history on vestibular disorders, with pure tone audiogram, and head-impulse tests to exclude the possibility of previous vestibular disorders or migraine which may cause abnormal VEMPs.
62621897|NCT05556941|EXPERIMENTAL|Metacognitive Group Intervention|Meta cognitive intervention protocol based on the dynamic interactional model of cognition (Toglia, 2005), and specifically tailored to individuals with schizophrenia.
62265102|NCT05229302|EXPERIMENTAL|Intervention|Secondary students with suicidal ideation participating in the intervention (Reframe-IT). The students will be referred to Primary care where they will be assessed by a physician who will determine if the adolescent could enter into the National Depression Treatment Program for people aged 15 and above, which is organized as a step care treatment
62265103|NCT05229302|ACTIVE_COMPARATOR|Control|Secondary students referred to Primary care where they will be assessed by a physician who will determine if the adolescent could enter into the National Depression Treatment Program for people aged 15 and above, which is organized as a step care treatment.
62621898|NCT05556941|ACTIVE_COMPARATOR|Occupational therapy standard care|Standard care of occupational therapy in mental health, focused on work occupations.
62265104|NCT06493474|EXPERIMENTAL|PABEP group|In the research, first of all, breastfeeding training will be given to a nurse mother who has given birth. After this training, the nurse will convey to the mothers the problems she has experienced and coping methods at the end of each training period during the training that the researcher will give to the mothers.
62621899|NCT02609984|EXPERIMENTAL|CMB305 (sequentially administered LV305 and G305)+Atezolizumab|Participants received CMB305 treatment in combination with 1200 mg/day atezolizumab administered by intravenous (IV) infusion every 3 weeks (Q3W) for up to approximately 2 years. CMB305 treatment consisted of 2 doses of LV305 administered intradermally (ID) on Days 0 and 14 followed every 2 weeks with alternating doses of G305 administered intramuscularly (IM) and LV305. LV305 was administered at a dose of 1×10\^10 vector genomes and G305 at a dose of 5 mcg glucopyranosyl lipid A stable emulsion mixed with 250 mcg of NY ESO-1 protein.
62621900|NCT02609984|ACTIVE_COMPARATOR|Atezolizumab|Participants received 1200 mg/day atezolizumab by IV infusion Q3W for up to approximately 2 years.
62265105|NCT06493474|ACTIVE_COMPARATOR|Control Group|They will only receive the routine training provided by the application center.
62265106|NCT03449095|EXPERIMENTAL|Alcohol Administration|A moderate dose of alcohol (Target BAC .08%)
62621901|NCT01331707|ACTIVE_COMPARATOR|Promus Element|
62848062|NCT03476590|NO_INTERVENTION|standard care|In standard care group the patients will be recommended to visit physician/cardiologists in standard healthcare system. Two non-interventional visits will be performed: recruitment visit (day of enrolment) and summary visit (12th month after the enrolment)
62265107|NCT03449095|NO_INTERVENTION|Control Beverage Administration|Participants consume a non-alcoholic beverage
62621902|NCT01331707|ACTIVE_COMPARATOR|Resolute Integrity|
62621903|NCT02394119|EXPERIMENTAL|Ofatumumab|"* Drug Name: Ofatumumab~* Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities~* Procedures: methylprednisolone 2 mg/kg infused in 30' IV diluted in 100 ml of normal saline (NaCl 0,9%); oral paracetamol 15 mg/kg ; cetirizine 0,4 mg/kg IV infused slowly in 5 ml of normal saline (NaCl 0,9%) prior to Ofatumumab infusion to reduce common reactions~* How: Ofatumumab IV: 1500 mg/1.73m2 at 12 ml/hour in the first 30'. Thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 200 ml/hour.~* When and how much: once; diluted in 1000 ml of normal saline."
62621904|NCT02394119|ACTIVE_COMPARATOR|Rituximab|"* Drug Name: Rituximab (RTX)~* Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities~* Procedures: the same as for Ofatumumab Arm~* How: Rituximab IV: 375 mg/m2; for dosage between 100 and 250 mg RTX will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg RTX will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg RTX will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.~* When and how much: once; diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg."
62621905|NCT03866629||Lifitegrast 5%|Patients will receive lifitegrast 0.5% eye drops twice daily 4 weeks prior to cataract surgery.
62848063|NCT03476590|EXPERIMENTAL|intervention group|"In intervention group patients will be referred to ambulatory care point (ACP) and the physicians will perform remote teleconsultations. The visits will be realized by nurses supported with vital sign assessment based on bioimpedance diagnostic methods (impedance cardiography, bioimpedance scale). The ambulatory visits will be performed according to the schedule: (1') recruitment visit (1st day of enrolment) performed by physician -\> 7 ambulatory visits: (1) 1st day of enrolment (performed by nurse and physician), (2) 7th-10th day (performed by nurse and physician), (3) 1st month, (4) 3th month, (5) 6th month, (6) 9th month, (7) 12th month after the enrolment (visits no 3-7 performed by nurse with tele-supervision by physician) and -\> (7') summary visit (12th month after the enrolment) performed by physician.~The plan of visits may be modified if required by the clinical status change, i.e. deterioration of clinical parameters and interim hospitalizations for worsening heart failure."
62848064|NCT03386916||Patient with a CT scan guide percutaneous biopsy of lytic bone|Patient with a CT scan guide percutaneous biopsy of lytic bone metastases register on CHU Grenoble Alpes radiology software between January 2010 and June 2017
62848065|NCT05246345||Cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax|Cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax
62848066|NCT01254708|ACTIVE_COMPARATOR|Control|Standard of care group. Medication as prescribed by the primary physician would be used by this group. Such medications might include azoles as voriconazole
62061095|NCT04598906|EXPERIMENTAL|Virtual environment rehabilitation - Paper-pencil rehabilitation|The participants in this arm completes Virtual environment rehabilitation as the first condition and then crossover to Paper-pencil rehabilitation.
62061096|NCT04598906|EXPERIMENTAL|Paper-pencil rehabilitation - Virtual environment rehabilitation|The participants in this arm completes Paper-pencil rehabilitation as the first condition and then crossover to Virtual environment rehabilitation.
62061097|NCT05848921||CAS-CN|Carotid Artery Stenosis with cognitive normality
62621906|NCT02775292|EXPERIMENTAL|Treatment (NY-ESO-1 TCR transduced PBMC, vaccine, nivolumab)|"CONDITIONING REGIMEN: Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 30 minutes on days -4 to -1.~NY-ESO-1 TCR PBMC INFUSION: Patients receive NY-ESO-1 TCR PBMC IV on day 0.~NIVOLUMAB: Patients receive nivolumab IV over 60 minutes on day 0 or 1. Treatment repeats every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.~NY-ESO-1(157-165) PEPTIDE PULSED DC: Patients receive NY-ESO-1(157-165) peptide pulsed DC ID on days 1, 14, and 28.~LOW DOSE ALDESLEUKIN ADMINISTRATION: Patients receive aldesleukin SC BID for 7 days beginning on day 1 for a maximum of 14 doses."
62621907|NCT04156386|ACTIVE_COMPARATOR|Animal Protein|
62621908|NCT04156386|ACTIVE_COMPARATOR|Vegan Protein|
62621909|NCT04156386|PLACEBO_COMPARATOR|Placebo|
62621910|NCT02534519||people negative in bg MNSs antigen U|"Blood group (bg) system MNSs. Individuals with phenotype U-. Homo- and heterozygous individuals may be considered."
62621911|NCT02534519||people positive in bg MNSs antigen St(a)|"Blood group (bg) system MNSs. Individuals with phenotype St(a)+. Homo- and heterozygous individuals may be considered."
62621912|NCT00784589|EXPERIMENTAL|Rituximab|
62621913|NCT00784589|ACTIVE_COMPARATOR|Corticotherapy|General Corticotherapy
62621914|NCT02700425|ACTIVE_COMPARATOR|His Bundle Pacing|Subjects will be randomized to the HB lead position with their cardiac resynchronization therapy (CRT) pacemaker. HB lead pacing will be performed with the Medtronic SelectSecure™, Model 3830 lead. Delivery of the lead utilizes a deflectable sheath, the Medtronic SelectSite™, Model C304. Both devices are FDA approved for the purpose of HB pacing. It is the only device available which is presently FDA approved for selective HB pacing.
62621915|NCT02700425|ACTIVE_COMPARATOR|Coronary Sinus Pacing|Subjects will be randomized to the CS lead position with their cardiac resynchronization therapy (CRT) pacemaker. CS lead and CRT device generator selected for implant will be left to the discretion of the operator. Only FDA approved CS leads and CRT generators will be utilized in the study. There are five present manufacturers of CS leads and CRT generators: Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical.
62621916|NCT03782571|EXPERIMENTAL|Test1/Test2/Control/Test3|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
62621917|NCT03782571|EXPERIMENTAL|Test2/Test3/Test1/Control|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
62621918|NCT03782571|EXPERIMENTAL|Test3/Control/Test2/Test1|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
62621919|NCT03782571|EXPERIMENTAL|Control/Test1/Test3/Test2|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
62621920|NCT01424241|EXPERIMENTAL|Sandostatin LAR|Nine months of open label dose escalation Sandostatin LAR therapy.
62623779|NCT02797509|NO_INTERVENTION|Minimally Enhanced Usual Care (MEUC)|Those in the MEUC will continue with their current care. This may include meeting with nurses, physical therapist, medical doctors, and other members of the stroke patient's medical team. Treatment as usual may also involve administration of Selective Serotonin Reuptake Inhibitors (SSRIs) to those patients with motor problems. They will also received a pamphlet with educational information on stroke and recovery
62848067|NCT01254708|EXPERIMENTAL|liposomal amphotericin B (AmBisome ®)|Inhaled Liposomal preparation of Amphotericin B.
62848068|NCT06522126|EXPERIMENTAL|effects of progressive relaxation exercise|Progressive relaxation exercises were given to female students who scored 111 and above on the PMS scale and were selected by randomization for the exercise group. The exercises were applied to those who participated in the study, met the inclusion criteria, and were able to participate in the study for 8 weeks. In the study, progressive relaxation exercises were applied by the researcher to the students in the exercise group with PMS complaints in the first three days of their first menstrual cycle.
62061098|NCT05848921||CAS-MCI|Carotid Artery Stenosis with mild cognitive impairment
62061099|NCT05848921||HC|Healthy controls
62061100|NCT02205216|ACTIVE_COMPARATOR|Active tDCS|Active tDCS combined with a rehabilitative intervention consisting of cognitive training and sensory cueing.
62061101|NCT02205216|SHAM_COMPARATOR|Sham tDCS|Sham tDCS combined with a rehabilitative intervention consisting of cognitive training and sensory cueing.
62265108|NCT04055792|EXPERIMENTAL|Sintilimab combine with Anlotinib|Sintilimab 200 mg on day 1 and oral daily Anlotinib 12 mg on days 1-14 once every 3 weeks
62265109|NCT01714687|ACTIVE_COMPARATOR|balloon sinus dilation|Balloon sinus dilation will be conducted in-office under local anesthesia.
62623780|NCT05768529|EXPERIMENTAL|U16|"Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to U16 infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
62848069|NCT06522126|NO_INTERVENTION|control groups|Control group standard care group
62848070|NCT00644891|ACTIVE_COMPARATOR|1|
62848071|NCT00644891|ACTIVE_COMPARATOR|2|
62848072|NCT05571319|EXPERIMENTAL|Open-label arm|All participants to receive metformin extended-release 1000mg to 2000mg daily for 12 weeks.
62265110|NCT01714687|ACTIVE_COMPARATOR|medical therapy|Medical therapy as needed per subject's specific disease and as determined by the investigators' clinical judgment.
62265111|NCT06004843|EXPERIMENTAL|Remimazolam|In this group, participants are sedated with remimazolam and remifentanil.
62848073|NCT03794336|EXPERIMENTAL|Alogliptin|Single dose of alogliptin once daily for 16 weeks
62848074|NCT03794336|ACTIVE_COMPARATOR|Acarbose|Thrice daily dose of acarbose Dose 1 for 7 days then titrate to thrice daily dose of of acarbose Dose 2
62848075|NCT00900588|EXPERIMENTAL|10 ug|10 microgram split-virion vaccine per dose
62848076|NCT00900588|EXPERIMENTAL|15 ug|15 microgram split-virion vaccine per dose
62848077|NCT00900588|EXPERIMENTAL|30 ug|30 microgram split-virion vaccine per dose
62265112|NCT06004843|ACTIVE_COMPARATOR|propofol|In this group, participants are sedated with propofol and remifentanil.
62265113|NCT00794157|EXPERIMENTAL|Indacaterol 150 µg|Patients received indacaterol 150 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62265114|NCT00794157|EXPERIMENTAL|Indacaterol 300 µg|Patients received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62623781|NCT01860716|PLACEBO_COMPARATOR|Solution for infusion|Solution for infusion administrated via nasogastric tube
62265115|NCT00794157|PLACEBO_COMPARATOR|Placebo|Patients received placebo delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62265116|NCT01280825||Adult Patients|Adults receiving health care at the University of Chicago Medical Center.
62265117|NCT04180293|OTHER|Military Veterans and their families|This group will participate in both the pilot psychoeducation program and its evaluation.
62265118|NCT01788254|EXPERIMENTAL|Drug cocktail|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
62265119|NCT06475456||Pre-Protocol Cohort|Patients enrolled retrospectively between 2016 and 2019
62848078|NCT00900588|ACTIVE_COMPARATOR|5 ug|5 microgram whole-virion vaccine per dose
62848079|NCT02613026|EXPERIMENTAL|Combined therapy group|pirarubicin 50mg/m2, iv, d1; docetaxel 75mg/m2, div, d1. 21 days were a cycle of treatment, with a total of 4-8 cycles.
62848080|NCT02613026|EXPERIMENTAL|Sequential therapy group|cyclophosphamide 600mg/m2, iv, d1; Pirarubicin 60mg/m2, iv, d1, 21 days were a cycle of treatment, with a total of 4 cycles. Then followed by Docetaxel 75- 100mg/m2, div, d1, 21 days were a cycle of treatment, with a total of 4 cycles.
62848081|NCT02122003|EXPERIMENTAL|sorafenib|Sorafenib 400 mg bid
62848082|NCT01599624|EXPERIMENTAL|iPad-based SRTS|
62848083|NCT01599624|EXPERIMENTAL|iPad-based PMR program|
62848084|NCT00329524|SHAM_COMPARATOR|Active versus Sham Treatment|Subjects randomly assigned to active and sham TMS separated by one week interval.
62848085|NCT00218218|EXPERIMENTAL|1|Transdermal nicotine, 42 mg
62848086|NCT00218218|EXPERIMENTAL|2|Transdermal nicotine, 21 mg
62848087|NCT00218218|PLACEBO_COMPARATOR|3|placebo patch
62848088|NCT04122469|EXPERIMENTAL|Oligo-Progression; GU|Receiving SBRT.
62848089|NCT04122469|EXPERIMENTAL|Oligo-metastatic Breast Cancer|Receiving SBRT.
62848090|NCT03878641|EXPERIMENTAL|Children in Grade 1 to 5 with literacy and language needs|The investigators intend to identify children in Grade 1 to 5 who demonstrate language-based learning difficulties. Using the two-stage screening, the investigators will identify children who produce substantial number of reading miscues and/or self-correct more less 25% of their miscues, and/or who present weaknesses in expressive language skills with a total CUBED score lower than grade-specific cut scores.
62848091|NCT01182844|NO_INTERVENTION|Control|Usual care
62848092|NCT01182844|EXPERIMENTAL|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
62848093|NCT00568165|EXPERIMENTAL|1|Mobile Team
62265120|NCT06475456||Post-protocol Cohort|Patients enrolled prospectively between 2024 and 2026
62621921|NCT04671940||Retrospective Cohort|"Patients who have previously had radiotherapy and then have had their local residual/recurrent disease managed with salvage TORS at the Royal Marsden Hospital will be eligible for inclusion. They will be informed of the RECUT+ study by a member of their usual care team at RMH during their routine outpatient appointments for follow up of their H\&N cancer.~Potential participants will be asked to consent to provide blood/saliva sample for germline DNA and for permission for their original tumour biopsy sample and their residual/recurrent resection to undergo DNA analysis. Where patients have returned to their referring institution and are no longer under active regular follow up at RMH, a research pack will be sent to the patient via post and email. This pack will contain the Cover Letter, the Participant Information Sheet and the Informed Consent Form. It will also contain a saliva collection tube, buccal swab, blood tubes and instructions for how to provide blood/saliva samples."
62848094|NCT00568165|ACTIVE_COMPARATOR|2|Standard care
62265121|NCT03143140|EXPERIMENTAL|PAFA and tumor ablation|first percutaneous frequency ablation of tumor feeding artery and then ablation of tumor
62265122|NCT03143140|OTHER|tumor ablation|ablation of tumor directly
62265123|NCT03303742|EXPERIMENTAL|feather edge finish line marginal design|intervention
62265124|NCT03303742|ACTIVE_COMPARATOR|deep chamfer finish line marginal design|comparator
62265125|NCT03926663|EXPERIMENTAL|group Bupivacaine|Group B; will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) as preincisional local infiltration of the nasal mucosa of the nasal septum ,injected once before surgical intervention
62265126|NCT03926663|ACTIVE_COMPARATOR|group Bupivacaine +Dexmedetomidine|group B+D; will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) + 0.2 μg/kg dexmedetomidine preincisional local infiltration of the nasal mucosa of the nasal septum,injected once before surgical intervention.
62848095|NCT04009811|EXPERIMENTAL|Suersen obturator then membraneous obturator|
62848096|NCT04009811|EXPERIMENTAL|Membraneous obturator then Suersen obturator|
62848097|NCT05773378|EXPERIMENTAL|Pessary Intervention|"Participants randomized to this group will receive an Uresta Incontinence Pessary to use each time they run over a 10-week period. They will be instructed to use the pessary only while running and remove it and wash it with soap and water when the training is over.~Uresta is a reusable and removable device made of hypoallergenic medical-grade resin that is inserted into the vagina to provide mechanical support. It comes with a starter kit with 3 different sizes which work for over 80% of women. Participants will be instructed on how to test the 3 sizes to find out which one is right for them."
62265127|NCT04351984||Severe Mitral Regurgitation|
62265128|NCT02952157|SHAM_COMPARATOR|Control|Normal saline will be applied to the endotracheal tube.
62265129|NCT02952157|ACTIVE_COMPARATOR|Lidocaine|Lidocaine jelly will be applied to the endotracheal tube.
62265130|NCT02967874|EXPERIMENTAL|Intra-articular auto-SVFs injection|"The participants will undergo a standard liposuction to harvest adipose tissue. The adipose tissue will then be processed to obtain the SVFs.~This group of subjects (n=16) will receive a single injection of auto-SVFs into affected knees (3.0 mL cell suspension/joint)."
62848098|NCT05773378|EXPERIMENTAL|Tampon Intervention|Participants randomized to this group will receive 60 regular Tampax tampons and will be instructed to use them each time they run over a 10-week period. The tampon should be used only while running and removed and discarded when the training is over. Four weeks after the intervention (at the 16 weeks follow-up), they will receive a pessary with instruction how to use it if they desire so.
62265131|NCT02967874|ACTIVE_COMPARATOR|Intra-articular Hyaluronic Acid|This group of subjects (n=11) will receive a single injection of Synocrom Forte 2% into affected knees (1.0 mL/joint).
62265132|NCT01930136|EXPERIMENTAL|Calorie restriction (25%)|CR will correspond to a reduction of 25% from the total daily calorie expenditure calculated as Total Daily Energy Expenditure (TDEE) (kcal/d) using the formula from the validated Seven-Day Physical Activity Recall (PAR) Questionnaire (RMR x activity levels).
62621922|NCT04671940||Prospective Cohort|Patients who have previously had radiotherapy and then are due to have their local residual/recurrent disease managed with salvage transoral robotic surgery at the Royal Marsden Hospital (RMH) will be approached prior to their salvage surgery at a routine outpatient appointment. They will be asked to consent to provide blood/saliva sample for germline DNA pre and post operatively. They will also be asked for permission for their original tumour biopsy sample and their residual/recurrent resection to undergo DNA analysis
62621923|NCT02824211|EXPERIMENTAL|Right Dose System|Use of automated oxygen titration during exertion
62621924|NCT00527124|EXPERIMENTAL|Arm I|Patients receive oral cediranib maleate once daily on days 1-21, docetaxel IV over 1 hour on day 1, and oral prednisone twice daily on days 1-21.
62265133|NCT01930136|ACTIVE_COMPARATOR|Ad libitum health diet|
62448769|NCT03049683||Acute unilateral vestibular neuritis|The criteria for inclusion as a patient with vestibular neuritis involving the superior division (superior VN) included the following: (1) acute onset of vertigo, (2) the appearance of mixed horizontal and torsional nystagmus, (3) impaired horizontal semicircular canal (SCC) function on head-impulse test and a unilaterally absent or reduced caloric response (i.e., a caloric paresis score \> 25%), (4) intact inferior division of vestibular nerve as evidenced by normal cVEMP and normal head-impulse test for vertical SCCs, and (5) the absence of auditory and neurologic signs. Thirty patients (aged 32-82 years; mean age, 51.7 years; 16 males) fulfilled the criteria of superior VN.
62448770|NCT05226910|EXPERIMENTAL|tDCS and intensive therapies|Cathodal tDCS and constraint induce movement therapy
62265134|NCT00629291||1|Sickle cell anemia patients
62448771|NCT05226910|SHAM_COMPARATOR|Sham and intensive therapies|Sham tDCS and constraint induce movement therapy
62448772|NCT05070156|EXPERIMENTAL|Experimental: B010-A injection for patient with GPC3 Positive Hepatocellular Carcinoma|
62448773|NCT00996190|ACTIVE_COMPARATOR|Phenylephrine Intermittent Bolus|Bolus syringe will contain 120 micrograms/mL of phenylephrine. Infusion solution bag will contain placebo (saline solution).
62448774|NCT00996190|ACTIVE_COMPARATOR|Phenylephrine Continuous Infusion|Infusion solution bag will contain 120 micrograms/mL of phenylephrine. Bolus syringe will contain placebo (saline solution).
62448775|NCT00757913|EXPERIMENTAL|1|n-3 enriched nutrition
62448776|NCT00757913|PLACEBO_COMPARATOR|2|isocaloric nutrition without n-3 supplement
62448777|NCT01579409|OTHER|1-25th percentile of the PNNS score|
62621925|NCT00527124|ACTIVE_COMPARATOR|Arm II|Patients receive docetaxel and prednisone as in arm I.
62621926|NCT05327595|EXPERIMENTAL|LY3549492 (Part A)|LY3549492 administered orally as multiple ascending doses.
62621927|NCT05327595|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered orally.
62848099|NCT05773378|NO_INTERVENTION|Control Group|Participants randomized to this group won't receive any intervention and will be asked to continue their running training as usual for 10-weeks. They will also be instructed to not begin any treatment for urinary incontinence until their reassessment. Four weeks after the intervention (at the 16 weeks follow-up), they will receive a pessary with instruction how to use it if they desire so.
62848100|NCT00904033|ACTIVE_COMPARATOR|Multivitamin|Multivitamin used as control group.
62265135|NCT00629291||2|Sickle cell β thalassemia
62265136|NCT01601028|ACTIVE_COMPARATOR|Hydroxychloroquine|Hydroxychloroquine 300 mg once daily p.o.
62448778|NCT01579409|OTHER|75-100th percentile of the PNNS score|
62448779|NCT02320942|EXPERIMENTAL|Exercise Intervention|At discharge from the inpatient unit, participants will receive a practical introduction by an exercise specialist and enrolled in the 12-week exercise intervention
62448780|NCT02741492|ACTIVE_COMPARATOR|Block Group|Continuous Transversus Abdominis Plane Catheter
62448781|NCT02741492|SHAM_COMPARATOR|Sham Group|Continuous Sham Catheter
62448782|NCT02970643|EXPERIMENTAL|Olanzapine group|Palonosetron and Olanzapine Without Dexamethasone in moderate risk chemotherapy induced nausea and vomiting group
62448783|NCT06143059|EXPERIMENTAL|Alcohol Administration - Late Luteal Phase|During the late luteal phase of a female participant's menstrual cycle, participants will complete a lab session where alcohol is administered intravenously. The infusion will include a 30-minute linear ascension from 0mg% breath alcohol content (BrAC) to 100mg%, followed by a 60-minute 'clamping' of BrAC at 100mg%. Subjects will then be monitored while they sleep, using polysomnography. Male subjects will complete this and the placebo session at intervals that are matched to the female subjects. The placebo and alcohol sessions during late luteal phase will take place 1-2 days apart, and their order will be randomized.
62621928|NCT05327595|EXPERIMENTAL|LY3549492 + Midazolam + Atorvastatin (Part B)|LY3549492 coadministered orally with midazolam and atorvastatin.
62621929|NCT05327595|PLACEBO_COMPARATOR|Placebo + Midazolam + Atorvastatin (Part B)|Placebo coadministered orally with midazolam and atorvastatin.
62265137|NCT01601028|PLACEBO_COMPARATOR|Placebo|Placebo
62265138|NCT03842423||Study Group|All patients under the age of 18 who were treated for upper extremity injuries between 2002 and 2018 and receiving brachial plexus anaesthesia.
62265139|NCT05252364|EXPERIMENTAL|Part 1 - Dose Escalation, 25mg/d (Cohort 1)|Oral tablet(s), once daily in 28-day cycles
62265140|NCT05252364|EXPERIMENTAL|Part 1 - Dose Escalation 100mg/d (Cohort 2)|Oral tablet(s), once daily in 28-day cycles
62265141|NCT05252364|EXPERIMENTAL|Part 1 - Dose Escalation 200mg/d (Cohort 3)|Oral tablet(s), once daily in 28-day cycles
62265142|NCT05252364|EXPERIMENTAL|Part 1 - Dose Escalation 300mg/d (Cohort 4)|Oral tablet(s), once daily in 28-day cycles
62621930|NCT05759065|EXPERIMENTAL|Tele-Brief Behavioral Treatment for Insomnia|
62621931|NCT05759065|ACTIVE_COMPARATOR|Tele-Cognitive-Behavioral Therapy for Insomnia|
62061102|NCT06450717|EXPERIMENTAL|VRRS group|"Participants will receive telerehabilitation treatment based delivered by Khymeia VRRS technology platform. The VRRS device, in the home version, is used in tele-rehabilitation mode. There are two modes of operation in tele-rehabilitation: on line mode: the therapist is able to take control of the system remotely and interact with the patient in real time through the integrated two-way video conferencing system with pan and zoom camera with which the VRRS is equipped; off-line mode: the therapist can prepare a list of exercises to be performed by the patient at home, assisted by the smart virtual assistant who guides the patient in the execution of the rehabilitation program. The home device automatically records all activities performed by the patient independently. The therapist can connect to the home device at any time to review the tests performed or modify the exercise list or make appropriate changes to the specific patient's rehabilitation program."
62265143|NCT05252364|EXPERIMENTAL|Part 1 - Dose Escalation 400mg/d (Cohort 5)|Oral tablet(s), once daily in 28-day cycles
62265144|NCT05252364|EXPERIMENTAL|Part 1 - Dose Escalation 500mg/d (Cohort 6)|Oral tablet(s), once daily in 28-day cycles
62265145|NCT05252364|EXPERIMENTAL|Part 2 - Dose Expansion|Oral tablet(s), once daily in 28-day cycles
62448784|NCT06143059|PLACEBO_COMPARATOR|Placebo - Late Luteal Phase|During the late luteal phase of a female participant's menstrual cycle, participants will complete a lab session where saline is administered intravenously, as placebo, for 90 minutes. Subjects will then be monitored while they sleep, using polysomnography. Male subjects will complete this and the experimental session at intervals that are matched to the female subjects. The placebo and alcohol sessions during late luteal phase will take place 1-2 days apart, and their order will be randomized.
62621932|NCT00564278|ACTIVE_COMPARATOR|Standard antidepressant therapy|Participants will receive standard antidepressant therapy, including selecting among 9 FDA-approved antidepressants from several classes.
62621933|NCT00564278|EXPERIMENTAL|Motivational antidepressant therapy|Participants will receive motivational antidepressant therapy, including selecting among the same list of 9 FDA-approved antidepressants from several classes as in the control arm.
62621934|NCT02651493|ACTIVE_COMPARATOR|Down syndrome|photographs of individuals less than 18 yo with Down syndrome
62621935|NCT02651493|ACTIVE_COMPARATOR|Control group|photographs of individuals less than 18 yo with a genetic referral (not Down syndrome) or a healthy sibling to a child with Down syndrome
62621936|NCT00082095|EXPERIMENTAL|Group 1 (doxorubicin)|Pegylated liposomal doxorubicin 40 mg/m2 administered intravenously on Day 1 of each cycle. Cycle is repeated every 28 days, up to one year.
62621937|NCT00082095|ACTIVE_COMPARATOR|Group 2 (capecitabine )|Capecitabine administered orally at a dosage of 2000 mg/m2/day (1000 mg/m2 BID) for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
62621938|NCT05942521|EXPERIMENTAL|Very brief extinction|Enrolled participants would receive very brief extinction approximately 25 minutes per day for 2 days.
62848101|NCT00904033|EXPERIMENTAL|Exercise|Exercise consisting of progressive walking and resistance band training.
62848102|NCT00904033|EXPERIMENTAL|Calcitriol|Calcitriol pill taken once per week.
62848103|NCT00904033|EXPERIMENTAL|Calcitriol and Exercise|Calcitriol pill taken once per week plus Exercise consisting of progressive walking and resistance band training.
62848104|NCT00600977|ACTIVE_COMPARATOR|doxorubicine|VAD
62265146|NCT03269435|EXPERIMENTAL|Greater Occipital Nerve Block|"Bilateral greater occipital nerve block with bupivacaine 0.5%~+ Normal saline IV"
62265147|NCT03269435|ACTIVE_COMPARATOR|Metoclopramide|"Metoclopramide 10mg IV~+ Bilateral greater occipital nerve block with normal saline"
62265148|NCT02228590|OTHER|APL-130277|open label baseline comparison
62265149|NCT01963312|EXPERIMENTAL|Transarterial Supraselective Embolization|Transarterial supraselective embolization of prostatic arteria with Bead Block 300-500 μm
62265150|NCT01963312|ACTIVE_COMPARATOR|Transurethral Resection|Surgery to remove part of the prostate gland
62265151|NCT02394873|EXPERIMENTAL|ALLO-ASC-DFU|
62265152|NCT01991340||Cohort|
62265153|NCT02982343|EXPERIMENTAL|Falls management plus exercise training|Falls management and education session. Home proximal lower limb strength training and multi-sensory balance training.
62265154|NCT02982343|ACTIVE_COMPARATOR|Falls management only|Falls management and education session only.
62265155|NCT00610987|ACTIVE_COMPARATOR|Cefazolin|Group I will receive 1-g doses of cefazolin every eight hours for the next 24 hours after surgical repair of the closed limb fracture.
62265156|NCT00610987|PLACEBO_COMPARATOR|Placebo|Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo, after the intraoperative dose(s) of cefazolin
62265157|NCT01951820|ACTIVE_COMPARATOR|Benzocaine|Benzocaine topical numbing gel will be applied to the gums before injection with other intervention, injection of local anesthetic articaine.
62265158|NCT01951820|EXPERIMENTAL|Pliaglis|Pliaglis topical numbing gel will be applied to the gums before injection with other intervention, injection of local anesthetic articaine.
62265159|NCT04661709|EXPERIMENTAL|Wen Xin granule|Patients are given Wen Xin granule by mouth, one dose daily for 2 months \& Conventional western medicine, including Aspirin Enteric-coated Tablets 100mg qd, Clopidogrel Hydrogen Sulfate 75 mg qd, Atorvastatin Calcium 20mg qn, Isosorbide Mononitrate Tab 20 mg bid, Metoprolol Tartrate Tab 25mg, Trimetazidine Dihydrochloride Tablets 20mg tid.
62265160|NCT04661709|PLACEBO_COMPARATOR|WXG placebo|Patients are given Wen Xin granule placebo by mouth, one dose daily for 2 months \& Conventional western medicine, including Aspirin Enteric-coated Tablets 100mg qd, Clopidogrel Hydrogen Sulfate 75 mg qd, Atorvastatin Calcium 20mg qn, Isosorbide Mononitrate Tab 20 mg bid, Metoprolol Tartrate Tab 25mg, Trimetazidine Dihydrochloride Tablets 20mg tid.
62621939|NCT05942521|SHAM_COMPARATOR|Very brief neutral extinction|Enrolled participants would receive very brief neutral extinction for approximately 25 minutes per day for 2 days.
62621940|NCT05942521|ACTIVE_COMPARATOR|Clearly visible extinction|Enrolled participants would receive clearly visible extinction therapy for approximately 25 minutes per day for 2 days.
62621941|NCT02210325|ACTIVE_COMPARATOR|Ceftriaxone plus Azithromycin|A single intramuscular dose of 500 mg ceftriaxone plus a single oral dose of 1000 mg azithromycin
62621942|NCT02210325|EXPERIMENTAL|Solithromycin|A single oral dose of 1000 mg solithromycin
62621943|NCT03812263|EXPERIMENTAL|RP-L201|RP-L201 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with Chim-CD18-WPRE lentiviral vector administered as a single intravenous infusion
62621944|NCT03550547|EXPERIMENTAL|7 educational workshops|"Intervention: 7 educational workshops in addition to spa therapy :~Knowledge of the pathology ; Educational physical activity ( 2 workshops); Dietary; Management of pain, fatigue and the medical treatments; Articular hygiene and ergonomics; Technical assistance, an adaptation of the living condition"
62621945|NCT03550547|ACTIVE_COMPARATOR|spa therapy|Approved Spa therapy
62061103|NCT03819725|OTHER|Glucose monitoring|FreeStyle® Libre Pro Interstitial Glucose Meter will be applied after skin preparation with anesthetic cream (Emla® ) and glucose measurements will be monitored during 2-5 days. Oral food intake will be recorded.
62061104|NCT04843722|EXPERIMENTAL|Cohort 1: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous|Cohort 1 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous on Day 1
62061105|NCT04843722|EXPERIMENTAL|Cohort 2: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Sublingual|Cohort 2 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Sublingual on Day 1
62061106|NCT05301270||Transtibial Amputees|Individuals aged 18-45 years, with unilateral transtibial amputation, traumatic amputation cause, using prosthesis for at least 1 year, no skin lesions-open wound on the stump, no phantom sensation or pain, no musculoskeletal problems that may affect balance other than amputation will be included.
62448785|NCT06143059|EXPERIMENTAL|Alcohol Administration - Mid-Follicular Phase|During the mid-follicular phase of a female participant's menstrual cycle, participants will complete a lab session where alcohol is administered intravenously. The infusion will include a 30-minute linear ascension from 0mg% breath alcohol content (BrAC) to 100mg%, followed by a 60-minute 'clamping' of BrAC at 100mg%. Subjects will then be monitored while they sleep, using polysomnography. Male subjects will complete this and the placebo session at intervals that are matched to the female subjects. The placebo and alcohol sessions during mid-follicular luteal phase will take place 1-2 days apart, and their order will be randomized.
62448786|NCT06143059|PLACEBO_COMPARATOR|Placebo - Mid-Follicular Phase|During the mid-follicular phase of a female participant's menstrual cycle, participants will complete a lab session where saline is administered intravenously, as placebo, for 90 minutes. Subjects will then be monitored while they sleep, using polysomnography. Male subjects will complete this and the experimental session at intervals that are matched to the female subjects. The placebo and alcohol sessions during mid-follicular phase will take place 1-2 days apart, and their order will be randomized.
62448787|NCT02942966|EXPERIMENTAL|Tack Implant|Implantation of a Tack using the Intact Vascular Tack Endovascular System for the repair of post angioplasty dissections below the knee.
62448788|NCT04152629|EXPERIMENTAL|FOQUEST adults|adult (≥18 years or older) patients with ADHD receiving FOQUEST (controlled-release methylphenidate 25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg, or 100 mg/day)
62621946|NCT05784402|EXPERIMENTAL|Sequence A: Semaglutide J-Semaglutide C-Semaglutide J|After 6 weeks of run-in dose escalation period participants will orally receive semaglutide J at dose level 1 once daily for 4 weeks followed by semaglutide C once daily for next 4 weeks and thereafter semaglutide J at dose level 3 once daily for next 4 weeks.
62621947|NCT05784402|EXPERIMENTAL|Sequence B: Semaglutide C-Semaglutide J-Semaglutide J|After 6 weeks of run-in dose escalation period participants will orally receive semaglutide C once daily for 4 weeks followed by semaglutide J at dose level 2 once daily for next 4 weeks and thereafter semaglutide J at dose level 4 once daily for next 4 weeks.
62621948|NCT05784402|EXPERIMENTAL|Sequence C: Semglutide J-Semaglutide J-Semaglutide C|After 6 weeks of run-in dose escalation period participants will orally receive semaglutide J at dose level 1 once daily for 4 weeks followed by semaglutide J at dose level 3 once daily for next 4 weeks and thereafter semaglutide C (2x dose) once daily for next 4 weeks.
62621949|NCT05784402|EXPERIMENTAL|Sequence D: Semaglutide J-Semaglutide C-Semaglutide J|After 6 weeks of run-in dose escalation period participants will orally receive semaglutide J at dose level 2 once daily for 4 weeks followed by semaglutide C (2x dose) once daily for next 4 weeks and thereafter semaglutide J at dose level 4 once daily for next 4 weeks.
62621950|NCT03637790|OTHER|PF 04965842|In Period 1, subjects will be administered a single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.
62621951|NCT03637790|OTHER|Rifampin and PF 04965842|In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.
62621952|NCT06410417|EXPERIMENTAL|Short abstinence time group|abstinence time is less than 48 hours
62621953|NCT06410417|NO_INTERVENTION|routine abstinence time group|Abstinence for 3-7 days
62621954|NCT01602497|ACTIVE_COMPARATOR|rTMS intervention group|The rTMS intervention group undergo ten session of real TMS therapy.
62621955|NCT01602497|PLACEBO_COMPARATOR|Sham group|Patients will undergo ten session of sham rTMS.
62623782|NCT01860716|EXPERIMENTAL|Melatonin|30 mg melatonin administrated via nasogastric tube in the Intensive Care Unit when included in the study and 30 mg melatonin 60 minutes before transfer to the operating room.
62848105|NCT00600977|EXPERIMENTAL|Doxorubicine pegylated|Doxorubicine pegylated 40 MG/M² J1
62848106|NCT00357279|PLACEBO_COMPARATOR|1|Placebo
62621956|NCT05327751|ACTIVE_COMPARATOR|Celecoxib arm|This arm will include 22 patients who will receive 6 cycles of capecitabine-based chemotherapy (cycle is every 3 weeks) in addition to 200 mg of oral celecoxib twice daily for 14 days of the 3-week cycle. The study duration will be the duration of the 6 cycles.
62621957|NCT05327751|PLACEBO_COMPARATOR|Control arm|This arm will include 22 patients who will receive 6 cycles of capecitabine-based chemotherapy (cycle is every 3 weeks).
62621958|NCT04889170||Biofeedback therapy + Voice training|The intervention has two parts. One part of the intervention is the biofeedback therapy. The biofeedback therapy means that the patient and a speech and language therapist watch the video of the FEES together and discuss the findings. The other part of the intervention is a voice training. The frequency of therapy is minimum 3 times a week, the duration of one therapy is minimum 25 minutes.
62621959|NCT04889170||Biofeedback therapy + Swallow training|The intervention has two parts. One part of the intervention is the biofeedback therapy. The biofeedback therapy means that the patient and a speech and language therapist watch the video of the FEES together and discuss the findings. The other part of the intervention is a swallow training. The frequency of therapy is minimum 3 times a week, the duration of one therapy is minimum 25 minutes.
62621960|NCT06027255|OTHER|Post- COVID 19 POTS patients|Inflammatory markers IL-6,Cytokines (IL-17, and IFN-ɣ), Autonomic symptoms assessment questionnaire (COMPASS 31): In post-COVID-19 POTS (cases).
62621961|NCT06027255|OTHER|POTS patients|Inflammatory markers IL-6,Cytokines (IL-17, and IFN-ɣ), Autonomic symptoms assessment questionnaire (COMPASS 31):Gender, age, and BMI-matched: patients with diagnosis of POTS
62621962|NCT06027255|OTHER|Post- COVID 19 POTS patients with Controls|Inflammatory markers IL-6,Cytokines (IL-17, and IFN-ɣ), Autonomic symptoms assessment questionnaire (COMPASS 31):Gender, age, and BMI-matched: Controls are :COVID-19 infected without sequelae
62621963|NCT05588934|PLACEBO_COMPARATOR|Placebo Dose Both Nights|Participants will be administer non-caffeinated, placebo gum during both nights of Phase 2.
62621964|NCT05588934|ACTIVE_COMPARATOR|Standard Caffeine Dose Both Nights|Participants will be administer the standard caffeine recommendation (200mg/2 hr. up to 800mg/24 hr.) using caffeinated and non-caffeinated gum during both nights of Phase 2.
62621965|NCT05588934|ACTIVE_COMPARATOR|Optimized Caffeine Dose Both Nights|Participants will be administer the optimized caffeine recommendation (0-300mg/2 hr. up to 800mg/24 hr.) potentially using caffeinated and non-caffeinated gum, depending on optimized dosage, during both nights of Phase 2.
62621966|NCT05588934|ACTIVE_COMPARATOR|Placebo Dose 1st Night/Standard Caffeine Dose 2nd Night|Participants will be administer non-caffeinated, placebo gum during the first night of Phase 2. Then, participants will be administer the standard caffeine recommendation (200mg/2 hr. up to 800mg/24 hr.) using caffeinated and non-caffeinated gum during the second night of Phase 2.
62621967|NCT05588934|ACTIVE_COMPARATOR|Placebo Dose 1st Night/Optimized Caffeine Dose 2nd Night|Participants will be administer non-caffeinated, placebo gum during the first night of Phase 2. Then, participants will be administer the optimized caffeine recommendation (0-300mg/2 hr. up to 800mg/24 hr.) potentially using caffeinated and non-caffeinated gum, depending on optimized dosage, during the second night of Phase 2.
62448789|NCT04152629|ACTIVE_COMPARATOR|VYVANSE adults|adult (≥18 years or older) patients with ADHD receiving VYVANSE (lisdexamfetamine 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg/day)
62448790|NCT04152629|EXPERIMENTAL|FOQUEST pediatric|pediatric (6 to 17 years old) patients with ADHD receiving FOQUEST (controlled-release methylphenidate 25 mg, 35 mg, 45 mg, 55 mg or 70 mg/day)
62448791|NCT04152629|ACTIVE_COMPARATOR|VYVANSE pediatric|pediatric (6 to 17 years old) patients with ADHD receiving VYVANSE (lisdexamfetamine 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg/day)
62448792|NCT02511509|EXPERIMENTAL|Bifrontal electroconvulsive therapy|The ECT courses will be held twice or three times a week. There is no stated minimal nor maximal number of ECT courses. If there is no improvement after 12 courses, the ECT will be regarded as ineffective.
62448793|NCT02511509|ACTIVE_COMPARATOR|Bitemporal electroconvulsive therapy|The ECT courses will be held twice or three times a week. There is no stated minimal nor maximal number of ECT courses. If there is no improvement after 12 courses, the ECT will be regarded as ineffective.
62448794|NCT02229240|EXPERIMENTAL|Albiglutide|Subjects will receive once-weekly subcutaneous injections of albiglutide 30 mg (with forced uptitration to albiglutide 50 mg at Week 4) in addition to intensification of background basal-bolus insulin therapy (with or without metformin) according to predefined titration algorithms.
62448795|NCT02229240|PLACEBO_COMPARATOR|Matching albiglutide placebo|Subjects will receive once-weekly subcutaneous injections of matching albiglutide placebo in addition to intensification of background basal-bolus insulin therapy (with or without metformin) according to predefined titration algorithms
62448796|NCT00981305|EXPERIMENTAL|Lactate-containing Vaginal Lubricant|apply 3cc of lactate-containing vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)
62621968|NCT05255445||Sickle cell disease (SCD)|Patients with SCD who are chronically transfused (in the U.S. and Brazil)
62621969|NCT05255445||Thalassemia|Patients with thalassemia who are chronically transfused in the U.S.
62621970|NCT05255445||Pediatric Hematology-Oncology|Patients in U.S. with pediatric oncologic diagnoses with hypo-proliferative bone marrow requiring single unit red blood cell transfusion
62848107|NCT00357279|EXPERIMENTAL|2|
62848108|NCT06044701|ACTIVE_COMPARATOR|Hologram fan|Hologram fan application during blood collection process
62848109|NCT06044701|ACTIVE_COMPARATOR|Bubble machine|Bubble machine application during blood collection
62448797|NCT00981305|PLACEBO_COMPARATOR|Placebo|apply 3cc of placebo vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)
62848110|NCT06044701|NO_INTERVENTION|Control Group|Performing routine application during the blood collection process
62848111|NCT02052076|EXPERIMENTAL|Irregular meal pattern|Participants will be asked to consume a standard diet, spread over a different number of meals/snacks per day, for a 2week intervention period. Number of meals will range from 3 to 9 per day.
62621971|NCT05255445||Blood Donors|Allogenic blood donors in the US (estimated: 10,200) and allogenic blood donors in Brazil (estimated: 2,100) with extended donation genotyping using an investigational hematology array.
62265161|NCT05970900|EXPERIMENTAL|Preoperative Imatinib + local excision|"Following the attainment of the maximum treatment response through imatinib mesylate administration, typically occurring within 6-12 months, as evidenced by two consecutive imaging evaluations, the tumor exhibited no further reduction in size, thus necessitating the selection of surgical intervention.~According to the characteristics of the location of the tumor, the surgeon decides the surgical approach based on the existing literature and the availability of surgical equipment, including:~1. Local transanal resection (TA)~2. Local resection transsacralapproach~3. Local resection via perineal approach~4. Local resection transvaginal approach"
62621972|NCT00499343|EXPERIMENTAL|Rituximab + Ifosfamide + Etoposide + 2 Growth Factors|Growth Factors = granulocyte-colony stimulating factor (G-CSF) + granulocyte macrophage-colony stimulating factor (GM-CSF)
62848112|NCT02052076|PLACEBO_COMPARATOR|Regular Meal Pattern|Participants will be asked to consume a standard diet, spread over 6 of meals/snacks every day, for a 2week intervention period.
62848113|NCT04045002|EXPERIMENTAL|Intervention|Intervention group receive 'MyPinkMom' educational intervention delivered through WhatsApp application for 2 weeks and routine antenatal care.
62848114|NCT04045002|NO_INTERVENTION|Control|Control group receive information on anaemia in pregnancy placed at respondents' antenatal card and routine antenatal care
62848115|NCT02849730||Young adults|Patients aged 20 to 39 who had used fentanyl/ropivacaine based Epi-PCA for postoperative pain.
62265162|NCT00913900|ACTIVE_COMPARATOR|Autologous Stem cells (CD133+)|Intramuscular injection
62621973|NCT00499343|EXPERIMENTAL|Rituximab + Ifosfamide + Etoposide + 1 Growth Factor|Growth Factor = granulocyte-colony stimulating factor (G-CSF)
62621974|NCT01502033|EXPERIMENTAL|Transcranial Magnetic Stimulation|Open-label course of 30 daily treatments with repetitive transcranial magnetic stimulation (rTMS) at 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
62848116|NCT02849730||Elderly patients|Patients aged 70 and over who had used fentanyl/ropivacaine based Epi-PCA for postoperative pain.
62848117|NCT02175199|EXPERIMENTAL|AIR OPTIX COLORS|Lotrafilcon B contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days.
62848118|NCT02175199|ACTIVE_COMPARATOR|FreshLook COLORBLENDS|Phemfilcon A contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days with a 2-week replacement.
62848119|NCT03847506|EXPERIMENTAL|EZE/ROS+CAN/AML|Ezetimibe/Rosuvastatin 10 mg/10 mg and Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg, once a day for 6 weeks
62848120|NCT03847506|ACTIVE_COMPARATOR|CAN/AML|Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg, once a day for 6 weeks
62848121|NCT03847506|ACTIVE_COMPARATOR|EZE/ROS+CAN|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil 8 mg, once a day for 6 weeks
62848122|NCT03228329|OTHER|cardiometry|fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
62848123|NCT05896267|EXPERIMENTAL|Masimo INVSENSOR00061|Experimental: INVSENSOR00061 All subjects are enrolled into this arm will have noninvasive blood oxygen measurements obtained.
62265163|NCT00913900|PLACEBO_COMPARATOR|Control|Intramuscular Injection
62265164|NCT04315181|PLACEBO_COMPARATOR|Placebo / Placebo|Participants will receive non-therapeutic experimental doses of gabapentin (600 and 1200 mg, p.o.), alone and in combination with oxycodone (20 and 40 mg, p.o.). The experimental sessions are designed to capture the time-action curves for the test drugs (Tmax for gabapentin ≈ 2.5 hr; oxycodone ≈ 1.5 hr). Therefore, oxycodone will be administered 1 hr after gabapentin to align peak responses.
62621975|NCT00809094|PLACEBO_COMPARATOR|Placebo|Placebo was administered oral tablet TID for 24 weeks.
62621976|NCT00809094|ACTIVE_COMPARATOR|N-Acetylcysteine|Participants received 900 mg of oral N-acetylcysteine TID for 24 weeks.
62621977|NCT06399991|EXPERIMENTAL|Adapted LOCI leadership and climate alignment strategy plus champion strategy|Implementation of LOCI strategy (adapted for the Malawian context) plus the champion strategy (enhanced usual care- usual outpatient care enhanced with use of trained champions).
62621978|NCT06399991|ACTIVE_COMPARATOR|Champion strategy|Enhanced usual care. Continue with usual outpatient care, enhanced with use of trained champions.
62621979|NCT05369143|EXPERIMENTAL|Chiropractic care Group|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor with at least five years of clinical experience.The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints. Chiropractors use these biomechanical characteristics as clinical indicators of spinal dysfunction and vertebral subluxation.
62621980|NCT05369143|PLACEBO_COMPARATOR|Control Group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The control intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust. No spinal adjustment will be performed during any control intervention. This control intervention is not intended to act as a sham treatment session
62621981|NCT04063722|EXPERIMENTAL|Modified Benelli Procedure|point x refers to the point where the nipple areola complex should be placed at 18 cm from the mid clavicular line. line A is marked above and medial to the areola and a second radial line above it and parallel to it passing in the point (X) was made and named line B. The ends of this line is curved to approximate and connect to both ends of the line A . two incisions were made on the lines A and B . Next, the whole thickness of the excess skin between line A and the line B was excised (Simon classification 2A, 2B and 3) and subcutaneous mastectomy was done and sent to histopathology. Later on, bleeding control was done by good hemostasis and suction drain was put in its proper site. Finally subcuticular suturing was done by approximation of two incisions using Nylon 3/0. Lastly, sterile pressure dressing was placed.
62621982|NCT04063722|ACTIVE_COMPARATOR|webester procedure|periareolar incision with excision of the breast tissue
62621983|NCT03762681|EXPERIMENTAL|Part 1: Single Ascending Dose, HV|Healthy volunteers will be administered a single dose of RO7239958 or placebo subcutaneously (SC).
62621984|NCT03762681|EXPERIMENTAL|Part 2a: Multi-dose, CHB|Participants with chronic hepatitis B will be administered different dose levels of RO7239958 or placebo SC. Dosages will be determined from data collected from Part 1.
62621985|NCT03762681|EXPERIMENTAL|Part 2b: Multi-dose, CHB (Optional)|Additional study arm to open based on data collected from Part 2a. Participants with chronic hepatitis B will be administered different doses and frequencies of RO7239958 or placebo SC.
62848124|NCT02750241|EXPERIMENTAL|Active video game-based intervention|This arm will receive the active video game-based intervention, which will include attending 12 weekly group sessions at the UTMB Breast Health Clinic, participate in self-paced home session, and monitor daily, weekly, and monthly steps using Wii Fit Meter. All participant will be provided a water bottle and a tote bag as a token of appreciation for participation.
62621986|NCT04233437|EXPERIMENTAL|CYP Cohort|MLC1501 \& CYP cocktail drugs
62621987|NCT04233437|EXPERIMENTAL|Transporter Cohort|MLC1501 \& Transporter cocktail drugs
62621988|NCT00349193|ACTIVE_COMPARATOR|Laquinimod 0.3 mg|Laquinimod 0.3 mg
62621989|NCT00349193|ACTIVE_COMPARATOR|Laquinimod 0.6 mg|Laquinimod 0.6 mg
62621990|NCT00349193|PLACEBO_COMPARATOR|Placebo|Blinded Placebo
62621991|NCT05401409|EXPERIMENTAL|Nitrate-rich beetroot juice|Beetroot juice containing naturally occurring nitrate (400mg total nitrate)
62621992|NCT05401409|PLACEBO_COMPARATOR|Nitrate-depleted beetroot juice|Beetroot juice with nitrate removed
62621993|NCT03872141||patients with stage I-III breast cancer|Patients with Stage I-III breast cancer who will receive paclitaxel or docetaxel treatments as part of their standard of care adjuvant or neoadjuvant therapy are eligible for this study.
62621994|NCT04251416|EXPERIMENTAL|Sacituzumab Govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
62621995|NCT06379529|EXPERIMENTAL|NuvoAir clinical service|Patients with COPD receiving usual care plus the NuvoAir clinical service.The NuvoAir clinical service offers comprehensive remote monitoring of health parameters and patient-reported outcomes as well as personalized clinical and behavioral interventions tailored to the patients' unique needs and clinical risk. The service involves virtual interaction with NuvoAir coaches who provide guidance and assistance in navigating and utilizing the service; dedicated NuvoAir care coordinators for self-management support and educational resources, aiming to enhance the management of COPD and other comorbidities including cardiovascular conditions. In situations where patients encounter new or worsening symptoms, the NuvoAir clinical team is accessible to advise and triage as required.
62621996|NCT06379529|NO_INTERVENTION|Standard Care|Propensity matched controls with COPD who receive usual care.
62848125|NCT02750241|ACTIVE_COMPARATOR|Pedometer|This arm will receive the pedometer intervention, which will include attending 3 monthly UTMB Breast Cancer Support Group sessions, and monitor daily, weekly, and monthly steps using a pedometer (Digit-Walker CW-700/701). All participant will be provided a water bottle and a tote bag as a token of appreciation for participation.
62621997|NCT02969083|OTHER|Radical nephro-ureterectomy (RNU)|Patients who dont fulfil inclusion criteria for chemotherapy treatment randomization (poor renal function: Glomerular Filtration Rate (GFR) \<55 ml/min or unfit for cisplatin-based chemotherapy)
62621998|NCT02969083|OTHER|Gemcitabine/Cisplatin plus RNU|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF \> or = 55 ml/min) receiving 3 cycles of Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) every 3 weeks before surgery
62448798|NCT05847582|EXPERIMENTAL|mSTARS|Participants randomized to the mSTARS condition will receive standard inpatient care while hospitalized at Duke. They will also receive an intervention that combines inpatient skills training and the mHealth telephone app. Inpatient emotional regulation skills training will be completed while participants are receiving inpatient treatment at Duke. Upon discharge from Duke, patients will download the mHealth app on their personal phones to use in their personal environments for 30 days. The app is designed to encourage participants to apply skills acquired in inpatient skills training to real-life situations.
62621999|NCT02969083|OTHER|RNU plus Gemcitabine/Cisplatin|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF \> or = 55 ml/min) receiving 3 cycles of Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) every 3 weeks after surgery
62622000|NCT02969083|OTHER|M-VAC protocol plus RNU|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF \> or = 55 ml/min) receiving 3 cycles of MVAC every 2 weeks (Methotrexate (30 mg /m²) , Vinblastine (3 mg /m²) , Adriamycin (30 mg /m²) , and Cisplatin (70 mg /m²) before surgery
62622001|NCT02969083|OTHER|RNU plus M-VAC protocol|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF \> or = 55 ml/min) receiving 3 cycles of MVAC every 2 weeks (Methotrexate (30 mg /m²) , Vinblastine (3 mg /m²) , Adriamycin (30 mg /m²) , and Cisplatin (70 mg /m²) after surgery
62622002|NCT04515277|ACTIVE_COMPARATOR|40 g (D1)|40 g gum acacia powder (D1). Treatment type is applied with the standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4).
62622003|NCT04515277|ACTIVE_COMPARATOR|20 g (D2)|20 g gum acacia powder (D2). Treatment type is applied with the standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4).
62622004|NCT04515277|OTHER|No treatment (NT)|0 g gum acacia powder. Standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4).
62622005|NCT01317004|EXPERIMENTAL|Fingolimod|Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period.
62622006|NCT01317004|ACTIVE_COMPARATOR|Multiple Sclerosis Disease Modifying Treatment (MS DMT)|Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months.
62622007|NCT00823485|ACTIVE_COMPARATOR|2|drainage of hemorraghia
62622008|NCT00823485|EXPERIMENTAL|1|Actylise
62622009|NCT02108899|EXPERIMENTAL|Patients with schizophrenia|
62622010|NCT02108899|ACTIVE_COMPARATOR|Healthy subjects|
62622011|NCT05765071|ACTIVE_COMPARATOR|Treatment|Botulinum toxin (Botox) injection
62622012|NCT05765071|PLACEBO_COMPARATOR|Control|Normal saline injection
62622013|NCT04627558||stroke patients, balance assessment|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
62848126|NCT01095198|ACTIVE_COMPARATOR|2nd Reminder Letter|50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be be mailed a standard second reminder letter
62848127|NCT01095198|EXPERIMENTAL|Offer of Vaginal Self Collection|50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be selected to be mailed a second reminder letter and offer of vaginal self collection
62848128|NCT02948036|EXPERIMENTAL|MMT|Mobile-device, plasticity-based adaptive cognitive treatment
62622014|NCT02776670|EXPERIMENTAL|SYSTANE BALANCE|Propylene glycol, 0.6% eye drops, 1 drop in each eye 4 times per day for 35 days
62622015|NCT02776670|ACTIVE_COMPARATOR|REFRESH OPTIVE|Lubricant eye drops, 1 drop in each eye 4 times per day for 35 days
62622016|NCT00660595|EXPERIMENTAL|1|Oral
62622017|NCT00660595|ACTIVE_COMPARATOR|2|Oral
62622018|NCT00470561|ACTIVE_COMPARATOR|Aspirin|
62622019|NCT00470561|PLACEBO_COMPARATOR|Placebo|
62622020|NCT01619072|ACTIVE_COMPARATOR|Misoprostol|800 mcg sublingual misoprostol + referral to higher level care
62622021|NCT01619072|PLACEBO_COMPARATOR|Placebo|Placebo + referral to higher level care
62622022|NCT03725826||Acute Myocardial Infarction|Patients (aged 18 and above) with either ST segment elevation or Non-ST segment elevation MI by biomarkers of cardiac injury and symptoms. Cut-off for CPK \>2 times and troponin \>3 times the upper limit for the lab. Only Patients who undergo coronary revascularization (PCI, CABG), New York Heart Association (NYHA) functional class I-III, and with LVEF \< 45% will be enrolled.
62622023|NCT06345014|EXPERIMENTAL|Study Drug: OM-89 (Uro-Vaxom® Capsule 60 mg (6 mg as a freeze-dried bacterial lysate))|- OM-89 (Uro-Vaxom® Capsule 60 mg (6 mg as a freeze-dried bacterial lysate)) Oral administration of the investigational product (OM-89 \[Uro-Vaxom® Capsule\] or the placebo) once a day.
62848129|NCT03463642|EXPERIMENTAL|Vitamin D3 pill|100 pills = 100,000IU + Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
62848130|NCT03463642|PLACEBO_COMPARATOR|Pill placebo|100 pills = Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
62848131|NCT03463642|EXPERIMENTAL|Vitamin D3 oral liquid|100 drops = 100,000IU in orange syrup
62848132|NCT03463642|PLACEBO_COMPARATOR|Oral liquid placebo|100 drops orange syrup
62848133|NCT03463642|EXPERIMENTAL|Skin oil + Vitamin D3 + penetrator|100,000IU + mineral oil+ Tangerine essential oil (10ml)
62848134|NCT03463642|EXPERIMENTAL|Skin oil + Vitamin D3|100,000IU + mineral oil
62448799|NCT05847582|ACTIVE_COMPARATOR|Treatment As Usual|Participants randomized to the treatment-as-usual condition will receive standard inpatient care provided at Duke.
62448800|NCT05847582|ACTIVE_COMPARATOR|Treatment As Usual + Skills Training|Participants randomized to this condition will receive standard inpatient care and inpatient emotional regulation skills training.
62848135|NCT03463642|PLACEBO_COMPARATOR|Skin oil placebo|Skin application: 100ml of mineral oil coloured with food colourant to match active oil sample
62848136|NCT01082549|ACTIVE_COMPARATOR|gemcitabine/carboplatin|
62448801|NCT05898178|EXPERIMENTAL|8-5-2% oxygen gradient concentration in the incubator|A physiological oxygen gradient concentration in the incubator (8-5-2% O2).
62848137|NCT01082549|EXPERIMENTAL|gemcitabine/carboplatin plus Iniparib|
62848138|NCT00612807|ACTIVE_COMPARATOR|Control|Medication management with a study doctor every other week.
62848139|NCT00612807|EXPERIMENTAL|Combination|Medication management with a study doctor every other week plus weekly marital therapy.
62848140|NCT01367067||Psychometric Questionnaire|Adult inpatients and outpatients with a clinical indication of any part of the body who have been referred to Charité for MR imaging and have filled out a psychometric questionnaire
62448802|NCT05898178|NO_INTERVENTION|Control (no intervention)|Arbitrary cultivation conditions (static 5% 02).
62448803|NCT04971057|NO_INTERVENTION|Control Group|The control group received routine care
62622024|NCT06345014|PLACEBO_COMPARATOR|Comparator:|- Placebo of Uro-Vaxom® Capsule Oral administration of the investigational product (OM-89 \[Uro-Vaxom® Capsule\] or the placebo) once a day.
62623783|NCT03279601|EXPERIMENTAL|A: Capecitabine Combined With Dacarbazine(CAPDTIC)|patients in arm A will receive chemotherapy of CAPDTIC regimen: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
62848141|NCT01367067||No Psychometric Questionnaire|Adult inpatients and outpatients with a clinical indication of any part of the body who have been referred to Charité for MR imaging and did not fill out a psychometric questionnaire
62448804|NCT04971057|EXPERIMENTAL|Multimedia information Group|The experimental group received a multimedia information
62448805|NCT02520115|EXPERIMENTAL|Arm I (induction)|Patients receive valproic acid PO BID on days -7 to -3 and QD on day -2 and dexamethasone PO QD on days -5 and -2 and BID on days -4 and -3. Patients undergo collection of serum and tissue samples for analysis via PCR and IHC at baseline, time of surgery, and 7-14 days after surgery.
62448806|NCT02520115|EXPERIMENTAL|Arm II (surveillance and recurrence)|Patients receive valproic acid PO BID on days -7 to -3 and QD on day -2 and dexamethasone PO QD on days -5 and -2 and BID on days -4 and -3. Patients undergo collection of serum samples for analysis via PCR and IHC at the time of clinically suspected recurrence, 2 days after completion of induction, and 7-14 days after induction.
62848142|NCT01490424||sepsis|SIRS plus inflammation
62848143|NCT01490424||Control|normal person under medical examination
62848144|NCT01086358|ACTIVE_COMPARATOR|Triptan|Arm 1 subjects began with their prescribed triptan
62848145|NCT01086358|ACTIVE_COMPARATOR|Treximet 85Mg-500Mg Tablet|Arm 2 subjects began with Treximet (sumatriptan 85 mg/naproxen sodium 500 mg)
62622025|NCT03309345||Case group, PKU group|Children and adults (10 - 45 years old) with PKU attending the metabolic medicine clinics in the area of National Health Services (NHS) Greater Glasgow and Clyde (GGC) will be approached for recruitment. Participants will be free from history of acute and chronic illness (other than PKU) requiring regular appointments to the doctor and/or chronic use of medication or major gastrointestinal surgery where major part of the gut has been resected as these conditions are known to impact on energy expenditure and dietary intake. Pregnant or lactating women will also be excluded from participation. People with learning or mobility difficulties or those with incapacity to provide informed consent will be excluded too. The clinical treatment team will evaluate patients' capacity to consent before considering them to participate in the study.
62622026|NCT03309345||Control group, healthy control|Gender, BMI and age matched healthy people will be recruited as a control group. Pregnant or lactating women will be excluded from participation. Those with any chronic illnesses or bone injuries will also be excluded.
62622027|NCT04733625|ACTIVE_COMPARATOR|Intervention(Vitamin D therapy|40 patients with diabetes and vitamin D deficinecy that are Covid-19 positive. a single dose of Cholecaciferol will be administered
62448807|NCT02761096|EXPERIMENTAL|Study group|The acupuncture intervention will start no more than 48 hours after craniotomy and will be given once a day for 6 days (a total of 6 sessions within 8 days). It will be given in addition to conventional treatments. All interventions will be performed by one Korean Medicine doctor with over 5 years of working experience with a college education of 6 years. This doctor will be trained in the study protocol before the start of the trial.
62622028|NCT04733625|PLACEBO_COMPARATOR|Placebo|16 diabetic patients with vitamin D deficiancy and COVID-19 POSITIVE
62622029|NCT01955317|EXPERIMENTAL|chlorhexidine intervention|The intervention arm will also receive hand hygiene counselling with chlorhexidine and a pump bottle with chlorhexidine lotion along with mothers and neonatal health counseling.
62622030|NCT01955317|ACTIVE_COMPARATOR|Control|This arm will receive maternal and neonatal health counselling which includes discussion and education about antenatal care, safe and clean delivery, recognition of danger signs for the mother and neonate, immediate new born care, and essential new born care. Each mother will receive a clean delivery kit and pictoral cue cards for danger sign recognition.
62622031|NCT00765947|EXPERIMENTAL|Aliskiren-based regimen|All pts starting on aliskiren 150 mg (uptitrated to aliskiren 300 mg), followed by the addition of HCTZ 12.5 mg (uptitrated to 25 mg) and amlodipine 5 mg (uptitrated to 10 mg), as necessary to achieve the Blood Pressure goal.
62848146|NCT00995293|EXPERIMENTAL|Docetaxel Cisplatin 5-Fluorouracil (DCF)|"4 cycles of the following products every 3 weeks (unless disease progression/relapse or unacceptable toxicity occured or the patient refused treatment):~* Docetaxel 60mg/m² on day 1~* Cisplatin 75mg/m² on day 1~* 5-FU 750mg/m²/day on day 1 to day 5"
62622032|NCT04651166|PLACEBO_COMPARATOR|Placebo|100mL saline or lactated ringer without tranexamic acid added given intravenously over 10 minutes at start of procedure
62848147|NCT00995293|EXPERIMENTAL|Cisplatin 5-Fluorouracil (CF)|"4 cycles of the following products every 3 weeks (unless disease progression/relapse or unacceptable toxicity occured or the patient refused treatment):~* Cisplatin 75mg/m² on day 1~* 5-FU 750mg/m²/day on day 1 to day 5"
62848148|NCT04476004|EXPERIMENTAL|experimental group|EMG group
62848149|NCT04476004|ACTIVE_COMPARATOR|control group|exercise group
62848150|NCT03073733|EXPERIMENTAL|Test (jCell injection) dose level 1|single intravitreal injection of 3.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
62848151|NCT03073733|OTHER|Sham treated Control|"a mock injection will be performed on the eye with the poorest vision in each Control subject (designated as the study eye)"
62848152|NCT03073733|EXPERIMENTAL|test (jCell injection) dose level 2|single intravitreal injection of 6.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
62848153|NCT01613846|EXPERIMENTAL|Sorafenib followed by pazopanib|"Sorafenib 400 mg bid orally until progression or intolerable toxicity, followed by pazopanib 800 mg once daily orally until progression or intolerable toxicity.~During first- and second-line, treatment visits are scheduled in weeks 0,2,4,8,12, and every 4 weeks thereafter, with tumor assessments and electrocardiogram after every second cycle (every 8 weeks)."
62848154|NCT01613846|EXPERIMENTAL|Pazopanib followed by Sorafenib|"Pazopanib 800 mg once daily orally until progression or intolerable toxicity, followed by Sorafenib 400 mg bid orally until progression or intolerable toxicity:~During first- and second-line, treatment visits are scheduled in weeks, 0,2,4,8,12, and every 4 weeks thereafter, with tumor assessments and electrocardiogram after every second cycle (every 8 weeks)."
62848155|NCT05979142||program (pre-exposure)|During the pre-exposure period, usual care was provided by two public hospitals, several Ministry of Health clinics, private clinics and pharmacies, and Siempre Salud.
62848156|NCT05979142||program (post-exposure)|The program had components of four Chronic Care Model (CCM) elements (delivery system design, self-management, decision support, and community resources), community health workers (CHWs), and no out-of-pocket costs for visits and medications.
62448808|NCT02761096|OTHER|Control group|The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery.
62848157|NCT05056844|EXPERIMENTAL|Diagnostic (CESM, DBT)|Patients receive iodine-based contrast agent IV then undergo CESM over 10-15 minutes. Patients who have not undergone standard of care DBT within 3 months from the study, also undergo DBT.
62848158|NCT05758636|EXPERIMENTAL|Emotional Freedom Technique Group|Nurses (40) enrolled in the emotional freedom technique group will receive a total of 4 rounds of EFT, 50 minutes, 3 days a week.
62848159|NCT05758636|NO_INTERVENTION|Control|Participants in the control group (n= 40) will not receive intervention throughout the study.
62448809|NCT05294575||OHCA in the general population|All Out-of-Hospital Cardiac Arrests
62448810|NCT05294575||Traumatic OHCA|OHCA related to Trauma
62622033|NCT04651166|ACTIVE_COMPARATOR|Active Comparator|1g tranexamic acid mixed in 100mL saline or lactated ringer given intravenously over 10 minutes at start of procedure
62622034|NCT05475834|EXPERIMENTAL|SIM0417|Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
62622035|NCT05186051|EXPERIMENTAL|ZYIL1 Capsule|subject will receive 50 mg twice daily (BD) dose for 7 days
62848160|NCT00702715|EXPERIMENTAL|Participants with severe renal impairment|Participants with severe renal impairment will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC. Severe renal impairment was defined as creatinine clearance \<30mL/min.
62848161|NCT00702715|ACTIVE_COMPARATOR|Participants with normal renal function|Participants with normal renal impairment will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC. Normal renal function was defined as creatinine clearance \>=80mL/min.
62848162|NCT06319950|EXPERIMENTAL|High-dose Furmonertinib group|Furmonertinib, 160mg po qd
62848163|NCT06319950|ACTIVE_COMPARATOR|Osimertinib group|Osimertinib, 80mg po qd
62848164|NCT01897129||Early pregnancy|Women in early pregnancy at around the time of the nuchal translucency scan. The prevalence of HPV will be determined
62448811|NCT03997266|ACTIVE_COMPARATOR|Empiric antibiotics|Infants will receive standard antibiotic coverage of ampicillin and gentamycin at site approved dosing guidelines while completing an evaluation for early-onset neonatal sepsis.
62448812|NCT03997266|PLACEBO_COMPARATOR|Placebo|Infants will receive a volume matched placebo of normal saline while completing an evaluation for early-onset neonatal sepsis.
62448813|NCT01576588|EXPERIMENTAL|R-HDMP|"Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).~Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion."
62448814|NCT04352374|EXPERIMENTAL|Aerobic exercise group|"The therapist advised all participants of this group to drink a plenty of water before and after the exercise session to avoid excessive loss of body water during the session. Pregnant women were instructed to have a light meal about one hour before the performance of exercise and to wear comfortable clothes.~Participants in this group were given a Low-Intensity Aerobic Exercise with Borg scale RPE at 11. Participants were asked to maintain this intensity of rate of perceived exertion throughout the 45 minutes' duration of the aerobic training.~During the training session, the therapist stood near the patient to observe and detect signs of stopping the exercise. The therapist continuously asked the patient if she felt pain, dizzy or shortens of breath.~No complications were observed during physical exercise sessions, for example, hypertensive crisis, hypotension, hyperthermia, musculoskeletal lesions, or other complications identified that demanded interruption of the exercise."
62448815|NCT04352374|ACTIVE_COMPARATOR|Device guided breathing group|"At the beginning the researcher explained the device and study procedures to every participant of this group .The device consists of a control box, headphones and a respiratory rate monitor attached as a sensor belt around the user's chest.~The participant is instructed to alter their breathing rate, aiming for up to 10 breaths per minute, in response to a melody played to them via the asked to use the device for at least 40 min per week, with each session lasting at least 10 min"
62448816|NCT02529059|EXPERIMENTAL|Switch from Atripla to Eviplera|
62448817|NCT06307028|EXPERIMENTAL|SISTA-P Intervention|Participants will complete four sessions lasting up to three hours each over the course of one week. The sessions will be overseen by two facilitators and a technical monitor. Core elements of SISTA-P are: (1) small group discussions, modeling and role-play that facilitate repetition, reinforcement and sequential approximation; (2) skilled facilitators; (3) gender and culturally specific materials to enhance pride and self-worth; (4) teaching negotiation, self-advocacy; and (5) HIV prevention relevant skills; (6) discussing gender and culture-specific barriers and facilitators to prevention; and (7) enhancing HIV prevention norms and self-efficacy. Each discussion group will consist of 12- 15 participants and each cycle will consist of one group. Participants will be asked to complete a follow up survey and two booster sessions. They will also be asked to submit photo-confirmation of PrEP prescription to the research team.
62448818|NCT05707299|EXPERIMENTAL|Observation group|This group will include 20 patients with MDD. Before signal collection, the subject will wear a helmet embedded with numerous near-infrared light sensors, covering the prefrontal region and both temporal lobes. The whole process will be monitored in real time by fNIRS. During needle retention, participants will be asked to keep their eyes closed and quiet throughout the intervention and to avoid physical movement as much as possible.
62448819|NCT05707299|OTHER|Control group|This group will include 20 healthy control participants without MDD. Before signal collection, the subject will wear a helmet embedded with numerous near-infrared light sensors, covering the prefrontal region and both temporal lobes. The whole process will be monitored in real time by fNIRS. During needle retention, participants will be asked to keep their eyes closed and quiet throughout the intervention and to avoid physical movement as much as possible.
62448820|NCT05400265|EXPERIMENTAL|Dose Cohort 1|In this cohort, the dose of HLX26 is 500mg. HLX26 will be intravenously administered every 3 weeks. HLX10 will be intravenously administered every 3 weeks with the fixed dose of 300mg. Patients will receive the treatment until they have been in therapy for 2 years, develop progressive disease (PD) without any clinical benefit, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
62622036|NCT01557192|ACTIVE_COMPARATOR|Active LFMS treatment|20 minute exposure to the LFMS electromagnetic field treatment
62622037|NCT01557192|PLACEBO_COMPARATOR|Sham LFMS treatment|20 minute exposure to either the sham (inactive) electromagnetic field treatment
62848165|NCT01897129||Chorionic villous sampling|Women undergoing chorionic villous sampling for the purpose of prenatal diagnostics.
62848166|NCT01897129||Spontaneous abortion|Women with miscarriage at a gestational age up to 22 weeks
62848167|NCT01897129||Preterm birth|Women with spontaneous preterm birth/premature primary rupture of membranes at a gestational age week 22-32
62848168|NCT01897129||Vaginal delivery at term|Women with spontaneous vaginal delivery at term (week 37+0-)
62848169|NCT01897129||Elective ceaserean section at term|Women undergoing elective cesarean section at term (week 37+0-)
62622038|NCT06364436|EXPERIMENTAL|Reiki Energy therapy|The women in the intervention group were explained how to perform the Reiki application, and the appropriate time for Reiki was planned. Pretest data were obtained by sending the data collection form, VAS-F and EPDS Google form link to women's phones via WhatsApp application.Then, according to Usui Reiki, researchers with Reiki Stage II and Reiki Master \& Teacher degrees applied Reiki to women for 30 minutes consecutively on the 13th, 14th, 20th and 21st postpartum days (in the second and third postpartum weeks). Before each Reiki application, a reminder message was sent to the women informing them that the application would begin, and they were asked to fill out the VAS-F and EPDS again on the 28th day (fourth week) and 56th day (eighth week) postpartum. During this process, women who did not fill out the scale forms were contacted via phone and SMS and were asked to fill out the forms, and those who did not fill out the forms were excluded from the study.
62265165|NCT04315181|EXPERIMENTAL|Placebo / Oxycodone 20mg|Participants will receive non-therapeutic experimental doses of gabapentin (600 and 1200 mg, p.o.), alone and in combination with oxycodone (20 and 40 mg, p.o.). The experimental sessions are designed to capture the time-action curves for the test drugs (Tmax for gabapentin ≈ 2.5 hr; oxycodone ≈ 1.5 hr). Therefore, oxycodone will be administered 1 hr after gabapentin to align peak responses.
62622039|NCT06364436|NO_INTERVENTION|Control|No intervention was made to the women in the control group during the research. Women in the control group were asked to fill out the introductory information form and VAS-F and EPDS on the 13th postpartum day, and the VAS-F and EPDS form links were sent to their phones via WhatsApp on the 28th and 56th days.
62622040|NCT04168320|ACTIVE_COMPARATOR|Less favorable time-position in immune cycle|"Starting two weeks prior to the initiation of radiotherapy serial, 7x blood samples will be taken every two days, excluding the weekend (for example, if starting on a Monday: Monday-Wednesday-Friday-Monday-Wednesday-Friday and Monday), but also on the day of the first radiotherapy treatment, to define the serial high-sensitivity C-reactive protein (hs-CRP) test, LDH and white cell differential count (leucocytes: neutrophils, basophils, eosinophils, lymphocytes, monocytes). Data from the assays will be assembled in a spreadsheet and analyzed for levels and cyclical fluctuations to determine each patient's idiosyncratic immune cycle's periodicity and then each patient's time-position of initiation of treatment and response to therapy.~SBRT-PATHY will be administered to this arm at an estimated less favorable time-Position in immune cycle."
62622041|NCT04168320|EXPERIMENTAL|Most favorable time-position in immune cycle|"Starting two weeks prior to the initiation of radiotherapy serial, 7x blood samples will be taken every two days, excluding the weekend (for example, if starting on a Monday: Monday-Wednesday-Friday-Monday-Wednesday-Friday and Monday), but also on the day of the first radiotherapy treatment, to define the serial high-sensitivity C-reactive protein (hs-CRP) test, LDH and white cell differential count (leucocytes: neutrophils, basophils, eosinophils, lymphocytes, monocytes). Data from the assays will be assembled in a spreadsheet and analyzed for levels and cyclical fluctuations to determine each patient's idiosyncratic immune cycle's periodicity and then each patient's time-position of initiation of treatment and response to therapy.~SBRT-PATHY will be administered to this arm at an estimated most favorable time-position in immune cycle."
62622042|NCT00429650|EXPERIMENTAL|1|Increased amount of exercise to maintain weight loss.
62622043|NCT00429650|EXPERIMENTAL|2|Combination of Exercise and Diet to maintain weight loss
62622044|NCT00429650|ACTIVE_COMPARATOR|3|Use diet alone to maintain weight loss.
62622045|NCT05109208|EXPERIMENTAL|Ultrasound viscoelastography (UVE) in radical proctectomy recovery|Subjects undergoing radical prostatectomy for prostate cancer disease as standard of care will have a ultrasound vibroelastography performed before surgery, 3 months, 6 months and 9 months post-prostatectomy.
62622046|NCT03457623|EXPERIMENTAL|Innovative supported|In addition to usual care, patients benefit from connected tools (overpoise, sphygmomanometer...), physical activity, a strong accompaniment with a referent person
62848170|NCT04586842|EXPERIMENTAL|Community-based Occupational Therapy|Experimental study group that will receive a domiciliary and community-based occupational therapy on mental health, developed on the basis of the Model Of Human Occupation.
62622047|NCT03457623|NO_INTERVENTION|conventional supported|Patients benefit from usual care
62622048|NCT00599742|ACTIVE_COMPARATOR|A|Balance training group
62848171|NCT04586842|ACTIVE_COMPARATOR|Standard community-based intervention|Control group of the study that will receive community-based interventions, public or private level (e.g. community nursing, social education and/or psychology).
62622049|NCT00599742|ACTIVE_COMPARATOR|B|Motor Training
62622050|NCT03999528||study group|RA Patients
62622051|NCT03999528||control group|normal control
62622052|NCT01742754|EXPERIMENTAL|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation by colonoscopic delivery of stool to the right colon.
62622053|NCT01789801|ACTIVE_COMPARATOR|Palpation only|"Patients randomized to this arm will have radial artery puncture via palpation of arteries.~Intervention: RAP palpation only"
62622054|NCT01789801|EXPERIMENTAL|Ultrasound guidance|"Patients randomized to this arm will have radial artery puncture with ultrasound guidance for artery localisation.~Intervention: RAP with ultrasound guidance"
62622055|NCT00069823|EXPERIMENTAL|Esomeprazole|Proton pump inhibitor of gastric acid
62622056|NCT00069823|PLACEBO_COMPARATOR|Placebo for esomeprazoe|Placebo
62622057|NCT05601180|ACTIVE_COMPARATOR|Stadard of care|standard treatment that is prescribed by the treating physician.
62848172|NCT02035254|EXPERIMENTAL|Intervention group|Web-based wellness program
62265166|NCT04315181|EXPERIMENTAL|Placebo / Oxycodone 40mg|Participants will receive non-therapeutic experimental doses of gabapentin (600 and 1200 mg, p.o.), alone and in combination with oxycodone (20 and 40 mg, p.o.). The experimental sessions are designed to capture the time-action curves for the test drugs (Tmax for gabapentin ≈ 2.5 hr; oxycodone ≈ 1.5 hr). Therefore, oxycodone will be administered 1 hr after gabapentin to align peak responses.
62622058|NCT05601180|EXPERIMENTAL|Standard of care + Respicure®|standard treatment that is prescribed by the treating physician in addition to Respicure®
62622059|NCT04686825|EXPERIMENTAL|T1|DA-8010 2.5 mg (Fasting)
62622060|NCT04686825|EXPERIMENTAL|T2|DA-8010 2.5 mg (Fed)
62622061|NCT04686825|EXPERIMENTAL|T3|DA-8010 5 mg (Fasting)
62622062|NCT04686825|EXPERIMENTAL|T4|DA-8010 5 mg (Fed)
62848173|NCT02035254|OTHER|Wait control group|Web-based wellness program after 3 month wait.
62848174|NCT01600534|EXPERIMENTAL|Lifestyle counseling|Participants obtain access to an internet-based educational intervention.
62622063|NCT01663857|EXPERIMENTAL|Phase 1b (Cohort 1) LY2228820 200 milligrams (mg)|"Cohort 1: Cycles 1-6 (21 day cycles)- LY2228820 200 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 milligrams per square meter (mg/m\^2) administered intravenously (IV) over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3..~Cohort 1: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
62061107|NCT05301270||Transfemoral Amputees|Individuals aged 18-45 years, with unilateral transfemoral amputation, traumatic amputation cause, using prosthesis for at least 1 year, no skin lesions-open wound on the stump, no phantom sensation or pain, no musculoskeletal problems that may affect balance other than amputation will be included.
62622064|NCT01663857|EXPERIMENTAL|Phase 1b (Cohort 2) LY2228820 300 mg|"Cohort 2: Cycles 1-6 (21 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m\^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Cohort 2: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
62265167|NCT04315181|EXPERIMENTAL|Gabapentin 600mg / Placebo|Participants will receive non-therapeutic experimental doses of gabapentin (600 and 1200 mg, p.o.), alone and in combination with oxycodone (20 and 40 mg, p.o.). The experimental sessions are designed to capture the time-action curves for the test drugs (Tmax for gabapentin ≈ 2.5 hr; oxycodone ≈ 1.5 hr). Therefore, oxycodone will be administered 1 hr after gabapentin to align peak responses.
62265168|NCT04315181|EXPERIMENTAL|Gabapentin 1200mg / Placebo|Participants will receive non-therapeutic experimental doses of gabapentin (600 and 1200 mg, p.o.), alone and in combination with oxycodone (20 and 40 mg, p.o.). The experimental sessions are designed to capture the time-action curves for the test drugs (Tmax for gabapentin ≈ 2.5 hr; oxycodone ≈ 1.5 hr). Therefore, oxycodone will be administered 1 hr after gabapentin to align peak responses.
62622065|NCT01663857|EXPERIMENTAL|Phase 2 (Arm A) LY2228820 200 mg|"Arm A: Cycles 1-6 (21 day cycles)- LY2228820 200 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m\^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Arm A: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
62622066|NCT01663857|PLACEBO_COMPARATOR|Phase 2 (Arm B) Placebo|"Arm B: Cycles 1-6 (21 day cycles)- Placebo administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m\^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Arm B: Cycle 7+ (28 day cycles)- Placebo administered orally on days 1-14 to maintain blind."
62622067|NCT04028323|EXPERIMENTAL|Experimental group|Drug: Terlipressin. Terlipressin should be administrated with an initial dose of 1-2 mg intravenously and slowly injected (over 1 minute) while monitoring the heart rate and blood pressure. The maintenance dose should be administrated every 4-6 hours. Each dose of terlipressin is 1mg. The usual duration of therapy is 3-5 days.
62622068|NCT04028323|ACTIVE_COMPARATOR|Control group|Drug: Octreotide. Octreotide should be continuously and intravenously dripped at the speed of 0.025-0.05 mg/h and could be diluted with saline with the maximum duration of 5 days. The usual duration of therapy is 3-5 days.
62622069|NCT03795883||Participants with atrial fibrillation|Patients with atrial fibrillation admitted for standard pulmonary vein ablation.
62622070|NCT03795883||Participants without atrial fibrillation|Patients without atrial fibrillation admitted for standard left sided supra ventricular tachycardia ablation or patients admitted to mitral clip procedure.
62622071|NCT06472687|EXPERIMENTAL|FIFA 11+ training group (FTG)|The participants recruited in the FIFA 11+ training group (FTG) and control group (CG) received different warm-up program twice a week for ten weeks. The FTG received the FIFA 11+ training program and the CG received standard warm-up protocol. All subjects received the initial participant education and training program instruction. All training protocols were continued for twice weekly. The same physiotherapist applied FIFA 11+ training protocol.
62848175|NCT01600534|OTHER|Usual Care Lifestyle counseling|Self directed educational intervention
62848176|NCT02756416|EXPERIMENTAL|ASL MRI and MRA|All participants will undergo ASL-MRI and MRA at three points; baseline, month 1, and month 3.
62848177|NCT04988360|EXPERIMENTAL|Group A: HMD first|Those assigned to group A will use the head-mounted display (HMD) VR intervention first. Caregivers will be trained to use the HMD-system and asked to use that system for the duration of T1 (weeks 1 \& 2). At the end of T1 they will be asked to complete standardized questionnaires and will participate in a semi-structured interview about their experiences. At the beginning of T2 (weeks 3 \& 4), they will then be trained to use the tablet-system, which will be used for the duration of T2. At the completion of T2, the dyad will again complete the same standardized questionnaires and will participate in a semi-structured interview about their experiences. Each session is expected to include 20 minutes of VR exposure. Each session throughout T1 and T2 is to be video-recorded by the caregiver-participant so that reactions and interactions can later be analyzed.
62848178|NCT04988360|EXPERIMENTAL|Group B: Tablet first|Those assigned to group B will use the tablet VR intervention first. Caregivers will be trained to use the tablet-system and asked to use that system for the duration of T1 (weeks 1 \& 2). At the end of T1 they will be asked to complete standardized questionnaires and will participate in a semi-structured interview about their experiences. At the beginning of T2 (weeks 3 \& 4), they will then be trained to use the HMD-system, which will be used for the duration of T2. At the completion of T2, the dyad will again complete the same standardized questionnaires and will participate in a semi-structured interview about their experiences. Each session is expected to include 20 minutes of VR exposure. Each session throughout T1 and T2 is to be video-recorded by the caregiver-participant so that reactions and interactions can later be analyzed.
62848179|NCT02964013|EXPERIMENTAL|vibostolimab|During an initial dose evaluation phase, participants will receive Dose A, B, C, D, E, or F of vibostolimab on Day 1 of each 21-day infusion cycle (for a maximum of 35 cycles) until the RPTD has been established. The RPTD will be established based on the number of dose limiting toxicities (DLTs) at each dose level. Once the RPTD is established, participants will continue receiving the RPTD of vibostolimab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
62061108|NCT05301270||Healthy Subjects|Healthy individuals between the ages of 18-45 will be included.
62265169|NCT04315181|EXPERIMENTAL|Gabapentin 600mg / Oxycodone 20mg|Participants will receive non-therapeutic experimental doses of gabapentin (600 and 1200 mg, p.o.), alone and in combination with oxycodone (20 and 40 mg, p.o.). The experimental sessions are designed to capture the time-action curves for the test drugs (Tmax for gabapentin ≈ 2.5 hr; oxycodone ≈ 1.5 hr). Therefore, oxycodone will be administered 1 hr after gabapentin to align peak responses.
62848180|NCT02964013|EXPERIMENTAL|vibostolimab + pembrolizumab|During an initial dose evaluation phase, participants will receive Dose A, B, C, D, E, or F of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle (for a maximum of 35 cycles) until the RPTD of vibostolimab has been established. The RPTD will be established based on the number of DLTs at each dose level. Once the RPTD of vibostolimab is established, participants will continue receiving the RPTD of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
62265170|NCT04315181|EXPERIMENTAL|Gabapentin 1200mg / Oxycodone 20mg|Participants will receive non-therapeutic experimental doses of gabapentin (600 and 1200 mg, p.o.), alone and in combination with oxycodone (20 and 40 mg, p.o.). The experimental sessions are designed to capture the time-action curves for the test drugs (Tmax for gabapentin ≈ 2.5 hr; oxycodone ≈ 1.5 hr). Therefore, oxycodone will be administered 1 hr after gabapentin to align peak responses.
62448821|NCT05400265|EXPERIMENTAL|Dose Cohort 2|In this cohort, the dose of HLX26 is 800mg. HLX26 will be intravenously administered every 3 weeks. HLX10 will be intravenously administered every 3 weeks with the fixed dose of 300mg. Patients will receive the treatment until they have been in therapy for 2 years, develop progressive disease (PD) without any clinical benefit, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
62448822|NCT05400265|EXPERIMENTAL|Dose Cohort 3|In this cohort, the dose of HLX26 is 1600mg. HLX26 will be intravenously administered every 3 weeks. HLX10 will be intravenously administered every 3 weeks with the fixed dose of 300mg. Patients will receive the treatment until they have been in therapy for 2 years, develop progressive disease (PD) without any clinical benefit, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
62448823|NCT01297010|PLACEBO_COMPARATOR|Dexamethasone|Children randomized to this group received a 10 ml syringe containing dexamethasone (0.15 mg / kg) at the beginning of the procedure.
62448824|NCT01297010|PLACEBO_COMPARATOR|Dexamethasone and ondasetron|Children randomized to this group received a 10 ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling) and ondansetron (0.1 mg / kg dose of 4mg ceiling)at the beginning of the procedure.
62448825|NCT04450303|EXPERIMENTAL|Telehealth Therapy|
62448826|NCT01576978|ACTIVE_COMPARATOR|postural orientations|The group of postural orientations receive a pamphlet containing information about the sitting, standing and lying postures to be performed at home for 10 weeks.The marking of the note pain will be before and after 10 weeks.
62448827|NCT01576978|ACTIVE_COMPARATOR|hatha yoga exercises|The allocates women will participate in the Hatha yoga class for 10 weeks. At first in class, the women will make a note of pain according to VAS. Class Moments: heating ten minutes, forty minutes postures of stretching and strengthening exercises and breathing exercises, ten minutes of relaxation and meditation. Marking note of pain after practice.
62448828|NCT00873951|EXPERIMENTAL|Intact casein|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as 15N-labelled intact casein
62448829|NCT00873951|EXPERIMENTAL|Hydrolyzed casein|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
62448830|NCT00873951|EXPERIMENTAL|AA|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
62448831|NCT04373577|EXPERIMENTAL|ESP group|Under ultrasound guidance, patients of this group will receive (0.5ml/kg) plain bupivacaine 0.25%with adrenaline 2.5 µg/ml injected beneath the erector spinae muscle sheath at the level of the transverse process of the second lumbar vertebrae
62448832|NCT04373577|EXPERIMENTAL|PENG group|Under ultrasound guidance, patients of this group will receive (0.5ml/kg) plain bupivacaine 0.25%with adrenaline 2.5 µg/ml injected as the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly
62448833|NCT06547138||Optilene® Silver Mesh Elastic|Prophylactic mesh in high-risk patients
62848181|NCT02964013|EXPERIMENTAL|Advanced solid tumor cohort|Participants will receive the RPTD of vibostolimab monotherapy or the RPTD of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
62265171|NCT04315181|EXPERIMENTAL|Gabapentin 600mg / Oxycodone 40mg|Participants will receive non-therapeutic experimental doses of gabapentin (600 and 1200 mg, p.o.), alone and in combination with oxycodone (20 and 40 mg, p.o.). The experimental sessions are designed to capture the time-action curves for the test drugs (Tmax for gabapentin ≈ 2.5 hr; oxycodone ≈ 1.5 hr). Therefore, oxycodone will be administered 1 hr after gabapentin to align peak responses.
62622072|NCT06472687|ACTIVE_COMPARATOR|control group (CG)|The participants recruited in the FIFA 11+ training group (FTG) and control group (CG) received different warm-up program twice a week for ten weeks. All subjects received the initial participant education and training program instruction. All training protocols were continued for twice weekly.The same physiotherapist applied FIFA 11+ training protocol. The control group performed the usual warm-up, which only included running, static and dynamic stretching.
62448834|NCT03739190|EXPERIMENTAL|Test Condom: Thin NRL Condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. Couples will return to the clinic site for collection of their next set of condoms on two additional occasions. Each couple will test a maximum of 21 condoms during their participation in the investigation.
62622073|NCT01456546|ACTIVE_COMPARATOR|Period A: proguanil|Proguanil pharmacokinetics
62622074|NCT01456546|ACTIVE_COMPARATOR|Period B: clopidogrel|Clopidogrel pharmacokinetics
62622075|NCT02245035||Low dairy intake|1 serving/day or less of dairy food characterized at enrollment using 24 hr dietary recall
62622076|NCT02245035||Moderate Dairy Intake|1-2 servings/day of dairy food characterized at enrollment using 24 hr dietary recall
62622077|NCT02245035||Recommended Dairy Intake|Greater than 3 servings/day of dairy food characterized at enrollment using 24 hr dietary recall
62622078|NCT03389880|ACTIVE_COMPARATOR|Patellar denervation|
62622079|NCT03389880|EXPERIMENTAL|Non-patellar denervation|
62848182|NCT02964013|EXPERIMENTAL|Randomized dose 1 comparison cohort|Participants will be randomized to receive a fixed dose (Dose 1) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
62848183|NCT02964013|EXPERIMENTAL|Randomized dose 2 comparison cohort|Participants will be randomized to receive a fixed dose (Dose 2) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
62848184|NCT02964013|EXPERIMENTAL|vibostolimab +pembrolizumab+pemetrexed+carboplatin|Participants will receive a fixed dose of vibostolimab in combination with 200 mg pembrolizumab, 500 mg/m\^2 pemetrexed, and Area Under Curve (AUC) 5 mg/mL/min carboplatin on Day 1 of each 21-day infusion cycle for up to 4 cycles followed by maintenance therapy with a fixed dose of vibostolimab in combination with 200 mg pembrolizumab and 500 mg/m\^2 pemetrexed on Day 1 of each 21-day infusion cycle for up to an additional 31 cycles.
62848185|NCT02964013|EXPERIMENTAL|vibostolimab Dose 1 Japanese cohort|Japanese participants will be randomized to receive a fixed dose (Dose 1) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
62848186|NCT02964013|EXPERIMENTAL|vibostolimab Dose 2 Japanese cohort|Japanese participants will be randomized to receive a fixed dose (Dose 2) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
62848187|NCT02964013|EXPERIMENTAL|pembrolizumab/vibostolimab coformulation|Participants will receive a fixed dose of pembrolizumab/vibostolimab coformulation, consisting of 200 mg of pembrolizumab + 200 mg vibostolimab, on Day 1 of each 21-day infusion cycle for up to 35 cycles.
62848188|NCT02964013|EXPERIMENTAL|vibostolimab+pembrolizumab+carboplatin OR cisplatin+etoposide|Participants will receive 200 mg vibostolimab in combination with 200 mg pembrolizumab, plus the investigator's choice of Area Under Curve (AUC) 5 mg/mL/min carboplatin OR 75 mg/m\^2 cisplatin on Day 1 of each 21-day cycle plus 100 mg/m\^2/day etoposide on Days 1-3 of each 21-day cycle for up to 4 cycles. Maintenance therapy with 200 mg vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day cycle will continue for up to an additional 31 cycles. A participant will be allowed to switch from cisplatin to carboplatin in the event of an adverse event (AE), ineligibility for further cisplatin therapy, and/or the investigator considers switching to carboplatin to be in the best interest of the participant.
62848189|NCT02964013|EXPERIMENTAL|pembrolizumab/vibostolimab coformulation China cohort|Participants from mainland China will receive a fixed dose of pembrolizumab/vibostolimab coformulation, consisting of 200 mg of pembrolizumab + 200 mg vibostolimab, on Day 1 of each 21-day infusion cycle for up to 35 cycles.
62848190|NCT02500940|EXPERIMENTAL|Control group|Neoadjuvant chemotherapy with tri-weekly cisplatin plus fluorouracil × 3 cycles (cisplatin 100 mg/m2, day 1, followed by fluorouracil 1000 mg/m2/d, days 1-4 continuous iv infusion, repeated every 3 weeks) + Intensity-Modulated Radiation Therapy ≧ 70 Gy/35 fractions
62848191|NCT02500940|ACTIVE_COMPARATOR|Test group|Neoadjuvant chemotherapy with weekly cisplatin, fluorouracil and leucovorin × 10 weeks (cisplatin 60 mg/m2 at days 1, 15, 29, 43, 57; alternatively with fluorouracil 2500 mg/m2 + leucovorin 250 mg/m2 at days 8, 22, 36, 50, 64) + Intensity-Modulated Radiation Therapy ≧ 70 Gy/35 fractions
62848192|NCT03336437|ACTIVE_COMPARATOR|Estrogen Vaginal Ring|At the time of initial study visit, a estrogen vaginal ring (Estring) will be placed. Participants will retain this ring for 12 weeks.
62061109|NCT00785707||cochlear implant|children less than 24 months at time of cochlear implantation
62061110|NCT01119430|PLACEBO_COMPARATOR|Fluoxetine plus placebo|
62448835|NCT03739190|ACTIVE_COMPARATOR|Reference condom A: Medium Thickness NRL Condom|
62622080|NCT03706716|OTHER|Intervention with use of decision aid in the consultation|With use of developed decision aid for pelvic organ prolapse / At the beginning of the consultation the IF will be opened within the patients electronic journal. The conversation will take its starting point from the generated IF which should define the area of interest rather for the patient.
62448836|NCT03739190|ACTIVE_COMPARATOR|Reference condom B: Thick NRL Condom|
62448837|NCT01234636|ACTIVE_COMPARATOR|cis9,trans 11 CLA oil|50 volunteers on cross over design , receiving 4g/day of cis9,trans11 CLA
62448838|NCT01234636|PLACEBO_COMPARATOR|Placebo oil|50 volunteers cross over design, placebo oil 4g/day
62448839|NCT01891513||ACE inhibitor + exercise|In addition to exercise training, participants will receive an initial perindopril dose of 4 mg/day which will be titrated to 8 mg/day.
62448840|NCT01891513||Thiazide diuretic + exercise|In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
62448841|NCT01891513||Angiotensin receptor blocker + exercise|In addition to exercise training, participants will receive an initial losartan dose of 50 mg/day which will be titrated to 100 mg/day.
62448842|NCT01075763|EXPERIMENTAL|Treatment arm - Rebif®|Subjets in this arm received interferon beta-1a (Rebif® 22 mcg tiw)
62448843|NCT01075763|PLACEBO_COMPARATOR|Placebo arm|Subjects in this arm received placebo
62622081|NCT03706716|NO_INTERVENTION|Control with no use of decision aid in the consultation|Without decision aid / The conversation during the consultation will follow the general standard for consultation conversations in the department.
62848193|NCT03336437|PLACEBO_COMPARATOR|Inactive Vaginal Placebo Ring|At the time of initial study visit, a placebo vaginal ring will be placed. Participants will retain this ring for 12 weeks.
62848194|NCT06113679|ACTIVE_COMPARATOR|Active|
62848195|NCT06113679|SHAM_COMPARATOR|Sham|
62848196|NCT03449641|OTHER|Positive airway pressure (PAP) treatment|Positive airway pressure (PAP),which reverses upper airway obstruction, is effective in the majority of patients with stable obesity hypoventilation syndrome (OHS).
62848197|NCT00194649|EXPERIMENTAL|1|100 mg Miglustat BID (twice daily) for six weeks
62848198|NCT02535156|EXPERIMENTAL|Schizotypal Personality Disorder|Schizotypal Personality Disorder (SPD) patients. They received two interventions: risperidone 1 mg and placebo (lactose).
62848199|NCT02535156|EXPERIMENTAL|Healthy controls|Control group consisting of healthy volunteers.They received two interventions: risperidone 1 mg and placebo (lactose).
62848200|NCT05682222|OTHER|Cohort 1|EDP1815 or placebo in capsule A, dosed for 60 days. Randomization is 2:1 active:placebo.
62848201|NCT05682222|OTHER|Cohort 2|EDP1815 or placebo in capsule B, dosed for 60 days. Randomization is 2:1 active:placebo.
62848202|NCT05682222|OTHER|Cohort 3|EDP2939 lower dose or placebo in capsule B, dosed for 60 days. Randomization is 2:1 active:placebo.
62848203|NCT05682222|OTHER|Cohort 4|EDP2939 higher dose or placebo in capsule B, dosed for 60 days. Randomization is 2:1 active:placebo.
62848204|NCT06087627||PN treatment|Participants ≥ 18 years suffering from moderate-to-severe PN who receive long-term dupilumab treatment for PN in a real-world setting in Germany.
62848205|NCT05377801|EXPERIMENTAL|The intervention group|The intervention group of this study is a multi-dimensional intervention conducted by nursing students over a 12-week period, consisting of four parts: individualized balance and strength training, vision screening, drug evaluation, home risk assessment and home repair and transformation. These components were carried out through a combination of personal home visits and telephone interviews.
62848206|NCT05377801|NO_INTERVENTION|The control group|The control group would receive the same amount of health education.
62265172|NCT04315181|EXPERIMENTAL|Gabapentin 1200mg / Oxycodone 40mg|Participants will receive non-therapeutic experimental doses of gabapentin (600 and 1200 mg, p.o.), alone and in combination with oxycodone (20 and 40 mg, p.o.). The experimental sessions are designed to capture the time-action curves for the test drugs (Tmax for gabapentin ≈ 2.5 hr; oxycodone ≈ 1.5 hr). Therefore, oxycodone will be administered 1 hr after gabapentin to align peak responses.
62448844|NCT03341065|EXPERIMENTAL|exoskeleton type robot|exoskeleton type robot assisted gait training (Lokomat orthosis)
62622082|NCT02116725|EXPERIMENTAL|Shower gel with zinc|Zinc gel is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
62848207|NCT00492635|EXPERIMENTAL|Arm 1|
62848208|NCT00492635|EXPERIMENTAL|Arm 2|
62848209|NCT00492635|PLACEBO_COMPARATOR|Arm 3|
62848210|NCT01097005||Klaricid|Those with an exposure
62848211|NCT06155396|EXPERIMENTAL|Disitamab Vedotin + Zimberelimab|Disitamab Vedotin（RC48-ADC）with Zimberelimab arm
62848212|NCT05113238|ACTIVE_COMPARATOR|AGT-Initial|Oocytes will be injected with spermatozoa and will be incubated in 10 mM calcium ionophore (Sigma-Aldrich) for two rounds of 10 minutes at 37 C, 30 minutes after ICSI injection, and then will be rinsed and transferred into culture medium.
62848213|NCT05113238|EXPERIMENTAL|AGT-revised|"ejaculated spermatozoa will be exposed to calcium ionophore in a drop on the ICSI dish before injection. During the ICSI procedure, spermatozoa will be aspirated individually from the drop containing calcium ionophore and immobilized in a separate PVP drop. Next, approximately 0.4 pL of calcium ionophore will be aspirated into the micropipette and injected into the oocyte with the spermatozoa.~Post-ICSI oocytes will be then exposed to 50 mM calcium ionophore for 10 minutes at 37C, and then will be washed and placed in culture medium."
62848214|NCT00704652||A|Diabetic patients suffering from renal insufficiency with stable haemoglobin levels (receiving no EPO supplementation)
62265173|NCT00529997|EXPERIMENTAL|1|Posterior Dynamic Stabilization with the Stabilimax NZ
62265174|NCT00529997|ACTIVE_COMPARATOR|2|Posteriolateral instrumented fusion
62265175|NCT00886600|PLACEBO_COMPARATOR|1|Placebo
62265176|NCT00886600|EXPERIMENTAL|2|losartan 50 mg q.d.
62265177|NCT00886600|EXPERIMENTAL|3|losartan 100 mg q.d.
62265178|NCT00886600|EXPERIMENTAL|4|losartan 50 mg b.i.d.
62265179|NCT04882592|EXPERIMENTAL|Therapeutic Arm|Spinal Cord Neuromodulation with SCiP during Activity Based NeuroRehab Therapy
62265180|NCT04882592|SHAM_COMPARATOR|Sham Arm|Sham Stimulation during Activity Based NeuroRehab Therapy
62265181|NCT02487420|OTHER|Arm 18m|arm 18m: 6 months between step 1 and step 2; 6 months between step 2 and step 3, 3 months between all other steps step by step gradual introduction of egg containing food products during 18 months, unless next step can not be taken
62848215|NCT00704652||B|Diabetic patients with renal insufficiency and in need of recombinant human EPO (darbepoetin alfa) substitution because of inadequate erythropoiesis. In both groups the target haemoglobin level is 10-12 gHb/ml, all treatment is performed according to label.
62848216|NCT04431921||Lung cancer patients|Lung cancer survivors who had stable conditions and routine follow-up at Hacettepe University Oncology Hospital
62848217|NCT04431921||Healthy subjects|No health problems related or affect outcome measure parameters examined in this study.
62848218|NCT01443624|EXPERIMENTAL|critical care patients venofer|Critically ill patients are injected with Venofer (ferric hydroxide sucrose) 100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
62848219|NCT03679507|ACTIVE_COMPARATOR|Group A|The first patient group will receive Low Intensity Ultrasound Therapy on the affected knee joint, using the CPI-LIPUS Device
62848220|NCT03679507|PLACEBO_COMPARATOR|Group B|"Will be treated with an identical device whose ultrasound emitting capabilities has been nullified. This device appears to operate, including illumination of the operating light."
62848221|NCT03679507|ACTIVE_COMPARATOR|Group B1|The first patient group will receive high CBD oil applied topically to the affected knee joint.
62848222|NCT03679507|NO_INTERVENTION|Group B2|This group of patients will not receive high CBD oil to the affected joint.
62622083|NCT02116725|PLACEBO_COMPARATOR|Plain shower gel|Plain shower gel is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
62622084|NCT02116725|SHAM_COMPARATOR|Distilled water|Distilled Water is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
62622085|NCT03102671|EXPERIMENTAL|AB sequence|Usual care followed by use of HeartHab application: Treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle), followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence.
62622086|NCT03102671|EXPERIMENTAL|BA sequence|Use of HeartHab application followed by usual care: patients will be followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence, followed by treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle)
62622087|NCT00623298|EXPERIMENTAL|1|NET
62622088|NCT00623298|NO_INTERVENTION|3|6-months baseline
62622089|NCT00623298|EXPERIMENTAL|2|group IPT
62622090|NCT05607121|EXPERIMENTAL|iTBS then cTBS|iTBS day 1, cTBS day 2
62622091|NCT05607121|EXPERIMENTAL|cTBS then iTBS|cTBS day 1, iTBS day 2
62622092|NCT00906854||Group I|practice of weight training exercises
62622093|NCT00906854||Group II|aerobic exercises as part of lessons jump, step and dance classes
62622094|NCT00906854||Group III|swimming (crawl mode)
62622095|NCT03843320||SAVR|"Patients with aortic stenosis undergoing surgical aortic valve replacement using an approved medical device for this intended use.~Patients will be enrolled in this group only if the device is one of the following:~* INSPIRIS RESILIA;~* EDWARDS INTUITY;~* Carpentier-Edwards PERIMOUNT Magna-Ease."
62848223|NCT05387434|EXPERIMENTAL|DPP-R|Weekly 60 min. group meetings, lead by trained KSRE staff, (12-15 participants) will be held by Zoom over 6 months followed by monthly 60 min. group meetings for the later 6 months. Approximately 5 min prior to the meeting time (typically early evening) participants will receive call in information to join the group meeting by video conferencing or phone.
62061111|NCT01119430|ACTIVE_COMPARATOR|Fluoxetine plus DU125530|
62622096|NCT03843320||TAVR|"Patients with aortic stenosis undergoing transcatheter aortic valve replacement using an approved medical device for this intended use.~Patients will be enrolled in this group only if the device is one of the following:~* SAPIEN 3;~* SAPIEN XT."
62061112|NCT03950180|ACTIVE_COMPARATOR|PCCI group|In addition to standard of care counseling the additional provision of the patient's specific Prostate Cancer Comorbidity Index score and life expectancy estimation was provided.
62622097|NCT05034380|ACTIVE_COMPARATOR|Lean|males aged 18-30 years with BMI \< 25
62061113|NCT03950180|NO_INTERVENTION|Standard care|Standard of care was defined as prostate cancer counseling reflecting the best practices of a multidisciplinary team of urologists, radiation oncologists and medical oncologists.
62061114|NCT06437236|ACTIVE_COMPARATOR|Group A|"will receive ondansetron 4mg diluted in normal saline,The total volume of the solution infused will kept at 10 mL.~After preloading, patients in the respective group will receive the infusion of the study drug over 1 minute just 5 minutes before performing the subarachnoid block."
62061115|NCT06437236|ACTIVE_COMPARATOR|group B|"will receive granisetron 1mg diluted in normal saline.The total volume of the solution infused will kept at 10 mL.~After preloading, patients in the respective group will receive the infusion of the study drug over 1 minute just 5 minutes before performing the subarachnoid block."
62061116|NCT04414280||type 1 diabetes patients using Medtronic MiniMed 670G|Patients with type 1 diabetes, aged 8 years or older, who start with the Medtronic MiniMed 670G system (as part of routine clinical practice) in one of the 17 participating centers and who signed informed consent are eligible to participate. The decision about which patient to start, is left to the clinical judgement of the treating health care professional.
62265182|NCT02487420|OTHER|arm 30 m|arm 30m: 9 months between step 1 and step 2; 9 months between step 2 and step 3, 6 months between all other steps step by step gradual introduction of egg containing food products during 30 months, unless next step can not be taken
62622098|NCT05034380|EXPERIMENTAL|Overweight/Obese|males aged 18-30 years with BMI \>= 25
62622099|NCT05176639|EXPERIMENTAL|Phase 1/2 MAD (HV and TED)|Healthy volunteers and participants with TED will be randomized to receive two intravenous infusions of veligrotug (VRDN-001) or placebo with an interval of 3
62265183|NCT01528514|ACTIVE_COMPARATOR|Curcuminoids|
62622100|NCT05176639|EXPERIMENTAL|Phase 3 Cohort (THRIVE)|Participants with TED will be randomized to either veligrotug (VRDN-001) 10mg/kg or placebo.
62622101|NCT01042392|ACTIVE_COMPARATOR|Ramipril|"In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.~In period II (double-blind treatment, randomized): Ramipril 5 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to Ramipril 10 mg only if BP remained ≥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.~In period III (double-blind withdrawal): At visit 4, part of patients received the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
62265184|NCT01528514|PLACEBO_COMPARATOR|Placebo|
62622102|NCT01042392|EXPERIMENTAL|Aliskiren|"In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.~In period II (double-blind treatment, randomized): Aliskiren 150 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to aliskiren 300 mg only if BP remained ≥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.~In period III (double-blind withdrawal ): At visit 4, part of the patients received the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
62622103|NCT01042392|PLACEBO_COMPARATOR|Placebo to Ramipril|In period III (double-blind withdrawal ): At visit 4, part of patients from Ramipril arm received placebo to Ramipril for 1 day. The study ended at visit 5 (48 hours later than visit 4).
62622104|NCT01042392|PLACEBO_COMPARATOR|Placebo to Aliskiren|In period III (double-blind withdrawal ): At visit 4, part of the patients from Aliskiren arm received placebo to Aliskiren for 1 day. The study ended at visit 5 (48 hours later than visit 4).
62061117|NCT04414280||type 1 diabetes patients using Medtronic MiniMed 780G|Patients with type 1 diabetes, aged 8 years or older, who start with the Medtronic MiniMed 780G system (as part of routine clinical practice) in one of the 17 participating centers and who signed informed consent are eligible to participate. The decision about which patient to start, is left to the clinical judgement of the treating health care professional.
62061118|NCT04414280||type 1 diabetes patients using Tandem Control-IQ|Patients with type 1 diabetes, aged 6 years or older, who start with the Tandem Control-IQ system (as part of routine clinical practice) in one of the 17 participating centers and who signed informed consent are eligible to participate. The decision about which patient to start, is left to the clinical judgement of the treating health care professional.
62622105|NCT03180931||Scaffold thrombosis|Any patients who suffered from scaffold thrombosis occurring beyond 1 year after implantation of a Absorb BVS 1.1 and investigated by OCT with sufficient image quality allowing for CoreLab analysis at the timepoint of thrombosis.
62622106|NCT01616758|EXPERIMENTAL|GTx-024 9mg|GTx-024 dosage of three soft gels once daily to equal 9mg
62622107|NCT05326438|EXPERIMENTAL|CIRCLE mHealth app|"The investigators will trial a modified version of the mHealth app called Connections with Alaska Native/American Indian people who want to change the way they use alcohol."
62061119|NCT01770301|ACTIVE_COMPARATOR|A - Paclitaxel|patients will receive paclitaxel alone at the dose 80 mg/m² administered by intravenous injection at D1, D8 and D15 every 4 weeks for 6 cycles. Thereafter, patients will be followed-up with imaging exams every 12 weeks. At the time of confirmed progression, patients could receive bevacizumab 15 mg/kg every 3 weeks for 12 months following investigator's decision. In some cases, longer therapy may be allowed after discussion with the Principal Investigator/Sponsor
62622108|NCT05667168|EXPERIMENTAL|High power laser|"The application of high-intensity laser on cervical muscles, 50J/cm2, 980nm, 0 Hz, on processus mastoideus and porus acusticus externus.~Administration of tinnitus intensity on scale 0-10 and questionary."
62622109|NCT05667168|EXPERIMENTAL|Low power laser|The application of low-intensity laser on cervical muscles, 4J/cm2, 980nm, 0 Hz, on processus mastoideus and porus acusticus externus. Administration of tinnitus intensity on scale 0-10 and questionary.
62622110|NCT05667168|EXPERIMENTAL|Radio-frequention therapy|Applying radio-frequentation current on cervical muscles, 10-50% of intensity, 0 Hz. Administration of tinnitus intensity on a scale of 0-10 and questionary.
62622111|NCT05667168|EXPERIMENTAL|Manual therapy of temporomandibular joint,.|A manual physiotherapeutic approach to the temporomandibular joint will treat participants. Administration of tinnitus intensity on a scale of 0-10 and questionary.
62622112|NCT05667168|EXPERIMENTAL|Manual therapy of the cervical spine.|A manual physiotherapeutic approach to the cervical spine will treat participants. Administration of tinnitus intensity on a scale of 0-10 and questionary.
62061120|NCT01770301|EXPERIMENTAL|B - Paclitaxel + Bevacizumab followed by Bevacizumab|patients will receive paclitaxel at the dose 80 mg/m² administered by intravenous injection at D1, D8 and D15 every 4 weeks + Bevacizumab at the dose 10 mg/kg administered by intravenous injection every 2 weeks (D1 and D15) for 6 cycles. Thereafter, patients will receive IV injection of bevacizumab 15 mg/kg every 3 weeks for up to 1 year
62061121|NCT06065813|EXPERIMENTAL|Toripalimab|
62622113|NCT05667168|ACTIVE_COMPARATOR|Physical exercising.|Participants will be treated by physical exercising in closing and opening muscle chains. Administration of tinnitus intensity on a scale of 0-10 and questionary.
62622114|NCT05667168|ACTIVE_COMPARATOR|Cognitive therapy|Participants will be treated with cognitive therapy by a psychologist. Administration of tinnitus intensity on a scale of 0-10 and questionary.
62622115|NCT05667168|PLACEBO_COMPARATOR|Life style.|Participants will be treated only by modulation of their lifestyle. Administration of tinnitus intensity on a scale of 0-10 and questionary.
62622116|NCT03672344|ACTIVE_COMPARATOR|Lookware TM|Lookware TM computer-based video game that requires the subject to engage in social skills related exercises during simulated social interactions with game characters.
62622117|NCT03672344|PLACEBO_COMPARATOR|Lookware TM Control Module|Lookware TM Control Module is a version of the Lookware TM computer-based video game that excludes the social skills related exercises.
62622118|NCT00417521|EXPERIMENTAL|Family therapy|
62622119|NCT04739592|EXPERIMENTAL|alendronate sodium vitamin D3 tablets|participants will receive alendronate sodium vitamin D3 tablets once per week for one year.
62622120|NCT04739592|PLACEBO_COMPARATOR|placebo|participants will receive a placebo tablet once per week for one year.
62622121|NCT03675971|EXPERIMENTAL|Medical Cannabis|Drug: Cannabidiol
62622122|NCT03675971|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62622123|NCT00843011|EXPERIMENTAL|Arm 1|Orvepitant 60 mg
62622124|NCT03696199|NO_INTERVENTION|Traditional Pain Control Care|Standard of care post-operative pain control with oral narcotics
62622125|NCT03696199|EXPERIMENTAL|Regional Anesthesia|Single injection perioperative peripheral nerve block + followed by administration of oral narcotics on a need-based system
62622126|NCT03696199|EXPERIMENTAL|Long-Acting Local Anesthesia|Subcutaneous local cocktail injection + followed by administration of oral narcotics on a need-based system
62622127|NCT01981811|ACTIVE_COMPARATOR|Aripiprazole and Ingestible Event Marker (IEM)|All subjects will continue to receive their previously prescribed dose of aripiprazole (10 mg, 15 mg, 20 mg, or 30 mg) through the trial. Subjects will discontinue dosing of the conventional oral aripiprazole tablet and will begin taking MIND1 (aripiprazole embedded with an Ingestible Event Marker) tablet once-daily for 12 weeks.
62622128|NCT00545935|ACTIVE_COMPARATOR|1-Methylenblue-Amodiaquine|
62622129|NCT00545935|ACTIVE_COMPARATOR|2-Methylenblue-Artesunate|
62622130|NCT00545935|ACTIVE_COMPARATOR|3-Artesunate-Amodiaquine|
62622131|NCT03937674|EXPERIMENTAL|HeartSteps Intervention|For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not.
62623784|NCT03279601|EXPERIMENTAL|B: Capecitabine Combined Temozolomide(CAPTEM)|patients in arm B will receive chemotherapy of CAPDTEM regimen: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o.d10-14 q4W
62448845|NCT03341065|EXPERIMENTAL|end-effector type robot|end-effector type robot assisted gait training (G-EO system)
62448846|NCT05037149|EXPERIMENTAL|Part 1: Arm A|Cohort 1: STP707 3 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
62448847|NCT05037149|EXPERIMENTAL|Part 1: Arm B|Cohort 2: STP707 6 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
62448848|NCT05037149|EXPERIMENTAL|Part 1: Arm C|Cohort 3: STP707 12 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
62848224|NCT05387434|EXPERIMENTAL|DPP-FB|Participants will be asked to join a secret, research team moderated, Facebook® group, which is only accessible by group members. The health educator will post the module, de-identified participant self-monitoring data, and comment on individuals posts weekly. Brief discussion prompts are designed to reinforce the primary objectives of each module and to facilitate inter-participant discussion around these topics. Responses will be monitored and tracked. This is analogous to attendance in the Zoom® group.
62848225|NCT03973060|EXPERIMENTAL|Concentric muscular work|4 series of 12 repetitions of concentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
62448849|NCT05037149|EXPERIMENTAL|Part 1: Arm D|Cohort 4: STP707 24 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
62448850|NCT05037149|EXPERIMENTAL|Part 1: Arm E|Cohort A: STP707 36 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
62848226|NCT03973060|EXPERIMENTAL|Eccentric muscular work|4 series of 12 repetitions of eccentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
62848227|NCT03973060|EXPERIMENTAL|Concentric-eccentric muscular work|4 series of 12 repetitions of concentric-eccentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
62848228|NCT03973060|EXPERIMENTAL|Isometric muscular work|6 seconds of contraction, with 20 seconds of rest with 24 repetitions, for a total working time of 12 minutes.
62848229|NCT03383341|EXPERIMENTAL|Cricket powder protein|Participants were provided with frozen 70 gram breakfast muffins and pre-mixed powder packets to prepare smoothies. Participants were asked to consume one muffin package and one smoothie (mixed with water or choice of milk/milk substitutes) daily for 14 days. The amount of intervention food consumed daily contained 25 grams of cricket protein powder.
62448851|NCT05037149|EXPERIMENTAL|Part 1: Arm F|Cohort 5: STP707 48 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
62848230|NCT03383341|PLACEBO_COMPARATOR|Placebo Control|Participants were provided with a placebo comparator that included frozen 70 gram breakfast muffins and pre-mixed powder packets to prepare smoothies. Participants were asked to consume one muffin package and one smoothie (mixed with water or choice of milk/milk substitutes) daily for 14 days. These foods were formulated to taste and appear similar to the cricket intervention foods but did not consume any cricket powder.
62848231|NCT03192358||Amyotrophic Lateral Sclerosis|We will be recruiting individuals with confirmed or probably ALS, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
62848232|NCT03192358||Parkinson's Disease|We will be recruiting individuals with a diagnosis of Parkinson's disease, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
62848233|NCT03253341|EXPERIMENTAL|Smart Aging Program|Participants will be enrolled into the Smart Aging Program.
62848234|NCT03253341|ACTIVE_COMPARATOR|Control Group|Participants will be enrolled into group that receives educational materials that reflect the current standard of care.
62848235|NCT03497013|EXPERIMENTAL|Active tDCS|All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
62848236|NCT03497013|SHAM_COMPARATOR|Sham tDCS|For sham stimulation, the device was set to turn off after 30 seconds(study model).
62848237|NCT06384118|EXPERIMENTAL|intervention group|Based on IMB Theory of Health Education A hypoglycemia coping intervention program based on IMB theory was implemented on top of the control group.
62848238|NCT06384118|NO_INTERVENTION|the control group|General diabetes health education Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.
62848239|NCT05663138||Early Hi-VNI|Group 1 of early shift to Hi-VNI after nasal cannula
62848240|NCT05663138||Late Hi-VNI|Group 2 of late use of Hi-VNI after NRM
62848241|NCT04536103||Cleveland Clinic Foundation (CCF) Volunteers|The group will be used for evaluating differences between standard T1rho and T2 imaging vs accelerated T1rho and T2 imaging techniques that will be developed from this study.
62848242|NCT04536103||Traveling Volunteers|The group will be recruited at CCF and be scanned at CCF, University of California San Francisco, University of Kentucky and Albert Einstein College of Medicine.
62622132|NCT01510964|EXPERIMENTAL|prompt-sheet|"Patients and companions of intervention group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and the prompt sheet. An introduction explains the importance of asking questions during the consultations. The patient (companion) is invited to select among a written list of about 50 possible questions those, if any, s/he would like to ask today to the oncology."
62622133|NCT01510964|OTHER|control group|"Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist"
62622134|NCT05805020|EXPERIMENTAL|Cellvizio|Cellvizio is a confocal laser endomicroscopy providing the possibility of obtaining in vivo high-magnification images of the gut epithelium. This allows real-time examination of the gastrointestinal mucosa at the cellular and subcellular level
62622135|NCT02303197|EXPERIMENTAL|ChiNing decoction|60ml ChiNing decoction by mouth，three times a day for 46 days.
62622136|NCT02303197|NO_INTERVENTION|rhEGF spray|The rhEGF spray spray on the oral mucosal surface irradiated area, 3 times a day for 46 days.
62622137|NCT03172377|EXPERIMENTAL|Intervention group|Lengthening adalimumab dosing interval: The adalimumab injection interval during maintenance therapy (40 mg sc / 2 weeks) will be extended through a stepwise disease activity guided manner to 3 weeks and subsequently - after 24 weeks - to 4 weeks. If a step-down leads to recurrence of disease activity patients will return to the preceding effective dosing interval.
62622138|NCT03172377|NO_INTERVENTION|Control group|Standard care: patients will continue adalimumab maintenance treatment of 40mg per 2 weeks. Treatment decisions are made at the discretion of the treating physician.
62848243|NCT04536103||ACL tear Volunteers|This group will be recruited at CCF and scanned at baseline and 1-year at all of the three MR systems at CCF (Siemens, GE, Philips).
62061122|NCT05286944|EXPERIMENTAL|Mobile daily alarm|A mobile smartphone with functioning alarm system and solely owned by the patient. The alarm will be set by the second investigator to alert the participant between 6am - 10am (based on participant's preference) in the morning daily. A recorded dual-language (English and Malay version) tone for alarm mobile phone will be used. Apart from that participants are also counseled and educated about allergic rhinitis and are also asked to fill up self monitored adherence card to document their nasal steroid intake.
62061123|NCT05286944|NO_INTERVENTION|Control|This group of participant will receive counseling and education regarding allergic rhinitis and the importance of compliance. Patients are also given a self monitored adherence card to document their nasal steroid intake.
62265185|NCT03857490|EXPERIMENTAL|Intervention|Lower leg heat therapy via water immersion up to the knee in a circulated bath (water temperature 42°C, 4 times per week, 45 minutes per session) for 8 weeks.
62448852|NCT00462982|EXPERIMENTAL|Sunitinib|Patients will be treated with 50 mg daily for four out of every six weeks.
62265186|NCT03857490|PLACEBO_COMPARATOR|Control|Lower leg immerse in a thermoneutral water bath (33°C), 4 times per week, 45 minutes per session for 8 weeks.
62265187|NCT02713958|EXPERIMENTAL|Tele rehabilitation|Telerehabilitation:The subjects in the study group will receive two treatments in Telerehabilitation and one treatment in the clinic weekly . At home they will be asked practice daily active exercises with the Meditouch Ltd. system.
62265188|NCT02713958|ACTIVE_COMPARATOR|rehabilitation|Traditional Occupational Therapy:The subjects in this group will receive three treatments in the clinic every week. At home they will be asked to practice daily active exercises in the same level of difficulty and duration as the study group but without the Meditouch Ltd. system
62265189|NCT04526561|ACTIVE_COMPARATOR|Breast reconstruction TDAP|Breast reconstruction performed with TDAP
62265190|NCT04526561|ACTIVE_COMPARATOR|Breast reconstruction latissimus dorsi|Breast reconstruction performed with latissimus dorsi
62448853|NCT02200900|ACTIVE_COMPARATOR|Group 1 ( CPAP followed by HFNC)|In this group pharyngeal pressure, transcutaneous carbon dioxide concentration, tidal volumes and pharyngeal gas concentrations will be recorded on CPAP first followed by HFNC.
62448854|NCT02200900|ACTIVE_COMPARATOR|Group 2 (HFNC followed by CPAP)|In this group pharyngeal pressure, transcutaneous carbon dioxide concentration, tidal volumes and pharyngeal gas concentrations will be recorded on HFNC first followed by CPAP.
62448855|NCT01100970||Unipolar electric needle|
62448856|NCT01100970||Bipolar electric needle|
62448857|NCT01100970||Control|Infants who were born in a vaginal birth
62448858|NCT04601584|EXPERIMENTAL|GNR-084, dose level 1|Anti-CD19/CD3 antibody
62448859|NCT04601584|EXPERIMENTAL|GNR-084, dose level 2|Anti-CD19/CD3 antibody
62448860|NCT04601584|EXPERIMENTAL|GNR-084, dose level 3|Anti-CD19/CD3 antibody
62448861|NCT04601584|EXPERIMENTAL|GNR-084, dose level 4|Anti-CD19/CD3 antibody
62622139|NCT04813107|ACTIVE_COMPARATOR|APL-1202 in combination with tislelizumab|
62622140|NCT04813107|PLACEBO_COMPARATOR|Tislelizumab alone|
62622141|NCT02204436|OTHER|Emulsion and gel|A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
62848244|NCT04536103||Group Matched to ACL tear Volunteers|This group will be recruited at CCF and scanned at baseline and 1-year at all of the three MR systems at CCF (Siemens, GE, Philips).Traveling Volunteers share the same inclusion and exclusion criteria as this group, therefore subjects can participate the study and serve as subjects within both groups
62848245|NCT02870478|ACTIVE_COMPARATOR|0.01% atropine daily|Nightly dosing of 0.01% atropine
62848246|NCT02870478|EXPERIMENTAL|0.01% atropine twice per week|Atropine dosed twice per week
62448862|NCT04601584|EXPERIMENTAL|GNR-084, dose level 5|Anti-CD19/CD3 antibody
62448863|NCT04601584|EXPERIMENTAL|GNR-084, dose level 6|Anti-CD19/CD3 antibody
62622142|NCT05643729|EXPERIMENTAL|Group 1: Zofin|Group 1 Treatment Arm (10 subjects): Zofin + Standard of care (SOC) Ten subjects will receive 1 mL of Zofin on Day 0, Day 4, and Day 8, containing 1-5 x 10\^11 particles/ml. The Zofin dose will be diluted in 100 mL of sterile saline at subject's bedside. In addition to Zofin all subjects in this trial will receive SOC throughout the study period.
62622143|NCT05643729|PLACEBO_COMPARATOR|Group 2: Placebo|Group 2 Control Arm (10 subjects): Placebo + SOC Ten subjects will receive placebo on Day 0, Day 4, and Day 8, containing 101 mL of sterile saline at subject's bedside. In addition to placebo all subjects in this trial will receive SOC throughout the study period.
62622144|NCT05552742|ACTIVE_COMPARATOR|Conservative Rehabilitation|Only conservative rehabilitation treatment was applied to the patients in group 1.
62622145|NCT05552742|EXPERIMENTAL|Conservative Rehabilitation + Virtual Balance Training|Conservative rehabilitation treatment and virtual balance study were applied to the patients in group 2.
62622146|NCT04876131|EXPERIMENTAL|Arm 1, 1 dose|"* Single dose IV to cover Gram negative bacteria followed by 2 days of oral antibiotics~* Single dose IV to cover Enterococcus spp~IV antibiotics are as per local institutional guidelines and microbiology eg: IV gentamicin with or without IV benzylpenicillin. Gentamicin is used when Gram Negative coverage is appropriate, benzylpenicillin is also used when Enterococcus coverage is appropriate, depending on local microbiology data. Once the IV component is complete the patient will be given an oral antibiotic (cefalexin) on day 2 and 3 of the study."
62061124|NCT02543190|EXPERIMENTAL|compliance surveillance|"* Prospective audits by study personnel~* Call from the clinic nurse practitioner or physician's assistant within 7 days of discharge to administer a screening questionnaire to identify patients at risk of dehydration. Study personnel will ensure this phone call is made."
62448864|NCT04102020|EXPERIMENTAL|Part 1: Dose Confirmation|Participants will receive venetoclax once daily (QD) (Days 1-28) for up to 24 cycles, azacitidine (AZA) QD on Days 1-5 of each 28 day cycle for up to 6 cycles.
62061125|NCT02543190|NO_INTERVENTION|Usual Care|educational session at the start of the study
62061126|NCT01899456|NO_INTERVENTION|Medical therapy|Best medical therapy using guideline recommended drugs in each disease state.
62622147|NCT04876131|ACTIVE_COMPARATOR|Arm 2, 3 doses|"* 3 doses IV to cover Gram negative bacteria~* 3 days IV antibiotics to cover Enterococcus spp~IV antibiotics are as per local institutional guidelines and microbiology eg: IV gentamicin with or without IV benzylpenicillin. Gentamicin is used when Gram Negative coverage is appropriate, benzylpenicillin is also used when Enterococcus coverage is appropriate, depending on local microbiology data."
62622148|NCT04723589|NO_INTERVENTION|Standard Arm|Participants randomized to standard care will not receive an intervention but will participate in other study procedures, which are blood collection and data collection.
62622149|NCT04723589|EXPERIMENTAL|Intervention Arm|Participants randomized to the intervention arm will receive standard care plus an infusion of thawed plasma, starting rate 30 ml/hour for 24 hours, increased to 50 ml/hour if deemed to be hypovolemic (low fluid volume). Only non-convalescent (COVID-antibody-free) plasma will be used.
62061127|NCT01899456|EXPERIMENTAL|Catheter-based renal denervation|Renal denervation will be performed in the native renal arteries of patients after renal transplantation. Access side is the contralateral femoral artery.
62622150|NCT06612931|EXPERIMENTAL|CMB|In ERCP procedures, catheter-guided mini-forceps biopsy (CMB) is performed before biliary brush cytology with vacuum aspiration (BCA).
62622151|NCT06612931|ACTIVE_COMPARATOR|BCA|In ERCP procedures, biliary brush cytology with vacuum aspiration (BCA) is performed before dilation catheter-guided mini-forceps biopsy (CMB).
62622152|NCT05948137||Pheochromocytoma / paraganglioma|
62622153|NCT02364076|EXPERIMENTAL|Pembrolizumab and Epacadostat|Pembrolizumab 200 mg intravenously every 3 weeks Epacadostat 100mg by mouth taken daily
62061128|NCT04822350||Locally advanced or metastatic urothelial carcinoma patients treated with avelumab|
62061129|NCT06149546|EXPERIMENTAL|Control|"* High protein, high energy diet~* Fish oil supplement (ProSure®)~* Pancreatic Enzymes (Creon®)~* A daily individualised step target (10% above your own baseline)~* Four scheduled appointments with a dietitian"
62061130|NCT06149546|EXPERIMENTAL|Intervention|"* High protein, high energy diet~* Fish oil supplement (ProSure®)~* Pancreatic Enzymes (Creon®)~* A daily individualised step target (10% above your own baseline)~* Seven scheduled appointments with a dietitian~* Six scheduled appointments with a physiotherapist"
62061131|NCT04772846|EXPERIMENTAL|Chloroquine group|
62448865|NCT04102020|EXPERIMENTAL|Part 3 (Dose Finding): Dose Escalation|Participants will receive venetoclax QD for up to 24 cycles, AZA QD on Days 1 to 14 of each 28-day cycle for up to 24 cycles to determine recommended phase 3 dose (RPTD).
62448866|NCT04102020|EXPERIMENTAL|Part 3 (Dose Finding): Safety Expansion|Participants will receive venetoclax QD for up to 24 cycles, AZA QD on Days 1 to 14 of each 28-day cycle for up to 24 cycles at the RPTD.
62448867|NCT01485536|EXPERIMENTAL|AUY922|AUY922 starting dose 70 mg/m2 intravenous on Days 1, 8, 15, and 22 of 28 day cycle.
62622154|NCT04930705|EXPERIMENTAL|TempSure FlexSure Applicator|Subjects will be treated with the TempSure FlexSure applicator device at each treatment.
62622155|NCT01397149|EXPERIMENTAL|Eltrombopag|In phase II, patients will be randomized (2:1 eltrombopag : placebo) to receive either eltrombopag or placebo to explore the efficacy and confirm the safety of the identified eltrombopag dose from Phase I.
62622156|NCT01397149|PLACEBO_COMPARATOR|Film coated tablet|
62622157|NCT02264938|NO_INTERVENTION|Observation|Patients with AREDS category 2 and 3 AMD are observed during 1 year
62623785|NCT04184011||SRT for keloid scars|Individuals who are voluntarily scheduled to be treated at one of the participating study sites with SRT (SRT-100™, SRT-Vision™ or SRT-100+™) for the treatment of one or more recurrent keloids.
62265191|NCT04526561|ACTIVE_COMPARATOR|Breast reconstruction with DIEP|Breast reconstruction performed with a deep inferior epigastric artery perforator flap
62265192|NCT02249650|EXPERIMENTAL|TSB-9-W1 cohort|TSB-9-W1 200 mg/day (Cohort 1) TSB-9-W1 400 mg/day (Cohort 2) TSB-9-W1 600 mg/day (Cohort 3) TSB-9-W1 800 mg/day (Cohort 4) TSB-9-W1 1000 mg/day (Cohort 5)
62265193|NCT01181011|EXPERIMENTAL|amlodipine/telmisartan/combination|all patients will be assigned to 6 treatment sequences. cross-over design was adopted to ensure each patient would take amlodipine/telmisartan/combination single dose in randomized order
62265194|NCT01970189||Primary Immune Thrombocytopaenia|Recently-diagnosed (i.e. \< 6 months) primary ITP adult patients (≥ 18 years) characterized by platelet counts less than 100x109/L as defined by the International Working Group.
62265195|NCT06496815|EXPERIMENTAL|Donafenib combined with or without immunotherapy and local therapy for uHCC|The patients who had previously received a targeted drug in combination with or without immunotherapy, local therapy (transhepatic arterial embolization chemotherapy (TACE), hepatic arterial infusion chemotherapy (HAIC)) and had not received donafenib, and the previous treatment has progressed. The specific experimental protocol was to replace the original targeted drug with donafenib (0.2g bid), while continuing immunotherapy and local therapy as previous (if have).
62448868|NCT04921280||Treatment group|Patients who have received treatment for severe health anxiety at the Internet Psychiatry Clinic, Psychiatry Southwest, Karolinska University Hospital Huddinge between April 2018 to April 2021.
62448869|NCT05285020|EXPERIMENTAL|Alter G group|"This group will perform the hospital's standard protocol for these injuries once a day during two weeks.~They carried out the re-education of the gait (at the parallel bars) with a progressive load in scale controlled by the patient.~Also, they carried out a re-education of the gait and progressive loading in the system Alter G (anti-gravity treadmill)."
62061132|NCT04772846|PLACEBO_COMPARATOR|Placebo drug group|
62061133|NCT01139463||Antipsychotic treatment|Patients were not taking any medications - apart from the prescribed antipsychotic - for a period of 1 month prior to the study with psychotic relapse or newly diagnosed psychotic disorder were recruited from psychiatric inpatient and outpatient clinics of the Split Clinical Hospital.
62061134|NCT02671201||Group A|Theoretical training will be scheduled for 2 hours with lectures in basics of emergency ultrasound. After the theoretical education the students will obtain a bedside-teaching on intensive care unit for 4 hours.
62061135|NCT02671201||Group B|Theoretical training will be scheduled for 3 hours and included lectures in echocardiography, lung ultrasound and abdominal ultrasound. After the theoretical education the students will obtain a bedside-teaching on intensive care unit for 3 hours.
62448870|NCT05285020|OTHER|Control group|"This group will perform the hospital's standard protocol for these injuries once a day during two weeks.~They just carried out the re-education of the gait (at the parallel bars) with a progressive load in scale controlled by the patient."
62622158|NCT02264938|ACTIVE_COMPARATOR|Antioxidant|Patients with AREDS category 2 and 3 AMD are enrolled to take daily oral supplementation with lutein (12mg) + zeaxanthin (2mg) + astaxanthin (8mg) + omega-3 fatty acids (docosahexaenoic acid \[DHA\] 540mg + eicosapentaenoic acid \[EPA\] 360mg) + vitamin C (40mg) + vitamin E (20mg) + zinc (16mg) + copper (2mg) during 1 year.
62061136|NCT02671201||Group C|Theoretical training will be scheduled for 3 hours and included lectures in echocardiography, lung ultrasound and abdominal ultrasound.
62061137|NCT03715400|NO_INTERVENTION|Control|The control group will not undergo the positive virtual reality training program. Instead, they will complete all self-report and behavioral measures and have the option to experience the positive virtual reality training program upon the conclusion of the study.
62061138|NCT03715400|EXPERIMENTAL|Positive Virtual Reality Training Intervention|The experimental group will undergo the positive virtual reality training program, which consists of 7 virtual reality (VR) sessions to be completed at home after orientation to the program, in addition to all self-report and behavioral measures.
62448871|NCT00743197|NO_INTERVENTION|Usual Care Group|USUAL CARE GROUP-therapy in this group will be no dictated medical therapy, but usual care, as dictated by their referring physician.
62848247|NCT01707576|OTHER|screening of adolescent mental suffering. Management|screening of adolescent mental suffering consultant to emergencies. Management and later monitoring
62061139|NCT02478346|EXPERIMENTAL|All Patients|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 500mg (100mg/ml) will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used).
62061140|NCT03723343||Experimental: GP+IMRT|Test group: GP-induced chemotherapy (Gemcitabine 1000 mg/m2 d1, 8+Cisplatin 80 mg/m2 d1, once every 3 weeks, 4/6 course) + IMRT radiotherapy alone
62265196|NCT03002415|EXPERIMENTAL|Guided water intake|"Verbal and written guidelines will be given for the patient to ingest the daily volume of water calculated by the weight (30 ml / kg / day) for 14 days. Patients will receive an acrylic glass with a mark in 200 ml and will be instructed to take the number of glasses a day corresponding to the calculated volume (30 ml / kg). Patients will also receive a leaflet indicating how many glasses of water they will need to take. They will also be instructed to mark with an X the number of glasses of water that they actually drank daily during the fourteen days of intervention.~Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days."
62265197|NCT03002415|PLACEBO_COMPARATOR|Placebo - free demand water intake|Patients are instructed to drink water and other liquids on demand. Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days.
62622159|NCT02168777|EXPERIMENTAL|Ph1b-Refametinib/Regorafenib Cohort 0|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort 0: Refametinib 30mg twice daily (b.i.d) + Regorafenib 80mg once daily (q.d), 3 weeks on/1 week off.
62622160|NCT02168777|EXPERIMENTAL|Ph1b-Refametinib/Regorafenib Cohort -1|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort -1: Refametinib 20mg b.i.d + Regorafenib 80mg q.d, 3 weeks on/1 week off.
62622161|NCT02168777|EXPERIMENTAL|Ph1b-Refametinib/Regorafenib Cohort -1a|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort -1a: Refametinib 20mg b.i.d + Regorafenib 120mg q.d, 3 weeks on/1 week off.
62622162|NCT01453790|EXPERIMENTAL|Parent-Specific Depression Education-Motivation|Mothers receive depression education (verbal and written) with messages targeted to parent status which are drawn from previous research. They also receive motivational messages at 2 days via telephone.
62622163|NCT01453790|ACTIVE_COMPARATOR|General Depression Education|Mothers receive general depression education (verbal and written) which are drawn from previous research. They also receive attention control telephone calls at 2 days.
62622164|NCT01662856|EXPERIMENTAL|Fibrin Sealant Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
62622165|NCT01662856|ACTIVE_COMPARATOR|Manual Compression|Direct manual compression of target bleeding site with gauze/laparotomy pads.
62622166|NCT05397340|EXPERIMENTAL|L-GPi/R-STN|Participants randomized in this arm will receive L-GPi/R-STN stimulation for 1 year.
62622167|NCT05397340|ACTIVE_COMPARATOR|Bi-STN|Participants randomized in this arm will receive bilateral STN stimulation for 1 year.
62622168|NCT04428528||Neoadjuvant Chemotherapy Monitoring|"The first arm Neoadjuvant Chemotherapy Monitoring will investigate changes of measured photoacoustic markers and compare to these to histopathological indicators of breast tumor response to NAC. Changes in photoacoustic parameters will be made to a pre-treatment point over the course of treatment. Treatment will not be modified on the basis of our observations.~in this pilot observational study"
62622169|NCT04428528||Breast Mass Characterization|The second arm Breast Mass Characterization will investigate if breast masses (benign vs. malignant) can be characterized during clinical diagnostic work-up. Differences in the photoacoustic tissue-properties will be compared to histopathological evaluation.
62622170|NCT03953599|EXPERIMENTAL|CD19-STAR-T cells|CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
62622171|NCT03397602|NO_INTERVENTION|standard care|Participants do not participate in a on site structured exercise training program.
62622172|NCT03397602|EXPERIMENTAL|standard care + MICE|standard care + moderate-intensity continuous exercise training (MICE)
62061141|NCT03723343||Active Comparator: TPF+IMRT|Control group: TPF-induced chemotherapy (Docetaxel: 75 mg/m2d1, Cisplatin 75 mg/m2, d1\~d5, 5-fluorouracil 750 mg/m2/dd1\~d5, 4/6 course) + IMRT radiotherapy alone
62061142|NCT01388348|EXPERIMENTAL|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
62061143|NCT00825097|EXPERIMENTAL|Neurotomy Group|8 patients undergoing a selective tibial neurotomy under general anesthesia
62061144|NCT00825097|ACTIVE_COMPARATOR|BTX Group|8 patients undergoing a botulinum toxin injection in the calf muscles under EMG-control
62265198|NCT04919980|EXPERIMENTAL|Treatment|MV replacement with Innovalve MR system
62265199|NCT04203524|EXPERIMENTAL|Procalcitonin Arm|The medical team will be provided with a daily PCT for the patient, along with the PCT-guided algorithm that outlines the suggested management based on the PCT levels.
62622173|NCT03397602|EXPERIMENTAL|standard care + HIIT|standard care + high-intensity interval training (HIIT)
62622174|NCT00888797|ACTIVE_COMPARATOR|1|Perioperative Propranolol and Etodolac
62848248|NCT00934440|EXPERIMENTAL|Dose Escalation: 5-azacitidine|A traditional 3+3 dose escalation trial was implemented. Successive cohorts of patients (3 participants/cohort) received bevacizumab at the standard dose of 10mg/kg in combination with escalating doses of 5-azacitidine. If no dose limiting toxicity (DLT) is seen, subsequent patients will be treated at the next dose level. If one DLT is seen, an additional three patients will be accrued at that dose level. If two or more DLTs are seen at one dose level, then the previous dose level will be chosen for phase IIA. If two DLT's are seen at dose level 1, the trial will end. The standard 5-azacitidine dose is 75mg/m2/day for 7 days. If no DLT is seen at dose level 3, then we will proceed with the phase IIA portion of the study.
62848249|NCT06169267|ACTIVE_COMPARATOR|Group I (no music)|Patients undergo standard of care bone marrow biopsy and/or aspiration.
62265200|NCT04203524|OTHER|Control Arm|Procalcitonin levels will be measured for those patients, but the medical team will be blinded from their results
62622175|NCT00888797|PLACEBO_COMPARATOR|2|Placebo
62622176|NCT03973398|ACTIVE_COMPARATOR|Quadratus Lumborum Block anterior subcostal (QLa)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.125 bupivacaine.
62061145|NCT02994602|EXPERIMENTAL|Nestorone (NES) + testosterone (T) combined gel|A combination gel with Nestorone® (NES) and Testosterone (T) applied transdermally. The volume of gel to be applied will be approximately 5 mL. This gel volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day and will also contain 8.3 mg of NES that will deliver about 0.8 mg NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel) in 5 ml of combined gel.
62061146|NCT02433002||Main study|1300 participants will undergo baseline (month 0) and final (month 36) reference GFR, estimated GFR (eGFR) and urinary albumin-to-creatinine ratio (ACR) tests. Additionally they will provide ACR and eGFR tests at 6-monthly intervals.
62061147|NCT02433002||Sub-study of patterns of progression|A subset of the cohort (n=375) will receive annual reference GFR tests.
62061148|NCT02433002||Biological variability study|In a further sub-study 20 participants will undergo the reference test four times over four weeks.
62622177|NCT03973398|ACTIVE_COMPARATOR|Quadratus Lumborum Block posterior (QLp)|Patients in this group will receive Posterior Quadratus Lumborum block postoperative with 30 ml of 0.125 bupivacaine.
62848250|NCT06169267|EXPERIMENTAL|Group II (listen to music)|Patients listen to music while undergoing standard of care bone marrow biopsy and/or aspiration.
62061149|NCT06298565||efgartigimod cohort|patients treated with efgartigimod
62061150|NCT06298565||non-efgartigimod cohort|patient treated with other MG medication
62622178|NCT03973398|PLACEBO_COMPARATOR|Quadratus Lumborum Block anterior subcostal control (QLca)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.9% normal saline.
62848251|NCT01947855|EXPERIMENTAL|Empagliflozin low dose|Empagliflozin low dose tablet once daily
62848252|NCT01947855|EXPERIMENTAL|Empagliflozin high dose|Empagliflozin high dose tablet once daily
62848253|NCT01947855|PLACEBO_COMPARATOR|Placebo|Placebo tablet once daily
62061151|NCT03833128|EXPERIMENTAL|Group 1 - Part A|REN001 Low Dose oral once daily x 12 weeks
62061152|NCT03833128|EXPERIMENTAL|Group 2 - Part A|REN001 High Dose oral once daily x 12 weeks
62061153|NCT03833128|EXPERIMENTAL|Group 3 - Part B|REN001 High Dose oral once daily x 12 weeks
62061154|NCT05076149|ACTIVE_COMPARATOR|ELX/TEZ/IVA|Following elexacftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) run-in period of 4 weeks, participants received ELX 200 milligram (mg) once daily (qd) /TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period for 52 weeks.
62061155|NCT05076149|EXPERIMENTAL|VX-121/TEZ/D-IVA|Following ELX/TEZ/IVA run-in period of 4 weeks, participants received VX-121 20 mg qd/TEZ 100 mg qd/D-IVA 250 mg qd in the treatment period for 52 weeks.
62061156|NCT04479033|NO_INTERVENTION|Control|Participants assigned to the control group had screened positive for cognitive impairment but refused the intervention. They were provided with a GP referral letter and information on helplines and caregiver support. Follow-up interviews were scheduled at week 24.
62448872|NCT00743197|ACTIVE_COMPARATOR|Medical Treatment Group|TREATMENT GROUP-therapy in this group will be conventional treatment for CAD but targeting endothelial function, which will include aspirin, ACE-inhibitor and statin therapy, and therapeutic lifestyle changes.
62848254|NCT02644616|ACTIVE_COMPARATOR|trial group(tolvaptan group)|trial group (tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv,n=20)
62848255|NCT02644616|PLACEBO_COMPARATOR|control group|control group(placebo 15mg/d po(10 days) +torasemide 20mg/d iv,n=20)
62848256|NCT05081297|EXPERIMENTAL|Qigong practitioner group|This arm is the experimental group where qigong intervention is going to be applied to practitioners with experience
62448873|NCT00160771||Joint Motion Analysis|Joint motion will be recorded for analysis.
62448874|NCT01400282|OTHER|Sequence 1|Conventional stimulation (2 weeks)- High frequeny stimulation (2 weeks)- Conventional stimulation (2 weeks)and sham stimulation (2 weeks)
62448875|NCT01400282|OTHER|Sequence 2|Conventional stimulation (2 weeks)- sham stimulation (2weeks) - Conventional stimulation (2 weeks) - high frequeny stimulation (2 weeks)
62448876|NCT04143113|NO_INTERVENTION|Usual Care (n=20)|Control: general information about stroke/Intracerebral Hemorrhage (ICH) from American Heart/Stroke Association
62448877|NCT04143113|EXPERIMENTAL|Decision Aid (n=20)|Paper Decision aid (share decision making tool) with worksheet for surrogates
62448878|NCT03462940|EXPERIMENTAL|TUDCA Group|All subjects will receive 500 mg/day in a one week run-in period and then 1750 mg/day in one week treatment period of of the nutritional supplement Tauroursodeoxycholic acid (TUDCA).
62848257|NCT05081297|NO_INTERVENTION|No practice|This group has no intervention and acts as control
62848258|NCT05081297|EXPERIMENTAL|Beginner Qigong practitioner group|This arm is the experimental group where qigong intervention is going to be applied to practitioners with no experience.
62848259|NCT01322282|EXPERIMENTAL|ODT with Water|Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken with 240 mL of water
62848260|NCT01322282|EXPERIMENTAL|ODT Without Water|Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken without 240 mL of water
62848261|NCT01322282|ACTIVE_COMPARATOR|FCT with Water|Marketed Cetirizine 10 mg Film-Coated Tablet (FCT) taken with 240 mL of water
62848262|NCT04381546|EXPERIMENTAL|FES in patients with hemiplegia|Patients will be equipped with 5 inertial measurement units. Two wireless bluetooth pressure insoles will be connected to the Raspberry. Electrical stimulation will be delivered via a wireless stimulator to the quadriceps and hamstrings via surface electrodes. Insoles will be used to online analyze Paretic Foot Support to discriminate between stance and swing phases. Stimulation will also be delivered just before initial contact at the end of swing phase. In stance phase, stimulation will be triggered either to quadriceps or hamstrings, depending on the paretic knee angle estimation relatively to the knee angle setpoint defined by the practitioner as the optimal flexion during stance phase (around 5°).
62848263|NCT02643134|OTHER|Group 1|Patients in Group 1 undergo extracorporeal shockwave lithotripsy(ESWL).
62848264|NCT02643134|OTHER|Group 2|Patients in Group 2 undergo external physical vibration lithecbole for the treatment after extracorporeal shockwave lithotripsy(ESWL).A multi-dimensional physical harmonic vibration inertial guidance technology
62848265|NCT04248283|EXPERIMENTAL|Adjustable Continence Therapy for Women|Implantation of the Adjustable Continence Therapy for the treatment of female SUI.
62848266|NCT03192371|EXPERIMENTAL|Zagreb 2-1-1 Group|4 doses of Rabipur vaccine, administered intramuscularly according to the Zagreb (2-1-1) regimen (i.e., 2 doses of vaccine administered on Day 1 and 1 dose of vaccine administered on Days 8 and 22).
62848267|NCT03192371|EXPERIMENTAL|Essen 1-1-1-1-1 Group|5 doses of Rabipur vaccine, administered intramuscularly according to the Essen (1-1-1-1-1) regimen (i.e., 1 dose of vaccine administered on Days 1, 4, 8, 15, and 29).
62061157|NCT04479033|EXPERIMENTAL|Intervention|Weekly meeting/communication sessions with members of intervention team for a total of 24 weeks.
62622179|NCT03973398|PLACEBO_COMPARATOR|Quadratus Lumborum Block posterior control (QLcp)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.9% normal saline.
62622180|NCT05999591||Intrauterine insemination|Patients undergoing intrauterine insemination
62848268|NCT03376295||Subjects diagnosed with COPD|Chronic obstructive pulmonary disease
62061158|NCT04795921||Patients with haemophilia|This investigation includes patients with haemophilia of all seventies (mild, moderate, severe), as well as female carriers and patients with Von-Willebrand-Disease (Typ III)
62061159|NCT04795921||Healthy controls|The control group consists of adult healthy female and male subjects.
62061160|NCT05466539|EXPERIMENTAL|Treatment Group|AbobotulinumtoxinA
62848269|NCT03470064||RV Dysfunction|All pediatric patients who present to pediatric cardiothoracic unit, Assiut University Hospital and who meet the listed inclusion and exclusion criteria will be eligible for the study. Patients' charts will be retrieved based on their surgical procedures. The charts will be reviewed and eligible patients will be filtered. The needed variables will be entered into our data base for later data analysis
62622181|NCT00662311|EXPERIMENTAL|Treatment (vorinostat with paclitaxel and radiotherapy)|Patients receive vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.
62848270|NCT03835949|EXPERIMENTAL|TJ004309 plus Atezolizumab|TJ004309 will be dose escalated in a 3+3 design in combination with atezolizumab.
62265201|NCT05843734|EXPERIMENTAL|Equia forte HT (glass-hybrid) group|This study planned to investigate the clinical performance of Equia Forte HT (permanent glass hybrid restorative) in the treatment of anterior class III restorations. This arm of the study is the group whose effectiveness was investigated. The results will be evaluated by comparing with a traditional anterior resin composite in terms of functional, biological and aesthetic properties.
62265202|NCT05843734|ACTIVE_COMPARATOR|"G-Aenial anterior"|"This group will serve as a control. Equia forte HT (glass-hybrid) restorations will compare with the G-Aenial anterior anterior resin composite restorations."
62848271|NCT05962567|NO_INTERVENTION|Healthy individuals|No intervention
62848272|NCT05962567|ACTIVE_COMPARATOR|Stage II periodontitis patients|Non-surgical periodontal therapy by ultrasonic and universal curettes
62265203|NCT00573573|OTHER|1|
62265204|NCT03600779|EXPERIMENTAL|experimental group 1.5T|Population of patients with myelin syndrome (MS) at the the disease onset with active lesions inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed.
62265205|NCT03600779|ACTIVE_COMPARATOR|control group 1.5 T|healthy volunteers matched in sex and age inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed.
62848273|NCT05854498|EXPERIMENTAL|Participants with Metastatic or Unresectable Colorectal Cancer|Male and females aged 18 years and older with histologically confirmed metastatic or unresectable (not amenable to curative therapy) colorectal cancer.
62848274|NCT06116513||Patients with old troublesome radical cavities|These patients would have old Canal Wall Down cavities that were troublesome
62848275|NCT03620864|ACTIVE_COMPARATOR|Motor control exercise|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling.
62848276|NCT03620864|EXPERIMENTAL|Motor control exercise plus neurodynamic intervention|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling. In addition, participants allocated to the neurodynamic group will also receive a nerve neurodynamic slider intervention targeting the main trunk of the sciatic nerve of the affected side during al treatment sessions (n=8).
62061161|NCT05466539|PLACEBO_COMPARATOR|Control Group|Normal Saline
62061162|NCT06139068|EXPERIMENTAL|intervention|Narrative group counseling consists of 8 sessions and will be applied to the intervention group by the researcher.
62061163|NCT06139068|ACTIVE_COMPARATOR|Control|For the control group, 4 sessions stress coping interviews will be held after the information meeting, apart from the students' routine practices.
62061164|NCT01971294||Systemic sclerosis|Adult suffering from systemic sclerosis included in the EUSTAR network of Brescia (I), Geneva (CH), Padova (I) and Paris (F).
62061165|NCT06134921|EXPERIMENTAL|Active tDCS and conventional physical therapy program|Participants will receive Active tDCS for 30 minutes prior conventional physical therapy program. They will be asked to perform this combination therapy for 15 sessions, occurring three times a week for five weeks.
62622182|NCT02044653|EXPERIMENTAL|Group A (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 3ug/kg
62622183|NCT02044653|EXPERIMENTAL|Group B (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg
62622184|NCT02044653|EXPERIMENTAL|Group C (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg
62622185|NCT02044653|EXPERIMENTAL|Group D (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 3ug/kg
62622186|NCT02044653|EXPERIMENTAL|Group E (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 5ug/kg
62622187|NCT02044653|EXPERIMENTAL|Group F (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 8ug/kg
62622188|NCT02044653|EXPERIMENTAL|Group G (Part B)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg
62061166|NCT06134921|EXPERIMENTAL|Active tACS and conventional physical therapy program|Participants will receive Active tACS for 30 minutes prior conventional physical therapy program. They will be asked to perform this combination therapy for 15 sessions, occurring three times a week for five weeks.
62622189|NCT02044653|EXPERIMENTAL|Group H (Part B)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg
62622190|NCT02044653|ACTIVE_COMPARATOR|Group I (Part B)|MIRCERA : Subcutaneously injection every 2 weeks (Q2W) at dose 0.6ug/kg
62848277|NCT03163017|EXPERIMENTAL|2D Fluoroscopy then 3D Fluoroscopy|"Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al (2D Fluoroscopy). After the attending surgeon is satisfied with the reduction quality, 3D fluoroscopy will be used to generate additional images to assess syndesmotic and fibular reductions. Both 2D and 3D Fluoroscopy will be performed using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system."
62622191|NCT02044653|EXPERIMENTAL|Group J (Part B)|GX-E2 : Intravenously injection every week (Q1W) at dose 5ug/kg
62622192|NCT02044653|EXPERIMENTAL|Group K (Part B)|GX-E2 : Intravenously injection every week (Q1W) at dose 8ug/kg
62622193|NCT02044653|EXPERIMENTAL|Group L (Part B)|GX-E2 : Intravenously injection every 2 weeks (Q2W) at dose 8ug/kg
62622194|NCT02044653|ACTIVE_COMPARATOR|Group M (Part B)|NESP : Intravenously injection every week (Q1W) at dose 30ug
62622195|NCT00311922|ACTIVE_COMPARATOR|Control|Active Control Arm receives Comprehensive Diabetes Education
62848278|NCT02270372|EXPERIMENTAL|Drug Combination|The drug combination of ONT-10 and varilumab
62848279|NCT03427580|EXPERIMENTAL|treatment group|
62061167|NCT06134921|SHAM_COMPARATOR|Sham stimulation and conventional physical therapy program|Participants will receive sham stimulation for 30 minutes prior conventional physical therapy program. They will be asked to perform this combination therapy for 15 sessions, occurring three times a week for five weeks.
62061168|NCT02202434|EXPERIMENTAL|Lotus Valve System - Randomized|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
62622196|NCT00311922|EXPERIMENTAL|Intervention Arm|Receives comprehensive education that is literacy/numeracy sensitive
62622197|NCT01956760|EXPERIMENTAL|Acupuncture|Acupuncture and intradermal acupuncture The acupuncture was applied at 5 acupoints(HT7 Shenmen, PC6 Neiguan, SP6 Sanyinjiao, KI6 Zhaohai, BL62 Shenmai) 3 times in a week. It was performed by a certified practitioner with sterile needles (0.25\*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same acupoints, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20\*8.0mm).attached to skin tape (10.0\*10.0mm). The needles were inserted 3.0\~5.0mm deep and maintained for 48\~72 hours
62622198|NCT01956760|PLACEBO_COMPARATOR|Placebo Acupuncture|Placebo acupuncture and placebo intradermal acupuncture The acupuncture was applied 3 times in a week at 2 sham points on the wrist and 3 sham points on the ankle, approximately 1cm lateral to the acupoints. It was performed by a certified practitioner with sterile needles (0.25\*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same sham points, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20\*8.0mm).attached to skin tape (10.0\*10.0mm). The needles were inserted 3.0\~5.0mm deep and maintained for 48\~72 hours
62848280|NCT03427580|EXPERIMENTAL|delayed treatment control group|
62061169|NCT02202434|ACTIVE_COMPARATOR|CoreValve TAVR System - Randomized|Transcatheter aortic valve replacement (TAVR) with CoreValve/Evolut R Transcatheter Aortic Valve Replacement System
62265206|NCT03600779|EXPERIMENTAL|experimental group 3T|Population of patients with myelin syndrome (MS) at the the disease onset with active lesions inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T will be performed.
62265207|NCT03600779|ACTIVE_COMPARATOR|control group 3T|inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed. inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T will be performed.
62265208|NCT03290235|EXPERIMENTAL|PEG-somatropin-1|Dosage 0.2mg/kg/w
62848281|NCT05227040|EXPERIMENTAL|Nintendo Ring Fit Adventure Exergame Group|Participants in the RFA group were required to exercise for 30 minutes three times per week (in adventure mode) for 4 weeks. The initial exercise intensity was set according to the instructions given by the virtual coach during the first game and was gradually adjusted according to the game instructions. The research continued to track the RFA group subjects and continued to encourage the completion of 4 weeks of physical activity training.
62848282|NCT05227040|NO_INTERVENTION|Control group|
62848283|NCT04995458|EXPERIMENTAL|Composite-ceramic|To assess the clinical performance and survival of posterior composite-ceramic implant-supported crowns
62265209|NCT03290235|EXPERIMENTAL|PEG-somatropin-2|Dosage 0.1-0.2mg/kg/w
62622199|NCT04302207|EXPERIMENTAL|High use hospitals|patients 1-23 months with Bronchiolitis seen in emergency department, urgent care or admitted patients will be included; provider surveys measuring the acceptability, appropriateness, feasibility, and perceived burden of piloted strategies; review of patient data extracted from electronic health record to include baseline, intervention and post-intervention data
62848284|NCT04995458|ACTIVE_COMPARATOR|Monolithic zirconia|To assess the clinical performance and survival of posterior monolitihic zirconia implant-supported crowns
62061170|NCT02202434|EXPERIMENTAL|Lotus Valve Sytem - Single-arm 21mm Cohort|Transcatheter aortic valve replacement (TAVR) with 21mm Lotus Valve System
62265210|NCT02223260|EXPERIMENTAL|dabigatran|open label arm with dabigatran oral liquid formulation as single dose
62848285|NCT04948983|ACTIVE_COMPARATOR|Intervention group|"The intervention group will access a web page, answer a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The intervention group will complete the same questionnaires two weeks later. Six months later we will confirm if the screening was undertaken by checking medical records.~The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?"
62061171|NCT02202434|EXPERIMENTAL|Lotus Valve System - Single-arm Continued Access Cohort|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
62061172|NCT02202434|EXPERIMENTAL|Lotus Valve System - Single-arm Roll-in Cohort|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
62848286|NCT04948983|PLACEBO_COMPARATOR|Control group|"The Control group will access a webpage, answer a set of questionnaires at baseline, and then receive standardised information given by the healthcare system.~The control group will complete the same questionnaires two weeks later, afterwards they will access the DA. Six months later we will confirm if the screening was undertaken by checking medical records."
62848287|NCT03801057|ACTIVE_COMPARATOR|MPH_active|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.
62448879|NCT00860028|EXPERIMENTAL|Extended Varenicline Pretreatment|Arm 1 (Experimental) = 4 weeks varenicline (Chantix) titrated to 1 mg oral tablet twice per day before the smoking quit date followed by 4 weeks varenicline (Chantix) 1 mg oral tablet twice per day treatment.
62061173|NCT02202434|EXPERIMENTAL|LOTUS Edge Valve System - Single-arm Edge Nested Registry|Transcatheter aortic valve replacement (TAVR) with 23mm, 25mm and 27mm LOTUS Edge Valve System.
62848288|NCT03801057|PLACEBO_COMPARATOR|MPH_placebo|Daily intake at breakfast of supplementary placebo. Random sequence of arms.
62848289|NCT01982188||Single incision sling|
62061174|NCT00525135|OTHER|1|If a patient exhibits increased radioiodine uptake on the Thyrogen scan post valproic acid therapy, patients will then prepare for ablative treatment and will remain on valproic acid for a total of 16 weeks, until receiving RAI ablation.
62061175|NCT00525135|OTHER|2|If no increased uptake is seen, patients will continue on valproic acid for 6 additional weeks at an increased dosage, totaling an overall treatment time of 16 weeks as well.
62265211|NCT05939310|EXPERIMENTAL|Fluorescence guided surgery|10 mg bevacizumab-IRDye800CW, to intraoperatively assess possible tumour-positive margins.
62265212|NCT04438473|EXPERIMENTAL|Pectin|sequential supplementation with combination of 90ml pectin and 500ml enteral nutrition formula for 7 days
62848290|NCT03733886|ACTIVE_COMPARATOR|Burst SCS|"In the active comparator the burst SCS system will be turned on according to randomisation.~A treatment period is a 2-week period where the patient receives either active treatment or sham. Each patient will go through 6 treatment periods (in total 12 weeks). A treatment cycle is a 4-week period with two treatment periods, one of active treatment and one of sham. Each patient will go through three treatment cycles."
62848291|NCT03733886|SHAM_COMPARATOR|Sham|In the sham comparator the burst SCS system will be turned off according to randomisation.
62848292|NCT04247867|EXPERIMENTAL|Interventional arm - MCO dialysis membrane|4 weeks of dialysis with MCO (Theranova) membrane then dialysis for 4 weeks with MCO membrane and increased fiber intake
62848293|NCT04247867|ACTIVE_COMPARATOR|Control arm - high-flux membrane haemodiafiltration|4 weeks of high-flux membrane haemodiafiltration and 4 weeks of high-flux membrane haemodiafiltration and increased fiber intake
62848294|NCT03500562||HCV participant population in China|
62848295|NCT05902052|EXPERIMENTAL|Open Heart Surgery Patient Care Protocol|"Specific Practices for Pain in the Protocol~* Evaluation of patients' pain in the extubated period with the Visual Anolog Scale~* Active participation of the patient in pain reporting~* Regular questioning of the patient's pain~* Questioning pain at rest and movement~* Implementing nursing interventions in painful condition (VAS≤ 4)"
62848296|NCT05902052|NO_INTERVENTION|Standart Care Protocol|Standard care of intensive care will be given.
62848297|NCT05048524|EXPERIMENTAL|SLOG|
62848298|NCT06342778|EXPERIMENTAL|RT-sequence|Group 1 (14 volunteers, RT sequence) will take 2 tablets of Diclectin in Period 1 and 2 tablets of Doxylamine + Pyridoxine in Period 2
62848299|NCT06342778|ACTIVE_COMPARATOR|TR-sequence|Group 2 (14 volunteers, TR sequence) will take 2 tablets of Doxylamine + Pyridoxine in Period 1 and 2 tablets of Diclectin in Period 2
62265213|NCT04438473|PLACEBO_COMPARATOR|Control|standard formula enteral nutrition feeding without pectin for 7 days
62265214|NCT04543643|EXPERIMENTAL|Carvedilol+ berberine|Carvedilol is started at a dose of 6.25 mg once per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day if systolic blood pressure does not fall below 85mm Hg and HR 55/min. Berberine is started at a dose of 0.3g twice per day.
62265215|NCT04543643|ACTIVE_COMPARATOR|Carvedilol|Carvedilol is started at a dose of 6.25 mg once per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day if systolic blood pressure does not fall below 85 mm Hg and HR 55/min.
62265216|NCT06220331||Elder patients diagnosed with cataract|Patients that diagnosed with cataract and had implantation with Hanita Intensity IOL or Intensity Toric Lenses in the clinic participating in the study.
62265217|NCT02891655||surgery for keratoconus|
62265218|NCT02891655||refractive surgery (control patients)|
62265219|NCT06254729||training group|The training group is used to train the model.
62265220|NCT06254729||validation group|The validation group is used to evaluate model performance.
62265221|NCT04423809||caregivers of adult patients hospitalized in psychiatry|a face-to-face interview with a nurse and self-assessment scales.
62265222|NCT05697601||Suspect of Ovarian Cancer|The participant with high suspicion of ovarian cancer and undergo gynaecology and pathology assessment
62848300|NCT03844204|EXPERIMENTAL|Servo-controlled system|The temperature probe of the servo-controlled system will be positioned on the patient's abdomen with an adhesive tape. The body temperature will be set at 37°C.
62848301|NCT03844204|ACTIVE_COMPARATOR|No servo-controlled system|The temperature of the infant warmer will be manually set at maximum of power output.
62848302|NCT03445949|OTHER|30 days DAPT and long-term treatment with a single antiplatelet agent|short postimplantation dual antiplatelet therapy and long-term treatment with a single antiplatelet agent
62848303|NCT03445949|OTHER|6 months DAPT and long-term treatment with a single antiplatelet agent|extended postimplantation dual antiplatelet therapy and long-term treatment with a single antiplatelet agent
62848304|NCT03445949|OTHER|30 days DAPT and 6 months treatment with a single antiplatelet agent|short postimplantation dual antiplatelet therapy and 6 months treatment with a single antiplatelet agent
62848305|NCT03445949|OTHER|6 months DAPT and 6 months treatment with a single antiplatelet agent|extended postimplantation dual antiplatelet therapy and 6 months treatment with a single antiplatelet agent
62848306|NCT04387240|EXPERIMENTAL|intervention group|this group will receive the Artemisinin / Artesunate 100mg once daily for 5 days
62848307|NCT04387240|PLACEBO_COMPARATOR|placibo|this group will receive a placebo of the same shape and picture of the study drug
62848308|NCT03945552|NO_INTERVENTION|Control|Care as usual
62848309|NCT03945552|EXPERIMENTAL|Video Interaction Project|VIP is a strengths-based, family-centered intervention that uses pediatric well-child visits to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines.
62848310|NCT02555904||Heart failure syndrome & pulmonary congestion|Patients who are admitted for inpatient management with acute heart failure syndrome with pulmonary congestion who require intravenous diuretics are potential candidates for the study and shall be screened for suitability based on the inclusion and exclusion criteria.
62848311|NCT04599764|ACTIVE_COMPARATOR|Cognitive training|Participants will receive Cognitive training daily for two weeks
62848312|NCT04599764|ACTIVE_COMPARATOR|Anodal tDCS with Cognitive training|Participants will receive anoale tDCS daily and cognitive training for two weeks
62848313|NCT06034639||Group 1|No Intervention
62448880|NCT00860028|EXPERIMENTAL|Short-term Varenicline Pretreatment|Arm 2 (Experimental) = 3 weeks placebo + 1 week varenicline (Chantix)pretreatment + 4 weeks varenicline 1 mg oral tablet twice per day treatment following the smoking quit date.
62448881|NCT00185419|ACTIVE_COMPARATOR|Arm 1|
62448882|NCT00185419|ACTIVE_COMPARATOR|Arm 2|
62848314|NCT05799248|EXPERIMENTAL|rhPSMA-7.3|Role of rhPSMA-7.3 PET/CT imaging in men with High-Risk prostate cancer following conventional imaging and associated changes in medical management
62848315|NCT04796090||Adolescents with genital warts (Study Group)|The Study group included adolescents who was diagnosed as positive for genital warts during the examination.
62448883|NCT05408286||inclusion criteria|All patients aged ≥18 years admitted for COVID-19 pneumonia treated with NIV/CPAP, discharged to their home with a negative molecular swab and signed informed consent were included in the study.
62848316|NCT04796090||Healthy adolescents (Control Group)|The Control group was composed of healthy adolescents who admitted for only contraceptive counselling.
62848317|NCT02120183|EXPERIMENTAL|Psycho-educational support group therapy|4 week psycho-educational support group focusing on topics specific to psychosocial and emotional aspects of the cancer caregiving role
62848318|NCT04662515||DOAC|Information about which type of DOAC and the dose that is prescribed to the patient will be collected.
62848319|NCT04662515||Warfarin|A PK-INR ≤3.0 retained whitin the last 24 hours have to be present for inclusion.
62848320|NCT03985969|EXPERIMENTAL|DDI|Period 1: study of elafibranor's pharmacokinetics Period 2: study of elafibranor's pharmacokinetics under CHRONO-INDOCID® (indomethacin) at steady state
62622200|NCT04302207|NO_INTERVENTION|Low use hospital (Children's Hospital Colorado)|patients 1-23 months with Bronchiolitis seen in emergency department, urgent care or admitted patients will be included; review of patient data extracted from electronic health record to include data over the same time periods as the experimental groups' baseline, intervention, and post-intervention data
62622201|NCT02861430||Patients|
62622202|NCT00003896|EXPERIMENTAL|Paclitaxel/cisplatin/Liposomal Doxorubicin|paclitaxel, cisplatin and liposomal doxorubicin
62622203|NCT05527795||Non-mutated|Non mutated (BRAF or NRAS) stage II, III or IV (resected) melanoma patients treated with first line adjuvant immunotherapy (anti-PD-1 with either pembrolizumab or nivolumab)
62622204|NCT05527795||BRAF-mutated|BRAF-mutated stage II, III or IV (resected) melanoma patients treated with first line adjuvant immunotherapy (anti-PD-1 with either pembrolizumab or nivolumab)
62622205|NCT05527795||NRAS-mutated|NRAS-mutated (BRAF or NRAS) stage II, III or IV (resected) melanoma patients treated with first line adjuvant immunotherapy (anti-PD-1 with either pembrolizumab or nivolumab)
62622206|NCT00287729|ACTIVE_COMPARATOR|2403 mg/day pirfenidone|2403 mg/day pirfenidone dose group.
62622207|NCT00287729|PLACEBO_COMPARATOR|placebo|Placebo equivalent.
62622208|NCT04690335|EXPERIMENTAL|MV-012-968|Dose: 1 x10\^6 Plaque Forming Unit (PFU), given intranasally, followed approximately 28 days later by inoculation with RSV-A (Memphis 37b).
62622209|NCT04690335|PLACEBO_COMPARATOR|Placebo|Sodium Chloride 0.9% w/v intravenous infusion B.P (Normal Saline) matched to reference article product, given intranasally.
62622210|NCT02417558|EXPERIMENTAL|Alterniity Augmented Reality (AAR)|AAR training Participants use the patent pending AAR exercise and gaming (exergaming) platform that combines a physical training component (PTC) and a cognitive training component (CTC) in closed-feedback loop with Personalized Brain Network Activity (PBNA) test from a portable EEG.
62622211|NCT02417558|NO_INTERVENTION|Passive Control Participants|Passive Control Participants do not receive an intervention serving as passive controls
62622212|NCT02417558|ACTIVE_COMPARATOR|Active|Active Control Participants receive an alternative cognitive training scheme; software was built on purpose by the Aristotle University of Thessaloniki. The software is called VideoGrade and uses videos from Youtube (YouTube) documentaries (VideoGrade).
62622213|NCT01994707|ACTIVE_COMPARATOR|Remote ischemic preconditioning|Left arm blood pressure cuff inflation for 5 min then deflation of cuff for 5 min- cycle repeated 3 times before coronary artery bypass grafting.
62622214|NCT01994707|PLACEBO_COMPARATOR|Placebo|Deflated cuff on arm for 30 minutes.
62622215|NCT03848897|EXPERIMENTAL|Non falling elderly|
62622216|NCT03848897|EXPERIMENTAL|Falling elderly|
62622217|NCT03848897|EXPERIMENTAL|Non falling patients with Parkinson's disease|
62622218|NCT03418597|EXPERIMENTAL|Deep local anesthesia + Virtual reality|Pre-medication procedures and lidocaïne injection are the same as in the current practice. During the intervention delay, the patient will also experience hypnosis through a virtual reality procedure .
62622219|NCT03418597|ACTIVE_COMPARATOR|Deep local anesthesia alone|The musculoskeletal biopsy is performed according to the standard practice using a deep local anesthesia with premedication and lidocaïne.
62622220|NCT01396551|EXPERIMENTAL|Transponder implantation|Implantation of anchored Beacon transponder in the lung
62622221|NCT05009134||Control|18-55 years, healthy
62622222|NCT05009134||Allergic rhinitis|patients with AR without AIT
62622223|NCT05009134||Allergen immunotherapy|patients with AR with AIT for more than 1 year
62622224|NCT05447026|ACTIVE_COMPARATOR|Control group|Regenerative surgical treatment of periodontal infrabony defects without any adjunctive therapies.
62622225|NCT05447026|ACTIVE_COMPARATOR|antimicrobial photodynamic therapy (aPDT) group|Regenerative surgical treatment of periodontal infrabony defects in conjunction with irradiation by a diode laser and a photosensitizer
62622226|NCT05447026|ACTIVE_COMPARATOR|LED photobiomodulation group|Regenerative surgical treatment of periodontal infrabony defects in conjunction with irradiation by a LED device
62622227|NCT05447026|ACTIVE_COMPARATOR|Topical ozone group|Regenerative surgical treatment of periodontal infrabony defects in conjunction with topical ozone application
62622228|NCT05509998|ACTIVE_COMPARATOR|Screening Method (SM)|In the SM condition all consecutive incoming patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Evaluating clinicians will meet with patients to discuss findings and make referrals to specialty care as appropriate. The evaluating clinician will follow-up with patients referred to CSC and CHR programs to determine date of initial engagement. This information will be corroborated with records from CHR and FEP programs.
62622229|NCT05509998|EXPERIMENTAL|Screening and Communication Method (SCM)|In the SCM condition, the same screening and evaluation procedures described above will continue, but clinicians conducting evaluations and making referrals will be trained to discuss findings and provide referrals using the ComPsych model. Following the evaluation, the clinician who conducted the evaluation will schedule a session with the patient, their family, and their treatment team (as applicable) and use the ComPsych model to discuss the findings of the evaluation, provide psychoeducation, and make referrals to specialty FEP or CHR services, as appropriate. The evaluating clinician will follow-up with patients referred to CSC and CHR programs to determine date of initial engagement. This information will be corroborated with records from CHR and FEP programs.
62622230|NCT04404348|EXPERIMENTAL|Intervention|Three times per week for four weeks, participants will complete a computerized cognitive training session (approximately 30 minutes long).
62622231|NCT04404348|PLACEBO_COMPARATOR|Control|Three times per week for four weeks, participants will complete a computerized session (approximately 30 minutes long) that consists of inert computer games.
62623786|NCT01817166|PLACEBO_COMPARATOR|Placebo|"Patients in this arm will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.~Intervention: Placebo Intervention: Imaging Intervention: Lumbar puncture Intervention: Blood sampling Intervention: Urine samples"
62622232|NCT05325372|EXPERIMENTAL|Ultrasound guided axillary block|the Ultrasound probe with a linear high frequency (8-14 MHZ) transducer will be placed parallel to the anterior axillary fold at the axilla to identify the axillary artery and to identify the hyperechoic median, ulnar, and radial nerves in relation to the axillary artery. The musculocutaneous nerve which supplies the skin of the lateral side of the forearm had to be blocked also. It is found between the biceps brachii and coracobrachialis muscles. Lidocaine 1% was infiltrated subcutaneously 1 cm lateral to the probe. The needle is inserted in-plane from the anterior aspect and directed toward the posterior aspect of the axillary artery. All four nerves in the axillary region will be blocked. A local anesthetic will be administered adjacent to each of the four nerves (at least 5 ml for each).
62622233|NCT05325372|EXPERIMENTAL|Ultrasound guided infraclavicular block block|The transducer is positioned in the parasagittal plane to identify the axillary artery. Surrounding the artery are the three cords of the brachial plexus: the lateral, posterior, and medial cords. The needle is inserted in-plane short-axis technique from the cephalad end of the probe, with the insertion point just inferior to the clavicle. A local anesthetic will be injected posterior to the axillary artery to achieve a U-shaped distribution around the artery (cephalad, caudad, and posterior).
62622234|NCT05028205|EXPERIMENTAL|Prevention Plus|Child's energy balance behavioral goals will be to consume \< 3 sugar-sweetened beverages (e.g., regular carbonated soft drinks, sports drinks, lemonades, ice teas, flavored milk, juice drinks \< 100% juice, and punches) servings /wk, ≥1 1/2 cups/day of whole vegetables and ≥ 1 cup/day of whole fruit, engage in ≥ 60 minutes/day of moderate- to vigorous-intensity physical activity, and reduce TV viewing to \< 2 hours/day. The caregiver's energy balance behavioral goals will be to consume \< 3 sugar-sweetened beverage servings/wk, ≥ 2 1/2 cups/day of whole vegetables and ≥ 1 1/2 cups/day of whole fruit, engage in ≥ 150 minutes of moderate- to vigorous-intensity physical activity per week and reduce TV viewing to \< 10 hours/wk.
62622235|NCT06239545|EXPERIMENTAL|Usual Practice + JoyPop|Participants will be monitored through the existing wait-list practices, and will receive access to the JoyPop app for 4 weeks.
62622236|NCT06239545|NO_INTERVENTION|Usual Practice|Participants will be monitored through existing wait-list practices. After 4 weeks in the Usual Practice condition, participants will be offered access to the JoyPop app.
62622237|NCT02905357||MINOCA|OCT and CMR imaging
62622238|NCT02905357||MI-CAD|Screen failures with MI found to have obstructive CAD. Limited data collection for comparison to MINOCA cohort.
62622239|NCT05251636|EXPERIMENTAL|ESB adjunct to IAI|Single ESB treatment adjunct to intravitreal aflibercept injections (IAI)
62622240|NCT05251636|ACTIVE_COMPARATOR|IAI monotherapy|Intravitreal aflibercept injections (IAI)
62622241|NCT01183507|ACTIVE_COMPARATOR|NIA intervention|
62622242|NCT01183507|EXPERIMENTAL|TSE intervention|
62622243|NCT03376113|EXPERIMENTAL|VHS group|Patients will be asked to make links between critical situations and appropriate solutions in the volitional help sheet (VHS).
62622244|NCT03376113|NO_INTERVENTION|Control group|Patients will be asked to read the VHS. This is an active control group. That means all patients in this study will be exposed to situations and solutions in the VHS.
62622245|NCT05767164|NO_INTERVENTION|Preoperative|
62622246|NCT05767164|EXPERIMENTAL|postoperative (3 months)|
62622247|NCT05767164|EXPERIMENTAL|postoperative (6 months)|
62622248|NCT05767164|EXPERIMENTAL|postoperative (1 year)|
62061176|NCT04092179|EXPERIMENTAL|Venetoclax and Enadisenib|"Enasidenib and venetoclax will be taken by mouth (orally), once a day, every day, continuously.~Every 28-day period will be called a cycle. Participants will start venetoclax alone on Cycle 1 Day 1 and continue the study drug alone until Day 15. On Day 15, participants will take enasidenib and venetoclax together and will continue to take the combination of study drugs until intolerable side effects or disease worsening."
62061177|NCT01953003|EXPERIMENTAL|Arm A : iv vinflunine plus Capecitabine|Vinflunine dose 280 mg/m² on day 1 of each cycle every 3 weeks, Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest.
62061178|NCT01953003|ACTIVE_COMPARATOR|capecitabineArm B : capecitabine|1250 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest
62061179|NCT06625814|EXPERIMENTAL|Levothyroxine|Participants will receive a single oral dose of levothyroxine.
62061180|NCT06625814|EXPERIMENTAL|Levothyroxine Plus Enlicitide Decanoate|Participants will receive a single oral dose of levothyroxine and a single oral dose of enlicitide decanoate at the same time.
62622249|NCT05316571|ACTIVE_COMPARATOR|One 5-Minute Walking Bout Each Hour|"A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.~The interruption strategy includes breaking up the 4-hour sitting bout with one 5-minute light intensity walking bout each hour. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed."
62622250|NCT05316571|ACTIVE_COMPARATOR|One 15-Minute Standing Bout Each Hour|"A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.~The interruption strategy includes breaking up the 4-hour sitting bout with one 15-minute standing bout each hour. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed."
62623787|NCT01817166|EXPERIMENTAL|Vit D|"Patients in this arm will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.~Intervention: Vitamin D Intervention: Imaging Intervention: Lumbar puncture Intervention: Blood sampling Intervention: Urine samples"
62061181|NCT00992537|EXPERIMENTAL|IDeg|
62061182|NCT00992537|EXPERIMENTAL|IDegAsp|
62061183|NCT00992537|ACTIVE_COMPARATOR|IAsp|
62061184|NCT00297193|EXPERIMENTAL|Transplant Arm|Hematopoietic stem cell mobilisation followed, within 4 weeks, by high dose immunoablation and autologous stem cell transplantation
62622251|NCT05316571|ACTIVE_COMPARATOR|One 5-Minute Walking Bout and One 15-Minute Standing Bout Each Hour|"A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.~The interruption strategy includes breaking up the 4-hour sitting bout with one 5-minute light intensity walking bout and one 15-minute standing bout each hour. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed."
62061185|NCT00297193|EXPERIMENTAL|Delayed Transplant|Hematopoietic stem cell mobilisation followed, after 59 weeks, by high dose immunoablation and autologous hematopoietic stem cell transplantation
62061186|NCT01516775|EXPERIMENTAL|1 hour fluid fasting|allowed to drink until 1 hour before scheduled anaesthesia induction
62061187|NCT01516775|ACTIVE_COMPARATOR|2 hours fluid fasting|allowed to drink until 2 hour before scheduled anaesthesia induction
62061188|NCT01798524||Kidney allograft recipients|
62061189|NCT01737684|EXPERIMENTAL|Participants With Moderate Hepatic Insufficiency|Participants with moderate hepatic insufficiency will receive a single oral dose of vibegron 100 mg.
62061190|NCT01737684|EXPERIMENTAL|Healthy Matched Control Participants|Participants who are healthy will receive a single oral dose of vibegron 100 mg.
62061191|NCT01737684|EXPERIMENTAL|Participants With Mild Hepatic Insufficiency|Participants with mild hepatic insufficiency will receive a single oral dose of vibegron 100 mg.
62448884|NCT02294071|EXPERIMENTAL|acetaminophen|acetaminophen 15mg/kg (max 975mg)
62622252|NCT05316571|ACTIVE_COMPARATOR|Uninterrupted Sitting|"A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.~This uninterrupted sedentary bout will serve as a control. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed."
62622253|NCT04647513|EXPERIMENTAL|Art Filler Fine Lines (forehead)|Injection of Art Filler Fine Lines in Forehead wrinkles
62622254|NCT04647513|EXPERIMENTAL|Art Filler Fine Lines (upper lip)|Injection of Art Filler Fine Lines in upper lip wrinkles
62622255|NCT04647513|EXPERIMENTAL|Art Filler Fine Lines (cheek folds)|Injection of Art Filler Fine Lines in cheek folds
62622256|NCT04647513|EXPERIMENTAL|Art Filler Fine Lines (crow's feet)|Injection of Art Filler Fine Lines in crow's feet
62622257|NCT04647513|EXPERIMENTAL|Art Filler Universal (lips volume)|Injection of Art Filler Universal in lips
62448885|NCT02294071|EXPERIMENTAL|ibuprofen|ibuprofen 10mg/kg (max 600mg)
62622258|NCT04647513|EXPERIMENTAL|Art Filler Universal (nasolabial folds)|Injection of Art Filler Universal in nasolabial folds
62622259|NCT04647513|EXPERIMENTAL|Art Filler Lips (lips volume)|Injection of Art Filler Lips in lips
62622260|NCT04647513|EXPERIMENTAL|Art Filler Lips (very deep nasolabial folds)|Injection of Art Filler Lips in very deep nasolabial folds
62622261|NCT01761929|EXPERIMENTAL|Stereotactic Body Radiation Therapy|All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
62622262|NCT05168618|EXPERIMENTAL|Treatment (cabozantinib, atezolizumab)|Patients receive cabozantinib PO QD on days 1-21 and atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62061192|NCT01282801|EXPERIMENTAL|Investigational Test Product|Venlafaxine Hydrochloride 150 mg Extended-Release Capsules
62061193|NCT01282801|ACTIVE_COMPARATOR|Reference Listed Drug|Effexor® XR 150 mg Extended-Release Capsules
62061194|NCT01920048|EXPERIMENTAL|Percutaneous Coronary Intervention and Optimal Medical Therapy|
62061195|NCT01920048|ACTIVE_COMPARATOR|Optimal Medical Therapy alone|
62061196|NCT03468933|ACTIVE_COMPARATOR|Fibrinolytic therapy group|Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.
62061197|NCT03468933|ACTIVE_COMPARATOR|Medical Thoracoscopy group|Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.
62061198|NCT01755624|EXPERIMENTAL|NovoTTF-100A device|Patients will be treated continuously with the NovoTTF-100A device. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
62061199|NCT01755624|ACTIVE_COMPARATOR|Best Standard of Care|Patients will be treated as the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain.
62061200|NCT02070705|EXPERIMENTAL|Arm I (High-risk for familial/hereditary pancreatic cancer)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) yearly for a minimum of 3 scans.
62061201|NCT02070705|EXPERIMENTAL|Arm II (IPMN)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) prior to surgery for resection of IPMN.
62265223|NCT05697601||Suspect of Endometrial Cancer|The participant with high suspicion of Endometrial cancer (and or endometrial hyperplasia) and undergo gynaecology and pathology assessment
62448886|NCT02294071|EXPERIMENTAL|combination|acetaminophen 15mg/kg (max 975mg) and ibuprofen 10mg/kg (max 600mg)
62448887|NCT00494104|ACTIVE_COMPARATOR|200 IU/day Vitamin D|200 IU/day Vitamin D
62448888|NCT00494104|EXPERIMENTAL|400 IU/day Vitamin D|400 IU/day Vitamin D
62448889|NCT00494104|EXPERIMENTAL|600 IU/day Vitamin D|600 IU/day Vitamin D
62448890|NCT00494104|EXPERIMENTAL|800 IU/day Vitamin D|800 IU/day Vitamin D
62623788|NCT02781818|EXPERIMENTAL|Triamcinolone Acetonide 10mg/mL|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of triamcinolone 10mg/mL solution.
62623789|NCT02781818|EXPERIMENTAL|Triamcinolone Acetonide 40mg/mL|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of triamcinolone 40mg/mL solution.
62265224|NCT05697601||Normal Cohort|The participant with lower suspicion of both types of cancer and undergo gynaecology and pathology assessment
62265225|NCT04546477|OTHER|Single Arm|"135 patients stratified into 2 groups:~* FEM-POP patients: SFA-P1~* Isolated POP Patients: P1, P2, P3 only~It is expected the majority of enrolled patients to be FEM-POP category. In case sufficient Isolated POP patients are enrolled, a sub-analysis will be performed on this group of patients."
62848321|NCT03564704|EXPERIMENTAL|PDT-ALL-LBL|The intervention of PDT-ALL-LBL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy (methotrexate, cytarabine, dexamethasone), radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
62061202|NCT02070705|EXPERIMENTAL|Arm III (Pancreatic cancer)|Patients who undergo chemotherapy prior to resection will have 2 DCE MRI scans; one study scan prior to undergoing neoadjuvant therapy, as well as one study scan following neoadjuvant therapy as part of their pre-operative work up in addition to the standard imaging studies. For patients that do not require chemotherapy treatment prior to resection they will have just one DCE MRI scan prior to surgical resection. Patients currently undergoing neoadjuvant therapy or who have already completed neoadjuvant therapy that were unable to undergo imaging at baseline and are now proceeding to resection will have one DCE MRI scan prior to surgical resection.
62061203|NCT02070705|ACTIVE_COMPARATOR|Arm IV (Healthy volunteers)|Patients undergo a single DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) examination.
62061204|NCT05348967|NO_INTERVENTION|Control|Ketogenic diet
62061205|NCT05348967|EXPERIMENTAL|TECADRIOL|Ketogenic diet plus a food supplement containing an association of D-chiro-inositol and alpha-lactalbumin
62061206|NCT01784692|PLACEBO_COMPARATOR|Placebo|10 participants will be randomized to take 1 capsule of placebo daily.
62061207|NCT01784692|EXPERIMENTAL|Immulina 200 mg/day|10 participants will be randomized to take 200 mg/day of Immulina.
62061208|NCT01784692|EXPERIMENTAL|Immulina 400 mg/day|10 participants will be randomized to take 400 mg/day of Immulina.
62061209|NCT01784692|EXPERIMENTAL|Immulina 800 mg/day|10 participants will be randomized to take 800 mg/day of Immulina.
62061210|NCT03604822|EXPERIMENTAL|Music therapy protocol|Each participant received 12 home-based music therapy treatment sessions over 6-week time period.
62061211|NCT04637464|EXPERIMENTAL|Experimental group|"Discontinuation of empirical antibiotics, despite neutrophil count below 0.5x10⁹ cells/L, after 48 hours of apyrexia and clinical stability.~A child is considered clinically stable when there is resolution of all symptoms and signs of infection, and normalization of vital signs including heart rate, respiratory rate, oxygen saturation, blood pressure, and daily diuresis."
62265226|NCT05882448|ACTIVE_COMPARATOR|Laparotomy|Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion
62265227|NCT05882448|EXPERIMENTAL|Laparotomy and laparoscopy|Exploratory and therapeutic laparotomy if necessary preceded by laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes.
62265228|NCT03284684||circulating DNA plasma level test|
62848322|NCT05255809|EXPERIMENTAL|Alexander Technique + Routine Physical Therapy|Routine Physical Therapy+Alexander Technique Verbal Instructions in Trunk stabilising exercises. The time duration will be 15 minutes. Verbal instructions in Stance Phase Time duration 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Lessons would be two days a week for 16 weeks.
62848323|NCT05255809|PLACEBO_COMPARATOR|Control Group|Routine Physical Therapy duration: two days a week for 16 weeks. Trunk stabilising exercises time duration will be 15 minutes. Stance Phase time duration will be 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes.
62848324|NCT02707263|ACTIVE_COMPARATOR|Intravenous continuous infusion of heparin (IV UFH)|Heparin will be administered intravenously.
62848325|NCT02707263|ACTIVE_COMPARATOR|Subcutaneous heparin|Heparin will be subcutaneously administered.
62061212|NCT04637464|NO_INTERVENTION|Control group|Discontinuation of antibiotics when neutrophil count is equal to or above 0.5x10⁹ cells/L, and the child is afebrile and clinical stable OR the child has received 10 days of antibiotics and have been afebrile and clinically stable for 7 days
62061213|NCT01986101|PLACEBO_COMPARATOR|Placebo|once daily orally
62061214|NCT01986101|EXPERIMENTAL|SM-13496 20 - 60 mg/day|once daily orally
62061215|NCT01986101|EXPERIMENTAL|SM-13496 80 - 120 mg/day|once daily orally
62061216|NCT02713711|NO_INTERVENTION|control group|The control group plaques did not receive any treatment.
62061217|NCT02713711|EXPERIMENTAL|phototherapy group|Twelve sessions of phototherapy (UV-B) applied on psoriatic plaques according to individual initial evaluation of Minimal Erythema Dose (MED).
62061218|NCT02713711|EXPERIMENTAL|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L) applied on psoriatic plaques.
62061219|NCT02713711|EXPERIMENTAL|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments on the same conditions described above applied on psoriatic plaques.
62061220|NCT04262765|EXPERIMENTAL|Treatment A-B-C-ABC|"The demographic characteristics of the 18 male subjects were as follows:~* Age: 18-49 years~* Weight: 55-105 kg~* Height: 163-188 cm~* BMI 18.5-29.9 kg/m²"
62265229|NCT00742768|ACTIVE_COMPARATOR|1|softgel capsules
62265230|NCT00742768|ACTIVE_COMPARATOR|2|Gelpell capsules
62265231|NCT01934556|ACTIVE_COMPARATOR|Monthly|Monthly Cohort (30 eyes) - Study eyes will receive intravitreal injections of 0.3 mg ranibizumab every 4 weeks for 24 months.
62448891|NCT05056181|EXPERIMENTAL|PAI|Participants assigned to the PAI arm will receive brief information on the benefits of being more active and will be given information about the best way to training. They will receive conventional medical treatment. They will also participate in 2 weeks of training (12 sessions), plus telematic assistance of a specialized practitioner who will follow them during the post-discharge training sessions for a period of 12 weeks, with 3 workouts per week.
62622263|NCT05475899|ACTIVE_COMPARATOR|Instrument assisted soft tissue mobilization|Patients in group A will be treated with the help of Instrument Assisted soft tissue mobilization GRASTON technique along with the conventional treatment. • Patient will be prone position with the foot over the edge of the table. Instrument will be applied from downward to upward direction with maximum of 10 - 15 strokes per session. These strokes will be applied in two sets of 10 strokes followed by stretches after each set. Conventional treatment includes icing and stretching of the calf muscles. Icing will be done for the total of 3-5 minutes. Both groups will be given session of 40 min/day, 3 days/week for 4 weeks, assessment will be done at baseline, at the end of 2nd week \& at the end of 4th week.
62622264|NCT05475899|EXPERIMENTAL|kinesiology taping|Patients in group B will be treated with the help of kinesiology taping along with the conventional treatment. Patient will be in prone position with the dorsiflexion of the foot supported on the bed. Fan shaped taping will be applied with 60 - 100 % tension in the centre of the tape. The ends of the tape; the anchor will be applied without any stretch while centre of the tape will be stretched to approximately 60 - 100 %. Length of the tape may vary from person to person depending upon the size of the foot. Patient will be instructed to keep the tape till the next session. Conventional treatment includes icing and stretching of the calf muscles. Icing will be done for the total of 3-5 minutes. Both groups will be given session of 40 min/day, 3 days/week for 4 weeks, assessment will be done at baseline, at the end of 2nd week \& at the end of 4th week.
62622265|NCT06529159|ACTIVE_COMPARATOR|HEAPE direct|This modality is the direct generation of PAL in the stomach. The stomach is filled with sodium chloride solution which is then treated with APC. With HEAPE direct a potential decrease of reactive species is avoided, as the treatment happens directly at the intended location in the H. pylori infected stomach.
62622266|NCT06529159|ACTIVE_COMPARATOR|Pre-HEAPE|This modality features the treatment of sodium chloride with APC outside of the patient in a sterile container. After the APC treatment, the generated PAL is administered into the stomach with a syringe through the working channel of the endoscope. Pre-HEAPE allows an easier handling of the APC probe as the treatment of the sodium chloride solution can be done without an endoscope.
62622267|NCT05411380|EXPERIMENTAL|Tucidinostat+Metronomic Capecitabine+Endocrine Therapy|This arm is divided into two groups. The main difference of this two groups lies in the selection of endocrine therapy. One is supposed to choose aromatase inhibitor, and the other is fulvestrant. The principle of making choice is based on the history of endocrine drug use.
62622268|NCT04246528|EXPERIMENTAL|Intervention group|Access to the online SPIN-SELF program
62622269|NCT04246528|NO_INTERVENTION|Control group|Usual care, no access to the online SPIN-SELF program
62622270|NCT06271343||Donor patients|
62622271|NCT06271343||Recipient patients|
62622272|NCT05134779||Cohort 1|Patients with breast cancer (BC), any stage will be considered for this study.
62622273|NCT04617405||Type A|Healthy normal-weight pregnant women
62622274|NCT04617405||Type B|Pregnant women with gestational diabetes diagnosed at early screening (before gestational week 20)
62622275|NCT04617405||Type C|Pregnant women with type 2 diabetes
62622276|NCT04617405||Type D|Healthy overweight pregnant women
62848326|NCT02090842|EXPERIMENTAL|Whey protein isolate|Subjects are asked to supplement their habitual diet with 56 g of whey protein isolate a day for 8 weeks.
62848327|NCT02090842|EXPERIMENTAL|Ca-caseinate|Subjects are asked to supplement their habitual diet with 56 g of Ca-caseinate a day for 8 weeks.
62061221|NCT03387202||pelvic organ prolapse|"Participants received Laparoscopic lateral suspension with mesh as part of routine medical care in apical prolapse, thus, the investigator does not assign a intervention but studies the effects.Vaginal length, bladder neck mobility and pelvic floor biometry with AP hiatal diameter and pelvic organ descent measurements are measured by Transperineal ultrasound to assess anatomic success in the preoperative and at postoperative 18th months. POP-Q assessment and translabial usg for objective success; Female Sexual Function Index (FSFI), Michigan Incontinence Severity Index (M-ISI), Prolapse Quality of Life questionnaire (PQoL), Pelvic Organ Prolapse Symptom Score (POP-SS) and Visual Analog Score (VAS) are used to assess subjective success."
62061222|NCT05802186|EXPERIMENTAL|Treatment (AI-directed analysis, SBRT)|Patients undergo radiation planning with AI-directed analysis for dose recommendations with Deep Profiler + iGray software on study. Patients then undergo SBRT on study. Patients also undergo PET, CT, MRI, and/or x-ray imaging during screening and follow-up.
62448892|NCT05056181|NO_INTERVENTION|TAU|Participants assigned to the TAU arm will receive brief information on the benefits of being more active and will be given information about the best way to training. They will also receive conventional medical treatment.
62448893|NCT05079009|EXPERIMENTAL|ECCO2R pulsatile configuration|Adult patients hospitalized in the medical ICU for whom a treatment by ECCO2R has been indicated.
62448894|NCT01104662|EXPERIMENTAL|Daptomycin, Bacteremia, Severe Renal Impairment|Cohort 1. Daptomycin was given intravenously 6 milligrams per kilogram (mg/kg) per administration. For bacteremia participants with Creatinine Clearance (CLcr) below 30 milliliters per minute (mL/min) and currently receiving hemodialysis, daptomycin was administered immediately following each hemodialysis session (3 per week) for 14 to 42 days based on disease resolution or Investigator discretion. For participants not receiving dialysis, daptomycin was administered every 48 hours for 14 to 42 days based on disease resolution or Investigator discretion.
62448895|NCT01104662|ACTIVE_COMPARATOR|Vancomycin or SSP, Bacteremia, Severe Renal Impairment|Cohort 1. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by Methicillin-Susceptible Staphylococcus Aureus (MSSA) could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered intravenously (IV) until end of antibiotic therapy for bacteremia or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
62448896|NCT01104662|EXPERIMENTAL|Daptomycin, Bacteremia, Moderate Renal Impairment|Cohort 2. Daptomycin was given intravenously 6 milligrams per kilogram (mg/kg) per administration. For bacteremia participants with CLcr values between 30 and 50 mL/min not receiving dialysis, daptomycin was administered every 24 hours for 14 to 42 days based on disease resolution or Investigator discretion.
62622277|NCT03934918|EXPERIMENTAL|Treatment|Patients for IOL with intracervical balloon placed in the outpatient clinic and sent home
62448897|NCT01104662|ACTIVE_COMPARATOR|Vancomycin or SSP , Bacteremia, Moderate Renal Impairment|Cohort 2. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for bacteremia or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
62448898|NCT01104662|EXPERIMENTAL|Daptomycin, cSSSI, Severe Renal Impairment|Cohort 3. Daptomycin was given intravenously 4 milligrams per kilogram (mg/kg) per administration. For cSSSI participants with CLcr below 30 mL/min and currently receiving hemodialysis, daptomycin was administered immediately following each hemodialysis session (3 per week) for 7 to 14 days based on disease resolution or Investigator discretion. For participants not receiving dialysis, daptomycin was administered every 48 hours for 7 to 14 days based on disease resolution or Investigator discretion.
62448899|NCT01104662|ACTIVE_COMPARATOR|Vancomycin or SSP , cSSSI, Severe Renal Impairment|Cohort 3. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
62448900|NCT01104662|EXPERIMENTAL|Daptomycin, cSSSI, Moderate Renal Impairment|Cohort 4. Daptomycin was given intravenously 4 milligrams per kilogram (mg/kg) per administration. For cSSSI participants with CLcr values between 30 and 50 mL/min not receiving dialysis, daptomycin was administered every 24 hours for 7 to 14 days based on disease resolution or Investigator discretion.
62448901|NCT01104662|ACTIVE_COMPARATOR|Vancomycin or SSP , cSSSI, Moderate Renal Impairment|Cohort 4. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
62448902|NCT04892459|EXPERIMENTAL|heterologous boost arm with Ad5 vectored vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster of recombinant SARS-CoV-2 Ad5 vectored vaccine after 3\~6 months.
62448903|NCT04892459|ACTIVE_COMPARATOR|homogeneous boost arm with inactive vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster dose of inactive SARS-CoV-2 vaccine after 3\~6 months.
62448904|NCT04892459|EXPERIMENTAL|heterologous regimen with Ad5 vectored vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of recombinant SARS-CoV-2 Ad5 vectored vaccine after 1\~3 months.
62448905|NCT04892459|ACTIVE_COMPARATOR|homogeneous regimen arm with inactive vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of inactive SARS-CoV-2 vaccine after 1\~3 months.
62448906|NCT01362634|EXPERIMENTAL|CAPI Intervention|an interviewer-administered comprehensive health and social risk assessment intervention
62448907|NCT01362634|EXPERIMENTAL|ACASI Intervention|self-administered comprehensive health and social risk assessment intervention
62448908|NCT01362634|NO_INTERVENTION|Control|waitlist control condition
62448909|NCT04314739|ACTIVE_COMPARATOR|Resveratrol|500mg of Veri-te Resveratrol (consumed as two 250mg tablets, at two timepoints each day).
62448910|NCT04314739|PLACEBO_COMPARATOR|Placebo|Matched placebo capsules (1 capsule consumed at two timepoints each day).
62448911|NCT01635985|EXPERIMENTAL|1|AZD5423 iv
62061223|NCT03578614|NO_INTERVENTION|Control Group|There is no intervention for Control Group
62448912|NCT01635985|EXPERIMENTAL|2|AZD5423 inhalation, Spira
62448913|NCT01635985|EXPERIMENTAL|3|AZD5423 inhalation I-neb
62448914|NCT01635985|EXPERIMENTAL|4|AZD5423 oral
62448915|NCT01635985|EXPERIMENTAL|5|AZD5423 inhalation Turbuhaler
62622278|NCT03934918|NO_INTERVENTION|Control|Patients for IOL admitted to Labor and Delivery
62622279|NCT04252963|EXPERIMENTAL|Mucolase|
62622280|NCT04252963|PLACEBO_COMPARATOR|Placebo|
62622281|NCT05567471|ACTIVE_COMPARATOR|Group 1(BBV154 in COVAXIN recipients)|250 participants will be recruited and administered with a booster dose of BBV154 vaccine in form of drops (0.5 mL) via intranasal route, in individuals previously vaccinated with COVAXIN.
62622282|NCT05567471|ACTIVE_COMPARATOR|Group 2 (COVAXIN in COVAXIN recipients)|125 participants will be recruited and administered with a booster dose of BBV152 vaccine, in individuals previously vaccinated with COVAXIN.
62061224|NCT03578614|EXPERIMENTAL|Intervention Group|Intervention Group will be submitted to three physical activity sessions (two supervised and one nonsupervised) conducted over 6 months
62061225|NCT00280657|EXPERIMENTAL|Arm 1|
62061226|NCT00280657|ACTIVE_COMPARATOR|Arm 2|
62061227|NCT00280657|PLACEBO_COMPARATOR|Arm 3|
62448916|NCT01635985|EXPERIMENTAL|6|AZD5423, New Dry Powder Inhaler
62448917|NCT04886375|ACTIVE_COMPARATOR|esp group|The investigators performed erector spina plane block to that patient group for postoperative analgesia
62448918|NCT04886375|ACTIVE_COMPARATOR|pecs group|The investigators performed modified pectoral nerve block to that patient group for postoperative analgesia
62448919|NCT00704418|EXPERIMENTAL|Bromfenac|Bromfenac ophthalmic solution 0.09%, dosed 1 drop daily
62622283|NCT05567471|ACTIVE_COMPARATOR|Group 3 (BBV154 in COVISHIELD recipients)|250 participants will be recruited and administered with a booster dose of BBV154 vaccine, in individuals previously vaccinated with COVISHIELD.
62848328|NCT02090842|OTHER|Maltodextrin|Subjects are asked to supplement their habitual diet with 54 g of maltodextrin a day for 8 weeks.
62848329|NCT01864005|EXPERIMENTAL|Ticagrelor|
62848330|NCT01864005|ACTIVE_COMPARATOR|clopidogrel|
62848331|NCT05861713|EXPERIMENTAL|Hydrating cream group|The subjects will be instructed to apply the Hydrating Cream to the more severely affected side as the experimental group (e.g., the more severely injured left or right hand of tug-of-war athletes). At the same time, the other limb will be regarded as the control group. The study lasted for two weeks, and after two weeks, the experimental and control groups were switched, with the entire observation process lasting four weeks.
62848332|NCT00587496|EXPERIMENTAL|1|placebo, 6 capsules per day for 30 days
62848333|NCT00587496|EXPERIMENTAL|2|500 mg Valtrex one capsule per day plus 5 capsules of placebo per day for 30 days
62848334|NCT00587496|EXPERIMENTAL|3|500 mg Valtrex capsule one per day, Acetylsalicylic acid (aspirin) 325 mg capsules three per day, plus 2 placebo capsules per day for 30 days
62848335|NCT03374852|EXPERIMENTAL|CPI-613 + mFOLFIRNOX|"CPI-613: 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port mFOLFIRNOX (given immediately after CPI-613 administration): Oxaliplatin (Eloxatin) at 65 mg/m2 given as a 2-hr IV infusion via a central venous port~* Folinic acid at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin, and concurrently with irinotecan (Camptosar).~* Irniotecan at 140 mg/m2 given as a 90-min IV infusion via a central venous port via a Yconnector.~* Flurouracil (5FU) at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan"
62848336|NCT02147561|EXPERIMENTAL|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
62848337|NCT06153719|ACTIVE_COMPARATOR|Exercise group|
62848338|NCT06153719|PLACEBO_COMPARATOR|Control group|
62848339|NCT01035411|EXPERIMENTAL|1|AZD9668 2X30mg tablet
62848340|NCT01305577|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
62848341|NCT01305577|EXPERIMENTAL|Deoxycholic Acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
62848342|NCT01305577|EXPERIMENTAL|Deoxycholic Acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
62848343|NCT00575146|EXPERIMENTAL|1|ketogenic diet
62848344|NCT00013156|OTHER|Arm 1|
62448920|NCT00704418|PLACEBO_COMPARATOR|Placebo|Placebo, dosed 1 drop daily
62448921|NCT00680875|EXPERIMENTAL|Intervention|5th and 6th grade students who attend schools randomly assigned to the intervention condition.
62622284|NCT05567471|ACTIVE_COMPARATOR|Group 4(COVAXIN in COVISHIELD recipients)|125 participants will be recruited and administered with a booster dose of BBV152 (COVAXIN) vaccine, in individuals previously vaccinated with COVISHIELD.
62848345|NCT04643717||intensive care patients|
62848346|NCT03723967|EXPERIMENTAL|Durvalumab with Carboplatin/Paclitaxel|Combination of Durvalumab with Carboplatin/Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy
62848347|NCT05368701|EXPERIMENTAL|App-based volitional help sheet (VHS) for self-harm|"A smartphone-based app version of the adapted VHS for self-harm. Participants read a brief statement designed to encourage them to avoid self-harming (We want you to plan to avoid self-harming). Participants are presented with ten 'high risk' situations (temptations). By selecting an appropriate situation, 10 appropriate responses (processes of change) are suggested (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to self-harm and identifying ways to overcome those temptations had been shown to help people change their behaviour.~Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
62448922|NCT00680875|NO_INTERVENTION|Usual Curriculum|5th and 6th grade students attending schools randomly assigned to the usual curriculum control condition.
62061228|NCT03708640|PLACEBO_COMPARATOR|Physical Activity Counseling|"Group receives baseline physical activity counseling.~Group does not receive personalized, health coaching via smart text messages."
62061229|NCT03708640|EXPERIMENTAL|Digital Activity Tracker/Smart Text Messaging|"Group receives baseline physical activity counseling.~Group receives personalized, health coaching via smart text messages informed by digital activity tracker."
62061230|NCT05158101|EXPERIMENTAL|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
62448923|NCT02727036|EXPERIMENTAL|Pumpkin seed oil|Pumpkin seed oil (1g) capsules - 2 capsules per day for 12 weeks
62448924|NCT02727036|ACTIVE_COMPARATOR|Pumpkin seeds|Packet of pumpkin seeds (4.1 grams /\~0.15ounces) - 1 pack per day for 12 weeks
62061231|NCT05568524|ACTIVE_COMPARATOR|Control|The training program for the control group consists of a telerehabilitation with traditional moderate-to-high load (60%-80% 1RM) exercises (the same as the intervention group sans BFR), utilizing elastic bands. This program for the control group will be conducted in an in-home real-time audio and video style and supervised by a physiotherapist.
62061232|NCT05568524|EXPERIMENTAL|BFRT|The BFR training program for the intervention group consists of elbow flexion and extension, and knee extension exercises performed with low load (elastic bands; equivalent to 30% 1RM) and concurrent BFR (upper limb 50% AOP; lower limb 60% AOP). Subjects will perform 4 sets (30, 15, 15 and 15 reps) of each exercise with 30 s rest between sets and 5-minute rest between exercises.
62448925|NCT00996736|ACTIVE_COMPARATOR|Topical Natamycin|
62061233|NCT05043701|EXPERIMENTAL|Treatment|Patients will be treated with drugs based on functional profiling of autologous tumor cells in vitro
62448926|NCT00996736|EXPERIMENTAL|Topical Voriconazole|
62448927|NCT04525807||Multiomics arm|Guide therapy based on multi-omics
62622285|NCT05567471|ACTIVE_COMPARATOR|Group 5 (COVISHIELD in COVISHIELD recipients)|125 participants will be recruited and administered with a booster dose of Covishield vaccine, in individuals previously vaccinated with COVISHIELD.
62622286|NCT01232088||Data collection group: ICU physicians|Online survey for ICU physicians (members of the European Society of Intensive Care Medicine (ESICM)).
62448928|NCT01336829|EXPERIMENTAL|001|ETR/telaprevir Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18 and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
62448929|NCT01336829|EXPERIMENTAL|002|telaprevir/ETR Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18 and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
62622287|NCT02711358|EXPERIMENTAL|indomethacin|indomethacin suppositories
62622288|NCT02711358|PLACEBO_COMPARATOR|placebo|placebo suppositories
62448930|NCT01336829|EXPERIMENTAL|003|TMC278/telaprevir Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18 and TMC278 25 mg once daily from Day 8 to Day 18.
62622289|NCT04730752||Right Low Quadrant Pain|AIR and AAS scores will be calculated for the patients with right low quadrant pain in emergency service.
62622290|NCT03307837|ACTIVE_COMPARATOR|CA-008 Cohort 1 0.5 mg|Intra-operative, local administration
62448931|NCT01336829|EXPERIMENTAL|004|telaprevir/TMC278 Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18 and TMC278 25 mg once daily from Day 8 to Day 18.
62448932|NCT00319111|EXPERIMENTAL|Bosentan|Open label bosentan treatment
62448933|NCT00863525|EXPERIMENTAL|1|Odanacatib
62448934|NCT00863525|PLACEBO_COMPARATOR|2|Placebo
62448935|NCT02362477|ACTIVE_COMPARATOR|Control CPT|'Cognitive Processing Therapy in-person. Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
62448936|NCT02362477|EXPERIMENTAL|Experimental CPT via VTC|'Cognitive Processing Therapy through videoteleconference. Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
62622291|NCT03307837|ACTIVE_COMPARATOR|CA-008 Cohort 2 1 mg|Intra-operative, local administration
62622292|NCT03307837|ACTIVE_COMPARATOR|CA-008 Cohort 3 2 mg|Intra-operative, local administration
62622293|NCT03307837|ACTIVE_COMPARATOR|CA-008 Cohort 4 3 mg|Intra-operative, local administration
62622294|NCT03307837|ACTIVE_COMPARATOR|CA-008 Cohort 5 4.2 mg|Intra-operative, local administration
62622295|NCT03307837|PLACEBO_COMPARATOR|Placebo|Intra-operative, local administration of saline (equivalent volume in active comparator arm)
62622296|NCT05511259|EXPERIMENTAL|Intervention|Square stepping exercise
62622297|NCT05511259|NO_INTERVENTION|Control|Passive control group
62622298|NCT00572455|EXPERIMENTAL|Stage 1: PF-04217329 - Lowest Dose|
62622299|NCT00572455|EXPERIMENTAL|Stage 1: PF-04217329 - Low Dose|
62061234|NCT00903734|EXPERIMENTAL|Erlotinib Hydrochloride|Those eligible for umbrella of studies and have not received Erlotinib hydrochloride in past, will first receive Erlotinib hydrochloride alone.
62061235|NCT02978001||Patients with Psoriasis|Patients with moderate to severe psoriasis (PASI\>8)
62061236|NCT02978001||Healthy Control Subjects|Healthy subjects matching the patients with psoriasis regarding age, gender and BMI
62061237|NCT05781139||Early onset Alzhiemer|before age of 65 and above age of 50
62061238|NCT05781139||Late onset Alzhiemer|Above the age of 65
62061239|NCT05781139||Vascular dementia|Any patient diagnosed with vascular dementia
62061240|NCT05781139||control group|persons who has no dementia
62061241|NCT06215690||Pregnant Women with Fetal Growth Restriction|Fetuses with fetal growth restriction according to Delphi consensus criteria between 32-37 weeks of gestation
62061242|NCT06215690||Healthy Pregnancies|Normally developing fetuses between 32-37 weeks of gestation
62061243|NCT03263689|EXPERIMENTAL|Intervention|"ITM group were given~1. Local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia~2. 100 micrograms of preservative-free morphine."
62061244|NCT03263689|ACTIVE_COMPARATOR|Control|TAP group were given only local anaesthesia (plain hyperbaric bupivacaine 10 mgs) during the spinal anaesthesia.
62622300|NCT00572455|EXPERIMENTAL|Stage 1: PF-04217329 - Middle Dose|
62061245|NCT02457416|ACTIVE_COMPARATOR|Peanut oral immunotherapy|Oral immunotherapy with peanut
62061246|NCT02457416|NO_INTERVENTION|Controls|Avoid peanut exposure
62622301|NCT00572455|EXPERIMENTAL|Stage 1: PF-04217329 - High Middle Dose|
62622302|NCT00572455|EXPERIMENTAL|Stage 1: PF-04217329 - High Dose|
62622303|NCT00572455|EXPERIMENTAL|Stage 1: PF-02417329 - Highest Dose|
62622304|NCT00572455|EXPERIMENTAL|Stage 1: PF-04217329 - Vehicle|
62061247|NCT02224963|EXPERIMENTAL|Preventive Problem-Solving Training|Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems. It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
62061248|NCT02224963|ACTIVE_COMPARATOR|Life and Health Review|Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
62061249|NCT03780114||interns|intern pediatric dentists
62061250|NCT05098106||Pneumonia patients with ARDS|Patients in the perioperative/intensive care setting with pneumonia-induced ARDS requiring bronchoscopy.
62061251|NCT05098106||Ventilated patients without ARDS|Patients without ARDS on mechanical ventilation.
62061252|NCT05291182|EXPERIMENTAL|Dose-escalation|The study is conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of SY-4835.
62061253|NCT03120754|EXPERIMENTAL|Experimental Group|Placement of peritoneal drainage
62061254|NCT03120754|ACTIVE_COMPARATOR|Control group|No peritoneal drainage
62622305|NCT00572455|EXPERIMENTAL|Stage 2: PF-04217329 - Low Dose + Latanoprost Vehicle|
62622306|NCT00572455|EXPERIMENTAL|Stage 2: PF-04217329 - Middle Dose + Latanoprost Vehicle|
62622307|NCT00572455|EXPERIMENTAL|Stage 2: PF-04217329 - High Dose + Latanoprost Vehicle|
62622308|NCT00572455|EXPERIMENTAL|Stage 2: PF-04217329 - Low Dose + Latanoprost 0.005%|
62622309|NCT00572455|EXPERIMENTAL|Stage 2: PF-04217329 - Middle Dose + Latanoprost 0.005%|
62622310|NCT00572455|EXPERIMENTAL|Stage 2: PF-04217329 - High Dose + Latanoprost 0.005%|
62622311|NCT00572455|EXPERIMENTAL|Stage 2: PF-04217329 - Vehicle + Latanoprost 0.005%|
62622312|NCT03964259|ACTIVE_COMPARATOR|Standard Hydration Regimen|In the standard intravenous fluid (IVF) protocol, following completion of HDMTX infusion, post HDMTX IVF will be initiated at 125 mL/m2/hr (no maximum mL/hr total rate).
62622313|NCT03964259|EXPERIMENTAL|Reduced hydration regimen|The reduced intravenous fluid (IVF) protocol, post HDMTX IVF will be initiated at 62.5 mL/m2/hr following completion of HDMTX infusion.
62622314|NCT01557868|ACTIVE_COMPARATOR|Synvisc (hylan G-F 20)|
62622315|NCT01557868|ACTIVE_COMPARATOR|Euflexxa (1% sodium hyaluronate)|
62622316|NCT06025201|EXPERIMENTAL|Single Arm|All participants will complete all interventions
62622317|NCT05496465|ACTIVE_COMPARATOR|ARS-1 1mg|1 mg per 100 µL dose of ARS-1
62622318|NCT05496465|ACTIVE_COMPARATOR|ARS-1 2mg|2 mg per 100 µL dose of ARS-1
62622319|NCT05496465|PLACEBO_COMPARATOR|Placebo|Placebo (100 µL)
62622320|NCT02103348||Mild-to-Moderate Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
62265232|NCT01934556|ACTIVE_COMPARATOR|TREX|(60 eyes) - Monthly intravitreal injections of 0.3 mg ranibizumab for four visits. At the fourth visit (Week 12), if the central foveal thickness is ≤ 325 μm then the eye will receive 0.3 mg ranibizumab and begin the extension phase of the study. For all subsequent visits in the extension phase, appropriate changes to the treatment interval with 0.3 mg ranibizumab (i.e. extend, maintain, reduce) will be made based on pre-specified SD (Spectral Domain)-OCT criteria. Treatment is rendered at every visit. The time between visits is individualized based on each subject's response to treatment. If the central foveal thickness is \> 325 μm at week 12, then the patient will continue to receive monthly intravitreal injections of 0.3 mg ranibizumab until the central foveal thickness is ≤ 325 μm. Once the central foveal thickness is ≤ 325 μm, then the study eye will begin the extension phase of the study.
62265233|NCT01934556|ACTIVE_COMPARATOR|GILA|(60 eyes) - Monthly intravitreal injections of 0.3 mg ranibizumab for four visits combined with guided laser photocoagulation to all microaneurysms in the area of DME at visit 2 (Week 4) and then again every 3 months, if leakage is present on fluorescein angiography. If the central foveal thickness is ≤ 325 μm at visit 4 (Week 12), eyes will receive 0.3 mg ranibizumab and the extension phase will begin. For all subsequent visits in the extension phase, appropriate changes to the treatment interval with 0.3 mg ranibizumab (i.e. extend, maintain, reduce) will be made based on pre-specified SD-Optical coherence tomography criteria. If the central foveal thickness is \> 325 μm at week 12, then the patient will continue to receive monthly intravitreal injections of 0.3 mg ranibizumab and possible guided laser every 3 months until the central foveal thickness is ≤ 325 μm. Once the central foveal thickness is ≤ 325 μm, then the study eye will begin the extension phase of the study.
62265234|NCT05926700|EXPERIMENTAL|intervention group|The subject will be treated with Candonilimab + anlotinib every 21 days as a treatment cycle: Candonilimab 10mg/kg, D1 administration; Anlotinib 12mg/ day was taken orally for 2 weeks and stopped for a week. Until the subject has disease progression, intolerable toxicity, and the investigator's decision, the subject withdraws informed consent, death or other reasons specified in the protocol.
62848348|NCT05368701|ACTIVE_COMPARATOR|App-based pencil-and-paper VHS|"The app will deliver a .pdf file (for printing) worksheet of the VHS for self-harm, with no integration into the app.~Participants read a brief statement designed to encourage them to avoid self-harming (We want you to plan to avoid self-harming). Participants are presented with a table with two columns and ten rows. Ten 'high risk' situations (temptations) are presented in the left hand column and 10 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to self-harm and identifying ways to overcome those temptations had been shown to help people change their behaviour.~Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response by drawing a line between the situation and response."
62848349|NCT05368701|NO_INTERVENTION|App with no VHS component|"An app with no VHS component that collects questionnaire survey data.~In this control condition, the app only contains the survey questions and links to helplines contained in the other two conditions.~A free text entry box will ask participants to think of important situations where they might self-harm. A second box asks participants to think of alternative plans that they can do instead of self-harming. Participants are not guided to make links between the situations and responses."
62848350|NCT03386838|EXPERIMENTAL|Nivolumab and BMS-986205|Nivolumab administered in combination with BMS-986205
62623790|NCT02781818|PLACEBO_COMPARATOR|Normal Saline Placebo|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of sterile normal saline solution.
62623791|NCT02370056|EXPERIMENTAL|3D Visualization|"3-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using 3D Laparoscopic Surgical Video System.~This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons.Effect of using 3D Laparoscopic Surgical Video System on operative outcomes will be evaluated."
62848351|NCT03386838|ACTIVE_COMPARATOR|EXTREME study regimen|Cetuximab + Cisplatin/Carboplatin + Fluorouracil
62848352|NCT06282133|EXPERIMENTAL|Behavioural Experiments (CBT)|"Behavioural experiments involve selecting a specific thought to test (for example, uncertainty makes me incapable of acting) and designing a detailed experiment to challenge this thought."
62848353|NCT02933684|EXPERIMENTAL|DCS|Participants will receive 50mg of Seromycin (aka D-cycloserine) in conjunction with virtual reality exposure therapy once a week for 4 weeks.
62848354|NCT02933684|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo in conjunction with virtual reality exposure therapy once a week for 4 weeks.
62848355|NCT05842161|EXPERIMENTAL|QUIT-AD|An six-session adapted cognitive-behavioral intervention for smoking cessation and treatment adherence. Intervention content will include psychoeducation related to cognitive-behavioral therapy, smoking, TB, and HIV; behavioral activation; distress tolerance; and relapse prevention.
62265235|NCT03420690||Family of patient|
62622321|NCT02103348||Severe Asthma|"Major Criteria: (1 required)~1. Treatment with oral corticosteroids for at least 6 of the previous 12 months~2. Treatment with high-dose inhaled corticosteroids for at least 10 of the previous 12 months~Minor Criteria: (2 required)~1. Daily treatment with an asthma controller medication in addition to inhaled, or~2. Asthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis (defined as at least 5 of 7 days), or~3. Persistent airway obstruction with baseline FEV1 \<80% predicted, or~4. ≥ 1 urgent visits for asthma in the previous 12 months, or~5. ≥ 3 systemic corticosteroid bursts in the previous 12 months, or~6. Prompt deterioration with a reduction in oral or inhaled corticosteroid dose, or~7. A near-fatal asthma event (i.e., intubation) in the past."
62622322|NCT02103348||Healthy Controls|Those without asthma or other chronic lung disease.
62622323|NCT03019029|EXPERIMENTAL|Peripheral nerve amyloidosis|Patients with pathologically-confirmed peripheral nerve amyloidosis will undergo 18-F Florbetapir PET/MR scan on a GE SIGNA PET/MR scanner.
62622324|NCT02974348|ACTIVE_COMPARATOR|arm 1: Arthemeter-lumefantrine|Arthemeter-lumefantrine (ART-LUM) is an antimalaria drug manufactured as fixed combination tablets, each containing 20 mg of artemether and 120 mg of lumefantrine. ART-LUM was administrated according to body weight as six consecutive doses: The first dose at diagnosis and the second dose eight hours later, 0- 24-48 hours
62622325|NCT02974348|ACTIVE_COMPARATOR|arm 2 : Artesunate mefloquine|Artesunate mefloquine (ASMQ) is an antimalaria drug administered as a combination of artesunate, 4 mg/kg/day, with mefloquine, 8 mg/kg/day orally once a day for 3 days or three times, at an interval of 24 hours (0 h - 24 h - 48 h).
62622326|NCT02974348|ACTIVE_COMPARATOR|arm 3 : Dihydroartemisinin piperaquine|Dihydroartemisinin piperaquine (DHA-PQ ) is an antimalaria drug administered as a combination of dihydroartemisinin, 2.5 mg per kg, with piperaquine phosphate, 20mg per kg daily for 3 days or three times, at an interval of 24 hours
62622327|NCT02974348|OTHER|Paracetamol|Oral paracetamol is administered at of 50mg/kg body weight per day in three divided doses for fever exceeding 37.5oC.
62622328|NCT02974348|OTHER|Amoxicillin|amoxicillin is an antibiotic administered at 50mg per kg body weight per day for seven days in the event of concomitant bacterial infection, absent on day 0 but present during the follow up.
62622329|NCT02974348|OTHER|Quinine|Quinine is an antimalarial recommended by the WHO and NMCP to be used as second line treatment for malaria. In this study, for cases of treatment failure with the artemisinin based combination therapies, quinine sulphate is administered as a second line or rescue drug at a dose of 25mg base per kg body weight per day in three divided doses for five days. The participant is then classified as ETF or LTF and excluded from the study.
62622330|NCT01718587|EXPERIMENTAL|stem cell transplantation therapy|umbilical cord mesenchyma stem cell transplantation through interventional procedures do in liver cirrhosis patients.
62622331|NCT01718587|ACTIVE_COMPARATOR|antiviral therapy|"Antiviral therapy: lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).~Supportive therapy are allowed to use on patients not including intravenous infusions of plasma or albumin."
62622332|NCT02693717|EXPERIMENTAL|Treatment (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62622333|NCT04322097|OTHER|Lingual Muscle Stimulation Patients|DISE
62622334|NCT06399016|EXPERIMENTAL|Group 1: Augmented Reality Applied Book Reading Group|"Children included in this group will be asked to read books supported by augmented reality technology. Approximately 1 hour before the surgery, a survey will be administered to the child and the accompanying parent using the Child and Family Introductory Data Form, which includes sociodemographic characteristics. The child himself/herself will be asked to score the level of surgery-related anxiety using the CAS score, and the child, the parent, and the researcher will be asked to score the child's fear level regarding the surgery using the CFS score. Data collection will take approximately 10 minutes in total. Immediately afterwards, the researcher will ask the child to read the book 'One Child, One Miracle', which is a technology-supported augmented reality application, with the help of an application previously downloaded free of charge from Google Play or IOS to a mobile phone or tablet."
62622335|NCT06399016|EXPERIMENTAL|Group 2: Control Group|"In the preoperative period, the researcher will conduct a survey on the morning of the surgery day, approximately 1 hour before the surgery, using the Child and Family Introductory Data Form, which includes the sociodemographic characteristics of the child and the accompanying parent. The child himself/herself will be asked to score the level of surgery-related anxiety using the CAS score, and the child, the parent, and the researcher will be asked to score the child's fear level regarding the surgery using the CFS score. Data collection will take approximately 10 minutes in total. Immediately afterwards, the child will be asked by the researcher to read the story book One Child, One Miracle. This group will be asked to just read the book without turning on the book's augmented reality feature. Afterwards, using the same scales, children will score the CAS scales, and the child, parent and researcher will score the CFS scales."
62622336|NCT04844008|EXPERIMENTAL|Nanobubble|Sports drink nanobubble drink
62622337|NCT04844008|PLACEBO_COMPARATOR|control|Flavoured drink- no active ingredients
62622338|NCT00869310|EXPERIMENTAL|1|Dexamethasone plus Aprepitant
62265236|NCT02021045||Patient on Hemodialysis|Renal hemodialysis
62265237|NCT02021045||Patient in a hemodialysis-free interval|No Renal hemodialysis
62265238|NCT03298581|EXPERIMENTAL|Halobetasol propionate spray 0.05%|Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.
62622339|NCT00869310|ACTIVE_COMPARATOR|2|dexamethasone plus metoclopramide
62622340|NCT04262011|OTHER|immediate treatment|After randomization, patients who are allocated to the immediate treatment group will receive treatment.
62622341|NCT04262011|OTHER|postponed treatment|After randomized patients will be allocated to this group, they will wait for the follow-up of the study to receive delayed treatment.
62622342|NCT04598308||patients undergoing invasive assessment of the microcirculation|All patients are eligible for participation in this registry if they are undergoing coronary angiography with or without coronary intervention for any reason and if an indication for the foreseen intracoronary physiologic measurements is present according to the discretion of the investigating operator. There are no specific exclusion criteria other than contraindications for physiologic measurements in general.
62622343|NCT02400619|ACTIVE_COMPARATOR|shock waves|A comparative study with patients with spasticity in gastrocnemius and soleus where a group start having shockwave treatment and receive three sessions at weekly intervals, gastrocnemius and soleus applied in 2000 impacts at a frequency of 8hz and energy intensity is proposed between 2.2-2.4 Bars (0,10-0,12mj ). Swiss dolor clast EMS. The other group will receive botulinum toxin Type A in the same muscles. The dose of toxin is in accordance with the weight of each patient, the dose normally used with each user and always with the same brand is always respected, Botox (4-8-12 U/Kg) Patients will be assessed before treatment, after three weeks, two months and three months after three months when the groups exchange the therapy.
62622344|NCT02400619|ACTIVE_COMPARATOR|botulinum toxin|A comparative study with patients with spasticity in gastrocnemius and soleus where a group start having shockwave treatment and receive three sessions at weekly intervals, gastrocnemius and soleus applied in 2000 impacts at a frequency of 8hz and energy intensity is proposed between 2.2-2.4 Bars (0,10-0,12mj ). Swiss dolor clast EMS.The other group will receive botulinum toxin type A in the same muscles. The dose of toxin is in accordance with the weight of each patient, the dose normally used with each user and always with the same brand is always respected. Botox (4-8-12 U/Kg)Patients will be assessed before treatment, after three weeks, two months and three months after three months when the groups exchange the therapy.
62622345|NCT06477640|EXPERIMENTAL|Exercise Intervention Group|
62622346|NCT06477640|PLACEBO_COMPARATOR|Standard of Care|
62622347|NCT00651300|EXPERIMENTAL|Group 1|
62265239|NCT02554123|EXPERIMENTAL|Vitamin E ointment|Vitamin E ointment application. Every 12 hours during 7 days.
62448937|NCT06161402|EXPERIMENTAL|EB-PRT|EB-PRT will implemented during week 1-14. A purposive sample of 12 participants invited for qualitative interview during 21st -22nd week. There are 2 post-test evaluations at 14th week and 26th week. After the second evaluation at week 26, the group will receive usual care with routine follow-up.
62622348|NCT00651300|PLACEBO_COMPARATOR|Group 2|
62622349|NCT03457324|EXPERIMENTAL|JCM-16021 Group|JCM-16021 granules 8g/sachet, three times daily for 8 weeks.
62448938|NCT06161402|NO_INTERVENTION|Usual care|The control group will receive usual care including the medical care offered by the specialist out-patient clinic during 1-26 week. There are 2 post-test evaluations at 14th week and 26th week. From week 27 to week 40, this wait-list control group will receive the same EB-PRT as the intervention group.
62622350|NCT03457324|PLACEBO_COMPARATOR|Placebo Group|Placebo granules 8g/sachet, three times daily for 8 weeks
62622351|NCT06124651|ACTIVE_COMPARATOR|CR knee|This type of total knee arthroplasty retains the posterior cruciate ligament.
62622352|NCT06124651|ACTIVE_COMPARATOR|PS knee|This type of total knee sacrifices the posterior cruciate ligament and cam and post mechanism replaces its function.
62622353|NCT03065153||Healthy|Healthy individuals without any neurological or orthopaedic disorder that could influence motor performance and balance
62622354|NCT03065153||Stroke|Individuals suffered from a haemorrhagic or ischaemic stroke. Diagnosis has to be confirmed on the basis of CT or MRI imaging.
62622355|NCT02442206|EXPERIMENTAL|Treatment sequence 1|QVA149 from day 1 to day 15 followed by Placebo from day 29 to day 43
62622356|NCT02442206|EXPERIMENTAL|Treatment sequence 2|Placebo from day 1 to day 15 followed by QVA149 from day 29 to day 43
62622357|NCT05576961|EXPERIMENTAL|regular dose of RX-af01|RX-af01 in combination with toripalimab
62848356|NCT05842161|ACTIVE_COMPARATOR|Enhanced Treatment as Usual (ETAU)|After randomization, participants in the ETAU condition will receive one session of psychoeducation on the HIV- and TB-related health benefits of smoking cessation.
62848357|NCT03586570|EXPERIMENTAL|Aprocitentan|
62848358|NCT03586570|PLACEBO_COMPARATOR|Placebo|
62848359|NCT03497351|EXPERIMENTAL|Group N|the group treated with nicardipine
62848360|NCT03497351|EXPERIMENTAL|Group U|the group treated with Urapidil
62848361|NCT00648960|EXPERIMENTAL|1|
62848362|NCT00648960|ACTIVE_COMPARATOR|2|
62848363|NCT05731349|EXPERIMENTAL|NEWS-1 care|During the interventional period, the 2018 Sepsis Hour-1 Bundle will be initiated in the ED if NEWS2 score ≥ 5.
62848364|NCT05731349|NO_INTERVENTION|Standard care|During the standard care period, emergency physicians will assess the patients based on history, physical examination, laboratory tests, chest radiography or other imaging studies, and will offer treatment based on clinical expertise, intuition, and local or international guidelines
62848365|NCT05161364||A: PFA|partial foot amputation secondary to peripheral neuropathy
62265240|NCT02554123|PLACEBO_COMPARATOR|Vaseline ointment|Vaseline ointment application. Every 12 hours during 7 days.
62622358|NCT05576961|EXPERIMENTAL|high dose of RX-af01|5 times dose of RX-af01 in combination with toripalimab
62622359|NCT05576961|EXPERIMENTAL|Mixed bacteria|Mixed bacteria in combination with toripalimab
62848366|NCT05161364||B: PN|peripheral neuropathy
62848367|NCT06218498|EXPERIMENTAL|ablative fractional 2940-nm erbium yttrium aluminum garnet (Er: YAG) laser|
62848368|NCT06218498|EXPERIMENTAL|non-ablative fractional 1565nm|
62848369|NCT06218498|ACTIVE_COMPARATOR|5% minoxidil|
62265241|NCT00948571||head down, laparoscopic|20 patients with laparoscopic surgery (radical robotic prostatectomy) in head down position
62265242|NCT00948571||head down, open|"20 patients undergoing opensurgery (open radical prostatectomy) in head down position."
62265243|NCT00948571||horizontal, open|"20 patients undergoing open surgery in horizontal position (open hemicolectomy)"
62265244|NCT00779649|ACTIVE_COMPARATOR|MoviPrep|
62265245|NCT00779649|ACTIVE_COMPARATOR|HalfLytely|
62448939|NCT01334788|EXPERIMENTAL|sleep deprivation|These are subjects who are randomized to undergo sleep deprivation.
62061255|NCT02000739|OTHER|Genetically Informed Therapy|"The treatment participants get will depend on the results of the DNA sequencing and the availability of targeted therapies that match the genetic profile of the tumor identified by the DNA sequencing.~If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant."
62061256|NCT03323580|EXPERIMENTAL|GDFT group|The patients will receive fluid therapy under goal directed.
62061257|NCT03323580|SHAM_COMPARATOR|Routine group|The patients will receive routine fluid therapy.
62265246|NCT03924609||Bone metastasis screening|The information about bone metastasis screening is retrospectively collected.
62265247|NCT04324359|EXPERIMENTAL|SURF-201|0.2% topical preservative-free corticosteroid solution (0.2% betamethasone sodium phosphate)
62622360|NCT04598295|EXPERIMENTAL|microbial consortia (DS-01)|DS-01 is a rationally defined microbial consortia consisting of 24 strains across 12 species, with polyphenolic and phenolic prebiotic bioactive compounds. Participants will be instructed to take 2 capsules daily for the duration of the trial.
62061258|NCT05159401|EXPERIMENTAL|"the first group: the method of vibroacoustic lung massage using the BARK VibroLUNG device"|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
62265248|NCT04324359|PLACEBO_COMPARATOR|Vehicle|Topical preservative-free vehicle (Placebo)
62265249|NCT00853671|EXPERIMENTAL|Adenosine Stress Dual-source CTP|A multiphase adenosine Stress Dual-source stress perfusion computed tomography imaging test, as described above, will be performed in all patients.
62265250|NCT01725555|EXPERIMENTAL|Fasted treatment|
62265251|NCT01725555|EXPERIMENTAL|Fed treatment|
62265252|NCT03563378|EXPERIMENTAL|Lactated ringers solution|Participants in this group will receive Lactated Ringer's solution during the intraoperative period.
62265253|NCT03563378|EXPERIMENTAL|Normal saline solution|Participants in this group will receive Normal saline solution during the intraoperative period.
62265254|NCT05177120||FMF patients|Patients with diagnosed FMF
62265255|NCT03129321|EXPERIMENTAL|Test|Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
62265256|NCT03129321|ACTIVE_COMPARATOR|Reference Standard|Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
62265257|NCT03129321|PLACEBO_COMPARATOR|Placebo|Placebo Cream, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
62848370|NCT02529553|EXPERIMENTAL|LY3076226|"Part A (dose escalation in advanced cancer): LY3076226 administered intravenously (IV) on day 1 of each 21 day cycle.~Part B (dose expansion in advanced urothelial carcinoma): LY3076226 administered IV on day 1 of each 21 day cycle."
62265258|NCT02882659|EXPERIMENTAL|Dendritic Killer Cell (DKC)|All enrolled patients received one treatment cycle of DKC cell therapy, which consists of 5 infusion cycles approximately 23 days apart. There were 3 dose levels: 5 x 10\^6, 1 x 10\^7, and 5 x 10\^7 cells, and the protocol followed a traditional 3+3 dose escalation design.
62848371|NCT04424953|ACTIVE_COMPARATOR|McGrath videolaryngoscope|Anesthetists randomized to this group will intubate patients using the McGrath videolaryngoscope
62848372|NCT04424953|ACTIVE_COMPARATOR|Direct laryngoscope|Anesthetists randomized to this group will intubate patients using the direct laryngoscope
62848373|NCT04264624|EXPERIMENTAL|Guided Biofilm Therapy with Perioflow|The entire mouth will be treated (supra-/subgingival) in a single session. If the patient has been identified to receive the adjunctive treatment, he/she will also receive subgingival biofilm removal with Perioflow combined with Erythritol powder at sites with PD≥ 5 mm, including the experimental sites, prior to subgingival biofilm removal with USD.
62848374|NCT04264624|ACTIVE_COMPARATOR|Guided Biofilm Therapy without Perioflow|The entire mouth will be treated (supra-/subgingival) in a single session. If the patient has been identified to receive the control treatment, all teeth present will receive the application of disclosing agent, full-mouth supragingival and intra-sulcular biofilm removal with Airflow at sites with PD up to 4 mm, full mouth supra gingival calculus removal with USD, and subgingival biofilm removal with USD at sites with PD\> 4 mm, including the experimental sites, as required.
62848375|NCT02609867|EXPERIMENTAL|Flowise Cerebral Flow Diverter|Flowise Cerebral Flow Diverter (TaeWoong Medical Co., Ltd. Korea)
62848376|NCT00133003|ACTIVE_COMPARATOR|1|
62848377|NCT00133003|PLACEBO_COMPARATOR|2|
62622361|NCT04598295|PLACEBO_COMPARATOR|placebo|Placebo capsules for DS-01 will contain rice flour matched for color and texture in an identical outer capsule shell. Participants will be instructed to take 2 capsules daily for the duration of the trial.
62622362|NCT06223308|EXPERIMENTAL|HB0028|HB0028 IV every 3 weeks (q3w)
62848378|NCT00880971|EXPERIMENTAL|PORT|Patients undergo thoracic radiotherapy using 3D-CRT or IMRT (50 Gy, 2 Gy once daily over 5 weeks) after postoperative chemotherapy.
62848379|NCT00880971|NO_INTERVENTION|Non-PORT|Patients undergo postoperative chemotherapy.
62848380|NCT02082756|EXPERIMENTAL|Bifidobacterium viable pharmaceutics|Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks
62848381|NCT02082756|EXPERIMENTAL|Berberine Hydrochloride|Berberine Hydrochloride, 0.5g, 2/day, 12 weeks
62848382|NCT02082756|NO_INTERVENTION|lifestyle counseling|
62848383|NCT04530136|EXPERIMENTAL|Ruconest|Patients receive (150 U/ml) of Ruconest at a 50 U/kg dose (max dose of 4200 U) as a slow intravenous injection via a peripheral every 12 hours; for 4 days. A total of 8 doses will be administered.
62848384|NCT04530136|OTHER|Standard of Care|SOC
62848385|NCT01671878|OTHER|Reference Glucose|Glucose standard
62265259|NCT02279680|OTHER|Patients|Adults between 18 and 30 years old right handing Patients with ASD
62265260|NCT02279680|OTHER|Healthy volunteers|Adults between 18 and 30 years old Right handing Healthy
62265261|NCT02941627|EXPERIMENTAL|Neuro Cochlear Implant System study group|All patients will receive a Neuro Zti implant and fitted with Neuro One sound processor
62448940|NCT01334788|OTHER|Normal sleep|These are subjects who are randomized to sleep normally.
62622363|NCT01744158||Children with cerebral palsy|No intervention applicable
62848386|NCT01671878|EXPERIMENTAL|Test Food 1|Cereal
62848387|NCT01671878|EXPERIMENTAL|Test Food 2|Biscuit
62848388|NCT01146587|EXPERIMENTAL|GangTrainer GT1|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo robotic treatment with the Gangtrainer GT1 for 30 minutes of gross therapy time every workday for a 8 weeks period
62848389|NCT01146587|EXPERIMENTAL|Lokomat|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo robotic treatment with the Lokomat for 30 minutes of gross therapy time every workday for a 8 weeks period
62622364|NCT03131687|PLACEBO_COMPARATOR|Placebo|Tirzepatide placebo and dulaglutide placebo administered subcutaneously (SC) once weekly.
62622365|NCT03131687|EXPERIMENTAL|1 mg Tirzepatide|1 milligrams (mg) tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
62848390|NCT01146587|ACTIVE_COMPARATOR|Conventional Physiotherapy|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo a conventional physiokinetherapeutic treatment session for 30 minutes of gross therapy time every workday for a 8 weeks period
62848391|NCT00234754|ACTIVE_COMPARATOR|1|Trans-vaginal tape Surgery
62848392|NCT00234754|EXPERIMENTAL|2|Trans-obturator tape surgery
62848393|NCT02616588|EXPERIMENTAL|Intervention Arm|All participants are enrolled into the intervention arm and receive the Veteran Patient Navigator and Social Work Intervention.
62848394|NCT04744987||Hypovolemic hyponatremia|Patients with any cause of hypovolemic hyponatremia were included.
62265262|NCT04457804|EXPERIMENTAL|Online ACT workshop for Emotional Eating|All participants will be assigned to 2, 1.5 hour interventions using Acceptance and Commitment Therapy (ACT) techniques to help reduce emotional eating.
62848395|NCT04744987||Euvolemic hyponatremia|Only patients with euvolemic hyponatremia secondary to Syndrome of inappropriate antidiuresis were included.
62848396|NCT05650359|EXPERIMENTAL|OrthoPulse|The study population includes a total of 41 patients (based on our sample size calculation), with 21 patients in group 1 and 21 patients in group 2. Eligible study participants are men and women over the age of 18 with permanent dentition who require orthodontic treatment.
62848397|NCT05650359|ACTIVE_COMPARATOR|Control|The study population includes a total of 41 patients (based on our sample size calculation), with 21 patients in group 1 and 21 patients in group 2. Eligible study participants are men and women over the age of 18 with permanent dentition who require orthodontic treatment.
62848398|NCT01076439|ACTIVE_COMPARATOR|Olopatadine Nasal Spray (Patanase)|
62848399|NCT01076439|ACTIVE_COMPARATOR|Fluticasone Furoate Nasal Spray (Veramyst)|
62848400|NCT01076439|PLACEBO_COMPARATOR|Saline Nasal Spray (Placebo)|
62848401|NCT00708487|EXPERIMENTAL|1|5% oxygen embryo culture condition
62848402|NCT00708487|ACTIVE_COMPARATOR|2|21% oxygen embryo culture condition
62622366|NCT03131687|EXPERIMENTAL|5 mg Tirzepatide|5 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
62622367|NCT03131687|EXPERIMENTAL|10 mg Tirzepatide|10 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
62848403|NCT02591498|ACTIVE_COMPARATOR|Auditory|Administration of 40 hours of auditory training exercises
62265263|NCT02215356|ACTIVE_COMPARATOR|Chemoradiotherapy|Etoposide 50mg/m2, ivgtt, d1-d5, cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles, while chest radiotherapy (total dose 60-66Gy, 2Gy per time, once a day, five times a week, a total of 30-33 times). Progressive patients will be administered oral icotinib 125 mg three times daily.
62622368|NCT03131687|EXPERIMENTAL|15 mg Tirzepatide|15 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
62622369|NCT03131687|ACTIVE_COMPARATOR|1.5 mg Dulaglutide|1.5 mg Dulaglutide administered SC once weekly. Tirzepatide placebo administered SC once weekly.
62622370|NCT02215889|EXPERIMENTAL|Surgery|
62848404|NCT02591498|ACTIVE_COMPARATOR|Visual|Administration of 40 hours of visual training exercises
62848405|NCT02591498|PLACEBO_COMPARATOR|Video Games|Administration of 40 hours of commercial video games
62848406|NCT01516034|EXPERIMENTAL|Treatment|Cupola Tattoo Removal Device
62848407|NCT03841630|EXPERIMENTAL|LY3437943|Escalating doses of LY3437943 administered as an injection under the skin in healthy participants
62848408|NCT03841630|PLACEBO_COMPARATOR|Placebo|Matching placebo administered as an injection under the skin in healthy participants
62448941|NCT00672854|ACTIVE_COMPARATOR|Intralipid 20% Intravenous Emulsion|Subjects who require Total Parenteral Nutrition TPN receiving Intralipid 20% (soybean-based)
62622371|NCT03668340|EXPERIMENTAL|Part A: AZD1775|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
62622372|NCT03668340|EXPERIMENTAL|Part B: AZD1775 in Carcinosarcoma|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
62622373|NCT03668340|EXPERIMENTAL|Part C: AZD1775 in Uterine Serous with biopsiable disease|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
62622374|NCT01290575|ACTIVE_COMPARATOR|Arm 1 BMS-820132 or placebo|
62622375|NCT01290575|ACTIVE_COMPARATOR|Arm 2 BMS-820132 or placebo|
62622376|NCT01290575|ACTIVE_COMPARATOR|Arm 3 BMS-820132 or placebo|
62622377|NCT01290575|ACTIVE_COMPARATOR|Arm 4 BMS-820132 or placebo|
62622378|NCT01290575|ACTIVE_COMPARATOR|Arm 5 BMS-820132 or placebo|
62848409|NCT03948945|NO_INTERVENTION|before treatment|The patient with facial and neck photoaging did not receive laser treatment.
62848410|NCT03948945|EXPERIMENTAL|after treatment|The patient with facial and neck photoaging received Profile HaloTM mixed fractional laser treatment
62848411|NCT00811096|EXPERIMENTAL|Treatment Arm|
62848412|NCT00811096|ACTIVE_COMPARATOR|Comparator Arm|Comparator Arm
62848413|NCT06279208||Children with Down Syndrome|30 boys with Down Syndrome, between 6 and 12 years old, coming for a routine car consultation during which blood sampling is scheduled (6 different care dedicated centers).
62848414|NCT06279208||Children without genetic abnormality|30 boys without genetic abnormality, between 6 and 12 years old, coming to an analysis laboratory for a blood test (3 different laboratories)
62265264|NCT02215356|EXPERIMENTAL|Icotinib with concurrent radiotherapy|Chest radiotherapy (total dose 60-66Gy, 2Gy per time, once a day, five times a week, a total of 30-33 times), while icotinib 125mg three times daily (375 mg per day) by mouth. Maintenance icotinib will be administered after radiotherapy. Progressive patients will receive chemotherapy, using the platinum-based two-drug chemotherapy regimen.
62265265|NCT02829840|EXPERIMENTAL|Cohort #1|"Cohort #1: Participants with no previous leukemia therapy (including no previous FLT3 inhibitor therapy) for either: a) front-line treatment of elderly (age 65 and greater) FLT3-mutated AML patients, or b) patients unable or unwilling to receive standard intensive therapy.~Part 1: Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant continues on to Part 2 of study.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
62265266|NCT02829840|EXPERIMENTAL|Cohort #2|"Cohort #2: Participants with relapsed/refractory FLT3-mutated AML that have not received prior FLT3 inhibitor therapy.~Part 1: Participants receive Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant continues on to Part 2 of study.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
62448942|NCT00672854|EXPERIMENTAL|ClinOleic 20% Intravenous Emulsion|Subjects who require Total Parenteral Nutrition TPN receiving ClinOleic 20% (olive oil based)
62448943|NCT02010047|EXPERIMENTAL|IHC, FISH and qPCR ALK assays|ALK testing by IHC and FISH will be compared to ALK qPCR testing on NSCLC FFPE tissue.
62622379|NCT01290575|ACTIVE_COMPARATOR|Arm 6 BMS-820132 or placebo|
62622380|NCT01290575|ACTIVE_COMPARATOR|Arm 7 BMS-820132 or placebo|
62622381|NCT01290575|ACTIVE_COMPARATOR|Arm 8 BMS-820132 or placebo|
62622382|NCT01290575|ACTIVE_COMPARATOR|Arm 9 BMS-820132 or placebo|
62622383|NCT02561546|EXPERIMENTAL|TAE plus p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
62622384|NCT02561546|ACTIVE_COMPARATOR|Trans-catheter embolization|Trans-catheter embolization (TAE) will be given once per month
62622385|NCT06121531|ACTIVE_COMPARATOR|Group I|Si-Hy (Samfilcon A)
62622386|NCT06121531|EXPERIMENTAL|Group II|Si-Hy (Otufilcon A)
62622387|NCT04297696|EXPERIMENTAL|exercise group|therapeutic exercises
62622388|NCT04297696|NO_INTERVENTION|control group|
62622389|NCT06435039|EXPERIMENTAL|Cohort 1, Sequence 1, R1T1: APL-1202 IR 375 mg + APL-1501 ER 764 mg|Participants will receive APL-1202 375 milligram (mg) IR tablets, orally, once on Day 1 of Period 1 (Treatment R1), followed by T1 APL-1501 764 mg ER capsules, orally, once, on Day 4 of Period 2 (Treatment T1). A washout period of more than or equal to (\>=) 72 hours will be maintained in between Period 1 and 2.
62622390|NCT06435039|EXPERIMENTAL|Cohort 1, Sequence 2, T1R1: APL-1501 ER 764 mg + APL-1202 IR 375 mg|Participants will receive APL-1501 764 mg ER capsules, orally, once on Day 1 of Period 1 (Treatment T1), followed by APL-1202 375 mg IR tablets, orally, once, on Day 4 of Period 2 (Treatment R1). A washout period of \>=72 hours will be maintained in between Period 1 and 2.
62622391|NCT06435039|EXPERIMENTAL|Cohort 2, Sequence 1, R1T2: APL-1202 IR 375 mg + APL-1501 ER 1146 mg|Participants will receive APL-1202 375 mg IR tablets, orally, once on Day 1 of Period 1 (Treatment R1), followed by APL-1501 1146 mg ER capsules, orally, once, on Day 4 of Period 2 (Treatment T2). A washout period of \>=72 hours will be maintained in between Period 1 and 2.
62622392|NCT06435039|EXPERIMENTAL|Cohort 2, Sequence 2, T2R1: APL-1501 ER 1146 mg + APL-1202 IR 375 mg|Participants will receive APL-1501 1146 mg ER capsules, orally, once on Day 1 of Period 1 (Treatment T2), followed by APL-1202 375 mg IR tablets, orally, once, on Day 4 of Period 2 (Treatment R1). A washout period of \>=72 hours will be maintained in between Period 1 and 2.
62622393|NCT06435039|EXPERIMENTAL|Cohort 3: APL-1501 ER 1528 mg|Participants will receive APL-1501 1528 mg ER capsules, orally, once on Day 1.
62622394|NCT02983175|EXPERIMENTAL|ultrasound assessment of gastric content|
62622395|NCT03862872|EXPERIMENTAL|Anti-Aging Formula|4 capsules daily of high-EPA fish oil, borage oil, zeaxanthin, lutein and vitamin D providing 1050 mg of Eicosapentaenoic acid (EPA) and 350 mg of Docosahexaenoic acid (DHA), 120 mg of Gamma-linolenic acid (GLA), 2.5 mg of zeaxanthin, 5 mg of lutein and 25 μg (1000 IU) of vitamin D3 for 90 days.
62622396|NCT03862872|ACTIVE_COMPARATOR|Control Fish Oil|4 capsules daily of 1,106 mg each of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil providing 816 mg EPA and 572 mg DHA total for 90 days.
62622397|NCT03862872|PLACEBO_COMPARATOR|Inert Placebo|4 capsules daily of 1040 mg each of corn oil for 90 days.
62622398|NCT00574093|EXPERIMENTAL|A|A: This will be a single arm study. Patients will be administered Lucentis™ on Day 1,at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
62061259|NCT05159401|EXPERIMENTAL|the second group:the method of oscillating REР therapy using Acapella DH Green|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
62061260|NCT05159401|EXPERIMENTAL|the third group:the method of hardware stimulation of cough (Comfortable cough Plus)|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
62622399|NCT05406271|EXPERIMENTAL|Hip Prosthesis with intraoperative fluoroscopy|
62622400|NCT05406271|NO_INTERVENTION|Hip Prosthesis without intraoperative fluoroscopy|
62622401|NCT00622583||Observation Group|Subjects who meet the inclusion/exclusion criteria who have had a hernia repair.
62848415|NCT01919281|EXPERIMENTAL|strength training|The subjects will attend for supervised training three sessions per week for 10 weeks (9-12). The strength training program involves dynamic contraction at intensities of 60 - 70 % of 1 repetition maximum (RM) to improve strength and muscle hypertrophy. Each session will contain 8 exercises on the major muscle groups. Each drill consists of 10-12 repetitions (reps) x 3 sets separated by one minute rest between sets.
62848416|NCT01919281|EXPERIMENTAL|interval training|"High intensity interval training (HIT) three times per week. The three weekly supervised HIT sessions will include two 4x4 min interval sessions and one 10x1 min session. The HIT consist of uphill treadmill running/walking."
62622402|NCT06341062||Patients recovering before hospital discharge|Recovery is defined as a return to normal serum creatinine and urine volume or more than 50% improvement in serum creatinine and/or urine volume from baseline
62848417|NCT01919281|NO_INTERVENTION|control|Based on the Norwegian recommendation we will encourage the control group to perform 60 minutes of physical activity at moderate to high intensity on a daily basis.
62448944|NCT06179966|EXPERIMENTAL|Dance group|The application will be taught to the participants' spouses by the researcher after they are admitted to labor, and the spouses will be asked to do it to the participants at regular intervals.
62448945|NCT06179966|EXPERIMENTAL|Massage group|After admission to travaya, the researcher will teach the pregnant woman's husband practically and the spouses will massage the participants' backs at certain intervals.
62622403|NCT06341062||Patients not recovering before hospital discharge|Non-recovery is defined as no significant improvement or further increase in serum creatinine and/or urine volume, the need for dialysis, or death.
62622404|NCT01677182|EXPERIMENTAL|Ramelteon SL (Dose 1)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 6 weeks.
62622405|NCT01677182|EXPERIMENTAL|Ramelteon (Dose 2)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 6 weeks.
62622406|NCT01677182|PLACEBO_COMPARATOR|Placebo|Ramelteon SL placebo-matching tablets, sublingual, once daily, at night time for up to 6 weeks.
62622407|NCT02640898|ACTIVE_COMPARATOR|FU-based chemoradiotherapy|patients will be treated with the INT0116 regimen.
62622408|NCT02640898|EXPERIMENTAL|docetaxel-based chemoradiotherapy|patients will be treated with modified DCF chemotherapy in combination with docetaxel-based chemoradiotherapy.
62622409|NCT03278236|EXPERIMENTAL|TRF|
62622410|NCT05253144|EXPERIMENTAL|Arm A: Prioritise Radiotherapy|Radical radiotherapy to macroscopic tumour and/or to the tumour bed if already excised, plus a wide margin.
62622411|NCT05253144|EXPERIMENTAL|Arm B: Prioritise Surgery|Wide Local Excision (WLE), aiming for complete excision of all MCC, plus a wide margin
62622412|NCT00003832|EXPERIMENTAL|Treatment (bromodeoxyuridine)|Patients receive broxuridine IV over 30 minutes on day -1. Approximately 12-96 hours later, patients undergo surgery to remove the prostate.Tumor tissue is examined by immunostaining for the presence of broxuridine to determine doubling times of the tumor.
62848418|NCT05870696||negative|normal:no findings on colonoscopy hyperplastic polyps: inflammatory or hyperplastic polyps low-risk adenoma:1 or 2 adenoma(s), ≤10 mm in size, non-advanced
62848419|NCT05870696||Positive|"advanced adenoma Advance adenoma, including the following subcategories:~* Adenoma with carcinoma in situ/high grade dysplasia, any size~* Adenoma, villous growth pattern (\>25%), any size~* Adenoma \> 1.0 cm in size~* Serrated lesion, \> 1.0 cm in size early stage CRC: CRC stage I advanced stage CRC: CRC stage II-IV"
62848420|NCT01974063||A. Nonsmokers|Subjects have smoked \<100 cigarettes or \<10 shisha pipes per lifetime and whose urine nicotine \<2 ng/mL and/or urine cotinine \<5 ng/mL, at entry into the study.
62848421|NCT01974063||B.Current cigarette smokers|Defined by self-report and urine nicotine \>30 ng/mL and/or urine cotinine \>50 ng/ml.
62848422|NCT01974063||C. Current shisha smokers|Defined by self-report of smoking \>4 pipes/wk and carboxyhemoglobin \>2.5.
62061261|NCT05159401|EXPERIMENTAL|the fourth group:classical manual chest massage with percussion|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
62061262|NCT06439940||Women aged 50 to 70 who attend the gynecological annual check-up|
62448946|NCT06179966|NO_INTERVENTION|Control Group|Routine midwifery care will be provided, and no applications other than routine midwifery care will be performed.
62622413|NCT01679028|PLACEBO_COMPARATOR|Placebo Group A|150mg Placebo Single dose
62622414|NCT01679028|EXPERIMENTAL|T89 Group A|150mg T89 single dose
62622415|NCT01679028|PLACEBO_COMPARATOR|Placebo Group B|300mg placebo single dose
62622416|NCT01679028|EXPERIMENTAL|T89 Group B|300mg T89 single dose
62622417|NCT01679028|PLACEBO_COMPARATOR|Placebo Group C|225mg Placebo bid for 14 days
62622418|NCT01679028|EXPERIMENTAL|T89 Group C|225mg T89 bid for 14 days
62848423|NCT01974063||D. smokers willing to quit|Defined by self-report and urine nicotine \>30 ng/ml and/or urine cotinine \>50 ng/ml. Subjects must be a current smoker willing to stop smoking. Subjects will stop smoking after the baseline bronchoscopy, and switch to taking a smoking cessation medication called varenicline. We will provide subjects with the smoking cessation medication as part of this study. They will also receive phone calls to help with smoking cessation counseling.
62848424|NCT01974063||E. Smokers switching to E-cigarettes|Defined by self-report and urine nicotine \>30 ng/ml and/or urine cotinine \>50 ng/ml. Must be willing to switch from tobacco cigarettes to electronic cigarettes. The switch will occur after the baseline bronchoscopy. The nicotine dose that will be given to each subject will be determined by the study physician based on the urine smoking metabolite test. It will be adjusted depending on whether the subject is a light smoker or heavy smoker (Light smoker defined as having either a urine nicotine value from 2ng/ml-1000ng/ml or a urine cotinine value from 5ng/ml-1000ng/ml. Heavy smoker is defined as having either a urine nicotine or cotinine value of over 1000ng/ml.) We will provide the subjects with the electronic cigarettes to use as part of this study.
62848425|NCT04039009||Infertility patients|Infertility patients will be examined according to the pelvic organ prolapse quantification classification system during hysteroscopy.
62848426|NCT03195309|ACTIVE_COMPARATOR|Group A|Group A patients received 0.08% ropivacaine plus 4 mcg /mL fentanyl
62848427|NCT03195309|ACTIVE_COMPARATOR|Group B|Group B patients received 0.08% ropivacaine plus 2mcg /mL fentanyl
62848428|NCT03195309|ACTIVE_COMPARATOR|Group C|Group C patients received 0.16 % ropivacaine plus 2 mcg /mL fentanyl
62848429|NCT03535727|EXPERIMENTAL|Phase 1, Cohort 1, Dose level 1|"Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Nab-paclitaxel: 40 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle~Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle~Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle"
62848430|NCT03535727|EXPERIMENTAL|Phase 1, Cohort 1, Dose level 2|"Gemcitabine 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Nab-paclitaxel 60 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Capecitabine: 500 mg BID: PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle~Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle~Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle"
62848431|NCT03535727|EXPERIMENTAL|Phase 1, Cohort 1, Dose level 3|"Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Nab-paclitaxel: 80 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle~Cisplatin 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle~Irinotecan:20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle"
62848432|NCT03535727|EXPERIMENTAL|Phase 1, Cohort 1, Dose level 4|"Gemcitabine:500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Nab-paclitaxel:100 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Capecitabine:500 PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle~Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle~Irinotecan:20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle"
62622419|NCT01913522|EXPERIMENTAL|Standard cryoablation|"Patients randomized to the standard group will undergo cryoablation with target duration of 240 seconds. Once PVI is achieved a single bonus application of 240 seconds will be delivered after the rewarming phase (to +20oC)."
62061263|NCT02629835|ACTIVE_COMPARATOR|Intravenous dexamethasone 8 mg|patients receiving intravenous 8 mg of dexamethasone in parallel to ultrasound guided axillary nerve block with a standardized local anesthetic solution
62265267|NCT02829840|EXPERIMENTAL|Cohort #3|"Cohort #3: Participants with relapsed/refractory FLT3-mutated AML, that have received previous FLT3 inhibitor therapy (including, but not limited to, quizartinib, crenolanib, sorafenib, other FLT3 inhibitors).~Part 1: Participants receive Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant will continue on to Part 2 of study.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
62622420|NCT01913522|ACTIVE_COMPARATOR|Irrigated RF Ablation|Patients randomized to irrigated RF group will undergo standard wide circumferential PVI with an irrigated radiofrequency catheter
62622421|NCT01913522|EXPERIMENTAL|Short Cryoablation|"Patients randomized to the multiple-freeze group will undergo cryoablation with target duration of 120 seconds. Once PVI is achieved a single bonus application of 120 seconds will be delivered after the rewarming phase (to +20oC)."
62622422|NCT03895450|EXPERIMENTAL|Aerobic Exercise Protocol (AEP)|Symptom threshold will be determined at baseline and repeated every 3 weeks using the Buffalo Concussion Treadmill Test. Briefly, there will be an initial 4min warm up at 1.7mph. The protocol will start with treadmill speed se to 3.3 mph and 0.0% incline. Each subsequent minute, the incline will increase by 1.0% to a max of 15%. At 15% grade, if the participant is still able to continue, treadmill speed will increase by 0.4mph each minute. Heart rate (HR) and rating of perceived excretion (RPE Borg scale) will be measured every minute. The test will be terminated upon symptom exacerbation at which time HR and RPE will be recorded. Every 3 weeks the symptom threshold test will be repeated for all participants and exercise prescription will be adjusted accordingly.
62622423|NCT03895450|PLACEBO_COMPARATOR|Stretching Protocol (SP)|The exercise testing for the stretching protocol to determine exercise prescription will be the same as described above.
62623792|NCT02370056|ACTIVE_COMPARATOR|2D Visualization|"2-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using conventional Laparoscopic Surgical Video System.~This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons and outcomes will be evaluated."
62265268|NCT05533983|EXPERIMENTAL|Preparation of Frozen Stool Suspensions for FMT|The study will enroll patients with advanced, unresectable, or metastatic solid cancer who have progressed during anti-PD-(L)1 therapy.
62848433|NCT03535727|EXPERIMENTAL|Phase 1, Cohort 1, Dose level 5|"Gemcitabine:500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Nab-paclitaxel:125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle~Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle~Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle"
62848434|NCT03535727|EXPERIMENTAL|Phase 1, Cohort 2, Dose level 1|"Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle~Nab-paclitaxel:40 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle~Capecitabine:500 mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle~Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle~Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle"
62848435|NCT03535727|EXPERIMENTAL|Phase 1, Cohort 2, Dose level 2|"Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle~Nab-paclitaxel:60 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle~Capecitabine:500mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle~Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle~Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle"
62848436|NCT03535727|EXPERIMENTAL|Phase 1, Cohort 2, Dose level 3|"Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle~Nab-paclitaxel:80 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle~Capecitabine:500mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle~Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle~Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle"
62848437|NCT03535727|EXPERIMENTAL|Phase 2 Dose Expansion (Cohort 1, DL5)|"Gemcitabine:500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Nab-paclitaxel:125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle~Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle~Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle"
62848438|NCT01629446|EXPERIMENTAL|Lofexidine HCl with 14C tracer|
62061264|NCT02629835|ACTIVE_COMPARATOR|Perineural dexamethasone 8 mg|patient receiving perineural 8 mg of dexamethasone in a mixture with a standardized local anesthetic solution for ultrasound guided axillary block
62061265|NCT02150200|OTHER|A group : Conventional hospitalization|Patients discharged after 3 days hospital stay after laparoscopic hysterectomy
62265269|NCT06235073||Manual implantation|
62622424|NCT03412292|EXPERIMENTAL|MAX-40279|"MAX-40279 is provided as a capsule for oral use at 5mg, 25mg. In the dose-escalation phase, patients will be enrolled sequentially into the 5 dose levels of MAX-40279 designated in this study: 20, 40, 70, 100 and 120 mg/day (3-6 patients per cohort),bid.For each dose level, a single dose of MAX-40279 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle).~After completion of the dose escalation, additional patients will be enrolled into dose expansion at the Maximum tolerated dose(MTD), up to 12 patients will be enrolled into expansion cohorts."
62061266|NCT02150200|EXPERIMENTAL|B group : shorter stay|Patients going home within 24 hours discharged the first day after laparoscopic hysterectomy.
62061267|NCT02729935|EXPERIMENTAL|Parecoxib|40 mg of intravenous parecoxib (DYNASTAT )30 min before surgery
62061268|NCT02729935|PLACEBO_COMPARATOR|Placebo|An equal volume of saline
62622425|NCT02961387|EXPERIMENTAL|Hydrogen generator treatment|Inhalation of hydrogen-oxygen mixed gas.
62622426|NCT02961387|SHAM_COMPARATOR|Oxygen-making machine treatment|Inhalation of oxygen.
62622427|NCT05699525|EXPERIMENTAL|Personalized|Participants receive the personalized Maya app intervention for 6 weeks
62622428|NCT05699525|ACTIVE_COMPARATOR|General Non-Personalized|Participants receive the general MAYA app intervention for 6 weeks
62848439|NCT05311878|EXPERIMENTAL|EEG based perceptual training|Subjects complete a perceptual learning task in which EEG-based visual feedback is provided
62848440|NCT05311878|ACTIVE_COMPARATOR|Behavior based perceptual training|Subjects complete a perceptual learning task in which ground truth visual feedback is provided
62848441|NCT04994002|EXPERIMENTAL|Cohort 1: CERC-006 (0.5 mg)|Approximately 5 participants will receive CERC-006 at a dose of 0.5 mg twice daily for 28 days.
62848442|NCT04994002|EXPERIMENTAL|Cohort 2: CERC-006 (1 mg)|Following a safety review, if there are no clinically important safety findings in Cohort 1, a second cohort of approximately 5 participants will be enrolled to receive CERC-006 at a dose of 1 mg twice daily for 28 days.
62848443|NCT06320652|NO_INTERVENTION|Standard care|"All willing patients who are offered cardiac rehabilitation will comprise the control group. Patients in the control group will have access to standard care at the cardiac outpatient clinic program comprising standard center-based cardiac rehabilitation. The cardiac outpatient clinic registers activities and monitors patient participation in cardiac rehabilitation. Data on patient demographic, diagnoses, educational backgrounds, civil status, and patient-reported outcomes will be collected from self-reported questionnaires at baseline, and 3 months after.~The family members attendig the patients cardiac rehabilitation will recive a questionnaire on support fra the outpatient clinic nurses 3 months after the first consultation."
62061269|NCT00906048|EXPERIMENTAL|1|Levofloxacin and Rifampicin
62061270|NCT03771196|EXPERIMENTAL|Bioactive-Restorative material|Activa Bioactive-Restorative is an enhanced resin modified glass ionomer (RMGI) with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
62265270|NCT06235073||Robot assisted implantation|
62265271|NCT01916837||Single arm|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery.
62265272|NCT01308008|EXPERIMENTAL|Functional exercise- home physical activity|On-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with telephonic behavioral support
62265273|NCT01308008|ACTIVE_COMPARATOR|Flex and tone- home health education|Initial on-site flex and toning program continued on follow-up along with health education
62265274|NCT05779475||Participants with Parkinson's disease|Participants will not receive any investigational treatment in this study. The participants will be treated with anti-Parkinson's disease medication according to local standard of care.
62622429|NCT03521752|EXPERIMENTAL|Experimental|Performed a specific program exercises (resistance training, balance, coordination and flexibility) during 4 weeks.
62622430|NCT03521752|NO_INTERVENTION|Control|The control group wasn't subjected to any intervention
62622431|NCT00734461|PLACEBO_COMPARATOR|Placebo|Placebo, single dose
62622432|NCT00734461|ACTIVE_COMPARATOR|Oxycodone 20 mg|Oxycodone 20 mg single dose tablet
62622433|NCT00734461|ACTIVE_COMPARATOR|Oxycodone 40 mg|Oxycodone 40 mg single dose tablet
62848444|NCT06320652|EXPERIMENTAL|Cardiac Telerehabilitation|"Patients in the intervention group will, in addition to standard care, be offered an individually tailored family-focused cardiac telerehabilitation (video consultations and home monitoring) developed through a co-creative process.~The cardiac outpatient clinic registers activities and monitors patient participation in cardiac rehabilitation. Data on patient demographic, diagnoses, educational backgrounds, civil status, and patient-reported outcomes will be collected from self-reported questionnaires at baseline, and 3 months after the intervention.~The family members attendig the patients cardiac rehabilitation will recive a questionnaire on support fra the outpatient clinic nurses 3 months after the first consultation."
62848445|NCT04520646|EXPERIMENTAL|empagliflozin|empagliflozin is added on the basis of the original treatment
62265275|NCT03426085|PLACEBO_COMPARATOR|Placebo|Same formulation as active medication minus the active ingredient. Patients will start with 0.1 mL of liraglutide placebo and will escalate the dose every week in 0.1 ml increments until the 0.3 ml dose is reached. Escalation will be done according to patients' tolerance and glucose control
62265276|NCT03426085|EXPERIMENTAL|Liraglutide 6 mg Solution for Injection|After randomization, patients will undergo a treatment dose escalation phase. Liraglutide will be started at 0.6 mg SQ QD for 1 week, increased to 1.2 mg subcutaneous, per day (SQ, QD) for 1 week, and then increased and maintained on 1.8 mg SQ QD or maximally tolerated dose if self monitored blood glucose (SMBG) is at goal. Escalation will be done according to patients' tolerance and glucose control
62265277|NCT02270242|ACTIVE_COMPARATOR|Aspirin + Ticagrelor|enteric coated aspirin 81mg-100mg daily p.o. for 12 months and ticagrelor 90mg tablet bid for 12 months
62265278|NCT02270242|PLACEBO_COMPARATOR|Placebo + Ticagrelor|placebo pill daily p.o. for 12 months - match for enteric coated aspirin 81mg-100mg and ticagrelor 90mg tablet bid for 12 months
62265279|NCT03024489|EXPERIMENTAL|Palbociclib-Cetuximab-IMRT|"* IMRT will be administered 5 days on/2 days off with a total dose of 70 Gy for 33-35 fractions.~* Cetuximab will be administered 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.~* Palbociclib will be administered orally daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49) on 3 dose levels and the MTD."
62265280|NCT02616289|EXPERIMENTAL|Emollient|Topical emollient (Sun Flower seed oil) in addition to routine standard of care for severe acute malnutrition.
62265281|NCT02616289|NO_INTERVENTION|Control|Routine Standard of care only for severe acute malnutrition.
62265282|NCT04165707|EXPERIMENTAL|Keyto intervention arm|Keyto device + app
62622434|NCT00734461|EXPERIMENTAL|PTI-801 20/.001 mg|Oxycodone 20 mg / Naltrexone 0.001 mg
62622435|NCT00734461|EXPERIMENTAL|PTI-801 40/.001 mg|Oxycodone 40 mg / Naltrexone 0.001 mg
62622436|NCT00734461|EXPERIMENTAL|PTI-801 20/.0001 mg|Oxycodone 40 mg / Naltrexone 0.0001 mg
62622437|NCT00734461|EXPERIMENTAL|PTI-801 40/.0001 mg|Oxycodone 40 mg / Naltrexone 0.0001 mg
62622438|NCT00625183|EXPERIMENTAL|Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy|Oxaliplatin: 50 mg/m2 weekly x 5 Capecitabine 725 mg/m2BID on days of RT Selenomethionine: 4000mcg/m2 PO BID X 7 days prior to RT, then 4000mcg/m2 PO QD from first to last day of RT, including weekends
62622439|NCT02362191|EXPERIMENTAL|Single Session tACS Across Menstrual Cycle|Participants assigned to receive a single session of tACS during the follicular and luteal phase of their menstrual cycle.
62622440|NCT05867966|EXPERIMENTAL|Intervention group|These participants will benefit from an 8-week group intervention combining psychoeducation, self-care learning and hypnosis exercises.
62622441|NCT05867966|NO_INTERVENTION|Control group|These participants will not benefit from any intervention. After the end of the study, they will have the possibility to participate in the group intervention if they want to.
62622442|NCT02066727|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
62622443|NCT02066727|PLACEBO_COMPARATOR|Normal Saline|Normal Saline is administrated as an adjuvant of lidocaine.
62622444|NCT01900847|ACTIVE_COMPARATOR|Morphine and placebo|Patient's will receive morphine during the usual course of their emergency department care and will receive a saline in a volume equivalent to the ketamine administered in the experimental arm of the stuy
62622445|NCT01900847|EXPERIMENTAL|Morphine and Ketamine|Patient's will receive a 0.3mg/kg dose of ketamine in addition to morphine given in the usual course of emergency department care
62622446|NCT01739504|EXPERIMENTAL|Autologous Adipose-derived Stromal Vascular Fraction infusion|Intervention: AD-SVF infusion directly into affected joints.
62265283|NCT04165707|ACTIVE_COMPARATOR|Weight Watchers comparator arm|Weight Watchers app
62622447|NCT02020135|EXPERIMENTAL|Arm 1: PSMA ADC|Subjects started the extension study at the same dose received upon completion of the core PSMA ADC 2301 study. Each Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) dose was administered as an IV infusion over approximately 60 minutes once every three weeks (Q3W) for up to eight doses, unless a dose delay or dose reduction was required.
62622448|NCT06174194|EXPERIMENTAL|Tulsi Gum Arm|All participants were instructed to masticate gum containing Tulsi extract for a duration of 5 minutes and subsequently discard the gum. Salivary samples were collected before commencing gum chewing and after 30 minutes following the conclusion of chewing gum for 5 minutes.
62622449|NCT03584425|EXPERIMENTAL|Healthy Controls|Subjects will undergo the following diagnostic tasks and assessments: Rasch Modified Version of the Fugl-Meyer Motor Assessment, Anatomical Image Acquisition, and the Functional MRI Task and Acquisition
62622450|NCT03584425|EXPERIMENTAL|Stroke Participants|Subjects will undergo the following diagnostic tasks and assessments: Rasch Modified Version of the Fugl-Meyer Motor Assessment, Anatomical Image Acquisition, and the Functional MRI Task and Acquisition
62622451|NCT05848544|OTHER|Symptomatic knee osteoarthritis|obese patients with symptomatic knee osteoarthritis eligible to a very low calories ketogenic diet
62622452|NCT05848544|OTHER|obese patients with fibromyalgia|obese patients with with fibromyalgia eligible to a very low calories ketogenic diet
62622453|NCT03074461|EXPERIMENTAL|Side-to-End|Side-to-End Anastomosis as neorectal reconstruction technique in low anterior resection (LAR)
62622454|NCT03074461|ACTIVE_COMPARATOR|Transverse Coloplasty|Transverse Coloplasty pouch as neorectal reconstruction technique in low anterior resection (LAR)
62622455|NCT05059925|EXPERIMENTAL|Structured gym activities|Planned and structured activities such as Strength training for 4 weeks
62622456|NCT05059925|ACTIVE_COMPARATOR|Traditional aerobic activities|Activities performed such as Treadmill , Cycle ergometer , Elliptical exercises for 4 weeks
62622457|NCT00270621|EXPERIMENTAL|Treatment|FHP Night time Enuresis intervention
62622458|NCT00270621|NO_INTERVENTION|Control|To receive standard/usual care for Nocturnal Enuresis- No FHP Night time Enuresis INtervention
62622459|NCT02745938||Mitochondrial disease|Patients with mitochondrial disease, investigated by blood samples and exercise test.
62622460|NCT02745938||Metabolic myopathy|Patients with metabolic myopathy, investigated by blood samples and exercise test.
62622461|NCT02745938||Muscular dystrophy|Patients with muscular dystrophy, investigated by blood samples and exercise test.
62622462|NCT02745938||Healthy controls|Healthy controls, investigated by blood samples and exercise test.
62848446|NCT02560025|EXPERIMENTAL|Alisertib / MLN8237|"Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with 5+2 chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles."
62848447|NCT06017037|EXPERIMENTAL|Citalopram|Citalopram 20mg p.o. once daily for 7-9 days
62061271|NCT03771196|ACTIVE_COMPARATOR|Resin Modified Glass Ionomer (RMGI)|Fuji II Lc, fluoride-releasing restorative system that combines fluoride release of glass ionomer cement and acceptable esthetics a wear-resistant, self-adhesive, light-cured resin coating.
62265284|NCT06279767|EXPERIMENTAL|Treatment with a combination of 6-mercaptopurine and temozolomide|
62622463|NCT02963519|EXPERIMENTAL|VistaCare®|VistaCare® Medical device for treatment into an editable atmosphere
62622464|NCT02963519|ACTIVE_COMPARATOR|Dressings|Dressings Adapted to the case
62622465|NCT06128681||Mediastinal open group|Mediastinal opening technique was performed with intraairway ultrasound guidance
62622466|NCT06128681||Non-mediastinal open group|Diagnosis and treatment are routinely performed without any manipulation of the mediastinum
62622467|NCT00482482|EXPERIMENTAL|Yoga|Yoga was offered twice a week for 8 weeks, 1.5 hours per session
62622468|NCT00482482|ACTIVE_COMPARATOR|Psychoeducation|Psychoeducation was offered twice a week for 8 weeks, 1.5 hours per session
62622469|NCT00835523||OHSS risk|
62622470|NCT03253536||entire cohort|none (observational study)
62622471|NCT01599481|EXPERIMENTAL|Intervention|Standard Care (IAPT Therapy) + Individual Career Management (ICM)
62265285|NCT04247633|EXPERIMENTAL|palbociclib plus endocrine therapy treatement|"* Patients with Clinical high risk/Genomic High risk (in BCT score)-high and ER positive/HER2 negative EBC after Curative Surgery~* Palbociclib at a dose of 125mg, orally once daily on Day 1 to Day 21 followed by 7 days off in a 28-day cycle for a total duration of 2 years~* Standard adjuvant endocrine therapy for a duration of at least 5 years from the start of the treatment."
62265286|NCT04563494|ACTIVE_COMPARATOR|IV Dexmethsone and oral placebo|
62265287|NCT04563494|ACTIVE_COMPARATOR|Oral dexamethasone and IV placebo|
62622472|NCT01599481|ACTIVE_COMPARATOR|Control|Standard Care (IAPT Therapy)
62622473|NCT03627078|EXPERIMENTAL|Motor Interference Therapy|Initial interview applying the Spanish version of the PTSD Symptom Severity Scale-Revised (EGS-R), the visual analogue scale (EQ-VAS) from EuroQol 5D (EQ-5D), and a simple visual-analogue scale (VAS). After that, patients will listen to an audio track twice and follow the instructions. The first four minutes of the audio track instruct the subjects to tap their fingers in response to specific sounds. During the remaining ten minutes, the patients will be asked to recall a traumatic memory while simultaneously are tapping their fingers. Patients must complete at least 80% of the motor task in order to be included. We will reassess a week, a month and six months after the intervention, using all three scales.
62848448|NCT06017037|PLACEBO_COMPARATOR|Placebo|Lactose p.o. once daily for 7-9 days
62848449|NCT05744843|EXPERIMENTAL|Smartphone-based exercise arm|Eight to twelve week smartphone delivered exercise programme
62848450|NCT05744843|ACTIVE_COMPARATOR|Stenting Arm|Deep venous stenting as standard of care
62848451|NCT05744843|NO_INTERVENTION|Healthy Volunteers|Healthy Volunteers for baseline testing
62622474|NCT03627078|SHAM_COMPARATOR|Relaxation Exercise|Initial interview applying the Spanish version of the PTSD Symptom Severity Scale-Revised (EGS-R), the visual analogue scale (EQ-VAS) from EuroQol 5D (EQ-5D), and a simple visual-analogue scale (VAS). After that, patients will listen to an audio track twice and follow the instructions. The first four minutes of the audio track instruct the subjects in how to do the exercises. During the remaining 10 minutes will hear commands for performing progressive muscle tension-relaxation exercises while the patient evoked the traumatic memory. Patients must complete at least 80% of the motor task in order to be included. We will reassess a week, a month and six months after the intervention, using all three scales.
62848452|NCT00856518|ACTIVE_COMPARATOR|Arm 1: EMST|The experimental group receives five weeks of expiratory muscle strength training (EMST) using a positive pressure threshold device
62622475|NCT04551365|EXPERIMENTAL|Obese patients I|Undergoing lifestyle changes (rehabilitation) along daily intake of chitosan supplement, 4 capsules twice daily at main meals.
62848453|NCT00856518|SHAM_COMPARATOR|Arm 2: Sham group|The Sham group undergoes the same 5-week EMST exercise as the experimental group using the same device but without a spring for minimal pressure load
62848454|NCT00022646|EXPERIMENTAL|Arm I: pemetrexed + gemcitabine|Patients receive pemetrexed disodium IV over 10 minutes on day 1 followed by gemcitabine IV over 30 minutes on days 1 and 8.
62848455|NCT00022646|EXPERIMENTAL|Arm II: pemetrexed + gemcitabine|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 followed by pemetrexed disodium IV over 10 minutes on day 1.
62848456|NCT00022646|EXPERIMENTAL|Arm III: pemetrexed + gemcitabine|Patients receive gemcitabine IV over 30 minutes on day 1 and pemetrexed disodium IV over 10 minutes followed by gemcitabine IV over 30 minutes on day 8.
62848457|NCT01911962||transabdominal laparoscope surgery|transabdominal laparoscope surgery
62848458|NCT01911962||transvaginal laparoscopic surgery|transvaginal laparoscopic surgery
62848459|NCT01886989|EXPERIMENTAL|Cocoa|Cocoa polyphenols (960mg)
62848460|NCT01886989|PLACEBO_COMPARATOR|Placebo|Placebo powder (109mg polyphenols) in water
62848461|NCT05423561|OTHER|hypertrophic non-union developing after femoral transverse diaphyseal fractures|
62848462|NCT04781751|NO_INTERVENTION|dexamethasone|dexamethasone with local anesthetics injected for carpal tunnel relief
62848463|NCT04781751|ACTIVE_COMPARATOR|Insulin group|insulin with local anesthetics and dexamehtasone injected for carpal tunnel relief
62848464|NCT04332458|OTHER|Patients with stroke without exercise experience|Patients who are discharged from the hospital within one month after a minor stroke or TIA and are not offered physical rehabilitation afterwards
62848465|NCT04332458|OTHER|Patients with stroke with exercise experience|Patients with a minor stroke who have participated in an exercise study (HITPALS)
62848466|NCT03698591|EXPERIMENTAL|Transcranial magnetic stimulation (TMS), then Sham TMS.|Experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates. Experimenters have defined the target coordinates for stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task. Thirty minutes after stimulation, experimenters will employ a sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject.
62848467|NCT03698591|SHAM_COMPARATOR|Sham TMS, then Transcranial magnetic stimulation (TMS)|Experimenters will employ a sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject. Experimenters have defined the target coordinates for the stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task. Thirty minutes post sham stimulation, experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates.
62848468|NCT03325101|EXPERIMENTAL|Treatment (apheresis, pembrolizumab, cryosurgery, mDCs)|Patients undergo apheresis over 4 hours on day 1 or course 1. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses with pembrolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Within 36 hours after receiving pembrolizumab, patients undergo cryosurgery over 45 minutes on day 1 or 2 of courses 2 and 3. Patients also receive mature dendritic cells IT on day 1 or 2 of courses 2 and 3 after cryosurgery.
62848469|NCT01114399|EXPERIMENTAL|Standard Broccoli|Standard Broccoli
62848470|NCT01114399|EXPERIMENTAL|High Glucosinolate Broccoli|High Glucosinolate Broccoli
62848471|NCT01114399|EXPERIMENTAL|Peas|Peas
62848472|NCT01338298|ACTIVE_COMPARATOR|Aripiprazole|
62848473|NCT01338298|PLACEBO_COMPARATOR|Placebo|
62848474|NCT01896791|ACTIVE_COMPARATOR|Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation: the anode electrode is placed in the area of the motor cortex M1 C3 or C4 position of the dominant hemisphere (International 10-20 EEG System). The cathode electrode is placed over the contralateral supraorbital region to the anode electrode. Treatment time and intensity of the stimulus: tDCS: 2mili Ampere, 20min, 10 days.
62848475|NCT01896791|PLACEBO_COMPARATOR|Sham Stimulation|Sham Stimulation: appliance off during the entire period without active stimulation, with the position of the electrodes in the same sites of active stimulation
62848476|NCT02565667|EXPERIMENTAL|KOL group|KOL stapler was used for rectal anastomosis
62848477|NCT02565667|ACTIVE_COMPARATOR|traditional stapler group|traditional stapler was used for rectal anastomosis
62848478|NCT02449343|EXPERIMENTAL|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62848479|NCT02449343|PLACEBO_COMPARATOR|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62848480|NCT00541814|ACTIVE_COMPARATOR|1|CNI \[Cyclosporine\] minimisation Group. Conversion from azathioprine to Myfortic followed by a three month period of cyclosporine weaning to target blood level of 50-100 ng/ml.
62622476|NCT04551365|PLACEBO_COMPARATOR|Obese patients II|Undergoing lifestyle changes (rehabilitation) along daily intake of placebo, 4 capsules twice daily at main meals.
62622477|NCT04551365|EXPERIMENTAL|Control I|Daily intake of chitosan supplement, 4 capsules twice daily at main meals.
62848481|NCT00541814|EXPERIMENTAL|2|CNI \[Cyclosporine\] withdrawal Group. Conversion from azathioprine to Myfortic followed by a three month period of cyclosporine weaning to the point of withdrawal.
62848482|NCT01612832|EXPERIMENTAL|Lyrica|Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
62848483|NCT01612832|ACTIVE_COMPARATOR|Control|no liryca treatment
62848484|NCT02086513|EXPERIMENTAL|LDE225|LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose of 200 mg, 400 mg, 600 mg, or 800 mg depending on the specific cohort. Starting dose 200 mg daily for a 28 day cycle. The DLT period will be for the first 2 cycles of therapy. Each cycle is 28 days in length, making the DLT period of minimum of 56 days.
62848485|NCT02633696|ACTIVE_COMPARATOR|Legalón Sil i.v 350 mg|8 healthy volunteers received 1 vial of 350 mg iv of sylibin lyophilisate for solution for infusion (legalon sil) in two hours (single dose).
62622478|NCT04551365|PLACEBO_COMPARATOR|Control II|Daily intake of placebo 4 capsules twice daily at main meals.
62622479|NCT01928199|ACTIVE_COMPARATOR|Sitagliptin|"Sitaglipitin tablets will be administered orally for 3 months from randomization~Initial dose will be 100mg/daily, adjusted per renal function:~Creatinine clearance \> or = 50mL/min: 100mg/day Creatinine clearance \> or = 30 and \<50mL/min: 50mg/day Creatinine clearance \<30 mL/min or on dialysis: 25mg/day"
62622480|NCT01928199|PLACEBO_COMPARATOR|Placebo|Placebo tablets (identical to active comparator in appearance) will be administered orally for 3 months. Starting dose and adjustment based on renal function will be identical to active comparator
62848486|NCT02633696|EXPERIMENTAL|Silybin-phosphatidylcholine oral 360 mg|8 healthy volunteers received 9 capsules of 40 mg of sylibin each one (360 mg in total) orally.
62848487|NCT00885222|ACTIVE_COMPARATOR|1|PD patient that were treated with STN DBS and developed depression after the surgery (n=5).
62622481|NCT05687409|EXPERIMENTAL|A 10-g packet of lactulose oral solution and three capsules of probiotics +entecavir group|"10-g packet of lactulose oral solution and three capsules of probiotics +entecavir group:Adults with histologically confirmed stable cirrhosis and BMI \< 25 kg m-2 were enrolled and assigned to receive boxes labeled A or B: one for the synbiotic, including a 10-g packet of lactulose oral solution and three capsules of probiotics (each containing \> 4.2×106 CFU Clostridium butyricum and \> 4.2×105 CFU Bifidobacterium longum infantis). Participants orally administered the contents three times daily after meals.~Entecavir 5mg, once a day. All of the above lasted for six months."
62622482|NCT05687409|PLACEBO_COMPARATOR|A 10-g packet of glucose oral solution and three capsules of starch+entecavir group|"A 10-g packet of glucose oral solution and three capsules of starch+entecavir group:Adults with histologically confirmed stable cirrhosis and BMI \< 25 kg m-2 were enrolled and assigned to receive boxes labeled A or B: one for the synbiotic, including a 10-g packet of lactulose oral solution and three capsules of probiotics (each containing \> 4.2×106 CFU Clostridium butyricum and \> 4.2×105 CFU Bifidobacterium longum infantis). Participants orally administered the contents three times daily after meals.~Entecavir 5mg, once a day. All of the above lasted for six months."
62622483|NCT05345366||the good collateral group|
62848488|NCT00885222|ACTIVE_COMPARATOR|2|PD patients with depression that are candidates for STN DBS (n=5).
62061272|NCT03866668|EXPERIMENTAL|Esomeprazole|Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks
62061273|NCT03916601|EXPERIMENTAL|Test (T)|SAR341402 Mix 70/30: single dose injection
62622484|NCT05345366||the poor collateral group|
62622485|NCT00957489|EXPERIMENTAL|Functional appliance-Dynamax|
62622486|NCT00957489|OTHER|Functional appliance- twin block|Conventional treatment
62622487|NCT02779075|PLACEBO_COMPARATOR|Saline|0.9% NaCL (saline) intravenously for 6 hours.
62622488|NCT02779075|ACTIVE_COMPARATOR|Exendin-9,39|Exendin-9,39 intravenously for 6 hours.
62622489|NCT03606057|EXPERIMENTAL|Treatment Group 1: JNJ-64565111+Moxifloxacin Placebo|Participant will receive JNJ-64565111 on days 2, 9, 16, and 23 and moxifloxacin-matching placebo on days 1 and 27.
62848489|NCT00885222|ACTIVE_COMPARATOR|3|PD patients without depression that are candidates for STN DBS (n=10).
62848490|NCT04183543|EXPERIMENTAL|Pulsed Electromagnetic Field Therapy|Study participants will receive 20 minutes of PEMFs (10 minutes per leg) on a weekly basis for 16 weeks (Week 1-16). Participants would not be aware of treatment/ sham allocation, as the PEMF device is indistinguishable in operational and non-operational modes. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
62061274|NCT03916601|ACTIVE_COMPARATOR|Reference 1 (R1)|NovoLog Mix 70/30: single dose injection
62061275|NCT03916601|ACTIVE_COMPARATOR|Reference 2 (R2)|NovoMix30: single dose injection
62265288|NCT06402864|NO_INTERVENTION|control arm A|Control arm A consists in TNT regimen, with an induction chemotherapy Modified FOLFIRINOX (mFOLFIRINOX) 6 cycles over 12 weeks, followed by neoadjuvant chemo radiotherapy (nCRT) 50 Gy over 5 weeks with concomitant capecitabine (CAP50 Gy).
62622490|NCT03606057|ACTIVE_COMPARATOR|Treatment Group 2: JNJ-64565111 Matching Placebo+Moxifloxacin|Participant will receive JNJ-64565111-matching placebo on days 2, 9, 16, and 23. Participants will also receive moxifloxacin on day 1 and moxifloxacin-matching placebo on day 27 (sequence 2a) or moxifloxacin-matching placebo on day 1 and moxifloxacin on day 27 (sequence 2b) in a nested crossover manner.
62265289|NCT06402864|EXPERIMENTAL|Experimental arm B|Experimental arm B consists in addition of three fractions of CXB every two weeks between end of mFOLFIRINOX and nCRT
62622491|NCT02706145|EXPERIMENTAL|Intervention Group (West Louisville)|This group will be exposed to the social norming campaign via traditional, mass, and social media over the three-year intervention period.
62622492|NCT02706145|NO_INTERVENTION|Control Group (East Nashville)|This group will serve as the control group, and measures of social norms and attitudes toward violence will be compared between this group and the intervention group.
62622493|NCT02829502|ACTIVE_COMPARATOR|Byetta|"Pre- and post treatment investigations:~1. Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler~2. Cerebral cortical oxygination by near infrared spectroscopy (NIRS)~Endothelial function/response by the methods:~* Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)~* EndoPAT2000~* Ankle-brachial index"
62622494|NCT02829502|PLACEBO_COMPARATOR|Normosaline|"Pre- and post treatment investigations:~1. Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler~2. Cerebral cortical oxygination by near infrared spectroscopy (NIRS)~Endothelial function/response by the methods:~* Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)~* EndoPAT2000~* Ankle-brachial index"
62622495|NCT01006590|EXPERIMENTAL|1|Saxagliptin 5 mg
62622496|NCT01006590|ACTIVE_COMPARATOR|2|Metformin 500 -1000 mg
62848491|NCT04183543|SHAM_COMPARATOR|Sham Therapy|Study participants will receive 20 minutes of placebo treatment (10 minutes per leg) on a weekly basis for 16 weeks (Week 1-16). Participants would not be aware of treatment/ sham allocation, as the PEMF device is indistinguishable in operational and non-operational modes. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
62848492|NCT00540410|EXPERIMENTAL|1|
62848493|NCT00540410|ACTIVE_COMPARATOR|2|
62848494|NCT02600039|EXPERIMENTAL|ELTGOL|
62848495|NCT02600039|ACTIVE_COMPARATOR|Acapella|
62848496|NCT04248491|ACTIVE_COMPARATOR|Emsella Chair Active Treatment|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will be decreased slightly and stay unchanged for the remainder of the treatment. The treatment threshold should be increased with every treatment until the subject reaches 100%.
62848497|NCT04248491|SHAM_COMPARATOR|Emsella Sham Treatment|Sham treatment subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level (\<10% power).
62061276|NCT03916601|EXPERIMENTAL|Reference 3 (R3)|SAR341402 rapid-acting solution: single dose injection
62265290|NCT05184608|EXPERIMENTAL|Cycling combined with cognitive tasks|
62622497|NCT05754671|EXPERIMENTAL|laryngectomized patients|
62622498|NCT05754671|EXPERIMENTAL|health professionals|
62061277|NCT02138643|ACTIVE_COMPARATOR|Endoscopic surgery|Patients with symptomatic achalasia confirmed by clinical and laboratory tests, which meet the criteria for inclusion and exclusion. These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)
62061278|NCT02138643|SHAM_COMPARATOR|Laparoscopic surgery|Patients with symptomatic achalasia confirmed by clinical and laboratory tests, which meet the criteria for inclusion and exclusion. These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
62061279|NCT02244164|ACTIVE_COMPARATOR|Sulfonylurea|Patient will received metformine with sulfonylurea
62061280|NCT02244164|ACTIVE_COMPARATOR|Incretinomimectics|Patients will received metformin with sulfonylurea with GLP-1 analogue
62061281|NCT02244164|ACTIVE_COMPARATOR|DPP-4 inhibitors|Patients will received metformin with DPP-4 inhibitors
62265291|NCT05184608|ACTIVE_COMPARATOR|Cycling|
62265292|NCT05193110|OTHER|CAD/CAM PEEK sub-periosteal implant retaining maxillary fixed prosthesis|4 PEEK sub-periosteal implants were surgically placed for patients demonstrated sever bone loss especially in the posterior region which complicate conventional implant placement for full arch prosthesis.The PEEK framework was fabricated by CAD/CAM method
62622499|NCT03539484|EXPERIMENTAL|Part I: Single Participant Cohorts IV/MAD-Escalation|Part I was a multiple-ascending dose-escalation in single participant cohorts. RO7172508 was administered intravenously once every 3 weeks (Q3W). The starting dose of RO7172508 was 65 microgram (mcg) and the maximum dose explored was 1.6 milligram (mg).
62622500|NCT03539484|EXPERIMENTAL|Part II: Multiple Participant Cohorts IV/MAD-Escalation|Multiple ascending dose-escalation of IV-administered RO7172508 in multiple participant cohorts: The starting-dose for the initiation of the IV dose-escalation was determined by Part I and RO7172508 was initially given Q3W. Dose-escalation was undertaken based on safety until determination of the MTD or the highest safe dose if MTD is not reached. If on-target toxicity was reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.
62061282|NCT05044325|EXPERIMENTAL|Part 1 Cohort 1 (C1): Placebo C1/ GSK3884464 3 milligrams (mg)/ GSK3884464 9mg|Participants received GSK3884464 or placebo through oral administration in the treatment sequence: Placebo C1/ GSK3884464 3 milligrams (mg)/ GSK3884464 9mg across 3 treatment periods. There was a minimum of 7 days washout period between dosing in each session.
62061283|NCT05044325|EXPERIMENTAL|Part 1 Cohort 1: GSK3884464 1 mg/ Placebo C1/ GSK3884464 9mg|Participants received GSK3884464 or placebo through oral administration in the treatment sequence: GSK3884464 1 mg/ Placebo C1/ GSK3884464 9mg across 3 treatment periods. There was a minimum of 7 days washout period between dosing in each session.
62061284|NCT05044325|EXPERIMENTAL|Part 1 Cohort 1: GSK3884464 1 mg/ GSK3884464 3 mg / Placebo C1|Participants received GSK3884464 or placebo through oral administration in the treatment sequence: GSK3884464 1 mg/ GSK3884464 3 mg / Placebo C1 across 3 treatment periods. There was a minimum of 7 days washout period between dosing in each session.
62061285|NCT05044325|EXPERIMENTAL|Part 1 Cohort 2 (C2): Placebo C2/ GSK3884464 110 mg/ SD6|Participants received GSK3884464 or placebo through oral administration in the treatment sequence: Placebo C2/ GSK3884464 110 mg/ Single Dose (SD) 6 across 3 treatment periods. There was a minimum of 7 days washout period between dosing in each session.
62061286|NCT05044325|EXPERIMENTAL|Part 1 Cohort 2: GSK3884464 30 mg/ Placebo C2/ SD6|Participants received GSK3884464 or placebo through oral administration in the treatment sequence: GSK3884464 30 mg/ Placebo C2/ SD6 across 3 treatment periods. There was a minimum of 7 days washout period between dosing in each session.
62061287|NCT05044325|EXPERIMENTAL|Part 1 Cohort 2: GSK3884464 30 mg/ GSK3884464 110 mg / Placebo C2|Participants received GSK3884464 or placebo through oral administration in the treatment sequence: GSK3884464 30 mg/ GSK3884464 110 mg / Placebo C2 across 3 treatment periods. There was a minimum of 7 days washout period between dosing in each session.
62622501|NCT03539484|EXPERIMENTAL|Part II: Multiple Participant Cohorts SC/MAD-Escalation (QW)|Multiple ascending dose-escalation of SC-administered RO7172508 in multiple participant cohorts. These will be initiated once the IV schedule has shown RO7172508 preliminary clinical activity or the MTD has been established and is equal to or above 2 mg. The starting-dose and regimen once a week or once every 3 weeks (QW or Q3W) for SC administration will be proposed based on the evaluation of the safety and PK data observed following IV administration but will not exceed the highest safe dose tested in the IV Q3W dose escalation; a minimum dose of 2 mg is defined for a single SC administration. In addition, the QW SC starting-dose will not exceed one third of the IV MTD or of the highest safe IV dose tested. Dose escalation will continue based on safety until determination of the MTD or the planned maximum dose of 400 mg. If on-target toxicity is reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.
62848498|NCT03041506|ACTIVE_COMPARATOR|Sedation|"Analgesia and sedation through IV medication for pain relief will be administered to the patient.~Midazolam: up to a maximum dosage of 0.1 mg/kg (bolus of 1 mg by titration every 30-60 second).~Ketamine: up to maximum dosage of 100 mg IV (bolus of 25 mg by titration every 30-60 seconds)."
62265293|NCT05193110|OTHER|Injection molding PEEK sub-periosteal implant retaining maxillary fixed prosthesis|4 CAD/CAM PEEK sub-periosteal implants were surgically placed for patients demonstrated sever bone loss especially in the posterior region which complicate conventional implant placement for full arch prosthesis.The PEEK framework was fabricated by injection molding technique method.
62848499|NCT03041506|EXPERIMENTAL|US guided ISCB|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15-20 ml."
62061288|NCT05044325|EXPERIMENTAL|Part 1 Cohort 3 (C3): Placebo C3/ SD8/ SD9|Participants received GSK3884464 or placebo through oral administration in the treatment sequence: Placebo C3/ SD8/ SD9 across 3 treatment periods. There was a minimum of 7 days washout period between dosing in each session.
62061289|NCT05044325|EXPERIMENTAL|Part 1 Cohort 3: GSK3884464 70 mg/ SD8/ Placebo C3|Participants received GSK3884464 or placebo through oral administration in the treatment sequence: GSK3884464 70 mg/ SD8/ Placebo C3 across 3 treatment periods. There was a minimum of 7 days washout period between dosing in each session.
62061290|NCT05044325|EXPERIMENTAL|Part 2 Cohort 4 (C4): GSK3884464 15 mg|Participants received GSK3884464 15 mg through oral administration.
62265294|NCT01541475|EXPERIMENTAL|Escitalopram + Bupropion|
62265295|NCT01541475|ACTIVE_COMPARATOR|Escitalopram|
62265296|NCT01356407|EXPERIMENTAL|PICOPREP|"Split Dose method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day before the colonoscopy."
62265297|NCT01356407|ACTIVE_COMPARATOR|PEG-ELS|PEG-ELS was used according to the approved labeled dosage and administration instructions. Only received one dose of 2 boxes (6 packets), administrated on the day of colonoscopy examination.
62265298|NCT00770614|ACTIVE_COMPARATOR|1|Sodium Bicarbonate (154 mEq/L in dextrose and H2O) 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
62061291|NCT05044325|EXPERIMENTAL|Part 2 Cohort 4: Placebo C4|Participants received placebo through oral administration in Cohort 4.
62061292|NCT00709059||PegIntron Plus Rebetol|Previously untreated patients infected with HCV genotype 1, 4, 5, or 6.
62061293|NCT05152134|EXPERIMENTAL|Empowered Relief On Demand|Empowered Relief On-Demand will include roughly 80 minutes of interactive and multimedia pain educational content that targets pain and stress self-regulation, pain medication misuse, a personalized plan for relief and an audio App for daily use.
62061294|NCT05152134|PLACEBO_COMPARATOR|"Health Education (HE; Living Better)"|"The HE arm is an interactive digital general health education intervention called Living Better that is devoid of specific content on pain, psychological skills, and has no active strategies or worksheets."
62265299|NCT00770614|ACTIVE_COMPARATOR|2|Isotonic Saline (0.9% sodium chloride) 1 mL/kg/h for 12 hours after the procedure
62265300|NCT00770614|PLACEBO_COMPARATOR|3|Placebo
62265301|NCT04326335|ACTIVE_COMPARATOR|Felt-tip marking|
62265302|NCT04326335|EXPERIMENTAL|Felt-tip marking + 3D printed ostomy button|
62265303|NCT05593250|EXPERIMENTAL|Cohort A|dose 1
62265304|NCT05593250|EXPERIMENTAL|Cohort B|dose 2
62265305|NCT05593250|EXPERIMENTAL|Cohort C|dose 3
62265306|NCT05593250|PLACEBO_COMPARATOR|Placebo|
62622502|NCT03531476|EXPERIMENTAL|Online chronic pain management program|There is only one arm. Those who consent to participate in the study and take the online self-directed chronic pain management program with therapist support.
62265307|NCT06220539|EXPERIMENTAL|Casting and Supervised Rehabilitation|Patients in the intervention group will undergo non-weightbearing immobilization for 8 weeks in phase one: 4 in a circular cast with non-weightbearing followed by 4 weeks toe-tip weightbearing (10-20% of body weight) in a walking boot during daytime and a removable cast at night. In phase 2, a supervised rehabilitation will be performed till week 16 after which phase 3 will start at week 16-18
62622503|NCT00580749|ACTIVE_COMPARATOR|DJ|Naso disal jejunal(DJ) feedings randomized to 50% of subjects meeting criteria.
62848500|NCT01898351|OTHER|Fava bean, Lupin, Beef meat, Green pea, Hemp, Buckwheat|"The intervention visit involves a test meal to be consumed by subjects attending the Human Nutrition Unit in the morning, following an overnight fast. The meal will be consumed within 15 minutes and blood (69 mL) and urine samples will be collected during 24 hours.~The test meals are designed to contain the same amount of proteins. Alternative protein meals: a number of bread buns for each meal containing individual alternative protein flours (green pea, lupin, hemp, buckwheat, fava beans). These will deliver 30 g of protein, the remainder being provided by white flour. The control (meat) meal: a lean beef steak containing 30 g of protein and a bun containing the same amount of white flour as used for the alternative protein bread buns.~The semi structured interview guide: will take place within the Human Nutrition Unit during one of the scheduled visits, once initial screening has taken place and participants have been selected. All interviews will be digitally recorded."
62848501|NCT01847729||Patients on OST prescribed to treat opiate dependence|Collecting socio-demographic data, data concerning opiate dependence, data about other substance use disorder, data regarding gambling practice, psychopathological data.
62061295|NCT00147901|EXPERIMENTAL|FCCam|After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
62061296|NCT05900622|NO_INTERVENTION|Control group|Lower extremity on the puncture side with a 4-hour brake+Get out of bed after 8 hours
62061297|NCT05900622|EXPERIMENTAL|Test group A|Lower extremity on the puncture side with a 2-hour brake+Get out of bed after 4 hours
62848502|NCT00899392|EXPERIMENTAL|Electronic Assisted Consent|Standard procedural consent performed by pediatric gastroenterologist plus assistance from computerized emmi module.
62061298|NCT05900622|EXPERIMENTAL|Test group B|No braking of the lower limb on the side of the puncture+Get out of bed after 2 hours
62061299|NCT04642963|EXPERIMENTAL|Cardiac Radiosurgery|Patients with ventricular tachycardia will undergo a non-invasive cardiac radiosurgery using one fraction of 25 Gy to the arrhythmia substrate, as determined by the electrophysiological cardiac mapping.
62061300|NCT00722384|EXPERIMENTAL|1|0.1 mg bevasiranib in the study eye
62448947|NCT04544371||normal weight patients|patients with body mass index =18-24.9 kg/m2 will be examined by abdominal ultrasound to assess gastric antrum cross sectional area in semi-sitting and right lateral positions
62622504|NCT00580749|ACTIVE_COMPARATOR|NG|Placement of naso gastric feeding tube through nare into stomach for enteral feeding.
62622505|NCT01489852|ACTIVE_COMPARATOR|Estrogen pre-treatment|
62622506|NCT01489852|NO_INTERVENTION|Control|The control group did not receive any pre-treatment.
62622507|NCT02094313|EXPERIMENTAL|atovastatin|
62622508|NCT00596453|PLACEBO_COMPARATOR|Placebo|
62848503|NCT00899392|NO_INTERVENTION|Control Consent|Standard procedural consent as performed by pediatric gastroenterologists
62848504|NCT00796978|EXPERIMENTAL|trastuzumab|
62848505|NCT05360862||Prone positioning session|
62848506|NCT03248791|ACTIVE_COMPARATOR|Phenylephrine|Will receive spinal anesthesia using Bupivacaine. Then, phenylephrine infusion by a starting rate of 0.75 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure
62848507|NCT03248791|EXPERIMENTAL|Norepinephrine|Will receive spinal anesthesia using Bupivacaine. Then, norepinephrine infusion by a starting rate of 0.1 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure
62848508|NCT04790110||Studie A ESO - monitoring|Patients that present themselves at the clinic through referral from their dentist with tooth wear, who have no request for help, receive a non-restorative 'counseling \& monitoring' strategy , in which appropriate preventive measures are recommended and wear and tear is monitored and recorded by periodically taking intra-oral photographs and 3D scans
62848509|NCT01766505|EXPERIMENTAL|Candemore tablet|Candemore tablet: candesartan cilexetil 8mg, 16mg, 32mg/tab, orally, 1 tablet once a day during 16 weeks
62848510|NCT01766505|ACTIVE_COMPARATOR|Cozzar tablet|Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks
62848511|NCT01019200||Psoriasis|Individuals with a diagnosis of psoriasis as confirmed by the principle investigator will comprise the psoriasis or case group. Participants must meet inclusion and exclusion criteria as defined below. This group will consist of 100 individuals.
62848512|NCT01019200||Control|Individuals without psoriasis, but meeting inclusion and exclusion criteria, will be selected to be within the control group. For each patient with psoriasis within the psoriasis group, an age, sex, and BMI-matched control will be selected. The group will consist of 100 individuals.
62848513|NCT04599634|EXPERIMENTAL|Experimental treatment: FL dose expansion|Window of magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg combination for two (2) cycles (28-days each, Cycles -2 and -1), then venetoclax will be added at target dose (dose determined from Arm 1). Triplet combination treatment with magrolimab + obinutuzumab + venetoclax will be 6 cycles (28-days each, Cycles 1-6); further treatment will be response-adapted.
62848514|NCT04599634|EXPERIMENTAL|Experimental treatment: FL Dose-finding|Magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg + venetoclax 800mg PO combination administered to 6 patients for six (6) cycles (28-days each, Cycles 1-6); further treatment with additional cycles will be response-adapted. Note: DLT assessment of the magrolimab + obinutuzumab + venetoclax triplet will take place during Cycle 1. If =2 patients experience DLT, an additional 6 patients will be enrolled at DL(-1) of venetoclax 600mg with magrolimab and obinutuzumab.
62448948|NCT04544371||obese patients|patients with body mass index \>30 kg/m2 will be examined by abdominal ultrasound to assess gastric antrum cross sectional area semi-sitting and right lateral positions
62622509|NCT00596453|EXPERIMENTAL|Ciprofloxacin hydrochloride|
62622510|NCT02566499|EXPERIMENTAL|Abnormal x-ray Mammography group|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
62061301|NCT00722384|EXPERIMENTAL|2|0.33 mg bevasiranib in the study eye,
62061302|NCT00722384|EXPERIMENTAL|3|1.0 mg bevasiranib in the study eye
62622511|NCT06500650|EXPERIMENTAL|Virtual Reality Intervention Group|"Virtual reality application and person-centered occupational therapy intervention were applied to the virtual reality intervention group. VR intervention was implemented in a 30 m2 virtual reality unit using a PC Microsoft Kinect and a screen (50 flat LED screen TV) located approximately 1.5 meters away. Kinect can monitor the client's movements in the VR environment in real time by displaying them on the screen. In our study, before starting VR interventions, suitable games for intervention were determined by analyzing which skills each game required and which skills it could develop. Before starting the VR intervention, clients were informed about the games and shown how to play them."
62622512|NCT06500650|EXPERIMENTAL|Person-centred Occupational Therapy Intervention Group|Person-centered occupational therapy intervention was applied to both groups according to the evaluation results. The basis of the person-centered occupational therapy intervention is the activities and visual skills that the participants stated in the COPM in the first evaluation and in which they had problems. Person-centered occupational therapy intervention consists of 5 stages: (1) person-centered goal setting, (2) creation of the therapy plan, (3) implementation of interventions, (4) evaluation of results, and (5) obtaining feedback.
62061303|NCT00722384|EXPERIMENTAL|4|1.5 mg bevasiranib in the study eye
62061304|NCT00722384|EXPERIMENTAL|5|3.0 mg bevasiranib in the study eye.
62061305|NCT00873236|EXPERIMENTAL|Arm I|Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks.
62061306|NCT00873236|EXPERIMENTAL|Arm II|Patients receive bevacizumab as in arm I and low-dose recombinant interferon alpha-2a subcutaneously (SC) 3 times weekly beginning on day 0.
62061307|NCT00873236|EXPERIMENTAL|Arm III|Patients receive bevacizumab as in arm I and standard-dose recombinant interferon alpha-2a SC 3 times weekly beginning on day 0.
62448949|NCT04360421|EXPERIMENTAL|Intraoperative liposomal bupivacaine field block|Patients will receive the maximum dosage of liposomal bupivacaine allowed for their body weight or the full vial, whichever is less. Injected once, along the incision before closure of the skin.
62622513|NCT06402877|EXPERIMENTAL|Healthy Periodontium|Full-mouth clinical periodontal measurements recorded and saliva obtain
62622514|NCT06402877|EXPERIMENTAL|Periodontitis|Full-mouth clinical periodontal measurements recorded and saliva obtained.
62622515|NCT06402877|EXPERIMENTAL|Gingivitis|Full-mouth clinical periodontal measurements recorded and saliva obtained.
62061308|NCT05936606|ACTIVE_COMPARATOR|Uniform Therapy|Patients will continue clopidogrel monotherapy for 24 months from randomization, irrespective of their PRU measurement.
62061309|NCT05936606|EXPERIMENTAL|Tailored Therapy|Patients in the intervention arm will receive tailored anti-platelet therapy according to PRU and bleeding risk
62061310|NCT01986361|EXPERIMENTAL|flurbiprofen 8.75 mg lozenge|A single flurbiprofen lozenge is sucked until fully dissolved.
62622516|NCT00568737|EXPERIMENTAL|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
62622517|NCT00568737|PLACEBO_COMPARATOR|2|0.9% sodium chloride
62622518|NCT03816618|EXPERIMENTAL|CONTROL|CONTROL GROUP
62622519|NCT03816618|EXPERIMENTAL|TREATMENT1|TREATMENT GROUP 1
62622520|NCT03816618|EXPERIMENTAL|TREATMENT2|TREATMENT GROUP 2
62622521|NCT03816618|EXPERIMENTAL|TREATMENT3|TREATMENT GROUP 3
62622522|NCT01025102|EXPERIMENTAL|Naropin 0.1%|
62622523|NCT04465084|OTHER|Case|Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis.
62622524|NCT04465084|OTHER|Witness|"Person matched to a case on age (+/-3 years) and education level"
62622525|NCT02330172|ACTIVE_COMPARATOR|rocuronium 0.45 - neostigmine|"when anesthetic induction, inrocuronium 0.45 mg/kg will be administered for muscle relaxation.~When the end of operation, a injection of neostigmine or sugammadex will be administered."
62622526|NCT02330172|ACTIVE_COMPARATOR|rocuronium 0.9 - sugammadex|"When anesthetic induction, rocuronium 0.9 mg/kg will be injected to rocuronium 0.9 - sugammadex group for muscle relaxation.~When the end of operation,, a injection of neostigmine or sugammadex be administered."
62622527|NCT03998371||Urothelial carcinoma group|Pre-surgery patients with urothelial carcinoma will be the experimental group to determine the sensitivity and specificity of UCAD analysis, the result will be compared with cytology and FISH.
62622528|NCT03998371||Non-cancer participants group|Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UCAD analysis.
62622529|NCT03917277|EXPERIMENTAL|Musculoskeletal ultrasound of the ankle|"see Intervention description"
62622530|NCT00768573||1. Taste test|
62622531|NCT02331784|EXPERIMENTAL|Computerized Plasticity-based Software|Computerized Plasticity-based software training requiring a total maximum of 50 treatment sessions, 4-5 times weekly, 40 minutes each session.
62622532|NCT02331784|ACTIVE_COMPARATOR|Commercially available video game|Commercially available video game training. Treatment is software based, will occur up to 50 times throughout study duration, 4-5 times per week, 40 minutes each session..
62622533|NCT03373357|OTHER|Patient not SAHOS|The medical follow-up of patients no SAHOS will be assured by the investigators of the unity of cardiovascular explorations: phone consultation in 1 month, 3mois, then every 6 months, and an annual visit.
62622534|NCT03373357|OTHER|Patient SAHOS sailed by the ventilation in PPC and not sailed|The patients who have a SAHOS sailed by the ventilation in PPC will be estimated and followed in 3 months then every 6 months by the investigators of the service of pneumology and the unity of cardiovascular explorations. The control of the material and its tolerance, the data supplied by the service providers (bodies of ventilation at home) will be estimated by the investigator of the service of pneumology. IDE the unity of cardiovascular explorations will plan and will realize a 2nd one MAPA after 3 months of ventilation in PPC.
62622535|NCT05979896|EXPERIMENTAL|Sulfadoxine-Pyrimethamine + Amodiaquine (SPAQ)|Children aged 3-59 months will receive directly observed therapy of standard aged based dosing of Sulfadoxine-Pyrimethamine + Amodiaquine (SPAQ) over 3 days.
62848515|NCT04599634|EXPERIMENTAL|Experimental treatment: MZL, MCL, and CLL Dose-finding|Magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg + venetoclax ramp-up to target dose of 400mg over 5 weeks (35 days, Cycle 1) administered to 6 patients. Triplet combination of magrolimab + obinutuzumab + venetoclax (target dose, no ramp-up) will continue for five (5) additional cycles (28-days each, Cycles 2-6); further treatment with additional cycles will be response-adapted. Note: DLT assessment of the magrolimab + obinutuzumab + venetoclax triplet will take place during Cycle 1. If =2 patients experience DLT, an additional 6 patients will be enrolled at DL(-1) of venetoclax 200mg with magrolimab and obinutuzumab.
62265308|NCT06220539|NO_INTERVENTION|Standard Care|Patients in the control group will undergo the standard care. Standard care (''skill-full'' neglect) is described as adjustment of activities within the boundaries of pain. They can perform all activities wanted, except for painful activities. Patients and caretakers will be advised on the amount of activities by specialized orthopedic surgeons and periodical evaluation, and adjustment, will take place at the regular follow-up moments which is the same as in the intervention group. In this group, no supervised training or rehabilitation will be performed.
62848516|NCT04599634|EXPERIMENTAL|Experimental treatment: mzl, MCL, CLL dose expansion|Window of magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg combination for two (2) cycles (28-day cycles, Cycles -2 and -1), then venetoclax safety ramp-up to target dose (dose determined from Arm 2) over 5 weeks (35-days, Cycle 1). Triplet combination treatment with magrolimab + obinutuzumab + venetoclax (target dose, no ramp-up) will continue for 5 additional cycles (28-days each, Cycles 2-6); further treatment will be response-adapted.
62848517|NCT00530816|EXPERIMENTAL|Carfilzomib|"Participants received carfilzomib 20 mg/m² intravenous (IV) injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.~Starting with Amendment 3, if all doses in Cycle 1 were well-tolerated the dose was escalated to 27 mg/m² IV for subsequent cycles."
62848518|NCT02181725|EXPERIMENTAL|Multimodal Rehabilitation Program|Multimodal Rehabilitation Program, consisting of a Graded Exposure Module (GE), a Combination Module (HMGE) and a Parent Module (PM)
62448950|NCT04414501|ACTIVE_COMPARATOR|Tablet study group|Anxiety at separation from caregiver was measured by the modified Yale Preoperative Anxiety Scale (mYPAS). Caregiver anxiety was measured using the State-Trait Anxiety Inventory for Adults (STAI), a validated self-evaluation questionnaire. Mask acceptance, a functional evaluation of stress at the time of induction, was determined using the Mask Acceptance Scale.
62448951|NCT04414501|ACTIVE_COMPARATOR|VR study group|Anxiety at separation from caregiver was measured by the modified Yale Preoperative Anxiety Scale (mYPAS). Caregiver anxiety was measured using the State-Trait Anxiety Inventory for Adults (STAI), a validated self-evaluation questionnaire. Mask acceptance, a functional evaluation of stress at the time of induction, was determined using the Mask Acceptance Scale.
62448952|NCT01142037|EXPERIMENTAL|Furanocoumarin|Includes participants first refraining from eating foods with furanocoumarins for one week, followed by 2 weeks of increasing furanocoumarin consumption. Participants will be asked to consume cooked parsnips and parsley.
62448953|NCT01596647|EXPERIMENTAL|TKI258 (dovitinib)|dovitinib, 5 days on / 2 days off dose schedule
62622536|NCT00003190|EXPERIMENTAL|Arm I (cytarabine, daunorubicin, etoposide)|Patients receive cytarabine IV continuously over 7 days and daunorubicin IV bolus followed by etoposide IV over 2 hours on days 1-3.
62848519|NCT02181725|ACTIVE_COMPARATOR|Care as Usual|Care as usual is the care currently provided to adolescents with musculoskeletal chronic pain and is based on the principles of Graded Activity.
62848520|NCT06515808||Direct Laryngoscope Group|Patients receiving tracheal intubation with direct laryngoscope
62848521|NCT06515808||GlideScope Group|Patients receiving tracheal intubation with GlideScope
62848522|NCT06515808||AirwayScope Group|Patients receiving tracheal intubation with AirwayScope
62848523|NCT06132139|EXPERIMENTAL|VisAR Navigation|Patients randomly assigned to this arm will have their EVD placed using VisAR navigation.
62061311|NCT01986361|PLACEBO_COMPARATOR|Placebo lozenge|A single placebo lozenge is sucked until fully dissolved.
62448954|NCT05329636|PLACEBO_COMPARATOR|Placebo FMT capsules|Glycerol and saline solution will be pipetted into commercially available acid-resistant hypromellose capsules (DRCaps, Capsugel) (650 μL), which will be closed and then secondarily sealed. Capsules will be stored frozen at -80°C (-112°F). Patients will swallow 30 frozen capsules on two consecutive days. Capsules look exactly the same as FMT capsules
62622537|NCT00003190|EXPERIMENTAL|Arm II (valspodar, daunorubicin, etoposide, cytarabine)|"Patients receive treatment as in arm I with the addition of PSC 833 induction. A loading dose of PSC 833 IV is given over 2 hours, followed by a 74-hour continuous infusion of PSC 833 beginning 2 hours before daunorubicin and etoposide. Patients may receive a second induction course if residual leukemia is present in the bone marrow. Patients who experience a CR and meet certain other criteria receive postremission chemotherapy consisting of cytarabine IV continuously over 5 days plus daunorubicin IV followed by etoposide IV over 2 hours on days 1 and 2. Patients who are randomized to receive PSC 833 during induction chemotherapy receive a loading dose of PSC 833 before beginning a 48-hour continuous infusion of PSC 833 concurrently with cytarabine/daunorubicin/etoposide postremission chemotherapy.~After completing postremission chemotherapy, patients are randomized to a no further treatment group or IL-2 immunotherapy."
62622538|NCT06046131|OTHER|Patients prostate cancer|Patient with a confirmed diagnosis of prostate cancer will be included before starting any treatment. Recruitment will be carried out by urologists from the urology departments of the CHU of Guadeloupe and the CHU of Rennes.
62622539|NCT02567097|ACTIVE_COMPARATOR|Control|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to form their plan to quit smoking.
62622540|NCT02567097|ACTIVE_COMPARATOR|Implementation Intention|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to form a specific 'if-then' plan using an implementation intention basis.
62622541|NCT02567097|EXPERIMENTAL|Weekly Self-Incentivising|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to specify a self-incentive on which they could implement at the end of each week which they have been successful in not smoking.
62622542|NCT02567097|EXPERIMENTAL|Monthly Self-Incentivising|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to specify a self-incentive on which they could implement at the end of each month which they have been successful in not smoking.
62848524|NCT06132139|NO_INTERVENTION|Freehand Navigation|Patients randomly assigned to this arm will have their EVD placed using freehand navigation, the typical standard of care.
62848525|NCT02292069|EXPERIMENTAL|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg of Dr. Reddys Laboratories Limited
62848526|NCT02292069|ACTIVE_COMPARATOR|Caduet|Caduet® 10/80 mg tablets of Pfizer, Ireland
62848527|NCT01124006|EXPERIMENTAL|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
62622543|NCT01089010|EXPERIMENTAL|Treatment Sequence 1|Treatment sequence 1 consisted of three dosing periods in which patients received single oral doses of placebo, 250 mg, and 500 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
62848528|NCT01124006|PLACEBO_COMPARATOR|Water for injection|Sterile water for injection
62848529|NCT04181125||Children with increased femoral anteversion|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
62061312|NCT00890175|EXPERIMENTAL|Inhaled loxapine @ 0 & 10 h|Inhalation of 10 mg of loxapine at 0 and 10 hours
62448955|NCT05329636|EXPERIMENTAL|FMT capsules|Fecal matter solution (feces, glycerol and saline solution) will be pipetted into commercially available acid-resistant hypromellose capsules (DRCaps, Capsugel) (650 μL), which will be closed and then secondarily sealed. Capsules will be stored frozen at -80°C (-112°F). Patients will swallow 30 frozen capsules on two consecutive days.
62448956|NCT05329636|ACTIVE_COMPARATOR|FMT enemas|patients will evacuate the bowel prior to the procedure and will fast for 3 hours prior to the procedure . Patients will receive 80 ml of enema/ Fecal matter solution (feces(25 gr of stool , glycerol and saline solution) will be stored at 50 ml tubes frozen at -80°C (-112°F).
62848530|NCT04181125||Healthy children|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
62448957|NCT01455454||coronary artery disease|patients undergoing coronary artery bypass grafting using cardiopulmonary bypass
62061313|NCT00890175|PLACEBO_COMPARATOR|Inhaled placebo @ 2 & 10 hours|Inhalation of 0 mg of loxapine (placebo) at 0 and 10 hours
62061314|NCT06175793|EXPERIMENTAL|ASPIRE Intervention Arm|The intervention arm will receive usual care, a free blood pressure cuff in addition to the ASPIRE Components.
62061315|NCT06175793|NO_INTERVENTION|Control Arm|The control group will receive usual care and a free blood pressure cuff.
62061316|NCT03076372|EXPERIMENTAL|MM-310 monotherapy|MM-310 will be administered by IV infusion over 90 minutes on the first day of each 21 day cycle.
62061317|NCT04976114|NO_INTERVENTION|Control group|Standard of care
62061318|NCT04976114|EXPERIMENTAL|story book|Parents read a book with the chid previous to surgery.
62061319|NCT04976114|EXPERIMENTAL|video|Parents watch a video with the chid previous to surgery.
62061320|NCT04976114|EXPERIMENTAL|both instrument|Parents read a book and watch a video with the chid previous to surgery.
62448958|NCT00023283|EXPERIMENTAL|1|Standard Medical Management with once-weekly medication dispensing
62448959|NCT00023283|EXPERIMENTAL|2|Standard Medical Management with thrice-weekly medication dispensing
62448960|NCT00023283|EXPERIMENTAL|3|Enhanced Medical Management with thrice-weekly medication dispensing
62061321|NCT03763955||PD patients|PD patients at 1-5 H\&Y stage undergoes 4week Multidisciplinary Intensive Rehabilitation Treatment
62061322|NCT01179360||Imaging group|
62448961|NCT02507856||investigational group|early/late dabigatran
62448962|NCT02507856||control group|vitamin k antagonist (vka)
62448963|NCT02780557|EXPERIMENTAL|Contingent Reading Intervention|
62448964|NCT02780557|OTHER|Book Provision Control|
62448965|NCT04552613|EXPERIMENTAL|Standard programme group|EGFR-TKI targeted therapy
62448966|NCT04552613|ACTIVE_COMPARATOR|controlled programme group|EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )
62448967|NCT01682174|PLACEBO_COMPARATOR|Control Test Drink|control drink
62448968|NCT01682174|EXPERIMENTAL|Experimental Test Drink|Experimental Drink
62448969|NCT01634828||Minimal blood loss patients|
62061323|NCT03620838||Group 1|Patients with endometrioma who had at least one endometrioma \>3 cm and who will not need hormonal or surgical treatment at the time of diagnosis and who will be expectantly managed
62061324|NCT03620838||Group 2|Patients with endometrioma who had at least one endometrioma \>3 cm and who will be treated with OCP during the study period
62061325|NCT03620838||Group 3|Patients with endometrioma who had at least one endometrioma \>3 cm and who will be treated with oral progesterone during the study period
62061326|NCT03620838||Group 4|Patients with endometrioma who had at least one endometrioma \>3 cm and who will be treated with surgery short after recruitment
62061327|NCT03620838||Group 5|The control group, who do not have endometrioma and any gynecological disorder
62061328|NCT04585438|EXPERIMENTAL|Single trans-mucosal bio-adhesive disc containing Diclofenac Potassium|Premedication 1 hour before starting endodontic treatment.
62061329|NCT04585438|PLACEBO_COMPARATOR|Placebo Control|Premedication 1 hour before starting endodontic treatment. Identically-appearing trans-mucosal bio-adhesive disc (Does not contain medication)
62061330|NCT03303469|EXPERIMENTAL|FMISO PET imaging post TACE and Stereotactic body radiation therapy (SBRT)|FMISO imaging at baseline, post-TACE and post-SBRT
62061331|NCT02875405|EXPERIMENTAL|Received pericardiotomy|Patient will receive a posterior left pericardiotomy at the time of surgery
62061332|NCT02875405|NO_INTERVENTION|No Pericardiotomy|Patient will not receive posterior left pericardiotomy.
62448970|NCT01634828||Moderate to heavy blood loss patients|
62622544|NCT01089010|EXPERIMENTAL|Treatment Sequence 2|Treatment sequence 2 consisted of three dosing periods in which patients received single oral doses of placebo, 500 mg, and 250 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
62622545|NCT01089010|EXPERIMENTAL|Treatment Sequence 3|Treatment sequence 3 consisted of three dosing periods in which patients received single oral doses of 250 mg, placebo and 500 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
62622546|NCT01089010|EXPERIMENTAL|Treatment Sequence 4|Treatment sequence 4 consisted of three dosing periods in which patients received single oral doses of 250 mg, 500 mg and placebo of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
62622547|NCT01089010|EXPERIMENTAL|Treatment Sequence 5|Treatment sequence 5 consisted of three dosing periods in which patients received single oral doses of 500 mg, placebo, and 250 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
62622548|NCT01089010|EXPERIMENTAL|Treatment Sequence 6|Treatment sequence6 consisted of three dosing periods in which patients received single oral doses of 500 mg, 250 mg, and placebo of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
62448971|NCT02941809|EXPERIMENTAL|Open-Label Placebo (OLP)|Participants who are randomly assigned to group OLP will receive placebo pills. In Phase 1 of the study (first two weeks), participants in this group are given one pill, to be taken concomitant with the methadone. In Phase 2 (3 weeks up to 3 months), OLP participants continue to take the single (morning, or AM) pill, and are given a second pill in a bottle as a take-home. OLP participants will meet with the study team at five time points: at baseline (entry into treatment), 2 weeks post-baseline, and 1-, 2- and 3-months post-baseline.
62448972|NCT02941809|NO_INTERVENTION|Treatment as Usual (TAU)|Participants assigned to TAU will not be given placebo pills, but all interactions with the study team (5 meetings total) will be matched in frequency and length.
62622549|NCT03867968|EXPERIMENTAL|TIPS Intervention|The Traumatic Brain Injury Positive Strategies (TIPS) program, is a comprehensive educational and training resource to help families. The web-based product will include: (a) the Training Center, which will provide training in a range of evidence-based strategies within a problem-solving framework; and (b) the TBI Resource Center, an extensive library of educational materials, information, and resources about childhood TBI.
62622550|NCT03867968|ACTIVE_COMPARATOR|Control|An existing website related to traumatic brain injury.
62848531|NCT00852488|EXPERIMENTAL|Catheter|Cohort undergoing catheter placement using the new technique being studied
62061333|NCT02387892|PLACEBO_COMPARATOR|Control|Cheese \& yogurt
62061334|NCT02387892|EXPERIMENTAL|Treatment|Cheese \& yogurt + Vitamin D
62061335|NCT05841238|EXPERIMENTAL|LY3502970 (Part A)|The multiple doses of LY3502970 administered orally either in tablet or capsule formulations.
62061336|NCT05841238|EXPERIMENTAL|LY3502970 (Part B)|The multiple doses of LY3502970 administered orally in tablet formulation.
62448973|NCT04371484||children from 0 to 5 years old, hospitalized|
62448974|NCT02823899|EXPERIMENTAL|HL-OCV|Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.
62448975|NCT02823899|ACTIVE_COMPARATOR|Shanchol|The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.
62448976|NCT05742633|EXPERIMENTAL|Group A|Group A received Active release technique (ART)
62448977|NCT05742633|OTHER|Group B|Group B received self-myofascial release (SMFR)
62448978|NCT01829464|PLACEBO_COMPARATOR|Placebo|TAK-875 placebo-matching tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up 24 weeks.
62448979|NCT01829464|EXPERIMENTAL|TAK-875 25 mg|TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up to 24 weeks
62622551|NCT01473225|EXPERIMENTAL|Calorie label|
62622552|NCT01473225|ACTIVE_COMPARATOR|No calorie label|
62622553|NCT02018432|EXPERIMENTAL|Roflumilast escalation dosage|Roflumilast 250 μg qd (4 weeks) →500 μg qd
62622554|NCT02018432|EXPERIMENTAL|Roflumilast conventional dosage|Roflumilast 500 μg qd
62622555|NCT01148459|EXPERIMENTAL|Group A|Infants enrolled to this group will receive 3 doses of the experimental vaccine.
62622556|NCT01148459|ACTIVE_COMPARATOR|Group B|Infants enrolled to this group will receive 3 doses of the rabies comparator vaccine.
62622557|NCT00259428|EXPERIMENTAL|Dronedarone 400mg bid|dronedarone 400mg tablets
62848532|NCT01958489|EXPERIMENTAL|Pravastatin|Single 40 milligram (mg) oral dose of pravastatin administered on Day 1.
62848533|NCT01958489|EXPERIMENTAL|Evacetrapib + Pravastatin|Oral doses of 130 mg evacetrapib administered once daily on Days 2 through 11, with a single oral dose of 40 mg pravastatin coadministered on Day 11.
62848534|NCT05926518||COVID-19 ICU patients|Patients were administered as standard care once daily nadroparin 5700 IU sc (below 100 kg) or twice daily nadroparin 5700 IU sc (above 100 kg).
62848535|NCT05926518||non-COVID-19 ICU patients|Patients were administered as standard care once daily nadroparin 2850 IU sc.
62848536|NCT03933891||Decompensated liver cirrhosis with TIPS|
62448980|NCT01829464|EXPERIMENTAL|TAK-875 50 mg|TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up to 24 weeks
62622558|NCT00259428|PLACEBO_COMPARATOR|Placebo|matching placebo tablets
62848537|NCT05741554||Myometrial involvement|Myometrial involvement by cancer metastasis after pathology examination
62061337|NCT05798039|EXPERIMENTAL|ENRICHed NFP|Participants will receive additional heart health-focused materials and guidance in sessions with their nurse home visitor. The nurse will help them choose and work towards behavior goals to support their health. This will include goals for activity, diet, weight, blood pressure, diabetes, smoking, social relationships, sleep, parenting, and getting health care.
62622559|NCT01506687|EXPERIMENTAL|Navigator intervention|
62622560|NCT01506687|ACTIVE_COMPARATOR|Usual Care Control|Usual care
62622561|NCT05677958|ACTIVE_COMPARATOR|Test group|125 mL Fortimel/Nutridrink Compact Protein
62848538|NCT05741554||No myometrial involvement|Absence of myometrial involvement by cancer metastasis after pathology examination
62848539|NCT03671850|EXPERIMENTAL|VT-EBV-N|Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)
62848540|NCT03671850|PLACEBO_COMPARATOR|Placebo|Peripheral blood mononuclear cell, PBMC
62061338|NCT03397680|ACTIVE_COMPARATOR|Rabeprazole-levofloxacin based quadruple therapy for 7 days|Participant will received 7-day once daily dose regimen of 1-tablet 750-mg Levofloxacin after meal, 2-tablet 500-mg Clarithromycin MR after meal, 3-tablet 20-mg Rabeprazole before meal and 1-tablet 1,048-mg Gastro bismol after meal.
62622562|NCT05677958|NO_INTERVENTION|Control group|
62622563|NCT01104987||alendronate|A cross sectional study assessing the prevalence of osteoporosis and vertebral fractures in AS has been conducted during the spring in 2009. Patients with osteoporosis that fulfilled the inclusion criteria and did not have any exclusion criteria for the present trial were asked to join this study.
62622564|NCT00571116|EXPERIMENTAL|Disulfiram and arsenic trioxide|"Patients receive disulfiram 250 mg PO twice daily and arsenic trioxide IV over 1-2 hours on Monday through Friday, alternating two weeks on treatment followed by two weeks off treatment. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~The Arsenic trioxide dose will be escalated or reduced until a tolerable dose is reached. Arsenic trioxide will be administered at a starting dose of 0.05 mg/kg. If the initial dose is tolerated, the patient will be dose escalated to 0.10 mg/kg/day. If the first dose escalation is tolerated, then a second dose escalation will be attempted to 0.15 mg/kg/day, the current dose recommended for leukemia. Dosing will be continued for two weeks on alternating with two weeks off as long as tolerated to a maximum of 60 doses."
62622565|NCT03992833|EXPERIMENTAL|lung cancer screening|"Participants will undergo a chest CT scan in the Department of Radiology at Tianjin Cancer Hospital. All scans will be performed using the same CT system: Definition AS. Two readings of the images will be performed. In the first image reading, the CT images will be read by specially trained Chinese resident radiologist and checked by one of two senior Chinese radiologists. Lung Cancer Screening (version 2. 2018) Guidelines of the National Comprehensive Cancer Network (NCCN) will be used for the management of lung nodules. This guideline recommends management of lung nodules based on diameter. In the second reading, a semi-automated volumetry software will be used to measure the volume and evaluate the other parameters of lung nodules.~At baseline and one year after baseline, data about general characteristics, risk factors of lung cancer, and health status of the participants will be collected."
62622566|NCT01023425|EXPERIMENTAL|switching group|switching patients with Alzheimer's disease(AD) from galantamine or rivastigmine to donepezil because they were not responding adequately
62622567|NCT01023425|EXPERIMENTAL|naive group|naive patients with AD who initiated therapy with donepezil
62848541|NCT02541396|PLACEBO_COMPARATOR|Group A|"Placebo wafers given every 2 hours Placebo capsule given every 4 hours Placebo wafers top-up dose given at hour 1"
62848542|NCT02541396|ACTIVE_COMPARATOR|Group B|"Placebo wafers given every 2 hours Oxycodone given every 4 hours Placebo wafers top-up dose given at hour 1"
62848543|NCT02541396|EXPERIMENTAL|Group C|"Wafermine™ 35 mg wafer + placebo wafer given every 2 hours Placebo capsule given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
62848544|NCT02541396|EXPERIMENTAL|Group D|"Wafermine™ 35 mg wafer + placebo wafer given every 2 hours Oxycodone 5 mg capsule every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
62848545|NCT02541396|EXPERIMENTAL|Group E|"Wafermine™ 35 mg + placebo wafer given every 4 hours Placebo wafers given every 2 hours Placebo capsule given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
62622568|NCT02772146|EXPERIMENTAL|Device: CLS UF|The purpose of CLS UF is ultrafiltration and drain of excess fluid in patients with congestive heart failure. The function of the device is to extra corporeally recirculate profiled glucose based PD fluid in a system and maintain glucose levels by adding extra glucose, to an adjustable and constant level, in order to maintain a stable ultrafiltration.
62622569|NCT00818740|EXPERIMENTAL|ORM-12741 i.v.|
62622570|NCT00818740|EXPERIMENTAL|ORM-12741 oral solution|
62622571|NCT00818740|EXPERIMENTAL|ORM-12741 oral capsule with food|
62622572|NCT00818740|EXPERIMENTAL|ORM-12741 oral capsule without food|
62622573|NCT03363893|EXPERIMENTAL|Module 1 Part A Multiple ascending dose cohort|Participants with advanced solid tumours receive CT7001 (samuraciclib) as oral monotherapy, in ascending dose cohorts, to identify the maximum tolerated dose (MTD), minimally biologically active dose (MBAD) and recommended dose for Phase II testing (RP2D).
62622574|NCT03363893|EXPERIMENTAL|Module 1 Part B-2 Castrate resistant prostate Cancer (CRPC) Expansion|Participants with castrate resistant prostate cancer will receive CT7001(samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.
62622575|NCT03363893|EXPERIMENTAL|Module 1 Part B-1 Triple-negative breast cancer (TNBC) Expansion|Participants with locally advanced or metastatic triple-negative breast cancer (TNBC) will receive CT7001(samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.
62622576|NCT03363893|EXPERIMENTAL|Module 2 Part A|Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer will receive CT7001 (samuraciclib) at the dose, frequency and schedule recommended from Module 1 part A and will receive Fulvestrant solution in pre-filled syringe for intramuscular (IM) injection
62622577|NCT03363893|EXPERIMENTAL|Module 4|Participants with advanced solid tumours will receive CT7001(samuraciclib) oral monotherapy in a randomized, balanced, single-dose, two-treatment (fed v fasting), two-period, two-sequence crossover study followed by once daily continuous dosing.
62622578|NCT03363893|EXPERIMENTAL|Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort|Participants with locally advanced or metastatic breast cancer will receive CT7001 (samuraciclib) as oral monotherapy at the minimally biologically active dose (MBAD) and recommended dose for Phase II testing (RP2D).
62622579|NCT02514200|EXPERIMENTAL|Topography-based CXL (KXL2)|Individualized pulsed topography-based corneal crosslinking; 1 second on, 1 second off; 7.2J/cm2 - 15.0J/cm2; arcuate treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.
62622580|NCT02514200|ACTIVE_COMPARATOR|Conventional pulsed CXL (pCXL)|Conventional pulsed corneal crosslinking; 1 second on, 1 second off; 5.4 J/cm2; 8 mm central treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.
62265309|NCT03134872|EXPERIMENTAL|SHR-1210+Chemotherapy|Subjects receive SHR-1210 200mg and pemetrexed 500 mg/m\^2 and carboplatin AUC 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional SHR-1210 200mg and pemetrexed 500 mg/m\^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
62265310|NCT03134872|ACTIVE_COMPARATOR|Chemotherapy|Subjects receive pemetrexed 500 mg/m\^2 and carboplatin Area Under the Curve (AUC) 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m\^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD. If PD occurs, Subjects may be able to receive SHR-1210 Q3W for the remainder of the study or until documented PD.
62265311|NCT01131377|EXPERIMENTAL|Acetazolamide|"If ABGA is pH ≥ 7.43 \& HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV.~If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip."
62448981|NCT05809674||Adult Cohort|"* Aged 21 and above~* Ability to provide informed consent~* 42 normal controls: No diabetes and free from clinically relevant eye disease that interferes with the aim of the study i.e. glaucoma, diabetic retinopathy, age-related macular degeneration, uveitis, or vascular occlusive diseases~* 76 subjects with pathological myopia (up to -12 dioptres) or staphyloma"
62265312|NCT01131377|PLACEBO_COMPARATOR|Placebo|This group will be managed with general metabolic alkalosis treatment such as electrolyte correction, hydration except acetazolamide.
62622581|NCT04231240||Adult cardiac surgery with normothermia|
62265313|NCT02588976|OTHER|ACT measurements|ACT measurements by SONOCLOT Analyzer during cardiac surgery
62622582|NCT04231240||Adult cardiac surgery with hypothermia|
62622583|NCT04231240||Pediatric cardiac surgery with normothermia|
62265314|NCT01050270|OTHER|Ondansetron /acetylcysteine 20.25h|Ondansetron followed by conventional acetylcysteine regimen
62265315|NCT01050270|OTHER|Placebo/acetylcysteine 20.25h|placebo followed by conventional acetylcysteine regimen
62448982|NCT05809674||Children Cohort|"* Aged 10 to 18~* 23 subjects with low to moderate myopia (-0.75 to -6 dioptres)~* 23 subjects with high myopia (more than -6 dioptres)~* Ability of legal representative and subject to provide informed consent"
62848546|NCT02541396|EXPERIMENTAL|Group F|"Wafermine™ 35 mg + placebo wafer given every 4 hours Placebo wafers given every 2 hours Oxycodone 5 mg given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
62265316|NCT01050270|OTHER|Ondansetron/acetylcysteine 12h|ondansetron followed by modified acetylcysteine regimen
62265317|NCT01050270|OTHER|Placebo/acetylcysteine 12h|placebo followed by modified acetylcysteine regimen
62448983|NCT05254366||Cohort 1|Painless gastroscopic sedation cohort
62265318|NCT00750633|EXPERIMENTAL|Moxidex|Moxidex otic solution
62448984|NCT05254366||Cohort 2|Painless colonoscopy sedation cohort
62622584|NCT04231240||Pediatric cardiac surgery with hypothermia|
62265319|NCT00750633|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin otic solution
62265320|NCT00750633|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone phosphate otic solution
62265321|NCT04225923|EXPERIMENTAL|NPC-21 Low dose|NPC-21 (6mg/kg) will be administered
62265322|NCT04225923|EXPERIMENTAL|NPC-21 High dose|NPC-21 (12mg/kg) will be administered
62622585|NCT04231240||Adult cardiac surgery without cardiopulmonary bypass|
62622586|NCT01681095|EXPERIMENTAL|Cardioplegia: Custodiol HTK Solution|"Custodiol HTK (histidine-tryptophan-ketoglutarate) cardioplegia: One liter of HTK solution (Custodiol; Koehler Chemi, Alsbach-Haenlien, Germany) contains the following components: 15 mmol/L sodium chloride, 9 mmol/L potassium chloride, 4 mmol/L magnesium chloride, 18 mmol/L histidine hydrochloride, 180 mmol/L histidine, 2 mmol/L tryptophan, 30 mmol/L mannitol, 0.015 mmol/L calcium chloride, 1 mmol/L potassium hydrogen 2-ketoglutarate, osmolarity 310 mOsm/kg, pH 7.02-7.20.~Custodiol-HTK was delivered to establish and maintain cardiac arrest. After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. Custodiol-HTK was delivered at a temperature of 4°C - 10°C."
62622587|NCT01681095|ACTIVE_COMPARATOR|Cold Blood Cardioplegia|"Cold Blood Cardioplegia: One liter of cold blood cardioplegic solution, mixed at a ratio of 4:1 per Beaumont standard of care (blood /cardioplegic solution), contains the following in a 500 cc bag of D5W (dextrose 5% in water): 50meq/L potassium chloride, 37.5 meq/L sodium bicarbonate and 7.5 meq/L magnesium sulfate.~After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional \> 200 mL was administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 8°C."
62622588|NCT04513171|EXPERIMENTAL|Y-shape pegylated somatropin low dose|
62622589|NCT04513171|EXPERIMENTAL|Y-shape pegylated somatropin middle dose|
62622590|NCT04513171|EXPERIMENTAL|Y-shape pegylated somatropin high dose|
62622591|NCT04513171|ACTIVE_COMPARATOR|Norditropin-1|
62448985|NCT00792649||1|screening colonoscopy with HD+ endoscopes
62622592|NCT04513171|EXPERIMENTAL|Y-shape pegylated somatropin optimal dose|
62622593|NCT04513171|ACTIVE_COMPARATOR|Norditropin-2|
62622594|NCT01468571|EXPERIMENTAL|Spironolactone|Drug: Spironolactone Drug: Placebo
62622595|NCT01468571|EXPERIMENTAL|Placebo|Drug: Placebo Drug: Spironolactone
62622596|NCT00507858|EXPERIMENTAL|Pemetrexed|Starting dose 500 mg/m\^2 IV once every 3 weeks
62622597|NCT00507858|EXPERIMENTAL|Pemetrexed + IV Dexamethasone|Pemetrexed Starting dose 500 mg/m\^2 IV once every 3 weeks + Dexamethasone 20 mg intravenous (IV) Day 1.
62061339|NCT03397680|ACTIVE_COMPARATOR|Rabeprazole-levofloxacin based quadruple therapy for14 days|Pparticipant will received 14-day once daily dose regimen of 1-tablet 750-mg Levofloxacin after meal, 2-tablet 500-mg Clarithromycin MR after meal, 3-tablet 20-mg Rabeprazole before meal and 1-tablet 1,048-mg Gastro bismol after meal
62265323|NCT04225923|PLACEBO_COMPARATOR|NPC-21 Placebo|Placebo (normal saline) will be administered
62265324|NCT04502485|EXPERIMENTAL|Gastric water exchange|Air will be minimally insufflated to partially open the lumen and any residual fluid will be suctioned when the scope passes through the esophagus. Upon entering the fundus of the stomach the air button will be turned off. Air pocket and gastric fluids will be removed by suctioning. Distilled water, delivered by a 50-ml syringe in 10ml-to-20 ml increments, will be infused to dislodge debris and air bubbles adhering the gastric mucosa and open the lumen. The infused water will be removed to keep the lumen almost completely collapsed before the scope advance further. Air will be opened when the scope enter the prepylorus area where there is usually an air pocket. The scope will enter the duodenal bulb and 2nd portion of duodenum where withdrawal inspection will start.
62265325|NCT04502485|ACTIVE_COMPARATOR|Traditional air insufflation|Air will be minimally insufflated and residual fluid suctioned during the entire insertion process. Usually, no water will be infused to cleanse the mucosa until the withdrawal phase.
62448986|NCT00792649||2|screening colonoscopy with standardvideoendoscopes
62622598|NCT00507858|EXPERIMENTAL|Pemetrexed + Oral Dexamethasone|Pemetrexed starting dose 500 mg/m\^2 IV once every 3 weeks + Dexamethasone 4 mg orally twice daily for 3 Days.
62622599|NCT06406166|EXPERIMENTAL|trial group|The patients in the trial group received routine Western medicine treatments, and oral Lifei Xiaoji Wan (10 pills/time, 3 times/day).
62622600|NCT06406166|NO_INTERVENTION|control group|The patients in the control group received routine Western medicine treatments.
62622601|NCT03151083|ACTIVE_COMPARATOR|Phase 1: Implementation As Usual (Implementation Through Rese|SHUTi digital CBTi Program was implemented in VACT primary care using implementation activities executed by the research team between June 2017 and January 2018 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders (information pamphlets in treatment rooms), Patient Advertising/Information (information pamphlets in treatment rooms), Single Referral Pathway Not Integrated Primary Care Workflow (Primary care provider contact research team for patient referral over email).
62622602|NCT03151083|EXPERIMENTAL|Phase 2: Primary Care Coached Digital CBTi Implementation (Im|SHUTi digital CBTi Program implemented in VACT primary care using implementation activities executed by primary care teams June 2018 and January 2019 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders (information pamphlets in treatment rooms), Patient Advertising/Information (information pamphlets in treatment rooms), patient education and motivational support supplied through a digital CBTi coach, the digital CBTi coach was a primary care nurse trained by the research team, technical support and oversight of the digital CBTi coach by the research team. Single Referral Pathway Not Integrated Primary Care Workflow.
62848547|NCT02541396|EXPERIMENTAL|Group G|"Wafermine™ 70 mg given every 4 hours Placebo wafer given every 2 hours Placebo capsule given every 4 hours 2 Placebo wafers top-up dose at hour 1"
62265326|NCT02051543|EXPERIMENTAL|Brief Behavioral Treatment of Insomnia-Military Version|
62848548|NCT06084871||Patient Blood Management group|Three pillars of patient blood management will be applied
62448987|NCT04065893||Catheter ablation group|Patients with reduced biventricular pacing due to PVC or VT receiving catheter ablation of PVC/VT according to guidelines and clinical practices
62448988|NCT04065893||Medical treatment group|Patients with reduced biventricular pacing due to PVC or VT receiving intensified medical therapy (antiarrhythmics/betablocker) according to guidelines and clinical practices
62623793|NCT01277432||Psychiatrist interview|"All patients will receive the same assessments as the 'active comparator' arm, but in addition those patients found to have positive symptoms for mild to severe depression by PHQ9 or CESD (PHQ\>10 and/or CES\>16) and a random sample of subjects with no or mild symptoms will also undergo a face-to-face interview by a trained clinician or psychiatrist using the following instruments:~* MINI~* SSI-28 (somatization)"
62848549|NCT06084871||Control group|Control
62265327|NCT02291120|ACTIVE_COMPARATOR|MTA|ProRoot® MTA is a root canal repair material that is a unique improvement over other materials used for root canal repair. Made up of fine hydrophilic particles that set in the presence of water, ProRoot® MTA seals off all pathways between the root canal system and surrounding tissues, significantly reducing bacterial migration. Its excellent compatibility with the dentinal wall allows for a predictable clinical healing response.
62265328|NCT02291120|EXPERIMENTAL|MedCem Portland Cement (PC)|MedCem PC is an excellent capping material for cariology on permanent teeth (direct and indirect capping) and in milk tooth endodontics (milk tooth amputation). Is characterized by excellent colour stability and neutrality and does not contain any additional ingredients
62448989|NCT06101836|OTHER|Interventional arm|All participant trainees will undergo the educational intervention, therefore there is only one arm since all participants will undergo the intervention. The intervention is a day where participants (the trainees) will undergo a full day of training in colonoscopy. Comparison of key performance measures in colonoscopy is made before and after the intervention.
62448990|NCT02941458||Non-small cell lung cancer|patients treated for a non small cell lung cancer
62448991|NCT02941458||Small cell lung cancer|patients treated for a small cell lung cancer
62448992|NCT02941458||Mesotelioma|patients treated for a mesotelioma
62448993|NCT02941458||timic cancer|patients treated for a timic cancer
62622603|NCT03151083|EXPERIMENTAL|Phase 3: Primary Care Mental Health Collaborative Care Implem|SHUTi digital CBTi Program implemented in VACT primary care using implementation activities executed by primary care teams April 2019 and November 2019 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders, Patient Advertising/Information, patient education and motivational support supplied through a digital CBTi coach, the digital CBTi coach was a peer support specialist working on the primary care mental health collaborative care team, the digital CBTi coach was trained by the research team, technical support and oversight of the digital CBTi coach by the research team. Additional members primary care mental health collaborative care team were educated to provide education about digital CBTi. Multiple referral pathways to digital CBTi: consults to the digital CBTi Coach, warm handoffs to primary care mental health collaborative care team. Digital CBTi coach consults integrated Primary Care Workflow.
62622604|NCT02310880||Low vision (virtual street training)|Low vision subjects trained in virtual streets and observed in real streets
62622605|NCT02310880||Low vision (real street training)|Low vision subjects trained in real streets and observed in real streets
62622606|NCT04296578|EXPERIMENTAL|Cohort 1: 5.5 mg selenite|Given orally, 5.5 mg selenite with food (within 30 mins of eating), for 5 weeks and monthly there after
62622607|NCT04296578|EXPERIMENTAL|Cohort 2: 11 mg selenite|Given orally, 11 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
62061340|NCT04402463|EXPERIMENTAL|GPR Group|"Global Postural Reeducation with 2 parts in each session:~1. st: 2 postures in lying position - without gravity load (15 minutes each posture): The aim of these postures is to achieve and maintain postural balance and to stretch the posterior muscle chain. In order to achieve this, specific exercises in the lying position are used. That exercises involve a precise use of contractions, stretch reflexes, light and controlled manual tractions and sustained elongations.~   The maintenance of alignment during posture will be achieved by verbal commands and manual contact of the therapist, guaranteeing the active engagement of patient to reach the correct posture.~2. st: Standing posture - integration under gravity load (10 minutes): With the participant standing the physiotherapist makes final corrections for postural integration."
62448994|NCT02941458||carcinoid cancer|patients treated for a carcinoid cancer
62448995|NCT01435681||DYT-1 Postive|This group includes those participants who enroll having a genetically confirmed primary generalized dystonia diagnosis.
62448996|NCT01435681||Control|This group includes healthy subjects between the ages of 18 and 80.
62448997|NCT05434403|PLACEBO_COMPARATOR|Sham stimulation group|
62448998|NCT05434403|EXPERIMENTAL|stimulation group|
62448999|NCT02980848||Screening group|Women without a history of breast cancer undergoing screening digital mammography, screening digital breast tomosynthesis, or screening breast magnetic resonance imaging.
62622608|NCT04296578|EXPERIMENTAL|Cohort 3: 16.5 mg selenite|Given orally, 16.5 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
62622609|NCT04296578|EXPERIMENTAL|Cohort 4: 22 mg selenite|Given orally, 22 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
62622610|NCT04296578|EXPERIMENTAL|Cohort 5: 27.5 mg selenite|Given orally, 27.5 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
62848550|NCT00573144|PLACEBO_COMPARATOR|Placebo|Infusion of 72 hours of saline solution (packaged to match active comparator).
62622611|NCT04296578|EXPERIMENTAL|Cohort 6: 33 mg selenite|Given orally, 33 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
62622612|NCT00822328|EXPERIMENTAL|1|Fermented milk with Lactobacillus casei strain Shirota 100ml per day
62622613|NCT00822328|PLACEBO_COMPARATOR|2|Unfermented milk without Lactobacillus casei strain Shirota 100ml per day
62622614|NCT03453957|EXPERIMENTAL|Professional Development Program|Therapists who participate in workshops and consultation sessions with study trainers during study-related therapy sessions and their participating patients/clients.
62848551|NCT00573144|ACTIVE_COMPARATOR|Nesiritide|Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
62848552|NCT02460796||hippotherapy group or study group|8 weeks of hippotherapy therapy: Familiarization sessions were initially 15 minutes and gradually evolved to 30 minutes in order to allow all participants to adapt to the horse's rhythmic movements and to the act of mounting the horse. Each session had warm up before the training and exercises for relaxation in the end of each session.
62061341|NCT04402463|EXPERIMENTAL|Exercise Group|"Therapeutic exercises. That they will be divided into 3 phases:~The exercises in these phases will consist in active exercises of the cervical spine and shoulder girdle, motor control exercises, and finally strength and endurance of the cervical flexors and extensors and of the musculature of the shoulder girdle."
62061342|NCT02820363|EXPERIMENTAL|Test|"Tibial fracture fixation with IM Nail. Apply CERAMENT™\|G applied to bony void(s)."
62265329|NCT06479421||Acute Respiratory Failure group|"Among patients admitted to the internal medicine intensive care unit at Samsung Seoul Hospital, if all of the following conditions are met:~1. Age 18 or older~2. Patients who require treatment with high flow nasal cannula (HFNC), non-invasive ventilation (NIV (BIPAP or CPAP)), or mechanical ventilation (MV) due to acute respiratory failure."
62265330|NCT06479421||Control group|"For comparative analysis, among patients admitted to the internal medicine intensive care unit at Samsung Seoul Hospital who meet all of the following conditions, they are registered as a control group with the consent of the subjects and undergo the same research procedure.~1. Age 18 or older~2. Patients who do not require high flow nasal cannula (HFNC), non-invasive ventilation (NIV (BIPAP or CPAP)), or mechanical ventilation (MV) treatment"
62265331|NCT00404014|ACTIVE_COMPARATOR|AL-208|1 dose of 300 mg
62265332|NCT00404014|PLACEBO_COMPARATOR|Placebo|
62265333|NCT02681237|EXPERIMENTAL|Cediranib and Olaparib|"Cediranib will be given by mouth, at a dose of 20 mg, once a day, everyday.~Olaparib will given by mouth, at a dose of 300 mg, twice a day, every day."
62265334|NCT00790907|EXPERIMENTAL|Open label fondaparinux background and standard dose UFH|Subjects indicated for PCI and randomized to receive standard dose UFH
62265335|NCT00790907|EXPERIMENTAL|Open label fondaparinux background and low dose UFH|Subjects indicated for PCI and randomized to receive low dose UFH
62265336|NCT00790907|OTHER|Open label fondapaparinux|Subjects not indicated for PCI and not randomized
62265337|NCT06118684|EXPERIMENTAL|Part A - EP395 as a 'victim' of DDIs|Part A will investigate EP395 as a 'victim' of DDIs. The impact of CYP3A4 and P-glycoprotein (Pgp) inhibition on the pharmacokinetics (PK) of EP395 will be assessed. Verapamil has been selected as a moderate inhibitor of CYP3A4 and an inhibitor of Pgp.
62265338|NCT06118684|EXPERIMENTAL|Part B - EP395 as a 'perpetrator' of DDIs|Part B will investigate EP395 as a 'perpetrator' of DDIs. The impact of EP395 on the PK of a CYP3A4 substrate and a Pgp substrate will be assessed. Midazolam has been selected as the CYP3A4 substrate and digoxin as the Pgp substrate.
62265339|NCT01081249|EXPERIMENTAL|Placebo then Oxytocin|Participant was randomized to receive placebo before the first psychotherapy session, and then received the active drug at the second visit.
62265340|NCT01081249|EXPERIMENTAL|Oxytocin then placebo|Participant was randomized to receive placebo before the first psychotherapy session, and then received the active drug at the second visit.
62622615|NCT03453957|NO_INTERVENTION|Control|Therapists who did not participate in workshops and consultations sessions while engaging in study-related therapy sessions and their participating patients/clients.
62622616|NCT00187278|ACTIVE_COMPARATOR|RV Pacing|Standard Pacemaker implant
62622617|NCT00187278|EXPERIMENTAL|Biventricular Pacing|Biventricular Pacemaker implant
62622618|NCT02025933||Salmon Group|Participants will eat 75 - 150 grams of salmon for dinner, three times a week for 12 weeks.
62622619|NCT02025933||Cod Group|Participants will eat 75-150 grams of cod for dinner, three times a week for 12 weeks.
62622620|NCT02025933||Meat Group|Participants will eat 75-150 grams of mixed meat for dinner, three times a week for 12 weeks.
62622621|NCT04010084|PLACEBO_COMPARATOR|Control group|
62622622|NCT04010084|ACTIVE_COMPARATOR|Laser group|
62848553|NCT02460796||control group|8 weeks of Parkinson's disease lectures: this group did not hippotherapy classes in the same period.
62848554|NCT00530504|EXPERIMENTAL|Device|Device
62848555|NCT02130791|EXPERIMENTAL|PSD then TSD|baseline sleep, five nights sleep restriction, four nights recovery sleep, one night total sleep deprivation, one night recovery sleep
62265341|NCT00879645|EXPERIMENTAL|Sodium Sulfide - Mild Cohort|Mild renal impairment (RI) Cohort administered 1.5 mg/kg/hr infusion of Sodium sulfide intravenously for 3 hours.
62622623|NCT03925181|EXPERIMENTAL|Intervention|Recovery counselling group.
62622624|NCT03925181|NO_INTERVENTION|Waitlist control|Waitlist control group. Will receive intervention after arm one is complete.
62622625|NCT02837302|ACTIVE_COMPARATOR|Livact|Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
62622626|NCT02837302|NO_INTERVENTION|General nutritional support|General nutritional support
62622627|NCT03365960|ACTIVE_COMPARATOR|Active1|watermelon rind
62622628|NCT03365960|ACTIVE_COMPARATOR|Active2|watermelon flesh
62848556|NCT02130791|EXPERIMENTAL|TSD then PSD|baseline sleep, one night total sleep deprivation, four nights recovery sleep, five nights sleep restriction, one night recovery sleep
62622629|NCT03365960|ACTIVE_COMPARATOR|Active3|watermelon seeds
62622630|NCT03365960|PLACEBO_COMPARATOR|Control Comparator|placebo
62265342|NCT00879645|EXPERIMENTAL|Sodium Sulfide - Healthy Cohort|Healthy subjects received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
62848557|NCT04500262|ACTIVE_COMPARATOR|Open-tip pulsed needle biopsy|"Biopsy procedure using the NeoNavia biopsy system. The needle used in this study is of the same outside diameter as a standard biopsy needle used in the breast or axilla (14-gauge) but does not have a notched trochar like a conventional spring-loaded device. It does not have a redundant portion of needle beyond the sampling zone and takes full circumference cylindrical cores.~A pneumatic system powered by a floor-standing base unit connected via a handheld driver to the biopsy device provides impulses to the needle, allowing the operator to advance the needle through tissue with little manual force (NeoNavia biopsy system, NeoDynamics, Sweden)."
62848558|NCT04500262|ACTIVE_COMPARATOR|Conventional core needle biopsy (CNB)|Standard of care core needle biopsy used currently in clinics for biopsy procedures
62848559|NCT02657785|EXPERIMENTAL|R-IDARAM plus intrathecal chemotherapy|Patients will be treated with systemic R-IDARAM plus intrathecal immunochemotherapy
62848560|NCT04267913|EXPERIMENTAL|Arm A (docetaxel, dexamethasone, sapanisertib)|Patients receive docetaxel IV and dexamethasone IV over 30 minutes on days 1 and 8 and sapanisertib PO QD on days 2-4, 9-11, and 16-18. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. If docetaxel is discontinued, patients receive sapanisertib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62848561|NCT04267913|ACTIVE_COMPARATOR|Arm B (standard of care treatment)|Patients receive standard of care treatment comprising either docetaxel IV and dexamethasone IV over 30 minutes on day 1 or docetaxel IV, dexamethasone IV over 30 minutes, and ramucirumab IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62848562|NCT04193644|ACTIVE_COMPARATOR|Walking-Group|Participants in this group walk 45 minutes 3 times a week (plus 15 minutes of warm up and cool-down) in a moderate intensity range (64-76% HRmax).
62848563|NCT04193644|EXPERIMENTAL|Mindfulness and Self-Compassion focussed Walking-Group|Participants in this group walk 45 minutes 3 times a week (plus 15 minutes of warm up and cool-down) in a moderate intensity range (64-76% HRmax) and additionally practice mindfulness exercises and self-compassion exercises during the 60 minutes.
62848564|NCT04193644|NO_INTERVENTION|TAU-Group|Participants in this group receive no intervention.
62622631|NCT03671785|EXPERIMENTAL|Active group treated with healthy fecal microbiota|
62622632|NCT03671785|EXPERIMENTAL|Placebo group|
62061343|NCT02820363|ACTIVE_COMPARATOR|Control|Tibial fracture fixation with IM nail.
62061344|NCT02385734|EXPERIMENTAL|Concentrated growth Factor Membrane|Autogenous platelet and leukocyte fibrin material was obtained from blood.
62265343|NCT00879645|EXPERIMENTAL|Sodium Sulfide - Moderate Cohort|Moderate RI cohort received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
62449000|NCT02980848||Women with breast cancer|Women diagnosed with stage 0-III breast cancer undergoing pre-operative work-up with diagnostic mammography alone or diagnostic mammography plus pre-operative breast magnetic resonance imaging.
62449001|NCT02007148|EXPERIMENTAL|micado|CAPECITABINE 500 mg twice a day, orally, continuously DOCETAXEL 60 mg/sqm i.v. over 1 hr on day 1 cycles repeated every 3 weeks Duration of treatment: Chemotherapy should be continued until: progressive disease; unacceptable toxicities; patients' refusal; or upon investigator's judgement is in the best interest for the patient.
62449002|NCT03097042|ACTIVE_COMPARATOR|Study group|The catheter will be pulled back slowly and without rotation
62622633|NCT00966732|EXPERIMENTAL|yoga condition|assigned to start the yoga program right away
62622634|NCT00966732|NO_INTERVENTION|wait-list control condition|This condition will control for any effects of symptom measurement reactivity in patients receiving routine fibromyalgia medical care. After the 3-month assessment, the yoga intervention program will be provided to these patients.
62061345|NCT02385734|ACTIVE_COMPARATOR|Coronally Advanced Flap|Periodontal plastic surgery procedure in the treatment of gingival recession
62061346|NCT01529281|EXPERIMENTAL|BCAA|Branched chain amino acid
62622635|NCT03678675|NO_INTERVENTION|Standard Protocol|Subjects randomized to the standard group will receive the standard postoperative pain protocol that is currently used at Tufts Medical Center. It includes two doses of IV Ketorolac every 6 hours as needed for postoperative pain. Ibuprofen would be ordered 6 hours following the last dose after the last study drug.
62848565|NCT06190197|NO_INTERVENTION|Control group|No prophylactic antibiotics post operatively. Participants will receive antibiotics only if needed post-operatively such as for infection
62061347|NCT01529281|PLACEBO_COMPARATOR|Asparmate|Placebo control containing no protein or carbohydrate
62265344|NCT00879645|EXPERIMENTAL|Sodium Sulfide - Severe Cohort|Severe RI cohort received sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
62265345|NCT03488875|EXPERIMENTAL|mMBRT|Individuals in the mMBRT group will receive an 8-week mindfulness-based intervention in groups of approximately 15 individuals in 8 weekly 2-hour classes (one of these classes, toward the end of the course, is approximately 4 hours and integrates many of the practices and teachings covered throughout the training program).
62449003|NCT03097042|ACTIVE_COMPARATOR|Control Group|The catheter will be pulled back by rotating 360 degrees round itself
62449004|NCT02005133||VEGF inhibitor naïve|
62848566|NCT06190197|EXPERIMENTAL|Treatment group|Prophylactic antibiotics postoperatively.
62061348|NCT05094401|EXPERIMENTAL|Intervention BT-001 + Standard of Care|BT-001 is a software program used with physician guidance, being investigated to improve glycemic control. Patients randomized to this arm of the study will interact with the BT-001 software program in addition to receiving Standard of Care for type 2 diabetes
62265346|NCT03488875|NO_INTERVENTION|Waitlist control group|Individuals in the waitlist control group will complete the same assessments as those in the active treatment group, but will not be offered any intervention until the conclusion of the trial. At this time, control group participants will be offered the intervention.
62265347|NCT03953066|ACTIVE_COMPARATOR|women with vaginal delivery|30 women with spontaneous vaginal delivery will be included in group 1 serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
62848567|NCT03418961|EXPERIMENTAL|Arm I (carvedilol)|Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive carvedilol PO BID. Courses repeat every 12 weeks for 108 weeks in the absence of disease progression or unacceptable toxicity.
62848568|NCT03418961|ACTIVE_COMPARATOR|Arm II (no intervention)|Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive no study intervention for up to 108 weeks.
62848569|NCT03418961|ACTIVE_COMPARATOR|Arm III (observation)|Patients undergo observation for up to 108 weeks.
62848570|NCT06071585||patients with Eosinophilic esophagitis (EoE)|
62848571|NCT06071585||patients with gastroesophageal reflux disease (GERD)|
62848572|NCT06071585||controls (patients without EoE e GERD)|
62848573|NCT00139477|EXPERIMENTAL|Diet/Exercise only, then Diet/Exercise plus Metformin|Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period).
62848574|NCT00139477|ACTIVE_COMPARATOR|Diet/Exercise plus Metformin, then Diet/Exercise only|Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period).
62848575|NCT04765267|ACTIVE_COMPARATOR|Topical Corticosteroid with Systemic Zinc.|Octozinc: Zinc sulphate heptahydrate 25 mg tablets - October Pharma
62848576|NCT04765267|ACTIVE_COMPARATOR|Topical Corticosteroid with Systemic Vitamin D|Cholecalciferol: vitamin D3 15 ml oral solution - Medical Union Pharmaceuticals
62848577|NCT04765267|OTHER|Topical Corticosteroid|Kenacort A Orabase: triamcinolone acetonide 0.1% adhesive paste - Dermapharm
62848578|NCT06149468||ASD group|child/adolescent (under 18 years of age) applying to an autism reference center or being followed up in an autism reference center
62848579|NCT03233984|NO_INTERVENTION|Leaflet only|Women will only receive a leaflet about endocrine disruptor at home.
62848580|NCT03233984|ACTIVE_COMPARATOR|non immersive program|In addition of the leaflet, women will sit in the sensibilisation program that will take place in a neutral environment
62848581|NCT03233984|EXPERIMENTAL|immersive program|In addition of the leaflet, women will si in the sensibilisation program that will take place in an immersive environment
62848582|NCT03278353|EXPERIMENTAL|Conservative care|Exercise and manual therapy
62848583|NCT01403597|EXPERIMENTAL|Treatment|The defined areas for treatment are the entire face or at least two facial sub areas (e.g., peri-orbital and peri oral) with the combination of two devices where a total of 5 treatments every 4 weeks will be administered
62848584|NCT01898481||Health Care Triads|This is an exploratory pilot study of 25 health care triads. Triads will include: (1) a patient diagnosed with advanced cancer, (2) a loved one, and (3) an oncology provider.
62848585|NCT01838980|EXPERIMENTAL|Colonoscopy|
62061349|NCT04534634|EXPERIMENTAL|Experimental group|IFN-α combined with CAR T-cells therapy
62061350|NCT04534634|NO_INTERVENTION|Control group|CAR T-cells therapy
62265348|NCT03953066|ACTIVE_COMPARATOR|women with emergency cesarean section|30 women with emergency cesarean section will be included in group 2 serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
62449005|NCT02005133||VEGF inhibitor prior treated|
62449006|NCT02837978|EXPERIMENTAL|Tacrolimus group|RA patients treated with tacrolimus, without MTX
62848586|NCT06519045||1|Dosed with 3x60mg codeine
62848587|NCT01311024||Sibling vaccinated with PCV GSK1024850A|"Older sibling of a child vaccinated with Pneumococcal conjugate vaccine GSK1024850A in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)~NOTE: the primary analysis cohort include siblings of the PCV-vaccinated according to infant schedules (excluding siblings of catch-up vaccinated children)"
62848588|NCT01311024||Control-vaccinated sibling|"Older sibling of a child vaccinated with control vaccine (hepatitis B vaccine or hepatitis A vaccine) in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)~NOTE: the primary analysis cohort include siblings of the PCV-vaccinated according to infant schedules (excluding siblings of catch-up vaccinated children)"
62848589|NCT02089893||Healthy subjects|Healthy subjects
62265349|NCT03953066|ACTIVE_COMPARATOR|women with elective cesarean section|30 women with elective cesarean section will be included in group 3serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
62449007|NCT02837978|ACTIVE_COMPARATOR|Tacrolimus + MTX group|RA patients treated with tacrolimus and MTX
62449008|NCT04767074|EXPERIMENTAL|Non-pharmacological Cough control therapy|"Participants will attend four virtual sessions of 45 to 60 minutes of educational and self-management. Sessions will be designed to target participants' needs and expectations according to the semi-structured theme.~Session 1 General assessment Prescription of cough technique~Session 2 Cough principles of cough Cough control~Session 3 Breathing pattern retraining and laryngeal hygiene~Session 4 Reinforcement of cough control therapies"
62449009|NCT06203314||Zhongshan cohort, Guangdong, China|30-59 years old healthy participants in Zhongshan city.
62449010|NCT06203314||Wuzhou cohort, Guangxi, China|30-69 years old healthy participants in Wuzhou city.
62622636|NCT03678675|EXPERIMENTAL|Ketorolac Protocol|Subjects randomized to the Ketorolac protocol will receive the study postoperative pain protocol. This includes 6 doses of IV Ketorolac, scheduled every 6 hours. The first dose is administered in the operating room or post-operative care unit.
62622637|NCT03514056||1|group Behcet
62622638|NCT03514056||2|group fibromyalgia
62848590|NCT02048319|EXPERIMENTAL|Experimental: Pasireotide LAR 60 mg|The subjects will be randomized (1:1) into two groups. Both groups will undergo aspiration sclerotherapy following the standard procedure. The intervention group will additionally receive two injections of 60 mg pasireotide long-acting release (LAR) intramuscularly: the first injection 14 days before and the second injection 14 days after the intervention.
62848591|NCT02048319|PLACEBO_COMPARATOR|Placebo|Patients in the placebo arm will receive two injections of saline solution corresponding to the scheme of the intervention group.
62848592|NCT03883841||Study group|patients with iron deficiency anemia
62848593|NCT03883841||control group|normal pregnant patients
62265350|NCT05113576||patient|patients with DLBCL
62848594|NCT04806555|EXPERIMENTAL|Compression ultrasound|All recruited patients
62848595|NCT03919578|EXPERIMENTAL|Hep B Batch 1|1 dose of 1 mL Hepatitis B Batch 1
62449011|NCT06138535|OTHER|Masticatory Muscle Disorder patients treated by digital stabilizing splint|digital stabilizing splint
62449012|NCT04976959|EXPERIMENTAL|Parkinson's patients|Parkinson's patients who will receive a high fiber supplement
62848596|NCT03919578|EXPERIMENTAL|Hep B Batch 2|1 dose of 1 mL Hepatitis B Batch 2
62061351|NCT01423422||Frequency exposed patients|Patients exposed to the magnetic field with the specific frequency
62449013|NCT04976959|NO_INTERVENTION|Control subjects|no supplement will be given
62449014|NCT03892759|OTHER|Evaluation and Treatment|Subjects will be evaluated through inspection and palpation of the thoracic and lumbar spine, and other body regions as necessary. The provider will make a diagnosis of somatic dysfunction based off the TART (tissue texture change, asymmetry, restriction of motion, tenderness/pain) findings.
62449015|NCT05892211||Group 1 (vasomotor symptoms present)|Participants who have vasomotor symptoms. Sleep is recorded by polysomnography for a night. Hot flashes during sleep are recorded by two electrodes measuring the skin conductance near sternum. Any hot flashes reported subjectively by the patient during the recording is noted. Their blood samples are obtained.
62449016|NCT05892211||Group 2 (vasomotor symptoms absent)|Participants who don't have vasomotor symptoms. Sleep is recorded by polysomnography for a night. Hot flashes during sleep are recorded by two electrodes measuring the skin conductance near sternum. Any hot flashes reported subjectively by the patient during the recording is noted. Their blood samples are obtained.
62449017|NCT03439163||PD patients|the entire group underwent MRI scan
62848597|NCT03919578|EXPERIMENTAL|Hep B Batch 3|1 dose of 1 mL Hepatitis B Batch 3
62848598|NCT03919578|ACTIVE_COMPARATOR|Hep B (Bio Farma)|1 dose of 1 mL Hepatitis B (Bio Farma)
62449018|NCT02669680|EXPERIMENTAL|G-CSF + Standard therapy|Standard care of acute-on-chronic liver failure and application of G-CSF
62449019|NCT02669680|ACTIVE_COMPARATOR|Standard therapy|Standard care of acute-on-chronic liver failure
62622639|NCT03061578||NDE|"Non Dry Eye (NDE) group will be used as control for DES diagnosis.~Subjects in the non-dry eye criteria must meet all of the following criteria:~1. Have a Schirmer's Test (without anesthesia) of ≥10mm/5min in both eyes~2. OSDI questionnaire score \<13.~3. Fluorescein TBUT \> 7 s in both eyes.~4. CFS of 0 in all areas in both eyes.~The NDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
62622640|NCT03061578||ADDE|"Aqueous Deficiency Dry Eye (ADDE) group will be define by commonly known signs and symptoms.~In order to classify subjects to the moderate to severe ADDE group, subjects must meet a predefined medical condition (Rheumatoid Arthritis, Dermatomyositis, Lupus or Sjögren's syndrome) and meet at least one of the following conditions:~1. Have a Schirmer's Test (without anesthesia) of ≤5mm/5min in either eye~2. Mean CFS of ≥1 in either eye.~3. Fluorescein TBUT ≤5 s in either eye.~4. OSDI questionnaire score ≥20~The ADDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
62265351|NCT02488369|EXPERIMENTAL|Patients with non-Hodgkin's lymphoma|
62265352|NCT00689468|PLACEBO_COMPARATOR|1|"Osteopathic sham treatment plus placebo Echinacea drops"
62265353|NCT00689468|ACTIVE_COMPARATOR|2|Active Echinacea drops plus sham osteopathic treatment
62848599|NCT04692636||Total study cohort|Patients with dysfunctional hemodialysis vascular access referred for PTA or patients who received maintenance hemodialysis will be prospectively enrolled.
62848600|NCT01324037|EXPERIMENTAL|clinically suspected upper extremity deep vein thrombosis|Patients with suspected upper extremity DVT
62848601|NCT03093571|EXPERIMENTAL|Auricular stimulation|Auricular stimulation using indwelling auricular acupuncture needles
62848602|NCT03093571|EXPERIMENTAL|Muscle relaxation|Progressive muscle relaxation according to Jacobsen
62848603|NCT03093571|NO_INTERVENTION|No intervention|No intervention, just monitoring of outcome parameters
62848604|NCT04986436|EXPERIMENTAL|HS-10360|Either single or multiple doses of varying dose levels
62265354|NCT00689468|ACTIVE_COMPARATOR|3|"Active osteopathic manipulation plus placebo Echinacea drops"
62265355|NCT00689468|ACTIVE_COMPARATOR|4|Active osteopathic manipulation plus active Echinacea drops.
62265356|NCT04876014|EXPERIMENTAL|GMBPMI group|Participants in the experimental group will receive GMBPMI. A new participant (a pregnant woman in the second trimester) is expected to complete the 6 EBMI lessons in 6 weeks, and do the mindfulness practice for about 30-60 minutes daily. The project RA will send prompt and guidance for daily mindfulness practice to each participant through social media platform. Participants will also be asked to keep log of daily mindfulness practice from T0 to T3 using Google Form. The project RA will be available online to support, and will initiate chat every week throughout the whole intervention period. The chats will focus on participants' experiences or difficulties of mindfulness practice. The RA is backed up by the PI and co-I's who are experienced mental health practitioner and mindfulness teacher. One of them is an obstetrics and gynaecology specialist.
62061352|NCT03859401|EXPERIMENTAL|Control - Experimental Admissions|Subjects will be randomized following the Data Collection Phase in a 1:1 ratio. Subjects in the Control-Experimental Arm will undergo the Control Admission first, utilizing an artificial pancreas (AP) controller that does not anticipate exercise (rMPC - naïve model predictive control), followed by the Experimental Admission, which will utilize an AP controller that has the ability to anticipate exercise (EnMPC - ensemble model predictive control). During the 36-hour admissions, subjects will begin using the study AP system (control or experimental) on Day 1 around midday with a scheduled exercise activity in the evening. Day 2 will consist of minimal activity and subjects will be discharged in the evening on Day 2.
62061353|NCT03859401|EXPERIMENTAL|Experimental - Control Admissions|Subjects will be randomized following the Data Collection Phase in a 1:1 ratio. Subjects in the Experimental-Control Arm will undergo the Experimental Admission first, utilizing an artificial pancreas (AP) controller that has the ability to anticipate exercise (EnMPC), followed by the Control Admission, which will utilize an AP controller that does not have the ability to anticipate exercise (rMPC). During the 36-hour admissions, subjects will begin using the study AP system (control or experimental) on Day 1 around midday with a scheduled exercise activity in the evening. Day 2 will consist of minimal activity and subjects will be discharged in the evening on Day 2.
62061354|NCT03704584|ACTIVE_COMPARATOR|Treatment Group (corticosteroid injection plus lidocaine)|Treatment Group (corticosteroid injection plus lidocaine) subjects will receive (Methylprednisolone acetate injectable suspension and Lidocaine HCl) for their upper extremity condition
62265357|NCT04876014|ACTIVE_COMPARATOR|Perinatal Psycho-education group|To control for attention and placebo effects, every new participant in the control group will receive weekly web-based psychoeducation program for perinatal care. The project RA will also be available online to support, and will initiate chat every week throughout the whole intervention period. The chats will focus on participants' experiences of the psychoeducation program.
62265358|NCT01660360|EXPERIMENTAL|Tanibirumab|The total dose of Tanibirumab for each patient will depend on dose level assignment and the patient's weight. Dose levels to be potentially tested in Phase I include: 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg, 16 mg/kg, and 20 mg/kg.
62265359|NCT00893724|PLACEBO_COMPARATOR|P (Placebo)|
62265360|NCT00893724|ACTIVE_COMPARATOR|S (Supplement)|
62449020|NCT05662553|EXPERIMENTAL|Ablation|After randomization, the enrolled patients in this arm should be performed path simulation under ENB with preoperative CT. On the operation day, single-cavity intubation will be carried out first, and the secondary lesion will be reached through the planned path. After that，the biopsy tissue of the lesion will be sent to ROSE for detection. If malignant，the ablation will be performed，and the location, energy and ablation time will be adjusted according to intraoperative CT. After ablation, radical surgery will be performed on the primary lesion.
62848605|NCT04986436|PLACEBO_COMPARATOR|Placebo|
62848606|NCT04009733|EXPERIMENTAL|Osteogenesis imperfecta type 1|Patients with OI type 1
62848607|NCT04009733|EXPERIMENTAL|Osteogenesis imperfecta type 3|Patients with OI type 3
62848608|NCT04009733|ACTIVE_COMPARATOR|Control population|The control population corresponds to a pre-existing serum collection of osteoarthritis cohorts (OFELY and MODAM for women, STRAMBO for men).
62848609|NCT06343480|ACTIVE_COMPARATOR|first arm - Oxytocin titration|Received vitamin c 100mg as placebo and had Oxytocin titration in 500ml of ringers lactate for labour induction
62061355|NCT03704584|OTHER|Control Group (corticosteroid alone)|Control Group (corticosteroid alone) subjects will receive (Methylprednisolone acetate injectable suspension) for their upper extremity condition
62265361|NCT00893724|ACTIVE_COMPARATOR|SM (Supplement with Minocycline)|
62265362|NCT04784182|EXPERIMENTAL|Synbiotic supplement group|Daily consumption of pills containing prebiotics and probiotics
62265363|NCT04784182|PLACEBO_COMPARATOR|Placebo group|Daily consumption of pills containing maltodextrin
62848610|NCT06343480|ACTIVE_COMPARATOR|second arm - Misoprostol give sublingual|received 25mcg of Misoprostol and titration of plane 500ml of ringers lactate as placebo
62848611|NCT01689532|EXPERIMENTAL|Sirukumab 100 mg|
62848612|NCT01689532|EXPERIMENTAL|Sirukumab 50 mg and Placebo|
62848613|NCT00243841|EXPERIMENTAL|Radiation Treatment Arm :A|Patients with a score of Childs A Will receive 3 fractions of radiation over 5-10 days
62848614|NCT00243841|EXPERIMENTAL|Radiation Treatment Arm: B|Patients with a score of Childs B will receive 5 fractions of radiation over 2-6 weeks.
62848615|NCT04076098|EXPERIMENTAL|Minocycline|Minocycline gel
62848616|NCT04076098|PLACEBO_COMPARATOR|Placebo|Similar gel without the active agent
62848617|NCT03405961||Manual PAR score|Patient will receive upper and lower impressions, which will be cast to produce plaster models. A calibrated individual will PAR score the casts in the traditional manner (regular care pathway)
62265364|NCT01674101|EXPERIMENTAL|Physical Therapy|"The intervention group will receive PT 3 times per week for 60 minutes each session. The therapy sessions will include endurance, strengthening, and stretching exercises.~Exercise time and resistance will be progressed per individual's medical status and per participant's tolerance. All participants will be given a tailored home exercise program (HEP).~Participants will participate in PT 10 weeks prior to surgery and 10-12 weeks after surgery. Subjects will be seen by the physical therapist both when inpatient and outpatient. Patients will not be seen for PT if platelet count is less than 20,000mm3 and/or hemoglobin is less than 8g/dL."
62265365|NCT03374189|EXPERIMENTAL|EZ Close arm|EZ close used for port-site closure.
62265366|NCT03374189|ACTIVE_COMPARATOR|Carter Thomason arm|Carter Thomason used for port-site closure.
62848618|NCT03405961||Direct digital PAR score|Patient will receive upper and lower intra-oral scans which will be PAR scored directly by the computer
62061356|NCT05813067|EXPERIMENTAL|Test Product: JDS-HF3.0 Capsules|Dietary supplement containing a proprietary botanical blend with NK3R antagonistic activity
62061357|NCT05813067|PLACEBO_COMPARATOR|Placebo Capsules|"Placebo capsule containing:~* Microcrystalline cellulose~* Silicon dioxide micronized~* Magnesium stearate"
62061358|NCT05582551|EXPERIMENTAL|Patients: Highlighting Patients at Risk for Sensory Screening (HPARSS)|"* The primary oncology team will utilize the HPARSS to identify patients who are at risk for sensory deficits based on prior treatment. The HPARSS will constitute a file of that will contain eligible patients based upon their past treatment and their corresponding risk for a particular sensory deficit based upon that treatment. The patient and parent/guardian will be approached to participate in the study.~* Sensory deficit screening will be completed in the clinic and any screening results that indicate the need for referral for diagnostic testing or therapy will be scheduled by the primary treatment team staff."
62265367|NCT02343159|EXPERIMENTAL|Arm 1: Standard MEMS Cap|A standard MEMS cap that records the time and date when the bottle is opened without a visual LCD reader. Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
62265368|NCT02343159|EXPERIMENTAL|Arm 2: Smart MEMS Cap|A smart MEMS cap with feedback (an LCD reader that allows the participant to monitor DMF bottle openings). Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
62265369|NCT02343159|EXPERIMENTAL|Arm 3: Smart MEMS Cap + Counseling|A smart MEMS cap with feedback (an LCD reader that allows the participant to monitor DMF bottle openings) and an adherence counseling intervention. Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
62265370|NCT02258451|EXPERIMENTAL|Radium-223 dichloride + exemestane/everolimus|Up to 6 cycles of radium-223 dichloride 50kBq/kg body weight (55 kBq/kg after implementation of National Institute of Standards and Technology \[NIST\] update) (randomized). Participants will also receive exemestane, 25-mg tablet once daily (after a meal), and everolimus, 10 mg once daily (with or without food), and supportive care as per the local or institutional standard of practice.
62265371|NCT02258451|PLACEBO_COMPARATOR|Placebo + exemestane/everolimus|Up to 6 cycles of saline injection (placebo) (randomized). Participants will also receive exemestane, 25-mg tablet once daily (after a meal), and everolimus, 10 mg once daily (with or without food), and supportive care as per the local or institutional standard of practice.
62265372|NCT05580133||Peroneus Longus Tendon autograft|All-Inside Single-Bundle for ACL Reconstruction with Full Thickness of the Peroneus Longus Tendon
62265373|NCT05580133||six-strand-hamstring autograft|All-Inside Single-Bundle for ACL Reconstruction with six-strand-hamstring autograft
62265374|NCT00864643|EXPERIMENTAL|Lapaquistat Acetate 100 mg QD + Atorvastatin QD|
62449021|NCT05662553|ACTIVE_COMPARATOR|Surgery|The control group will undergo VATS treatment on the primary lesion on the day of operation, and will be re-admitted to the hospital after discharge and recovery (3-4 months) for contralateral secondary lesion surgery.
62848619|NCT03405961||Indirect digital PAR score|Patient will receive upper and lower impressions which will be cast to produce plater models (regular care pathway). The casts will be scanned with Carestream 3600 intra oral scanner and scored digitally by the computer.
62848620|NCT06465407|EXPERIMENTAL|Collagen|Collagen supplementation group will have 12 participants. They will perform various physical assessments that include pain scale, pain pressure threshold assessment, body composition, calf circumference measurements, muscle thickness measurements, Achilles tendon length and thickness measurements, myotonography of the calf, isometric force assessments during standing and seated plantarflexion positions, a heel raise test, and a standardized exercise routine focused on eccentric movements, targeting a leg chosen at random. Additionally, they will consume a daily dose of two 30-g amount of collagen peptides derived from bovine hide (commercially available as Vital Proteins or Peptan).
62848621|NCT06465407|PLACEBO_COMPARATOR|Placebo|Placebo supplementation group will have 12 participants. They will perform various physical assessments that include pain scale, pain pressure threshold assessment, body composition, calf circumference measurements, muscle thickness measurements, Achilles tendon length and thickness measurements, myotonography of the calf, isometric force assessments during standing and seated plantarflexion positions, a heel raise test, and a standardized exercise routine focused on eccentric movements, targeting a leg chosen at random. Additionally, they will consume a daily dose of placebo (two 30 g of pure maltodextrin with no amino acids) mixed in 300 ml of orange Gatorade zero.
62061359|NCT05582551|NO_INTERVENTION|Providers: Highlighting Patients at Risk for Sensory Screening (HPARSS)|-Providers will complete a survey regarding their views of the HPARSS. The Acceptability of Intervention Measure has 4 questions and the Feasibility of Intervention Measure has 4 questions.
62061360|NCT04045821|PLACEBO_COMPARATOR|Control|Patients in this arm will not receive the study drug. A placebo of normal saline will be injected subcutaneously and the D\&C procedure will be completed.
62061361|NCT04045821|EXPERIMENTAL|Intervention|Patients in this arm will receive a dose of the study drug, AMD3100, injected subcutaneously and the D\&C procedure will be completed.
62061362|NCT01352585||JAK2 Positive Participants|
62061363|NCT01352585||JAK2 Negative Participants|
62061364|NCT05996328|ACTIVE_COMPARATOR|Control|Study-defined standard of care
62061365|NCT05996328|EXPERIMENTAL|Home-delivered meals and short-term dietary counseling|Home-delivered, low-sodium, nutritionally robust meals for 6 weeks plus two additional remotely delivered dietary counseling sessions in addition to the study-defined standard of care.
62848622|NCT06465407|NO_INTERVENTION|Control|Control group (n=12) will receive no supplement. Control group participants will do all the assessments that the intervention participants are performing, except for the standardized exercise routine focused on the eccentric movements. Randomization will be performed via www.randomizer.org website.
62061366|NCT03145571|OTHER|Continuity of midwifery care|Clinics where the continuity of midwifery care program was implemented during 2013
62061367|NCT03145571|NO_INTERVENTION|Control|Clinics where no structured changes had been made to the ante- and post- natal care during the period 2013-2015
62061368|NCT04264793|EXPERIMENTAL|Intervention|Behavioral Lifestyle Intervention (3 health centers): In addition to usual care in the health center, the intervention included individual counseling and group education on nutrition and physical activity.
62061369|NCT04264793|ACTIVE_COMPARATOR|Control|Control (4 health centers): Patients received usual care including education as part of the diabetes management from their healthcare professionals (physicians and nurses), normally every 2-3 months. Visits with the health center dietitian were arranged as per physician referral.
62061370|NCT01954368|PLACEBO_COMPARATOR|Intranasal placebo|Patients receiving intranasal placebo at ED admission
62061371|NCT01954368|EXPERIMENTAL|Intranasal sufentanil|Patients receiving intranasal sufentanil at ED admission
62061372|NCT05751031||European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)|Pregnant women living with HIV and their infants from 9 European cohorts and studies within the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)
62061373|NCT03653507|EXPERIMENTAL|Arm A (zolbetuximab plus CAPOX)|Participants will receive a loading dose of zolbetuximab at Cycle 1 Day 1 followed by a lower dose in subsequent cycles every 3 weeks. Additionally, participants will receive CAPOX (capecitabine/oxaliplatin) treatment until IRC confirmed disease progression or a total of 8 treatments (each cycle is defined as 3 weeks = approximately 21 days). Oxaliplatin is administered on day 1 of each cycle, whereas capecitabine is taken twice daily on days 1 through 14. After a maximum of 8 treatments of Oxaplatin, subjects may continue to receive capecitabine twice daily on days 1 through 14 of each cycle at the investigator's discretion until the subject meets study treatment discontinuation criteria.
62061374|NCT03653507|PLACEBO_COMPARATOR|Arm B (Placebo plus CAPOX)|Participants will receive placebo starting at Cycle 1 Day 1 and every 3 weeks thereafter. Additionally, participants will receive CAPOX (capecitabine/oxaliplatin) treatment until IRC confirmed disease progression or a total of 8 treatments (each cycle is defined as 3 weeks = approximately 21 days). Oxaliplatin is administered on day 1 of each cycle, whereas capecitabine is taken twice daily on days 1 through 14. After a maximum of 8 treatments of Oxaplatin, subjects may continue to receive capecitabine twice daily on days 1 through 14 of each cycle at the investigator's discretion until the subject meets study treatment discontinuation criteria.
62061375|NCT05493423|EXPERIMENTAL|Standard of Care vs. V Needle Performance Assessment|Subjects will undergo three dialysis sessions using standard of care needles (control) and results will be compare to 6 dialysis sessions using the V Needle (experimental).
62265375|NCT00864643|ACTIVE_COMPARATOR|Atorvastatin QD|
62265376|NCT02989558|ACTIVE_COMPARATOR|Ticagrelor plus ASA|Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.
62265377|NCT02989558|ACTIVE_COMPARATOR|Clopidogrel plus ASA|Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
62449022|NCT02923466|EXPERIMENTAL|VSV-IFNβ-NIS|VSV-IFNβ-NIS will be administered intratumorally as a single dose on day 1.
62449023|NCT02923466|EXPERIMENTAL|Selection of VSV-IFNβ-NIS Monotherapy|VSV-IFNβ-NIS will be administered either intratumorally, intravenously or with a combination of intratumorally and intravenously as a single dose on day 1.
62449024|NCT02923466|EXPERIMENTAL|VSV-IFNβ-NIS and avelumab|"VSV-IFNβ-NIS will be administered as determined in arm 2 as a single dose on day 1.~Avelumab will be administered intravenously every 2 weeks starting on day 1."
62449025|NCT00390312|ACTIVE_COMPARATOR|4|Intravenous morphine
62265378|NCT02639000|EXPERIMENTAL|Blastocyst|Embryo transfer of at maximum 2 embryos at blastocyst stage
62265379|NCT02639000|ACTIVE_COMPARATOR|Cleavage|Embryo transfer of at maximum 2 embryos at cleavage stage
62265380|NCT01441830|SHAM_COMPARATOR|sham rESWT|
62265381|NCT01441830|ACTIVE_COMPARATOR|rESWT|
62265382|NCT01892358|ACTIVE_COMPARATOR|SKIN Intervention|Participants will receive the SKIN intervention at Baseline and 1-mo interviews.
62265383|NCT01892358|PLACEBO_COMPARATOR|Assessment-Only|Participants in this arm will receive treatment-as-usual
62265384|NCT02175732|EXPERIMENTAL|KnowIt|Please see the 'KnowIt' intervention description below. Diabetes education, behavioral management
62061376|NCT03881280|NO_INTERVENTION|Control group|Treatment as usual for 4 weeks
62449026|NCT00390312|EXPERIMENTAL|1|Intranasal morphine 7.5 mg
62848623|NCT05582928|EXPERIMENTAL|healthy population group|"The experimental design includes three sessions:~* session 1 will be used to evaluate diagnostic using different targeted questionnaires.~* sessions 2 and 3 will be decomposed into 3 consecutives parts:~  1. Pre evaluation~ 2. Neurofeedback~ 3. Post evaluation"
62061377|NCT03881280|EXPERIMENTAL|Intervention group|Education through the app for 4 weeks
62848624|NCT05582928|EXPERIMENTAL|ADHD population group|"The experimental design includes three sessions:~* session 1 will be used to evaluate diagnostic using different targeted questionnaires.~* sessions 2 and 3 will be decomposed into 3 consecutives parts:~  1. Pre evaluation~ 2. Neurofeedback~ 3. Post evaluation"
62622641|NCT03061578||LDDE|"Lipid Deficiency Dry Eye (LDDE) group will be define by commonly known signs and symptoms.~In order to classify subjects to the moderate to severe LDDE group, subjects must have moderate to severe Meibomian Gland Dysfunction (MGD score of 3-6) and meet at least one of the following conditions:~1. Have a Schirmer's Test (without anesthesia) of ≤5mm/5min in either eye~2. Mean CFS of ≥1 in either eye.~3. Fluorescein TBUT ≤5 s in either eye.~4. OSDI questionnaire score ≥20~The LDDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
62449027|NCT00390312|EXPERIMENTAL|2|Intranasal morphine 15 mg
62061378|NCT01478074|EXPERIMENTAL|FLAG + NK Cells + ALT-801|
62061379|NCT05075187||Participants diagnosed with Frontotemporal Dementia|Participants diagnosed with Frontotemporal Dementia
62061380|NCT04859660|EXPERIMENTAL|Tamsulosin- intervention group|
62061381|NCT04859660|PLACEBO_COMPARATOR|Placebo group|
62061382|NCT03611504||Hemospray® group|Patients with gastrointestinal bleeding treated with Hemospray®.
62061383|NCT04214119||Control|Patients age 18 or greater who have undergone esophagogastroduodenoscopy and does not have a diagnosis of Barrett's esophagus or esophageal/gastric malignancy.
62061384|NCT04214119||Barrett's esophagus|Patients age 18 or greater who have undergone esophagogastroduodenoscopy and diagnosed with Barrett's esophagus via pathology.
62061385|NCT04214119||Esophageal carcinoma|Patients age 18 or greater who have diagnosis of primary esophageal carcinoma.
62061386|NCT04214119||Gastric cancer|Patients age 18 or greater who have diagnosis of primary esophageal cancer.
62449028|NCT00390312|ACTIVE_COMPARATOR|3|Oral morphine 60 mg
62449029|NCT00390312|PLACEBO_COMPARATOR|5|Intranasal placebo
62449030|NCT00390312|PLACEBO_COMPARATOR|6|Oral placebo
62449031|NCT00390312|PLACEBO_COMPARATOR|7|Intravenous placebo
62622642|NCT03210012||1|Three dives with different gas mixture : AIR (21% di O2 e 79% di N2), NITROX 32 (32% di O2 e 68% di N2) and TRIMIX (21% O2, 44% N2 e 35% He)
62848625|NCT05376033|EXPERIMENTAL|Premixed Sealer + Single cone|Premixed flowable hydraulic calcium silicate sealer was applied with a a K File #15 that was inserted into the canal to reach the WL - 3mm and gently moved around the root canal walls. Then, gutta-percha points were gently inserted at the WL -0.5mm and compacted with lateral condensation/vertical condensation.
62449032|NCT02730715||Thymoglobulin|blood specimen collection
62449033|NCT02730715||Basiliximab|blood specimen collection
62449034|NCT01003886||Open Label|Adult male diagnosed with BPH and prescribed with Doxazosin mesylate GITS
62265385|NCT02175732|EXPERIMENTAL|OnTrack|Please see the 'OnTrack' intervention description below. Diabetes Distress Reduction, Problem Solving Therapy
62848626|NCT05376033|EXPERIMENTAL|Premixed Sealer + Thermafil|Premixed bioceramic sealer was applied and previously described. Pre-heated carrier was inserted in the canal at WL-0.5mm. The carrier excess was removed with a Thermacut bur.
62848627|NCT05376033|OTHER|Sealer + Thermafil|Epoxy-resin-based sealer was mixed and immediately inserted into the root canal using a K File #15. Pre-heated carrier was inserted in the canal at WL -0.5mm. The carriers excess was removed with a bur.
62061387|NCT05673590|EXPERIMENTAL|The treatment group-Utidelone monotherapy|Drug: Utidelone Injection Dose: 40 mg/m2/d intravenously Regimen: once daily on days 1-5 in a 21-day cycle
62848628|NCT04122352|EXPERIMENTAL|Exercises + ischemic compression group|volunteer patients with temporomandibular joint dysfunction with trigger points
62848629|NCT04122352|OTHER|Exercises group|volunteer patients with temporomandibular joint dysfunction with trigger points
62848630|NCT00641641|EXPERIMENTAL|antiretroviral therapy|tenofovir (TDF) + emtricitabine (FTC) as a fixed dose combination administered orally once per day and raltegravir (RAL) administered orally twice per day.
62265386|NCT04496401|EXPERIMENTAL|Tacrolimus then Envarsus|Tacrolimus will be started on the day of surgery. After a stable trough level is achieved (on postoperative day 7-17) the first PK profile will be measured. Subsequently, the switch to ENVARSUS® will be performed
62265387|NCT01973777|EXPERIMENTAL|IUB|There is one arm of women who will have IUBs inserted
62265388|NCT00543426|EXPERIMENTAL|1|Fuzheng Huayu Tablets
62265389|NCT00543426|SHAM_COMPARATOR|2|sham Fuzheng Huayu Tablets
62061388|NCT05673590|ACTIVE_COMPARATOR|The control group-Docetaxel monotherapy|Drug: Docetaxel Injection Dose:75 mg/m2/d, administered intravenously Regimen: once on day 1 in a 21-day cycle
62265390|NCT01588795|EXPERIMENTAL|Denervation + TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
62622643|NCT05056155|EXPERIMENTAL|Systane Complete|First dose of Systane Complete in both eyes on Day 0, followed by Systane Complete self-administered 4 times daily for 28 days
62622644|NCT04170946|EXPERIMENTAL|Talazoparib in Combination with Low Dose RT|Patients will start on talazoparib on day 1 of study intervention, and will continue to orally take talazoparib until the last day of RT (until day 20-23). Patient will start low dose RT on day 6-9, and will continue for 10 fractions throughout 2 weeks. Talazoparib dose levels will start at 0.5mg daily and increase to 1mg if dose limiting toxicites are not observed. Toxicities include renal impairment and other treatment related toxicities Grade ≥3. Patients will be monitored weekly during study treatment, and followed up at 3 weeks, and every 3 months after for 1 year.
62622645|NCT01180023|EXPERIMENTAL|Sweeping|
62265391|NCT01588795|ACTIVE_COMPARATOR|TMNS|Patients are maintained on standardized anti-proteinuric medications
62265392|NCT02070029|EXPERIMENTAL|Acupuncture|"Acupuncture Therapy~- twice weekly sessions for 5 weeks: 1st session 60 minutes with remaining 9 session approximately 45 minutes each. Physical exam at 1st session includes evaluation of peripheral pulses, head, neck, throat/tongue. No pelvic exam required."
62265393|NCT05180942|EXPERIMENTAL|Statin treatment|Atorvastatin 40mg, daily, orally for 18 months
62449035|NCT01803152|EXPERIMENTAL|Part 1-DC Vaccine/Lysate|"* Leukapheresis: Baseline, post-surgery;~* Dendritic Cells Vaccine (DC Vaccine): Post-Leukapheresis, administered once weekly in dose-escalation scheme for 4 weeks;~* Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 8, 12, 16 and 20;~* Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
62449036|NCT01803152|ACTIVE_COMPARATOR|Part 2-Gemcitabine/DC Vaccine/Lysate|"* Leukapheresis: Baseline, post-surgery;~* Gemcitabine: Post-Leukapheresis, administered once weekly for 3 weeks;~* Dendritic Cells Vaccine (DC Vaccine): Post-Gemcitabine therapy, Recommended Phase 2 Dose (RP2D) administered once weekly for 4 weeks;~* Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 12, 16, 20 and 32;~* Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
62622646|NCT01180023|NO_INTERVENTION|No sweeping|
62622647|NCT01589588|EXPERIMENTAL|Mask 1|
62622648|NCT01589588|EXPERIMENTAL|Mask 2|
62622649|NCT01589588|EXPERIMENTAL|Mask 3|
62622650|NCT01589588|PLACEBO_COMPARATOR|Mask 3, placebo|
62622651|NCT01306214|EXPERIMENTAL|BI 10773 low dose|BI 10773 low dose once daily
62622652|NCT01306214|EXPERIMENTAL|BI 10773 high dose|BI 10733 high dose once daily
62622653|NCT01306214|PLACEBO_COMPARATOR|Placebo|Placebo tablets matching BI 10773
62622654|NCT04687189|EXPERIMENTAL|Women with a known history of submucosal fibroids|
62622655|NCT04687189|EXPERIMENTAL|Women recruited from a general population subject to I/E criteria|
62449037|NCT06482307|EXPERIMENTAL|Stage I|Five patients with HNSCC will undergo a dynamic \[18F\]-olaparib PET during 30 min, followed by a static whole body PET scans at 120 min post-injection of \[18F\]-olaparib.
62449038|NCT06482307|EXPERIMENTAL|Stage II|After determination of the most optimal time point for imaging, five patients with HNSCC scheduled for chemoradiotherapy will undergo serial \[18F\]-olaparib PET at baseline (i.e. prior to treatment initiation) and a second scan during the first week of chemoradiotherapy. Patients in stage II will undergo a study biopsy in the first week of chemoradiotherapy to evaluate changes in PARP protein expression.
62622656|NCT06613243|ACTIVE_COMPARATOR|Esketamine 0.2 mg/kg|Esketamine 0.2 mg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
62848631|NCT04832568||Delirium is determined by CAM or CAM-ICU score|
62449039|NCT03592875||Professional nurses|A semi-structured interview will be used for data collection with 16 guiding questions addressing aspects related to Nursing Care Systematization knowledge and practices.
62449040|NCT02940743|ACTIVE_COMPARATOR|Education (Edu)|
62449041|NCT02940743|ACTIVE_COMPARATOR|Edu + Self-Monitoring (SM)|
62449042|NCT02940743|ACTIVE_COMPARATOR|Edu + SM + Social Cognitive Theory (SCT)|
62449043|NCT01182233|EXPERIMENTAL|Total Skeletal Irradiation|Three subjects determined to be eligible for study and agree to participate are assigned to receive 200 cGy of TSI-HT for 5 days. If this dose level is well tolerated in the first 3 subjects, the dose will be increased and given over 5 days. The dose will continue to be increased until the maximum toelrated dose is reached.
62848632|NCT04832568||No delirium is determined by CAM or CAM-ICU score|
62848633|NCT01659476|EXPERIMENTAL|Asthma|Individuals diagnosed with asthma.
62848634|NCT01659476|EXPERIMENTAL|Cough Variant Asthma|Individuals diagnosed with cough variant asthma.
62848635|NCT01659476|EXPERIMENTAL|Mch-induced cough w/normal airway sensitivity|Individuals with chronic cough normal PC20 MCh(\>16 mg/mL) \& who cough during Mch challenge testing.
62449044|NCT05561413|EXPERIMENTAL|Mindfulness and exercise|This group will undertake exercise and mindfulness for 8 weeks. The home based walking and strengthening intervention is individually tailored for each participant. All exercise demonstrations, information, reporting of activity and setting of goals will take place in the app that participants will download. Additionally this group will receive a hard copy of the goal setting diary. All mindfulness information and practices are available in the app. New content will be released each week as the participants progress through the program. Participants will be phoned weekly over the 8 weeks to monitor progress.
62622657|NCT06613243|EXPERIMENTAL|Esketamine 0.2 mg/kg + dexmedetomidine 0.1 µg/kg|A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.1 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
62622658|NCT06613243|EXPERIMENTAL|Esketamine 0.2 mg/kg + dexmedetomidine 0.15 µg/kg|A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.15 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
62061389|NCT05135546|EXPERIMENTAL|Experimental|Recombinant nonimmunogenic staphylokinase lyophilisate for preparation of a solution for inhaled administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, regardless of body weight.
62061390|NCT05135546|PLACEBO_COMPARATOR|Placebo control|Placebo
62265394|NCT05180942|NO_INTERVENTION|No statin treatment|No comparator treatment/placebo allocated
62848636|NCT01659476|EXPERIMENTAL|Normal|Individuals with no history of asthma or chronic cough
62848637|NCT03622918|SHAM_COMPARATOR|colistin monotherapy|The subjects will be treated with colistin monotherapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
62848638|NCT03622918|EXPERIMENTAL|colistin-rifampin combination|The subjects will be treated with colistin and rifampin combination therapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
62848639|NCT02509117|EXPERIMENTAL|Single Ascending Dose Cross-over|Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
62848640|NCT02509117|EXPERIMENTAL|Multiple Ascending Dose PF-06751979|Multiple dose administration to Healthy Subjects in parallel cohorts(PF-06751979)
62848641|NCT02509117|PLACEBO_COMPARATOR|Multiple Ascending Dose Placebo|Multiple dose administration to Healthy Subjects in parallel cohorts(Placebo)
62061391|NCT04804995||Heathy participants|
62061392|NCT04804995||migraine patients|
62061393|NCT02002884|EXPERIMENTAL|8 Units per kg body weight incobotulinumtoxinA (Xeomin)|8 Units per kg body weight (maximum of 200 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 300 Units per injection cycle. Overall maximum dose per injection cycle: 500 Units.
62061394|NCT02002884|EXPERIMENTAL|6 Units per kg body weight incobotulinumtoxinA (Xeomin)|6 Units per kg body weight (maximum of 150 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 225 Units per injection cycle. Overall maximum dose per injection cycle: 375 Units.
62622659|NCT06613243|EXPERIMENTAL|Esketamine 0.2 mg/kg + dexmedetomidine 0.2 µg/kg|A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.2 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
62622660|NCT01490840|EXPERIMENTAL|E-training|Fingolimod as baseline immunomodulatory multiple sclerosis treatment was prescribed as per clinical practice. During phase 1, participants randomized to this arm had an introductory group session, hosted by a sports therapist. The individual training schedule was comprised of strength exercises twice a week for 30-45 minutes and endurance training once a week for 20-60 minutes for 6 months. The participants documented each training session thoroughly via the web-based application (duration, type of exercises, number of repetitions and sets, perceived exertion). A standard course of corticosteroids (methylprednisolone) on an inpatient or outpatient basis was allowed for treatment of relapses as clinically warranted. Steroid treatment consisted of 3-5 days and up to 1,000 mg methylprednisolone/day. After 6 months, Phase 2, the same Phase 1 regimen applied.
62622661|NCT01490840|EXPERIMENTAL|Waiting|Fingolimod as baseline immunomodulatory multiple sclerosis treatment is prescribed as per clinical practice. During Phase 1, participants randomized to this arm did not receive e-training exercise. After a 6 months waiting period, phase 2, participants had an introductory group session, hosted by a sports therapist. The individual training schedule was comprised of strength exercises twice a week for 30-45 minutes and endurance training once a week for 20-60 minutes for 6 months. The participants documented each training session thoroughly via the web-based application (duration, type of exercises, number of repetitions and sets, perceived exertion). A standard course of corticosteroids (methylprednisolone) on an inpatient or outpatient basis was allowed for treatment of relapses as clinically warranted. Steroid treatment consisted of 3-5 days and up to 1,000 mg methylprednisolone/day.
62622662|NCT06613256||Part 1 - control patients|"25 healthy volunteers~1 X Endothelial cell biopsy"
62622663|NCT06613256||Part 1 - surgical patients|"20 surgical patients~1 X Endothelial cell biopsy~Samples collected at 24 hours post knife to skin to capture peak inflammation"
62622664|NCT06613256||Part 1 - sepsis patients|"20 sepsis patients~1 X Endothelial cell biopsy~Samples collected on admission to ICU"
62622665|NCT06613256||Part 2 - surgical patients|"20 surgical patients 3 X Endothelial cell biopsy~Samples collected pre-surgery, 24 hours and 48 hours post knife to skin"
62622666|NCT06613256||Part 2 - sepsis patients|"20 sepsis patients 3 X Endothelial cell biopsy~Samples collected on admission, 24 hours and 48 hours post admission to ICU"
62622667|NCT03319810|EXPERIMENTAL|infusion of IVIG|
62622668|NCT02192983||chemotherapy regimen|those with XELOX regimen and those with EOX regimen
62622669|NCT05240703|EXPERIMENTAL|Stabilization splint group|The patients in the splint group were treated with a stabilization splint and received counseling and instructions for masticatory muscle exercises
62622670|NCT05240703|NO_INTERVENTION|Control group|The controls received only counseling and instructions for masticatory muscles exercises.
62622671|NCT04709497|ACTIVE_COMPARATOR|viscotrabeculotomy (VT)).|
62622672|NCT04709497|ACTIVE_COMPARATOR|visco-circumferential-suture-trabeculotomy (VCST)|
62061395|NCT02002884|EXPERIMENTAL|2 Units per kg body weight incobotulinumtoxinA (Xeomin)|2 Units per kg body weight (maximum of 50 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 75 Units per injection cycle. Overall maximum dose per injection cycle: 125 Units.
62622673|NCT04709497|ACTIVE_COMPARATOR|Combined VT-Trabeculectomy with MMC (VT-Trab).|
62061396|NCT04935814|EXPERIMENTAL|Continuous vasopressin infusion|After general anesthesia, patients will receive a continuous infusion of vasopressin in order to improve mean arterial pressure by 20 mmHg.
62061397|NCT02497898|NO_INTERVENTION|regular chemotherapy|Patients after chemotherapy are just followed up.
62265395|NCT05938192||Patients with HPV-related disease|Patients with HPV-related disease including cervical and vaginal lesions
62622674|NCT02390713|EXPERIMENTAL|MID-AVR|Tolerance and functionality of MID-AVR during surgery (Phase A) and after surgery (Phase B)
62622675|NCT00077155|EXPERIMENTAL|Treatment (cilengitide)|Patients receive cilengitide (EMD 121974) IV continuously on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
62622676|NCT05779787||TAVR performed with commissural alignment technique (Aligned Group)|Patients with severe aortic stenosis undergoing TAVR procedure performed with commissural alignment technique. We consider in this groups only the Accurate and Accurate Neo 2 Valve which are the first choice due to the best stent frames position predictability with this technique
62848642|NCT02509117|EXPERIMENTAL|Multiple Dose Elderly PF-06751979|Multiple dose administration to Healthy Elderly Subjects (PF-06751979)
62848643|NCT02509117|PLACEBO_COMPARATOR|Multiple Dose Elderly Placebo|Multiple dose administration to Healthy Elderly Subjects (Placebo)
62622677|NCT05779787||TAVR performed with random implantation of Navitor valve (Random Group)|Patients with severe aortic stenosis undergoing TAVR procedure performed with random implantation of Navitor Valve
62622678|NCT00190398|EXPERIMENTAL|1|Carotid angioplasty and stenting with cerebral protection
62848644|NCT06163508||Cohort 1: 10 microliters of Q cells|10 microliters of Q cells per site
62848645|NCT06163508||Cohort 2: 15 microliters of Q cells|15 microliters of Q cells per site
62848646|NCT06163508||Cohort 3: 20 microliters of Q cells|20 microliters of Q cells per site
62622679|NCT03743727|EXPERIMENTAL|Combined Therapy LDV and SOF|
62622680|NCT02685332|EXPERIMENTAL|Stereotactic Radiation|"Single Fraction Stereotactic Radiation. Step No. Fractions Dose per fraction~-1 1 20 0 (starting) 1 22.5~1. 1 26.5~2. 1 30"
62622681|NCT00915603|ACTIVE_COMPARATOR|paclitaxel/bevacizumab/everolimus|Systemic Therapy
62622682|NCT00915603|PLACEBO_COMPARATOR|paclitaxel/bevacizumab/placebo|Systemic Therapy
62622683|NCT04788186|NO_INTERVENTION|Continue beta blocker therapy|Participants in this arm will continue their beta blocker therapy as per their usual clinical care
62622684|NCT04788186|EXPERIMENTAL|De-prescribe beta blocker therapy|Beta blocker therapy will be de-prescribed in this arm
62622685|NCT03994237||ALZHEIMER CAREGIVER|Caregiver available to accompany the patient to the consultation, helping calling for the first time the memory center, aidant who noticed a cognitive disorder help, having a family link identified with the patient
62622686|NCT01009255|EXPERIMENTAL|GSK239512|Oral tablets
62622687|NCT01009255|PLACEBO_COMPARATOR|Placebo|Placebo to match GSK239512.
62622688|NCT04230772|EXPERIMENTAL|Natural Orifice Specimen Extraction Surgery|Natural orifice specimen extraction surgery will performed in patients assigned to this group.
62622689|NCT04230772|ACTIVE_COMPARATOR|Traditional Robotic-assisted Surgery|Traditional robotic-assisted surgery will performed in patients assigned to this group.
62622690|NCT01476800|EXPERIMENTAL|YM178 OCAS alone|
62622691|NCT01476800|ACTIVE_COMPARATOR|Ketoconazole alone|
62622692|NCT01476800|EXPERIMENTAL|YM178 OCAS and ketoconazole|
62622693|NCT05916053|NO_INTERVENTION|Control|Nutritional education about food sources of vitamin D
62622694|NCT05916053|EXPERIMENTAL|VItamin D supplemented|Vitamin D supplementation of 50.000 IU weekly for 3 months.
62622695|NCT04442152|EXPERIMENTAL|Intervention|See intervention description
62622696|NCT04442152|NO_INTERVENTION|Control|Participants who were randomized into the control arm were and will be surveyed at the same time point as intervention participants, but did not receive any intervention.
62622697|NCT06439693|EXPERIMENTAL|HER2+ Breast Cancer|"Participants will complete:~* Screening visit with tumor biopsy and imaging.~* Imaging on Day I of cycles for Parts A through D.~* Part A:~  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab (or biosimilar) 1X daily~ * Day 1 of 21 day cycle: Predetermined dose of Pertuzumab 1X daily~ * Predetermined dose of Taxane (Paclitaxel, Docetaxel, or Nab-Paclitaxel)~* Part B:~  --Day 1 of 21 day cycle: Predetermined dose of trastuzumab deruxtecan 1X daily~* Part C:~  * Day 1 of 21 day cycle: Predetermined dose of T-DM1 1X daily~ * Days 1 through 21 of 21 day cycle: Predetermined dose of Tucatinib 2X daily~* Part D:~* Imaging every 9 weeks~  * Days 1 through 21 of 21 day cycle: Predetermined dose of Tucatinib 2X daily~ * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab (biosimilar or SC) 1X daily~ * Day 1 of 21 day cycle: Predetermined dose of Pertuzumab (or PHESGO) 1X daily~* Follow Up: visits every 12 weeks with imaging every 9 weeks."
62622698|NCT03115593|EXPERIMENTAL|postmenopausal patients with metrorrhagia|"Postmenopausal patients with metrorrhagia and endometrial hypertrophy defined by an endometrium ticker than 3 mm (ultrasound result).~The threshold choice of 3 mm was chosen according to a recent review of the literature to limit the risk of false negatives for cancer."
62622699|NCT05840549|ACTIVE_COMPARATOR|TURP|Transurethral Resection of Prostate
62622700|NCT05840549|EXPERIMENTAL|UroLift|UroLift
62622701|NCT06101888|EXPERIMENTAL|A single set of test|The experimental apparatus consisted of TaurusTrio™ Heart Valve (THV), Delivery Catheter \& Introducer Sheath ,Loading Tools
62622702|NCT04409977||Patient group|Patients suffering from cluster headache will be included in this group. When analysing the data, the investigators will distinguish those in the in-bout period from those in the out-bout period. People in this group may participate twice: once in the in-bout and once in the out-bout period.
62848647|NCT05170932|NO_INTERVENTION|open flap + mechanical debridement|This group included 10 patients with periodontitis stage 2 or 3, grade A infra-bony defect sites (Caton, 2018) that had undergone proper curettage ensuring complete removal of all granulation tissue present within the defect by scaling and root planning then open flap debridement only.
62848648|NCT05170932|EXPERIMENTAL|open flap +CHX gel 2 % + 24% EDTA|This group included 10 patients with periodontitis stage 2 or 3, grade A infra-bony defect sites (Caton, 2018) that had undergone proper curettage ensuring complete removal of all granulation tissue present within the defect by scaling and root planning then open flap debridement before treating root and bony walls of the pocket surfaces by application of 24% EDTA etching and washing with saline, then application of 2% chlorhexidine gel on root surface.
62622703|NCT04409977||Control group|Participants not suffering from cluster headache will be included in this group.
62622704|NCT06337734|EXPERIMENTAL|AI-Driven Lifestyle Coaching Group|
62622705|NCT05689567|EXPERIMENTAL|DEFOG group|Subjescts will wear DEFOG glasses(peripheral focus-out glasses).
62449045|NCT05561413|ACTIVE_COMPARATOR|Mindfulness|This group will undertake mindfulness only over 8 weeks. The mindfulness program is based on mindfulness-based stress reduction (MBSR). All information, practices and logging of the mindfulness practice will be done via the app that participants will download. Participants will be phoned weekly over the 8 weeks to monitor progress. New content will be released each week as participants progress through the program.
62622706|NCT05689567|NO_INTERVENTION|Control group|Subjects in the control group will just be observed.
62622707|NCT05498142||SICS I|Prospective cohort study based on the 'Simple Intensive Care Studies' (SICS) registry (NCT02912624)
62622708|NCT05498142||SICS II|Prospective cohort study based on the 'Simple Intensive Care Studies' (SICS) registry (NCT03577405)
62622709|NCT05498142||AFIB-ICU|An international inception cohort study.
62622710|NCT05498142||Emmen|Patients admitted to the ICU of a community hospital in the Netherlands.
62622711|NCT04539548|EXPERIMENTAL|Dextenza|1 dosing group - 37 eyes treated with Dextenza
62622712|NCT04539548|ACTIVE_COMPARATOR|Prednisolone|1 dosing group - 32 eyes treated with Prednisolone
62622713|NCT01301079|ACTIVE_COMPARATOR|Ketamine|"A cardioscope, a capnograph, a pulse oximeter, and a noninvasive blood pressure meter were used to monitor the patients. Propofol (2-4 mg/kg), remifentanil (1 μg/kg), and atracurium (0.5 mg/kg) were administered for intubation. Atracurium was titrated to maintain muscle relaxation. Anesthesia was maintained with remifentanil, 0.8% isoflurane, and 50% oxygen without nitrous oxide. Infusion of the solutions was continued until skin closure.~The patients in group ketamine received remifentanil (0.4 μg/kg/min) and ketamine (5 μg/kg/min).~Remifentanil was administered as necessary until skin closure. Neostigmine was used for antagonizing the neuromuscular block."
62622714|NCT01301079|PLACEBO_COMPARATOR|Saline|"A cardioscope, a capnograph, a pulse oximeter, and a noninvasive blood pressure meter were used to monitor the patients. Propofol (2-4 mg/kg), 1 μg/kg remifentanil, and atracurium (0.5 mg/kg) were administered for intubation. Atracurium was titrated to maintain muscle relaxation. Anesthesia was maintained with remifentanil, 0.8% isoflurane, and 50% oxygen without nitrous oxide. Infusion of the solutions was continued until skin closure.~The patients in group saline received remifentanil (0.4 μg/kg/min) and saline solution.~Remifentanil was administered as necessary until skin closure. Neostigmine was used for antagonizing the neuromuscular block."
62622715|NCT02414217|EXPERIMENTAL|In-Person Diabetes Numeracy Education|"Participants randomized to the in-person education group attended four group classes, each addressing a specific set of diabetes self-care skills (i.e., understanding and using blood glucose numbers, counting carbohydrates, taking medications at the right dose and time). So that each class included a stable group of 8 and 16 participants, we ran classes in cohorts of 8-16 people. A participant always attended classes with his/her cohort."
62622716|NCT02414217|EXPERIMENTAL|Online Diabetes Numeracy Education|Participants randomized to the online education group attended a single session, at which he/she completed a computerized education module that addressed understanding blood sugar values and using them to examine the impact of food, exercise, and medicines on blood sugar.
62622717|NCT02414217|NO_INTERVENTION|Control|Participants were given written educational materials about diabetes.
62622718|NCT02092649|EXPERIMENTAL|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
62622719|NCT02092649|PLACEBO_COMPARATOR|Placebo Pill|Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.
62622720|NCT00717795||1|Arm 1 - Physical Activity intervention
62622721|NCT00717795||2|Arm 2 - Wait-list control
62622722|NCT06145997||Persons with chronic pain|Standard acupuncture care will be provided to persons (n=50) with chronic pain. Standard care is defined as the care a participant was already receiving and that care will not be interrupted in any way for any study participant.
62622723|NCT03668977|NO_INTERVENTION|Routine care|"In all four groups, the following antenatal and post-natal interventions will be offered:~* Women encouraged to enroll in routine antenatal care at their local health post/center.~* A clean birthing kit consisting of a clean blade, string, and plastic disc for cutting the cord, a plastic sheet, a bar of soap, and a tube of chlorhexidine ointment for application to the umbilical stump.~* Women encouraged to deliver at a certified birthing facility and participate in the government's incentive scheme.~* Nutritional, hygiene, and infant care counseling.~* Tetanus toxoid (if needed) and iron-folic acid supplements."
62265396|NCT06424184|EXPERIMENTAL|rTMS Intervention|Eligible participants who are enrolled will receive an accelerated course of repetitive Transcranial Magnetic Stimulation.
62265397|NCT02060578|OTHER|Intervention|Questionnaire completed by the parents Interview with the parents and the psychologist (University Rennes 2)
62449046|NCT04620174|OTHER|Custom-made zirconia crowns Group|Ten decayed primary molars will be restored with custom-made zirconia crowns.
62449047|NCT04620174|OTHER|Prefabricated zirconia crowns Group|Ten decayed primary molars will be restored with prefabricated zirconia crowns.
62848649|NCT02627976|ACTIVE_COMPARATOR|breast edema vest|
62848650|NCT05826171|EXPERIMENTAL|Group 1|High-Intensity Aerobic Exercise Prior to Balance Training
62848651|NCT05826171|ACTIVE_COMPARATOR|Group 2|Low-Intensity Exercise Prior to Balance Training
62848652|NCT02806583|EXPERIMENTAL|intervention|telephone based structured support groups
62848653|NCT02806583|NO_INTERVENTION|control|Active Comparator: Usual care (intervention as experimental group after 3 month (after T1)
62622724|NCT03668977|EXPERIMENTAL|Supplementation-pregnancy|A daily fortified balanced protein-energy nutritional supplement beginning in the 2nd trimester and continuing throughout pregnancy. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B\&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
62622725|NCT03668977|EXPERIMENTAL|Supplementation-lactation|A daily fortified balanced protein-energy nutritional supplement beginning after delivery and continuing through 6 months post-partum. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B\&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
62622726|NCT03668977|EXPERIMENTAL|Supplementation-pregnancy & lactation|A daily fortified balanced protein-energy nutritional supplement beginning in the 2nd trimester and continuing through 6 months post-partum. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B\&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
62622727|NCT02419391|EXPERIMENTAL|Group 1|18-49 year old healthy subjects, receiving either 1x10E7TCID50 MVA BN RSV or Placebo
62622728|NCT02419391|EXPERIMENTAL|Group 2|18-49 year old healthy subjects, receiving either 1x10E8TCID50 MVA BN RSV or Placebo
62265398|NCT05913661|EXPERIMENTAL|pemigatinib combined with PD-1 inhibitor|pemigatinib combined with PD-1 inhibitor as first-line treatment within advanced unresectable or metastatic intrahepatic cholangiocarcinoma
62265399|NCT00890032|EXPERIMENTAL|BTSC mRNA-loaded DCs|BTSC mRNA-loaded DCs administered intradermally weekly for first 3 vaccines, then monthly until progression or withdrawal.
62265400|NCT03150771|EXPERIMENTAL|Cohort 1|Aripiprazole; single; gluteal
62622729|NCT02419391|EXPERIMENTAL|Group 3|50-65 year old healthy subjects, receiving either 1x10E8TCID50 MVA BN RSV or Placebo
62622730|NCT02016911|EXPERIMENTAL|Subjects with hepatic impairment|
62449048|NCT05892978|EXPERIMENTAL|Vascular imaging device with the infrared light group|The patient's vital signs, skin color and skin turgor will be evaluated and recorded in the PIVC procedure registration form. The skill duration will be measured and recorded by the researcher with a stopwatch. The selection of the necessary materials will not be added to this time, the chronometer will be started after the tourniquet is attached, and the time will end with the blood coming to the PIVC. Data obtained on PIVC placement; vein visibility, the catheter number used in the procedure, the time to identify the appropriate vein, the successful PIVC placement time, the number of attempts for successful catheter placement, the vein in which the catheter was placed, the pain and fear levels before, during and after the procedure. These data will be recorded in the data form regarding the PIVC application. Finally, patients will be asked about their level of satisfaction with the procedure at the end of the infusion.
62622731|NCT02016911|ACTIVE_COMPARATOR|Subjects with normal hepatic function|
62848654|NCT03647891|EXPERIMENTAL|CPAP Intervention Pathway|"Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.~The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying cardiac condition(s). They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms."
62848655|NCT03647891|NO_INTERVENTION|Usual Care Pathway|Patients will receive contemporary standard of care pharmacotherapy for their underlying cardiac condition(s) and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
62848656|NCT04667884|EXPERIMENTAL|Group A|a mixture of Xylooligosaccharides, Stachyose, Fructooligosaccharides, and Water-soluble Dietary Fiber, 12 g/d, 4 weeks
62848657|NCT04667884|EXPERIMENTAL|Group B|a mixture of Fructooligosaccharide, water-soluble dietary fiber, polydextrose, and isomalt oligosaccharide, 12 g/d, 4 weeks
62265401|NCT03150771|EXPERIMENTAL|Cohort 2|Aripiprazole; single; gluteal
62265402|NCT05075811|EXPERIMENTAL|Vertebral Bone Marrow Derived Mesenchymal Stem Cells (vBM-MSC)|Direct injection of vertebral bone marrow derived mesenchymal stem cells at a dose of 100 million cells into the ileal pouch fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
62265403|NCT05075811|PLACEBO_COMPARATOR|Placebo|Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of vertebral allogeneic bone marrow derived mesenchymal stem cells at a dose of 100 million cells into ileal pouch fistula(s).
62265404|NCT06090734|EXPERIMENTAL|My Voice|"Intervention arm patients will complete the patient version of 'My Voice' at least once every 3 months for 1 year or until they pass away (whichever is earlier).~Caregivers of patients in the intervention arm will complete the caregiver version of 'My Voice' at least once every 3 months for 1 year (or until the patient passes away, whichever is earlier)."
62265405|NCT06090734|NO_INTERVENTION|Control|Control arm patients and caregivers will receive usual care.
62265406|NCT04270110||Case|Patients with subclinical hypothyroidism
62265407|NCT04270110||Control|Patients with Normal thyroid function
62265408|NCT05234606|EXPERIMENTAL|Part 1: SBT6290|SBT6290 every 3 weeks
62622732|NCT02521727||exposed siblings/children|"Consecutive subjects with non-advanced adenomas will be identified from the colonoscopy database at Prince of Wales Hospital, Alice Ho Miu Ling Nethersole Hospital, Queen Elizabeth Hospital and the bowel cancer screening center at Siu Lek Yuen. Figure 1 illustrates subject recruitment flow chart. They will be consented to provide details on their number of FDR, their FDR contact details, and cause of death in FDR who are deceased. FDR aged 40 to 70 years of consecutive patients with newly diagnosed non-advanced adenomas confirmed from endoscopy and pathology reports will be contacted via phone and invited for an interview and a colonoscopy.~COLONOSCOPY With informed consents, experienced colonoscopists (GI physicians, colorectal surgeons) will perform colonoscopy under intravenous sedation, midazolam and pethidine after adequate bowel preparation."
62622733|NCT02521727||unexposed siblings/children|"Subjects (Control) FDR aged 40 to 70 years of asymptomatic average risk subjects who had undergone a colonoscopy in our bowel cancer screening programme between 2010 and 2014 and found to have a normal colonoscopy will be invited to participate by phone and invitation letters, to attend a health talk and to undergo a colonoscopy.~Confounding factors including use of drugs (aspirin and non-steroidal anti-inflammatory drugs), lifestyle factors (smoking, and diet questionnaire) and history of medical conditions (obesity with calculation of body mass index, diabetes, history of cardiovascular disease) between cases and controls will be recorded.~COLONOSCOPY With informed consents, experienced colonoscopists (GI physicians, colorectal surgeons) will perform colonoscopy under intravenous sedation, midazolam and pethidine after adequate bowel preparation."
62622734|NCT04480996||Road traffic accidents with medicines|Road traffic accidents cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Drugs Responsible for Cognitive and Psychomotor Side Effects
62622735|NCT00315614|EXPERIMENTAL|Islet Transplantation and Bone Marrow|Administration of islets and infusion of CD34 enriched Bone Marrow cells in subjects with type 1 diabetes, impaired awareness of hypoglycemia and severe hypoglycemia.
62622736|NCT01949142|EXPERIMENTAL|OTO-201|"OTO-201: Single, intratympanic injection:~One injection of 6 mg OTO-201 (ciprofloxacin in poloxamer 407) into each ear during surgery."
62622737|NCT01949142|SHAM_COMPARATOR|Sham|"Sham: Simulated single, intratympanic injection:~One sham injection into each ear during surgery."
62622738|NCT01324921|PLACEBO_COMPARATOR|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
62622739|NCT01324921|ACTIVE_COMPARATOR|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
62622740|NCT01324921|EXPERIMENTAL|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
62622741|NCT01516736|EXPERIMENTAL|LA-EP2006|During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.
62622742|NCT01516736|ACTIVE_COMPARATOR|Neulasta®|During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.
62622743|NCT03374163|EXPERIMENTAL|treatment group who recived intralipid|71 patients who recived intralipid on day of embryo transfer day, pregnancy day.
62848658|NCT04667884|EXPERIMENTAL|Group C|a mixture of Polydextrose, wheat fiber, and Seed shell of Plantago rotundifolia, 12 g/d, 4 weeks
62848659|NCT04667884|EXPERIMENTAL|Group D|a mixture of Fructooligosaccharides, Bifidobacterium lactis HN019 and Lactobacillus rhamnosus HN001, 3 g/d, 4 weeks
62848660|NCT04667884|PLACEBO_COMPARATOR|Group E|Maltodextrin， 3 g/d, 4 weeks
62622744|NCT03374163|NO_INTERVENTION|control group|71 patient not recived intralipid
62622745|NCT02897466|EXPERIMENTAL|Direct Antimicrobial Susceptibility Testing|"At day 0: Direct antibiotic susceptibility testing performed directly (DAST) on the respiratory sample At day 1: both results of isolated GNB identification using mass spectrometry and DAST will be given to the physician in charge in order to switch antimicrobial therapy to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems. Conventional antibiotic susceptibility testing (CAST) performed on isolated GNB.~At day 2-3: results of CAST will be given to the physician in charge in order to change antimicrobial therapy in case of differences between CAST and DAST (2nd switch to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems)"
62622746|NCT02897466|NO_INTERVENTION|Conventional Antimicrobial Susceptibility Testing|"At day 1 identification of isolated GNB bacilli using mass spectrometry will be given to the physician in charge (usual care in ICU involved) to adapt antibiotic regimen. Conventional antibiotic susceptibility testing (CAST) performed on isolated GNB.~At day 2-3: results of CAST will be given to the physician in charge in order to switch antimicrobial therapy to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems."
62622747|NCT06006598|EXPERIMENTAL|BI 1584862 treatment arm|
62622748|NCT06006598|PLACEBO_COMPARATOR|Placebo arm|
62622749|NCT06006598|EXPERIMENTAL|BI 1584862 + midazolam treatment arm|
62622750|NCT01541072|EXPERIMENTAL|Pegfilgrastim|
62622751|NCT01541072|ACTIVE_COMPARATOR|Filgrastim|
62622752|NCT01310582|ACTIVE_COMPARATOR|Desflurane|During the surgery the subjects were given Desflurane, general anesthesia, that will keep the patient asleep during the surgery. The dosage form was inhalation gas, dosage equivalent to 1 MAC, frequency was once and the duration was throughout the surgery (30-45 minutes).
62848661|NCT04618432||Patients|Patients at risk, suspected of having, have a history of, or currently have a diagnosed head and neck or communication disorder.
62848662|NCT02371915|EXPERIMENTAL|Videoconference follow-up|These subjects will remain in or near their home communities for rheumatology follow-up visits. Follow-up visits will occur via telehealth/videoconferencing, with a physiotherapist present, performing the in-person assessment, supported by the rheumatologist via videoconference.
62848663|NCT02371915|NO_INTERVENTION|Control|These subjects will continue to travel into Saskatoon for the rheumatology visits, as they normally would for routine follow-up visits with their rheumatologist.
62061398|NCT02497898|EXPERIMENTAL|CIK regimen|Patients after chemotherapy will receive at least 3 cycles of Cytokine-induced killer cells (CIK) treatment every 3 months.
62622753|NCT01310582|ACTIVE_COMPARATOR|Sevoflurane|During the surgery the subjects were given Sevoflurane, general anesthesia, that will keep the patient asleep during the surgery. The dosage form was inhalation gas, dosage equivalent to 1 MAC, frequency was once and the duration was throughout the surgery (30-45 minutes).
62622754|NCT01007383|EXPERIMENTAL|LEO 27847 oral solution (0.05 mg/mL)|LEO 27847
62622755|NCT01007383|EXPERIMENTAL|LEO 27847 oral solution (0.75 mg/mL)|LEO 27847
62622756|NCT01007383|PLACEBO_COMPARATOR|LEO 27847 oral solution (placebo)|Placebo
62622757|NCT05671159|EXPERIMENTAL|bacterial infection|
62848664|NCT03181737|EXPERIMENTAL|Covivio|"Covivio is an internet intervention for people with diabetes mellitus type 2. Content is continuously adapted to patients´ concerns and needs. Techniques to promote the disease self-management (i.e. nutrition, exercise), the motivation for health behavior (i.e. discussing pros and cons) conveying goal setting, mediating knowledge about diabetes (i.e. basics, symptoms \& complications, diagnosis, therapy) , and reducing depressive symptoms (i.e. increasing activation, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets.~Patients are also prompted complete brief adherence self-monitoring questionnaires (adherence index) regularly. Optional text messages with motivational content accompany the program daily. The program can be accessed for 56 days after registration."
62848665|NCT03181737|ACTIVE_COMPARATOR|Relaxio|Relaxio is a psychological online-relaxation-training. The purpose of the program is to improve the self-management of diabetes by relaxation and stress reduction. The program consist of three types of exercises (1) imagination (i.e. sunset, mountain lake), (2) breathing techniques (i.e. balancing, calm breathing), and (3) body exercises (i.e. relaxing body journey, progressive muscle relaxation (PMR)). The exercises are supported by audio files (optionally also for reading). Optional weekly text messages with motivational content accompany the program. The program can be accessed for 56 days after registration.
62848666|NCT03181737|NO_INTERVENTION|Care-as-Usual (CAU) / wait list|In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Covivio six months post-baseline (i.e., wait list with respect to Covivio access).
62848667|NCT06086340||Palbociclib + AI|Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy in SEER-Medicare
62848668|NCT06086340||AI alone|Adult metastatic breast cancer patients who initiated an aromatase inhibitor (alone) as first line therapy
62848669|NCT03569345|EXPERIMENTAL|Arm|Basal cell carcinoma (BCC) patients Patients (\>18 pr) with histologically-verified superficial or nodular basal cell carcinoma (\<20 mm on face/scalp, \<50 mm on trunk/extremities)
62848670|NCT05788471|ACTIVE_COMPARATOR|Conventional treatment group|Twenty patients will receive conventional treatment in the form of superficial heat, ultrasound with freq of 1 MHz, pulsed mode 1:4 for 5 min and stretching exercise to lumbrical muscles of the hand.
62848671|NCT05788471|EXPERIMENTAL|Neurodynamic mobilization therapy group|Twenty patients will receive neurodynamic mobilization therapy (upper limb tension test 1) in addition to conventional treatment.
62848672|NCT06160648|EXPERIMENTAL|Mechanical Diagnosis and Therapy (MDT)|MDT is a system of examination and intervention based on the patient's response to repeated end range neck movements.
62848673|NCT06160648|ACTIVE_COMPARATOR|Cervical Spine Clinical Practice Guidelines (CPGs)|The CPGs are guidelines for examination and intervention based on a summary of research conducted on people with neck pain.
62848674|NCT04504409|ACTIVE_COMPARATOR|Exercise group (ExG)|The exercise program consisted of; Codman , wand, stretching and strengthening exercises \[25\] applied twice a day, 5 times a week and duration of 3 weeks in all groups. All exercises were performed for 10 repetitions and 3 sets. Patients performed exercises with under supervision of physiotherapist in the clinic settings. In ExG, patients received only this exercise protocol for 3-weeks.
62848675|NCT04504409|EXPERIMENTAL|KT application combined with exercise (KTG)|Before KT application, their skin was shaved, cleaned with alcohol, and dried. Prior to application, the patient was seated and asked to flex their neck laterally to the contralateral side and to rotate their head to the same side. KTs (Ares®) tape was used. The first strip was a Y-strip representative of the supraspinatus, which was applied from its insertion to origin with paper off tension. A Y-strip refers to a section of tape that has a portion cut down the middle to produce 2 tails. In KTG, patients wore the KT for a 3-week duration (renewed twice a week periodically in this time).
62061399|NCT03690830|EXPERIMENTAL|Case group RIF|blood samples, analyzing endometrial cells
62061400|NCT03690830|EXPERIMENTAL|Case group IRPL|blood samples, analyzing endometrial cells
62061401|NCT03690830|ACTIVE_COMPARATOR|Control group|blood samples, analyzing endometrial cells
62061402|NCT00412048|OTHER|ALZHEIMER DISEASE|
62061403|NCT00412048|OTHER|MOLD COGNITIVE IMPAIRMENT|
62061404|NCT00412048|OTHER|CONTROLS|
62061405|NCT00934869||Metacarpal Shaft Fractures|
62061406|NCT01581840|EXPERIMENTAL|5Fu-mitomycine-panitumumab + radiotherapy|5 FU = 400 or 600 or 80 or 1000 mg depending of phase I results, days 1 to 4 weeks 1, 5 and 8 mitomicyne = 10 mg/m² day 1 week 1 and days 1, weeks 5 and 8 Panitumumab = 3 or 6 mg/kg (depending of phase I results) days 1, weeks: 1, 3, 5, 8 and 10
62622758|NCT05671159|OTHER|viral infection|
62622759|NCT04204304|EXPERIMENTAL|Isotretinoin-induced adverse effect group|Patients receiving isotretinoin with dose of 0.5-1 mg/kg/day and had musculoskeletal adverse effects
62622760|NCT04204304|ACTIVE_COMPARATOR|Control group|Pateients receiving isotretinoin with dose of 0.5-1 mg/kg/day had no musculoskeletal adverse effects
62622761|NCT01961024||Type 2 diabetic men|
62622762|NCT01961024||Age- and weight-matched controls|
62622763|NCT04502784||Chronic Kidney Disease|This group will consist of 10 patients who have previously been diagnosed with chronic kidney disease and are receiving intravenous iron due to anaemia.
62622764|NCT04502784||Intestinal failure|This group will consist of 10 patients who have previously been diagnosed with intestinal conditions and are receiving intravenous iron due to anaemia.
62622765|NCT04502784||Healthy Volunteers|This group will consist of 20 healthy volunteers. This group will act as a comparator for the CKD and intestinal failure groups.
62622766|NCT04564105|OTHER|Staff of the ICU|The whole staff (nurses and doctors) of the ICU will be recruited to this trial. When they give their informed consent, video-recording of the intubations will be started. After 20 videos, simulations will be run. Also simulations will be recorded. Thereafter 20 further real-life intubations will be recorded. Staff intubating patients before and after won't be same but they will be adjusted for experience related to intubations.
62848676|NCT04504409|ACTIVE_COMPARATOR|DN combined with exercise (DNG)|The MTrP dry needling procedure employed was similar to the MTrP injection described by Hong. The MTrP was located by palpating the taut band and identifying the point of maximal tenderness. This was then firmly compressed by the index finger or middle finger of the nondominant hand to direct the placement of the needle tip while inserting the needle. The needle was inserted into the skin at a point above the taut band, approximately 1 cm from the MTrP region. After penetration of the needle into the subcutaneous layer, it was kept there and obliquely (about 45 degrees) directed to the MTrP region under the fingertip of the non-dominant hand. Then, the needle was inserted rapidly into the MTrP region and withdrawn rapidly. In DNG, patients received DN for a 3-week duration (twice a week periodically in this time).
62848677|NCT05740878|EXPERIMENTAL|immunonutrients ONS|the intervention group received ONS which contained immunonutrients (omega 3 and anthocyanin)
62848678|NCT05740878|ACTIVE_COMPARATOR|standard ONS|the control group received standard ONS (isocaloric)
62061407|NCT02801669|EXPERIMENTAL|DU-176b 15 mg group|DU-176b orally administered at a dose of 15 mg once daily.
62848679|NCT05504642|EXPERIMENTAL|Study medication|"All eligible patients will receive study medication:~* Pre-Chemo-radio-immunotherapy Treatment for two weeks before start of Chemo-radio-immunotherapy~* Concurrent Chemo-radio-immunotherapy (week 1-7)~* Maintenance Treatment (six months) after Chemo-radio-immunotherapy"
62848680|NCT05590078|OTHER|Control group|General routine care. This group will undergo to ambulatory surgery without preoperative virtual reality session. Will be applied the usual treatment to reduce preoperative anxiety.
62848681|NCT05590078|EXPERIMENTAL|Virtual reality group|Virtual Reality. This group will undergo to 20 min virtual reality before ambulatory surgery. In addition to virtual reality session, will be applied the usual treatment to reduce preoperative anxiety, after virtual reality, if necessary.
62848682|NCT03792828|ACTIVE_COMPARATOR|Control|Duloxetine HCl 30mg is not used.
62061408|NCT02801669|PLACEBO_COMPARATOR|Placebo group|Placebo orally administered once daily.
62061409|NCT03933111|EXPERIMENTAL|patients with pancreatic solid neoplasms|Patients with pancreatic solid neoplasms are enrolled in this study and accept the test.
62265409|NCT05234606|EXPERIMENTAL|Part 2: SBT6290|SBT6290 every 3 weeks
62265410|NCT05234606|EXPERIMENTAL|Part 3: SBT6290 + pembrolizumab|SBT6290 plus pembrolizumab every 3 weeks
62265411|NCT05234606|EXPERIMENTAL|Part 4: SBT6290 + pembrolizumab|SBT6290 plus pembrolizumab every 3 weeks
62848683|NCT03792828|EXPERIMENTAL|Duloxetine|One capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation.
62848684|NCT03258528|ACTIVE_COMPARATOR|right lateral position group|Neonates kept in the right lateral position for 6 hours with head tilted 30 degree upward with rolled towel supports the infant back at 90 degree angle on the bed.
62848685|NCT03258528|ACTIVE_COMPARATOR|supine position group|"Neonates kept in supine position for 6 hours with head tilted 30 degrees upward.~Infants were fed while in their positions via feeding tube."
62848686|NCT03189238|PLACEBO_COMPARATOR|Placebo|
62061410|NCT02932059|EXPERIMENTAL|Adult schizophrenic patients (18-45 years)|4 groups formed by the case-control study in two age strata
62061411|NCT02932059|EXPERIMENTAL|Aged patients with schizophrenia (≥ 55 years)|4 groups formed by the case-control study in two age strata
62061412|NCT02932059|EXPERIMENTAL|Adults controls (18-45 years)|4 groups formed by the case-control study in two age strata
62061413|NCT02932059|EXPERIMENTAL|Aged Controls (≥ 55 years)|4 groups formed by the case-control study in two age strata
62061414|NCT03784690|EXPERIMENTAL|Individualized BP group|Individualized intraoperative BP management
62061415|NCT03784690|PLACEBO_COMPARATOR|Standard treatment group|Standard intraoperative BP management
62265412|NCT03744351|OTHER|Healthy volunteer|"* 45 subjects~* A single visit"
62265413|NCT03744351|OTHER|Clinically Isolated Syndrome|• 35 subjects
62265414|NCT03744351|OTHER|Non-MS patients with neurological inflammatory disease|• 30 subjects
62265415|NCT03744351|OTHER|MS patients (remitting or progressive untreated)|"* 30 untreated remittent patients~* 30 progressive untreated patients"
62265416|NCT04322773|EXPERIMENTAL|Roactemra iv|Single dose treatment with 400 mg tocilizumab intravensously
62265417|NCT04322773|EXPERIMENTAL|Roactemra sc|Single dose treatment with 2 x 162 mg tocilizumab subcutaneously
62622767|NCT01142505|PLACEBO_COMPARATOR|Placebo|Patients in the placebo arm will be given an inactive version of the investigational medical product formed of the excipient mannitol (which is coated with the active drug montelukast in the active comparator arm)
62848687|NCT03189238|ACTIVE_COMPARATOR|PRP|
62848688|NCT04230135|ACTIVE_COMPARATOR|Generic (surface adaptation)|The generic version of Hap-pas-Hapi includes only surface adaptations (i.e., adaptation of text and illustrations that are inacceptable or non-meaningful for the target group)
62622768|NCT01142505|ACTIVE_COMPARATOR|Montelukast|Patients in the active arm will be given an active version of the investigational medical product formed of the inactive excipient mannitol with a coating of active drug montelukast.
62622769|NCT03724045|EXPERIMENTAL|Back Side of the Moon|"Patients will be screened and enrolled at the ICU. Extraordinary measurements concerning nutritional status will be performed, to investigate whether patients at the ICU actually meet their nutritional needs. The same patients as above will be followed up, once discharge from ICU to a low-care ward has taken place. From there, they will be followed up until discharge from the hospital. The procedures are the same as in the ICU. The results obtained at the low-care ward will be compared to those from the ICU. 6 months after hospital discharge, morbidity and mortality will be assessed.~A substudy of included COVID-19 positive patients will be analysed and compared to non COVID-19 patients."
62622770|NCT04529317|NO_INTERVENTION|Regular diet|The study was a cross-over pilot clinical study consisting of two periods. The first period was only an observational and monitoring phase where participants just continued with their regular diet (RD), for this reason all participants initiated this period and wash-out term was no needed.
62622771|NCT04529317|EXPERIMENTAL|Quinoa diet|With the data of the first phase obtained, the subjects began the second period in which they had to undergo a nutritional intervention with a quinoa diet (QD).
62622772|NCT05726513|OTHER|Low support, high Positive end-expiratory pressure|Low support, high Positive end-expiratory pressure
62622773|NCT05726513|OTHER|Low support, zero positive end-expiratory pressure|Low support, zero positive end-expiratory pressure
62622774|NCT05726513|OTHER|Zero support, zero positive end-expiratory pressure|Zero support, zero positive end-expiratory pressure
62622775|NCT00824629|EXPERIMENTAL|1|Afterloading embryo transfer procedure
62622776|NCT00824629|ACTIVE_COMPARATOR|2|Direct embryo transfer procedure
62622777|NCT01285479||fingolimod|prescribed fingolimod 0.5 mg/day, including generic versions of fingolimod
62622778|NCT05622643||Patients with MS|250 patients with MRI, OCT and bio sample
62848689|NCT04230135|EXPERIMENTAL|Adapted (deep structure adaptation)|For the experimental intervention, Hap-pas-Hapi was adapted to Albanian immigrants' cultural concepts of distress (CCD). An ethnopsychological study was conducted for this purpose, since evidence on CCD in South Eastern Europe is scarce. Based on this study, three deep-structure adaptations were done: i) the symptom narrative provided by the narrator in the app was re-written to reflect Albanian immigrants' CCD; ii) a new explanatory model builder was implemented to address the target group's fatalistic beliefs; and iii) a goal-setting task was programmed to address the target group's socio-centric notion of the self.
62848690|NCT03976648|EXPERIMENTAL|GLPG1690 600 mg|Participants who received GLPG1690 600 milligrams (mg) in the GLPG1690-CL-204 (NCT03798366) study received GLPG1690 600 mg orally once daily up to 91 weeks.
62265418|NCT04322773|EXPERIMENTAL|Kevzara sc|Single dose treatment with 1 x 200 mg sarilumab subcutaneously
62622779|NCT05622643||Healthy subjects|50 healthy subjects with MRI
62622780|NCT02347072|EXPERIMENTAL|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
62622781|NCT02347072|PLACEBO_COMPARATOR|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
62622782|NCT02347072|ACTIVE_COMPARATOR|Spiriva® Respimat® (Tiotropium Bromide)|Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
62622783|NCT01887678|EXPERIMENTAL|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one intra articular (IA) injection) on treatment days 1, 8 and 15.
62622784|NCT01887678|PLACEBO_COMPARATOR|Placebo injectable solution|Injection volume of placebo is 4.2 mL as well (taken from the 10.0 mL vial by unblinded staff member, rest to be kept for drug accountability)
62622785|NCT05206396||TIL in breast cancer patients who completed neoadjuvant therapy|"* Tumour infiltrating lymphocytes will be examined on pre-existing histopathologic samples.~* Data will be extracted from the files of the patients including:~* Demographic data, clinicopathologic data, pathologic complete response, and date of last follow up."
62622786|NCT06397053||laparoscopic surgery with visceral obesity|
62848691|NCT03976648|EXPERIMENTAL|Placebo|Participants who received placebo matched to GLPG1690 in the GLPG1690-CL-204 (NCT03798366) study received GLPG1690 600 mg orally once daily up to 91 weeks.
62061416|NCT03036059|ACTIVE_COMPARATOR|Control group|400 μg/kg Ivermectin + 400 mg Albendazole Tablets given every year for 2 years
62061417|NCT03036059|EXPERIMENTAL|Expanded frequency group|400 μg/kg Ivermectin + 400 mg Albendazole, Tablets given every 6 months for 2 years
62265419|NCT04322773|ACTIVE_COMPARATOR|Standard care|Management as usual
62265420|NCT06162299|EXPERIMENTAL|Low dose 0.5mL|Group A ：The first 4 enrollees in Group A will be sentinel patients and will be allocated at a 1:1 ratio to receive 0.5mL of either YS-HBV-002 or placebo(saline solution), The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 0.5mL of either YS-HBV-002 or placebo.
62622787|NCT06397053||robotic surgery with visceral obesity|
62622788|NCT04926285|EXPERIMENTAL|Cohort 1|Omacetaxine 0.625 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
62622789|NCT04926285|EXPERIMENTAL|Cohort 2|Omacetaxine 1.25 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
62622790|NCT04926285|EXPERIMENTAL|Cohort 3|Omacetaxine 2.0 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
62622791|NCT04926285|EXPERIMENTAL|Cohort 4|Omacetaxine 2.5 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
62622792|NCT02434159|ACTIVE_COMPARATOR|Scan|Heart scan prior to device insertion
62622793|NCT02434159|NO_INTERVENTION|No scan|No heart scan prior to device insertion
62622794|NCT01272505|PLACEBO_COMPARATOR|conventional SILC|Conventional method of single incision laparoscopic cholecystectomy
62622795|NCT01272505|ACTIVE_COMPARATOR|HS-SILC|
62061418|NCT04748016|EXPERIMENTAL|3D-printed models plus CT imaging|Fracture repair surgery using sterilized 3DP models, CT-MPR and CT-3DR for planning and intraoperative visualization
62061419|NCT04748016|ACTIVE_COMPARATOR|CT imaging alone|Fracture repair surgery using CT-MPR and CT-3DR for planning and intraoperative visualization
62265421|NCT06162299|EXPERIMENTAL|Mid-dose 1.0mL|Group B ：The first 4 enrollees in Group B will be sentinel patients and will be allocated at a 1:1 ratio to receive 1.0mL of either YS-HBV-002 or placebo(saline solution), The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 1.0mL of either YS-HBV-002 or placebo.
62622796|NCT05912075|EXPERIMENTAL|LCRT|"LCRT: Long-course pelvic radiotherapy given concomitantly with capecitabine chemotherapy and TOLINAPANT (ASTX660):~* mFOLFIRINOX will be given prior to tolinapant (ASTX660) for 6 cycles over 12 weeks;~* Pelvic radiotherapy to a planned volume at a 50-Gy total dose in 25 daily fractions of 2 Gy (5 days per week from Monday to Friday) for 5 weeks;~* Chemotherapy (capecitabine) at 800 mg/m2 bid for 5 days per week (From Monday to Friday) for 25 days will be given concomitantly during the 5 weeks of radiotherapy;~* TOLINAPANT (ASTX660) starting from 14 days before the first dose of radiotherapy, for 10 weeks. Tolinapant (ASTX660) will be given concomitantly with RT and chemotherapy for 5 weeks."
62265422|NCT06162299|EXPERIMENTAL|High dose 2.0mL|Group C ：The first 4 enrollees in Group C will be sentinel patients and will be allocated at a 1:1 ratio to receive 2.0mL of either YS-HBV-002 or placebo(saline solution), The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 2.0mL of either YS-HBV-002 or placebo.
62265423|NCT05949905|EXPERIMENTAL|Precontemplation, Contemplation, Preparation, Action, and Maintenance-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Precontemplation Stage of Change.
62848692|NCT01812668|EXPERIMENTAL|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.
62848693|NCT01572987|ACTIVE_COMPARATOR|RFA arm|Under this arm, study patients will undergo radiofrequency ablation.
62848694|NCT01572987|ACTIVE_COMPARATOR|EMR arm|Under this arm, the individuals will undergo endoscopic mucosal resection.
62848695|NCT00982059||All|All patients enrolled in the study will be undergoing the same procedures.
62848696|NCT03078829||Trans female adolescents|All transgender males to females youth in pubertal stage Tanner stage 4-5, starting GnRH agonist and estrogen treatment
62848697|NCT04535453|EXPERIMENTAL|Groups 1-6|Participants will receive a 2-dose Ad26.COV2.S vaccination regimen at Days 1 and 57 at different dose levels (Groups 1-3), or a single-dose Ad26.COV2.S vaccination regimen at different dose levels (Groups 4-5), or placebo (Group 6). At unblinded phase, participants in Group 6 initially receiving placebo will be offered 2 doses of Ad26.COV2.S vaccine at a single dose level, at a 28-day interval. Participants will also receive a single antigen presentation injection with single dose level of Ad26.COV2.S at 4 months after second vaccination (Groups 1-5) or placebo (Group 6).
62848698|NCT04535453|EXPERIMENTAL|Groups 7-8|Participants will receive 2-dose Ad26.COV2.S vaccination regimen at Days 1 and 29 at fixed dose level (Groups 7) or placebo (Groups 8). At unblinded phase, participants in Group 8 initially receiving placebo will be offered 2 doses of Ad26.COV2.S vaccine at a single dose level, at a 28-day interval. Participants will also receive a single antigen presentation injection with single dose level of Ad26.COV2.S at 4 months after second vaccination (Group 7) or placebo (Group 8).
62848699|NCT04535453|EXPERIMENTAL|Groups 9-10|Participants will receive 2-dose Ad26.COV2.S vaccination regimen at Days 1 and 85 at fixed dose level (Group 9) or placebo (Group 10). At unblinded phase, participants in Group 10 initially receiving placebo will be offered 2 doses of Ad26.COV2.S vaccine at a single dose level, at a 28-day interval. Participants will also receive a single antigen presentation injection with single dose level of Ad26.COV2.S at 4 months after second vaccination (Group 9) or placebo (Group 10).
62848700|NCT04535453|EXPERIMENTAL|Groups A-C|Participants will receive a single dose Ad26.COV2.S vaccination regimen at Day 1 at fixed dose level (Groups A and B) or placebo (Group C). At approximately 6 months of study participation (unblinded phase), participants in Group C initially receiving placebo will receive Ad26.COV2.S vaccine at a single dose level, at a 56-day interval.
62848701|NCT02562664|ACTIVE_COMPARATOR|CC with placebo|100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle with placebo tablets taken twice daily continuously for three cycles.
62848702|NCT02562664|ACTIVE_COMPARATOR|CC plus Metformin|received t100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle with plus Metformin 500 mg twice daily continuously for three cycles.
62265424|NCT05949905|EXPERIMENTAL|Contemplation-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Contemplation Stage of Change.
62265425|NCT05949905|EXPERIMENTAL|Preparation-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Preparation Stage of Change.
62265426|NCT05949905|EXPERIMENTAL|Action-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Action Stage of Change.
62061420|NCT03440502||control group.|Parturients aged 18 or older (American Society of Anesthesiologist physical status II-III parturients ASA II-III) undergoing cesarean delivery under spinal anaesthesia, singleton pregnancy, full term, elective
62265427|NCT05949905|EXPERIMENTAL|Maintenance-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Maintenance Stage of Change.
62265428|NCT06494046||Observational Musical Toxicity Group|Patients complete a questionnaire, participate in an interview and their medical records reviewed on study.
62622797|NCT05912075|EXPERIMENTAL|SCRT|"SCRT: Short course pelvic radiotherapy followed by chemotherapy in combination with TOLINAPANT (ASTX660):~* Pelvic radiotherapy will be given to a planned volume at a total dose of 25 Gy, in 5 daily fractions of 5 Gy for 1 week (5 days from Monday-Friday)~* Chemotherapy (FOLFOX4): given every 2 weeks for 9 cycles, starting 10 days after the last session of short course radiotherapy. Alternative: CAPOX given every 3 weeks for 6 cycles, starting 10 days after the last session of short course radiotherapy.~* Tolinapant (ASTX660) starting from 14 days before the first dose of radiotherapy, for 10 weeks. Tolinapant (ASTX660) will be given concomitantly with RT for 5 days."
62622798|NCT01048944|ACTIVE_COMPARATOR|Bupropion SR|150 mg bid bupropion SR
62622799|NCT01048944|ACTIVE_COMPARATOR|Nicotine Patch|21mg, 14mg, 7mg
62622800|NCT01048944|PLACEBO_COMPARATOR|Placebo Patch and Placebo Pill|Individuals were placed on both a placebo patch that were the same size as active patches given to the Nicotine Patch group and were also given placebo pills were the same size and identically packaged as the active pills (bupropion) given to the Bupropion SR group.
62622801|NCT01048944|NO_INTERVENTION|Delayed-quit control|Smoke for 67 days while others have quit, then quit.
62622802|NCT04356599|EXPERIMENTAL|Intervention Group|All participants will receive study intervention
62622803|NCT03638830|EXPERIMENTAL|Group 1|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)1/2 dose + placebo+ Maxipime®"
62622804|NCT03638830|EXPERIMENTAL|Group 2|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation) full dose + Maxipime®"
62622805|NCT03638830|PLACEBO_COMPARATOR|Group 3|placebo (like full dose) in combination with the drug Maxipime®
62622806|NCT04719845|EXPERIMENTAL|Endoscopic laser resection|Using CO2, diode or similar wavelenght laser the stenotic tracheal segment will be vaporized allowing a less than 20% residual stenosis. Dilatation will not be performed after laser resection for residual stenosis.
62622807|NCT04719845|EXPERIMENTAL|Dilatation|Using a ballon or rigid bronchoscope the stenotic tracheal segment will be dilated with or without previous radial incision with electrocautery or laser.
62622808|NCT01447641||Cluster headache|Cluster headache sufferers (both chronic and episodic)
62622809|NCT01015105||patients with hip fracture|
62061421|NCT03440502||study group|The same as control group but with DM or gestational diabetes Parturients aged 18 or older (American Society of Anesthesiologist physical status II-III parturients ASA II-III) undergoing cesarean delivery under spinal anaesthesia, singleton pregnancy, full term, elective
62265429|NCT06494046||Observational No Musical Toxicity Group|Patients have their medical records reviewed on study.
62265430|NCT01970995|EXPERIMENTAL|THS 2.2 Menthol (mTHS 2.2)|Ad libitum use of THS 2.2 Menthol for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
62622810|NCT02333500|EXPERIMENTAL|olfactory workshop|Influence of sensory therapy on the rate of oxytocin
62265431|NCT01970995|ACTIVE_COMPARATOR|Smoking abstinence (SA)|Abstinence from smoking for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
62265432|NCT01970995|ACTIVE_COMPARATOR|Menthol Conventional Cigarette (mCC)|Ad libitum use of subject's own preferred brand of mCC for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
62622811|NCT02333500|ACTIVE_COMPARATOR|other workshop|Influence of other workshop on the rate of oxytocin
62622812|NCT02333500|OTHER|control group|Rate of oxytocin of the control group
62622813|NCT01727362|ACTIVE_COMPARATOR|Usual care + acupuncture|
62622814|NCT01727362|ACTIVE_COMPARATOR|Usual care|
62622815|NCT03959488|EXPERIMENTAL|MEDI8897|anti-RSV monoclonal antibody with an extended half-life
62622816|NCT03959488|ACTIVE_COMPARATOR|Palivizumab|anti-RSV monoclonal antibody
62622817|NCT00559143|ACTIVE_COMPARATOR|1|DDD(R)-RV pacing
62622818|NCT00559143|EXPERIMENTAL|2|DDD(R)- BIV pacing
62622819|NCT04110899|EXPERIMENTAL|Different paratracheal force|Esophageal occlusion is assessed by inserting an esophageal stethoscope under different paratracheal forces.
62622820|NCT04630782||Aim 1|"The investigators will compare PET-MRI imaging and stool biomarkers between patients with VEDOSS/early SSc (n=40) and those with late SSc (n=20) not on immunosuppressive treatment.~Participants will undergo a PET-MRI scan once at baseline."
62265433|NCT01351935|EXPERIMENTAL|AVL-292|
62265434|NCT04094571|EXPERIMENTAL|Healthy Individuals and those with Movement Disorders|Participants will perform the FES cycling protocol along with the FES angle protocol.
62265435|NCT06474754|EXPERIMENTAL|Submaximal cardiopulmonary exercise testing|Single arm design; selected participants will receive both usual care (Duke Activity Status Index) and submaximal cardiopulmonary exercise testing. All participants will receive high-sensitivity troponin measurements on operative day 1 and postoperative day 1,2,3
62622821|NCT04630782||Aim 2|"In early SSc patients (n=35), the investigators will determine change in biomarker levels from pre-treatment baseline to 6 months (primary end-point) and 12-months (secondary end-point) following MMF treatment.~Participants will undergo PET-MRI scans at baseline, 6-month and 12-month."
62622822|NCT04630782||Exploratory aim|"In patients with VEDOSS/early SSc (n=15) not on immunosuppressive treatment, the investigators will characterize imaging and stool biomarker changes over one year.~Participants will undergo PET-MRI scans at baseline and 12-month."
62622823|NCT05247346|EXPERIMENTAL|probe-based endoscopic Raman and scattering measurements of GI tissue|probe-based integrated Raman spectroscopy and scattering measurements of BE and colorectal tissue during GI endoscopy
62622824|NCT05816850||Patients enrolled|Patient affected by advanced Follicular Lymphoma treated with immunochemotherapy in the FIL_FOLL12 trial
62622825|NCT03910881|EXPERIMENTAL|open-platform patient support system|Proof of concept testing of app
62265436|NCT04486950|EXPERIMENTAL|Cohort 1 (Low Dose): TAK-951 20 mcg Infusion Over 60 Minutes|TAK-951 20 microgram (mcg) or TAK-951 placebo-matching, infusion, intravenously, over a period of 60 minutes on Day 1.
62265437|NCT04486950|EXPERIMENTAL|Cohort 2 (High Dose): TAK-951 1 mg Infusion Over 60 Minutes|TAK-951 1 milligram (mg) or TAK-951 placebo-matching, infusion, intravenously, over a period of 60 minutes on Day 1. Dose level will be determined based on safety, tolerability and PK data from previous cohorts.
62265438|NCT04486950|EXPERIMENTAL|Cohort 3: TAK-951 1 mg Infusion Over 120 Minutes|TAK-951 1 mg or TAK-951 placebo-matching, infusion, intravenously, over a period of 120 minutes on Day 1. Dose level will be determined based on safety, tolerability and PK data from previous cohorts.
62265439|NCT03456921|EXPERIMENTAL|Game participants|"All participants will engage in playing the end-of-life conversation game called Hello, which involves answering open-ended questions about medical decision making and end-of-life issues."
62265440|NCT04027114|EXPERIMENTAL|Behavioural Physical Activity (PA) intervention|
62265441|NCT04027114|NO_INTERVENTION|Wait list control|
62265442|NCT05363475|EXPERIMENTAL|Prospective|Participants will be monitored by the ForeSite Intelligent Surface system for 2-3 weeks.
62265443|NCT00829907|EXPERIMENTAL|1|Orm-12741
62449049|NCT05892978|EXPERIMENTAL|Vascular access transillumination group|The patient's vital signs, skin color and skin turgor will be evaluated and recorded in the PIVC procedure registration form. Before the tourniquet is attached before the procedure, the patient's vein visibility will be evaluated by the research nurse. The vein imaging device will be opened with transilluminator, the tourniquet will be connected, and the vein visibility will be re-evaluated by the operator. The skill duration will be measured and recorded by the researcher with a stopwatch. The selection of the necessary materials will not be added to this time, the chronometer will be started after the tourniquet is attached, and the time will end with the blood coming to the PIVC. Data obtained on PIVC placement; the pain and fear levels before, during and after the procedure. Finally, patients will be asked about their level of satisfaction with the procedure at the end of the infusion.
62848703|NCT05466201|OTHER|supportive care|patients in this group will receive supportive care, including blood products transfusion, anti-infective therapy rather than rhTPO or TPO-RAs.
62848704|NCT05466201|EXPERIMENTAL|Eltrombopag group|Eltrombopag treatment will be started at the dose of 50mg/d from the 1st day post hematopoietic stem cell transplantation, and the dose will be titrated by 25mg each every 7 days up to 100mg/d according to the tolerability. If not tolerable, reduce the dose to the previous tolerable level (if not tolerable at 50mg/d, reduce to 25mg/d) and maintain this dose for the following 7 days, with the attempt to restart dose escalation after this 7-day period.
62848705|NCT02267798|EXPERIMENTAL|arm training combined with FES|"Arm training protocol Training sessions will last for 60 minutes and will focus on repetitive tasks that incorporate multidirectional reaching actions. In this robot-assisted therapy a robot manipulator applies forces to the paretic arm during goal-directed movements.~Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists of a battery powered programmable stimulator and a forearm-wrist-hand orthosis containing 5 electrodes positioned to provide reliable activation of muscles. The intensity of stimulation will be set to a level that provided comfortable and consistent activation of the extensor and flexor muscles to achieve whole hand opening and functional grasping."
62848706|NCT02267798|ACTIVE_COMPARATOR|conventional therapy|The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence, Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques based on neuro-developmental treatment.
62265444|NCT01647971|EXPERIMENTAL|ublituximab|"Phase I:~4 cohorts with IV ublituximab starting with 450 mg followed by 600 mg, 900 mg or 1200 mg in each cohort (3 - 6 patients per cohort). Infusions will be on days 1, 8, 15 and 22 of cycle 1 followed by a planned maintenance with a single infusion monthly starting cycle 3. Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) will have infusions on Days 1, 8 and 15 of cycle 1 \& 2 followed by a planned maintenance with a single infusion monthly starting cycle 3. Expansion of patient enrollment in select cohorts will apply."
62622826|NCT05943431|EXPERIMENTAL|Paired taVNS|Upper extremity motor rehabilitation training will be paired with taVNS.
62848707|NCT03293901|NO_INTERVENTION|Rest|
62848708|NCT03293901|ACTIVE_COMPARATOR|Exercise|Militarily relevant exercise
62848709|NCT01680029|EXPERIMENTAL|PBASE-system 2.0|
62848710|NCT01693978|EXPERIMENTAL|Reinforced Prolonged Exposure (RPE)|All participants will be scheduled to attend a weekly Prolonged Exposure therapy session for 12 consecutive weeks, and followed for 12 additional weeks. RPE participants will receive voucher-based reinforcement contingent on attendance to scheduled Prolonged Exposure therapy sessions.
62061422|NCT04302623|EXPERIMENTAL|Online yoga program|An 8-week online live facilitator-led yoga program.
62061423|NCT04302623|EXPERIMENTAL|Control|Advice only group.
62265445|NCT05413382|ACTIVE_COMPARATOR|Investigational lozenge|Lozenge containing the enzyme polyphenol oxidase and green coffee extract
62265446|NCT05413382|PLACEBO_COMPARATOR|Placebo lozenge|Lozenge equal to active comparator but without active ingredients
62265447|NCT04510233|EXPERIMENTAL|Ivermectin nasal spray|Ivermectin administered as nasal spray (one ml in each nostril two times daily)
62265448|NCT04510233|EXPERIMENTAL|Ivermectin oral|Ivermectin administered orally (one tablet 6 mg three times daily) for 72 hours plus the standard care of COVID-19 cases.
62265449|NCT04510233|EXPERIMENTAL|standard care|COVID-19 cases will receive standard of care \[oxygen via masks or ventilators\]
62265450|NCT04677959|EXPERIMENTAL|Digital System (DS)|DS group participants utilizing the eMDPI DS, including inhaler, smart device application (App), DHP (Cloud solution), and dashboard
62265451|NCT04677959|ACTIVE_COMPARATOR|Standard of Care (SoC) Group|SoC group participants will be treated with their standard of care medications
62265452|NCT00464334|EXPERIMENTAL|Placebo to V950/IMX 0 mcg|Participants receive Placebo to V950/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
62265453|NCT00464334|EXPERIMENTAL|Placebo to V950/IMX 16 mcg|Participants receive Placebo to V950/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
62265454|NCT00464334|EXPERIMENTAL|V950 0.5 mcg/IMX 0 mcg|Participants receive V950 0.5 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
62265455|NCT00464334|EXPERIMENTAL|V950 0.5 mcg/IMX 16 mcg|Participants receive V950 0.5 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
62622827|NCT05943431|ACTIVE_COMPARATOR|Unpaired taVNS|Unpaired transcutaneous vagus nerve stimulation for upper limb motor rehabilitation will be administered.
62622828|NCT05943431|SHAM_COMPARATOR|Sham taVNS|Upper limb motor rehabilitation training will be paired with sham-stimulation.
62622829|NCT01654263|EXPERIMENTAL|Group IA: Pneumococcal vaccine-naive, age 55 - 64|Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to 147 subjects vaccine-naive adults
62622830|NCT01654263|EXPERIMENTAL|Group IB: Pneumococcal vaccine-naive, age 65 - 74|Open- label, PCV13 given as 0.5 mL IM injection to 147 subjects vaccine-naive adults
62622831|NCT01654263|EXPERIMENTAL|Group IIA: age 55 - 64, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
62622832|NCT01654263|EXPERIMENTAL|Group IIAA: age 55 - 64, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
62622833|NCT01654263|EXPERIMENTAL|Group IIB: age 65 - 74, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
62622834|NCT01654263|EXPERIMENTAL|Group IIBB: age 65 - 74, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
62622835|NCT01327092|NO_INTERVENTION|Literacy Group|Families in the Literacy Group (control group)will receive a program which seeks to promote literacy by providing developmentally appropriate books and other reading-related materials to children and encouraging mothers to develop an interest in reading with their child. After enrollment and randomization, CHIP staff will visit these control group homes, assess the mother's interest in and barriers to reading with her child, council mothers about the importance of literacy and reading books to their child, and children will be given age appropriate books and other materials to promote literacy.
62265456|NCT00464334|EXPERIMENTAL|V950 0.5 mcg/IMX 47 mcg|Participants receive V950 0.5 mcg/IMX 47 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
62265457|NCT00464334|EXPERIMENTAL|V950 0.5 mcg/IMX 94 mcg|Participants receive V950 0.5 mcg/IMX 94 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
62622836|NCT01327092|EXPERIMENTAL|Injury Intervention Group|Injury Intervention Group: In homes of children who are randomized to the injury intervention arm of the trial, a comprehensive survey of injury hazards in living spaces will be undertaken. In addition to quantifying hazards, the area of living spaces will be obtained to allow the determination of both the number and density (number of hazards per 100 sq ft) of injury hazards. If one or more injury hazards are identified, they will be removed and/or modified to reduce exposure and injury risk. The intervention is focused on areas in living spaces below 1 meter (\~39 inches) in height from (the 75th percentile in height or eye-level for a 3-year old US male toddler) which might be easily reached or climbed on by children less than 4 years
62622837|NCT04146857|PLACEBO_COMPARATOR|Normoxia|20.9% oxygen
62622838|NCT04146857|ACTIVE_COMPARATOR|Hypoxia 1|15.0% oxygen
62622839|NCT04146857|ACTIVE_COMPARATOR|Hypoxia 2|12.8% oxygen
62265458|NCT00464334|EXPERIMENTAL|V950 5 mcg/IMX 0 mcg|Participants receive V950 5 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
62622840|NCT05243069|EXPERIMENTAL|Screening (3D scan)|Patients undergo 3D scanning of lower head and neck region over 90-120 seconds before surgery and then every 3 months for up to 1 year after surgery.
62622841|NCT02652702|EXPERIMENTAL|Circular Stapler-assisted Colostomy|Using Circular Stapler-assisted Technique to Finish Colostomy after colorectal carcinoma surgery when patient need permanent sigmoid stoma.
62622842|NCT02652702|EXPERIMENTAL|Hand-stitching Colostomy|Using Conventional Hand-stitching Technique to Finish Colostomy after colorectal carcinoma surgery when patient need permanent sigmoid stoma.
62622843|NCT00675077|EXPERIMENTAL|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
62622844|NCT02330224|EXPERIMENTAL|Hypertension Management Intervention|Multifaceted hypertension management intervention
62622845|NCT02330224|NO_INTERVENTION|Usual Care|Control group
62061424|NCT02269371|EXPERIMENTAL|Group 1|Group 1: Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.
62265459|NCT00464334|EXPERIMENTAL|V950 5 mcg/IMX 16 mcg|Participants receive V950 5 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
62265460|NCT00464334|EXPERIMENTAL|V950 5 mcg/IMX 47 mcg|Participants receive V950 5 mcg/IMX 47 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
62265461|NCT00464334|EXPERIMENTAL|V950 50 mcg/IMX 0 mcg|Participants receive V950 50 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
62265462|NCT00464334|EXPERIMENTAL|V950 50 mcg/IMX 16 mcg|Participants receive V950 50 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
62265463|NCT03631732|EXPERIMENTAL|B/F/TAF|Participants will receive B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.
62622846|NCT01134263|EXPERIMENTAL|CYD Dengue Vaccine Phase III Lot 1|Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1),Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
62622847|NCT01134263|EXPERIMENTAL|CYD Dengue vaccine - Phase III Lot 2|Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
62622848|NCT01134263|EXPERIMENTAL|CYD Dengue vaccine - Phase III Lot 3|Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
62622849|NCT01134263|EXPERIMENTAL|CYD Dengue vaccine - Phase II Lot|Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
62622850|NCT01134263|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
62622851|NCT00960973|EXPERIMENTAL|Vitamin K|Vitamin K supplementation (menatetrenone 30 mg, 3 times a day for 4 weeks)
62265464|NCT03631732|ACTIVE_COMPARATOR|Stay on Baseline Regimen (SBR)/ Delayed B/F/TAF|Participants will stay on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks with a delayed switch to B/F/TAF (50/200/25 mg) FDC tablet administered orally, once daily until Week 48 without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.
62265465|NCT05428787|ACTIVE_COMPARATOR|Cardiac Resynchronization Therapy + AV node ablation|The active comparator group will be treated with CRT followed by an Atrioventricular Node Ablation.
62265466|NCT05428787|EXPERIMENTAL|Left Bundle Branch Area Pacing + AV node ablation|The experimental group will be treated with LBBAP followed by an Atrioventricular Node Ablation.
62265467|NCT01168362||High risk group|positive cardiovascular risk group
62265468|NCT01168362||Low risk group|negative cardiovascular risk group
62265469|NCT04479579|EXPERIMENTAL|Apixaban|apixaban for extended prophylaxis against VTE after discharge
62265470|NCT01701739|EXPERIMENTAL|aleglitazar / digoxin|
62622852|NCT00960973|PLACEBO_COMPARATOR|Placebo control|Placebo control
62622853|NCT03528382|EXPERIMENTAL|period I group|
62622854|NCT03528382|EXPERIMENTAL|period II group|
62622855|NCT03528382|EXPERIMENTAL|period III group|
62622856|NCT05201443|EXPERIMENTAL|Diode Laser|At baseline, diode laser is applied to one group.
62622857|NCT05201443|ACTIVE_COMPARATOR|Titanium curettes|At baseline, titanium curettes are used to both of the groups
62622858|NCT04705532|EXPERIMENTAL|tDCS/music|active tDCS combined with music
62622859|NCT04705532|EXPERIMENTAL|sham tDCS/music|Sham tDCS combined with music
62622860|NCT04705532|EXPERIMENTAL|tDCS/white noise|active tDCS combined with white noise
62622861|NCT04705532|EXPERIMENTAL|sham tDCS/white noise|sham tDCS combined with white noise
62622862|NCT05873868||Patients|Patients hATTR with neurological and cardiac damages treated with Patisiran or Vutrisiran
62622863|NCT02447770|EXPERIMENTAL|Cocoa Flavanol intake escalation|Ingestion of increasing number of capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process (500 mg of cocoa flavanols/capsule) during 6 weeks followed by a 2 week of washout (no capsule intake)
62622864|NCT00510055|EXPERIMENTAL|A|scars receive subdermal manipulation ONLY
62622865|NCT00510055|EXPERIMENTAL|B|scars receive subdermal manipulation AND injection of a filler
62622866|NCT05383066||those with anti-angiogenesis combined with PD-1/PD-L1 therapy|This study includes patients with advanced liver cancer who can benefit from anti-angiogenesis combined PD-1/PD-L1 treatment and observes the relationship between overall survival and their therpay.
62265471|NCT00075023|EXPERIMENTAL|Thalidomide gel|Thalidomide gel 20 mg applied topically 4 times daily for 4 weeks to a maximum of 3 target oral ulcers
62265472|NCT00075023|EXPERIMENTAL|Placebo|Placebo gel with no Thalidomide applied topically 4 times daily for 4 weeks to a maximum of 3 target oral ulcers
62265473|NCT02611388|EXPERIMENTAL|2/10HZ TEAS pretreatment|Patients were given 30min of 2/10HZ TEAS before anesthesia
62265474|NCT02611388|EXPERIMENTAL|10/50HZ TEAS pretreatment|Patients were given 30min of 10/50HZ TEAS before anesthesia
62265475|NCT02611388|SHAM_COMPARATOR|fake stimulation|Patients were only attached electrodes without electric current
62265476|NCT02966509|EXPERIMENTAL|A: Intervention Arm|All participants randomized to Arm A will receive the EPAC intervention as well as usual oncologic care.
62265477|NCT02966509|NO_INTERVENTION|B: Control Group Arm|All participants randomized to Arm B will receive usual oncologic care.
62265478|NCT02330159||Novel Wound Healing Protocol|Subjects who have pilonidal disease that are being scheduled for surgical excision with our novel wound healing protocol. The disease can be actively infected or chronic.
62622867|NCT05080738|EXPERIMENTAL|Intervention group|The patients in the intervention group will be asked to practice upper extremity home exercises including stretching, mobility and strengthening, as home exercises, 5 days a week for 8 weeks, which will be taught by the physiotherapist.
62622868|NCT05080738|NO_INTERVENTION|Control|Education group:Patients will be informed about joint protection principles by a physiotherapist for once.
62265479|NCT00935480|EXPERIMENTAL|HAART+Raltegravir 12 months (+/-) Maraviroc|
62265480|NCT00935480|NO_INTERVENTION|HAART|
62265481|NCT03814070|ACTIVE_COMPARATOR|Non-reinforced full arch acrylic restorations|
62265482|NCT03814070|EXPERIMENTAL|full arch acrylic restorations with fiber-reinforced framework|
62265483|NCT01744600|EXPERIMENTAL|Music Therapy|Participants in the experimental group will receive one active individual music therapy session each week for 22 weeks. Each session will last thirty minutes.
62265484|NCT01744600|NO_INTERVENTION|Control|Participants in the control group will receive normal, standard daily care for the 22 week period.
62622869|NCT01421147|EXPERIMENTAL|LY2963016 + Insulin Lispro|LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily at the same timing (daytime or evening/bedtime) as participant's prestudy basal insulin injection schedule in combination with premeal insulin lispro. Insulin lispro titrated based on blood glucose readings, administered subcutaneously, three times a day for 52 weeks.
62622870|NCT01421147|ACTIVE_COMPARATOR|Lantus + Insulin Lispro|Lantus titrated based on blood glucose readings, administered subcutaneously, once daily at the same timing (daytime or evening/bedtime) as participant's prestudy basal insulin injection schedule in combination with premeal insulin lispro. Insulin lispro titrated based on blood glucose readings, administered subcutaneously, three times a day for 52 weeks.
62622871|NCT00833404|EXPERIMENTAL|Smoking Cessation|8-week nicotine patch regimen
62622872|NCT00833404|NO_INTERVENTION|Wait List Control|Smoking as usual
62622873|NCT02484768|EXPERIMENTAL|Group A|Infusion of 1000 mg iron isomaltoside 1000 at baseline. The infusion is diluted in 100 mL 0.9 % sodium chloride and given over approximately 15 min
62622874|NCT02484768|PLACEBO_COMPARATOR|Group B|Infusion of 100 mL 0.9 % sodium chloride at baseline given over approximately 15 min
62622875|NCT04416919|OTHER|Assembled Mask|Participant will be fitted with a full-face mask that covers the mouth and nose or a Whole face mask that covers the eyes, nose, and mouth depending on participant's preferences. The Fitted Mask will be attached to a bacterial/viral filter for fit testing. After completing the Fit test, the mask will be placed on the face for 15 minutes while the participant performs various activities to document the ability to tolerate the respirator. Participants oxygen and carbon dioxide level will be measured in the beginning and at the end of the 15 minutes. The individuals will be able to remove the Mask anytime if they experience significant discomfort or claustrophobia. At the end, the mask will be removed.
62622876|NCT04919148|NO_INTERVENTION|Participants receive control message|Participants only receive standard heat risk warning
62061425|NCT02269371|SHAM_COMPARATOR|Group 2|Group 2: Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
62061426|NCT05034848|OTHER|PAD group|PAD patients, diagnosis after undergoing an echo-doppler in the Vascular Medicine Department of Orleans regional Hospital
62061427|NCT04551599|EXPERIMENTAL|Part 1: Sequence 1|"Healthy, young, adult participants will receive danicopan once each Period as follows:~Period 1: Danicopan administered under fed conditions.~Period 2: Danicopan administered under fasted conditions.~There will be a washout period of at least 7 days between the dose of danicopan in Period 1 and the dose of danicopan in Period 2."
62061428|NCT04551599|EXPERIMENTAL|Part 1: Sequence 2|"Healthy, young, adult participants will receive danicopan once each Period as follows:~Period 1: Danicopan administered under fasted conditions.~Period 2: Danicopan administered under fed conditions.~There will be a washout period of at least 7 days between the dose of danicopan in Period 1 and the dose of danicopan in Period 2."
62061429|NCT04551599|EXPERIMENTAL|Part 2|Healthy, elderly, male participants will receive a single dose of danicopan under fed conditions.
62061430|NCT01320943|EXPERIMENTAL|Stop TDF|Participants randomized to this arm will stop TDF therapy at baseline.
62061431|NCT01320943|ACTIVE_COMPARATOR|Continue TDF|Participants randomized to this arm will continue TDF therapy.
62061432|NCT05529160||Study Population|Up to 20 subjects will be recruited from the patient population at the Principal Investigator's clinic. Subject recruitment will end once 15 evaluable subjects have completed the study.
62061433|NCT05799326|EXPERIMENTAL|Levofloxacin group|Levofloxacin 200mg twice per day is administrated.
62622877|NCT04919148|EXPERIMENTAL|Participants receive intervention message|Participants receive standard heat risk warning plus figures incorporating the health impacts of heat and pro-environment behaviors.
62622878|NCT00463489|ACTIVE_COMPARATOR|Mail-based|Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
62848711|NCT01693978|ACTIVE_COMPARATOR|Standard Prolonged Exposure (SPE)|All participants will be scheduled to attend a weekly Prolonged Exposure therapy session for 12 consecutive weeks, and followed for 12 additional weeks.
62848712|NCT02842190|ACTIVE_COMPARATOR|NIPPV|NIPPV after ekstubation
62848713|NCT02842190|NO_INTERVENTION|BIPAP|BIPAP after ekstubation
62061434|NCT05799326|PLACEBO_COMPARATOR|Levofloxacin simulant group|Levofloxacin simulant 200mg twice per day is administrated.
62061435|NCT03192644|EXPERIMENTAL|Group A (TAI)|
62061436|NCT03192644|ACTIVE_COMPARATOR|Group B (TACE)|
62265485|NCT03641664|EXPERIMENTAL|Treatment: Family Centered Treatment|Family is offered choice of FCT or Level III out-of-home placement
62265486|NCT03641664|ACTIVE_COMPARATOR|Control: Level III Out of Home Placement|Family is offered Level III out-of-home placement
62265487|NCT04467424|EXPERIMENTAL|Pediatric anesthesia with ketofol|ketamine, propofol
62848714|NCT04181814||Diabetic patients|Diagnosed as diabetes
62848715|NCT02082119|EXPERIMENTAL|High Grade Glioma|To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed High Grade Glioma after biopsy.total dose of 60 Gy/ 4 Gy fraction/15 fractions (BED10 84 Gy) will prescribed to the PTV1; a total dose of 42 Gy/2.8 Gy fraction/15 fractions (BED10 53.76 Gy) will prescribed to PTV2 with SIB.
62848716|NCT01386866|EXPERIMENTAL|A|
62848717|NCT03574519|EXPERIMENTAL|Non-contingent incentives and weekly feedback|Participants will receive payment for participating in the study (regardless of goal attainment) and will receive weekly updates about their performance.
62848718|NCT03574519|EXPERIMENTAL|Non-contingent incentives and daily feedback|Participants will receive payment for participating in the study (regardless of goal attainment) and will receive daily updates about their performance.
62848719|NCT03574519|EXPERIMENTAL|Contingent incentives and weekly feedback|Participants will receive payment for meeting their daily goals and will receive weekly updates about their performance.
62848720|NCT03574519|EXPERIMENTAL|Contingent incentives and daily feedback|Participants will receive payment for meeting their daily goals and will receive daily updates about their performance.
62061437|NCT00374660|EXPERIMENTAL|1|
62265488|NCT04467424|EXPERIMENTAL|Pediatric anesthesia with ketofol plus lidocaine|ketamine, propofol, lidocaine
62265489|NCT02662036|ACTIVE_COMPARATOR|Group 1: Bupivicaine|-TAP block of 30 cc of 0.25% bupivicaine
62265490|NCT02662036|EXPERIMENTAL|Group 2: Liposomal bupivacaine|-TAP block of 266 mg/30 cc liposomal bupivacaine
62848721|NCT03914222|OTHER|CardioSpire Device|Patients blows into Respirix device or uses BIPAP machine for a few breaths solely to obtain signal.
62848722|NCT01638182|ACTIVE_COMPARATOR|vitamin K1 capsules|27 participants received for three months 1 vitamin K1-capsule per day containing 52 µg of K1
62848723|NCT01638182|ACTIVE_COMPARATOR|Vitamin K2-capsules|27 participants received for three months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
62848724|NCT01638182|PLACEBO_COMPARATOR|Placebo capsules|27 participants received for 3 months 1 placebo capsule per day
62848725|NCT04370119||(1) Healthcare workers|All healthcare workers at University Medicine Greifswald who were enrolled in the study between 04/2020-08/2020
62622879|NCT00463489|EXPERIMENTAL|Individualized Lifestyle Intervention|Women randomized to the individualized lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
62622880|NCT02104167||Operated Subjects|ROIC interbody cage with VerteBRIDGE plating
62622881|NCT00475293|EXPERIMENTAL|1|
62061438|NCT05732792||Anesth-CIPS|The survey is endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC) and will be distributed from February 2023 onwards to its members for a period of 6 months.
62061439|NCT04962399||DKD group|Patients with type 2 diabetes mellitus complicated with diabetic nephropathy diagnosed by the second hospital of Shanxi Medical University
62622882|NCT02936089|EXPERIMENTAL|Low risk group|Patients with KIT-ASXL1- (non-mutation, NM) and acquiring main molecular response (MMR) after two cycles of consolidation.
62622883|NCT02936089|EXPERIMENTAL|Intermediate risk group|Patients with KIT+/ASXL1+ (single mutation, 1M) and acquiring MMR after two cycles of consolidation.
62061440|NCT04962399||TDM group|Type 2 diabetes mellitus without diabetic nephropathy
62061441|NCT04962399||control group|Health examination population in the same period
62061442|NCT02717169|OTHER|Biometrical Tracker|The participants are equipped with an wrist watch. The activity tracker measures biometrical information like, steps, sleep duration and heart rate.
62061443|NCT03572660|OTHER|BMMNC intervention arm|Bone marrow derived mononuclear cells and G-CSF
62061444|NCT06129253||Cross-Sectional Survey|There are total 14 CSS groups among 8 participating countries: Bangladesh has 3 groups for CSS (urban CSS, rural CSS, displaced population CSS); Pakistan has 3 groups for CSS (urban CSS, rural CSS, commercial sex worker population CSS); Nepal has 1 nationally representative CSS; Sierra Leon has 1 rural CSS; Tanzania has 2 groups for CSS (pastoralists CSS, displaced population CSS); Ghana has 1 urban CSS; Zambia has 1 group for urban \& rural representative CSS; DR Congo has 2 groups for CSS (population representative sample for urban and rural CSS, displaced population CSS)
62265491|NCT03682523|NO_INTERVENTION|Control Group|Fitted with an accelerometer to measure time spent out of bed while in hospital. Otherwise, participants in the control group will receive usual care from the hospital medical team during their hospital stay. Daily activities of participants will not be restricted if patients are assigned to the control group.
62265492|NCT03682523|EXPERIMENTAL|Intervention Group|Fitted with accelerometer to measure time spent out of bed while in hospital; daily goals set for time spent out of bed; mobilization feedback real-time feedback on goal attainment; hands on mobilization by physiotherapist for participants in late afternoon for participants who do not meet daily goal.
62265493|NCT00238251|ACTIVE_COMPARATOR|Arm I|Patients undergo whole-brain radiotherapy (WBRT) once daily on days 1-5 and 8-12 and receive oral gefitinib once daily on days 1-28. Gefitinib treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity
62622884|NCT02936089|EXPERIMENTAL|High risk group|Patients with KIT+ASXL1+ (two mutations ,2M) or without acquiring MMR after two cycles of consolidation.
62622885|NCT01532258|NO_INTERVENTION|Control Group|No intervention provided. These participants will receive access to the Go! Foods for You program after the research trial has been completed (12 weeks after registration).
62061445|NCT06129253||Longitudinal Study|There are total 11 LS groups: Bangladesh has 2 LS groups (married women up to 25 years-old \& 26-35 years old); Sierra Leone has 2 LS groups (Young girls subject to child marriage/early pregnancy \& general population); Tanzania has 2 LS groups (fishing, mining/tuck stop community \& general population) Other 5 countries have 1 LS group in each country.
62265494|NCT00238251|ACTIVE_COMPARATOR|Arm II|Patients undergo WBRT as in arm I and receive oral temozolomide once daily on days 1-21. Temozolomide treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity
62265495|NCT04294719||Inpatient Clients|Have a chart diagnosis of a schizophrenia spectrum illness, capacity to consent or availability of a substitute decision-maker to consent with the assent of the participant and is residing on a CAMH inpatient forensic unit (general security)
62265496|NCT02477059|EXPERIMENTAL|tocilizumab|2 infusions four weeks apart
62622886|NCT01532258|ACTIVE_COMPARATOR|GFFY-1 without weekly MA support|Utilization of the 8-week online nutrition program Go! Foods for You without weekly contact from staff at the medical provider's office.
62622887|NCT01532258|ACTIVE_COMPARATOR|GFFY-2 with weekly MA support|Utilization of the 8-week online nutrition program combined with weekly contact from the staff at the medical provider's office.
62622888|NCT04611139|EXPERIMENTAL|SP-2577 Plus Pembrolizumab|
62265497|NCT02477059|PLACEBO_COMPARATOR|saline solution|2 infusions four weeks apart
62265498|NCT05129059|EXPERIMENTAL|Logotherapy|Participants will receive individual logotherapy counseling by the investigator for 8 visits in 4 weeks.
62265499|NCT05129059|NO_INTERVENTION|Control|Participants will receive routine care.
62265500|NCT00780247||Alaska residents|"50 healthy community dwelling males or females."
62622889|NCT03010241|EXPERIMENTAL|Tangbi Prescription|Based on the standard medical care, experimental group were treated with Tangbi Prescription 4.87g granules, 2 times/d, which The prescripton was composed by five Chinese herbal medicines.
62622890|NCT03010241|PLACEBO_COMPARATOR|Placebo|Based on the standard medical care, placebo-controlled group were treated with Placebo 4.87g granules, 2 times/d
62848726|NCT04370119||(2) Healthcare workers in high-risk areas of the hospital (intensive care, emergency medicine)|Healthcare workers at University Medicine Greifswald who were enrolled in the study between 01/2021-03/2021
62848727|NCT04370119||(3) Healthcare workers after SARS-CoV-2 vaccination|Healthcare workers at University Medicine Greifswald who received a SARS-CoV-2 vaccination within the last 7-21 days
62265501|NCT00780247||Hawaiian residents|"50 healthy community dwelling males or females at each site"
62265502|NCT04169373|EXPERIMENTAL|Study 1: Upadacitinib 15 mg|Participants receive 15 mg upadacitinib orally once a day for 104 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).
62061446|NCT06129253||Qualitative Study|The qualitative sub-studies in five selected countries (Bangladesh, Nepal, Pakistan, Sierra Leone, DR Congo) will follow and draw on findings from the CSS, focusing on girls and women of different age strata as well as community members (including boys and men) and key informants in the health care system in each study site. Qualitative study methods will vary depending on the site and CSS findings, but will include both individual in- depth interviews (IDIs) (up to \~ 30 individuals per site), key informant interviews as well as multiple focus group discussions (FGDs) with \~6-8 participants/group. Detailed qualitative study methodology will be developed separately as another study protocol and adapted according to the procedures for each site.
62449050|NCT05892978|NO_INTERVENTION|Control group|The patient's vital signs, skin color, and skin turgor will be evaluated and recorded in the PIVC procedure registration form. Before the tourniquet is attached before the procedure, the patient's vein visibility will be evaluated by the research nurse. Vein imaging will not be performed. No intervention will be carried out the tourniquet will be connected, and the vein visibility will be re-evaluated by the operator. The skill duration will be measured and recorded by the researcher with a stopwatch. The selection of the necessary materials will not be added to this time, the chronometer will be started after the tourniquet is attached, and the time will end with the blood coming to the PIVC. Data will obtained on PIVC placement; the pain and fear levels before, during, and after the procedure. Finally, patients will be asked about their level of satisfaction with the procedure at the end of the infusion.
62622891|NCT06438887|EXPERIMENTAL|Creatine Before Training|5 grams of creatine monohydrate + 3 grams of placebo immediately before training sessions; 8 grams of placebo immediately after training sessions; 8 grams of placebo on non-training days.
62622892|NCT06438887|EXPERIMENTAL|Creatine After Training|5 grams of creatine monohydrate + 3 grams of placebo immediately after training sessions; 8 grams of placebo immediately before training sessions; 8 grams of placebo on non-training days.
62622893|NCT06438887|EXPERIMENTAL|Creatine Non-Training|5 grams of creatine monohydrate + 3 grams of placebo on non-training days; 8 grams of placebo immediately before training sessions; 8 grams of placebo immediately after training sessions.
62622894|NCT06438887|PLACEBO_COMPARATOR|Placebo|8 grams of placebo immediately before training sessions; 8 grams of placebo immediately after training sessions; 8 grams of placebo on non-training days
62622895|NCT03961750|EXPERIMENTAL|Intervention|A feasibility study examining a single patient group undertaking a 12 week, student-led, OTAGO exercise class for community dwelling older adults at Glasgow Caledonian University. OTAGO consists of progressive strength and balance exercises.
62622896|NCT00004088|EXPERIMENTAL|HD chemotherapy followed by PBPC Rescue|Patients receive high-dose (HD) melphalan intra-venously (IV) on day -1. Peripheral blood progenitor cells (PBPCs) are reinfused on day 0. Filgrastim (G-CSF) is administered IV or SC daily beginning on day 1 and continuing until blood counts recover. Between 8 and 14 weeks later, patients receive IV high-dose busulfan every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. PBPCs are reinfused on day 0 and G-CSF is administered IV or subcutaneously (SC) daily until blood counts recover.
62622897|NCT04626661||Health volunteers|The study population will consist, initially, of healthy volunteers. This group was chosen to perform measurements on, to eliminate the effect of critical illness and interventions on the critically ill patients and to better explore the effect of time-since-application of the 5-aminolevulinic acid-patches.
62622898|NCT04626661||Patients admitted to the ICU after neurosurgery|This study population will consist of patients undergoing elective neurosurgery with planned postoperative recovery of at least 24 hours in the intensive care unit or medium care unit. Leiden University Medical Center is a neurosurgical center in which a wide variety of surgeries including tumor resection in the posterior cranial fossa (including vestibular schwannoma) are performed. Clinical experience has shown that this cohort of patients are in general, hemodynamically the most stable patients and receive the least amount of interventions compared to other cohorts of patients in the intensive care unit and medium care unit. For these reasons, the cohort of elective neurosurgical patients would be ideal to investigate the reason of the increased between- and within-subject variability of mitochondrial oxygen tension in the intensive care unit and medium care unit setting.
62622899|NCT04210739|EXPERIMENTAL|trus guided betamethason injection arm|
62622900|NCT02155088|EXPERIMENTAL|Combination Therapy: BYL719, Gemcitabine, (Nab)-Paciltaxel|Dose escalation, followed by expansion, of BYL719 in combination with Gemcitabine and (Nab)-Paclitaxel. BYL719: once daily. Gemcitabine: Days 1,8, 15 of 28-day cycle. (Nab)-Paclitaxel: Days 1,8, 15 of 28-day cycle.
62622901|NCT06144541||General public|This survey and ITA measurements will be performed among the general public
62622902|NCT05988346||type 2 diabetes mellitus (T2DM) obese patients without left ventricle (LV) diastolic dysfunction.|
62265503|NCT04169373|PLACEBO_COMPARATOR|Study 1: Placebo|Participants receive matching placebo for 14 weeks and then switch to receive 15 mg upadacitinib orally once a day for 90 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).
62622903|NCT05988346||T2DM obese patients with first degree of left ventricle (LV) diastolic dysfunction.|
62622904|NCT05988346||T2DM obese patients with second degree of left ventricle (LV) diastolic dysfunction.|
62622905|NCT02338115||Weekly paclitaxel treatment group|Breast cancer patients initiating paclitaxel 80mg/m2 weekly x 12 weeks for curative treatment will be followed prospectively for collection of samples and longitudinal neuropathy data.
62622906|NCT02756819||Azilsartan Medoxomil|Overweight or obese participants with hypertension who received azilsartan medoxomil tablets, orally, as prescribed by physician according to local summary of product characteristics (SmPC) were observed for approximately 6 months.
62848728|NCT01866085|ACTIVE_COMPARATOR|AdVance|sling procedure
62848729|NCT01866085|ACTIVE_COMPARATOR|ARGUS|sling procedure
62848730|NCT04109677||SHE player|Female player in the top Swedish handball league
62848731|NCT04109677||Handbollsligan player|Male player in the top Swedish handball league
62848732|NCT01640392|EXPERIMENTAL|HIV prevention groups|Participants randomly assigned to the MyLife Intervention arm receive three 1.5-hour HIV behavioral risk-reduction group sessions over a 1-3 week period.
62848733|NCT01640392|NO_INTERVENTION|Wait-list control|Participants randomly assigned to the Wait-list Control arm receive the MyLife MyStyle group sessions once they have completed a 6-month follow-up assessment.
62848734|NCT03539549|EXPERIMENTAL|Abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
62848735|NCT02370108|EXPERIMENTAL|PD patient|Parkinson's disease patients will get the electrical muscle stimulation at the most tremulous hand at 50 Hz frequency, maximal tolerate pulse amplitude (not over 20 mA), duration of stimulation for 10 second.
62848736|NCT02370108|EXPERIMENTAL|OT patients|others tremor patients will get the electrical muscle stimulation at the most tremulous hand at 50 Hz frequency, maximal tolerate pulse amplitude (not over 20 mA), duration of stimulation for 10 second.
62848737|NCT04880291|ACTIVE_COMPARATOR|GFB-024 SAD Active|Single ascending dose arm of GFB-024 treatment
62265504|NCT04169373|EXPERIMENTAL|Study 2: Upadacitinib 15 mg|Participants receive 15 mg upadacitinib orally once a day for 104 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).
62265505|NCT04169373|PLACEBO_COMPARATOR|Study 2: Placebo|Participants receive matching placebo for 52 weeks and then switch to receive 15 mg upadacitinib orally once a day for 52 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).
62449051|NCT03656796|EXPERIMENTAL|PD with freezing of gait (FOG)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
62265506|NCT03332563|EXPERIMENTAL|WebMAP Mobile|Adolescent participants assigned to this arm will receive access to the WebMAP mobile program delivering cognitive-behavioral intervention for chronic pain. Parents of adolescents will receive access to cognitive-behavioral strategies for parents on the WebMAP parent web site.
62449052|NCT03656796|EXPERIMENTAL|PD without freezing of gait (FOG)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
62449053|NCT03656796|EXPERIMENTAL|Healthy subjects (Control)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
62449054|NCT02194309|EXPERIMENTAL|Telmisartan low + amlodipine|
62449055|NCT02194309|EXPERIMENTAL|Telmisartan high + amlodipine|
62449056|NCT04498923||Bupivacaine with dexamethasone|"Ultrasound guided peripheral nerve block for upper or lower extremity was performed before orthopedic surgery using neurostimulator.~Twenty milliliters solution of bupivacaine 0,375% with dexamethasone was injected for one plexus or peripheral nerve."
62449057|NCT04498923||Bupivacaine with dexamethasone and epinephrine|"Ultrasound guided peripheral nerve block for upper or lower extremity was performed before orthopedic surgery using neurostimulator.~Twenty milliliters solution of bupivacaine 0,375% with dexamethasone 0,02% and epinephrine 0,00018% was injected for one plexus or peripheral nerve."
62449058|NCT03932266|EXPERIMENTAL|Experimental group|Drug: Endostar Drug: Cisplatin Drug: Docetaxel Radiation
62449059|NCT03932266|OTHER|Control group|Drug: Cisplatin Drug: Docetaxel Radiation
62449060|NCT06265935|EXPERIMENTAL|Experimental Group|Breathing exercise will be explained to the pregnant woman, taught and applied for 5 minutes. When doing the diaphragmatic breathing exercise, you will be told to take chest breaths after 4-5 diaphragmatic breaths to prevent hyperventilation. Feedback will be received, questions will be answered, a training brochure will be given and the program will be completed. Pregnant women will be asked to bring the questionnaire with them to their follow-up in two weeks. The Visual Similarity Scale for Fatigue and the SF-36 Quality of Life Scale will be refilled. How he did the exercise, whether he felt any effects and his satisfaction will be questioned. Your questions will be answered. You will be notified that you need to come for a check-up again in two weeks. Visual Similarity Scale for Fatigue and SF-36 Quality of Life Scale will be completed.
62449061|NCT06265935|NO_INTERVENTION|Control Group|"No treatment will be performed on the participants in the control group, and they will be asked not to engage in regular physical activity or sports for 4 weeks and not to make any changes in their living habits.~Pregnant women will be asked to bring the survey form with them at the follow-up visits two weeks later. The Visual Similarity Scale for Fatigue and the SF-36 Quality of Life Scale will be refilled. You will be notified that you need to come for a check-up again in two weeks. At the follow-up after the fourth week, the Visual Similarity Scale for Fatigue and the SF-36 Quality of Life Scale will be filled out again. At the end of thirty days, the program will be completed and the forms will be filled."
62449062|NCT01143025|ACTIVE_COMPARATOR|Ropivacaine 50 mg|Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity
62449063|NCT01143025|EXPERIMENTAL|Ropivacaine 100 mg|Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity
62449064|NCT01143025|EXPERIMENTAL|Ropivacaine 150 mg|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
62449065|NCT06138379|NO_INTERVENTION|Control Group|"No Intervention: Control group The research will begin after obtaining the necessary legal and ethical permissions to collect data. At this stage of the research, participants who agree to participate in the research will be asked to fill out an informed consent form. All forms will be filled in to obtain pre-test data for the research.~These individuals who receive and continue to receive standard care will be informed about the research. Pre-test and post-test data from the control group will be obtained simultaneously with the study groups."
62449066|NCT06138379|EXPERIMENTAL|1. Experimental Group|"Experimental: Experimental group given video-supported training in line with the health belief model.~All forms (Patient Information Monitoring Form, Chronic Disease Adaptation Scale, Rational Drug Use Scale and Immunosuppressive Drug Form Scale) will be filled in to obtain pre-test data for the research. Individuals will be trained according to the training materials prepared for the Health Belief Model. They will be monitored one day each week. After 30 days, all forms will be filled out again to examine the sustainability of the training data."
62449067|NCT06138379|EXPERIMENTAL|2. Experimental Group|"Experimental: The experimental group was given video-supported training in line with Classical Education.~All forms (Patient Information Monitoring Form, Chronic Disease Adaptation Scale, Rational Drug Use Scale and Immunosuppressive Drug Form Scale) will be filled in to obtain pre-test data for the research. Individuals will be trained according to the training materials prepared for the Health Belief Model. They will be monitored one day each week. After 30 days, all forms will be filled out again to examine the sustainability of the training data."
62622907|NCT02348008|EXPERIMENTAL|Arm A - Phase 1b Dose Escalation Cohort|"Cohort 1 will consist of 3-6 patients who will receive MK-3475 200mg and bevacizumab 10mg on day 1 of the 21-day cycle. The drugs are administered 15-30 minutes apart in separate intravenous infusions.~Cohort 2 will consist of 3-9 patients who will receive MK-3475 200mg and bevacizumab 15mg on day 1 of the 21-day cycle. The drugs are administered 15-30 minutes apart in separate intravenous infusions.~If none of the 3 subjects experience a dose limiting toxicity (DLT) during the first cycle of therapy, an additional 3 subjects will be enrolled at dose level 2. If all three subjects in dose level 2 complete the first cycle of therapy without DLT, 3 more subjects will be enrolled to ensure only 0-1 of 6 subjects have a DLT. There will be no further escalation beyond dose level 2."
62848738|NCT04880291|PLACEBO_COMPARATOR|SAD Placebo|Single ascending dose arm of placebo treatment
62848739|NCT04880291|ACTIVE_COMPARATOR|GFB-024 Repeat-dose Active|Repeat-dose arm of GFB-024 treatment
62848740|NCT04880291|PLACEBO_COMPARATOR|Repeat-dose Placebo|Repeat-dose arm of placebo treatment
62848741|NCT02514993||Study group|Inclusion criteria for the study were (a) sternal fracture and concomitant thoracic spine fracture, (b) Injury Severity scale (ISS) ≥ 16, (c) age under 50 years, (d) presence of a whole body computed-tomography (CT-scan) performed at admission of the patient to the hospital.
62061447|NCT04837872|EXPERIMENTAL|Multimodal Physical Therapy (MPT)|The multimodal physical therapy (MPT) program consisted of manual therapy, therapeutic exercise, and utilization of a static progressive splint (Joint Active Systems SPS Knee, Effingham, IL). Although the primary focus of this study was on improving knee flexion ROM, two protocols were developed: one to improve flexion deficits and one to improve extension deficits. Participants in the MPT group received physical therapy 2x per week for 4 weeks. They were instructed to use the static progressive splint(s) 3x per day for 30 minute sessions (90 minutes total per day) for each splint (e.g., 90 minutes for flexion splint, 90 minutes for extension splint).
62265507|NCT03332563|NO_INTERVENTION|Usual care|Participants assigned to this arm will receive usual care from the pain or specialty clinic during the non-exposure periods in the stepped wedge design.
62848742|NCT02514993||Control group|The inclusion criteria for the control group included: (a) Thoracic spine fracture without concomitant sternal fracture, (b) ISS ≥ 16, (c) age under 50 years, (d) presence of a whole body computed-tomography (CT-scan) performed at admission of the patient to the hospital.
62848743|NCT02724397|EXPERIMENTAL|Experimental group|(White endoscopy and then LCI/BLI) The patients will be evaluated by Standard White Light and then Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI).
62848744|NCT02724397|ACTIVE_COMPARATOR|Control group|(LCI/BLI then white endoscopy) The patients will be evaluated by Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) and then White Light Endoscopy.
62265508|NCT02813551|EXPERIMENTAL|Torsemide|Torsemide 20 mg daily for 5 days
62061448|NCT02335151|EXPERIMENTAL|Desflurane|General anesthesia with Desflurane
62449068|NCT02042391|EXPERIMENTAL|Low-risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered low-risk if they reached a complete remission with the first 4 applications of rituximab monotherapy or if they reached a partial remission and had a baseline IPI of 0, 1 or 2. Patients considered low-risk will receive rituximab sc consolidation.
62622908|NCT02348008|OTHER|Arm B - Phase II Investigational Treatment|The maximum safe dose of MK-3475 in combination bevacizumab (as determined in the phase 1b cohort) will be given on day 1 of each 21 day cycle.
62622909|NCT03232216|EXPERIMENTAL|Vitamin D3 supplementation. Deficiency.|Vitamin D3 50.000 UI in each packet of powder for solution. Two packets every week for 5 weeks.
62622910|NCT03232216|PLACEBO_COMPARATOR|Placebo. Deficiency.|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 5 weeks.
62622911|NCT03232216|EXPERIMENTAL|Vitamin D3 supplementation.Insufficiency|Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 3 weeks.
62622912|NCT03232216|PLACEBO_COMPARATOR|Placebo. Insufficiency.|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 3 weeks.
62622913|NCT05614401||RIPC group|Patients underwent RIPC treatment after IV thrombolysis in the index stroke.
62622914|NCT05614401||Control group|The control group underwent no inflations or deflations in the index stroke.
62622915|NCT02469012|EXPERIMENTAL|IFN-free antiviral treatment|Combination #1 or Combination #2 or Combination #3 or Combination #4 or Combination #5
62622916|NCT01597297|EXPERIMENTAL|Fampridine-PR|Prolonged-Release Fampridine (Fampridine-PR) 10 mg twice daily (every 12 hours) for up to 24 weeks.
62061449|NCT02335151|NO_INTERVENTION|Propofol|General anesthesia with Propofol
62061450|NCT01177514|EXPERIMENTAL|GABAPENTIN|Group of patients treated with oral gabapentin
62061451|NCT01177514|PLACEBO_COMPARATOR|PLACEBO|Group given the placebo capsules
62061452|NCT01187914||Open Irrigation|Those individuals who had an ablation using open irrigation cooled-tip RF ablation.
62265509|NCT02813551|PLACEBO_COMPARATOR|Placebo|Placebo 20 mg daily for 5 days
62265510|NCT05726500|OTHER|Open Abdomen|
62265511|NCT05726500|OTHER|Closed Abdomen|
62265512|NCT01441037|EXPERIMENTAL|Danazol|Single arm in which danazol is administered orally at 800 mg daily for 2 years.
62265513|NCT01988064|EXPERIMENTAL|Face-to-face training|One-to-one face-to-face training on calculating the pulse rate and detecting pulse abnormalities performed by the nurse.
62265514|NCT01988064|EXPERIMENTAL|Group training|Group training using a tutorial film on calculating the pulse rate and detecting pulse abnormalities.
62265515|NCT03009266|EXPERIMENTAL|Normal controls|Normal controls who will undergo dose-ranging studies to determine the optimal dose of phosphatidylserine-containing microbubbles that does not produce delayed myocardial opacification on myocardial contrast echocardiography (MCE).
62622917|NCT01597297|PLACEBO_COMPARATOR|Placebo|Matched placebo twice daily (every 12 hours) for up to 24 weeks.
62622918|NCT05844072|ACTIVE_COMPARATOR|Ankle dorsiflexion range of motion with inclinometer in standing|The Standing Ankle Dorsiflexion Screen (SADS) will be used as a categorical outcome measure which is a more functional way to measure ankle dorsiflexion and does not require the use of additional equipment. The participant will be instructed to stand in tandem stance, one foot directly in front of the other, and bend both knees as far as they can while keeping their heel in contact with the ground. The examiner will then use a ruler to align the posterior knee with the medial malleolus and determine the position of behind, within, or in front of the malleolus.
62265516|NCT03009266|EXPERIMENTAL|Patients with ACS|Subjects with ACS who have undergone primary percutaneous intervention in whom MCE with phosphatidylserine-containing microbubbles will be performed to determine whether the risk area can be detected and spatially defined.
62265517|NCT05298891|EXPERIMENTAL|Acromegalic adult in therapy with somatostatin analogues|Patients will continue the usual medical outpatient visits cadency and will keep the same pharmacological therapy throughout the whole duration of the study. Drugs have to include somatostatin analogues. At the same time, patients will be trained by an expert dietician in the habit of an isocaloric and hypoproteic diet and will come back at 2,4,6 and 8 weeks after T0 for all the necessary study assessments and compliance checking.
62265518|NCT02942745|PLACEBO_COMPARATOR|Control|Minimal interaction between participant and facilitator regarding cessation strategies. Participants will only be given a betel nut cessation booklet.
62265519|NCT02942745|EXPERIMENTAL|Experimental|Intensive 5-session intervention program over the span of 22 days, with an additional follow up session after 6 months. The sessions will utilize betel nut cessation social support groups, as well as interactive discussion on how to quit chewing.
62265520|NCT01106170|EXPERIMENTAL|Arm 1|Participants will consume 330 mg of Provex CV supplement, by mouth, per day, for 4 weeks followed by 4 weeks of 330 mg of placebo (cornstarch)
62265521|NCT01106170|EXPERIMENTAL|Arm 2|Participants will consume 330 mg placebo (cornstarch), by mouth, per day for 4 weeks followed by 4 weeks of 330 mg of ProvexCV for 4 weeks.
62265522|NCT02457637||Acute-on-Chronic Liver Disease Inpatient|"1. chronic liver disease: including chronic liver hepatitis patients without cirrhosis, compensated cirrhosis patients, decompensated cirrhosis patients; and non-alcoholic fatty liver disease patients.~2. ALI(acute liver injury): including \[ALT\>3NL(normal level),AST\>3NL or TB\>2NL within 1 week before enrollment\] or AD(acute decompensation) : including \[(having ascites, hepatic encephalopathy, bacterial infection gastrointestinal bleeding or jaundice(TB\>5NL)within 1 month before enrollment)\].~3. Standary therapy"
62449069|NCT02042391|EXPERIMENTAL|High risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered high-risk, if the reached a partial remission and were IPI 3, 4 or 5 at time of diagnosis of PTLD, if they show stable disease or if they had progressive disease but are not recipients of heart or lung transplants. Patients considered high-risk will receive four more applications of rituximab sc combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113.
62622919|NCT05844072|ACTIVE_COMPARATOR|Weight bearing lunge test|The Weight Bearing Lunge Test (WBLT) will be used to measure closed chain dorsiflexion in participants. A bubble inclinometer will be placed 15 cm below the tibial tuberosity for measurement during the WBLT. Participants will place their foot on a line on the floor which is perpendicular to the wall to help maintain alignment. The participant's heel will be stabilized by an examiner, and they will then be instructed to lunge forward so that their knee reaches a vertical line on the wall. The measurement will then be taken using the inclinometer placed at 15 cm below the tibial tuberosity. The examiner stabilizing the heel will hold the inclinometer in place, while another examiner ensures proper placement of the inclinometer and takes the reading. The WBLT will be completed twice and the average of the two measurements will be taken.
62265523|NCT01910259|EXPERIMENTAL|Amiloride|Amiloride 5 mg twice per day (5 mg once per day for first 4 weeks) for 96 weeks
62265524|NCT01910259|EXPERIMENTAL|Riluzole|Riluzole 50 mg twice per day (50 mg once per day for first 4 weeks) for 96 weeks
62848745|NCT03233321|EXPERIMENTAL|Experimental group|30 patients were selected in experimental group. Dry cold was applied to the subcutaneous injection site using ice bag filled with crushed ice with half table spoon of salt for 20 minutes after the administration of injection.Pain intensity was measured using numeric pain rating scale immediately after dry cold application and bruise size was assessed using bruise assessment scale after 12, 48 and 72 hrs of injection administration.
62265525|NCT01910259|EXPERIMENTAL|Fluoxetine|Fluoxetine 20 mg twice per day (20 mg once per day for first 4 weeks) for 96 weeks
62265526|NCT01910259|PLACEBO_COMPARATOR|Placebo|Matched placebo 1 capsule twice per day (1 capsule a day for first 4 weeks) for 96 weeks
62265527|NCT03446066||case group|20 cases suffering from excessive daytime sleepiness (4 females and 16 males) with their age range 32-58yrs and BMI range is 24.97-39.06 kg/m2
62265528|NCT03446066||control group|20 healthy subjects (5 females and 15 males) with their age range 31-55yrs and BMI range is 23.40-43.0 kg/m2
62265529|NCT02721680|EXPERIMENTAL|Healthy Subjects- Awareness Training Group 1|Subjects in this arm will undergo an internal awareness training program.
62265530|NCT02721680|EXPERIMENTAL|Healthy Subjects - Awareness Training Group 2|Subjects in this arm will undergo an external awareness training program.
62265531|NCT04640467||Pregnant women|Women with uncomplicated singleton pregnancy who are planning a vaginal delivery, gestational age from 36 ± 0/7 weeks until onset of active labor (cervical dilatation ≤ 4cm) and cephalic presentation
62265532|NCT01111851|EXPERIMENTAL|Fosaprepitant 150 mg|Fosaprepitant 150 mg
62265533|NCT01111851|EXPERIMENTAL|Aprepitant 165 mg|Aprepitant 165 mg
62265534|NCT01111851|EXPERIMENTAL|Aprepitant 250 mg|Aprepitant 250 mg
62265535|NCT02756507|EXPERIMENTAL|video-based transdiagnostic REBT|Children and adolescents in the experimental group attend 6 modules of video-based transdiagnostic rational emotive behavioral therapy (REBT). Each of the six modules aimes a different component: Psychoeducation, Relaxation, Relationship between cognitive distortions/irrational beliefs and emotions, Cognitive restructuring, Exposure/ behavior activation and problem solving, Maintenance of gaining.
62265536|NCT02756507|SHAM_COMPARATOR|wait list|The wait-list is a delayed treatment condition.
62265537|NCT02922374|EXPERIMENTAL|CS|Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
62265538|NCT03424707|EXPERIMENTAL|combination|
62265539|NCT03424707|ACTIVE_COMPARATOR|single|
62265540|NCT03424707|PLACEBO_COMPARATOR|placebo|
62265541|NCT06497205||Control Group|low risk ASPRE
62265542|NCT06497205||FGR Group|FGR according to definition of ISUOG
62265543|NCT06497205||Diabetic Group|insulin dependent diabetes
62265544|NCT02466711|ACTIVE_COMPARATOR|Relamorelin|
62265545|NCT02466711|PLACEBO_COMPARATOR|Placebo|
62061453|NCT05537402|EXPERIMENTAL|Arm A: Atezolizumab and bevacizumab|"Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle. Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.~Atezolizumab will be administered first followed by bevacizumab, with a minimum of 5 minutes between dosing."
62265546|NCT01537562|ACTIVE_COMPARATOR|Delayed IUC insertion|Patients randomised to delayed, routine, insertion had their IUC inserted at 3-4 weeks (day 21-35 after mifepristone treatment
62265547|NCT01537562|ACTIVE_COMPARATOR|Early IUC insertion|Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment.
62061454|NCT05537402|ACTIVE_COMPARATOR|Arm B: Locoregional therapy with TACE or TARE|"Patients will undergo locoregional therapy with TACE or TARE per investigator preference.~TACE will be administered every 8 +/- 4 weeks; TARE will be administered every 12 +/- 4 weeks. Proportion of patients being treated with TARE will be capped at 50% of cohort at a protocol level. After 50% cap is reached, patients randomized to Arm B will be treated with TACE."
62061455|NCT05235620||Pharmacy staff|Pharmacy staff working at pharmacies which have chosen to implement PatientToc software for this implementation science project and evaluation. Pharmacy staff will be observed and participate in interviews pertaining to their experiences using PatientToc.
62265548|NCT06183723|EXPERIMENTAL|People living with HIV with poor adherence to HAART|People living with HIV (PLWH) with adherence below the specific proportion of days covered (PDC), which is defined as the specific level that corresponds to 90% at viral suppression (\< 200 copies/mL).
62265549|NCT01202656|EXPERIMENTAL|G-CSF then Saline|G-CSF (Granulocyte colony stimulating factor)
62265550|NCT01202656|PLACEBO_COMPARATOR|Saline then G-CSF|Normal Saline
62265551|NCT00574275|PLACEBO_COMPARATOR|Placebo and Gemcitabine|Participants with metastatic pancreatic cancer administered Placebo and 1000 mg/m\^2 Gemcitabine.
62265552|NCT00574275|EXPERIMENTAL|Aflibercept and Gemcitabine|Participants with metastatic pancreatic cancer administered 4 mg/kg Aflibercept and 1000 mg/m\^2 Gemcitabine.
62265553|NCT03734796||suspected NSTEMI|Patients aged 18-75 years old and highly suspected NSTEMI without Left bundle branch block (LBBB) will be included. Patients will be excluded if who is STEMI, underwent surgical operation within four weeks, medium and several kidney dysfunction (Ccr\<30ml/min), anemia, acute myocarditis, chronic cardiac dysfunction (NYHA III-IV), serious cardiac arrhythmias, with history of intravenous drug, oncosis and recent thrombolysis treatment, or pregnant.
62265554|NCT01885611|ACTIVE_COMPARATOR|Multi-Drug Therapy (Novartis Ⓡ)|"Multi-Drug Therapy PB pack consists of 600 milligrams (mg) of rifampicin (NovartisⓇ) single dose once a month and 100mg of dapsone (NovartisⓇ) daily for six months (PB patients)~Multi-Drug Therapy MB pack consists of 600mg of rifampicin (NovartisⓇ), 300mg of clofazimine (NovartisⓇ) as a single dose monthly and 50mg of clofazimine (NovartisⓇ) and 100mg of dapsone (NovartisⓇ) daily for six months (MB patients)"
62265555|NCT01885611|EXPERIMENTAL|Virgin Coconut Oil (VCO) with MDT|"VCO 10 milliliters (mL) three times a day in addition to MDT of 600mg of rifampicin (NovartisⓇ) single dose once a month and 100mg of dapsone (NovartisⓇ) daily for a period of six months (PB patients)~VCO 10mL three times a day in addition to MDT of 600mg of rifampicin (NovartisⓇ), 300mg of clofazimine (NovartisⓇ) as a single dose monthly and 50mg of clofazimine (NovartisⓇ) and 100mg of dapsone (NovartisⓇ) daily or a period of six months (MB patients)"
62265556|NCT03656861||Athletes|122 were athletes (41 females and 81 males). Of the 41 female athletes, 32 were endurance athletes, and 9 strength athletes. From 81 male athletes, 56 were endurance athletes, and 25 were strength athletes.
62265557|NCT03656861||Non-athletes|29 were non-athletes (14 females and 15 males)
62265558|NCT03971201|EXPERIMENTAL|Surgery plus sorafenib|surgical resection followed by adjuvant sorafenib
62265559|NCT03971201|ACTIVE_COMPARATOR|sorafenib only|sorafenib only
62848746|NCT03233321|NO_INTERVENTION|Comparison group|No intervention was given. Pain intensity was measured using numeric pain rating after 20 minutes of subcutaneous injection and bruise size was assessed using bruise assessment scale after 12, 48 and 72 hrs of injection administration.
62848747|NCT01587898|EXPERIMENTAL|0.5mg GSK1278863|Once daily
62265560|NCT02610595|EXPERIMENTAL|experimental group|Jianpixiaozhong particles and Wuse Dietotherapy
62265561|NCT00142467|EXPERIMENTAL|Bevacizumab, Gemcitabine, Oxaliplatin|For cycle 1 (14 days), bevacizumab 10 mg/kg was administered alone on day 1. For cycle 2 and beyond (28 days/cycle), bevacizumab 10 mg/kg was administered on days 1 and 15, gemcitabine 1,000 mg/m2 was administered as a dose rate infusion at 10 mg/m2/min followed by oxaliplatin at 85 mg/m2 on days 2 and 16. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
62265562|NCT03366298|ACTIVE_COMPARATOR|1|Visit 1: Emerade 300mcg then Epipen 0.3mg Visit 2: Emerade 500mcg
62848748|NCT01587898|EXPERIMENTAL|2mg GSK1278863|Once daily
62848749|NCT01587898|EXPERIMENTAL|5mg GSK1278863|Once daily
62848750|NCT01587898|EXPERIMENTAL|Placebo|Once daily
62848751|NCT04514380||Group C|Patients drank carbohydrate fluid 2 hours prior to surgery according to the routine fasting protocol by surgeon A.
62848752|NCT04514380||Group N|Patients did not drink carbohydrate fluid 2 hours prior to surgery according to the routine fasting protocol by surgeon B.
62848753|NCT00822549||1|all the patients included in the study received intravenous morphine in PACU and in the wards
62848754|NCT01932437|EXPERIMENTAL|Cohort 1|"3 subjects will receive an IM dose of 4 mg/kg ETI-204, administered as two injections with a maximum volume of 2 mL at each injection site.~1 subject will receive an IM dose of ETI-204-placebo in an identical fashion."
62848755|NCT01932437|EXPERIMENTAL|Cohort 2|"6 subjects will receive an IM dose of 8 mg/kg ETI-204, administered as two injections with a maximum volume of 4 mL at each injection site.~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
62848756|NCT01932437|EXPERIMENTAL|Cohort 3|"6 subjects will receive an IM dose of 16 mg/kg ETI-204, administered at four sites, with administration of 4 mL at one site and the remaining volume given in three additional injections with a maximum volume of 4 mL at each injection site.~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
62265563|NCT03366298|ACTIVE_COMPARATOR|2|Visit 1: Epipen 0.3mg then Emerade 300mcg Visit 2: Emerade 500mcg
62449070|NCT02042391|EXPERIMENTAL|Very high-risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, heart and lung transplant recipients and patients with a combination of organs transplanted including a heart or lung transplant who show disease progression during rituximab monotherapy or at interim staging will be considered very high-risk. Patients considered very high-risk will receive six more applications of rituximab sc combined with alternating chemotherapy with CHOP and DHAOx.
62061456|NCT05235620||Pharmacy patients|Patients engaged in completing medication adherence-related questionnaires in the PatientToc software at their pharmacies. Patient-level medication, health history, and self-reported adherence information will be collected from patients meeting eligibility criteria. Patients will also be observed and interviewed about their experiences using PatientToc.
62061457|NCT03146039|OTHER|Radiation Therapy|The patient will receive Whole Pelvis Radiation Therapy 40 - 50.4 Gy in 1.8 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks followed by Stereotactic Body Radiotherapy 5.5 - 8.0 Gy per fraction x 5 fractions using arc therapy.
62061458|NCT01273428|ACTIVE_COMPARATOR|HP011-101|
62061459|NCT01273428|ACTIVE_COMPARATOR|HP828-101|
62061460|NCT01273428|OTHER|Standard Care|
62265564|NCT03366298|ACTIVE_COMPARATOR|3|Visit 1: Emerade 500mcg Visit 2: Emerade 300mcg then Epipen 0.3mg
62265565|NCT03366298|ACTIVE_COMPARATOR|4|Visit 1: Emerade 500mcg Visit 2: Epipen 0.3mg then Emerade 300mcg
62622920|NCT04177966|EXPERIMENTAL|women watching the pre-prepared video before surgery|Women undergoing primary elective cesarean surgery at term The day before surgery the women will watch a pre-prepared video, approximately 10 minutes in length, showing in detail the course of events around the operation
62622921|NCT04177966|PLACEBO_COMPARATOR|women not watching the pre-prepared video before surgery|Women undergoing primary elective cesarean surgery at term Women will receive general information about the surgery as part of informed consent, without watching a pre- prepared film.
62265566|NCT02458755|EXPERIMENTAL|High-dose statin treatment|Atorvastatin (40mg) or Rosuvastatin (20mg)
62265567|NCT06062186|PLACEBO_COMPARATOR|Placebo|650 mg of placebo, given as two capsules containing maltodextrin
62061461|NCT03082716|ACTIVE_COMPARATOR|blood cardioplegia group|patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
62265568|NCT06062186|EXPERIMENTAL|AmaTea Max Guayusa extract|650 mg of AmaTea Guayusa Extract, given as two capsules
62265569|NCT06062186|EXPERIMENTAL|Lion's Mane|1000 mg of Lion's Mane, given as two capsules
62449071|NCT00252551|EXPERIMENTAL|1|osteosynthesis
62449072|NCT00252551|ACTIVE_COMPARATOR|2|Simple surgery
62449073|NCT03036579|EXPERIMENTAL|Glazed Fired, Calibra Céram|Celtra Duo crowns will be glaze-fired in a porcelain oven and cemented with Calibra Ceram Cement
62061462|NCT03082716|EXPERIMENTAL|custodiol group|patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
62061463|NCT06539975|ACTIVE_COMPARATOR|Evening primrose oil + misoprostol|combination of both drugs for induction of labor adminstrated vaginally.
62061464|NCT06539975|OTHER|misoprostol only|misoprostol alone for induction of labor adminstrated vaginally.
62265570|NCT01899833|EXPERIMENTAL|99mTc-EC-DG, Diagnostic|99mTc-EC-DG (25 ± 5 mCi, up to 250 µg EC-DG) will be administered by intravenous (IV) bolus injection. Other Name:Technetium-99m-labeled Ethylenedicysteine-Deoxyglucose
62265571|NCT04002635|ACTIVE_COMPARATOR|Hormonal Replacement Therapy|Artificial preparation of the endometrium using estradiol valerate 2mg 3x/day, and vaginal micronized progesterone 2x 400mg/day.
62265572|NCT04002635|EXPERIMENTAL|Letrozole|Using letrozole for ovulation induction before planning the frozen embryo transfer
62265573|NCT01663597||Cohort 1|40 subjects with high grarde myopia ranging from -10 diopters to -4.01 diopters
62265574|NCT01663597||Cohort 2|40 subjects with moderate myopia ranging from -4 diopters to -1.01 diopter
62061465|NCT06183814|EXPERIMENTAL|Dose escalation-Cohort 1|Genetic : EXG102-031
62061466|NCT06183814|EXPERIMENTAL|Dose escalation-Cohort 2|Genetic : EXG102-031
62061467|NCT06183814|EXPERIMENTAL|Dose escalation-Cohort 3|Genetic : EXG102-031
62061468|NCT06183814|EXPERIMENTAL|Dose escalation-Cohort 4|Genetic : EXG102-031
62061469|NCT06183814|EXPERIMENTAL|Dose escalation-Cohort 5|Genetic : EXG102-031
62265575|NCT01663597||Cohort 3|40 subjects with emmetropia, -1 diopter to +1 diopter
62265576|NCT01663597||Cohort 4|40 subjects with hyperopia, +1.01 diopter and more
62449074|NCT03036579|EXPERIMENTAL|Hand Polished, Calibra Universal|Celtra Duo crowns will be hand-polished and cemented with Calibra Universal Cement
62848757|NCT01932437|EXPERIMENTAL|Cohort 4|"6 subjects will receive an IM dose of 20 mg/kg ETI-204, administered at up to five sites, with the injection volume distributed equally between injections and a maximum volume of 4 mL per injection site.~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
62265577|NCT00326209|EXPERIMENTAL|Encapsulated Mesalamine Granules (eMG)|Participants will receive eMG 1.5 grams (4 capsules of eMG 0.375 grams each) QD orally in the morning for up to 24 months.
62622922|NCT03809325||Participants with Schizophrenia|No intervention will be administered as a part of this study. Participants diagnosed with schizophrenia, who have been treated with 4 to 6 injections of paliperidone palmitate 3-month formulation (PP3M), together with the corresponding physician, and the corresponding nurse and carer where applicable for each participant will be enrolled in this survey. The data source for this study will be the online questionnaire used for each participant, physician, and the corresponding nurse and carer where applicable.
62265578|NCT04209751||Children with summer diarrhea|Children aged 0 to 16 years with diarrhea
62622923|NCT06458777||Patients diagnosed with manual report of polygraphy|
62622924|NCT06458777||Patients diagnosed with automatical report of polygraphy|
62622925|NCT01537380|EXPERIMENTAL|Cefazoline|
62622926|NCT04973709||Delirium with dementia|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
62061470|NCT04667364|NO_INTERVENTION|Group MED|A group of participants that receives treatment as usual that consists of medicinal treatment, prescribed by a specialist doctor (Carsten Kock-Jensen, MD) from the CRPS clinic and will be monitored using patients' medicinal records.
62061471|NCT04667364|EXPERIMENTAL|Group TENS|A group of participants that receives transcutaneous electrical nerve stimulation (TENS) which is an inexpensive, noninvasive and safe treatment for pain.
62265579|NCT03452696|EXPERIMENTAL|Calcium supplement 10/90|Microencapsulated calcium, 1389 mg orally (10% protein and 90% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 doses of 1389 mg each orally, to make a total contribution of 1,000 mg. of calcium element.
62265580|NCT03452696|EXPERIMENTAL|Calcium supplement 5/95|Microencapsulated calcium1316 mg orally (5% protein and 95% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 shots of 1,316 mg each orally, to make a total contribution of 1,000 mg. calcium element
62265581|NCT03452696|ACTIVE_COMPARATOR|Calcium carbonate supplement|1,250 mg orally (500 mg of calcium element). There will be 2 doses of 1,250 mg. each orally, to make a total contribution of 1,000 mg. of calcium element.
62265582|NCT03452696|ACTIVE_COMPARATOR|Calcium citrate supplement|1,500 mg orally (315 mg of calcium element). There will be 2 taken orally, to make a total contribution of 945 mg. calcium element
62265583|NCT02565030||CTEPH surgical disease, operated|Patients with proximal CTEPH who have undergone Pulmonary Endarterectomy (PEA) surgery
62265584|NCT02565030||CTEPH surgical disease, not operated|"Patients with proximal CTEPH with operable distribution of disease\& have not undergone PEA surgery due to the following reasons:~1. Multiple co-morbidities~2. Patients choice~3. Mild disease /symptoms~4. Awaiting Surgery"
62265585|NCT02565030||CTEPH non surgical|Patients with distal CTEPH with inoperable distribution of disease inaccessable to surgery.
62265586|NCT02565030||IPAH|Patients with IPAH as per European Society of Cardiology(ESC) criteria
62622927|NCT04973709||Dementia without Delirium|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
62622928|NCT04973709||Delirium without Dementia|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
62061472|NCT02261584|EXPERIMENTAL|Microwave Thermal Coagulation|MW ablation performed either laparoscopically or percutaneously is a safe, effective, and minimally invasive technique for the management of hypersplenism in patients with liver cirrhosis. It may significantly increase platelet count and white blood cell (WBC) count and improve hepatic blood supply with fewer complications. Ablating more than 40% of the splenic parenchyma may yield better long term results. This method may provide a new and promising minimally invasive alternative for treating hypersplenism.
62848758|NCT01932437|EXPERIMENTAL|Cohort 5|"6 subjects will receive an IM dose of 24 mg/kg ETI-204, administered at up to six sites, with administration of 5 mL at one site and the remaining volume given in up to five additional injections distributed equally with a maximum volume of 4 mL per injection site.~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
62265587|NCT01535456|EXPERIMENTAL|F-FLT PET scan, 5-azacitidine treatment|F-FLT Pet scan followed by 5-azacitidine treatment followed by FLT-PET scan. Three additional cycles of 5-azacytidine and follow up FLT-PET scan.
62265588|NCT02335827|EXPERIMENTAL|Group A|irreversible electroporation with voltage in level A for renal tumors
62265589|NCT02335827|EXPERIMENTAL|Group B|irreversible electroporation with voltage in level B for renal tumors
62265590|NCT02335827|EXPERIMENTAL|Group C|irreversible electroporation with voltage in level C for renal tumors
62449075|NCT00332293|EXPERIMENTAL|Moxifloxacin|
62449076|NCT00332293|ACTIVE_COMPARATOR|VIGAMOX|
62449077|NCT00684333|EXPERIMENTAL|group 1|volunteers
62848759|NCT01751945|EXPERIMENTAL|EmONC package|"The EmONC package consists of:~1. Maternal and neonatal health pack(clean delivery kit, emollient, chlorhexidine, sms messages) for safe motherhood and newborn wellbeing.~2. Enhanced trainings of community-level health care providers to provide effective maternal and neonatal health services and referral of complicated cases to health facilities and creation of linkages amongst health care providers.~3. Community mobilisation"
62061473|NCT02261584|EXPERIMENTAL|Partial Splenic Embolization Catheter|Partial splenic embolization (PSE), which was first performed by Spigos et al in 1979, has been considered first-line therapy for hypersplenism in many institutions, and has been proposed as an effective alternative to splenectomy for improving peripheral blood cell counts. However, PSE is associated with many complications, including intermittent fever, abdominal pain, nausea, vomiting, post-embolization syndrome, splenic abscess, splenic rupture, pneumonia, refractory ascites, pleural effusion and gastrointestinal bleeding. To ensure a sustained and long-term increase in platelet and leucocytic counts, the splenic infarction rate needs to be greater than 50% (8). Thus, severe complications can ensue.
62061474|NCT00910455|EXPERIMENTAL|Active|Single oral dose of SRX246 capsule
62061475|NCT00910455|PLACEBO_COMPARATOR|Placebo|Single oral dose of placebo capsule
62061476|NCT04378023||Study group|Patients with unresectable hilar cholangiocarcinoma (hCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases
62061477|NCT05381298|EXPERIMENTAL|Deep Margin Elevation|
62061478|NCT05381298|EXPERIMENTAL|Surgical Crown Lengthtening|
62265591|NCT04455880|ACTIVE_COMPARATOR|GDM with insulin therapy|Singleton pregnancies above 36 gestational weeks diagnosed Gestational Diabetes Mellitus and treated with insulin therapy.
62265592|NCT04455880|ACTIVE_COMPARATOR|GDM treated with only diet (without any medical therapy)|Singleton pregnancies above 36 gestational weeks diagnosed Gestational Diabetes Mellitus and treated with insulin therapy.
62449078|NCT04886336||Tenofovir Disoproxil Fumarate(TDF) switch to TAF|The indications of TDF switching to TAF due to adverse events of TDF or physician's judgement according to clinical conditions.
62622929|NCT04973709||No dementia, No delirium|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
62622930|NCT02226263|EXPERIMENTAL|probiotics Lactobacillus acidophilus boucardii strain.|Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks .The probiotic presentation used was powder in an envelope with 160mg (Carnot ® Laboratories), scientific products, Mexico, (Registration Number 274M91SSA). This was stored in a dry place at room temperature, avoiding sunlight.
62622931|NCT05868239|EXPERIMENTAL|Aerosol Box|The team will complete the resuscitation scenario with an Aerosol box placed.
62848760|NCT01751945|NO_INTERVENTION|Standard of care|Standard care as per national policy
62848761|NCT06278818|EXPERIMENTAL|Network-based Cognitive Training (NBCT)|The training will be delivered through a virtual platform for TR.
62848762|NCT06278818|EXPERIMENTAL|Home-based Cognitive Rehabilitation (HomeCoRe)|The training will be delivered through a touch-screen laptop in a home-based setting.
62848763|NCT06278818|EXPERIMENTAL|Semantic Memory Rehabilitation Training (SMRT)|The training will be delivered through TR with the assistance of an online therapist.
62265593|NCT04455880|ACTIVE_COMPARATOR|Non-diabetic Controls|Singleton non diabetic healthy pregnancies above 36 gestational weeks
62622932|NCT05868239|NO_INTERVENTION|No Aerosol Box|The team will complete the resuscitation scenario without an Aerosol box placed.
62622933|NCT01597492|EXPERIMENTAL|Belimumab plus Early Vaccination|Belimumab plus Early Vaccination
62622934|NCT01597492|EXPERIMENTAL|Belimumab plus Late Vaccination|Belimumab plus Late Vaccination
62622935|NCT01915901|EXPERIMENTAL|bismuth subsalicylate (Pepto-Bismol®) + DMF|Subjects will receive dimethyl fumarate (DMF) and bismuth subsalicylate (Pepto-Bismol®).
62622936|NCT01915901|EXPERIMENTAL|Placebo + DMF|Subjects will receive dimethyl fumarate (DMF) and placebo.
62622937|NCT06308900|EXPERIMENTAL|Experimental|Physitherapy students
62848764|NCT06278818|SHAM_COMPARATOR|Unstructured Home-based Cognitive Stimulation (Control)|The Control stimulation will be delivered through TR with therapist assistance.
62848765|NCT00795119|EXPERIMENTAL|NIRS|Children who undergo NIRS
62848766|NCT04177576||Patients with myeloproliferative neoplasms (MPN)|Patients diagnosed with Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
62061479|NCT05688735|ACTIVE_COMPARATOR|Experimental Topical Product|Topical moisturizer With Colloidal Oatmeal and Isosorbide Diesters + Topical Steroids
62061480|NCT05688735|PLACEBO_COMPARATOR|Control Topical Product|Topical moisturizer With Colloidal Oatmeal WITHOUT Isosorbide Diesters + Topical Steroids
62061481|NCT05481216||PLWHIV with COVID-19 cases|Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
62061482|NCT05481216||PLWHIV without COVID-19 controls|Patients at least 18 years of age with documented HIV-1 infection.
62061483|NCT05481216||HIV seronegative patients with COVID-19 controls|Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
62061484|NCT04902222||Patients undergoing primary hip or knee arthroplasty|Patients undergoing primary hip or knee arthroplasty
62061485|NCT04187391|EXPERIMENTAL|Active tDCS plus individual language training|Active tDCS plus individual language training
62265594|NCT03500900|EXPERIMENTAL|Vildagliptin|DPP-4 inhibitor, acute administration (50 mg.)
62265595|NCT03500900|PLACEBO_COMPARATOR|Placebo|Placebo treatment, acute administration
62848767|NCT05726084|EXPERIMENTAL|Convacell, 1 dose (Stage IIb)|Participants (230) will be vaccinated Convacell Vaccine, recombinant subunit vaccine for prevention of coronavirus infection, once intramuscularly. A cohort of participants will be allocated (115 participants) for evaluating cell-mediated immunity parameters.
62061486|NCT04187391|ACTIVE_COMPARATOR|placebo tDCS plus individual language training|placebo tDCS plus individual language training
62061487|NCT04187391|ACTIVE_COMPARATOR|Active tDCS plus unstructured cognitive stimulation|Active tDCS plus unstructured cognitive stimulation
62061488|NCT01165073|EXPERIMENTAL|Naso-gastric tube feeding|
62061489|NCT01165073|ACTIVE_COMPARATOR|Oral feeding|
62265596|NCT03256500|EXPERIMENTAL|tDCS administered|Subjects will receive stimulation via tDCS (Transcranial Direct Current Stimulation) for 20 minutes per day, 5 days per week, for 1 week.
62848768|NCT05726084|EXPERIMENTAL|Convacell, 2 doses (Stage IIb)|Participants (230) will be vaccinated Convacell Vaccine, recombinant subunit vaccine for prevention of coronavirus infection, twice intramuscularly. A cohort of participants will be allocated (115 participants) for evaluating cell-mediated immunity parameters.
62848769|NCT05726084|EXPERIMENTAL|Convacell, chosen regimen (Stage III)|Participants (10 562) will be vaccinated Convacell Vaccine, recombinant subunit vaccine for prevention of coronavirus infection, the regimen chosen in Stage IIb intramuscularly.
62848770|NCT05726084|PLACEBO_COMPARATOR|Placebo, chosen regimen (Stage III)|Participants (5 282) will be vaccinated Placebo, the regimen chosen in Stage IIb intramuscularly.
62848771|NCT04534816|EXPERIMENTAL|Indocyanine Green|patients abdominal injuries and repair will be investigated using Indocyanine Green
62848772|NCT02105662|EXPERIMENTAL|Grazoprevir+Elbasvir|Participants receive a fixed-dose combination (FDC) of grazoprevir 100 mg plus elbasvir 50 mg once daily for 12 weeks and are followed-up for 24 weeks.
62848773|NCT03291366|EXPERIMENTAL|MSC|infusion of aUCMSC and conventional therapy
62848774|NCT03291366|ACTIVE_COMPARATOR|conventional|conventional therapy
62848775|NCT04383418|EXPERIMENTAL|High dose group|In the low dose group, 36 subjects will receive a low dose of dexmedetomidine nasal spray.
62061490|NCT06624709|ACTIVE_COMPARATOR|Alternate (4 times/week) iron supplementation|This arm will receive 2-3mg/kg/d of maltofer 4 times a day
62061491|NCT06624709|SHAM_COMPARATOR|Daily iron substitution|This arm will receive 2-3mg/kg/d of maltofer 7 times per week.
62061492|NCT03844022||McArdle disease|Glycogen storage disease
62061493|NCT03844022||Healty controls|Age and gender matched
62061494|NCT03264963|ACTIVE_COMPARATOR|Control|
62061495|NCT03264963|EXPERIMENTAL|Intervention|
62061496|NCT04285632|EXPERIMENTAL|Experimental group|"Each session will last 15 minutes, taking place for 2 days a week, over a period of 4 weeks. The intervention will take place at the beginning of each training session.~Prior to training, the Counter Movement Jump and Drop Jump exercises will be performed"
62061497|NCT04285632|NO_INTERVENTION|Control group|Athletes included in the control group will continue with their usual warm-up routine.
62061498|NCT01949688|EXPERIMENTAL|HLA-A*2402 restricted peptides|HLA-A\*2402 restricted peptides with adjuvant
62061499|NCT01949688|EXPERIMENTAL|HLA-A*0201 restricted peptides|HLA-A\*0201 restricted peptides with adjuvant
62061500|NCT06510452|EXPERIMENTAL|NACL0.9%|Group A will receive 100 ml NACL0.9% without any antibiotics in it.
62061501|NCT06510452|ACTIVE_COMPARATOR|Cefazolin +Metronidazole|Group B will receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%. Both antibiotics will be administered at least 30 minutes before surgery to ensure adequate tissue concentrations at the time of incision.
62061502|NCT02013388|EXPERIMENTAL|10 mg|single oral daily dose of 10 mg N91115 for 14 days
62265597|NCT03256500|SHAM_COMPARATOR|Sham tDCS administered|Subjects will receive sham tDCS (Transcranial Direct Current Stimulation) for 20 minutes per day, 5 days per week, for 1 week.
62265598|NCT05158374|NO_INTERVENTION|Control|No medication, 6 weeks
62265599|NCT05158374|ACTIVE_COMPARATOR|Aspirin 24 Hours|24 Hours Aspirin
62848776|NCT04383418|EXPERIMENTAL|Low dose group|In the high dose group, 36 subjects will receive a high dose of dexmedetomidine nasal spray.
62848777|NCT04383418|PLACEBO_COMPARATOR|Placebo group|In the placebo group，36 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
62622938|NCT01366183||Observational (quality of life questionnaire)|"Patients receive chemotherapy comprising carboplatin, paclitaxel, and filgrastim (regimen 1) or carboplatin alone (regimen 2) every 21 days for 4 courses according to their physicians and/or patients' choice. Patients may undergo surgery and/or further chemotherapy at the discretion of treating physician. Patients undergo blood sample collection at baseline and periodically during course 1 for pharmacokinetic studies.~Patients' quality of life is assessed by the FACT-O, the FACT-Ntx subscale, the IADL, and the Ability to Complete Social Activity questionnaires at baseline, prior to courses 1 and 3, and then 3-6 weeks after completion of course 4. Nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment are also assessed."
62622939|NCT05060107|EXPERIMENTAL|Experimental group - sEVs|Intra-articular knee injection of exosomes (3-5 x 10e11 particles) derived from allogeneic mesenchymal stromal cells. Single dose.
62622940|NCT04668443||Prospective participants in D²EFT study|HIV-positive persons who are eligible for the D²EFT study will be proposed to receive the research-related information with the set of pictures (GIC)
62622941|NCT04668443||Researchers obtaining informed consent for D²EFT study|Healthcare givers involved in the participant informed consent process of D²EFT
62622942|NCT01216332|EXPERIMENTAL|High-Dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
62622943|NCT01216332|ACTIVE_COMPARATOR|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
62622944|NCT05754541|EXPERIMENTAL|WeFlow-Tribranch Aortic Arch Stent Graft System|
62622945|NCT06101537||Brain temperature-pressure monitoring group|From a neurointensive care unit with intracranial pressure monitoring during treatment, which allows continuous recording of brain temperature-pressure data, in patients with moderate and severe acute brain injury due to subarachnoid hemorrhage, cerebral hemorrhage, and craniocerebral trauma.
62622946|NCT06349915|EXPERIMENTAL|Intervention|This is a single-arm study. All participants will be allocated to the intervention arm, in which they will receive the digital narrative therapy.
62622947|NCT05472805||CIMT ≥1mm|The measurement of CIMT will be carried by a cardiologist in the cardiovascular department using B mode ultrasound. The cardiologist will measure both of the carotid artery, and higher measurement of CIMT will be recorded. This group includes individual with CIMT ≥1mm
62622948|NCT05472805||CIMT <1mm|The measurement of CIMT will be carried by a cardiologist in the cardiovascular department using B mode ultrasound. The cardiologist will measure both of the carotid artery, and higher measurement of CIMT will be recorded. This group includes individual with CIMT \<1mm
62622949|NCT03403452|EXPERIMENTAL|arm for Apatinib|500 mg,p.o.,qd
62622950|NCT05346354|EXPERIMENTAL|Ravulizumab|"During the Primary Treatment Period, all participants will receive weight-based dosing of ravulizumab IV for a total of 50 weeks of treatment.~During the Extension Period, participants will continue to receive weight-based dosing of ravulizumab IV for up to 104 weeks."
62622951|NCT04529707|EXPERIMENTAL|Sleep Intervention|All participants will engage in a 10-week, parent mediated sleep intervention with weekly education sessions.
62622952|NCT02209818|EXPERIMENTAL|Laser Irradiation One Dose|Laser irradiation will be applied in one dose for patients in this group, but only on one side of the jaw. The other side of the jaw will receive a placebo procedure (i.e. a red light beam will be emitted on the gingival tissues as if they are irradiated by a laser beam).
62622953|NCT02209818|EXPERIMENTAL|Laser Irradiation Two doses|Laser irradiation will be applied in two doses for patients in this group, but only on one side of the jaw. The second dose will be given after 24 hour of the first one. The other side of the jaw will receive a placebo procedure (i.e. a red light beam will be emitted on the gingival tissues as if they are irradiated by a laser beam).
62622954|NCT06538857|EXPERIMENTAL|Arm 1|standard surgery and CEB-01 implant after surgery
62622955|NCT06538857|ACTIVE_COMPARATOR|Arm 2|standard surgery
62265600|NCT05158374|ACTIVE_COMPARATOR|Aspirin 7 Days|7 Days Aspirin
62265601|NCT05158374|ACTIVE_COMPARATOR|Aspirin 28 Days|28 Days Aspirin
62265602|NCT05158374|ACTIVE_COMPARATOR|Aspirin 6 Weeks|6 Weeks Aspirin
62265603|NCT05158374|ACTIVE_COMPARATOR|Metformin 24 Hours|24 Hours Metformin
62265604|NCT05158374|ACTIVE_COMPARATOR|Metformin 7 Days|7 Days Metformin
62265605|NCT05158374|ACTIVE_COMPARATOR|Metformin 28 Days|28 Days Metformin
62265606|NCT05158374|ACTIVE_COMPARATOR|Metformin 6 Weeks|6 Weeks Metformin
62265607|NCT05158374|ACTIVE_COMPARATOR|Aspirin & Metformin 24 Hours|24 Hours Aspirin \& Metformin
62265608|NCT05158374|ACTIVE_COMPARATOR|Aspirin & Metformin 7 Days|7 Days Aspirin \& Metformin
62622956|NCT00479830||Group 1|South Asian, Subgroup: Asian Indian, population in the Greater Houston area.
62622957|NCT00479830||Group 2|South Asian, Subgroup: Bangladeshi, population in the Greater Houston area.
62622958|NCT00479830||Group 3|South Asian, Subgroup: Pakistani, population in the Greater Houston area.
62622959|NCT00479830||Group 4|South Asian, Subgroup: Sri Lankan, population in the Greater Houston area.
62622960|NCT02461056|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen: Patients receive ibuprofen 50 mg, 100 mg, 200 mg, 400mg or 800 mg intravenously once at post-anesthesia care unit.
62061503|NCT02013388|PLACEBO_COMPARATOR|Placebo|single oral daily dose of placebo for 14 days
62265609|NCT05158374|ACTIVE_COMPARATOR|Aspirin & Metformin 28 Days|28 Days Aspirin \& Metformin
62265610|NCT05158374|ACTIVE_COMPARATOR|Aspirin & Metformin 6 Weeks|6 Weeks Aspirin \& Metformin
62265611|NCT00905736|EXPERIMENTAL|current controlled|a current controlled microcurent device providing a primarily monophasic waveform of typical amplitude 40 microamps
62265612|NCT00905736|EXPERIMENTAL|voltage controlled|constant voltage amplitude delivering high frequency AC waveform
62265613|NCT04778254|ACTIVE_COMPARATOR|conventional obturator|conventional group received conventional clasp-retained obturators with metallic framework (Control group).
62265614|NCT04778254|EXPERIMENTAL|metallic attachment retained obturator|metal group received an attachment-retained obturator with metallic framework
62265615|NCT04778254|EXPERIMENTAL|PEEk attachment retained obturator|PEEK group received attachment-retained obturators with milled PEEK framework,
62265616|NCT00975156|EXPERIMENTAL|Lokomat Intervention|Lokomat gait training (five days a week for eight weeks for a total of 40 sessions).
62265617|NCT00975156|ACTIVE_COMPARATOR|Standard of Care|Conventional physical therapy focusing on gait training for five days a week for eight weeks for a total of 40 sessions.
62622961|NCT02461056|ACTIVE_COMPARATOR|hydromorphone|Hydromorphone: Patients receive hydromorphone 0.25 mg, 0.5 mg, 1 mg, 1.5 mg, or 2 mg intravenously once at post-anesthesia care unit.
62061504|NCT02013388|EXPERIMENTAL|50 mg|single oral daily dose of 50 mg N91115 for 14 days
62622962|NCT02461056|ACTIVE_COMPARATOR|ibuprofen+hydromorphone|Ibuprofen+Hydromorphone: Patients receive ibuprofen 25 mg + hydromorphone 0.125 mg, ibuprofen 50 mg + hydromorphone 0.25 mg, ibuprofen 100 mg + hydromorphone 0.5 mg, ibuprofen 200 mg + hydromorphone 0.75 mg, or ibuprofen 400 mg + hydromorphone 1 mg intravenously once at post-anesthesia care unit.
62622963|NCT04551768|EXPERIMENTAL|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
62622964|NCT04551768|EXPERIMENTAL|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
62622965|NCT04714645|EXPERIMENTAL|Intervention group|VR+ training
62622966|NCT04714645|SHAM_COMPARATOR|Control group|VR- training
62622967|NCT03571178|EXPERIMENTAL|Treatment|Patients who will receive physical therapy
62622968|NCT01526434||Certolizumab Pegol treatment|Patients with RA who begin therapy with Certolizumab Pegol (CZP) will be consecutively included in accordance with the selection criteria. The choice of medical treatment is made independently by the physician before evaluating the possible participation of the patient in the protocol.
62622969|NCT06307405||pulmonry infection group|50 cases of suspected pulmonary infection (based on clinical manifestations and imaging findings). These patients have collected two different samples of alveolar lavage fluid (BALF) and sputum and have undergone metagenomic next generation sequencing (mNGS) and routine pathogen detection, respectively.
62622970|NCT02075008|EXPERIMENTAL|QGE031 every 4 weeks (q4w)|QGE031 240 mg subcutaneously q4w
62622971|NCT01314027|EXPERIMENTAL|neoadjuvant + adjuvant chemotherapy|neoadjuvant chemotherapy is based on gemcitabine/oxaliplatin adjuvant therapy is based on gemcitabine
62622972|NCT01314027|ACTIVE_COMPARATOR|adjuvant chemotherapy|adjuvant therapy is based on gemcitabine
62622973|NCT02481752|EXPERIMENTAL|AAT Training Group|Individuals in this condition will receive four sessions of AAT training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the training may weaken automatic cigarette-approach and strengthen automatic cigarette-avoidance. Furthermore, they will be told that the opposite effect will be true for the stimuli not related to cigarettes (i.e., the positive stimuli).
62622974|NCT02481752|SHAM_COMPARATOR|SHAM Training Group|Individuals in this condition will receive four sessions of SHAM training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the purpose of the training is to improve control over these automatic tendencies and that following the training sessions, they will easily be able to push or pull the stimuli regardless of content.
62622975|NCT01716520|EXPERIMENTAL|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
62622976|NCT01716520|EXPERIMENTAL|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
62449079|NCT04886336||Entecavir(ETV)switch to Tenofovir Alafenamide(TAF)|In entecavir switch group, at least 30 patients should have baseline BW data before entecavir treatment. The indications of entecavir switching to TAF include suboptimal HBV suppression (defined as detectable HBV DNA after at least one year of entecavir treatment), adverse events due to entecavir, physician's judgement according to clinical conditions.
62449080|NCT04886336||observation groups with take either entecavir (25patients) or TDF (25 patients).|observation groups with total 50 patients who continuously take either entecavir (25patients) or TDF (25 patients) will be enrolled.Examination schedules for these two additional groups are the same as switching groups.
62449081|NCT04509609||LGMD 2E with a genetic diagnosis|Any patient affected by LGMD 2E with a genetic diagnosis
62061505|NCT02013388|EXPERIMENTAL|50 mg (single dose)|single oral dose of 50 mg N91115
62061506|NCT02013388|EXPERIMENTAL|250 mg|single oral daily dose of 250 mg N91115 for 14 days (fasted)
62061507|NCT02013388|EXPERIMENTAL|250 mg (Fed)|single oral daily dose of 250 mg N91115 for 1 day (fed fat meal)
62061508|NCT02013388|EXPERIMENTAL|500 mg|single oral daily dose of 500 mg N91115 for 14 days
62061509|NCT02013388|PLACEBO_COMPARATOR|Placebo-Day 1 only|Single oral dose of placebo (Day 1 only)
62449082|NCT03246295||Gestational diabetes mellitus|Those women were diagnosed as gestational diabetes mellitus
62449083|NCT03246295||Control|Those women were diagnosed without gestational diabetes mellitus
62449084|NCT01418326||Sevoflurane|Sevoflurane exposure for radical cancer surgery
62449085|NCT01418326||Propofol|Propofol exposure for cancer surgery
62622977|NCT01716520|EXPERIMENTAL|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
62622978|NCT02855710|OTHER|No training|Parkinsonian Patients with no Rhythm Workers training perceptive timing and senrorimotor timing
62622979|NCT02855710|OTHER|Perceptive timing training|Parkinsonian Patients with Rhythm Workers training perceptive timing
62622980|NCT02855710|OTHER|Sensorimotor timing training|Parkinsonian Patients with Rhythm Workers training sensorimotor timing
62622981|NCT02855710|OTHER|Healthy volunteers|Healthy people with Rhythm Workers training perceptive timing
62622982|NCT01038154|NO_INTERVENTION|control|Not Receive pravastatin
62622983|NCT01038154|EXPERIMENTAL|Pravastatin|
62622984|NCT05667818|EXPERIMENTAL|Amlodipine besylate controlled-release tablets|Test preparation (T): amlodipine besylate controlled-release tablets Specification: 5 mg Batch No.: 22102501 Content: 100.9% Expiry date: October 24, 2024 Storage conditions: dark, sealed at room temperature. Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
62622985|NCT05667818|ACTIVE_COMPARATOR|Amlodipine besylate tablets (trade name: Norfloxacin ®）|Specification: 5 mg Batch No.: FX3445 Content: 100.2% Expiry date: January 2027 Storage conditions: dark and sealed Manufacturer: Pfizer Inc. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
62622986|NCT02461680|EXPERIMENTAL|Tangential resection|the tendon's injury is treated with a tangential resection
62622987|NCT02461680|ACTIVE_COMPARATOR|Suture|The tendon's injury is sutured
62622988|NCT00997347|EXPERIMENTAL|64-70 days' gestational age|Women whose pregnancies are estimated to have a gestational age of 64-70 days
62622989|NCT00997347|NO_INTERVENTION|57-63 days' gestational age|Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range.)
62622990|NCT01050335||Surgical resident or attending|
62622991|NCT04078854|EXPERIMENTAL|Foot amputation, sexual health|Group 1, Experimental arm: inpatient diabetics after initial minor foot amputation, who will be shown video on diabetes and foot amputations plus sexual health
62622992|NCT04078854|ACTIVE_COMPARATOR|Foot amputation, no sexual health|Group 2, Control arm: inpatient diabetics after initial minor foot amputation, who will be shown video on diabetes and foot amputations, with no mention about sexual health
62622993|NCT02051335|EXPERIMENTAL|Sequence 1 (ABDC)|Roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
62622994|NCT02051335|EXPERIMENTAL|Sequence 2 (BCAD)|Roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
62622995|NCT02051335|EXPERIMENTAL|Sequence 3 (CDBA)|Roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
62622996|NCT02051335|EXPERIMENTAL|Sequence 4 (DACB)|Roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
62622997|NCT03454451|EXPERIMENTAL|Cohort 1a|CPI-006
62622998|NCT03454451|EXPERIMENTAL|Cohort1b|CPI-006 + ciforadenant
62449086|NCT01270048|EXPERIMENTAL|Bunsimgieum extract|"* name of product: 'mild-x-gwarip'~* standard code for item: 200005689~* shape, type: extract(brown)~* usage, content: adults;three times a day, each taken before or between meals~* dose, standard: 2.5g for each sack, capsulated~* storage : airtight container, stored in room temperature~* expiration date : 36months after manufacture~* macufacturing company: KyungBangnShinYak inc."
62848778|NCT03853278|EXPERIMENTAL|colorectal cancer self-management|The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill trainings and 12 follow-up telephone calls.These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables.
62449087|NCT01270048|PLACEBO_COMPARATOR|Placebo; corn flour,|"* raw material: total contents(500㎎); cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)~* shape, type: extract(brown)~* usage, dose: adults: three times a day, 1 sack before or between meals~* dose, standard: 2.5g for each sack, capsulated~* storage : airtight container, stored in room temperature~* expiration date : 36 months after manufacture~* manufacturing company: KyungBangnShinYak inc."
62449088|NCT06057519|EXPERIMENTAL|Optimized dose rifampicin|1800 mg flat dose
62622999|NCT03454451|EXPERIMENTAL|Cohort 1c|CPI-006 + pembrolizumab
62623000|NCT03454451|EXPERIMENTAL|Cohort 2a|CPI-006
62623001|NCT03454451|EXPERIMENTAL|Cohort 2b|CPI-006 + ciforadenant
62623002|NCT03454451|EXPERIMENTAL|Cohort 2c|CPI-006 + pembrolizumab
62848779|NCT03853278|NO_INTERVENTION|No intervention control group|The control group will receive health education leaflets.
62848780|NCT03691194|EXPERIMENTAL|fresh orange juice|Subject will take 8 ounces of fresh orange every day for 28 days.
62848781|NCT03691194|ACTIVE_COMPARATOR|concentrated orange juice|Subject will take 8 ounces of concentrated orange juice every day for 28 days.
62848782|NCT01933568|EXPERIMENTAL|Radiation|combined CFRT and SABR with concurrent cisplatin
62061510|NCT03587298||Group 1|NAFLK criteria met (by definition: sonographic fatty liver)
62449089|NCT06057519|ACTIVE_COMPARATOR|Standard dose rifampicin|450 mg for patients under 50 kg and 600 mg for patients over 50 kg
62449090|NCT04359095|ACTIVE_COMPARATOR|I1 Emtricitabine + Tenofovir|Intervention 1: Emtricitabine (200 mg) + tenofovir (300 mg): 500 mg once a day for 10 days
62449091|NCT04359095|ACTIVE_COMPARATOR|I2 Colchicine + rosuvatatine|Intervention 2: Colchicine: 0.5 mg every 12 hours for 14 days + Rosuvatatin: 40 mg / day for 14 days
62848783|NCT06089551|EXPERIMENTAL|Early supplementary|Start of study drug on postoperative day 2
62848784|NCT06089551|ACTIVE_COMPARATOR|Late supplementary|Start of study drug on postoperative day 5
62061511|NCT03587298||Group 2|Control group: matched age; no NAFKL
62061512|NCT05137379||Elher-Danlos syndrome patients treated with orthopedic surgery|
62265618|NCT03294785|EXPERIMENTAL|Chuna manual therapy|The Chuna manual therapy group will receive Chuna manual therapy alone. Chuna manual therapy will employ a semi-standardized treatment plan of Chuna manual therapy through Chuna technique selection based on physician judgement of techniques from Chuna Medicine (Korean Society of Chuna Manual Medicine for Spine \& Nerves: Chuna Medicine: Seoul: Korean Society of Chuna Manual Medicine for Spine \& Nerves; 2017) and osteopathic manipulative medicine. The Chuna techniques employed in this study are divided into cervical, thoracic and rib cage, lumbar, pelvic, sacral, pubic, and hip joint area techniques. Chuna manual therapy sessions will be administered 2 sessions/week over a period of 5 weeks (total 10 sessions). The time duration of 1 Chuna manual therapy session will consist of approximately 10-20 minutes of diagnosis and approximately 10 minutes of treatment.
62265619|NCT03294785|ACTIVE_COMPARATOR|Usual care|The usual care group will receive usual care alone. Usual care will be limited to physical therapy and conventional medication in this study. Usual care will be provided with reference to a list of most frequently used treatments in neck pain-related patients from Korean Health Insurance Review and Assessment (HIRA) 2014 statistics. Frequency and types of physical therapy used will be recorded in a separate electronic case report form for outcome assessor blinding purposes.
62265620|NCT03171220|EXPERIMENTAL|Neoantigen Reactive T Cells + SHR-1210|Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory;Both Fludarabine 30mg/m2/D and Cyclophosphamide 300mg/m2/D will be i.v. for 3 days before cell infusion; NRTs 0.5\~1 x 10\^10, will be i.v.Q3 weeks for total 4 doses;programmed cell death-1（PD1） inhibitor SHR-1210,200mg,will be i.v. Q3 weeks for total 4 doses,2 day2 prior to each NRTs infusion;Interleukin-2 (IL-2) will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.All Patients will receive a total of 4 cycles of treatment.
62265621|NCT01119170|PLACEBO_COMPARATOR|control starter formula|
62623003|NCT00550576|EXPERIMENTAL|digibind|Injection of digibind and psychological tests
62623004|NCT00177645|EXPERIMENTAL|sodium bicarbonate|inhaled sodium bicarbonate
62265622|NCT01119170|EXPERIMENTAL|D-lactate probiotics|
62265623|NCT02365714|OTHER|Treatment-Radiation|CyberKnife (CK) Stereotactic Accelerated Partial Breast Irradiation. Adjuvant radiation therapy delivered to the region around the lumpectomy cavity. Patients will receive 30 Gy in 5 fractions over 5-14 days.
62265624|NCT05146921|ACTIVE_COMPARATOR|food supplement: multi-strain probiotic (Symprove)|70 ml daily for 12 weeks
62265625|NCT05146921|PLACEBO_COMPARATOR|Placebo|70 ml daily for 12 weeks
62848785|NCT06311877|EXPERIMENTAL|Experimental group given mBerry tablet|For the experiment group, the clinician will be providing participant with daily 0.4 gram mBerry tablets (total of 112 tablets) to consume twice a day (for two meals) over an 8-week period. The participant will be provided with a log form to track mBerry use for the two meals each day for the 8-week period. They will be requested to bring log to each of the clinical visits which include bi-weekly taste assessments.
62848786|NCT06311877|ACTIVE_COMPARATOR|Control group not receiving mBerry|The control group will not be given a placebo. The control group will come to clinic for bi-weekly taste assessments.
62623005|NCT03221179|EXPERIMENTAL|RO7049665|Participants will be administered a single SC dose of RO7049665 administered in up to 4 SC injection.
62623006|NCT03221179|PLACEBO_COMPARATOR|Placebo|Participants will be administered a single SC dose of matching placebo formulation administered in up to 4 SC injections.
62623007|NCT00845936|EXPERIMENTAL|1|850 mg of Metformin bid
62623008|NCT00845936|PLACEBO_COMPARATOR|placebo|Tablets Identical to Metformin, bid
62623009|NCT03005639|EXPERIMENTAL|Vemurafenib/Cobimetinib|Vemurafenib and cobimetinib as a combination has been approved by the United States Food and Drug Administration (FDA) for patients with more advanced melanoma. In this trial, vemurafenib and cobimetinib combination is considered to be experimental since safety of this combination prior to lymph node surgery has not been studied.
62848787|NCT04172818|EXPERIMENTAL|Patients with diary|Evaluation the psychological impact of a diary on the patients hospitalized for allogenic hematopoetic stem cell transplantation and on their relatives.
62265626|NCT03422315|EXPERIMENTAL|External control|propofol;injection;2mg/kg;single-dose
62449092|NCT04359095|ACTIVE_COMPARATOR|I3 Emtricitabine/ tenofobir + colchicine+ rosuvastatin|Intervention 3: Emtricitabine (200 mg) + tenofovir (300 mg): 500 mg once a day for 10 days + Colchicine: 0.5 mg every 12 hours for 14 days + Rosuvatatin: 40 mg / day for 14 days
62623010|NCT03545620||Difficult intubation,|Patients who underwent surgery under general anesthesia will be follow up. Patients predicted difficult intubation/airway or established difficult intubation/airway after anesthesia induction will be included. Which rescue technique will be used after unsuccessful direct laryngoscopy will be recorded.
62848788|NCT02432755|EXPERIMENTAL|home-based MTOT|Home-based mirror therapy combined with task-oriented training (MTOT)
62848789|NCT02432755|ACTIVE_COMPARATOR|hospital-based therapy|hospital-based individualized occupational therapy
62265627|NCT03729063|EXPERIMENTAL|Twice daily expired CO measurements|Patients included in this arm will have expired CO measurements every morning and evening during their initial hospitalization.
62623011|NCT06322277|OTHER|Patients with viral/bacterial infection|
62623012|NCT04711343|EXPERIMENTAL|BAT2306 injection|150mg /1ml; subcutaneous injection
62623013|NCT04711343|ACTIVE_COMPARATOR|Cosentyx (US-licensed)|150mg /1ml; subcutaneous injection
62623014|NCT04711343|ACTIVE_COMPARATOR|Cosentyx (EU-licensed)|150mg /1ml; subcutaneous injection
62623015|NCT01088711|EXPERIMENTAL|Healthy Omarigliptin|Obese healthy participants receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel A).
62623016|NCT01088711|PLACEBO_COMPARATOR|Healthy Placebo|Obese healthy participants receive once-weekly placebo by mouth for 4 weeks (Panel A).
62623017|NCT01088711|EXPERIMENTAL|T2D Omarigliptin|Obese participants with T2D receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel B).
62623018|NCT01088711|PLACEBO_COMPARATOR|T2D Placebo|Obese participants with T2D receive once-weekly placebo by mouth for 4 weeks (Panel B).
62848790|NCT02432755|EXPERIMENTAL|hospital-based MTOT|hospital-based mirror therapy combined with task-oriented training (MTOT)
62848791|NCT03235232|EXPERIMENTAL|BREMEN eye drops|1 drop in affected eye(s), each 12 hours for 8 weeks.
62848792|NCT03235232|ACTIVE_COMPARATOR|Combigan®|1 drop of Combigan® in affected eye(s), each 12 hours for 8 weeks.
62265628|NCT03729063|ACTIVE_COMPARATOR|Control|Patients included in this arm will have one expired CO measurement on the morning just after initial hospital admission and a second expired CO measurement one the morning prior to discharge.
62265629|NCT01505569|OTHER|Arm A: Patients with High Risk or Relapsed Solid Tumor|Treatment consists of a mobilization chemotherapy (ifosfamide 1.8 g/m\^2/day intravenously \[IV\], etoposide 100 mg/mg\^2 IV, mesna 1.8 g/m\^2 divided in every 6 hours dosing, and granulocyte colony stimulating factor 10 mcg/kg subcutaneously or IV until absolute neutrophils \> 1,000/mm\^2) for 5 days in a 30-100 day pretransplant window, busulfan (1.1 mg/kg IV every 6 hours on days -8 through -6), melphalan (50 mg/mg\^2 on days -5 and -4), thiotepa conditioning (250 mg/m\^2 IV over 2 hours on days -3 and -2) followed by an autologous peripheral blood stem cell transplant (infusion on Day 0) and, if appropriate, disease specific radiation therapy at day +60.
62265630|NCT01505569|OTHER|Arm B: Certain CNS Tumors|Treatment consists of a mobilization chemotherapy (ifosfamide 1.8 g/m\^2/day intravenously \[IV\], etoposide 100 mg/mg\^2 IV, mesna 1.8 g/m\^2 divided in every 6 hours dosing, and granulocyte colony stimulating factor 10 mcg/kg subcutaneously or IV until absolute neutrophils \> 1,000/mm\^2) for 5 days in a 30-100 day pretransplant window, carboplatin (dose based on GFR and age 17 mg/kg/day IV or 510 mg/m\^2/day IV) , thiotepa conditioning (10 mg/kg/day or 300 mg/m\^2 IV on days -3 and -2) followed by an autologous peripheral blood stem cell transplant (infusion on Day 0). This will be repeated up to 2 additional 30 day cycles.
62265631|NCT01505569|OTHER|Arm C: Germ Cell Tumors|"1. High-Dose Chemotherapy (3 cycles)~   * Carboplatin AUC=8 \& Etoposide 400 mg/m\^2 daily, days -4, -3, and -2 every 21 days~2. Autologous Stem Cell Infusion ≥ 3 x 106 CD34+ cells/kg Day 0 Cycles 1, 2 and 3~3. TI Chemotherapy \& PBSC Collection.~   * Paclitaxel 200mg/m\^2 IV over 3 hours on Day 1 every 14 days for 2 cycles~  * Ifosfamide 2000 mg/m\^2 IV daily on Days 1-3 every 14 days for 2 cycles~  * Mesna 2000 mg/m\^2 on Days 1-3 every 14 days for 2 cycles~  * G-CSF 10 μg/kg sub q daily on day 3 until adequate CD34+ cell collection or day 15, whichever occurs first~  * Leukapheresis starting on approx. day 11 and continued daily until reaching the collection goal of ≥ 8 x 106 CD34+ cells/kg) or day 15, whichever occurs first"
62265632|NCT01505569|OTHER|Arm D: Certain CNS Tumors|"1. Mobilization Chemotherapy and PBSC Collection (day -100 to day -30)~2. Pre-Transplant Conditioning Chemotherapy (3 cycles)~   * Day -8, -7, -6: Carboplatin as calculated from AUC of 7 approx.~  * Day -5, -4, -3: Thiotepa 10 mg/kg, Etoposide 8.3 mg/kg~  * Day 0: Autologous Hematopoietic Cell Reinfusion~  * Day +1: Begin G-CSF(filgrastim) 5 mcg/kg"
62265633|NCT01505569|OTHER|Arm E: Neuroblastoma|"1. Mobilization Chemotherapy and PBSC Collection (day -100 to day -30)~2. Pre-Transplant Conditioning Chemotherapy (day -7 to day -0)~   * Day -7: anti-seizure prophylaxis with lorazepam or levetiracetam~  * Day -6 - -3: Busulfan IV q24 hours x 4 doses~  * Day -1: Melphalan 140 mg/m2 IV~  * Day 0: Autologous Hematopoietic Cell Reinfusion"
62623019|NCT00642954|EXPERIMENTAL|Level 1: Vorinostat 300 mg + lenalidomide 10 mg|Participants will receive vorinostat 300 mg orally once-daily (QD) on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
62623020|NCT00642954|EXPERIMENTAL|Level 2: Vorinostat 400 mg + lenalidomide 10 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
62623021|NCT00642954|EXPERIMENTAL|Level 3: Vorinostat 400 mg + lenalidomide 15 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 15 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
62623022|NCT00642954|EXPERIMENTAL|Level 4: Vorinostat 400 mg + lenalidomide 20 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 20 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
62265634|NCT01183559|OTHER|Vandetanib|Vandetanib 100 mg (6 patients) or 200 mg (3 patients) orally daily during the conventional 3D-guided conformal radiation therapy plus chemotherapy with carboplatin (AUC 5) on days 1 and 29, paclitaxel 50 mg/m2 i.v. weekly on days 1, 8, 15, 22, 29; and continuous infusion of 5-fluorouracil at 225 mg/m2 for 96 hours Monday-Friday during the radiation.
62848793|NCT01205867|EXPERIMENTAL|1|AZD8848 given to BChE deficient subjects and age \& gender matched control subjects
62848794|NCT05297981|EXPERIMENTAL|Group E|Erector spinae plane block
62061513|NCT02889666|EXPERIMENTAL|Carboplatin|Carboplatin-based chemotherapy (Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Carboplatin was done for 3 cycles with 30 days after last surgery.
62848795|NCT05297981|EXPERIMENTAL|Group Q|Quadratus lumborum block
62848796|NCT01670305|EXPERIMENTAL|Residual pocket - PDT|Photosensitizer plus diiodo laser
62848797|NCT01670305|PLACEBO_COMPARATOR|Residual pocket - Photosensitizer|Photosensitizer alone
62848798|NCT01670305|ACTIVE_COMPARATOR|Residual pocket - SRP|scaling and root planing alone
62848799|NCT01670305|EXPERIMENTAL|Furcation - PDT+SRP|Photosensitizer plus diiodo laser associated with scaling and root planing
62848800|NCT01670305|ACTIVE_COMPARATOR|Furcation - SRP|Photosensitizer associated with scaling and root planing
62623023|NCT00642954|EXPERIMENTAL|Level 5: Vorinostat 400 mg + lenalidomide 25 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 25 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
62623024|NCT03636048|EXPERIMENTAL|Spinal anesthesia group|Spinal anesthesia is used for operation with epidural patient-controlled device for pain control. Bupivacaine Hcl 0.5% Inj. 9-10mg is injected into intrathecal space for anesthesia. 0.2% ropivacaine is used for postoperative pain control with continuous infusion into epidural space.
62623025|NCT03636048|ACTIVE_COMPARATOR|General anesthesia group|General anesthesia is used for operation with wound patient-controlled device for pain control. propofol (10milligram/ML) 1.5-2 mg/ml is used as bolus intravascular injection for induction of anesthesia. 0.5% ropivacaine is used for postoperative pain control with continous infusion through wound catheter.
62623026|NCT00779753|EXPERIMENTAL|Neonates|Sixteen neonates admitted to the Neonatal Intensive Care Unit (NICU) at the Hospital for Sick Children (SickKids) will be required for this study. The diagnoses will include, but are not limited to, the following: Trachea-esophageal fistula and/or esophageal atresia, Congenital diaphragmatic hernia, imperforate anus, Hirschsprung's disease, Malrotation with or without volvulus, Intestinal atresias, Gastroschisis, Omphalocele, Necrotizing enterocolitis, Respiratory distress syndrome.
62623027|NCT05576428|ACTIVE_COMPARATOR|DIET& EXERCISE|diet plan \& daily 20 minutes brisk walking.
62623028|NCT05576428|EXPERIMENTAL|N Acetylcysteine WITH DIET & EXERCISE|NAC 200mg BD along with diet plan \& exercise.
62265635|NCT05914168|EXPERIMENTAL|Study arm|Subjects with investigational acquisition
62265636|NCT00851539|NO_INTERVENTION|Control|Participants received counseling from a live counselor.
62265637|NCT00851539|EXPERIMENTAL|Video|Behavioral Intervention Video
62265638|NCT03841071||ROM/CFS intervention|The ROM/CFS group (N\>100), consists of patients who have undergone urostomy, colostomy, or ileostomy operations, and who are included in the routine follow-up program of the outpatient ostomy clinic at the Department of Surgery, Førde Central Hospital from April 2018 to June 2021.
62265639|NCT03670212|PLACEBO_COMPARATOR|Placebo|The placebo compound, Lactose Monohydrate Powder, was encapsulated in generic opaque capsules identical to the capsules used in the acute stress session. During the placebo session, two capsules were self-administered (swallowed) by each subject. At 11:45am, subjects self-administered a capsule containing 54mg of lactose. At 12:15pm, subjects self-administered a capsule containing 10mg of lactose.
62265640|NCT03670212|EXPERIMENTAL|Acute Stress|During the acute stress experimental session, subjects self-administered two generic opaque capsules. At 11:45am, subjects self-administered a capsule containing 54mg of Yohimbine Hydrochloride powder. At 12:15pm, subjects self-administered a capsule containing 10mg of Hydrocortisone.
62265641|NCT02131558|EXPERIMENTAL|ICG Dye|Patients received injections of Indocyanine green (ICG) for sentinel lymph node (SLN) visualization using near-infrared (NIR) imaging.
62265642|NCT04729036||mandibular fracture group|
62265643|NCT03710109||Concussion|Individuals who have sustained a recent concussion
62265644|NCT03710109||Control Healthy Volunteers|No Intervention
62449093|NCT04359095|OTHER|I4 Standard Treatment|Intervention 4: Standard treatment. It is defined as treatment aimed to control symptoms including fever and pain, multiple organ failure related to the acute infection including respiratory support (oxygen, positive end-expiration pressure with external devices or invasive ventilatory support), cardiovascular, renal, haematological or coagulation, or co-infection with bacterial or mycotic organisms, standard care to prevent pressure ulcers or other care required by the patient, might include Dexamethasone. No viral therapies are included.
62449094|NCT04595136|EXPERIMENTAL|COVID19-0001-USR|Group 1 Patients with SARS-COV-2 (COVID19) positive test will receive Investigational Drug administer by nebulization ( COVID-19-0001-USR) Dosage: 3ml Frequency and Duration: Three times a day for 7 days
62623029|NCT02404129|OTHER|Non-fallers|"The subjects had to report having no difficulties with mobility, activities of daily living, or turning while walking and had no falls for a year period. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
62623030|NCT02404129|OTHER|In a risk to fall|"Subjects who report about 1-2 falls in a year period. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
62623031|NCT02404129|OTHER|Multiple fallers|"Subjects who reported to have more than two falls per year. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
62623032|NCT05695963|EXPERIMENTAL|Restless Legs Syndrome|
62623033|NCT05689853|EXPERIMENTAL|AK119 in combination with AK112|AK119 and AK112, IV, every 3 weeks
62623034|NCT04628000||Vitamin D deficiency and COVID19|Vitamin D deficiency and COVID19
62623035|NCT06462170|EXPERIMENTAL|Pancreatic insulin production after drinking meal replacement shake|Nutritional intervention, and then blood work will be drawn to measure pancreatic insulin production capacity.
62265645|NCT00542269|EXPERIMENTAL|Aliskiren / ramipril / amlodipine|6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
62265646|NCT00542269|EXPERIMENTAL|Aliskiren / amlodipine|6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
62623036|NCT05769478|EXPERIMENTAL|Amifampridine will be orally administered to study participants|Amifampridine will be orally administered to study participants following completion of the baseline SFEMG. Post-dose SFEMG will commence at 30 minutes following dosing and will be completed within 30 minutes. The participant will remain under observation in the Diagnostic Neurology suite for 2 hours after dosing so it is estimated that the entire protocol including monitoring will be completed within 2-3 hours.
62623037|NCT05177549|EXPERIMENTAL|on estrogen-progestin contraception|
62623038|NCT05177549|EXPERIMENTAL|under micro-progestational contraception|
62623039|NCT05177549|EXPERIMENTAL|without hormonal contraception|
62623040|NCT05424354|EXPERIMENTAL|Transforming Powder Dressing|Half of the subjects will be randomized to Transforming Powder Dressing (TPD) to treat the burn wound(s). Subjects will be evaluated on Treatment Day 0, 3, 7, 10, 14, 21, and 28 (or sooner if the wound heals prior to end of study visit on Day 28). On each study visit, wound care will be performed. TPD will be applied directly on the burn wound, followed by another dressing (often called a secondary dressing).
62623041|NCT05424354|ACTIVE_COMPARATOR|Standard of Care Dressing|Half of the subjects will be randomized to Standard of Care (SOC) to treat the burn wound(s). Subjects will be evaluated on Treatment Day 0, 3, 7, 10, 14, 21, and 28 (or sooner if the wound heals prior to end of study visit on Day 28). On each study visit, wound care will be performed. The standard of care burn dressing will be applied directly on the burn wound, followed by another dressing (often called a secondary dressing).
62623042|NCT06097871|EXPERIMENTAL|Nutraceutical Dietary Supplement|A novel nutraceutical skin supplement, scientifically formulated to specifically target the multiple underlying causes of acne in women. The supplement is comprised of primary and secondary ingredients, designed to improve skin from the inside out.
62265647|NCT00542269|ACTIVE_COMPARATOR|Ramipril / amlodipine|6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
62623043|NCT06097871|PLACEBO_COMPARATOR|Placebo|Oral supplement containing non-active ingredients.
62623044|NCT04325867|EXPERIMENTAL|All patients with known cardiovascular disease|"All these patients will be provided an electronic account on a dedicated platform were they can be supervised and can call for advice / help.~This kind of tele-medical project aims to keep these patients in a so-called proximity, monitoring their vital parameters, checking their medication and providing dedicated advices according to their complaints.~Moreover, all these patients will receive digital watches with ecg-recording capabilities, thus a dedicated physician could correlate their symptoms with few clear paraclinical variables.~All of these patients' complaints will be stratified according to elaborated protocols based on the European Cardiovascular Guidelines.~Moreover, a psychologist and a chaplain will deal with their (new) problems due to social isolation."
62623045|NCT00921635|EXPERIMENTAL|Maintain hemoglobin level above 120 g/L|Hemoglobin level from 120 g/L to 130 g/L
62623046|NCT00921635|ACTIVE_COMPARATOR|Maintain hemoglobin level above 100 g/L|Hemoglobin level from 100 g/L to 110 g/L
62623047|NCT05469620|NO_INTERVENTION|Control|Receive usual care.
62623048|NCT05469620|EXPERIMENTAL|Education|Receive nutrition education.
62623049|NCT05469620|EXPERIMENTAL|Meal|Receive meal kit.
62623050|NCT05469620|EXPERIMENTAL|Education and Meal|Receive both nutrition education and meal kit.
62623051|NCT04970407|EXPERIMENTAL|Dysport®|40 Units (U) Intramuscular (IM) injection at day 1.
62623052|NCT04970407|ACTIVE_COMPARATOR|Botox®|16U IM at day 1.
62623053|NCT04970407|ACTIVE_COMPARATOR|Xeomin®|16U IM at day 1.
62623054|NCT06212284|OTHER|citalopram first, placebo second|Citalopram was taken first. Placebo was taken at least 7 days later.
62623055|NCT06212284|OTHER|placebo first, citalopram second|Placebo was taken first. Citalopram was taken at least 7 days later.
62623056|NCT04105842|EXPERIMENTAL|Delfilcon A|All study participants will be refit with Delfilcon A (Dailies Total 1) lenses which they will wear for 1 month.
62623057|NCT03692923|NO_INTERVENTION|control group|participants received ordinary prenatal care.
62623058|NCT03692923|EXPERIMENTAL|virtual community group|participants were invited to join a virtual community to interact with peers in addition to their ordinary prenatal care.
62848801|NCT03665519|EXPERIMENTAL|Dietary supplement and ursodeoxycholic acid therapy.|Participants will take a supplement (sublimated mare milk) of 1 sachet (20 mg) dissolved in 200 ml of warm water (36-37 °C) twice/day accompanied with standard therapy of ursodeoxycholic acid therapy (dosage of 15/kg/day) for 3 months.
62848802|NCT03665519|OTHER|Ursodeoxycholic acid therapy only.|Patients would be given the standard treatment of ursodeoxycholic acid only for 3 months.
62848803|NCT02948517|EXPERIMENTAL|Time restricted feeding|Time restricted feeding
62623059|NCT01066663|EXPERIMENTAL|DL1: Pyrimethamine 12.5 mg|Pyrimethamine single daily oral 12.5 mg dose.
62623060|NCT01066663|EXPERIMENTAL|DL2: Pyrimethamine 25 mg|Pyrimethamine single daily oral 25 mg dose.
62265648|NCT06337071|EXPERIMENTAL|Experimental Group 2~15 years|2\~15 years old participants who vaccinated by experimental vaccine
62265649|NCT06337071|ACTIVE_COMPARATOR|Control Group 2~15 years|2\~15 years old participants who vaccinated by control vaccine 2
62623061|NCT01066663|EXPERIMENTAL|DL3: Pyrimethamine 50 mg|Pyrimethamine single daily oral 50 mg dose.
62623062|NCT02228018|EXPERIMENTAL|CALSA and FRI repeatability|CT-Scan No medication used
62848804|NCT02948517|NO_INTERVENTION|Control|No intervention
62623063|NCT00821197|ACTIVE_COMPARATOR|long-limb bypass|Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)
62265650|NCT06337071|EXPERIMENTAL|Experimental Group 6~23 months(0,1)|6\~23 months old participants who vaccinated by experimental vaccine at month 0 and 1
62623064|NCT00821197|ACTIVE_COMPARATOR|Distal gastric bypass|Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)
62623065|NCT02950038|EXPERIMENTAL|Ibrutinib + Nivolumab|"Ibrutinib administered by mouth daily in 28 day cycles.~Nivolumab administered by vein beginning with cycle 2, and given on Days 1 and 15 of every 28 day cycle."
62623066|NCT01210482||Temsirolimus|Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma)
62623067|NCT03377062||EEG monitoring|Patients arriving to the emergency room with decreased consciousness, severe headaches or dizziness
62623068|NCT00844779||T|(n=30): without central adiposity, without insulin resistance, operated for cholecystectomy or a benign liver tumor.
62623069|NCT00844779||A|(n=30): with central adiposity, insulin resistance and hepatic steatosis (histology).
62623070|NCT00844779||B|(n=30): with central adiposity, insulin resistance and steatohepatitis ± hepatic fibrosis (histology).
62623071|NCT00632125|EXPERIMENTAL|HX575 epoetin alfa i.v.|This post-authorization safety study was designed as a multi-center, multinational, prospective, single-arm clinical study with a 6-month HX575 (recombinant human) erythropoietin alfa treatment period. It was planned to include approximately 1,500 patients.
62848805|NCT03415711|EXPERIMENTAL|Mesalamine plus high-probiotic preparation VSL#3®|Mesalamine 2.4 g/day in once daily administration plus VSL#3® 450 billion sachets, two sachets per day (900 billion of bacteria per day) for 12 months.
62848806|NCT03415711|EXPERIMENTAL|Mesalamine plus low-probiotic preparation VSL#3®|Mesalamine 2.4 g/day in once daily administration plus VSL#3® 450 billion sachets, two sachets twice a day (1800 billion of bacteria per day) for 12 months.
62848807|NCT03415711|ACTIVE_COMPARATOR|Mesalamine plus Placebo|Mesalamine 2.4 g/day in once daily administration plus placebo for 12 months.
62848808|NCT02536417|ACTIVE_COMPARATOR|Treatment arm: melatonin|melatonin 0.5 mg as treatment, to be given daily at bedtime
62848809|NCT02536417|PLACEBO_COMPARATOR|Placebo arm|Sugar pill identical in appearance to the melatonin 0.5 mg tablets used in treatment arm
62848810|NCT05118659|EXPERIMENTAL|SNAG GROUP|The SNAG group received a treatment based on sustained apophyseal glides in a postero-anterior direction on C2 with a dose of three series of ten repetitions each, combined with active cervical extension.
62848811|NCT05118659|SHAM_COMPARATOR|SHAM SNAG GROUP|The placebo SNAG group received a simulation of the contact used for the SNAGs, without any vertebral glide, and with an active cervical extension.
62848812|NCT05118659|NO_INTERVENTION|CONTROL GROUP|The control group did not receive any type of intervention, they only waited for four minutes, sat down on a chair
62848813|NCT05613062|EXPERIMENTAL|Active treatment (Modified Huang-Lian-Jie-Du Decoction (MHLJDD))|Chinese medicine
62449095|NCT04595136|PLACEBO_COMPARATOR|Normal Saline|Group 2 of patients with positive tests intervention SARS-COV-2 (COVID19) with placebo (i.e., normal saline 0.9% NS) plus standard baseline treatment for covid provided by Primary care provider ( Azithromycin, dexamethasone, and/or anticoagulants) Dosage: 3ml Frequency and Duration: Three times a day for 7 days
62449096|NCT03092908|PLACEBO_COMPARATOR|Control group|Administer 5 ml placebo (purified water) three times a day.
62449097|NCT03092908|EXPERIMENTAL|Intervention group|Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.
62449098|NCT02686840|EXPERIMENTAL|sublingual misoprostol|Group A (100 patients): will be treated with sublingual misoprostol
62449099|NCT02686840|ACTIVE_COMPARATOR|vaginal misoprostol|Group B (100 patients): will be treated with vaginal misoprostol
62449100|NCT00268346|EXPERIMENTAL|ZD1839|
62449101|NCT03468036||Extubation with 100% O2|for further information please refer to study protocol
62449102|NCT03468036||Extubation with 35% O2|for further information please refer to study protocol
62449103|NCT03987438|EXPERIMENTAL|Behavioral intervention|Participants randomized to the behavioral intervention group will be provided with a mobile APP which incorporates behavioral support including health knowledge education, mental health counseling, diet advice, exercise guidance and weight management. Meanwhile, the behavioral support will be modified by endocrinologists, dieticians, sports medicine professionals and psychologists individually based on the feedback of their performance recorded in the APP. Every three months, participants in the intervention group will be back to their research centers and be collected with information including HbA1c levels, blood pressure, heart rate tests and adverse events. Investigators conduct face-to-face health education, lifestyle guidance, mobile APP software inspection. Every one year, 75g OGTT (0min,60min, 120min points of blood glucose and insulin levels), liver and kidney function, blood lipids, glycosylated hemoglobin, urine routine and electrocardiogram will be evaluated.
62449104|NCT03987438|NO_INTERVENTION|Control group|Participants randomized to the control group have regular care in their local hospitals. Every three months, participants in the intervention group will be back to their research centers and be collected with information including HbA1c levels, blood pressure, heart rate tests and adverse events. Every one year, 75g OGTT (0min,60min, 120min points of blood glucose and insulin levels), liver and kidney function, blood lipids, glycosylated hemoglobin, urine routine and electrocardiogram will be evaluated.
62449105|NCT04485052|EXPERIMENTAL|IBI188+azacitidine|1L unfit AML receive IBI188 every week by intravenous(IV) and azacitidine daily in Day 1-7 of each four weeks(Q4W) by subcutaneous(IH)
62449106|NCT04485052|EXPERIMENTAL|IBI188+decitabine|R/R AML receive IBI188 every week by intravenous(IV) and decitabine daily in Day 1-10 of each four weeks(Q4W) by subcutaneous(IH)
62449107|NCT03422926|EXPERIMENTAL|Intervention|Social marketing messaging campaign
62848814|NCT05613062|PLACEBO_COMPARATOR|Placebo|Placebo
62848815|NCT05300204|EXPERIMENTAL|Intervention Group 1 - Self-help Strategies for depression|Exposure to information about self-help strategies for depression
62848816|NCT05300204|EXPERIMENTAL|Intervention Group 2 - General information about depression|Exposure to general information about depression
62848817|NCT02350764|EXPERIMENTAL|Nivolumab|Patients will begin treatment with nivolumab IV 3mg/kg and ipilimumab 1mg/kg. Treatment with nivolumab will continue every 2 weeks (+/- 3 days) thereafter and treatment with ipilimumab will continue every 6 weeks (+/- 3 days) thereafter. Treatment will continue until protocol-defined toxicity, confirmed progression of disease\*, withdrawal of consent, or death.
62848818|NCT03506893|EXPERIMENTAL|Alphapump|Alfapump® device implantation under general anesthesia (30-45 minutes)
62848819|NCT03506893|ACTIVE_COMPARATOR|Ascites puncture|Iterative paracentesis compensated for by albumin infusions in ambulatory care.
62848820|NCT00534599|OTHER|1|Adjunctive Placebo Seroquel XR to anxiety treatment
62848821|NCT00534599|EXPERIMENTAL|2|Adjunctive Seroquel XR to anxiety treatment
62848822|NCT03448484|EXPERIMENTAL|Intervention|Intervention (agriculture-focused package + nutrition-sensitive and nutrition-specific interventions=integrated package)
62848823|NCT03448484|OTHER|Control|Control (agriculture-focused package)
62848824|NCT05403216||OLP(-)|Oral lichen planus (OLP) with negative thyroid antibody group
62848825|NCT05403216||OLP(+)|OLP with positive thyroid antibody group
62848826|NCT04593199|SHAM_COMPARATOR|Physical Activity Tracking App Only|Over a four week period, participants were asked to use the Fitbit app to track their daily physical activity.
62848827|NCT04593199|ACTIVE_COMPARATOR|Physical Activity Tracking + Gamified Smartphone App|Over a four week period, participants were asked to use the Fitbit app to track their daily physical activity. Additionally, they were asked to use the gamified smartphone app, Draco, during the intervention period.
62848828|NCT04655794||had >= grade 2 adverse reactions|
62848829|NCT04655794||had <2 frade 2 adverse reactions|
62848830|NCT01707238|EXPERIMENTAL|stenfilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
62848831|NCT01707238|ACTIVE_COMPARATOR|etafilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
62848832|NCT05155189|EXPERIMENTAL|C-CAR031|Autologous C-CAR031 administered by intravenous (IV) infusion
62848833|NCT05155189|EXPERIMENTAL|C-CAR031 combined with Lenvatinb|Autologous C-CAR031 combination with Lenvatinib
62848834|NCT05155189|EXPERIMENTAL|C-CAR031 combined with PD-1(L1) antibody|Autologous C-CAR031 combination with PD-1(L1) monoclonal antibody
62848835|NCT06132815|EXPERIMENTAL|Laser troughing|
62848836|NCT06132815|EXPERIMENTAL|Retraction cord and astringent|
62848837|NCT06132815|EXPERIMENTAL|Cordless retraction paste with astringent|
62848838|NCT06132815|ACTIVE_COMPARATOR|Cordless retraction paste without astringent|
62848839|NCT00196092|OTHER|1|Roll-in
62848840|NCT00196092|OTHER|2|Surgical
62848841|NCT00196092|OTHER|3|Standard Risk
62848842|NCT00196092|OTHER|4|High Risk
62848843|NCT00196092|OTHER|5|Compassionate Use
62061514|NCT02889666|EXPERIMENTAL|Docetaxel|Docetaxel-based chemotherapy (Docetaxel 120mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Docetaxel was done for 3 cycles with 30 days after last surgery.
62061515|NCT02889666|EXPERIMENTAL|Gemcitabine/Cisplatin|Gemcitabine/Cisplatin-based combinational chemotherapy (Gemcitabine 200mg + Cisplatin 60mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
62061516|NCT02889666|EXPERIMENTAL|Cisplatin|Cisplatin-based chemotherapy (Cisplatin 60mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Cisplatin was done for 3 cycles with 30 days after last surgery.
62848844|NCT00196092|OTHER|6|Treatment for females.
62265651|NCT06337071|ACTIVE_COMPARATOR|Control Group 6~23 months(0,1)|6\~23 months old participants who vaccinated by control vaccine 1 at month 0 and 1
62265652|NCT06337071|EXPERIMENTAL|Experimental Group 6~23 months(0,3)|6\~23 months old participants who vaccinated by experimental vaccine at month 0 and 3
62848845|NCT00196092|OTHER|7|Standard Risk Continued Access
62848846|NCT00196092|OTHER|8|High Risk Continued Access
62848847|NCT03816709|OTHER|Therapeutic ultrasound treatment|All subjects received a therapeutic ultrasound treatment with the Chattanooga Intelect Legend XT machine with the following parameters: 3 MHz, 1.0 W/cm2, 15 minute treatment time.
62848848|NCT02766985||FSHD|Participants with FSHD-1 or FSHD-2. No intervention is given to participants. Participants will undergo series of tests and procedures in order to make a standardized and scalable Rasch-built clinical severity scale.
62848849|NCT05143372|ACTIVE_COMPARATOR|SaO2 (oxygen status)|Measurment 4 times per day, ABA (acid-bases analyses)
62848850|NCT05143372|ACTIVE_COMPARATOR|PaO2/FiO2 (respiratory index)|Measurment 4 times per day, ABA (acid-bases analyses)
62848851|NCT04771091|EXPERIMENTAL|Mesure of head-perineum distance by transperineal ultrasound|A mesure of head-perineum distance by ultrasound will be realized at the beginning of maternal pushing efforts by a junior gynecologist.
62848852|NCT02872285|EXPERIMENTAL|LYC-30937-EC 25 mg PO once daily (QD)|LYC-30937-EC 25 mg by mouth once daily for 12 weeks
62848853|NCT02872285|PLACEBO_COMPARATOR|Matching Placebo PO QD|Placebo enteric coated (EC) by mouth once daily for 12 weeks
62848854|NCT05396599|EXPERIMENTAL|Eyhance Toric II IOL|Model DIU
62848855|NCT05396599|EXPERIMENTAL|TECNIS Synergy Toric II|Model DFW
62848856|NCT05396599|ACTIVE_COMPARATOR|TECNIS Toric 1-Piece IOL|Model ZCT
62848857|NCT03504176||Intervention|Patients will be ventilated according to the bundle; including ventilation targets, tidal volume, end expiratory pressure-fraction of inspired oxygen titration.
62848858|NCT03504176||Control|Standard of care prior to implementation of the ventilation bundle
62848859|NCT03599232|ACTIVE_COMPARATOR|intervention( formative OSCE)|"students attended a formative objective structured clinical examination (OSCE) on the first day of their pediatric module to assess the competencies they gained from previous modules. the formative OSCE composed of 8 stations, which were both interactive and static. The interactive stations include history taking, examination, communication (counseling about breastfeeding), and procedural skills (pediatric basic life support) while non-interactive stations include data interpretation, management (linked-station) and a video-station (emergency).~assessed at end of the module(7 weeks) through summative OSCE"
62265653|NCT06337071|ACTIVE_COMPARATOR|Control Group 6~23 months(0,3)|6\~23 months old participants who vaccinated by control vaccine 1 at month 0 and 3
62265654|NCT06337071|EXPERIMENTAL|Experimental Group 3~5 months|3\~5 months old participants who vaccinated by experimental vaccine at month 0, 1, 2 for primary vaccination, and vaccinated by experimental vaccine at 12-month old for booster vaccination
62848860|NCT03599232|NO_INTERVENTION|control|students in this group have attended pediatric module without formative OSCE and assessed at end of the module(7 weeks) through summative OSCE
62848861|NCT01290796|OTHER|Ajust Adjustable Single-Incision Sling|Urinary incontinence sling
62848862|NCT01760785|ACTIVE_COMPARATOR|divalproex sodium|
62848863|NCT01760785|PLACEBO_COMPARATOR|sugar pill|
62449108|NCT03422926|NO_INTERVENTION|Control|No messaging campaign
62848864|NCT00561548|OTHER|A|Patients with active Crohn disease and with azathioprine treatment
62848865|NCT00561548|OTHER|B|Patient with active crohn disease and without azathioprine disease
62848866|NCT04827667||Patients with lung cancer|In lung cancer patients with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes.
62848867|NCT04827667||Patients wiht interstitial lung disease|In patients with interstitial lung disease with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes.
62848868|NCT04827667||Patients with asthma|In patients with asthma with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes.
62848869|NCT00581880||1|Terminally Ill patients
62848870|NCT01338779||Group 1 - kidney tolerant|Renal allograft recipients showing functional tolerance (normal and stable renal function) after discontinuation of immunosuppressive medications for at least 1 year (or based on the investigator's discretion).
62848871|NCT01338779||Group 2 - acceptor|Enrollment for group 2 was closed. Renal transplant recipients with functioning allografts (not on dialysis) who had not received immunosuppressive medications for at least 1 year (or at investigator's discretion) but who had moderately impaired or gradually deteriorating renal function, defined as creatinine clearance (CrCl) \< 40 mL/min and/or creatinine \> 50% above baseline value, and thus did not qualify for group 1.
62848872|NCT01338779||Group 3 - kidney graft loss|Enrollment for group 3 is closed. These were renal transplant recipients who had subsequently rejected and lost function of their transplanted kidney.
62848873|NCT01338779||Group 4 - kidney monotherapy|Renal transplant recipients showing stable and normal renal function after receiving only prednisone 10 mg/day for at least 1 year (or based on the investigator's discretion).
62623072|NCT03885245|EXPERIMENTAL|L-citrulline|L-citrulline with a dose of 15 g/day will be administered in powder form that is mixed with water and taken orally, continuously and daily for at least 7 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 5 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
62265655|NCT06337071|ACTIVE_COMPARATOR|Control Group 3~5 months|3\~5 months old participants who vaccinated by control vaccine 1 at month 0, 1, 2 for primary vaccination, and vaccinated by control vaccine at 12-month old for booster vaccination
62623073|NCT03885245|PLACEBO_COMPARATOR|Matching Placebo|Administered in powder form that is mixed with water and taken orally, continuously, and daily for at least 7 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 5 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
62623074|NCT04035122|EXPERIMENTAL|Robotic Treatment|The Lokomat is a robotic device. For treatment with the robotic system, the amount of body weight supported will initially set at 70% of every patient's weight, then decreasing in accordance with load tolerance, although not providing less than 20% support. The selected speed will be adapted to the patient's working comfort under the supervision of a trained physiotherapist. The rehabilitation protocol consists of 40 training sessions (3 sessions per week lasting 45 minutes).
62265656|NCT01740375|NO_INTERVENTION|Arm B: observation:|No additional treatment after concurrent chemoradiotherapy. However, esophagectomy will be considered as a salvage treatment for local recurrence during observation.
62265657|NCT01740375|EXPERIMENTAL|Arm A: esophagectomy|Esophagectomy will be performed preferentially within 8 weeks (maximum 12 weeks) after completion of concurrent chemoradiotherapy
62061517|NCT02889666|EXPERIMENTAL|Docetaxel/Oxaliplatin|Docetaxel/Oxaliplatin-based chemotherapy (Docetaxel 120mg + Oxaliplatin 200mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
62265658|NCT03422107||TAVI|Transcatheter Aortic Valve Implantation
62848874|NCT01338779||Group 5 - kidney standard immunotherapy|Enrollment for group 5 is closed. Stable renal transplant recipients currently on standard immunosuppression.
62265659|NCT03422107||cAVR|Conventional Valve Replacement
62265660|NCT03422107||rCABG|minimally invasive coronary artery bypass graft
62265661|NCT03422107||cCABG|Conventional Coronary Artery Bypass Graft
62061518|NCT02889666|EXPERIMENTAL|Docetaxel/Carboplatin|Docetaxel/Carboplatin-based chemotherapy (Docetaxel 120mg + Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
62061519|NCT02889666|EXPERIMENTAL|Gemcitabine/Carboplatin|Gemcitabine/Carboplatin-based chemotherapy (Gemcitabine 200mg + Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
62265662|NCT01002235|EXPERIMENTAL|Cohort 1|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 4 mg.
62265663|NCT01002235|EXPERIMENTAL|Cohort 2|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 8mg.
62265664|NCT01002235|EXPERIMENTAL|Cohort 3|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 16mg.
62265665|NCT01394627|EXPERIMENTAL|Eplerenone|hypoglycemia (50 mg/dl) with pretreatment with two doses of eplerenone (100 mg of eplerenone per dose)
62623075|NCT04035122|ACTIVE_COMPARATOR|Conventional Treatment|The CG will perform traditional overgroung gait rehabilitation. Exercises in this program are designed with gradual increments to meet each patient's abilities and were supervised by a physical therapist. The rehabilitation protocol consists of 40 training sessions (3 sessions per week lasting 45 minutes).
62623076|NCT03286621||Children with Autism Spectrum Disorder|Children with an Autism Spectrum Disorder according to DSM-5 criteria
62623077|NCT03286621||Typically Developing Children|Typically developing children
62623078|NCT03286621||Children with Delayed Development Disorders|Children with Delayed Developmental Disorders other than ASD
62623079|NCT04671394|EXPERIMENTAL|Test (FMUD + DLIG)|Periodontal pockets are treated by ultrasonic debridement and, after 7 and 28 days, by irrigation with indocyanine green solution and diode laser irradiation.
62848875|NCT01338779||Group 6 - kidney chronic rejector|Enrollment for group 6 is closed. Chronic allograft nephropathy group.
62061520|NCT02889666|PLACEBO_COMPARATOR|Placebo|No Adjuvant chemotherapy using CCODG was done for patients who had previous surgery to remove the primary non-small cell lung carcinoma but subject to tumor relapse. Instead, placebo was supplied to these patients as a comparator Arm.
62265666|NCT01394627|PLACEBO_COMPARATOR|placebo|hypoglycemia of 50 mg/dl plus placebo
62265667|NCT06090942|EXPERIMENTAL|Cognitive training|Smartphone-based cognitive training
62265668|NCT06090942|NO_INTERVENTION|Usual care|No intervention
62265669|NCT04193007|EXPERIMENTAL|molecular targeted therapy group|Molecular targeted therapy(according to the results of gene detection, targeted drugs were selected, such as EGFR mutation using the first generation of EGFR-TKI,ALK or ROS1 mutation using the first generation of ALK inhibitors)
62449109|NCT02879721|NO_INTERVENTION|no drug|No drug and no intervention
62449110|NCT02879721|ACTIVE_COMPARATOR|AT1R-antagonist|Angiotensin II, type 1 receptor inhibitor, (candesartan) 8 mg once daily
62449111|NCT02879721|ACTIVE_COMPARATOR|ACE-inhibitor|Angiotensin converting enzyme inhibitor, (enalapril) 5 mg once daily
62265670|NCT04193007|EXPERIMENTAL|Brain Radiotherapy and molecular targeted therapy group|Brain Radiotherapy (stereotactic radiotherapy was used for 1-3 intracranial lesions, and simultaneous modulated accelerated radiation therapy for Brain(SMART-Brain )was used for more than 3 intracranial lesions);Molecular targeted therapy(according to the results of gene detection, targeted drugs were selected, such as EGFR mutation using the first generation of EGFR-TKI,ALK or ROS1 mutation using the first generation of ALK inhibitors)
62265671|NCT01202929||Type I achalasia|classic achalasia: complete esophageal motor failure
62265672|NCT01202929||Type II achalasia|compression achalasia: simultaneous panesophageal pressurization with aperistalsis
62265673|NCT01202929||Type III achalasia|spastic achalasia with aperistalsis: 100% spasm
62848876|NCT01338779||Group 7 - kidney identical twin|Enrollment for group 7 is closed.
62623080|NCT04671394|SHAM_COMPARATOR|Control (FMUD + ST)|Periodontal pockets are treated by ultrasonic debridement and, after 7 and 28 days, by sham therapy.
62265674|NCT05537597|EXPERIMENTAL|M1-rTMS group|
62623081|NCT00635921|ACTIVE_COMPARATOR|I ziprasidone|
62623082|NCT00635921|PLACEBO_COMPARATOR|II placebo|
62623083|NCT03352505||control|healthy walking control participants
62623084|NCT03352505||wheelchair dancer|wheelchair users, who are performing wheelchair dancing
62623085|NCT03352505||wheelchair marathon participants|wheelchair users, who are participants in wheelchair/ handbike Marathon competitions
62623086|NCT03352505||sedentary wheelchair patients|wheelchair users, who conduct exercise bouts less than 2 times per month
62623087|NCT05157555||"with laryngectomy group"|"with laryngectomy group: patients with laryngectomy for any type of cancer"
62265675|NCT05537597|SHAM_COMPARATOR|sham-rTMS group|
62265676|NCT03961815|EXPERIMENTAL|Brazikumab Induction Dose|Administer at Week 0, Week 4, and Week 8
62623088|NCT02309450|EXPERIMENTAL|Asunaprevir, Daclatasvir and BMS - 791325|
62265677|NCT03961815|EXPERIMENTAL|Brazikumab Maintenance Dose|Administer at 4-week intervals through Week 52 Participants who receive IV induction dosing will be administered brazikumab SC at 4-week intervals starting Week 12 through Week 52
62265678|NCT02763202|NO_INTERVENTION|Usual Care Group|Participants assigned to the usual care group will continue have the current standard of care including any discharge services for example those usually arranged by case managers, hospitalists, and primary care physicians.
62449112|NCT01537484|EXPERIMENTAL|Swedish Massage|Swedish massage for one hour, once per week, for eight weeks. At week 10, 50% of patients will be randomized to a maintenance dose (one hour of Swedish massage every two weeks), and 50% will be randomized to Usual Care.
62623089|NCT04985227|EXPERIMENTAL|Home weight monitoring|Weighing scales will be provided to the parents to weigh their infant and enter the weight daily during the weekdays into the patient portal.
62623090|NCT04985227|NO_INTERVENTION|Control|The parents will visit their Primary Care office in the usual manner as recommended by their Pediatrician.
62623091|NCT00459719|EXPERIMENTAL|1|In combination with steroids
62623092|NCT00459719|ACTIVE_COMPARATOR|2|In combination with steroids
62623093|NCT01605825|PLACEBO_COMPARATOR|placebo/dalfampridine-ER|"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:~Period 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36"
62623094|NCT01605825|PLACEBO_COMPARATOR|dalfampridine-ER/placebo|"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:~Period 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36"
62623095|NCT06329986|EXPERIMENTAL|Group A|TAMER lenses are used first for 6 months, followed by SV lenses for 6 months.
62623096|NCT06329986|EXPERIMENTAL|Group B|SV lenses are used first for 6 months, followed by TAMER lenses for 6 months.
62623097|NCT06612710|EXPERIMENTAL|extracellular vesicles group|Patients in this arm will be given extracellular vesicles derived from human-induced neural stem cells for intravenous injection once a day for 7 days.
62623098|NCT06612710|PLACEBO_COMPARATOR|extracellular vesicles placebo group|Patients in this arm will be given a placebo of extracellular vesicles derived from human-induced neural stem cells for intravenous injection once a day for 7 days.
62623099|NCT00461097|EXPERIMENTAL|Egg Oral Immunotherapy (OIT)|Subjects ingest egg white solid (EWS) on Visit 1 (initial day dose escalation up to 50 mg), followed by a build-up phase (escalating daily egg doses every 2 wks, achieving a maintenance dose by 32-40 wks). Thereafter, subjects are on a maximally tolerated daily egg dose (306 mg to 2 gm) for ≥8 wks. After wk 44, subjects are given a 5 gm Oral Food Challenge (OFC) using EWS to identify desensitized \[1\] subjects. Subjects/study staff are unblinded following this OFC and either continue on their egg OIT maintenance dose of 2 gm/day or are allowed to attempt escalation up to 2 gm/day for the remainder of the study (1-3 years). A 10 gm OFC to identify desensitized \[1\] subjects occurs at specified intervals under prescribed conditions (yrs 2 - 4). Subjects who pass this 1st 10 gm OFC stop study therapy for 4-6 wks, then have a 2nd 10 gm OFC. Subjects that pass this 2nd 10 gm OFC are considered tolerant \[2\], stop EWS dosing and add egg to their diet.
62848877|NCT01338779||Group 8 - living kidney donors|Corresponding to recipients in group 1 or 4.
62848878|NCT01338779||Group 9 - healthy controls|Enrollment for group 9 is closed.
62848879|NCT01338779||Group 10 - liver tolerant|Enrollment for group 10 is closed. Liver allograft recipients with functional tolerance (stable and normal liver function) after cessation of immunosuppressive medications for at least three years (or at investigator's discretion).
62061521|NCT06040034|ACTIVE_COMPARATOR|Continuous Lidocaine Intravenous Infusion|Patients were given a loading dose of 1.5 mg/kgBW intravenous lidocaine for 10 minutes before induction of anesthesia using a syringe pump, followed by continuous intravenous administration of 1.5 mg/kgBW/hour lidocaine until 30 minutes before the end of the surgery (when the skin is being sutured by the surgeon) using a syringe pump. Continuous administration of lidocaine was prepared by the research team as 10 cc of 20 mg/cc lidocaine in a 10 cc syringe and 10 cc of 0.9% NaCl in a 10 cc syringe.
62623100|NCT00461097|PLACEBO_COMPARATOR|Control Group|Subjects ingest placebo (cornstarch) during Visit 1 (initial day of dose escalation up to 50 mg), followed by a build-up phase (escalating daily placebo doses every 2 wks, achieving a maintenance dose by 32-40 wks). Thereafter, subjects were on a maximally tolerated daily placebo dose (306 mg to 2 gm) for ≥8 wks. After wk 44, subjects were given a 5 gm Oral Food Challenge (OFC) using egg white solid to identify desensitized \[1\] subjects. Subjects/study staff were unblinded following this initial 5 gm OFC. After unblinding, subjects discontinued further placebo dosing and continued on an egg-restricted diet. A 10 gm OFC was administered under prescribed conditions to subjects if their egg-specific serum IgE level was below 2 kUA/L. They were followed in the study up to 2 years. \[1\] Desensitized: Subject does not react to egg during OFC while taking daily doses of therapy. \[2\] Tolerant: Subject does not react to egg during OFC 4-6 wks after abstinence from egg consumption.
62623101|NCT03386188|EXPERIMENTAL|Healthy arm|posterior parietal cortex (PPC) transitory inactivation
62623102|NCT01305707|EXPERIMENTAL|C-ECT and Pharmacotherapy|Consolidation treatment with ECT will be considered finished after 9 months of being started, at which time patients will stay only on the pharmacological treatment they already had. The study will be completed within 15 months of patient inclusion (six months after the end of C-ECT). Patient assessment and follow-up will be conducted by participant researchers. Blind rater will conduct clinical and adverse effects ratings. A neuropsychologist will conduct neuropsychological assessments.
62061522|NCT06040034|ACTIVE_COMPARATOR|Bolus Lidocaine Intravenous|Patients were given a loading dose of 1.5 mg/kgBW intravenous lidocaine for 10 minutes before induction of anesthesia using a syringe pump, followed by intravenous infusion of saline with the same volume until 30 minutes before the end of the surgery (when the skin is being sutured by the surgeon) using syringe pump.
62623103|NCT01305707|ACTIVE_COMPARATOR|Pharmacotherapy|Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet.
62623104|NCT03290391|EXPERIMENTAL|LINC-II|LINC-II is a multi-faceted intervention combining pharmacological therapy (i.e., ART and naltrexone for opioid use disorder) and 12 months of strengths-based case management delivered to coordinate care across the narcology and HIV health care systems.
62061523|NCT06318442|EXPERIMENTAL|Once daily semaglutide|Once daily semaglutide 3 mg (uptitrated to 3 mg twice daily after two days).
62061524|NCT06318442|ACTIVE_COMPARATOR|- Metformin|Metformin modified release tablets (500mg once daily for the first two days, then 500 mg twice daily).
62061525|NCT06318442|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62061526|NCT04966143|EXPERIMENTAL|Treatment group|
62061527|NCT02464683|PLACEBO_COMPARATOR|Placebo|The patient will take a single tablet of placebo daily for 60 days. Each patient will go to the hospital in order to take the blood sample.
62061528|NCT02464683|EXPERIMENTAL|VitaminD|The patient will take a single tablet of Vitamin D (200 International Units) daily for 60 days. Each patient will go to the hospital in order to take the blood sample.
62061529|NCT03021135|ACTIVE_COMPARATOR|Conventional Mucosal Resection|C-EMR will be made with saline injection with the indigo carmine.
62061530|NCT03021135|EXPERIMENTAL|Underwater Mucosal Resection|UW-EMR will be made after the complete filling of lumen with water.
62061531|NCT05514262|EXPERIMENTAL|The stress ball group|With this group, a yellow stress ball will be used which is 6cm in diameter, of medium hardness and made of high quality silicone, and which returns to its original shape after being squeezed. The researcher will explain to the individuals in the group how they should use the stress ball five minutes before beginning the vaccination and during the procedure. The individuals will be taught to take the stress ball in their right hand, the side on which the vaccination will not be given, and, counting from one to three, to squeeze and release the ball, continuing until the procedure is finished. It will be explained that during the procedure, they should give their attention to the stress ball and focus on squeezing it.
62265679|NCT02763202|EXPERIMENTAL|CHS-TS Group|Participants assigned to the Carolinas Healthcare Services Transition Services (CHS-TS) group will be introduced to a patient navigator prior to discharge from the hospital and if interested enter the CHS-TS pathway that includes the following key services: integrated access to medical, pharmacist, and specialty providers; access to CHS disease specific management programs; dedicated care management services delivered in home and at the clinic; lab and infusion services; palliative care consultations when appropriate; and paramedicine for 24 hour support.
62265680|NCT06281184||MTX -- MTX|MERINO trial: randomized to methotrexate (MTX) MERINO:2 study: continues with MTX
62848880|NCT01338779||Group 11 - liver standard immunotherapy|Enrollment for group 11 is closed. Subjects with a liver transplant who never had an attempt made to discontinue gradually their immunosuppression and who are currently taking standard immunosuppressive medications and have stable and normal liver allograft function after at least 1 year of receiving these drugs.
62265681|NCT06281184||MTX -- No treatment|MERINO trial: randomized to methotrexate (MTX) MERINO:2 study: continues without MTX
62848881|NCT02230670|EXPERIMENTAL|IDN-6556|25 mg BID of IDN-6556
62848882|NCT02230670|PLACEBO_COMPARATOR|Placebo|Placebo BID
62848883|NCT02123472|ACTIVE_COMPARATOR|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
62848884|NCT02123472|EXPERIMENTAL|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
62848885|NCT03138980|EXPERIMENTAL|Mobile application|
62848886|NCT06053125|EXPERIMENTAL|Older adults with obesity|Participants with a body mass index (BMI) between 30 and 40 and aged 65-85 years will have an adipose tissue biopsy taken from the abdomen before and after exercise.
62848887|NCT06053125|EXPERIMENTAL|Older adults without obesity|Participants with a BMI between 18.5 and 28 and aged 65-85 years will have an adipose tissue biopsy taken from the abdomen before and after exercise.
62265682|NCT06281184||Placebo -- MTX|MERINO trial: randomized to placebo MERINO:2 study: continues with MTX
62265683|NCT06281184||Placebo -- No treatment|MERINO trial: randomized to placebo MERINO:2 study: continues without MTX
62265684|NCT04360070|EXPERIMENTAL|Ketamine Arm|Patients randomized to the ketamine arm will receive ketamine as part of their sedation medications during their cardiac arrest treatment
62265685|NCT04360070|NO_INTERVENTION|Control Arm|Patients randomized to the control arm will not receive ketamine as part of their sedation medications during their cardiac arrest treatment.
62265686|NCT01360554|EXPERIMENTAL|A|Blinded active PF-00299804 + blinded placebo comparator (erlotinib)
62265687|NCT01360554|ACTIVE_COMPARATOR|B|Blinded active comparator (erlotinib) + blinded placebo PF-00299804
62265688|NCT05084911|EXPERIMENTAL|Test|Pyramax tablet
62265689|NCT05084911|PLACEBO_COMPARATOR|Control|Placebo tablet
62265690|NCT00764595|EXPERIMENTAL|imatinib mesylate|All patients start imatinib mesylate as oral dose of 400 mg/d once daily after meal within 28 days after enrollment, and continue the treatment until 3 years after enrollment of the last patient.
62265691|NCT04253795|ACTIVE_COMPARATOR|Laryngeal mask group (Group 1)|Laryngeal mask will be placed in the airway by the anesthesiologist. Lung isolation will be achieved with an artificial pneumothorax induced during opening the pleura, which resulted to the collapse of the nondependent lung with the patient's spontaneous breathing
62449113|NCT01537484|ACTIVE_COMPARATOR|Light Touch Bodywork|Light-touch bodywork for one hour, once per week, for eight weeks. At week 10, 50% of the patients will be randomized to a maintenance dose (one hour of light-touch massage every two weeks, and 50% will be randomized to Usual Care.
62265692|NCT04253795|ACTIVE_COMPARATOR|Double lumen tube Group (Group 2)|After the correct position of double lumen tube will be determined, one lung ventilation will be started. Lung isolation will be achieved by deflation of the nondependent lung.
62449114|NCT01537484|OTHER|Usual Care|Those initially randomized to the usual care control will be rolled into the Swedish massage intervention (one hour of Swedish massage, once/week for eight weeks) at week 25. At week 34, 50% of patients will be randomized to a maintenance dose (one hour of Swedish massage every two weeks), while 50% will be randomized back to Usual Care.
62449115|NCT06125613|EXPERIMENTAL|Experimental|Double pulse TMS method used to investigate the influence of the pIPS on M1 excitability. We set the ST intensity to evoke a 1mV MEP in the first dorsal interosseous muscle. The SC is applied at 90% of the MT on the pIPS. Our study involves two phases: Resting Phase: 10 single ST and 10 SC+ST doublets with a 4ms interstimulus interval. ST intensity is set to evoke a 1mV MEP, and SC is at 90% of the motor threshold. Movement Phase: Subjects perform a specific hand movement in response to colored light signals (green or red) projected on a screen. A brief but non-painful stimulus may coincide with the red signal to induce a fear response. A test stimulus (ST) or SC+ST doublet is delivered with a 500ms delay after each signal, allowing us to explore corticocortical influences during motor programming. 40 stimulations in total are delivered during this phase. Note that only 40 trials will be performed, and there will be no painful stimuli.
62623105|NCT03290391|NO_INTERVENTION|Standard of Care|Participants randomized to the control group will receive the narcology hospital's standard of care, which is detoxification with or without stabilization. Prior to discharge, those identified as HIV-infected are given contact details for an HIV clinic, not an appointment. Upon discharge, patients are encouraged to receive outpatient narcology treatment, monthly, for 1 year. For this study, with regard to linkage to HIV medical care, patients will be given printed information about where to obtain HIV medical care and a resource card containing harm reduction information.
62848888|NCT06053125|EXPERIMENTAL|Young adults with obesity|Participants with a BMI between 30 and 40 and aged 18-35 years will have an adipose tissue biopsy taken from the abdomen before and after exercise.
62848889|NCT06053125|EXPERIMENTAL|Young adults without obesity|Participants with a BMI between 18.5 and 28 and aged 18-35 years will have an adipose tissue biopsy taken from the abdomen before and after exercise.
62848890|NCT01909011|EXPERIMENTAL|Active CES|The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.
62848891|NCT01909011|SHAM_COMPARATOR|Sham CES|The CES sham group will receive sham CES (device off)for 20 minutes 5 times per week for two weeks.
62848892|NCT02423369|EXPERIMENTAL|neonates and infants requiring surgery|neonates and infants in whom blood samples for measurement of S-100 B protein in serum and NSE protein in serum are taken pre-operatively and 1-st, 2-nd and 3-rd post-operatively. During anesthesia cerebral near infrared spectroscopy is continuously applied until the wound closure.
62848893|NCT05107869|ACTIVE_COMPARATOR|Medium Chain Fatty Acid High Fat Meal|This arm will assess the effect of increased plasma ceramide on peripheral microvascular function after consuming a medium chain fatty acid high fat meal.
62265693|NCT04059770|EXPERIMENTAL|single dose of L-AmB|single IV dose of 10 mg/kg of L-AmB on day 1;
62265694|NCT04059770|EXPERIMENTAL|2 doses of L-AmB|IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;
62265695|NCT04059770|ACTIVE_COMPARATOR|2 weeks of L-AmB|IV dose of 3 mg/kg of L-AmB for 2 weeks.
62623106|NCT01808261|PLACEBO_COMPARATOR|Placebo|Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
62623107|NCT01808261|ACTIVE_COMPARATOR|GSK249320 100/mg|Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
62623108|NCT00383370|EXPERIMENTAL|ITV-1|VEGF Trap formulation 1
62623109|NCT00383370|EXPERIMENTAL|ITV-2|VEGF Trap formulation 2
62623110|NCT00383370|EXPERIMENTAL|ITV-2 OL|VEGF Trap formulation 2 open label, higher concentration
62623111|NCT06137820|EXPERIMENTAL|Treatment group (Cetilar®)|Participants received Cetilar® topical cream twice daily for 30 days. An average amount of 5 g per day
62623112|NCT06137820|PLACEBO_COMPARATOR|Control group (Placebo)|Participants received Cetilar Placebo topical cream twice daily for 30 days. An average amount of 5 g per day
62623113|NCT01863342||CSI score < 40|CSI cutoff value\<40
62623114|NCT01863342||Group 2: CSI score ≥ 40|CSI cutoff value≥40
62623115|NCT01064362||Prophylaxis following major orthopedic surgery|Patients age 18 years and older in the PHARMO RLS database treated with either fondaparinux sodium or LMWH for thromboprophylaxis following hip fracture and/or hip/knee replacement surgery.
62623116|NCT01821274|EXPERIMENTAL|topical Diltiazem Hydrochloride 2% Cream|0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.
62623117|NCT01821274|PLACEBO_COMPARATOR|Vehicle Cream|0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.
62623118|NCT01821274|ACTIVE_COMPARATOR|0.2% sodium lauryl sulfate (SLS)|0.2 mL applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a positive control.
62449116|NCT02508961|EXPERIMENTAL|Web-based physio|Participants receive an online individualised exercise programme to complete over the internet twice per week. Exercises can be a combination of aerobic, strengthening and balance exercises. Participants receive a weekly phone call from a physiotherapist for the first two weeks to check on progress. After this, every 2 weeks online exercise diaries are remotely monitored by a physiotherapist and exercise programmes progressed as appropriate.
62623119|NCT01821274|PLACEBO_COMPARATOR|0.9% saline|0.2 mL, applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a negative control.
62623120|NCT01962194|EXPERIMENTAL|PD and OCD paients for DBS intervention|Parkinson's disease (PD; n=5) and obsessive-compulsive disorder (OCD; n=5) patients that are candidates for treatment with STN DBS will be recruited over a period of two years.
62623121|NCT03033160|EXPERIMENTAL|Estradiol Ring|Estradiol Ring per vagina every 3 months
62623122|NCT03033160|NO_INTERVENTION|Observation|Observation
62623123|NCT03291028||Patients treated with immune check point blocker|Patients who were treated with immune checkpoint inhibitor targeting PD1 and developed metastatic lesion later
62623124|NCT03291028||Patients treated with targeted/ observational therapy|Patients who were not treated with immune checkpoint inhihibitor and developed metastatic lesion following other targeted therapy
62623125|NCT02728284|ACTIVE_COMPARATOR|Normal Cardiovascular System|70 with a history of heart or lung disease
62623126|NCT02728284|ACTIVE_COMPARATOR|Abnormal Cardiovascular System|30 without any history of heart or lung disease
62623127|NCT04886297|PLACEBO_COMPARATOR|placebo|"The placebo capsules only contained pullulan and maltodextrin. During the trial period, the participants were instructed to consume two Mega Resveratrol® placebo capsules once daily (30 min after breakfast).~Intervention: Drug: Mega Resveratrol® capsules"
62623128|NCT04886297|EXPERIMENTAL|100mg/d resveratrol|"During the trial period, the participants will be instructed to consume one Mega Resveratrol® capsules and one Mega Resveratrol® placebo capsules 30 min after breakfast. The resveratrol capsules (100 mg anthocyanins per capsule) will provid a total daily intake of 100 mg resveratrol.~Intervention: Drug: Mega Resveratrol® capsules"
62623129|NCT04886297|EXPERIMENTAL|300mg/d resveratrol|"During the trial period, the participants will be instructed to consume one Mega Resveratrol® capsules and one Mega Resveratrol® placebo capsules 30 min after breakfast. The resveratrol capsules (300 mg anthocyanins per capsule) will provid a total daily intake of 300 mg resveratrol.~Intervention: Drug: Mega Resveratrol® capsules"
62623130|NCT04886297|EXPERIMENTAL|600mg/d resveratrol|"During the trial period, the participants will be instructed to consume two Mega Resveratrol® capsules 30 min after breakfast. The resveratrol capsules (300 mg anthocyanins per capsule, 2 per day) will provid a total daily intake of 600 mg resveratrol.~Intervention: Drug: Mega Resveratrol® capsules"
62623131|NCT02460432|EXPERIMENTAL|Paclitaxel-eluting metal Stent|Niti-S Mira-Cover III Biliary Stent (TaeWoong Medical Co., Ltd. Korea)
62623132|NCT02460432|ACTIVE_COMPARATOR|Covered Metal Stent|ComVi Biliary Covered Stent (TaeWoong Medical Co., Ltd. Korea)
62623133|NCT00428428|PLACEBO_COMPARATOR|1|Saline irrigation
62265696|NCT02268721|NO_INTERVENTION|Controle Group|Patients in the control group are undergoing the same measurements and records before discharge, and at six and twelve weeks, as the intervention group. The control group receives no special treatment or care after discharge.
62265697|NCT02268721|OTHER|App for food delivery|"Intervention: Tablet Computer~Patients in the intervention group receives a tablet upon discharge from the hospital. The tablet contains an app, which the patients in the intervention group can use for ordering meals for delivery from the kitchen at the hospital three times a week. The app also ask the patients to register their own dietary intake, and give them feedback on their daily energy and protein intake.~Baseline measurements and records are taken at prior to discharge from the hospital, and after six and twelve weeks."
62623134|NCT00428428|ACTIVE_COMPARATOR|2|ISO irrigation
62623135|NCT05089812|EXPERIMENTAL|Test-Group|PRF-Group
62265698|NCT02285621|EXPERIMENTAL|Optimized brace|Test group: Patient will receive optimized brace (3D computer assisted design of the brace)
62265699|NCT02285621|ACTIVE_COMPARATOR|Standard brace|Control goup: Patient will receive the Boston Thoracolumbosacral orthosis (TLSO) (conventional design method)
62265700|NCT06007300||Normal Group|Patients with normal endometrium
62265701|NCT06007300||Precancerous Group|Patients with atypical hyperplasia of endometrium
62265702|NCT06007300||Carcinoma Group|Patients with endometrial cancer
62265703|NCT05627284|EXPERIMENTAL|Stoma reversal with bio-mesh placement|
62265704|NCT04052685|EXPERIMENTAL|Selective removal to soft dentin (SRSD)|The patients in SRSD group will be randomized into two subgroups as Group A and Group C. After caries removal to soft dentin calcium silicate based material (Biodentine) will be applied in Group A while will not be applied in Group C prior to placement of the resin composite restoration. The procedure, starts with access to caries tissue by the removal of surrounding unsupported enamel.Carious tissue at the periphery of the cavity will be prepared to hard dentin using round tungsten carbide burs and/or an excavator, while soft carious dentin will remain in the pulpal aspect of the cavity to prevent pulp exposure. Operative procedures will be performed by an experienced (over 10 years) specialist. Moisture control will be provided using cotton rolls and continuous aspiration.
62265705|NCT04052685|ACTIVE_COMPARATOR|Selective removal to firm dentin (SRSD)|Procedures will be done using local anesthesia. The procedure, starts with access to caries tissue by the removal of surrounding unsupported enamel. Caries tissue in the periphery including the enamel-dentinal junction will be removed using round tungsten carbide burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries tissue will be removed until hard or leathery dentin remains. Operative procedures will be performed by an experienced (over 10 years) specialist. Moisture control will be provided using cotton rolls and continuous aspiration. Restoration will be performed after caries removal to firm dentin and placement of calcium silicate based material (Biodentine).
62265706|NCT04811456||MIS-C|"Cases fulfilling following criteria:~1. fever ≥3 days~2. at least two of the following:~   * rash or bilateral conjunctivitis or mucocutaneous inflammation signs~  * hypotension~  * features of myocardial dysfunction, pericarditis, or coronary artery abnormality, based on echocardiographic findings or elevated B-type natriuretic peptide (BNP)/N-terminal-pro-BNP (NT-proBNP) or troponin~  * evidence of coagulopathy~  * acute gastrointestinal problems~3. elevated inflammatory markers AND~4. no other apparent microbial cause~5. evidence of COVID-19 (positive real-time polymerase chain reaction, antigen test or serology), or personal history of COVID-19 or contact with a proven COVID-19 case"
62265707|NCT04265846||bifocal IOL group|The cataract patients who ask for bilateral phacoemulsification and bifocal IOLs implantation.
62265708|NCT04265846||mix bifocal IOL group|The cataract patients who ask for phacoemulsification and mix different bifocal IOLs implantation bilaterally
62265709|NCT04265846||trifocal IOL group|The cataract patients who ask for bilateral phacoemulsification and trifocal IOLs implantation.
62265710|NCT04265846||EDOF IOL group|The cataract patients who ask for bilateral phacoemulsification and EDOF IOLs implantation.
62265711|NCT04265846||blend vision group|The cataract patients who ask for phacoemulsification and different IOLs implantation bilaterally.
62265712|NCT04265846||monovision designed group|The cataract patients who ask for bilateral phacoemulsification and monofocal IOLs implantation with monovision designed.
62265713|NCT04265846||monofocal IOL group|The cataract patients who ask for bilateral phacoemulsification and monofocal IOLs implantation with emmetropia designed.
62265714|NCT04122014|EXPERIMENTAL|Control group|Usual daily activities
62623136|NCT05089812|PLACEBO_COMPARATOR|Control-Group|
62623137|NCT04892199|ACTIVE_COMPARATOR|Semaglutide injection once-weekly|
62623138|NCT04892199|PLACEBO_COMPARATOR|Semaglutide-Placebo injection once-weekly|
62623139|NCT03020277|OTHER|ASD children families|
62623140|NCT05266482|EXPERIMENTAL|Intervention group|Next to the usual care, patients also get the opportunity to download and read a personal report.
62623141|NCT05266482|NO_INTERVENTION|Control group|Patients will receive the usual care.
62623142|NCT03228940|EXPERIMENTAL|treatment|RVX000222 (apabetalone) 100 mg to be administered orally BID 12 hours apart.
62623143|NCT02976402|EXPERIMENTAL|SBRT|"Postoperative RT consisting in:~* 31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week~* 32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week"
62623144|NCT01408901|EXPERIMENTAL|A: GM-CSF + supervised treadmill exercise therapy|
62623145|NCT01408901|ACTIVE_COMPARATOR|B: GM-CSF + attention control group|
62623146|NCT01408901|ACTIVE_COMPARATOR|C: placebo + supervised exercise therapy|
62623147|NCT01408901|PLACEBO_COMPARATOR|D: placebo + attention control group|
62623148|NCT02020889|EXPERIMENTAL|Mepolizumab 300 mg|Each subject will receive mepolizumab 300 mg subcutaneous (SC) injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections (100 mg each- total dose 300 mg); individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.
62623149|NCT02020889|PLACEBO_COMPARATOR|Placebo|Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections; individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.
62623150|NCT03313531||Study group 1|Patients with severe hemophilia A
62623151|NCT03313531||Study group 2|Healthy volunteers
62623152|NCT03313531||Study group 3|Healthy volunteers ) that at previous measurements have been shown to have a TGC\>2SD of the median of the control population.
62265715|NCT04122014|EXPERIMENTAL|Training group|Each subject will participate in 2 sessions each week during 3 months.
62265716|NCT05547451||Trial population|Children from 12 to 18 years old followed up for juvenile arthritis in Angers, Nantes and Rennes.
62623153|NCT03313531||Treated HA person|One patient with severe hemophilia A (HA) will be treated with two factor FVIII concentrates, one with standard half- life (Advate™) and one with a pro-longed half-life (Adynovate™) at two separate occasions
62623154|NCT05980897|EXPERIMENTAL|Naming Treatment|Participants will complete three sessions of baseline probe testing (40 treatment items) occurring virtually on three consecutive days prior to treatment onset. Participants will then complete 10 sessions of therapy scheduled five days a week for two weeks, all occurring virtually. The treatment approach for this study will be a hierarchical, cueing-based treatment for naming.
62623155|NCT05041803|EXPERIMENTAL|CTP-543|Patients who previously completed a qualifying CTP-543 clinical trial
62265717|NCT05461612|EXPERIMENTAL|SRT Pacing|SRT sensing and pacing of the left atrium to detect AF and restore sinus rhythm.
62265718|NCT04914689|ACTIVE_COMPARATOR|Internal focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback in a mirror of their movement patterns.
62265719|NCT04914689|EXPERIMENTAL|Visual external focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback of their movement patterns from a laser.
62265720|NCT04914689|EXPERIMENTAL|Auditory external focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving auditory feedback of their movement patterns.
62623156|NCT03448172|EXPERIMENTAL|Investigational Product|\[14C\]PF-05221304
62623157|NCT05680428|EXPERIMENTAL|early feeding group|after stoma reversal in patients in this group oral feeding was started with in 12 hrs after surgery
62623158|NCT05680428|ACTIVE_COMPARATOR|conventional feeding group|after stoma reversal in patients in this group oral feeding was started 48hrs after surgery
62623159|NCT05298436||Retrospective Cohort (ICD-10)|All participants with stroke according to WHO ICD-10 definition registered on the SLSR prior to the protocol change in April 2022 will be followed up by interview at 3 months, 1 year, and 5, 10 and 15 years after stroke.
62623160|NCT05298436||Prospective Cohort (ICD-11)|All participants with stroke according to WHO ICD-11 definition registered on the SLSR following the protocol change in April 2022 will be followed up by interview at 3 months and then annually up to 5 years.
62623161|NCT01317498|PLACEBO_COMPARATOR|Standard Monitoring|The patients in the standard monitoring arm will receive routine laboratory monitoring as provided to all patients in public HIV clinics in Vietnam, including CD4 count, complete blood count, and liver functions tests every 6 months.
62623162|NCT01317498|ACTIVE_COMPARATOR|Virological Monitoring|The patients in the virological monitoring arm will have routine laboratory monitoring as in the standard monitoring arm and in addition will have a viral load test performed every 6 months while in treatment. The first test will be done 6 months after initiating ART.
62623163|NCT05307679|EXPERIMENTAL|Basmisanil|Participants will receive oral basmisanil twice daily (BID) on the first day of treatment, then three times per day (TID) until the end of Part 1 of the trial (Day 365) or the end of Part 2 (Day 1095)
62623164|NCT05307679|PLACEBO_COMPARATOR|Placebo|Participants will receive oral placebo BID on the first day of treatment, then TID until the end of Part 1 of the trial (Day 365).
62848894|NCT05107869|EXPERIMENTAL|Long Chain Fatty Acid High Fat Meal|This arm will assess the effect of increased plasma ceramide on peripheral microvascular function after consuming a long chain fatty acid high fat meal.
62848895|NCT02024490||RDS group, non-RDS group|RDS group; infants with clinical, radiological and laboratory findings of RDS non-RDS group; infants without clinical, radiological and laboratory findings of RDS
62623165|NCT01058291|EXPERIMENTAL|KW-6500|
62623166|NCT01058291|PLACEBO_COMPARATOR|KW-6500 Placebo|
62848896|NCT01373957||1|Patients hospitalized and diagnosed with UA, STEMI or NSTEMI
62623167|NCT01342445|EXPERIMENTAL|lisdexamfetamine dimesylate|All participants will be assessed across five conditions (baseline, placebo, 30-mg, 50-mg, \& 70-mg) in a double-blind, crossover design
62623168|NCT04070248||Group 1|50 HIV-seropositive with spirometry confirmed COPD
62848897|NCT00918736|EXPERIMENTAL|hyaluronate injection|All patients with unilateral ankle OA received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
62848898|NCT01552421|ACTIVE_COMPARATOR|TV NOTES cholecystectomy|Participants randomized to TV NOTES cholecystectomy
62265721|NCT02821871|ACTIVE_COMPARATOR|SP2086|All subjects were ransomed to A and B sequence.In A sequence,subjects take SP2086 100mg once in fasting the first day,and the B sequence subjects need to take SP2086 100mg after the high fat diet.In Day 8，the medicine strategy of two sequence subjects were alternately.
62265722|NCT02821871|OTHER|high fat diet|All subjects were ransomed to A and B sequence.In A sequence,subjects take SP2086 100mg once in fasting the first day,and the B sequence subjects need to take SP2086 100mg after the high fat diet.In Day 8，the medicine strategy of two sequence subjects were alternately.
62265723|NCT04117464|EXPERIMENTAL|Behavioral activation therapy|Behavioral activation therapy was applied following the protocol designed by Martell, Dimidjian \& Herman-Dunn (2013).
62265724|NCT04117464|EXPERIMENTAL|Acceptance and Commitment Therapy|Acceptance and Commitment therapy was applied following the protocol designed by Hayes, Strosahl \& Wilson, (2011).
62623169|NCT04070248||Group 2|50 HIV-seropositive without COPD
62623170|NCT04070248||Group 3|50 HIV-seronegative with spirometry confirmed COPD
62623171|NCT04070248||Group 4|50 HIV-seronegative without COPD
62623172|NCT03461783|EXPERIMENTAL|Zorflex Activated Carbon Dressing|Patients randomized into the experimental group will only be treated using an activated carbon dressing (Zorflex® Activated Carbon Cloth Dressing; Chemviron Carbon Cloth Carbon, West Midlands, United Kingdom; a division of Calgon Carbon Corporation, Pittsburgh, PA) for wet wounds or with saline and Zorflex® Activated Carbon Cloth Dressing for dry wounds.
62623173|NCT03461783|ACTIVE_COMPARATOR|Standard of Care for Wound Care|Patients with wet wounds randomized into the control group will be treated using foam, calcium alginate or compressive dressings, whereas those with dry wounds will be treated with hydrogel and compressive dressings.
62623174|NCT02872909|ACTIVE_COMPARATOR|low irradiance LED PDT|Ambulight LED portable PDT treatment
62623175|NCT02872909|ACTIVE_COMPARATOR|conventional higher irradiance LED|Conventional LED hospital based standard PDT treatment
62623176|NCT05095883||healthy|Children in this group will be healthy category according to CDC chart which ranged from BMI-for-age 5th to 85th percentiles
62623177|NCT05095883||overweight|Children in this group will be overweight category according to CDC chart which ranged from BMI-for-age 85th to 95th percentiles
62623178|NCT05095883||obese|Children in this group will be obese category according to CDC chart which ranged from BMI-for-age \> 95th percentiles
62623179|NCT05095883||underweight|Children in this group will be underweight category according to CDC chart ranged from BMI-for-age \< 5th percentiles
62623180|NCT00985660|EXPERIMENTAL|Test:|Nisoldipine ER Tablets, 30 mg
62623181|NCT00985660|ACTIVE_COMPARATOR|Reference|Sular Extended-release Tablets, 30 mg
62265725|NCT04117464|EXPERIMENTAL|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy was applied following the protocol designed by Barlow, Allen and Choate (2004).
62623182|NCT05846568|EXPERIMENTAL|Experimental Group: GR1801+Rabies vaccine(CHENGDA PHARMACEUTICALS)|"GR1801 injections are administered by wound infiltration injection or by intramuscular injection.GR1801 injections are a bispecific monoclonal antibody that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.~Dosage form:2mg/1mL/vial, liquid, Dosage: 0.05mg/kg of GR1801 Frequency/duration: at Day 0.~Rabies vaccine should be administered in deltoid muscle Dosage form: \>=2.5 IU, freeze-dried vaccine, 0.5 mL after reconstitution, Frequency/duration: at Day 0, 3, 7, 14, 28."
62623183|NCT05846568|ACTIVE_COMPARATOR|Control Group:HRIG（BOYA-BIO）+Rabies vaccine(CHENGDA PHARMACEUTICALS)|"HRIG is administered by wound infiltration injection or by intramuscular injection. Dosage form: 200 IU/2mL/vial, liquid, Dosage: 20 IU/kg, Frequency/duration: at Day 0.~Rabies vaccine should be administered in deltoid muscle Dosage form: \>=2.5 IU, freeze-dried vaccine, 0.5 mL after reconstitution, Frequency/duration: at Day 0, 3, 7, 14, 28."
62265726|NCT04117464|OTHER|Wait List Group|Participants at Wait List Group will be evaluated pre-post and 3, 6, 9 and 12 months follow up periods, like experimental groups.
62265727|NCT05288790|EXPERIMENTAL|Study Supplement|Probiotic
62623184|NCT03831919|EXPERIMENTAL|SYNC III accommodative support lenses|Wear spectacles with SYNC III accommodative support lenses (add +0.75)
62623185|NCT03831919|PLACEBO_COMPARATOR|control|Wear single vision spectacles (no add)
62623186|NCT01785017||Chidren with critical asthma|Pre- and post-SCAMP
62623187|NCT01491841|EXPERIMENTAL|Phase 1: Pixantrone, 55mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 55mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
62623188|NCT01491841|EXPERIMENTAL|Phase 1: Pixantrone, 85mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 85mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
62623189|NCT01491841|EXPERIMENTAL|Phase 1: Pixantrone, 115mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 115mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
62623190|NCT02036684|NO_INTERVENTION|Healthy Lifestyle Booklet|Standard care for radical prostatectomy (RP) patients includes the provision of preoperative information from a urology nurse educator. Usual care (UC) participants will be given generic instructions by the research coordinator about pelvic floor muscle exercises (PFMX), mobilization and general timeframes for a return to normal activities. The UC group will receive the same PFMX prescription as the PREHAB (Experimental) group and will receive weekly communication from the research coordinator regarding compliance with the PFMX prescription to provide an attentional-control. These instructions are provided in a healthy lifestyle booklet for men with prostate cancer.
62623794|NCT01277432||Depression screening|"All study participants will undergo a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal.~All patients will also undergo detailed psychological and behavioral assessments using validated questionnaires.~Several specialist questionnaires will also be conducted with all patients, including those on depression, self care and quality of life;~1. Patient Health Questionnaire (PHQ-9)~2. Depression Anxiety and Stress Scale (DASS-21)~3. Diabetes Distress Scale (DDS-17)~4. Life events questions (Inter-Heart Study)~5. Diabetes Empowerment Scale (C-DES 20)~6. Summary of Diabetes Self Care Activities (SDSCA-15)~7. Euroqol-5D (EQ-5D)"
62623795|NCT02721914|EXPERIMENTAL|GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC|Subjects will receive 4 massotherapy sessions and 4 of HYPOPRESSIVE ABDOMINAL GYMNASTIC (HAG).
62265728|NCT05288790|PLACEBO_COMPARATOR|Study placebo|Placebo
62265729|NCT05789030|EXPERIMENTAL|Group I|Patients are treated with Diprospan (1mL im) and then with iguratimod (25mg bid) for 12 months
62265730|NCT05789030|EXPERIMENTAL|Group II|Patients are treated with Diprospan (1mL im) and then with leflunomide (10-20mg qd) for 12 months.
62265731|NCT05789030|EXPERIMENTAL|Group Ⅲ|Patients are treated with prednisone (20 mg qd and taper to ≦ 5mg in 3 months) and leflunomide (10-20mg qd) for 12 months.
62265732|NCT05932940|EXPERIMENTAL|GATT group|detection of incidence of Descemet membrane detachment post gonioscopy-assisted transluminal trabeculotomy by anterior segment optical coherence tomography in patients with open angle glaucoma.
62623191|NCT02036684|EXPERIMENTAL|Prehabilitation (PREHAB)|The prehabilitation (PREHAB) program focuses on total-body physical exercises and pelvic floor muscle exercises (PFMX). The total-body exercise prescription will consist of 60 minutes of home-based, unsupervised exercise on 3-4 days per week, alternating between aerobic and resistance training. Each session will include: a 5-minute warm-up, 25 minutes of aerobic exercise, 25 minutes of resistance training (5 exercises targeting major muscle groups), and a 5-minute cool-down. Training intensity progression will occur throughout the intervention. Participants will be provided with resistance bands, a stability ball, and an exercise mat. The PFMX prescription will include a gradual increase in PFMX exercises from 60 per day during weeks 1-2, 120 per day during weeks 3-4, and 180 per day during weeks 5-6 until the surgery date. The total number of repetitions of the PFMXs will be divided equally between the rhythmic and sustained contractions.
62623192|NCT05911789|EXPERIMENTAL|Online adaptive radiation therapy|Patients receive adaptive radiotherapy therapy and concurrent chemotherapy.
62623193|NCT01884545|ACTIVE_COMPARATOR|Standard Risk Assessment (SRA)|Subjects will receive a standard risk assessment only for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
62623194|NCT01884545|EXPERIMENTAL|SRA plus Health Coaching (HC)|In addition to the standard risk assessment for CHD and T2D subjects will receive health coaching intervention for 6 months
62623195|NCT01884545|EXPERIMENTAL|SRA plus Genetic Risk Counseling (GRC)|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
62623196|NCT01884545|EXPERIMENTAL|SRA+HC+GRC|In addition to the standard risk assessment for CHD and T2D subjects will receive genetic risk counseling and health coaching intervention for 6 months.
62623197|NCT03260114|NO_INTERVENTION|Physical activity recommendations|Participants in this group will be advised to engage in physical activity recommendations from health authorities, i.e., 150 minutes per week of moderate intensity activity or 75 minutes per week of vigourous intensity activity or combination of both that results in same caloric expenditure.
62623198|NCT03260114|ACTIVE_COMPARATOR|PAI equal to or more than 100|Participants in this group will be advised to obtain a PAI score of 100 or more over a week.
62265733|NCT00910793|OTHER|Inuvair|
62265734|NCT04176263|EXPERIMENTAL|SBT|The SBT group will receive a 4-week split-belt treadmill training program consisting of 3 training sessions every week. The training will have a progression of training duration over the four weeks. Participants will start at a total training duration of 30 minutes and this will be increased with 5 minutes every week. The maximal length will be 45 minutes of training. One session including breaks will take approximately 1 hour.
62265735|NCT04176263|ACTIVE_COMPARATOR|TBT|The TBT group will receive a 4-week tied-belt treadmill training program consisting of 3 training sessions every week. The training will have a progression of training duration over the four weeks. Participants will start at a total training duration of 30 minutes and this will be increased with 5 minutes every week. The maximal length will be 45 minutes of training. One session including breaks will take approximately 1 hour.
62265736|NCT02295527|EXPERIMENTAL|Home-based physical exercise|Participants randomized to the Intervention Group (IG) will be submitted to a physical exercise program involving a progressive and challenging balance training and a neuromuscular and functional training of the lower limbs, conducted at home by physiotherapists, once a week, lasting about one hour, in the first, second and third month after randomization and will be oriented to perform exercises, twice a week, through a booklet. Visits to follow up exercises progression will be conducted once a month, from de fourth to the sixth month and each two months until the end of the follow up at the 12th month, summing up 18 sessions. Participants will receive monthly phone calls to increase exercise adherence.
62623199|NCT03260114|ACTIVE_COMPARATOR|PAI between 50 and 99|Participants in this group will be advised to obtain a PAI score between 50-99 over a week.
62623200|NCT04729751|EXPERIMENTAL|Maralixibat|Participants will receive up to 600 μg/kg twice daily (PFIC) or up to 400 μg/kg once daily (ALGS) over 13 weeks in the core study and for the duration of the Long Term Extension (LTE) where applicable.
62623201|NCT02298088|ACTIVE_COMPARATOR|Ticagrelor 180 mg|Patients assigned to Ticagrelor will receive oral Ticagrelor, 180 mg as early as possible after the index event and not \>24 h post event followed by 90 mg twice daily for 12 months.
62623796|NCT02721914|EXPERIMENTAL|GROUP RECEIVING MASSOTHERAPY|The subjects of this group will receive a total of 8 sessions of 30 minutes each.
62061532|NCT05514262|EXPERIMENTAL|The Buzzy® group|Individuals in this group will use the Buzzy® device. Before the vaccination procedure, the researcher will place the Buzzy® device, which will be at room temperature, on the vaccination site, and it will vibrate in a non-discomforting way for one minute. After this, the Buzzy® device will be removed from the site, and the nurse will perform the vaccination. Because Buzzy® is a device which can be re-used, it will be disinfected after each vaccination procedure, and re-used with other individuals. The Buzzy® device also has ice wings which will not be used in this study, and only the body of the device will be used to provide vibration.
62623202|NCT02298088|ACTIVE_COMPARATOR|Clopidogrel|"Patients will take the 300 mg clopidogrel as early as possible after the index event and not \> 24h post event, followed by 75mg/day for 12 months.~For patients with \> 75 years the recommended load dose is 75 mg instead 300 mg."
62265737|NCT02295527|OTHER|Control Group Usual Care|This group will receive usual care and the booklet regarding bone health information.
62848899|NCT01552421|NO_INTERVENTION|Laparoscopic cholecystectomy|Participants randomized to laparoscopic cholecystectomy
62848900|NCT03986593|OTHER|Cryoablation +- cementoplasty treated patients|cone beam computed tomography guided cryoablation +- cementoplasty
62848901|NCT05905978|EXPERIMENTAL|CXL graft group|Corneal donors predisposed by CXL were used and the conventional DALK procedure was conducted in patients
62848902|NCT05905978|ACTIVE_COMPARATOR|Conventional graft group|Corneal donors stored in corneal storage media were used and the conventional DALK procedure was conducted in patients
62061533|NCT05514262|NO_INTERVENTION|The control group|Individuals included in the control group will receive no intervention before the vaccination procedure, and the routine Covid-19 vaccination procedure will be used.
62061534|NCT01644201|ACTIVE_COMPARATOR|High viscosity non-starch polysaccharide, PolyGlycopleX®-PGX®|
62061535|NCT01644201|PLACEBO_COMPARATOR|Placebo (Rice Flour)|
62061536|NCT00390195|EXPERIMENTAL|1. Daily|Taking orally the investigational drug daily
62061537|NCT00390195|EXPERIMENTAL|2. Weekly|Taking orally the investigational drug weekly
62061538|NCT03794375|ACTIVE_COMPARATOR|Usual care|The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
62265738|NCT01169155|ACTIVE_COMPARATOR|Study 3. Adults 20-49 Years of Age|"Using a randomized, non-blinded, repeated measures, clinical intervention design, our two working hypotheses as stated in Specific Aims 1 and 2 will be tested in a linked study, Study 3, with adult participants 20-49 years of age to ensure that the alarms tested will also work for adults in this age group.~This arm will use the alarm signal identified in Study 2 that is significantly associated with Electroencephalography (EEG)-defined awakening and successful completion of simulated escape behaviors by children after awakening from slow wave sleep. A lower frequency tone smoke alarm will evaluate the influence of alarm signal frequency on awakening. A conventional residential tone smoke alarm will be used as a reference stimulus. Both a male and a female voice will be used as alarm stimuli. Note that these will be strangers' voices, and not a mother's voice."
62623797|NCT02721914|EXPERIMENTAL|GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC|The subjects of this group will receive a total of 8 sessions of 30 minutes each.
62848903|NCT04854447|EXPERIMENTAL|Study Group|Part-time myopia correction with single-vision spectacles
62848904|NCT04854447|ACTIVE_COMPARATOR|Control Group|Full-time myopia correction with single-vision spectacles
62623798|NCT00726258|PLACEBO_COMPARATOR|1|Drip of physiological serum
62623799|NCT00726258|ACTIVE_COMPARATOR|2|Drip of ketamine
62623800|NCT03795285||Septic neonates:|fifty neonates with sepsis.
62623801|NCT03795285||Controls:|twenty healthy neonates.
62848905|NCT05330247|EXPERIMENTAL|Therapeutic Diet: CRHP Diet|Carbohydrate-reduced high-protein (CRHP) dietary intervention. Intervention: Therapeutic Diet: CRHP Diet.
62061539|NCT03794375|EXPERIMENTAL|Telehealth|"The patients will be discharged from the HCPA thyroid disease outpatient clinic, being instructed to seek the primary care level according to their place of residence to schedule a routine consultation in up to six months.~After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed."
62061540|NCT04845464||Study Group|A group of young adults aged between 18 to 25
62061541|NCT03583645|EXPERIMENTAL|Incremental theory of personality|1 hour behavioral intervention (based on ITP) consisting on several tasks to be completed on paper individually.
62848906|NCT05330247|ACTIVE_COMPARATOR|Therapeutic Diet: CD Diet|Conventional diabetes (CD) dietary intervention. Intervention: Therapeutic Diet: CD Diet.
62848907|NCT00973011|EXPERIMENTAL|A|
62848908|NCT06533436|ACTIVE_COMPARATOR|Cord attachement|"Caregivers follow the Tensoplast® white cord and elastic plaster fixation protocol, which has been revised and validated by the care department.~Tube care is carried out in two stages: preparing the patient for the procedure (safety and hygiene) then renewal of the fixation device."
62848909|NCT06533436|EXPERIMENTAL|AnchorFast|"The AnchorFastTM fixation device developed by Laboratoire Hollister is a single-use medical device. This fixation system consists of a hard plastic guide on which the intubation tube can slide laterally.~It facilitate access to the oral cavity and limit pressure points on the corners of the mouth."
62265739|NCT01169155|ACTIVE_COMPARATOR|Study 4. Older Adults 60-84 Years of Age|Study 4 of this project will take the voice alarm script in Study 2 and compare it with a low-frequency 520 Hz square wave tone smoke alarm in awakening older adults 60-84 years of age from slow wave sleep and prompting their performance of a simulated escape procedure. Note that this will necessarily be a female stranger's voice, and not a mother's voice, in this older age group. As in Studies 1 and 2, a conventional residential tone smoke alarm will be used as a reference stimulus in Study 4. In order to maintain the same experimental design across these studies, a fourth alarm type will be introduced. This fourth alarm will be a hybrid of the low-frequency 520 Hz square wave tone smoke alarm and the voice alarm, i.e., the stimulus will begin with the 520 Hz square wave tone in a T-3 pattern followed by the voice script, with this stimulus being repeated until the subject completes the escape procedure.
62449117|NCT02508961|ACTIVE_COMPARATOR|Print-out exercise programme|Participants receive printed exercise programme to complete twice per week. Exercises can be a combination of aerobic, strengthening and balance exercises. Participants receive a weekly phone call from a physiotherapist for the first two weeks to check on progress. Participants complete a paper exercise diary and after the first 2 weeks if they require a progression to their exercise programme they contact their physiotherapist.
62449118|NCT03262298|EXPERIMENTAL|anti-CD22 CAR-T|Patients will receive a full dose CART infusion at day 0.
62623203|NCT02874716|EXPERIMENTAL|Tuberculosis Program (PPIA)|In Patna, 171 of the 321 participants were randomly selected to be sensitized and engaged into the program in Phase 1, and subsequently to receive the benefits of the PPIA intervention. Providers in the PPIA arm if engaged into the program will receive the benefits of the program, including but not limited to: ability to provide presumptive TB patients and TB cases vouchers for free or subsidized diagnostic testing and free first line anti-TB treatment (TB cases only); reimbursements for subsidized tests and anti-TB treatment; financial incentives to providers based on certain indicators; training opportunities, and access to a referral network.
62449119|NCT00546390|EXPERIMENTAL|Ischemic Preconditioned Group (rIP)|A 15-cm sterile blood pressure cuff was placed around the right thigh and connected to the inflating device, and the patient was draped obscuring the visibility of the cuff. Subsequently, the patient was randomly allocated (by opening of an envelope) to RIPC consisting of four 5-min cycles of lower limb ischemia-reperfusion induced by a tourniquet inflated to 300 mmHg
62623204|NCT02874716|NO_INTERVENTION|No Tuberculosis Program (Non-PPIA)|The remaining part of the sample in Patna selected randomly will be phased into the program at least a year after the PPIA arm in Phase 2. However, during the year of the study, they will not be engaged into the program.
62623205|NCT03769701|ACTIVE_COMPARATOR|Group 1, SMGC four times/day|Women with GDM and SMGC 4 times/day; fasting and 1-hour post-prandial of breakfast, lunch and dinner
62623206|NCT03769701|EXPERIMENTAL|SMGC two times/day|Women with GDM and SMGC 2 times/day; pre-prandial and 1-hour post-prandial of breakfast, lunch or dinner alternating the meal each day.
62623207|NCT01994421|SHAM_COMPARATOR|Kinesiotape|
62623208|NCT03491787||Ultrasound guidance|The ultrasound guidance was used to establish intraosseous access
62623209|NCT03491787||Not ultrasound guidance|The ultrasound guidance was not used to obtain intraosseous access
62623210|NCT01220726|ACTIVE_COMPARATOR|Botox|200U onabotulinumtoxinA (botox)
62623211|NCT01220726|PLACEBO_COMPARATOR|Placebo|200U Saline
62623212|NCT01269099|ACTIVE_COMPARATOR|Control|Control-group
62623213|NCT01269099|EXPERIMENTAL|IV-PCA|IV-PCA group
62623214|NCT02099383|ACTIVE_COMPARATOR|normal saline, bolus|Patients of study group will receive intravenous normal saline 20cc per kilogram of body weight, one third of which will be given as a bolus followed by delivery of the remaining two third as a constant infusion over a period of 8 hours.
62623215|NCT02099383|NO_INTERVENTION|normal saline, control|Patients of control group will receive intravenous normal saline 60 cc per hour.
62623216|NCT03682289|EXPERIMENTAL|Arm I (Ceralasertib Monotherapy)|As monotherapy ceralasertib will be given at a starting dose of 160 mg two times per day (BID), on days 1-14 of a 28-day cycle for participants who are BAF250a negative or show an ATM-Mutation by CLIA assay. Treatment will continue until disease progression, unacceptable toxicity, or participant withdrawal from study, whichever occurs first.
62449120|NCT00546390|NO_INTERVENTION|No Cuff|No rIP
62623217|NCT03682289|EXPERIMENTAL|Arm II (Ceralasertib, Olaparib)|In combination with olaparib, ceralasertib will be given at a continuous daily dose of 160 mg daily days 1-7 in each 28-day cycle. Olaparib will be given at a starting dose of 300 mg twice daily days 1-28 of a 28-day cycle for participants who are BAF250a positive. Treatment will continue until disease progression, unacceptable toxicity, or participant withdrawal from study, whichever occurs first.
62449121|NCT04299997||171 mpMRIs corresponding to consecutive patients who underwent|The mpMRIs were performed on a 1.5T GE MR unit or on a 3T GE or Philips MR units. All mpMRIs included T2-weighted imaging, diffusion-weighted imaging (maximal b value: 2000 s/mm²) and dynamic contrast-enhanced imaging.
62623218|NCT03682289|EXPERIMENTAL|Arm III (Ceralasertib, Durvalumab)|In combination with durvalumab, ceralasertib will be given at a continuous daily dose of 240 mg BID days 1-7 of a 28-day dosing schedule. Durvalumab will be given at a flat dose of 1500 mg IV on day 8 of a 28-day cycle for participants with histologically confirmed endometrial cancers. Participants treated with the combination of ceralasertib plus durvalumab may continue treatment beyond first radiographic progression until the occurrence of either confirmed radiographic progression or clinical progression, whichever occurs first.
62623219|NCT01651975|OTHER|Thickenup|
62061542|NCT03583645|OTHER|Educational intervention|1 hour educational intervention (about the human brain) consisting on several tasks to be completed on paper individually.
62449122|NCT02767193|EXPERIMENTAL|DCV3|Autologus differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus
62623802|NCT04676724|EXPERIMENTAL|GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks)|Participants on stable NA therapy received 300 milligrams per week (mg/week) GSK3228836 for 24 weeks (plus a loading dose on Day 4 and 11), followed by Pegylated Interferon (PegIFN) 180 microgram per week (mcg/week) up to 24 weeks.
62449123|NCT02767193|EXPERIMENTAL|DCV3 with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus with PEG-INF
62449124|NCT02767193|PLACEBO_COMPARATOR|CD placebo|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded
62623220|NCT03122873||Myelopathy of any cause|Male or female 18 years or older with myelopathy and detectable finger extension weakness due to 1) prototypic multiple sclerosis (N=50) 2) other etiologies of myelopathy (N=50), including other inflammatory conditions (e.g. idiopathic transverse myelitis, neuromyelitis optica, acute disseminated encephalomyelitis, sarcoidosis) or other etiologies (compression, vascular disorders, degenerative disorders, neoplasms).
62623221|NCT03122873||Peripheral neuropathy|Male or female 18 years or older with C7 radiculopathy, radial neuropathy, plexopathy, peripheral neuropathy, who have detectable finger extension weakness.
62623222|NCT03122873||Healthy Controls|Male and female 18 year or older with no finger extension weakness and no known neurological conditions.
62623223|NCT03190980|EXPERIMENTAL|5% glucose|neonates will receive 2 ml of 5% glucose before heel prick
62623224|NCT03190980|EXPERIMENTAL|30% glucose|neonates will receive 2 ml of 30% glucose before heel prick
62623225|NCT03190980|PLACEBO_COMPARATOR|Placebo|neonates will receive 2 ml of sterile water before heel prick
62623226|NCT05691777||Healthy participants|right handed healthy participants aged between 18 and 40.
62623227|NCT00715871|EXPERIMENTAL|Active Smokers|Active smokers who used the Smoke-Break nicotine delivery device in an attempt to quit smoking cigarettes.
62623228|NCT01709409|EXPERIMENTAL|Curosurf (Group 1)|Surfactant(Curosurf in this arm) is given for treatment of RDS after the diagnosis has been made by the Neonatologist. The treatment dose for Curosurf® is 2.5 ml/kg (200mg/kg) for the first dose and 1.25 ml/kg (100mg/kg) for repeat doses, given by endotracheal method. There is a maximum of 3 doses in the study.
62623229|NCT01709409|ACTIVE_COMPARATOR|BLES (Group 2)|Surfactant(BLES in this arm) is given for treatment of RDS after the diagnosis has been made by the Neonatologist. For BLES the recommended dose is 5 ml/kg. given by endotracheal method. There is a maximum of 3 doses in the study.
62623230|NCT02649517|OTHER|chronic inflammation|All patients will be held PCI to exclude ischemic heart failure decompensation. Also, all patients will be performed endomyocardial biopsy.
62623231|NCT06415474|OTHER|Phenotyping arm|There is only one arm in the study. All patients (i.e. our 4 target populations) will undergo the same phenotyping procedure.
62848910|NCT06533436|OTHER|Caregivers|The caregivers will be included as a study population. Caregivers will conduct the search for the other two arms (ancofast and by cord) and then fill in questionnaires assessing the workload and comfort of tube care.
62848911|NCT00369291|EXPERIMENTAL|CpG 7909|Patients treated with CpG 7909 oligodeoxynucleotides (ODNs) after autologous transplantation to enhance immune reconstitution.
62449125|NCT02767193|PLACEBO_COMPARATOR|CD placebo + PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded with PEG-INF
62623232|NCT04581018|ACTIVE_COMPARATOR|Health supplements + standard care|28 days of health supplements (Synbiotic) daily plus standard care
62623233|NCT04581018|NO_INTERVENTION|Standard care|No intervention
62623234|NCT04769674|EXPERIMENTAL|STAR intervention|Each research participant will receive individual 30-minute therapy sessions two times per week for fifteen weeks. Fifteen weekly ten-minute consultations with the teacher will also be conducted for each participant.
62623235|NCT06065189|EXPERIMENTAL|CS-101 injection|Autologous CD34+(cluster of differentiation 34) hematopoietic stem cell suspension modified by in vitro base editing technique
62848912|NCT00859456|EXPERIMENTAL|Sunitinib|Patients with unresectable or metastatic angiosarcoma, epithelioid sarcoma-like hemangioendothelioma and Kaposi's sarcoma, either receiving Sunitinib as first-line therapy or failure after no more than 2 prior chemotherapy regimens.
62848913|NCT03298971||Survivors of Childhood Osteosarcoma|Survivors of Childhood Osteosarcoma were invited to fill in a set of questionnaires.
62848914|NCT03298971||Healthy Subjects|Healthy Subjects were invited to fill in a set of questionnaires.
62449126|NCT05370521|EXPERIMENTAL|Treatment with Tildacerfont|Subjects randomized in this arm will receive 4 weeks of 50mg of oral tildacerfont tablet, followed by 4 weeks of 100 mg oral tildacerfont tablet, and then 4 weeks of 200 mg oral tildacerfont tablet for a total of 12 weeks of treatment.
62449127|NCT05370521|PLACEBO_COMPARATOR|Placebo Control Arm|Subjects randomized in this arm will receive 12 weeks of oral matched-placebo tablet
62623236|NCT03328442|EXPERIMENTAL|Vista technique|The vista technique with PRF membrane uses a Vestibular incision subperiosteal tunnel access in combination with Platelet rich fibrin membrane to treat gingival recession defects.
62848915|NCT00301613|ACTIVE_COMPARATOR|Mycophenolate mofetil|
62623237|NCT03328442|ACTIVE_COMPARATOR|modified coronally advanced flap|A modified coronally advanced flap utilising Platelet rich fibrin membrane to treat gingival recession defects.
62623238|NCT04927923|ACTIVE_COMPARATOR|hope-focused motivational interview-experimental group|"* Volunteering to participate in research~* Being over the age of 18~* Being able to read and write"
62623239|NCT04927923|NO_INTERVENTION|control group|"* Volunteering to participate in research~* Being over the age of 18~* Being able to read and write"
62623240|NCT03945071|ACTIVE_COMPARATOR|Puntal plug|Subjects will receive temporary punctal plug after intravitreal injection
62623241|NCT03945071|NO_INTERVENTION|Non-Punctual plug|Subjects will not receive temporary punctal plug after intravitreal injection
62265740|NCT01169155|ACTIVE_COMPARATOR|Study 1. Maternal Voice Smoke Alarm Characteristics|"Study 1. Identification of Specific Maternal Voice Smoke Alarm Characteristics Associated With Awakening and Escaping.~Using a randomized, non-blinded, repeated measures, clinical intervention design, Study 1 will identify the critical elements (i.e., use of child's first name and/or behavior commands in message content) in the maternal voice signal that are significantly associated with EEG-defined awakening (and completion of simulated escape behaviors by children after awakening from S4). A conventional residential tone smoke alarm meeting current NFPA 72 National Fire Alarm Code will be used as a reference stimulus to allow comparison of responses to the voice alarm stimuli with responses to a conventional residential tone alarm stimulus."
62623242|NCT04936178|EXPERIMENTAL|Dose Escalation Phase and Dose Expansion Phase|"Dose escalation cohort:~NB003 tablets will be administered orally twice daily for repeated 28-day cycles until discontinuation criteria are met.~RP2D: one or more putative RP2D(s) will be explored in dose escalation phase with approximately 15 patients for each provisional RP2D(s)~Dose expansion phase:~In the dose expansion phase, additional patients will be enrolled at RP2D to further explore the safety, tolerability, PK, efficacy and biological activity of NB003 in specific disease cohorts, including GIST and other malignancies harboring genomic alterations of KIT or PDGFRα."
62623243|NCT01087203|EXPERIMENTAL|Tanezumab|
62623244|NCT01087203|PLACEBO_COMPARATOR|Placebo|
62623245|NCT04687540|PLACEBO_COMPARATOR|Study day 1 (study visit 1)|Baseline measurements (pre-intervention) are obtained on study visit 1.
62623246|NCT04687540|ACTIVE_COMPARATOR|Study day 21 (study visit 2)|Post-intervention measurements: Participants will be under the influence of tocilizumab, which was injected at the end of study visit 1.
62623247|NCT06584812|OTHER|Tiprogrel-Clopidogrel-Ticagrelor|Period 1: Dose 1 Tiprogrel; Period 2: Dose 2 Tiprogrel ; Period 3: Clopidogrel; Period 4: Ticagrelor
62623248|NCT03418142|EXPERIMENTAL|Priovi|Priovi is an Internet-administered intervention for people with BPD.
62848916|NCT02683603|ACTIVE_COMPARATOR|aerosolised (AS) colistin group|"the intervention was: AS colistin and imipenem. the drug administered was colimycin (colistin) powder 1 million units (MU) by a flakon (Sanofi Winthrop Industry) at the dosage of 4 million units (MU) for 30 minutes 3 times per day for at least 14 days in addition to IV imipenem 1 g three times per day. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland). Inhaled colimycin® requires specific settings of the ventilator to limit turbulence inspiratory flow. The adjustment consisted in a volume controlled mode with a Tidal volume \<8 ml / kg, respiratory rate at 12 cycles / min, I / E: 1/1 and an end inspiratory break \> 20%."
62449128|NCT03089398|ACTIVE_COMPARATOR|Hybrid Coronary Revascularization Group|HCR is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization, combined with percutaneous revascularization of at least one non-LAD target.
62449129|NCT03089398|ACTIVE_COMPARATOR|Percutaneous Coronary Intervention|PCI will be performed using standard techniques at the discretion of the operator. Only Food and Drug Administration (FDA) and Health Canada approved commercially available metallic drug-eluting stents may be used in this protocol.
62623249|NCT03418142|ACTIVE_COMPARATOR|Care-as-Usual (CAU) / wait list|Additionaly, they will be informed about helpful and free available online self-help-proposals for BPD patients immediately after randomization.
62623250|NCT05869396||echocardiogrpahy|Patients with with previously unknown systolic murmurs, unstable cardiovascular clinical conditions, recent (within 6 months) de-compensation of heart failure or hospital admission for coronary disease (high-risk group).
62623251|NCT05869396||non echocardiography|Patients without previously unknown systolic murmurs, unstable cardiovascular clinical conditions, recent (within 6 months) de-compensation of heart failure or hospital admission for coronary disease (low-risk group).
62449130|NCT01497236|EXPERIMENTAL|Experimental: Ready to Use Terapeutic Food (RUTF)|
62449131|NCT01497236|EXPERIMENTAL|Multi Micronutrient Powder (MNP)|
62449132|NCT01497236|NO_INTERVENTION|no supplement|
62449133|NCT05317156|EXPERIMENTAL|Prone position-Cold vapor group|Cold vapor will be applied to the prone position experimental group patients for 15 minutes in the recovery room. For the study, Nebtime UN600A Ultrasonic Nebulizer Device will be used to apply cold steam to the patients which used in the hospital and calibrated (https://elmaslarmedikal.com.tr/urunler/nebtimeun600aultrasonik-nebulizator/). The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5 (1-10), air blowing intensity 5 (1-10), heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
62449134|NCT05317156|EXPERIMENTAL|Supine position-Cold vapor group|Cold vapor will be applied to the supine position experimental group patients for 15 minutes in the recovery room. For the study, Nebtime UN600A Ultrasonic Nebulizer Device will be used to apply cold steam to the patients which used in the hospital and calibrated (https://elmaslarmedikal.com.tr/urunler/nebtimeun600aultrasonik-nebulizator/). The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5 (1-10), air blowing intensity 5 (1-10), heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
62623252|NCT06218342|EXPERIMENTAL|Henagliflozin|Participants in this group will receive a combination of lifestyle intervention, background medication, and Henagliflozin. The choice of hypoglycemic drugs within the background medication is restricted to either one, two, or three among metformin, DPP-4 inhibitors, alpha-glucosidase inhibitors, or secretagogues.
62623253|NCT06218342|OTHER|Control|Participants in this group will receive lifestyle intervention and background medication. The choice of hypoglycemic drugs within the background medication is restricted to either one, two, or three among metformin, DPP-4 inhibitors, alpha-glucosidase inhibitors, or secretagogues.
62623254|NCT01299896|ACTIVE_COMPARATOR|Usual Care|Participants will continue to receive all the care currently offered in the VAPHS, including medications for smoking cessation and use of the in-person or telephone counseling options for quit smoking classes. For veterans with a co-pay, incurred fees with be reimbursed.
62265741|NCT01169155|ACTIVE_COMPARATOR|Study 2. Mother's Versus Stranger's Voice Alarms & Alarm Freq.|"Study 2. Comparison of Mother's Versus Stranger's Voice Smoke Alarms and Alarm Frequency.~Study 2 will take the voice alarm script that was the most successful in Study 1 in awakening and prompting children to perform the simulated escape behaviors, and will compare mother's voice to a female stranger's voice using this script. This will determine whether mother's voice is a critical factor for success of the voice smoke alarm. In addition, a Temporal-Three (T-3) pattern smoke alarm with dominant tones in lower frequency ranges similar to the human voice range will be included as a stimulus in Study 2 to evaluate the influence of alarm signal frequency on EEG-defined awakening (as well as completion of simulated escape behaviors by children after awakening from S4). As in Study 1, a conventional residential tone smoke alarm will be used as a reference stimulus in Study 2. This conventional residential tone alarm has a higher frequency signal than the other T-3 tone alarm."
62623255|NCT01299896|ACTIVE_COMPARATOR|Coordinated Care|A CTQ Coordinator will coordinate the delivery of smoking related care.
62623256|NCT05695118|EXPERIMENTAL|non-contrast low-dose abdomen CT|non-contrast low-dose abdomen CT (target effective dose: \< 1.5 mSv). CT based body composition analysis is performedd with commercially available automatic segmentation software (DeepCatch, Medical IP, South Korea).
62623257|NCT05443074|ACTIVE_COMPARATOR|Face to face intervention group|This group will be composed of participants who will receive face to face physiotherapy instruction session.
62623258|NCT05443074|EXPERIMENTAL|Remote intervention group|This group will be composed of participants who will receive real time remote physiotherapy instruction session.
62623259|NCT05443074|ACTIVE_COMPARATOR|Control group|This group will be composed of participants who will not receive any type of physiotherapy instruction session during the period of the study.
62623260|NCT02603510|EXPERIMENTAL|SAR342434/Humalog|SAR342434 and Humalog will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.
62623261|NCT02603510|EXPERIMENTAL|Humalog/SAR342434|Humalog and SAR342434 will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.
62623262|NCT00652717|EXPERIMENTAL|1|arm 1 - Ezetimibe 10 mg daily that was added on Statin Therapy (prescribed clinically suitable dose by the physician).
62848917|NCT02683603|ACTIVE_COMPARATOR|intravenous (IV) colistin goup|"the intervention was: IV colistin and imipenem. the intravenous (IV) colistin goup received IV colimycin (colistin) as a loading dose of 9 MU during 60 minutes followed by 4.5 million units 2 times per day in addition to IV imipenem 1 g three times per day."
62848918|NCT04304638||Radiation(Chemo-radiation)|Patients in this group had been treated with definitive radiation/Chemo-radiation followed by no treatment until progression.
62848919|NCT04304638||radiation+EGFR-TKI|Patients in this group had been treated with one of the following three ways: 1) definitive radiation and concurrent EGFR-TKI followed by EGFR-TKI till progression; 2) EGFR-TKI followed by radiation and continue TKI util progression; 3) radiation and TKI thereafter until progression.
62848920|NCT04304638||EGFR-TKI|Patients in this group had been treated with EGFR-TKI without any other treatment until progression.
62848921|NCT02766582|EXPERIMENTAL|Chemotherapy combined with pembrolizumab|"Single arm study:~Pembrolizumab IV every 21 days (200 mg) Carboplatin IV every 21 days Paclitaxel IV infusion (80 mg/m2) every 7 days for 6 cycles Followed by 12 months pembrolizumab IV every 21 days"
62848922|NCT00838032|EXPERIMENTAL|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
62623263|NCT00652717|ACTIVE_COMPARATOR|2|arm 2- simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
62623264|NCT04636411|EXPERIMENTAL|Intervention group|This group group will receive oral magnesium supplementation (250 mg of elemental magnesium daily for three months) plus the standard care for diabetic patients
62623265|NCT04636411|ACTIVE_COMPARATOR|Control group|This group will receive the standard care for diabetic patients
62623266|NCT03363685||Low risk|For NSCLC spinal metastasis patients with 0-3 of novel survival prediction algorithm.
62623267|NCT03363685||Intermediate risk|For NSCLC spinal metastasis patients with 4-6 of novel survival prediction algorithm.
62623268|NCT03363685||High risk|For NSCLC spinal metastasis patients with 7-10 of novel survival prediction algorithm.
62623269|NCT03173456|ACTIVE_COMPARATOR|oxycodone/acetaminophen (APAP)|5 mg oxycodone + 325 mg acetaminophen
62623270|NCT03173456|ACTIVE_COMPARATOR|hydrocodone/APAP|5 mg hydrocodone + 300 mg acetaminophen
62623271|NCT03173456|ACTIVE_COMPARATOR|codeine/APAP|30 mg codeine + 300 mg acetaminophen
62623272|NCT03173456|ACTIVE_COMPARATOR|400 ibuprofen/APAP|400 mg ibuprofen + 1000 mg acetaminophen
62623273|NCT03173456|ACTIVE_COMPARATOR|800 ibuprofen/APAP|800 mg ibuprofen + 1000 mg acetaminophen
62623274|NCT05446532||Not apply|None. Just registration epidemiology dates
62623275|NCT05977868|EXPERIMENTAL|Group 1 (Experimental)|COpAT (oral antimicrobial therapy) on hospital discharge
62623276|NCT05977868|ACTIVE_COMPARATOR|Group 2 (Control)|Standard of care (IV antimicrobial therapy) on hospital discharge
62623277|NCT04474054|EXPERIMENTAL|FARAPULSE Ablation System Plus|Ablation using the FARAPULSE Ablation System Plus
62265742|NCT01169155|ACTIVE_COMPARATOR|Study 5. Male Voice and Hybrid Tone/Voice Alarm for Children|Study 5. Children 5-12 Years of Age (Testing Male Voice and Hybrid Tone/Voice Alarm) Using a randomized, non-blinded, repeated measures, clinical intervention design, our two working hypotheses as stated in Specific Aims 1 and 2 will be tested in Study 5 among children 5-12 years of age using the following 4 alarm stimuli: female stranger's voice, male stranger's voice, hybrid of the low-frequency 520 Hz square wave tone smoke alarm and the voice alarm (from Study 4), and conventional high frequency tone residential alarm. This study arm will allow comparison of a male versus female voice and also evaluate the hybrid low frequency tone/voice alarm among children 5-12 years of age. The same protocol will be used for children in this study arm as was used in Studies 1 and 2.
62265743|NCT02984527|ACTIVE_COMPARATOR|water and soap first day|Intimate hygiene performed with water and soap first day and disposable wet wipes second day
62623278|NCT03193333|EXPERIMENTAL|PRO-122 group|"To validate the 3 flasks of the triple therapy will be used 1 bottle with the three active principles (PRO-122) and two placebos and thus comply with the masking.~Drug substances: Timolol 5 mg/mL, brimonidine 2 mg/mL and dorzolamide 20 mg/mL. preservative free.~Pharmaceutical form: Ophthalmic solution~Made by: Laboratorios Sophia, S.A. de C.V.~Posology: 1 drop every 12 hours for 90 days~Description of the solution: clear, visibly particle free, slightly yellow solution, preservative free~* Package description: 5 m multidose dropper bottle.~  * Placebo (for~* Two pieces of approved placebo. Administered in 2 multidose dropper bottles.~* Posology: 1 drop of each dropper bottle every 12 hours for 90 days"
62623279|NCT03193333|ACTIVE_COMPARATOR|Concomitant triple therapy group|"Imot Ofteno~Drug substance: Timolol 5 mg/mL~Pharmaceutical form: Ophthalmic solution~Made by Laboratorios Sophia S.A. de C.V.~Alphagan~Drug substance Brimonidine 2 mg/mL~Pharmaceutical form: Ophthalmic solution~Made by: Allergan, Inc.~Trusopt~Drug substance: Dorzolamide 20 mg/mL~Pharmaceutical form: Ophthalmic solution~Made by: Merck Sharp and Dohme Corp.~Posology: 1 drop every 12 hours for 90 days"
62848923|NCT00838032|ACTIVE_COMPARATOR|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
62848924|NCT06224374||Validity and Reliability|"Participants will be evaluated with the Postural Stability Test, Limits of Stability Test, Sensory Integration Test and Bilateral Comparison Test within the AlBalance and Biodex Balance Evaluation System. To calculate the test-retest reliability and validity of the devices, these measurements will be made by the same evaluator in two sessions, 7 days apart. To eliminate the learning effect, participants who try AlBalance first in the first session will be the first to try Biodex in the second session (reverse test order will be used). Participants who complete all evaluations with the first device will rest for 5 minutes and move on to the other device. Then, parallel clinical tests will be applied to the participants, Functional Reaching Test and One Leg Standing Test. The relationship of outcome measurements between devices and measurements of each test will be evaluated with statistical methods."
62848925|NCT06367712|ACTIVE_COMPARATOR|Group A: letrozole only|About 66 Patients took Letrozole drug only for induction of ovulation at the time of suspected ovulation maturity.
62848926|NCT06367712|ACTIVE_COMPARATOR|Group B: letrozole + HCG|About 66 Patients took Letrozole drug in addition to HCG for induction of ovulation at the time of suspected ovulation maturity.
62848927|NCT02980861|EXPERIMENTAL|Laparoscopic total gastrectomy|Participants including in the laparoscopic total gastrectomy (LTG) group will undergo LTG with spleen-preserving splenic hilum lymph nodes dissection.
62848928|NCT02980861|ACTIVE_COMPARATOR|Open total gastrectomy|Participants who are included in the open total gastrectomy (OTG) group will OTG with spleen-preserving splenic hilum lymph nodes dissection.
62848929|NCT05231213|EXPERIMENTAL|Active tDCS|Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
62848930|NCT05231213|SHAM_COMPARATOR|Sham tDCS|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
62848931|NCT00792493|EXPERIMENTAL|ORM-12741|
62848932|NCT00792493|PLACEBO_COMPARATOR|Placebo|
62848933|NCT04156633||conventional identification methods (controls)|Patients with positive blood cultures from 2016 to 2018 receiving a conventional identification methods (controls). The conventional identification method consisted in general of an over-night subculture and subsequent identification of the bacterial pathogen using either biochemical profiling or MALDI-TOF MS.
62848934|NCT04156633||new identification method (cases)Biofire FilmArray© BCID panel|Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification method is the Biofire FilmArray© Blood Culture Identification (BCID) panel, a polymerase chain reaction-based method, performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies. The assays allow to identify a panel of 20 most commonly Gram-positive and -negative bacteria and yeast causing blood stream infections. It also allows to determine three resistance genes (mecA, vanA/B and KPC).
62848935|NCT04156633||new identification method (cases) WGS approaches|Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification of positive blood cultures methods in a subset of patients is a whole genome sequencing approach. This so called shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene.
62265744|NCT02984527|ACTIVE_COMPARATOR|disposable wet wipes first day|Intimate hygiene performed with wet wipes first day and water and soap second day
62265745|NCT02526459|EXPERIMENTAL|birth plan|Use of birth plan
62265746|NCT02526459|NO_INTERVENTION|no birth plan|No use of birth plan
62265747|NCT01820364|EXPERIMENTAL|LGX818 single agent|Patients had to have written documentation of a BRAFV600 mutation, which was to have been obtained locally on a fresh tumor biopsy (preferred) or on the most recent archival tumor sample available.
62265748|NCT05590260|EXPERIMENTAL|IV iron arm|Which will result in receipt of a single-dose IV iron infusion between 6 and 48 hours after delivery and prior to discharge from the facility; folate tablets per local guidelines.
62265749|NCT05590260|ACTIVE_COMPARATOR|Oral iron comparator arm|Oral iron tablets (containing 60 mg of elemental iron (± folate as per local guidelines)) to be taken at a treatment dose of twice daily for 6 weeks.
62848936|NCT01731938|EXPERIMENTAL|Fibrin Sealant (FS) Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
62848937|NCT01731938|ACTIVE_COMPARATOR|Surgicel®|Surgicel® is a sterile, absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
62848938|NCT02909608||Controls|
62848939|NCT02909608||Children With Pulmonary Hypertension|
62265750|NCT01696526|EXPERIMENTAL|vitamin D fortified fish|Human volunteers receiving vitamin D fortified fish, 4 weeks
62265751|NCT01696526|PLACEBO_COMPARATOR|conventional fish|consumption of conventional fish , 4 weeks
62265752|NCT01539681||Group 1|
62265753|NCT01770132|EXPERIMENTAL|porfimer sodium, EUS-PDT, gemcitabine|Patients receive porfimer sodium IV over 3-5 minutes on day 1 and undergo endoscopic ultrasonography-photodynamic therapy (EUS-PDT) on days 1, 3, 8, and 21. After completion of EUS-PDT, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 of courses 1 and 2 and on day 22 of courses 3 and 5. During courses 1-5, treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After course 5, treatment with gemcitabine hydrochloride repeats every 2 months in the absence of disease progression or unacceptable toxicity.
62265754|NCT01744665|EXPERIMENTAL|Treatment Free Remission|Patients entered a monitoring phase for 2 years and received 300 mg nilotinib mg bid. Patients who achieved MR4.5 entered a Consolidation Phase and were treated with nilotinib for 2 years. If MR4.5 was sustained during the Consolidation phase, patients were eligible to stop taking niltoinib during the treatment-free remission (TFR) phase.
62265755|NCT02563847|ACTIVE_COMPARATOR|0.52 g L-Tryptophan|0.52 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
62265756|NCT02563847|ACTIVE_COMPARATOR|1.56 g L-Tryptophan|1.56 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
62061543|NCT02282410|EXPERIMENTAL|ADVATE standard prophylaxis|This study is a prospective, open-label, interventional, multicenter study in a total of 15 PTPs with hemophilia A (FVIII≤2 %).The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year. Subjects must be prescribed ADVATE by the treating physician. Data will be collected over a period of 2 years from the time of study enrollment. Study visits are to coincide with routinely rescheduled and emergency visits. Available data from these visits shall be transcribed onto the case report forms (CRFs).
62061544|NCT06449716|EXPERIMENTAL|Individualized resistance exercise program|Individualized exercise dose. Individuals with a velocity deficit only perform low-load exercises. Individuals with a force deficit only perform high-load exercises.
62265757|NCT02563847|ACTIVE_COMPARATOR|1.56 g L-Leucine|1.56 g L-Leucine in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
62061545|NCT06449716|ACTIVE_COMPARATOR|Non-individualized resistance exercise program|Non-individualized exercise dose. All individuals perform a combination of low-load and high-load resistance exercises, regardless of their deficit.
62061546|NCT05058209|ACTIVE_COMPARATOR|Arm 1|Triamcinolone acetonide extended-release injectable suspension. Single intra-articular extended-release injection of triamcinolone acetonide, to deliver 32 mg (5 mL). For intra-articular use only and should not be administered by the following routes: epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, subcutaneous.
62061547|NCT05058209|ACTIVE_COMPARATOR|Arm 2|Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL, 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. When oral therapy is not feasible, the Injectable Suspension is indicated for intramuscular use only.
62061548|NCT06324019|EXPERIMENTAL|Developing Gynecological Examination Dress|Gown will be put on the patient before gynaecological examination and their satisfaction will be evaluated
62061549|NCT05779306||Carlevale|Patients who had a Carlevale lens implanted
62449135|NCT05317156|NO_INTERVENTION|Prone position-Control group|Patients in the prone position control group will receive standard care that includes all medical and non-medical treatments in the hospital. Nursing care, which is routinely applied to patients in the postoperative period, both in the recovery room and in the service, will be continued within the standard care. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia when they come to the recovery room and at the 6th,12th, and 24th hours after the surgery in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
62848940|NCT05983081|EXPERIMENTAL|Injection Treatment|A- Experimental Group: Intra-articular Hyaluronic Acid Injection Treatment Regimen Patients in the experimental group received ultrasound-guided intra-articular injections of hyaluronic acid (Artibest, 60 mg/3 ml, 2%, manufactured by Kang Stem Biotech, Taiwan) into the affected shoulder joint. The injections were administered once a week for three consecutive weeks, totaling three injections per patient. The subjects were evaluated for shoulder function using the Shoulder Pain and Disability Index (SPADI) and Range of Motion (ROM) assessment at the following time points: before the treatment, 4 weeks after the treatment, 6 weeks after the treatment, and 8 weeks after the treatment.
62848941|NCT05983081|NO_INTERVENTION|Physical Therapy|B- Control Group: Physical Therapy Patients in the control group underwent a 6-week physical therapy program, consisting of two sessions per week, with each session lasting approximately 30 minutes. The physical therapy program was conducted under the guidance and supervision of a physical therapist and included joint exercises, stretching, and muscle strengthening exercises.
62848942|NCT00147069||Controls|Non-smoking control subjects without lung disease
62848943|NCT00147069||Asthmatics|Non-smokers patients with asthma
62848944|NCT00147069||Non-COPD smokers|Current smokers without airways obstruction, FEV1 \>80% predicted
62848945|NCT00147069||COPD smokers|Patients with COPD and cigarette smokers
62848946|NCT02637349|EXPERIMENTAL|POST SCP|Patient receives Survivorship Care Plan (SCP) after active treatment ends. It will be discussed with the patient. SCP includes medical and psychosocial history, medical contact information, 5-year follow-up plan and educational materials.
62848947|NCT02637349|ACTIVE_COMPARATOR|POST TAU|Patient receives treatment as usual (TAU) after active treatment ends.
62848948|NCT02061839|EXPERIMENTAL|Teinted sunscream|UVA, UVB and visible light protection (exactly the same UVA and UVB protection as the comparator)
62848949|NCT02061839|ACTIVE_COMPARATOR|Regular sunscream|UVA and UVB protection
62848950|NCT05664568|ACTIVE_COMPARATOR|Standard of care TB|Standard of care treatment for TB (rifampicin, isoniazid, ethambutol and pyrazinamide according to WHO)
62848951|NCT05664568|EXPERIMENTAL|Cephalexin + amoxicillin-clavulanate|Intervention arm: cephalexin 1g thrice daily + amoxicillin-clavulanate 500/125 mg thrice daily.
62848952|NCT03211052|EXPERIMENTAL|TAK-700 + LHRH agonist + Prostatectomy|Neoadjuvant TAK-700 for 6 months with LHRH agonists prior to prostatectomy
62848953|NCT03211052|OTHER|Prostatectomy|Prostatectomy only-Within 28 days of randomisation
62848954|NCT00615901|EXPERIMENTAL|1|This is a pilot study using 8 cycles of CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2), at 14 day intervals supported by PEG-filgrastim for a cohort of 38 patients. A safety analysis will then be performed.
62848955|NCT02078960|EXPERIMENTAL|Omacetaxine mepesuccinate.|The study will consist of up to a 7-day screening period, and treatment for up to 12 months, in Phase 1 and Phase 2 portions, depending on response and tolerability. Patients will also have an end-of-treatment follow-up visit approximately 28 days after the last dose of omacetaxine. Each patient will be monitored for progression and survival for at least 1 year after their last dose of omacetaxine, death, or lost to follow-up, whichever comes first, regardless of patients receiving other anticancer treatment.
62848956|NCT01623557|ACTIVE_COMPARATOR|Group 1: ChAd63-MVA CS|1 dose of ChAd63 CS 5 x 10\^10 vp intramuscularly and 1 dose MVA CS 2 x 10\^8 pfu intramuscularly 8 weeks later.
62848957|NCT01623557|ACTIVE_COMPARATOR|Group 2: ChAd63-MVA ME-TRAP|1 dose of ChAd63 ME-TRAP 5 x 10\^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10\^8 pfu intramuscularly 8 weeks later.
62265758|NCT02563847|ACTIVE_COMPARATOR|50 g Xylitol|50 g Xylitol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
62265759|NCT02563847|ACTIVE_COMPARATOR|75 g Erythritol|75 g Erythritol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
62623280|NCT03193333|ACTIVE_COMPARATOR|Krytantek Ofteno Group|"To validate the three flasks of the triple therapy will be used 1 bottle with the three active principles (Krytantek) and two placebos and thus comply with the masking.~Drug substances: Timolol 5 mg/mL, brimonidine 2 mg/mL and dorzolamide 20 mg/mL.~Pharmaceutical form: Ophthalmic solution~Made by: Laboratorios Sophia, S.A. de C.V.~Posology: 1 drop every 12 hours for 90 days~Description of the solution: clear, visibly particle free, slightly yellow solution Package description: 5 m multidose dropper bottle.~Placebo (for two pieces of approved placebo. Administered in 2 multidose dropper bottles.~Posology: 1 drop of each dropper bottle every 12 hours for 90 days"
62623281|NCT03955588||Women undergoing invasive prenatal diagnostic procedures|For women requiring invasive prenatal diagnosis by chorionic villus sampling or amniocentesis, they will be offered the options of having either conventional cytogenetics or aCGH.
62623282|NCT02999841|EXPERIMENTAL|Group A|Acarbose
62623283|NCT02999841|ACTIVE_COMPARATOR|Group B|Vildagliptin
62623284|NCT05955144|OTHER|Repeatable bilirubin measurement independent of phone|all subjects will receive bilirubin measurement from 4 different smartphones and a transcutaneous device to ensure that the measurement of bilirubin is not affected by phone camera
62848958|NCT01623557|ACTIVE_COMPARATOR|Group 3: Unvaccinated Infectivity Controls|
62848959|NCT06143930|ACTIVE_COMPARATOR|The control group (A) will receive therapeutic strengthening training program for lower extremities.|low intensity strengthening exercise program
62848960|NCT06143930|ACTIVE_COMPARATOR|The study group (B) will receive strengthening training with blood flow restriction|the same selected low intensity resisted exercise program as group (A) with blood flow restriction
62848961|NCT00801619||Intervention|Receive decision support when reviewing bilirubin results in the clinical information systems/electronic health record
62265760|NCT02563847|PLACEBO_COMPARATOR|75 g Glucose|75 g Glucose in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
62848962|NCT00801619||Control|No decision support
62265761|NCT02563847|PLACEBO_COMPARATOR|Tap water|300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
62265762|NCT02951871||LP: Lymphoma Progression|
62265763|NCT02951871||TRM: Treatment Related Mortality|
62623285|NCT06359197|EXPERIMENTAL|Caffeine - Phase 1|The sample size of this arm is 5 participants. In this arm, participants will have to come to the Population Health Research Institute building to complete study procedures. They will undergo an overnight fast of at least 8 hours, then undergo blood collection by intravenous sampling, as well as by the TASSO+ device and finger prick and collection on Whatman Protein 903 Saver Cards. They will then ingest a 400mg dose of caffeine and remain fasted for the following 6 hours. At 3 hours and 6 hours post caffeine consumption, participants will have their blood collected in the same manner as the initial blood collection.
62061550|NCT05779306||Yamane|Patients who had a lens implanted using Yamane technique
62623803|NCT04676724|EXPERIMENTAL|GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks)|Participants on stable NA therapy received 300mg/week GSK3228836 for 12 weeks (plus a loading dose on Day 4 and 11), followed by PegIFN 180 mcg/week up to 24 weeks.
62623804|NCT02802696|EXPERIMENTAL|Furosemide|Diuretic
62623805|NCT02802696|PLACEBO_COMPARATOR|Placebo|Normal saline
62848963|NCT00830895|EXPERIMENTAL|RAD001|RAD001 10mg/day
62848964|NCT04519242|ACTIVE_COMPARATOR|Patients enrolled in the ORIF group|Open reduction and internal fixation (ORIF), ORIF will be done by using bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS). For fixation, TMT4 and/or TMT5 K-wires (1.6 or 2.0mm) can be used instead.
62061551|NCT02364180|OTHER|Electromyography|Subjects taking pyridostigmine bromide for more than 6 weeks for a condition other than myasthenia gravis were observed with Electromyography (EMG)
62061552|NCT01996358|ACTIVE_COMPARATOR|Succinylcholine|Succinylcholine 0,5mg/kg as muscle relaxant during induction of anaesthesia for rigid bronchoscopy
62848965|NCT04519242|ACTIVE_COMPARATOR|Patients enrolled in the PA group|PA will be done by removal of the articular surface and subsequent stabilization with bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS).
62848966|NCT01540955|EXPERIMENTAL|Group Intervention program|
62848967|NCT01540955|NO_INTERVENTION|Wait-list control group|The wait-list-control group will also be able to participate in the group intervention, but not until after all the study visits have been completed.
62848968|NCT02467426||Chemotherapy|intraarterial chemotherapy with cisplatin and mitoxantrone
62848969|NCT04491071||Volunteers|volunteers over 18 years of age
62848970|NCT00262054|EXPERIMENTAL|A|bivalirudin is to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
62061553|NCT01996358|ACTIVE_COMPARATOR|Rocuronium 0,3|Rocuronium 0,3 mg/kg during induction of anaesthesia for rigid bronchoscopy. At the end of procedure 2mg/kg sugammadex for reversal of neuromuscular block are applied.
62265764|NCT02951871||NHM: Non hematologic malignancy|
62265765|NCT02951871||OC: Other Cause|
62265766|NCT05479214|EXPERIMENTAL|Metformin Group|will include 75 patients who will be treated with metformin ( 1gm with the 2 main meals ) combined with insulin therapy
62265767|NCT05479214|EXPERIMENTAL|Insulin alone group|will include 75 patients who will be treated with insulin alone
62265768|NCT02282943|ACTIVE_COMPARATOR|Laser|vapourisation/excision of endometriosis using CO2 laser
62265769|NCT02282943|EXPERIMENTAL|Harmonic scalpel|excision of endometriosis using Harmonic scalpel
62265770|NCT05209633|EXPERIMENTAL|Active treatment (Granules Dendrobii)|6g each, 3 times per day, total 18 weeks
62265771|NCT05209633|PLACEBO_COMPARATOR|Placebo|6g each, 3 times per day, total 18 weeks
62265772|NCT01616407|EXPERIMENTAL|MDMA, methylphenidate, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but three treatment conditions in the same subject.
62265773|NCT00337870|EXPERIMENTAL|Treatment|50% randomized to receive distraction intervention during painful procedure
62061554|NCT01996358|ACTIVE_COMPARATOR|Rocuronium 0,6|Rocuronium 0,6 mg/kg during induction of anaesthesia for rigid bronchoscopy. At the end of procedure 2mg/kg sugammadex for reversal of neuromuscular block are applied.
62623286|NCT06359197|PLACEBO_COMPARATOR|Control - Phase 1|The sample size of this arm is 5 participants. In this arm, participants will have to come to the Population Health Research Institute building to complete study procedures. They will undergo an overnight fast of at least 8 hours, then undergo blood collection by intravenous sampling, as well as by the TASSO+ device and finger prick and collection on Whatman Protein 903 Saver Cards. They will then ingest 2 placebo pills and remain fasted for the following 6 hours. At 3 hours and 6 hours post caffeine consumption, participants will have their blood collected in the same manner as the initial blood collection.
62623287|NCT06359197|EXPERIMENTAL|Caffeine - Phase 2|The sample size of this arm is 13 participants. In this arm, participants will remain at home to complete study procedures. They will undergo an overnight fast of at least 8 hours, then self-collect blood using the TASSO+ device. They will then ingest a 400mg dose of caffeine and remain fasted for the following 6 hours. At 3 hours and 6 hours post caffeine consumption, participants will collect their blood using the TASSO+ device.
62848971|NCT00262054|ACTIVE_COMPARATOR|B|UFH given as an intravenous bolus of 140 units/kg. Double blinding will be maintained by using a double-dummy technique consisting of identical UFH and bivalirudin syringes and bivalirudin or placebo infusion bags.
62848972|NCT01420094|EXPERIMENTAL|Arm 1|
62848973|NCT01420094|ACTIVE_COMPARATOR|Arm 2|
62848974|NCT01420094|PLACEBO_COMPARATOR|Arm 3|
62848975|NCT04313413|EXPERIMENTAL|Yoga@Work|Yoga sessions specifically designed for office workers were provided in work settings. participants were given handouts and encouraged to practice in their own time and space during work days.
62848976|NCT01490905|ACTIVE_COMPARATOR|Theramine active and ibuprofen placebo|2 capsules Theramine twice daily with one ibuprofen-like placebo once daily.
62848977|NCT01490905|ACTIVE_COMPARATOR|Theramine and Ibuprofen (Theraprofen)|Two capsules Theramine twice daily with Ibuprofen 400mg once daily.
62061555|NCT04006925|ACTIVE_COMPARATOR|Sodium Oxybate (SXB) arm|Sodium Oxybate (SXB) will be dispensed to the participants.
62061556|NCT04006925|PLACEBO_COMPARATOR|Placebo (PBO) arm|Placebo will be dispensed to the participants.
62061557|NCT02206217|NO_INTERVENTION|Single vision spectacle lens|Single vision lens with power for correcting distance refraction.
62265774|NCT00337870|NO_INTERVENTION|Control|50% RANDOMIZED TO RECEIVE NO INTERVENITON
62623288|NCT06359197|PLACEBO_COMPARATOR|Control - Phase 2|The sample size of this arm is 13 participants. In this arm, participants will remain at home to complete study procedures. They will undergo an overnight fast of at least 8 hours, then self-collect blood using the TASSO+ device. They will then ingest 2 placebo pills and remain fasted for the following 6 hours. At 3 hours and 6 hours post caffeine consumption, participants will collect their blood using the TASSO+ device.
62623289|NCT06107855|EXPERIMENTAL|Maximal-intent Resistance Training|The MI group was instructed and encouraged to deliberately commit to exerting maximal effort and force during the concentric phase of the leg press with the intention of achieving the greatest velocity possible.
62848978|NCT01490905|ACTIVE_COMPARATOR|Theramine placebo and Ibuprofen|Two Theramine-like placebo twice daily and one ibuprofen 400mg.
62848979|NCT00528554|ACTIVE_COMPARATOR|A|Active laser acupuncture
62848980|NCT00528554|PLACEBO_COMPARATOR|B|Placebo laser acupuncture
62848981|NCT02298660|EXPERIMENTAL|BOTOX|BOTOX® Total dose per patient: 200U Number of cycles:1 cycle Treatments will be conducted according to established protocol, 200 BOTOX® units with intradetrusor injections under cystoscopic guided injections into 20 sites, trigone sparing. One month later, urodynamics with continuous arterial blood pressure and electrocardiogram measurements will be repeated, as well as 24 hour ambulatory blood pressure monitoring. AD- HR QoL and I-QOL questionnaires will be administered to evaluate the effect of Botox on AD HR-QoL and bladder-related QoL.
62848982|NCT04323579||prospective cohort of stage I-II lung cancer patients|A prospective cohort of stage I-II lung cancer patients (N=80) candidates to surgery at Humanitas, and 40 controls with benign nodules.
62265775|NCT03997955|EXPERIMENTAL|Experimental group|Myofascial induction
62848983|NCT04323579||retrospective screening cohort of 50 patients|A retrospective screening cohort of 50 patients with screened lung cancer at MUG.
62848984|NCT04323579||prospective screening cohort of 30 patients|A prospective screening cohort of 30 patients with screened lung cancer and 100 matched negative controls enrolled at Humanitas cohort of 1000 participants (expected annual rate 1.5%).
62848985|NCT04323579||retrospective screening cohort from the NELSON study|A retrospective screening cohort from the NELSON study.
62848986|NCT04323579||Prospective cohort of stage IV lung cancer patients|A Prospective cohort of stage IV lung cancer patients (N=30) candidate to systemic therapy.
62061558|NCT02206217|EXPERIMENTAL|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus at the same time.
62061559|NCT03371264||Cohort R1 and Cohort T1|Cohort R1 (patients on the waiting list between 2009 and 2013) and Cohort T1 (transplanted patients between 2009 and 2013)
62061560|NCT03371264||Cohort R2 and Cohort T2|Cohort R2 (patients on the waiting list in 2014) and Cohort T2 (transplanted patients in 2014)
62061561|NCT01923805|EXPERIMENTAL|Treatment Group|Vitagel
62061562|NCT01923805|NO_INTERVENTION|Control|Standard of care for surgical hemostasis.
62061563|NCT05480020|ACTIVE_COMPARATOR|Streptococcus salivarius M18 toothpaste dose 1|Streptococcus salivarius M18 toothpaste containing 1 million cfu/g
62061564|NCT05480020|ACTIVE_COMPARATOR|Streptococcus salivarius M18 toothpaste dose 2|Streptococcus salivarius M18 toothpaste containing 10 million cfu/g
62061565|NCT05480020|ACTIVE_COMPARATOR|Streptococcus salivarius M18 toothpaste dose 3|Streptococcus salivarius M18 toothpaste containing 100 million cfu/g
62061566|NCT01032980||HUMENZA Vaccine Group|Participants vaccinated with HUMENZA according to the recommendations provided in the product leaflet and local recommendations.
62061567|NCT01032980||PANENZA Vaccine Group|Participants vaccinated with PANENZA according to the recommendations provided in the product leaflet and local recommendations.
62265776|NCT03997955|SHAM_COMPARATOR|Control group|Sham myofascial induction
62265777|NCT06150235||Chronic hemodialysis patients|patients with chronic hemodialysis
62848987|NCT01699516||Intestinal graft vs host disease|Patients with biopsy-proven intestinal acute GVHD in the setting of an allogenic transplant
62265778|NCT01970501|EXPERIMENTAL|bucindolol hydrochloride|"bucindolol hydrochloride (bucindolol)~Participants were randomized (1:1) to blinded treatment with bucindolol or metoprolol and titrated weekly to target doses of 50 mg twice daily (BID; \< 75 kg) or 100 mg BID (≥ 75 kg) for bucindolol or 200 mg once daily (QD) for metoprolol. 84% of bucindolol participants attained target dose and 72% of metoprolol participants attained target dose.~The lowest starting dose of bucindolol was 6.25 mg BID with weekly dose titrations to the weight-based target dose or to the maximum tolerated dose. The starting dose assigned was based on the patient's beta-blocker treatment prior to randomization. Capsules for titration were available in the following dosage strengths to be taken twice daily (with or without food): 6.25mg, 12.5mg, 25mg, 50mg, and 100mg."
62848988|NCT01699516||Control group|In the setting of an allogenic bone marrow transplant: patients with biopsy-proven stomach GVHD without intestinal symptoms and patients with neutropenic enterocolitis. Normal volunteers.
62265779|NCT01970501|ACTIVE_COMPARATOR|metoprolol succinate|"metoprolol succinate (Toprol-XL)~Participants were randomized (1:1) to blinded treatment with bucindolol or metoprolol and titrated weekly to target doses of 50 mg twice daily (BID; \< 75 kg) or 100 mg BID (≥ 75 kg) for bucindolol or 200 mg once daily (QD) for metoprolol. 84% of bucindolol participants attained target dose and 72% of metoprolol participants attained target dose.~The lowest starting dose of metoprolol was 25 mg QD with weekly dose titrations to the target dose or to the maximum tolerated dose. The starting dose assigned was based upon the patient's beta-blocker treatment prior to randomization. Capsules for titration were available in the following dosage strengths to be taken twice daily (with or without food): 25mg, 50mg, 100mg, 200mg and/or matching placebo oral capsule to maintain blinded dosing."
62265780|NCT03198052|EXPERIMENTAL|CAR-T cell therapy group|Patients will receive 3 or more cycles of the CAR-T cells treatment via systemic or regional injection, from 1x10e6/kg-10x10e6/kg weight.
62265781|NCT02232802|EXPERIMENTAL|Enoxaparin Sodium Chemi|Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.
62848989|NCT05171062|EXPERIMENTAL|Cohort 1|Study patients will receive 0.1-1 mg/kg bexmarilimab (FP-1350) given in combination with Pembrolizumab 200mg IV once every three weeks. The first subject will be started on 0.1mg to establish toleration, for one dose, and then the dose will be escalated to 1mg. This subject will be included in Cohort 1 data.
62265782|NCT02232802|EXPERIMENTAL|Clexane|Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.
62265783|NCT04289844|EXPERIMENTAL|Experimental group|Each session of the intervention will have a duration of 15 minutes of specific training taking place two sessions a week, during a period of 5 weeks. The exercises will be performed in the first 15 minutes of the training session. The intervention will include specific exercises of elastic-explosive strength and resistance strength
62623290|NCT06107855|EXPERIMENTAL|Controlled-tempo Resistance Training|While the CT group followed the metronome for both eccentric and concentric phases.
62623291|NCT01945476|EXPERIMENTAL|midazolam|midazolam group
62848990|NCT05171062|EXPERIMENTAL|Cohort 2|Study participants will receive 3mg/kg Bexmarilimab given in combination with Pembrolizumab 200mg IV once every three weeks. 3 participants will need to complete this level before the next cohort dosing begins.
62848991|NCT05171062|EXPERIMENTAL|Cohort 3|Study participants will receive 10 mg/kg Bexmarilimab plus pembrolizumab 200mg IV once every 3 weeks. 3 participants will need to complete this level before the next cohort dosing begins.
62848992|NCT05171062|EXPERIMENTAL|Cohort 4|Study participants will receive 30 mg/kg Bexmarilimab plus pembrolizumab 200mg IV once every 3 weeks.
62265784|NCT04289844|ACTIVE_COMPARATOR|Control group|Each session of the intervention will have a duration of 10 minutes of specific training taking place two sessions a week, during a period of 5 weeks. The exercises will be performed in the first 15 minutes of the training session. The intervention will include specific exercises of elastic-explosive strength
62265785|NCT05438823|EXPERIMENTAL|İntervention group|The sample of the study will be the parents of children who have had hematopoietic stem cell transplantation at Akdeniz University Hospital and whose discharge is planned (n=20).
62449136|NCT05317156|NO_INTERVENTION|Supine position-Control Group|Patients in the supine position control group will receive standard care that includes all medical and non-medical treatments in the hospital. Nursing care, which is routinely applied to patients in the postoperative period, both in the recovery room and in the service, will be continued within the standard care. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia when they come to the recovery room and at the 6th,12th, and 24th hours after the surgery in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
62449137|NCT01999309|EXPERIMENTAL|Simvastatin|The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
62265786|NCT05438823|NO_INTERVENTION|Control group|The control group will be the parents of children who underwent hematopoietic stem cell transplantation at Akdeniz University Hospital and are planned to be discharged (n=20). Participants in this group will receive routine care, and at the end of the study, training program will be applied.
62265787|NCT03507920|EXPERIMENTAL|Neck passive mobilizations|
62265788|NCT03507920|PLACEBO_COMPARATOR|Manual contact|
62265789|NCT05326542|EXPERIMENTAL|ESWL and ERCP|The patients will receive intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). The time scale between the last ESWL session and following ERCP will be greater than 48h. ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent or a nasopancreatic catheter will be inserted for temporary drainage if necessary.
62265790|NCT05326542|ACTIVE_COMPARATOR|LL and ERCP|ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. After that, laser lithotripsy will be performed. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent or a nasopancreatic catheter will be inserted for temporary drainage if necessary.
62265791|NCT00841789|EXPERIMENTAL|Arm 1 -Etanercept|Drug - Treatment with Etanercept as adjunct to standard treatment with IVIG and aspirin
62265792|NCT00841789|PLACEBO_COMPARATOR|2|Placebo
62265793|NCT01183143|EXPERIMENTAL|GONAL-f®|
62265794|NCT04395339|EXPERIMENTAL|Experimental arm(GM1)|This arm will be treated with GM1.
62265795|NCT04395339|PLACEBO_COMPARATOR|Control arm|This arm will be treat with blank placebo.
62265796|NCT02955615|EXPERIMENTAL|ILT-101|Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12
62265797|NCT02955615|PLACEBO_COMPARATOR|Placebo|Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12
62265798|NCT04503954|EXPERIMENTAL|Self-management group|Self-management group Chronic disease self-management program is conduct training skills, person how to live together with personal chronic disease to make life quality better.
62265799|NCT04503954|PLACEBO_COMPARATOR|Control group|Control group will continue general psychiatric intervention.
62265800|NCT06407037|ACTIVE_COMPARATOR|Erector Spinae Plane Block|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 30 ml of 0.25% bupivacaine was injected into the area.
62449138|NCT01999309|PLACEBO_COMPARATOR|Placebo|Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
62449139|NCT05072301|EXPERIMENTAL|Contingency Management|The treatment group will receive a onetime offer of $80 (a reactive carrot) to forego all abstinence (contingency management) reward payments in the future.
62449140|NCT05072301|PLACEBO_COMPARATOR|Control|The control group will receive contingency management payments and other monetary benefits for completing the trial.
62623292|NCT01945476|ACTIVE_COMPARATOR|normal saline|control group
62623293|NCT00190164|EXPERIMENTAL|1|Macular hole surgery with alleviated positioning
62623294|NCT00190164|NO_INTERVENTION|2|Macular hole surgery with no alleviated positioning
62449141|NCT03181438|EXPERIMENTAL|TAP Block|"The TAP block will be performed under general anesthesia, according to the technique described below:~* The patient will be placed supine with the abdomen exposed between the iliac crest and the costal margin~* After skin antisepsis, a high-frequency ultrasound transducer will be placed transversely across the anterior axillary line above the iliac crest~* In this region, the abdominal musculature (external oblique, internal oblique and transverse abdomen) is identified, and the transverse abdominal plane of the abdomen~* The needle (BD-A-50mm) will be inserted in the technique in plane to the region of the transverse plane of the abdomen, where the solution will be administered.~* In this group, will be administered 20 mL of 0.375% ropivacaine"
62623295|NCT06463197|EXPERIMENTAL|Self-acupressure group|Subjects will attend two weekly 120-minute of self-administered acupressure training according to the group allocation in a classroom at the School Nursing, the Hong Kong Polytechnic University. The subjects will be trained to perform self-administered acupressure by an acupuncturist. To enhance interaction and ensure the quality of teaching, each class will be conducted in a small group of 5 to 7 subjects. Participants in this group will learn the self-acupressure technique and passed fidelity check. The treatment protocol included 6 acupoints, namely, Baihui (GV20) and bilateral Fenchi (GB20), Neiguan (PC6), Shenmen (HT7), Shenxu (BL23) and Yongquan (KI1) (Table 1). Subjects were given an acupressure log to record their practice at home, and they were phoned twice a week to remind their practice during the 4-week treatment period.
62623296|NCT06463197|ACTIVE_COMPARATOR|Sleep Hygiene Education group|The participants in this group will receive education on sleep hygiene. The treatment duration, frequency, and telephone follow-up schedule for the SHE group will be the same as the self-administered acupressure group (2 sessions, 2 hours each). Sleep hygiene education is often used as a comparison group in randomized controlled trials of self-help and psychological interventions for insomnia. The SHE group will provide subjects with the same amount of contact hours with the healthcare professional (instructor) in order to control the non-specific effects of practitioner-patient interaction in the self-administered acupressure group.
62623297|NCT04087369|EXPERIMENTAL|Bundled NCD WHO PEN Intervention|Mixed-methods type 2 hybrid effectiveness-implementation study to evaluate an integrated NCD care management intervention
62623298|NCT00948922|OTHER|A: Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant: Fludarabine+Melphalan+Bortezomib followed by Allogeneic Rescue.
62623299|NCT00948922|OTHER|B: Autologous Stem Cell Transplant|Autologous Stem Cell Transplant: Melphalan+Bortezomib followed by Autologous Rescue.
62623300|NCT00948922|OTHER|BE: Group B Expansion|Group B Expansion on Bortezomib Maintenance: Autologous Only.
62623301|NCT03038711|EXPERIMENTAL|Dose Panel 1|BMS-986166 or Placebo matching BMS-986166
62623302|NCT03038711|EXPERIMENTAL|Dose Panel 2|BMS-986166 or Placebo matching BMS-986166
62623303|NCT03038711|EXPERIMENTAL|Dose Panel 3|BMS-986166 or Placebo matching BMS-986166
62623304|NCT02831946|EXPERIMENTAL|MODIFIED VICRYL PLUS|The intra-cuticular layer will closed with with VICRYL PLUS suture
62623305|NCT02831946|EXPERIMENTAL|DERMABOND GLUE|The intra-cuticular layer will closed with with DERMABOND GLUE
62061568|NCT02556151|ACTIVE_COMPARATOR|1 Hz|Six sessions of weekly therapy with 1 Hz magnetic stimulations of the lumbar and sacral regions.
62265801|NCT06407037|ACTIVE_COMPARATOR|Serratus Posterior Superior Intercostal Plane Block|The probe was placed on the spinae scapula in the sagittal plane to identify the second and third ribs. The trapezius, rhomboid, serratus posterior superior muscle were visualized. The needle was inserted just above the third rib deeply into the serratus posterior superior muscle. Two mL isotonic was administrated for the correction. Then, 30 mL of 0.25% bupivacaine was administrated between serratus posterior superior muscle and rib.
62623306|NCT02182154|EXPERIMENTAL|BIBF 1120 ES|
62623307|NCT04073290|ACTIVE_COMPARATOR|Rifaximin and lactulose|Rifaximin 550 milligram b.i.d. combined with lactulose
62623308|NCT04073290|PLACEBO_COMPARATOR|Placebo and lactulose|Placebo b.i.d. combined with lactulose
62623309|NCT03369626|OTHER|FareWell Program|All participants receive the FareWell Program intervention in this evaluation study
62265802|NCT02337400|EXPERIMENTAL|Smoking Reduction Program|"Cognitive behavioral smoking reduction program Smoke_less Duration: 5 weeks with 4 weekly sessions over 2,5 hours and two phone calls"
62265803|NCT02337400|ACTIVE_COMPARATOR|Counseling Interview|15 minute counseling interview
62265804|NCT02337400|NO_INTERVENTION|Waiting Control Group|
62265805|NCT01263171|OTHER|Neo-adjuvant chemotherapy|Neo-adjuvant chemotherapy prior to short course pre-operative radiotherapy followed by adjuvant chemotherapy.
62265806|NCT00861952|EXPERIMENTAL|Neuragen|Ad lib use of Neuragen (a natural health product) applied topically 2-3 times per day in 2-3 drops per application
62265807|NCT00861952|SHAM_COMPARATOR|Mineral oil|Mineral oil, scent and color matched to intervention
62623310|NCT03852498|EXPERIMENTAL|Lenti-D Drug Product|Participants received a single intravenous (IV) infusion of eli-cel (also referred to as Lenti-D Drug Product) on Day 1 at a dose of \> or = 5.0\*10\^6 CD34+ cells/kilogram (kg). All participants received myeloablative conditioning with busulfan and fludarabine over a number of days prior to drug product infusion.
62061569|NCT02556151|ACTIVE_COMPARATOR|5 Hz|Six sessions of weekly therapy with 5 Hz magnetic stimulations of the lumbar and sacral regions.
62061570|NCT02556151|ACTIVE_COMPARATOR|15 Hz|Six sessions of weekly therapy with 15 Hz magnetic stimulations of the lumbar and sacral regions.
62061571|NCT04131478||Cases|Cachectic lung, pancreas, or colon cancer patients.
62061572|NCT04131478||Control|Non- cachectic lung, pancreas, or colon cancer patients.
62265808|NCT03001050|OTHER|PINPOINT system|The operative intervention will proceed as current standard protocol dictates for the described procedure. No changes in the operative technique will be undertaken apart from injection of the dye and visualization with the camera. The idea would be to place the Pinpoint probe within the subacromial space, to check the vascular status of the tendon, and then take a bite of the tendon and place the pinpoint back to check if the vascularity has decreased. The Indocyanine Green dye kit will be used along with the PINPOINT system .
62265809|NCT04472585|ACTIVE_COMPARATOR|Ivermectin alone|Sub-cutaneous injection ivermectin 200ug/kg body weight once every 48 hourly plus standard care
62265810|NCT04472585|ACTIVE_COMPARATOR|Ivermectin with Zinc|Sub-cutaneous injection ivermectin 200ug/kg body weight once every 48 hourly with 20mg Zinc Sulphate 8 hourly plus standard care
62623311|NCT02906579|EXPERIMENTAL|IW-1973|Placebo taken once daily Day 1-Day 3; 10 mg IW-1973 take once daily Day 4-Day 6; 20 mg IW-1973 taken once daily Day 7-Day 9; 30 mg IW-1973 taken once daily Day 10-Day 12; 40 mg IW-1973 taken once daily Day 13-Day 15; 50 mg IW-1973 taken once daily Day 16-Day 18
62623312|NCT02253576|EXPERIMENTAL|inhaled 7% hypertonic saline|Three consecutive 4ml doses of 7% NaCl solution with salbutamol(0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) nebulized over a 1-hour period
62848993|NCT02249897|PLACEBO_COMPARATOR|PLACEBO|AFTER COMPLETING THE INITIAL EVALUATION (ANTHROPOMETRY, SERUM BIOCHEMISTRY AND CML LEVELS, FUNDUS, MUTIFOCAL ELECTRORETINOGRAM AND OPTIC NERVE CONDUCTION VELOCITY) PATIENTS WILL RECEIVE ORAL PLACEBO CAPSULES 4 PER EACH MEAL/DAY DURING 12 WEEKS
62265811|NCT04472585|PLACEBO_COMPARATOR|Placebo|Placebo drug plus standard care
62848994|NCT02249897|ACTIVE_COMPARATOR|CHOLESTIRAMINE|AFTER COMPLETING THE CONTROL PERIOD (PLACEBO CAPSULES) PATIENTS WILL BE REASSESSED, AND THEN TREATED WITH ORAL CHOLESTYRAMINE 6 G/DAY (500 MG CAPSULES -\> 4 CAPSULES PER EACH MEAL/DAY) DURING 12 WEEKS AND E SAME INITIAL EVALUATION WILL BE REPEATED
62848995|NCT04382014|EXPERIMENTAL|MAG fish oil + Curcumin|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1,5 g MAG fish oil + 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
62061573|NCT01918696|EXPERIMENTAL|Anger Reduction Treatment|"This treatment consists of eight 15-minute sessions. Participants will read scenarios and imagine themselves in these situations: A driver does not let you over even though you have your blinker on. Next, another will appear to provide a less ambiguous interpretation. One letter will be missing from the key word of this sentence. The sentence will read They can't s_e you. The participant will fill in the missing letter (to form see). Next, this interpretation will be reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is the driver being disrespectful?). In each session 64 training scenarios will be presented. Participants will never see the same scenario twice over the course of the study."
62061574|NCT01918696|ACTIVE_COMPARATOR|Progressive Muscle Relaxation|"Participants will receive eight 15-minute sessions of PMR. They will listen to a PMR script (Kassinove \& Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release 10 different muscle groups. At the end of this procedure, participants will create a plan for when they will use the exercise. They will then type out the sentence: When I feel \[write the feeling you decided on\], then I will use this relaxation technique. They will then be told, Now, go over what you have written and say it quietly to yourself until you can repeat it word for word without having to read what you have written."
62265812|NCT04472585|ACTIVE_COMPARATOR|Ivermectin (oral) alone|Oral ivermectin 0.2mg/kg/day
62265813|NCT04472585|ACTIVE_COMPARATOR|Ivermectin (oral) with Zinc|Oral ivermectin 0.2mg/kg/day with 20mg Zinc Sulphate 8 hourly plus standard care
62265814|NCT04472585|ACTIVE_COMPARATOR|Zinc Alone|20mg Zinc Sulphate 8 hourly plus standard care
62265815|NCT03388411||Obese children|Children ≥95 ‰ between age 7 and 12 years
62265816|NCT03388411||Non-obese children|5‰\< BMI \<85 ‰ for children between the ages of 7 and 12 years
62265817|NCT00985335|EXPERIMENTAL|External Application of Neem-based Cream|Non Controlled, non-randomized, single group pilot study.
62265818|NCT01251107|EXPERIMENTAL|Arm B|BEACOPP (Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) for 4 escalated cycles followed by 4 standard cycles
62265819|NCT01251107|ACTIVE_COMPARATOR|Arm A|ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 6 to 8 cycles
62623313|NCT02253576|ACTIVE_COMPARATOR|inhaled nebulized normal saline|Three consecutive 4ml doses of 0.9 NaCl solution added to salbutamol(0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) nebulized over a 1-hour period
62623806|NCT03450616|EXPERIMENTAL|Negative Pressure Wound Therapy|Subjects will have one venous stasis ulcer treated with the PICO Negative Pressure Wound Therapy Device
62265820|NCT00698243|EXPERIMENTAL|Schedule 1|Once daily for 3 days every 7 days
62265821|NCT00698243|EXPERIMENTAL|Schedule 2|Once weekly
62265822|NCT00698243|EXPERIMENTAL|Schedule 3|Once daily
62061575|NCT01918696|PLACEBO_COMPARATOR|Control Condition|To control for expectancy effects, participants assigned to the control condition will complete eight computerized sessions consisting of psychoeducation on healthy behaviors. These sessions will be matched for time with the active conditions, lasting 15 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep, and will be taken from protocols developed from our ongoing research. This psychoeducation is perceived as credible but has no detectable impact on behavior. After the post-treatment session, participants will be provided with the active ART treatment free of charge if they wish to receive it.
62061576|NCT02173730|EXPERIMENTAL|BIBR 1048 MS without Pantoprazole|150 mg BIBR 1048 MS capsules administered twice daily over 6 days and once in the morning of the seventh day
62061577|NCT02173730|EXPERIMENTAL|BIBR 1048 MS with Pantoprazole|150 mg BIBR 1048 MS capsules administered twice daily over 6 days and once in the morning of the seventh day together with Pantoprazole. Pantoprazole administration (40 mg bid) started two days before administration og BIBR 1048 and ended in the morning of the seventh day.
62265823|NCT03577730|EXPERIMENTAL|Experimental|Prepared intravenous piggyback solution of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.
62265824|NCT03577730|PLACEBO_COMPARATOR|Control|Prepared intravenous piggyback solution of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.
62265825|NCT00639249|PLACEBO_COMPARATOR|P|Placebo
62265826|NCT00639249|EXPERIMENTAL|A1|SA4503
62265827|NCT00639249|EXPERIMENTAL|A2|SA4503
62265828|NCT02531581|EXPERIMENTAL|Furosémide|"Furosemide: a dose of 40 mg IV bolus initially and live according to the diuretic response: possibility of 2nd Live IV bolus 40 mg if urine output \<500 cc / 24 at the 4th hour.~Establishment of an infusion G5 500cc% in vein custody."
62623314|NCT04074330|EXPERIMENTAL|Phase 1: TAK-981 10mg QW|Participants with indolent or aggressive non-Hodgkin lymphoma (NHL) received TAK-981 10 mg, infusion, intravenously (IV), once weekly (QW) on Days 1 and 8 every 21 days in each 21-day treatment cycle in combination with rituximab 375 milligram per square meter (mg/m\^2), infusion, IV, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or disease progression (PD) or unacceptable toxicity.
62623807|NCT03450616|ACTIVE_COMPARATOR|Compression Dressing- Standard of Care|Subjects will have one venous stasis ulcer treated with the standard of care compression dressing.
62265829|NCT02531581|ACTIVE_COMPARATOR|NaCl 9% isotonic|"Infusion of 500 cc of isotonic NaCl 9% in 4 hours and 1000 cc 24-hour peripheral vein. The filling is being used in an empirical in severe EP and this group is therefore the control group."
62265830|NCT00053417|PLACEBO_COMPARATOR|1|Placebo control, twice a day (b.i.d.)
62265831|NCT00053417|EXPERIMENTAL|2|10 milligram (mg) fampridine b.i.d.
62265832|NCT00053417|EXPERIMENTAL|3|15 mg fampridine b.i.d.
62265833|NCT00053417|EXPERIMENTAL|4|20 mg fampridine b.i.d.
62265834|NCT04203615|ACTIVE_COMPARATOR|PD patients with real rTMS|Patients will receive real rTMS in a two weeks long sessions (10 sessions).
62623315|NCT04074330|EXPERIMENTAL|Phase 1: TAK-981 40mg QW|Participants with indolent or aggressive NHL received TAK-981 40 mg, infusion, IV, QW on Days 1 and 8 every 21 days in each 21-day treatment cycle in combination with rituximab 375 mg/m\^2, infusion, IV, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity.
62623316|NCT04074330|EXPERIMENTAL|Phase 1: TAK-981 60mg QW|Participants with indolent or aggressive NHL received TAK-981 60 mg, infusion, IV, QW on Days 1 and 8 every 21 days in each 21-day treatment cycle in combination with rituximab 375 mg/m\^2, infusion, IV, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity.
62623317|NCT04074330|EXPERIMENTAL|Phase 1: TAK-981 90mg QW|Participants with indolent or aggressive NHL received TAK-981 90 mg, infusion, IV, QW on Days 1 and 8 every 21 days in each 21-day treatment cycle in combination with rituximab 375 mg/m\^2, infusion, IV, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity.
62848996|NCT04382014|ACTIVE_COMPARATOR|Rice bran oil + Curcumin|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of rice bran oil + 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
62848997|NCT04382014|ACTIVE_COMPARATOR|Curcumin extract|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
62848998|NCT00653939|ACTIVE_COMPARATOR|Arm 1: Chemotherapy+Bevacizumab|Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg)administered intravenously on Day 1 of a 21-day cycle for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab (15 mg/kg) alone on Day 1 every 3 weeks until progression or until 12 months from randomization.
62848999|NCT00653939|EXPERIMENTAL|Arm 2: Active Comparator+Fosbretabulin|Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg), administered intravenously Day 1 of a 21-day cycle and fosbretabulin (60 mg/m2) on Days 7, 14, and 21 for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab (15 mg/kg) on Day 1 and fosbretabulin on Days 1, 7 and 14 every 3 weeks until progression or until 12 months from randomization.
62849000|NCT00575484|PLACEBO_COMPARATOR|1|
62623808|NCT03315598|EXPERIMENTAL|An open-labeled, single-arm, exploratory pilot study|Electroacupunture for 2months
62849001|NCT00575484|ACTIVE_COMPARATOR|2|
62849002|NCT00673530|EXPERIMENTAL|1|evidence based clinical nutrition concept
62849003|NCT00673530|OTHER|2|care as usual
62849004|NCT01549639||General Anaesthesia|Patients undergoing general anaesthesia using Marsh model target controlled infusion in effect site mode.
62061578|NCT02415348|EXPERIMENTAL|Fibroscan|Fibroscan under simultaneous cardiac monitoring
62061579|NCT02110732|ACTIVE_COMPARATOR|Lactobacillus rhamnosus GG|Lactobacillus rhamnosus GG 8-9 x 10 -9 pmy 2x2 for 3 weeks
62623318|NCT04074330|EXPERIMENTAL|Phase 1: TAK-981 90mg BIW|Participants with indolent or aggressive NHL received TAK-981 90 mg, infusion, IV, BIW on Days 1, 4, 8, and 11 every 21 days in each 21-day treatment cycle in combination with rituximab 375 mg/m\^2, infusion, IV, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity.
62623319|NCT04074330|EXPERIMENTAL|Phase 1: TAK-981 120mg QW|Participants with indolent or aggressive NHL received TAK-981 120 mg, infusion, IV, QW on Days 1 and 8 every 21 days in each 21-day treatment cycle in combination with rituximab 375 mg/m\^2, infusion, IV, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity.
62623320|NCT04074330|EXPERIMENTAL|Phase 1: Japan Lead-in: TAK-981 60mg QW|Japanese participants with indolent or aggressive NHL received TAK-981 60 mg, infusion, IV, QW on Days 1 and 8 every 21 days in each 21-day treatment cycle in combination with rituximab 375 mg/m\^2, infusion, IV, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity.
62061580|NCT02110732|PLACEBO_COMPARATOR|Crystalline cellulose|Crystalline cellulose
62623321|NCT04074330|EXPERIMENTAL|Phase 1: Japan Lead-in: TAK-981 60mg BIW|Japanese participants with indolent or aggressive NHL received TAK-981 60 mg, infusion, IV, BIW on Days 1, 4, 8, and 11 every 21 days in each 21-day treatment cycle for up to 12 months or PD or unacceptable toxicity.
62623322|NCT04074330|EXPERIMENTAL|Phase 2 (A): TAK-981 120 mg|Participants with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) received TAK-981 120 mg, infusion, IV, QW on Days 1 and 8 every 21 days in each 21-day treatment cycle in combination with rituximab infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity.
62623323|NCT04074330|EXPERIMENTAL|Phase 2 (C): TAK-981 120 mg|Participants with follicular lymphoma (FL) received TAK-981 120 mg, infusion, IV, QW on Days 1 and 8 every 21 days in each 21-day treatment cycle in combination with rituximab infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity.
62623324|NCT01716611|ACTIVE_COMPARATOR|Tolvaptan group|Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days
62623325|NCT01716611|PLACEBO_COMPARATOR|Placebo group|Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days
62849005|NCT02735135|EXPERIMENTAL|Airsoft Duo First|"Patients randomized to this arm will be placed on an AIRSOFT DUO mattress for day 0. They will then be switched to a SENTRY 1200 mattress until the end of month 1.~Intervention: AIRSOFT DUO for 1 day Intervention: SENTRY 1200 for 1 month"
62849006|NCT02735135|EXPERIMENTAL|SENTRY 1200 First|"Patients randomized to this arm will be placed on a SENTRY 1200 mattress for day 0. They will then be switched to an AIRSOFT DUO mattress until the end of month 1.~Intervention: SENTRY 1200 for 1 day Intervention: AIRSOFT DUO for 1 month"
62849007|NCT05260684||Encorafenib + binimetinib|Encorafenib 450 mg once a day (QD) Binimetinib 45 mg twice a day (BID)
62849008|NCT05260684||Vemurafenib + Cobimetinib|Vemurafenib 960 mg twice a day (BID) for 28 days of 28 day cycle Cobimetinib 60 mg once a day (QD) for 21 days of 28 day cycle
62265835|NCT04203615|SHAM_COMPARATOR|PD patients with sham rTMS|Patients will receive sham rTMS in a two weeks long sessions (10 sessions).
62265836|NCT04670185|EXPERIMENTAL|Internet-based parent training|Five weeks of therapist-guided online delivered parents training
62849009|NCT05260684||Dabrafenib + trametinib|Dabrafenib 150 mg twice a day (BID) Trametinib 2 mg once a day (QD)
62265837|NCT04670185|NO_INTERVENTION|Waitlist|Five weeks of waitlist
62265838|NCT05094700|EXPERIMENTAL|Non-marketed Cosmetic Facial Cleanser|Participants will receive non-marketed cosmetic facial cleanser to apply on cleanse facial skin, twice daily for 4 weeks.
62265839|NCT03285737|EXPERIMENTAL|Whey protein supplement|Supplement will be delivered twice daily (30g per supplement) of whey protein isolate
62265840|NCT03285737|ACTIVE_COMPARATOR|Collagen peptide supplement|Supplement will be delivered twice daily (30g per supplement) of hydrolyzed collagen peptides.
62265841|NCT01142102|EXPERIMENTAL|Arm 1|Radiation Therapy
62265842|NCT00805480|EXPERIMENTAL|AIN457 3 mg/kg|Participants randomized to this arm received AIN457 3 mg/kg on day 1, and then matching placebo on days 15 and 29.
62265843|NCT00805480|EXPERIMENTAL|AIN457 10 mg/kg|Participants randomized to this arm received AIN457 10 mg/kg on day 1, and then matching placebo on days 15 and 29.
62265844|NCT00805480|EXPERIMENTAL|AIN457 10 mg/kg x3|Participants randomized to this arm received AIN457 3 mg/kg on days 1, 15 and 29.
62265845|NCT00805480|PLACEBO_COMPARATOR|Placebo|Participants randomized to this arm received matching placebo to AIN457 on days 1, 15 and 29
62849010|NCT03063320|ACTIVE_COMPARATOR|Low Spice|The test meal (\~1200kcal and 44g fat) will contain \~0.6g of spice blend
62849011|NCT03063320|EXPERIMENTAL|Moderate Spice|The test meal (\~1200kcal and 44g fat) will contain \~3.7g of spice blend
62849012|NCT03063320|EXPERIMENTAL|Culinary Spice|The test meal (\~1200kcal and 44g fat) will contain \~7.4g of spice blend
62849013|NCT04659213|EXPERIMENTAL|Interventional Group|Placement of a luminal esophageal temperature probe (LET) and insertion of esolution esophageal retractor. In the intervention group, esolution will be utilized to deviate the esophagus during RF catheter ablation
62849014|NCT04659213|NO_INTERVENTION|Control Group|Placement of a luminal esophageal temperature probe (LET) during RF ablation
62061581|NCT03600675||South Asian Indians|No intervention will be applied for any group
62061582|NCT03600675||Caucasians|No intervention will be applied for any group
62061583|NCT06618105|PLACEBO_COMPARATOR|Zero dose (Placebo)|One actuation (oral inhalation) each from two different placebo R inhalation aerosols and one actuation (oral inhalation) each from two different placebo T inhalation aerosols
62265846|NCT04921735||Elderly|patients aged 80 years or older
62265847|NCT04921735||young|patients aged 18-40 years
62265848|NCT00763815|EXPERIMENTAL|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
62265849|NCT00763815|PLACEBO_COMPARATOR|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
62623326|NCT06171516|EXPERIMENTAL|Internet-based Cognitive Behavioral Therapy|10 guided therapy sessions (once-weekly) with each session lasting 20 minutes.
62849015|NCT03952949|EXPERIMENTAL|Default|Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections.
62849016|NCT03952949|ACTIVE_COMPARATOR|Nutrition Education|Participants in the nutrition education condition were instructed to read a brief education brochure before online grocery shopping.
62849017|NCT00501904|ACTIVE_COMPARATOR|Group A|Short protocol
62849018|NCT00501904|ACTIVE_COMPARATOR|Group B|Long protocol
62849019|NCT05172583|ACTIVE_COMPARATOR|Control|The control groups will receive the nursing interventions that are performed daily in the adult ICU
62265850|NCT03963011|NO_INTERVENTION|Arm A: AXR Only|Infants randomized to Arm A will obtain an abdominal x-ray (AXR) as per standard of care
62849020|NCT05172583|EXPERIMENTAL|Experimental|Interventions for this group are based on the Dynamic Symptom Model and scientific evidence
62849021|NCT03030976|EXPERIMENTAL|Reduce B cells|Patients receive cyclophosphamide to reduce B cells before CD19-CART infusion. It will also reduce the side effects of cell damage due to antitumor activity.
62849022|NCT03030976|EXPERIMENTAL|Treatment of SLE|Patients receive anti-CD19-CAR-T cells to treatment of SLE. The purpose of this study is to assess the safety and efficacy of CD19 CAR-T cells in the treatment of SLE.
62849023|NCT03217253|EXPERIMENTAL|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62849024|NCT04798651|EXPERIMENTAL|patients with multiple sclerosis or clinically isolated syndrome|subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome
62849025|NCT02600780|ACTIVE_COMPARATOR|Allopurinol|Allopurinol 300mg Tablets once daily for 90 days
62849026|NCT02600780|EXPERIMENTAL|Febuxostat|Febuxostat 40mg Tablets once daily for 90 days
62849027|NCT01221935||Patients initiated on Pristiq as a first line treatment|
62849028|NCT01221935||Patients initiated on Pristiq as a 2nd-line treatment|
62849029|NCT01221935||Patients initiated on a SNRI or SSRI as a first-line treatment|
62849030|NCT01221935||Patients initiated on a SNRI or SSRI as a 2nd-line treatment|
62849031|NCT03153722|EXPERIMENTAL|Pediatric discharge process intervention|All patients hospitalized on the pediatric ward under the pediatric hospitalist service will participate in pediatric discharge process interventions.
62849032|NCT04942977|EXPERIMENTAL|Cardiac tele-rehabilitation|Patients in the Intervention Group will come to the hospital 4 times during two consecutive weeks, undergoing physical exercise sessions and the same educational talks as in the control group. Subsequently, they will follow the scheduled physical activities and adherence to the risk factor management according to individualised guidelines in their App, until the end of the study period. All data generated are recorded on the professional website. The degree of compliance with the objectives set is monitored by means of 7 coloured icons, which vary according to the target achievement.
62849033|NCT04942977|ACTIVE_COMPARATOR|Centre-based cardiac rehabilitation|Patients in the control group will come to the hospital 16 times during eight weeks for cycling and muscle strengthening exercises. Educational talks will be given. At the end of the hospital phase, a conventional outpatient follow-up by primary care and the corresponding specialist will be carried out.
62849034|NCT02034409|SHAM_COMPARATOR|Sham|Treatment to index knee with sham device for 48 weeks
62849035|NCT02034409|EXPERIMENTAL|PLIUS|Treatment to index knee with PLIUS device for 48 weeks
62623327|NCT05833867|EXPERIMENTAL|SG + Adaptive radiotherapy|Sacituzumab Govitecan, IV, 8 mg/kg, 21-day cycles for 1 loading cycle prior to radiation and two subsequent cycles with concurrent adaptive radiotherapy
62849036|NCT05533229||Pregnant patients scheduled for C section|Spinal anesthesia
62623328|NCT04336475|EXPERIMENTAL|Group 1|exercise regimen and oral hygiene care advices
62849037|NCT02537158|EXPERIMENTAL|sorafenib group|sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
62849038|NCT02537158|EXPERIMENTAL|TACE group|TACE group patients will accept TACE therapy once at a month after resection.
62849039|NCT02537158|NO_INTERVENTION|control group|Control group patients will not accept any intervention,except necessary supportive treatment.
62265851|NCT03963011|ACTIVE_COMPARATOR|Arm B: AXR + Bowel US|Infants randomized to Arm B will obtain an abdominal x-ray (AXR) as per standard of care and a bowel ultrasound (BUS) as the intervention
62623329|NCT04336475|ACTIVE_COMPARATOR|Group 2|oral hygiene care advices
62623330|NCT05362149||Darolutamide cohort (daro)|Adult men with nmCRPC previously untreated with a Novel antihormonal (NAH) agent and starting the first treatment with Darolutamide during the study period.
62623331|NCT05362149||Enzalutamide cohort (enza)|Adult men with nmCRPC previously untreated with a Novel antihormonal (NAH) agent and starting the first treatment with Enzalutamide during the study period.
62623332|NCT05362149||Apalutamide cohort (apa)|Adult men with nmCRPC previously untreated with a Novel antihormonal (NAH) agent and starting the first treatment with Apalutamide during the study period.
62623333|NCT04753333|EXPERIMENTAL|Experimental|The participants in the experimental group will receive Electromyographic-biofeedback guided (EMG-BF) isometric quadriceps strengthening with patellar taping five days a week for four weeks.
62849040|NCT02073409||CF patients|Male and female subjects with CF age 6 years and older who have a positive sputum culture for NTM.
62849041|NCT05963737|EXPERIMENTAL|Experimental arm|The initial PS level is set up based on VT/PBW (6-8ml/kg) and RR (20-30 breaths/min) when patients are enrolled in the experimental arm. The following steps need to be repeated every 2 hours for 48 hours. Step 1: 3 times short EIOs (2-3s) are performed. At least 1 minute between each occlusion. PMI is calculated as the mean value of 3 measured values. Step 2: Clarify whether PMI is in the target range (PMI 0-2cmH2O). If yes, keep this PS level. If not, implement step 3. Step 3: A downward or upward PS setting adjustment is performed at a 1cmH2O interval. Every PS level is maintained for 3-5 minutes. PMI is measured again and step 3 is repeated until the PMI target is reached. Step 4: supplemental adjustment: PS setting needs to be returned to the previous level if the patient presents the following signs: VT \< 4 ml/Kg, RR \> 35 breaths/min, respiratory acidosis, respiratory distress, VT \> 10ml/Kg, Pplat \> 30 cmH2O, respiratory alkalosis.
62849042|NCT05963737|NO_INTERVENTION|Control arm|Patients randomized to the control arm need to continue to accept the traditional ventilation strategy which is VT/PBW (6-8ml/kg) and RR (20-30breaths/min) guide PS setting.
62265852|NCT04499261|EXPERIMENTAL|laparoscopic surgery|The laparoscopic view is caudal to cephalic, which is consistent with the direction of hepatic transection. In addition, the high-definition magnified view and ability to change perspectives with the laparoscope are conducive to subtle manipulation, and compression of the carbon dioxide pneumoperitoneum can reduce venous bleeding. Therefore, laparoscopic surgery may have certain advantages in the treatment of paracaval-originating lesions.
62623334|NCT04753333|PLACEBO_COMPARATOR|Control|The participants in the experimental group will receive Sham EMG-BF guided isometric quadriceps strengthening without patellar taping five days a week for four weeks.
62623335|NCT05361135|EXPERIMENTAL|PET/CT|Enhanced imaging with PET/CT
62623336|NCT05361135|NO_INTERVENTION|Routine Imaging|Standard of Care Imaging
62623337|NCT04879706||AKI necessitating KRT|Patients with AKI necessitating KRT
62623338|NCT01256099|EXPERIMENTAL|Guided Internet-CBT for insomnia|
62265853|NCT04499261|ACTIVE_COMPARATOR|Open surgery|Open surgery is the traditional surgical method for resection of paracaval-originating lesions.
62265854|NCT05099861||healthy volunteers|Healthy volunteers with no sign of internal disease. Age 18-50, both women and men.
62265855|NCT05099861||patients with internal disease|Patients with internal disease, both women and men.
62265856|NCT00427609|PLACEBO_COMPARATOR|1|
62265857|NCT00427609|ACTIVE_COMPARATOR|2|
62265858|NCT02302482|EXPERIMENTAL|Functional autonomy level collection|Collection of the Functional autonomy level every 6 - 12 months by phone
62265859|NCT04599777|EXPERIMENTAL|TACE-Sor-Tis|TACE combined with sorafenib and tislelizumab.
62265860|NCT04840043|EXPERIMENTAL|Osteopathy Group|Stimulation on the sympathetic truncus and prevertebral ganglia
62265861|NCT04840043|SHAM_COMPARATOR|Control Group|Stimulation on similar areas with lighter touch and shorter duration
62265862|NCT01923597|ACTIVE_COMPARATOR|Green tea extract|Patients will receive four capsules ( one capsula = 200mg of epigallocatechin gallate) of green tea extract per day for 3 months.
62623339|NCT01256099|PLACEBO_COMPARATOR|Control treatment|
62623340|NCT01256099|EXPERIMENTAL|Guided Internet-CBT for insomnia (9)|(9 weeks instead of 8)
62623341|NCT01256099|ACTIVE_COMPARATOR|Guided Internet-CBT for depression|
62623342|NCT04537013|ACTIVE_COMPARATOR|Control Arm|Patients with small chondral lesions of the knee
62623343|NCT04537013|EXPERIMENTAL|Investigational Group|Patients with large chondral lesions of the knee
62623344|NCT06224686|EXPERIMENTAL|The experimental group|conventional dysphagia treatment and motor imagery based on action observation treatment
62623345|NCT06224686|ACTIVE_COMPARATOR|The control group|conventional dysphagia treatment
62623346|NCT02841358|OTHER|Psychiatric adults patients presenting psychologic disorders|
62849043|NCT05437497|EXPERIMENTAL|Remimazolam group|"1. Background oxycodone injection: Slowly inject oxycodone(0.05mg/kg) intravenously. Three minutes (± 1min) after the end of oxycodone injection , begin sedation induction as follows.~2. Sedation induction before EUS-FNA/FNB: the initial dose of remimazolam is 0.15-0.2 mg/kg, and the intravenous injection time is about 1 minute. If the subject's MOAA/S score is 1 point or below after the initial dose, EUS-FNA/FNB can be started; if the degree of sedation is insufficient, additional remimazolam(0.05 mg/kg each time) is allowed. The injection time of additional remimazolam is not less than 15 seconds, and the time interval between each additional administration is ≥ 2 minutes.~3. Maintenance of sedation: In order to maintain the MOAA/S≤1, the investigator can decide to add remimazolam 0.05mg/kg each time, and the intravenous injection time should not be less than 15 seconds, with an additional administration interval of ≥ 2 minutes."
62849044|NCT05437497|ACTIVE_COMPARATOR|Propofol group|"1. Background oxycodone injection: Slowly inject oxycodone(0.05mg/kg) intravenously. Three minutes (± 1min) after the end of oxycodone injection , begin sedation induction as follows.~2. Sedation induction before EUS-FNA/FNB: the initial dose of propofol is 1.5-2.0 mg/kg, and the intravenous injection time is about 1 minute. If the subject's MOAA/S score is 1 point or below after the initial dose, EUS-FNA/FNB can be started; if the degree of sedation is insufficient, additional propofol(0.5 mg/kg each time) is allowed. The injection time of additional propofol is not less than 15 seconds, and the time interval between each additional administration is ≥ 2 minutes.~3. Maintenance of sedation: In order to maintain the MOAA/S≤1, the investigator can decide to add propofol 0.5mg/kg each time, and the intravenous injection time should not be less than 15 seconds, with an additional administration interval of ≥ 2 minutes."
62623347|NCT02081014|EXPERIMENTAL|G-Pen Mini™ (glucagon injection) 75 ug|G-Pen Mini™ (glucagon injection), two 75 microgram subcutaneous injections given approximately 4-5 hours apart
62849045|NCT02902484|EXPERIMENTAL|Nintedanib Monotherapy|"One cycle of Nintedanib monotherapy followed by a total of eight cycles of both Nintedanib and the chemotherapeutic agents, or until disease progression, whichever comes first.~1. Nintedanib dose escalation: 150, 200 mg PO BID~2. Nab-paclitaxel: 125 mg/m2 day 1,8,15 every 28 days~3. Gemcitabine: 1000 mg /m2 day 1,8,15 every 28 days"
62849046|NCT00764764|ACTIVE_COMPARATOR|I|Group I - Shoulder treatment only
62849047|NCT00764764|EXPERIMENTAL|II|Cervical and shoulder treatment
62849048|NCT00228553|EXPERIMENTAL|1|Armodafinil 100 to 250 mg/day
62849049|NCT00759564|EXPERIMENTAL|IV CP-70,429 and cross over to PF-03709270|
62849050|NCT00591318|EXPERIMENTAL|IV Ceftriaxone|IV Ceftriaxone 2 grams/day
62623348|NCT02081014|EXPERIMENTAL|G-Pen Mini™ (glucagon injection) 150 ug|G-Pen Mini™ (glucagon injection), two 150 microgram subcutaneous injections given approximately 4-5 hours apart
62623349|NCT02081014|EXPERIMENTAL|G-Pen Mini™ (glucagon injection) 300 ug|G-Pen Mini™ (glucagon injection), two 300 microgram subcutaneous injections given approximately 4-5 hours apart
62623350|NCT01509664|EXPERIMENTAL|Discount intervention|Receives 50% discount intervention on selected fruits and vegetables at participating supermarket.
62623351|NCT01509664|NO_INTERVENTION|Control|Received no discount at the participating supermarket.
62623352|NCT02082769|EXPERIMENTAL|Febuxostat 40 mg QD|Febuxostat 40 mg, orally, once daily for up to 24 weeks
62623353|NCT02082769|EXPERIMENTAL|Febuxostat 80 mg QD|Febuxostat 80 mg, orally, once daily for up to 24 weeks
62623354|NCT02082769|ACTIVE_COMPARATOR|Allopurinol 100mg QD|Allopurinol 100mg, orally, three times daily for up to 24 weeks
62623355|NCT03083808|EXPERIMENTAL|Pembrolizumab 200mg IV every 21 days|Patients who have been treated with a PD-1 or PD-L1 inhibitor and experienced a PFS of ≥3 months will be enrolled within 6 weeks of last dose of PD-1 or PD-L1 inhibitor. On Day 1 of each 3-week cycle, subjects will first receive pembrolizumab at a dose of 200mg IV every three weeks in combination with chemotherapy. Partner chemotherapy will be either gemcitabine 1000mg/m\^2 IV D1 and D8 every three weeks, docetaxel 75mg/m\^2 IV D1 every three weeks, or pemetrexed 500mg/m\^2 IV D1 every 3 weeks (pemetrexed for non-squamous histologies only). Subjects will continue to receive this combination until progression or intolerable toxicity.
62623356|NCT03881202|EXPERIMENTAL|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
62623357|NCT03891355|EXPERIMENTAL|Carfilzomib (K) plus Lenalidomide (R) and Dexamethasone (D)|"Carfilzomib (K) (maximum period of treatment= 24 cycles)~* K on days 1-2, 8-9, 15-16 during cycles 1-12. The dosage of K will be 20 mg/m2 10' iv infusion on day 1 and 2 during cycle 1 and then 27 mg/m2 10' iv infusion thereafter;~* K: on days 1-2, 15-16 during cycles 13-24. The dosage of K will be 27 mg/m2 10' iv infusion. Lenalidomide (R) (maximum period of treatment= 24 cycles)~* R: 25 mg/daily on day 1 to 21 of a 28 days course; for patients with creatinine clearance ≥ 30 mL/min but \< 50 mL/min the dosage of R will be 10 mg/daily on day 1 to 21 of a 28 days course.~Dexamethasone (D) (maximum period of treatment= 24 cycles) PO or IV D on days 1-2, 8-9, 15-16, 22-23. The dosage will be 20 mg between 30 minutes and 4 hours prior to K. For patients older than 75 years the dosage may be reduced at 10 mg."
62623358|NCT02472262|EXPERIMENTAL|Cow pea complementary food|A legume-based complementary food made from cowpeas will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
62623359|NCT02472262|EXPERIMENTAL|Common bean|A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
62623360|NCT02472262|ACTIVE_COMPARATOR|Corn Soy Flour|Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
62623361|NCT01344694||patient with liver fat|30 patients with liver fat
62623362|NCT01344694||excess of visceral fat|50 pts. with excess of visceral fat
62623363|NCT01344694||control|30 control subjects
62623364|NCT01887288|EXPERIMENTAL|Capecitabine with Digoxin|"Capecitabine PO daily b.i.d., no breaks, starts at day 1 of the first cycle; Digoxin: once daily, starts at day -7 of the first cycle~(1 cycle - 4 weeks)"
62623365|NCT04330222||Patients with lacunar stroke due to SVD|
62623366|NCT04330222||Healthy stroke free volunteers|
62849051|NCT00591318|PLACEBO_COMPARATOR|IV Placebo|IV Placebo (Normal Saline)
62849052|NCT05480111|EXPERIMENTAL|QL Block|
62849053|NCT05480111|ACTIVE_COMPARATOR|Local Anesthesia at incision site|
62849054|NCT02267993|EXPERIMENTAL|Arm A|At the first chemotherapy cycle (treatment cycle), patients receive recombinant human thrombopoietin treatment. At the second chemotherapy cycle (control cycle), recombinant human thrombopoietin therapy is not given.
62849055|NCT02267993|EXPERIMENTAL|Arm B|At the first chemotherapy cycle (control cycle), recombinant human thrombopoietin therapy is not given; at the second chemotherapy cycle (treatment cycle), patients receive recombinant human thrombopoietin treatment.
62849056|NCT04655170|EXPERIMENTAL|Group 1: Revefenacin (YUPELRI) & Formoterol (Perforomist)|Revefenacin 175 μg once per day and Formoterol 20 μg twice per day via jet nebulizer for 7 days or until discharge if prior to day 7.
62849057|NCT04655170|ACTIVE_COMPARATOR|Group 2: Ipratropium Bromide (Atrovent) & Albuterol (Ventolin) as Standard of Care|Albuterol and Ipratropium every 6 hours nebulized over the 7-day treatment period or until discharge if prior to day 7.
62849058|NCT01792544|EXPERIMENTAL|Statement|A statement is added to the echocardiography report describing if and when a follow-up echocardiogram is recommended. The statement may be positive (e.g. follow-up recommended in 6 months) or negative (e.g. no follow-up recommended).
62849059|NCT01792544|EXPERIMENTAL|No Statement|No statement is added to the echocardiography report
62849060|NCT03063034|ACTIVE_COMPARATOR|PD21864AA, PD21864AB|Subjects will use PD21864AA for 1 week and then PD21864AB for 1 week.
62849061|NCT03063034|ACTIVE_COMPARATOR|PD21864AB, PD21864AA|Subjects will use PD21864AB for 1 week and then PD21864AA for 1 week.
62849062|NCT04556383|PLACEBO_COMPARATOR|PCP Placebo|PCP Placebo for oral administration for 36 weeks
62849063|NCT04556383|EXPERIMENTAL|PCP GB004 480 mg QD|PCP GB004 480 mg QD for oral administration for 36 weeks
62849064|NCT04556383|EXPERIMENTAL|PCP GB004 480 mg BID|PCP GB004 480 mg BID for oral administration for 36 weeks
62849065|NCT04556383|EXPERIMENTAL|Open-Label Extension (OLE) GB004 480 mg BID|OLE GB004 480 mg BID for oral administration for 24 weeks
62849066|NCT05571566|NO_INTERVENTION|Pre-implementation phase|All patients with acute appendicitis who undergo appendectomies will be eligible to participate, and families will be consented prior to surgery. The explanation of the procedure will be done verbally by the surgeon as it is the standard care at the hospital. A parental anxiety assessment will be done before surgery with the Amsterdam Preoperative Anxiety and Information Scale (APAIS). In addition, an email from one of the primary caregivers will be collected, and the caregiver will receive an email with a link to the post-operative questionnaire 10 days post-discharge. At 14 days post-discharge, they will receive a reminder email again with the link to the questionnaire. All responses to the questionnaire are voluntary and anonymous.
62849067|NCT05571566|ACTIVE_COMPARATOR|Post-implementation phase|The education tool will be distributed to families whose child is undergoing an appendectomy. The explanation of the procedure will also be done verbally by the surgeon as it is the standard care at the hospital. The parental anxiety assessment will be done in the same way as above, before surgery with the Amsterdam Preoperative Anxiety and Information Scale (APAIS). In addition, the email of one of the primary caregivers will be collected, and the caregiver will receive an email with a link to the post-operative questionnaire 10 days post-discharge. At 14 days post-discharge, they will receive a reminder email with the link to the questionnaire. All responses to the questionnaire are voluntary and anonymous.
62265863|NCT01923597|PLACEBO_COMPARATOR|Placebo (celulose)|Patients will receive four capsules of placebo (celulose) daily for 3 months.
62265864|NCT03319485|EXPERIMENTAL|ExAblate Pallidotomy|ExAblate treatment for Advanced Idiopathic Parkinson's Disease
62265865|NCT03319485|SHAM_COMPARATOR|Sham ExAblate Pallidotomy|Sham (fake) treatment
62265866|NCT02256540|PLACEBO_COMPARATOR|Placebo patch - placebo tablets|Postmenopausal women will be given a placebo patch to wear two days prior to exercise visit and a placebo tablet to take the morning of the exercise visit.
62265867|NCT02256540|EXPERIMENTAL|Placebo patch - Resveratrol tablets|Postmenopausal women will be given a placebo patch to wear for two days prior to the exercise visit and a resveratrol tablet (dosed at 250mg) to take the morning of the exercise visit.
62265868|NCT02256540|ACTIVE_COMPARATOR|Climara patch - placebo tablets|Postmenopausal women will be given a transdermal estrogen patch to wear (0.05mg/day) for two days prior to the exercise visit and a placebo tablet to take the morning of the exercise visit.
62265869|NCT02812277||Anastrozole treatment group|The study group was about HR positive postmenopausal breast cancer patients who were hospitalized between January, 2008 and October, 2010, and ever accepted anastrozole therapy with the completed follow-up data.
62623367|NCT06082726|EXPERIMENTAL|small intestinal delivery capsules|Participants will ingest small intestinal delivery capsules filled with short-chain fatty acids.
62849068|NCT03696459|EXPERIMENTAL|Part 1 (Dose Escalation): Panel 1|Participants will receive single oral dose of JNJ-53718678, 2000 milligram (mg) suspension or matching placebo on Day 1, under fasted conditions.
62849069|NCT03696459|EXPERIMENTAL|Part 1 (Dose Escalation): Panel 2|Participants will receive single oral dose of JNJ-53718678, of maximum 3000 mg suspension or matching placebo on Day 1, under fasted conditions.
62849070|NCT03696459|EXPERIMENTAL|Part 1 (Dose escalation): Panel 3|Participants will receive single oral dose of JNJ-53718678 4500 mg suspension (this dose may be used in Part 2, Treatment F) or matching placebo on Day 1, under fasted condition.
62849071|NCT03696459|EXPERIMENTAL|Part 1 (Dose Escalation): Panel 4 (Optional)|Participants will receive single oral dose of JNJ-53718678 (dose to be decided \[this dose may be used in Part 2, Treatment F\]) suspension or matching placebo on Day 1, under fasted condition, if 4500 mg dose in Panel 3 is considered safe and tolerable and if pharmacokinetic data require further dose escalation to reach the target exposure.
62849072|NCT03696459|EXPERIMENTAL|Part 2 Group 1: Treatment Sequence EHFG|Participants will receive single oral dose of JNJ-53718678, 500 mg suspension with single oral dose of moxifloxacin placebo and JNJ 53718678 placebo (Treatment E) in Period 1, then participants will receive single oral dose of moxifloxacin 400 mg with single oral dose of JNJ-53718678 placebo (Treatment H) in Period 2 then will receive single oral dose of JNJ-53718678, 4500 mg (dose will be based on review of safety, tolerability, and PK data obtained in Part 1 \[either from Panel 3 or 4\], this dose may be lower/higher) suspension with single oral dose of moxifloxacin placebo (Treatment F) in Period 3 followed by single oral dose of JNJ-53718678 placebo with single oral dose of moxifloxacin placebo (Treatment G) in Period 4, on Day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods.
62265870|NCT02812277||letrozole treatment group|The study group was about HR positive postmenopausal breast cancer patients who were hospitalized between January, 2008 and October, 2010, and ever accepted letrozole therapy with the completed follow-up data.
62265871|NCT01545856||New levodopa users|Individuals with one or more prescriptions of levodopa between 1st July 2004 and 30th June 2010 but no previous levodopa prescriptions prior to study period
62265872|NCT06205888||Compare 18F-LNC1007 injection (18F-FAPI-RGD) PET/CT and 18F-FDG PET/CT imaging|This is a prospective, controlled, open-label (with blind members), single-center clinical trial to evaluate the diagnostic efficacy and safety of 18F-LNC1007 injection PET/CT for suspected tumor or tumor initial staging, recurrence monitoring, etc.
62265873|NCT01381432||Subjects prescribed azathioprine tablet|Subjects prescribed azathioprine tablet during study period after the lung transplantation
62849073|NCT03696459|EXPERIMENTAL|Part 2 Group 2: Treatment Sequence FEGH|Participants will receive Treatment F in Period 1, then Treatment E in Period 2, then Treatment G in Period 3 followed by Treatment H in Period 4 on Day 1 of each treatment period.
62849074|NCT03696459|EXPERIMENTAL|Part 2 Group 3: Treatment Sequence GFHE|Participants will receive Treatment G in Period 1, then Treatment F in Period 2, then Treatment H in Period 3 followed by Treatment E in Period 4 on Day 1 of each treatment period.
62849075|NCT03696459|EXPERIMENTAL|Part 2 Group 4: Treatment Sequence HGEF|Participants will receive Treatment H in Period 1, then Treatment G in Period 2, then Treatment E in Period 3 followed by Treatment F in Period 4 on Day 1 of each treatment period.
62265874|NCT01239342|EXPERIMENTAL|Arm I (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who are progression free after 1 year may receive a 12 week study drug supply of Akt inhibitor MK2206.
62265875|NCT01239342|EXPERIMENTAL|Arm II (everolimus)|Patients receive everolimus PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62265876|NCT05482685||Demographic variables|Include gender, age, BMI, education level, marital status, attended health promotion program or not, average monthly income, years of experience, average hours of work per week, chronic illness, smoking habit, drinking habit
62623368|NCT06082726|EXPERIMENTAL|Colon-delivery capsules|Participants will ingest colon-delivery capsules filled with short-chain fatty acids.
62623369|NCT03845244|ACTIVE_COMPARATOR|Flow reduction first group|Flow reduction first -\> FiO2 reduction -\> conventional oxygen therapy
62849294|NCT04154527||postpartum women with no pelvic floor disorders|"This group realised a set of 6 abdominal and pelvic floor exercises, with a muscle recruitment of 25% of maximum force.~Exercise A: Pelvic Floor contraction Exercise B: Pelvic Floor and Deep Abdominal muscles contraction Exercise C: Pelvic Floor, Deep Abdominal muscles contraction, and axial Stretching Exercise D: Pelvic Floor, Deep and Superficial Abdominal muscles contraction Exercise E: Abdominal Crunch Exercise Exercise F: Low pressure Abdominal Exercise The correct muscle contraction execution was controlled by superficial pelvic floor and abdominal electromyography.~The bladder base and neck displacement was registered by Transabdominal Ultrasound (TAUS) and Transperineal Ultrasound (TPUS) respectively. To image the bladder base and the bladder neck a 3.5 MHz (megahertz) curved linear array ultrasound transducer was used (LOGIQe Ultrasound,General Electric Healthcare, USA) with the ultrasound unit set in B mode."
62849295|NCT04154527||nulliparous women with no pelvic floor disorders|"This group realised a set of 6 abdominal and pelvic floor exercises, with a muscle recruitment of 25% of maximum force.~Exercise A: Pelvic Floor contraction Exercise B: Pelvic Floor and Deep Abdominal muscles contraction Exercise C: Pelvic Floor, Deep Abdominal muscles contraction, and axial Stretching Exercise D: Pelvic Floor, Deep and Superficial Abdominal muscles contraction Exercise E: Abdominal Crunch Exercise Exercise F: Low pressure Abdominal Exercise The correct muscle contraction execution was controlled by superficial pelvic floor and abdominal electromyography.~The bladder base and neck displacement was registered by Transabdominal Ultrasound (TAUS) and Transperineal Ultrasound (TPUS) respectively. To image the bladder base and the bladder neck a 3.5 MHz (megahertz)curved linear array ultrasound transducer was used (LOGIQe Ultrasound,GE eneral Electric Healthcare, USA) with the ultrasound unit set in B mode."
62849296|NCT01701050||Blood collection|Female patients 18 years or older with estrogen receptor (ER) positive, HER2 negative, progressive metastatic breast cancer after one or more lines of endocrine therapy (ET) who are initiating a new ET will be enrolled into the study. Patients must have immunohistochemistry (IHC) proven ER positive disease, IHC and/or fluorescence in-situ hybridization (FISH) proven HER2 negative disease, and an ECOG performance status of 0-2. Patients with brain metastases only or those who are progressing on fulvestrant are not eligible for the study.
62849297|NCT01411813||Alprazolam|Patients receiving Alprazolam.
62849298|NCT01047605|EXPERIMENTAL|PP1|Neurapas balance
62849299|NCT01047605|EXPERIMENTAL|PP2|Pascoflair 425 mg
62849300|NCT01047605|PLACEBO_COMPARATOR|PL1|P-Tabletten weiß
62461242|NCT02947243|EXPERIMENTAL|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention.
62849301|NCT02152917|ACTIVE_COMPARATOR|Tranexamic acid|A dose of tranexamic acid (10mg/Kg) will be administered 20 minutes before inflating the pneumatic tourniquet and another dose 15 minutes after the tourniquet release.
62849302|NCT02152917|ACTIVE_COMPARATOR|Floseal®|Floseal® will be applied in regions of potential bleeding before the release of the pneumatic tourniquet.
62849303|NCT02152917|NO_INTERVENTION|Control group|
62087905|NCT01325987|PLACEBO_COMPARATOR|sugar pill|Subjects with vitamin D deficiency (serum 25(OH)D \<20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
62461243|NCT03083171|PLACEBO_COMPARATOR|Placebo|
62461244|NCT03083171|ACTIVE_COMPARATOR|Adrecizumab 0.5 mg/kg|A single intravenous dose of 0.5 mg/kg Adrecizumab given over a 1 hour period.
62849304|NCT06046300||Amputees|Individuals with a transtibial amputation
62849305|NCT06046300||Healthy|Healthy individuals
62849306|NCT04367909|EXPERIMENTAL|Nimotuzumab plus TC Regimen chemotherapy|Nimotuzumab (200 mg) plus TC Regimen chemotherapy every 3 weeks
62849307|NCT04367909|ACTIVE_COMPARATOR|TC Regimen chemotherapy|TC Regimen chemotherapy every 3 weeks
62849308|NCT04463459|NO_INTERVENTION|Chemotherapy + Placebo|Patients receiving chemotherapy This group will be received chemotherapy and placebo
62849309|NCT04463459|ACTIVE_COMPARATOR|Chemotherapy + Vitamin C + Vitamin E|Patients receiving vitamin C and E with Chemotherapy This group will be received vitamin C (500 mg) twice daily and vitamin E (400 mg) once daily with chemotherapy for 6 weeks
62265929|NCT04082871|ACTIVE_COMPARATOR|Intervention|"All pharmacist level counseling and education regarding treatment, adherence and self-care activities were delivered to the active group patients only (planned to take 15 minutes). Patient level TRPs (any TRP that could be resolved via patient education and counseling) were resolved directly with the patient by the clinical pharmacist.~A letter with the identified TRPs (prioritized from most important to least important) for each patient in the active group was sent to the patient's psychiatrist by the researcher in sealed envelopes. The psychiatrist either accepted or rejected the recommendations. In case the recommendations were accepted, the psychiatrist implemented the recommended changes. Patients were informed by a phone call by the pharmacist to visit their psychiatrist soon after the recommendations were approved for the changes to be applied.~If the recommendations were rejected, the psychiatrist stated the reason of rejection and discussed it with the pharmacist."
62849310|NCT02883868||patients treated with CXL|
62849311|NCT05488496|EXPERIMENTAL|Intervention arm|"The intervention arm will undergo the following steps:~1. Groups of 5-15 persons living in the same area. Two trained facilitators support the group dynamics fostering empowerment.~2. Each participant undergoes a one-to one personalized interview with the facilitator(s) to build the relationship and know participants' expectations and characteristics.~3. 9 sessions of group-based activities to promote peer support and accessibility and engagement with nature-based activities available in their area according to participant's preferences. A collaborative mapping of nature-based community assets will guide the group to the activities they want to approach and test."
62265930|NCT04082871|ACTIVE_COMPARATOR|Control|"Control group patients also underwent the baseline interview with the researcher at the psychiatric clinic, TRPs were identified and documented. No intervention was provided by the pharmacist and no letter was sent to the patients' psychiatrists. In case a patient was found to have a life-threatening TRP, the patient was excluded from the study and reported to the psychiatrist due to ethical considerations.~After study completion, all patients in the control group received the MMR service, and a letter with their TRPs and recommendations to resolve them was sent by the pharmacist to their psychologist"
62265931|NCT02343172|EXPERIMENTAL|HDM201+LEE011|
62849312|NCT05488496|ACTIVE_COMPARATOR|Control arm|The control arm will receive individually usual care (e.g. the existing social prescription as available) and a list of community resources based in nature in the area. Usual care is the appropriate comparison rather than a placebo for complex interventions.
62849313|NCT05764707|EXPERIMENTAL|Intravenous Acetaminophen|Intravenous acetaminophen (1000mg) will be administered within 30 minutes of skin closure.
62849314|NCT05764707|PLACEBO_COMPARATOR|Intravenous Placebo|Intravenous normal saline will be administered within 30 minutes of skin closure.
62849315|NCT05072613||Pregnant women|Pregnant women attending Antenatal Care Services
62849316|NCT05072613||School children|Children attending Primary Schools
62265932|NCT04852107|ACTIVE_COMPARATOR|SCS/ DRGS/DUAL /Dual*|
62849317|NCT03381638||Normal Volunteer|Volunteers who report to have never had a concussion and are not at high risk of getting a concussion are scanned to obtain a baseline of all ages, sex, race, etc. All patients will be scanned with the Blink Reflexometer.
62849318|NCT03381638||Concussion Protocol|Athletes who had a potential concussion and will go through any stage of the approved protocol, are scanned by the Blink Reflexometer device. Results are then analyzed prior to unblinding the clinical diagnosis from an Athletic Trainer and/or Neurologist.
62265933|NCT04852107|ACTIVE_COMPARATOR|SCS/DUAL/DRGS/DRGS*|
62265934|NCT04852107|ACTIVE_COMPARATOR|DRGS/SCS/DUAL/DUAL*|
62265935|NCT04852107|ACTIVE_COMPARATOR|DRGS/DUAL/SCS/SCS*|
62265936|NCT04852107|ACTIVE_COMPARATOR|Dual/DRGS/SCS/SCS*|
62623877|NCT03058718|EXPERIMENTAL|Procalcitonin-guided antibiotic treatment group|"Patients were divided into 2 subgroups:~1. No infection group (including patients with procalcitonin\<0.1 ng/ml at enrollment, and patients with 0.1 ng/ml ≤procalcitonin ≤0.25 ng/ml at enrollment who are with stable respiratory and hemodynamics, and without serious complications) : the group is not given the application of antibiotics.~2. Infection group (including patients with procalcitonin\>0.25 ng/ml at the time of enrollment, and patients with 0.1 ng/ml ≤ procalcitonin≤0.25 ng/ml at enrollment who have severe disease, unstable hemodynamics, and severe complications or intensive care unit treatment): the group is given the application of antibiotics. According to the guidelines for severe sepsis / septic shock treatment, the standard for discontinuation of antimicrobial agents: If the procalcitonin level falls below \<0.1 ng/ml or more than 80%, compared with the baseline before enrollment, it is recommended to discontinue the antimicrobial agent."
62623878|NCT03058718|ACTIVE_COMPARATOR|Standard antibiotic therapy group|The application of antibiotics is given to patiens according to the doctor's experience.
62849319|NCT03662581|EXPERIMENTAL|Mindfulness Group Program|A primary care mindfulness-based rolling admissions program where subjects must attend 4 of 8 consecutive group sessions, to be considered to have completed the program.
62623879|NCT05624190|EXPERIMENTAL|TNK group|Patients of this group will receive IA rhTNK-tPA plus Best Medical Management (BMM) after successful mechanical thrombectomy (MT) recanalization
62623880|NCT05624190|ACTIVE_COMPARATOR|control group|Patients of this group will receive Best Medical Management (BMM) alone after successful mechanical thrombectomy (MT) recanalization
62623881|NCT04069143|EXPERIMENTAL|Part 1|
62623882|NCT04069143|EXPERIMENTAL|Part 2|
62623883|NCT04069143|EXPERIMENTAL|Part 3|
62849320|NCT01508533||Cohort 1|Cohort 1: Infants enrolled at ≤1 week and followed up weekly till one year of age.
62849321|NCT01508533||Cohort 2|Cohort 2: Infants enrolled at 12 months and followed up weekly till they are aged 24 months.
62849322|NCT00579384|EXPERIMENTAL|001|
62849323|NCT00945828|EXPERIMENTAL|Annual Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study.
62087906|NCT01325987|EXPERIMENTAL|vitamin D2|Subjects with vitamin D deficiency (serum 25(OH)D \<20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
62265937|NCT04852107|ACTIVE_COMPARATOR|Dual/SCS/DRGS/DRGS*|
62265938|NCT01083004|ACTIVE_COMPARATOR|Indocyanine green arm|
62623884|NCT02660437|ACTIVE_COMPARATOR|Effect of PR in MCI-group|Evaluation of the acute effect of a 3-week Pulmonary Rehabilitation (PR) program in cognitive function of MCI-Group using SMMSE, ACE-R, MoCA, TICS and Stroop test clinical instruments in reference to potential changes in pCO2 oscillation patterns (post-PR). Intervention: Pulmonary Rehabilitation program; 12 sessions of exercise training/breathing techniques.
62623885|NCT02660437|PLACEBO_COMPARATOR|Effect of PR in control-group|"Evaluation of the acute effect of a 3-week Pulmonary Rehabilitation (PR) program in cognitive function of control-group using SMMSE, ACE-R, MoCA, TICS and Stroop test clinical instruments in reference to potential changes in pCO2 oscillation patterns (post-PR).~Intervention: Pulmonary Rehabilitation program; 12 sessions of exercise training/breathing techniques."
62652834|NCT01189448|ACTIVE_COMPARATOR|Spiramycine|Spiramycin group : spiramycin 1g tid orally
62087907|NCT00305890|EXPERIMENTAL|1|Participants will partake in a lifestyle behavioral weight management program for 24 weeks.
62087908|NCT00305890|EXPERIMENTAL|2|Participants will partake in pain-coping skills training for 24 weeks.
62623886|NCT05891717|EXPERIMENTAL|Resistance training|Group A will receive resistance training. Twice per week for 8 weeks. Total 16 sessions will given.
62623887|NCT05891717|ACTIVE_COMPARATOR|Flexibility training|Group B will receive flexibility training. Twice per week for 8 weeks. Total 16 sessions will given.
62623888|NCT03945318|EXPERIMENTAL|Part 1: BION-1301|Up to 5 cohorts with single ascending doses of BION-1301 administered by intravenous (IV) infusion.
62849324|NCT00945828|EXPERIMENTAL|Quarterly Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study.
62849325|NCT06344897|EXPERIMENTAL|Kinesio Taping|"The taping process will be done immediately after appendicitis surgery. Kinesio taping will continue until child's first gas is released.~In addition to the standard pain management applied in the clinic, Kinesio tape will be applied to children who have had appendicitis surgery."
62849326|NCT06344897|NO_INTERVENTION|Control group|The control group will receive standard pain treatment without any intervention. The group will not receive any other intervention.
62849327|NCT05326854|EXPERIMENTAL|intervention group|"1., 2., 3. İnterview (in hospital) The patient will be educated. Measuring tools will be applied. (Personal Information Form- Coping and Adaptation Process Scale)( discharge: Perinatal Grief Scale, Depression Anxiety Stress Scale) The mobile application developed within the scope of post-termination support will be downloaded to the patient's phone. Informed consent form will be signed by the patient.~Sharing problems, presenting solutions. Follow-up of the patient and strengthening and supporting in this process.~4., 5., 6. Interview at home (following the patient with mobile application and phone calls)~7. and 8., Interview at home (following the patient with mobile application and phone calls) Measuring tools will be appliedPerinatal Grief Scale, Depression, Anxiety and Stress Scale, Coping and Adaptation Process Scale"
62849328|NCT05326854|NO_INTERVENTION|Control Group|"In the control group, data collection forms will be applied at admission and discharge to the service. There will be no application other than the routine care of the hospital. The routine care of the hospital applied to the control group within the scope of the research includes the information that should be given before, during and after the procedure that should be done depending on the medical intervention. In addition, there is no support program planned in the hospital and at discharge, and there is no follow-up after discharge.~1. Interview at hospital Measuring tools will be applied Perinatal Grief Scale, Depression, Anxiety and Stress Scale, Coping and Adaptation Process Scale, Discharge time, labor pain.~2. and 3. Interview at home Measuring tools will be applied Perinatal Grief Scale, Depression, Anxiety and Stress Scale, Coping and Adaptation Process Scale"
62849329|NCT04640662|EXPERIMENTAL|Platelet-Rich plasma|2 ml PRP using commercial kit- YCell Biokit
62849330|NCT04640662|ACTIVE_COMPARATOR|Prolotherapy|2 ml 16.5% Dextrose solution
62849331|NCT03835832||HIV-infected participants who receive TST test|0.1 ml of tuberculin purified protein derivative will be intra-dermally inoculated on the forearm of the HIV-infected participants. They will learn how to interpret the results of the TST test. When they return to the clinic, the nurse will also interpret the results of the TST test. The results from the participants will be compared to the nurses' interpretation. We will assess the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the innovative method.
62623889|NCT03945318|PLACEBO_COMPARATOR|Part 1: Placebo|Participants will receive a single dose of placebo administered by IV infusion.
62265939|NCT01083004|ACTIVE_COMPARATOR|Brilliant blue|
62623890|NCT03945318|EXPERIMENTAL|Part 2: BION-1301|Up to 4 cohorts with multiple doses of BION-1301 administered by intravenous (IV) infusion.
62623891|NCT03945318|PLACEBO_COMPARATOR|Part 2: Placebo|Participants will receive placebo by IV infusion.
62623892|NCT03945318|EXPERIMENTAL|Part 3: BION-1301|Two cohorts of participants will receive multiple doses of BION-1301 by IV infusion (Cohort 1) or SC injection (Cohort 2) at 600mg/biweekly.
62061618|NCT04639193|EXPERIMENTAL|Placebo, then Dual-Therapy, then Single/Triple-Therapy|"Subjects will start with a 3-day PLACEBO regimen:~* Day 1: Placebo (matching Acetazolamide 250mg) at bedtime at home.~* Day 2: Placebo (matching Acetazolamide 500mg) at bedtime at home.~* Day 3: Placebo (matching Acetazolamide 500mg + Eszopiclone 2mg) at bedtime in the sleep laboratory.~After a wash-out period of 4+ days, subjects will then cross-over to a 3-day EXPERIMENTAL DUAL-regimen:~* Day 1: Acetazolamide 250mg at bedtime at home.~* Day 2: Acetazolamide 500mg at bedtime at home.~* Day 3: Acetazolamide 500mg + Eszopiclone 2mg at bedtime in the sleep laboratory.~After a wash-out period of 4+ days, subjects will then undergo an OPEN-LABEL SINGLE/TRIPLE-regimen:~* Day 1: Acetazolamide 250mg at bedtime at home.~* Day 2: Acetazolamide 500mg at bedtime at home.~* Day 3: Acetazolamide 500mg alone or Acetazolamide 500mg + Eszopiclone 2mg + Venlafaxine 50mg at bedtime in the sleep laboratory, if sleep apnea resolved or did not resolve with the dual regimen, respectively."
62087909|NCT00305890|EXPERIMENTAL|3|Participants will partake in lifestyle behavioral weight management program plus pain-coping skills training for 24 weeks.
62087910|NCT00305890|ACTIVE_COMPARATOR|4|Participants will receive standard care for 24 weeks.
62087911|NCT01642134|ACTIVE_COMPARATOR|Duoplavin|Both active substances in DuoPlavin: clopidogrel and acetylsalicylic acid, are inhibitors of platelet aggregation. Clopidogrel stops the platelets aggregating by blocking ADP. Acetylsalicylic acid the platelets aggregating by blocking the prostaglandin cyclo oxygenase.
62849332|NCT02045641|NO_INTERVENTION|current postoperative regimen|The group will follow the current postoperative regimen at the surgical ward; screening for pleural effusions with x-ray and further diagnostic procedures in case of symptoms. Treatment will be entirely in the hands of the clinical personnel.
62849333|NCT02045641|EXPERIMENTAL|pleuracentesis|The group will follow the current postoperative regimen. In addition they will be followed with ultrasound examination, clinical examination, spirometry examination and 6 minute walk test. In case of either a) pleural effusion \> 400ml OR b) pleural effusion\< 400ml with symptoms in rest or during the walk test, the effusion will be drained and examinations will be repeated. In case of pericardial effusion of predefined size and location, either the surgeon on call or a cardiologist will be consulted.
62849334|NCT05140720|EXPERIMENTAL|6 weeks - 6 months of age|Group 1: Age group from 6 weeks - 6 months
62849335|NCT05140720|EXPERIMENTAL|7 - 11 months of age|Group 2: Age group from 7 - 11 months
62849336|NCT05140720|EXPERIMENTAL|12 - 24 months of age|Group 3: Age group from 12 - 24 months
62849337|NCT02741518|ACTIVE_COMPARATOR|Treatment Arm|The treatment arm will receive an induction dose of FMT via capsules (30) followed by monthly maintenance oral capsules(12) at week 4 and week 8. Donor Stool from healthy lean donors and placebo material will be obtained from OpenBiome. OpenBiome, is a nonprofit 501(c)(3) organization that provides hospitals with screened, filtered, and frozen material ready for clinical use
62849338|NCT02741518|PLACEBO_COMPARATOR|Placebo Arm|The placebo group will receive a placebo FMT capsules at the time of their screening colonoscopy followed by monthly intake of oral placebo capsules at week 4 and week 8
62849339|NCT01846767|EXPERIMENTAL|Type 2 diabetes|Diabetic patients Oral glucose breath test
62849340|NCT01846767|EXPERIMENTAL|Healthy controls|non-diabetic Oral glucose breath test
62849341|NCT01290913|EXPERIMENTAL|omalizumab, oral desensitization|Patients receive omalizumab along with oral peanut desensitization.
62849342|NCT02527603|EXPERIMENTAL|Spaso Method|Randomized for Sp method + 1 initial dose of 50mg dexketoprofen IM or 25mg Oral
62849343|NCT02527603|EXPERIMENTAL|Boss-Holzach-Matter Method|Randomized for BHM method +1 initial dose of 50mg dexketoprofen IM or 25mg Oral
62849344|NCT01622309|ACTIVE_COMPARATOR|eggplant meal|13 g meal of eggplant/day
62849345|NCT01622309|PLACEBO_COMPARATOR|cassava meal|13 g of placebo/day
62849346|NCT01446783|ACTIVE_COMPARATOR|mecasermin + Ehlers-Danlos|
62849347|NCT01446783|PLACEBO_COMPARATOR|Saline + Ehlers-Danlos|
62849348|NCT01446783|ACTIVE_COMPARATOR|Mecasamin + healthy control|
62849349|NCT01446783|PLACEBO_COMPARATOR|Saline + healthy control|
62849350|NCT00773539|ACTIVE_COMPARATOR|1|
62849351|NCT00773539|ACTIVE_COMPARATOR|2|
62849352|NCT00773539|ACTIVE_COMPARATOR|3|
62849353|NCT00743106|PLACEBO_COMPARATOR|Placebo Comparator|Placebo (0.9% Nacl)infusion beginning during surgery and lasting for up to 24 hours
62849354|NCT00743106|ACTIVE_COMPARATOR|Fenoldopam Comparator|Fenoldopam (0.1 \~g/kg/min)infusion will commence after placing the patient in a lateral/flex position during the operation. The infusion will continue for a total of 24 hours.
62849355|NCT04450381|EXPERIMENTAL|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter \& DCI Mini sensor for measurement of hemoglobin.
62849356|NCT03892278|EXPERIMENTAL|Aerobic training|Participants who will be randomized for the intervention in the aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle and participants will carry out three 3-minute series of each exercise. In the first mesocycle (weeks 1-2) the intensity will correspond to 80-85% of heart rate corresponding to the anaerobic threshold (HRat). In the second mesocycle (weeks 3-4) the intensity will correspond to 85-90% of HRat. In the third mesocycle, the intensity will correspond to 90-95% of HRat from weeks 5-7. In the fourth mesocycle, the intensity will correspond to 95-100% of HRat from weeks 8-10. In the fifth mesocycle (weeks 11-13) the intensity will correspond to the 100-105% of HRat for 2 minutes and \<85% of HRat for 1 minute. The last mesocycle (weeks 14-16) the intensity will correspond to the 105-110% of HRat for 2 minutes and \<85% of HRat for 1 minute.
62061619|NCT04639193|EXPERIMENTAL|Dual-Therapy, then Placebo, then Single/Triple-Therapy|"Subjects will start with a 3-day EXPERIMENTAL DUAL-regimen:~* Day 1: Acetazolamide 250mg at bedtime at home.~* Day 2: Acetazolamide 500mg at bedtime at home.~* Day 3: Acetazolamide 500mg + Eszopiclone 2mg at bedtime in the sleep laboratory.~After a wash-out period of 4+ days, subjects will then cross-over to a 3-day PLACEBO regimen:~* Day 1: Placebo (matching Acetazolamide 250mg) at bedtime at home.~* Day 2: Placebo (matching Acetazolamide 500mg) at bedtime at home.~* Day 3: Placebo (matching Acetazolamide 500mg + Eszopiclone 2mg) at bedtime in the sleep laboratory.~After a wash-out period of 4+ days, subjects will then undergo an OPEN-LABEL SINGLE/TRIPLE-regimen:~* Day 1: Acetazolamide 250mg at bedtime at home.~* Day 2: Acetazolamide 500mg at bedtime at home.~* Day 3: Acetazolamide 500mg alone or Acetazolamide 500mg + Eszopiclone 2mg + Venlafaxine 50mg at bedtime in the sleep laboratory, if sleep apnea resolved or did not resolve with the dual regimen, respectively."
62061620|NCT01359267|EXPERIMENTAL|Imaging|
62623893|NCT03945318|EXPERIMENTAL|Part 4 Retreatment: BION-1301|Eligible participants from Part 3 may enroll in Part 4 due to disease progression or by choice for optional retreatment and receive SC injection at 600mg/biweekly.
62623894|NCT02651337|EXPERIMENTAL|Drainage with Alivio in-line Flusher|Volume of saline needed to drain CSF using the Alivio in-line Flusher historically compared with volume of saline needed to drain CSF using a standard syringe
62623895|NCT02144077|ACTIVE_COMPARATOR|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
62265940|NCT00428142|EXPERIMENTAL|Bortezomib + BCVP-R|BCVP-R - q 21 days x 4 cycles Bortezomib: 1.3 mg/m2 Days 1 \& 8 Cyclophosphamide: 750 mg/m2 IV Day 1 Vincristine: 1.4 mg/m2 IV Day 1 (dose capped at 2 mg) Prednisone: 40 mg/m2 po Days 1-5 Rituximab: 375 mg/m2 IV Day 1
62265941|NCT05309187|EXPERIMENTAL|IO-202 Monotherapy (dose escalation)|
62265942|NCT05309187|EXPERIMENTAL|IO-202 dose escalation + pembrolizumab|Increasing dose levels of IO-202 with fixed dose of pembrolizumab
62265943|NCT05309187|EXPERIMENTAL|IO-202 + pembrolizumab combination therapy (dose expansion)|RP2D + pembrolizumab combination therapy in solid tumor cohorts
62265944|NCT05523037||Group S|"Anesthesia induction was achieved by continuous infusion of 6 mg/kg/h of remimazolam, and the maintenance of anesthesia was maintained at a BIS between 40 and 60.~For the maintenance of anesthesia, the end-tidal concentration of 1 minimum alveolar concentration (MAC) sevoflurane was administered"
62265945|NCT05523037||Group R|"Anesthesia induction was achieved by continuous infusion of 6 mg/kg/h of remimazolam, and the maintenance of anesthesia was maintained at a BIS between 40 and 60.~For the maintenance of anesthesia, 1-2 mg/kg/h of remimazolam was continuously infused."
62623896|NCT02144077|ACTIVE_COMPARATOR|methyl-aminolevulinate|Topical application of Metvix creme containing 160 mg/g methyl-aminolevulinate. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
62623897|NCT01619098|EXPERIMENTAL|Patient Navigator|Hospital-based Patient Navigator (a bilingual community health worker) engaged in discharge planning and made outreach phone calls to patients for 30 days after discharge and assisted patints with follow-up appointments, obtaining and taking medications, transportation, financial barriers, and linkages to community resources
62623898|NCT01619098|NO_INTERVENTION|Usual Care|Home care plan at discharge, outreach phone call from RN at patient's primary care clinic
62265946|NCT04594590||Patients with SLC25A46 deficiency|Male and female patients from age 2 to age 65 with clinically confirmed SLC25A46 mutations. Both living and deceased patients will be included, if eligible. For deceased patients, the patient's medical history records will be reviewed, and an interview of the parent(s) or caregiver(s) will be performed.
62061621|NCT05398380|EXPERIMENTAL|Transplantation|Liver transplantation for the treatment of unresectable colorectal cancer liver metastases
62087912|NCT01642134|SHAM_COMPARATOR|acenocumarol|
62849357|NCT03892278|EXPERIMENTAL|Aerobic and combined training|Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and \<85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and \<85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).
62849358|NCT03892278|ACTIVE_COMPARATOR|Control group|The control group will perform a weekly session composed of 30 minutes of therapeutic and playfull exercises in the aquatic environment, involving games, relaxation, massage and conversation.The participants will receive instructions to perform the movements as slowly as possible to avoid physical effort.
62265947|NCT05923632|EXPERIMENTAL|Pediatric patients with type 1 diabetes|By providing standard diabetes education before the digital game intervention, the child who enters the game will be asked to fill out the Child with Type 1 Diabetes Descriptive Information Form, the Quality of Life in Children with Type 1 Diabetes Scale, and the Diabetes Management Self-Efficacy Scale in Children with Type 1 Diabetes.After the children in the experimental group are informed about the digital game designed according to the Information-Motivation-Behavioral Skills Model (IIMB) in diabetes management, active participation of the children in the digital game will be ensured for 9 weeks, and participation status will be followed in the background of the game.At the end of 9 weeks, children will be asked to complete all stages of the game.Children who do not complete the game will be contacted once a week in line with the follow-up, and reminders will be made.At the 12th and 15th weeks (3 and 6 weeks after the training), all the scales will be administered again.
62849359|NCT05543772|EXPERIMENTAL|Normal saline|Study will be held in King Fahad University Hospital during a year after obtaining the IRB approval. Selection of study participants will be depending on their health status and the investigators will exclude pediatric participants. Two blood samples will be collected from participants. First one is after the insertion of the intravenous peripheral line. The second is after fluid infusion through the same line. Samples will be sent to the laboratory then. Results will be collected and analyzed.
62849360|NCT02594020|OTHER|dental bur versus air abrasion|1 tooth prepared with air abrasion versus one prepared tooth with dental bur
62849361|NCT02594020|OTHER|sono abrasion versus dental bur|1 tooth prepared with sono abrasion ans 1 tooth prepared with dental bur
62849362|NCT02594020|OTHER|air abrasion versus sono abrasion|1 tooth prepared with air abrasion versus 1 tooth prepared with sono abrasion
62265948|NCT05923632|NO_INTERVENTION|Pediatric patients with type 1 diabetes receiving routine care|At the beginning of the study, standard diabetes education will be given, and they will be asked to fill out the Children with Type 1 Diabetes Information Form, the Quality of Life Scale for Children with Type 1 Diabetes, and the Diabetes Management Self-Efficacy Scale. All scales will be administered again in the 12th and 15th weeks from the beginning of the study.
62849363|NCT02445794|EXPERIMENTAL|RT001, oral, 1.8 g/day|RT001, oral, 1.8 g QD for 28 days or matching comparator
62849364|NCT02445794|EXPERIMENTAL|RT001, oral, 9 g/day|RT001, oral, 4.5 g BID for 28 days or matching comparator
62849365|NCT03555019|EXPERIMENTAL|Formulaid|The intervention group will receive enteral supplementation with Formulaid containing ARA and DHA at a ratio of 2:1, from birth until 36 weeks PMA
62849366|NCT03555019|ACTIVE_COMPARATOR|MCT-oil|The control group will receive enteral supplementation with MCT oil containing coconut and/or palm kern oil, from birth until 36 weeks PMA
62849367|NCT00724867|EXPERIMENTAL|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV every 28 days
62265949|NCT04610021|NO_INTERVENTION|Control|Control group: autologous bone + bench bone
62265950|NCT04610021|EXPERIMENTAL|i-Factor|I-Factor group: autologous bone + bench bone + i-Factor™ bone graft
62849368|NCT00724867|EXPERIMENTAL|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV every 28 days
62849369|NCT06205680|EXPERIMENTAL|NAA with Lidocaine|One 1 ml syringes with lidocaine 2 % will be prepared and connected to the NAA device. The device will be placed in front of a nostril and the subject is asked not to breath until 0,5 ml of lidocaine has been administered. The lidocaine will be sprayed by the attending anaesthesiologist. After a waiting period of 2 minutes another 0,5 ml of lidocaine will be administered (= total of 1 ml lidocaine 2%).
62849370|NCT06205680|EXPERIMENTAL|NAA with NaCl 0,9%|"One 1 ml syringes with NaCl 0,9 % will be prepared and connected to the NAA device.~The device will be placed in front of the other nostril and the subject is asked not to breath until 0,5 ml of NaCl has been administered. The NaCl will be sprayed by the attending anaesthesiologist. After a waiting period of 2 minutes another 0,5 ml of NaCl will be administered (= total of 1 ml NaCl 0,9%)."
62849371|NCT01787162||myeloproliferative disorders|Echocardiography, spiroergometry, cardiac catheterization
62849372|NCT02284698||Study Group|Study Group will have the field workers and active health education with referral mechanism
62461245|NCT03083171|ACTIVE_COMPARATOR|Adrecizumab 2.0 mg/kg|A single intravenous dose of 2.0 mg/kg Adrecizumab given over a 1 hour period.
62849373|NCT02284698||Control Group|Control group will not have field workers and active health education. They will follow routine health care
62849374|NCT04447469|ACTIVE_COMPARATOR|10 mg/kg (Cohort 1)|Non-mechanically ventilated participants administered mavrilimumab 10 mg/kg as a single IV infusion
62849375|NCT04447469|ACTIVE_COMPARATOR|6 mg/kg (Cohort 1)|Non-mechanically ventilated participants administered mavrilimumab 6 mg/kg as a single IV infusion
62849376|NCT04447469|PLACEBO_COMPARATOR|Placebo (Cohort 1)|Non-mechanically ventilated participants administered placebo as a single IV infusion
62087913|NCT06405321||Conversion or Neoadjuvant Therapy|Patients with hepatocellular carcinoma received conversion or neoadjuvant therapy.
62061622|NCT03292601|EXPERIMENTAL|Feedback Group|Patients in the Feedback Group will receive their brace-wear (Cinch Smart Strap) compliance data via the Wellinks phone application (Cinch Mobile App). Patients will also receive their brace-wear compliance information at their standard of care follow-up visits.
62849377|NCT04447469|ACTIVE_COMPARATOR|10 mg/kg (Cohort 2)|Mechanically ventilated participants administered mavrilimumab 10 mg/kg as a single IV infusion
62849378|NCT04447469|ACTIVE_COMPARATOR|6 mg/kg (Cohort 2)|Mechanically ventilated participants administered mavrilimumab 6 mg/kg as a single IV infusion
62265951|NCT04668859|ACTIVE_COMPARATOR|Midodrine Arm|Patients will receive the drug Midodrine
62461246|NCT03083171|ACTIVE_COMPARATOR|Adrecizumab 8.0 mg/kg|A single intravenous dose of 8.0 mg/kg Adrecizumab given over a 1 hour period.
62461247|NCT02242292|EXPERIMENTAL|Hyoscine butylbromide|"5 tablets taken in a 24-hour period/each episode:~* for up to 7 episodes, or~* over a period of up to 6 weeks"
62849379|NCT04447469|PLACEBO_COMPARATOR|Placebo (Cohort 2)|Mechanically ventilated participants administered placebo as a single IV infusion
62849380|NCT02302612|EXPERIMENTAL|CREATE Wellness|Patients allocated to the intervention arm will receive three group sessions with between visit contacts designed to increase activation and engagement with their care plans. They will also continue to be enrolled in the KP PHASE disease management program.
62849381|NCT02302612|ACTIVE_COMPARATOR|Usual Care Control|Patients allocated to the control arm will continue to receive usual care, including disease management within the KP PHASE program.
62849382|NCT05164419||Wide margin|Patients who underwent surgery with a final pathologic margin of more than 5mm.
62849383|NCT05164419||Close margin|Patients who underwent surgery with a final pathologic margin of less than 5mm
62849384|NCT04052178|ACTIVE_COMPARATOR|Repetitive transcranial magnetic stimulation (rtMS)|"Acute repetitive transcranial magnetic stimulation on the pharyngeal sensory cortex. Applied intensity 90% of the resting motor threshold, 1250 pulses at 5 Hz.~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized."
62849385|NCT04052178|ACTIVE_COMPARATOR|Intrapharyngeal electrical stimulation (PES)|"Intrapharyngeal electrical stimulation applied to an intensity of 75% of the tolerance threshold with 0.2 ms pulses at 5 Hz during 10 min.~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized."
62849386|NCT04052178|ACTIVE_COMPARATOR|Capsaicin|"100 mL of oral capsaicin solution at a concentration of 10-5M.~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized"
62849387|NCT05339776|ACTIVE_COMPARATOR|One of groups: amputees group|"We planned to enroll two groups to the study. One group is named amputees the other one is control. Both groups will enroll hand lateralization for at least 10 days. Before and after comparisons will be analyzed."
62849388|NCT05339776|ACTIVE_COMPARATOR|One of groups: control group|Control group will be matched in terms of age and gender with the amputees group.
62849389|NCT01168869||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
62849390|NCT05742308|EXPERIMENTAL|Experimental: Laughter yoga|The intervention group received laughter yoga twice a week for three weeks.
62849391|NCT05742308|NO_INTERVENTION|No Intervention: Control group|The control group did not take part in the laughter yoga program.
62849392|NCT04329338|NO_INTERVENTION|Gut and vaginal sample collection|Gut and vaginal samples were collected for Nugent score, and 16S rRNA metagenomics communities.
62849393|NCT04329338|EXPERIMENTAL|Gut and Vaginal sample after Lactobacillus|Seven women diagnosed with BV by Nugent score (7-10) provided vaginal and gut sample after 14 days oral intake of 3 grams (2.5X108 cfu/g) of Lactobacillus pentosus KCA1
62849394|NCT01839604|EXPERIMENTAL|AZD9150|There are two parts, dose escalation phase (Part A) and dose expansion phase (Part B).
62849395|NCT04834089|EXPERIMENTAL|Experimental product group (Stage A)|Anti-SARS-CoV-2 Serum Dose: 5 mL/dose or 10 mL/dose Administration Route: Intravenous
62849396|NCT04834089|PLACEBO_COMPARATOR|Placebo group (Stage C)|Saline solution Administration Route: Intravenous
62849397|NCT04834089|EXPERIMENTAL|Experimental product group (Stage B)|Anti-SARS-CoV-2 Serum Dose: 5 mL/dose or 10 mL/dose Administration Route: Intravenous
62061623|NCT01942902|EXPERIMENTAL|Continuous Glucose Monitoring System|
62061624|NCT01995448||SEPSIS Blood test|Patient with two criteria of systemic inflammatory response syndrome and a progressive infection which is clinically or microbiologically documented.
62849398|NCT04834089|EXPERIMENTAL|Experimental product group (Stage C)|Anti-SARS-CoV-2 Serum Dose: 5 mL/dose or 10 mL/dose Administration Route: Intravenous
62849399|NCT01676779|EXPERIMENTAL|Arm A dendritic cell therapy|Arm-A, patients will receive Dendritic Cell therapy during one year following randomization.
62061625|NCT01454635|OTHER|Sertraline, Treatment response|dosage, frequency and duration
62265952|NCT04668859|PLACEBO_COMPARATOR|Placebo Arm|Patients will receive placebo.
62265953|NCT04106700|EXPERIMENTAL|Apixaban (single arm)|
62286823|NCT02787772|EXPERIMENTAL|Elective Hernia Repair|Elective abdominal wall hernia surgery was performed in randomized cirrhotic patients.
62286824|NCT02787772|NO_INTERVENTION|Clinical follow up|"Cirrhotic patients were kept in clinical follow up concerning their abdominal wall hernia.~If a complication occured at the hernia site (such as skin rupture, bowel strangulation,..) the patient underwent emergency hernia repair."
62286825|NCT03118193|EXPERIMENTAL|Depressive patient|olfactive tests ; blood test ; optional: Tissue Pulsatility imaging ; optional: Collection of faeces
62849400|NCT01676779|EXPERIMENTAL|Arm B Dendritic cell therapy|Arm-B, patients will initiate Dendritic Cell therapy only after documented recurrence of the melanoma that cannot be salvaged by local therapy.
62849401|NCT05646849|NO_INTERVENTION|Classic care|Home exercise book, personalized advices and development of an individualized project post-cardiac rehabilitation.
62849402|NCT05646849|EXPERIMENTAL|Connected application|Recording and sharing sessions. Exchanges and interactions with other patients. Participation in three collective challenges.
62849403|NCT04588454|EXPERIMENTAL|18F-PSMA-1007 PET/CT|
62849404|NCT02977962|EXPERIMENTAL|Cognitive-Behavior Therapy|This consists of 16 weekly sessions up to 90 minutes each that helps the participant learn to cope with anxiety by facing fears, thinking more logically, and calming oneself.
62286826|NCT05959889|PLACEBO_COMPARATOR|Placebo Group|group (A) will recieved placebo tablet.
62286827|NCT05959889|ACTIVE_COMPARATOR|Motelukast Group|Patients will receive motelukast 10 mg for 4 cycles of AC.
62461248|NCT02242292|PLACEBO_COMPARATOR|Placebo|
62849405|NCT02977962|PLACEBO_COMPARATOR|Treatment as Usual|Participants randomized to this condition will wait for a period of 16 weeks before receiving treatment in the context of the study. During this time, youth may receive psychotherapy and/or initiate or change current psychiatric medication (if applicable).
62849406|NCT02069860|EXPERIMENTAL|Access for heamodialysis treatment|The Bone Anchored Port System (BAP) will be implanted in the mastoid bone behind the ear, connected with a double lumen central venous catheter inserted in the jugular vein, and will be used in conjunction with an adapter as a permanent vascular access for hemodialysis treatment
62849407|NCT01210859||Ureteral stents Detrusitol treatment Lyfestyle outcome|Ureteral stents Detrusitol treatment Lyfestyle outcome
62849408|NCT05018208||Arm 1 (wearable device[s], smartphone app)|Patients undergoing CAR-T therapy use the Biofourmis wearable device(s) and smartphone app to answer a series of questions about health and neurologic symptoms a few times a day for 5 weeks.
62849409|NCT05018208||Arm 2 (wearable device[s], smartphone app, questionnaires)|Patients undergoing radiation therapy (RT) for head and neck, lung, or gastrointestinal cancers use the Biofourmis wearable device(s) for 90 days after completion of RT. Patients also use the smartphone app to answer a series of questions about health and neurologic symptoms before start of RT, after completion of RT, 3 months after completion of RT, and 1 year after completion of RT. In addition, patients complete weekly questionnaires regarding side effects and tolerance of the device.
62849410|NCT00335764|EXPERIMENTAL|Group 1|Patients receive oral sorafenib tosylate twice daily and oral erlotinib hydrochloride once daily on days 1-28.
62849411|NCT00335764|EXPERIMENTAL|Group 2|Patients receive sorafenib tosylate as in group 1. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
62849412|NCT00335764|EXPERIMENTAL|Group 3|Patients receive sorafenib tosylate as in group 1. Patients also receive oral tipifarnib twice daily on days 1-21.
62849413|NCT03021993|EXPERIMENTAL|Nivolumab|Nivolumab (OPDIVO) will be administered every two weeks for up to four doses prior to surgery at 3mg/kg
62849414|NCT03297905|EXPERIMENTAL|Complementary and Integrative Therapies|Chiropractic, Acupuncture, Yoga, Biofeedback (if indicated), and Foam roller instruction
62849415|NCT03297905|ACTIVE_COMPARATOR|Standard Rehabilitative Care|Cognitive Behavioral Therapy (CBT) 60-minute orientation, CBT psychoeducation group, and Physical therapy/occupational therapy
62849416|NCT02980575|EXPERIMENTAL|Exercise with music|Participants will listen to music when they exercise
62849417|NCT02980575|ACTIVE_COMPARATOR|Exercise|Participants will not listen to music when they exercise
62623899|NCT04825756|EXPERIMENTAL|Treatment Group|A total of up to 80 child/caregiver dyads will be enrolled in the study, anticipating that 40 dyads will complete the 10 week intervention. An equine assisted therapy called Reining in Anxiety for children with anxiety and their caregivers.
62623900|NCT00696319|EXPERIMENTAL|1|Arm 1 will go through a rehabilitation protocol with perturbation training exercises.
62849418|NCT00572130|EXPERIMENTAL|Rexin-G Dose 1|
62849419|NCT00572130|EXPERIMENTAL|Rexin-G Dose 2|
62849420|NCT02410889||Patients with Epilepsy|A group of patients with a variety of types of epilepsy.
62849421|NCT04847713||Fabry's disease|children and adults male or female between 6 and 70 years old, patients with diagnosis of FD, treated and non-treated
62849422|NCT04847713||Healthy controls|age and sex-matched group of healthy subjects with a negative family history for lysosomal storage disorders and no clinical signs of FD.
62849423|NCT04877951|OTHER|Effect of LSVT BIG therapy on Postural Control and Gait Parameters|LSVT BIG is a commonly used protocol to manage functional movement for those with Parkinson's Disease. This study measured postural control and gait parameters following a 4-week course of LSVT BIG therapy.
62849424|NCT05974059|EXPERIMENTAL|Cadonilimab|10 mg/kg, d1, Q3W;
62849425|NCT00475982|EXPERIMENTAL|Arm 1: Weight Loss|Weight Loss Group
62849426|NCT00475982|ACTIVE_COMPARATOR|Arm 2: No Weight Loss|No Weight Loss Group
62849427|NCT02646241|EXPERIMENTAL|unroofing biopsy|
62849428|NCT02646241|ACTIVE_COMPARATOR|EUS-FNB|
62849429|NCT02299791|ACTIVE_COMPARATOR|Early Intervention|6 study clinics received the ALL intervention starting 6/1/11
62849430|NCT02299791|ACTIVE_COMPARATOR|Late implementation|5 study clinics received the ALL intervention starting 6/1/12
62849431|NCT05686044|EXPERIMENTAL|7.5mg Buntanetap/Posiphen|Buntanetap/Posiphen 7.5mg oral capsule with daily administration for a period of 12 weeks
62849432|NCT05686044|EXPERIMENTAL|15mg Buntanetap/Posiphen|Buntanetap/Posiphen 15mg oral capsule with daily administration for a period of 12 weeks
62849433|NCT05686044|EXPERIMENTAL|30mg Buntanetap/Posiphen|Buntanetap/Posiphen 30mg oral capsule with daily administration for a period of 12 weeks
62286828|NCT05299073|EXPERIMENTAL|MB09 (denosumab biosimilar)|Sterile vial 120mg/1.7mL, Single dose, 35mg SC
62286829|NCT05299073|ACTIVE_COMPARATOR|US-sourced Xgeva|Sterile vial 120mg/1.7mL, Single dose, 35mg SC
62286830|NCT05299073|ACTIVE_COMPARATOR|EU-sourced Xgeva|Sterile vial 120mg/1.7mL, Single dose, 35mg SC
62461249|NCT01185808|ACTIVE_COMPARATOR|Vitamin D|Vitamin D 5,000IU/day for 6 weeks
62623901|NCT00696319|EXPERIMENTAL|2|Arm 2 will go through a rehabilitation protocol with traditional exercises for balance and stability training.
62849434|NCT05686044|PLACEBO_COMPARATOR|Placebo|Placebo oral capsule with daily administration for a period of 12 weeks
62849435|NCT05172934|EXPERIMENTAL|Intra-arterial Tenecteplase|Participants will receive intra-arterial Tenecteplase after achieving mTICI 2b or 2c reperfusion with standard of care MT.
62849436|NCT04388462||locked plating with predicted distribution of loc|
62849437|NCT04388462||unlocked plating with predicted distribution of loc|
62849438|NCT04388462||Interlocking nail +/- blocking screws|
62849439|NCT01559740|EXPERIMENTAL|0.25% Bupivacaine|All children will receive a single dose of 1 mcg/kg of Fentanyl intravenously prior to incision. Group TAP 1 receiving a TAP block with 0.25% bupivacaine with 1:200,000 epinephrine at a dose of 1 mL/kg.
62265954|NCT06029621|EXPERIMENTAL|RATS for Thymectomy|The operator of the surgical incision and the route of entry were determined, and the endoscope and surgical instruments were inserted through the operating hole. The phrenic nerve and diaphragm began to gradually separate upward while avoiding nerve damage. Subsequently, the innominate vein was dissected to observe the branches of the thymus vessels and clamped with a 5 mm Hem-o-Lok clamp. Continue to dissect the left side of the thymus until near the phrenic nerve. After the thymus was removed entirely, it was placed in a bag and removed through an incision. After the operation, a 28 Fr chest tube was placed through the incision to the chest top. An 18 G central venous catheter was placed at the level of the posterior axillary line to the posterior costophrenic angle, and about 10 cm was inserted.
62849440|NCT01559740|EXPERIMENTAL|0.125% Bupivacaine|All children will receive a single dose of 1 mcg/kg of Fentanyl intravenously prior to incision. Group TAP 2 will receive a TAP block with a total dose of 1 mL/kg given at a concentration of 0.125% bupivacaine with 1:200,000 epinephrine.
62849441|NCT02794675|EXPERIMENTAL|Cesium 131 brachytherapy|Cesium 131 is the radioactive isotope in the protocol. The prescribed dose will range from 50-80 Gy at maximal delivery. It comes in 0.5 cm seeds that will be placed in the tumor resection bed at 1cm intervals. They are implantable seeds that do not require removal.
62849442|NCT03098615|OTHER|Jublia (Efinaconazole 10% Topical Solution) + nail polish|Subjects with distal lateral subungual onychomycosis (DLSO) with dermatophytoma.
62623902|NCT02401035|EXPERIMENTAL|IV pantoprazole|Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight.
62623903|NCT02070445||Patients undergoing CABG|Patients will have no ventilation during CABG. There will be non-invasive assessments of the lung using ultrasound at different times during the perioperative period.The first assessment will be conducted before anesthesia induction (i.e. patients will be awake). A second assessment will be conducted after anesthesiology induction, but before the beginning of surgery. A third assessment will be conducted at the end of the surgery in the operating room. And two subsequent assessments will be conducted in ICU before and after extubation.
62623904|NCT02830074|EXPERIMENTAL|The BEST Program|a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + patient Education + ongoing Support and Training)
62623905|NCT02830074|ACTIVE_COMPARATOR|Sleep Education and standard SDB treatment|This program includes non-directive sleep education plus standard treatment of SDB.
62623906|NCT04525040|EXPERIMENTAL|Intervention arm|Children in this arm were given ProbioKid®; one capsule daily, for 6 weeks.
62623907|NCT04525040|OTHER|Pragmatic arm|Children in this arm received standard of care as usual without a preventive intervention
62623908|NCT05356650|EXPERIMENTAL|Mulligan Mobilization|Treatment will be given with frequency of 3 sets with 10 repetitions on sacroiliac joint 3 times a week for 6 weeks
62265955|NCT06029621|ACTIVE_COMPARATOR|VATS for Thymectomy|The main operation principles and procedures of the operation are basically similar to those of the RATS and are completed under video-assisted thoracoscopic surgery.
62623909|NCT05356650|EXPERIMENTAL|PNF Technique|Three sets of stretching of each muscle will be performed for each position with the frequency of 3 times a week for 6 weeks.
62623910|NCT04994808|EXPERIMENTAL|Arm A (treosulfan, fludarabine, TBI, HCT)|Patients receive treosulfan IV over 2 hours on days -6 to -4 and fludarabine IV over 30 minutes on days -6 to -2. Patients also undergo TBI followed by HCT on day 0. Patients undergo ECHO or MUGA and lumbar puncture pre-transplant and undergo bone marrow aspiration, bone marrow biopsy, and collection of blood samples at pre-transplant and post-transplant.
62623911|NCT04994808|EXPERIMENTAL|Arm B (clofarabine, TBI, HCT)|Patients receive clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI followed by HCT on day 0. Patients undergo ECHO or MUGA and lumbar puncture pre-transplant and undergo bone marrow aspiration, bone marrow biopsy, and collection of blood samples at pre-transplant and post-transplant.
62265956|NCT05000385||Healthy|healthy complete dentition
62265957|NCT05000385||Dental caries|complete dentition with bilateral dental caries (ICDAS 4,5 or 6)
62265958|NCT05000385||Occlusal contacts|occlusal contacts are lost bilaterally due to extraction, changing dentition or orthodontic anomalies; no dental caries
62849443|NCT04780919|EXPERIMENTAL|Treatment Group (A)|Group of patients with Achilles tendinopathy which are treated by focused extracorporeal shockwave therapy once a week for 5 weeks. ESWT parameters: 0,12 mJ/mm2, 10 Hz, 1300 shocks.
62849444|NCT04780919|SHAM_COMPARATOR|Sham Group (B)|Group of patients with Achilles tendinopathy in which sham extracorporeal shockwave therapy is applied once a week for 5 weeks. Total applications are 5, applicated weekly. Sham ESWT parameters are same as in Group A (0,12 mJ/mm2, 10 Hz, 1300 shocks) but with modified applicator which does not allow wave transmission.
62265959|NCT05000385||Dentures|patients with dentures, no caries and/or missing occlusal contacts on remaining teeth
62265960|NCT00500526|EXPERIMENTAL|1 Singing Group|Patients who will receive singing classes
62623912|NCT04211558|EXPERIMENTAL|Ozanimod 0.46mg|Ozanimod single doses of 0.46 mg (1 x 0.46 mg capsule) will be administered on Day 1. Ozanimod will be administered following an overnight fast of at least 10 hours before dosing and with approximately 240 mL of nonrefrigerated, noncarbonated water (additional water may be allowed if required for the subject to complete dosing). Subjects will remain fasted for 4 hours after ozanimod dosing.
62623913|NCT04211558|EXPERIMENTAL|Ozanimod 0.92mg|Ozanimod single doses of 0.92 mg (1 x 0.92-mg capsule) will be administered on Day 1. Ozanimod will be administered following an overnight fast of at least 10 hours before dosing and with approximately 240 mL of nonrefrigerated, noncarbonated water (additional water may be allowed if required for the subject to complete dosing). Subjects will remain fasted for 4 hours after ozanimod dosing.
62652835|NCT05627804|EXPERIMENTAL|Moderate hypoxia|The participant will perform different exercise modes under moderate hypoxia (fraction oxygen: 16.5%). Blood samples immediately after exercise oral glucose tolerance test will be collected.
62061626|NCT01407354|EXPERIMENTAL|Lokomat Training|Lokomat robotic assisted treadmill training Lokomat Treadmill Training
62265961|NCT00500526|OTHER|2 Control group|Patients who will attend hand craft classes
62265962|NCT02309229||Cystic fibrosis patients|patients with cystic fibrosis
62061627|NCT01407354|ACTIVE_COMPARATOR|Aquatic Therapy|Aquatic exercise therapy
62461250|NCT01185808|PLACEBO_COMPARATOR|Placebo|Placebo for 6 weeks.
62461251|NCT04335578|EXPERIMENTAL|Zampilimab Cohorts|Participants will be randomized to receive zampilimab (UCB7858).
62849445|NCT02312193||Case|Hypertensive subjects
62849446|NCT02312193||Control|Normotensive subjects
62849447|NCT03690635|EXPERIMENTAL|VISTA technique|evolution of a newer approach known as Vestibular Incision Subperiosteal Tunnel Access (VISTA) was proposed to avoid some of the potential complications occurring with other intrasulcular tunneling techniques
62849448|NCT03690635|ACTIVE_COMPARATOR|tunneling technique|Several modifications of tunnel technique have been described in order to preserve esthetics, avoid relapse of gingival recession and maintain papillary integrity. These modifications also attend to avoid scar formation and delayed healing related to vertical releasing incision
62849449|NCT02452788|OTHER|Intervention|Pharmaceutical care with educational intervention provided by a pharmacist to ambulatory hemodialysis patients
62849450|NCT02452788|NO_INTERVENTION|Usual Care|Usual Care
62849451|NCT05328557|EXPERIMENTAL|CUG252|Participants will be randomized in a 3:1 ratio to CUG252 or placebo. CUG252 or placebo will be administered at a single ascending dose in healthy volunteers.
62849452|NCT05328557|PLACEBO_COMPARATOR|Placebo|Participants will be randomized in a 3:1 ratio to CUG252 or placebo. CUG252 or placebo will be administered at a single ascending dose in healthy volunteers.
62061628|NCT02780830|EXPERIMENTAL|AZD2014 plus Ibrutinib Combination|AZD2014 and ibrutinib will be dosed together in the morning under fasting conditions. When possible, the morning doses of AZD2014 and ibrutinib should be taken at approximately the same time each day. The morning doses must be taken in a fasted state (water to drink only) from at least 2 hours prior to the dose to at least 1 hour post dose. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
62061629|NCT05643599||Group 1:|Mad honey
62061630|NCT05643599||Group 2:|Normal honey
62061631|NCT05643599||Group 3:|without intervention
62061632|NCT02645786||Case|"Differentiated thyroid cancer group:~who received total- or near-total thyroidectomy, and thereafter regularly visited the endocrine out-patient department (OPD) of Chuncheon Sacred Heart Hospital.~1) age less than 45 years old when receiving total or near-total thyroidectomy, 2) serum level of TSH\<0.1 mU/L in the intermediate recurrence-risk or TSH\<0.3 mU/L in the low recurrence-risk group13, 14 over 2 years before study entry, 3) receiving TSH suppressive therapy for 5 to 9 years with fixed dose of LT4 more than 2 years before study entry, and 4) no history of structural heart disease, arrhythmia, or cardiac symptoms (palpitation, exertional dyspnea and chest discomfort) during therapy."
62061633|NCT02645786||Control|"Control group As each DTC patient was enrolled, control subjects were selected from patients who visited endocrinology department for thyroid nodule work-up. The control group had to meet the following criteria~1) the subject matched to a patient by age (±2 years), sex, and body mass index (BMI) (±2 kg/m2), 2) within the reference range of serum TSH (0.3-4.6 mU/L), 3) no history of structural heart disease, arrhythmia, or cardiac symptoms, 4) no history of comorbid diseases which affect thyroxine metabolism and cardiac structure, including hepatic or renal disease, anemia, and hypertension."
62061634|NCT05767528||Case Group|Participants who were diagnosed as MIBC and plan to receive neoadjuvant therapy before the surgery, above 18 years of age, regardless of gender
62087914|NCT00636714|EXPERIMENTAL|Nurse-directed|Using nursing judgement to control blood glucose
62265963|NCT04870528|EXPERIMENTAL|Experimental group|- This group will be composed of 30 patients with lower limb burn of second-degree. Subjects will receive pulsed magnetic field over thigh areas for 24 sessions over a period of 8 weeks (3sessions/week) with receiving strengthening exercises for quadriceps muscle and traditional physical therapy program in the form of range of motion exercise, stretching, splinting, massage, functional training for ambulation and activities of daily living.
62265964|NCT04870528|ACTIVE_COMPARATOR|control group|Subjects will receive strengthening exercises for quadriceps muscle and traditional physical therapy program in the form of range of motion exercise, stretching, splinting, massage, functional training for ambulation and activities of daily living for 24 sessions over a period of 8 weeks (3sessions/week)
62265965|NCT01154374|EXPERIMENTAL|MEBO Wound Ointment|Topical application twice daily
62265966|NCT01154374|ACTIVE_COMPARATOR|Standard of Care (sterile saline moistened gauze)|Topical application twice daily
62849453|NCT05208840|EXPERIMENTAL|LMCE-positive|LMCE-positive participants enrolled in the study will receive therapy with ocrelizumab for 2 years.
62849454|NCT05208840|EXPERIMENTAL|LMCE-negative|LMCE-negative participants enrolled in the study will receive therapy with ocrelizumab for 2 years.
62849455|NCT04035434|EXPERIMENTAL|CTX110|Administered by IV infusion following lymphodepleting chemotherapy.
62849456|NCT05713149||Subjects with osteomyelitis-associated pressure ulcers|Subjects with neuromotor disability and admitted for the treatment of osteomyelitis-associated pressure ulcers
62849457|NCT02260180|ACTIVE_COMPARATOR|A-101 40%|A-101 40% Topical Solution
62849458|NCT02260180|ACTIVE_COMPARATOR|A-101 32.5%|A-101 32.5% Topical Solution
62849459|NCT02260180|PLACEBO_COMPARATOR|A-101 Vehicle Topical Solution|A-101 0% Topical Solution (vehicle)
62849460|NCT05659160||Endovascular therapy|Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombus aspiration, others, or combination methods.
62087915|NCT00636714|ACTIVE_COMPARATOR|Nomogram-directed|Blood glucose control directed by pre-approved paper nomogram
62849461|NCT05659160||Best medical management|Patients enrolled in this group received the best medical management.
62849462|NCT05426603|EXPERIMENTAL|Pulmonary vein isolation + Waveform Periodicity Group|Pulmonary vein isolation + Substrate ablation
62849463|NCT05426603|OTHER|Pulmonary vein isolation group|Pulmonary vein isolation (Conventional treatment)
62849464|NCT05218291|EXPERIMENTAL|Technology-Supported Yoga Applied Group|"The yoga initiative to be applied to the intervention group; Yoga, which is mind-breath-body work; It includes meditation, pranayama (breath work), and asanas (yoga poses).~The content of the yoga practice consists of the following poses:~-Tadasana (Mountain pose), -Urdhvahastasana, -Uttanasana, -Ardha Uttanasana, -Plank, -Ashtang Pranam, -Bhujangasana (Mini cobra), -Adho Mukha Svanasana (Downward facing dog), -Vrksasana (Tree Pose), - Utthita Trikonasana (Triangle Pose), -Virabhadrasana I (Warrior I), -Virabhadrasana II (Warrior II), -Virabhadrasana I with Anjali Mudra (Hands Reverse Namaste), -Utkatasana (Chair Pose), -Salabhasana, -Paschimottanasana , -Dandasana, -Salamba Sarvangasana (Shoulder pose), -Ardha Urdhva Dhanurasana (Half Wheel Pose), -Reverse Warrior, -Child's pose, -Ananda Balasana (Happy baby), -Wipers, -Corpse Pose"
62265967|NCT05578729|OTHER|Single surgical mask group|Participants wore single surgical masks.
62623914|NCT02748759|ACTIVE_COMPARATOR|EXP 1: Manual mobilization / CPM|Patients were subjected to a manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist. After a pause of 5 minutes, the patient was collocated in a commercially available CPM device (Kinetec Advanced Prima) and received 15 repetitions of flexo-extension.
62849465|NCT05218291|ACTIVE_COMPARATOR|Control Group|No intervention was made in caregivers.
62849466|NCT01292824|NO_INTERVENTION|Standard liver transplant care|Liver Transplantation as per Standard of Care
62849467|NCT01292824|EXPERIMENTAL|ITX 5061|Liver Transplantation as per Standard of Care + ITX5061
62849468|NCT03423199|EXPERIMENTAL|Palbociclib + Tamoxifen ± Goserelin|Palbociclib 125 mg/day, orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
62265968|NCT05578729|OTHER|Double surgical mask group|Participants wore double surgical masks.
62265969|NCT05578729|OTHER|N95 mask group|Participants wore N95 masks.
62265970|NCT02271828|ACTIVE_COMPARATOR|Sentinel lymph node procedure|Sentinel lymph node procedure according to the Dutch breast cancer guideline
62265971|NCT02271828|NO_INTERVENTION|No sentinel lymph node procedure|No sentinel lymph node procedure
62849469|NCT03423199|ACTIVE_COMPARATOR|Placebo + Tamoxifen ± Goserelin|Placebo orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
62849470|NCT03565328|EXPERIMENTAL|Nicotinamide Riboside in patients with stable heart failure|Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) then increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000 mg PO BID (2000 mg/day) in patients with stable, systolic heart failure.
62849471|NCT01483417|EXPERIMENTAL|SILS|Laparoscopic hysterectomy including LAVH, LH(a), and TLH using SILS port
62849472|NCT01483417|ACTIVE_COMPARATOR|Conventional multi-port laparoscopic hysterectomy|3-4 ports laparoscopic hysterectomy including LAVH, LH(a), or TLH
62849473|NCT00147836|ACTIVE_COMPARATOR|CSII|Patients in continuous subcutaneous insulin infusion group received Human Insulin (Novolin-R, Novo Nordisk) with an insulin pump (H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland);
62849474|NCT00147836|ACTIVE_COMPARATOR|MDI|Patients in MDI group were treated with pre-meal Novolin-R, and Human Insulin NPH (Novolin-N, Novo Nordisk) at bedtime. Initial insulin doses were 0.4-0.5 IU/kg and total daily doses were divided into 50% of basal and 50% of bolus injection in CSII group and 30%-20%-20%-30% in multiple daily insulin injection group
62849475|NCT00147836|ACTIVE_COMPARATOR|OHA|In oral hpoglycemic agents group, the patients with 20 kg/m2\<BMI≤25kg/m2 were initiated with Gliclazide (Diamicron, Servier) 80mg Bid (maximum to 160mg Bid), the patients with 25kg/m2\<BMI≤35kg/m2 were initiated with Metformin (Glucophage, BMS) 0.5 Bid (maximum to 2.0g/d), the combination of Diamicron and Glucophage was used in patients who could not achieve glycaemic control goal with one OHA or with FPG≥11.1mmol/l at randomization
62265972|NCT06494189|EXPERIMENTAL|Treatment Cohort|"1. Tislelizumab administration on days 1 and 22, and afatinib continuous administration from days 1 to 42~2. Low dose radiotherapy(The phase Ia clinical trial took low dose radiotherapy doses of 2Gy/1f (on day 1) for group 1, 4Gy/2f (from days 1 to 2) for group 2, and 10Gy/5f (from days 1 to 5) for group 3. The radiotherapy doses in phase Ib were judged according to the efficacy and toxicity of phase Ia.)~3. Standard of care surgery"
62849476|NCT05189041|OTHER|Ruptured Cerebral Aneurysm|Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm
62849477|NCT05189041|OTHER|Non Ruptured Cerebral Aneurysm|Quantify the aneurysmal pulsation in functional MRI on the patient with Non Ruptured Cerebral Aneurysm
62849478|NCT02817932|EXPERIMENTAL|Group 1 (Korean, 375 mg)|Group 1 (Korean, 375 mg): Ranolazine PR 375 mg
62849479|NCT02817932|EXPERIMENTAL|Group 2 (Korean, 500 mg):|Group 2 (Korean, 500 mg): Ranolazine PR 500 mg
62849480|NCT02817932|EXPERIMENTAL|Group 3 (Korean, 750 mg):|Group 3 (Korean, 750 mg): Ranolazine PR 750 mg
62265973|NCT04342975|ACTIVE_COMPARATOR|Basis|The investigational product, Basis™, contains a synthetic NR that is nature-identical to naturally-occurring NR, does not induce flushing or pruritus and has no effect on lipid levels. Also contains Pterostilbene (Ptero) that is a stilbenoid compound, characterized by two aromatic rings connected by a methylene bridge backbone, and it has two methoxy groups and one hydroxyl group extending from the aromatic rings.
62623915|NCT02748759|ACTIVE_COMPARATOR|EXP 2: CPM / Manual mobilization|Patients were collocated in a commercially available CPM device (Kinetec Advanced Prima) and received 15 repetitions of flexo-extension. After a pause of 5 minutes, patients were subjected to a manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist.
62623916|NCT03163316||Breast cancer patients|Patients will undergo unenhanced magnetic resonance imaging on both axillae.
62849481|NCT02817932|EXPERIMENTAL|Group 4 (Caucasian, 375mg)|Group 4 (Caucasian, 375mg) : Ranolazine PR 375 mg
62849482|NCT02817932|EXPERIMENTAL|Group 5 (Caucasian, 750mg)|Group 5 (Caucasian, 750mg) : Ranolazine PR 750 mg
62849483|NCT00700388|EXPERIMENTAL|1|TPEP added to conventional manually assisted breathing techniques (MABT)
62849484|NCT00700388|ACTIVE_COMPARATOR|2|Manually assisted breathing techniques (MABT) alone
62849485|NCT05541536|EXPERIMENTAL|General information pamphlet plus Consultation meeting|Study team member will approach mothers \< 24 hrs (up to 5 min prior) of CRC approach for NRN trial. During the consultation meeting (5 minutes), the study team member will review the pamphlet and answer any questions. Visits will ideally occur in person. If the mother is not at bedside, 1 attempt will be made to reach the mother by phone in which case the pamphlet will be forwarded by mail.
62849486|NCT05541536|ACTIVE_COMPARATOR|Usual Care|Study participants will not receive the general information pamphlet or consultation.
62849487|NCT03171181|EXPERIMENTAL|UPVD non compensated|Intervention group: 30 participants with unilateral peripheral vestibular disorders. Exposed to vestibular reeducation.
62849488|NCT03171181|NO_INTERVENTION|control group|Control group, to obtain reference values.
62849489|NCT03171181|NO_INTERVENTION|UPVD compensated|Registered spatial orientation in a group of 30 participants with compensated lesion.
62849490|NCT04409860|ACTIVE_COMPARATOR|control group|In this group, observation is given after CCRT.
62849491|NCT04409860|EXPERIMENTAL|trial group|In this group, adjuvant chemotherapy is given after CCRT.
62849492|NCT05503238|EXPERIMENTAL|Skin-to-skin contact group|Provide maternal-infant skin-to-skin contact for preterm infants in the neonatal intensive care unit.
62849493|NCT05503238|OTHER|Routine care group|Perform routine nursing care for preterm infants in the neonatal intensive care unit.
62623917|NCT00078845|EXPERIMENTAL|Amifostine|500 mg subcutaneous three times a week on Monday, Wednesday and Friday for 4 weeks.
62061635|NCT05103163|EXPERIMENTAL|Foot reflexology group|Before the reflexology application, a personal information form was applied to the patients who had abdominal surgery. As a pre-test, satisfaction levels in terms of pain and nursing were evaluated. Then, vital signs (systolic blood pressure, diastolic blood pressure, pulse, respiration and saturation) were measured. Foot warming movements were started and then the warming movements were terminated by applying pressure to the solar plexus area of the left foot. Then in order; Reflexology was applied to the brain, lymphatic system, blood pressure area, lung, adrenal gland, thyroid, diaphragm, stomach and joint areas. Afterwards, relaxation movements were made for the foot, pressure was applied to the solar plexus and the reflexology application was completed within 30 minutes. Immediately after the application, vital signs were re-measured as a post-test, and the numerical pain scale and care satisfaction scale were applied again.
62061636|NCT05103163|NO_INTERVENTION|No treatment group|To the patients in the control group; Personal Information Form, Numerical Pain Scale (NPS) and Newcastle Nursing Care Satisfaction Scale (NNCSS) were applied as pre-test. After the questions were answered, NNCSS with NPS was applied again 40 minutes later as a final test, without any intervention other than the clinical protocol.
62087916|NCT00255814|OTHER|Radiation therapy dose level II: 4.0 Gy/fx|Radiation therapy dose level II: 4.0 Gy/fraction
62087917|NCT00255814|OTHER|Radiation therapy dose level III: 4.5 Gy/fx|Radiation therapy dose level III: 4.5 Gy/fraction
62087918|NCT00255814|OTHER|Radiation therapy dose level IV: 5.0 Gy/fx|Radiation therapy dose level IV: 5.0 Gy/fraction
62623918|NCT06127758|EXPERIMENTAL|VRG|
62849494|NCT00571168|EXPERIMENTAL|A|Aprepitant plus standard therapy (Kevatril + Dexamethason) on day 1-4
62849495|NCT00571168|PLACEBO_COMPARATOR|B|Placebo plus standard therapy (Kevatril + Dexamethason) on day 1-4
62849496|NCT01924416|EXPERIMENTAL|Enhanced Care|Enhanced Care: Decision aid; QL-PRO immediate summary results; chemotherapy cycles and imaging studies as needed
62849497|NCT01924416|ACTIVE_COMPARATOR|Usual Care|Usual Care: Routine chemotherapy cycles and imaging studies
62849498|NCT01409811|EXPERIMENTAL|Treatment (zoledronic acid)|"Patients receive a single dose of zoledronic acid 4 mg IV over 15 minutes on day 1. Patients then undergo planned definitive surgery (lumpectomy or mastectomy) on day 10-23. Tissue and blood samples from the initial biopsy and definitive surgery are collected to measure changes in biomarkers of tumor growth and metastasis, immunologic function, and the expression of genes important to breast cancer progression and metastasis.~zoledronic acid: Given IV~laboratory biomarker analysis: Correlative studies~therapeutic conventional surgery: Undergo definitive lumpectomy or mastectomy"
62849499|NCT02586779|EXPERIMENTAL|whatsApp messages|consultations in the experimental group will be generated with whatsApp. Patients' all radiographies, laboratory results, electrocardiographs, tomography images, wound images and/or extremity pictures will be sent to consultant physician via whatsApp.
62849500|NCT02586779|OTHER|control group|consultations in the control group will be generated without whatsApp.
62061637|NCT02815995|EXPERIMENTAL|Adipocytic Tumors Group|"Adipocytic Tumors Group consists of well-diff/de-differentiated, pleomorphic and myxoid LPS.~Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
62087919|NCT03528135|EXPERIMENTAL|Project PRIDE|"Those in the Project PRIDE condition will receive 8 weekly sessions, each lasting 2.5 hours and consisting of approximately 10 men (estimated number given expected attrition). Each session will be co-led by two trained group facilitators. The intervention sessions are described in the Detailed Description section. The will complete a pre-test, post-test, and follow-up assessment."
62265974|NCT04342975|PLACEBO_COMPARATOR|Placebo|Correspondent placebo, a capsule not containing the active component.
62849501|NCT02618499|ACTIVE_COMPARATOR|oxytocin inmediately at birth|Intervention: Timing of administration of postpartum Oxytocin. 10 international Units (IU) immediately at birth will be given intravenously (IV) to the mother.
62849502|NCT02618499|EXPERIMENTAL|oxytocin at 3 minutes|Intervention: Timing of administration of postpartum Oxytocin. 10 IU IV at 3 minutes immediately after the cord is clamped
62849503|NCT06426706|EXPERIMENTAL|Group S|Participants who will be receiving a serratus posterior superior intercostal plane block
62849504|NCT06426706|ACTIVE_COMPARATOR|Group P|Participants who will be receiving a thoracal paravertebral block
62849505|NCT00951197||elderly subjects retired from agriculture|
62849506|NCT06443931|EXPERIMENTAL|Cryoablation of intercostal nerves group|"Patients in the CryoINB group will undergo cryoablation of the intercostal nerves, at the end of surgery before weaning from CPB, using the ArtiCue device for 120 seconds at a temperature of -50°C to -70°C, in the intercostal spaces where the surgical approach is located, one intercostal space above and one below it."
62849507|NCT06443931|NO_INTERVENTION|Standard pain management protocol group|Patients in the group with the standard anesthesia protocol will receive an intercostal block in the area of surgical access - a single injection of 0.75% ropivacaine solution 20 ml.
62849508|NCT05957471|EXPERIMENTAL|BC3195 treatment group.|BC3195 via intravenous(IV).
62849509|NCT05611333|EXPERIMENTAL|Physician-Led Remote Exercise Program Intervention|Participants randomized to the intervention arm will attend three 45-minute walking sessions over Zoom per week for 4 weeks. All participants will be asked to wear Fitbit activity trackers to track steps every day and to regularly use blood pressure cuffs to measure blood pressure at home. All participants will also be asked to complete a brief set of surveys at the beginning of the study, after 4 weeks, and after 12 weeks.
62849510|NCT05611333|NO_INTERVENTION|Control|Participants in the control group will continue with usual care. All participants will be asked to wear Fitbit activity trackers to track steps every day and to regularly use blood pressure cuffs to measure blood pressure at home. All participants will also be asked to complete a brief set of surveys at the beginning of the study, after 4 weeks, and after 12 weeks.
62265975|NCT05243264|EXPERIMENTAL|Internet-Based Program|Participants will be provided with access to a 10-session online program and will receive supportive remote assistance throughout regarding technical and programmatic issues.
62849511|NCT05149885|EXPERIMENTAL|Investigational SenseGuard Device|"Subjects with suspected diagnosis of Asthma and eligible for MCT will be recruited to the study.~The MCT procedure will be performed as usual, with the addition of SG measurements after each spirometry for each Methacholine dose."
62849512|NCT04425213||Normal weight|BMI \< 25 kg/m2
62849513|NCT04425213||Overweight|BMI : 25 - 29.9 kg/m2
62849514|NCT04425213||Moderate obesity|BMI : 30 - 39.9 kg/m2
62849515|NCT04425213||Severe obesity|BMI : \> or = 40 kg/m2
62849516|NCT00906633||Outcome of combination antifungal therapy|
62849517|NCT02508818|OTHER|Cardiovascular measurements|
62849518|NCT03084783|EXPERIMENTAL|Intervention group|Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
62265976|NCT02830100|OTHER|Healthy volunteers|
62265977|NCT04503239||Prediabetes (both IGT and IFG)|Device: G6 Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
62623919|NCT06127758|ACTIVE_COMPARATOR|control group|
62849519|NCT03084783|NO_INTERVENTION|Control group|Participants receive standard care and no dexamethasone.
62849520|NCT01756170|ACTIVE_COMPARATOR|Arm 2|Patients receive radiotherapy alone as in arm 1.
62849521|NCT01756170|EXPERIMENTAL|Arm 1|Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area.
62849522|NCT01688531|EXPERIMENTAL|CD0271 0.1%/CD1579 2.5% gel|Split-face design, one application a day for 6 months
62849523|NCT01688531|PLACEBO_COMPARATOR|CD0271 0.1%/CD1579 2.5% gel vehicle|Split-face design, one application a day for 6 months
62849524|NCT04192383||Cyberknife|
62849525|NCT01368328|PLACEBO_COMPARATOR|Placebo|
62849526|NCT01368328|ACTIVE_COMPARATOR|Chromium nicotinate 50 mcg|
62849527|NCT01368328|ACTIVE_COMPARATOR|Chromium nicotinate 200 mcg|
62849528|NCT02110459|EXPERIMENTAL|Mild renal impairment|3h IV POL7080 infusion
62849529|NCT02110459|EXPERIMENTAL|Moderate renal impairment|3h IV POL7080 infusion
62849530|NCT02110459|EXPERIMENTAL|Severe renal impairment|3h IV POL7080 infusion
62849531|NCT02110459|EXPERIMENTAL|End stage renal disease arm 1|3h IV POL7080 infusion
62849532|NCT02110459|EXPERIMENTAL|End stage renal disease arm 2|3h IV POL7080 infusion
62849533|NCT02110459|EXPERIMENTAL|Normal Renal function|3h IV POL7080 infusion
62849534|NCT06259656|OTHER|Thai term pregnant woman who have at least One dose of Covid vaccination|Maternal and cord blood was collected to test COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)
62849535|NCT02936648|EXPERIMENTAL|quality improvement intervention|The intervention activities included: assessment, planning, stakeholder engagement, education, ongoing process monitoring, program adaptation, problem identification and problem solving, data audit/feedback, program marketing, network development, among others.
62849536|NCT04291989|EXPERIMENTAL|Earlobe and Finger Prick versus venous blood lactate sampling|Compare blood Lactate levels between ear lobe and finger against venous forearm blood sample using the electronic hand held lactate device in hip fracture patients with good cognitive function (AMT \>/= 7)
62849537|NCT02490670|EXPERIMENTAL|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
62849538|NCT02490670|ACTIVE_COMPARATOR|Cephalexin (Test)|Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods.
62849539|NCT06083922|EXPERIMENTAL|Arm A will include patients with cast nephropathy|Planned 8 cycles of CyBorD-Dara SC, treatment will be left to the discretion of the treating physician. It is recommended that patients eligible for ASCT undergo ASCT after 8 cycles of induction and that patient ineligible for ASCT, continue maintenance Bortezomib/Dexamethasone administered every other week with daratumumab SC administered every 4 weeks, for a period of 2 years from start of treatment.
62849540|NCT06083922|EXPERIMENTAL|Arm B will include all other MGRS associated diseases with the exclusion of AL amyloidosis|Planned 8 cycles of CyBorD-Dara SC, treatment will be left to the discretion of the treating physician. It is recommended that patients eligible for ASCT undergo ASCT after 8 cycles of induction and that patient ineligible for ASCT, continue maintenance Bortezomib/Dexamethasone administered every other week with daratumumab SC administered every 4 weeks, for a period of 2 years from start of treatment.
62265978|NCT04503239||Type 2 Diabetes on 1 OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
62061638|NCT02815995|EXPERIMENTAL|Vascular Tumors Group|"Vascular Tumors Group consists of leiomyosarcomas, angiosarcomas, epithelioid hemangioendotheliomas, and hemangiopericytomas.~Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
62265979|NCT04503239||Type 2 Diabetes on 2 or more OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
62623920|NCT03336931||High-risk childhood cancers|Expected survival \< 30%
62623921|NCT04035525|EXPERIMENTAL|MaxSimil® fish oil + CoQ10|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g MaxSimil® fish oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
62461252|NCT04335578|PLACEBO_COMPARATOR|Placebo|Participants randomized to this arm will receive matching Placebo.
62461253|NCT02244034||760 patients who underwent open cardiac and/or thoracic aortic surgery using CPB|
62265980|NCT04503239||Type 2 Diabetes using Basal insulin with or without OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
62623922|NCT04035525|ACTIVE_COMPARATOR|Rice bran oil + CoQ10|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g rice bran oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
62623923|NCT04035525|ACTIVE_COMPARATOR|CoQ10 as powder form|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g rice bran oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
62623924|NCT03758235|EXPERIMENTAL|Incobot/A 100 U|Incobot/A 100 U diluted in 10 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (20 injections, 0.5 ml of solution for each injection) will be administered in patients able to perform spontaneous micturitions
62623925|NCT03758235|EXPERIMENTAL|Incobot/A 200 U|Incobot/A 200 U diluted in 30 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (30 injections, 1 ml of solution for each injection) will be administered in patients performin intermittent catheterization.
62623926|NCT03758235|ACTIVE_COMPARATOR|Onabot/A 100 U|Onabot/A 100 U diluted in 10 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (20 injections, 0.5 ml of solution for each injection) will be administered in patients able to perform spontaneous micturitions
62265981|NCT04503239||Type 2 Diabetes in GLP-1 with or without OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
62265982|NCT04503239||Type 2 Diabetes using intense insulin treatment-Multiple Dail|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
62265983|NCT04503239||Type 2 Diabetes in MDI or basal insulin plus GLP-1|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
62265984|NCT04503239||Type 2 Diabetes on 0 OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
62265985|NCT04503239||High Risk to Develop Prediabetes / Type 2 Diabetes|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
62265986|NCT01527214|EXPERIMENTAL|CT scan and education|All general practices referring to the Department of Pulmonary Medicine, Aarhus University Hospital.Randomized 1:1. In the intervention group, GPs continue to refer to the lung cancer fast track when indicated. In addition, they are allowed to refer directly to a rapid chest CT scan in cases where they find reasons to examine the patient for lung diseases without having sufficient suspicion of lung cancer to refer the patient to the lung cancer fast track. The GPs will be offered special training related to the diagnosis of lung cancer in general practice before the new referral option is introduced. This will be done by offering training sessions and written material.
62849541|NCT01548833|EXPERIMENTAL|Dailies Total 1|Delefilcon A, followed by narafilcon A and filcon II 3 in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
62849542|NCT01548833|ACTIVE_COMPARATOR|TruEye|Narafilcon A, followed by delefilcon A and filcon II 3 in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
62849543|NCT01548833|ACTIVE_COMPARATOR|Clariti|Filcon II 3, followed by narafilcon A and delefilcon A in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
62061639|NCT02815995|EXPERIMENTAL|Undifferentiated Pleomorphic Sarcoma Group|"Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
62623927|NCT03758235|ACTIVE_COMPARATOR|Onabot/A 200 U|Onabot/A 200 U diluted in 30 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (30 injections, 1 ml of solution for each injection) will be administered to patients performing intermittent catheterization
62623928|NCT04987931||Primary population: Talazoparib-treated patients with HER2- ABC with gBRCA1/2m|HER2-negative ABC patients with gBRCA1/2 mutations treated with talazoparib monotherapy initiated on or after October 16, 2018 and ≥18 years of age at initiation of talazoparib.
62849544|NCT03609606|EXPERIMENTAL|Part A, Sequence1|"* Period 1: Treatment of D013, D326 and D337 on Day1\~Day7~* Period 2: Treatment of D013 on Day22\~Day28"
62849545|NCT03609606|EXPERIMENTAL|Part A, Sequence 2|"* Period 1: Treatment of D013 on Day1\~Day7~* Period 2: Treatment of D013, D326 and D337 on Day22\~Day28"
62461254|NCT06266052|EXPERIMENTAL|Group 1|triangular flep design will be use in third molar impacted surgery
62849546|NCT03609606|EXPERIMENTAL|Part B, Sequence 1|"* Period 1: Treatment of D013, D326 and D337 on Day1\~Day7~* Period 2: Treatment of D326 and D337 on Day22\~Day28"
62849547|NCT03609606|EXPERIMENTAL|Part B, Sequence 2|"* Period 1: Treatment of D326 and D337 on Day1\~Day7~* Period 2: Treatment of D013, D326 and D337 on Day22\~Day28"
62849548|NCT02385422|EXPERIMENTAL|Carvedilol|Carvedilol，6.25mg-25mg/d,oral,6 months
62849549|NCT02385422|ACTIVE_COMPARATOR|Propranolol|Propranolol,30mg-160mg/d,oral,6 months
62849550|NCT01467219|EXPERIMENTAL|PET Probe|"Patients will receive an IV injection of approximately 5 MBq/kg body weight of 18F-FDG (Fludeoxyglucose) (up to 550 MBq). Following injection, patients will undergo CT and PET scans. Intraoperatively, a hand held gamma counter will be used to identify hot lymph nodes."
62849551|NCT00284453||1|Forty(40)subjects that have received \>2 appropriate ICD shock therapies
62849552|NCT00284453||2|Twenty(20)subjects that have received 1-2(low level)appropriate ICD therapies
62849553|NCT00284453||3|Ten(10)subjects that received inappropriate therapies from their ICD
62849554|NCT01343381|ACTIVE_COMPARATOR|Hepalean Heparin|
62849555|NCT01343381|ACTIVE_COMPARATOR|PPC Heparin|
62265987|NCT01527214|NO_INTERVENTION|Control|Cluster eligibility: all practices referring to the Department of Pulmonary Medicine, Aarhus University Hospital. Randomized 1:1. Control arm continues with the usual referral pattern
62265988|NCT00579852||1|Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day.
62849556|NCT05322668|EXPERIMENTAL|Condition 1|"All the subjects will receive all the treatment in the same order.~The following prototypes will be applied on hands areas:~Application of the prototype (812A-v1) at Day 0, Application of the prototype (812C-v1) at Day 0, Application of the prototype (812D-v1) at Day 0, Application of the prototype (812F-v1) at Day 0,"
62849557|NCT04235296|ACTIVE_COMPARATOR|control group|epidermal growth factor
62087920|NCT03528135|NO_INTERVENTION|Wait-list|Those in the wait-list arm will wait approximately 5 months before receiving the intervention. They will complete the same pre-test, post-test, and follow-up assessments as those in the PRIDE arm. After they have completed the follow-up assessment, they will be offered the intervention.
62265989|NCT05941078|EXPERIMENTAL|ICF-based post-stroke rehabilitation program group|The ICF-PSRP based on the ICF Core Set for Stroke targeted to facilitate patients' functional improvement, and community and social reintegration. Duration of the ICF-PSRP was eight or 12 weeks, comprising of 30 or 48 two-hour sessions depending on the patients' needs and progress.
62849558|NCT04235296|EXPERIMENTAL|experimental group|mesenchymal stem cell conditioned medium-derived pleiotropic factor
62849559|NCT06521528||Feasibility cohort|patients who underwent gastrectomy between September 2019 and August 2020 across nine hospitals.
62265990|NCT04793256|EXPERIMENTAL|intervention|Fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride). Group (1)
62265991|NCT04793256|ACTIVE_COMPARATOR|comparator|Resin based fissure sealant (3M Clinpro Sealant, light cure, low viscosity, fluoride release).group (2)
62849560|NCT04166240|EXPERIMENTAL|SAFER TRACKS Intervention|Each cluster starts receiving the intervention in sequence per cluster randomized control trial designs. Each cluster will participate in attending monthly coaching calls and compare their data on test results from pre-intervention to receiving the intervention.
62849561|NCT04166240|NO_INTERVENTION|Non-intervention period|When the cluster is not in active intervention, they are in the non-intervention period. The amount of time that each site contributes to the intervention depends on which cluster they belong to.
62849562|NCT06462092|EXPERIMENTAL|Group|A minimum of 3 patients and a maximum of 6 patients were recruited per cohort in phase 1 study.. When dose-limiting toxicity occurred in ≥2 patients, the treatment regimen was considered to have too many side effects, and a reduction in the intrathecal chemotherapy dose of pemetrexed to a single dose of 10 mg was given, with continued enrollment of 6 consecutive patients. If DLT occurred again in ≥2 patients, the trial would be stopped. Otherwise, the study entered a phase 2 trial when DLT occurred in ≤1 patient.
62849563|NCT04036188|EXPERIMENTAL|Triamcinolone Cream + Vitamin D3|This arm will continue to take Vitamin D3 at Week 16 to Week 28.
62849564|NCT04036188|PLACEBO_COMPARATOR|Triamcinolone Cream + Placebo|Starting at Week 16, this arm will be given Vitamin D3 to take until Week 28.
62849565|NCT03702413|NO_INTERVENTION|Best medical treatment|Best medical treatment
62265992|NCT03998046|ACTIVE_COMPARATOR|Basic Resources and Services|Patients will receive outreach engagement in goal setting via MyChart, an electronic scale, telemonitoring of self weighing, and information about linkages to extant intensive lifestyle interventions in the community
62265993|NCT03998046|EXPERIMENTAL|Coordinated Primary Care Population Management (C3PO)|Patients will receive outreach engagement in goal setting via MyChart, an electronic scale, telemonitoring of self weighing, information about linkages to extant intensive lifestyle interventions, and outreach MyChart messages that are tailored to each individual's pattern of self-weighing and progress towards their weight goal, and more intensive support from a primary care nurse based on self-weighing behavior and weight loss success.
62265994|NCT00283114|EXPERIMENTAL|1|
62461255|NCT06266052|EXPERIMENTAL|Group 2|Berwick flep design will be use in third molar impacted surgery
62461256|NCT06266052|EXPERIMENTAL|Group 3|Saurez flep design will be use in third molar impacted surgery
62461257|NCT06266052|EXPERIMENTAL|Group 4|Heitz
62849566|NCT03702413|EXPERIMENTAL|Endovascular treatment|Best medical treatment plus endovascular treatment
62849567|NCT00223080|ACTIVE_COMPARATOR|Vaccine|ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.
62849568|NCT00223080|PLACEBO_COMPARATOR|Placebo|ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.
62849569|NCT03471416||Children with ALL|Children undergoing ALL treatment at UNOP Guatemala who are under the age of 18 years.
62849570|NCT03471416||Healthy siblings|Healthy siblings of children undergoing ALL treatment at UNOP Guatemala who are under the age of 18 years.
62849571|NCT03486626|EXPERIMENTAL|Patients|
62849572|NCT04043741|EXPERIMENTAL|Dry Needling|Dry needling (04 Sessions) and exercises
62265995|NCT06098768|OTHER|Floreo BSC|Subjects and their caregiver will engage in the Floreo VR Building Social Connections VR sessions: three sessions per week, for 12 weeks. Each session will consist of 2 VR (Floreo BSC) lessons separated by a brief break, for a total of approximately 15 minutes of direct VR time over a 30-minute period. Treatment sessions will be scheduled over a 12-week period, with an allowance of up to 15 weeks for make-up sessions (e.g., illness or travel).
62265996|NCT04460976|EXPERIMENTAL|Experimental group|Experiment group that receives the psychoeducation direct after the baseline measurement.
62265997|NCT04460976|OTHER|Control group|Standard care / treatment as usual. Comparison group alos receives Prisma psychoeducation after the three-month follow-up time period.
62265998|NCT06267196|ACTIVE_COMPARATOR|Stress ball group|The patient group in which a stress ball is used during spinal anesthesia.
62265999|NCT06267196|NO_INTERVENTION|The control group|The group that receives only standard spinal anesthesia
62849573|NCT04043741|ACTIVE_COMPARATOR|Sustain Pressure|sustained pressure and Exercises
62849574|NCT03705013||Baseline Cologuard positive and negative colonoscopy|Those whose Cologuard T0 result was positive and colonoscopy result was negative.
62849575|NCT03705013||Baseline Cologuard positive and no colonoscopy|Those whose Cologuard T0 result was positive and subject declined to complete a colonoscopy per protocol.
62849576|NCT03705013||3-year follow-up Cologuard positive and negative colonoscopy|Those whose Cologuard result at T3 was positive and colonoscopy result at T3 was negative.
62849577|NCT03705013||3-year follow-up Cologuard positive and no colonoscopy|Those whose Cologuard result at T3 was positive and subject declined to complete a colonoscopy per protocol.
62266000|NCT00729456|NO_INTERVENTION|1|
62266001|NCT00729456|OTHER|2|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
62286831|NCT03642145|EXPERIMENTAL|Arm A: Deflazacort 0.9 mg/kg|Participants will receive approximately 0.9 mg/kg deflazacort once daily orally for 52 weeks in Period 1 and for 52 weeks in Period 2. The target dose could be varied +/- 20 percent (%) depending upon the available tablet strengths and change in participant's weight.
62461258|NCT01522352|EXPERIMENTAL|pericardial aortic valves|Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
62461259|NCT05352386|OTHER|Patients with familial hypercholesterolemia, early treated|
62266002|NCT02180360|EXPERIMENTAL|Capoeira training group|"The Capoeira training was performed during eight weeks, twice a week with duration of 60min each session, divided in 1) initial part: 10min warm-up with activities of low intensity or the ginga used in Capoeira; 2) main part: from the Basic Programmed Lesson (40min) and ; 3) final part: Capoeira presentation of 10min. In this last moment, the participants remained in a circle and, in pairs, executed the movements practiced earlier in the sessions. In order to perform the Basic Programmed Lesson, the activities were divided in four stages, composed by ginga and other movements: dodging, unbalancing, traumatizing and acrobatic. The volunteers would perform the initial part of the basic lesson (ex. 1st stage) and afterwards, when performing the subsequent part (ex. 2nd stage), would first repeat the 1st basic lesson, with the purpose of continuing the learning process and improving the previous lesson."
62849578|NCT01105767|NO_INTERVENTION|Group 1 Standard|Trainees received a preventive medicine briefing augmented with SSTI and MRSA SSTI prevention information and personal hygiene instructions. Trainees seeking medical care for an SSTI received standardized SSTI care (e.g., antimicrobial therapy, wound management, patient education) at the Troop Medical Clinic. High-touch common surfaces within the battalion areas were cleaned with standard Environmental Protection Agency-registered disinfectants.
62849579|NCT01105767|ACTIVE_COMPARATOR|Group 2 Enhanced Standard|Trainees received the components of the Standard group as well as supplemental training, education and hygiene. They were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit. Supplemental SSTI education for trainees and drill sergeants was also provided (e.g., pocket cards, posters). Drill sergeants received briefings on SSTI and skin inspection/minor wound care.
62849580|NCT01105767|ACTIVE_COMPARATOR|Group 3 Chlorhexidine|Trainees received the components of the Standard and Enhanced Standard groups and were offered chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) to use with a wash cloth after using their personal soap for the additional once-weekly shower. Trainees were provided with verbal and written/graphic instructions for use.
62849581|NCT05589558|EXPERIMENTAL|Patients with suspected prostate cancer underwent 4 biopsy methods|Patients with suspected prostate cancer consequently underwent TRUS-guided, cognitive, fusion and transperineal template mapping biopsy
62849582|NCT01716416|EXPERIMENTAL|Dose Level 1|"Pazopanib 200 mg PO QD~Cetuximab 400 mg/m\^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m\^2"
62849583|NCT01716416|EXPERIMENTAL|Dose Level 2|"Pazopanib 400 mg PO QD~Cetuximab 400 mg/m\^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m\^2"
62849584|NCT01716416|EXPERIMENTAL|Dose Level 3|"Pazopanib 600 mg PO QD~Cetuximab 400 mg/m\^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m\^2"
62849585|NCT01716416|EXPERIMENTAL|Dose Level 4|"Pazopanib 800 mg PO QD~Cetuximab 400 mg/m\^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m\^2"
62266003|NCT02180360|NO_INTERVENTION|Control group|The Control group did not perform any physical exercise during the intervention period (eight weeks).
62266004|NCT01073332|PLACEBO_COMPARATOR|Placebo|The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
62849586|NCT01716416|EXPERIMENTAL|Part 2 Dose|"Pazopanib (dose to be determined in Part 1 of study) mg PO QD~Cetuximab 400 mg/m\^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m\^2"
62849587|NCT04734561|EXPERIMENTAL|Inspiratory muscle training group|Participants will perform an inspiratory muscle training by a threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
62849588|NCT04734561|SHAM_COMPARATOR|Inspiratory muscle training placebo group|Participants will perform an inspiratory muscle training by a placebo threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
62849589|NCT04734561|EXPERIMENTAL|Inspiratory + expiratory muscle training group|Participants will perform an inspiratory and expiratory muscle training by a threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
62087921|NCT01222247|ACTIVE_COMPARATOR|Betamethasone|A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart
62266005|NCT01073332|EXPERIMENTAL|Arginine antioxidant supplements|Dietary Supplement: Niteworks
62461260|NCT05352386|OTHER|Patients without familial hypercholesterolemia, late treated|
62461261|NCT05352386|OTHER|Healthy individuals|
62087922|NCT01222247|PLACEBO_COMPARATOR|Placebo|A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
62266006|NCT04986397|EXPERIMENTAL|Cold Therapy & Standard Post Operative Analgesia|Patients in the cryotherapy group will have the ice water in their cryotherapy device maintained continuously for 2 days from initial application as this is the reported time of average patient disability and children typically return to school by post-operative day 3. The device will not be placed directly on the skin to minimize tissue damage. An additional protective barrier pad included with the cold therapy device will provide a barrier between the skin and the cooling device. This allows for continuous cooling at a higher target skin temperature. Aside from the cryotherapy, all surgical treatment will be standard of care.
62449515|NCT05743218|EXPERIMENTAL|liver meridian group|Four acupoints; LR3 Taichong, LR5 Ligou, LR8 Ququan, and LR12 Jiman. Based on the national standard of the People's Republic of China in 2006 (GB/T 12346-2006). The patient will be in a supine position. Taichong will be punctured at a 25-mm depth using a 0.35×25-mm filiform needle, Ligou will be punctured at a 15-20-mm depth with a 0.35×25-mm filiform needle, Ququan at a 20-25-mm depth with a 0.30×40-mm filiform needle, and an acute pulse of 15-20 mm. Each acupoint will be subject to a small amount of uniform lifting and twisting to the degree of local acid distension. An auxiliary needle (0.16×13 mm) will be inserted approximately 5 mm into the needle, 2 mm proximal to the heart of each acupoint along the meridian. The negative electrode will be connected to the main point, and the positive electrode will be connected to the auxiliary needle, and connect the electroacupuncture instrument. The needles will be retained for 30 min respectively, once every other day, 36 treatments.
62849590|NCT04734561|SHAM_COMPARATOR|Inspiratory + expiratory muscle training placebo group|Participants will perform an inspiratory and expiratory muscle training by a placebo threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
62849591|NCT05690867|OTHER|Group 1|group 1 starts with volume controlled ventilation
62849592|NCT05690867|OTHER|Group 2|group 2 starts with pressure controlled ventilation
62849593|NCT04180540|EXPERIMENTAL|Percutaneous Closure|Participants randomized to undergo percutaneous closure with PerClose after radiofrequency ablation or cryoablation for treatment of atrial fibrillation.
62623929|NCT02990871||early rehabilitation|Patients started rehabilitative treatment during ICU hospitalization
62849594|NCT04180540|ACTIVE_COMPARATOR|Manual Compression|Participants randomized to undergo manual compression after radiofrequency ablation or cryoablation for treatment of atrial fibrillation.
62849595|NCT04509622|EXPERIMENTAL|Venetoclax + Low-Dose Cytarabine (LDAC)|Participants will receive venetoclax once daily (QD) on days 1 through 28 plus LDAC QD on days 1 through 10 during the 28-day treatment cycles.
62849596|NCT03284892|EXPERIMENTAL|SOC group|Received SOC program addition to usual care
62849597|NCT03284892|NO_INTERVENTION|Control group|Received usual care only
62849598|NCT05583578|EXPERIMENTAL|Active tDCS|
62849599|NCT05583578|SHAM_COMPARATOR|Sham tDCS|
62266007|NCT04986397|ACTIVE_COMPARATOR|Standard Post Operative Analgesia|
62623930|NCT02990871||no-early rehabilitation|Patients started rehabilitative treatment after admission in Neuro-rehabilitation department
62623931|NCT00734656|PLACEBO_COMPARATOR|Placebo medication + placebo alcohol|
62623932|NCT00734656|EXPERIMENTAL|Placebo Medication + 0.8 gr/kg Ethanol|
62623933|NCT00734656|EXPERIMENTAL|4 mg Dutasteride + Placebo Alcohol|
62623934|NCT00734656|EXPERIMENTAL|4 mg Dutasteride + 0.8 gr/kg Ethanol|
62849600|NCT06094491|EXPERIMENTAL|Virtual Group Visit Arm|These subjects will attend 6 monthly virtual group visits hosted by ACCESS or Advocate research staff.
62849601|NCT06094491|NO_INTERVENTION|Usual Care Arm|These subjects will receive usual diabetes care at ACCESS or Advocate health centers.
62849602|NCT05520554||Telerehabilitation Satisfaction|Telerehabilitation Satisfaction Group
62849603|NCT01189019|EXPERIMENTAL|Group 1 - 2mg ranibizumab monthly|2mg ranibizumab monthly
62849604|NCT01189019|ACTIVE_COMPARATOR|Group 2 - 2mg x 3 then PRN|
62849605|NCT04589026|ACTIVE_COMPARATOR|Active Arm: Candin + Consentyx|Participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% sodium chloride (NaCl), and a single dose of Cosentyx injection subcutaneously.
62849606|NCT04589026|NO_INTERVENTION|Control Arm: Candin|All participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% NaCl, and no Cosentyx.
62849607|NCT03010488|EXPERIMENTAL|Rapid Sleep Shift|Assigned Sleep Times designed to shift sleep times over several days from Baseline to desired through morning light therapy while wearing goggles.
62849608|NCT03010488|ACTIVE_COMPARATOR|Gradual Sleep Shift|Assigned Sleep Times designed gradually shift sleep from current to desired sleep times while using morning light therapy while wearing goggles.
62849609|NCT03499535|ACTIVE_COMPARATOR|Study 1: Radon&Smoking Synergistic/EPA|Participants viewed radon and smoking risk information taken from the EPA's pamphlet on the dangers of radon gas exposure.
62849610|NCT03499535|ACTIVE_COMPARATOR|Study 1: Radon&Smoking Synergistic/Idaho|Participants viewed radon and smoking risk information taken from Idaho's Department of Health and Human Welfare's pamphlet on the dangers of radon gas exposure.
62849611|NCT03499535|EXPERIMENTAL|Study 1: Radon Only / EPA|Participants viewed only radon risk information taken from the EPA's pamphlet on the dangers of radon gas exposure.
62849612|NCT03499535|EXPERIMENTAL|Study 1: Radon Only / Idaho|Participants viewed only radon risk information taken from Idaho's Department of Health and Human Welfare's pamphlet on the dangers of radon gas exposure.
62849613|NCT03499535|EXPERIMENTAL|Study 2: Radon Only|Participants viewed a radon-only message that focused only on the effect of radon on lung-cancer risk.
62849614|NCT03499535|OTHER|Study 2: Radon and Smoking Isolated|Participants viewed a radon-and-smoking-isolated message that covered the individual effects of radon and of smoking on lung cancer, but without mentioning their synergistic effect.
62849615|NCT03499535|ACTIVE_COMPARATOR|Study 2: Radon & Smoking Synergistic|Participants viewed a radon-and-smoking-synergistic message that covered the individual effects of radon and of smoking but that also included information about their synergistic effect.
62849616|NCT00946985|EXPERIMENTAL|001|paliperidone palmitate 50 75 100 or 150 mg eq. monthly injection for 2 years
62849617|NCT00946985|ACTIVE_COMPARATOR|002|oral risperidone 2 4 6 or 8 mg tabs once daily for two years
62849618|NCT05290571|EXPERIMENTAL|Intervention Group|Intervention Group will be asked to follow the actions in the provided video. It lasts for approximately 30 minutes, with 5-minute warm-up and cool-down exercises respectively, a 4-minute song repeating for 4 times and a 1-minute rest in between each repetition. Videos, in the form of a YouTube link, will be distributed for the Intervention Group, as well as the leaflets.
62849619|NCT05290571|ACTIVE_COMPARATOR|Control Group|Control Group will receive a leaflet on 10 actions extracted from mOEP, 2 actions from conventional OEP and 1 action from Mini-BESTest. The participants will perform 8-16 repetitions for each action, with 3-5 seconds of rest between actions.
62849620|NCT01641419|PLACEBO_COMPARATOR|Placebo|Ropivacaine 0.5% plus 2ml of normal saline used for nerve block
62849621|NCT01641419|ACTIVE_COMPARATOR|Dexamethasone 4 mg|Ropivacaine 0.5% plus 2ml of dexamethasone 4 mg used for nerve block
62849622|NCT01641419|ACTIVE_COMPARATOR|Dexamethasone 8 mg|Ropivacaine 0.5% plus 2ml of dexamethasone 8 mg used for nerve block
62849623|NCT02270944|EXPERIMENTAL|Liquid GBS trivalent vaccine|Healthy non-pregnant women aged 18-40 years that received a single dose of liquid GBS trivalent vaccine
62849624|NCT02270944|ACTIVE_COMPARATOR|Lyophilized GBS trivalent vaccine|Healthy non-pregnant women aged 18-40 years that received a single dose of lyophilized GBS trivalent vaccine
62849625|NCT00710216|ACTIVE_COMPARATOR|A|
62849626|NCT00710216|EXPERIMENTAL|B|
62849627|NCT00933556|EXPERIMENTAL|probiotic|subjects will be given a powder formulation of a probiotic VSL#3 to be taken once a day, at a dose of 6 gms
62849628|NCT00933556|PLACEBO_COMPARATOR|sugar pill|placebo identical to the active product will be given
62849629|NCT01745497|EXPERIMENTAL|Ferrous Sulfate|3mg/kg divided twice per day, 30 minutes before a meal or 2 hours after a meal
62849630|NCT01745497|PLACEBO_COMPARATOR|Placebo|Equivalent volume of liquid placebo administered twice daily, before a meal or 2 hours after a meal
62849631|NCT02059096|EXPERIMENTAL|Repetitive transcranial magnetic stimulation (rTMS)|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation
62849632|NCT02059096|OTHER|Theta-Burst Stimulation (pcTBS)|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation.
62849633|NCT02059096|OTHER|repetitive Transcranial Magnetic Stimulation (rTMS)placebo|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation.
62849634|NCT05241977||Anterior suprasscapular nerve block|A single researcher will perform the nerve blocks of all participants.
62849635|NCT03408704|EXPERIMENTAL|ASP-arm|This group of primary health care centers get the internal education (ASP).
62849636|NCT03408704|NO_INTERVENTION|Control-arm|No intervention at all.
62849637|NCT05025956|EXPERIMENTAL|Fisetin group (investigational group)|"20mg/kg of Fisetin per day for days 1 and 2 prior to surgery and days 33, 34, 63, 64, 93, and 94 post surgery.~(The pills are 100mg each. For example, if a participant weighs 160 pounds (about 73 kg), the participant will need to take 15 pills per day)"
62849638|NCT05025956|PLACEBO_COMPARATOR|Placebo group (control group)|"20mg/kg of Placebo per day for days 1 and 2 prior to surgery and days 33, 34, 63, 64, 93, and 94 post surgery.~(The pills are 100mg each. For example, if a participant weighs 160 pounds (about 73 kg), the participant will need to take 15 pills per day)"
62849639|NCT05563155|PLACEBO_COMPARATOR|Placebo tablet on day 1 after surgery given as one single dose.|"Control Group (CG):~Intervention: Postoperative oral placebo tablet on day 1 after surgery given as one single dose."
62849640|NCT05563155|ACTIVE_COMPARATOR|Dexamethasone 24 mg on day 1 after surgery given as one single dose.|"Repeat Dose Group (RDG):~Intervention: Postoperative oral dexamethasone 24 mg on day 1 after surgery given as one single dose."
62849641|NCT06396104|EXPERIMENTAL|Mobilization with movement group|
62849642|NCT06396104|SHAM_COMPARATOR|Sham group|
62849643|NCT02637830|EXPERIMENTAL|Fluoride varnish and fluoride toothpaste|Application of fluoride varnish (Duraphat) at the begining of the study. Application of fluoride toothpaste (Crest) twice a day for 3 days.
62849644|NCT02637830|PLACEBO_COMPARATOR|placebo toothpaste|Application of placebo toothpaste twice a day for 3 days
62849645|NCT02637830|ACTIVE_COMPARATOR|Fluoride toothpaste|Application of fluoride toothpaste (Crest) twice a day for 3 days
62849646|NCT04046614|EXPERIMENTAL|nintedanib nivolumab|nintedanib-nivolumab combination therapy
62061640|NCT02815995|EXPERIMENTAL|Synovial Sarcoma Group|"Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
62461262|NCT02724800|ACTIVE_COMPARATOR|CBTI|CBTI consists of five in-person sessions within an eight week period. Topics covered include: sleep education, stimulus control, sleep restriction, relaxation strategies, cognitive therapy, and sleep hygiene.
62061641|NCT02815995|EXPERIMENTAL|Osteosarcoma Group|"Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
62061642|NCT02815995|EXPERIMENTAL|Other Sarcomas Group|"Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
62849647|NCT00093379|EXPERIMENTAL|Capecitabine + Oxaliplatin + XRT|Capecitabine (825 mg/m\^2 twice a day, Monday-Friday during weeks 1, 2, 4, and 5) and Oxaliplatin (50 mg/m\^2, Days 1, 8, 22, 29) during the duration of radiation therapy only. Radiotherapy once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. Participants with T3-4 lesions undergo radiotherapy once daily on days 43 and 44. The final dose of radiation therapy determined by the T stage of the primary tumor. Radiotherapy = XRT.
62849648|NCT01456897|EXPERIMENTAL|OPC-34712|
62849649|NCT06140953|EXPERIMENTAL|control group (conventional treatment)|control group Weight reduction and life style modification(modification in diet like decrease lipids intak).pateints will recieve their conventional therapy
62849650|NCT06140953|EXPERIMENTAL|interventions: drug trimetazidine|trinetazidine group Weight reduction and life style modification and receive (trimetazidine) 20 mg three times dialy for 24 weeks plus their conventional treatment
62849651|NCT04613427||Unruptured intracranial aneurysm|Patients admitted at Haukeland University Hospital in the study period for treatment of UIA.
62849652|NCT04613427||Aneurysmal subarachnoid hemorrhage|Patients admitted at Haukeland University Hospital in the study period for treatment of aSAH.
62849653|NCT02751385|EXPERIMENTAL|All Patients|Microgynon alone in Period 1 then with Nintedanib in Period 2
62849654|NCT04095429|EXPERIMENTAL|Expect Respect Support Group|"Experimental: Expect Respect Support Group Expect Respect is a program intended to create safe, trauma-informed space for young people who have been exposed to violence, to promote positive bystander intervention and healthy relationship skills, to alter norms that foster TDV/SV perpetration, and reduce violence perpetration through weekly support groups with students at elevated risk for such perpetration. Youth with prior history of exposure to violence are invited to in-school gender specific support groups that take place over 24 in-classroom sessions.~Expect Respect addresses violence perpetration prevention with youth already exposed to violence by recognizing violence as a problem that is fueled by gender norms that promote dominance and challenging the need to control and exert power in relationships especially with the use of violence, while simultaneously strengthening emotion regulation, social skills, and connectedness."
62849655|NCT04095429|ACTIVE_COMPARATOR|Enhanced Usual Care|Comparator: Enhanced Usual Care The control arm will receive enhanced usual care. Enhanced care means that the investigators will ensure each school has information, resource lists, and connection to services for individual youth who are referred to the study, including warm referrals to victim service agencies, behavioral health services, as well as resources (e.g., assistance with food insecurity, and so forth).
62849656|NCT03352908||YSP|The Yale Swallow Protocol (YSP) consists of a brief cognitive screen, a brief oral motor exam, and a 3oz water challenge (subjects instructed to drink 3oz of water without stopping). Pass/fail is determined based on the subjects ability to drink the 3oz of water uninterrupted without immediate cough.
62849657|NCT03352908||FEES|Flexible Endoscopic Evaluation of Swallowing (FEES) uses a flexible endoscope that will be passed transnasally into the pharynx by a speech pathologist specializing in dysphagia management. FEES will be treated as a placebo comparator.
62849658|NCT02560077|PLACEBO_COMPARATOR|placebo|The placebo and cashew apple fruit juice had the same color and smell
62849659|NCT02560077|ACTIVE_COMPARATOR|cashew apple juice 120 mg/day|The subjects who were assigned as the low dose treatment group received cashew apple fruit juice extract at dose of 120 mg/day
62849660|NCT02560077|ACTIVE_COMPARATOR|cashew apple juice 240 mg/day|The subjects who were assigned as the high dose treatment group received cashew apple fruit juice extract at dose of 240 mg/day
62849661|NCT05839158|EXPERIMENTAL|HFMT treated|The experimental group will receive treatment with HFMT ointment prepared in a homogenized mixture, applied once immediately after surgery to the treatment area.
62849662|NCT05839158|PLACEBO_COMPARATOR|Mupirocin treated|The control group will receive treatment with Mupirocin applied once immediately after surgery to the control area.
62849663|NCT04497051||Embolized patients|subjects receiving preoperative embolization for aggressive spinal debulking surgery
62849664|NCT02507167|PLACEBO_COMPARATOR|mixed meal|
62849665|NCT02507167|ACTIVE_COMPARATOR|mixed meal 2 h after single dose rifampin (600 mg)|
62849666|NCT02055222||Lung disease (IPF) and smoking history|50 IPF and 50 COPD patients, and 30 subjects with early interstitial lung abnormalities seen on previous radiographs
62849667|NCT02055222||Lung disease COPD and smoking history|50 IPF and 50 COPD patients, and 30 subjects with early interstitial lung abnormalities seen on previous radiographs
62849668|NCT02055222||Normal Volunteers- Non-smokers, and Smokers|50 smoking and 30 non-smoking controls
62266008|NCT02181829|EXPERIMENTAL|Whole Lung IMRT|This is a single institution study involving patients with synovial sarcoma who have completed all standard therapy (e.g. surgery +/- radiation to the primary site) +/- any adjuvant chemotherapy. The sequence and types of therapy offered prior to WLI will likely vary based on primary tumor site, tumor resectability, extent of metastatic disease, performance status, and comorbidity. Each patient's therapy will be determined by the disease management team irrespective of participation on this protocol.
62266009|NCT04318899|EXPERIMENTAL|Dialectical Behaviour Therapy|Dialectical Behavior Therapy, delivered for 20 weeks for adolescents (DBT-A) or 52 weeks for adults (standard DBT.
62266010|NCT05344521|ACTIVE_COMPARATOR|Control|After removal of the temporary wound coverage (allograft), Integra® is applied directly onto the wound surface.
62266011|NCT05344521|EXPERIMENTAL|Integra®-SC|After removal of the temporary wound coverage (allograft), Integra®-SC is applied to the contralateral area of the site where Integra® is applied.
62849669|NCT01241045||misoprostol|"2 groups:-~* Group 1:-those with Ph\<5. (n=50).~* Group 2:-those with Ph \> or=5. (n=50). -Each group is subdivided into another two groups:-~  * Group 1A (n=25). - Group 1B (n=25).~ * Group 2A (n=25). - Group 2B (n=25).~ * All the women in group 1A and group 2A will receive intravaginal misoprostol tablets moistened with 3 ml of 5% acetic acid, and all the women in group 1B and group 2B will receive intravaginal misoprostol tablets moistened with water, 400 micrograms every 4 hours for a maximum of 5 doses within 24 hours. If the patient will not have adequate uterine contractions, the same regimen will be repeated over the following 24 hours"
62849670|NCT04237142|EXPERIMENTAL|Eligible patients who had consented to participate|Eligible patients who had consented to participate to the study, namely parturient admitted to the Clermont-Ferrand Hospital maternity for preterm premature rupture of membranes between 24+0 and 36+4 gestation week with cervical dilation \< 4cm and without known uterine malformation, fetal malformation, placenta previa or abundant metrorrhagia. Patients underwent vaginal swabbing and blood sample collection at the admission.
62849671|NCT03219970||EGFR T790M positive NSCLC patients|Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI treatment.
62849672|NCT05858424|EXPERIMENTAL|Group A : former patients with multidisciplinary day hospitalization|In this group, a multidisciplinary day hospitalization will be programmed after the end-of-treatment evaluation and 2 months after the end of treatment at the latest. This day hospitalization will consist at least of a psychological interview, an interview with a social worker and a medical interview.
62849673|NCT05858424|NO_INTERVENTION|Group B : former patients without multidisciplinary day hospitalization|In this group, the former patients will experiment the standard of care, with an oncological follow-up.
62849674|NCT06264804||progressive suction loss group|Progressive suction loss occurs during the SMILE procedure
62266012|NCT05666427|NO_INTERVENTION|Control Group|No application will be made until the end of this group work. After the end of the study, the effective protocol will be applied.
62266013|NCT05666427|ACTIVE_COMPARATOR|Classic Application Group|In this group, classical pelvic floor muscle training will be applied.
62266014|NCT05666427|ACTIVE_COMPARATOR|Study Group|The protocol determined for the study will be applied in this group. This protocol is planned as follows: It will perform stabilization exercises with the activation of the pelvic floor muscles.
62266015|NCT01520935||Cohort Group|
62849675|NCT06264804||Normal group|There was no progressive suction during the SMILE procedure
62849676|NCT02408757||All study participants|The study population consists of consecutive patients undergoing clamping of EVD/LD treated at the Departments of Neurosurgery or Intensive Care Medicine at the University Hospital Bern
62849677|NCT00814060|EXPERIMENTAL|1|40-mg tablet
62849678|NCT00814060|EXPERIMENTAL|2|240-mg tablet
62849679|NCT00814060|EXPERIMENTAL|3|80-mg capsule
62849680|NCT02133690|EXPERIMENTAL|Vaccine Arm|3 doses, 4 weeks apart, of Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10\^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent
62849681|NCT02133690|PLACEBO_COMPARATOR|Placebo group|3 doses, 4 weeks apart, of Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents
62849682|NCT04548869|EXPERIMENTAL|CDX-0159|20 patients with Cold Contact Urticaria, 10 patients with Symptomatic Dermographism, and 10 patients with Cholinergic Urticaria will be enrolled and treated with a single dose of CDX-0159
62849683|NCT03207035|ACTIVE_COMPARATOR|20 ml of lidocaine 2% with epinephrine|Patients will receive axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine.
62849684|NCT03207035|EXPERIMENTAL|40 ml 0f lidocaine 1% with epinephrine|Patients will receive axillary brachial plexus block with 20 ml of lidocaine 1% with epinephrine diluted with 20 ml of nacl 0.9% ( total 40 ml)
62849685|NCT00945295|ACTIVE_COMPARATOR|Cohort #1|Cohort 1 will receive BoNT-A plus rehabilitation therapy for the duration of the study (for up to 2 injections of BoNT-A).
62849686|NCT00945295|ACTIVE_COMPARATOR|Cohort #2|Cohort 2 will receive BoNT-A alone
62849687|NCT04072406|ACTIVE_COMPARATOR|Arm I: Usual Care|"* Participants assigned to usual care will receive a packet of instructions with information about how to complete weekly surveys via a link that will be emailed to them~* Participants in both arms will be asked to complete a total of five surveys: baseline, at the end of each of three weeks, and a final survey one month later"
62849688|NCT04072406|EXPERIMENTAL|Arm II: Mindfulness Meditation|"* Participants will listen to mindfulness meditations daily over the course of three weeks.~* Participants in both arms will be asked to complete a total of five surveys: baseline, at the end of each of three weeks, and a final survey one month later"
62849689|NCT06226857|ACTIVE_COMPARATOR|A|All patients will recieve chemotherapy FOLFOX (oxaliplatin 85 mg/m2 + folinic acid 400 mg/m2 + FU 400 mg/m2 bolus and FU 2400 mg/m2 46-hour insusion q2w) + anti-EGFR monoclonal antibody (cetuximab 500 mg/m2 q2w or panitumumab 6 mg/kg q2w) until disease progression or unacceptable toxicity. It is permited to withdraw oxaliplatin after 8 cycles.
62849690|NCT06226857|EXPERIMENTAL|BC|"All patients will recieve chemotherapy FOLFOX (oxaliplatin 85 mg/m2 + folinic acid 400 mg/m2 + FU 400 mg/m2 bolus and FU 2400mg/m2 46-hour insusion q2w). Monoclonal antibody will be added to chemotherapy after 1-2 cycles based on molecular profile results: anti-EGFR (cetuximab 500 mg/m2 q2w or panitumumab 6 mg/kg q2w) for hyperselected wild type tumors or bevacizumab 5 mg/m2 q2w for mutant profile.~Patients will recieve therapy until disease progression or unacceptable toxicity. It is permited to withdraw oxaliplatin after 8 cycles."
62623935|NCT04003376|ACTIVE_COMPARATOR|fractional carbon dioxide laser alone|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata
62849691|NCT00586781|EXPERIMENTAL|3|The S.T.A.R. ankle system is the study device. The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants. Both ankles of every subject will be treated with the STAR ankle.
62061643|NCT06192147|EXPERIMENTAL|intervention group|On the basis of conventional treatment, a protein restricted diet combined with vitamin D intervention plan is given
62061644|NCT06192147|NO_INTERVENTION|control group|basic conventional treatment
62061645|NCT04963894|EXPERIMENTAL|Home functional balance physiotherapy|Participants perform physical therapy at home individually with a physical therapist. The experimental program of the study of balance exercise in functional context is implemented.
62461263|NCT02724800|ACTIVE_COMPARATOR|BBTI|BBTI consists of one in-person session with three weekly follow-up sessions (in-person or phone) in a four week period. Topics covered include: sleep education, stimulus control, and sleep restriction.
62461264|NCT01024439|ACTIVE_COMPARATOR|single port|Patients will undergo transumbilical single incision laparoscopic appendicectomy.
62623936|NCT04003376|EXPERIMENTAL|fractional carbon dioxide laser and triamcinolone acetonide|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide (10mg/ml)
62623937|NCT04003376|EXPERIMENTAL|fractional carbon dioxide laser and platelet rich plasma|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma
62623938|NCT04003376|EXPERIMENTAL|fractional carbon dioxide laser and vitamin D solution|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution
62849692|NCT04174404|EXPERIMENTAL|Intervention group|The participants in the intervention group will receive the routine care plus the ICory-Circumcision which is specially developed for this study based on preliminary studies, other literature, and most importantly, the surgical pathway currently practiced in the study hospital. The ICory-Circumcision programme has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children.
62849693|NCT04174404|ACTIVE_COMPARATOR|Control group|The participants in the control group will receive routine care provided by the hospital which consists of normal doctor consultant, preoperative preparation, and postoperative care.
62849694|NCT04784442|EXPERIMENTAL|ETC-1002 180mg|
62623939|NCT01861002|EXPERIMENTAL|AML Arm|"Participants with Acute Myeloid Leukemia (AML)~Intervention:~* Azacytidine (Dose Level 1 @ 75 mg/m2/day)~* Fludarabine 30 mg/m2/dose~* Cytarabine 2000 mg/m2/dose~* Intrathecal (IT) Cytarabine"
62061646|NCT04963894|NO_INTERVENTION|Home functional daily activity|Participants stay in home without physiotherapy. Participants maintained their normal daily activities, which included housework, shopping, or daily walks.
62266016|NCT00330382|EXPERIMENTAL|Arm I (Bowman-Birk inhibitor concentrate)|Patients receive oral Bowman-Birk inhibitor concentrate twice daily for 6 months
62266017|NCT00330382|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive oral placebo twice daily for 6 months
62266018|NCT06377787|EXPERIMENTAL|ELDOA and conventional therapy|hot pack and TENS for10 min, cervical PIR (MET) in flexion, extension, side bending and rotation (single set of 4rep with 6 sec hold once a day) and ELDOA method C0-C1-C2, C2 \& C3 positions for cervical spine (2 sets of five repetitions with 45 sec hold and 15sec rest between each set once a day).
62266019|NCT06377787|OTHER|conventional therapy|hot pack and TENS for 10 minutes, cervical PIR (MET) in flexion, extension, side bending and rotation (single set of 4 reps with 6 seconds hold once a day).
62266020|NCT04707157|EXPERIMENTAL|600 Milligram (mg) LY3556050|Participants received 600 mg LY3556050 twice daily (BID) every 12 hours for up to 8 weeks.
62461265|NCT01024439|ACTIVE_COMPARATOR|conventional Lap|Patients will undergo conventional laparoscopic appendicectomy.
62266021|NCT04707157|PLACEBO_COMPARATOR|Placebo|Participants received placebo BID every 12 hours for up to 8 weeks.
62266022|NCT02706821|ACTIVE_COMPARATOR|Treatment sequence 1|PLE (persimmon leaf extract) once a day during 8 weeks cross-over to placebo once a day during 8 weeks.
62849695|NCT04784442|EXPERIMENTAL|ETC-1002 120mg|
62849696|NCT04784442|EXPERIMENTAL|ETC-1002 60mg|
62849697|NCT04784442|PLACEBO_COMPARATOR|Placebo|
62849698|NCT05780424|EXPERIMENTAL|BRII-196/BRII-198 plus SOC|"* BRII-196 1000 mg solution; administered as IV infusion~* BRII-198 1000 mg solution; administered as IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
62266023|NCT02706821|ACTIVE_COMPARATOR|Treatment sequence 2|Placebo once a day during 8 weeks cross-over to PLE once a day during 8 weeks.
62266024|NCT03875898|EXPERIMENTAL|150 g bread fortified (15 g mix fibre)|Volunteers will have to consume daily 150 g of a bread instead of usual bread during eight weeks
62266025|NCT03875898|PLACEBO_COMPARATOR|150 g unfortified bread|Volunteers will have to consume daily 150 g of an unfortified usual bread during eight weeks
62266026|NCT02774837|EXPERIMENTAL|combination|Tenofovir disoproxil oral tablets 300mg once daily for 96 weeks and Telbivudine 600mg oral tablets once daily for 96 weeks
62266027|NCT02774837|ACTIVE_COMPARATOR|mono therapy|Tenofovir disoproxil oral tablets 300mg once daily for 96 weeks
62449516|NCT05743218|ACTIVE_COMPARATOR|stomach meridian group|Four acupoints have been selected for the gastric meridian group, including ST42 Chongyang, ST40 Fenglong, ST36 Zusanli, and ST31 Biguan. The acupoint locations are based on the national standard of the People's Republic of China in 2006 (GB/T 12346-2006). The patient will be supine during the procedure, and the needles will be routinely sterilized. Straight needling will be performed in the hip region using a 0.30×50-mm-filiform needle, a 0.30×50-mm filiform needle in Zusanli, and a 0.30×40-mm filiform needle in Fenglong. A 0.35×25-mm filiform needle will be used to stimulate Chongyang for 10-15 mm, and each acupoint will be gently and evenly lifted, inserted, and twisted to local acid distension. Electroacupuncture will be applied in the same manner as for the liver meridian group. The needles will be retained for 30 min respectively, once every other day, then thrice weekly for a total of 36 treatments in the three groups.
62461266|NCT04038710||Patients with severe disease|Patients that are eligible to enroll in Vertex's triple combination therapy through the expanded access program.
62461267|NCT01379664|EXPERIMENTAL|Isoflurane|Isoflurane is to be administered to patients in this arm during surgery
62461268|NCT01379664|EXPERIMENTAL|Sevoflurane|Sevoflurane is to be administered to patients in this arm during surgery
62461269|NCT03228693|ACTIVE_COMPARATOR|Group 1|Baseline lesional and non-lesional biopsies and re-biopsy 6-8 weeks later with intralesional triamcinolone injections at 9-10, 12-16, and 24-32 weeks.
62461270|NCT03228693|ACTIVE_COMPARATOR|Group 2|Baseline lesional biopsy and re-biopsy at 6-8 weeks with intralesional triamcinolone injections at 3-4, 9-10, 12-16, and 24-32 weeks
62849699|NCT05780424|PLACEBO_COMPARATOR|Placebo plus SOC|"* Placebo administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
62849700|NCT03391739|EXPERIMENTAL|Arm 1|CART-19 cells treat
62849701|NCT06133504|ACTIVE_COMPARATOR|Early arm|Early multimodal therapy is characterized by a comprehensive set of therapeutic interventions executed by the physiotherapy, speech therapy, respiratory therapy, and occupational therapy teams precisely at the moment of study inclusion. This tailored approach ensures that patients receive a coordinated and multidisciplinary therapeutic regimen right from the outset of their participation in the study
62849702|NCT06133504|ACTIVE_COMPARATOR|Late arm|While late multimodal therapy is characterized by the same type of maneuvers carried out by the same disciplinary team but initiated once indicated by the attending physician.
62849703|NCT03726229||Fontan patient|Cholate assay will be administered once to Fontan patients and blood specimens will be collected to analyze cholate clearance.
62849704|NCT05536271|EXPERIMENTAL|Acute coronary syndrome patients|Acute coronary syndrome patients prescribed with bisoprolol
62849705|NCT01499277|EXPERIMENTAL|Ceftaroline fosamil|Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
62849706|NCT01499277|ACTIVE_COMPARATOR|Vancomycin plus aztreonam|Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function
62849707|NCT02649751|EXPERIMENTAL|Group 1|"200 mg roscovitine (8) or placebo (4) once daily for 4 cycles of 7 days (4 days on and 3 days off)"
62849708|NCT02649751|EXPERIMENTAL|Group 2|"400 mg roscovitine (8) or placebo (4) once daily for 4 cycles of 7 days (4 days on and 3 days off)"
62849709|NCT02649751|EXPERIMENTAL|Group 3|"400 mg roscovitine (8) or (4) placebo twice daily for cycles of 7 days (4 days on and 3 days off)"
62849710|NCT02219867|EXPERIMENTAL|Ketamine|Active Comparator
62623940|NCT01861002|EXPERIMENTAL|ALL Arm|"Patients with Acute Lymphocytic Leukemia~Intervention:~* Azacytidine (Dose Level 1 @ 75 mg/m2/day)~* Fludarabine 30 mg/m2/dose~* Cytarabine 2000 mg/m2/dose~* Intrathecal Methotrexate (IT MTX)"
62061647|NCT04963894|ACTIVE_COMPARATOR|Conventional physiotherapy|Participants perform physical therapy in a rehabilitation gym and in groups of 10 people. The conventional program of physiotherapy is implemented.
62623941|NCT00198523|EXPERIMENTAL|Prednisolone and Tobramycin|Prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension. One drop of test agent will be instilled in the inferior cul de sac of the operative eye prior to cataract extraction.
62061648|NCT04389502|EXPERIMENTAL|CaPtyVa app group|Those assigned to the CaPtyVa app group will receive a tutorial video describing its operation and will have to complete 10-item clinical vignette quiz according to the app recommendations based on local current CRC screening and surveillance guidelines on every question. Physicians in this group will download a free of charge application (CaPtyVa CCR APP, Digital Means, Argentina) on their iOs or Android device.
62061649|NCT04389502|ACTIVE_COMPARATOR|Control group|The ones assigned to the control group will be asked to complete the 10-item clinical vignette quiz according to their current knowledge on local current CRC screening and surveillance guidelines
62461271|NCT03228693|ACTIVE_COMPARATOR|Group 3|Baseline lesional and non-lesional biopsy and re-biopsy 3-4 months later with intralesional triamcinolone injections at 18-20 and 24-32 weeks.
62623942|NCT00198523|ACTIVE_COMPARATOR|Prednisolone|Prednisolone acetate 1.0% ophthalmic suspension. One drop of test agent will be instilled in the inferior cul de sac of the operative eye prior to cataract extraction.
62623943|NCT01315522|ACTIVE_COMPARATOR|ComVi stent|ComVi stent (Niti-S stent, ComVi type, Taewoong Medical Inc, Korea)
62623944|NCT01315522|ACTIVE_COMPARATOR|Uncovered SEMS|uncovered nitinol metal stent (HANAROSTENT, M.I. Tech Co., Ltd., Korea)
62623945|NCT06580340|EXPERIMENTAL|patients|patients with emophilia receiving a program of adapted physical activity
62623946|NCT01008813|EXPERIMENTAL|adjuvanted A(H1N1)v influenza vaccine|Two injections at day 0 and day 21
62623947|NCT01008813|EXPERIMENTAL|non-adjuvanted A(H1N1)v influenza vaccine|Two injection at day 0 and day 21
62623948|NCT04218279|EXPERIMENTAL|Sleep Health Education|At baseline, the experimental group will have immediate access to 10 brief education modules focused on diverse elements of sleep health and fatigue.
62849711|NCT05409534|ACTIVE_COMPARATOR|Backward Walking|Participants who walk backward gait in the form of exercise program
62623949|NCT04218279|ACTIVE_COMPARATOR|Wait List Control|At 3 months after baseline, the wait-list control group will be provided access to the 10 education modules focused on diverse elements of sleep health and fatigue..
62849712|NCT05409534|ACTIVE_COMPARATOR|Forward Walking|Participants who walk forward gait in the form of home program
62849713|NCT06165315|EXPERIMENTAL|Parenting Program|This community-based group parenting program aims improve caregiver knowledge, attitudes, and practices on nurturing care to ultimate improve early childhood development. A secondary aim of the program is to support caregiver psychosocial wellbeing. The curriculum covers various topics relating to responsive caregiving, early learning, child protection, maternal and child health and nutrition, and caregiver mental health. Intervention will be delivered through existing community group networks. Each parenting group will comprise of 10 caregivers that will be facilitated by trained volunteers.
62849714|NCT06165315|NO_INTERVENTION|Waitlist-Control|Villages in the control group will not immediately receive the parenting program. Instead, they will receive whatever standard of care services are delivered at the community-level (e.g., routine services from community health volunteers that are primarily focused on maternal and child health and nutrition). After endline data collection is completed for the trial, then villages in the control group will receive the parenting program.
62849715|NCT06134024|EXPERIMENTAL|LAMS with Double Pigtail Plastic Stents|The group of participants with post-inflammatory pancreatic and peripancreatic fluid collections with double pigtail plastic stents introduced through the LAMS during endoscopic transmural drainage.
62623950|NCT02815267|EXPERIMENTAL|FMX-101, 4% minocycline foam|Subjects will apply the assigned FMX-101, 4% minocycline foam topically once daily for 12 weeks as directed
62623951|NCT02815267|PLACEBO_COMPARATOR|Vehicle foam|Subjects will apply the assigned vehicle foam topically once daily for 12 weeks as directed
62623952|NCT02469233|EXPERIMENTAL|TranS-C|The Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) is comprised of cross-cutting interventions, 'core modules' and 'optional modules'. TranS-C is derived and adapted from our previous disorder-focused research, firmly grounded in basic science and treatment literature.
62623953|NCT02469233|ACTIVE_COMPARATOR|UC-DT|Usual Care, Delayed Treatment (DT) is comprised of a case manager who co-ordinates care and refers each client for a medication review and to rehabilitation programs. At the end of 6-months in UC-DT, the participants will receive TranS-C.
62623954|NCT02432209|ACTIVE_COMPARATOR|Intensive Lifestyle Mod. Intervention|The intensive lifestyle modification intervention will consist of caloric restriction (consumption of approximately 1200-1500 kcal/d), use of an over-the-counter weight loss medication (Alli, which is brand name Orlistat, a gastric lipase inhibitor that limits gut fat absorption), and moderate physical activity (goal of reaching 10,000 steps a day). The pretreatment intervention will last 16 weeks and is designed to promote a weight loss of approximately 7% of total body weight.
62623955|NCT02432209|PLACEBO_COMPARATOR|Standard Lifestyle Intervention|Women in the standard lifestyle intervention (standard) will receive publicly available written materials that promote engagement in moderate physical activity with target of 10,000 steps a day. Detailed instruction of physical activity will not be provided.
62623956|NCT02383303|EXPERIMENTAL|Program|The program group is eligible to participate in the Individual Development Account savings program.
62623957|NCT02383303|NO_INTERVENTION|Comparison|The comparison group cannot enter the Individual Development Account program.
62061650|NCT04048863|ACTIVE_COMPARATOR|Stage 1 Baseline|Study site to use standard of care PIVC device(s) and procedure(s) on patients.
62623958|NCT06611670|EXPERIMENTAL|Cataract surgery with Active Sentry|Cataract surgery with low IOP values (32mmHg)
62623959|NCT06611670|ACTIVE_COMPARATOR|High IOP|Cataract surgery with high IOP (60mmHg) which is the average pressure at which cataract surgery is being performed currently
62061651|NCT04048863|OTHER|Stage 2 Education|RN education and training in the use of B. Braun PIVC products, devices and procedures.
62061652|NCT04048863|OTHER|Stage 3 Run-In|Familiarization of study RNs with the B. Braun devices and procedures in a clinical setting.
62061653|NCT04048863|OTHER|Stage 4 Post-Education|Study site uses B. Braun PIVC device(s) and procedure(s) on patients.
62061654|NCT00673062|EXPERIMENTAL|SCH 900538|
62623960|NCT01310127|EXPERIMENTAL|Bromday|Patients receiving Bromday self-administered one drop of bromfenac 0.09% daily as a topical ophthalmic drop three days prior to cataract surgery, on the day of cataract surgery and 21 days post operatively.
62623961|NCT01310127|ACTIVE_COMPARATOR|Nevanac|Patients in this arm self-administered nepafenac topical ophthalmic drops three times daily beginning 3 days prior to cataract surgery, on the day of surgery and for 21 days postoperatively in addition to usual cataract procedure.
62623962|NCT06477380|EXPERIMENTAL|Intervention arm|Community mental health team staff will receive the intervention (training, toolkit, reflective supervision group and changes to the physical environment) over a period of six months.
62623963|NCT03883477|EXPERIMENTAL|Endoscopic Release|12 patients recommended for surgical treatment of trigger finger will undergo endoscopic release.
62623964|NCT03883477|ACTIVE_COMPARATOR|Standard Open Release|12 patients recommended for surgical treatment of trigger finger will undergo standard open surgical release.
62623965|NCT06075550|EXPERIMENTAL|TotalFill BC Sealer|single cone technique with TotalFill BC Sealer
62623966|NCT06075550|EXPERIMENTAL|TotalFill BC Sealer HiFlow|warm vertical compaction technique with TotalFill BC Sealer HiFlow
62623967|NCT05185635|EXPERIMENTAL|Healthy Spanish-speakers|
62623968|NCT01150903||PDE5 inhibitor prescription|
62623969|NCT01150903||Age-matched Control|
62623970|NCT00704951||Patients|Immunosuppressed/Immunocompromised patients at high risk for invasive fungal infections
62623971|NCT00819481||3DKnee|Post Market Study
62623972|NCT00152243|EXPERIMENTAL|1|UFT (uracil, tegafur)
62623973|NCT00152243|OTHER|2|Surgery alone
62623974|NCT03061487||Group I|"Patients affected by central and peripheral aneurismatic disease with maximum statin daily dose ( Atorvastatin 80 mg, Simvastatin 40 mg, Rosuvastatin 40 mg).~Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).~The investigation consist in:~* taking a preoperative blood sample to evaluate the MMPs circulating levels~* taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels"
62061655|NCT00673062|ACTIVE_COMPARATOR|Encapsulated pseudoephedrine|Encapsulated pseudoephedrine (2X30 mg immediate release tablets)
62061656|NCT00673062|PLACEBO_COMPARATOR|Placebo Capsules|
62266028|NCT03046875|EXPERIMENTAL|Transcutaneous Spinal Cord Stimulation|Subjects will participate in a single session of Transcutaneous Spinal Cord Stimulation, involving 30 minutes of stimulation with isokinetic strength testing of knee extension.
62449517|NCT05743218|PLACEBO_COMPARATOR|non-acupoint acupuncture group|Four points: (1) On the lateral thigh, between the vastus lateralis and biceps femoris, the midpoint of the popliteal stria, and the highest point of the greater trochanter. (2) On the lateral side of the calf, beside the level of Zusanli, and at the lateral edge of the tibia. (3) On the fibular side of the calf, the midpoint of the stomach meridian, and the bile meridian, 3 cm above the tip of the lateral malleolus and in front of the hanging bell. (4) On the lateral side of the calcaneus, and the servant enters the midpoint of the line connecting the posterior edge of the calcaneus at the same level. The 0.30×25-mm filiform needles are inserted straight for 3-5 mm at the points, the needles can stand without Deqi. The auxiliary needle will be inserted and electroacupuncture will be connected (same as in the other group). The internal wire of the electroacupuncture instrument will be interrupted, no current passed through. The treatment time is the same as the other two groups.
62449518|NCT04646174|EXPERIMENTAL|Multi-component Behavioral Treatment|This treatment consists of nine weekly phone-based individual treatment sessions, 45-60 minutes each, delivered by a trained study therapist.
62449519|NCT04646174|EXPERIMENTAL|Self-guided Treatment|This treatment consists of self-help materials from the American Lung Association that address evidence-based smoking cessation and self-management strategies.
62449520|NCT05164809||Tungsten/Teflon +|Dissection with novel electrodes (Tungsten needle electrode + Teflon coated Spatula electrode)
62449521|NCT05164809||Tungsten/Teflon -|Dissection without novel electrodes (Scalpel + Steel Spatula Electrode)
62623975|NCT03061487||Group II|"Patients affected by central and peripheral aneurismatic disease with minimum statin daily dose.~Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).~The investigation consist in:~* taking a preoperative blood sample to evaluate the MMPs circulating levels~* taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels"
62623976|NCT00632645|EXPERIMENTAL|1|Olanzapine Mylan
62623977|NCT00632645|ACTIVE_COMPARATOR|2|Xenazine
62061657|NCT04614883|OTHER|Asymptomatic patients or Healthy volunteers|Patient with no symptom of COVID-19 infection but for whom a PCR test needs to be done because he has been in contact with a COVID-19 positive person
62061658|NCT04614883|OTHER|Symptomatic patients with positive PCR|Patients with symptoms of COVID-19 and whose PCR result is positive
62266029|NCT03046875|SHAM_COMPARATOR|Sham|Subjects will participate in a single session of isokinetic strength testing of knee extension with sham stimulation.
62449522|NCT01945632|NO_INTERVENTION|no treatment|Control group with no treatment.
62449523|NCT01945632|EXPERIMENTAL|root planing (gracey curettes)|treatment with root planing using conventional gracey curettes
62449524|NCT01945632|EXPERIMENTAL|Vertically oscillating ultrasonic device|Treatment done with vertically oscillating ultrasonic device
62449525|NCT01945632|EXPERIMENTAL|Device: piezoelectric ultrasonic scraper|Treatment using a piezoelectric ultrasonic scraper
62449526|NCT02492490|EXPERIMENTAL|SVF(Stromal Vascular Fraction) derived MSC transprlantation|"transplantation of autologous SVF derived MSC to the recipients of DCD kidney transplant.~1. Subjects with uremia in the intervention group will undergo puncture to collect SVF~2. SVF will be cultured to abstain MSC~3. The abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD."
62623978|NCT00632645|ACTIVE_COMPARATOR|3|Tiapridal
62623979|NCT02080208|EXPERIMENTAL|High Flow Oxygen|Patients receiving oxygen via high flow oxygen therapy (Optiflow)
62623980|NCT02080208|NO_INTERVENTION|Conventionnal|patients receiving oxygen via conventional way (low flow)
62623981|NCT06078644|EXPERIMENTAL|Intervention group|Patients in this group will be asked to perform breathing exercises in the form of using a spirometer 10 times every hour during the preoperative period while they are awake for three days, starting from the first day after the surgery. Patients in this group will be given a breathing exercise diary.
62266030|NCT06494722|ACTIVE_COMPARATOR|Diabetes Education|Participants in this arm will receive traditional diabetes education following a baseline assessment. During months 1-3, participants will attend 5 sessions. Follow up will be conducted at 3-months and 6-months.
62266031|NCT06494722|EXPERIMENTAL|T1DES|Participants in this arm will receive a emotion regulation intervention called T1DES following a baseline assessment. During months 1-3, participants will attend 5 sessions. Follow-up will be conducted at 3-months and 6-months.
62652836|NCT05627804|OTHER|Control normoxia|The participant will not perform any exercise under normoxia and moderate hypoxia. Blood samples of oral glucose tolerance test will be collected.
62652837|NCT04560842|EXPERIMENTAL|Conventional oxygen devise|Chose devise to keep patient's SpO2 \> 92%
62652838|NCT04560842|ACTIVE_COMPARATOR|High flow nasal cannula|High flow oxygen device
62061659|NCT04614883|OTHER|Symptomatic patients with negative PCR but with seroconversion within 4 to 8 weeks|Patients with symptoms of COVID-19 and whose PCR result is negative at inclusion but presents a seroconversion within 4 to 8 weeks post inclusion
62061660|NCT00725465||LAP surgery with CO2 colonoscopy|30 surgical patients, male and female undergoing laparoscopic surgical treatment for colorectal conditions such as neoplasm or rectal prolapse managed with intra-operative carbon dioxide (co2)colonoscopy for standard care of their medical condition.
62061661|NCT03233061|ACTIVE_COMPARATOR|NO|NON OBESE WOMEN GROUP ( same age and same physical activities ) cardiorespiratory exercise testing with evaluation of peak oxygen uptake, heart rate and maximal cycling power output. Cardiorespiratory functioning is assessed during household activities such as ironing,cleaning floor,walking and climbing stairs.
62623982|NCT06078644|NO_INTERVENTION|Control group|Patients in this group will not undergo any treatment and will continue to receive care according to their clinical routine. In the clinic, when patients are admitted to the hospital, nurses give them a spirometer during the pre-operative period and it is stated that they should use it before and after the surgery. After the data collection tools are applied to the patients in this group, they will be asked how many times a day they use a spirometry.
62061662|NCT03233061|EXPERIMENTAL|OB|OBESE GROUP cardiorespiratory exercise testing with evaluation of peak oxygen uptake,heart rate and maximal cycling power output.Cardiorespiratory functioning is assessed during household activities such as ironing, cleaning floor, walking and climbing stairs
62061663|NCT06524076|EXPERIMENTAL|Partial Pulpotomy|
62061664|NCT06524076|ACTIVE_COMPARATOR|Complete pulpotomy|
62061665|NCT00508352|EXPERIMENTAL|Helical tomotherapy|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
62061666|NCT03109821||THA patients|
62061667|NCT03036501|EXPERIMENTAL|[^14C]-Risdiplam|Participants will be administered with \[\^14C\]-Risdiplam solution orally under fasted conditions on Day 1.
62061668|NCT00744094|PLACEBO_COMPARATOR|1|placebo drink
62623983|NCT04560868|ACTIVE_COMPARATOR|Control|
62623984|NCT04560868|EXPERIMENTAL|Experimental|
62623985|NCT00620646|EXPERIMENTAL|A|Aspirin plus increasing clopidogrel group
62623986|NCT00620646|EXPERIMENTAL|B|Aspirin, clopidogrel plus cilostazol group
62623987|NCT01888653|PLACEBO_COMPARATOR|Comparison-Training-Program|Placebo-training program: attention control training (ACT), is identical to the ABM protocol except that during the presentation of the trials where a threat word is presented, the probe will appear with equal frequency in the position of the threat and neutral word. Thus, neither threat nor neutral words provide information regarding the position of the target probe, and there is no contingency between the position of either threat or neutral words, and the position of the probes
62061669|NCT00744094|EXPERIMENTAL|2|protein drink
62061670|NCT06089252|OTHER|HSV-1, HSV-2|All participants were assigned to receive topical treatment with Lazolex® Gel. Patients were given the gel at the end of the screening visit (day 0) by the attending physicians.,e gel was applied to the lesion four times a day over a 10-day period, with the Lrst application at 9 am and the fourth at 9 pm. Patients administered Lazolex® Gel to the a2ected areas themselves.
62061671|NCT04121481|PLACEBO_COMPARATOR|Placebo|Approximately a total of 75 participants will be assigned in the Placebo Group (two divided doses will be given)
62623988|NCT01888653|ACTIVE_COMPARATOR|Attention Biased Modification|Attention-bias-modification treatment (ABM) is designed to implicitly modify patients' biased threat attendance via computerized training protocols. During each session, 240 trials (80 neutral-neutral pairs, 160 threat-neutral pairs) will be presented. On trials where participants see one neutral word and one threat word, the probe will always follow the neutral word location. Thus, although there is no specific instruction to direct attention away from threat words, on 66% of all trials (and 100% of the threat-neutral trials) the position of the neutral word will indicate the position of the target probe.
62061672|NCT04121481|ACTIVE_COMPARATOR|Treatment Group|Approximately a total of 75 participants will be assigned in the Treatment Group (two divided doses will be given) Adverse Event Monitoring will be Strictly Enforced
62061673|NCT03592225|OTHER|Educational workshop intervention arm|The group of general practitioners (GP) from Lyon (France), about 300, that will be invited to attend the 3 hours educational workshop about HPV vaccination. After the workshop, the GPs will return to their normal health care practice.
62061674|NCT03592225|NO_INTERVENTION|Control arm|The group of general practitioners (GP) from Lyon (France), about 300, that will NOT be invited to attend the 3 hours educational workshop about HPV vaccination. These GPs perform their normal health care practice.
62061675|NCT05095363|EXPERIMENTAL|PCplanner mobile app platform|Participants who are randomized to the intervention arm will complete surveys at 3 timepoints and will be given resources on advance care planning via PCplanner, the mobile app platform. They will receive a telephone call by the study team about a week after enrollment to answer any questions about the resources provided. If needs and questions are not resolved quickly after the clinic visit, then another layer of patient support with a telephone call by a palliative care specialist will be provided to the participant to help develop potential management plans.
62266032|NCT01114074||Factor XII deficiency|Patients deficient in coagulation factor XII
62266033|NCT01114074||Factor XI Deficiency|Patients deficient in coagulation factor XI
62623989|NCT04284384||HUNT4 70+|All inhabitants of Nord-Trøndelag 70 years of age or older were invited to participate in HUNT4 70+.
62266034|NCT01114074||Prekallikrein deficiency|Patients deficient in prekallikrein
62266035|NCT01114074||HMWK deficiency|Patients deficient in high molecular weight kininogen (HMWK)
62266036|NCT01114074||Control group|Healthy controls
62266037|NCT01584973||cruciate ligament group|
62266038|NCT01584973||control group|
62266039|NCT01086800|OTHER|HLSE plus PAP|
62266040|NCT01086800|OTHER|HLSE plus Oxygen|
62266041|NCT01086800|OTHER|Healthy Lifestyles and Sleep Education|
62266042|NCT04233190|EXPERIMENTAL|Formoterol + budesonide Eurofarma (12/400mcg e 6/200mcg)|Formoterol 12mcg + budesonide 400mcg / Formoterol 6mcg + budesonide 200mcg
62266043|NCT04233190|ACTIVE_COMPARATOR|Alenia® (12/400mcg e 6/200mcg)|Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg
62266044|NCT02177968||Elderly fallers or non-fallers|characteristics of these groups
62266045|NCT02592239|EXPERIMENTAL|Patients|Functional dyspepsia patients will be studied using functional brain MRI before and after receiving a test meal. Cognitive and hedonic response will be evaluated using 10 score scales.
62061676|NCT05095363|NO_INTERVENTION|Usual Care|Participants who are randomized to the usual care arm will complete surveys at 3 timepoints and receive usual care by pulmonary clinician.
62061677|NCT01653080|EXPERIMENTAL|Dynamic contrast-enhanced MRI|Patients undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
62061678|NCT00258180|EXPERIMENTAL|severe autoimmune enteropathy|Young patients with severe autoimmune enteropathy receive cyclophosphamide IV over 1 hour on days 1-4. Patients then receive filgrastim (G-CSF) IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover
62266046|NCT02592239|EXPERIMENTAL|Controls|Healthy subjects recruited by public advertisement will be studied using functional brain MRI before and after receiving a test meal. Cognitive and hedonic response will be evaluated using 10 score scales.
62266047|NCT01007578|EXPERIMENTAL|Paclitaxel treatment|Paclitaxel-coated balloon catheter angioplasty treated subjects
62449527|NCT02492490|ACTIVE_COMPARATOR|Basiliximab|induction with Basiliximab during kidney transplantation from DCD
62623990|NCT04284384||HUNT Trondheim 70+|All inhabitants of one district in Trondheim 70 years of age or older were invited to participate in HUNT4 70+.
62849716|NCT06134024|ACTIVE_COMPARATOR|LAMS without Double Pigtail Plastic Stents|The group of participants with post-inflammatory pancreatic and peripancreatic fluid collections without double pigtail plastic stents introduced through the LAMS during endoscopic transmural drainage.
62061679|NCT05298098|ACTIVE_COMPARATOR|Hypertonic Saline Solution|50 ml of intravenous Hypertonic Saline Solution over 1 hour + 250mg of IV furosemide over 1 hour
62061680|NCT05298098|PLACEBO_COMPARATOR|5% Dextrose solution|50ml of 5% Dextrose solution over 1 hour + 250mg of IV furosemide over 1 hour
62061681|NCT03166475|EXPERIMENTAL|Palatal pedicle flap (Group 1)|On patients of this group were performed the palatal pedicle subepithelial connective tissue flap after the extraction, following the technique described by Khoury \& Happe (2000), which consists of total detachment of the palatal flap followed by division of the flap to release the connective tissue, maintain a pedicle and sliding it to cover the fresh socket by primary intention. The sutures were removed seven to ten days of postoperative.
62061682|NCT03166475|EXPERIMENTAL|Graft + palatal pedicle flap (Group 2)|On patients of this group were performed the palatal pedicle flap like the group 1, however, the sockets were previously filled with a graft of synthetic bone substitute (Bone Ceramic®, Straumann, Switzerland) and then recovered with the connective flap and sutured by primary intention. The sutures were removed seven to ten days of postoperative.
62061683|NCT03166475|EXPERIMENTAL|Provisional ovoid pontic (Group 3)|On patients of this group, after the extraction of the tooth, were made a provisional ovoid pontic with acrylic resin or with the crown of the removed tooth itself, cut and sealed with composite resin. The pontics were placed to seal the entire gingival margin of the socket and penetrating 2 to 3 mm into it, stabilized laterally by the adjacent teeth with orthodontic and composite resin or acrylic resin. No sutures were made.
62061684|NCT02245347||Patients with expected MDR TB|
62061685|NCT01571934||Mild or moderate hemophilia A|Subjects with mild or moderate hemophilia A (fVIII activity 1-40%) who are scheduled to undergo surgery for which at least 5 consecutive days of fVIII replacement therapy is required.
62061686|NCT02991144|EXPERIMENTAL|Cohort 1: DTX301 2.0 × 10^12 GC/kg|DTX301 (scAAV8OTC) 2.0 × 10\^12 GC/kg will be administered as a single peripheral IV infusion. A reactive corticosteroid taper regimen will be administered to control transient vector-induced hepatic effects. Sodium acetate will be used as a tracer to measure the rate of ureagenesis.
62061687|NCT02991144|EXPERIMENTAL|Cohort 2: DTX301 6.0 × 10^12 GC/kg|DTX301 (scAAV8OTC) 6.0 × 10\^12 GC/kg will be administered as a single peripheral IV infusion. A reactive corticosteroid taper regimen will be administered to control transient vector-induced hepatic effects. Sodium acetate will be used as a tracer to measure the rate of ureagenesis.
62061688|NCT02991144|EXPERIMENTAL|Cohort 3: DTX301 1.0 × 10^13 GC/kg|DTX301 (scAAV8OTC) 1.0 × 10\^13 GC/kg will be administered as a single peripheral IV infusion. A reactive corticosteroid taper regimen will be administered to control transient vector-induced hepatic effects. Sodium acetate will be used as a tracer to measure the rate of ureagenesis.
62061689|NCT02991144|EXPERIMENTAL|Cohort 4: DTX301 1.0x10^13 GC/kg + Prophylactic Corticosteroids|A prophylactic corticosteroid taper regimen (oral prednisone \[or prednisolone\], 60 mg tapered over 9 weeks) will be administered before dosing with DTX301 (scAAV8OTC) to prevent or minimize transient vector-induced hepatic effects. DTX301 (scAAV8OTC) 1.0x10\^13 GC/kg administered as a single peripheral IV infusion. Sodium acetate will be used as a tracer to measure the rate of ureagenesis.
62449528|NCT00368966|EXPERIMENTAL|1|
62449529|NCT00368966|ACTIVE_COMPARATOR|2|
62623991|NCT05063084|EXPERIMENTAL|OHD (HFNO)|High flow nasal oxygen
62623992|NCT05063084|OTHER|Control|Classic pre-oxygenation with facemask
62623993|NCT05008471|EXPERIMENTAL|Intervention group|The recommended target energy for NPC radiotherapy patients is 25-30kcal/(kg·d), in addition，the intervention group begins with an additional 50% daily energy increase during the peri-radiotherapy.
62623994|NCT05008471|NO_INTERVENTION|Conventional group|Unlike the intervention group,conventional group should be treated according to the consensus of experts on standardized nutrition management.
62849717|NCT05741606|ACTIVE_COMPARATOR|Capsules containing sodium pentaborate pentahydrate 200 mg|Capsules containing sodium pentaborate pentahydrate 200 mg orally once a day
62623995|NCT03374488|EXPERIMENTAL|Pembrolizumab 200 mg + Epacadostat 100 mg BID|Pembrolizumab + epacadostat
62849718|NCT05741606|ACTIVE_COMPARATOR|Capsules containing sodium pentaborate pentahydrate 400 mg|Capsules containing sodium pentaborate pentahydrate 400 mg orally once a day
62849719|NCT05741606|ACTIVE_COMPARATOR|Capsules containing sodium pentaborate pentahydrate 600 mg|Capsules containing sodium pentaborate pentahydrate 600 mg orally once a day
62849720|NCT05741606|ACTIVE_COMPARATOR|Capsules containing sodium pentaborate pentahydrate 800 mg|Capsules containing sodium pentaborate pentahydrate 800 mg orally once a day
62849721|NCT05741606|ACTIVE_COMPARATOR|Capsules containing sodium pentaborate pentahydrate 1000 mg|Capsules containing sodium pentaborate pentahydrate 1000 mg orally once a day
62849722|NCT05741606|PLACEBO_COMPARATOR|Placebo capsules|Placebo capsules of the same shape, smell, and color orally once a day
62849723|NCT04037332||Pre-RAS roll-out . Group I|I. Children presenting directly to a referral health facility without prior administration of RAS (pre-RAS): provides a baseline assessment of artemisinin resistance marker prevalence before the introduction of RAS
62849724|NCT04037332||Post-RAS roll-out - Group II|II. Children presenting directly to a referral health facility without prior administration of RAS (post-RAS): group not receiving pre-referral RAS and hence having baseline pressure for K13 resistance markers.
62849725|NCT04037332||Post-RAS roll-out - Group III|III. Children receiving pre-referral RAS from community-based provider and successfully referred to a referral health facility: group receiving pre-referral RAS (monotherapy).
62849726|NCT04037332||Post-RAS roll-out - Group IV|IV. Children receiving pre-referral RAS from community-based provider but not completing referral to a referral health facility, followed-up at their home on day 28: children malaria-positive on Day 28 may have an increased chance of harboring a resistant infection.
62849727|NCT06153303|EXPERIMENTAL|treatment group|Acceptance and commitment therapy
62849728|NCT01282580|EXPERIMENTAL|Dietary fish (canned salmon, albacore)|Fish products: Canned albacore and salmon will be provided at no cost to the patient. Supplies of tuna and salmon will be provided in quantities sufficient for one month of daily intake by the subject. If desired, a subject can request a sufficient amount to allow for preparation of a meal for the family or household at no more than two times per week. Labels or portions of labels from the cans will be collected at the monthly study visits, and canned supplies will be replenished monthly or at more frequent intervals if needed. Subjects will be allowed to keep unused cans.
62849729|NCT01282580|EXPERIMENTAL|Lovaza-Omega 3 fatty acid capsules|Lovaza capsules will be provided at no cost to the patient. Pill bottles will be provided to the patient, with the start date and number of pills recorded. The supplement will be provided in sufficient supply for one month at a time. Pill bottles will be collected at monthly follow-up visits, and any unused capsules will be documented and discarded as biohazardous waste.
62849730|NCT04027478|ACTIVE_COMPARATOR|FMD (fasting-mimicking diet)|Over the course of three rounds of chemotherapy, patients in the FMD will consume a diet that consists of 10 cal/kg/day and includes 50% fat, 40% carbohydrates, and no more than 10% protein. The diet includes nuts, olives, vegetable broth, broccoli/cauliflower, white rice/puffed rice cake, onion, tea/coffee, almond milk. The diet prohibits meat products, dairy, alcohol, sugar, and artificial sweeteners. Patients will be instructed to drink 2 cups of water each morning, take their usual medications and limit exercise to walking.
62266048|NCT04432883|ACTIVE_COMPARATOR|Experimental: Active cathodal tDCS + Speech-language training|In this arm, 31 patients with stroke induced Aphasia will undergo 15 sessions of active tDCS (x 30 minutes of stimulation) combined with 1 hour simultaneous speech-language training on consecutive weekdays.
62266049|NCT04432883|SHAM_COMPARATOR|Comparator: Placebo cathodal tDCS + Speech-language training|In this arm, 31 patients with stroke induced Aphasia will undergo 15 sessions of sham tDCS (x 30 minutes sham) combined with 1 hour simultaneous speech-language training on consecutive weekdays..
62266050|NCT01389752|EXPERIMENTAL|LY2216684 without Charcoal, then with Charcoal|Period 1: Single 18-mg (milligram) (two 9-mg tablets) oral dose of LY2216684 administered without Activated Charcoal. Period 2: Single 18-mg (two 9-mg tablets) oral dose of LY2216684 administered with single oral dose of 1 g/kg (gram/kilogram) of Activated Charcoal. Periods will be separated by a minimum of 7 days.
62266051|NCT01389752|EXPERIMENTAL|LY2216684 with Charcoal, then without Charcoal|Period 1: Single 18-mg (two 9-mg tablets) oral dose of LY2216684 administered with single oral dose of 1 g/kg of Activated Charcoal. Period 2: Single 18-mg (two 9-mg tablets) oral dose of LY2216684 administered without Activated Charcoal. Periods will be separated by a minimum of 7 days.
62266052|NCT01227733||Breast Tumor|Breast Tumor Blocks
62266053|NCT00583362|EXPERIMENTAL|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV over one hour every 28 days.
62849731|NCT04027478|NO_INTERVENTION|regular diet|Diet not influenced by a fast-mimicking diet.
62266054|NCT01682135|EXPERIMENTAL|Ramucirumab|Ramucirumab administered intravenously (IV) at escalating doses (6 milligrams per kilogram \[mg/kg\] up to 10 mg/kg) every 2-3 weeks for 6 weeks (1 Cycle). Treatment may continue until discontinuation criterion is met.
62623996|NCT03374488|ACTIVE_COMPARATOR|Pembrolizumab 200 mg + placebo BID|Pembrolizumab + placebo
62849732|NCT01105546|EXPERIMENTAL|prophylaxis|prophylaxis with recombinant activated FVII 90 µg/kg/day i.v.
62849733|NCT01105546|ACTIVE_COMPARATOR|on demand treatment|treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
62849734|NCT06136767||Methotrexate|Participants who have received methotrexate for atopic dermatitis.
62849735|NCT06136767||Cyclosporine|Participants who have received cyclosporine for atopic dermatitis.
62849736|NCT06136767||Mycophenolate mofetil|Participants who have received mycophenolate mofetil for atopic dermatitis.
62623997|NCT04412798|OTHER|group 1|orange juice concentrate
62623998|NCT04412798|OTHER|Group 2|Sugar-sweetened orange-flavoured beverage
62623999|NCT04412798|OTHER|Group 3|Whole orange juice with skin removed
62624000|NCT06611852|EXPERIMENTAL|Group (A)|received aerobic exercises
62624001|NCT06611852|EXPERIMENTAL|Group (B)|received electronic cupping therapy
62849737|NCT06136767||Azathioprine|Participants who have received azathioprine for atopic dermatitis.
62849738|NCT06136767||Dupilumab|Participants who have received dupilumab for atopic dermatitis.
62286832|NCT03642145|EXPERIMENTAL|Arm B: Deflazacort 0.45 mg/kg|Participants will receive approximately 0.45 mg/kg deflazacort once daily orally for 52 weeks in Period 1. Participants will either continue to receive 0.45 mg/kg deflazacort or escalated dose of deflazacort (0.9 mg/kg) once daily orally in Period 2 at the investigator's discretion and in consultation with the caregiver. The target dose could be varied +/- 20% depending upon the available tablet strengths and change in participant's weight.
62849739|NCT06136767||Tralokinumab|Participants who have received tralokinumab for atopic dermatitis.
62449530|NCT00334490|ACTIVE_COMPARATOR|1|Oral Sildenafil 12.5 mg
62849740|NCT06136767||Upadacitinib|Participants who have received upadacitinib for atopic dermatitis.
62849741|NCT06136767||Abrocitinib|Participants who have received abrocitinib for atopic dermatitis.
62849742|NCT00892736|EXPERIMENTAL|Treatment (veliparib)|"Patients receive veliparib PO BID\* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: \*Patients receive veliparib once on day 1 of course 1 for pharmacokinetic and pharmacodynamic studies."
62849743|NCT06125080|EXPERIMENTAL|Utidelone+Tirelizumab+Bevacizumab|
62849744|NCT05166837|EXPERIMENTAL|Cohort 1:2mg/kg|All participants (fasted) received either 2 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
62849745|NCT05166837|EXPERIMENTAL|Cohort 2:5mg/kg|All participants (fasted) received either 5 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
62266055|NCT03994939|EXPERIMENTAL|Intervention|Received Families Talking Together (FTT) intervention, an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative sexual and reproductive health outcomes in adolescents age 10-14. The FTT intervention consisted of two components. Component 1 was comprised of 2 FTT intervention sessions between a parent and bilingual/bicultural promotor trained to deliver FTT in English or Spanish. These sessions highlighted adverse health consequences of sex to motivate parents to communicate with their adolescent and provided guidance to parents on communication strategies. Component 2 was comprised of written supplemental materials that promotores used to guide each intervention session. Experimental condition families will complete all measurement assessments.
62266056|NCT03994939|NO_INTERVENTION|Control|Parents randomized to the control group did not receive any intervention sessions and only completed assessment questionnaires.
62849746|NCT05166837|EXPERIMENTAL|Cohort 3:10mg/kg|All participants (fasted) received either 10 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
62849747|NCT05166837|EXPERIMENTAL|Cohort 4:20mg/kg|All participants (fasted) received either 20 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
62266057|NCT05618821|EXPERIMENTAL|ICG|Laparoscopic gastrectomy Group with the use of near-infrared imaging (ICG group)
62849748|NCT05166837|EXPERIMENTAL|Cohort 5:30mg/kg|All participants (fasted) received either 30 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
62849749|NCT04228029|ACTIVE_COMPARATOR|Carboxytherapy|
62849750|NCT04228029|ACTIVE_COMPARATOR|Intralesional steroids|
62849751|NCT04228029|ACTIVE_COMPARATOR|Combination of carboxytherapy and intralesional steroids|
62849752|NCT05283512|OTHER|IV-hydration group (standard of care according to international guidelines)|"The IV-hydration with isotonic 0.9% NaCl will be initiated three hours prior to the IV CECT and completed four hours after IV CECT (infusion rate of 1-3 mL/kg/hour). Patients are prescribed a fixed volume of 1000 mL, which is equally distributed before and after IV CECT (500 mL before and 500 mL after).~Patients with heart failure (LVEF ≤ 40%) are prescribed a reduced volume of 500 mL, which is also equally distributed before and after IV CECT (250 mL before and 250 mL after)."
62849753|NCT05283512|ACTIVE_COMPARATOR|Oral hydration group|"The oral hydration regimen will be initiated one-two hours prior to IV CECT and completed within four hours after IV CECT. Patients are prescribed a fixed volume of 1000 mL, which is distributed equally before and after IV CECT (500 mL before and 500 mL after).~Patients with heart failure (LVEF ≤ 40%) are prescribed a reduced volume of 500 mL, which is equally distributed before and after IV CECT (250 mL before and 250 mL after)."
62849754|NCT00194870|OTHER|Digital EEG|Digital EEG
62849755|NCT00152269|EXPERIMENTAL|1|
62849756|NCT00152269|EXPERIMENTAL|2|
62849757|NCT00152269|PLACEBO_COMPARATOR|3|
62849758|NCT04141904|EXPERIMENTAL|Tofacitinib|Tofacitinib 5mg capsule twice a day for 7-10 days
62849759|NCT04141904|PLACEBO_COMPARATOR|Placebo|Placebo capsule twice a day for 7-10 days
62849760|NCT03695770|EXPERIMENTAL|target population|All the target population should be included in the experimental arm
62849761|NCT00125528|EXPERIMENTAL|1|D-cycloserine 50mg bid/100mg bid/200 mg bid
62849762|NCT00125528|PLACEBO_COMPARATOR|2|placebo
62849763|NCT05593263|EXPERIMENTAL|Clear corneal incisions|the Steep meridian will be identified and marked, One clear corneal incision will be made on one side of the steep axis using 2.4mm keratome knife then enlarged to 4mm after completion of cataract surgery \& other corneal 4mm incision is added to the other side of the steep axis
62849764|NCT05593263|EXPERIMENTAL|Limbal relaxing incision|Single or paired LRI will be performed on the steep axis prior to phaco-emulsification procedure using a 600 μm diamond guarded blade.
62849765|NCT02813577|OTHER|Lutonix® 035 Drug Coated Balloon PTA Catheter|This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
62849766|NCT06228677||Adrenal Venous Sampling Group|Adrenal veinous sampling in patients with primary aldosteronism who underwent percutaneous selective adrenal artery embolization
62849767|NCT06228677||Peripheral Venous Sampling Group|Peripheral veinous sampling in patients with primary aldosteronism who underwent percutaneous selective adrenal artery embolization
62849768|NCT00575939||HIV positive|HIV infected treatment naive with CD4 cell count of at least 400
62849769|NCT00575939||Healthy controls|Healthy controls
62849770|NCT03899181|ACTIVE_COMPARATOR|1 Hz 2400 TNT Treatment|Intervention: TNT treatment intervention with 2400 total stimulations with the magnetic coil..
62849771|NCT03899181|ACTIVE_COMPARATOR|1 Hz 3600 TNT Treatment|Intervention: TNT treatment intervention with 3600 total stimulations with the magnetic coil.
62849772|NCT03899181|SHAM_COMPARATOR|Sham TNT Treatment|This arm will have the sham treatment session. First we will assess the motor threshold intensity described above. Next, a sham coil is placed on each of 4 regions (2 lumbar \& 2 sacral), and 600 stimulations will be given at each site in 2 trains, with a 5 minutes rest period between each site and 3 minutes between trains.
62849773|NCT01141413||RA patients using Remicade®|
62849774|NCT01141413||RA patients using Orencia®|
62266058|NCT05618821|ACTIVE_COMPARATOR|Non-ICG|Laparoscopic gastrectomy Group without the use of near-infrared imaging (Non-ICG group)
62849775|NCT01895478|EXPERIMENTAL|PACCI-ED|PACCI-ED attendings were given the PACCI-ED use intervention.
62849776|NCT01895478|NO_INTERVENTION|Control|Control attendings were not given the PACCI-ED use intervention.
62849777|NCT03412565|EXPERIMENTAL|Daratumumab(D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)|Participants will receive daratumumab 1800 milligram (mg) by subcutaneous (SC) injection on Days 1, 8 and 15 of Cycles 1 to 3 (each cycle of 21 days) and on Day 1 of Cycle 4; bortezomib 1.3 milligram per square meter (mg/m\^2) SC injection on Days 1, 4, 8 and 11 of Cycles 1 to 4; lenalidomide 25 mg orally on Day 1 through Day 14 of Cycles 1 to 4 and dexamethasone 20 mg orally or intravenously on Days 1, 2 ,8, 9, 15 and 16 of Cycle 1 to 4.
62624002|NCT06611852|EXPERIMENTAL|Group (C)|received interferential therapy
62061690|NCT05684913|EXPERIMENTAL|Zinc granulate group|The patients in this group will receive a chair-side prepared surgical stent from Zn granulates on the palatal wound after FGG surgery.
62061691|NCT05684913|ACTIVE_COMPARATOR|Hemostatic agent group|The patients in this group will receive hemostatic agent sutured on the palatal wound after FGG surgery.
62061692|NCT04879459||Intervention Group IG|"The IG is constituted of participants, naïve to ultrasound use. Participants undergo a web-based video learning about gallbladder evaluation using CUS on day 0 (same video as in CG). Participants undertake 3 times a one-day CUS course consisting in 2 practical sessions of 10 times 10 minutes on 10 healthy volunteers on day 0, day 7 and day 10. One practical session takes place before lunchtime, the second one after lunchtime.~Participants of IG don't have any contact with CG during study days. An evaluation is organized on day 60 to evaluate primary and secondary endpoints."
62061693|NCT04879459||Control Group CG|"The CG is constituted of participants, naïve to ultrasound use. Participants undergo a web-based video learning about gallbladder evaluation using CUS on day 0. Participants of CG undertake 2 practical CUS sessions of 10 times 10 minutes on 10 volunteers, at least 50% of them suffering from gallstones on day 0, day 7 and day 10. One session takes place before lunchtime, the second one after lunchtime.~Participants of CG don't have any contact with IG during study days. An evaluation is organized on day 60 to evaluate primary and secondary endpoints."
62061694|NCT06540001|EXPERIMENTAL|Patients will undergo both automated and manual visual acuity testing|Patient will perform manual visual acuity first, then be guided to another room to have the visual acuity tested on the automated VA device
62061695|NCT05694403||Neurologists|
62061696|NCT05694403||General practitioners|
62849778|NCT03412565|EXPERIMENTAL|D + Bortezomib + Melphalan + Prednisone (D-VMP)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15, 22, 29 and 36 of Cycle 1 then on Days 1 and 22 in Cycles 2 to 9 and Day 1 of Cycle 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; bortezomib 1.3 mg/m\^2 SC injection on Day 1, 4, 8, 11, 22, 25, 29 and 32 of Cycle 1 and on Days 1, 8, 22 and 29 of Cycles 2 to 9; melphalan 9 mg/m\^2 orally on Day 1 through Day 4 of Cycles 1 to 9; prednisone 60 mg/m\^2 orally on Days 1 to 4 of cycles 1 to 9.
62061697|NCT01781390|PLACEBO_COMPARATOR|Placebo|Participants received matching-placebo solution 2 milliliters per minute (mL/min) infused Intracoronary for 60 min including line flush \[0 Mesenchymal Precursor Cells (MPCs)/min\] on Day 0.
62061698|NCT01781390|EXPERIMENTAL|Mesenchymal Precursor Cells (MPC) 12.5 M|Participants received MPC 12.5 solution 2 mL/min infused Intracoronary for 60 min including line flush (2.5x10\^5 MPCs/min) on Day 0.
62061699|NCT01781390|EXPERIMENTAL|Mesenchymal Precursor Cells (MPC) 25 M|Participants received MPC 12.5 solution 2 mL/min infused Intracoronary for 60 min including line flush (5.0x10\^5 MPCs/min) on Day 0.
62061700|NCT01320930|ACTIVE_COMPARATOR|Pulmonary rehabilitation|A standardized 7 week rehabilitation program, including physical training and education.
62061701|NCT01320930|PLACEBO_COMPARATOR|Control|Conventional care
62061702|NCT02529475|EXPERIMENTAL|Gadoteric acid|Gadoteric acid 0.2 mmol/kg
62061703|NCT05338918|EXPERIMENTAL|Mental Imagery with Virtual Reality Group|Mental Imagery with Virtual Reality
62061704|NCT05338918|ACTIVE_COMPARATOR|Virtual Reality Alone Group|Virtual Reality Alone
62266059|NCT04091529|EXPERIMENTAL|Radiofrequency myolysis of uterine fibroids|54 premenopausal participants with symptomatic uterine myomas
62266060|NCT02821702|EXPERIMENTAL|Post surgery and embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
62061705|NCT01978366|EXPERIMENTAL|Cohort 1: HT-100 tablet, Dose 1|• Multiple dose administration: Dose 1
62061706|NCT01978366|EXPERIMENTAL|Cohort 2: HT-100 tablet, Dose 2|• Multiple dose administration: Dose 2
62061707|NCT01978366|EXPERIMENTAL|Cohort 3: HT-100 tablet, Dose 3|• Multiple dose administration: Dose 3
62061708|NCT01978366|EXPERIMENTAL|Cohort 4: HT-100 tablet, Dose 4|• Multiple dose administration: Dose 4
62624003|NCT06611852|EXPERIMENTAL|Group (D)|
62624004|NCT04421157|EXPERIMENTAL|Schroth group|The Schroth group received Schroth exercises in addition to traditional rehabilitation.
62624005|NCT04421157|EXPERIMENTAL|Stabilization group|The stabilization group received core stabilization in addition to traditional rehabilitation.
62652839|NCT04480879|EXPERIMENTAL|AZD8154 nebuliser suspension|The study subjects will receive 1 mg delivered dose of AZD8154 nebuliser suspension
62652840|NCT04480879|EXPERIMENTAL|AZD8154 Monodose|The study subjects will receive 1 mg capsule delivered dose of AZD8154 Monodose DPI formulation
62849779|NCT03412565|EXPERIMENTAL|Daratumumab + Lenalidomide + Dexamethasone (D-Rd)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; lenalidomide 25 mg orally on Day 1 through Day 21 of each cycle until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or intravenously weekly until documented progression of disease, unacceptable toxicity, or end of study.
62849780|NCT03412565|EXPERIMENTAL|Daratumumab + Carfilzomib + Dexamethasone (D-Kd)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 (each cycle is of 28 days) then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; Carfilzomib 20 mg/m\^2 intravenously (IV) on Day 1 of Cycle 1 only then 70 mg/m\^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or IV weekly for Cycles 1-9 then on Days 1, 8, 15 of each cycle for Cycles 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study.
62849781|NCT05707039|EXPERIMENTAL|Open chain kinetic exercises|In open chain exercises extremities are free to move and there is no weight bearing. Subjects performed group of exercises, 3sets of 10 repetitions for each exercise after warm-up and stretching exercises The open kinetic chain exercise program consisted of 1) maximal static quadriceps muscle contractions
62849782|NCT05707039|EXPERIMENTAL|Closed Chain Kinetic Exercises|In closed kinetic chain exercises extremities are fixed and weight bearing is done. Subjects performed group of exercises, 3sets with 10 repetitions for each exercise after warm up and stretching exercises. The closed kinetic chain exercise program consisted of 1) seated leg presses, 2) one-third knee bends on one leg and on both legs, 3) stationary bicycling, 4) rowing-machine exercises, 5) step-up and step-down exercises. Each exercise in the closed kinetic chain protocol was performed dynamically with a 3-second rest between repetitions.
62849783|NCT01579851|ACTIVE_COMPARATOR|Propofol-Remifentanil|Anesthesia is maintained with Propofol and Remifentanil; myorelaxation is obtained with rocuronium
62849784|NCT01579851|ACTIVE_COMPARATOR|Sevoflurane-Remifentanil|Anesthesia is maintained with Sevoflurane and Remifentanil; myorelaxation is obtained with rocuronium
62849785|NCT04939142|EXPERIMENTAL|SVd (Selinexor+Bortezomib+dexamethasone)|Enrolled patients will be treated with ATG-010( 100 mg/QW, oral ) with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5cycles.
62849786|NCT04939142|EXPERIMENTAL|Vd(Bortezomib+dexamethasone)|Enrolled patients will be treated with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5 cycles.
62849787|NCT00970684|EXPERIMENTAL|Bevacizumab, Docetaxel, and Gemcitabine|Treatment repeats every 21 days for up to 6 courses.
62266061|NCT02821702|ACTIVE_COMPARATOR|Control group|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
62266062|NCT02821702|ACTIVE_COMPARATOR|Post surgery with accreta without embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
62849788|NCT01156337||low sodium diet 80 mmol/day|
62849789|NCT01156337||moderate sodium intake 120 mmol/day|
62849790|NCT04048330||Women of reproductive age|Women 15 to 49 years of age who are not pregnant or lactating
62849791|NCT05099367|OTHER|Group 1 : healthy subject|15 healthy subject without diabetes
62266063|NCT02821702|ACTIVE_COMPARATOR|Post surgery without accreta without embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH)
62266064|NCT02821702|ACTIVE_COMPARATOR|Normal Vaginal Delivery - no suspected accreta|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH)
62266065|NCT01040559|EXPERIMENTAL|Idarubicin|Dose escalation: level0 = idarubicin 5mg, level1 = idarubicin 10mg, level2 = idarubicin 15mg, level3 = idarubicin 20mg, level4 = idarubicin 25mg
62266066|NCT01250015||control|given standard nhs advice leaflet
62849792|NCT05099367|OTHER|Group 2 : diabetes without ulcer|15 patients with diabetes type II and without foot ulcer
62849793|NCT05099367|OTHER|Group 3 : diabetes with ulcer active or <2 years|15 patients with diabetes type II and with foot ulcer (active or \<2years)
62266067|NCT01250015||interventional|given standard nhs advice leaflet with numerical information and pictograms
62449531|NCT00334490|PLACEBO_COMPARATOR|2|Placebo in 5 mls distilled water
62266068|NCT01793155|EXPERIMENTAL|Inspiratory muscle training|Inspiratory muscle training for two weeks following surgery
62624006|NCT06060340|EXPERIMENTAL|class II furcation defects|"Inclusion criteria:~1. Lower molars with class II furcation defects.~2. Full mouth plaque score (FMPS )\<20% at baseline.~3. Full mouth bleeding score (FMBS )\<10% at baseline.~4. Systemically healthy.~5. Cooperative patients.~Exclusion criteria:~1. Smokers.~2. Pregnancy and lactation.~3. Stage 4 Grade C periodontitis."
62624007|NCT05733845|OTHER|Samples|The intervention is to collect blood; urine; saliva and stool samples but also mucosal biopsies at each protocol visits (baseline and follow up visits).
62624008|NCT02154958||Unexplained infertility|
62266069|NCT01793155|PLACEBO_COMPARATOR|Standard physiotherapy|Breathing exercises, cough/hugh, advice on early and active mobilization
62624009|NCT03613792|ACTIVE_COMPARATOR|Remifentanil and Ketamine Group|Patients in Group 1 will receive remifentanil and ketamine. Remifentanil will be administered initially with a 1mcg/kg IV bolus followed by a continuous infusion, 0.1 to 0.15 mcg/kg/min IV (using ideal body weight) with titration to a maximum dose of 0.2 to 0.4 mcg/kg/min IV. Total dose of ketamine will be titrated from 10 to 40 mg, based on clinical judgment, and it will be recorded. Ketamine will be delivered using 2mL syringes, previously filled with ketamine in normal saline at a 10mg/mL concentration.
62624010|NCT03613792|ACTIVE_COMPARATOR|Fentanyl and Midazolam|The patients in this group will receive fentanyl doses that range between 0.5 to 2 mcg/kg (25 - 50 mcg) IV bolus in combination with midazolam 1-5 mg bolus over at least 2 minutes as determined by attending anesthesiologist (not to exceed 2.5 mg / 2 min per package insert). Total dosing of fentanyl and midazolam may be titrated, based on clinical judgment, and it will be recorded. Maintenance, additional midazolam doses of 25% of total initial dose required to achieved desired sedation may be administered IV if additional sedation is considered necessary
62624011|NCT02588729|EXPERIMENTAL|Pregnant+ app for smartphone (Gravid+)|The intervention consists of the Pregnant+app downloaded on women's smartphone. The app contains culturally adapted information about physical activity, diet and management of GDM. The Gravid+app will be available in Norwegain, Urdu and Somali. Women will have the opportunity to automatically transfer their blood glucose levels to their smartphones via Bluetooth.
62266070|NCT05447494|EXPERIMENTAL|Low-dose CAN103|Low dose intravenous infusion of CAN103 every other week for 37 weeks
62624012|NCT02588729|NO_INTERVENTION|No admission to Pregnant+ app (Gravid+)|The control group will receive standard care at the outpatient departments. Participants to not receive the Pregnancy
62624013|NCT05803759|ACTIVE_COMPARATOR|Allicor|Dietary Supplement: Allicor 150 mg capsule by mouth two times a day
62624014|NCT05803759|PLACEBO_COMPARATOR|Placebo|Placebo capsule manufactured to mimic Allicor 150 mg capsule by by mouth two times a day
62624015|NCT01761643|NO_INTERVENTION|Standard of Care (SoC)|"This proposal will perform a study of potential methods to improve adherence and retention by evaluating standard procedures versus the use of the iTAB platform.~All subjects will receive SoC that will include health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psycho-social barriers, adherence counseling, and completion of a computer based survey."
62624016|NCT01761643|ACTIVE_COMPARATOR|SoC + iTab|"Subjects assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.~Subjects will have visits with the study coordinator to introduce the iTAB texting system.~Once the time is identified, the text reminder system is automated. Patients will confirm medication taking via text responses to the personalized reminders. If a participant does not respond on three consecutive occasions, a high alert message (chosen by the participant) will be sent. If the subject does not respond to this message, the study coordinator would initiate phone calls to contact the subject and explore barriers."
62849794|NCT05099367|OTHER|Group 4 : Patients with type 2 diabetes, neuropathy and DFU undergoing lower limb|Patients with type 2 diabetes and neuropathy and DFU undergoing lower lunb surgery for skin ulcer
62624017|NCT04553770|ACTIVE_COMPARATOR|Arm A (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 90 minutes on cycle 1 day 1 and 30 minutes on day 1 of each subsequent cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
62061709|NCT01978366|EXPERIMENTAL|Cohort 5: HT-100 tablet, Dose 5|• Multiple dose administration: Dose 5
62266071|NCT05447494|EXPERIMENTAL|High-dose CAN103|High dose intravenous infusion of CAN103 every other week for 37 weeks
62624018|NCT04553770|EXPERIMENTAL|Arm B (trastuzumab deruxtecan, anastrozole)|Patients receive trastuzumab deruxtecan IV over 90 minutes on cycle 1 day 1 and 30 minutes on day 1 of each subsequent cycle and anastrozole PO QD on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
62061710|NCT01759654|EXPERIMENTAL|AdimFlu-V|
62266072|NCT02054026|EXPERIMENTAL|Reducing the Risk|An eight-lesson (approximately eight-hour) version of Reducing the Risk
62266073|NCT02054026|NO_INTERVENTION|Control|
62266074|NCT01854619|ACTIVE_COMPARATOR|Saline irrigation|Saline irrigation via syringe will be administered using a sinus irrigation catheter under endoscopic control.
62266075|NCT01854619|ACTIVE_COMPARATOR|Double photodisinfection treatment|Patients in the double treatment arm will receive a second photodisinfection treatment 4 weeks following the first treatment with regular follow-up visits
62266076|NCT01854619|ACTIVE_COMPARATOR|Single photodisinfection treatment|The single-treatment group will receive a single photodisinfection treatment of all involved paranasal sinuses with multiple follow-up visits.
62061711|NCT06625294|EXPERIMENTAL|Experimental group A|It includes participants receiving task oriented combined with bilateral functional task training exercises for 10 weeks treatment.
62061712|NCT06625294|EXPERIMENTAL|Experimental group B|This group involves participants receiving task oriented training with constrained induced movement therapy exercises for a period of 10 weeks.
62061713|NCT01491074|PLACEBO_COMPARATOR|NaCl 0.9% 100 ml|
62061714|NCT01491074|EXPERIMENTAL|Tocilizumab 280 mg|Intravenous infusion, 280 mg Tocilizumab (14 ml) added to 86 ml of 0.9% NaCl
62061715|NCT02684201|EXPERIMENTAL|Boston Scientific cord stimulator lead|A Boston Scientific Stimulator Lead (PMA P030017) will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance.
62061716|NCT01671839|EXPERIMENTAL|Subcutaneous tissue release|Device: Subcutaneous tissue release with the Cabochon System
62449532|NCT01790022|EXPERIMENTAL|Methylprednisolone 500 mg|Methylprednisolone 500 mg administered intravenously at baseline
62849795|NCT03156387|EXPERIMENTAL|Diode laser|A 2.8 W, 980 nm diode laser(Sirona Advanced) in continuous wave mode with an air cooling handpiece was used in the alternative frenectomy technique. The frenulum was held with a hemostat, and a repeated continuous wave mode was applied for the excision. It was also used to remove the periosteal adhesion. The remnants of the ablated tissue were removed with saline, and no sutures were placed after the diode laser treatment.
62849796|NCT03156387|ACTIVE_COMPARATOR|Scalpel|(1) topical anesthesia (20% benzocaine), (2) local anesthesia using the bilateral vestibular infiltration technique, with 0.6 ml (1/3 of the carpule contents) of 4% articaine and 1:200,000 epinephrine, (3) hemostatic clamping of the frenulum, (4) excision of the whole band of tissue, together with its alveolar attachment, with a 15C scalpel blade, (5) relaxation and unbending of any fibrous adhesions to the underlying periosteum, and (6) simple suturing with 5-0 silk thread
62849797|NCT04835675||Cancer Arm|Participants with new diagnosis of hepatobiliary malignancies, from whom blood samples will be collected
62849798|NCT04835675||Benign Diseases Arm|Participants with benign diseases of the hepatobiliary system, from whom blood samples will be collected
62849799|NCT00830297|ACTIVE_COMPARATOR|1 Insulatard (long-acting insulin)|
62061717|NCT04498195|EXPERIMENTAL|Increase physical activity and exercise|
62061718|NCT05296291|ACTIVE_COMPARATOR|High-translucent monolithic zirconia,|
62061719|NCT05296291|ACTIVE_COMPARATOR|Zirconia ceramic with porcelain|
62061720|NCT05296291|ACTIVE_COMPARATOR|Metal ceramics.|
62061721|NCT05084222|EXPERIMENTAL|Buventol® Easyhaler® 200 µg/inhalation dmDPI|400 μg of salbutamol from Buventol Easyhaler is administered as two inhalations.
62061722|NCT05084222|EXPERIMENTAL|Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI|320 μg of budesonide and 9 μg of formoterol are administered from Bufomix Easyhaler as two inhalations.
62061723|NCT05084222|ACTIVE_COMPARATOR|Ventoline® Evohaler® 100 µg/inhalation pMDI|400 μg of salbutamol from Ventoline Evohaler is administered via Volumatic spacer as four inhalations.
62061724|NCT01074892|ACTIVE_COMPARATOR|MPA 10 mg per oral cyclic for 6 months|The peroral treatment is used 10 days each month
62061725|NCT01074892|ACTIVE_COMPARATOR|MPA 10 mg per os continuous 6 months|Per oral MPA 10 mg is taken daily for 6 months
62061726|NCT01074892|ACTIVE_COMPARATOR|LNG-IUD for 6 months|Levonorgestrel impregnated IUD is inserted into the uterine cavity and kept in situ for 6 months
62061727|NCT00219440|EXPERIMENTAL|A|ACTOS plus standard diet
62061728|NCT00219440|EXPERIMENTAL|B|Actos plus structured diet
62061729|NCT00219440|EXPERIMENTAL|C|Metformin plus standard diet
62286833|NCT03642145|NO_INTERVENTION|Natural History Control Group|Control participants matching to the study population as closely as possible, will be used as a comparator to characterize the safety and tolerability of deflazacort.
62449533|NCT01447264|PLACEBO_COMPARATOR|Land exercises|The patients of this group will perform the same exercises from water exercises
62449534|NCT01447264|ACTIVE_COMPARATOR|Water exercises|The patients of this group will perform the same exercises from land exercises
62849800|NCT00830297|ACTIVE_COMPARATOR|2 Conventional treatment|
62849801|NCT01739062|EXPERIMENTAL|Genetic risk assessment|At least 40 SNP (single nucleotide polymorphisms)increase the risk of PCa. The individual risk of PCa accumulates with the increasing number of these genetic variants. The risk is doubled if patient has familial disposition as well. In retrospective studies, non-genetic risk-prediction models were compared to risk-prediction models containing both non-genetic factors and SNPs analyses. The genetic models had a significantly higher specificity than the non-genetic models. It has been argued that genetic PCa risk assessment could reduce the inexpedient use of PSA tests, saving it for patients at high risk of PCa.
62849802|NCT01739062|NO_INTERVENTION|Familial disposition risk assessment|
62061730|NCT03044522|NO_INTERVENTION|No Nurse Education|Subjects who are enrolled into study arm with no Nurse Pain Educator will be monitored every month to assess their use of their medication, quality of life, physical and mental well-being. No intervention will be conducted with these subjects beyond that of standard of care at the facility.
62849803|NCT04004871|EXPERIMENTAL|Induction chemotherapy and concurrent chemoradiotherapy|Patients receive induction chemotherapy with Nab-paclitaxel, cisplatin and fluorouracil every three weeks for three cycles before radiotherapy, and then receive concurrent chemoradiotherapy.
62266077|NCT05461911||The Study Group|30 adult patients aged 30-75 years to receive a specialized tube feeding product Nutrison Advanced Cubison (20% protein energy 100 kcal, 5.5 g protein, 0.85 g arginine, 38 mg of vitamin C and 2 mg of zinc) in a volume not exceeding 1.5 liters / day and, if necessary, to replenish nutritional needs based on the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g of protein / kg body weight / day according to the recommendations for nutritional support for patients with pressure ulcers during the entire observation period
62286834|NCT02104414|ACTIVE_COMPARATOR|Exparel|266mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
62624019|NCT01832883||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
62624020|NCT01832883||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~* VA \<20/40 and 2 logMAR lines difference in normal eye~* Mild amblyopia (\>20/40)~* Moderate amblyopia (20/40 and \<20/100)~* Severe amblyopia (≥20/100 or worse)~* Bilateral amblyopia: \>4 years age VA\<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~* Constant: \>2 PD at near and or distance.~* Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~* 'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~* 'hypermetropia' (≥3.5 D),~* 'myopia' (≥-4.0 D),~* 'astigmatism' (≥1.5 D).~* 'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
62652841|NCT04480879|PLACEBO_COMPARATOR|AZD8154 Placebo Monodose DPI|The study subjects will receive AZD8154 placebo Monodose DPI formulation dosed to correspond to 1 mg delivered dose AZD8154 Monodose DPI formulation
62849804|NCT02384798|EXPERIMENTAL|ventilatory support|noninvasive ventilatory support to 5cmH2O used before the session of interval training and resistance exercises performed three times a week for 12 weeks
62849805|NCT02384798|ACTIVE_COMPARATOR|interval training|sessions of interval training and resistance exercises performed three times a week for 12 weeks
62849806|NCT06109818|EXPERIMENTAL|ICP-488 low dose|
62849807|NCT06109818|EXPERIMENTAL|ICP-488 high dose|
62849808|NCT06109818|PLACEBO_COMPARATOR|Placebo|
62849809|NCT00543959|EXPERIMENTAL|Part1 - Arm 1|Part1: Arm 1: drug
62849810|NCT00543959|PLACEBO_COMPARATOR|Part1 - Arm 2|Part1 - Arm 2: Pbo comparator
62849811|NCT00543959|PLACEBO_COMPARATOR|Part 2 - Arm 1|Part 2 - Arm 1: Pbo
62849812|NCT00543959|EXPERIMENTAL|Part 2 - Arm 2|Part 2- Arm 2: drug 5mg
62849813|NCT00543959|EXPERIMENTAL|Part 2 - Arm 3|Part 2 - Arm 3: drug 15mg
62849814|NCT00543959|EXPERIMENTAL|Part 2 - Arm 4|Part 2 - Arm 4: drug 30mg
62849815|NCT00543959|ACTIVE_COMPARATOR|Part 2 - Arm 5|Part 2 - Arm 5: active comparator
62849816|NCT03846518|ACTIVE_COMPARATOR|Hyrax group|Seventeen patients will be submitted to rapid maxillary expansion (RME) using the Hyrax expander. The activation protocol will be 2 turns a day up to obtain transverse overcorrection.
62849817|NCT03846518|EXPERIMENTAL|mini Hyrax group|Seventeen patients will be submitted to rapid maxillary expansion (RME) using the mini Hyrax expander. The activation protocol will be 2 turns a day up to obtain transverse overcorrection.
62849818|NCT00523445|EXPERIMENTAL|Varenicline|The effect of varenicline on cognitive function of Varenicline(Chantix) is being compared to that of placebo
62849819|NCT00523445|PLACEBO_COMPARATOR|Placebo|The effect of placebo comparator is being compared to that of varenicline
62849820|NCT03844945|EXPERIMENTAL|Netarsudil Ophthalmic Solution 0.01%|1 drop daily into each eye in the evening for 28 days
62849821|NCT03844945|EXPERIMENTAL|Netarsudil Ophthalmic Solution 0.02%|1 drop daily into each eye in the evening for 28 days
62849822|NCT03844945|EXPERIMENTAL|Netarsudil Ophthalmic Solution 0.04%|1 drop daily into each eye in the evening for 28 days
62286835|NCT02104414|ACTIVE_COMPARATOR|Bupivacaine HCl with epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
62849823|NCT03844945|PLACEBO_COMPARATOR|Netarsudil Ophthalmic Solution Placebo|1 drop daily into each eye in the evening for 28 days
62849824|NCT03675854|EXPERIMENTAL|Extended Group|3 weeks of antibiotics
62849825|NCT03675854|ACTIVE_COMPARATOR|Conventional Group|2 weeks of antibiotics
62849826|NCT01051154|ACTIVE_COMPARATOR|Docosahexaenoic acid (DHA)|This group will be receive the DHA supplement
62849827|NCT01051154|PLACEBO_COMPARATOR|Placebo|This group will be receive placebo
62849828|NCT02080819|NO_INTERVENTION|Healthy Control|Non drug using healthy controls
62849829|NCT02080819|PLACEBO_COMPARATOR|Placebo|Placebo BID for 7 weeks
62849830|NCT02080819|EXPERIMENTAL|Medication|Levodopa/carbidopa 400/100 BID for 7 weeks
62849831|NCT03028454|EXPERIMENTAL|Ginger Root Capsule|
62849832|NCT03028454|PLACEBO_COMPARATOR|Placebo Capsule|
62849833|NCT04044170|EXPERIMENTAL|Poziotinib|"* Cohort 1 : Previously treated patients with EGFR exon 20 insertion mutation positive NSCLC~* Cohort 2: Previously treated patients with HER2 exon 20 insertion mutation positive NSCLC"
62849834|NCT00807560|EXPERIMENTAL|FBT-PO|Family Based Therapy for Pediatric Overweight.
62849835|NCT00807560|ACTIVE_COMPARATOR|NEC-control|Nutritional Educational Control Condition (NEC).
62849836|NCT06196671|EXPERIMENTAL|Oncolytic virus plus PD-1 inhibitor|"* H101 intratumorally injection starts at day 1.~* Camrelizumab will be administered at 200 mg i.v. every 3 weeks at day 2.~* After two cycles of treatment, Camrelizumab will be administered alone at 200 mg i.v. every 3 weeks from cycle 3 until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.~* The following treatment will be applied according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline."
62849837|NCT00870428||Preeclampsia Evaluation|Patients who are admitted for the evaluation of preeclampsia
62061731|NCT03044522|OTHER|Nurse Education|Subject enrolled into the Nurse Pain Educator arm will be educated (Opioid Education) on different opioid pain management topics with a focus on safe and appropriate use and consumption of opioid analgesics.
62061732|NCT06386263||HER2-positive|This cohort includes patients with HER2+ mBC who started treatment with T-DXd in the PSP.
62061733|NCT06386263||HER2-low|This cohort includes patients with HER2-low mBC who started treatment with T-DXd in the PSP.
62061734|NCT03117725|EXPERIMENTAL|melatonin administration group|"Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. After randomization, participants are to under go melatonin administration intervention from the time of controlled ovarian hyperstimulation(COH) to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.~For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval."
62061735|NCT03117725|PLACEBO_COMPARATOR|placebo comparator|"Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. Participants for placebo comparator are advised to take the drug (placebo) from the time of COH to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.~For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval."
62061736|NCT06321458|EXPERIMENTAL|Intensive weight loss intervention|The intensive weight loss intervention (IWL) includes total dietary replacements, behavioural support, and weight loss medication. The intervention consists of three phases: induction, weight loss continuation, maintenance, and it will lasts two years in total.
62061737|NCT06321458|ACTIVE_COMPARATOR|Usual care|Denmark: usual care offered by the GP or local municipality. The UK: tier 3 weight management services.
62061738|NCT01295723|EXPERIMENTAL|Intraoperative Electron Radiation Therapy|A single dose of electron irradiation given at the surgical site during the operation to remove the cancerous tumor will replace the usual 5-8 days of localized radiation. Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days post operatively.
62061739|NCT00434889||1|Memory problems
62061740|NCT00434889||2|No memory problems
62061741|NCT03396484|EXPERIMENTAL|Methyldopa|"Adults: methyldopa 500mg twice daily for one week and then increased to 500mg three times a day~Children: methyldopa dose based on weight twice daily for one week then increased to three times a day"
62061742|NCT03396484|PLACEBO_COMPARATOR|Placebo|Inactive agent to match active drug in appearance and dose frequency.
62061743|NCT02034253||first episode psychosis|Unmedicated first episode psychosis patients that wish to enroll in a 16 week treatment regimen with the drug Risperidone.
62624021|NCT01832883||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
62061744|NCT02034253||healthy demographic-matched controls|healthy controls will be matched to patients one to one based on: age, smoking status, parental socio-economic status, and gender. Healthy controls must be free from current or past Axis I mental disorders, 1st degree relative current or past Axis I mental disorders, and any other neurological conditions.
62624022|NCT02081001|EXPERIMENTAL|G-Pump™ (glucagon infusion)|G-Pump™ (glucagon infusion); single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
62624023|NCT02081001|ACTIVE_COMPARATOR|Novo Nordisk GlucaGen®|Novo Nordisk GlucaGen®; single subcutaneous infusion doses 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
62849838|NCT02619383|EXPERIMENTAL|HBOT|All patients were treated with 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
62849839|NCT02929407|EXPERIMENTAL|FE 204205|
62849840|NCT02929407|PLACEBO_COMPARATOR|Placebo|
62849841|NCT01229696|ACTIVE_COMPARATOR|At Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.
62849842|NCT01229696|ACTIVE_COMPARATOR|5cm Above Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
62849843|NCT06519695|EXPERIMENTAL|Multicomponent exercises group|Multicomponent exercise intervention under the guidance of the wellness motivation theory
62849844|NCT06519695|NO_INTERVENTION|Control group|Health education about exercise only once.
62849845|NCT04749511|OTHER|DIG-PROMs-h|Patients who underwent THA are given conventional and digital surveys of the WOMAC index. Patients adhesion to both surveys will be compared.
62061745|NCT00817375|EXPERIMENTAL|SSRI treated group|SSRI treated group is depressive patients treated with fluoxetine, paroxetine, or sertraline
62061746|NCT00817375|ACTIVE_COMPARATOR|non-SSRI treated group|non-SSRI treated group is depressive patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine
62061747|NCT05157074|EXPERIMENTAL|Parkinson's Disease (PD) Group|Participants with PD and their caregivers receive group drum classes twice a week for 12 weeks (24 lessons).
62061748|NCT05157074|EXPERIMENTAL|Huntington's Disease (HD) Group|Participants with HD and their caregivers receive group drum classes twice a week for 12 weeks (24 lessons).
62061749|NCT01614639|EXPERIMENTAL|Traditional Acupuncture|Traditional Acupuncture given at 2 visits.
62061750|NCT01614639|EXPERIMENTAL|Electroacupuncture|Electro-acupuncture given at 2 visits.
62061751|NCT03736343|ACTIVE_COMPARATOR|Young Adult Heavy Drinkers Group 1|Young adult heavy drinkers, aged 21-30, will be administered varying doses of oral alcohol.
62061752|NCT03736343|ACTIVE_COMPARATOR|Young Adult Heavy Drinkers Group 2|Young adult heavy drinkers, aged 21-30, will be administered varying doses of oral alcohol.
62286836|NCT02104414|PLACEBO_COMPARATOR|Normal Saline|30mL Normal Saline
62849846|NCT02269085|EXPERIMENTAL|Ibrutinib + Carfilzomib|"Phase I: Ibrutinib administered by mouth daily at 420 or 560 mg on Days 1 - 28 of a 28-day cycle. Carfilzomib administered by vein 20/27 mg/m\^2, 20/36 mg/m\^2, 20/45 mg/m\^2 or 20/56 mg/m\^2 on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle for Cycles 1- 12 and on Days 1, 2, 15 and 16 for Cycle 13 and higher.~Phase II: Once the MTD has been established 5 additional patients treated at the MTD to a maximum of 35 patients with MCL.~Study staff calls participant after end-of-dosing visit every 6 months for 5 years."
62849847|NCT00337675|ACTIVE_COMPARATOR|Arm 1: drug + episodic supplemental placebo|Montelukast once a day (qd) + episode driven supplemental placebo qd for 12 days for a 52-wk treatment period
62849848|NCT00337675|ACTIVE_COMPARATOR|Arm 2: placebo comparator + episodic supplemental drug|Placebo qd + episode driven supplemental Montelukast qd for 12 days for a 52-wk treatment period
62449535|NCT01447264|NO_INTERVENTION|Control group|No intervention will be recommended
62449536|NCT01083875|EXPERIMENTAL|0.5% amlexanox oral rinse|Patients treated with an oral rinse containing the active 0.5% amlexanox
62266078|NCT05461911||The Control Group|30 patients aged 30-75 years to receive a standard (available in the clinic) tube feeding product (energetically similar to the product in group 1) with a standard content of arginine, vitamins and minerals from calculating the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g protein / kg body weight / day according to the recommendations for nutritional support for patients with pressure ulcers during the entire observation period
62266079|NCT02872766|EXPERIMENTAL|Corneal cross linking (CXL)|Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to Ultraviolet A light with the KXL II system according to the programmed treatment pattern.
62266080|NCT00482430|OTHER|1|MK0557 10mg tablet qd, crossing over to MK0557 Pbo tablet qd.
62624024|NCT00320697|OTHER|Bupropion + Nicotine patch + Nicotine gum or lozenges|Open label phase All enrolled subjects received weekly CBT group sessions, bupropion 300 mg/daily (if medically eligible), nicotine patch 21 mg/day, and up to 20 mg/day of nicotine gum or lozenge for prn use. Subjects set a quit date between weeks 3 and 4; a ½ hour individual CBT session to help prepare them for the quit date. The open phase groups consisted of 8 weekly CBT meetings.
62624025|NCT00320697|ACTIVE_COMPARATOR|Bupropion + Nicotine Patch|Randomized phase: Subjects who achieved 2 weeks continuous abstinence at the end of the open intervention and who are medically eligible for bupropion were eligible for the double blind, relapse prevention trial.Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
62624026|NCT00320697|PLACEBO_COMPARATOR|Placebo pill + placebo patch|Randomized phase: Subjects who achieved 2 weeks continuous abstinence at the end of the open intervention and who are medically eligible for bupropion were eligible for the double blind, relapse prevention trial. Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
62624027|NCT03632070||Stroke|Patients with ischemic or hemorrhagic stroke who were admitted to Samsung Medical Center and transferred to the Department of Physical and Rehabilitation Medicine
62624028|NCT03646942|ACTIVE_COMPARATOR|Lingual orthodontics|Patients will be treated with lingual braces without being irradiation with low level laser therapy. Treatment will go forward in the normal manner. Archwires will be changed in the traditional way.
62624029|NCT03646942|EXPERIMENTAL|Low level laser therapy|Patients will be subjected to low level laser therapy during their orthodontic treatment using lingual braces.
62624030|NCT06613035|EXPERIMENTAL|SMBF group will receive the following Sel2Mel2BU2FLU3 conditioning regimen|"* Selinexor: 60 mg/day from days -9 to -5.~* Melphalan: 60 mg/m² on days -8 and -7.~* Intravenous Busulfan (Bu): 3.2 mg/kg on days -6 and -5.~* Fludarabine (Flu): 30 mg/m² on days -4, -3, and -2."
62624031|NCT06613035|EXPERIMENTAL|Patients in the BF group will receive the BU3FLU5 conditioning regimen|"* Intravenous Busulfan (Bu): 3.2 mg/kg on days -9, -8, and -7.~* Fludarabine (Flu): 30 mg/m² on days -6, -5, -4, -3, and -2."
62849849|NCT00337675|PLACEBO_COMPARATOR|Arm 3: placebo comparator + episodic supplemental placebo|Placebo qd + episode driven supplemental placebo qd for 12 days for a 52-wk treatment period
62849850|NCT06392399|ACTIVE_COMPARATOR|Conventional radiofrequency|In this group we will use conventional radiofrequency thermocoagulation in the management of perineal cancer pain
62849851|NCT06392399|ACTIVE_COMPARATOR|Cooled radiofrequency|In this group we will use cooled radiofrequency in the management of perineal cancer pain
62849852|NCT06392399|ACTIVE_COMPARATOR|Neurolytic block of Ganglion|In this group we will use neurolysis of ganglion impar in the management of perineal cancer pain
62849853|NCT00550641|ACTIVE_COMPARATOR|1|
62849854|NCT00550641|EXPERIMENTAL|2|
62449537|NCT01083875|PLACEBO_COMPARATOR|Vehicle|Patients treated with an oral rinse containing no active
62449538|NCT00646945|EXPERIMENTAL|A|50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)
62849855|NCT01977872|EXPERIMENTAL|A worksite activity-diet intervention|A 12 month intensive program that includes individual sessions, interactive group sessions and online activities.
62266081|NCT00482430|OTHER|2|MK0557 Pbo tablet qd, crossing over to MK0557 10mg tablet qd.
62266082|NCT02613390|EXPERIMENTAL|MRI-Based Image Guidance|"MRI images of the spine taken of anesthetized participant in the operative prone position. These images are exported into a computer navigation program, and used to help the doctor perform surgery.~Pain and symptom questionnaires completed at baseline and at follow up."
62266083|NCT01358409|EXPERIMENTAL|Nebivolol|Nebivolol (Bystolic® by Forest/Mylan) is a third-generation beta-blocker; it selectively blocks β1-adrenergic receptors and increases peripheral vasodilation.
62286837|NCT01285427||DNA loci (SeCore vs. SSP UniTray platforms)|
62449539|NCT00646945|PLACEBO_COMPARATOR|B|50% oxygen/50% Nitrogen premix
62449540|NCT02992405|EXPERIMENTAL|FOCUS Resilience Enhancement Program|Those assigned to the immediate treatment group will participate in the 10-week treatment.
62449541|NCT02992405|EXPERIMENTAL|Waitlist Treatment|After the 10-week immediate treatment period, wait-list control participants will be administered the treatment.
62449542|NCT01440530|EXPERIMENTAL|Educational Intervention|
62449543|NCT01440530|ACTIVE_COMPARATOR|Control Group (usual care)|
62266084|NCT00473707|ACTIVE_COMPARATOR|1|Active management of the third stage of labor- oxytocin infusion after delivery of fetus, gentle cord traction, and fundal massage
62061753|NCT01694602||Newly Diagnosed NSCLC patients|In this study, newly diagnosed NSCLC patients who are not candidates for curative resection, will receive a (non-radioactive) oral dose of deuterated 3-methylhistidine (D-3MH).
62061754|NCT06116201|EXPERIMENTAL|Transgender women with orchiectomy|Transgender women who took medication for sex transition form male to female via estradiol hormone therapy and orchiectomy surgery. They were recruited for measurement of all variables in the study to compare with another group.
62266085|NCT00473707|OTHER|2|Expectant management of the third stage of labor
62061755|NCT06116201|EXPERIMENTAL|Transgender women without orchiectomy|Transgender women who took medication for sex transition form male to female via estradiol hormone and anti-androgen hormone therapy. They were recruited for measurement of all variables in the study to compare with another group.
62061756|NCT06116201|SHAM_COMPARATOR|Cisgender men|Cisgender men who lived in normal life were not used medication process for sex transition. They were recruited for measurement of all variables in the study to compare with another group.
62061757|NCT06116201|SHAM_COMPARATOR|Cisgender women|Cisgender women who lived in normal life were not used medication process for sex transition. They were recruited for measurement of all variables in the study to compare with another group.
62061758|NCT05425251||BRAINI2-ELDERLY DIAGNOSTIC & PROGNOSTIC|2370 patients suffering mild Traumatic brain injury
62061759|NCT05425251||BRAINI2-ELDERLY REFERENCE|480 non-tbi elderly reference patients
62266086|NCT05782621|EXPERIMENTAL|Acupoint focused ultrasound|the patients will receive Acupoint focused ultrasound therapy three times a week for four weeks
62266087|NCT05782621|EXPERIMENTAL|Laserpuncture|the patients will receive Laserpuncture therapy three times a week for four weeks
62266088|NCT05782621|ACTIVE_COMPARATOR|conventional treatment|the patients will receive conventional treatment three times a week for four weeks
62461272|NCT03228693|ACTIVE_COMPARATOR|Group 4|Baseline lesional biopsy and re-biopsy at 3-4 months with intralesional triamcinolone injections at 3-4, 6-8, 18-20 and 24-32 weeks.
62461273|NCT03228693|ACTIVE_COMPARATOR|Group 5|Normal patient skin (surgical or adjacent to other biopsy) from subjects with no self-reported history of keloids.
62061760|NCT03482856|EXPERIMENTAL|Modern Neuroscience Approach (MNA) plus CBT-I|MNA (i.e. modern pain neuroscience approach) combined with CBT-I (i.e. cognitive-behavioural therapy for insomnia)
62061761|NCT03482856|ACTIVE_COMPARATOR|MNA alone|The MNA (i.e. modern pain neuroscience approach) alone
62061762|NCT02060591|ACTIVE_COMPARATOR|Exparel|
62061763|NCT02060591|ACTIVE_COMPARATOR|Marcaine|
62061764|NCT01615354|PLACEBO_COMPARATOR|Placebo|
62061765|NCT01615354|EXPERIMENTAL|Treatment|
62061766|NCT02585596|EXPERIMENTAL|YH23537 1000mg/day|YH23537 500mg 1 tab, placebo 500mg 2tab twice a day (before morning,evening meal) during 12 weeks
62061767|NCT02585596|EXPERIMENTAL|YH23537 2000mg/day|YH23537 500mg 2tab, placebo 500mg 1tab twice day (before morning,evening meal) during 12 weeks
62061768|NCT02585596|EXPERIMENTAL|YH23537 3000mg/day|YH23537 500mg 3tab a day twice day (before morning,evening meal) during 12 weeks
62061769|NCT02585596|EXPERIMENTAL|YH23537 3000mg/day loading 1000mg/day|YH23537 500mg 3tab twice a day (before morning,evening meal) during 4weeks and YH23537 500mg tab twice a day (before morning,evening meal) during 8weeks
62061770|NCT02585596|PLACEBO_COMPARATOR|Placebo|YH23537 500mg placebo 3tab twice a day
62266089|NCT03045562|PLACEBO_COMPARATOR|Control group|Patients will be assigned to receive 100ml of normal saline
62266090|NCT03045562|EXPERIMENTAL|Experimental group|Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline
62266091|NCT03775421|EXPERIMENTAL|Open-label treatment period|oral administration of 10 mg macitentan once daily
62266092|NCT02390011||MRI|Day 1
62286838|NCT06151652|PLACEBO_COMPARATOR|Group 1 (Control group, N = 175 patients)|which will include patients adopted to the hospital standard of care.
62286839|NCT06151652|ACTIVE_COMPARATOR|Group 2 (Test group, N = 175 patients)|which will include patients who will receive Alpha-lipoic acid (Thiotacid 600 mg ®) at a dose of 600 mg three times daily for one day prior to surgery, followed by Alpha-lipoic acid 600 mg twice daily for 5 days post-surgery plus the standard care.
62624032|NCT02406963|ACTIVE_COMPARATOR|TTC|Current standard of care- a telephone call with the NP in the event of a post-operative concern where advice/interventions/reassurance is provided based on information provided by family
62624033|NCT02406963|EXPERIMENTAL|PEC|Experimental arm, the standard telephone call with the NP and the addition of a digital photograph of the surgical site for assessment prior to the administration of advice
62849856|NCT01977872|NO_INTERVENTION|Motiva Program|The Motiva Program is the internal corporate wellness program offered to all BCBSIL employees.
62849857|NCT05189353|EXPERIMENTAL|Gastric sleeve operated|12 subjects with normal glucose tolerance (NGT) operated with SG minimum 12 month earlier
62849858|NCT05189353|PLACEBO_COMPARATOR|Matched control group|12 weight-matched unoperated subjects with NGT
62849859|NCT04202419|EXPERIMENTAL|Single Group|Single Arm: All subjects will undergo treatment of pigmented lesions with a 1940 nm diode laser
62061771|NCT06287996|EXPERIMENTAL|Warm water foot-bath and actigraphy|Warm water foot-bath and actigraphy
62061772|NCT06287996|ACTIVE_COMPARATOR|actigraphy|actigraphy
62061773|NCT02555462|EXPERIMENTAL|Real-Ear Measurement|The study arm goes through a comparative test run followed by a comparative hearing aid fitting.
62061774|NCT02635165|ACTIVE_COMPARATOR|Surgical treatment with Stracos|The patient was placed in the lateral decubitus position. The procedure involved a curvilinear thoracic incision overlying the center of the fractured segments. The intercostal muscles were dissected off the rib on its superior aspect away from the fracture site, and the fracture was then reduced. The investigators then chose the most suitable Stracos, which is to be found in two available sizes, 6 or 9 claws, according to the length of the fracture. The clip chosen was molded according to the shape of the corresponding rib and the claws were crimped using special pliers on and around the fractured rib.The investigators treated only one rib out of two with Stracos, and as for displaced or comminuted fractures, the adjacent rib was wrapped using vicryl suture on the osteosynthesis rib.
62061775|NCT02635165|NO_INTERVENTION|Medical treatment|
62061776|NCT02293746|OTHER|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System.
62061777|NCT04630990||Participants Treated With Elagolix|Participants will receive Elagolix according to the local label.
62061778|NCT00600379|EXPERIMENTAL|A,|Virtual Reality training for an overall of 18 sessions 2/week + usual care.
62061779|NCT00600379|NO_INTERVENTION|B,|Usual care
62061780|NCT03713021|EXPERIMENTAL|TraceIT Tissue Marker|"* Following successful tumor resection, TraceIT Tissue Marker will be applied in 0.2 to 0.5 mL injections at 5 locations to mark the tumor bed: superiorly, inferiorly, laterally, medially, and center of resection. The marginal injections will be within 3 mm of the resection edge and within 5 mm deep. The center of the resection bed will be injected within 5 mm deep if possible.~* Within 6 weeks after surgery, a CT simulation scan will be performed per normal protocol for patients receiving surgery followed by adjuvant therapy. This scan will be used to generate the intensity-modulated radiation therapy (IMRT) treatment plan~* Two treatment plans will be performed per patient using the simulation CT scan. One will be the standard of care treatment plan and will be the basis of the actual radiation treatment they receive. The second treatment plan will be based on utilizing the TraceIT hydrogel markers as a guide for the resection bed."
62061781|NCT05023135||Subjects with Thermal Burn Injury|An initial imaging with the DV-SSP would be completed at the Study Site within 72 hours of suffering a thermal burn injury.
62061782|NCT00487734|EXPERIMENTAL|1|Subjects in this arm will receive testosterone gel
62061783|NCT00487734|PLACEBO_COMPARATOR|2|
62061784|NCT05582096|EXPERIMENTAL|LY3457263 + Tirzepatide|LY3457263 administered subcutaneously (SC) in combination with tirzepatide given SC.
62061785|NCT05582096|PLACEBO_COMPARATOR|Placebo + Tirzepatide|Placebo administered SC in combination with tirzepatide given SC.
62061786|NCT04079530|EXPERIMENTAL|Treatment A|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.4 mg/day (pre-meal)
62061787|NCT04079530|EXPERIMENTAL|Treatment B|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.4 mg/day (postprandial)
62849860|NCT05086614|EXPERIMENTAL|Thymosin|Patients with pathological high-risk stage II and stage III colorectal cancer after radical resection.
62061788|NCT04079530|EXPERIMENTAL|Treatment C|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.8 mg/day (pre-meal)
62061789|NCT04079530|EXPERIMENTAL|Treatment D|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.8 mg/day (postprandial)
62624034|NCT04877418|EXPERIMENTAL|TeleCIMT group|"One month after baseline evaluations, patients will receive a 3-week program through TeleCIMT.~* Task Oriented Repetitive Training~* Use of the Affected Upper Extremity~* Transfer Package"
62624035|NCT05350813|EXPERIMENTAL|PCT-guided arm|Group of patients whose duration of antibiotic therapy will depend on procalcitonin (PCT) plasma levels on days 0 and 1, then on PCT plasma level every 48 hours and on patient clinical evolution evaluated by the fever, the infected organ, and the pSOFA (Pediatric Sequential Organ Failure Assessment) score every day until cessation of antibiotics in hospital or until discharge from hospital if the patient is discharged with an antibiotic treatment.
62849861|NCT05086614|NO_INTERVENTION|Observe|Patients with pathological high-risk stage II and stage III colorectal cancer after radical resection.
62849862|NCT03583619|EXPERIMENTAL|APBI|Patients receive accelerated partial breast irradiation to tumour bed to a total dose of 40Gy, 4.0Gy per fraction, 5 fractions a week, within 2 weeks.
62849863|NCT03583619|ACTIVE_COMPARATOR|WBI|Patients receive whole breast irradiation to a total dose of 43.5Gy, at 2.9Gy per fraction, 5 fractions a week, within 3 weeks.
62849864|NCT02177071|NO_INTERVENTION|INFLIXIMAB AND ANTI METABOLITE|continuing scheduled infliximab treatment and anti-metabolite
62061790|NCT04079530|EXPERIMENTAL|Treatment E|Period1:K-877 CR 0.4 mg/day, Period2:K-877 IR 0.2 mg/day (pre-meal)
62061791|NCT04079530|EXPERIMENTAL|Treatment F|Period1:K-877 CR 0.4 mg/day, Period2:K-877 IR 0.2 mg/day (postprandial)
62286840|NCT01629797|OTHER|Acne Vulgaris|Patients with Acne vulgaris will receive educational teaching on Acne
62449544|NCT02623829|EXPERIMENTAL|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered. The forehead will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml(2.5 units) and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml(5 units) each in addition to the lateral aspect of each corrugator with 0.05ml(2.5 units). The injections will be administered with a 30G needle perpendicular to the skin.
62849865|NCT02177071|OTHER|STOP INFLIXIMAB CONTINUING ANTI METABOLITE|discontinuing infliximab and continuing the anti-metabolite
62849866|NCT02177071|OTHER|CONTINUING INFLIXIMAB AND discontinuing anti-metabolites|CONTINUING INFLIXIMAB AND DISCONTINUING ANTI METABOLITE
62849867|NCT00280384|ACTIVE_COMPARATOR|E2014 (Botulinum toxin type B)|
62849868|NCT00280384|PLACEBO_COMPARATOR|E2014 (Botulinum toxin type B) Placebo|
62849869|NCT04331743|EXPERIMENTAL|PLM60|"Three dose levels will be tested according to the 3 + 3 dose-escalation design.The dose-limiting toxicity (DLT) will be assessed from the first administration of PLM60 to the end of the first cycle (28 days)."
62849870|NCT03345290|EXPERIMENTAL|Subjects|Subjects referred to a FDG PET scan (standard PET without cerebral step) without any oncologic setting. Patients will be included as following critera: 25% of subjects will have under 40 years old, 25% between 40 and 60 yeard old et 50% higher than 60 years old.
62849871|NCT05787548|NO_INTERVENTION|Standard practice|Patients in this arm will receive the current standard practice AVS.
62061792|NCT04079530|EXPERIMENTAL|Treatment G|Period1:K-877 CR 0.4 mg/day, Period2:K-877 CR 0.8 mg/day (pre-meal)
62061793|NCT04079530|EXPERIMENTAL|Treatment H|Period1:K-877 CR 0.4 mg/day, Period2:K-877 CR 0.8 mg/day (postprandial)
62266093|NCT00665457|EXPERIMENTAL|Celecoxib|"•Neoadjuvant chemotherapy: Patients receive docetaxel IV over 1 hour on days 1, 8, and 15, oral capecitabine twice daily on days 1-14, and oral celecoxib twice daily on days 1-21. Courses repeat every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV once daily on day 1, oral celecoxib twice daily on days 1-14, and filgrastim subcutaneously once daily on days 3-10. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Celecoxib is stopped one week prior to surgery.~•Surgery: Patients undergo definitive surgery (either modified radical mastectomy or lumpectomy combined with axillary node dissection). Patients may also undergo adjuvant radiotherapy and hormonal therapy at the discretion of multidisciplinary breast team."
62266094|NCT04220957|EXPERIMENTAL|Digital Impression Technique|Impression with an intraoral scanner (TRIOS 3, 3Shape, Denmark)
62266095|NCT04220957|ACTIVE_COMPARATOR|Conventional Impression Technique|Conventional impression with alginate (Orthoprint, Zhermack)
62266096|NCT04036968|PLACEBO_COMPARATOR|Placebo+Placebo|Within-subject double-blind, double-dummy administration of placebo + placebo. Order of dose randomized session days 2-5.
62449545|NCT02623829|SHAM_COMPARATOR|Saline|1ml of normal saline will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml each in addition to the lateral aspect of each corrugator with 0.05ml. The injections will be administered with a 30G needle perpendicular to the skin.
62624036|NCT05350813|ACTIVE_COMPARATOR|standard-of-care arm|A group of patients whose duration of antibiotic therapy will be determined by the type of infection, microbiological findings and clinical, biological and/or radiological course, according to standard practice based on guidelines.
62449546|NCT02470195|EXPERIMENTAL|workshop|workshop of procedural simulation
62624037|NCT04441632|OTHER|Positive feedback|Participants in the study will provide consistent positive feedback to the colleagues they work with in the medical ICU (MICU) over a 4 week duration.
62849872|NCT05787548|EXPERIMENTAL|Contact us first|Patients in this arm will receive the standard AVS, plus information on how to contact Geisinger if they need medical attention.
62061794|NCT04079530|EXPERIMENTAL|Treatment I|Period1:K-877 CR 0.8 mg/day, Period2:K-877 IR 0.2 mg/day (pre-meal)
62061795|NCT04079530|EXPERIMENTAL|Treatment J|Period1:K-877 CR 0.8 mg/day, Period2:K-877 IR 0.2 mg/day (postprandial)
62849873|NCT05787548|EXPERIMENTAL|Contact us first + urgent care map|Patients in this arm will receive the standard AVS, plus information on how to contact Geisinger if they need medical attention, plus a map to their nearest Geisinger urgent care location and additional information about urgent care.
62849874|NCT05787548|EXPERIMENTAL|Contact us first + urgent care map + self-triage|Patients in this arm will receive the standard AVS, plus information on how to contact Geisinger if they need medical attention, plus a map to their nearest Geisinger urgent care location and additional information about urgent care. This arm will also receive a self-triage chart, with common reasons patients go to the ED and situations where seeking alternative care might be appropriate.
62849875|NCT01363349|EXPERIMENTAL|CYP-1020|Dose titration 15-35mg/day for 6 months
62061796|NCT04079530|EXPERIMENTAL|Treatment K|Period1:K-877 CR 0.8 mg/day, Period2:K-877 CR 0.4 mg/day (pre-meal)
62061797|NCT04079530|EXPERIMENTAL|Treatment L|Period1:K-877 CR 0.8 mg/day, Period2:K-877 CR 0.4 mg/day (postprandial)
62061798|NCT04222062|NO_INTERVENTION|Standard of Care Arm|The tumor will be removed surgically. Within 6 weeks after surgery, the resection will be treated with stereotactic radiosurgery (SRS).
62061799|NCT04222062|EXPERIMENTAL|GLIADEL Arm|Once the tumor has been removed, GLIADEL wafers will be applied to the resection cavity. The number of wafers used will be determined by the size of the cavity. Enough wafers should be used so that as much of the cavity is covered as possible.
62449547|NCT02470195|NO_INTERVENTION|control|no specific workshop of procedural simulation
62849876|NCT01363349|ACTIVE_COMPARATOR|Risperidone|Dose titration 2-6mg/day for 6 months
62849877|NCT00246740|PLACEBO_COMPARATOR|Placebo oral tablet|Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
62061800|NCT01201603|EXPERIMENTAL|Orange Juice|Orange Juice reconstituted from frozen concerntrate
62061801|NCT01201603|PLACEBO_COMPARATOR|Orange drink|Sugars matched orange drink
62061802|NCT01031901|PLACEBO_COMPARATOR|TSC Placebo Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating alone to facial angiofibromas
62061803|NCT01031901|EXPERIMENTAL|TSC 1% Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to facial angiofibromas
62061804|NCT01031901|EXPERIMENTAL|TSC 5% Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to facial angiofibromas
62849878|NCT00246740|EXPERIMENTAL|Periostat|Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
62061805|NCT01031901|PLACEBO_COMPARATOR|NF1 Placebo Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating alone to cutaneous neurofibromas
62624038|NCT05960175|NO_INTERVENTION|Standard CPAP telemonitoring|Patients are treated with CPAP and the home healthcare provider carries out monitoring in line with current practice (telemonitoring of treatment and regular home visits).
62624039|NCT05960175|EXPERIMENTAL|New CPAP telemonitoring approach|Patients are treated with CPAP and the home healthcare provider is offering a new approach to remote monitoring in which patients are involved in managing their CPAP treatment using two connected devices (the Scanwatch connected watch + the mobile application Asten\&masanté) in the first 4 months of treatment.
62624040|NCT03961516||Cystic Fibrosis, Pancreatic Sufficient|CF patients with exocrine pancreatic sufficiency
62624041|NCT03961516||Cystic Fibrosis, Pancreatic Insufficient, No Insulin|CF patients with exocrine pancreatic insufficiency but not treated with insulin therapy
62624042|NCT03961516||Cystic Fibrosis, Pancreatic Insufficient, Treated with Insulin|CF patients with exocrine pancreatic insufficiency who are treated with insulin therapy for CFRD
62624043|NCT05048615|EXPERIMENTAL|Low-dose Ventoclax and oral itraconazol plus subcutaneous Azacitdine|Patients will recieve Low-dose Venetoclax at a dose of 100mg/day por 21 days, oral itraconazol 100mg every 12 hours, and subcutaneous Azacitidine 75mg/m2 (maximun dose 100mg) daily for seven days. Each cycle duration is 21 days and patients will recieve a maximun of two cycles.
62624044|NCT03782129||Diabetic patients with DFU|Diabetic patients with DFU diagnosed in 2010
62061806|NCT01031901|EXPERIMENTAL|NF1 1% Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to cutaneous neurofibromas
62624045|NCT06423794|EXPERIMENTAL|BHV-7000|
62849879|NCT00131053|EXPERIMENTAL|A|
62061807|NCT01031901|EXPERIMENTAL|NF1 5% Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to cutaneous neurofibromas
62061808|NCT01021774|ACTIVE_COMPARATOR|Advancement flap surgery|
62266097|NCT04036968|ACTIVE_COMPARATOR|Hydromorphone+Placebo|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + placebo. Always administered during session 1.
62266098|NCT04036968|EXPERIMENTAL|Hydromorphone (oral) 4mg + Cannabidiol 50mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + cannabidiol (oral) 50mg. Order of dose randomized session days 2-5.
62461274|NCT03228693|OTHER|Earlobe Keloid|Complete excision of an earlobe keloid measuring \> 10mm will be taken.
62849880|NCT05200234|EXPERIMENTAL|Intervention group|Nattokinase + standard medical treatment
62849881|NCT05200234|PLACEBO_COMPARATOR|Control group|Placebo + Standard medical treatment
62061809|NCT01021774|ACTIVE_COMPARATOR|Collagen plug|
62061810|NCT02675790|ACTIVE_COMPARATOR|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
62461275|NCT05328141|EXPERIMENTAL|Bread and butter|A toast bread with butter meal without insect biomass with FeSO4 (isotopic iron 54)
62461276|NCT05328141|EXPERIMENTAL|X.gideon|Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58)
62461277|NCT05328141|EXPERIMENTAL|X.gideon with ascorbic acid|Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58) and ascorbic acid
62461278|NCT04922424|EXPERIMENTAL|atorvastatin|We are testing that the lipid sensitive statin, atorvastatin treatment will reduce low density lipoprotein cholesterone, sympathetic nerve activity, increase endothelium-dependent vasodilation and improve autonomic function in trans men, while having little impact on cis women.
62461279|NCT04922424|PLACEBO_COMPARATOR|Placebo|We are testing that the placebo will have little effect on low density lipoprotein cholesterone, sympathetic nerve activity, endothelium-dependent vasodilation, autonomic function in trans men or cis women.
62461280|NCT03004300|ACTIVE_COMPARATOR|group 1|Patients with atresic maxilla without upper airway obstruction submitted to rapid maxillary expansion
62461281|NCT03004300|EXPERIMENTAL|group 2|Patients with atresic maxilla and adenotonsillar hypertrophy submitted to rapid maxillary expansion before adenotonsillectomy
62461282|NCT03004300|EXPERIMENTAL|group 3|Patients with atresic maxilla and adenotonsillar hypertrophy submitted to rapid maxillary expansion after adenotonsillectomy
62461283|NCT05471817|EXPERIMENTAL|EZN - DBG|Participants will receive a single oral dose of dabigatran (DBG) etexilate in fasted state in Period 1; followed by a single oral dose of elinzanetant (EZN) and DBG etexilate (30 min after EZN) in fasted state in Period 2.
62461284|NCT01856309|EXPERIMENTAL|Sirukumab 100 mg|
62461285|NCT01856309|EXPERIMENTAL|Sirukumab 50 mg / placebo|
62461286|NCT05469009|EXPERIMENTAL|Infusion plus Exablate BBBO Treatment|Intravenous infusion of Aducanumab or Lecanemab every 2-4 weeks (per standard of care) followed by blood brain barrier opening by FUS.
62461287|NCT05520788||Precise medicine|All patients should accept next-generation sequencing (NGS) test before treatment.
62849882|NCT04303676|ACTIVE_COMPARATOR|Virtual Practice Facilitation with e-Learning|A virtual practice facilitation intervention, with a practice facilitator working with practices in virtual one-on-one or group sessions utilizing alcohol use e-learning modules to guide and focus the process and content
62849883|NCT04303676|ACTIVE_COMPARATOR|Virtual Practice Facilitation without e-Learning|A virtual practice facilitation intervention, with a practice facilitator working with practices in virtual one-on-one or group sessions without utilizing alcohol use e-learning modules
62849884|NCT02273596|EXPERIMENTAL|ALXN1840|"Treatment Period: ALXN1840 at individualized doses ranging from 15 to 60 milligram (mg) per day. Dose increases or dose reductions were dependent on the individual NCC concentrations adjusted for Mo plasma concentration. ALXN1840 may have been administered every other day, once daily, or twice daily, depending on individualized dosing regimen, for 24 weeks.~Extension Period: Participants continued the same ALXN1840 daily dose maintained at Week 24 of the Treatment Period and the same dosing regimen. During the Extension Period, no up-titration was made unless NCC concentrations adjusted for Mo plasma concentration did not remain stable within (or below) the reference range. ALXN1840 could have been received for up to 36 months in the Extension Period."
62849885|NCT02730013|EXPERIMENTAL|Square Stepping Exercise|Square-Stepping Exercise (SSE) Intervention Participants in this group will attend a square-stepping exercise intervention 60 minutes: 5 minute for attendance, 5-10 minute warm-up 40-45 minute SSE and 5-10 minute cool-down, on two days a week for a duration of 12 weeks.
62849886|NCT02730013|NO_INTERVENTION|Usual-care wait-list control|This group will receive standard care and be invited to partake in the intervention after all assessments have been completed.
62849887|NCT01501877|EXPERIMENTAL|Distress Tolerance|Acceptance and Commitment Therapy based Distress Tolerance (DT) smoking cessation intervention delivered in 7 2-hour group, 1 50-minute individual, and 2 10-minute phone sessions and 8 weeks of transdermal nicotine patch.
62849888|NCT01501877|ACTIVE_COMPARATOR|Standard Smoking Cessation|Standard smoking cessation intervention delivered in 7 2-hour group, 1 50-minute individual, and 2 10-minute phone sessions and 8 weeks of transdermal nicotine patch.
62849889|NCT04075253|EXPERIMENTAL|VO2 peak test|All participants enrolled in the planned study on physical activity and ventricular arrhythmias and on baseline will complete an exercise treadmill test to determine VO2 peak
62061811|NCT02675790|ACTIVE_COMPARATOR|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
62061812|NCT05116449||Patient seeking supportive care|
62061813|NCT05116449||Patient without any supportive care|
62061814|NCT05634967||Disease-matched cohort (Comparison Group 1)|comparison group consisting of women diagnosed with MS who have not used Kesimpta during pregnancy (unexposed disease-matched comparison group).
62061815|NCT05634967||Healthy cohort (only applicable in the Kesimpta-OTIS sub-study) (Comparison Group 2)|healthy women who are not diagnosed with MS or any other autoimmune disease, have not had exposure to a known human teratogen, and have not taken Kesimpta in pregnancy (healthy comparison group). Since the DMSKW register is an MS population specific register that does not collect data on non-MS population, this cohort is only applicable in the Kesimpta-OTIS sub-study.
62061816|NCT05634967||Kesimpta-exposed cohort|women and infants who are exposed to Kesimpta during pregnancy to treat MS.
62061817|NCT06456099|EXPERIMENTAL|Home Exercise Program With the Addition of a Corticosteroid Injection|"All participants in this study will receive the following interventions:~* Ultrasound-guided corticosteroid injection~* Home exercise program~* Patient information leaflet"
62624046|NCT05340296|EXPERIMENTAL|Acute Youth Connect + TAU|Subjects will receive 12 weeks of post-discharge Acute Youth Connect intervention, in addition to regular post-discharge treatment as usual.
62624047|NCT05485714||Patient with non-alcoholic fatty liver with advanced liver fibrosis|Patient with non-alcoholic fatty liver with advanced liver fibrosis with F3 or F4 stage on Fibroscan without any evidence of previous decompensation like ascites, jaundice or encephalopathy
62849890|NCT01067092|EXPERIMENTAL|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
62061818|NCT04795310|EXPERIMENTAL|Pulsed Dye Laser|PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD)
62061819|NCT04795310|ACTIVE_COMPARATOR|Intense Pulsed Light|Vascular wavelength bands of 530-650nm and 900-1200nm
62061820|NCT05649345|EXPERIMENTAL|TR64|Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 25mg, with escalation to 400mg, and subsequent dose escalation using a modified Fibonacci algorithm.
62061821|NCT03281824|EXPERIMENTAL|ALT-P7|"* 8 groups: 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.2 mg/kg, 4.5 mg/kg, 4.8 mg/kg,~* Administration: Day 1 of each 3-week cycle"
62087923|NCT02537353|PLACEBO_COMPARATOR|Group 1|Patients with a clinical diagnosis of upper gastrointestinal bleeding and that during endoscopy revealed to non-varicose bleeding lesions in the endoscopic treatment being necessary. The group will be submitted to injection of adrenaline at a proportion of 1: 10,000 in the four quadrants of the lesion associated with application of metal clips. The patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
62652842|NCT05453383|EXPERIMENTAL|Anlotinib and Toripalimab treatment|Anlotinib Hydrochloride and Toripalimab Injection
62652843|NCT04748978|EXPERIMENTAL|symptomatic uterine fibroids|patients aged between 18 and 48 years with clinical and/or ultrasound diagnosis of uterine fibromatosis
62849891|NCT01067092|ACTIVE_COMPARATOR|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
62061822|NCT02833441|EXPERIMENTAL|Peer Support Intervention|Adolescents/young adults in the Peer Support Intervention arm will be referred to a Peer Support Intervention support group within their own or nearby community. This support group will meet monthly and will be facilitated by a professional HIV counsellor together with a Peer Support Intervention counselor. The Peer Support Intervention counsellors will provide regular counselling to their allocated participants through home visits and SMS messages. Each participant will be visited once a week in their home. Whatsapp messages will be delivered daily to each participant by the Community Adolescent Treatment Supporters. The agreed messages will briefly enquire about the participant's well-being without specifically making reference to HIV or ARVs. In addition, participants' caregivers will be invited to a 3-session intervention to build knowledge, skills and confidence to better support their adolescents.
62624048|NCT05573256|EXPERIMENTAL|Group 1 (Sleep hygiene education together with lavender oil inhalation)|the participants assigned to Group 1 will be given sleep hygiene education and instructed how to apply lavender oil inhalation. The participants will be provided with charts on sleep hygiene education and lavender oil inhalation and shown how to regularly keep daily records using their charts. The participants in this group will be given a copy of the sleep hygiene education brochure and lavender oil in a 10 ml bottle.
62849892|NCT06405308||R-NOSES group|Participants in this group underwent robotic natural orifice specimen extraction surgery
62849893|NCT06405308||R-TSES group|Participants in this group underwent robotic transabdominal specimen extraction surgery
62849894|NCT06076967|EXPERIMENTAL|Adapted Mindful Awareness Practices (MAPS)|The Mindful Awareness Practices (MAPs) for ADHD program, an 8-week, group-based mindfulness program for adults with ADHD, has been shown to reduce ADHD, depression, and anxiety symptoms. While promising, it is unknown as to whether the MAPs protocol is feasible, acceptable, and efficacious for college students with ADHD. The current study takes the first step towards enhanced study of mindfulness for college students with ADHD by testing the feasibility, acceptability, and preliminary efficacy of an adapted MAPs protocol delivered within university counseling center settings during the first semester of college.
62849895|NCT06076967|ACTIVE_COMPARATOR|Services-As-Usual|Services-As-Usual includes the standard academic support services provided by university disability/accessibility offices.
62061823|NCT02833441|NO_INTERVENTION|Standard of Care Practice|"Participants in the standard of care group will receive adherence evaluations and counseling at the clinic as per the current standard of care. Current procedures involve a group counseling session given on Monday morning during which topics are discussed that are relevant to adolescents. In general children aged between 13-19 years attend these sessions. After the group counseling, adolescents also receive an individual counseling session before being evaluated by the clinic doctor. Youth are also encouraged to complete a self reported adherence questionnaire and may periodically undergo pill counts by the clinic counselors.~The adolescents may belong to peer support groups in their communities, however these activities are not part of the clinic program. No interventions are typically targeted at their caregivers."
62061824|NCT06564636||CATALYSTEM|Participants who have already received or are due to receive the CATALYSTEM Cementless Primary Hip System
62624049|NCT05573256|EXPERIMENTAL|Group 2 (Sleep hygiene education)|The participants assigned to Group 2 will only be given sleep hygiene education. They will be provided with a copy of the sleep hygiene education brochure and a chart on which to record their sleep hygiene practices.
62624050|NCT05573256|EXPERIMENTAL|Group 3 (Lavender oil inhalation)|The participants assigned to Group 3 will only be instructed on how to apply lavender oil inhalation and keep regular daily records on the chart given. The participants in this group will be given lavender oil in a 10 ml bottle.
62849896|NCT01039103|EXPERIMENTAL|Nanocort|PEG-liposomal prednisolone sodium phosphate (Nanocort) 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
62849897|NCT01039103|ACTIVE_COMPARATOR|Solu-Medrol|Methylprednisolone (Solu-Medrol) 1 g, IV, infusion over 2 hours on days 1, 2 and 3
62266099|NCT04036968|EXPERIMENTAL|Hydromorphone (oral) 4mg + Cannabidiol 100mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + cannabidiol (oral) 100mg. Order of dose randomized session days 2-5.
62266100|NCT04036968|EXPERIMENTAL|Hydromorphone (oral) 4mg + Cannabidiol 200mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + cannabidiol (oral) 200mg. Order of dose randomized session days 2-5.
62849898|NCT05591313|EXPERIMENTAL|Low-intensity with longer duration (40-min) exercise (LI-40)|The participants were instructed to complete a volume-matched low-intensity with longer duration (40-min) exercise (LI-40) treatment.
62849899|NCT05591313|EXPERIMENTAL|Moderate-intensity with 30 min exercise (MI-30)|The participants were instructed to complete a volume-matched moderate-intensity with 30 min exercise (MI-30) treatment.
62652844|NCT05692440|OTHER|Basivertebral Nerve Ablation|Intraosseous radiofrequency basivertebral nerve ablation
62652845|NCT04096131||SURGERY|subjects with early DME undergoing cataract surgery
62652846|NCT04096131||OBSERVATION|subjects with early DME
62449548|NCT02301247|EXPERIMENTAL|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
62449549|NCT02301247|PLACEBO_COMPARATOR|Placebo|The placebo group will receive placebo control memory exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
62624051|NCT05573256|NO_INTERVENTION|Group 4 (Routine care)|"Participants assigned to Group 4 will be given routine care and no application will be made.~Patient care and follow-up are routinely performed as follows: Following the patient's admission to the clinic, the first evaluation of the patient is made by the ostomy and wound care nurses within 24 hours, and patient education is initiated accompanied by the primary caregiver from the family. Throughout the period from admission to clinic to discharge, the ostomy care and education of the patient is repeated by the ostomy and wound care nurses every 72 hours. In addition, the patient and caregiver are given the contact information of the ostomy and wound care nurses and informed that they can call them at any time when they need it after discharge from the hospital."
62624052|NCT02942121|EXPERIMENTAL|LST App|Participants will use the LifeScience Technologies application (LST app) before surgery, and post surgery. Participants will use the app as an educational tool to learn more about their surgery. Participants will also answer questions about themselves in the app.
62624053|NCT03798548|EXPERIMENTAL|Brief Bedside CBT|
62624054|NCT03798548|NO_INTERVENTION|Treatment As Usual|
62652847|NCT03736018|ACTIVE_COMPARATOR|CTCA + ICA|Computed Tomography Cardiac Angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
62849900|NCT05591313|EXPERIMENTAL|High-intensity with shorter duration (16-min) exercise (HI-16)|The participants were instructed to complete a volume-matched high-intensity with shorter duration (16-min) exercise (HI-16) treatment.
62849901|NCT05591313|NO_INTERVENTION|Control treatment (CON)|The participants in the control treatment (CON) were instructed to complete book reading for 30-min.
62849902|NCT02873494||PHYSIOFLOW PF05 Lab1TM|Impedance cardiography
62849903|NCT02326480||Syndromic obesity|Identification of genetic causes of obesity
62849904|NCT02326480||Familial obesity|Identification of genetic causes of obesity
62849905|NCT02326480||Isolated obesity|Identification of genetic causes of obesity
62849906|NCT02023333|EXPERIMENTAL|Regorafenib|This is an open-label, phase II study of regorafenib for patients with metastatic colorectal carcinoma. The treatment will be repeated every week for three weeks on and one week off. Patients will be evaluated for response after every 2 cycles (8 weeks).
62849907|NCT02551042|EXPERIMENTAL|Active treatment arm|Fibrogammin®P, coagulation factor XIII concentrate (Human) IV infusion
62849908|NCT02551042|PLACEBO_COMPARATOR|Placebo arm|Placebo will be 0.9 % Sodium chloride solution IV infusion
62849909|NCT02928263||Patients treated with IV agents|Metastatic renal cell carcinoma patients treated with IV agents
62849910|NCT02928263||Patients treated with oral agents|Metastatic renal cell carcinoma patients treated with oral agents
62849911|NCT05953233|EXPERIMENTAL|Active HEPA cleaner|Active HEPA cleaners will be placed in classrooms throughout the school year
62849912|NCT05953233|PLACEBO_COMPARATOR|Sham HEPA cleaner|Sham HEPA cleaners will be placed in classrooms throughout the school year
62652848|NCT03736018|NO_INTERVENTION|ICA only|Invasive coronary angiogram (ICA) performed only.
62849913|NCT05086029||Psoriatic arthritis patients|
62849914|NCT05086029||healthy volunteers|
62849915|NCT04344964||Phone consult group|Information collected prospectively on FTA patients and questionnaire (satisfaction)
62849916|NCT04344964||Face-to-face consult group|Information collected retrospectively on FTA patients
62849917|NCT02499133|OTHER|adult who suffered traumatic brain injury|
62849918|NCT02499133|OTHER|control group|
62849919|NCT01755000|OTHER|Aim 1: Hemodynamically Healthy Patients|"Nurse 1 will perform an USCOM scan and record values of Vpk and SV on the clinical data sheet.~Nurse 2 will perform the USCOM second scan within five minutes of Nurse 1's scan and record the values of Vpk and SV on the clinical data sheet.~Nurse 1 and 2 will be blinded to each other's scans by using separate clinical data forms"
62849920|NCT01755000|OTHER|Aim 2: Hemodynamically Unstable Patients|"Nurse 1 will perform an USCOM scan and record values of Vpk and SV on the clinical data sheet.~Nurse 2 will also be notified of the hypotensive event, will then perform the USCOM second scan within five minutes of PI's scan and record the values of Vpk and SV on the clinical data sheet.~The two USCOM scans will be completed within 10 minutes of the hypotensive episode.~Nurse 1 and Nurse 2 will be blinded to each other's scans by using separate clinical data forms."
62849921|NCT01755000|OTHER|Aim 3: Hemodynamically Unstable Patients + Fluid Bolus|"At the time that an enrolled patient meets one of the following criteria; SBP drops below 95 mmHg or MAP drops below 65 mmHg the PI will be notified to PI to perform the USCOM scan and record the Vpk, SV, systolic blood pressure and mean arterial pressure on the clinical data sheet within 10 minutes of the hypotensive episode, prior to the patient receiving a fluid bolus (fluid bolus is part of standard of care).~The USCOM scan will then be repeated within 5 minutes after fluid bolus delivery.~Before the hemodynamically unstable patient receives subsequent fluid boluses (multiple boluses are common standard of care), the PI will perform an USCOM scan. Then within 5 minutes after the delivered fluid bolus, the PI will perform another USCOM scan. This will continue, until no further boluses are prescribed."
62849922|NCT06415500|EXPERIMENTAL|NK042|
62849923|NCT03432806||presumptive Stage II or III colon cancer|
62849924|NCT03432806||Stage IV colon cancer with resectable hepatic metastases|
62849925|NCT03432806||Stage IV colon cancer with unresectable hepatic metastases|
62849926|NCT03432806||Stage I colon cancer, pre-neoplastic or benign colon lesions|
62461288|NCT05885139|ACTIVE_COMPARATOR|Active Stimulation|Active sessions will last 1 hour of stimulation per day for 2 weeks. The following parameters will be used for electric stimulation: low frequency (20 Hz), low current intensity (2 mA), with a small pulse width of 25-170 microseconds.
62461289|NCT05885139|SHAM_COMPARATOR|Sham Stimulation|In the sham condition, subjects will be asked to wear the device for 1 hour per day for 2 weeks. During 1 hour use per day, the actual stimulation will last only 1 minute and then will shut off.
62624055|NCT06538259|EXPERIMENTAL|anodal group|In the anodal group, the anode was placed over the left DLPFC (F3), and the cathode was placed over the contralateral supraorbital area (FP2). A direct current of 2mA was applied for 20 minutes during each stimulation session. Stimulation was conducted twice a day, at 9 a.m. and 2 p.m., for 5 consecutive days, totaling 10 sessions.
62266101|NCT06155370||cohort of cervical cancer organoids|organoids derived from cervical cancer
62266102|NCT06155370||cohort of endometrial cancer organoids|organoids derived from endometrial cancer
62266103|NCT06155370||cohort of ovarian cancer organoids|organoids derived from ovarian cancer
62266104|NCT06155370||cohort of vulva cancer organoids|organoids derived from vulva cancer
62266105|NCT06155370||cohort of vaginal cancer organoids|organoids derived from vaginal cancer
62624056|NCT06538259|SHAM_COMPARATOR|sham group|In the sham group, the stimulation parameters, including the stimulation site and duration, were identical to those of the anodal group. However, during the 10-second ramp-up and ramp-down periods before and after stimulation, patients were unaware that the current was turned off.
62461290|NCT04418388|EXPERIMENTAL|A|
62461291|NCT04418388|EXPERIMENTAL|B|
62624057|NCT05599386||Patients Undergoing VATS|Only one group as primary endpoints are continous
62624058|NCT03594799|EXPERIMENTAL|Bed Rest Control Group|60 days of strict head-down tilt bed rest
62652849|NCT06550921|EXPERIMENTAL|Ablation-Len-PD-1 inhibitor|ablation of oligometastasis therapy combined with lenvatinib and PD-1 inhibitor
62266106|NCT06155370||cohort of gestational trophoblastic tumor organoids|organoids derived from gestational trophoblastic tumor
62266107|NCT03976011|EXPERIMENTAL|Transcutaneous Laryngeal Ultrasonography|All patients operated on endocrine surgery in the three referral centers and responding to the inclusion criteria will be included after obtaining their writing consent. The gold standard NF will be performed between D1 and D15, as usually performed after these surgeries. TLU will be performed during the same time period by an investigator blind to the NF results. The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments.
62266108|NCT04716790|EXPERIMENTAL|Ultrasounds once a week|Patients will undergo the application of ultrasound therapy with a frequency of once a week.
62266109|NCT04716790|EXPERIMENTAL|Ultrasounds once every two weeks|Patients will undergo the application of ultrasound therapy with a frequency of once every two weeks.
62266110|NCT04716790|ACTIVE_COMPARATOR|Standard of care|Patients will be treated using the conventional treatment established by the protocol of the Diabetic Foot Unit of the University Podiatry Clinic of Complutense University of Madrid.
62266111|NCT05517642|EXPERIMENTAL|Ad5-nCoV-IH|Participates age 18 or older who have completed a course of primary and first booster vaccination at least 16 weeks before, and who have sub-optimal antibody response to the first booster dose, will receive a second booster dose of IH Convidecia vaccine.
62461292|NCT04418388|EXPERIMENTAL|C|
62461293|NCT02404194|EXPERIMENTAL|Targeted Cognitive Training|40 hours of computerized cognitive training
62461294|NCT02404194|PLACEBO_COMPARATOR|Computer Games|40 hours of computer games
62849927|NCT04986956|PLACEBO_COMPARATOR|Placebo|The placebo will be a simple microcellulose, which is generally-recognized-as-safe (GRAS) and commonly used in food products.
62849928|NCT04986956|ACTIVE_COMPARATOR|Whole coffee cherry extract|Whole coffee cherry extract (WCCE; otherwise known as the generally-recognized-as-safe (GRAS) supplement Neurofactor(TM)), is a proprietary, safe, powdered extract of whole coffee cherries from coffea arabica with high levels of polyphenols and substantially low (\<2%; \<4mg) levels of caffeine. The only content of the supplement is WCCE - there are no excipients, binders, or flow agents, nor are there any other materials. The coffee cherry is subjected to a food-grade water ethanol extraction; thus, after extraction, only 100% coffee-based components remain. 200mg of WCCE will be administered daily for 28 days.
62849929|NCT00207285|OTHER|In Person Training|These firefighters received the sleep education and sleep disorders screening in person by one of our research staff.
62849930|NCT00207285|OTHER|Train the Trainer|These firefighters received the education and sleep disorder screening in person with someone taught by our research staff.
62061825|NCT02813746||Obese non smoker vs Normoweight non smoker|Endometrial fluid (EF) will be obtained from non-smokers normo-weight and obese patients in the receptive state. Samples will be collected 7 days after Luteinizing Hormone (LH) peak. They will be classified following the guidelines of the obesity classification system by the World Human Organization (WHO). Patients will be subjected to a fitness program during a year with the aim to achieve a weight reduction to normal values (19-24.9 kg/m2). The modifications in the miRNAs expression will be studied. After the weight loss, new EF will be collected from these patients.
62061826|NCT02813746||Normoweight smoker vs Normoweight non-smoker|EF will be obtained from non-smokers and smokers normo-weight in the receptive state. Samples will be collected 7 days after Luteinizing Hormone (LH) peak. Smokers patients will be urge to give up smoking during at least one year. After this time, new samples will be collected to determine if the non-exposition to this contaminant could exert any effect in the miRNAs signature. A regular control will be done in this group of patients to ensure that they have not been exposed to tobacco in 12 months. Professional support will be given in the same centre of the study to help the patient to accomplish its objective.
62624059|NCT03594799|EXPERIMENTAL|Cocktail intervention|60 days of strict head-down tilt bed rest along with a Cocktail supplementation composed of natural antioxidants XXS-2A-BR2 comprising vitamin E, Selenium and coupled with omega-3
62624060|NCT01698944|EXPERIMENTAL|Somatropin|
62061827|NCT05093387|EXPERIMENTAL|Interventional (SGT-53, pembrolizumab, carboplatin)|Patients receive SGT-53 IV over 90-120 minutes on days 1, 8, and 15, pembrolizumab IV over 30 minutes on day 3, and carboplatin IV over 30-60 minutes on day 3. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
62849931|NCT00207285|OTHER|Online Group|These firefighters took the sleep disorder screening and education online.
62849932|NCT03624010|EXPERIMENTAL|Levosimendan|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
62461295|NCT01902680|EXPERIMENTAL|Focal brachytherapy|Focal brachytherapy with permanent I125 localized implant.
62061828|NCT03245255|EXPERIMENTAL|Sonazoid for pressure measurements|48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% sodium chloride solution infused at a rate of at least 2 ml/min.
62061829|NCT04699916|NO_INTERVENTION|Control (Usual care)|Sedation will be guided with a standard protocol based on Sedation Agitation Scale already implemented in the Intensive Care Unit
62061830|NCT04699916|EXPERIMENTAL|EEG-based sedation protocol|Sedation will be guided using a protocol based on 2 parameters from the EEG: Suppression Rate and Spectral Edge Frequency
62061831|NCT00576732|EXPERIMENTAL|001|Risperidone low dose Risperidone oral solution 0.125 mg (if \<45 kg) or 0.175 mg (if \>=45 kg) qd or bid for 6 weeks
62624061|NCT05140252|EXPERIMENTAL|Breast cancer decision aid|Participants receive a breast cancer decision aid.
62624062|NCT02796521|OTHER|control group|The control group will receive usual dietary counseling for enrichment.
62624063|NCT02796521|OTHER|workshop group|The workshop group will have informations about interest of foods. They will enrich a meal with foods which can easily be added without cooking.
62624064|NCT05022888|ACTIVE_COMPARATOR|myofascial pain syndrome|Patients diagnosed with myofascial pain syndrome Tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle
62849933|NCT03243292||Treated|Subjects that received Bronchial Thermoplasty in a prior study (AIR, RISA, or AIR2)
62849934|NCT03243292||Control|Subjects that participated in prior study (AIR) or (RISA) but did not receive Bronchial Thermoplasty Treatment. Determine if the Control group of subjects asthma has progressed any different from those subjects treated with BT.
62849935|NCT03243292||Sham|Subjects that participated in the AIR2 study, were blinded and did not receive the treatment. Determine if the Sham group of subjects asthma has progressed any different from those subjects treated with BT.
62849936|NCT04226768|EXPERIMENTAL|"Enhanced Haematology Palliative Care (Fast-track) Group"|"Patients who are assigned to enhanced haematology palliative care (fast-track group) will be seen, within 2 days of enrollment, at the out-patient clinic or in-patient setting by the haematology palliative care team that comprises a palliative medicine specialist or a haematologist with palliative care experience, a full-time palliative care nurse, and a medical social worker concentrating on haematology palliative patients."
62061832|NCT00576732|EXPERIMENTAL|002|Risperidone high dose Risperidone oral solution 1.25 mg (if \<45 kg) or 1.75 mg (if \>=45 kg) qd or bid for 6 weeks
62061833|NCT00576732|PLACEBO_COMPARATOR|003|Placebo Oral solution qd or bid for 6 weeks
62061834|NCT03999268|EXPERIMENTAL|Intervention|Participants assigned to the intervention group will receive insulin administration education according to standard procedures plus have access to the I-START app. Over the course of the study period, participants will be able to use I-START as much or as little as they prefer.
62461296|NCT04040348|EXPERIMENTAL|hMSC Treatment group|Participants in the hMSC treatment group will receive a total of 4 doses of the hMSC intervention. Each dose will be administered once about every 13 weeks within a year period.
62461297|NCT01661452||patients in UAB ER,|
62461298|NCT01604850|EXPERIMENTAL|SOF+RBV+placebo|Participants were randomized to receive SOF+RBV for 12 weeks followed by placebo to match SOF plus placebo to match RBV for 4 weeks.
62849937|NCT04226768|ACTIVE_COMPARATOR|Conventional Supportive Care Group|"Patients who are assigned to the conventional supportive care group will be under care of haematologists and nurse specialists in haematology After 12 weeks of conventional supportive care, patients randomized to this group will receive services from the palliative care team and assessed every two weeks same the fast-track group"
62061835|NCT03999268|ACTIVE_COMPARATOR|Usual Care|Participants in the usual care group will receive insulin administration education according to standard procedures. They will not have access to the I-START app.
62624065|NCT05022888|ACTIVE_COMPARATOR|Healthy volunteers|Healthy volunteers Tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle
62849938|NCT02806141|EXPERIMENTAL|Aerosolized plus intravenous colistin|Neonates with VAP due to PDR-A. baumannii who receive aerosolized colistin (4 mg/kg/dose twice daily) plus intravenous colistin (3.5 mg/kg/dose twice daily)
62849939|NCT02806141|ACTIVE_COMPARATOR|Intravenous colistin|Neonates with VAP due to PDR-A. baumannii who receive only intravenous colistin (3.5 mg/kg/dose twice daily)
62849940|NCT03227783|ACTIVE_COMPARATOR|Real tDCS|"* Constant weak electric currents through scalp via two electrodes will be delivered.~* Current intensity: 2mA, 20min/day"
62849941|NCT03227783|SHAM_COMPARATOR|Sham tDCS|"* a 1 mA current, for 30 s giving an initial sensation of tDCS while minimizing stimulatory effects~* Ramp up and ramp down was over 10 s. (Ref. Loo CK et al., Br J Psychiatry 2012;200:52-9)"
62652850|NCT03410316||Participants of the NEO study|Men and women aged 45 oy 65 years, with an oversampling of individuals with a BMI of 27 kg/m2 or higher
62652851|NCT05687539|EXPERIMENTAL|Mastiha water|Patients will receive 10ml of Mastiha water before every meal for one month
62061836|NCT02452684||Participants with insomnia|Participants with insomnia who will receive eszopiclone, per approved label.
62266112|NCT05517642|ACTIVE_COMPARATOR|mRNA vaccine BNT162b2 (Pfizer)|Participates age 18 or older who have completed a course of primary and first booster vaccination at least 16 weeks before, and who have sub-optimal antibody response to the first booster dose,will receive a second booster dose of mRNA vaccine BNT162b2 (Pfizer).
62266113|NCT00301951|EXPERIMENTAL|cord blood transplant|
62266114|NCT05430035|EXPERIMENTAL|HIPEC|Prophylactic Heated Intra-peritoneal Chemotherapy (HIPEC) 30 mg of mitomycin C (MMC) over the first 60 minutes followed by 10 mg over an additional 30 minutes. Perfusate will be heated to obtain a tissue temperature of 42°.
62461299|NCT01604850|EXPERIMENTAL|SOF+RBV|Participants were randomized to receive SOF+RBV for 16 weeks.
62849942|NCT01690676|ACTIVE_COMPARATOR|Epicatechin|The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
62061837|NCT02696902|EXPERIMENTAL|MEDI3902 500 mg|Participants will receive a single intravenous (IV) dose of 500 mg MEDI3902.
62061838|NCT02696902|PLACEBO_COMPARATOR|Placebo|Participants will receive a single IV dose of placebo matched to MEDI3902.
62061839|NCT02696902|EXPERIMENTAL|MEDI3902 1500 mg|Participants will receive a single IV dose of 1500 mg MEDI3902.
62061840|NCT01235572|EXPERIMENTAL|Health services research (early discharge, outpatient care)|Patients are discharged within 72 hours after completion of chemotherapy and undergo standard outpatient care by a RN, PA, or resident/fellow at a local facility or the study center approximately 3 times per week, as clinically indicated for up to 45 days.
62266115|NCT00631371|EXPERIMENTAL|1|Bevacizumab 10 mg/kg intravenous (IV) q8wks + Temsirolimus 25 mg IV weekly
62461300|NCT02898909|EXPERIMENTAL|16 pieces fragmentation|
62266116|NCT00631371|ACTIVE_COMPARATOR|2|Bevacizumab 10 mg/kg intravenous (IV) q8wks + Interferon-Alfa 9MU SC TIW
62266117|NCT03894930|EXPERIMENTAL|Metta meditation|Eight-week, guided metta meditation training that is administered online
62266118|NCT03894930|NO_INTERVENTION|Wait-list|Eight-week wait-list control with no training
62061841|NCT02080182|ACTIVE_COMPARATOR|Acetylcysteine|Effervescent tablet of acetylcysteine 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily less than 8.5 kg: 70 mg/kg
62061842|NCT02080182|PLACEBO_COMPARATOR|Placebo|Placebo effervescent tablet of acetylcysteine 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily: more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily less than 8.5 kg: 70 mg/kg
62266119|NCT00205855|EXPERIMENTAL|Precision SCS|Precision SCS. Patients who receive Precision Spinal Cord Stimulator (SCS) Stimulus system
62061843|NCT05022095||SCI Patients with ongoing spasticity|SCI Patients that are either seen in clinical routine due to fillings or controls of their intrathecal injection pumps or stationary patients will be informed about the project, they are granted with enough time to decide whether they want participate or not. After giving Informed Consent they will be administered a set of questionnaires including SCI-SETde, PSFS (adapted to german), SCIM-SR in german as well as self-evaluation of spasticity severity and intensity. The SCI-SETde will be filled in again one week later to evaluate test-retest reliability. Overall, the burden for the patients is kept at minimum. There are no expected risks or harm to the patients.
62061844|NCT04942314||Complete remission off therapy|"1. no clinical activity and serological activity~2. stop taking corticosteroid and immunosuppressive drugs~3. antimalarials allowed"
62061845|NCT04942314||Complete remission on therapy|"1. no clinical activity and serological activity~2. corticosteroid≤5 mg/day and immunosuppressive drugs allowed~3. antimalarials allowed"
62266120|NCT03283189||Group 1|Pregnancy follow-up in the only maternity type III of the region (CHU) and in an urban area (around Clermont-Ferrand)
62266121|NCT03283189||Group 2|Pregnancy follow-up in the only maternity type III of the region (CHU) and in an urban area (around Clermont-Ferrand)
62266122|NCT03283189||Group 3|Pregnancy follow-up in the only private maternity (type II) of the region and in an urban area (around Clermont-Ferrand)
62266123|NCT03283189||Group 4|Pregnancy follow-up in the only private maternity (type II) of the region and in an urban area (around Clermont-Ferrand)
62266124|NCT03283189||Group 5|Pregnancy follow-up in a type I maternity and in a rural area (around Saint-Flour)
62266125|NCT03283189||Group 6|Liberal follow-up of pregnancy
62461301|NCT02898909|ACTIVE_COMPARATOR|8 pieces fragmentation|
62461302|NCT01692405|NO_INTERVENTION|Standard method|Standard method- shaking the biopsy needle into a formalin container.
62849943|NCT01690676|PLACEBO_COMPARATOR|Microcrystalline cellulose|The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
62849944|NCT03934099|EXPERIMENTAL|LC350189 50mg|LC350189 50mg, Once a day (QD)
62849945|NCT03934099|EXPERIMENTAL|LC350189 100mg|LC350189 100mg, QD
62849946|NCT03934099|EXPERIMENTAL|LC350189 200mg|LC350189 200mg, QD
62849947|NCT03934099|PLACEBO_COMPARATOR|Placebo|Placebo, QD
62849948|NCT01339520|EXPERIMENTAL|Scorecard|Score of points for variables.
62061846|NCT04942314||Clinical remission off therapy|"1. no clinical activity but serological activity allowed~2. stop taking corticosteroid and immunosuppressive drugs~3. antimalarials allowed"
62061847|NCT04942314||Clinical remission on therapy|"1. no clinical activity but serological activity allowed~2. corticosteroid≤5 mg/day and immunosuppressive drugs allowed~3. antimalarials allowed"
62461303|NCT01692405|ACTIVE_COMPARATOR|Download onto a biopsy sponge pad|Samples will be downloaded by moving the needle notch on a biopsy sponge pad.
62461304|NCT01692405|EXPERIMENTAL|Dowloading the biopsy cores using NavigoBx system|Downloading the biopsy cores using NavigoBx™ system. The NaviGoBx™ device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.
62849949|NCT01339520|NO_INTERVENTION|Control|Standard of care for diabetes subjects
62849950|NCT01934270|EXPERIMENTAL|Anaerobic Test|
62849951|NCT03595228|EXPERIMENTAL|BN-Brachyury plus radiation|BN-Brachyury as both MVA and FPV are given before radiation, and followed by FPV-Brachyury
62061848|NCT04942314||Low disease activity state|(1) SLEDAI-2K ≤4, with no activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever), and no haemolytic anaemia or gastrointestinal active involvement; (2) no new lupus disease activity compared with the previous assessment; (3) a PGA ≤1; (4) a current predni- sone (or equivalent) dose ≤7.5mg/day; and (5) well-tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents.
62266126|NCT02312635|EXPERIMENTAL|Cogmed + D-cycloserine|Partifcipants will receive 6 weeks of cogmed working memory training M-F for 45 min each day. Participants in this arm will also take drug Monday, Wednesday, Friday throughout 6 weeks.
62266127|NCT02312635|PLACEBO_COMPARATOR|Cogmed + Placebo|Participants will receive 6 weeks of cogmed training M-F and also take a placebo pill Monday, Wednesday, Friday throughout 6 week period.
62449550|NCT06543576|EXPERIMENTAL|Treatment (EBRT, brachytherapy, chemotherapy, immunotherapy)|"PART 1: Patients receive cisplatin IV, paclitaxel IV, pembrolizumab IV over 30 minutes, and bevacizumab IV on day 1 of each cycle. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients receive no treatment for 3 weeks.~PART 2: Patients undergo EBRT for 25 treatments delivered over 5 weeks, and brachytherapy over 3-5 treatments. Patients also receive pembrolizumab IV over 30 minutes and bevacizumab IV on day 1 of each cycle. Cycles for immunotherapy repeat every 21 days for a total of 2 years in the absence of disease progression or unacceptable toxicity. Participants who complete study intervention after 2 years of pembrolizumab are eligible for up to 1 year of additional pembrolizumab (second course) upon experiencing disease progression.~Patients undergo CT, PET/CT, and/or MRI throughout the study. Patients also undergo blood sample collection throughout the study."
62849952|NCT03514810|PLACEBO_COMPARATOR|Sertralin & Ketoprofen in MDD|To compare the median of Beck Depression Inventory-II (BDI-II) score of MDD patients after treatment with sertralin (50mg) daily+placebo and after treatment with combination of (sertralin \& ketoprofen) for two months.
62449551|NCT00455052|EXPERIMENTAL|XMT-1001|XMT-1001 is administered I.V. every 21 days. Groups of 3 patients are given one dose and the dose increases for each group. The first dose level is 17 mg/m\^2, the next dose level is 30 mg/m\^2, followed by dose levels: 50 mg/m\^2, 80 mg/m\^2, 120 mg/m\^2, 150 mg/m\^2, and 190 mg/m\^2 until disease progressions or unacceptable side effects are experienced.
62849953|NCT03514810|EXPERIMENTAL|Interleukins in MDD after treatment|Some Interleukines level were estimated before and after treatment with sertralin 50 mg in combination with either placebo or ketoprofen 100mg daily.
62266128|NCT02806297|EXPERIMENTAL|Early cholecystectomy with IOC|The experimental arm will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.
62266129|NCT02806297|ACTIVE_COMPARATOR|Late cholecystectomy with IOC|The comparator will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
62266130|NCT00599040|ACTIVE_COMPARATOR|Weight loss|Weight loss diet focused on the DASH diet
62449552|NCT05632965||Healthy preterm infants|Thyroid function in Preterm infants not needing hospital admission will be estimated at day 3 and day 10 of life.
62449553|NCT05632965||Sick preterm infants|Thyroid function in sick preterm infants admitted to NICU will be estimated at day 3 and day 10 of life .
62449554|NCT04452578|EXPERIMENTAL|Experimental: Recipient of HCV positive heart graft|A single center, open-label, pilot study examining 10 adult HCV negative heart transplant subjects who will receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after heart transplantation.
62449555|NCT05462288||Patient Group|
62449556|NCT05690568|OTHER|Pre-intervention and post-intervention FMS scores|multimodal chiropractic care with FMS scores assessed pre- and post-intervention
62449557|NCT03392974|EXPERIMENTAL|Valoctocogene Roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 4E13 vg/kg
62449558|NCT03320408||Asymptomatic AAA|These patients will be included while their AAA is asymptomatic and while they are under surveillance by their vascular surgeon.
62449559|NCT03320408||Acute AAA|These are the patients that are included while they presented in the participating hospitals because either a symptomatic or ruptured AAA. For this group, a different recruitment procedure exists which has been approved by the appropriate medical ethical committee.
62449560|NCT03320408||Repaired AAA|These patients are included while they already had had AAA repair (both elective and emergency repair).
62449561|NCT03718338||Clinical Evaluations|Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
62449562|NCT03872999|EXPERIMENTAL|Attentional Control|Visuo-spatial attentional tasks with simple stimuli during functional magnetic resonance imaging (fMRI) scanning.
62449563|NCT03317613|EXPERIMENTAL|Capsaicin|Cancer patients presenting neuropathic pain secondary to their anti cancer treatments will receive patch of capsaicin (qutenza) on the painful zones..
62849954|NCT00835562|EXPERIMENTAL|Osteosynthesis|
62849955|NCT00835562|EXPERIMENTAL|Non-surgical|
62266131|NCT00599040|ACTIVE_COMPARATOR|DASH diet|The DASH diet without weight loss
62266132|NCT00599040|ACTIVE_COMPARATOR|Diary|Dairy Intervention
62449564|NCT06231758|ACTIVE_COMPARATOR|control group|35 patients will receive celecoxib 200 mg capsule plus placebo tablets
62449565|NCT06231758|ACTIVE_COMPARATOR|Comparative group|35 patients will receive celecoxib 200 mg capsule plus 1000 mg metformin daily
62449566|NCT02228174|EXPERIMENTAL|Subjects Treated with Sonata|Intervention: Intrauterine Ultrasound-Guided Radiofreq. Ablation System or the Sonata, which is a sonography guided transcervical ablation device intended for treatment of symptomatic uterine fibroids. Subjects with symptomatic uterine fibroids and heavy menstrual bleeding who met the study population selection criteria received treatment with Sonata.
62449567|NCT02378103||Case|Diagnosis of aortic dissection was based on history and physical examination, and confirmed by imaging, visualization at surgery, and/or postmortem examination. Simple aortic aneurysm and pseudoaneurysm were excluded. Simple aortic aneurysm and pseudoaneurysm were excluded. Surgical and endovascular treatments were the main interventions and performed in the case group.
62061849|NCT04942314||Not in LDAS or Remission|At the end of follow-up, the disease state of SLE children was not in LDAS or any remissions defined above.
62061850|NCT04942314||Never in LDAS|During the follow-up, the disease state was never get LDAS.
62849956|NCT00835562|EXPERIMENTAL|Hemiarthroplasty|
62849957|NCT02661009||Plasma and tissue matching|
62266133|NCT02586675|EXPERIMENTAL|Tamoxifen and Ribociclib with Goserelin|Phase I dose escalation followed by Phase Ib dose expansion. Tamoxifen and Ribociclib, with Goserelin added for premenopausal or peri-menopausal participants. Ribociclib: Capsules/Tablets for oral use 400 mg OR 600 mg Days 1-21 of each 28 day cycle or daily. Tamoxifen: Tablets for oral use 20 mg daily (all days of every cycle without interruption). Goserelin: Subcutaneous injection 3.6 mg Day 1 of each 28 day cycle.
62266134|NCT05468268|EXPERIMENTAL|20 Hz rTMS|"rTMS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode.~Stimulation parameters will be rTMS delivery of 1600 pulses divided into blocks: 20 Hz for 2 seconds (40 pulses) followed by 28 seconds of pause, with a stimulation intensity equal to 100% of the motor threshold value at rest."
62849958|NCT02661009||predicting clinical efficacy|
62061851|NCT01460160|EXPERIMENTAL|Arm 1: Dasatinib|
62061852|NCT06625827|EXPERIMENTAL|Digoxin|Participants receive a single oral dose of digoxin (Treatment A).
62061853|NCT06625827|EXPERIMENTAL|Digoxin + Nemtabrutinib|Participants receive a single oral dose of digoxin coadministered with a single oral dose of nemtabrutinib (Treatment B).
62061854|NCT05978505|EXPERIMENTAL|Reboxetine|7-day course of 4mg reboxetine, taken nightly before bed time. Reboxetine will be taken for 7-nights post-surgery.
62061855|NCT05978505|PLACEBO_COMPARATOR|Placebo|Placebo sugar pill in the form of one capsule, taken before bedtime. Dosage is taken for 7 nights post-surgery.
62061856|NCT05011123|EXPERIMENTAL|Group 1|1 injection of vYF vaccine at Day 1
62266135|NCT05468268|SHAM_COMPARATOR|Sham rTMS|"Sham rTMS will be administered by applying a 30mm thick piece of wood or plastic to a real TMS coil during stimulation, and this additional element will be constructed in such a way that it appears to be an integral part of the apparatus such that the patient remains unaware that they are not receiving stimulation. This 30 mm distance is adequate to ensure that the magnetic pulse does not reach the cortex."
62266136|NCT04791774|ACTIVE_COMPARATOR|Protein group|Patients receive 20 grams of Intrinsically labelled milk protein.
62624066|NCT03272347|EXPERIMENTAL|Islatravir 0.25 mg|Participants will be treated once daily (QD) with 0.25 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to DOR/3TC/TDF may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
62849959|NCT01373541|ACTIVE_COMPARATOR|InFat group|Infant formula with structured triglycerides (high palmitic acid content at the sn-2 position)
62849960|NCT01373541|ACTIVE_COMPARATOR|Control group|Infant formula with standard vegetable blend (low palmitic acid content at the sn-2 position)
62266137|NCT04791774|EXPERIMENTAL|Free amino acid group|Patients receive 20 grams of free amino acids equivalent to the milk protein labelled with 13C-Phenylalanine
62849961|NCT01373541|NO_INTERVENTION|Referance group|Human milk breastfeeding
62849962|NCT06259006|EXPERIMENTAL|Dexamethasone|Participants will receive oral dexamethasone 20mg/m2/day in three divided doses, (maximum dose 24mg/day), for 3 days
62061857|NCT05011123|ACTIVE_COMPARATOR|Group 2|1 injection of Stamaril vaccine at Day 1
62061858|NCT05299021|EXPERIMENTAL|Double-point SAPB|SAPB will be performed simultaneously in both the third and fifth rib levels.
62061859|NCT05299021|EXPERIMENTAL|Single-point SAPB|SAPB will be performed only in the fifth rib level.
62652852|NCT05687539|EXPERIMENTAL|Mastiha capsules|Patients will receive 2 Mastiha capsules (2x350mg) before every meal for one month
62652853|NCT05687539|NO_INTERVENTION|Control-Mastiha free|Patients will follow a Mastiha free one month period
62849963|NCT06259006|PLACEBO_COMPARATOR|Placebo control|Participants will receive oral placebo tablet three times a day for 3 days
62849964|NCT03229694|EXPERIMENTAL|Tracleer (or Bosentan)|Tracleer (Tracleer 125Mg Tablet) was administered orally at two hours before surgery and six hours after surgery
62849965|NCT03229694|PLACEBO_COMPARATOR|Placebo|Placebo was administered orally at two hours before surgery and six hours after surgery
62849966|NCT05917782|EXPERIMENTAL|Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)|Strength: pre-filled syringe, 150 mg/1 mL
62849967|NCT05917782|EXPERIMENTAL|Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)|Strength: pre-filled syringe, 300 mg/2 mL
62061860|NCT04006561||newly-diagnosed patients with primary CNS lymphoma|
62061861|NCT04860960|EXPERIMENTAL|Experimental|Intravenous administration of 2000 mg/kg hydroxypropyl betacyclodextrin (Trappsol Cyclo) (based on body weight) diluted with 0.5N saline over at least 6.5 hours every 2 weeks
62061862|NCT04860960|PLACEBO_COMPARATOR|Placebo comparator|Intravenous administration of 0.5N saline over at least 6.5 hours every 2 weeks
62061863|NCT04860960|EXPERIMENTAL|Open Label sub-study for Infants up to age 3|Up to 12 patients age 0 - 3 yrs in countries following EMA guidance may be enrolled in this open label sub-study. All patients will receive 2000 mg/kg hydroxypropyl betacyclodextrin (Trappsol Cyclo) diluted with 0.5N saline at the clinician's discretion over 6.5 hours every 2 weeks. Outcome measures are safety, clinician and caregiver impressions.
62849968|NCT05917782|ACTIVE_COMPARATOR|Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL)|Strength: vial, 150 mg/1 mL
62849969|NCT02405338|EXPERIMENTAL|WT1/PRAME vaccination|
62061864|NCT06230068|OTHER|Expressive writing|The intervention consists of expressive writing during 20 minutes. The writing should be of the breast cancer, the treatment or other related topics. The patient is invited to write once every week in a separate place. The intervention ends after four weeks. The written text is not collected.
62849970|NCT06144580||Intervention|Community Health and Wellbeing Worker + usual care
62061865|NCT04919902||Electric cardioversion|Patients who underwent elective cardioversion for atrial arrhythmia
62061866|NCT04472377|EXPERIMENTAL|study population|"We enroll a total of 1,200 women, as follows,~1. 120 cases with no history or current cervical intraepithelial lesion or malignancy.~2. 180 cases with a history of abnormal Pap test including ASCUS, CIN1, or atypical glandular cell.~3. 240 cases with a history of atypical squamous cells favor HSIL, dysplasia cannot exclude HSIL, CIN2, CIN3, cervical carcinoma in situ, squamous cell carcinoma, atypical glandular cells favor neoplasm, adenocarcinoma in situ, or cervical adenocarcinoma.~4. 240 cases with current ASCUS, CIN1, or atypical glandular cell.~5. 420 cases with current abnormal Pap test as atypical squamous cells favor HSIL, dysplasia cannot exclude HSIL, CIN2, CIN3, cervical carcinoma in situ, squamous cell carcinoma, atypical glandular cells favor neoplasm, adenocarcinoma in situ, or cervical adenocarcinoma."
62061867|NCT03051022|ACTIVE_COMPARATOR|Dexamethasone 8 mg|Bupivacaine 0,125% 12,5 mg combined with dexamethasone 8 mg plus NaCl 0,9% until the volume was 10 cc, prepared in a 10 cc syringe.
62061868|NCT03051022|ACTIVE_COMPARATOR|Morphine 2 mg|Bupivacaine 0,125% 12,5 mg combined with morphine 2 mg plus NaCl 0,9% until the volume was 10 cc, prepared in a 10 cc syringe.
62061869|NCT04636346||COMPASS (Psychoeducational / Behavioral Program)|Group Acceptance and Commitment Therapy program as part of clinical service for cancer patients
62061870|NCT04116749||Non-obese women|body mass index lower than 30 (kg/m\^2) at term
62652854|NCT02576496|EXPERIMENTAL|Tinostamustine 20mg/m2 over 60min|Tinostamustine as a single agent administered by IV infusion on D1 of 21-day cycle.
62849971|NCT06144580||Control|Usual care
62849972|NCT04306796|EXPERIMENTAL|intervention group|Patients receiving 3D-printed made to measure splints for postoperative or post-traumatic treatment in hand surgical patients
62849973|NCT04306796|ACTIVE_COMPARATOR|control group|Patients receiving thermoplastic splints individually adjusted by occupational therapists
62061871|NCT04116749||Obese women|body mass index equal or greater than 30 (kg/m\^2) at term
62061872|NCT00186498|PLACEBO_COMPARATOR|Placebo Oral Capsule|Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
62061873|NCT00186498|EXPERIMENTAL|memantine|Patients receive memantine starting the day before ECT begins and while receiving ECT
62061874|NCT01364922|EXPERIMENTAL|Open-label Hydrocodone/Acetaminophen Extended Release|Hydrocodone/acetaminophen extended release, 2 tablets twice daily
62061875|NCT01364922|EXPERIMENTAL|Double-blind Hydrocodone/Acetaminophen Extended Release|Hydrocodone/acetaminophen extended release, 1 tablet twice daily
62266138|NCT01776515|ACTIVE_COMPARATOR|Tramadol hydrochloride/Acetaminophen Tab.|
62849974|NCT06069895|EXPERIMENTAL|NNC0113-6856|Participants will receive NNC0113-6856 oral tablets.
62849975|NCT06069895|EXPERIMENTAL|Placebo|Participants will receive NNC0113-6856 matching placebo oral tablets.
62849976|NCT05547204|EXPERIMENTAL|Coffeeberry beverage|300 ml drink containing 300 mg coffeeberry extract
62849977|NCT05547204|PLACEBO_COMPARATOR|Color and flavor matched beverage|300 ml drink (0 mg coffeeberry extract, 0 mg caffeine)
62849978|NCT00003497|EXPERIMENTAL|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
62849979|NCT06142578|EXPERIMENTAL|Device under investigation|
62061876|NCT01364922|PLACEBO_COMPARATOR|Double-blind Placebo|Placebo, 1 tablet twice daily
62061877|NCT05999708|EXPERIMENTAL|Part 1: Cohort 1 - GSK4381406 or placebo|Participants in Part 1 Cohort 1 will receive a single dose of GSK4381406 dose level 1 or placebo in Treatment Period 1 in fasted state, followed by GSK4381406 dose level 3 or placebo in Treatment Period 2 in fasted state with washout period of at least 40 days between each dose.
62061878|NCT05999708|EXPERIMENTAL|Part 1: Cohort 2 - GSK4381406 or placebo|Participants in Part 1 Cohort 2 will receive a single dose of GSK4381406 dose level 2 or placebo in Treatment Period 1 in fasted state, followed by GSK4381406 dose level 4 or placebo in Treatment Period 2 in fasted state with washout period of at least 40 days between each dose.
62266139|NCT01776515|EXPERIMENTAL|Tramadol hydrochloride/Acetaminophen SR Tab.|
62266140|NCT01314677|EXPERIMENTAL|Group A (FDG PET/CT between RT fractions 5-6)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 5-6 (before course 2 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
62449568|NCT02378103||Control|As the control group, patients without AD were obtained from the hospitalized patients in the same period.
62449569|NCT05485909|EXPERIMENTAL|Regorafenib and Toripalimab Combined with RFA|
62849980|NCT04796194|EXPERIMENTAL|LTX-315 in combination with pembrolizumab|"LTX-315 will be injected directly into the selected tumor lesion(s).~Pembrolizumab will be dispensed and administered as an IV infusion."
62849981|NCT04461067|EXPERIMENTAL|Gastric antrum measurement|
62449570|NCT03110666|EXPERIMENTAL|Autologous concentrated bone marrow aspirate|autologous concentrated bone marrow aspirate obtained from the BioCUE Concentration System
62449571|NCT06291883|EXPERIMENTAL|Treat|four packets of concentrated powder per day.
62061879|NCT05999708|EXPERIMENTAL|Part 1: Cohort 3 - GSK4381406 or placebo|Participants in Part 1 Cohort 3 will receive a single dose of GSK4381406 dose level 5 or placebo in Treatment Period 1 in fasted state, followed by GSK4381406 dose level 7 or placebo in Treatment Period 2 in fasted state with washout period of at least 40 days between each dose. Note: Requirement for Treatment Period 2 (dose level 7) will be determined by PK data of previous doses.
62061880|NCT05999708|EXPERIMENTAL|Part 1: Cohort 4 - GSK4381406 or placebo|Participants in Part 1 Cohort 4 will receive a single dose of GSK4381406 dose level 6 or placebo in Treatment Period 1 in fasted state, followed by GSK4381406 dose level 6 in Treatment Period 2 in fed state with washout period of at least 40 days between each dose.
62061881|NCT05999708|EXPERIMENTAL|Part 2: Cohort 5 - GSK4381406 or placebo|Participants in Part 2 Cohort 5 will receive 14 days of once daily repeat dosing of GSK4381406 dose level A or placebo in fasted state.
62061882|NCT05999708|EXPERIMENTAL|Part 2: Cohort 6 - GSK4381406 or placebo|Participants in Part 2 Cohort 6 will receive 14 days of once daily repeat dosing of GSK4381406 dose level B or placebo in fasted state.
62061883|NCT05999708|EXPERIMENTAL|Part 2: Cohort 7 - GSK4381406 or placebo|Participants in Part 2 Cohort 7 will receive 14 days of once daily repeat dosing of GSK4381406 dose level C or placebo in fasted state.
62061884|NCT05999708|EXPERIMENTAL|Part 3 - GSK4381406 or Placebo and Indomethacin|Participants in Part 3 will receive 3 days of once daily repeat dosing of GSK4381406 in Treatment Period 1 followed by placebo in Treatment Period 2, or placebo in Treatment Period 1 and GSK4381406 in Treatment Period 2 in a cross-over design with a washout period of at least 14 days between each dosing period. Participants will be dosed in fasted state. The participants will be challenged with indomethacin during the final 2 days of each dosing period.
62061885|NCT05929235|EXPERIMENTAL|Dose Escalation|3+3 design, 5 dose levels,
62266141|NCT01314677|EXPERIMENTAL|Group B (FDG PET/CT between RT fractions 10-11)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 10-11 (before course 3 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
62652855|NCT02576496|EXPERIMENTAL|Tinostamustine 40mg/m2 over 60min|Tinostamustine as a single agent administered by IV infusion on D1 of 21-day cycle.
62061886|NCT05929235|EXPERIMENTAL|Expansion Expansion|When a preliminary RP2D has been identified (this dose may be equal to or below the MTD) evaluate the antitumor activity in locally advanced (unresectable) and metastatic urothelial carcinoma.
62061887|NCT06283446|EXPERIMENTAL|High-Intensity|Participants will receive high-intensity episodic future-thinking cue images, and high-intensity episodic recent-thinking cue images during an MRI decision-making task.
62061888|NCT06283446|ACTIVE_COMPARATOR|Low-Intensity (Control)|Participants will receive low-intensity episodic future-thinking cue images, and low-intensity episodic recent-thinking cue images during an MRI decision-making task.
62061889|NCT01081041|EXPERIMENTAL|Safety Lead-In (cetuximab manufactured by ImClone)|"Cycle 1:~Week 1 - Cetuximab 400 milligrams per square meter (mg/m\^2) on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin area under the curve (AUC) 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m\^2 on Day 1~Week 3 - Cetuximab 250 mg/m\^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m\^2 on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m\^2 on Day 1~Week 3 - Cetuximab 250 mg/m\^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m\^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
62061890|NCT01081041|EXPERIMENTAL|Cetuximab manufactured by ImClone|"Cycle 1:~Week 1 - Cetuximab 400 mg/m\^2 on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m\^2 on Day 1~Week 3 - Cetuximab 250 mg/m\^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m\^2 on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m\^2 on Day 1~Week 3 - Cetuximab 250 mg/m\^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m\^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
62061891|NCT01081041|EXPERIMENTAL|Cetuximab manufactured by Boehringer Ingelheim|"Cycle 1:~Week 1 - Cetuximab 400 mg/m\^2 on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m\^2 on Day 1~Week 3 - Cetuximab 250 mg/m\^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m\^2 on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m\^2 on Day 1~Week 3 - Cetuximab 250 mg/m\^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m\^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
62061892|NCT04501289|EXPERIMENTAL|Low dose magnesium sulphate|Experimental - participants in this arm will be pregnant women with severe preeclampsia/eclampsia who will receive low dose magnesium sulphate
62061893|NCT04501289|EXPERIMENTAL|Magnesium sulphate Pritchard regimen|Experimental - participants in this arm will be pregnant women with severe preeclampsia/eclampsia who will receive Pritchard regimen of magnesium sulphate
62061894|NCT04338425|NO_INTERVENTION|No Communication group|Participants will not communicate with their surgeons until the post operative office visit.
62061895|NCT04338425|ACTIVE_COMPARATOR|Voice call group|Participants will receive voice call from the surgeon after being discharged and before their post operative office visit.
62266142|NCT01314677|EXPERIMENTAL|Group C (FDG PET/CT between RT fractions 15-16)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 15-16 (before course 4 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
62266143|NCT05744999||Patients treated with the reported technique|Two females and 1 male with a mean age of 50 years were diagnosed by CT scan with stage II acute cholecystitis according to the Tokyo guidelines and were operated on within three days of symptom onset
62652856|NCT02576496|EXPERIMENTAL|Tinostamustine 60mg/m2 over 60min|Tinostamustine as a single agent administered by IV infusion on D1 of 21-day cycle.
62061896|NCT04338425|ACTIVE_COMPARATOR|Video call group|Participants will receive video call from surgeon after being discharged and before their post operative office visit
62061897|NCT06315140|EXPERIMENTAL|Ramapough Lunaape Nation|The tribe will be provided with nutrition-rich foods and recipes for nutritious cooking.
62061898|NCT06061432|EXPERIMENTAL|Endoscopic Ultrasound- Guided Hartmann Reversal Procedure|Participants after Hartmann procedure, who were qualified and underwent Endoscopic Ultrasound- Guided Hartmann Reversal Procedure.
62061899|NCT01386996|EXPERIMENTAL|Charcoal and Budesonide/formoterol Easyhaler|
62449572|NCT06291883|PLACEBO_COMPARATOR|Control|four packets of concentrated powder per day.
62266144|NCT04217187|EXPERIMENTAL|Electrical Stimulation Group|This arm will receive neuromuscular electrical stimulation to the antagonist muscles of the upper extremity.
62266145|NCT04217187|SHAM_COMPARATOR|Sham Stimulation Group|This arm will receive sensory stimulation without muscle contraction to the antagonist muscles of the upper extremity.
62266146|NCT05296187|ACTIVE_COMPARATOR|GROUP TEAS|Patients will receive TEAS bilaterally at two acupoints: Hegu (L14) and Neiguan (PC6).
62266147|NCT05296187|PLACEBO_COMPARATOR|Control Sham Group|Patients in the sham group will be undergoing electrode attachment on the target acupoints without electronic stimulation.
62266148|NCT03233555|ACTIVE_COMPARATOR|Arm I (brochure)|Participants receive National Cancer Institute's Facing Forward brochure.
62266149|NCT03233555|EXPERIMENTAL|Arm II (EXCELS website)|Participants have untimed access to the EXCELS mobile web application.
62266150|NCT03233555|EXPERIMENTAL|Arm III (Healthcare coaching call)|Participants also receive 4 quarterly calls of 15-20 minutes each over 3 months. These calls focus on checking if patients have received preventive and cancer related follow-up care.
62266151|NCT03233555|EXPERIMENTAL|Arm IV (EXCELS website, health coaching calls)|Participants have access to EXCELS as in Arm II. Participants also receive 4 calls as in Arm III.
62266152|NCT05030012|EXPERIMENTAL|Automated Control (OAM)|In this arm, FiO2 levels delivered via high-velocity nasal insufflation therapy (Vapotherm Precision Flow) will be adjusted by the Oxygen Assist Module (OAM) to keep the infants pulse oxygen saturation within a target range (90-95%). Clinical staff will have the ability to override FiO2 levels when required, and instructed to do so.
62266153|NCT05030012|ACTIVE_COMPARATOR|Manual Control (Manual)|In this arm, FiO2 levels delivered via high-velocity nasal insufflation therapy (Vapotherm Precision Flow) will be manually adjusted by clinical staff to keep infants' oxygen saturation between 90-95%.
62624067|NCT03272347|EXPERIMENTAL|Islatravir 0.75 mg|Participants will be treated QD with 0.75 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to DOR/3TC/TDF for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to DOR/3TC/TDF may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and will continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
62624068|NCT03272347|EXPERIMENTAL|Islatravir 2.25 mg|Participants will be treated QD with 2.25 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to DOR/3TC/TDF for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to DOR/3TC/TDF may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and will continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
62652857|NCT02576496|EXPERIMENTAL|Tinostamustine 80mg/m2 over 60min|Tinostamustine as a single agent administered by IV infusion on D1 of 21-day cycle.
62061900|NCT01386996|ACTIVE_COMPARATOR|Charcoal and Symbicort Turbuhaler|
62061901|NCT01386996|EXPERIMENTAL|Budesonide/formoterol Easyhaler|
62061902|NCT01386996|ACTIVE_COMPARATOR|Symbicort Turbuhaler|
62061903|NCT03863522|OTHER|Fine Needle Aspiration|Participants will receive fine needle aspiration (FNA) later read by the cytopathologist and the cartridge. All patients will receive standard of care (Ultrasound-guided core needle biopsy and diagnosis).
62061904|NCT00844116|ACTIVE_COMPARATOR|Conventional Spirometry|personal spirometry
62061905|NCT00844116|EXPERIMENTAL|Telematic Spirometry|"performed remotely on line"
62266154|NCT04096196|EXPERIMENTAL|Game intervention group|Participants assigned to the intervention group will be given a manual containing instructions to play the Safe City game. A research assistant will provide a briefing session on the game in each participating school. A unique username and password set will be created for each user to log in the game. This login information will be provided to the student participants in a sealed envelope after the briefing session. The participants will be instructed to play the game as many times as desired within a 4-week time frame. The players ranked in the top 20 will receive a reward in the form of book coupon after the intervention ends.
62449573|NCT04910490||Patients received stereotaxic aspiration|No new/additional patients will be enrolled within this project. Only retrospective data will be collected on survival time and life quality
62449574|NCT04910490||Patients received conservative therapy|No new/additional patients will be enrolled within this project. Only retrospective data will be collected on survival time and life quality
62449575|NCT01438723|EXPERIMENTAL|metformin|
62449576|NCT01438723|PLACEBO_COMPARATOR|placebo|
62449577|NCT01654380|EXPERIMENTAL|Part A, Cohort A; LY2605541|Healthy participants received 5.1 milliunits/minute (mU/min) in Period 1, 10.2 mU/min in Period 2, and 15.3 mU/min in Period 3, administered intravenously (IV) over 8 hours. All periods were separated by a minimum 6-day washout period
62849982|NCT02675673|ACTIVE_COMPARATOR|GJ-Tube arm|Patients randomized to his arm would usually have a small tube is inserted through the nose into the stomach first, so that air can be used to fill the stomach to make it visible on X-ray. A fine needle is then used to inject freezing medicine (local anesthetic) into the skin of the abdomen. Using an x-ray machine for guidance, a puncture is made into the stomach through the frozen skin. The feeding tube is placed through this puncture into the stomach and the tube tip is placed in the small bowel. Once the GJ-tube has been inserted, the tube in the nose is removed.
62849983|NCT02675673|ACTIVE_COMPARATOR|G-Tube arm|Patients who are randomized to this arm will usually have a small tube is inserted through the nose into the stomach first, so that air can be used to fill the stomach to make it visible on X-ray. A fine needle is then used to inject freezing medicine (local anesthetic) into the skin of the abdomen. Using an x-ray machine for guidance, a puncture is made through the frozen skin. A small guiding tube or catheter is placed through this puncture into the stomach, and is advanced up the esophagus and out of the mouth. The feeding tube is then pulled into the mouth, down the esophagus, and positioned through the abdomen with its inside tip in the stomach.
62849984|NCT06523413|EXPERIMENTAL|Intervention Group 1|The game designated for the group game activity will be played with the patient, the patient's relative, and the researcher before the surgery. Data will be collected by another researcher before the game is played, and measurements will be taken again using data collection tools after the group game activity.
62849985|NCT06523413|EXPERIMENTAL|Intervention Group 2|Patients will use the stress ball for 15 minutes before surgery. Data will be collected with data collection tools before and after using the stress ball.
62849986|NCT06523413|NO_INTERVENTION|Control Group|No intervention will be performed on patients. Data will be collected twice before surgery.
62849987|NCT02863536|OTHER|Polybactum®|"Polybactum® ovules are administered intravaginally on 3 cycles, 1 cycle per month.~Polybactum is a medical device Class IIa used and marketed for the recurrence of Bacterial Vaginosis."
62849988|NCT03307655|EXPERIMENTAL|Control (fertile semen donors)|Sperm from fertile men (donors who attend the IVI Murcia clinic) will be included in this arm.
62849989|NCT03307655|EXPERIMENTAL|Patients (subfertile men)|Sperm from patients (subfertile men, i.e. men who possess one altered spermiogram parameter, according to the WHO 2010 guidelines) will be included in this arm.
62849990|NCT03680118|EXPERIMENTAL|autogenous rings with GBR and autogenous graft with ti-mesh|Augmentation with autogenous onlay ring blocks covered by guided bone regeneration (GBR) using collagen membrane and autogenous bone graft using titanium mesh (ti-mesh) only
62849991|NCT04231370|EXPERIMENTAL|treatment arm|Sintilimab, 200mg, iv day1 Lenalidomide, 25mg/d, oral, day 1-14 repeated every 3 weeks
62449578|NCT01654380|ACTIVE_COMPARATOR|Part A, Cohort A; Insulin Glargine|Healthy participants received insulin glargine (30 milliunits/meter squared/minute \[mU/m\^2/min\]) administered IV over 8 hours in Period 4. All periods were separated by a minimum 6-day washout period
62849992|NCT03069105||Family caregivers|The sample for this study will consist of caregivers of patients with cancer. Eligible subjects who agrees to participate in the research study and sign the consent form will participate by completing paper and pencil or electronic questionnaires.
62849993|NCT03558880|ACTIVE_COMPARATOR|Erector Spinae Plane Block|Before the general anesthesia Erector Spinae Plane Block was performed.
62849994|NCT03558880|ACTIVE_COMPARATOR|Tumescent Anesthesia|After the general anesthesia was given, 1 mL of 0.1% adrenaline (1/1000) and as 20 mL of 0.5% bupivacaine solution of tumescent in a total of 1000 mL Ringer's lactate applied by the surgeon applied equally to both breasts
62849995|NCT04497038|EXPERIMENTAL|Cabozantinib|Cabozantinib 20-60 mg by mouth once daily.
62061906|NCT04703296|EXPERIMENTAL|Mindfulness training (MT) group|Receives 4 weeks of mindfulness training followed by a testing session.
62061907|NCT04703296|NO_INTERVENTION|No-training control (NTC) group|Receives 4 weeks of no mindfulness training followed by a testing session.
62061908|NCT03450655|EXPERIMENTAL|Intervention Group|Weeks 1-10: exercise program in group. Weeks 11-20: no intervention. Weeks 21-31: no intervention.
62849996|NCT00791817|EXPERIMENTAL|200 mg PG 760564, Subjects Fasted|200 mg PG 760564, Subjects Fasted, single dose
62849997|NCT00791817|EXPERIMENTAL|200 mg PG 760564, Subjects Fed|200 mg PG 760564, Subjects Fed high fat meal
62266155|NCT04096196|ACTIVE_COMPARATOR|"Health education (control) group"|All students in the health education group will receive a comprehensive package on safety information. The information package includes both printed and electronic promotional materials regarding safety and a comprehensive list of relevant website and information sources. The information from these relevant websites and information sources are similar to those used in setting the safety case scenarios for the Safe City game. As a result, both intervention arms will have comparable accessibility to safety-related information and the major contrast between the two groups will be the method of presentation (game-based learning vs traditional health promotion approach, i.e. unidirectional information package).
62061909|NCT03450655|EXPERIMENTAL|Control group|Weeks 1-10: no intervention. Weeks 11-20: no intervention. Weeks 21-31: exercise program at home.
62266156|NCT00015977|EXPERIMENTAL|PSMA peptide vaccine|Immunization with PSMA peptide vaccine followed by injection of Interleukin-12 (IL-12) on Day 1 of a 21-day cycle. Additional injections of IL-12 given on Days 3 and 5 of each cycle.
62266157|NCT06096597|EXPERIMENTAL|Amniotic Membrane Therapy|Under general anesthesia, cystoscopy will be performed. A needle will be inserted into the detrusor muscle to a depth of approximately 2 mm. 100mg of commercially available micronized amniotic membrane (Clarix Flo; BioTissue, Miami, FL) diluted in 10 mL of 0.9% preservative-free sodium chloride, and 0.5 mL of the solution will be injected into 20 equally spaced sites into the posterior and lateral walls of the bladder, sparing the dome and the trigone.
62449579|NCT01654380|EXPERIMENTAL|Part A, Cohort B; LY2605541|Healthy participants received 15.3 mU/min in Period 1, 37.0 mU/min in Period 2, and 74.1 mU/min in Period 3, administered IV over 8 hours. All periods were separated by a minimum 6-day washout period.
62449580|NCT01654380|ACTIVE_COMPARATOR|Part A, Cohort B; Insulin Glargine|Healthy participants received insulin glargine (60 mU/m\^2/min) administered IV over 8 hours in Period 4. All periods were separated by a minimum 6-day washout period.
62449581|NCT01654380|EXPERIMENTAL|Part B; LY2605541|Participants with T1DM received 15.3 mU/min in 1 of 4 study periods, administered IV up to 8 hours and received 74.1 mU/min in 1 of 4 Periods, administered IV up to 10 hours. Each dose was separated by a minimum 6-day washout period.
62849998|NCT06092268|EXPERIMENTAL|Treatment Part A: SHR-A2009 for injection in combination with Almonertinib Mesilate Tablets|
62849999|NCT06092268|EXPERIMENTAL|Treatment Part B: SHR-A2009 for injection in combination with Adebrelimab Injection|
62850000|NCT01827423|EXPERIMENTAL|Surgical removal of sinonasal papiloma|The study group consisted of patients following a surgical removal of sinonasal papiloma, in which the SCCA blood levels were assessed in pre-defined intervals.
62850001|NCT02745015|EXPERIMENTAL|treatment|immediate non-surgical periodontal treatment
62449582|NCT01654380|ACTIVE_COMPARATOR|Part B; Insulin Glargine|Participants with T1DM received 1 insulin glargine dose per study period (10 and 20 mU/m\^2/min) administered IV over 8 hours in 2 of 4 study periods. Each dose was separated by a minimum 6-day washout period.
62449583|NCT03676777||Infection|Patients admitted or developed bacterial/fungal infection while hospitalization
62449584|NCT03676777||Non-infection|Patients without bacterial/fungal infection
62461305|NCT02303678|EXPERIMENTAL|D2C7-IT|Recurrent malignant glioma patients will receive D2C7-IT, delivered intratumorally by CED following confirmatory diagnostic biopsy.
62461306|NCT01458405|PLACEBO_COMPARATOR|Placebo|
62850002|NCT02745015|OTHER|control|non-surgical periodontal treatment scheduled for the following 3-monthly visit
62850003|NCT02091557||GnRH-analogue|CA125 levels and VAS pain score changes will be assessed after GnRH-a administration in all patients
62461307|NCT01458405|ACTIVE_COMPARATOR|CAP-1002 Allogeneic Cardiosphere-Derived Cells|
62461308|NCT05567614||75|patients with chronic hepatitis B infection will be collected and underwill liver fibroscan then corelate between platelets indicies and predict degree of liver fibrosis
62850004|NCT00654433|EXPERIMENTAL|I|
62850005|NCT05323058|EXPERIMENTAL|tulsi extract|4% tulsi extract as intervention
62850006|NCT05323058|ACTIVE_COMPARATOR|benzydamine hydrochloride|0.15% benzydamine hydrochloride
62850007|NCT05448443|EXPERIMENTAL|AD981|AD981
62850008|NCT05448443|PLACEBO_COMPARATOR|Placebo|Placebo
62850009|NCT02036970|EXPERIMENTAL|Part 1 Dose-Ranging Bardoxolone methyl 2.5 mg/Part 2: Open-Label|Participants received bardoxolone methyl 2.5 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 2.5 mg once-daily in Part 2 (Week 16 and onwards)
62850010|NCT02036970|EXPERIMENTAL|Part 1: Dose-Ranging Bardoxolone methyl 5 mg/Part 2: Open-Label|Participants received bardoxolone methyl 5 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 5 mg once-daily in Part 2 (Week 16 and onwards)
62850011|NCT02036970|EXPERIMENTAL|Part 1: Dose-Ranging Bardoxolone methyl 10 mg/Part 2: Open-Label|Participants received bardoxolone methyl 10 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 10 mg once-daily in Part 2 (Week 16 and onwards)
62061910|NCT00405639|ACTIVE_COMPARATOR|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is \>90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
62061911|NCT00405639|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive self administered SQ placebo (normal saline) injections to match those of the study drug group. That is, first dose on Day 1, second dose 12 hours after the first dose, third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
62061912|NCT04623320||NAFLD+T1DM+|Subjects with type 1 diabetes and ultrasound-defined NAFLD
62061913|NCT04623320||NAFLD-T1DM+|Subjects with type 1 diabetes without ultrasound-defined NAFLD
62266158|NCT06096597|PLACEBO_COMPARATOR|Placebo|Under general anesthesia, cystoscopy will be performed. A needle will be inserted into the detrusor muscle to a depth of approximately 2 mm. 0.5 mL of 10 mL of 0.9% preservative-free sodium chloride will be injected into 20 equally spaced sites into the posterior and lateral walls of the bladder, sparing the dome and the trigone.
62850012|NCT02036970|EXPERIMENTAL|Part 1: Dose-Ranging Bardoxolone methyl 20 mg/Part 2: Open-Label|Participants received bardoxolone methyl 20 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 20 mg once-daily in Part 2 (Week 16 and onwards)
62850013|NCT02036970|PLACEBO_COMPARATOR|Part 1: Dose-Ranging Placebo 2.5 mg/Part 2: Bardoxolone methyl 2.5 mg|Participants received bardoxolone methyl 2.5 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 2.5 mg once-daily in Part 2 (Week 16 and onwards)
62850014|NCT02036970|PLACEBO_COMPARATOR|Part 1: Dose-Ranging Placebo 5 mg/Part 2: Bardoxolone methyl 5 mg|Participants received bardoxolone methyl 5 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 5 mg once-daily in Part 2 (Week 16 and onwards)
62850015|NCT02036970|PLACEBO_COMPARATOR|Part 1: Dose-Ranging Placebo 10 mg/Part 2: Bardoxolone methyl 10 mg|Participants received bardoxolone methyl 10 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 10 mg once-daily in Part 2 (Week 16 and onwards)
62850016|NCT02036970|PLACEBO_COMPARATOR|Part 1: Dose-Ranging Placebo 20 mg/Part 2: Bardoxolone methyl 20 mg|Participants received bardoxolone methyl 20 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 20 mg once-daily in Part 2 (Week 16 and onwards)
62850017|NCT02036970|EXPERIMENTAL|Part 1: Dose Titration: Bardoxolone methyl 10 mg/Part 2: Bardoxolone methyl 10 mg|Participants in Part 1 started with bardoxolone methyl 5 mg once-daily from Day 1 and escalated to bardoxolone methyl 10 mg once-daily starting at Week 4 thru Week 16. Participants who continued to Part 2 continued to receive the same bardoxolone methyl dose once-daily in Part 2 (Week 16 and onwards)
62266159|NCT01696240|PLACEBO_COMPARATOR|Placebo|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
62266160|NCT01696240|ACTIVE_COMPARATOR|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
62266161|NCT03162770|EXPERIMENTAL|Intervention Group|This group will receive the Mindfulness meditation practice and after that patients will not receive any other intervention.
62266162|NCT03162770|NO_INTERVENTION|No Control Group|Initially this control group will wait and after 12 weeks this group will receive the intervention
62266163|NCT03239366|ACTIVE_COMPARATOR|Active arm|Active product 'BioK+ 100% probiotic: Bio-K+50B® probiotic will be administered orally for a period of 12 weeks. Dose: two (2) capsules of 50 billion (B) colony forming units (CFU) providing a dosage of 100 billion CFU per day
62266164|NCT03239366|PLACEBO_COMPARATOR|Placebo arm|Placebo product (without the 3 strains of bacterias) will be administered orally for a period of 12 weeks. Dose: Two (2) capsules of Placebo per day
62266165|NCT05817877||over 5 hours|people with an average daily phone use of more than 5 hours.
62266166|NCT05817877||under 5 hours|People with an average daily phone use of less than 5 hours.
62461309|NCT03223233||No secondary suture|The participants who developed post-cesarean surgical site infection and follow-up only antibiotic treatment for their wound care.
62061914|NCT00067990|EXPERIMENTAL|Losartan 100mg|Losartan 100 mg per day to be started within three months of transplantation and continuing treatment for five years.
62061915|NCT00067990|PLACEBO_COMPARATOR|Placebo|No intervention with continuing follow-up for five years.
62061916|NCT06291155|OTHER|SGLT2i Arm|
62061917|NCT03443713|EXPERIMENTAL|Aerobic exercise|Subjects in this arm will complete aerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
62061918|NCT03443713|EXPERIMENTAL|Anaerobic exercise|Subjects in this arm will complete anaerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
62061919|NCT03443713|EXPERIMENTAL|High intensity interval exercise|Subjects in this arm will complete high intensity interval exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
62061920|NCT06624423|NO_INTERVENTION|Control group|Control Group treated with only antihypertensive medications
62061921|NCT06624423|EXPERIMENTAL|Treatment group 1|T1 group treated with 2g of Corn Silk Tea twice per day.
62061922|NCT06624423|EXPERIMENTAL|Treatment group 2|T2 group treated with 4g of Corn Silk tea twice per day
62061923|NCT04425343|EXPERIMENTAL|Periodontitis, Adult|Plaque samples were taken from subgingival pocket and send to the lab for metagenomic analysis
62061924|NCT04425343|EXPERIMENTAL|Metgenomic analysis|Analysis for whole bacterial count
62850018|NCT02036970|PLACEBO_COMPARATOR|Part 1: Dose Titration: Placebo 10 mg/Part 2: Bardoxolone methyl 10 mg|Participants in Part 1 received Placebo once-daily from Day 1 thru Week 16. Participants who continued to Part 2 initially received bardoxolone methyl 5 mg once-daily from Week 16 thru Week 20 and bardoxolone methyl 10 mg from week 20 onwards
62624069|NCT03272347|ACTIVE_COMPARATOR|DOR/3TC/TDF|Participants will be treated QD with placebo to islatravir, placebo to DOR, placebo to 3TC, and a fixed dose combination of DOR/3TC/TDF consisting of 100 mg DOR + 300 mg 3TC + 300 mg TDF for a minimum of 24 weeks. Between week 24 through week 52 placebo treatments may be discontinued and participants will receive only DOR/3TC/TDF QD open label up to Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
62850019|NCT01831583|EXPERIMENTAL|Measurement of PPG waveforms|Collection of photoplethysmograph(PPG)waveform data from patients with obstructive sleep apnea for 4-8 hours
62850020|NCT01831583|EXPERIMENTAL|Measurement of Pulse Arrival Time (PAT)|Collection of PAT waveform data from patients with obstructive sleep apnea for 4-8 hours
62850021|NCT05262829|EXPERIMENTAL|MSCs local treatment group/combined treatment group|In the local treatment group, 60 million umbilical cord MSCs were injected into the diseased intestinal mucosa on the first day. In the combined treatment group, 60 million umbilical cord MSCs were injected into the diseased intestinal mucosa on the first day; on the second day, 1 million cells/kg of body weight were administered intravenously.
62850022|NCT02160899|PLACEBO_COMPARATOR|Cohort A: Placebo|Participants will receive placebo (normal saline) subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
62061925|NCT04547439|ACTIVE_COMPARATOR|Control|Placebo
62061926|NCT04547439|ACTIVE_COMPARATOR|Melatonin|Melatonin
62461310|NCT03223233||Secondary suture|The participants who developed post-cesarean surgical site infection and need a secondary suture for their wound care
62061927|NCT02648984|OTHER|Patient group|Patients with ventricular septal defect
62624070|NCT06609642|EXPERIMENTAL|Young adults|Male and female, aged 18 to 35 years
62266167|NCT02520232|EXPERIMENTAL|Physical activity program (A)|Physical exercises
62461311|NCT00790959|EXPERIMENTAL|SASA!|
62461312|NCT00790959|ACTIVE_COMPARATOR|Control|
62061928|NCT02648984|OTHER|Control group|Healthy control subjects
62061929|NCT02412501|OTHER|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent
62061930|NCT01233583||Betamethasone/Calcipotriol (Dovobet)|patients in whom decision to treat with Dovobet by their dermatologist
62061931|NCT01233583||Acitretin (neotigason)|patients in whom decision to treat with neotigason by their dermatologist
62061932|NCT01233583||narrow-band UVB|patients in whom decision to treat with narrow band UVB by their dermatologist
62061933|NCT01233583||Anti TNF-alpha|patients in whom decision to treat with anti TNF-alpha(adalimumab-etanercept-infliximab) by their dermatologist
62061934|NCT01885260|EXPERIMENTAL|ISIS-GCGRRx Dose Level 1|ISIS-GCGRRx Dose Level 1
62061935|NCT01885260|EXPERIMENTAL|ISIS-GCGRRx Dose Level 2|ISIS-GCGRRx Dose Level 2
62061936|NCT01885260|PLACEBO_COMPARATOR|Placebo|Placebo
62061937|NCT02671383|ACTIVE_COMPARATOR|Darunavir|Darunavir/Ritonavir 400/100mg once daily
62061938|NCT02671383|ACTIVE_COMPARATOR|Lopinavir|Lopinavir/Ritonavir 400/100mg twice daily
62266168|NCT02520232|EXPERIMENTAL|Physical activity program (B)|Physical exercises
62266169|NCT02520232|NO_INTERVENTION|Control|No physical exercices assigned by the protocol
62266170|NCT00814775|ACTIVE_COMPARATOR|Group 1|Fastrach Laryngeal Mask Airway intubation
62266171|NCT00814775|ACTIVE_COMPARATOR|Group 2|Intubation of difficult airway using CTrach Laryngeal Mask
62266172|NCT03067883|EXPERIMENTAL|interventional Qurevo group|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.~* These patients will receive intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.~* Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).~* Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
62624071|NCT06609642|EXPERIMENTAL|Old adults|Male and female, aged 60 years and more
62624072|NCT05194683|EXPERIMENTAL|Letter Writing Arm|Relational letter writing intervention
62850023|NCT02160899|EXPERIMENTAL|Cohort A: ISIS-APO(a)Rx < 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
62850024|NCT02160899|EXPERIMENTAL|Cohort A: ISIS-APO(a)Rx >= 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
62850025|NCT02160899|PLACEBO_COMPARATOR|Cohort B: Placebo|Participants will receive placebo (normal saline) subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
62850026|NCT02160899|EXPERIMENTAL|Cohort B: ISIS-APO(a)Rx < 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
62624073|NCT05194683|NO_INTERVENTION|Control Arm|No intervention
62850027|NCT02160899|EXPERIMENTAL|Cohort B: ISIS-APO(a)Rx >= 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
62850028|NCT03603678|EXPERIMENTAL|Part A single dose BAY2253651|Single dose BAY2253651
62850029|NCT03603678|PLACEBO_COMPARATOR|Part A single dose Placebo|Single dose matching placebo
62850030|NCT03603678|EXPERIMENTAL|Part B multiple dose BAY2253651|Multiple dose BAY2253651 on 5 consecutive nights
62850031|NCT01667419|EXPERIMENTAL|Cohort 1 Vemurafenib|Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib, 960 milligrams (mg) twice daily, in 28-day cycles, for up to 52 weeks
62850032|NCT01667419|PLACEBO_COMPARATOR|Cohort 1 Placebo|Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks
62850033|NCT01667419|EXPERIMENTAL|Cohort 2 Vemurafenib|Participants with Stage IIIC cutaneous melanoma received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks
62461313|NCT04963725||Participants Initiating Therapy with Ustekinumab|Data will be collected for participants in Japan who have had an inadequate response, or been intolerant to, conventional or biologic therapies. The treating physician has made the decision to initiate ustekinumab induction therapy in the routine clinical practice - either as a first or subsequent biologic therapy initiating for their moderate to severe ulcerative colitis.
62461314|NCT00113789|ACTIVE_COMPARATOR|Pegfilgrastim|
62850034|NCT01667419|PLACEBO_COMPARATOR|Cohort 2 Placebo|Participants with Stage IIIC cutaneous melanoma received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks
62850035|NCT06088472|EXPERIMENTAL|TIL injection treatment group|
62850036|NCT03007641|EXPERIMENTAL|Provider Didactic Intervention|"Phase 1 - Providers complete a needs assessment questionnaire.~Phase 2 - Providers participate in an hour long didactic session, and begin enrolling eligible metastatic breast cancer (MBC) patients. Enrolled MBC patients complete a comprehensive geriatric assessment (CGA). Providers complete a treatment plan questionnaire and a CGA utility questionnaire.~Phase 3 - Providers are administered a final questionnaire evaluating their overall view of this educational intervention."
62850037|NCT01828151||Developed skin lesions|Patients treated with noninvasive ventilation for an episode of acute respiratory failure
62850038|NCT01316198|EXPERIMENTAL|Lutein and zeaxanthin|
62850039|NCT01316198|EXPERIMENTAL|Placebo|
62850040|NCT01401660||Group A|Subjects who do not currently have low back pain.
62850041|NCT01401660||Group B|Subjects who have low back pain at the time of the study, and who are currently being treated or have been previously treated for their low back pain and do not wish to receive further treatment for their pain.
62850042|NCT01401660||Group C|Subjects who have low back pain at the time of the study, and wish to receive physical therapy to reduce their low back pain.
62850043|NCT02862340|OTHER|Autistic disorder|Children over 4 years with an autistic disorder of unknown etiology with the techniques currently available and accessible in routine diagnostics.
62061939|NCT00325221|EXPERIMENTAL|Home Monitoring On|Home Monitoring activated after implantation (Intervention HM On)
62061940|NCT00325221|EXPERIMENTAL|Home Monitoring Off|Home Monitoring activated 9 months after implantation (Intervention HM Off)
62461315|NCT00113789|PLACEBO_COMPARATOR|Placebo|
62461316|NCT05677698|EXPERIMENTAL|Peppermint oil|Peppermint oil has an effect on menopausal symptoms
62461317|NCT05677698|EXPERIMENTAL|Lemon oil|Lemon oil has an effect on menopausal symptoms.
62624074|NCT00966407||Healthy Young Adults|College-age (18-35 years) participants recruited from Howard University, East Carolina University, and University of Massachusetts, Amherst, University of Calgary, Winston-Salem University
62624075|NCT04423562||Durable LVAD recipient with post implant VO2|
62624076|NCT04582383|EXPERIMENTAL|Spironolactone|In this arm, participants will receive spironolactone 100mg/day for the entirety of the study. To maximize the generalizability of the study, participants will be allowed to continue their current topical regimen as long as no changes were made in the 4 weeks prior to randomization. No additions to their topical regimen may be made during the study period.
62061941|NCT00550550|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62061942|NCT00550550|EXPERIMENTAL|SCH 697243|Grass Sublingual Tablet (Phleum pratense extract)
62061943|NCT04152343|EXPERIMENTAL|RFA Physics Library- PGP|The RFA Physics Library will be used during during percutaneous liver RFA procedures.
62061944|NCT06261684|EXPERIMENTAL|Intralesional Acyclovir|Intralesional acyclovir will be prepared by diluting 1 ampoule of Acyclovir 250mg into 3.5ml of saline solution to achieve a concentration of approximately 70mg/ml. Then 0.1ml will be injected intra-lesionally into the base of the wart. Any hyperkeratotic lesions should be pared before the treatment. This process will be repeated every 2 weeks for 5 sessions, and can be discontinued if complete resolution is achieved early.
62061945|NCT06261684|ACTIVE_COMPARATOR|Cryotherapy|Patients allocated to Group B will undergo cryotherapy using a liquid nitrogen spray gun. Any hyperkeratotic lesions should be pared before the treatment. Two freeze-thaw cycles will be applied each session, the spray gun should be held 1cm away from the wart and maintained until the wart and the 1-3mm of surrounding skin shows freezing, and each cycle should last 15 seconds. Next, the lesion will be left to thaw completely before starting the second cycle. This process will be repeated every 2 weeks for 5 sessions, and can be discontinued if complete resolution is achieved early
62061946|NCT01382602|EXPERIMENTAL|AMDC-USR|Subjects received 1 or 2 treatments of 150 million AMDC-USR delivered via transurethral intrasphincteric injection. After completing 12 months follow-up subjects were unblinded. Subjects were followed for 2 years after initial AMDC-USR treatment.
62449585|NCT01941095|EXPERIMENTAL|Tocilizumab|Participants will receive tocilizumab 162 milligrams (mg) SC injection once a week (QW) either as monotherapy or in combination with methotrexate or other non-biologic DMARDs during the treatment period of 52 weeks. The choice of monotherapy or combination treatment is according to the physician's judgment up to Week 24. Depending upon the participant's response to study regimen at Week 24, participant may either continue/discontinue/switch to tocilizumab monotherapy or may lead to intensification of methotrexate/non-biologic DMARDs with tocilizumab at a fixed dose of 162 mg SC QW till Week 52. After Week 52, participants who remain in study will enter a 8 week wash-out period and then (from Week 60) will proceed to the extension phase until tocilizumab is commercially available in Greece. Permitted DMARDs include methotrexate, azathioprine, chloroquine, hydroxychloroquine, leflunomide, and sulfasalazine.
62850044|NCT04380519|EXPERIMENTAL|RPH -104 80 mg|Subject randomized to receive subcutaneous single injection of 2 ml solution of RPH-104 on Day 1, in addition to standard therapy
62850045|NCT04380519|EXPERIMENTAL|Olokizumab 64 mg|Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy
62850046|NCT04380519|PLACEBO_COMPARATOR|Placebo|Subject randomized to receive subcutaneous single injection of 2 ml solution of Placebo on Day 1, in addition to standard therapy
62850047|NCT02340351|ACTIVE_COMPARATOR|Auricular acupuncture|Within this arm, patients were treated with auricular acupuncture according to the NADA protocol. Each setting involved not more than eight patients at a time and was performed in a sitting position. Each session lasted 30 minutes and took place twice a week over a period of 4 weeks.
62061947|NCT01382602|PLACEBO_COMPARATOR|Placebo|Subjects received 1 or 2 treatments of placebo delivered via transurethral intrasphincteric injection. After completing 12 months follow-up subjects were unblinded and could elect to receive open-label AMDC-USR treatment. Subjects that received unblinded AMDC-USR treatment were followed for 2 years after initial placebo treatment.
62061948|NCT05578586|EXPERIMENTAL|Experimental vs Control|The patients who are randomized to receive meropenem 1 gram 6 times daily in 15 minutes infusions.
62061949|NCT05578586|ACTIVE_COMPARATOR|Controls|The patients who are randomized to receive meropenem 2 gram 3 times daily in 3 hours infusions.
62061950|NCT05829980||Group A|Contoura topography-guided LASIK
62461318|NCT05677698|PLACEBO_COMPARATOR|almond oil|Almond oil has an effect on menopausal symptoms.
62850048|NCT02340351|ACTIVE_COMPARATOR|Progressive muscle relaxation|Within this arm, patients were treated with who chose treatment with progressive muscle relaxation. Each setting involved not more than eight patients at a time and was performed in a sitting position. Each session lasted 30 minutes, took place twice a week over a period of 4 weeks.
62850049|NCT03482934||hypertensive patients|
62850050|NCT05067309||Missed abortion received letrozole then misoprostol|
62850051|NCT05067309||Missed abortion received misoprostol alone|
62850052|NCT04158843|EXPERIMENTAL|Radical local treatment|Radical resection is performed, and the cutting edge is negative, or radical local radiotherapy is feasible (cumulative radiotherapy dose is greater than or equal to 50Gy). Systemic endocrine therapy and targeted therapy are allowed after radical local therapy. However, whether systemic chemotherapy should be used is determined by clinicians according to clinical experience or guidelines.
62850053|NCT04158843|ACTIVE_COMPARATOR|Palliative treatment|No radical surgical resection or radical surgical resection or radiotherapy is performed in this group. But palliative internal fixation or radiotherapy for pain relief is permitted. Moreover, systemic chemotherapy, endocrine therapy and targeted therapy are allowed.
62850054|NCT04680182|EXPERIMENTAL|Study group|Wound drain is kept until until a scheduled visit three weeks after the surgery unless the drain produced less than 30 ml/day for two consecutive days, in which case it could be removed earlier.
62061951|NCT05829980||Group B|Contoura topography-guided PRK
62061952|NCT05829980||Group C|Wavefront-optimized LASIK
62061953|NCT05829980||Group D|Wavefront-optimized PRK
62266173|NCT05972811|EXPERIMENTAL|Cold application|"A frozen ice pack at -10 °C will be prepared for the patients in the experimental group. With these ice packs, the JP will be cooled to 13.6 °C, taking into account the literature, in order to create a local anesthetic effect on the drain outlet area before the drain is removed. Skin temperature will be measured intermittently with an infrared thermometer. When the skin temperature reaches 13.6 °C, the doctor will be informed and the drain will be removed. Before starting the cold application, immediately after the drain is removed, and after 15 minutes, considering the literature, pain will be measured with the Visual Analog Scale. By ensuring that the drain removal procedure is performed by the same physician, individual differences that may arise will be prevented."
62266174|NCT05972811|NO_INTERVENTION|Control|No treatment will be applied to the patients in the control group. Pain measurement will be made with Visual Analog Scale before drain removal, immediately after drain removal, and 15 minutes later.
62266175|NCT04739514|ACTIVE_COMPARATOR|Mild dysphagia|
62266176|NCT04739514|ACTIVE_COMPARATOR|Moderate dysphagia|
62266177|NCT04739514|ACTIVE_COMPARATOR|Severe dysphagia|
62266178|NCT02193074|EXPERIMENTAL|nusinersen|
62266179|NCT02193074|SHAM_COMPARATOR|Sham procedure|
62266180|NCT01014689|ACTIVE_COMPARATOR|Adapalene 0.1% / BPO 2.5% gel|
62449586|NCT03262181|EXPERIMENTAL|Isometric Exercise Condition|The participant will perform 5 sets of a 45-second isometric contractions at 70% of their maximum voluntary isometric contraction (MVIC). During the 45-second contraction, the participant will be provided with visual biofeedback on a computer screen (70% MVIC target line and +/- 5% error lines). The participant will be instructed to produce a level of isometric quadriceps contraction that maintains the isometric torque output line as close the target line as possible and always between the two error lines.
62461319|NCT04059965|EXPERIMENTAL|Intervention Arm|This cohort of patients will receive panel management through a customize software that integrates with the electronic health record
62850055|NCT04680182|ACTIVE_COMPARATOR|Control group|When the drain produces less than 100 mL over 24 hours, the self-suction bulb is removed and the drain is shortened and drained into a colostomy bag placed around the site of drain insertion. A request is filed with the community nursing system to have a visiting nurse to pull out the drain 1-2 cm per day.
62850056|NCT05483218|EXPERIMENTAL|wrist orthosis|group benefiting from an orthosis that supports the wrist by covering the palm of the hand only
62850057|NCT05483218|EXPERIMENTAL|wrist-hand-finger orthosis|group benefiting from an orthosis that supports the wrist by covering the palm of the hand and the fingers
62850058|NCT00697138|EXPERIMENTAL|A|
62850059|NCT05996913|EXPERIMENTAL|Intervention|Imagery rescripting intervention for somatic flashback
62850060|NCT00922727|ACTIVE_COMPARATOR|L. reuteri|Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment and maintenance of a well-functioning gastro-intestinal (GI) tract microflora and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment. The oil drops contain a dietary supplement of Lactobacillus reuteri DSM 17938.
62850061|NCT00922727|PLACEBO_COMPARATOR|Sunflower Oil|Placebo will be the equivalent number of drops of suspended sunflower oil (without LR), provided by Biogaia.
62850062|NCT05710445|EXPERIMENTAL|Augmented Reality|Subjects in this group will have their intravenous catheter placed while the physician uses a mixed reality headset to view the ultrasound images being used to guide the catheter placement.
62850063|NCT05710445|NO_INTERVENTION|Control|Subjects in this group will have their intravenous catheter placed using standard of care. The physician will use the monitor on the ultrasound machine only to view the ultrasound images being used to guide the catheter placement.
62850064|NCT05041608||Subjects undergoing Endoscopic Surgery|These procedures include: POEM (Peroral Endoscopic Myotomy) for Achalasia, G-POEM (Gastric Peroral Endoscopic Myotomy) for gastric outlet obstruction, Z-POEM (Peroral endoscopic myotomy for Zenker's Diverticulum), EMR (Endoscopic Mucosal Resection), ESD (Endoscopic submucosal dissection), STER (Submucosal tunneling endoscopic resection), NOTES (Natural Orifice Translumenal Endoscopic Surgery), TIF (Transoral Incisionless Fundoplication), Endoscopic Fistula Closure, Endoscopic Suturing, Capsule Endoscopy and EFTR (Endoscopic full-thickness resection).
62850065|NCT02265159|OTHER|Focal Therapy Using High Intensity Focused Ultrasound|
62850066|NCT01808092|EXPERIMENTAL|CAZ-AVI|Intra-Venous treatment
62850067|NCT01808092|ACTIVE_COMPARATOR|Meropenem|Intra-Venous treatment
62850068|NCT03712085|ACTIVE_COMPARATOR|Treatment Group A|Abdominal acupuncture and upper limb rehabilitation training
62850069|NCT03712085|SHAM_COMPARATOR|Treatment Group B|Sham abdominal acupuncture and upper limb rehabilitation training
62850070|NCT03712085|NO_INTERVENTION|Control Group|Upper limb rehabilitation only
62266181|NCT01014689|PLACEBO_COMPARATOR|Adapalene 0.1% / BPO 2.5% Vehicle Gel|
62266182|NCT01888185||Parkinson's Disease (PD)|Patients with a clinical diagnosis of PD (in various stages)
62266183|NCT01888185||Progressive supranuclear palsy (PSP)|Patients with a clinical diagnosis of PSP (in various stages)
62266184|NCT01888185||Multiple system atrophy (MSA)|Patients with a clinical diagnosis of MSA (in various stages)
62266185|NCT01888185||Controls|Age and gender-matched adults free from neurological disease
62461320|NCT04059965|ACTIVE_COMPARATOR|Control Arm|This cohort of patients will receive usual care
62850071|NCT03702881|EXPERIMENTAL|Bonded Spurs associated with posterior build-ups Group|The experimental group will consist of 25 patients treated with bonded spurs associated with build-ups.
62624077|NCT04582383|ACTIVE_COMPARATOR|Doxycycline hyclate|This arm is an active-comparator arm in which participants will receive doxycycline hyclate 100mg/day for the entirety of the study. To maximize the generalizability of the study, participants will be allowed to continue their current topical regimen as long as no changes were made in the 4 weeks prior to randomization. No additions to their topical regimen may be made during the study period.
62061954|NCT00555022|EXPERIMENTAL|All subjects|Eligible subjects will receive one of the following treatment in cohort I and cohort II in five different treatment periods; Placebo, GSK1160724 (10 micrograms, 50 micrograms or 125 micrograms) and tiotropium bromide
62266186|NCT05071950|OTHER|14 days continuous glucose monitoring|The participants started and completed the control period for continuous 7 days and followed with D-allulose period for 7 days
62266187|NCT00576043|ACTIVE_COMPARATOR|1: Training|3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator
62624078|NCT00038805|EXPERIMENTAL|Mylotarg|
62449587|NCT03262181|SHAM_COMPARATOR|Sham TENS Condition|"Two electrodes of the Select System TENS unit (Empi, Inc., St. Paul, MN) will be placed on either side of the patellar tendon on the test limb. The same instruction script will be used for each participant, stating, A surface electrode has been placed on either side of your patellar tendon. I will turn on the stimulation unit to emit a stimulus to your patellar tendon. This is a special sub-sensory stimulation treatment, so you will not feel anything during this period as the stimulus is set at a very low, non-detectable threshold. Please remain still during this 45-second period, letting your leg rest passively in the machine without contracting your leg muscles. After the 45-second period, the stimulation unit will be turned off and you will have a 2-minute rest period. We will repeat this same treatment/rest sequence 5 total times."
62624079|NCT03508180|EXPERIMENTAL|foot reflexology|patients WITH foot reflexology session during chemotherapy treatments
62850072|NCT03702881|ACTIVE_COMPARATOR|Conventional bonded spurs Group|Active comparator group will consist of 25 patients treated with conventional bonded spurs
62266188|NCT00576043|NO_INTERVENTION|2: No Training|No simulator training before starting endoscopy training on real patients
62266189|NCT01197404|ACTIVE_COMPARATOR|General Health Promotion|
62850073|NCT04708249|EXPERIMENTAL|D-chiroinositol treatment|
62266190|NCT01197404|EXPERIMENTAL|Affect Management|
62850074|NCT00597597|EXPERIMENTAL|Open label Erlotinib|Open label; In this open label study, all enrolled subjects receive active drug, Erlotinib
62850075|NCT06517030|EXPERIMENTAL|Test group (DBBM+HA)|In Test group, the gap between the implant surface and the bone plates will be filled with deproteinized bovine bone mineral with hyaluronic acid (Botiss Cerabone Plus; Botiss biomaterials, Hauptstr. 28 15806 Zossen, Germany). The material will be pre-wetted in saline, inserted in the gap and once soaked in blood, it will be gently pressed to the bone walls to completely fill the space and around buccal aspects of the exposed implant surface, up to the top of the abutment.
62266191|NCT01659008|EXPERIMENTAL|estradiol|estradiol PO 0.5mg 2 tabs three times a day for 2 days
62266192|NCT01659008|EXPERIMENTAL|Lysteda|Lysteda 650mg PO 2 tabs three times a day for 2 days
62624080|NCT03508180|PLACEBO_COMPARATOR|platinum-based treatment|Patients WITHOUT ANY foot reflexology session during chemotherapy treatments
62624081|NCT03513471|EXPERIMENTAL|Anakinra then Placebo Treatment|Subjects randomized to this arm will receive the experimental treatment of Anakinra on their first exposure to the Dermatophagoides Farinae (dust mite) allergen challenge, followed by the Anakinra matching placebo on their second exposure.
62850076|NCT06517030|ACTIVE_COMPARATOR|Control group (DBBM)|In Control group, deproteinized bovine bone mineral (DBBM) (Bio-Oss Collagen; Geistlich Pharma, Wolhusen, Switzerland) will be positioned in the gap. The material will be pre-wetted in saline, inserted in the gap and once soaked in blood, it will be gently pressed to the bone walls to completely fill the space and around buccal aspects of the exposed implant surface, up to the top of the abutment.
62850077|NCT03502551|EXPERIMENTAL|Treatment with Ketamine|In this arm an IV infusion of 0.5 mg/kg of ketamine will be administered over 40 minutes.
62061955|NCT00980005|EXPERIMENTAL|Flulaval Group|"subjects received Flulaval™ vaccine according to their priming status and age:~* 3-8 years: primed subjects 1 dose at Day 0; unprimed subjects 1 dose at Day 0 and a second dose at Day 28~* 9-17 years: 1 dose at Day 0 Flulaval vaccine was administered intramuscularly into the non-dominant deltoid."
62266193|NCT05807061|EXPERIMENTAL|EmBARK|Parents receive a narrated training program about children's racial biases and read books that are focused on race with their children.
62449588|NCT00203307|OTHER|Olanzapine then Placebo|Olazepam
62624082|NCT03513471|EXPERIMENTAL|Placebo then Anakinra Treatment|Subjects randomized to this arm will receive the inactive placebo on their first exposure to the Dust Mite Allergen challenge, followed by the experimental treatment of Anakinra on their second exposure.
62850078|NCT02857634||Bladder tumor resection|
62061956|NCT00980005|ACTIVE_COMPARATOR|Fluzone Group|"subjects received Fluzone® Sanofi Pasteur's vaccine according to their priming status and age:~* 3-8 years: primed subjects 1 dose at Day 0; unprimed subjects 1 dose at Day 0 and a second dose at Day 28~* 9-17 years: 1 dose at Day 0 Fluzone vaccine was administered intramuscularly into the non-dominant deltoid."
62061957|NCT06625658|EXPERIMENTAL|clear aligner therapy|
62266194|NCT05807061|EXPERIMENTAL|Popular guidance|Parents receive interesting popular press articles about children's racial biases and read books that are focused on race with their children.
62449589|NCT00203307|OTHER|Placebo then olanzapine|
62449590|NCT05063461|EXPERIMENTAL|Sevoflurane with different site effect concentrations of remifentanil|The tetanic stimulus is conducted between laryngeal mask intubation and surgical stimulation, while no other noxious stimuli are presented. The effect site concentration of remifentanil is increased step-by-step via a Target Controlled infusion device to a concentration of 2, 4, 6 ng/ml. At least 5min of the steady-state period is maintained before tetanic stimulus.
62850079|NCT00635258||GnRH-ant|Patients were treated with a GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
62449591|NCT04685421|EXPERIMENTAL|Liposomal Bupivacaine PK|Liposomal Bupivacaine PKs collections up to 96 hours on children from 2 to 17 years in pediatric cardiac surgeries.
62850080|NCT00635258||GnRH-a|GnRH long protocol using 0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state. Furthermore, the triptorelin administration was maintained until the day of donor's hCG administration.
62449592|NCT03673826|EXPERIMENTAL|Arm A|Rd combination (Cycles 1-9 lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).
62449593|NCT03673826|EXPERIMENTAL|Arm B|KRd combination (Cycles 1-9 carfilzomib 20/36 mg/m2, lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).
62850081|NCT00495898|EXPERIMENTAL|1|CYPHER sirolimus-eluting stent
62850082|NCT00495898|ACTIVE_COMPARATOR|2|uncoated Bx VELOCITY balloon-expandable stent
62850083|NCT04339244|ACTIVE_COMPARATOR|ONSD measurement under lower blood pressure|ONSD measurement under mean blood pressure of 60\~70 mmHg
62850084|NCT04339244|ACTIVE_COMPARATOR|ONSD measurement under highly normal blood pressure|ONSD measurement under mean blood pressure of 90\~100 mmHg
62850085|NCT03568656|EXPERIMENTAL|CCS1477 dose escalation - mCRPC|CCS1477 monotherapy in patients with mCRPC
62850086|NCT03568656|EXPERIMENTAL|CCS1477 expansion phase - mCRPC|CCS1477 monotherapy in patients with mCRPC
62850087|NCT03568656|EXPERIMENTAL|CCS1477 and abiraterone acetate, combination dose finding and expansion - mCRPC|CCS1477 plus abiraterone acetate in patients with mCRPC
62850088|NCT03568656|EXPERIMENTAL|CCS1477 and enzalutamide, combination dose finding and expansion - mCRPC|CCS1477 plus enzalutamide in patients with mCRPC
62850089|NCT03568656|EXPERIMENTAL|CCS1477 Monotherapy - Solid tumours|CCS1477 expansion phase in patients with advanced solid tumours with molecular markers which may indicate potential for response to p300/CBP inhibition
62850090|NCT03568656|EXPERIMENTAL|CCS1477 and darolutamide, combination dose finding and expansion - mCRPC|CCS1477 plus darolutamide in patients with mCRPC
62266195|NCT05807061|EXPERIMENTAL|Practice first|Parents practice discussing books about animals with their children first, and then receive a narrated training program about children's racial biases and read books that are focused on race with their children.
62449594|NCT00775697|EXPERIMENTAL|Montelukast|the single arm will receive montelukast
62461321|NCT02291900|ACTIVE_COMPARATOR|medial femoral condyle|Patients in this arm receive core decompression followed by free vascularized medial femoral condyle graft
62850091|NCT03568656|EXPERIMENTAL|CCS1477 and olaparib, combination dose finding and expansion - mCRPC and metastatic breast cancer|CCS1477 plus olaparib in patients with mCRPC or metastatic breast cancer.
62850092|NCT03568656|EXPERIMENTAL|CCS1477 and atezolizumab, combination dose finding and expansion - non-small cell lung cancer|CCS1477 plus atezolizumab in patients with non-small cell lung cancer
62850093|NCT01485172|EXPERIMENTAL|ropinirole|ropinirole 2, 4, 8, 12, or 24 mg/day
62850094|NCT01485172|PLACEBO_COMPARATOR|placebo|placebo comparator 2, 4, 8, 12, or 24 mg/day
62266196|NCT03724864|EXPERIMENTAL|Stevia snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
62624083|NCT05742074|EXPERIMENTAL|FMT (faecal microbiota transplantation)|25-30 capsules of faecal material.
62461322|NCT02291900|ACTIVE_COMPARATOR|core decompression|Patients in this arm receive core decompression followed by osseous autograft from the iliac crest
62850095|NCT04230252|EXPERIMENTAL|Treatment Sequence 1: Reference Drug + Test Drug (RT)|Participants will receive 8 hour (H) extended-release (ER) acetaminophen tablet orally in period 1 (Reference) followed by newly formulated acetaminophen tablet orally in period 2 (Test). Each period will be separated by a washout period of at least 7 days.
62850096|NCT04230252|EXPERIMENTAL|Treatment Sequence 2: Test Drug + Reference Drug (TR)|Participants will receive newly formulated acetaminophen tablet orally in period 1 (Test) followed by 8 hour ER acetaminophen tablet orally in period 2 (Reference). Each period will be separated by a washout period of at least 7 days.
62850097|NCT04340271|EXPERIMENTAL|Extracorporeal shock wave therapy group|Patients in the ESWT group were explained to select the most hypertrophic and retracting area for the treatment on dominant hand. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave (Fig. 2). ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
62850098|NCT04340271|SHAM_COMPARATOR|sham stimulation group|The same shock wave equipment used in the experimental group was used with a sham adapter that had the same shape but emitted no energy
62850099|NCT03288142|EXPERIMENTAL|Intervention: Hypertension Coaching Application and Home Monitor:|"The intervention group will receive all the interventions provided to the control group. In addition, intervention group participants will install on their mobile phone the hypertension personal control program (HPCP) (Lark HTN Pro), which is a smartphone application. The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD. The HPCP has blood pressure, medication, and weight monitoring, including periodic reminders for the user to measure blood pressure, measure weight, and take their medication(s). The HPCP provides real-time feedback based on user input, such as out-of-range measurements and has additional features designed to encourage behavior change in areas such as dietary intake, physical activity, sleep, and stress reduction. Users can set goals and receive guidance and feedback through the app."
62266197|NCT03724864|ACTIVE_COMPARATOR|Maltitol snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
62266198|NCT03724864|PLACEBO_COMPARATOR|Sugared snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
62266199|NCT04823104|EXPERIMENTAL|Intervention group with home visitation|pregnant women who are included in this group will be assigned an intervention by home visitation for pregnancy follow-up
62266200|NCT04823104|NO_INTERVENTION|control group without home visitation|pregnant women will be free to choose their pregnancy follow-up without home visitation
62266201|NCT01202331|NO_INTERVENTION|J|Stop Annual Treatment
62461323|NCT04714047|EXPERIMENTAL|Group 1:|PRT
62266202|NCT01202331|NO_INTERVENTION|K|Stop Biannual Treatment
62266203|NCT01202331|OTHER|L|Continue Annual Treatment
62266204|NCT01202331|OTHER|M|Continue Biannual Treatment
62266205|NCT01202331|EXPERIMENTAL|N|Targeted Treatment by Age
62461324|NCT04714047|EXPERIMENTAL|Group 2:|PRT + Booster sessions
62461325|NCT04714047|ACTIVE_COMPARATOR|Group 3:|NEMEX
62461326|NCT04714047|EXPERIMENTAL|Group 4:|NEMEX + Booster sessions
62461327|NCT06234670||Patients with uterine fibroids accepted myomectomy.|Complete the observation and follow-up, to identify the outcome （recur or not recur).
62461328|NCT02048111|EXPERIMENTAL|IB1001|
62461329|NCT05169554|ACTIVE_COMPARATOR|RC8, Rifampicin plus Clarithromycin for 8 weeks|Rifampicin plus Clarithromycin (RC) therapy for 8 weeks
62461330|NCT05169554|EXPERIMENTAL|RCA4, Rifampicin plus Clarithromycin plus Amoxicillin/clavulanate for 4 weeks.|Rifampicin plus Clarithromycin (RC) plus Amoxicillin/clavulanate (A) for 4 weeks.
62461331|NCT02339233|EXPERIMENTAL|Epidural Stimulator|Eligible participants will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord
62461332|NCT04212949|EXPERIMENTAL|Repetitive transcranial magnetic stimulation following TESI|Active repetitive transcranial magnetic stimulation will be performed to the patients with lumbar radiculopathy who receive transforaminal epidural steroid injection.
62461333|NCT04212949|ACTIVE_COMPARATOR|Transforaminal epidural steroid injection|Transforaminal epidural steroid injection will be applied to the patients with lumbar radiculopathy.
62461334|NCT05575180|EXPERIMENTAL|Methazolamide|Drug: Methazolamide Dose: 100 mg b.i.d Duration: 2 days prior to testing + 1 hr prior to testing start Form: Oral
62461335|NCT05575180|ACTIVE_COMPARATOR|Acetazolamide|Drug: Acetazolamide Dose: 250 mg t.i.d Duration: 2 days prior to testing + 1 hr prior to testing start Form: Oral
62461336|NCT05575180|PLACEBO_COMPARATOR|Placebo|Drug: Placebo (microcrystalline cellulose) Dose: 250 mg t.i.d Duration: 2 days prior to testing + 1 hr prior to testing start Form: Oral
62461337|NCT03727100|ACTIVE_COMPARATOR|Clonidine Micropellets|single dose injection into the lumbar epidural space
62461338|NCT03727100|SHAM_COMPARATOR|Sham Control|non-epidural needle placement
62266206|NCT01202331|EXPERIMENTAL|O|Targeted Treatment by Clinical Exam
62266207|NCT01033734|EXPERIMENTAL|Single arm|
62850100|NCT03288142|ACTIVE_COMPARATOR|Control:Tracking Application and Home Monitor:|Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.
62266208|NCT00903175|EXPERIMENTAL|everolimus 1L/sunitinib 2L|everolimus First Line: 10 mg orally, once daily, (two 5 mg tablets), continuous treatment. sunitinib Second Line: 50 mg orally, once daily, 4 weeks on treatment followed by 2 weeks off (4/2)
62266209|NCT00903175|ACTIVE_COMPARATOR|sunitinib 1L/everolimus 2L|sunitinib First Line: 50 mg orally, once daily, 4 weeks on treatment followed by 2 weeks off (4/2) everolimus Second Line: 10 mg orally, once daily (two 5 mg tablets), continuous treatment
62266210|NCT04017481|EXPERIMENTAL|Repetitive stimulating transcranial stimulation (rTMS)|Subjects receive 8 sessions M1 Neuromodulation using rTMS according to the protocol ( 80% resting motor threshold, 10 Hertz; 1000 pulses; 25 trains de 4 seconds con 25 seconds intertrain.
62266211|NCT04017481|EXPERIMENTAL|EEG guided Neurofeedback (NFB)|Subjects receive 8 sessions M1 EEG guided NFB with virtual reality goggles in order to modify the beta rhythm. The sessions have a duration of 20min
62266212|NCT04017481|EXPERIMENTAL|rTMS + NFB|Subjects receive both interventions sequentially
62850101|NCT01110642|EXPERIMENTAL|Lovastatin solution|All patients will receive lovastatin solution
62266213|NCT04017481|NO_INTERVENTION|No intervention|No interventions, the patient just comes to be evaluated sequentially according to the timing of experimental groups.
62061958|NCT03645135|NO_INTERVENTION|Control|Patients in the control group will be asked to complete a demographics survey and assess their perceived involvement in care after their visit
62061959|NCT03645135|EXPERIMENTAL|Goal elicitation|Patients in the intervention group will be asked to list 2 goals for their visit. They will also be asked to complete a demographics survey and access their perceived involvement in care after their visit.
62061960|NCT04617548|EXPERIMENTAL|tDCS and CO-OP Group|One-hour session three times per week for 4 weeks. Participants will receive anodal tDCS (1.5 mA) to the dorsolateral prefrontal cortex (dlPFC) for 20 minutes at the beginning of each session. Following each tDCS session, the participants will complete a sensations questionnaire.The basis for each session will be task-based practice of client-chosen goals and the use of cognitive strategies using CO-OP.
62266214|NCT03669302|SHAM_COMPARATOR|Robotic gait training|Robotic gait training only
62449595|NCT01243554|EXPERIMENTAL|Exercise training|Supervised exercise training at the hospital during pregnancy: the women will attend at least 2 weekly sessions consisting of aerobic exercise (walking on treadmills), strength training (for upper body, back, abdomen and legs) as well as pelvic floor muscle exercises. Each session is 60 minutes and lead by a physiotherapist or experienced exercise physiologist. The women will also go through motivational interviewing sessions throughout the intervention period and are encouraged to do home exercise training in addition to the exercise at the hospital
62850102|NCT01874769||Blood collection and skin biopsies|
62061961|NCT00462670|PLACEBO_COMPARATOR|1|0mg
62266215|NCT03669302|EXPERIMENTAL|Robotic gait training & low-frequeny transspinal stimulation.|Robotic gait training will be administered along with non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping at low frequency (0.3 Hz).
62266216|NCT03669302|EXPERIMENTAL|Robotic gait training & high-frequeny transspinal stimulation.|Robotic gait training will be administered along with non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping at high frequency (30 Hz).
62850103|NCT01779258|OTHER|Group 2|Active control arm, Locatop@, Locapred@
62850104|NCT01779258|OTHER|Group 3|Absence of emollient treatment, Locatop@, Locapred@
62850105|NCT01779258|EXPERIMENTAL|Group 1|"glycerol, paraffin (liquid and white soft), Locatop@~, Locapred@"
62850106|NCT00929448||Immunoglobulin|
62850107|NCT04363541|EXPERIMENTAL|Thermotherapy|"Electric heat pad applied in the thorax for 90 minutes, twice daily, for 5 days.~+ Usual in-hospital care"
62850108|NCT04363541|NO_INTERVENTION|Control|Usual in-hospital care
62061962|NCT00462670|EXPERIMENTAL|2|15mg OPC-41061
62449596|NCT01243554|NO_INTERVENTION|Control|Usual care as provided by the health services in Norway. The investigators will not advice the women to be inactive
62461339|NCT01422538|ACTIVE_COMPARATOR|Group A|Subjects will receive Ulthera® System alone.
62061963|NCT01268202|EXPERIMENTAL|Pravastatin|Pravastatin : 40mg/day during 12 months
62087924|NCT02537353|ACTIVE_COMPARATOR|Group 2|Patients with a clinical diagnosis of upper gastrointestinal bleeding and that during endoscopy revealed to non-varicose bleeding lesions in the endoscopic treatment being necessary. The group will be submitted to injection of adrenaline at a proportion of 1: 10,000 in the four quadrants of the lesion associated with application adsorption powder, marketed under the name Hemospray. The patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
62266217|NCT02568813|EXPERIMENTAL|Scales passation|
62461340|NCT01422538|ACTIVE_COMPARATOR|Group B|Sculptra® only
62624084|NCT05742074|PLACEBO_COMPARATOR|Placebo|25-30 placebo capsules.
62850109|NCT01840917||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
62850110|NCT01900210|EXPERIMENTAL|WaySafe|WaySafe -- Participants in this arm received a curriculum titled WaySafe that focused on identifying, planning for, and avoiding HIV risk behaviors after release from prison. WaySafe included 6 hour-long, group-based, highly interactive sessions normally held weekly with homework assignments given between sessions.
62850111|NCT01900210|NO_INTERVENTION|Treatment as usual|Participants in this arm completed pre- and post-surveys and attended normal substance abuse programming.
62850112|NCT02163603||Pelvic osteotomy|
62850113|NCT05094778|OTHER|single-portal group|The patients in single-portal group were treated with single-portal palm approach
62850114|NCT00693082|EXPERIMENTAL|1|
62087925|NCT03157011|EXPERIMENTAL|Global symptom score (GSS) questionary|systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary.
62087926|NCT05126758|EXPERIMENTAL|CAP-1002|"Cohort A: Approximatetly 29 subjects will receive CAP-1002A active treatment consisting of 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months~Cohort B: Approximately 22 participants will receive CAP-1002B active treatment consisting of 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months"
62850115|NCT00476008|PLACEBO_COMPARATOR|Placebo|One tablet placebo morning and evening (BID) for 12 months
62850116|NCT00476008|ACTIVE_COMPARATOR|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months.
62850117|NCT01634191|EXPERIMENTAL|Elderly: Apremilast 30 mg|Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.
62850118|NCT01634191|EXPERIMENTAL|Younger: Apremilast 30 mg|Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.
62850119|NCT06332456||Control|15 healthy volunteers
62850120|NCT06332456||CKD|15 patients with CKD and CAD risk factors with GFR between 30 and 45 mL/min/1.73m2
62850121|NCT04281134|EXPERIMENTAL|Summit RC+S DBS Implant for OCD|all subjects will receive surgical implantation of DBS system
62850122|NCT04281134|EXPERIMENTAL|One Month Blinded Discontinuation Period|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline"
62850123|NCT06073145||Blood flow monitoring in the brain|A group/cohort of 60 participants will be recruited. The group/cohort has a broad range distribution of different physiological parameters, such as age, gender, race, BMI, and etc.
62850124|NCT01350193|ACTIVE_COMPARATOR|Saline Nasal Irrigation|Saline Nasal Irrigation is actively being used as the standard of care. It does not contain any active ingredients.
62266218|NCT03673007|EXPERIMENTAL|Treatment Group|Women in this arm of the study receive a voucher which can be used to buy contraception and related services at Planned Parenthood
62461341|NCT01422538|ACTIVE_COMPARATOR|Group C|Sculptra® treatment followed by Ultherapy™ treatment
62850125|NCT01350193|EXPERIMENTAL|Manuka Honey Irrigation|Manuka Honey Irrigation involves the experimental treatment of manuka honey nasal irrigation.
62850126|NCT04517890|EXPERIMENTAL|lidocaine patch|5% lidocaine patch applied at 3 hours before the procedure
62850127|NCT04517890|PLACEBO_COMPARATOR|Sham patch|Sham patch containing no study medication applied 3 hours before the procedure
62850128|NCT00502203|EXPERIMENTAL|Paclitaxel + Carboplatin|Paclitaxel 175 mg/m\^2 intravenously (IV) over 3 hours and Carboplatin AUC 5 IV over 1 hour every 21 Days for 6 courses.
62850129|NCT02155478|OTHER|AMO ZCB00|AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL
62850130|NCT02155478|ACTIVE_COMPARATOR|ISERT 250|ISERT 250 (HOYA, Japan): a standard IOL
62850131|NCT03043105|EXPERIMENTAL|TCP regimen|Thalidomide, cyclophosphamide and prednisone （TCP regimen）would be used for newly-diagnosed symptomatic MCD patients
62850132|NCT02739685|EXPERIMENTAL|Bioresorbable vascular scaffold|Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion
62850133|NCT02739685|ACTIVE_COMPARATOR|Stent|Implantation everolimus-eluting stent in chronic total occlusion
62850134|NCT02150434|SHAM_COMPARATOR|Compressed Air|compressed air delivered at a fixed flow of 2 L/min
62850135|NCT02150434|ACTIVE_COMPARATOR|Oxygen constant flow|oxygen delivered at a fixed flow of 2L/min
62850136|NCT02150434|EXPERIMENTAL|Automated oxygen titration|oxygen at a variable flows delivered by the FreeO2
62061964|NCT05650723|EXPERIMENTAL|Double Therapy (Zanubrutinib plus Venetoclax)|All participants will receive an initial 3 cycles of zanubrutinib monotherapy. This lead-in period will then be followed by 12 cycles of zanubrutinib and venetoclax combination therapy. All participants will complete 12 cycles of zanubrutinib and venetoclax combination therapy or 15 cycles of total treatment. Peripheral blood and bone marrow MRD assessments will occur at C16D1. Participants will continue on double combination treatment for an additional 1 month while results of MRD testing are obtained. In total, all participants will be on treatment for at least 16 full cycles. Participants that meet definition of MRD negativity will stop therapy at C17D1 and enter an observation phase with study visits every 3 months. Participants that remain MRD positive at C16D1 will enter the triple therapy (zanubrutinib, venetoclax, and obinutuzumab) arm.
62850137|NCT05439785|EXPERIMENTAL|Group 1|Dental floss
62850138|NCT05439785|EXPERIMENTAL|Group 2|Interdental brush
62850139|NCT05279573|EXPERIMENTAL|Combination of Omega-3 based product and botanical ingredient|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
62850140|NCT05279573|EXPERIMENTAL|Omega-3 based product|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
62624085|NCT00639106|EXPERIMENTAL|A|Expander Placement WITH Alloderm
62266219|NCT03673007|NO_INTERVENTION|Control Group|Women in this arm of the study DO NOT receive a voucher for contraceptives. Women in this arm receive the Planned Parenthood standard of care priced according to the Planned Parenthood sliding scale.
62266220|NCT06330389||COVID-19 Positive and Negative status|Burn injuries with COVID-19 Positive and Negative status underwent surgery
62449597|NCT04534283|EXPERIMENTAL|Abemaciclib + LY3214996|Subjects will receive Abemaciclib 150 mg orally twice daily with LY3214996 200 mg orally daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
62850141|NCT05279573|EXPERIMENTAL|Botanical ingredient|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
62087927|NCT05126758|PLACEBO_COMPARATOR|Placebo|"Cohort A: Approximately 29 subjects will receive a Placebo solution via intravenous infusion every 3 months~Cohort B: Approximately 22 participants will receive a Placebo solution via intravenous infusion every 3 months"
62087928|NCT06208124|EXPERIMENTAL|IMM-6-415|Dose Escalation and Dose Expansion
62087929|NCT06613516|EXPERIMENTAL|Subject to be dose with Capivasertib bidaily|400mg of Capivasertib to be dosed to patients and taken twice a day for a maximum of two years
62266221|NCT02414386||Acute Kidney Injury - CRRT|Multi-organ failure with acute kidney injury critically ill patients admitted to the critical care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure. Biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels.
62449598|NCT00619385|EXPERIMENTAL|Proellex 100 mg|Proellex 100 mg daily for 7 days
62449599|NCT00619385|EXPERIMENTAL|Proellex 150 mg|Proellex 150 mg daily for 7 days
62449600|NCT00619385|EXPERIMENTAL|Proellex 200 mg|Proellex 200 mg daily for 7 days
62449601|NCT05690685|EXPERIMENTAL|Silver I Alginate Non-Woven Dressing (Hydro-Alginate)|Subjects will undergo treatment of their chronic or acute wound (Pressure ulcer, and Donor sites) as indicated in the instructions for use with Silver I Non-Woven Dressing
62449602|NCT03879213|EXPERIMENTAL|Active|freeze-dried red raspberry powder (25 g) in active breakfast meal
62449603|NCT03879213|PLACEBO_COMPARATOR|Placebo|Placebo breakfast
62449604|NCT04302948|NO_INTERVENTION|Treatment as usual|TaU includes screening for anti-HCV using a rapid point-of-care (PoC) test to screen for exposure to HCV followed by counseling, brief education and referral to provider for further evaluation for HCV treatment.
62449605|NCT04302948|EXPERIMENTAL|Rapid PoC RNA testing|Intervention arm includes Tau ( screening for anti-HCV using a rapid point-of-care (PoC) test, and a rapid PoC screening test for HCV RNA, counseling plus, brief education and referral to a provider for further evaluation for HCV treatment. Rapid HCV RNA testing will be conducted using Cepheid Xpert (r) system.
62449606|NCT04642456|OTHER|Control group|"Healthy subjects or volunteers~Intervention:~Balance Assesment Scale Trunk strength measurement with EMG MRI spine/pelvis EOS stereoradiographic full body exam"
62449607|NCT04642456|OTHER|ASD group|"Patient group with ASD~Intervention:~Balance Assesment Scale Trunk strength measurement with EMG MRI spine/pelvis 2 EOS stereoradiographic full body exam Balance Assesment Scale 2 Trunk strength measurement with EMG 2"
62449608|NCT04576546|ACTIVE_COMPARATOR|comparator group|myo-inositol treatment
62449609|NCT04576546|EXPERIMENTAL|study group|D-chiro-inositol treatment
62449610|NCT01775215||A - Symptomatic severe AS|Patients with symptomatic severe aortic stenosis (AS) as per ESC guidelines, requiring aortic valve replacement.
62461342|NCT05696639||Undeveloped venous group|patients with undeveloped cerebral venous
62624086|NCT00639106|ACTIVE_COMPARATOR|B|Expander Placement WITHOUT Alloderm
62850142|NCT05279573|PLACEBO_COMPARATOR|Control group|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
62461343|NCT05696639||Well Developed venous group|patients with well-developed cerebral venous
62061965|NCT05650723|EXPERIMENTAL|Triple Therapy (Zanubrutinib, Venetoclax, and Obinutuzumab)|Participants that meet definition of MRD positivity at C16D1 will enter the triple therapy arm (zanubrutinib, venetoclax, and obinutuzumab). These participants will continue combination therapy with zanubrutinib and venetoclax, but will also receive 6 cycles of obinutuzumab starting at C17D1. In this subgroup, peripheral blood and bone marrow MRD assessments will occur after an additional 6 cycles of the triplet combination therapy (C23D1) at which point all participants will stop study treatment regardless of MRD status.
62061966|NCT04459286|ACTIVE_COMPARATOR|Standard of Care (SOC)|Participants in this arm will receive SOC alone, which will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
62061967|NCT04459286|EXPERIMENTAL|SOC plus Intervention|Participants in this arm will receive SOC plus study intervention composed of orally administered nitazoxanide and atazanavir/ritonavir tablets
62061968|NCT03154281|EXPERIMENTAL|Cohort 1|(each cycle is 28 days long) Everolimus 5mg daily on Mondays, Wednesdays, and Fridays Niraparib 100mg daily
62061969|NCT03154281|EXPERIMENTAL|Cohort 2|(each cycle is 28 days long) Everolimus 5 mg daily on Mondays, Wednesdays, and Fridays Niraparib 200 mg daily
62061970|NCT03154281|EXPERIMENTAL|Cohort 3|(each cycle is 28 days long) Everolimus 5 mg daily Niraparib 200 mg daily
62061971|NCT03154281|EXPERIMENTAL|Cohort 4|(each cycle is 28 days long) Everolimus 5 mg daily Niraparib 300 mg daily
62266222|NCT02414386||Control|Multi-organ failure non acute kidney injury critically ill patients admitted to the critical care unit. Multi-organ failure is defined as a respiratory and circulatory failure. Biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels.
62266223|NCT00610831|EXPERIMENTAL|DirectView CR Mammography|Each subject will have routine clinical care imaging obtained and 4 standard mammogram views (RMLO, RCC, LMLO, LCC) using CR mammography. If routine mammograms were obtained on a day previous to enrollment in the study, those images (4 views; 2 views for mastectomy patients) will not be repeated for this study; only the CR images will be obtained.
62266224|NCT02788942|NO_INTERVENTION|Umbilical|The cholecystectomy material will be removed from umbilical port as usual. This will be control group. Port site infection rates will be measured.
62266225|NCT02788942|EXPERIMENTAL|Epigastric|The cholecystectomy material will be removed from epigastric port. This will be experimental group. Port site infection rates will be measured.
62266226|NCT04588779|EXPERIMENTAL|Graston|Ultrasound, Graston technique, piriformis stretching, home plan (hip abductor and extensor strengthening)
62061972|NCT05434117|EXPERIMENTAL|High-intensity interval Nordic walking|Participants will receive high-intensity interval Nordic walking training.
62449611|NCT01775215||B - Asymptomatic moderate to severe AS|Asymptomatic patients with moderate to severe aortic stenosis (AS) as per ESC guidelines ,with Left Ventricular ejection fraction \>50%, not yet requiring aortic valve replacement.
62061973|NCT05434117|ACTIVE_COMPARATOR|Control|Participants will undergo standard cardiovascular rehabilitation.
62266227|NCT04588779|ACTIVE_COMPARATOR|Manual myofascial release|Ultrasound, Manual myofascial release, piriformis stretching, home plan (hip abductor and extensor strengthening)
62624087|NCT03941028|EXPERIMENTAL|bone defects caused by trauma|Large bone defects (\>6cm) caused by trauma
62266228|NCT01554137|EXPERIMENTAL|With isokinetic strength training|60 minutes isokinetic strength training on concentric mode
62266229|NCT01554137|PLACEBO_COMPARATOR|without isokinetic strength training|passive motion 60 minutes
62266230|NCT02358642|EXPERIMENTAL|Angiotensin converting enzyme inhibitor|Angiotensin converting enzyme inhibitor (Lisinopril), 2.5mg, nocte, 26 weeks
62266231|NCT02358642|PLACEBO_COMPARATOR|Placebo|Placebo
62449612|NCT03713138|EXPERIMENTAL|Intervention Flaxseed powder|"Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.~Intervention/ Dietary Supplement:~Flax seed powder~Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.~Other Name: intervention"
62449613|NCT03713138|NO_INTERVENTION|Control group; Comparison group|"The controlled group was given no intervention. No intervention was done to this group.~Three different quantities of white flour were intervened to the subjects. One group was given 15 grams of white flour a day. Second group was given 20 grams and third group was given 25 grams of white flour a day."
62266232|NCT06392646|NO_INTERVENTION|routine care|Taking routine care measures
62266233|NCT06392646|EXPERIMENTAL|self-management education program|Intervention in accordance with the constructed self-management education program
62266234|NCT03587454|EXPERIMENTAL|Tele-Glaucoma arm|Subjects enrolled in tele-glaucoma arm for remote assessment
62449614|NCT02397070|EXPERIMENTAL|Jaw exercise program|
62449615|NCT02397070|ACTIVE_COMPARATOR|Occlusal splint and counseling|
62266235|NCT01797575|ACTIVE_COMPARATOR|Aspirin|research subject will be taking aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
62449616|NCT01636856|ACTIVE_COMPARATOR|1|Oropharyngeal exercises and oropharyngeal functions
62266236|NCT01797575|ACTIVE_COMPARATOR|N-acetyl-cysteine|research subject will be taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
62449617|NCT01636856|SHAM_COMPARATOR|2|Nasal dilator, respiratory exercise, nasal lavage
62449618|NCT02426619|EXPERIMENTAL|SDF regular|3 applications of a 30% SDF solution will be applied onto the surface of dental caries lesions by a small brush regularly once a year
62461344|NCT00291057|EXPERIMENTAL|1|MALG
62061974|NCT04175301|EXPERIMENTAL|Hydrogen|Five times per day for 6 weeks subjects will dissolve a hydrogen generating tablet into water and drink the effervescent water. Dissolving one tablet in 250 mL of water will achieve a saturating hydrogen concentration of approximately 1.6 ppm.
62061975|NCT04175301|PLACEBO_COMPARATOR|Placebo|Five times per day for 6 weeks subjects will dissolve an placebo tablet into water and drink the effervescent water. The effervescent placebo tablet does not generate hydrogen-enriched water.
62266237|NCT01797575|ACTIVE_COMPARATOR|Aspirin and NAC|research subject will be taking aspirin 1000mg (2 capsules of 500mg) every morning and NAC 1000mg (2 capsules of 500mg) two times a day in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations.
62266238|NCT01797575|PLACEBO_COMPARATOR|Sugar Pill|research subject will be taking 4 capsules of matching sugar pill( placebo) in the morning and 2 capsules of matching placebo in the evenings in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
62266239|NCT00429403|EXPERIMENTAL|Goserelin|3.6 mg subcutaneously 1 week before chemotherapy, then once a month until 3 weeks after chemotherapy.
62266240|NCT00429403|NO_INTERVENTION|No Goserelin|
62266241|NCT04634500|EXPERIMENTAL|Study group|DWP16001 A mg, Dapagliflozin placebo
62449619|NCT02426619|EXPERIMENTAL|SDF intensive|3 applications of a 30% SDF solution will be applied onto the surface of dental caries lesions by a small brush at weekly interval at baseline
62449620|NCT02426619|ACTIVE_COMPARATOR|NaF varnish|3 applications of a 5% NaF varnish will be applied onto the surface of dental caries lesions by a small brush at weekly interval at baseline
62624088|NCT03941028|EXPERIMENTAL|bone defects caused by infection|Large bone defects caused by chronic osteomyelitis
62624089|NCT03941028|EXPERIMENTAL|bone defects caused by tumor|Large bone defects caused by benign tumor
62624090|NCT03295032|EXPERIMENTAL|group-based ACT|Stroke survivors were randomised into group-based ACT intervention consisting of 2hr sessions for four consecutive weeks.
62624091|NCT03295032|NO_INTERVENTION|Waiting list control|Waiting list control - received treatment as usual.
62850143|NCT01421472|EXPERIMENTAL|MM-121 (SAR256212) + paclitaxel|2 week run-in of MM-121 followed by MM-121 + dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
62850144|NCT01421472|ACTIVE_COMPARATOR|Paclitaxel only|Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
62624092|NCT01695382|EXPERIMENTAL|Navigation|Participants randomized to the control arm of the study will receive a packet of written materials that are appropriate linguistically and written for individuals with low health literacy. In addition they will have 5 navigator initiated home visits to review the educational materials and help patients and families address barriers to palliative care through education, advocacy, and activation.
62850145|NCT04801056|EXPERIMENTAL|TB006|"During the SAD study, subjects will receive a single dose of TB006 (at the dosage level of 10 \~ 50 mg/kg) administered via i.v. infusion for 60 mins.~In addition, a sentinel cohort of 5 mg/kg will be open for enrollment and double-blinded randomization first, with 2 patients randomized to active/TB006 arm, to assess preliminary safety and tolerability of study drug, and to determine cohort expansion and dose escalation. Upon the completion of sentinel cohort and all subjects are safe and well tolerate study treatment, regular dose escalation will start."
62850146|NCT04801056|PLACEBO_COMPARATOR|Placebo|"During the SAD study, subjects will receive a single dose of the placebo administered via i.v. infusion for 60 mins.~In addition, the corresponding sentinel placebo group will include 1 patient to placebo arm. Upon the completion of sentinel cohort and all subjects are safe and well tolerate study treatment, regular dose escalation will start."
62850147|NCT03438071||Control group|
62850148|NCT03438071||Videoconference group|
62061976|NCT02962856|EXPERIMENTAL|BAY987517|All subjects are patched with the same product.
62266242|NCT04634500|ACTIVE_COMPARATOR|Control group|DWP16001 A mg placebo, Dapagliflozin
62266243|NCT04840108|EXPERIMENTAL|Support Person Coaching Intervention|Support persons in the intervention arm will receive existing written materials on effective social support strategies for smoking cessation. Materials will be sent via postal mail. Support persons in this arm will also complete a one-session coaching intervention (15-25 minutes) delivered virtually by research staff via phone.
62266244|NCT04840108|ACTIVE_COMPARATOR|Support Person Written Materials|Support persons in the intervention arm will receive existing written materials on effective social support strategies for smoking cessation. Materials will be sent via postal mail.
62449621|NCT05337956|ACTIVE_COMPARATOR|ESPB catheter group|Patient in this group will receive ESP block
62449622|NCT05337956|NO_INTERVENTION|Control group|Patient in this group will not receive any block
62449623|NCT02709356|EXPERIMENTAL|Alzheimer's disease|"Patients with mild Alzheimer's disease.~1-month of 60-40 MCT oil and 1-month of C8 MCT oil (order of the two intervention are randomized)"
62449624|NCT02709356|EXPERIMENTAL|Controls|"Healthy elderly people~1-month of 60-40 MCT oil and 1-month of C8 MCT oil (order of the two intervention are randomized)"
62449625|NCT02463513|PLACEBO_COMPARATOR|Treatment 1|
62449626|NCT02463513|ACTIVE_COMPARATOR|Treatment 2|
62449627|NCT02463513|ACTIVE_COMPARATOR|Treatment 3|
62461345|NCT02102425||Chronic kidney disease, PD|Patients with or without bandage over exit site
62061977|NCT05177406||Full cohort|patients newly initiating Aimovig therapy
62061978|NCT06436001||BlueDop Vascular Expert|BlueDop Vascular Expert assessment vs Full Leg Arterial Duplex
62061979|NCT06436001||Ankle Brachial Index|ABI assessment verses Full Leg Arterial Duplex
62061980|NCT03894150|EXPERIMENTAL|F0002-ADC|
62061981|NCT06382038|EXPERIMENTAL|mVTEA Management Group|Patients randomly assigned to the mVTEA management group will be discharged with mVTEA-assisted patient-centered PTE management.
62061982|NCT06382038|NO_INTERVENTION|Routine Management Group|Patients randomly assigned to the routine management group will be given routine post-discharge management in accordance with local clinical practice.
62266245|NCT00408694|EXPERIMENTAL|Treatment (bevacizumab, cisplatin, fluorouracil, IMRT, 3D-CRT)|"BEVACIZUMAB AND CHEMORADIOTHERAPY: Patients receive bevacizumab IV over 30-90 minutes and cisplatin IV over 20-30 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 1, patients also undergo three-dimensional conformal radiotherapy or intensity-modulated radiotherapy once daily 5 days a week for a total of 33 fractions.~ADJUVANT THERAPY: Beginning in week 10, patients receive fluorouracil IV continuously over 96 hours on days 1-4, cisplatin IV over 20-30 minutes on day 1 OR days 1 and 2, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
62266246|NCT00912249|EXPERIMENTAL|Horticultural Therapy|
62266247|NCT01743911|PLACEBO_COMPARATOR|sugar pill|Intervention: sugar pill
62449628|NCT03352427|EXPERIMENTAL|Dasatinib+Everolimus|"Dasatinib = 60 mg/m2 orally twice daily~Everolimus = starting dose of 3.0 mg/m2, with titration of dosing after first cycle to keep everolimus trough level of 5-15 ug/ml~Both agents will be taken daily for 28 day cycles. Cycles will be repeated every 28 days and patients may receive up to 24 cycles."
62449629|NCT02106065|EXPERIMENTAL|In-person Education and Skill-Building Rehabilitation (ESBR-i) Condition|Education and Skill-Building Rehabilitation delivered in clinic
62624093|NCT01695382|NO_INTERVENTION|Control|Participants randomized to the control arm of the study will receive a packet of written materials that are appropriate linguistically and written for individuals with low health literacy.
62624094|NCT03181945|ACTIVE_COMPARATOR|Group 4 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
62850149|NCT02873429||Integrative Medicine (Complementary /Alternative)Group|Patients receiving chiropractic care, acupuncture, massage therapy, or meditation training for chronic pain
62266248|NCT01743911|ACTIVE_COMPARATOR|tadalafil|Intervention: tadalafil
62266249|NCT05013762|ACTIVE_COMPARATOR|Speed-biased complex motor skill training|"Participants will perform 400 complex movements per day over 4 days over a one-week period. The task requires participants to navigate their hand through a track projected on the surface of a table with a width of 5cm. Participants receive adaptive score based on their movement time. ."
62449630|NCT02106065|EXPERIMENTAL|Education and Skill-Building Rehabilitation over Video (ESBR-V) Condition|Education and Skill-Building Rehabilitation delivered via video telehealth.
62061983|NCT02320032|EXPERIMENTAL|Aripiprazole Lauroxil - A|Intramuscular (IM) injection Dose and Dosing Sequence A
62061984|NCT02320032|EXPERIMENTAL|Aripiprazole Lauroxil - B|Intramuscular (IM) injection Dose and Dosing Sequence B
62624095|NCT03181945|ACTIVE_COMPARATOR|Group 12 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
62061985|NCT02320032|EXPERIMENTAL|Aripiprazole Lauroxil - C|Intramuscular (IM) injection Dose and Dosing Sequence C
62061986|NCT02320032|EXPERIMENTAL|Aripiprazole Lauroxil - D|Intramuscular (IM) injection Dose and Dosing Sequence D
62624096|NCT02624882|EXPERIMENTAL|Positive rapid Group A Streptococcus (GAS) test|In case of positive rapid GAS test, patients will be treated by antibiotics: amoxicillin 50mg/kg/d during 10 days or cefpodoxime 8mg/kg/d during 10 days in case of betalactamine allergy
62624097|NCT02624882|ACTIVE_COMPARATOR|Negative rapid GAS test|If case of negative rapid GAS test, usual care: local antiseptic or surgical intervention
62850150|NCT02873429||Conventional Medicine Group|Patients receiving conventional medicine care (physical therapy, medication management, injections, etc.) for chronic pain.
62850151|NCT05867771|EXPERIMENTAL|PM1022|PM1022 Injection
62850152|NCT04554121|EXPERIMENTAL|Brain Basics|Brain Basics is a cognitive remediation intervention that emphasizes training in early auditory processing.
62449631|NCT02106065|ACTIVE_COMPARATOR|Usual Care Condition|Usual Care plus supplemental paper education materials
62624098|NCT04780633|EXPERIMENTAL|Precede-Proceed based Training Program|The experimental group is the group in which five training sessions interventions are applied.
62850153|NCT04554121|ACTIVE_COMPARATOR|Brain Training|Brain Training is a cognitive remediation intervention that targets a range of cognitive abilities
62850154|NCT00647270|PLACEBO_COMPARATOR|Placebo|Placebo 12 weeks, 40mg adalimumab remaining 12 weeks
62850155|NCT00647270|ACTIVE_COMPARATOR|40 mg|40 mg every other week
62850156|NCT00647270|ACTIVE_COMPARATOR|80 mg|80 mg monthly
62850157|NCT00492713|ACTIVE_COMPARATOR|1|Dark chocolate
62850158|NCT00492713|ACTIVE_COMPARATOR|2|Milk chocolate 1
62850159|NCT00492713|ACTIVE_COMPARATOR|3|Milk chocolate 2
62449632|NCT06458790|EXPERIMENTAL|AARC Intervention|This intervention will adapt an already-existing evidence-based Centering Parenting program. Investigators will not provide clinical care to participants. Investigators will also address topics that are specific to African American families. Investigators will conduct 9 90 min sessions via zoom and in person.
62449633|NCT04933513||preoperative Parkinson' disease|pre DBS parkinson's disease patients responding to the DBS-PS scale preoperatively
62449634|NCT05344183|EXPERIMENTAL|Lasertherapy|
62449635|NCT05344183|SHAM_COMPARATOR|Sham lasertherapy|
62449636|NCT06444074|EXPERIMENTAL|PACT Arm|Participants in the intervention arm will undergo the PACT Program, which is a 3-month long health coaching program.
62449637|NCT06444074|PLACEBO_COMPARATOR|Usual Care|Patients in the Usual Care Arm will undergo routine follow-up for their Diabetes Mellitus. In NHGP, this involves Teamlet care, where patients are taken care of by a team comprising of Family Physicians, a Care Manager (a nurse trained in chronic disease management), and a Care Coordinator, and are seen typically every three to six months for monitoring of their diabetic control.
62449638|NCT05859165|EXPERIMENTAL|Nutren Diabetes group|Product Replacement phase: 1-5 days, tube-feeding, 25kcal/kg/day Formal intervention phase:7 days, tube-feeding, 25kcal/kg/day
62449639|NCT05859165|ACTIVE_COMPARATOR|Fresubin Diabetes group|Product Replacement phase: 1-5 days, tube-feeding, 25kcal/kg/day Formal intervention phase:7 days, tube-feeding, 25kcal/kg/day
62449640|NCT02506647|EXPERIMENTAL|Sequence 1|Gan \& Lee insulin glargine followed by Lantus
62449641|NCT02506647|ACTIVE_COMPARATOR|Sequence 2|Lantus followed by Gan \& Lee insulin glargine
62624099|NCT04780633|NO_INTERVENTION|Control group|The control group is the group in which have no educational intervention.
62449642|NCT02112240|EXPERIMENTAL|Surgery with pre- and intra-op imaging|Subjects will have a preoperative flexible sigmoidoscopy where they will receive an endoscopic injection of 99mTc-sulfur colloid (up to 0.5 mCi) and 3 to 5 cc of circumferential endoscopic injections of Spot. A SPECT/CT will be performed prior to surgery to identify lymph nodes in the rectum. Subjects will proceed to their standard surgery. Intraoperative mobile gamma camera imaging of the rectum will occur before and after resection in attempt to identify sentinel lymph nodes.
62850160|NCT06044051|OTHER|All patients|All patients included will be followed for 1 year, every 3 months
62850161|NCT03563924||Historical cohort|Patients with venous thromboembolism and cancer who follow traditional management of venous thromboembolism
62850162|NCT03563924||AlloTC cohort|"Patients with venous thromboembolism and cancer who follow AlloTC specific management. AlloTC specific care path way develop a personalized care plan (PPS) and ensure the transmission of data (to all the interlocutors: patients and caregivers) at each step of the patient care path."
62850163|NCT00748904|EXPERIMENTAL|A|35 patients receiving rifaximin
62061987|NCT06625164|NO_INTERVENTION|Control group|diaphragm training exercises within the scope of basic acting education;The control group was evaluated at the beginning and at the end of the study.
62449643|NCT04930081|EXPERIMENTAL|Parent Management Training|The well-researched Postivie Parenting Program (Triple P) is selected as the intervention program for the parent management training arm. It is an 8-week program that aims at equipping parents with effective parenting strategies.
62850164|NCT00748904|EXPERIMENTAL|B|35 patients receiving lactulose
62624100|NCT02378974|OTHER|Cohort 1|Cordstem-ST cells or Placebo on day 0
62624101|NCT02378974|OTHER|Cohort 2|Cordstem-ST cells or Placebo on day 0 and day 7
62624102|NCT03278366|EXPERIMENTAL|Dancing students|Students will participate in dance activities from a video with their teacher in class.
62624103|NCT03278366|NO_INTERVENTION|Non-Dancing Students|Students will continue with typical classroom activities in class and will not participate in dancing activities
62624104|NCT06169826|PLACEBO_COMPARATOR|Control|Control
62624105|NCT06169826|ACTIVE_COMPARATOR|Treatment-Histidine|Treatment-Histidine
62624106|NCT00159107|EXPERIMENTAL|2|Placebo +Integrative behavior therapy
62624107|NCT00159107|EXPERIMENTAL|3|Acamprosate + treatment as usual
62624108|NCT00159107|EXPERIMENTAL|1|Acamprosate + Integrative behavior therapy
62266250|NCT05013762|OTHER|Accuracy-biased complex motor skill training|The accuracy-biased group receives a dose equivalent intervention with a emphasize on accuracy. The width of the track projected on the table is narrower (less than 2cm) and the adaptive score received are based on their accuracy to say within the boundary of the track.
62266251|NCT01760668||Turner syndrome (TS)|TS verified by genotyping Age \> 18 years awaiting operation due to aortic dilation
62449644|NCT04930081|EXPERIMENTAL|Mindful Parenting Program|The Mindful Parenting program, developed by Prof Susan Bogel is selected as the intervention program for the mindful parenting arm. It is an 8-week program that trains parents in mindfulness and support them to apply mindfulness in the parenting context.
62449645|NCT04930081|NO_INTERVENTION|Waitlist Control Group|The waitlist control group will not receive any service until two months after the intervention arms complete their training. Depending of the availability of the program instructor, either the Parent Management Training or the Mindful Parenting program will be offered to this group.
62624109|NCT06355726|EXPERIMENTAL|PLEX with SMT|3 sessions to 5 max, alternate day with SMT
62624110|NCT06355726|ACTIVE_COMPARATOR|SMT|High calorie intake 35 to 40 Kcal/kg, protein 1.2 to 1.5 g/kg,albumin,antibiotics as required
62624111|NCT03840941||Frail patients with COPD|No intervention
62624112|NCT03840941||Non-frail patients with COPD|No intervention
62449646|NCT04702620||healthy children without symptoms|healthy children without symptoms
62449647|NCT04702620||sick children without wheezing|sick children without respiratory wheezing
62624113|NCT00057525|EXPERIMENTAL|Anthrax vaccine with or without PBS|Administor 1 dose 5 μg rPA with PBS (5 Volunteers)
62266252|NCT01760668||Marfan syndrome (MS)|Females with MS verified clinically or by genotyping Age \> 18 years awaiting operation due to aortic dilation
62624114|NCT00057525|PLACEBO_COMPARATOR|Placebo|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combinedwith phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
62266253|NCT01760668||Bicuspid aortic valve|females with bicuspid aortic valve Age \> 18 years awaiting operation due to aortic dilation
62449648|NCT04702620||sick children with respiratory wheezing|
62266254|NCT01760668||Controls|Men/females who died from conditions other than aortic dilation or dissection. Age 20-60 years.
62266255|NCT03237377|EXPERIMENTAL|Durvalumab with Radiation|"Drug: Durvalumab Other Names: MEDI4736~MEDI4736 1500mg via IV infusion every 4 weeks for up to 3 doses/cycles Intervention: Radiation: Thoracic Radiation 5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction~Intervention: Procedure/Surgery: lobectomy patients may proceed to surgery post drug and radiation intervention for lung lobectomy~Intervention: Drug: Standard of care adjuvant chemotherapy patients may or may not proceed to adjuvant chemotherapy post trial drug and radiation intervention and surgery"
62449649|NCT05854654|EXPERIMENTAL|Air Leaks|Lungs from patients undergoing lung transplantation after their removal from the recipient patient with previous informed consent signed before transplantation will be obtained. The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. In order to reproduce intraoperative air leaks, various manipulations, including stapling and creating lacerations of different depts and lengths on the parenchyma, will be performed on deflated lungs. Following the introduction of a leak, condensed gas will be pushed through the airway to precisely localize the defect. The sealant prepared at room temperature will then be applied in a thin layer to cover the defect and will be left to dry for 5 minutes. The seal will be tested using the condensed gas with the lung still deflated as well as with the water immersion technique after inflating the lung.
62449650|NCT01773148|EXPERIMENTAL|Arstasis Access System (AXERA) placement|Placement of AXERA device in subjects undergoing common femoral artery access for PCI and/or PVI through a 5F or 6F introducer sheath.
62624115|NCT05984108||Meningeal melanocytoma|
62624116|NCT05984108||Meningeal melanoma|
62624117|NCT05984108||Meningeal melanomatosis|
62624118|NCT05984108||Meningeal melanocytosis|
62624119|NCT00212264|EXPERIMENTAL|Behavioral Therapy|Behavioral Therapy (Pelvic floor muscle training, bladder control strategies)
62624120|NCT00212264|EXPERIMENTAL|Behavioral Therapy Plus Technologies|Behavioral therapy plus technologies (home pelvic floor electrical stimulation and biofeedback)
62624121|NCT00212264|PLACEBO_COMPARATOR|Placebo Comparator|No treatment control
62624122|NCT01772459||Paper/Paper|This group will complete paper questionnaires at baseline and two week follow up.
62624123|NCT01772459||Paper/Internet|This group will complete paper questionnaires at baseline and internet questionnaires at two week follow up.
62624124|NCT01772459||Internet/Paper|This group will complete internet questionnaires at baseline and paper questionnaires at two week follow up.
62624125|NCT01772459||Internet/Internet|This group will complete internet questionnaires at baseline and two week follow up.
62624126|NCT05727748|OTHER|Control group|The control group continued their daily activities for 12 weeks and did not participate in any new physical activity program during the study.
62624127|NCT05727748|EXPERIMENTAL|Multimodal training group|The session consisted of four stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed).
62652858|NCT02576496|EXPERIMENTAL|Tinostamustine 100mg/m2 over 60min|Tinostamustine as a single agent administered by IV infusion on D1 of 21-day cycle.
62652859|NCT02576496|EXPERIMENTAL|Tinostamustine 120mg/m2 over 60min|Tinostamustine as a single agent administered by IV infusion on D1 of 21-day cycle.
62061988|NCT06625164|ACTIVE_COMPARATOR|exercise group|diaphragm training exercises within the scope of basic acting education and Planned exercises started to be implemented after one session of training. Exercise group was given exercises by the physiotherapist for 8 weeks, two days a week, during 45 minutes before the acting lessons started.
62266256|NCT03237377|EXPERIMENTAL|Durvalumab and Trememlimumab with Radiation|"Drugs: Durvalumab + Tremelimumab Other Names: MEDI4736 and CP-675 MEDI4736 1500mg via IV infusion every 4 weeks for up to 3 doses/cycles + CP-675 206 75mg via IV infusion every 4 weeks up 3 doses/cycles Intervention: Radiation: Thoracic Radiation 5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction Intervention: Procedure/Surgery: lobectomy patients may proceed to surgery post drug and radiation intervention for lung lobectomy~Intervention: Drug: Standard of care adjuvant chemotherapy patients may or may not proceed to adjuvant chemotherapy post trial drug and radiation intervention and surgery"
62266257|NCT05290025|EXPERIMENTAL|Intervention|Patients will be offered brief weekly behavioural interventions for smoking cessation and prescription-free nicotine replacement products in addidition standard opioid replacement therapy.
62624128|NCT05727748|EXPERIMENTAL|Multimodal training group with augmented reality|The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed). Four stations are the same of the previous group and the other 2 stations are with augmented reality. These 2 stations worked the same cognitive and physical components but through the portable exergame platform for the elderly.
62624129|NCT05030571|EXPERIMENTAL|Intervention|Intervention group will receive DPMAS extracorporeal treatment one session per day for 3 consecutive days plus standard therapy. We plan to use blood flow rate of 100-120 ml/hour with filtration fraction for plasma separation of 25-30%. DPMAS circuit consist of Plasmaflo OP cartridge (Asahi Medical, Tokyo, Japan), Ion exchange resin hemoperfusion cartridge (BS330; Jafron, Zhuhai City, China), and Neutral adsorption resin hemoperfusion cartridge (HA330-II; Jafron, Zhuhai City, China) We do not use any anticoagulant.
62624130|NCT05030571|ACTIVE_COMPARATOR|Standard care|Standard treatment according to EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure 2017
62624131|NCT05323175|ACTIVE_COMPARATOR|ESP Nerve Block for Renal colic|On top of receiving standard of care, At T8 nerve level, with ultrasound guidance to bathe the nerve
62624132|NCT05323175|ACTIVE_COMPARATOR|Standard of care|Whatever medications the clinician normally treats renal colic with
62624133|NCT06385327|EXPERIMENTAL|Part A: SAD Cohorts 1-5, ABI-5366|Single dose of ABI-5366 (tablet) in Part A for Cohorts 1-5
62624134|NCT06385327|PLACEBO_COMPARATOR|Part A: SAD Cohorts 1-5, Placebo|Single dose of matching placebo (tablet) in Part A for Cohorts 1-5
62624135|NCT06385327|EXPERIMENTAL|Part A: SAD Fed Cohort 6, ABI-5366|Single dose of ABI-5366 (tablet) in Part A for Cohort 6, food effect
62061989|NCT01749072|OTHER|Gefitinib|Gefitinib group Gefitinib (Iressa) 250mg once per day until progression disease or intolerant side effects
62061990|NCT01749072|OTHER|Vinorelbine-Ifosfamide|VI group Vinorelbine 25mg/m2 d1,d8;Ifosfamide 1.25g/m2 d1-d3(Usually Ifosfamide 2g d1-d3 with Mesna 400mg 0,4,8hours after Ifosfamide administration for 3 days);every 3 weeks;at least for 2-6 cycles depending on the progression disease or the patient's physical condition
62061991|NCT05118230||Inclisiran Cohort|patients treated with inclisiran in certain special territories in China
62061992|NCT05118230||SoC Historical Cohort|patients treated with standard of care (SoC) in routine clinical practice from EMR database
62061993|NCT03118284||Foley catheter group|Urine collection and blood collection and NRS for pain in patients having surgery for which their surgeon has ordered placement of a Foley catheter.
62266258|NCT05290025|OTHER|Intitial screening only|Participants will receive standard opioid replacement therapy. At the start of the intervention number of cigarettes smoked during the past week will be recorded. Smokers will be adviced to make a cessation or reduction attempt. Advice that nicotine replacement products ( patches, lozenges or gum) may be bought over the counter in grocery-stores and pharmacies and information about goverment home-pages giving cessation advice.
62624136|NCT06385327|EXPERIMENTAL|Part B: MAD Cohorts 1-4 ABI-5366|Weekly or monthly dose of ABI-5366 (tablet) in Part B for Cohorts 1-4. May have a loading dose.
62624137|NCT06385327|PLACEBO_COMPARATOR|Part B: MAD Cohorts 1-4 Placebo|Weekly or monthly dose of matching placebo (tablet) in Part B for Cohorts 1-4. May have a loading dose.
62624138|NCT03416478||ctDNA test group|
62266259|NCT05660720|EXPERIMENTAL|Orelabrutinib tablet 150 mg (study drug) and placebo 250 mg (orelabrutinib tablet simulator)|The subjects will be dosed once on Day1 or Day6 or Day11 or Day16 according to randomization.
62266260|NCT05660720|EXPERIMENTAL|Orelabrutinib 400 mg (study drug)|The subjects will be dosed once on Day1 or Day6 or Day11 or Day16 according to randomization.
62266261|NCT05660720|PLACEBO_COMPARATOR|Placebo 400mg (orelabrutinib tablet simulator)|The subjects will be dosed once on Day1 or Day6 or Day11 or Day16according to randomization.
62266262|NCT05660720|ACTIVE_COMPARATOR|Moxifloxacin hydrochloride 400 mg|he subjects will be dosed once on Day1 or Day6 or Day11 or Day16 according to randomization.
62449651|NCT05782790|EXPERIMENTAL|Action Observation Therapy Group|In this method, patients will be seated in a comfortable chair in front of a 32-inch television placed approximately 2 meters away in a quiet room. On television, videos that will be used in swallowing rehabilitation prepared on realistic animations and/or real models will be shown to the patients. Patients will be asked to watch these exercise videos for 20 minutes with their full attention and concentrate on how the actions are done. Patients; While watching the videos, they will not be asked to do any movement, they will be asked to imitate the exercises after the videos are finished.
62624139|NCT02683408|EXPERIMENTAL|diosmiplex|diosmiplex 630 mg BID administered orally
62624140|NCT02683408|PLACEBO_COMPARATOR|placebo|placebo BID administrered orally
62624141|NCT01155349|EXPERIMENTAL|InSight Brain Fitness|
62266263|NCT00573430|EXPERIMENTAL|1|Candesartan Cilexetil
62266264|NCT00573430|EXPERIMENTAL|2|Candesartan Cilexetil
62266265|NCT00573430|EXPERIMENTAL|3|Candesartan Cilexetil
62266266|NCT00872807|EXPERIMENTAL|Group intervention|Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality. They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months.
62266267|NCT00872807|ACTIVE_COMPARATOR|Individual intervention|Lifestyle counseling for each separate family practiced by single health professionals both in hospital and municipality. A more conventional model.
62266268|NCT02500680|EXPERIMENTAL|Group 1 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV \[Fluzone quadrivalent influenza vaccine, Sanofi Pasteur\]) 1µg (Standard Dose) Single Dose
62449652|NCT05782790|EXPERIMENTAL|Classic Swallowing Exercise Group|Exercises include positioning, swallowing maneuvers, food modification, and swallowing exercises, which are sensory stimulation, oral motor exercises, head-neck mobilization, Shaker exercises, and neck region and tongue strengthening exercises, which are compensatory strategies according to the swallowing rehabilitation program accepted in the literature.
62624142|NCT01155349|PLACEBO_COMPARATOR|No contact-control|
62624143|NCT02485756|EXPERIMENTAL|Educational handout|Participants in the intervention group will read an educational handout on hormonal contraceptives/antiepileptic interactions.
62624144|NCT02485756|NO_INTERVENTION|Control (no educational handout)|Those in the standard care group will not receive the educational handout.
62624145|NCT02532283|EXPERIMENTAL|JNJ-63623872 plus Oseltamivir|Participants will be administered JNJ-63623872 600 milligram (mg) tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
62624146|NCT02532283|EXPERIMENTAL|Placebo plus Oseltamivir|Participants will be administered placebo tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
62266269|NCT02500680|EXPERIMENTAL|Group 2 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV \[Fluzone quadrivalent influenza vaccine, Sanofi Pasteur\]) 3µg (Standard Dose) Single Dose
62266270|NCT02500680|EXPERIMENTAL|Group 3 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV \[Fluzone quadrivalent influenza vaccine, Sanofi Pasteur\]) 5µg (Standard Dose) Single Dose
62266271|NCT02500680|EXPERIMENTAL|Group 4 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV \[Fluzone quadrivalent influenza vaccine, Sanofi Pasteur\]) 9µg (Standard Dose) Single Dose
62624147|NCT04893681|EXPERIMENTAL|Fluoridated bottle water|5-gallon bottles containing water from the New Bern Water Resources Division's Black Creek aquifer which contains naturally-occurring fluoride in a concentration of approximately 0.8 mg/L F
62624148|NCT04893681|PLACEBO_COMPARATOR|Non-fluoridated bottled water|5-gallon bottles containing water from the North Lenoir Water Corporation's Black Creek aquifer which contains a negligible concentration of fluoride.
62266272|NCT02500680|ACTIVE_COMPARATOR|Group 5A (Phase 1A)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 15µg (Standard Dose) Single Dose
62266273|NCT02500680|ACTIVE_COMPARATOR|Group 5B (Phase 1B)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose
62266274|NCT02500680|EXPERIMENTAL|Group 6 (Phase 1B)|MER4101 (MAS-1 Adjuvanted IIV \[Fluzone quadrivalent influenza vaccine, Sanofi Pasteur\]) Optimal Vaccine Dose from Phase 1A (9µg) (Standard Dose) Single Dose
62266275|NCT02500680|EXPERIMENTAL|Group 7A (Phase 1B extension)|MER4101 (MAS-1 Adjuvanted IIV \[Fluzone quadrivalent influenza vaccine, Sanofi Pasteur\]) 9µg/HA in 0.5 mL MAS-1 emulsion (Standard Dose) Single Dose
62266276|NCT02500680|ACTIVE_COMPARATOR|Group 7B (Phase 1B extension)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose
62266277|NCT02500680|EXPERIMENTAL|Group 8A (Phase 1B extension)|MER4101 (MAS-1 Adjuvanted IIV \[Fluzone quadrivalent influenza vaccine, Sanofi Pasteur\]) 15µg/HA in 0.5 mL MAS-1 emulsion (Standard Dose) Single Dose (as 2 x 0.25 mL in each arm)
62624149|NCT04360473|ACTIVE_COMPARATOR|Control group|The patients in this group will receive general balanced anesthesia
62624150|NCT04360473|EXPERIMENTAL|Ketamine group|The patients in this group will receive 0.3 mg / kg of ketamine in saline (total volume of 100 ml) 15 min before general balanced anesthetic induction
62266278|NCT02500680|ACTIVE_COMPARATOR|Group 8B (Phase 1B extension)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose (0.5 mL) in one arm and 0.5 mL of PBS in the other arm
62061994|NCT03118284||Healthy control group|Blood collection in healthy volunteers from the Research Participant Registry or recruited from posters around the Washington University campus
62061995|NCT05335109|EXPERIMENTAL|Xenon|
62061996|NCT05335109|PLACEBO_COMPARATOR|Oxygen|
62061997|NCT05091853|ACTIVE_COMPARATOR|Self-adhesive mesh|
62061998|NCT05091853|ACTIVE_COMPARATOR|Self-gripping mesh|
62266279|NCT05492929|EXPERIMENTAL|The deep breathing group|The deep breathing group was administered the nightly state and trait anxiety scale and SAAQ before the operation, and then they were informed about the deep breathing exercise. Between the 1st and 6th hours of the postoperative period, deep breathing exercise was performed, with 10 breaths per hour. At the end of the 6th hour, the state anxiety scale and SSWS were administered.
62624151|NCT04360473|EXPERIMENTAL|Magnesium sulfate group|The patients in this group will receive 40 mg / kg of magnesium sulfate in saline solution (total volume of 100 ml) 15 min before general balanced anesthetic induction
62624152|NCT04360473|EXPERIMENTAL|Magnesium / ketamine group|The patients in this group will receive 0.15 mg / kg of ketamine + 20 mg / kg of magnesium sulfate in saline solution (total volume of 100 ml) 15 min before general balanced anesthetic induction
62624153|NCT02801461|EXPERIMENTAL|Three-sessions of ESWT|ESWT was given once a week for 3 weeks.
62266280|NCT05492929|EXPERIMENTAL|4-7-8 breathing technique Group|The nightly state and trait anxiety scale and the PSSQ were applied to the 4-7-8 breathing group before the operation, and then they were given information about the 4-7-8 breathing technique. Between the 1st and 6th hours postoperatively, the 4-7-8 breathing technique was applied for 1 set (4 breaths) every hour. At the end of the 6th hour, the state anxiety scale and SSWS were administered.
62266281|NCT05492929|NO_INTERVENTION|control group|In the control group, the nightly state and trait anxiety scale and PSSQ were applied before the operation. At the end of the 6th hour postoperatively, without any application, the state anxiety scale and PSSQ were applied.
62266282|NCT04456309||Atrial fibrillation|stroke patients with atrial fibrillation
62266283|NCT04456309||Intracardiac thrombus|stroke patients with intracardiac thrombus
62624154|NCT02801461|ACTIVE_COMPARATOR|One-session of ESWT|Single ESWT was given.
62061999|NCT00214825|EXPERIMENTAL|1|MR antagonist (Eplerenone) + placebo
62266284|NCT04570553|EXPERIMENTAL|V-care uterine manipulator|Patients in the V-care uterine manipulator arm will undergo standard staging surgery utilizing a V-care uterine manipulator in the standard fashion
62266285|NCT04570553|ACTIVE_COMPARATOR|Sponge stick|Patients in the sponge stick arm will undergo standard staging surgery utilizing a non-invasive sponge stick for cervical delineation.
62624155|NCT03134911||anticoagulation controlled patients|Treated with DOAC or VKA
62624156|NCT03134911||anticoagulation non controlled patients|Treated with VKA
62624157|NCT02903420|EXPERIMENTAL|SAPIEN 3|Transcatheter Aortic Valve Implantation (TAVI) with the Edwards SAPIEN 3 Transcatheter Heart Valve and Delivery System
62062000|NCT00214825|PLACEBO_COMPARATOR|2|Hydrochlorothiazide plus potassium
62062001|NCT03610737|ACTIVE_COMPARATOR|MILD with CMM|The MILD procedure is an image-guided minimally-invasive lumbar decompression with conventional medical managment
62062002|NCT03610737|ACTIVE_COMPARATOR|CMM alone|Patient in the CMM alone group can have physical therapy, home exercise, pain medication, epidural steroid injections, nerve blocks, and other lumbar steroid injections.
62062003|NCT04942301|EXPERIMENTAL|Endostar pump for three days|Group A: The first cycle, Endostar 7.5mg/m2/day, intravenous infusion for 4 hours, D1-14 First 2-4 cycles, Endo 105mg/m2/cycle D1 starts intravenous pump for 72 hours;
62062004|NCT04942301|EXPERIMENTAL|Endostar pump for seven days|Group B: Cycle 1, Endo 7.5mg/m2/day, intravenous infusion for 4 hours, D1-14 First 2-4 cycles, Endo 105mg/m2/cycle D1 starts intravenous pump injection for 168 hours;
62062005|NCT01319292||Asthma children|children with asthma symptoms through screening
62062006|NCT01319292||normal children|children without symptoms of asthma
62062007|NCT03628963|EXPERIMENTAL|Concerto+ (Intervention group)|Patients with two or more targeted chronic diseases (diabetes, hypertension, dyslipidemia) and who had three or more visits in the last 12 months will use Concerto+ application during 6 months.
62266286|NCT05504954|EXPERIMENTAL|IMARA-SA intervention arm|Participants randomized to the IMARA-SA arm will receive the IMARA-SA intervention (i.e., the intervention group).
62266287|NCT05504954|EXPERIMENTAL|Health promotion control arm|Participants randomized to the health promotion control arm will receive the health promotion intervention (i.e., the control group).
62624158|NCT03833232|EXPERIMENTAL|omentopexy and cyanoacrilate glue|Apposition of omentum with cyanoacrilate glue after gastric section
62624159|NCT03833232|NO_INTERVENTION|gastrectomy without omentopexy|Gastric section without omentopexy
62266288|NCT06260254|NO_INTERVENTION|Control Night|Single study night with no noise exposure, to determine normal baseline sleep.
62624160|NCT05791526||Participants Receiving Upadacitinib|Participants receiving upadacitinib for moderate to severe Ulcerative colitis (UC) in real-world practice.
62624161|NCT00528359||A|36 lean schizophrenic subjects free of metabolic syndrome(M:F 24:12; Caucasian n=23; North-African n=12; South-Asian n=1)aged 35±9 years
62624162|NCT00547157|ACTIVE_COMPARATOR|ARM 1 CRT|Cisplatin plus RT
62624163|NCT00547157|EXPERIMENTAL|ARM 2 PRT|Panitumumab plus RT
62624164|NCT00070564|ACTIVE_COMPARATOR|Arm I|(closed 11/10/10) Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim subcutaneously (SC) on day 2 or filgrastim (G-CSF) SC on days 3-10. Treatment repeats every 14 days for 6 courses. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.
62624165|NCT00070564|EXPERIMENTAL|Arm II|(closed 11/10/10) Patients receive doxorubicin IV on day 1, oral cyclophosphamide on days 1-7, and G-CSF SC on days 2-7. Treatment repeats every 7 days for 15 courses. Beginning 2 weeks after completion of cyclophosphamide, patients receive paclitaxel and pegfilgrastim as in arm I.
62624166|NCT00070564|ACTIVE_COMPARATOR|Arm III|(closed 11/10/10) Patients receive doxorubicin, cyclophosphamide, and pegfilgrastim or G-CSF as in arm I. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 7 days for 12 courses.
62624167|NCT00070564|EXPERIMENTAL|Arm IV|(closed 11/10/10) Patients receive doxorubicin, cyclophosphamide, and G-CSF as in arm II. Beginning 2 weeks after completion of cyclophosphamide, patients receive paclitaxel as in arm III.
62449653|NCT03168074|EXPERIMENTAL|lenvatinib|Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).
62449654|NCT00993187|EXPERIMENTAL|Sitagliptin/Metformin FDC|Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks.
62449655|NCT00993187|ACTIVE_COMPARATOR|Glimepiride|Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day.
62449656|NCT05677607||Intracranial atherosclerosis and small vessel disease|Patients diagnosed with intracranial large artery atherosclerosis and cerebral small vessel disease based on imaging screening.
62449657|NCT05673668|EXPERIMENTAL|The endovascular denervation (EDN) group|Receive endovascular denervation (EDN) treatment
62449658|NCT02441426||Bangladesh|"Birth cohort study community in Bangladesh is urban, and located in the Mirpur neighborhood of Dhaka.~Case control study is being conducted in the same catchment area. Cases defined as children 6-24 months of age with \<-2WAZ (weight for age) score, controls are age and community matched with \>-1WAZ."
62449659|NCT02441426||Brazil|"Birth cohort study community in Brazil is urban, and located within the Papoco area of Fortaleza.~Case control study is being conducted in the same area as the cohort study. Cases are children 6 - 24 months of age, with \<-2 WAZ (weight for age) score, controls are age and community matched children with \>-1 WAZ."
62449660|NCT02441426||India|Birth cohort study community in India is urban, and located in the southern state of Tamil Nadu, specifically in Vellore.
62449661|NCT02441426||Nepal|Birth cohort study community in Nepal is semi-urban, and located in Bhaktapur, approximately 25km from Kathmandu.
62449662|NCT02441426||Pakistan|Birth cohort study community in Pakistan is rural, and located in Naushero Feroze, Sindh.
62449663|NCT02441426||Peru|Birth cohort study community in Peru is rural, and located approximately 15km from Iquitos in Loreto.
62449664|NCT02441426||South Africa|Birth cohort study community in South Africa is rural/peri-urban, and comprised of nine settlements within Limpopo Province.
62624168|NCT00070564|EXPERIMENTAL|Arm V|Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 4 courses. Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.
62850165|NCT06197919|EXPERIMENTAL|postural exercises with breathing exercises|"The postural exercise program consisted of two strengthening and stretching exercises. The exercises involved chin tucks in, shoulder retraction , and unilateral and bilateral pectoralis stretches alternating each 2-week period. 36 Participants were instructed to complete 3 sets of 12 repetitions of the strengthening exercises and 3 stretching exercises held for 30 seconds each.~For the breathing exercises in experimental group, breathing program includes respiratory muscle training, relaxation techniques, breathing techniques, e.g., deep breathing, hand controlled abdominal/diaphragmatic breathing, aimed stretching and strengthening exercises are combined with each other. Deep breathing, controlled diaphragmatic breathing, slow relaxed exhalation with pursed lips technique, direct apnoea exercises and segmental breathing techniques. exercise protocol will be continued for 10 weeks with and initial, after 5 weeks and final assessment of pain and CVA."
62850166|NCT06197919|EXPERIMENTAL|postural exercises without breathing exercises|"In this study forward head posture will be defined as CVA\<49°, which was diagnosed by photogrammetry method.~The postural exercise program consisted of two strengthening and stretching exercises. The exercises involved~(a) chin tucks in (c) shoulder retraction , and (d) unilateral and bilateral pectoralis stretches alternating each 2-week period. 36 Participants were instructed to complete 3 sets of 12 repetitions of the strengthening exercises and 3 stretching exercises held for 30 seconds each. This program was to be repeated 4 times per week. They also returned for a consultation every 2 weeks to be checked for exercise technique and progression, if appropriate. Progress to the next exercise level was indicated if the participant could complete 12 repetitions, 3 times easily with correct form."
62266289|NCT06260254|EXPERIMENTAL|Low Vibration Night|Single study night with railway vibration and noise events, to determine consequences of sleep disturbance by railway vibration at a lower level
62850167|NCT01433289|EXPERIMENTAL|Polyphenon E 1600 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Four capsules twice a day.
62850168|NCT01433289|EXPERIMENTAL|Polyphenon E 2400 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Six capsules twice a day.
62850169|NCT01433289|EXPERIMENTAL|Polyphenon E 3200 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Eight capsules twice a day.
62850170|NCT01433289|PLACEBO_COMPARATOR|Placebo|
62850171|NCT01008423|EXPERIMENTAL|Budesonide|Participants who were diagnosed with active mild to moderate UP or UPS, will receive 2 milligrams (mg)/25 milliliter (mL) of budesonide foam, rectally twice daily for a period of 2 weeks followed by 2 mg/25 mL of budesonide foam, rectally once daily for a period of 4 weeks.
62850172|NCT01008423|PLACEBO_COMPARATOR|Placebo|Participants who were diagnosed with active mild to moderate UP or UPS will receive 25 mL of placebo matching to budesonide foam twice daily for a period of 2 weeks followed by once daily for a period of 4 weeks.
62850173|NCT01645943|NO_INTERVENTION|Conservative|Coronary angiogram only if recurrent ischemia or peristent heart failure or inducible ischemia in predischarge stress test if perfomed
62850174|NCT01645943|ACTIVE_COMPARATOR|Invasive|Routine coronary angiogram
62850175|NCT05250453||Cardiac arrest|All patients having sudden cardiac arrest out-of-hospital in Pirkanmaa, Finland
62449665|NCT02441426||Tanzania|Birth cohort study community in Tanzania is rural, and located within Haydom.
62449666|NCT00493571|EXPERIMENTAL|Gimatecan|Gimatecan Starting dose: 0.6 mg capsules administered orally once daily.
62624169|NCT00070564|EXPERIMENTAL|Arm VI|Patients receive doxorubicin, cyclophosphamide, and pegfilgrastim as in arm V. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 7 days for 12 courses.
62266290|NCT06260254|EXPERIMENTAL|Intermediate Vibration Night|Single study night with railway vibration and noise events, to determine consequences of sleep disturbance by railway vibration at an intermediate level
62266291|NCT06260254|EXPERIMENTAL|High Vibration Night|Single study night with railway vibration and noise events, to determine consequences of sleep disturbance by railway vibration at a higher level
62652860|NCT02576496|EXPERIMENTAL|Tinostamustine 80mg/m2 over 45min|Tinostamustine as a single agent administered by IV infusion on D1 of 21-day cycle.
62266292|NCT02671136|OTHER|CWC with HBO|Conventional Wound Therapies (CWC) with adjunctive Hyperbaric Oxygen Therapy
62266293|NCT02671136|OTHER|CWC without HBO|Conventional Wound Therapies (CWC) without adjunctive Hyperbaric Oxygen Therapy
62266294|NCT04676997|EXPERIMENTAL|Camrelizumab+Chemotherapy|Participants receive Camrelizumab d1,15 (Q2W) + nab-paclitaxel d1,8,15(QW 3/4) x 4 cycles, followed by Camrelizumab Q2W + epirubicin + cyclophosphamide Q2W x 4 cycles as neoadjuvant therapy prior to surgery
62449667|NCT02789306||Peri-implantitis|"Peri-implantitis' - Loss radiographic bone beyond the biological bone remodeling at baseline (after prosthesis delivery) from the implant neck~* Early:\> 4 mm probing depth; \<25% radiographic bone loss~* Moderate:\> 6mm probing depth; \<50% radiographic bone loss~* Severa:\> 8 mm probing depth; \> 50% radiographic bone loss"
62624170|NCT05006274||Group 1-Traditional soft tissue balance|Patients in group 1 will receive traditional, manual soft-tissue balancing during surgery. For the purpose of the study, the balance will be quantitatively assessed at the end of the case, by means of surgeon-blinded VERASENSE measurements before and after cementation.
62624171|NCT05006274||Group 2-Soft tissue balance using VERASENSE|For the patients in Group 2, intra-operative sensor feedback will be used in creating a quantitatively balanced knee (VERASENSE, OrthoSensor Inc.). Thereby, a quantitatively balanced knee is characterized by a mediolateral load differential below 15lbs at 10-45-90 degrees of flexion.
62624172|NCT04565405|EXPERIMENTAL|AB (Detergent (A) followed by sterile water (B))|"Sequence: Detergent (A) followed by sterile water (B)~The inner cannula will be cleaned with commercially available tracheostomy cleaning fluid / powder (Ex: Trachoe - Kapitex healthcare, UK) in the first visit, and then cleaned with sterile water in the second visit, at a minimum period of 24 hrs apart. Laboratory analysis of colony counts will be conducted on the saline flushing pre- and post-decontamination for each washing."
62062008|NCT03628963|NO_INTERVENTION|Usual care (Control group)|Patients with two or more targeted chronic diseases (diabetes, hypertension, dyslipidemia) and who had three or more visits in the last 12 months will not use the application Concerto+ but receive usual care from FMG.
62624173|NCT04565405|EXPERIMENTAL|BA (Sterile water (B) followed by detergent (A))|"Sequence: Sterile water (B) followed by detergent (A)~The inner cannula will be cleaned with sterile water in the first visit, and then cleaned with commercially available tracheostomy cleaning fluid / powder (Ex: Trachoe - Kapitex healthcare, UK) in the second visit, at a minimum period of 24 hrs apart. Laboratory analysis of colony counts will be conducted on the saline flushing pre- and post-decontamination for each washing."
62624174|NCT00532727|EXPERIMENTAL|Arm A|Carboplatin
62624175|NCT00532727|ACTIVE_COMPARATOR|Arm B|Docetaxel
62624176|NCT04013880|EXPERIMENTAL|Treatment (ASTX727, FT-2102)|Patients receive CDA inhibitor E7727/decitabine combination agent ASTX727 PO QD on days 1-5 and IDH-1 inhibitor FT-2102 PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62850176|NCT05250453||ResusInj|OHCA survivors having CPR related injuries or carotid stenosis analyzed by CT
62062009|NCT04398446|EXPERIMENTAL|Hemp-based CBD|
62266295|NCT02017327|EXPERIMENTAL|Monoprost|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
62449668|NCT02789306||Healthy|No signs of inflammation and otherwise no bone loss beyond the biological bone remodeling
62449669|NCT03339349|EXPERIMENTAL|Enoxaparin Metabolism|Eligible patients will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.2-0.4 IU/mL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
62449670|NCT04190290|EXPERIMENTAL|Intervention|Mobilizations and exercises training Respiratory exercises Body image exercises
62449671|NCT04190290|ACTIVE_COMPARATOR|Control|Muscle strength evaluation and Eating behavior evaluation and Quality of life
62624177|NCT06608407|EXPERIMENTAL|PRP Group|After the completion of hysteroscopic adhesiolysis, recruited participants will be randomized to one of the two treatment groups by computer-generated numbers: Immediately administer uterine perfusion with PRP after surgery, and administered PRP perfusion during hysteroscopy at 4 and 8 weeks after hysteroscopic adhesiolysis, A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery.
62624178|NCT06608407|NO_INTERVENTION|Control group|Control group without PRP treatment.
62850177|NCT05250453||ResusCPC|OHCA survivors neurological outcome
62850178|NCT01125488|EXPERIMENTAL|LNG-IUS|LNG-IUS insertion during conservative surgery and GnRH agonist 6 doses.
62850179|NCT01125488|ACTIVE_COMPARATOR|GnRH agonist|The second group of patients receive GnRH agonist (triptorelin 3.75 mg, sc q28day) alone for 24 weeks.
62449672|NCT06364605|EXPERIMENTAL|iReach Device Group|
62652861|NCT02576496|EXPERIMENTAL|Tinostamustine 60mg/m2 over 30min|Tinostamustine as a single agent administered by IV infusion on D1 of 21-day cycle.
62850180|NCT01930578|EXPERIMENTAL|Treatment with 0.9% normal saline|1 litre of normal saline infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
62850181|NCT01930578|EXPERIMENTAL|Treatment with D5, 0.45 saline|1 litre of D5, 0.45 saline infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
62062010|NCT04398446|PLACEBO_COMPARATOR|Placebo Oral Tablet|
62266296|NCT02017327|ACTIVE_COMPARATOR|Lumigan 0.01%|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
62062011|NCT01218945||Fat Removal|Patients undergoing surgical fat removal
62624179|NCT01563198|EXPERIMENTAL|Comfort Talk® Training|The MRI units of three clinical sites form the group. Their personnel will be trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests
62624180|NCT02486172|OTHER|Peer supporter|Peer support program
62624181|NCT04388176|EXPERIMENTAL|C21 followed by placebo|
62624182|NCT04388176|EXPERIMENTAL|Placebo followed by C21|
62624183|NCT02849704|EXPERIMENTAL|Chronic Pancreatitis (CP) Subjects|"CP subjects will fast for 12 hours prior to the malabsorption blood test (MBT) testing, consume the MBT breakfast meal following this fast, have blood drawn (MBT, vitamins A, D, E and K, zinc, selenium, and prealbumin) prior to MBT breakfast consumption and each hour for 8 hours after consumption, consume a low-fat study lunch, eat a moderate fat diet for 4 days during home diet and stool collection, maintain a 3-day food record, collect stool over 72 hours, have body size and composition assessment, complete quality of life questionnaires, home environment and health questionnaires, and adverse events diary.~Subjects will take Creon36™ for 9 days.~Subjects will have two study visits, one before and one after treatment initiation with Creon36™. Both visits will be identical with the exception of completion of questionnaires and fecal elastase assessment (only Visit 1)."
62624184|NCT02849704|NO_INTERVENTION|Healthy Controls|Healthy controls will fast for 12 hours prior to the malabsorption blood test (MBT) testing, consume the MBT breakfast meal following this fast, have blood drawn (MBT, vitamins A, D, E and K, zinc, selenium, and prealbumin) prior to MBT breakfast consumption and each hour for 8 hours after consumption, consume a low-fat study lunch, eat a moderate fat diet for 4 days during home diet and stool collection, maintain a 3-day food record, collect stool over 72 hours, have body size and composition assessment, complete quality of life questionnaires, home environment and health questionnaires, and adverse events diary. Controls will only have 1 study visit and receive no intervention.
62624185|NCT05857410|NO_INTERVENTION|control group (group N)|
62850182|NCT01930578|EXPERIMENTAL|Treatment with D5|1 litre of D5 infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
62850183|NCT04166799|EXPERIMENTAL|Mepitel Film Arm|Patients randomized to the Mepitel Film arm will receive the film for the entire duration of their radiation treatment and will be worn up to 2 weeks after completion of radiotherapy.
62850184|NCT04166799|NO_INTERVENTION|Standard of Care Arm|Patients randomized to the Standard of Care arm will be instructed to use the institutional standard of care skin treatments for the entire duration of their radiation treatment and up to 2 weeks after completion of radiotherapy.
62850185|NCT05620121||Minimally invasive IH surgery|Minimally invasive approach to incisional hernias in non-electice settings
62850186|NCT05620121||Laparotomic IH surgery|Laparotomic approach to incisional hernias in non-electice settings
62850187|NCT05676268||Patients with oral implants supporting full ceramic fixed dental prostheses|
62850188|NCT03334786|EXPERIMENTAL|FLX-787-ODT (orally disintegrating tablet)|Single dose
62850189|NCT01204008|EXPERIMENTAL|CS|conservative discectomy
62850190|NCT01204008|ACTIVE_COMPARATOR|AS|
62850191|NCT03706248||No recurrence|"CT scan has confirmed that subjects are without recurrence. Blood can be drawn up to 4 weeks after scan.~Effective Feb 28, 2019, this group is closed to accrual as it has reached the goal."
62062012|NCT02623816|NO_INTERVENTION|Sub-optimal dosing|No change will be made to the sub-optimal dosing regimen of omeprazole 20 mg. Rescue antacid use is permitted. Total duration of 6 weeks.
62062013|NCT02623816|EXPERIMENTAL|Optimal dosing|Patients will be administered optimal dosing regimen of Omeprazole 20 mg for 4 weeks starting at week 2. Rescue antacid use is permitted. Total duration of 6 weeks.
62266297|NCT02017327|ACTIVE_COMPARATOR|Lumigan 0.03% Unit Dose|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
62266298|NCT00978315|ACTIVE_COMPARATOR|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
62266299|NCT00978315|PLACEBO_COMPARATOR|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
62624186|NCT05857410|ACTIVE_COMPARATOR|heating group (group T)|
62624187|NCT05857410|ACTIVE_COMPARATOR|DEX group (group D)|
62624188|NCT05857410|EXPERIMENTAL|heating combined with DEX group (group TD)|
62624189|NCT04308252||Pharmaco-resistant epilepsy (PRE)|Pharmaco resistant patients are defined by seizures despite adequate dosing of ≥2 anticonvulsant drugs.
62624190|NCT04308252||Pharmaco-sensitive epilepsy (PSE)|Pharmaco-sensitive patients are defined by no seizures for 6 months.
62624191|NCT04308252||Sibling control|Sibling of the of the PRE study participants.
62652862|NCT02576496|EXPERIMENTAL|Tinostamustine 80mg/m2 over 30min|Tinostamustine as a single agent administered by IV infusion on D1 of 21-day cycle.
62850192|NCT03706248||Recurrence|CT scan has confirmed that subjects are have recurrence of their colorectal cancer. Blood can be drawn prior to any treatment for the recurrent disease.
62850193|NCT00007618||1|
62850194|NCT00687141|EXPERIMENTAL|1|
62850195|NCT00687141|PLACEBO_COMPARATOR|2|
62850196|NCT02803346||septic shock patients|
62850197|NCT03181256||Screening|Patients are followed up at 1, 2, 3, 4, and 5 years and undergo collection of sputum, nasal epithelium, buccal epithelium, blood, and urine samples. Patients also undergo pulmonary function tests, chest CT, and review of medical records
62850198|NCT02267876||BD VIPER LT|
62850199|NCT01305590|OTHER|Survey|"We will survey participants to see if they would prefer more commitment, in the form of a Take-Medication-Get-Paid plan; less commitment, in the form of an Attend-Clinic-Get-Paid plan; or if they would prefer to designate their own levels of commitment."
62850200|NCT01041534||Adjustable Gastric Band (AGB) surgery|Patients who have undergone adjustable gastric band (AGB) surgery at the UWMC or other sites that have agreed to cooperate with our site (letter of cooperation and HIPAA waiver approved by our IRB) between April 1, 2007 and July 1, 2008.
62850201|NCT06426589|NO_INTERVENTION|Control Group|The control group (CG) will not undergo treatment, which will be evaluated in the pre- and post-phase of the study. Participants assigned to this group will receive general advice on the positive effects of regular physical activity, and they will be given the guide of recommendations for the promotion of physical activity.
62624192|NCT04595929|EXPERIMENTAL|PIPAC group|"1. Staging laparoscopy + peritoneal lavage.~2. 4 cycles of neoadjuvant chemotherapy: FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m² every 2 weeks.~3. Radical gastrectomy with D2 - lymph node dissection.~4. Intraoperative Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin 7,5 mg/m², doxorubicin 1,5 mg/m².~5. Adjuvant chemotherapy according to indications."
62624193|NCT04595929|ACTIVE_COMPARATOR|Control group|"1. Staging laparoscopy + peritoneal lavage.~2. 4 cycles of neoadjuvant chemotherapy: FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m² every 2 weeks.~3. Radical gastrectomy with D2 - lymph node dissection.~4. Adjuvant chemotherapy according to indications."
62624194|NCT00614978|EXPERIMENTAL|I|Lapatinib plus temozolomide
62624195|NCT04386005|EXPERIMENTAL|Continuous Glucose Monitoring|All participants will have the continuous glucose monitoring device placed.
62624196|NCT06007560|OTHER|<80% eNK|Women with low eNK bright cell numbers, defined as \<80% of the total endometrial NK cell population
62624197|NCT02855567|ACTIVE_COMPARATOR|Acupuncture|Receives acupuncture during gynecological surgery at 5 known points for pain control. Needles will be placed prior to the start of surgery by an anesthesiologist trained in acupuncture after induction of anesthesia and while the patient is prepped for surgery. They will be in place for 15 minutes.
62624198|NCT02855567|SHAM_COMPARATOR|Sham acupuncture|Receives acupuncture during gynecological surgery at sham points not associated with pain control. Needles will be placed by the gynecologic surgeon who is not trained in acupuncture after induction of anesthesia and prior to the start of the surgery. The needles will be removed immediately after placement.
62624199|NCT02500719|EXPERIMENTAL|Healthy Participants|A group of healthy participants will be enrolled first in the pilot phase of the study. This phase allows for the refinement (prior to the implementing in our PTSD participant group) the application of our support vector machine based real-time functional magnetic resonance imaging (rt-fMRI) algorithm, which evaluates brain networks thought to mediate emotional arousal and presents them (in real time) to subjects to aide in volitional manipulation of arousal.
62624200|NCT02500719|EXPERIMENTAL|PTSD Participants|A group of participants with symptoms of PTSD will be enrolled in the implementation phase of the study. This phase allows for the evaluation of rt-fMRI guidance of brain networks thought to mediate emotional arousal, specifically whether participants can learn volitional control of these networks.
62624201|NCT04350879||Diabetic patients|Women between 18 and 40 years old with type 1 and type 2 diabetes
62624202|NCT04615221|OTHER|Graft recipient|During each of the visits carried out with a cervical biopsy as part of the uterine transplant project, samples will be taken.
62624203|NCT04615221|OTHER|Living donor|The donors will benefit from a blood sample and a sample of the vaginal microbiota during the transplant under general anesthesia or after it during a consultation scheduled as part of the uterine transplant protocol.
62624204|NCT04615221|OTHER|Witness|10 non-menopausal control patients will each have a cervical biopsy (at different times of the cycle) and a smear, samples of the vaginal microbiota and a blood sample. Among the 10 controls, 4 patients will have to undergo a hysterectomy for which multiple staged biopsies and samples uterine microbiota will be produced.
62624205|NCT00962078|OTHER|interval training|interval training in lung transplant candidates
62266300|NCT00446511|EXPERIMENTAL|CKD patients: Valsartan+enalapril|
62266301|NCT00446511|ACTIVE_COMPARATOR|CKD patients: Enalapril|
62266302|NCT00446511|EXPERIMENTAL|Non-CKD patients: Valsartan|
62449673|NCT05825053|EXPERIMENTAL|Booster group|Participants assigned to the booster group will receive a three single training sessions 3 months apart targeting gait adaptability using the C-mill. Assessments will take place after giving informed consent which is indicated as the start of the study (baseline), 6 months and 12 months post-baseline.
62449674|NCT05825053|EXPERIMENTAL|Home-based exercise group|Participants assigned to the home-based exercise group will receive a program for training at home aiming at a minimum training time of 60 minutes per week. Assessments will take place after giving informed consent which is indicated as the start of the study (baseline), 6 months and 12 months post-baseline
62624206|NCT00962078|OTHER|Continuous Training|continuous training in lung transplant candidates
62624207|NCT03092648|EXPERIMENTAL|Bronchial basal cells|
62624208|NCT03092648|NO_INTERVENTION|Control|
62624209|NCT02335385|ACTIVE_COMPARATOR|SIL-V|single incision laparoscopic varicocelectomy
62624210|NCT02335385|ACTIVE_COMPARATOR|CTL-V|conventional transperitoneal laparoscopic varicocelectomy
62624211|NCT01288365|EXPERIMENTAL|Exercise training|Protocol of 3 month exercise training program.
62624212|NCT01288365|NO_INTERVENTION|Control|Control group
62624213|NCT01902511|EXPERIMENTAL|G-CSF + Erythropoietin|
62624214|NCT01902511|ACTIVE_COMPARATOR|G-CSF|
62266303|NCT00446511|ACTIVE_COMPARATOR|Non-CKD patients: Enalapril|
62266304|NCT00805831|EXPERIMENTAL|A|Aortic anastomosis surgery will be conducted using HDH device.
62266305|NCT05361772|EXPERIMENTAL|low-dose colchicine group|colchicine 0.5mg per day for 24 months
62266306|NCT05361772|PLACEBO_COMPARATOR|placebo group|placebo 0.5mg per day for 24 months
62449675|NCT05825053|NO_INTERVENTION|Control group|Participants assigned to the control group will not follow any additional intervention other than the standard care they already receive for the year following the completion of the 5-week gait adaptability training using the C-Mill from the ATTAINS study. Assessments will take place after giving informed consent which is indicated as the start of the study(baseline), 6 months and 12 months post-baseline.
62449676|NCT05154721|EXPERIMENTAL|EXPE Group|The experimental group (EXPE Group) will receive the Mila-Learn game.
62449677|NCT05154721|PLACEBO_COMPARATOR|CONT Group|The control group (CONT Group) will receive the Mila-Placebo game.
62449678|NCT00980603|ACTIVE_COMPARATOR|docetaxel|
62449679|NCT00980603|EXPERIMENTAL|doctaxel plus cisplatin|
62449680|NCT00980603|EXPERIMENTAL|docetaxel plus S-1|
62449681|NCT06232083|EXPERIMENTAL|PLDR+αPD-1|
62449682|NCT04054024|ACTIVE_COMPARATOR|Active drug|
62449683|NCT04054024|PLACEBO_COMPARATOR|Placebo|
62624215|NCT06248593|ACTIVE_COMPARATOR|Phenylephrine|The infusion will have a concentration of Phenylephrine of 25 μg/mL and will be initiated at a rate of 96 mL/hour (1.6 mL/minute), that correspond to a phenylephrine rate infusion of 40 μg/min, then the infusion rate will be manually adjusted within the range 0-144 mL/h : PHE (0-60 μg/min).
62624216|NCT06248593|EXPERIMENTAL|Norepinephrine|The infusion will have a concentration of Norepinephrine of 4 μg/mL and will be initiated at a rate of 96 mL/hour (1.6 mL/minute), that correspond to norepinephrine rate infusion of 6.4 μg/min, then the infusion rate will be manually adjusted within the range 0-144 mL/h : Norepinephrine (0-9.6 µg/min).
62624217|NCT00405340|EXPERIMENTAL|Drug|Rituximab
62850202|NCT06426589|EXPERIMENTAL|Experimental Group|The experimental group (EG), after an initial evaluation, will be subjected to a physical training program based on the resistance training, for 12 weeks with 2 weekly sessions (Tuesday and Thursday), with a duration of 45 minutes per session. Once the intervention is finished, you will undergo a final evaluation again to see if there is a difference or not with the results obtained at the beginning. In addition to the resistance training intervention, the experimental group received a Mediterranean diet protocol.
62850203|NCT01783691|EXPERIMENTAL|NKTT120|
62266307|NCT05626270|OTHER|LunulaLaser OTC|The user will be presented with the device in its intended packaging as if receiving it at their place of employment. No additional information, instruction or training will be provided by the Study Observer, or any other individual associated with the study. The user will be left to work out how to operate the Erchonia LunulaLaser™ OTC as independently and naturally as possible without interference or influence from the Study Observer. While the user will have received the instructional information in the packaging as in intended use, he or she will not be instructed to use any of the information. It will be up to the user as to if or how he or she chooses to use that information to set up operation of the device as would occur under actual conditions of intended use.
62062014|NCT04999358|EXPERIMENTAL|Protein group|Participants in the protein group will receive their usual education session(s) as part of standard practice cardiac rehabilitation. The session(s) will be the same for both study arms and will align with the dietary education sessions that these patients would usually be given during their normal cardiac rehabilitation programme. Participants in the protein group will be provided with an additional targeted protein education session, which will aim to increase the amount of foods eaten with protein in them (≥1.2 g/kg protein/day) and improve the quality of protein sources that are eaten. The content and materials for these sessions can be provided in-person or are available as pre-recorded videos, accessed by participants via the internet or DVD
62266308|NCT00333359|EXPERIMENTAL|XP13512 (GEn)|1200 mg XP13512, orally, once daily for 52 weeks
62266309|NCT03505021|EXPERIMENTAL|Levosimendan|Levosimendan 1 mg capsules for oral administration, once to twice a day. The total duration of treatment 48 weeks
62266310|NCT03505021|PLACEBO_COMPARATOR|Placebo for levosimendan|Placebo capsule for oral administration, once to twice a day. The total duration of treatment 48 weeks.
62266311|NCT03742414|ACTIVE_COMPARATOR|Control arm (Standard of care)|The study doctors will provide standard of care with routine reactive topical products for atopic dermatitis flares
62449684|NCT01519583|EXPERIMENTAL|Basic Pedometry Intervention|Basic pedometry intervention: Participants will have a goal of obtaining 10,000 steps/day (with no direction with regards to walking intensity/speed/cadence)
62449685|NCT01519583|EXPERIMENTAL|Enhanced Pedometry Intervention|Enhanced pedometry Intervention: Participants will have the goal of obtaining 10,000 steps/day and at least 30 minutes in moderate intensity (i.e., at a cadence of at least 100 steps/min);
62449686|NCT01519583|PLACEBO_COMPARATOR|Control Group|Control group: Will maintain their usual activity and return for follow-up measures
62449687|NCT05478993|EXPERIMENTAL|Selinexor, pomalidomide and dexamethasone|Patients diagnosed with multiple myeloma with CNS involvement to receive SPD treatment.
62449688|NCT02026414|EXPERIMENTAL|PrimaVie Exercise|Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
62449689|NCT04943809||POD 26P AY FT|26 patients with corneal astigmatism higher than 1.0D in both eyes and lower than 2.5D and will be implanted with the POD 26P AY FT
62449690|NCT04943809||POD 26P AY F|26 patients with corneal astigmatism lower than 1.0D in both eyes will be implanted with the POD 26P AY F
62449691|NCT01103037|EXPERIMENTAL|QAV680|
62449692|NCT01103037|PLACEBO_COMPARATOR|QAV680 Placebo|
62449693|NCT02093689|EXPERIMENTAL|Part 1 OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
62449694|NCT02093689|EXPERIMENTAL|Part 2 OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
62449695|NCT02093689|PLACEBO_COMPARATOR|Part 2 Placebo|Placebo contains 20mM sodium citrate diluted in BSS and administered as irrigation solution.
62449696|NCT04956419|EXPERIMENTAL|Treatment group A|SHR8008 capsule
62624218|NCT01800799|EXPERIMENTAL|UTI (WBC>10 per high power field)|"1. Antimicrobial agent (Baktar 800mg h.s.)~2. Anti-inflammatory agent (Celecoxib 200mg QD)"
62624219|NCT01800799|EXPERIMENTAL|Recurrent UTI|"1. Antimicrobial agent (Baktar 800mg h.s.)~2. Anti-inflammatory agent (Celecoxib 200mg QD)"
62624220|NCT01800799|NO_INTERVENTION|Normal control|Normal control
62850204|NCT05675644|EXPERIMENTAL|Dose finding|Drospirenone-only pill single-dose ranging from 16mg to 32mg
62850205|NCT05675644|EXPERIMENTAL|Primary ovulation inhibition testing|Drospirenone-only pill single-dose at dose determined by dose finding arm
62449697|NCT04956419|ACTIVE_COMPARATOR|Treatment group B|Fluconazole capsule
62850206|NCT01732601|EXPERIMENTAL|Intensive Outpatient CBT|Intensive CBT for both parents and adolescents as well as family sessions to increase communication.
62850207|NCT01732601|ACTIVE_COMPARATOR|Standard Care|Standard Treatment in the Community
62850208|NCT05878262|EXPERIMENTAL|pre-emptive analgesia group|For the pre-emptive analgesia group children, the nurse delivered the ibuprofen suppository at the dose of 5-10 mg/Kg.
62850209|NCT05878262|NO_INTERVENTION|control group|No medicine was taken for the control group.
62850210|NCT03637088|EXPERIMENTAL|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
62850211|NCT03637088|EXPERIMENTAL|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
62850212|NCT02585336|NO_INTERVENTION|Observation|
62850213|NCT02585336|EXPERIMENTAL|Brief intervention|
62850214|NCT02408159|EXPERIMENTAL|Varicella Zoster Vaccine|Sterile, lyophilized white to off-white compact crystalline plug in a single-dose vial. Each vial contains one dose of lyophilized vaccine (approximately 0.65 mL when reconstituted as directed). The diluent (0.7 mL) is a sterile, clear, colorless fluid supplied separately in a 3 mL single-dose vial. A single dose will be administered to subjects at baseline.
62850215|NCT02408159|PLACEBO_COMPARATOR|0.9% Sodium Chloride|"United States Pharmacopeia (USP), preservative free for injection supplied in a single dose vial.~A single dose will be administered to subjects at baseline."
62850216|NCT03754478||overweight subjects|Overweight male and females referred to a physical activity program by their primary care physician Intervention is being included in a 3-month physical activity training program
62850217|NCT03735524|EXPERIMENTAL|Exercise|Conventional rehabilitation
62850218|NCT03018483|EXPERIMENTAL|Variable PSV|
62850219|NCT03018483|ACTIVE_COMPARATOR|Conventional PSV|
62062015|NCT04999358|PLACEBO_COMPARATOR|Control group|Participants in the control group will receive their usual education session(s) as part of standard practice cardiac rehabilitation. The session(s) will be the same for both study arms and will align with the dietary education sessions that these patients would usually be given during their normal cardiac rehabilitation programme. Participants in the control group will receive an additional dietary education session that is similar to the standard practice sessions, containing only information that is usually provided in the cardiac rehabilitation programme.The content and materials for these sessions can be provided in-person or are available as pre-recorded videos, accessed by participants via the internet or DVD.
62062016|NCT01121198|EXPERIMENTAL|ASP1941 single arm|
62850220|NCT03018483|ACTIVE_COMPARATOR|Automated PSV|
62850221|NCT03018483|ACTIVE_COMPARATOR|NAVA|
62850222|NCT00640224|ACTIVE_COMPARATOR|Rosiglitazone|Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
62850223|NCT00640224|ACTIVE_COMPARATOR|Drospirenone/ethinyl estradiol|Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
62062017|NCT01121198|EXPERIMENTAL|ASP1941 repeated arm|
62062018|NCT01121198|PLACEBO_COMPARATOR|placebo single arm|
62062019|NCT01121198|PLACEBO_COMPARATOR|placebo repeated arm|
62266312|NCT03742414|EXPERIMENTAL|Active Intervention arm (proactive treatment)- Epiceram|Participants will receive proactive sequential skin care with the twice-daily use of a tri-lipid skin barrier cream (SBC). Clinically apparent eczema in this group will be managed with a short course of topical steroids (fluticasone propionate cream and/or hydrocortisone).
62449698|NCT02673164|ACTIVE_COMPARATOR|CSCC_ASC|Cardiology Stem Cell Centre_adipose derived stem cells (CSCC_ASC)
62062020|NCT02390856|ACTIVE_COMPARATOR|Volar Plate|Patients in this group will undergo distal radius fracture fixation with a traditional volar plate.
62062021|NCT02390856|EXPERIMENTAL|Conventus DRS|Patients in this group will undergo distal radius fracture fixation with the Conventus DRS intramedullary fixation device.
62266313|NCT00848861|ACTIVE_COMPARATOR|1 propofol|
62266314|NCT00848861|ACTIVE_COMPARATOR|2 midazolam plus meperidine|
62449699|NCT02673164|PLACEBO_COMPARATOR|Placebo|Saline
62850224|NCT00640224|NO_INTERVENTION|Overweight/Obese without PCOS|Overweight adolescent females without PCOS to use as comparison of normal developmental changes. \*No participants were enrolled in this Arm.
62850225|NCT00640224|NO_INTERVENTION|Lean without PCOS|Lean healthy girls without PCOS to serve as controls for the cardiovascular markers. \*No participants were enrolled in this Arm.
62850226|NCT04243382|EXPERIMENTAL|group 1|Autologous umbilical cord blood transfusion Single dose of an Autologous umbilical cord blood transfusion
62850227|NCT04243382|EXPERIMENTAL|group 2|The placebo product will consist of the standard ingredients of the acellular content of the UCB unit. It will consist of 20 ml Dextran (Plander 40.000 - 50g/500ml, solution for infusion) and 20 ml of human Albumin 5% (solution for infusion). The volume of placebo product will be 40 ml,
62850228|NCT03811860|ACTIVE_COMPARATOR|Once Daily Dosing|In this arm of the study, participants receive the prescribed dose of lithium once daily at bedtime. After 4-6 days, a steady state lithium serum level and serum creatinine are taken, and they crossover to the other arm (twice daily dosing, if they have not already done so). Frequency of selected medication use is noted.
62850229|NCT03811860|ACTIVE_COMPARATOR|Twice Daily Dosing|In this arm of the study, participants receive the prescribed dose of lithium divided into two daily doses. After 4-6 days a steady state lithium serum level and serum creatinine are taken, and they crossover to the other arm (once daily dosing, if they have not already done so).Frequency of selected medication use is noted.
62850230|NCT00636363|EXPERIMENTAL|Multipurpose Solution - Rub Care|Bausch \& Lomb Multipurpose Solution for use with contact lens care
62850231|NCT00636363|EXPERIMENTAL|Multipurpose Solution - No Rub Care|Bausch \& Lomb Multipurpose Solution for use with contact lens care
62850232|NCT00636363|ACTIVE_COMPARATOR|Ciba Vision Aquify Multipurpose Solution|Ciba Vision Aquify Multipurpose Solution for use with contact lens care
62850233|NCT01763008||Doripenem|Patients will be administered doripenem as per the dosing regimen given on product insert approved in Philippines.
62266315|NCT05022329|EXPERIMENTAL|Patients who received two doses Pfizer-BioNTech vaccine, Arm 1|
62266316|NCT05022329|EXPERIMENTAL|Patients who received two doses MODERNA vaccine, Arm 2|
62062022|NCT05732532|ACTIVE_COMPARATOR|Anesthetic without steroid group|Subjects scheduled for bilateral greater/lesser occipital nerve blocks as part of clinical care will receive standard of care medication, including lidocaine and bupivacaine and normal saline.
62266317|NCT05022329|EXPERIMENTAL|Patients who received two doses Pfizer-BioNTech vaccine ,Arm 3|
62266318|NCT05022329|EXPERIMENTAL|Patients who received two doses MODERNA vaccine, Arm 4|
62624221|NCT05702099||Detorsion|The group in which only adnexal detorsion was performed during the operation (Because there is no ovarian mass)
62062023|NCT05732532|EXPERIMENTAL|Anesthetic with dexamethasone group|Subjects scheduled for bilateral greater/lesser occipital nerve blocks as part of clinical care will receive standard of care medication, including lidocaine and bupivacaine and dexamethasone.
62266319|NCT06046144||Patients with a pigmented skin lesion|Patients with a pigmented skin lesion of more than 3mm diameter which have benefited systematically of all 3 imaging techniques at the same time, followed by either a surgical excision or annual imaging monitoring.
62266320|NCT05711004|EXPERIMENTAL|SMS group|Participants in the experimental group will receive three messages per week in the morning (9-10 am) for three months. The investigators will call them every month to ensure that the SMS is delivered.
62266321|NCT05711004|NO_INTERVENTION|Control group|Patients in the control group will also receive the usual primary health care.
62266322|NCT06373809|EXPERIMENTAL|Foot Ulcer|"The intervention at the foot in group 1 will be carried out by PDSC suspension in 60cc Lactated Ringer's (LR) solution. There will be 3 sequential blocks of subjects with increasing PDSC dose:~* Block 1 (4 subjects) Total dosage (30 x 10\*6 cells)~* Block 2 (3 subjects) Total dosage (40 x 10\*6 cells)~* Block 3 (3 subjects) Total dosage (60 x 10\*6 cells)~Administration to the ipsilateral foot / ankle in group 1 is performed by four injection sites: (1) 20 cc into the wound bed, (2) 20 cc subcutaneously around the perimeter of the wound, (3) 10 cc along the tibialis posterior pathway at the ankle prior to entry into the plantar surface, and (4) 10 cc along the tibialis anterior / dorsal foot pathway from the ankle to the dorsum of the foot."
62266323|NCT06373809|EXPERIMENTAL|Foot Ulcer and Leg neurophathy|"Dosing to the leg in group 2 will be carried out by PDSC suspension of the dose in 90cc LR solution, which will be divided equally among the three compartments of the leg. There will be 3 sequential blocks of subjects with increasing PDSC dose:~* Block 1 (4 subjects) Total dosage (30 x 10\*6 cells)~* Block 2 (3 subjects) Total dosage (40 x 10\*6 cells)~* Block 3 (3 subjects) Total dosage (60 x 10\*6 cells)~Administration to the leg will be performed through a 5 mm incision in each compartment (anterior, posterior, and lateral) at a level lower than the anterior tibial tubercle plane. These incisions will allow the introduction of a liposuction cannula of 3-4 mm in diameter and 20 cc in length, with an aroma tip and a single port that will be passed distally until the limit of the compartment is reached and, from there, the PDSCs will be injected retrograde throughout the compartment."
62449700|NCT02849821|OTHER|hypobaric pressure chamber|The healthy volunteers and IBD patients will have a 3-hour exposure to hypoxic conditions simulating an altitude of 4,000 meters above sea level (m.a.s.l.) in a hypobaric pressure chamber. Before and after the pressure chamber sigmoidoscopy will be performed. During stay in the pressure chamber repetitive measurements of bladder volume will be performed by sonography.
62449701|NCT01874951|PLACEBO_COMPARATOR|Placebo|In this arm, patients will receive placebo for three weeks.
62850234|NCT05168111||patients of Diquat poisoning|
62850235|NCT05168111||normal persons|
62850236|NCT04280237||Cefazolin in liver transplantation|Patient undergoing liver transplant surgery and receiving antibiotic prophylaxis with Cefazolin
62850237|NCT02895867|EXPERIMENTAL|Full fat dairy group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietitian and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
62850238|NCT02895867|EXPERIMENTAL|Low fat dairy group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietitian and will be instructed to include at least ≥3 servings of low fat dairy products into their diet
62850239|NCT02895867|OTHER|Control group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
62850240|NCT03225508||Phase 1|"The first phase will be to evaluate a new lung ultrasound technique to measure diaphragmatic excursion using a linear probe in the mid-axillary line. This will involve scanning 75 healthy patients undergoing elective surgery to determine normal reference values in men and women.~The following interventions will be carried out:~(i) Measurement of diaphragmatic movement with a linear ultrasound probe on both sides of the chest (ii) Measurement of diaphragmatic movement with a curved ultrasound probe on both sides of the chest"
62850241|NCT03225508||Phase 2|"This will involve patients undergoing an interscalene / supraclavicular brachial plexus block for their routine care, it will examine the reduction in diaphragmatic motion due to phrenic nerve palsy.~Interventions:~(i) Measurement of diaphragmatic movement with a linear ultrasound probe bilaterally.~(ii) Measurement of diaphragmatic movement with a curved ultrasound probe bilaterally.~(iii) Pulmonary function tests prior to the brachial plexus block (iv) Planned supraclavicular / interscalene block by the clinical team. (v) Repeat measurement of diaphragmatic movement with linear ultrasound, only on the side of the brachial plexus block.~(vi) Repeat measurement of diaphragmatic movement with curved ultrasound, only on the side of the brachial plexus block."
62062024|NCT01337414|EXPERIMENTAL|VMS diary booklet|
62850242|NCT05160064||Patients Treated with Loncastuximab Tesirine|Patients with B-cell lymphomas and other diagnoses who have been treated with loncastuximab tesirine will have their medical chart data entered into the registry.
62266324|NCT03223428||Carcinoid Syndrome patients initiating Xermelo|Patients with Carcinoid Syndrome who are initiating treatment with XERMELO.
62850243|NCT03616808|NO_INTERVENTION|Conventional therapy|Intraoperative haemostatic treatment is based on conventional coagulation assays.
62850244|NCT03616808|ACTIVE_COMPARATOR|Goal-directed therapy|Thromboelastometry-guided haemostatic treatment is provided intraoperatively.
62850245|NCT03939741|EXPERIMENTAL|Group A|"Participants having a harvested total Adipose Derived Stem Cell (ADSC) count (in 5 ml SVF solution) more than 1 x 10\^6.~Genetic: SVF containing Autologous Non Expanded ADSC."
62850246|NCT05072067|EXPERIMENTAL|OBESE PATIENT|OverStitch™ Sx with a Single channel endoscop CO2 Insufflation, patient on decubitus dorsal, with intubate 3 to 7 sutures, from the antral ogiv to the cardia are done
62850247|NCT06227793|EXPERIMENTAL|intervention|With health education
62850248|NCT06227793|NO_INTERVENTION|control|Without health education
62850249|NCT01657461|EXPERIMENTAL|IV t-PA with Solitaire™ revascularization device|Dual IV tPA therapy and adjunctive treatment with the Solitaire revascularization device
62850250|NCT01657461|ACTIVE_COMPARATOR|IV t-PA|Infusion of intravenous tissue plasminogen activator (IV t-PA)
62850251|NCT02343549|EXPERIMENTAL|Planned RT + TMZ + BEV + NovoTTF100A Device|Best standard of care radiation therapy (RT, 2 Gy given daily 5 days per week), temozolomide (TMZ, 75 mg/m2 administered daily), and bevacizumab (BEV, 10 mg/kg administered every 2 weeks as an IV infusion) for 6 weeks. After completion of chemoradiation, NovoTTF100A system was initiated, to be worn on average 18 hours or more a day for up to 12 months. The patients also continued with maintenance TMZ/BEV.
62850252|NCT01015638|EXPERIMENTAL|Clindamycin and BPO 5% gel|Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
62850253|NCT01015638|ACTIVE_COMPARATOR|Clindamycin phosphate and BPO 2.5% gel|Once Daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel.
62850254|NCT01343693||Anterior cervical discectomy and fusion|Any subject with DDD, tumor, deformity ot trauma to the cervical spine in which the investigator determines the subject will require an ACDF using the MaxAn Plate.
62850255|NCT04050280|EXPERIMENTAL|CLAG-GO|Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)
62850256|NCT03736772|EXPERIMENTAL|LY3090106|LY3090106 administered subcutaneously (SC)
62850257|NCT03736772|PLACEBO_COMPARATOR|Placebo|Placebo administered SC
62850258|NCT00512980|ACTIVE_COMPARATOR|1|
62850259|NCT00512980|ACTIVE_COMPARATOR|2|
62850260|NCT00799214|PLACEBO_COMPARATOR|1|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
62850261|NCT00799214|EXPERIMENTAL|2|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
62850262|NCT00799214|ACTIVE_COMPARATOR|3|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
62850263|NCT00508664|EXPERIMENTAL|A|TP + Radiation (TPF until Feb 2009)
62850264|NCT00508664|EXPERIMENTAL|B|TP + Cetuximab + Radiation (TPF until Feb 2009)
62850265|NCT04214964||Gynecological cancer|patients who has been pathological diagnosed with Gynecological cancers between 2002 and 2022 in China
62062025|NCT01337414|ACTIVE_COMPARATOR|Usual Care (e.g. Amsler grid monitoring)|
62850266|NCT00891540|ACTIVE_COMPARATOR|1|Local infiltration with Ropivacaine
62850267|NCT00891540|ACTIVE_COMPARATOR|2|Local infiltration with Ropivacaine
62850268|NCT00891540|PLACEBO_COMPARATOR|3|Local infiltration with NaCl
62850269|NCT06044597|EXPERIMENTAL|SyncAV plus group|Patients implanted with a CRT-D programmed with SyncAV plus function ON.
62850270|NCT06044597|NO_INTERVENTION|Biv Trad|Patients implanted with a CRT-D programmed with fixed AV delay.
62850271|NCT00749112|EXPERIMENTAL|A|
62850272|NCT03922113||Critically ill patients|Patients who spent a minimum of 48h in ICU
62850273|NCT03922113||Surgical patients|Patients who were scheduled for elective colorectal surgery
62850274|NCT03922113||Healthy subjects|Healthy volunteers
62850275|NCT01640834|EXPERIMENTAL|100 mg LY2409021|"LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.~Placebo: 2 capsules, administered as a single oral dose on Day 2.~Glucagon: 1 mg administered via intramuscular injection on Day 3."
62266325|NCT02114437|EXPERIMENTAL|Closed-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
62850276|NCT01640834|EXPERIMENTAL|300 mg LY2409021|"LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.~Glucagon: 1 mg administered via intramuscular injection on Day 3."
62850277|NCT01640834|PLACEBO_COMPARATOR|Placebo|"Placebo: 3 capsules administered as a single oral dose on Day 2.~Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3."
62850278|NCT06531551|EXPERIMENTAL|Study|Acupressure
62850279|NCT06531551|NO_INTERVENTION|Control|Only routine practices of the clinic will be carried out
62850280|NCT01681355|EXPERIMENTAL|Intervention group|Healthy infants receiving standard cow's milk-based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition.
62850281|NCT01090323|EXPERIMENTAL|ICL670|
62266326|NCT02114437|PLACEBO_COMPARATOR|Opened-loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits to maintain NI at approximately 36 within a range of 26 to 46 to the extent possible.
62266327|NCT06300658|EXPERIMENTAL|Stellate ganglion blockade|Patient will receive preemptive stellate ganglion blockade (SGB) just before spinal anesthesia.
62624222|NCT05702099||Detorsion+cystectomy|Women with an ovarian mass who underwent emergency surgery for torsion, who underwent both detorsion and cystectomy in the same session.
62624223|NCT01586377||CRPS Type 1|Patients with CRPS 1 affecting a single upper limb
62624224|NCT01586377||Healthy volunteers|Volunteers without the diagnosis of CRPS Type 1
62624225|NCT01502956|ACTIVE_COMPARATOR|InterStim® device|The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/\>50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.
62624226|NCT01502956|ACTIVE_COMPARATOR|Botox® injection|Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.
62624227|NCT02334345|EXPERIMENTAL|EVOSKIN|Patients are to apply Evoskin ( topical agent) in the half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.
62624228|NCT02334345|ACTIVE_COMPARATOR|TRIXIERA|Patients are to apply Trixiera ( topical agent) in the other half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.
62624229|NCT01642706||RA patients|Patients affected by Rheumatoid arthritis.
62624230|NCT01642706||Control|"Subjects affected by either :~* mechanical pathology~* systemic auto-immune pathology~* other inflammatory rheumatism"
62624231|NCT04153565|EXPERIMENTAL|Pembrolizumab + Cisplatin + Pemetrexed|Pembrolizumab 200 mg IV every 3 weeks (Q3W) in combination with Cisplatin 75 mg/m\^2 IV, and Pemetrexed 500 mg/m\^2 IV for 4-6 cycles followed by monotherapy of Pembrolizumab up to 35 cycles from the first dose of the study in treatment phase (approximately 2 years).
62624232|NCT06399354|EXPERIMENTAL|Meal test in patients|Effect of medium-chain fatty acids on heart function measured by cardiac magnetic resonance imaging (CMR) in individuals with heart failure.
62062026|NCT01140334|EXPERIMENTAL|Reinforced On-Site Integrated Care (ROIC)|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. In addition, they will be able to earn a voucher incentive for each week of psychiatric compliance.
62266328|NCT06300658|NO_INTERVENTION|Control group|Patient will not receive preemptive stellate ganglion blockade (SGB).
62266329|NCT02102321|EXPERIMENTAL|albendazole|albendazole 400 mg
62266330|NCT02102321|ACTIVE_COMPARATOR|placebo|placebo
62266331|NCT01705600|EXPERIMENTAL|Pain Verbalization Repression Rules|This group will wear a bracelet with a set of rules which will restrict ones verbalization of pain complaints
62449702|NCT01874951|EXPERIMENTAL|Naltrexone|In this arm, patients will receive low dose naltrexone for three weeks.
62449703|NCT01492062|EXPERIMENTAL|closed-loop control|Multiple Model Predictive Controller
62449704|NCT04642352||SLN intervention group|Participants will undergo a superior laryngeal nerve (SLN) block
62449705|NCT01725984||AdVance|Subjects previously implanted with the AdVance Male Sling
62449706|NCT01725984||AdVance XP|Subjects previously implanted with the AdVance XP male sling
62449707|NCT02520557||Case|Cases will be individuals with documented definite or probable Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), or drug reaction with eosinophilia and systemic symptoms (DRESS) or symptom onset consistent with one of these conditions within the first 4 months of using ESL (including up to 14 days after discontinuing ESL) will be considered a potential case. Blood draw or Saliva.
62449708|NCT02520557||Control|Controls will be individuals who have used ESL for at least 6 weeks and who have not developed SCAR. Blood draw or saliva.
62449709|NCT03919201|SHAM_COMPARATOR|Control group|No exercise intervention
62449710|NCT03919201|EXPERIMENTAL|Resistance band exercise intervention|Exercise intervention group (resistance band exercise training for 12 weeks, 5x per week, for 60 minutes per day).
62449711|NCT03672110|ACTIVE_COMPARATOR|Standard tacrolimus group|Control group: Advagraf will be administered as usual (0.2mg/kg bodyweight), trough levels will be measured every day in the first week after kidney transplantation (TX) and Advagraf dose will be adjusted accordingly.
62449712|NCT03672110|EXPERIMENTAL|Fixed dose tacrolimus group|Study group: Advagraf will be administered per fix dose 5mg/day, trough levels will be blinded during the first week, there will be no adjustments in the first week after TX.
62449713|NCT00372788|ACTIVE_COMPARATOR|1|Pemetrexed
62449714|NCT00372788|EXPERIMENTAL|2|AZD6244
62449715|NCT03211559|ACTIVE_COMPARATOR|AEROBİC EXERCİSE (walking on treadmill)|Patients walked on treadmill for 8 weeks, 3 days in a week,30-40 minutes each.
62449716|NCT03211559|EXPERIMENTAL|Aerobic Exercise+Clinical Pilates|Patients walked on treamill for 8 weeks, 3 days in a week, 30-40 minutes each. Additionally they did clinical pilates exercise for 8 weeks, 3 days in a week.
62449717|NCT04588259|EXPERIMENTAL|Faster aspart|4 daily injections of faster aspart given with insulin degludec and with or without metformin
62449718|NCT04588259|ACTIVE_COMPARATOR|Insulin aspart|4 daily injections of insulin aspart given with insulin degludec and with or without metformin
62449719|NCT05252481|ACTIVE_COMPARATOR|Active tDCS|Transcranial current direct stimulation. 8 days.
62449720|NCT05252481|SHAM_COMPARATOR|Sham tDCS|Sham transcranial current direct stimulation. 8 days.
62449721|NCT00217256|EXPERIMENTAL|1|Endeavor Drug Eluting Stent
62624233|NCT06399354|EXPERIMENTAL|Meal test in healthy individuals|Acute intake of a meal comprising either MCT of LCT in healthy individuals and the effects onheart function.
62624234|NCT01493115|EXPERIMENTAL|Sequence 1|Reference (insulin glargine) - Test1 (insulin glargine - new formulation dose 1) - Test2 (insulin glargine - new formulation dose 2)
62624235|NCT01493115|EXPERIMENTAL|Sequence 2|Test1 (insulin glargine - new formulation dose 1) - Test2 (insulin glargine - new formulation dose 2) - Reference (insulin glargine)
62624236|NCT01493115|EXPERIMENTAL|Sequence 3|Test2 (insulin glargine - new formulation dose 2) - Reference (insulin glargine) - Test1 (insulin glargine - new formulation dose 1)
62850282|NCT06438510|EXPERIMENTAL|Single arm|All patients undergo Endoscopic Sleeve Gastroplasty (ESG) and HybridAPC. ESG will be performed using a flexible endoscopic suturing system (OverStitchTM; Apollo Endosurgery, Austin, TX, USA) connected to a gastroscope. Full- thickness sutures will be placed from the angulus to the gastric fundus using a U-shaped pattern with 2.0 nonabsorbable suture thread. Biopsy tissue will be collected from the gastric fundus and the samples will be fixed for histopathologic examination. HybridAPC is an highly controlled mucosal lift applied by the waterjet function and the subsequent thermal ablation applied by APC. First the fluid cushion is injected into submucosa until a size in the range of 2 - 3 cm is achieved (pressure setting of E20 up to E 30). Second the mucosa is being ablated on the surface of this fluid cushion (30 - 50 Watts, argon gas flow 0.8 L/min)
62850283|NCT02305810|EXPERIMENTAL|Single arm receiving everolimus|single treatment arm receiving everolimus 10 mg daily
62624237|NCT01936207||One Group|
62850284|NCT05343767|ACTIVE_COMPARATOR|Control Arm 1 Metformin ( 64 patients)|"Metformin 1000 mg tablets were used.~* First Dose: One Metformin 1000 mg tablet + Two Placebo Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~* Second Dose: Two Placebo Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~* Third Dose: One Metformin 1000 mg tablet + Two Placebo Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~A total dose of 2000 mg was administered per day."
62850285|NCT05343767|EXPERIMENTAL|Experimental Arm 2: Low Dose NW Low-Glu ( 65 patients)|"The contents of 4 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses as follows:~* First Dose: One Placebo tablet + Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~* Second Dose: Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~* Third Dose: One Placebo tablet + Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals."
62850286|NCT05343767|EXPERIMENTAL|Experimental Arm 3: High Dose NW Low-Glu ( 69 patients)|"The contents of 5 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses as follows:~* First Dose: One Placebo tablet + Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~* Second Dose: Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~* Third Dose: One Placebo tablet + Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals."
62850287|NCT02661048|EXPERIMENTAL|Open label|Non-randomized, open label clinical trial that intends to treat 10 subjects with refractory ventricular tachycardia with the CyberHeart system using standard radiosurgical techniques.
62850288|NCT00913952|EXPERIMENTAL|1|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions.
62850289|NCT00913952|EXPERIMENTAL|2|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.
62062027|NCT01140334|ACTIVE_COMPARATOR|Standard On-Site Integrated Care (SOIC).|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week.
62624238|NCT06246097||group 1|early loading of dental implants within a month
62624239|NCT06246097||group 2|delayed loading of dental implants within 3 months
62850290|NCT00913952|ACTIVE_COMPARATOR|3|Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.
62850291|NCT01937832|ACTIVE_COMPARATOR|Ertapenem|
62850292|NCT01937832|EXPERIMENTAL|Faropenem|
62850293|NCT01334619|OTHER|ropivacaine volume titration|
62062028|NCT01377480|EXPERIMENTAL|Posaconazole|Posaconazole (POS) 400 mg (10 mL) oral suspension twice daily for 60 days
62062029|NCT01377480|PLACEBO_COMPARATOR|Placebo|Posaconazole placebo (10 mL) oral suspension twice daily for 60 days
62062030|NCT01377480|EXPERIMENTAL|Posaconazole + Benznidazole|Posaconazole 400 mg (10 mL) oral suspension twice daily for 60 days and benznidazole (BNZ) 100 mg oral tablet twice daily (200-mg daily dose) for 60 days
62449722|NCT00217256|ACTIVE_COMPARATOR|2|Cypher Drug Eluting Stent
62449723|NCT02058056|EXPERIMENTAL|Experimental: HA-PCI treatment|Irradiation HA-PCI concomitant to the second cycle of CHT and to tRT for patients with LD SCLC
62850294|NCT03753945|EXPERIMENTAL|DBS electrode placement|"Participants in this study will be patients who have already undergone surgery for implantation of DBS electrodes.~Patients who have already undergone surgery for implantation of DBS electrodes and patients for whom the treating physicians recommends (based on clinical grounds) a spine MRI (cervical, thoracic or lumbar) shall be recruited for the study.This eligible patient population is broad but unified by the fact that they have undergone DBS to treat specific circuit dysfunctions. Patients with internalized leads and IPG may be included. Patients will undergo routine clinical MRI sequences used for the spine (structural in axial and sagittal planes). The choice of imaging the cervical, thoracic or lumbar will depend on the requisition from the treating physician."
62449724|NCT05414474|ACTIVE_COMPARATOR|Reference|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 54Fe).
62449725|NCT05414474|EXPERIMENTAL|Ascorbic acid (AA) 500 mg|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 57Fe) and 500 mg AA.
62624240|NCT06443515|OTHER|study group|All infants undergoing blood transfusions will be enrolled in the study
62624241|NCT01639703|EXPERIMENTAL|CT perfusion|arm with CT perfusion
62624242|NCT00613379|EXPERIMENTAL|Arm 1|10 mg/kg PRO 140, one IV dose (N=10)
62624243|NCT00613379|EXPERIMENTAL|Arm 2|5 mg/kg PRO 140, one IV dose (N=10)
62624244|NCT00613379|PLACEBO_COMPARATOR|Arm 3|Placebo, one IV dose (N=10)
62624245|NCT06076122|EXPERIMENTAL|Food supplement based on Salicornia extracts|Participants will receive food supplement based on halophyte plant (Salicornia) extracts, 1 g (two 0.5 gram capsules) orally once a day for a treatment period of 3 months (substudy A), 11 months (substudy B), 1 year (substudy C) or 7-30 days (substudy D).
62624246|NCT06076122|PLACEBO_COMPARATOR|Placebo|Participants will receive two capsules once a day of placebo physically equal to the nutritional supplement for a treatment period of 3 months (substudy A), 11 months (substudy B), 1 year (substudy C) or 7-30 days (substudy D).
62624247|NCT03646071|EXPERIMENTAL|Dose Escalation Phase|The Dose-Escalation Phase will employ a standard 3+3 algorithm to investigate ascending dose cohorts of RX108.
62624248|NCT03646071|EXPERIMENTAL|Dose Expansion Phase|In the Expansion Phase, subjects will receive RX108 at the maximum tolerated dose.
62624249|NCT02468999|ACTIVE_COMPARATOR|insulin nasal spray|160 Units of human insulin as nasal spray
62624250|NCT02468999|PLACEBO_COMPARATOR|placebo nasal spray|Nasal spray containing placebo solution
62624251|NCT04760535|EXPERIMENTAL|Arm A: Invisalign® First clear aligners|"The Invisalign® First aligners are fabricated in a multilayer aromatic thermoplastic polyurethane/co-polyester 0.75mm (.030)-thick with a fine 3D manufacturing process."
62624252|NCT04760535|ACTIVE_COMPARATOR|Arm B: tooth-borne Hyrax-type maxillary expander|The Hyrax-type maxillary expander is a tooth-borne expansion appliance that is fixed to the upper second deciduous molars (or to the first permanent molars) using bands and includes a midline 12-mm self-locking screw (Forestadent, Pforzheim, Germany; 0.9 mm, complete turn). The expansion screw is connected to the conventional molar bands or printed clasps, modeled surrounding the molars, via a framework of 0.9mm stainless-steel wire. The framework is soldered to the bands and extending on the palatal side to the deciduous canines. The expander will be fabricated by qualified laboratory technician.
62850295|NCT04241900|EXPERIMENTAL|Shuttle run test|At the shuttle run test, participants were required to run between two lines 20 meters apart, while keeping pace with audio signals emitted from a pre-recorded CD. The frequency of the sound signals increases in such way that running speed was increased by 0.5 km h-1 each minute from the starting speed 8.5 km h-1.
62850296|NCT01128660||RSD-citizens|Residents of Southern Denmark, who filed more than 9 prescriptions during 2009.
62266332|NCT03797586|EXPERIMENTAL|Electroacupuncture group|Bilateral ST25,SP14, ST37 will be used in the EA group. For ST25 and SP14, 0.30×50mm or 0.30×75mm needles will be vertically inserted to the muscle layer of the abdominal , where patients will feel sharp pain and acupuncturists will feel resistance from the needle tip. For ST37, 0.30×40 mm needles will be vertically inserted approximately 15 mm deep, followed by three-time manipulation of even lifting and twisting method to elicit the sensation of deqi. Then paired alligator clips of the EA apparatus will be attached to the needle holders of the bilateral ST25, SP14, and ST37. EA stimulation will be retained for 30 minutes with a continuous wave of 10 Hz and current intensity of 0.5 to 4 mA.
62449726|NCT05414474|EXPERIMENTAL|Ascorbic acid (AA) 80 mg|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 58Fe) and 80 mg AA.
62449727|NCT05414474|EXPERIMENTAL|Coffee|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 54Fe) and 150 mL coffee.
62449728|NCT05414474|EXPERIMENTAL|Breakfast|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 57Fe) and 1 bread roll (\~100 g) with butter and honey, 1 cup of plain yoghurt (180 mL), 1 cup of coffee (150 mL) and 1 glass of orange juice (250 mL).
62850297|NCT03179904|EXPERIMENTAL|Cohort A (FASN inhibitor TVB-2640, paclitaxel, trastuzumab)|Patients receive FASN inhibitor TVB-2640 PO QD on days 1-28, paclitaxel IV over 1-96 hours on days 1, 8, and 15, and trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22 and optionally every 21 days after 3 cycles and paclitaxel is discontinued. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity. Patients also undergo ECHO and CT or MRI at screening and on study and undergo collection of blood samples and biopsy on study.
62449729|NCT05414474|EXPERIMENTAL|Afternoon|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 58Fe) in the afternoon .
62449730|NCT05731427||Pseudomonas aeruginosa colonization group|Colonization of Pseudomonas aeruginosa in the airways of patients with bronchiectasis
62449731|NCT05731427||Non-Pseudomonas aeruginosa colonization group|No colonization of Pseudomonas aeruginosa in the airways of patients with bronchiectasis
62449732|NCT05731427||Before treatment with macrolides|Before treatment with macrolides in patients with bronchiectasis
62449733|NCT05731427||After treatment with macrolides|After 6 months of treatment with macrolides for patients with bronchiectasis
62449734|NCT03963570|EXPERIMENTAL|Safe Step - digital exercise program|Participants randomized to the experimental group will receive full access to the Safe Step application and create their own individual program of strength and balance exercises. During 1 year the participants are recommended to exercise at least 30 minutes, 3 times a week and continuously progress their program. In addition they will every month receive an email with general falls prevention information in a short video.
62449735|NCT03963570|OTHER|Control group|During 1 year, the participants randomized to the control group will receive an email every month with general falls prevention information in a short video.
62449736|NCT04752436|EXPERIMENTAL|Supra high intensity interval training|The experimental group will engage in the high intensity interval training.
62449737|NCT00535106|ACTIVE_COMPARATOR|Standard resusc|Patients in this arm will be treated with standard resuscitation efforts, including the delivery of an immediate defibrillatory shock for all patients presenting in VF.
62850298|NCT03179904|EXPERIMENTAL|Cohort B (TVB-2640, trastuzumab, endocrine therapy)|Patients receive FASN inhibitor TVB-2640 PO QD on days 1-28 and trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22 and optionally every 21 days after 3 cycles and paclitaxel is discontinued. Patients also continue endocrine therapy of either anastrozole PO QD, exemestane PO QD, fulvestrant IM on days 1 and 14 of cycle 1 and day 1 of subsequent cycles, or letrozole PO QD. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity. Patients also undergo ECHO and CT or MRI at screening and on study and undergo collection of blood samples and biopsy on study.
62850299|NCT05127746|EXPERIMENTAL|Sequence 1|Period 1, Aricept 5mg → DA-5207 A; Period 2, Aricept 5mg → Aricept 10mg
62266333|NCT03797586|SHAM_COMPARATOR|Sham electroacupuncture group|Bilateral sham ST25, SP14, and ST37 will be used in the SA group. After sterilizing the skin, 0.30×40mm needles will be straightly inserted at the sham points about 2-3mm until they can be fixed on the skin when attached by the alligator clips. No manipulation will be used, and no deqi sensation are elicited for all sham points. The bilateral sham ST25, SP14, and ST37 points will be attached by the same EA apparatus with a continuous wave of 10 Hz and current intensity of 0.1 to 0.2 mA for 30 minutes with only the initial 30 seconds on.
62266334|NCT03270735|EXPERIMENTAL|Treatment|Snake venom thrombin
62850300|NCT05127746|EXPERIMENTAL|Sequence 2|Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg → DA-5207 A
62850301|NCT05127746|EXPERIMENTAL|Sequence 3|Period 1, Aricept 5mg → DA-5207 B; Period 2, Aricept 5mg → Aricept 10mg
62850302|NCT05127746|EXPERIMENTAL|Sequence 4|Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg → DA-5207 B
62850303|NCT06287177||Subjects with hyperlipidaemia under Inclisiran treatment|
62850304|NCT02543424|EXPERIMENTAL|Patient group|Brain damaged adults with either hemiparesis and/or hemineglect. Brain damaged children with developmental and/or acquired disease inducing hemiparesis and/or hemineglect.
62850305|NCT02543424|SHAM_COMPARATOR|Control group|Healthy adults and children.
62850306|NCT03364270|EXPERIMENTAL|[F-18] RDG-K5|PET/CT Imaging with administration of \[F-18\] RGD-K5
62266335|NCT03270735|PLACEBO_COMPARATOR|Placebo|Snake venom thrombin simulant
62624253|NCT01616160|EXPERIMENTAL|Nasal polyps subjects|24 subjects with nasal polyps. Intervention: Each subject will receive Nasonex (mometasone furoate) 2 spray per nostril twice daily for 4 weeks.
62624254|NCT03791801|ACTIVE_COMPARATOR|Neostigmine|Will receive rocuronium and neostigmine (5-70microg/kg) + glycopyrrolate (10microg/kg) at train of four 1
62624255|NCT03791801|ACTIVE_COMPARATOR|Sugammadex|Will receive rocuronium and sugammadex (4mg/kg) after a successful intubation (ETT is in the trachea and secure).
62850307|NCT01614678|OTHER|AIR OPTIX® COLORS Auto, then AIR OPTIX® COLORS Semi-auto|Lotrafilcon B contact lens with color, automated, worn first, with Lotrafilcon B contact lens with color, semi-automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
62850308|NCT01614678|OTHER|AIR OPTIX® COLORS Semi-auto, then AIR OPTIX® COLORS Auto|Lotrafilcon B contact lens with color, semi-automated, worn first, with Lotrafilcon B contact lens with color, automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
62850309|NCT02005861|EXPERIMENTAL|bone marrow cells transplantation|"surgical procedure :the day before the surgery: platelet gel production. The day of the surgery: bone marrow aspiration from the posterior iliac crest of the patient and concentration. After the bone marrow harvesting, ankle arthroscopy will be performed. The lesion will be detected and cleaned.~An equine collagen type 1 scaffold (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) will be loaded with 2 ml of bone marrow concentrate and implanted.~After that platelet gel will be loaded on the top of implant"
62850310|NCT05317325|EXPERIMENTAL|Experimental Group|Autologous DCs pulsed with HOCl-oxidized autologous tumor lysate (OCDC) vaccine is administered in prime phase and personal neoantigen-sensitized DC(NeoDC) vaccine is administered in boost phase.
62850311|NCT01094522|EXPERIMENTAL|Methadone|One half the Study patients will be randomized to receive a loading dose of IV methadone, followed by IV doses (given by the ICU nurse), on a PRN basis, for pain control for up to 24 hours during their postoperative course while they are intubated.
62850312|NCT01094522|ACTIVE_COMPARATOR|Morphine|One half the Study patients will be randomized to receive a loading dose of IV morphine, followed by IV doses (given by the ICU nurse), on a PRN basis, for pain control for up to 24 hours during their postoperative course while they are intubated.
62850313|NCT05162937|EXPERIMENTAL|Treatment group 1|Drug：GR1501 100mg
62850314|NCT05162937|EXPERIMENTAL|Treatment group 2|Drug：GR1501 200mg
62850315|NCT05162937|EXPERIMENTAL|Treatment group 3|Drug：GR1501 300mg
62850316|NCT05162937|PLACEBO_COMPARATOR|Treatment group 4|Drug：placebo
62449738|NCT00535106|EXPERIMENTAL|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
62624256|NCT05853029|EXPERIMENTAL|Group A|Group (1): Twenty patients will receive 2000 pulses of Focused shock wave therapy with (4 Hz; 0.2 millijoule (mJ)/mm2) in addition to conventional therapy including eccentric exercises, stretching, hot packs and deep transverse friction(Johnson et al., 2007). Each patient will have 3 treatment sessions held at weekly basis(Król et al., 2015).
62624257|NCT05853029|EXPERIMENTAL|Group B|Group (2): Twenty patients will receive both 2000 pulses of (Focused shockwave therapy with (4 Hz; 0.2 mJ/mm2) and 2000 pulses of Radial shockwave therapy with (8 Hz, 2.5 bars) )= combined shockwave therapy in addition to conventional therapy including eccentric exercises, stretching, hot packs and deep transverse friction(Johnson et al., 2007). Each patient will have 3 treatment sessions held at weekly basis(Król et al., 2015).
62624258|NCT05853029|EXPERIMENTAL|Group C|Group (3): Control group of twenty patients that will only receive conventional therapy including eccentric exercises, stretching, hot packs and deep transverse friction(Johnson et al., 2007).
62624259|NCT06610097|NO_INTERVENTION|Educational Handout|Participants will receive usual standard of care for early-stage triple negative breast cancer and an educational handout on increasing dietary fiber.
62850317|NCT03890042|ACTIVE_COMPARATOR|Dienogest group|
62850318|NCT03890042|ACTIVE_COMPARATOR|Gynera group|
62850319|NCT01863836|EXPERIMENTAL|Fluoroscopy|Patients will undergo bronchoscopy and radial endobronchial ultrasound-guided biopsy of a peripheral lung lesion like patients in the other group. However, single-plane fluoroscopy will be used to help locate the lesion (with the help of a steerable curette) in case of failure to locate the lesion, and it will also be used to guide tissue sampling and ensure appropriate sampling tool function. Transbronchial biopsies, transbronchial needle aspiration, brushings, and bronchoalveolar lavage will be performed for each lesion.
62449739|NCT00535106|ACTIVE_COMPARATOR|Delayed defib|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation. Data is being collected on this population as well, thereby providing a cohort population for comparative purposes.
62850320|NCT01863836|ACTIVE_COMPARATOR|No fluoroscopy|Patients will undergo biopsy of peripheral lung lesions using radial endobronchial ultrasound guidance only, without the use of fluoroscopy. Transbronchial biopsies, transbronchial needle aspiration, brushings, and bronchoalveolar lavage will be performed for each lesion.
62850321|NCT02073344|EXPERIMENTAL|Intevention group|A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG 6 months after the beginning of a renal replacement therapy
62850322|NCT02073344|EXPERIMENTAL|Control group|No intervention A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG at 6 months if the patient is not already on renal replacement therapy
62449740|NCT04168541|ACTIVE_COMPARATOR|Oral Nutrition Supplement A|Product containing calories from carbohydrate, protein, and fat
62624260|NCT06610097|EXPERIMENTAL|High Fiber Dietary Counseling|Participants will receive usual standard of care for early-stage triple negative breast cancer and personalized nutritional counseling (initial 1 hour session with up to 2 30-minute follow-up sessions) on how to increase dietary fiber.
62624261|NCT04122209|EXPERIMENTAL|HIIE-First|60-min of exercise split into; firstly 30-min HIIE (10 x 1min of PPO, followed by 2-min rest). Secondly 30-min of continuous exercise (50% peak maximal oxygen uptake).
62624262|NCT04122209|EXPERIMENTAL|Continuous-First|60-min of exercise split into; firstly 30-min of continuous exercise (50% peak maximal oxygen uptake). Secondly 30-min HIIE (10 x 1min of PPO, followed by 2-min rest)
62624263|NCT00573872|EXPERIMENTAL|Spinal Radiosurgery|Patients will be fitted in a custom immobilization device. A CT simulation scan will then be performed to pinpoint intended radiosurgery target producing a computer optimized radiation plan to be confirmed by planning radiation physicist. Patient will then be placed in their immobilization device and aligned with the treatment planning position. Patient then receives radiosurgery. Treatment delivery will be divided into components of 3-5Gy with repeat CT based localization in between each of these components. For all patients, a nominal prescription dose of 24Gy will be entered into the tomotherapy cost function. Once the plan that provides maximal spinal sparing has been generated, the plan will be renormalized to produce no more than 8Gy (prior RT) or 10Gy (no prior RT) to 0.5cc of spinal cord by dividing the single fraction treatment into fractions of 3-5Gy.
62624264|NCT01515566|EXPERIMENTAL|Fentanyl|Fentanyl subcutaneously (SQ) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before walk test, and 6 minute walk test (6MWT) at baseline and 15 minutes after Fentanyl. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.
62850323|NCT03238014|EXPERIMENTAL|High-intensity noninvasive ventilation|High-intensity noninvasive positive pressure ventilation aims at maximally improving PaCO2.
62850324|NCT03238014|ACTIVE_COMPARATOR|Low-intensity noninvasive ventilation|Low-intensity noninvasive positive pressure ventilation is a classic setting of noninvasive ventilation.
62850325|NCT05680532|EXPERIMENTAL|BR group|Experimental group AZ subjects were requested to take 50 g of BR powder dissolved in 240 ml of water for 4 weeks.
62850326|NCT05680532|PLACEBO_COMPARATOR|Placebo group|Placebo group AZ subjects were requested to take 50 g of dextrin powder dissolved in 240 ml of water for 4 weeks.
62449741|NCT04168541|ACTIVE_COMPARATOR|Oral Nutrition Supplement B|Product containing calories from carbohydrate, protein, and fat
62449742|NCT04168541|ACTIVE_COMPARATOR|Oral Nutrition Supplement C|Product containing calories from carbohydrate, protein, and fat
62449743|NCT04168541|ACTIVE_COMPARATOR|Oral Nutrition Supplement D|Product containing calories from carbohydrate, protein, and fat
62266336|NCT05304702||NEGBAL|"Negative Fluid Balance (NEGBAL) Approach:~COVID-19 patients with tomographic detection of pulmonary edema (dilated superior vena cava, large pulmonary arteries, diffuse interstitial infiltrates with Kerley lines, and dilated right ventricle or dilated cardiac axis) treated with NEGBAL approach. This consisted of oral hydric restriction and use of diuretics (20 mg of furosemide, intravenous bolus, followed by furosemide in endovenous continuous infusion, starting at 60 mg/day).~The objective of this approach was to achieve negative fluid balance, between 600 to 1400 mL/day adjusted to body surface area, with a final target of 8-10% of body weight in up to 8 days. The furosemide dose was titrated considering heart rate and blood pressure, target fluid balance, hematocrit, and serum creatinine."
62266337|NCT05304702||NO-NEGBAL|"Treatment for COVID-19 pneumonia in this series were based on standard recommendations.~All patients in this group received dexamethasone 6 mg/day and thromboembolic prevention with enoxaparin 40 mg/day.~Participants in the NO-NEGBAL group, did not received a NEGBAL approach as treatment."
62266338|NCT03741829||Samples from transbronchial Biopsy|Samples from participants with SCLC.
62266339|NCT05511272|EXPERIMENTAL|Frozen embryo transfer cycle|Patients who will undergo a frozen embryo transfer in the modified natural cycle and in an artificially prepared cycle will be included
62266340|NCT05875259|EXPERIMENTAL|Sequence 1|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 1: A-B-C"
62266341|NCT05875259|EXPERIMENTAL|Sequence 2|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 2: A-C-B"
62624265|NCT01515566|ACTIVE_COMPARATOR|Placebo|Normal saline 0.9% preservative free SQ 15 minutes before walk test, and 6 minute walk test at baseline and 15 minutes after Placebo. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.
62624266|NCT01592604|EXPERIMENTAL|Treatment A|Patients receive supportive compressive bandage for 4 weeks
62624267|NCT01592604|EXPERIMENTAL|Treatment B|Below knee walking plaster cast for 4 weeks
62624268|NCT05463588|EXPERIMENTAL|Collection of pre-test data from the experimental and control groups|Asking vas, ODI, sf-36 quality of life scale questions
62624269|NCT05463588|EXPERIMENTAL|Calculation of the pre-test fall risk index|Calculation of patients' fall risk indices
62266342|NCT05875259|EXPERIMENTAL|Sequence 3|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 3: B-A-C"
62062031|NCT01377480|ACTIVE_COMPARATOR|Benznidazole + Placebo|Posaconazole placebo (10 mL) oral suspension twice daily for 60 days and benznidazole 100 mg oral tablet twice daily (200-mg daily dose) for 60 days
62266343|NCT05875259|EXPERIMENTAL|Sequence 4|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 4: B-C-A"
62266344|NCT05875259|EXPERIMENTAL|Sequence 5|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 5: C-A-B"
62266345|NCT05875259|EXPERIMENTAL|Sequence 6|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 6: C-B-A"
62266346|NCT02858414|EXPERIMENTAL|blood sample|
62266347|NCT06076512||Adult chronic pain patients|Adult chronic pain patients who received pain management and/or addiction therapy
62266348|NCT05314608||Subjects with subchondral bone pathology|Subjects with subchondral bone pathology
62449744|NCT04168541|ACTIVE_COMPARATOR|Oral Nutrition Supplement E|Product containing calories from carbohydrate, protein, and fat
62062032|NCT02765022|EXPERIMENTAL|Clip|Clip closure of mucosal defects after endoscopic mucosal resection.
62449745|NCT04168541|ACTIVE_COMPARATOR|Oral Nutrition Supplement F|Product containing calories from carbohydrate, protein, and fat
62624270|NCT05463588|EXPERIMENTAL|giving back health education to the experimental and control groups|Back health training was given to both groups, and the experimental group was given training on using virtual glasses.
62624271|NCT05463588|EXPERIMENTAL|collection of post-test data for the experimental and control group|Asking vas, ODI, sf-36 quality of life scale questions
62624272|NCT05463588|EXPERIMENTAL|Calculation of the post-test fall risk index|Calculation of patients' fall risk indices
62624273|NCT04684108|EXPERIMENTAL|SG301|SG301 monotherapy intravenous (IV) infusion
62624274|NCT00985686|EXPERIMENTAL|Study Arm|Arm where participants began the LEAP Project intervention upon recruitment for an 8 week period.
62624275|NCT00985686|ACTIVE_COMPARATOR|Waitlist Arm|"Arm where participants received the LEAP Project intervention after an 8 week wait period.~At 8 weeks, the results from the wait-list arm (no intervention) were compared to the results of the study arm (intervention completed)."
62624276|NCT05449444|EXPERIMENTAL|Masitinib (4.5) & BSC|Masitinib 4.5 mg/kg/day administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC). Participants receive masitinib (3.0 mg/kg/day) for 4 weeks, given orally twice daily, with a dose escalation to 4.5 mg/kg/day for the remainder of the treatment period. Each ascending dose titration is subjected to a safety control.
62624277|NCT05449444|EXPERIMENTAL|Masitinib (6.0) & BSC|Masitinib 6.0 mg/kg/day administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC). Participants receive masitinib (3.0 mg/kg/day) for 4 weeks, given orally twice daily, with a dose escalation to 4.5 mg/kg/day for4 weeks of treatment, then a second dose escalation to 6 mg/kg/day for the remainder of the treatment period. Each ascending dose titration is subjected to a safety control.
62624278|NCT05449444|PLACEBO_COMPARATOR|Placebo & BSC|Placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC). Participants receive a matched dose placebo, given orally twice daily.
62266349|NCT03186170|EXPERIMENTAL|SSA|"The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSA versus traditional technique of swin up) as well as embryo development.~In this arm, the sperm selection for IVF will be performed by the new proposed technique of Sperm Selection Assay which consist to expose spermatozoa a progesterone quemoatractant Sperm selection via SSA technique"
62624279|NCT04027179|EXPERIMENTAL|FMS chlorhexidine mouthwash|Full-mouth scaling and root planning with manual curettes, 20 ml of 0.12% chlorhexidine gluconate mouthwash irrigation of each periodontal pocket of 5mm of more. Patients will rinse with 0.12% chlorhexidine gluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
62624280|NCT04027179|PLACEBO_COMPARATOR|FMS placebo mouthwash|Full-mouth scaling and root planning with manual curettes, 20 ml of placebo mouthwash irrigation of each periodontal pocket of 5mm of more. Patients will rinse with placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
62624281|NCT04027179|ACTIVE_COMPARATOR|FMS no mouthwash|Full-mouth scaling and root planning with manual curettes.
62624282|NCT04724785||patients with persistant low level HBV DNA (<10 IU/ml)|No further intervention(s) to be administered except for monitoring of HBV DNA viraemia
62624283|NCT04724785||patients with persistant HBV DNA (>10 IU/ml) but refuse to change the regimen|All patients with CHB receiving ETV or second-line NA(LAM/ADV/LdT) treatment for more than six months to one year will receive HBV-DNA detection, and patients with HBV-DNA≥10 IU/ml will be informed and recommended to adjust the treatment regimen. If those patients refuse to change the regimen which they are using , No further intervention(s) to be administered except for monitoring of HBV DNA viraemia until those patients change their idea
62624284|NCT04724785||patients with persistant HBV DNA (>10 IU/ml) and agree to change the regimen|All patients with CHB receiving ETV or second-line NA(LAM/ADV/LdT) treatment for more than six months to one year will receive HBV-DNA detection, and patients with HBV-DNA≥10 IU/ml will be informed and recommended to adjust the treatment regimen.They will change their regimen according one which they are using.
62624285|NCT03955809|ACTIVE_COMPARATOR|Ketamine 0.5 mg/kg|ketamin 0.5 mg/kg intraarticular
62624286|NCT03955809|ACTIVE_COMPARATOR|Ketamine 1 mg/kg|ketamin 1 mg/kg intraarticular injection
62624287|NCT03955809|SHAM_COMPARATOR|% 0.9 Saline|% 0.9 NaCL intraarticular injection
62624288|NCT00186485|EXPERIMENTAL|Right Sided Low Frequency Unilateral TMS|1Hz unilateral TMS delivered to the right DLPFC using the MagStim device
62624289|NCT06253247|EXPERIMENTAL|Patients with necrotic mandibular premolars will be treated with NanoChitosan impregnated Ca(OH)2|25-45 years old patients with necrotic single rooted mandibular premolars with single canal will be treated with NanoChitosan impregnated Calcium Hydroxide as an intracanal medicament for 7 days
62624290|NCT06253247|ACTIVE_COMPARATOR|Patients with necrotic mandibular premolars will be treated with Calcium Hydroxide|25-45 years old patients with necrotic single rooted mandibular premolars with single canal will be treated with calcium hydroxide as an intracanal medicament for 7 days
62624291|NCT03334188|OTHER|Control|Patients will receive care-as-usual. The only study procedures patients will be exposed to will be a baseline survey at time of enrollment about their sense of engagement around their HFrEF medication prescribing, as well as a follow-up survey with the same general content one month after their next clinic appointment. Medical record review will occur at baseline (enrollment), 1 month after the next clinic appointment post-enrollment, and at 12 months from enrollment.This arm will include 'No Intervention--Usual Care'.
62624292|NCT03334188|ACTIVE_COMPARATOR|Intervention|Patients will receive the patient engagement video and HFrEF medication checklist by email one week prior to their next clinic appointment after enrollment. Patients in the intervention arm will also receive a baseline survey at time of enrollment about their sense of engagement around their HFrEF medication prescribing, as well as a follow-up survey with the same general content one month after their next clinic appointment. Medical record review will occur at baseline (enrollment), 1 month after the next clinic appointment post-enrollment, and at 12 months from enrollment. This arm will include the 'Intervention :Behavioral: Patient engagement materials.'
62850327|NCT05224193||Paediatric Patients with Inflammatory Bowel Disease|
62624293|NCT04299867||< 34 weeks gestational age|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
62266350|NCT03186170|ACTIVE_COMPARATOR|control|"The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up for sperm selection) as well as embryo development.~In this arm, the sperm selection for IVF will be the traditional swin up technique with different Percoll gradient Sperm selection via traditional swin-up"
62266351|NCT03443674|EXPERIMENTAL|SCB-313|Dose escalation cohorts--10mg, 20mg, 40mg, 80mg, 160mg. For each cohort: administered twice weekly (eg.. Monday and Thursday or Tuesday and Friday) for 2 weeks (Days 1, 4, 8, and 11) by IP bolus injection.
62652863|NCT02576496|EXPERIMENTAL|Stage 2 cohort 1: relapsed/refractory Multiple Myeloma|Tinostamustine as a single agent administered at a dose of 60mg/m2 by IV infusion over 60min on D1 and D15 of 28-day cycle.
62850328|NCT02211677||Low Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hb, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 1-4 called the low risk group.
62624294|NCT04299867||34 weeks gestational age|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
62266352|NCT03278470|EXPERIMENTAL|HL237 50mg|take oral tablet once
62266353|NCT03278470|EXPERIMENTAL|HL237 100mg|take oral tablet once
62850329|NCT02211677||Intermediate Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hemoglobin, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 5-11 called the intermediate risk group.
62850330|NCT02211677||High Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hemoglobin, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 12-17 called the high risk group.
62850331|NCT05173116||prospective study|API-VIGIE program adult participant who agreed to participate in the study
62850332|NCT05173116||retrospective study|Any stay for adults patients in the emergency room of the ARRAS hospital for API during the period covered (from 1 year before to 1 year after the installation of the APIVIGIE program) (main diagnosis or associated with an API (F10.0 according to the ICD-10 classification used by Department of Medical Information)
62850333|NCT04096768|EXPERIMENTAL|Dexmedetomidine + Ketamine|
62850334|NCT04096768|PLACEBO_COMPARATOR|Dexmedetomidine + Placebo|
62850335|NCT04930341|EXPERIMENTAL|Self-Acupressure|Each application to the acupressure points (H17, L14, ST36, SP6) will be done in 2 minutes and right and left)
62850336|NCT04930341|NO_INTERVENTION|Control group|Routine maintenance will be applied
62850337|NCT05412602|EXPERIMENTAL|Intervention|experimental group will receive 36 chiropractic treatments designed to correct vertebral subluxation over \~12 weeks
62850338|NCT05412602|NO_INTERVENTION|waitlist control|waitlist control will receive no chiropractic interventions and will be reminded that to successfully complete their condition, they do not seek alternative chiropractic treatments
62850339|NCT00967980|ACTIVE_COMPARATOR|1. Femoral Nerve Block|Patients will be randomized with a computer program to receive a femoral catheter. The catheter will be placed using standard technique. The time of catheter placement will be recorded as well as the pain/discomfort of catheter placement as reported by the patient on a 0-10 scale where 0=no pain/discomfort and 10=worst imaginable pain/discomfort.
62850340|NCT00967980|ACTIVE_COMPARATOR|2. Psoas Compartment Catheter|Patients will be randomized with a computer program to receive a psoas compartment catheter. The catheter will be placed using standard technique. The time of catheter placement will be recorded as well as the pain/discomfort of catheter placement as reported by the patient on a 0-10 scale where 0=no pain/discomfort and 10=worst imaginable pain/discomfort.
62850341|NCT01801228|EXPERIMENTAL|Eplerenone|oral daily treatment with doses 100 to 400 mg
62850342|NCT01801228|ACTIVE_COMPARATOR|Spironolactone|oral daily treatment with doses 100 to 400 mg
62062033|NCT02765022|ACTIVE_COMPARATOR|No clip|No clip closure of mucosal defects after endoscopic mucosal resection. Observation.
62266354|NCT03278470|EXPERIMENTAL|HL237 200mg|take oral tablet once
62266355|NCT03278470|EXPERIMENTAL|HL237 400mg|take oral tablet once
62266356|NCT03278470|EXPERIMENTAL|HL237 800mg|take oral tablet once
62266357|NCT03278470|EXPERIMENTAL|HL237 1200mg|take oral tablet once
62266358|NCT03278470|EXPERIMENTAL|HL237 1600mg|take oral tablet once
62266359|NCT05735431|EXPERIMENTAL|Formoterol 6 mcg/fluticasone 125 mcg|Formoterol 6 mcg/fluticasone 125 mcg Eurofarma.
62266360|NCT05735431|ACTIVE_COMPARATOR|Alenia® 6 mcg/200 mcg|Alenia® 6 mcg/200 mcg.
62266361|NCT03287219|ACTIVE_COMPARATOR|150 mg Methylene Blue-MMX tablets|take 6 x 25mg Methylene Blue-MMX tablets equivalent to 150 mg
62266362|NCT03287219|ACTIVE_COMPARATOR|200 mg Methylene Blue-MMX tablets|take 8 x 25mg Methylene Blue-MMX tablets equivalent to 200 mg
62266363|NCT03958227|EXPERIMENTAL|''Manuel Therapy group''|This treatment group will be received Manuel Therapy techniques and exercise interventions.
62624295|NCT03603288|EXPERIMENTAL|idebenone 150 mg film-coated tablets|900 mg idebenone/day (2 tablets to be taken 3 times a day with meal)
62624296|NCT01156493|EXPERIMENTAL|Protein Hydrolyzed Formula|Infants assigned to this group will receive HP formula when breast milk not available or indicated to receive formula by the attending physician
62624297|NCT01156493|NO_INTERVENTION|Control|Infants in this group will receive standard prematrue formula when no breast milk available or indicated by the attending physician
62624298|NCT03526991|EXPERIMENTAL|Spinal Cord Stimulation (SCS) Tonic stimulation|Tonic stimulation
62624299|NCT03526991|EXPERIMENTAL|Spinal Cord Stimulation (SCS) Burst stimulation|Burst stimulation.
62624300|NCT00501137|ACTIVE_COMPARATOR|16-26 year olds 3 doses HPV Vaccine|Group 3 - 16-26 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0, 2, 6 mths
62624301|NCT00501137|ACTIVE_COMPARATOR|3 dose 9-13 HPV Vaccine|Group 2 - 9-13 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0,2,6 mths
62624302|NCT00501137|ACTIVE_COMPARATOR|2 dose 9-13 yrs HPV Vaccine|Group 1 9-13 year olds 2 doses HPV (Human Papillomavirus) Vaccine at 0 and 6 mths
62850343|NCT03615040|EXPERIMENTAL|Anti-ST2|Anti-ST2 (MSTT1041A) received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period.
62850344|NCT03615040|PLACEBO_COMPARATOR|Placebo|Placebo (no active component) received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period.
62850345|NCT06092281|EXPERIMENTAL|Control Arm|Patients after ESD are informed on follow-up instructions by doctors about the follow-up requirements before discharge, and complete a questionnaire without compliance-related education.
62850346|NCT06092281|EXPERIMENTAL|Questionnaire Arm|In addition to receiving the same follow-up instructions as the control group, patients need to complete a questionnaire on compliance-related education before discharge. Based on the responses, nurses provide feedback and guidance.
62850347|NCT05194423|EXPERIMENTAL|Tricuspid Valve Replacement System via jugular vein|Subjects who received transcatheter tricuspid valve replacement with LuX-Valve and delivery system via jugular vein will be included in this arm.
62266364|NCT03958227|EXPERIMENTAL|''Exercise group''|This treatment group will be received only exercise interventions.
62624303|NCT02699827|ACTIVE_COMPARATOR|Magnesium sulphate group|Patients will receive epidural levobupivacaine hydrochloride + magnesium sulphate
62624304|NCT02699827|PLACEBO_COMPARATOR|Placebo group|Patients will receive epidural levobupivacaine hydrochloride + saline 0.9%
62850348|NCT01175083|EXPERIMENTAL|Tritanrix-HepB/Hib+Polio Sabin <6S Group|Children below (\<) 6 months of age at time of enrolment, diagnosed with sickle cell disease (S), who received a 3-dose primary vaccination at Study Months 0, 1 and 2 with Synflorix vaccine co-administered with Tritanrix-HepB/Hib and Polio Sabin vaccines, followed by a booster vaccination at Study Month 8.
62266365|NCT00094055|EXPERIMENTAL|Axitinib [AG-013736]|
62266366|NCT00934570|ACTIVE_COMPARATOR|Metformin, Standard exercise|Lifestyle intervention with metformin and standard exercise program.
62624305|NCT03817099|EXPERIMENTAL|My Dia-RNP|In the My Dia-RNP group, participants will undergo the pre-RNP assessment 2 weeks before Ramadan. They will be given a nutrition education based on the Ramadan Nutrition Plan Guide published by IDF-DAR Practical Guidelines. They will also be asked to incorporate diabetes-specific nutrition formula (Nutren untuk Diabetik®) within the prescribed calories before Ramadan period to help them familiarise with a dietary change.
62624306|NCT03817099|ACTIVE_COMPARATOR|Usual Care|Participant in this group will continue in a usual care (UC) group. They will receive dietary advice based on the Practical Guide to Diabetes Management in Ramadan produced by Ministry of Health (2015).
62624307|NCT00612651|OTHER|enzyme-inducing anti-epileptic drugs (EIAEDs)|Patients receiving enzyme-inducing anti-epileptic drugs (EIAEDs)such as carbamazepine, phenobarbitol, phenytoin, phosphenytoin, oxcarbamazepine, primadone)
62624308|NCT00612651|OTHER|no enyzme-inducing anti-epileptic drugs|Patients on non CYP3A4-inducing anti-convulsants or patients not on any anti-convulsants.
62624309|NCT01504191|EXPERIMENTAL|Internet-based CBT|Randomized patients with symptoms of anxiety and/or depression after MI will participate in an Internet-based CBT-program.
62624310|NCT01504191|NO_INTERVENTION|Treatment as usual (TAU)|"Control: After randomization patients with symptoms of anxiety and/or depression after MI will participate in the treatment as usual (TAU).~Reference: A reference group without depressive or anxiety symptoms will participate in the treatment as usual (TAU)."
62624311|NCT03989596|EXPERIMENTAL|Radiotherapy with hyperthermia|10x 3.25 Gy + hyperthermia + surgery or radiotherapy boost (4x 4 Gy + hyperthermia)
62850349|NCT01175083|ACTIVE_COMPARATOR|Tritanrix-HepB/Hib+Polio Sabin <6NS Group|Healthy children, below (\<) 6 months of age at time of enrolment, who received a 3-dose primary vaccination at Study Months 0, 1 and 2 with Synflorix vaccine co-administered with Tritanrix-HepB/Hib and Polio Sabin vaccines, followed by a booster vaccination at Study Month 8.
62850350|NCT01175083|EXPERIMENTAL|Synflorix 7-11S Group|Children between 7-11 months of age at time of enrolment, diagnosed with sickle cell disease (S), who received a 2-dose primary vaccination at Study Months 0 and 1 with Synflorix vaccine, followed by a booster vaccination at Study Month 3.
62266367|NCT00934570|PLACEBO_COMPARATOR|Placebo, Standard exercise|Lifestyle intervention with placebo and standard exercise program
62266368|NCT00934570|ACTIVE_COMPARATOR|Metformin, Intensive exercise|Lifestyle intervention with metformin and intensive exercise
62266369|NCT00934570|PLACEBO_COMPARATOR|Placebo, Intensive exercise|Lifestyle intervention with placebo and intensive exercise program.
62266370|NCT03245073|ACTIVE_COMPARATOR|Exercise|Strengthening and stretching exercises for hip and knee muscles, balance and proprioceptive exercises
62266371|NCT03245073|EXPERIMENTAL|Action observation therapy and exercise|Video of normal human movement and Strengthening and stretching exercises for hip and knee muscles
62624312|NCT05942391|EXPERIMENTAL|Brief-Intensive CBT|16 sessions in 2 weeks + 4 follow up sessions. The CBT consists of 16 sessions exposure therapy, spread over 4 half-days in 2 weeks, + 4 sessions within 3 months.
62624313|NCT05942391|ACTIVE_COMPARATOR|weekly CBT|20 weekly CBT sessions within 5 to 6 months. The CBT consists of exposure therapy.
62652864|NCT02576496|EXPERIMENTAL|Stage 2 cohort 2: relapsed/refractory Hodgkin Lymphoma|Tinostamustine as a single agent administered at a dose of 100mg/m2 by IV infusion over 60min on D1 of 21-day cycle.
62062034|NCT04489420|EXPERIMENTAL|Intravenous IV ( Recurrent and Surgical ) GBM|Cohort 1A ( recurrent GBM) will receive CYNK-001 at a dose of 1.2 x 10\^9 cells intravenous ( IV) on Days 0, 7, and 14 and will include up to 6 subjects. The subjects will be followed for a 42 day DLT period from the initial CYNK-001 infusion (or 28 days after the last dose). No other treatment interventions are planned between the last day of CYNK-001. In the event of DLTs, Cohort 1C ( recurrent GBM dose-De escalation) will receive CYNK-001 at a dose of 600 x 10\^6 cells (IV) on Days 0, 7, 14, and will include up to 6 subjects who will be followed for a 42-day DLT period from the initial CYNK-001 infusion (or 28 days after the last dose. Cohort 1B (surgical cohort) will receive CYNK-001 at the maximum safe dose (MSD) (either 1.2x10\^9 cells or 600x10\^6 cells) (IV) at Days 0, 7, 14, and will include up to 6 subjects. The tumor resection surgery will be performed after the last CYNK-001 infusion during the DLT period.
62062035|NCT04489420|EXPERIMENTAL|Intratumoral IT ( Recurrent and Surgical ) GBM)|The cohort 2A or cohort 2C (recurrent GBM) IT route of administration can be started only after the safety results were acceptable from the completion of cohort 1A or Cohort 1C (IV route of administration). The Treatment Period for the IT cohorts will begin with having the Ommaya catheter placement per institutional policy, which is planned to occur within one week prior to the CYNK-001 administration on Day 0. Cohort 2A will be treated with CYNK-001 IT at 200 x 10\^6 ± 50 x 10\^6 cells IT on Day 0, 7 and 14 includes up to 6 recurrent GBM subjects Cohort 2C ( dose de-escalation) will be treated with CYNK-001 200 x 106 ± 50 x 106 cells IT on Day 0, and Day 7 ( only two days dosing) and include up to 6 recurrent GBM subjects. Cohort 2B ( the surgical IT cohort) will be treated with CYNK-001 at the maximum safe dose ( MSD) (either 200 x 10\^6 ± 50 x 10\^6 cells on Days 0, 7 and 14 or at 200 x 10\^6 ±50x10\^6 cells on Days 0 and 7) and include up to 6 surgical GBM subjects
62062036|NCT06100302||MD group|Patients with depression who met the inclusion criteria
62062037|NCT06100302||HC group|Healthy subjects meeting enrollment criteria
62062038|NCT00345319|ACTIVE_COMPARATOR|Group 1|
62062039|NCT00345319|ACTIVE_COMPARATOR|Group 2|
62062040|NCT02889601||Fronto-temporal lobar degeneration|DAPHNE score building and internal validation through Fronto-temporal lobar degeneration patients.
62062041|NCT02889601||Control|External validation of DAPHNE score among patients with Alzheimer's disease, progressive supranuclear palsy and bipolar disorder with cognitive disorders.
62062042|NCT02576756||with difficult intubation|Control population
62062043|NCT02576756||without difficult intubation|Control population
62062044|NCT00656318||Group 1 (Zovia)|Subjects will be randomized to receive either the oral contraceptive pill (OCP) Zovia or Necon for 2 months. Prior to beginning the OCP, women will undergo 1 imaging scan. Upon completion of the scan they will receive their first dose of their OCP. Three hours later they will undergo a 2nd imaging scan. Each scan last approximately 1 hour and 15 minutes. This test day is typically scheduled on a Saturday, and lasts approximately 7 hours. Upon completion of the Saturday test day, subjects will remain on their OCP for the remainder of that month and continue taking the pill for a 2nd month. At the end of the 2 months on the pill, subjects will have the option of discontinuing the pill or receiving 1 additional month at no charge before being discharged from the study.
62266372|NCT01595152|ACTIVE_COMPARATOR|solifenacin succinate (10 mg OD)|
62266373|NCT01595152|ACTIVE_COMPARATOR|fesoterodine (8mg OD)|
62266374|NCT05810064||Discharged ED Patients prior to Intervention|Patients aged 65 and older who are in the emergency department and subsequently discharged (not admitted)
62266375|NCT05810064||Discharged ED Patients after Intervention|Patients aged 65 and older who are in the emergency department and subsequently discharged (not admitted)
62266376|NCT04291950||Control group|Hispanic and NHW women undergoing either a benign breast surgery or prophylactic mastectomy.
62850351|NCT01175083|ACTIVE_COMPARATOR|Synflorix 7-11NS Group|Healthy children between 7-11 months of age at time of enrolment, who received a 2-dose primary vaccination at Study Months 0 and 1 with Synflorix vaccine, followed by a booster vaccination at Study Month 3.
62266377|NCT04291950||Newly diagnosed TNBC|Hispanic and NHW with newly diagnosed TNBC. Patients with TNBC will be eligible regardless of whether their treatment plan is surgery first or chemotherapy first (neoadjuvant chemotherapy).
62266378|NCT02823691|EXPERIMENTAL|Lanreotide and Metformin|"Dose and Treatment Regimen:~LANREOTIDE ATG 120 mg/28 days (equivalent to 1 cycle), deep subcutaneous injection (SC) in combination with METFORMIN 2550 mg daily (maximum dose), oral administration (OS).~Metformin starting dose 850 mg/day to be increased up to 1700 mg/day at day 14, 2550 mg/day at day 28, (maximum dose), if well tolerated."
62449746|NCT02483637|EXPERIMENTAL|RejuvenAir|RejuvenAir treatment of the right lower lobe and right main stem bronchus. Each MCS will be tailored to the bronchial area undergoing treatment and the amount of liquid nitrogen delivered will vary depending on the airway diameter.
62850352|NCT01175083|EXPERIMENTAL|Synflorix 12-23S Group|Children between 12-23 months of age at time of enrolment, diagnosed with sickle cell disease (S), who received a 2-dose vaccination with Synflorix vaccine, at Study Months 0 and 2.
62850353|NCT01175083|ACTIVE_COMPARATOR|Synflorix 12-23NS Group|Healthy children between 12-23 months of age at time of enrolment, who received a 2-dose vaccination with Synflorix vaccine, at Study Months 0 and 2.
62850354|NCT00200343|EXPERIMENTAL|Ursodeoxycholic acid 150mg / day|
62850355|NCT00200343|EXPERIMENTAL|Ursodeoxycholic acid 600mg / day|
62850356|NCT00200343|EXPERIMENTAL|Ursodeoxycholic acid 900mg / day|
62850357|NCT02411864||Group 1|Low b=(0,50,150,200)，NEX=(1,3,2,2)
62850358|NCT02411864||Group 2|Low b=(0,30,50,100,200)，NEX=(1,3,3,2,2)
62624314|NCT01393522|ACTIVE_COMPARATOR|Milnacipran|Oral Milnacipran titration was Day 1-2 - 12.5mg/d; Day 3-6 - 12.5mg bid; Day 7-14 - 25mg bid; Day 15 and on - 50mg bid. After the first 30 days, patients did not continue to increase the dose beyond the dose they have achieved at 30 days. At study completion medication taper as follows: patients who at their completion visit were taking 50mg bid decreased to 25mg bid for 4 days, then decreased to 12.5mg bid for 2 days, then 12.5mg once a day for one day and then stopped. Patients on 25mg bid, decreased to 12.5mg bid for 2 days, 12.5mg once a day for one day and then stopped.
62624315|NCT01393522|PLACEBO_COMPARATOR|Placebo|Sugar Pill No active ingredients
62624316|NCT03335683|EXPERIMENTAL|Phytoterapy agent|Subjects were allocated to receive 1 h and 12 h after surgery: group 1, Lenidase® (Enfarma SRL, Misterbianco, Italy)
62624317|NCT03335683|PLACEBO_COMPARATOR|Placebo|Subjects were allocated to received 1 h and 12 h after surgery: placebo (Sugar pill, Sucratol - Placebo Capsules).
62266379|NCT04389021|EXPERIMENTAL|VR|The intervention group will receive VR support upon the standard of care during the procedure.
62266380|NCT04389021|NO_INTERVENTION|Control|The control group will have standard care without the VR support.
62266381|NCT05992389||Children with asthma|School aged participants (6-14 yrs) with an established diagnosis of asthma
62624318|NCT02290119|SHAM_COMPARATOR|Control - Without the use of Verasense|Total Knee Replacement without the use of intraoperative sensors
62266382|NCT05992389||Non-asthmatic subjects (healthy control)|School aged participants (6-14 yrs), non-asthmatic subjects (negative history of allergic diseases)
62624319|NCT02290119|ACTIVE_COMPARATOR|Sensor-assisted TKR (Verasense)|Total Knee Replacement with the use of intraoperative sensors
62850359|NCT02411864||Group 3|Low b=(0,30,60,90,120,150,180,200)，NEX=(1,3,3,3,2,2,2,2)
62850360|NCT02411864||Group 4|Low b=(0,30,60,90,120,150,180,200)，NEX=(1,1,1,1,1,1,1,1)
62850361|NCT02411864||Group 5|Low b=(0,20,40,60,80,100,120,140,160,180,200)NEX=(1,3,3,3,3,2,2
62850362|NCT00512057|EXPERIMENTAL|1|
62850363|NCT00512057|PLACEBO_COMPARATOR|2|
62850364|NCT01504646|PLACEBO_COMPARATOR|Olive Oil Capsule|Ten subjects will take eight placebo olive oil capsules per day for three weeks.
62850365|NCT01504646|EXPERIMENTAL|Lyprinol|Ten subjects will take eight Lyprinol capsules per day for three weeks.
62266383|NCT05988060|EXPERIMENTAL|Patients who were randomized in the PEI group and accepted the invitation|The experimental intervention consist of a PEI for 10 weeks. The PEI will be executed 6 to 7 weeks during and 3 to 4 weeks after (C/B)RT.
62266384|NCT05988060|NO_INTERVENTION|Patients who were not randomized in the PEI group|Patients will receive usual care.
62266385|NCT03430921|OTHER|Enlighten™ Laser and a MLA Attachment|Enlighten™ Laser and a Micro-Lens Array Handpiece Attachment
62266386|NCT04608812|EXPERIMENTAL|Direct Infusion of OS2966|OS2966 will be directly infused into the brain tumor and surrounding tumor infiltrated brain via convection-enhanced delivery
62266387|NCT02562456|ACTIVE_COMPARATOR|Conventional Treatment|Occlusal and occlusoproximal composite resin restorations in primary molars (rubber dam isolation + Adhesive system + composite resin Filtek z350)
62266388|NCT02562456|EXPERIMENTAL|ART using Fuji IX|Occlusal and occlusoproximal ART restorations in primary molars with GIC Fuji IX
62266389|NCT06022952|ACTIVE_COMPARATOR|Group A|Patients who have used the Stone MD mobile app
62266390|NCT06022952|ACTIVE_COMPARATOR|Group B|Patients who have not used the Stone MD mobile app
62266391|NCT04450121|ACTIVE_COMPARATOR|GA (n =22)|Patients will be intubated using Air-Q airway
62266392|NCT04450121|ACTIVE_COMPARATOR|GF (n =22)|Patients will be intubated using Fekry airway
62266393|NCT05044208||No atrial fibrillation detected|In this cohort, AF is not detected in 7-day ECG monitoring or 2-years follow-up period
62624320|NCT04404049|NO_INTERVENTION|Standard ART|Subjects will receive standard ART for 48 weeks
62624321|NCT04404049|EXPERIMENTAL|UB-421(25mg/kg) Q2W add-on treatment|UB-421(25 mg/kg) Q2W plus standard ART for 48 weeks
62624322|NCT04404049|EXPERIMENTAL|UB-421(25mg/kg) Q4W add-on treatment|UB-421(25 mg/kg) Q4W plus standard ART for 48 weeks
62624323|NCT02548663|EXPERIMENTAL|active; sport therapy|active exercise carefully calibrated on residual capacities.
62624324|NCT02548663|EXPERIMENTAL|passive; osteopathic treatment|manipulative treatment according to osteopathic principles.
62624325|NCT04644159||Housolds|Pupils, teachers and non-teaching staff who attended schools of the city during the 2019-2020 school year and members of their households
62624326|NCT04644159||Subjects hospitalized or residing in health care facilities|Residents and patients from retirement homes and long-term care units
62624327|NCT04644159||Staff of health care institutions|Staff of health care institutions
62624328|NCT02966717|ACTIVE_COMPARATOR|parallel control of conventional therapy|Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.
62652865|NCT02576496|EXPERIMENTAL|Stage 2 cohort 3: relapsed/refractory peripheral T-cell lymphoma (PTCL)|Tinostamustine as a single agent administered at a dose of 100mg/m2 by IV infusion over 60min on D1 of 21-day cycle.
62850366|NCT06161298||Healthy control group|age\> 18, without lung disease
62266394|NCT05044208||Atrial fibrillation detected|In this cohort, AF is detected in 7-day ECG monitoring or 2-years follow-up period
62266395|NCT01664728|EXPERIMENTAL|Abiraterone acetate|
62266396|NCT00931359|EXPERIMENTAL|Treatment with DTS-G2 System|Subjects receive treatment with the DTS-G2 System (an energy-based medical device) in both axilla. Multiple treatment sessions may be used.
62850367|NCT06161298||NSAP group|patients with no stroke pneumonia
62850368|NCT06161298||SAP group|Those diagnosed with stroke-related pneumonia
62850369|NCT00504946|ACTIVE_COMPARATOR|I|
62850370|NCT00504946|ACTIVE_COMPARATOR|II|
62850371|NCT00504946|PLACEBO_COMPARATOR|III|
62850372|NCT00504946|ACTIVE_COMPARATOR|A|
62850373|NCT00504946|PLACEBO_COMPARATOR|B|
62850374|NCT01786070|ACTIVE_COMPARATOR|Budesonide|Budesonide : 1 mg/4ml every 12 hrs for 48 hrs
62850375|NCT01786070|PLACEBO_COMPARATOR|Placebo|Normal saline at an equivalent volume (4 ml every 12 hrs for 48 hrs)
62624329|NCT02966717|EXPERIMENTAL|experimental group|Intervention of Rituximab combined with mesenchymal stem cells group: as follows, Rituximab, 100mg/time every one week, the infusion should be a total of 4 times; and then after at least 4 days interval after the first and the third infusion of the Rituximab , the dosage of mesenchymal stem cells tends to be 10\^6/kg/time every 2 weeks, while the infusion should be a total of 2 times.
62624330|NCT01277120||Cohort|
62624331|NCT05171205|EXPERIMENTAL|Spinal cord stimulation(SCS) implantation|"Phase I:~1. Spinal cord segment is selected as the puncture location according to the patient's symptom and the condition of the patient's spinal cord. Percutaneous puncture is performed under X-ray guidance. One or two electrodes are placed in the patient's epidural cavity, and the electrode position is adjusted intraoperatively and by the patient's feedback of the current stimulation position until the current can cover the entire area.~2. An extension lead is connected, an external temporary stimulator is attached, and the patient decides whether to proceed to full implantation in phase II after 7-10 days of phase I testing experience.~Phase II:~The complete SCS system is implanted under local anesthesia or epidural anesthesia after successful testing. A subcutaneous capsular bag is usually created in the lower abdomen and the implanted electrodes are connected to the pulse generator through a connecting wire in the subcutaneous tunnel."
62850376|NCT05129033|ACTIVE_COMPARATOR|anti-fungal agent plus OCS|Prednisone tablets is given orally 0.5mg/kg/d for 4 weeks and gradually reduced to stop for a total usage of 6 months Itraconazole is given orally 200mg bid for 8 months and 100mg bid for another 8 months
62850377|NCT05129033|ACTIVE_COMPARATOR|anti-IgE mAb plus OCS|Prednisone tablets is given orally 0.5mg/kg/d for 4 weeks and gradually reduced to stop for a total usage of 6 months Omalizumab is given by subcutaneous injection of 600mg q4w for at least 6 months
62850378|NCT02027090|EXPERIMENTAL|Higher dose icotinib|Patients with stable disease after 8-week routine dose icotinib treatment, are randomly assigned to higher dose icotinib group to receive icotinib with a dose of 375 mg three times per day, till progressive disease or unaccepted toxicity.
62850379|NCT02027090|ACTIVE_COMPARATOR|Routine dose icotinib|Patients with stable disease after 8-week routine dose icotinib treatment, are administered with icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity.
62266397|NCT00931359|SHAM_COMPARATOR|Sham treatment|All elements of the treatment are given except that no energy is delivered. Multiple treatment sessions may be used.
62266398|NCT05266378|EXPERIMENTAL|Block group|The group undergoing PECs block
62850380|NCT01571687|ACTIVE_COMPARATOR|antioxidant supplements|800 I.E. Vitamin E, 1000mg Vitamin C, 200000 I.E. Vitamin A, 600mg Acetylcystein.
62850381|NCT01571687|PLACEBO_COMPARATOR|Placebo|identically appearing placebo
62266399|NCT05266378|PLACEBO_COMPARATOR|Control group|The group not receiving PECs block
62850382|NCT05815875|EXPERIMENTAL|Intervention|The STEADI program will be applied to this group of participants. The STEADI involves frequent assessment of patients' risk for falls and making appropriate changes to decrease the risk for falls.
62850383|NCT05815875|ACTIVE_COMPARATOR|Control|The STEADI program will not be applied to the control group participants. This group will receive the usual care provided to the patients in the hospital.
62266400|NCT05999188||Aortic dissection group|Patients diagnosed with aortic dissection at any of the centres and regularly consulted and followed up.
62266401|NCT02820428|OTHER|Healthy participants|Submission of the scale 'Evaluation of behaviour in Parkinson's Disease' to healthy subjects
62624332|NCT06258707|EXPERIMENTAL|LuxBoost Group|the experimental group will receive the LuxBoost intraocular lens.
62850384|NCT01521754||Perspective|Prospective cohort: new patients who are initially implanted with a Medtronic neurostimulation system on or after a site's activation date. The classification is static and will not change in the case of a re-implant.
62266402|NCT02562924|ACTIVE_COMPARATOR|Budesonide rinse group|"1a. Days 0-7: 40 mg prednisone daily, saline sinus rinse 4 times daily, nasal saline spray q 1 hour while awake b. Days 7-91: 8oz saline/budesonide sinus rinse BID (twice daily) c. After day 91: i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse once daily.~Reevaluate at day 119:~1. In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.~2. In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182."
62624333|NCT06258707|ACTIVE_COMPARATOR|LuxGood group|the control group will receive the LuxGood parent intraocular lens.
62624334|NCT04130152|EXPERIMENTAL|Palbociclib + Letrozole|"Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.~If the patient is pre-menopausal, ovarian suppression with luteinizing hormone-releasing hormone (LHRH) analogues (ie, triptorelin 3.75 mg intra-muscular (IM) or Goserelin 3,6 mg SC) must be initiated at least 2 weeks before palbociclib plus letrozole administration."
62624335|NCT05141929|EXPERIMENTAL|intervention group|web based education and routine clinical procedure
62850385|NCT01521754||Retrospective|Retrospective cohort: existing patients comprised the sub-group of patients who were implanted with a Medtronic neurostimulation system prior to a site's activation date. This cohort contains a part of retrospective data and a part of prospective data according to the enrolment date. The classification is static and will not change even when an existing patient will be subsequently re-implanted after the site's activation date.
62850386|NCT01715441|ACTIVE_COMPARATOR|Irinotecan monotherapy|Intravenous infusion irinotecan 180 mg/m2 over 90 minutes (D1=D15) with cross over to irinotecan and sorafenib combination at progression.
62062045|NCT00656318||Group 2 (Necon)|Subjects will be randomized to receive either the oral contraceptive pill (OCP) Zovia or Necon for 2 months. Prior to beginning the OCP, women will undergo 1 imaging scan. Upon completion of the scan they will receive their first dose of their OCP. Three hours later they will undergo a 2nd imaging scan. Each scan last approximately 1 hour and 15 minutes. This test day is typically scheduled on a Saturday, and lasts approximately 7 hours. Upon completion of the Saturday test day, subjects will remain on their OCP for the remainder of that month and continue taking the pill for a 2nd month. At the end of the 2 months on the pill, subjects will have the option of discontinuing the pill or receiving 1 additional month at no charge before being discharged from the study.
62624336|NCT05141929|NO_INTERVENTION|control group|only routine clinical procedure
62624337|NCT04288427|EXPERIMENTAL|Finasteride Treatment|Patients who are eligible will be given 5ARI therapy, Finasteride, for medical management of Benign Prostatic Hyperplasia (BPH) symptoms. Only patients with lower urinary tract symptoms (LUTS) as assessed by American Urologic Association (AUA) urinary symptom score \> than 8, (suggestive of moderate LUTS) prostate size \> 40cc, no prostate nodule/tenderness/firmness and increased PSA between 4-10ng/ml requiring prostate biopsy will be enrolled. Then, they will have prostate MRIs/needle biopsies and blood/urine collection followed by treatment with Finasteride (standard of care). They will be followed in urology clinic for assessment of LUTS every 6 months and Finasteride responsiveness at the 12-month time point. Prostate biopsy samples will be evaluated for SRD5A2 gene expression/methylation, hormonal androgen/estrogen levels (which will be repeated in blood samples). Prostate MRIs will assess size/inflammatory changes at the start and 3-year time points.
62624338|NCT05723952|EXPERIMENTAL|Barcelona scoliosis physical therapy school|procedure for treating scoliosis
62266403|NCT02562924|EXPERIMENTAL|MEDIHONEY® rinse alone group|"1. Days 0-7: Same as 1a;~2. Days 7-91: 8oz saline sinus rinse followed with 0.5oz of MEDIHONEY® in 50 cc of normal saline.~3. After day 91:~i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse once daily. Reevaluate at day 119:~1. In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.~2. In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182."
62624339|NCT05723952|EXPERIMENTAL|International scoliosis schroth therapy|procedure for treating scoliosis
62624340|NCT02766036|ACTIVE_COMPARATOR|Propolis|Patients will continue to receive standard treatment for their comorbidities, determined by the attending physician. Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses.
62624341|NCT02766036|PLACEBO_COMPARATOR|Placebo|Patients will continue to receive standard treatment for their comorbidities, determined by the attending physician. Patients will receive 500 mg / day of the propolis-placebo in the form of tablets split in two daily doses.
62624342|NCT02193555|OTHER|Non-presbyopic group|"Non-presbyopic group: age ranging from 7 to 39 years~At each scheduled lens fitting visit, subjects will be allocated one pair of CLs to correct their refractive error. One pair of control (Acuvue 1- Day Moist, etafilcon A) or prototype (Iteration X, etafilcon A) CLs will be allocated for each lens fitting/assessment visit. Lenses will be worn for approximately 1 hour per visit.~For each fitting visit, lenses will be fitted bilaterally."
62652866|NCT02576496|EXPERIMENTAL|Stage 2 cohort 4: relapsed/refractorycutaneous T-cell lymphoma (CTCL)|Tinostamustine as a single agent administered at a dose of 100mg/m2 by IV infusion over 60min on D1 of 21-day cycle. Patients are of subtypes mycosis fungoides (MF) or Sézary syndrome (SS).
62624343|NCT02193555|OTHER|Presbyopic group|"Presbyopic group: age 40 and above~At each scheduled lens fitting visit, subjects will be allocated one pair of CLs to correct their refractive error. One pair of control (Acuvue Oasys for Presbyopia, senofilcon A) or prototype (Iteration X, etafilcon A) CLs will be allocated for each lens fitting/assessment visit. Lenses will be worn for approximately 1 hour per visit.~For each fitting visit, lenses will be fitted bilaterally."
62624344|NCT03960333||Healthy Lean|Healthy lean individuals (n=20) defined with a Body Mass Index (BMI) ≥ 5th percentile and \<85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
62062046|NCT04754139|EXPERIMENTAL|WeChat mobile mini-application|WeChat mini-application will increase knowledge base about sexual health through interactive health education and counseling support on HIV/STI prevention as well as PrEP initiation and/or adherence management.
62624345|NCT03960333||Overweight/Obese|Overweight/Obese individuals (n=20) defined with a Body Mass Index (BMI) ≥ 85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
62624346|NCT03960333||Type 2 Diabetes or Insulin Resistant|Obese individuals with Type 2 Diabetes or insulin resistance who have been recently prescribed Metformin and have a Body Mass Index (BMI) ≥ 85th percentile for age/sex (n=20) will be recruited. Participants in this cohort will be asked to complete a two study visits approximately 6 months apart.
62624347|NCT05312970|ACTIVE_COMPARATOR|Varithena®|Varithena® (polidocanol injectable foam) 1%
62624348|NCT05312970|ACTIVE_COMPARATOR|FDA-approved ETA systems|FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.
62624349|NCT00814723|ACTIVE_COMPARATOR|Fluvastatin|Fluvastatin 80 mg MR
62624350|NCT00814723|ACTIVE_COMPARATOR|Fluvastatin + Ezetimibe|Fluvastatin MR 80 mg plus Ezetimibe 10 mg
62062047|NCT00885963|EXPERIMENTAL|sapacitabine|"Part A (lead-in phase): Two dosing schedules, i.e., once daily (q.d.) or twice daily (b.i.d.) x 5 days/week x 2 weeks every 3 weeks will be evaluated.~Part B (Phase 2): Receive the recommended phase 2 dose of once daily or twice daily dosing schedule derived from Part A."
62062048|NCT04005027|EXPERIMENTAL|Intermittent graded exercise (INT)|The intermittent graded exercise test (INT) increase treadmill speed incrementally using three minute stage duration on a motorised treadmill. However, the speed within each three minute exercise bout will vary every 30 s between the target speed, and a complete pause for 30 s. The acceleration of the treadmill belt will be set to its maximum capability.
62624351|NCT03552601|OTHER|traditional speed|The target amount of every day's net negative fluid balance for the first three days is 1000mL.
62266404|NCT02562924|EXPERIMENTAL|MEDIHONEY® and budesonide rinse group|"1. Days 0-7: Same as 1a.;~2. Days 7-91: 8oz saline/budesonide sinus rinse followed by 0.5oz of MEDIHONEY® in 50 cc of normal saline BID.~3. After day 91:~i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse BID. Continue with this regimen till day 182.~ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse once a day.~Reevaluate at day 119:~1. In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 3.c.i till day 182.~2. In case endoscopy shows no polyps, edema and discharge: Continue as per 3.c.ii till day 182."
62266405|NCT00784420|ACTIVE_COMPARATOR|UK-453,061|
62266406|NCT00784420|ACTIVE_COMPARATOR|Raltegravir|
62266407|NCT00784420|EXPERIMENTAL|UK-453,061 plus Raltegravir|
62624352|NCT03552601|OTHER|faster speed|The target amount of every day's net negative fluid balance for the first three days is 1500mL.
62850387|NCT01715441|ACTIVE_COMPARATOR|Sorafenib monotherapy|Oral sorafenib 400 mg twice daily (total dose 800 mg/day) with cross over to irinotecan and sorafenib combination at progression
62062049|NCT04005027|ACTIVE_COMPARATOR|Continuous graded exercise (CONT)|The continuous graded exercise test (CONT) will increase treadmill speed incrementally using three minute stage duration on a motorised treadmill
62062050|NCT05492526|OTHER|Usual Cardiac Rehabilitation|Patients receive usual care and wear Ki monitor - doesn't receive any feedback during the cardiac rehabilitation period.
62266408|NCT04350853|EXPERIMENTAL|Surgical extrusion group|Surgical extrusion is performed in each patient of this group
62266409|NCT06539910|EXPERIMENTAL|Modified TIPS Block|Modified Triple Injection Peri-sartorial Block Patients will receive ultrasound guided single puncture triple injections through medial to lateral approach. LA will be injected at the distal FT lateral to the superficial femoral artery (FA), deep to adductor longus muscle (ALM), and at the supra-sartorial plane
62266410|NCT06539910|ACTIVE_COMPARATOR|TIPS Block|Triple Injection Peri-sartorial Block Patients will receive distal FTB through conventional lateral to medial approach, in addition to a supra-sartorial plane injection
62266411|NCT03269071|EXPERIMENTAL|Treatment Cohort A|"See Study Description~TC-A: 0.7 x 10\^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
62624353|NCT03381859|EXPERIMENTAL|Treatment Arm|Patients to receive 12 weeks of Elbasvir (50mg) / Grazoprevir (100mg)
62624354|NCT02888990|EXPERIMENTAL|Treatment Arm|standard treatment + dasatinib
62624355|NCT01308892|ACTIVE_COMPARATOR|High flavaonol chocolate|
62624356|NCT01308892|PLACEBO_COMPARATOR|Low flavanol chocolate|
62624357|NCT06082310|EXPERIMENTAL|High Intensity Interval Training - Biking (HIITBIKE)|Cycling exercise: 5 min warm-up + 9-12 x \[45 seconds at 80% of HRmax followed by 1 minute 30 seconds of active recovery at a power equivalent to 40% of HRmax\].
62624358|NCT06082310|EXPERIMENTAL|High Intensity Interval Training - Running (HIITRUN)|Running exercise: 5 min warm-up + 9-12 x \[45 seconds at 80% of HRmax followed by 1 minute 30 seconds of active recovery at a treadmill speed equivalent to 40% of HRmax\].
62624359|NCT04003623|EXPERIMENTAL|Pemigatinib|
62850388|NCT01715441|EXPERIMENTAL|Sorafenib and irinotecan combination|"Intravenous infusion irinotecan 120 mg/m2 over 90 minutes (D1=D15) at Cycle 1, 150 mg/m² at C2 if no diarrhea \> grade 1 and no other toxicity \> grade 2, and 180 mg/m² at C3 in the same conditions~* Oral sorafenib 400 mg twice daily (total dose 800 mg/day) from C1. 1 cycle = 15 days and 1 course = 4 weeks."
62850389|NCT03989505||Cohort|214 consecutive patients undergoing contrast-enhanced diagnostic and/ or therapeutical intervention in the cath lab of the University Heart Center Hamburg
62624360|NCT05815277||parents who have children aged from 6 to 12 years|
62850390|NCT01313741|EXPERIMENTAL|Single arm shoulder arthroplasty|
62850391|NCT05098262|EXPERIMENTAL|Sequence A|
62850392|NCT05098262|EXPERIMENTAL|Sequence B|
62850393|NCT06246006||Patients with suspected MPN|
62266412|NCT03269071|EXPERIMENTAL|Treatment Cohort B|"See Study Description~TC-B: 1.4 x 10\^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
62266413|NCT03269071|EXPERIMENTAL|Treatment Cohort C|"See Study Description~TC-C: 2.8 x 10\^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
62850394|NCT04228133|EXPERIMENTAL|Home-delivered attention control training (ACT)|A home-delivered ACT comprised of 8 sessions with a variation of the dot-probe task in which the target probe replaces the neutral and threat stimuli with an equal probability to reduce attention bias variability (ABV).
62062051|NCT05492526|EXPERIMENTAL|Intervention Arm - Usual Cardiac Rehabilitation plus contextualised Data feedback|Patient receives usual care and also wears Ki monitor and receives contextualised data feedback
62062052|NCT05826080||operative group|Procedure/Surgery:Adrenal Vein Sampling;Adrenalectomy
62062053|NCT06232668||Cases group|Women recruited between 9 and 14 gestational weeks diagnosed with preeclampsia or other complication at the end of pregnancy.
62266414|NCT03269071|EXPERIMENTAL|Treatment Cohort D|"See Study Description~TC-D: 5.7 x 10\^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
62266415|NCT04961788|EXPERIMENTAL|Gemox combined PD1 antibody|"1. Toripalimab (240mg) intravenously, the administration time is 60 (+15) minutes, Q3W is administered once.~2. Gemox chemotherapy D1: oxaliplatin 85mg/m2, gemcitabine 1g/m2 D8: Gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 6-8 courses."
62266416|NCT02474732|OTHER|Usability|Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
62266417|NCT02120105||Cystinuria|
62266418|NCT03718286|EXPERIMENTAL|Alirocumab|
62266419|NCT03718286|SHAM_COMPARATOR|Sham Control|
62449747|NCT04514393|EXPERIMENTAL|methotrexate, ibrutinib, and temozolomide (MIT regimen)|Methotrexate will be given on day 1 of each 28-day cycle；Ibrutinib will be given day 1-28 of each 28-day cycle; Temozolomide will be given day 1-5 of each 28-day cycle. Methotrexate and Temozolomide are given for up to 4 cycles; Ibrutinib is continued until disease progression, intolerable toxicity, or death.
62449748|NCT04383756|EXPERIMENTAL|Donor Blood|Between 2-4 units of donor leukoreduced whole blood (each unit will contain up to 350mL) transfused as needed in Liver transplantation participants
62449749|NCT04383756|ACTIVE_COMPARATOR|Banked Blood|Standard of Care - Up to 350mL Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets) transfused as needed in Liver transplantation participants
62449750|NCT02976298|SHAM_COMPARATOR|transcranial magnetic stimulation|sham transcranial magnetic stimulation
62449751|NCT02976298|EXPERIMENTAL|supplementary motor area stimulation|supplementary motor area transcranial magnetic stimulation
62449752|NCT02976298|EXPERIMENTAL|cerebellar stimulation|cerebellar transcranial magnetic stimulation
62449753|NCT02220907|EXPERIMENTAL|Teneligliptin/Canagliflozin|Patients receive Teneligliptin and Canagliflozin once daily for 52 weeks.
62449754|NCT01183000|ACTIVE_COMPARATOR|peritoneal closure|
62449755|NCT01183000|NO_INTERVENTION|Non closure of the peritoneum|
62449756|NCT05409911|EXPERIMENTAL|S-217622: Group A|Participants with mild hepatic impairment will receive a single dose of S-217622 on Day 1, in a fasted state.
62449757|NCT05409911|EXPERIMENTAL|S-217622: Group B|Participants with moderate hepatic impairment will receive a single dose of S-217622 on Day 1, in a fasted state.
62449758|NCT05409911|EXPERIMENTAL|S-217622: Group C|Participants with normal hepatic function will receive a single dose of S-217622 on Day 1, in a fasted state.
62449759|NCT02506166|NO_INTERVENTION|No or Mild Sleep Apnea Group (Group 1)|"ICM patients with no or mild sleep apnea enrolled in this arm will continue with standard therapy (ICD/CRT-D implant + maximal medical therapy), but will receive no active Positive Airway Pressure (PAP) therapy for sleep apnea treatment. See Part: Study Population for more details.~In all ICM patients enrolled into ESCAPE-SCD Study, the ICD/CRT-D devices will be implanted based on current ESC Guidelines for primary prevention of sudden cardiac death (see Section: References)"
62449760|NCT02506166|NO_INTERVENTION|Obstructive Sleep Apnea - Control Group (Group 2)|"ICM patients with predominant obstructive sleep apnea randomised to this arm will receive standard therapy (ICD/CRT-D implant + maximal medical therapy), but no PAP therapy for sleep apnea treatment. See Part: Study Population for more details."
62449761|NCT02506166|ACTIVE_COMPARATOR|Obstructive Sleep Apnea - Active Group (Group 3)|"ICM patients with predominant obstructive sleep apnea randomised to this arm will receive standard therapy (ICD/CRT-D implant + maximal medical therapy), plus as intervention, all patinets in this group will receive sleep apnea treatment by using PAP device. See Part: Study Population for more details."
62449762|NCT02506166|NO_INTERVENTION|Central Sleep Apnea Group (Group 4)|"ICM patients with predominant central sleep apnea enrolled in this group will receive standard therapy (ICD/CRT-D implant + maximal medical therapy). Because the SERVE-HF Trial demonstrated a negative effect of predominantly central sleep apnea treatment on cardiovascular mortality in patients with HFrEF by using adaptive servo-ventilation therapy, patients in Group 4 will not receive any PAP therapy for treatment of sleep disordered breathing. See Part: Study Population for more details."
62449763|NCT03466957|EXPERIMENTAL|3D printed applicator|individually designed applicator for BT
62449764|NCT02707536|NO_INTERVENTION|No socket grafting|Extraction with normal socket healing
62624361|NCT02090387|ACTIVE_COMPARATOR|Control ONS|ONS without AN777
62624362|NCT02090387|EXPERIMENTAL|Investigational ONS|ONS containing AN777
62850395|NCT04228133|PLACEBO_COMPARATOR|Home-delivered attention bias modification (ABM)|A home-delivered ABM comprised of 8 sessions with a variation of the dot-probe task in which the target probe always replaces the threat stimuli to induce diversion of attention away from threat.
62850396|NCT06063603|EXPERIMENTAL|Group I (Pain management)|See detailed description.
62850397|NCT06063603|ACTIVE_COMPARATOR|Group II (Interview)|ASCENT study interventionists complete an interview on study.
62850398|NCT06063603|ACTIVE_COMPARATOR|Group III (Focus group)|Medical oncology providers participate in a focus group on study.
62624363|NCT04563637||Computer Based Vision|A 15 second long video will be obtained at the research site using a smart phone or tablet. Then subjects will undergo a whole body dual energy x-ray absorptiometry scan . Then the subject will go home and take a second 15 second long video. The videos will then be analyzed by computer based vision application and the body fat percentage measured by dual energy x-ray absorptiometry scan will be compared.
62624364|NCT05989919||study group|patients with antrochoanal polyps
62624365|NCT05989919||control group|patients with unilateral sinonasal disease other than antrochoanal polyps
62624366|NCT00683488|EXPERIMENTAL|1|Focus groups with adolescents with SA (Substance Abuse) will be conducted at each site (one group with 5 to 6 adolescents per site) to provide information on the areas of the intervention in need of adaptation in order to reflect the context of HIV infection.
62624367|NCT00683488|EXPERIMENTAL|2|The first intervention trial will enroll 9 participants (3 participants per site). Exit interviews of participants will assess acceptability, feasibility, and relevance of the intervention. Quantitative assessments pre and post intervention using audio computer-assisted self-interviewing (ACASI) will document immediate changes in substance use, sexual risk, and adherence to medical care. Additional qualitative feedback from interviews with mental health providers and study coordinators will address feasibility, acceptability, and relevance of the intervention and its methods.
62624368|NCT00683488|EXPERIMENTAL|3|The revised intervention will be implemented with 20 participants (6 to 8 at each site). Exit interviews with subjects and feedback from mental health providers and study coordinators will provide the same qualitative information as in the first intervention trial. Quantitative data on participant outcomes such as substance use, sexual risk, and adherence to medical care will be collected pre, post and 3 month post intervention through ACASI.
62624369|NCT04769102|EXPERIMENTAL|Spastic Cerebral Palsy|spastic Cerebral palsy children will be adapted in adaptive seat with flat and then Contoured cushions while kinematic changes of upper limb reaching movement are monitored through video capture with kinovea 2D software motion analysis system.
62624370|NCT03282422|EXPERIMENTAL|Intervention group|Upper-limb splint and home-based protocol in specific tasks
62062054|NCT06232668||Control group|Women recruited between 9 and 14 gestational weeks without diagnosis of preeclampsia or other complication at the end of the pregnancy
62624371|NCT03282422|ACTIVE_COMPARATOR|Control group|Home-based protocol in specific tasks
62624372|NCT02904083|EXPERIMENTAL|specific training of professionals|patients from centers where professionals have received specific training
62624373|NCT02904083|ACTIVE_COMPARATOR|control training of professionals|patients from centers where professionals have received control training
62624374|NCT01825746|ACTIVE_COMPARATOR|Early implementation practices|"9 practices that will initially field the MOHR assessment for up to 6 months. These practices will serve as intervention sites for the effectiveness outcomes measured by the patient experience survey."
62624375|NCT01825746|OTHER|Delayed implementation practices|"9 practices that will field the MOHR assessment for up to 6 months but starting 4 months after the early implementation practices. These practices will serve as control sites for the effectiveness outcomes measured by the patient experience survey. However, they will provide intervention data with respect to Reach and cost during the delayed phase."
62062055|NCT01645826|EXPERIMENTAL|Diltiazem|The study agent will be Diltiazem and will start at 60 mg po BID then titrated up every two weeks until at a maximum dose of 180mg po BID.
62062056|NCT01645826|PLACEBO_COMPARATOR|Sugar Pill|The placebo group of patients will be treated with Drug A (sugar pill) PO bid and titrated up every two weeks for next titration dose (actually will be an unchanged concentration).
62062057|NCT03844243|EXPERIMENTAL|NGF condition + Control condition|"All participants will receive 3 single injection of NGF (1ug/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle.~After 4 weeks:~All participants will receive 3 single injection of isotonic-saline (9%/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle."
62624376|NCT02995629|EXPERIMENTAL|green (532 nm) laser|scatter laser indirect ophthalmoscopy pan retinal photocoagulation
62624377|NCT02995629|EXPERIMENTAL|yellow (577 nm) laser|scatter laser indirect ophthalmoscopy pan retinal photocoagulation
62624378|NCT04387409|ACTIVE_COMPARATOR|VPM1002|"The active ingredient of the recombinant BCG vaccine, VPM1002, is Mycobacterium bovis rBCGΔureC::hly, freeze-dried and standardized to the number of viable mycobacteria (colony forming units; CFU) per application.~Dose: 2-8 x 10e5 CFU VPM1002 administered in 0.1 ml reconstituted suspension."
62624379|NCT04387409|PLACEBO_COMPARATOR|Placebo|Physiological saline 0.1ml
62624380|NCT06236048||Healthy volunteers|
62624381|NCT06236048||Schizophrenia - remission|
62850399|NCT04342507|OTHER|Group A: conservative|conservative treatment with lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
62624382|NCT06236048||Treatment resistant schizophrenia|
62624383|NCT06272149|EXPERIMENTAL|type II Gaucher disease|This is a single-center, open, dose-climbing investigator-sponsored exploratory clinical study that included a dose-climbing phase and a dose-expanding phase. The sponsor plans to explore two dose levels in dose-climbing phase (one subject each cohort), then have additional 2\~4 subjects in dose-expanding phase
62624384|NCT01744483|ACTIVE_COMPARATOR|PVC ETT|Polyvinylchloride cuff endotracheal tube
62624385|NCT01744483|EXPERIMENTAL|PUC ETT|Polyurethane cuff endotracheal tube
62624386|NCT01744483|EXPERIMENTAL|PUC-CASS ETT|Polyurethane cuff with continuous aspiration of subglottic secretions endotracheal tube
62624387|NCT03603561|ACTIVE_COMPARATOR|Active cTBS|
62266420|NCT00500084|EXPERIMENTAL|Liprotamase|Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units) administered orally with each of three meals and two snacks daily for 12 months
62850400|NCT04342507|EXPERIMENTAL|Group B: probiotics|in addition to the conservative treatment they receive probiotics mixture (Streptococcus thermophilus, Lactococcus lactis, Lactobacillus delbrueckii subsp. bulgaricus) once a day up to 3 months.
62850401|NCT03854994|EXPERIMENTAL|Anti-CD19 CAR-T Cells Injection|Dosage form：injection Dosage:1-5x10\^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes Frequency: total one time
62266421|NCT06073496|NO_INTERVENTION|Control|The Patient are cancer patient that experience cancer pain that only receive analgetic drug treatment according to WHO Stepledder of Pain
62266422|NCT06073496|EXPERIMENTAL|Electroacupuncture and standard Therapy|The Patient are cancer patient that experience cancer paint that receive analgetic drug treatement according WHO stepledder of pain and receive electroacupuncture
62266423|NCT03006510|ACTIVE_COMPARATOR|Alert|If glucose \<90 mg/dl and hypoglycemia prediction score \>35, then alert with suggestion for intervention sent to treating team
62266424|NCT03006510|NO_INTERVENTION|No alert|Routine standard care. If glucose \<90 mg/dl and hypoglycemia prediction score \>35, then report for investigators will be collected, but no active alert will be sent to teams.
62624388|NCT03603561|SHAM_COMPARATOR|Sham cTBS|
62850402|NCT00602758|EXPERIMENTAL|Enhanced Counseling|Participants meet with a counselor trained in motivational interviewing and cognitive behavioral techniques
62850403|NCT00602758|NO_INTERVENTION|Standard Care|Participants receive usual clinical care provided by health care providers and they participate only in evaluation components of the study
62850404|NCT00602758|EXPERIMENTAL|Enhanced Counseling/Modified Directly Observed Therapy|Participants receive their ART medications delivered to them by study staff and they receive the enhanced counseling
62850405|NCT04326426|EXPERIMENTAL|Tradipitant|Tradipitant 85 mg PO BID
62850406|NCT04326426|PLACEBO_COMPARATOR|Placebo|2 capsules of matching placebo
62266425|NCT06333509|EXPERIMENTAL|Phase 1|Dose Escalation followed a dose expansion.
62266426|NCT06333509|EXPERIMENTAL|Phase 2|Single group of patients for each indication (rrMM, RRpPCL).
62266427|NCT03551444|ACTIVE_COMPARATOR|Administration of DAA-based treatment (Arm 1)|"Arm 1 will be divided into 2 groups by randomization according to a 1:1 ratio into:~Group A: Administration of DAA-based treatment after 3 months of complete remission of HCC.~Group B: Administration of DAA-based treatment after 6 months of complete remission of HCC."
62624389|NCT04767971||Standard Colonoscopy|Colonoscopy with a standard colonoscope
62624390|NCT04767971||G-EYE® Colonoscopy|Colonoscopy with a G-EYE Colonoscopy
62624391|NCT02296762|EXPERIMENTAL|Sirolimus tablets 2 mg|Sirolimus tablets 2 mg of Dr. Reddys Laboratories Limited
62266428|NCT03551444|EXPERIMENTAL|Control arm (Arm 2)|Not receiving DAAs after complete remission of HCC and to be kept on follow-up
62624392|NCT02296762|ACTIVE_COMPARATOR|Rapamune|Rapamune® 2 mg tablets of Wyeth Laboratories, Philadelphia
62624393|NCT03056014|ACTIVE_COMPARATOR|N-acetylcysteine 600 mg|
62624394|NCT03056014|ACTIVE_COMPARATOR|N-acetylcysteine 1200 mg|
62624395|NCT03056014|PLACEBO_COMPARATOR|placebo|
62624396|NCT03056014|ACTIVE_COMPARATOR|PUFA 1000 mg|
62624397|NCT03056014|ACTIVE_COMPARATOR|PUFA 2000 mg|
62624398|NCT03056014|PLACEBO_COMPARATOR|Placebo|
62624399|NCT03887208|EXPERIMENTAL|Autologous adipose derived stem cells|Autologous ADSC injection combined with laser therapy of the skin.
62624400|NCT03887208|PLACEBO_COMPARATOR|Placebo - Normal saline injection|Normal sline injection combined with laser therapy of the skin.
62624401|NCT04798326|EXPERIMENTAL|MW032|MW032 injection (120mg) by subcutaneous injection once on the first day of treatment.
62624402|NCT04798326|ACTIVE_COMPARATOR|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day of treatment.
62624403|NCT04662723|EXPERIMENTAL|Corticosteroids combined with RASBs|Patients assigned to the corticosteroid group will receive (pulse) methylprednisolone succinate 500-1000 mg/day for 3 consecutive days followed by oral prednisolone (0.5 mg/kg/bw) on alternate days until the end of month. This treatment will be repeated for three consecutive months. In addition, patients will receive RASBs that will be titrated to their maximum anti-proteinuric effect. The dose of methylprednisolone succinate will be individualized (15 mg/kg) based on the ideal body weight. In overweight and obese IgAN patients the ideal body weight will be considered. The drug will be administered in a single daily dose intravenously for 30-60 min. To avoid obesity and diabetes corticosteroids will be administered only in the morning.
62624404|NCT04662723|ACTIVE_COMPARATOR|RASBs|Patients will receive RASBs for 3 months, titrated to their maximum anti-proteinuric effectf followed by oral corticosteroids.
62850407|NCT06027957|EXPERIMENTAL|Treatment Regimen|"* Experimental: Treatment Regimen.~* Leukapheresis to collect white blood cells using Spectra Optia Apheresis system.~* T cells selection, transduction, and CAR T-cell manufacturing using CliniMACS Prodigy. During this process, T cells will be genetically modified to express CD19 CAR.~* Lymphodepleting chemotherapy conditioning regimen for 3 days.~* CAR T-cells targeting CD19 will be infused intravenously at a dose between 1 and 2x10e6 cells/kg for 15-30 minutes.~* Following the T-cell infusion, patients will stay in the clinic for approximately 21-28 days to monitor toxicity.~* Outpatient follow-up will take place after 1 month, 3 months, and 6 months after infusion."
62850408|NCT03436602||Training cohort|Cohort of follicular lymphoma patients for the development of the multilayer risk stratification model
62850409|NCT03436602||Validation cohort|Cohort of follicular lymphoma patients for the validation of the developed multilayer risk stratification model
62850410|NCT06148324|EXPERIMENTAL|Immediate treatment (IT)|Participants randomized to the IT arm will receive the 8-week MENTOR program, followed by an 8-week retention period.
62850411|NCT06148324|EXPERIMENTAL|Delayed treatment (DT)|Participants randomized to the DT arm will have an 8-week waitlist period prior to starting the 8-week MENTOR program, followed by an 8-week retention period.
62850412|NCT06284824|EXPERIMENTAL|MAKO group|Patients in this arm will receive the Stryker Triathlon implant and the MAKO robotic arm will be used during surgery.
62624405|NCT04662723|EXPERIMENTAL|SGLT2i combined with Ramipril|IgAN patients with chronic renal lesions (T1,2) or moderate renal lesions (M0,1; S0,1; T0; E0; C0) at high or very high CKD risk (proteinuria\> 0.5 g/day and GFR \>30ml/min/1.73 m2) will receive SGLT2i combined with RASBs.
62624406|NCT04662723|ACTIVE_COMPARATOR|Ramipril combined with corticosteroids|IgAN patients with chronic renal lesions (T1,2) or moderate renal lesions (M0,1; S0,1; T0; E0; C0) at high or very high CKD risk (proteinuria\> 0.5 g/day and GFR \>30ml/min/1.73 m2) will receive RASBs for 3 months followed by oral corticosteroids.
62624407|NCT00642603|EXPERIMENTAL|XELOX + bevacizumab (Q2W)|
62624408|NCT00642603|EXPERIMENTAL|XELIRI + bevacizumab (Q2W)|
62624409|NCT01113307||Hard to heal wounds|
62850413|NCT06284824|EXPERIMENTAL|VELYS group|Patients in this arm will receive the DePuy Attune implant and the VELYS robotic arm will be used during surgery.
62850414|NCT00133549|EXPERIMENTAL|2|Vaccine dose 1: CRM-PS; Vaccine dose 2 (month 4): CRM-PS; Vaccine dose 3 (month 8): PS.
62850415|NCT00133549|EXPERIMENTAL|1|Vaccine dose 1: CRM-PS; Vaccine dose 2 (month 4): saline placebo; Vaccine dose 3 (month 8): PS.
62850416|NCT00133549|ACTIVE_COMPARATOR|3|Vaccine dose 1: PS; Vaccine dose 2 (month 4): saline placebo; Vaccine dose 3 (month 8): saline placebo.
62850417|NCT05877742|EXPERIMENTAL|AA group|AA for drug abusers.
62624410|NCT00199849|EXPERIMENTAL|Cohort 1|"4 µg NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine~NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device. The 4 µg dosage of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered as 4 X 1 µg PMEDs in close proximity.~The vaccine was administered in weeks 1, 5, and 9 of Cycle 1. In the absence of \> Grade 3 toxicity and in the absence of progressive disease requiring other treatment or the presence of NY-ESO-1 immunity, patients could receive an additional cycle of vaccinations of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine."
62624411|NCT00199849|EXPERIMENTAL|Cohort 2|"8 µg NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine~NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.~The 8 µg dosage of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered as 8 X 1 µg PMEDs.~The vaccine was administered in weeks 1, 5, and 9 of Cycle 1. In the absence of \> Grade 3 toxicity and in the absence of progressive disease requiring other treatment or the presence of NY-ESO-1 immunity, patients could receive an additional cycle of vaccinations of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine."
62624412|NCT00199849|EXPERIMENTAL|Cohort 3|"8 µg NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine~NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.~The 8 µg dosage of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered as a cluster dosage of 4 doses (day 1, 3, 5, 8) as 2 X 1 µg PMEDs per day.~The vaccine was administered in weeks 1, 5, and 9 of Cycle 1. In the absence of \> grade 3 toxicity and in the absence of progressive disease requiring other treatment or the presence of NY-ESO-1 immunity, patients could receive an additional cycle of vaccinations of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine."
62850418|NCT05877742|PLACEBO_COMPARATOR|Control group|Routine seminar for drug abusers.
62624413|NCT02799888|EXPERIMENTAL|Maraviroc + standard GVHD prophylaxis|Maraviroc administration (in addition to the standard prophylaxis therapy of cyclosporine/tacrolimus and methotrexate) will start on day -2 and will end on day +30 after stem cell transplant, making the total number of days of drug administration 33 days. Maraviroc will be administered 300mg twice daily orally.
62624414|NCT02508103|EXPERIMENTAL|Oxytocin, then Placebo|"Participants were randomized to receive Intransal Oxytocin for late luteal phase administration during one menstrual cycle, then received Intranasal Placebo for late luteal phase administration of a subsequent menstrual cycle.~Intranasal Oxytocin spray (40 IU, 3x/day) for 4-5 days; Intranasal Placebo spray (3x/day) for 4-5 days"
62850419|NCT01060280|ACTIVE_COMPARATOR|Education group|Routine clinical practice (includes usual physiotherapy)plus education on active management.
62850420|NCT01060280|ACTIVE_COMPARATOR|Group GDS physiotherapy|Routine clinical practice (except usual physiotherapy, which is substituted for Group GDS)plus education on active management.
62850421|NCT01060280|ACTIVE_COMPARATOR|Individual GDS physiotherapy|Routine clinical practice (except for usual physiotherapy, which will be substituted by Group and Individual GDS) plus education on active management.
62850422|NCT04259918|EXPERIMENTAL|Control|no applying alveolar recuritment maneuver
62850423|NCT04259918|ACTIVE_COMPARATOR|Low ARM|Applying 30 cmH2O of alveolar recruitment maneuver 5 times every 5sec
62850424|NCT04259918|ACTIVE_COMPARATOR|High ARM|Applying 60 cmH2O of alveolar recruitment maneuver 5 times every 5sec
62850425|NCT04633044|PLACEBO_COMPARATOR|Placebo|400 mg of lactose daily for 12 weeks
62850426|NCT04633044|EXPERIMENTAL|Supplement|400 mg of betaine daily for 12 weeks
62850427|NCT01695759|EXPERIMENTAL|Epoetin alpha|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
62266429|NCT01049594||Preterm infants|Delivery at less than 33 completed weeks of gestation
62266430|NCT06129266|EXPERIMENTAL|İntervention (Oral care with breastmilk) group|Newborns selected according to the randomization group will receive nursing care, including oral care and feeding, from the same person twice a day, at 09:00 in the morning and 15:00 in the afternoon. Breast milk (BM) will be used for oral care. At each treatment, two ml BM should be dropped onto sterile gauze to clean the cheeks, tongue and palate. Process steps; After hand hygiene is achieved, it will be done using disposable gloves.
62624415|NCT02508103|EXPERIMENTAL|Placebo, then Oxytocin|"Participants were randomized to receive Intranasal Placebo for late luteal phase administration during one menstrual cycle, then received Intransal Oxytocin for late luteal phase administration of a subsequent menstrual cycle.~Intranasal Oxytocin spray (40 IU, 3x/day) for 4-5 days; Intranasal Placebo spray (3x/day) for 4-5 days"
62850428|NCT01695759|ACTIVE_COMPARATOR|Eprex|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
62850429|NCT03951350|NO_INTERVENTION|Control (TAU)|Patients will follow the usual treatment provided by their GP (treatment-as-usual, TAU).
62850430|NCT03951350|EXPERIMENTAL|Lifestyle Modification Program (LMP)|It will consist of 6 weekly group sessions (lasting 90 minutes each).
62850431|NCT03951350|EXPERIMENTAL|Lifestyle Modification Program (LMP) + ICTs|It will consist of 6 weekly group sessions (lasting 90 minutes each).
62850432|NCT02068716||Adults with HAIs|"Adult cardiac surgery patients who develop infections in hospitals within 30 days post surgery.~We will exclude patients presenting with endocarditis."
62266431|NCT06129266|NO_INTERVENTION|Routine maintenance group|No intervention will be applied to the control group other than oral care with sterile distilled water, which is routine clinical practice.
62850433|NCT01790997|EXPERIMENTAL|Treatment I|1 tablet of DLBS1033 490 mg thrice daily, after meal
62850434|NCT01790997|ACTIVE_COMPARATOR|Treatment II|1 tablet of aspirin 80 mg once daily, after meal
62266432|NCT03801655|EXPERIMENTAL|Bio-Kult|4 capsules/day
62266433|NCT03801655|PLACEBO_COMPARATOR|Placebo|4 capsules/day
62652867|NCT02576496|EXPERIMENTAL|Stage 2 cohort 5: relapsed/refractory T-cell Prolymphocytic leukemia (T-PLL)|Tinostamustine as a single agent administered at a dose of 100mg/m2 by IV infusion over 60min on D1 of 21-day cycle.
62624416|NCT02477371|EXPERIMENTAL|Fractional flow reserve-guided CABG|Patients are randomized to an FFR-guided CABG. FFR-measurements are made on coronary arteries with intermediate stenoses, that are planned for grafting. The FFR-values are blinded for both the operator, the patient and the heart team meeting. The graft plan form the heart team meeting are changed by the study investigator according to the FFR-measurements and randomization, so that coronary arteries with FFR ≤ 0,8 receive grafting and coronary arteries with FFR \> 0,8 are deferred.
62624417|NCT02477371|ACTIVE_COMPARATOR|Angiography-guided CABG|Patients are randomized to an angiography-guided CABG. FFR-measurements are made on coronary arteries with intermediate stenoses, that are planned for grafting. The FFR-values are blinded for both the operator, the patient and the heart team meeting. The graft plan are based on the coronary angiography.
62624418|NCT02237989|ACTIVE_COMPARATOR|paracetamol|The 1st group includes 19 patients given 1500mg/day paracetamol for three months
62266434|NCT02868697|ACTIVE_COMPARATOR|A|We will lock the dialysis catheter post HD with TauroLock Hep500 at the end of of all Hemodialysis sessions and during all interdialytic periods
62062058|NCT03844243|EXPERIMENTAL|Control condition + NGF condition|"All participants will receive 3 single injection of isotonic-saline (9%/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle.~After 4 weeks:~All participants will receive 3 single injection of NGF (1ug/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle."
62850435|NCT01790997|ACTIVE_COMPARATOR|Treatment III|1 tablet of clopidogrel 75 mg once daily, after meal
62062059|NCT03982043|EXPERIMENTAL|Text2Connect|Participants receiving Text2Connect (T2C) personalized messages aimed at increasing motivations in at-risk adolescents and their parents. The most salient of the following behavior change techniques will be selected and targeted messaging will be deployed on the participants' phone: psychoeducation, cued mood monitoring, adolescent-parent communication prompts, cognitive bias modification, and cues to action. Intervention material will be tailored to baseline characteristics and T2C will generate reports to providers.
62062060|NCT03718962|ACTIVE_COMPARATOR|needling|needling + phototherapy
62062061|NCT03718962|PLACEBO_COMPARATOR|phototherapy|phototherapy
62266435|NCT02868697|EXPERIMENTAL|B|We will lock the dialysis catheter post HD with TauroLock Hep500 at the end of the first two session only per week and during first two interdialytic periods then TauroLock U 25000at the end of third session before week end, (over the week end).
62266436|NCT02788747|EXPERIMENTAL|4 mg elamipretide|4 mg elamipretide once daily for 28 consecutive days
62266437|NCT02788747|EXPERIMENTAL|40 mg elamipretide|40 mg elamipretide once daily for 28 consecutive days
62266438|NCT02788747|PLACEBO_COMPARATOR|Placebo|Placebo once daily for 28 consecutive days
62266439|NCT00754832|EXPERIMENTAL|1|Period 1 with Ginseng therapy intervention; Washout Period with no drug; Period 2 with placebo
62266440|NCT00754832|EXPERIMENTAL|2|Period 1 with placebo; Washout period with no drug; Period 2 with ginseng therapy intervention
62624419|NCT02237989|EXPERIMENTAL|native collagen type 2 + paracetamol|The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months
62624420|NCT00680615|EXPERIMENTAL|Usual Care|
62624421|NCT00680615|EXPERIMENTAL|Enhanced|
62624422|NCT01411514|EXPERIMENTAL|Prednisone|
62624423|NCT01411514|PLACEBO_COMPARATOR|Placebo|
62624424|NCT02550236||LIFE Child Health|The LIFE Child HEALTH cohort is a sample of over 5.000 children and adolescents. A basic program that will be carried out annually at each study centre visit. This program includes clinical history (perinatal and past medical history, medications, allergies, immunizations, developmental history and family history) clinical examination, collection of blood, hair, stool and urine samples, anthropometry and different age-dependent questionnaires. Questionnaires are completed by the parents and starting at the age of ten years also by the child itself.
62624425|NCT02550236||LIFE Child Obesity|The LIFE Child OBESITY cohort is a sample of 500 obese children and adolescents that will be assessed and compared to a lean control group (N=500) with equally detailed phenotyping including metabolic and cardiovascular evaluation. The LIFE Child OBESITY cohort (including the control group) performs the basic program of the LIFE Child HEALTH cohort plus additional parameters such as electrical bioimpedance, assessment of basal metabolic rate, oral glucose tolerance test, liver elastography and spirometry.
62652868|NCT02576496|EXPERIMENTAL|Substudy|Tinostamustine as a single agent administered at a dose of 100mg/m2 by IV infusion over 100min on D1 of 21-day cycle.
62087930|NCT02668432|EXPERIMENTAL|Partial Load|All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive \<4g IV or \< 8g PO. The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).
62850436|NCT04254328|EXPERIMENTAL|Nintendo Wii Fit|Nintendo Wii Fit group work program; 13 exercises in 5 groups including 3 yoga exercises, 3 balance exercises, 2 aerobic, 2 training plus exercises and 3 muscle-workout will be done respectively. Patients in this group will exercise for 8 weeks, 3 days in a week and 40-50 minutes of exercise within resting interval.
62087931|NCT02668432|ACTIVE_COMPARATOR|Full Load|All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive (≥ 5g IV or ≥10g PO +/- 20%). The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).
62087932|NCT04499040|EXPERIMENTAL|patients with SD/THE|
62087933|NCT04499040|PLACEBO_COMPARATOR|control group|
62850437|NCT04254328|EXPERIMENTAL|Respiratory|Respiratory training group participants' will do deep breathing exercise against resistance of 30% of intraoral pressure. This exercise will be applied for 8 weeks, each day of the week, twice in a day for 15 minutes and 4-5 normal breaths after 4-5 deep breaths. Each week, intraoral pressure will be measured and new training intensity values will be determined.
62266441|NCT04517747|EXPERIMENTAL|Ramucirumab plus TAS-102|Ramucirumab 8 mg/kg i.v. on day 1 and day 15 of a 28-day cycle and TAS-102 35 mg/m2/dose p.o. twice daily on days 1 to 5 and days 8 to 12 of a 28-day cycle Each cycle will be repeated after 28 days (from day 1) for a maximum of 4 cycles.
62062062|NCT03312608||mild myelopathy (JOA>12)|40 patients (JOA\>12) suffering from symptomatic or asymptomatic degenerative cervical myelopathy scheduled for surgery or conservative treatment. The radiological inclusion criteria are cervical spinal stenosis associated with or without intramedullary high signal intensity lesion on T2-weighted MRI. Exclusion criteria are other pathologies in the vicinity of the corticospinal tract above the lesion site (i.e. tumor, infarction), neuroinflammatory disease, high grade paresis of the upper extremity (BMRC\<3), the existence of a cardiac pacemaker, deep brain stimulation electrodes or pregnancy. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
62062063|NCT03312608||moderate myelopathy|40 patients (JOA≤12) suffering from symptomatic degenerative cervical myelopathy scheduled for surgery (anterior and/ or posterior decompression) or conservative treatment. The radiological inclusion criteria are cervical spinal stenosis associated with or without intramedullary high signal intensity lesion on T2-weighted MRI. Exclusion criteria are other pathologies in the vicinity of the corticospinal tract above the lesion site (i.e. tumor, infarction), neuroinflammatory disease, high grade paresis of the upper extremity (BMRC\<3), the existence of a cardiac pacemaker, deep brain stimulation electrodes or pregnancy. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
62062064|NCT03312608||healthy control|As a control group, 40 subjects will be included into the study. Exclusion criteria and examination protocol are identical with the patient group. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
62062065|NCT04328402||Children and adolescents submitted to PSG in sleep laboratory|Children (1 to 11 years) and adolescents (12 to 18 years), who were referred to a sleep laboratory and submitted to full-night polysomnography due to suspicious of sleep disorders.
62850438|NCT04254328|NO_INTERVENTION|Control|Patients in the control group will not be included in any exercise program, but all groups will be advised of walking in order to increase physical activity level.
62624426|NCT02550236||LIFE Child Health: Pregnancy/Birth|The LIFE child Pregnancy/Birth cohort is a sample of over 1,200 pregnant women and their offspring. Prenatal examinations are conducted during the 24th to 26th and 34th to 36th week of gestation. During the first year of life, data is collected from children at 3, 6 and 12 month of age.
62624427|NCT02254356|EXPERIMENTAL|Zilver|
62850439|NCT00381290|ACTIVE_COMPARATOR|1|Participants will follow an exercise regimen
62850440|NCT00381290|ACTIVE_COMPARATOR|2|Participants will follow a calorie-restricted diet
62850441|NCT00381290|ACTIVE_COMPARATOR|3|Participants will follow a calorie-restricted diet and an exercise regimen
62850442|NCT05952128|EXPERIMENTAL|Fluzoparib+ Dalpiciclib|Fluzoparib in combination with Dalpiciclib
62062066|NCT02733783|EXPERIMENTAL|septorhinoplasty patients|Elective septorhinoplasty patients that will undergo bilateral osteotomies. All the patients will undergo cold dry air provocation and 3 hours later capsaicin provocation, during a preoperative visit, one week before the intervention and during three post-operative visits two weeks, three months and six months.
62062067|NCT01043016|EXPERIMENTAL|Photocyanine injection|Patients receive intravenous injection of Photocyanine injection from dosage of 0.1 mg/kg,0.2 mg/kg,0.33 mg/kg,0.5 mg/kg to 0.6 6mg/kg till the dose-limiting effect occur.
62062068|NCT00058019|EXPERIMENTAL|Treatment (chemotherapy)|Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or if the patient becomes a candidate for stem cell transplantation.
62624428|NCT00768885|ACTIVE_COMPARATOR|PureVision 1|PureVision soft contact lens design #1.
62624429|NCT00768885|EXPERIMENTAL|PureVision 2|PureVision soft contact lens design #2
62850443|NCT06087861|EXPERIMENTAL|External beam radiotherapy|Patients will receive treatment with external beam radiotherapy at a total of 30 Gy delivered over five fractions delivered daily.
62850444|NCT01675544||Heart Failure Admission|Patients admitted for acute decompensated heart failure
62850445|NCT00229515|ACTIVE_COMPARATOR|1|Patients will receive abciximab infusion at standard regimen prior undergoing percutaneous coronary intervention for STEMI followed by BMS implantation in the culprit lesion
62266442|NCT01741649|EXPERIMENTAL|Clorhexidine|Skin prior to the surgical incision will be cleaned for five minutes with Clorhexidine.
62266443|NCT01741649|EXPERIMENTAL|Povidone|Skin prior to surgical incision will be cleaned for five minutes with a povidine solution.
62266444|NCT06145295|EXPERIMENTAL|experiment group (online support group)|The experimental group engaged with the mobile application use for four weeks, with specific tasks including completing the four mandatory courses within one month and submitting at least two health records and online posts every week.
62624430|NCT06013514||Smooth Silicone Breast Implant|
62624431|NCT04645329|EXPERIMENTAL|group I (no immobilization)|patients will be allowed to freely use their arm without any immobilization after surgery
62850446|NCT00229515|EXPERIMENTAL|2|Abciximab followed by implantation of sirolimus-eluting stent in the culprit lesion
62850447|NCT00229515|EXPERIMENTAL|3|tirofiban infusion followed by bare metal stent implantation
62850448|NCT00229515|EXPERIMENTAL|4|tirofiban and sirolimus-eluting stent
62850449|NCT05165693|EXPERIMENTAL|Experimental Formula|One 296 mL serving of study product
62624432|NCT04645329|ACTIVE_COMPARATOR|group II (3-week immobilization)|patients will be kept in an immobilization device for three weeks after surgery
62850450|NCT05165693|ACTIVE_COMPARATOR|Test Meal|48 g Instant oatmeal
62624433|NCT06045494|ACTIVE_COMPARATOR|Meiji Yogurt Group|"Meiji LG21 yogurt: 180 g/bottle, main ingredients:~Raw milk, water, sugar, skim milk powder, food additives (hydroxypropyl distarch phosphate, pectin), cream, whey protein powder, food flavor, Lactobacillus grigi, Lactobacillus bulgaricus, Streptococcus thermophilus."
62624434|NCT06045494|NO_INTERVENTION|Blank Control Group|No interventional product for this arm
62624435|NCT01540747|EXPERIMENTAL|Inofolic plus|178 patients
62624436|NCT01540747|ACTIVE_COMPARATOR|Inofolic|180 patients
62624437|NCT01219192|EXPERIMENTAL|M2ES 15mg|
62624438|NCT01219192|EXPERIMENTAL|M2ES 30mg|
62624439|NCT01219192|EXPERIMENTAL|M2ES 45mg|
62624440|NCT01219192|EXPERIMENTAL|M2ES 60mg|
62624441|NCT03075332|EXPERIMENTAL|protocol with physical exercise|Both groups underwent a combined training intervention consisting of aerobic and resisted exercises in the same training session
62624442|NCT05659303||Laparoscopic hysterectomy|Patient having undergone a hysterectomy, planned as an outpatient during the pre-operative consultation, by laparoscopic route.
62624443|NCT04040647||colorectal surgery|50 consecutive patients scheduled to colorectal surgery in an enhanced recovery programme
62624444|NCT04040647||bariatric surgery|50 consecutive patients scheduled to bariatric surgery (gastric by-pass, sleeve gastrectomy) in an enhanced recovery programme
62624445|NCT03373253||Participants With Diagnosis of Depression|This study will evaluate participant's socio-demographic, disease-related and treatment-related characteristics along with outcomes in routine clinical practice across the European region. Only data available within clinical practice, through routine therapeutic procedures and diagnostic assessments, will be recorded. Individual participant information will be recorded from participant's medical records or by use of specific questionnaires.
62624446|NCT04464408|EXPERIMENTAL|Favipiravir|Favipiravir: 1800 mg (9 tablets) by mouth twice daily for one day, followed by 800mg (4 tablets) twice daily (Maximum days of therapy is 7 days)
62624447|NCT04464408|PLACEBO_COMPARATOR|Placebo|9 tablets by mouth twice daily for one day, followed by 4 tablets twice daily (Maximum days of therapy is 7 days).
62624448|NCT04140812|ACTIVE_COMPARATOR|Term infants (≥37+0 weeks)|Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (\<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS).
62624449|NCT04140812|EXPERIMENTAL|Preterm infants (≤32+0 weeks)|Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (\<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS).
62449765|NCT02707536|ACTIVE_COMPARATOR|Socket grafting with platelet rich fibrin (PRF) alone|Extraction with socket grafting with platelet rich fibrin (PRF) alone.
62624450|NCT02442648|EXPERIMENTAL|Group A (5-8 patients) - Carfilzomib|Two cycles of carfilzomib desensitization given.
62624451|NCT02442648|EXPERIMENTAL|Group B (5-8 patients) - Carfilzomib/plasmapheresis|Two cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
62624452|NCT02442648|EXPERIMENTAL|Group C (5-8 patients) - Rituximab/Carfilzomib/plasmapheresis|1 dose of rituximab prior to two cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
62624453|NCT02442648|EXPERIMENTAL|Group D (5-8 patients) - Rituximab/Carfilzomib/plasmapheresis|1 dose of rituximab prior to three cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
62449766|NCT02707536|ACTIVE_COMPARATOR|Socket grafting with bone grafting alone|Extraction with socket grafting using bone graft (xenograft).
62449767|NCT02707536|ACTIVE_COMPARATOR|Socket grafting with PRF and bone grafting|Extraction with socket grafting using PRF combined with bone graft (xenograft).
62449768|NCT06546293|EXPERIMENTAL|Core stabilization group|lumbo-pelvic/core strength and stability exercises group
62449769|NCT06546293|ACTIVE_COMPARATOR|Control group|the group that will have a daily physical activity program established and monitored for participation through weekly exercise tracking chart
62449770|NCT01903577|EXPERIMENTAL|Novice Laparoscopic and Robotic Surgeons|"Students and surgical trainees with less than 100 laparoscopic and less than 50 robotic cases.~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
62449771|NCT01903577|EXPERIMENTAL|Expert Laparoscopists, Novice Roboticists|"Surgeons with more than 100 laparoscopic cases, less than 50 robotic cases.~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
62449772|NCT01903577|EXPERIMENTAL|Expert robotic and laparoscopic surgeons|"Surgeons with greater than 100 laparoscopic and greater than 50 robotic cases.~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
62449773|NCT00809042|EXPERIMENTAL|1|Hydroxyurea
62449774|NCT00809042|ACTIVE_COMPARATOR|2|L-carnitine and hydroxyurea
62624454|NCT06253910|OTHER|Patient selection|A total of 15 (female) patients, between 31 and 70 years, who were systemically and periodontally healthy and applied to the periodontology clinic for treatment, were included in our study. Criteria for inclusion in the study are having ≥15 permanent teeth excluding third molars, not using any orthodontic appliance, not being pregnant or breastfeeding, not having any uncontrolled chronic and/or auto-immune disease, and not smoking.
62624455|NCT06253910|OTHER|MARF and FGG tehcniques|Free gingival graft for the treatment of a total of 21 teeth with gingival recession in the lower jaw incisors area, no bone dehiscence, and the amount of attached gingiva being at least 0.5 mm and at most 1.5 mm and modified apically positioned flap methods were randomly selected (coin toss) and applied by a single investigator (MY). Surgical methods were performed on a minimum of 1 and a maximum of 2 teeth in the treated areas.
62624456|NCT06253910|OTHER|Post-surgical evalution and periodontal measurements|Clinical periodontal parameters (plaque index (PI), pocket probing depth (PPD), bleeding on probing (BOP), gingival recession (GR) and clinical attachment level (CAL)) were recorded and evaluated at baseline, third months, first and second years. Periodontal measurements (keratinized tissue width (KTW), attached gingiva width (AGW)) recorded and evaluated at baseline, third months, first and second years.
62624457|NCT00299403|ACTIVE_COMPARATOR|1|Right frontal low frequency rTMS
62624458|NCT00299403|ACTIVE_COMPARATOR|2|electroconvulsive therapy (ECT). Right unilateral ECT 3 time a week in 3 weeks
62266445|NCT06145295|OTHER|control group|The control group participates in the offline group intervention that last for four weeks. Participants in the control group will participant in four weekly workshop that last between 1 hour to 1.5 hours.
62266446|NCT05880446|OTHER|Bowel symptoms & QoL assessment|This single arm study represent a group a patient with prostate cancer who are candidate for pelvic radiotherapy. Patient reported outcomes on bowel toxicity and overall quality of life will be systematically assessed right before and after RT. Various potential predictive factors will be analysed.
62624459|NCT03000322|EXPERIMENTAL|Cooling Vest|During the four-week Treatment Period, participants should use the Cooling Vest two times per day (once in the morning for one hour and once in the evening for one hour.)
62624460|NCT02308228|EXPERIMENTAL|Metformin|Participants will be randomized to receive Metformin (1700 mg/day) for a period of 16 weeks; 2 weeks of Metformin only followed by 14 weeks of continued Metformin use in combination with progressive resistance training.
62624461|NCT02308228|PLACEBO_COMPARATOR|Placebo, Sugar Pill|Participants will be randomized to receive placebo sugar pills (1700 mg/day) for a period of 16 weeks; 2 weeks of placebo only followed by 14 weeks of continued placebo use in combination with progressive resistance training. Placebos will be almost identical to the Metformin medication.
62624462|NCT03570203||Retrospective Cohort|Supratentorial/Suprasellar brain tumor patients with Glasgow Coma Score \> 3 at time of admission.
62624463|NCT03570203||Prospective Cohort|Supratentorial/Suprasellar brain tumor patients with Glasgow Coma Score \> 3 at time of recruitment.
62624464|NCT05329350||muscular ventricular septal defects|patients with muscular ventricular septal defects
62266447|NCT03362021||DEX|Sedation with dexmedetomidine (solution 4 γ/ml) continuously infused at a dose of 1 γ/kg/ and fentanyl 100γ iv. Dexmedetomidine infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure.
62624465|NCT00528918|ACTIVE_COMPARATOR|Apidra|Direct 1:1 comparison of Apidra and Regular insulin.
62624466|NCT00528918|ACTIVE_COMPARATOR|Regular|Direct 1:1 comparison of Apidra and Regular insulin.
62624467|NCT02066597|EXPERIMENTAL|Intervention|
62266448|NCT03362021||MZM|Sedation with remifentanil (solution 50γ/ml) continuously infused at a dose of 0.2 γ/kg/min and midazolam 1 mg iv. Remifentanil infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure.
62266449|NCT01533376|EXPERIMENTAL|Timolol|Participants in this group will receive topical timolol
62624468|NCT05756751|OTHER|Treatment with Impella 5.5 System|
62624469|NCT02379455|EXPERIMENTAL|Comprehensive drug review|
62624470|NCT02379455|NO_INTERVENTION|Control group|"Follow-up by family physician as usual."
62266450|NCT01533376|PLACEBO_COMPARATOR|Placebo|Participants in this group will receive Preservative free artificial tear gel.
62266451|NCT01745250|EXPERIMENTAL|Emervel Lips|Emervel Lips
62266452|NCT01745250|EXPERIMENTAL|Juvederm Ultra Smile|Juvederm Ultra Smile
62266453|NCT04818593|EXPERIMENTAL|ZyMot Separation|Treatment
62266454|NCT04818593|ACTIVE_COMPARATOR|Density Gradient Centrifugation|Control
62266455|NCT02878954|OTHER|No intervention|160 men and women with PAD will be recruited.
62624471|NCT05391880|EXPERIMENTAL|Drug:BEBT-503|BEBT-503
62062069|NCT02061696|ACTIVE_COMPARATOR|Standard Manual Compression|Standard manual compression at the access site applied as per standard of care protocol for sheath removal.
62266456|NCT02878954|OTHER|Control session|40 patients (men and women) will complete this session.
62266457|NCT02878954|OTHER|Exercise session|40 patients (men and women) will complete this session.
62266458|NCT04136223||RA-ILD|"Consecutive adult patients (aged \>18 years) with RA\* and interstitial lung disease~\*in accordance with the American College of Rheumatology (ACR) classification criteria of 2010"
62624472|NCT05391880|PLACEBO_COMPARATOR|Drug: Placebo|Placebo
62624473|NCT02100735|EXPERIMENTAL|Sedation protocol|Sedation protocol is a document that will be used to guide the adjustment of sedation in the ICU.
62624474|NCT02100735|ACTIVE_COMPARATOR|Standard of care|Current practices
62624475|NCT00151086|EXPERIMENTAL|Estramustine and Vinorelbine|Treatment will consist of 28-day cycles with estramustine at a dose of 140mg orally 3 times per day on days 1-3 and 8-10 and vinorelbine orally on days 2 and 9 beginning at dose 50mg/m\^2.
62624476|NCT05649696|EXPERIMENTAL|r-SAK group|intravenous injection of single bolus 5 mg r-SAK in 3min
62624477|NCT05649696|PLACEBO_COMPARATOR|normal saline group|intravenous injection of 10ml saline in 3min, r-SAK and saline are the same in appearance
62624478|NCT05649696|NO_INTERVENTION|patients with coronary artery disease|20 ml arterial blood samples and 5 ml venous blood samples were collected from patients before coronary angiography
62624479|NCT03180957|EXPERIMENTAL|Anti-TNF|adalimumab
62624480|NCT03180957|PLACEBO_COMPARATOR|Placebo|saline
62624481|NCT06199427|EXPERIMENTAL|intervention/treatment|"Conditioning regimen containing treosulfan 30-42 g/m2, fludarabine 150 mg/mg, thymoglobulin 5 mg/kg and thiotepa 10 mg/kg or melphalan 140 mg/m2~GVHD prophylaxis regimen for matched unrelated (MUD) and matched related donors (MRD):~Cyclophosphamide (PTCY) 25 mg/kg/day (days +3, +4) Ruxolitinib 7 mg/m2 from day +5~GVHD prophylaxis regimen for mismatched related donor (MMRD):~Cyclophosphamide (PTCY) 50 mg/kg/day (days +3, +4) Ruxolitinib 7 mg/m2 from day +5"
62624482|NCT02816320||Inpatient stays|All patients who were hospitalized in participating hospitals in France during the study period were eligible for inclusion.
62624483|NCT04520906|EXPERIMENTAL|single-arm|Subjects will be treated with microwave ablation.
62624484|NCT03664921|EXPERIMENTAL|Omnitram|Oral Omnitram (10 mg tablets) dosed three times daily. During the first two weeks each dose will be titrated between 1 tablet (10 mg) and 4 tablets (40 mg) to provide pain relief. The doses administered at the end of two weeks will be maintained during the final two weeks of treatment.
62624485|NCT03664921|PLACEBO_COMPARATOR|Placebo|Oral placebo (tablets) dosed three times daily. During the first two weeks each dose will be titrated between 1 tablet and 4 tablets to provide pain relief. The doses administered at the end of two weeks will be maintained during the final two weeks of treatment.
62062070|NCT02061696|ACTIVE_COMPARATOR|AXERA 2 Access System|The Vascular Access device used is the AXERA 2 Access System for patients randomized to this arm.
62062071|NCT03913208|EXPERIMENTAL|Study group|Will be subjected to priority to freeze
62062072|NCT03913208|ACTIVE_COMPARATOR|Control group|Will receive fresh embryo transfere
62266459|NCT02742285|OTHER|Artemether + lumefantrine|One single adult dose of artemether + lumefantrine 80 + 480 mg
62266460|NCT02788097|EXPERIMENTAL|Progesterone + 4|the transfer of day 5 blastocyst on the 5th day of progesterone supplementation
62266461|NCT02788097|ACTIVE_COMPARATOR|Progesterone + 5|the transfer of day 5 blastocysts on the 6th day of progesterone supplementation
62449775|NCT00809042|ACTIVE_COMPARATOR|4|L-carnitine , magnesium chloride and hydroxyurea
62624486|NCT03049423||the trial group|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
62850451|NCT05391789|EXPERIMENTAL|normal dose|Patients would be given 400000 units of ulinastatin (specification: 100000 units / vial) dissolved in 50 ml of 0.9% normal saline intravenously for at least 1 hour, once every 8 hours. It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), halve the dose and continue to use it for 2 days, with a total course of treatment of at least 3 days
62062073|NCT02454829||Adults, gonadotoxic treatment|Women 18 years of age or older who underwent ovarian cortex cryopreservation before gonadotoxic treatment (chemotherapy, radiotherapy)
62449776|NCT00809042|ACTIVE_COMPARATOR|3|magnesium chloride and hydroxyurea
62850452|NCT05391789|EXPERIMENTAL|high dose|Patients would be given 800000 units of ulinastatin (specification: 100000 units / vial) dissolved in 50 ml of 0.9% normal saline intravenously for at least 1 hour, once every 8 hours. It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), halve the dose and continue to use it for 2 days, with a total course of treatment of at least 3 days
62850453|NCT05391789|PLACEBO_COMPARATOR|placebo|Patients would be given 50 ml of 0.9% normal saline intravenously for at least 1 hour once every 8 hours.It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), continue to use it for 2 days, with a total course of treatment of at least 3 days.
62062074|NCT02454829||Girls, gonadotoxic treatment|Girls under 18 years of age who underwent ovarian cortex cryopreservation before gonadotoxic treatment (chemotherapy, radiotherapy)
62652869|NCT04501900|ACTIVE_COMPARATOR|prolonged DAPT group|
62266462|NCT02409654|ACTIVE_COMPARATOR|Individualized stroke prevention|(i) Patient education (ii) Assess individual risk of stroke using the CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii) Recommendation of evidence-based stroke prevention therapy based on international guidelines (iv) Patient audit and follow-up (v) Patients not on appropriate OAC without adequate explanation will be referred to Cardiology Outpatient Clinic for second opinion
62266463|NCT02409654|PLACEBO_COMPARATOR|Routine Care|The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.
62266464|NCT01808300|EXPERIMENTAL|A-B-C|Drug will be administered to according to A-B-C sequence for 3 period.
62850454|NCT06044441|EXPERIMENTAL|ENABLE-SG (immediate group)|"* Participants will receive the ENABLE-SG model immediately (six sessions for patients and four sessions for caregivers) at an approximately weekly interval.~* Interventions: ENABLE-SG model"
62266465|NCT01808300|EXPERIMENTAL|A-C-B|Drug will be administered to according to A-C-B sequence for 3 period.
62850455|NCT06044441|OTHER|Wait-list control|"* 6-month wait-list control. Participants will receive the ENABLE-SG model six months after baseline (six sessions for patients and four sessions for caregivers) at an approximately weekly interval.~* Interventions: ENABLE-SG model"
62850456|NCT05044299|ACTIVE_COMPARATOR|Isoped mobilization with resistance load|Use of Isoped with movement at 3 levels of resistance load: zero, low, high, each condition lasts 3 minutes at 9 minutes total work
62850457|NCT05044299|ACTIVE_COMPARATOR|Isoped mobilization without resistance load|Use of Isoped with movement at zero resistance load lasts 9 minutes of work
62850458|NCT01068600|EXPERIMENTAL|Indacaterol 75 µg|"Indacaterol 75 µg inhaled once daily in the morning via Concept1, a single dose dry powder inhaler (SDDPI), for 12 weeks.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
62062075|NCT02454829||Adults, ovarian pathology|Women 18 years of age or older who underwent ovarian cortex cryopreservation for an ovarian pathology not requiring gonadotoxic treatment but surgery
62266466|NCT01808300|EXPERIMENTAL|B-C-A|Drug will be administered to according to B-C-A sequence for 3 period.
62266467|NCT01808300|EXPERIMENTAL|B-A-C|Drug will be administered to according to B-A-C sequence for 3 period.
62266468|NCT01808300|EXPERIMENTAL|C-A-B|Drug will be administered to according to C-A-B sequence for 3 period.
62449777|NCT03866850||Cochlear implant users with late-onset deafness|"Examine charge integration (Detection threshold as a function of phase duration).~Examine neural spatial excitation patterns with long and short phase duration. Measure speech recognition using long and short phase duration stimulation patterns."
62449778|NCT03866850||Cochlear implant users with early-onset deafness|"Examine charge integration (Detection threshold as a function of phase duration) and compare that with the late-onset group.~Examine neural spatial excitation patterns with long and short phase duration within the non-leaky phase duration range.~Measure speech recognition using long and short phase duration stimulation patterns."
62652870|NCT04501900|NO_INTERVENTION|standard DAPT group|
62449779|NCT03473782||Voiding Diary|
62449780|NCT03473782||Urodynamics Correlation Study|
62062076|NCT02454829||Girls, ovarian pathology|Girls under 18 years of age who underwent ovarian cortex cryopreservation for an ovarian pathology not requiring gonadotoxic treatment but surgery
62062077|NCT02454829||Adults, genetic disorders|Women 18 years of age or older who underwent ovarian cortex cryopreservation in the context of a genetic risk of premature ovarian failure
62624487|NCT03049423||the control group|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
62624488|NCT00823030|PLACEBO_COMPARATOR|Placebo|Placebo instillation: 20 ml of normal saline instilled intravesically
62266469|NCT01808300|EXPERIMENTAL|C-B-A|Drug will be administered to according to C-B-A sequence for 3 period.
62449781|NCT00752323|EXPERIMENTAL|Arm I: Newly diagnosed GBM 10mg/kg|Arm I: Newly diagnosed GBM patients receive oral aminolevulinic acid(10mg/kg)at 6 hours before the midpoint of surgery.
62624489|NCT00823030|EXPERIMENTAL|experimental arm|The experimental instillation will include 8 ml of 2% lidocaine, 3 ml of sodium bicarbonate, and 9 ml of normal saline.
62624490|NCT01998347|EXPERIMENTAL|Paclitaxel liposome and Cisplatin|"Drug: paclitaxel liposome 175mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles:up to 6 cycles.~Drug: cisplatin 37.5 mg/m2, IV (in the vein) on day 1\~2 of each 21 day cycle. Number of Cycles: up to 6 cycles."
62624491|NCT01998347|ACTIVE_COMPARATOR|Cisplatin plus 5-fluorouracil|"Cisplatin:~37.5 mg/m2, IV (in the vein) on day 1-2 of each 21 day cycle. Number of Cycles: up to 6 cycles.~5-fluorouracil: 200mg/m2, CIV (continuous intravenous infusion) on day 1\~5 of each 21 day cycle. Number of Cycles: up to 6 cycles."
62624492|NCT05365919|EXPERIMENTAL|Intervention|The intervention group will be offered to participate in the Family Talk Intervention
62624493|NCT05365919|NO_INTERVENTION|Standard support|The control group will receive standard support
62624494|NCT04351880|ACTIVE_COMPARATOR|Meals - 2 weeks|Receive meal delivery for 2 weeks (1 meal per day for a total of 14 days). The medically tailored meal ordered for each participant will depend on their medical conditions.
62624495|NCT04351880|ACTIVE_COMPARATOR|Meals - 4 weeks|Receive meal delivery for 4 weeks (1 meal per day for a total of 28 days). The medically tailored meal ordered for each participant will depend on their medical conditions.
62850459|NCT01068600|PLACEBO_COMPARATOR|Placebo|"Placebo to indacaterol inhaled once daily in the morning via Concept1, a SDDPI, for 12 weeks.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
62624496|NCT03300362|EXPERIMENTAL|Seasonal influenza & MVA-NP+M1|Two vaccinations will be administered: Seasonal influenza vaccine \& MVA-NP+M1
62624497|NCT03300362|PLACEBO_COMPARATOR|Seasonal influenza & saline placebo|Two vaccinations will be administered: Seasonal influenza vaccine \& sodium chloride
62624498|NCT06414772|EXPERIMENTAL|With MARTI e-tool|
62624499|NCT06414772|NO_INTERVENTION|Without MARTI e-tool|
62624500|NCT03070756|OTHER|treatment group (auto-CPAP)|"Participants of this study undergo an diagnostic PSG night. The diagnostic night is followed by an auto-CPAP treatment night.~Interventions:~The treatment night is in line with the routine procedure of the laboratory except the following intervention: the device settings for the treatment night are applied according to the study protocol (minimal intervention)."
62850460|NCT02967341|OTHER|Ciprofloxacin administration|Blood will be drawn, in all participants, via Port A Cath and via a peripheral draw.
62850461|NCT00669123|PLACEBO_COMPARATOR|2|
62850462|NCT00669123|EXPERIMENTAL|1|Chondroitin sulphate
62850463|NCT00776919|EXPERIMENTAL|1|clindamycin / benzoyl peroxide gel
62850464|NCT00776919|ACTIVE_COMPARATOR|2|Clindamycin gel
62850465|NCT00776919|ACTIVE_COMPARATOR|3|BPO gel
62850466|NCT00776919|PLACEBO_COMPARATOR|4|vehicle gel
62850467|NCT04215302||laryngeal mask size|laryngeal mask size determines according to weight measurement
62850468|NCT00448643|EXPERIMENTAL|Whole-Abdominal Radiation Therapy and Chemotherapy|
62850469|NCT00856232|NO_INTERVENTION|Standard therapy|Standard emergency department evaluation and treatment for headache
62850470|NCT00856232|PLACEBO_COMPARATOR|Medical Air|Air inhalation at 15L / min x 15 minutes followed by standard emergency department evaluation and treatment for headache
62850471|NCT00856232|EXPERIMENTAL|Oxygen|Oxygen inhalation at 15 L/min for 15 minutes followed by standard emergency department evaluation and treatment for headache
62850472|NCT03060161|EXPERIMENTAL|Health in the right measure|"Nutrition counseling and guidance for regular physical activity. An individualized physical exercise program will be proposed according to each participant's level of physical activity and health conditions.~Participants will also receive individualized nutritional guidance. Throughout the project, collective motivational activities will be carried out to promote healthy eating (culinary workshops, talk wheels and others) and individual activities with all participants, in order to evaluate the adherence of nutritional guidelines and to exchange experiences among them."
62850473|NCT01269242|EXPERIMENTAL|bindarit 600 mg|
62850474|NCT01269242|EXPERIMENTAL|bindarit 1200 mg|
62062078|NCT02454829||Girls, genetic disorders|Girls under 18 years of age who underwent ovarian cortex cryopreservation in the context of a genetic risk of premature ovarian failure
62062079|NCT05556317|EXPERIMENTAL|Group A|Receive advices to reduce insomnia
62062080|NCT05556317|ACTIVE_COMPARATOR|Group B|Receive advices and resistive exercise
62062081|NCT05764343|NO_INTERVENTION|Routine support/care arm|As the followed routine implementation, this group will be given a brief smoking cessation intervention and will be recommended to apply to smoking cessation outpatient clinics by getting an appointment from quit services.
62266470|NCT00513500|EXPERIMENTAL|1|Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on rapid diagnostic test. For pneumonia, give one half tablet (250mg amoxicillin) for children weighing (5-9.9kg) and one tablet for children weighing (10-20kg) three times a day for five days.
62266471|NCT00513500|ACTIVE_COMPARATOR|2|Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on clinical diagnosis. For pneumonia, refer to the nearest health facility
62062082|NCT05764343|ACTIVE_COMPARATOR|Immediate support arm|Those randomized to this group will have an immediate appointment at the smoking cessation outpatient clinic in addition to the brief smoking cessation intervention.
62062083|NCT04815317|ACTIVE_COMPARATOR|Basal|"The impact of these stimulations will be compared to that of a control stimulus.~The auditory control condition will consist of listening to a pink noise. The pink noise, like the white noise, is a normalized noise. The sound produced on a TV set that is out of adjustment during the snow effect is a representative example of such noise. Pink noise is a random signal whose power spectral density decreases by 3dB per octave. This signal is closer to the sensitivity of the ear than white noise.~The sensitive control condition will be achieved by administering fresh air on the calf.~An pressure support (+5) increment will be performed to ensure comparability of subsequent experimental sequences and their effect on dyspnea."
62449782|NCT00752323|EXPERIMENTAL|Arm II: Newly diagnosed GBM 20mg/kg|Arm II: Newly diagnosed GBM patients receive oral aminolevulinic acid (20mg/kg)at 6 hours before the midpoint of surgery.
62624501|NCT04396379|EXPERIMENTAL|Device Implantation|To epicardially reshape the mitral valve annulus and left ventricle without the need for cardiopulmonary bypass (CPB) and open-heart access (atriotomy) using an epicardial implant.
62850475|NCT01269242|PLACEBO_COMPARATOR|placebo|
62850476|NCT01301898|EXPERIMENTAL|GC1111_0.5mg/kg|
62850477|NCT01301898|EXPERIMENTAL|GC1111_1.0mg/kg|
62850478|NCT01301898|ACTIVE_COMPARATOR|Elaprase_0.5mg/kg|
62850479|NCT04345367|EXPERIMENTAL|Abrocitinib 200 mg plus placebo injection|Abrocitinib 200 mg daily through Week 26, plus placebo injections every other week through Week 24
62850480|NCT04345367|ACTIVE_COMPARATOR|Dupilumab 300 mg plus placebo tablets|Dupilumab 300 mg every other week (2 injections on Day 1) through Week 24, plus placebo tablets daily through Week 26
62850481|NCT02931669||Adult AAC users|Will be accessed via online forums to fill in online anonymous survey link
62850482|NCT02931669||Children who use AAC|Parents at local special schools will be given the opportunity for their child to participate in a face to face symbol based interview. They will give written consent and children's assent will also be obtained.
62850483|NCT02931669||Family members|The paper version of the survey will be distributed among parents at local special schools for them to fill in at home with their families. Online groups of families will also be sent the online survey link.
62087934|NCT01539434|EXPERIMENTAL|Behavioural intervention|Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.
62449783|NCT00752323|EXPERIMENTAL|Arm III: Recurrent GBM 10mg/kg|Arm III: Recurrent GBM patients receive oral aminolevulinic acid (10mg/kg)at 6 hours before the midpoint of surgery.
62624502|NCT05460858|EXPERIMENTAL|N-acetyl cystein|Seventy participants who randomly assigned in the intervention group, during 6 weeks simultaneous to start standard long agonist protocol or antagonist induction, will be received 1200 (2×600) mg of effervescent tablets of NAC daily. Plasma blood will collect before the intervention and at the time of oocyte retrieval (end of 6 week), in addition to, follicular fluid will be obtained from the mature follicles. Also, we will measure severity of dysmenorea by visual analogue scale (VAS) technique.
62850484|NCT02931669||Teachers|Teachers at local special schools will be given the paper survey forms. Online groups of teachers will receive the online link.
62850485|NCT02931669||Health Professionals|Online groups of health professionals will receive the online link
62850486|NCT03010644||Underserved school-aged children|Underserved school-aged children at risk for obesity
62266472|NCT03609021||Observational (bilateral screening mammogram)|Participants provide bilateral screening mammogram taken prior to all cancer treatment and within 8 weeks prior to registration to A011502 and an annual bilateral mammogram as near as possible to 1 year post-registration to A011502 and as near as possible to 2 years post-registration to A011502. Participants also undergo collection of blood sample and menstrual cycle data within 2 weeks after registration and at 1 and 2 years after registration to A011502.
62087935|NCT01539434|ACTIVE_COMPARATOR|Usual care group|Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
62266473|NCT01107678|EXPERIMENTAL|YMCA PAN|YMCA PAN (Physical activity and nutrition)- Consists of organized physical activity and controlled serving sizes of healthy low fat snacks
62266474|NCT01107678|EXPERIMENTAL|YMCA Standard CAre|YMCA standard care - Follow the standard care of the YMCA after school Y-Care program for physical activity and nutrition
62266475|NCT00996944|EXPERIMENTAL|Ropinirole IR|
62266476|NCT00996944|PLACEBO_COMPARATOR|Placebo|
62266477|NCT03778619|EXPERIMENTAL|single arm|"1. Phase 1~   1. MG4101 (Allogeneic Natural Killer cell): i.v bi-weekly~      * Group 1: 1 x 10\^7 cells/㎏~     * Group 2: 3 x 10\^7 cells/㎏~     * Group 3: 9 x 10\^7 cells/㎏~  2. Interleukin-2 (IL-2): s.c bi-weekly with MG4101 at 1X10\^6 IU/m2 per day.~  3. Rituximab: 375mg/m2. i.v. weekly for the first 2 cycles only (8 doses). monthly (3-6 cycle)~  4. Lymphodepletion: Fludarabine 20mg/m2 + Cyclophosphamide 250 mg/m2 i.v. D-3, D-2, D-1 of 1st, 3rd, and 5th cycle~2. Phase 2a Administration of recommended dosage of MG4101 determined from Phase 1 will be applied in Phase 2a. Dosage regimens for lymphodepletion, IL-2 and Rituximab will be the same as Phase 1."
62266478|NCT00183274|ACTIVE_COMPARATOR|Open-Label Group|6-month randomized phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d
62624503|NCT05460858|PLACEBO_COMPARATOR|effervescent placebo|Seventy participants who randomly assigned to the control group, during 6 weeks simultaneous to start the standard long agonist protocol, or antagonist induction, will be received 1200 (2×600) mg of effervescent placebo tablets daily. Plasma blood will collect before the intervention and at the time of oocyte retrieval, in addition to, follicular fluid will be obtained from the mature follicles. Also, we measure severity of dysmenorrhea by visual analogue scale (VAS) technique.
62266479|NCT00183274|ACTIVE_COMPARATOR|Double-Blind Drug Group|6-month randomized, double-blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 6 - 12 of the study
62266480|NCT00183274|PLACEBO_COMPARATOR|Double-Blind Placebo Group|6-month randomized, double blind phase of placebo occurring between months 6 - 12 of the study
62449784|NCT00752323|EXPERIMENTAL|Arm IV: Recurrent GBM 20mg/kg|Arm IV: Recurrent GBM patients receive oral aminolevulinic acid (20mg/kg)at 6 hours before the midpoint of surgery.
62266481|NCT00183274|ACTIVE_COMPARATOR|Double-Blind Drug-After-Drug Group|6-month randomized, double blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 13 - 19 of the study
62266482|NCT00183274|PLACEBO_COMPARATOR|Double-Blind Placebo-After-Drug Group|6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study
62087936|NCT03100695|NO_INTERVENTION|Control|Patients will undergo operative procedure with no additional intervention.
62062084|NCT04815317|EXPERIMENTAL|Intervention|"Patients will be subjected to sensory stimuli that may be auditory or sensitive.~The sensory stimulations will be administered by a research nurse. The auditory stimulation will consist of listening to relaxing pieces of music from MP3 files from the International Center for Music Therapy (Noisy le Grand, France).~Listening will be done through noise-cancelling headphones (PLANTRONICS, Gamecom 780, Santa Cruz, California, USA) for 10 minutes.~Sensitive stimulation will consist of administering fresh air to the patient's face by means of a fan without blades (DYSON AM01, Malmesbury, UK) for 10 minutes."
62266483|NCT00183274|PLACEBO_COMPARATOR|Double-Blind Placebo-After-Placebo Group|6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study
62266484|NCT02595723|EXPERIMENTAL|Phenytoin, Then Megestrol|Participants first received pretreatment with Phenytoin 200 mg capsule twice/day for one day. Participants then received both Phenytoin (200 mg capsule twice/day) and liquid Megestrol (800 mg/day) for three consecutive days.
62266485|NCT02595723|EXPERIMENTAL|Placebo, Then Megestrol|Participants first received pretreatment with Placebo (matching Phenytoin 200 mg capsule) twice/day for one day. Participants then received both Placebo (matching Phenytoin 200 mg capsule) twice/day and liquid Megestrol (800 mg/day) for three consecutive days.
62266486|NCT02595723|EXPERIMENTAL|Placebo, Then Placebo|Participants first received pretreatment with Placebo (matching Phenytoin 200 mg capsule) twice/day for one day. Participants then received both Placebo (matching Phenytoin 200 mg capsule) twice/day and liquid Placebo (matching liquid Megestrol 800 mg/day) for three consecutive days.
62266487|NCT04631146||Camrelizumab-treated advanced NSCLC|Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
62266488|NCT00322283|EXPERIMENTAL|Oglemilast|
62266489|NCT00322283|PLACEBO_COMPARATOR|Placebo|
62624504|NCT04757805|EXPERIMENTAL|Spinal anesthesia|Infants receiving spinal anesthesia for standard of care procedure
62266490|NCT03792815|EXPERIMENTAL|busulfan melphalan etoposide|busulfan 3.2 mg/kg/day i.v. on day -7, -6, and -5 etoposide 400 mg/m2 i.v. on day -5 and -4 melphalan 50mg/m2/day i.v. on day -3 and -2
62266491|NCT04743102|EXPERIMENTAL|Biopsy cCR|Based on digital examination, serum CEA level, rectal MRI, endoscopy presentation, we add multi-points and full-thickness Biopsy to further improve the accuracy of cCR after neoadjuvant therapy for rectal cancer.
62850487|NCT04176484||Survey|Women, 18 years of age or older, who are scheduled for an abdominal procedure after being seen in the General Surgery clinic will be given a handout (attached) by clinic staff during routine pre-op counseling informing them that they may be called and asked to participate in a research survey. Women age 25 and above who are scheduled for an abdominal procedure and were seen in the General Surgery Clinic will be called and asked to complete a 5-10 minute verbal survey prior to their date of surgery. Some additional information will be gleaned from the medical record during the interview. Participation will be voluntary and all data collected will be recorded without any identifiers.
62850488|NCT04176484||Operating Room Feasibility|A list of women 25 or older who are scheduled for an abdominal procedure after being seen in the General Surgery clinic will be generated to include MRN, procedure date, and pocedure type. A medical record review will be undertaken of these women and we will collect information about conditions that would facilitate or hinder the ability to perform a salpingectomy. No patient interaction will occur by the study team and all data will be de-identified at the time of collection.
62850489|NCT01586754||With Metabolic Syndrome|
62850490|NCT01586754||Without Metabolic Syndrome|
62062085|NCT05171413||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
62062086|NCT05171413||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is an external validation cohort.
62266492|NCT04743102|ACTIVE_COMPARATOR|Conventional cCR|Based on digital examination, serum CEA level, rectal MRI, endoscopy presentation, to study accuracy of cCR after neoadjuvant therapy for rectal cancer.
62266493|NCT00579397||1|"For Objective #1:~* Healthy adult volunteers"
62850491|NCT04726540||Group I|
62266494|NCT00579397||2|"For Objectives #2 \& #3:~* Recipients undergoing an allogeneic stem cell transplant"
62266495|NCT04245007|EXPERIMENTAL|Intervention|Subject will ask to do 5:2 intermittent fasting (2 non-consecutive days a week) within 8 weeks
62266496|NCT04245007|NO_INTERVENTION|Control|Subject will prohibited from doing fasting or intake restriction within 8 weeks
62266497|NCT05821803|EXPERIMENTAL|Experimental Group|"Insoles~Foot Core Exercises"
62266498|NCT05821803|ACTIVE_COMPARATOR|Control Group|Insoles
62266499|NCT04622007|EXPERIMENTAL|A1 Tomi + Current Pembro|Subjects who have initiated pembrolizumab as a single agent and in accordance with the package insert will receive tomivosertib in addition to pembrolizumab.
62266500|NCT04622007|PLACEBO_COMPARATOR|Pbo + Current Pembro|Subjects who have initiated pembrolizumab as a single agent and in accordance with the package insert, will receive matching placebo in addition to pembrolizumab.
62624505|NCT03474445|ACTIVE_COMPARATOR|Control group|Volar Plate Osteosynthesis Aptus 2.5
62624506|NCT03474445|ACTIVE_COMPARATOR|Study Group|Volar Plate Osteosynthesis Inteos 2.5
62624507|NCT00885378|ACTIVE_COMPARATOR|Saxagliptin plus metformin IR|
62624508|NCT00885378|PLACEBO_COMPARATOR|Placebo plus metformin IR|
62266501|NCT04622007|EXPERIMENTAL|B1 Tomi + Pembro|Subjects will initiate pembrolizumab as first-line therapy and receive tomivosertib.
62624509|NCT04499833|EXPERIMENTAL|"liver transplant outside the Milan Criteria"|"patients with hepatocellular carcinoma, outside the Milan Criteria, that complied with the proposed HepatoPredictTool, submitted to liver transplant"
62266502|NCT04622007|PLACEBO_COMPARATOR|Pbo + Pembro|Subjects will initiate pembrolizumab as first-line therapy and receive matching placebo.
62266503|NCT04622007|EXPERIMENTAL|C1 Tomi + Pembro + Pemetrexed (Non-sqamous) or Tomi + Pembro (Squamous)|Subjects who have completed 4 to 6 cycles of platinum-based chemotherapy doublet will receive tomi plus pembrolizumab and pemetrexed (non-squamous NSCLC) or tomi plus pembro as a single agent (squamous) in accordance with the package insert.
62266504|NCT04622007|PLACEBO_COMPARATOR|Pbo + Pembro + Pemetrexed (Non-sqamous) or Pbo + Pembro (Squamous)|Subjects who have completed 4 to 6 cycles of platinum-based chemotherapy doublet will receive placebo plus pembrolizumab and pemetrexed (non-squamous NSCLC) or placebo plus pembro as a single agent (squamous) in accordance with the package insert.
62624510|NCT04446429|ACTIVE_COMPARATOR|Usual Care|Usual care as determined by the PI
62624511|NCT04446429|EXPERIMENTAL|Proxalutamide + Usual Care|Proxalutamide + Usual care as determined by the PI
62850492|NCT04726540||Group II|
62850493|NCT00093249|EXPERIMENTAL|clevidipine|Clevidipine was administered in a blinded fashion by intravenous (IV) infusion, starting at a rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/hr) and titrating upward, as tolerated, in doubling increments approximately every 90 seconds to achieve the desired blood pressure-lowering effect. Up-titration to 3.2 μg/kg/min (16 mg/hr) was allowed. Infusion rates above 3.2 μg/kg/min could be used, guided by the patient's response, by increasing in serial increments of 1.5 μg/kg/min up to the maximum recommended clevidipine infusion rate of 8.0 μg/kg/min. Clevidipine was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
62850494|NCT00093249|PLACEBO_COMPARATOR|placebo|Placebo consisted of 20% lipid emulsion (the same lipid vehicle used for clevidipine) administered in a blinded fashion intravenously following the same study drug administration guidelines as with clevidipine study drug administration guidelines. As with clevidipine, placebo was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
62850495|NCT03353337|EXPERIMENTAL|aerobic exercise|Cycling at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 1 month.
62266505|NCT02821715|ACTIVE_COMPARATOR|Modafinil + placebo|3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks
62266506|NCT02821715|EXPERIMENTAL|THN102 300/3|3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks
62266507|NCT02821715|EXPERIMENTAL|THN102 300/27|3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks
62266508|NCT00977951|EXPERIMENTAL|Intradermal avotermin|
62449785|NCT02028936|EXPERIMENTAL|Grape juice rich in polyphenols|
62449786|NCT02028936|ACTIVE_COMPARATOR|grape juice not enriched with polyphenols|
62449787|NCT01989065|ACTIVE_COMPARATOR|Lifestyle counseling|The Duke Healthy Lifestyles program is a comprehensive childhood obesity treatment program. Standard of care is active engagement and Lifestyle Counseling of families by nutritionist, physician, mental health provider, and physical therapist. Monthly visits for 1 year are recommended.
62449788|NCT01989065|EXPERIMENTAL|Lifestyle counseling PLUS text messaging|Patients in this arm will receive full standard of care as described for the Active Comparison group. In addition, parents will be texted daily with a motivational message that provides information and support for healthy behaviors.
62449789|NCT05197946||Participants with CP (survey-only)|Subjects in this group are age 8 and older with a diagnosis of cerebral palsy. Participants are either able to affirmatively consent or assent with LAR consent. This sample will have a CFCS score ranging between 1 and 3 and should be able to unambiguously respond to a 65 item multiple choice survey.
62624512|NCT02584374||Patients|with suspected iliac vein compression, but with no signs of compression on venography and if venography with balloon occlusion test is performed.
62624513|NCT02584374||Healthy controls|"Healthy subjects between 18-45 years of age~Venography with balloon occlusion test will be performed."
62266509|NCT00977951|PLACEBO_COMPARATOR|Placebo (vehicle)|
62449790|NCT05197946||Neurotypical participants (survey-only)|Subjects in this group are age 8 and older with no clinically significant neurologic or developmental diagnosis. Participants are either able to affirmatively consent or assent with LAR consent.
62449791|NCT05197946||Participants with CP (Survey + MRI)|Subjects are 8 years or older with a diagnosis of cerebral palsy and clinical imaging demonstrating isolated periventricular white matter injury. Clinical assessment states that neurologic symptoms are attributed to this isolated injury. Subjects in this group must be able to lie still in a scanner for 1.5 hours in at most 2 sessions and be able to have an MRI. Participants must be able to affirmatively consent or assent with LAR consent.
62449792|NCT05197946||Neurotypical participants (Survey + MRI)|Subjects in this group are age 8 and older with no clinically significant neurologic or developmental diagnosis. Participants are able to affirmatively consent and are able to have an MRI. Subjects also should be able to lie still in a scanner for 1.5 hours.
62624514|NCT04023214||ADPKD|ADPKD patients
62624515|NCT04023214||Controls|Healthy volunteers
62624516|NCT00076310|EXPERIMENTAL|Cisplatin + Docetaxel + OSI-774|"Cisplatin 75 mg/m\^2 IV every 21 days.~Docetaxel 60 mg/m\^2 IV repeated every 21 days.~OSI-774 100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached."
62449793|NCT00555256|EXPERIMENTAL|1|Patients will be instructed to take sunitinib and rapamycin every morning for 4 weeks, then to take 2 weeks off. The sunitinib dose will be 25mg in the first cohort and the rapamycin dose will be 2 mg.
62449794|NCT02720003|EXPERIMENTAL|LTX DCB|Patients treated with Bard Lutonix DCB
62624517|NCT06285370|EXPERIMENTAL|KW-0761|Patients will receive KW-0761 in this arm
62624518|NCT05682599|EXPERIMENTAL|A：Azvudine 5 mg|Azvudine 5 mg, QD PO, D1-D7
62624519|NCT05682599|EXPERIMENTAL|B：Azvudine 3 mg|Azvudine 3 mg + placebo 2 mg, QD PO, D1-D7
62062087|NCT03919786|EXPERIMENTAL|intervention group|"Durg：0.375% Ropivacaine and 1% lidocaine~topical local anesthesia of pulmonary vein with lidocaine+ropivacaine at the beginning and the end of surgery operation.~Block vagus nerve with lidocaine+ropivacaine 1ml after exposing the pleural apex"
62062088|NCT03919786|PLACEBO_COMPARATOR|normal saline group|Same volume of normal saline will be administrated
62062089|NCT04369638|EXPERIMENTAL|3D NAM|
62062090|NCT04369638|ACTIVE_COMPARATOR|Traditional NAM|
62062091|NCT02920775||Pain|
62062092|NCT02920775||PCP|
62266510|NCT03655756|EXPERIMENTAL|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion/time point|"Therapeutic Classification:~* Noncellular, Therapeutic Cancer Vaccine \> Immunomodulator~Route of Administration:~* Intratumoral injection of cutaneous, subcutaneous or nodal lesions~Mechanism of Action:~* Injection of the IFx-Hu2.0 plasmid DNA construct into the target lesion facilitates the localized expression of the highly immunogenic Emm55 protein by the tumor cells on their cell surface.~Physiological Effect:~* This expression then primes a cascade of immune events that exposes the patient-specific abnormal tumor antigens to the effector mechanisms of the immune system. The immune response becomes systemic as inter-antigenic epitope spreading produces neoantigens to naïve T cells. Therefore, injected lesions are targeted along with non-injected lesions (abscopal effect). This is especially important in conditions where the mutational phenotype varies greatly among individual lesions."
62266511|NCT00153686|EXPERIMENTAL|Capsule Endoscopy|Capsule Endoscopy examination of small intestine
62266512|NCT00153686|OTHER|Mesenteric Angiogram|Mesenteric Angiogram of the small intestine
62266513|NCT02127437|EXPERIMENTAL|A - treated group|
62266514|NCT02127437|PLACEBO_COMPARATOR|B - control group|
62850496|NCT03353337|PLACEBO_COMPARATOR|Placebo controlled group|General intensity activities of recreation therapy, including Handicraft manufacture, reading activity, singing entertainment, walking.
62850497|NCT04744090|EXPERIMENTAL|Roflumilast add-on|Eligible patients will take 500 Mcg of roflumilast once daily (up to 28 days) plus standard of care.
62850498|NCT04744090|PLACEBO_COMPARATOR|Placebo control|Eligible patients will take placebo plus standard of care.
62266515|NCT01208714|ACTIVE_COMPARATOR|revascularization|The patients randomized to this treatment will undergo PTA with stenting of the renal artery.
62266516|NCT01208714|ACTIVE_COMPARATOR|medical therapy|The patients randomized to this treatment will undergo optimal medical therapy
62266517|NCT04540042|EXPERIMENTAL|SelK2 (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
62266518|NCT04540042|PLACEBO_COMPARATOR|Placebo (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
62266519|NCT04540042|EXPERIMENTAL|SelK2 (Part 2)|I.V., single-dose (Day 1)
62850499|NCT01775397|EXPERIMENTAL|Fidaxomicin|Fidaxomicin with alternating matching placebo
62850500|NCT01775397|ACTIVE_COMPARATOR|Vancomycin|Participants received 4 doses (1 dose every 6 hours) of oral vancomycin hydrochloride each day for the duration of the 10-day treatment period
62266520|NCT04540042|PLACEBO_COMPARATOR|Placebo (Part 2)|I.V., single-dose (Day 1)
62266521|NCT02211027|EXPERIMENTAL|Vaccine|The vaccine is composed of lethally irradiated semi-allogenic human fibroblasts (MRC-5) transfected with genomic tumor DNA from the patients own tumor.
62266522|NCT05458076|EXPERIMENTAL|QLS1128 A-Dose 1~5|single dose
62266523|NCT05458076|EXPERIMENTAL|QLS1128 C-Dose 1~3|Twice daily for 7 days
62266524|NCT05458076|EXPERIMENTAL|QLS1128 D-Dose 1|fasting，high fat meal
62266525|NCT02115464|EXPERIMENTAL|Metformin plus Chemo-radiotherapy|Metformin orally 500 mg twice daily for the first week, 1500 mg a day in week 2 and 2000 mg a day at week 3 and then for a period of 12 months. Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
62850501|NCT01903980||EFN Cases|Cases of patients with epipericardial fat necrosis CT findings
62850502|NCT04783558|EXPERIMENTAL|Adapted NAS tool Intervention|Pregnant women in this condition will receive the adapted mobile-based NAS instructional tool and TAU. Women in this condition will go through the NAS instructional tool at least once during pregnancy, with their choice of going through the modules gradually while waiting at the OAT clinic to receive their dose, or by scheduling a time to review the modules. Participants will have free online access to the tool throughout their third trimester as well as through 12-weeks postpartum so they can access the modules at any time, and as many times as desired, including after giving birth.
62062093|NCT02920775||Dentist|
62062094|NCT02920775||Surgery|
62062095|NCT02920775||Emergency Medicine|
62062096|NCT02920775||Oncology|
62062097|NCT02920775||Hospice and Palliative Medicine|
62062098|NCT02920775||Anesthesiology|
62062099|NCT02920775||Neurology|
62062100|NCT02920775||Nurse Practitioners|
62062101|NCT02920775||Pediatrics|
62062102|NCT02920775||Physical Medicine & Rehabilitation|
62062103|NCT02920775||Physician Assistant|
62062104|NCT02920775||Rheumatology|
62062105|NCT02920775||All Other Specialties|
62062106|NCT03541772|EXPERIMENTAL|Oncoxin-Viusid®|Radiotherapy + Chemotherapy + Oncoxin-viusid®
62062107|NCT03541772|PLACEBO_COMPARATOR|Placebo|Radiotherapy + Chemotherapy + Placebo
62062108|NCT00730379|EXPERIMENTAL|1|ridaforolimus (MK8669) + dalotuzumab (MK0646)
62062109|NCT01285284|EXPERIMENTAL|Music|A previously defined list of songs will be administered by headphones to these patients during the colonoscopy.
62062110|NCT01285284|SHAM_COMPARATOR|Control|These patients will receive an MP3 device (and headphones) which will be functioning but without volume.
62062111|NCT02558270|ACTIVE_COMPARATOR|patients dapa|Patients will be administered Dapagliflozin 10mg
62624520|NCT05682599|PLACEBO_COMPARATOR|C：placebo|placebo 5 mg, QD PO, D1-D7
62624521|NCT00389467|ACTIVE_COMPARATOR|1 Mechanical Embolectomy|Participants will be randomized to receive mechanical embolectomy treatment either with the Merci Retriever or Penumbra System and standard medical care or treatment with standard medical care alone.
62624522|NCT00389467|NO_INTERVENTION|2|standard medical care
62624523|NCT04321083|EXPERIMENTAL|O2 brain (central) measurement|INVOS will be applied simultaneously for monitoring along with the regular polysomnography (sleep lab) workup
62624524|NCT03124498|EXPERIMENTAL|CIK Cell|"Phase I - Three dose levels escalated according to 3+3 rule~Phase II - The recommended dose level according to the results from Phase I"
62624525|NCT04473534|EXPERIMENTAL|Arm of CBT-I treatment|Web cognitive behavioral therapy was administered before starting CPAP use by a psychologist expert in behavioral sleep medicine and expert in CBT-I. CBT-I was administered according to the same model and standard visual approach in patients with insomnia. Five sessions are scheduled: sleep psycho-education, sleep restriction, stimulus control, sleep hygiene and challenging beliefs and perception of sleep.
62850503|NCT04783558|NO_INTERVENTION|Treatment-as-Usual (TAU)|Pregnant women in this condition will receive care as usual that involves continued enrollment in OAT and continued obstetric care. We will also provide them with a printed handout containing information on NAS and local resources. Participants in the TAU condition will not receive iPads with accompanying modules, however the handout constitutes more information than they normally receive.
62624526|NCT04473534|EXPERIMENTAL|Arm of psycho-education session|Single session of psycho-education about sleep, OSA, insomnia and interaction among them will be administered by web before beginning CPAP use
62850504|NCT01578850|EXPERIMENTAL|Group A|
62624527|NCT04473534|NO_INTERVENTION|Arm of control TAU (Treatment As Usual)|The control group will receive TAU. Each patient will start to use CPAP after the diagnosis according to AASM (American Academy of Sleep Medicine) guideline.
62624528|NCT06612125|ACTIVE_COMPARATOR|vCV group|Pediatric patients in the PCV group(n=30) received pressure-controlled ventilation. The initial parameters will be as follows: the peak inspiratory pressure (PIP) will set to provide a tidal volume of 7 ml/kg , respiratory rate will be 16 breaths/min, inspiratory to expiratory ratio was 1:2 with an upper limit of PIP of 20 cm H2O.
62850505|NCT01578850|PLACEBO_COMPARATOR|Group B|
62850506|NCT02333617|EXPERIMENTAL|Dry Needling and Exercise|Dry Needling to treat gluteus medius trigger points followed by hip and core exercises.
62062112|NCT02558270|PLACEBO_COMPARATOR|patients placebo|Patients will be administered a placebo
62266526|NCT02115464|ACTIVE_COMPARATOR|Chemo-radiotherapy|Concurrent cisplatin based chemotherapy with or without consolidation and radiotherapy of 60-63 Gy for 6 weeks.
62624529|NCT06612125|ACTIVE_COMPARATOR|PCV group|Pediatric patients in the PCV group(n=30) received pressure-controlled ventilation. The initial parameters will be as follows: the peak inspiratory pressure (PIP) will set to provide a tidal volume of 7 ml/kg , respiratory rate will be 16 breaths/min, inspiratory to expiratory ratio was 1:2 with an upper limit of PIP of 20 cm H2O.
62624530|NCT06612125|ACTIVE_COMPARATOR|PCV-VG group|Pediatric patients in the PCV-VG group (n=30)will be conducted with pressure-controlled volume-guaranteed ventilation, target tidal volume will set at 7 mL/kg, with a respiratory rate of 16 breaths/min and a respiratory ratio of 1:2.
62624531|NCT01624285|EXPERIMENTAL|Arm I (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID.
62624532|NCT01624285|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID.
62624533|NCT04730401|EXPERIMENTAL|High-titre CP|200mL high-titre CP on admittance
62624534|NCT04730401|ACTIVE_COMPARATOR|low-titre CP|200ml low-titre CP on admittance
62624535|NCT04730401|PLACEBO_COMPARATOR|Placebo|200mL saline as placebo on admittance
62624536|NCT05016375||T2DM|Individuals with T2DM.
62652871|NCT03357757|EXPERIMENTAL|Avelumab with VPA|Valproic Acid (VPA, 12.5 mg/kg) once per day and Avelumab (10 mg/kg IV) every 2 weeks for up to 2 years.
62850507|NCT02333617|ACTIVE_COMPARATOR|Soft Tissue Mobilization|Soft tissue mobilization to treat gluteus medius trigger points followed by hip and core exercises.
62850508|NCT02333617|PLACEBO_COMPARATOR|Placebo Control|Placebo to control for hands on time and attention from therapist followed by hip and core exercises.
62850509|NCT04364984||ARB group|Hypertensive patients with COVID-19 who received ARBs
62850510|NCT04364984||ACEi group|Hypertensive patients with COVID-19 who received ACEis
62850511|NCT04364984||DRi group|Hypertensive patients with COVID-19 who received direct renin inhibitor (DRis)
62850512|NCT02785796|EXPERIMENTAL|CV4|The practitioner will contact the participant's occiput (lateral to the external occipital protuberances, but medial to the occipital-mastoid suture) with his or her thenar eminences. When no cranial mobility will be found, operators will be free to use any kind of technique to enhance the cranial movement before CV4 procedure. Once the practitioner will detect the CRI, the practitioner will resist the flexion phase of the CRI and exaggerate the extension phase. This compressive pressure will be maintained until the CRI stopped, and the still-point is reached. The still-point will be held until the CRI return, at which point the compressive pressure will be slowly release
62850513|NCT02785796|PLACEBO_COMPARATOR|sham technique|"The operator will overlap the hands so that the thumbs formed a V. The operator's thenar eminences will contact the occiput very lightly well below the positioning used in the CV4 procedure but with no pressure on the occiput between the occipitomastoid sutures. Once placement will be achieved, the operator's hands will remain motionless for 10 min. Finally, the practitioner's hands will be gently removed and the participant's head will be placed on the table for both procedures"
62850514|NCT02785796|NO_INTERVENTION|Control|The control group will not receive ant type of treatment: subject just stay quietly in supine position in ambulatory room for ten minutes
62850515|NCT04019756||Patients with cancer|50 patients ultimately diagnosed with bladder cancer and 50 control patients (diagnosis of cancer reversed at cystoscopy or cystoscopy for another cause)
62624537|NCT05621707|EXPERIMENTAL|experimental arm|Two cycles of induction chemotherapy (nab-paclitaxel, 200 mg/m2/day, day1; carboplatin, area under the curve of 5 mg/ml/min, day 1) combined with PD-1 inhibitors （Sintilimab, 200 mg/day, day 1）every 3 weeks followed by concurrent chemoradiotherapy. Patients without progressive disease（PD） will proceed to receive immunotherapy (Sintilimab, 200 mg/day, every 3 weeks) as maintenance treatment for at least 1 year.
62624538|NCT01514877|EXPERIMENTAL|Icotinib plus Whole Brain Radiotherapy|Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have shown efficacy in advanced non-small cell lung cancer (NSCLC) patients with brain metastases (BM). Icotinib is a new first generation EGFR-TKI. We conducted a phase II study to evaluate the efficacy and safety of icotinib in combination with whole brain radiotherapy （WBRT） in Chinese NSCLC patients with BM and investigated the cerebrospinal fluid (CSF)/ plasma concentrations of icotinib.
62624539|NCT05355077|EXPERIMENTAL|Group 1|JT001 (VV116):200 mg, oral, Twice a day
62850516|NCT02303132|OTHER|Active MC|Patients with active MC will be included
62850517|NCT02303132|OTHER|MC in remission|Patients with MC in remission will be included
62624540|NCT05355077|EXPERIMENTAL|Group 2|JT001 (VV116):400 mg, oral, Twice a day
62850518|NCT02303132|OTHER|Controls|Patients without MC will be included
62850519|NCT04384081|EXPERIMENTAL|Dose group 1|
62850520|NCT04384081|EXPERIMENTAL|Dose group 2|
62850521|NCT04384081|EXPERIMENTAL|Dose group 3|
62850522|NCT04384081|PLACEBO_COMPARATOR|Placebo group|
62850523|NCT06171477|EXPERIMENTAL|20-40-60|
62850524|NCT06171477|EXPERIMENTAL|60-40-20|
62850525|NCT06171477|EXPERIMENTAL|40-60-20|
62850526|NCT02902341|ACTIVE_COMPARATOR|Control|Standard protocol nutrition.
62850527|NCT02902341|EXPERIMENTAL|Nutrition Therapy|Resting energy expenditure was measured using indirect calorimetry or calculated. A dietician assessed daily caloric intake during the entire hospitalization. Caloric deficits were calculated. According to a predefined flow-chart protocol, nutritional interventions were launched on different time points. Interventions varied from nutritional modifications to oral supplementation, tube feeding, and parenteral nutrition.
62850528|NCT00771862|PLACEBO_COMPARATOR|1. standard care|1 day of perineural ropivacaine 0.2% infusion followed by 4-5 days of normal saline infusion.
62850529|NCT00771862|ACTIVE_COMPARATOR|2: experimental care|4-5 days of perineural ropivacaine 0.4% infusion.
62850530|NCT05606471|ACTIVE_COMPARATOR|VLCD only|Participants in this group will be placed on a very-low calorie diet with a daily energy intake limit of 800 kilocalories. 600 kilocalories will be made up of total meal replacement products supplied by Lighterlife UK. The remaining 200 kilocalories will be flexible for participants to add additional vegetables to supplement the total meal replacement products, allowing some variety to the diet.
62624541|NCT05355077|EXPERIMENTAL|Group 3|JT001 (VV116):600 mg, oral, Twice a day
62266527|NCT01732809|ACTIVE_COMPARATOR|abobotulinumtoxin A|Patients were randomized to the side of the forehead (left or right) in which the products were administered. All the patients received abobotulinumtoxin A in one of the sides of the forehead.
62266528|NCT01732809|ACTIVE_COMPARATOR|onabotulinumtoxin A|Patients were randomized to the side of the forehead (left or right) in which the products were administered. All the patients received onabotulinumtoxin A in one of the sides of the forehead.
62266529|NCT05266937|EXPERIMENTAL|Single Arm|Single-arm study with the primary objective of providing preliminary evidence on the efficacy of atezolizumab plus carboplatin plus nab-paclitaxel as first-line therapy in metastatic triple-negative PD-L1 positive breast cancer patients as evaluated by % 2years OS.
62624542|NCT01671137|ACTIVE_COMPARATOR|Lactobacillus Rhamnosus Strain GG|LGG (6 × 109 colony forming units)
62624543|NCT01671137|PLACEBO_COMPARATOR|Placebo|Placebo
62624544|NCT05725824|ACTIVE_COMPARATOR|Third-party control|Ear canal impressions will be will be packaged and sent to a professional third-party manufacturer for fabrication in an acrylic material-type. These will serve as the control earmolds, by which the in-house study/intervention earmolds will be compared against. To control for style of earmolds, all earmolds will be made in a skeleton style with a sound bore that accommodates size #13 tubing and a separate select-a-vent (SAV).
62624545|NCT05725824|EXPERIMENTAL|In-house Study group_Resin|Custom earmold impressions will be scanned and edited using computer-aided design software. These 3D earmold meshes will then be converted to g-code using licensed software and sent to a stereolithography 3D printer for fabrication. Participants will only wear these study earmolds for the duration of testing.To control for style of earmolds, all earmolds will be made in a skeleton style with a sound bore that accommodates size #13 tubing and a separate select-a-vent (SAV).
62624546|NCT05725824|EXPERIMENTAL|In-house Study group_PLA|Custom earmold impressions will be scanned and edited using computer-aided design software. These 3D earmold meshes will then be converted to g-code using licensed software and sent to a fused deposition modeling 3D printer for fabrication. Participants will only wear these study earmolds for the duration of testing. To control for style of earmolds, all earmolds will be made in a skeleton style with a sound bore that accommodates size #13 tubing and a separate select-a-vent (SAV).
62624547|NCT01962948|EXPERIMENTAL|Phase 1: 100 mg/m2 ganetespib, 80 mg/m2 paclitaxel|Patients receive paclitaxel IV over 1 hour and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ganetespib escalation will follow a modified 3+3 design and escalate from 100mg/m2 to 125mg/m2 to 150mg/m2.
62624548|NCT01962948|EXPERIMENTAL|Phase I: 125 mg/m2 ganetespib, 80 mg/m2 paclitaxel|Patients receive paclitaxel IV over 1 hour and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ganetespib escalation will follow a modified 3+3 design and escalate from 100mg/m2 to 125mg/m2 to 150mg/m2.
62266530|NCT01489839||Periodontal diseased|Subjects with periodontal disease will be enrolled. Subjects with mild disease will have at least 4 teeth with at least 1 site with pocketing of 5 mm or more and concomitant attachment greater than or equal to 2 mm, and radiographic evidence of mesial or distal alveolar bone loss around at least 2 of the affected teeth. Subjects with severe disease will have at least 8 teeth with a site having \>5mm pocketing and loss of 3 mm attachment with evidence of alveolar bone loss in 2 teeth.
62266531|NCT01489839||Periodontally healthy|Periodontally healthy subjects have no teeth with pocketing of 4 mm or greater and attachment loss, with the exception of the distal of the second molars where a pocket of 4 mm and concomitant attachment of up to 2 mm will be acceptable. Healthy subjects can have up to 3 sites with gingival recession and no radiographic evidence of alveolar bone loss.
62266532|NCT06378814|EXPERIMENTAL|Selective Caries Removal|This process will be conducted under an operating microscope to ensure precise removal of carious dentin on cavity walls. Only disorganized carious dentin on the cavity floor will be removed using hand instruments in the control group which is SCR group
62266533|NCT06378814|EXPERIMENTAL|Non selective caries removal|On the other hand, removal of carious dentin on cavity floor will be completely up to hard sound dentine in NSCR group.
62266534|NCT02486198|PLACEBO_COMPARATOR|placebo+oxaliplatin-based chemotherapy|equal saline as placebo, one hour before chemotherapy (if with chemotherapy) with oxaliplatin-based chemotherapy (every 2 or 3 weeks), or daily use until neurotoxicity progress.
62266535|NCT02486198|EXPERIMENTAL|GM+oxaliplatin-based chemotherapy|monosialotetrahexosylganglioside Sodium Injection, 40mg or 60mg, one hour before chemotherapy (if with chemotherapy) with oxaliplatin-based chemotherapy (every 2 or 3 weeks), or daily use until neurotoxicity progress.
62266536|NCT04075721|EXPERIMENTAL|M3258 10 mg QD|
62624549|NCT01962948|EXPERIMENTAL|Phase I: 150 mg/m2 ganetespib, 80 mg/m2 paclitaxel|Patients receive paclitaxel IV over 1 hour and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ganetespib escalation will follow a modified 3+3 design and escalate from 100mg/m2 to 125mg/m2 to 150mg/m2.
62266537|NCT04075721|EXPERIMENTAL|M3258 10 mg Twice per Week|
62266538|NCT04075721|EXPERIMENTAL|M3258 20 mg Twice per Week|
62266539|NCT03999762|ACTIVE_COMPARATOR|Density gradient sample prep|Standard density gradient sample preparation
62624550|NCT01962948|EXPERIMENTAL|Phase II: MTD/MED of ganetespib, 80 mg/m2 paclitaxel|Paclitaxel IV given over 1 hour at 80 mg/m2 days 1, 8 and 15 of a 28-day cycle. PLUS ganetespib IV at MTD/MED from Phase I on days 1, 8 and 15 of a 28-day cycle.
62062113|NCT02558270|ACTIVE_COMPARATOR|controls dapa|controls will be administered Dapagliflozin 10mg
62062114|NCT02558270|PLACEBO_COMPARATOR|controls placebo|controls will be administered a placebo
62062115|NCT01175148|EXPERIMENTAL|Recipient - Atorvastatin to prevent GVHD|Atorvastatin calcium (Lipitor) will be administered at dose of 40mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning. Patients will receive atorvastatin until +180 days or development of grade 2 GVHD. This is the experimental arm for outcome measures.
62062116|NCT01175148|OTHER|Donor - Atorvastatin conditioning for donors|Sibling donors will start taking Atorvastatin calcium (Lipitor) orally at 40mg once daily between 14-28 days before the anticipated first day of apheresis or bone marrow harvest.
62062117|NCT03352843|EXPERIMENTAL|Single arm|
62062118|NCT03962725|ACTIVE_COMPARATOR|Control Group (C)|Endotracheal intubation would be facilitated by either Rocuronium (0.6-1mg kg-1) or Succinylcholine (1-1.5mg kg-1) and further dosing of Rocuronium would be left at the discretion of the anesthesia team members. Choice and technique of induction and maintenance of anesthesia, use of vasopressors, perioperative antibiotics, analgesics/adjunct regional techniques, prophylaxis for postoperative nausea and vomiting, fluid and blood component therapy would be left at the discretion of the anesthesia team. Neuromuscular blockade would be reversed with either Sugammadex or Neostigmine (based on institutional availability) and trachea would be extubated once patient meets criteria per attending anesthesiologist.
62062119|NCT03962725|EXPERIMENTAL|No Relaxant Group (NR)|Endotracheal intubation would be facilitated by Succinylcholine (1-1.5mg/kg) or Remifentanil (1-2mcg kg-1) if Succinylcholine use is contraindicated. No non-depolarizing NMBA would be administered to the patients randomized to the NR group. Choice and technique of induction and maintenance of anesthesia, use of vasopressors, perioperative antibiotics, analgesics/adjunct regional techniques, prophylaxis for postoperative nausea and vomiting, fluid and blood component therapy would be left at the discretion of the anesthesia team. Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine) either as boluses or infusion would be recommended in case of sustained high peak airway pressures (\>35mm Hg), high intra-abdominal pressure, involuntary patient/diaphragmatic movement hindering surgical exposure and dissection. Choice and dose of adjunct/s to optimize operating conditions would be left to the discretion of the anesthesia team.
62062120|NCT05566639|EXPERIMENTAL|mRNA-1010|Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
62624551|NCT04425811|NO_INTERVENTION|No tape applied|Walking parameters were evaluated without any intervention.
62624552|NCT04425811|EXPERIMENTAL|Kinesiological Tape|Walking parameters were evaluated after kinesiological taping on the tibialis anterior muscle
62850531|NCT05606471|ACTIVE_COMPARATOR|Semaglutide only|Participants will be asked to self-administer the GLP-1 agonist Semaglutide weekly, as per clinical practice. They will be asked to start at 0.25mg and increase every two weeks (if tolerated) to the maintenance dose of 1mg, which they will continue until the end of the study.
62266540|NCT03999762|EXPERIMENTAL|Automated sample prep|Automated experimental sample preparation
62850532|NCT05606471|EXPERIMENTAL|Combined VLCD plus Semaglutide|Participants in this group will both partake in the VLCD, and take the weekly dose of Semaglutide (as described above).
62850533|NCT05657574|EXPERIMENTAL|CKD-391|D377 + CKD-331 + placebo (for D086)
62850534|NCT05657574|ACTIVE_COMPARATOR|CKD-331|CKD-331 + placebo (for D377) + placebo (for D086)
62850535|NCT05657574|ACTIVE_COMPARATOR|D377|D377 + placebo (for CKD-331) + placebo (for D086)
62850536|NCT05657574|ACTIVE_COMPARATOR|D086|D086 + placebo (for D377) + placebo (for CKD-331)
62850537|NCT04420936|EXPERIMENTAL|Lifestyle coaching|
62850538|NCT04420936|ACTIVE_COMPARATOR|Control tracking|
62624553|NCT04425811|SHAM_COMPARATOR|Sham taping|Walking parameters were evaluated after sham taping on the tibialis anterior muscle
62624554|NCT05221320|EXPERIMENTAL|Stage 1 - 5 baskets included, based on primary disease|"Ulixertinib: 450mg twice daily (BID), orally, days 1-28~Hydroxychloroquine: 600mg BID, orally, days 1-28~Cycles repeat every 28 days in absence of disease progression or unacceptable toxicity"
62850539|NCT01713101|EXPERIMENTAL|Early intravenous tranexamic acid administration|"Early intraveous administration of tranexamic acid~(1g IV bolus over 10 minutes followed by 1g slow infusion over 8 hours"
62850540|NCT01713101|PLACEBO_COMPARATOR|Placebo group|Normal saline (placebo) administration instead of tranexamic acid solution
62850541|NCT03310489|EXPERIMENTAL|Digitalized cognitive-behavioral intervention|
62850542|NCT03310489|ACTIVE_COMPARATOR|Psychoeducation about anxiety|
62850543|NCT00984113|EXPERIMENTAL|A-Patients with mild renal impairment|
62624555|NCT05221320|EXPERIMENTAL|Stage 2 - basket expansion based on Stage 1|"Ulixertinib: 450mg BID, orally, days 1-28~Hydroxychloroquine: 600mg BID, orally, days 1-28~Cycles repeat every 28 days in absence of disease progression or unacceptable toxicity"
62624556|NCT06188325|EXPERIMENTAL|Group 1|CYP2D6 Extensive metabolizers - dose 1, 2 and 3 of eliglustat
62624557|NCT06188325|EXPERIMENTAL|Group 2|CYP2D6 Poor metabolizers - dose 1, 2 and 3 of eliglustat
62652872|NCT03252158|EXPERIMENTAL|Decrease less healthy item availability|"Intervention: Availability of healthier vs. less healthy foods~Remove less healthy items in 20% of slots, then fill the empty slots with healthier items."
62850544|NCT00984113|EXPERIMENTAL|B-Healthy subjects matched to Group A|
62850545|NCT00984113|EXPERIMENTAL|C-Patients with moderate renal impairment|
62266541|NCT01319409|EXPERIMENTAL|Anatomic Double-Bundle ACL Reconstruction|Subjects in this arm will undergo anatomic double-bundle ACL reconstruction using an autograft quadriceps tendon with a bone block. The graft will be split into 2 strands, 1 to recreate the posterolateral (PL) bundle, the other to recreate the anteromedial (AM) bundle of the ACL. The bone block will be placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft will be placed in tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle will be fixed with the knee in full extension and the AM bundle will be fixed with the knee at 45 degrees of flexion.
62266542|NCT01319409|ACTIVE_COMPARATOR|Anatomic Single-Bundle ACL Reconstruction|Subjects in this arm will undergo anatomic single-bundle ACL reconstruction using an autograft quadriceps tendon with a bone block. The graft will not be split. The bone block will be placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free end of the graft will be placed in single tunnel located in the center of the tibial ACL insertion site. The graft will be fixed with the knee at 10 20 20 degrees of flexion.
62266543|NCT05690529||No recurrence|No recurrence of AF
62266544|NCT05690529||Recurrence|Recurrence of AF
62266545|NCT05555537||Drug resistant epilepsy|failure to achieve sustained seizure freedom after adequate and well tolerated trials of two antiseizure medications
62266546|NCT05555537||Medically controled epilepsy|seizure freedom for at least the last 6months) matched in sex and age.
62266547|NCT04309240|EXPERIMENTAL|rivaroxaban|oral Rivaroxaban 10mg per day for 90days
62266548|NCT04309240|NO_INTERVENTION|blank control|mechanical prophylaxis
62266549|NCT01387243||60 mg Orlistat|Purchased by consumer
62266550|NCT03430115||Weight loss plus exercise (WL+EX)|This group was randomized and previously assigned to weight loss plus exercise.
62266551|NCT03430115||Exercise alone (EX)|This group was randomized and previously assigned to exercise alone.
62266552|NCT03430115||Weight loss alone (WL)|This group was randomized and previously assigned to weight loss alone.
62266553|NCT03430115||Control|This group was randomized and previously assigned to control.
62266554|NCT05899244|EXPERIMENTAL|Muscle limitation subgroup receiving muscle stretching exercice|This subgroup of participants will have to perform 2 muscle stretching exercices every day during a month and to report the frequency of realisation on a smartphone or a web application.
62266555|NCT05899244|EXPERIMENTAL|Muscle limitation subgroup receiving a slider exercice|This subgroup of participants will have to perform two series of ten repetitions of a slider exercice every day during a month and to report the frequency of realisation on a smartphone or a web application.
62624558|NCT03459508||Primary antiphospholipid syndrome women|"1. Informed consent~2. Detailed history emphasizing on~   a. obstetric complications related to antiphospholipid syndrome: i. Recurrent miscarriage ii. Fetal demise iii. Fetal growth restriction iv. Severe pre-eclampsia or eclampsia v. Placental insufficiency vi. Placental abruption b. Systemic vascular complications related to antiphospholipid syndrome: i. Arterial thrombosis ii. Venous thrombosis iii. Small-vessel thrombosis~3. Revision of diagnosis of primary antiphospholipid syndrome:~4. Exclusion of antiphospholipid syndrome secondary to SLE and other autoimmune diseases by: antinuclear (ANA), anti-Smith (Sm) and anti-double stranded DNA (dsDNA) antibodies.~5. Ophthalmological examination:"
62624559|NCT05291923||Post whipple's procedure patients|
62624560|NCT02450838|EXPERIMENTAL|Adjuvanted V180 vaccine|Participants will receive one intramuscular (IM) injection of adjuvanted (with Alhydrogel™) V180 at study entry.
62624561|NCT02450838|EXPERIMENTAL|Nonadjuvanted V180 vaccine|Participants will receive one IM injection of nonadjuvanted V180 at study entry.
62266556|NCT05899244|EXPERIMENTAL|Muscle limitation subgroup receiving a tensioner exercice|This subgroup of participants will have to perform two series of ten repetitions of a tensioner exercice every day during a month and to report the frequency of realisation on a smartphone or a web application.
62266557|NCT05899244|EXPERIMENTAL|Neural limitation subgroup receiving a muscle stretching exercice|This subgroup of participants will have to perform 2 muscle stretching exercices every day during a month and to report the frequency of realisation on a smartphone or a web application.
62266558|NCT05899244|EXPERIMENTAL|Neural limitation subgroup receiving a slider exercice|This subgroup of participants will have to perform two series of ten repetitions of a slider exercice every day during a month and to report the frequency of realisation on a smartphone or a web application.
62266559|NCT05899244|EXPERIMENTAL|Neural limitation subgroup receiving a tensioner exercice|This subgroup of participants will have to perform two series of ten repetitions of a tensioner exercice every day during a month and to report the frequency of realisation on a smartphone or a web application.
62266560|NCT05899244|NO_INTERVENTION|Neural limitation Control subgroup|Participants in this subgroup will not receive an intervention.
62266561|NCT05899244|NO_INTERVENTION|Muscle limitation Control subgroup|Participants in this subgroup will not receive an intervention.
62266562|NCT01066364|PLACEBO_COMPARATOR|Placebo (sugar) pill|Six tablets per day (identical to colesevelam)
62266563|NCT01066364|EXPERIMENTAL|Colesevelam arm|3.75 grams per day
62624562|NCT02450838|PLACEBO_COMPARATOR|Placebo|Participants will receive one IM injection of placebo at study entry.
62624563|NCT01861353|EXPERIMENTAL|Cranberry-lingonberry juice|"Cranberry-lingonberry juice. Cranberry 12.8%, Lingonberry 12.4%, together 38g/l, contains added sugars 10g/dL.~Dose is 5 mL/kg/day, max. 300 ml/day per day. Juice was manufactured and donated by Eckes-Granini, Finland"
62624564|NCT01861353|PLACEBO_COMPARATOR|Placebo juice|"Contains no cranberry or lingonberry extracts. Added sugars 10g/dL (same as in the active juice group). Contains natural cranberry flavour and red anthocyanin colour. Contains 5.5 g/L citric acid. Has been tested by chemists and does not contains PAC-compounds which are thought to be the main active compound in cranberry juice.~Placebo juice was manufactured by Eckes-Granini. Dose is 5 mL/kg/day, max. 300 mL/day."
62624565|NCT04226014||Patients with echo-endoscopic ultrasound of the pancreas|Patients requiring endoscopic ultrasound of the pancreas were included in the cohort.
62850546|NCT00984113|EXPERIMENTAL|D-Healthy subjects matched to Group C|
62850547|NCT00984113|EXPERIMENTAL|E-Patients with severe renal impairment|
62266564|NCT06336252|EXPERIMENTAL|Arm 1 digital nudging|"In hospital Participants in the intervention group will receive usual hospital care and be provided with a sensor collecting data on physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level, in terms of time spent bedridden, sitting, standing, and walking. This information will be visible to the health personnel, the patients, and their relatives. This feedback system is developed and provided by SENS Innovation.~After discharge The visual feedback system from SENS will be continued after discharge and include an E-sport biking system provided by 4Mvideo. This integrated new system will combine an ergometer bike or sofa bike installed in the patient's own home or nursing home, and data from the sensor that the participants continue to wear after discharge will go into the SENS system, feeding back a visual track of their activities"
62266565|NCT06336252|NO_INTERVENTION|Arm 2 usual care|The participants in the non-exposed cohort will receive usual hospital care and be provided with a sensor collecting data on activity level during hospitalisation.
62624566|NCT04872387|EXPERIMENTAL|BAY2586116 Dose step 1 and Placebo|"Each participant of Dose step 1 will receive a single dose of BAY2586116 or placebo.~In this dose step, 12 participants will be included (9 on active treatment, 3 on placebo)."
62624567|NCT04872387|EXPERIMENTAL|BAY2586116 Dose step 2 and Placebo|"Each participant of Dose step 2 will receive a single dose of BAY2586116 or placebo.~In this dose step, 12 participants will be included (9 on active treatment, 3 on placebo)."
62266566|NCT05223946|ACTIVE_COMPARATOR|Passive Microwave Radiometry|Diagnostic Test: Passive Microwave Radiometry The MWR2020 (former RTM-01-RES) device is a unique commercially available CE marked device. The device is already registered in Russia and Kyrgyzstan for diagnostics of different diseases.
62266567|NCT05223946|EXPERIMENTAL|SCENAR|Percutaneous electroneurostimulation (TENS) using the Self Controlled Energy Neuro Adaptive Regulator SCENAR-CHENS-01 device (ZAO OKB RITM, Taganrog, Russia)
62266568|NCT03001674|EXPERIMENTAL|IABP recipient|Referred for clinically indicated right heart catheterization with intervention of IABP placement prior to LVAD surgery.
62266569|NCT03001674|EXPERIMENTAL|Control|Control subjects undergoing left heart catheterization with an LV ejection fraction \> 50%, and without a history of heart failure symptoms who did not receive IABP therapy were enrolled.
62266570|NCT06503172|EXPERIMENTAL|Taiwanese whole grain job's tear (Red job's tear)|Taiwanese whole grain job's tear (Red job's tear)
62266571|NCT06503172|ACTIVE_COMPARATOR|White job's tear|White job's tear
62266572|NCT06503172|ACTIVE_COMPARATOR|Active comparator group|"Active comparator group~* serve as comparator group from week 0 to week 8,~* assigned to red job's tear or white job's tear group from week 8 to week 16"
62266573|NCT03579784|EXPERIMENTAL|Durvalumab+Olaparib+Paclitaxel|"1. st cycle : Paclitaxel+Olaparib~   * Olaparib 150mg bid on D1-28~  * Paclitaxel 80 mg/m2 mg iv on D1, D8, D15~2. nd cycle and thereafter: Durvalumab+Olaparib+Paclitaxel :~   * Olaparib 150mg bid on D1-28~  * Durvalumab 1.5 g iv on D1~  * Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks~During first 4 weeks, palictaxel/olaparib dual combination will be used. Since 2nd cycle, palictaxel/olaparib/Durvalumab combination will be used."
62266574|NCT01271283|EXPERIMENTAL|Arm I|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (by morphological criteria but have persistent minimal residual disease by molecular criteria) or partial response may continue treatment beyond 8 courses. Patients may undergo bone marrow, peripheral blood, and/or lymph node sample collection at baseline and periodically during study for correlative studies.
62266575|NCT05815108||RIS Patient|RIS patients validated by the RIS expert group
62266576|NCT00940589|EXPERIMENTAL|Circadin|Drug
62266577|NCT00940589|PLACEBO_COMPARATOR|Placebo|drug
62266578|NCT06375109|EXPERIMENTAL|neoCIT|Neoadjuvant chemotherapy + Tislelizumab(2-3 cycles), Adjuvant chemotherapy + Tislelizumab (1-2 cycles), Maintenance Tislelizumab
62266579|NCT06375109|ACTIVE_COMPARATOR|neoCT|Neoadjuvant chemotherapy (2-3 cycles), Adjuvant chemotherapy (1-2 cycles)
62266580|NCT03302845|EXPERIMENTAL|Omeprazole|Subjects will receive one 40 mg omeprazole capsule per day for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
62266581|NCT03302845|EXPERIMENTAL|Famotidine|Subjects will receive one 40 mg famotidine tablet given twice daily for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
62266582|NCT02765568|EXPERIMENTAL|Moderate Intensity Continuous Exercise|Moderate Intensity Continuous Exercise Training
62266583|NCT02765568|EXPERIMENTAL|Nordic Walking|Nordic Walking
62266584|NCT02765568|EXPERIMENTAL|High Intensity Interval Training|High Intensity Interval Training
62266585|NCT05988671|PLACEBO_COMPARATOR|Control group|received 20 ml normal saline
62266586|NCT05988671|ACTIVE_COMPARATOR|dexamethasone group|received 8mg dexamethasone
62266587|NCT05988671|ACTIVE_COMPARATOR|dexmedetomidine group|received dexmedetomidine 1mic/kg
62624568|NCT04872387|EXPERIMENTAL|BAY2586116 Dose step 3 and Placebo|"Each participant of Dose step 3 will receive single and multiple doses of BAY2586116 or placebo administered once daily (OD) for 5 consecutive days.~In this dose step, 12 participants will be included (9 on active treatment, 3 on placebo)."
62850548|NCT00984113|EXPERIMENTAL|F-Healthy subjects matched to Group E|
62266588|NCT05988671|ACTIVE_COMPARATOR|combined group|received combination of both 8mg dexamethasone+ dexmedetomidine 1mic/kg
62266589|NCT04435509|EXPERIMENTAL|Greek Mountain Tea|50 patients Greek Mountain Tea 50 grams one per 30 days. Dietary Supplement: Greek Mountain Tea dietary intake of the content of 12 grams Intervention:Greek Mountain Tea in a plastic bag.
62266590|NCT04435509|PLACEBO_COMPARATOR|Mediterranean Diet|50 patients same dietary habits and a Mediterranean dietary protocol Intervention: Mediterranean diet.
62266591|NCT03263507|EXPERIMENTAL|Donidalorsen|Ascending single and multiple doses of Donidalorsen administered subcutaneously
62266592|NCT03263507|PLACEBO_COMPARATOR|Placebo (sterile saline 0.9%)|Calculated volume to match active comparator
62266593|NCT02956551|EXPERIMENTAL|cell_therapy|tumor neoantigen primed DC vaccines are administrated, 2-week interval, totally 5 times
62266594|NCT06213090||Autism|Children with autism will be followed in regards to their clinical management.
62624569|NCT04361760|EXPERIMENTAL|Healthy younger participants (20-30y)|Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.
62062121|NCT05566639|ACTIVE_COMPARATOR|Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine|Participants will receive a single dose of licensed quadrivalent inactivated seasonal influenza vaccine by IM injection on Day 1.
62624570|NCT04361760|EXPERIMENTAL|Healthy older participants (65-75y)|Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.
62624571|NCT04433923|ACTIVE_COMPARATOR|GROUP1|Phototherapy with aluminum foil
62062122|NCT00510458|OTHER|LFIT™Femoral Heads With X3® Insert|LFIT™ Femoral Heads With X3® Insert
62062123|NCT01212536|NO_INTERVENTION|Conventional|conventional laryngoscopy for intubation
62062124|NCT01212536|EXPERIMENTAL|Airtraq|laryngoscopy with Airtraq for intubation
62062125|NCT05102422||1-Propofol|"Induction and maintenance of general anesthesia using the intravenous anesthetic.~Every patient received an intravenous bolus of 0,2 μg.kg-1 sufentanil, and the propofol (P) infusion was started using target-controlled infusion (TCI - Schnider's pharmacokinetic/pharmacodynamic data set); targeting the effect-concentration of 3 µg.ml-1. The effect concentration was gradually increased by 1µg.ml-1 every 2 to 3 minutes until loss of consciousness occurred. 0.1 mg.kg-1 of iv cisatracurium was given to prepare definitive intubation. The P effect-concentration were increased of 1 µg.ml-1 until test laryngoscope was successful and oro-tracheal intubation was performed.~The effect concentration of propofol is reduced to 3 to 4 µg.ml-1 while awaiting the surgical incision. It is then left to the discretion of the anesthetist to add either an iv bolus of sufentanil (0.1 μg.kg-1) and/or an iv bolus of cisatracurium (0.1 mg.kg-1) only if necessary, in the clinical judgment of the practitioner."
62087937|NCT03100695|EXPERIMENTAL|Study|Patients will undergo usual operative procedure with the addition of an injection of autologous, concentrated PRP-BMA at the site of fixation.
62266595|NCT06213090||Mitochondrial Encephalopathy|Children with Mitochondrial Encephalopathy will be followed in regards to their clinical management.
62624572|NCT04433923|PLACEBO_COMPARATOR|GROUP2|Phototherapy without aluminum foil
62624573|NCT00240968|EXPERIMENTAL|3|Subjects will receive a single 45 mcg IM dose of the influenza A/H5N1 virus vaccine.
62624574|NCT00240968|EXPERIMENTAL|4|Subjects will receive a single 90 mcg IM dose of the influenza A/H5N1 virus vaccine.
62624575|NCT00240968|EXPERIMENTAL|1|Subjects will receive a single 7.5 mcg IM dose of the influenza A/H5N1 virus vaccine.
62624576|NCT00240968|EXPERIMENTAL|2|Subjects will receive a single 15 mcg IM dose of the influenza A/H5N1 virus vaccine.
62624577|NCT01909960|EXPERIMENTAL|Surgery|Patients who will undergo flow imaging and neurosurgery (shunting). (25% of the studied population)
62624578|NCT01909960|EXPERIMENTAL|Clinical follow-up|Patients who will undergo flow imaging but not surgery (75% of the studied population)
62624579|NCT06155474|PLACEBO_COMPARATOR|Healthy/Control (Starch)|The Healthy Controls will be given starch packed in the same way as the active prebiotics
62624580|NCT06155474|EXPERIMENTAL|Malnutrition (RUTF + Starch)|The Malnutrition group with RUTF and Starch only. The RUTF will be given as per the WHO guidelines
62624581|NCT06155474|ACTIVE_COMPARATOR|Malnutrition (RUTF + prebiotics)|The Malnutrition group with RUTF and Prebiotic only. The RUTF will be given as per the WHO guidelines
62624582|NCT04693299||Study cohort|"Inclusion criteria:~Outpatient and hospitalized patients, adults, candidates for colonoscopy for any pathology, as part of the normal care process, with the need to repeat bowel preparation due to inadequate cleansing.~Exclusion criteria:~* Emergency regime~* Inability to obtain consent~* Refusal of the patient"
62624583|NCT02617498|ACTIVE_COMPARATOR|harmonic scalpel|parenchymal liver transection was performed either by harmonic scalpel after demarcation of line of transection by intraoperative US and doppler. The clearly exposed vessels were ligated by 5/0 proline or clipped according to their size.
62652873|NCT03252158|EXPERIMENTAL|Decrease healthier item availability|"Intervention: Availability of healthier vs. less healthy foods~Remove healthier items in 20% of slots, then fill the empty slots with less healthy items."
62087938|NCT06252389||Achilles Regeneten|bovine collagen patch to augmented repair in acute Achilles tendon rupture with pre-existing tendinopathy
62087939|NCT06359795|EXPERIMENTAL|Experimental arm|"Patients with TED will be recruited in the study.~Interventions:~Diagnostic Test: 18F-AlF-FAPI PET/CT and 99mTc-DTPA SPECT/CT."
62266596|NCT06213090||Down Syndrome|Children with Down Syndrome will be followed in regards to their clinical management.
62624584|NCT02617498|ACTIVE_COMPARATOR|spray mode diathermy|parenchymal liver transection was performed either by spray mode diathermy after demarcation of line of transection by intraoperative US and doppler. The clearly exposed vessels were ligated by 5/0 proline or clipped according to their size.
62062126|NCT05102422||2-Sevoflurane|"Induction and maintenance of general anesthesia using the inhaled anesthetic sevoflurane.~Every patient received an intravenous (iv) bolus of 0,2 μg.kg-1 sufentanil, then sevoflurane (S) is started at one minimal alveolar concentration (2% in 50% oxygen) during mask assisted ventilation. The S concentration is gradually incremented by 2% until the LOC when the mask ventilation became fully assisted. 0.1 mg.kg-1 of iv cisatracurium was given to prepare definitive intubation. The S end-tidal concentration were increased of 1% until the test laryngoscope was successful and oro-tracheal intubation was performed. The end-tidal concentration of sevoflurane is reduced to one MAC while awaiting the surgical incision.~After surgical incision, it is left to the discretion of the anesthetist to add either an iv bolus of sufentanil (0.1 μg.kg-1) and/or an iv bolus of cisatracurium (0.1 mg.kg-1) only if necessary, in the clinical judgment of the practitioner."
62266597|NCT06213090||Cerebral Folate Deficiency|Children with Cerebral Folate Deficiency will be followed in regards to their clinical management.
62266598|NCT06213090||PANS|Children with PANS will be followed in regards to their clinical management.
62266599|NCT06213090||PANDAS|Children with PANDAS will be followed in regards to their clinical management.
62266600|NCT06213090||Epilepsy|Children with Epilepsy will be followed in regards to their clinical management.
62266601|NCT06213090||ADHD|Children with ADHD will be followed in regards to their clinical management.
62266602|NCT06213090||Dyslexia and other learning disabilities|Children with Dyslexia and other learning disabilities will be followed in regards to their clinical management.
62266603|NCT06213090||Other Neurodevelopmental Disorders|Children with Other Neurodevelopmental Disorders will be followed in regards to their clinical management.
62266604|NCT06206759||study group- ICU patients treated with vitamin C|ICU patients treated with vitamin C
62449795|NCT00108732|EXPERIMENTAL|Treatment (vaccine therapy)|"Patients receive vaccinia-PSA-TRICOM vaccine SC on day 1 and sargramostim (GM-CSF) SC on days 1-4 during weeks 1-4. Beginning in week 5, patients receive fowlpox-PSA-TRICOM vaccine SC on day 1 and GM-CSF SC on days 1-4. Treatment with fowlpox-PSA-TRICOM vaccine and GM-CSF repeats every 4 weeks for 3 courses (weeks 5-16). Beginning in week 17, patients receive fowlpox-PSA-TRICOM vaccine and GM-CSF as above every 12 weeks in the absence of clinical or biochemical disease progression or unacceptable toxicity.~Patients with biochemical or clinical disease progression receive androgen ablation therapy comprising oral bicalutamide once daily for 1 month and goserelin SC once every 4 weeks in addition to fowlpox-PSA-TRICOM vaccine and GM-CSF. Treatment continues in the absence of further clinical or biochemical disease progression."
62449796|NCT00865709|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6|Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m\^2 bolus and 2400 mg/m\^2 for 46-48 hrs; levo-leucovorin 200 mg/m\^2; 85 mg/m\^2 oxaliplatin) every 14 days until progressive disease (PD)
62449797|NCT00865709|PLACEBO_COMPARATOR|Matching placebo + mFOLFOX6|Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m\^2 bolus and 2400 mg/m\^2 for 46-48 hrs; levo-leucovorin 200 mg/m\^2; 85 mg/m\^2 oxaliplatin) every 14 days until progressive disease
62449798|NCT01627873|EXPERIMENTAL|Remifentanyl|In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
62449799|NCT01627873|ACTIVE_COMPARATOR|Fentanyl|In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
62449800|NCT03513393|EXPERIMENTAL|A: Epclusa + omeprazole + Coca Cola (test 1)|Day 1 - 6 40mg omeprazole QD; on Day 5 a single-dose of SOF/VEL with 250 mL of Coca Cola Classic is administered (test 1).
62449801|NCT03513393|EXPERIMENTAL|B: Epclusa + omeprazole + water (test 2)|Day 8 - 13: 40mg omeprazole QD; on Day 12 a single-dose of SOF/VEL is administered (test 2).
62624585|NCT06524167||Adjuvant radiotherapy|Locally advanced recurrent high-risk thyroid cancer patients who had adjuvant radiotherapy.
62624586|NCT00481364|ACTIVE_COMPARATOR|Statin|Atorvastatin 40 mg/day
62266605|NCT06206759||control group- ICU patients not treated with vitamin C|ICU patients not treated with vitamin C
62266606|NCT00985062|ACTIVE_COMPARATOR|Mild Ovarian Stimulation|
62624587|NCT00481364|PLACEBO_COMPARATOR|Placebo|placebo
62652874|NCT00440843|EXPERIMENTAL|OLZ|
62266607|NCT00985062|ACTIVE_COMPARATOR|Conventional Ovarian Stimulation|
62266608|NCT02248727|ACTIVE_COMPARATOR|enfilcon A|All participants are habitual wearers of enfilcon A lens and who are refitted with somofilcon A lens
62266609|NCT02248727|EXPERIMENTAL|somofilcon A|All participants are habitual wearers of enfilcon A lens and who are refitted with somofilcon A lens
62266610|NCT04155671|EXPERIMENTAL|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. The combined chemotheraphy will be treated for 9 circle. then，the capetabine was allowed
62266611|NCT04155671|EXPERIMENTAL|FOLFOX plus PAC(ip)|The regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2) plus paclitaxel (80 mg/m2) intra-peritoneally.Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
62266612|NCT03711500|EXPERIMENTAL|D-serine 80 mg/kg|
62266613|NCT03711500|PLACEBO_COMPARATOR|Placebo|
62850549|NCT04416360|EXPERIMENTAL|Interview by psychologists|Children and adolescent interview Parents interview Referring caregiver interview
62266614|NCT03711500|EXPERIMENTAL|D-serine 100 mg/kg|
62266615|NCT03711500|EXPERIMENTAL|D-serine 120 mg/g|
62266616|NCT00414102|EXPERIMENTAL|Ramelteon 8 mg QD|
62266617|NCT00414102|PLACEBO_COMPARATOR|Placebo QD|
62266618|NCT02530528|EXPERIMENTAL|2% CHG 1 min|single administration, 1 min application time
62062127|NCT05351476|EXPERIMENTAL|Resistance Exercise|Participants do regular resistance exercise for 12 weeks.
62062128|NCT05351476|EXPERIMENTAL|Endurance Exercise|Participants do regular endurance exercise for 12 weeks.
62062129|NCT03620721|EXPERIMENTAL|M-Body|mindfulness group intervention
62266619|NCT02530528|EXPERIMENTAL|2% CHG 2 min|single administration, 2 min application time
62266620|NCT02530528|EXPERIMENTAL|2% CHG 3 min|single administration, 3 min application time
62449802|NCT03513393|ACTIVE_COMPARATOR|C: Epclusa + water (Reference)|Day 15 - 21: no treatment with omeprazole; on Day 19 a single-dose of SOF/VEL is administered (reference).
62266621|NCT02530528|ACTIVE_COMPARATOR|Comparator 2% CHG|Single administration, Marketed CHG
62266622|NCT01849471||patients with prostate cancer|questionnaires
62266623|NCT01714271|EXPERIMENTAL|Home environs-based lifestyle counseling|Home environs-based lifestyle counseling Involves Spanish-speaking community health workers interacting with intervention subjects in home visits and phone calls - 12 contacts overall. The counseling focuses on promoting subject adherence to the Dietary Guidelines for Americans (DGA) and the Physical Activity Guidelines for Americans (PAGA) with special attention devoted to changing the home environment to make it optimally supportive of the lifestyle choices consistent with the DGA and PAGA. Study participants will also be provided 4 group education sessions that will be devoted to improving subject adherence to the DGA and PAGA.
62266624|NCT01714271|EXPERIMENTAL|Cancer early detection|Cancer Early Detection Spanish-speaking health educators will interact with study participants via a home visit and four telephone calls. The focus of the health education will be on practical strategies to detect cancer early to help prevent death from cancer. Cancer sites of interest will be: breast, cervical, skin, colon, prostate and testicular cancers. In addition, study participants will be provided two group education classes that will focus on the basics of the cancer process and why early detection and intervention can be life-saving.
62266625|NCT01319695|EXPERIMENTAL|corifollitropin alfa|
62266626|NCT01319695|ACTIVE_COMPARATOR|recombinant follicle stimulating hormone (FSH)|150-300 IU of FSH for ovarian stimulation in women undergoing IVF
62449803|NCT01332409||Patients prescribed salmeterol and fluticasone|Patients with chronic obstructive pulmonary disease prescribed salmeterol and fluticasone during study period
62449804|NCT06338397|EXPERIMENTAL|Social & affective cognition assessment|
62449805|NCT05569148|EXPERIMENTAL|Faricimab PFS Configuration|
62850550|NCT05861817|EXPERIMENTAL|Study group|The participants were treated using LLLT (904nm and 2.5 J/ sinus) for one month
62062130|NCT03620721|NO_INTERVENTION|Usual Care|treatment as usual
62062131|NCT05012475|EXPERIMENTAL|Participants|The study involves a pre-intervention phase (4 weeks long), followed by a cause and effect training phase (1 week long), followed by an intervention phase (12 weeks long), and ending with a post-intervention phase (4-weeks long) for a total of 5-6 months from start to finish.
62850551|NCT05861817|SHAM_COMPARATOR|Control group|using LLLT without output adjustment of the parameters
62850552|NCT00994344|EXPERIMENTAL|Darunavir/ritonavir|to switch from the triple therapy based regimens to Darunavir/ritonavir
62062132|NCT03873194|EXPERIMENTAL|Meditation group|Patients who are going to practice meditation and will receive only the usual outpatient care, with the aim of observing reduction of systemic blood pressure in this period.
62624588|NCT00748163|EXPERIMENTAL|Stage IV Non-Small Cell Lung Cancer Patients|Patients with stage IV non-small cell lung cancer treated with paclitaxel albumin-stabilized nanoparticle formulation and sunitinib malate as first-line therapy.
62624589|NCT01706432||All participants|"Patients will undergo standard of care radiation therapy and have research blood samples collected at following time points:~* pre-treatment~* 3-4 weeks post-treatment~* every 9-12 weeks post-treatment for 1 year"
62624590|NCT02924233|EXPERIMENTAL|Sym004 + nivolumab|"Phase 1b, dose-escalation:~Dose Level 1: Sym004 + nivolumab (Q2W)~Dose Level 2: Sym004 + nivolumab (Q2W)~Dose Level -1: Sym004 + nivolumab, if needed"
62624591|NCT02924233|EXPERIMENTAL|Sym004 (RP2D) + nivolumab|"Phase 2b, dose-expansion:~Receiving Sym004 in the RP2D in combination with nivolumab (Q2W)"
62624592|NCT02924233|ACTIVE_COMPARATOR|Nivolumab|"Phase 2b, dose-expansion:~Receiving nivolumab monotherapy (Q2W)"
62624593|NCT03403881|ACTIVE_COMPARATOR|Physical activity promotion + TAU|"Physical activity promotion based on:~* Pedometers use;~* Weekly contact (telephone or face-to-face);~* Contact based on a self-determination theory.~TAU:~Treatment as usual, which include medications. Medications were prescribed by psychiatrists not involved in the study participation."
62850553|NCT00994344|ACTIVE_COMPARATOR|Lopinavir/ritonavir|to switch from the triple therapy based regimens to Lopinavir/ritonavir
62062133|NCT03873194|OTHER|conventional treatment|Patients that will receive only the usual outpatient care, with the aim of observing the systemic blood pressure in this period.
62624594|NCT03403881|PLACEBO_COMPARATOR|Control|"Weekly calls with general health content.~TAU:~Treatment as usual, which include medications. Medications were prescribed by psychiatrists not involved in the study participation."
62624595|NCT01983163|ACTIVE_COMPARATOR|ketogenic diet|ketogenic diet (2.5 to 4:1)
62850554|NCT02771613||Active experience feedback|Multi professional, in situ simulation , with scenarios based on the adverse events analyzed in MMR : After analysis of adverse effects in Morbidity Mortality reviews, we will create scenarios adapted to these events. Education of the randomized department's arm's staff will be performed by multi professional in situ simulation with these scenarios
62062134|NCT02640443|EXPERIMENTAL|Treatment|Treatment with sulfamethoxazole. Subjects will serve as their own control, by using the data from baseline and after treatment stop.
62062135|NCT05518292|ACTIVE_COMPARATOR|rhomboid intercostal block|Ultrasound guided RIB will apply with 10-12 MHz linear ultrasound transducer, in plane technique. Patients will placed in the sitting position. 22G spinal needle needle will be inserted to plane between the rhomboid muscle and intercostal muscles over the T5-6 ribs 2 cm to 3 cm medially from the medial border of the scapula. 20 ml of bupivacaine 0.25% will inject into the fascial plane.
62624596|NCT01983163|ACTIVE_COMPARATOR|Modifid Atkin's diet|Modified Atkin's Diet
62624597|NCT03368118|EXPERIMENTAL|ABX464 Treatment arm|All subjects will receive ABX464 at 50 mg o.d for an overall period of 48 months.
62624598|NCT03292614||Multifocal intraocular lens implantation|Patients who have undergone a cataract surgery with implantation of a multifocal intraocular lens LS313 MF30, Oculentis Berlin, will be invited for Measurements of the postoperative refraction
62624599|NCT05234268|EXPERIMENTAL|Manual Cervical Traction|The patient is in supine lying. The head and neck of patient are held in the hands of the practitioner, and then a gentle traction of a pulling force is applied. Intermittent periods of traction can be applied, holding each position for about 10 seconds. Traction is usually applied at about 20-30 degrees of neck flexion.
62850555|NCT02771613||Passive experience feedback|Large diffusion of information about discussions and decisions of Morbidity Mortality Reviews : after the analysis of adverse effects in Morbidity Mortality reviews, a large scale dissemination activity of information about discussions and decisions towards the staff of the randomized departments' arms will be carried out.
62850556|NCT02771613||No experience feedback|MMR will be performed as usual, without any feedback to the medical staff
62850557|NCT02996279||group 1|maternal chorioamnionitis
62850558|NCT02996279||group 2|no maternal chorioamnionitis
62850559|NCT02351427|ACTIVE_COMPARATOR|Bortezomib|"Bortezomib (subcutaneous) 1.3mg/m2 on day 1, 4 and 7~with~Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage"
62087940|NCT00005305||Hemophilic individuals|Subjects receiving multiple blood products for treatment of hemophilia
62449806|NCT05816876||Patients with primary ciliary dyskinesia|"Exercise capacity assessed using six minute walk test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, life quality using The Primary Ciliary Dyskinesia Quality of Life scale (Turkish version)."
62449807|NCT05816876||Patients with Kartagener Syndrome|"Exercise capacity assessed using six minute walk test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, life quality using The Primary Ciliary Dyskinesia Quality of Life scale (Turkish version)."
62850560|NCT02351427|ACTIVE_COMPARATOR|Steroid|Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage
62624600|NCT05234268|EXPERIMENTAL|Passive Accessory Intervertebral Movements|Patient lying in prone. Therapist stands to side of patient placing their pisiform/ulnar surface of hand over the selected spinous process (SP) with their wrist in full extension. Other hand placed on top of hand to reinforce. Therapist's shoulders should be directly above the SP with elbows slightly bent. Therapist uses their body weight to apply a PA force to the selected SP by leaning their body over their arms and performing rocking movements to provide oscillatory movements of the vertebra.
62624601|NCT05234268|EXPERIMENTAL|Active Strength Training|The progression of exercises will be done using different colours of Thera-band indicating varied resistance
62624602|NCT03465709|EXPERIMENTAL|Pegcetacoplan Study Drug|
62624603|NCT06304480|EXPERIMENTAL|100g fermented Tofu|Participants will consume 100 g Miso fermented tofu per day which may be consumed any way i.e. fried, grilled, baked, etc to taste or prepared from the list of recipes provided.
62624604|NCT06304480|NO_INTERVENTION|Control|Participants will consume their regular diet
62624605|NCT04923880|OTHER|Implementation of Primary Palliative Care Intervention in CF Centers|Implement a Primary Palliative Care intervention comprising screening-and-triage workflows, best practice treatment guides for high frequency problems, patient/family and provider education, and a quality improvement (QI) toolkit in 5 CF centers.
62624606|NCT01564316||neurodegeneration patients|•neurodegeneration patients and control group include dementia patients visited the part of neurology
62624607|NCT03748368|ACTIVE_COMPARATOR|Cataract presentation|Cataract presentation prior to surgery
62624608|NCT03748368|PLACEBO_COMPARATOR|Placebo presentation|Placebo presentation prior to surgery
62624609|NCT01124799|EXPERIMENTAL|001|TMC435 one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening for 9 days
62624610|NCT01124799|PLACEBO_COMPARATOR|002|Placebo placebo dose in the morning at noon and in the evening for 9 days
62624611|NCT01124799|ACTIVE_COMPARATOR|003|Ciprofloxacin one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg for 9 days
62624612|NCT04084587|EXPERIMENTAL|Treated Group|"Group A: 15 patients rehabilitated with Retimax Vision Trainer, 10 consecutive sessions of 8 minutes each, performed twice a week in the best eye.~Exams performed before and after treatment:~* BCVA (ETDRS)~* Reading speed (MNREAD)~* Contrast sensitivity (Pelli-Robson)~* Microperimetry and analysis of fixation (OCT-SLO OPTOS)~* QoL (VFQ-25)"
62624613|NCT04084587|NO_INTERVENTION|Control Group|"Group B: 9 patients control group without rehabilitation.~Exams performed twice, at the same time interval elapsed for the treated group:~* BCVA (ETDRS)~* Reading speed (MNREAD)~* Contrast sensitivity (Pelli-Robson)~* QoL (VFQ-25)"
62850561|NCT05344196|EXPERIMENTAL|Modified EAET for Prediabetes|Small groups of people with prediabetes will meet for 4, weekly, 2-hour sessions by telehealth, and will engage in modified EAET for prediabetes
62850562|NCT05988606|EXPERIMENTAL|15TEMP|Participants cycled at 70% heart rate max for 8 min as a warm-up and then completed one round of HIIT, i.e., 4 min at 90% heart rate max followed by 3 min at 70% heart rate max for a total of 15 minutes in a temperate environment, followed by a graded exercise test to measure maximal aerobic capacity.
62449808|NCT05816876||Healthy controls|"Exercise capacity assessed using six minute walk test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, life quality using The Primary Ciliary Dyskinesia Quality of Life scale (Turkish version)."
62624614|NCT05223803|ACTIVE_COMPARATOR|Best systemic therapy (BST) + primary prostate radiation (XRT)|
62624615|NCT05223803|ACTIVE_COMPARATOR|BST + XRT + SABR metastasis-directed therapy (MDT)|
62624616|NCT02740790|EXPERIMENTAL|HPV vaccine 1|300 women between 9-17 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
62624617|NCT02740790|PLACEBO_COMPARATOR|Placebo 1|300 women between 9-17 yeas of age, receiving 0,2,6 month-schedule Placebo.
62624618|NCT02740790|EXPERIMENTAL|HPV vaccine 2|120 women between 18-26 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
62624619|NCT02740790|EXPERIMENTAL|HPV vaccine 3|180 women between 27-45 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
62624620|NCT02740790|PLACEBO_COMPARATOR|Placebo 2|120 women between 18-26 yeas of age, receiving 0,2,6 month-schedule Placebo.
62624621|NCT02740790|PLACEBO_COMPARATOR|Placebo 3|180 women between 27-45 yeas of age, receiving 0,2,6 month-schedule Placebo.
62624622|NCT06411522|ACTIVE_COMPARATOR|Treatment Test 1|"Following the completion of a comprehensive periodontal charting, and prior to assigning the patient to one of the two experimental groups, patients will undergo an Oral Hygiene Instruction and Motivation (OHIM) session using a manual toothbrush, individualized interdental brushes, and a commercially available toothpaste containing sodium fluoride. Subsequently, a professional mechanical plaque removal (PMPR) will be performed by the operator, consisting of a conventional dental hygiene session.~In treatment Test 1 patients will receive mouthwash containing 0.2% CHX (Chlorhexidine). Each patient will be instructed to use the assigned mouthwash twice a day (15 ml for 30 s) after common practices of home oral hygiene. Follow-up visits will occur at 1, 2, 3, and 6 months, during which participants will be clinically examined. Microbiological samples will be collected at 1, 2, and 3 months."
62652875|NCT00440843|ACTIVE_COMPARATOR|Typicals|
62652876|NCT00297401|EXPERIMENTAL|1|
62652877|NCT00297401|PLACEBO_COMPARATOR|2|
62652878|NCT06132802|EXPERIMENTAL|Group I: Patients who received treatment involving ARS and arthrocentesis only|
62266627|NCT03723382||Patients with stroke with structured management|Patients with the Acute Brain injury, Transient Ischemic Attack, Acute and Chronic Ischemic and Hemorrhagic Stroke, Subarachnoid hemorrhage, and cerebral venous thrombosis from pre-hospitalization, hospitalization (in-patient) and post hospitalization (clinic) data
62062136|NCT05518292|ACTIVE_COMPARATOR|serratus anterior plane block|Patients will placed in the lateral position with the diseased side up. A 10-12 MHz linear ultrasound transducer is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The fifth rib is identified in the mid-axillary line. The following muscles are identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). As an extra-reference point, the thoracodorsal artery is used to aid the identification of the plane superficial to the serratus muscle. The needle (22G spinal needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance, 20 ml of bupivacaine 0.25% will inject.
62062137|NCT05923580|EXPERIMENTAL|Goup-based cardiac telerehabilitation|Group-based cardiac telerehabilitation promotes information, skills, and support for the management of coronary artery disease in coronary patients. The rehabilitation model includes independent familiarization with information content, assignments, and group meetings, as well as the opportunity for a chat and peer support. The intervention is a health professional- lead, and registered rehabilitation model with a start and end.
62266628|NCT03723382||Patients with stroke without structured management|Control subject who have stroke and did not managed according to the SECRET 6 level metrics
62266629|NCT03557892|EXPERIMENTAL|CSII+CGM|
62266630|NCT03557892|ACTIVE_COMPARATOR|MDI with degludec|
62266631|NCT04392518|ACTIVE_COMPARATOR|Hospital based rehabilitation group|This group will perform the exercises in the hospital under the supervision of a physiotherapist
62266632|NCT04392518|ACTIVE_COMPARATOR|Telerehabilitation group|This group will perform the exercises at their home under remote supervision of a physiotherapist via internet connection
62266633|NCT04684446|EXPERIMENTAL|Arm 1|AZD1222 on Day 1 followed by rAd26-S on Day 29
62266634|NCT04684446|EXPERIMENTAL|Arm 2|rAd26-S on Day 1 followed by AZD1222 on Day 29
62266635|NCT04006964||Identification Group|Subjects \>= 3 years old will measure as a minimum FOT and spirometry. Final diagnosis will be made by the physician as per current guidelines.
62266636|NCT04006964||Validation Group|Subjects \>= 3 years old will measure as a minimum FOT and spirometry. Final diagnosis will be made by the physician as per current guidelines.
62850563|NCT05988606|EXPERIMENTAL|15HEAT|Participants cycled at 70% heart rate max for 8 min as a warm-up and then completed one round of HIIT, i.e., 4 min at 90% heart rate max followed by 3 min at 70% heart rate max for a total of 15 minutes in a hot environment, followed by a graded exercise test to measure maximal aerobic capacity.
62062138|NCT05923580|NO_INTERVENTION|Usual care for cardiac patients|The coronary patient is in primary care under the supervision of a nurse and a doctor.
62062139|NCT05174923||Age Range 45 to </= 60|
62624623|NCT06411522|EXPERIMENTAL|Treatment Test 2|"After completing a thorough periodontal charting and before allocating patients to one of the two experimental groups, they will receive an Oral Hygiene Instruction and Motivation (OHIM) session using a manual toothbrush, personalized interdental brushes, and a commercially available toothpaste containing sodium fluoride. Following this, an operator will conduct a professional mechanical plaque removal (PMPR), which entails a standard dental hygiene procedure.~In Treatment Test 2 patients will receive mouthwash containing 0.05% CHX (Chlorhexidine) and 0.05% CPC (Cetylpyridinium Chloride) as the main active ingredients in a patented formulation with optimized bioavailability and they will be instructed to use it twice daily (15 ml for 30 s) following their regular home oral hygiene routine.~Follow-up appointments will be scheduled at 1, 2, 3, and 6 months for clinical examinations of participants, with microbiological samples being collected at 1, 2, and 3 months."
62624624|NCT04990609|EXPERIMENTAL|Neoadjuvant chemotherapy (NAC) plus endoscopic ultrasound (EUS) radiofrequency ablation (RFA)|
62850564|NCT05988606|EXPERIMENTAL|43TEMP|Participants cycled at 70% heart rate max for 8 min as a warm-up and then performed the HIIT protocol (4 min at 90% heart rate max and 3 min at 70% heart rate max, repeated 4 times for a total of 43 minutes) in a temperate environment followed by a graded exercise test to measure maximal aerobic capacity.
62850565|NCT05988606|EXPERIMENTAL|43HEAT|Participants cycled at 70% heart rate max for 8 min as a warm-up and then performed the HIIT protocol (4 min at 90% heart rate max and 3 min at 70% heart rate max, repeated 4 times for a total of 43 minutes) in a hot environment followed by a graded exercise test to measure maximal aerobic capacity.
62850566|NCT05988606|NO_INTERVENTION|Control|Participants completed a graded exercise test on a stationary bicycle in a temperate environment (\~ 22 °C (72 °F), \~40% RH) to measure maximal aerobic capacity and maximal heart rate.
62850567|NCT01660438||Stress urinary incontinence|Stress urinary incontinence
62850568|NCT03179605|EXPERIMENTAL|DFD-06 Cream|This is a single arm, open label study and there will be no reference or control product used in this study
62850569|NCT02101710|EXPERIMENTAL|Elantan SR 60 mg fed|Elantan SR 60 mg is orally administered on Day 1 of treatment period 1 for Fed group 2 and on Day 1 of treatment period 2 for Fed group 1.
62850570|NCT02101710|EXPERIMENTAL|Imdur SR 60 mg fed|Imdur SR 60 mg is orally administered on Day 1 of treatment period 1 for Fed group 1 and on Day 1 of treatment period 2 for Fed group 2.
62850571|NCT02101710|EXPERIMENTAL|Elantan SR 60 mg fasted|Elantan SR 60 mg is orally administered on Day 1 of treatment period 1 for Fasted group 2 and on Day 1 of treatment period 2 for Fasted group 1.
62850572|NCT02101710|EXPERIMENTAL|Imdur SR 60 mg fasted|Imdur SR 60 mg is orally administered on Day 1 of treatment period 1 for Fasted group 1 and on Day 1 of treatment period 2 for Fasted group 2.
62062140|NCT05174923||Age Range 61 to </= 75|
62062141|NCT05174923||Age >/= 76|
62062142|NCT05889923|EXPERIMENTAL|learning with the EDU|Students will perform 5 ultrasound-guided regional anesthesia procedures on a phantom using the EDU which shows the student how to hold the needle and probe to hit the target.
62062143|NCT06444022|EXPERIMENTAL|hAESCs|Intravenous infusion of hAESCs to 9 subjects at the day before HSCT and 7th days after HSCT. The dose is 1×10\^6 cell/kg.
62062144|NCT06444022|PLACEBO_COMPARATOR|placebo (cell preservation solution)|Intravenous infusion of placebo (cell preservation solution with no hAESCs) to other 9 subjects at the day before HSCT and 7th days after HSCT.
62062145|NCT01526590|EXPERIMENTAL|Definity|Patients enrolled in the study will undergo contrast enhanced endoscopic ultrasound of the pancreas with Definity contrast after they have undergone their standard of care endoscopic ultrasound of the pancreas.
62062146|NCT04157998|PLACEBO_COMPARATOR|control|patient receive 10 ml normal saline intravenous
62062147|NCT04157998|ACTIVE_COMPARATOR|metoclopramide group|"patient receive 10 mg metoclopramide intravenously diluted in 10 mL saline 0.9%.~intravenous"
62062148|NCT06576687|EXPERIMENTAL|Balance Training|Exercises include (1) single-limb hops to stabilization, (2) hop to stabilization and reach, (3) unanticipated hop to stabilization, (4) single-limb stance activities, and (5) continuous choice-reaction hopping.
62062149|NCT00347997|EXPERIMENTAL|LASIK|LASIK correction of myopia and myopic astigmatism
62062150|NCT02749851||Non-smokers|Pregnant women that identify as non-smokers with low risk for placental insufficiency will receive the MRI Imaging intervention.
62062151|NCT02749851||Smokers|Pregnant women that identify as smokers will receive the MRI Imaging intervention.
62062152|NCT02749851||High risk/Non-Smokers|Pregnant women that identify as non-smokers who are at a high risk for adverse outcomes based on prior clinical history will receive the MRI Imaging intervention.
62062153|NCT02749851||Confirmed IUGR|Pregnant women identified by their clinical care provided to have confirmed IUGR during their current pregnancy
62062154|NCT03760263|ACTIVE_COMPARATOR|Envarsus|Once-daily extended-release tacrolimus
62062155|NCT03760263|ACTIVE_COMPARATOR|Prograf|twice-daily tacrolimus
62266637|NCT01201239|EXPERIMENTAL|raltegravir|HIV-infected patients aged over 18 who have failed previous antiretroviral treatment with multi-drug resistant or with multi-drug intolerance are to accept Ral plus OBT.
62850573|NCT03425253|EXPERIMENTAL|BELKYRA® and Juvéderm® VOLUMA™ with Lidocaine|BELKYRA® was injected into subcutaneous preplatysma fat tissue in the submental area (at least 1 plus up to 5 optional treatments, for maximum of 6 treatments 8 weeks apart). When the investigator and participant agreed that no further intervention was required to achieve the desired result, participants were eligible to receive VOLUMA™ treatment. VOLUMA™ was injected along the mandibular border, with an optional touch-up visit 2 weeks later if applicable.
62624625|NCT03086005|EXPERIMENTAL|Metformin|Metformin 500mg tablet by mouth, every 12 hours, from the first day of oral contraceptive pills taken to the day of oocyte retrieval
62850574|NCT04078646|EXPERIMENTAL|Dietary intervention|Intervention with test meal only
62850575|NCT04078646|EXPERIMENTAL|Dietary intervention 2|Intervention with test meal and whey protein isolate (30 g)
62850576|NCT04078646|EXPERIMENTAL|Dietary intervention 3|Intervention with test meal and soy protein (30 g)
62062156|NCT06539507|EXPERIMENTAL|Part 1 - BCX17725 single dose|Participants randomized to BCX17725 will receive BCX17725 as a single dose in sequential ascending dose cohorts
62062157|NCT06539507|EXPERIMENTAL|Part 1 - placebo single dose|Participants randomized to placebo will receive placebo as a single dose
62062158|NCT06539507|EXPERIMENTAL|Part 2 - BCX17725 multiple doses|Participants randomized to BCX17725 will receive BCX17725 as multiple doses in sequential ascending dose cohorts
62062159|NCT06539507|EXPERIMENTAL|Part 2 - placebo multiple doses|Participants randomized to placebo will receive placebo as multiple doses
62266638|NCT01914380||Group 1|
62624626|NCT03086005|PLACEBO_COMPARATOR|Placebo|Placebo(identical in appearance to metformin), every 12 hours, from the first day of oral contraceptive pills taken to the day of oocyte retrieval
62652879|NCT06132802|EXPERIMENTAL|Group II: Patients who received treatment involving ARS, arthrocentesis, and an I-PRF injection|
62850577|NCT00646854|ACTIVE_COMPARATOR|Arm A|
62850578|NCT00646854|EXPERIMENTAL|Arm B|
62850579|NCT05519540|EXPERIMENTAL|Group 1: Japanese: Xevinapant (Debio 1143)|
62266639|NCT05747456|EXPERIMENTAL|IPN-21-SENSE Treatment Group|Subjects randomized (5:1 ratio) to receive an initial treatment with IPN-21-SENSE Crosslinked Hyaluronic Acid Gel up to 8mL, based on the PI's assessment, in combination with the aesthetic goal of the subject, then an optional touch-up treatment session 4 weeks later, up to 4mL.
62850580|NCT05519540|EXPERIMENTAL|Group 2: Non-Japanese East Asian: Xevinapant (Debio 1143)|
62850581|NCT02282241|PLACEBO_COMPARATOR|Placebo|Patients given once daily placebo (cellulose) orally in the evening, for 14 days.
62850582|NCT02282241|EXPERIMENTAL|Melatonin|Patients given once daily melatonin 1.5mg orally in the evening, for 14 days.
62850583|NCT05969847|EXPERIMENTAL|split-course hypofraction radiotherapy plus CAPOX and Envafolimab followed by local excision|"Patients diagnosed with locally advanced very low rectal cancer were chosen to undergo a total neoadjuvant therapy (TNT) regimen. This regimen consisted of preoperative fractionated radiotherapy (5×7Gy) combined with 6 cycles of CAPOX chemotherapy and enverolimab.~For patients who achieved clinical complete response (cCR) or near-clinical complete response (ncCR) after TNT, an organ-preserving strategy involving local full-thickness resection was implemented. Patients who achieve non-clinical complete response are subjected to traditional TME surgery."
62850584|NCT06408961||Type II Diabetes (+)|Subject medical records will be used to determine the presence of Type II Diabetes.
62850585|NCT06408961||No Type II Diabetes (-)|Subject medical records will be used to determine the presence of Type II Diabetes.
62850586|NCT03647813|ACTIVE_COMPARATOR|Photobiomodulation group|Patients were submitted to three sessions of PBM (baseline, 7 and 14 days). PBMT was administered by a single professional using a continuous wave AsGaAl diode laser (Photon Lase III - DMC, São Paulo, Brazil) with a wavelength of 808 nm (infrared). Irradiation was performed in punctual contact mode (ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point). A total of 20 points were applied in each session/day being three extraoral points in the parotid region (right and left n=6), three points in buccal mucosa (right and left, n=6), two extraoral (right and left, n=4) and two intraoral (right and left, n=4) points in the submandibular and sublingual regions.
62624627|NCT05481827|EXPERIMENTAL|GT005|GT005 is a gene therapy for GA and is a recombinant adeno-associated viral serotype 2 (AAV2) vector encoding for human complement factor I. GT005 was administered to all participants in an antecedent study prior to enrollment in ORACLE and GT005 is not administered in the ORACLE study
62624628|NCT03644420||Knee osteoarthritis|"Patients with knee osteoarthritis, classified Kellgren-Lawrence 3 or 4, with asymmetric femorotibial joint space narrowing that will follow a surgery for a prosthetic replacement of the knee wil follow the following interventions:~* Clinical evaluation~* Radiographic assessment of osteoarthritis~* Magnetic resonance imaging (MRI)~* Histological evaluation of the surgical piece"
62850587|NCT03647813|PLACEBO_COMPARATOR|Placebo group|Patients were submitted to same protocol as the photobiomodulation group, but the laser was turned off.
62624629|NCT02542592|ACTIVE_COMPARATOR|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
62624630|NCT02542592|PLACEBO_COMPARATOR|Placebo|Preoperative single dose of isotonic Sodium Chloride
62624631|NCT04033406|EXPERIMENTAL|VIR-2482|VIR-2482
62850588|NCT02737891|EXPERIMENTAL|Tesofensine/Metoprolol|Oral tablets Tesofensine/Metoprolol
62850589|NCT02737891|PLACEBO_COMPARATOR|Placebo|Placebo tablets matching oral Tesofensine/Metoprolol
62850590|NCT04009564|EXPERIMENTAL|Date seeds filtered coffee|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 45 g of date seeds coffee in 280 ml of boiled water, coffee flavour and brown food colouring ( made using a filter coffee machine). it will be served in a paper cup with lid
62850591|NCT04009564|EXPERIMENTAL|Normal filtered coffee|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 6 g of coffee in 280 ml of boiled water (made using a filter coffee machine) it will be served in a paper cup with lid
62850592|NCT04009564|PLACEBO_COMPARATOR|Placebo|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 280 of boiled water, coffee flavour and brown food colouring it will be served in a paper cup with lid
62266640|NCT05747456|OTHER|No-Treatment Control Group, then Delayed Treatment with IPN-21-SENSE|No-Treatment for the first 6-month, then subjects will receive a delayed treatment with IPN-21-SENSE Crosslinked Hyaluronic Acid Gel up to 8mL, based on the PI's assessment, in combination with the aesthetic goal of the subject, then an optional touch-up treatment session 4 weeks later, up to 4mL.
62266641|NCT00368511|NO_INTERVENTION|1|Listening to music and posture changes
62449809|NCT01769209|EXPERIMENTAL|Bortezomib + Chemotherapy|Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.
62624632|NCT04033406|PLACEBO_COMPARATOR|Placebo|Placebo
62062160|NCT06539507|EXPERIMENTAL|Part 3 - BCX17725 multiple doses|Participants will receive BCX17725 as multiple doses
62449810|NCT04493450||Smartphone-users|Cancer patients who use smartphones
62652880|NCT05041686|EXPERIMENTAL|CADISS® System|
62850593|NCT01546623|EXPERIMENTAL|TAP-144-SR(6M)|TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.
62850594|NCT01546623|ACTIVE_COMPARATOR|TAP-144-SR(3M)|TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.
62850595|NCT03297411|ACTIVE_COMPARATOR|Brief Temporoparietal ECT|Brief Pulse Temporoparietal ECT
62850596|NCT03297411|ACTIVE_COMPARATOR|Ultrabrief Temporoparietal ECT|Ultrabrief Pulse Temporoparietal ECT
62624633|NCT03338504||Suspected type 2 myocardial infarction|The investigators will identify consecutive patients with acute myocardial injury (defined as a rise and or fall in cardiac troponin concentration on serial testing, with at least one value \>99th centile) where the likely mechanism of injury is thought to be myocardial oxygen supply and demand imbalance (e.g secondary to hypoxia, hypotension, tachycardia or anaemia). Patients will be identified through screening of cardiac troponin measurements. Patients who meet both the inclusion and exclusion criteria, will be approached and those who provide consent will comprise the study population. All patients will have a Cardiac MRI scan, with invasive coronary angiography or CT coronary angiography dependent on baseline fitness. The investigators will record demographic and clinical information from the electronic patient record for patients who meet inclusion criteria but have one or more exclusion criteria.
62624634|NCT06376409|EXPERIMENTAL|Nutrafol Hair Growth Supplement|4 commercially available hair growth nutraceuticals will be evaluated. Treatment groups will be assigned according to the investigator's discretion. Efficacy comparisons will not be made across treatment groups.
62624635|NCT03446118|EXPERIMENTAL|MRI to detect inflammation and fibrosis in EoE patients|To assess through MRI the existence of an inflammatory and fibrotic component in strictures of eosinophilic esophagitis patients and to determine if this component is responsive to a therapeutic course of budesonide.
62624636|NCT00401518|EXPERIMENTAL|ACADIA®|Investigational surgical treatment using the ACADIA Facet Replacement system
62624637|NCT00401518|ACTIVE_COMPARATOR|Control Instrumented PLF|Control surgical treatment using an instrumented posterolateral fusion
62624638|NCT02535650|EXPERIMENTAL|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles.
62624639|NCT04605653|EXPERIMENTAL|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating.
62624640|NCT02841384|OTHER|Group taping McConnell|Taping patellar McConnell: Lateralization correction of the patella with self-adhesive rigid bandage Johnson® positioned lateral border of the patella to the medial condyle of the femur, allowing the lifting of the medial border of the patella and stretching of the knee lateral structures.
62624641|NCT02841384|OTHER|Group placebo taping|Placebo taping through vertical application of patellar rigid taping, with the knee in flexion without medialization of the patella.
62624642|NCT01808222|EXPERIMENTAL|FACBC|Participants receiving a bolus of anti-\[18F\]FACBC injected with PET-CT detection of cancer recurrence.
62624643|NCT04875780|EXPERIMENTAL|Digital diabetes prevention app intervention|Participants will receive web-based diabetes prevention curriculum, virtual social group support and digital tracking via the smartphone app.
62624644|NCT04875780|ACTIVE_COMPARATOR|Digital weight loss tracking app intervention|Participants will receive the same intervention as the digital diabetes prevention curriculum app group except the web-based diabetes prevention curriculum.
62624645|NCT04875780|OTHER|Wait-list control (usual care)|Participants will receive usual care in the form of an annual review and blood test, together with general lifestyle advice.
62624646|NCT01703169|EXPERIMENTAL|Eltrombopag|Single arm study. Dose Escalation.
62624647|NCT00523692|EXPERIMENTAL|1|Intensive therapy
62624648|NCT00523692|ACTIVE_COMPARATOR|2|Standard therapy
62624649|NCT05861895|EXPERIMENTAL|Dose escalation cohort 1: HF158K1 given Q3W at 2 mg/m²|Participants in this dose group(2 mg/m²) will receive HF158K1 on D1 of each treatment cycle (3 weeks as a treatment cycle) through intravenous infusion.
62850597|NCT03297411|ACTIVE_COMPARATOR|Brief Frontoparietal ECT|Brief Pulse Frontoparietal ECT
62850598|NCT03297411|ACTIVE_COMPARATOR|Ultrabrief Frontoparietal ECT|Ultrabrief Pulse Frontoparietal ECT
62850599|NCT03808259|EXPERIMENTAL|Part 1: OTF Sublingual and IV|Participants will receive (S)-ketamine oral thin film (OTF) at a dose of 7 milligram (mg) \[cohort 1\], 14 mg \[cohort 2\], and 28 mg \[cohort 3\] via sublingual route or 14 mg (S)-ketamine intravenous (IV) infusion for 40 minutes or matching placebo in 1 of 3 serial cohorts. Dose escalation decisions to further cohorts of Part 1 will be made based on safety and tolerability profile of the preceding lower dose level.
62624650|NCT05861895|EXPERIMENTAL|Dose escalation cohort 1: HF158K1 given Q3W at 6 mg/m²|Participants in this dose group(6 mg/m²) will receive HF158K1 on D1 of each treatment cycle (3 weeks as a treatment cycle) through intravenous infusion.
62624651|NCT05861895|EXPERIMENTAL|Dose escalation cohort 1: HF158K1 given Q3W at 15 mg/m²|Participants in this dose group(15 mg/m²) will receive HF158K1 on D1 of each treatment cycle (3 weeks as a treatment cycle) through intravenous infusion.
62624652|NCT05861895|EXPERIMENTAL|Dose escalation cohort 1: HF158K1 given Q3W at 30 mg/m²|Participants in this dose group(30 mg/m²) will receive HF158K1 on D1 of each treatment cycle (3 weeks as a treatment cycle) through intravenous infusion.
62266642|NCT02201407||CHB Participants Treated With Peginterferon alfa-2a|As this is an observational study, treatment schedule will be at the clinician's discretion in accordance with local labeling and not directed by the protocol. Participants with CHB who are receiving peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics, and in line with the local labeling will be followed for the duration of treatment with peginterferon alfa-2a (48 weeks) and up to 24 weeks after peginterferon alfa-2a treatment (72 weeks in total).
62624653|NCT05861895|EXPERIMENTAL|Dose escalation cohort 1: HF158K1 given Q3W at 45 mg/m²|Participants in this dose group(45 mg/m²) will receive HF158K1 on D1 of each treatment cycle (3 weeks as a treatment cycle) through intravenous infusion.
62624654|NCT05861895|EXPERIMENTAL|Dose escalation cohort 1: HF158K1 given Q3W at 60 mg/m²|Participants in this dose group(60 mg/m²) will receive HF158K1 on D1 of each treatment cycle (3 weeks as a treatment cycle) through intravenous infusion.
62624655|NCT01563913|EXPERIMENTAL|Arm 1|Docosahexaenoic Acid (DHA)
62624656|NCT01563913|PLACEBO_COMPARATOR|Arm 2|Placebo
62062161|NCT05477277|EXPERIMENTAL|Define MAsS cut-point at transplant evaluation to identify those with high risk for adverse outcomes|
62266643|NCT05839873||Treatment Group|Single Arm Group to receive ablation.
62266644|NCT04730843|EXPERIMENTAL|Part A dose escalation|ES102 will be escalated in patients with advanced solid tumors.
62266645|NCT04730843|EXPERIMENTAL|Part B expansion|Subjects with advanced non-small cell lung cancer, advanced esophageal squamous cell carcinoma, other advanced solid tumors (such as nasopharyngeal carcinoma, cervical cancer, gastrointestinal tumors, other reproductive system tumors, etc.) will be treated with ES102 at the RP2D.
62266646|NCT01798589|EXPERIMENTAL|Ethylenediamine dihydrochloride|Ethylenediamine dihydrochloride in methylcellulose 50 mcg/cm2 Ethylenediamine dihydrochloride in polyvinylpyrrolidone 50 mcg/cm2 Methylcellulose (negative control 1) Polyvinylpyrrolidone (negative control 2)
62266647|NCT01905280|EXPERIMENTAL|Acellular dermal matrix|A ridge preservation graft will be performed and then covered using acellular dermal matrix as a membrane.
62266648|NCT01905280|ACTIVE_COMPARATOR|Non-resorbable membrane|A ridge preservation graft will be performed and then covered using a non-resorbable PTFE membrane.
62266649|NCT02400788|EXPERIMENTAL|Resminostat + Sorafenib|oral administration
62266650|NCT02400788|ACTIVE_COMPARATOR|Sorafenib|oral administration
62266651|NCT05967637|EXPERIMENTAL|Whole-body vibration|Standard patient education and exercise training + whole body vibration
62266652|NCT05967637|SHAM_COMPARATOR|Sham-whole-body vibration|Standard patient education and exercise training + sham whole body vibration
62266653|NCT00421356||Transfemoral Power Knee group|Transfemoral amputees who used the power assisted Ossur Power Knee who used the knee daily without adjustments for at least 90 days prior to the study.
62624657|NCT06373055||Platinum-based Neoadjuvant Chemotherapy Sensitive Patients|Patients with newly confirmed muscle-invasive bladder cancer who have favorable treatment response to platinum-based neoadjuvant chemotherapy
62624658|NCT06373055||Platinum-based Neoadjuvant Chemotherapy Resistant Patients|Patients with newly confirmed muscle-invasive bladder cancer who have unfavorable treatment response to platinum-based neoadjuvant chemotherapy
62624659|NCT00664118|ACTIVE_COMPARATOR|1|Doula combined epidural analgesia in the latent phase of first stage of labor
62624660|NCT00664118|SHAM_COMPARATOR|2|Epidural analgesia in the latent phase of the first stage of labor without doula accompany
62624661|NCT03246061|ACTIVE_COMPARATOR|BVN Ablation|BVN ablation with continued standard care
62624662|NCT03246061|ACTIVE_COMPARATOR|Standard Care Control|Continue with non-surgical standard care
62062162|NCT02322541|EXPERIMENTAL|Time Course|Measurement of garlic metabolites over 24 hours following garlic intervention.
62062163|NCT04699357|ACTIVE_COMPARATOR|Group 1|0.01% atropine
62062164|NCT04699357|EXPERIMENTAL|Group 2|0.04% atropine
62062165|NCT04699357|EXPERIMENTAL|Group 3|0.1% atropine
62624663|NCT01289301|EXPERIMENTAL|mTOR-receiving arm|switching from calcineurin-inhibitor-based immunosuppression to mTOR-based immunosuppression
62850600|NCT03808259|EXPERIMENTAL|Part 2: IV Different Infusion Duration|Participants will receive single dose (S)-ketamine less than or equal to (\<=)14 mg IV at a different infusion duration or matching placebo at a different infusion duration. The infusion duration and dose will be chosen after completion of Part 1.
62850601|NCT03500445|EXPERIMENTAL|Treatment Arm (D-KRd)|
62266654|NCT00421356||Transfemoral C-Leg knee group|Transfemoral amputees who used the stance control Otto Bock C-Leg who used the knee daily without adjustments for at least 90 days prior to the study.
62850602|NCT03083990|EXPERIMENTAL|Group A|IBI 305 ,3mg/kg, infusion in 90 minutes
62850603|NCT03083990|ACTIVE_COMPARATOR|Group B|Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes
62850604|NCT04448028|PLACEBO_COMPARATOR|Intervention group|Patients randomized to the intervention group discontinue their pre-existing PPI treatment and replace it with placebo (day 15 to 360). During the first 14 days (dose tapering phase) patients in the intervention group will receive placebo on day 1, 3, 5, 7, 9, 10, 12, 13 and esomeprazole 20mg on day 2, 4, 6, 8, 11, 14, to minimize the risk for gastric acid rebound symptoms.
62850605|NCT04448028|ACTIVE_COMPARATOR|Control group|Patients randomized to the control group continue their pre-existing PPI therapy with esomeprazole 20mg/day (day 15 to 360). During the first 14 days (dose tapering phase) patients in the control group receive esomeprazole 20mg/day on day 1 to 14.
62850606|NCT01131013|EXPERIMENTAL|Treatment Sequence 1|Dosing Period 1 - Placebo; Dosing Period 2 - 375 mg CK-2017357; Dosing Period 3 - 500 mg CK-2017357
62062166|NCT00161395|ACTIVE_COMPARATOR|1|Preconception advice.
62062167|NCT00161395|EXPERIMENTAL|2|Instruction in the Creighton Model Fertility Care System.
62266655|NCT00421356||Transfemoral Mauch knee group|Transfemoral amputees who used the mechanical fluid controlled Mauch Swing and Stance Knee who used the knee daily without adjustments for at least 90 days prior to the study.
62266656|NCT00421356||Non amputee control group|Healthy, non-amputee control group
62624664|NCT01289301|ACTIVE_COMPARATOR|calcineurin-inhibitor keeping arm|continuing calcineurin-inhibitor based immunosuppression
62850607|NCT01131013|EXPERIMENTAL|Treatment Sequence 2|Dosing Period 1 - Placebo; Dosing Period 2 - 500 mg CK-2017357; Dosing Period 3 - 375 mg CK-2017357
62062168|NCT01488565|EXPERIMENTAL|Azacitidine and Eltrombopag|Vidaza (azacitidine) Revolade (eltrombopag)
62062169|NCT01860443|EXPERIMENTAL|Telepsychiatry collaborative program|"* Online training on the diagnosis and management of adolescent depression for health professionals from primary care clinics participating in active branch.~* Clinical management of depression by primary care professionals, according to algorithms based on the Clinical Guidelines of the Chilean Ministry of Health (MINSAL).~* Supervision of primary care professionals through an internet site run by a team of specialists.~* Telephone monitoring of patients by personnel trained on clinical progress, treatment adherence, and side effects (applicable for patients taking drugs)."
62062170|NCT01860443|ACTIVE_COMPARATOR|Usual care|"* Online training on the diagnosis and management of adolescent depression for health professionals from primary care centers participating in active branch.~* Clinical management of depression by primary care professionals, according to algorithms based on the Clinical Guidelines of the Chilean Ministry of Health (MINSAL)."
62062171|NCT00405405|EXPERIMENTAL|Treatment|A combination of Cisplatin, Docetaxel, Bevacizumab, Erlotinib, and Radiotherapy
62062172|NCT06625385|EXPERIMENTAL|3M™ V.A.C.® Peel and Place Dressing|3M™ V.A.C.® Peel and Place Dressing used in conjunction with 3M™ V.A.C.® Therapy
62062173|NCT03322826|ACTIVE_COMPARATOR|Lymphadenectomy|systematically Lymphadenectomy of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side
62062174|NCT03322826|EXPERIMENTAL|systematic sampling of the lymph nodes|systematic sampling of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side
62062175|NCT05737433|EXPERIMENTAL|[14C]-RCF 225mg|\[14C\]-rencofilstat, 225mg oral dose, self-micro-emulsifying drug delivery system, single dose
62062176|NCT02816034|EXPERIMENTAL|Experimental Explicit|Cannabis user performs visuo-motor rotation tasks informed of an explicit strategy to maximise performance
62266657|NCT03757533|EXPERIMENTAL|Health Coaching|Participants in the Health Coaching (HC) arm will be assigned to a health coach for a period of 5 months along with receiving usual care (UC). An initial telephone call with the coach will include a discussion about the participant's self-assessment of health perceptions and goals. This self-assessment creates the foundation for the personalization of the behavioral intervention. From this point, the participant schedules the remaining 9 biweekly sessions (30-45 minute in length), for a total of 10 coaching calls over 5 months. Sociodemographic, behavioral, and psychosocial data will be collected over a period of 24 months by surveys and from the medical record.
62850608|NCT01131013|EXPERIMENTAL|Treatment Sequence 3|Dosing Period 1 - 375 mg CK-2017357; Dosing Period 2 - Placebo; Dosing Period 3 - 500 mg CK-2017357
62850609|NCT01131013|EXPERIMENTAL|Treatment Sequence 4|Dosing Period 1 - 375 mg CK-2017357; Dosing Period 2 - 500 mg CK-2017357; Dosing Period 3 - Placebo
62850610|NCT01131013|EXPERIMENTAL|Treatment Sequence 5|Dosing Period 1 - 500 mg CK-2017357; Dosing Period 2 - Placebo; Dosing Period 3 - 375 mg CK-2017357
62850611|NCT01131013|EXPERIMENTAL|Treatment Sequence 6|Dosing Period 1 - 500 mg CK-2017357; Dosing Period 2 - 375 mg CK-2017357; Dosing Period 3 - Placebo
62850612|NCT04765085|EXPERIMENTAL|CBIT Group|Patients in this group would only receive the CBIT treatment.
62850613|NCT04765085|EXPERIMENTAL|Drug therapy Group|Patients in this group would only receive the drug therapy.
62850614|NCT01037764|EXPERIMENTAL|alloHCT|alloHCT arm: For HLA-matched sibling HCT, if a patient is 55 years old or less and without co-morbidity, the patient will receive Bu-Cy conditioning therapy and be transplanted with bone marrow cells. Patients who are older than 55 years or with co-morbidity will receive Bu-Flu-ATG conditioning and be transplanted with mobilized peripheral blood hematopoietic cells. For HLA-matched unrelated donor or HLA-mismatched familial donor HCT, the patient will receive Bu-Flu-ATG conditioning and well be transplanted with mobilized peripheral blood hematopoietic cells.
62850615|NCT01710137|ACTIVE_COMPARATOR|Varenicline|"12 weeks of active varenicline + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally"
62850616|NCT01710137|PLACEBO_COMPARATOR|Placebo|"12 weeks of placebo + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally"
62850617|NCT03946696||Dementia|Observations of communication and interactions between people with dementia living in a care home and therapy-animals.
62850618|NCT05751018|EXPERIMENTAL|pyrotinib|
62850619|NCT02523144|ACTIVE_COMPARATOR|Chloral Hydrate + placebo|Oral chloral hydrate sedation in flavored syrup plus nasal saline placebo
62850620|NCT02523144|ACTIVE_COMPARATOR|Dexmedetomidine 2mcg/kg + placebo|Nasal dexmedetomidine sedation 2 mcg/kg plus oral flavored syrup placebo
62850621|NCT02523144|ACTIVE_COMPARATOR|Dexmedetomidine 3mcg/kg + placebo|Nasal dexmedetomidine sedation 3 mcg/kg plus oral flavored syrup placebo
62850622|NCT01331213|ACTIVE_COMPARATOR|Pregabalin|Subjects randomized to this arm received a single dose of pregabalin 200mg orally.
62850623|NCT01331213|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm received a single dose of placebo orally.
62850624|NCT02817425|ACTIVE_COMPARATOR|SOX Sequential S-1 Group|"Patients received chemotherapy with oxaliplatin+ S-1  for 6 months and sequential S-1 for 6 months"
62850625|NCT02817425|ACTIVE_COMPARATOR|SOX Group|"Patients received chemotherapy with oxaliplatin+ S-1  for 12 months"
62850626|NCT02817425|EXPERIMENTAL|TEGAFOX Sequential S-1|"Patients received chemotherapy with TEGAFOX (oxaliplatin+ Tegafur +Leucovorin Calcium)  for 6 months and sequential S-1 for 6 months"
62850627|NCT04170985||Single Cohort|All participants will receive cWGS testing revealed to the site PI/clinician at Day 180. Participants will all receive standard of care testing throughout the study.
62850628|NCT00416039|EXPERIMENTAL|1|Midazolam and morphine
62062177|NCT02816034|ACTIVE_COMPARATOR|Control Explicit|Healthy subject performs visuo-motor rotation tasks informed of an explicit strategy to maximise performance
62062178|NCT02816034|EXPERIMENTAL|Experimental Implicit|Cannabis user performs visuo-motor rotation tasks without being informed of the explicit strategy
62062179|NCT02816034|ACTIVE_COMPARATOR|Control Implicit|Healthy subject performs visuo-motor rotation tasks without being informed of the explicit strategy
62062180|NCT02010801|EXPERIMENTAL|IRE for tumor before tumor resection|
62624665|NCT04239352||healthy pregnant women|"Blood samples taken from 40 healthy pregnant women will be obtained by taking patient consent forms and storing their serum at -80 degrees. Then, serum Pentraxin 3 and Lp-PLA2 levels will be checked in these blood by ELISA method.~this group will be the control group."
62850629|NCT00416039|PLACEBO_COMPARATOR|2|placebo, Nacl 0.9 %, morphine 0.5 mg/kg
62850630|NCT03873090|EXPERIMENTAL|SBRT in 4 fraction|Selected intermediate risk prostate cancer patients treated with 4 fraction SBRT
62850631|NCT01499706|NO_INTERVENTION|Standard of Care Control|Participants will receive standard sexual risk reduction services available to them through medical and community-based organizations
62850632|NCT01499706|EXPERIMENTAL|1-session motivational interviewing|Participants will receive a single session of motivational interviewing delivered over the telephone
62624666|NCT04239352||preeclamptic pregnant women|"Blood samples taken from 40 preeclamptic pregnant women will be obtained by taking patient consent forms and storing their serum at -80 degrees. Then, serum Pentraxin 3 and Lp-PLA2 levels will be checked in these blood by ELISA method.~this group will be the study group."
62624667|NCT00771940|ACTIVE_COMPARATOR|Ghrelin|
62850633|NCT01499706|EXPERIMENTAL|4-session motivational interviewing|Participants will receive four weekly sessions of motivational interviewing delivered over the telephone.
62850634|NCT03369080||Danish National Cohort|This study includes all patients with a new Spinal Cord Injury hospitalized at Clinic for Spinal Cord Injuries, Rigshospitalet or Spinal Cord Injury Center of Western Denmark
62850635|NCT03033550|EXPERIMENTAL|single|single arm- behavioral educational intervention of a brief negotiated mobile application
62850636|NCT04408222||Awake Proning|COVID-19 patients with hypoxemic respiratory failure with awake prone positioning, as tolerated, up to 24 hours daily.
62624668|NCT01240499|EXPERIMENTAL|Health-At-Every-Size (HAES)|
62850637|NCT02972567|EXPERIMENTAL|Probiotic|Lactobacillus strain
62850638|NCT02972567|PLACEBO_COMPARATOR|Control|Maltodextrin
62850639|NCT00754637||510(k) Inclusion Criteria|Any person meeting the inclusion criteria for the device may be included in this study. These patients tend to be those seeking relief from painful or debilitating knee joint disease.
62850640|NCT05984550|EXPERIMENTAL|treated group|NMN(Vital NAD) treated group
62850641|NCT02713074|ACTIVE_COMPARATOR|Group A|povidone-iodine group
62850642|NCT02713074|ACTIVE_COMPARATOR|Group B|Normal saline group
62062181|NCT01641926|EXPERIMENTAL|HBeAg(+) PEG-Intron|HBeAg-positive participants receive 1.5 mcg/kg/wk PEG-Intron subcutaneously (SC) once weekly for 48 weeks.
62062182|NCT01641926|ACTIVE_COMPARATOR|HBeAg(+) PEGASYS|HBeAg-positive participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
62624669|NCT01240499|ACTIVE_COMPARATOR|Social Support (SS)|
62624670|NCT01240499|NO_INTERVENTION|Control|
62624671|NCT04161521|OTHER|Placenta Accreta patients|of 60 pregnant female diagnosed as placenta previa accreta recuirted from Obstetrics and Gynecology Department , Menoufia University Hospital.
62624672|NCT01463943|EXPERIMENTAL|Saccharomyces boulardii capsules (200 mg).|
62624673|NCT01463943|ACTIVE_COMPARATOR|Floratil®|
62624674|NCT01463943|EXPERIMENTAL|Saccharomyces boulardii powder (200 mg).|
62624675|NCT04981197|EXPERIMENTAL|Baduanjin exercise group|The Baduanjin exercise group received a 12-week Baduanjin exercise programme.
62624676|NCT04981197|NO_INTERVENTION|Control group|Patients in this group maintain their daily life activities, and there is no intervention given.
62624677|NCT05401461|EXPERIMENTAL|Intervention|Evening mobilisation delivered between 7pm and 9pm
62624678|NCT05401461|NO_INTERVENTION|Control|Patients in the control arm will receive standard care which incorporates physiotherapy and mobilisation as appropriate between 8am and 5pm
62624679|NCT06480136|EXPERIMENTAL|Treatment group|SHR-A1921+adebrelimab
62624680|NCT04692116|EXPERIMENTAL|ExAblate Arm|ExAblate Model 4000 System for the treatment of Parkinson's disease
62624681|NCT00824655|EXPERIMENTAL|Group 1|
62624682|NCT00824655|EXPERIMENTAL|Group 2|
62624683|NCT01462305|EXPERIMENTAL|goLITE|light therapy using 467nm LED source, within 30 minutes of waking in the morning every day for 6 weeks
62624684|NCT01462305|ACTIVE_COMPARATOR|Control|light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks
62624685|NCT04099238||Subjects with ischemic stroke|Adult subjects from the UK THIN database who were hospitalized for ischemic stroke between 01-Jul-2016 to 30-Jun-2018
62624686|NCT04099238||NVAF patients with ischemic stroke|Adult subjects from the UK THIN database who were hospitalized for ischemic stroke between 01-Jul-2016 to 30-Jun-2018 and had a diagnosis of NVAF prior to ischemic stroke (Subgroup)
62624687|NCT02788188|EXPERIMENTAL|Cohort 1|Cohort 1: 1mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%)
62624688|NCT02788188|PLACEBO_COMPARATOR|Placebo|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
62624689|NCT02788188|EXPERIMENTAL|Cohort 2|Cohort 2: 2.5 mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%)
62266658|NCT03757533|OTHER|Control|Participants in the control arm will receive usual care (UC). Sociodemographic, behavioral, and psychosocial data will be collected over a period of 24 months by surveys and from the medical record. To enhance recruitment, those subjects randomized to the usual care control group will be offered to participate in the health coaching arm of the study as well after a period of 6 months. If they refuse, they will continue in the usual care control group.
62266659|NCT01309503||Normal hearing|Children and adults
62624690|NCT02788188|EXPERIMENTAL|Cohort 3|Cohort 3: 5mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%)
62266660|NCT01309503||Unilateral hearing loss|
62624691|NCT02788188|EXPERIMENTAL|Cohort 4|Cohort 4: 10mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%)
62850643|NCT03785223|EXPERIMENTAL|Methylphenidate Hydrochloride Controlled-Release Capsules|Flexibly dosed at 25-100 mg per day
62624692|NCT02788188|EXPERIMENTAL|Cohort 5|Cohort 5: 20mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
62850644|NCT03785223|PLACEBO_COMPARATOR|Placebo Capsules|1-4 capsules daily
62062183|NCT01641926|EXPERIMENTAL|HBeAg(-) PEG-Intron|HBeAg-negative participants receive 1.5 mcg/kg/wk PEG-Intron SC once weekly for 48 weeks.
62850645|NCT03162367|EXPERIMENTAL|Autologous epidermal cell suspension group|
62850646|NCT03162367|ACTIVE_COMPARATOR|Silver sulfadiazine ointment group|
62062184|NCT01641926|ACTIVE_COMPARATOR|HBeAG(-) PEGASYS|HBeAg-negative participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
62266661|NCT01309503||Severe hearing loss high frequencies|
62266662|NCT01309503||Adult CI users|Unilateral and bilateral CI
62266663|NCT01309503||Bilateral CI users|"Children and adults~Sequential CIs~Simultaneous CIs"
62266664|NCT04601948|EXPERIMENTAL|Intervention|Participants will receive a Fitbit activity monitor and access to the mHealth physical activity intervention for 6 weeks. The intervention will include regular motivational messages to encourage activity, a social media thread to provide social support, and a series of fun virtual walking races.
62266665|NCT06539013|ACTIVE_COMPARATOR|group 1 Remifentanily|Patients in Group 1 received 0.05-0.2 μg/kg/min IV remifentanil infusion as analgesic.
62266666|NCT06539013|ACTIVE_COMPARATOR|group 2 N2O|N2O instead of 50% air was applied to patients in Group 2 for intraoperative analgesia.
62624693|NCT02788188|EXPERIMENTAL|Cohort 6|Cohort 6: 50mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
62624694|NCT03877588|OTHER|Primary retroperitoneal sarcoma|All eligible patients are screened in preoperative phase, at least 30 days before surgery, for presence of protein energetic malnutrition (PEM). PEM is defined according to biochemical and physiological parameters (Table). 3 class of PEM are identified: no PEM, mild PEM and serious PEM. Different nutritional oral supplements are provided according to the degree of malnutrition.
62624695|NCT01980628|EXPERIMENTAL|ibrutinib|ibrutinib capsules: 560 mg once daily
62624696|NCT06229964|ACTIVE_COMPARATOR|SSNB + IACI|"Patients randomized to this arm will receive a SSNB (40-mg methylprednisolone acetate and 5-mL Ropivacaine 2mg/ml) than a IACI (40-mg methylprednisolone acetate and 1-mL Ropivacaine 2mg/ml).~Rehabilitation/physiotherapy is considered standard of care."
62624697|NCT06229964|PLACEBO_COMPARATOR|Sham SSNB + IACI|"Patients randomized to this arm will receive a SSNB (5-mL Linisol 10mg/ml) than a IACI (80-mg methylprednisolone acetate and 1-mL Ropivacaine 2mg/ml)~Rehabilitation/physiotherapy is considered standard of care."
62624698|NCT01653340|EXPERIMENTAL|High Frequency Spinal Cord Stimulation through Senza™|"During the trial implant of Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine, the 2 leads will be positioned to cover the C2-C3 cervical levels.~Over the following 2 weeks, the investigator will optimize therapy delivery by identifying the stimulation settings providing maximal headache pain relief.~The subject will be asked to attend the clinic at the end of the trial period. Together with his/her physician, the subject will discuss his/her experience over the past 2 weeks (satisfaction with the therapy), and decide whether or not move forward with a Nevro Senza IPG.~The Nevro Senza IPG will be implanted in the buttock or abdomen area as outlined in the Physician's Manual. Fluoroscopy and impedance measurements may be used during the procedure to confirm lead placement and location.~Before hospital discharge, the IPG will be programmed with the optimal settings identified during the trial phase."
62850647|NCT04093024|EXPERIMENTAL|Double-blind period (DBP) + open-label Nintedanib period (OLNP): Randomised Nintedanib|"This arm shows Nintedanib randomised participants treated orally with Nintedanib in the DBP and OLNP twice daily with a dose interval of approximately 12 hours from one dose to the next dose.~Medication dosage was per administration 50 milligram (mg) \[2 capsules with strength 25 mg\],75 mg \[3 capsules with strength 25 mg\], 100 mg \[1 capsule with strength 100 mg or 4 capsules with strength 25 mg\] or 150 mg \[1 capsule with strength 150 mg or 6 capsules with strength 25 mg\] based on the participant's weight at baseline (= 0 weeks). The dosage was adjusted at subsequent visits if the participant's weight had changed.~In this arm participants received Nintedanib in both periods (DBP + OLNP). Participants in this arm do not entail participants from the 'randomised to placebo' arms.~DBP: Planned was from first randomised trial drug intake to last blinded drug intake.~OLNP: Planned was from first open-label Nintedanib intake to last open-label Nintedanib intake."
62850648|NCT04093024|PLACEBO_COMPARATOR|DBP+OLNP: Randomised placebo|"Placebo randomised participants were treated orally with a Nintedanib matching placebo soft capsule twice daily in the double-blind period (DBP).~Participants who continued with the open-label Nintedanib period (OLNP) after the DBP switched to active Nintedanib treatment in the OLNP and were treated orally with Nintedanib twice daily.~Medication dosage was per administration 50 milligram (mg) \[2 25 mg capsules (cap)\],75 mg \[3 25 mg cap\], 100 mg \[1 100 mg or 4 25 mg cap\] or 150 mg \[1 150 mg or 6 25 mg cap\] based on the participant's weight at baseline (= 0 weeks). The dosage was adjusted at subsequent visits if the participant's weight had changed.~The dose interval was approximately 12 hours between one and the next dose.~Here participants received placebo first (DBP) and then Nintedanib (OLNP). DBP: Planned was from first to last randomised blinded drug intake. OLNP: Planned was from first to last open-label Nintedanib intake."
62850649|NCT06391632||positive event group|"The following complications occur within 3-7 days after surgery：~1. all-cause death;~2. non-fatal myocardial infarction/angina pectoris (new or recurring);~3. non-fatal heart failure (new onset or recurrence);~4. non-fatal cerebral infarction (new or reappeared);~5. new or recurrent malignant arrhythmias (ventricular tachycardia/ventricular fibrillation, atrial flutter/atrial fibrillation, hemodynamically unstable second/third degree atrioventricular block);"
62850650|NCT06391632||negative event group|"The following complications did not occur within 3-7 days after surgery：~1. all-cause death;~2. non-fatal myocardial infarction/angina pectoris (new or recurring);~3. non-fatal heart failure (new onset or recurrence);~4. non-fatal cerebral infarction (new or reappeared);~5. new or recurrent malignant arrhythmias (ventricular tachycardia/ventricular fibrillation, atrial flutter/atrial fibrillation, hemodynamically unstable second/third degree atrioventricular block);"
62850651|NCT02183740|EXPERIMENTAL|Multifaceted educational program|"A multifaceted educational program for nursing home staff consisting of:~1. One seven hours educational meeting (interactive workshop) conducted in the nursing home. Theoretical input and case-base discussions considering guidelines for nurse led assessment og interventions of patients fecal incontinence.The content will be made available as educational material.~2. Recruitment of one local opinion leader per nursing home unit.~3. Seven educational outreach meetings (1 hour 30 minutes per meeting) during the three months intervention period."
62266667|NCT06539013|ACTIVE_COMPARATOR|group 3 Fentanly|In addition to Desflurane, 50% oxygen and 50% air, 1 μg/kg IV fentanyl bolus was administered as analgesic when there was a 20% increase in heart rate and blood pressure values during the operation for patients in Group 3.
62266668|NCT05416762|EXPERIMENTAL|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5 mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5 mg
62266669|NCT05416762|EXPERIMENTAL|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10 mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10 mg
62266670|NCT05416762|EXPERIMENTAL|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg
62266671|NCT01967537|EXPERIMENTAL|68Gallium DOTATATE imaging|68Gallium DOTATATE imaging
62266672|NCT04733690||Healthy Volunteers (Glycemic Index)|The glycemic index (GI) of the common bean product will be assessed in this cohort among 10 study participants. The GI of the product will be assessed on 3 test days over a 120 min period on each study day.
62624699|NCT05771454||Prophylactic risk reducing mastectomy|"Patients who underwent genetic testing and came out positive for BRCA and other genes of breast cancer; afterwards opted for prophylactic risk-reducing mastectomy.~After mastectomy, the specimens will be assessed for the presence of occult breast cancers in removed specimens. Histopathology is set as gold standard for occult breast cancer confirmation."
62062185|NCT06623214|EXPERIMENTAL|treatment|receive treatment
62062186|NCT01931969||IJVC intervention|
62062187|NCT04244851||Malnourished patients|Malnourished patients
62266673|NCT04733690||Healthy Volunteers(Food Insulin Index)|The food insulin index (FII) of the common bean product will be assessed in this cohort among 10 study participants. This study will recruit 10 participants. The FII of the product will be assessed on 3 test days over a 120 min period on each study day.
62266674|NCT04733690||Type-2 diabetes (T2DM) patients|Glycemic, insulinemic and satiety responses associated with the consumption of the common bean product will be assessed in this cohort among 10 T2DM patients. Participants will attend one study visit lasting approximately 120 min.
62266675|NCT00707070|EXPERIMENTAL|1|efalizumab 1 mg/kg/week subcutaneous plus acitretin 0.4 mg/kg/day oral
62266676|NCT00707070|PLACEBO_COMPARATOR|2|efalizumab 1 mg/Kg/week subcutaneous plus oral placebo
62624700|NCT04801043|EXPERIMENTAL|Cohort 1: Healthy young females|Healthy young females participants, ≥ 18 to ≤ 45 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.
62624701|NCT04801043|EXPERIMENTAL|Cohort 2: Healthy elderly males|Healthy elderly male participants, ≥ 65 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.
62624702|NCT04801043|EXPERIMENTAL|Cohort 3: Healthy elderly females|Healthy elderly female participants, ≥ 65 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.
62624703|NCT04801043|PLACEBO_COMPARATOR|Placebo to XNW 4107 & imipenem/cilastatin|Matching placebo for XNW4107 and imipenem/cilastatin
62624704|NCT05085470|EXPERIMENTAL|Reinfection group|Participants will be exposed three times to 20 male Schistosoma mansoni cercariae (weeks 0, 9, and 18)
62624705|NCT05085470|ACTIVE_COMPARATOR|Infection control group|12 participants who will undergo a placebo mock infection with water twice (weeks 0 and 9) and will be exposed once to 20 male Schistosoma mansoni cercariae (week 18)
62624706|NCT06480760|NO_INTERVENTION|Placebo|Cellulose
62624707|NCT06480760|EXPERIMENTAL|Carnosine|Carnosine 1 g daily for 6 months
62850652|NCT02183740|NO_INTERVENTION|Control|The control arm will not receive any educational program and will continue with usual care. Data with information about ordinary care will be gathered as part of the data collection procedure in the study.
62850653|NCT01208753|EXPERIMENTAL|Aqueous formulations for formulation selection|50 mg once daily for 3 days of two different aqueous suspensions, with four day wash-out between formulation
62624708|NCT01270360||asymptomatic subjects with positive FOBT|individuals having undergone a positive faecal occult blood test (FOBT) and a reference colonoscopy
62850654|NCT01208753|EXPERIMENTAL|GLPG0555 ascending doses|multiple ascending doses for 13 days, ranging from 100 mg once daily upto a maximum to be determined during escalation (given as once or twice daily)
62850655|NCT01208753|PLACEBO_COMPARATOR|3|once or twice daily for 13 days, matching the scheme of the multiple ascending dose.
62062188|NCT06444295|ACTIVE_COMPARATOR|No experimental components|Participants are invited to use a version of the app for 21 days. Participants receive only the non-core intervention components and do not attend coaching calls.
62062189|NCT06444295|EXPERIMENTAL|Activities + Thoughts|Participants are invited to use a version of the app for 21 days. Participants receive the Activities and Thoughts app modules, but do not attend coaching calls.
62062190|NCT06444295|EXPERIMENTAL|Activities only|Participants are invited to use a version of the app for 21 days. Participants receive the Activities app module, but do not attend coaching calls.
62624709|NCT02800369|EXPERIMENTAL|ZFN-603 and ZFN-758|Subjects will receive suppository with ZFN-603 or ZFN-758
62850656|NCT00603694||1|(Experimental group): Receiving \> 2 Gy SRS to left hippocampus (n=10)
62062191|NCT06444295|EXPERIMENTAL|Thoughts only|Participants are invited to use a version of the app for 21 days. Participants receive the Thoughts app module, but do not attend coaching calls.
62062192|NCT06444295|EXPERIMENTAL|Activities, Thoughts, & Coaching|Participants are invited to use a version of the app for 21 days. Participants receive the Activities and Thoughts app modules and attend coaching calls.
62062193|NCT06444295|EXPERIMENTAL|Activities + Coaching|Participants are invited to use a version of the app for 21 days. Participants receive the Activities app module and attend coaching calls.
62624710|NCT01679730||irritable bowel syndrome patients|
62624711|NCT06144450|EXPERIMENTAL|Intervention Group|The presented modules will be made accessible to mothers in the experimental group through a website. The modules will be completed in order and the necessary forms and follow-ups will be completed at the end of each module.
62624712|NCT06144450|NO_INTERVENTION|Control Group|No intervention will be made in the control group.
62624713|NCT01005017|ACTIVE_COMPARATOR|Percutanous RF lesioning|Radiofrequent lesioning uses a high frequency alternating current to heat tissues leading to thermal coagulation. It produces predictable and accurate lesions of the splanchnic nerves.
62624714|NCT01005017|NO_INTERVENTION|Optimal medical treatment|
62624715|NCT01857804|EXPERIMENTAL|antibiotics and local antiseptics|systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with chlorhexidine gluconate 0,2%
62624716|NCT01857804|EXPERIMENTAL|antibiotics without local antiseptics|systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with saline
62624717|NCT01857804|EXPERIMENTAL|local antiseptics no antibiotics|no systemic antibiotics + implant surface decontamination with chlorhexidine gluconate 0,2%
62624718|NCT01857804|PLACEBO_COMPARATOR|no antibiotics and no local antiseptics|no systemic antibiotics + implant surface decontamination with saline
62624719|NCT01512433|ACTIVE_COMPARATOR|True acupuncture|True acupuncture was a real acupuncture which had been used in conventional Chinese medicine practice
62850657|NCT00603694||2|(Low-dose control group): Receiving \< 0.5 Gy SRS to left hippocampus (n=10)
62850658|NCT00603694||3|(High-dose control group): Receiving whole brain PCI (n=10)
62624720|NCT01512433|SHAM_COMPARATOR|Sham acupuncture|Sham acupuncture was a procedure which mimicked the real acupuncture procedure.
62850659|NCT01639729|EXPERIMENTAL|Sequence 1 - Treatment A, B, C, D|15 mcg: Sufentanil IV, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Buccal, Sufentanil NanoTab Oral
62850660|NCT01639729|EXPERIMENTAL|Sequence 2 - Treatment A, B, D, C|15 mcg: IV, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Oral,Sufentanil NanoTab Buccal
62266677|NCT03413280|EXPERIMENTAL|preoperative Rectus sheath block: group Pre|ultrasound guided Rectus sheath block block with 0.25% ropivacaine 40ml Before surgical incision
62850661|NCT01639729|EXPERIMENTAL|Sequence 3 - Treatment A, C, B, D|15 mcg: Sufentanil IV, Sufentanil NanoTab Buccal, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Oral
62850662|NCT01639729|EXPERIMENTAL|Sequence 4 - Treatment A, C, D, B|15 mcg: Sufentanil IV, Sufentanil NanoTab Buccal, Sufentanil NanoTab Oral, Sufentanil NanoTab Sublingual
62850663|NCT01639729|EXPERIMENTAL|Sequence 5 - Treatment A, D, B, C|15 mcg: Sufentanil IV, Sufentanil NanoTab Oral, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Buccal
62850664|NCT01639729|EXPERIMENTAL|Sequence 6 - Treatment A, D, C, B|15 mcg: Sufentanil IV, Sufentanil NanoTab Oral, Sufentanil NanoTab Buccal, Sufentanil NanoTab Sublingual
62850665|NCT01504906|EXPERIMENTAL|A|cyclosporine 600 mg+ a single oral dose of 180 mg ticagrelor
62062194|NCT06444295|EXPERIMENTAL|Thoughts + Coaching|Participants are invited to use a version of the app for 21 days. Participants receive the Thoughts app module and attend coaching calls.
62062195|NCT06444295|EXPERIMENTAL|Coaching only|Participants are invited to use a version of the app for 21 days. Participants receive the non-core intervention components in the app and attend coaching calls.
62062196|NCT05666986||Adolescents who had CDH surgery in the first month of life,|without any other pathology, now aged 12-18 and followed up at the CDH Lille Reference Center
62062197|NCT05967780|ACTIVE_COMPARATOR|Group A: Patients with FHP receiving standard cardiac rehabilitation|Consenting participants in this group will receive a standard cardiac rehabilitation protocol.
62062198|NCT05967780|EXPERIMENTAL|Group B: Patients with FHP receiving standard cardiac rehabilitation + therapeutic exercises|The participants who give consent will receive standard cardiac rehabilitation protocol (as Group A) with therapeutic exercise in the intervention group.
62062199|NCT05967780|ACTIVE_COMPARATOR|Group C: Patients without FHP receiving standard cardiac rehabilitation|The participants without forward head posture will be included in this group and will receive same standard cardiac rehabilitation as the participants in group A.
62624721|NCT04819100|EXPERIMENTAL|Selpercatinib|Selpercatinib administered orally.
62624722|NCT04819100|PLACEBO_COMPARATOR|Placebo|Placebo administered orally.
62624723|NCT01238419|EXPERIMENTAL|Physiotulle|
62850666|NCT01504906|EXPERIMENTAL|B|single dose cyclosporine 600 mg
62850667|NCT01504906|EXPERIMENTAL|C|single dose 180 mg ticagrelor
62850668|NCT02234518|EXPERIMENTAL|High quantity fiber food product|
62850669|NCT02234518|EXPERIMENTAL|Low quantity fiber food product|
62062200|NCT04570813|EXPERIMENTAL|artistic activities|"participants will do a 3-month cycle of weekly artistic activities at the MAMAC Museum, which are structured 2-h-long art-based workshops"
62062201|NCT04570813|NO_INTERVENTION|No artistic activities|The control group is composed of participants who do not take part in art-based activities,
62062202|NCT06625983|EXPERIMENTAL|CRC decision tool|intervention arm
62062203|NCT06625983|NO_INTERVENTION|control|control arm
62266678|NCT03413280|ACTIVE_COMPARATOR|postoperative Rectus sheath block: group Post|ultrasound guided Rectus sheath block block with 0.25% ropivacaine 40ml After surgical incision
62266679|NCT00390546|EXPERIMENTAL|Propranolol|Single dose of 0.5 mg/kg per dose and increased to 1.0 mg/kg per dose ITD for the second and subsequent doses.
62266680|NCT00390546|EXPERIMENTAL|Digoxin|First 2 doses at 0.010 mg/kg per dose TID, then 0.0035 mg/kg per dose TID for the third and subsequent doses
62266681|NCT04654494||Chron's disease patients with colorectal cancer|This group of patients with Chron's disease have been diagnosed with colorectal cancer and treated surgically
62624724|NCT01238419|PLACEBO_COMPARATOR|Urgotul|
62624725|NCT02681458||Drug Users|Case group that consisted of drug users with fungal infections
62624726|NCT02681458||Non-drug Users|Control group that consisted of non drug users with fungal infections
62624727|NCT00864305|EXPERIMENTAL|A|Gabapentin 400 mg capsules
62850670|NCT02234518|PLACEBO_COMPARATOR|Placebo|
62850671|NCT00207064|EXPERIMENTAL|1|
62850672|NCT02078856|EXPERIMENTAL|A3384 Low dose|Administered twice daily for the duration of the study
62850673|NCT02078856|EXPERIMENTAL|A3384 High dose|Administered twice daily for the duration of the study
62850674|NCT02078856|PLACEBO_COMPARATOR|Placebo|Administered twice daily for the duration of the study
62850675|NCT04468997|EXPERIMENTAL|601 dose level 1 treatment|
62850676|NCT04468997|EXPERIMENTAL|601 dose level 2 treatment|
62624728|NCT00864305|ACTIVE_COMPARATOR|B|Neurontin 400 mg capsules
62624729|NCT00565201|EXPERIMENTAL|Botox and Rehab|"Patients will receive BOTOX® (100 to 360 U) injected into the any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site).~Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs."
62624730|NCT00565201|PLACEBO_COMPARATOR|Placebo and Rehab|Patients will placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
62624731|NCT05477875|EXPERIMENTAL|Oral cannabinoid|Oral cannabinoid
62624732|NCT05477875|ACTIVE_COMPARATOR|Oral codeine/acetaminophen|Oral codeine-acetaminophen for controlling pain
62624733|NCT04571216|EXPERIMENTAL|NFL-101 Dose 1|50 µg per injection (in each arm), two injections at day 1, two injections at day 8, optional injections later on
62624734|NCT04571216|EXPERIMENTAL|NFL-101 Dose 2|100 µg per injection (in each arm), two injections at day 1, two injections at day 8, optional injections later on
62624735|NCT04571216|PLACEBO_COMPARATOR|Placebo|The placebo will consist of two syringes containing 1 mL of dilution solution, two injections at day 1, two injections at day 8, optional injections later on
62624736|NCT06272825|EXPERIMENTAL|Experimental Group|In addition to the conventional rehabilitation program at the hospital, virtual reality exercise will be applied in 15 sessions, 5 days a week.
62624737|NCT06272825|ACTIVE_COMPARATOR|Control group|The conventional rehabilitation program at the hospital will be implemented in 15 sessions, 5 days a week.
62266682|NCT02678481|EXPERIMENTAL|MR-targeted biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MR imaging two targeted biopsy cores will be taken.
62266683|NCT02678481|EXPERIMENTAL|TRUS-guided biopsy|Patients of arm B receive a saturation TRUS-guided prostate biopsy.
62850677|NCT04468997|EXPERIMENTAL|601 dose level 3 treatment|
62850678|NCT04468997|EXPERIMENTAL|601 dose level 4 treatment|
62062204|NCT04172805|EXPERIMENTAL|anlotinib combined with Toripalimab|Anlotinib 12mg orally per day, two weeks on , one week off; 240 mg of toripalimab (fixed dose) every three weeks.
62062205|NCT00813137|EXPERIMENTAL|Folfox4 plus Endostar|
62062206|NCT03279055|EXPERIMENTAL|SHUTi|"* Participants will be provided with an individual access code for SHUTi~* SHUTi is delivered over 6 sessions, each taking 20-30 minutes~* SHUTi is delivered by a virtual therapist~* Participants will learn about the etiology and maintenance of their insomnia~* Participants will learn how to maintain their sleep log~* Participants will learn how to address lifestyle barriers that impact their sleep~* Participants will be taught stimulus control techniques targeting non-sleep behaviors in the bedroom~* Participants will learn a range of cognitive techniques that address the key cognitive factors that perpetuate poor sleep behavior~* Participants will be taught how to gradually expand their restricted sleep"
62266684|NCT01028664|EXPERIMENTAL|Glaucoma or ocular hypertension patients|
62624738|NCT05418959|EXPERIMENTAL|DermTech PLA noninvasive adhesive biopsy|Prior to surgical biopsy, a DermTech PLA noninvasive adhesive will be pressed over the lesion to collect superficial skin cells.
62062207|NCT05413525||Women undergoing USG- MVA for the treatment of early pregnancy loss|Medical notes of all women undergoing USG- MVA for the treatment of early pregnancy loss with gestation \< 12 weeks at the Department of Obstetrics and Gynaecology in The Prince of Wales Hospital and Union Hospital will be reviewed.
62062208|NCT02688465|EXPERIMENTAL|Apomorphine pump|
62062209|NCT05720013|EXPERIMENTAL|Beetroot Juice Supplement|140 mL of beetroot juice supplement will be ingested orally (Beet-It Nitrate 400, James White Co).
62062210|NCT05720013|PLACEBO_COMPARATOR|Placebo Supplement|140 mL of placebo supplement will be ingested orally (Beet-It Nitrate 400, James White Co).
62062211|NCT03613623||Patients|Patients diagnosed with acromegaly and currently taking long-acting somatostatin analogues for treatment.
62062212|NCT03613623||Physicians|Physicians for those treating the patients enrolled in the study.
62062213|NCT01181505|EXPERIMENTAL|Tolterodine|
62624739|NCT04889053||D2M, Vascular calcification-free|Meet the inclusion criteria, there is no calcification detected by low dose prospectively triggered sequential dual-source CT coronary angiography
62624740|NCT04889053||D2M with vascular calcification|Meet the inclusion criteria, and have coronary artery calcification ( be confirmed by low dose prospectively triggered sequential dual-source CT coronary angiography)
62624741|NCT06608095|EXPERIMENTAL|hypothermia group|Combined target temperature management (TTM) in patients undergoing extracorporeal cardiopulmonary resuscitation (ECPR) and with a target temperature control of 34°C.
62624742|NCT06608095|EXPERIMENTAL|normothermia group|Combined target temperature management (TTM) in patients undergoing extracorporeal cardiopulmonary resuscitation (ECPR) and with a target temperature control of 36.5-37.2°C.
62624743|NCT01398657|EXPERIMENTAL|Adjuvant Androgen-Deprivation Therapy|Cryotherapy with Short-term Adjuvant Androgen-Deprivation Therapy
62624744|NCT01398657|NO_INTERVENTION|No adjuvant therapy|Cryotherapy without any adjuvant therapy
62624745|NCT05226117|EXPERIMENTAL|Treatment arm|Patients with muscle-invasive urothelial carcinoma of the bladder, who are suited for and accept radical cystectomy (RC)
62850679|NCT04468997|EXPERIMENTAL|601 dose level 5 treatment|
62850680|NCT04468997|EXPERIMENTAL|601 dose level 6 treatment|
62850681|NCT00835211|EXPERIMENTAL|1|
62850682|NCT00835211|ACTIVE_COMPARATOR|2|
62850683|NCT05798000||Control|The control group without WHO and equipment checklist used
62850684|NCT05798000||Study|Other group, where WHO safety check-list and equipment check-list were implemented
62850685|NCT05149521||Patients who have received radiotherapy|This is a consensus study with no interventions Patients who previously participated in COMFORT study interviews (NCT03984435)
62624746|NCT02482753|EXPERIMENTAL|Chidamide + exemestane, open-label|Patients receive 30 mg Chidamide per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62624747|NCT02482753|EXPERIMENTAL|Chidamide + exemestane, double-blinded|Patients receive 30 mg Chidamide twice per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62624748|NCT02482753|PLACEBO_COMPARATOR|placebo + exemestane, double-blinded|Patients receive placebo twice per week and 25 mg exemestane PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62624749|NCT01569282|ACTIVE_COMPARATOR|Double bypass|
62624750|NCT01569282|ACTIVE_COMPARATOR|Stent Strategy|
62624751|NCT04442477||Experimental: Enriched Protein Fractions|This group was given Infant formula with enriched protein fractions
62624752|NCT04442477||Active Comparator: Protein Fractions|This group was given Infant formula with protein fractions
62850686|NCT05149521||Therapeutic radiographers who deliver radiotherapy|This is a consensus study with no interventions Therapeutic radiographers who previously participated in COMFORT study interviews (NCT03984435)
62850687|NCT06349889|EXPERIMENTAL|Adebrelimab arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 \& 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Adebrelimab 20mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.
62062214|NCT01548937|EXPERIMENTAL|I-123 ADAM|I-123 ADAM Serotonin transporter imaging
62266685|NCT05648279|NO_INTERVENTION|Routine hemodynamic management (control)|In patients assigned to routine hemodynamic management, hemodynamic management will performed as per anesthesiologist preference. Cardiac index monitoring will be will measured using the Baxter Starling Fluid Management System (Baxter, Deerfield, IL, USA). The attending anesthesiologist will be blinded to cardiac index measurements. Cardiac index monitoring can be unblinded upon request. Mean arterial blood pressure will be maintained above 65 mmHg.
62266686|NCT05648279|EXPERIMENTAL|Personalized hemodynamic management (intervention)|"In patients assigned to personalized hemodynamic management, intraoperative cardiac index will be maintained at least at the preoperative baseline cardiac index measured the day before surgery using a predefined treatment algorithm.~Preoperative baseline cardiac index will be determined at least one day before surgery with the patient being awake and resting in supine position using the Starling Fluid Management System (Baxter, Deerfield, IL, USA). We will define the individual preoperative baseline cardiac index as the average value over a 5 min period at rest (minimum cardiac index threshold: 2.2 L min-1 m-2).~Mean arterial blood pressure will be maintained above 65 mmHg. The study intervention will start at the beginning of surgery and will end at the end of surgery."
62062215|NCT04139980|EXPERIMENTAL|Virtual Reality supported therapy|"The Virtual Reality (VR) interface will be used during patients stay at the rehabilitation center. A research employee will install the VR system in the patient's room. Participants will be comfortable sitting while in VR session. Each interface consists of a head mounted display (HMD) allowing participants to see their arms and legs represented in the virtual environment. Participants will be able to control their virtual legs using hand controllers, which will allow them to walk through several virtual environments and gather points (no additional gaming elements are included)."
62087941|NCT04025372|EXPERIMENTAL|Bicalutamide+GnRH Agonist+Radiation Therapy|"* Bicalutamide is administered orally on a daily basis~* GnRH Agonist as prescribed~* Radiation therapy is administered starting 4-16 weeks after ADT"
62266687|NCT06044480|ACTIVE_COMPARATOR|dexamethasone|This group of participans will be submitted to a single preoperative dose of 4 mg of dexamethasone given intravenously 30 minutes before operation.
62266688|NCT06044480|PLACEBO_COMPARATOR|placebo|This group of patients will be submitted to a same amount of saline solution.
62266689|NCT01755715|NO_INTERVENTION|Control group|Insertion of IUD at 2-4 weeks after abortion.
62266690|NCT01755715|EXPERIMENTAL|Immediate IUD insertion|Insertion of IUD immediately (at the same day to 3 days) after expulsion of placenta.
62266691|NCT03216473|EXPERIMENTAL|Neuronox|Botulinum Toxin Type A for injection
62624753|NCT02330185|EXPERIMENTAL|spinal anesthesia for knee arthroscopy|The intervention is spinal anesthesia. Tenth rib line or Tuffier's line will be examined as application landmarks by ultrasonography for spinal anesthesia.
62624754|NCT03900572|EXPERIMENTAL|HPV vaccine|Subjects receive 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
62624755|NCT03900572|PLACEBO_COMPARATOR|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
62624756|NCT01215149|EXPERIMENTAL|Group A|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 6. Vaccine:Placebo=10:3
62624757|NCT01215149|EXPERIMENTAL|Group B|Ad35-ENVA at Month 0 followed by Ad26.ENVA.01 at Month 6. Vaccine:Placebo=10:3
62624758|NCT01215149|EXPERIMENTAL|Group C|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=10:3
62624759|NCT01215149|EXPERIMENTAL|Group D|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=10:3
62624760|NCT01215149|EXPERIMENTAL|Group E|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
62624761|NCT01215149|EXPERIMENTAL|Group F|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
62624762|NCT01215149|EXPERIMENTAL|Group G|Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
62624763|NCT01215149|EXPERIMENTAL|Group H|Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
62624764|NCT01215149|EXPERIMENTAL|Group I|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
62624765|NCT01215149|EXPERIMENTAL|Group J|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
62624766|NCT01215149|EXPERIMENTAL|Group K|Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
62624767|NCT01215149|EXPERIMENTAL|Group L|Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
62624768|NCT01533402|PLACEBO_COMPARATOR|Attention control|Weekly support from therapist without CBT-interventions
62850688|NCT00970619|NO_INTERVENTION|Conventional anticoagulation therapy|Conservative treatment consists of an initial treatment with therapeutic doses of low molecular weight heparin (LMWH) in combination with vitamin K-antagonists, followed by treatment with vitamin K-antagonist alone (after completing LMWH treatment of at least 5-7 days and after an international normalized ratio (INR) above 2 has been reached on two consecutive measurements). Or alternatively the new direct activated factor X inhibitors can be used as anticoagulation therapy. Anticoagulant treatment will be installed according to national and international guidelines (ACCP 2008 \[23\], CBO 2008 \[24\]) tailored based on the character of the event (6 months of therapy for idiopathic DVT and 3 months for provoked DVT).
62850689|NCT00970619|EXPERIMENTAL|Ekos Endowave system thrombolysis|Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
62850690|NCT01836978|NO_INTERVENTION|Control|Patients in this group will follow standard MUHC clinical guidelines. This group will receive general instructions, by the preoperative clinic nurse, on exercises (breathing, ankle rotation) to be done before and after surgery. They will also be seen by a nutritionist who will provide general counseling for healthy eating.
62087942|NCT04025372|EXPERIMENTAL|Darolutamide+Radiation Therapy|"* Darolutamide is administered orally twice daily~* Radiation therapy is administered starting 4-16 weeks after Darolutamide"
62087943|NCT06697626|ACTIVE_COMPARATOR|Dietary Supplement (Functional drink)|"An enriched functional drink containing chicory inulin (10g), folic acid (100µg), vitamin B12 (5µg), vitamin B6 (5mg), riboflavin (2.5mg) and vitamin D (5µg).~This drink will be consumed twice daily for an intervention period of 12 weeks"
62266692|NCT03216473|ACTIVE_COMPARATOR|Botox|Botulinum Toxin Type A for injection
62266693|NCT03766048|EXPERIMENTAL|Single-Anterior-Mesh, SAM|
62624769|NCT01533402|EXPERIMENTAL|Internet CBT|Internet-delivered cognitive behavioural therapy with therapy support
62624770|NCT05890014|EXPERIMENTAL|High flavonoid group|"Participants will be encouraged to consume 2 x flavonoid-rich food items per day from the following list of flavonoid-rich foods across 30-days, above what they already consume each day, typically.~Orange juice (190 mls) Grapefruit juice (169mls) Dark chocolate (64g) Spinach (109g) Blueberry (64g) Strawberry (157g) Blackberry (81g) Blackcurrant (61g) Cherries (182g) Plums (90g) Black grapes (142g) Oranges (247g) Black olives (89g) Red grapes (339g)"
62624771|NCT05890014|EXPERIMENTAL|Low flavonoid group|"Participants will be encouraged to consume 1 x flavonoid-rich food items per day from the following list of flavonoid-rich foods across 30-days, above what they already consume each day, typically.~Orange juice (190 mls) Grapefruit juice (169mls) Dark chocolate (64g) Spinach (109g) Blueberry (64g) Strawberry (157g) Blackberry (81g) Blackcurrant (61g) Cherries (182g) Plums (90g) Black grapes (142g) Oranges (247g) Black olives (89g) Red grapes (339g)"
62624772|NCT05890014|NO_INTERVENTION|Control|Participants will be given no instructions regarding adding food items to their diet. They will be encouraged to continue their diet as normal for 30-days.
62624773|NCT02555917|EXPERIMENTAL|Remnant preserving|"Anterior cruciate ligament reconstruction:~anterior cruciate ligament remnant will be preserved in the operation"
62624774|NCT02555917|ACTIVE_COMPARATOR|Remnant resecting|"Anterior cruciate ligament reconstruction:~anterior cruciate ligament remnant will be removed in the operation"
62624775|NCT04127396|EXPERIMENTAL|lenvatinib and TACE|Patients in Lenvatinib + TACE group will take oral lenvatinib within one day of randomization and receive TACE 1 day after oral administration of lenvatinib.
62266694|NCT03766048|SHAM_COMPARATOR|Double-Mesh, DM|
62624776|NCT04127396|ACTIVE_COMPARATOR|Sorafenib and TACE|Patients in Sorafenib + TACE group will take oral sorafenib within one day of randomization and receive TACE 1 day after oral administration of lenvatinib.
62624777|NCT04999085|EXPERIMENTAL|Supportive Care|
62624778|NCT03161067|EXPERIMENTAL|Surgical implantation of BiCNS|
62624779|NCT03589157|EXPERIMENTAL|Drug-coated balloon group|
62624780|NCT03589157|ACTIVE_COMPARATOR|second-generation drug-eluting stent group|
62624781|NCT06372314|EXPERIMENTAL|Isoleucine, leucine, valine, tryptophan requirement|isoleucine, leucine, valine and tryptophan intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
62624782|NCT06109350|EXPERIMENTAL|Supporting play exploration and early development intervention|Preterm infants will receive supporting play exploration and early developmental intervention till 3 months of corrected age.
62624783|NCT06109350|ACTIVE_COMPARATOR|Standard care|Preterm infants will receive standard care mostly including health education till 3 months of corrected age.
62624784|NCT01319942||Unresectable hepatoma|Unresectable hepatoma, unsuitable for transarterial embolization or local failure after transarterial embolization
62624785|NCT02279615|ACTIVE_COMPARATOR|Treatment Group|(Mirabegron + Tamsulosin)
62624786|NCT02279615|PLACEBO_COMPARATOR|Control Group|(Placebo + Tamsulosin)
62624787|NCT02660684|EXPERIMENTAL|Prograf + MTX|
62624788|NCT02660684|ACTIVE_COMPARATOR|Cyclosporine + MTX (historical control)|
62624789|NCT00437060||Ancillary/Correlative (neurocognitive assessment, biomarkers))|"Patients complete neurocognitive tests to assess thinking, memory, attention, and concentration. The baseline test is administered during the consolidation phase of chemotherapy and further tests are done at 1 year from baseline and 1 year after\* the completion of study therapy.~Patients undergo blood and cerebrospinal fluid collection periodically for biomarker, genotypic polymorphisms, and pharmacokinetic analysis. Patients undergo MRI diffusion-tensor imaging to correlate imaging with neuropsychological outcomes."
62850691|NCT01836978|EXPERIMENTAL|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program, and stress reduction strategies.
62266695|NCT01612260|EXPERIMENTAL|Shensong Yangxin capsule|Shensong Yangxin capsule 4 granules t.i.d. po for 12weeks
62087944|NCT06697626|PLACEBO_COMPARATOR|Placebo drink|"A placebo drink drink with similar energy content but without the additional nutrient provision.~This drink will be consumed twice daily an intervention period of 12 weeks."
62266696|NCT01612260|PLACEBO_COMPARATOR|placebo Capsule|placebo Capsule 4 granules t.i.d. po for 12weeks
62266697|NCT02189642||Genito-Urinary/Urology Surgical Procedure Types|Pediatric patients undergoing circumcision, orchidopexy, hypospadias repair, hernia repair, cystoscopy, pyeloplasty, and ureteral reimplants or ureteral stents.
62624790|NCT03271632|EXPERIMENTAL|Single arm|CAR T cells to treat MM
62266698|NCT02189642||Otolaryngology Surgical Procedure Types|Pediatric patients undergoing tonsil and/or adenoid removal, tympanostomy, tympanoplasty, and mastoidectomy.
62266699|NCT02189642||Orthopaedics Surgical Procedure Types|Patients undergoing hip and knee arthroscopies, hardware removal, and tendon lengthening.
62624791|NCT05341973|EXPERIMENTAL|Education|The Self- Management Program Developed will increase Self-Efficacy, Self-Care Management in Hypertension Patients.
62266700|NCT02189642||Plastic Surgery Surgical Procedure Type|Pediatric patients undergoing alveolar cleft repair.
62266701|NCT00893321|OTHER|Inferior Oblique Muscle Recession and Myectomy|
62266702|NCT04391699|EXPERIMENTAL|CPAP + Heated humidification|CPAP + Heated humidification
62266703|NCT04391699|NO_INTERVENTION|CPAP alone|CPAP
62266704|NCT03569527|ACTIVE_COMPARATOR|Kiwifruit|Treating chronic constipation with 2 kiwifruit (6g fiber) per day
62266705|NCT03569527|ACTIVE_COMPARATOR|Psyllium fiber|Treating chronic constipation with 24g psyllium fiber (6g fiber) per day
62266706|NCT03569527|ACTIVE_COMPARATOR|Prune|Treating chronic constipation with 100g dried plums (6g fiber) per day
62266707|NCT03080909|ACTIVE_COMPARATOR|Encapsulated nutients|"Encapsulated nutrients known to be able to stimulate GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum) expected to start approximately 3 hour following ingestion.~The encapsulated nutrients will be provided 30 minutes prior to the standardized fixed breakfast (providing 2000 kJ) and 60 minutes prior to the standardized fixed mid-morning snack (providing 1500 kJ), i.e. test products will be provided 6 hour and 4 hour before the ad libitum test meal, respectively."
62266708|NCT03080909|PLACEBO_COMPARATOR|Placebo|"Nutrients known to have limited stimulation on GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum) expected to start approximately 3 hour following ingestion.~The placebo products will be provided 30 minutes prior to the standardized fixed breakfast (providing 2000 kJ) and 60 minutes prior to the standardized fixed mid-morning snack (providing 1500 kJ), i.e. placebo products will be provided 6 hour and 4 hour before the ad libitum test meal, respectively."
62624792|NCT05341973|NO_INTERVENTION|Control|It will not change the Self-Efficacy, Self-Care Management in Hypertension Patients of the Self-Management Program.
62850692|NCT02687191|EXPERIMENTAL|PF-05230907 (Cohort 1)|PF-05230907 IV bolus injection
62850693|NCT02687191|EXPERIMENTAL|PF-05230907 (Cohort 2)|PF-05230907 IV bolus injection
62850694|NCT02687191|EXPERIMENTAL|PF-05230907 (Cohort 3)|PF-05230907 IV bolus injection
62850695|NCT02687191|EXPERIMENTAL|PF-05230907 (Cohort 4)|PF-05230907 IV bolus injection
62850696|NCT02687191|EXPERIMENTAL|PF-05230907 (Cohort 5)|PF-05230907 IV bolus injection
62624793|NCT04754542||Discontinuation|This study is only observing participants that received an intervention from a previous study. Participants that were randomized to discontinue their disease modifying therapy (DMT) in the DISCOMS study and consent to this extension trial will remain in this arm for the extension.
62624794|NCT04754542||Continuation|This study is only observing participants that received an intervention from a previous study. Participants that were randomized to continue their disease modifying therapy (DMT) in the DISCOMS study and consent to this extension trial will remain in this arm for the extension.
62624795|NCT05500014|EXPERIMENTAL|Biofortified potato|500 g of biofortified, cooked potato, comsumed over 5 consecutive days (500g for each day, for a total of 2500 g of cooked potato). Potato meals will be labelled with a total of 3 mg 57FeSO4.
62624796|NCT05285059||Patients|8- to 14-years-old children with epilepsy
62624797|NCT05285059||Control|8- to 14-years-old children without neurological, psychiatric, or developmental impairments
62624798|NCT00537355|ACTIVE_COMPARATOR|TOLAMBA™|
62850697|NCT02687191|EXPERIMENTAL|PF-05230907 (Cohort 6)|PF-05230907 IV bolus injection
62266709|NCT03760575|EXPERIMENTAL|Pembrolizumab with image-guided surgery and chemotherapy|
62624799|NCT00537355|SHAM_COMPARATOR|Histamine|Histamine simulates mild redness/swelling effect seen with active comparator, TOLAMBA™. Prevents study staff from easily identifying subjects who received active comparator.
62624800|NCT06120478||xi'an|
62850698|NCT02687191|EXPERIMENTAL|PF-05230907 (Cohort 7)|PF-05230907 IV bolus injection
62850699|NCT02687191|EXPERIMENTAL|PF-05230907 (Cohort 8)|PF-05230907 IV bolus injection
62850700|NCT02687191|EXPERIMENTAL|PF-05230907 (Cohort 9)|PF-05230907 IV bolus injection
62850701|NCT02687191|EXPERIMENTAL|PF-05230907 (Cohort 10)|PF-05230907 IV bolus injection
62850702|NCT02687191|EXPERIMENTAL|PF-05230907 (Cohort 11)|PF-05230907 IV bolus injection
62850703|NCT02687191|EXPERIMENTAL|PF-05230907 (Cohort 12)|PF-05230907 IV bolus injection
62850704|NCT02687191|EXPERIMENTAL|PF-05230907 (Cohort 13)|PF-05230907 IV bolus injection
62850705|NCT02687191|EXPERIMENTAL|PF-05230907 (Cohort 14)|PF-05230907 IV bolus injection
62850706|NCT02687191|EXPERIMENTAL|PF-05230907 (Cohort 15)|PF-05230907 IV bolus injection
62850707|NCT06131099|ACTIVE_COMPARATOR|Group A|In this group patient will be treated with standard treatment protocol. This group will receive therapy session for 1 hour, three sessions in a week and for 6 weeks, total sessions will be 18. Group A will receive soft tissue massage therapy for 5 mins and the task specific training interventions include bicycle training for 10 mins. After that aerobic exercises includes and finally some of progressive resistive exercises will involve in it.
62850708|NCT06131099|ACTIVE_COMPARATOR|Group B|In this group patient will be treated with Dohsa hou exercises. This group will receive therapy session for 1 hour, three sessions in a week and for 6 weeks, total sessions will be 18. Group B will receive Dohsa hou exercises, session will be included three activity parts: (a) 10 minutes of instruction and preparation, (b) 45 minutes of skill instruction and practice, and (c) 5 minutes in a closing activity.
62850709|NCT03869463|EXPERIMENTAL|EF/PS CCT|This group will complete EF/PS (executive functioning/processing speed) computerized cognitive training (CCT) which includes games specifically focused on executive function \& processing speed.
62087945|NCT03597893|EXPERIMENTAL|Oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland) .
62266710|NCT05736900|OTHER|Patients with COVID-19|Patients admitted as in-patients with SARS-CoV-2 Infection
62624801|NCT06120478||shanxi|
62850710|NCT03869463|ACTIVE_COMPARATOR|Verbal CCT|This group will complete verbal-focused computerized cognitive training.
62266711|NCT03368170|EXPERIMENTAL|Mesdopetam (IRL790)|Capsule 2.5 mg, oral administration
62266712|NCT03368170|PLACEBO_COMPARATOR|Placebo|Identical capsule, oral administration
62624802|NCT03923777|OTHER|Active Surveillance|Active surveillance is a way of either delaying or avoiding treatment and its possible side effects through carefully watching for changes in the tumor. Patients continue on this regimen, watching for tumor growth, up to 2 years on study or until rate or extent of growth leads to a shared decision to initiate treatment, whichever comes first.
62624803|NCT00786253|EXPERIMENTAL|Arm 1|
62850711|NCT03869463|PLACEBO_COMPARATOR|Waitlist Control|This group will not receive cognitive training during study participation.
62850712|NCT02914002|EXPERIMENTAL|Psychoeducational intervention|Participants will be receiving a cooking lesson in their community every 2 weeks for 1 year.
62850713|NCT02914002|NO_INTERVENTION|Usual Food Practices - AC|These are participants from the communities where the intervention is active but are not attending the cooking lessons.
62850714|NCT02914002|NO_INTERVENTION|Usual Food Practices - NAC|These are participants from a community where the intervention is not active.
62850715|NCT04363788||Cardiopulmonary resuscitation|The study was based on dying gloves used during resuscitation. The gloves were secured with disposable hermetically sealed pouches and described by one of the EMS team members - each time after resuscitation was completed.
62624804|NCT00786253|EXPERIMENTAL|Arm 2|
62266713|NCT03791788||QFR Group|Patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, NSTEMI (non ST-segment elevation myocardial infarction), or STEMI (ST-segment elevation myocardial infarction) with non-culprit stenosis who underwent FFR measurement and were able to analyze QFR.
62624805|NCT06198998|EXPERIMENTAL|CorVad Percutaneous Ventricular Assist System|Subjects with coronary artery disease receiving high-risk PCI will be supported by the CorVad Percutaneous Ventricular Assist System during the procedure.
62624806|NCT00501709|EXPERIMENTAL|Treatment|Allogenic pancreatic islet transplant using belatacept and raptiva
62624807|NCT03301077||General population|recruited from schools and other institutions like job-centers or child and adolescent psychiatries
62624808|NCT01526278|OTHER|Maxmarvil®|single-arm study
62624809|NCT03460626|PLACEBO_COMPARATOR|Group-I (Control group)|This group will be administered a placebo that is an odorless oil without any therapeutic effect)
62850716|NCT04321135|EXPERIMENTAL|Guided Lifestyle Program|The Intervention will be conducted in a cohort of 20 (anticipated) and is designed to increase self-efficacy, social support and perceived access to healthy eating and exercise resources and promote weight loss. Participants assigned to the Guided Lifestyle Program will participate in twice weekly sessions - the first weekly session will be 120 minutes in length with the first hour addressing lifestyle change education and strategies. The second hour will be supervised exercise including aerobics and resistance training. The second weekly session will be a one-hour supervised exercise session. Participants will also receive 2-3 text messages weekly.They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.The Guided Lifestyle program is four months long (16 weeks). Please note, the Guided Lifestyle program participants will be offered a booster session off-study.
62087946|NCT03597893|PLACEBO_COMPARATOR|Placebo|Placebo contains all ingredients except for the peptide in three puffs of 3.99 IU per 6.72mg nostril.
62087947|NCT05258396|EXPERIMENTAL|Patients with MS|Children with MS
62266714|NCT02305355|EXPERIMENTAL|Omega-3-acids ethylesters 90 4g, any statin|
62266715|NCT02305355|ACTIVE_COMPARATOR|any statin|
62266716|NCT06188156|ACTIVE_COMPARATOR|Thoracic Epidural Block(Group 1)|About 33 Patients will receive thoracic epidural block with an injection of a single shot of 15ml of 0.25% bupivacaine between T4 and T5 vertebrae.
62624810|NCT03460626|EXPERIMENTAL|Group-II (Treated group)|This group will be administered lavender oil.
62624811|NCT03460626|NO_INTERVENTION|Group-III (Untreated group)|No intervention will be provided in this group.
62624812|NCT03373760|EXPERIMENTAL|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes on day 1 for courses 1-4 and durvalumab IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62624813|NCT04237545|EXPERIMENTAL|T3 short implant|The short implants are available in lengths of 5mm and 6mm and in diameters of 5mm and 6mm. For study both configurations, T3 short without nano-scale Discrete Crystalline Deposition (non DCD- surface treatment) and T3 short with nano-scale Discrete Crystalline Deposition (with DCD- surface treatment), will be used.
62624814|NCT04237545|ACTIVE_COMPARATOR|T3 standard length|The T3 external hex implants available for this study will consist of lengths of 10mm, 11.5mm, 13mm, 15mm, 18mm and diameters of 4mm, 5mm, and 6mm. They have integrated platform switching (medialized implant/abutment junction). For study both configurations, T3 without nano-scale Discrete Crystalline Deposition (non DCD- surface treatment) and T3 with nano-scale Discrete Crystalline Deposition (with DCD- surface treatment), will be used.
62266717|NCT06188156|ACTIVE_COMPARATOR|Ultrasound Guided Sserratus Anterior Plane Block (Group 2)|About 33 Patients will receive Ultrasound Guided Sserratus Anterior Plane Block( SAPB) with an injection of 30 ml bupivacaine 0.25% .
62266718|NCT06188156|ACTIVE_COMPARATOR|Ultrasound Guided Pectoral Nerve Block (Group 3)|About 33 Patients will receive Ultrasound Guided Pectoral Nerve Block ( PECS II) with an injection of 20 ml bupivacaine 0.25% of pectoral-minor above the Serratus anterior muscle.
62266719|NCT05107856|EXPERIMENTAL|PRT1419 Monotherapy|PRT1419 will be administered by intravenous infusion once weekly on a 28-day treatment cycle at the dose level assigned.
62449811|NCT03403764|EXPERIMENTAL|Wellness Intention Transmission Groups|"Aim of this part of the study is to examine whether intention broadcasted from an Intention Host Device (a device which stores and transmits an intention) will affect self-compassion, general wellness, and awakening. 300 trial participants will be randomly allocated to 1/3 in control and 2/3 in the experimental IHD group, respectively. Differences in outcomes between control and experimental groups are expected.~To address potential bias, those who enter the study but drop out are compared to those who complete the study to gauge potential differences between the two groups, and will report on this potential bias in the published manuscript."
62624815|NCT03213392||SUPRA ORBITAL KEYHOLE CLIPPING/ COILING|Aneurysms should be either clipped or coiled to prevent re rupture general anesthesia is required to carry out these procedures.various anesthetic agents are used as an maintenance agents.
62449812|NCT03403764|NO_INTERVENTION|Independent Control Group|"Due to the global, emergent entanglement phenomenon, the investigators are curious if the investigators can test this idea within the context of the proposed study. The investigators added an additional but smaller control group which will complete the same three questionnaires for the first 6 months only and will be unaware of the larger study being conducted. These 50 subjects will be told they are completing the questionnaires in the context of a distinct, separate study and will be unaware of the Consciousness Field Project."
62449813|NCT04653220|OTHER|Control 1|Glucose 25g
62850717|NCT04321135|ACTIVE_COMPARATOR|Self-Guided Lifestyle Program|In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging. The study team will call these participants once a month to check in.
62850718|NCT03112083|ACTIVE_COMPARATOR|Krill oil|Krill powder capsules, 4 g
62850719|NCT03112083|PLACEBO_COMPARATOR|Placebo|Placebo capsules, maize strach, 4 g
62850720|NCT01028300|OTHER|ProDisc L|
62850721|NCT04709627||60 minute surgery|Patients completing at least 60 minutes of surgery
62062216|NCT03520465|EXPERIMENTAL|Supraaponeurotic mesh|"Patients with laparotomy closure by conventional approach of aponeurosis (continuous suture with monofilament of slow absorption), and posterior placement of supraaponeurotic mesh of polyvinylidene fluoride (PVDF) medium / low density and wide pore. The mesh has a longitudinal measurement that exceeds about 3 cm the upper and lower ends of the wound and width should not be less than 10 cm, therefore the mesh selected is DynaMesh®-CICAT longitudinal measure 10x35 cm.~The mesh is fixed to the aponeurosis with a crown of loose stitches and points to the midline. A prolene 2/0 non-reabsorbable monofilament suture of cylindrical needle is used.~A 10 Fr suction drainage is placed in the supraaponeurotic plane, with an exit to the exterior beyond the edges of the prosthesis. Drainage will be preserved for a minimum of 48 hours after surgery, and will be withdrawn when a debit of less than 50 ml is presented in 24 h."
62062217|NCT03520465|NO_INTERVENTION|Monofilament|Patients with conventional closure of the middle laparotomy with approach of aponeurosis in a plane by continuous suture with monofilament of slow absorption. In this study, the suture used in all patients will be poly-4-hydroxybutyrate or Mono-max loop®.
62850722|NCT03758300|EXPERIMENTAL|Radiofrequency group|In this group patients will receive in a sterile fashion continuous radiofrequency for 4 minutes to the 3 genicular nerves in the operative knee as well as Pulsed Radiofrequency at 42 degrees celsius, for 4 minutes (60-70 volts) to the saphenous nerve and the nerve to the Vastus Medialis, at the level of the adductor canal. The procedure is done under local anesthesia on an ambulatory basis. After the radiofrequency, Ropivacaine 0.5% 5 ml is injected to each one of the nerves, along with 5 milligrams of Methylprednisolone to each nerve. Once the procedure is completed (takes about 20 minutes), patients will be observed in the preoperative program facility for 30 minutes and then discharged home.
62850723|NCT03758300|SHAM_COMPARATOR|Control (Sham Radiofrequency) group|In this group patients will receive injections of the local anesthetic and steroids in the same anatomical locations, without activating the radiofrequency generator.
62850724|NCT01804738|NO_INTERVENTION|Glucose|Glucose anhydrous 50g dissolved in 250ml water
62062218|NCT03098940|EXPERIMENTAL|Chewing gum|Chewing gum with various doses of dronabinol
62062219|NCT03098940|ACTIVE_COMPARATOR|Capsule (Marinol)|Marinol is a product manufactured by AbbVie Capsule with various strengths of Marinol
62062220|NCT01861886|EXPERIMENTAL|ESS505|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
62449814|NCT04653220|OTHER|Control 2|Glucose 25g
62449815|NCT04653220|EXPERIMENTAL|Standard Crokao|Commercially available snack bar
62449816|NCT04653220|EXPERIMENTAL|Low sugar variant 1|Low sugar snack bar with sticky rice
62449817|NCT04653220|EXPERIMENTAL|Low sugar variant 2|Low sugar snack bar with promitor
62449818|NCT04653220|EXPERIMENTAL|Low sugar variant 3|Low sugar snack bar with inulin
62449819|NCT04653220|EXPERIMENTAL|Low sugar variant 4|Low sugar snack bar with yellow soy
62850725|NCT01804738|ACTIVE_COMPARATOR|Jasmine rice|50g available carbohydrate portion
62850726|NCT01804738|ACTIVE_COMPARATOR|Parboiled basmati rice|50g available carbohydrate portion
62449820|NCT04653220|EXPERIMENTAL|Low sugar variant 5|Low sugar snack bar with rice syrup
62449821|NCT05814081||Pressure Control Ventilation Supine Group|20 patients were ventilated in the supine position with pressure control mode.
62062221|NCT00100932|EXPERIMENTAL|1|E7389 28 day cycle
62062222|NCT00100932|EXPERIMENTAL|2|E7389 21 day cycle
62449822|NCT05814081||Pressure Control Ventilation Prone Group|20 patients were ventilated in the prone position with pressure control mode.
62449823|NCT05814081||Volume Control Ventilation Supine Group|20 patients were ventilated in the supine position with volume control mode.
62449824|NCT05814081||Volume Control Ventilation Prone Group|20 patients were ventilated in the prone position with volume control mode.
62449825|NCT02134522|EXPERIMENTAL|C-PAP intervention|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
62449826|NCT01943071|EXPERIMENTAL|Day care for patients with dementia|Day care for patients with dementia
62449827|NCT01943071|NO_INTERVENTION|Care as usual|Care as usual
62850727|NCT04204551|EXPERIMENTAL|PD-TR|"Intervention~exercise, dose: two cycles of 12-week HIIT program (three times a week) separated with 3 months break~\& conventional physical therapy"
62850728|NCT04204551|ACTIVE_COMPARATOR|PD-NTR|conventional physical therapy
62850729|NCT04204551|NO_INTERVENTION|Healthy Controls|healthy controls without any kind of therapy
62850730|NCT02942732|OTHER|normal-weight adult subjects|normal-weight adult subjects (n=30, age ≤ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
62062223|NCT03541044|EXPERIMENTAL|Test Product|Participants will receive a single Nicotine Prototype Mini lozenge (2mg) by oral/buccal route of administration.
62062224|NCT03541044|ACTIVE_COMPARATOR|Reference Product|Participants will receive a single Nicorette Mini lozenge (2 mg) by oral/buccal route of administration.
62062225|NCT00297115|ACTIVE_COMPARATOR|Roflumilast|500 mcg, once daily, oral administration in the morning
62449828|NCT05646680|OTHER|two step adnexectomy|Patients planned for unilateral or bilateral adnexectomy (removal of ovary and salpinx) will have their adnexectomy performed in two steps in the same surgical episode: first the salpingectomy (removal of the salpinx), then the oophorectomy (the removal of the ovary).
62449829|NCT04582266||Arm 1|Pregnant women hospitalized and receiving RDV for treatment of COVID-19.
62449830|NCT04582266||Arm 2|Non-pregnant women of childbearing potential hospitalized and receiving RDV for treatment of COVID-19.
62449831|NCT04566159|EXPERIMENTAL|CBI + CHW|2 Session Computer Delivered Intervention with use of Nicotine Replacement Therapy and Community Health Worker Follow Up
62449832|NCT04566159|OTHER|Routine Care|Routine Tobacco Cessation Advice to Stop Smoking and Nicotine Replacement Therapy as offered by the inpatient team
62449833|NCT05002907||General adult population living along the Maroni River in French Guiana and Suriname|General adult population living along the Maroni River in French Guiana and Suriname, upstream from Apatou. All adults (men and women) 18 years or older of both sexes will be able to participate in the study, in French Guiana and Suriname. Participation will be based on volunteering and signing informed consent. The acceptability and diversity of recruitment will be improved by seeking community support through community leaders and local associations and through appropriate communication (radio spots, posters in health centers and public establishments) before the survey .
62449834|NCT03363295|EXPERIMENTAL|Intracameral moxifloxacin|Injection of 0,03ml of moxifloxacin in the anterior chamber following phacoemulsification surgery
62449835|NCT03363295|NO_INTERVENTION|No - Intracameral moxifloxacin|This group won't receive any prophylaxis after phacoemulsification surgery
62449836|NCT04811768|EXPERIMENTAL|Bony wall group|In the bony wall group, following piezosurgery the retrieved bony wall was repositioned.
62449837|NCT04811768|EXPERIMENTAL|Collagen membrane group|In the collagen membrane group, the lateral window was created by rotary instruments, covered via a native collagen membrane (collprotect, botiss biomaterials GmbH, Zossen, Germany).
62449838|NCT00528281|EXPERIMENTAL|Lapatinib + pemetrexed|This is a single-arm, two-stage, multicenter Phase II study to determine the clinical activity of pemetrexed with lapatinib.
62449839|NCT06546813||Fifty patients in need of ICT prosthetic interventions|Persons with communication, mobility or cognitive disability
62449840|NCT01432171|EXPERIMENTAL|Arm I (lacosamide)|Participants receive lacosamide PO BID for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
62449841|NCT01432171|PLACEBO_COMPARATOR|Arm II (placebo)|Participants receive a placebo PO BID for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
62449842|NCT01428505|OTHER|no treatment|
62449843|NCT00952783||1|
62449844|NCT05050409|EXPERIMENTAL|Brief mindfulness followed by brief mindfulness for non-responders|1 session of brief mindfulness, plus standard of care. At the one-month post-surgical follow-up, non-responders will receive another single session of brief mindfulness. Responders will continue to receive standard of care.
62449845|NCT05050409|EXPERIMENTAL|Standard care followed by brief mindfulness for non-responders|Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. At the one-month post-surgical follow-up, non-responders will receive one session of brief mindfulness. Responders will continue to receive standard of care.
62449846|NCT05050409|EXPERIMENTAL|Brief mindfulness followed by MORE for non-responders|1 session of brief mindfulness, plus standard of care. At the one-month post-surgical follow-up, non-responders will receive the 8 session MORE intervention. Responders will continue to receive standard of care.
62449847|NCT05050409|EXPERIMENTAL|Standard care followed by MORE for non-responders|Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. At the one-month post-surgical follow-up, non-responders will receive the 8 session MORE intervention. Responders will continue to receive standard of care.
62449848|NCT06206395||Cancer patients receiving chemotherapeutic drugs|Cancer patients ≥ 18 years of age, and scheduled to receive chemotherapy will be included.
62449849|NCT03992196|EXPERIMENTAL|Rotigotine|Subjects will be initiated on 1 mg/24 h rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine, with the aim of achieving the individually optimized dosage. Dose adjustment of rotigotine is allowed at any time during the following Maintenance Period up to a maximum dose of 3 mg/24 h. At the end of the Maintenance Period, subjects will be down-titrated.
62449850|NCT06046027|EXPERIMENTAL|Accupressure Group|Patient in Accupressure Group applied an acupressure band (ACU-STRAPTM) on bilateral hands with a plastic bead at P6 acupoint, which is situated at the wrist between the tendons of the palmaris longus and flexor carpi radialis, 2 cun proximal from the distal palmar crease as shown in Figure 1, half an hour prior to surgery at the operation theatre reception
62449851|NCT06046027|PLACEBO_COMPARATOR|Placebo Group|Patients in Placebo Group will receive a standard elastic band without acuppresure bead, which will be applied to the patient's wrist.
62062226|NCT00297115|PLACEBO_COMPARATOR|Placebo|once daily
62062227|NCT02813356||naloxegol|patients exposed to naloxegol
62062228|NCT02813356||non-PAMORA|patients exposed to non-peripherally acting mu-opioid antagonist
62624816|NCT02372994|EXPERIMENTAL|Intervention Group|The randomization is at the level of attending healthcare professional who identifies patients for recruitment. For each participant in the intervention arm, a secure space (called a Patient Loop) is created in the online clinical communication system. A Patient Loop can be accessed by the patient, their caregiver, and the healthcare providers who have permission to do so through an algorithm of invitation, authentication and careful partitioning. In each Patient Loop, team members can post messages that can be read and responded to by the entire team. Each Patient Loop consists of a patient, their caregiver and at least two healthcare professionals.
62624817|NCT02372994|NO_INTERVENTION|Control Group|Participants receive usual care.
62624818|NCT02421783||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
62850731|NCT02942732|OTHER|overweight adult subjects|overweight adult subjects (n=30, age ≤ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
62850732|NCT02942732|OTHER|normal-weight elderly|normal-weight elderly (n=60, age ≥ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
62062229|NCT00722579|EXPERIMENTAL|A|The PRESILLION TM Coronary Stent is an L-605 cobalt chromium (CoCr) stent.
62062230|NCT02875275|NO_INTERVENTION|Glucose Solution only|Control drink containing 50 g carbohydrate
62062231|NCT02875275|ACTIVE_COMPARATOR|Glucose with grass jelly solution|Control drink plus 3.12 g grass jelly powder
62062232|NCT02875275|ACTIVE_COMPARATOR|Glucose with grass jelly (solid)|Control drink plus 3.12 g grass jelly powder in solid form
62062233|NCT02875275|NO_INTERVENTION|Porridge and juice only|Control breakfast containing 50 g carbohydrate.
62266720|NCT05107856|EXPERIMENTAL|PRT1419/Azacitidine Combination|PRT1419 will be administered by intravenous infusion once weekly on a 28-day treatment cycle at the dose level assigned and Azacitidine will be administered by intravenous or subcutaneous on Days 1 through 7 (or alternatively on Days 1 through 5, 8 and 9) of each 28-day treatment cycle.
62449852|NCT05159635|EXPERIMENTAL|Active Living programme and wearable technical aids|Active Living programme and wearable technical aids
62624819|NCT02421783||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group
62062234|NCT02875275|ACTIVE_COMPARATOR|Porridge and juice with coconut oil|Control breakfast, plus 25g coconut oil
62062235|NCT02875275|ACTIVE_COMPARATOR|Porridge and juice with coconut oil gel|Control breakfast, plus 25g coconut oil gel
62062236|NCT04433442||Moderate to Severe Plaque Psoriasis or Psoriatic Arthritis|Participants will receive risankizumab as prescribed by the physician in routine clinical practice.
62850733|NCT02942732|OTHER|overweight elderly|overweight elderly (n=60, age ≥ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
62266721|NCT05107856|EXPERIMENTAL|PRT1419/Venetoclax Combination|PRT1419 will be administered by intravenous infusion once weekly on a 28-day treatment cycle at the dose level assigned and Venetoclax will be administered orally after either a 3-day or 5-week ramp-up period to reach 400 mg daily administration, prior to commencing PRT1419 administration.
62266722|NCT06297668|ACTIVE_COMPARATOR|BGF MDI HFA|Budesonide/Glycoperronium/formoterol fumarate pressurised inhalation suspension 160/7.2/4.8 μg per actuation, hydroﬂuoroalkane with AeroChamber Plus Flow-Vu spacer-reference formulation
62449853|NCT05159635|ACTIVE_COMPARATOR|Wearable technical aids|Wearable technical aids
62624820|NCT02421783||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group
62624821|NCT05462236|EXPERIMENTAL|Module 1: Arm A: Multiple dose finding cohorts|Monotherapy with Tinodasertib administered orally QOD
62850734|NCT00961909|EXPERIMENTAL|1active|
62850735|NCT00961909|PLACEBO_COMPARATOR|1placebo|
62062237|NCT03968003|EXPERIMENTAL|Inulin|Group A (intervention group) will receive inulin 10 g.
62062238|NCT03968003|PLACEBO_COMPARATOR|Maltodextrin|Group B will receive placebo of isocaloric maltodextrin.
62062239|NCT03968003|ACTIVE_COMPARATOR|Dietary fiber|Group C will receive dietary fiber advice aimed to match the recommended fiber intake for age.
62062240|NCT06439641|OTHER|Patients with Inflammatory bowel diseases|patients with IBD
62266723|NCT06297668|ACTIVE_COMPARATOR|BGF MDI HFO with spacer|Budesonide/Glycoperronium/formoterol fumarate pressurised inhalation suspension 160/7.2/4.8 μg per actuation, hydrofluoroolefin with AeroChamber Plus Flow-Vu spacer-test formulation
62266724|NCT06297668|ACTIVE_COMPARATOR|BGF MDI HFO without spacer|Budesonide/Glycoperronium/formoterol fumarate pressurised inhalation suspension 160/7.2/4.8 μg per actuation, hydrofluoroolefin without AeroChamber Plus Flow-Vu spacer
62266725|NCT04842201|EXPERIMENTAL|CM326|subcutaneous injection
62266726|NCT04842201|PLACEBO_COMPARATOR|Placebo|subcutaneous injection
62266727|NCT00650910|EXPERIMENTAL|lapatinib + digoxin|All subjects received 0.5mg digoxin on Days 1 and 9 with daily dosing of 1500mg oral lapatinib starting on Day 2 and continuing through Day 9. Subjects could continue past Day 9 on daily oral lapatinib until Week 10 when they could transfer into a rollover study (EGF19060 or EGF111767).
62266728|NCT02463175|EXPERIMENTAL|Intervention group|Fluid management, boluses of 5ml/kg of plasmalyte, will follow a specific goal-directed fluid therapy (GDT) protocol guided by transesophageal doppler measurement
62449854|NCT05602922|ACTIVE_COMPARATOR|basic treatment+ swallowing rehabilitation treatment|Swallowing function training mainly includes indirect training, direct training, and compensatory techniques, once a day for 20 minutes each time. In addition, a low-frequency electric VitalStim swallowing therapy device (produced by Chattanooga, USA) was also used for electrical stimulation therapy. The treatment parameters were 700ms in width, two-way square wave, 0～25mA in amplitude, and 30～80Hz in fixed frequency. The A electrode of channel 1 is placed above the hyoid bone, and the B electrode is placed above the notch on the thyroid cartilage. The channel 2 electrode C and electrode D of the therapeutic apparatus are arranged vertically and equidistantly according to the electrode A and electrode B. After the electrodes are placed, turn on the power. The stimulation intensity is based on the maximum stimulation that the patient can tolerate. 1 time a day, 30min each time, a total of 4 weeks.
62449855|NCT05602922|EXPERIMENTAL|basic treatment+ swallowing rehabilitation treatment+ Liu-Zi-Jue|"On the basis of the control group, the Liu-Zi-Jue exercises were performed, including Xu, He, Hu, Si, Chui, Xi, 6 times each time, 5 times a week, each exercise for 30 minutes, and continuous treatment for 4 weeks."
62449856|NCT03551249|EXPERIMENTAL|Focused Ultrasound (FUS)|The ExAblate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing initial standard of care chemotherapy.
62449857|NCT02462824|EXPERIMENTAL|Home-based exercise intervention|PAD Participants randomized to the home-based exercise intervention will be asked to take part in walking exercise to determine whether a patient-centered home-based exercise program improves walking ability, mobility, pain, and social functioning.
62449858|NCT02462824|NO_INTERVENTION|Usual care group|PAD participants randomized to usual care will not receive any study interventions. Rather, they will receive usual care from their own physicians.
62449859|NCT05409677||1-month survivors; 1-month non-survivors|Depending on mortality within 1 month, the patients were divided into two groups named 1-month survivors and 1-month non-survivors.There was no intervention other than normal treatment
62449860|NCT01977092|EXPERIMENTAL|Motivational interviewing case management|MICM intervention combines aspects of motivational interviewing along with case management to influence HIV risk and recovery from alcohol and drug problems. Participants assigned to the MICM condition will be contacted to receive 3 individual sessions within the first 4 weeks of entering the study. Thereafter they will have contact with the MICM therapist monthly throughout the duration of their enrollment in the study (12 months).
62449861|NCT01977092|OTHER|Resource referrals|Respondents will receive SLH services as usual along with a list of resources that can be used to address a variety of problems.
62449862|NCT01171066|EXPERIMENTAL|Tasman CPAP|
62449863|NCT01096927|EXPERIMENTAL|Non operative Treatment group|Patients with Lower Abdominal and suspected Acute Appendicitis, treated non-operatively with 7 days antibiotic therapy (Amoxicillin and Clavulanic Acid)
62850736|NCT00961909|EXPERIMENTAL|2active|
62850737|NCT00961909|PLACEBO_COMPARATOR|2placebo|
62850738|NCT00381576|EXPERIMENTAL|A|12 weeks of resistance training
62850739|NCT05790278||Adults with Early Stage Cancer|
62850740|NCT05790278||Adults with Traumatic Brain Injury|
62850741|NCT05790278||Health Control Adults|
62850742|NCT05148195|EXPERIMENTAL|A: Solid tumor|Envofolimab（300mg，Q3W）+BD0801（2mg/kg，Q3W）
62266729|NCT02463175|EXPERIMENTAL|Control group|Fluid management, using boluses of 5ml/kg of plasmalyte, will follow the current standard of care guided by clinical judgment
62449864|NCT03967002|EXPERIMENTAL|Test group with corticotomy surgery|Orthodontic treatment and minimally invasive corticotomy surgery with piezoelectric device and surgical guide
62449865|NCT03967002|NO_INTERVENTION|Control group without corticotomy surgery|Standard orthodontic treatment without surgery
62449866|NCT05092490|EXPERIMENTAL|Combined serratus anterior plane block and transversus thoracis plane block|The study group will receive a combined plane block by a dedicated anesthesia team prior to their procedure. 20 mL of local anesthetic (0.25% bupivacaine) will be injected for the Serratus anterior plane block and another 20 mL of local anesthetic (0.25% bupivacaine) will be injected in transversus thoracis plane block
62850743|NCT05148195|EXPERIMENTAL|B: HCC|Envofolimab（300mg，Q3W）+BD0801（2mg/kg，Q3W）
62850744|NCT05148195|EXPERIMENTAL|D：NSCLC|Envofolimab（300mg，Q3W）+BD0801（2mg/kg，Q3W）+Docetaxel(75mg/m2，Q3W)
62850745|NCT05148195|EXPERIMENTAL|D：CRC|Envofolimab（200mg，Q2W）+BD0801（2mg/kg，Q2W）+FOLFIRI（Irinotecan 180 mg/m2，Leucovorin 400mg/m2，5-Fluorouridine 2400 mg/m2，Q2W）
62850746|NCT05090774|EXPERIMENTAL|Supervised Exercise Therapy (SET) Plus Balance Exercises|Intervention meetings surrounding supervised exercise therapy (SET) with the addition of the adapted Otago Exercise Program (OEP) will occur individually with participants in a 1:1 format once per week for 30 minutes over 8 weeks. Additionally, participants will be encouraged to practice exercises at home at least 2 additional days between intervention meetings using visual handouts (up to 7 times/week total, approximately 140 minutes/week).
62062241|NCT03305874||Study Group|Prospectively, inpatients undergoing percutaneous coronary intervention (PCI) will be consented, and the computer-based contrast induced nephropathy (CBCIN) risk score will be calculated and displayed to the operator, along with suggested standard CIN-avoidance strategies during the PCI. Following the PCI, serum creatinine will be measured as per treating physician, but those who undergo at least two consecutive daily serum creatinine measurements starting the day after the procedure will be included in the study. These patients will be called 6 months and 12 months post-procedure to determine mortality and re-hospitalization status.
62624822|NCT05462236|EXPERIMENTAL|Module1: Arm B/C: Multiple cohorts of Tinodasertib with fixed dose of pembrolizumab or irinotecan|Combination doses with Tinodasertib administered orally QOD with intravenous pembrolizumab at 200mg Q3W or Irinotecan at 180mg/m2 Q2W
62624823|NCT05462236|EXPERIMENTAL|Module 2: Arm B' and C': Dose Expansion|Combination therapy with Tinodasertib administered orally QOD at RP2D (as determined in Module 1) and either pembrolizumab at 200mg IV Q3W (arm B') or irinotecan 180mg/m2 IV Q2W (arm C')
62624824|NCT00571103|EXPERIMENTAL|1 Open Label|Open Label. At visit 2, all participants were started on Acamprosate, 1,998 mg divided into 3 equal doses.
62624825|NCT04255537||Patients with STEACS intended for urgent angio/reperfusion.|This population mostly includes STEACS patients for whom primary PCI is intended. A minority of this population includes patients with STEACS intended for urgent angiography for persistent ST elevation and/or symptoms but with symptoms onset \> 12 hours (secondary PCI), urgent angiography after failed fibrinolysis (rescue PCI), or patients receiving fibrinolysis.
62624826|NCT04255537||Patients with STEACS NOT intended for urgent angio/reperfusion|This population mostly includes STEACS patients not receiving reperfusion for late presentation (i.e. \> 12 hours) or patient preference. Note that patient in this category may receive diagnostic angiography for better diagnostic assessment and/or risk stratification but NOT on an urgent basis.
62624827|NCT04255537||Patients with NSTEACS intended for invasive management|This population includes patients with NSTEACS managed invasively with coronary angiography within 72 hours. Most patients are a high-risk feature (i.e. positive troponin, GRACE risk score \> 140, hemodynamic/electrical instability) for whom angiography is intended.
62624828|NCT04255537||Patients with NSTEACS NOT intended for invasive management|This population includes patients who are candidate for an initially conservative strategy. Note that this category may include patients who are subsequently managed with coronary angiography, including recurring symptoms of myocardial ischemia, or hemodynamic/ electrical instability.
62624829|NCT01212159|NO_INTERVENTION|No self monitoring device|Standard or usual care of high LDL including lab lipid profiles after treatment with statin therapy. No device or telemedicine education will be provided
62624830|NCT01212159|EXPERIMENTAL|Self Monitoring Lipid Analyzer|Self measured blood lipids using a home lipidometer, and telephone reporting of data to the clinical center.
62624831|NCT02097511|EXPERIMENTAL|Sarpogrelate pretreatment and Metoprolol|Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days and Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day
62624832|NCT02097511|ACTIVE_COMPARATOR|Sarpogrelate and Metoprolol|Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day
62624833|NCT02097511|ACTIVE_COMPARATOR|Metoprolol only|Metoprolol Tartrate 100 mg once a day
62624834|NCT03188783|EXPERIMENTAL|Cohort 1: GDC-0853 Low Dose|Japanese subjects will receive a single low dose of GDC-0853 or matching placebo by mouth.
62624835|NCT03188783|EXPERIMENTAL|Cohort 2: GDC-0853 Intermediate Dose|Japanese subjects will receive a single intermediate dose of GDC-0853 or matching placebo by mouth. Subsequently, participants will receive twice-daily intermediate doses of GDC-0853 or matching placebo by mouth for 4 days followed by a single intermediate dose of GDC-0853 or matching placebo by mouth.
62624836|NCT03188783|EXPERIMENTAL|Cohort 3: GDC-0853 Intermediate Dose|Caucasian subjects will receive a single intermediate dose of GDC-0853 or matching placebo by mouth. Subsequently, participants will receive twice-daily intermediate doses of GDC-0853 or matching placebo by mouth for 4 days followed by a single intermediate dose of GDC-0853 or matching placebo by mouth.
62624837|NCT03188783|EXPERIMENTAL|Cohort 4: GDC-0853 Low Dose|Japanese subjects will receive a single high dose of GDC-0853 or matching placebo by mouth.
62624838|NCT03750877|ACTIVE_COMPARATOR|median approach|Spinal anesthesia will be performed with a conventional median approach
62624839|NCT03750877|ACTIVE_COMPARATOR|paramedian approach|Spinal anesthesia will be applied with a paramedian approach.
62624840|NCT06149104|EXPERIMENTAL|sacubitril/valsartan|single arm, open label sacubitril/valsartan
62624841|NCT06404255||Medical students|Medical students from the University of Paris-Saclay, during hospital internships Stress assessement with or without a stress management training
62087948|NCT05258396|EXPERIMENTAL|Volunteers|matched in age and sex with patients. Volunteers will perform only one brain MRI, as requested by the neurologist
62449867|NCT05092490|ACTIVE_COMPARATOR|Stand local anesthetic infiltration|Local anesthetic infiltration of the incision sites will be performed by the cardiologist prior to, and as, necessary during the procedure. The amount of local anesthetic used will be determined intraoperatively by the cardiologist according to the patients' requirements.
62449868|NCT00984685||depression|Patients diagnosed with depression before April 15, 2009
62449869|NCT05059756|EXPERIMENTAL|Treatment group|PTNS and PFR (twice daily)
62449870|NCT05059756|EXPERIMENTAL|Control group|Sham PTNS and PFR (twice daily)
62624842|NCT00777335|EXPERIMENTAL|Panobinostat i.v.|
62624843|NCT00777335|EXPERIMENTAL|Panobinostat oral|
62624844|NCT02497937|EXPERIMENTAL|GSK2798745 and Placebo|Each subject will be randomized to receive GSK2798745 2.4 milligrams (mg) and Placebo once daily for 7 days, each in one of the two treatment periods. Two treatment periods will be separated by a 14-day washout period.
62624845|NCT02044003|EXPERIMENTAL|Post Angioplasty Dissection Repair|Implant of Innovasc Tack Intravascular Staple System (Tack) to repair post angioplasty dissections
62624846|NCT05187091|NO_INTERVENTION|Standard IMRT|Standard IMRT with radical CRT/RT
62624847|NCT05187091|EXPERIMENTAL|Swallowing Sparing IMRT|Standard IMRT with radical CRT/RT with additional sparing of dysphagia-aspiration related structures \& submandibular gland sparing by SWOAR-IMRT
62624848|NCT01084902|EXPERIMENTAL|latnoprost|once daily
62624849|NCT01084902|ACTIVE_COMPARATOR|Brinzolamide|two times daily
62850747|NCT05090774|NO_INTERVENTION|Supervised Exercise Therapy (SET) Only|Intervention meetings surrounding supervised exercise therapy (SET) will occur individually with participants in a 1:1 format once per week for 30 minutes over 8 weeks. Additionally, participants will be encouraged to practice exercises at home at least 2 additional days between intervention meetings using visual handouts (up to 7 times/week total, approximately 140 minutes/week).
62850748|NCT02237222||Gait rehabilitation|"Multi-modal therapy program including physiotherapy with the aim of gait improvement, Lokomat or treadmill training, strength training, sports therapy.~Frequency and intensity are individually assigned."
62850749|NCT06225479|ACTIVE_COMPARATOR|Control Arm|"Participants in this study arm will receive a remote health education program which consists of twice-monthly Successful Aging newsletters and phone calls to reinforce and discuss topics in each newsletter."
62850750|NCT06225479|EXPERIMENTAL|Exercise Arm|Participants in this study arm will receive an individualized 12-week exercise intervention plus a remote health education program.
62850751|NCT00834080|EXPERIMENTAL|Medisorb naltrexone 380 mg (VIVITROL)|
62850752|NCT05089786|EXPERIMENTAL|Exablate Neuro System Treatment|MR-Guided Focused Ultrasound with Echo-Focusing will be used to ablate a target area selected by the physician.
62850753|NCT04407949|OTHER|event detection|
62850754|NCT01537614|EXPERIMENTAL|COLIMYCINE injectable|
62850755|NCT01537614|EXPERIMENTAL|COLIMYCINE inhalation|
62266730|NCT04091633|ACTIVE_COMPARATOR|School Mental Health Program-Conventional (cSMHP)|The teachers of schools randomized to control arm will receive training in World Health Organization (WHO) School Mental Health Program (SMHP) by mental health experts at WHO collaborating center for mental health research and training, Institute of Psychiatry. The training of teachers will consist of a mix of both didactic and interactive training methodologies in the form of a workshop. The workshop will consist of lectures/presentations, incorporating group discussions/activities. Through didactic methods, teachers will be taught basic theoretical knowledge related to mental health in schools. Training will be followed by monthly supervision meeting of teachers for 9-months.
62449871|NCT00116935|ACTIVE_COMPARATOR|1|1 year of adjuvant imatinib mesylate 400 mg/day orally
62850756|NCT01760642|EXPERIMENTAL|Midazolam|"period 1: midazolam 1 mg IV single dose administration. period 2: midazolam 1 mg IV single dose after ketoconazole 400 mg oral dosing for 3 days.~period 3: midazolam 2.5 mg IV single dose after rifampicin 600 mg oral dosing for 10 days."
62850757|NCT02121613|EXPERIMENTAL|Permixon® 160 mg & Placebo|
62850758|NCT02121613|PLACEBO_COMPARATOR|Placebo|
62850759|NCT02121613|OTHER|Tamsulosine LP & Placebo|Active control arm
62449872|NCT00116935|EXPERIMENTAL|2|3 years of adjuvant imatinib mesylate 400 mg/day orally
62449873|NCT01136538|EXPERIMENTAL|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
62624850|NCT02388087|ACTIVE_COMPARATOR|ROX COUPLER|Iliac arterio-venous anastamosis created by insertion of ROX coupler device.
62624851|NCT02388087|SHAM_COMPARATOR|ROUTINE CARE|Right heart catheterisation and Routine care of Neurally mediated syncope.
62624852|NCT05400044|EXPERIMENTAL|bone marrow aspirate mixed with xenograft|
62624853|NCT05400044|ACTIVE_COMPARATOR|xenograft mixed with autografts only:|
62624854|NCT00921258||control group|Patient with latent prostate cancer who agree to be controled instead of to be treated
62624855|NCT00926341|NO_INTERVENTION|Active control|1. Active Control: (n=20), intervention: no intervention
62624856|NCT00926341|ACTIVE_COMPARATOR|PIO arm|PIO arm (n=30), Pioglitazone 30 mg/day, given for 24 weeks.
62624857|NCT00926341|ACTIVE_COMPARATOR|Telmi arm|Telmia arm (n=30): Tab. Telmisartan 40 mg/day given for 2 weeks.
62624858|NCT04047732|EXPERIMENTAL|Topical KB105|HSV1-TGM1 vector (KB105)
62850760|NCT05881070|EXPERIMENTAL|Mobile health self-management|
62850761|NCT02917564|SHAM_COMPARATOR|Control|"Patients placed in a semi supine position. A cotton-tipped applicator saturated with proparacaine 0.5% (Alcaine, Alcon Labs) is placed into the conjunctival fornix of the supero-temporal quadrant for 5 minutes following initial proparacaine drops.~After anaesthetic medication is placed, a 3 ml syringe will be placed into the superotemporal conjunctival fornix but no needle is present and no drug injected."
62850762|NCT02917564|ACTIVE_COMPARATOR|Injection|"Patients placed in a semi supine position. A cotton-tipped applicator saturated with proparacaine 0.5% (Alcaine, Alcon Labs) is placed into the conjunctival fornix of the supero-temporal quadrant for 5 minutes following initial proparacaine drops.~After anaesthetic medication is placed, 1mL of a 40 mg/ml suspension of triamcinolone acetonide is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down."
62850763|NCT06337019||Cohort observational|Overall study cohort
62850764|NCT00490529|EXPERIMENTAL|CpG-MCL Vaccine|An autologous anti-tumor vaccine.
62266731|NCT04091633|EXPERIMENTAL|Enhanced-School Mental Health Program (eSMHP)|The teachers of schools randomized to intervention arm will receive online training in adapted version of School Mental Health Program. The online training in adapted School Mental Health Program consists of 4-5 hour, self-paced online training course for teachers. The teachers will register themselves in the online course in the form of a group of 4-5 teachers from each school. The teachers will complete the online training course in a group, with interactive group activities and role plays. Progress to the next module in the online training is conditional upon completion of post-module mental health literacy quiz. A certificate of training completion in adapted SMHP shall be awarded to those teachers who complete the post-test. Teachers will be supported online and in-person by the trainers who are trained in SMHP in monthly supervision meeting of teachers for 9-months.
62449874|NCT01136538|ACTIVE_COMPARATOR|Valtrex (R)|Valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline
62850765|NCT02401425|ACTIVE_COMPARATOR|letrozole|Women will receive three tablets of letrozole(FemaraR, NOVARTIS) as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) for two days at home and will be told to bring back the empty packs. The third dose will be given on admission to hospital on day three and will be followed by 4 tablets of vaginal misoprostol (200 mcg) (MisotacR,SIGMA)soaked with saline every three hours up to maximum 2 doses.
62850766|NCT02401425|PLACEBO_COMPARATOR|placebo|Women will receive three tablets of placebo as a single dose, for two days at home and will be told to bring back the empty packs. The third dose will be given on admission to hospital on day three and will be followed by 4 tablets of vaginal misoprostol (200 mcg) (MisotacR,SIGMA)soaked with saline every three hours up to maximum 2 doses.
62850767|NCT05842356|NO_INTERVENTION|Communication Technique 1|A standard communication technique will be used in this group.
62266732|NCT06519786|EXPERIMENTAL|Metformin group|Patients will receive metformin immediate-release tablets orally for 24 weeks. Starting dose will be 500 mg once daily for all patients and the dose will be increased by 500 mg weekly until the goal dose is achieved (500 mg twice daily for patients \< 10 years of age, and 1000 mg twice daily for patients 10 years or older).
62266733|NCT06519786|NO_INTERVENTION|Other treatment group|Patients will receive supportive treatment as indicated
62266734|NCT01003496|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|
62266735|NCT01003496|EXPERIMENTAL|TAU + Long-Term Recovery Management (LTRM)|
62266736|NCT00119535|OTHER|Arm 1|
62266737|NCT04509778||SHARP|ShangHai At Risk for Psychosis
62266738|NCT04636619|EXPERIMENTAL|On-line training course|Each participant will receive the global data, the results obtained by all the endoscopists (anonymously except for each interested party, the rest being identified by codes), as well as a detailed analysis of their results, comparing them with the joint data and the 3 tertiles.
62266739|NCT03031301|ACTIVE_COMPARATOR|Vibrant capsule|Patients will receive the Vibrant capsule 5 times a week for 8 weeks of treatment
62266740|NCT03031301|SHAM_COMPARATOR|Sham capsule|Patients will receive the sham capsule (activated, non-vibrating) 5 times a week for 8 weeks of treatment
62266741|NCT04839380|EXPERIMENTAL|Treatment Group : Ruxolitinib|ruxolitinib cream 1.5% will be applied twice daily as a thin film.
62266742|NCT05054972||A|Group of patients in whom the left renal vein was divided for exposure of the aorta.
62266743|NCT05054972||A+|Subgroup of group A in whom a communicating vein to the left ascending lumbar vein was present.
62266744|NCT05054972||A-|Subgroup of group A in whom a communicating vein to the left ascending lumbar vein was not present.
62266745|NCT05054972||B|Group of patients in whom the left renal vein was mobilized but not divided for exposure of the aorta.
62449875|NCT06126081|EXPERIMENTAL|LBBP+GDMT group|Patients in the LBBP+GDMT group will receive LBBP using dual-chamber device as priority and guideline-directed medical therapy. The pacing lead will be implanted at the left bundle branch and whether LBB is captured will be judged during the procedure. For patients who LBBP is failed, CRTP using triple-chamber device or LVSP by using dual-chamber device will be an alternative option according to the co-determination after consultation between doctors and patients .
62449876|NCT06126081|ACTIVE_COMPARATOR|GDMT group|Patients in the GDMT group will receive guideline-directed medical therapy according to their complications, heart rate, blood pressure and so on. During follow-up of 6 months, patients may transfer to LBBP group if the LVEF decreased to \<35% and patients accepted the device implantation.
62449877|NCT01046123|EXPERIMENTAL|Whole brain radiotherapy|whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy
62624859|NCT04870632|SHAM_COMPARATOR|Control group|Patients in control group received the education booklet with words and pictures.
62850768|NCT05842356|EXPERIMENTAL|Communication Technique 2|A new communication technique will be used in this group.
62850769|NCT00012597|OTHER|Arm 1|
62850770|NCT05167006|EXPERIMENTAL|Group A:|Participants will be treated with routine physical therapy for 20 minutes, five days a week for 12th weeks. Each participant will receive his/her arms training therapy. Only one participant per therapist, with or without caregiver observation.
62850771|NCT05167006|ACTIVE_COMPARATOR|Group B|The participants will be treated with Perfetti's method and routine physical therapy for 35 minutes, five times a week for 12th weeks. Each participant will receive his/her arms training therapy.
62850772|NCT04119830|EXPERIMENTAL|Treatment (rintatolimod, pembrolizumab)|Patients receive rintatolimod IV over 30 minutes on days 1-3 and pembrolizumab IV over 30 minutes on day 3. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 4, patients receive rintatolimod IV over 30 minutes and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months from the first dose in the absence of disease progression or unacceptable toxicity.
62850773|NCT05202340||Prostate Cancer|Patients diagnosed with prostate cancer
62850774|NCT04375540|EXPERIMENTAL|Upper first premolars extraction|Included 24 patients (7 males,17 females) with a mean age of 21.56±3.19years who were treated with fixed orthodontic appliance for 2.22±0.31years.
62850775|NCT04375540|EXPERIMENTAL|Upper second premolars extraction|Included 26 patients (8 males,18 females) with a mean age of 22.16±3.59years who were treated with fixed orthodontic appliance for 2.25±0.30 years.
62624860|NCT04870632|EXPERIMENTAL|Video group|Patients in intervention group watched YOUTUBE videos to rehab and recorded the intensity after the exercise by RPE scores. During the intervention, a physical therapist would have weekly telephone calls or LINE calls for 6 times to monitor and modify the intensity of exercise.
62624861|NCT04870632|EXPERIMENTAL|Booklet group|Patients in intervention group read education booklet with words and pictures to rehab and recorded the intensity after the exercise by RPE scores. During the intervention, a physical therapist would have weekly telephone calls or LINE calls for 6 times to monitor and modify the intensity of exercise.
62624862|NCT00405015|EXPERIMENTAL|1|Placebo first
62624863|NCT00405015|EXPERIMENTAL|2|Rosiglitazone first
62624864|NCT05388656|EXPERIMENTAL|Estradiol, Then Placebo|Participants will first receive 0.1 mg/day of transdermal estradiol patch for 3 weeks. After a washout period of 3 weeks, participants will then receive transdermal placebo patch (matching transdermal estradiol 0.1 mg/day patch) for 3 weeks. Upon completion of the second intervention, all participants will receive 200 mg/day of progesterone for 10 days.
62624865|NCT05388656|EXPERIMENTAL|Placebo, Then Estradiol|Participants will first receive transdermal placebo patch (matching transdermal estradiol 0.1 mg/day patch) for 3 weeks. After a washout period of 3 weeks, participants will then receive 0.1 mg/day of transdermal estradiol patch for 3 weeks. Upon completion of the second intervention, all participants will receive 200 mg/day of progesterone for 10 days.
62624866|NCT01135043|EXPERIMENTAL|education|educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.
62624867|NCT01135043|PLACEBO_COMPARATOR|control|patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure.
62624868|NCT02927574||DCB|Treatment with Paclitaxel drug-coated balloon angioplasty (DCB)
62624869|NCT02927574||POBA|Treatment with plain old balloon angioplasty (POBA)
62624870|NCT02693457|ACTIVE_COMPARATOR|Drain|Intra-articular drain will be placed at closure of randomized knee for 24 hours
62624871|NCT02693457|EXPERIMENTAL|No Drain|No intra-articular will be placed in the contralateral knee of the same patient. A placebo drain will be placed so patient is unaware of which knee contains working drain.
62624872|NCT04037514|EXPERIMENTAL|Paracetamol|Intravenous paracetamol 15 mg/kg/6h for 3 or 6 days
62624873|NCT04037514|ACTIVE_COMPARATOR|Ibuprofen|Intravenous ibuprofen 10 mg/kg/24 h (day 1) and 5 mg/kg/24h (day 2 and 3) for 3 or 6 days
62624874|NCT02469168|EXPERIMENTAL|ReCell|Allocation of treatments (Recell vs Control) to the INTEGRA™ Meshed Bilayer Wound Matrix (MBWM). Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
62266746|NCT05965284|OTHER|Azathioprine treatment arm|Patients will be treated with Azathioprine 100mg per day for 12 months combined with prednisone no more than 10mg daily. The dosage of prednisone is tapered in the study period while sustained remission achieved. All included patients will be treated with TMPco 2 tablets per day during the study period if not contraindicated or intolerant.
62449878|NCT02203565|EXPERIMENTAL|Supportive care (Dakin's solution, radiation therapy)|Patients apply Dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks.
62449879|NCT05428852|ACTIVE_COMPARATOR|Standard of Care|Patients receive standard of care therapy with SRS and AICR Diet education.
62850776|NCT04375540|NO_INTERVENTION|No intervention|Included 26 subjects (10 males, 16 females) with a mean age of 20.45±3.29years.This group was included to observe any changes in the vertical gingival display over the 2 years' observation period (1.65±0.17 years).
62850777|NCT03701035|EXPERIMENTAL|Aerobic Training & UL Motor Training|Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if \< 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 \* weekly, 12 weeks
62449880|NCT05428852|EXPERIMENTAL|Standard of Care + Ketogenic Diet|(standard of care, ketogenic diet) Patients receive standard of care with SRS. Patients undergo a controlled feeding period ketogenic diet comprising of meals for the first week and then transition into a free living with guided support type of intervention.
62624875|NCT02469168|ACTIVE_COMPARATOR|Control|Allocation of treatments (Recell vs Control) to the INTEGRA™ Meshed Bilayer Wound Matrix (MBWM). Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
62624876|NCT04056312|EXPERIMENTAL|Group memory retraining|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
62624877|NCT04056312|PLACEBO_COMPARATOR|Placebo|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
62624878|NCT03904810|NO_INTERVENTION|Control|Subjects in this group do not received any intervention
62624879|NCT03904810|ACTIVE_COMPARATOR|Moderate Intensity Continuous Training ×3/wk|Subjects in this group will receive three sessions of Moderate-Intensity Continuous Training per week throughout the 8 weeks experimental period
62624880|NCT03904810|ACTIVE_COMPARATOR|High Intensity Interval Training×3/wk|Subjects in this group will receive three sessions of High-Intensity Interval Training per week throughout the 8 weeks experimental period
62850778|NCT03701035|ACTIVE_COMPARATOR|Non-aerobic Training & UL Motor Training|40 minutes non-aerobic gait \& balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 \* weekly, 12 weeks
62850779|NCT02933450|ACTIVE_COMPARATOR|Patiromer group|Patiromer 25.2 g dose
62850780|NCT02933450|NO_INTERVENTION|Standard of Care group|Standard of Care
62624881|NCT03904810|ACTIVE_COMPARATOR|High Intensity Interval Training×2/wk|Subjects in this group will receive two session of High-Intensity Interval Training per week throughout the 8 weeks experimental period
62062242|NCT03305874||Comparator Group|Retrospectively, inpatients who underwent PCI and had at least two consecutive daily serum creatinine measurements will be selected. These patients will then be matched to the prospective patients, and matched by age and gender. Baseline CBCIN score will be calculated and other demographic and outcomes information will be obtained from medical records review.
62624882|NCT03904810|ACTIVE_COMPARATOR|High Intensity Interval Training×1/wk|Subjects in this group will receive one session of High-Intensity Interval Training per week throughout the 8 weeks experimental period
62266747|NCT05965284|EXPERIMENTAL|Telitacicept treatment arm|Patients will be treated with Telitacicept 160mg per week combined with Azathioprine 100mg per day for 12 months combined with prednisone no more than 10mg daily. The dosage of prednisone is tapered in the study period while sustained remission achieved. All included patients will be treated with TMPco 2 tablets per day during the study period if not contraindicated or intolerant.
62266748|NCT04840160|PLACEBO_COMPARATOR|Placebo|Participants supplied with 30 ml of a low fruit (\<1%) cordial mixed with maltodextrin and protein diluted in 100 ml water twice daily, once in the morning and evening.
62624883|NCT01983826|EXPERIMENTAL|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
62624884|NCT01983826|PLACEBO_COMPARATOR|Placebo capsule|Microcrystalline cellulose (daily) for 8 weeks
62266749|NCT04840160|EXPERIMENTAL|Cherry juice|Participants supplied with 30 ml of a tart cherry juice concentrate (CherryActive, United Kingdom; (containing 36.8 mg of anthocyanins) diluted in 100 ml of water twice daily, once in the morning and evening.
62266750|NCT03629457|EXPERIMENTAL|Intervention group 4s (mindfulness)|Abbreviated program of 4 weeks: will consist of 4 weekly sessions of 2 hours. Participants must practice at home for 15 minutes a day
62624885|NCT01698268|EXPERIMENTAL|TAP Group|Enrolled subjects will receive a TAP block with 0.5cc/kg of 0.25% ropivacaine.
62449881|NCT00422656|EXPERIMENTAL|Perifosine|Patients receive oral perifosine (150 mg) daily each cycle. Cycle duration is 28 days. After cycle 2, response is assessed and patients with stable or responding disease can continue for another 4 cycles or until disease progression (PD). Protocol treatment duration is 6 cycles but patients may receive perifosine maintenance per investigator discretion in absence of PD.
62624886|NCT01698268|ACTIVE_COMPARATOR|Local Infiltration Group|Enrolled subjects will receive will receive local infiltration of 0.5 cc/kg of 0.25% ropivacaine.
62624887|NCT02878096|EXPERIMENTAL|[14C]-SK-1404|
62624888|NCT03175315|EXPERIMENTAL|FLASH|"Intervention: Conduct of the newly developed treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH).~FLASH consists of 4 lessons focusing on empowering patients to autonomously use flash glucose monitoring (FGM) in their daily routine. Patients learn to effectively interpret the different information provided by FGM in order to improve not only glycemic control but also to improve the implementation of insulin therapy in daily life. Psychological and motivational aspects of living with diabetes and handling of the FGM are addressed as well."
62624889|NCT03175315|NO_INTERVENTION|Waiting List|Diabetic patients using FGM receive treatment as usual until the last measurement point. After completion of the study, they are offered participation in the FLASH program.
62624890|NCT00672607|EXPERIMENTAL|1|
62850781|NCT01155128|EXPERIMENTAL|Lifestyle interventions|After recruitment of the participants and consented to participate those deemed eligible for inclusion completed baseline surveys will be randomly assigned to an intervention group and another control group that will receive the usual care
62850782|NCT01155128|PLACEBO_COMPARATOR|lifestyle interventions|After recruitment of the participants and consented to participate those deemed eligible for inclusion completed baseline surveys will be randomly assigned to an intervention group and another control group that will receive the usual care
62062243|NCT02024672||Immediate postpartum placement of IUD|Women who plan to have an IUD placed at the time of cesarean section or vaginal delivery, or women who have had an IUD placed at the time of cesarean section or vaginal delivery.
62266751|NCT03629457|EXPERIMENTAL|Intervention group 8s (mindfulness)|Program of 8 weeks: The format will be 8 weekly sessions of 2 hours. Participants must practice at home for 30 minutes a day
62266752|NCT03629457|NO_INTERVENTION|Control group|The participants will only receive a one-hour information session and will be invited to complete the questionnaires provided in two moments of the time (coinciding with the interventions in the experimental groups)
62266753|NCT01860924|ACTIVE_COMPARATOR|health education|health education control
62266754|NCT01860924|EXPERIMENTAL|exercise|vigorous supervised exercise
62266755|NCT02550886||Patient/Caregiver Dyad|
62624891|NCT00672607|PLACEBO_COMPARATOR|2|
62624892|NCT05456724|EXPERIMENTAL|A (TO-O-1001)|Drug: TO-O-1001 Dose level: 0.05% and 0.1% Dosage form: ophthalmic solution Route of administration: topical ocular
62624893|NCT05456724|PLACEBO_COMPARATOR|B (Placebo)|Dosage form: ophthalmic solution Route of administration: topical ocular
62624894|NCT01645956||Single group|
62624895|NCT00376532||ICD pacing or shock event|Subjects who experienced a device treatment, defined as a pacing event or a shock event
62624896|NCT00376532||No ICD pacing or shock event|Subjects who did not experience a treatment defined as a pacing event or a shock event
62624897|NCT05752747|EXPERIMENTAL|Cold Massage Group|Just before the application, it will be taken out of the cabinet and the area to be vaccinated will be massaged with rollers with back and forth movements.
62624898|NCT05752747|EXPERIMENTAL|ShotBlocker© Group|It is a small flexible drug-free plastic tool. It is a small, flat-shaped instrument with a short, blunt, skin-contact ridge on the bottom and a hole in the center to inject. It is placed on the skin before injection. The protrusions on the inside do not harm the skin.
62624899|NCT05752747|NO_INTERVENTION|Control Group|No intervention will be applied to the control group.
62624900|NCT05971264|EXPERIMENTAL|Single Arm|
62624901|NCT02096276||Exposure Group_Prospective|Pregnant women within the United States (US) who are exposed to Boostrix vaccine during pregnancy or within 28 days preceding conception and with known pregnancy outcomes. Reporting of exposed pregnancies is voluntary and prospective (i.e., registration to registry is done before the outcome of the pregnancy is known)
62266756|NCT04925609|OTHER|Phase 1|"Phase 1:~* To estimate the MTD/RP2D regimen of brigatinib monotherapy when administered in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors.~* To characterize the PK of brigatinib administered as monotherapy in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors.~Note that:~* If the MTD is not reached at the highest proposed test dose, no further dose-escalation will be performed.~* Pediatric PK data, compared to exposure in adults, and cumulative toxicity, will be taken into consideration to determine the RP2D regimen."
62266757|NCT04925609|OTHER|Phase 2|"Phase 2:~• B1, ALK+ IMT: To establish the activity (ORR by RECIST 1.1) of single agent brigatinib when administered to children with ALK+ IMT.~• B2, ALK+ ALCL: To establish the efficacy (EFS) of single agent brigatinib when administered to children with ALK+ ALCL for a duration of 2 years, without SCT in consolidation."
62062244|NCT04827433||Women having a persistent low-lying placenta with an IOD between 6 and 20 mm|Women having a persistent low-lying placenta with an IOD between 6 and 20 mm who will be offered a vaginal birth, considering 3 subgroups: 1) 6-10 mm; 2) 11-20mm; 3) \> 20 mm (resolution of previa or low-lying placenta)
62062245|NCT04827433||Women with normal located placenta|Women with a normally located placenta at the II trimester scan will represent the control group.
62062246|NCT02184780||GUSTO Neurocognitive Cohort|This study involves retrospective analysis of data from an existing cohort of 600 infants who were enrolled in the neurocognitve arm of the GUSTO study (Growing up in Singapore Towards Healthy Outcomes). GUSTO is a prospective observational cohort study done in Singapore, where subjects were followed up from in-utero up to 36 months of age and beyond. The infants have already undergone a rigorous battery of neurocognitive tests at 6, 18, 24 and 36 months of age and their detailed demographic and medical information are available.
62062247|NCT06319846|EXPERIMENTAL|Tirofiban group|Initial infusion of tirofiban 0.4μg/kg body weight/minute for 30 minutes (a maximum dose of 1mg) within 24 hours of symptom onset, followed by a continuous infusion of tirofiban 0.1μg/kg body weight/minute for 48 hours.
62062248|NCT06319846|PLACEBO_COMPARATOR|Placebo group|Initial infusion of saline placebo for 30 minutes within 24 hours of symptom onset, followed by a continuous infusion of placebo for 48 hours.
62062249|NCT02465996|OTHER|postprandial distress syndrome (PDS)|"FD patients fulfilled Rome III criteria were subclassified into postprandial distress syndrome (PDS) or epigastric pain syndrome (EPS).~pCLE examination was performed in PDS patients, and then those who were willing to receive Puyuanhewei to treat FD were given 4 pills three times a day for 4 weeks after pCLE examination."
62266758|NCT06430281||Participants|Chiropractors will administer manual therapies on a manikin utilizing three distinct levels of force (typical force, low force, high force), determined by the trial label on the scale. A sensor will gauge the magnitude of force applied.
62624902|NCT02096276||Exposure Group_Retrospective|Pregnant women within the United States (US) who are exposed to Boostrix vaccine during pregnancy or within 28 days preceding conception and with known pregnancy outcomes. Reporting of exposed pregnancies is voluntary and retrospective (i.e., pregnancy outcome is already known at the time of registration to Registry)
62062250|NCT02465996|OTHER|epigastric pain syndrome (EPS)|pCLE examination was performed in EPS patients, and then those who were willing to receive Puyuanhewei to treat FD were given 4 pills three times a day for 4 weeks after pCLE examination.
62087949|NCT03980405|EXPERIMENTAL|Group 1|Control Diet 6 weeks of Oral 5ASA (standard recommended dosing 60-75 mg/kg/day; minimum 2.5, maximum 4 grams/day)+ Low residue diet and 6 more weeks of Oral 5ASA+ Free diet
62266759|NCT01749943||EDSS Score 0-3.5|21 Subjects Total : 7 with normal to mildly limited walking
62266760|NCT01749943||EDSS Score 4.0-5.5|21 Subjects total: 7 subjects with moderately limited walking ability.
62266761|NCT01749943||EDSS Score 6.0-7.5|21 Subjects total: 7 subjects with severely limited walking ability
62624903|NCT06479408|OTHER|progressive muscle relaxation (PMR) and vestibular rehabilitation exercises|GROUP A will be treated by progressive muscle relaxation (PMR) technique as a mean of stress relaxation and vestibular rehabilitation exercises for postural stability through Swiss ball, BOSU ball, balance board etc.
62624904|NCT06479408|OTHER|virtual reality (VR)|GROUP B will follow virtual reality (VR) based intervention program where three dimensional-3D environments will be used reduce stress and improve balance.
62850783|NCT03745885|EXPERIMENTAL|0.15mg Supaglutide or placebo|0.15 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
62266762|NCT04248439|EXPERIMENTAL|RP-L102|RP-L102 is CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene
62266763|NCT04295161|ACTIVE_COMPARATOR|Reference|
62266764|NCT04295161|EXPERIMENTAL|Prototype 1|
62266765|NCT04295161|EXPERIMENTAL|Prototype 2|
62266766|NCT04295161|EXPERIMENTAL|Prototype 3|
62266767|NCT04295161|EXPERIMENTAL|Prototype 4 fasted|administered in fasted state
62624905|NCT05395156|EXPERIMENTAL|sham acupoint|Control group: (placebo group) will be consisted of twenty-five females diagnosed with premenstrual syndrome. They will receive TEAS on sham acupoint (the acupoint selection site was 1 inch away from the acupoint selection in the study group) daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles with average of 7 sessions per month for 3 months
62850784|NCT03745885|EXPERIMENTAL|0.375mg Supaglutide or placebo|0.375 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
62850785|NCT03745885|EXPERIMENTAL|0.75mg Supaglutide or placebo|0.75 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
62850786|NCT03745885|EXPERIMENTAL|1.5mg Supaglutide or placebo|1.5 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
62062251|NCT06625229||Consecutive patients|Consecutive patients aged 16 years and over, who had exhausted conservative treatment and subsequently underwent primary correction of hallux valgus (of any deformity severity) were included. Patients who underwent additional forefoot procedures eg. hammer toe corrections, distal metaphyseal metatarsal osteotomy, were included. Patients who had previously had hallux valgus surgery, or first ray degenerative joint disease were excluded.
62062252|NCT04354766||Convalescent patients diagnosed with COVID +|Five convalescent patients (minimum 12 days after the onset of symptoms), diagnosed COVID + on the temporary sampling platform that was set up at HCL at the start of the epidemic, which notably concerns symptomatic healthcare professionals for whom hospitalization does not was not necessary.
62062253|NCT04354766||Hospitalized convalescent patients diagnosed with COVID +|Five convalescent patients (minimum 12 days after the onset of symptoms), diagnosed COVID +, hospitalized in the infectious diseases department of the Croix-Rousse hospital living in the metropolitan area of Lyon, having presented hypoxaemic pneumonia requiring hospitalization.
62266768|NCT04295161|EXPERIMENTAL|Prototype 4 fed|Administered in fed state
62624906|NCT05395156|EXPERIMENTAL|Electroacupuncture|Study group: (Electroacupuncture group) will be consisted of twenty-five females diagnosed with premenstrual syndrome. They will receive TEAS on neurogenic acupoints daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles with average of 7 sessions per month for 3 months.
62624907|NCT02588586|EXPERIMENTAL|3BNC117 + ART Interruption|Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.
62624908|NCT04129294|EXPERIMENTAL|NS-089/NCNP-02|NS-089/NCNP-02
62624909|NCT02797977|EXPERIMENTAL|Standard-Dose Triplet Combination|SRA737 will be administered orally on Days 2, 3, 9, and 10 of each 21-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Gemcitabine will be administered intravenously on Days 1 and 8 of each 21-day cycle. Cisplatin will be administered on Day 1 of each 21-day cycle. Subjects can continue taking the study treatment if they are safely receiving clinical benefit and able to follow the requirements of the study.
62624910|NCT02797977|EXPERIMENTAL|Low-Dose Gemcitabine Combination|SRA737 will be administered orally on Days 2, 3, 9, 10, 16, and 17 of each 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle. Gemcitabine will be administered intravenously on Days 1, 8, and 15 of each 28-day cycle. Subjects can continue taking the study treatment if they are safely receiving clinical benefit and able to follow the requirements of the study.
62624911|NCT02320448|EXPERIMENTAL|PIPAC|"PIPAC with cisplatin (7.5mg/m2 in 150 ml saline) and doxorubicin (1.5mg/m2 in 50 ml saline) in patients with peritoneal metastases (PM) from any origin besides colorectal/appendiceal cancers in whom oxaliplatin (92mg/m2 in 150 ml dextrose) will be used.~The aerosolised chemotherapy will be nebulized at a flow of 0.5ml/min at a maximum pressure of 200 PSI during a standard laparoscopy with an intraabdominal pressure of 12mmHg. The CO2 will be evacuated 30 minutes after administration of chemotherapy and the patient is closed similar to a standard laparoscopy."
62624912|NCT05259319|EXPERIMENTAL|Atezolizumab + Tiragolumab + SBRT|"Atezolizumab + Tiragolumab (every 21 days during 24 months or until progression) + SBRT (treatment will be delivered on 5 days).~The combination of SBRT and Immunotherapies will be performed using to different schemes. For the 6 first inclusions the combination will use a sequential scheme. If the safety criteria are respected the following patients will be able to be treated by concomitant scheme."
62850787|NCT03745885|EXPERIMENTAL|3.0mg Supaglutide or placebo|3.0 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
62850788|NCT02736890|ACTIVE_COMPARATOR|Botulinum Toxin A|Each vial of botulin toxin (100U, BOTOX, Allergan) will be reconstituted with 4ml non-preserved saline solution (0.9%) as recommended by the manufacturer (concentration of 5 units Botulinum Toxin A/0.2ml). Each injection will be 0.2mL (BOTOX, 5 units), administered through a 25 gauge needle. The marked area will have subcutaneous injections, each separated by a radius of 1 cm, from the other injections into the marked area,(maximum of 80 injections, 400 Units).
62850789|NCT02736890|PLACEBO_COMPARATOR|Placebo|Placebo consists of 0.9% normal saline. Each injection will be 0.2mL, administered with a 25 gauge needle subcutaneously into the affected area. The marked area will have subcutaneous injections (maximum of 80) each separated from the surrounding ones by a radius of 1 cm.
62850790|NCT05460091|SHAM_COMPARATOR|Control Group|Control group - sham Ptech device(does not vibrate)
62062254|NCT00542048|EXPERIMENTAL|1|
62266769|NCT00811135|EXPERIMENTAL|1|
62266770|NCT02188875|EXPERIMENTAL|SMS Text Messages & Fitbit One|All study participants were provided a Fitbit One to facilitate self-monitoring of PA. Those who were randomly assigned to the intervention group were asked to indicate 3 preferred times of the day to receive text message prompts to do PA throughout the 6-week study period.
62266771|NCT02188875|ACTIVE_COMPARATOR|Fitbit One Only|An active control group was also provided the Fitbit One to facilitate self-monitoring of PA throughout the 6-week study period.
62266772|NCT02079571|EXPERIMENTAL|water+ Coconut water|forty subjects
62266773|NCT02079571|EXPERIMENTAL|ginger tea +water|
62449882|NCT01363037|EXPERIMENTAL|Dapivirine-Maraviroc Vaginal Ring|
62449883|NCT01363037|PLACEBO_COMPARATOR|Placebo Vaginal Ring|
62449884|NCT01363037|ACTIVE_COMPARATOR|Maraviroc Vaginal Ring|
62449885|NCT01363037|ACTIVE_COMPARATOR|Dapivirine Vaginal Ring|
62449886|NCT02745977|OTHER|Dairy Free Diet- guaiac + on dairy free diet|Dairy Free Diet x 3 weeks then stool guaiac positive
62449887|NCT02745977|OTHER|Guaiac negative on dairy free diet|on dairy free diet x 3 weeks, then stool guaiac negative
62449888|NCT06027840|EXPERIMENTAL|QUIT-C (Concurrent)|Treatment in this arm will emphasize concurrent cessation of cigarettes and e-cigarettes. All participants will receive 12-weeks of varenicline, weekly individual counseling, and access to cessation resources including a guided self-change booklet and links to free text-based support. Counseling and cessation resources will emphasize concurrent cessation.
62449889|NCT06027840|EXPERIMENTAL|QUIT-S (Sequential)|Treatment in this arm will focus on cessation of cigarettes followed sequentially by cessation of e-cigarettes. All participants will receive 12-weeks of varenicline, weekly individual counseling, and access to cessation resources including a guided self-change booklet and links to free text-based support. Counseling and cessation resources will emphasize sequential cessation.
62624913|NCT00308516|EXPERIMENTAL|Cohort A - Preoperative|"Each patient enrolled in the preoperative cohort received 5-fluorouracil (5-FU) 225 mg/m2 as a continuous infusion (IVCI) on days 1-42 through a portable infusion pump and central venous catheter. Bevacizumab 5 mg/kg was administered intravenously (IV) on days 1 and 15. Additionally these patients received radiation therapy to 50.4 Gy (1.8 Gy/day or 28 fractions) Monday through Friday during weeks 1-6.~At least 8 weeks after surgery, patients in cohort A began 4 months of chemotherapy and bevacizumab. This adjuvant treatment consisted of 5-FU 400 mg/m2 IV bolus over 2-4 minutes followed by 2400 mg/m2 IVCI over 46 hours, leucovorin 350 mg as a 2-hour infusion, oxaliplatin 85 mg/m2 IV (modified FOLFOX6) and bevacizumab 5 mg/kg IV all on days 1 and 15 of each cycle."
62624914|NCT00308516|EXPERIMENTAL|Cohort B - Combined Modality|"All patients enrolled in cohort B received 5-fluorouracil (5-FU) 225 mg/m2 IVCI on days 1-42. Bevacizumab was administered at 5 mg/kg IV on day 1 every 2 weeks. These patients also received radiation to 50.4 Gy (1.8 Gy/day or 28 fractions)Monday through Friday during weeks 1-6.~Six weeks after the completion of adjuvant 5-FU/radiation, patients began treatment with 5-FU 400 mg/m2 IV bolus over 2-4 minutes followed by 2400 mg/m2 IVCI over 46 hours, leucovorin 350 mg as a 2-hour infusion, oxaliplatin 85 mg/m2 IV (modified FOLFOX6) and bevacizumab 5 mg/kg IV all on days 1 and 15 of each cycle."
62624915|NCT02076347|EXPERIMENTAL|Office visit-based intervention|
62624916|NCT02076347|EXPERIMENTAL|Electronic message-based intervention|
62624917|NCT04067596|EXPERIMENTAL|epiphysiodesis|The procedure consists of sterilizing the growth cartilage of the various localizations (distal femur and proximal tibia).
62624918|NCT04141397||POG patients|Patients enrolled in POG who initiated WGTA between July 2014 and December 2017
62624919|NCT04141397||Usual care controls|Matched controls who received usual care and were diagnosed with metastatic cancer prior to December 2017
62624920|NCT05753735|ACTIVE_COMPARATOR|Standard perioperative antibiotics|The control group will be treated according to current standard perioperative antibiotic practice, and perioperative antibiotics will not exceed 24 hours postoperatively.
62624921|NCT05753735|EXPERIMENTAL|Extended antibiotic prophylaxis|The intervention group will receive an extended duration of current standard perioperative antibiotics, then converted to amoxicillin/clavulanic at discharge
62624922|NCT02957617|EXPERIMENTAL|BIIB074|BIIB074 orally twice daily
62062255|NCT01650519|ACTIVE_COMPARATOR|IV ibuprofen|Intravenous ibuprofen (800 mg) administered intravenously over 10 minutes at study hour 0 and again at study hour 4 (Ibuprofen arm) and a corresponding volume of normal saline (ketorolac arm) will be administered intravenously over no less than 15 seconds at the end of the arthroscopic procedure
62062256|NCT01650519|ACTIVE_COMPARATOR|IV ketorolac|A corresponding volume of normal saline (Ibuprofen arm) administered intravenously over 10 minutes at study hour 0 and again at study hour 4 and 30 mg ketorolac for patients \< 65 years of age (15 mg ketorolac for patients \> 65 years of age) (ketorolac arm) will be administered intravenously over no less than 15 seconds at the end of the arthroscopic procedure
62062257|NCT03421496|EXPERIMENTAL|CBD with Vigabatrin|Participants received up to 40 milligrams per kilogram per day (mg/kg/day) divided twice daily (BID) of CBD with food. Participants also received up to 150 mg/kg/day BID of vigabatrin with food.
62449890|NCT03269110||Mother and child(ren)|FACT 4 Child is the post-delivery follow-up of the offspring born to FACT mothers once these children are between the age of 4 - 6 years.
62624923|NCT03909737|EXPERIMENTAL|Azithromycin to pregnant women and azithromycin to infants|2 gram oral dose of Azithromycin to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus 20 mg/kg to 1 gram oral dose of azithromycin to infants at 6 and 14 week Expanded Programme on Immunization (EPI) visits
62624924|NCT03909737|EXPERIMENTAL|Azithromycin to pregnant women and placebo to infants|2 gram oral dose of Azithromycin to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus oral placebo to infants at 6 and 14 week EPI visits
62624925|NCT03909737|EXPERIMENTAL|Placebo to pregnant women and azithromycin to infants|Oral placebo to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus 20 mg/kg to 1 gram oral dose of azithromycin to infants at 6 and 14 week EPI visits
62624926|NCT03909737|PLACEBO_COMPARATOR|Placebo to pregnant women and placebo to infants|Placebo to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus oral placebo to infants at 6 and 14 week EPI visits
62624927|NCT03909737|EXPERIMENTAL|No intervention to pregnant women and azithromycin to infants|No intervention to pregnant women and 20 mg/kg to 1 gram oral dose of azithromycin to infants at 6 and 14 week EPI visits
62624928|NCT03909737|PLACEBO_COMPARATOR|No intervention to pregnant women and Placebo to infants|No intervention to pregnant women and placebo to infants at 6 and 14 week EPI visits
62624929|NCT03963921|EXPERIMENTAL|F4 patient population|A total of 2 doses are planned to be administered as single or repeated infusions in an ascending manner:
62624930|NCT03963921|EXPERIMENTAL|F3 patient population|A total of 2 doses are planned to be administered as single or repeated infusions in an ascending manner:
62850791|NCT05460091|ACTIVE_COMPARATOR|Test group|Test group - active Ptech device (High-Frequency Vibrational device)
62062258|NCT03421496|PLACEBO_COMPARATOR|Placebo with Vigabatrin|Participants received a matching placebo to CBD with food, and also received up to 150 mg/kg/day BID of vigabatrin with food.
62449891|NCT04059601||Patients with acute cholecystitis|All patients with acute cholecystitis are included in the study cohort during year 2019. MRCP and IOC will be performed to all patients whenever feasible.
62449892|NCT04725084||High Flow Nasal Cannula oxygen therapy treatment|Patients treated only by high flow nasal cannula oxygen therapy
62624931|NCT02447913|EXPERIMENTAL|Voucher|
62624932|NCT02447913|NO_INTERVENTION|Control|
62624933|NCT02105285|EXPERIMENTAL|OPC-1085EL ophthalmic solution|Once daily
62624934|NCT02105285|ACTIVE_COMPARATOR|Carteolol long-acting ophthalmic solution|Once daily
62449893|NCT04725084||Non-Invasive Ventilation treatment|Patients treated by non-invasive ventilation (combined or not with HFNC)
62850792|NCT00263185|EXPERIMENTAL|Active Treatment Group|"Patients with baseline 25OH vitamin D level of 10-19 ng/ml.~* Calcium carbonate 1000 mg/day~* Vitamin D 400 units daily.~* Vitamin 50,000 IU/wk x 16 weeks and then once a month for a total of 6 months.~Patients with baseline 25OH vitamin D level of 20-29 ng/ml.~* Calcium carbonate 1000 mg/day~* Vitamin D 400 units daily.~* Vitamin 50,000 IU/wk x 8 weeks and then once a month for a total of 6 months."
62062259|NCT02160171||Term neonates|Term neonates who are undergoing continuous video amplified Electroencephalogram (aEEG)/Electroencephalogram (EEG) monitoring for clinical purposes (e.g. because seizures were suspected, or the neonate is being treated with therapeutic hypothermia). EEGs will be analysed off line by 'Algorithm for Neonatal Seizure Recognition'
62062260|NCT06616844|NO_INTERVENTION|Standard of Care (SOC)|"Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~Wound bed debridement, if clinically indicated.~Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~Appropriate use of systemic antibiotics."
62062261|NCT06616844|EXPERIMENTAL|Standard of Care + Intervention|"SOC arm with the following modifications:~* Consecutive weekly application of PPECM for the 12-week study period.~* Subjects will receive no more than 12 applications of PPECM~Note: PPECM should be applied after standard wound cleansing and debridement procedures, prior to the application of primary wound dressing, in accordance with the IFU."
62062262|NCT02063100|EXPERIMENTAL|Shenyankangfu tablets and Losartan potassium 100mg|
62062263|NCT02063100|EXPERIMENTAL|Shenyankangfu tablets and Losartan potassium 50mg|
62624935|NCT04501055|EXPERIMENTAL|Perineal nerve block|Man receive the perineal nerve block before under the transperineal prostate biopsy
62062264|NCT02063100|EXPERIMENTAL|Losartan potassium 50mg|
62062265|NCT02063100|EXPERIMENTAL|Shenyankangfu tablets|
62062266|NCT02063100|EXPERIMENTAL|Losartan potassium 100mg|
62062267|NCT03347175|EXPERIMENTAL|Volume controlled ventilation|Intervention1: Ventilation with Volume controlled ventilation
62062268|NCT03347175|ACTIVE_COMPARATOR|Pressure controlled ventilation|Intervention2: Ventilation with Pressure controlled ventilation
62062269|NCT03347175|ACTIVE_COMPARATOR|CPAP mode|Intervention3: Ventilation with Continuous Positive Airway Pressure mode only
62062270|NCT06028035|EXPERIMENTAL|BB01 Supplement Bars|Subjects will consume two BB01 supplement bars daily for 21 days.
62266774|NCT01671852|ACTIVE_COMPARATOR|Nasonex|The intervention group will receive mometasone nasal sprays at the dosage outlined below for 8 weeks. For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks.
62266775|NCT01671852|PLACEBO_COMPARATOR|Saline|The placebo group will receive saline nasal sprays for 8 weeks.
62449894|NCT04725084||Continuous Positive Airway Pressure treatment|Patients treated by continuous positive airway pressure (combined or not with HFNC)
62449895|NCT05150236|EXPERIMENTAL|Combination 177Lu-PSMA-617, Ipilimumab & Nivolumab|177Lu-PSMA (7.5GBq) given every 6 weeks up to 6 cycles in combination with concurrent ipilimumab (3mg/kg Q6W x 4 doses) and nivolumab (1mg/kg Q3W x 8 doses) followed by nivolumab monotherapy (480mg Q4W up to 18 doses) or until disease progression or unacceptable toxicity.
62449896|NCT05150236|EXPERIMENTAL|177Lu-PSMA-617|177Lu-PSMA (7.5GBq) given every 6 weeks up to 6 cycles or until disease progression or unacceptable toxicity.
62449897|NCT01631864|EXPERIMENTAL|LCZ696|LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks
62449898|NCT01631864|ACTIVE_COMPARATOR|amlodipine|amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks
62449899|NCT00635778|EXPERIMENTAL|dalotuzumab 2.5/2.5 mg/kg|Participants received a loading dose of dalotuzumab 2.5 mg/kg administered by intravenous (IV) infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 2.5 mg/kg administered by IV infusion every two weeks for up to 18 months.
62624936|NCT04501055|ACTIVE_COMPARATOR|Periprostatic block|Man receive the periprostatic block before under the transperineal prostate biopsy
62624937|NCT06303206|EXPERIMENTAL|Home Blood Pressure Telemonitoring (HBPT) + Case Management (CM)|This group will be asked to follow home BP monitoring as per instructions. Results will be transmitted and telemonitored using an app, where case managers (designated pharmacists) will monitor BP values to provide counselling for medication adherence and behavioural support and review telemonitored BP summaries and adjust BP medications according to protocol. Case management teams will contact participants at baseline and every month until the end of the study, or more frequently if BP is uncontrolled.
62062271|NCT06433310|EXPERIMENTAL|Healthy|Participants will receive one bottle of L-Phenylalanine 500 mg Veg Capsule product on Day 0. All subjects will be asked to start taking the supplement on Day 1 continuing until Day 14. They will be asked to take 2x 500 mg capsules in the morning and 1x 500 mg capsule in the evening daily for 14 days.
62062272|NCT04707404||PEEK|Cranioplasty patients with PEEK.
62449900|NCT00635778|EXPERIMENTAL|dalotuzumab 5.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 5.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
62062273|NCT04707404||Titanium|Cranioplasty patients with titanium mesh.
62449901|NCT00635778|EXPERIMENTAL|dalotuzumab 10.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 10.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
62624938|NCT06303206|NO_INTERVENTION|Usual Care|This group will receive usual care by their primary care provider and provided with hypertension education materials similar to the intervention group. Participants will receive the same home BP monitor to encourage monitoring of home BP based on hypertension guideline recommendations. Home BP readings will tele-transmit via the app for study purposes, but not made available to the case managers or primary care providers, except if necessary for safety reasons, or at the discretion of the data safety monitoring physician.
62624939|NCT04585243|EXPERIMENTAL|Self-Sampling Kit|Participants will be mailed a Self-Sampling kit (Evalyn Brush) to collect samples for analysis for HPV/Cervical cancer screening.
62624940|NCT02595112|EXPERIMENTAL|Patient undergoing otorhinolaryngologic surgery|Staphylococcus aureus carriage is measured in the vestibulum nasi and posterior nasal cavity. Posterior nasal cavity is measured during endoscopic procedure.
62062274|NCT05086250|EXPERIMENTAL|Arm A: Ketamine Followed by Placebo|Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
62062275|NCT05086250|EXPERIMENTAL|Arm B: Placebo Followed by Ketamine|Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
62062276|NCT00787319||AMD|
62062277|NCT02584348|EXPERIMENTAL|Gastric Ultrasound|Preoperative qualitative ultrasound assessment of gastric contents will be performed
62062278|NCT02263001|EXPERIMENTAL|Auricular Acupuncture Plus Usual Care|Auricular acupuncture therapy for treatment of musculoskeletal pain, plus usual care therapy consisting of over-the-counter and prescribed pharmacotherapy.
62062279|NCT02263001|ACTIVE_COMPARATOR|Usual Care Only|Usual care therapy for treatment of musculoskeletal pain. Usual care therapy consists of over-the-counter and prescribed pharmacotherapy.
62062280|NCT01433523|PLACEBO_COMPARATOR|Placebo|
62449902|NCT00635778|EXPERIMENTAL|dalotuzumab 15.0/5.0mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
62449903|NCT00635778|EXPERIMENTAL|dalotuzumab 20.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 20.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
62449904|NCT00635778|EXPERIMENTAL|dalotuzumab 15.0/10.0 mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 10.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
62449905|NCT00635778|EXPERIMENTAL|dalotuzumab 15.0/15.0 mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 15.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
62449906|NCT00282256|EXPERIMENTAL|Tacrolimus MR|Participants continued to receive their stable twice daily dose of tacrolimus twice daily on Day 1 through Day 7 and on Day 8 were converted to tacrolimus modified release (MR) once-daily in the morning for 7 days on a 1:1 (mg:mg) basis for their total daily dose. Patients who completed the 2-week pharmacokinetic treatment period were eligible to continue receiving tacrolimus MR as part of the extension treatment period of the study. The extended treatment period began on Day 15 and consisted of a single dose of tacrolimus MR once every morning through the end of the study.
62449907|NCT01063530|EXPERIMENTAL|Diammine Silver Fluoride|Application fo diammine silver fluoride in cervical lesions
62449908|NCT01063530|PLACEBO_COMPARATOR|Distilled water|Application of distilled water in cervical lesions
62449909|NCT03713268||Healthy (ocular health) participants|"Adult subjects with normal, ocular health will be enrolled to evaluate and obtain multiple images from the microscope integrated optical coherence tomography system for reproducibility testing in humans, provide feedback to engineers, and verify that the system functions to produce high quality images of the desired areas of the eye after ex vivo development before surgical use.~Each healthy subject will be imaged by the MIOCT system. There will be no surgery or intervention on these healthy volunteer subjects. We anticipate that a portion of the volunteer subjects would have repeat imaging (e.g. for reproducibility testing)."
62449910|NCT03713268||Surgeons as research subjects|Duke Eye Center surgical trainees (residents and fellows), attending surgeons, and surgeons from other medical institutions will be enrolled as subjects as we will test their performance with and without microscope integrated optical coherence tomography and with and without advances in 4D MIOCT in model surgeries in the research wet lab to better understand the utility of specific aspects and of this next generation MIOCT as a whole for specific anterior segment and retinal surgical tasks.
62624941|NCT00940576|EXPERIMENTAL|mare´s milk|oral intake of of 250 ml mare´s milk
62624942|NCT00940576|PLACEBO_COMPARATOR|placebo drink|oral intake of of 250 ml placebo drink
62624943|NCT06553079||Surgeons Performing Shoulder Arthroscopy|This is the main group of interest and includes surgeons who regularly perform shoulder arthroscopy. They will be the primary respondents to the survey and will provide insights into the factors affecting their surgical satisfaction.
62062281|NCT01433523|EXPERIMENTAL|ALK HDM AIT 6 DU|
62062282|NCT01433523|EXPERIMENTAL|ALK HDM AIT 12 DU|
62062283|NCT05636462|EXPERIMENTAL|Global postural re-education|It consists of 27 patients who will receive conventional exercises and global postural re-education which will be divided in three components First in lying posture to stretch anterior muscles of neck for 15 min, second component in supine position and stretching posterior muscles for 15 min and final component is in standing position under a load of gravity for 5 min for 3 days a week .
62624944|NCT02149264|EXPERIMENTAL|Testosterone gel (FE 999303)|Subjects received at least one dose of testosterone gel (23 mg), which was further titrated, if needed (upto three doses \[69 mg\]), based on serum testosterone concentrations. Testosterone gel was delivered using an applicator to the contralateral shoulder/upper arm.
62624945|NCT04227405|NO_INTERVENTION|Control group|Control group of couples will receive no intervention
62062284|NCT05636462|ACTIVE_COMPARATOR|Conventional Physical therapy|It consists of 27 patients who will receive conventional therapy including stretching and strengthening exercises of neck for 3 days a week.
62062285|NCT05019274|EXPERIMENTAL|Culinary Medicine|Series of 6 virtual group Culinary Medicine sessions delivered monthly for 6 months
62624946|NCT04227405|EXPERIMENTAL|Intervention|Intervention group of couples received the intervention: case management (connection to community services), 20 hour pscycho-educational workshop on communication, conflict resolution, problem-solving, stress management, and financial management, booster session, and employment support services if needed
62624947|NCT03017196|EXPERIMENTAL|Intervention|Sites randomized to intervention will be expected to implement the My Life, My Healthcare Discussion Aid in their practice for at least a 6-month period.
62624948|NCT03017196|NO_INTERVENTION|Control|Sites randomized to control will not be expected to implement the My Life, My Healthcare Discussion Aid in practice. They will be expected to practice chronic care as usual.
62624949|NCT06076187||Group 1: Patients over 65 years of age who had undergone Roux-en-Y bariatric surgery|Group 1: Patients over 65 years of age who had undergone Roux-en-Y bariatric surgery
62624950|NCT06076187||Group 2: Patients over 65 years of age who had undergone sleeve gastrectomy surgery|Group 2: Patients over 65 years of age who had undergone sleeve gastrectomy surgery
62624951|NCT06076187||Group 3: Patients over 65 years of age without previous bariatric surgery|Group 3: Patients over 65 years of age without previous bariatric surgery
62624952|NCT00992017|EXPERIMENTAL|H1N1 vaccine|Pregnant women enrolled received two doses of H1N1 vaccine, administered 21 days apart.
62624953|NCT01610856|EXPERIMENTAL|PEG - 4 L|4 Litres PEG bowel preparation given the day prior to colonoscopy with a clear fluid diet
62624954|NCT01610856|ACTIVE_COMPARATOR|Split Dose PEG|4 Litres of Colyte given as two split doses of 2L each either the day before colonoscopy 8 hours apart in the case of an AM colonoscopy or in the case of an afternoon colonoscopy given 5PM the day before and 6:00AM the day of the colonoscopy
62624955|NCT00701792|ACTIVE_COMPARATOR|1|surgery : liver transplantation
62624956|NCT00701792|ACTIVE_COMPARATOR|2|standard care for liver disease
62624957|NCT02811991|ACTIVE_COMPARATOR|Experimental:Paracetamol Injection|325mg(32.5mL)or 500mg(50mL) iv q6h according to assignment
62624958|NCT02811991|PLACEBO_COMPARATOR|Placebo:Normal Saline Injcetion|32.5mLor 50mL iv q6h according to assignment.
62624959|NCT06490783||healthy elderly|The sample consists of healthy elderly volunteers who will wear noninvasive wearable devices (smartwatch and heart rate monitor band) to monitor physiological parameters and emotional states related to anxiety and stress.
62624960|NCT04322669|EXPERIMENTAL|Pidotimod|
62624961|NCT04322669|PLACEBO_COMPARATOR|Placebo|
62850793|NCT00263185|PLACEBO_COMPARATOR|Control Group|"Patients with baseline 25OH vitamin D level of 10-19 ng/ml.~* Calcium carbonate 1000 mg/day~* Vitamin D 400 units daily.~* Placebo once per week x 16 weeks and then once a month for a total of 6 months.~Patients with baseline 25OH vitamin D level of 20-29 ng/ml.~* Calcium carbonate 1000 mg/day~* Vitamin D 400 units daily.~* Placebo once per week x 8 weeks and then once a month for a total of 6 months."
62062286|NCT05019274|ACTIVE_COMPARATOR|Nutrition Education|Series of 6 standard of care nutrition visits delivered by clinic dieticians. These are a mix of individual and group sessions.
62062287|NCT02481492|EXPERIMENTAL|No flip technique|One group of boys will undergo a circumcision with no flip technique of Shang Ring Circumcision and receive regular follow-up to evaluate pain, operation associated adverse events, wound healing time. The Shang Ring will detach spontaneously without intervention, and the participants are asked to have a visit soon after ring detached. The last scheduled follow-up visit is at 90 days.
62062288|NCT02481492|EXPERIMENTAL|Flip technique|One group of boys will undergo a circumcision with flip technique of Shang Ring Circumcision and receive regular follow-up to evaluate pain, operation associated adverse events, wound healing time. The Shang Ring will be removed at 7 days, and the last scheduled follow-up visit is at 90 days.
62266776|NCT05213377|NO_INTERVENTION|Group C|"Patients undergoing total hip replacement surgery by anterior approach, with general anesthesia and continuous core body temperature measurement via nasopharyngeal thermic probe.~Patients recruited for surgery who will not receive the 30 minutes of preoperative warming through pulsed air thermal coverage."
62062289|NCT02281396|EXPERIMENTAL|2.5IU/ml in humans aged 10-20 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml in 20 humans aged 10-20 years old on day 0,3,7,14,28
62062290|NCT02281396|EXPERIMENTAL|2.5IU/ml in humans aged 21-60 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml in 20 humans aged 21-60 years old on day 0,3,7,14,28
62266777|NCT05213377|EXPERIMENTAL|Group W|"Patients undergoing total hip replacement surgery by anterior approach, with general anesthesia and continuous core body temperature measurement via nasopharyngeal thermic probe.~Patients recruited for surgery who will receive the 30 minutes of preoperative warming through pulsed air thermal coverage."
62624962|NCT04391179|EXPERIMENTAL|Dipyridamole 100 Milligram(mg)|100 milligrams (mg) by mouth (PO) four times a day (QID)
62624963|NCT04391179|PLACEBO_COMPARATOR|Placebo|Placebo given by mouth four times a day
62624964|NCT01306279||Cystic Fibrosis, infection|Cystic Fibrosis patients with an infective exacerbation
62624965|NCT05013502|EXPERIMENTAL|Empagliflozin 10mg PO daily for 12 weeks|Single arm trial
62624966|NCT00789685|EXPERIMENTAL|Interferon Beta|Interferon Beta
62624967|NCT06099925|EXPERIMENTAL|Hetrombopag|All the 48 patients will be given hetrombopag 5mg/day within 24 hours after chemotherapy
62624968|NCT01110577||Traveling cohort|Overweight patients with or without type 2 diabetes or pre-diabetes
62624969|NCT01869218||Pre-treatment tumor biopsies|Patients who meet eligibility criteria will undergo a fresh tumor biopsy and collection of research blood samples. Archived tumor specimens will also be obtained and analyzed. At the time of disease progression, fresh tumor biopsies and blood samples will be collected in patients who have evaluable pre-biopsy specimens and who are eligible to be screened for another study.
62624970|NCT05965765|EXPERIMENTAL|Total Knee Arthroplasty|Individuals who have previously undergone Unilateral total knee arthroplasty
62624971|NCT05965765|ACTIVE_COMPARATOR|Osteoarthritis without surgery|According to Kellgren-Lawrence, individuals diagnosed with osteoarthritis between II and IV
62850794|NCT00263185|OTHER|Observational Group|"Patients with a baseline Vitamin D level below 10 ng/ml.~* Calcium carbonate 1000 mg/day~* Vitamin D 400 units daily."
62266778|NCT01632514|ACTIVE_COMPARATOR|Vitamin D deficiency treatment|subjects with 25OHD \< 20 ng/mL that will receive 100,000U of cholecalciferol weekly for 4 weeks before surgery
62624972|NCT05965765|ACTIVE_COMPARATOR|Control Group|healthy individuals who have not had any knee problems in the last 6 months
62624973|NCT03243123|EXPERIMENTAL|Passive mobilization|Upper limb passive mobilization assisted with robotic device
62850795|NCT04316832|EXPERIMENTAL|Intervention/treatment|The mindfulness based cognitive training will be delivered in one session and will include short mindfulness exercises.
62850796|NCT04316832|PLACEBO_COMPARATOR|No intervention|Control exercise, participants will listen to the first chapter of the audiobook The Hobbit, JRR Tolkien.
62850797|NCT03137069|PLACEBO_COMPARATOR|Cohort 1: Placebo|Participants received matching placebo twice daily from Day 1 to 56.
62850798|NCT03137069|EXPERIMENTAL|Cohort 1: GDC-0853 200mg BID|Participants received GDC-0853 200mg twice daily from Day 1 to 56.
62850799|NCT03137069|PLACEBO_COMPARATOR|Cohort 2: Placebo|Participants received matching placebo up to twice daily from Day 1 to 56.
62850800|NCT03137069|EXPERIMENTAL|Cohort 2: GDC-0853 50mg QD|Participants received GDC-0853 50mg once daily from Day 1 to 56.
62850801|NCT03137069|EXPERIMENTAL|Cohort 2: GDC-0853 150mg QD|Participants received GDC-0853 150mg once daily from Day 1 to 56.
62850802|NCT03137069|EXPERIMENTAL|Cohort 2: GDC-0853 200mg BID|Participants received GDC-0853 200mg twice daily from Day 1 to 56.
62850803|NCT05998889|EXPERIMENTAL|Intervention group: GPE+GMI|Pain Education program based on Neuroscience of pain and the Fear-Avoidance model + Graded Pain Exposure Exercises + Graded Motor Imagery
62266779|NCT01632514|NO_INTERVENTION|Vitamin D deficiency observation|subjects with 25OHD \< 20 ng/mL that will not receive cholecalciferol before surgery
62266780|NCT01632514|NO_INTERVENTION|Vitamin D sufficiency|controls with 25OHD \>= 20 ng/mL that will not receive cholecalciferol before surgery
62449911|NCT03713268||Surgical patients|Adult and minor (\> 4 months of age) surgical patients will be enrolled to evaluate and obtain multiple images from the microscope integrated optical coherence tomography system during clinically indicated vitreoretinal and anterior segment surgical procedures.
62449912|NCT00309075|EXPERIMENTAL|Arm 1|
62449913|NCT05777538|EXPERIMENTAL|Foot exercise with hydrotherapy|Hydrotherapy will be performed by immersing the women's foot in a container filled with 3 liters water with a temperature of 30-32°C. The water level must cover the women's feet up to ankle. During the immersion the therapist will ask the women to perform exercise with legs being fully supported, then alternatively stretch and flex the ankle for 30 times. which will be followed by circling each foot at ankle in clock wise and anticlock wise direction, 30 times each. The duration of water immersion session will be (30 min) for 5 consecutive days
62449914|NCT05777538|ACTIVE_COMPARATOR|Foot exercise|The therapist will ask the women to perform exercise with legs being fully supported, then alternatively stretch and flex the ankle for 30 times. which will be followed by circling each foot at ankle in clock wise and anticlock wise direction, 30 times each
62449915|NCT03828045||Psoriatic Arthritis patients on Apremilast|Patients diagnosed with PsA (according to the CASPAR diagnosis criteria), naïve to biological treatments, who have - following the routine practice in their centers - initiated treatment with apremilast 6 months (±1 months) before their inclusion in the study, irrespective of treatment duration.
62449916|NCT05133895||Tocilizumab monotherapy|"Patients with a definite or possible diagnosis of CP at acute active stage were enrolled for this study. Clinical diagnostic criteria consist of: (1) imaging findings show perivascular soft tissue density mass surrounding thoracic aorta, abdominal aorta or iliac arteries; (2) histopathological findings show fibrous tissue with chronic inflammatory infiltrate comprised of lymphocytes, plasma cells and macrophages (Neutrophils and granulomas are rare). Patients who satisfied (1) but without histopathological examination were perceived as possible CP. Secondary forms of CP related to drugs, infections, malignancies, Erdheim-Chester disease or other autoimmune diseases were excluded.~Patients enrolled received intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months."
62449917|NCT05750628|EXPERIMENTAL|Cohort A1: Dose Level 1 INE963|Cohort A1: Dose Level 1 INE963
62449918|NCT05750628|EXPERIMENTAL|Cohort A1: Dose Level 2 INE963|Cohort A1: Dose Level 2 INE963
62449919|NCT05750628|EXPERIMENTAL|Cohort A1: Dose Level 3 INE963|Cohort A1: Dose Level 3 INE963
62449920|NCT05750628|EXPERIMENTAL|Cohort B1: KAE609 + INE963|Cohort B1: KAE609 + INE963
62449921|NCT05750628|ACTIVE_COMPARATOR|Cohort B1: SoC (Coartem)|Cohort B1: SoC (Coartem)
62449922|NCT05750628|EXPERIMENTAL|Cohort B2: KAE609 + KLU156|Cohort B2: KAE609 + KLU156
62624974|NCT06017895|EXPERIMENTAL|doxepin solution|Patients received a doxepin solution spray to the posterior pharyngeal wall 10 minutes before eating. At least 12 hours later, when the swallowing-induced pain score ≥4, a placebo spray was administered to the posterior pharyngeal wall 10 minutes before eating.
62624975|NCT06017895|PLACEBO_COMPARATOR|placebo|Patients received a placebo spray to the posterior pharyngeal wall 10 minutes before eating. At least 12 hours later, when the swallowing-induced pain score ≥4, a doxepin solution spray was administered to the posterior pharyngeal wall 10 minutes before eating.
62850804|NCT05998889|ACTIVE_COMPARATOR|Control group: GMI|Graded Motor Imagery
62850805|NCT03223168|EXPERIMENTAL|Hayek RTX ventilator|Participants will receive noninvasive negative pressure ventilation.
62850806|NCT01944852|EXPERIMENTAL|2 icodextrin bags/day|2 icodextrin bags + 1 glucose per day
62850807|NCT01944852|ACTIVE_COMPARATOR|1 icodextrin bag/day|1 icodextrin bag + 2 glucose bags per day
62850808|NCT04799808||BioNTech cohort|The BioNTech cohort is composed of 1000 study participants who will be protected from SARS-CoV-2 infection by comirnaty vaccine from BioNTech. The study participants consist of mildly immunocompromised dialysis patients, severely immunocompromised solid organ transplant recipients, and the staff caring for them in the nephrology dispensaries.
62266781|NCT01677806|EXPERIMENTAL|Percutaneous vertebroplasty|
62266782|NCT01677806|ACTIVE_COMPARATOR|Conservative therapy|
62624976|NCT06433843|OTHER|cPTSD patients participating in 12-weeks DBT-PTSD program|The study consists of one arm including cPTSD patients, who participated in a 12-weeks dialectical behavioral therapy for the treatment of posttraumatic stress disorder (DBT-PTSD)
62624977|NCT02870556|EXPERIMENTAL|EP, Cervical epidural group|patients undergoing salvage laryngectomy (failed radiotherapy to treat laryngeal cancer) will receive cervical epidural analgesia in addition to the standard general anesthesia (induction with propofol 2 mg / kg, endotracheal intubation facilitated by cis-atracurium 0.3 mg / kg and 0.15 mg /kg on demand and maintained with inhalational anesthetic sevoflurane) Cervical epidural technique: epidural needle will be inserted at C 6-C7 or C7-T1 under fluoroscopy in prone position, 6 ml of 0.125% bupivacaine and fentanyl 2 mic/ ml will be administered before skin incision followed by 4 ml of the same injectate, will be infused continously for 2 days
62624978|NCT02870556|ACTIVE_COMPARATOR|GA, General anesthesia|patients undergoing salvage laryngectomy (failed radiotherapy to treat laryngeal cancer) will receive standard general anesthesia only (induction with propofol 2 mg / kg, endotracheal intubation facilitated by cis-atracurium 0.3 mg / kg and 0.15 mg /kg on demand and maintained with inhalational anesthetic sevoflurane) in addition to postoperative analgesia through patient controlled intravenous morphine analgesia (PCA), that involve 1 mg continuous infusion and 2 mg boluses with lockout interval 10 min
62624979|NCT00700128|EXPERIMENTAL|Group 2|Frovatriptan or placebo given in a certain sequence depending on what group that the woman are randomized to.
62624980|NCT00700128|EXPERIMENTAL|Group1|Group I will receive in a different sequence either frovatriptan 2.5 mg or placebo bid starting the last day of taking OC and continuing during the hormone free interval (HFI) of 4 days.
62624981|NCT02456025|ACTIVE_COMPARATOR|Topical tacrolimus|20 eyes with active Vernal Keratoconjunctivitis
62624982|NCT02456025|PLACEBO_COMPARATOR|Placebo|20 eyes with active Vernal Keratoconjunctivitis
62624983|NCT04116008|ACTIVE_COMPARATOR|Erector Spinae Block|Ultrasound-guided bilateral Erector spinae plane block performed at end of the surgery with 40 ml of a bupivacaine/prilocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
62624984|NCT04116008|ACTIVE_COMPARATOR|Subcostal Abdominis Plane Block|Ultrasound-guided bilateral STAP block performed at end of the surgery with 40 ml of a bupivacaine/prilocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
62624985|NCT02677597|EXPERIMENTAL|Cisplatin Combined With S-1|Cisplatin 75mg/m2 ivgtt d1 S-1 BSA\<1.5 50mg bid，BSA≥1.5 60mg bid po d1-14
62624986|NCT02677597|EXPERIMENTAL|Cisplatin Combined With Paclitaxel|Cisplatin 75mg/m2 ivgtt d1 Paclitaxel 175mg/m2 d1 ivgtt 3h
62624987|NCT04108741|EXPERIMENTAL|treadmill training with augmented reality dual tasking|
62624988|NCT04108741|EXPERIMENTAL|treadmill training with random number generation dual tasking|
62624989|NCT04108741|ACTIVE_COMPARATOR|treadmill training|
62652881|NCT06014645|EXPERIMENTAL|Intervention Group|This program will include reeducation isometric contraction exercises for transversus obdominus, oblique abdominals, multifidus lumborum muscles and strengthening stretching exercises for other extremities. These interventions will be sent to the patients via telerehabitation method and the patients will always have access to the programs and training.
62652882|NCT06014645|ACTIVE_COMPARATOR|Control Group|The control group will receive post-operative exercise training and will be encouraged to move as described by Moseley et al., 2004.
62652883|NCT01770964|OTHER|Training Type A, pregabalin|Subjects randomized to receive pregabalin at a site that received training Type A
62062291|NCT02281396|ACTIVE_COMPARATOR|2.5IU/ml in humans(from 10-20 years old)|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml in 20 humans aged 10-20 years old on day 0,3,7,14,28
62449923|NCT05750628|ACTIVE_COMPARATOR|Cohort B2: SoC (Coartem)|Cohort B2: SoC (Coartem)
62449924|NCT03849599|EXPERIMENTAL|PRV-300|Subjects in this arm will receive the study drug, PRV-300, via IV infusion, followed by an 8-week follow-up period.
62449925|NCT03849599|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive placebo via IV infusion, followed by an 8-week follow-up period.
62449926|NCT04094870|ACTIVE_COMPARATOR|Antidepressant medication|Daily self-administered selective serotonin reuptake inhibitor (SSRI) Sertraline 25 mg table
62449927|NCT04094870|ACTIVE_COMPARATOR|Interpersonal therapy|Up to 11 planned therapy sessions over a 24-week period beginning the day of randomization
62449928|NCT00814099|ACTIVE_COMPARATOR|1|Participants will receive care at a pediatric ICU that is continuing the usual approach to sedation management.
62449929|NCT00814099|EXPERIMENTAL|2|Participants will receive care at a pediatric ICU that is implementing the team approach to sedation management.
62449930|NCT01575678|ACTIVE_COMPARATOR|Melatonin|
62449931|NCT01575678|PLACEBO_COMPARATOR|Lactose|
62449932|NCT03312062|EXPERIMENTAL|Foam Rolling Group|The participants in this group will receive foam rolling exercise.
62449933|NCT03312062|NO_INTERVENTION|Control Group|The participants in this group will receive no foam rolling. They will only be evaluated.
62449934|NCT03821220|ACTIVE_COMPARATOR|Group A|Patients will receive an activity tracker and written information for pre-diabetic, on top of their usual care.
62449935|NCT03821220|ACTIVE_COMPARATOR|Group B|Patients will receive an activity tracker, written information for pre-diabetic, and personalized physical activity prescription, on top of their usual care.
62449936|NCT03821220|ACTIVE_COMPARATOR|Group C|Patients will receive an activity tracker, written information for pre-diabetic, personalized physical activity prescription, three sessions of motivational interview support from trained physician assistants, and two session of dietitian support, on top of their usual care.
62624990|NCT05088681||Peripheral neuropathies patients|"Peripheral neuropathies patients will be assessed at baseline, after a 20 session 2-3/w program of physical therapy and at a follow up of 3 months with:~* Total Neuropathy Score-clinical version (TNSc©)~* Nerve conduction studies~* Short Form Health Survey 36 (SF-36)~* Functional Independence Measure (FIM)~* postural evaluation recording during three different postural tasks (quiet standing, voluntary sway and shoulder flexion):centre of pressure (COP) displacement of force platform; surface muscle activation using electromyography (EMG) of 13 muscle on the right side of the body (tibialis anterior, soleus,gastrocnemius lateralis-medialis, biceps femoris, semitendinosus, rectus femoris, vastus lateralis and medialis, tensor fasciae latae, lumbar and thoracic erector spinae and rectus abdominis)~* Six Minute Walking Test (6MWT), Mini Balance Evaluation System Test (MiniBESTest) and Timed Up and Go test (TUG)."
62624991|NCT05088681||Healthy age-matched subjects|"Healthy age-matched subjects will receive a postural evaluation recording during three different postural tasks (quiet standing, voluntary sway and shoulder flexion):~* centre of pressure (COP) displacement of force platform;~* surface muscle activation using electromyography (EMG) of 13 muscle on the right side of the body (tibialis anterior, soleus,gastrocnemius lateralis-medialis, biceps femoris, semitendinosus, rectus femoris, vastus lateralis and medialis, tensor fasciae latae, lumbar and thoracic erector spinae and rectus abdominis)."
62624992|NCT00171158|EXPERIMENTAL|Imatinib Mesylate (STI571)|Participants initially received STI571 capsules or tablets, orally, initially once daily (400 mg) or (600 mg). The dosage was escalated from 400 mg to 600 mg and from 600 mg to 800 mg, on an individual basis as per the investigator's judgement. Treatment continued until death, or the development of intolerable toxicity, or the participant was considered not to benefit from treatment, whichever came first.
62624993|NCT00531947|EXPERIMENTAL|EMSAM|Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg
62624994|NCT00531947|PLACEBO_COMPARATOR|Placebo|Placebo Selegiline Transdermal System 6, 9 or 12
62624995|NCT04316260|EXPERIMENTAL|Smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking and 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit.
62624996|NCT04316260|ACTIVE_COMPARATOR|Treatment As Usual|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
62624997|NCT05013632||Exposed pregnant women|Pregnant or recently pregnant women 18 years of age and older treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 at any time during pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.
62624998|NCT05013632||Active comparator pregnant women|Pregnant women treated with another therapy for mild, moderate, or severe COVID-19
62624999|NCT05013632||Unexposed pregnant women|Pregnant women hospitalized but not treated with a medication specifically indicated for the treatment of mild, moderate, or severe COVID-19
62625000|NCT03821246|EXPERIMENTAL|Cohort A (atezolizumab)|Patients receive one (1) cycle of atezolizumab, 1200mg intravenously (IV) over 30-60 minutes on day 1 of a 14 day cycle. Radical Prostatectomy (RP) will occur 21 days (+/- 7 days) following the final dose of atezolizumab. No further study therapy will be administered following RP.
62625001|NCT03821246|EXPERIMENTAL|Cohort B (atezolizumab, etrumadenant)|Patients will receive one (1) cycle of atezolizumab, 1200mg intravenously (IV) over 30-60 minutes on day 1 of a 14 day cycle and etrumadenant will be taken at a dose of 150mg PO, once daily, until 48 hours prior to RP, for at least 12 days. Radical Prostatectomy (RP) will occur 21 days (+/- 7 days) following the final dose of atezolizumab. No further study therapy will be administered following RP.
62625002|NCT03821246|EXPERIMENTAL|Cohort C (atezolizumab, tocilizumab)|Patients will receive one (1) cycle of neoadjuvant atezolizumab and one (1) cycle of tocilizumab, 6mg/kg will be administered IV on day 1 of a 14 day IV prior to RP; atezolizumab will be administered in an identical fashion as Cohort A. RP will occur 21 days (+/- 7 days) following the final dose of atezolizumab. No further study therapy will be administered following RP.
62625003|NCT03914274|NO_INTERVENTION|"Thermometer FTN Medisana, precision 0.18º C),"|"Temperatures were taken with an infrared thermometer FTN Medisana, precision 0.18º C.~The temperature will be taken into account to see if it will vary according to the socket used as the temperature is a favoring element of dermic injuries on the feet."
62625004|NCT03914274|NO_INTERVENTION|Non-elastic tape measure|"Perimeter was measured with a flexible, non-elastic tape measure Lawton 18-0160, precision 1 mm.~The measurement of the feet perimeters will be taken into account to see if it will vary according to the socket used and related to injuries in the feet."
62625005|NCT03914274|NO_INTERVENTION|Bascule|"Weight was measured using scales (Tanita UM-076, precision 0.1kg). The scale is used to control the weight of the participants in order to find out their body mass index since the weight can influence the appearance of lesions on the feet."
62266783|NCT03739632|EXPERIMENTAL|10 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 10mg/day Study,5mg tablet is to be given orally, twice daily, for 6 weeks
62266784|NCT03739632|EXPERIMENTAL|20 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 20mg/day Study,10mg tablet is to be given orally, twice daily, for 6 weeks
62266785|NCT03739632|EXPERIMENTAL|40 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 40mg/day Study,20mg tablet is to be given orally, twice daily, for 6 weeks
62266786|NCT03739632|PLACEBO_COMPARATOR|comparator|Placebo tablets is to be given orally, twice daily, for 6 weeks
62266787|NCT04643951||Dental students|Dental students in their two final years. No intervention.
62266788|NCT04643951||Dental professionals|Dental professionals aged 18-65, regularly working with children. No intervention.
62266789|NCT03398577|EXPERIMENTAL|Intervention group|Eligible patients (HbA1C ≥ 7% and ≤ 9%) , who were allocated to the Intervention group will receive Dapagliflozin 10 mg in addition to oral anti-diabetic medication administered prior to study enrollment.
62625006|NCT03914274|NO_INTERVENTION|Altimeter|"Height was measured using the weight rod of different scales SECA 704, precision 1 mm) The altimeter is used to measure the participants in order to find out their body mass index."
62625007|NCT03914274|EXPERIMENTAL|Socks|"Socks were of two types: technical socks, designed for high performance sports use Lurbel brand, models Tierra and Set, and non-technical socks for everyday use. The socks had different composition: Tierra:50% regeneractiv, 25% cool-teak, 17% polyamide ions, 8% lycra; Set:75% cotton, 17% polyamide, 8% lycra and cotton: 98% cotton, 2% elastane.~Different socks were given to the participants to see if the different compositions influenced the appearance of injuries in a short route route and little difficulty"
62625008|NCT03914274|NO_INTERVENTION|"Geographical Position System Garmin ETREX 20"|"The height range and the pace hikers were controlled with a Garmin ETREX 20X Geographical Position System"
62625009|NCT02764476|EXPERIMENTAL|Virtual Reality Therapy|Eight 30 minute sessions of embodied virtual reality therapy with use of a body transfer experience into an egocentric perspective avatar that encourages motor activity and desensitization to emotional cues.
62625010|NCT02764476|ACTIVE_COMPARATOR|Control|Eight 30 minute sessions of virtual reality therapy.
62625011|NCT05415436|NO_INTERVENTION|Group A- propofol given at FDA approved administration speed|
62625012|NCT05415436|EXPERIMENTAL|Group B- propofol given over 120 seconds|
62625013|NCT00825838|EXPERIMENTAL|1|Oral ingestion of 6mg chili pepper extract
62625014|NCT00825838|PLACEBO_COMPARATOR|2|Oral ingestion of 0 mg chili pepper extract (matching placebo)
62625015|NCT02787122|ACTIVE_COMPARATOR|CBT-E|"Emotion-focussed Cognitive behavior therapy:~Patients receive 25 sessions of individual emotion-focused Cognitive Behavior Therapy. Interventions are behavioral activation, training of emotion regulation strategies, improvement of self-esteem and relapse prevention."
62625016|NCT02787122|PLACEBO_COMPARATOR|Treatment as Usual|Patients who are randomized and assigned to the Wait list are required to wait for half a year, while they receive standardized care (antipsychotic medication). After half a year, they receive CBT-E, as well.
62850809|NCT04799808||Moderna cohort|The Moderna cohort is composed of 1000 study participants who will be protected from SARS-CoV-2 infection by Moderna Biotech vaccine. The study participants consist of mildly immunocompromised dialysis patients, severely immunocompromised kidney transplant recipients, and the staff caring for them in the nephrology dispensaries.
62625017|NCT03223012||Participants not included in the AbbVie care program|Participants receiving adalimumab not included in the AbbVie care patient support program.
62625018|NCT03223012||Participants included in the AbbVie care program|Participants receiving adalimumab included in the AbbVie care patient support program.
62625019|NCT05183347|EXPERIMENTAL|SRD: Dose Group 1|SRD: single-rising dose
62850810|NCT02398006|ACTIVE_COMPARATOR|Group 1: a standard arm sling|Group 1: the orthopaedic surgeon will apply a standard arm sling that will be used for four weeks; however, during these weeks, participants will be encouraged to discard the sling when their pain has subsided. After four weeks the same orientations of group 1 will be done to this group.
62850811|NCT02398006|ACTIVE_COMPARATOR|Group 2: a figure-of-eight bandage|Group 2: a figure-of-eight bandage will be used for four weeks, and every week the participants will return to check and adjust the immobilisation. In this way, the dominant hand can remain free and simple activities will be allowed (writing, keyboarding and other). After four weeks, participants will be encouraged to discard the bandage, but load bearing will not be allowed before osseous consolidation (around 10 weeks).
62850812|NCT04581707||Kyphoplasty Single Balloon Catheter Allevo|
62850813|NCT04581707||Quattroplasty Double Balloon Catheter Stop'n GO|
62850814|NCT06523829|ACTIVE_COMPARATOR|Group given video-based training|"The application of the study to the active group;~* In addition to routine nursing care in the ward, video and education booklet were used. Video education was given to the patient and caregiver individually in the patient room. Watching the video takes 12 minutes.~* Video-based education was given in the preoperative period, on the 2nd-3rd postoperative day and at the discharge stage."
62850815|NCT06523829|NO_INTERVENTION|GROUP RECEIVING ROUTINE NURSING CARE|The application of the study to the control group; The patient was informed about the process before and after the surgery by the physician and the nurse working in the ward that day. The patient's pre-operative, surgical preparation, post-operative and discharge periods were carried out by different nurses due to work schedules. The patients were prepared by the nurse working in the ward that day on the day of surgery and sent to the operating room. After the surgery, the patients were given patient care in the ward and their follow-up and treatments were performed. During the discharge period, discharge information was given and discharge procedures were carried out.
62850816|NCT04816968|EXPERIMENTAL|Arm A - Cefepime|Continuous infusion of Cefepime at home.
62850817|NCT04816968|EXPERIMENTAL|Arm B - Piperacillin/tazobactam|Continuous infusion of Piperacillin/tazobactam at home.
62062292|NCT02281396|ACTIVE_COMPARATOR|2.5IU/ml in humans(from 21-60 years old)|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml in 20 humans aged 21-60 years old on day 0,3,7,14,28
62062293|NCT01153269||HIV-infected patients with hepatitis co-infection|HIV-infected patients with co-infections of Hepatitis B or Hepatitis C
62625020|NCT05183347|EXPERIMENTAL|SRD: Dose Group 2|SRD: single-rising dose
62625021|NCT05183347|EXPERIMENTAL|SRD: Dose Group 3|SRD: single-rising dose
62625022|NCT05183347|EXPERIMENTAL|MD: Dose Group 4|MD: multiple doses
62625023|NCT05183347|PLACEBO_COMPARATOR|Placebo|
62625024|NCT04912479|NO_INTERVENTION|control|Patients will be given a plan to reduce progressively their dosage of Benzodiazepin every 2 weeks. Over a 6-month period they will receive a phone call from the hospital twice a month to reinforce their motivation.
62087950|NCT03980405|EXPERIMENTAL|Group 2|6 weeks of Oral 5ASA (standard recommended dosing 60-75 mg/kg/day; minimum 2.5, maximum 4 grams/day)+ UC diet and 6 more weeks of Oral 5ASA+ UC diet stage 2
62625025|NCT04912479|EXPERIMENTAL|intervention group|In addition to the progressive withdrawal of BZD, patients will be given a connected watch that provide them with information on their sleep quality and their performed activities. They will also receive a check-up phone call twice a month over a 6-month period.
62625026|NCT02963636|EXPERIMENTAL|Pharmacist clinical intervention|Patients exposed to the pharmacist intervention
62625027|NCT05703334|EXPERIMENTAL|Kinesio tap|group (A) mean age (21.03+3.6 years), and mean BMI values (27.6+.9 kg/m2 Group(A) 30 subjects were treated by kinesio tap therapy 2sessions per week.
62062294|NCT04788953|EXPERIMENTAL|Solriamfetol (Sunosi)|"Participants will start at 75 mg and take that dose for 3 consecutive days. Participants will take their first 75mg dose on an early morning work day and take the next two 75 mg doses upon awakening regardless of their work schedule.~They will then move to 150mg on the next early morning work day and for all subsequent early morning shift work days. The drug/placebo will be taken orally within 30 minutes after awakening, before the start of each early morning shift. Prior to the end of study of visit (Visit 5), drug will be taken at home within 30 minutes of awakening."
62266790|NCT03398577|PLACEBO_COMPARATOR|Control group|Eligible patients (HbA1C ≥ 7% and ≤ 9%) , who were allocated to the Control group will receive placebo in addition to oral anti-diabetic medication administered prior to study enrollment.
62850818|NCT04816968|EXPERIMENTAL|Arm C - Meropenem|Continuous infusion of meropenem at home.
62850819|NCT04816968|EXPERIMENTAL|Arm D - Vancomycin|Continuous infusion of vancomycin at home.
62850820|NCT05783557|EXPERIMENTAL|Experimental Group|Experimental Group
62266791|NCT03361397|ACTIVE_COMPARATOR|Lidocaine nebulization|Inhalation of 10 mL nebulized lidocaine hydrochloride via mask nebulizer 5 min before laryngeal mask insertion.
62266792|NCT03361397|PLACEBO_COMPARATOR|Distilled water nebulization|Inhalation of 10 mL of nebulized distilled water solution via mask nebulizer 5 min before laryngeal mask insertion in the preoperative period.
62850821|NCT05783557|ACTIVE_COMPARATOR|Active-compared Group|Active-compared Group
62850822|NCT05805618|EXPERIMENTAL|KH002|at low dose,150 mg(Cohort 1 ), 20 subjects are dosed Vaccine as experimental at high dose,300mg (Cohort 2), 20 subjects are dosed Vaccine as experimental
62850823|NCT05805618|PLACEBO_COMPARATOR|matching placebo|at low dose,150 mg(Cohort 1 ), 10 subjects are dosed placebo at high dose, 300mg(Cohort 2),10 subjects are dosed placebo
62266793|NCT04990466|EXPERIMENTAL|Active Vaccine|IIBR-100 (VSV-ΔG) vaccine at 10 to the 8th strength in prime/boost separated by 28 days
62850824|NCT03479333|EXPERIMENTAL|Short implant|
62850825|NCT03479333|ACTIVE_COMPARATOR|standard implant with sinus lift|
62850826|NCT03535246|EXPERIMENTAL|Single arm|EIE cells to treat cancer.
62062295|NCT04788953|PLACEBO_COMPARATOR|Control|Participants randomized into the Control arm will receive a placebo
62087951|NCT02061761|EXPERIMENTAL|Part A - relatlimab (Dose escalation)|
62850827|NCT05518318|EXPERIMENTAL|GLS-010|GLS-010 therapy
62850828|NCT05518318|ACTIVE_COMPARATOR|chemotherapy|chemotherapy
62850829|NCT04561726|EXPERIMENTAL|Study Group|"All of the 20 participants in the study group were asked to do the given 11 home exercises (balance, stretching and strengthening exercises) twice a week for 6 weeks. The exercises were progressed day by day. All of the exercises were taught in the first assessment day, after the all measurements collected. All participants were controlled every week by social media and face-to-face conversations.~Additionally, CTM was applied to the volunteers in study group for 6 weeks, 2 sessions in a week.CTM applied to lumbosacral area (basic region), lower toracal, scapular, interscapular and cervical regions, respectively."
62850830|NCT04561726|ACTIVE_COMPARATOR|Exercise Group|All of the 20 participants in the exercise group were asked to do the given 11 home exercises (balance, stretching and strengthening exercises) twice a week for 6 weeks. The exercises were progressed day by day. All of the exercises were taught in the first assessment day, after the all measurements collected. All participants were controlled every week by social media and face-to-face conversations.
62850831|NCT03753789|EXPERIMENTAL|Microwave Ablation|NEUWAVE Microwave Ablation System with AC software for patients undergoing a percutaneous ablation of a soft tissue liver lesion by an interventional radiologist.
62850832|NCT04565743|ACTIVE_COMPARATOR|Intervention|Multiprofessional education for health professionals in primary care on secondary prevention of osteoporotic fractures. Identification and referral of patients with recent osteoporotic fracture.
62850833|NCT04565743|NO_INTERVENTION|Control|No intervention from study. No restrictions regarding education or the local organization of care for the prevention of osteoporotic fractures.
62266794|NCT04990466|ACTIVE_COMPARATOR|Active Comparator|A currently approved vaccine for COVID-19 administered in prime/boost separated by 28 days
62266795|NCT03002155|EXPERIMENTAL|Exercise|EnhanceFitness exercise class, 1 hour, 3 times a week, duration of 12 weeks.
62266796|NCT03002155|NO_INTERVENTION|Control|Usual care.
62266797|NCT06078969|EXPERIMENTAL|Oral prednisone|Oral prednisone, 0.5mg/kg/day, first 5 days/month, 6months
62266798|NCT06078969|NO_INTERVENTION|Regular observation|Regular observation and follow up without medication
62266799|NCT02007174||Bevacizumab injection|Three subconjunctival intralesional injections of bevacizumab. Bevacizumab injections were 2.5 mg/0.05 ml, subconjunctivally applied near to the pterygium recurrence. Application of bevacizumab was performed three times: basal, 2 and 4 weeks.
62850834|NCT04276909|EXPERIMENTAL|Lum Imaging System|Single dose of LUM015 (1.0 mg/kg) will be administered by intravenous injection at the beginning of the surgery. All subjects will have intraoperative imaging using the LUM Imaging Device
62850835|NCT02889367|EXPERIMENTAL|Treatment A|Participants will receive odalasvir 100 milligram (mg) or odalasvir matching placebo once on Day 1.
62850836|NCT02889367|EXPERIMENTAL|Treatment B|Participants will receive odalasvir 500 mg or odalasvir matching placebo once on Day 1.
62850837|NCT02889367|EXPERIMENTAL|Treatment C|Participants will receive odalasvir (dose to be determined based on pharmacokinetic data from treatment A and B but no more than 1000 mg) or odalasvir matching placebo once on Day 1.
62850838|NCT01876004|EXPERIMENTAL|Methotrexate|Administered a single intramuscular dose of 50 mg/m2 of Methotrexate.
62850839|NCT01876004|PLACEBO_COMPARATOR|Placebo|Prescribed Placebo intramuscularly.
62850840|NCT02055638|EXPERIMENTAL|SRX246|SRX246 capsules, 120mg bid for 4 weeks followed by 160mg bid for 4 weeks
62850841|NCT02055638|PLACEBO_COMPARATOR|Placebo|Placebo capsules to match the amount of SRX246 capsules for 8 weeks
62850842|NCT06144099|ACTIVE_COMPARATOR|fresh frozen plasma|according to the Thromboelastography (TEG) test, CK r-time prolongation, fresh frozen plasma transfusion (FFP) is performed
62850843|NCT06144099|EXPERIMENTAL|prothrombin complex concentrate|according to the Thromboelastography (TEG) test, CK r-time prolongation,prothrombin complex concentrate (PCC) administration
62850844|NCT02215980|EXPERIMENTAL|A|"* Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21.~* Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days until progression or intolerance."
62850845|NCT02215980|EXPERIMENTAL|B|"* Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21~* Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days, for a total of 9 cycles.~Maintenance until progression or intolerance:~- Lenalidomide: 10 mg/daily on days 1-21 of each 28-day cycle"
62850846|NCT03480724|ACTIVE_COMPARATOR|Google Cardboard VRA|This group of subjects will receive VRA intervention using Google Cardboard Virtual reality head- mounted display powered by a iPod touch.
62850847|NCT03480724|ACTIVE_COMPARATOR|Oculus Rift VRA|This group of subjects will receive VRA with Oculus Rift
62850848|NCT03480724|NO_INTERVENTION|Control|This group of subjects will receive no intervention beyond standard sedation, anesthetic, and/or restraint-this group will serve as the control group
62850849|NCT04001530|EXPERIMENTAL|Half-normal saline|Use of half-normal saline (0.45% NaCl) as an irrigant for open-irrigated ablation catheters
62850850|NCT04001530|ACTIVE_COMPARATOR|Normal saline|Use of normal saline (0.9% NaCl) as an irrigant for open-irrigated ablation catheters
62850851|NCT00644085|EXPERIMENTAL|1|oral administration of aspirin 100 mg
62850852|NCT00644085|PLACEBO_COMPARATOR|2|oral administration of placebo
62062296|NCT02821819|EXPERIMENTAL|Random start ovarian stimulation|"Egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase at luteinizing hormone (LH) peak +3,+5,+7,+9 or +11. They will receive urinary follicle stimulating hormone (FSH) 150-225 International units / daily (IU/d) and five days later the gonadotropin-releasing hormone (GnRH) antagonist: cetrorelix acetate 0,25 mg/d will be added until achieving criteria for receiving triptorelin 0,2 mg to induce final follicular maturation. Egg collection will take place 36 hours later.~Interventions:~* Random start ovarian stimulation~* Gonadotrophins: Urinary FSH 150-225 IU/d~* GnRH antagonists: Cetrorelix 0,25 mg/d~* GnRH agonist for triggering: Triptorelin 0,2 mg single dose"
62266800|NCT02007174||Medical Treatment|In order to reduce the patient bias, the control eye received a sham laser treatment, under slit lamp, topical anesthesia using 0.5% tetracaine hydrochloride eye drops (Ponti-Ofteno, Laboratorios Sophia, Jalisco, Mexico) and topical 1 mg fluorescein Sodium staining (Bio-Glo, Hub Pharmaceuticals, Rancho Cucamonga CA). Post sham laser care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
62449937|NCT04519307||Group 1|The newborns with covid 19 infection
62062297|NCT06070584|ACTIVE_COMPARATOR|group A|received aerobic exercises only
62652884|NCT01770964|OTHER|Training Type B, pregabalin|Subjects randomized to receive pregabalin at a site that received training Type B
62850853|NCT05827198|PLACEBO_COMPARATOR|Control sugar candies|Control chewable candy made with sugar and provided at a dose of 50 g (corresponding to 2 servings)
62850854|NCT05827198|ACTIVE_COMPARATOR|Test low sugar candies dose 1|low-sugar chewable candy containing Soluble Corn Fiber + Inulin + Erythritol provided at a dose of 50 g (corresponding to 2 servings)
62850855|NCT05827198|ACTIVE_COMPARATOR|Test low sugar candies dose 2|64% reduced sugar chewable candy containing Soluble Corn Fiber + Resistant wheat dextrins provided at a dose of 50 g (corresponding to 2 servings)
62850856|NCT05827198|ACTIVE_COMPARATOR|Test low sugar candies dose 3|82% reduced sugar chewable candy containing Soluble Corn Fiber + Resistant wheat dextrins provided at a dose of 50 g (corresponding to 2 servings)
62850857|NCT05220475|EXPERIMENTAL|fc-SEMS with anchoring plastic stent|fully covered self-expanable metal stent with an external anchoring plastic stent
62850858|NCT05220475|ACTIVE_COMPARATOR|uc-SEMS|uncovered self-expandable metal stent
62850859|NCT04338061|EXPERIMENTAL|Evobrutinib + Teriflunomide matched Placebo: DB Period|
62850860|NCT04338061|ACTIVE_COMPARATOR|Teriflunomide + Evobrutinib matched Placebo: DB Period|
62850861|NCT00420043|EXPERIMENTAL|imatinib 800mg|
62850862|NCT00420043|ACTIVE_COMPARATOR|imatinib 400mg|
62625028|NCT05703334|EXPERIMENTAL|Myofascial release|group (B) mean age (21.9+3.8 years),and mean BMI values (27.8+1.3 kg/m2 Ground(B) 30 subjects were treated by myofascial release therapy 3 sessions per week .
62625029|NCT05703334|NO_INTERVENTION|Control group|
62625030|NCT00314808|EXPERIMENTAL|Dronabinol|
62625031|NCT00158262|EXPERIMENTAL|Propranolol|Following the occurrence of an acute psychologically traumatic event, an initial dose of short-acting propranolol 40 mg orally then one hour later, long-acting propranolol 60 mg capsule orally on Day 1 followed by a 19-day course of long-acting propranolol starting with 120 mg every morning and evening for 10 days, and then tapering to 120 mg in the morning and 60 mg in the evening for 3 days, then 60 mg in the morning and 60 mg the evening for 3 days, then 60 mg in the morning for 3 days.
62625032|NCT00158262|PLACEBO_COMPARATOR|Placebo|Following the occurrence of an acute psychologically traumatic event, an initial dose of placebo-matching short-acting propranolol 40 mg orally then one hour later, placebo-matching long-acting propranolol 60 mg capsule orally on Day 1 followed by a 19-day course of placebo-matching long-acting propranolol starting with 120 mg every morning and evening for 10 days, and then tapering to 120 mg in the morning and 60 mg in the evening for 3 days, then 60 mg in the morning and 60 mg the evening for 3 days, then 60 mg in the morning for 3 days.
62625033|NCT02834858|EXPERIMENTAL|Umbilical Cord Mesenchymal Stem Cells|Umbilical Cord Mesenchymal Stem Cells Infusion.
62625034|NCT02834858|PLACEBO_COMPARATOR|saline|saline injection
62625035|NCT00951158|EXPERIMENTAL|CLA|Open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. oral dose 7.5 g/day 28 day cycle
62625036|NCT06060028|EXPERIMENTAL|General Practitioner (GP) care plus interoceptive non-invasive tactile stimulation treatment|Participants will receive General Practitioner (GP) care and interoceptive non-invasive tactile stimulation (affective touch) for 30 min two times a week for 12 weeks.
62625037|NCT06060028|SHAM_COMPARATOR|GP care plus sham treatment|Participants will receive General Practitioner (GP) care and a sham stimulation for 30 min two times a week for 12 weeks.
62449938|NCT04519307||Group 2|The newborns with no covid 19 infection
62625038|NCT03670511|EXPERIMENTAL|sit-to-stand|
62625039|NCT03670511|ACTIVE_COMPARATOR|six minute walking test|
62625040|NCT05503017|EXPERIMENTAL|Intervention|
62625041|NCT05503017|ACTIVE_COMPARATOR|Control Condition|
62625042|NCT04762563|EXPERIMENTAL|Experimental: Study Group|Patients in the IASTM group were asked to lie face down on a stretcher, exposing the entire lumbar region. IASTM was applied to all paraspinal muscles for a total of 5 minutes after massage cream was applied. Immediately afterwards, the same application was performed for the right and left hamstring muscles from the gluteal line to the bottom of the popliteal fossa for 3 minutes after massage cream was applied. IASTM application was performed vertically, horizontally and diagonally using instruments of different sizes and shapes at an angle of 45 degrees to the skin surface.
62625043|NCT04762563|ACTIVE_COMPARATOR|Active Comparator|"KT application (Kinesio Tape® Tex Gold) was performed using the muscle technique. In lumbar region application, while the patient was standing, the tape was cut as a Y-strip with a base of 5 cm."
62625044|NCT04050085|EXPERIMENTAL|Treatment (SD-101, radiation therapy, nivolumab)|Patients receive TLR9 agonist SD-101 intratumorally on days 1 and 8 of cycle 1 and day 1 of cycles 2-5. Treatment repeats every 2 weeks for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy on days 1, 3, 5, 8, and 10 of cycle 1. Patients also receive nivolumab IV over 30 minutes on day 2. Cycles with nivolumab repeat every 2 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
62625045|NCT04204083|OTHER|Monovisc|
62625046|NCT02258594|NO_INTERVENTION|Baseline - Usual Care|"Usual Care on two Medical Intensive Care Units units~Usual Care on four Oncology units"
62625047|NCT02258594|EXPERIMENTAL|Post-Implementation - Intervention Units|"PROSPECT Intervention (Web-Based Patient Centered Toolkit (PCTK) + The Patient-SatisfActive® Model) on two MICU units~PROSPECT Intervention (Web-Based Patient Centered Toolkit (PCTK) + The Patient-SatisfActive® Model) on two Oncology units"
62625048|NCT02258594|NO_INTERVENTION|Post-Implementation - Usual Care|Usual Care on two Oncology Units
62625049|NCT02425735|EXPERIMENTAL|Group A|DC-CIK cells will be used against tumor cells.
62625050|NCT02425735|EXPERIMENTAL|Group B|γδ T cells will be used against tumor cells.
62062298|NCT06070584|EXPERIMENTAL|Group B|aerobic exercises with moderate intensity in the form of walking on electrical treadmill
62625051|NCT02425735|EXPERIMENTAL|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
62625052|NCT00583011|EXPERIMENTAL|Local Anesthesia|Local anesthesia group. 2cc of 1% lidocaine with epinephrine administered 2 minutes before amniocentesis, using a 21 gauge needle initially as an intradermal wheal followed by a deeper infiltration of 2cc of 1% lidocaine to the depth of the peritoneum.
62625053|NCT00583011|PLACEBO_COMPARATOR|Placebo-Normal saline|Placebo normal saline group. 2cc of normal saline epinephrine administered 2 minutes before amniocentesis, using a 21 gauge needle initially as an intradermal wheal followed by a deeper infiltration of 2cc of normal saline to the depth of the peritoneum.
62625054|NCT02168023|EXPERIMENTAL|DACC impregnated dressing|Patients undergoing elective or emergency caesarean section with DACC impregnated dressing Sorbact Surgical Dressing ® (ABIGO Medical AB, Sweden) placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
62625055|NCT02168023|ACTIVE_COMPARATOR|Standard surgical dressing|Patients undergoing elective or emergency caesarean section with standard surgical dressing placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
62062299|NCT03432884|EXPERIMENTAL|Part A: BGB-3111|
62449939|NCT05219227|EXPERIMENTAL|body fat mass (BFM)|body fat mass will be measured before and after interventions
62449940|NCT05219227|EXPERIMENTAL|Body mass index (BMI)|BMI will be calculated before and after interventions
62449941|NCT04121390||Newborn Parenting Class|New Mother who attended the Newborn Parenting Class
62449942|NCT04121390||New Mothers|New Mothers who expressed interest, but did not attend the Newborn Parenting Class
62449943|NCT01929109|EXPERIMENTAL|LY2409021 Control|Healthy participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
62449944|NCT01929109|EXPERIMENTAL|LY2409021 Mild Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
62625056|NCT00703677|OTHER|1|All participants will receive lithium. The dosage will be titrated over a 5-week period. Participants will then be followed prospectively for 6 months. Participants will be evaluated at the screening visit, baseline visit, and weeks 2 and 5 during the titration phase. Clinic study visits will then occur on alternate months through week 28. Telephone visits will occur between clinic study visits.
62625057|NCT04954417||MSCT image|Scanning of the vertebral body using MSCT
62625058|NCT04954417||micro-CT image|Scanning of the vertebral body using micro-CT
62625059|NCT00556257|ACTIVE_COMPARATOR|Treatment Arm 1|Treatment Arm 1 will also receive standard of care medications.
62625060|NCT00556257|EXPERIMENTAL|Treatment Arm 2|Treatment Arm 2 will also receive select standard of care medications.
62625061|NCT02662335|EXPERIMENTAL|Arm I (computer-assisted cognitive training)|Patients complete a computerized working memory training program (Cogmed) over 35 minutes a day, 5 times a week for 6 weeks.
62625062|NCT02662335|ACTIVE_COMPARATOR|Arm II (wait-list)|Patients undergo standard follow-up care for 6 weeks. Following standard follow-up care, patients may complete Cogmed as in the Intervention Group in weeks 7-13.
62625063|NCT05376761|EXPERIMENTAL|DEX for STN-DBS|
62625064|NCT03367234|EXPERIMENTAL|Personalized Addiction-to-Health (PATH)|Cognitive Behavioral Therapy (CBT) sessions with a behavioral health consultant twice weekly for weeks 1-13, once weekly for weeks 14-26, as needed weeks 27-52; Contingency management rewards for specified recovery behaviors which could include medication adherence, attendance at CB/RP sessions and/or CB/RP exercise participation; Medication-assisted treatment, either extended-release naltrexone once monthly or buprenorphine once daily; Peer recovery specialist support twice weekly for weeks 1-13, once weekly for weeks 14-26, as needed for weeks 27-52; Psychiatric consultation as needed.
62062300|NCT03432884|PLACEBO_COMPARATOR|Part A: Placebo|
62062301|NCT03432884|EXPERIMENTAL|Part B: BGB-3111, Placebo, and Moxifloxicin|
62062302|NCT01289418||Health care workers in Québec|Health care workers from CHUQ hospitals
62449945|NCT01929109|EXPERIMENTAL|LY2409021 Moderate Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
62449946|NCT01929109|EXPERIMENTAL|LY2409021 Severe Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
62449947|NCT01929109|EXPERIMENTAL|LY2409021 End Stage Renal Disease|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of Period 1 of the study and a single 80 mg dose of LY2409021 orally on Day 1 of Period 2 of the study.
62449948|NCT04017936|EXPERIMENTAL|Anakinra|100 mg/0.67 mL daily subcutaneous injection for 4 weeks
62449949|NCT04017936|NO_INTERVENTION|Standard of Care|Continue standard of care treatment
62449950|NCT02933866|EXPERIMENTAL|DSXS topical|applied once daily for 28 days
62449951|NCT02933866|PLACEBO_COMPARATOR|Vehicle topical|applied once daily for 28 days
62449952|NCT03560609|ACTIVE_COMPARATOR|Subjects With Keratoconus|
62449953|NCT03560609|ACTIVE_COMPARATOR|Subjects with Glaucoma|
62449954|NCT03387098|EXPERIMENTAL|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011, GI-4000, haNK, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ehtyl esters, oxaliplatin, SBRT.
62449955|NCT00751946|ACTIVE_COMPARATOR|1|12 weekly sessions of one-to-one TARGET (psychotherapy)
62652885|NCT01770964|OTHER|Training Type A, placebo|Subjects randomized to receive placebo at a site that received training Type A
62652886|NCT01770964|OTHER|Training Type B, placebo|Subjects randomized to receive placebo at a site that received training Type B
62062303|NCT01289418||Health care workers in Toronto|Health care workers from the Mount Sinai Hospital
62062304|NCT01289418||Health care workers in Halifax|Health care workers from the Queen Elizabeth Hospital
62087952|NCT02061761|EXPERIMENTAL|Part C - relatlimab + nivolumab (Dose escalation)|
62449956|NCT00751946|ACTIVE_COMPARATOR|2|12 weekly sessions of one-to-one ETAU (psychotherapy)
62449957|NCT04022499|EXPERIMENTAL|Pre-NDPP|Presessions + usual care NDPP
62449958|NCT04022499|ACTIVE_COMPARATOR|Usual care NDPP|Usual care NDPP only
62449959|NCT00113490|EXPERIMENTAL|motavizumab (MEDI-524) 15 mg/kg|A single IM injection every 30 days beginning at Day 0 for a total of 4-5 injections determined by when in the RSV season a child was enrolled.
62449960|NCT00113490|ACTIVE_COMPARATOR|palivizumab 15 mg/kg|A single IM injection every 30 days beginning at Day 0 for a total of 4-5 injections determined by when in the RSV season a child was enrolled.
62449961|NCT01626820|EXPERIMENTAL|Fluviral Adults Group|Subjects 18-60 years of age received 1 dose of Fluviral® vaccine, administered intramuscularly in the deltoid of the non-dominant arm, at Day 0.
62449962|NCT01626820|EXPERIMENTAL|Fluviral Elderly Group|Subjects above 60 years of age received 1 dose of Fluviral® vaccine, administered intramuscularly in the deltoid of the non-dominant arm, at Day 0.
62449963|NCT04175496|EXPERIMENTAL|Test Foods|Blueberry Cake, Snack with Cheese and spicy Crackers will be used as test foods.
62449964|NCT04175496|EXPERIMENTAL|Reference Food|Glucose solution will use as reference food.
62449965|NCT05411809|NO_INTERVENTION|Arm1|The ctDNA is positive after SBRT and no adjuvant therapy is used after SBRT.
62449966|NCT05411809|EXPERIMENTAL|Arm 2|The ctDNA is positive after SBRT and adjuvant therapy is used after SBRT.
62449967|NCT05411809|NO_INTERVENTION|Arm 3|The ctDNA is negative after SBRT and no adjuvant therapy is used after SBRT.
62850863|NCT00146848|ACTIVE_COMPARATOR|DDD-40|DDD-40 for this trial is the comparator arm. Even though patients are receiving a CRT-D device, atrial support pacing in this arm will be limited as the device will not pace unless the rate falls below 40 bpm.
62449968|NCT00404274|EXPERIMENTAL|Treatment regimen A|In treatment regimen A subject will co-administer casopitant and warfarin over three-day period (Day 1 150 milligram per day \[mg/day\], Day 2 50 mg/day, Day 3 50 mg/day) and from Days 4 to 10 subject will administer only warfarin.
62449969|NCT00404274|EXPERIMENTAL|Treatment regimen B|In treatment regimen B subject will co-administer casopitant 60 mg/day and warfarin for 14 days.
62449970|NCT00404274|EXPERIMENTAL|Treatment regimen C|In treatment regimen C subject will co-administer warfarin and casopitant 30 mg/day for 14 days.
62449971|NCT04287881|OTHER|Adult patients who have epileptic seizures|Patients with adult-onset epileptic seizures and diagnosed ischemic stroke.
62449972|NCT05259111|NO_INTERVENTION|Control, Care in the Hospital|After bariatric sleeve gastrectomy, patients receive their care in the hospital, as usual.
62449973|NCT05259111|EXPERIMENTAL|Intervention, Care in the Home|After bariatric sleeve gastrectomy, patients receive their care in the home.
62449974|NCT03978884|EXPERIMENTAL|Mild Hypertensive|Mild Hypertensive with systolic BP \>=140 mmHg but less than 160 mmHg at baseline with diastolic \>=90 but \<100 mmHg
62449975|NCT03978884|EXPERIMENTAL|Mild Hypertensive with Diabetes|Mild Hypertensive with systolic BP \>=140 mmHg but less than 160 mmHg at baseline with diastolic \>=90 but \<100 mmHg and diabetes.
62449976|NCT03978884|EXPERIMENTAL|Severe Hypertension|Severe Hypertensive with systolic BP \>=160 mmHg at baseline or with diastolic \>=100 mmHg
62449977|NCT03978884|EXPERIMENTAL|Severe Hypertension with Diabetes|Severe Hypertensive with systolic BP \>=160 mmHg at baseline or with diastolic \>=100 mmHg with diabetes
62449978|NCT01799590|EXPERIMENTAL|Topiramate|
62449979|NCT05563909|EXPERIMENTAL|Virtual Reality Group|Tendon and nerve gliding exercises will be applied to the patients in the virtual reality group for 2 weeks, for a total of 10 sessions, through the developed software. Patients will be asked to come for 2 weeks for the virtual reality mediated exercise program. Patients will be asked to do their exercises in a virtual reality-mediated exercise protocol, with 1 session of approximately 30 minutes. Apart from the exercise program, patients will be asked to use wrist splints.
62449980|NCT05563909|ACTIVE_COMPARATOR|Conventional Exercise Group|For the patients in the classical exercise group; The classical exercise program will be taught in the company of a physiotherapist and they will be asked to do these exercises for a total of 10 sessions for 2 weeks. The patients' home exercise programs will be controlled by weekly phone calls. Apart from the exercise program, patients will be asked to use wrist splints.
62449981|NCT05563909|ACTIVE_COMPARATOR|Control Group|Patients in the control group will be advised to continue using splints. It will be evaluated by repeated examinations.
62449982|NCT02873390|EXPERIMENTAL|HerinCAR-PD1 cells|Patients will receive 3 cycles of HerinCAR-PD1 cells treatment.
62449983|NCT04241159|EXPERIMENTAL|Geriatric participants with frailty|"Geriatric participants aged 65-80 who have a diagnosis of frailty (Fried Frailty score of 3 or greater).~Experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days)."
62449984|NCT04241159|EXPERIMENTAL|Geriatric participants with HFpEF|"Geriatric participants aged 65-80 who have a diagnosis of HFpEF.~Experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days)."
62449985|NCT01536223|ACTIVE_COMPARATOR|PF group|the group of participants who undergoing cisplatin and 5-fluorouracil(PF)neoadjuvant chemotherapy
62449986|NCT01536223|EXPERIMENTAL|TPF group|TPF(docetaxel , cisplatin and 5-fluorouracil)neoadjuvant chemotherapy
62449987|NCT06542965||Case (Patients with carbapenem-resistant P. mirabilis)|Patients with carbapenem-resistant P. mirabilis (CRPM) growth in blood culture were included in the case group
62449988|NCT06542965||Control (Patients with carbapenem- susceptible P. mirabilis)|Patients with carbapenem- susceptible P. mirabilis (CSPM) growth in blood culture were included in the control group
62449989|NCT00433381|EXPERIMENTAL|Arm I (bevacizumab and temozolomide)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral temozolomide once daily on days 1-21.
62449990|NCT00433381|EXPERIMENTAL|Arm II (bevacizumab & irinotecan hydrochloride)|Patients receive bevacizumab IV as in Arm I followed by irinotecan hydrochloride IV over 90 minutes on days 1 and 15.
62449991|NCT06016465|EXPERIMENTAL|Dexamethasone|single oral dose of dexamethasone (8mg)
62449992|NCT06016465|PLACEBO_COMPARATOR|Placebo|Single oral dose of placebo pill
62449993|NCT02586766|EXPERIMENTAL|Behavioral: Project Sync|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care
62449994|NCT02586766|NO_INTERVENTION|Comparison Group|This group did not receive an intervention, but did receive an informational pamphlet of resources in the area (enhanced usual care).
62449995|NCT03432195|EXPERIMENTAL|Donepezil TDS Back|Corplex Donepezil TDS 10 mg/day applied to the Back for 1 week (7 days)
62449996|NCT03432195|EXPERIMENTAL|Donepezil TDS Buttock|Corplex Donepezil TDS 10 mg/day applied to the Buttock for 1 week (7 days)
62850864|NCT00146848|ACTIVE_COMPARATOR|DDDR-40|DDDR-40 programming will initiate atrial support pacing if the rate falls below 40 bpm or if atrial support is needed in response to increased activity.
62449997|NCT03432195|EXPERIMENTAL|Donepezil TDS Leg|Corplex Donepezil TDS 10 mg/day applied to the Leg for 1 week (7 days)
62449998|NCT00513851|EXPERIMENTAL|1|Once Daily Dosing
62449999|NCT00513851|EXPERIMENTAL|2|Twice Daily Dosing
62850865|NCT00146848|ACTIVE_COMPARATOR|DDD-70|Atrial support pacing in this arm will be delivered when the rate falls below 70 bpm.
62850866|NCT03927378|EXPERIMENTAL|S-katamine group|For women in this group, study drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. Women will be monitored for 60 minutes and then sent back to the ward.
62850867|NCT03927378|PLACEBO_COMPARATOR|Placebo group|For women in this group, study drug (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. Women will be monitored for 60 minutes and then sent back to the ward.
62850868|NCT05569590|ACTIVE_COMPARATOR|Control|One visit three application of bleaching agent (hydrogen peroxide 35%) will be performed and desensitizing agent (fluoride varnish) will be applied for 10 minutes after bleaching.
62450000|NCT04582721|ACTIVE_COMPARATOR|CON-SCS with subcutaneous stimulation|7 days Conventional Spinal Cord Stimulation with subcutaneous stimulation
62450001|NCT04582721|ACTIVE_COMPARATOR|HF-SCS|7 days High Frequency Spinal Cord Stimulation
62450002|NCT04582721|ACTIVE_COMPARATOR|Combination Therapy|7 days a combination of CON-SCS with subcutaneous stimulation and HF-SCS
62450003|NCT05899166|EXPERIMENTAL|ketogenic diet|"The diet will be high in protein and healthy fats and comprise meat, fish, fibrous vegetables, nuts, dairy, and berries. Macronutrient composition will be \~ 5% carbohydrate, 20% protein, 70% fat.~Participants will receive a daily multi-vitamin, magnesium supplement, and supplemental salt (bouillon cubes) to ascertain micronutrient sufficiency and help with transition to the diet."
62450004|NCT05899166|ACTIVE_COMPARATOR|standard diet|"The diet will be consistent with prevailing dietary guidelines and recommendations and contain meat, fish, grains, vegetables, fruit and dairy. At least 50% of grain-based products will be whole grains. Meats will be primarily lean, and dairy products will be fat-free or low-fat. Macronutrient composition will be \~50% carbohydrate (\<10% added sugars), 20% protein, 30% fat.~Participants will receive a daily multi-vitamin supplement to ascertain micronutrient sufficiency."
62450005|NCT05263219|EXPERIMENTAL|Transarterial chemoembolization with drug-eluting beads plus hepatic arterial infusion chemotherapy|Patients will receive the combination treatment of DEB-TACE and HAIC.
62450006|NCT05263219|ACTIVE_COMPARATOR|Hepatic arterial infusion chemotherapy|Patients will receive HAIC treatment alone.
62450007|NCT05487456|ACTIVE_COMPARATOR|P4M3 CA35|Ad libitum use of P4M3 using CA35 Cartridges
62450008|NCT05487456|ACTIVE_COMPARATOR|P4M3 CM35|Ad libitum use of P4M3 using CM35 Cartridges
62450009|NCT05487456|ACTIVE_COMPARATOR|Cigarette|Ad libitum use of subject's own preferred CIG brand
62450010|NCT05487456|ACTIVE_COMPARATOR|Smoking Abstinence|Smoking abstinence
62450011|NCT03182257|EXPERIMENTAL|ONO-7579 Part A|Single Ascending doses of ONO-7579
62450012|NCT03182257|EXPERIMENTAL|ONO-7579 Part B|Expansion phase of ONO-7579
62450013|NCT04714619|EXPERIMENTAL|CB-103 + NSAI therapy|Hormone Receptor (HR)-positive and HER2-negative advanced breast cancer, including metastatic (ABC).Approximately 80 patients
62450014|NCT05795491|PLACEBO_COMPARATOR|Group A|"This group includes 30 patients will receive routine medical treatment with antifungal, azole (vaginal route).~100 ml ( one Suppository ) at bedtime for three nights in a row"
62450015|NCT05795491|EXPERIMENTAL|Group B|This group includes 30 patients. The vulva and vagina will be exposed to 401 ± 5 nm ultraviolet A/ blue LED irradiation in a single session, divided into two applications.
62450016|NCT05865054||Ocular GCA|GCA with clinical diagnosis of ischemic optic neuropathy or other ocular condition
62450017|NCT05865054||Non-Ocular GCA|GCA without ocular manifestations
62450018|NCT05865054||Non-GCA|Initially suspected to have GCA but final clinical diagnosis not GCA
62450019|NCT05258656|EXPERIMENTAL|Intervention|The intervention group will receive education about nutrition, resources, and specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
62450020|NCT05258656|PLACEBO_COMPARATOR|Control|The control group will receive specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
62450021|NCT04373759||Unexpected in-intensive care unit cardiac arrest patients|ICUCA Patients admitted in intensive care unit for a confirmed COVID-19 and presenting an unexpected in-intensive care unit cardiac arrest
62450022|NCT04373759||In-hospital cardiac arrest patients|IHCA Patients admitted in intensive care unit for an in-hospital cardiac arrest with a confirmed Covid-19
62450023|NCT04373759||Out-of-hospital cardiac arrest|OHCA Patients admitted in intensive care unit for an out-hospital cardiac arrest with a confirmed Covid-19
62450024|NCT04544176||Exposed Cohort|This group will include patients attending radiology outpatient appointments in 2020 in our period of interest from the peak of the first wave of the pandemic, who were subsequently tested for SARS-COV2 within 28-days of their attendance.
62450025|NCT04544176||Unexposed Cohort|This group will form the control group and comprises all individuals who attended radiological appointments during the same period for each hospital in 2019 but not 2020.
62450026|NCT01185990||Tinnitus subjects|Subjects with chronic, moderate to severe unilateral tinnitus.
62450027|NCT01185990||Healthy control subjects|
62450028|NCT03800069||Arm 1|A finger stick sample is collected and tested on the study device.
62450029|NCT04059796|EXPERIMENTAL|Study Eye|Study device in conjunction with an approved monofocal or toric IOL after cataract extraction
62450030|NCT04059796|ACTIVE_COMPARATOR|Control Eye|approved monofocal or toric IOL after cataract extraction
62450031|NCT02565095|OTHER|Carotid Baroreflex measurements|
62450032|NCT00368277|EXPERIMENTAL|Aliskiren-based regimen|Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg
62450033|NCT00368277|ACTIVE_COMPARATOR|Ramipril-based regimen|Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg
62450034|NCT05427097|ACTIVE_COMPARATOR|Active|"The treatment consisted of placing 10 active Helical patches spread as follows:~* Two in the upper cervical area (suboccipital);~* Two in the lower cervical area (near the 5th and 6th vertebrae);~* Two in the upper trapezius muscle area (between neck and shoulder);~* Four in the tender point area (as reported by the patient)."
62450035|NCT05427097|PLACEBO_COMPARATOR|Placebo|"The treatment consisted of placing 10 placebo Helical patches spread as follows:~* Two in the upper cervical area (suboccipital);~* Two in the lower cervical area (near the 5th and 6th vertebrae);~* Two in the upper trapezius muscle area (between neck and shoulder);~* Four in the tender point area (as reported by the patient)."
62450036|NCT04872907|EXPERIMENTAL|adhesive system + flowable composite|Side of the mouth randomlly assigned to this arm will receive self etch adhesive system and flowable composite combination on temporary molars and self etch adhesive system on anterior temporary teeth at baseline, M6, M12, M18
62062305|NCT02167217|EXPERIMENTAL|Oral Prednisolone|Oral Prednisolone 5mg/kg/ day on two consecutive days, Friday and Saturday with breakfast
62625065|NCT03367234|ACTIVE_COMPARATOR|Standard Care|Treatment may differ slightly by treatment program, but addiction specialty Intensive Outpatient Treatment (ASAM Level 2.1) will generally include individual therapy sessions with a counselor 1 hour per week for week; Medication-assisted treatment, either extended-release naltrexone once monthly or suboxone once daily; Group therapy sessions 9 hours per week then decreasing to 3 hours per week; Psychiatric consultation as needed.
62625066|NCT02555085|EXPERIMENTAL|IV Dose 1|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
62625067|NCT02555085|EXPERIMENTAL|IV Dose 2|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
62625068|NCT02555085|EXPERIMENTAL|IV Dose 3|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
62625069|NCT02555085|EXPERIMENTAL|IV Dose 4|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
62625070|NCT02555085|EXPERIMENTAL|IV Dose 5|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
62625071|NCT02555085|EXPERIMENTAL|IV Dose 6|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
62625072|NCT02555085|EXPERIMENTAL|IV Dose 7|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
62625073|NCT02555085|EXPERIMENTAL|SC Dose|Single SC dose or matching placebo
62450037|NCT04872907|ACTIVE_COMPARATOR|Fluoride varnish|Side of the mouth randomly assigned to this arm will receive the fluride varnish at baseline, M6, M12, M18 on the temporary teeth
62850869|NCT05569590|EXPERIMENTAL|Propolis|One sitting vital tooth bleaching procedure will be performed. Three application each of 15 minutes of bleaching agent (hydrogen peroxide 35%) will be applied and desensitizing agent propolis in paste form will be applied for 10 minutes.
62850870|NCT05569590|EXPERIMENTAL|Propolis mixed with bleaching agent|One visit vital tooth bleaching procedure will be performed. three application each of 15 minutes of Propolis mixed with bleaching agent (hydrogen peroxide 35%) will be applied.
62850871|NCT04301310|EXPERIMENTAL|Treatment Group|
62450038|NCT00275002|EXPERIMENTAL|O6-BG and TMZ|O6-benzylguanine (O6-BG) and temozolomide (TMZ)
62450039|NCT04319484|EXPERIMENTAL|lenvatinib|Patients in the lenvatinib group are given lenvatinib within 1-2 months after operation (dose: body weight \< 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
62625074|NCT03442231||Journey™ UNI Unicompartmental Knee System|Subjects previously received knee replacement
62625075|NCT02295332|EXPERIMENTAL|Cohort A|
62625076|NCT02295332|EXPERIMENTAL|Cohort B|
62625077|NCT00921713|ACTIVE_COMPARATOR|Enhanced Usual Care|An extensive packet of information including cancer education materials and treatment resources will be mailed to patients.
62625078|NCT00921713|EXPERIMENTAL|Oncology Nurse Care Management|In addition to this mailed information packet, patients in OCNM will be contacted by an experienced Oncology nurse with additional training in self-management support and psychosocial care. The intervention nurse, supported by a Medical Oncologist and Clinical Psychologist, will work closely with patients, their primary care physicians, and other clinicians to assure that patient needs discussed are met. The nurses will be trained in and employ proven counseling and psychotherapeutic approaches-behavioral activation and problem-solving treatment. The multi-component intervention will be based on the Chronic Care Model's six elements (health care organization, community resources, self-management support, delivery system design, decision support, and clinical information system).
62850872|NCT01252732|EXPERIMENTAL|Single-Dose IV Oritavancin Diphosphate|
62850873|NCT01252732|ACTIVE_COMPARATOR|IV Vancomycin|
62850874|NCT00848159||1|Group 1 was composed of six women with a densitometric diagnosis of osteoporosis in column (DP =- 2.70 to -4.97), with an average weight of 57.5 (+6.9) kg, mean height of 1 , 4 (+ 0.07) my body mass index (BMI) of 26.1 (+1.8) Kg/m2
62850875|NCT00848159||2|Group 2 consists of six women with a densitometric diagnosis of osteopenia in column (DP =- 1.07 to -2.09), with an average weight of 62.1 (+9.9) kg, mean height of 1, 5 (+0.03) I BMI 25.3 (3.3) kg/m2, both compared with young adults
62850876|NCT02873949|OTHER|1. Periodontitis patients|30 patients consulting at Odontology department for periodontal treatment
62850877|NCT02873949|OTHER|2. Control|10 patients not affected by periodontitis consulting at Odontology department for checkup of teeth state and/or scaling
62850878|NCT05573048|EXPERIMENTAL|Trans-Perineal Grid for prostate interventions|Subjects will have the trans-perineal guide grid placed the prostate biopsy or ablation procedure.
62850879|NCT03730142|EXPERIMENTAL|WXFL10030390 tablet|"WXFL10030390 continuous oral dosing (0.1 mg once a day)~WXFL10030390 continuous oral dosing (0.2 mg once a day)~WXFL10030390 continuous oral dosing (0.4 mg once a day)~WXFL10030390 continuous oral dosing (0.7 mg once a day)~WXFL10030390 continuous oral dosing (1.1 mg once a day)~WXFL10030390 continuous oral dosing (1.4 mg once a day)~WXFL10030390 continuous oral dosing (1.7 mg once a day)"
62850880|NCT03564483||Registry Observational Study|All women presenting for evaluation of Extramammary Paget's Disease (EMPD) at Mayo Clinic in Rochester MN.
62062306|NCT01595412|ACTIVE_COMPARATOR|Cohort 2|Cohort 2 (two) will consist of 120 patients with an external rectal prolapse (Oxford Grade V)treated by Laparoscopic Resection Rectopexy (LRR). These patients will be included in the US centers involved in this study and treated by LRR.
62062307|NCT01595412|ACTIVE_COMPARATOR|Cohort 1|Cohort one will consist of 120 patients with an external rectal prolapse (Oxford Grade V) which will be treated with Laparoscopic Ventral Rectopexy. As this is the standard treatment in the European centers involved in this study these patients will be selected in the participating centers in the Netherlands, Belgium and England.
62087953|NCT02061761|EXPERIMENTAL|Part B - relatlimab (Cohort expansion)|
62450040|NCT04319484|PLACEBO_COMPARATOR|Placebo|The placebo pills are made identical to the investigating lenvatinib in appearance
62625079|NCT05352880|EXPERIMENTAL|transplant recipients|They will be recruited from the Renal Transplantation Clinic at Alexandria Main University hospital
62625080|NCT02029482|EXPERIMENTAL|ACT-128800|ACT-128800 tablets, once daily for 3 days at each dose level: 10 mg, 20 mg, 40 mg, 60 mg, 80 mg, and 100 mg.
62625081|NCT02029482|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets, once daily, for 18 days
62625082|NCT02099253|EXPERIMENTAL|Youth Group|People in this group, aged 18\~39,were accepted an initial dose of 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
62625083|NCT02099253|EXPERIMENTAL|Middle-aged Group|People in this group, aged 40\~64,were accepted an initial dose of 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
62850881|NCT02113254|EXPERIMENTAL|Healthy volunteer|
62850882|NCT01285011||Ipp-On|Patient implanted with the Ipp-On
62625084|NCT02099253|EXPERIMENTAL|Older Group|People in this group, aged 65\~80,were accepted an initial dose of 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
62625085|NCT02725437|EXPERIMENTAL|Low-dose C. difficile Vaccine (accelerated schedule)|
62625086|NCT02725437|EXPERIMENTAL|High-dose C. difficile Vaccine (accelerated schedule)|
62625087|NCT02725437|PLACEBO_COMPARATOR|Placebo (accelerated schedule)|
62625088|NCT02725437|EXPERIMENTAL|Low-dose C. difficile Vaccine (non-accelerated schedule)|
62625089|NCT02725437|EXPERIMENTAL|High-dose C. difficile Vaccine (non-accelerated schedule)|
62625090|NCT02725437|PLACEBO_COMPARATOR|Placebo (non-accelerated schedule)|
62625091|NCT03140540|ACTIVE_COMPARATOR|Group A (stroke volume variation) guided fluid|Stroke volume variation guided intraoperative intravenous fluid will be administered.
62625092|NCT03140540|ACTIVE_COMPARATOR|Group B(Study group) TEE guided fluid|Transesophageal echocardiography will be used to guide the fluid therapy.
62850883|NCT06131164|EXPERIMENTAL|Diaphragmatic Breathing Exercise Group|This group will perform baseline treatment along with balloon breathing exercises also known as diaphragmatic breathing exercise for pulmonary function improvement and FHP Diaphragmatic breathing is done slowly and deeply through nose with minimum usage of chest movement. Only diaphragm is used for breathing in supine lying position with one hand placed on chest and other hand is placed on abdomen. Focus should be on the contraction of diaphragm that can be checked by hand placed on abdomen while there is as little movement in chest as possible which is also checked by hand placed on chest. Inhalation and exhalation should be for 6 second approximately. Each exercise session consist of 4 sets and each set has 4 complete breathing breaks. Will be done 2 times a day and 3 times per week for total of 8 weeks.
62266801|NCT02007174||Argon Laser Treatment|Argon laser therapies were performed on an outpatient basis only by one ophthalmologist. Under slit lamp, topical anesthesia using 0.5% tetracaine hydrochloride eye drops (Ponti-Ofteno, Laboratorios Sophia, Jalisco, Mex) and topical 1 mg fluorescein Sodium staining (Bio-Glo, Hub Pharmaceuticals, Rancho Cucamonga CA) was applied. Argon laser was applied along the vessels of the pterygium apex with power between 450mW to 780 mW, spot size of 100 u with 10 milliseconds duration. Additional grill pattern treatment was given to pterygium body using a 200 microns spot size. Treatments were given in one only session. Post laser care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, CA, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
62625093|NCT00790556|EXPERIMENTAL|1|MK8245
62625094|NCT00790556|PLACEBO_COMPARATOR|2|Placebo Comparator
62625095|NCT00484926|ACTIVE_COMPARATOR|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
62266802|NCT00719927|EXPERIMENTAL|1|Comadre Treatment
62266803|NCT00719927|ACTIVE_COMPARATOR|2|Non Support Partner Treatment
62266804|NCT06264895|EXPERIMENTAL|Evaluation of an exercise intervention for women experiencing homelessness and addiction.|A 3 times weekly exercise intervention with protein supplementation will be delivered to all study participants for 10 weeks.
62266805|NCT01816009|EXPERIMENTAL|6 weeks|the duration of antibiotic treatment will be six weeks.
62266806|NCT01816009|ACTIVE_COMPARATOR|12 weeks|the duration of antibiotic treatment will be 12 weeks.
62266807|NCT06017596|EXPERIMENTAL|PEEK group|Patients received PEEK framework prosthesis
62450041|NCT00662129|EXPERIMENTAL|paclitaxel + gemcitabine + bevacizumab|"Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and after every other course, and then after completion of treatment.~After completion of study treatment, patients are followed periodically for 5 years."
62450042|NCT04471935|OTHER|At home Speech Hero therapy|
62625096|NCT00484926|EXPERIMENTAL|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
62625097|NCT01853748|ACTIVE_COMPARATOR|Trastuzumab emtansine (T-DM1)|T-DM1 3.6mg/kg every three weeks by IV for 17 doses for a total of 51 weeks
62625098|NCT01853748|ACTIVE_COMPARATOR|Paclitaxel + Trastuzumab|paclitaxel 80 mg/m2 IV weekly and trastuzumab 4 mg/kg IV load, followed by 2 mg/kg IV weekly for 12 weeks, followed by trastuzumab 6 mg/kg IV every 3 weeks for 13 treatments
62625099|NCT03162068||Control group|Cases are recruited thanks to advertisement within CHU.
62625100|NCT03162068||Post menopausal women|Post-menopausal women are recruited within rheumatology service.
62625101|NCT03162068||Cushing' syndrome group|Cushing' syndrome patients are recruited during hospitalisation in endocrinology service
62625102|NCT04687826||Pancreaticoduodenectomy in 2015|Patients who underwent pancreaticoduodenectomy in 2015 got intraoperative fluid therapy in goal directed fluid therapy technique. Most of the patients spent the first postoperative night in ICU where the monitoring of urine output and fluid balance are more specific than in a normal ward.
62625103|NCT04687826||Pancreaticoduodenectomy in 2017|Patients who underwent pancreaticoduodenectomy in 2017 got liberal intraoperative fluid therapy and most of the patients spent the first postoperative night in a regular ward.
62625104|NCT00667303||1|
62625105|NCT01509612|ACTIVE_COMPARATOR|Additive homeopathy in cancer patients|Lung cancer patients receiving conventional chemo- and/or radiation therapy receive additive classical homeopathy with homeopathic globules
62625106|NCT01509612|PLACEBO_COMPARATOR|Additive homeopathic placebo globules|Lung cancer patients receiving conventional chemo- and/or radiation therapy receive homeopathic placebo globules
62450043|NCT01056874|ACTIVE_COMPARATOR|Digoxin|
62625107|NCT01509612|NO_INTERVENTION|No intervention|No intervention
62625108|NCT02916134|ACTIVE_COMPARATOR|Operative Intervention|Laparoscopic +/- open appendicectomy, with antibiotics at induction and 3 further doses of intravenous antibiotics. Co-amoxiclav, or cefuroxime and metronidazole if previous rash-allergy to penicillin.
62625109|NCT02916134|EXPERIMENTAL|Antibiotic Treatment|Intravenous antibiotics until clinical improvement and then 5 further days of oral antibiotics. Co-amoxiclav, or if rash-allergy to penicillin, cefuroxime and metronidazole.
62450044|NCT01056874|EXPERIMENTAL|Digoxin + Maraviroc|
62450045|NCT03803566|EXPERIMENTAL|Faster|This group will comprise participants who complete the grooved pegboard test at baseline with a time of less than 71 seconds. One half of the members in this group will perform the two interventions in the order of pegboard practice and then force control practice, whereas the other half of the group will perform the two practice interventions in the opposite order.
62450046|NCT03803566|EXPERIMENTAL|Slower|This group will comprise participants who complete the grooved pegboard test at baseline with a time of greater than 70 seconds. One half of the members in this group will perform the two interventions in the order of pegboard practice and then force control practice, whereas the other half of the group will perform the two practice interventions in the opposite order.
62450047|NCT02018146|OTHER|Nasopharyngeal then mask|Patients will be randomized to nasopharyngeal airway placement and ventilation followed by mask ventilation
62450048|NCT02018146|OTHER|Mask then nasopharyngeal|Patients will be randomized to mask ventilation followed by nasopharyngeal airway placement and ventilation
62625110|NCT05162430|EXPERIMENTAL|P1 group|Administration of 0.1 mg/kg of propofol and 5mg dexamethasone phosphate sodium
62625111|NCT05162430|EXPERIMENTAL|P2 group|Administration of 0.2mg/kg of propofol and 5mg dexamethasone phosphate sodium
62625112|NCT05162430|EXPERIMENTAL|P3 group|Administration of 0.3mg/kg of propofol and 5mg dexamethasone phosphate sodium
62625113|NCT05162430|EXPERIMENTAL|P4 group|Administration of 0.4 mg/kg of propofol and 5mg dexamethasone phosphate sodium
62625114|NCT05162430|EXPERIMENTAL|P5 group|Administration of 0.5mg/kg of propofol and 5mg dexamethasone phosphate sodium
62625115|NCT05162430|NO_INTERVENTION|D1 group|Administration of 5mg dexamethasone phosphate sodium
62850884|NCT06131164|ACTIVE_COMPARATOR|Thoracic Extension Exercise Group|This group along with baseline treatment will do Thoracic Extension Exercises (TEE) for FHP and Pulmonary function improvements. This is done in 3 steps. The restricted upper thoracic area is placed on foam roller with subject lying supine with knees flexed, buttock slightly lifted up from the floor and crossed hands on the chest. Roll the foam roller slightly up and down. Swiss ball is place in front of the subject who is sitting with knees flexed and then the ball is pushed slightly forward with both hands placed on it. While lying prone lift up and then pushing down the upper body while the upper body is supported by elbows places just below shoulders. All these steps will be followed by 2 sets of 15 repetitions and holding 10 sec for each repetition.
62625116|NCT02335346|EXPERIMENTAL|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. During tapering period, dose of 40 mg for one week and then 20 mg for the last week.
62850885|NCT01964755|EXPERIMENTAL|Chemotherapy + Antiviral-Based Therapy|"Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy:~* Chemotherapy: Up to 6 cycles, 21 days each:~  * Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1 per study protocol;~ * Rituximab: 375mg/m2 (optional) IV on Day 1 per study protocol;~ * Methotrexate: 3.5 gm/m2 IV on Day 2 per study protocol;~ * Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses per study protocol;~* Antiviral-Based Therapy~  * Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses per study protocol;~ * Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses per study protocol."
62450049|NCT02546908||High-risk localized Prostate Cancer (PC)|No intervention will be administered in this study. Participants with High-risk localized PC will be enrolled. High-risk localized PC involves clinical T stage greater than or equal to (\>=) cT3a and one of the following high risk features: Gleason score 8-10 or prostate specific antigen (PSA) level above 20 nanogram per milliliter (ng/mL).
62625117|NCT06265909||AmDTx engaged|Data were collected between March 2015 and December 2022 on 36,160 unique users in a manner compliant with the Health Insurance Portability and Accountability Act (HIPAA), Personal Health Information Protection Act (PHIPA), and General Data Protection Regulation (GDPR). Of these, 2,786 unique individuals engaged in biometric and self-report data collection. To protect the real-world applicability of the results, users were not given any special instruction or information about the nature or possibility of the current analyses. As consequence, user data varied greatly in terms of engagement and app-use characteristics. To create a single, unified, and consistent dataset that could be leveraged across all intended analyses, data were filtered to only include English-language psychotherapy sessions that contained the required session payloads for algorithm inclusion (see below), and only when all the objective and two subjective measures were completed both before and after each session.
62450050|NCT02546908||Non-metastatic Biochemically Recurrent PC|No intervention will be administered in this study. Participants with Non-metastatic biochemically recurrent PC will be enrolled. A non-metastatic biochemically recurrent PC involves a confirmed PSA value of \>0.2 ng/mL following prostatectomy (European Association of Urology (EAU) guidelines), a PSA value of 2 ng/mL or more above the nadir following radiation therapy (American Society for Radiation Oncology (ASTRO) guidelines).
62625118|NCT00581932||A|One group, all subjects with DSM-IV diagnosis of Schizophrenia, age 18-65 who are initiating clozapine therapy.
62652887|NCT03932708|EXPERIMENTAL|Urgent Care Antibiotic Stewardship Intervention|All 38 urgent care clinics will implement CDC Core Elements of outpatient antibiotic stewardship as described above.
62450051|NCT02546908||Metastatic PC|No intervention will be administered in this study. Participants with Metastatic PC will be enrolled.
62450052|NCT01229085|EXPERIMENTAL|Test|mometasone 0,1% + salicylic acid 5%
62450053|NCT04842110|EXPERIMENTAL|1064 Full Abdomen|eonTM FR 1064 nm device Patient will be treated with the eonTM FR 1064 nm device
62450054|NCT02189083|EXPERIMENTAL|High dose TSD|Subjects in this arm receive high dose (217 g/day) TSD for 16 weeks.
62450055|NCT02189083|ACTIVE_COMPARATOR|Low dose TSD|Subjects in this arm receive low dose (69 g/day) TSD for 16 weeks.
62625119|NCT04481594|EXPERIMENTAL|HPN-01|"Part 1: Including 6 dose cohorts (25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg). Each dose cohort will receive a single dose of HPN-01. One cohort of Part 1 will receive HPN-01 after a standard high fat/high calorie breakfast (the fed condition) to investigate the effect of food on the pharmacokinetics of HPN-01.~Part 2: Including 3 dose cohorts (50 mg, 100 mg and 200 mg). Each dose cohort will receive HPN-01 once daily for a consecutive 14 days."
62625120|NCT04481594|PLACEBO_COMPARATOR|Placebo|"Part 1: Including 6 dose cohorts (25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg). Each dose cohort will receive a single dose of HPN-01 placebo.~Part 2: Including 3 dose cohorts (50 mg, 100 mg and 200 mg). Each dose cohort will receive HPN-01 placebo once daily for a consecutive 14 days."
62625121|NCT06291129|OTHER|Hematological and Periodontal Parameters|Hematological parameters were recorded - fasting blood glucose and glycosylated hemoglobin - to confirm the allocation of each participant between the groups: diabetic (DM) and control (NDM). The clinical periodontal parameters, including plaque index (PI) and bleeding on probing (GI) full mouth (Ainamo \& Bay 1975), and plaque index (PI), probing depth of pocket (PPD), gingival recession (GR) and clinical attachment level (CAL). Gingival biotype clinical parameters were evaluated by three aspects: Gingival transparency to probing, Height of keratinized mucosa and Gingival thickness on permanent incisors and molars. For the periodontal parameters' examination, a periodontal probe PCP15 (PCP-UNC15, Hu-Friedy, Chicago, IL) was used, excluding third molars and erupting teeth. The intraexaminer agreement of the categorical variables (CAL) using the kappa calculation was 7.64, at the tooth level.
62625122|NCT06291129|NO_INTERVENTION|Orthodontic Parameters|The clinical orthodontic parameters were recorded by the Angle's Classification, witch evaluated occlusion of right and left canines and molars, and the Dental Aesthetic Index (DAI) that evaluates the prevalence of malocclusions, its severity and the need for treatment. DAI aspects evaluated were: upper teeth loss, lower teeth loss, crowding, spacing, diastema, maxillary misalignment, mandibular misalignment, anterior maxillary overjet, anterior mandibular overjet, anterior open bite, molar relationship.
62625123|NCT02705378|ACTIVE_COMPARATOR|Polyethylene glycol|17g power qday; reconstituted in water for naso/orogastric tube administration
62625124|NCT02705378|EXPERIMENTAL|naloxegol|25mg qday; crushed pill reconstituted in water for naso/orogastric tube administration
62625125|NCT01450618||Atazanavir|HIV patients on antiretroviral therapy using Atazanavir
62625126|NCT01450618||Darunavir|HIV patients on antiretroviral therapy using Darunavir
62625127|NCT01450618||Fosamprenavir|HIV patients on antiretroviral therapy using Fosamprenavir
62625128|NCT01450618||Lopinavir|HIV patients on antiretroviral therapy using Lopinavir
62625129|NCT00817388||1|patients will be asked to provide a urine specimen and complete a questionnaire.
62625130|NCT00851188|EXPERIMENTAL|internet CBT self-help|CBT via the internet
62625131|NCT00851188|EXPERIMENTAL|CBT self-help booklet|
62625132|NCT00851188|ACTIVE_COMPARATOR|Waiting list|
62450056|NCT00698906|EXPERIMENTAL|Group A|
62450057|NCT00698906|EXPERIMENTAL|Group B|
62450058|NCT00698906|EXPERIMENTAL|Group C|
62450059|NCT00698906|EXPERIMENTAL|Group D|
62450060|NCT00698906|EXPERIMENTAL|Group E|
62450061|NCT00698906|ACTIVE_COMPARATOR|Group F|
62450062|NCT01834053|OTHER|STEM CELL|Transfer of autologous Stem cell( MNCs) intrathecally
62625133|NCT01013831|EXPERIMENTAL|Prevention (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
62625134|NCT03488797|EXPERIMENTAL|Experimental|Supervised web- and home-based exercise intervention
62625135|NCT03488797|NO_INTERVENTION|No Intervention|"Control group - Standard of Care~* Re-assessment 24 weeks (6 month) after enrolment.~* Afterwards crossover into experimental group"
62625136|NCT00402623|PLACEBO_COMPARATOR|1|placebo
62625137|NCT00402623|ACTIVE_COMPARATOR|2|quercetin (food supplement)
62625138|NCT01420341|ACTIVE_COMPARATOR|Co-trimoxazole 12|Receive treatment with co-trimoxazole for 12 weeks.
62625139|NCT01420341|EXPERIMENTAL|Co-trimoxazole 20|Receive treatment with co-trimoxazole for 20 weeks.
62625140|NCT06321120|EXPERIMENTAL|Variability-based lenvatinib treatment|Dosages and administration times were tailored within individual predefined ranges to accommodate personalized therapeutic regimens. The first level of the algorithm, employed in the present study, utilizes a pseudo-random number generator to select dosages and administration times from the ranges stipulated by the physician.
62625141|NCT03791112|EXPERIMENTAL|50mg QD|Participants received 50 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
62625142|NCT03791112|EXPERIMENTAL|100mg QD|Participants received 100 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
62625143|NCT03791112|EXPERIMENTAL|200mg QD|Participants received 200 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
62625144|NCT03791112|EXPERIMENTAL|300mg QD|Participants received 300 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
62625145|NCT03791112|EXPERIMENTAL|400mg QD|Participants received 400 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
62625146|NCT03791112|EXPERIMENTAL|500mg QD|Participants received 500 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
62625147|NCT01401946|ACTIVE_COMPARATOR|soy isoflavones|
62625148|NCT01401946|PLACEBO_COMPARATOR|Placebo|
62625149|NCT01337817|EXPERIMENTAL|Ariva Silver Wintergreen|Subjects allow study product lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
62625150|NCT01337817|ACTIVE_COMPARATOR|Ariva Wintergreen|Subjects allow study comparator lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
62625151|NCT00821405||peritoneal dialysis|peritoneal dialysis patient lasting for more than 3 months
62850886|NCT02215811|EXPERIMENTAL|Mesenchymal stromal cells|
62850887|NCT05995067||control group|-healthy groups/without the condition
62850888|NCT05995067||study group|-diseased group-/with the condition (periodontitis)
62450063|NCT05720572|EXPERIMENTAL|Antazoline|"Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line.~After drug administration the patient will be observed for 3 hours after the first dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines."
62625152|NCT05258682|EXPERIMENTAL|BromAc|BromAc (Bromelain and Acetylcysteine combination) will be administered three times (3x) per day for five (5) days in a dose escalation format via inhalation using an approved vibrating mesh nebuliser (Aerogen Pro). Dose escalation concentration levels are BromAc 125ug/20mg/ml, 250ug/20mg/ml, 375ug/20mg/ml. All levels will receive 5ml of BromAc.
62625153|NCT02382809|EXPERIMENTAL|DC071 (0.2% chlorhexidine digluconate)|
62625154|NCT02382809|PLACEBO_COMPARATOR|Placebo|
62625155|NCT04472494|EXPERIMENTAL|Abatacept + Standard of care|
62625156|NCT04472494|PLACEBO_COMPARATOR|Placebo infusion + Standard of care|
62625157|NCT05964153|EXPERIMENTAL|Circulating free DNA analysis|"* Correlate the results of the tissue samples with those of the blood samples, the concentration of ctDNA found, and the magnetic resonance images prior to the biopsies.~* Compare other variables such as time, money, and the impact on the patient (recovery time after biopsies, pain, sequelae,...) between the liquid biopsy procedure and the conventional tissue biopsy procedure."
62625158|NCT02359279|EXPERIMENTAL|Contrast|All subjects will be in one group who will have a control radiograph before applying sodium iodide to interproximal surfaces of teeth when another radiograph will be taken to test for the presence of caries cavitation.
62625159|NCT01580566||Group 1 - Control|"Non-Q wave MI subjects with normal cardiac and renal function (defined as eGFR \>60ml/min) not undergoing a cardiac procedure involving contrast will serve as control for renal injury subjects."
62625160|NCT01580566||Group 2 - stable CAD or non-Q wave MI|Patients undergoing coronary angiography +/- PCI for stable CAD or non-Q wave MI with normal cardiac and renal function (defined as eGFR \>60ml/min) will control for the contrast STEMI patients are likely to receive as part of their post-MI management
62625161|NCT01580566||Group 3 - Acute STEMI without chronic kidney disease|Acute STEMI patients (n=40), without chronic kidney disease (defined as eGFR ≥60ml/min).
62625162|NCT01580566||Group 4 - Acute STEMI with kidney disease|Acute STEMI patients (n=40), with evidence of background chronic kidney disease (eGFR \<60ml/min).
62625163|NCT02447471||study group|all participants
62625164|NCT05485870||Panvascular disease group|patients with panvascular diseases
62625165|NCT05485870||Healthy controls|Healthy controls
62625166|NCT00629759|EXPERIMENTAL|1|1e8 pfu (plaque forming units)total dose each treatment day
62625167|NCT00629759|EXPERIMENTAL|2|3e8 pfu (plaque forming units) total dose each treatment day
62625168|NCT00629759|EXPERIMENTAL|3|1e9 pfu (plaque forming units) total dose each treatment day
62850889|NCT05724706||Patients with peri-implantitis (PI)|The PI group consisted of 23 patients (9M/14F) with ages ranging from 29 to 66 years (mean 51,91 ± 10,63). This group was selected based on the success criteria of Misch et al. 2008; patients with clinical findings such as bleeding and/or sweeping in their implants, pain or tenderness during function, and exudation in peri-implant tissues, with at least 1 implant with a pocket depth of more than 7 mm and radiographic bone loss of at least 4 mm or more around the implant were included.
62625169|NCT00629759|EXPERIMENTAL|4|3e9 pfu (plaque forming units) total dose each treatment day
62625170|NCT03835507|PLACEBO_COMPARATOR|Control group|Inject Normal saline 100ml \* 12 times (1month apart)
62625171|NCT03835507|EXPERIMENTAL|Low dose group|Inject 500IU/kg of EPO mixed with normal saline 100ml \* 12 times (1month apart)
62625172|NCT03835507|EXPERIMENTAL|High dose group|Inject 750IU/kg of EPO mixed with normal saline 100ml \* 12 times (1month apart)
62625173|NCT01388712|PLACEBO_COMPARATOR|Placebo|
62625174|NCT01388712|ACTIVE_COMPARATOR|Probiotics|Lactobacillus reuteri DSM 17938
62087954|NCT02061761|EXPERIMENTAL|Part D - relatlimab + nivolumab (Cohort expansion)|
62625175|NCT02347735||Anastomotic leakage|Of the entire cohort, data collected from patients suffering from anastomotic leakage will be evaluated and compared to patients that did not develop anastomotic leakage. No interventions, only data collection.
62625176|NCT02347735||No anastomotic leakage|Of the entire cohort, data collected from patients suffering from anastomotic leakage will be evaluated and compared to patients that did not develop anastomotic leakage. No interventions, only data collection.
62625177|NCT02162095||Chronic obstructive pulmonary disease|Approximately 100 participants with documented chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) \< 0.7).
62625178|NCT02162095||Control|Approximately 100 participants with exclusion of chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) \> 0.7).
62625179|NCT01017081|ACTIVE_COMPARATOR|Control|Non-mandatory request to maintain lateral positioning to improve air exchange, to cough in order to clear secretion, and to perform diaphragmatic and deep breathing, for five minutes, once a day, during hospital stay.
62625180|NCT01017081|EXPERIMENTAL|Physiotherapy|"Physiotherapy: Children younger than 5 years: Manual Thoracic vibration (TV), thoracic compression (TC), positive expiratory pressure (PEP), and forced exhalation with the glottis open (huffing). Children aged 5 years or older: same procedures in addition to the ventilatory patterns, and a forced expiratory technique (FET), consisting of one or two huffs (forced expirations) followed by a period of relaxed, controlled diaphragmatic breathing, three times per day, for 10 to 12 minutes, during hospital admission."
62625181|NCT01758614|EXPERIMENTAL|bypass group|all the participants in this group will be performed EC-IC bypass surgery
62625182|NCT01758614|ACTIVE_COMPARATOR|medical group|all the participants in this group will be given medical therapy including aspirin 100mg per day or clopidogrel 75mg per day
62625183|NCT01497067|EXPERIMENTAL|CACHET|ACRYSOF CACHET Phakic Lens (L-series) previously implanted
62625184|NCT05230797|EXPERIMENTAL|zinc-oxide propolis|Propolis is a natural resinous mixture produced by honeybees from substances collected from parts of plants, buds, and exudates. The essential principle compounds responsible for biological activities are polyphenols, aromatic acids, and diterpenic acids. Numerous biological properties of propolis have been reported including cytotoxic, antiherpes, free radical scavenging, antimicrobial, and anti-HIV activities The antibacterial effect of propolis is bactericidal by inhibiting their mobility. Propolis kills the fungi and also inhibits the growth of the viruses.
62625185|NCT05230797|ACTIVE_COMPARATOR|zinc-oxide eugenol|Zinc oxide-eugenol cement (ZOE) has been used as a root canal filling material for primary teeth and has long been the material of choice of pediatric dentists worldwide, although it fails to meet the ideal requirements of root canal filling material for primary teeth due to limited antimicrobial action, and a slower rate of resorption than the roots of the primary teeth. Studies report that the success rate of ZOE ranges from 65% to 86% so it's materials of choice if primary teeth are not nearing exfoliation.
62625186|NCT04469634|EXPERIMENTAL|antibody response and memory B-cell|Regular blood draws to measure antibody responses and memory B-cell responses Regular swab collection to test for re-infection
62625187|NCT02073539|EXPERIMENTAL|chest compression with 5cm feedback|We will feedback by one accelerometer (U-cpr). U-cpr is android based smartphone application.
62625188|NCT02073539|EXPERIMENTAL|chest compression with 6cm feedback|We will feedback by one accelerometer(U-cpr). U-cpr is android based smartphone application.
62625189|NCT02073539|EXPERIMENTAL|chest compression with 7cm feedback|We will feedback by one accelerometer(U-cpr). U-cpr is android based smartphone application.
62450064|NCT05720572|ACTIVE_COMPARATOR|Propafenone|"Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line.~After drug administration the patient will be observed for 3 hours after the first dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines."
62625190|NCT03171597|OTHER|conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
62625191|NCT03171597|EXPERIMENTAL|Qi deficiency and blood stasis|Patients in this group will be treated by Shuanghe Decoction at the base of conventional western medicine.
62625192|NCT03171597|EXPERIMENTAL|Qi stagnation and blood stasis|Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.
62625193|NCT03171597|EXPERIMENTAL|Phlegm and blood stasis|Patients in this group will be treated by Gualou Xiebai Banxia Decoction \& Danshen Decoction at the base of conventional western medicine.
62625194|NCT02839031|EXPERIMENTAL|"CBT group"|
62625195|NCT02839031|SHAM_COMPARATOR|Control group|
62850890|NCT05724706||Patients with marginal bone loss (MBL)|The MBL group consisted of 22 patients (14M /8F) aged between 27 and 67 years (mean 53,00 ± 8,92). This group was based on the success criteria defined by Misch et al. 2008; patients for whom, in the clinical examination of implants, there was no bleeding, non-sweeping, non-mobility, with no exudation history of peri-implant tissues, no pain or sensitivity when in function, and there was at least 1 implant with 2-4 mm radiographic bone loss around the implant were included.
62450065|NCT04897828||Covered Stent Group|Patients with a dysfunctional hemodialysis vascular access undergoing treatment procedure using a covered stent (stent graft).
62625196|NCT03056612||Group 1|Group 1 patients with high risk of ACLF development (CLIF-C AD score ≥ 50)
62625197|NCT03056612||Group 2|Group 2 patients with low risk of ACLF (CLIF-C AD score \<50)
62625198|NCT03056612||ACLF|ACLF-patients were specified the patients who were admitted at hospital with ACLF,
62625199|NCT00738855|ACTIVE_COMPARATOR|1|Gastrografin group
62625200|NCT00738855|PLACEBO_COMPARATOR|2|Control group
62625201|NCT03076515|ACTIVE_COMPARATOR|Nerivio Migra active|This arm will use the active device for acute treatment of migraine at the migraine symptoms onset. the device will be applied on the upper arm and controlled by a dedicated smartphone application.
62625202|NCT03076515|SHAM_COMPARATOR|Nerivio Migra placebo|This arm will use the sham device for acute treatment of migraine at the migraine symptoms onset. the device will be applied on the upper arm and controlled by a dedicated smartphone application.
62625203|NCT05631145|EXPERIMENTAL|Morita therapy (MT) combined with Xingnao Kaiqiao self-administered acupressure (XKSA)|MT combined with XKSA for 2 weeks.
62625204|NCT05631145|PLACEBO_COMPARATOR|Morita therapy (MT)|MT alone for 2 weeks
62625205|NCT03852186|ACTIVE_COMPARATOR|Cognitive behavioral therapy|Manualized group-based cognitive behavioual therapy delivered by clinical psychologists and psychiatrists. The treatment consists of 14 sessions of each 2 hours.
62450066|NCT00299156|EXPERIMENTAL|Oral Clofarabine|10 mg (Group 1) or 20 mg (Group 2) tablets once a day for 5 days in a row and repeated every 4-8 week cycle.
62625206|NCT03852186|EXPERIMENTAL|Acceptance and commitment therapy|Manualized group-based Acceptance and Commitment therapy delivered by clinical psychologists and psychiatrists. The treatment consists of 14 sessions of each 2 hours.
62625207|NCT03088228||healthy pregnants|
62625208|NCT03088228||mild preeclampsia|
62625209|NCT03088228||severe preeclampsia|
62625210|NCT05730855||Oral Lichen Planus|
62625211|NCT05730855||Leukoplakia|
62625212|NCT05730855||Healthy control|
62625213|NCT05455619|EXPERIMENTAL|Evexomostat|Each subject will receive repeat doses (C1, C2...) for 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
62625214|NCT03939533|EXPERIMENTAL|Increased Volume Cohort - Cohort 1|Increased volume at each infusion site - patients will receive CUTAQUIG weekly and increase infusion volumes every 4 weeks
62625215|NCT03939533|EXPERIMENTAL|Increased Infusion Rate Cohort - Cohort 2|Increased infusion rate - patients will receive CUTAQUIG weekly and increase infusion rates every 4 weeks
62450067|NCT06288282||Patients with chronic back pain with lumbar, cervical or thoracic spine diagnoses.|
62850891|NCT05724706||Patients with healthy peri-implant tissues (HI)|The HI group consisted of 22 patients(7M/15F) with ages ranging from 29 to 62 years (mean 51,00 ± 8,45). This group was based on the success criteria defined by Misch et al. in 2008: Patients with no history of exudation in the periimplant tissues, no bleeding and suppuration during probing, no pain or sensitivity in function, no mobility, and at least 1 implant with a radiographic bone loss around the implant of less than 2 mm were included.
62850892|NCT05724706||Healthy control (HC)|21 individuals (8M/ 13F) whose ages ranged between 27 and 67 (mean 21.88 ± 11.21 years), who did not have any dental implants, and who were selected among the patient community were included the study as a healthy control group (HC).
62062308|NCT05492773|EXPERIMENTAL|Micro-osteoperforations|Experimental: Micro-Osteoperforations Technique(MOPs) Experimental: Micro-Osteoperforations Technique(MOPs) Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement.
62062309|NCT05492773|EXPERIMENTAL|Clear aligner|Traditional treatment The patients in this group will be receive treatment with the traditional clear aligners technique without any surgical procedure.
62062310|NCT05720585|EXPERIMENTAL|Intervention group|
62450068|NCT02852564|EXPERIMENTAL|Enrolled Participants|Administration of a single, 50 mg oral dose of ethacrynic acid prior to bladder tumor removal surgery (Transurethral Resection of Bladder Tumor \[TURBT\])
62450069|NCT06348836|ACTIVE_COMPARATOR|Closed-Chain exercise|4 exercises: 1)Single leg bridge, 2)side plank (with testing side down), 3) single leg squat, 4) banded squat Exercises to be performed with 3 sets of 10 repetitions each. Frequency will be 2 times per week for 6 weeks.
62450070|NCT06348836|ACTIVE_COMPARATOR|Open-Chain exercise|4 exercises: 1) Side plank (with testing side up), 2) clamshells, 3) front plank with hip extension, 4)wall slide Exercises to be performed with 3 sets of 10 repetitions each. Frequency will be 2 times per week for 6 weeks.
62450071|NCT04559607|EXPERIMENTAL|Experimental group: TACE+Camrelizumab+Apatinib|Camrelizumab (iv. infusion of 200 mg); Apatinib (po. administration of 250 mg); TACE
62450072|NCT04559607|ACTIVE_COMPARATOR|Control group: TACE|TACE
62450073|NCT04842487|EXPERIMENTAL|Treatment arm|"1. Lenalidomide：25mg po QN,D1-10~2. Rituximab: 375mg/m2, ivdrip, D1~3. CTX: 750mg/m2, iv or ivdrip, D1~4. THP: 50mg/m2, iv or ivdrip, D1~5. VCR： 1.4 mg/m2 , iv（max：2mg）, D1~6. Pred: 60mg/m2, po, D1-5"
62450074|NCT02750306|EXPERIMENTAL|Suvorexant|Participants will receive 1 suvorexant tablet every night for up to 4 weeks. After 2 weeks of double-blind treatment at 10 mg, participants' suvorexant dose may be increased to 20 mg if their Clinical Global Impression of Insomnia Severity (CGI-S) is ≥3 and investigators feel they can tolerate the increased dose.
62450075|NCT02750306|PLACEBO_COMPARATOR|Placebo|Participants receive 1 placebo-matching suvorexant tablet every night for up to 4 weeks. After 2 weeks of double-blind treatment at 10 mg, participants' placebo-matching dose can be increased to 20 mg if their CGI-S is ≥3 and investigators feel they can tolerate the increased dose.
62450076|NCT01362933||VTE treatment in cancer patient|All patients with cancer present in the clinic, hospital, out patient diagnosed with a VTE during the 6 previous months.
62450077|NCT04165681|EXPERIMENTAL|Limbix Spark|A 5 week mobile + virtual reality CBT-based program
62450078|NCT03567213|EXPERIMENTAL|Surgical implantation of the CortiCom system|
62450079|NCT02763722|EXPERIMENTAL|Emollient spray product|"Study design~A 3 visits are planned:~0 week (first visit) 2nd week (second visit) 4th week (third visit)~B. During each visit will be made:~1. The clinical examination (including an assessment of any adverse effects)~2. Evaluation of transepidermal water loss (TEWL) and capacitance of outer areas of the stratum corneum as an indirect assessment of skin hydration,~3. fill out questionnaires CDLQI (The Children's Dermatology Life Quality Index)~4. will assess VAS (visual analogue scale)~C. All patients will be instructed to use emollients spray the entire surface of the skin at least twice daily for four weeks."
62450080|NCT02320279||Women in labor|Pregnant women, women in labor, and women who are admitted to labor and delivery for scheduled c-sections will form the eligible population for recruitment into our study.
62450081|NCT04569500|EXPERIMENTAL|PETAL program|Patients with total laryngectomy and their close relatives, benefiting from the therapeutic education program PETAL
62450082|NCT04569500|NO_INTERVENTION|Usual care|Patients with total laryngectomy and their close relatives, benefiting from the usual care
62450083|NCT04191564|EXPERIMENTAL|low perfusion|fluid restriction based on the goal directed fluid therapy is maintained during the whole case and a state of low perfusion is created by reducing the systolic blood pressure below 100 mmHg by vasoactive medications like cleviprex or nicardipine, by increasing positive end expiratory pressure (PEEP) and by a very short period of a high IAP of 20 mmHg only during firing.
62450084|NCT04191564|EXPERIMENTAL|normal perfusion|Perfusion pressure is maintained above 100 mmHg with free fluid loading iv and the lowest IAP possible during the whole procedure.
62450085|NCT01717898|EXPERIMENTAL|Abiraterone/prednisone + BEZ235|In Phase I, a dose escalation of BEZ235 will be performed using a standard 3 + 3 design to determine the maximum tolerated dose (MTD) of BEZ235 given in combination with continuous fixed doses of Abiraterone Acetate and prednisone. This BEZ235 dose will be used in the phase II portion of the study.
62062311|NCT03946800|EXPERIMENTAL|MEDI1191 escalation in combination with durvalumab|MEDI1191 escalation in sequential and concurrent combination with durvalumab
62062312|NCT03946800|EXPERIMENTAL|MEDI1191 expansion in combination with durvalumab|MEDI1191 expansion in concurrent combination with durvalumab
62062313|NCT00449098|EXPERIMENTAL|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
62062314|NCT00449098|ACTIVE_COMPARATOR|MMC|Trabeculectomy with MMC
62062315|NCT03584503|ACTIVE_COMPARATOR|Group SA|Group SA intubated with Suction Above Cuff Endotracheal Tube
62062316|NCT03584503|NO_INTERVENTION|Group C|Group C intubated with classic endotracheal tube
62062317|NCT00535743|PLACEBO_COMPARATOR|Arm A. Placebo; 3 min after 1 mg/kg Esmeron®|Placebo (single intravenous (IV) bolus) administered 3 minutes (min) after the bolus intubation dose of 1 mg/kg Esmeron®.
62062318|NCT00535743|EXPERIMENTAL|Arm B. 2 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
62625216|NCT03939533|EXPERIMENTAL|Every Other Week Dosing Cohort - Cohort 3|Every other week dosing - patients will receive CUTAQUIG every other week at the equivalent of twice their body-weight dependent \[mg/kg\] weekly dose
62062319|NCT00535743|EXPERIMENTAL|Arm C. 4 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
62062320|NCT00535743|EXPERIMENTAL|Arm D. 8 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
62062321|NCT00535743|EXPERIMENTAL|Arm E. 12 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
62450086|NCT01977261|EXPERIMENTAL|Opening-wedge HTO|Opening-wedge high tibial osteotomy fixated with a Puddu-plate
62450087|NCT01977261|ACTIVE_COMPARATOR|Closing-wedge HTO|Closing-wedge high tibial osteotomy fixated with 2 staples
62450088|NCT00928837|ACTIVE_COMPARATOR|flavocoxid 250 mg|Medical Food product
62450089|NCT00928837|ACTIVE_COMPARATOR|Naproxen|antiinflammatory
62450090|NCT00928837|PLACEBO_COMPARATOR|Placebo|Placebo
62450091|NCT00928837|EXPERIMENTAL|flavocoxid 500 mg|medical food product
62450092|NCT04177264|EXPERIMENTAL|Osteopathic Manipulative Treatment (OMT)|In 4 randomized study sessions, combinations of two different osteopathic manipulative treatment (OMT) techniques (occipito-atlantal decompression \[OA DC\] and splenic lymphatic pump technique \[SpLPT\]) or their respective sham interventions will be performed. The 4 study sessions are at least one month apart and consist of 3 consecutive study days on which the same combination of OMT techniques or sham interventions will be performed.
62450093|NCT04177264|EXPERIMENTAL|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|In 4 randomized study sessions, combinations of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), osteopathic splenic lymphatic pump technique (SpLPT) or their respective sham interventions will be performed. The 4 study sessions are at least one month apart and consist of 3 consecutive study days on which the same combination of taVNS, SpLPT, or sham interventions will be performed.
62450094|NCT04177264|NO_INTERVENTION|Time Control|In 4 study sessions, no intervention will be performed. As with the two experimental arms, the 4 study sessions are at least one month apart and consist of 3 consecutive study days on which no intervention will be performed. This arm serves as a time control group.
62450095|NCT00801190|ACTIVE_COMPARATOR|HES (130/0.4)|33 ml/kg i.v. HES (130/0.4)
62450096|NCT00801190|PLACEBO_COMPARATOR|Ringer's Lactate|33 ml/kg i.v. Rigner's Lactate
62450097|NCT04709159|ACTIVE_COMPARATOR|Intervention|"Participants on this arm will use Interactive Voice Response (IVR) daily pill reminders, thrice-weekly health messages, clinic appointment reminders, remote symptom reporting service and a 24 hour toll-free number to access services. These participants will also have the option to co-register a caregiver who will also receive daily pill reminders, clinic appointment reminder, weekly health tips and remote symptom reporting service.~In addition, these participants will receive the standard of care according to Uganda National Tuberculosis Treatment guidelines."
62450098|NCT04709159|NO_INTERVENTION|Standard|These participants will receive the standard of care according to Uganda National Tuberculosis Treatment guidelines.
62450099|NCT05958290|EXPERIMENTAL|Discontinuation of antibiotics|
62450100|NCT05958290|NO_INTERVENTION|Standard treatment|
62450101|NCT01189864||Ciprofloxicin or Vigamox or other.|
62625217|NCT01935986|EXPERIMENTAL|probiotic|dietary supplement
62625218|NCT01935986|PLACEBO_COMPARATOR|placebo|dietary supplement without probiotic
62850893|NCT02372227|EXPERIMENTAL|VS-5584 and VS-6063|
62850894|NCT03120351|EXPERIMENTAL|Lidocaine patch 5%|1) Group I: Patients will receive topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off. They will also receive opioids as needed after the surgery. Initially, they may receive IV fentanyl repeated clinician boluses, later oxycodone will be given 5-10 mg q4-6 hours as needed for pain.
62850895|NCT03120351|PLACEBO_COMPARATOR|Placebo Patch|2) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off. They will also receive opioids as needed after the surgery. Initially, they may receive IV fentanyl clinician boluses, later oxycodone will be given in doses from 5-10 mg q4-6 hours as needed for pain.
62266808|NCT04778098|EXPERIMENTAL|SMS group|"After postoperative standard discharge education was provided to the patients in the SMS group, they were given an individualized written Postoperative Medication Reference Chart. The patient/relative, whose contact information was received, was informed that they would be reminded via text message (SMS). SMS reminders which were individualized according to the patient based on the doctor's directive, were sent to the patients in the SMS group by the researcher clinical nurse (A. Ş). SMS sending started on postoperative day 1 and ended on day seven.~SAI was applied again to all patients who came to the outpatient clinic for control on postoperative day seven. Unlike the control group, the Patient Satisfaction Form, which was prepared for the use of SMS reminders, was applied to the patients in the SMS group. Confirmation was obtained from the patients and their relatives that SMS reminders were received every day."
62625219|NCT05514613||Group G|Group G is a tracheostomy group opened using the anatomical sign technique (Griggs technique).
62625220|NCT05514613||Group U|Group U; Ultrasound-guided is used during tracheostomy technique.
62625221|NCT01941199|EXPERIMENTAL|D → M → D+M|D : DA-1229 5mg qd, M : metformin 1000mg bid
62625222|NCT01941199|EXPERIMENTAL|D → D+M → M|D : DA-1229 5mg qd, M : metformin 1000mg bid
62625223|NCT01941199|EXPERIMENTAL|M → D → D+M|D : DA-1229 5mg qd, M : metformin 1000mg bid
62625224|NCT01941199|EXPERIMENTAL|M → D+M → D|D : DA-1229 5mg qd, M : metformin 1000mg bid
62625225|NCT01941199|EXPERIMENTAL|D+M → M → D|D : DA-1229 5mg qd, M : metformin 1000mg bid
62450102|NCT01189864||Nonsteroidal (Acular, Voltaren Xibrom, etc)|
62450103|NCT01189864||Steroid (FML, Pred Forte, Flarex, etc.)|
62850896|NCT01379144|EXPERIMENTAL|latanoprost 75 ug|
62850897|NCT01379144|EXPERIMENTAL|latanoprost 100 ug|
62850898|NCT01379144|EXPERIMENTAL|latanoprost 125 ug|
62850899|NCT01379144|ACTIVE_COMPARATOR|latanoprost 50 ug|
62850900|NCT01870076|EXPERIMENTAL|Healing Touch Intervention|Healing Touch performed one hour prior to bed.
62850901|NCT01870076|SHAM_COMPARATOR|Healing Touch Sham|Healing Touch Sham provided one hour prior to bed.
62450104|NCT01065103|EXPERIMENTAL|FFR measurement|
62450105|NCT02678195|EXPERIMENTAL|3 days amoxicillin + 2 days placebo|3 days amoxicillin DT + 2 days placebo DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age).
62450106|NCT02678195|ACTIVE_COMPARATOR|5 days amoxicillin|5 days amoxicillin DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age).
62450107|NCT00882622|ACTIVE_COMPARATOR|RIPC|
62450108|NCT00882622|SHAM_COMPARATOR|CONTROL|
62625226|NCT01941199|EXPERIMENTAL|D+M → D → M|D : DA-1229 5mg qd, M : metformin 1000mg bid
62625227|NCT03678415|EXPERIMENTAL|Control|In the control arm, the community healthcare providers serve usual health education like counseling as they provided in perinatal period of enrolled mothers regular follow up basis. This health education is different from developed intervention. But service provider does not know. The investigators select community clinic before provide training regarding training manual. For this, the investigators selected 11 cluster randomly among the 23 community clinics' in the primary health care in study area and provide common health education instructions to the enrolled mothers. But service providers does not know the intervention package services that will provide in intervention arm's service providers.
62625228|NCT06365190|EXPERIMENTAL|cTBS group|On the basis of drug treatment, a course of TBS treatment is performed every eight weeks.
62625229|NCT06365190|OTHER|Drug group|Take antiparkinsonian medications regularly, with follow-up every 8 weeks including medication guidance and symptom assessment
62625230|NCT02932800|ACTIVE_COMPARATOR|"Ballerina associated with flap fixation"|"The catheter is anchored to the skin begins by a point U around the catheter insertion site and followed by a series of woven points around the catheter , commonly referred to as  node dancer  to pass the wires on each side of the orifices located at the catheter distal flaps and hold three consecutive nodes . Then, the clamping is carried out of the catheter to the skin by means of a simple point and hold three consecutive nodes in each lateral hole of the fastening flap while leaving, between the fastening flap and the puncture site a space 2 cm distance for viewing the ostium ."
62625231|NCT02932800|ACTIVE_COMPARATOR|the usual fixation technique|The catheter is attached to the skin with a simple point and holding three we row on each side hole fixing fin while leaving, between the fastening flap and the puncture site , an area of 2 cm away for viewing ostium . The catheter is anchored to the skin by a simple point and holding three consecutive us in each hole of the side flap in the distal region.
62850902|NCT01870076|ACTIVE_COMPARATOR|Control, Presence|Control, Presence Intervention in the room one hour prior to bed.
62850903|NCT01870076|NO_INTERVENTION|Control, No Presence|No Presence in the room one hour prior to bed.
62850904|NCT05755061|EXPERIMENTAL|GEMS Plus|Home-based aerobic walking exercise that exceeds published physical activity guidelines for adults with MS
62850905|NCT05755061|ACTIVE_COMPARATOR|GEMS|Home-based aerobic walking exercise that meets published physical activity guidelines for adults with MS
62850906|NCT04491604|EXPERIMENTAL|B-VEC|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
62850907|NCT04491604|PLACEBO_COMPARATOR|Placebo|Matching masked inactive topical gel
62450109|NCT04161144|ACTIVE_COMPARATOR|Rapamycin 15mg (sirolimus)|Participants will receive three 5mg pills from a nurse in the Research Nexus, some participants will receive the study medication and others will be randomized to the placebo control group.
62625232|NCT02344511|EXPERIMENTAL|Dalbavancin|"Patients with Creatine Clearance (CrCl) greater than 30 mL/min and patients receiving regular hemodialysis or peritoneal dialysis will receive 15 mg/kg Intravenous (IV) dalbavancin over 30 (+/- 5) minutes on Day 1 and on Day 8, not to exceed 1500 mg per administration in children at least 12 years and not to exceed 1000 mg per administration in children less than 12 years of age.~• Patients with CrCl \< 30 mL/min who are not receiving regular hemodialysis or peritoneal dialysis will receive 10 mg/kg IV dalbavancin over 30 (+/- 5) minutes on Day 1 and on Day 8, not to exceed 1000 mg per administration in children at least 12 years and not to exceed 750 mg per administration in children less than 12 years of age.~Additionally, subjects randomized to the dalbavancin group will receive an IV placebo infusion at times corresponding to comparator group dosage times for the first eight days."
62625233|NCT02344511|ACTIVE_COMPARATOR|4 Comparators|"cefazolin, oxacillin, nafcillin or vancomycin according to the commercial label~Patients with normal renal function will receive either vancomycin 15 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour) not to exceed a daily total dose of 4000 mg, with dose adjustment based on local standard of care to achieve serum trough concentrations of 10 μg/mL to 20 μg/mL; or cefazolin 25 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour); or nafcillin or oxacillin 50 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour)."
62062322|NCT00535743|EXPERIMENTAL|Arm F. 16 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
62450110|NCT04161144|PLACEBO_COMPARATOR|Placebo|Participants will receive three 5mg pills from a nurse in the Research Nexus, some participants will receive the study medication and others will be randomized to the placebo control group.
62450111|NCT02224391|EXPERIMENTAL|Arm I (ABM training)|Patients receive ABM training over 30 minutes through a smartphone on days 1-14. Patients then receive nicotine patches for up to 8 weeks.
62450112|NCT02224391|SHAM_COMPARATOR|Arm II (sham training)|Patients undergo sham training on days 1-14. Patients then receive nicotine patches for up to 8 weeks.
62450113|NCT01158456||African Americans|Subjects will be classified as African American if they report themselves, biological parents and both sets of biological grandparents as African American or African descent.
62450114|NCT01158456||European American|Subjects will be classified as European American if they report themselves, biological parents and both sets of biological grandparents as European American or European descent.
62450115|NCT06167538||SABI patients with a tracheal tube treated with the new decannulation procedure.|All adult SABI patients ≥ 18 years with a tracheal tube at admission to the Department of Brain Injury from September 2021 to October 2022 and treated with the new decannulation procedure.
62450116|NCT06167538||SABI patients in whom decannulation was attempted before implementation of the new procedure.|Patients with SABI and a tracheal tube in whom decannulation was attempted between July 2019 until December 2020 will serve as a historical control group.
62450117|NCT02848599|ACTIVE_COMPARATOR|morphine|The patient-controlled intravenous analgesia with morphine (basal flow of 0.5-2 mg / h, bolus dose of 0.5 mg, lockout interval of 20 minutes, hour limit of 3 doses), which will be carried out 72 hours after the surgery
62450118|NCT02848599|ACTIVE_COMPARATOR|levobupivacaine|Upon completion of the operation for a period of 72 hours will be implemented continuous epidural local anesthetic through the Patient Controlled Analgesia (PCA) pump (Levobupivacaine 0.125%, basal flow of 6 ml / hour, a bolus dose of 2 ml, lockout interval of 20 minutes, hour limit of 3 doses).
62450119|NCT00780026|EXPERIMENTAL|Strict Glycemic Control|strict glycemic control (80 to 110 mg/dl)
62450120|NCT00780026|NO_INTERVENTION|Standard of Care Control|standard of care insulin dosing
62450121|NCT02848703|EXPERIMENTAL|healthy volunteers|
62450122|NCT00678067|PLACEBO_COMPARATOR|Placebo|12 hypercholesterolemic children 3-13 years of age
62450123|NCT00678067|EXPERIMENTAL|DHA+EPA group|12 hypercholesterolemic children 3-13 years of age
62450124|NCT00678067|EXPERIMENTAL|DHA Group|12 hypercholesterolemic children 3-13 years of age
62450125|NCT02611024|EXPERIMENTAL|Lurbinectedin Escalation Group|Irinotecan 75 mg/m\^2 as a 90-min (-5-min/+30-min) intravenous (i.v.) infusion, followed by Lurbinectedin with starting dose of 1.0 mg/m\^2 as a 60-min (-5-min/+20-min) i.v. infusion followed by Irinotecan alone on Day 8 (at the same dose as Day 1 and as a 90-min \[-5-min/+30-min\] i.v. infusion)
62450126|NCT02611024|EXPERIMENTAL|Irinotecan Escalation Group|Starting dose of Irinotecan 15 mg/m\^2 as a 90-min (-5-min/+30-min) i.v. infusion, followed by Lurbinectedin 3.0 mg/m\^2 as a 60-min (-5-min/+20-min) i.v. infusion followed by Irinotecan alone on Day 8 (at the same dose as Day 1 and as a 90-min \[-5-min/+30-min\] i.v. infusion).
62450127|NCT02611024|EXPERIMENTAL|Intermediate Escalation Group|Starting dose of Irinotecan 50 mg/m\^2 as a 90-min (-5-min/+30-min) i.v. infusion, followed by Lurbinectedin 2.6 mg/m\^2 as a 60-min (-5-min/+20-min) i.v. infusion. No Irinotecan dose will be administered on Day 8 in this group.
62450128|NCT04039542|EXPERIMENTAL|Compassion focused therapy (CFT)|A group programme of CFT running for 10 sessions lasting 90 minutes per session.
62450129|NCT02920164|ACTIVE_COMPARATOR|Auricular acupuncture|Auricular acupuncture with indwelling fixed auricular acupuncture needles
62450130|NCT02920164|PLACEBO_COMPARATOR|Placebo acupuncture|"Placebo acupuncture with placebo fixed needles"
62450131|NCT02920164|NO_INTERVENTION|Standard therapy|No intervention, just observation
62062323|NCT00535743|PLACEBO_COMPARATOR|Arm G. Placebo; 15 min after 1 mg/kg Esmeron®|Placebo (single intravenous (IV) bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
62062324|NCT00535743|EXPERIMENTAL|Arm H. 2 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
62625234|NCT04482088|EXPERIMENTAL|OTC & OTEE|Every participant will receive 10 weeks of occupational therapy in a clinic environment (OTC) followed by 10 weeks of occupational therapy in an equine environment
62625235|NCT05055154|EXPERIMENTAL|Very low calorie diet|Use of very low calorie diet prepared in the hospital
62625236|NCT00520039|EXPERIMENTAL|Standard Care Plus OMM|Subjects will receive active intervention with osteopathic manipulative medicine (OMM) using a prescribed standardized treatment protocol which is age appropriate. Subjects will also receive standard care for otitis media from their referring physician.
62625237|NCT00520039|NO_INTERVENTION|Standard Care Only|Subjects will receive standard care only for otitis media from their regular referring physician
62625238|NCT03195322|EXPERIMENTAL|Pre-pectoral Tissue Expander|Pre-pectoral immediate tissue expander breast reconstruction with complete AlloDerm® coverage to reinforce breast tissues.
62625239|NCT03357848||Study group|Surgical patients receiving nutritional support (enteral and/or parenteral nutrition) pre and/or after surgery
62850908|NCT02428478|ACTIVE_COMPARATOR|Desipramine First, Placebo Second|Desipramine 200 mg administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching desipramine administered 2 hours before normal sleep time on second study night.
62850909|NCT02428478|ACTIVE_COMPARATOR|Placebo First, Desipramine Second|Placebo-matching desipramine administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then desipramine administered 2 hours before normal sleep time on second study night.
62850910|NCT04036370|ACTIVE_COMPARATOR|PECS group|In addition to routine analgesic protocol; before anaesthesia induction; following the PECS I + II block, a continuous infusion catheter will be placed at the PECS II block level under the guidance of USG, and local anesthetic infusion will be started via the catheter at the end of the operation.
62062325|NCT00535743|EXPERIMENTAL|Arm I. 4 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
62450132|NCT04712656||OSA Subjects Treated with CPAP|Patients with moderate to severe OSA (ODI4\>15/h) who accept CPAP therapy.
62450133|NCT04331756|OTHER|Guiding Emergence From Anaesthesia Without Tragus Pressure|Monitoring of patients and removal of laryngeal mask airway (LMA) as per routine practice in post anaesthesia care unit (PACU)
62850911|NCT04036370|SHAM_COMPARATOR|Control group|Peroperative and postoperative routine analgesic protocol will be performed with no additional intervention (block).
62062326|NCT00535743|EXPERIMENTAL|Arm J. 8 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
62450134|NCT04331756|EXPERIMENTAL|Guiding Emergence From Anaesthesia With Tragus Pressure|Tragus pressure documentation of planes of emergence from anaesthesia - regular 3-5 minutes follow up with Tragus pressure till removal of airway device or rejection of it by patient
62450135|NCT03763500|NO_INTERVENTION|Care as usual|"Regular care at participating hospitals:~Extended written information and education of patients with atrial fibrillation."
62062327|NCT00535743|EXPERIMENTAL|Arm K. 12 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
62450136|NCT03763500|ACTIVE_COMPARATOR|Internet-based education|Patients randomized in this arm receive an Internet-based educational program in addition to extended written information. This includes 6 steps with detailed information on background, symptoms, investigations, treatment options, life-style as well as one part with guides to self management.
62450137|NCT01703507|EXPERIMENTAL|Arm A (Ipilimumab and Whole Brain Radiation Therapy)|Patients receive ipilimumab IV over 90 minutes once in weeks 1, 4, 7, and 10. Patients also undergo WBRT 5 days a week in weeks 1-2.
62450138|NCT01703507|EXPERIMENTAL|Arm B (Ipilimumab and Stereotactic Radiosurgery)|Patients receive ipilimumab IV over 90 minutes as in Arm A. Patients also undergo SRS on day 1 in week 1.
62625240|NCT03357848||Control group|Surgical patients without nutritional support during the perioperative period
62625241|NCT04481763|OTHER|camrelizumab + radiotherapy|This is a open-labeled, single-arm, Investigator-initiated clinical trial ,Compared with historical data
62625242|NCT03518086|PLACEBO_COMPARATOR|Placebo Intravenous (IV) Every 4 Weeks (Q4W)|Placebo given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
62625243|NCT03518086|EXPERIMENTAL|300 Milligram (mg) Mirikizumab IV Q4W|300 mg mirikizumab given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
62062328|NCT00535743|EXPERIMENTAL|Arm L. 16 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
62625244|NCT03518086|PLACEBO_COMPARATOR|Placebo IV Q4W Maximum Extended Enrollment (ME2)|Placebo given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
62625245|NCT03518086|EXPERIMENTAL|300 mg Mirikizumab IV Q4W ME2|300 mg mirikizumab given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
62625246|NCT04328428|EXPERIMENTAL|(A)modified BL40 acupuncture|modified BL40 acupuncture Participants receive BL40 acupuncture once on the same site of low back pain.
62625247|NCT04328428|ACTIVE_COMPARATOR|(B)EM32 acupuncture|EM32 acupuncture Participants receive EM32 acupuncture once on the opposite site.
62850912|NCT05873218|EXPERIMENTAL|Ephedrine|3 minutes after the placement of a combined spinal epidural with 25 mcg fentanyl, 7.5 mg ephedrine IV will be administered to the patient, 12 minutes later, a second dose of 7.5mg will be administered to the patient as long as the patient is not hypertensive (BP no greater than 140/90)
62850913|NCT05873218|PLACEBO_COMPARATOR|Placebo|3 minutes after the placement of a combined spinal epidural with 25 mcg fentanyl, 2.5cc 0.9% NS IV will be administered to the patient, 12 minutes later, a second dose of , 2.5cc 0.9% NS will be administered to the patient.
62850914|NCT04911985||ICU Patients with PAC|All patients admitted to the Medical ICU of the University Hospital Zürich, complying with the inclusion criteria and monitored by a pilmonary artery catheter
62850915|NCT04900532|EXPERIMENTAL|Effects of supplementation with tocotrienol on chronic kidney disease patients|Administration of tocotrienol-rich-fraction (TRF) capsules, containing 360mg of tocotrienol and 80mg of tocopherol twice a day for six months.
62850916|NCT04900532|PLACEBO_COMPARATOR|Effects of supplementation with tocotrienol on lipid profile of chronic kidney disease patients|Administration of placebo containing 0,96mg of tocotrienol and 1,76mg of tocopherol twice a day for three months.
62850917|NCT03890666|EXPERIMENTAL|Digital System (DS)|Participants will be trained on the use of the albuterol eMDPI DS (including instructions on how to use both the eMDPI and the App) and, upon demonstrating competency, will receive 2 albuterol eMDPI devices for use as reliever bronchodilators to replace their reliever treatment during the study. The eMDPI Digital System consists of 4 devices: Device 1: albuterol eMDPI (the test investigational medicinal product \[IMP\]); Device 2: Patient-facing App; Device 3: Digital health platform (DHP) (Cloud solution); and Device 4: Provider-facing Dashboard. Participants will receive 90 micrograms (mcg) albuterol, 1 to 2 oral inhalations every 4 to 6 hours, as needed for 12 weeks.
62450139|NCT03528408|EXPERIMENTAL|Nivolumab and Ipilimumab|All patients enrolled to the study will be treated with nivolumab 240 mg IV every 2 weeks plus ipilimumab 1mg/kg IV every 6 weeks. 1 cycle = 6 weeks.
62450140|NCT00681720|EXPERIMENTAL|1|
62450141|NCT05260645|EXPERIMENTAL|Experimental group|Intervention based on the Back School was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min.
62450142|NCT05260645|NO_INTERVENTION|Control group|I declare that I will not change my lifestyle during the study process.
62450143|NCT02012309|EXPERIMENTAL|HIV-seronegative|HIV-seronegative subjects will receive Prevnar (PCV-13) at week 0.
62450144|NCT02012309|EXPERIMENTAL|HIV-infected|HIV-infected subjects will receive Prevnar (PCV-13) at week 0, and Pneumovax (PPSV-23) at week 8 per Advisory Committee on Immunization Practices (ACIP) guidelines.
62450145|NCT02162758|EXPERIMENTAL|Dexlansoprazole 60 milligram (mg) QD|Dexlansoprazole 60 mg, delayed-release capsules, orally, QD and dexlansoprazole 60 mg placebo-matching capsules, orally, once daily for up to 12 months.
62450146|NCT02162758|EXPERIMENTAL|Dexlansoprazole 60 mg BID|Dexlansoprazole 60 mg, delayed-release capsules, orally, BID for up to 12 months.
62450147|NCT00977834||Group 1|Patients with lymphoma or lung cancer
62450148|NCT00977834||Group 2|Caregivers
62450149|NCT05588284|EXPERIMENTAL|Pharmacomechanical Catheter-directed Thrombolysis for acute DVT|AngioJet, Boston Scientific
62450150|NCT05588284|PLACEBO_COMPARATOR|anticoagulation alone for acute DVT|anticoagulation alone for acute DVT
62450151|NCT02371525|NO_INTERVENTION|Standard of Care|
62450152|NCT02371525|EXPERIMENTAL|Prepmate|
62450153|NCT04291066|EXPERIMENTAL|Treatment|oral N-acetyl cysteine and oral multivitamin tablets
62450154|NCT04291066|NO_INTERVENTION|Non-Treatment|Routine Care
62625248|NCT04328428|ACTIVE_COMPARATOR|(C)BL40 acupuncture|BL40 acupuncture Participants receive BL40 acupuncture once on the same site of low back pain
62450155|NCT00720798|EXPERIMENTAL|Tocilizumab|Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.
62625249|NCT04168255|OTHER|Retinal detachment|Retinal detachment with proliferative vitreoretinopathy and inferior breaks
62625250|NCT06612294|EXPERIMENTAL|PEF group with active booster|This arm will have 3 intervention sessions over 6 weeks and an additional (active) session at 6-month time point.
62450156|NCT03912207|EXPERIMENTAL|Group 1, 2 Day Bronchoscopy|Group 1: 10 volunteers will receive 1 x 10\^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 1 volunteers will have a bronchoscopy 2 days post challenge
62450157|NCT03912207|EXPERIMENTAL|Group 2, 7 Day Bronchoscopy|Group 2: 10 volunteers will receive 1 x 10\^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 2 volunteers will have a bronchoscopy 7 days post challenge
62450158|NCT03912207|EXPERIMENTAL|Group 3, 14 Day Bronchoscopy|Group 3: 10 volunteers will receive 1 x 10\^7 cfu aerosol inhaled BCG (Arm A) and 3 volunteers will receive aerosol inhaled normal saline placebo (Arm B). All Group 3 volunteers will have a bronchoscopy 14 days post challenge Volunteers in group 7 and group 3 (arm A) will be offered an optional follow up at 12 months, in order of enrolment until 10 such visits have been conducted. For group 3 volunteers this will be offered after unblinding.
62625251|NCT06612294|EXPERIMENTAL|PEF group with control booster|This arm will have 3 intervention sessions over 6 weeks and a control booster session at the 6-month time point.
62625252|NCT06612294|PLACEBO_COMPARATOR|Control Group|This arm will have 3 control sessions over 6 weeks and a control booster session at 6-month time point.
62625253|NCT02349139|EXPERIMENTAL|ASN001: Escalating dose Part A|The dose of ASN001 will be based on the assigned study group. The initial dose level of ASN001 will be 50 mg daily. After a safety review, the dose may be escalated for the next group of subjects. Additional dose levels are 100 mg, 200 mg, 300 mg, and 400 mg.
62850918|NCT03890666|ACTIVE_COMPARATOR|Concurrent Control (CC)|Participants will be treated with their standard of care albuterol-administering reliever inhalers and will use the digital system during the treatment period. Participants will be reimbursed or given a voucher to use to purchase their existing reliever medications.
62266809|NCT04778098|NO_INTERVENTION|Control group|the Patient Identification Form and SAI were applied to patients in the control on the day of surgery (postoperative day 0). Routine discharge education was provided to all patients by clinical nurses. During the discharge of the patients in the control group, they were informed about the change of dressing on the next day (postoperative day one) and control in the outpatient clinic on postoperative day seven. The patients were given an individualized written Postoperative Medication Reference Chart indicating the dosage and application time of eye drops they must follow for seven days at home.
62850919|NCT04022395|EXPERIMENTAL|stress cardiac MRI|"* To optimize the scan protocol and the sequence parameters~* To investigate the clinical compliance of stress induced cardiac MRI in pediatric patients~* To test the ability of stress cMRI to visualize coronary arteries morphological irregularities, the corresponding wall motion abnormalities and perfusion - viability features"
62850920|NCT05722444|EXPERIMENTAL|Women with reported heavy menses|
62850921|NCT04855084|EXPERIMENTAL|Complete Digital Fixed Dental Prosthesis|"Following the Digital Impression using 3 Shape Trios Intraoral scanner, digital design, and manufacturing of the Monolithic Zirconia FDPs.~Monolithic FDPs: before adjustment~Using Intraoral Scanner, occlusal relationship assessment of the Monolithic FDPs before the occlusal adjustment.~Monolithic FDPs: after adjustment~Using Intraoral Scanner, occlusal relationship assessment of the Monolithic FDPs after the occlusal adjustment."
62850922|NCT04855084|ACTIVE_COMPARATOR|Analog Fixed Dental Prosthesis|"Following the Conventional Impression, transfer to the articulator with Face bow. Manufacturing of the FDPs with lost wax technique and veneering.~Metal fused porcelain FDPs: before adjustment~Using Intraoral Scanner, occlusal relationship assessment of the metal fused to porcelain FDPs before the occlusal adjustment.~Metal fused porcelain FDPs: after adjustment~Using Intraoral Scanner, occlusal relationship assessment of the metal fused to porcelain FDPs after the occlusal adjustment."
62850923|NCT01509885||Complete Spinal Cord Injured Subjects|Patients with no motor scores in their legs and suffering a complete spinal cord injury.
62850924|NCT01509885||Incomplete Spinal Cord Injured Subjects|Patient with some motor preservation below the injury and suffering an incomplete spinal cord injury.
62062329|NCT00535743|PLACEBO_COMPARATOR|Arm M. Placebo; 3 min after 1.2 mg/kg Esmeron®|Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
62062330|NCT00535743|EXPERIMENTAL|Arm N. 2 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
62062331|NCT00535743|EXPERIMENTAL|Arm O. 4 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
62062332|NCT00535743|EXPERIMENTAL|Arm P. 8 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
62062333|NCT00535743|EXPERIMENTAL|Arm Q. 12 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
62266810|NCT03576937||Cohort 1|Patients with advanced (incurable stage IIIB or IV), histologically proven, non-squamous NSCLC who are never- or light-smokers (≤10 pack year smoking history) and are being considered for systemic therapy in the first line setting are eligible. Blood will be collected prior to first line treatment for testing cfDNA with the GUARDANT360 assay. Testing of available diagnostic tissue for genomic abnormalities will be performed in all patients per standard of care at the participating sites.
62266811|NCT03576937||Cohort 2|Patients with advanced non-squamous NSCLC with known oncogenic drivers (such as EGFR, ALK, ROS-1, BRAF) that have failed tyrosine kinase inhibitor (TKI) therapy, and are being considered for subsequent therapy. Blood will be collected from patients at time of progression on TKI therapy for cfDNA testing with the GUARDANT360 assay. Testing of available diagnostic tissue for genomic abnormalities will be performed in all patients per standard of care at the participating sites.
62450159|NCT03912207|EXPERIMENTAL|Group 4, 28 Day Bronchoscopy|Group 4: 10 volunteers will receive 1 x 10\^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 4 volunteers will have a bronchoscopy 28 days post challenge
62266812|NCT01676714|EXPERIMENTAL|Dovitinib|500 mg of dovitinib (5 capsules) once a day for 5 continuous days and stop for 2 days. Continue to take dovitinib capsules in this manner until until progression or unacceptable toxicity develops.
62850925|NCT04228159|EXPERIMENTAL|Perturbation training|"Session1 - baseline assessment (detailed above) Session2 - 13 - each session will begin with reassessment and documentation of balance tutor parameters for each participant as were calibrated at the end of previous session.~After reassessment the training program will include:~* Warm up - walking without perturbation.~* Perturbation during standing position.~* Perturbation during walking.~* Perturbation during tandem position.~* Perturbation with vestibular stimulation.~* Rest according to patient needs The relative duration of each component, as well as intensity and frequency of perturbations, will be adjusted to each individual according to his ability, reassessment parameters and progression.~Session14 - full reassessment of all baseline examinations including: Mini-BESTest, ABC scale, PASE, and number of falls."
62266813|NCT03851900|EXPERIMENTAL|Teethmate Desensitizer (TM)|Calcium phosphate biomimetic material that forms hydroxyapatite from tetracalcium phosphate and dicalcium phosphate anhydrous and plug the dentin tubules causing remineralization and dentin hypersensitivity relief.
62450160|NCT03912207|EXPERIMENTAL|Group 5, 56 Day Bronchoscopy|Group 5: 10 volunteers will receive 1 x 10\^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 5 volunteers will have a bronchoscopy 56 days post challenge
62450161|NCT03912207|EXPERIMENTAL|Group 6, Intradermal injection, 14 Day Bronchoscopy|Group 6: 6 volunteers will receive 1 x 10\^6 cfu intradermal injection BCG + aerosol saline and will have a bronchoscopy 14 days post challenge All volunteers in group 6 will be offered an optional follow up at 12 months
62450162|NCT03912207|EXPERIMENTAL|Group 7, 14 Day Bronchoscopy|"Group 7: 10 volunteers will receive 1 x 10\^7cfu aerosol inhaled BCG. All Group 7 volunteers will have a bronchoscopy 14 days post challenge.~Volunteers in group 7 and group 3 (arm A) will be offered an optional follow up at 12 months, in order of enrolment until 10 such visits have been conducted"
62450163|NCT03912207|EXPERIMENTAL|Group 8, Bronchoscopy Day 14|Group 8: 10 historically BCG vaccinated volunteers will receive aerosol inhaled BCG at a dose to be confirmed from emerging study data TB044 (Clinicaltrials.gov NCT04777721). All Group 8 volunteers will have a bronchoscopy 14 days post challenge.
62450164|NCT02243956|EXPERIMENTAL|Flavanol rich food product|A portion of a common flavanol rich food product is consumed daily for 4 weeks
62450165|NCT02243956|PLACEBO_COMPARATOR|Non-flavanol food product|A portion of a product similar to the experimental Product, but instead contains low amounts of flavanol, is consumed Daily for 4 weeks as a control.
62450166|NCT00284102|EXPERIMENTAL|1|ALI/ARDS patients
62450167|NCT04644133||Healthy|Subjects without bowel issues will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
62450168|NCT04644133||Constipation|Subjects diagnosed with constipation will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
62450169|NCT04644133||Fecal Incontinence|Subjects diagnosed with fecal incontinence will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
62450170|NCT04998409||Monofocal IOL|
62450171|NCT04873583|EXPERIMENTAL|Steroids + Standard of care|Standard of care (including aspirin) and intravenous steroids, followed by oral tapering.
62450172|NCT04873583|NO_INTERVENTION|Standard of care|Standard of care (including aspirin)
62450173|NCT01609764|EXPERIMENTAL|Exercise|Follows the fitness program as described in the intervention
62450174|NCT01609764|NO_INTERVENTION|Control|Will not follow any regular fitness activity during one year
62450175|NCT01499914|EXPERIMENTAL|Influenza vaccination|Influenza vaccination in patients with cystic fibrosis
62450176|NCT00724555||1|Adults living in DC neighborhoods with high proportions of underserved adults. The age of the cohort members will reflect the age of DC residents who suffer most from stroke.
62450177|NCT00663221|PLACEBO_COMPARATOR|1|
62450178|NCT00663221|EXPERIMENTAL|2|
62450179|NCT01699581|EXPERIMENTAL|Nestle Impact Advanced Recovery|"Nestle Impact Advanced Recovery~1 dose of Nestle Impact Advanced Recovery orally three times a day"
62450180|NCT05100745|EXPERIMENTAL|Activated Therapy|Therapy: these subjects will undergo 30 treatments with an activated Vibratosleeve TUS device.
62450181|NCT05100745|SHAM_COMPARATOR|Sham Therapy|An inactive (sham) device will be used in these subjects for the first 30 treatments followed by a 30-treatment regimen with an activated VibratoSleeve TUS device after crossover.
62450182|NCT04536259|EXPERIMENTAL|Video Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person."
62266814|NCT03851900|ACTIVE_COMPARATOR|Clearfil SE Bond 2 (SE)|Two-step self etch adhesive resin treating dentin hypersensitivity b covering a film layer after light-curing.
62266815|NCT03851900|PLACEBO_COMPARATOR|Distilled water|Distilled water with no desensitizing components.
62266816|NCT01974544|EXPERIMENTAL|Best medical treatment|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will will be treated using the American Diabetes Association protocol. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
62850926|NCT04228159|ACTIVE_COMPARATOR|Balance and strengthening exercise|"Session1 - baseline assessment (detailed above).~Session2 - 13 - each session will include:~* Warm up (free walking or cycling).~* Static balance exercise - standing position. Exercise will be performed using different bases of support (narrow, tandem, and one leg stance), eyes open/closed, unstable surfaces, functional and cognitive dual task, and vestibular stimulation.~* Dynamic balance exercise - walking position. Exercise will be performed using different bases of support (narrow, tandem, and one leg stance), eyes open/closed, unstable surfaces, functional and cognitive dual task, and vestibular stimulation.~* Strengthening exercise - general strengthening, particularly for lower limb.~* Cool down. Level of difficulty and duration of each component will be adjusted to each individual according to his ability and progression.~Session14 - full reassessment of all baseline examinations including: Mini-BESTest, ABC scale, PASE, and number of falls."
62850927|NCT02328378|ACTIVE_COMPARATOR|Quadratus Lumborum block group (QL)|patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
62850928|NCT02328378|PLACEBO_COMPARATOR|Control Group|patients will receive a bilateral placebo block
62850929|NCT01962324|EXPERIMENTAL|SIB Dose-Escalation radiotherapy|Simultaneous integrated boost to intraprostatatic tumor and lymph nodes
62850930|NCT04182802||eosinophilic asthma|
62850931|NCT01223742|EXPERIMENTAL|ACETYL-L-CARNITINE|
62850932|NCT01223742|PLACEBO_COMPARATOR|placebo|
62266817|NCT01974544|EXPERIMENTAL|gastric bypass surgery|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will undergo gastric bypass surgery, in the conventional procedure. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
62450183|NCT04536259|EXPERIMENTAL|In-Person Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video."
62850933|NCT04848857|EXPERIMENTAL|Treatment Group|colchicine (0.5mg), one pill a day, oral intake
62850934|NCT04848857|PLACEBO_COMPARATOR|Control Group|placebo, one pill a day, oral intake
62850935|NCT04694924||Localized and locally advanced prostate cancer|Localized prostate cancer (cT1a-T2c N0 M0) refers to the clinical condition where cancer is confined to the prostate gland, in the absence of lymph node invasion or metastases. Locally advanced refers to the extension of the tumor beyond the capsule of the prostate (cT3-T4) or the clinical presence of nodal invasion (cN+), without metastases.
62062334|NCT00535743|EXPERIMENTAL|Arm R. 16 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
62266818|NCT01974544|EXPERIMENTAL|sleeve gastrectomy|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will undergo sleeve gastrectomy surgery, in the conventional procedure. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
62266819|NCT04856553|EXPERIMENTAL|Handgrip exercise (morning)|The handgrip exercise session will be executed with four series (two in each arm) of two minutes of isometric contraction at 30% of maximum voluntary contraction, with a one-minute interval between series in the morning.
62266820|NCT04856553|NO_INTERVENTION|Control|In the control session, the participants will remain at rest for the same period of time as in the handgrip exercise protocol.
62850936|NCT06244290|ACTIVE_COMPARATOR|Group I|Colgate SnF Toothpaste Colgate Adult Extra Clean soft-bristle toothbrush
62850937|NCT06244290|ACTIVE_COMPARATOR|Group II|Sensodyne Extra Whitening Toothpaste Colgate Adult Extra Clean soft-bristle toothbrush
62850938|NCT06244290|PLACEBO_COMPARATOR|Group III|Colgate Fluoride Toothpaste (CDC) Colgate Adult Extra Clean soft-bristle toothbrush
62850939|NCT02149667||Total Hip Arthroplasty|Single study group previously implanted with the following combination of components: MicroPort Orthopedics Femoral Stems, DYNASTY® BioFoam® Acetabular Components, DYNASTY® A-Class® Cross Linked Polyethylene Liners, and MicroPort Orthopedics Metal or Ceramic Femoral Heads
62850940|NCT00863213|EXPERIMENTAL|Atrial Fibrillation Ablation|
62850941|NCT00863213|ACTIVE_COMPARATOR|Drug therapy|
62062335|NCT00535743|PLACEBO_COMPARATOR|Arm S. Placebo; 15 min after 1.2 mg/kg Esmeron®|Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
62062336|NCT00535743|EXPERIMENTAL|Arm T. 2 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
62625254|NCT02204345|EXPERIMENTAL|RO5479599 + Carboplatin + Paclitaxel|RO5479599 800 milligrams (mg) will be administered in the Safety Run-In Phase by intravenous infusion q3w on Day 1 of 3-weekly cycles (each cycle of 21 days) in combination with carboplatin (to produce an area under the curve \[AUC\] of 6 mg/milliliter \[mL\]\*minute) and paclitaxel 200 mg per square meter (mg/m\^2) by intravenous infusion q3w for 4 to 6 cycles. Thereafter, RO5479599 will be continued as a monotherapy (carboplatin and paclitaxel may be continued at the investigator's discretion) until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
62625255|NCT03703674|ACTIVE_COMPARATOR|Standard Medical Therapy|Drug: standard medical therapy Standard medical therapy involves primary treatment and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
62625256|NCT03703674|EXPERIMENTAL|G-CSF + Standard Medical Therapy|"Drug: standard medical therapy Standard medical therapy involves primary treatment and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.~Drug: G-CSF G-CSF- 5 μg/Kg s.c every 12 hours for 5 consecutive days"
62625257|NCT01051440|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo for lisdexamfetamine.
62625258|NCT01051440|ACTIVE_COMPARATOR|Lisdexamfetamine|Subjects will start with 20 mg per day of lisdexamfetamine and may increase to a maximum of 40 mg.
62625259|NCT00394888|OTHER|Facial Hemangioma|Patients with large facial hemangioma.
62625260|NCT00394888|OTHER|Lumbosacral Hemangioma|Patients with lumbosacral hemangioma.
62625261|NCT00394888|OTHER|Multiple Hemangiomas|patients with multiple hemangiomas (\>5)
62625262|NCT04162405||Patients with tinnitus and hearing loss|Patients with tinnitus and average speech-frequency tonal audiogram threshold \>30 dB
62625263|NCT04162405||Patients with tinnitus without hearing loss|Patients with tinnitus and average speech-frequency tonal audiogram threshold \<30 dB
62625264|NCT05524454|EXPERIMENTAL|Novel CBCT Imaging|All subjects undergo one additional imaging session with the novel CBCT imaging system.
62850942|NCT04285281|EXPERIMENTAL|Gabapentin|Participants will be treated with a maximum of 1800 mg per day, subdivided in 3 intakes of 600 mg each 8 hours during a time lapse of 4 weeks.
62266821|NCT04856553|EXPERIMENTAL|Handgrip exercise (afternoon)|The handgrip exercise session will be executed with four series (two in each arm) of two minutes of isometric contraction at 30% of maximum voluntary contraction, with a one-minute interval between series in the afternoon.
62625265|NCT06296277||Intraoperative mechanical ventilation|Patients subjected to invasive mechanical ventilation (IMV) during general anesthesia for surgery
62625266|NCT05446051|EXPERIMENTAL|Experimental Group|New patients and take the TRAEs Questionnaire on week.
62625267|NCT05446051|NO_INTERVENTION|Control group|Control Group：Old patients and usual care.
62850943|NCT04285281|NO_INTERVENTION|Control group|Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
62266822|NCT04194099|EXPERIMENTAL|rTMS (Brain) + tsES (Spinal)|"First part 20 Hz rTMS (Brain) + Anode tsDCS (Spinal)~Brain:~1. Train pulse: 2 sec~2. Inter-train: 28 sec~3. Total time: 1200 sec~Spinal:~Continuous direct current (DC): 1200 sec~Second part iTBS rTMS(Brain) + 2.5-mA tsDCS (Spinal)~Brain:~1. Train pulse: 2 sec~2. Inter-train: 8 sec~3. Total time: 200 sec~Spinal:~Continuous direct current (DC): 600 sec"
62266823|NCT04194099|EXPERIMENTAL|rTMS (Brain) + tsES (Spinal) or sham stimulation|"First part 20 Hz rTMS (Brain) + 20 Hz current square-wave pulses (Spinal)~Brain and spinal:~1. Train pulse: 2 sec~2. Inter-train: 28 sec~3. Total time: 1200 sec~Second part iTBS rTMS(Brain) + sham 2.5-mA tsDCS (Spinal)~Brain:~1. Train pulse: 2 sec~2. Inter-train: 8 sec~3. Total time: 200 sec~Spinal:~Sham direct current (DC) stimulation"
62625268|NCT06199544|EXPERIMENTAL|Control group|metformin 500 mg twice a day
62625269|NCT06199544|EXPERIMENTAL|Picolin group|Picolin 500mg thrice a day
62625270|NCT06199544|EXPERIMENTAL|Rasoline|Rasoline 500mg thrice a day
62625271|NCT04484194|EXPERIMENTAL|eHA Screening|Patients receiving eHA screening tool.
62625272|NCT05348954|EXPERIMENTAL|Sexual dysfunction of women|Sexual dysfunction of women
62625273|NCT05348954|EXPERIMENTAL|Quality of sexual life|Quality of sexual life
62625274|NCT04307524|EXPERIMENTAL|laparoscopic repair|suture repair of cesarean scar niche using laparoscopy
62625275|NCT04307524|ACTIVE_COMPARATOR|medical treatment|conservative management
62625276|NCT04932135||Group Treatment|Patients with newly diagnosed hyperthyroidism due to Graves' disease, if anti thyroid drug treatment is planned.
62625277|NCT04932135||Group Surveillance|Patients suffering from Graves' disease in whom discontinuation of the anti-thyroid therapy is planned.
62625278|NCT00223002|EXPERIMENTAL|1|PI
62625279|NCT00223002|EXPERIMENTAL|2|Chlorohex
62625280|NCT04198909|EXPERIMENTAL|Cohort 1|
62625281|NCT01249859||Signet ring cell carcinoma|
62625282|NCT01249859||non signet ring cell adenocarcinoma|
62625283|NCT01462656||Patients with urinary retention|Patients with urinary retention
62625284|NCT01775787|OTHER|Tobacco Flavor/ Tobacco & Menthol Flavor|"Subjects randomized to Tobacco Flavor group 7-10 days, then crossed over to Tobacco and Menthol Flavor for 7-10 days.~Nicotine with Tobacco Flavor and Tobacco \& Menthol Flavor (18mg/mL nicotine)"
62625285|NCT01775787|OTHER|Tobacco & Menthol Flavor/Tobacco Flavor|"Subjects randomized to Tobacco and Menthol Flavor for 7-10 days,then crossed over to Tobacco Flavor for 7-10 days.~Nicotine with Tobacco Flavor and Tobacco \& Menthol Flavor (18mg/mL nicotine)"
62850944|NCT01282463|ACTIVE_COMPARATOR|Docetaxel|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
62850945|NCT01282463|EXPERIMENTAL|Docetaxel + Ramucirumab DP|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
62850946|NCT01282463|EXPERIMENTAL|Docetaxel + Icrucumab|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
62266824|NCT04194099|EXPERIMENTAL|iTBS rTMS or sham (Brain) + tsES or sham (Spinal)|"First part~Brain:~1. Train pulse: 2 sec~2. Inter-train: 8 sec~3. Total time: 200 sec~Spinal:~Continuous direct current (DC): 190 sec~Second part Sham iTBS rTMS (Brain) + 2.5-mA tsDCS (Spinal)~Sham iTBS rTMS Brain:~Spinal:~Continuous direct current (DC): 600 sec"
62850947|NCT04496570|ACTIVE_COMPARATOR|Periodontitis patients|gingival crevicular fluid and saliva collection were taken before and after nonsurgical periodontal treatment
62850948|NCT04496570|NO_INTERVENTION|Healthy individuals|gingival crevicular fluid and saliva collection were taken at baseline after oral hygiene instructions
62850949|NCT03549832|ACTIVE_COMPARATOR|sof/sim/dac|Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin
62266825|NCT04194099|EXPERIMENTAL|iTBS rTMS or sham (Brain) + iTBS or sham (Spinal)|"First part~Brain and spinal:~1. Train pulse: 2 sec~2. Inter-train: 8 sec~3. Total time: 200 sec~Second part Sham iTBS rTMS (Brain) + Sham 2.5-mA tsDCS (Spinal)~Brain:~Sham iTBS rTMS~Spinal:~Sham direct current (DC) stimulation"
62062337|NCT00535743|EXPERIMENTAL|Arm U. 4 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
62062338|NCT00535743|EXPERIMENTAL|Arm V. 8 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
62062339|NCT00535743|EXPERIMENTAL|Arm W. 12 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
62266826|NCT04194099|SHAM_COMPARATOR|sham (no stimulation on brain nor spinal)|"First part Sham stimulation.~No second part"
62266827|NCT01996800|EXPERIMENTAL|Spinal Manipulative Therapy (SMT)|Patients will receive 12 weeks of chiropractic SMT
62652888|NCT03912272|PLACEBO_COMPARATOR|Usual Care Control|Subjects in the usual care control group will receive a health education program. This program includes 12-month twice-a-month sessions (70 minutes each session) for obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation. The class will be conducted in small group setting (4-8 participants each group). The same health information will be delivered to the subjects in the HIIT group throughout the 12-month intervention period. Subjects will be asked to attend \>70% of the classes.
62850950|NCT03549832|ACTIVE_COMPARATOR|sof/omb/parit|Sofosbuvir /Ombitasvir/ Paritaprevir /Ritonavir/Ribavirin
62850951|NCT03893695|EXPERIMENTAL|metastatic HCC|"Stage one - Dose de-escalation:~Each dose cohort will assess toxicity within the 28 days following the first dose of nivolumab and GT90001.~Stage two- the expansion cohort:~14 patients will be enrolled to the expansion cohort where one or no DLT takes place in planned study cohort."
62850952|NCT04291404|NO_INTERVENTION|Standard of Care (Control) Arm|Standard of care treatment, which may include a combination of the following, at the discretion of the treating team and family: parent/ caregiver support, child life services, healthcare provider support, etc.
62850953|NCT04291404|EXPERIMENTAL|Intervention Arm|Addition of distraction via an immersive, interactive VR experience to Standard of Care
62062340|NCT00535743|EXPERIMENTAL|Arm X. 16 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
62062341|NCT04230655|ACTIVE_COMPARATOR|Control group|"All participants in the control group are treated with LED and CBT-based group treatment as described below.~All participants (control and intervention) receive 2.5-hour sessions of CBT-based group treatment every 4 weeks for 1 year. Participants are randomly assigned to groups of 8-16 participants. Two groups of about the same size start simultaneously.~The LED phase (from baseline to 24 weeks) consists of 12 weeks with 4 portions/day of liquid meal replacements, for a total of 800-880 kcal/day, followed by a 12-week slow phasing out to a regular diet. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended."
62062342|NCT04230655|EXPERIMENTAL|IGB group|"All participants in the IGB group are treated with LED and CBT-based group treatment as described for the control group.~Participants in the intervention group are treated with an IGB for 6 months from 6 months from start."
62850954|NCT02459288|EXPERIMENTAL|Clopidogrel first|Clopidogrel (Plavix) 75 mg qd, 2 weeks; followed with Ticagrelor (Brilinta) 90 mg bd, 2 weeks
62850955|NCT02459288|EXPERIMENTAL|Ticagrelor first|Ticagrelor (Brilinta) 90 mg bd, 2 weeks; followed with Clopidogrel (Plavix) 75 mg qd, 2 weeks
62850956|NCT00863811||2|POAG patients with IOP under control by prostaglandins eye drops treatment and assuming two tablets per day of the food supplement KRONEK
62850957|NCT00863811||1|POAG patients compensated by the treatment of betablockers eye drops and taking two tablets per day of KRONEK
62062343|NCT02221102|ACTIVE_COMPARATOR|aspirin|Receiving a 100-mg dose of aspirin and placebo edoxaban from day 1 to day 30
62450184|NCT04536259|EXPERIMENTAL|Active Choice|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) I would prefer a video consultation. B) I would prefer an in-person consultation."
62625286|NCT04337021|ACTIVE_COMPARATOR|Caregiver SOS|SOS care is brief, telephonic care (6 one-hour sessions over 3-4 months) tailored to the CG's needs, preferences, and priorities. SOS care addresses both work and caregiving-related stress. The five pillars of behavior change in SOS care are: 1) knowledge of work and CG stress; 2) stress management skills and abilities; 3) supports and resources; 4) confidence and motivation to modify stress; and 5) work and CG-focused problem-solving skills. The pillars are addressed through seven modules. In six sessions, the CM will cover each module at least once. SOS care involves an ongoing process of formulating self-management goals and action plans and preparing CGs to succeed in implementing them. Addressing both work and caregiving contexts, CMs will educate CGs about stress. CMs introduce strategies for self-managing stress and collaboratively design experiments to test these strategies. The CG's progress is monitored to identify strategies that effectively achieve self management goals.
62625287|NCT04337021|NO_INTERVENTION|Usual Care|CGs in this arm will be contacted telephonically once by a CM. After a brief needs assessment, the CM will provide contact information for appropriate VA (e.g., local CSP clinicians) and non-VA community resources/services. CGs will be sent brochures for the national VA CSP. Information on both the program's website (which includes links to training, education, resources, and outreach programs for CGs) and the national CG hotline number will be included in the mailed packet. After this initial contact, CGs in this group will only be contacted again 4 and 9 months after baseline for administration of follow-up research assessments. CGs will be encouraged to seek medical, psychological, social support, and social services that are available to them through VAMCs or any other non-VA/community source. CGs in the SOS group will be offered similar information.
62850958|NCT04065737|EXPERIMENTAL|Sintilimab|Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W; duration: 8cycles (6 months) or randomization to the date of the first documented oral cancer incidence
62625288|NCT06613282|EXPERIMENTAL|LI-TMS and AVS|Participants receive low-intensity transcranial magnetic stimulation interventions with audio-visual stimulation for 14 days. On days 6, 7, 13, and 14 of the study, participants will not receive any interventions. Participants will be screened and tested on days 1 and 14 of treatment and two weeks after the end of the intervention.
62850959|NCT01115322|EXPERIMENTAL|Tazarotene Foam without irradiation|Subjects will be exposed to Tazarotene Foam Patch without irradiation
62850960|NCT01115322|EXPERIMENTAL|Tazarotene Foam with UVA and UVB irradiation|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB irradiation
62850961|NCT01115322|EXPERIMENTAL|Tazarotene Foam with UVA , UVB, and visible light irradiation|Subjects will be exposed to Tazarotene Foam with UVA and UVB and visible light irradiation
62062344|NCT02221102|EXPERIMENTAL|edoxaban 30mg|Receiving a 30-mg dose of edoxaban and placebo aspirin from day 1 to day 30
62850962|NCT01115322|PLACEBO_COMPARATOR|Vehicle Foam without irradiation|Subjects will be exposed to Vehicle Foam Patch without irradiation
62850963|NCT01115322|PLACEBO_COMPARATOR|Vehicle Foam with UVA and UVB irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB irradiation
62850964|NCT01115322|PLACEBO_COMPARATOR|Vehicle Foam with UVA and UVB and visible light irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB and visible light irradiation
62850965|NCT01115322|SHAM_COMPARATOR|No Treatment without irradiation|Subjects will be exposed to a Blank Patch without irradiation
62062345|NCT02221102|EXPERIMENTAL|edoxaban 60mg|Receiving a 60-mg dose of edoxaban and placebo aspirin from day 1 to day 30
62062346|NCT02801188|PLACEBO_COMPARATOR|Bupivacaine group|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
62062347|NCT02801188|ACTIVE_COMPARATOR|Mixture of bupivacaine and dexmedetomidine group|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye and 1 ug/kg of dexmedetomidine
62087955|NCT03279705|EXPERIMENTAL|Two-channel group|The colonoscopy was done with the new designed colonoscopy that integrated a separate water jet channel for infusing water. The dirty water was removed through other accessory channel.
62850966|NCT01115322|SHAM_COMPARATOR|No Treatment with UVA and UVB irradiation|Subjects will be exposed to a Blank Patch with UVA and UVB irradiation
62062348|NCT03701295|EXPERIMENTAL|Treatment (pinometostat, azacitidine)|Patients receive pinometostat IV continuously on days 1-28 and azacitidine IV over 10-40 minutes or SC for 7 of the first 10 days of the cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
62625289|NCT06613282|NO_INTERVENTION|Control|Participants receive no interventions for 14 days. Participants will be screened and tested on days 1, 14 and 28.
62625290|NCT02905045|ACTIVE_COMPARATOR|Ketoprofen|women will take one tablet 150 mg one hour before the procedure
62062349|NCT01336634|EXPERIMENTAL|Cohort A (Dabrafenib Monotherapy)|"Participants received Dabrafenib 150mg BID and continued treatment until disease progression, death, or unacceptable adverse event.~Participants receiving and adequately tolerating dabrafenib as a single agent and who continue to meet the inclusion and exclusion criteria had the option to switch to Dabrafenib (150 mg BID) and Trametinib (2 mg once daily) combination treatment within 4 weeks of radiologic disease progression with prior approval from a medical monitor."
62625291|NCT02905045|PLACEBO_COMPARATOR|Placebo|women will take one tablet placebo one hour before the procedure
62625292|NCT04457401|EXPERIMENTAL|Probiotic|1 capsule daily for 8 weeks, containing 3 x 10\^9 colony forming units/capsule of a Bifidobacterium strain
62266828|NCT01996800|ACTIVE_COMPARATOR|SMT and Neuromuscular Reeducation|"Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.~A neuromuscular re-education program will consist of repetitive movements, posturing, and stimulation designed to reinforce nerve signals for functional movements. It is theorized that when the nerve signals are retrained and appropriate muscle movements are repeated, movement patterns become automatic again. Neuromuscular re-education is usually done along with other types of treatment to promote functional muscle movement."
62625293|NCT04457401|PLACEBO_COMPARATOR|Placebo|1 capsule daily for 8 weeks containing the same carrier material and is similar in size, shape and taste to probiotic
62625294|NCT01939223|EXPERIMENTAL|Regorafenib|4 regorafenib tablets taken orally in the morning daily, followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.
62266829|NCT01384227|EXPERIMENTAL|Proflavine Hemisulfate|
62266830|NCT06247709||Cases|All patients undergone surgery for the removal of a pituitary adenoma. Tissue samples of these cases were sent to biochemical essay to measure the expression and localisation of KLHL14.
62625295|NCT01939223|PLACEBO_COMPARATOR|Placebo|4 placebo tablets taken orally in the morning daily,followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.
62625296|NCT03484624|EXPERIMENTAL|Treadmill walking|All subjects underwent measurements of muscle fatigue and respiratory metabolism energy during treadmill walking at a comfortable speed for 6 minutes and measured by three conditions (①NoGEMS-free gait, ②Torque off with GEMS, and ③Torque on with GEMS)
62625297|NCT00000411|ACTIVE_COMPARATOR|Surgery|Decompressive laminectomy
62625298|NCT00000411|ACTIVE_COMPARATOR|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
62625299|NCT02278029||Concussed|those subjects with a concussion
62625300|NCT02278029||Controls|those subjects without a concussion
62625301|NCT06039137||Clemastine group|Subjects receiving standard of care treatment with paclitaxel either as monotherapy or as part of a combination for any standard of care oncologic indication. Subjects received a paclitaxel premedication regimen containing dexamethasone 10 mg IV and clemastine 2 mg IV
62625302|NCT06039137||Cetirizine group|Subjects receiving standard of care treatment with paclitaxel either as monotherapy or as part of a combination for any standard of care oncologic indication. Subjects received a paclitaxel premedication regimen containing dexamethasone 10 mg IV and cetirizine 10 mg PO
62625303|NCT01505231|ACTIVE_COMPARATOR|Norepinephrine group|Blinded norepinephrine
62625304|NCT01505231|ACTIVE_COMPARATOR|Vasopressin Group|Blinded vasopressin
62625305|NCT02847910|EXPERIMENTAL|experimental group|device： High-tech disposable tissue suction set for uterine cavity tissue is produced by Xi'an Mejiajia Medical Equipment Company ; The participants will be use the disposable tissue suction set during the induced abortion procedure.
62062350|NCT01336634|EXPERIMENTAL|Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E|Participants received Dabrafenib 150 mg BID in combination with Trametinib 2 mg once daily and continued treatment until disease progression, death, or unacceptable adverse event.
62062351|NCT01336634|EXPERIMENTAL|Cohort C - Double Combination (Dabrafenib+Trametinib) naive mBRAF V600E|Participants received Dabrafenib 150 mg BID in combination with Trametinib 2 mg once daily and continued treatment until disease progression, death, or unacceptable adverse event.
62062352|NCT02736968|EXPERIMENTAL|E. histolytica- Active|N=34, 6mg auranofin daily x 7 days
62062353|NCT02736968|PLACEBO_COMPARATOR|E. histolytica- Placebo|N=34, 6mg placebo daily x 7 days
62062354|NCT02736968|EXPERIMENTAL|Giardia- Active|N=34, 6mg auranofin daily x 5 days
62625306|NCT02847910|EXPERIMENTAL|control group|device： Traditional metal instruments for induced abortion procedure; The participants will be use traditional metal instruments during induced abortion procedure.
62850967|NCT01115322|SHAM_COMPARATOR|No Treatment with UVA and UVB and visible light irradiation|Subjects will be exposed to a Blank Patch with UVA and UVB and visible light irradiation
62850968|NCT00119678|ACTIVE_COMPARATOR|Abatacept + Prednisone|Double Blind Period
62450185|NCT03208426|EXPERIMENTAL|Sequential therapy for 14 days|Sequential therapy for 14 days (experimental) D1-D7: (Nexium, esomeprazole 40mg bid + amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid) for 7 days D8-D14: (Nexium, esomeprazole 40mg bid + Klaricid XL, clarithromycin 500mg bid + Flagyl, metronidazole 500mg bid) for another 7 days
62625307|NCT05978219|EXPERIMENTAL|Patients with MDD with insomnia|"Diagnosed MDD patients with insomnia problems will be approached and enrolled from NIMH, Dhaka.~Trial medications will be self-administered and treatment regimen will be continued until serious adverse effect develops or for 42 days, whichever occurs sooner.~Patients will receive mirtazapine at 15-30 mg/day (tablet form, once or twice daily, orally) from start. Depending on the response, doses might be increased at 2 weeks up to 45 mg/day for mirtazapine.~The clinical trial for each patient will last for 42 days. Clinical data will be collected at the beginning - Day 0 and then on Day 14 and Day 42 of the trial by face-to-face interview. A clinical follow up will be provided to trial patients on Day 28 of the trial over telephone. Research psychiatrists will also conduct follow up, medication and side effect monitoring and overall management of the patients."
62625308|NCT03247322|EXPERIMENTAL|mHealth Group|Patients in the intervention cohort will have enhanced medication safety monitoring utilizing a Pharmacist-led medication therapy using mHealth application. The application will provide patients a useful tool to conduct self-care monitoring and management, including timely reminders to take medications, automated messages when patients miss multiple medication doses, tracking of medication side effects and reporting trends in blood pressures and glucoses (when applicable).
62850969|NCT00119678|PLACEBO_COMPARATOR|Placebo + Prednisone|Double Blind Period
62850970|NCT00119678|EXPERIMENTAL|Abatacept|Open Label
62850971|NCT02935426|EXPERIMENTAL|Cyanoacrylate group|Wound closure after harvesting of connective tissue graft in the donor site will be achieved with application of cyanoacrylate tissue adhesive
62062355|NCT02736968|PLACEBO_COMPARATOR|Giardia- Placebo|N=34, 6mg placebo daily x 5 days
62450186|NCT03208426|ACTIVE_COMPARATOR|bismuth quadruple therapy for 10 days|Bismuth quadruple therapy for 10 days (active comparator) D1-D10: (Nexium, esomeprazole 40mg bid + KCB F.C. TABLETS, dibismuth trioxide 120mg qid + Flagyl, metronidazole 500mg tid + tetracycline (Brand name: Tetracycline Capsule ) 500mg qid) for 10 days
62850972|NCT02935426|ACTIVE_COMPARATOR|Suture group|Wound closure after harvesting of connective tissue graft in the donor site will be achieved with polytetrafluoroethylene (PTFE) continuous interlocking sutures
62850973|NCT05960721|EXPERIMENTAL|Low-dose novel oral anti-coagulation (NOAC)-based anti-thrombotic therapy|"HAS-BLED\<3: Rivaroxaban 15 mg QD for 3 months, followed by Rivaroxaban 10 mg QD indefinitely~HAS-BLED≥3: Rivaroxaban 10 mg QD for 3 months, followed by Rivaroxaban 2.5 mg bid indefinitely"
62450187|NCT01545635|ACTIVE_COMPARATOR|Coagulation factor concentrates|
62850974|NCT05960721|ACTIVE_COMPARATOR|Guideline determined medication therapy (GDMT)|"HAS-BLED\<3: Rivaroxaban 15 mg QD + Aspirin 100mg QD for 3 months, then Aspirin 100mg QD indefinitely~HAS-BLED≥3: Aspirin 100mg QD + Clopidogrel 75mg QD for 3 months, then Aspirin 100mg QD indefinitely"
62850975|NCT01743859|EXPERIMENTAL|Azacitidine + Lenalidomide + Off Therapy|Patients will receive 7 days of azacitidine followed by 3 weeks of lenalidomide. They will then have 2 weeks off therapy, for a maximum of 12 cycles.
62450188|NCT01545635|ACTIVE_COMPARATOR|Fresh Frozen Plasma|
62450189|NCT03491436|EXPERIMENTAL|Remote monitoring group|Women (at risk of) GDM will be included in this study. They receive a iHealth Align (a glucose monitor) and associated glycemiestrips. The app of iHealth will be downloaded on the pregnant women's Smartphone to collect the data and to send them to the researcher in the hospital.
62450190|NCT04403048|ACTIVE_COMPARATOR|Patients in which standard provisional approach is preformed|Detailed technique is described in the Detailed study description paragraph
62450191|NCT04403048|EXPERIMENTAL|Patients in which provisional DCB approach is preformed|Detailed technique is described in the Detailed study description paragraph
62850976|NCT05212818|EXPERIMENTAL|Low Dose of Active Drug|80 patients will be randomly assigned to low dose, take active drug BID.
62850977|NCT05212818|EXPERIMENTAL|Low Dose Placebo Control|80 patients will be randomly assigned to Low dose placebo, take the placebo BID.
62062356|NCT05195619|EXPERIMENTAL|Cohort 1|metastatic NSCLC of any histology without any actionable oncogenic driver treated by SOC. Maintenance treatment with pemetrexed and/or maintenance/continuation of pembrolizumab, nivolumab or atezolizumab is allowed.
62062357|NCT05195619|EXPERIMENTAL|Cohort 2|metastatic NSCLC with actionable oncogenic driver such as EGFR mutation, ROS-1 or ALK rearrangement, currently receiving osimertinib, alectinib, lorlatinib or crizotinib as per SOC in each disease entity.
62266831|NCT02705638|EXPERIMENTAL|Rituximab and Lenalidomide|All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15, as well as Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
62266832|NCT04160702|EXPERIMENTAL|Motivate-The-Bystander|Participants assigned to the MTB condition arm.
62850978|NCT05212818|EXPERIMENTAL|High Dose of Active Drug|160 patients will be randomly assigned to high dose, take the active drug BID.
62850979|NCT05212818|EXPERIMENTAL|High Dose Placebo Control|80 will be randomly assigned to high dose placebo, take the placebo BID.
62850980|NCT01256632|ACTIVE_COMPARATOR|Subfoveal CNV, secondary to AMD with PVD|20 eyes with Subfoveal Choroidal Neovascularization, secondary to Age Related Macular Degeneration, with Posterior Vitreous Detachment (PVD Positive). All study eyes will receive 0.5mg, of intravitreous monthly injections of Ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
62850981|NCT01256632|ACTIVE_COMPARATOR|Subfoveal CNV, secondary to AMD w/o PVD|20 eyes with Subfoveal Choroidal Neovascularization, secondary to Age Related Macular Degeneration, without Posterior Vitreous Detachment (PVD Negative). All study eyes will receive 0.5mg, of intravitreous monthly injections of Ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after the first 4 injections, will be on an as needed basis, based on predefined criteria.
62850982|NCT03838458||Study|Children with isolated hypospadias
62850983|NCT03838458||Control|Children with planned circumcision
62266833|NCT04160702|NO_INTERVENTION|Assessment only control condition|Participants assigned to the assessment only condition arm.
62266834|NCT03048669|EXPERIMENTAL|Continuous quality improvement (CQI)|Quality improvement initiatives implemented at facility level using participatory data-driven approaches and on-site monitoring and supervisory support
62450192|NCT00600795||A|Patients diagnosed with Normal Pressure Hydrocephalus
62450193|NCT01434342|EXPERIMENTAL|Arm I - Quitline|"Participants receive a letter from their physician advising them to quit smoking, and undergo a 15-30-minute smoking-cessation counseling session by a trained research staff.~The participants are educated and motivated about the importance of quitting smoking, and cancer-specific quitting issues. They will be called by Quitline in 2-3 days and receive a fact sheet about benefits of SC for cancer patients.~Participants receive 8 weeks of nicotine replacement patches and up to 5 proactive telephone calls over a 12-week period.~Participants also learn behavioral tips and coping skills."
62450194|NCT01434342|NO_INTERVENTION|Arm II - Usual Care|"Participants receive a letter from their physician advising them to quit smoking, the importance of quitting smoking for cancer patients, and a copy of the National Cancer Institute's Clearing the Air smoking cessation booklet. Participants also receive standard of care from their oncology and other treatment providers which may or may not include nicotine replacement therapy."
62625309|NCT03247322|NO_INTERVENTION|Usual Care Group|Subjects in the control group will receive the usual standard of follow up care for kidney transplant patients.
62625310|NCT04350047||Transabdominal inferior vena cava thrombectomy|Patients undergoing radical nephrectomy and inferior vena cava thrombectomy transabdominal without thoracotomy
62625311|NCT02391792||patients|patients with septic shock
62625312|NCT02391792||control|patients without septic shock
62625313|NCT02391792||healthy volunteers|
62450195|NCT00625807|ACTIVE_COMPARATOR|Program A - Relaxation Response (RR)|One of the 2 stress reduction courses
62450196|NCT00625807|ACTIVE_COMPARATOR|Program B - Mindfullness-based stress reduction (MBSR)|One of the 2 stress reduction courses
62625314|NCT01856998|ACTIVE_COMPARATOR|Diprivan® 20 mg/mL (AstraZeneca)|"Dosage form: lipid emulsion~Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER~Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS \<40 with regard to individual condition and the respective surgery)~Duration: Until end of surgery"
62850984|NCT00618085|EXPERIMENTAL|1|"All patients will receive the occupational therapy and physiotherapy normally given in their setting.~In addition; the experimental group will receive 2 instruction DVD's introducing them to motor imagery practice, taking 35 minutes in total. The research therapist will also attend the first session with the physiotherapist and with the occupational therapist to help incorporate motor imagery within the therapy. Thereafter the therapist will help the patient use motor imagery as part of their normal treatment. The total amount spent on motor imagery during therapy sessions will be 6.5 hours in 6 weeks."
62850985|NCT00618085|ACTIVE_COMPARATOR|2|"All patients will receive the occupational therapy and physiotherapy normally given in their setting.~In addition; the control group will receive 2 DVDs for 35 minutes in total. These will show background information on their condition, explaining the importance of practice of activities, and on the principles of motor learning and phased movement which underlie most therapy.The research therapist will also attend the first session with the physiotherapist and with the occupational therapist to control for attention. The total amount the physiotherapist and occupational therapist spend with the patients should be the same in both groups."
62850986|NCT03541395|OTHER|Testosterone|A Gonadotropin releasing hormone agonist (GnRH-agonist) is administered to lower the testosterone to castration levels. After four weeks testosterone undecanoate is administered to increase the testosterone to normal levels.
62850987|NCT03671317|EXPERIMENTAL|Intervention group|This arm will receive a medical clowning intervention in addition to pre and post surveys about the blood draw process.
62625315|NCT01856998|EXPERIMENTAL|Propofol 2% (20 mg/mL) MCT Fresenius|"Dosage form: lipid emulsion~Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER~Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS \<40 with regard to individual condition and the respective surgery)~Duration: Until end of surgery"
62062358|NCT03755635|NO_INTERVENTION|Standard of care|Continuously monitoring of neonatal sepsis under standard of care at one site
62062359|NCT03755635|EXPERIMENTAL|Hand hygiene|The WHO multimodal hand hygiene strategy is implemented at one site
62062360|NCT05445544||Pregnant women and Follow-up of pregnant women's newborns|The pregnant woman is pregnant until she gives birth. The fecal ,serum,saliva,urine,vaginal secretions,umbilical cord blood,placenta and amniotic fluids who are were caesarean delivered will be collected
62062361|NCT05904223|NO_INTERVENTION|Standard of Care|"standard of care (SOC) group = control group:~* Routine laboratory parameters (CBC, CRP, kidney and liver parameters, etc.) on the day of admission and when clinically necessary - decision is made by the physician in charge~* Sputum microscopy for quality assessment (via Bartlett score)~* Chest X-ray on the day of admission or the day after~* 2 Sets of blood cultures (if temperature \>38°)~* Pneumococcus urine antigen test for every patient with proven or suspected pneumonia~* Legionella urine antigen test for every patient with proven or suspected pneumonia and clinical suspicion for Legionella infection (travel history, air condition, elevated CK, hyponatremia, reduced kidney function)~* Antibiotic treatment if deemed necessary by the treating physician"
62062362|NCT05904223|EXPERIMENTAL|Standard of Care + Respiratory Panel|"Pneumonia panel plus group = intervention group~* Sputum analysis via the BIOFIRE® FILMARRAY® Pneumonia Panel plus~* Routine laboratory parameters (CBC, CRP, kidney and liver parameters, etc.) on the day of admission and when clinically necessary - decision is made by the physician in charge~* Sputum microscopy for quality assessment (via Bartlett score)~* Chest X-ray on the day of admission or the day after~* 2 Sets of blood cultures~* Pneumococcus urine antigen test for every patient with proven or suspected pneumonia~* Legionella urine antigen test for every patient with proven or suspected pneumonia and~* Antibiotic treatment if deemed necessary by the treating physician"
62062363|NCT06453122|ACTIVE_COMPARATOR|Chlorhexidine|patients with oral hygiene performed with tooth brushing and washing with 0.12% chlorhexidine
62062364|NCT06453122|SHAM_COMPARATOR|Water|patients with oral hygiene performed with tooth brushing and washing with filtered water.
62062365|NCT03288090||Treated|
62062366|NCT03288090||Non-treated|
62625316|NCT04851366|EXPERIMENTAL|PROCARE+ (with add-on modules)|In addition to core UP-A preventive intervention, PROCARE will apply an innovative personalized medicine approach by adding specific modules according to the risk factor evidenced by adolescents. Different modules will be suited for the stratified groups in a more personalized format. Add-on young-focused modules would include, but not limited to social, parental, stress-related (including CoVid19 impact) risk factors, and health. Dosage (number of modules) will be included as covariate in all subsequent analyses.
62625317|NCT04851366|EXPERIMENTAL|PROCARE (UP-A for selective purposes)|To ensure cost-effectiveness, PROCARE core intervention will be designed as a brief 8-session child-focused programme which aims to build resilience for adolescents by adapting the core modules from UP-A, along with one individual session with adolescent and parents. Sessions will be delivered in reduced groups, using a typical selective preventive intervention format focused on cost-effectiveness.
62625318|NCT04851366|ACTIVE_COMPARATOR|Active control condition.|"The active control condition will be based on the U talk programme developed by Prf. Jill Ehrenreich-May at University of Miami and colleagues. It follows a similar structure as the UP-A original programme and allows for two alternative compare conditions to PROCARE. The U Talk programme support-based group condition will be used as active control condition."
62062367|NCT03148236|ACTIVE_COMPARATOR|Vitamin C|
62062368|NCT03148236|PLACEBO_COMPARATOR|Placebo|
62062369|NCT01695733|EXPERIMENTAL|Schedule A|Influenza vaccination on the first day of chemotherapy
62062370|NCT01695733|EXPERIMENTAL|Schedule B|Influenza vaccination 1 week (+/- 1 day) prior to chemotherapy
62062371|NCT05806502|EXPERIMENTAL|Type 1 diabetes|Endothelium-dependent and -independent vasodilatation before and after 120 min intra-arterial administration of arginase the inhibitor N-omega-hydroxy-nor-l-arginine (nor-NOHA).
62450197|NCT04000009|EXPERIMENTAL|Drug - pimavanserin|Pimavanserin 34 mg tablets
62062372|NCT05806502|EXPERIMENTAL|Type 2 diabetes|Endothelium-dependent and -independent vasodilatation before and after 120 min intra-arterial administration of arginase the inhibitor N-omega-hydroxy-nor-l-arginine (nor-NOHA).
62062373|NCT02375282|EXPERIMENTAL|Ambulation Orderly Intervention|Patients that are in this group are those randomized to receive visits from the ambulation orderly (ambulation group). The patients in this group will receive the visits from the ambulation orderly in addition to the standard of care that occurs with the rest of the hospital and with the control group.
62062374|NCT02375282|NO_INTERVENTION|Control Group|This is for the patients who are randomized to receive the standard care of Baystate Medical Center. The standard of care will be nurse-directed ambulation, as is currently done in all other nursing floors at Baystate Medical Center. Nurses will be instructed to walk with the patients as they did before the initiation of the ambulation orderly and as they do when the orderly is on vacation, at conferences, training, or away for illness. These patients will not receive visits from the ambulation orderly.
62450198|NCT00358826|EXPERIMENTAL|VIA-2291 25 mg|VIA-2291 25 mg
62450199|NCT00358826|EXPERIMENTAL|VIA-2291 50 mg|VIA-2291 50 mg
62450200|NCT00358826|EXPERIMENTAL|VIA-2291 100 mg|VIA-2291 100 mg
62062375|NCT00584402|EXPERIMENTAL|Contrast sonography|Contrast-enhanced sonography perflutren lipid microspheres
62625319|NCT01007370|ACTIVE_COMPARATOR|LMA-Fastrach|"* Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~* Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~* Insertion of LMA-Fastrach (sizes 3,4 or 5), establishment of ventilation~* Evaluation of glottic view through LMA-Fastrach using fibrescope (one out of ten patients)~* Tracheal intubation through the LMA-Fastrach~* With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
62625320|NCT01007370|ACTIVE_COMPARATOR|I-gel|"* Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~* Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~* Insertion of I-gel (sizes 3,4 or 5), establishment of ventilation~* Evaluation of glottic view through I-gel using fibrescope (one out of ten patients)~* Tracheal intubation through the I-gel~* With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
62625321|NCT05256966|ACTIVE_COMPARATOR|Sauna|Firefighters/participants based at the station with an existing sauna will be allocated to the intervention arm/sauna group. They will include a sauna session, as per study protocol, which is the intervention.
62625322|NCT05256966|NO_INTERVENTION|Non Sauna|Firefighters/participants based at the stations without a sauna will be allocated to the control arm/Non sauna group. They will not sauna, as per study protocol, as to not receive the study intervention.
62625323|NCT02255071|EXPERIMENTAL|Acupressure|Patients will band a acupressure wristband over Neiguan (P6 point) and acupressure for seven days.
62625324|NCT02255071|SHAM_COMPARATOR|Sham-Acupressure|Patients will band a sham wristband over wrist but no acupressure for seven days.
62625325|NCT03454477|EXPERIMENTAL|conventional open surgery|Patients who met the inclusion criteria were selected for a conventional open surgery procedure for a conventional neck incision for thyroid surgery.
62625326|NCT03454477|EXPERIMENTAL|endoscopic thyroidectomy|Patients who met the inclusion criteria were selected to undergo thyroid surgery via endoscopic thyroidectomy
62062376|NCT03465020||ITP patients|On active treatment
62062377|NCT05465512||good response to neoadjuvant chemotherapy (GRNC)|Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC)
62062378|NCT05465512||poor response to neoadjuvant chemotherapy (PRNC)|TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).
62450201|NCT00358826|PLACEBO_COMPARATOR|Placebo|Placebo
62450202|NCT02419352|ACTIVE_COMPARATOR|Sugammadex|Sugammadex is administered to reverse rocuronium-induced neuromuscular blockade at the end of elective surgery.
62450203|NCT02419352|ACTIVE_COMPARATOR|Neostigmine/atropine|Neostigmine combined to atropine is administered to reverse rocuronium-induced neuromuscular blockade at the end of elective surgery.
62062379|NCT01145807|PLACEBO_COMPARATOR|Placebo|non Transfersome® placebo
62062380|NCT01145807|SHAM_COMPARATOR|Transfersome® vehicle|Transfersome® vehicle
62062381|NCT01145807|EXPERIMENTAL|TDT 067|TDT 067
62062382|NCT01837329|EXPERIMENTAL|Tetrathiomolybdate|"Dose Escalation - It is aimed at determining the maximum tolerated dose of TM in combination with carboplatin and pemetrexed.~Dose Expansion - The dose expansion portion of the study will begin after completion of the dose escalation phase."
62450204|NCT06528665||4 groups subjects will be recruited. Each group will be composed of 6 subjects, sex ratio 1:1|Group1, 2,3 will be administered with 3 different patches (TDS) once for a week, respectively; Group 4 will be oral administered with one capsule (0.92 mg) only.
62450205|NCT02768298|EXPERIMENTAL|LCZ696|LCZ696 100 mg oral twice daily (bid) for 2 weeks followed by LCZ696 200 mg oral bid for 10 weeks.
62450206|NCT02768298|ACTIVE_COMPARATOR|Enalapril|"Enalapril 5 mg oral twice daily (bid) for 2 weeks followed by enalapril 10 mg oral bid for 10 weeks.~Patients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."
62450207|NCT06004609|EXPERIMENTAL|Treatment group (low-level laser therapy with conventional physical therapy)|Low-level laser therapy two to three times a week, 10 minutes each time, totally 24 times, for 8 to 10 weeks. Along with conventional physical therapy, two to three times a week, for 12 to 14 weeks.
62450208|NCT06004609|ACTIVE_COMPARATOR|Conventional group (conventional physical therapy only)|Conventional physical therapy, two to three times a week, for 12 to 14 weeks.
62625327|NCT03454477|EXPERIMENTAL|robotic thyroidectomy|Patients who met the inclusion criteria chose the Da Vinci robot for thyroid surgery.
62625328|NCT03612479|EXPERIMENTAL|KIDFIT Healthy|
62625329|NCT03612479|ACTIVE_COMPARATOR|KIDFIT Safe|
62850988|NCT03671317|NO_INTERVENTION|Non-intervention group|This arm will continue usual care with no intervention from medical clowns. They will be asked to complete pre and post surveys about the blood draw process.
62850989|NCT05253261|EXPERIMENTAL|Odontogenic cyst treated by decompression with an appliance.|Cystostomy procedure is carried out with the same day delivery of a decompression appliance fabricated with a fully digital workflow. Enucleation of the cyst is carried out following decompression.
62850990|NCT01686997|ACTIVE_COMPARATOR|Primairy long biliopancreatic limb RYGB|Roux limb 75 cm and Biliopancreatic Limb 150 cm
62850991|NCT01686997|ACTIVE_COMPARATOR|Redo Long biliopancreatic limb RYGB|Roux limb 75 cm and Biliopancreatic limb 150 cm
62850992|NCT01686997|ACTIVE_COMPARATOR|Primairy standard RYGB|Roux limb 150 cm and Biliopancreatic limb 75 cm
62850993|NCT01686997|ACTIVE_COMPARATOR|Redo standard RYGB|Roux limb 150 cm and Biliopancreatic limb 75 cm
62850994|NCT02299102|OTHER|Jamshidi Manual Standard Device|The Jamshidi manual standard device will be randomized for use on the right or left iliac crest
62850995|NCT02299102|OTHER|OnControl Powered Ported Device|The OnControl power ported device will be used on the opposite iliac crest
62625330|NCT02080364|EXPERIMENTAL|Azeliragon 5mg|Azeliragon (TTP488) 5mg orally once daily for 18 months
62062383|NCT06625866|EXPERIMENTAL|Behavioral intervention|The healthcare professionals in this hospital will be exposed to behavioral interventions, including feedback and information strategies.
62062384|NCT06625866|NO_INTERVENTION|Standard of care|The standard of care will be provided in this hospital without exposure to behavioral interventions for healthcare professionals.
62062385|NCT06001983|EXPERIMENTAL|Imaginary resisted exercises|• Handgrip exercises with the imagination of resistance in hand by getting feedback in VR Box will be given as an intervention. Stretching will be given at the beginning and the end of each session. This will include imaginary resistance exercises for handgrip by using Virtual Reality Box. Five types of different resistances will be imagined by patients by watching their own videos in VR box, which will be recorded on day one to make them familiar with the resistive objects and the resistance experienced from them by asking patients to perform 15-15 repetitions of each object. Every imaginary resistance exercise will have 15 repetitions. After performing exercises, the participants will ask to perform Finger-to-Nose Test and Purdue Pegboard Test.
62062386|NCT06001983|EXPERIMENTAL|Physical resisted exercises|Handgrip exercises with physical resistance in hand will be given as an intervention. Stretching will be given at the beginning and the end of the session. 5 different types of resistances will be given to patients for making themselves familiarize themselves with the type of resistance applied by each object, that they will experience in further sessions, by asking them to perform 15-15 repetitions of each object. Every physical resistance exercise will have 15 repetitions. After performing exercises, the participants will ask to perform Finger-to-Nose Test and Purdue Pegboard Test. In physical resistance exercises, resistive force is applied to the targeted region by using different and appropriate resistive objects
62062387|NCT02531178|EXPERIMENTAL|low dose ABBV-257|Low dose every other week (eow), Weeks 0-8
62062388|NCT02531178|EXPERIMENTAL|Medium dose of ABBV-257|Medium dose every other week (eow), Weeks 0-8
62850996|NCT04458480||Exposed Group|Both exposed group and control group are undertaken TKA surgery and routine postoperative management for 2 days in orthopedics department. Exposed group patients are transferred from orthopedics department to rehabilitation department on 2nd day after TKA, and accept fast inpatient rehabilitation for 1 week before hospital discharge, while control group patients continue to accept routine peri-operative management and conventional oral instructions of exercises in orthopedics department until hospital discharge.
62450209|NCT00720486|EXPERIMENTAL|1|Participants will receive Juvenile Justice Anger Management for Girls plus treatment as usual.
62850997|NCT04458480||Control Group|Both exposed group and control group are undertaken TKA surgery and routine postoperative management for 2 days in orthopedics department. Exposed group patients are transferred from orthopedics department to rehabilitation department on 2nd day after TKA, and accept fast inpatient rehabilitation for 1 week before hospital discharge, while control group patients continue to accept routine peri-operative management and conventional oral instructions of exercises in orthopedics department until hospital discharge.
62062389|NCT02531178|EXPERIMENTAL|high dose of ABBV-257|high dose every other week (eow), Weeks 0-8
62450210|NCT00720486|ACTIVE_COMPARATOR|2|Participants will receive treatment as usual.
62450211|NCT05760664|EXPERIMENTAL|Experimental Group|The fascial fitness® method (12 sessions, twice a week, for six weeks, 15 minutes a day, for 2 sets of 40 seconds each side). Assessments and reassessments will be carried out in the first, fourth and sixth week.
62450212|NCT05760664|ACTIVE_COMPARATOR|Sham Group|Static stretching exercises (12 sessions, twice a week, for six weeks, 15 minutes a day, for 2 sets of 40 seconds each side). Assessments and reassessments will be carried out in the first, fourth and sixth week.
62625331|NCT02080364|PLACEBO_COMPARATOR|Placebo|Placebo orally once daily for 18 months
62625332|NCT00931112|OTHER|exercise|
62625333|NCT04648657||acute hypoxemic respiratory failure patients|Mechanically ventilated patients with acute hypoxemic respiratory failure (AHRF) with P/F ratio \< 300 with at least PEEP 5 cmH2O)
62625334|NCT04285216|EXPERIMENTAL|Dry needling|Hot pack 10 mints,stretching,Neck isometrics, dry needling(DN) and Strain counterstrain(SCS)
62625335|NCT04285216|ACTIVE_COMPARATOR|Strain counter strain|Hot pack 10 minutes, stretching,Neck isometrics, Strain counter strain (S C S)
62062390|NCT04484714|EXPERIMENTAL|Behavioural: Exercise|"Participants will take part in a twelve week resistance and aerobic exercise program twice per week delivered virtually.~Exercise sessions will include a combination of aerobic, resistance, balance, and flexibility exercises"
62062391|NCT03559218|OTHER|Standard of care|Patients undergoing radiation therapy for breast cancer will be provided instructions for radiation dermatitis per institutional standard of care
62266835|NCT03048669|NO_INTERVENTION|Standard of care|In health districts randomized to standard of care, the same strengthening of the data collection system for the monitoring of indicators as in the intervention group will be implemented. At least once a month, a study staff will visit each clinics irrespective of their randomization to extract information for the mother-infant register into an electronic database. No report on indicators will be produced for those clinic for the duration of the study. Staff from clinics and health district bureau in the standard of care group will not be associated with the quarterly review of the indicators. The study will not influence with any other HIV service provision activity in the standard of care group.
62450213|NCT05760664|PLACEBO_COMPARATOR|Control Group|The placebo intervention will be performed using ultrasound turned off in the thoracolumbar region for 15 minutes followed by rest for 15 minutes for 6 weeks, twice a week. Ultrasound was chosen because it is easy-to-use equipment and because this form of placebo used, equipment turned off, does not have any treatment effect and has already been established in another study (CHAIBI; BENTH; RUSSELL, 2015). Assessments and reassessments will be carried out in the first, fourth and sixth week.
62450214|NCT06437080|ACTIVE_COMPARATOR|Oral iron supplement|"100 participants of Group A will get oral iron supplementation (Iron III Hydroxide Polymaltose Complex eq. to Elemental Iron), 100 mg for 03 months. Participants will consume 01 tablet per day for 03 months.~After completion of the treatment period blood samples will be taken to evaluate the effect of iron supplementation on serum ferritin levels and severity of symptoms to assess the effectiveness of the intervention."
62850998|NCT05815979|EXPERIMENTAL|Experimental Group:virtual reality, low-reality simple simulation dummy/model|Presentation of the From this point of view, the research was planned as a randomized, control group, experimental study to evaluate the effect of virtual reality-based nasogastric tube application skill on the knowledge, skills and self-confidence of graduate nursing students. glasses and an information meeting will be held for all students in the experimental group, and the working procedure of the virtual reality glasses will be introduced. Afterwards, students will monitor the practice skill at least once using virtual reality glasses. After the completed follow-up, the students will be asked to practice their nasogastric tube application skill on a simple simulation mannequin/model with low reality in the laboratory environment.
62850999|NCT05815979|NO_INTERVENTION|Control Group:low-reality simple simulation dummy/model|Students will be shown the ability to apply a nasogastric tube on a low-reality simple simulation mannequin/model in the laboratory with a demonstration method by the same researcher. Afterwards, students will be asked to practice the skill of applying a nasogastric tube on a simple simulation manikin/model. While practicing on a low simple simulation mannequin/model, students will be evaluated according to the 'Nasogastric Catheter Application Skill Checklist' by a person who works as a nurse and has a graduate education in the field of Nursing Fundamentals, and the application time of the student's nasogastric tube will be recorded. After the application, the students will be asked to fill the 'Nasogastric Catheter Application Skill Knowledge Test' and 'Self-Confidence Evaluation Form'. In addition, students will be required to fill in the Anxiety, Stress, Satisfaction and Motivation Evaluation Form.
62851000|NCT04306484||patients with tumoral brain lesion|The 48 tumor patients included 8 low grade (grade II glioma, n=7; grade II ependymoma, n=1), and 40 high grade (grade III glioma, n=12; grade IV glioma, n=25, primary cerebral lymphoma, n=1; medulloblastoma, n=1, and metastatic cerebral breast cancer, n=1) tumors. Histology was available for all tumor patients.
62851001|NCT04306484||patients with non-tumoral brain lesion|The non-tumor group included patients with an inflammatory lesion (n=11), lobar primary intracerebral haemorrhage (n=3), cortical dysplasia (n=3), infectious lesion (n=2, both toxoplasmosis), cerebral cavernomatous malformation (n=1), seronegative autoimmune limbic encephalitis (n=1), deep venous sinus thrombosis-related oedema (n=1), brain infarction (n=1), chronic posttraumatic brain lesion (n=1), radionecrosis after radiation therapy for arteriovenous malformation (n=1), and mixed inflammatory/infectious lesion (n=1, multiple sclerosis lesion complicated by biopsy-related infection).
62851002|NCT00749047|EXPERIMENTAL|1|Open label arm
62062392|NCT03559218|EXPERIMENTAL|KeraStat Cream|Patients undergoing radiation therapy for breast cancer will be provided KeraStat Cream for twice daily application.
62062393|NCT02477280|EXPERIMENTAL|Methylphenidate|Methylphenidate 20 mg Tablet single-dose per os
62266836|NCT02803021|EXPERIMENTAL|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62062394|NCT02477280|PLACEBO_COMPARATOR|Placebo|Placebo 20 mg Tablet single-dose per os
62062395|NCT01835262|ACTIVE_COMPARATOR|Morphine|Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP
62062396|NCT01835262|EXPERIMENTAL|Ketamine Group|Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP
62062397|NCT03626532|EXPERIMENTAL|Mindfulness-Based Stress Reduction|Participants will meet once a week for 8 weeks (2.5 hours per session), plus a 4-hour retreat day, to engage in mindfulness meditation exercises. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will require participants to engage in guided practices for 30 minutes a day for 5 days a week.
62062398|NCT03626532|ACTIVE_COMPARATOR|Lifestyle Education|Participants will meet once a week for 2.5 hours for 8 weeks, plus a 4-hour retreat day, to engage in light stretching exercises and interactive discussions on health topics, such as physical activity, nutrition, sleep, stress, etc. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will ask participants to engage in stretching, read or watch informational content, and answer reflection questions for 30 minutes a day for 5 days a week.
62062399|NCT02446795|EXPERIMENTAL|Experimental Arm|Phase I Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Isoquercetin: 225mg twice a day (at 08 a.m. and at 4 p.m). Phase II Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Isoquercetin: 450 mg twice a day (at 08 a.m. and at 4 p.m).
62625336|NCT04142398||Screening (health information collection)|Participants receive a questionnaire and undergo a targeted physical and anal clinical exam at months 0, 6, and 12. Participants also undergo a penile skin cell and anal swab at months 0, 6, and 12 for cytology, HPV DNA, and CD4+ T-cell count at months 0 and 6 and HIV viral load testing at months 0 and 12. Participants also undergo HRA and penile clinical exam at month 12.
62625337|NCT01156805|EXPERIMENTAL|Educational intervention, Control|Experimental, intervention group has received specific educational training to improve food habits and physical activity during the period of the study.
62625338|NCT01156805|NO_INTERVENTION|Educational program|No intervention has been made.
62062400|NCT02446795|PLACEBO_COMPARATOR|Placebo Arm|Phase I Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Placebo: 225mg twice a day (at 08 a.m. and at 4 p.m). Phase II Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Placebo: 450 mg twice a day (at 08 a.m. and at 4 p.m).
62062401|NCT00793156|PLACEBO_COMPARATOR|Placebo|Patients will be randomized into Placebo group
62062402|NCT00793156|ACTIVE_COMPARATOR|2|2.5 µg group randomized
62625339|NCT05825963|EXPERIMENTAL|PEHM/CHM|In this arm, participants received psyllium-enriched hamburger meatballs first, then after the washout period, they received classic hamburger meatballs.
62625340|NCT05825963|EXPERIMENTAL|CHM/PEHM|In this arm, participants received classic hamburger meatballs first, then after the washout period, they received psyllium-enriched hamburger meatballs.
62625341|NCT02714010|EXPERIMENTAL|Arm 1|Patients take EGFR-TKI alone till tumor progression
62625342|NCT02714010|ACTIVE_COMPARATOR|Arm 2|Patients take EGFR-TKI concurrent with whole brain radiotherapy (WBRT) till tumor progression, WBRT started within the first week of taking TKI
62625343|NCT06326086||CMT for patients receiving chemotherapy,|
62625344|NCT06326086||TKI/IO for patients receiving targeted and immunotherapy|
62625345|NCT03026283||1: HeartFlow CT-FFR Arm|All patients who consent will receive HeartFlow CT-FFR and medically acceptable care based on the study protocol, commonly accepted standards of care, and the patients condition.
62625346|NCT00568893|EXPERIMENTAL|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
62062403|NCT00793156|ACTIVE_COMPARATOR|3|5.0 µg group randomized
62062404|NCT02326350|EXPERIMENTAL|Aspirin 75mg|Aspirin 75mg enterally once daily for a maximum of 14 days
62625347|NCT02745483|EXPERIMENTAL|Separable clustered electrodes|Enrolled patients in the prospective study (RFA using separable clustered electrodes (Octopus®)) for treatment-naive HCC (n=79)
62625348|NCT02745483|NO_INTERVENTION|Historical control group|Patients who received RFA according to routine protocol in our center (multiple internally-cooled electrodes) for treatment-naive HCC from Jan 2011 to July 2013 in our institution (n=74) .
62625349|NCT00137787|EXPERIMENTAL|1|
62062405|NCT02326350|PLACEBO_COMPARATOR|Placebo|Lactose powder placebo enterally once daily for a maximum of 14 days
62062406|NCT06293300|EXPERIMENTAL|BoNT-A Group|Participants will receive BoNT-A intervention for up to 6 months.
62062407|NCT03944044|OTHER|Subcutaneous route first|The first route of administration is designated by randomization. In the subcutaneous group, patients received intravenous route in a second time.
62062408|NCT03944044|OTHER|Intravenous route first|The first route of administration is designated by randomization. In the intravenous group, patients received subcutaneous route in a second time.
62062409|NCT02649062|EXPERIMENTAL|NGM282 Dose 1|NGM282
62266837|NCT06033079|EXPERIMENTAL|CDS Intervention|The prognostic decision support application will be provided to those randomized to the intervention arm. Due to the nature of the intervention, blinding of treating providers will not be possible. All children will receive usual care and all treatment decisions will be made by the clinical providers and will not be restricted or altered in any way.
62625350|NCT00137787|ACTIVE_COMPARATOR|2|
62625351|NCT01972464|PLACEBO_COMPARATOR|placebo|In this group women will receive a placebo pill which will appear similar to progesterone and will be inert.
62625352|NCT01972464|EXPERIMENTAL|Progesterone|In this group women will receive oral micronized progesterone twice a day.
62625353|NCT06163027|EXPERIMENTAL|Shotblocker|Shotblocker (experimental) group: Patients will undergo standard monitoring. The shotblocker will be sterilized before the procedure. Sterilization of the shotblocker will be controlled by the indicator on the packaging. Necessary sterilization conditions for spinal anesthesia application will be met and the procedure will be performed from the L3 -L4 or L4 -L5 spinal range. During the spinal anesthesia process, the protruding surface of the shot blocker will be placed in the area to be inserted, just before the spinal needle application. The shotblocker will be kept stationary throughout the procedure and pressure will continue to be applied. After entering for the spinal anesthesia procedure, the shot blocker will be removed. During the spinal anesthesia procedure, VAS, patient satisfaction and comfort scale will be applied to the patient in the first 1 minute and at the 24th hour after surgery.
62625354|NCT06163027|PLACEBO_COMPARATOR|Placebo|Placebo group: Patients will undergo standard monitoring (electrocardiogram, noninvasive blood pressure, peripheral oxygen saturation). The shotblocker will be sterilized before the procedure. Sterilization of the shotblocker will be controlled by the indicator on the packaging. Necessary sterilization conditions for spinal anesthesia application will be met and the procedure will be performed from the L3 -L4 or L4 -L5 spinal range. During the spinal anesthesia procedure, the reverse side of the shotblocker (without protrusions) will be placed on the skin surface and gently pressed with the fingertips. The shotblocker will be kept stationary throughout the procedure and pressure will continue to be applied. After entering for the spinal anesthesia procedure, the shot blocker will be removed. During the spinal anesthesia procedure, VAS, patient satisfaction and comfort scale will be applied to the patient in the first 1 minute and at the 24th hour after surgery.
62851003|NCT00375609|EXPERIMENTAL|Betrixaban 15 mg|Betrixaban 15 mg oral twice daily for 10 to 14 days
62851004|NCT00375609|EXPERIMENTAL|Betrixaban 40 mg|Betrixaban 40 mg oral twice daily for 10 to 14 days
62062410|NCT02649062|EXPERIMENTAL|NGM282 Dose 2|NGM282
62062411|NCT02649062|PLACEBO_COMPARATOR|Placebo|Placebo
62851005|NCT00375609|EXPERIMENTAL|Enoxaparin|Enoxaparin 30 mg administered subcutaneously every 12 hours for 10 to 14 days
62851006|NCT04620876|EXPERIMENTAL|Bimodal and coaxial high resolution imaging of the retina|Optical coherence tomography and Scanning laser ophthalmoscope system using adaptive optics (AO-SLO-OCT)
62851007|NCT02727439|EXPERIMENTAL|Sedentary Subjects|Healthy lean sedentary subjects.
62851008|NCT02727439|EXPERIMENTAL|Athletes|Active athletes.
62062412|NCT04539457|NO_INTERVENTION|Usual care|Neither the 'Desktop Helper (version 10)' will be integrated in the EMR system nor the 'e-learning' will be offered to GPs. However, to prevent attenuation of usual care, GPs will be free to adjust any medication on their own initiative or to use any other aid to decrease inappropriate prescribing in COPD patients.
62062413|NCT04539457|ACTIVE_COMPARATOR|Only desktop helper|Only the 'Desktop Helper (version 10)' will be integrated in the EMR system. Specifically, GPs will receive a notification about the 'Desktop Helper (version 10)'. This notification will inform general practitioners about the option in the Medicom Smart Module to identify COPD patients with comorbidities who have one or more 'medication-comorbidity clashes' (i.e. undesired interactions between medications for COPD and comorbid conditions).
62062414|NCT04539457|ACTIVE_COMPARATOR|Only E-learning|Only the 'e-learning' will be offered to GPs. Herein, GPs, will be invited to perform an e-learning module which provide information about COPD and their (co)morbidities and the 'medication-comorbidity clashes'.
62062415|NCT04539457|ACTIVE_COMPARATOR|Both dekstop helper and e-learning|Both 'Desktop Helper (version 10)' will be implemented in the EMR system. GPs will subsequently be notified about the possibility to detect COPD patients with 'medication-comorbidity clashes'. The implementation of the 'Desktop Helper (version 10), will be accompanied by e-learning offered to GPs. about COPD and their (co)morbidities and the 'medication-comorbidity clashes'.
62062416|NCT02352363|EXPERIMENTAL|CVT-301|Capsules of Levodopa Inhalational Powder (LIP) used up to 5 times per day for OFF episodes, for up to 54 weeks duration.
62062417|NCT02352363|OTHER|Observational Cohort|Standard of care. Patients in both the CVT-301 treatment group and the observational cohort will be managed with their standard PD treatment throughout the study.
62062418|NCT05493384|EXPERIMENTAL|Telerehabilitation group|The Telerehabilitation Group will be performed exercise program including stretching, strengthening, posture and relaxation exercises by an experienced physiotherapist for 3 times a week for 8 weeks via Zoom.
62062419|NCT05493384|NO_INTERVENTION|No Intervention group|No additional therapy will be performed to the Control Group and they were suggested to continue their usual physical activity.
62062420|NCT03987425|EXPERIMENTAL|CPAP treatment|Group of patients who will receive CPAP treatment
62851009|NCT01523847|EXPERIMENTAL|MBVD (Myocet+BVD)|"2 MBVD courses, after early restaging with PET scan (PET-2)~The subsequent treatment will be planned as follows:~* -Stage I and IIA patients will go on with 1 more course of MBVD (total of 3 courses) followed by involved field radiotherapy (30 Gy-36 Gy).~* -Advanced stage (IIB-IV) patients will go on with 4 more courses of MBVD (total of 6 courses). Radiotherapy limited to bulky or non complete responder areas (30 Gy) is optional."
62062421|NCT03987425|NO_INTERVENTION|Conservative measures|Group of patients who will receive conservative treatment based on hygienic-dietetic measures
62062422|NCT01542021|EXPERIMENTAL|Untreated patients degarelix injection occur at days 4± 1|Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy
62062423|NCT01542021|EXPERIMENTAL|Untreated patients degarelix injection occur at days and 7± 1.|Treatment will consist of a single 240 mg injection of degarelix 7±1 day before radical prostatectomy
62062424|NCT01542021|EXPERIMENTAL|treated patients with androgen deprivation|Patients already treated with androgen deprivation are assigned to Cohort 3 and maintained on current androgen deprivation therapy until they undergo or have already undergone RP at MSKCC. Will include patients who have already undergone hormonal therapy (of any duration between 1 and 6 months) prior to prostatectomy.
62062425|NCT01542021|EXPERIMENTAL|Untreated patients degarelix injection occur at days 14±1|Treatment will consist of a single 240 mg injection of degarelix 14±1 day before radical prostatectomy
62851010|NCT04114617||Healthy Adults|Participants will be asked to swallow a series of up to 54 liquid stimuli: a) liquid barium (different brands and concentrations); b) a 20% w/v concentration liquid barium thickened to different consistencies using either a starch-based or xanthan-gum based food thickener; and c) lemon-flavored water thickened to different consistencies using either a starch-based or xanthan-gum based food thickener.
62851011|NCT05140824|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride solution
62851012|NCT05140824|EXPERIMENTAL|TJ202|TJ202 injection
62851013|NCT02090751||No Maculopathy|Aged 50 to 80 with no macular disease
62851014|NCT02090751||Early Maculopathy|Aged 50 to 80 with early AREDS defined 2,3 age related maculopathy
62851015|NCT04966663|EXPERIMENTAL|Adjuvant chemo-immunotherapy therapy|"All participants will have blood taken for ctDNA testing.~A cycle is 21 days. Pemetrexed (for participants with non-squamous non-small cell lung cancer), intravenously (by vein) on Day 1 of Cycles 1-4, OR gemcitabine (for all other participants) on Days 1 and 8 of Cycles 1-4.~Cisplatin\*, intravenously (by vein) on Day 1 of Cycles 1-4 Nivolumab, intravenously (by vein) on Day 1 of Cycles 1-4~\*If cisplatin is not tolerated, carboplatin may be given instead"
62851016|NCT04966663|OTHER|Observation|"All participants will have blood taken for ctDNA testing.~Participants will be followed as per standard of care every 3 months."
62851017|NCT03093662|EXPERIMENTAL|Ventilation with nasal cannula|Non-invasive positive pressure ventilation with nasal cannula.
62851018|NCT03093662|ACTIVE_COMPARATOR|Ventilation without nasal cannula|Non-invasive positive pressure ventilation without nasal cannula.
62851019|NCT02173067||2% lidocaine|35 patients received 5.4 mL of 2% lidocaine.
62851020|NCT02173067||2% lidocaine with epinephrine|35 patients recieved 5.4 mL of 2% lidocaine with 1:100,000 epinephrine.
62851021|NCT00470834|EXPERIMENTAL|Arm 1|50 mg bicalutamide and 3.5 mg Dutasteride (IP)
62851022|NCT00470834|PLACEBO_COMPARATOR|Arm 2|50 mg bicalutamide and placebo
62851023|NCT00664001|PLACEBO_COMPARATOR|Control|Placebo tablet
62851024|NCT00664001|ACTIVE_COMPARATOR|Intervention|Anti-oxidant supplementation
62851025|NCT00833664|EXPERIMENTAL|Terbinafine|Terbinafine 250 mg Tablet (test) dosed in first period followed by Lamisil® 250 mg Tablet (reference) dosed in second period
62062426|NCT01226563|EXPERIMENTAL|IK-5001|IK-5001 Sodium Alginate Calcium Gluconate intracoronary injection
62062427|NCT01226563|PLACEBO_COMPARATOR|Saline Solution|Saline Solution intracoronary injection
62062428|NCT03372824||Pregnant women|Primiparas above 25 years of age, singleton pregnancy
62450215|NCT06437080|ACTIVE_COMPARATOR|Intravenous (IV) iron supplementation|"100 participants of Group B will get IV iron supplementation (Ferric Carboxymaltose) for 03 months (01 dose per month for 03 months).~After completion of the treatment period blood samples will be taken to evaluate the effect of iron supplementation on serum ferritin levels and severity of symptoms to assess the effectiveness of the intervention."
62851026|NCT00833664|ACTIVE_COMPARATOR|Lamisil®|Lamisil® 250 mg Tablet (reference) dosed in first period followed by Terbinafine 250 mg Tablet (test) dosed in second period
62851027|NCT02921334|EXPERIMENTAL|Intervention group|Patients in this group are received ventilator weaning by switching between invasive and noninvasive ventilation.
62851028|NCT02921334|NO_INTERVENTION|Control group|Patients in this group are weaned from ventilator as conventional methods.
62851029|NCT01529138|EXPERIMENTAL|Temsirolimus|An ester of the macrocyclic immunosuppressive agent sirolimus.
62851030|NCT01529138|EXPERIMENTAL|Axitinib|An oral, selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3.
62851031|NCT02395432|ACTIVE_COMPARATOR|Totaltrack|OTI with Totaltrack
62851032|NCT02395432|ACTIVE_COMPARATOR|Macintosh Laryngoscope|OTI with Macintosh Laryngoscope
62851033|NCT00323011|ACTIVE_COMPARATOR|Arm A: 5-FU/LV/CPT-11/Bevacizumab|5-FU 400 mg/m2, days 1, 15, \& 29 Leucovorin Calcium 200 mg/m2, days 1, 15, \& 29 CPT-11 180 mg/m2, days 1, 15 \& 29 Bevacizumab 5mg/kg, days 1, 15, \& 29
62851034|NCT00323011|EXPERIMENTAL|Arm B: 5-FU/LV/CPT-11/Bevacizumab + Dalteparin|5-FU 400 mg/m2, days 1, 15, \& 29 5-FU 2400 continuous infusion days 1-2, 15-16, 29-30. Leucovorin Calcium 200 mg/m2, days 1, 15, \& 29 CPT-11 180 mg/m2, days 1, 15 \& 29 Bevacizumab 5mg/kg, days 1, 15, \& 29 Dalteparin 5000 IU subcutaneous starting cycle 2, days 1, 15, \& 29
62266838|NCT06033079|NO_INTERVENTION|Control|No experimental decision support will be provided to those randomized to the control arm. All children will receive usual care and treatment will not be restricted or altered in any way by the study.
62450216|NCT06437080|NO_INTERVENTION|Normal diet|100 participants will remain on their normal diet for 03 months. After 03 months blood samples will be taken to evaluate the effect of iron supplementation on serum ferritin levels and severity of symptoms to assess the effectiveness of the intervention.
62851035|NCT00323011|EXPERIMENTAL|5-FU/LV/CPT-11/Bevacizumab+Dalteparin daily|5-FU 400 mg/m2, days 1, 15, \& 29 5-FU 2400 continuous infusion days 1-2, 15-16, 29-30. Leucovorin Calcium 200 mg/m2, days 1, 15, \& 29 CPT-11 180 mg/m2, days 1, 15 \& 29 Bevacizumab 5mg/kg, days 1, 15, \& 29 Dalteparin 5000 IU subcutaneous starting cycle 2, daily
62851036|NCT04050202|EXPERIMENTAL|ABC|ABC delivers therapy through 10, home-based, in-person sessions led by a trained professional. Treatment content is based on attachment theory and an understanding of children's stress neurobiology. Components aim to improve parental sensitivity, nurturance, and responsivity, as well as children's biological and behavioral reactivity through dyadic interactions between parents and children.
62851037|NCT00443963|EXPERIMENTAL|PPI|PPI Medication
62062429|NCT04040881|EXPERIMENTAL|Remote monitoring using Smartphone|Patients will be provided with a Global System for Mobile communications (GSM) accelerometer-equipped Android smartphone (specific model to be decided) with an installed open source, freely available pedometer application (Google Fit, Google, CA, United States) which will record their daily steps. Patients will receive daily calls from a research assistant to document the presence of clinically significant chemotherapy-related toxicity.
62062430|NCT04985006|EXPERIMENTAL|Moderate intensity aerobic exercise|each subject will undergo running in medium intensity.
62062431|NCT04985006|ACTIVE_COMPARATOR|High intensity aerobic exercise|each subject will undergo running in high intensity.
62266839|NCT03849378|EXPERIMENTAL|Sargassum Horneri Extract group|This group takes Sargassum Horneri Extract for 12 weeks.
62266840|NCT03849378|PLACEBO_COMPARATOR|Placebo group|This group takes Placebo Extract for 12 weeks.
62450217|NCT02547857||Cohort 1|All women who undergo pelvic US in the ED, assuming they meet inclusion/exclusion criteria
62851038|NCT00443963|EXPERIMENTAL|H2RA|H2RA Medication
62851039|NCT05952609|EXPERIMENTAL|Group 1|Patients receiving Surefil One
62851040|NCT05952609|EXPERIMENTAL|Group 2|Patients receiving Cention N
62851041|NCT05952609|ACTIVE_COMPARATOR|Group 3|Patients receiving bulkfil resin composite
62625355|NCT06163027|NO_INTERVENTION|Control|Routine treatment and care will be applied to the control group and no intervention will be made. During the spinal anesthesia procedure, VAS, patient satisfaction and comfort scale will be applied to the patient in the first 1 minute and at the 24th hour after surgery. The data obtained will be recorded in the patient diagnosis form. All interventions will be performed by the same anesthesiologist. The data will be filled in by a healthcare professional who is blinded to the study.
62851042|NCT00271713|ACTIVE_COMPARATOR|ibandronate|150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily
62062432|NCT03861858|EXPERIMENTAL|DBT-A|The standard treatment to be delivered to all participants is DBT-A, which is a treatment model adapted from DBT. DBT-A is an adaptation for adolescents with emotion dysregulation and BPD features (Miller, Rathus, \& Linehan, 2007; Rathus \& Miller, 2015). DBT-A involves weekly individual therapy with the adolescent, weekly multifamily skills group in which adolescents and family members participate, as needed phone coaching, and weekly consultation team for the therapists.
62266841|NCT04089007|EXPERIMENTAL|SOmNI intervention group|"Participants will receive an iPhone with the SOmNI app and will be instructed to move their bedtime earlier by 5 minutes (from their average baseline week bedtime) on each school night (Sunday to Thursday). Participants will also be given sleep hygiene information related to the embedded features of the SOmNI app. A research assistant will help the participant to enter the appropriate goal bedtime in the SOmNI app and orient them to the features of the SOmNI app. Participants will also be instructed to aim for \<1 hour difference between school night and weekend bedtimes and wake times (i.e. avoid staying up late and sleeping in on weekends).~The SOmNI application will allow the user to graphically track sleep behaviour across the four-week intervention period as recorded by the wearable sensor (e.g. bedtimes, wake times, amount of sleep achieved will all be displayed in the app)."
62266842|NCT04089007|ACTIVE_COMPARATOR|Control group|The research assistant will advise the participant to increase the amount of nighttime sleep achieved but will not give any sleep hygiene advice or instructions for moving their bedtime earlier.
62266843|NCT04091087|EXPERIMENTAL|crisaborole ointment|crisaborole ointment
62625356|NCT00604747|OTHER|1, 2|
62851043|NCT00271713|PLACEBO_COMPARATOR|2|placebo monthly plus 500mg calcium and 800 UI vitamin D daily
62851044|NCT05865041|EXPERIMENTAL|Farudodstat for 12 weeks followed by placebo for 12 weeks|Farudodstat 100mg twice daily for 12 weeks followed by matching Placebo twice daily for 12 weeks
62851045|NCT05865041|EXPERIMENTAL|Placebo for 12 weeks followed by farudodstat for 12 weeks|Matching Placebo twice daily for 12 weeks followed by farudodstat 100mg twice daily for 12 weeks
62851046|NCT03718780|EXPERIMENTAL|A1: Patient in intensive care|"Patient in intensive care (n=10):~in patients in the intensive care unit of the Centre Hospitalier Metropole Savoie (Chambéry, France), where repeated arterial blood gas analysis is routinely performed (Patients equipped for their usual care with an arterial catheter, enabling repeated arterial blood gas determination ).~PaCO2 and Pt CO2 will be measured simultaneously at rest, and during conditions inducing PaCO2 modifications (ventilator settings modifications, or exercise as per routine rehabilitation) Comparison will be done between arterial PaCO2 and PtCO2"
62851047|NCT03718780|EXPERIMENTAL|A2: Healthy subjects|"Healthy subjects performing a voluntary hyperventilation, in the laboratory room where routine exercise testing is usually done.~Comparison will be done between arterialized PaCO2 and PtCO2, at rest, and during an induced voluntary hyperventilation."
62851048|NCT03718780|EXPERIMENTAL|B1: Healthy subject|"Subjects, referred for exercise diagnostic testing, and whose results indicate normal cardiac and pulmonary exercise physiology.~Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points."
62266844|NCT04091087|SHAM_COMPARATOR|vehicle ointment|vehicle ointment
62266845|NCT00345176|ACTIVE_COMPARATOR|Lutein/Zeaxanthin|lutein (10mg)/zeaxanthin (2 mg)
62266846|NCT00345176|ACTIVE_COMPARATOR|DHA/EPA|DHA (350 mg)/EPA (650 mg)
62266847|NCT00345176|ACTIVE_COMPARATOR|Lutein/Zeaxanthin + DHA/EPA|lutein (10 mg)/zeaxanthin (2 mg) + DHA (350 mg)/EPA (650 mg)
62266848|NCT00345176|PLACEBO_COMPARATOR|Placebo/Control|Considered control because all participants received the AREDS formulation
62087956|NCT03279705|ACTIVE_COMPARATOR|One-channel group|The colonoscopy was done with the traditional colonoscopy. Water exchange was done by using the accessory channel for both infusing and suctioning of water.
62851049|NCT03718780|EXPERIMENTAL|B2: Chronic Obstructive Pulmonary Disease|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
62450218|NCT05591196|ACTIVE_COMPARATOR|Activity Based Rehabilitation|Activity Based Rehabilitation is comprised of intensive, progressive, functional task practice. The protocol consists of repetitive activities of gross upper limb movement, isolated finger movements, bimanual task performance, simple and complex pinch, and grip performance. Several activities with various difficulty levels are designated for each category, and the participant will perform 1-2 activities within each category in each rehabilitation session. Rehabilitation sessions will be three times per week, 90 minutes per session for six weeks (total of 18 sessions).
62450219|NCT05591196|EXPERIMENTAL|Non-invasive Electrical Spinal Cord Stimulation + Activity Based Rehabilitation|Non-invasive electrical spinal cord stimulation will be performed using surface electrodes placed over the skin of the neck. Biphasic rectangular pulses of 1 millisecond per phase duration will be delivered with a 10 kiloHertz overlapping frequency and between 20-120 Hertzz burst frequency. Non-invasive electrical spinal cord stimulation will be paired with Activity Based Rehabilitation sessions. Stimulation plus rehabilitation sessions will be three times per week, 90 minutes per session for six weeks (total of 18 sessions).
62450220|NCT00040378||Combination therapy|vitamin E (alphatocopherol) and selenium
62851050|NCT03718780|EXPERIMENTAL|B3: Interstitial Lung Disease (ILD)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
62851051|NCT03718780|EXPERIMENTAL|B4: Chronic heart failure (CHF)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
62851052|NCT03718780|EXPERIMENTAL|B5: Pulmonary Arterial Hypertension (PAH)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
62851053|NCT03718780|EXPERIMENTAL|B6: inappropriate hyperventilation syndrome|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
62851054|NCT05883241|EXPERIMENTAL|SAM Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 12 weeks combined with 2.5% diclofenac patch. The SAM Device emits continuous ultrasound at 3-megahertz (MHz) frequency and 0.132 watts/cm\^2 intensity.
62450221|NCT00040378||Vitamin E only|vitamine E (alphatocopherol) and placebo
62450222|NCT00040378||Selenium only|selenium and placebo (Placebo replacement for vitamin E)
62450223|NCT00040378||Placebo|placebo (Placebo replacement for vitamin E) and placebo (Placebo replacement for selenium)
62450224|NCT01073436||Discontinuation|Subjects who agree to discontinue their tyrosine kinase inhibitor(TKI)therapy, namely,imatinib mesylate, dasatinib, or nilotinib,and then followed to see if they can maintain a durable remission.
62450225|NCT03401710|EXPERIMENTAL|Group 1|Recombinant human erythropoietin 4000 UI will be administered subcutaneously every other day
62625357|NCT02506062|EXPERIMENTAL|Active Arm - 200 mmHg|Patients who start in the active arm of the study will receive ischemic preconditioning (IPC) treatment consisting of applying the blood pressure cuff to a pressure of 200 mmHg for 2 minutes and thirty seconds with a resting period of two minutes and thirty seconds between treatments. This procedure is performed four times, for a total of twenty minutes per treatment. This treatment will be done three times a week. Patients may choose to treat at home with a portable manual blood pressure machine or may be treated in clinic by research staff. Patients will receive treatment for two weeks followed by a wash-out period (no treatment) of two weeks. Patients will then receive the placebo treatment. This completes their participation in the study.
62062433|NCT03990584|EXPERIMENTAL|three irrigation activation methods|"Manual dynamic irrigation was performed using a well-fitting gutta-percha cone inserted to WL with in-and-out vertical strokes of 5 mm at a rate of approximately 100 strokes per minute in order to hydrodynamically displace the irrigant.~Passive ultrasonic irrigation was performed using a non-cutting size 25 file attached to a piezoelectric ultrasonic unit.~Sonic irrigation was performed using an EndoActivator sonic handpiece (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA). A suitable-size activator tip was selected and loosely placed at 2 mm from working length, and the device was operated at 10,000 cycles/min using a pumping action to move the tip to produce vertical strokes of 2-3 mm."
62062434|NCT03990584|ACTIVE_COMPARATOR|Conventional needle irrigation (control)|Conventional needle irrigation was performed with short, in-and-out vertical strokes of 2-3 mm at a rate of approximately 100 strokes per minute.
62062435|NCT00939731|EXPERIMENTAL|PIC|
62450226|NCT03401710|NO_INTERVENTION|Group 2|No recombinant human erythropoietin will be administered to this group
62450227|NCT04932356|OTHER|Therapeutic Education by phone|Therapeutic education in diabetes mellitus (pharmacological, nutritional, physical exercise, social adherence ... etc) on face-to-face visit and then reinforcement each 15 days over the weak points of this visit.
62851055|NCT03956537||Pedicle screw system alone|
62851056|NCT03956537||Pedicle screw system with cages|
62851057|NCT00388583|EXPERIMENTAL|Fluzone Intradermal (ID) Vaccine Group|Participants received a dose of Fluzone Intradermal (ID) Influenza Vaccine
62851058|NCT00388583|ACTIVE_COMPARATOR|Fluzone Intramuscular (IM) Vaccine Group|Participants received a dose of Fluzone Intramuscular (IM) Influenza Vaccine.
62851059|NCT04028544|EXPERIMENTAL|The Treatment Group|standard treatment + Qishenyiqi dropping pills (QSYQ) (oral use, 1 bag each time, three times a day)
62851060|NCT04028544|PLACEBO_COMPARATOR|The Control Group|standard treatment + placebo (oral use, 1 bag each time, three times a day).
62062436|NCT00939731|EXPERIMENTAL|IRT|
62062437|NCT05968040|ACTIVE_COMPARATOR|responder|
62062438|NCT05968040|ACTIVE_COMPARATOR|non responder|
62062439|NCT02162303|EXPERIMENTAL|Colchicine|Colchicine 0.6 mg tablets,once daily, for 6 months
62851061|NCT02989454||Tako Tsubo Cardiomyopathy patients|Any patient who has suffered from Tako Tsubo Cardiomyopathy since 2011.
62851062|NCT01658306|EXPERIMENTAL|remote ischemic preconditioning|Receiving remote ischemic preconditioning (RIPC) treatment with pressure set at 200 mmHg.
62062440|NCT02162303|PLACEBO_COMPARATOR|Placebo|Sugar,given once daily, over 6 months.To mimic active treatment.
62266849|NCT02970292|EXPERIMENTAL|Pimavanserin|Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth
62266850|NCT02970292|PLACEBO_COMPARATOR|Placebo|Placebo + background antipsychotic, taken as two tablets, once daily by mouth
62266851|NCT01348997|ACTIVE_COMPARATOR|Project Onward website + 16 person social network|
62851063|NCT01658306|SHAM_COMPARATOR|placebo remote ischemic preconditioning|Receiving sham RIPC treatment with pressure set at 50 mmHg
62851064|NCT02133703|EXPERIMENTAL|Mutation Carrier: Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool.
62266852|NCT01348997|ACTIVE_COMPARATOR|Project Onward website + 8 person social network|
62450228|NCT04932356|OTHER|Traditional Therapeutic Education|Therapeutic education in diabetes mellitus (pharmacological, nutritional, physical exercise, social adherence ... etc) on face-to-face visit.
62450229|NCT02512354||Fetus|
62450230|NCT04581005|EXPERIMENTAL|Supervised Prehabilitation|"Prehabilitation will include exercise, nutrition, and anxiety-coping intervention.~This group will receive a supervised, in-hospital training."
62851065|NCT02133703|EXPERIMENTAL|Mutation Carrier: Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support intervention without a preference clarification tool.
62851066|NCT02133703|ACTIVE_COMPARATOR|Mutation Carrier: Enhanced Print DA|BRCA1/2 carriers randomized to this arm will be sent a print-based decision aid with a print preference clarification tool.
62851067|NCT02133703|ACTIVE_COMPARATOR|Mutation Carrier: Print DA|BRCA1/2 carriers randomized to this arm will receive a print decision aid without a preference clarification tool.
62851068|NCT02133703|EXPERIMENTAL|Inconclusive Results: DA|Participants who receive inconclusive results who are randomized to this arm will have access to an Internet decision tool designed to facilitate management decision making
62062441|NCT05497427||Normative|BrainCheck assessment values from participants that have indications of healthy cognition at the time of testing ( a SLUMS result considered 'normal', more than 4 hours of sleep the night before, not having consumed alcohol or drugs within the last 6 hours, or not have participated in high capacity and strenuous physical activity within the last hour.)
62450231|NCT04581005|EXPERIMENTAL|Home-based Prehabilitation|"Prehabilitation will include exercise, nutrition, and anxiety-coping intervention.~This group will receive a home-based training."
62851069|NCT02133703|NO_INTERVENTION|Inconclusive Results: Usual care|Participants who receive inconclusive/uninformative results who are randomized to this arm will receive usual care but no additional decision support intervention
62851070|NCT03506230|EXPERIMENTAL|Incentives group|a bonus to buy their medications if they improve their HbA1c
62851071|NCT03506230|NO_INTERVENTION|Standard group|Will buy their medications as usual
62450232|NCT04965571||WD-seizures|Chinese WD patients with generalized epilepsy
62450233|NCT06328283||cases group|cirrhotic patients with early hepatocellular carcinoma
62450234|NCT06328283||control group|cirrhotic patients with no hepatocellular carcinoma
62450235|NCT01082783||patients with acute media infarct|
62450236|NCT01082783||controls with cardiovascular risks|
62450237|NCT03615937|EXPERIMENTAL|Comprehensive Intervention|"This is a holistic package of interventions, including:~1. Child interactive intervention (dialogic reading and play intervention)~2. Family Empowerment (positive parenting and grandparenting)~3. Access to Community Hub and its services~4. Enhancement to the kindergartens~5. Health education, screening, and support"
62450238|NCT03615937|ACTIVE_COMPARATOR|Health Support|"This is a control arm with only health components.~1. Health education, screening, and support"
62450239|NCT00535522|EXPERIMENTAL|TAK-285|
62450240|NCT01296932|EXPERIMENTAL|Patients with relapsed CLL|Patients with relapsed CLL after at least two prior treatment regimens will receive BI 836826.
62450241|NCT02159105||Women undergoing cesarean delivery|"FAST scan and non-invasive hemoglobin measurement~Women undergoing cesarean delivery will undergo a non-invasive hemoglobin measurement both before and after surgery. An abdominal ultrasound will be performed to establish normal levels of intra-abdominal fluid after cesarean delivery."
62450242|NCT03218592|EXPERIMENTAL|Maraviroc|12 Healthy subjects will dose with Maraviroc Pill and we will collect blood and hair over all three phases
62625358|NCT02506062|PLACEBO_COMPARATOR|Placebo Arm - 60 mmHg|Patients who start in the placebo arm will receive placebo treatment, consisting of applying the blood pressure cuff to a pressure of 60 mmHg for 2 minutes and thirty seconds with a resting period of two minutes and thirty seconds between treatments. This procedure is performed four times, for a total of twenty minutes per treatment. This treatment will be done three times a week for two weeks followed by a two week wash-out and then two weeks in the active treatment phase, thus completing their participation in the study.
62851072|NCT04325841|EXPERIMENTAL|Autologous Murine Anti-CD19 CAR-T treatment|
62851073|NCT02535390|EXPERIMENTAL|Action based cognitive remediation|Participants in this condition will engage in simulated real world tasks in addition to standard cognitive remediation and group therapy sessions.
62851074|NCT02535390|ACTIVE_COMPARATOR|Standard cognitive remediation|Participants in this condition will engage in computerized cognitive training exercises in addition to standard cognitive remediation and group therapy sessions.
62851075|NCT06349759|ACTIVE_COMPARATOR|0.75% phentolamine ophthalmic solution|Daily dosing
62851076|NCT06349759|PLACEBO_COMPARATOR|phentolamine ophthalmic solution vehicle|Daily dosing
62851077|NCT04175847|EXPERIMENTAL|RC88|
62851078|NCT01573234|EXPERIMENTAL|MySkin patch|Hydrogel and polyurethane film
62851079|NCT01573234|ACTIVE_COMPARATOR|Traditional Dressing|
62062442|NCT05497427||Test-Retest|Comparing BrainCheck assessment values between an initial visit test and a follow-up visit test 7-14 days later within subjects.
62062443|NCT05497427||Per Protocol|BrainCheck assessment values from participants that completed all procedures with no protocol deviations
62087957|NCT01339325|ACTIVE_COMPARATOR|LESS cholecystectomy|Laparo-endoscopic single site cholecystectomy, the entire surface of the patient's abdomen is covered by plaster at the end of the operation. Patient does not know which kind of procedure he underwent before discharge.
62450243|NCT03218592|EXPERIMENTAL|Dolutegravir|12 Healthy volunteers will dose with Dolutegravir Pill and we will collect blood and hair over all three phases
62450244|NCT03218592|EXPERIMENTAL|Truvada|12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases
62450245|NCT02943525|EXPERIMENTAL|packing|Patients after laparoscopic sacrocolpopexy with a vaginal packing at the end of surgery
62450246|NCT02943525|NO_INTERVENTION|no packing|Patients after laparoscopic sacrocolpopexy without a vaginal packing at the end of surgery
62450247|NCT01775033|EXPERIMENTAL|Multicomponent intervention|Hospitals in the experimental arm will receive a four-component intervention that integrates local education, community outreach, telemedicine and protocolized triage and transport
62450248|NCT01775033|NO_INTERVENTION|Control|Hospitals in the control arm will receive usual care.
62450249|NCT02472392|ACTIVE_COMPARATOR|Treatment Plan A|Rabbit anti-thymocyte globulin (ATG) will be given only to unrelated donor transplant recipients at a dose of 3 mg/kg/day I.V. Equine ATG at a dose of 30mg/kg/day may be substituted in the event of severe allergic reaction to the rabbit ATG. Rabbit ATG is only used with recipients of unrelated donor marrow or peripheral blood transplants. Busulfan (BU) will be given at a dose of 0.8 mg/kg IV q 6 hrs. BU doses will be modified based upon pharmacokinetics data to maintain steady state levels of 600-900 ng/dl. Seizure prophylaxis with levetiracetam should begin prior to the 1st dose of BU and stoped 24 hrs after the last dose of BU. Melphalan will be given at a dose of 60 mg/m2 I.V. over 15-20 min per Pediatric SCT Standards of Practice Manual.
62625359|NCT03972501|PLACEBO_COMPARATOR|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to once daily.
62062444|NCT03513601|EXPERIMENTAL|(R)-CHOP regimen|(R)-CHOP regimen((rituximab)，cyclophosphamide，epirubicin，vincristine and prednisone)，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
62062445|NCT03513601|EXPERIMENTAL|(R)-CVP regimen|(R)-CVP regimen((rituximab)，cyclophosphamide，vincristine and prednisone) The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .
62450250|NCT02472392|ACTIVE_COMPARATOR|Treatment Plan B|Rabbit anti-thymocyte globulin (ATG) will be given only to unrelated donor transplant recipients at a dose of 3 mg/kg/day I.V. Equine ATG at a dose of 30mg/kg/day may be substituted in the event of severe allergic reaction to the rabbit ATG. Rabbit ATG is only used with recipients of unrelated donor marrow or peripheral blood transplants. Fludarabine will be given at a dose of 30 mg/m2/day IV over 30 mins for 5 doses. Cyclophosphamide will be given at a dose of 50 mg/kg/day IV over 2 hrs for 4 doses.
62062446|NCT00955786|EXPERIMENTAL|CX-3543|
62450251|NCT02117583|EXPERIMENTAL|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62062447|NCT00094328|OTHER|Bicalutamide with Anastrozole|Bicalutamide in combination with Anastrozole
62062448|NCT04028310|EXPERIMENTAL|Phonological group|
62062449|NCT04028310|EXPERIMENTAL|visual-attention group|
62062450|NCT04524143|OTHER|control group|There was no intervention in the control group during the study (At the end of study all patients were received home-based exercise)
62450252|NCT02117583|EXPERIMENTAL|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62450253|NCT02117583|EXPERIMENTAL|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62450254|NCT02117583|EXPERIMENTAL|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62625360|NCT03972501|EXPERIMENTAL|AZR-MD-001 Active Dose|AZR-MD-001 Active Dose will be dosed up to once daily.
62625361|NCT04192890|EXPERIMENTAL|IRE patients|patients who will underwent 'Focal irreversible electroporation of the prostate cancer'
62625362|NCT06235320||Paracetamol group|
62625363|NCT06235320||Ibuprofen group|
62625364|NCT03845621|ACTIVE_COMPARATOR|CM-OA-OA-CM Sequence|Use of a conventional custom-made mouthguard (CM) while playing water polo for first and fourth weeks and the occlusal-adjusted custom-made mouthguard (OA) for the second and third weeks.
62625365|NCT03845621|ACTIVE_COMPARATOR|OA-CM-CM-OA Sequence|Use of an occlusal-adjusted custom-made mouthguard (OA) for the first and fourth weeks and a conventional custom-made mouthguard (CM) while playing water polo for the second and third weeks.
62625366|NCT01450514|PLACEBO_COMPARATOR|Placebo|Sugar pill
62851080|NCT04600271||Study Group|Patients over the age of 18 and who undergone major elective non-cardiac abdominal surgery.
62851081|NCT02654717|EXPERIMENTAL|DFD-07 cream|DFD-07 cream applied twice daily
62851082|NCT02654717|PLACEBO_COMPARATOR|Placebo cream|Placebo cream applied twice daily
62851083|NCT00924859||1|Patients with clinical suspicion of CVT
62851084|NCT04038216||Test|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery.
62625367|NCT01450514|EXPERIMENTAL|Pipamperone|15 mg once daily
62625368|NCT02311608||High Dose Somatostatin/Octreotide|continuous IV infusion of 500μg/h of Somatostatin or continuous IV infusion of 50μg/h of Octreotide when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
62625369|NCT02311608||Terlipressin as salvage|an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
62851085|NCT04038216||Control|Historical control group, these patients already underwent BAHI insertion using two-stage surgery. The implant and abutment were inserted in two different procedures.
62851086|NCT02874144|EXPERIMENTAL|AZ Compound|40 mg 12 weeks TID po
62851087|NCT02874144|PLACEBO_COMPARATOR|Placebo|40 mg 12 weeks TID po
62062451|NCT04524143|EXPERIMENTAL|mobilization group|Cervical mobilization was applied to the mobilization group. Cervical mobilization techniques were applied for 10 minutes in the supine position. (At the end of study all patients were received home- based exercise)
62266853|NCT03747250|EXPERIMENTAL|Videolaryngoscopy|Pediatric patients undergoing elective surgery with planned tracheal intubation for airway management. The tracheal intubation will be performed with the use of videolaryngoscope
62266854|NCT03747250|ACTIVE_COMPARATOR|Direct laryngoscopy|Pediatric patients undergoing elective surgery with planned tracheal intubation for airway management. The tracheal intubation will be performed with the use of direct laryngoscopy
62625370|NCT02311608||Terlipr+usual dose somato/Octreo|an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h together with continuous IV infusion of 250μg/h of Somatostatin or continuous IV infusion of 25μg/h of Octreotide when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
62625371|NCT02311608||Control:Usual Dose Somato/Octreo|Hemostasis achieved by continuous IV infusion of 250μg/h of Somatostatin or continuous IV infusion of 25μg/h of Octreotide
62625372|NCT02311608||Control: Initial Terlipressin|Hemostasis achieved by an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h
62851088|NCT03079960|EXPERIMENTAL|Original patient group (PG-O)|"DBS implantation: patients undergo standard stereotactical neurosurgery for DBS implantation. Decision for DBS treatment has been made prior to inclusion into this study.~Cables and connectors of the macro electrodes will stay externalized for four days for cDBS adjustment procedures. During externalization, patients take part in test stimulation and recording sessions during which they perform short motor tasks.~The externalized connectors of the macroelectrodes allow for simultaneous stimulation of the STN and obtaining LFP recordings with electrophysiological recording and measurement devices from the STN for the fitting of DBS parameters, according to the standard clinical procedure."
62851089|NCT03079960|NO_INTERVENTION|Chronic patient group (PG-chronic)|"Patients in this group will take part in one recording session at any desired point in time after they have been implanted with a DBS system as part of their clinical routine treatment. During this session, which will be lasting for approx. 60 minutes, patients will execute different motor tasks while neural activity is recorded non-invasively from cortical areas via surface EEG electrodes.~Recordings are performed while applying different DBS strategies. The different DBS strategies are selected as a set of safe configurations as they are used in clinical routine. The behavioral tests performed for PG-chronic are the same as conducted for PG-O."
62851090|NCT03079960|NO_INTERVENTION|Preoperative patient group (PG-pre)|"Patients in this group will take part in one recording session that will take place one week prior to implantation surgery at the earliest, i.e. between day -7 and day 0. Decision for DBS treatment has been made prior to inclusion into this study.~During this recording session, which will be lasting for approx. 60 minutes, patients will execute different motor tasks while neural activity is recorded non-invasively from cortical areas via surface EEG electrodes.~The behavioral tests performed for PG-pre are the same as conducted for PG-O."
62851091|NCT04650867||Patients with Crohn's disease|Patients diagnosed or with suspected Crohn's disease.
62851092|NCT04650867||Patients with Ulcerative colitis|Patients diagnosed or with suspected Ulcerative colitis
62851093|NCT04650867||Patients with unclassified inflammatory bowel disease (U-IBD)|Patients diagnosed or with suspected unclassified inflammatory bowel disease (U-IBD)
62851094|NCT02238184||Chronic Obstructive Pulmonary Disease|patients receiving Atrovent®
62851095|NCT02238184||Cronic Obstructive Pulmonary Disease|patients receiving Ventilat®
62851096|NCT00611403|ACTIVE_COMPARATOR|RESTASIS®|Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)
62851097|NCT00611403|ACTIVE_COMPARATOR|REFRESH ENDURA®|Artificial Tears (REFRESH ENDURA®)
62851098|NCT06118788|EXPERIMENTAL|BG1805|"Dose escalation: Three dose levels were designed, and if the maximum tolerated dose (MTD) was not found at the highest level, no further dose escalation was to be performed. Approximately 12-18 subjects were planned to be enrolled in the dose-escalation phase to evaluate the safety and tolerability of BG1805 injection and to determine the MTD and/or the recommended phase II dose (RP2D).~Dose Expansion: During or after the dose escalation process, if a certain dose group is determined to have preliminary anti-tumor effects and controllable safety, it can be extended at this dose level to further evaluate the tolerance and safety of BG1805 injection, and to preliminarily evaluate its effectiveness."
62851099|NCT05243693|EXPERIMENTAL|Brentuximab vedotin and DHAP|A clinical study of safety and efficacy of treatment with Brentuximab vedotin and DHAP in patients with relapsed/refractory Hodgkin lymphoma
62851100|NCT01250145|EXPERIMENTAL|LY333334 + placebo|"Part A:~Both a placebo and an 80 microgram active patch will be applied to the same arm for at least 6 hours daily, test arms will be alternated daily, for 22 days~Part B:~Induction phase: Both a placebo and an 80 microgram active patch will be applied to the same arm for at least 6 hours daily, test arms will be alternated daily, 4 times a week for 3 weeks~Rest phase: 2 weeks with no patch application~Challenge phase: 80 microgram active patch given once for at least 6 hours"
62625373|NCT00048633|EXPERIMENTAL|Tariquidar|
62062452|NCT05290246|EXPERIMENTAL|Time restricted eating|daily 8 hour eating window
62625374|NCT05006456||Cohort 1|Cohort 1 consists of 2000 subjects undergoing catheter ablation with STSF catheter, in which AI is used to guide the ablation lesion creation.
62625375|NCT05006456||Cohort 2|Cohort 2 consists of 2000 subjects who undergoing catheter ablation using QDOT or HELIOSTAR catheter.
62625376|NCT01472133||Young Healthy Volunteers|Healthy volunteers under the age of 40
62062453|NCT05290246|ACTIVE_COMPARATOR|Caloric Restriction|reduction of caloric intake by 15%
62087958|NCT01339325|ACTIVE_COMPARATOR|Standard LAP-CHOLE|Standard laparoscopic cholecystectomy. The entire surface of the patient's abdomen is covered by plaster at the end of the operation. Patient does not know which kind of procedure he underwent before discharge.
62266855|NCT00622648|EXPERIMENTAL|A|Enoxaparin: 40 mg once daily for 6 to 14 days (10 ± 4 days)
62625377|NCT01472133||Older healthy volunteers|Healthy volunteers over the age of 70
62625378|NCT01472133||Patients with atrial fibrillation|Patients with permanent AF
62625379|NCT01472133||Patients with a pacemaker|Patients who have an implanted pacemaker that is continually pacing
62625380|NCT01472133||Patients with restricted chest movement|Patients whose chest expansion is less than 2.5cm
62625381|NCT05772117|EXPERIMENTAL|Intervention|Participants receive Chatbot-delivered interventions tailored to their stage of change regarding PV uptake in a conversational way at Month 0, 1, 2, and 3.
62625382|NCT05772117|ACTIVE_COMPARATOR|Control|Participants receive Chatbot-delivered general information related to PV at Month 0, 1, 2, and 3.
62625383|NCT05019573|EXPERIMENTAL|Black tea group|Volunteers meeting inclusion/exclusion criteria will be given an appropriate number of black tea samples twice a day with main meals for the 4 weeks of the treatment.
62062454|NCT06248840|EXPERIMENTAL|The observation group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on health condition. The observation group receives IOE for enteral nutrition support
62625384|NCT05019573|PLACEBO_COMPARATOR|Placebo group|Volunteers meeting inclusion/exclusion criteria will be given an appropriate number of placebo tea samples twice a day with main meals for the 4 weeks of the treatment.
62625385|NCT04536116|EXPERIMENTAL|MRI simulation|MRI simulation with a Virtual Reality headset
62625386|NCT04536116|NO_INTERVENTION|Standard medical care|Standard medical care
62625387|NCT05895643|EXPERIMENTAL|semaglutide|Wegovy once-weekly s.c.titrated to a maximum dose of 2.4 mg
62625388|NCT05895643|PLACEBO_COMPARATOR|placebo|Saline s.c. once-weekly
62625389|NCT03633253||MCR syndroms|
62625390|NCT03633253||Non MCR syndroms|
62625391|NCT05435352||Early TNBC patient Cohort A|"Early TNBC patients receiving neoadjuvant therapy and providing core needle biopsy.~Any approved neoadjuvant therapy can be used based on physician's choice."
62062455|NCT06248840|ACTIVE_COMPARATOR|The control group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on health condition.The control group receives NGT for enteral nutrition support
62062456|NCT06082921|EXPERIMENTAL|Beef Diet|Participants will eat 3 chef prepared meals a day that contain beef as main protein source. Snacks and desserts will be provided. All aspects of the meals, except for meat type (beef/impossible beef) will be the same during each arm. The base diet will be comprised of whole foods. Meals will meet acceptable macronutrient distribution ranges of the USDA.
62062457|NCT06082921|EXPERIMENTAL|Impossible Beef Diet|Participants will eat 3 chef prepared meals a day that contain impossible beef as main protein source. Snacks and desserts will be provided. All aspects of the meals, except for meat type (beef/impossible beef) will be the same during each arm. The base diet will be comprised of whole foods. Meals will meet acceptable macronutrient distribution ranges of the USDA.
62625392|NCT05435352||Early TNBC patient Cohort B|"Early TNBC patients receiving neoadjuvant therapy and providing core needle biopsy and blood.~Any approved neoadjuvant therapy can be used based on physician's choice."
62625393|NCT00700024|ACTIVE_COMPARATOR|1|testim
62625394|NCT00700024|EXPERIMENTAL|2|placebo
62062458|NCT05842213|EXPERIMENTAL|AVT05|"AVT05 is the proposed biosimilar to Simponi. Subjects in this arm will receive AVT05 50mg s.c. every 4 weeks until week 48.~Intervention: Biological: Golimumab"
62062459|NCT05842213|ACTIVE_COMPARATOR|Simponi|"Subjects in this arm will receive EU Simponi 50mg s.c. every 4 weeks until week 12. At week 16 responders will be re-randomized in a 1:1 ratio to receive either:~AVT05 50mg s.c. every 4 weeks until week 48 Simponi 50mg s.c. every 4 weeks until week 48 Intervention: Biological: Golimumab"
62062460|NCT03381001|ACTIVE_COMPARATOR|embryo transfer after embryo thaw|Embryos will be transferred at the same day of the thawing procedure
62062461|NCT03381001|EXPERIMENTAL|embryo transfer after thaw and culture|Embryos will be transferred one day after thawing procedure
62450255|NCT03170648|EXPERIMENTAL|Acupuncture|Patients will receive a 30-minute session of a standardized ear acupuncture treatment Acupuncture needles will be gently manipulated to increase stimulation For each ear acupuncture session, the patient will have ear acupuncture therapy administered to each ear
62450256|NCT03708913|EXPERIMENTAL|Open-Label Lateral Hypothalamic DBS Stimulation|Open-label lateral hypothalamic DBS stimulation for 1 year.
62450257|NCT00907309|NO_INTERVENTION|Treatment as usual|Participants will receive treatment as usual from their provider.
62625395|NCT00700024|EXPERIMENTAL|3|training
62625396|NCT00524771||1|Users of NuvaRing
62625397|NCT00524771||2|Users of combined oral contraceptives
62625398|NCT03222453|EXPERIMENTAL|Intervention Patient|Hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells.
62625399|NCT03222453|NO_INTERVENTION|non-intervention Patient|No treatment
62625400|NCT02477436|EXPERIMENTAL|Avanafil 50mg group|Avanafil 50mg tablet + Placebo 100mg tablet
62625401|NCT02477436|EXPERIMENTAL|Avanafil 100mg group|Avanafil 100mg tablet + Placebo 100mg tablet
62625402|NCT02477436|EXPERIMENTAL|Avanafil 200mg group|Avanafil 100mg 2 tablets
62625403|NCT02477436|PLACEBO_COMPARATOR|Placebo group|Placebo 100mg 2tablets
62625404|NCT02498977|ACTIVE_COMPARATOR|Arm A (weaning)|All participants satisfying clinical criteria will be weaned off immunosuppression drugs irrespective of biomarker result.
62625405|NCT02498977|ACTIVE_COMPARATOR|Arm B+ (weaning- positive biomarker)|Participants with a positive biomarker will be weaned of immunosuppression drugs.
62625406|NCT02498977|ACTIVE_COMPARATOR|Arm B- (maintenance)|Participant with negative biomarker test result will be informed of the result and will remain on baseline maintenance immunosuppression drugs.
62625407|NCT01070433|EXPERIMENTAL|MEBO Wound Ointment (MEBO)|Topical application twice a day
62625408|NCT01070433|ACTIVE_COMPARATOR|Standard of Care|Topical application twice a day
62625409|NCT00790504||1 study group|Women with multiple gestations recruited from the prenatal care or high risk pregnancy units
62062462|NCT04573543||Patients with Non-alcoholic fatty liver disease|120 patients diagnosed with NAFLD
62625410|NCT00790504||2 control group|Women with singleton gestation recruited from the prenatal care or high risk pregnancy units
62625411|NCT01551017||c-treatment|test group
62625412|NCT01551017||standard cooling|comparison group
62625413|NCT04324528|EXPERIMENTAL|vv-ECMO + cytokine adsorption|after indication of treatment with vv-ECMO in acute respiratory failure in COVID-19-disease, patients will additionally receive cytokine adsorption using a Cytosorb adsorber
62062463|NCT04573543||Controls|40 healthy controls
62062464|NCT06344234||Cohort (n=60)|"All hypoxemic patients with a PaO2/FiO2 ratio equal or lower than 300, receiving post-extubation noninvasive ventilation.~Participants will undergo the following tasks and treatments:~* Complete written informed consent before enrollment.~* Post-extubation noninvasive ventilation via nose-to-mouth and full-face masks.~* Monitoring of esophageal pressure~* Continuous recording of airway pressure, flow, and esophageal pressure (Pes), using a dedicated pneumotachograph and pressure transducer.~* Sudden end-inspiratory and end-expiratory occlusion maneuvers.~* Collection of hemodynamic and arterial blood-gas parameters, performed according to clinical judgment, along with assessments of dyspnea and discomfort using a modified visual analogue scale (VAS).~* Diaphragm ultrasound during occlusion maneuvers, measuring diaphragm displacement, diaphragm thickening fraction (DTF%), and diaphragmatic excursion (Ex) under various conditions."
62625414|NCT04324528|OTHER|control-arm: vv-ECMO (no cytokine adsorption)|treatment with vv-ECMO in acute respiratory failure in COVID-19-disease (standard treatment without additional cytokine adsorption)
62062465|NCT05190302||Phase I - Patients undergoing regional anesthesia with a block allowing a neurostimulation.|The investigators propose to conduct a single-blind, prospective observational study on all eligible patients undergoing regional anesthesia with a peripheral nerve block allowing a neurostimulation.
62062466|NCT05915390|ACTIVE_COMPARATOR|walnut group|walnut group will receive 15% of their total energy as walnuts
62062467|NCT05915390|ACTIVE_COMPARATOR|control group|continue with habitual diet and abstain from eating walnuts
62851101|NCT06193551|OTHER|Patients undergoing a paraesophageal or large (>5 cm) hiatal hernia repair|This is a single arm, open label, nonrandomized study evaluating 100 subjects diagnosed with a paraesophageal or large hiatal hernia planning to undergo surgical repair with the study investigators.
62851102|NCT06356480|EXPERIMENTAL|1% acetic acid dressing in chronic diabetic wounds|1% Acetic acid dressing in chronic diabetic wounds twice daily along with oral antibiotics to see the early epithelialization of the wounds
62851103|NCT06356480|NO_INTERVENTION|Normal saline soaked dressing in chronic diabetic wounds|Normal Saline soaked dressing in chronic diabetic wounds along with antibiotics to see early epithelialization over diabetic wounds
62851104|NCT05857475|EXPERIMENTAL|CPAP therapy|CPAP therapy will be used in this arm for 2 month.
62851105|NCT05857475|OTHER|Control|CPAP therapy will not be used in this arm for 2 month. (subject were assign to normal waiting list in order to borrowing hospital PAP machine.)
62062468|NCT00861614|ACTIVE_COMPARATOR|Ipilimumab|
62062469|NCT00861614|PLACEBO_COMPARATOR|Placebo|
62062470|NCT00415584|EXPERIMENTAL|Cinacalcet HCl|
62266856|NCT00622648|PLACEBO_COMPARATOR|B|Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
62450258|NCT00907309|EXPERIMENTAL|iMET|Participants will receive the iMET intervention.
62450259|NCT00907309|EXPERIMENTAL|iMET/TE|Participants will receive the iMET intervention and Technological Extenders (TEs).
62625415|NCT06500429|EXPERIMENTAL|NG101 20 mg BID|NG101 (metopimazine mesylate) 20 mg capsule BID + single SC dose of 0.5 or 1 mg semaglutide
62625416|NCT06500429|PLACEBO_COMPARATOR|Placebo|Placebo capsule BID + single SC dose of 0.5 or 1 mg semaglutide
62625417|NCT00778791|EXPERIMENTAL|1|metformin HC1 750 mg extended-release tablets
62625418|NCT00778791|EXPERIMENTAL|2|Glucophage® XR 750 mg tablets
62625419|NCT00622492||VV-ECMO|newborn infants with reversible causes of PPHN eligible for ECMO treatment
62625420|NCT00622492||VA-ECMO|newborn infants with reversible causes of PPHN eligible for ECMO treatment
62625421|NCT03529214|OTHER|Implemented Health Facility|"Health facility that has piloted the Team Birth Project"
62625422|NCT04435899|EXPERIMENTAL|EFFECTS OF A CHAIR-YOGA EXERCISES ON STRESS HORMONE LEVELS.|assess the changes mediated by exercise on activities of daily life and falls (autonomy), physical fitness, salivary cortisol and alpha amylase in older adults living in social care givers centers. Methods: 35 women (83.81 ± 6.6 years old) were divided into two groups: chair-yoga exercises (CY, n=20) and control group (CG, n=15). All subjects were evaluated before and after 14-weeks of intervention. CY was involved in classes two times per week, while the GC did not participate in any exercise.
62851106|NCT01852396|EXPERIMENTAL|Regional anesthesia|Recruit 50 patient having elbow, forearm, wrist or hand surgery and block brachial plexus using the novel retroclavicular approach
62851107|NCT05068882|EXPERIMENTAL|Immunonutrition|Oral immunonutrition containing arginine, omega-PUFAs and antioxidants
62851108|NCT05068882|ACTIVE_COMPARATOR|High-protein diet|Oral nutrition with high-protein content
62851109|NCT05068882|ACTIVE_COMPARATOR|Standard nutrition|Oral nutrition with standard ingredients
62062471|NCT03350126|EXPERIMENTAL|Experimental arm|Therapy induction (12 weeks) Nivolumab (IV) and Ipilimumab (IV) - every 21 days - 4 cycles Then Nivolumab (IV) alone every 15 days - 20 cycles - until 12 months
62625423|NCT04435899|EXPERIMENTAL|Physical fralty and health outcomes of fitness, sex hormones.|The study aimed to investigate the association of frailty with diverse geriatric health characteristics and how the latter might contribute to the former. Cross-sectional data of 140 women aged over 75 years were analyzed. Fried's definition of physical frailty, psychological, sex hormones, disability and physical fitness outcomes were examined. Prevalence of frailty was 40%. Frail women had lower scores in cognitive and physical fitness, and high scores for depression and comorbidities. Significant correlations emerged between frailty and disability, fear of falling, aerobic resistance and cognition showed that only aerobic resistance and cognition. A trend towards lower systolic blood pressure in the frail group may reflect being less physically active and/or having more systemic comorbidity. Using simple functional fitness and cognitive measures rather than using less reliable self-report assessments can better identify those with physical frailty.
62625424|NCT04435899|EXPERIMENTAL|physical fitness and frailty syndrome institutionalized older|"This study analyzed the relationship between old physical frailty syndrome (PF) and PhFi indicators and assessed how the latter might predict the former. Participants were 119 elderly women (81.96 ±7.89 years) recruited from four social and healthcare centers. PhFi was assessed through muscle strength tests of upper and lower limbs, endurance, agility-dynamic balance, flexibility and body composition.~The following PF indicators were assessed: weight loss, exhaustion, weakness, slowness and low physical activity level."
62266857|NCT03787498|EXPERIMENTAL|PLX2853|Approximately 30 subjects will be enrolled as part of dose escalation to identify the MTD/RP2D of PLX2853. Up to 6 additional subjects may be enrolled at the MTD/RP2D to further characterize the PK and PDy of PLX2853.
62625425|NCT04435899|EXPERIMENTAL|THE RELATIONSHIP BETWEEN FUNCTIONAL DISABILITY OUTCOMES|The associations between functional disability activities of life activities and frailty have already been explored. The contribution of each component of physical frailty and their contribution to understanding the early physical decline of older individuals are poorly explored. The relationships between PF and functional disability and to identify the independent components of frailty that most influence on disability in older women. A cross-sectional study of 119 (81,96±7,89) older women aged 75 and over. Functional disability was assessed through Agility-dynamic and Static balance tests, Activities of daily life and Falls risk screen outcomes.
62625426|NCT06087497|EXPERIMENTAL|1 hour bedrest|One hour of bedrest, elevate head of bed to 30 degrees at 30 minutes, ambulate at 60 minutes, Z stitches out at 4 hours, eligible for discharge (if appropriate) at 4.5 hours.
62625427|NCT06087497|NO_INTERVENTION|4 hour bedrest|Four hours of bedrest, elevate head of bed to 30 degrees at 2 hours, Z stitches out at 4 hours, ambulate at 4 hours, eligible for discharge at 4.5 hours.
62625428|NCT03327857|EXPERIMENTAL|Neihulizumab (ALTB-168)|Intravenous doses of Neihulizumab (ALTB-168)
62625429|NCT06228235|EXPERIMENTAL|Active rTMS|There is a single arm in this open-label pilot study. All participants will receive active rTMS paired with different types of behavioral priming (upregulation of craving, downregulation of craving, no regulation of craving).
62625430|NCT04333212|OTHER|study arm|We projected a total of 1,100 study cases, which encompassed 100 cases of women with no intraepithelial lesion or malignancy (NILM) cytology, 300 cases of ASCUS, 300 cases of low grade squamous intraepithelial lesion (LSIL) and 400 cases high grade squamous intraepithelial lesion (HSIL) in cervical cytology.
62625431|NCT04702451|EXPERIMENTAL|Tailored|Tailored ablation strategy
62625432|NCT04702451|ACTIVE_COMPARATOR|Anatomical|Anatomical ablation strategy
62625433|NCT04039659|NO_INTERVENTION|Control Group|Patients will be cured with dressings wound everyday or before if there are complications in surgical incisions.
62625434|NCT04039659|ACTIVE_COMPARATOR|PICO group|Patients will carry the device for 7 days uninterrupted until its withdrawal.
62625435|NCT04272047|EXPERIMENTAL|Knee Control+|Knee Control+ consists of 6 different exercises, with 10 different variations/progressions, and takes 10-15 minutes to complete. In addition, teams are instructed to perform a 5-minute running warm-up before the Knee Control+ exercises. Teams are to carry out the running warm-up and Knee Control+ at all training sessions, and the running warm-up before all matches, during the whole season. Knee Control+ is based on the Knee Control program but with more variations for each exercise making it easier to tailor for the needs in the respective teams.
62625436|NCT04272047|EXPERIMENTAL|Adductor strengthening program|The Adductor strengthening program consists of a single exercise with three levels of difficulty. The exercise is based on the Copenhagen Adduction exercise. Teams are to carry out the Adductor strengthening program as part of their regular warm-up 2-3 times per week, one set per side, during the pre-season, and 1 time per week, one set per side during the in-season.
62851110|NCT05068882|NO_INTERVENTION|No intervention|No intervention
62851111|NCT02129504|EXPERIMENTAL|coronal advanced technique|root coverage with the porcine collagen matrix using the coronal advanced technique (standard technique)
62851112|NCT02129504|EXPERIMENTAL|extended flap technique|root coverage with the porcine collagen matrix using the extended flap technique (new surgical technique)
62851113|NCT04291170|EXPERIMENTAL|QDASH|Completing the tasks on the QuickDASH
62851114|NCT04291170|ACTIVE_COMPARATOR|KOOSJR|Completing the tasks on the KOOSJR
62062472|NCT06103084|EXPERIMENTAL|Bahgina group|The Bahgina treatment group will be supplemented with Bahgina, a locally produced cereal based product for a maximum of six months at 200g/day.
62062473|NCT06103084|EXPERIMENTAL|SQLNS group|The small quantity lipid based nutrient supplements (SQLNS) group will be provided with 20g of SQLNS/day for a maximum of six months.
62625437|NCT04272047|ACTIVE_COMPARATOR|Knee Control|Teams will carry on their normal training and warm-up routines using the Knee Control program with no intervention from the researchers. Knee Control consists of 6 different exercises, with 4 different variations/progressions and 1 pair-exercise.
62625438|NCT02834078|EXPERIMENTAL|BGG|Dose: 01 tablet three times daily just before all major meals (breakfast, lunch and dinner)
62625439|NCT02834078|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules \[for BGG tablet\] composed of micro crystalline cellulose and added colors and odors. Dose: 01 tablet three times daily just before all major meals (breakfast, lunch and dinner)
62625440|NCT05076877|EXPERIMENTAL|Lazertinib + Probe Substrates of Midazolam, Rosuvastatin, and Metformin|Participants will receive a single oral dose of probe substrates of midazolam, rosuvastatin, and metformin on Day 1 under fasted conditions followed by a single oral dose of lazertinib under fed conditions from Day 5 to Day 14 except Day 13 which is under fasted conditions and co-administered with probe substrates under fasted conditions on Day 13.
62625441|NCT04241822|EXPERIMENTAL|Vestibular exercises combined with cognitive therapy|The intervention is in groups of 8-10 patients. The interventions consists of cognitive therapy, vestibular exercises and body awareness therapy, 8 group sessions
62625442|NCT04241822|EXPERIMENTAL|Exergaming|The intervention is individual and consist of non-immersive virtual reality exercises to improve balance
62625443|NCT01963507|EXPERIMENTAL|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
62625444|NCT01963507|NO_INTERVENTION|Control|
62450260|NCT01429311||ADEH+|Subjects classified as Atopic Dermatitis (AD) and history of previous Eczema Herpeticum (EH) as defined by the ADRN Standard Diagnostic Criteria
62625445|NCT05301582||Group|A total of 70 consecutive adult patients, aged 18-65 years scheduled for elective laparoscopic surgery under general anesthesia will be included in the study.
62625446|NCT02876861|ACTIVE_COMPARATOR|Surgery alone|"Surgeons: the operation shall be performed by senior urologic surgeons. Try to achieve the consistency of operation quality.~Operation: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff or distal ureterectomy."
62625447|NCT02876861|EXPERIMENTAL|Neoadjuvant chemotherapy and Surgery|"Experimental: Neoadjuvant chemotherapy group~Neoadjuvant chemotherapy(Gemcitabine and Cisplatin):~Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.~Surgery:~2-3weeks after Neoadjuvant chemotherapy~Surgeons: the operation shall be performed by senior urologic surgeons. Try to achieve the consistency of operation quality.~Operation: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff or distal ureterectomy."
62625448|NCT02716584|EXPERIMENTAL|Physical exercise|Participants participate in brisk walking exercises.
62625449|NCT02716584|ACTIVE_COMPARATOR|Stretching exercise|Participants participate in non-aerobic, non-Yoga stretching exercises
62625450|NCT04531332|EXPERIMENTAL|Continuous infusion|Patients will be received linezolid 600 mg intravenous Loading dose over 30 to 60 minutes followed by 1200 mg/ day by Continuous infusion (50 mg /hr)
62625451|NCT04531332|ACTIVE_COMPARATOR|Intermittent dosing|Patients will be received Linezolid 600 mg intravenous twice daily over 30 to 60 minutes
62625452|NCT00587938||A|BNP level from protocol blood tests initiated in the ED, reported to ED physician prior to ED disposition.
62625453|NCT00587938||B|BNP level from protocol blood tests initiated in the ED, NOT reported to ED physician prior to ED disposition.
62450261|NCT01429311||ADEH-|Subjects classified as AD without a history of EH as defined by the ADRN Standard Diagnostic Criteria
62625454|NCT01027468|EXPERIMENTAL|group 1|bevacizumab intravitreal injection
62625455|NCT01999764|PLACEBO_COMPARATOR|Placebo (for QLT091001)|Placebo is supplied to mimic QLT091001 oral solution.
62625456|NCT01999764|EXPERIMENTAL|QLT091001 - first oral dose|Subjects will receive an oral dose of 10mg/m2 of QLT091001.
62625457|NCT01999764|EXPERIMENTAL|QLT091001 - second oral dose|Subjects will receive an oral dose of 40 mg/m2 of QLT091001.
62625458|NCT03116295|EXPERIMENTAL|Group 1 - 25 mg OPC|In Group 1, subjects will receive randomly in Period 1 and 2, either a single 25 mg dose of OPC \[AF\] or a single 25 mg dose of OPC \[NF\]. Treatments will be administered in the fasting state, the subjects having fasted for at least 10 hours
62625459|NCT03116295|EXPERIMENTAL|Group 2 - 50 mg OPC|In Group 2, subjects will receive randomly on Period 1 and 2, either a single 50 mg dose of OPC \[AF\], or a single 50 mg dose of OPC \[NF\]. Treatments will be administered in the fasting state, the subjects having fasted for at least 10 hours
62625460|NCT06314360||Subjects with Patellofemoral Pain|Demographic data, pain information, limb dominancy will be collected. Then, functional status will be assessed with Kujala Patellofemoral Pain Form; foot posture will be evaluated with Foot Posture Index; plantar pressure and postural balance values will be collected with the K-Invent K-Plates device.
62625461|NCT06314360||Healthy Control Subjects|Demographic data, limb dominancy will be collected. Then, functional status will be assessed with Kujala Patellofemoral Pain Form; foot posture will be evaluated with Foot Posture Index; plantar pressure and postural balance values will be collected with the K-Invent K-Plates device.
62087959|NCT01339325|ACTIVE_COMPARATOR|LESS Cholecystectomy not blind|Laparo-endoscopic single site cholecystectomy. The patient is aware of the procedure he underwent.
62450262|NCT01429311||Non-atopic Controls|"Subjects classified as Non-Atopic controls as defined by the ADRN Standard Diagnostic Criteria"
62450263|NCT02241603|EXPERIMENTAL|Weight loss|Obese Veterans will aim to lose 5-10% body weight
62450264|NCT02241603|NO_INTERVENTION|Baseline comparator|Obese Veterans similar to Aim 1 in BMI, age, gender but not insulin sensitivity will not undergo weight loss
62450265|NCT01478620|EXPERIMENTAL|Canephron® N|
62851115|NCT03567343|ACTIVE_COMPARATOR|Proprietary Spearmint Extract Blend|"Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the Proprietary Spearmint Extract Blend blend by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.~A subset of this group will undergo 2 overnight polysomnography studies"
62851116|NCT03567343|PLACEBO_COMPARATOR|Control|"Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the excipient, microcrystalline cellulose by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.~A subset of this group will undergo 2 overnight polysomnography studies"
62625462|NCT05205980|EXPERIMENTAL|Training group|This arm will receive a single-session perturbation training treatment on a treadmill under the protection of a safety harness.
62625463|NCT05205980|SHAM_COMPARATOR|Control group|This arm will not receive perturbation training but will go through harnessed walking on the same treadmill for the same time as the other group.
62625464|NCT01625442|ACTIVE_COMPARATOR|Saffron|Saffron treatment group received saffron tablets daily for 45 days
62625465|NCT01625442|ACTIVE_COMPARATOR|Barberry|Barberry group received barberry tablets daily for 45 days
62625466|NCT01625442|PLACEBO_COMPARATOR|Placebo|Placebo group received placebo tablets daily for 45 days
62625467|NCT06454123|EXPERIMENTAL|Treatment|
62625468|NCT05926141|NO_INTERVENTION|Control phase|"After the first data collection session, participants spend 12 weeks and enter a control phase where they receive no intervention. At the end of the 12 weeks, participants will attend another data collection session."
62851117|NCT01981551|EXPERIMENTAL|PF-03084014 in Desmoid Tumors/Aggressive Fibromatosis|PF-03084014 will be administered orally at 150 mg twice a day in 21-day cycles
62851118|NCT02807675|EXPERIMENTAL|CVT-301, levodopa inhalation powder (LIP)|designed to deliver l-dopa to the lung using the CVT-301 inhaler.
62851119|NCT02807675|PLACEBO_COMPARATOR|Placebo|Administered in the same way as the investigational product, except that it does not contain l-dopa.
62851120|NCT02079272|OTHER|Helical tomotherapy for breast cancer|"All women included in REBECCA cohort will be treated with helical tomotherapy for theur breast cancer.~Their cardiac follow-up will be based on echocardiography, CT coronary angiogram and blood samples"
62062474|NCT06103084|NO_INTERVENTION|Control|The control group will get nothing except the routine nutrition services and products provided by the local government sectors.
62450266|NCT02201251|EXPERIMENTAL|Topiramate|Topiramate weight based dosing for participants 2 to less than (\<) 10 years of age not to exceed 350 mg/day (milligram per day), as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
62625469|NCT05926141|EXPERIMENTAL|ACE intervention|The ACE Program is a culturally inclusive, 4-H after school club where youth meet once a week for 12 weeks after school in person. They also receive groceries to make a meal 1 day a week.
62625470|NCT02667314|EXPERIMENTAL|Jigsaw Puzzle Group|Jigsaw puzzles \& Cognitive health counseling
62625471|NCT02667314|ACTIVE_COMPARATOR|Cognitive Health Counseling Group|Cognitive health counseling only
62625472|NCT03475758|NO_INTERVENTION|chemotherapy without goserelin|these patients will receive their chemotherapy without addition of Goserelin
62851121|NCT01917253|EXPERIMENTAL|standard length catheter|Standard Device for peripheral vein cannulation
62851122|NCT01917253|EXPERIMENTAL|Long catheter|Standard Device for peripheral vein cannulation
62851123|NCT02547363|EXPERIMENTAL|LEO 43204|Treatment once daily for 3 days
62851124|NCT02547363|PLACEBO_COMPARATOR|Vehicle gel|Treatment once daily for 3 days
62851125|NCT01112306|EXPERIMENTAL|1|ACT-293987, twice daily
62851126|NCT00870376||urodynamic studies|
62450267|NCT02201251|ACTIVE_COMPARATOR|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 milligram per kilogram per day (mg/kg/day), as tolerated. The maximum recommended daily dosage is 3,000 milligram (mg).
62450268|NCT03561506|EXPERIMENTAL|Ferric carboxymaltose group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50Kg .
62450269|NCT03561506|ACTIVE_COMPARATOR|Placebo group|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight \<50 Kg.
62450270|NCT02537756|EXPERIMENTAL|1- Verbalize, Choice|Parents will use a tablet-based application (Project Voice) that directs them to verbalize their own arguments based on topics they choose
62450271|NCT02537756|EXPERIMENTAL|2- Listen, Choice|Parents will use a tablet-based application (Project Voice) that directs them to listen to peer-generated arguments based on topics they choose
62450272|NCT02537756|EXPERIMENTAL|3- Verbalize, Assigned|Parents will use a tablet-based application (Project Voice) that directs them to verbalize their own arguments based on topics assigned to them
62450273|NCT02537756|EXPERIMENTAL|4- Listen, Assigned|Parents will use a tablet-based application (Project Voice) that directs them to listen to peer-generated arguments based on topics assigned to them
62450274|NCT01961908|EXPERIMENTAL|12 mg Proellex|12 mg capsules, orally, once daily for 8 months, including off-drug interval
62450275|NCT02762097|EXPERIMENTAL|intervention|All women would undergo saline sonography with normal saline. Women with endometrial polyps who consent to the removal of polyps will be offered polypectomy
62450276|NCT02762097|PLACEBO_COMPARATOR|control|All women would undergo saline sonography with normal saline. Women with endometrial polyps who do not consent to the removal would serve as controls
62625473|NCT03475758|EXPERIMENTAL|chemotherapy with goserelin|these patients will receive their chemotherapy with addition of Goserelin
62625474|NCT02862938|EXPERIMENTAL|NT-501 ECT Implant|"On eligible participants that are randomized to this group, the NT-501 Investigational product will be implanted in the study eye, and participants will be followed for 24 months.~The investigational treatment, NT-501 ECT, provides intravitreal sustained release of soluble ciliary neurotrophic factor (CNTF) receptor after intraocular implantation."
62625475|NCT02862938|SHAM_COMPARATOR|Sham|To maintain masking, participants randomized to this group receive sham surgery and will be followed for 12 months. Following analysis of the 6 month data, if the open label extension (OLE) is not triggered, patients in the control group will continue on the original study schedule timeline trough month 24. If OLE is triggered participants will be offered the NT-501 ECT investigational product and will followed for additional 12 months.
62625476|NCT05341778|EXPERIMENTAL|Pilates exercises|The Pilates method's exercises emphasize breathing and the activation of the deep stabilizing muscles of the trunk in coordination with the PFM. The pilates method consists of exercises that emphasize pelvic stability, mobility, and body alignment. PMFE are performed in tandem with breathing, with concurrent trunk muscle recruitment in various positions.
62625477|NCT05341778|ACTIVE_COMPARATOR|Pelvic floor exercise|These exercises are intended to strengthen weak perineal and pelvic floor muscles.
62851127|NCT02460601|EXPERIMENTAL|Qizhiweitong granule|2.5g/time,tid,oral administration,6 weeks
62851128|NCT02460601|PLACEBO_COMPARATOR|Placebo|2.5g/time,tid,oral administration,6 weeks
62851129|NCT02669485|EXPERIMENTAL|ICG|Administering indocyanine green during surgery and the use of ICG fluorescence imaging to assess bowel perfusion during surgery
62851130|NCT06111118|EXPERIMENTAL|Immediate ThermaCare HeatWraps|Immediately after the completion of standardized exercise ThermaCare HeatWraps will be applied on each leg centered over the quadriceps and lying longitudinally over the muscle for 8 hours. The application of a new ThermaCare HeatWraps will be repeated in the same manner, for 8 hours each, at 24 and 48 hours after exercise (i.e., 3 applications in total).
62062475|NCT02286167|OTHER|Single arm diet|Intermittent, modified Atkins diet
62851131|NCT06111118|EXPERIMENTAL|Delayed ThermaCare HeatWraps|On Day 2, 24 hours after the completion of standardized exercise, Group 2 subjects will apply ThermaCare HeatWraps in the same manner as described above for 8 hours. Subsequent heat wraps will be applied for 8 hours each at 48 and 72 hours after exercise (i.e., 3 applications in total).
62851132|NCT06111118|NO_INTERVENTION|No treatment|Standardized exercise alone
62851133|NCT05147233|EXPERIMENTAL|Active Treatment Arm|OCS-01 (Ophthalmic Suspension) - topical use
62851134|NCT05147233|PLACEBO_COMPARATOR|Vehicle Placebo Arm|Vehicle
62851135|NCT03968133|EXPERIMENTAL|Probiotic|Ecologic® BARRIER 849 (Maize starch, maltodextrin, vegetable protein, potassium chloride, +/- probiotic bacteria (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lc. lactis W19, Lc. lactis W58; ≥ 2,5\*10\^9 colony forming unit (CFU)/g), magnesium sulphate, manganese sulphate.) sachet, two times daily dosing for a total of 2 grams (viable cell count of 2.5 × 10\^9 CFU/gram) per day.
62062476|NCT01838408|EXPERIMENTAL|EZ2go Complete|EZ2go complete: Peg 3350, Magnesium Citrate and Simethicone
62625478|NCT01034228|ACTIVE_COMPARATOR|Isoleucine|Glucose ORS with L-Isoleucine
62851136|NCT03968133|PLACEBO_COMPARATOR|Placebo|Placebo (maize starch, maltodextrin, vegetable protein, magnesium sulphate, manganese sulphate)
62851137|NCT06123234|EXPERIMENTAL|Verum|Partecipants received a food supplement with probiotics, chamomile, vitamin A, vitamin D in single-dose vials every day for 60 days.
62851138|NCT06123234|PLACEBO_COMPARATOR|Placebo|Placebo does not contain any active ingredients. Partecipants received placebo in single-dose vials every day for 60 days.
62851139|NCT01451437|EXPERIMENTAL|Pt 1 Arm A: MK-8242 30 mg QD|Participants received MK-8242 30 mg once daily (QD) monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
62851140|NCT01451437|EXPERIMENTAL|Pt 1 Arm A: MK-8242 60 mg QD|Participants received MK-8242 60 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
62062477|NCT01838408|ACTIVE_COMPARATOR|LoSo Prep ™|LoSo Prep ™: Magnesium citrate and Bisacodyl
62851141|NCT01451437|EXPERIMENTAL|Pt 1 Arm A: MK-8242 120 mg QD|Participants received MK-8242 120 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
62062478|NCT03486262||Lung carcinoma on IPF|Lung carcinoma on IPF
62625479|NCT01034228|PLACEBO_COMPARATOR|ORS without Isoleucine|ORS without Isoleucine for the treatment of diarrhoea in children
62625480|NCT04504578|EXPERIMENTAL|patients with progressive keratoconus with thin corneas|patients with progressive keratoconus with thin corneas , with thickness less than 400 micron ,will do conventional cross linking but with putting contact lens over the cornea ( will receive Contact lens assisted corneal cross liking )
62851142|NCT01451437|EXPERIMENTAL|Pt 1 Arm A: MK-8242 250 mg QD|Participants received MK-8242 250 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
62851143|NCT01451437|EXPERIMENTAL|Pt 1 Arm A: MK-8242 120 mg BID|Participants received MK-8242 120 mg twice daily (BID) monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 120 mg was administered QD in the morning) in Part 1 Arm A.
62851144|NCT01451437|EXPERIMENTAL|Pt 1 Arm A: MK-8242 170 mg BID|Participants received MK-8242 170 mg BID monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 170 mg was administered QD in the morning) in Part 1 Arm A.
62062479|NCT01958840|EXPERIMENTAL|Behavioral Activation Treatment for Depression|Behavioral Activation Condition - 10 sessions
62062480|NCT01958840|ACTIVE_COMPARATOR|Supportive Counseling|Supportive Counseling Condition - 10 sessions
62062481|NCT03183388|EXPERIMENTAL|BE-SMART|Psychobehavioral intervention with focus either on teaching emotional regulation skills or regularizing daily sleep and activity levels.
62062482|NCT04804098|ACTIVE_COMPARATOR|15 Minute Non-linear Compression Profile|Compression Profile/Schedule 1 = 15 minute non-linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Non-Linear rate of compression = 2 fsw/min to a depth of 13 fsw, then 3 fsw/min up to a depth of 35 fsw, then 5 fsw/min to arrival at the treatment depth of 45 fsw
62062483|NCT04804098|ACTIVE_COMPARATOR|15 Minute Linear Compression Profile|Compression Profile/Schedule 2 = 15 minute linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Linear rate of compression = 4.5 fsw/min to arrival at the treatment depth 45 fsw
62062484|NCT04775121|EXPERIMENTAL|Experimental|Oral administration of 20 g Deuterium Glucose on a 3-hour period followed by sequential blood sampling to sort monocytes on a 30-days period of time
62851145|NCT01451437|EXPERIMENTAL|Pt 1 Arm A: MK-8242 210 mg BID|Participants received MK-8242 210 mg BID monotherapy on Days 1-7 of a 21-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 210 mg was administered QD in the morning) in Part 1 Arm A.
62062485|NCT04775121|EXPERIMENTAL|Healthy volunteers|Oral administration of 20 g Deuterium Glucose on a 3-hour period followed by sequential blood sampling to sort monocytes on a 30-days period of time
62450277|NCT00966225|EXPERIMENTAL|One gram LIP-01 per day|One gram LIP-01 per day for 12 weeks
62851146|NCT01451437|EXPERIMENTAL|Pt 1 Arm A: MK-8242 250 mg BID|Participants received MK-8242 250 mg BID monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 250 mg was administered QD in the morning) in Part 1 Arm A.
62851147|NCT01451437|EXPERIMENTAL|Pt 1 Arm A: MK-8242 300 mg BID|Participants received MK-8242 300 mg BID monotherapy on Days 1-7 of a 21-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 300 mg was administered QD in the morning) in Part 1 Arm A.
62062486|NCT05494827|EXPERIMENTAL|Borjomi|Healthy volunteers (N16, 8 males and 8 females) 30.63±1.04 y.o. with BMI 22.17±0.75 kg/m2 were randomly allocated to Borjomi group. Participants received 30 bottles (500 ml) of natural mineral water Borjomi® for daily 1000 ml (2 bottles) water consumption for 14 days (from visits 1 and 2). Participants drank the first bottle on the visit 1 after the first study Wingate test and the last bottle on the visit 3 before the second study Wingate test
62851148|NCT04952155|EXPERIMENTAL|IL-2|The administration period was divided into 6 courses. 6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment.
62851149|NCT02200809|EXPERIMENTAL|MR-guided focal laser ablation|
62851150|NCT00178776|EXPERIMENTAL|Transtheoretical Model Group|
62851151|NCT00178776|ACTIVE_COMPARATOR|Education / Advice|
62851152|NCT02871037|EXPERIMENTAL|Part 1_Cohort 1_Active|Single, escalating dose of PF-05221304
62062487|NCT05494827|ACTIVE_COMPARATOR|Smart Spring|Healthy volunteers (N16, 8 males and 8 females) 28.56±1.61 y.o. with BMI 23.14±0.60 kg/m2 were randomly allocated to Smart Spring group. Participants received 30 bottles (500 ml) of processed drinking water Smart Spring® for daily 1000 ml (2 bottles) water consumption for 14 days (from visits 1 and 2). Participants drank the first bottle on the visit 1 after the first study Wingate test and the last bottle on the visit 3 before the second study Wingate test.
62062488|NCT05494827|PLACEBO_COMPARATOR|Control group|Healthy volunteers (N16, 8 males and 8 females) 30.69±1.74 y.o. with BMI 22.67±0.51 kg/m2 were randomly allocated to Control group. Participants received 30 bottles (500 ml) of steal drinking water Святой Источник® for daily 1000 ml (2 bottles) water consumption for 14 days (from visits 1 and 2). Participants drank the first bottle on the visit 1 after the first study Wingate test and the last bottle on the visit 3 before the second study Wingate test.
62062489|NCT05420922||Systemic therapy|ICIs (PD1 or PDL-1)+TKIs (Lenvatinib or Sorafenib)
62625481|NCT04919603|EXPERIMENTAL|Enhanced physical activity group|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
62851153|NCT02871037|PLACEBO_COMPARATOR|Part 1_Cohort 1_Placebo|Single dose of Placebo
62851154|NCT02871037|EXPERIMENTAL|Part 1_Cohort 2_Active|Single, escalating dose of PF-05221304
62062490|NCT05420922||Local treatment|local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.
62450278|NCT00966225|EXPERIMENTAL|Two grams LIP-01 per day|Two grams LIP-01 per day for 12 weeks
62062491|NCT05420922||Triple therapy|"Systemic therapy plus Local treatment:~ICIs (PD1 or PDL-1)+TKIs (Lenvatinib or Sorafenib) plus local treatment (TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc)"
62087960|NCT01034761|EXPERIMENTAL|Pop-up alerts|Providers will receive pop-up alerts in the electronic medical record when prescribing one of the specified medications from the Beers list.
62087961|NCT01034761|NO_INTERVENTION|Usual care|
62450279|NCT00966225|EXPERIMENTAL|0.333 grams LIP-01 per day|0.333 grams LIP-01 per day for 12 weeks
62450280|NCT05538884|EXPERIMENTAL|Intertransverse process block|Using a simple transverse ultrasound imaging technique to visualize the superior costotransverse ligament (SCTL) and the retro-SCTL space, we can perform a novel ITPB. Local anesthetic will be injected at the retro SCTL space.
62450281|NCT04122222|ACTIVE_COMPARATOR|Hemodialysis|ESRD patients treated by hemodialysis
62851155|NCT02871037|EXPERIMENTAL|Part 1_Cohort 2_Placebo|Single dose of Placebo
62851156|NCT02871037|EXPERIMENTAL|Part 2_Active|Repeated, escalating doses of PF-05221304
62851157|NCT02871037|PLACEBO_COMPARATOR|Part 2_Placebo|Repeated doses of placebo
62851158|NCT02871037|EXPERIMENTAL|Part 3|Single dose of PF-05221304 with and without food
62851159|NCT04459208|ACTIVE_COMPARATOR|Manta|plug-based vascular closure
62851160|NCT04459208|ACTIVE_COMPARATOR|ProGlide|suture-based vascular closure
62851161|NCT00742833|EXPERIMENTAL|3|
62851162|NCT00742833|PLACEBO_COMPARATOR|1|
62851163|NCT03642132|EXPERIMENTAL|chemotherapy, avelumab and talazoparib|Platinum-based chemotherapy + avelumab followed by avelumab + talazoparib maintenance
62851164|NCT03642132|EXPERIMENTAL|chemotherapy, and talazoparib|Platinum-based chemotherapy followed by talazoparib maintenance
62851165|NCT03642132|ACTIVE_COMPARATOR|chemotherapy and bevacizumab|Platinum-based chemotherapy + bevacizumab followed by bevacizumab maintenance
62851166|NCT01629225|NO_INTERVENTION|candesartan|All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.
62851167|NCT00644007|PLACEBO_COMPARATOR|Group 1|
62851168|NCT00644007|EXPERIMENTAL|Group 2|
62851169|NCT03614208|EXPERIMENTAL|Home-care rehabilitation group (HCRG)|"The home-based exercise program consists of aerobic exercise on a stationary bike, muscular endurance training of the upper limb and stretching exercises for finger joint motion. The exercise on the stationary bike and muscular endurance training will be performed on alternate days, three times a week. For finger stretching the patients will be directed to perform it every day, both in the morning and in the evening.~During the rehabilitation period, the patients will report each day on a diary for each type of exercise. They received a phone call monthly, only for the first 3 months, to encourage them about the adherence and investigate any problems with the exercise program."
62851170|NCT03614208|NO_INTERVENTION|Control group|Control group was encouraged to perform the generic aerobic physical activity at the baseline. Also, they received a monthly phone call, only for the first 3 months, to encourage them about the importance of doing aerobic exercise.
62851171|NCT02809222|OTHER|Patients with MDS at diagnosis|The intervention, specific to the study, is to take blood samples on patients with MDS at diagnosis. A quality of life questionnaire will also be used to monitor patients
62851172|NCT02809222|OTHER|Patients with MDS in treatment|The intervention, specific to the study, is to take blood samples on patients with MDS receiving treatment. A quality of life questionnaire will also be used to monitor patients
62851173|NCT02809222|OTHER|Healthy volunteers|The intervention, specific to the study, is to take blood samples on patients healthy volunteers.
62851174|NCT01258322|EXPERIMENTAL|pioglitazone|
62851175|NCT02559492|EXPERIMENTAL|Group A: Itacitinib + epacadostat|Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
62450282|NCT04122222|ACTIVE_COMPARATOR|Hemodiafiltration|ESRD patients treated by on-line hemodiafiltration
62625482|NCT04919603|EXPERIMENTAL|Standard education group|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on diabetes prevention according to \< Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)telephone. The education is mainly consisted of instructions on diabetes prevention according to \< Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)\>.
62450283|NCT01645306|PLACEBO_COMPARATOR|Phosphate buffered saline (PBS), 1% sucrose, 4% mannitol|Placebo control with PBS, 1% sucrose and 4% mannitol
62851176|NCT02559492|EXPERIMENTAL|Group B: Itacitinib + INCB050465|Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
62851177|NCT00918931|EXPERIMENTAL|Obatoclax Mesylate|30 mg by vein over 3 hours Days 1-3, 14-day cycle
62625483|NCT03566381||Healthy adults|Healthy adults without a history of medical or surgical problems
62625484|NCT04039204|EXPERIMENTAL|Elagolix|Elagolix will be dosed at the higher dose used in pelvic pain trials, 200 mg twice a day for 2 months.
62851178|NCT04136847|EXPERIMENTAL|Hand Aging|Microneedling treatment of the dorsum of the hands
62851179|NCT04152564|ACTIVE_COMPARATOR|levo-bupivacaine continuous epidural infusion [CEI])|The epidural catheter will be placed via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T7 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine infusion. Proper placement of the catheter was verified through an aspiration test and a test dose (2 ml) of lidocaine 2%. At the end of surgery, a 14 ml bolus of L-bupivacaine 0.125 will be administered through the catheter and then a continuous rate of .1 ml/kg/h infusion of L-bupivacaine 0.125 will be delivered.
62851180|NCT04152564|ACTIVE_COMPARATOR|Levo-bupivacaine continuous preperitoneal infusion [CPI]),|At the end of surgery and after the closure of the peritoneal layer, the preperitoneal catheter will be allocated above the peritoneum within the musculofascial layer and secured to the skin with an occlusive dressing. Thereafter, a 20 ml bolus of L-bupivacaine 0.25% will be administered through the catheter and then a continuous fixed-rate infusion of L-bupivacaine 0.25% will be delivered.
62851181|NCT02215941|EXPERIMENTAL|TV-45070 7%|twice daily topical application to 7% body surface area for 7.5 days (15 applications)
62851182|NCT02215941|EXPERIMENTAL|TV-45070 21%|twice daily topical application to 21% body surface area for 7.5 days (15 applications)
62851183|NCT02215941|EXPERIMENTAL|TV-45070 53%|twice daily topical application to 53% body surface area for 7.5 days (15 applications)
62851184|NCT02215941|PLACEBO_COMPARATOR|Placebo|
62851185|NCT02899572|EXPERIMENTAL|Sexology consultation|specialized sexology consultation planned in the 15 days after inclusion. Randomisation is performed at D7 during a phone call to the patient.
62450284|NCT01645306|ACTIVE_COMPARATOR|40 mg Revacept|low dose Revacept 40mg in PBS, 1% sucrose, 4% mannitol
62450285|NCT01645306|ACTIVE_COMPARATOR|120 mg Revacept|high dose revacept 120mg in PBS, 1% sucrose, 4% mannitol
62450286|NCT00696449|EXPERIMENTAL|Frequent visits|This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.
62625485|NCT04039204|ACTIVE_COMPARATOR|Oral contraceptives (Ortho Cyclen)|Elagolix will be compared to a less potent standard commonly used prior to IVF or embryo transfer, namely estrogen containing birth control pills.
62625486|NCT03290118|EXPERIMENTAL|Traffic Light|"Participants in this group will be provided with a survey that shows the food and beverage packages with traffic light front of pack labels only.~Intervention is the Nutrition Rating System - Traffic Light"
62450287|NCT00696449|EXPERIMENTAL|Electronic reminder|This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.
62851186|NCT02899572|NO_INTERVENTION|Leaflet concerning erectile disorders|leaflet explaining erectile disorders related to type 2 diabetes will be sent by post to the patients. Randomisation is performed at D7 during a phone call to the patient.
62851187|NCT04188444||Agonist|Ovarian stimulation with agonist of GnRH
62851188|NCT04188444||Antagonist|Ovarian stimulation with antagonist of GnRH
62062492|NCT05214313|EXPERIMENTAL|"Music therapy Intervention group (G1)"|"Patients in the Music therapy intervention group will also perform the 1st session of the program during the inclusion visit (V0). The patients will benefit from fourteen 1-hour music therapy sessions (15 min of reception, installation and debriefing at the end of the session and 45 min of program). The 14 individual sessions will be spread over three months at the rate of 2 weekly sessions the first month then a single weekly session the following month and finally 2 monthly sessions the last month. Patients will be assessed at inclusion, then the first month (V1) and at the end of the intervention (V2)."
62625487|NCT03290118|EXPERIMENTAL|Star System|"Participants in this group will be provided with a survey that shows the food and beverage packages with health star rating front of pack labels only.~Intervention is the Nutrition Rating System - Health Star Rating"
62625488|NCT03290118|EXPERIMENTAL|Warning Label|"Participants in this group will be provided with a survey that shows the food and beverage packages with warning front of pack labels only.~Intervention is the Nutrition Rating System - Warning Labels"
62625489|NCT03290118|NO_INTERVENTION|Control|Participants in this group will be provided with a survey that shows the food and beverage packages without any front of pack labels.
62625490|NCT03351634|EXPERIMENTAL|Children with neurogenic incontinence with spinal dysraphism|
62625491|NCT03043963|ACTIVE_COMPARATOR|Sleep Timing|Intervention will include basic education concerning sleep hygiene and regularity of sleep timing
62625492|NCT03043963|EXPERIMENTAL|Sleep Extension|Intervention will include basic education concerning sleep hygiene and an extension of the sleep period.
62851189|NCT06248580||Family Physicians|1. 250 Family Physicians
62851190|NCT06248580||HDV Screening|2. 20,000 HBsAg positive patients
62851191|NCT04193618|EXPERIMENTAL|Conservative surgery for placenta accretta|
62087962|NCT06078683|EXPERIMENTAL|Ketone Ester|This arm will provide a Keto Ester Beverage for consumption.
62625493|NCT06524154|EXPERIMENTAL|positive reinforcement|apply normal treatment with praising the child with encouraging words and pleasing smiles.
62851192|NCT00097656|EXPERIMENTAL|Periodontal Treatment|maternal periodontal therapy
62851193|NCT00832624|EXPERIMENTAL|1|sitagliptin
62851194|NCT06357676|EXPERIMENTAL|Treatment (glofitamab, ibrutinib, obinutuzumab)|Patients receive ibrutinib PO QD on days 1-21 of cycles 1-17. Cycles repeat every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients receive glofitamab IV over 2-4 hours on days 8 and 15 of cycle 2 and then on day 1 of cycles 3-13. Cycles repeat every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab IV over 4 hours at least 7 days and 24 hours prior to first dose of glofitamab. Additionally, patients undergo echocardiography during screening, bone marrow biopsy on study, and CT scans, FDG PET/CT scans or MRI, and blood sample collection throughout the study.
62851195|NCT04327193|EXPERIMENTAL|Driving pressure|The selected PEEP which makes the driving pressure lowest is applied during the operation.
62450288|NCT00696449|EXPERIMENTAL|Parent reminder|In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.
62851196|NCT04327193|ACTIVE_COMPARATOR|Conventional|Conventional PEEP (5cmH2O) is applied.
62625494|NCT06524154|EXPERIMENTAL|contingent escape|apply normal treatment with giving some rest of the procedure while the child on the chair.
62851197|NCT04494568|EXPERIMENTAL|HIFU intervention|patients will benefit of an HIFU Treatment of their rectal endometriosis
62851198|NCT05547009|EXPERIMENTAL|Blended-learning group|The BL program included paced, asynchronous online learning modules and scheduled online activities with strategic face-to-face lectures.
62851199|NCT05547009|ACTIVE_COMPARATOR|Face-to-face learning group|Face-to-face classes.
62625495|NCT06524154|EXPERIMENTAL|rewarding the child|"apply normal treatment with giving simple gifts like stickers at the end of the procedure.~8"
62851200|NCT02575547||NC+CCRT|Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin)
62851201|NCT06427434|ACTIVE_COMPARATOR|Strengthening and stretching exercises|The participants will be asked to perform strengthening and stretching exercises to the back and abdominal muscles for 30 min, three times per week for 4 weeks.
62851202|NCT06427434|EXPERIMENTAL|Modified Lumbar Sustained Natural Apophyseal Glide|The participants will receive Modified Sustained Natural Apophyseal Glide on the affected lumbar level for 30 sec three times per week for 4 weeks. In addition to strengthening and stretching exercises to the back and abdominal muscles for 30 min, three times per week for 4 weeks
62851203|NCT05282953|EXPERIMENTAL|Patients with Retinitis Pigmentosa and Choroideremia|
62851204|NCT00451503|EXPERIMENTAL|1|surgery
62851205|NCT02194985|EXPERIMENTAL|Migalastat HCl 150 mg|Migalastat HCl 150 milligram (mg).
62851206|NCT02471326|EXPERIMENTAL|HIV Positive Subjects|VRC-HIVMAB060-00-AB (VRC01) given in HIV-infected Adults (age 18-65 years) on cART with suppressed viremia
62851207|NCT01137201|EXPERIMENTAL|Mesenteric defects sutured|Closure of the mesenteric defects using running, non-absorbable suture
62625496|NCT01748019|EXPERIMENTAL|ST1968|"ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks~--------------------------------------------------------------------------------"
62851208|NCT01137201|NO_INTERVENTION|Mesenteric defects not sutured|Non-closure of the mesenteric defects
62851209|NCT00973817|EXPERIMENTAL|ELAD|Use of ELAD for up to 6 days to stabilize liver function plus standard of care treatment plus standard of care treatment. Standard of care for acute on chronic hepatitis patients including medications and treatments typically given to patients admitted with acute hepatitis (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
62851210|NCT00973817|OTHER|Standard of care|Standard of care for acute on chronic hepatitis patients including medications and treatments typically given to patients admitted with acute hepatitis (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
62851211|NCT01700387|EXPERIMENTAL|OnabotulinumtoxinA + Topiramate|"Subject will receive 155 U onabotulinumtoxinA injections at 31 sites every 3 months for 12 months and treat daily with topiramate. During the first month of the treatment period, subjects will titrate as follows:~Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
62851212|NCT01700387|PLACEBO_COMPARATOR|OnabotulinumtoxinA + Placebo|"Subject will receive 155 U onabotulinumtoxinA injections at 31 sites every 3 months for 12 months and treat daily with placebo. During the first month of the treatment period, subjects will titrate as follows:~Week 1: 1 tab qhs Week 2: 1 tab bid Week 3: 1 tab q am + 2 tabs qhs Week 4: 2 tabs bid"
62851213|NCT06092814|ACTIVE_COMPARATOR|real-tACS|The active stimulation will consist of an alternating current delivered in the alpha frequency band with a peak-to-peak intensity of 4 milliamps (mA) for 20 minutes. Participants will complete sentence completion and verb generation task during stimulation.
62851214|NCT06092814|PLACEBO_COMPARATOR|sham-tACS|"Sham stimulation involves the delivery of 60 seconds of the actual stimulation waveform (ramp up) which is then gradually reduced to 0 milliamps (mA) (ramp down). Participants will complete sentence completion and verb generation task during stimulation."
62851215|NCT04007354|NO_INTERVENTION|Intubated|The patient was intubated with a left-sided double-lumen endobronchial tube. The protective ventilation was performed as follows: a tidal volume of 6 mL/kg predicted body weight, I:E ratio of 1:2, a respiratory rate to maintain PaCO2 within 35 to 45 mmHg, and positive end-expiratory pressure at 5 cmH2O. If the airway pressure exceeded 25 cmH2O, tidal volume was adjusted.
62851216|NCT04007354|EXPERIMENTAL|Non-intubated|The patients were oxygenated via facial mask with O2 5\~10 L/min during the whole procedure. The end-tidal carbon dioxide (EtCO2) was measured by insertion of a detector inside one of the nostrils. Respiration rate was maintained between 12 and 20 breaths/min with adjustment of anesthetics.
62851217|NCT01158170|EXPERIMENTAL|prophylactic cranial irradiation|Patients receive Erlotinib or gefitinib until disease progression or intolerable toxicity, and prophylactic cranial irradiation 25GY over 10 fractions.
62851218|NCT01158170|ACTIVE_COMPARATOR|Conctrol|Patients received Erlotinib or gefitinib until disease progression,or intolerable toxicity
62851219|NCT03050229|EXPERIMENTAL|Empagliflozin|Empagliflozin 10mg/day is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker \[ARB\]) and diabetes.
62851220|NCT03050229|PLACEBO_COMPARATOR|Placebo|Placebo is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker \[ARB\]) and diabetes.
62062493|NCT05214313|NO_INTERVENTION|" Control  group (G2)"|The patients in this group will benefit from the usual care corresponding to a quarterly medical examination. The patients will be assessed on the day of inclusion (V0) and then during the routine three-month medical examination (V2). At the end of the study, these patients will be able to benefit from the same music therapy program, offered under the same operating conditions.
62062494|NCT03078153|EXPERIMENTAL|Financial Incentive|Provided financial incentive at 3-month and 6-month follow-up visits
62062495|NCT03078153|EXPERIMENTAL|Social Media Group|Provided social media support through a facebook group for 6 months
62851221|NCT01411735|ACTIVE_COMPARATOR|Enalapril|2.5mg titrated up to 10mg- twice daily
62851222|NCT01411735|PLACEBO_COMPARATOR|placebo|2.5 mg titrate up to 10mg twice daily placebo comparator
62851223|NCT01765010|PLACEBO_COMPARATOR|Placebo control|Placebo control
62851224|NCT01765010|ACTIVE_COMPARATOR|Cholecalciferol 1000IU|Cholecalciferol 1000IU qd for 8 weeks
62851225|NCT01765010|EXPERIMENTAL|alfacalcidol|alfacalcidol 0.5ug qd for 8 weeks
62851226|NCT01765010|EXPERIMENTAL|Calcitriol|Calcitriol 0.25ug qd for 8 weeks
62851227|NCT00741845|ACTIVE_COMPARATOR|1|intravaginal metronidazole 750mg + 200mg miconazole
62062496|NCT03078153|NO_INTERVENTION|Control|No intervention
62062497|NCT05287425|EXPERIMENTAL|Gentamicin eye drops|4 drops daily in both eyes for 7 ± 1 days
62062498|NCT05287425|EXPERIMENTAL|Ciprofloxacin eye drops|4 drops daily in both eyes for 7 ± 1 days
62062499|NCT05287425|ACTIVE_COMPARATOR|Povidone eye drops unpreserved|4 drops daily in both eyes for 7 ± 1 days
62062500|NCT05287425|ACTIVE_COMPARATOR|Povidone eye drops preserved|4 drops daily in both eyes for 7 ± 1 days
62062501|NCT06310902||Borderline Resectable Pancreatic Cancer|Cancer tissue specimens can be collected postoperatively following neoadjuvant chemotherapy.
62062502|NCT06310902||Resectable Pancreatic Cancer|Cancer tissue specimens can be directly collected postoperatively
62062503|NCT02448667|EXPERIMENTAL|FAXE Kondi - a sugary soft-drink|100 ml FAXE Kondi (10 grams of carbohydrates per 100 ml) is ingested every ten minutes during exercise plus 400 ml before exercise start.
62062504|NCT02448667|PLACEBO_COMPARATOR|FAXE Kondi Free - a sugarfree soft-drink|100 ml FAXE Kondi Free (0 grams of carbohydrates per 100 ml) is ingested every ten minutes during exercise plus 400 ml before exercise start.
62062505|NCT00426426|ACTIVE_COMPARATOR|Meta-Cognitive Therapy|first Meta-cognitive therapy then Cognitive Behaviour Therapy
62062506|NCT00426426|ACTIVE_COMPARATOR|Cognitive Behaviour Therapy|first Cognitive Behaviour Therapy then Meta-cognitive therapy
62062507|NCT00426426|OTHER|Waiting List|Waiting List
62087963|NCT06078683|PLACEBO_COMPARATOR|Placebo|This arm will provide a Placebo Beverage for consumption.
62851228|NCT00741845|ACTIVE_COMPARATOR|2|intravaginal metronidazole 750mg
62851229|NCT00741845|ACTIVE_COMPARATOR|3|intravaginal metronidazole 37.5mg
62851230|NCT01217333|ACTIVE_COMPARATOR|In-person|Participants in this arm have been randomized to receive Consultation Planning in-person
62851231|NCT01217333|ACTIVE_COMPARATOR|Telephone|Participants in this arm have been randomized to receive Consultation Planning by telephone.
62851232|NCT03241030|EXPERIMENTAL|Experimental Group|Subjects will receive sucralfate
62851233|NCT03241030|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive a placebo
62625497|NCT02211664|EXPERIMENTAL|Passeo-18-Lux & Pulsar-18|"The interventional procedure sequence consists of the following steps:~1. pre-dilation of the lesion with a Passeo-18 balloon (mandatory)~2. dilation of the lesion with a Passeo-18 Lux drug releasing balloon (mandatory); a maximum of 2 Passeo-18 Lux balloons can be used per lesion (drug load cannot exceed 12µg)~3. stenting of the lesion with a Pulsar-18 stent (mandatory)~4. post-dilation of the lesion with a Passeo-18 balloon (not mandatory)"
62625498|NCT02281955|EXPERIMENTAL|De-escalated Radiation and Chemotherapy|Patients will receive Intensity Modulated Radiotherapy Treatments (IMRT), 60 Gy at 2 Gy/fx. The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 total doses. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history. Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
62625499|NCT00177866|ACTIVE_COMPARATOR|A Placebo or Celebrex|either placebo PO BID for the first eight weeks or Celebrex 200 mg PO BID for the first eight weeks
62625500|NCT00177866|PLACEBO_COMPARATOR|B Placebo or Celebrex|either placebo PO BID for the last eight weeks or Celebrex 200 mg PO BID for the last eight weeks
62625501|NCT03921632|EXPERIMENTAL|Education Program Effectiveness|Outpatients and inpatients from UNC Center of Excellence for Eating Disorders clinic
62625502|NCT02511132|EXPERIMENTAL|Part 1: Vigil Alone|Vigil immunotherapy 1.0 x 107 cells/injection; minimum of 4 to a maximum of 12 administrations every 28 days
62625503|NCT02511132|ACTIVE_COMPARATOR|Part 1: Gemicitabine and Docetaxel|Gemcitabine 675 mg/m2 IV at 10 mg/m2/min D1 and Docetaxel 75 mg/m2 IV starting on D8 and given every 21 days.
62625504|NCT02511132|EXPERIMENTAL|Part 2: Vigil plus Temozolomide and Irinotecan|(i) oral temozolomide 100 mg/m2 daily (Days 1 - 5, total dose 500 mg/m2/cycle), (ii) irinotecan 50 mg/m2 daily (Days 1 - 5, total dose 250mg/m2/cycle), orally or irinotecan 20mg/m2 daily (Days 1 - 5, total dose 100mg/m2/cycle ), intravenously (iii) peg-filgrastim 100μg/kg (Day 6) subcutaneously (optional and may be administered at home), and (iv) Vigil 1.0 x 107 cells/injection, intradermally on Day 15 and every 3 weeks thereafter. One cycle = 21 days.
62625505|NCT01442649|EXPERIMENTAL|Arm A : bevacizumab + fluoropyrimidine-based chemotherapy|"Every 2 weeks :~- mFOLFOX6 : Oxaliplatin 85 mg/m2 over 120 mn IV on D1, Folinic Acide 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~OR~- FOLFIRI : Irinotecan 180 mg/m2 en 90 mn IV on day D1, Folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~AND~Bevacizumab 5 mg/kg IV every 2 weeks."
62625506|NCT01442649|EXPERIMENTAL|Arm B : cetuximab + fluoropyrimidine-based chemotherapy|"Every 2 weeks :~- mFOLFOX6 : Oxaliplatin 85 mg/m2 over 120 mn IV on D1, Folinic Acide 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~OR~- FOLFIRI : Irinotecan 180 mg/m2 en 90 mn IV on day D1, Folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~AND~Cetuximab : 500 mg/m² IV every 2 weeks"
62625507|NCT04326387||Research Participants (Patients)|"Inpatients symptomatic of suspected COVID-19 Baseline swab of nose/throat, nasopharyx, or endotracheal tube aspirate. SAMBA II point of care test on this swab.~Standard of care bloods taken for PHE and additional confirmatory diagnostic PCR assessment.~Serum antibody tests on any excess blood tests during inpatient stay for immune response monitoring.~Outcome assessment at 1 month"
62625508|NCT02806271|EXPERIMENTAL|Worry Postponement|Two weeks of daily worry postponement
62625509|NCT02806271|ACTIVE_COMPARATOR|Worry Monitoring|Two weeks of daily worry monitoring
62851234|NCT03801031|ACTIVE_COMPARATOR|Lidocaine|Patients being treated for gynecologic cancer assigned aqueous lidocaine solution as intervention to use during sexual encounters.
62851235|NCT03801031|PLACEBO_COMPARATOR|Placebo|Patients being treated for gynecologic cancer assigned placebo solution as intervention to use during sexual encounters.
62851236|NCT02936531||FXTAS|Patients positive for FMR1 premutation and meet diagnostic criteria for FXTAS
62851237|NCT02936531||FMR1 premutation asymptomatic|Patients positive for FMR1 premutation and do not meet diagnostic criteria for FXTAS
62062508|NCT03151915||Patients who underwent fetoscopic laser coagulation with TTTS|This is an retrospektive trial. We use data of patients who underwent fetoscopic laser coagulation with TTTS retrospectively. All patients meet eligibility criteria and give written informed consent before therapy. As part of the ongoing quality control we were able to safely store patient data relating to fetoscopic laser coagulation with TTTS.
62062509|NCT03510624|EXPERIMENTAL|First rebaudioside A and then placebo|
62062510|NCT03510624|EXPERIMENTAL|First placebo and then rebaudioside A|
62625510|NCT02806271|NO_INTERVENTION|Assessment Only Control|No intervention, participants will complete three assessment time points
62625511|NCT06613178|ACTIVE_COMPARATOR|Oral Placebo|Subject receives active intravenous acetaminophen and oral placebo acetaminophen
62625512|NCT06613178|PLACEBO_COMPARATOR|Oral Acetaminophen|Subject receives placebo IV fluid (saline) and active oral acetaminophen
62625513|NCT01913574|EXPERIMENTAL|Acupuncture & NCPB|The NCPB will be administered once at the start of the trial and the acupuncture will be performed 3 times per week for 2 weeks (6 times in total).
62625514|NCT01913574|ACTIVE_COMPARATOR|NCPB|The NCPB alone will be applied to the patients in this group, once at the start of the trial.
62625515|NCT04553081|ACTIVE_COMPARATOR|Dovato|We aim to include 134 adult HIV-infected patients with HIV RNA \< 50 copies/mL for at least 3 months on any stable 2nd generation integrase based triple therapy antiretroviral regimen. Patients will be randomized 1:2 to switch to or stay on the triple regimen BIC/TAF/FTC (Biktarvy) (N=45) or to switch to the dual regimen DTG/3TC (Dovato) (N=89).
62625516|NCT04553081|ACTIVE_COMPARATOR|Biktarvy|We aim to include 134 adult HIV-infected patients with HIV RNA \< 50 copies/mL for at least 3 months on any stable 2nd generation integrase based triple therapy antiretroviral regimen. Patients will be randomized 1:2 to switch to or stay on the triple regimen BIC/TAF/FTC (Biktarvy) (N=45) or to switch to the dual regimen DTG/3TC (Dovato) (N=89).
62062511|NCT06013501|EXPERIMENTAL|Puppet Show Group|puppet show before and during subcutaneous injection
62266858|NCT04358835|EXPERIMENTAL|Intubated patients with COVID-19 on a ketogenic diet only|4:1 ketogenic diet formula
62625517|NCT02688803|ACTIVE_COMPARATOR|Dose dense AC-P|Dose dense AC-P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)
62625518|NCT02688803|ACTIVE_COMPARATOR|Dose dense AC|Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)
62625519|NCT02688803|ACTIVE_COMPARATOR|FEC-D|FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
62625520|NCT04854057|EXPERIMENTAL|Intermittent Hypoxia (AIH) + Transcutaneous Electrical Spinal Cord Stimulation (TESS) First|"Round 1 1st Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice alone for 45 mins.~Round 1 2nd Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice for 45 mins after AIH (15x 1.5 mins bouts of 10% oxygen with 1 min intervals of room air).~Round 1 3rd Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice for 45 mins after SHAM (15x 1.5 mins bouts of 21% oxygen with 1 min intervals of room air).~Washout (1 month)~Round 2 1st Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice alone for 45 mins.~Round 2 2nd Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice for 45 mins after SHAM.~Round 2 3rd Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice for 45 mins after AIH."
62625521|NCT04854057|EXPERIMENTAL|Intermittent Room Air (SHAM) + Transcutaneous Electrical Spinal Cord Stimulation (TESS) First|"Round 1 1st Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice alone for 45 mins.~Round 1 2nd Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice for 45 mins after SHAM.~Round 1 3rd Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice for 45 mins after AIH.~Washout (1 month)~Round 2 1st Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice alone for 45 mins.~Round 2 2nd Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice for 45 mins after AIH (15x 1.5 mins bouts of 10% oxygen with 1 min intervals of room air).~Round 2 3rd Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice for 45 mins after SHAM (15x 1.5 mins bouts of 21% oxygen with 1 min intervals of room air)."
62062512|NCT06013501|NO_INTERVENTION|Control group|standart care
62266859|NCT03057925|EXPERIMENTAL|Group A|MWA Percutaneous Microwave Ablation intervention procedure: Ultrasound-guided Percutaneous Microwave Ablation
62625522|NCT06462742||MWA|iCCA patients who underwent microwave ablation (MWA).
62625523|NCT06462742||LR|iCCA patients who underwent liver resection (LR)
62625524|NCT00669188|EXPERIMENTAL|Information Type 1|genetic risk information
62625525|NCT00669188|SHAM_COMPARATOR|Information Type 2|information absent
62625526|NCT04095325|ACTIVE_COMPARATOR|transversus abdominis plane block|Group 1 (n: 50): those who underwent TAP block after induction of propofol atropine and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
62625527|NCT04095325|ACTIVE_COMPARATOR|erector spinae block|Group 2 (n: 50): those who underwent ESP block after propofol atropine induction and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
62625528|NCT03944278|EXPERIMENTAL|Thulium Device|1927 Laser Treatment
62851238|NCT02368561|EXPERIMENTAL|Hyaluronic Acid Injection|Hyaluronic Acid Injection in 20 adult patients with IAT
62851239|NCT00197548|ACTIVE_COMPARATOR|Multivitamins|Multivitamins-vitamins B-complex, C, and E
62062513|NCT03626441|PLACEBO_COMPARATOR|Placebo|Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger, given 2 hours before the scheduled start of surgery.
62062514|NCT03626441|EXPERIMENTAL|Ginger|Two coloured capsules containing 0.5g ginger powder, flavoured with non-active essence of ginger, given 2 hours before the scheduled start of surgery.
62062515|NCT01350505|EXPERIMENTAL|All subjects|13 minutes of light at night (2 hours after bedtime)
62062516|NCT00628914|EXPERIMENTAL|1|Open label escitalopram plus eszopiclone for 8 weeks
62266860|NCT03057925|NO_INTERVENTION|Group B|untreated no treatment; regular ultrasonic image follow-up
62266861|NCT05630079||Metaneb®|"Patients admitted for severe acquired brain injury (sABI) in Neurological Rehabilitation Unit of IRCCS Santa Maria Nascente - Fondazione Don Gnocchi received the MetaNeb® system treatment. It consist of simultaneous combination of positive pressure, continuous high frequency oscillations and aerosol delivery"
62450289|NCT00696449|EXPERIMENTAL|Standard of care|"This group is considered to be the standard of care arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits."
62851240|NCT00197548|PLACEBO_COMPARATOR|Placebo|Placebo pill
62851241|NCT05419193|PLACEBO_COMPARATOR|Control group|Patients will receive usual care and drug use in hospital.
62062517|NCT00628914|OTHER|2|Escitalopram and eszopiclone for initial 4 weeks, then switch to escitalopram and placebo for final 4 weeks.
62062518|NCT00628914|PLACEBO_COMPARATOR|3|Escitalopram plus placebo for 8 weeks
62062519|NCT04372225||477 patients|the biological tests of 477 patients undergoing total thyroidectomy were analyzed
62851242|NCT05419193|EXPERIMENTAL|Propranolol group|Propranolol hydrochloride will be administered intravenously via pump at a initial dose of 5mg/day over a course of 7 consecutive days after randomization.
62062520|NCT05012371|EXPERIMENTAL|Arm A (lenvatinib, everolimus)|Patients receive lenvatinib PO QD and everolimus PO QD. Cycles repeat every 30 days in the absence of disease progression or unacceptable toxicity.
62062521|NCT05012371|ACTIVE_COMPARATOR|Arm B (cabozantinib)|Patients receive cabozantinib PO QD. Cycles repeat every 30 days in the absence of disease progression or unacceptable toxicity.
62062522|NCT05345379|EXPERIMENTAL|Transbond MIP|Transbond primer group will be randomly allocated using a split-mouth, cross-quadrant design and two diagonal quadrants (i.e. upper right and lower left, or vice versa) for each participant.
62851243|NCT01788215|ACTIVE_COMPARATOR|Doxycycline|Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
62062523|NCT05345379|EXPERIMENTAL|Assure plus|Assure Plus primer group will be randomly allocated using a split-mouth, cross-quadrant design and two diagonal quadrants (i.e. upper right and lower left, or vice versa) for each participant.
62062524|NCT03324464|EXPERIMENTAL|CET-Working Memory (WM)|Central Executive Training: Working Memory
62851244|NCT01788215|PLACEBO_COMPARATOR|Sugar Pill|The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
62851245|NCT01307644|EXPERIMENTAL|Web-based only (WO) weight intervention|A comprehensive lifestyle modification intervention for healthy eating and activity delivered by web only to facilitate Phase I weight loss (weekly messages baseline to 6 months), Phase 2 guided weight loss and weight maintenance (bi-weekly hot topics news, 6-18 months) and Phase 3 self-managed weight maintenance (6 monthly and 3 bi-monthly new content, 18-30 months).
62062525|NCT03324464|ACTIVE_COMPARATOR|CET-Behavioral Inhibition (BI)|Central Executive Training: Inhibitory Control
62062526|NCT01642602|EXPERIMENTAL|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg delayed-release capsules orally once daily for up to 4 weeks.
62062527|NCT02463201||Obese children and adolescents|Attending a weightloss programme, that consist of lifestyle counseling, dietary restriction and exercise. The prevalence of obstructive sleep apnea (OSA) will be investigated in group. Children diagnosed with OSA will be followed to investigate if weight loss changes the condition.
62851246|NCT01307644|EXPERIMENTAL|WO & peer-led discussion board (WD)|Includes WO intervention, including all 3 Phases for weight loss and weight maintenance, supplemented with peer-lead discussion board. A peer leader will facilitate the asynchronous discussion group. The primary purpose of this group is to provide support, increase self-efficacy (role modeling by successful women and leader) and discuss progress toward goals.
62851247|NCT01307644|EXPERIMENTAL|WO & professional email counseling (WE)|Includes WO intervention, including all 3 Phases for weight loss and weight maintenance, supplemented with professional email-counseling by experienced counselor who will review women's web-logs of eating, activity, weight and goal-setting on web-site and send e-mail feedback.
62851248|NCT03000439|EXPERIMENTAL|Tofacitinib 5 mg BID|oral, twice daily, tablet or solution.
62062528|NCT01950065|EXPERIMENTAL|Immediate Treatment with iovera|Immediate treatment with iovera
62062529|NCT01950065|ACTIVE_COMPARATOR|Delayed Treatment with iovera|Delayed Treatment with iovera
62087964|NCT06078683|EXPERIMENTAL|Keto Ester Acute|This arm will provide a Keto Ester Beverage for consumption.
62087965|NCT06078683|PLACEBO_COMPARATOR|Placebo Acute|This arm will provide a Placebo Beverage for consumption.
62851249|NCT03000439|PLACEBO_COMPARATOR|Placebo|
62851250|NCT01627730|EXPERIMENTAL|3th year medical students|
62851251|NCT01627730|EXPERIMENTAL|nurses in critical care units|
62625529|NCT01471444|EXPERIMENTAL|Flu + Bu|Fludarabine 40 mg/m2 intravenous (IV) over 1 hour. Busulfan dose calculated to achieve a systemic exposure dose of 6000 µMol-min IV over 3 hours every 24 hours. Both delivered for 4 consecutive days (days -6 to -3). Stem cell transplant Day 0.
62266862|NCT05630079||IPV®|Patients with severe acquired brain injury from Neurological Rehabilitation Unit of IRCCS Fondazione Don Gnocchi, S.M. Nascente received the IPV® treatment. The principle of IPV® is to open collapsed airways and mobilize intrabronchial secretions through the delivery of small tidal volume at high frequency. IPV® adjusts the percussions to the changes in the mechanical properties of the patient's respiratory system: in case of high resistance, it produces small tidal volume at high pressure and low frequency; vice versa in case of low resistance, it produces large tidal volume at low pressure and high frequency
62266863|NCT04454190||Glaucoma - Slow progressors|Rates of MD change slower than -0.50 dB/year Rates of global RNFL thickness change slower than -1.0 µm/year
62625530|NCT01471444|EXPERIMENTAL|Flu +Clo + Bu|Fludarabine 10 mg/m2 over 1 hour. Clofarabine 40 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, infused over 1 hour. Busulfan dose calculated to achieve a systemic exposure dose of 6000 µMol-min IV over 3 hours every 24 hours, immediately after Clofarabine. All delivered on 4 consecutive days (days -6 through -3). Stem cell transplant Day 0.
62625531|NCT05103800|NO_INTERVENTION|control group|Babies in the control group will not listen to any sound during the invasive procedures, the procedure will be recorded with a camera, and at the end of the study, the camera images will be watched by two experts in the field and the pain and comfort scale will be filled.
62625532|NCT05103800|EXPERIMENTAL|Experimental group|During the invasive interventions, the white noise prepared by the researcher for the babies in the experimental group will be started to be listened to 5 minutes before the start of the intervention and will be listened to for 5 more minutes during and after the intervention. At the same time, the procedure will be recorded with a camera. At the end of the study, the camera images will be watched by two experts in the field. comfort scale will be filled.
62625533|NCT01353391|ACTIVE_COMPARATOR|Metformin|
62625534|NCT01353391|PLACEBO_COMPARATOR|Placebo|
62625535|NCT05573438|EXPERIMENTAL|Fructose|Participants received a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with fructose. The meals provided 25% of the energy requirements. The meal consisted of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of fructose).
62851252|NCT04124679|EXPERIMENTAL|TAES group|In TEAS group, an experienced acupuncturist performed 30 minutes of TEAS treatment at the HT7 (Shenmen) and Neiguan (PC6) acupoints on bilateral side, which were identiﬁed in accordance with the TCM anatomic localizations on the first night before surgery by a stimulator (Hwato Electronic Acupuncture Treatment Instrument, model no.: SDZ-II; Suzhou Medical Appliances Co. Ltd, Suzhou, China). And after surgery, ST36 (Zusanli) and LI4 (Hegu) acupoints were added for the effect of relieving postoperative complications. 30 minutes of TEAS treatment was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints on the first three nights after surgery
62851253|NCT04124679|NO_INTERVENTION|Control group|Patients in the control group were attached the gel electrodes at the sham acupoints
62851254|NCT04951661|EXPERIMENTAL|All Participants|Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
62625536|NCT05573438|EXPERIMENTAL|Sucrose|Participants received a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with sucrose. The meals provided 25% of the energy requirements. The meal consisted of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose).
62625537|NCT05573438|PLACEBO_COMPARATOR|Glucose|Participants received a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with glucose. The meals provided 25% of the energy requirements. The meal consisted of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of glucose).
62625538|NCT05103306||Triple OADs failure|Inadequatelly controlled type 2 diabetes patients despite triple combination therapy with metformin, glimepiride, and DPP-4 inhibitor
62625539|NCT04895852|EXPERIMENTAL|TEAS group|30 minutes TEAS therapy on DU20, EX-HN3, LI4, LR3 once per day for three days before surgery.
62851255|NCT02925338||Patients treated with Inflectra|
62851256|NCT01588470|EXPERIMENTAL|Pioglitazone|Only subjects with T2DM or non-diabetic subjects with coronary heart disease will receive Pioglitazone
62851257|NCT03236155|ACTIVE_COMPARATOR|1 prescription|Receives 90 pills in single prescription at discharge from hospital
62851258|NCT03236155|ACTIVE_COMPARATOR|3 prescriptions|Receives 30 pill prescription at discharge from hospital. Two refills available if requested.
62851259|NCT03828071|OTHER|stem cell transplantation|patients enrolled in this study will received autologous hematopoietic stem cell transplantation as the initial treatment.
62851260|NCT02113137|EXPERIMENTAL|group 1: drug|Drug: group 1: drug: chlorine dioxide 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks
62851261|NCT02113137|EXPERIMENTAL|group 2: device:|group 2: device: small tooth brush for tongue cleaning small tooth brush for tongue cleaning
62851262|NCT00744042|OTHER|asfotase alfa|asfotase alfa
62087966|NCT01349751|ACTIVE_COMPARATOR|isobaric levobupivacaine|spinal isobaric levobupivacaine
62266864|NCT04454190||Glaucoma - Fast progressors|Rates of MD change faster -0.50 to -2.00 dB/year Rates of global RNFL thickness change -1.0 to -4.0 µm/year
62087967|NCT01349751|ACTIVE_COMPARATOR|hyperbaric levobupivacaine|hyperbaric levobupivacaine
62266865|NCT04454190||Glaucoma - Catastrophic progressors|Rates of MD change faster than -2.00 dB/year Rates of global RNFL thickness change faster than -4.0 µm/year
62266866|NCT02195388||CR with AH|Patients after ACS with arterial hypertension treat with comprehensive cardiac rehabilitation
62625540|NCT04895852|SHAM_COMPARATOR|Control group|The control group selects the same acupoints as the TEAS group and other intervention measures are the same as the TEAS group except for the current intensity is set to 0-mA.
62625541|NCT05109026||Older people|Members of the population aged 65 years and older.
62625542|NCT05109026||Recent migrants|Members of the population who are recent migrants to the community.
62625543|NCT05109026||Members of the travelling community|Members of the population who are members of the travelling community.
62625544|NCT05109026||Perinatal women.|Members of the population who are pregnant or within a year of giving birth.
62625545|NCT05109026||Lone-parents|Members of the population who are raising children alone.
62625546|NCT05109026||Individuals with physical disabilities|Members of the population who have a physical disability.
62625547|NCT05109026||Secondary school students|Members of the population attending secondary school.
62625548|NCT05109026||Remote workers|Members of the population currently working from home.
62625549|NCT02072941|EXPERIMENTAL|PREPARE intervention|The PREPARE arm will review the PREPARE website plus the easy-to-read advance directive (AD). Participants will review PREPARE on their own for ≥20 minutes with staff present to answer questions. During PREPARE, participants answer preference questions and make an action plan (i.e., commitment to engage in advance care planning). To ensure home access to PREPARE content, participants will be given a website login and PREPARE content in digital video disc (DVD), booklet, and pamphlet format as well as the action plan and AD. One to three days before a primary care visit, the PREPARE arm will receive a reminder to come to their appointment and to bring their action plan.
62450290|NCT05528757||LGMDs Patients|Patients with a genetically confirmed diagnosis of a LGMD subtype 2A, 2B, or 2I
62625550|NCT02072941|NO_INTERVENTION|Control|The control arm will review an easy-to-read AD. Controls will review the AD for ≥15 minutes with study staff present to answer questions and will take the AD home to complete if desired. One to three days before a primary care visit, controls will receive a reminder to come to their appointment.
62625551|NCT03894475|ACTIVE_COMPARATOR|Sequence A|Patient would first perform an examination with handheld spirometer (AioCare), followed by measurements with the reference spirometer (MGC)
62625552|NCT03894475|ACTIVE_COMPARATOR|Sequence B|Patient would first perform an examination with the reference spirometer (MGC), followed by measurements with handheld spirometer (AioCare)
62625553|NCT06402461|EXPERIMENTAL|Allocation by preference|Participants are allocated to the one of the two mindfulness practices that they would prefer to do, based on a short description.
62851263|NCT03159260|EXPERIMENTAL|Theraworx|Subjects will receive two 3 ounce foam dispensers corresponding to their group assignment (Foam A or Foam B) and a 2-week Compliance and Symptom Log. The contents of these two foams will remain blind to the subjects and the data collectors until all 50 subjects complete the study protocol. One of the foams will contain Theraworx/\[pH\]uel (treatment) and the other will contain a physiologically inert substance (placebo control).
62851264|NCT03159260|PLACEBO_COMPARATOR|Placebo|Subjects will receive two 3 ounce foam dispensers corresponding to their group assignment (Foam A or Foam B) and a 2-week Compliance and Symptom Log. The contents of these two foams will remain blind to the subjects and the data collectors until all 50 subjects complete the study protocol. One of the foams will contain Theraworx/\[pH\]uel (treatment) and the other will contain a physiologically inert substance (placebo control).
62062530|NCT02298816||new B-Cell Hematologic Malignancy diagnosis|All adult patients who are newly diagnosed at Aurora Health Care with the following B-Cell Hematologic Malignancies: Monoclonal gammopathy of undetermined significance (MGUS), Smoldering multiple myeloma (SMM), Multiple myeloma (MM), Waldenstroms Macroglobulinemia (WM), Monoclonal B-cell lymphocytosis (MBL), Chronic lymphocytic leukemia (CLL), or B-Cell Non-Hodgkin lymphoma (NHL).
62062531|NCT01028261|EXPERIMENTAL|ZGN-433|
62450291|NCT00738673|EXPERIMENTAL|Degarelix|"Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0.~Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections."
62450292|NCT01024933|PLACEBO_COMPARATOR|Educational and Behavioral|The Education and Behavioral Contract (Control group) will receive an educational workbook and behavioral contract. Each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
62450293|NCT01024933|EXPERIMENTAL|PASA group-intervention|The PASA group (Positive Affect/Self-Affirmation/Motivational Interviewing) will receive a positive-affect and self-affirmation intervention with motivational interviewing.These patients will also receive an educational workbook and behavioral contract. This is the intervention.
62625554|NCT06402461|EXPERIMENTAL|Allocation by random|Participants are randomly allocated to one of the two mindfulness practices.
62625555|NCT06402461|ACTIVE_COMPARATOR|Control|Participants listen to an excerpt from an audiobook for an equivalent length of time to the mindfulness practices.
62625556|NCT02338401|EXPERIMENTAL|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
62625557|NCT02338401|PLACEBO_COMPARATOR|Placebo Pill|Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.
62625558|NCT04310293|OTHER|POOR RESPONDERS|poor responders low AMH LOW AFC
62625559|NCT06238219||NMBA cohort|Patients undergoing surgery under general anesthesia with use of neuromuscular blocking agents
62851265|NCT05711082|ACTIVE_COMPARATOR|Dopamine precursor|In the first condition, volunteers will receive a dopamine (DA) precursor (L-dopa, 100mg). L-dopa will be combined with a dose of an Aromatic amino acid decarboxylase inhibitor (Benserazide) 25mg to multiplicate its bioavailability and with a dose of domperidone 10mg (peripheral antagonist of DA) to minimize the risk of side effects.
62851266|NCT05711082|ACTIVE_COMPARATOR|D2 antagonist|In the second condition, volunteers will receive a D2 antagonist (Sulpiride, 800mg)
62851267|NCT05711082|PLACEBO_COMPARATOR|PLACEBO|In the third condition, volunteers will receive a placebo (lactose)
62851268|NCT05515185|EXPERIMENTAL|KT095 CAR-T|KT095 CAR-T injection Intravenous infusion
62625560|NCT05805852||patients with surgical intervention|
62625561|NCT05805852||patients with no surgical intervention|
62625562|NCT02819440|ACTIVE_COMPARATOR|Tadalafil|Subjects will be randomized to one of two arms. 100 obese adult subjects will be randomized to the Tadalafil arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of Tadalafil (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the active comparator subjects will undergo the following visit protocol: baseline visit (two half-days), an interim visit (6 weeks post-baseline), and a 12-week visit (two half-days).
62625563|NCT02819440|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to one of two arms. 100 obese adult subjects will be randomized to the placebo arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of a placebo pill (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the placebo comparator subjects will undergo the following visit protocol: baseline visit (two half-days), an interim visit (6 weeks post-baseline), and a 12-week visit (two half-days).
62625564|NCT03886584|EXPERIMENTAL|Patients with with neuropsychiatric conditions|"In this arm, five groups :~* Patients with DFT, diagnosed according Racovsky criteria~* Patients with Lewi Body dementia, diagnosed according McKeith criteria~* Patients with pre-demential Alzheimer, diagnosed according Dubois criteria~* Patients with Alzheimer, diagnosed according MMSE~* Patients with bipolar disorder, diagnosed according DSM 5"
62625565|NCT03886584|ACTIVE_COMPARATOR|Healthy subjects|Healthy controls appaired in age, sex and educational level
62062532|NCT01028261|PLACEBO_COMPARATOR|Normal Saline|
62450294|NCT01338636|OTHER|Exercise-induced PAH|Open-label ambrisentan
62450295|NCT04204148||Clinical characteristics of the patients|including sex,age,smoking history,tumor location and tumor diameter
62450296|NCT04204148||Logistic regression analysis of influencing factors of c|The Leicester Cough Questionnaire in Mandarin Chinese (LCQ-MC) was used to evaluate the degree of cough in patients. The LCQ-MC is divided into three dimensions: physical, psychological and social. There are a total of 19 questions, and each question has seven options (positive scoring, grades 1-7; the higher the score is, the lighter the cough).
62450297|NCT03106090|NO_INTERVENTION|No SCP Control|Patients returning for early follow-up who did not receive SCP.
62450298|NCT03106090|NO_INTERVENTION|SOC SCP Control|Patients returning for early follow-up who received a standard of care SCP.
62450299|NCT03106090|EXPERIMENTAL|eSCP Intervention|"Patients currently receiving treatment who will be enrolled to receive an enhanced SCP (eSCP) with additional information beyond ASCO guidelines tailored to patient concerns and preferences."
62450300|NCT03801161|NO_INTERVENTION|Healthy infants|
62450301|NCT03801161|EXPERIMENTAL|Infants with an inflammatory condition|Investigators will also use pentavalent (PENTA) vaccine as a means to induce controlled inflammation (closely mimic to natural infection). PENTA is a combination of five different vaccine antigens (Hepatitis B (HBV)/ Haemophilus influenza type b (Hib) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
62450302|NCT02040766|EXPERIMENTAL|BDP 80 mcg BAI|"Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (40 mcg twice a day).~Placebo MDI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
62450303|NCT02040766|EXPERIMENTAL|BDP 160 mcg BAI|"Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (80 mcg twice a day).~Placebo MDI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
62450304|NCT02040766|ACTIVE_COMPARATOR|BDP 80 mcg MDI|"Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (40 mcg twice a day).~Placebo BAI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
62450305|NCT02040766|ACTIVE_COMPARATOR|BDP 160 mcg MDI|"Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (80 mcg twice a day).~Placebo BAI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
62625566|NCT04501952|EXPERIMENTAL|Remdesivir (RDV)|Participants will receive a single dose of intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2 and 3.
62625567|NCT04501952|PLACEBO_COMPARATOR|Placebo|Participants will receive IV placebo to match (PTM) RDV on Days 1 to 3.
62625568|NCT03504189|EXPERIMENTAL|PregSense™|PregSense™ wearable device and the standard of care CTG (cardiotocography) will be applied for maternal-fetal monitoring
62625569|NCT02417857|EXPERIMENTAL|Laparoscopic Cholecystectomy (SILC)|Group 1: Single Incision Laparoscopic Cholecystectomy (Intervention)
62625570|NCT02417857|EXPERIMENTAL|Laparoscopic Cholecystectomy (CLC)|Group 2: Conventional Laparoscopic Cholecystectomy (Intervention)
62625571|NCT02728817|ACTIVE_COMPARATOR|arteriovenous fistula (AVF)|Patient receiving a traditional arteriovenous fistula at the wrist (end-cephalic vein to side-radial artery)
62625572|NCT02728817|EXPERIMENTAL|RADAR|Patient receiving an arteriovenous fistula at the wrist using the Radial Artery Deviation And Reimplantation technique (end-radial artery to side-cephalic vein)
62625573|NCT01845571||Retinal detachment group|400 patients patients, who received surgery due to retinal detachment exclusion: if patients had prior vitrectomy or scleral buckel if patients have no adequate follow-up
62625574|NCT06045000|EXPERIMENTAL|[14C]-DC-806|Participants will receive a single oral dose of unlabeled DC-806 tablets followed by DC-806 capsule containing 3.7 MBq (100 μCi) of \[14C\]-DC-806 on Day 1.
62625575|NCT06462729|EXPERIMENTAL|LDGraft 0.5mg/cc|
62625576|NCT06462729|EXPERIMENTAL|LDGraft 1.0mg/cc|
62625577|NCT06462729|ACTIVE_COMPARATOR|Control Allograft Bone|
62625578|NCT06407492|ACTIVE_COMPARATOR|Conventional Physiotherapy|transcutaneous electrical nerve stimulation, Hotpack, US.
62625579|NCT06407492|EXPERIMENTAL|Leech Therapy|Leech Therapy
62625580|NCT06407492|EXPERIMENTAL|Kinesiotape|Kinesiotape Practice
62851269|NCT05909488|EXPERIMENTAL|EYESTEM 001-X|1.8 ml cell preparations are suspended in Conditioned Media (CM) until it reaches a 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected into the peribulbar.
62625581|NCT03061188|EXPERIMENTAL|Treatment (veliparib, nivolumab)|Patients receive veliparib PO BID on day 1 and nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4 and IV over 60 minutes on day 1 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62625582|NCT06014879|OTHER|Teen Videos|All participants in the teen video phase of this project will make brief videos about living well with type 1 diabetes. Guidance will be provided about requirements for the videos. Participants may make up to 4 brief videos. The videos will be used in the upcoming clinical trial of the new behavioral intervention.
62062533|NCT04585893|EXPERIMENTAL|Single Arm Rituximab|"The safety and efficacy of first-line rituximab will be assessed through a risk-stratified rituximab-based Multicentric Castleman disease (MCD) The planned sample size is 27 adult patients accrued at a rate of 10 patients annually.~High-risk patients (defined as patients with ECOG performance status \>2 or hemoglobin \<8 g/dL) will receive four weekly doses of rituximab (375 mg/m2) and etoposide (100 mg/m2).~Low-risk patients will receive the same dose of rituximab (four weekly doses at 375 mg/m2) alone."
62266867|NCT02195388||N-CR with AH|Patients after ACS with arterial hypertension don't treat with comprehensive cardiac rehabilitation.
62266868|NCT02195388||CR without AH|Patients after ACS without arterial hypertension treat with comprehensive cardiac rehabilitation
62266869|NCT02500121|PLACEBO_COMPARATOR|Control Arm A|Commercially available normal saline will be used as the placebo. No active placebo drug will be mixed with the normal saline. Treatment will continue, in the absence of prohibitive toxicities or disease progression, for up to 24 months.
62625583|NCT06014879|EXPERIMENTAL|Type 1 Doing Well (T1DW) Program|Youth with type 1 diabetes (ages 10-13) and their parents or legal guardians who are receiving care from enrolled diabetes care providers will be randomized to either the T1DW Program or the EUC Program. After being randomized to the T1DW Program at the orientation session, parents and youth will receive an overview of the web-based mobile application and intervention activities that they will engage with for 6 months. The app-based intervention activities include brief daily use of the app for parents to recognize and reinforce their child's positive diabetes-related behaviors, brief weekly activities for parents and youth to reflect on and discuss what the child has done well for diabetes, family diabetes goal-setting, and videos for parents and youth about living well with T1D. Parents and youth will also engage in a brief strengths-based conversation with their diabetes care provider at one medical appointment during the study period.
62625584|NCT06014879|ACTIVE_COMPARATOR|Diabetes-Related Information and Resources Program (Enhanced Usual Care; EUC)|Youth with type 1 diabetes (ages 10-13) and their parents or legal guardians who are receiving care from enrolled diabetes care providers will be randomized to either the T1DW Program or the EUC Program. After being randomized to the EUC Program at the orientation session, parents and youth will receive monthly email handouts with diabetes-related information and resources for 6 months.
62625585|NCT06014879|OTHER|Diabetes Care Provider|Diabetes care providers will deliver the provider portion of the intervention and will also be enrolled as study participants.
62851270|NCT05909488|EXPERIMENTAL|EYESTEM 001-XF|1.8 ml cell preparations are suspended in Conditioned Media (CM) until it reaches a 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected into the peribulbar.
62851271|NCT03903315||medical treatment alone|Patients with central malignant airway obstructions undergoing medical treatment alone
62851272|NCT03903315||endoscopic + medical treatment|Patients with central malignant airway obstructions undergoing medical and endoscopic treatment
62851273|NCT03838471||Central sensitization symptoms|This group will contain persons with a clinically relevant degree of symptoms of CS (CSI score ≥40).
62851274|NCT03838471||No Central sensitization symptoms|This group will contain persons with a lower degree of symptoms of CS (CSI score \< 40).
62266870|NCT02500121|EXPERIMENTAL|Experimental Arm B|Pembrolizumab, 200mg IV every 3 weeks. Treatment will continue, in the absence of prohibitive toxicities or disease progression, for up to 24 months.
62266871|NCT02195752||Prescribed Compounded Pain Cream|The study is limited to patients who have been prescribed treatment with a topical compounded pain cream as a component of their ordinary care by a qualified physician.
62625586|NCT04116775|EXPERIMENTAL|Treatment|"INITIAL TREATMENT PHASE: Patients progressing on enzalutamide will receive 200 mg of pembrolizumab IV over 30 minutes. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily and androgen deprivation therapy.~ASSESSMENT PHASE: After completion of the initial treatment phase, patients will have their disease assessed by tumor imaging. Patients who respond to treatment will become stool donors to patients who do not respond. Non-responders will move on to the retreatment phase.~RETREATMENT PHASE: Non-responders will undergo a fecal transplant and be retreated with 200 mg of pembrolizumab IV over 30 minutes. Treatment repeats every 3 weeks for an additional 4 cycles in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily and androgen deprivation therapy."
62266872|NCT03561571|ACTIVE_COMPARATOR|Butter based breakfast|
62266873|NCT03561571|ACTIVE_COMPARATOR|Chocolate spread based breakfast|
62266874|NCT06087055|EXPERIMENTAL|Period 1|GST-HG171/ritonavir orally
62266875|NCT06087055|EXPERIMENTAL|Period 2|Itraconazole+GST-HG171/ritonavir orally
62266876|NCT01452152|EXPERIMENTAL|Genotype-directed, clopidogrel|Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.
62266877|NCT01452152|EXPERIMENTAL|Genotype-directed, prasugrel|Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.
62266878|NCT01452152|NO_INTERVENTION|Standard of Care|Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.
62266879|NCT05121974|EXPERIMENTAL|Tebipenem-pivoxil arm (Pilot study)|Oral Tebipenem-pivoxil in children with shigellosis
62625587|NCT00869128|OTHER|Placebo First|Subjects were treated for 3 weeks with 1 tablet per night of Placebo and then with 2 mg melatonin (Circadin).
62266880|NCT05121974|ACTIVE_COMPARATOR|Azithromycin arm (Pilot study)|Oral Azithromycin in children with shigellosis
62625588|NCT00869128|OTHER|Circadin first|Subjects were treated for 3 weeks with 1 tablet per night of 2 mg melatonin (Circadin) and then with placebo.
62625589|NCT05924841|EXPERIMENTAL|Study treatment|Participants received BL-B01D1 monotherapy, SI-B003 monotherapy or BL-B01D1 plus SI-B003 dual therapy in the first cycle (3 weeks). Participants who had a clinical benefit could receive additional cycles of additional treatment. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
62266881|NCT05121974|EXPERIMENTAL|Tebipenem-pivoxil arm (Main trial)|Oral Tebipenem-pivoxil in children with shigellosis
62266882|NCT05121974|ACTIVE_COMPARATOR|Ceftriaxone arm (Main trial)|Intravenous Ceftriaxone in children with shigellosis
62266883|NCT05381818|EXPERIMENTAL|Daily IMT (dIMT)|IMT (inspiratory muscle training) is a treatment strategy aimed to strengthen the muscles of inspiration, the diaphragm and external intercostals, by increasing their force-generating capacity. Participants in the dIMT (daily IMT) will complete daily inspiratory training exercises 2-4 weeks prior to surgery. A pressure threshold training device containing an adjustable-tension spring to provide resistance during inspiration will be used. Subjects will complete 5 sets of 5 maximal volume and speed breaths daily at a pressure 70% of MIP and will rest 1 minute between sets. They will be asked to keep a log to track their sessions to evaluate compliance with the exercise regimen.
62450306|NCT02040766|PLACEBO_COMPARATOR|Placebo BAI and MDI|"Placebo was administered via breath-actuated inhaler (BAI) twice daily. Additionally placebo was administered via metered-dose inhaler (MDI) twice daily.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
62266884|NCT05381818|ACTIVE_COMPARATOR|Acute IMT (aIMT)|Patients in the aIMT (acute IMT) experimental group will complete a single session of IMT guided by a physical therapist within 30 minutes of anesthesia induction in addition to standard of care. The adjustable pressure threshold training device to provide resistance during inspiration will be used. Subjects will complete 5 sets of 5 maximal volume and speed breaths, and rest 1 minute between sets. The training intensity will be set at 70% of MIP.
62266885|NCT05381818|ACTIVE_COMPARATOR|Standard of Care (SOC)|The SOC group will receive the usual surgical standard of care only.
62450307|NCT04484337|EXPERIMENTAL|Part 1:Cohort 1: CAB 400 mg/mL IM gluteal|
62450308|NCT04484337|ACTIVE_COMPARATOR|Part 1:Cohort 1: CAB 200 mg/mL IM gluteal|
62450309|NCT04484337|EXPERIMENTAL|Part 1:Cohort 2: CAB 400 mg/mL SC abdominal|
62450310|NCT04484337|ACTIVE_COMPARATOR|Part 1:Cohort 2: CAB 200 mg/mL SC abdominal|
62625590|NCT02371876|EXPERIMENTAL|Users of the Monitoring System|Untrained subjects with diabetes used the ONYX PLUS Investigational Blood Glucose Monitoring System.
62625591|NCT03967041||Sarcopenic patients|
62087968|NCT04321200||Cross-sectional-150 infants (atypical vs typical)|Arm (Study)1: To assess the concurrent validity of a multimodal instrumented gym with existing clinical tools. Here, using 150 infants, we will focus on converting data from an instrumented gym into estimates of the standard clinical tests.
62450311|NCT04484337|EXPERIMENTAL|Part 1:Cohort 3: CAB 400 mg/mL IM (lateral thigh)|
62625592|NCT03967041||Non-sarcopenic patients|
62625593|NCT05834218|EXPERIMENTAL|split-body resistance training|"Split-group training regime:~Day 1 (Leg press, Stiffed-legged deadlift, Leg extension, Hip thrust) 3x12 repetitions for each exercise Day 2 ( Lat pulldown, Bench press, Cabled seated row)3x12 reps (Triceps press and biceps curls in cable (superset) Day 3 (Day 1 exercise repeated) Day 4 (Day 2 exercise repeated)"
62625594|NCT05834218|ACTIVE_COMPARATOR|Full body resistance training|"Full body training regime:~Day 1 (Leg press, Stiffed-legged deadlift, Leg extension, Hip thrust, Lat pulldown, Bench press, Cabled seated) 3x12 reps for each exercise, (Triceps press and biceps curls in cable (superset) Day 2 (Repeat first day exercise)"
62851275|NCT05499299|ACTIVE_COMPARATOR|Government|Participants were shown with the government slogan for the COVID-19 vaccine campaign in 2021. This was the control arm.
62851276|NCT05499299|EXPERIMENTAL|Comparison|The ad emphasized that vaccine uptake in Hong Kong substantially lagged behind that in comparable populations such as Singapore and the UK.
62851277|NCT05499299|EXPERIMENTAL|Exemption|The ad emphasized that vaccinated people could be exempted from some disruptive control measures such as mandatory testing
62851278|NCT05499299|EXPERIMENTAL|Family|The ad prompted people to get vaccinated in order to protect their family.
62851279|NCT05499299|EXPERIMENTAL|Lottery|The ad prompted people to get vaccinated in order to be eligible for the numerous COVID-19 lotteries in Hong Kong
62851280|NCT05499299|EXPERIMENTAL|Mortality|The ad emphasized that COVID-19 has caused millions of deaths worldwide.
62851281|NCT05499299|EXPERIMENTAL|Reopen|The ad prompted people to get vaccinated to help Hong Kong reopen sooner.
62851282|NCT05693012||Cancer Arm|participants with newly diagnosed multiple myeloma, from whom blood samples will be collected.
62851283|NCT05693012||Benign Arm|Participants with newly diagnosed benign hematologic disorders, from whom blood samples will be collected.
62851284|NCT05693012||Healthy arm|Participants without known presence of malignancies or certain benign diseases, from whom blood samples will be collected.
62851285|NCT05646524|EXPERIMENTAL|Cohort 1|6 subjects will receive an intravenous (IV) infusion of NM8074 at 20 mg/kg every two weeks.
62851286|NCT05646524|EXPERIMENTAL|Cohort 2|6 subjects will receive an intravenous (IV) infusion of NM8074 at 10 mg/kg weekly for four weeks followed by a 20 mg/kg dose of NM8074 every two weeks for the remainder of the treatment period.
62851287|NCT02891070|EXPERIMENTAL|FS VH S/D 500 s-apr|FS VH S/D 500 s-apr (Tisseel), single use treatment, intraoperative
62851288|NCT02891070|ACTIVE_COMPARATOR|DuraSeal Dural Sealant|DuraSeal Dural Sealant, single use treatment, intraoperative
62625595|NCT01839071|OTHER|biopsy of fat tissue|
62625596|NCT00866112|EXPERIMENTAL|1|Intervention group to promote physical activity
62625597|NCT00866112|OTHER|2|Minimal contact control group
62625598|NCT01190904||Coronary Artery Disease (≥50%) with or without PCI|We propose to investigate four specific aims using 1,143 diabetic men who have CAD (≥50%) lesion in at least one major epicardial vessel with or without PCI.
62625599|NCT00565604|EXPERIMENTAL|Short Catheter Delviery|Patients with duplex ultrasound documented incompetent perforator veins will be treated using a short catheter delivery system in conjunction with a Bright Tip Laser fiber.
62625600|NCT01266005|EXPERIMENTAL|1|Clevudine 30mg
62625601|NCT01266005|ACTIVE_COMPARATOR|2|Entecavir 0.5mg
62851289|NCT04453553|ACTIVE_COMPARATOR|Standard of care|Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14
62851290|NCT04453553|EXPERIMENTAL|Near Patient Testing|Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14, with the addition of daily nasal swabs tested via rapid test system
62851291|NCT02894697|ACTIVE_COMPARATOR|Angiography-guidance|
62851292|NCT02894697|EXPERIMENTAL|OCT-guidance|
62851293|NCT03542396|EXPERIMENTAL|ImPuls|Participants receive an supervised exercise intervention and behaviour change techniques for 4 weeks and, after that, they are encouraged to engage in physical activity for 8 weeks independently. During this 8-week individual phase, patients have weekly phone contacts with a psychotherapist
62851294|NCT03542396|NO_INTERVENTION|Control|Participants do not receive any intervention. Participants receive treatment as usual, which means they are on a waiting list of an outpatient unit to receive individual psychotherapeutic treatment
62851295|NCT04502940||Mild pancreatitis|Patients with mild acute biliary pancreatitis according to Atlanta classification
62851296|NCT04502940||Moderate Pancreatitis|Patients with moderate acute biliary pancreatitis according to Atlanta classification
62851297|NCT04502940||Severe pancreatitis|Patients with severe acute biliary pancreatitis according to Atlanta classification
62851298|NCT04502940||Control|Healthy volunteers
62087969|NCT04321200||Longitudinal cohort - 50 infants (atypical vs typical)|Arm (Study) 2: To discover the features related to long-term motor development. Here we will convert data collected longitudinally from 50 infants, using both instrumented gym and video recordings, into estimates standard clinical tests change over time and track features over developmental timescales.
62450312|NCT04484337|ACTIVE_COMPARATOR|Part 1:Cohort 3: CAB 200 mg/mL IM (lateral thigh)|
62450313|NCT04484337|EXPERIMENTAL|Part 1: Cohort 4: CAB 400 mg/mL (IM or SC)|
62450314|NCT04484337|ACTIVE_COMPARATOR|Part 1: Cohort 4: CAB 200 mg/mL (IM or SC)|
62450315|NCT04484337|EXPERIMENTAL|Part 2: Cohort 5: CAB 400 mg/mL IM (gluteus medius)|
62625602|NCT01556555||Primary sclerosing cholangitis|Patients with a definite diagnosis of sclerosing cholangitis and a clinical indication for ERCP.
62851299|NCT04825730|EXPERIMENTAL|Long Term Follow-up after Jointstem Transplantation|
62851300|NCT01311167|EXPERIMENTAL|Dexamethasone|
62851301|NCT01311167|PLACEBO_COMPARATOR|Placebo|
62851302|NCT02796417|EXPERIMENTAL|Rehacop group|Cognitive rehabilitation
62851303|NCT02796417|ACTIVE_COMPARATOR|Control group|Occupational activities
62625603|NCT03939650|EXPERIMENTAL|Diaana|"1. The patient fulfill Diaana~2. The resident physician reads the Diaana summary~3. The resident physician see the patient in consultation. He establishes his DD without having access to the complementray exams (blood tests, x-ray, ...)~4. The senior physician see the patient at the follow-up consultation. He establishes the gold-standard diagnosis highlighted by complementary exams and imagery."
62625604|NCT03939650|NO_INTERVENTION|Control|"1. The resident physician see the patient in consultation. He establishes his DD without having access to the complementray exams (blood tests, x-ray, ...)~2. The senior physician see the patient at the follow-up consultation. He establishes the gold-standard diagnosis highlighted by complementary exams and imagery."
62625605|NCT05802303|ACTIVE_COMPARATOR|Transdermal Gel|In the Estradiol gel group patients will be administered transdermal Estradiol gel (17-beta Estradiol gel 0.06%)
62625606|NCT05802303|OTHER|Oral Estradiol|In the Oral Estradiol group, all women will be given oral Estradiol valerate tablets
62625607|NCT04522570|ACTIVE_COMPARATOR|laser ablation|Percutaneous Laser Ablation for the treatment of metastatic cervical lymph nodes with \> 0.8 cm diameter with biopsy-proven diagnosis of differentiated thyroid carcinoma or medullary thyroid carcinoma.
62625608|NCT04522570|ACTIVE_COMPARATOR|cryoablation|Percutaneous cryoablation for the treatment of metastatic cervical lymph nodes with \> 0.8 cm diameter with biopsy-proven diagnosis of differentiated thyroid carcinoma or medullary thyroid carcinoma.
62625609|NCT04522570|ACTIVE_COMPARATOR|Radiofrequency ablation|Percutaneous radio frequency ablation for the treatment of metastatic cervical lymph nodes with \> 0.8 cm diameter with biopsy-proven diagnosis of differentiated thyroid carcinoma or medullary thyroid carcinoma.
62625610|NCT02213770||Intervention group|Group that followed high- intensity interval training program in TEX study.
62266886|NCT03937180|OTHER|Usual care|Patients will receive 'usual care' left at the discretion of the treating general practitioner (GP). They are expected to follow the Belgian guidelines, which propose education of the patient about the harmful effects of chronic benzodiazepines and z-drugs ((z-)BZD) use, the alternatives, and the advice to discontinue (z-)BZD use. A stepped approach is recommended. First, a minimal intervention strategy such as a discontinuation letter or a short advice is applied. If unsuccessful, a brief intervention, which may span one or more consults, is recommended. During such an intervention, the GP will - based on the principles of motivational interviewing- assess the patient's readiness for change and match the appropriate intervention. A tapering scheme will be developed which typically consists of a 10-20% reduction in the daily dose of the (z-)BZD every 2-4 weeks.
62266887|NCT03937180|EXPERIMENTAL|Blended care|Usual care is supported by the use of an interactive e-tool. The e-tool provides psycho-education about sleep and sleep medication, and exercises featuring cognitive behavioural techniques to enhance the self-management of the patient. It's purpose is to motivate patients to discontinue the use of (z-)BZD, to adapt alternative remedies and to support them in this process. The patient can grant the participating GP access to all his answers in the e-tool, making it possible to discuss their findings and experiences face-to-face. During consultations, the GP will also assess the patients' readiness for change and match the appropriate intervention. A tailored gradual taper of the (z-)BZD will be agreed upon, which typically consists of a 10-20% reduction in the daily dose every 2-4 weeks. Follow-up appointments are scheduled depending on the needs of the patient until the end of dose reduction.
62625611|NCT02213770||Control group|Followed up on a regular basis for HTx recipients in Norway.
62625612|NCT00311753|EXPERIMENTAL|1|Certoparin
62625613|NCT00311753|ACTIVE_COMPARATOR|2|Heparin
62266888|NCT06470269||Expert|Physicians
62062534|NCT02914314|EXPERIMENTAL|Perampanel up to 12 or 16 mg/day|Pediatric participants, ranging from 1 month to less than 4 years of age, will receive perampanel oral suspension once a day in titration period starting at Week 0 at a dose of 0.50 mg per day (mg/day) titrated up to 4 mg/day (for participants taking non-EIAED) or up to 8 mg/day (for participants taking EIAED). Depending on participants clinical response, tolerability and investigator's decision, dose can be up titrated to 6 mg/day (for participants taking non-EIAED) and up titrated to 8 mg/day (for participants taking EIAED). Dose titration must not exceed 12 mg/day (non-EIAED) and 16 mg/day (EIAED). Participants will continue taking the perampanel oral suspension at dose level achieved at end of titration period through maintenance period of core study and maintenance period of extension phase (Up to Week 52).
62062535|NCT03117283|EXPERIMENTAL|LTG with Bursectomy|laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach
62450316|NCT04484337|ACTIVE_COMPARATOR|Part 2: Cohort 5: CAB 200 mg/mL IM (gluteus medius)|
62625614|NCT02922465|EXPERIMENTAL|K-877 & Clopidogrel|K-877 \& Clopidogrel orally
62625615|NCT01843803|EXPERIMENTAL|patient inventory tool|prior to the encounter with his/her provider, the patient completes an inventory that includes information about patient contextual factors (e.g., life circumstances), resources and preferences for care delivery. This information is presented to the provider to facilitate care delivery.
62266889|NCT06470269||Novice|Medical Students
62450317|NCT04484337|EXPERIMENTAL|Part 2: Cohort 6: CAB 400 mg/mL IM (gluteus medius)|
62450318|NCT04484337|ACTIVE_COMPARATOR|Part 2: Cohort 6: CAB 200 mg/mL IM (gluteus medius)|
62450319|NCT04484337|EXPERIMENTAL|Part 1: Cohort 4b: CAB 400 mg/mL (SC)|
62625616|NCT01843803|ACTIVE_COMPARATOR|attention control|prior to the encounter, the patient will view a brief video containing general health information.
62625617|NCT01874626|ACTIVE_COMPARATOR|Active|SST-0225 Topical Ibuprofen Cream (investigational product) Dose: 2.7 grams of cream containing 200 mg ibuprofen
62625618|NCT01874626|PLACEBO_COMPARATOR|Placebo|Placebo topical formulation (Reference product)
62851304|NCT02766140|EXPERIMENTAL|SHR1020 plus Docetaxel|
62062536|NCT03117283|SHAM_COMPARATOR|LTG without Bursectomy|laparoscopic D2 radical total gastrectomy without bursectomy
62266890|NCT03902509|EXPERIMENTAL|Pirfenidone|pirfenidone + basic treatment
62266891|NCT03902509|OTHER|Controll|with basic treatment and without pirfenidone treatment
62450320|NCT04484337|EXPERIMENTAL|Part 1: Cohort 4h: CAB 400 mg/mL (SC)|
62450321|NCT04484337|ACTIVE_COMPARATOR|Part 1: Cohort 4h: CAB 200 mg/mL (SC)|
62450322|NCT01665170|PLACEBO_COMPARATOR|Placebo|Placebo arm
62450323|NCT01665170|ACTIVE_COMPARATOR|Verum|Verum arm - Pascoflair 425mg
62851305|NCT02766140|PLACEBO_COMPARATOR|Placebo plus Docetaxel|
62266892|NCT01805622|EXPERIMENTAL|Passive Arm #1|Active Arm #1, 2; Passive Arm #1, 2 Community coalitions randomized to the Passive Arm #1-Web Access Without Technical Assistance will receive access to EPICS facilitator training materials and toolkits via the Research-Tested Intervention Programs (RTIPs) website and will not participate in monthly technical assistance teleconferences.
62266893|NCT01805622|EXPERIMENTAL|Passive Arm #2|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to the Passive Arm #2-Web Access With Technical Assistance will receive access to EPICS facilitator training materials and toolkits via the Research-Tested Intervention Programs (RTIPs) website and will participate in monthly technical assistance teleconferences.
62266894|NCT01805622|ACTIVE_COMPARATOR|Active Arm #1|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to Active Arm #1-In-Person Access Without Technical Assistance will receive training from intervention developers with access to facilitator training materials but will not participate in monthly technical assistance teleconferences.
62062537|NCT03166371|EXPERIMENTAL|Liposomal Glutathione (GSH)|Participants will be randomized to receive two teaspoons containing 840 mg GSH (420 mg/tsp) twice daily for 90 days after discharge from Emory University Hospital (EUH).
62266895|NCT01805622|ACTIVE_COMPARATOR|Active Arm #2|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to Active Arm #2-In-Person Access with Technical Assistance will receive training from intervention developers with access to facilitator training materials and will participate in monthly technical assistance teleconferences.
62266896|NCT01689298|ACTIVE_COMPARATOR|No drug pre-treatment|A control sample from each patient (no uterotonic drug will be applied during pre-treatment) will be measured concurrently with samples pre-treated with oxytocin. Controls will undergo the same dose response of oxytocin or carbetocin after pre-treatment period as the groups given oxytocin for pre-treatment.
62266897|NCT01689298|ACTIVE_COMPARATOR|Drug pre-treatment|A sample from each patient will be pre-treated with oxytocin 10-5mol/L. These samples will undergo the same dose response of oxytocin or carbetocin after pre-treatment period as the groups given no drug for pre-treatment (controls).
62266898|NCT06302907|ACTIVE_COMPARATOR|Buffered LA|AA buffered 2% lidocaine with 1:80000 epinephrine and sodium bicarbonate 8.4% was used for one site
62266899|NCT06302907|ACTIVE_COMPARATOR|Unbuffered LA|an unbuffered 2% lidocaine with 1: 80000 epinephrine for the other site at the same appointment.
62851306|NCT02990624|ACTIVE_COMPARATOR|High risk group|Patients with psoriasis and atherosclerosis will receive PUVA therapy for 36 sessions divided as 3 sessions weekly
62266900|NCT02561598||Malignant Hyperthermia|Samples from persons who have a malignant hyperthermia diagnosis.
62062538|NCT03166371|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive a placebo product identical to liposomal glutathione (GSH) twice daily for 90 days after discharge from Emory University Hospital (EUH).
62625619|NCT05122780|ACTIVE_COMPARATOR|"Precision medicine approach"|"Comprehensive diagnostic work-up with:~* Coronary angiography and ventriculography in all patients~* OCT at the time of coronary angiography in the cath-lab.~* Acetylcholine provocative test (to assess the presence of coronary vasospasm) at the time of coronary angiography in the cath-lab.~* TE-Echo and/or CE-Echo (if distal/microvascular embolization is suspected)~* Blood sampling for circulating biomarkers and miRNA expression profile~* Trans-thoracic echocardiography in all patients during the index hospitalization~* CMR in all cases during the index hospitalization.~Targeted pharmacological treatment specific for the underlying cause:~* DAPT ± stent implantation (if required), statins, beta-blockers, ACEi/ARB (in case of evidence of plaque rupture/erosion)~* CCB and/or nitrates (in case of documentation of coronary vasospasm)~* Anticoagulation (in case of coronary embolism)."
62625620|NCT05122780|OTHER|"Standard approach"|"Routine diagnostic work-up with:~* Coronary angiography and ventriculography~* Transthoracic echocardiography in all patients during the index hospitalization~* CMR with contrast media only if clinically indicated (i.e. to exclude myocarditis or takotsubo syndrome)~Standard medical treatment with:~* DAPT in all patients~* Beta-blockers (if indicated by the clinical context, i.e. documentation of left ventricular ejection fraction \<50%, tachycardia).~* High intensity statins in all patients~* ACEi/ARB (if clinically indicated)."
62625621|NCT00460239|EXPERIMENTAL|Placebo|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
62851307|NCT02990624|ACTIVE_COMPARATOR|Low risk group|Patients with psoriasis but no atherosclerosis detected, will receive PUVA therapy for 36 sessions divided as 3 sessions weekly
62851308|NCT02990624|NO_INTERVENTION|Control group|Age-matching apparently normal individuals will receive no interventions but will perform investigational tests.
62062539|NCT01741116|EXPERIMENTAL|TKI258, inhibitor of RTKs|"Intervention: TKI258~Investigational drug, TKI258, will be administered to all of the patients after enrollments. Treatment will initially be administered as 28-day cycles as follows:~- Daily 500mg of TKI258 will be self-administered orally by the patient for 5 days, followed by 2 days of treatment off."
62266901|NCT02561598||Controls|Children who participated in pharmacogenetic research and had exposure to malignant hyperthermia triggering agents.
62266902|NCT05605600||Patients with Low Anterior Resection Syndrome|Patients with lived-experience of anterior resection surgery, who may or may not have subsequently developed bowel dysfunction symptoms, will be invited to take part in a focus group. They will discuss a new questionnaire and the phrasing of the questions, ensuring clarity and reducing the potential variability in interpretation of each question.
62266903|NCT05364242|EXPERIMENTAL|VLA2001|
62266904|NCT03302715|EXPERIMENTAL|Mucosal biopsies|Only blood samples and mucosal biopsies
62266905|NCT05468632||Glucagon like peptide-1 (GLP-1) naive participants with Type 2 Diabetes (T2D)|Glucagon like peptide-1 (GLP-1) naive adult type 2 diabetes (T2D) participants who initiated once weekly (OW) semaglutide were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion.
62266906|NCT04502251|ACTIVE_COMPARATOR|LDN + tDCS|Low Dose Naltrexone and Transcranial Direct Current Stimulation
62851309|NCT00921167|EXPERIMENTAL|Bevacizumab/Irinotecan|
62851310|NCT02549599|OTHER|Delayed Treatment|Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered.
62851311|NCT02549599|EXPERIMENTAL|Chat/Text Program|Participants will receive real-time answers to questions they have about sexual and reproductive health topics from trained chat agents via the digital intervention program.
62851312|NCT02549599|OTHER|Website Content|Participants will be routed to the Planned Parenthood website to information and content about issues regarding sexual and reproductive health.
62851313|NCT05739084||Retrospective cohort|A total sample size of 200 patients is expected in the retrospective thanks to the NETSARC/ CONTICABASE databases (French sarcoma reference network)
62851314|NCT05739084||Prospective cohort|"To ensure an external validation, patients from NETsarc centers experiencing preoperative RT will be prospectively accrued and transcriptomic signature will be tested.~Up to 100 patients will be enrolled in this prospective cohort."
62851315|NCT00301184|EXPERIMENTAL|1A|One 0.3 mg dose of DNA HIV vaccine or placebo administered at study entry and Month 2, followed by one dose of 1x10\^7 TCID50 MVA or placebo at Months 4 and 6
62851316|NCT00301184|EXPERIMENTAL|1B|One 3.0 mg dose of DNA HIV vaccine or placebo administered at study entry and Month 2, followed by one dose of 1x10\^8 TCID50MVA or placebo administered at Months 4 and 6
62851317|NCT00301184|EXPERIMENTAL|2A|One MTD (determined in Part 1) of DNA HIV vaccine or placebo administered at study entry. One dose of placebo or MTD of MVA at Months 2 and 6
62851318|NCT00301184|EXPERIMENTAL|2B|One dose of placebo or MTD of MVA administered at study entry and Months 2 and 6
62851319|NCT02730780|OTHER|African-American|40 healthy African-American subjects will be enrolled and each will undergo study procedures at 4 separate visits, with each visit occurring 7-days apart. After a baseline visit, the subject will begin either a low-salt or high-salt diet, based upon randomization assignment to one of the two following dietary protocols: A) low-salt diet, washout, then high-salt diet; or B) high-salt diet, washout, then low-salt diet. Each dietary or washout period lasts for 7 days.
62266907|NCT04502251|SHAM_COMPARATOR|LDN + Sham tDCS|Low Dose Naltrexone and Sham Transcranial Direct Current Stimulation
62266908|NCT04502251|PLACEBO_COMPARATOR|Placebo + tDCS|Placebo and Transcranial Direct Current Stimulation
62625622|NCT00460239|EXPERIMENTAL|Morphine 15|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
62625623|NCT00460239|EXPERIMENTAL|Morphine 30|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
62625624|NCT00460239|EXPERIMENTAL|Buprenorphine 8|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
62625625|NCT00460239|EXPERIMENTAL|Buprenorphine 16|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
62625626|NCT00460239|EXPERIMENTAL|Buprenorphine 32|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
62625627|NCT00460239|EXPERIMENTAL|Buprenorphine 48|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
62625628|NCT00460239|EXPERIMENTAL|Buprenorphine 60|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
62625629|NCT04953143|EXPERIMENTAL|Pilot|"Inpatient longitudinal palliative care intervention that includes the following domains:~* Therapeutic relationship: Developing trust and credibility with patients and their families~* Symptom management: Proactive symptom management for common advanced liver disease symptoms including pain, fatigue, anorexia, breathlessness, depression and anxiety~* Coping with illness: Introduction of strategies to improve adjustment and meaning in life; bolstering caregiver coping~* Prognostic awareness and illness understanding: Assessing patients' level of prognostic awareness and discussing strategies to help patients cope with uncertainty~* Treatment decision-making: Supporting patients and caregivers in their medical decision-making and assessing their values in decision-making~* End-of-life care: Review/discuss selection of healthcare proxy, preferences for end-of-life care"
62625630|NCT06172738|EXPERIMENTAL|group A.|surgical closure of the left atrial appendage.
62625631|NCT06172738|NO_INTERVENTION|group B.|There was no surgical closure of the left atrial appendage.
62625632|NCT06549738|EXPERIMENTAL|Treatment|"Lympha Press Treatment. While the first IPCD treatment takes place in Visit 2, subjects will be educated on the use of the IPCD and the protocol they will follow for the home treatment phase. During the hour-long treatment session in the clinic, the pressure will be gradually increased per subject tolerance starting at 20 mm Hg. Subjects will be instructed to use the IPCD at home for 1-2 hours a day, with pressure set to patient tolerance (recommended setting of 45 mmHg).~In addition to IPCD treatment, subjects will be provided compression leggings at Visit 1 and instructed to wear them daily during all waking hours until Visit 3."
62851320|NCT02730780|OTHER|Whites|40 healthy white subjects will be enrolled and each will undergo study procedures at 4 separate visits, with each visit occurring 7-days apart. After a baseline visit, the subject will begin either a low-salt or high-salt diet, based upon randomization assignment to one of the two following dietary protocols: A) low-salt diet, washout, then high-salt diet; or B) high-salt diet, washout, then low-salt diet. Each dietary or washout period lasts for 7 days.
62062540|NCT00015821|EXPERIMENTAL|Treatment (thalidomide)|Patients receive oral thalidomide once daily for 1 year in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may receive 1 additional year of therapy.
62266909|NCT04502251|OTHER|Placebo + Sham tDCS|Placebo and Sham Transcranial Direct Current Stimulation
62851321|NCT02778113|EXPERIMENTAL|Nasal Glucagon (NG) - 0.5 mg|Ng dose at 0.5 milligram (mg) administered once in one of four study periods.
62266910|NCT04370080|EXPERIMENTAL|Silver Diamine Fluoride|Topical application of one drop of silver diamine fluoride 38% to active untreated roof surface caries, lesions at the furcation, or lesions at crown margins. Application was repeated once each six months.
62266911|NCT03837470|EXPERIMENTAL|Saline Loading and Diuretic Challenge|Subjects receive intravenous infusion of 0.9% Sodium Chloride, followed by diuretic challenge with bolus injection of Furosemide 40 mg
62851322|NCT02778113|EXPERIMENTAL|NG - 1.0 mg|Ng dose at 1.0 milligram (mg) administered once in one of four study periods.
62625633|NCT06549738|NO_INTERVENTION|Control|Subjects will be provided compression leggings at Visit 1 and instructed to wear them daily during all waking hours until Visit 3.
62851323|NCT02778113|EXPERIMENTAL|NG - 2.0 mg|Ng dose at 2.0 milligram (mg) administered once in one of four study periods.
62851324|NCT02778113|ACTIVE_COMPARATOR|SC Glucagon 1 mg|Subcutaneous (SC) glucagon dose of 1 mg, in one of four study periods.
62851325|NCT04760743|EXPERIMENTAL|low dose level cohort|2 dose of NBP2001 adjuvanted with alum (Receptor Binding domain (RBD) 30μg/dose), 1 dose each on Day 0 and 28
62851326|NCT04760743|EXPERIMENTAL|high dose level cohort|2 dose of NBP2001 adjuvanted with alum (Receptor Binding domain (RBD) 50μg/dose), 1 dose each on Day 0 and 28
62851327|NCT04760743|PLACEBO_COMPARATOR|Placebo group|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
62266912|NCT02984046|EXPERIMENTAL|acute bronchiolitis|Prospective, monocentric, case-control and study Primary end-point: correlation between serum CC16 level and severity of the bronchiolitis, evaluated by a clinical scoring system
62266913|NCT05110053|ACTIVE_COMPARATOR|Active|All patients will receive surgery with implantation of a SCS device. Patients randomized to the active arm, will receive active stimulation. However, for the purposes of this study, the stimulation paradigm and intensity is designed to be below perceptional thresholds so as to assure appropriate blinding. Blinding will continue for 6 months, followed by a 6 month voluntary open-phase, active extension.
62625634|NCT03558685|EXPERIMENTAL|Diet|Nutritional recommendation consisted of moderate caloric restriction, set at 25% to 30% less than calories needed for resting metabolic rate. We applied a high protein Mediterranean diet with the following food group distribution: 30% as protein (\> 0.8 g/kg/d); 40% as carbohydrates with medium/low glycemic index; 30% as fat (≥10%monounsaturated fatty acid, ≤7% saturated fatty acid, no trans fats, and 1.6 g omega-3 for men and 1.1 g omega-3 for women). Diet was rich in olive oil, fish, chicken, nuts, white milk products, fruits, and vegetables but low in artificial sugars, commercial sweets, pastries, butter, margarine, and red meat. Dietary fiber content ≥25 g/day
62625635|NCT01765569|EXPERIMENTAL|Vemurafenib + Digoxin|Single oral dose of digoxin 0.25 mg tablet on Day 1 in Period A, followed by vemurafenib 960 mg tablet orally BID from Day 8 to Day 28 in Period B, and then single oral dose of digoxin 0.25 mg on Day 29, and vemurafenib 960 mg orally BID from Day 29 to Day 35 in Period C.
62625636|NCT04378595||During Pandemic|During Pandemic: The investigators will query the parent/guardian with the 2-question food insecurity validated tool during their regular appointment, either in person or on the phone/telehealth. If a positive response is given, the investigators will ask if the food insecurity began or worsened during the pandemic in the past 1 to 2 months.
62625637|NCT04378595||Post-Pandemic|Post-Pandemic: The investigators will query the parent/guardian with the 2-question food insecurity validated tool during their regular appointment, either in person or on the phone/telehealth. The investigators will assess if food insecurity has stopped or lessened after the pandemic.
62266914|NCT05110053|PLACEBO_COMPARATOR|Placebo|All patients will receive surgery with implantation of a SCS device. Patients randomized to the placebo-arm of the trial will have the device switched of or set to a stimulation intensity of zero. Blinding will continue for 6 months, followed by a 6 month voluntary open-phase, active extension.
62266915|NCT04453046|EXPERIMENTAL|Hemopurifier and Pembrolizumab|In this clinical trial, the exosome-depleting device, the Hemopurifier, will be combined with standard of care therapy, Pembrolizumab. The purpose of the combination is to more effectively reduce immune suppression and provide a combined benefit of immune restoration for patients with recurrent/metastatic HNSCC. Therapy with the Hemopurifier will be initiated on the same day as and prior to Pembrolizumab infusion. The Hemopurifier treatment will be 4h. The subject treated with the Hemopurifier will remain in the Hemopurifier treatment area for the duration of the treatment. Pembrolizumab infusion will take place shortly after Hemopurifier treatment and may take place through the next day if needed.
62450324|NCT04502342|ACTIVE_COMPARATOR|Hydroxychloroquine/Azythromycin|Patients received Hydroxychloroquine 200 mg tablet orally 3 times daily for 10 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days.
62450325|NCT04502342|EXPERIMENTAL|Cospherunate/Azithromycine|Patients received Cospherunate (50 mg Artésunate/125 mg Amodiaquine) at the rate of 2 tablets orally twice daily for 6 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days.
62450326|NCT04502342|EXPERIMENTAL|Cospherunate/Phytomedicine/Azithromycine|Patients received Cospherunate (50 mg Artésunate/125 mg Amodiaquine) at the rate of 2 tablets orally twice daily for 6 days and Phytomedicine tablet 350 mg at the rate of 2 tablets orally twice daily for 6 days, and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days.
62625638|NCT04982744||Patients affected by Li Fraumeni and Li Fraumeni Like syndromes|The group comprises all patients affected by Li Fraumeni and Li Fraumeni Like syndromes
62625639|NCT00645372|ACTIVE_COMPARATOR|A|
62625640|NCT00645372|EXPERIMENTAL|B|
62625641|NCT02629185||normal weight|BMI 18.5 to 25.0 Healthy men and women ages 25-40 and 55-75
62625642|NCT02629185||overweight|BMI 25.0 to 30.0 Healthy men and women ages 25-40 and 55-75
62625643|NCT02629185||obese|BMI over 30.0 Healthy men and women ages 25-40 and 55-75
62625644|NCT04245176|EXPERIMENTAL|Quantitative Genetic Counseling|"The research study procedures include screening for eligibility and study interventions including evaluations and follow up visits - After receiving genetic testing, participants will be placed into one of two counseling methodology groups:~-- Quantitative genetic counseling: Discussion is guided by tables and graphs."
62062541|NCT03668262||0.15mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.
62625645|NCT04245176|ACTIVE_COMPARATOR|STANDARD GENETIC COUNSELING|"The research study procedures include screening for eligibility and study interventions including evaluations and follow up visits - After receiving genetic testing, participants will be placed into one of two counseling methodology groups:~-- Standard genetic counseling: Standard of care discussion"
62851328|NCT01764919|EXPERIMENTAL|[124I]FIAU|Single intravenous injection of \[124I\]FIAU in patients with diabetic foot infection
62851329|NCT00658164|EXPERIMENTAL|1|
62851330|NCT00544700|ACTIVE_COMPARATOR|Arm A: Bevacizumab monotherapy|Bevacizumab maintenance monotherapy
62851331|NCT00544700|OTHER|Arm B: No maintenance|No antitumor treatment until progression
62851332|NCT06138860|EXPERIMENTAL|strain counter strain technique|the patients will receive strain counter strain technique plus physical therapy exercises three times a week for four weeks
62851333|NCT06138860|ACTIVE_COMPARATOR|physical therapy exercises|the patients will receive physical therapy exercise three times a week for four week
62851334|NCT01502215|ACTIVE_COMPARATOR|Liberal Transfusion Strategy|Liberal Group - transfusion when hemoglobin is lower than 9 g/dL. Intervention: Other: Red blood cell transfusion
62851335|NCT01502215|ACTIVE_COMPARATOR|Restrictive Transfusion Strategy|Restrictive Group - transfusion when hemoglobin is lower than 7 g/dL Intervention: Other: Red blood cell transfusion
62851336|NCT01155011|EXPERIMENTAL|MIPARC intervention|"Eleven Continuing Care Retirement Communities were randomized to either the MIPARC intervention or an attention-control condition. The intervention focused on increasing light to moderate PA.~The MIPARC study intervenes on four levels: individual (pedometer self monitoring, educational materials and monthly counseling calls, support), interpersonal (monthly group educational sessions and peer mentoring), environment (walking signage prompts, tailored environmental resources, step counts)and policies (review of on-site activity opportunities and walkability, recommendations for policy change and peer led advocacy)to increase the activity levels of residents.~For the first 3 months, intervention participants will engage in either a group educational session, phone counseling call, or a peer led session, on a rotating basis."
62851337|NCT01155011|ACTIVE_COMPARATOR|Health Education Control|The control group received an active health education intervention. The education curriculum will involve both lectures and mailed materials. The lectures were delivered to match the MIPARC intervention schedule. Sessions included information on general health and healthy aging. Physical activity was not discussed in these sessions but participants received information on the benefits of PA. Control participants also received health check phone calls to match the individual attention paid to participants in the MIPARC intervention sites.
62851338|NCT03799302|NO_INTERVENTION|Standard Consultation|Sites in this arm will receive the standard consultation from the TFCO or MDFT purveyors
62851339|NCT03799302|EXPERIMENTAL|SIC Coaching Consultation|In addition to the standard consultation from the TFCO or MDFT purveyors, sites in this arm will also receive feedback on how they are doing in terms of completing expected activities in their efforts to implement the designated EBP.
62851340|NCT05194579|OTHER|PF-06881894 by on-body injector (OBI)|PF-06881894 given by on-body injector (OBI) as test arm, 6 mg administered as a single SC injection
62851341|NCT05194579|OTHER|PF-06881894 by prefilled syringe (PFS)|PF-06881894 given by prefilled syringe (PFS) as reference arm, 6 mg administered as a single SC injection
62851342|NCT03975244|EXPERIMENTAL|Exercise group|Three months of semi-supervised exercise program in patients awaiting bariatric surgery. Body composition, cardiovascular risk factors, physical fitness, physical activity levels and quality of life will be assessed before and at the end of the study. In addition, surgery time, hospital length of stay and operative complications also will be evaluated.
62851343|NCT03975244|NO_INTERVENTION|Control group|The control group only will perform the evaluations of the study.
62851344|NCT06409156|ACTIVE_COMPARATOR|Oblique Subcostal Transversus Abdominis Plane Block|Researchers will perform the Oblique Subcostal Transversus Abdominis Plane Block using sterile technique under ultrasound guidance. Once the target is visualized, a 20-gauge, 4-inch echogenic needle will be advanced in-plane to the fascial plane. 5 ml of 0.9% normal saline will be injected through the needle to open the fascial plane and then a single dose (10 ml) of liposomal bupivacaine mixed with 20 mL of bupivacaine 0.25% will be injected on each side.
62851345|NCT06409156|EXPERIMENTAL|External Oblique Intercostal Fascial Plane block|Researchers will perform the External Oblique Intercostal Fascial Plane block using sterile technique under ultrasound guidance. Once the target is visualized, a 20-gauge, 4-inch echogenic needle will be advanced in-plane to the fascial plane. 5 ml of 0.9% normal saline will be injected through the needle to open the fascial plane and then a single dose (10 ml) of liposomal bupivacaine mixed with 20 mL of bupivacaine 0.25% will be injected on each side.
62851346|NCT02999438||Patients with hemodynamically significant heart disease|"Patients with either:~1. Single ventricle physiology s/p Fontan~2. Heart failure diagnosed by a cardiologist~3. Pulmonary hypertension diagnosed by cath"
62851347|NCT02999438||Controls|Healthy controls as defined in inclusion- exclusion criteria
62851348|NCT02957214|EXPERIMENTAL|Pain education|The patient education provides a basic set of information that includes the explanation of possible pathophysiological mechanisms involved in the development of chronic pain. The main objective is to reduce pain threatening and alarmist interpretation. The patient must understand that the pain is not necessarily a sign of injury, but the consequence of a maladaptive central sensitization. One element of this therapeutic strategy is to help the patient to perform physical activities that involve a gradual exposition to stimuli associated with their pain and promote physical recovery exposure. Pain education also aims to reduce fear-avoidance behavior and the patient's disability.
62851349|NCT02884505||Patients with Hypersomnolence|Patients referred for polysomnography and multiple sleep latency test
62625646|NCT01269619|EXPERIMENTAL|Dynamic|Use of Dynamic back support
62851350|NCT03347370||SC Peginterferon beta-1a|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
62625647|NCT01269619|ACTIVE_COMPARATOR|Static|Use of static back support
62625648|NCT02664064|EXPERIMENTAL|online Diabetes Prevention Program|Participants will receive access to a 12-month online diabetes prevention program modeled after the CDC DPP curriculum. Participants receive online curriculum, access to a live health coach, interactive group message forums, and connected weight and activity monitoring devices.
62851351|NCT03347370||SC interferon beta-1a|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
62851352|NCT03347370||SC interferon beta-1b|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
62625649|NCT02664064|NO_INTERVENTION|Matched Control|A de-identified dataset of control subjects matched on age, gender, prediabetes diagnosis, body mass index, comorbidities and socioeconomic status will be cultivated for comparison to the active intervention arm.
62625650|NCT05466292||Healthcare Professionals (HPs) employed at the Local Health Authority of Reggio Emilia,|HPs will be included if they are employed at the Health Care Authority of Reggio Emilia. They will receive a closed-ended questions survey.
62625651|NCT05466292||Local Health Authority's Managers/Wards Heads|Managers/Heads who formally supported and promoted the intervention or have been contacted during the dissemination process will be interviewed by semi-structured interview.
62625652|NCT05466292||Clinical Ethics Committee (CEC)'s members|CEC's members will be interviewed by semi-structured interview.
62625653|NCT05466292||Healthcare Professionals who submitted an ethics consultation request|Healthcare Professionals who submitted an ethics consultation request will be interviewed by semi-structured interview.
62625654|NCT05466292||Healthcare Professionals who attended the training provided by the Clinical Ethics Committee|Healthcare Professionals who attended at least one of the five training courses on ethics consultation provided by the Clinical Ethics Committee. They will receive a survey of 20 multiple-choice questions and supplemented by free-text questions.
62625655|NCT05951452||ENDO +|Patients with endometriosis diagnosed by Magnetic Resonance Imaging (MRI) or laparoscopy
62851353|NCT04530760||intraabdominal hypertension group|patients with intraabdominal hypertension defined as intravesical pressure more than 12 mmHg
62851354|NCT04530760||control group|patients with no intraabdominal hypertension
62625656|NCT05951452||ENDO -|Patients without endometriosis diagnosed by laparoscopy
62625657|NCT04817176|EXPERIMENTAL|MI-CBT KNA Program|The program is a 6-week group, telehealth intervention for older adults with possible MCI. The intervention uses Motivational interviewing and cognitive behavioral therapy strategies to enhance motivation and help participants overcome personal obstacles to following health-behavior recommendations. Specifically, the program examines the use of a Mediterranean ketogenic type of nutrition to target mild cognitive impairment. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
62851355|NCT05511077|OTHER|Liquid oat product|
62851356|NCT05511077|OTHER|Solid oat product|
62450327|NCT05938790|ACTIVE_COMPARATOR|Continuous Fetal Monitoring|A nurse will turn on the Obix cEFM machine which will automatically register the patient in the Obix system and begin the timer which will be used to measure time to fetal monitoring. The patient will lay on the triage stretcher and the continuous external fetal monitor doppler probe will be placed on the abdomen over the fetus, identified via Leopold maneuvers. Nurses will adjust the cEFM as needed until a full fetal heart rate signal is obtained. At this point the timer will be counted as the time to monitor. Once the fetal heart rate signal is obtained via cEFM, the patient's participation in the study ends.
62851357|NCT02161900|ACTIVE_COMPARATOR|Routine exercise|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
62851358|NCT02161900|EXPERIMENTAL|Yogic and Routine exrcises (exercise I)|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
62851359|NCT05025319||Taditional Grid|Patients imaged with traditional grid
62851360|NCT05025319||Virtual Grid|Patients imaged with virtual grid
62851361|NCT03079102|EXPERIMENTAL|inhaled nitric oxide (iNO)|20 ppm iNO delivered via mechanical ventilator connected to the iNO ventilator delivery system (iNOvent). Drug will be started as soon as possible after return of spontaneous circulation (ROSC) but no later than 4h after ROSC. Study drug will be dosed for 12h then tapered off over 1h.
62062542|NCT03668262||0.1mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.15/1.5=0.1 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
62625658|NCT04817176|ACTIVE_COMPARATOR|KN Information-Only Program|6-week group, telehealth intervention for older adults. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
62625659|NCT04516239|ACTIVE_COMPARATOR|LDH THA|large diameter head total hip arthroplasty
62625660|NCT04516239|ACTIVE_COMPARATOR|HR|metal-on-metalhip resurfacing
62851362|NCT03079102|PLACEBO_COMPARATOR|Placebo|Nitrogen carrier gas delivered by identical system with similar dose/taper.
62851363|NCT03572205|EXPERIMENTAL|CC genotype LA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of sunflower oil (source of LA: linoleic acid) daily, depending on body weight. The same diet will be instructed for both genotypes.
62062543|NCT03668262||0.07mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.1/1.5=0.0667 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
62062544|NCT03668262||0.05mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.07/1.5=0.0466( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
62062545|NCT03668262||0.03mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.05/1.5=0.0333 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
62266916|NCT04155138|OTHER|Naida Hearing Aid|"Adults (\> 18 years of age)~* Unilaterally implanted with an Advanced Bionics implant (CII or later)~* At least six months of CI use experience~* Limited bimodal benefit as perceived by the recipient and/or the clinician~* Participants may or may not currently be using a hearing aid in the unimplanted ear.~* Open set performance with current device configuration:~  * ≥40% AzBio sentence score in quiet (S0)~ * If currently bimodal:~* Hearing aid ear only CNC score \<50%~* AzBio Scores bimodal benefit \<15%~* Unaided audiometric threshold of ≤100 dBHL up to 500 Hz~* Ability and willingness to participate in multiple sets of open speech testing (and chronically evaluate HA and CROS benefit)"
62266917|NCT04155138|OTHER|Naida CROS Device|The same cohort will cross over to each arm.
62625661|NCT01030913||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
62625662|NCT06612372|EXPERIMENTAL|Long term bed rest intervention group|60-day-6° head-down bed rest
62625663|NCT02279290|EXPERIMENTAL|Healthy Mind Intervention (HMI)|This intervention will focus on teaching individuals a way to manage acute and chronic stressors more effectively.
62851364|NCT03572205|EXPERIMENTAL|TT genotype LA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of sunflower oil (source of LA: linoleic acid) daily, depending on body weight. The same diet will be instructed for both genotypes.
62266918|NCT05746221||INSVD Cohort|200 patients with cerebral small vessel disease - 100 recruited from Cambridge, UK; 100 recruited from Nijmegen, Netherlands.
62625664|NCT02279290|ACTIVE_COMPARATOR|Healthy Body Intervention (HBI)|This intervention will focus on important health-related topics.
62625665|NCT03943797|EXPERIMENTAL|Cultivated oral mucosal epithelial cell transplantation|Cell therapy for treating severe limbal stem cell deficiency using cultivated autologous oral mucosal epithelial cells.
62851365|NCT03572205|EXPERIMENTAL|CC genotype ALA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of camelina oil (source of alpha-linolenic acid: ALA) daily, depending on body weight. The same diet will be instructed for both genotypes.
62625666|NCT03300414||Collection of blood specimen|Collection of blood specimen from patients will be performed during the course of routine medical care at UC Davis with no prospective follow up period. The duration anticipated to enroll all 10 study subjects will be 1 year. The estimated date for the investigator to complete analysis and publication is 2 years.
62625667|NCT03300414||Liver Biopsy slides|Up to twenty (20) de-identified hepatocellular carcinoma (HCC) tissue sections on biopsy slides or frozen sections and associated information such as age, sex, race, ethnicity, treatment status, pathological diagnoses, and date of procedure will be obtained from UC Davis Cancer Center Biorepository (CCB) and outside tissue biobanks, including, but not limited to, Cooperative Human Tissue Network (CHTN). The duration anticipated to complete analysis and publication is 2 years.
62851366|NCT03572205|EXPERIMENTAL|TT genotype ALA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of camelina oil (source of alpha-linolenic acid: ALA) daily, depending on body weight. The same diet will be instructed for both genotypes.
62851367|NCT03395236|EXPERIMENTAL|Treatment|StellarexTM 0.014 OTW Drug-coated Angioplasty Balloon (Stellarex Balloon)
62851368|NCT04371588||Deep neuro-muscular blockade|
62266919|NCT03464994|OTHER|ichthyosis patients|patients presenting an Hereditary ichthyosis, whatever form or ongoing therapy will have an ophthalmological examination.
62851369|NCT04371588||Moderate neuro-muscular blockade|
62851370|NCT00856414|EXPERIMENTAL|1|botulinum toxin Type A 20U
62266920|NCT03464994|OTHER|control population|patient without ichthyosis disease and consulting an ophthalmologist for refractive surgery screening or systematic eye examination will have an ophthalmological examination
62266921|NCT04703075|EXPERIMENTAL|Rifapentine 600 mg and Isoniazid 300 mg|Participants will receive Rifapentine 600 mg daily and isoniazid (INH) 300 mg daily for 4 weeks.
62266922|NCT04703075|ACTIVE_COMPARATOR|Rifapentine 900 mg and Isoniazid 900 mg|Participants will receive Rifapentine 900 mg and isoniazid 900 mg weekly for 12 weeks.
62266923|NCT00522431|EXPERIMENTAL|1|2% testosterone gel
62266924|NCT01830504|EXPERIMENTAL|NVP-BKM120 (BKM120) PI3K inhibitor|
62851371|NCT02482038|EXPERIMENTAL|geko device|
62266925|NCT03767075|EXPERIMENTAL|Module 1 - Atezolizumab|"Genomically selected populations will all receive the same drug~* Arm 1A: BRCA1 or BRCA2 mutations~* Arm 1B: MLH1, MSH2, MSH6, or PMS2 mutations~* Arm 1C: tumors with POLE mutation, POLD1 mutation~* Arm 1D: hypermutated tumors~* Arm 1E: tumors with other mutations in DNA-repair genes~* Arm 1F: tumors with amplified PDL1~* Arm 1G: tumours with CDK12 mutations~Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 1000 subjects will need to be screened in part A in order to enroll 120 patients in part B of module 1."
62625668|NCT01995344|ACTIVE_COMPARATOR|ARM A: High Dose Interleukin-2 (HD IL2)|Eligible participants will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Participants will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused on day 0 and the patients will receive up to 12 doses of intravenous HD IL2
62625669|NCT01995344|ACTIVE_COMPARATOR|ARM B: Low Dose Interleukin-2 (LD IL2)|Eligible participants will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Participants will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused on day 0 and the patients will receive up to 12 doses of intravenous LD-IL2
62851372|NCT03891797|EXPERIMENTAL|Cognitive Processing Therapy|12 sessions of group-based Cognitive Processing Therapy administered 1x/week for 90 minutes each session.
62266926|NCT03767075|EXPERIMENTAL|Module 2 - Futibatinib|"Genomically selected populations will all receive the same drug~* Arm 2A: Known pathogenic FGFR1-3 mutations~* Arm 2B: Variants of unknown significance in FGFR1-3 with functional relevance or pathogenic FGFR4 mutations.~* Arm 2C: Highly amplified FGFR1-3 with high FGFR1-3 mRNA (with the exception of gastric and breast cancer)~* Arm 2D: Highly amplifiedFGFR1-3 without high FGFR1-3 mRNA (with the exception of gastric and breast cancer)~Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 2000 subjects will need to be screened in part A in order to enroll 80 patients in part B of module 2."
62851373|NCT03891797|NO_INTERVENTION|Control|No treatment/treatment as usual. Participants will complete questionnaires at three time points with no intervention.
62851374|NCT02527772|EXPERIMENTAL|Liposomal Doxorubicin+Gemcitabine|Gemcitabine 1000mg/m2,d1,8;Liposomal Doxorubicin 30mg/m2,d1.q4w
62851375|NCT02527772|ACTIVE_COMPARATOR|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks
62266927|NCT03767075|EXPERIMENTAL|Module 3 - Amivantamab|"Genomically selected populations will all receive the same drug~* Arm 3A: kinase domain mutations/ MET fusion-genes (including intragene exon skipping MET-MET fusions)~* Arm 3B: MET copy number gain (equivalent CNG ≥6) (exception: colorectal cancer)~* Arm 3C: EGFR mutations (exception: primary lung malignancies)~Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 1725 subjects will need to be screened in part A in order to enroll 69 patients in part B of module 3."
62851376|NCT01319604|EXPERIMENTAL|Study device during 3 hours|
62851377|NCT01319604|EXPERIMENTAL|Study device during 6 hours|
62851378|NCT01319604|EXPERIMENTAL|Study device during 9 hours|
62851379|NCT01319604|EXPERIMENTAL|Study device during 12 hours|
62851380|NCT01319604|EXPERIMENTAL|Study device during 15 hours|
62450328|NCT05938790|EXPERIMENTAL|Point of Care Handheld Ultrasound|A nurse will turn on the Obix cEFM machine which will automatically register the patient in the Obix system and begin the timer which will be used to measure time to fetal monitoring. The patient will lay on the triage stretcher and a Butterfly ultrasound (Figure 1) probe will be used with a secure institutional Ipad by the triage nurse to identify the fetal position and location of the fetal heart. All images are deidentified and not stored since it will be a live real time aid to obtain a fetal heart tracing via cEFM. The cEFM will be placed on the maternal abdomen according to the imaging obtained by the ultrasound. Once fetal heart rate signal is obtained via cEFM, the patient's participation in the study ends.
62450329|NCT00878995|PLACEBO_COMPARATOR|Standard of Care Therapy + Placebo Testosterone|Patients receive standard of care chemotherapy and/or radiation plus placebo testosterone intramuscularly (IM) weekly for 7 weeks.
62851381|NCT01319604|EXPERIMENTAL|Study device during 18 hours|
62851382|NCT01319604|EXPERIMENTAL|Study device during 21 hours|
62450330|NCT00878995|ACTIVE_COMPARATOR|Standard of Care Therapy + Testosterone|Patients receive standard of care chemotherapy and/or radiation plus testosterone (Testosterone Enanthate 100mg/ml) intramuscularly (IM) weekly for 7 weeks.
62851383|NCT01319604|EXPERIMENTAL|Study device during 24 hours|
62851384|NCT01319604|ACTIVE_COMPARATOR|Tonometric assessment during 24 hours|
62851385|NCT03339154|EXPERIMENTAL|Methionine bioavailability in chickpeas|"Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods).~You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or chickpeas with or without rice, which will be provided by the investigators"
62851386|NCT00003745|EXPERIMENTAL|Arm I|Patients receive topotecan IV continuously on days 1-21. Treatment continues at least every 4 weeks in the absence of unacceptable toxicity or disease progression.
62851387|NCT05857865|EXPERIMENTAL|Experimental|Caregivers in this group will participate in one 90-minute session delivered by a parenting coach via Zoom. This group will be asked to complete questionnaires at baseline, immediately post-program, approximately one month after the baseline assessment, and three months after the baseline assessment.
62851388|NCT05857865|EXPERIMENTAL|Services as Usual (SAU)|Caregivers in this group will not participate in a single-session intervention (SSI). Rather, this group will receive services as usual on the Specialized Services for Children and Youth (SCCY) waitlist. This group will be asked to complete questionnaires at baseline, approximately one month after the baseline assessment, and three months after the baseline assessment.
62851389|NCT03919097||Control|No atrial arrhythmia post-ablation of a flutter by radiofrequency of the isthmus of the cavotricuspid valva.
62450331|NCT00526578||Questionnaire|Pancreatic cancer patients or family member.
62450332|NCT02736500|EXPERIMENTAL|28 GBq 177Lu-DOTATATE|5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) 177Lu-DOTATATE
62450333|NCT02736500|EXPERIMENTAL|22 GBq 177Lu-DOTATATE|6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi) 177Lu-DOTATATE
62851390|NCT03919097||Atrial fibrillation post ablation|Atrial arrhythmia (Atrial Fibrillation) post-ablation of a flutter by radiofrequency of the isthmus of the cavotricuspid valva.
62851391|NCT03919097||Flutter recidive|Recidive of the flutter after ablation.
62625670|NCT06611527|ACTIVE_COMPARATOR|PS+PEEP group|PS+PEEP modality involves the application of two levels of positive pressure intermittently.
62625671|NCT06611527|EXPERIMENTAL|CPAP group|Continuous positive airway pressure modality.
62266928|NCT05374538|EXPERIMENTAL|Dose Escalation Phase, Cohort 1a: VIC-1911 monotherapy|Subjects with locally advanced or metastatic KRAS G12C-mutated NSCLC refractory to or relapsed on prior KRASG12C inhibitor therapy will receive VIC-1911 monotherapy.
62266929|NCT05374538|EXPERIMENTAL|Dose Escalation Phase, Cohort 1b: VIC-1911 plus sotorasib combination therapy|Subjects with locally advanced or metastatic KRAS G12C-mutated NSCLC refractory to or relapsed on prior KRASG12C inhibitor therapy or are naive to KRAS G12C inhibitor therapy will receive VIC-1911 plus sotorasib combination therapy.
62625672|NCT03699371|EXPERIMENTAL|Early Supplemental Parenteral Nutrition|Intervention group: would receive EN reaching up to 20 % of daily nutritional requirements and early (on first day of stay in ICU) provision (of up to 80%) of protein (2 g/kg/ day or in case of continuous renal replacement therapy (CRRT) 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day) needs in SPN that would be continued until 7th day of stay in ICU for the purpose of the study.
62625673|NCT03699371|NO_INTERVENTION|Late Supplemental Parenteral Nutrition|Control group: would receive EN reaching up to 20 % of daily nutritional requirements and late (of up to 80%) of protein (2 g/kg/ day or in case of CRRT 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day ) in SPN on 7th day of stay in ICU if it is not already met via enteral route.
62625674|NCT02179346||Cartilage defects in the hip joint|NOVOCART® Inject Autologous Chondrocyte Implantation
62625675|NCT01773629|EXPERIMENTAL|Intervention|Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.
62625676|NCT01773629|OTHER|Control|"Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a perinatal depression champion for a timely formal diagnostic interview."
62625677|NCT06376617|OTHER|Study patern of fungal inection which cause excerbation|Take bal through fob and send for fungal stain and culure
62851392|NCT03919097||Atrial Fibrillation antecedents|Patients with atrial fibrillation after flutter ablation, with previous antecedents of atrial fibrillation.
62851393|NCT03919097||No Atrial Fibrillation antecedents|Patients with atrial fibrillation after flutter ablation, without antecedents of atrial fibrillation.
62851394|NCT05254977||B.V. HOSPITAL|Local population in surrounding premises of site
62851395|NCT05254977||Baldia Hall Yazman|Local population in surrounding premises of site
62851396|NCT05254977||CIVIL HOSPITAL Bahahwalpur|Local population in surrounding premises of site
62625678|NCT01514942|OTHER|Insulin resistant patients|
62625679|NCT01514942|OTHER|Non-insulin resistant patients|
62625680|NCT05497297|EXPERIMENTAL|Mild Renal Impairment|A1 group subjects will receive a single dose of 10 mg HSK7653
62851397|NCT05254977||DDHO KPT|Local population in surrounding premises of site
62851398|NCT05254977||Govt Girls Elementry School|Local population in surrounding premises of site
62625681|NCT05497297|EXPERIMENTAL|Moderate Renal Impairment|B1 group subjects will receive a single dose of 10 mg HSK7653
62625682|NCT05497297|EXPERIMENTAL|Severe Renal Impairment|C1 group subjects will receive a single dose of 10 mg HSK7653
62625683|NCT05497297|EXPERIMENTAL|Kidney failure|D1 group subjects will receive a single dose of 10 mg HSK7653
62625684|NCT05497297|EXPERIMENTAL|Normal Renal function|A2, B2, C2 and D2 group subjects will receive a single dose of 10 mg HSK7653, If the age, sex and weight of the subjects in group A2 can be matched with the subjects in groups A1 and B1 at the same time, the subjects in group B2 will not be enrolled, and so on.
62625685|NCT02263378|EXPERIMENTAL|supplement|
62625686|NCT02263378|PLACEBO_COMPARATOR|not intervention|
62266930|NCT05374538|EXPERIMENTAL|Expansion Phase, Cohort 2a: VIC-1911 monotherapy|Subjects with locally advanced or metastatic KRAS G12C-mutated NSCLC refractory to or relapsed on prior KRASG12C inhibitor therapy will receive VIC-1911 monotherapy.
62266931|NCT05374538|EXPERIMENTAL|Expansion Phase, Cohort 2b: VIC-1911 plus sotorasib combination therapy|Subjects with locally advanced or metastatic KRAS G12C-mutated NSCLC refractory to or relapsed on prior KRASG12C inhibitor therapy will receive VIC-1911 plus sotorasib combination therapy.
62625687|NCT03876483|NO_INTERVENTION|Standard of Care|Youth enrolled in care at control facilities will receive current standard of care related to HIV care and transition to adult care.
62625688|NCT03876483|EXPERIMENTAL|Virtual peer support group|Youth enrolled in care at intervention facilities will be invited to participate in a virtual peer support program
62625689|NCT06593834|EXPERIMENTAL|Experimental group|bacillus coagulans combined with the best treatment options for preventing aGVHD
62625690|NCT06593834|ACTIVE_COMPARATOR|Control group|The best treatment options for preventing aGVHD
62625691|NCT03183843|ACTIVE_COMPARATOR|Dabigatran|Dabigatran etexilate 150 mg by mouth every 12 hours for a year
62625692|NCT03183843|ACTIVE_COMPARATOR|Warfarin|Warfarin by mouth every 24 hours in a dose providing international normalized ratio (INR) 2.5-3.5 for a year
62851399|NCT05254977||Govt Higher Secondary School|Local population in surrounding premises of site
62851400|NCT05254977||Govt Sadiq Higher Secondary School|Local population in surrounding premises of site
62851401|NCT05254977||Govt TibIA College Bahawalpur|Local population in surrounding premises of site
62851402|NCT05254977||CEO Office DHA BWP|Local population in surrounding premises of site
62851403|NCT05254977||Papulation Welfare office APE|Local population in surrounding premises of site
62851404|NCT05254977||RHC Ballah Jhulan|Local population in surrounding premises of site
62851405|NCT05254977||RHC Channi Goth|Local population in surrounding premises of site
62851406|NCT05254977||RHC Choona wala|Local population in surrounding premises of site
62851407|NCT05254977||RHC Dera Bakha|Local population in surrounding premises of site
62087970|NCT04321200||Cross-sectional-1500 infants (atypical vs typical)|Arm (Study) 3: To develop a computer vision-based algorithm to quantify infant motor performance from a single-camera video. Here using video data from 1200 infants, plus those gathered from Arm 1 and Arm 2, we will extract pose data from single-camera video recordings and convert these into kinematic features and relevant scores needed to classify infant movement.
62266932|NCT05374538|EXPERIMENTAL|Expansion Phase, Cohort 2c: VIC-1911 plus sotorasib combination therapy|Subjects with locally advanced or metastatic KRAS G12C-mutated NSCLC naive to KRAS G12C inhibitor therapy will receive VIC-1911 plus sotorasib combination therapy.
62266933|NCT02246062|NO_INTERVENTION|Control group|in which the relative receive only conventional verbal information one day before the procedure at ward.
62266934|NCT02246062|ACTIVE_COMPARATOR|info group|in which the relative, in addition to conventional verbal information, received a leaflet containing information about the anesthetic procedure one day before the surgery at ward.
62266935|NCT02246062|ACTIVE_COMPARATOR|smartphone group|in which the relative received only conventional verbal information one day before the procedure and the child received smartphone application immediately before entering the operating room
62625693|NCT02157571|EXPERIMENTAL|Prulifloxacin|"Prulifloxacin film-coated tablet : 600 mg/tablet, oral administration of a single tablet.~Placebo of levofloxacin hydrochloride tablet, without active components."
62625694|NCT02157571|ACTIVE_COMPARATOR|Levofloxacin|"Levofloxacin hydrochloride tablet 500 mg/tablet, oral administration of a tablet daily.~Placebo of prulifloxacin film-coated tablet without active components."
62625695|NCT01674465||CNI-induced nephrotoxicity|Hypoxyprobe-1
62266936|NCT02246062|ACTIVE_COMPARATOR|smartphone and info group|in which the relative, in addition to conventional verbal information, received a leaflet containing information about the anesthetic procedure one day before the surgery and the child received smartphone application immediately before entering the operating room.
62266937|NCT04141228||Patients receiving apixaban|With or without low molecular weight heparin in the inpatient/emergency department (ED) setting
62266938|NCT04141228||Patients receiving warfarin|With or without low molecular weight heparin in the inpatient/emergency department (ED) setting
62625696|NCT06164899||Patients with bilateral knee osteoarthritis treated with hyaluronic acid injection|"Patients with bilateral osteoarthritis treated with hyaluronic acid injection treated within the research protocol OA-bi-blind"
62851408|NCT05254977||RHC Headrajkan|Local population in surrounding premises of site
62851409|NCT05254977||RHC Khanqah sharif|Local population in surrounding premises of site
62625697|NCT06164899||Patients with bilateral knee osteoarthritis treated with BMAC injection|"Patients with bilateral knee osteoarthritis treated with autologous bone marrow concentrate injection treated within the research protocol OA-bi-blind"
62851410|NCT05254977||RHC Khutri Banglow|Local population in surrounding premises of site
62851411|NCT05254977||RHC Kud Wala|Local population in surrounding premises of site
62087971|NCT02647918|EXPERIMENTAL|Group 1|Subjects with normal renal function
62625698|NCT00929487|EXPERIMENTAL|Contact lens solution #1|
62851412|NCT05254977||RHC Lal Sohanra|Local population in surrounding premises of site
62851413|NCT05254977||RHC Mubarkpur|Local population in surrounding premises of site
62087972|NCT02647918|EXPERIMENTAL|Group 2|Subjects with mild renal impairment
62087973|NCT02647918|EXPERIMENTAL|Group 3|Subjects with moderate renal impairment
62087974|NCT02647918|EXPERIMENTAL|Group 4|Subjects with severe renal impairment
62087975|NCT02647918|EXPERIMENTAL|Group 5|Subjects with ESRD requiring HD
62087976|NCT00419003|EXPERIMENTAL|Lamotrigine Pre-Treatment|Patients who met enrolment criteria for phase 1 were randomly allocated to lamotrigine or placebo by a permuted block procedure consisting of blocks of two or four patients. The randomization list was created by a biostatistician with no patient contact. 300 mg of lamotrigine 2 hrs prior to ketamine infusion. Responders were randomized to one of two continuation pharmacotherapy groups, receiving either two capsules of riluzole 50 mg each (100 mg/d) or matching pill placebo under double-blind conditions.
62087977|NCT00419003|PLACEBO_COMPARATOR|Placebo Pre-Treatment|2 hours prior to ketamine infusion each patient received three capsules of placebo identical in size, weight, appearance, and taste to the lamotrigine tablets. Responders were randomized to one of two continuation pharmacotherapy groups, receiving either two capsules of riluzole 50 mg each (100 mg/d) or matching pill placebo under double-blind conditions.
62625699|NCT00929487|EXPERIMENTAL|Contact lens solution #2|
62625700|NCT00929487|EXPERIMENTAL|Contact lens solution #3|
62625701|NCT00929487|EXPERIMENTAL|Contact lens solution #4|
62625702|NCT00929487|ACTIVE_COMPARATOR|Saline/blister pack solution|
62851414|NCT05254977||RHC Qaimpur|Local population in surrounding premises of site
62851415|NCT05254977||RHC Uch Sharif|Local population in surrounding premises of site
62851416|NCT05254977||Special Education Degree Colage|Local population in surrounding premises of site
62851417|NCT05254977||THQ HOSPITAL, AHMADPUR|Local population in surrounding premises of site
62851418|NCT05254977||THQ HOSPITAL, HASILPUR.|Local population in surrounding premises of site
62851419|NCT05254977||THQ KHAIR PUR TAMEWALI|Local population in surrounding premises of site
62851420|NCT05254977||THQ YAZMAN|Local population in surrounding premises of site
62062546|NCT03668262||0.02mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.03/1.5=0.02( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
62062547|NCT00003511|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62062548|NCT05355480||Healthy Subjects|Collection of handwriting samples
62062549|NCT05355480||Patients with Parkinson's disease|Collection of handwriting samples
62625703|NCT02934555|PLACEBO_COMPARATOR|Control|Patients in the control group will receive a liquid placebo, which is 50 mL of Ensure (a dietary supplement). This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.
62625704|NCT02934555|EXPERIMENTAL|Ubiquinol|Patients in the experimental group will receive 300 mg of Ubiquinol in a liquid mixture. The liquid Ubiquinol will be mixed with 50 mL of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.
62625705|NCT05686460|EXPERIMENTAL|ice massage|The application applied 2 minutes of ice massage 7 times at 15-second intervals. The procedure was performed once on the first day and once on the second day of menstruation.
62625706|NCT05686460|EXPERIMENTAL|music medicine|Depending on their preference, each participant wearing personalized headphones was played instrumental music in the pre-menstruation period for 30 minutes. The procedure was performed once on the first day and once on the second day of menstruation.
62625707|NCT05686460|NO_INTERVENTION|control|On the first and second days of menstruation, their pain levels of were assessed 4 times: when the pain started (pre-test), and then 30, 60 and 90 minutes after the pain started.
62625708|NCT02211703||Observation|This is an epidemiology study in which all the data from the subjects enrolled will be collected and analysis to investigate the current patient warming condition and actual perioperative hyperthermia rate in the elective operation with general anesthesia. During the whole procedure none intervention is administered.
62625709|NCT03304106|EXPERIMENTAL|Newly Implanted CI Recipients|Use of AI technology to assist in audiologist's evaluation and programming of new (standard of care-commercial) cochlear implant recipients
62625710|NCT03304106|EXPERIMENTAL|Existing CI recipients|Use of AI technology to assist in audiologist's evaluation and programming of existing cochlear implant recipients
62625711|NCT04075136|ACTIVE_COMPARATOR|Arm A: Lucentis|A standard of care treatment of 0.05ml/0.5mg Lucentis given every 4 weeks for 48 weeks.
62625712|NCT04075136|EXPERIMENTAL|Arm B: Lucentis & PDT Laser|A one time treatment of 0.05ml/0.5mg Lucentis in combination with PDT laser administered at half-fluence.
62625713|NCT04075136|EXPERIMENTAL|Arm C: Lucentis, PDT Laser and Triescense|A one time treatment of 0.05ml/0.5mg Lucentis in combination with PDT laser administered at half-fluence and an intravitreal injection of 0.5ml-2mg Triescence at the time of PDT treatment.
62625714|NCT01942876|EXPERIMENTAL|Intervention|The Quit Using Drugs Intervention Trial (QUIT) experimental arm includes: screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
62625715|NCT01942876|SHAM_COMPARATOR|Control|This arm will receive a sham telephone intervention of equivalent duration on health behavior maintenance.
62625716|NCT01463800|ACTIVE_COMPARATOR|Structured Exercise training|12 weeks ambulatory low level exercise training
62625717|NCT01463800|NO_INTERVENTION|Control group|No structured exercise training
62625718|NCT00657657|EXPERIMENTAL|Group 1|Neonates from mother HBsAg (+) and HBeAg (+) had received HBV vaccine at Month 0, 1, 2, 12, 60 (5 doses)
62625719|NCT00657657|EXPERIMENTAL|Group 2|Neonates from mother HBsAg (+) and HBeAg (+) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
62851421|NCT05254977||TMA Office Hasilpur (NEW)|Local population in surrounding premises of site
62851422|NCT00846950|EXPERIMENTAL|healthy volunteers|
62625720|NCT00657657|EXPERIMENTAL|Group 4|Neonates from mother HBsAg (+) and HBeAg (-) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
62625721|NCT00657657|EXPERIMENTAL|Group 6|Neonates from mother HBsAg (-) and HBeAg (-) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
62625722|NCT02827175|EXPERIMENTAL|fevers of the travelers|
62625723|NCT03965520|ACTIVE_COMPARATOR|usual training|exercise intensity arranged by cardiopulmonary exercise test results
62625724|NCT03965520|EXPERIMENTAL|Novel exercise training|exercise intensity monitor by near-infrared spectrometer
62625725|NCT02800005|OTHER|BMI group (Successive patients)|All successive patients meeting the including criteria and signed the informed consent will be measured BMI and the data will be recorded in the prospective database. The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese. Investigators declare that there exists no conflicts of interest.
62851423|NCT00539968|EXPERIMENTAL|Docetaxel plus lonafarnib (single arm)|Docetaxel plus lonafarnib
62851424|NCT01417013|ACTIVE_COMPARATOR|Systane Ultra|Systane Ultra Lubricant Eye Drops
62851425|NCT01417013|ACTIVE_COMPARATOR|Optive|Optive Lubricant eye drops
62851426|NCT04295824||Mild AD|"20 subjects with mild local AD on their volar forearm (At least 10 with lesions on the face \| At least 10 which are globally mild)."
62851427|NCT04295824||Moderate AD|"20 subjects with moderate local AD on their volar forearm (At least 10 with lesions on the face \| At least 10 which are globally moderate)."
62851428|NCT04295824||Severe AD|"20 subjects with severe local AD on their volar forearm (At least 10 with lesions on the face \| At least 10 which are globally severe)."
62087978|NCT03047603||Healthy control|The healthy control group consist of people undergoing routine medical examination. Serum samples are collected.
62087979|NCT03047603||Metastatic liver cancer patients|Serum samples are collected.
62266939|NCT04829851||Health Care Professionals|Registered health care professional, such as a General Practitioner/ Dietitian/ Nutritionist/ Registered Exercise Professional (REPs) etc. who sees clients for assistance with weight management and / or iron deficiency or diet quality.
62266940|NCT04829851||Adults who are Overweight|Adults (\> 18 years) who are considered to be overweight (25 - 30 kg/m2) but are otherwise in good physical health and a regular android smart phone/ tablet user.
62266941|NCT04829851||Adults with Iron Deficiency Anaemia|Adults (\> 18 years) who have been diagnosed with Iron deficiency anaemia but are otherwise in good physical health and a regular android smart phone/ tablet user.
62266942|NCT04829851||Adults with Low- Fruit/ Vegetable Intake|Adults ( \> 18 years) with a low fruit and vegetable intake (2-3 portions/ d) but are otherwise in good physical health and a regular android smart phone/ tablet user.
62851429|NCT04295824||Healthy|20 healthy volunteers
62266943|NCT05536765||Patients with impacted tooth|
62851430|NCT01235650||Spinal fusion|Patients who underwent complex surgical procedures (spinal fusions) which necessitated arterial line placement and intermittent arterial blood gas analysis
62851431|NCT00488553||Cases|Participants of study with newly diagnosed lymphoma.
62851432|NCT00488553||Control|Participants of study from matched control group.
62851433|NCT00888199|EXPERIMENTAL|Congenital/Traumatic|Individuals who were born with a limb deficiency or who have had a traumatic amputation.
62851434|NCT00888199|EXPERIMENTAL|Dysvascular/Diabetic|Individuals who have had an amputation as a result of vascular disease.
62851435|NCT06010043|EXPERIMENTAL|"Dumpling suture for ileostomy"|The stoma is fixed with sutures in a skin fold method, and the incision is progressively reduced in a process similar to the process of folding and pinching the Chinese small dumplings. This procedure may reduce stoma complications by progressively reducing the incision and realizing the effect of hiding the skin incision.
62851436|NCT06010043|OTHER|Traditional suture for ileostomy|The stoma was fixed at the skin using traditional sutures. The incision is narrowed by 2-3 interrupted sutures at the distal and proximal ends of the skin incision on the abdominal wall. The stoma is then fixed at the right lower abdominal incision with sutures.
62851437|NCT03007251|EXPERIMENTAL|"Eurythmy Therapy Movement R"|"EYT exercise R: Positioned between two steps and forearms parallel to the ground, the patient performs a rolling movement like wheels on a wagon. The movement is positioned below shoulder height and is initiated from the shoulder blade."
62851438|NCT03007251|EXPERIMENTAL|"Eurythmy Therapy Movement L"|"EYT exercise L: In a circular and flowing movement the patient leads his hands upwards in front of his body and down again laterally. During elevation of the arms, the patient performs a small hop onto the toes and into knock knees. Lowering his arms, he releases the legs and straightens up again."
62266944|NCT03846752|ACTIVE_COMPARATOR|7 Fr. radial access|radial artery access for complex PCI
62266945|NCT03846752|ACTIVE_COMPARATOR|7 Fr. femoral access|femoral artery access for complex PCI
62266946|NCT02892474||Hybrid Coronary Revascularization (HCR)|Patients who are scheduled to have the hybrid coronary revascularization (HCR) procedure for treatment of multi-vessel coronary artery disease. The treatment plan is determined by the patient's doctor.
62266947|NCT02892474||Coronary Artery Bypass Grafting (CABG)|Patients who are scheduled to have the coronary artery bypass grafting (CABG) procedure for treatment of multi-vessel coronary artery disease. The treatment plan is determined by the patient's doctor.
62851439|NCT03007251|EXPERIMENTAL|"Eurythmy Therapy Movement B"|"EYT exercise B: The patient describes an embracing movement with both arms and the left leg while balancing on one foot. He then returns to the initial position and repeats the movement using the other leg."
62851440|NCT03007251|ACTIVE_COMPARATOR|Normal movements during walking or standing|Control exercise: Participants slowly walk across the room, their arms swinging in a natural way. This was designed to control for the most basic upright movement, shifting thermoregulation from resting conditions to exercise conditions, triggering non-thermal factors.
62851441|NCT01302145|EXPERIMENTAL|ASP1941 + metformin|Oral
62087980|NCT03047603||Hepatocellular carcinoma patients|Serum samples are collected before liver resection.
62625726|NCT02800005|EXPERIMENTAL|AFA group(Successive patients)|All successive patients meeting the including criteria and signed the informed consent will be measured BMI and the data will be recorded in the prospective database. The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit. No contrast agent is needed. Patients in the AFA group will be also measured by BMI. Investigators declare that there exists no conflicts of interest.
62625727|NCT05358990|EXPERIMENTAL|Plain Language Recommendation (PLR)|New easy to read COVID-19 recommendations available on the COVID19 Living Map of Recommendations and Gateway to Contextualization (RecMap).
62625728|NCT05358990|ACTIVE_COMPARATOR|Standard Language Version (SLV)|Original recommendation as initially published by the guideline organization.
62266948|NCT01437397|EXPERIMENTAL|1|Aclidinium/formoterol Fixed Dose Combination (FDC) 400/12μg
62266949|NCT01437397|EXPERIMENTAL|2|Aclidinium/formoterol Fixed Dose Combination (FDC) 400/6μg
62266950|NCT01437397|ACTIVE_COMPARATOR|3|Aclidinium monotherapy 400 μg
62625729|NCT04717089||postoperative patients admitted to TMH extended post anaesthetic care in PACU|"Exclusion criteria:~* Patients awaiting ICU admission in the ordinary recovery room~* Patients requiring level 3 intensive care on arrival at the recovery room"
62625730|NCT04717089||Postoperative patient admitted to ICU with case matched|"Inclusion criteria:~o Based on case matched with the extended post anaesthetic care in PACU"
62851442|NCT01302145|PLACEBO_COMPARATOR|Placebo + metformin|Oral
62851443|NCT05693961|EXPERIMENTAL|CART-I plus|CART-I pulse oximeter with a ring-type wearable PPG sensor was placed on each volunteer to evaluate the SpO2 accuracy during steady-state, non-motion conditions.
62851444|NCT02402998|EXPERIMENTAL|Eltrombopag|Eltrombopag 50 mg/daily.
62851445|NCT05532293|EXPERIMENTAL|MSP008-22|"MSP008-22 is a New Chemical Entity (NCE) that has demonstrated positive outcomes during in vitro and in vivo studies for COVID19.~Formulated as tablets intended for oral dosing to trial participants."
62851446|NCT05532293|PLACEBO_COMPARATOR|Placebo|placebo will be identical in smell, taste, and appearance to the tablets of MSP008-22
62851447|NCT06312475|EXPERIMENTAL|Arm 1: KN057 Prophylaxis|Successfully screened participants will be randomly assigned to KN057 Prophylaxis versus No Prophylaxis at a ratio of 2:1. Participants in Arm 1 (KN057 Prophylaxis) will receive KN057 through the main trial (26 weeks) and extension period (26 weeks) for total of approximately 1 year.
62266951|NCT01437397|ACTIVE_COMPARATOR|4|Formoterol monotherapy 12 μg
62266952|NCT01437397|PLACEBO_COMPARATOR|5|Placebo
62266953|NCT05057169|EXPERIMENTAL|BNT162b2 third dose after two doses of BNT162b2|
62266954|NCT05057169|EXPERIMENTAL|CoronaVac third dose after two doses of BNT162b2|
62266955|NCT05057169|EXPERIMENTAL|BNT162b2 third dose after two doses of CoronaVac|
62266956|NCT05057169|EXPERIMENTAL|CoronaVac third dose after two doses of CoronaVac|
62266957|NCT04707898|EXPERIMENTAL|Group Single Bond Universal|Single Bond Universal adhesive system with selective-etch approach following the manufacturer's instruction
62266958|NCT04707898|EXPERIMENTAL|Group G-Premio Bond|G-Premio Bond Adhesive System with selective-etch approach following the manufacturer's instruction
62266959|NCT05862181||HEPA-HAIC group|HEPA-HAIC group is composed of advanced HCC patients treated with HepaSphere DEB-TACE combined with HAIC as the interventional therapy
62266960|NCT05862181||HAIC group|HAIC group is composed of advanced HCC patients treated with only HAIC as the interventional therapy
62266961|NCT03987503|EXPERIMENTAL|at Point-of-Diagnosis HCV treatment|At the point of HCV infection diagnosis, (HCV RNA positive and anti-HCV positive) individuals who meet eligibility criteria and elect to start HCV treatment at the same visit and monitored at two-week intervals at the community-site.
62266962|NCT03987503|ACTIVE_COMPARATOR|Passive observation|Participants who test positive for HCV chronic infection (HCV RNA positive, and anti-HCV positive) but elect to not enroll in the intervention arm. Electronic medical record data will be reviewed for up to 2 years for HCV related care information (e.g., HCV treatment start date, end date, SVR-12).
62266963|NCT03373305|EXPERIMENTAL|Treatment (brentuximab vedotin, lenalidomide)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
62266964|NCT01614314|ACTIVE_COMPARATOR|Auto-instructional guide|The subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
62266965|NCT01614314|EXPERIMENTAL|Preceptorship|The subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
62625731|NCT05165719||Vaccinated|SARS-CoV-2 vaccination with 'Sputnik V' (Gam-COVID-Vac) in a period 7-14 days after the second vaccination before recruitment
62851448|NCT06312475|EXPERIMENTAL|Arm 2: No Prophylaxis|Successfully screened participants will be randomly assigned to KN057 Prophylaxis versus No Prophylaxis at a ratio of 2:1. Participants in Arm 2 (No Prophylaxis) will continue on-demand treatment with their usual bypass agents (rFVIIa or PCC) through the main trial for 26 weeks, in the extension period they will switch to prophylaxis treatment and receive KN057 for 26 weeks.
62266966|NCT04286061|EXPERIMENTAL|Experimental group|Each session will last 1 or 2 minutes, with one intervention being carried out a week, over a period of 4 weeks. Prior to the start of training, the instrument-assisted soft tissue mobilization technique will be performed
62266967|NCT04286061|NO_INTERVENTION|Control group|Players included in the control group will follow their usual training routine.
62062550|NCT02206295|EXPERIMENTAL|Treatment Sequence AB|"Subjects will receive Treatment A in Period 1 followed by Treatment B in Period 2. There will be a washout period lasting at least 6 days between treatments.~Treatment A: up-titration from Day 1-18 will performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with 8 film-coated tablets, 200 μg each, b.i.d. from Day 19 to the morning dose of Day 23.~Treatment B: up-titration from Day 1-18 will be performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with one single film-coated tablet, 1600 μg, b.i.d. from Day 19 to the morning dose of Day 23."
62851449|NCT04997356|EXPERIMENTAL|Hostile Bias Modification (HBM) Training plus Unambiguous Feedback|Volunteers will complete a novel computer-based hostile bias modification training where they are instructed to respond to word fragments (words with missing letters) based on whether the word fragments can be completed to form aggressive or positive/neutral words. They are instructed not to respond if only an aggressive word can be formed. They will receive unambiguously hostile feedback to an essay.
62062551|NCT02206295|EXPERIMENTAL|Treatment Sequence BA|"Subjects will receive Treatment B in Period 1 followed by Treatment A in Period 2. There will be a washout period lasting at least 6 days between treatments.~Treatment A: up-titration from Day 1-18 will performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with 8 film-coated tablets, 200 μg each, b.i.d. from Day 19 to the morning dose of Day 23.~Treatment B: up-titration from Day 1-18 will be performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with one single film-coated tablet, 1600 μg, b.i.d. from Day 19 to the morning dose of Day 23."
62062552|NCT04601363||Patients with Personalized SpineRods|The patient is being treated with the patient-specific rod with a surgery date planned
62062553|NCT04601363||Patient with other hardware|Patients with other hardware not patient-specific
62266968|NCT02082509||Traumatic Brain Injury (TBI)|Patient who have sustained a TBI over 1 month prior to enrollment, and endorse at least 1 post-concussive symptom at the time of enrollment.
62266969|NCT02082509||Healthy Controls (no TBI)|Subjects who match the TBI group's demographic characteristics, except that they have not sustained a TBI and they are otherwise physically and mentally healthy.
62266970|NCT05931146|EXPERIMENTAL|MyNetDiary app group|Smart phone application MyNetDiary will be used to track calories and exercise log. The intervention period would last for 3 months.
62266971|NCT05931146|EXPERIMENTAL|Paper diary group|This group will follow paper diary to track calories and exercise log for 3 months.
62450334|NCT04963426|EXPERIMENTAL|Intervention arm|"The intervention consists of interactive workshops that will be facilitated by WHO and trained local personnel and involve students, teachers and local authorities. In the workshops, the Global Accelerated Action for the Health of Adolescents (Global AA-HA!) approach will be used to:~* identify adolescent health needs through exploring the collected baseline data;~* assess policies and practices already in place;~* identify gaps and needs for action to improve health. A menu of actions will be identified, prioritized, implemented and monitored."
62450335|NCT04963426|NO_INTERVENTION|Control arm|The schools in the control arm will not participate in any intervention and continue 'as usual' after the baseline surveys.
62450336|NCT04699422|ACTIVE_COMPARATOR|Experimental group|Patients in the experimental group will receive the serratus anterior plane block combined with postoperative PCIA with Piritramide.
62851450|NCT04997356|PLACEBO_COMPARATOR|Other training plus Unambiguous Feedback|Volunteers will complete a computer-based task where they are instructed to respond to word fragments (words with missing letters) regardless of whether the fragments can make hostile or ambiguous words. They will receive unambiguously hostile feedback to an essay.
62851451|NCT04997356|EXPERIMENTAL|Hostile Bias Modification (HBM) Training plus Ambiguous Feedback|Volunteers will complete a novel computer-based hostile bias modification training where they are instructed to respond to word fragments (words with missing letters) based on whether the word fragments can be completed to form aggressive or positive/neutral words. They are instructed not to respond if only an aggressive word can be formed. They will receive ambiguously hostile feedback to an essay.
62266972|NCT04226820|EXPERIMENTAL|participant|Participants are divided into 3 groups based on their diagnosis: diabetes mellitus type 1, diabetes mellitus type 2, and healthy persons. Each participant (independent of group) will have the same examinations. There is no retesting of the same participant in other conditions.
62266973|NCT01401725|EXPERIMENTAL|Hamilton General Hospital|
62266974|NCT01401725|ACTIVE_COMPARATOR|Juravinski Hospital|
62266975|NCT01401725|OTHER|St. Joseph's Hospital|
62450337|NCT04699422|SHAM_COMPARATOR|Control group|Patients in the control group will receive postoperative PCIA with Piritramide.
62450338|NCT00266409|EXPERIMENTAL|Panic: Niravam+SSRI/SNRI|Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI
62851452|NCT04997356|PLACEBO_COMPARATOR|Other training plus Ambiguous Feedback|Volunteers will complete a computer-based task where they are instructed to respond to word fragments (words with missing letters) regardless of whether the fragments can make hostile or ambiguous words. They will receive ambiguously hostile feedback to an essay.
62266976|NCT02027142||Cases|Women referred to two academic centres for the diagnosis and treatment of endometriosis.
62450339|NCT00266409|EXPERIMENTAL|Panic: SSRI/SNRI alone|Panic Disorder: Newly prescribed SSRI or SNRI alone
62450340|NCT00266409|EXPERIMENTAL|GAD: Niravam+SSRI/SNRI|Generalized Anxiety Disorder: Niravam plus a newly prescribed SSRI or SNRI
62450341|NCT00266409|EXPERIMENTAL|GAD: SSRI/SNRI alone|Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone
62450342|NCT01368003|EXPERIMENTAL|STA9090 with Dutasteride|STA9090 with Dutasteride
62450343|NCT01368003|EXPERIMENTAL|STA9090|STA9090
62450344|NCT03232203||Health care providers|A HCP survey instrument of approximately 20 questions will be provided. Survey questions will be based on the STRIMVELIS summary of product characteristics and educational materials
62450345|NCT03232203||Parent/carer|A parent/carer survey instrument of approximately 20 questions will be provided. Survey questions will be based on the STRIMVELIS Patient Information Leaflet and educational materials
62625732|NCT05165719||Convalescents|PCR (polymerase chain reaction) confirmed COVID-19 in a period 14-45 days before recruitment
62266977|NCT02027142||Controls|Women referred to our Institutions because of routine gynaecologic consultations.
62851453|NCT00749567|EXPERIMENTAL|1|Erlotinib/Bevacizumab
62450346|NCT02098993|EXPERIMENTAL|Unfractionated heparin|"Subjects will be randomized within 24 hours of diagnosis to one of two treatment arms, Arm A, anticoagulation and standard of care, or Arm B, no anticoagulation and standard of care. Weight-adjusted UFH will be given at doses of 80 units per kilogram followed by 18 units per kilogram per hour intravenously for 7 days, or until discharge, if discharge is shorter than 7 days. UFH will be monitored by standard protocol to maintain the activated partial thromboplastin time in the therapeutic range per institutional guidelines.~The experimental arm will receive standard of care, too, which will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions."
62266978|NCT06079450||experimental group|Artificial intelligence-based mobile application initiative was implemented for diabetes patients
62450347|NCT02098993|NO_INTERVENTION|Standard of care|Standard care will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions.
62450348|NCT05911607|ACTIVE_COMPARATOR|Red Laser|Photobiomodulation using nm Diode.
62450349|NCT05911607|ACTIVE_COMPARATOR|Infrared Laser|Photobiomodulation using nm Diode.
62450350|NCT04148222||Patients|Patients who have been diagnosed with Lyme Disease
62450351|NCT01893138|PLACEBO_COMPARATOR|Placebo|Placebo control is the vehicle solution used for the study product.
62450352|NCT01893138|EXPERIMENTAL|Iltamiocel|AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intraurethral injection of 150 x 10\^6 cells.
62450353|NCT02660242|NO_INTERVENTION|Control|No basal insulin adjustment, no carbohydrate intake (until glucose drops \<70 mg/dL).
62450354|NCT02660242|ACTIVE_COMPARATOR|Basal insulin reduction|Basal insulin reduction to 50% five minutes before the start of exercise.
62450355|NCT02660242|ACTIVE_COMPARATOR|Glucose Tabs|Dextrose tabs orally (20 grams) five minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
62450356|NCT02660242|EXPERIMENTAL|G-Pen Mini™ (glucagon injection)|Glucagon (150 µg) five minutes before the start of exercise (SQ-abdomen).
62450357|NCT05805475|ACTIVE_COMPARATOR|Endotracheal suctioning without expiratory pause|Conventional endotracheal suctioning in closed suction system
62450358|NCT05805475|EXPERIMENTAL|Endotracheal suctioning with expiratory pause|Endotracheal suctioning in closed suction system associated with expiratory pause maneuver
62450359|NCT06543966|EXPERIMENTAL|Aprepitant Injection|Before anesthesia induction, 4.4ml(32mg） was given by a single intravenous injection, which was completed within 30 seconds
62450360|NCT06543966|PLACEBO_COMPARATOR|Placebo|Before anesthesia induction, 4.4ml(0mg）was given by a single intravenous injection, which was completed within 30 seconds
62450361|NCT00981786|ACTIVE_COMPARATOR|Brinzolamide/Timolol therapy|Chronic therapy for 3 months with brinzolamide/timolol drops given twice daily added to travoprost drops
62450362|NCT00981786|ACTIVE_COMPARATOR|Brimonidine/Timolol therapy|Chronic therapy for 3 months with brimonidine/timolol drops given twice daily added to travoprost drops
62450363|NCT01973114|EXPERIMENTAL|Group 1|One intratympanic injection of latanoprost (Day1)
62266979|NCT06079450||control group|no intervention was applied
62266980|NCT00768521|EXPERIMENTAL|1|Part I, Sequence 1: tolterodine tartrate crossing over to matching placebo
62450364|NCT01973114|PLACEBO_COMPARATOR|Group 2|One intratympanic injection of placebo
62450365|NCT01973114|EXPERIMENTAL|Group 3|Three intratympanic injections of latanoprost (Day 1, 2 and 3)
62450366|NCT01973114|PLACEBO_COMPARATOR|Group 4|Three intratympanic injections of placebo (Day 1, 2 and 3)
62450367|NCT01904500|OTHER|Cefazolin 2 grams|
62450368|NCT01904500|ACTIVE_COMPARATOR|Cefazolin 3 grams|
62450369|NCT03086356|EXPERIMENTAL|All Subjects|Dabigatran etexilate alone (days 1-4) and (days 8-10) and with Idarucizumab (day 11)
62450370|NCT01721525|EXPERIMENTAL|afatinib, ribavirin, and weekly carboplatin/paclitaxel|This will be a single institution phase I study with an expansion cohort. Up to 2 dose levels of daily afatinib will be studied: 30 mg/day and 40 mg/day. The doses of ribavirin, carboplatin, and paclitaxel are fixed. A standard 3 + 3 phase I dose escalation design will be used.
62450371|NCT06094374||Community Dwellling Healthy Older Adults|"* 65 years or older~* able to give informed consent~* community dwelling~* no severe illness (neurological, cardiovascular, respiratory, metabolic, cognitive disorder)~* dutch language profiency"
62450372|NCT06436196|ACTIVE_COMPARATOR|Direct Laryngoscopy Group|Group of patients in which standard direct laryngoscopy will be used to secure airway.
62266981|NCT00768521|EXPERIMENTAL|2|Part I, Sequence 2: placebo crossing over to study drug 4 mg once a Day (qd)
62266982|NCT00768521|EXPERIMENTAL|3|Part II, Sequence 1: study drug crossing over to placebo
62266983|NCT00768521|EXPERIMENTAL|4|Part II, Sequence 2: placebo crossing over to study drug
62266984|NCT04174781|EXPERIMENTAL|DEB-TACE+Sintilimab|Participants with BCLC Stage A/B Hepatocellular Carcinoma Beyond the Milan Criteria
62851454|NCT05618691|EXPERIMENTAL|GFH312 40mg|Participant will receive GFH312 40mg once daily approximately at same time each day for 12 weeks.
62851455|NCT05618691|EXPERIMENTAL|GFH312 80mg|Participant will receive GFH312 80mg once daily approximately at same time each day for 12 weeks.
62625733|NCT05165719||Healthy donors|No self-reported COVID-19 infection
62625734|NCT01443234|EXPERIMENTAL|OxIGen program|Internet based intervention taking place over 4 weeks
62625735|NCT01443234|PLACEBO_COMPARATOR|OxIGen: control version|A control version of the internet-based OxIGen intervention
62625736|NCT03159299|EXPERIMENTAL|Yo Puedo|This group will receive the modified Yo Puedo + mHealth program.
62625737|NCT03159299|NO_INTERVENTION|Wait-list Control|This group will not receive the Yo Puedo + mHealth program during the 6 month data collection period, but will be invited to participate in it after data collection has finished.
62062554|NCT04100122||Wheat-allergic|"The diagnosis of IgE-mediated wheat allergy was made if they have one of the following criteria~1. a convincing clinical history of the reactions within 4 hours after wheat ingestion during the past 12 months combined with positive skin prick test (SPT) and/or the level of specific IgE (sIgE) to wheat or~2. a positive oral food challenge (OFC) result to wheat during the past 12 months"
62062555|NCT04100122||Wheat tolerant|Patients with wheat tolerant confirmed by negative oral food challenge (OFC) result to wheat during the past 12 months
62625738|NCT00391872|ACTIVE_COMPARATOR|Clopidogrel|Oral treatment
62625739|NCT00391872|EXPERIMENTAL|Ticagrelor|Oral treatment
62625740|NCT02807831|EXPERIMENTAL|Executive functions training|
62625741|NCT02807831|EXPERIMENTAL|Language skills training|
62625742|NCT02807831|ACTIVE_COMPARATOR|Regular school curriculum|
62625743|NCT01888952|EXPERIMENTAL|Roflumilast and Prednisone|"Roflumilast 500 mcg will be administered orally daily for 21 consecutive days (a 21-day cycle).~In Cycle 1, prednisone 60 mg/m2 up to a maximum of 100 mg oral (PO) daily will be taken on Days 8 through 14 at the same time as roflumilast.~In Cycle 2 and subsequent cycles, prednisone 60 mg/m2 PO up to a maximum of 100 mg daily will be taken on Days 1 through 7 at the same time as roflumilast."
62851456|NCT05618691|EXPERIMENTAL|GFH312 120mg|Participant will receive GFH312 120mg once daily approximately at same time each day for 12 weeks.
62625744|NCT05314777|EXPERIMENTAL|Low dose ESWT application group|Exercise Training Low dose ESWT application
62625745|NCT05314777|EXPERIMENTAL|High dose ESWT group|Exercise Training High dose ESWT application
62851457|NCT05618691|EXPERIMENTAL|Placebo|Participant will receive placebo once daily approximately at same time each day for 12 weeks.
62851458|NCT04264481|EXPERIMENTAL|Adductor Canal Block|Adductor Canal Block (Saphaenous Nerve Block) done under Ultrasonographic guidance with 5cc of Bupivacaine, 5cc of lidocaine diluted with 10 cc of Normal Saline
62851459|NCT04264481|ACTIVE_COMPARATOR|Intra-articular Steroid and Lignocaine|Intra-articular knee joint injection of 40mg triamcinolone and 1-2cc of lidocaine
62851460|NCT04636216|EXPERIMENTAL|Community Parent Education Program (COPE) parent training program|Parents will enroll in an 8-week, group parenting program.
62851461|NCT03074019|EXPERIMENTAL|Xylooligosaccharide (Low Dose)|1.5g XOS95 + 1.5g Maltodextrin powder, taken orally mixed in water, once daily
62062556|NCT04100122||Wheat oral immunotherapy|Patients with IgE-mediated wheat allergy and underwent wheat oral immunotherapy for at least 6 months or at the maintenance phase of the treatment
62062557|NCT00525772|ACTIVE_COMPARATOR|1|ciclesonide 50 and 200ug
62062558|NCT00525772|ACTIVE_COMPARATOR|2|ciclesonide 100ug and 400ug
62625746|NCT05314777|ACTIVE_COMPARATOR|Control group|Exercise Training Sham ESWT
62625747|NCT01443741|ACTIVE_COMPARATOR|FIT Therapy|Patient with functional insulin therapy
62625748|NCT01443741|ACTIVE_COMPARATOR|Traditional way|Patient with traditional way
62625749|NCT05693753|EXPERIMENTAL|Xenogenic collagen matrix (XCM)|Multiple coronally advanced flap technique (mCAF) with the use of a XCM
62625750|NCT05693753|ACTIVE_COMPARATOR|Connective tissue graft (CTG)|Multiple coronally advanced flap technique (mCAF) with the use of a CTG
62625751|NCT03774888|EXPERIMENTAL|connective tissue graft|Connective tissue grafting (CTG) will be placed at the time of lateral ridge augmentation.Following the placement of the bone graft and the membrane, a CTG will be harvested and sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
62062559|NCT01119768|ACTIVE_COMPARATOR|Esomeprazole 8 weeks treatment|20 mg q.d. (quaque die) once a day dosing for 8 weeks
62062560|NCT01119768|ACTIVE_COMPARATOR|Esomeprazole 2 Weeks Treatment|20 mg q.d. (quaque die) once a day dosing for 2 weeks
62625752|NCT03774888|EXPERIMENTAL|Acellular Dermal Matrix|Acellular Dermal matrix (ADM) will be placed at the time of lateral ridge augmentation.Following the placement of the bone graft and the membrane, an ADM will be sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
62625753|NCT03774888|ACTIVE_COMPARATOR|No soft tissue graft (Control)|Control group where no soft tissue graft is added to the lateral ridge augmentation.Following the placement of the bone graft and the membrane, the flaps passively sutured on top on the bone. No soft tissue graft will be added.
62625754|NCT02494856|EXPERIMENTAL|Surgery with Naproxen|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, will be treated to control pain, swelling and trismus with naproxen 500mg.
62625755|NCT02494856|EXPERIMENTAL|Surgery with Naproxen and Esomeprazole|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, will be treated to control pain, swelling and trismus with naproxen 500mg and esomeprazole 20mg.
62851462|NCT03074019|EXPERIMENTAL|Xylooligosaccharide (High Dose)|3g XOS95 powder, taken orally mixed in water, once daily
62851463|NCT03074019|PLACEBO_COMPARATOR|Placebo|3g maltodextrin powder, taken orally mixed in water, once daily
62062561|NCT04263103|EXPERIMENTAL|Experimental group with SJ-RS-WL2015|Item code: SJ-RS-WL2015, a visual training software program, 15 minutes of one section, twice a day, and for 1 year
62266985|NCT02157675|EXPERIMENTAL|Polyherbal capsule|Subjects take 1 capsule with breakfast and 1 capsule with lunch. Subjects should take capsules immediately prior to meals and not with carbonated beverages.
62266986|NCT02157675|PLACEBO_COMPARATOR|Placebo capsule|Subjects take 1 capsule with breakfast and 1 capsule with lunch. Subjects should take capsules immediately prior to meals and not with carbonated beverages.
62450373|NCT06436196|ACTIVE_COMPARATOR|Video Laryngoscopy group|Group of patients in which Video Laryngoscopy will be used to secure airways.
62625756|NCT05764954|EXPERIMENTAL|NovoTTF-200T System Tumor-Treating Fields (TTFields)|Following pathological confirmation on of lung ADC, patients will proceed with TTFields treatment. The NovoTTF-200T System is an investigational medical device delivering 150 kHz TTFields to the patient's chest. The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week).
62625757|NCT05916807|EXPERIMENTAL|Stabilization Exercises|Twenty-six (26) patients will be treated with stabilization exercises in breast feeding females suffering from scapular dyskinesia.
62625758|NCT05916807|EXPERIMENTAL|Posture Training|Twenty-six (26) patients will be treated with posture training of breast-feeding females suffering from scapular dyskinesia.
62625759|NCT01712971||OPD|standard open pancreaticoduodenectomy
62625760|NCT01712971||LPD|laparoscopic pancreaticoduodenectomy
62851464|NCT03743935|EXPERIMENTAL|Early cardiac MRI post-STEMI|Early stages post-STEMI (within the first 5 days)
62851465|NCT02224248|EXPERIMENTAL|Health checks with fitness testing|
62625761|NCT03163537||Kidney transplantation, postmortal, day|
62625762|NCT03163537||Kidney transplantation, postmortal, night|
62625763|NCT03163537||Kidney transplantation, living donor|
62851466|NCT02224248|ACTIVE_COMPARATOR|Health checks without fitness testing|
62851467|NCT03145818||Veterans|Veterans will be the primary group for whom the VD-HCBS Program is implemented. Veterans enrolled in VD-HCBS will be functionally impaired
62851468|NCT03145818||Caregivers|Caregivers support Veterans independence in their home and community
62851469|NCT03145818||VHA Coordinators|VHA VD-HCBS Coordinators allow the program to operate within the VA
62851470|NCT03145818||ADNA Coordinators|ADNA Coordinators engage with the Veteran, Caregivers, and VA Coordinators to ensure the Veteran is able to maintain independence
62625764|NCT01730716|EXPERIMENTAL|Surgery|There will be 5 sequential cohorts (Groups A-E) with 3 subjects in each cohort. Each cohort will follow a dose escalation plan. New patients will be enrolled into each group. No control group is included. All patients will received spinal cord injections of HSSC.
62450374|NCT00521248|ACTIVE_COMPARATOR|Oral morphine solution|Oral morphine solution
62652889|NCT03912272|EXPERIMENTAL|High-intensity Interval Training Group|HIIT will be prescribed once weekly under the supervision of certified athletics coaches for 12 months. HIIT training will be performed in a small group setting (4-8 participants each group) in laboratories. In each session, subjects will run for four 4-minute intervals at 85%-95% of the peak heart rate (HRpeak) with a 3-minute active recovery at 50%-70% of the HRpeak between each interval. A 5-minute jog at an intensity of 70% of the HRpeak will be included for warm-up and cool-down before and after, respectively. Subjects will be asked to attend \>70% of the classes.
62450375|NCT00521248|EXPERIMENTAL|Buprenorphine|Sublingual buprenorphine
62450376|NCT00816959|ACTIVE_COMPARATOR|Arm I: R-mabHDI and ABVD|
62625765|NCT05003869|EXPERIMENTAL|Intraoperative resection of intrauterine scar tissue by TCRA|Study group: patients took the bladder lithotomy position, routinely disinfected vulva and vagina, and laid sterile towel and sheet.pliers Clamp the front lip of the cervix, explore the depth of the uterine cavity, dilate the cervical canal one by one, place the endoscopy, and examine the uterine cavity.After the scar tissue contracted on one side, the scar tissue was disintegrated at the boundary between the intima and scar tissue. The scar tissue was removed with the annular electrode, and a balloon was placed after surgery to prevent re-adhesion.Complete adhesion release is defined as a return to normal shape of the uterine cavity with bilateral uterine angles exposed.
62625766|NCT05003869|NO_INTERVENTION|No scar tissue resection group|During the operation, the scar tissue covering the anterior, posterior and lateral walls of the uterine cavity was ploughed longitudinally into several narrow strips with needle-like electrodes, and scar tissue was not excised.
62625767|NCT05498597|EXPERIMENTAL|AMT-151 Dose Escalation|
62625768|NCT05398796|EXPERIMENTAL|Group 1|25 mcg IM
62450377|NCT00816959|ACTIVE_COMPARATOR|Arm II: ABVD|
62450378|NCT03621709||CoreValve™ Evolut R™ 34mm|All consecutive real-world patients with aortic stenosis selected for TAVI as part of routine clinical care, using a CoreValve™ Evolut R™ 34mm during the inclusion period will be entered the registry.
62450379|NCT01503775||TRUFILL® DCS Orbit Galaxy|
62450380|NCT04844177|EXPERIMENTAL|intervention/treatment|"Total lymphoid irradiation 4 Gy (days -7, -6) in combination with:~* Fludarabine 150 mg/m2 (days-6, -5, -4, -3, -2)~* Cyclophosphamide 120 mg/kg (days -5, -4, -3)~* Thymoglogulin (Genzyme) 5 mg/kg (days -5, -4)~* Melphalan 180 mg/m2 (day -2)~* Rituximab 100 mg/m2 (day -1)~* Hematopoietic stem cell graft infusion after TCRab/CD19 depletion - day 0"
62450381|NCT03366909|EXPERIMENTAL|MBRP group|20 patients 2 groups of 10 patients
62625769|NCT05398796|EXPERIMENTAL|Group 2|50 mcg IM
62625770|NCT05398796|EXPERIMENTAL|Group 3|100 mcg IM
62851471|NCT05249478|ACTIVE_COMPARATOR|epidural catheter inserted before spinal anesthesia.|"As for the epidural analgesia, it will be performed under complete aseptic precautions, by introducing a needle between the lumbar vertebrae at level of L3-L4 or L4-L5 and injecting anesthetic medication into the epidural space, via the epidural catheter inserted through the needle into the epidural space.~A small amount of air (1 to 2 mL) may be injected into the epidural space, avoid injecting larger amounts of air as this may contribute to patchy anesthesia."
62851472|NCT05249478|ACTIVE_COMPARATOR|ultrasound guided femoral nerve catheter inserted before spinal anesthesia.|"As for the femoral nerve block, it will be performed under complete aseptic precautions, using a transportable Sonosite M-Turbo ultrasound system with linear transducer placed on the femoral crease to obtain the images of the femoral nerve \& artery.~The needle used for the block will be an echogenic needle of 18 Gauge and 3.5 inches. Before proceeding, skin infiltration with local anesthesia will be done using a syringe containing 5ml of 1% lidocaine, Once the femoral nerve is visualized, the needle will be inserted in-plane in a lateral to medial orientation and advanced towards the nerve. Once the tip placed adjacent to the nerve, the catheter is introduced through it, then the needle is removed, the location of the catheter can be confirmed by visualization of the catheter and spread of local anesthetic (LA)."
62266987|NCT02972255|EXPERIMENTAL|Part I: RO7079901|Participants will be randomized in two dose cohorts to receive single dose of RO7079901 1000 and 2000 milligrams (mg) intravenous (IV) infusion on Days 1 through Day 7 every 8 hours (q8h), for a total of 19 doses, with the last dose administered on the morning of Day 7.
62851473|NCT05249478|ACTIVE_COMPARATOR|ultrasound guided adductor canal block inserted before spinal anesthesia.|As for the adductor canal block,using a transportable Sonosite M-Turbo ultrasound system with linear transducer placed perpendicular to the thigh at the midpoint between the anterior superior iliac spine and the base of the patella,The needle used for the block will be an echogenic needle of 18 Gauge and 3.5 inches. Before proceeding, skin infiltration with local anesthesia will be done using a syringe containing 5ml of 1% lidocaine, the saphenous nerve is identified as it lies adjacent proximally lateral then distally superior to the femoral artery. Saphenous nerve is followed distally as it becomes more superficial, traveling with an arterial branch just deep to the sartorius muscle. Using an in-plane approach, after negative aspiration, the tip of the needle is placed deep to the sartorius muscle, at the lateral border of the artery, Once the needle is in position, the catheter is introduced through it, then the needle is removed.
62851474|NCT04657666|EXPERIMENTAL|Nabiximols|"Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides. Each spray delivers 100 microliters (μL) of nabiximols.~Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks."
62851475|NCT04657666|PLACEBO_COMPARATOR|Placebo|"Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 μL containing no active ingredients.~Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks."
62851476|NCT02047721|EXPERIMENTAL|Physical Intervention|A supervised exercise program
62851477|NCT02047721|EXPERIMENTAL|Nutritional Intervention|A supervised diet program
62851478|NCT00983008|EXPERIMENTAL|Protected Time Group|Interns working 30 hour shifts every 3rd night and an average of 80 hours per week in a medical intensive care unit.
62851479|NCT04126278|EXPERIMENTAL|Barbotage Injection|Subjects receiving barbotage with saline injection
62851480|NCT04126278|ACTIVE_COMPARATOR|Barbotage with Cortisone Injection|Subjects receiving barbotage with cortisone injection
62851481|NCT01788358|EXPERIMENTAL|Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)|Subjects received nifedipine gastrointestinal therapeutic system (GITS) / candesartan cilexetil fixed dose combination (FDC) (BAY98-7106) tablet orally, once daily in the morning of Visit 1 (Week 0) for 28 or 52 weeks. The starting dose (30/8 milligram \[mg\] or 30/16 mg) was determined based on local practice and clinical judgment by the investigator. Based on the experience of symptomatic and asymptomatic hypotension, peripheral edema or significant tolerability, the doses were up-titrated to the highest target dose (60/32 mg).
62851482|NCT00358540|EXPERIMENTAL|Group B|Group B is a dose escalation phase designed to determine the optimal biological dose of eltrombopag in subjects with sarcoma who received chemotherapy treatment with Adriamycin and Ifosfamide
62266988|NCT02972255|PLACEBO_COMPARATOR|Part I: Placebo|Participants will be randomized in two dose cohorts to receive single dose of placebo matching to RO7079901 on Days 1 through Day 7 q8h, for a total of 19 doses, with the last dose administered on the morning of Day 7.
62266989|NCT02972255|EXPERIMENTAL|Part II - Single Dose and Repeat Dose: RO7079901|Participants will be randomized in two dose cohorts to receive single dose of RO7079901 IV infusion at a dose above the previously studied dose levels in Part I (greater than \[\>\] 2000 mg) on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.
62266990|NCT02972255|PLACEBO_COMPARATOR|Part II - Single Dose and Repeat Dose: Placebo|Participants will be randomized in two dose cohorts to receive single dose placebo matching to RO7079901 on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.
62450382|NCT03366909|ACTIVE_COMPARATOR|classic care in addictology center|20 patients
62625771|NCT05398796|EXPERIMENTAL|Group 4|
62062562|NCT04263103|NO_INTERVENTION|control group|No special treatment, but observation
62062563|NCT00171873|EXPERIMENTAL|Octreotide LAR (Long Acting Release)|Octreotide LAR 30 mg intramuscularly every 28 days
62062564|NCT00171873|PLACEBO_COMPARATOR|Placebo|Placebo - Sodium chloride intramuscularly every 28 days
62062565|NCT06010901|EXPERIMENTAL|TQB2618 injection+Penpulimab injection +Anlotinib hydrochloride capsules|TQB2618 injection combined with Penpulimab injection and Anlotinib hydrochloride capsules, 3 weeks as a treatment cycle.
62062566|NCT06010901|EXPERIMENTAL|TQB2618 injection+Penpulimab injection|TQB2618 injection combined with Penpulimab injection, 3 weeks as a treatment cycle.
62062567|NCT06010901|EXPERIMENTAL|TQB2618 injection|TQB2618 injection, 3 weeks as a treatment cycle.
62450383|NCT01439893|ACTIVE_COMPARATOR|rhNRG-1|Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure
62851483|NCT00358540|EXPERIMENTAL|Group A|Group A will be used for further exploration of the optimal biological dose (as initially established by completion of Group B), by using 2 different dosing schedules of eltrombopag.
62851484|NCT02381483|EXPERIMENTAL|Lean|Cold exposure
62851485|NCT02381483|EXPERIMENTAL|Obese|Cold exposure
62062568|NCT06261190||Active surveillance|Group with active surveillance of their Papillary Thyroid Cancer
62062569|NCT06261190||Immediate surgery|Group who underwent surgery after diagnosis Papillary Thyroid Cancer
62062570|NCT01528449|EXPERIMENTAL|retrospective|archived specimens from blood donors whose units have already been released and transfused into recipients will be tested. Attempts will be made to contact and obtain follow up specimens from both the donor and recipient of units initially testing positive for B.microti. the interventions are investigational diagnostic tests for B.microti (PCR and IFA).
62062571|NCT01528449|EXPERIMENTAL|prospective, real time|specimens from current blood donors will be tested and those testing positive for B.microti will not be released and the units will be disgarded, and the donors notified and deferred from future blood donation. the interventions are investigational diagnostic tests for B.microti (PCR and IFA).
62062572|NCT05923086|PLACEBO_COMPARATOR|Placebo|Placebo treatment (4 tablets)
62851486|NCT02740803|EXPERIMENTAL|NaF - R|Participants will use sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
62062573|NCT05923086|EXPERIMENTAL|ORE001|ORE001 treatment (4 tablets)
62851487|NCT02740803|EXPERIMENTAL|NaF - NR|Participants will use sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
62851488|NCT02740803|EXPERIMENTAL|NaMFP- R|Participants will use sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
62851489|NCT02740803|EXPERIMENTAL|NaMFP- NR|Participants will use sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
62851490|NCT02740803|EXPERIMENTAL|SnF + NaF - R|Participants will use stannous fluoride combined with sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
62851491|NCT02740803|EXPERIMENTAL|SnF + NaF - NR|Participants will use stannous fluoride combined with sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
62851492|NCT02740803|EXPERIMENTAL|NaF + NaMFP - R|Participants will use sodium fluoride combined sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
62851493|NCT02740803|EXPERIMENTAL|NaF + NaMFP - NR|Participants will use sodium fluoride combined sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
62062574|NCT04866121|NO_INTERVENTION|Standard Treatment|Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia.
62087981|NCT03047603||Chronic liver disease patients|This group is comprised of liver cirrhosis and chronic hepatitis B patients. The diagnosis of liver cirrhosis are based on triple-phase contrast enhanced computed tomography, magnetic resonance imaging.
62087982|NCT05934097|EXPERIMENTAL|Regimen A (FT596 in combination with standard schedule R-CHOP)|FT596 in combination with standard schedule R-CHOP (rituximab, cyclophosphamide, doxorubicin, and vincristine on Day 1; prednisone on Days 1-5; and FT596 on Day 8) for a total of six 21-day cycles.
62087983|NCT05934097|EXPERIMENTAL|Regimen B (FT596 in combination with alternate schedule R-CHOP)|FT596 in combination with alternate schedule R-CHOP (prednisone on Days 1-5; rituximab, cyclophosphamide, doxorubicin, and vincristine on Day 5; and FT596 on Day 8) for a total of six 21-day cycles
62087984|NCT04908436|EXPERIMENTAL|Normal renal function|Healthy participants with creatinine clearance (CLCR) \>80 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
62087985|NCT04908436|EXPERIMENTAL|Mild renal impairment|Participants with CLCR 50-80 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
62087986|NCT04908436|EXPERIMENTAL|Moderate renal impairment|Participants with CLCR 30-\<50 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
62087987|NCT04908436|EXPERIMENTAL|Severe renal impairment|Participants with CLCR \<30 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
62087988|NCT04159961|EXPERIMENTAL|GroupA|Inject the Drug into submental fat and abdominal fat via subcutaneous
62087989|NCT04159961|EXPERIMENTAL|GroupB|Inject the Drug into submental fat and abdominal fat via subcutaneous
62087990|NCT04159961|EXPERIMENTAL|GroupC|Inject the Drug into submental fat and abdominal fat via subcutaneous
62087991|NCT04289285|EXPERIMENTAL|IBI306 450mg SC Q4W|
62087992|NCT04289285|PLACEBO_COMPARATOR|Placebo SC Q4W|
62087993|NCT04289285|EXPERIMENTAL|IBI306 600mg SC Q6W|
62087994|NCT04289285|PLACEBO_COMPARATOR|Placebo SC Q6W|
62062575|NCT04866121|ACTIVE_COMPARATOR|Single point (P6) Acupuncture|"Prior to the anesthesia induction, the same certified medical doctor will perform a standard acupuncture protocol to the P6 point bilaterally. For P6 acupuncture stimulation 0,25x25mm steel needles will be immersed for 2cm. For stimulation, the needles will be turned clock-wise 3 times. This stimulation will be repeated for 3 times with 10 seconds intervals. The needles will be held in place for 20 minutes and will be removed afterwards.~Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia."
62062576|NCT04866121|EXPERIMENTAL|Double point (P6+ST36) Acupuncture|Prior to the anesthesia induction, the same certified medical doctor will perform a standard acupuncture protocol both to the P6 and ST36 points bilaterally. For P6 acupuncture stimulation 0,25x25mm steel needles will be immersed for 2cm. For ST6 acupuncture stimulation 0,25x50mm steel needles will be immersed for 5cm. For stimulation, the needles will be turned clock-wise 3 times. This stimulation will be repeated for 3 times with 10 seconds intervals. The needles will be held in place for 20 minutes and will be removed afterwards. Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia.
62062577|NCT04407013|EXPERIMENTAL|A|Experimental group with application of the standardized care pathways and symptom management education
62851494|NCT02740803|EXPERIMENTAL|AmF - R|Participants will use amine fluoride toothpaste (1,400 ppmF) to brush for two minutes followed by rinsing with distilled water.
62062578|NCT04407013|OTHER|B|Control group with usual care (symptom monitoring only)
62266991|NCT02972255|EXPERIMENTAL|Part III: RO7079901 + Meropenem|Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem IV infusion in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of 2000 mg meropenem IV infusion on Day 1. On Day 2, participants will receive a single dose of RO7079901 IV infusion. Participants randomized to Sequence 2 will receive a single dose of RO7079901 IV infusion on Day 1. On Day 2, participants will receive a single dose of 2000 mg meropenem IV infusion. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 in combination with meropenem IV infusion q8h, regardless of sequence. Escalation to a maximum dose of RO7079901 5000 mg q8h may be considered on the basis of safety and tolerability data from the previous cohorts.
62062579|NCT06626035|EXPERIMENTAL|Methadone-Based ERAS Group|Children randomized to the methadone arm will receive standardized perioperative care and analgesia, including intraoperative intravenous methadone (0.1 mg/kg up to a maximum of 5 mg before incision and 0.05 mg at the end of surgery) and postoperatively, up to 4 oral doses of methadone every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.
62062580|NCT06626035|ACTIVE_COMPARATOR|SOC Non-Methadone-Based Group|Children randomized to the standard-of-care arm will receive standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards.
62450384|NCT01439893|PLACEBO_COMPARATOR|Placebo|Excipient placebo in addition to basic therapy of chronic heart failure
62450385|NCT04857619||Retrospective|Patients who are diagnosed with HER2-positive unresectable or mBC and have received at least 1 LOT in the advanced setting will be included. Approximately a total of 570-830 patients will be enrolled in the study.
62450386|NCT04458077|EXPERIMENTAL|Mobile-phone-based SEIL Intervention|This group will receive the Discover Learning 10-session intervention through a mobile-phone based platform over the course of 10 weeks (1 session per week).
62450387|NCT00858000||Group A|No intervention
62450388|NCT00005842|EXPERIMENTAL|Arm I|Patients receive trastuzumab (Herceptin) IV over 90 minutes on days 1, 8, 15, and 22 plus oral R115777 twice daily for 3 weeks. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R115777 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.
62851495|NCT02740803|EXPERIMENTAL|AmF - NR|Participants will use amine fluoride toothpaste (1,400 ppmF) to brush for two minutes not followed by rinsing with distilled water.
62851496|NCT02740803|EXPERIMENTAL|0 Fluoride - R|Participants will use non-fluoridated toothpaste (0 ppmF) to brush for two minutes followed by rinsing with distilled water.
62851497|NCT02740803|EXPERIMENTAL|0 Fluoride - NR|Participants will use non-fluoridated toothpaste (0 ppmF) to brush for two minutes not followed by rinsing with distilled water.
62625772|NCT03731390|EXPERIMENTAL|GR1405 injection 3 mg/kg|According to the patient's weight, the dose of this group is 3mg/kg.
62625773|NCT03731390|EXPERIMENTAL|GR1405 injection 10 mg/kg|According to the patient's weight, the dose of this group is 10mg/kg.
62625774|NCT03731390|EXPERIMENTAL|GR1405 injection 20 mg/kg|According to the patient's weight, the dose of this group is 20mg/kg.
62625775|NCT03731390|EXPERIMENTAL|GR1405 injection 30 mg/kg|According to the patient's weight, the dose of this group is 30mg/kg.
62266992|NCT02972255|PLACEBO_COMPARATOR|Part III: RO7079901 Placebo + Meropenem Placebo|Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem matching placebos in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of placebo matching to meropenem on Day 1. On Day 2, participants will receive a single dose of placebo matching to RO7079901. Participants randomized to Sequence 2 will receive a single dose of placebo matching to RO7079901 on Day 1. On Day 2, participants will receive a single dose of placebo matching to meropenem. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 and meropenem matching placebos q8h, regardless of sequence.
62266993|NCT05664087|EXPERIMENTAL|Experimental group|Debridement of tooth extraction sockets was assisted by photodynamic equipment
62625776|NCT00884078|EXPERIMENTAL|1|C-MAPS (Culturally adapted manualized problem solving training) will be a brief problem focused therapy comprising of 8 sessions within three months after a self-harm episode. We will have two engagement sessions before the actual therapy. The adapted therapy/training will be delivered by therapists/trained counselors in the patient's home/GP practice depending upon patient's choice. Sessions will be offered weekly in the first month and than fortnightly and will last 50 minutes.
62625777|NCT00884078|NO_INTERVENTION|2 Control group|"Patients who will be randomized to the treatment as usual arm will receive routine care. In most cases this consists of an assessment by a casualty doctor or a junior psychiatrist in the emergency department, on the basis of which about one third patients are referred for follow up as a psychiatry outpatient, a small number are referred to addiction services, and the remainder are advised to consult their own general practitioner (Kapur 1998) this is particularly so in case of Asian females (Cooper et al, 2006). No patients are routinely referred to psychotherapy or psychology services. Participants will receive an initial assessment along with treatment as usual (TAU) as ascertained by the general practitioner or mental health professional any type of treatment apart from C-MAPS will be permitted. We will record the degree of patient adherence to standard care."
62625778|NCT02913781|EXPERIMENTAL|polar body removal|polar body removal by zona drilling with laser then suction by injecting pipette then ICSI procedure is done
62625779|NCT06033261|EXPERIMENTAL|mRNA-1608 Dose A|Participants will receive 2 intramuscular (IM) injections of mRNA-1608 at Dose Level A, each dose administered at 0 and 2 months (Day 1 and Day 57).
62625780|NCT06033261|EXPERIMENTAL|mRNA-1608 Dose B|Participants will receive 2 IM injections of mRNA-1608 at Dose Level B, each dose administered at 0 and 2 months (Day 1 and Day 57).
62625781|NCT06033261|EXPERIMENTAL|mRNA-1608 Dose C|Participants will receive 2 IM injections of mRNA-1608 at Dose Level C, each dose administered at 0 and 2 months (Day 1 and Day 57).
62625782|NCT06033261|OTHER|BEXSERO|Participants will receive 2 IM injections of BEXSERO, each dose administered at 0 and 2 months (Day 1 and Day 57).
62625783|NCT00647595|EXPERIMENTAL|A|Women in this group will exercise 3x per week at a moderate/vigorous level for 45 min per session through their 36 week of pregnancy.
62062581|NCT01316770|PLACEBO_COMPARATOR|Placebo Parotid Irrigation|Within-Subject, Double-Blind, Placebo-Controlled Study. This parotid gland is irrigated with saline (placebo). { UPDATE: drug(generic) was administered at what time pt, dose of drug, route administration, frequency}
62266994|NCT05664087|NO_INTERVENTION|control group|Routine tooth extraction and debridement were performed
62266995|NCT02298829||No Treatment|Subjects who received AA4500 in a 12-month double blind placebo-controlled study (AUX CC 803 or AUX-CC-804) or in a 9-month open label study (AUX-CC-802 or AUX-CC-806) sponsored by Auxilium Pharmaceuticals, Inc.
62450389|NCT00782509|EXPERIMENTAL|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
62625784|NCT00647595|NO_INTERVENTION|B|Women in this group will continue their usual activities throughout their pregnancy.
62625785|NCT04035499|EXPERIMENTAL|Experimental Arm:single|GO-EXCAP Mobile App involves the use of a mobile app delivery platform to deliver an exercise program \[Exercise for Cancer Patients (EXCAP©®)\]. EXCAP©® is a progressive walking and resistance exercise program
62625786|NCT04693078|EXPERIMENTAL|Intervention Arm|Consecutive patients undergoing screening or surveillance colonoscopy in whom a new polyp detection system based on deep learning will be used during the procedure.
62851498|NCT02532699|ACTIVE_COMPARATOR|AC mycelia|Subjects receive three capsules per day containing either 420 mg of AC mycelia.
62266996|NCT03725878|EXPERIMENTAL|Interventional|Standard tertiary interventions of birth defects; Additional preconception health care; Additional health care procedures during and after pregnancy.
62450390|NCT00782509|PLACEBO_COMPARATOR|Placebo|Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
62450391|NCT00782509|EXPERIMENTAL|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
62625787|NCT00810498|EXPERIMENTAL|Trilogy|Trilogy Device
62625788|NCT00810498|ACTIVE_COMPARATOR|Standard of Care|Participants prescribed ventilator
62851499|NCT02532699|PLACEBO_COMPARATOR|Placebo|Subjects receive three capsules per day containing starch placebo of similar appearance.
62450392|NCT05443243||Varus Stems|Patients with a THA Stem implanted in Varus position
62450393|NCT05443243||Neutral stems|Patients with a THA Stem implanted in Neutral position
62851500|NCT02492607|ACTIVE_COMPARATOR|Standard treatment|"Standard treatment according to local policy. This can be either wide local excision only, wide local excision and radiotherapy, or mastectomy. Hormonal therapy is also allowed.~Follow-up:by annual digital mammography for a period of 5 years and a digital mammography at 7 and 10 years."
62266997|NCT03725878|ACTIVE_COMPARATOR|Control|Standard tertiary interventions of birth defects; Additional health care procedures during and after pregnancy.
62851501|NCT02492607|EXPERIMENTAL|Active surveillance|Active surveillance : monitoring by annual digital mammography for a period of 5 years and a digital mammography at 7 and 10 years.
62851502|NCT02878798|PLACEBO_COMPARATOR|Placebo|An overencapsulated placebo of identical color, shape and packaging to topiramate will be used.
62851503|NCT02878798|EXPERIMENTAL|Topiramate|Oral topiramate
62851504|NCT03868644|EXPERIMENTAL|Voluntary Counseling and Testing for HIV (VCT)|Youth are offered VCT conducted onsite via mobile clinics in accordance with Kenya National HIV Testing Guidelines by certified VCT counselors trained by the National AIDS and STI Control Program (NASCOP).
62062582|NCT01316770|EXPERIMENTAL|Dexamethasone Parotid Irrigation|Within-Subject, Double-Blind, Placebo-Controlled Study. This parotid gland is irrigated with dexamethasone {UPDATE: drug (generic) was administered at what time pt, dose of drug, route administration, frequency}
62266998|NCT01708109|EXPERIMENTAL|Biliary calculus remain|biliary calculus, less than or equal to 6 mm, remains
62266999|NCT01708109|EXPERIMENTAL|Biliary calculus removed|biliary calculus, less than or equal to 6 mm, removed
62450394|NCT05683509|ACTIVE_COMPARATOR|deep collagen layer, xenograft and collagen membrane|Alveolar ridge preservation is done using deep collagen layer, xenograft and collagen membrane
62450395|NCT05683509|ACTIVE_COMPARATOR|xenograft and collagen membrane|Alveolar ridge preservation is done using xenograft and collagen membrane alone
62450396|NCT01106183|ACTIVE_COMPARATOR|Transfer Factor|Transfer factor supplement; 2 capsules per day
62450397|NCT01106183|PLACEBO_COMPARATOR|Sugar pill|
62450398|NCT03301909|EXPERIMENTAL|PillCam™ Endoscopy System|"PillCam™ Endoscopy System consists of the following subunits:~* PillCam™ Capsule products' family:~  1. PillCam™ COLON 2~ 2. PillCam™ UGI (upper gastrointestinal)~ 3. PillCam™ SB3 (small bowel 3)~ 4. PillCam™ Crohn's capsule~* Patency capsule: PillCam™ Patency capsule~All the bellow system subunits are part of the Pillcam™ systems:~* PillCam™ Recorder~* PillCam™ Sensor Arrays \& Sensor Belt~* PillCam™ Software v. 9~* Workstation unit"
62450399|NCT02178709|EXPERIMENTAL|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~2. Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~3. Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle~4. 5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5. 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
62450400|NCT03696381|EXPERIMENTAL|Real tRNS|Real tRNS + Guttmann NeuroPersonalTrainer (GNPT) 3 days per week over 8 weeks.
62450401|NCT03696381|SHAM_COMPARATOR|Sham tRNS|Sham tRNS + Guttmann NeuroPersonalTrainer (GNPT) 3 days per week over 8 weeks.
62450402|NCT01620177|EXPERIMENTAL|0% THC with 0.065 g/dL BAC|
62450403|NCT01620177|EXPERIMENTAL|2.5-3.5% THC with 0.065 g/dL BAC|
62450404|NCT01620177|EXPERIMENTAL|6.0-7.5% THC and 0.065 g/dL BAC|
62450405|NCT01620177|EXPERIMENTAL|2.5-3.5% THC with 0 g/dL BAC|
62851505|NCT03868644|EXPERIMENTAL|Condoms|Youth are offered 50 packages containing 3 condoms each of Trust brand condoms free of charge.
62851506|NCT03868644|EXPERIMENTAL|VCT and Condoms|Youth are offered both VCT and condoms.
62851507|NCT03868644|NO_INTERVENTION|Control|No intervention is provided (beyond the standard available HIV prevention services within the area)
62851508|NCT02371941|EXPERIMENTAL|Oral cromolyn|"Subjects randomized to the experimental arm will receive oral cromolyn sodium. The dose will be per current package insert for oral cromolyn:~Subjects 2-12 years of age - 100 mg (1 ampule) 4 times daily Subjects 13-18 years of age - 200 mg (2 ampules) 4 times daily"
62851509|NCT02371941|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo will receive normal saline ampules Subjects 2-12 years of age - 1 ampule 4 times daily Subjects 13-18 years of age - 2 ampules 4 times daily
62851510|NCT01724554|EXPERIMENTAL|Every Month Treatment|Patients will receive Intravitreal Aflibercept Injection (IAI) every month for the 12 month duration of the study.
62851511|NCT01724554|EXPERIMENTAL|Every Month, then Every Other Month|Patients will receive Intravitreal Aflibercept Injection (IAI) every month for the first 6 months, then every other month for the next 6 months. Retreatment criteria will allow for patients to be treated every month in the second 6 months if needed.
62062583|NCT00880425||Participants with continuous headache|
62267000|NCT03182270|EXPERIMENTAL|pancreatic cysts|
62267001|NCT00385255|EXPERIMENTAL|BOOSTRIX+FLUARIX GROUP|Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Boostrix® vaccine co-administered with Fluarix® vaccine at Day 0, injected intramuscularly in the left and right upper deltoid regions, respectively.
62450406|NCT01620177|EXPERIMENTAL|6.0-7.5% THC with 0 g/dL BAC|
62450407|NCT01620177|EXPERIMENTAL|0% THC with 0 g/dL BAC|
62450408|NCT03305029|EXPERIMENTAL|SCNT-hES-RPE Cells|Pars plana vitrectomy and Sub-retinal Transplantation of Human Somatic cell nuclear transfer Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells (SCNT-hES-RPE Cells) in Patients with Advanced Dry Age-related Macular Degeneration(AMD)
62450409|NCT03824626||TEVAR patients|patients scheduled for thoracic endovascular aortic repair
62450410|NCT03530956|ACTIVE_COMPARATOR|Current prosthesis|A unilateral transtibial amputee will conduct experiments with the current prosthesis
62450411|NCT03530956|EXPERIMENTAL|Novel prosthesis|A unilateral transtibial amputee will conduct experiments with the novel prosthesis
62625789|NCT01018914|ACTIVE_COMPARATOR|Prograf with Myfortic|
62625790|NCT01018914|EXPERIMENTAL|Advagraf with Myfortic|
62625791|NCT00494429|EXPERIMENTAL|1|Gestational Age\< 29 weeks will be administered a loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/hr.
62625792|NCT00494429|EXPERIMENTAL|2|Gestational Age\>= 29 weeks will be administered a loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
62625793|NCT05372185|EXPERIMENTAL|VA CALM-S|Active psychotherapy using VA CALM-S, a weekly (9-12 sessions) cognitive behavioral therapy addressing co-occurring anxiety and substance use disorders, using disorder specific and transdiagnostic tools.
62851512|NCT03635658|ACTIVE_COMPARATOR|titanium mesh|using non resorbable titanium mesh to fix and cover the onlay bone graft mixture to the atrophic maxillary ridge.
62851513|NCT03635658|EXPERIMENTAL|collagen membrane(Sausage technique)|using resorbable collagen membrane with the sausage technique to fix the onlay bone graft mixture to the resorbed atrophic maxillary ridge
62851514|NCT04708236|EXPERIMENTAL|ORTD-1 Low dose|Arm 1: ORTD-1
62851515|NCT04708236|EXPERIMENTAL|ORTD-1 Mid Dose|Arm 2: ORTD-1
62851516|NCT04708236|EXPERIMENTAL|ORTD-1 High Dose|Arm 3 : ORTD-1
62851517|NCT04708236|PLACEBO_COMPARATOR|Vehicle Control|Arm 4: Vehicle control
62851518|NCT02145650||All Participants|Patients with a diagnosis of CP, MS, Stroke, SCI, or TBI will be evaluated for spasticity by their healthcare provider. Patients diagnosed with spasticity requiring treatment will be enrolled in the study. There is no intervention administered in this study.
62267002|NCT00385255|EXPERIMENTAL|FLUARIX BOOSTRIX GROUP|Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Fluarix® vaccine at Day 0 and Boostrix® vaccine at Month 1, both injected intramuscularly in the upper left deltoid region.
62625794|NCT05372185|ACTIVE_COMPARATOR|Usual Care|Participants in usual care will engage with VA healthcare using standard procedures of their facility.
62062584|NCT00880425||Participnts with non-continuous headache|
62062585|NCT02871830|EXPERIMENTAL|Physical activity intervention group|
62625795|NCT02634619|ACTIVE_COMPARATOR|Ventral Buccal Mucosa Graft Onlay|Standard of care method for repairing urethral strictures
62625796|NCT02634619|ACTIVE_COMPARATOR|Dorsal Buccal Mucosa Graft Onlay|Standard of care method for repairing urethral strictures
62625797|NCT05621850|EXPERIMENTAL|cerebral AVM embolization|
62625798|NCT05621850|OTHER|cerebral aneurism embolization|
62625799|NCT05593653|EXPERIMENTAL|suvorexant|20mg taken at bedtime for 4 weeks
62625800|NCT05593653|PLACEBO_COMPARATOR|placebo|placebo taken at bedtime for 4 weeks
62625801|NCT02697916|ACTIVE_COMPARATOR|ASA 81mg|aspirin 81mg
62625802|NCT02697916|ACTIVE_COMPARATOR|ASA 325mg|aspirin 325mg
62652890|NCT04202835|EXPERIMENTAL|ATG/PTCy|Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1); cyclophosphamide (Post Transplant Cyclophosphamide, PTCy) 50 mg/kg IV daily on days +3 and +4.
62851519|NCT02384915|EXPERIMENTAL|Spinal anesthesia|Intrathecal injection of 2 ml (40 mg) of 2% hyperbaric prilocaine at L3-L4 interspaces through a 100mm Sprotte 25 G spinal needle (Pencan, b-brawn, Germay) in lateral decubitus position, (with limb to operate declive).
62267003|NCT04505241|EXPERIMENTAL|Adaptive Goal-Setting|Participants in this condition will receive daily step goals calculated as the 60th percentile of their last 9 days of available daily steps data. Goals will be transmitted over text message, and will be accompanied by information about the participant's steps on the previous day and whether they met their goal the previous day.
62450412|NCT04120428|EXPERIMENTAL|Experimental protocol|24-week aquatic exercise training program
62851520|NCT02384915|ACTIVE_COMPARATOR|peripheral nerve block|Ultrasound-guided sciatic-femoral nerve block injecting 25 ml of a 2% mepivacaine solution,15 ml on femoral nerve and 10 ml on sciatic nerve through a 80 mm 22g eco-reflex needle (Sonoplex, Pajunk, Germany)
62851521|NCT04814199||Patients using epidural management algorithm|Patients will be educated and given an algorithm to follow while in labour and after having an epidural catheter placed.
62851522|NCT04129437|ACTIVE_COMPARATOR|NSAID|Ibuprofen, 800 mg, one time dose
62851523|NCT04129437|ACTIVE_COMPARATOR|OMT/NSAID|Ibuprofen, 800 mg, one time dose
62851524|NCT04129437|ACTIVE_COMPARATOR|OMT alone|low velocity osteopathic manipulative medicine
62851525|NCT04876300||Menotropin Cohort|
62851526|NCT04109885|EXPERIMENTAL|Paracervical injection|1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
62851527|NCT04109885|ACTIVE_COMPARATOR|Standard treatment|Intravenous administration of prochlorperazine and diphenhydramine.
62625803|NCT05298683|EXPERIMENTAL|Single-Arm|"Eligible patients will initially receive six 28-day cycles of isatuximab, pomalidomide, and low-dose dexamethasone. Patients will be allowed to continue treatment until disease progression, death, unacceptable AEs, lost to follow-up, or consent withdrawal.~Isatuximab will be given at a dose of 10 mg/kg QW by IV infusion.~Pomalidomide will be given at 4 mg orally(PO) on Days 1-21 of each cycle.~Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) PO, or IV on days 1, 8, 15, and 22 in each cycle.~Acetaminophen (paracetamol) will be given at 650-1000 mg PO 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.~Ranitidine or equivalent will be given at 50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.~Diphenhydramine or equivalent will be given at 25-50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion."
62267004|NCT04505241|EXPERIMENTAL|Static Goal-Setting|Participants in this condition will receive daily a uniform daily goal of 10,000 steps per day. Participants will receive daily texts including information about the participant's steps on the previous day, whether they met their goal the previous day, and encouraging them to continue striving for 10,000 steps each day.
62267005|NCT05015088||Gastrocnemius Stretching Group|The study will enroll 20 healthy subjects between the ages of 18 to 65 years old. Individuals will be recruited from multiple locations. Exclusion criteria include: any boney or tendinous foot/ankle operative procedure, diagnosis of neuromuscular disorder, any previous ankle fracture or degenerative changes that would limit dorsiflexion range of motion. Participants must have no obvious gait asymmetries demonstrated through observation. In addition, participants who are pregnant will be excluded from participation in the study.
62450413|NCT04120428|NO_INTERVENTION|Control protocol|Maintain lifestyle routine as usual
62625804|NCT04589884||Parathyroid disease|
62625805|NCT04589884||Thyroid disease|
62625806|NCT04589884||Liver tumors and metastases|
62625807|NCT04589884||Digestive tumors|
62625808|NCT04589884||Digestive perfusion|
62625809|NCT02927054|OTHER|Internal Medicine Residents|Sepsis education provided to internal medicine residents
62625810|NCT02927054|OTHER|Emergency Medicine Residents|Sepsis education provided to emergency medicine residents
62625811|NCT02927054|OTHER|Orthopedic Residents|Sepsis education provided to orthopedic residents
62625812|NCT02927054|OTHER|Neurosurgery Residents|Sepsis education provided to neurosurgery residents
62625813|NCT02927054|OTHER|General Surgery Residents|Sepsis education provided to general surgery residents
62851528|NCT03180632|ACTIVE_COMPARATOR|Group A|Patient will receive a single dose of either 0,5mg or 1mg of oral Lorazepam depending on their body weight.
62851529|NCT03180632|PLACEBO_COMPARATOR|Group B|Patient will receive a placebo similar in color, form and size.
62851530|NCT03180632|NO_INTERVENTION|Group 3|Patient will receive no intervention.
62851531|NCT05466864|EXPERIMENTAL|TMU Hospital|Potential participants with suspected OSA will be identified from the schedule of the TMU sleep labs. Those subjects who satisfy the study conclusion and exclusion criteria will be approached and invited to participate in the study.
62851532|NCT04096378|EXPERIMENTAL|EMBRace Intervention Group|Over 13 weeks, participants will engage in a pretest (week 1) 5 weekly sessions (weeks 2-6), a posttest (week 7) and a follow-up (week 13). The intervention (Engaging, Managing, and Bonding through Race: EMBRace) seeks to reduce racial trauma for both youth and caregivers and increase family functioning via psychoeducation and therapy.
62450414|NCT01310049|EXPERIMENTAL|LP0058 oral solution (0.050 mg/mL)|LEO 32731
62851533|NCT04096378|OTHER|EMBRace Waitlist Group|Participants will wait for thirteen weeks without receiving EMBRace or alternative therapeutic sessions. The waitlist group will subsequently become the intervention group with the opportunity to participate in the EMBRace intervention protocol above.
62851534|NCT05404672|EXPERIMENTAL|Aerobic Training|Progressive breathing training exercises for a period of 4 weeks, for 15 minutes twice daily. As patients progressed to the seated posture, the controlled pause technique (exercise) will be introduced. 4 times a day followed by a sustained period of breathing control. In addition to this Aerobic Training (cycling, treadmill) will also be practiced for 30 minutes constituting 5 days/ week. Initial training would avoid upright position. Mild-to-moderate-intensity endurance training, progressing from semi-recumbent to upright position plus strength training will be practiced.
62062586|NCT02871830|NO_INTERVENTION|Control group|
62625814|NCT00806858||A|
62625815|NCT03541148|EXPERIMENTAL|Oncoxin-Viusid|Nutritional supplement Oncoxin-Viusid 25 mL in oral solution twice a day
62625816|NCT05613959||Veress +|The Veress+ system was used
62625817|NCT05613959||Veress conventional|The Conventional Veress needle was used
62625818|NCT00458861|EXPERIMENTAL|BG9924|Subcutaneous administration of BG9924 given every other week for 12 weeks
62625819|NCT00458861|PLACEBO_COMPARATOR|Placebo|Subcutaneous administration of placebo given every other week for 12 weeks
62625820|NCT03608813||Controls|Healthy subjects
62625821|NCT03608813||Case|PCOS affected subjects
62625822|NCT04833062||Diabetes mellitus group|Based on DM type, all women will be divided into four groups: prepregnancy/preexisting DM insulin-dependent or independent (types I and II; classes B, C, and D) and gestational DM (GDM) with or without the need for insulin therapy (DM classes A1 and A2). In the case of gestational DM, the gestational week at the time of diagnosis will be registered. We will consider whether women are diagnosed with another preexisting disease (endocrinological or another one) before or during pregnancy, in order to check the relationship of this disease and their DM and potential risks for pregnancy.
62625823|NCT04833062||Nondiabetic group|Nondiabetic women who received birth assistance at our referral centers and who agreed to participate in the study were included in the control group. A control of healthy (non-diabetic women) mothers so to compare characteristics and outcomes across diabetic groups will comprise the control group.
62625824|NCT01166711|EXPERIMENTAL|Bare Metal Stent (BMS) followed by Drug Eluting Balloon (DEB)|
62625825|NCT01166711|ACTIVE_COMPARATOR|Drug Eluting Stent (DES)|
62625826|NCT05542251|EXPERIMENTAL|Parent Educational Program|Caregivers of children with gross motor delays who are randomized to receive an educational intervention delivered through social media.
62625827|NCT05542251|NO_INTERVENTION|Control Group|Caregivers of children with gross motor delays who are randomized to the waitlist control group who will receive an educational intervention delivered through social media after a 9 week waiting period.
62267006|NCT04010396||Recipients of Bovine Graft|Recruitment and informed consent procedure for blood sampling to conduct immunological testing. In addition a questionnaire on QOL (SF-12) will be used to evaluate the most actual quality of life of these patients.
62267007|NCT04010396||Recipients of Mechanical Graft|Recruitment and informed consent procedure for blood sampling to conduct immunological testing. In addition a questionnaire on QOL (SF-12) will be used to evaluate the most actual quality of life of these patients.
62851535|NCT05404672|ACTIVE_COMPARATOR|Conventional Treatment|Progressive breathing retraining exercises for a period of 4 weeks, for 15 minutes twice daily. As patients progressed to the seated posture, the controlled pause technique (exercise) will be introduced. 4 times a day followed by a sustained period of breathing control.
62851536|NCT03147157|EXPERIMENTAL|research group,low MR group|tacrolimus regimen guided by HLA matching rate
62851537|NCT03147157|NO_INTERVENTION|observation group,low MR group|tacrolimus regimen is applied according to clinical experience
62851538|NCT03147157|EXPERIMENTAL|research group,middle MR group|tacrolimus regimen guided by HLA matching rate
62851539|NCT03147157|NO_INTERVENTION|observation group,middle MR group|tacrolimus regimen is applied according to clinical experience
62851540|NCT03147157|EXPERIMENTAL|research group,high MR group|tacrolimus regimen guided by HLA matching rate
62851541|NCT03147157|NO_INTERVENTION|observation group,high MR group|tacrolimus regimen is applied according to clinical experience
62851542|NCT05529095|EXPERIMENTAL|Sublingual Apomorphine (Kynmobi)|Sublingual apomorphine to be titrated after initial dose of 10 mg. Titration is dependent on subjects response.
62267008|NCT02185950|EXPERIMENTAL|Ultrasound group|Therapeutic ultrasound, 3 MHz, continuous with intensity 1W/cm2 will be applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) with exposure time of 2 minutes for each effective radiation area head (ERA), a total of 4 minutes of application in an area of 9X5 cm, and the application parameters with a matched control side of the patient, in a region with contralateral uninjured skin.
62267009|NCT02185950|EXPERIMENTAL|Group paraffin|Paraffin therapy is heated with thermostat own equipment, being applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) and control (uninjured), with a length of 9X5 cm, at a temperature of 38 ° C with appropriate brush in layers (4 layers), remaining for 20 minutes. After the period of application of paraffin will be removed and discarded, with no reuse.
62267010|NCT02185950|EXPERIMENTAL|Ultrasound group + endermotherapy|Therapeutic ultrasound, 3 MHz, continuous with intensity 1W/cm2 will be applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) with exposure time of 2 minutes for each effective radiation area head (ERA), a total of 4 minutes of application in an area of 9X5 cm. The application of endermotherapy will be held shortly after the therapeutic ultrasound in a timely manner across the surface of the scar, for about 2 seconds per head area with a negative pressure between 100-200 mmHg, a total of 4 minutes application in an area of 9 x 5 cm. The same application parameters will be performed with one hand matched control patient, in a region with contralateral uninjured skin.
62851543|NCT05529095|PLACEBO_COMPARATOR|Placebo|At week 4, subjects will be given randomization packet including 2 drug doses and 2 placebos.
62851544|NCT02642055|EXPERIMENTAL|Neuro+ Intervention|30 sessions (900 minutes) of Neuro+ Attention Training administered over 10 weeks.
62851545|NCT02642055|ACTIVE_COMPARATOR|Treatment as Usual|Continuation of current treatment for ADHD
62851546|NCT04909983|EXPERIMENTAL|Intervention|Medical Device, an occlusive patch for 3 days.
62851547|NCT04909983|ACTIVE_COMPARATOR|Control|Standard of Care
62851548|NCT02987062||Acenocoumarol|Patients with AF treated with acenocoumarol.
62851549|NCT02987062||Warfarin|Patients with AF treated with warfarin.
62062587|NCT03059407|OTHER|Dog therapy only|Canine assisted therapy only during echocardiogram
62851550|NCT02987062||Apixaban|Patients with AF treated with apixaban.
62625828|NCT00730574|NO_INTERVENTION|B|The control group, marked B, gets only B12 vitamin 1mg/day treatment to comply with ethics regulations seeing as they do suffer from B12 deficiency .
62625829|NCT00730574|EXPERIMENTAL|A|The trial group which receives daily treatment of 1mg Vitamin B12 (sublingual tablets) combined with 5 mg Folic acid (tablets)
62625830|NCT02122315|EXPERIMENTAL|Physical therapy plus dry needling|Best-evidence physical therapy intervention in addition to a single session of TrP-DN targeted to active TrPs in the neck-shoulder muscles.
62625831|NCT02122315|ACTIVE_COMPARATOR|Physical therapy|Best-evidence physical therapy intervention
62625832|NCT05230355|ACTIVE_COMPARATOR|group A the standard technique|cyclophotocoagulation is applied along the upper and lower hemispheres over pars plana -3 mm behind the limbus
62625833|NCT05230355|ACTIVE_COMPARATOR|Group B a modified technique|cyclophotocoagulation is applied over one hemisphere only (180 degrees) along pars plana-3 mm behind the limbus- followed by a second application over pars plicata-1.2 mm behind the limbus- along the same hemisphere (ie, in a double arc fashion).
62625834|NCT06609408|EXPERIMENTAL|Experimental Group|Nature and game based activities will be applied to the participants in the experimental group once a week for 60 minutes for 8 weeks in this study.
62625835|NCT06609408|NO_INTERVENTION|Control Group|Individuals in the control group will not participate in the intervention. Individuals in control group will continue their routine activities in nursing home.
62625836|NCT01302795|EXPERIMENTAL|Canakinumab|Canakinumab s.c. 150-300mg Week 0, (2), 8
62851551|NCT02987062||Dabigatran|Patients with AF treated with dabigatran.
62851552|NCT02987062||Rivaroxaban|Patients with AF treated with rivaroxaban.
62062588|NCT03059407|OTHER|Dog plus standard distraction tech|Canine assisted therapy plus standard distraction techniques during echocardiogram
62851553|NCT00732407|EXPERIMENTAL|1|Patients with diabetes melittus treated with an ACE inhibitor will be treated with aliskiren
62267011|NCT02185950|EXPERIMENTAL|Group paraffin + endermotherapy|Paraffin therapy is heated with thermostat own equipment, being applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) and control (uninjured), with a length of 9X5 cm, at a temperature of 38 ° C with appropriate brush in layers (4 layers), remaining for 20 minutes. After the period of application of paraffin will be removed and discarded, with no reuse.The application of endermotherapy will be held shortly after the paraffin therapy in a timely manner across the surface of the scar, for about 2 seconds per head area with a negative pressure between 100-200 mmHg, a total of 4 minutes application in an area of 9 x 5 cm. The same application parameters will be performed with one hand matched control patient, in a region with contralateral uninjured skin.
62267012|NCT03042507|OTHER|Open Trial|This is a non-randomized open trial of a behavioral intervention for young children with tics
62267013|NCT03951623|ACTIVE_COMPARATOR|treatment arm|Eligible subjects will be treated with planned dose of 100 mg, 200 mg and 300 mg HMPL-523 once daily for 8 weeks and 16 weeks open-label treatment.
62267014|NCT03951623|PLACEBO_COMPARATOR|placebo arm|Eligible subjects will be treated with HMPL-523 matching placebo once daily for 8 weeks and 16 weeks open-label treatment.
62267015|NCT01757678|OTHER|Standard of care: FFR, ICA, cCTA, FFRct|(ICA) Invasive coronary angiography with (FFR) fractional flow reserve measurement in standard of care environment, and cCTA (computed coronary tomography angiography) and FFRct Analysis (fractional flow reserve computed tomography)
62267016|NCT03825770|EXPERIMENTAL|"The PEP Program"|"The PEP (Personal Energy Planning) Program"
62267017|NCT03825770|ACTIVE_COMPARATOR|General Education|General Education about Kidney Disease
62267018|NCT06229795|EXPERIMENTAL|Intervention|Metformin 500 mg tablet twice daily and Green tea 300 mg film coated tablet three times daily.
62267019|NCT06229795|ACTIVE_COMPARATOR|Control|Metformin 500 mg tablet twice daily
62267020|NCT00849732|EXPERIMENTAL|1|V520 (1x10\^9 vp/d)
62267021|NCT00849732|EXPERIMENTAL|2|V520 (1x10\^10 vp/d)
62267022|NCT00849732|PLACEBO_COMPARATOR|3|Placebo to V520
62267023|NCT01157221|EXPERIMENTAL|intervention group|intervention group: end-range mobilization/scapular mobilization treatment approach group
62267024|NCT01157221|ACTIVE_COMPARATOR|control|
62851554|NCT00732407|EXPERIMENTAL|2|Patients with diabetes melittus treated with an ACE inhibitor will be given losartan
62267025|NCT01157221|SHAM_COMPARATOR|control-criteria group|
62267026|NCT03445455||De novo AHRF|"Acute hypoxemic non hypercapnic respiratory failure with a PaO2/FiO2 ratio \< 200.~The following oxygenation devices are used and assessed during routine care:~High concentration mask, High flow nasal canula, NIV using buco-nasal mask or Helmet.~Electro impedence tomography signal will be recorded throughout this assessement for tidal volume measurement"
62267027|NCT03652662|EXPERIMENTAL|RESP-FIT Intervention|"Intervention:~IMST/EMST Training (5 breaths, 5 times a day, 5 times a week) Fitbit activity monitoring Daily symptom and training log entered into mobile application (SAMS)"
62267028|NCT03652662|ACTIVE_COMPARATOR|RESP-FIT Comparator|"Active Comparator:~Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)"
62267029|NCT05858905|EXPERIMENTAL|JAVELIN Study Catheter|The JAVELIN catheter will be used to treat subjects with moderate to severely calcified peripheral artery disease (PAD) with target lesion located in a native, de novo superficial femoral, popliteal or infrapopliteal artery.
62450415|NCT01310049|EXPERIMENTAL|LP0058 oral solution (0.200 mg/mL)|LEO 32731
62450416|NCT01310049|PLACEBO_COMPARATOR|LP0058 oral solution (placebo)|Placebo
62450417|NCT01310049|EXPERIMENTAL|LP0058 capsule 1-120 mg|LEO 32731
62450418|NCT01310049|PLACEBO_COMPARATOR|LP0058 capsule (placebo)|Placebo
62450419|NCT04547946||dabrafenib + trametinib|Patients administered dabrafenib and trametinib
62652891|NCT04202835|ACTIVE_COMPARATOR|ATG|Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1).
62851555|NCT03285022|EXPERIMENTAL|Zinc modified glass ionomer|Zinc modified glass ionomer (chemfill rock) galss ionomer used as restoration for posterior teeth in case of partial caries removel
62851556|NCT03285022|ACTIVE_COMPARATOR|Conventionel glass ionomer|Conventional glass ionomer used as restoration for posterior teeth in case of partial caries removel
62851557|NCT02133300|EXPERIMENTAL|electrical stimulation|Compex 3 professional NMES for 60' per day
62851558|NCT02133300|NO_INTERVENTION|control|
62625837|NCT03182881|EXPERIMENTAL|Miofascial-reléase|Myofascial Release (MR), with the purpose of releasing fascial restriction zones and major fibrosis (thoraco-brachial) caused by restriction after CM tto. IM therapy was applied to the affected area. The position of the patient was identical during both treatment sessions.
62851559|NCT05180396||Cases with the diagnosis of Heart Failure (Acute and Chronic)|Application of a questionnaire consisting of different questions to patients.
62851560|NCT01912313|EXPERIMENTAL|Rectal biopsy|
62625838|NCT03182881|ACTIVE_COMPARATOR|Manual Lymphatic Drainage (MLD)|It was applied following the Leduc method with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, in the chest region and in the arm with the same sequence as Guerero et al. The objective of the application in our study is to obtain a beneficial treatment for the patient since it produces an increase of blood and lymphatic circulation, with positive effects on the peripheral vegetative nervous system.
62625839|NCT03107208|EXPERIMENTAL|Early glargine (Lantus)|A dose of glargine (Lantus®) is given subcutaneously early in the management of DKA (i.e. while the participant is still receiving intravenous insulin). Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
62625840|NCT03107208|OTHER|Control group|A dose of glargine (Lantus®) is given subcutaneously after resolution of the DKA (i.e. when the intravenous insulin is stopped). This is currently the standard-of-care practice for children in DKA. Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
62625841|NCT04969783|EXPERIMENTAL|Ventilated Cigarette Filter|Filters with approximately 24-32% filter ventilation
62625842|NCT04969783|EXPERIMENTAL|Unventilated Cigarette Filter|Filters with approximately 0-5.0% filter ventilation
62851561|NCT05089851|ACTIVE_COMPARATOR|Peptide Antiaging Serum|"Dosage Form: Serum composed of water, thickener, and bioactive ingredients including peptides and antioxidants.~Frequency of Dosage: Twice daily. Subjects will be asked to pump 1x and apply to assigned facial side (left or right) corresponding to randomization.~Study Duration: 12 weeks"
62062589|NCT03059407|OTHER|Standard distraction technique only|Standard distraction techniques only during echocardiogram.
62450420|NCT04578470|NO_INTERVENTION|Group C|Patients with replete VitaminD levels (≥30ng/ml) will be serving as a control in group C. Group C will not receive any Vitamin D intervention for the entire 12- month study period but will receive dietary interventions.
62625843|NCT02214303||Allergic asthma|Allergic asthma (sensibilisation to D. pteronyssinus, 5 grass mixture allergens or birch pollen allergens)
62625844|NCT02214303||Allergic rhinitis|allergic rhinitis patients (sensibilisation to D. pteronyssinus, 5 grass mixture allergens or birch pollen allergens)
62625845|NCT02214303||Control group|Healthy subjects
62625846|NCT05660668|EXPERIMENTAL|Transbond LR|in finished orthodontic cases a light cured resin composite (Transbond LR) will be added on fixed lingual retainer to see the failure rate (detachment) with follow up every month for 6 months
62625847|NCT05660668|ACTIVE_COMPARATOR|Transbond XT|in finished orthodontic cases a light cured resin composite (Transbond XT) will be added on fixed lingual retainer to see the failure rate (detachment) with follow up every month for 6 months
62625848|NCT02959333|EXPERIMENTAL|hAEC treatment|hAEC: human amniotic epithelial cells 3-5\*10\^7 /5 ml
62625849|NCT00116714||Observation|
62625850|NCT06015230|EXPERIMENTAL|Treatment group 1-Ⅰb|6 subjects in GR1603 low dose，2 subjects in placebo
62625851|NCT06015230|EXPERIMENTAL|Treatment group 2-Ⅰb|6 subjects in GR1603 high dose，2 subjects in placebo
62625852|NCT06015230|EXPERIMENTAL|treatment group 3-Ⅱ|low dose GR1603 monthly
62625853|NCT06015230|EXPERIMENTAL|treatment group 4-Ⅱ|high dose GR1603 monthly
62625854|NCT06015230|PLACEBO_COMPARATOR|treatment group 5-Ⅱ|placebo
62625855|NCT02047435|EXPERIMENTAL|Information, event and workshops at a cartoon museum|
62625856|NCT02047435|ACTIVE_COMPARATOR|Information and event at a cartoon museum|
62625857|NCT06404879||children group|"Are between the ages of 2-6, are planned to undergo surgery under general anesthesia due to inguinal area pathology, No mental or neurological disorders in both mother and child No vision, hearing or speech problems in both mother and child Parents and children who volunteer to participate in the research will be included in the study.~Those who did not volunteer to participate in the study, Undergoing surgery with a pathology other than the inguinal area, Having emergency surgery Children with pathologies (mental retardation, neurological problems, etc.) that may cause difficulty in communicating with both the family and the child will not be included in the study."
62851562|NCT05089851|PLACEBO_COMPARATOR|Placebo Serum|"Dosage Form: Serum composed of water and thickener~Frequency of Dosage: Twice daily. Subjects will be asked to pump 1x and apply to assigned facial side (left or right) corresponding to randomization.~Study Duration: 12 weeks"
62625858|NCT01010802|EXPERIMENTAL|Erythropoietin|"There are evidences of neuroprotecting therapeutic alternatives in such substances as erythropoietin (EPO) which is a well-known cytokine as a hematopoietic growth factor, so, it is therefore important to control tissular oxygenation. It is considered that EPO protects the neurons by a combination of several mechanisms.~EPOrh is used with high effectiveness in the treatment of anemias with deficiency of erythropoietin."
62625859|NCT04140721|EXPERIMENTAL|Moxonidine then Placebo|After screening/baseline evaluations, patients will be discharged home on moxonidine 0.2-0.4 mg/day PO. After two weeks, the patients will be re-admitted for study testing while on moxonidine. At completion of this testing, patients will start taking matching placebo once daily PO to be continued at home. After two, the patients will be re-admitted for study testing while on placebo.
62625860|NCT04140721|EXPERIMENTAL|Placebo then Moxonidine|After screening/baseline evaluations, patients will be discharged home on placebo identical to moxonidine once daily PO. After two weeks, the patients will be re-admitted for study testing while on placebo. At completion of this testing, patients will start taking moxonidine 0.2-0.4 mg/day PO to be continued at home. After two weeks, the patients will be re-admitted for study testing while on moxonidine.
62625861|NCT01494012|EXPERIMENTAL|Treatment (SBRT)|Patients undergo SBRT 5 days a week for approximately 1 week in the absence of disease progression or unacceptable toxicity.
62625862|NCT06606366|EXPERIMENTAL|Experimental|For this study, the included patients will have a blood sample (36 mL) taken. Molecular analyses will be performed on this blood sample (liquid biopsy) in addition to the molecular analyses routinely conducted on the tumor sample (solid biopsy).
62625863|NCT00056303|EXPERIMENTAL|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up targets nurturance, synchrony, and non-frightening behavior, as well as providing caregivers with help calming toddlers.
62625864|NCT00056303|ACTIVE_COMPARATOR|Developmental Education for Families|Developmental Education for Families targets providing cognitive stimulation to their children.
62625865|NCT01542086|ACTIVE_COMPARATOR|Myocardial SPECT|
62625866|NCT01542086|EXPERIMENTAL|64-channel coronary CT angiography (CCTA)|
62625867|NCT00913211|EXPERIMENTAL|rTMS only|brain stimulation to non-stroke primary motor area
62625868|NCT00913211|EXPERIMENTAL|Finger tracking training|Motor learning training using finger flexion/extension tracking movements toward a target.
62625869|NCT00913211|EXPERIMENTAL|rTMS and finger tracking|Combination of rTMS and tracking
62625870|NCT00913211|PLACEBO_COMPARATOR|Sham|Sham rTMS treatment
62625871|NCT04663165|OTHER|Flap surgery alone|Access flap
62625872|NCT04663165|OTHER|Flap surgery with adjunctive EMD|Access flap and adjunctive enamel matrix derivative
62625873|NCT02499263||Participants with Ulcerative Colitis (UC)|Adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg every other week per the Korean label in participants with active moderate-to-severe UC.
62267030|NCT01836432|EXPERIMENTAL|FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy|"Arm 1A: SOC FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy~Day 71-80 Disease evaluated: New distant disease = salvage regimen Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total.~Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation+ HAPa on days 1 and 15 of Chemoradiotherapy.~Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for up to 18 doses total.~Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue FOLFIRINOX bi-weekly + HAPa bi-weekly 7 days offset from FOLFIRINOX up to18 doses of algenpantucel-L Immunotherapy.~Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total."
62625874|NCT01259934|NO_INTERVENTION|Arm A|Observation only - no therapy
62625875|NCT01259934|EXPERIMENTAL|Arm B Interferon 1 year|Interferon Therapy: Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 12 months
62625876|NCT01259934|EXPERIMENTAL|Arm C Interferon 2 years|"Two year arm Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months"
62625877|NCT03085719|EXPERIMENTAL|High Dose Radiation + Pembrolizumab|"* High dose radiation will be given in 3 fractions~* Pembrolizumab administered intravenously on day one of each cycle."
62851563|NCT04655937|NO_INTERVENTION|non-randomised no treatment arm|Participants who do not opt in to group support will only provide self-report data on their wellbeing and quality of life every 3 months for up to 12 months. Data collected through online survey platforms using validated questionnaires
62625878|NCT03085719|EXPERIMENTAL|High Dose + Low Dose Radiation + Pembrolizumab|"* High Dose radiation will be given in 3 fractions~* Low Dose Radiation will be given in 2 fractions~* Pembrolizumab administered intravenously on day one of each cycle."
62625879|NCT00447551|EXPERIMENTAL|single group|
62851564|NCT04655937|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT) Group|Only those who opt in to group support will be invited and allocated into treatment groups at random. Participants in this arm will be invited to 9 weekly ACT-informed therapy sessions involving core values identification, mindfulness practices and committed action plans. There will be homework in between sessions.
62851565|NCT05348278|NO_INTERVENTION|standard of care|standard of care including hand and foot care, avoid friction
62851566|NCT05348278|EXPERIMENTAL|urea cream|use 10% urea cream apply at both hands and feet twice a day from time of starting capecitabine
62062590|NCT05778721||adult patients with a diagnosis of idiopathic hypersomnia|adult patients with a diagnosis of idiopathic hypersomnia according to the International Classification of Sleep Disorders (ICSD 3) criteria and the performance of a 48-hour polysomnography at the Sleep Laboratory, between 2004 and today.
62062591|NCT04079868|EXPERIMENTAL|Bone Health Service arm|Interventional arm
62851567|NCT05822765|ACTIVE_COMPARATOR|Group A|Tumescence fluid contained Epinephrine concentration of 1:1000000 (one ampoule 1 mg per liter) Llidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter.
62851568|NCT05822765|ACTIVE_COMPARATOR|Group B|"Tumescence fluid contained Epinephrine concentration of 1:500000 two ampoule 2 mg/liter.~Lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter."
62851569|NCT05006300|EXPERIMENTAL|Group 1|One application of Topialyse Baume Barrière per day
62851570|NCT05006300|EXPERIMENTAL|Group 2|Two applications of Topialyse Baume Barrière per day
62851571|NCT01682304||History of Preeclampsia|Chronic hypertension with history of preeclampsia Chronic hypertension without history of preeclampsia
62851572|NCT06110832|EXPERIMENTAL|Mindfulness-based Meditation and Yoga Intervention Group|"After randomization, participants in the experimental group underwent mindfulness-based meditation and yoga practices with 90-minute sessions on Thursdays for 8 weeks. In these practices, a different theme was determined each week.~The 8-week theme headings are as follows:~Week 1 exploring mindfulness Week 2: How do we perceive the world? week 3 being in the body Week 4 meeting stress with mindful awareness Week 5 our relationship with stress-inducing thoughts Week 6 Communication with mindfulness Week 7 taking care of yourself Week 8 farewell and a new beginning"
62851573|NCT06110832|NO_INTERVENTION|Control Group|No intervention was applied to the control group
62851574|NCT02277561|EXPERIMENTAL|Diagnostic (VB-DTI, MRI)|Patients undergoing WBRT for a total of 10 fractions also undergo VB-DTI MRI at baseline, 1 week after WBRT initiation, and 7-11 days after completion of WBRT. Patients undergoing SRS without WBRT also undergo VB-DTI MRI at baseline and 7-11 days after completion of SRS.
62851575|NCT06141356||Healthy participants|"Drug: \[18F\]Florbetazine (\[18F\]92). A dosage of 10 mCi +/- 20% of Florbetazine will be injected by a PET-certified medical professional followed by 5ml 0.9% sodium chloride (normal saline) flush.~Drug: \[11C\]PIB. A dosage range between 6.0-20.0 mCi of PIB will be injected by a PET-certified medical professional followed by 5ml 0.9% sodium chloride (normal saline) flush."
62851576|NCT06141356||Patients with cognitive impairment|"Drug: \[18F\]Florbetazine (\[18F\]92). A dosage of 10 mCi +/- 20% of Florbetazine will be injected by a PET-certified medical professional followed by 5ml 0.9% sodium chloride (normal saline) flush.~Drug: \[11C\]PIB. A dosage range between 6.0-20.0 mCi of PIB will be injected by a PET-certified medical professional followed by 5ml 0.9% sodium chloride (normal saline) flush."
62062592|NCT04079868|NO_INTERVENTION|Usual care (control) arm|"This arm represents a no practice management support control group."
62625880|NCT03665077|EXPERIMENTAL|Participants|Patients with breast cancer who have completed all their primary treatments (surgery±radiation therapy) and are scheduled to start their adjuvant hormonal therapy.
62851577|NCT01868542|EXPERIMENTAL|3-0-3 Algorithm|A once daily dosage of Insulin detemir (Levemir®) 100 U/mL 3 mL FlexPen® for subcutaneous administration was selected for this trial.During the treatment period insulin detemir was adjusted by the subject themselves (self-titration). Self-titration was performed every 3 days based on the lowest of three previous consecutive pre-breakfast SMPG values.Based on this glucose value, self-adjustment of insulin detemir dose was done. Metformin and Sulfonlylurea were allowed as OADs. For SMPG values, the following insulin detemir dose adjustments were done : \>6.1 mmol/L (\>110 mg/dL) +3U insulin detemir, 4.4-6.1 mmol/L (80-100 mg/dL) No adjustment in insulin detemir, \< 4.4 mmol/L (\<80 mg/dL) -3U insulin detemir.
62062593|NCT02450721||Acute stroke|"Patients in the acute phase of atherothrombotic stroke or TIAs with 50-99% ACAS within the first 3 days af vascular event.~Interventions to be administered: Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE, National Institutes of Health Stroke Scale (NIHSS)"
62062594|NCT02450721||Stable carotid artery stenosis|"Patients with 50-99% ACAS without history of vascular events during one month before enrollment.~Interventions to be administered: Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE"
62062595|NCT02450721||Control group|Healthy volunteers without ACAS Interventions to be administered:Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE
62062596|NCT02922894|EXPERIMENTAL|Acute episodic hypoxia|To test development of ventilatory augmentation following episodic hypoxia, defined as increased Hypoxic Ventilatory Response (HVR) from early to late hypoxic exposure episodes.
62062597|NCT02922894|EXPERIMENTAL|Supplemental oxygen|To use supplemental oxygen to decrease peripheral chemoreceptor activity in patients with SCI and central SDB. In addition, perform a repeat evaluation after treatment with supplemental oxygen or sham O2 for 6 weeks to determine if correction of chronic intermittent hypoxia, which mitigates sensory LTF, results in decreased propensity to central apnea.
62062598|NCT02922894|EXPERIMENTAL|Trazodone or placebo|examine the effect of trazodone on breathing during sleep
62625881|NCT03208894|EXPERIMENTAL|with salbutamol|
62625882|NCT03208894|EXPERIMENTAL|with furosemide|
62625883|NCT03208894|EXPERIMENTAL|both furosemide and salbutamol|
62625884|NCT03208894|NO_INTERVENTION|no inervention|
62625885|NCT05876884|EXPERIMENTAL|Hypothermic Neonates (90)|Any neonate who been identified as in need of thermal care defined as having a moderate hypothermic temperature (32.0 - 36.0°C) as the last temperature recorded in hospital chart, or during recruitment procedures will be placed on the Celsi Warmer mattress
62851578|NCT01868542|EXPERIMENTAL|2-4-6-8 Algorithm|A once daily dosage of Insulin detemir (Levemir®) 100 U/mL 3 mL FlexPen® for subcutaneous administration was selected for this trial. During the treatment period insulin detemir was adjusted by the subject themselves (self-titration). Self-titration was performed every 3 days based on the lowest of three previous consecutive pre-breakfast SMPG values.Based on this glucose value, self-adjustment of insulin detemir dose was done. Metformin and Sulfonlylurea were allowed as OADs. For SMPG values , the following insulin detemir dose adjustments were done : \>10.0 mmol/L (180 mg/dL) +8U insulin detemir, 9.1-10.0 mmol/L (163-180 mg/dL) +6U insulin detemir, 8.1-9.0 mmol/L (145-162 mg/dL) +4 U insulin detemir, 7.1-8.0 mmol/L (127-144 mg/dL) +2U insulin detemir, 6.1-7.0 mmol/L (109-126 mg/dL) +2U insulin detemir, 4.1-6.0 mmol/L (73-108 mg/dL) No adjustment in insulin detemir, 3.1-4.0 mmol/L (56-72 mg/dL) -2U insulin detemir, \<3.1 mmol/L (\<56 mg/dL) -4U insulin detemir.
62851579|NCT06065085|EXPERIMENTAL|Mobile Education|An education application was installed on the mobile phones of the experimental group. Individuals with hypertension were provided with a training for three months through the mobile application. Data collection forms were filled in by the individuals with hypertension in the experimental and controlled groups at the beginning and at the 3rd month via the mobile application.
62851580|NCT02765009|NO_INTERVENTION|Control|Usual care provided according to the ward policy. Patients have to be weighed at least on admission (day 0), day 7 and day 14.
62851581|NCT02765009|EXPERIMENTAL|Strategy|Patients have to be weighed every day. Use of an algorithm based on weight changes from day 2 to day 14 in order to reduce weight gain (fluid overload) using diuretics, fluid restriction,albumin, and ultrafiltration (the latter when ongoing renal replacement)
62851582|NCT05835102||Patients With SARS-CoV-2 Infection|Patients who test positive for SARS-CoV-2 nucleic acid or SARS-CoV-2 antigen
62851583|NCT00271284|EXPERIMENTAL|I|
62851584|NCT00271284|ACTIVE_COMPARATOR|II|
62851585|NCT05887596|NO_INTERVENTION|Control group|The training given to the control group included preoperative preparation, operating theatre environment, breathing exercises, cough exercises, etc. to be performed after surgery. In both groups, temperature, pulse rate, blood pressure, oxygen saturation level, and pain level with a Visual/Visual Analogue Scale were measured on the morning of the operation day, before the operation, every 4 hours for 24 hours after the operation and on the day of discharge. Again, pain fear level was measured with the Fear of Pain Scale-III on the day of discharge in both groups.
62851586|NCT05887596|EXPERIMENTAL|Intervention group|The education given to the intervention group included preoperative preparation, operating room environment, breathing exercises, cough exercises, etc. to be performed after surgery, non-pharmacological methods related to pain management (cold application, positioning, distraction), and pharmacological methods related to pain management.
62851587|NCT05509868|EXPERIMENTAL|PBK_L1704 0.35mg|
62625886|NCT01472822|EXPERIMENTAL|Omija extract.|
62851588|NCT05509868|EXPERIMENTAL|PBK_L1704 0.5mg|
62062599|NCT01073800|ACTIVE_COMPARATOR|atorvastatin 80 mg|active treatment
62062600|NCT01073800|PLACEBO_COMPARATOR|placebo|
62851589|NCT05509868|PLACEBO_COMPARATOR|Placebo|
62851590|NCT03820700|NO_INTERVENTION|Control group|\[Randomized\] Patients in control group will receive regular nursing care but no behavioral therapy intervention.
62851591|NCT03820700|EXPERIMENTAL|Hypnosis (Hypn)|\[Randomized\] Patients will receive a hypnosis recorded audiotape.
62851592|NCT03820700|EXPERIMENTAL|Virtual reality (VR)|\[Randomized\] Patients will see a 3D movie with a beautiful landscape.
62851593|NCT03820700|EXPERIMENTAL|Virtual reality hypnosis (VRH)|\[Randomized\] Patients will see the same 3D film combined with a hypnotic voice.
62851594|NCT05802953||Temporomandibular joint dysfunction group|The group will include patients with temporomandibular joint dysfunction.
62851595|NCT00985777|EXPERIMENTAL|Phase I Dose Escalation|Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days and one dose on Day 15.
62851596|NCT05913037|EXPERIMENTAL|FCN-159|Experimental: FCN-159 Dosage form:tablet Specification: 1mg，4mg Dose: FCN-159 8 mg, orally, once daily Method of administration: Oral
62851597|NCT05913037|PLACEBO_COMPARATOR|placebo|Experimental: placebo Dosage form:tablet Specification: 1mg，4mg Dose: placebo 8 mg, orally, once daily Method of administration: Oral
62062601|NCT02630524|EXPERIMENTAL|Low Carbohydrate Diet|
62062602|NCT02630524|ACTIVE_COMPARATOR|Standard Diet|
62625887|NCT01472822|PLACEBO_COMPARATOR|Placebo|
62625888|NCT03023267|EXPERIMENTAL|Interventional|Applying music therapy with kangaroo care to mothers and fathers during their NICU hospitalization
62625889|NCT03023267|ACTIVE_COMPARATOR|Control|Applying only Kangaroo care to mothers and fathers during their stay in the NICU
62062603|NCT06151990||newly diagnosed juvenile systemic lupus erythematosus|
62062604|NCT06151990||old cases of juvenile systemic lupus in activity|
62062605|NCT06151990||old cases of juvenile systemic lupus not in activity(controlled)|
62062606|NCT02093039|EXPERIMENTAL|Decision aid group|Women allocated to the decision aid group received an invitation to participate in the national breast cancer screening program and the specially-designed decision aid (a leaflet), by mail.
62062607|NCT02093039|NO_INTERVENTION|Control group|Women in the control group received an invitation and the usual standard information by mail.
62062608|NCT01304121|EXPERIMENTAL|Bioactive glass|Resorbable bioactive glass granules
62062609|NCT02496767|PLACEBO_COMPARATOR|Group 1 - Placebo|Day 1 through Week 48: 2 placebo tablets twice daily
62625890|NCT05555277||Anorexia Nervosa|Individuals aged 18 years and younger with anorexia nervosa who have beck depression inventory, beck anxiety inventory, eating attitude test-40 and EEG data in their patient file.
62450421|NCT04578470|EXPERIMENTAL|Group A|Group A will be prescribed Vitamin D supplementation in the form of daily 2000 IU cholecalciferol (two tablets)for 13 weeks, and daily1000 IU cholecalciferol(1tablet) for another 13 weeks and then treatment will be discontinued but dietary interventions will continue across the 12-month study period.
62625891|NCT05555277||Bulimia Nervosa|Individuals aged 18 years and younger with bulimia nervosa who have beck depression inventory, beck anxiety inventory, eating attitude test-40 and EEG data in their patient file.
62851598|NCT06321380||Alzheimer disease|"Alzheimer's disease is define on the basis of the medical diagnostic. As part of routine care, they undergo a standardized clinical neuropsychological assessment that evaluates several cognitive functions.~For the study and during the day of medical consultations, each patient will perform a working memory task, lasting approximately 30 minutes.~If the patient is accompanied by a family member, the investigators ask the latter to complete a questionnaire on patient's daily executive functioning (French version of the Behavior rating inventory of executive function \[BRIEF-A\])."
62625892|NCT00005067|EXPERIMENTAL|Treatment (motexafin lutetium, PDT)|Patients receive lutetium texaphyrin IV over 10-15 minutes 3-24 hours before photodynamic therapy (PDT). Optical fibers attached to a laser are inserted through a catheter into the prostate. The laser delivers 730 nm light to the prostate until the specified fluence is delivered. Patients undergo biopsy of the prostate and bladder before and after PDT. Cohorts of 3-6 patients receive escalating doses of lutetium texaphyrin and light fluence until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
62851599|NCT06321380||Vascular dementia|"Vascular dementia is define on the basis of the medical diagnostic. As part of routine care, they undergo a standardized clinical neuropsychological assessment that evaluates several cognitive functions.~For the study and during the day of medical consultations, each patient will perform a working memory task, lasting approximately 30 minutes.~If the patient is accompanied by a family member, the investigators ask the latter to complete a questionnaire on patient's daily executive functioning (French version of the Behavior rating inventory of executive function \[BRIEF-A\])."
62625893|NCT03922282|EXPERIMENTAL|Gasless BABA|BABA robotic-thyroidectomy that do not using carbon dioxide but using elevation of flap.
62625894|NCT03922282|ACTIVE_COMPARATOR|Classic BABA|BABA robotic-thyroidectomy using carbon dioxide.
62625895|NCT05981092||BAG3 DCM|A single arm observational trial where all participants will undergo the same schedule of assessments.
62851600|NCT06321380||Mixed dementia|"Mixed dementia (i.e., Alzheimer's disease and vascular dementia) is define on the basis of the medical diagnostic. As part of routine care, they undergo a standardized clinical neuropsychological assessment that evaluates several cognitive functions .~For the study and during the day of medical consultations, each patient will perform a working memory task, lasting approximately 30 minutes.~If the patient is accompanied by a family member, the investigators ask the latter to complete a questionnaire on patient's daily executive functioning (French version of the Behavior rating inventory of executive function \[BRIEF-A\])."
62851601|NCT06321380||Control group|Control group includes healthy older adults (without cognitive impairment). As patient group, control group will perform the working memory task. However, control group does not undergo the clinical neuropsychological assessment.
62851602|NCT00932828|EXPERIMENTAL|Peanut oral immunotherapy|Newly diagnosed allergic children receiving peanut flour as oral immunotherapy for the treatment of peanut allergy.
62450422|NCT04578470|PLACEBO_COMPARATOR|Group B|Group B will be prescribed placebo of Vitamin D with two tablets daily for 13 weeks then 1 tablet daily for13 weeks then no treatment for 26 weeks but dietary interventions will continue across the 12-month study period.
62625896|NCT04077749|EXPERIMENTAL|Probiotic|
62625897|NCT04077749|PLACEBO_COMPARATOR|Placebo|
62851603|NCT01788436|EXPERIMENTAL|Group 1: Patients with schizophrenia|
62625898|NCT01424917||Heart Transplant|Heart Transplant subjects
62625899|NCT01383408|SHAM_COMPARATOR|healthy individual|healthy individual with no lung disease and no history of cancer including lung cancer
62625900|NCT01383408|EXPERIMENTAL|lung cancer|patients with histologically confirmed lung cancer, but no history of other cancer
62625901|NCT01383408|EXPERIMENTAL|breast cancer|patients with histologically confirmed breast cancer, but no history of other cancer
62625902|NCT01383408|EXPERIMENTAL|ovarian cancer|patients with histologically confirmed ovarian cancer, but no history of other cancer
62625903|NCT05274529|EXPERIMENTAL|Study group|All the participants will be in the same group and have the same intervention programmes options to choose from.
62625904|NCT06222762|NO_INTERVENTION|Commun practice|Patient in the control arm will not beneficiate from a follow-up in adapted physical activities (commun practice)
62851604|NCT01788436|ACTIVE_COMPARATOR|Group 2: Young healthy volunteers|
62851605|NCT01788436|EXPERIMENTAL|Group 3: Elderly healthy volunteers|
62851606|NCT00577616|OTHER|1|Endovascular repair
62851607|NCT00577616|OTHER|2|conventional surgery repair
62851608|NCT04185116|EXPERIMENTAL|3D Optic Surgeons|Full-trained surgeons randomised into this interventional arm will be performing laparoscopic gastric bypass using a 3D optic system.
62851609|NCT04185116|NO_INTERVENTION|2D Optic Surgeons|Full-trained surgeons randomised into this interventional arm will be performing laparoscopic gastric bypass using a 2D optic system.
62062610|NCT02496767|EXPERIMENTAL|Group 2 - 250 mg tirasemtiv|Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM
62851610|NCT04185116|EXPERIMENTAL|3D Optic Residents|4th and 5th year General Surgery residentes randomised into this interventional arm will be performing laparoscopic gastric bypass using a 3D optic system.
62062611|NCT02496767|EXPERIMENTAL|Group 3 - 375 mg tirasemtiv|Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM
62851611|NCT04185116|NO_INTERVENTION|2D Optic Residents|4th and 5th year General Surgery residentes randomised into this interventional arm will be performing laparoscopic gastric bypass using a 2D optic system.
62851612|NCT02102204|EXPERIMENTAL|Etelcalcetide|Participants received etelcalcetide three times a week (TIW) by bolus injection at the end of hemodialysis. The minimum etelcalcetide dose in this study was 2.5 mg and the maximum dose was 15 mg. Etelcalcetide dose was titrated to maintain parathyroid hormone levels within 2x to 9x the upper limit of normal based on the reference range of the assay used at the individual study center.
62851613|NCT04730661|NO_INTERVENTION|Conventional arm|For the patients enrolled in this conventional arm, the decision of hospitalisation or discharge will be taken with usual criteria (pulsed oxygen saturation (SpO2) in room air \<92% and respiratory rate\> 22/min, respiratory rate\> 30/min, Blood gas hypoxemia, decompensation of comorbidity, home monitoring not possible, other intercurrent pathology requiring hospitalization, several risk factors for COVID infection requiring hospitalization in intensive care (age\> 65y, hypertension complicated by a cardiovascular event, chronic cardiovascular disease, unbalanced diabetes with complications, chronic respiratory disease (excluding well-controlled asthma), chronic renal failure dialysis, obesity, progressive cancer under treatment, congenital or acquired immunosuppression)
62851614|NCT04730661|EXPERIMENTAL|Interventional arm|For the patients enrolled in this interventional arm, the decision of hospitalisation or discharge will be taken with usual criteria and the result of Sit to Stand Test.
62851615|NCT04194385|ACTIVE_COMPARATOR|Upper trunk block|In the supraclavicular region, UTB will be applied with 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine.
62851616|NCT04194385|ACTIVE_COMPARATOR|Costoclavicular brachial plexus block|In the infraclavicular region, CCBPB will be applied with 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine.
62851617|NCT03485300||Patients with chronic liver or kidney diseases|"Patients with chronic liver diseases may affect warfarin therapeutic outcome as liver is the site of metabolism of the drug by cytochrome p 450 enzymes so it decrease warfarin absorption~Kidney diseases also affect the clearance of the drug these patients will undergo liver function tests and kidney function tests"
62851618|NCT03485300||Non compliance of the patient|Missed dose of the warfarin or intermittent drug intake may affect drug therapeutic outcome as well as changing time of drug administration during the day
62851619|NCT03485300||Drugs or food interactions|Administration of other drugs beside warfarin may affect its therapeutic outcome either by inhibition or synergism certain food may also interfere with warfarin especially vitamin k and c rich food so patients will be followed up for drug or food interactions
62851620|NCT06275633|EXPERIMENTAL|Effect of levodopa|"1. Patients with PD are first being tested off medication~2. After examination OFF, the same group is being tested after adm of 200 mg Madopar Q"
62851621|NCT04032509||Mild TBI|Mild TBI (GCS 13-15 on admission) within 12 hours after injury
62062612|NCT02496767|EXPERIMENTAL|Group 4 - 500 mg tirasemtiv|Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM
62450423|NCT04663126|EXPERIMENTAL|Treatment group|Patients diagnosed with advanced melanoma (stage III-IV) will receive IV 250 µg Tilmanocept, labelled with 370 MBq of Tc-99m before the first cycle of clinically scheduled anti-PD-1 immunotherapy.
62450424|NCT02986009|EXPERIMENTAL|Parenting|To receive the parenting intervention
62625905|NCT06222762|EXPERIMENTAL|Follow-up in adapted physical activities|Patient in the control arm will beneficiate from a follow-up in adapted physical activities
62851622|NCT01064375|EXPERIMENTAL|CEA DNA prime (cohort I)|5 patients, tetwtCEA DNA intradermal delivery with electroporation, not previously vaccinated with CEA66 DNA. Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration. One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
62450425|NCT02986009|EXPERIMENTAL|Information|To receive the information intervention
62625906|NCT01594918|EXPERIMENTAL|Cabazitaxel, Mitoxantrone, Prednisone|
62062613|NCT03155932|EXPERIMENTAL|APD334|APD334 active treatment for 24 weeks.
62625907|NCT04652726|EXPERIMENTAL|Inclisiran|Year 1 - inclisiran sodium 300 mg subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 450 and 630)
62625908|NCT04652726|PLACEBO_COMPARATOR|Placebo|Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 360, 450, and 630)
62851623|NCT01064375|EXPERIMENTAL|CEA DNA boost (cohort II)|10 patients, tetwtCEA DNA intradermal delivery with electroporation, previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
62851624|NCT01064375|EXPERIMENTAL|CEA DNA prime + GM-CSF (cohort III)|5 patients, tetwtCEA DNA intradermal delivery with electroporation + GM-CSF, not previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
62625909|NCT04520048|EXPERIMENTAL|Women with gestational hypertension and/or preeclampsia|Pregnant patients from the 20th week of amenorrhea with the initial diagnosis of gestational hypertension and/or preeclampsia. Patients in a stable state undergoing follow-up consultation (day hospital and week hospitalization)
62625910|NCT03128853|EXPERIMENTAL|Test subjects|Each subject receives the Rad-67 and DCI Mini sensor that will measure hemoglobin repeatedly in order to compare those measurements against a blood sample reference.
62625911|NCT04567004|OTHER|Control|The control arm will show the products with no label.
62625912|NCT04567004|EXPERIMENTAL|Nutriscore Label|The Nutriscore label applies a letter grade (A, B, C, D or E) to a product based on certain nutrient criteria.
62625913|NCT04567004|EXPERIMENTAL|Adapted Peruvian Nutrient Label|"The adapted label is a black octagon with the words in Spanish saying Excess of sugar,Excess of saturated fat, or Excess of salt/sodium depending on the nutrition contents of the product. Below the octagon is a box with words in Spanish saying Avoid high consumption"
62625914|NCT04567004|EXPERIMENTAL|Guideline Daily Amount Label|The Guideline Daily Amount label highlights the nutrient contents of the product by serving. It lists the calories, total fat, saturated fat, sugar, and sodium, as well are their % of the daily value.
62625915|NCT05206110|EXPERIMENTAL|Peri- and postoperative 10 mg Ketolorac|Patients undergoing LAVH, RARP or TLH will receive dosages of 10 mg ketolorac (IV).
62625916|NCT05206110|ACTIVE_COMPARATOR|Peri- and postoperative standard-dose 30 mg Ketolorac|Patients undergoing LAVH, RARP or TLH will receive standard dosages of 30 mg ketolorac (IV).
62625917|NCT05121805|EXPERIMENTAL|EMR plus snare tip soft coagulation|Post procedural prophylactic coagulation of the entire margin of the resection site creating a 2-3mm rim.
62625918|NCT05121805|NO_INTERVENTION|Standard EMR|No prophylactic coagulation
62851625|NCT00766350|ACTIVE_COMPARATOR|amitriptyline|
62851626|NCT00766350|EXPERIMENTAL|quetiapine|
62851627|NCT02587182|EXPERIMENTAL|Dry needling|Dry needling in the masseter and temporalis muscles
62851628|NCT05352633|EXPERIMENTAL|Intensive BP Arm|Participants randomized into the Intensive treatment group will have a goal of SBP \<120 mmHg. A two- or three-drug regimen should be initiated at randomization for most participants. Drug doses should be increased and/or additional antihypertensive medications should be added at each visit in the intensive treatment group, usually at monthly intervals, until the participant's goal of \<120 mmHg has been reached or the local investigator decides no further antihypertensive medications may be added.
62851629|NCT05352633|ACTIVE_COMPARATOR|Standard BP Arm|Participants randomized into the Standard treatment group will have a goal of SBP \<140 mmHg. It is expected to achieve a SBP of 135-139 mmHg in as many participants as possible. Medication dose titration or addition of another drug is indicated if SBP is ≥160 mmHg at a single visit or is ≥140 mmHg at two consecutive visits. Down titration should be carried out if the SBP is \<130 mmHg at a single visit or \<135 mmHg at two consecutive visits.
62851630|NCT02106819||Cerebellar Ataxia subjects|40 individuals with either hereditary or sporadic ataxia will have testing of emotional communication ability and may have magnetic resonance imaging (MRI) of the brain.
62851631|NCT02106819||Healthy Control subjects|40 age matched controls will have testing of emotional communication ability and may have magnetic resonance imaging (MRI) of the brain.
62851632|NCT05429736|EXPERIMENTAL|MST + TSS|Individuals will participate in 6 training sessions of MST combined with TSS.
62851633|NCT05429736|SHAM_COMPARATOR|MST + ShamTSS|Individuals will participate in 6 training sessions of MST while receiving shamTSS.
62851634|NCT02859584|OTHER|no serious acute hepatitis|
62851635|NCT02859584|OTHER|Serious acute hepatitis|
62062614|NCT02112760|EXPERIMENTAL|Patient|To evaluate the effect of specific stabilization intervention in recurrent low back pain participants
62062615|NCT06624605|NO_INTERVENTION|Control|Participants receive standard ophthalmology notes without any additions.
62625919|NCT01039779|ACTIVE_COMPARATOR|Lower-extremity exercise training|This training will be tailored by physical therapists for each participant. A series of exercises will be applied to increase the stability of the trunk muscles and to strengthen the leg muscles.
62851636|NCT02859584|OTHER|Healthy volunteers|
62625920|NCT01039779|ACTIVE_COMPARATOR|Tai chi exercise|Yang-style tai chi with 18 movements will be taught every week over the 6-month intervention period at a subject's residence by tai chi instructors
62625921|NCT01997801|PLACEBO_COMPARATOR|C group|In C group, NS infusion will be done intraoperatively.
62625922|NCT01997801|EXPERIMENTAL|KET group|In KET group, ketamine infusion will be done intraoperatively(0.25 mg/kg bolus injection following 100 mcg/kg/hr till the end of surgery).
62625923|NCT05612217||patients with CVD|20 patients per 1 center: patients with CVD C1 class 4 patients with CVD C2 class; 2 patients with CVD with classes other than C1-C2 (C4-C6); 8 patients with either C0s CVD or with skin pathologic conditions of lower extremities other than CVD;
62625924|NCT01084148|EXPERIMENTAL|V0034CR01B|cream
62625925|NCT01084148|PLACEBO_COMPARATOR|V0034 CR 01B vehicle|cream
62625926|NCT06612580|EXPERIMENTAL|68Ga-AAZTA-NI-093 PET/ CT|68Ga-AAZTA-NI-093 Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-NI-093. Tracer doses of 68Ga-AAZTA-NI-093 will be used to image lesions of prostate cancer by PET/CT
62625927|NCT00558805|ACTIVE_COMPARATOR|1|Usual Care + Family Intervention for Suicide Prevention (FISP)
62625928|NCT00558805|OTHER|2|Usual Care
62851637|NCT02859584|OTHER|Surrenal insufficiency|
62851638|NCT04585061|ACTIVE_COMPARATOR|sweet test group|Local anesthesia with conventional syringe Procedure: Local anesthesia with conventional syringe + xylitol sublingual tablet Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.
62625929|NCT05464420|EXPERIMENTAL|V116 Lot 1|Participants will receive a single 0.5 mL intramuscular (IM) dose of V116 Lot 1 on Day 1.
62851639|NCT04585061|ACTIVE_COMPARATOR|Virtual reality group|"Local anesthesia with conventional syringe + VR device Device: Local anesthesia with conventional syringe + VR device Virtual reality device (Harga Miniso Vr Glass 3d terbaru) is placed on the face of the patient, playing a video of Tom and Jerry cartoon.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized."
62851640|NCT06150118|EXPERIMENTAL|CBT+VR (Cognitive behavioral therapy and virtual reality)|
62851641|NCT06150118|EXPERIMENTAL|VR (Virtual reality)|
62851642|NCT06150118|EXPERIMENTAL|CBT (Cognitive behavioral therapy)|
62851643|NCT06150118|PLACEBO_COMPARATOR|Control|
62625930|NCT05464420|EXPERIMENTAL|V116 Lot 2|Participants will receive a single 0.5 mL IM dose of V116 Lot 2 on Day 1.
62625931|NCT05464420|EXPERIMENTAL|V116 Lot 3|Participants will receive a single 0.5 mL IM dose of V116 Lot 3 on Day 1.
62625932|NCT05464420|ACTIVE_COMPARATOR|PPSV23|Participants will receive a single 0.5 mL IM dose of PPSV23 on Day 1.
62625933|NCT02801799|ACTIVE_COMPARATOR|Infusion group 1|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 12 mL/h. This infusion rate is normal clinical practice when administering a perineural infusion of ropivacaine."
62625934|NCT02801799|EXPERIMENTAL|Infusion group 2|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 60 mL/h. This infusion rate is experimental."
62625935|NCT02801799|EXPERIMENTAL|Infusion group 3|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 300 mL/h. This infusion rate is experimental."
62851644|NCT01660958|EXPERIMENTAL|Infants: MNP|• Infants will receive sachets of multiple micronutrient powder (MNP) vs. placebo.
62625936|NCT02801799|EXPERIMENTAL|Infusion group 4|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 600 mL/h. This infusion rate is experimental."
62625937|NCT02801799|ACTIVE_COMPARATOR|Infusion group 5|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 1800 mL/h. This infusion rate is normal clinical practice when administering a perineural bolus of ropivacaine."
62625938|NCT02256735|EXPERIMENTAL|Treatment A|
62625939|NCT02256735|EXPERIMENTAL|Treatment B|
62625940|NCT02256735|EXPERIMENTAL|Treatment C|
62625941|NCT02256735|EXPERIMENTAL|Treatment D|
62625942|NCT02256735|PLACEBO_COMPARATOR|Placebo|
62625943|NCT02256735|ACTIVE_COMPARATOR|Moxifloxacin|
62625944|NCT02447328|EXPERIMENTAL|Single Arm|Faslodex treated in the study
62851645|NCT01660958|EXPERIMENTAL|Infants: Early Learning|• Infant will receive early learning messages delivered in the home by village level workers vs. routine care.
62851646|NCT01660958|NO_INTERVENTION|Infants: No intervention|"* Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~* Infant phase. Routine care - no early learning intervention"
62851647|NCT01660958|EXPERIMENTAL|Infants: MNP/Early Learning|"* Infants receive the MNP plus early learning intervention by receiving MNP sachets~* Caregivers receive early learning messaged delivered at home biweekly for one year"
62851648|NCT01660958|EXPERIMENTAL|Preschoolers:MNP/High qual preschool|"* Preschoolers will receive MNP fortified food in their Anganwadi Centers at the mid-day meal.~* Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~* Preschools that are classified as high quality preschools."
62851649|NCT01660958|NO_INTERVENTION|Preschoolers:Placebo/High qual preschool|"* Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~* Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~* Preschools that are classified as high quality preschools."
62450426|NCT02079948|ACTIVE_COMPARATOR|Methotrexate + Folic Acid|Participants in the methotrexate condition will consume a dose of 15 mg/week of methotrexate during months 2 - 6. Participants will also consume 1 mg of folic acid/day for six days per week.
62851650|NCT01660958|EXPERIMENTAL|Preschoolers:MNP/Low qual preschool|"* Preschoolers will receive MNP fortified food in their Anganwadi Centers at the mid-day meal.~* Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~* Preschools that are classified as low quality preschools."
62625945|NCT01384747|EXPERIMENTAL|Fimasartan|Initial dose will be started with 60mg per day. At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
62851651|NCT01660958|NO_INTERVENTION|Preschoolers:Placebo/Low qual preschool|"* Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~* Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~* Preschools that are classified as low quality preschools."
62851652|NCT01539044|ACTIVE_COMPARATOR|IB-neostigmine|subject will be given intermittent bolus of rocuronium during the surgery and reversal of neostigmine at the end of surgery at TOF 2
62851653|NCT01539044|EXPERIMENTAL|CI-Sugammadex|subject will be given continuous infusion of rocuronium and reversal of sugammadex at the end of surgery at PTC 1-2
62851654|NCT02193906|EXPERIMENTAL|Intervention group|Cognitive training.
62851655|NCT02193906|PLACEBO_COMPARATOR|Placebo group|Placebo task.
62851656|NCT04330313|EXPERIMENTAL|Traction and stretching|This grup received stretching exercises after traction therapy for 18 sessions, 3 times per week.
62851657|NCT04330313|EXPERIMENTAL|Laser therapy and stretching|This grup received stretching exercises after laser therapy for 18 sessions, 3 times per week.
62851658|NCT04330313|EXPERIMENTAL|Hot pack and stretching|This grup received stretching exercises after hotpack therapy for 18 sessions, 3 times per week.
62851659|NCT04330313|EXPERIMENTAL|Stretching only|This grup received only stretching exercises for 18 sessions, 3 times per week.
62851660|NCT02087007|EXPERIMENTAL|group 1|Cilostazol 50mg, Cilostzaol 100mg
62851661|NCT02087007|PLACEBO_COMPARATOR|group 2|placebo
62851662|NCT02249000|EXPERIMENTAL|BIOVALVE prosthesis|Transcatheter Aortic Valve Replacement (TAVR)
62851663|NCT01781468|EXPERIMENTAL|Arm I|Patients receive 150 mg armodafinil orally every day in the morning for 8 weeks.
62851664|NCT01781468|PLACEBO_COMPARATOR|Arm II|Patients receive placebo orally every day in the morning for 8 weeks.
62851665|NCT01781468|EXPERIMENTAL|Arm III|Patients receive 250 mg armodafinil orally every day in the morning for 8 weeks.
62851666|NCT03810872|OTHER|Open label|Afatinib 40 mg/day during Period 1 Afatinib 40 mg/day + Paclitaxel 80mg/kg/3w during Period 2
62851667|NCT03209739|ACTIVE_COMPARATOR|WhatsApp reminder|An additional WhatsApp reminder with same content of the written instruction and a video of explanation of bowel preparation by a nurse 4 days prior colonoscopy
62851668|NCT03209739|NO_INTERVENTION|No reminder|No additional reminder will be given
62851669|NCT01915303|EXPERIMENTAL|pasireotide +/- cabergoline|pasireotide alone or with cabergoline
62851670|NCT00773838|EXPERIMENTAL|Vorinostat + Bortezomib|Participants receive vorinostat 400 mg, orally, once daily (QD) on Days 1-14 of each 21-day treatment cycle and bortezomib 1.3mg/m\^2 intravenous (IV) injection QD on Days 1, 4, 8 and 11 of each 21-day treatment cycle for up to 26 cycles. Participants with progressive disease (PD) after 2 cycles of treatment or no change (NC) after 4 cycles of treatment receive additional treatment of Dexamethasone, 20 mg of total daily dose, orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle for up to 26 cycles. Eligible participants could receive additional treatment on an extension.
62851671|NCT05478031|ACTIVE_COMPARATOR|REM0046127 high dose: 1400mg (700mg bid) oral suspension|REM0046127 high dose: 1400mg (700mg bid) oral suspension per day for 28 days
62851672|NCT05478031|ACTIVE_COMPARATOR|REM0046127 low dose: 350mg (175mg bid) oral suspension|REM0046127 low dose: 350mg (175mg bid) oral suspension per day for 28 days
62851673|NCT05478031|PLACEBO_COMPARATOR|Placebo|Placebo: placebo oral suspension bid for 28 days
62851674|NCT00585598||1|all patients that are admitted to the trauma bay with a supralaryngeal airway
62625946|NCT01384747|PLACEBO_COMPARATOR|Placebo|Initial dose will be started with 60mg per day. At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
62625947|NCT03492879|EXPERIMENTAL|Biopsy: Routine tests & EIT Technology|The patients will undergo a routine liver biopsy and also routine liver Ultrasonography, Shear wave elastography and Electrical Impedance Technology (EIT).
62851675|NCT00912184|EXPERIMENTAL|1|CVVH with high cut-off polyamide membrane (P2SH) using standard continuous veno-venous hemofiltration (CVVH) settings
62851676|NCT00912184|ACTIVE_COMPARATOR|2|CVVH using standard high flux membrane with standard CVVH settings
62851677|NCT03263663||Chemotherapy plus targeted treatment|Patients are treated in second-line with chemotherapy plus a targeted treatment according to the resistance mechanism to cetuximab pretreatment
62267031|NCT01836432|ACTIVE_COMPARATOR|FOLFIRINOX (SOC) ALONE|"Arm 2A: FOLFIRINOX (Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours) given days 1, 15, 29, 43 \& 57~Day 71-80 Disease eval: New disease = salvage Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m\^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m\^2 IV over 30-60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest~Day 71-80 Disease eval: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m\^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m\^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy~Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine~Ineligible for surgical resection \& stable disease = continue FOLFIRINOX~Ineligible for surgical resection \& progressive disease = salvage Gem/Nab-Paclitaxel"
62450427|NCT02079948|PLACEBO_COMPARATOR|Placebo + Folic Acid|Participants in the placebo condition will consume microcrystalline cellulose once per week. The number of capsules consumed on this day will match the number of capsules consumed by participants in the methotrexate condition. There are no active ingredients in the placebo capsules.
62851678|NCT03263663||Chemotherapy according to physician choice standard|Patients are treated in second-line with chemotherapy according to physicians choice after cetuximab pretreatment
62851679|NCT02801812||Systemic Lupus Erythematosus|patients ≥18 years diagnosed SLE upon classification according to 2012 SLICC criteria and disease onset ≥16 years.
62062616|NCT06624605|EXPERIMENTAL|Intervention|Participants receive standard ophthalmology notes with an appended LLM-generated plain language summary, reviewed and edited by the ophthalmologist. The plain language summary is clearly marked as generated as part of a Quality Improvement initiative.
62062617|NCT05364684|OTHER|Open-label Treatment|Open-label study of oral LUM-201 (ibutamoren mesylate) 25mg daily in otherwise healthy adults with BMI ≥25 kg/m2 and histologic or radiologic diagnosis of NAFLD.
62851680|NCT02801812||Healthy controls|subjects ≥18 years fulfilling the definition proposed in the protocol.
62851681|NCT01494623|ACTIVE_COMPARATOR|Active rTMS|Active treatment will be delivered at an intensity that is 90% of the RMT. Stimulation will be delivered at either 20 Hz or 10 Hz, depending on the patients' tolerance to the stimulation, with 50 stimulation trains of 30 stimuli each (i.e., 1500 stimuli) and an intertrain interval of 30 sec. 25 trains will be applied to to the left or right hemisphere followed by the other hemisphere.
62062618|NCT04775238|ACTIVE_COMPARATOR|Group 1 (Staphylococcus aureus)|Staphylococcus aureus is an example of gram positive bacteria which is a strong biofilm producer and highly resistant to antibiotics. Staphylococcus aureus will be exposed to silver nanoparticles and copper nanoparticles separately to study their antibacterial and biofilm inhibiting properties and their synergistic effect in combination with antibiotics.
62062619|NCT04775238|ACTIVE_COMPARATOR|Group 2 (Pseudomonas aeruginosa )|Pseudomonas aeruginosa is an example of gram negative bacteria which is a strong biofilm producer and highly resistant to antibiotics. Pseudomonas aeruginosa will be exposed to silver nanoparticles and copper nanoparticles separately to study their antibacterial and biofilm inhibiting properties and their synergistic effect in combination with antibiotics.
62450428|NCT02079948|EXPERIMENTAL|Functional MRI Experimental Tasks|15 participants will be randomly assigned to complete the fMRI visits at the baseline and 6 month.
62450429|NCT02079948|EXPERIMENTAL|Muscle Biopsy|10 participants will be randomly assigned to complete the skeletal muscle tissue sample at the baseline and 6 month visits.
62851682|NCT01494623|SHAM_COMPARATOR|Sham rTMS|Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
62851683|NCT04742582|ACTIVE_COMPARATOR|Preterm Infants - fed fermented formula|Feeding infants with fermented formula milk. Preterm infants will be fed either with fermented formula milk or with standard formula
62450430|NCT05567380||Methotrexate|Patients newly diagnosed with active Rheumatoid Arthritis and receiving lowest effective dosage of Methotrexate as initial therapy.
62267032|NCT01836432|EXPERIMENTAL|Gemcitabine/Nab-Paclitaxel+Algenpantucel-L HAPa Immunotherapy|"Arm 1B: Gemcitabine/Nab-Paclitaxel + Algenpantucel-L (HAPa) Immunotherapy~Day 71-80 Disease evaluated: New distant disease = salvage regimen FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total.~Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation + HAPa on days 1 and 15 of Chemoradiotherapy.~Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given days 1 and 15 for up to 18 doses total.~Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue Gem/Nab-Paclitaxel + HAPa given on days 8 and 22 for up to18 doses of algenpantucel-L Immunotherapy.~Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total."
62062620|NCT04698317|EXPERIMENTAL|beta-tricalcium phosphate plus concentrated growth factors|surgery plus biodegradable gelatin sponge loaded with Beta-tricalcium phosphate socked in concentrated growth factors (test group).
62062621|NCT04698317|PLACEBO_COMPARATOR|beta tricalcium phosphate alone(control group)|surgery plus biodegradable gelatin/beta-tricalcium phosphate sponges alone. (control group),
62062622|NCT02357290|EXPERIMENTAL|Open-label Treatment with NAC|"12-week, open-label treatment with NAC. Subjects will be treated with the following dose:~Subjects ages 5-12:~Week 1: 900mg po daily Weeks 2+: 900mg po QAM, 900mg po QPM~Subjects ages 13-17:~Week 1: 900mg po daily Weeks 2-3: 900mg po QAM, 900mg po QPM Weeks 4+: 1800mg po QAM, 900mg po QPM~In Weeks 3-12 for subjects ages 13-17, we will encourage twice per day dosing, but we will permit daily dosing if needed for adherence."
62087995|NCT04387890||Serologic Screening|Participants will be screened for IgM and IgG SARS-CoV-2 antibodies at baseline and every 2 weeks. Participants showing symptoms compatible with COVID-19 will undergo nasopharyngeal swab for PCR testing for diagnosis. Participants recovered from COVID-19 will have to have 2 negative and consecutive nasopharyngeal swab PCR tests in order to return to work.
62286841|NCT01868984|SHAM_COMPARATOR|Standard Therapy Alone|"Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (\>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).~For this control group, no paclitaxel is administered. The sham treatment is a period of 10 minutes that is allowed to elapse followed by the performance of a final completion angiogram to be labeled as PaciFIST Study Completion Angiogram. Any additional lesions identified with this study are then treated appropriately following standard technique."
62625948|NCT03492879|EXPERIMENTAL|Routine tests & EIT Technology|The patients will undergo a routine liver Ultrasonography, Shear wave elastography and Electrical Impedance Technology (EIT).
62625949|NCT03492879|EXPERIMENTAL|NASH : Routine tests & EIT Technology|The patients will undergo a routine liver Ultrasonography, Shear wave elastography and quantification of liver steatosis using the Electrical Impedance Technology (EIT).
62625950|NCT02435888||Polycystic ovary syndrome|
62625951|NCT03963219|EXPERIMENTAL|ABC4D|The complete integrated system consists of a smartphone that holds the advanced decision support algorithm. The system requires regular updates of cases derived from continuous glucose monitoring (CGM) data. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (post-prandial blood glucose).
62851684|NCT04742582|PLACEBO_COMPARATOR|Preterm Infants - fed standard formula|Feeding infants with standard formula milk. Preterm infants will be fed either with fermented formula milk or with standard formula
62851685|NCT04742582|OTHER|Reference Group: Pre-term Infants - breastfed|The breastfeeding infants were the reference group
62851686|NCT04881942|EXPERIMENTAL|ABDC|"Subjects administered 2 menthol and and 2 non-menthol test e-vapor products:~Product A (XL25F) on Day 1, Product B (XL40CB) on Day 2, Product D (XL40MB) on Day 3 and Product C (XL35WM) on Day 4"
62851687|NCT04881942|EXPERIMENTAL|BCAD|"Subjects administered 2 menthol and and 2 non-menthol test e-vapor products:~Product B (XL40CB) on Day 1, Product C (XL35WM) on Day 2, Product A (XL25F) on Day 3 and Product D (XL40MB) on Day 4"
62625952|NCT03963219|ACTIVE_COMPARATOR|Standard Bolus Calculator|Standard bolus calculator
62625953|NCT02357745||Pre-menopausal with periodontitis|non surgical periodontal therapy ( scaling and root planing)
62851688|NCT04881942|EXPERIMENTAL|CDBA|"Subjects administered 2 menthol and and 2 non-menthol test e-vapor products:~Product C (XL35WM) on Day 1 Product D (XL40MB) on Day 2, Product B (XL40CB) on Day 3 and Product A (XL25F) on Day 4"
62851689|NCT04881942|EXPERIMENTAL|DACB|"Subjects administered 2 menthol and and 2 non-menthol test e-vapor products:~Product D (XL40MB) on Day 1, Product A (XL25F) on Day 2, Product C (XL35WM) on Day 3 and Product B (XL40CB) on Day 4"
62851690|NCT04894877||Active Comparator: Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization plus optimal medical therapy.
62062623|NCT00873665|EXPERIMENTAL|Aerobic exercise|"To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.~The test of the arm effect of incidence of ED will be made with the Wald chi-square test from the logistic regression model. A dichotomous variable indicating whether the patient received PDE-5 inhibitor therapy will be used as a covariate in the model. The arm effect will be summarized by giving arm-specific covariate-adjusted proportions and their 80% confidence intervals, and the p-value."
62062624|NCT00873665|OTHER|Wait-list control|"To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.~For the analyses of arm differences in erectile dysfunction (IIEF) score, sexual functioning, urinary incontinence, and QOL, the primary endpoints will be the change across time in these continuous variables. Specifically, change across time for LTF patients will be imputed to be zero for all these analyses."
62267033|NCT01836432|ACTIVE_COMPARATOR|Gemcitabine/Nab-Paclitaxel (SOC) Alone|"Arm 2B: Gemcitabine/Nab-Paclitaxel (SOC) Alone~SOC Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m\^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m\^2 IV over 30-60 minutes for 3 weeks with 1 week rest. Given on days 1, 8, 15, 29, 36, 43, 57, 64 and 71~Day 71-80 Disease evaluated: New distant disease = salvage FOLFIRINOX given every 14 days~Day 71-80 Disease evaluation: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m\^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m\^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy~Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine~Ineligible for surgical resection \& stable disease = continue gem/nab-paclitaxel given for 3 weeks (days 1, 8 and 15) with 1 week rest~Ineligible for surgical resection \& progressive disease = salvage FOLFIRINOX given every 14 days"
62267034|NCT00432614|EXPERIMENTAL|Group 1|SR58611A 350mg twice daily with escitalopram 10mg once daily
62625954|NCT02357745||Post-menopausal with periodontitis|non surgical periodontal therapy ( scaling and root planing)
62062625|NCT04387981|EXPERIMENTAL|[14C]-orvepitant|\[14C\]-orvepitant administered as 30mg single dose in oral solution
62062626|NCT02648971|ACTIVE_COMPARATOR|Single Portal Knee Arthroscopy|After randomization for each patient is complete, the website will document the name of the person who logged on to perform the randomization, the date and time of the log in, and the surgical group assignment for each patient. This randomization information will be forwarded to the operating room staff so that they can prepare for each study participant's surgical procedure. Patients in Group 1 will undergo knee arthroscopy using a single portal. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
62267035|NCT00432614|ACTIVE_COMPARATOR|Group 2|placebo with escitalopram 10mg once daily
62267036|NCT00432614|PLACEBO_COMPARATOR|Group 3|placebo
62267037|NCT03464656|EXPERIMENTAL|Patients|"Patients presenting with male infertility, who are found to have abnormal semen analysis shall be recruited to this study.~Interventions:~* Patients will be given Fairhaven Pro for Men as antioxidant in a dose of 3 tablets twice daily for 3 months.~* Full assessment of fertility will be done."
62450431|NCT05567380||Methotrexate + JAK Inhibitors|Patients diagnosed with active Rheumatoid Arthritis and have shown intolerance or inadequate response to Methotrexate so JAK Inhibitor (Barcitinib) was added at 4mg/day orally to their therapy.
62450432|NCT05567380||Methotrexate + TNF Inhibitors|Patients diagnosed with active rheumatoid arthritis and have shown intolerance or inadequate response to Methotrexate so TNF Inhibitor was added to their therapy (either Golimumab at 50mg subcutaneous injection/m, or Etanercept at 50mg subcutaneous injection/wk)
62851691|NCT04894877||Active Comparator: Conservative Strategy|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with acute coronary syndrome, ischemic heart failure, resuscitated cardiac arrest or refractory symptoms.
62851692|NCT02663544|ACTIVE_COMPARATOR|Limited dairy diet|Three 8 oz. servings per week of non-fat milk. Participants will otherwise eat their usual diet, but will be asked not to consume any dairy products not provided by the study.
62851693|NCT02663544|EXPERIMENTAL|Low-fat dairy diet|3.3 daily servings of non-fat and low-fat dairy products in the form of fluid milk, cheese and yogurt. Participants will otherwise eat their usual diet, and will be asked not to consume any dairy products not provided by the study.
62851694|NCT02663544|EXPERIMENTAL|Full-fat dairy diet|3.3 daily servings of full-fat dairy products in the form of fluid milk, cheese and yogurt. Participants will otherwise eat their usual diet, and will be asked not to consume any dairy products not provided by the study.
62851695|NCT04314297|EXPERIMENTAL|Anlotinib In Combination With Durvalumab|
62851696|NCT05215548|EXPERIMENTAL|Group I : Surgery group|The surgery group would receive take 12 weeks of EGFR TKI before randomization. After randomization, the surgery group would receive thoracic surgery with maximal regional control intent. Patients continue afatinib 1 to 2 weeks after surgery until disease progression or unacceptable toxicity. The residual local and metastatic sites of disease could undergo either surveillance or maintenance radio-treatment at the discretion of the treating physician.
62625955|NCT04575090|NO_INTERVENTION|Arm 1 (Observational Arm)|Patients in substudy 1 will be identified by the PI from the clinic as individuals who are currently experiencing statin related muscle complaints or who have had severe reactions to statins in the past. There is going to be only one visit which will last for apprximately 3.5 hrs. Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS.
62851697|NCT05215548|ACTIVE_COMPARATOR|Group II : Maintenance group|The control group would receive take 12 weeks of EGFR TKI before randomization. After randomization, the control group would receive afatinib until disease progression or unacceptable toxicity. The residual local and metastatic sites of disease could undergo either surveillance or maintenance radio-treatment at the discretion of the treating physician.
62851698|NCT03484793|EXPERIMENTAL|AESOP integrated to CPOE for reducing medication errors|18 were assigned to the experimental group
62851699|NCT03484793|NO_INTERVENTION|Non AESOP|19 were assigned to the traditional CPOE system
62851700|NCT06317545|EXPERIMENTAL|Nirshl exercise with Mulligan Taping|This group will be treated with Nirshl exercises with Mulligan taping
62851701|NCT06317545|NO_INTERVENTION|Nirshl exercise without Mulligan taping|This group will be treated with Nirshl exercises only.
62851702|NCT04708457|ACTIVE_COMPARATOR|Early ECMO|Early ECMO therapy for patients who have SARI and have been mechanically ventilated for 5-7 days.
62851703|NCT04708457|NO_INTERVENTION|Standard Care|Patients with SARI who are already mechanically ventilated will continue to receive the standard intensive care therapies, including ECMO if required.
62851704|NCT00572767|EXPERIMENTAL|1|
62851705|NCT00572767|PLACEBO_COMPARATOR|2|
62851706|NCT04812600||Cardiac Rehabilitation|Individuals assigned to phase II (outpatient) cardiac rehabilitation program will undergo their normal exercise routines while the investigators make the measurements pre and post exercise at 0 week, and following 1 and 4 weeks of exercise.
62851707|NCT02864654|EXPERIMENTAL|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate Adipose-derived regenerative cells (ADRC). After isolation 10 mL of autologous ADRC suspension will be injected intramuscularly, close to the site of muscle injury. 10 to 20 injections will be performed so as to infiltrate the injured muscle
62450433|NCT01076803|EXPERIMENTAL|Lanreotide (acetate)|
62450434|NCT01540175||Participants|Participants enrolled on the study will have blood samples obtained.
62450435|NCT01521559|SHAM_COMPARATOR|Macular Laser Photocoagulation Treatment (Control)|Participants will receive macular laser treatment at Baseline and then according to laser re-treatment criteria up to week 24. Participants will receive treatment with Intravitreal Aflibercept Injection (IAI) starting at week 24 if they met rescue criteria. Treatment with IAI once initiated was 3 initial monthly doses followed by Q8 week dosing.
62625956|NCT04575090|EXPERIMENTAL|Arm 2 (Interventional Experimental Arm)|"Subjects with statin related muscle complaints were enrolled in this arm and will have 3 visits. First visit is screening visit which will last for about 2 hrs and the next 2 visits will last for about 3.5 hrs. The screening visit will occur 2 weeks prior to visit 1.~Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS.~Some volunteers who do/do not regularly exercise or are/are not active in sports may be asked to exercise prior to the MRS. This exercise may be in the form of hand grasps, toe-raises, bicycling on a stationary bike or walking on a treadmill. Exercise will be limited to up to one hour, during which time the subject's vital signs and blood oxygenation will be monitored. During the scan, the subject's heart rate and respiratory rate may be monitored"
62851708|NCT03887702|EXPERIMENTAL|Arm 1 (TAF, TDF, entecavir: prophylactic)|\[Cohort 1\] Patients receive TAF PO QD or TDF PO QD or entecavir PO QD immediately or within 42 days after initial dose of chemotherapy. Treatment continues for up to 6 months after the last dose of chemotherapy or a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
62267038|NCT05916365|EXPERIMENTAL|Lebrikizumab|Adult and adolescent participants (12 to less than \[\<\] 18 years and weighing greater than or equal to \[\>=\] 40 kilogram \[kg\]) with moderate-to-severe AD will receive lebrikizumab 250 milligrams (mg) subcutaneous (SC) injection via pre-filled syringe (PFS) for every fourth week (Q4W) for up to Week 104. If participants response is below EASI50 at any visit, lebrikizumab dosing frequency may be increased to every two weeks (Q2W) at any time during the course of the study; thereafter, lebrikizumab Q4W dosing may be resumed at the Investigator's discretion. Lebrikizumab will be administered up to Week 106 for participants who continue Q2W dosing, and these participants will undergo a safety follow-up assessment at Week 110.
62267039|NCT04170361|ACTIVE_COMPARATOR|Control Group|Patients will be admitted to chest physiotherapy program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization.
62267040|NCT04170361|EXPERIMENTAL|Training Group|In addition to conventional chest physiotherapy program, patients in this group will also be taught to use Triflo ® and apply at two-hour intervals.
62267041|NCT01418885||SIVD,VaD|vascular disease in patients with SIVD
62267042|NCT01418885||SIVD,VCIND|vascular cognitive impairment no dementia in patients with SIVD
62267043|NCT01418885||normal controls|normal elderly controls
62267044|NCT00599482|OTHER|1|Far Infrared Radiation
62267045|NCT05957289|EXPERIMENTAL|Multidimensional rehabilitation group|The intervention is based on the behavior change wheel and includes dietary intervention, exercise intervention, psychological support, and behavior management. Through various methods such as training, education, and motivation, the patient's ability, opportunities, and motivation will be increased, thereby promoting healthy behavior.
62267046|NCT03320759|NO_INTERVENTION|No rehabilitation|
62851709|NCT03887702|EXPERIMENTAL|Arm 2 (TAF, TDF, entecavir: upon indication)|\[Cohort 1\] Patients receive TAF PO QD or TDF PO QD or entecavir PO QD after HBV reactivation during chemotherapy. Treatment continues for up to 6 months after the last dose of chemotherapy or a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
62267047|NCT03320759|EXPERIMENTAL|Rehabilitation|
62267048|NCT01490437|EXPERIMENTAL|PemCis|Pemetrexed plus Cisplatin
62267049|NCT01653548|EXPERIMENTAL|HR training + Portable HR|100 subjects who receive Habituation Reminder training and who have access to the HR via a cellular phone.
62267050|NCT01653548|EXPERIMENTAL|HR Training + no portable HR|50 subjects who receive Habituation Reminder training and who do not have access to the HR via a cellular phone.
62267051|NCT01653548|EXPERIMENTAL|No HR training|50 subjects who do not receive HR training.
62267052|NCT01924455||HBV-HIV coinfected subjects|HBV-HIV coinfected subjects seen at one of 7 participating centers.
62267053|NCT05686200|EXPERIMENTAL|Experimental group|Participants performed wrist-forearm exercise training within 2 weeks after the operation, that is, from 24 hours to 2 weeks after the operation, twice a day in the morning and evening, 3 groups each time, and each single item was repeated 5 times in each group (maintain for 5 seconds). Exercise for 40 minutes a day, use the mobile phone to install the forearm isometric exercise software program within the 3rd to 8th week, use the Bluetooth device to connect the hand-held gripper to perform the forearm isometric exercise, 2 times a day, morning and evening, and train 3 groups each time, 20 times each time , hand grip strength for 3 seconds each time, increase by 1 second per week, and rest for 90 seconds between groups.
62450436|NCT01521559|EXPERIMENTAL|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4|Participants will receive 2 milligrams (mg) Intravitreal Aflibercept Injection (IAI) every 4 weeks (2Q4) through week 24 followed by injections every 8 weeks (2Q8) through week 48. Participants in this group may receive laser rescue at week 36.
62450437|NCT03231254||Chinese patients with OSA|
62450438|NCT03231254||Canada patients with OSA|
62450439|NCT03774667||Placenta Previa|Pregnant women is diagnosed with placenta previa after delivery. Placenta previa is diagnosed by experienced ultrasonologists based on a transabdominal ultrasonic finding of placental tissue covering the internal cervical os before delivery, and further confirmed by obstetricians at delivery.
62450440|NCT03774667||None-Placenta Previa|Pregnant women is diagnosed without placenta previa after delivery. Placenta previa is diagnosed by experienced ultrasonologists based on a transabdominal ultrasonic finding of placental tissue covering the internal cervical os before delivery, and further confirmed by obstetricians at delivery.
62267054|NCT05686200|OTHER|Control group|The control group began to use soft rubber balls for isometric contraction exercise from the 2nd day to the 8th week after operation. 2 times a day in the morning and evening, 3 groups of training each time, each group holds the ball for 5 minutes, and rests for 90 seconds between groups. Each grip training must be completed 20 times within 1 minute (keep 3 seconds each time in the first week) , increase by 2 seconds every week, and keep each grasping time for 10 seconds from the 5th to the 8th week.
62267055|NCT05317520|EXPERIMENTAL|Intervention group|Cold vapor was applied 3 times in total at 0th,2nd and 6th hours.
62267056|NCT05317520|NO_INTERVENTION|Control group|No cold vapor was applied at 0th,2nd and 6th hours.
62851710|NCT03887702|EXPERIMENTAL|Arm 3 (TAF, TDF, entecavir: upon indication)|\[Cohort 2\] Patients receive TAF PO QD or TDF PO QD or entecavir PO QD after HBV reactivation during chemotherapy. Treatment continues for up to 6 months after the last dose of chemotherapy or a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
62851711|NCT03887702|ACTIVE_COMPARATOR|Arm 4 (Anti-Viral therapy: usual care)|\[Cohort 2\] Patients receive anti-HBV therapy at the discretion of the physician. Any Food and Drug Administration (FDA) approved anti-viral medication for treatment of HBV may be utilized.
62851712|NCT01203085||Pediatric patients|All patients 21 years of age and under who are enrolled in the 6601 study and have undergone the pediatric scale tests.
62851713|NCT00606905|ACTIVE_COMPARATOR|1|IVIG, either Gamimune N (Talecris Biotherapeutics, Inc., Clayton, NC) or Gamunex 10% (Talecris Biotherapeutics, Inc., Clayton, NC), both as a 10% solution
62851714|NCT00606905|PLACEBO_COMPARATOR|2|normal saline
62851715|NCT00233454|EXPERIMENTAL|Midostaurin|100 mg midostaurin twice daily as oral capsules
62851716|NCT06280742|EXPERIMENTAL|Patients|MRI with added injection of gadolinium
62851717|NCT06280742|ACTIVE_COMPARATOR|Healthy Volunteers|
62851718|NCT03353233|EXPERIMENTAL|iPACK Block Group|A nerve block technique using a numbing medication called ropivacaine.
62062627|NCT02648971|ACTIVE_COMPARATOR|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
62062628|NCT02757482|EXPERIMENTAL|intervention|Patient training
62062629|NCT02757482|NO_INTERVENTION|control|no patient training
62062630|NCT06120673|EXPERIMENTAL|Obinutuzumab|
62062631|NCT06120673|ACTIVE_COMPARATOR|Oral prednisolone and cyclophosphamide|
62062632|NCT05585138|EXPERIMENTAL|Segmental breathing exercise|"segmental breathing exercise (apical costal expansion exercises, lateral costal expansion exercises, posterior costal expansion exercises) combined with Conventional Treatment ( deep breathing exercise ).~Group-A (interventional group) will receive segmental breathing exercises for one month 5 days a week and 2 sessions per day for 15 minutes for each patient"
62062633|NCT05585138|ACTIVE_COMPARATOR|conventional therapy|Conventional Treatment (deep breathing exercise). conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2times a day.
62062634|NCT00621712|ACTIVE_COMPARATOR|A|Patients in group A will be provided with a commercially available and CE certified standard double lumen catheter without surface coating (GamCath® catheter, No. CE 76891).
62062635|NCT00621712|EXPERIMENTAL|B|Patients in group B will be treated with a CE certified double lumen catheter with a new antibacterial bismuth-containing surface coating (GamCath Dolphin® Protect, No. CE 90671).
62450441|NCT06409962|EXPERIMENTAL|Technological intervention|The experimental arm integrates technology-based interventions-podcasts, gamification, and virtual reality-to promote nutritional education and healthy behaviors. Tailored podcasts cover topics like healthy eating habits and balanced nutrition, while gamification enhances motivation. Virtual reality offers immersive environments for exploring healthy choices. Both experimental and control groups enable a comprehensive evaluation, collecting data through measurements, biometrics, and activity records.
62851719|NCT03353233|PLACEBO_COMPARATOR|Sham Group|The same nerve block technique as above, however using an inactive solution of salt water.
62851720|NCT04941170|ACTIVE_COMPARATOR|Group (T)|receive preoperative bilateral ultrasound-guided oblique subcostal transversus abdominis plane block.
62851721|NCT04941170|ACTIVE_COMPARATOR|Group (E)|receive preoperative bilateral ultrasound-guided erector spinae plane block.
62851722|NCT06471283|EXPERIMENTAL|Single group. This group will practice physical activity during dialysis sessions.|Exercise using the LEMCO Hospital Bed Pedal Exerciser during dialysis.
62851723|NCT01440257|PLACEBO_COMPARATOR|Placebo (Group A)|
62851724|NCT01440257|EXPERIMENTAL|Active study medication (Group B)|CCX140-B
62851725|NCT06193109||the patients with sepsis or septic shock|devide two groups : (1) They had right ventricular dysfunction and (2) They had no right venticular dysfunction.
62851726|NCT03248349||1|Pharmacokinetics
62267057|NCT04863300|EXPERIMENTAL|Intervention group|Participants in the intervention group will receive a collaborative stepped care programme provided by registered social workers and trained Peer Supporters from aged care service units - the Districts Elderly Community Centres (DECC), and mental health service units - the Integrated Community Centre on Mental Wellness (ICCMW), all are local NGOs. In the collaborative stepped care model (see attachment Table 1), older persons are matched to the intervention module that most suits their current needs. The person does not have to start at the lowest level of intervention to progress to the next level of intervention. Rather, they enter the service with the intervention level aligned to their needs, e.g., level of risks, symptom severity (measured by the Patient Health Questionnaire, PHQ-9), and intervention response. Home visits or other format of contact will be delivered by trained Peer Supporters employed by the NGOs to detect and engage hidden cases.
62625957|NCT04575090|EXPERIMENTAL|Arm 3 (Interventional Control Arm)|"Subjects with no statin related muscle complaints were enrolled in this arm and will have 3 visits. First visit is screening visit which will last for about 2 hrs and the next 2 visits will last for about 3.5 hrs. The screening visit will occur 2 weeks prior to visit 1.~Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS.~Some volunteers who do/do not regularly exercise or are/are not active in sports may be asked to exercise prior to the MRS. This exercise may be in the form of hand grasps, toe-raises, bicycling on a stationary bike or walking on a treadmill. Exercise will be limited to up to one hour, during which time the subject's vital signs and blood oxygenation will be monitored. During the scan, the subject's heart rate and respiratory rate may be monitored"
62625958|NCT03848793|OTHER|HS-20004 or placebo treatment (Low dose)|HS-20004 or placebo SC once daily (Low dose)
62625959|NCT03848793|OTHER|HS-20004 or placebo treatment (median dose 1)|HS-20004 or placebo SC once daily (median dose 1)
62851727|NCT04157673|EXPERIMENTAL|Episodic Future Thinking introduced at 6 weeks|The intervention being researched is called episodic future thinking (EFT), which consists of imagining specific instances of one's future. In this study, participants will engage in EFT focused on imagining taking one's medication, guided by a research staff member in their intervention sessions in addition to weekly check-in calls across an 8-week period following a 6-week, 8-week or 10-week baseline period. The research staff member will conduct the intervention session using a semi-structured interview format in which they work to identify situations in which the participant encounters challenges with taking their medication and will ask questions to prompt the participant to imagine what successful medication adherence would consist of. Sessions may also involve imagining positive events resulting from successful medication adherence and the details surrounding those events.
62851728|NCT04023734|EXPERIMENTAL|Intervention|A targeted and tailored pharmacist intervention at baseline and at 1-month follow-up.
62851729|NCT04023734|ACTIVE_COMPARATOR|Control group|Usual care based on the Indonesian guideline at baseline and 1-month follow-up.
62851730|NCT00701662|EXPERIMENTAL|Vivaglobin|Vivaglobin® is a 16% (160 mg/mL) liquid formulation of human normal immunoglobulin for subcutaneous infusion. Subjects will receive weekly infusions of Vivaglobin® at a weekly dosage calculated based on previous intravenous immunoglobulin treatment (between 0.1 to 0.5 g/kg body weight per week).
62851731|NCT00655174|PLACEBO_COMPARATOR|1|
62851732|NCT00655174|EXPERIMENTAL|2|
62851733|NCT00655174|EXPERIMENTAL|3|
62851734|NCT03830892|ACTIVE_COMPARATOR|E-cigarette User (Exclusive)|Other: E-cigarette Lab Session 15 watts, 10 mg nicotine Other: E-cigarette Lab Session 15 watts, 30 mg nicotine Other: E-cigarette Lab Session 30 watts, 10 mg nicotine Other: E-cigarette Lab Session 30 watts, 30 mg nicotine Other: Own Brand Session - E-cigarette
62851735|NCT03830892|ACTIVE_COMPARATOR|Dual User|Other: E-cigarette Lab Session 15 watts, 10 mg nicotine Other: E-cigarette Lab Session 15 watts, 30 mg nicotine Other: E-cigarette Lab Session 30 watts, 10 mg nicotine Other: E-cigarette Lab Session 30 watts, 30 mg nicotine Other: Own Brand Session - E-cigarette/Cigarette
62851736|NCT00662467|ACTIVE_COMPARATOR|1|aspirin and clopidogrel
62851737|NCT00662467|EXPERIMENTAL|2|aspirin, clopidogrel, and warfarin
62851738|NCT00667108|EXPERIMENTAL|Gabapentin 250 mg|
62851739|NCT00667108|EXPERIMENTAL|Gabapentin 500 mg|
62851740|NCT00667108|PLACEBO_COMPARATOR|Placebo|
62851741|NCT02466659|EXPERIMENTAL|CIAO Therapy|Intervention with wearing 3-hour daily CIAO therapy glasses
62851742|NCT02466659|NO_INTERVENTION|Observation|To observe as one kind of standard care for IXT.
62851743|NCT00502411|EXPERIMENTAL|Doxorubicin + Radiation Therapy|Doxorubicin 17.5 mg/m\^2 IV bolus infusion, followed by continuous IV infusion on days 1-4. Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
62851744|NCT02890641||Children undergoing epilepsy surgery at the Rothschild Foundation, Paris.|Sequencing of paired blood-brain DNA samples
62851745|NCT01478048|EXPERIMENTAL|Arm A: Elotuzumab + Bortezomib + Dexamethasone|On days of Elotuzumab infusion: Dexamethasone (8mg IV + 8mg Oral) will be administered other days Dexamethasone 20 mg Oral will be administered
62851746|NCT01478048|ACTIVE_COMPARATOR|Arm B: Bortezomib + Dexamethasone|
62851747|NCT06297278|EXPERIMENTAL|Moderate Intensity Exercise|
62851748|NCT06297278|NO_INTERVENTION|Control (Coloring)|
62851749|NCT02317744|EXPERIMENTAL|Naltrexone/ Bupropion combination|50 mg naltrexone and 300 mg bupropion per day for 3 months
62851750|NCT02317744|PLACEBO_COMPARATOR|Pill placebo|Daily placebo medication for 3 months
62267058|NCT02586935|ACTIVE_COMPARATOR|Tideglusib|
62625960|NCT03848793|OTHER|HS-20004 or placebo treatment (median dose 2)|HS-20004 or placebo SC once daily (median dose 2)
62625961|NCT03848793|OTHER|HS-20004 or placebo treatment (high dose)|HS-20004 or placebo SC once daily (high dose)
62625962|NCT04995809||EPRIMM study participants|No intervention: Questionnaires, food diaries and stool sample.
62625963|NCT00063336|EXPERIMENTAL|1|Participants will receive cognitive remediation treatment.
62625964|NCT00063336|EXPERIMENTAL|2|Participants will receive computer-skills training.
62851751|NCT05331859|PLACEBO_COMPARATOR|conventional|Corneal epithelial wound healing in patients who received photorefractive keratectomy (PRK) treated only with conventional postoperative eye drops.
62851752|NCT05331859|ACTIVE_COMPARATOR|Insulin|Corneal epithelial wound healing in patients who received photorefractive keratectomy (PRK) treated with topical insulin and conventional postoperative eye drops.
62062636|NCT04331535|EXPERIMENTAL|Polygenic risk score (PRS) - high risk stratum|Patient-participants in the PRS-high arm and their providers will receive their high-PRS results at baseline, along with educational resources about the results.
62062637|NCT04331535|ACTIVE_COMPARATOR|Usual care (UC) - high risk stratum|Patient-participants in the UC-high arm and their providers will receive their high-PRS results after a 24-month observation period, along with educational resources about the results.
62062638|NCT04331535|EXPERIMENTAL|Polygenic risk score (PRS) - average risk stratum|Patient-participants in the PRS-average arm and their providers will receive their average-PRS results at baseline, along with educational resources about the results.
62267059|NCT02586935|PLACEBO_COMPARATOR|Placebo|
62062639|NCT04331535|ACTIVE_COMPARATOR|Usual care (UC) - average risk stratum|Patient-participants in the UC-average arm and their providers will receive their average-PRS results after a 24-month observation period, along with educational resources about the results..
62062640|NCT04916119|EXPERIMENTAL|IBI323|Phase Ia enrolls patients with advanced malignancies. Phase Ib cohort A enrolls patients with NSCLC(IO-refractory), cohort B NSCLC(IO-naive), cohort C NSCLC(PD-L1 TPS≥1%), cohort D ES-SCLC or neuroendocrine tumors, cohort E MPM, cohort F UC, cohort G nccRCC, cohort H HCC, cohort I NPC, cohort J CC or HNSCC, cohort K GC or GEJC with HER2 negative, cohort L TNBC
62450442|NCT06409962|NO_INTERVENTION|No-technological intervention: traditional brochure|The control arm will focus on a non-technological intervention, specifically utilizing traditional brochures. Participants in this arm will receive printed materials containing information on basic nutritional guidelines, healthy eating habits, and the importance of balanced nutrition. The brochure-based intervention aims to provide essential information in a straightforward format, emphasizing key messages related to healthy eating practices. Participants will have access to pamphlets outlining dietary recommendations, portion control, and tips for making nutritious food choices.
62450443|NCT03562806|EXPERIMENTAL|PET/MR (single arm)|PET and MR sequence acquisition on SIGNA PET/MR device
62851753|NCT05331859|ACTIVE_COMPARATOR|Autologous serum eye drops|Corneal epithelial wound healing in patients who received photorefractive keratectomy (PRK) treated with Autologous serum eye and conventional postoperative eye drops.
62851754|NCT05366504|ACTIVE_COMPARATOR|Group A|
62851755|NCT05366504|PLACEBO_COMPARATOR|Group B|
62851756|NCT05089422|EXPERIMENTAL|Children with exotropia|squint surgery
62062641|NCT01681108|OTHER|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
62062642|NCT01147692|EXPERIMENTAL|simvastatin plus albiglutide|A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
62062643|NCT00004011|EXPERIMENTAL|preooperative chemo followed by surgery|carboplatin paclitaxel conventional surgery
62062644|NCT00004011|ACTIVE_COMPARATOR|Surgery alone|conventional surgery
62062645|NCT02920203||index cases group|unexpected sudden death cases recruited by forensic institutes or pathology departements
62062646|NCT02920203||first degree relatives group|Relatives enrolled of unexpected sudden death index cases
62062647|NCT01994356|ACTIVE_COMPARATOR|Usual contraceptive counseling|subjects received usual contraceptive counseling
62062648|NCT01994356|EXPERIMENTAL|Physician self-disclosure of IUC use|subjects received usual contraceptive counseling plus intervention which was Physician self-disclosure of personal IUC use during the counseling
62267060|NCT05373927||Study group 1|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients in Fontaine stage II (intermittent claudication) or one leg in healthy volunteers (total 1 site)~Physical assessment: Pulse status / Color-Coded Duplex Sonography / Ankle-Brachial Index / 6-minute walk test (6MWT) / Continued heel raises for at least 30s"
62851757|NCT01589653|EXPERIMENTAL|Subject-driven titration|
62851758|NCT01589653|EXPERIMENTAL|Investigator-driven titration|
62851759|NCT04341428|EXPERIMENTAL|DWP14012 20mg|Orally, once daily
62851760|NCT04341428|ACTIVE_COMPARATOR|Lansoprazole 15mg|Orally, once daily
62450444|NCT01254409|EXPERIMENTAL|PRM-151|PRM-151 administered at escalating doses of 1, 5, and 10 mg/kg by 30 minute intravenous (IV) infusion days 1, 3, 5, 8 and 15.
62851761|NCT04825470|EXPERIMENTAL|Liver Transplantation|
62087996|NCT02449044|EXPERIMENTAL|Tolvaptan|Enrolled subjects began treatment with 15 mg tolvaptan QD. A titration between target doses of 15 mg, 30 mg, or 60 mg of trial medication was based on the subject's change in serum sodium concentration and clinical tolerance of the trial medication.
62087997|NCT01866917|EXPERIMENTAL|TAP|Patients will receive Ropivicaine 0.5% 20cc injectate from a study labeled syringe
62267061|NCT05373927||Study group 2|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients in Fontaine stage II (intermittent claudication) or one leg in healthy volunteers (total 1 site)~Physical assessment: Pulse status / Color-Coded Duplex Sonography / Ankle-Brachial Index / 6-minute walk test (6MWT) / Continued heel raises for at least 30s"
62450445|NCT01254409|PLACEBO_COMPARATOR|Placebo|0.9% saline administered by 30 minute IV infusion Days 1, 3, 5, 8, and 15.
62450446|NCT05520424|EXPERIMENTAL|The Daily Supplement|Participants will use test product daily, and complete Biomarker assessments (at 1st dose, Day 7, Day 31), as well as surveys (at 1st dose, Day 7, Day 31), and Cognitive battery Assessments (at 1st dose, Day 7, Day 31).
62450447|NCT06048900|OTHER|Optic nerve sheath diameter measurements|A total of 7 measurements were planned to be made at specified times.
62851762|NCT03300596|EXPERIMENTAL|brief intervention to prevent suicide attempt|Individuals presenting to hospital following a suicide attempt who are age 18-plus and screen positive for alcohol or drug use problem
62625965|NCT03334422|EXPERIMENTAL|4 Milligram (mg) Baricitinib|4mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every day to match
62851763|NCT03300596|OTHER|standard of care|Individuals presenting to hospital following a suicide attempt who are age 18-plus and screen positive for alcohol or drug use problem
62851764|NCT04696887|EXPERIMENTAL|Tele Tai Chi|8-week Tele Tai Chi intervention
62851765|NCT05427617||Control group|Control group includes patients without ctDNA abnormality and patients without druggable ctDNA abnormality.
62851766|NCT05427617||Case group|Case group includes patients with druggable ctDNA abnormality.
62851767|NCT04264832||observation group|Participants were eligible if they met the Rotterdam diagnostic criteria of polycystic ovary syndrome (PCOS) and meet the inclusion and exclusion criteria , and all study participants received questionnaires and underwent the physical, transvaginal ultrasound and body composition examination. Blood samples were collected for analysis of metabolic markers, metabonomics and hormones.
62267062|NCT00993928|EXPERIMENTAL|Arm A: Home-based sleep intervention with Device #1|Participants listen to a pre-recorded mp3 device #1 before retiring to sleep. Only patients in Arm A will have assigned bed and wake times based on their baseline diary.
62450448|NCT05753384|EXPERIMENTAL|continued treatment with TKI at 50% dose reduction|continued treatment with TKI at 50% dose reduction compared to dosing received at randomization and then stopped treatment 12 months after randomization
62450449|NCT05753384|ACTIVE_COMPARATOR|continuation of TKI treatment without dose change|continued treatment with TKI at same dose compared to dosing received at randomization and then stopped treatment 12 months after randomization
62087998|NCT01866917|PLACEBO_COMPARATOR|Saline|Patients will receive Normal saline 20cc injectate from a study labeled syringe
62087999|NCT05420987|EXPERIMENTAL|active arm|Jing Si herbal tea liquid packet
62267063|NCT00993928|ACTIVE_COMPARATOR|Arm B: Home-based sleep intervention with Device #2|Participants will listen to a pre-recorded mp3 device #2 before retiring to sleep. At the end of the study, participants assigned to pre-recorded mp3 device #2 will be offered pre-recorded mp3 device #1 for their own use.
62267064|NCT01959711|EXPERIMENTAL|Posterior RA|Posterior retroperitoneoscopic adrenalectomy
62267065|NCT01959711|ACTIVE_COMPARATOR|Lateral transperitoneal LA|Lateral transperitoneal laparoscopic adrenalectomy
62062649|NCT01774071|EXPERIMENTAL|89Zr DFOMSTP2109A tracer Group 1|The first group of participants will include 6 participants whom will receive 10mg of 89Zr-DFO-MSTP2109A. A second group of 6 participants may receive twice the amount of antibody to determine if this results in better pictures of your tumors. Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2.
62267066|NCT00710528|EXPERIMENTAL|one arm|
62267067|NCT05725616|EXPERIMENTAL|Snuff box puncture|Puncture of the radial artery at of the anatomical snuff box or on the back of the hand during coronary angiography
62267068|NCT05725616|ACTIVE_COMPARATOR|Wrist puncture|Puncture of the radial artery at the level of the base of the wrist during coronary angiography
62267069|NCT03284736|EXPERIMENTAL|Periapical surgery with membrane|"After retrofilling of teeth with MTA , defect was covered with collagen resorbable membrane.~healiguide collagen type 1 resorbable membrane covering the defect by extending 2-3 mm in every direction."
62450450|NCT05355597|EXPERIMENTAL|Exparel Group|70 subjects will receive Exparel
62450451|NCT05355597|EXPERIMENTAL|Multi-Drug Cocktail Group|70 subjects will receive a Multi-drug Cocktail
62625966|NCT03334422|EXPERIMENTAL|2mg Baricitinib|2mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
62625967|NCT03334422|EXPERIMENTAL|1mg Baricitinib|1mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
62088000|NCT05420987|PLACEBO_COMPARATOR|control arm|Jing Si herbal tea placebo
62267070|NCT03284736|ACTIVE_COMPARATOR|Periapical surgery without membrane.|After retrofilling of teeth with MTA, flap was closed without application of collagen resorbable membrane.
62267071|NCT02524509||CHONDRON|Patients who already received autologous chondrocyte implantation using CHONDRON (Autologous Cultured Chondrocyte) for knee cartilage defects
62267072|NCT02524509||Microfracture|patients already underwent microfracture
62267073|NCT05011929|EXPERIMENTAL|online CBT-I with support (individualized feedback and reminders)|The mobile-APP based CBT-I consists of 6 weekly session. The treatment is structured and based on the well-established CBT elements for treating insomnia. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention. reminders and individualized feedback regarding the behavioral strategies will be sent to the participant every week.
62267074|NCT05011929|ACTIVE_COMPARATOR|online CBT-I without support|same as the experimental arm but without reminders and individualized feedback
62267075|NCT02010164|EXPERIMENTAL|Old-CoQ10|
62267076|NCT02010164|NO_INTERVENTION|Old|
62267077|NCT02010164|NO_INTERVENTION|Young|Young less than 33 years old participants
62267078|NCT04589273|EXPERIMENTAL|Alginate capsule|The participants of this arm will be give the alginate capsules
62267079|NCT04589273|PLACEBO_COMPARATOR|Placebo|The participants of this arm will be give the placebo capsules
62267080|NCT04850053||Alzheimer's disease|Criteria for AD according to the 2011 NIA-AA
62450452|NCT03534986|EXPERIMENTAL|AffloVest The Vest Arm|Devices placed on highest intensity / highest frequency
62450453|NCT03534986|EXPERIMENTAL|AffloVest inCourage Arm|Devices placed on highest intensity / highest frequency
62625968|NCT03334422|PLACEBO_COMPARATOR|Placebo|Placebo administered orally once daily.
62625969|NCT04644120|EXPERIMENTAL|Part A: Group 1: ABBV-47D11 Dose A|Participants will receive ABBV-47D11 Dose A on Day 1.
62851768|NCT04264832||control group|The control group participants are normal women and had no history of any type of diabetes, cardiovascular disease (myocardial infarction, unstable angina, stroke or cardiovascular revascularization), stage 2 hypertension , malignant disease or severe renal or hepatic disease. They accepted the same examinations as the observation group.
62851769|NCT02204475|ACTIVE_COMPARATOR|BOC/PR|All participants begin treatment with a 4-week lead-in of PR followed by 24 weeks of BOC/PR. At Treatment Week (TW) 28 TN participants who have undetectable HCV RNA at TW 8 will complete BOC/PR therapy. At TW 28 TN participants who have detectable HCV RNA at TW 8, as well as prior relapsers and prior partial responders, will continue on BOC/PR for an additional 8 weeks and then continue on PR for an additional 12 weeks. At TW 28 all cirrhotics and previous null responders will continue on BOC/PR for an additional 20 weeks.
62851770|NCT02204475|EXPERIMENTAL|Grazoprevir/Elbasvir|Participants will undergo treatment with grazoprevir 100 mg + elbasvir 50 mg for 12 weeks.
62851771|NCT02720029|EXPERIMENTAL|pH/impedance monitor|
62851772|NCT02706964|EXPERIMENTAL|Proactive imaging|All enrolled subjects will under go a single whole-body Positron emission tomography/x-ray computed tomography (PET/CT) scan and a diagnostic-quality x-ray computed tomography (CT) scan with contrast acquired in the same imaging session; and a single brain magnetic resonance imaging (MRI) scan with contrast to be completed in separate imaging session but within 2 weeks of the PET/CT scan. Imaging will take place within 7 months after enrollment.
62267081|NCT04850053||Non-AD dementia|Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or vascular dementia (VaD); or corticobasal degeneration (CBD); or dementia not otherwise specified.
62851773|NCT03316989||obese children|Children and adolescents with BMI according to the CDC greater that 95%ile
62851774|NCT03316989||normal weight|Children and adolescents with BMI according to the CDC less than the 85%ile
62851775|NCT03316989||obese with the MetS|obese children with metabolic syndrome compared to obese children with out the MetS and normal weight children
62851776|NCT04042090|EXPERIMENTAL|Intervention group: use of therapeutic virtual reality|Intervention group: use of virtual reality intervention at home over a period of 28 days (with a maximum of 35 days) at least ten minutes a day (excluding day 1, in which the participants should do the entire education module of 25 minutes) and in addition, when participants feel the need. Meanwhile, participant is placed on the waiting list to receive normal chronic pain treatment.
62851777|NCT04042090|NO_INTERVENTION|Control group: no use of therapeutic virtual reality|Control group: no intervention, patient is waiting to receive normal chronic pain treatment.
62851778|NCT06020872|EXPERIMENTAL|Health literacy group|Participants received the health literacy related to healthy plate.
62851779|NCT06020872|NO_INTERVENTION|Control group|Participants did not receive the health literacy related to healthy plate.
62851780|NCT02250729|EXPERIMENTAL|cases with NMBA anaphylaxis|Patients who experienced NMBA anaphylaxis during anesthesia
62851781|NCT02250729|OTHER|controls|Patients who underwent anesthesia with NMBA injection but did not experience anaphylaxis
62851782|NCT02500056|ACTIVE_COMPARATOR|OM group|Optilene LP mesh
62267082|NCT04850053||Cognitively normal controls|Individuals with normal cognitive function
62450454|NCT03534986|EXPERIMENTAL|AffloVest SmartVest Arm|Devices placed on highest intensity / highest frequency
62450455|NCT01441661||Sunitinib Renal Cell Carcinoma|Patients diagnosed with Renal Cell Carcinoma (RCC) and treated with Sunitinib from 2008 to present will be eligible. This will include current active patients as well as patients who have expired and have medical records available.
62851783|NCT02500056|ACTIVE_COMPARATOR|UM group|Ultrapro mesh
62851784|NCT04139889||normal mucosa|Flat and relatively uniform polygonal epithelial cells with alternating dark and light bands were noted in pCLE images of normal mucosa after intravenous injecting 10% fluorescein.
62851785|NCT04139889||non-malignant lesions|An unorganized tissue architecture, irregular cells (difference of cell shape, color and size), slightly intensified fluorescein leakage, and vessels not assessable were found in the lymphoid hyperplasia of non-malignant lesions after intravenous injecting 10% fluorescein.
62851786|NCT04139889||malignant lesions|pCLE images of malignant lesions were associated with crowded unorganized tissue architecture (a dark-gray background without identification of mucosal structures), irregular cells like cell clusters, amplified fluorescein leakage, and irregular vessels changes after intravenous injecting 10% fluorescein.
62851787|NCT03288233||Primary Group|
62267083|NCT05326984|NO_INTERVENTION|Control group|This subjets will receive conventional chemotherapy alone. The Remission induction chemotherapy includes a steroid pre-phase of 7 days of prednisone 60mgm2SCD. The proper remission induction phase consist in prednisone 60mgm2 daily from day 0 to 28; Vincristine 1.5mgm2 on days 0, 7, 14 and 21; Doxorubicin 25mgm2 on days 0, 7, 21; L-asparaginase 10, 000 Um2 on days 2, 4, 6, 8, 10 and 12. Etoposide 300mgm2 and cytarabine 300mgm2 on days 22, 25 and 29. Intrathecal chemotherapy is administered on days 0, 7, 14 and 21.
62625970|NCT04644120|PLACEBO_COMPARATOR|Part A: Group 1: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
62625971|NCT04644120|EXPERIMENTAL|Part A: Group 2: ABBV-47D11 Dose B|Participants will receive ABBV-47D11 Dose B on Day 1.
62625972|NCT04644120|PLACEBO_COMPARATOR|Part A: Group 2: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
62450456|NCT00505609|EXPERIMENTAL|A|The Institute for Reproductive Health trained health providers in teaching the Standard Days Method to study subjects and in study procedures. Providers counseled study participants in method use. Participants were followed for up to 13 cycles of method use.
62625973|NCT04644120|EXPERIMENTAL|Part A: Group 3: ABBV-47D11 Dose C|Participants will receive ABBV-47D11 Dose C on Day 1.
62851788|NCT01754402|EXPERIMENTAL|Cohort 1: benda 120mg + pom 3mg|"* Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days~* Bendamustine: once intravenous (IV) dosing on day 1, every 28 days~* Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
62851789|NCT01754402|EXPERIMENTAL|Cohort 2: benda 120mg + pom 4mg|"* Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days~* Bendamustine: once intravenous (IV) dosing on day 1, every 28 days~* Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
62851790|NCT01754402|EXPERIMENTAL|Expansion|"* Pomalidomide 3mg: once daily oral (PO) dosing on days 1-21, every 28 days~* Bendamustine 120 mg: once intravenous (IV) dosing on day 1, every 28 days~* Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
62062650|NCT01774071|EXPERIMENTAL|89Zr-DFO-MSTP2109A tracer Group 2|Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2. Group 2 will include up to 15 participants whom may receive a dose of up to 20mg.
62851791|NCT01531855|OTHER|Insulin dose|Reducing rapid-acting insulin dose (insulin aspart or lispro) after exercise.
62851792|NCT00127270|EXPERIMENTAL|1|Darifenacin
62851793|NCT00127270|OTHER|2|Darifenacin in combination with Behavioral Modification Programme for Symptoms of Overactive Bladder
62851794|NCT01626937|EXPERIMENTAL|Non invasive ventilation with conventional treatment|
62851795|NCT01626937|ACTIVE_COMPARATOR|conventional medical treatment|
62851796|NCT02712047|EXPERIMENTAL|Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg|Subjects will receive FF/VI 100/25 mcg each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
62062651|NCT03007784|EXPERIMENTAL|2 mA anodal tDCS stimulation|Anodal tDCS stimulation at 2 mA applied to the left dorsolateral prefrontal during 20 minutes five days a week for two consecutive weeks
62062652|NCT03007784|ACTIVE_COMPARATOR|0.2 mA anodal tDCS stimulation|Anodal tDCS stimulation at 0.2 mA applied to the left dorsolateral prefrontal during 20 minutes five days a week for two consecutive weeks
62062653|NCT02166450||Control group|Denture wearers without clinical signs of denture-related stomatitis confirmed with negative Candida swabs.
62062654|NCT02166450||Denture-related stomatitis group|"Denture wearers with clinical signs of denture-related stomatitis, confirmed with positive Candida swabs.~Treated for fungal infection, with nystatin \[100 000 IU every 6 h for 3 weeks, applied on the infected area of the mucous membrane of the palate and cheeks\]."
62062655|NCT06188520|EXPERIMENTAL|Module 1|AZD8421 monotherapy
62062656|NCT06188520|EXPERIMENTAL|Module 2A_abema|AZD8421 with camizestrant and abemaciclib
62851797|NCT02712047|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
62062657|NCT06188520|EXPERIMENTAL|Module 2A_ribo|AZD8421 with camizestrant and ribociclib
62062658|NCT06188520|EXPERIMENTAL|Module 2A_palbo|AZD8421 with camizestrant and palbociclib
62450457|NCT04632823|EXPERIMENTAL|Comprehensive non-pharmacological program intervention|The experimental group receives usual diabetes care plus 24 weeks of the comprehensive non-pharmacological program intervention.
62450458|NCT04632823|NO_INTERVENTION|Usual diabetes care|This group is control, the patients receive usual diabetes care routines.
62450459|NCT06047145|EXPERIMENTAL|soy isoflavones|One oral capsule daily containing 200mg soy isoflavones for 84 days
62450460|NCT06047145|PLACEBO_COMPARATOR|placebo|One oral capsule daily containing equivalent placebo for 84 days
62450461|NCT02619123|ACTIVE_COMPARATOR|invitation to mammography screening|44-45 years old women in this arm are invited to attend for a mammography screening every 1 year. After the age of 50, all women will continue to be screened in the usual service screening programme.
62625974|NCT04644120|PLACEBO_COMPARATOR|Part A: Group 3: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
62625975|NCT04644120|EXPERIMENTAL|Part B: Group 1: ABBV-2B04 Dose A|Participants will receive ABBV-2B04 Dose A on Day 1.
62625976|NCT04644120|EXPERIMENTAL|Part B: Group 1: ABBV-2B04 Dose A + ABBV-47D11|Participants will receive ABBV-2B04 Dose A in combination with ABBV-47D11 on Day 1.
62851798|NCT04790565|EXPERIMENTAL|Fecal microbiota transplantation (FMT)|Patients will be given capsulized FMT, 15 capsules a day for two consecutive days after a fast of 8 hours before FMT. Patients will continue fasting for 2 hours after the intervention. Stool will be collected before and after the intervention for genomic analysis of CRE strains, analysis of microbiome and metabolome.
62851799|NCT05575050|ACTIVE_COMPARATOR|Standard oral procedure|"Standard mouth cleaning protocol (without brushing) included:~1. Preparation of sterile catheter (12F lub 14F), suction of excess fluid from the oral cavity.~2. Using Sage Suction Swab (Toothette®), soaking in Perox-A-Mint Solution and cleaning with circular movements of each mucosal site for 10 seconds:~   1. Right cheek mucosa and right upper quadrant~  2. Left cheek mucosa and left upper quadrant~  3. Left lower buccal quadrant~  4. Right lower buccal quadrant~3. Moisturizing with Mouth Moisturizer /firma/ of oral cavity mucosa, tongue and lips.~4. Repeated suction of excess fluid from the oral cavity."
62062659|NCT06190262|EXPERIMENTAL|Psychoeducation|"The experimental condition consists of a psychoeducation program with six sessions. Two of the sessions are online. A teacher and a volunteer will lead the sessions. The topic of the sessions are diverse and cover topics such as mental illness, the diathesis-stress model, treatment of mental illness, caregiver coping mechanisms and caregiver rights.~Before the first session, participants are asked to fill in an online questionnaire with background information and well-being indicators. After the last session, participants are asked to fill in another short questionnaire with the same well-being indicators and also a measure of their satisfaction with the program."
62062660|NCT04183634|EXPERIMENTAL|Period 1: Rotigotine TTS (Test) - Period 2: Neupro (Reference)|For each period: an 18 mg transdermal patch to deliver 8 mg/24h will be applied for 24 h
62625977|NCT04644120|PLACEBO_COMPARATOR|Part B: Group 1: Placebo|Participants will receive Placebo for ABBV-2B04 followed by Placebo for ABBV-47D11 on Day 1.
62625978|NCT04644120|EXPERIMENTAL|Part B: Group 2: ABBV-2B04 Dose B|Participants will receive ABBV-2B04 Dose B on Day 1.
62625979|NCT04644120|EXPERIMENTAL|Part B: Group 2: ABBV-2B04 Dose B + ABBV-47D11|Participants will receive ABBV-2B04 Dose B in combination with ABBV-47D11 on Day 1.
62625980|NCT04644120|PLACEBO_COMPARATOR|Part B: Group 2: Placebo|Participants will receive Placebo for ABBV-2B04 followed by Placebo for ABBV-47D11 on Day 1.
62625981|NCT03812445|NO_INTERVENTION|No Intervention|the patients in this arm will not receive probiotics.
62851800|NCT05575050|ACTIVE_COMPARATOR|Extended oral procedure|"Extended mouth cleaning protocol (with brushing) included:~1. Preparation of sterile catheter (12F lub 14F), suction of excess fluid from the oral cavity.~2. Teeth brushing (each teeth quadrant for 30) using Sage Untreated Suction Toothbrush (SUST) connected to suction unit, moistured with sterile water.~3. Using Sage Untreated Suction Toothbrush (SUST) moisturised with sterile water and cleaning with circular movements of each mucosal site for 10 seconds:~   1. Right cheek mucosa and right upper quadrant~  2. Left cheek mucosa and left upper quadrant~  3. Left lower buccal quadrant~  4. Right lower buccal quadrant~4. Moisturizing with Mouth Moisturizer of oral cavity mucosa, tongue and lips.~5. Repeated suction of excess fluid from the oral cavity."
62625982|NCT03812445|EXPERIMENTAL|Experimental|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus for 3 months.
62851801|NCT00851162|EXPERIMENTAL|Trinity|Trinity multipotent stem cells
62851802|NCT00851162|ACTIVE_COMPARATOR|Demineralized bone matrix|Demineralized bone matrix
62851803|NCT00680641|ACTIVE_COMPARATOR|A|Simvastatin 40mg
62625983|NCT02095197|OTHER|No Catheter delivery|"Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.~No Catheter Delivery will be used to deliver the medication."
62625984|NCT02095197|ACTIVE_COMPARATOR|Catheter targeted delivery|"Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.~Catheter targeted delivery will be used to deliver the medication."
62625985|NCT02852057|EXPERIMENTAL|Subjects Receiving Lenses|All subjects who meet inclusion criteria will receive lenses loaded with timolol maleate and dorzolamide hydrochloride.
62625986|NCT03049020||With levator ani avulsion|Patients indicated for sacrocolpopexy for pelvic organ prolapse and suffering with levator ani avulsion
62625987|NCT03049020||Without levator ani avulsion|Patients indicated for sacrocolpopexy for pelvic organ prolapse and without levator ani avulsion
62625988|NCT01358942||Cohort|
62851804|NCT00680641|PLACEBO_COMPARATOR|B|Placebo
62851805|NCT03679520|EXPERIMENTAL|New programme|A new programme of antenatal parental preparation provided by midwives to groups with 8-16 individuals. It will include 5 sessions á 2 hours and start in gestational week 25.
62851806|NCT03679520|ACTIVE_COMPARATOR|Regular programme|A regular programme of antenatal parental preparation provided by midwives to groups of 8-16 individuals and encompassing between 5 and 7 hours of antenatal parental preparation.
62851807|NCT04360382||Enhanced recovery|"Part I: Preoperative evaluation and preparation:~Part II: Postoperative daily intervention:~Part III: Expected daily outcome :~Phase three: Implementing enhanced recovery program:~The established pathway will implement on the study group by researcher from admission till discharge as conventional care group assessment in phase one.~Phase four: Evaluating enhanced recovery program outcomes:~The efficacy of enhanced recovery program will be determined by comparing outcomes for patients of both control and study groups"
62851808|NCT04360382||Regular care|usual care for all cases of cesarean section at our hospital.
62851809|NCT03900325|EXPERIMENTAL|Nimacimab|2.5 mg/kg
62851810|NCT03900325|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride
62625989|NCT05936814||Intraarticular|The control group with intraarticular varus deformity and Kellgren and Lawrence grade 4 gonarthrosis.
62625990|NCT05936814||Metaphyseal|The case group with Metaphyseal varus deformity and Kellgren and Lawrence grade 4 gonarthrosis.
62625991|NCT02849886|EXPERIMENTAL|LT icasp9 ΔCD19 (cohort1)|Injection T lymphocytes iCASP9 ΔCD19 (2.10e6, 5.10e6 and 10.10e6 Gene Modified Cells (GMC)/kg).
62851811|NCT01676636||Pregnant Women|Women who are 13 to 30 weeks pregnant. Each participant will take all 4 different calcium vehicles and decide which one they prefer.
62851812|NCT03480087||Chemotherapy alone|Patient treated with anthracycline containing chemotherapy
62851813|NCT03480087||Chemotherapy plus radiotherapy|Patient treated with anthracycline containing chemotherapy followed by mediastinal radiotherapy
62851814|NCT01505764|EXPERIMENTAL|Arm 1 (Anamorelin HCl)|Anamorelin HCl
62625992|NCT02849886|EXPERIMENTAL|LT iCASP9 ΔCD19 & GvHD (cohort2)|Injection T lymphocytes iCASP9 ΔCD19 (2.10e6, 5.10e6 and 10.10e6 GMC/kg). Patients who develop GVHD after administration of Gene Modified Cells (GMC) will be treated with dimerizer drug (AP1903)
62625993|NCT01189461|EXPERIMENTAL|pegaptanib sodium arm|all patients will receive pegaptanib sodium
62625994|NCT01078142|EXPERIMENTAL|Single arm|Bendamustin, Rituximab, Temsirolimus
62625995|NCT00778349|EXPERIMENTAL|1|Metformin solution 100 mg/mL under fasting condition
62625996|NCT00778349|EXPERIMENTAL|2|Metformin solution 100 mg/mL, after low fat meal
62625997|NCT00778349|EXPERIMENTAL|3|Metformin solution 100 mg/mL, after high fat meal
62625998|NCT06613230||Cancer|"Blood plasma samples from female patients with ovarian cancer of stage I-IV or borderline tumours, stored in biobanks in Sweden.~Also blood samples from female patients with other cancer types (endometrial, lymphoma, breast, malignant melanoma and sarcoma)"
62625999|NCT06613230||Healthy blood donors|Healthy blood donors samples from women aged 18-70 years
62626000|NCT00626652|EXPERIMENTAL|1|
62626001|NCT06369831|EXPERIMENTAL|68Ga-ABS011 PET/CT|All Hormone receptor positive/HER2 negative, triple-negative or HER2 positive metastatic Breast Cancer (mBC) patients will undergo a HER2 targeted PET/CT using 68Ga-ABS011 after completion of a 18F-FDG PET/CT and lesion biopsy (and IHC/ISH analysis).
62626002|NCT01561157||Acute Intermittent Porphyria (AIP)|Patients with a documented diagnosis of AIP
62626003|NCT01561157||Hereditary Coproporphyria (HCP)|Patients with a documented diagnosis of HCP
62626004|NCT01561157||Variegate Porphyria (VP)|Patients with a documented diagnosis of VP
62626005|NCT01561157||Congenital Erythropoietic Porphyria (CEP)|Patients with a documented diagnosis of CEP
62626006|NCT01561157||Hepatoerythropoietic Porphyria (HEP)|Patients with a documented diagnosis of HEP
62626007|NCT01561157||Porphyria Cutanea Tarda (PCT)|Patients with a documented diagnosis of PCT
62626008|NCT01561157||Erythropoietic Protoporphyria (EPP)|Patients with a documented diagnosis of EPP
62851815|NCT01505764|PLACEBO_COMPARATOR|Arm 2 (Placebo)|Placebo
62851816|NCT03316495|NO_INTERVENTION|without pamphlet|NOT EXPOSED TO PAMPHLETS
62851817|NCT03316495|EXPERIMENTAL|with pamphlet|EXPOSED TO PAMPHLETS
62626009|NCT01561157||X-Linked Protoporphyria (XLP)|Patients with a documented diagnosis of XLP
62626010|NCT01561157||Aminolevulinate-Dehydratase Deficiency Porphyria (ALAD, ADP)|Patients with a documented diagnosis of ALAD, ADP
62626011|NCT01561157||Homozygous Dominant Acute Hepatic Porphyria|Patients with a documented diagnosis of Homozygous Dominant AHP
62626012|NCT00717652|EXPERIMENTAL|1|arbutin, tretinoin, triamcinolone
62062661|NCT04183634|ACTIVE_COMPARATOR|Period 1: Neupro (Reference) - Period 2: Rotigotine TTS (Test)|For each period: an 18 mg transdermal patch to deliver 8 mg/24h will be applied for 24 h
62626013|NCT00717652|ACTIVE_COMPARATOR|2|Triluma
62626014|NCT06056453|EXPERIMENTAL|IPT|Participate in IPT 6-week intervention group.
62626015|NCT06056453|NO_INTERVENTION|UC|Continue with usual care.
62626016|NCT03317717|EXPERIMENTAL|botulinum toxin 2U|
62626017|NCT03317717|EXPERIMENTAL|botulinum toxin 5U|
62626018|NCT03317717|EXPERIMENTAL|botulinum toxin 10U|
62626019|NCT03317717|EXPERIMENTAL|botulinum toxin 20U|
62626020|NCT03317717|EXPERIMENTAL|botulinum toxin 30U|
62626021|NCT06350201|EXPERIMENTAL|8 weeks Problem-solving therapy|Problem-solving therapy-based holistic emotion management interventions matched to individual symptoms
62626022|NCT06350201|PLACEBO_COMPARATOR|treatment as usual|Routine psychological care and guidance on mood management
62626023|NCT02706769|ACTIVE_COMPARATOR|Paracetamol|Participants will take blinded Paracetamol (as they were taking before entering the study)
62626024|NCT02706769|PLACEBO_COMPARATOR|Placebo|Participants will take blinded Paracetamol
62626025|NCT03739424|EXPERIMENTAL|Whole egg powder arm|The whole egg powder arm will be part of our food product intervention. Food products created using whole egg powder will be provided and consumed 10x/week for 9 months. Each food item will contain the equivalent of one whole egg.
62626026|NCT03739424|ACTIVE_COMPARATOR|Whole milk powder arm|The whole milk powder arm will be part of our food product intervention. Food products created using whole milk powder will be provided and consumed 10x/week for 9 months. These items will have the equivalent amount of protein as the whole egg group. They will be isocaloric in nature.
62626027|NCT03739424|PLACEBO_COMPARATOR|Gelatin arm|The gelatin food products will be a part of our food product intervention. Food products created using gelatin will be provided and consumed 10x/week for 9 months. These items will be isocaloric in nature to the other treatment arms but will not contain additional protein.
62626028|NCT03540797||Intensive care unit (ICU) patients with sepsis|
62626029|NCT00398047|EXPERIMENTAL|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine andHematopoietic Growth Factors
62626030|NCT00519584|PLACEBO_COMPARATOR|Ropivacaine/saline|Ropivacaine 30ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block and 0.9% saline 2 ml (systemic placebo) for intravenous injection with sedation for the block
62626031|NCT00519584|ACTIVE_COMPARATOR|Ropivacaine/dex|Ropivacaine and local steroid: 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic and 0.9% saline 2ml (systemic placebo) for intravenous injection with sedation for the block;
62851818|NCT01243242|EXPERIMENTAL|METADOXINE|Eligible subjects will be randomly assigned to receive MG01CI (1,400 mg)
62851819|NCT01243242|PLACEBO_COMPARATOR|Placebo|Eligible subjects will be randomly assigned to receive Placebo (1,400 mg)
62851820|NCT01039129|EXPERIMENTAL|Endoscopic Cholecystectomy|20 patients in this arm will undergo cholecystectomy, or removal of the gallbladder, through this experimental approach. This arm will compose of patients with symptomatic gallstones (cholelithiasis).
62851821|NCT01039129|EXPERIMENTAL|Endoscopic Appendectomy|Participants will with chronic appendicitis will undergo appendectomy through this experimental approach.
62851822|NCT01039129|EXPERIMENTAL|Endoscopic Peritoneoscopy|20 patients in this arm will undergo diagnostic peritoneoscopy with or without biopsy for any indication.
62851823|NCT04884464||Hyaluronic acid-based gel|The composition of the gel, ranked by weight is: xylitol, glycerin, Rosa damascena petal extract, xanthan gum, polycarbophil, hyaluronic acid sodium salt (0.24%), pectin, potassium sorbate, sodium benzoate, panthenol, Aloe barbadensis leaf extract, stevia.
62062662|NCT02722343|EXPERIMENTAL|Tenofovir intravaginal ring|The tenofovir intravaginal ring (TFV IVR) is 55.0 mm in diameter, consisting of a single segment of polyurethane tubing with an outer diameter of 5.5 mm and filled with white TFV-containing paste. The IVR delivers 8-10mg/day of TFV.
62626032|NCT00519584|ACTIVE_COMPARATOR|bupivacaine/dex|bupivacaine and systemic steroid: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block plus dexamethasone 8 mg (2 ml) administered intravenously with sedation administered for the block.
62062663|NCT02722343|ACTIVE_COMPARATOR|Truvada oral tablets|"The tablets contain 200mg emtricitabine combined with 300mg tenofovir disoproxil fumarate (300mg). The tablets are commercially available as Truvada. The tablets are blue, capsule-shaped, film-coated, debossed with GILEAD on one side and with 701 on the other side"
62062664|NCT02837562||Interventional Cardiology/Cath Lab Staff|"This is considered to be the case or group under study. These are Interventional Cardiology/ Cardiac Cath lab staff that are exposed to radiation as a result of their role as Cardiac Cath lab staff.~Intervention: Slit lamp eye examination"
62626033|NCT00519584|PLACEBO_COMPARATOR|bupivacaine/Saline|bupivacaine 30ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block and 0.9% saline 2 ml (systemic placebo) for intravenous injection with sedation for the block
62062665|NCT02837562||Non-Interventional Cardiology/ Controls|"This is considered to be the control or comparison group. These are non-interventional cardiology/ non-cardiac cath lab staff that are not exposed to radiation as they do no operate/ work in the Cardiac Cath Lab.~Intervention: Slit lamp eye examination"
62062666|NCT03644901||Patients whose blood type is A|Applying nonsurgical periodontal treatment (scaling and root planning).
62062667|NCT03644901||Patients whose blood type is B|Applying nonsurgical periodontal treatment (scaling and root planning).
62062668|NCT03644901||Patients whose blood type is AB|Applying nonsurgical periodontal treatment (scaling and root planning).
62062669|NCT03644901||Patients whose blood type is O|Applying nonsurgical periodontal treatment (scaling and root planning).
62062670|NCT00560664|EXPERIMENTAL|1|Autologous chondrocytes transplantation
62267084|NCT05326984|EXPERIMENTAL|Interventional group|"This group will receive conventional chemotherapy plus metformin 1000mgm2 per day, with maximum dose of 850mg three times a day, from day -7 to the end of the remission induction period.~The Remission induction chemotherapy includes a steroid pre-phase of 7 days of prednisone 60mgm2SCD. The proper remission induction phase consist in prednisone 60mgm2 daily from day 0 to 28; Vincristine 1.5mgm2 on days 0, 7, 14 and 21; Doxorubicin 25mgm2 on days 0, 7, 21; L-asparaginase 10, 000 Um2 on days 2, 4, 6, 8, 10 and 12. Etoposide 300mgm2 and cytarabine 300mgm2 on days 22, 25 and 29. Intrathecal chemotherapy is administered on days 0, 7, 14 and 21."
62267085|NCT02752516|EXPERIMENTAL|Anlotinib|
62450462|NCT02619123|EXPERIMENTAL|invitation to tailored screening|44-45 years old women in this arm with a dense breast (3-4 categories in BI-RADS) at the baseline mammography are invited again after 1 year, while the lower-density group in the intervention arm are invited after 2 years. After the age of 50, all women will continue to be screened in the usual service screening programme.
62450463|NCT00721877|EXPERIMENTAL|Arm I|Participants receive oral resveratrol once daily for 4 weeks.
62450464|NCT02072564||Couples with indication for IVF|Couples with primary or secondary infertility with indication of IVF
62450465|NCT00298870|EXPERIMENTAL|PGx-treatment|NAT2 genotype-guided treatment with stratified isoniazid dose (approx. 7.5 mg/kg b.w., patients homozygous for NAT2\*4: rapid acetylators; 5 mg/kg, patients heterozygous for NAT2\*4: intermediate acetylators; 2.5 mg/kg, patientes without NAT2\*4: slow acetylators)
62851824|NCT04884464||Chlorhexidine gluconate|Chlorhexidine gluconate at a concentration of 0.2%.
62851825|NCT00675467||Group 1|Early cancer group-children ages 10-13 years
62450466|NCT00298870|ACTIVE_COMPARATOR|STD-treatment|Treatment with conventional standard isoniazid dose (approx. 5 mg/kg b.w.)
62450467|NCT02496026|EXPERIMENTAL|tDCS plus wrist robot therapy|In addition to standard rehabilitation treatment Group A will perform daily sessions of wrist robot-assisted treatment in combination with tDCS (30 minutes). During first 20 min of each session the patient receives a direct current stimulation through surface sponge electrodes (35 cm2), 2 milliampere intensity: the anodal electrode is placed on presumed lesional area, the cathodal electrode is placed on the controlateral orbital bone.
62450468|NCT02496026|SHAM_COMPARATOR|Sham tDCS plus wrist robot therapy|Group B is treated as Group A, but tDCS, even if the cap is applied on the patient head, is not activated and no current is delivered.
62450469|NCT01823003|EXPERIMENTAL|A. 34 Gy in a single fraction|34 Gy by single fraction Risk-adapted radiation dose.
62450470|NCT01823003|EXPERIMENTAL|B. 54Gy (18Gy/fr. x 3 fractions)|54Gy administered in 3 fraction of 18 Gy, risk adapted radiation dose
62626034|NCT02951026||0.03mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.03mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
62851826|NCT00675467||Group 2|Early cancer group-children ages 14 to 18 years
62851827|NCT00675467||Group 3|Early cancer group-parents of patients ages 10-18 years
62062671|NCT00560664|ACTIVE_COMPARATOR|2|Mosaicoplasty
62088001|NCT02633319|EXPERIMENTAL|Parenting Training|Skilful Parenting: 12-week group-based parent intervention delivered by Investing in Children and Our Societies to caregivers who are members of farmer groups in participating villages.
62851828|NCT00675467||Group 4|Advanced cancer group-children ages 10-13 years
62851829|NCT00675467||Group 5|Advanced cancer group-children ages 14-18 years
62851830|NCT00675467||Group 6|Advanced cancer group-parents of children ages 10-18 years
62851831|NCT00675467||Group 7|End of life group - parents of children ages birth to 18 years of age at time of death
62062672|NCT02244801|OTHER|Cohort 1|"3 subjects treated with a target dose of 300 million darTreg with the possibility of expanding to 5 patients if safety signals should require additional patients be observed at the 300 million dose.~The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients."
62626035|NCT02951026||0.07mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.07mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
62851832|NCT03597204|OTHER|fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for selected high risk individuals to undergo CRC screening. And colonoscopy for those with FIT positive result
62450471|NCT01823003|EXPERIMENTAL|C. 50Gy (12 x 5 fr.s)|54Gy administered in 5 fraction of 12 Gy, risk adapted radiation dose
62626036|NCT02951026||0.23mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.23mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
62626037|NCT02951026||Placebo (previously injected)|"Subjects in this group received a single intra-articular injection of placebo into the target knee during the parent study prior to enrolling in this observational study."
62626038|NCT02559570|PLACEBO_COMPARATOR|Placebo|Participants aged 6 to 11 or 12 to 17 years received matching placebo linaclotide (LIN), 30 minutes before evening meal, once daily for 4 weeks. Administered as liquid oral solution for participants 6 to 11 years of age and solid oral capsule or liquid oral solution for participants 12 to 17 years of age.
62626039|NCT02559570|EXPERIMENTAL|LIN Dose A (9 ug or 18 ug)|Participants aged 6 to 11 years with weight 18 to \<35 kg received LIN 9 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 18 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
62626040|NCT02559570|EXPERIMENTAL|LIN Dose B (18 ug or 36 ug)|Participants aged 6 to 11 years with weight 18 to \<35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 36 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
62626041|NCT02559570|EXPERIMENTAL|LIN Dose C (36 ug or 72 ug)|Participants aged 6 to 11 years with weight 18 to \<35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 72 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 72 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
62626042|NCT02559570|EXPERIMENTAL|LIN 145 µg|Participants aged 12 to 17 years received LIN 145 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
62626043|NCT03091738|EXPERIMENTAL|Ramelteon Pill|Patients given ramelteon and re-evaluated after 15 days of therapy
62626044|NCT04235166||Patient cohort|Different risk score was used to assess the prognosis of acute upper gastrointestinal bleeding in cirrhosis.
62626045|NCT06229041|EXPERIMENTAL|Total Neoadjuvant Treatment ＋Immunotherapy|
62626046|NCT06229041|NO_INTERVENTION|Total Neoadjuvant Treatment|
62626047|NCT06225661|EXPERIMENTAL|SAFE Intervention|This group will receive the SAFE individual youth and family-based intervention.
62626048|NCT06225661|ACTIVE_COMPARATOR|NAV (Telephone Navigation)|This group will receive telephone-based case navigation.
62626049|NCT01614444|ACTIVE_COMPARATOR|Acupressure Treatment|
62851833|NCT04220476|ACTIVE_COMPARATOR|ARM 1 - Letrozole and Palbociclib|Patients randomized to arm 1 will start standard Letrozole followed by Palbociclib at day 21.
62626050|NCT01614444|PLACEBO_COMPARATOR|Placebo Acupressure Treatment|
62851834|NCT04220476|ACTIVE_COMPARATOR|ARM 2 - Letrozole and Palbociclib + I-SBRT|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions.
62851835|NCT03904056|ACTIVE_COMPARATOR|ETDRS-PRP group|Patients with proliferative diabetic retinopathy submitted to panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab (IVR) (ETDRS-PRP group) if angluofluoresceinography demonstrated the presence of actively leaking retinal neovascularization or SD-OCT demonstrated a CSFT of more than 300 µm.
62851836|NCT03904056|EXPERIMENTAL|ISQ-RP group|Patients with proliferative diabetic retinopathy submitted to retinal photocoagulation targeted to ischemic retina combined with intravitreal injection of ranibizumab (IVR) if angluofluoresceinography demonstrated the presence of actively leaking retinal neovascularization or SD-OCT demonstrated a CSFT of more than 300 µm.
62851837|NCT01620320||Stress echography|Nine to twelve months after their left main angioplasty, patients will go through a stress echo and then the usual control angiography (done routinely in most patient in our center). Patients will act as their own control.
62851838|NCT05413434|EXPERIMENTAL|HIIT with a supervisor|These individuals will be given HIIT training on the treadmill, accompanied by a physiotherapist, 3 days a week for 8 weeks.
62851839|NCT05413434|EXPERIMENTAL|Hiit and respiratory muscle training with a supervisor|HIIT program and respiratory muscle training will be applied to these individuals 3 days a week for 8 weeks.
62851840|NCT05413434|NO_INTERVENTION|control group|The importance of physical activity will be explained and appropriate physical activity recommendations will be made.
62851841|NCT04681352|EXPERIMENTAL|Octave System|Single treatment of décolleté tissue.
62450472|NCT01823003|EXPERIMENTAL|D. 60Gy (7.5Gy x 8fr.)|60 Gy administered in 8 fraction of 7.5 Gy, risk adapted radiation dose
62450473|NCT04790851|EXPERIMENTAL|Experimental group|Experimental Group (384 subjects) will receive: 1st dose : combined vaccination of COVAX+IIV4; 2nd dose: combined vaccination of COVAX+PPV23
62450474|NCT04790851|ACTIVE_COMPARATOR|Control group A|Control Group A (384 subjects) will receive: 1st dose: COVAX only; 2nd dose: COVAX only
62652892|NCT01697579|EXPERIMENTAL|Fosaprepitant 5 mg/kg-Cycle 1|Participants were administered intravenous (IV) fosaprepitant at the following weight-adjusted doses: participants 4 months to \<12 years old were administered 5 mg/kg (not to exceed 150 mg); participants 1 to \<4 months old were administered 2.5 mg/kg; participants 0 to \<1 month old were administered 1.25 mg/kg. Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children \<6 months of age), with or without dexamethasone.
62062673|NCT02244801|OTHER|Cohort 2|"The second cohort will comprise a minimum of 3 and up to 5 subjects treated at a target dose of 900 million darTreg, depending on how many patients were required to be treated in lower dose group.~The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients."
62062674|NCT02574000||Single group baseline and follow-up|"Single group of adult stroke patients assessed using ShoulderQ shoulder pain questionnaire and Clinical shoulder examination at two time-points:~Baseline: within 72 hours post-stroke Follow-up: at 8-10 weeks post-stroke"
62062675|NCT06388811||Early Knee Osteoarthritis Patients|
62450475|NCT04790851|ACTIVE_COMPARATOR|Control group B|Control Group B (384 subjects) will receive: 1st dose: IIV4 only; 2nd dose: PPV23 only
62450476|NCT05474625|ACTIVE_COMPARATOR|Exercise Group|Only exercises
62450477|NCT05474625|ACTIVE_COMPARATOR|High Intensity Laser Therapy(HILT) Group|Exercises+HILT
62450478|NCT05474625|ACTIVE_COMPARATOR|Conventional Physiotherapy Group|Exercise+Hotpack+Transcutaneous nerve stimulation (TENS)+Ultrasound
62450479|NCT02574052|OTHER|Behavioral|"The whole experiment was divided into three phases with each phase lasting two weeks.~First Stage-Behavioral: just record participants' food choices Second Stage-Behavioral: menu labelling without nutrition education Third Stage- Behavioral; menu labelling with nutrition education"
62450480|NCT00099736|EXPERIMENTAL|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids,|
62450481|NCT00099736|EXPERIMENTAL|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids|
62450482|NCT00099736|EXPERIMENTAL|MMF 2 g + full-dose Neoral (FDN) + corticosteroids|
62450483|NCT04474938|EXPERIMENTAL|Dara-BD|Daratumumab combined with bortezomib and dexamethasone
62450484|NCT02318121|ACTIVE_COMPARATOR|Amniotomy first|Will be done with sterile gloves after insurance that is the baby's head fits in the pelvis ( 3\\5 or less of fetal head felt by first pelvic grip ) and by vaginal examination the head at station zero . The membranes are then punctured using an a hook during uterine contractions.
62450485|NCT02318121|ACTIVE_COMPARATOR|Oxytocin first|The starting dose will be the low dose rate equal or less than 4 m unit\\minute (4 drops\\minute doubled every 15 minutes up to 40 drops \\minute) as intravenous drip on dextrose ,Ringer's lactate or saline solution.
62450486|NCT02318121|ACTIVE_COMPARATOR|Amniotomy and oxytocin|Amniotomy will be done (as explained above) and oxytocin (the same regimen mentioned above) at the same time.
62450487|NCT01776281|EXPERIMENTAL|Kangaroo Mother Care|Other than routine clinical care per hospital policy. Infants will receive skin-to-skin contact for minimum one hour daily during hospital stay and at home till one month.
62450488|NCT01776281|ACTIVE_COMPARATOR|Standard Care|Routine incubator or cot care with breastfeeding support from nurses as per policy.
62450489|NCT04535908|EXPERIMENTAL|Hypofractionated radiotherapy|
62450490|NCT03629158|EXPERIMENTAL|CLIMB intervention|"The intervention group will receive the Cardiac Lifestyle Intervention for Maintaining healthy Behaviors (CLIMB) intervention. Participants will participate in a 3-session, one-on-one intervention that takes place over the course of two weeks."
62062676|NCT06388811||Population Without Knee Pain|
62062677|NCT02826122|ACTIVE_COMPARATOR|FitBit APP|FitBit Zip APP registers and give feed-back on number of steps per day, distance and calories burned.
62062678|NCT02826122|EXPERIMENTAL|Pai APP|Mio Pai APP registers duration and intensity of the Activity and give feed back as activity Points.
62450491|NCT03629158|NO_INTERVENTION|Treatment as usual (TAU)|The TAU group will continue to receive their regular medical care.
62450492|NCT06193278|ACTIVE_COMPARATOR|muti-site stimulation group1|The intervention period: 2 weeks muti-site: individual target (iTBS OR cTBS) / M1 (iTBS)
62450493|NCT06193278|ACTIVE_COMPARATOR|single-site stimulation group2|The intervention period: 2 weeks muti-site: individual target (sham) / M1 (iTBS)
62450494|NCT06193278|SHAM_COMPARATOR|sham stimulation group3|The intervention period: 2 weeks muti-site: individual target (sham) / M1 (sham)
62450495|NCT02204371|EXPERIMENTAL|Part A- Dose Escalation phase|Part A will be an open label, dose-escalation study in which 4 cohorts of approximately 6 subjects will receive increasing doses of pazopanib for a maximum of 12 weeks. The dose in the first cohort will be 50mg per day and the maximum dose in a cohort will be 400 mg per day. Dose escalation will not occur if the predefined safety stopping criteria are met or at least 4 subjects in a cohort have demonstrated efficacy. Cohort 4 receiving 400 mg dosing schedule may involve cycles of up to 3 weeks of active treatment, followed by up to 3 weeks wash-out (instead of 12 weeks continuous dosing). Decision will be based on safety data obtained from lower doses
62450496|NCT02204371|EXPERIMENTAL|Part B-Dose Optimization phase|If efficacy is demonstrated in Part A with an acceptable safety profile, Part B will be initiated to further define the optimal dose(s) including dose duration/schedule and to provide further support for the proof of mechanism. Approximately 15 subjects will participate and will be randomised to active or placebo in a ratio of 3:2. This part of the study will be double-blind
62450497|NCT05128409|ACTIVE_COMPARATOR|XKH001 Injection|XKH001 Injection,hypodermic injection，single dose，5 dose cohorts: 0.5 mg/kg, 1.67 mg/kg, 3.34 mg/kg, 5.0 mg/kg and 10.0 mg/kg.
62450498|NCT05128409|PLACEBO_COMPARATOR|XKH001 Placebo Injection|XKH001 Placebo Injection,hypodermic injection，single dose，4 dose cohorts: 1.67 mg/kg, 3.34 mg/kg, 5.0 mg/kg and 10.0 mg/kg.
62450499|NCT01891292|NO_INTERVENTION|Control|
62450500|NCT01891292|ACTIVE_COMPARATOR|Enalapril|
62450501|NCT01891292|ACTIVE_COMPARATOR|N-Acetylcysteine|
62450502|NCT01199757||FF|Cohort of patients receiving fluticasome furoate
62450503|NCT01199757||MF|cohort of patients on mometasone furoate
62450504|NCT01199757||FP|cohort of patients receiving fluticasone propionate
62450505|NCT00584766|EXPERIMENTAL|1|
62851842|NCT00995059|EXPERIMENTAL|Arm 1|CONDITIONING: Patients receive bortezomib IV and then undergo fractionated total-body irradiation on days -5 and -2. Patients receive thymoglobulin IV over 6 hours on days -5 to -2 and melphalan IV over 30 minutes on days -4 to -3. ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -3, patients receive oral sirolimus and taper beginning on day 61. Beginning on day -2, patients receive oral or IV tacrolimus and taper beginning on day 101.
62062679|NCT03570983|EXPERIMENTAL|BEAM Regimen- Experimental Arm|"Allopurinol Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.~BCNU (Carmustine) Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.~Etoposide (VP-16, Vepesid) Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.~Cytarabine (Ara-C) Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3."
62088002|NCT02633319|EXPERIMENTAL|Agricultural Training|Agrics: Initial 3-month agricultural training intervention with ongoing support afterwards.
62267086|NCT05069246|EXPERIMENTAL|Group 1 / Nigella Sativa oil / NS|"Group 1- Nigella Sativa (NS) N. sativa oil (Al-Hussan Food Products Factory, Riyadh, Kingdom of Saudi Arabia), which was brought from the local market in Riyadh.~Each participant was given a 3 weeks supply of oil, and a sterile plastic 15ml graduated measuring cap. They were asked to measure 5ml of oil into the cap and add 5ml of normal drinking water to this and rinse their mouth for 3mins with this solution and spit it out at the end. This was done morning and evening for 14 days.~Group 1: Maintained adequate plaque control levels using mechanical methods + N.sativa oil (5ml oil + 5ml water) pulling for 3 mins twice daily in the morning and at night (after brushing/breakfast in the morning, and after brushing and before sleeping at night).~Unified oral hygiene instructions and instructions for each intervention were provided to all participants."
62267087|NCT05069246|ACTIVE_COMPARATOR|Group 2 / Chlorohexidine / CHX|"Group 2- Chlorohexidine (CHX).~Chlorohexidine (Middle East Pharmaceutical Industries Ltd, Riyadh, Kingdom of Saudi Arabia).~Each participant was given a 3 week supply of chlorohexidine. They were asked to use 10ml of CHX morning and evening, rinsing their mouth for 3 mins and then spit it out at the end. This was done morning and evening for 14 days.~Group2: maintained adequate plaque control levels using mechanical methods + chlorohexidine rinse twice daily 10ml in the morning and at the night (after brushing/breakfast in the morning, and after brushing and before sleeping at night).~Unified oral hygiene instructions and instructions for each intervention were provided to all participants."
62267088|NCT05194540|EXPERIMENTAL|Tralokinumab subcutaneous dosing by an autoinjector|An initial SC dose of 600 mg tralokinumab at baseline followed by self-administration of a 300 mg dose of tralokinumab every other week for 14 weeks.
62267089|NCT03919526|EXPERIMENTAL|anti-CD19/CD22 CAR-T cells|Administration with anti-CD19/ CD22 CAR-T cells in the MRD-positive ALL patients.
62450506|NCT05346549|EXPERIMENTAL|High energy|"Child will be given a high energy drink: sugar free ribena squash (2kcal/100ml) plus a weighed amount of super soluble maxijul. Super Soluble Maxijul is a powdered carbohydrate energy source, which can be mixed with sweet or savoury foods/ liquids. It is safe for use in both children and adults that require fortification with a high or readily available carbohydrate. It is flavourless and tasteless offering little to no change in taste, flavor and texture of food being added to. It supplies 380 kcal energy per 100g powder. The amount given will supply 10% of the child's daily energy requirements per Kg - for example a 3-year old child weighing about 16 kg requires approximately 1300 kcal/day. Hence the high energy drink will supply the child with 130kcal.~They will be given 10 minutes to drink the preload and 30 minutes after this they will eat standardized weighed buffet lunch of known energy content suitable for their age, chosen in consultation with the parents."
62450507|NCT05346549|EXPERIMENTAL|Low energy|"Child will be given a low energy drink of the same volume selected to be as similar as possible to the high energy drink: sugar free ribena squash containing 2kcal per 100ml.~They will be given 10 minutes to drink the preload and 30 minutes after this they will eat lunch containing the same range of weighed buffet foods as above."
62450508|NCT01747850|EXPERIMENTAL|Sativex|Intervention consist on Sativex Spray (Δ9-tetrahydrocannabinol/cannabidiol). Study subjects will be randomized in blocks of ten to one of the two groups (Sativex vs. placebo) in a double blind manner. There will be a gradual increase of the maximal allowed dose starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays per day at the end of week 2. There will be a total of 12 weeks of drug exposure. All participants will receive a combination of pharmacotherapy (Sativex or Placebo) associated with a weekly intervention of combined Motivational Enhancement/Cognitive Behavioral Therapy.
62450509|NCT01747850|PLACEBO_COMPARATOR|Placebo spray|Participants will receive a combination of Placebo spray associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy
62450510|NCT01747850|EXPERIMENTAL|Pilot Study|The first five subjects will be treatment-seekers that fit our inclusion/exclusion criteria and that will be treated open-label. These subjects will be instructed to use the Sativex Spray according to the induction schedule provided above. These first subjects will allow us to determine if our schedule for dosing is appropriate for the subsequent phase of the study.
62450511|NCT03233620|OTHER|working age patients|Prospective cohort of 250 patients.
62267090|NCT05082103|ACTIVE_COMPARATOR|Enzyme lozenge 1|The lozenge contains three plaque extracellular matrix degrading enzymes
62267091|NCT05082103|ACTIVE_COMPARATOR|Enzyme lozenge 2|"The concentration of the three enzymes in the Enzyme lozenge 2 is threefold the enzyme concentration than in the Enzyme lozenge 1"
62267092|NCT05082103|PLACEBO_COMPARATOR|Placebo lozenge|The placebo lozenge contains the same ingredients except for the enzymes and has an identical taste, color and texture
62267093|NCT01251809|EXPERIMENTAL|PEG-rASNase 500|500 U/m2 BSA at day 0
62267094|NCT01251809|EXPERIMENTAL|PEG-rASNase 1000|1000 U/m2 BSA at day 0
62267095|NCT01251809|EXPERIMENTAL|PEG-rASNase 1500|1500 U/m2 at day 0
62267096|NCT01251809|ACTIVE_COMPARATOR|Oncaspar|2000 U/m2 at day 0
62267097|NCT00004259|EXPERIMENTAL|Radiation therapy + temozolomide (TMZ)|Radiation therapy (RT) for 6 weeks concurrent with and followed by TMZ 200mg/m2 for twelve 28-day cycles
62062680|NCT03570983|ACTIVE_COMPARATOR|Melphalan Regimen- Control Arm|"Melphalan Dosage: Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.~Allopurinol Dosage: Allopurinol 200 mg/m2/day starts on the day prior to melphalan (day -3) and stops on day -1."
62062681|NCT01338012|EXPERIMENTAL|sipuleucel-T|Men with metastatic castrate resistant prostate cancer previously treated with sipuleucel-T in the androgen dependent setting in the Dendreon P-11 study. Subjects received one infusion of sipuleucel-T every two weeks for for a total of three infusions.
62062682|NCT03244462|EXPERIMENTAL|Oral BAY1834845|"Study Part A, cross over sequence:~1. single oral dose of BAY1834845~2. single oral dose of BAY1834845 + i.v. BAY1834845~3. single oral dose of BAY1834845 under fed conditions"
62267098|NCT00004259|ACTIVE_COMPARATOR|RT + BCNU/CCNU|Radiation therapy for 6 weeks concurrent with and followed by BCNU 80mg/m2 or CCNU 130 mg/m2 for six 8-week cycles
62851843|NCT03917407|ACTIVE_COMPARATOR|Arm1: DUR-928 treatment for moderate alcoholic hepatitis|Enrolled alcoholic hepatitis patients would have MELD of 11-20; and have met inclusion and exclusion criteria. DUR-928 as a novel study treatment would be administered in patients with moderate alcoholic hepatitis (AH) as determined by the absence of suspected unexpected serious adverse reaction (SUSAR).
62851844|NCT03917407|ACTIVE_COMPARATOR|Arm 2: DUR-928 treatment for severe alcoholic hepatitis.|Enrolled alcoholic hepatitis patients would have MELD of 21-30; and have met inclusion and exclusion criteria. DUR-928 as a novel study treatment would be administered in patients with severe alcoholic hepatitis (AH) as determined by the absence of suspected unexpected serious adverse reaction (SUSAR).
62851845|NCT03811236|EXPERIMENTAL|Cold exposure|
62851846|NCT03811236|NO_INTERVENTION|Room temperature|
62851847|NCT01105065|EXPERIMENTAL|Patients with RVD|Patients who exhibited retinal vascular dysregulation at the initial visit. Intervention: brimonidine 0.15% three times per day for 8 weeks.
62851848|NCT05919836|ACTIVE_COMPARATOR|Percutaneous assisted laparoscopic hernia|
62851849|NCT05919836|ACTIVE_COMPARATOR|Laparoscopic Purse string closure of hernial sac|
62851850|NCT05919836|ACTIVE_COMPARATOR|Laparoscopic Total dissection of hernial sac|
62851851|NCT02193464||inflammatory bowel disease|
62851852|NCT06160934|EXPERIMENTAL|Intervention Group|The T1D Parent Check-in Group (Intervention Group) will participate in three sessions that will be delivered by a licensed clinical psychologist. In the larger RCT, the intervention will be manualized with training and a treatment protocol that can be delivered by any trained member of the diabetes psychosocial team (e.g., social workers, licensed mental health clinicians, and/or clinical psychologists). The intervention is designed to be both tailored and flexible but with fidelity to a basic structure. Diabetes-specific handouts and videos will be created as part of the intervention and will be provided to families throughout the course of the study.
62851853|NCT06160934|NO_INTERVENTION|Treatment as Usual (TAU) Group|Parents assigned to the Treatment As Usual (TAU) group will complete T1-T4 study questionnaires alongside the intervention group. They will also take the Motivation Quiz as part of their T2 questionnaires. Instead of a one-month phone call, these participants will be scheduled for a one-time consultation with a study psychologist after completing their T4 questionnaires. This consultation will entail reviewing the family's specific questionnaire results, discussing challenges/strategies relevant to the family's needs, and providing additional recommendations/referrals as indicated. Families will also be provided access to study resources that will assist with their family's overall adjustment to T1D.
62267099|NCT00004259|EXPERIMENTAL|Pilot Arm #1: RT+TMZ+BCNU|Radiation therapy for 6 weeks concurrent with and followed by BCNU 200mg/m2 and TMZ 150mg/m2 six 6-week cycles
62267100|NCT00004259|EXPERIMENTAL|Pilot Arm #2: RT+TMZ+BCNU|Radiation therapy for 6 weeks concurrent with and followed by BCNU 150mg/m2 and TMZ 150mg/m2 six 8-week cycles
62062683|NCT03244462|EXPERIMENTAL|Oral BAY1834845 + i.v. BAY1834845|"Study Part A, cross over sequence:~1. single oral dose of BAY1834845+ i.v. BAY1834845~2. single oral dose of BAY1834845~3. single oral dose of BAY1834845 under fed conditions"
62626051|NCT02726594||Patients|For the present study, patients who are assigned to the clinically indicated MRI scan, as well as healthy subjects will be included. Healthy volunteers will be recruited through public notices (flyer) (mainly in the district of the University Zurich / USZ). For all patients, the duration of clinical MRI routine examination is 30-90 minutes, depending on the requirements to answer the clinical question. The subjects are interviewed after the MRI scan by a visual analog scale oral and written on various aspects of their perception during the examination. This means an additional expenditure of time of about 10 minutes. The patients arises except for this additional time not a disadvantage by taking part in the study.
62626052|NCT02726594||Subjects|For the present study, patients who are assigned to the clinically indicated MRI scan, as well as healthy subjects will be included. Healthy volunteers will be recruited through public notices (flyer) (mainly in the district ETH / USZ). For all patients, the duration of clinical MRI routine examination is 30-90 minutes, depending on the requirements to answer the clinical question. The subjects are interviewed after the MRI scan by a visual analog scale oral and written on various aspects of their perception during the examination. This means an additional expenditure of time of about 10 minutes. The patients arises except for this additional time not a disadvantage by taking part in the study.
62626053|NCT03971916|EXPERIMENTAL|HBM9161 340mg|
62626054|NCT03971916|EXPERIMENTAL|HBM9161 510mg|
62626055|NCT03971916|EXPERIMENTAL|HBM9161 680mg|
62626056|NCT03971916|PLACEBO_COMPARATOR|Placebo|
62626057|NCT06105814|NO_INTERVENTION|Standard diagnostics|Standard microbiological diagnostics, with nasopharyngeal swab and induced sputum or endotracheal aspirate for real-time polymerase chain reaction (PCR) and culture, blood cultures and urinary antigen tests
62851854|NCT06049901|NO_INTERVENTION|Control Group|This group will include 30 patients who will be scheduled to receive 6 cycles of 5-Fluorouracil and Oxaliplatin- based regimens every 2 weeks for 3 months.
62851855|NCT06049901|ACTIVE_COMPARATOR|Nitazoxanide Group|This group will include 30 patients who will be scheduled to receive 6 cycles of 5-Fluorouracil and Oxaliplatin- based regimens every 2 weeks plus nitazoxanide (500 mg orally twice daily) for 3 months.
62626058|NCT06105814|EXPERIMENTAL|Rapid diagnostics|In addition to standard diagnostics, induced sputum or endotracheal aspirate analyzed with multiplex PCR (FilmArray).
62626059|NCT05265832|EXPERIMENTAL|Cataract surgery|Phacoemulsification cataract surgery
62626060|NCT00608218||Artist|
62626061|NCT01681953|ACTIVE_COMPARATOR|Lamazym|1 mg Lamazym/kg body weight
62626062|NCT01681953|PLACEBO_COMPARATOR|Placebo|Placebo is formulated as an isotonic phosphate buffer with glycine and mannitol
62626063|NCT04060797|OTHER|The control group|Treating with balloon dilation or stent implantation only,
62626064|NCT04060797|EXPERIMENTAL|The EDN group|Treating with (Endovascular Denervation) EDN at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation.
62626065|NCT01357005||Schizophrenia Family|
62851856|NCT00637702|EXPERIMENTAL|ARRY-334543|
62626066|NCT04319926|EXPERIMENTAL|Lidocaine Patch (Sequence T1T2)|Subjects receive both lidocaine topical system 1.8% and the generic lidocaine patch 5%. The sequence in which they receive the lidocaine products is determined by random assignment. For subjects in Arm 1, lidocaine 1.8% topical systems are applied in Period 1, and the generic lidocaine 5% patches are applied in Period 2.
62851857|NCT02103296|ACTIVE_COMPARATOR|Infant Blood|Control group. Admission labs to be drawn directly from the infant.
62851858|NCT02103296|EXPERIMENTAL|Cord Blood|Admission labs to be drawn from the infant's cord blood
62851859|NCT03675009|OTHER|Early Intervention|Educational curriculum will be delivered earlier in the timeframe after IAQ monitoring has initiated.
62062684|NCT03244462|EXPERIMENTAL|Oral Methotrexate|"Study part B, cross over sequence:~1. single oral dose of methotrexate (MTX)~2. single oral dose of MTX + single oral dose of BAY1834845"
62267101|NCT05070221|EXPERIMENTAL|Arm A|Patients histologically confirmed mucosal melanoma will get OH2 （once every two weeks）and HX-008 (once every three weeks)and Axitinib (once every day).
62062685|NCT03244462|EXPERIMENTAL|Oral Methotrexate + oral BAY1834845|"Study part B, cross over sequence:~1. single oral dose of methotrexate (MTX) + single oral dose of BAY1834845~2. single oral dose of MTX"
62062686|NCT04933201|EXPERIMENTAL|Music group|Perioperative music intervention
62851860|NCT03675009|OTHER|Late Intervention|Educational curriculum will be delivered later in the timeframe after IAQ monitoring has initiated.
62851861|NCT01043939|ACTIVE_COMPARATOR|Purple Grape Juice First|After 4 week run-in period, drink 6 ounces of purple grape juice twice daily, then 4 week washout, week 12 drink 6 ounces of clear apple juice for 4 weeks twice daily
62851862|NCT01043939|ACTIVE_COMPARATOR|Apple Juice First|After 4 week run-in period, drink 6 ounces of clear apple juice twice daily, then 4 week washout, week 12 drink 6 ounces of purple grape juice for 4 weeks twice daily
62062687|NCT04933201|ACTIVE_COMPARATOR|Control group|No perioperative music
62062688|NCT05643820|ACTIVE_COMPARATOR|Group A|Patients prescribed with topical 5% Permethrin lotion two applications seven days apart and applied overnight.
62062689|NCT05643820|ACTIVE_COMPARATOR|group B|Patients weighing greater than 15kgs prescribed with oral ivermectin 200microgram/kg two doses seven days apart
62267102|NCT05070221|EXPERIMENTAL|Arm B|Patients histologically confirmed non-mucosal melanoma will get OH2 （once every two weeks）and HX-008 (once every three weeks)and Axitinib (once every day).
62267103|NCT01258504||CYP2C9 wild type|"CYP2C9 wild type =extensive metaboliser~* Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19~* Administration of St. Johns Wort: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
62267104|NCT01258504||CYP2C9 mutant|"CYP2C9 \*2/\*2 or 2\*/\*3 or \*3/\*3 = poor metaboliser~* Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19~* Administration of St. Johns Wort: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
62450512|NCT02275364|EXPERIMENTAL|Test nasal strip|Marketed Nasal Strip to be applied for up to two hours, and during the third scanning session for approximately 20 minutes.
62450513|NCT02275364|PLACEBO_COMPARATOR|Placebo nasal strip|Placebo nasal strip to be applied for up to two hours in either of the first two scans only.
62851863|NCT00614770|EXPERIMENTAL|1|Standard White Light Colonoscopy
62851864|NCT00614770|EXPERIMENTAL|2|High Definition White Light Colonoscopy
62851865|NCT00614770|EXPERIMENTAL|3|Narrow Band Imaging Colonoscopy
62851866|NCT00572442||1|"Subjects without any cardiovascular risk factors:~1. Age ≥ 45 in men; Age ≥ 55 in women.~2. Hypertension: BP \> 140/90 mmHg or on BP meds.~3. Diabetes Mellitus: Known fasting blood sugar \>126 mg/dl or on DM meds.~4. Dyslipidemia: On lipid lowering medication or LDL ≥ 160 mg/dl in absence of other risk factors; ≥ 130 mg/dl if other non-diabetic risk factors; ≥ 100 mg/dl if diabetic. Known HDL \< 40 mg/dl.~5. Cigarette smoking (past or present).~6. Family history of premature CAD in first degree relatives: Age \< 55 in men; Age \< 65 in women."
62851867|NCT00572442||2|Subjects with 1 cardiovascular risk factor (listed above)
62062690|NCT04845724|ACTIVE_COMPARATOR|Standard Diet|The standard diet was based on the current dialysis diet sheet. The standard diet main meal contained a higher proportion of foods with a higher phosphorus to protein ratio (salmon and dairy), and foods with higher phosphorus bioavailability (cake). The diet was tailored for each participant to provide 1.1g protein/kg ideal body weight. The major differences between the diets were at the main meal.
62062691|NCT04845724|EXPERIMENTAL|Modified Diet|The modified diet, representative of the proposed modified phosphorus diet used food of lower phosphorus to protein ratio such as beef and less dairy. Approximately 30% dietary phosphorus in the modified diet came from foods with significant phytate content such as pulses, nuts and whole grains. The modified diet was tailored for each participant to provide 1.1g protein/kg ideal body weight.
62062692|NCT06516627|EXPERIMENTAL|Positive Labels|"Products that meet Guiding Stars' criteria for earning 1 or more Guiding Star will display labels indicating their healthfulness using star ratings: 1 star (Good), 2 stars (Better), or 3 stars (Best). The Guiding Stars rating system uses a patented algorithm to rate foods based on their nutrients and ingredients per 100-calorie serving of the food. Products that do not meet Guiding Stars' criteria for earning stars will not display any new front-of-package label."
62088003|NCT02633319|EXPERIMENTAL|Parenting and Agricultural Training|Village farmer groups receiving both Skilful Parenting and Agrics interventions.
62088004|NCT02633319|NO_INTERVENTION|Control|6-month wait-list control group
62088005|NCT01779921||FVII|
62267105|NCT02918383|OTHER|Indocyanin Green Dye (ICG)|Once the patient is in the operating room, the operative intervention will take proceed as current standard protocol dictates for the described procedure. No changes in operative technique will be undertaken apart from injection of the dye and visualization with the camera. After the articular surface of the distal femur or proximal tibia has been exposed, 2.5 mg of indocyanin green will be injected intravenously by anesthetist through a pre-existing IV line outside the sterile field. The operating surgeon will grade 6 locations on a standard scale of chondromalacia or cartilage damage.
62626067|NCT04319926|EXPERIMENTAL|Lidocaine Patch (Sequence T2T1)|Subjects receive both lidocaine topical system 1.8% and the generic lidocaine patch 5%. The sequence in which they receive the lidocaine products is determined by random assignment. For subjects in Arm 2, generic lidocaine 5% patches are applied in Period 1, and the lidocaine 1.8% topical systems are applied in Period 2.
62626068|NCT04557436|OTHER|Standard of care|"Follow-up period:~For patients achieving molecular remission by day 28, allo-HSCT will be scheduled as soon as practicable. Routine transplant care for 24 months will incorporate the disease monitoring and recording of adverse events of special interest and document elimination of PBLTT52CAR19 through the transplant conditioning period.~For patients with refractory disease at Day 56, the monitoring of adverse events of special interest, the disease outcome will be monitored monthly up to 24 months or until a palliative therapy approach is adopted.~Assessments will be carried out after the treatment period at the following time points: 1m, 2m, 3m, 6m, and 12m, 24m~* Physical examination, ECOG~* Laboratory tests~* Vital signs (temperature, BP, HR, respiratory rate, weight)~* Persistence of PBLTT52CAR19, VCN by qPCR in blood and bone marrow (if sampled)~* Chimerism and MRD in blood and bone marrow (if sampled)~* Adverse events~* Concomitant treatments"
62626069|NCT04034511|EXPERIMENTAL|Medically-tailored meal delivery and medical nutrition therapy|Participants assigned to this arm will receive home-delivered, medically-tailored meals for 3 months combined with monthly individual Medical Nutrition Therapy sessions for 6 months. Participants will also receive participants' usual case management services from participants' Medicaid insurance program.
62626070|NCT04034511|NO_INTERVENTION|Usual care|Participants assigned to this arm of the study will receive usual care and case management services from participants' Medicaid insurance program.
62626071|NCT03141515|ACTIVE_COMPARATOR|Control group|After anesthesia induction patients received lung recruitment maneuver using pressure-control ventilation with a patient in supine position with 10 cmH2O level of positive end-expiratory pressure PEEP during 180 seconds. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
62626072|NCT03141515|EXPERIMENTAL|Recruitment maneuver group|Patients received lung recruitment maneuver with postural changes of lateral decubitus using pressure-control ventilation, 10 cmH2O level of PEEP in left and in right lateral decubitus during 90 seconds in each one. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
62626073|NCT04959864|EXPERIMENTAL|Isitol® (Food supplement treated group)|"36 eligible males between 20 and 45 yo. (included limits) will take 1 sachet of Isitol® per day during 16 (± 2) weeks. The sachet of powder is to dissolve in a glass of water or directly in mouth.~1 sachet of Isitol® (2,1g) contains 1000 mg of myo-inositol, 300 mg of N-acetyl-cysteine, 150 % of the Nutritional Reference Values (NRV) in zinc and 100 % of the NRV: in vitamins B2, B3, B6, B9 and E."
62626074|NCT04959864|PLACEBO_COMPARATOR|Placebo treated group|"36 eligible males between 20 and 45 yo. (included limits) will take 1 sachet of placebo per day during 16 (± 2) weeks. The sachet of powder is to dissolve in a glass of water or directly in mouth.~1 sachet of placebo (2,1g) contains only excipients used in Isitol® and excipients to get similar organoleptic aspect (maltodextrin, sucralose, silicon dioxide, magnesium carbonate, citric acid and beta-carotene)."
62851868|NCT00572442||3|Subjects with 2 cardiovascular risk factors (listed above)
62851869|NCT00572442||4|Subjects with more than 2 cardiovascular risk factors (listed above)
62851870|NCT00864695||Surgical patients|Individuals who were hospitalized in the Botucatu Medical School Hospital to undergo surgery under anesthesia administered by the Anesthesiology Service of BMS Department of Anesthesiology.
62851871|NCT01149148|ACTIVE_COMPARATOR|Intervention INVOS Cerebral Oximetry Monitoring|Intervention will be initiated if rSO2 drops \> 20% from baseline or rSO2 declines below 50%.
62851872|NCT01149148|ACTIVE_COMPARATOR|Standard of Care|Blinded cerebral oximetry monitoring with no intervention in surgical procedures and anesthesia without deviation from standard of care.
62851873|NCT02264145|EXPERIMENTAL|Ethanolic Solution From HFA134a-MDI - low|
62851874|NCT02264145|EXPERIMENTAL|Ethanolic Solution From HFA134a-MDI - medium|
62851875|NCT02264145|EXPERIMENTAL|Ethanolic Solution From HFA134a-MDI - high|
62851876|NCT02264145|EXPERIMENTAL|Ethanolic Solution From Respimat®|
62851877|NCT01075594||1|Patients with dyslipidemia on lipid lowering therapy
62851878|NCT02009540|PLACEBO_COMPARATOR|Botulinum toxin injected to bladder body|arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor.
62851879|NCT02009540|ACTIVE_COMPARATOR|Botulinum toxin injected into trigone|Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml).
62626075|NCT02164071||Multiple Myeloma (MM)|Patients with Myltiple Myeloma, symptomatic or asymptomatic
62626076|NCT02164071||Myelodysplastic Syndromes or Acute Myeloid Leukemia|Patients with Myelodysplastic Syndromes (MDS), any International Prognostic Scoring System (IPSS) risk, or Acute Myeloid Leukemia (AML)
62626077|NCT02164071||Chronic Lymphocytic Leukemia (CLL)|Patients with Chronic Lymphocytic Leukemia
62626078|NCT06352866|EXPERIMENTAL|Siltuximab|Participants will receive a single dose of prophylactic siltuximab, 11 mg/kg, 2 hours prior to the administration of the first dose of teclistamab on day 1. There is no planned dose escalation of siltuximab, and teclistamab dosing will be done following the standard planned ramp-up mentioned below. Participants will be hospitalized for 9 days according to teclistamab package insert and Cleveland Clinic institutional practice. Participants will be followed for the incidence of CRS and ICANS for the first two 22-day cycles of treatment.
62626079|NCT05320419|ACTIVE_COMPARATOR|Amniotic membrane preparation and injection (AM group)|The dehydrated AM product used in this study is derived from donated human placental tissue following healthy, live, caesarian section, full-term births which are then cleaned of blood under aseptic conditions. The product comes as a 20mg dry powder in a small vial stored at room temperature and mixed with 2 mL 0.9% sterile normal saline. Then the suspended AM will be injected to the injured tendon and the surrounding area with ultrasound-guidance via a 7cm, 23-gauge needle.
62626080|NCT05320419|ACTIVE_COMPARATOR|Physiotherapy (PT group )|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretching, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, and scapular stabilization exercise, 3 times a week, and will be continued for 12 weeks.
62626081|NCT06132984||Patients with gynecologic malignancies who are preparing for ICIs treatment|
62626082|NCT01602705|PLACEBO_COMPARATOR|Usual care|
62626083|NCT01602705|ACTIVE_COMPARATOR|Usual care + feedback of practice performance|
62626084|NCT01602705|ACTIVE_COMPARATOR|Usual care + feedback + health psychology intervention|
62626085|NCT03009227|ACTIVE_COMPARATOR|D2 lymph node dissection|Colonic resection with D2 lymph node dissection
62626086|NCT03009227|EXPERIMENTAL|D3 lymph node dissection|Colonic resection with D3 lymph node dissection
62851880|NCT04617496|EXPERIMENTAL|Combined speech and exercise intervention|Home-based exercise intervention with interactive automated speech response features that encourage a higher level of speech performance.
62267106|NCT04252430|ACTIVE_COMPARATOR|Patients with renal impaired function|6 patients with mild renal impaired function, 6 patients with moderate renal impaired function and 6 patients with severe ranal impaired function
62626087|NCT06185439|EXPERIMENTAL|Experimental: Study group|In this study, the study group was provided with prenatal pilates-assisted childbirth preparation training and follow-up, in addition to the usual care provided by health professionals.
62626088|NCT06185439|NO_INTERVENTION|Control group|The control group was in the usual care.
62626089|NCT05940961|EXPERIMENTAL|Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL|intravenous infusion: Cycle 1: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2, if the MRD turn negative, cycle 2: D1 0.5mg/m2, D8 0.5mg/m2, D15 0.5mg/m2， if not，cycle 2: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2
62626090|NCT03578445|EXPERIMENTAL|Patients with a pancreatic cystic lesion|
62626091|NCT01850394|PLACEBO_COMPARATOR|Control group|physiologic saline 25 ml
62626092|NCT01850394|ACTIVE_COMPARATOR|TXA-250 group|A total of 25-ml solution with 250-mg tranexamic acid
62626093|NCT01850394|ACTIVE_COMPARATOR|TXA-500 group|A total of 25-ml solution with 500-mg tranexamic acid
62626094|NCT05003284|EXPERIMENTAL|acupressure wristband|On the day before the surgery, the patients in the experimental groups were introduced to the wristband and given an explanation regarding how it should be used. Approximately 30 minutes before the experimental group patients went to surgery, the PC6 acupressure point was determined for the patients. Immediately after the experimental group patients were taken to the wards after surgery, wristbands were placed on both wrists. İt was stated to the patients that the wristbands should remain on for 24 hours. The wristband was removed at the end of the 24th hour.
62626095|NCT05003284|PLACEBO_COMPARATOR|placebo wristband|On the day before the surgery, the patients in the placebo groups were introduced to the wristband and given an explanation regarding how it should be used. Approximately 30 minutes before the placebo group patients went to surgery, the PC6 acupressure point was determined for the patients. Right after their surgery, patients in the placebo group were fitted with a wristband that looked the same as the acupressure wristband but did not have an acupressure application head. İt was stated to the patients that the wristbands should remain on for 24 hours. The wristband was removed at the end of the 24th hour.
62626096|NCT05519956|ACTIVE_COMPARATOR|level Ib-covering IMRT|Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II.
62851881|NCT04617496|ACTIVE_COMPARATOR|Control group|Health education
62851882|NCT05666050|EXPERIMENTAL|Intervention group|The intervention group will receive mobile health intervention sending message service(SMS)
62851883|NCT05666050|NO_INTERVENTION|Control group|The control group will receive the existed current health delivery approach, no mobile health sending message service
62851884|NCT01121809|OTHER|Raltegravir|Raltegravir 400 mg bid
62851885|NCT01121809|OTHER|Etravirine|Etravirine 200 mg bid
62851886|NCT05692336|EXPERIMENTAL|vestibular training|balance training that focus on vestibular system stimulation like when the eyes are folded while standing on a balance board or walking on swinging boards
62088006|NCT03230929|EXPERIMENTAL|BIS-PLE|Anesthesiologist attaches the sensors of BIS and PLEM 100 on the forehead of the patient, and monitor the monitor and record the values of BIS, PLEM 100, and neuromuscular monitoring.
62088007|NCT04612114||Possible OSA|Patients with OSA symptoms (snoring, excessive daytime sleepiness or witnessed apnea, etc.)
62088008|NCT01023308|EXPERIMENTAL|Panobinostat + Bortezomib + Dexamethasone|
62088009|NCT01023308|PLACEBO_COMPARATOR|Placebo + Bortezomib + Dexamethasone|
62267107|NCT04252430|ACTIVE_COMPARATOR|Healthy subjects|Healthy volunteers will be matched with impaired renal function patients
62626097|NCT05519956|EXPERIMENTAL|level Ib-sparing IMRT|Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II
62851887|NCT05692336|EXPERIMENTAL|dual task training|The children received special balance training in the form of dual-task training performing balance activities as a basic task in conjunction with second task that includes upper limb activity using basketball and long rings shaft or cognitive task like telling a story during balance training .
62450514|NCT02359890|EXPERIMENTAL|Treatment Group|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH® SF family of contact force sensing catheters (study device)
62450515|NCT03222141|EXPERIMENTAL|SAPIEN 3™ valve|
62626098|NCT02171117|NO_INTERVENTION|CT-group|standard induction and consolidation chemotherapy only, without microtransplantation
62626099|NCT02171117|EXPERIMENTAL|MST-group|standard induction and consolidation chemotherapy with microtransplantation
62626100|NCT04786405|EXPERIMENTAL|Mindfulness Meditation|Participants in this arm will complete five, 20-minute mindfulness meditation sessions delivered over consecutive days.
62626101|NCT04786405|ACTIVE_COMPARATOR|Clinical Hypnosis|Participants in this arm will complete five, 20-minute clinical hypnosis sessions delivered over consecutive days.
62851888|NCT04030156||ultrasonographic tonsil volume|All measurements were done by the same radiologist with over 20 years of experience. GE LOGIQ E9 (GE Healthcare, Milwaukee, WI, USA) was used in USG examination. The patients were viewed using a 2-9 MHz linear probe from the submental region. The examination was done while the patient was in a supine position, with a neck support. Right tonsil measurement was done by turning the neck slightly to the upper left whereas left tonsil measurement was done by turning the neck slightly to the upper right. Tonsil volume was calculated with standard ultrasonography formula (height x length x thickness x 0.52) due to its ellipsoid shape.
62626102|NCT05678712|NO_INTERVENTION|Standard treatment|"After a two weeks run-in baseline period (blinded CGM) some of the participants (1:1) were randomly assigned to six weeks of standard treatment, i.e. self monitoring of blood glucose (the last two weeks with blinded CGM → 2 weeks wash-out (baseline for next period) (blinded CGM) → six weeks with non-blinded CGM with data available for the patient himself/herself and dialysis staff"
62626103|NCT05678712|EXPERIMENTAL|Intervention (access to CGM data)|"After a two weeks run-in baseline period (blinded CGM) some of the participants (1:1) were randomly assigned to six weeks with non-blinded CGM with data available for the patient himself/herself and dialysis staff → 2 weeks wash-out (baseline for next period) (blinded CGM) → Six weeks of standard treatment, i.e. self monitoring of blood glucose (the last two weeks with blinded CGM"
62626104|NCT05627947|ACTIVE_COMPARATOR|mitomycine-C Group|This is the First Group and consists of !9 Patients and received 0.02% topical mitomycine C , 4 times per day for five days after the surgery.
62626105|NCT05627947|ACTIVE_COMPARATOR|Cyclosporine Group|This is the Second Group and consists of !9 Patients and received topical 0.05% Cyclosporine, 4 times per day for three months after the surgery.
62851889|NCT04030156||Actual tonsil volume|Excised tonsil volumes were calculated by water replacement method.
62851890|NCT03719833||1-control group-T1-T2 N0 M0|"Breast cancer patients in T1 N0 M0 stage at the time of diagnosis who initially undergo surgical treatment (quadrantectomy/mastectomy + sentinel lymph node biopsy).~All patients will be followed for 5 years after surgery"
62450516|NCT02503579|EXPERIMENTAL|physical training|Participant receive a submaximal (60% -75% maximal oxygen uptake) physical activity training of 30 minutes during 8 weeks, 2 times a week. Individual heart rates will be monitored during the training.
62450517|NCT02503579|NO_INTERVENTION|control|"1 training at the beginning of the study~1 training at the end of the study"
62450518|NCT04516148|EXPERIMENTAL|Antibiotics|Patients randomized to the treatment arm of the study will have orders placed by a physician on the clinical team, with preparation and delivery of the antibiotics dose by the pharmacy following standard procedures. Antibiotic administration will occur after induction of anesthesia, with delivery by the Anesthesia staff no more than one hour prior to incision. Those with known allergy to beta-lactams will receive clindamycin instead of cefazolin.
62450519|NCT04516148|NO_INTERVENTION|Standard of Care|Patients randomized to the standard of care arm of the study will receive no perioperative antibiotic administration and will proceed with routine pre-operative care.
62088010|NCT02965144||HGG patients|single-group study- long term survivors
62088011|NCT03142217|OTHER|Patient with Huntington's Disease|
62088012|NCT06126419|EXPERIMENTAL|Group 1: Effect of high-dose insulin therapy on pre-operative liver function|Group 1 will consist of participants scheduled for liver resection and will undergo high-dose insulin pre-operatively to determine if baseline liver function can be optimized/improved, as measured by 99mTc-Mebrofenin HBS.
62088013|NCT06126419|EXPERIMENTAL|Group 2: Effect of high-dose insulin therapy on pre-operative liver function after LVD|Group 2 will consist of participants scheduled for liver resection that require LVD. The participants in the experimental arm will receive high-dose insulin therapy after LVD.
62450520|NCT04196465|EXPERIMENTAL|Neoadjuvant IMC-001|Neoadjuvant immune check point inhibitor of IMC-001 in participants with resectable and localized gastric cancer, esophageal cancer, and hepatocellular carcinoma
62450521|NCT05657548||Child with Cerebral Palsy|Children and adolescents from 4 to 17 years old with cerebral palsy GMFCS III, IV or V followed in the Physical Medicine and Rehabilitation Department, Children's Rehabilitation Unit of the University Hospital of Nîmes (Carémeau Hospital)
62267108|NCT05618665|EXPERIMENTAL|Intervention Group - Children and parents|Asthma education which consisted of asthma disease, its symptoms, diagnosis, treatment, risk factors, use of medication, use of medication apparatus, vaccination treatment, follow-up of the asthmatic child, precautions to be taken in prevention, what to do during an attack, what to do for adaptation to the disease and things to do in school life was prepared and presented in 40 minutes. The booklets about education would be given at the end of the education.
62450522|NCT05665582||Affected family members of patients with Substance use disorders|The family sample was recruited from at a Norwegian addiction treatment unit where close relatives of patients in treatment for SUD participated in a family program.
62450523|NCT02578732|EXPERIMENTAL|FOLFOXA|"Schema:~1 cycle = 14 days \*\*It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG\*\*~Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)~* It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment~* Antiemetics will be administered as per standard institutional policy."
62450524|NCT02637193|EXPERIMENTAL|Venlafaxine|Maximum dose of 450 mg/day (225 mg BID given at approximately 12 hours apart) Venlafaxine, dose titrated from a starting single dose (QD) of 75 mg venlafaxine in the morning of Days 1 and 2, followed by BID escalating doses administered on Days 3 through 10, followed by 450 mg/day (BID) on Days 11 through 13, and on Day 14 only the morning dose of 225 mg will be administered, then 3 days (Days 15, 16 and 17) of down titration
62450525|NCT02637193|ACTIVE_COMPARATOR|Moxifloxacin|400 mg single dose of moxifloxacin (Avelox®) administered on Day 14
62626106|NCT05627947|ACTIVE_COMPARATOR|artificial eye drops Group|This is the Third Group and consists of !9 Patients and received artificial eye drops, 4 times per day for three months after the surgery.
62450526|NCT02637193|PLACEBO_COMPARATOR|Drug -- placebo|Placebo administered on Days 1 through 13 and on Days 15 to 17
62450527|NCT04356521|ACTIVE_COMPARATOR|Group LS|Ultrasound-guided infraclavicular block - lateral sagittal approach (20 ml 0.5% bupivacaine)
62626107|NCT04827758|OTHER|Patients hospitalized in the follow-up care and rehabilitation units|
62626108|NCT04053907|NO_INTERVENTION|CCM:Standard of Care|Community Case Management (CCM), with passively monitored malaria incidence by community health workers using standard RDTs and artemisinin-based combination therapy (ACT), artemether-lumefantrine (AL) according to national guidelines.
62626109|NCT04053907|EXPERIMENTAL|CCM plus weekly fever screening and treatment|CCM plus active case detection (ACD) by fever screening and treatment if positive. Trained village health workers (VHW) recruited for this study will carry out weekly visits of all residents and screen for fever using research-grade thermometers. A standard RDT will be performed in all individuals with a body temperature ≥37.5°C or with reported fever in the last 24 hours. RDT positive individuals will be treated with AL according to national guidelines.
62626110|NCT04053907|EXPERIMENTAL|CCM plus MSAT|CCM plus monthly screening for malaria infection and treatment of positive individuals, regardless of symptoms. Screening will be performed by research staff and timed to ensure a gap of 25-35 days between screening rounds; Positive individuals will be treated with AL, according to national guidelines.
62626111|NCT04053907|EXPERIMENTAL|CCM plus dry season MDA|CCM plus plus 3 monthly rounds of MDA with a long-acting ACT (dihydroartemisinin-piperaquine, DP) starting in the dry season (April, May, June) (tablets of 320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight).
62626112|NCT03823820||Cesarean section|Women attending for elective CS.
62626113|NCT03823820||Induction of labour|Women admitted for induction of labour and expected to stayed in hospital for more than 24 hours.
62626114|NCT03823820||pregnancy complication group|"Maternal condition that could affect body fluid including:~* Pre-eclampsia requiring hospital admission.~* Hyperemesis gravidarum.~* Major postpartum haemorrhage."
62626115|NCT03823820||control|Gestational age matched controls.
62626116|NCT04285905|ACTIVE_COMPARATOR|Enhanced standard of care|"* Access to Fast Track TB Clinic~* Information leaflet for primary male partner"
62626117|NCT04285905|ACTIVE_COMPARATOR|Group 2|"* Access to Fast Track TB Clinic~* Information leaflet for primary male partner~* Female participant sputum collection from male partners"
62626118|NCT04285905|ACTIVE_COMPARATOR|Group 3|"* Access to Fast Track TB Clinic~* Information leaflet for primary male partner~* Female participant sputum collection from male partners~* Voucher for financial incentive (MKW 5000) that can be collected by the male partner upon attendance at the Fast Track Clinic"
62450528|NCT04356521|ACTIVE_COMPARATOR|Group CC|Ultrasound-guided infraclavicular block - costoclavicular approach (20 ml 0.5% bupivacaine)
62450529|NCT00926744|EXPERIMENTAL|Intervention|Physically inactive participants receiving both physical activity and dietary counseling
62626119|NCT04285905|ACTIVE_COMPARATOR|Group 4|"* Access to Fast Track TB Clinic~* Information leaflet for primary male partner~* Female participant sputum collection from male partners~* Female partner delivered oral HIV self-testing kits for primary male partner"
62626120|NCT04285905|ACTIVE_COMPARATOR|Group 5|"* Access to Fast Track TB Clinic~* Information leaflet for primary male partner~* Female participant sputum collection from male partners~* Female partner delivered oral HIV self-testing kits for primary male partner~* Voucher for financial incentive (MKW 5000) that can be collected by the male partner upon attendance at the Fast Track Clinic"
62450530|NCT00926744|NO_INTERVENTION|Active|Physically active participants receiving only dietary counseling
62450531|NCT00926744|NO_INTERVENTION|Control|Physically inactive participants receiving only dietary counseling
62450532|NCT06325878|EXPERIMENTAL|Chronic inflammatory demyelinating polyneuropathy (CIDP)|Single nucleotide polymorphisms (SNPs) of 1000 patients with chronic inflammatory demyelinating polyneuropathy will be genotyped using the Illumina Global Screening Array
62626121|NCT05530655|NO_INTERVENTION|Control group|Patients who receive radiation but no intervention
62851891|NCT03719833||2-T2-T3 N0 M0|"Breast cancer patients in the T2-T3 N0 M0 stage at the time of diagnosis who undergo neoadjuvant oncological treatment followed by surgery (quadrantectomy/mastectomy + sentinel lymph node biopsy). For the presence of any residual tumour in lymph node(s) at the final pathology report, ALND will be performed.~All patients will be followed for 5 years after surgery"
62851892|NCT03719833||3-T1-T3 N1-N2 M0|"Breast cancer patients in T1-T3 N1-N2 M0 stage at the time of diagnosis who undergo neoadjuvant oncological treatment followed by ultrasound reevaluation of axillary lymph nodes that indicate complete clinical axillary remission. The surgical procedure that would be performed is quadrantectomy/mastectomy + sentinel lymph node biopsy.~Before initiating neoadjuvant treatment biopsy (FNA) proven positive node will be marked with a titanium clip and at the time of surgery removed and pathologically examined regardless presenting as a sentinel node or not.~For the presence of any residual tumour in lymph node(s) at the final pathology report, ALND will be performed All patients will be followed for 5 years after surgery"
62851893|NCT05831683||Group A - Current state|In this group, ventilator parameters will be recorded before the SOP introduction. We will analyze PEEP, Pplat, driving pressure, VT/IBW, and the number and phase of recruitment maneuvers during general anesthesia.
62851894|NCT05831683||Group B - After SOP introduction|In this group, ventilator parameters will be collected after the SOP introduction. We will analyze PEEP, Pplat, driving pressure, VT/IBW, and the number and phase of recruitment maneuvers during general anesthesia.
62851895|NCT02540278|EXPERIMENTAL|Treatment|Received the 11 lesson Positive Prevention Curriculum
62851896|NCT02540278|NO_INTERVENTION|Control|Did not receive any sex-related instruction
62851897|NCT02900989|OTHER|ASQ-Fr|Adolescents undergo the ASQ-Fr questionnaire composed of 5 items.
62851898|NCT02900989|OTHER|SIQ-Fr|Adolescents undergo the SIQ-Fr questionnaire composed of 30 items if \>=15 yo and the SIQ-Fr Junior composed of 15 items if \<15 yo
62851899|NCT03490812|EXPERIMENTAL|Prospective population|
62851900|NCT03490812|EXPERIMENTAL|Retrospective population|
62851901|NCT05915156|OTHER|Post-acute home physiotherapy program (PAHP)|This health services research aimed to assess the effects of a post-acute home physiotherapy program that was designed to provide home physiotherapy services to patients recently discharged from acute or post-acute care.
62851902|NCT03716154|EXPERIMENTAL|SRP and diode laser|In a split mouth design either left or right sites randomly treated by SRP and diode laser as an adjunct
62851903|NCT03716154|NO_INTERVENTION|SRP alone|The other sites in the other side will be treated by SRP alone
62851904|NCT01809093||Blood draw|Blood (approximately equal to 3 to 4 tablespoons) will be drawn at the Wills Eye Institute, 1 time.
62851905|NCT01087736|EXPERIMENTAL|Topiramate|Participants will be randomly assigned to either the topiramate arm or placebo arm. Neither the participant nor the researchers will know which arm the participant is in. Participants in the topiramate arm will be ingesting daily doses of topiramate that will gradually increase to a maximum, and then taper off.
62851906|NCT01087736|PLACEBO_COMPARATOR|Placebo|The Drug Product Services Laboratory at UCSF will purchase and supply our lab with USP or NF grade topiramate study capsules and matching placebo capsules. Randomization will be done by a consulting biostatistician, who will be the only one to know which participants are assigned to placebo. Dosing will follow the same procedures as with topiramate in that arm of the study. If adverse events occur, there will be a procedure in place for unblinding only that participant.
62851907|NCT05216744|EXPERIMENTAL|Doxycycline plus ceftriaxone|Each subject will receive 100 mg doxycycline twice daily for seven days and a single dose of ceftriaxone 1000 mg intravenously
62851908|NCT05216744|ACTIVE_COMPARATOR|Doxycycline plus cefixime|Each subject will receive 100 mg doxycycline twice daily for seven days and a single oral dose of cefixime 800 mg
62851909|NCT00875693|EXPERIMENTAL|Arm A dose of CPX - 351|Dose level 1A: 60 units/m2 days -28, -26 and -24 Dose level 2A: 80 units/m2 days -28, -26 and -24 Dose level 3A: 100 units/m2 days -28, -26 and -24 Dose level 4A: 120 units/m2 days -28, -26 and -24 Dose level 5A: 140 units/m2 days -28, -26 and -24 Dose level 6A: 160 units/m2 days -28, -26 and -24
62450533|NCT06325878|EXPERIMENTAL|Control Subjects|Single nucleotide polymorphisms (SNPs) of 2500 control subjects without chronic inflammatory demyelinating polyneuropathy will be genotyped using the Illumina Global Screening Array
62851910|NCT00875693|EXPERIMENTAL|Arm B dose of CPX-351|Dose level 1B: 60 units/m2 days -21, -19 and -17 Dose level 2B: 80 units/m2 days -21, -19 and -17 Dose level 3B: 100 units/m2 days -21, -19 and -17 Dose level 4B: 120 units/m2 days -21, -19 and -17 Dose level 5B: 140 units/m2 days -21, -19 and -17
62851911|NCT03289624|EXPERIMENTAL|SHARE for Chronic Conditions|"Six weekly SHARE for Chronic Conditions (SHARE-CC) sessions will be conducted in the dyad's home or another location preferred by the participants. A care plan (the SHARE plan) is created that reflects the mutual decisions made by the dyad as a result of their participation in the SHARE-CC program. The SHARE plan is intended to help the caregiver (CG) ensure the PWCC's values and preferences are supported when decisions have to be made in an emergency or in the end stages of the disease. SHARE plans will be documented in a notebook that also contains information on key topics and provides links to local and online resources and services."
62450534|NCT04212039|ACTIVE_COMPARATOR|ultrasound guided pericapsular nerve group block|Ultrasound guided 0.5 ml/kg % 0.250 bupivacaine injection between to iliopubic eminentia and psoas tendon
62450535|NCT04212039|SHAM_COMPARATOR|ultrasound guided sham block|Ultrasound guided 0.5 ml/kg saline injection injection between to iliopubic eminentia and psoas tendon
62626122|NCT05530655|EXPERIMENTAL|Intervention group|
62626123|NCT06019026|EXPERIMENTAL|Tri-Lock|Total hip arthroplasty performed through posterolateral access using the uncemented Tri-Lock short stem.
62626124|NCT06019026|ACTIVE_COMPARATOR|Summit|Total hip arthroplasty performed through posterolateral access using the uncemented Summit standard stem.
62851912|NCT03289624|NO_INTERVENTION|Health Coaching|Six 30-minute weekly telephone calls to provide information and education related to the PWCC's conditions and information about services and care options will be conducted.
62851913|NCT00881868|ACTIVE_COMPARATOR|Clobex Spray|
62062693|NCT06516627|EXPERIMENTAL|Spectrum Labels|"All products will display an expanded Guiding Stars label that shows an overall rating indicating their healthfulness using star ratings: 1 star (Poor), 2 stars (Fair), 3 stars (Good), 4 stars (Better), or 5 stars (Best). The Guiding Stars rating system uses a patented algorithm to rate foods based on their nutrients and ingredients per 100-calorie serving of the food. Products that display 1-, 2-, or 3-star labels in the Positive Labels arm will display 3-, 4-, or 5-star labels, respectively, in the Spectrum Labels arm. The remaining products that do not earn stars in the Positive Labels arm will be divided in half based on their underlying Guiding Stars scores; the bottom half of these products will display 1-star labels and the top half of these products will display 2-star labels."
62450536|NCT04603963|NO_INTERVENTION|group control|alternate exercises: in one day breathing exercises, active or with a load of large muscle groups (according to tolerance) with a maximum limit of 2 kg, sedation out of bed, walking. On another day aerobic exercise with cycle ergometer limited to 30 minutes.
62450537|NCT04603963|EXPERIMENTAL|intervention group|He received the same intervention as the control group, associating respiratory muscle training 1 time a day with power breathe 3 series of 10 repetitions (started with 30% of the Pimax value) with readjusted load every 7 days.
62851914|NCT00881868|PLACEBO_COMPARATOR|Vehicle spray|
62851915|NCT03241147|EXPERIMENTAL|Subjects with severe renal impairment (Group A)|
62851916|NCT03241147|EXPERIMENTAL|Healthy subjects (Group B)|
62851917|NCT03241147|EXPERIMENTAL|Subjects with moderate renal impairment (Group C)|
62851918|NCT03241147|EXPERIMENTAL|Subjects with mild renal impairment (Group D)|
62062694|NCT06516627|EXPERIMENTAL|FDA High In Labels|Products that contain high levels (i.e., ≥20% DV per serving) of saturated fat, sodium, or added sugars will display a label indicating which of these nutrients the product is high in. The investigators will use DVs of 20g for saturated fat, 2,300mg for sodium, and 50g for added sugars per FDA definitions.
62626125|NCT01473017|EXPERIMENTAL|CBT-based guided self-help|Providing a guided self-help booklet to patients with anxiety/depression meeting criteria, with two telephone calls by a clinician to provide support with this.
62626126|NCT01473017|NO_INTERVENTION|No CBT intervention|Control group in comparison to CBT guided self-help group
62851919|NCT05114642|EXPERIMENTAL|Skeletal Class III Malocclusion Treatment with Face Mask Group|In patients with skeletal class III malocclusion (ANB angle \< 0,0) due to maxillary deficiency, rapid maxillary expansion appliances prepared on dental plaster models made of acrylic material covering all the upper dental posterior tooth surfaces were applied before the upper jaw was orthopedically brought forward with a face mask. This process was stopped when the expansion was made so that the palatal tubercles of the maxillary permanent first molars align with the buccal tubercles of the mandibular permanent first molars. Immediately afterwards, the petit-type face mask was applied to the hooks of the maxillary expansion device with the help of elastic bands and used continuously for at least 18 hours a day. After obtaining a positive overjet, the face mask appliance was used at night to ensure retention, and then the treatment was terminated.
62062695|NCT06516627|EXPERIMENTAL|FDA Traffic Light Labels|"All products will display a Nutrition Info label showing whether the amount of saturated fat, sodium, and added sugars in 1 serving of the product is low (\<5% DV), medium (≥5 to \<20% DV), or high (≥20% DV). Low will be shown in green, Medium in yellow, and High in red. The investigators will use DVs of 20g for saturated fat, 2,300mg for sodium, and 50g for added sugars per FDA definitions."
62851920|NCT05114642|NO_INTERVENTION|Control Group|A control group was formed from patients in the same age group who had skeletal class III malocclusion due to maxillary growth deficiency but were not treated. In this way, the changes that occurred in the normal process in the head, craniocervical postures, pharyngeal airway and hyoid bones of the patients whose growth and development continued could be distinguished.
62851921|NCT01715857||Chinese Patients Requiring Surgery with Sevoflurane Anesthesia|Participants who were scheduled for surgery requiring sevoflurane anesthesia with endotracheal intubation or laryngeal mask airway (LMA) per approved product information of sevoflurane in China
62851922|NCT05600777|EXPERIMENTAL|BLU-5937 25 mg|BLU-5937 oral dose 25 mg twice a day.
62626127|NCT01551446|EXPERIMENTAL|Bardoxolone Methyl 20mg|
62851923|NCT05600777|EXPERIMENTAL|BLU-5937 50 mg|BLU-5937 oral dose 50 mg twice a day.
62851924|NCT05600777|PLACEBO_COMPARATOR|Placebo|Matching Placebo for BLU-5937 oral dose twice a day.
62851925|NCT05483829|EXPERIMENTAL|Long COVID prospective group|
62851926|NCT04013685|EXPERIMENTAL|Subjects with Acute Leukemia or Myelodysplasic Syndrome, or BPDCN|This is a non-randomized, single-arm study. All enrolled subjects will receive an allogeneic HCT with the Orca-T product.
62088014|NCT06126419|NO_INTERVENTION|Group 3: Effect of high-dose insulin therapy on pre-operative liver function after LVD|Group 3 will consist of participants scheduled for liver resection that require LVD. The participants in the no intervention arm will not undergo intervention with high-dose insulin therapy after LVD.
62450538|NCT00944970|OTHER|binodenoson then adenosine|binodenoson (experimental); adenosine (active comparator)
62450539|NCT00944970|OTHER|adenosine then binodenoson|adenosine (active comparator); binodenoson (experimental)
62626128|NCT05565170|ACTIVE_COMPARATOR|Structured ICT-assisted multimodal lifestyle intervention|Participants assigned to this study arm follow an intensive structured, digitally supported multimodal lifestyle intervention programme (combination of individual and group-based in-person consultations/sessions and digital activities in the LETHE mobile phone App). Intervention duration is 2 years.
62851927|NCT02715440|EXPERIMENTAL|Immediate intervention|Gradual withdrawal of benzodiazepines or related drugs : 25% reduction of the benzodiazepines dose or related drugs every 2 weeks during nine weeks in order to stop the treatment .
62626129|NCT05565170|SHAM_COMPARATOR|Self-guided multimodal lifestyle intervention|Participants assigned to this study arm receive regular health advice in connection with the study visits (and through a simplified version of the LETHE mobile phone App), and are recommended and encouraged to independently implement healthy lifestyle changes that are suitable and fit in with their daily routine. Intervention duration is 2 years.
62626130|NCT02860962|ACTIVE_COMPARATOR|Dextromethorphan|2 doses of Dextromethorphan 75mg oral (PO), separated by 4 hours
62851928|NCT02715440|NO_INTERVENTION|Delayed intervention|usual care without intervention
62851929|NCT03288051|ACTIVE_COMPARATOR|Crystalloid group|
62450540|NCT00944970|ACTIVE_COMPARATOR|adenosine then adenosine|
62450541|NCT05498246|ACTIVE_COMPARATOR|group (A) included 30 cases in which we used bipolar coagulation for hemostasis|group (A) included 30 cases in which we used bipolar coagulation for hemostasis
62851930|NCT03288051|ACTIVE_COMPARATOR|Colloid group|
62062696|NCT06516627|EXPERIMENTAL|FDA High In Labels Plus Positive Labels|"Products that contain high levels (i.e., ≥20% DV per serving) of saturated fat, sodium, or added sugars will display a label indicating which of these nutrients the product is high in. The investigators will use DVs of 20g for saturated fat, 2,300mg for sodium, and 50g for added sugars per FDA definitions.~Additionally, products that meet Guiding Stars' criteria for earning 1 or more Guiding Star will display labels indicating their healthfulness using star ratings: 1 star (Good), 2 stars (Better), or 3 stars (Best). The Guiding Stars rating system uses a patented algorithm to rate foods based on their nutrients and ingredients per 100-calorie serving of the food."
62062697|NCT06516627|EXPERIMENTAL|FDA Traffic Light Labels Plus Positive Labels|"All products will display a Nutrition Info label showing whether the amount of saturated fat, sodium, and added sugars in 1 serving of the product is low (\<5% DV), medium (≥5 to \<20% DV), or high (≥20% DV). Low will be shown in green, Medium in yellow, and High in red. The investigators will use DVs of 20g for saturated fat, 2,300mg for sodium, and 50g for added sugars per FDA definitions.~Additionally, products that meet Guiding Stars' criteria for earning 1 or more Guiding Star will display labels indicating their healthfulness using star ratings: 1 star (Good), 2 stars (Better), or 3 stars (Best). The Guiding Stars rating system uses a patented algorithm to rate foods based on their nutrients and ingredients per 100-calorie serving of the food."
62062698|NCT04786314|EXPERIMENTAL|Hot Water Application Group|Pregnant women will apply hot water to their legs before going to sleep for a week, depending on the groups they are in.
62062699|NCT04786314|EXPERIMENTAL|Cold Water Application Group|Pregnant women will apply cold water to their legs before going to sleep for a week, depending on the groups they are in.
62062700|NCT04786314|NO_INTERVENTION|Control Group|There will be no intervention other than routine follow-up and maintenance.
62062701|NCT01862796|EXPERIMENTAL|Obese underfeeding (UF)|Obese randomized to received a 35% calorie reduced diet
62062702|NCT01862796|EXPERIMENTAL|Obese weight maintaining (WMEN)|Randomized to receive a weight-maintaining diet
62062703|NCT01862796|EXPERIMENTAL|Lean weight maintaining (WMEN)|Normal weight individuals receiving a weight-maintaining energy needs diet
62062704|NCT05677932|EXPERIMENTAL|Bright light therapy|10,000lux bright light
62062705|NCT05677932|EXPERIMENTAL|Placebo group|50 lux dim red light
62062706|NCT03885466|EXPERIMENTAL|Nordic walking|Nordic walking exercise intervention, 3 times per week over 12 weeks
62062707|NCT03885466|NO_INTERVENTION|Control|Waiting list controls will be offered same Nordic walking intervention after 3 month follow-up measurements
62062708|NCT00039325|EXPERIMENTAL|Group A - first dose for phase 1|A\*0201 positive subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^6. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
62062709|NCT00039325|EXPERIMENTAL|Arm B - dose increase for phase 1|A\*0201 positive subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
62062710|NCT00039325|EXPERIMENTAL|Arm C - A*0201+/DR*04+ subjects - Phase II|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
62062711|NCT00039325|EXPERIMENTAL|Arm D - A*0201+/DR*04- - phase 2|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
62062712|NCT00039325|EXPERIMENTAL|Arm E - A*0201-/DR*04+ - phase 2|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
62062713|NCT04599101|EXPERIMENTAL|Nasal suction device: Nose Frida|Nose Frida nasal suction device to clear nasal secretions
62062714|NCT04599101|ACTIVE_COMPARATOR|Nasal suction device: Bulb|Bulb syringe suction device to clear nasal secretions
62062715|NCT03424590|ACTIVE_COMPARATOR|COTS|Volunteers will be provided with Clearblue connected Ovulation test system to use during the study period, accortding to the instructions for use.
62851931|NCT02042716|EXPERIMENTAL|diagnosis of white matter damage|Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
62851932|NCT01138917|EXPERIMENTAL|all participants|All participants will receive both ReCell and split-thickness skin graft
62851933|NCT02013258|ACTIVE_COMPARATOR|Intranasal oxytocin|Intranasal oxytocin. 16 IU intranasal oxytocin x 5 days. One month interval between arms of treatment.
62851934|NCT02013258|PLACEBO_COMPARATOR|Placebo|Placebo will be administered via nasal spray - 1 spray in each nostril x5 days.
62851935|NCT03390842|EXPERIMENTAL|TRC101|Administered once daily (QD) for 40 weeks
62851936|NCT03390842|PLACEBO_COMPARATOR|Placebo|Administered once daily (QD) for 40 weeks
62851937|NCT05204693|SHAM_COMPARATOR|Start with: Concentric (normal) cycling|
62851938|NCT05204693|EXPERIMENTAL|Start with: Eccentric cycling|
62851939|NCT02711267|EXPERIMENTAL|Phase 1: Optimization Study|6 subjects will be included in this study, each with 3 application sites on the arm and 3 on the leg. 2 dOFM probes (OFM Probe) will be implanted per site resulting in 12 dOFM probes per subject (operated by OFM pump). On each the arm and the leg the proximal and distal site of the 3 adjacent sites will be treated by 5% Zovirax® cream. The central site on arm and leg will be left untreated in order to test a potential lateral carry-over of acyclovir from one application site to the other. Blood samples will be taken to test for uptake into the blood stream and redistribution to other application sites.
62062716|NCT03424590|NO_INTERVENTION|Control|Volunteers will not be provided with Clearblue Connected Ovulation Test System and will be instructed not to use any other ovulation predictions tests during the study period.
62062717|NCT03480217|EXPERIMENTAL|Multifaceted Implementation Strategy|Patients will be screened for hypertension by primary care providers, registered nurses, medical assistants, and front desk staff from clinics randomized to receive the intervention, Multifaceted Implementation Strategy.
62062718|NCT03480217|NO_INTERVENTION|Usual Care|Patients will be screened for hypertension by primary care providers, nurses, medical assistants, and front desk staff of clinics randomized to the usual care group that do not intentionally receive any parts of the multifaceted implementation strategy.
62267109|NCT05618665|EXPERIMENTAL|Intervention Group - Children|Asthma education which consisted of asthma disease, its symptoms, diagnosis, treatment, risk factors, use of medication, use of medication apparatus, vaccination treatment, follow-up of the asthmatic child, precautions to be taken in prevention, what to do during an attack, what to do for adaptation to the disease and things to do in school life was prepared and presented in 40 minutes. The booklets about education would be given at the end of the education.
62267110|NCT05618665|NO_INTERVENTION|Control group|No intervention was applied to the control group.
62450542|NCT05498246|ACTIVE_COMPARATOR|group (B) included 30 cases in which we used suture renorrhaphy|group (B) included 30 cases in which we used suture renorrhaphy
62267111|NCT05488587||hepatocellular carcinoma|
62267112|NCT05488587||liver cirrhosis|
62267113|NCT05488587||healthy individuals|
62267114|NCT02388438|EXPERIMENTAL|Demineralized bone matrix|Applied demineralized bone matrix when investigator conduct hallux valgus surgery.
62267115|NCT04314856|EXPERIMENTAL|Fragile X Syndrome|"Adult males aged 18-30 years diagnosed with FXS will undergo a PET/MRI scan using 18F-FTC-146 to determine sigma-1 receptor density.~These participants will only be administered once with 18F-FTC-146."
62450543|NCT00221507|NO_INTERVENTION|Historical Cohort|This study will first examine risk factors in a defined population of inner city children, using a historical cohort.
62450544|NCT00221507|ACTIVE_COMPARATOR|Reminder Recall Outreach|"To determine how well Reminder Recall Outreach will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
62626131|NCT02860962|PLACEBO_COMPARATOR|Placebo|2 doses of placebo (oral/PO), separated by 4 hours
62626132|NCT02375425||No contraceptive use|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
62626133|NCT02375425||levonorgestrel IUD|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
62851940|NCT02711267|EXPERIMENTAL|Phase 2: Formulation Study|6 subjects will be included in this study, each with 3 application sites on the arm and 3 on the leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. Different topical 5% acyclovir formulations currently available on the market will be tested. One application site on the arm and one on the leg will be used for U.S. Zovirax® cream 5% application. The remaining two application sites on the arm and the remaining 2 on the leg will be used to randomly administer two of the remaining formulations (5% Aciclostad cream, 5% Aciclovir cream 1A Pharma, 5% Zovirax® cream (Austria), 5% Zovirax Cold Sore Cream) according to an application pattern.
62626134|NCT02375425||paraguard IUD|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
62626135|NCT02375425||DMPA|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
62626136|NCT01482988||Critical care patients antipated to stay more than 72 hours|
62626137|NCT06364371||Observational cohort|Patients with locally advanced (T3-4NxM0) rectal adenocarcinoma
62626138|NCT00990509|EXPERIMENTAL|Albumin|
62626139|NCT00990509|PLACEBO_COMPARATOR|Placebo|
62851941|NCT02711267|EXPERIMENTAL|Phase 3: Pilot BE study|4 subjects will be included in the pilot BE study with 3 application sites on each leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. One reference drug product (R) and one test drug product (T) will be applied on the application sites in order to test for BE between duplicate sites with R applied, and to test for non-BE between application sites with R and T applied.
62851942|NCT02711267|EXPERIMENTAL|Phase 4: Main BE Study|20 subjects will be included in the pilot BE study with 3 application sites on each leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. One reference drug (R) and one test drug (T) will be applied on the application sites in order to test for BE between duplicate sites with R applied and to test for non-BE between application sites with R and T applied.
62062719|NCT04399356|ACTIVE_COMPARATOR|Niclosamide|Participants in the treatment arm will receive Niclosamide 2 grams orally on day 1 and daily for 6 more days (total 7 days of treatment)
62626140|NCT02491970|EXPERIMENTAL|Fluticasone/Formoterol|Brand name: Flutiform Dose: 250/10μg (2 puffs/once, BID) Duration of treatment: 12 weeks Mode of administration: oral inhalation
62626141|NCT02491970|ACTIVE_COMPARATOR|Fluticasone/Salmeterol|Brand name: Seretide Dose: 250/50μg (2 puffs/once, BID) Duration of treatment: 12 weeks Mode of administration: oral inhalation
62626142|NCT00064415|EXPERIMENTAL|1|Arformoterol tartrate 50 mcg QD
62626143|NCT00064415|ACTIVE_COMPARATOR|2|Salmeterol 42 mcg BID
62626144|NCT04331509||Symptom tracker users|No Intervention
62062720|NCT04399356|PLACEBO_COMPARATOR|Control|Participants in the control group will receive identical-appearing placebo by mouth in the same numbers of pills on day 1 and daily for 6 more days (total 7 days of treatment)
62062721|NCT03400501|EXPERIMENTAL|subjects receiving insulin degludec|Youth aged 8-18 years with T1D whose diabetes is poorly-controlled (A1c ≥8.5%) will receive insulin degludec injections.
62062722|NCT03400501|ACTIVE_COMPARATOR|Subjects receiving insulin glargine|Youth aged 8-18 years with T1D whose diabetes is poorly-controlled (A1c ≥8.5%) will receive insulin glargine injections.
62626145|NCT03655600|ACTIVE_COMPARATOR|Self-administered acupressure|Acupressure administered by participant self-taught from computer application
62062723|NCT06624631|EXPERIMENTAL|Arm A|The final choice of the two delivery strategies to be evaluated will be informed by formative research conducted under a separate standalone protocol. For example, these could include A: Delivery of PDMC at the primary admitting facility or B: Referral to the closest peripheral facility for dispensing of PDMC two weeks post discharge.
62626146|NCT03655600|NO_INTERVENTION|Usual care|Usual care
62626147|NCT03694223|EXPERIMENTAL|Booklets|Health education delivery method: Booklet. Patients will be given 2 leaflets on the low FOMDAP diet produced by the Department of Nutrition and Dietetic in Guy's \& St Thomas' NHS Foundation Trust, and the Diabetes and Nutritional Sciences Division at King's College London. These booklets have been produced by dietitians and are commonly used in clinical practice across the UK.
62626148|NCT03694223|EXPERIMENTAL|Mobile application|Health education delivery method: Mobile application. Patients will be asked to download an application on their mobile phones or tablets. This application has been produced by dietitians from the Department of Nutrition and Dietetic in Guy's \& St Thomas' NHS Foundation Trust, and the Diabetes and Nutritional Sciences Division at King's College London.
62626149|NCT03694223|ACTIVE_COMPARATOR|One to one consultation with dietitian|Health education delivery method:One-to-one consultation with dietitian. Patients will attend a clinic visit for a one-to-one consultation with a dietitian. As per current clinical practice, the initial visit will last for 1 hour. During the visit, tailored information on the low FOMDAP diet will be given to match patients' individual needs. During the visit, either the leaflets (used in group 1) or the application (used in group 2) will be used to facilitate the visit. The choice of using the leaflets or the app during the visit will be based on the dietitian's judgment based on the patients' needs.
62626150|NCT04824742|EXPERIMENTAL|neoadjuvant PDT + radical surgery|Photodynamic therapy for neoadjuvant treatment of cholangiocarcinoma
62626151|NCT04824742|ACTIVE_COMPARATOR|radical surgery|Patients with cholangiocarcinoma undergo radical surgical resection
62626152|NCT05177068|EXPERIMENTAL|Experimental|fruquintinib + sintilimab + SOX (S-1 + oxaliplatin)
62626153|NCT01008774|EXPERIMENTAL|A|
62626154|NCT01008774|ACTIVE_COMPARATOR|B|
62626155|NCT01008774|NO_INTERVENTION|C|
62626156|NCT02686814|EXPERIMENTAL|MDT-2215|17mm MDT-2215 aortic valve bioprosthesis
62626157|NCT04810910|EXPERIMENTAL|Personalized neoantigen vaccines|"iNeo-Vac-P01 (peptides)： 4 x 300 mcg per peptide given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses;~GM-CSF: 4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses"
62851943|NCT05439005|EXPERIMENTAL|OFA group|OFA (Opioid Free Anaesthesia) group:
62851944|NCT05439005|NO_INTERVENTION|CA control group|CA (Conventional Anaesthesia) control group:
62851945|NCT03113890|EXPERIMENTAL|Assay Guided Group (AGG)|These patients will undergo a cheek swab to collect DNA for the Genecept assay. Study doctors will receive the Genecept report prior to patient discharge and use it to guide psychoeducation and medication management.
62062724|NCT06624631|ACTIVE_COMPARATOR|Arm B|The final choice of the two delivery strategies to be evaluated will be informed by formative research conducted under a separate standalone protocol. For example, these could include A: Delivery of PDMC at the primary admitting facility or B: Referral to the closest peripheral facility for dispensing of PDMC two weeks post discharge.
62062725|NCT01331668||renal allograft donors and recipients|All de novo renal allograft recipients transplanted at the University Hospitals Leuven
62062726|NCT02390739|EXPERIMENTAL|Single Arm|All patients will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine followed by antithyroglobulin mTCR PBL and aldesleukin.
62062727|NCT00695747|NO_INTERVENTION|1|Standard 1 site Procedure using a fornix based incision, performed superiorly
62450545|NCT00221507|ACTIVE_COMPARATOR|Case Management|"To determine how well Case Management will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
62450546|NCT00221507|ACTIVE_COMPARATOR|Patient Navigation|"To determine how well Patient Navigation will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
62450547|NCT01711021|ACTIVE_COMPARATOR|d-Amphetamine Transdermal patch|"The study was conducted in 2 parts: a 5-week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Subjects who reached the optimal dose by end of dose optimization treatment period were randomized to receive double-blind treatment.~Participants first received study patches everyday for one week, then subjects were crossed-over to receive the placebo treatment.~d-Amphetamine Transdermal System: Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied."
62626158|NCT02601222|EXPERIMENTAL|Runzao zhiyang capsule|Runzao zhiyang capsule: 4 pills each time, 3 times a day, oral， Urea Cream (topical application, apply to the affected area and gently rub) 2 times a day.
62626159|NCT02601222|PLACEBO_COMPARATOR|Runzaozhiyang capsule agent simulation|Runzaozhiyang capsule agent simulation:4 pills each time, 3 times a day, oral, Urea Cream (topical application, apply to the affected area and gently rub) 2 times a day.
62851946|NCT03113890|OTHER|Treatment as Usual (TAU)|Thus this group will serve as the control group for the outcomes related to Genecept-guided decision making. These patients will undergo a cheek swab to collect DNA for the Genecept assay. Study doctors will receive the Genecept report at the 12-week follow up visit (12 weeks after patient discharge) and will use it to guide psychoeducation. The Study Doctors will not receive the report during the patient's inpatient stay (treatment as usual, TAU). Clinicians will receive the assay report for patients in the treatment-as-usual group at the 3-month followup period.
62851947|NCT05213728|EXPERIMENTAL|Cohort 1|Single 1E11 dose administered via multiple sub-doses over a 4-hour period in adults (18-55 yrs).
62062728|NCT00695747|EXPERIMENTAL|2|2 Site Combined Procedure
62851948|NCT03129399|EXPERIMENTAL|King Vision video laryngoscope|
62851949|NCT03129399|ACTIVE_COMPARATOR|McGrath MAC video laryngoscope|
62626160|NCT05392530|EXPERIMENTAL|Treatment Sequence ABC|Participants will receive single oral dose of final marketing image (FMI) candidate #1 of macitentan (Treatment A \[test\]) under fed condition in Treatment Period 1, followed by single oral dose of FMI candidate #2 of macitentan (Treatment B \[test\]) under fed conditions in Treatment Period 2, and then single oral dose of the reference formulation of macitentan (Treatment C) under fed conditions in Treatment Period 3. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
62062729|NCT01611584|EXPERIMENTAL|ALA|No arms for the trial. Participants will have proven or presumed lung cancer and will be assessed for participant by a research team member.
62062730|NCT04550663|EXPERIMENTAL|KD-025 CAR-T cells|NKG2D-based CAR-T cells infusion
62062731|NCT05720234|EXPERIMENTAL|Treatment group|53 subjects will be enrolled with the indicated treatment dose of avatrombopag.
62267116|NCT04314856|EXPERIMENTAL|Healthy Volunteers (Control)|"Adults aged 18-65 years undergo a PET/MRI scan using 18F-FTC-146 to determine sigma-1 receptor density.~Test-retest studies will be performed where these individuals will each be injected twice with 18F-FTC-146."
62851950|NCT02916537|EXPERIMENTAL|Cohort A: Pre-prostatectomy patients|Patients with prostate cancer prior to radical prostatectomy (N = 5). Single IV dose (370 MBq, or 10 mCi). Combined PET/MR imaging (prostate + whole body) will be performed following tracer injection. Patients in cohort A will undergo radical prostatectomy (plus lymph node dissection) within 12 weeks following CTT1057 PET/MR.
62267117|NCT06279156|EXPERIMENTAL|the first group (every-1-month BIA and then every-2-month BIA)|measure Bioelectrical Impedance analysis (BIA) for patients' dry weight every 1 month for 4 months, and then every 2 months for 4 months
62267118|NCT06279156|EXPERIMENTAL|the second group (every-2-month BIA and then every-1-month BIA)|measure Bioelectrical Impedance analysis (BIA) for patients' dry weight every 2 months for 4 months, and then every 1 month for 4 months
62267119|NCT05068336||desflurane|Anesthesia maintenance of the first group will be provided with desflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
62267120|NCT05068336||sevoflurane|Anesthesia maintenance of the first group will be provided with sevoflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
62267121|NCT01050309|ACTIVE_COMPARATOR|Cervix|
62267122|NCT01050309|ACTIVE_COMPARATOR|colon|
62267123|NCT01050309|ACTIVE_COMPARATOR|Intravenous|
62267124|NCT05382975|OTHER|Wedge 1 includes Schools 1 and 2.|
62267125|NCT05382975|OTHER|Wedge 2 includes Schools 3, 4, and 5.|
62267126|NCT05382975|OTHER|Wedge 3 includes Schools 6, 7, and 8.|
62267127|NCT00651066|EXPERIMENTAL|1|RBT (150 mg TPW during 3 weeks switch to 150mg OD for the following 3 weeks) associated with LPV/r based ART
62267128|NCT00651066|EXPERIMENTAL|2|RBT (150 mg OD during 3 weeks switch to 150mg TPW for the following 3 weeks) associated with LPV/r based ART
62626161|NCT05392530|EXPERIMENTAL|Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1 followed by Treatment C in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
62626162|NCT05392530|EXPERIMENTAL|Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1 followed by Treatment A in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
62851951|NCT02916537|EXPERIMENTAL|Cohort B: Metastatic prostate cancer|"Patients with evidence of metastatic castration-resistant prostate cancer (N = 15).~Single IV dose (370 MBq, or 10 mCi). Combined PET/MR imaging (prostate + whole body) will be performed following tracer injection. Patients in cohort B (metastatic prostate cancer) will have the option for metastatic tumor biopsy following CTT1057 PET imaging."
62851952|NCT04636983|EXPERIMENTAL|BV100|BV100 intravenous infusion
62851953|NCT04636983|PLACEBO_COMPARATOR|Placebo|Saline intravenous infusion
62851954|NCT03537300|EXPERIMENTAL|experimental group|
62626163|NCT05392530|EXPERIMENTAL|Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1 followed by Treatment C in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
62851955|NCT03537300|ACTIVE_COMPARATOR|control group|
62851956|NCT00095940|EXPERIMENTAL|Treatment (surgery, lapatinib)|"Molecular Biology Phase: Patients randomized to receive lapatinib prior to surgery receive oral lapatinib twice daily for 7-14 days. Surgery is performed after 7-14 days of lapatinib treatment. For patients randomized to not receive lapatinib, surgery is performed within 3 weeks of registration. After surgical resection, all molecular biology participants start lapatinib treatment within 10 days post-surgery. The first dose of lapatinib post-surgery initiates course 1. Patients receive oral lapatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity.~Lapatinib Continuation/Phase II: Patients receive oral lapatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity."
62851957|NCT00747357|EXPERIMENTAL|1|Balloon first
62851958|NCT00747357|EXPERIMENTAL|2|Stent First
62267129|NCT04240327||GG2+ Prostate Cancer Risk|Participants at risk for Grade Group 2 (GG2+) prostate cancer. Participants will be followed for up to two years to rule out the presence of GG2+ prostate cancer
62267130|NCT04068480||Capsule endoscopy patients|Patients swallowed the capsules in left lateral position, leaning on their left forearms and elbows, while we were positioning the magnet tightly against their backs. With the magnetic field vector X,Y,Z axis 180, -90 and 90, respectively. After swallowing the capsules with a small amount of water, they remained in this left lateral decubitus position.
62267131|NCT05609890|EXPERIMENTAL|Active intervention|A formulation made of natural components. Each sachet contains saffron, tea extract, lemon balm and valerian.
62267132|NCT05609890|PLACEBO_COMPARATOR|Placebo|Placebo sachet will contain inert excipient.
62267133|NCT00082888|EXPERIMENTAL|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62062732|NCT02118662|EXPERIMENTAL|Male Cohort|"Eight Male participants per cohort will complete the following:~Energy Expenditure during seated in an office chair during normal rest. Energy Expenditure during seated and typing. Energy Expenditure during Treadmill walking work condition. Energy Expenditure during cycling work condition"
62062733|NCT02118662|EXPERIMENTAL|Female Cohort|"Eight femalel participants per cohort will complete the following:~Energy Expenditure during seated in an office chair during normal rest. Energy Expenditure during seated and typing. Energy Expenditure during Treadmill walking work condition. Energy Expenditure during cycling work condition"
62267134|NCT05220826|NO_INTERVENTION|Surgical drainaje (the standar of care)|Surgery will consist of performing a craniotomy (burr hole or drill) and evacuation of the hematoma. Depending on the operator, the surgical procedure may incorporate the use of subdural space drainage devices (e.g. Jackson Pratt drainage) connected to a soft suction reservoir. If used, these devices should be removed within 48 hours of installation.
62267135|NCT05220826|EXPERIMENTAL|Surgical drainaje plus early embolization of middle meningeal artery|The endovascular procedure will be performed until 72 hours after surgical evacuation of chronic subdural hematoma. Embolization will be performed with non-adhesive embolizing fluids such as Onix®, Phil®, Squid® or Libro®.
62267136|NCT04599556|EXPERIMENTAL|T-ALL/LBL|
62626164|NCT05392530|EXPERIMENTAL|Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1 followed by Treatment B in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
62626165|NCT05392530|EXPERIMENTAL|Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1 followed by Treatment A in treatment period 2, and then Treatment C in Treatment Period 3 on Day 1. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
62626166|NCT05061147|EXPERIMENTAL|Max-40279-01 in combination with Azacitidine (AZA)|"This is an open-label Phase Ib/II clinical study. The study will be conducted in two parts:~Part I: Phase Ib dose escalation. Participants receive Max-40279-01 in combination with azacytidine (AZA), with different dose schedules.~Part II: Phase II dose expansion. Participants divide into positive group and negative group according to whether FLT3 gene mutation occurs, approximately 40 people per group.~All participants receive the recommended dose for Part 2 of Max-40279-01 with azacytidine (AZA)."
62626167|NCT01067417|ACTIVE_COMPARATOR|Hydroxychloroquine|
62626168|NCT01067417|PLACEBO_COMPARATOR|Placebo|
62626169|NCT03800680|NO_INTERVENTION|Usual Care (Arm 1)|Participants will receive usual care by their diabetes clinics.
62626170|NCT03800680|EXPERIMENTAL|DMP (Arm 2)|Participants will receive usual care by their diabetes clinics and the Diabetes Management Package (DMP).
62626171|NCT03800680|EXPERIMENTAL|DMP + M-POWER Rewards (Arm 3)|Participants will receive usual care by their diabetes clinics, the Diabetes Management Package (DMP), and the financial incentive program, M-POWER Rewards.
62851959|NCT05622760|EXPERIMENTAL|Audiovisual information|Group of participants to whom the information is given through an audiovisual medium.
62851960|NCT05622760|PLACEBO_COMPARATOR|Written information|Group of participants to whom the information is given through the writing that is available on the website of the health organization.
62851961|NCT05726188||Stage I colon cancer|Patients aged 18 years or above with pT1 or pT2 N0 colon cancer (up to the recto-sigmoid junction) who underwent curative resection between January 2010 and December 2019
62267137|NCT04599556|EXPERIMENTAL|T-NHL|
62267138|NCT04599556|EXPERIMENTAL|AML|
62626172|NCT05603572|EXPERIMENTAL|Oral experimental arm|Oral administration (KAT-101) taken once per day for 4 consecutive days out of 7 (4 days on / 3 days off weekly). Each cycle is 28 days. Treatment will continue for up to 12 cycles until progressive disease (PD), unacceptable toxicity, or any reason for discontinuing its administration, whichever occurs first.
62851962|NCT00336856|EXPERIMENTAL|IRINOTECAN AND CETUXIMAB|Cetuximab will be administered at the dose of 500 mg/m2 intravenously (IV) over 120 minutes, followed by 500 mg/m2 every 2 weeks, IV over 2 hours at an infusion rate not to exceed 5 ml/min. Followed immediately by Irinotecan administered at a dose of 180 mg/m2 IV over 60 minutes every two weeks.
62626173|NCT05603572|EXPERIMENTAL|IT experimental arm|IT administration (KAT-201) will be injected via percutaneous IT injection with ultrasound and/or computed tomography (CT) guidance once a week (on Day 1 weekly). Each cycle is 28 days. Treatment will continue for up to 2 cycles until PD, unacceptable toxicity, or any reason for discontinuing its administration, whichever occurs first.
62626174|NCT05603572|EXPERIMENTAL|Oral + IT experimental arm|Once optimal oral and IT dose are determined, oral + IT will be administered as follows: oral administration (KAT-101) will be taken once per day for 4 consecutive days out of 7 (4 days on / 3 days off weekly). Treatment will continue for up to 12 cycles (each cycle 28 days). IT administration (KAT-201) will be injected via percutaneous IT injection with ultrasound and/or CT guidance once a week (on Day 1 weekly). Treatment will continue for up to 2 cycles (each cycle 28 days) until PD, unacceptable toxicity, or any reason for discontinuing its administration, whichever occurs first.
62626175|NCT00635934|EXPERIMENTAL|A-MAV™disc|
62062734|NCT02178410|ACTIVE_COMPARATOR|Vitamin D + fish oil|
62062735|NCT02178410|ACTIVE_COMPARATOR|Vitamin D + fish oil placebo|
62062736|NCT02178410|ACTIVE_COMPARATOR|Vitamin D placebo + fish oil|
62062737|NCT02178410|PLACEBO_COMPARATOR|Vitamin D placebo + fish oil placebo|
62062738|NCT04138342|ACTIVE_COMPARATOR|Quantum dots nanoparticles group|A group of female volunteers infected with breast cancer will receive topical Quantum dots in different dosage forms.
62267139|NCT03785990||preterms with enterostomy|GA 23±0/7 - 31±6/7 with clinically indicated operations because of NEC (necrotising enterocolitis) or FIP (focal intestinal perforation). Operation after birth (within 14 days) and at term (enterostomy closure) Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)
62267140|NCT03785990||preterms without enterostomy|"GA 23±0/7 bis 31±6/7 with a clinically indicated operation (e.g. herniotomy) at term, without any abdominal problems.~Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)"
62267141|NCT03785990||term infants|"GA ≥34±0/7 with a clinically indicated operation directly after birth (within 14 days) (e.g. gastroschisis).~Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)"
62851963|NCT06420609|EXPERIMENTAL|Go-TAD|the participants will receive a medical visit that will include the 4 open-ended questions comprising the Go-TAD intervention
62851964|NCT06420609|NO_INTERVENTION|CONTROL|the participants will receive a medical visit that will include the 4 open-ended questions comprising hobbies and other personal themes, but not death.
62851965|NCT03571698|NO_INTERVENTION|Exercise programme only|The treatment group received only exercise programme. The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
62851966|NCT03571698|ACTIVE_COMPARATOR|Exercise with NMES standard electrodes|The treatment group received exercise programme with simultaneously active contraction with NMES with standard electrodes.The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
62851967|NCT03571698|ACTIVE_COMPARATOR|Exercise with NMES large electrodes|The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
62851968|NCT04135586|EXPERIMENTAL|Exercise|The patients in this arm will follow an exercise program for 24 weeks (i.e., during neo-adjuvant treatment), with two sessions per week including both aerobic and resistance training. Exercise intensity will range between 65% and 100% of the maximum score in the scale of Rated Perceived Exertion (RPE).
62851969|NCT04135586|OTHER|Control|The patients follow their usual habits as well as a Yoga program. They will also receive educational sessions on the benefits of regular physical activity (brisk walking).
62851970|NCT05453149|EXPERIMENTAL|Persons with Neurological Conditions|
62267142|NCT05883891||severe alcoholic hepatitis|Patients admitted with a clinical diagnosis of severe alcoholic hepatitis eligible to corticosteroid treatment. Prothrombin time at diagnosis was registered to evaluate wether it correlated with Lille score at day 7 and therefore response to standard medical treatment.
62267143|NCT02559440|ACTIVE_COMPARATOR|mometasone furoate|In the first treatment stage, 120 children were assigned to mometasone furoate (50μg, 1 puff in each nostril every evening) after two week's run-in period.
62267144|NCT02559440|PLACEBO_COMPARATOR|Placebo|In the first treatment stage, 120 children were assigned to control group (normal saline) after two week's run-in period.
62267145|NCT02559440|ACTIVE_COMPARATOR|Oxymetazoline + Placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving Oxymetazoline and placebo.
62450548|NCT01711021|PLACEBO_COMPARATOR|Placebo patch|"The study was conducted in 2 parts: a 5-week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Subjects who reached the optimal dose by end of dose optimization treatment period were randomized to receive double-blind treatment.~Participants first received placebo patches everyday for one week, then subjects were crossed-over to receive the study treatment.~Placebo patch: Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied."
62851971|NCT02482818|PLACEBO_COMPARATOR|Control-Placebo|"Administration of Placebo (Lactose instead of Pregabalin) pills in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial.~Initially an increasing dosage of placebo (Lactose) will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days).~Eight days after initial placebo administration, following an assessment by the Doctor of how well subjects are doing on their (drug or placebo), the study placebo will be increased to 100 mg twice a day.~Twenty eight days after initial placebo administration subjects will begin to receive the study placebo in a reducing dose regimen for 7 days then follow up at day 42."
62450549|NCT05174611|EXPERIMENTAL|Treatment group|Subject in treatment group will receive one capsule of 2000IU Vitamin D3 supplement per day with the duration of 16 weeks.
62267146|NCT02559440|PLACEBO_COMPARATOR|Placebo + placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving placebo and placebo.
62267147|NCT02559440|ACTIVE_COMPARATOR|mometasone furoate + Placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving mometasone furoate and placebo.
62267148|NCT02559440|ACTIVE_COMPARATOR|mometasone furoate + Oxymetazoline|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving mometasone furoate and Oxymetazoline.
62450550|NCT05174611|PLACEBO_COMPARATOR|Placebo group|Subject in placebo group will receive one capsule of placebo per day which looks exactly same as the Vitamin D3 capsule with the duration of 16 weeks.
62450551|NCT02744183|ACTIVE_COMPARATOR|Control Group|Maintain habitual habits
62450552|NCT02744183|ACTIVE_COMPARATOR|Fed Exercise|6 weeks of moderate intensity exercise with breakfast consumption
62267149|NCT01632462|ACTIVE_COMPARATOR|VSL#3 arm|15 patients with a diagnosis of Crohn's disease will be exposed to VSL#3 for 8 weeks
62450553|NCT02744183|EXPERIMENTAL|Fasted Exercise|6 weeks of moderate intensity exercise with breakfast omission
62450554|NCT00002583|NO_INTERVENTION|Observation|Observation only
62450555|NCT00002583|ACTIVE_COMPARATOR|Chemotherapy|Cisplatin and Vinorelbine
62062739|NCT04138342|PLACEBO_COMPARATOR|Topical approved placebo cream|A group of female volunteers infected with breast cancer will receive placebo cream as a negative control.
62062740|NCT01872910|PLACEBO_COMPARATOR|Placebo|"Part A: Single oral administration of placebo matching corresponding LY3023703 dose administered orally once as a capsule post dental surgery.~Part B: Single oral administration of placebo matching corresponding LY3023703 administered orally once as a capsule, post dental surgery and post dialysate probe placement.~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
62062741|NCT01872910|EXPERIMENTAL|30 milligrams (mg) LY3023703|"Part A: Single oral administration of 30 milligrams (mg) LY3023703 administered orally once as a 30-milligrams (mg) capsule post dental surgery.~Part B: Single oral administration of 30 milligrams (mg) LY3023703 administered orally once as a 30-mg capsule, post dental surgery and post dialysate probe placement.~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
62267150|NCT01632462|PLACEBO_COMPARATOR|placebo group|15 patients affected by Crohn's disease will be exposed to a placebo for 8 weeks
62267151|NCT02350270||cognitively healthy individuals (CHI)|CHI were participants without objective cognitive impairment
62267152|NCT02350270||mild cognitive impairment (MCI)|MCI was diagnosed if participants met the following criteria: presence of spontaneous cognitive complaints and objective cognitive impairment
62450556|NCT01016509|NO_INTERVENTION|control|No hyperglycemia patient group
62450557|NCT01016509|ACTIVE_COMPARATOR|Insulin 1|Conventional insulin treatment
62450558|NCT01016509|EXPERIMENTAL|Insulin|Intensive insulin treatment
62450559|NCT02113306|EXPERIMENTAL|t-VNS|"electrical stimulation of the concha of the ear~30sec trains of 0.25msec-duration monophasic square wave pulses at 25Hz, with a stimulation intensity not exceeding 0.5 mA"
62450560|NCT02113306|SHAM_COMPARATOR|sham t-VNS|"Sham stimulation of the earlobe will be conducted by positioning the electrode upside down~30sec trains of 0.25msec-duration monophasic square wave pulses at 25Hz, with a stimulation intensity not exceeding 0.5 mA"
62450561|NCT02207309|ACTIVE_COMPARATOR|Pazopanib|800mg, oral, 24 months
62450562|NCT02207309|PLACEBO_COMPARATOR|Placebo|800mg, oral, 24 months
62450563|NCT03965312|EXPERIMENTAL|Temperature monitoring (1) and incubator test (2) groups|"In the first (1) phase of the study, the temperature probe and monitor will be attached to infants along with the Philips Intellivue patient monitor. Temperature will be monitored continuously for up to 72 hours.~In the second (2) phase of this study, infants at risk for hypothermia and not eligible for skin-to-skin care will be placed in the incubator."
62450564|NCT04905264||Adults admitted in participating Rehabilitation Units for Severe Acquired Brain Injuries|Adults admitted in study's participants Rehabilitation Units for Severe Acquired Brain Injuries from the 1st of July 2021 to the 31st of December 2023. Patients entered into these units more than 14 weeks after the acute event are excluded
62450565|NCT06456307|NO_INTERVENTION|Control arm: Enhanced Standard of care|"Control facilities will provide enhanced standard of care. The enhanced standard of care will include two enhancements:~1. HIV Testing Services (HTS) providers and lay workers will conduct screening for perinatal mood and anxiety disorders (PMAD) using the PHQ-2 and GAD-2.~2. The study team will provide a PMAD referral information sheet to all control facilities describing inpatient and outpatient psychiatry services at the nearby referral hospitals"
62450566|NCT06456307|EXPERIMENTAL|Intervention arm: Integrated Perinatal Mental Health Program (IPMH)|"Intervention facilities will receive the Integrated Perinatal Mental Health Program (IPMH). This includes:~1. Systematic screening for PMAD symptoms using PHQ-2 and GAD-2. Positive screeners (PHQ-2≥3 and/or GAD-2≥3) will then be referred to nurses to administer additional screening by PHQ-9 and GAD-7~2. Non-specialist delivery of PM+ for participants with likely depression (PHQ-9≥10) or anxiety (GAD-7≥10) delivered weekly~3. In-facility tele-linkage to mental health specialist for participants with severe depressive symptoms (PHQ-9≥15), those who endorse suicidality, or non-responders to Problem Management+"
62450567|NCT01872143|EXPERIMENTAL|transcranial Direct Current Stimulation|daily or twice-a-day administration of transcranial Direct Current Stimulation
62450568|NCT05528458|EXPERIMENTAL|Osimertinib|Subjects should continue on study treatment until objective disease progression, or for three years since osimertinib administration. If progression of remaining GGN on serial CT scan, patients will receive proper treatment for progressed GGN.
62450569|NCT05528458|NO_INTERVENTION|Obsevation|Subjects with confirmation of pathologic stage IA NSCLC after surgery will be allocated to the control group.
62450570|NCT03820713|EXPERIMENTAL|Investigational arm|Treatment group receives a concentrate of coagulation factors. The device concentrates coagulation factors from donor plasma; the concentrate is applied to the surgical site intended to reduce the incidence, extent and severity of postoperative adhesions.
62450571|NCT03820713|PLACEBO_COMPARATOR|Control arm|Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.
62450572|NCT02238223||Patients without experience in treatment with epinastine|
62652893|NCT01697579|EXPERIMENTAL|Fosaprepitant 3 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 150 mg IV fosaprepitant. Participants 2 to \<12 years old were administered a weight-adjusted dose of 3 mg/kg (not to exceed 150 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children \<6 months of age), with or without dexamethasone.
62267153|NCT02350270||mild and moderate dementia|Diagnoses of dementia were assigned according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV TR, 2000; Association, 2000; 22) at consensus diagnostic case conferences
62652894|NCT01697579|EXPERIMENTAL|Fosaprepitant 1.2 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 60 mg IV fosaprepitant. Participants 2 to \<12 years old were administered a weight-adjusted dose of 1.2 mg/kg (not to exceed 60 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children \<6 months of age), with or without dexamethasone.
62851972|NCT02482818|EXPERIMENTAL|Pregabalin|"Administration of Pregabalin in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial.~Initially an increasing dosage of Pregabalin will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days).~Eight days after initial medication administration, following an assessment by the Doctor of how well subjects are doing on the medication, the study medication will be increased to 100 mg twice a day.~Twenty eight days after initial drug administration subjects will begin to receive the study medication in a reducing dose regimen for 7 days.~Forty two days after initial drug administration the Doctor will meet with subjects to follow up."
62851973|NCT03338413|EXPERIMENTAL|Goal Management Training|
62267154|NCT02715037||Acute tonsillitis|Patients referred to the tertiary care center with severe acute tonsillitis but without peritonsillar cellulitis, infectious mononucleosis, or abscess formation.
62267155|NCT02715037||Peritonsillar cellulitis|Patients referred to the tertiary care center with severe acute tonsillitis and peritonsillar cellulitis but without abscess formation.
62267156|NCT02715037||Infectious mononucleosis|Patients referred to the tertiary care center with acute tonsillitis and biochemical or serological signs of infectious mononucleosis but without abscess formation.
62267157|NCT02715037||Controls|Patients treated for conditions not related to the throat and without signs or symptoms of recent throat disease.
62267158|NCT05517941|EXPERIMENTAL|active cycle breathing exercise|patients will receive Active cycle of breathing techniques daily for 2 weeks
62267159|NCT05517941|EXPERIMENTAL|incentive spirometer|patients will receive incentive spirometer and active cycle breathing daily for 2 weeks
62267160|NCT00645957|ACTIVE_COMPARATOR|2|This group will have a red rubber drain(s) placed during surgery. This drain(s) will be irrigated intra and post-operatively
62652895|NCT01697579|EXPERIMENTAL|Fosaprepitant 0.4 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 20 mg IV fosaprepitant. Participants 2 to \<12 years old were administered a weight-adjusted dose of 0.4 mg/kg (not to exceed 20 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children \<6 months of age), with or without dexamethasone.
62851974|NCT03338413|EXPERIMENTAL|Computerized Cognitive Training|
62267161|NCT00645957|ACTIVE_COMPARATOR|1|This group will have a penrose drain(s) placed during surgery to facilitate drainage post-operatively. This drain (s) will not be irrigated.
62267162|NCT04503278|EXPERIMENTAL|Part 1 - CLDN6 CAR-T|Dose escalation in lymphodepleted patients until the MTD and/or RP2D.
62267163|NCT04503278|EXPERIMENTAL|Part 2 Vaccine-modulated - CLDN6 uRNA-LPX/CLDN6 modRNA-LPX|Dose escalation until the MTD and/or RP2D.
62267164|NCT00446602|EXPERIMENTAL|001|Epoetin alfa Type=exact unit=units number=80 000 form=solution for injection route=subcutaneous use once every week or once every 2 weeks.
62851975|NCT00006409|EXPERIMENTAL|School-based intervention|TAAG health education included six lessons in each of 7th and 8th grades designed to enhance behavioral skills known to influence physical activity. TAAG physical education classes promoted moderate-vigorous physical activity for at least 50% of class time and encouraged teachers to promote physical activity outside of class. In conjunction with community partners, programs that were promoted outside of school included Dance Dance Revolution, after-school step aerobics class, before-school open gym, basketball camp, touch football, and weekend canoe programs. TAAG promotions used a social marketing approach to promote awareness of and participation in activities through media and promotional events.
62851976|NCT00006409|NO_INTERVENTION|Control group|
62851977|NCT05236699|EXPERIMENTAL|DEB-TACE combined with Surufatinib and Camrelizumab|
62851978|NCT02801019|EXPERIMENTAL|E-XLPE|E-poly
62851979|NCT02801019|ACTIVE_COMPARATOR|C-XLPE|ArComXL
62851980|NCT06073483|EXPERIMENTAL|5G remote gastrectomy|
62267165|NCT00273104|ACTIVE_COMPARATOR|Bariatric surgery|Bariatric surgery (gastric bypass) offered to patients after informed consent and shared decision. The surgical procedure was performed at Vestfold Hospital Trust by experienced bariatric surgeons.
62267166|NCT00273104|ACTIVE_COMPARATOR|Intensive lifestyle intervention|Intensive lifestyle intervention (1-year endurance) at a rehabilitation centre. The intervention consisted of motivation for behaviour change including calorie restriction and increased physical activity.
62450573|NCT03812081|ACTIVE_COMPARATOR|Group A Baska Mask|In which Baska Mask Airway (size 3,4,5) will used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment. The Baska Mask is available in four sizes: size three (30 to 50 kg), size four (50 to 70 kg), size five (70 to 100 kg),The membranous cuff of the Baska Mask appears bulkier than the equivalent inflatable cuff on cuffed laryngeal masks. The mask can easily be decreased in size during insertion by compressing the proximal, firmer part of the mask below the airway tube, between the thumb and two fingers
62851981|NCT01643772|EXPERIMENTAL|Oxycodone Hydrochloride 5 mg Capsules|Group 1: single dose Oxycodone Hydrochloride 5 mg Capsules after 10 hours fasting
62851982|NCT01643772|EXPERIMENTAL|Oxycodone Hydrochloride 10 mg Capsules|Group 2: single dose Oxycodone Hydrochloride 10 mg Capsules after 10 hours fasting
62851983|NCT01643772|EXPERIMENTAL|Oxycodone Hydrochloride 20 mg Capsules|Group 3: single dose Oxycodone Hydrochloride 20 mg Capsules after 10 hours fasting
62851984|NCT01643772|EXPERIMENTAL|Oxycodone Hydrochloride 10 mg Capsules(multi-dose)|Group 4: multi-dose 4 times per day Oxycodone Hydrochloride 10mg Capsules for 3 days, and one dose on 4th day morning
62851985|NCT03998839||Intervention|Children tested will live within an area targeted for community IPTp distribution for pregnant women.
62851986|NCT03998839||Control|Children tested will live within an area NOT targeted for C-IPTp, but will live in an area nearby.
62851987|NCT05350696|ACTIVE_COMPARATOR|Erector Spinae Plane block group|(30 patients) will receive bilateral ultrasound guided erector spinae plane block using plain bupivacaine 100 mg diluted to volume using normal saline to achieve 50% concentration ( 50 mg plain pubivicaine in each side ).
62267167|NCT03655613|EXPERIMENTAL|Arm A: Hepatocellular Carcinoma|PD-1 inhibitor (APL-501) 3 mg/kg intravenously every 2 weeks + c-Met inhibitor (APL-101) 150 mg or 200 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
62450574|NCT03812081|ACTIVE_COMPARATOR|Group B Proseal Mask|In which Laryngeal Mask Airway- Proseal LMA (size 3,4,5) was used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment.
62450575|NCT02324998|EXPERIMENTAL|Group A|Olaparib Monotherapy
62450576|NCT02324998|EXPERIMENTAL|Group B|Olaparib in combination with degarelix
62851988|NCT05350696|ACTIVE_COMPARATOR|Intravenous Morphine group|(30 patients) will receive 0.1 mg /kg of intravenous morphine diluted to 10 ml volume using saline at the end of the operation.
62851989|NCT03381976|ACTIVE_COMPARATOR|Intervention 2X/week (G2X)|This group performed resistance training twice a week (Tuesdays and Thursdays)
62851990|NCT03381976|ACTIVE_COMPARATOR|Intervention 3X/week (G3X)|This group performed resistance training three sessions a week (Mondays, Wednesdays, and Fridays).
62851991|NCT03381976|NO_INTERVENTION|Control group (GC)|This group did not perform any type of organized physical exercise during the study period.
62851992|NCT02682862|EXPERIMENTAL|Spiolto Respimat|olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg 2 puffs OD (once daily) for 2-4 weeks. Participants then enter washout period and receive alternative treatment arm
62450577|NCT02631928|EXPERIMENTAL|Julphar Insulin 30/70|human biphasic insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/ kg body weight
62450578|NCT02631928|ACTIVE_COMPARATOR|Huminsulin® Profil III|human biphasic insulin, reference, 100 IU/mL, single subcutaneous injection of 0.6 IU/ kg body weight
62652896|NCT01697579|PLACEBO_COMPARATOR|Placebo Control-Cycle 1|Participants were administered IV normal saline at volume to match age and weight specific doses of fosaprepitant. Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children \<6 months of age), with or without dexamethasone.
62851993|NCT02682862|ACTIVE_COMPARATOR|Striverdi Respimat|olodaterol 2.5mcg 2 puffs OD (once daily) for 2-4 weeks. Participants then enter washout period and receive alternative treatment arm
62626176|NCT04653259|EXPERIMENTAL|Intervention Group|The INT group will meet with their health coach over the phone or video chat. The health coach will orient them to the LyfeMD, app and ensure the participant has received a nutrition plan in the app. They will be asked to complete the app assessment tools to design a personalized nutrition, physical activity and yoga and meditation program. They will set goals in each area they are interested in implementing. The health coach will then follow-up by phone, video or email 2 weeks after the initial meeting, then monthly with the patient for 2 more months (total of 4 meetings). The health coach will use the following schedule to discuss app related content: First visit nutrition content; second visit behaviour change tools; third visit Yoga, meditation and breathing plans, and; the fourth visit the physical activity plans. The health coach will also be available to answer questions when required using email. Goal attainment will be collected weekly within the app.
62626177|NCT04653259|NO_INTERVENTION|Conventional Management Group|The CM group (n=22) will receive conventional care as well as a similar health coaching schedule as the intervention group. The health coach will meet the patient over the phone or video chat to outline their role over the next 3 months and to provide general nutrition guidelines using Canada's Food Guide and Alberta Health Services online resources. The health coach will then follow-up by phone, video chat or email 2 weeks after the initial meeting, then monthly with the patient for 2 more months (total of 4 meetings). The health coach session topics will be the same as the intervention group. For example, the second visit will provide online resources from Alberta Health Services focused on promoting behaviour change, the third visit will orient the patient to Alberta Health Services focused online stress management tools and the final visit will share online versions of the Canadian guidelines for physical activity and sedentary time.
62088015|NCT03110679|EXPERIMENTAL|autologous bone marrow concentrate|concentration of bone marrow taken from the patient's right tibia using Bio-MAC® suction catheter, company Biologic Therapies, Inc., and concentrated by centrifuge Bio.SPINTM Magellan®, company Biologic Therapies , Inc., and its injection in the intra-articular.
62626178|NCT03438942|EXPERIMENTAL|Folic acid and iron supplementation|Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months
62626179|NCT03438942|ACTIVE_COMPARATOR|Control group|Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months
62626180|NCT00893074|OTHER|0, 30, 60, and 120mg dronabinol|0, 30, 60, and 120mf dronabinol was administered in a randomized within-subjects crossover study to compare the medication dose effects of cannabis withdrawal, cognitive performance, and response to acute cannabis dosing
62267168|NCT03655613|EXPERIMENTAL|Arm B: Renal Cell Carcinoma|PD-1 inhibitor (nivolumab) 3 mg/kg or 240 mg intravenously every 2 weeks + c-Met inhibitor (APL-101) 300 mg or 400 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
62626181|NCT02106741|EXPERIMENTAL|Relaxation acupressure|
62626182|NCT02106741|ACTIVE_COMPARATOR|Stimulating acupressure|
62851994|NCT05224167|ACTIVE_COMPARATOR|Group A|patients of this group will receive 5 mg of Melatonin 12 hours and 5 mg 2 hours prior to surgery
62851995|NCT05224167|ACTIVE_COMPARATOR|Group B|patients of this group will receive 1 mg/kg of Hydroxizin 12 hours and 1 mg/ kg 2 hours prior to surgery
62267169|NCT06067737|EXPERIMENTAL|High-dose psilocybin + buprenorphine|High-dose psilocybin (30 mg) session following standard-of-care outpatient buprenorphine induction
62851996|NCT03294564|ACTIVE_COMPARATOR|Typhoid Vi Polysaccharide Vaccine|Patients will receive one intramuscular 0.5 mL injection of Typhoid Vi Polysaccharide Vaccine containing 0.025 mg purified Vi polysaccharide.
62851997|NCT03294564|PLACEBO_COMPARATOR|Placebo|Patients will receive one intramuscular 0.5 mL injection of saline placebo.
62851998|NCT05032170||Locator Group|The participant has a mandibular overdenture supported by two implants with locator attachments. The implants are scanned with each of two intraoral scanners both with and without the use of artificial landmarks. The implant scans are analyzed in terms of scanning accuracy (trueness and precision) by comparison with a reference model (3D implant positions in the working cast of the immediately loaded overdenture).
62851999|NCT05032170||Bar Group|The participant has a mandibular overdenture supported by two implants with a dolder bar attachment. The implants are scanned with each of two intraoral scanners both with and without the use of artificial landmarks. The implant scans are analyzed in terms of scanning accuracy (trueness and precision) by comparison with a reference model (3D implant positions in the working cast of the immediately loaded overdenture).
62267170|NCT06067737|ACTIVE_COMPARATOR|Very low-dose psilocybin + buprenorphine|Very low dose psilocybin session (1 mg) following standard-of-care outpatient buprenorphine induction
62267171|NCT02868008|EXPERIMENTAL|fMRI guided AVM resection|fMRI guided microsurgical resection of brain AVMs
62626183|NCT02106741|NO_INTERVENTION|Wait-list control|
62626184|NCT02935257|EXPERIMENTAL|CD19CAT-41BBZ CAR T-cells|Treatment with the ATIMP: CD19CAT-41BBZ CAR T-cells
62852000|NCT02587377|OTHER|Cohort 1|single cohort of patient
62852001|NCT02468245|ACTIVE_COMPARATOR|Control Arm|"This is a usual care group. Patients in this arm will receive the standard pre-drug initiation training and 4 week clinic follow up visit."
62852002|NCT02468245|EXPERIMENTAL|Intervention arm|Patients in this arm will also receive the standard pre-drug initiation training followed by telephone follow up by an oncology certified chemotherapy nurse (OCN) at week one, two, and three. Patients will then have the standard 4 week follow up clinic visit.
62852003|NCT04900740|ACTIVE_COMPARATOR|Standard care - catheter fixation with surgical stitch|In patients indicated for this type of treatment, as per the attending physician, the catheter will be fixed in the standard way, using a surgical stitch.
62088016|NCT03110679|EXPERIMENTAL|hyaluronic acid.|single injection of intra-articular hyaluronic acid 60mg (4 cc), and serve as a control.
62088017|NCT02790762|EXPERIMENTAL|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
62088018|NCT06312631|EXPERIMENTAL|Task handover model #1|"At each visit, the patient will perform the tasks with the gripping glove (A) or without the gripping glove (B).~The order of administration with then without the glove (AB) or without then with the glove (BA) is drawn at random for each patient.~The 1st model follows the following diagram:~Visit T1 = AB; Visit T2 = AB; Visit T3 = AB"
62852004|NCT04900740|EXPERIMENTAL|Experimental - catheter fixation with glue|In patients indicated for this type of treatment, as per the attending physician, the catheter will be fixed using the glue.
62626185|NCT03836534||patient coming to the emergency department|the group studied only concern adult adults consulting in the emergency departments and leaving after their consultations, during the permanence of care
62626186|NCT03565705||Spinal anesthesia with propofol sedation|Patients receive spinal anesthesia for analgesia to undergo open abdominal prostatectomy. Ventilation is secured via a laryngeal mask under propofol sedation and no muscular blocking is necessary.
62852005|NCT03554343||All newborn from Southern Belgium|All newborns except newborns for which parents refuse newborn screening will be tested for exon 7 deletion in survival motor neuron 1 (SMN1)
62852006|NCT06190769||Observation study - cross-sectional survey.|"sample size of monks will be 400 subjects of both genders (monks and nuns) randomly selected from different monasteries, Participants aged from 24 years old and above thought monastic years. As:~* (1-3) years novice or probationary~* (4-10) years of monasticism~* more than 10 years of monasticism"
62852007|NCT01318824|PLACEBO_COMPARATOR|I=NIPPV|This group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment.
62088019|NCT06312631|EXPERIMENTAL|Task handover model #2|"At each visit, the patient will perform the tasks with the gripping glove (A) or without the gripping glove (B).~The order of administration with then without the glove (AB) or without then with the glove (BA) is drawn at random for each patient.~The 2nd model follows the following diagram:~Visit T1 = BA ; Visit T2 = AB ; Visit T3 = AB"
62267172|NCT05106309|EXPERIMENTAL|Part A: Single doses of CVL-231 IR/MR formulations in healthy participants under fasted conditions|Oral Dose
62267173|NCT05106309|EXPERIMENTAL|Part B: Single doses of CVL-231 target release formulation under fasted and fed conditions|Oral Dose
62626187|NCT03565705||General anesthesia|General anesthesia is conducted with a combination of intravenous opioid (sufentanil) and neuromuscular blocking agent for open abdominal prostatectomy. Patients receive an induction bolus of propofol, undergo tracheal intubation and maintenance of sedation by sevoflurane.
62852008|NCT01318824|EXPERIMENTAL|II=BiPAP|This group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
62852009|NCT03930264|ACTIVE_COMPARATOR|Imurek®,|Generic name : Azathioprine Trade name : Imurek® 50mg tablet Dosage form : Tablet containing 50 mg azathioprine Dose : 1 x Imurek 50mg Tablet per treatment period under fasting conditions Mode of administration : Orally Manufacturer : Aspen Pharma Trading Limited, Dublin, Ireland Country of origin : Ireland
62852010|NCT03930264|EXPERIMENTAL|Jayempi™|"Generic name : Azathioprine~Trade name : (Jayempi™) 10 mg/ mL Oral solution Dosage form : Oral suspension containing 10 mg/mL Azathioprine Dose : 1 x 5mL (50 mg) of Jayempi™ Oral Suspension 10mg/mL per treatment period under fasting conditions Mode of administration : Orally Manufacturer : Nova Laboratories Ltd. Country of origin : Leicester, UK"
62626188|NCT04656301|EXPERIMENTAL|Psilocybin|A single dose of Psilocybin 25mg p.o.
62626189|NCT04727736|EXPERIMENTAL|18F-DCFPyL + PET imaging|"Participants will receive a single dose of 18F-DCFPyL and undergo a PET imaging study.~(The PET imaging may be repeated at a later date if the biopsy of the lesion is negative and if the lesion is present on follow-up imaging.)"
62852011|NCT01795170||Test Group|Patients receiving a lysine restricted diet adjunct to pyridoxine therapy will be considered as participants in the 'exposure'/test group
62852012|NCT01795170||Control Group|Patients on pyridoxine mono-therapy will be participants in the 'control' group
62852013|NCT06057961|EXPERIMENTAL|Experimental|"Personal Information Form, Difficulties in Emotion Regulation Scale-Brief Form (DERS-16), Coopersmith Self-Esteem Scale, Beck Hopelessness Scale will be applied to the intervention group as part of the pre-test application. In the research, art therapy will be applied face to face to the participants in the intervention group, in groups of 4-12 people, in the group guide room, on a common day and time determined by the group members and the researchers.The art therapy to be applied to the participants in the intervention group in the study consists of eight sessions.Each session is planned to last approximately 60-90 minutes."
62852014|NCT06057961|NO_INTERVENTION|Control|"Individuals who meet the inclusion criteria and agree to participate in the research will be informed about the research and their verbal and written consent will be obtained. Interviews will be held to implement the pre-tests (Personal Information Form, Emotion Regulation Difficulties Scale-Short Form (DERS-16), Coopersmith Self-Esteem Scale, Beck Hopelessness Scale). A session will be held to implement the post-tests and to implement the Awareness of Emotions themed session with the intervention group to the control group."
62267174|NCT06166186|ACTIVE_COMPARATOR|Music Group|Music will be delivered via headphones intraoperatively. Blood samples will be collected as per the protocol.
62626190|NCT03562858|ACTIVE_COMPARATOR|Delayed dentine sealing|
62267175|NCT06166186|ACTIVE_COMPARATOR|Control Group|Headphones will be applied but no music will be played intraoperatively. Blood samples will be collected as per the protocol.
62267176|NCT05595083|EXPERIMENTAL|intranasal dexmedetomidine group|patients will receive 1.5 ug/kg intranasal dexmedetomidine diluted with saline + infusion saline
62267177|NCT05595083|EXPERIMENTAL|intravenous dexmedetomidine group|patients will receive 0.1- 0.4 ug/kg intravenous infusion dexmedetomidine + intranasal saline.
62626191|NCT03562858|EXPERIMENTAL|Immediate dentin sealing|
62626192|NCT00552214|OTHER|Human Blood Donor Plasma Specimens|
62626193|NCT02233621|EXPERIMENTAL|PET with [18F]-FES|PET with \[18F\]-FES compared to histological analysis performed at least on one biopsy done during coelioscopy.
62626194|NCT03872843|ACTIVE_COMPARATOR|Opioid Group|This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Norco 5milligram-325milligram Tablet for postoperative pain after ureteroscopy with stent placement.
62626195|NCT03872843|ACTIVE_COMPARATOR|Non-Opioid Group|This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Ibuprofen 400 milligram for postoperative pain after ureteroscopy with stent placement.
62626196|NCT04158505||non-interventional study|
62626197|NCT01135524|EXPERIMENTAL|BTDS|Buprenorphine transdermal patch
62626198|NCT01579669|EXPERIMENTAL|Use of Toolkit|All participants will have access to the toolkit
62267178|NCT01981590|EXPERIMENTAL|All enrolled patients|All enrolled patients that underwent a scheduled cardiac catheterization involving an atrial fibrillation (AF) ablation procedure as per clinical practice
62626199|NCT04306393|EXPERIMENTAL|Treatment Group|Inhaled Nitric Oxide until PaO2/FiO2 \>/= 300 mmHg
62626200|NCT04306393|NO_INTERVENTION|Control Group|
62626201|NCT04020978|OTHER|Patients with GUC|Each patient with GUC will first undergo an X-ray CT scan for attenuation correction purpose. After that, 10 mCi 18F-Fludeoxyglucose (18F-FDG) will be injected into the patient through the IV in a period of 10 seconds. The PET scan commences 10 seconds before the FDG injection and lasts for 60 minutes. After the PET scan, the patient gets off the scanner. One blood sample (10cc) will be drawn using a butterfly method with the time recorded.
62626202|NCT00204061|PLACEBO_COMPARATOR|supportive management|needs-focused, unspecific supportive management
62852015|NCT02028208|EXPERIMENTAL|Ammoniated mercury|Subjects will be patch tested with 4 experimental doses of ammoniated mercury, 0.013 mg/cm², 0.040 mg/cm², 0.12 mg/cm², and 0.36 mg/cm², a negative control and corresponding reference allergens, 1.0% ammoniated mercury in petrolatum and 0.5% elemental mercury in petrolatum. Patch tests will be worn for 48 hours.
62852016|NCT02028208|EXPERIMENTAL|Aluminum chloride and aluminum lactate|Subjects will be patch tested with 4 experimental doses of aluminum chloride, 0.040 mg/cm², 0.12 mg/cm², 0.36 mg/cm² and 0.72 mg/cm², 4 experimental doses of aluminum lactate 0.047 mg/cm², 0.14 mg/cm², 0.42 mg/cm² and 0.84 mg/cm², a negative control and corresponding reference allergens, 2.0% aluminum chloride in petrolatum and 12.0% aluminum lactate in petrolatum. Patch tests will be worn for 48 hours.
62852017|NCT02028208|EXPERIMENTAL|Sodium tetrachloropalladaate (Palladium)|Subjects will be patch tested with 5 experimental doses of sodium tetrachloropalladate 0.011 mg/cm², 0.033 mg/cm², 0.10 mg/cm², 0.30 mg/cm² and 0.60 mg/cm², a negative control and corresponding reference allergens, 3.0% sodium tetrachloropalladate in petrolatum and 1.0% palladium chloride 1.0% in petrolatum. Patch tests will be worn for 48 hours.
62267179|NCT05261022|EXPERIMENTAL|Love Together, Parent Together Intervention|"Participants will take part in a 3-session writing intervention over the course of 12-week. They will complete a fact-based summary of a recent conflict and answer questions on conflict/conflict-related distress. Next, they will be asked to complete a 9-minute writing task where they reappraise the conflict they previously reported. First, they will watch an instructional video of how to engage in the writing task, by providing definitions and examples of potentially useful conflict reappraisal strategies. Writing prompts include: ... Think about this disagreement ... from the perspective of a neutral third party who wants the best for all involved...; ...what obstacles do you face in trying to take this perspective...?;... How might you be most successful in taking this perspective ... over the next 2 weeks? Participants in the intervention group will receive emails to prompt use of the reappraisal strategy between writing sessions."
62450579|NCT02270879||Main group|Patients having performed bilateral consecutive cataract surgery between 1st October 2012 and 24th April 2014 in a single ophthalmological center (Centro Hospitalar Baixo Vouga, Portugal).
62626203|NCT00204061|EXPERIMENTAL|amisulpride|24 months amisulpride 50 to 800 mg, needs-focused, unspecific supportive management.
62852018|NCT00344487|EXPERIMENTAL|lopinavir/ritonavir (Kaletra)|lopinavir/ritonavir (Kaletra)400/100mg tablets by mouth twice a day for 48 weeks.
62450580|NCT06015048|EXPERIMENTAL|Part A: Intervention: Drug: SHR-A1811 combined with Pyrotinib|
62450581|NCT06015048|EXPERIMENTAL|Part B1: Intervention: Drug: SHR-A1811 combined with other antitumor therapies|
62450582|NCT05803915|EXPERIMENTAL|Neoadjuvant Toripalimab plus Nimotuzumab|The participants will receive 2 doses of neoadjuvant Toripalimab plus Nimotuzumab, then the participants will take a radical surgery or radiotherapy according to the efficacy assessed by investigator per RECIST1.1
62450583|NCT01290263|EXPERIMENTAL|Amgen 386|Cohort A will assess recurrent Glioblastoma Multiforme (GBM) patients who receive AMG 386 monotherapy at 30mg/kg every week. As of August 1, 2013, Cohort A was closed to new accrual following early interim analysis of first 10 participants enrolled on study. None of these patients had achieved stable disease or response at their initial evaluation after 1-2 months of study therapy. Therefore, study investigators and sponsor agreed that the level of single-agent anti-tumor activity associated with AMG386 for recurrent glioblastoma patients is most likely insufficient to satisfy the stopping rule for low efficacy outlined in Section 14.5 for Cohort A.
62450584|NCT01290263|EXPERIMENTAL|Amgen 386 and Bevacizumab|Cohort B will assess recurrent Glioblastoma Multiforme(GBM) patients who receive AMG 386 plus bevacizumab. Because the maximum tolerated dose of this combination therapy has not yet been established, a 3x3 Phase I study was used to determine the maximum tolerated dose. As of June 6, 2014, the MTD was determined to be AMG386 30 mg/kg administered intravenously every week(dose level +1) in combination with bevacizumab at 10mg/kg administered intravenously every other week. As of July 25, 2014 the Cohort B, Phase II portion of the study was opened to accrual.
62450585|NCT01595503|EXPERIMENTAL|fMRI-based targeting|
62450586|NCT01595503|ACTIVE_COMPARATOR|landmark-based targeting|
62450587|NCT00992407|EXPERIMENTAL|Risperidone long acting injectables|
62626204|NCT06294119|OTHER|Cardiac surgery|An experimental setup will be devised for the simultaneous monitoring and recording of EEG, ECG, AP, and R together with CBF in patients scheduled for major cardiac surgery. Recording sessions will take place 1 day before (PRE) and within 7 days after (POST) surgery. The experimental protocol including physiological data recordings includes three sessions lasting 10 minutes each: a session at resting state in supine position, a session during autonomic challenge obtained via active standing evoking reflex sympathetic activation, and a session of emotional elicitation via the administration of videos. The overall duration of the experiment is therefore 30 minutes in PRE and POST. A total of 40 short video clips of the duration of 15 seconds each will be presented to a total of 80 voluteers will be recruited for the MANCAVA study.
62626205|NCT01535469|EXPERIMENTAL|CrAg Screening and Fluconazole|Cryptococcal Antigen (CrAg) Screening with preemptive antifungal treatment per World Health Organization (WHO) guidelines. Randomized Stepped Wedge design of phased implementation.
62626206|NCT02287688||Exposure group|Subjects aged 2-23 months who received at least one dose of the MenACWY-CRM vaccine at a Kaiser Permanente Southern California (KPSC) facility while enrolled as a KPSC health plan member.
62626207|NCT03144791||elderly , young adults|Participants are in 9 light conditions, 5 minute for each condition.
62626208|NCT04900649|EXPERIMENTAL|study group|the study group has conducted chest resisted exercise combined with chest expansion exercise in addition to a usual chest physiotherapy. For chest resistance exercise, the children in the study group underwent sequential 12-week chest resistance exercise and chest expansion exercise, three sessions a week. Chest resistance exercises have been consisted of manual resistance exercise and resistance exercise via POWER breath KH2.
62626209|NCT04900649|EXPERIMENTAL|control group|12-week usual chest physiotherapy in form of bilateral vibration and gentle percussion for 3-5 minutes with distal finger phalanges to the upper apical lobes in modified drainage positions, placing the patient in a side-lying position or a prone position to increase oxygenation, at least 2-3 times a week
62852019|NCT02373085|EXPERIMENTAL|A: Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria beyond 2 months after transplantation and during the first 2 years after transplantation
62852020|NCT02373085|NO_INTERVENTION|B: no treatment|No treatment of any episode of asymptomatic bacteriuria beyond 2 months after transplantation in kidney transplant recipients.
62852021|NCT03329014|EXPERIMENTAL|Intravenous Remimazolam|4 mg intravenous remimazolam as an intravenous control
62852022|NCT03329014|EXPERIMENTAL|10 mg Powder Remimazolam|Powder containing 10 mg remimazolam for intranasal administration
62852023|NCT03329014|EXPERIMENTAL|10 mg Solution Remimazolam|Solution containing 10 mg remimazolam for intranasal administration
62852024|NCT03329014|EXPERIMENTAL|20 mg Powder Remimazolam|Powder containing 20 mg remimazolam for intranasal administration
62852025|NCT03329014|EXPERIMENTAL|20 mg solution Remimazolam|Solution containing 20 mg remimazolam for intranasal administration
62852026|NCT03329014|EXPERIMENTAL|40 mg Powder Remimazolam|Powder containing 40 mg remimazolam for intranasal administration
62852027|NCT03329014|EXPERIMENTAL|40 mg Solution Remimazolam|Solution containing 40 mg remimazolam for intranasal administration
62852028|NCT03329014|PLACEBO_COMPARATOR|Placebo Powder|Powder containing 20 mg placebo for intranasal administration
62852029|NCT03329014|PLACEBO_COMPARATOR|Placebo solution|Solution containing 20 mg placebo for intranasal administration
62852030|NCT03141294|PLACEBO_COMPARATOR|sd-PDT group|The investigators applied the traditional standard dilation technique when operating tracheostomy on the standard group.
62852031|NCT03141294|EXPERIMENTAL|re-PDT group|The investigators applied the reformative dilation technique when operating tracheostomy on the re-PDT group.
62852032|NCT01475240||Group 1: Controls|HIV-infected patients on stable \> 6 months on TDF/FTC or ABC/3TC plus PI/r based ARV regimen with normal bilirubin
62852033|NCT01475240||Group 2: Cases|HIV-infected patients on stable \>6 months on TDF/FTC or ABC/3TC plus PI/r based ARV regimen with HBR (\>2.5 X upper limit)
62852034|NCT00531427|EXPERIMENTAL|1|Buprenorphine transdermal system 10 and 20 applied for 7-day wear
62852035|NCT00531427|PLACEBO_COMPARATOR|2|Placebo transdermal system to match BTDS patches, applied for 7-day wear
62852036|NCT05176171|EXPERIMENTAL|Photorefractive Keratectomy with Corneal Cross-Linking|For correction of refractive error
62450588|NCT00992407|ACTIVE_COMPARATOR|Risperidone tablets|
62450589|NCT01066052|EXPERIMENTAL|r-hGH|Participants (girls) will receive r-hGH as a subcutaneous injection administered by a parent in the evening. During Years 1-2, the dose of r-hGH received will depend on participants' baseline height standard deviation score (SDS) relative to the general population standard: participants with a height SDS of -2 standard deviation (SD) or lower will receive 0.05 milligrams per kilogram (mg/kg) per day r-hGH and those with a height SDS between -1 and -2 SD will receive 0.035 mg/kg per day r-hGH. After 2 years of treatment, all participants will receive a fixed dose of 0.05 mg/kg per day for a further 2 years.
62450590|NCT01066052|NO_INTERVENTION|Historical Control|This arm will include matching (age and height) historical control participants (girls) with turner syndrome, who were born between 1961 and 1990 and were untreated.
62450591|NCT03199157|ACTIVE_COMPARATOR|Fentanyl Group|Patients received the fentanyl 12 mcg transdermal patch (FG, n=38) 8 hours preoperatively and until 24 hours after the surgery
62450592|NCT03199157|NO_INTERVENTION|Control group|
62450593|NCT01530815|EXPERIMENTAL|Bupivicaine Infusion|We will infuse bupivicaine between the abdominal wall and mesh to try and reduce postoperative pain
62450594|NCT02370407|EXPERIMENTAL|Laparoscopic simulator|20 study participants will be randomized to perform peg transfer task on a laparoscopic simulator 10 times (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA).
62450595|NCT02370407|EXPERIMENTAL|Mimic da Vinci robotic simulator|20 study participants will be randomized to perform peg board 1 exercise 10 times on a Mimic da Vinci robotic simulator (Mimic da Vinci Simulator, Intuitive Surgical, Sunnyvale, CA).
62450596|NCT01373775||Revisit|HF patients who revisit the emergency department before the next appointment date.
62450597|NCT01373775||Non-revisit|HF patients who follow up on the appointment date.
62450598|NCT06412133|EXPERIMENTAL|intervention group|photography therapy
62450599|NCT00482547|EXPERIMENTAL|Silver-coated catheter|Bard Hydrogel Silver Salts Coated Latex Urinary Catheter System
62852037|NCT03550521|EXPERIMENTAL|Mindfulness condition|The brief mindfulness induction will be modeled after basic mindfulness skills commonly used in mindfulness-based interventions and tailored to target distressing thoughts and feelings.
62852038|NCT03550521|NO_INTERVENTION|Control condition|"Participants assigned to the control task will be instructed to let your mind wander freely without trying to focus on anything in particular."
62852039|NCT01814709|EXPERIMENTAL|Itraconazole Arm|
62088020|NCT06312631|EXPERIMENTAL|Task handover model #3|"At each visit, the patient will perform the tasks with the gripping glove (A) or without the gripping glove (B).~The order of administration with then without the glove (AB) or without then with the glove (BA) is drawn at random for each patient.~The 3rd model follows the following diagram:~Visit T1 = AB ; Visit T2 = BA ; Visit T3 = AB"
62450600|NCT00482547|PLACEBO_COMPARATOR|Silicone-coated catheter|Bard silicone elastomer coated latex catheter system
62450601|NCT05295758|EXPERIMENTAL|PAL2 Intervention|Overall study cohort will be enrolled into non-randomized active treatment
62450602|NCT05966064|ACTIVE_COMPARATOR|Denosumab|Denosumab randomized at baseline and 3 months in a double-blinded fashion and in case of open label at 6 and 9 months
62450603|NCT05966064|PLACEBO_COMPARATOR|Placebo|Placebo randomized at baseline and 3 months in a double-blinded fashion.
62450604|NCT00719290|ACTIVE_COMPARATOR|1|Phacoemulsification with intraocular lens implant alone
62450605|NCT00719290|ACTIVE_COMPARATOR|2|Phacoemulsification with intraocular lens implant and goniosynechialysis
62450606|NCT03643666|PLACEBO_COMPARATOR|control group|this group will include 25 patients receiving intraperitoneal 40 ml of normal saline only at the end of laparoscopic cholecystectomy
62852040|NCT01814709|EXPERIMENTAL|Rifampin Arm|
62852041|NCT03089385|EXPERIMENTAL|Implementation group|This group will have the hypertension tool implemented on them.
62852042|NCT03089385|NO_INTERVENTION|Control group|This group will not have the tool implemented.
62088021|NCT06312631|EXPERIMENTAL|Task handover model #4|"At each visit, the patient will perform the tasks with the gripping glove (A) or without the gripping glove (B).~The order of administration with then without the glove (AB) or without then with the glove (BA) is drawn at random for each patient.~The 4th model follows the following diagram:~Visit T1 = AB ; Visit T2 = AB ; Visit T3 = BA"
62450607|NCT03643666|ACTIVE_COMPARATOR|dexamethasone group|this group will include 25 patients receiving intraperitoneal 16 mg dexamethasone in 40 ml saline at the end of laparoscopic cholecystectomy
62450608|NCT03643666|ACTIVE_COMPARATOR|dexamethasone plus magnesium sulphate group|this group will include 25 patients receiving intraperitoneal 16 mg dexamethasone plus 2 gm magnesium sulphate at the end of laparoscopic cholecystectomy
62450609|NCT02326077||Intervention group|"Clinical evaluation in active labor: Leopold manoeuvres, vaginal digital examination.~Transabdominal and transperineal ultrasound evaluations of the mechanism of labor: fetal head position, progression and rotation.~Investigation by questionnaire regarding the psychological impact of labor monitoring assisted by sonoraphy."
62450610|NCT01760603|EXPERIMENTAL|ISFF|The patients performed ischia spinous fascia fixation surgery.
62450611|NCT00843609|EXPERIMENTAL|Continuous glucose monitoring|Continuously wearing the FreeStyle Navigator continuous glucose monitor, displaying real-time glucose values and sounding alarms
62450612|NCT00843609|NO_INTERVENTION|Control|Using SMBG with standard routine instructions
62450613|NCT05485675|ACTIVE_COMPARATOR|Stand & Move at Work|Given an evidence-based workplace program to reduce sedentary behavior and increase standing and moving using a web-based platform. The web platform has a toolkit with strategies and guides for the worksite Champions to address changes at the environmental, social, and cultural levels.
62450614|NCT05485675|EXPERIMENTAL|Stand & Move at Work+|This arm will receive access to the same web-based platform and toolkit as the other arm. Additionally, worksites in this arm will be assigned and expert facilitator who will meet regularly with the worksite Champions to assist with implementation.
62450615|NCT03879356|OTHER|Aluminum phosphide patients|effect of N-acetyl cysteine and supportive measures in outcome of aluminum phosphide poisoning cases
62450616|NCT06074471|EXPERIMENTAL|MS-SCBPB Group (n=22)|"receive ultrasound-guided supraclavicular brachial plexus block with total volume 20 mL bupivacaine (concentration 0.20%) 9 ml Bupivacaine+9ml lignocaine +2ml Dexamethasone 8mg "
62450617|NCT06074471|ACTIVE_COMPARATOR|SCBPB Group (n=22):|"receive ultrasound-guided supraclavicular brachial plexus block with total volume 20 mL bupivacaine (concentration 0.5%) 18 ml Bupivacaine+2ml Dexamethasone 8mg"
62626210|NCT06612047||Patients with clinical suspicion of prostate cancer undergo 5.0T and 3.0T bpMRI|All enrolled patients need to undergo 5.0TbpMRI and 3.0TbpMRI (within one month). The magnetic resonance imaging sequences mainly include T1WI, multi-plane T2WI and multi-b-value DWI images.
62626211|NCT04736719||Warfarin|Reference group
62626212|NCT04736719||Apixaban|Exposure group
62852043|NCT01685151|EXPERIMENTAL|Ramelteon SL (Dose 1)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 12 months.
62852044|NCT01685151|EXPERIMENTAL|Ramelteon SL (Dose 2)|Ramelteon SL tablets, sublingual, once daily, at nigh time for up to 12 months
62450618|NCT05387265|EXPERIMENTAL|CX-904|
62450619|NCT01569152|EXPERIMENTAL|Base Study Phase IIa: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
62450620|NCT01569152|PLACEBO_COMPARATOR|Base Study Phase IIa: Placebo|Participants received placebo dosed BID orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
62450621|NCT01569152|EXPERIMENTAL|Safety Extension Period 3: MK-8457|Participants received MK-8457 100 mg BID orally with MTX at the stable dose received upon study enrollment. Period 3 was to last up to 2 years.
62450622|NCT05013671|ACTIVE_COMPARATOR|residents with BPPV|
62450623|NCT05013671|OTHER|residents without BPPV|
62450624|NCT01316653|ACTIVE_COMPARATOR|GROW Smarter|Library based program to promote early literacy
62450625|NCT01316653|EXPERIMENTAL|GROW Healthier|Healthy lifestyle intervention focused on building healthy lifestyle skills for preschool children and participating parents and building new social networks between the intervention group members.
62450626|NCT04016636||Single Group Study. Patients with CLL receiving ibrutinib.|"In this study the investigator does not assign specific interventions to the study participants. Participants will receive interventions as part of routine medical care, and the investigator will observe the effect of the intervention.~This study will collect prospective real-world data to describe the quality of life (QOL) in patients with CLL receiving ibrutinib in routine Argentinian clinical practice over a 12-month follow-up period.~The primary data source for this observational study will be the medical records of each enrolled patient, as well as questionnaires concerning quality of life. Data will be collected at baseline and on months 1,3,6 and 12 during a prospective period."
62450627|NCT02703077|ACTIVE_COMPARATOR|1: ERCP + Spyglass + EHL|This group after the diagnosis of difficult bile duct stones, will be submitted to spyglass cholangioscopy + EHL (electrohydraulic lithotripsy)
62450628|NCT02703077|ACTIVE_COMPARATOR|2: ERCP + Balloon Dilation|This group after the diagnosis of difficult bile duct stones, will be submitted to Balloon dilation of the papilla
62450629|NCT02277769|PLACEBO_COMPARATOR|Placebo|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
62450630|NCT02277769|EXPERIMENTAL|Dupilumab 300 mg every 2 weeks (q2w)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a placebo alternating with single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
62450631|NCT02277769|EXPERIMENTAL|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
62450632|NCT00506909|EXPERIMENTAL|Group 1|Group 1: 20 IU BID for the first week, 40IU BID for the following two weeks, 1 week washout, 3 week placebo trial.
62450633|NCT00506909|EXPERIMENTAL|Group 2|Group 2: 3 week placebo trial, 1 week washout, 20 IU BID for the first week, 40IU BID for the following two weeks.
62450634|NCT05345132|ACTIVE_COMPARATOR|A|Nifedipine + Magnesium sulfate
62450635|NCT05345132|ACTIVE_COMPARATOR|B|Magnesium Sulfate
62450636|NCT05961800|EXPERIMENTAL|Quantitative Sensory Testing|Participants with chronic low back pain and a scheduled lumbar medial branch block undergo quantitative sensory testing.
62450637|NCT00648323|EXPERIMENTAL|A|
62626213|NCT02893046||Population at Risk|Population with at least one risk factor of being infected with hepatitis C; MSM population; people in precarious situations and / or attending support from addictions care structures.
62626214|NCT02893046||Prison population|"Proposal of participation to a  consultation arrivants  by the staff of medical units correctional"
62626215|NCT05978700|EXPERIMENTAL|Video-game group|Received the video-game intervention
62626216|NCT05978700|ACTIVE_COMPARATOR|Conventional therapy group|Received the conventional therapy intervention
62852045|NCT01685151|PLACEBO_COMPARATOR|Placebo|Ramelteon SL placebo-matching tablets, sublingual, once daily, at night time for up to 12 months.
62062742|NCT01872910|ACTIVE_COMPARATOR|400 mg Celecoxib|"Part A: Single oral administration of 400 mg celecoxib (Positive control) administered orally once as two 200-mg capsules post dental surgery (Positive control).~Participants received two 200-mg celecoxib capsules during Pre-Part B.The purpose of Pre-Part B was to develop proficiency in the dialysate placement, collection, and maintenance techniques before moving to Part B.~Celecoxib was not administered in Part B.~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
62852046|NCT04211675|OTHER|Treatment|"The planned therapy will involve 6 cycles of 21 days each consisting of irinotecan, temozolomide, dinutuximab, sargramostim, and natural killer (NK) cells.~Treatment cycles will be repeated every 21 days based upon disease response and toxicity criteria. Tumor response will be assessed after Cycles 2, 4 and 6. Patients who do not experience dose-limiting toxicities and achieve complete response, partial response or stable disease may continue to receive the assigned therapy."
62062743|NCT05461690|EXPERIMENTAL|Niraparib group|200mg once a day for patients with body weight \<77kg or baseline platelet count \<150,000/µL, and 300mg once a day for patients with body weight ≥ 77kg and baseline platelet count ≥ 150,000/µL until disease progression or intolerable toxicity whichever occurs first.
62267180|NCT05261022|NO_INTERVENTION|Wait-List Control Group|"Participants will take part in a waitlist control group. They will participate in the same number of assessment/sessions as the experimental group. In the sessions that correspond to the intervention (one session every 4 weeks over the course of 12 weeks as in the intervention group), the waitlist group will complete a basic writing task (identical to the intervention group, wherein they provide a fact-based summary of a recent conflict) and they will complete questions regarding conflict history and conflict-related distress. No other writing tasks will take place.~Following the 3-month assessment, they will be offered the writing intervention."
62267181|NCT02126709|EXPERIMENTAL|Treatment Arm|"Name: Repigel Active ingredient: Povidone iodine Dosage form: Liposomal hydrogel Administration route: Topical Strength: 3%~Application of study cream twice a day during the 8 week study period~* It will be applied once in the morning and once in the night~* We recommend the application to occur after the face is washed~* One Finger Tip Unit is required per application to the entire face~* The gel should be left on and not washed of for at least15 -30 minutes"
62267182|NCT02126709|PLACEBO_COMPARATOR|Placebo Arm|"Name: Neutrogena hydroboost gel Active ingredient: NA Strength: NA Dosage form: Water gel Administration route: Topical~Application of placebo cream twice a day during the 8 week study period~* It will be applied once in the morning and once in the night~* We recommend the application to occur after the face is washed~* One Finger Tip Unit is required per application to the entire face~* The gel should be left on and not washed of for at least15 -30 minutes"
62267183|NCT02370615|EXPERIMENTAL|Cohort 1: TAK-272 + Itraconazole|TAK-272 40 mg, tablet, orally, once on Day 1 and 10, followed by Itraconazole 200 mg, solution, orally, twice on Day 4, further followed by Itraconazole 200 mg, solution, orally, once from Day 5 to 12.
62267184|NCT02370615|EXPERIMENTAL|Cohort 2: Midazolam + Digoxin + TAK-272|Midazolam 2 mg, syrup, and Digoxin 0.25 mg, tablet, orally, once on Day 1 and 7, followed by TAK-272 80 mg, tablet, orally, once from Day 3 to 8.
62267185|NCT00032565||1|No intervention. Telephone interview.
62267186|NCT03603821||LUTS male|Clinical assesment of males older than 50 years with lower urinary tract symptoms presumably related to benign prostate enlargement
62267187|NCT01883635|ACTIVE_COMPARATOR|Individual Exercise Intervention|Survivor-only progressive walking and resistance exercise
62267188|NCT01883635|EXPERIMENTAL|Dyadic Exercise Intervention|Dyadic progressive walking and resistance exercise
62267189|NCT05687071|EXPERIMENTAL|ETC-1002 180mg|
62267190|NCT05006469|EXPERIMENTAL|BAd treatment|Bendamustine 70-90mg/m2, d1, d2 Liposome Adriamycin 15-20mg/m2, d1 or Adriamycin 10mg d1-d4 Dexamethasone 40mg qw po. (20mg, \>70 years old) There is a course of treatment every 28 days, and a total of 6 courses are completed.
62267191|NCT02037932|EXPERIMENTAL|Balloon Assisted Coiling|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
62062744|NCT03324984|EXPERIMENTAL|1% Chloroprocaine (PF)|1% Chloroprocaine is an ester-linked local anesthetic with the shortest duration of action of all local anesthetics.
62267192|NCT00713427|OTHER|WallFlex Stent|All patients meeting eligibility criteria recieve the WallFlex™ Biliary Partially-Covered Stent, which has regulatory clearance in the areas in which the study is being conducted.
62062745|NCT03324984|ACTIVE_COMPARATOR|0.75% bupivacaine|0.75% bupivacaine is a amino-amide anesthetic local anesthetic. It is hyperbaric in nature due to addition of dextrose.
62062746|NCT03548805|EXPERIMENTAL|Trabeculectomy with Ologen|ologen® Collagen Matrix
62062747|NCT03548805|ACTIVE_COMPARATOR|Trabeculectomy with low dose mitomycin C|Trabeculectomy with low dose MMC (0.02%)
62062748|NCT01213108|EXPERIMENTAL|Örebro prevention program|
62062749|NCT01213108|ACTIVE_COMPARATOR|Control|Business as usual
62267193|NCT04133532|EXPERIMENTAL|metoprolol-no metoprolol|After a washout period of one month following discontinuation of preceding beta-blocker medication patients will be given metoprolol 50 mg daily. The effect will be evaluated after three months of treatment. After that, another one-month washout period will commence followed by three months without metoprolol medication. Then, a final reevaluation will be performed.
62450638|NCT04113343|ACTIVE_COMPARATOR|Treatment A: remimazolam|Oral administration of 360 mg remimazolam
62450639|NCT04113343|EXPERIMENTAL|Treatment B: remimazolam + 5% v/v alcohol|Oral administration of 360 mg remimazolam and 5% v/v alcohol
62852047|NCT03113136|ACTIVE_COMPARATOR|Low wattage E cigarette device|
62852048|NCT03113136|ACTIVE_COMPARATOR|High wattage E cigarette device|
62626217|NCT05288322|EXPERIMENTAL|Mostafa Maged maneuver to prevent and control post-partum haemorrhage|"all pregnant females ( primigravida and multi-gravida ) . this study includes forty pregnant females with normal vaginal delivery .this study includes pregnant females Inclusion criteria :-~1. All pregnant patients~2. Age is between (18) to (40) years old~The Mostafa Maged maneuveur has been applied to those all female patients to prevent or control post-partum bleeding in normal delivery ."
62626218|NCT02771860|ACTIVE_COMPARATOR|Experimental: denosumab|50 patients will be enrolled in this group for a total treatment duration of 24 months (96 weeks): 48 weeks denosumab 60mg sc every 12 weeks followed by a 48-weeks open label phase denosumab 60mg sc every 12 weeks. Calcium and vit D supplementation will be installed at baseline.
62626219|NCT02771860|PLACEBO_COMPARATOR|Comparator|"50 patients will be enrolled in this group for a total treatment duration of 24 months (96 weeks): 48 weeks placebo sc every 12 weeks followed by a 48-weeks open label phase denosumab 60mg sc every 12 weeks.~Calcium and vit D supplementation will be installed at baseline"
62626220|NCT04030234|EXPERIMENTAL|Intensive treatment group|Participants randomized into the Intensive treatment group will have a goal of SBP \<120 mmHg. A two- or three-drug regimen should be initiated at randomization for most participants. Drug doses should be increased and/or additional antihypertensive medications should be added at each visit in the intensive treatment group, usually at monthly intervals, until the participant's goal of \<120 mmHg has been reached or the local investigator decides no further antihypertensive medications may be added.
62626221|NCT04030234|ACTIVE_COMPARATOR|Standard treatment group|Participants randomized into the Standard treatment group will have a goal of SBP \<140 mmHg. It is expected to achieve a SBP of 135-139 mmHg in as many participants as possible. Medication dose titration or addition of another drug is indicated if SBP is ≥160 mmHg at a single visit or is ≥140 mmHg at two consecutive visits. Down titration should be carried out if the SBP is \<130 mmHg at a single visit or \<135 mmHg at two consecutive visits.
62626222|NCT02633280||COPD-Untreated (Group 1)|In this Group will be enrolled patients of both sex and older than 40-years with COPD stage GOLD 2 and 3 that did not receive COPD treatment in the last 6 months (beta 2 agonists, corticosteroids, anticholinergics).
62626223|NCT02633280||COPD-uncontrolled (Group 2)|In this Group will be enrolled patients of both sex and older than 40-years with COPD stage GOLD 2 and 3 that receive a COPD treatment (e.g. beta 2 agonists, corticosteroids, anticholinergics) but with a post-bronchodilator FEV1\< 80% and an FEV1/FVC \< 0.7 or with 1-2 exacerbation/year
62626224|NCT02633280||Control subjects (Group 3)|In this Group will be enrolled patients of both sex and older than 40 years; (2) will be free from lung disease as determined by a physician; (3) will have a normal spirometry (FEV1\> 85% and FEV1/FVC \> 0.7)
62626225|NCT03499106|EXPERIMENTAL|Healthy Volunteers|Period 1: Single dose of IW-1973. Period 2: ITZ is dosed once daily (QD) for 17 days; a single dose of IW-1973 is administered 1 hour after the fourth ITZ QD dose.
62626226|NCT02734862|EXPERIMENTAL|Group 1|"Subjects in the CD101 IV treatment group 1 (Part A Only - up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 400 mg on Day 15 (for all subjects) and an optional dose of 400 mg on Day 22 (only for subjects with IC), if needed.~Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down."
62626227|NCT02734862|ACTIVE_COMPARATOR|Group 3|"Subjects in the caspofungin group will receive IV caspofungin (a single 70 mg loading dose on Day 1 followed by 50 mg once daily) for ≥3 days up to a maximum of 21 days for subjects with candidemia only and up to a maximum of 28 days for subjects with IC (with or without candidemia).~After ≥3 days of IV therapy, subjects in the caspofungin group can be switched to oral step-down therapy of fluconazole (a loading dose of 800 mg \[4 capsules\] on the first day followed by 400 mg \[2 capsules\]/day thereafter). After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind."
62626228|NCT02734862|EXPERIMENTAL|Group 2|"Subjects in the CD101 IV treatment group 2 (Part B Only - up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 200 mg on Day 15 (for all subjects) and an optional dose of 200 mg on Day 22 (only for subjects with IC), if needed.~Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down."
62267194|NCT04133532|EXPERIMENTAL|no metoprolol-metoprol|After a one-month washout period following discontinuation of preceding beta-blocker medication patients will continue another three months without a metoprolol medication. After that, an evaluation will be performed. Then they will be given metoprolol 50 mg daily for three months followed by a reevaluation.
62267195|NCT06542055|EXPERIMENTAL|Preoperative & postoperative exercise|Will receive preoperative thoracic surgery health education manuals. Tailored preoperative pulmonary rehabilitation exercises and postoperative regular pulmonary rehabilitation exercises.
62267196|NCT06542055|ACTIVE_COMPARATOR|Postoperative exercise|Preoperatively, an education manual was provided; postoperatively, routine rehabilitation exercises were given.
62267197|NCT01253655|EXPERIMENTAL|PF-05212365|
62267198|NCT02358070||HCC group|
62852049|NCT03113136|ACTIVE_COMPARATOR|Usual brand cigarette|
62852050|NCT05879094|EXPERIMENTAL|Morton extension|Experimental group con Morton Extension application
62062750|NCT01342822||PROMUS Element™|All patients enrolled will be randomized 2:1 to receive the PROMUS Element™ stent (N=1987)
62267199|NCT02358070||control group|
62267200|NCT04753827|EXPERIMENTAL|Experimental Group Stent only|Stents were implanted in MV and SB respectively, and DKcrush or Culotte technology was selected according to the lesion characteristics.
62267201|NCT04753827|EXPERIMENTAL|Experimental Group Stent+DCB|The MV was stented and the SB were treated with just drug-coated balloon(DCB)
62267202|NCT04753827|EXPERIMENTAL|Experimental Group L-Sandwich|Stents were implanted in the MV and the shaft of side branch SB respectively, then a DCB was applied to the ostium of the SB
62062751|NCT01342822||Xience™ Prime stent|All patients enrolled will be randomized 2:1 to receive the PROMUS Element™ stent (N=1987) versus the Xience™ Prime Stent (N=993).
62062752|NCT00142922|EXPERIMENTAL|1|Attended Breaking Down Barriers program
62062753|NCT00142922|ACTIVE_COMPARATOR|2|Attention control group
62267203|NCT04459780|EXPERIMENTAL|Group 1 : 20 subjects with plaque psoriasis|Intervention: skin biopsies and blood sample
62267204|NCT04459780|EXPERIMENTAL|Group 2 : 10 subjects with atopic dermatitis|Intervention: skin biopsies
62062754|NCT00142922|ACTIVE_COMPARATOR|3|Indivdual attention control group
62062755|NCT02105805|EXPERIMENTAL|low energy diet|low energy diet treatment
62267205|NCT01697735|EXPERIMENTAL|Berberine;Atorvastatin or Rosuvastatin|Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily; Besides taking statins, Participants will receive 500mg berberine twice a day for 8 weeks.
62626229|NCT03839615|ACTIVE_COMPARATOR|guided bone regeneration using ptfe|"Augmented anterior maxillary bone ridge using ptfe with 1:1 autogenous bone and xenograft mixture~* Patients of both groups will be subjected to CBCT (diagnostic for upper arch).~* Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~intervention:~* Flap will be done.~* In the group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a ptfe membrane which will be stabilized by tacks."
62626230|NCT03839615|EXPERIMENTAL|collagen membrane|"* Local anesthesia will be given to the patient. intervention:~* Flap will be done.~* In the group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks."
62626231|NCT05718440||patient with spinal dysraphism|
62626232|NCT06299267|OTHER|effect of dual task|effect of dual task
62626233|NCT01158937|EXPERIMENTAL|Extended Meropenem Infusion|Meropenem Infusion over 3 hours
62626234|NCT01158937|EXPERIMENTAL|Bolus Meropenem Infusion|Meropenem infusion over 30 minutes
62626235|NCT04843540|EXPERIMENTAL|CTP-543|On Day 1, participants will receive a single oral dose of CTP-543. Following a washout period on Days 2 and 3, participants will receive a single oral dose of rifampin on Day 4 through Day 15, with a single oral dose of CTP-543 being co-administered on Day 14.
62626236|NCT02297425|EXPERIMENTAL|Single agent - study drug|The study will evaluate single-agent PF-06459988
62626237|NCT04604977|OTHER|Mindfulness by Smartphone|an approach that is alternative to current practice, particularly as far as reducing face-to-face hospital visits taking advantage of facilities offered by new technologies, besides including innovative and emerging treatment choices, namely a behavioural approach base on mindfulness
62626238|NCT02702362|ACTIVE_COMPARATOR|anodal stimulation|"Patients received anodal tDCS (on the precuneus ) every day for 5 days (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after each tDCS.~A final CRS-R is performed 5 days after the end of the session to assess the potential long term effects of the tDCS."
62626239|NCT02702362|SHAM_COMPARATOR|sham stimulation|Patients received sham tDCS (5 secondes of stimulation) every day for 5 days. A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed 5 days after the end of the session.
62626240|NCT02585713|EXPERIMENTAL|Arm I (apixaban)|Patients receive apixaban 10 mg PO BID on days 1-7 and lower-dose apixaban 5 mg PO BID on days 8-180.
62626241|NCT02585713|EXPERIMENTAL|Arm II (dalteparin)|Patients receive dalteparin 200 IU/kg/day SC QD on days 1-30 and lower-dose dalteparin 150 IU/kg/day SC QD on days 31-180.
62267206|NCT01697735|ACTIVE_COMPARATOR|Atorvastatin or Rosuvastatin|Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
62062756|NCT02105805|ACTIVE_COMPARATOR|Nordic recommendation|Nordic recommendation, no restrictions on energy
62062757|NCT02078505|EXPERIMENTAL|PCOS after diet|Patients after 2 months of diet
62062758|NCT02078505|NO_INTERVENTION|control|Ovulatory women
62062759|NCT01541163||Acute Ischemic Stroke|Patients with acute ischemic stroke admitted within 12 hours after onset.
62062760|NCT03066843|EXPERIMENTAL|Zero incubation with ALA (5-aminolevulinic acid)|Subjects will receive zero time of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.
62062761|NCT03066843|EXPERIMENTAL|One hour incubation with ALA (5-aminolevulinic acid)|Subjects will receive one hour of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.
62062762|NCT02753205|EXPERIMENTAL|Control|Infusion of normal saline
62267207|NCT02937818|EXPERIMENTAL|ARM A|
62267208|NCT02937818|EXPERIMENTAL|ARM B|
62626242|NCT03581370|ACTIVE_COMPARATOR|1 hour infusion|"The first group corresponds to 1-hour infusion : First administration of ceftolozane-tazobactam with 2000 mg by infusion for 60 minutes every 8 hours.~24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48."
62626243|NCT03581370|EXPERIMENTAL|4 hours infusion|"The second group corresponds to 4-hours infusion: First administration of ceftolozane-tazobactam with 2000 mg by infusion for 4 hours every 8 hours. 24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48.~."
62626244|NCT01349530|EXPERIMENTAL|Anticoagulation clinic care|Monitoring by CREATIF
62626245|NCT01349530|ACTIVE_COMPARATOR|Usual care|Monitoring by GP.
62626246|NCT03569826||Observational|There is no intervention being administered. This registry only observes patients through their regular standard of care visits.
62626247|NCT00098670|EXPERIMENTAL|Treatment (alemtuzumab, rituximab, fludarabine phosphate)|"Patients receive induction therapy comprising rituximab IV over 4 hours on days 1, 3, and 5 of course 1 and day 1 of all subsequent courses and fludarabine IV over 30 minutes on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression.~Approximately 4 months after completion of induction therapy, patients achieving a partial response, nodular partial response, or stable disease receive consolidation therapy comprising alemtuzumab subcutaneously on days 1-3. Treatment repeats weekly for up to 6 courses in the absence of disease progression."
62626248|NCT04685642|NO_INTERVENTION|non-drug|
62626249|NCT04685642|ACTIVE_COMPARATOR|Aspirin|
62626250|NCT04685642|ACTIVE_COMPARATOR|Statin|
62852051|NCT04017845|ACTIVE_COMPARATOR|Household-Open Invitation (HOI)|Precolonoscopy cleansing regimen and referral to conventional colonoscopy is based on Positive FIT (level ≥75ng/ml) in any of the two collected samples. Histopathological examinations of screen-detected lesions are reported and lesion with the worst prognosis is indicated as the final colonoscopic outcome used for evaluation purposes. Screenees with intermediate and high risk polyp were referred to a follow-up surveillance programme.Treatments were initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment for anal fissure, and tribenoside 400 mg + lidocaine 40 mg suppositories for hemorrhoids. Positive FIT results in participants who were identified with no adenomas, advance adenomas, or adenocarcinomas are considered False-positive FIT (FP-FIT) results.
62626251|NCT00540644|EXPERIMENTAL|Revlimid, Cyclophosphamide, Prednisone|"Lenalidomide orally on Days 1-21 followed by 7 days rest, repeated every 28 days.~Cyclophosphamide twice daily, orally on Days 1-21 followed by 7 days rest, repeated every 28 days.~Prednisone every other day orally."
62626252|NCT06314126|EXPERIMENTAL|D-Chiro-Inositol|Patients will receive oral D-Chiro-Inositol.
62626253|NCT06314126|PLACEBO_COMPARATOR|Placebo|Patients will receive oral placebo.
62626254|NCT05145257|OTHER|Elix Cycle Balance|Elix Cycle Balance supplement
62626255|NCT05927103||Coffee drinkers|Healthy adults between 30 and 50 years-old that consume 3 to 5 cups of caffeinate coffee daily
62626256|NCT05927103||Non-coffee drinkers|Healthy adults between 30 and 50 years-old that never consume coffee
62626257|NCT03782987|EXPERIMENTAL|BI 730357 + Itraconazole (T)|Participants were administered 50 mg BI 730357 tablet orally on Day 1 along with 20 mL of 10 mg/ mL Itraconazole oral solution in treatment period 2 only (T). Itraconazole was administered once daily for 12 days from Day -3 to Day 9.
62852052|NCT04017845|ACTIVE_COMPARATOR|Recommendation By Physician (RBP)|Precolonoscopy cleansing regimen and referral to conventional colonoscopy is based on Positive FIT (level ≥75ng/ml) in any of the two collected samples. Histopathological examinations of screen-detected lesions are reported and lesion with the worst prognosis is indicated as the final colonoscopic outcome used for evaluation purposes. Screenees with intermediate and high risk polyp were referred to a follow-up surveillance programme.Treatments were initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment for anal fissure, and tribenoside 400 mg + lidocaine 40 mg suppositories for hemorrhoids. Positive FIT results in participants who were identified with no adenomas, advance adenomas, or adenocarcinomas are considered False-positive FIT (FP-FIT) results.
62852053|NCT06174090|EXPERIMENTAL|Video-education|Participants will receive video-education about bypass surgery care, the day before the surgery, for once.
62852054|NCT06174090|NO_INTERVENTION|Control|Participants will receive verbal education about bypass surgery care, the day before the surgery, once
62267209|NCT02937818|EXPERIMENTAL|ARM C|
62852055|NCT03030846|EXPERIMENTAL|stabilization exercises|stabilization exercises for 6 weeks, 3 sessions per week and each session was 40 minutes for the training group.
62450640|NCT04113343|EXPERIMENTAL|Treatment C: remimazolam + 15% v/v alcohol|Oral administration of 360 mg remimazolam + 15% v/v alcohol
62450641|NCT04113343|EXPERIMENTAL|Treatment D: remimazolam + 40% v/v alcohol|Oral administration of 360 mg remimazolam + 40% v/v alcohol
62450642|NCT04113343|PLACEBO_COMPARATOR|Treatment E: placebo + 40% v/v alcohol|Oral administration of Placebo + 40% v/v alcohol
62450643|NCT05156242|EXPERIMENTAL|Active-tDCS priming MCE|The subjects in active-tDCS priming with MCE group will receive the tDCS using 5X7 cm electrodes in which anodal electrode will be placed on M1 representing the back muscles (1 cm anterior and 4 cm lateral to the vertex), while cathodal electrode will be placed on contralateral supraorbital area. The intensity will be set at 2 mA with 10-second fade in/out. The subject will be stimulated by tDCS for 20 minutes. After that, the subjects will receive 20-minute MCE.
62450644|NCT05156242|SHAM_COMPARATOR|Sham-tDCCS priming MCE|The subjects in sham-tDCS priming with MCE group will receive a 20-minute sham tDCS by setting the intensity at zero mA. After that, the subjects will receive 20-minute MCE.
62450645|NCT05156242|ACTIVE_COMPARATOR|NMES priming MCE|The subjects in NMES priming with MCE group will receive the NMES using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral LM. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total NMES time is 20 minutes. After that, the subjects will receive 20-minute MCE.
62450646|NCT05156242|ACTIVE_COMPARATOR|Conventional physical therapy|The subjects in conventional physical therapy group will receive physical therapy modality (e.g., ultrasound, TENS, etc.) and general exercises.
62626258|NCT03782987|EXPERIMENTAL|BI 730357 (R)|Participants were administered 50 mg BI 730357 tablet orally on Day 1 alone in treatment period 1 (R).
62626259|NCT02185456|NO_INTERVENTION|Healthy|Patients with no history of bacterial vaginosis. These women will be monitored monthly and with daily self swabs.
62626260|NCT02185456|ACTIVE_COMPARATOR|G1 BV in clinical & molecular remission|Patients will receive standard of care intervention, oral metronidazole 500 mg twice a day for 7 days. They will then be monitored to confirm that initial BV treatment was effective by Nugent and Amsel, and by the qPCR test (LbRC). These will be monitored with monthly visits and daily self swabs. Those who recur with symptomatic BV may enroll in the B2 arm for more aggressive treatment.
62626261|NCT02185456|EXPERIMENTAL|G2. Molecular conversion subarm|Half of G1 patients who convert to poor qPCR test results while remaining asymptomatic will be randomized into this G2 arm and receive intervention: 750 mg metronidazole/ 200 mg miconazole vaginal suppository daily for 7 days, with continued monthly visits and daily swabs.
62852056|NCT03030846|EXPERIMENTAL|control group|electrotherapy include of 20 minutes TENS conventional and Ultrasound pulse for 10 minutes without any exercises for the control group.
62852057|NCT05303402|EXPERIMENTAL|Experimental: COVID-19 Vaccine HIPRA 40 mcg/dose|Intramuscular injection of HIPRA's COVID-19 vaccine, consisting of 40 mcg/dose.
62852058|NCT00616538|ACTIVE_COMPARATOR|Cutivate(r)|Topical mid-strength steroid
62852059|NCT00616538|EXPERIMENTAL|EpiCeram(r)|EpiCeram(r) topical barrier repair cream.
62852060|NCT01300013|EXPERIMENTAL|Omecamtiv mecarbil|
62062763|NCT02753205|ACTIVE_COMPARATOR|Dexmedetomidine|infusion of dexmedetomidine 0.5ug/kg/h for 10 min and after that, infusion of dexmedetomidine 0.4ug/kg/h until the end of surgery
62626262|NCT02185456|ACTIVE_COMPARATOR|B1 Initially poor qPCR responders|The B1 arm are patients who enter remission after standard of care treatment, oral metronidazole 500 mg twice a day for 7 days, but who have poor initial qPCR scores. Half of such patients will be randomized into B1, half into B2. B1 patients will be monitored with monthly visits and via daily swabs, but will receive no further treatment while BV negative. Patients who recur with BV may enroll as B2 patients for more aggressive treatment.
62626263|NCT02185456|EXPERIMENTAL|B2 BV Remission to conversion|A subgroup of B1 patients who convert to consistently poor qPCR scores during the study (conversion) will be randomized into Arm B2 and receive intervention: 750 mg metronidazole/ 200 mg miconazole vaginal suppository daily for 7 days. These patients will continue monthly visits and daily self swabs. B2 patients who recur with symptomatic BV will be dropped from the study and given other options for therapy.
62626264|NCT05645861|ACTIVE_COMPARATOR|Augmented - Systolic Blood Pressure (SBP) at 170mmHg +/- 10 mmHg|Techniques used to target SBP will not be controlled for and will be at the discretion of the procedural anaesthetist to manage blood pressure, this can include vasopressors, intravenous fluids, titration of anaesthetic maintenance drugs and use of other vasoactive drugs.
62852061|NCT01300013|PLACEBO_COMPARATOR|Placebo|
62852062|NCT02511223|EXPERIMENTAL|Single Arm|Only one Arm,All patients will receive Olaparib 300 (mg) milligram bid p.o till disease progression
62852063|NCT04516954|EXPERIMENTAL|Convalescent COVID 19 Plasma|A total of 500 ml of convalescent COVID 19 plasma will be transfused intravenously per subject
62852064|NCT02575027|EXPERIMENTAL|Treatment (4pi radiotherapy)|Patients undergo 4pi radiation simulation and planning followed by 5 to 10 daily fractions of 4pi palliative radiotherapy. If an acceptable plan cannot be achieved using 4pi planning, then the patient will be treated with standard radiation therapy planning for palliative re-irradiation.
62852065|NCT02299583|EXPERIMENTAL|Preventive intervention|In this arm HCPs will conduct a trauma-informed early intervention with children and families after exposure to potentially traumatic events (PTE).
62852066|NCT02299583|NO_INTERVENTION|Control group|There will be no intervention in this arm. The outcome will show the efficiency of usual care.
62267210|NCT05056532||patients|Maximal mouth pressure will be evaluated for determine respiratory muscle strength, m. pectoralis, m. serratus anterior, m. sternocloideumasteoideus and quadriceps muscles strengths will be measured to evaluate accessory respiratory muscle strength, London chest activity of daily living scale will be done for assessment of dyspnea and six minute walk test will be used for determination of functionally capacity
62267211|NCT05056532||Control group|Maximal mouth pressure will be evaluated for determine respiratory muscle strength, m. pectoralis, m. serratus anterior, m. sternocloideumasteoideus and quadriceps muscles strengths will be measured to evaluate accessory respiratory muscle strength, London chest activity of daily living scale will be done for assessment of dyspnea and six minute walk test will be used for determination of functionally capacity
62267212|NCT01221064|OTHER|Early drainage removal|Patients randomised to early drainage removal arm will have the drain removed in postoperative day 1. Lymph will be punctured on a regular basis
62267213|NCT01221064|OTHER|Late drainage removal|Patients randomised to late drainage removal arm will have the drains kept until total daily drainage is 30ml and then removed
62626265|NCT05645861|ACTIVE_COMPARATOR|Standard - Systolic Blood Pressure (SBP) at 140mmHg +/- 10 mmHg|Techniques used to target SBP will not be controlled for and will be at the discretion of the procedural anaesthetist to manage blood pressure, this can include vasopressors, intravenous fluids, titration of anaesthetic maintenance drugs and use of other vasoactive drugs.
62852067|NCT00499616|EXPERIMENTAL|Group 2 (chemotherapy, surgery)|2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.
62267214|NCT01310894|EXPERIMENTAL|TOOKAD® Soluble|TOOKAD® Soluble, lyophilized formulation, given at a dose of 4mg/Kg.
62267215|NCT01310894|NO_INTERVENTION|Active Surveillance|Active surveillance is one of the management strategy in men who have low-risk prostate cancer
62267216|NCT05444595|EXPERIMENTAL|Behavioral and Plant-based Dietary Intervention|In this arm, participants will receive the behavioral plant-based intervention from community health workers.
62267217|NCT05444595|ACTIVE_COMPARATOR|Standard Care|In this arm, participants will receive the standard care intervention from community health workers.
62267218|NCT03685539|EXPERIMENTAL|Diagnostic (DECT)|Within 7 days before the standard Gamma Knife MRI, patients undergo DECT scan over 6 seconds at 1.5, 5, 10, and 20 minutes after receiving the contrast agent.
62267219|NCT03940859||DEMAT|Patients with intramural hematoma in intracranial dissecting aneurysm treated by endovascular treatment will be recruited.
62267220|NCT03424252|EXPERIMENTAL|FDL169 Dose Level 1,sublingual to oral|Dose level 1 sublingual first and oral second.
62267221|NCT03424252|EXPERIMENTAL|FDL169 Dose Level 1 dosing,oral to sublingual|Dose level 1 oral first and sublingual second.
62267222|NCT03424252|EXPERIMENTAL|FDL169 Dose Level 2 sublingual to oral,Optional|Dose level 2 sublingual first and oral second.
62267223|NCT03424252|EXPERIMENTAL|FDL169 Dose Level 2 oral to sublingual,Optional|Dose level 2 oral first and sublingual second.
62626266|NCT00791037|EXPERIMENTAL|Treatment (vaccine therapy)|"Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2 weeks later, patients undergo leukapheresis to isolate and collect peripheral blood mononuclear cells for T-cell expansion.~Patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10 days for up to three immunizations. Patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion, followed by 2 additional booster vaccines at 2-month intervals."
62626267|NCT04094116|ACTIVE_COMPARATOR|ear wax syringing with pre ear oil treatment|patients in Fanling Family Medicine Centre with ear wax will be given ear oil one week before performing ear syringing.
62852068|NCT00499616|EXPERIMENTAL|Group 3 (chemotherapy, surgery)|4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
62267224|NCT05651295|ACTIVE_COMPARATOR|Personalized Condition|Participants will learn one of three emotion regulation skills (i.e., cognitive restructuring, opposite to emotion action, mindfulness) that is their personal strength, based on pre-Baseline emotion regulation capacities. They will watch an interactive video, created for the current study, in which they are taught the skill that is their personal strength. They will also be asked to complete a survey during the video in which they will input their own examples to practice the skill and to ensure attention to and comprehension of the material.
62852069|NCT00499616|EXPERIMENTAL|Group 4 (chemotherapy, surgery, antineoplastic therapy)|8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients \< 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
62450647|NCT06130358|EXPERIMENTAL|Well-Being Museum intervention|The well-being intervention comprises six weeks of weekly museum visits, performed in groups of 10 participants. The well-being approach is based on the support of a museum mediator. His role is to help visitors to develop a more personal and sensitive understanding of artworks. To do this, he encourages the expression of feelings, impressions, and interpretations of the artwork, and supports exchanges within the group of visitors. With the mediator's support, the participants should be able to adopt a more subjective approach to the artwork, favoring their engagement when contemplating it.
62852070|NCT00499616|EXPERIMENTAL|Non-intermediate risk enrolled on intermediate risk trial|The no treatment group assignment patients may have received some treatment on ANBL0531 but they were not evaluable on this study due to being non-intermediate risk and hence did not receive a treatment assignment on ANBL0531.
62852071|NCT01362478||Case group|
62852072|NCT01362478||Control group|
62852073|NCT01077921|EXPERIMENTAL|Propranolol|Drug arm
62852074|NCT01077921|PLACEBO_COMPARATOR|Sugar pill|Placebo arm
62852075|NCT05667337|EXPERIMENTAL|CLP-PEG-MPC DALK|Subjects having successfully undergone implantation of CLP-PEG-MPC implant using DALK technique
62852076|NCT05667337|ACTIVE_COMPARATOR|HDC PKP|Subjects having undergone DALK conversion to PKP using a human donor cornea tissue
62852077|NCT00817310||Severe IVH|Infants born at less than 1500g with diagnosis of Grade II or IV IVH
62852078|NCT00817310||control|infants born at less than 1500g without IVH on HUS
62852079|NCT02925949|ACTIVE_COMPARATOR|DuoPACT|A 6-session HIV medication adherence support program for couples.
62267225|NCT05651295|ACTIVE_COMPARATOR|Standardized Condition|Participants will learn all three ER skills: cognitive restructuring, opposite to emotion action, and mindfulness. Participants will be asked to watch three interactive videos that cover each skill to provide an analogue to clinical practice in which clinicians must choose whether to provide greater breadth or depth of skill coverage. These videos will be presented in a randomized order and will include the same surveys for attention and comprehension used in the Personalized Condition.
62267226|NCT04519385|EXPERIMENTAL|Tocilizumab|Tocilizumab
62267227|NCT04519385|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone therapy
62267228|NCT01713023|EXPERIMENTAL|Glucose solution|Solution containing 75g of glucose diluted in 200 mL of water
62267229|NCT01713023|EXPERIMENTAL|Fructose solution|Solution containing 75g of fructose diluted in 200 mL of water
62450648|NCT06130358|ACTIVE_COMPARATOR|Classic Museum intervention|The classic intervention comprises six weeks of weekly museum visits, performed in groups of 10 participants. The classic museum session will be performed according to what is typically provided to visitors as part of a guided visit to the museum. Each visit will be accompanied by a volunteer guide trained in art history. He will guide participants across artworks and provide information about art pieces, the artist, and the historical context. The volunteer guide will provide context and informative content about the artwork without intending to influence the discussions and the visitor's apprehension of the artwork.
62450649|NCT00676000|ACTIVE_COMPARATOR|1|Interrupted vaginal closure
62450650|NCT00676000|ACTIVE_COMPARATOR|2|Continuous vaginal closure
62450651|NCT05137756||Amyoplasia|patient with diagnosis of Amyoplasia
62852080|NCT02925949|ACTIVE_COMPARATOR|LifeSteps|A 3-session HIV medication adherence support program for individuals.
62852081|NCT06171841|ACTIVE_COMPARATOR|Low-Intensity Normoxia|Participants will be breathing room air, and perform low-intensity lower-body resistance exercise.
62852082|NCT06171841|ACTIVE_COMPARATOR|High-Intensity Normoxia|Participants will be breathing room air, and perform high-intensity lower-body resistance exercise.
62852083|NCT06171841|EXPERIMENTAL|Low-Intensity Normoxia with Blood Flow Restriction|Participants will be breathing room air, and perform low-intensity lower-body resistance exercise combined with blood flow restriction.
62852084|NCT06171841|EXPERIMENTAL|Low-Intensity Hypoxia|Participants will be breathing a 13% oxygen gas mixture, and perform low-intensity lower-body resistance exercise.
62267230|NCT04131335|EXPERIMENTAL|Experimental Arm|Experimental arm receives lubricant eye-drops (phosphate-free, preservative-free lubricant eye drops containing 0.15% Sodium Hyaluronate with vitamins A and E (AEONTM Repair) to be administered four times a day for 6 weeks following cataract surgery (in addition to the usual post-operative topical medications of Chloramphenicol 0.5 % eye drops for 1 week and topical dexamethasone 0.1% eyedrops (Maxidex) four times a day for 4 weeks).
62267231|NCT04131335|ACTIVE_COMPARATOR|Control Arm|The control arm group receive the usual post-operative topical medications of Chloramphenicol 0.5 % eye drops for 1 week and topical dexamethasone 0.1% eyedrops (Maxidex) four times a day for 4 weeks after cataract surgery.
62267232|NCT02972073|EXPERIMENTAL|Exercise intervention|"There are 4 different exercise interventions (4 independent intervention studies) based on different concepts in this entire project. Interventions include:~1. core stabilization exercise~2. movement system impairment approach~3. neuromuscular activation using suspension~4. kinematic linkage imbalance"
62267233|NCT02972073|NO_INTERVENTION|Healthy control|This healthy control group will be informed to maintain usual daily activities and avoid participating in activities that involve trunk muscle exercise
62267234|NCT02646982|EXPERIMENTAL|Candesartan|Candesartan will be given orally once a day in a stepwise manner as follows: All participants will be initiated on 8 mg candesartan. The dose will be increased in 2 week increments to 16 mg and 32 mg as long as the systolic blood pressure (SBP) \>100 mm Hg, diastolic blood pressure (DBP) \>40 mm Hg and participant reports no symptoms of hypotension (dizziness or weakness). The highest achievable dose will be the Maximal Tolerated Dose (MTD) and the participant will receive this dose for the remaining duration of the study (participants will be treated for 1 year).
62267235|NCT02646982|PLACEBO_COMPARATOR|Placebo|Participants will receive a matched placebo once a day orally for 12 months.
62267236|NCT06460090|EXPERIMENTAL|Intervention arm|"The intervention has two components, parent and preschool. The parent component includes twelve 1-hour sessions delivered in two 30-min units, over the three terms of the preschool year (in 4 week blocks). For the first 30 min, parents engage in group training with the SLT in a room within the preschool, in which they are introduced to language promoting strategies and techniques. This is followed by 30 min of coaching, with parents practising their newly acquired skills, with their children in the preschool.~The preschool component is made up of 4 workshops. The first takes place in each preschool before the 12-week parent programme begins and the remaining three take place following each 4-week parent intervention block. Workshops focus on core interaction skills covered with parents as well as literacy skills and phonological awareness skills. Staff also get the opportunity to practice their skills and engage in coaching."
62450652|NCT05137756||Distal arthrogryposis|patient with diagnosis of Distal arthrogryposis
62626268|NCT04094116|SHAM_COMPARATOR|ear wax syringing without pre ear oil treatment|Patients in Wong Siu Ching Clinic and Tai Po Clinic who are found to have ear wax after physical examination will have ear syringing done, without pre-ear oil application.
62626269|NCT02306850|EXPERIMENTAL|Pembrolizumab|Open-label non-randomized trial. All subjects will receive active drug (pembrolizumab).
62852085|NCT06171841|EXPERIMENTAL|Low-Intensity Hypoxia with Blood Flow Restriction|Participants will be breathing a 13% oxygen gas mixture, and perform low-intensity lower-body resistance exercise combined with blood flow restriction.
62852086|NCT01511120|ACTIVE_COMPARATOR|Tetraspan|
62852087|NCT02677233||preeclamptic group|"1. Blood pressure: greater than or equal to 140 mmHg systolic or greater than or equal to 90 mmHg diastolic on two occasions at least 4 hours apart after 20 weeks of gestation (Roberts et al., 2013).~2. Proteinuria: protein/creatinine ratio greater than or equal to 0.3~3. In the absence of proteinuria, a new-onset hypertension with new onset of the following:~   * thrombocytopenia: platelet count less than 100.000/microliter~  * renal insufficiency: serum creatinine greater than 1.1 mg/dl~  * impaired liver function: elevated concentration of liver transaminases~  * pulmonary edema~  * cerebral or visual symptoms~  * Severe right upper quadrant or epigastric pain unresponsive to medication."
62852088|NCT02677233||non preeclamptic group|All are normotensive with blood pressure \<140/90 with no proteinuria.
62852089|NCT03419585|EXPERIMENTAL|Intervention light|30 minutes of intervention systematic light exposure daily for the course of radiation therapy (approximately 8 weeks).
62852090|NCT03419585|ACTIVE_COMPARATOR|Comparison light|30 minutes of comparison systematic light exposure daily for the course of radiation therapy (approximately 8 weeks).
62852091|NCT05784272||Initiators|These will be the participants who initiate into phase IV cardiac reahb
62450653|NCT01059500|EXPERIMENTAL|Webtool Output|The webtool output group will receive the numeric PTP estimate from webtool output.
62450654|NCT01059500|NO_INTERVENTION|Standard of Care/No Webtool Output|The control group will not receive the numeric PTP estimate.
62852092|NCT05784272||Non-initiators|These will be the participants who do not initiate into phase IV cardiac reahb
62852093|NCT05971576|EXPERIMENTAL|Intravenous of LM103|≥5×10\^9 cells (LM103) will be infused i.v. to patients after non-myeloablative lymphodepletion treatment with Cyclophosphamide for Injection and Fludarabine Phosphate for Injection.
62852094|NCT02784639|OTHER|determination of KRAS mutation|circulating cell free DNA (ccfDNA) plasma analysis
62852095|NCT03963271||Patients with unexplained polymorphic VT and/or VF|"1. Unexplained polymorphic VT and/or VF patients.~2. Patients with VF and the DPP6 risk haplotype, reported by the AUMC team.~3. The Worm population of patients with a SCN5A founder mutation and other conspiring genetic variants at MUMC+"
62450655|NCT06054932|EXPERIMENTAL|2weeks-intervals prime dose procedure|LK101 will be administered in a prime-boost schedule, which is 4 priming vaccination as 2-weeks-intervals followed by 3 booster vaccinations
62626270|NCT04407143||lung cancer+COVID-19|Lung cancer patients infected by COVID-19
62626271|NCT00831402|OTHER|Arm without iodized vitamin (VITAMIN OLIGOBS PREGNANCY)|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
62267237|NCT06460090|NO_INTERVENTION|Usual Care|"Usual care is the Early Childhood care and Education programme (ECCE) for preschool. The programme is provided for three hours per day, five days per week over 38 weeks per year. Childcare services taking part in the programme provide a pre-school educational programme which adheres to the principles of Síolta, the national framework for early years care and education. The most commonly implemented programme is 'Aistear' which is based on 12 principles of early learning and development, presented in three groups 1) children and their lives in early childhood 2) children's connections with others and 3) how children learn and develop. Communication and language is one element of the third component.~Junior infants is the first year of an 8 year cycle in primary education. The primary curriculum is presented in 7 areas: Art; Mathematics, Social Environmental and Scientific Education; Physical Education; Religious Education; Primary Language; and Social, personal and Health Education."
62626272|NCT00831402|ACTIVE_COMPARATOR|Arm with iodized vitamin|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
62626273|NCT00609544|EXPERIMENTAL|1|
62267238|NCT01605526|EXPERIMENTAL|Single Arm|
62626274|NCT00609544|PLACEBO_COMPARATOR|2|
62062764|NCT05280769|EXPERIMENTAL|Single arm design|On four separate occasions, participants will come to the research center and be asked to use a nicotine pouch or smokeless tobacco provided by the study team two separate times. The nicotine pouches or smokeless tobacco contain different amounts of nicotine. Participants will not know the concentration of nicotine in the nicotine pouch, but they will know the concentration and brand of the smokeless tobacco (it will be their usual brand). All participants will complete all four study conditions.
62267239|NCT01058096|EXPERIMENTAL|Cariprazine|Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
62626275|NCT02754518|OTHER|Open label Entresto|All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.
62626276|NCT06432101|ACTIVE_COMPARATOR|acupuncture combined with hydroxychloroquine sulfate tablets|Acupuncture combined with oral hydroxychloroquine sulfate tablets
62626277|NCT06432101|NO_INTERVENTION|oral hydroxychloroquine sulfate tablets|Oral hydroxychloroquine sulfate tablets (Shanghai Shangyao Sino-Western Pharmaceutical Co., LTD., Fenle, Sinopyma approval number H19990263, 0.1g x 14 tablets) were treated with 0.2g each time, twice a day, 4 weeks for 1 course of treatment, a total of 2 courses of treatment.
62852096|NCT03963271||Family members|Family members of index patients of group(s) mentioned above
62267240|NCT01058096|PLACEBO_COMPARATOR|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
62267241|NCT00801879|ACTIVE_COMPARATOR|Mupirocin ointment|0.25g mupirocin calcium ointment, 2% in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
62267242|NCT00801879|PLACEBO_COMPARATOR|Placebo ointment|0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
62267243|NCT04689529|EXPERIMENTAL|Breast cancer patients undergoing mastectomy after neoadjuvant chemotherapy|Patients who underwent total mastectomy (including simultaneous reconstruction surgery) through preoperative examinations (MRI, breast ultrasound, mammography, etc.) after receiving neoadjuvant chemotherapy
62450656|NCT06054932|EXPERIMENTAL|1weeks-intervals prime dose procedure|LK101 will be administered in a prime-boost schedule, which is 4 priming vaccination as 1-weeks-intervals followed by 3 booster vaccinations
62450657|NCT04251065|EXPERIMENTAL|Daratumumab-GDP|"This is an open-label, multicenter, single arm, single-stage phase II trial. After the patient signs the written informed consent the patient will enter the screening phase planning baseline assessments and a concomitant upfront confirmation of diagnosis of PTCL-NOS, AITL or nodal lymphoma of TFH cell origin and a central evaluation of immunohistochemical positivity of CD38 on bioptic material used to perform local diagnosis of relapsed disease, or that used for the more recent biopsy in the case of refractory patients. A core needle biopsy is considered sufficient for review and CD38 evaluation. Evaluation at central laboratory can be performed in bone marrow sections in those patients with only bone marrow lymphoma infiltration.~Only patients with confirmed eligible diagnosis and a percentage of CD38 positive tumor cells ≥ 5% will be considered eligible for study treatment.~The treatment consists of an induction phase and a maintenance phase."
62450658|NCT00612326||1|Patients with newly diagnosed locally or regionally advanced transitional cell carcinoma of the bladder.
62450659|NCT04669665|EXPERIMENTAL|SLS-002 + Standard of care|Participants will receive SLS-002 (intranasal racemic ketamine) 90 milligram (mg) two times per week for 2 weeks with standard of care treatment
62267244|NCT04689529|ACTIVE_COMPARATOR|Breast cancer patients without neoadjuvant chemotherapy and undergoing mastectomy|Patients who underwent total mastectomy (including simultaneous reconstruction surgery) through preoperative examinations (MRI, breast ultrasound, mammography, etc.) even in patients who did not receive neoadjuvant chemotherapy as a control group.
62267245|NCT02787863|EXPERIMENTAL|COPD with Prevenar-13 (1)|33 patients with COPD. Standard therapy with Prevenar-13.
62267246|NCT02787863|EXPERIMENTAL|Asthma with Prevenar 13 (2)|34 patients with asthma. Standard therapy with Prevenar 13.
62267247|NCT02787863|EXPERIMENTAL|COPD with Pneumo-23 (3)|25 patients with COPD. Standard therapy with Pneumo-23.
62267248|NCT02787863|EXPERIMENTAL|Asthma with Pneumo-23 (4)|25 patients with asthma. Standard therapy with Pneumo-23.
62267249|NCT02787863|EXPERIMENTAL|COPD with Pneumo-23/Prevenar-13 (5)|32 patients with COPD. Standard therapy, vaccinated with pneumococcal polysaccharide vaccine/pneumococcal conjugate vaccine (PPV23/PCV13).
62267250|NCT02787863|EXPERIMENTAL|Asthma with Pneumo-23/Prevenar-13 (6)|18 patients with Asthma. Standard therapy, vaccinated with PPV23/PCV13.
62267251|NCT02787863|EXPERIMENTAL|COPD with Prevenar-13/Pneumo-23 (7)|25 patients with COPD. Standard therapy, vaccinated with PCV13/PPV23.
62450660|NCT04669665|PLACEBO_COMPARATOR|Placebo + Standard of care|Participants will receive intranasal placebo two times per week for 2 weeks with standard of care treatment
62450661|NCT01908127|ACTIVE_COMPARATOR|tell- show- do procedure|"Group I (Tell- Show- Do Group): Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant in the operation room.~In the second session,injection of loal anesthesia solution including a mandibular alveolar nerve block technique and the occlusal cavity preparation was performed."
62450662|NCT01908127|EXPERIMENTAL|film modelling|"Group II (Filmed modelling Group): the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.~In the second session, injection of loal anesthesia solution including a mandibular alveolar nerve block technique and the occlusal cavity preparation was performed."
62450663|NCT03788499|NO_INTERVENTION|Control arm|routine oral care and functional exercise.
62450664|NCT03788499|EXPERIMENTAL|Massage arm|Massage of Maxillofacial and oral cavity plus routine oral care and functional exercise
62450665|NCT00629616|EXPERIMENTAL|Arm A|Anastrozole
62450666|NCT00629616|EXPERIMENTAL|Arm B|Fulvestrant
62450667|NCT01662466|ACTIVE_COMPARATOR|DHEA+Testosterone|These patients will be administered the testosterone cream along with standard DHEA supplements
62450668|NCT01662466|PLACEBO_COMPARATOR|DHEA+Placebo|These patients will receive the placebo cream along with her DHEA supplements. In other words, no testosterone will be administered.
62450669|NCT00858195|EXPERIMENTAL|1|Indomethacin 75mg ER Capsules
62450670|NCT00858195|ACTIVE_COMPARATOR|2|Indocin 75mg SR Capsules
62450671|NCT05767723|ACTIVE_COMPARATOR|Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel|"Subjects randomized to Dual Antiplatelet Therapy Control Group will be treated with a regimen of acetylsalicylic acid combined with ticagrelor or prasugrel for 12 months.~Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)"
62450672|NCT05767723|EXPERIMENTAL|Ticagrelor alone or prasugrel alone|"All subjects randomized to Monotherapy Group will have acetylsalicylic acid discontinued immediately after randomization.~Subjects randomized to Monotherapy Group will be treated with ticagrelor (90 mg twice daily) or prasugrel alone (10 mg once daily) for 12 months.~Ticagrelor alone (90 mg twice daily) Or Prasugrel alone (10 mg once daily)"
62450673|NCT01096290|EXPERIMENTAL|Lubiprostone 24mcg BID for 30 days|Active medication
62450674|NCT01096290|PLACEBO_COMPARATOR|Placebo|Placebo, matched, blinded
62450675|NCT05339009||All patients receive conventional dialysis treatment at inclusion|All patients receive conventional dialysis treatment at inclusion
62450676|NCT02343120|EXPERIMENTAL|Zanubrutinib|Participants were administered up to 320 mg total daily dose of zanubrutinib until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up
62450677|NCT03891056|ACTIVE_COMPARATOR|Gastric bypass|Twenty patients will be randomly assigned to perform a laparoscopic gastric bypass.
62450678|NCT03891056|ACTIVE_COMPARATOR|Slevee gastrectomy|Twenty patients will be randomly assigned to perform a sleeve gastrectomy
62450679|NCT02796235|OTHER|Spinal cord injury (SCI) patient|
62450680|NCT05664256|EXPERIMENTAL|policy intervention group|The group will receive the policy intervention package.
62267252|NCT02787863|EXPERIMENTAL|Asthma with Prevenar-13/Pneumo-23 (8)|27 patients with Asthma. Standard therapy, vaccinated with PCV13/PPV23.
62267253|NCT02362958|EXPERIMENTAL|Lapatinib and Capecitabine or Vinorelbine|Lapatinib 1250mg qd and Capecitabine 1000mg/m2 bid or Vinorelbine 25mg/m2 iv (d1,d8)
62267254|NCT04793178|ACTIVE_COMPARATOR|Oxygen Reserve Index Blinded Group|Aneshesist will be blinded for oxygen reserve index monitoring (ORI, Masimo Corporation), but he will be allowed to use pulse oxymetry and end-tidal carbon dioxide monitoring to manage the respiratory conditions and depth of sedation.
62450681|NCT05664256|NO_INTERVENTION|policy control group|The group will follow the usual guidelines for food procurement policy at the canteen. After three months, the group will receive the policy intervention package.
62450682|NCT03138070|EXPERIMENTAL|Arm 1|14 days of BYL719 treatment, open label
62450683|NCT06041256|EXPERIMENTAL|AURN001 High|Neltependocel High and Rho-associated protein kinase
62450684|NCT06041256|EXPERIMENTAL|AURN001 Medium|Neltependocel Medium and Rho-associated protein kinase
62450685|NCT06041256|EXPERIMENTAL|AURN001 Low|Neltependocel Low and Rho-associated protein kinase
62450686|NCT06041256|EXPERIMENTAL|Neltependocel - High|Neltependocel - High
62450687|NCT06041256|EXPERIMENTAL|ROCK|Rho-associated protein kinase (ROCK)
62626278|NCT01093586|EXPERIMENTAL|Arm I|PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
62267255|NCT04793178|EXPERIMENTAL|Oxygen Reserve Index Group|Aneshesist will be allowed to use pulse oxymetry, end-tidal carbon dioxide and oxygen reserve index (ORI) monitoring. He will manage the depth of sedation, respiaratory conditions.
62267256|NCT01748539|EXPERIMENTAL|KHK4827 70mg SC|
62267257|NCT01748539|EXPERIMENTAL|KHK4827 140mg SC|
62267258|NCT01748539|EXPERIMENTAL|KHK4827 210mg SC|
62267259|NCT01748539|PLACEBO_COMPARATOR|Placebo SC|
62652897|NCT01697579|EXPERIMENTAL|Fosaprepitant 5 mg/kg-Cycles 2-6|For optional Cycles 2-6, participants from the 5 mg/kg fosaprepitant arm in Cycle 1 were administered fosaprepitant 5 mg/kg IV (or age-adjusted equivalent). For Cycle 2, fosaprepitant was administered IV plus ondansetron with or without dexamethasone. For Cycles 3-6, fosaprepitant was administered IV plus a 5- hydroxytryptamine 3 (5-HT3) antagonist with or without dexamethasone. Participants 1 year or less were required to receive ondansetron in all cycles as the 5-HT3 antagonist.
62267260|NCT03608176|EXPERIMENTAL|PASO diet group|
62450688|NCT01531205|EXPERIMENTAL|Drug and Hormonal Therapy with Salvage Surgery|Androgen Ablation (hormonal therapy before surgery), Cabazitaxel (chemotherapy before surgery), Salvage Surgery (radical prostatectomy), Post-operative Hormonal Therapy, Post-operative Follow-up
62450689|NCT04191239||PRVC|Preterm infants with need of mechanical ventilation will receive PRVC mode until extubation
62450690|NCT04191239||Bilevel VG|Preterm infants with need of mechanical ventilation will receive Bilevel VG mode until extubation
62450691|NCT05029323|ACTIVE_COMPARATOR|Conventional HUTT|"All patients with unexplained syncope at initial evaluation with indication to perform a Head up tilt test (HUTT) randomized to conventional HUTT protocol characterized by a stabilization phase of 5 min in the supine position; a passive phase of 10 min at a tilt angle of 60 degrees; aprovocation phase of further 10 min after 300 micrograms NTG sublingual spray."
62450692|NCT05029323|EXPERIMENTAL|Fast HUTT|"All patients with unexplained syncope at initial evaluation with indication to perform a Head up tilt test (HUTT) randomized to fast HUTT protocol characterized by a stabilization phase of 5 min in the supine position; a passive phase of 10 min at a tilt angle of 60 degrees; a provocation phase of further 10 min after 300 micrograms NTG sublingual spray."
62450693|NCT05366764|EXPERIMENTAL|SAR443765|Single dose administration of SAR443765
62450694|NCT05366764|PLACEBO_COMPARATOR|Placebo|Placebo to match SAR443765
62450695|NCT02928848|EXPERIMENTAL|Real tDCS|Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
62450696|NCT02928848|SHAM_COMPARATOR|Sham tDCS|Sham tDCS uses identical stimulation parameters as the active condition, however terminates after 30 seconds in order to mimic the sensation of real tDCS.
62450697|NCT04883736|EXPERIMENTAL|Tretinoin Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
62450698|NCT04883736|ACTIVE_COMPARATOR|RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
62450699|NCT04883736|PLACEBO_COMPARATOR|Placebo Control|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
62450700|NCT00913107|EXPERIMENTAL|Lamictal®|"Lamictal® was used as the active medication in this study."
62450701|NCT00913107|ACTIVE_COMPARATOR|Tegretol®|"Tegretol® was employed as the control for comparative purposes in order to check and evaluate the efficacy (pain-relief) and occurrence of side- effects of Lamictal®."
62450702|NCT02155907||Rtest, Atrial fibrillation|Patients with ischemic stroke or TIA within the last week. Sinus rhythm on the surface ECG. Age ≥ 60 years. Given written informed consent
62267261|NCT03608176|ACTIVE_COMPARATOR|Low-fat diet group|
62267262|NCT03608176|OTHER|Waiting list group|
62267263|NCT00600574|ACTIVE_COMPARATOR|S|physiotherapy in warm pool by means of stretching
62267264|NCT00600574|EXPERIMENTAL|AI|physiotherapy in warm pool by means of Ai Chi
62267265|NCT03223064|EXPERIMENTAL|PSMA PET-CT and USPIO MRI|
62267266|NCT00586495|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 200 mg tablets (400 mg \[2 x 200 mg tablets\] twice daily \[bid\] or 400 mg once daily \[od\] or 400 mg every other day \[qod\]) administered orally
62267267|NCT01489566|ACTIVE_COMPARATOR|Tyroserleutide for injection|the Tyroserleutide for injection at the dosage of 6mg/d
62267268|NCT01489566|PLACEBO_COMPARATOR|the placebo|
62267269|NCT04191382|EXPERIMENTAL|Amcenestrant 400 mg|Participants received 4 capsules of 100 milligrams (mg) of amcenestrant once daily (QD) from Day 1 to Day 14.
62267270|NCT04191382|EXPERIMENTAL|Amcenestrant 200 mg|Participants received 2 capsules of 100 mg of amcenestrant QD from Day 1 to Day 14.
62267271|NCT04191382|ACTIVE_COMPARATOR|Letrozole 2.5 mg|Participants received 2.5 mg of letrozole tablet QD from Day 1 to Day 14.
62267272|NCT06275360|EXPERIMENTAL|Chemoimmunotherapy followed by radiotherapy|Nivolumab (Opdivo) + plus platinum-doublet chemotherapy followed by radiotherapy
62267273|NCT02567890|EXPERIMENTAL|Internet-based DBI|Internet-based DBI, which consists of four interactive occasions, some homework assignments, and monitoring
62267274|NCT02567890|PLACEBO_COMPARATOR|Expressive writing|Expressive Writing (placebo/attention control) where participants write texts. This is the active control condition.
62267275|NCT02567890|NO_INTERVENTION|Waiting list|A wait-list control condition.Those in the wait-list condition will not receive any treatment until they have done the 6-month follow-up assessment.
62267276|NCT04936295|EXPERIMENTAL|Fulvestrant plus Anlotinib|Each participant receives fulvestrant combined with anlotinib.
62267277|NCT06476067||Patients with postoperative early tumor recurrence with ESCC （Training)|Patients with early tumor recurrence defined as patients who developed tumor recurrence within 2 years after esophagectomy A panel of DNA methylation, whose specific methylation level is tested DNA from resection tissue with Methylation-specific PCR(MSP)
62267278|NCT06476067||Patients without postoperative early tumor recurrence with ESCC （Training)|Patients without early tumor recurrence defined as patients who did not develope tumor recurrence within 2 years after esophagectomy A panel of DNA methylation, whose specific methylation level is tested DNA from resection tissue with Methylation-specific PCR(MSP)
62626279|NCT06195176|EXPERIMENTAL|SHOULDER EXERCISES|Patients randomized to the exercise routine group will be instructed, upon recovery, about the exercise routine. The routine consists of lifting the shoulders as high as possible towards the ears, holding for 3 seconds, and then resting. This should be repeated 10 times at the beginning of each hour during the immediate postoperative period while on the hospital ward. The routine will be suspended at night. The procedure will be standardized, as the principal investigators will personally explain and demonstrate it to all involved individuals who are responsible for explaining it to the patients. In-person reminders will be made, and pain in the shoulders, incisions, and abdomen will be recorded at 6 hours and 24 hours postoperatively, as well as during the follow-up consultations on day post-surgery
62852097|NCT03963271||Control group|Control subjects with structurally normal hearts with an indication for a cardiac CT,
62267279|NCT06476067||Patients with postoperative early tumor recurrence with ESCC （Validation)|Patients with early tumor recurrence defined as patients who developed tumor recurrence within 2 years after esophagectomy A panel of DNA methylation, whose specific methylation level is tested DNA from resection tissue with Methylation-specific PCR(MSP)
62267280|NCT06476067||Patients without postoperative early tumor recurrence with ESCC （Validation)|Patients without early tumor recurrence defined as patients who did not develope tumor recurrence within 2 years after esophagectomy A panel of DNA methylation, whose specific methylation level is tested DNA from resection tissue with Methylation-specific PCR(MSP)
62267281|NCT05769335|EXPERIMENTAL|early calorie restriction (eCR)|Individuals will be provided with menus prescribed at 70% of calculated energy requirements and instructed to eat within 8 h/day (e.g. 8:00 - 16:00) every day for 8 weeks, except 1 evening meal per week off the program (i.e. Saturday nights) to assist with overall adherence.
62267282|NCT05769335|EXPERIMENTAL|delayed calorie restriction (dCR)|Individuals will be provided with menus prescribed at 70% of calculated energy requirements and instructed to eat within 8 h/day (e.g 12:00 - 20:00) every day for 8 weeks, except 1 evening meal per week off the program (i.e. Saturday nights) to assist with overall adherence.
62267283|NCT05769335|ACTIVE_COMPARATOR|Calorie restriction (CR)|Individuals will be provided with menus prescribed at 70% of calculated energy requirements every day for 8 weeks. The menus will encourage breakfast and after-dinner consumption of the snack to eat over at least a 12 hour time frame per day (e.g. 8:00 - 20:00), except 1 evening meal per week off the program (i.e. Saturday nights) to assist with overall adherence.
62267284|NCT01425008|EXPERIMENTAL|MLN2480|
62267285|NCT05256407|EXPERIMENTAL|Intervention, digital support|Parents are offered participation in a digital channel consisting of video consultations, parental support gruops and parental education.
62267286|NCT05256407|NO_INTERVENTION|Control, usual care|Usual child health care.
62267287|NCT00000874||1|Participants who are failing a regimen of ZDV, 3TC, and IDV
62267288|NCT00000874||2|Participants who are failing a regimen of ZDV, 3TC, and SRQ
62267289|NCT00000874||3|Participants who are failing a regimen of ZDV, 3TC, and RTV
62267290|NCT00000874||4|Participants who are failing a regimen of d4T, 3TC, and IDV
62450703|NCT05557565|EXPERIMENTAL|QL1706 injection|The dosage of QL1706 is 5.0 mg/kg, and QL1706 is administered every 3 weeks (Q3W) by intravenous infusion
62450704|NCT04366609||ADHD patients|Treatment of young ADHD patients with methylphenidate following The Danish guidelines, which are similar to The NICE guidelines: use of an initial low oral dose of MPH and an up-titration period of at least 4 weeks, until no further effect is measured on a standard ADHD rating scale, or the appearance of intolerable ARs, or a maximum dose of 2.1 mg/kg/day.
62450705|NCT03504111|ACTIVE_COMPARATOR|Needle Tenotomy|1 group will be assigned to get the standard treatment for chronic tendinopathy, percutaneous needle tenotomy (PNT). It is currently considered a standard treatment option. Ultrasound guided PNT with approximately 25 passes through the tendon and enthesis with approximately an 18 gauge needle with adequate amount of anesthetic (lidocaine) for effective anesthesia. Investigators will keep track of the number of passes through the tendon. Investigators will keep track of the amount and type of anesthetic used
62450706|NCT03504111|ACTIVE_COMPARATOR|Platelet Rich Plasma|1 group will be assigned to the PRP arm. Investigators will have a trained provider draw the blood, and prepare the PRP according to manufacturer and departmental (KP) protocol. Ultrasound guided injection of this PRP using approximately an 18 gauge needle with a single pass through the tendon into affected area as demonstrated on ultrasound. Adequate amount of anesthetic will be given in a separate syringe with adequate amount of anesthetic (lidocaine) for effective anesthesia. Investigators will keep track of amount and type of anesthetic used. The amount of anesthesia will be the same in both arms of the study
62450707|NCT04356859|NO_INTERVENTION|Crystalloid|Subjects in the crystalloid group will receive fluid resuscitation with Lactated Ringer's titrated each hour to achieve a urine output of 0.5-1mL/kg predicted body weight.
62450708|NCT04356859|ACTIVE_COMPARATOR|Colloid|Subjects in the colloid group will receive fluid resuscitation with Lactated Ringer's and 5% human albumin solution introduced no earlier than 8 hours post burn and no later than 12 hours post burn in a ratio by volume of 1/3 albumin to 2/3 Lactated Ringer's, and titrated each hour to achieve a urine output of 0.5-1mL/kg (milliliter/kilogram) predicted body weight.
62450709|NCT00879242|EXPERIMENTAL|Deferasirox|30 mg/kg/day. The daily dose can be increased to 40 mg/kg in case of unsatisfactory response after 12 weeks of treatment.
62267291|NCT03053479|EXPERIMENTAL|Laparoscopic sacrocolpopexy|Laparoscopic sacrocolpopexy will be performed in the following way: Identification of the promontory, dissection of the peritoneum above the promontory and preparation of the ligamentum longitudinale anterior, peritoneum dissection, dissection of the vesicovaginal septum up to the bladder neck, dissection of the rectovaginal septum towards the perineum, application of Y mesh, fixation to the vaginal apex using non-absorbable sutures, and for anterior and posterior vaginal wall absorbable sutures. Fixation of the upper mesh arm to the ligamentum longitudinale anterior using non-absorbable suture, following with complete peritoneum closure above the mesh. The procedure could include salpingo-oophorectomy, supracervical hysterectomy or total hysterectomy (concomitant procedures are not exclusion criteria).
62626280|NCT06195176|SHAM_COMPARATOR|HAND EXERCISES|Patients randomized to the exercise routine group will be instructed, upon recovery, about the exercise routine. The sham routine consists of tightly opening and closing the hands, holding for 3 seconds, and then resting. This should be repeated 10 times at the beginning of each hour during the immediate postoperative period while on the hospital ward. The routine will be suspended at night. The procedure will be standardized, as the principal investigator will personally explain and demonstrate it to all individuals responsible for instructing the patients. In-person reminders will be issued, and pain in the shoulders, incisions, and abdomen will be recorded at 6 hours and 24 hours postoperatively, as well as during the follow-up consultations on the 7th day after surgery.
62852098|NCT04578821|EXPERIMENTAL|Deney group|"Education Program:The education program consists of theoretical didactic education, case discussion, film and video screening in class, Web-based laboratory work, SSI practice, poster preparation and awareness activities for a total of 12 weeks and 2 hours per week (24 hours per week).~Theoretical didactic education, film screening, video screening, Web-based laboratory work, Social Security Institution study, poster preparation, poster presentation at University Campus."
62852099|NCT04578821|NO_INTERVENTION|Kontrol group|The control group participated in the courses and practices included in the routine curriculum.
62852100|NCT02375061|EXPERIMENTAL|e-BPS intervention|"Participants are asked to write and imagine about a future in which they have reached all their goals in four different domains: personal, professional, social and health domain. They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero \& Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform (TEO-Emotional Therapy Online) in which they can visualize all the content they had developed previously."
62852101|NCT02375061|PLACEBO_COMPARATOR|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
62852102|NCT02127099||Patients with OSA|Post operative patients with OSA
62852103|NCT02127099||Post-operative Patients without OSA|All post operative patients without OSA
62852104|NCT01298908|OTHER|Operative treatment|vein stripping
62852105|NCT01298908|OTHER|Laser ablation|Ultrasound guided laser ablation
62267292|NCT03053479|EXPERIMENTAL|Transvaginal mesh procedure|Hydrodissection of the anterior vaginal wall, midline anterior colporrhaphy, preparation beyond the endopelvic fascia, mesh kit with bilateral fixation to sacrospinous ligaments should be used. The procedure could include salpingo-oophorectomy, total hysterectomy and posterior vaginal wall repair (concomitant procedures are not exclusion criteria).
62267293|NCT03053479|EXPERIMENTAL|Amreich-Richter procedure:|At least unilateral fixation with non-absorbable suture to sacrospinous ligament (fixation could be performed from the anterior approach). At the time of anterior vaginal wall repair or traditional posterior approach, it is possible to use a device for stich fixation (for example Capio, I- stitch etc). The procedure could include salpingo-oophorectomy, total hysterectomy and posterior vaginal wall repair (concomitant procedures are not exclusion criteria).
62267294|NCT04578795|EXPERIMENTAL|Pt underwent single use flexible ureteroscopy|Patients with renal stones who will operated by single use flexible ureteroscopy
62267295|NCT04509921|NO_INTERVENTION|symptoms group|The asthma treatment adjustments guided by GINA guidelines
62267296|NCT04509921|EXPERIMENTAL|BHR group|The asthma treatment adjustments additionally taking account to the results of the bronchial hyperresponsiveness test
62450710|NCT05273619|EXPERIMENTAL|XC8, film-coated tablets, 10 mg|
62267297|NCT03064737|OTHER|This study is a non-drug one arm study|Skin biopsy for genetic analyze
62450711|NCT05273619|PLACEBO_COMPARATOR|Placebo|
62267298|NCT00870961|EXPERIMENTAL|Arm I|Patients receive oral cholecalciferol (vitamin D3) supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
62267299|NCT00870961|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
62450712|NCT03979248|EXPERIMENTAL|BMS-986165 + Rabeprazole|
62450713|NCT05361122|EXPERIMENTAL|Xylitol-exposed formerly term children|n=250 formerly term children born during the PPaX trial who were born to gravidae in the interventional arm (received xylitol chewing gum but had access to a dentist and received prenatal counseling)
62450714|NCT05361122|ACTIVE_COMPARATOR|Non xylitol-exposed formerly term children|n=250 formerly term children born during the PPaX trial who were born to gravidae in the active comparator arm (no xylitol chewing gum but had access to a dentist and received prenatal counseling)
62450715|NCT05361122|EXPERIMENTAL|Xylitol-exposed formerly preterm children|n=250 formerly preterm children born during the PPaX trial who were born to gravidae in the interventional arm (received xylitol chewing gum but had access to a dentist and received prenatal counseling)
62450716|NCT05361122|ACTIVE_COMPARATOR|Non xylitol-exposed formerly preterm children|n=250 formerly preterm children born during the PPaX trial who were born to gravidae in the active comparator arm (no xylitol chewing gum but had access to a dentist and received prenatal counseling)
62450717|NCT00479622|EXPERIMENTAL|1|
62450718|NCT00479622|EXPERIMENTAL|2|
62450719|NCT01979848||MRI Mapping Group|After Subjects arrive at the MRI facility, subjects will fill out a medical questionnaire that will be used to determine whether a MRI study can be performed. The investigators will determine whether there are any problems that make the subject not suitable for participating in this study.
62267300|NCT03344315|ACTIVE_COMPARATOR|autologous connective tissue graft|Soft tissue harvesting from patient palate
62450720|NCT04238520|OTHER|Control|10 PWD/CG dyads
62852106|NCT01298908|OTHER|Foam sclerotherapy|Ultrasound guided foam sclerotherapy
62852107|NCT04442035|EXPERIMENTAL|The teatment group|5-element misic therapy
62450721|NCT04238520|EXPERIMENTAL|Interventional|30 PWD/CG dyads
62450722|NCT04384172|EXPERIMENTAL|Tibial e-stim followed by genital e-stim|Tibial e-stim followed by genital e-stim
62852108|NCT04442035|EXPERIMENTAL|The control group|health education
62267301|NCT03344315|EXPERIMENTAL|collagen matrix|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland Device: Collagen matrix
62267302|NCT01982292|EXPERIMENTAL|RLX030 (serelaxin)|Randomized patients received an IV infusion of 30 μg/kg/day of serelaxin for 48 hours at randomization and at Weeks 4 and 8
62450723|NCT04384172|EXPERIMENTAL|Genital e-stim followed by tibial e-stim|Genital e-stim followed by tibial e-stim
62450724|NCT00436358||Group A|IS case deemed children
62450725|NCT00436358||Group B|LRTI-related post-neonatal deaths deemed Children
62450726|NCT00436358||Group C|A random sample of children from an annual birth cohort within the electronic IMSS dataset
62450727|NCT00436358||Group D|All children from a single annual birth cohort with IS identified in their electronic IMSS data
62450728|NCT00436358||Group E|A sample of children from the electronic IMSS dataset selected to match the selected IS cases on age, gender, and hospital of birth.
62450729|NCT04627376|NO_INTERVENTION|Control|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires.
62450730|NCT04627376|EXPERIMENTAL|Intervention|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.
62450731|NCT00942461|ACTIVE_COMPARATOR|Laparoscopic Surgery group|Group of patients that are operated with laparoscopic approach
62450732|NCT00942461|ACTIVE_COMPARATOR|Open surgery Group|Group of patients operated with open approach
62450733|NCT01409044|EXPERIMENTAL|Music|Research participant listened to music
62450734|NCT01878370|EXPERIMENTAL|High risk|Feedback reports focusing on the identification and management of patients who appear to have poorly managed diseases and who may require recall into clinic.
62450735|NCT01878370|EXPERIMENTAL|Best Practice|Feedback reports focusing on the achievement of optimal care targets for patients with chronic disease.
62450736|NCT00764309|EXPERIMENTAL|A1|
62450737|NCT05638503||Hypertension with left ventricular hypertrophy group|"2015 ASE/EACVI guideline standard: Eccentric hypertrophy, EH: LVMI\>115g/ m2（male）or LVMI\>95g/ m2（female）and RWT≤0.42 Concentric hypertrophy, CH: LVMI\>115g/ m2（male）or LVMI\>95g/ m2（female）and RWT\>0.42~Reference Values for Chinese (EMINCA) and Configuration Analysis Based on Ganau Typing:~Eccentric hypertrophy, EH: LVMI\>108g/ m2（male）and RWT≤0.51or LVMI\>99g/ m2（female）and RWT≤0.49 Concentric hypertrophy, CH: LVMI\>108g/ m2（male）and RWT\>0.51 or LVMI\>99g/ m2（female）and RWT\>0.49"
62450738|NCT05638503||Hypertension with left ventricular non-hypertrophy group|"2015 ASE/EACVI guideline standard: Normal left ventricular geometry, NG: LVMI≤115g/m2（male）or LVMI≤95g/m2（female）and RWT≤0.42 Concentric remodeling, CR: LVMI≤115g/m2（male）or LVMI≤95g/ m2（female）and RWT\>0.42~Reference Values for Chinese (EMINCA) and Configuration Analysis Based on Ganau Typing:~Normal left ventricular geometry, NG: LVMI≤108g/ m2（male）and RWT≤0.51 or LVMI≤99g/ m2（female）and RWT\>0.49 Concentric remodeling, CR: LVMI≤108g/ m2（male）and RWT\>0.51 or LVMI≤99g/ m2（female）and RWT\>0.49"
62450739|NCT01349439|EXPERIMENTAL|Propranolol + Memory Reactivation|This arm involves recalling the traumatic event after administration of propranolol
62852109|NCT04308967|EXPERIMENTAL|Balance exercises and information|Balance exercises six weeks and three days in a week and information about central sensitisation.
62852110|NCT04308967|NO_INTERVENTION|Information|Information about central sensitisation.
62852111|NCT03268655|EXPERIMENTAL|Ginger extract|Ginger extract, 2000 mg daily for 6 weeks, followed by 6 week washout.
62852112|NCT03268655|EXPERIMENTAL|Placebo|Placebo, daily for 6 weeks, followed by 6 week washout.
62852113|NCT04073524|EXPERIMENTAL|Nature-Body-Mind-Community (NBMC) + treatment as usual|9 weeks of nature-based therapy (Nature-Body-Mind-Community (NBMC)) treatment as usual
62852114|NCT04073524|OTHER|Treatment as usual|Treatment as usual
62852115|NCT03229642|EXPERIMENTAL|Active rTMS treatment|The rTMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions.
62267303|NCT01982292|PLACEBO_COMPARATOR|Placebo|Randomized patients received an IV infusion of placebo of serelaxin for 48 hours at randomization and at Weeks 4 and 8
62267304|NCT03129490|ACTIVE_COMPARATOR|Dabigatran|After randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
62267305|NCT03129490|ACTIVE_COMPARATOR|Rivaroxaban|After randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
62267306|NCT03129490|ACTIVE_COMPARATOR|Edoxaban|After randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
62267307|NCT03129490|ACTIVE_COMPARATOR|Apixaban|After randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
62626281|NCT05592002|EXPERIMENTAL|Genio® 2.1 System|System Component Genio® System 2.1 Implantable Stimulator (IS) Genio® Implantable Stimulator External Stimulator (ES) Genio® External Stimulator Disposable Patch (DP) Genio® Disposable Patch Activation Chip (AC) Genio® Activation Chip (AC) Model #2364 Charging Unit (CU) Genio® Charging Unit (CU) Model #2238 Sleep Lab Application Genio® Sleep Lab Application Smartphone Application (optional) Genio® Smartphone Application
62626282|NCT04678609|EXPERIMENTAL|Open kinetic chain exercise|In the OKC exercise group, participants will be taught by a physiotherapist about open kinetic chain exercises. Then, they will do the exercises at their home for eight weeks, with three session per week. The physiotherapist will contact the participants to monitor their adherence to the intervention. A diary is also provided to monitor their progress, pain level and any adverse events related to the intervention.
62626283|NCT04678609|EXPERIMENTAL|Closed kinetic chain exercise|In the OKC exercise group, participants will be taught by a physiotherapist about open kinetic chain exercises. Then, they will do the exercises at their home for eight weeks, with three session per week. The physiotherapist will contact the participants to monitor their adherence to the intervention. A diary is also provided to monitor their progress, pain level and any adverse events related to the intervention.
62626284|NCT04678609|NO_INTERVENTION|Control|The untreated control group will receive patient's usual care of local government hospital which includes information about clinical manifestations, risk factors, diagnosis, treatment and nursing care for knee OA. Control group did not receive any home exercises guidance.
62267308|NCT05773001|OTHER|Cohort 1|No history of SARS-CoV-2
62267309|NCT05773001|OTHER|Cohort 2|Documented mild SARS-CoV-2 infection
62267310|NCT05773001|OTHER|Cohort 3|SARS-CoV-2 pneumonia
62852116|NCT03229642|SHAM_COMPARATOR|Sham rTMS treatment|The rTMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min, with a figure-of-eight sham coil. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions.
62062765|NCT05297643|EXPERIMENTAL|Experimental Group|"A Complex decongestive treatment program consisting of manual lymphatic drainage, compression therapy, skin care and remedal exercise will be applied to the patients in this group. Exercise progame includes breathing exercises, joint range of motion exercise, pumping, stretching exercises and aerobic exercises( same with control grup).~In addition, ESWT will be applied as 2 sessions in the first two weeks and 1 session in the 3rd week. In ESWT, 2500 shocks will be applied per session with a frequency of 4 Hz at 2 bar pressure while the patient is in the supine position.~The distribution of this treatment is planned to be 750 shocks to the axillary lymph nodes and 250 shocks to the cubital lymph nodes.~The remaining 1500 shocks will be applied to the arm, forearm, and hand. While determining the dose and duration of ESWT to be applied in the study, it was arranged to be similar to the studies and reviews in the literature."
62062766|NCT05297643|OTHER|control group|A Complex decongestive treatment program consisting of manual lymphatic drainage, compression therapy, skin care and remedal exercise will be applied to the patients in this group. Exercise progame includes breathing exercises, joint range of motion exercise, pumping, stretching exercises and aerobic exercises
62062767|NCT00920023|EXPERIMENTAL|SPIO MRI|
62267311|NCT04720482||Comatose survivors of cardiac arrest|Adult (\>18 years) patients remaining comatose during intensive care 48 hours after cardiac arrest. All patients are submitted to both clinical routine measurements: pupillometry and somatosensory evoked potentials.
62267312|NCT06320769|EXPERIMENTAL|Rotational Guided Growth|"o On a radiolucent operating table with the child supine, a torniquet is applied. The limb is prepped and draped.~oA Kirschner wire is inserted in midsagittal plane of the distal femoral physis from medial to lateral under fluoroscopic guidance.~After the initial step, One of three Surgical techniques might be used according to surgeon preference and patient age:~* Plate technique~* Non-absorbable suture technique~* Cerclage wire technique"
62267313|NCT06256510|EXPERIMENTAL|Midazolam with and without Vepdegestrant|Midazolam administered as a single dose in Period 1 Day 1, and Period 2 Day 1 and Day 15. Vepdegestrant administered once a day for 15 days in Period 2.
62267314|NCT00991523|EXPERIMENTAL|sweetened beverage|
62267315|NCT00991523|PLACEBO_COMPARATOR|placebo control|placebo
62267316|NCT04268121|EXPERIMENTAL|Phase II|Prospective, open, multi center, one-arm, national phase II study evaluating the benefits in terms of disease-free survival (DFS) at 12 months after the administration of neoadjuvant treatment in patients with localized digestive neuroendocrine carcinomas
62626285|NCT00412789|EXPERIMENTAL|EPO906|
62626286|NCT06549153|EXPERIMENTAL|ACT-Together Intervention|Participants will be randomized into one of two arms through REDCap
62626287|NCT06549153|EXPERIMENTAL|Standard of Care|Participants will be randomized into one of two arms through REDCap
62626288|NCT06095479|EXPERIMENTAL|undergo standard abdominal ultrasound imaging and MRI-PDFF|"Study-related procedures will consist of one investigational exam conducted with the Philips EPIQ Ultrasound System with investigational LFQ software and a standard MRI-PDFF examination.~All imaging procedures (investigational LFQ ultrasound exam and MRI-PDFF exam) must be completed within an 8-week window (+ 5 days)."
62626289|NCT02579382|PLACEBO_COMPARATOR|TDF + placebo|"Main Study Phase: Tenofovir disoproxil fumarate (TDF) 300 mg tablets orally once daily for up to 48 weeks + placebo administered orally once a week (every 7 days) for 12 doses.~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
62626290|NCT02579382|EXPERIMENTAL|TDF + Vesatolimod 1 mg|"Main Study Phase:TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 1 mg tablet orally once a week (every 7 days) for 12 doses.~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
62626291|NCT02579382|EXPERIMENTAL|TDF + Vesatolimod 2 mg|"Main Study Phase: TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 2 mg tablet orally once a week (every 7 days) for 12 doses.~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
62626292|NCT02579382|EXPERIMENTAL|TDF + Vesatolimod 4 mg|"Main Study Phase: TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 4 mg tablet orally once a week (every 7 days) for 12 doses.~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
62626293|NCT04078724|ACTIVE_COMPARATOR|Normal subject without 5-HTP|Subjects with normal cognition will be randomly assigned to not consuming 5-HTP.
62626294|NCT04078724|EXPERIMENTAL|Normal subject with 5-HTP|Subjects with normal cognition will be randomly assigned to consuming 100 mg of 5-HTP.
62626295|NCT01505556||Diaphragm paresis|
62626296|NCT01505556||Healthy controls|
62626297|NCT02479113||Lean with normal glucose tolerance|"Pregnant women who are lean with normal glucose tolerance~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
62626298|NCT02479113||Obese with Normal glucose tolerance|"Pregnant women who are obese with normal glucose tolerance~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
62626299|NCT02479113||Gestational diabetes mellitus|"Pregnant women who have Gestational Diabetes Mellitus~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
62626300|NCT03240276|ACTIVE_COMPARATOR|ICSI Procedure|The ICSI procedure is the standard procedure of selection and injection of sperm into the oocyte
62626301|NCT03240276|ACTIVE_COMPARATOR|IMSI Procedure|The IMSI procedure is the injection of normal ultramorphological spermatozoa that have been selected using an inverted microscope with magnification of 6300x (MSOME)
62626302|NCT05516771||group 1|toddlers and small children undergoing surgery at a tertiary referral, university-affiliated hospital
62626303|NCT03260790|EXPERIMENTAL|PCV13 and PPSV23|Participants randomized to receive PPSV23 primed with PCV13. Participants will receive PCV13 8 weeks prior to receiving PPSV23
62626304|NCT03260790|ACTIVE_COMPARATOR|PPSV23|Participants randomized to receive PPSV23 alone
62267317|NCT04268121|ACTIVE_COMPARATOR|Prospective cohort|Evaluation of DFS at 12 months in patients who underwent surgery and received adjuvant chemotherapy
62267318|NCT01072214|EXPERIMENTAL|1.6 mg|The actual dosage is 10 mg/ml (GW786034) given 4 times a day for a maximum daily dosage of 1.6mg
62267319|NCT01072214|EXPERIMENTAL|TBD COHORT 2|Dose escalation amount to be determined (TBD) after results from Cohort 1 analyzed
62062768|NCT04875832|EXPERIMENTAL|Intervetion Group|EMDR intervention group
62062769|NCT05851599|EXPERIMENTAL|SKF7® - 375 mg|Patients who meet the entry criteria for the study will be randomized to receive 375 mg SKF7® for 16 weeks
62267320|NCT01072214|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo (drops without drug).
62267321|NCT01072214|EXPERIMENTAL|TBD COHORT 3|Dose escalation amount to be determined (TBD) after results from Cohort 2 analyzed
62450740|NCT01349439|EXPERIMENTAL|Placebo + Memory reactivation|This arm involves recalling the traumatic event after administration of a placebo
62450741|NCT01349439|EXPERIMENTAL|Placebo + No Memory Reactivation|This arm involves administration of a placebo without recalling the traumatic event
62450742|NCT01349439|EXPERIMENTAL|Propranolol + No Memory Reactivation|This arm involves administration of propranolol without recalling the traumatic event
62450743|NCT01349439|OTHER|Open-label Propranolol + Memory Reactivation|All participants terminating the double-blind phase of the study will receive open-label reconsolidation blockade treatment with propranolol combined with recall of the traumatic event for six weeks.
62450744|NCT05682495|EXPERIMENTAL|ARM A：SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2|
62450745|NCT05682495|EXPERIMENTAL|ARM B：HR20031 FDC 10/100/1000 mg|
62450746|NCT05682495|EXPERIMENTAL|ARM C：SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2|
62450747|NCT05682495|EXPERIMENTAL|ARM D：SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3|
62450748|NCT05682495|EXPERIMENTAL|ARM E：HR20031 FDC 5/50/750 mg*2|
62450749|NCT05682495|EXPERIMENTAL|ARM F：SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3|
62450750|NCT00379548|NO_INTERVENTION|1|Control group- subjects are on the Asian diet for the entire duration of the study
62450751|NCT00379548|EXPERIMENTAL|2|Asian and Caucasian subjects switch from an Asian Diet to a Western Diet midway through the study.
62450752|NCT02623959|EXPERIMENTAL|Indwelling Pleural Catheter (IPC) + Saline|"Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Saline in the catheter.~After the IPC is removed, participant is called one time each month by study staff to check on their status."
62450753|NCT02623959|ACTIVE_COMPARATOR|Indwelling Pleural Catheter (IPC) + Doxycycline|"Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Doxycycline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Doxycycline in the catheter.~After the IPC is removed, participant is called one time each month by study staff to check on their status"
62450754|NCT04697966|EXPERIMENTAL|Mindfulness (Headspace app)|
62450755|NCT04697966|ACTIVE_COMPARATOR|Active Control Condition|
62450756|NCT01298570|ACTIVE_COMPARATOR|Regorafenib + FOLFIRI|regorafenib 160 mg + FOLFIRI
62450757|NCT01298570|PLACEBO_COMPARATOR|Placebo + FOLFIRI|Placebo + FOLFIRI
62626305|NCT00572871||Exercise after fasting|Will complete 2 resistance exercise sessions and 2 plyometric exercise sessions after a 10-hour fast
62267322|NCT06320561||Patients in the first 3 months after stroke|"Inclusion criteria:~Adults (≥ 18 years old) Diagnosed with a first-ever stroke (as defined by WHO) Stroke onset ≤ 1 week (± 3 days) Able to provide written or verbal informed consent at admission Presence of gait problems as a consequence of the stroke (FAC≤4)~Exclusion criteria:~Presence of other neurological or orthopedic problems present prior to, or not caused as a direct consequence of, the stroke leading to impaired gait.~Modified Ranking scale pre-stroke \> 1/6, meaning presence of slight disability before the stroke.~Presence of severe comorbidities (e.g. osteoporosis, cardiovascular instability or chronic obstructive pulmonary disease).~Cerebellar or bilateral stroke. Presence of severe deficits in communication, memory or understanding precluding informed consent."
62267323|NCT06077266||Normalizing weight|Children classified as having normalized weight (iso-BMI 18.5-25 for age and sex) at the last observation defined by IOTF.
62267324|NCT06077266||Overweight or obesity|Children classified as having overweight or obesity (iso-BMI 25 ≤ for age and sex) at the last observation defined by IOTF.
62267325|NCT01445951|EXPERIMENTAL|Technosphere® Insulin with MedTone C Inhaler|Subjects will receive TI with the MedToneC inhaler and remain on the basal insulin they were taking prior to study entry
62267326|NCT01445951|ACTIVE_COMPARATOR|Aspart Group|Subjects will receive insulin aspart and remain on the basal insulin they were taking prior to study entry
62267327|NCT01445951|EXPERIMENTAL|Technosphere ® Insulin-Gen2 Group|Subject will receive Technosphere Insulin with Gen2 Inhaler and remain on the basal insulin they were taking prior to study entry
62267328|NCT06463613|EXPERIMENTAL|Skin Tag removal using the Manual Version of the STR|Goal: successful removal of 80% of the skin tags treated with the manual version of the STR device. Subjects will have up to two (2) tags treated, therefore, 50-100 subjects are anticipated for this arm. A total of 100 skin tags is the ITT (intention to treat). Subject pool to be divided (as equal as possible) between two band sizes; 2-4mm (micro), or 4-6mm (standard).
62267329|NCT06463613|EXPERIMENTAL|Skin Tag removal using the Auto Version of the STR|Goal: successful removal of 80% of the skin tags treated with the auto version of the STR device. Subjects will have up to two (2) tags treated, therefore, 50-100 subjects are anticipated for this arm. A total of 100 skin tags is the ITT (intention to treat). Subject pool to be divided (as equal as possible) between two band sizes; 2-4mm (micro), or 4-6mm (standard).
62267330|NCT04713865||PFA slightly jailed by proximal SFA stent(100 pts)|
62267331|NCT04713865||PFA moderately jailed by proximal SFA stent(100 pts)|
62267332|NCT04713865||PFA totally jailed by proximal SFA stent (100pts)|
62267333|NCT02033564|ACTIVE_COMPARATOR|Macintosh/Miller Laryngoscope|Macintosh or Miller laryngoscopy blade, preference left up to practitioner conducting intubation. These are the gold standards currently used in laryngoscopy.
62267334|NCT02033564|ACTIVE_COMPARATOR|Glidescope Laryngoscope|Glidescope video-guided laryngoscopy blade
62267335|NCT03884738|ACTIVE_COMPARATOR|Concentric|Leg Curl Training
62267336|NCT03884738|ACTIVE_COMPARATOR|Eccentric|Nordic Hamstring Training
62267337|NCT03884738|ACTIVE_COMPARATOR|Neuromuscular Electrical Stimulation|Stimulation Training
62267338|NCT01526902|ACTIVE_COMPARATOR|omafilcon A / PC 1-D MF|"omafilcon A (PC 1-D MF) / lotrafilcon B (AIR OPTIX MF)~Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses."
62267339|NCT01526902|ACTIVE_COMPARATOR|lotrafilcon B / Air Optix MF|"lotrafilcon B (AIR OPTIX MF) / omafilcon A (PC 1-D MF)~Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses."
62267340|NCT00177944||patients with funal infections|
62267341|NCT02177201|SHAM_COMPARATOR|Group 1|intravenous administration of 10 ml/kg/h 0.9% saline solution
62267342|NCT02177201|ACTIVE_COMPARATOR|Group 2|intravenous administration of 20 ml/kg/h 0.9% saline solution
62267343|NCT00743951|EXPERIMENTAL|1 Patient decision aid|Patient decision aid about treatment options for osteoarthritis
62267344|NCT00743951|ACTIVE_COMPARATOR|2 Usual care|Usual patient educational materials
62267345|NCT00578682|EXPERIMENTAL|1|Single IV dose of 0.3 mg/kg MEDI-557
62267346|NCT00578682|EXPERIMENTAL|2|Single IV dose of 3 mg/kg MEDI-557
62267347|NCT00578682|EXPERIMENTAL|3|Single IV dose of 15 mg/kg MEDI-557
62267348|NCT00578682|EXPERIMENTAL|4|Single IV dose of 30 mg/kg MEDI-557
62267349|NCT04194255|EXPERIMENTAL|ferrous fumarate|labelled iron as ferrous fumarate
62267350|NCT04194255|EXPERIMENTAL|ferrous fumarate + 15 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g GOS
62267351|NCT04194255|EXPERIMENTAL|ferrous fumarate + 15 g FOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g FOS
62267352|NCT04194255|EXPERIMENTAL|ferrous fumarate + 15 g acacia gum|labelled iron as ferrous fumarate + prebiotics in the form of 15 g acacia gum
62267353|NCT02154282|EXPERIMENTAL|ipod games|Administered ipod games with cognitive testing before and after
62267354|NCT04286204|EXPERIMENTAL|Basic Life Support Training based on ICTs|It will be conformed with students from one highschool random selected. They will receive a basic life support training based on Information and communication technologies.
62267355|NCT04286204|ACTIVE_COMPARATOR|Classic Basic Life Support Training|It will be conformed with students from another highschool random selected. They will receive a full and conventional basic life support training based on American and Hear Association recommendations.
62267356|NCT04073771||Cohort study|Patients with septic shock undergoing continuous renal replacement therapy
62267357|NCT04213612|EXPERIMENTAL|PLD+CTX+VCR|CTX 1g/m2/d，D1-2 VCR 1.5mg/m2，D1
62267358|NCT03098784||Air France employees working near runways|"Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports.~Intervention: Exposure to aircraft exhaust"
62267359|NCT03098784||Air France employees working inside|"Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports.~Intervention: Non exposure to aircraft exhaust"
62267360|NCT03363815|EXPERIMENTAL|Part1:Omeprazole + Midazolam + Warfarin + Vitamin K + CC-90001|Patient will receive CC-90001, 20mg Omeprazole, 2mg Midazolam 10mg Warfarin and 10mg Vitamin K
62852117|NCT00874939|EXPERIMENTAL|PBO→MK-7.5→DON→MK-25|Treatment by single oral dose with Placebo (PBO) in the first crossover period; MK-0249 7.5 mg (MK-7.5) in the second crossover period; Donepezil 5 mg (DON) in the third crossover period; and MK-0249 25 mg (MK-25) in the fourth crossover period.
62626306|NCT00572871||No exercise|Will complete a ten-hour fast but do no exercise
62626307|NCT00572871||Exercise after snack|Will complete 2 resistance exercise sessions and 2 plyometric exercise sessions 2 hours following a 500 calorie nutritional supplement
62626308|NCT02087670|ACTIVE_COMPARATOR|controlled, supervised exercise protocol|controlled, supervised exercise protocol within a cardiac rehabilitation program
62626309|NCT02087670|PLACEBO_COMPARATOR|community based exercise|educational program and not supervises exercise program
62626310|NCT05660785|EXPERIMENTAL|CsA + Herombopag|Herombopag combined with cyclosporine
62626311|NCT00257738|EXPERIMENTAL|MAGE -A3 vaccine|for those individuals in which tumor tests positive for MAGE-A3
62267361|NCT03363815|EXPERIMENTAL|Part 2- Rosuvastatin and CC-90001|Patients will receive CC-90001 and 10mg of Rosuvastatin
62267362|NCT03363815|EXPERIMENTAL|Part 3: Metformin + Digoxin and CC-90001|Patients will receive CC-90001, 500mg Metformin and 0.25mg, Digoxin
62626312|NCT00257738|EXPERIMENTAL|HPV 16 vaccine|for patients with HPV 16 positive tumor
62626313|NCT03300050|EXPERIMENTAL|Group 1: cH8/1N1 LAIV and cH5/1N1 IIV + adjuvant|Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85.
62626314|NCT03300050|EXPERIMENTAL|Group 2: cH8/1N1 LAIV and cH5/1N1 IIV|Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL cH5/1N1 IIV administered as an intramuscular injection on Day 85.
62626315|NCT03300050|PLACEBO_COMPARATOR|Group 3: Placebo|Participants received 0.5 mL of normal saline administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL phosphate buffered saline (PBS) administered as an intramuscular injection on Day 85.
62626316|NCT03300050|EXPERIMENTAL|Group 4: cH8/1N1 IIV + adjuvant and cH5/1N1 IIV + adjuvant|Participants received 0.5 mL AS03-adjuvanted cH8/1N1 IIV administered as an intramuscular injection on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85.
62626317|NCT03300050|PLACEBO_COMPARATOR|Group 5: Placebo|Participants received 0.5 mL PBS administered as an intramuscular injection on Day 1 followed by 0.5 mL PBS administered as an intramuscular injection on Day 85.
62626318|NCT05436639|EXPERIMENTAL|SPI-62 dose|2mg dose level of SPI-62. Active drug by mouth.
62626319|NCT02666820|ACTIVE_COMPARATOR|Large balloon dilatation|Patients underwent clearance of common bile duct stones using a papillary large balloon dilatation.
62852118|NCT00874939|EXPERIMENTAL|MK-7.5→PBO→MK-25→DON|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; Placebo in the second crossover period; MK-0249 25 mg in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
62852119|NCT00874939|EXPERIMENTAL|DON→MK-25→PBO→MK-7.5|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; MK-0249 25 mg in the second crossover period; Placebo in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
62852120|NCT00874939|EXPERIMENTAL|MK-25→DON→MK-7.5→PBO|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; Donepezil 5 mg in the second crossover period; MK-0249 7.5 mg in the third crossover period; and Placebo in the fourth crossover period.
62626320|NCT02666820|ACTIVE_COMPARATOR|Mechanical lithotripsy|Patients underwent clearance of common bile duct stones using a mechanical lithotripsy.
62852121|NCT00874939|EXPERIMENTAL|PBO→MK-25→MK-7.5→DON|Treatment by single oral dose with Placebo in the first crossover period; MK-0249 25 mg in the second crossover period; MK-0249 7.5 mg in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
62852122|NCT00874939|EXPERIMENTAL|MK-7.5→DON→PBO→MK-25|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; Donepezil 5 mg in the second crossover period; Placebo in the third crossover period; and MK-0249 25 mg in the fourth crossover period.
62852123|NCT00874939|EXPERIMENTAL|DON→MK-7.5→MK-25→PBO|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; MK-0249 7.5 mg in the second crossover period; MK-0249 25 mg in the third crossover period; and Placebo in the fourth crossover period.
62062770|NCT05851599|EXPERIMENTAL|SKF7® - 562.5 mg|Patients who meet the entry criteria for the study will be randomized to receive 562.5 mg SKF7® for 16 weeks
62062771|NCT05851599|EXPERIMENTAL|SKF7® - 750 mg|Patients who meet the entry criteria for the study will be randomised to receive 750 mg SKF7® for 16 weeks
62267363|NCT03363815|EXPERIMENTAL|Part 4: Nintedanib and CC-90001|Patients will receive CC-90001 and 100mg of Nintedanib
62626321|NCT01827592|EXPERIMENTAL|EBX 10|Elobixibat 10 mg/day
62626322|NCT01827592|EXPERIMENTAL|EBX 5|Elobixibat 5 mg/day
62626323|NCT01827592|PLACEBO_COMPARATOR|PLCBO|Placebo
62626324|NCT01344473|EXPERIMENTAL|Casein phosphopeptide in the form of TM|Experimental group will be given TM to use daily for 12 weeks
62626325|NCT01344473|NO_INTERVENTION|No intervention|Standard oral care
62626326|NCT03001908|ACTIVE_COMPARATOR|control oscillation|control subjects with normal shoulders will undergo the glenohumeral mobilization-oscillation
62626327|NCT03001908|ACTIVE_COMPARATOR|control sustained|control subjects with normal shoulders will undergo the glenohumeral mobilization-sustained
62626328|NCT03001908|EXPERIMENTAL|stiff oscillation|subjects with stiff shoulders will undergo the glenohumeral mobilization-oscillation
62626329|NCT03001908|EXPERIMENTAL|stiff sustained|subjects with stiff shoulders will undergo the glenohumeral mobilization-sustained
62062772|NCT05851599|PLACEBO_COMPARATOR|Placebo|Placebo
62062773|NCT01538108|EXPERIMENTAL|NMB's PTA Balloon catheter with paclitaxel|
62062774|NCT01538108|ACTIVE_COMPARATOR|Standard Angioplasty Balloon|
62626330|NCT05118217||Clinical DPN without pain|"* Score above 2.5 on the Michigan Neuropathy Screening Instrument~* Score below 4 on the DN4"
62626331|NCT05118217||Painful DPN|"* Score above 2.5 on the MNSI~* Score above 4 on the DN4"
62626332|NCT03440138||University Hospital Zurich|
62626333|NCT03440138||St Pierre University Hospital, Brussels, Belgium|
62626334|NCT03440138||Sana Klinikum, Offenbach, Germany|
62852124|NCT00874939|EXPERIMENTAL|MK-25→PBO→DON→MK-7.5|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; Placebo in the second crossover period; Donepezil 5 mg in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
62852125|NCT00874939|EXPERIMENTAL|PBO→DON→MK-25→MK-7.5|Treatment by single oral dose with Placebo in the first crossover period; Donepezil 5 mg in the second crossover period; MK-0249 25 mg in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
62088022|NCT06312631|EXPERIMENTAL|Task handover model #5|"At each visit, the patient will perform the tasks with the gripping glove (A) or without the gripping glove (B).~The order of administration with then without the glove (AB) or without then with the glove (BA) is drawn at random for each patient.~The 5th model follows the following diagram:~Visit T1 = BA ; Visit T2 = BA ; Visit T3 = AB"
62267364|NCT00623428|EXPERIMENTAL|PEG-IFN alfa-2a + Ribavirin for 24 weeks|After 24 weeks of treatment with pegylated interferon alfa-2a (PEG-IFN alfa-2a) 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA \<15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, at which time treatment was stopped. Participants were followed for an additional 48 weeks during the treatment-free follow-up period.
62267365|NCT00623428|ACTIVE_COMPARATOR|PEG-IFN alfa-2a + Ribavirin for 48 weeks|After 24 weeks of treatment with PEG-IFN alfa-2a 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA \<15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, and continued treatment for another 24 weeks (for a total of 48 weeks of treatment). Participants were followed for an additional 24 weeks during the treatment-free follow-up period.
62267366|NCT04922476|EXPERIMENTAL|Probiotic|Alflorex® The participants consume one probiotic capsule a day for 12 weeks.
62267367|NCT01617980|OTHER|Multimodal hypoxia imaging|Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
62626335|NCT03440138||Complutense University of Madrid, Spain|
62626336|NCT03440138||Musgrove Park Hospital, Taunton, UK|
62852126|NCT00874939|EXPERIMENTAL|MK-7.5→MK-25→DON→PBO|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; MK-0249 25 mg in the second crossover period; Donepezil 5 mg in the third crossover period; and Placebo in the fourth crossover period.
62626337|NCT03440138||University of Gothenburg, Sweden|
62626338|NCT03440138||AZ Sint-Jan Hospital in Bruges, Belgium|
62626339|NCT03440138||Bristol|
62626340|NCT03440138||Cleveland Clinic, Weston, Florida, USA|
62626341|NCT03440138||Oswaldo Cruz German Hospital, Sao Paolo, Brazil|
62626342|NCT03440138||Clínica Las Condes, Santiago, Chile|
62852127|NCT00874939|EXPERIMENTAL|DON→PBO→MK-7.5→MK-25|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; Placebo in the second crossover period; MK-0249 7.5 mg in the third crossover period; and MK-0249 25 mg in the fourth crossover period.
62852128|NCT00874939|EXPERIMENTAL|MK-25→MK-7.5→PBO→DON|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; MK-0249 7.5 mg in the second crossover period; Placebo in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
62852129|NCT05630963||MDD subjects|Subjects diagnosed with Major Depression Disorder
62852130|NCT05630963||Remitted MDD subjects|Subjects with a history of major depressive disorder episode in the past
62852131|NCT05630963||Control subjects|Subjects with no history of known neurological and psychiatric illness.
62852132|NCT00609531|EXPERIMENTAL|Active|Individuals with an Autism Spectrum Disorder receiving citalopram
62626343|NCT03440138||Brown University, Providence Rhode Island|
62626344|NCT03440138||Fresno Bariatric, CA, USA|
62626345|NCT03440138||Rijnstate Hospital, Arnhem, The Netherlands|
62626346|NCT03440138||CHU Nice, France|
62852133|NCT00609531|PLACEBO_COMPARATOR|Placebo|Individuals with an Autistic Spectrum Disorder receiving placebo
62267368|NCT00456989|EXPERIMENTAL|Taxotere and Doxil|Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively. Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
62267369|NCT00193063|EXPERIMENTAL|Intervention|All patients entering this trial received treatment with a combination of gemcitabine and trastuzumab. Gemcitabine 1000 mg/m2 was administered intravenously on days 1, 8,and 15 of a 28-day cycle. Trastuzumab was administered as a 4 mg/kg intravenous loading dose on day 1 and subsequently at a dose of 2 mg/kg on a weekly basis.
62852134|NCT00003590|EXPERIMENTAL|Hydroxyurea|
62267370|NCT01972048|ACTIVE_COMPARATOR|Control group|Participants in the control group will receive the mailed print brochure about breast cancer screening and community resources.
62267371|NCT01972048|EXPERIMENTAL|Intervention group|Participants will receive the mMammogram intervention.
62267372|NCT00879697|ACTIVE_COMPARATOR|Strength training|Patients who performed strength training. The strength training program was composed by 8 exercises for whole body performed at sub-maximal intensity prescribed according to the patients self-perceived effort
62267373|NCT00879697|ACTIVE_COMPARATOR|Walking training|Patients who performed walking training. The walking training was performed in a treadmill using sub-maximal intensity prescribed based in patients self perceived effort
62267374|NCT01206959||monitor method|"blood pressure monitor Cuff circumference:22cm-48cm~stethoscopy Cuff circumference: 22cm-48cm"
62267375|NCT01527773||COPD cohort|Cohort of patients with proven COPD
62267376|NCT05852535||case report|
62267377|NCT06203561|EXPERIMENTAL|The observation group|"The patients were provided with 1) basic treatment including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control, and 2) comprehensive rehabilitation therapy including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.~For the observation group, the nasogastric tube was removed, and Intermittent oro-esophageal tube feeding was initiated for nutrition support within 4 hours after completing the admission assessment, following the standard Intermittent oro-esophageal tube feeding procedure."
62267378|NCT06203561|ACTIVE_COMPARATOR|The control group|"The patients were provided with 1) basic treatment including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control, and 2) comprehensive rehabilitation therapy including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.~Patients in the control group were provided with nutrition support by the indwelling nasogastric tube. The entire feeding process strictly followed the standardized procedure for nasogastric feeding."
62267379|NCT01481038||Group dialysis patients|Patient on hemodialysis with central venous catheter
62267380|NCT01481038||Group hematology patients|Patients with hemato-oncologic underlying disease (plus/minus hematopoietic stem cell transplantation HSCT) and central venous catheter
62267381|NCT05430763||Williams syndrome|Nerve conduction test (NCT) Nerve ultrasound Clinical evaluation GAITRite walkway Motor questionnaire
62267382|NCT05430763||Control, age matched|Nerve conduction test (NCT) Nerve ultrasound Clinical evaluation GAITRite walkway Motor questionnaire
62267383|NCT00800332|EXPERIMENTAL|1|
62267384|NCT00800332|EXPERIMENTAL|2|
62267385|NCT00800332|PLACEBO_COMPARATOR|3|
62267386|NCT01991782|NO_INTERVENTION|Control|Control patients with all follow-up visits in person at the Vanderbilt Orthopaedic Trauma clinic (2 weeks, 6 weeks, 3 months, and 6 months post-operative).
62267387|NCT01991782|EXPERIMENTAL|Telemedicine|Experimental cohort with two follow-up visits (6 weeks and 6 months) occurring via telemedicine video calls and two follow-up visits (2 weeks and 3 months) occurring in person.
62267388|NCT01588977||All-Inside TightRope technique|
62267389|NCT01588977||ACL reconstruction with TLS system|
62267390|NCT01588977||Hamstring Tendon Graft Reconstruction of the ACL|
62267391|NCT02519933|ACTIVE_COMPARATOR|mNT-BBAVF|Patients in Chronic Kidney Disease (CKD) stage 4-5 without previous dysfunctional fistula access
62267392|NCT02519933|ACTIVE_COMPARATOR|BCAVF|Patients in CKD stage 4-5 without previous dysfunctional fistula access
62267393|NCT03809611|EXPERIMENTAL|UNR844-Cl Ophthalmic Solution|1.5% UNR844-Cl ophthalmic solution for twice-daily dosing
62267394|NCT03809611|PLACEBO_COMPARATOR|Placebo Ophthalmic Solution|placebo ophthalmic solution for twice-daily dosing
62267395|NCT02263716||Accelerometer|Utilize accelerometers to measure activity in a diverse population of patients with medical or surgical critical illness.
62852135|NCT01192802|ACTIVE_COMPARATOR|1 dose, Albendazole , tablet|
62267396|NCT05178238||Patients with high viral load of SARS-CoV-2 in feces|
62267397|NCT05178238||Patients with low viral load of SARS-CoV-2 in feces|
62267398|NCT01223703|ACTIVE_COMPARATOR|n-3 PUFAs|
62267399|NCT01223703|PLACEBO_COMPARATOR|Placebo|
62267400|NCT02879565|OTHER|qualitative and neuroimaging research|
62267401|NCT04765800|ACTIVE_COMPARATOR|Unified Psychodynamic Protocol for Emotional Disorders (UPP-EMO)|manualized treatment with a focus on core psychodynamic treatment principles; no use of imagery-based interventions.
62267402|NCT04765800|EXPERIMENTAL|Guided Imagery Psychotherapy for Emotional Disorders (GIP-EMO)|manualized treatment with regular applications (every 4-5 sessions) of guided affective imagery; the therapeutic work is explicitly focused on the patient's guided imagery.
62852136|NCT01192802|ACTIVE_COMPARATOR|2 doses, albendazole, tablet|1 tablet of 400 mg of albendazole per day for two consecutive days
62852137|NCT01192802|ACTIVE_COMPARATOR|3 doses albendazole, 400mg, tablet|
62852138|NCT01651962|EXPERIMENTAL|Terbutaline|Terbutaline 0.125mg i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
62852139|NCT01651962|ACTIVE_COMPARATOR|Fentanyl|Fentanyl 100mcg i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
62450758|NCT05608356|EXPERIMENTAL|intervention group|"Intervention group subjects will receive injectable platelet rich fibrin (i-prf) . The (i-prf) will be injected in the periodontal ligament of maxillary anterior teeth during en masse retraction.The injection sites will be the sites of bone compression to target the surfaces of the bone where osteoclastogenesis and bone resorption occurs during en masse retraction.~Considering that the obtained (i-prf) after centrifuging would be 4 ml, 1 ml will be injected intraligamentally distal to the right and left canines, and 0.5 ml will be injected intraligamentally palatal to each incisor. The study group will receive i-PRF intraligamentally in the periodontal ligament space of the maxillary six anterior teeth three times as follow, just before anterior teeth retraction, and after 21 days of the retraction, and after 42 days of the retraction. Before each time of injection, an anesthetic solution will be administered for pain control."
62267403|NCT01621633|EXPERIMENTAL|Group 1: mild hepatic impairment|LCZ696 200 mg, given as a single oral dose
62267404|NCT01621633|EXPERIMENTAL|Group 2: moderate hepatic impairment|LCZ696 200 mg, given as a single oral dose
62267405|NCT01621633|EXPERIMENTAL|Group 3: healthy volunteers|LCZ696 200 mg, given as a single oral dose. Each healthy volunteer will match in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in groups 1 and 2
62267406|NCT05985031|EXPERIMENTAL|Spinal cord injuries|This was the patient group. Achilles tendon hits were performed for eliciting the soleus T reflex while the ankle was in neutral, dorsiflexion, and plantar flexion. Surface and multi-unit EMG recordings were taken from the anterior and soles muscles of the tibialis during the tendon tapping.
62267407|NCT05985031|ACTIVE_COMPARATOR|Healthy Control|This was the healthy control group. Achilles tendon hits were performed for eliciting the soleus T reflex while the ankle was in neutral, dorsiflexion, and plantar flexion. Surface and multi-unit EMG recordings were taken from the anterior and soles muscles of the tibialis during the tendon tapping.
62450759|NCT05608356|SHAM_COMPARATOR|control group|Subjects in the control group will only receive sham (placebo) injection three successive times with and interval of 21days between each injection, similar to the timepoints of (i-prf) injection in the intervention group. Also the sites of injection will be similar to the sites of injection of the intervention group; 1 ml of the placebo agent will be injected intraligamentally distal to the right and left canines, and 0.5 ml will be injected intraligamentally palatal to each incisor. An anesthetic solution will be administered for pain control before the administration of the sham injections.
62450760|NCT01138683|ACTIVE_COMPARATOR|ultrafiltration group|
62852140|NCT01651962|PLACEBO_COMPARATOR|Placebo|0.9% NaCl i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
62852141|NCT02878187||placenta previa|all women managed by conservative surgical techniques during cesarean section after intraoperative hemorrhage due to placenta previa/accreta
62267408|NCT06399887|ACTIVE_COMPARATOR|Group I : Dynamic neuromuscular stabilization exercise training|"Group I~• dynamic neuromuscular stabilization exercise training~* 45 minute/ 3 sessions/ week~* 12 weeks"
62267409|NCT06399887|ACTIVE_COMPARATOR|Group II : Biofeedback training|"Group II~• biofeedback training~* 20 minute/ 1 sessions/ week~* 12 weeks"
62267410|NCT06399887|ACTIVE_COMPARATOR|Group III : Dynamic neuromuscular stabilization exercise training + biofeedback training|"Group III~* dynamic neuromuscular stabilization exercise training~  * 45 minute/ 3 sessions/ week~ * 12 weeks~* biofeedback training~  * 20 minute/1 sessions/week~ * 12 weeks"
62267411|NCT02152852|EXPERIMENTAL|Community Health Worker Intervention|Community Health Worker Intervention-home visits from community health workers providing education and support for self-management of type 2 diabetes, resources for diabetes control, and assistance in effective communication with medical providers
62267412|NCT02152852|NO_INTERVENTION|Usual Care Control Group|Usual Care Control Group- Usual care is defined as services received by participants in the absence of the intervention plus information about community resources that support diabetes self-management (such as classes and support groups) and educational pamphlets.
62267413|NCT00533442|ACTIVE_COMPARATOR|Tacrolimus plus MMF plus Steroids|Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Mycophenolate Mofetil (MMF), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.
62852142|NCT02878187||healthy controls|women delivered by Cesarean for any other indication with no intraoperative hemorrhage or any additional surgical techniques performed during Cesarean
62852143|NCT06126250|EXPERIMENTAL|U-shaped power toothbrush|Device: U-shaped Power Toothbrush with fluoride toothpaste
62852144|NCT06126250|PLACEBO_COMPARATOR|Manual Toothbrush|Device: Soft Manual Toothbrush with fluoride toothpaste
62852145|NCT03047824|OTHER|Continuous monitoring-guided therapy|Healthcare providers were allowed to use the blood glucose values displayed on the intravascular continuous monitoring to adapt insulin therapy
62852146|NCT03047824|OTHER|Standard of care|Healthcare providers used the usual intermittent method to adapt insulin therapy; the blood glucose values measured by the intravascular continuous monitoring were not displayed but recorded. Usual care involves the adjustment of insulin infusion based on BG values measured with a blood gas analyser 4-6 times per day.
62852147|NCT03287518|ACTIVE_COMPARATOR|Verum|WAK2017 One (1) ml IP should be taken with breakfast and one (1) ml with supper every day.
62852148|NCT03287518|PLACEBO_COMPARATOR|Placebo|"The placebo liquid is identical in colour and flavor to the verum. In order to maintain the blind with respect to the odour, the placebo will contain 3% Concentrated Aged Garlic Extract (DER 0.9-1.2:1), which is considered as inactive with respect to a potential beneficial effect.~One (1) ml IP should be taken with breakfast and one (1) ml with supper every day."
62852149|NCT04508218|EXPERIMENTAL|Protein+ Exercise group|Received oral protein supplementation, exercise program and traditional burn care
62852150|NCT04508218|EXPERIMENTAL|Protein group|Received oral protein supplementation and traditional burn care
62852151|NCT04508218|EXPERIMENTAL|Exercise group|Received exercise program and traditional burn care
62450761|NCT01138683|ACTIVE_COMPARATOR|diuretics group|
62450762|NCT00383890|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine 1 mcg/kg load for 10 minutes and Dexmedetomidine Maintenance (0.7 mcg/kg/hr) for 15 min
62450763|NCT00383890|PLACEBO_COMPARATOR|Placebo (PBO)|Placebo load for 10 min and Placebo maintenance for 15 min
62450764|NCT05468229|ACTIVE_COMPARATOR|dorzagliatin|Dorzagliatin 50 mg single dose
62450765|NCT05468229|PLACEBO_COMPARATOR|placebo|matching placebo
62626347|NCT03440138||Claraspital Basel, Switzerland|
62626348|NCT03440138||Gastro-Obeso-Center Advanced Med Inst, Brazil|
62626349|NCT03440138||Hospital Dipreca Santiago Región Metropolitana , Chile|
62626350|NCT03440138||Medical University Wien, Austria|
62626351|NCT04304508|EXPERIMENTAL|BAY2433334 high dose|
62626352|NCT04304508|EXPERIMENTAL|BAY2433334 medium dose|
62626353|NCT04304508|EXPERIMENTAL|BAY2433334 low dose|
62626354|NCT04304508|PLACEBO_COMPARATOR|BAY2433334 matching placebo|
62626355|NCT05667506|EXPERIMENTAL|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
62626356|NCT01563315||Adults with CAP admitted to hospital|All adult patients with CAP admitted to Vestre Viken HF-Buskerud Hospital (VVHF-BH), a 400-bed community general hospital, between January 2008 og January 2011 were evaluated for inclusion in the study.
62626357|NCT04164797|EXPERIMENTAL|treatment group|endostar : 7.5mg/m2/d,continuous infusion for 5 days in week 1、3、5、7, chemotherapy：paclitaxel liposomes 50mg / m2, ivgtt, d8, 15, 22, 29, 36, carboplatin AUC 2, ivgtt d8, 15, 22, 29, 36 radiotherapy：EBRT，61.2 Gy，1.8Gy/d
62267414|NCT00533442|EXPERIMENTAL|Tacrolimus plus Rapamycin plus Steroids|Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Rapamycin (Sirolimus), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.
62267415|NCT02915081|EXPERIMENTAL|Blue light|Subjects will be exposed to 24 hours of bright (1700 lux) blue (peak 442 nm) spectrum light the day prior to operative intervention and for the 24 hours after the operative intervention.
62267416|NCT02915081|NO_INTERVENTION|Ambient light|Subjects will be exposed preoperatively to the lighting conditions of their living environment and postoperatively to the standard, white fluorescent lighting environment of the hospital.
62267417|NCT02739607|EXPERIMENTAL|Transdiagnostic program|This arm represents the Transdiagnostic intervention program for emotional disorders. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms.
62626358|NCT04164797|ACTIVE_COMPARATOR|control group|chemotherapy：paclitaxel liposomes 50mg / m2, ivgtt, d8, 15, 22, 29, 36, carboplatin AUC 2, ivgtt d8, 15, 22, 29, 36 radiotherapy：EBRT，61.2 Gy，1.8Gy/d
62626359|NCT01966744||Clinicians/Nurses|Clinicians and nurses who treat patients diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
62852152|NCT04508218|OTHER|Control group|Received traditional burn care
62267418|NCT02739607|NO_INTERVENTION|Wait list control group|This arm represents the wait-list comparison group.
62267419|NCT03048929|ACTIVE_COMPARATOR|Typhoid Vi Polysaccharide Vaccine|Patients will receive one intramuscular 0.5 mL injection of Typhoid Vi Polysaccharide Vaccine containing 0.025 mg purified Vi polysaccharide.
62267420|NCT03048929|PLACEBO_COMPARATOR|Placebo|Patients will receive one intramuscular 0.5 mL injection of saline placebo.
62267421|NCT05026398|EXPERIMENTAL|Fenfluramine|Drug: Fenfluramine - 15mg twice daily oral solution for seven days
62267422|NCT05026398|PLACEBO_COMPARATOR|Placebo|Placebo - 15mg twice daily oral solution for seven days
62267423|NCT05286970|EXPERIMENTAL|0.5mg AK115 SC|
62267424|NCT05286970|EXPERIMENTAL|1mg AK115or placebo SC|
62267425|NCT05286970|EXPERIMENTAL|3mg AK115or placebo SC|
62852153|NCT00262938|ACTIVE_COMPARATOR|Lifestyle counseling|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling.Patients undergo quality of life, exercise, and clinical assessments at baseline and at 3, 6, and 12 months.
62626360|NCT01966744||Patients|Patients age 11-18 years diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
62626361|NCT01966744||Caregivers|Caregivers of patients diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
62626362|NCT01750645||Intervention Group|
62626363|NCT01750645||Control Group|
62267426|NCT05286970|EXPERIMENTAL|10mg AK115or placebo SC|
62267427|NCT05286970|EXPERIMENTAL|30mg AK115or placebo SC|
62267428|NCT05286970|EXPERIMENTAL|60mg AK115or placebo SC|
62626364|NCT01675674||Dried blood spot test for MPS|"For the prospective study, subjects will be drawn from all children (aged 6 months to 18 years) with a history of presenting to selected clinics (pediatric rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE highly suspicious symptom or at least TWO less suspicious symptoms that may be indicative of an MPS disorder (see inclusion criteria).~For the retrospective chart review, subjects will be drawn from all children who were 6 months to 18 years of age at the time of first presentation to selected clinics (pediatric rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE highly suspicious symptom or at least TWO less suspicious symptoms that may be indicative of an MPS disorder (see inclusion criteria)."
62626365|NCT06612112||Thoracic SCI individuals|According to the ASIA (American Spinal Injury Association) Scale criteria, ASIA A patients had a complete lesion; ASIA B, ASIA C and ASIA D patients had an incomplete lesion.
62626366|NCT04275453|EXPERIMENTAL|Ketogenic diet - 24 hours|Subjects will undergo FDG PET/CT after 1 day of dietary modification (ketogenic diet for at least 3 meals) and 12 hours of fasting prior to FDG injection.
62626367|NCT04275453|EXPERIMENTAL|Ketogenic diet - 72 hours|Subjects will then undergo FDG PET/CT after 3 day of dietary modification (ketogenic diet for at least 9 meals) and 12 hours of fasting prior to FDG injection.
62652898|NCT01697579|EXPERIMENTAL|Fosaprepitant 3 mg/kg-Cycles 2-6|For optional Cycles 2-6, participants from Cycle 1 fosaprepitant arms (3, 1.2, or 0.4 mg/kg) or Cycle 1 control arm were administered fosaprepitant 3 mg/kg IV (or age-adjusted equivalent). For Cycle 2, fosaprepitant was administered IV plus ondansetron with or without dexamethasone. For Cycles 3-6, fosaprepitant was administered IV plus a 5-HT3 antagonist with or without dexamethasone.
62852154|NCT00262938|ACTIVE_COMPARATOR|Without Counseling|Patients undergo quality of life, exercise, and clinical assessments at baseline and at 3, 6, and 12 months.
62852155|NCT02949479|OTHER|Dissociation Investigation in Sex Offenders|The study will be proposed to the subjects after their usual clinical evaluation in the center for sexual offence, and to extend this evaluation by a specific focus on childhood abuse and neglect, trauma and dissociative history
62062775|NCT05932056|EXPERIMENTAL|Miles de Manos (Thousands of Hands) Intervention|"Parents and teachers from schools randomized to this arm will receive the Miles de Manos (Thousands of Hands) intervention. Miles de Manos (Thousands of Hands) comprises 3 components: a cognitive-behavioral skills training component for parents (8 sessions), a cognitive-behavioral skills training component for school staff (10 sessions), and a bridge component that brings parents, teachers, and school administrators together to talk about how to support each other's efforts related to youth violence prevention (4 sessions). Core elements include effective communication, clear expectations, limits and consequences, positive reinforcement, adult supervision and monitoring, effective problem solving, and emotion regulation. Miles de Manos (Thousands of Hands) is highly interactive and involves brief lectures, small and large group discussions, role-plays, and interactive exercises."
62062776|NCT05932056|NO_INTERVENTION|Control|Parents and teachers from schools randomized to this arm will receive services as usual as provided by their schools.
62267429|NCT02034890|EXPERIMENTAL|hyaluronic acid|intravesical instillation of 40 mg of hyaluronic acid at 6 specific time points: 1,2,3 and 4 weeks postoperatively 2 and 3 months postoperatively
62267430|NCT02034890|NO_INTERVENTION|retrospective control patients|retrospective control patients
62267431|NCT00776607|EXPERIMENTAL|Insulin|Insulin: NovoMix 30. Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal.
62450766|NCT03587207|EXPERIMENTAL|MenABCWY Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenABCWY twice, 2 months apart (Day 1 and Day 61).
62450767|NCT03587207|ACTIVE_COMPARATOR|rMenBOMV+ACWY_S Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in the same arm twice, 2 months apart (Day 1 and Day 61).
62062777|NCT05694897|ACTIVE_COMPARATOR|Erector spinae block using a combination of bupivacaine and magnesium sulfate|Ultrasound guided erector spinae block at the level of T10 using a combination of 20 ml bupivacaine 0.25% and 3.75ml magnesium sulfate for treatment of postoperative pain
62852156|NCT02045043||Cardiomyopathy patients with ICDs|
62062778|NCT05694897|ACTIVE_COMPARATOR|Erector spinae block using a combination of bupivacaine and dexmedetomidine|Ultrasound guided erector spinae block at the level of T10 using a combination of 20 ml bupivacaine 0.25% and 1ug/kg dexmedetomidine for treatment of postoperative pain
62267432|NCT00776607|ACTIVE_COMPARATOR|Tablet|Patients will progress from lifestyle modification to metformin, to metformin with Rosiglitazone and finally insulin depending on HbA1c levels.
62267433|NCT02702765|EXPERIMENTAL|Wilsons disease|All patients will receive all interventions (galactose elimination capacity test , ultrasound, fibroscan, continuous reaction time test and functional hepatic nitrogen clearance ), except liver biopsy.
62267434|NCT06103201|EXPERIMENTAL|Metabolic MRI in traumatic brain injury patients|Perform metabolic magnetic resonance imaging on patients who have traumatic brain injury to understand early brain metabolism changes in this population
62267435|NCT06103201|EXPERIMENTAL|Metabolic MRI in subarachnoid hemorrhage patients|Perform metabolic magnetic resonance imaging on patients who have subarachnoid hemorrhage to understand early brain metabolism changes in this population
62267436|NCT06103201|EXPERIMENTAL|Metabolic MRI in healthy volunteers|Perform metabolic magnetic resonance imaging on healthy volunteers to understand early brain metabolism changes in this population
62450768|NCT03587207|ACTIVE_COMPARATOR|rMenBOMV+ACWY_D Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in 2 different arms twice, 2 months apart (Day 1 and Day 61).
62450769|NCT03587207|ACTIVE_COMPARATOR|rMenBOMV Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of rMenB+OMV NZ (Bexsero) twice, 2 months apart (Day 1 and Day 61).
62450770|NCT03587207|ACTIVE_COMPARATOR|MenACWY Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenACWY (Menveo) once at Day 1, which was the first and last vaccination for MenACWY group.
62852157|NCT01757990|EXPERIMENTAL|Stevioside extract|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the solution containing Stevioside extract. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
62450771|NCT02949323||children with urinary stones|children with urinary stones
62450772|NCT02949323||children without urinary stones|children without urinary stones
62626368|NCT04275453|EXPERIMENTAL|Exogenous ketone ester|Subjects will undergo FDG PET/CT after 1 dose of ketone drink administration after 12 hours of fasting prior to FDG injection. The dosing of ketone drink administration (approximately 65 mL) will be weight based (714 mg/kg), which is crucial to replicating ketone levels between participants. The KE drink will be administered approximately 45 minutes prior to FDG injection as concentrations of \~3 mmol/L are reached within 60 minutes . By way of comparison, website marketing of the commercial drink recommends ingestion 30 minutes prior to athletic performance. We will also perform echocardiography immediately before and 30 minutes after the drink.
62626369|NCT02484092|EXPERIMENTAL|SPK-9001|Single intravenous (i.v.) infusion of SPK-9001 \[an adeno-associated viral (AAV) vector with human factor IX gene\] Intervention: Gene Therapy / Gene Transfer
62626370|NCT06612528|EXPERIMENTAL|M1 and vocal exercise|anodal tDCS over primary motor cortex associated with the vocal exercise using the flexible tube in water.
62626371|NCT06612528|ACTIVE_COMPARATOR|Cerebellum and vocal exercise|anodal tDCS over cerebellum associated with the vocal exercise using the flexible tube in water.
62062779|NCT01054573|EXPERIMENTAL|Telaprevir + Standard Treatment|Telaprevir 750 mg orally (by mouth) every 8h for 12 weeks plus standard treatment. Standard treatment is 180 mcg subcutaneous (under the skin) injection pegylated interferon (Peg-IFN) alfa-2a and 1000-1200 mg twice daily ribavirin (RBV) for 48 weeks.
62852158|NCT01757990|EXPERIMENTAL|Rebauside extract|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the solution containing Rebaudioside extract. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
62852159|NCT01757990|SHAM_COMPARATOR|Saccarosio|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
62852160|NCT05862506|EXPERIMENTAL|The Daily Mile|The intervention consisted of walking, jogging or running for \~ 15 min (\~ one mile) of exercise at a pace self-selected by each individual child, outside the school buildings during recess time, three times a week during 10 weeks. Children were instructed to maintain active for the full 15 min and, if necessary, to stop for resting only occasionally.
62062780|NCT05563363|EXPERIMENTAL|Home treatment|Home visits by care staff at the same frequency as in hospital
62062781|NCT05563363|ACTIVE_COMPARATOR|Standard inpatient treatment|Inpatient treatment on hospital ward
62267437|NCT01500109|EXPERIMENTAL|Ofirmev®|Oral inert cherry syrup will be administered preoperatively as placebo for oral acetaminophen. Ofirmev® will be administered in the operating room once intravenous access is established. Patients will receive standardized dose of local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon before surgical incision as well as at the completion of surgery with Bupivacaine 0.25% with Epinephrine. Postoperatively patients will receive Ofirmev® every 6 hours as well as placebo oral cherry elixir every 6 hours and morphine as needed for 24 hours.
62450773|NCT03770923|NO_INTERVENTION|No intervention|No intervention
62450774|NCT03770923|ACTIVE_COMPARATOR|Rupatadine|Rupatadine 10 mg once daily.
62062782|NCT06050902|NO_INTERVENTION|Standard ultrasound guidance for subclavian venipuncture|62 patients undergoing the usual standard ultrasound guidance technique for subclavian venipuncture
62062783|NCT06050902|EXPERIMENTAL|Subclavian venipuncture using the needle-steering device|62 patients undergoing subclavian venipuncture using the needle-steering device
62062784|NCT05483933|EXPERIMENTAL|Pegylated Liposomal Doxorubicin + SL-172154 (SIRPα-Fc-CD40L)|Pegylated Liposomal Doxorubicin (PLD) will be administered via intravenous administration + SL-172154 (SIRPα-Fc-CD40L) will be administered via intravenous administration.
62450775|NCT03770923|ACTIVE_COMPARATOR|Montelukast|Montelukast 10 mg daily
62450776|NCT01392898|EXPERIMENTAL|liraglutide|
62450777|NCT01392898|ACTIVE_COMPARATOR|insulin|
62450778|NCT02801877|EXPERIMENTAL|IntelliCare Hub recommender, coach|Participant is randomly assigned to receive the IntelliCare Hub App with the recommender system, and receive coaching for the 8 week IntelliCare program.
62450779|NCT02801877|EXPERIMENTAL|IntelliCare Hub recommender, no coach|Participant is randomly assigned to receive the IntelliCare Hub App with the recommender system, and independently use the IntelliCare program for 8 weeks.
62450780|NCT02801877|EXPERIMENTAL|IntelliCare Hub no recommender, coach|Participant is randomly assigned to receive the IntelliCare Hub App without the recommender system, and receive coaching for the 8 week IntelliCare program.
62450781|NCT02801877|EXPERIMENTAL|IntelliCare Hub no recommender, no coach|Participant is randomly assigned to receive the IntelliCare Hub App without the recommender system, and independently use the IntelliCare program for 8 weeks.
62450782|NCT03832465|EXPERIMENTAL|Intraluminal Levofloxacin powder therapy|Group A Crashed powder of film-coated Levofloxacin Tablet (1 gm) for the Intraluminal therapy
62450783|NCT03832465|ACTIVE_COMPARATOR|Intraluminal Levofloxacin solution therapy|Group B Intravenous solution of Levofloxacin (1 gm) for the Intraluminal therapy
62450784|NCT03202758|OTHER|Durvalumab + Tremelimumab + FOLFOX|"* Durvalumab for 12 months~* Tremelimumab for up to 4 doses/cycles~* FOLFOX"
62450785|NCT01953666|EXPERIMENTAL|Rehabilitation Group|People with spinal cord injury who have a rehabilitation program on a word prediction software with an occupational therapist.
62450786|NCT01953666|ACTIVE_COMPARATOR|Self Training at Home Group|People with spinal cord injury who don't have a rehabilitation program with an occupational therapist but who have instructions for learning at home on a word prediction software
62450787|NCT01953666|NO_INTERVENTION|No treatment Group|People with spinal cord injury who don't have instructions, rehabilitation programm on word prediction software. They have no treatment.
62450788|NCT04582396|EXPERIMENTAL|Stellate Ganglion Block + Psychoeducation|For the active SGB arm, 7 to 8 mL of ropivacaine, 0.5%, will be injected around and into the site of the ganglion once before the hospital discharge. They will also receive a 30 minutes session of psychoeducation by a health professional with experience working with CA patients.
62652899|NCT01290328|NO_INTERVENTION|Standard of care|
62652900|NCT01290328|EXPERIMENTAL|Epoetin alfa|150 units/kg/week
62852161|NCT05862506|NO_INTERVENTION|Control Group|This group will be received only the physical education lessons and it will be followed-up equally to compare outcomes in the future.
62852162|NCT00783484|EXPERIMENTAL|Cohort 1|PF-03716539 crossover, single dose escalation (doses subject to change).
62852163|NCT00783484|EXPERIMENTAL|Cohort 2|PF-03716539 crossover, single dose escalation (doses subject to change).
62267438|NCT01500109|ACTIVE_COMPARATOR|Oral acetaminophen|Patients will receive oral acetaminophen cherry elixir preoperatively. After intravenous access is obtained intraoperatively patients will receive placebo for Ofirmev® (saline). Patients will receive standardized dose of local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon prior to surgical incision as wel as at the completion of surgery with Bupivacaine 0.25% with Epinephrine. Postoperatively patient will receive oral acetaminophen every six hours and intravenous placebo (normal saline) for intravenous acetaminophen. Intravenous morphine will be administered as needed for 24 hours.
62267439|NCT01500109|PLACEBO_COMPARATOR|Opioid only|This group will receive placebo oral cherry elixir prior to going to the operating room and placebo Ofirmev® after securing intravenous access in the operating room with redosing every six hours. They will receive local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon prior to incision as well as at the completion of surgery with Bupivicaine 0.25% with Epinephrine. Postoperatively they will receive only Morphine prn for pain control.
62267440|NCT04523077||Oral lichen planus|Female patients of the Department of Oral Medicine with oral lichen planus
62267441|NCT04523077||Control|Female patients of the Department of Oral Medicine without oral lichen planus or other immune disorders
62267442|NCT02707367|EXPERIMENTAL|Recovery Roadmap (RR) Wave 1|All participants, in both Wave 1 and Wave 2, will act as their own comparator in a randomized stepped wedge design. Data collection in Wave 1 will include two pre-tests and two post-tests, building in an observation period that is not present in Wave 2.
62267443|NCT02707367|EXPERIMENTAL|Recovery Roadmap (RR) Wave 2|All participants, in both Wave 1 and Wave 2, will act as their own comparator in a randomized stepped wedge design. Data collection in Wave 1 will include one pre-test and three post-tests.
62267444|NCT01836783|EXPERIMENTAL|Amnion Allograft|Atraumatic tooth extractions and amnion allograft procedures
62267445|NCT01836783|ACTIVE_COMPARATOR|Allograft|Atraumatic tooth extractions and allograft procedures
62267446|NCT01432691|OTHER|Surgery|RSA study on hemi
62267447|NCT05372523||Trauma+ & PTSD|Patients diagnosed with significant trauma exposure and PTSD
62267448|NCT05372523||Trauma+ & No PTSD|Patients diagnosed with significant trauma exposure but no PTSD
62267449|NCT05372523||No trauma or PTSD|Healthy adults without known major psychiatric disorders
62267450|NCT04989920|EXPERIMENTAL|CIMT (Constraint-Induced Movement Therapy)|Therapy intervention: This arm will deliver the signature Constraint-induced therapy protocol for 60 hrs of training over a two-week period.
62267451|NCT04989920|NO_INTERVENTION|Delayed (Control) intervention group|"Subjects randomized to the delayed intervention group will receive the usual and customary services provided by their personal health care system."
62267452|NCT06123065|EXPERIMENTAL|Active|Immediately enrolled into Yoga intervention. Completed orientation and baseline measures then began 8-week yoga group intervention.
62267453|NCT06123065|OTHER|Waitlist|Delayed Intervention. Waitlist individuals attended orientation and completed baseline measures. After completion of re-assessment of measures 8 weeks later, then enrolled into Active arm.
62267454|NCT03784976|EXPERIMENTAL|Intervention|Patients in the intervention group will first undergo 3 months of regular care and then 3 months of biweekly yoga classes. Participants will complete surveys at baseline, 3 months (after of control care), 6 months (after 3 months of biweekly yoga classes), and 12 months (after 6 months of observation and optional yoga practice).
62267455|NCT03784976|NO_INTERVENTION|Control|The study lasts 12 months for the intervention and 9 months for the control group with an optional 3 month yoga therapy session offered at the end
62267456|NCT04943991|OTHER|Patients with HCM/LVH at University Hospital Wuerzburg|
62267457|NCT01564186||MulitPoint Pacing|
62267458|NCT01564186||BiV Conventional|
62267459|NCT05754814||Controls|Healthy participants
62267460|NCT05754814||Cases|Patients with malignant lymph nodes on the neck
62267461|NCT05186142||Patients hospitalized for treatment of lymphoedema|Patients hospitalized for treatment of lymphoedema
62267462|NCT01243710|EXPERIMENTAL|Taurolidine with heparin|
62267463|NCT01243710|ACTIVE_COMPARATOR|Heparin|
62450789|NCT04582396|PLACEBO_COMPARATOR|Normal saline injection + Psychoeducation|For the sham procedure, 1 to 2 mL of preservative-free normal saline will be injected into deep musculature in the neck. They will also receive a 30 minutes session of psychoeducation by a health professional with experience working with CA patients.
62450790|NCT03258359|EXPERIMENTAL|PACTN|Open label 3+3 dose escalation phase 1 trial; 200 to 1000 mL of immunized T cells infused at 0.3, 1, and 3 x 10e7 nucleated cells/kg body weight.
62450791|NCT00100165|EXPERIMENTAL|3-(2,4 dimethoxybenzylidene anabaseine) 150 mg|Patient receives 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg twice per day in a blinded capsule.
62450792|NCT00100165|EXPERIMENTAL|3-(2,4 dimethoxybenzylidene anabaseine)75 mg|Patient receives 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg twice per day in a blinded capsule.
62450793|NCT00100165|PLACEBO_COMPARATOR|placebo|Patient receives placebo twice per day in a blinded capsule.
62461346|NCT03759678|EXPERIMENTAL|Treatment with IB1001|"6-weeks treatment with IB1001 administered orally.~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).~Patients 6-12 years old will receive weight-tiered doses:~* Patients aged 6-12 years weighing 15 to \<25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.~* Patients aged 6-12 years weighing 25 to \<35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.~* Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)~After the 6-week treatment period, patients will enter a 6-week post-treatment washout period."
62626372|NCT06612528|PLACEBO_COMPARATOR|Sham and vocal exercise|tDCS sham associated with the vocal exercise using the flexible tube in water.
62626373|NCT05891769|EXPERIMENTAL|18FCH PET/CT|Participant receive 18F Fluorocholine injection and approximately 45-60 minutes later receive a low dose CT scan from skull base to mid thighs, followed by a static PET emission scan over the same area.
62652901|NCT02049996||Robotic-assisted prolapse repair|Subjects already scheduled for robotic-assisted prolapse repair in conjunction with vaginal hysterectomy
62652902|NCT02049996||Vaginal prolapse repair|Subjects already scheduled for vaginal prolapse repair in conjunction with vaginal hysterectomy.
62852164|NCT00783484|EXPERIMENTAL|Cohort 3|Midazolam-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
62461347|NCT03759678|NO_INTERVENTION|Post-Treatment Washout|After the 6-week treatment period, patients will enter a 6-week post-treatment washout period.
62852165|NCT00783484|EXPERIMENTAL|Cohort 4|Darunavir-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
62852166|NCT00783484|EXPERIMENTAL|Cohort 5|Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
62852167|NCT00783484|EXPERIMENTAL|Cohort 6|Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 200 mg).
62852168|NCT02907632|EXPERIMENTAL|Metoclopramide|Blind and randomized allocation to the experimental treatment: Metoclopramide
62461348|NCT01891266|EXPERIMENTAL|Non-tourniquet assisted TKA|
62461349|NCT01891266|OTHER|Tourniquet assisted TKA|
62852169|NCT02907632|PLACEBO_COMPARATOR|Placebo|Blind and randomized allocation to placebo
62852170|NCT02527044|EXPERIMENTAL|Functional graft|"Follow-up angiography of all bypass grafts and anastomoses six months after surgery: anastomotic function was scored as 0 for an occluded graft, 1 when the flow from the native coronary artery was dominant, 2 when flow supply from the native coronary and from the graft was balanced, and 3 when the native coronary was fully opacified by the graft. An anastomosis was considered functional for score of 3."
62852171|NCT02527044|ACTIVE_COMPARATOR|Non functional graft|"Follow-up angiography of all bypass grafts and anastomoses six months after surgery: anastomotic function was scored as 0 for an occluded graft, 1 when the flow from the native coronary artery was dominant, 2 when flow supply from the native coronary and from the graft was balanced, and 3 when the native coronary was fully opacified by the graft. An anastomosis was considered non functional for scores of 0 to 2."
62852172|NCT04623853|EXPERIMENTAL|Aim 2|Participants will carry out a protocol comprised of treadmill walking in a laboratory setting while wearing the Dynamic AFO device.
62852173|NCT04623853|EXPERIMENTAL|Aim 3|"Participants will be asked to take the Dynamic AFO home and wear the device for up to 4 weeks. The device will be set in either an adjustment-capable mode, or a locked mode that functions similar to their own orthotic--the order in which they are tested will be randomized."
62852174|NCT00271505|EXPERIMENTAL|Avastin + Docetaxel + Carboplatin|Avastin 15 mg/kg intravenously (IV) every 3 weeks. Docetaxel 75 mg/m2 IV every 3 weeks. Carboplatin AUC 6 IV every 3 weeks.
62852175|NCT02888678|EXPERIMENTAL|ES + HIV Prevention|"Economic Strengthening + HIV prevention education combined intervention consists of 2 parts.~Impumelelo: This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.~Vhutshilo 2.2: . This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy."
62852176|NCT02888678|EXPERIMENTAL|ES only|Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
62461350|NCT06282705|EXPERIMENTAL|0 cm Diagonal drop jump|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 0 cm (floor). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
62461351|NCT06282705|EXPERIMENTAL|40 cm diagonal drop jump|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 40 cm (plyometric box). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
62461352|NCT06282705|EXPERIMENTAL|60 cm diagonal drop jump|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 60 cm (plyometric box). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
62461353|NCT06282705|NO_INTERVENTION|Control|No exercise intervention performed.
62652903|NCT06406504|EXPERIMENTAL|in-laboratory simulation group|The simulation practices of the students in the simulation practices of the students in the simulation in-laboratory simulation group (n=30) were performed with moulage application on a standardised patient in the simulation laboratory
62652904|NCT06406504|EXPERIMENTAL|in-situ simulation group|The simulation practices of the students in the simulation practices of the students in the in-situ simulation group (n=30) were performed with moulage application on a standardised patient in a clinic of a university hospital.
62852177|NCT02888678|EXPERIMENTAL|HIV only|HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
62852178|NCT02888678|NO_INTERVENTION|No intervention (control)|The control group will not receive the ES or HIV prevention interventions. They will receive the basic package of services available to all beneficiaries of Future Families.
62852179|NCT05192447|EXPERIMENTAL|Intervention Group = Exercise Group|EG will perform complementary cognitive and physical training (120 min./5/per week during study observation)
62267464|NCT04627272|EXPERIMENTAL|AutoDX and Gold Standard|A licensed clinician will obtain 60° wide single-field retinal fundus images from subjects who are diabetic patients in primary care environments (i.e. non-eye care settings, such as internal medicine, family medicine, and endocrinology). The fundus images will be uploaded to the RetinaVue Network software using the AutoDx-DR with Over-read modality, where images are transmitted to both AutoDx-DR and a remote ophthalmologist. Subjects participating in this study will undergo further retinal fundus imaging: four mydriatic, stereoscopic 45° field of view (4W) retinal images and spectral domain optical coherence tomography (SD-OCT) captured with the Reference Standard Camera
62461354|NCT00115726|EXPERIMENTAL|1|furosemide
62461355|NCT00115726|PLACEBO_COMPARATOR|2|placebo
62461356|NCT05865691||controls without liver disease|blood collection on the day of inclusion
62461357|NCT05865691||patients with chronic liver disease without cirrhosis|blood collection on the day of inclusion
62461358|NCT05865691||patients with chronic liver disease with compensated cirrhosis|blood collection on the day of inclusion
62461359|NCT05865691||patients with chronic liver disease with stable decompensated cirrhosis|blood collection on the day of inclusion
62461360|NCT05865691||patients with chronic liver disease with decompensated cirrhosis in the acute phase|blood collection on the day of inclusion
62461361|NCT05865691||patients with chronic liver disease with decompensated cirrhosis and organ failure|blood collection on the day of inclusion
62461362|NCT04663360|EXPERIMENTAL|Intervention|Intervention to be administered: Adverse Drug Reactions (ADRe) Profile. asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the BNF and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts.
62461363|NCT04663360|NO_INTERVENTION|Control|Usual clinical care.
62461364|NCT00764985||Syncope|
62461365|NCT00945165|EXPERIMENTAL|Exercise|
62461366|NCT00945165|EXPERIMENTAL|No exercise|
62461367|NCT01293422|EXPERIMENTAL|Rifampicin|
62461368|NCT02911597|EXPERIMENTAL|A: Ketamine + Naltrexone or placebo|"Patients will receive two infusions of Ketamine 0.5mg/kg divided into two phases Phase A and Phase B, which are separated by 30 days.~Patients will be randomly assigned to receive either Naltrexone 50 mg or a matched placebo in both Phase A and B. The Naltrexone or placebo will be given 45 min prior to the administration of ketamine 0.5 mg/kg (e.g. patient X assigned to arm X. Arm X is assigned to Ketamine 0.5mg/kg plus Naltrexone 50 mg during Phase A then when transitioning to Phase B they would receive Ketamine 0.5mg/kg plus a matched placebo). In Phase A will then be followed for 30 days with study assessments to examine the durability of Ketamine effects then once at day 30 for transition."
62461369|NCT02911597|EXPERIMENTAL|B: Ketamine + Naltrexone or placebo|"Patients will receive two infusions of Ketamine 0.5mg/kg divided into two phases Phase A and Phase B, which are separated by 30 days.~Patients will be randomly assigned to receive either Naltrexone 50 mg or a matched placebo in both Phase B and A. The Naltrexone or placebo will be given 45 min prior to the administration of ketamine 0.5 mg/kg (e.g. patient X assigned to arm X. Arm X is assigned to Ketamine 0.5mg/kg plus Naltrexone 50 mg during Phase A then when transitioning to Phase B they would receive Ketamine 0.5mg/kg plus a matched placebo). In Phase B will then be followed for 30 days with study assessments to examine the durability of Ketamine effects then once at day 30 for transition."
62461370|NCT02965326|OTHER|Cystic fibrosis, treated|Cystic fibrosis patients treated either by Ivacaftor or by the association Ivacaftor-Lumacaftor
62461371|NCT02965326|OTHER|Cystic fibrosis, non treated|Cystic fibrosis patients, non treated by a CFTR modulator
62461372|NCT02965326|OTHER|Non-Cystic fibrosis|Patients in whom cystic fibrosis diagnosis has been suspected, but excluded by physiological and genetic investigations
62461373|NCT01769183|EXPERIMENTAL|Squalamine|Study eyes will be assigned to receive Squalamine. The dose will be one drop twice daily. If neovascularization fails to regress at week one or if neovascularization returns within the study, the dose will be increased to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Patients will continue administering study drug until week 20.
62461374|NCT06280690|EXPERIMENTAL|10mg SGM-101|This cohort receives 10mg
62626374|NCT03184571|EXPERIMENTAL|Bemcentinib + pembrolizumab|"Cohort A enrols participants who received a maximum of 1 prior line of platinum-containing chemotherapy and no prior immunotherapy of any kind to receive bemcentinib (BGB324) in combination with pembrolizumab.~Cohort B enrolls participants who received a maximum of one prior line of an anti-PD-(L)1 therapy (monotherapy) to receive bemcentinib (BGB324) in combination with pembrolizumab.~Cohort C enrolls participants who received a maximum of one prior line of therapy with an anti-PD-(L)1 therapy in combination with a platinum-containing chemotherapy.~Bemcentinib capsules are administered at 400mg for days 1-3, and 200mg thereafter. Pembrolizumab is an IV infusion, administered at a dose of 200mg every 3 weeks."
62626375|NCT01673087|EXPERIMENTAL|laboratory HPA probes|"All subjects will be studied with multiple probes of HPA axis function over the course of one to two months:~Metyrapone, oral, 750 mg, administered twice 3.5 hrs apart; Dexamethasone, oral, 1.5 mg administered once; oral, 0.25 mg administered once; Corticorelin ovine triflutate (CRH), intravenous, 100 mcg, administered once over 30 seconds; Cortrosyn (ACTH), intravenous, 250 mcg, administered once by bolus."
62852180|NCT05192447|NO_INTERVENTION|Control Group|CG will be provided with normal hospital care during RT and next will conduct a normal daily activity at home.
62852181|NCT06105905|EXPERIMENTAL|One arm pilot trial|The developed intervention will be delivered in a workshop format by facilitators, over 8 sessions for teens and 2 sessions for parent/guardian(s). Feedback will be elicited on delivery mode (virtual, in-person, or hybrid) during the co-development sessions. If in-person/hybrid is suggested, feedback will be elicited about preferred location (e.g., a local community center, sports club, etc.). Sessions will be hosted in either Spanish or English depending on participants' preference, using video conference tools. Parent/guardian(s) will complete a 5-minute survey pre-intervention and immediately post-intervention. Teens will complete a 15-minute survey pre-intervention, immediately after the 8 session intervention, three-month post-intervention, six-month post-intervention, and twelve-month post-intervention. Surveys will assess acceptability and risk behaviors. As in the published Cuidate trials, previously used measures will be used to document validity and comparability.
62852182|NCT03400605||Program Clients|Parkdale Parents' Primary Prevention Project (5P's) clients
62852183|NCT01349049|EXPERIMENTAL|oral dose of 3000 mg/day PLX3397 (RP2D)|Subjects will be dosed at the recommended Phase 2 dose (RP2D)
62852184|NCT01349049|EXPERIMENTAL|oral dose of 800 mg/day of PLX3397|Level 0
62852185|NCT01349049|EXPERIMENTAL|oral dose of 1000 mg/day PLX3397|Level 1
62852186|NCT01349049|EXPERIMENTAL|oral dose of 1200 mg/day PLX3397|Level 2
62062785|NCT05483933|EXPERIMENTAL|Mirvetuximab + SL-172154 (SIRPα-Fc-CD40L)|Mirvetuximab (MIRV) will be administered via intravenous administration + SL-172154 (SIRPα-Fc-CD40L) will be administered via intravenous administration
62461375|NCT06280690|EXPERIMENTAL|5mg SGM-101|This cohort receives 5mg
62461376|NCT02063893||non-vaccine|
62852187|NCT01349049|EXPERIMENTAL|oral dose of 1400 mg/day PLX3397|Level 3
62852188|NCT01349049|EXPERIMENTAL|oral dose of 2000 mg/day PLX3397|Level 4
62852189|NCT01349049|EXPERIMENTAL|oral dose of 3000 mg/day PLX3397|Level 5
62852190|NCT01349049|EXPERIMENTAL|oral dose of 4000 mg/day PLX3397|Level 6
62852191|NCT01349049|EXPERIMENTAL|oral dose of 5000 mg/day PLX3397|Level 7
62852192|NCT02628080|EXPERIMENTAL|Cohort 1|Atovaquone suspension, 750mg/5ml bd and 1000mg (6.25ml) bd for 7-17 days. Device: PET-CT, Device: DWI-MRI
62461377|NCT02063893||giving low vaccine|
62461378|NCT02063893||giving middle vaccine|
62461379|NCT02063893||giving high vaccine|
62461380|NCT02996656|ACTIVE_COMPARATOR|Cefazolin|During an open shoulder surgery, the Cefazolin will be administered to some patient. The Cefazolin is a first generation cephalosporin. It is a beta lactam which targets gram positive cocci and some gram negative bacilli. The INESS Antibiotic Prophylaxis in Orthopedic Guide recommends the use of Cefazolin at induction for all orthopaedic procedure with implantation of internal fixation device. The dosage is 2g intravenous if the patient weights less than 120kg or 3g if the patient weights more than 120kg. The dose should be repeated if the procedure lasts for more than three hours or if the blood loss is greater than 1500mL.
62461381|NCT02996656|EXPERIMENTAL|Ceftriaxone|During an open shoulder surgery, the Ceftriaxone will be administered to some patient. The Ceftriaxone is a third generation cephalosporin. It targets gram positive cocci such as staphylococcus and streptococcus, gram negative bacilli and some anaerobes, including P. acnes. The prophylactic dose is of 2g IV given a minimum of 30 minutes prior to skin incision. It is effective 12h so no other dose is needed during surgery.
62461382|NCT01535859|EXPERIMENTAL|Cabergoline|
62461383|NCT01535859|PLACEBO_COMPARATOR|Placebo|
62652905|NCT03710954|EXPERIMENTAL|Experimental Group|All the volunteers were evaluated through numerical evaluation of pain that assumes a subjective condition, the researcher showed the numerical scale of pain, being 0 without pain, 1 to 4 mild pain, 5 moderate pain, 6 to 9 severe pain and 10 worse pain possible pain, which was interpreted by the volunteer. In the Fuzzy Pain Scale, the evaluation of the range of motion was done where the evaluator used the goniometer (plastic instrument that verifies the angulation of the joint movement) and supplied the Fuzzy system with these data.
62852193|NCT02628080|NO_INTERVENTION|Cohort 2|Device: PET-CT, Device: DWI-MRI
62852194|NCT01801267|EXPERIMENTAL|Endoscopic third ventriculostomy (ETV)|Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV).
62852195|NCT01801267|ACTIVE_COMPARATOR|Ventricular shunt|Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision.
62852196|NCT01278940|EXPERIMENTAL|Dendritic Cells (DC) malignant melanoma|22 patients were included in this arm.
62852197|NCT01278940|EXPERIMENTAL|DC vaccine plus IL-2|To improve the efficacy of the DC vaccine, IL-2 was administrated at the vaccination site through direct lymph node injection. 9 patients were included in this arm.
62852198|NCT01703182||leg amputation|Patients undergoing below-knee and above ankle amputation for vascular reasons will receive transcutaneous oximetry and transcutaneous carbon dioxide measurement
62267465|NCT05619198|ACTIVE_COMPARATOR|High Intensity Interval Exercise|Plasma and sensor glucose is monitored before, during and after a bout of high intensity interval exercise
62267466|NCT05619198|ACTIVE_COMPARATOR|Moderate Intensity Continous Exercise|Plasma and sensor glucose is monitored before, during and after a bout of moderate intensity continous exercise
62852199|NCT00582075|EXPERIMENTAL|Radiosurgery 15-24 Gy + Adjuvant Temozolomide|
62852200|NCT03945617|EXPERIMENTAL|Unified treatment protocol|This intervention group receives 16 sessions of CBT-based, individual psychotherapy using to the Unified Treatment Protocol for the treatment of emotional disorders by Barlow et al. (2011).
62267467|NCT00751400|EXPERIMENTAL|Naproxen Sodium ER (BAYH6689)|subjects take one tablet Naproxen Sodium ER (extended release) every 24 hours while symptoms last for no more than 10 consecutive days for pain and no more than 3 consecutive days for fever
62461384|NCT00944203|EXPERIMENTAL|Test Area|Test Area = Standard Treatment plus Ipomea pes-caprae oinment
62461385|NCT00944203|NO_INTERVENTION|Control Area|Control = Standard Treatment
62461386|NCT04562662|EXPERIMENTAL|Intervention group|Single arm (all participants receive interventions)
62461387|NCT00660426|EXPERIMENTAL|Dose Level 1 (starting level)|"Oxaliplatin 85 mg/m2 IV on days 1 and 15.~Gemcitabine 800 mg/m2 IV on days 1 and 15.~Capecitabine 600 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
62461388|NCT00660426|EXPERIMENTAL|Dose Level 2|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.~Gemcitabine 800 mg/m2 IV on days 1 and 15.~Capecitabine 600 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
62461389|NCT00660426|EXPERIMENTAL|Dose Level 3|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.~Gemcitabine 800 mg/m2 IV on days 1 and 15.~Capecitabine 800 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
62461390|NCT00660426|EXPERIMENTAL|Dose Level 4|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.~Gemcitabine 1000 mg/m2 IV on days 1 and 15.~Capecitabine 800 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
62461391|NCT02066207|EXPERIMENTAL|Fenofibrate|Subjects received Fenofibrate
62461392|NCT02066207|EXPERIMENTAL|Atorvastatin|Subjects received Atorvastatin
62652906|NCT01582347|EXPERIMENTAL|RBP-6300|During the Double-Blind Transfer Period (Days 1-7), participants take RBP-6300 at a level (either 10, 20 or 30 mg/day) equivalent to dosing during the Run-In Period, plus Placebo for Subutex®/Suboxone®. This is followed by a 3-day Transition Period (Days 8-10) in which participants take active Subutex®/Suboxone® equal to the dose taken during the Run-In Period plus placebo matching RBP-6000.
62852201|NCT03945617|NO_INTERVENTION|Waitlist Control Group|Participants in the waitlist control group gain access to the Unified Treatment after a waiting period of 16 weeks
62852202|NCT06192199||Patients with acute pulmonary embolism|
62852203|NCT06192199||Patients without acute pulmonary embolism|
62852204|NCT01078818|EXPERIMENTAL|IV trivalent saccharose hydroxide ferrous|
62062786|NCT02720822|PLACEBO_COMPARATOR|Placebo|Double-blind placebo capsule, looking identical to capsules with active treatment, during all three treatment weeks.
62852205|NCT01078818|ACTIVE_COMPARATOR|Oral ferrous fumarate|
62852206|NCT01078818|PLACEBO_COMPARATOR|Oral and intravenous Placebo|
62852207|NCT05826561|NO_INTERVENTION|Control Clinicians - post test only|N=25 control pediatric clinicians, who will receive the post test only. Each clinician will be presented with 10 randomly selected vignettes of 10 children \[5 with and 5 without asthma\] and asked to provide a prediction of a child's asthma risk at 6-10 years.
62852208|NCT05826561|EXPERIMENTAL|PDM Intervention Clinicians - post test only|N=25 intervention pediatric clinicians, who will receive the post test only. Using the PDM, each clinician will be presented with 10 randomly selected vignettes of 10 children \[5 with and 5 without asthma\] and asked to provide a prediction of a child's asthma risk at 6-10 years.
62062787|NCT02720822|EXPERIMENTAL|Morphine Sulfate (0, 0, 8 mg)|Placebo on weeks one and two. Morphine 8 mg/day on week three.
62062788|NCT02720822|EXPERIMENTAL|Morphine sulfate (0, 8, 8 mg)|Placebo on week one. Morphine 8 mg/day on weeks two and three.
62062789|NCT02720822|EXPERIMENTAL|Morphine sulfate (0, 8, 16 mg)|Placebo on week one. Morphine 8 mg/day on week two. Morphine 16 mg/day on week three.
62852209|NCT05826561|NO_INTERVENTION|Control Clinicians - pre and post test|N=25 control pediatric clinicians, who will receive the pre and post test. Each clinician will be presented with 10 randomly selected vignettes of 10 children \[5 with and 5 without asthma\] and asked to provide a prediction of a child's asthma risk at 6-10 years.
62852210|NCT05826561|ACTIVE_COMPARATOR|PDM Intervention Clinicians - pre and post test|N=25 intervention pediatric clinicians, who will receive the pre and post test. Using the PDM, each clinician will be presented with 10 randomly selected vignettes of 10 children \[5 with and 5 without asthma\] and asked to provide a prediction of a child's asthma risk at 6-10 years.
62852211|NCT05777291|EXPERIMENTAL|Experimental arm|Patients will be given physical activity recommendations ABD will be using the study devices: activity watch (Fitbit Sense) and a sleep monitoring mattress (Withings, Sleep Analyzer)
62852212|NCT05777291|ACTIVE_COMPARATOR|Control arm|Patients will be given physical activity recommendations only
62062790|NCT02720822|EXPERIMENTAL|Morphine sulfate (8, 8, 8 mg)|Morphine 8 mg/day on weeks one, two and three.
62062791|NCT02720822|EXPERIMENTAL|Morphine sulfate (8, 8, 16 mg)|Morphine 8 mg/day on weeks one and two. Morphine 16 mg/day on week three.
62461393|NCT02066207|EXPERIMENTAL|Fenofibrate and Atorvastatin|Subjects received Fenofibrate and Atorvastatin
62461394|NCT03499171|EXPERIMENTAL|Citalopram|20mg, once a day
62062792|NCT02720822|EXPERIMENTAL|Morphine sulfate (8, 16, 16 mg)|Morphine 8 mg/day on week one. Morphine 16 mg/day on weeks two and three.
62062793|NCT02720822|EXPERIMENTAL|Morphine sulfate (8, 16, 24 mg)|Morphine 8 mg/day on week one. Morphine 16 mg/day on week two. Morphine 24 mg/day on week three.
62062794|NCT02720822|EXPERIMENTAL|Morphine sulfate (16, 16, 16 mg)|Morphine 16 mg/day on weeks one, two and three.
62062795|NCT02720822|EXPERIMENTAL|Morphine sulfate (16, 16, 24 mg)|Morphine 16 mg/day on weeks one and two. Morphine 24 mg/day on week three.
62062796|NCT02720822|EXPERIMENTAL|Morphine sulfate (16, 24, 24 mg)|Morphine 16 mg/day on week one. Morphine 24 mg/day on weeks two and three.
62062797|NCT02720822|EXPERIMENTAL|Morphine sulfate (16, 24, 32 mg)|Morphine 16 mg/day on week one. Morphine 24 mg/day on week two. Morphine 32 mg/day on week three.
62461395|NCT03499171|PLACEBO_COMPARATOR|Placebo|Once a day
62461396|NCT03282838|EXPERIMENTAL|DFN-15 (fasted)|
62461397|NCT03282838|EXPERIMENTAL|DFN-15 (fed)|
62461398|NCT03282838|EXPERIMENTAL|Comparator (fed)|
62461399|NCT01536626||BIAsp 30 users|
62461400|NCT00905125|EXPERIMENTAL|Arm 2, Fluarix®|Single 0.5 mL intramuscular injection of Fluarix®.
62461401|NCT00905125|EXPERIMENTAL|Arm 1, Fluzone®|Single 0.5 mL intramuscular injection of Fluzone®.
62461402|NCT05966571||PCOS women|Ovarian biopsy will be performed on PCOS women meeting the inclusion criteria undergoing surgery for other reasons . A sample of the ovarian tissue will be of a few millimeters in size and taken on only one of the ovaries.
62461403|NCT05710341|ACTIVE_COMPARATOR|Water with added nitrate|137 mg sodium nitrate or 164 mg potassium nitrate (100mg of nitrate) in a 500 mL water bottle (200 mg/L) provided twice, one with breakfast and one with lunch. This is equivalent to 200mg nitrate in total.
62461404|NCT05710341|PLACEBO_COMPARATOR|Water without added nitrate|137 mg sodium chloride or 164 mg potassium chloride in a 500 mL water bottle provided twice, one with breakfast and one with lunch.
62461405|NCT01465295|EXPERIMENTAL|HemiBridge|Patients meeting eligibility criteria will be treated with the HemiBridge System.
62461406|NCT05455073|EXPERIMENTAL|Full package intervention arm|"* Dietary Supplement of Weekly Iron and Folic Acid (WIFA) Supplementation (containing 60 mg of elemental iron and 2800 µg of folic acid) and;~* Associated behavior change intervention (BCI) to change the knowledge, attitudes, and practices of nutrition (including dietary diversity), IFA, deworming~* Water, sanitation and hygiene (WASH) intervention: ensure availability (or provision) of water, sanitation, and hygiene supplies~* Menstrual hygiene management (MHM) intervention: support for menstrual hygiene, including sale of menstrual products in schools~* Associated behavior change intervention (BCI) to change the knowledge, attitudes, and practices (KAP) of WASH and menstrual hygiene management (MHM)"
62062798|NCT02237235|EXPERIMENTAL|MMFS-202 -302|"MMFS-202: evening dose~MMFS-302: morning dose"
62062799|NCT02237235|PLACEBO_COMPARATOR|Placebo|Placebo
62461407|NCT05455073|EXPERIMENTAL|Limited package intervention arm|"* Dietary Supplement of Weekly Iron and Folic Acid (WIFA) Supplementation (containing 60 mg of elemental iron and 2800 µg of folic acid; weekly school provision of WIFA tablets) and;~* Associated behavior change intervention (BCI) to change the knowledge, attitudes, and practices of nutrition (including dietary diversity), IFA, deworming"
62626376|NCT06165198|EXPERIMENTAL|Closed-loop tACS stimulation based on addiction-induced states|In the initial phase of this study, participants will be subjected to individual closed-loop tACS interventions at varying frequencies for one-week intervals. Concurrently, they will be exposed to MA-related cue paradigms to induce brain addiction states, while scalp EEG signals are collected. Stimulation will be initiated only upon identifying specific neural signals associated with MA cues, aiming to ascertain the optimal frequency for single-session closed-loop tACS stimulation that could elicit individual neurological responses. Subsequently, we will embark on a longitudinal closed-loop tACS intervention control study for MA dependents at one-week intervals, which involves addiction-induced closed-loop tACS stimulation, random time-point stimulation, and traditional continuous stimulation, to rectify potential sequence effects and delineate the disparities in neurological and behavioral impacts between discrete and continuous stimulations based on brain states.
62626377|NCT00428012|EXPERIMENTAL|QOLT|Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions
62626378|NCT00428012|ACTIVE_COMPARATOR|ST|Supportive Therapy (ST) 8 weekly individual counseling sessions
62852213|NCT00444561|ACTIVE_COMPARATOR|Pramlintide acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC administration. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
62852214|NCT03713905|EXPERIMENTAL|GLS-010|Use Full-human anti-pd-1 monoclonal antibodies for treatment
62852215|NCT02345564|OTHER|osteochondral lesions in knee/ankle|patients with traumatic and atraumatic osteochondral lesions in knee/ankle, implantation of MaioRegen fleece into osteochondral lesion
62852216|NCT03680846|OTHER|CMM|Conventional Medical Management
62852217|NCT03680846|ACTIVE_COMPARATOR|HF10 + CMM|Addition of HF10 therapy to CMM
62852218|NCT02817529|EXPERIMENTAL|Pulmonica|The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through the PEP device at least ten times daily for up to six months.
62852219|NCT02817529|ACTIVE_COMPARATOR|RC-Cornet|The RC-Cornet is a device that provides oscillatory positive expiratory pressure (OPEP) therapy for the detachment and removal of pulmonary secretions. Through variable pressure settings and optional aerosolized medication delivery, patients realize maximum efficacy specific to their unique clinical needs.The RC-Cornet uses the patient's full expired air volume to produce pressure and oscillatory vibrations. Participants who will be instructed to inhale and exhale through the PEP device at least ten times daily for up to six months.
62461408|NCT05455073|NO_INTERVENTION|Control|No intervention.
62461409|NCT02136095|EXPERIMENTAL|IFC-group|The investigators included patients undergoing laparoscopic cholecystectomy by a single surgeon between September and December 2013 at a single centre university department with unrestricted referral of patients. The included patients represented all patients undergoing laparoscopic cholecystectomy by one surgeon during the study period. All patients underwent intra-operative fluorescent cholangiography (IFC) with concomitant angiography, according to a standardized protocol, during their laparoscopic cholecystectomy.
62626379|NCT00428012|NO_INTERVENTION|Standard Care|
62852220|NCT04169932|EXPERIMENTAL|CD20 CAR-T|
62461410|NCT00388544|EXPERIMENTAL|1|
62852221|NCT00349050|ACTIVE_COMPARATOR|1|laboratory pain assessment
62852222|NCT00349050|ACTIVE_COMPARATOR|2|transcranial magnetic stimulation
62852223|NCT01835509|EXPERIMENTAL|Intervention, Camp + Reunions|5 day , day camp plus 5 monthly reunions
62852224|NCT01835509|NO_INTERVENTION|Control, Newsletters|
62852225|NCT04313140|EXPERIMENTAL|Patient's Glioma grade|magnetic resonance spectroscopy
62852226|NCT04155242|EXPERIMENTAL|Study group|As part of the post RFA treatment follow up patients will receive a Cytosponge test followed by an endoscopy with NBI magnification and biopsies. Four endoscopies will be performed during 2 years of active follow up together with up to 2 Cytosponge procedures. Molecular biomarkers including a methylation panel on DNA and immunohistochemical markers on formalin fixed paraffin embedded samples obtained during the examinations will be assessed. Patients will be then followed up for up to 3 years with standard endoscopy to assess for relapse of Barrett's oesophagus/IM/dysplasia.
62852227|NCT02190565|PLACEBO_COMPARATOR|Placebo|Placebo consisting of two sham multivitamin and mineral tablets and two capsules of oil
62852228|NCT02190565|ACTIVE_COMPARATOR|Food supplement|Food supplement consisting of fish oil (omega 3 fatty acids DHA and EPA) and multivitamin and mineral tablets with extra iron and folic acid
62852229|NCT03196492||No hormone|Half of the cohort (n=40) will have opted to forgo hormonal contraception (HC).
62852230|NCT03196492||Depo-provera|Half of the cohort (n=40) will have opted to initiate injectable depo-provera (DMPA).
62461411|NCT00388544|EXPERIMENTAL|2|
62461412|NCT00388544|EXPERIMENTAL|3|
62626380|NCT03283046|EXPERIMENTAL|Nivolumab + Ipilimumab + Dexamethasone + Lenalidomide|"The first 4 study cycles are 21 days long, and all remaining cycles are 28 days long.~On Day 1 of Cycles 1-4, Nivolumab by vein over 60 minutes. Thirty (30)minutes after Nivolumab, Ipilimumab given by vein over 90 minutes. On Days 1 and 15 of Cycles 5 and beyond, Nivolumab given by vein over 60 minutes.~Lenalidomide tablets take by mouth on Days 1-14 of Cycles 1-4 and on Days 1-21 of Cycles 5 and beyond. Dexamethasone tablets taken by mouth on Days 1, 8, and 15 of Cycles 1-4, and on Days 1, 8, 15, and 22 of Cycles 5 and beyond.~For participants who are eligible for autologous stem cell transplant, those who achieve at least a partial response after at least 4 cycles of initial therapy will be eligible for:~EITHER Stem cell collection and storage OR Stem cell collection and autologous stem cell transplantation."
62626381|NCT02695862|EXPERIMENTAL|Bolus Terlipressin|Injection terlipressin after 2 mg bolus it will be given 2 mg QID
62626382|NCT02695862|ACTIVE_COMPARATOR|Terlipressin continuous(4mg/24hours)|Injection terlipressin after 2 mg bolus it will be given 4 mg over 24 hours,and dose will be titrated as per HVPG (Hepatic Venous Pressure Gradient)
62852231|NCT02604901|EXPERIMENTAL|Screening and Brief Intervention (BI)|Screening and Brief Intervention (BI) at initial prescription fill and at each additional refill.
62852232|NCT02604901|EXPERIMENTAL|Pill Box (PB)|Pill Box (PB) and information about their medications at the initial fill and at each additional refill.
62062800|NCT01712555|EXPERIMENTAL|fat grafting with PRP to anophthalmic orbits|There is only one arm to this study. People with orbital atrophy and loss of an eye are to be injected with autologous fat mixed with autologous PRP (platelet rich plasma) and observed for at least one year for evidence of retention of the injected fat
62267468|NCT02951715|EXPERIMENTAL|Zinc|A full medical history assessment was performed, and each patient completed the NIHL questionnaire (Supplementary S1), audiogram, tympanogram, speech discrimination test, distortion product otoacoustic emissions (DPOAE) testing, pitch and loudness match of the tinnitus, Tinnitus Handicap Inventory (THI) and serum zinc level analyses. All tests were repeated after 2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day).
62267469|NCT04766021|PLACEBO_COMPARATOR|Placebo|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
62852233|NCT02604901|EXPERIMENTAL|Brief Intervention + Pill Box (BI+PB)|Screening and Brief Intervention (BI) and Pill Box (PB) at initial prescription fill and at each additional refill.
62626383|NCT05310435||Pregnant women with lower leg edema|Pregnant women with clinical lower leg edema measured two times with Edema Stocking device, two times with water displacement volumetry and two with tape measure each day for three days.
62852234|NCT02604901|NO_INTERVENTION|Standard Care (SC)|The Standard Care (SC) arm administered traditional dispensing and counseling by Rite Aid® pharmacists.
62852235|NCT02720042|EXPERIMENTAL|Phasix™ Mesh|Patients treated with Phasix™ Mesh for hernia repair
62852236|NCT02422368|EXPERIMENTAL|Methylprednisolone + ASTED|"ASTED (Antioxidant Supplements for Thyroid Eye Disease) includes : B-Carotene (6 mg)+ Vit.C (200 mg) + Vit.E (200 mg) + Nicotinamide(20mg) + Selenium(200mic.) + Zinc oxide (8 mg) + Copper gluconate or oxide (1mg) + Manganese chloride (1.8 mg), Twice a day for 6 months~Methylprednisolone includes :~Methylprednisolone tablet of 50 and 5 mg, company....) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow up."
62852237|NCT02422368|PLACEBO_COMPARATOR|Methylprednisolone + Placebo|Placebo Twice a day for 6 months Methylprednisolone prescribes as the same as arm 1
62062801|NCT02567825|ACTIVE_COMPARATOR|Surgical Management|Tympanostomy Tube Placement Topical antimicrobial treatment of acute otitis media episodes with ofloxacin drops
62062802|NCT02567825|OTHER|Non-Surgical Management|Antimicrobial treatment of acute otitis media episodes with amoxicillin-clavulanate and/or ceftriaxone
62062803|NCT04280822|EXPERIMENTAL|Neoadjuvant immunochemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, \>30min, 3week, 2 cycles~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).~After surgery/ maintain period:~JS001, 240mg ivgtt, d3, \>30min, 3week (8 cycles at most)"
62267470|NCT04766021|EXPERIMENTAL|100 mg Mirabegron|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
62852238|NCT01071018|EXPERIMENTAL|QOD Schedule|QOD Schedule, MK2206 every other day
62852239|NCT01071018|EXPERIMENTAL|QW Schedule|QW Schedule, MK2206 once weekly
62852240|NCT05949502|EXPERIMENTAL|Low shrinkage giomer.|Low-shrinkage bioactive material (giomer) will be applied according to the manufacturer's instructions. Centripetal technique will be performed to restore the proximal wall followed by oblique incrementation of approximately 2 mm thick composite resin. This will be followed by light curing of each increment for 40 seconds using light curing unit till the whole cavity is filled.
62267471|NCT04766021|EXPERIMENTAL|150 mg Mirabegron|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
62626384|NCT04472598|EXPERIMENTAL|Navitoclax + Ruxolitinib|Participants will receive Navitoclax in combination with Ruxolitinib
62626385|NCT04472598|ACTIVE_COMPARATOR|Placebo for Navitoclax + Ruxolitinib|Participants will receive placebo for Navitoclax and Ruxolitinib
62626386|NCT01818089||Lung Sound Analyzer|Patient with pneumonia admitted to hospital will receive additional auscultation with lung sound analyzing stethoscope
62852241|NCT05949502|ACTIVE_COMPARATOR|Nano-hybrid resin composite|Nano-hybrid resin composite will be applied according to the manufacturer's instructions. Centripetal technique will be performed to restore the proximal wall followed by oblique incrementation of approximately 2 mm thick composite resin. Composite increments will be adapted obliquely on each cusp. This will be followed by light curing for 40 seconds using light curing unit of each increment till the whole cavity is filled.
62852242|NCT06348290|EXPERIMENTAL|JMKX001899+Itraconazole|Enrolled subjects were treated with JMKX001899 on Day 1. Itraconazole was administered orally once daily after a standardized meal from Day 4 to Day 6. JMKX001899 and itraconazole were administered simultaneously after a standardized meal on Day 7. On Day 8 to Day 9, itraconazole was orally administered once after a standard meal
62062804|NCT04280822|ACTIVE_COMPARATOR|Neoadjuvant chemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
62062805|NCT03434002|EXPERIMENTAL|Arm-A|Randomized 15 residents out of 30 Post Graduate Year 1 or 2 anesthesia residents (not involved in initial Virtual Reality testing) will be receive Local Anesthetic Systemic Toxicity simulation training by Virtual Reality simulation
62062806|NCT03434002|EXPERIMENTAL|Arm-B|Randomized other 15 residents out of 30 Post Graduate Year 1 or 2 anesthesia residents (not involved in initial Virtual Reality testing) will be receive Local Anesthetic Systemic Toxicity simulation training by mannequin based simulation
62088023|NCT06312631|EXPERIMENTAL|Task handover model #6|"At each visit, the patient will perform the tasks with the gripping glove (A) or without the gripping glove (B).~The order of administration with then without the glove (AB) or without then with the glove (BA) is drawn at random for each patient.~The 6th model follows the following diagram:~Visit T1 = BA ; Visit T2 = AB ; Visit T3 = BA"
62267472|NCT04766021|EXPERIMENTAL|200 mg Mirabegron|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
62852243|NCT06348290|EXPERIMENTAL|JMKX001899+Rifampin|Enrolled subjects were treated with JMKX001899 after high fat meal on Day 1 and an empty stomach on Day 4. Rifampin was administered orally once daily on an empty stomac from Day 7 to Day 15, Day 17and Day 18. JMKX001899 and Rigampin were administered simultaneously on an empty stomach on Day 16.
62852244|NCT06348290|EXPERIMENTAL|JMKX001899+Cocktail substrate (Midazolam, dextromethorphan, Rosuvastatin and digoxin)|Enrolled subjects were treated with Cocktail substrate (Midazolam, dextromethorphan, Rosuvastatin and digoxin) on an empty stomach on Day 1. JMKX001899 was administered orally once daily after a standardized meal from Day 9 to Day 20 and Day 22. Cocktail and JMKX001899 were administered simultaneously on an empty stomach on Day 8 and Day 21.
62852245|NCT01748240|EXPERIMENTAL|Azacitidine and oral vorinostat|"Patients who meet eligibility criteria will be administered vorinostat orally at 300mg two times daily for 7 days. AZA will be administered SC at 75 mg/m2/day x 7 consecutive days or at maximum tolerated dose if a dose reduction of AZA was needed before entering the trial with a minimum dose of 50mg/m2/d for 7 consecutive days.~Each cycle will last 28 days with AZA starting on day 1 of each cycle and vorinostat starting on day 3."
62852246|NCT06230601|EXPERIMENTAL|experimental group|cough trick method will be used in the blood collection process from the children in the experimental group.
62267473|NCT01318109|ACTIVE_COMPARATOR|Alogliptin 12.5 mg QD and metformin 500mg BID or 750mg TID|
62267474|NCT01318109|ACTIVE_COMPARATOR|Alogliptin 25mg QD and metformin 500mg BID or 750mg TID|
62852247|NCT06230601|ACTIVE_COMPARATOR|Active comprator|Pinwheel Blowing method will be used in the blood collection process from the children in the experimental group.
62852248|NCT06230601|NO_INTERVENTION|control group|Routine application of the unit will be made
62267475|NCT01318109|ACTIVE_COMPARATOR|Metformin 500mg BID or 750mg TID|
62461413|NCT00388544|NO_INTERVENTION|4|Recreational activities are not tailored to either style of interest or function
62461414|NCT05738525||Automated peritoneal dialysis with remote patient management (APD-RPM)|APD mode is recommended but not limited to continuous circulating peritoneal dialysis (CCPD). Dialysis dose ranges from 5 to 10 liters per day and glucose concentration starts from low concentration (1.5%).
62626387|NCT04332003|ACTIVE_COMPARATOR|RIC Treatment|Participants will receive active RIC treatment 3 times per week over the course of the study. Each session will last approximately 45 minutes
62626388|NCT04332003|NO_INTERVENTION|SHAM Comparator|Participants will receive sham treatment 3 times per week over the course of the study. Each session will last approximately 45 minutes
62626389|NCT03932916|EXPERIMENTAL|experimental group 1|HHT201 17mg injection
62626390|NCT03932916|EXPERIMENTAL|experimental group 2|HHT201 34mg injection
62626391|NCT03932916|ACTIVE_COMPARATOR|experimental group 3|Donepezil Hydrochloride oral tablet 5mg
62267476|NCT06474559|EXPERIMENTAL|LMA Protector|LMA Protector will be inserted by a researcher after standard anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale. Mini bronchoalveolar lavage will be colected at the end of the procedure
62626392|NCT05964920|PLACEBO_COMPARATOR|Placebo|"The placebo group will complete 10-week treatment period where they continue with their regular habitual daily physical activity and receive two placebo (saline) injections (at baseline and week 3). They will then undergo a 12-week period with no treatment and no training, where they just do their regular habitual daily physical activity. Before they undertake a period of structured, progressive resistance training for 10-weeks.~Questionnaires, physiological and psychological measures, skeletal muscle biopsies and blood samples will be taken at time points of:~1. Baseline (week 0)~2. Treatment period (week 10)~3. Detraining and placebo abstinence (week 22)~4. Retraining (week 32)"
62626393|NCT05964920|EXPERIMENTAL|Testosterone Undecanoate|"The testosterone group will complete 10-week treatment period where they continue with their regular habitual daily physical activity and receive two testosterone undecanoate (Nebido) injections (1000 mg/4 ml at baseline and 500 mg/2 ml week 3). They will then undergo a 12-week period with no treatment and no training, where they just do their regular habitual daily physical activity. Before they undertake a period of structured, progressive resistance training for 10-weeks.~Questionnaires, physiological and psychological measures, skeletal muscle biopsies and blood samples will be taken at time points of:~1. Baseline (week 0)~2. Treatment period (week 10)~3. Detraining and testosterone abstinence (week 22)~4. Retraining (week 32)"
62626394|NCT05964920|PLACEBO_COMPARATOR|Resistance exercise training + Placebo|"The resistance exercise training + placebo group will complete 10-week treatment period where they undergo a period of structured, progressive resistance training and receive two placebo (saline) injections (at baseline and week 3). They will then undergo a 12-week period with no treatment and no training, where they return to their regular habitual daily physical activity. Before they undertake a second period of structured, progressive resistance training for 10-weeks.~Questionnaires, physiological and psychological measures, skeletal muscle biopsies and blood samples will be taken at time points of:~1. Baseline (week 0)~2. Treatment period (week 10)~3. Detraining and placebo abstinence (week 22)~4. Retraining (week 32)"
62626395|NCT05964920|EXPERIMENTAL|Resistance exercise training + Testosterone Undecanoate|"The resistance exercise training + testosterone group will complete 10-week treatment period where they undergo a period of structured, progressive resistance training and receive two testosterone undecanoate (Nebido) injections (1000 mg/4 ml at baseline and 500 mg/2 ml week 3). They will then undergo a 12-week period with no treatment and no training, where they return to their regular habitual daily physical activity. Before they undertake a second period of structured, progressive resistance training for 10-weeks.~Questionnaires, physiological and psychological measures, skeletal muscle biopsies and blood samples will be taken at time points of:~1. Baseline (week 0)~2. Treatment period (week 10)~3. Detraining and testosterone abstinence (week 22)~4. Retraining (week 32)"
62852249|NCT00973713|EXPERIMENTAL|RAD001 10mg/d|
62626396|NCT04873635||Patients who had excised pathological jaw lesions and will receive implant rehabilitation|
62626397|NCT03289013|EXPERIMENTAL|Testing of new adhesive strips|"Each subject will test six adhesive strips on pre-stripped skin.~1. Standard adhesive 1~2. Standard adhesive 2~3. LT-2~4. LT-21~5. LT-25~6. 33-20~The six strips are applied on the abdominal skin. The order of the adhesive strips on the skin is randomized. The subjects will change the adhesive strips at home and the adhesion of adhesive strips will be measured at 5 visits."
62626398|NCT03114085|EXPERIMENTAL|Apatinib Combined with Capecitabine|Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group; Capecitabine,1000mg/m2,twice a day (at intervals of 12 hours,equivalent to a total daily dose of 2000 mg / m2),orally,sustained 14 days, off for 7 days, every 21 days for a cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group.
62626399|NCT03114085|ACTIVE_COMPARATOR|Apatinib|Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group;
62626400|NCT04098796|EXPERIMENTAL|Experimental: Anti-PD-1 antibody＋XELOX|Every patient will receive anti-PD-1 antibody (200 mg intravenous drip every 3 weeks) and XELOX regimen chemotherapy (Oxaliplatin 130 mg/m2, intravenous drip, d1; Capecitabine 1000mg/ kg, twice a day, orally, d1-14;every 21 days). Anti-PD-1 antibody will be administered until the disease progresses or lasts for two years. XELOX will be administered 6-8cycles，followed by capecitabine monotherapy, the course of treatment is determined by the investigators according to clinical practice.
62626401|NCT00516685|EXPERIMENTAL|Vaccine Group|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
62626402|NCT00516685|NO_INTERVENTION|Control Group|Patients in this arm will only receive Best Supportive Care.
62267477|NCT06474559|EXPERIMENTAL|Endotracheal tube|Patients will be intubated after standard anesthesia induction.The view of the larynx will be assessed ( Cormack Lehane system).Mini bronchoalveolar lavage will be colected at the end of the procedure
62267478|NCT02369614|ACTIVE_COMPARATOR|Active Comparator:1 Hz rTMS|Active Comparator: 1 Hz rTMS
62267479|NCT02369614|ACTIVE_COMPARATOR|Active Comparator:10 Hz rTMS|Active Comparator:10 Hz rTMS
62267480|NCT02369614|SHAM_COMPARATOR|Sham Comparator:Sham rTMS|Sham Comparator: Sham rTMS
62626403|NCT02426034|EXPERIMENTAL|Treatment group|Apatinib Tablets
62626404|NCT03206827|ACTIVE_COMPARATOR|70% animal, 30% plant proteins in diet|Dietary proteins from animal sources 70% and from plant sources 30%, representing an average Finnish diet consumed at the moment.
62626405|NCT03206827|EXPERIMENTAL|50% animal, 50% plant proteins in diet|Dietary proteins from animal sources 50% and from plant sources 50%, containing at most 500 g red meat/week (according to the current Finnish Nutrition Recommendations).
62626406|NCT03206827|EXPERIMENTAL|30% animal, 70% plant proteins in diet|Dietary proteins from animal sources 30% and from plant sources 70%.
62626407|NCT01423929|EXPERIMENTAL|10 L O2/min|Oxygen breathing via Oxymask TM
62852250|NCT06394882|EXPERIMENTAL|Intervention Group|The program will provide a seven-month program comprising two primary therapies: a three-month intensive behavioral therapy (IBT) and a four-month maintenance behavioral therapy (MBT). The three-month IBT will involve 12-week visits and exercise sessions. The program will encompass in-person (clinic/ health center) and online (telehealth) 12-weekly visits. The 60-minute consultations and booster sessions will be provided by a qualified multidisciplinary team (obesity nurse, psychologist, nutritionist, and physiotherapist), each consulting in their expertise. In collaboration with the physical education and sports science department at Sultan Qaboos University, mothers in the intervention group will be provided exercise sessions based on their individual metabolic and physiological parameters. The maintenance behavioral therapy will start one month after the end of the IBT and will involve four monthly support meetings on a group level.
62852251|NCT06394882|NO_INTERVENTION|Treatment as usual|Participants in the control group will receive treatment as usual, which is the regular care provided by the center for adults and children with obesity.
62852252|NCT05486624|NO_INTERVENTION|Control group|Introductory Information Form was used in the control group on the 1st day of birth with face-to-face interviews. REEDA Scale, MAI-SF were used on the 1st, 2nd, 7th and 14th days of delivery. On the 1st day of birth, the Episiotomy Care Education Brochure and the Follow-up Form to be filled in within 14 days and to be obtained from them at the last follow-up were given. control group; It was evaluated by making a home visit on the 1st day and the 2nd day in the hospital, and on the 7th and 14th days. The records of the forms were filled by the researcher. Data collection time took approximately 15 minutes for the control group. Reiki was not applied to this group.
62852253|NCT05486624|EXPERIMENTAL|Intervention group|Introductory Information Form was used in the intervention group on the 1st day of birth with face-to-face interviews. REEDA Scale, MAI-SF were used on the 1st, 2nd, 7th and 14th days of delivery. On the 1st day of birth, the Episiotomy Care Education Brochure and the Follow-up Form to be filled in within 14 days and to be obtained from them at the last follow-up were given. intervention group; It was evaluated by making a home visit on the 1st day and the 2nd day in the hospital, and on the 7th and 14th days. Reiki was applied on the 1st, 2nd and 7th days of birth. In total, 3 sessions of Reiki were applied. The records of the forms were filled by the researcher. Data collection took approximately 50-55 minutes for the intervention group.
62626408|NCT01423929|SHAM_COMPARATOR|Room air|Room air breathing via Oxymask TM
62062807|NCT01536184|EXPERIMENTAL|Receives COS Intervention|Circle of Security (COS) Family Intervention (B. Marvin model) is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour. The protocol itself involves a series of activities and repeated videotaped interactions between the child and their caregiver which are reviewed by the therapist who has established themselves with the caregiver as a secure base from which the attachment relationship may be explored.
62626409|NCT05102071||Treatment with empagliflozin|as add-on therapy with metformin
62626410|NCT05102071||Treatment with a sulfonylurea|as add-on therapy with metformin
62062808|NCT01536184|NO_INTERVENTION|Control Group-Regular FASD Services|Regular FASD Services include general information on Fetal Alcohol Spectrum Disorder (FASD) with general behavioural management strategies and parental supports.
62062809|NCT05529745|EXPERIMENTAL|Treatment in cerebellar lesioned patient|Group of patients with a lesion of the cerebellum gaining a neurorehabilitation intervention
62062810|NCT05529745|ACTIVE_COMPARATOR|Treatment in supratentorial lesioned patient|Group of patients with a lesion of the supratentorial area gaining a neurorehabilitation intervention
62626411|NCT06067581|EXPERIMENTAL|BCMA CART|"This study will follow the classic 3+3 design and increase the dose according to three dose groups. Each dose group will have 3-6 eligible subjects selected according to the inclusion/exclusion criteria, with a dose of 1.0 × 10\^6, 2.0 × 10\^6, 3.0 × Increase the dose by 10\^6 CAR-T cells/kg."
62626412|NCT06357520|EXPERIMENTAL|Baxdrostat and Itraconazole|Participants will receive single dose of baxdrostat tablet orally on Day 1 in Period 1, followed by itraconazole capsule orally twice a day on Day 6 and once daily on Days 7 to 8 in Period 2, and then single dose of baxdrostat tablet orally on Day 9 with itraconazole capsule orally once daily on Days 9 to 16 in Period 3.
62626413|NCT04691804|EXPERIMENTAL|Treatment group A|Fuzuloparib plus AA-P
62852254|NCT04661579|EXPERIMENTAL|Group 1: Positive Parasitemia; Anti-malarial treatment + RTS,S/AS01E Vaccine|"Participants with detectable P. falciparum parasitemia at baseline received anti-malarial treatment with dihydroartemisinin-piperaquine (DHA/Pip) plus low dose primaquine (LD PQ) 4 weeks prior to the first vaccination and another course of DHA/Pip plus LD PQ two weeks before the second vaccination. One week before the third vaccination, a course of artemether/lumefantrine (A/L) plus LD PQ was administered.~Participants received 3 vaccinations with malarial vaccine RTS,S/AS01E by intramuscular injection given on a 0, 1, and 7 month schedule with the final dose being 1/5 of the dose of the first two immunizations."
62626414|NCT04691804|PLACEBO_COMPARATOR|Treatment group B|Fuzuloparib Placebo plus AA-P
62852255|NCT04661579|EXPERIMENTAL|Group 2: No Parasitemia; Anti-malarial Prophylaxis + RTS,S/AS01E Vaccine|"Participants with no detectable P. falciparum parasitemia at baseline received anti-malarial prophylaxis with DHA/Pip plus LD PQ 4 weeks prior to the first vaccination and a 2nd course of DHA/Pip plus LD PQ 2 weeks before the second vaccination. One week before the third vaccination, a course of A/L plus LD PQ was administered.~Participants received 3 vaccinations with malarial vaccine RTS,S/AS01E by intramuscular injection given on a 0, 1, and 7 month schedule with the final dose being 1/5 of the dose of the first two immunizations."
62626415|NCT06003075|EXPERIMENTAL|Combination Chemotherapy and Nivolumab and Surgery|Patients with lung cancer receiving combination therapy with surgery
62852256|NCT04661579|EXPERIMENTAL|Group 3: Positive Parasitemia; RTS,S/AS01E Vaccine|"Participants with detectable P. falciparum parasitemia at baseline did not receive any anti-malarial medications to clear parasites.~Participants received 3 vaccinations with malarial vaccine RTS,S/AS01E by intramuscular injection given on a 0, 1, and 7 month schedule with the final dose being 1/5 of the dose of the first two immunizations.~This group is included only for immunological assessment and not for vaccine efficacy."
62852257|NCT04661579|PLACEBO_COMPARATOR|Group 4: Positive Parasitemia; Anti-malarial Treatment + Rabies Vaccine|"Participants with detectable P. falciparum parasitemia at baseline received anti-malarial treatment with dihydroartemisinin-piperaquine (DHA/Pip) plus low dose primaquine (LD PQ) 4 weeks prior to the first vaccination and another course of DHA/Pip plus LD PQ two weeks before the second vaccination. One week before the third vaccination, a three-day course of artemether/lumefantrine (A/L) plus LD PQ was administered.~Participants received 3 vaccinations of Abhayrab rabies vaccine on a 0, 1, 7 month schedule."
62852258|NCT04661579|PLACEBO_COMPARATOR|Group 5: No Parasitemia, Anti-malarial Prophylaxis + Rabies Vaccine|"Participants with no detectable P. falciparum parasitemia at baseline received anti-malarial prophylaxis with DHA/Pip plus LD PQ 4 weeks prior to the first vaccination and a 2nd course of DHA/Pip plus LD PQ 2 weeks before the second vaccination. One week before the third vaccination, a course of A/L plus LD PQ was administered.~Participants received 3 vaccinations of Abhayrab rabies vaccine on a 0, 1, 7 month schedule."
62852259|NCT04876690||CD Participants With CPF|Participants diagnosed with CD and CPF in the Portuguese routine clinical practice were assessed. Retrospective data on healthcare resource utilization related with CPF management in the previous three years was obtained from the medical records.
62852260|NCT02262208|OTHER|Patients with type 2 diabetes|
62852261|NCT02262208|OTHER|Healthy|
62852262|NCT03438370|NO_INTERVENTION|Three monthly ART supply at facilities|Sites at which patients will be provided three monthly ART supply at health facilities.
62852263|NCT03438370|EXPERIMENTAL|Three monthly ART supply at CAGs|Sites at which patients will be provided three monthly ART supply at Community ART Groups (CAGs).
62852264|NCT03438370|EXPERIMENTAL|Six monthly ART supply at outreaches|Sites at which patients will be provided six monthly ART supply at Community distribution points or outreaches.
62852265|NCT03405233|EXPERIMENTAL|Group A|Double vein cuff PTFE graft both at the inflow and outflow ends
62852266|NCT03405233|ACTIVE_COMPARATOR|Group B|Single vein cuffed PTFE graft at the outflow end
62852267|NCT03405233|ACTIVE_COMPARATOR|Group C|PTFE graft without vein cuff will be used
62852268|NCT05237089|ACTIVE_COMPARATOR|EA group：Electroacupuncture+health education|Acupuncture is the most popular adjuvant and alternative therapy in China, and it has been used to treat various diseases for thousands of years. Electroacupuncture is an innovation of traditional Chinese acupuncture, which improves the clinical effect by transmitting electrical pulses to the needles and then enhances the stimulation at the acupoints to receive better effects. Studies show that EA has been used as an alternative therapy for obesity in clinical practice.
62852269|NCT05237089|SHAM_COMPARATOR|Sham acupuncture group：shallow acupuncture+health education|Sham acupuncture method in this study is set as the superficial acupuncture manipulated at the same main acupoints with the thinner and shorter needles. The aim of the sham acupuncture is to eliminate the possible placebo effect of EA treatment.
62852270|NCT00638638|EXPERIMENTAL|1|"* Early Abciximab bolus during prehospital transportation in ambulance 0.25 mg/Kg iv with Heparin 40 UI/kg bolus.~* Abciximab placebo bolus and Abciximab infusion 10 µg/Kg/min after coronary angiography and before angioplasty."
62626416|NCT06003075|EXPERIMENTAL|Combination Chemotherapy and Nivolumab and Radiation|Patients with lung cancer receiving combination therapy with radiation
62626417|NCT06037018|EXPERIMENTAL|CC312|
62626418|NCT03595059|EXPERIMENTAL|Escalation 1a: ABBV-155|Participants will be administered ABBV-155 (various doses).
62852271|NCT00638638|EXPERIMENTAL|2|"* Abciximab placebo bolus during prehospital transportation in ambulance with Heparin 40 UI/kg bolus.~* Abciximab 0.25 mg/Kg bolus after coronary angiography and before angioplasty followed by Abciximab infusion 10 µg/Kg/min."
62852272|NCT03424941|EXPERIMENTAL|FFR-guided PCI and TAVI|FFR-guided PCI and subsequently TAVI treatment with the Medtronic CoreValve Evolut R or Medtronic CoreValve Evolut R PRO
62852273|NCT03424941|ACTIVE_COMPARATOR|CABG and SAVR|CABG and SAVR
62626419|NCT03595059|EXPERIMENTAL|Escalation 1b: ABBV-155 + paclitaxel or docetaxel|Participants will be administered ABBV-155 (various doses) in combination with paclitaxel or docetaxel .
62626420|NCT03595059|EXPERIMENTAL|Expansion 2a: ABBV-155 in SCLC|Description: Participants with small cell lung cancer (SCLC) will administer ABBV-155 (at the recommended Phase 2 dose).
62626421|NCT03595059|EXPERIMENTAL|Expansion 2b: ABBV-155 + paclitaxel in Breast Cancer|Participants with breast cancer will be administered ABBV-155 (at the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with paclitaxel.
62062811|NCT01452282||Ankle Brachial Index|
62852274|NCT03562988|OTHER|Vitamin C gummy, Then Vitamin C Caplet|The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period.
62626422|NCT03595059|EXPERIMENTAL|Expansion 2b: ABBV-155 + docetaxel in NSCLC|Participants with non-small cell lung cancer (NSCLC) will be administered ABBV-155 (at or near the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with docetaxel.
62626423|NCT01066312||Practitioners|Healthcare practitioners who either use, have used or do not use MMT in practice
62626424|NCT01066312||Testees|Healthy adults with no experience with MMT
62626425|NCT03629808||Group1: 4-6cm|4-6cm from starting point of gastrectomy to pylorus
62626426|NCT03629808||Group2: 2-4cm|2-4cm from starting point of gastrectomy to pylorus
62626427|NCT01322087|EXPERIMENTAL|Nutritional intervention|
62626428|NCT03046771|EXPERIMENTAL|Transport PLUS group|EMTs randomized to the Transport Plus group will view a 60-minute training video and then complete a 60-minute simulation training exercise on how to conduct the home fall hazard assessment (FHA) and the discharge comprehension assessment (DCA) and how to complete the FHA and DCA checklists. The FHA involves performing a visual assessment of the home environment and noting certain fall hazards. The DCA involves engaging the patient or caregiver in a conversation to assess their level of understanding of the elements of the discharge instructions. The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence
62852275|NCT03562988|OTHER|Vitamin C tablet, Then Vitamin C gummy|The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period.
62852276|NCT04202042|EXPERIMENTAL|Psychological first aid|PFA responders are trained to deliver 8 core actions in the aftermath of traumatic event (: contact and engagement, safety and comfort, stabilization, information gathering, practical assistance, connection with social supports, information on coping, and linkage with collaborative services (within the first 24 hours)
62852277|NCT04202042|ACTIVE_COMPARATOR|Usual organisational intervention|One phone call by workplace psychologist (within the first 48 hours) and reference to employee aid program
62852278|NCT00625664|EXPERIMENTAL|1|
62062812|NCT03032354|EXPERIMENTAL|Probiotics arm: Probiotics group|combination of probiotics: Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12 in the same capsule
62626429|NCT03046771|NO_INTERVENTION|Routine Care|Providers randomized to routine care will not be trained on the FHA or DCA or the completion of the checklists. All EMTs in both groups (Transport Plus and standard education), will be asked to answer some demographic questions and will be trained to collect responses to 3questions commonly used to assess a patient's risk of falling and to collect best contact information for phone follow up from patients or their caregivers and to obtain permission for a follow-up phone call from research personnel.
62626430|NCT03029455|EXPERIMENTAL|Part A: VX-659 or Matching Placebo|Part A includes single-dose escalation.
62626431|NCT03029455|EXPERIMENTAL|Part B: VX-659 or Matching Placebo|Part B includes multiple-dose escalation.
62626432|NCT03029455|EXPERIMENTAL|Part C: VX-659 in TC with TEZ/IVA or Matching Triple Placebo|Part C includes multiple dose escalation of VX-659 administered in Triple Combination (TC).
62852279|NCT00625664|ACTIVE_COMPARATOR|2|
62852280|NCT02619916|EXPERIMENTAL|MBCT|Mindfulness-Based Cognitive Therapy
62852281|NCT02619916|EXPERIMENTAL|CBT|Cognitive Behavioral Therapy
62852282|NCT02619916|NO_INTERVENTION|TAU|Treatment as usual
62062813|NCT03032354|PLACEBO_COMPARATOR|Placebo arm: Placebo group|Placebo - maltodextrin
62062814|NCT02437474||Omnivorous diet|Participants are consuming meat, fish, milk/milk products, eggs, plant products.
62626433|NCT03029455|EXPERIMENTAL|Part D: VX-659 in TC with TEZ/IVA or Matching Triple Placebo|Part D includes subjects with CF. Participants will receive TC or matching placebos.
62626434|NCT02981914|EXPERIMENTAL|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks. Treatment will be administered for up to 24 months, provided that neither disease progression, nor development of a dose-limiting toxicity (DLT), has occurred.
62626435|NCT02482545|EXPERIMENTAL|Breakfast Meal Replacement|Once daily of a powdered meal replacement (high fat, high protein) will be consumed, mixed with water, at breakfast.
62852283|NCT03601884|EXPERIMENTAL|OHP and Treatment as usual (TAU)|"Optimal Health Program (OHP) A self-management program that promotes patients to be actively involved in their own healthcare and overall well-being through enhancing self-efficacy.~Treatment is delivered by a trained facilitator in OHP. The OHP is delivered in groups of 8 to 10 participants It consists of 5 weekly, 1.5 hour sessions and an additional booster session post-program at 3 months a The group facilitator will contact the participants by phone at 8 weeks and 16 weeks.~Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
62852284|NCT03601884|OTHER|TAU Alone|"Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
62852285|NCT03664596|EXPERIMENTAL|Dietary supplement only|Participants will take a sublimated mare milk of 1 sachet 3 times a day during 2 months.
62852286|NCT03664596|OTHER|Dietary supplement and ursodeoxycholic acid therapy|Patients with non-alcoholic steatohepatitis will take ursodeoxycholic acid (2-3 times/day) combined with the mare's milk supplement (1 sachet, 3 times/day) for two months.
62062815|NCT02437474||Lacto-ovo-vegetarian diet|Participants are consuming milk/milk products, eggs, plant products but no meat, fish or by-products.
62626436|NCT02482545|NO_INTERVENTION|Control|No placebo or intervention
62626437|NCT04633772|PLACEBO_COMPARATOR|Placebo|
62626438|NCT04633772|EXPERIMENTAL|Angiotensin-(1-7)|
62062816|NCT02437474||Vegan diet|Participants are consuming plant products but no meat, fish, milk/milk products, eggs or by-products as well as honey.
62626439|NCT03770026|ACTIVE_COMPARATOR|Clomiphene citrate only|Infertile women (30 women) with prior clomiphene citrate failure (ovulation was documented without conception), with thin endometrium (\<7mm) in at least 3 cycles. Saline cervical flushing will be done at cycle day 8 and 10 to convince patient-blinded procedure.
62852287|NCT03664596|ACTIVE_COMPARATOR|Ursodeoxycholic acid therapy only|Patients with verified diagnosis of non-alcoholic steatohepatitis would be given treatment of ursodeoxycholic acid (2-3 times/day) for a two-month period.
62461415|NCT05738525||Continuous ambulatory peritoneal dialysis (CAPD)|(1) Dialysis dose ranges from 5 to 10 liters per day at the run-in period. For those with regular peritoneal dialysis, the original dose can be used according to the volume status and solute clearance effect in the past 3 months; (2) Exchange time and abdominal retention time is generally 2-5 times and 1 time at daytime and night, separately; (3) Glucose concentration includes 1.5%, 2.5% or 4.25%; (4) The treatments can be adjusted according to the change of residual renal function, peritoneal transport characteristics, volume status, solute clearance, clinical status and peritonitis.
62626440|NCT03770026|EXPERIMENTAL|Platelet-rich plasma plus Clomiphene|Women who did not conceive on the Clomiphene citrate-only cycle will receive Clomiphene citrate 100 mg/ day starting from the third day of the cycle. Intrauterine Autologous platelet-rich plasma will be done on the cycle days 8 and 10.
62852288|NCT02567604||Focus groups|AMD patients' caregivers defined as people actively taking part in providing support for AMD patients (e.g. family members, unpaid friends, volunteers)
62852289|NCT02716012|EXPERIMENTAL|MTL-CEBPA Monotherapy|MTL-CEBPA administered weekly, twice weekly or thrice weekly over 3 weeks followed by 1 week of rest defining a 28-day cycle.
62852290|NCT02716012|EXPERIMENTAL|MTL-CEBPA & Sorafenib (combination)|MTL-CEBPA is administered weekly or twice weekly in combination with sorafenib over 3 weeks followed by 1 week of rest defining a 28-day cycle.
62852291|NCT02716012|EXPERIMENTAL|MTL-CEBPA & Sorafenib (sequential)|MTL-CEBPA is administered weekly or twice weekly for 2 cycles (28-day cycle) followed by 2 cycles of sorafenib
62852292|NCT04480970|EXPERIMENTAL|Nasogastric tube placement|
62852293|NCT04085900||Screening cohort|30-69 years old healthy participants in Zhongshan and Wuzhou.
62852294|NCT01123551|EXPERIMENTAL|Nebulized Morphine|After randomization, patients will receive 10 mg of morphine (1ml) diluted in 4 ml normal saline and nebulized with 6 l/mn during 10 min. Nebulization will be repeated systematically 3 times every twenty minutes unless the patient pain was resolved (VAPS 30%). In addition, patients receive a bolus of IV placebo(5 ml normal saline . IV placebo (2 ml) will be repeated every 10 minutes if the objective of analgesia was not reached .
62852295|NCT01123551|ACTIVE_COMPARATOR|Intravenous morphine|After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS \>30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS \>30%).
62062817|NCT03393702|EXPERIMENTAL|Gabapentin|"1. Single dose preoperative gabapentin.~2. After surgery gabapentin 2 times per day for 3 days."
62062818|NCT03393702|PLACEBO_COMPARATOR|Placebo Control|"1. Single dose preoperative placebo control.~2. After surgery placebo 2 times per day for 3 days."
62062819|NCT02444663|ACTIVE_COMPARATOR|Clinician Valgus|Clinician performed fluoroscopic valgus and varus stress X-rays
62062820|NCT02444663|ACTIVE_COMPARATOR|Clinician Varus|Clinician performed fluoroscopic varus stress X-rays
62461416|NCT01709032|EXPERIMENTAL|Deferasirox and deferiprone|
62626441|NCT02429102|EXPERIMENTAL|Single ascending dose, MT-8554 or Placebo|
62062821|NCT02444663|EXPERIMENTAL|Device Valgus - 0 Newton force|Device performed fluoroscopic valgus stress X-rays - 0 Newton force
62062822|NCT02444663|EXPERIMENTAL|Device Valgus - 10 Newton force|Device performed fluoroscopic valgus stress X-rays - 10 Newton force
62062823|NCT02444663|EXPERIMENTAL|Device Valgus - 20 Newton force|Device performed fluoroscopic valgus stress X-rays - 20 Newton force
62062824|NCT02444663|EXPERIMENTAL|Device Valgus - 30 Newton force|Device performed fluoroscopic valgus stress X-rays - 30 Newton force
62062825|NCT02444663|EXPERIMENTAL|Device Varus - 0 Newton force|Device performed fluoroscopic varus stress X-rays - 0 Newton force
62062826|NCT02444663|EXPERIMENTAL|Device Varus - 10 Newton force|Device performed fluoroscopic varus stress X-rays - 10 Newton force
62062827|NCT02444663|EXPERIMENTAL|Device Varus - 20 Newton force|Device performed fluoroscopic varus stress X-rays - 20 Newton force
62062828|NCT02444663|EXPERIMENTAL|Device Varus - 30 Newton force|Device performed fluoroscopic varus stress X-rays - 30 Newton force
62267481|NCT02369614|NO_INTERVENTION|OASIS treatment as usual|OASIS treatment as usual
62626442|NCT02429102|EXPERIMENTAL|Multiple ascending dose, MT-8554 or Placebo|
62626443|NCT01859949|EXPERIMENTAL|Genotropin (somatropin)|
62626444|NCT02117219|EXPERIMENTAL|MEDI4736 Evaluate MEDI4736 in MDS|Evaluate MEDI4736 monotherapy and MEDI4736 in combination with azacitidine after monotherapy progression in MDS
62626445|NCT02117219|EXPERIMENTAL|MEDI4736 + tremelimumab|Evaluate MEDI4736 in combination with tremelimumab
62626446|NCT02117219|EXPERIMENTAL|MEDI4736 + tremelimumab + azacitidine|Evaluate MEDI4736 in combination with tremelimumab and azacitidine
62852296|NCT02992197|ACTIVE_COMPARATOR|Rotarix, single dose|Rotarix 1.5 mL (standard single dose) and 1.5 mL of placebo by mouth (sterile, pharmacy-grade water) at both 6 and 10 weeks of life
62852297|NCT02992197|EXPERIMENTAL|Rotarix, double dose|Rotarix 3 mL by mouth (two standard doses administered simultaneously) at both 6 and 10 weeks of life
62852298|NCT05917678|OTHER|Repositioning Therapy|Infants will be treated with at-home repositioning strategies for their deformational head shape. Physical therapy will be provided, if indicated, for treatment of torticollis. This is a standard treatment.
62852299|NCT05917678|OTHER|Repositioning Therapy + Cranial Remolding Orthoses|After attempting at 2-4 months of repositioning therapy, infants with residual cranial deformation may be treated with a custom made helmet (cranial remolding orthosis) which is adjusted every few weeks to direct skull growth. It is worn 23 hours per day. Physical therapy will be provided, if indicated, for treatment of torticollis. This is a standard treatment.
62852300|NCT05917678|NO_INTERVENTION|Control|Healthy infants without deformational head shapes or need for physical therapy will be followed and measured. No intervention.
62626447|NCT05568797|EXPERIMENTAL|Co-Ad Group|Participants received one dose of FLU-aQIV vaccine and one dose of RSVPreF3 OA vaccine, both doses administered at Day 1, and were followed until end of study.
62852301|NCT04500561|EXPERIMENTAL|YY-20394|YY-20394 tablets will be given daily for 21 days in 21-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons
62852302|NCT02083861|EXPERIMENTAL|Active ultrasound device|Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
62062829|NCT03176238|EXPERIMENTAL|everolimus + exemestane|Everolimus (10 mg) and exemestane (25 mg) tablets taken orally in combination once daily
62062830|NCT06362902|EXPERIMENTAL|Laparoscopic Right Hemicolectomy With Transrectal Specimen Extraction|"STEP 1: Dissection and separation The mesentery and vessels were dissected and separated according to the principle of complete mesocolic excision.~STEP 2: Intracorporeal anastomosis An enterotomy was performed on the antimesenteric side of the ileum at the edge of the staple line. This maneuver was replicated on the transverse colic side. Subsequently, the cartridge jaw of the stapler was inserted into the transverse colon. The stapler was fired and withdrawn, and the common enterotomy was sealed by using another linear stapler.~STEP 3: Transrectal specimen extraction A longitudinal incision was made on the anterior of wall of the upper rectum. The assistant employed oval forceps to extract the specimen along with the protective sleeve through the incision in the upper rectum. After the complete extraction of the specimen, a full-layer running suturing was performed to close the incision."
62450794|NCT04401566|EXPERIMENTAL|Internal Myofascial Release Group|Internal myofascial trigger point release therapy consists of 30 minutes massage directly to the pelvic floor musculature by vaginally. Patients were instructed in internal myofascial release techniques. Experienced pelvic health physiotherapist (A.B.) to use her fingers with a lubricated glove when the finger could easily reach internal trigger points and follows these steps: (a) finding internal and external trigger points associated with pelvic muscles, especially around sensitive areas of the vagina, anus, and/or pelvic floor; (b) releasing with the fingers the trigger point associated pelvic muscle tension by carefully pressing on the trigger point. Releasing pelvic muscle tension includes applying varying amounts of pressure, sometimes gradually stroking and strumming the muscle region while systematically contracting and relaxing the affected muscles to aid in a trigger point release.
62062831|NCT04616014|EXPERIMENTAL|ORMD-0801 QD|16 mg QD, daily, in the morning (two capsules of ORMD--801, 8 mg each
62062832|NCT05857111||Study population|An estimate of 255 adult women (≥ 18 years old) who come to consult at the Breast Pathology Unit of La Paz Hospital (Madrid, Spain), because of discomfort, breast symptoms, or because they have been sent for specialized evaluation because of a diagnostic doubt will be included.
62062833|NCT04477421|ACTIVE_COMPARATOR|FS-LASIK Group|100 eyes of 50 patients underwent bilateral FS-LASIK (Femtosecond laser Insitu Keratomileusis)
62062834|NCT04477421|EXPERIMENTAL|FS-SMILE|100 eyes of 50 patients who underwent bilateral FS-SMILE (femtosecond small incision lenticule extraction)
62062835|NCT03673462|EXPERIMENTAL|Group 1: MenACYW Conjugate Vaccine|Healthy infants aged greater than equal to (\>=) 42 to less than equal to (\<=) 89 days (at the time of enrollment) received MenACYW Conjugate Vaccine at the age of Months 2, 4, 6, and 12 along with Pentacel® (DTaP-IPV/Hib vaccine) at 2, 4, and 6 months of age; PREVNAR 13® (pneumococcal 13-valent conjugate vaccine; PCV13) at 2, 4, 6, and 12 months of age; RotaTeq® (rotavirus vaccine) at 2, 4, and 6 months of age; ENGERIX-B® (hepatitis B vaccine) at 2 and 6 months of age; and M-M-R® II (measles, mumps, and rubella vaccine) and VARIVAX® (varicella vaccine) at 12 months of age.
62450795|NCT04401566|EXPERIMENTAL|External Myofascial Release Group|Eksternal myofascial trigger point release therapy consists of 30 minutes massage to the abdominal wall, gluteal area and abductors, and hamstring muscles. Pain in trigger points may exist at both locations of muscle insertion as well as in the belly and the lower extremity of the muscle.
62450796|NCT04401566|OTHER|Control Group|The Control group will have a video about exercises recommended in pelvic pain for 30 minutes. A physiotherapist will teach and show the exercises for pelvic pain. The home exercise for pelvic pain contains diaphragm breathing, pelvic floor muscle stretching, and releasing.
62450797|NCT03335371|EXPERIMENTAL|TTP399 400 mg|
62450798|NCT03335371|PLACEBO_COMPARATOR|Placebo|
62450799|NCT03707873|EXPERIMENTAL|In-person education|Education will be given on a regular basis via predefined consultation visits. Medication adherence (oral anticoagulation) will also be measured using a special cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
62450800|NCT03707873|EXPERIMENTAL|Online education|Education will be given on a regular basis via a special designed online platform. Medication adherence (oral anticoagulation) will also be measured using a special cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
62450801|NCT03707873|NO_INTERVENTION|Standard Care|This group of AF patients will serve as a control group and no extra focused educational reinforcements will be provided beyond standard care (i.e. information of the treating physician and a brochure).
62626448|NCT05568797|ACTIVE_COMPARATOR|Control Group|Participants received one dose of FLU-aQIV vaccine at Day 1, followed by one dose of RSVPreF3 OA vaccine at Day 31, and were followed until end of study.
62626449|NCT06542900|EXPERIMENTAL|Patients with Treatment-Resistant Depression (TRD)|Patients will undergo bilateral DBS lead implantation.
62626450|NCT04993872|EXPERIMENTAL|BIC/FTC/TAF|Development phase 4: Biktarvy®
62626451|NCT03787602|EXPERIMENTAL|Cohort 1, Arm 1|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 21-day cycle.
62852303|NCT02083861|PLACEBO_COMPARATOR|Placebo ultrasound device|Patients wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
62852304|NCT03236324|PLACEBO_COMPARATOR|TFP block with saline|Placebo bilateral ultrasound-guided nerve block \[transversalis fascia plane (TFP) block\] with 40 mL saline, single shot
62852305|NCT03236324|EXPERIMENTAL|TFP block with local anesthetic|Experimental bilateral ultrasound-guided nerve block \[transversalis fascia plane (TFP) block\] with local anesthesic of Bupivacaine-epinephrine \[0.25% bupivacaine with 2.5 mcg/mL epinephrine 40 mL (maximum 2.5 mg/kg)\], single shot
62062836|NCT03673462|ACTIVE_COMPARATOR|Group 2: MENVEO®|Healthy infants aged \>= 42 to \<= 89 days (at the time of enrollment) received MENVEO® Conjugate Vaccine at the age of Months 2, 4, 6, and 12 along with Pentacel® (DTaP-IPV/Hib vaccine) at 2, 4, and 6 months of age; PREVNAR 13® (PCV13) at 2, 4, 6, and 12 months of age; RotaTeq® (rotavirus vaccine) at 2, 4, and 6 months of age; ENGERIX-B® (hepatitis B vaccine) at 2 and 6 months of age; and M-M-R® II (measles, mumps, and rubella vaccine) and VARIVAX® (varicella vaccine) at 12 months of age.
62062837|NCT05151497|EXPERIMENTAL|Experimental group: Halliwick + Método Watsu|"The experimental group is made up of 7 subjects, the duration of the session being 75 minutes, divided into 45 minutes of Halliwick, 15 minutes of Watsu and finally 15 minutes of immersion in hot water. .~In the application of the Halliwick Concept, it will be carried out in a pool at a temperature of 30ºC, and through the Ten Points Program.~To carry out Watsu, the pool water must be at a temperature of 35ºC. The Watsu Basic Maneuver will be performed, consisting of a sequence of various positions where the subject must be as relaxed as possible, placed in a supine position, floating with eyes closed, and supported by the physiotherapist who is standing, with a wide base of support."
62062838|NCT05151497|ACTIVE_COMPARATOR|Control group:Halliwick|The control group is made up of 7 subjects, the duration of the session being 75 minutes, divided into 60 minutes of Halliwick and 15 minutes of immersion in hot water. Treatment using the Halliwick Concept is carried out in a pool where the water temperature is 30ºC, following the Ten Points Program.
62626452|NCT03787602|EXPERIMENTAL|Cohort 1, Arm 1b|KRT-232 will be administered orally, once daily (QD) on Days 1-5 in a 23-day cycle.
62626453|NCT03787602|EXPERIMENTAL|Cohort 1, Arm 2b|KRT-232 will be administered orally, once daily (QD) on Days 1-5 in a 28-day cycle.
62626454|NCT03787602|EXPERIMENTAL|Cohort 1, Arm 3|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 21-day cycle.
62062839|NCT00671008||A|
62062840|NCT00671008||B|
62062841|NCT02938923|EXPERIMENTAL|Exercise + Testosterone (EX + T)|Supervised exercise training 2 times per week and topical testosterone 1% gel (12.5 mg per pump depression) daily, both for six months duration.
62062842|NCT02938923|PLACEBO_COMPARATOR|Exercise + Placebo (EX + P)|Supervised exercise training 2 times per week and placebo gel daily, both for six months duration.
62062843|NCT02938923|OTHER|Enhanced Usual Care (EUC)|Home exercise program 3 times per week and monthly health education modules, both for six months duration.
62062844|NCT05007145|EXPERIMENTAL|PD-1 Inhibitor+albumin-bound paclitaxel+cisplatin|Participants receive PD-1 Inhibitor 200mg on Day 1 every 3 weeks (Q3W), albumin-bound paclitaxel 125 mg/m\^2 on Day 1, 8 Q3W, and cisplatin 75 mg/m\^2 on Day 1 Q3W, a total of 2-4 cycles，followed by surgery.
62626455|NCT03787602|EXPERIMENTAL|Cohort 1, Arm 5|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle.
62626456|NCT03787602|EXPERIMENTAL|Cohort 1 Expansion|KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.
62852306|NCT01310205||Hepatitis C treatment|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
62062845|NCT05007145|ACTIVE_COMPARATOR|Albumin-bound paclitaxel+cisplatin+radiotherapy|Participants receive albumin-bound paclitaxel 125 mg/m\^2 on Day 1, 8 Q3W, and cisplatin 75 mg/m\^2 on Day 1 Q3W, a total of 2 cycles combined with radiotherapy(40Gy/2Gy),followed by surgery.
62062846|NCT04667013|EXPERIMENTAL|Cohort 1|2 x 300 mg TBN tablets for a total dose of 600 mg or 2 matching placebo tablets (given approximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7.
62626457|NCT03787602|EXPERIMENTAL|Cohort 2, Arm 1 KRT-232 in combination with avelumab|KRT-232 will be administered orally, once daily (QD) on Days 1-5, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.
62626458|NCT03787602|EXPERIMENTAL|Cohort 2, Arm 2 KRT-232 in combination with avelumab|KRT-232 will be administered orally, once daily (QD) on Days 1-7, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.
62626459|NCT03787602|EXPERIMENTAL|Cohort 2 Expansion|KRT-232 will be administered orally, once daily (QD) per RP2D dose and schedule, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.
62626460|NCT03787602|EXPERIMENTAL|Cohort 3|KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.
62626461|NCT03787602|EXPERIMENTAL|Cohort 4|KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.
62626462|NCT03451955|EXPERIMENTAL|Intervention group|Patients in the intervention group follow a gluten-free diet for six months.
62626463|NCT03451955|NO_INTERVENTION|Control group|Patients in the control group follow their usual diet for six months
62626464|NCT03457818|EXPERIMENTAL|Treatment Group|Denosumab 60 mg/ml \[Prolia\] SC at baseline and 6 months.
62626465|NCT03457818|PLACEBO_COMPARATOR|Control Group|Placebo SC at Baseline and 6 months.
62626466|NCT04569929|ACTIVE_COMPARATOR|control|conventionally manufactured Polymethyl Methacrylate (PMMA) mandibular implant overdentures
62626467|NCT04569929|EXPERIMENTAL|intervention|digital light processed (DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdentures
62626468|NCT00760487|EXPERIMENTAL|AcrySof Toric IOL|AcrySof Toric Intraocular Lens (IOL)
62626469|NCT03327038|EXPERIMENTAL|Psychological Intervention|Patients will be randomized to the intervention group after they have complete the study screening form. Patients randomized to the intervention group will receive a multifaceted intervention consisting of the following components (administered over an 8 week period): (1) Web-Based Cognitive Behavioral Therapy: (2) Short Questionnaires; (3) Ongoing Nurse Monitoring.
62626470|NCT03327038|ACTIVE_COMPARATOR|Control|Patients will be randomized to the control group after they have completed the study screening form. Patients randomized to the control group will receive the usual standard of care that is available to patients with moderate anxiety or depression. Additionally, control patients will completed detailed questionnaires for assessment of primary and secondary outcomes.
62626471|NCT04854759|EXPERIMENTAL|Study group|
62626472|NCT04854759|PLACEBO_COMPARATOR|Control group|
62626473|NCT02768792|OTHER|open-label, multicenter, single-arm|Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2-years of maintenance therapy (i.e., beginning on day 1 of maintenance). Patients who are ineligible for pembrolizumab administration by day 21 will be removed from the study.
62450802|NCT00602030|EXPERIMENTAL|Lead-in Phase: Erlotinib + Entinostat 5 mg|Erlotinib 150 mg, tablets, orally, daily plus entinostat 5 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase.
62626474|NCT02096562|PLACEBO_COMPARATOR|B - No compression stockings|normal therapy - no compression stockings
62626475|NCT02096562|ACTIVE_COMPARATOR|A - Use of compression stockings|Patients use compression stockings for 10 days after surgery
62626476|NCT03130374|EXPERIMENTAL|Mesenchymal stem cell treated group|Patients treated according to current clinical protocols plus autologous olfactory mucosa-derived mesenchymal stem cells
62626477|NCT03130374|NO_INTERVENTION|Control group|Patients treated according to current clinical protocols
62626478|NCT06478329|NO_INTERVENTION|Control group|Routine volleyball training
62626479|NCT06478329|EXPERIMENTAL|Study Group|Study group continued 6 weeks of core stability training additional to routine volleyball training
62626480|NCT04909515|EXPERIMENTAL|naxitamab + GM-CSF + isotretinoin|8 cycles. Cycles 1+2 naxitamab + GM-CSF, cycles 3-5 naxitamab + GM-CSF + isotretinoin, cycles 6-8 isotretinoin
62626481|NCT05314829||Study group|Data will be collected from 2 child advocacy centers
62450803|NCT00602030|EXPERIMENTAL|Lead-in Phase: Erlotinib + Entinostat 10 mg|Erlotinib 150 mg tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase.
62626482|NCT01486823|EXPERIMENTAL|Cohort A|
62626483|NCT01486823|EXPERIMENTAL|Cohort B|
62626484|NCT02164318|NO_INTERVENTION|Control group|Standard of care
62626485|NCT02164318|EXPERIMENTAL|Handgrip training group|Perform isometric handgrip exercises for 15 minutes twice per day for a total of 30 minutes
62626486|NCT02164318|EXPERIMENTAL|Nitroglycerin ointment group|Apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
62626487|NCT02164318|EXPERIMENTAL|Combined handgrip training /Nitroglycerin ointment group|Perform isometric handgrip exercises for 15 minutes twice each day for a total of 30 minutes and apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
62626488|NCT00565552|ACTIVE_COMPARATOR|1|Each patient uses the silicone gel on one half of the scar, leaving the other one blank as an internal control.
62626489|NCT00170274|NO_INTERVENTION|Control Arm|Algorithms for prevention and termination of AF not activated
62626490|NCT00170274|ACTIVE_COMPARATOR|Prevention and Therapy Algorithms on|Activation of preventive and therapeutic algorithms
62626491|NCT00767598|ACTIVE_COMPARATOR|A|Vardenafil
62626492|NCT00767598|ACTIVE_COMPARATOR|B|Sildenafil
62450804|NCT00602030|EXPERIMENTAL|Double-blind Phase: Erlotinib + Entinostat 10 mg|Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase.
62626493|NCT00767598|ACTIVE_COMPARATOR|C|Udenafil
62652907|NCT01582347|ACTIVE_COMPARATOR|Subutex®/Suboxone®|During the Double-Blind Transfer Period (Days 1-7), participants take Subutex®/Suboxone® at a level (either 8, 16 or 240 mg/day) equivalent to dosing during the Run-In Period, plus Placebo for RBP-6000. This is followed by a 3-day Transition Period (Days 8-10) in which participants take active Subutex®/Suboxone® equal to the dose taken during the Run-In Period plus placebo matching RBP-6000.
62267482|NCT00549367|OTHER|1|Clients in the control arm of the study will receive nutrition assessment only for the first 24 weeks and the be transferred to nutrition counselling group
62267483|NCT05637918||Group 1 (Patients who recorded as Grade 0)|"Patients whose antrum appears empty in supine and right lateral decubitus (RLD) positions by gastric ultrasound (Grade 0). Groups are classified according to the qualitative evaluation of the antrum by gastric sonographic examination.~The nature of the gastric contents (empty, clear liquid, dark liquid/solid) is established based on the qualitative findings by gastric antral ultrasonography. The qualitative evaluation of the antrum was recorded according to the 3-point grading system as Grade 0, Grade 1, and Grade 2.~Grade 0: antrum appears empty in both positions. Grade 1: antrum appears empty in the supine position but a small volume of gastric clear fluid is visible in the RLD position.~Grade 2: antral clear fluid visualized in both the supine and RLD position"
62652908|NCT01031082||HIV-negative Group|This group is sub-divided into two sub-groups. One sub-group includes HIV-negative/ presumed negative subjects with a new episode of acute otitis media who have not yet received antibiotic therapy for the episode and the other sub-group includes HIV-negative/ presumed negative subjects with treatment failure who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment.
62852307|NCT01310205||non cirrhotic subjects|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
62852308|NCT00809302|EXPERIMENTAL|1|aplindore 2 mg MR total daily dose
62852309|NCT00809302|EXPERIMENTAL|2|aplindore 6 mg MR total daily dose
62852310|NCT00809302|EXPERIMENTAL|3|aplindore 12 mg MR total daily dose
62852311|NCT00809302|PLACEBO_COMPARATOR|4|Placebo
62852312|NCT04582253||Keratoconus|"Those with a clinical diagnosis of keratoconus such as:~a) the presence of a central protrusion of the cornea with Fleischer ring, Vogt striae, or both by slitlamp examination.(b) an irregular cornea determined by distorted keratometry mires and distortion of retinoscopic red reflex or both in addition to the following topographic findings as summarized by Pińero and colleagues: focal steepening located in a zone of protrusion surrounded by concentrically decreasing power zones, focal areas with dioptric (D) values \>47.0D, inferior- superior(I-S) asymmetry measured to be \> 1.4 D or angling of the hemimeridians in an asymmetric or broken bowtie pattern with skewing of the steepest radial axis (SRAX) 2."
62450805|NCT00602030|PLACEBO_COMPARATOR|Double-blind Phase: Erlotinib + Placebo|Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase.
62852313|NCT04582253||Subclinical keratoconus|Defined as subtle corneal tomographic changes as the aforementioned keratoconus abnormalities in the absence of slit- lamp or visual acuity changes typical of keratoconus (subclinical keratoconus).
62852314|NCT04582253||Normal|This group comprised refractive surgery candidates and subjects applying for a contact lens fitting with a refractive error of less than 8.0 D sphere with less than 3.0 D of astigmatism and without clinical, topographic or tomographic signs of keratoconus nor suspected keratoconus.
62852315|NCT00899353|EXPERIMENTAL|Omega 3 supplement|Omega 3 supplement will be added to diet, 3 capsules per day for one month then 6 capsules per day for one month then 9 capsules per day as tolerated
62852316|NCT01284491|ACTIVE_COMPARATOR|Standard of Care (SOC)|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
62852317|NCT01284491|EXPERIMENTAL|PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
62852318|NCT00264459|PLACEBO_COMPARATOR|Placebo|Placebo was given the same way as a sublingual preparation.
62267484|NCT05637918||Group 2 ( Patients who recorded as Grade 1)|"Patients whose antrum appears empty in the supine position but a small volume of gastric clear fluid is visible in the RLD position by gastric ultrasound (Grade 1). Groups are classified according to the qualitative evaluation of the antrum by gastric sonographic examination The nature of the gastric contents (empty, clear liquid, dark liquid/solid) is established based on the qualitative findings by gastric antral ultrasonography. The qualitative evaluation of the antrum was recorded according to the 3-point grading system as Grade 0, Grade 1, and Grade 2.~Grade 0: antrum appears empty in both positions. Grade 1: antrum appears empty in the supine position but a small volume of gastric clear fluid is visible in the RLD position.~Grade 2: antral clear fluid visualized in both the supine and RLD position"
62267485|NCT05640778|EXPERIMENTAL|neoadjuvant endocrine therapy|CDK4/6 inhibitor combined with aromatase inhibitor
62626494|NCT03343366|EXPERIMENTAL|Test Group 1|The participants in this group will receive a combination of ultrasonic scaling and hand instrumentation required for planing of the root surfaces (SRP) followed by systemic AAT followed by routine warm salt water rinses for 3-5 days and OHI. SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth. Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days. OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
62626495|NCT03343366|ACTIVE_COMPARATOR|Test Group 2|The participants in this group will receive a combination of Scaling Root Planing followed by routine warm salt water rinses for 3-5 days and OHI. Same procedure for SRP and OHI will be followed as that followed in Test Group 1
62626496|NCT03343366|OTHER|Control Group 3|The participants in this group will receive only routine warm salt water rinses for 3-5 days and Oral Hygiene Instructions as that followed in Test Group 1 and Test Group 2. However, after completing six (6) months of evaluation they will be provided DT either in the form of SRP+MET or SRP only in addition to OHI, whichever would be found to have a significant beneficial effect on CP.
62626497|NCT02568462|EXPERIMENTAL|Coronary Scaffold Implantation|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
62626498|NCT05110365|EXPERIMENTAL|proprioceptive neuromuscular facilitation|proprioceptive neuromuscular facilitation techniques
62852319|NCT00264459|EXPERIMENTAL|Liquid formulation of an extract of a 6 grass pollen mixture|"Sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter. Initial treatment was applied on the first day of treatment with a starting dose of 25% of the maintenance dose. Increasing doses of 50% were applied with the second and 100% with the third dose to give the maximum (=maintenance) dose. This was followed by a daily patient selfadministered treatment with the maintenance dose."
62852320|NCT01346995|EXPERIMENTAL|Experimental Knee Pain|Experimental knee pain induced by injections of 1 ml hypertonic saline in to the infrapatellar fat pad
62852321|NCT01346995|ACTIVE_COMPARATOR|Control|non-painful injections of isotonic saline into the infrapatellar fatpad.
62852322|NCT03697889|EXPERIMENTAL|Treatment Sequence AB|Participants will receive Treatment A (test product Naproxen sodium tablet, 1 x 275 mg) at dosing period 1 followed by Treatment B (reference product Nalgesin, 1 x 275 mg) dosing period 2. There is a wash-out period of 7 days between the two dosing periods.
62852323|NCT03697889|EXPERIMENTAL|Treatment Sequence BA|Participants will receive Treatment B (reference product Nalgesin, 1 x 275 mg) at dosing period 1 followed by Treatment A (test product Naproxen sodium tablet, 1 x 275 mg) at dosing period 2. There is a wash-out period of 7 days between the two dosing periods.
62450806|NCT00602030|EXPERIMENTAL|Crossover Phase: Erlotinib + Entinostat 10 mg|Participants in the Double-blind Phase Erlotinib + Placebo arm who experienced disease progression crossed over to receive open-label erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities.
62267486|NCT04418076|EXPERIMENTAL|No feedback|For participants in the control group (Group A), no feedback from the TowerView Health® smart pill box or clinical nurse will be given.
62852324|NCT04466579|EXPERIMENTAL|BIS monitoring|Study subjects randomized in this study arm will have the depth of anesthesia controlled with the BIS monitor.
62852325|NCT04466579|ACTIVE_COMPARATOR|Standard care|Study subjects randomized in this study arm will receive standard anesthesiology care according to the usual procedures used at the study centre.
62852326|NCT04870580|OTHER|Intervention arm|PET/CT with fluorodopa tracer
62852327|NCT05555420|ACTIVE_COMPARATOR|SRP only|
62267487|NCT04418076|EXPERIMENTAL|Automated feedback|For participants in Group B (automated feedback), automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages.
62450807|NCT02454673||Group A|"* 3-4 cycles of preoperative chemotherapy~* Surgery"
62450808|NCT02454673||Group B|"* 3-4 cycles of induction chemotherapy~* Radiotherapy with concurrent chemotherapy for 5 weeks~* Surgery"
62450809|NCT03943251|EXPERIMENTAL|HEC113995PA•H2O tablet|Including 7 dose groups(2.5-、5、10-、20-、40-、60-、80mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
62626499|NCT05110365|NO_INTERVENTION|control|no intervention
62626500|NCT01792102|EXPERIMENTAL|Carfilzomib and Dexamethasone|"Phase 1: Carfilzomib will be administered at an escalating dose with dexamethasone administered at 8mg.~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: Carfilzomib and dexamethasone will be administered in the same fashion as the previous treatment cycles, but only on days 1, 2, 15, and 16."
62852328|NCT05555420|EXPERIMENTAL|SRP+Laser|
62626501|NCT01409915|EXPERIMENTAL|Sagramostim (Leukine)|5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
62626502|NCT01409915|PLACEBO_COMPARATOR|Control Group|Saline -- placebo comparator. Given as a subcutaneous injection.
62626503|NCT01639248|EXPERIMENTAL|ENMD-2076 Treatment|ENMD-2076
62626504|NCT06260917||urination through zipper|
62267488|NCT04418076|EXPERIMENTAL|Automated feedback + Clinician feedback|For participants in Group C, automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages. In addition, clinical nurse will also send personalized feedback and suggestions to the participants in this group.
62267489|NCT04418076|EXPERIMENTAL|Automated feedback + Social Network feedback|For participants in Group D, automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages. In addition, a weekly text reminder will be sent to each participant from a social network designee chosen by the participant.
62626505|NCT06260917||urinating by pulling down trousers|
62626506|NCT01199887|EXPERIMENTAL|IW001|Three dose cohorts, 0.1 mg, 0.5 mg, 1.0 mg
62652909|NCT01031082||HIV-positive Group|This group is sub-divided into two sub-groups. One sub-group includes HIV-positive subjects with a new episode of acute otitis media who have not yet received antibiotic therapy for the episode and the other sub-group includes HIV-positive subjects with treatment failure who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment.
62267490|NCT00264238|EXPERIMENTAL|Memantine open label|All subjects knowingly received (open label) memantine for up to 12 weeks with a target dose of 10 mg twice a day (20mg/d) taken orally.
62267491|NCT00865826||1|HIV-infected males and females who are not currently receiving ART
62461417|NCT02329678|ACTIVE_COMPARATOR|collagen membrane group and control group|GTR group: a bioresorbable collagen membrane (Healiguide, Advanced Biotech Products (P) Ltd., Encoll Corp., Fremont, CA, USA) was placed over the apicomarginal defect, covering 2-3mm of the healthy bone around all the margins after periodical surgery.
62461418|NCT02329678|ACTIVE_COMPARATOR|Control group|Control Group:No membrane was placed after periapical surgery.
62461419|NCT04922112|EXPERIMENTAL|Research group|Sleep apnea testing will be performed with this group, in the form of quality of life and sleep questionnaires, home sleep study results, as well as information collected from their electronic medical record. The investigator will also obtain blood laboratory specimens to measure serum TNF-alpha and IL-6.
62461420|NCT04259528|EXPERIMENTAL|Patients with esophageal stricture following surgical repair|Patients with esophageal atresia following surgical repair who developed an esophageal stricture
62461421|NCT01159132|ACTIVE_COMPARATOR|1|RAL 400 mg OD
62461422|NCT01159132|ACTIVE_COMPARATOR|2|RAL 800 mg OD
62461423|NCT05682118|EXPERIMENTAL|tested using the roadmap system|tested using the roadmap system
62461424|NCT05682118|ACTIVE_COMPARATOR|tested without using the roadmap system|tested without using the roadmap system.
62461425|NCT01180569|EXPERIMENTAL|lenalidomide|Eligible patients for this clinical trial will be treated for 6 cycles with lenalidomide at 15 mg daily by mouth on Days1-21 of 28 day cycle, preceded by an escalating schema for safety (5mg daily for 2 weeks; 10 mg daily for 2 weeks; and 15 mg daily for 2 weeks) and then a one week rest).
62461426|NCT05081258|ACTIVE_COMPARATOR|NAM treatment|Study Group: newborns with UCLP will be treated with a palate plate with nasal stent (Nasoalveolar Molding = NAM)
62461427|NCT05081258|SHAM_COMPARATOR|pAM treatment|Control Group: newborns with UCLP will be treated with a palate plate without nasal stent (passive Alveolar Molding = pAM)
62461428|NCT00403039|OTHER|Open-label ranibizumab|Subjects will receive open-label intravitreal injections of ranibizumab administered every 28 ± 7 days for a total of 3 injections. Thereafter they are to be evaluated monthly for re-treatment until Month 48.
62461429|NCT01582672|EXPERIMENTAL|AGS-003 + Standard Treatment|Subjects on this arm will receive standard treatment for Renal Cell Carcinoma. In addition, subjects will receive AGS-003.
62461430|NCT01582672|ACTIVE_COMPARATOR|Standard Treatment|Subjects on this arm will receive standard treatment for Renal Cell Carcinoma.
62461431|NCT06212453|EXPERIMENTAL|patients with BPH|Targeted Microwave Ablation
62461432|NCT05165056|EXPERIMENTAL|Treatment group|Patients allocated to the treatment group will receive institutional standard vaginal care in combined with twice weekly PBMT sessions during the radiotherapy course and until two weeks after the end of radiotherapy.
62461433|NCT05165056|NO_INTERVENTION|Control group|Patients allocated to the control group will receive institutional standard vaginal care.
62461434|NCT05968209|ACTIVE_COMPARATOR|Active group|
62461435|NCT05968209|PLACEBO_COMPARATOR|Placebo Group|
62461436|NCT05826262|EXPERIMENTAL|patients with penetrating anterior abdominal wall injuries|
62461437|NCT04887142||The discharged subjects|The COVID-19 inpatients treated with standard care who survived the disease and discharged from hospital.
62461438|NCT04887142||The deceased subjects|The COVID-19 inpatients treated with standard care who died from the disease.
62626507|NCT03597191|EXPERIMENTAL|Spinal Stabilization Exercise Program|"Participants in the spinal stabilization exercise group will be instructed to perform four exercises in total, one exercise from each of the following four categories: (a) abdominal bracing, (b) quadruped, (c) prone plank, and (d) side plank exercises. Each exercise will be progressed and advanced in difficulty by increasing repetitions, hold times, and/or extremity movements.~The progression of exercises will be based on the participants' performance at each supervised physical therapy session based on pre-established criteria by Hicks et al. (2005)."
62852329|NCT06522594|EXPERIMENTAL|Beta receptor inhibition arm|"In the beta receptor (BR) inhibition arm, patients are randomized to a biphasic strategy where BR stimulation is phased out and esmolol (BR blockade) is initiated in a sequential way. During a first phase, milrinone (a phosphodiesterase inhibitor which is routinely used in V-A ECMO supported patients) infusion will be initiated (if not already being given) at 0.25 mcg/kg/min and dobutamine dosages will be decreased every hour and eventually stopped according to the following sequence; 6 - 4 - 2 - 1 - 0 mcg/kg/min.~In a second phase, esmolol is initiated with a dosage of 25 mcg/kg/min. The dose of the BB will be increased with increments of 25 mcg/kg/min every hour until reaching a heart rate between 50 and 70 bpm or a maximum dose of 200 mcg/kg/min. Prior to each dosage escalation, a reassessment of the hemodynamic situation will be done.~The BR inhibition strategy will be continued until 48 hours after randomization or earlier when deemed necessary by the treating physician."
62852330|NCT06522594|NO_INTERVENTION|Routine care arm|The dosage of dobutamine infusion is at the discretion of the treating physician but is typically continued until 48 hours after randomization. All other medication will be managed according to the needs of the patient at the discretion of the treating physician.
62852331|NCT02184052||Meloxicam|
62852332|NCT03303508|OTHER|anti-ds DNA|anti-ds DNA
62852333|NCT02501187|EXPERIMENTAL|Patients operated for ptosis by levator advancement|patients undergoing surgical repair for aponeurotic ptosis by the procedure- levator advancement.
62852334|NCT02501187|EXPERIMENTAL|Patients operated for ptosis by white line advancement|patients undergoing surgical repair for aponeurotic ptosis by the procedure- white line advancement
62852335|NCT02501187|EXPERIMENTAL|Patients operated for ptosis by Müller resection|patients undergoing surgical repair for aponeurotic ptosis by the procedure- Müller's muscle-conjunctival resection.
62267492|NCT04334980|EXPERIMENTAL|bacTRL-Spike|"* Group 1 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 1 billion colony forming units (cfu) of Bifidobacterium longum (B. longum);~* Group 2 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 3 billion cfu of B. longum;~* Group 3 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 10 billion cfu of B. longum;~* Group 4 (n=3): Single Data and Safety Monitoring Board (DSMB)-defined dose of bacTRL-Spike among subjects 56 years of age and older.~* Group 5 (n=12): DSMB-defined prime and boost doses of bacTRL-Spike delivered with a 28-day intervening interval."
62267493|NCT04655443||Control Group|"Patients will be scheduled for an electrocardiogram thirty days after their electrical cardioversion. Based on the electrocardiogram result, patients that maintained sinus rhythm will be assigned to Control."
62267494|NCT04655443||Afib Group|"Patients will be scheduled for an electrocardiogram thirty days after their electrical cardioversion. Based on the electrocardiogram result, patients that developed persistent atrial fibrillation will be assigned to Afib."
62267495|NCT05482230|NO_INTERVENTION|DLT in supine position|The double-lumen bronchial group was inserted in supine position
62852336|NCT05648045||Groups classified based on BMI|"Group 1: Overweight BMI Cut-Off Points (kg/m²) by International Obesity Task Force; IOTF Overweight (including obesity) ≥25.00~Group 2: Obese BMI Cut-Off Points (kg/m²) by International Obesity Task Force; IOTF~Obese ≥30.00~Group 3: Normal-weight BMI Cut-Off Points (kg/m²) by International Obesity Task Force; IOTF~Healthy Weight - 18.5-24.99"
62852337|NCT02646371|ACTIVE_COMPARATOR|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
62852338|NCT02646371|PLACEBO_COMPARATOR|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
62062847|NCT04667013|EXPERIMENTAL|Cohort 2|4 x 300 mg TBN tablets for a total dose of 1200 mg or 4 matching placebo tablets (given approximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7.
62088024|NCT06312631|EXPERIMENTAL|Task handover model #7|"At each visit, the patient will perform the tasks with the gripping glove (A) or without the gripping glove (B).~The order of administration with then without the glove (AB) or without then with the glove (BA) is drawn at random for each patient.~The 7th model follows the following diagram:~Visit T1 = AB ; Visit T2 = BA ; Visit T3 = BA"
62267496|NCT05482230|EXPERIMENTAL|DLT in lateral position|The double-lumen bronchial group was inserted in lateral position
62267497|NCT05482230|NO_INTERVENTION|BB in supine position|The bronchial blocker group was inserted in supine position
62267498|NCT05482230|EXPERIMENTAL|BB in lateral position|The bronchial blocker group was inserted in lateral position
62267499|NCT01250379|ACTIVE_COMPARATOR|1|
62267500|NCT01250379|EXPERIMENTAL|2|
62267501|NCT04906174||Observational (medical record review)|Patients' medical records are reviewed retrospectively.
62267502|NCT01246440|EXPERIMENTAL|Catumaxomab|
62267503|NCT03561909|OTHER|Platelet transfusion|HLA-A2 and/or HLA A9 negative healthy study subjects will be transfused with a small dose of platelets from an HLA-A2 and/or HLA-A9 positive donor.
62267504|NCT01508871||Cardiomyopathy|
62267505|NCT05210530|EXPERIMENTAL|VCTX210A combination product|Up to seven (7) units will be implanted
62267506|NCT05541809|EXPERIMENTAL|Peppermint group|This group will receive peppermint oil aroma
62267507|NCT05541809|PLACEBO_COMPARATOR|Water group|This group will receive water as an aroma oil
62267508|NCT02940509|ACTIVE_COMPARATOR|Ketamine plus Magnesium sulfate|Ketamine 0.5mg/kg IV dose with 2g magnesium IV dose
62852339|NCT01761162||Pacemaker Therapy|Patients with a ProMRI Pacemaker System
62852340|NCT01536392|EXPERIMENTAL|Granisetron|Group A: 34.3 mg of granisetron formulated in transdermal patch replaced every 7 days. Transdermal patch placed/replaced prior to the intravenous (IV) infusion of cisplatin. At cycle 1, participants receive IV granisetron prior to IV cisplatin and prior to administration of transdermal patch.
62852341|NCT01536392|EXPERIMENTAL|Ondansetron|Group B: 8 mg of ondansetron orally thrice daily starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
62852342|NCT03144609|ACTIVE_COMPARATOR|PEEP 4|Active Comparator low PEEP: obese patient during oral-surgical procedures under general anesthesia ventilated with Positive endexpiratory pressure (PEEP) 4 cm H2O(water)
62062848|NCT03412968|EXPERIMENTAL|Polysulfone Filter Group|The purpose of the research is to determine whether, by controlling the patient's hemodilution level and, therefore, the acute anaemia caused by the Cardiopulmonary Bypass (CPB) priming fluid, continuous conventional ultrafiltration (CUF) can decrease serum lactate levels during normothermic CPB by increasing the haematocrit and, consequently, the supply of oxygen to the tissues, and whether the haemofiltration membrane can remove lactate molecules in situations of hyperlactataemia in CPB.
62626508|NCT03597191|PLACEBO_COMPARATOR|General Exercises Program|Participants in the general exercise group will perform a range of motion (ROM) and flexibility exercises of low back and lower extremities. Each participant will be instructed to perform four exercises in total, one exercise from each of the following four categories: (a) knee to chest, (b) lower trunk rotation, (c) prone press-ups, and (d) hamstring stretch exercises. These exercises will be progressed by increasing repetitions and pain-free ROM.
62626509|NCT00397189|EXPERIMENTAL|Circadin|
62626510|NCT00397189|PLACEBO_COMPARATOR|placebo|
62626511|NCT02104245|EXPERIMENTAL|Ciprofloxacin dispersion for inhalation|Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin
62626512|NCT02104245|PLACEBO_COMPARATOR|Placebo|Liquid formulation of empty liposomes
62626513|NCT01504373||NAVA-PSV|Subject will receive 4 hours of NAVA followed by 4 hours of PSV.
62852343|NCT03144609|EXPERIMENTAL|PEEP 7 & ARM|Experimental ARM \& Experimental high PEEP: obese patient during oral-surgical procedures under general anesthesia ventilated with PEEP( positive endexpiratory pressure) 7 cm H2O with ARM(alveolar recruitment maneuver) provided every 30 min
62852344|NCT03144609|EXPERIMENTAL|PEEP 10 & ARM|Experimental ARM \& Experimental high PEEP:obese patient during oral-surgical procedures under general anesthesia ventilated with PEEP( positive endexpiratory pressure) 10 cm H2O with ARM(alveolar recruitment maneuver) provided every 30 min
62852345|NCT01250444|EXPERIMENTAL|Inspiratory Muscle Training|It will me performed a loaded training of ventilatory muscles in patients with Hypertension. Its is done with the practice of breathing exercises associated to an training device, specific for this kind of intervention.
62852346|NCT02938715|EXPERIMENTAL|Feedback group (teledermatology)|
62852347|NCT02938715|NO_INTERVENTION|Control group (phone only)|
62852348|NCT01074385|OTHER|Immediate Dignity Therapy|At registration, subjects will be mailed a questionnaire. The subject will then receive two separate dignity therapy sessions, about a week apart. Subjects will then be asked to complete a questionnaire 1-2 weeks after completing therapy sessions and one month after completing therapy sessions.
62852349|NCT01074385|OTHER|Wait List Dignity Therapy|At registration, subjects will be mailed a questionnaire. The subject will then receive two separate dignity therapy sessions; the first session will take place about 6 weeks after registration, with the second session occurring 1-3 weeks after the first. Subjects will then be asked to complete a questionnaire about one month after completing therapy sessions.
62267509|NCT02940509|PLACEBO_COMPARATOR|Placebo|Normal Saline (NaCl 0.9%)
62852350|NCT06326983|EXPERIMENTAL|Opioid-Sparing Anesthetic Plan|For their tonsil surgery, subjects will receive Dexmedetomidine (1mcg/kg bolus given intravenously at induction of anesthesia) and Acetaminophen (12.5mg/kg with a maximum dose of 1 gram given intravenously at induction of anesthesia). Ketorolac 0.5mg/kg with a max dose of 30mg given intravenously at the end of surgery. No opioids will be given during the procedure.
62852351|NCT06326983|ACTIVE_COMPARATOR|Opioid Anesthetic Plan|For their tonsil surgery, subjects will receive Morphine (0.1mg/kg given intravenously at induction of anesthesia) and Acetaminophen (12.5mg/kg with a maximum dose of 1 gram given intravenously at induction of anesthesia). Ketorolac 0.5mg/kg with a max dose of 30mg intravenously at the end of surgery.
62852352|NCT04529486|EXPERIMENTAL|Group 1: Kinesio taping|Kinesio taping was applied to the study group to improve posture and improve function in the shoulder area. Measurements were carried out for the study group before and after application (with tape on). The tape was then removed and the measurements were repeated after 1 week.
62062849|NCT03412968|ACTIVE_COMPARATOR|Control Group|The purpose of the research is to determine serum lactate levels during normothermic cardiopulmonary bypass procedure (CPB) without continuous hemofiltration of the patient during the CPB.
62267510|NCT01203384|EXPERIMENTAL|CHF5074 1x|oral tablet, multidose
62267511|NCT01203384|EXPERIMENTAL|CHF5074 2x|oral tablet, multidose
62267512|NCT01203384|EXPERIMENTAL|CHF5074 3x|oral tablet, multidose
62267513|NCT01203384|PLACEBO_COMPARATOR|Placebo|placebo, oral tablet, multidose
62626514|NCT01504373||PSV-NAVA|Subject will receive 4 hours of PSV followed by 4 hours of NAVA.
62626515|NCT04462822|EXPERIMENTAL|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
62626516|NCT04462822|ACTIVE_COMPARATOR|Reference Product|ADVAIR DISKUS® 250/50
62626517|NCT01212146|EXPERIMENTAL|Probiotic-enriched Artichokes|Artichokes containing approximately 1.20 x 10\^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme
62626518|NCT01212146|ACTIVE_COMPARATOR|Ordinary artichokes|Ordinary artichokes (probiotic free) of identical shape, texture, and appearance of probiotic-enriched artichokes
62852353|NCT04529486|NO_INTERVENTION|Group 2: Control|No application was made to the control group.
62626519|NCT03790865|EXPERIMENTAL|Low-Dose Livoletide|Daily subcutaneous injection of \~ 60 mcg/kg for 3 month double-blind core period and 9 month open label extension period.
62626520|NCT03790865|EXPERIMENTAL|High-Dose Livoletide|Daily subcutaneous injection of \~120 mcg/kg for 3 month double-blind core period and 9 month open label extension period.
62626521|NCT03790865|PLACEBO_COMPARATOR|Placebo|Daily subcutaneous injection of 0.9% NaCl for the 3 month double-blind core period and then low-dose or high-dose livoletide for 9 month open label extension period.
62626522|NCT05098366|EXPERIMENTAL|Furosemide|Participants will receive a 20mL/kg (max 1000mL) IV fluid bolus and a 0.1mg/kg (max 5mg) furosemide dose
62626523|NCT05098366|PLACEBO_COMPARATOR|IV fluids|Participants will receive a 20mL/kg (max 1000mL) IV fluid bolus and an IV fluid flush
62652910|NCT03539510|EXPERIMENTAL|HF-ACP Website|The HF-ACP website leads participants through 4 e-learning modules. Each module contains 3 core elements: (1) educational content which provides information and support to help patients complete the module (2) interactive tools for documenting their thoughts and progress and (3) motivational video clips that encourage behavior change by validating participants ambivalence, suggesting strategies to help participants complete the task and to encourage and reassure participants that they can do this.
62267514|NCT04163250||Patients with ACS undergoing cardiac catheterization|"Adults with moderate / high risk acute coronary syndrome undergoing coronary intervention.~The sample will be selected consecutively, including patients admitted to the Cardiac Coronary Unit and who require a radiological test with intra-arterial IC administration, for diagnostic or diagnostic / therapeutic purposes"
62267515|NCT01604265|PLACEBO_COMPARATOR|Placebo|Placebo control.
62062850|NCT00964457|ACTIVE_COMPARATOR|Capecitabine, oxaliplatin|
62626524|NCT06549192|ACTIVE_COMPARATOR|Group 1: Boxers|Before the assessment begins, the children will be asked whether they have consumed any beverages containing theine and caffeine, such as tea, coffee, cola and energy drinks, which can affect the heart, in the last two hours. If this is the case, the shooting will be postponed to the next day without consuming such beverages. Participants will first have their information recorded on the general evaluation form. Their resting heart rate variability, blood pressure, heart rate and respiratory function will then be measured. After these initial measurements at rest, the participants will be given a 20 meter shuttle run test. At the end of the test, the participant will be taken to the first assessment room for a second assessment. Here, ECG, blood pressure and heart rate, spirometer measurements will be repeated. All outcome measurements will be recorded on the evaluation form.
62852354|NCT03269929|EXPERIMENTAL|Music therapy|
62062851|NCT00964457|ACTIVE_COMPARATOR|capecitabine, oxaliplatin and cetuximab|capecitabine, oxaliplatin ane cetuximab
62267516|NCT01604265|EXPERIMENTAL|Sativex|Active treatment.
62267517|NCT04338503||HF patients|Decompensated heart failure patients undergoing right heart catheterization.
62267518|NCT04411264|NO_INTERVENTION|Classic protocol for pain management|classic protocol for pain management during chronic wound dressing
62267519|NCT04411264|EXPERIMENTAL|Virtual reality for pain management|protocol associating virtual reality with the classic protocol for pain management during the treatment of chronic wound dressings
62267520|NCT01337128|EXPERIMENTAL|Carotid endarterectomy (CEA)|Patients with carotid stenosis who are randomly assigned to a carotid endarterectomy.
62267521|NCT01337128|EXPERIMENTAL|Carotid Stenting (CAS)|Patients with carotid stenosis who are randomly assigned to a carotid stenting.
62852355|NCT03269929|ACTIVE_COMPARATOR|Midazolam|
62852356|NCT00852839|EXPERIMENTAL|552-02|
62852357|NCT00852839|PLACEBO_COMPARATOR|Placebo|
62852358|NCT01672177|NO_INTERVENTION|Control|Individuals in the control group will not receive any training.
62852359|NCT01672177|EXPERIMENTAL|Intervention|Individuals in the intervention group will receive two hour long weekly training sessions for seven to eight months. The content of the training focuses on health promotion, health seeking behaviours and chronic disease management.
62852360|NCT06426524|EXPERIMENTAL|Test group|In test group, after reflection of flap and degranulation, IGF-1 gel with hydroxyapatite will be placed in the defect and sutures will be placed.
62852361|NCT06426524|ACTIVE_COMPARATOR|Control group|In control group, after reflection of flap and degranulation, hydroxyapatite will be placed in the defect and sutures will be placed.
62267522|NCT01337128|NO_INTERVENTION|matched control group|Matched control group.
62267523|NCT04246879|EXPERIMENTAL|MRI|
62267524|NCT01566773|EXPERIMENTAL|PT001 MDI (Dose 1)|
62852362|NCT05950646|EXPERIMENTAL|Dexmedetomidine-esketamine combination|Dexmedetomidine-esketamine combination will be infused at a rate of 0.01 ml/kg/h (dexmedetomidine 0.02 μg/kg/h and esketamine 5 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.
62852363|NCT05950646|PLACEBO_COMPARATOR|Normal saline|Placebo (normal saline) will be infused at a rate of 0.01 ml/kg/h from 8 pm in the night before surgery until 8 am in the third morning after surgery.
62852364|NCT01948856|EXPERIMENTAL|J022X ST|
62852365|NCT01948856|PLACEBO_COMPARATOR|Placebo|
62852366|NCT06194045|EXPERIMENTAL|LC-MUFA oil|2x1g capsules containing concentrated marine oil from north atlantic fish
62852367|NCT06194045|PLACEBO_COMPARATOR|Placebo|2x1g capsules containing corn oil
62852368|NCT02438475|ACTIVE_COMPARATOR|Mynx Vascular Closure System|Where subjects will have venous hemostasis attempted to be achieved using the Mynx Vascular Closure system alone
62852369|NCT02438475|OTHER|Manual Compression|Where patients will have venous hemostasis attempted to be achieved using manual compression alone
62852370|NCT03762096|EXPERIMENTAL|Resveratrol|
62852371|NCT03762096|PLACEBO_COMPARATOR|Placebo|
62062852|NCT05555888|EXPERIMENTAL|Treatment Arm|A total of 34 patients will receive 5\*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TEM or TME surgery.
62062853|NCT01600222|EXPERIMENTAL|LEO 90100|
62062854|NCT02759185|EXPERIMENTAL|High THC cannabis|Provided up to 1.8 g of cannabis per day with more tetrahydrocannabinol than cannabidiol
62062855|NCT02759185|EXPERIMENTAL|High CBD cannabis|Provided up to 1.8 g of cannabis per day of marijuana with more cannabidiol than tetrahydrocannabinol
62267525|NCT01566773|EXPERIMENTAL|PT001 MDI (Dose 2)|
62267526|NCT01566773|EXPERIMENTAL|PT001 MDI (Dose 3)|
62267527|NCT01566773|EXPERIMENTAL|PT001 MDI (Dose 4)|
62267528|NCT01566773|EXPERIMENTAL|PT001 MDI (Dose 5)|
62267529|NCT01566773|EXPERIMENTAL|PT001 MDI (Dose 6)|
62267530|NCT01566773|PLACEBO_COMPARATOR|PT001 Placebo MDI|
62267531|NCT01566773|ACTIVE_COMPARATOR|Spiriva® Handihaler® (Tiotropium Bromide)|
62267532|NCT04004650|NO_INTERVENTION|Primary closure|Primary perineal closure after extralevator abdomino perineal resection
62267533|NCT04004650|EXPERIMENTAL|Gluteal turnover flap|Gluteal flap reconstruction of the pelvic floor after extralevator abdomino perineal resection
62267534|NCT04687800|EXPERIMENTAL|Dextenza 0.4mg|Intracanalicular insert
62267535|NCT04687800|ACTIVE_COMPARATOR|Durezol 0.05%|difluprednate ophthalmic emulsion
62852372|NCT02576145|EXPERIMENTAL|Group A (With Daclizumab Therapy)|Participants who were receiving a full course of 5 doses of daclizumab (1 milligram per kilogram \[mg/kg\]) with Day 1 vaccine administered immediately prior to the fifth dose.
62852373|NCT02576145|ACTIVE_COMPARATOR|Group B (Post Daclizumab Therapy)|Participants who completed a full course of daclizumab therapy in the previous 4 to 18 months.
62852374|NCT06418139||Morning group|
62852375|NCT06418139||Afternoon group|
62852376|NCT03472170|EXPERIMENTAL|Experimental Arm|"The nutritional supplement used will be bovine lactoferrin, a product marketed according to the regulations of the European Union, and approved by the European Food Safety Agency (EFSA) in 2012, and by the American Agency for Food and Drug Administration ( FDA) in 2013. It will be acquired after purchase from Dicofarm® (Rome, Italy).~The Hospital Pharmacy Service will provide the established dose of lactoferrin, according to the administration schedule of 150 mg / kg / day (maximum 300 mg / day).~The treatments will be administered in liquid form, in the least amount possible. The administration of lactoferrin will be carried out enterally, orally or by nasogastric tube.~The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the NB with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before."
62626525|NCT06549192|ACTIVE_COMPARATOR|Group 2: Weightlifters|Before the assessment begins, the children will be asked whether they have consumed any beverages containing theine and caffeine, such as tea, coffee, cola and energy drinks, which can affect the heart, in the last two hours. If this is the case, the shooting will be postponed to the next day without consuming such beverages. Participants will first have their information recorded on the general evaluation form. Their resting heart rate variability, blood pressure, heart rate and respiratory function will then be measured. After these initial measurements at rest, the participants will be given a 20 meter shuttle run test. At the end of the test, the participant will be taken to the first assessment room for a second assessment. Here, ECG, blood pressure and heart rate, spirometer measurements will be repeated. All outcome measurements will be recorded on the evaluation form.
62626526|NCT06549192|ACTIVE_COMPARATOR|Group 3: Taekwondo players|Before the assessment begins, the children will be asked whether they have consumed any beverages containing theine and caffeine, such as tea, coffee, cola and energy drinks, which can affect the heart, in the last two hours. If this is the case, the shooting will be postponed to the next day without consuming such beverages. Participants will first have their information recorded on the general evaluation form. Their resting heart rate variability, blood pressure, heart rate and respiratory function will then be measured. After these initial measurements at rest, the participants will be given a 20 meter shuttle run test. At the end of the test, the participant will be taken to the first assessment room for a second assessment. Here, ECG, blood pressure and heart rate, spirometer measurements will be repeated. All outcome measurements will be recorded on the evaluation form.
62626527|NCT06549192|ACTIVE_COMPARATOR|Group 4: Swimmer|Before the assessment begins, the children will be asked whether they have consumed any beverages containing theine and caffeine, such as tea, coffee, cola and energy drinks, which can affect the heart, in the last two hours. If this is the case, the shooting will be postponed to the next day without consuming such beverages. Participants will first have their information recorded on the general evaluation form. Their resting heart rate variability, blood pressure, heart rate and respiratory function will then be measured. After these initial measurements at rest, the participants will be given a 20 meter shuttle run test. At the end of the test, the participant will be taken to the first assessment room for a second assessment. Here, ECG, blood pressure and heart rate, spirometer measurements will be repeated. All outcome measurements will be recorded on the evaluation form.
62626528|NCT06269146|ACTIVE_COMPARATOR|Pramipexole 1 mg/d|Each participant will take pramipexole in identical capsular form twice daily for 6 weeks.
62626529|NCT06269146|ACTIVE_COMPARATOR|Pramipexole 2.5 mg/d|Each participant will take pramipexole in identical capsular form twice daily for 6 weeks.
62626530|NCT06269146|PLACEBO_COMPARATOR|Placebo|Each participant will take placebo in identical capsular form twice daily for 6 weeks.
62626531|NCT02358265|ACTIVE_COMPARATOR|10 mg Rupatadine on demand|Rupatadine 10 mg, on demand
62626532|NCT02358265|ACTIVE_COMPARATOR|10 mg Rupatadin|Rupatadine 10 mg, continuously
62626533|NCT02358265|ACTIVE_COMPARATOR|20 mg Rupatadine|Rupatadine 20 mg, continuously
62626534|NCT02358265|ACTIVE_COMPARATOR|10 mg rupatadine on demand (sham upd.)|Rupatadine 10 mg, on demand (sham updosing to 20 mg)
62626535|NCT02329236||children with constitutional growth delay|
62626536|NCT02329236||children with Familial short stature|
62626537|NCT05305456|EXPERIMENTAL|Tanreqing capsule|3 capsules per time, 3 times a day，7 days of treatment
62626538|NCT05305456|PLACEBO_COMPARATOR|Tanreqing capsule simulator|3 capsules per time, 3 times a day，7 days of treatment
62626539|NCT01721447|EXPERIMENTAL|Echo arm|Subjects with atrial fibrillation who are undergoing a TEE procedure will be assessed using Optison echocardiography contrast agent
62626540|NCT04547686|EXPERIMENTAL|Smoke-Free Homes Intervention|Participants in the intervention condition will receive the expanded Smoke-Free Homes intervention coupled with a connection to the quitline. Follow-up will be at six and twelve months, including saliva cotinine validation for reported 7-day cessation.
62626541|NCT04547686|ACTIVE_COMPARATOR|Control|The usual care/control arm will receive mailed information on the quitline and a connection to the quitline at their request. Follow-up will be at six and twelve months, including saliva cotinine validation for reported 7-day cessation.
62626542|NCT06194162|EXPERIMENTAL|Weighted blanket|The intervention group will receive a weighted blanket classified as a medical device class 1 as an add on to usual treatment.
62626543|NCT06194162|SHAM_COMPARATOR|Non-weighted blanket|The control comparator group will receive a sham intervention in the form of a non-weighted blanket. as an add on to usual treatment.
62626544|NCT04062721|EXPERIMENTAL|Chemotherapy + RFA + in situ immunotherapy|Patients with non-resectable CRC liver-only metastases.
62626545|NCT00551395|EXPERIMENTAL|SLT Early Completion (Arm 1)|Intervention: 180 degrees of laser on Day 1, 180 degrees of laser on the other 180 degree on Day 2
62626546|NCT00551395|ACTIVE_COMPARATOR|SLT Late Completion (Arm 2)|Intervention: 180 degrees of laser on Day 1, 180 degrees of laser on the other 180 degrees at 1 month follow up appointment.
62626547|NCT04577794|EXPERIMENTAL|GLPG3970|Participants received 400 milligrams (mg) GLPG3970 oral solution, once daily (QD) for a period of 6 weeks.
62626548|NCT04577794|PLACEBO_COMPARATOR|Placebo|Participants received GLPG3970 matching placebo oral solution, QD for a period of 6 weeks.
62267536|NCT04087525|EXPERIMENTAL|Sequence 1|Period 1 : Fasted state + HIP1701, Period 2 : Fasted state + HGP1809
62267537|NCT04087525|EXPERIMENTAL|Sequence 2|Period 1 : Fasted state + HGP1809, Period 2 : Fasted state + HIP1701
62450810|NCT03943251|PLACEBO_COMPARATOR|placebo tablet|Including 7 dose groups(2.5-、5、10-、20-、40-、60-、80mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
62626549|NCT03486405|EXPERIMENTAL|Intervention group|The experimental group will have no in person education by researchers. All education and running modification will be performed via video. Education on running form, a home exercise program, and a 4 week return to run program will be provided to the subjects through e-mail. They will also receive the same in person video analysis performed at weeks 0 (initial), 10 and 6 months to assess running kinematics.
62626550|NCT03486405|ACTIVE_COMPARATOR|Control group|This group will have the same 4 week return to run program, home exercise program, and video analysis performed at weeks 0 (initial), 10 and 6 months to assess running kinematics.
62626551|NCT01808937||Morphea|Those having the condition morphea or other synonymous diagnosis (such as localized scleroderma, linear scleroderma, Parry-Romberg syndrome, en coup de sabre)
62852377|NCT03472170|PLACEBO_COMPARATOR|Control Arm|"Placebo with similar visual and taste characteristics to the nutritional supplement of bovine lactoferrin.~It will be administered in liquid form, in the least amount possible. The administration of placebo will be carried out enterally, orally or by nasogastric tube. The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the NB with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before."
62062856|NCT02759185|EXPERIMENTAL|THC/CBD cannabis|Provided up to 1.8 g of cannabis per day with an approximately equal amount of tetrahydrocannabinol and cannabidiol
62062857|NCT02759185|PLACEBO_COMPARATOR|Placebo cannabis|Provided 1.8 g of cannabis per day with very low levels of tetrahydrocannabinol and cannabidiol
62267538|NCT00414453|ACTIVE_COMPARATOR|Lidocaine 5% + placebo patch, ER and placebo pills|5% lidocaine patch used as intervention placebo patch used with extended release oxycodone or with placebo pills and placebo patches a randomized subjects given extended release oxycodone and placebo patches during this treatment placebo pills used with lidocaine 5% patch group and with placebo patch/placebo pill group period
62267539|NCT00837109|EXPERIMENTAL|1|Imagery Rescripting Nightmare Treatment
62450811|NCT05915052|ACTIVE_COMPARATOR|the B-type suture ileostomy group|the B-type suture ileostomy group underwent laparoscopic low anterior resection and a B-type suture ileostomy
62450812|NCT05915052|ACTIVE_COMPARATOR|the traditional ileostomy group|the traditional ileostomy group underwent laparoscopic low anterior resection and a traditional ileostomy
62450813|NCT05755425||CPAP|When a patient needs FiO2 \>50% to keep SpO2 \>93%, or SpO2 \>95% in case of persistent respiratory distress defined as RR\>35/min, full face CPAP will be applied
62450814|NCT05755425||HFNO|When a patient needs FiO2 \>50% to keep SpO2 \>93%, or SpO2 \>95% in case of persistent respiratory distress defined as RR\>35/min, HFNO will be applied
62450815|NCT04164953|EXPERIMENTAL|Dupuytren's|Surgical intervention as second-line surgery for the treatment of Dupuytren's disease.
62450816|NCT04554654||frozen embryo transfer cycles|patients undergoing frozen embryo transfer with artificial hormone replacement
62450817|NCT01941420||1 Blood cardioplegia|Blood cardioplegia
62450818|NCT01941420||2 Crytalloid Cardioplegia|Crytalloid Cardioplegia
62450819|NCT04464044|EXPERIMENTAL|DDT2 Toric|Verofilcon A toric contact lenses worn in both eyes
62626552|NCT00090870|EXPERIMENTAL|PEG-Intron, BM-CSF and thalidomide|
62626553|NCT04682379||Scoliotic patients with proprioceptive deficits|Study subjects possessed statistically significant differences in testing outcomes of proprioception compared with healthy controls.
62626554|NCT04682379||Scoliotic patients without proprioceptive deficits|Study subjects with similar testing results of proprioception compared with healthy controls.
62450820|NCT00531206||All participants|
62450821|NCT01346852||Pediatric participants|Pediatric participants (age 4 to 17) with a diagnosis of asthma
62626555|NCT06231134|ACTIVE_COMPARATOR|Conventional surgery|
62062858|NCT01059032|NO_INTERVENTION|Unenhanced images|
62626556|NCT06231134|EXPERIMENTAL|Dioad laser|
62626557|NCT06231134|EXPERIMENTAL|Electrosuregry|
62626558|NCT00321906|ACTIVE_COMPARATOR|Azathioprine|(tacrolimus,azathioprine/prednisone)
62626559|NCT00321906|ACTIVE_COMPARATOR|Sirolimus|tacrolimus/sirolimus/prednisone
62626560|NCT01017562||condition of joint implant|
62267540|NCT00837109|ACTIVE_COMPARATOR|2|Treatment-as-usual in the Trauma Recovery Program
62450822|NCT01346852||Adult participants|Adult participants (age 18 and older) with a diagnosis of asthma
62450823|NCT06233253|ACTIVE_COMPARATOR|Group I (usual care)|Patients receive usual care prior to their scheduled screening colonoscopy.
62450824|NCT06233253|EXPERIMENTAL|Group II (online mindfulness intervention)|Patients receive an online mindfulness intervention including infographics and 5-minute meditations QD for 5 days prior to their scheduled screening colonoscopy.
62450825|NCT06312683|EXPERIMENTAL|All Participants|550 mg Rifaximin (Xifaxan) twice a day x 365 days
62062859|NCT01059032|OTHER|Enhanced images|Enhanced images
62062860|NCT02480816|EXPERIMENTAL|Bicarbonated mineral water (BW)|Bicarbonated mineral water
62450826|NCT01241981||Digital Breast Tomosynthesis|Digital Breast Tomosynthesis
62626561|NCT04301726|EXPERIMENTAL|Deutetrabenazine|The participants randomized to this group will receive oral deutetrabenazine for 8 weeks. Week 1: 6 mg once daily; Week 2: 6 mg twice daily (BID); Week 3: 9 mg BID; Week 4: 12 BID; Week 5: 15 mg BID; Week 6: 18 mg BID; Week 7: 21 mg BID; Week 8: 24 mg BID.
62062861|NCT02480816|ACTIVE_COMPARATOR|Control mineral water (CW)|Mineral water low in mineral content (control)
62626562|NCT04301726|PLACEBO_COMPARATOR|Placebo|The participants randomized to this group will receive oral placebo for 8 weeks. Week 1: 6 mg once daily; Week 2: 6 mg twice daily (BID); Week 3: 9 mg BID; Week 4: 12 BID; Week 5: 15 mg BID; Week 6: 18 mg BID; Week 7: 21 mg BID; Week 8: 24 mg BID.
62626563|NCT02049983|EXPERIMENTAL|Use of Levita Magnetics Grasper|
62626564|NCT04633993|EXPERIMENTAL|PCSMP|Patient-centered self-management program for patients with hypertensive nephropathy into 4 units, including: Unit 1: hypertensive nephropathy brief introduction and complications. Unit 2: dietary precautions for patients with hypertensive nephropathy. Unit 3: medication treatments for patients with hypertensive nephropathy. Unit 4: the content included stress management (emotional control, spiritual support). This program was implemented in small groups with 5-10 patients. This study used patient-centered self-management group activity manual as the tool. The group activities with 4 units lasting for 400 minutes were expected to be designed. The group activities were expected to last for 4 weeks and be implemented once per week and 100 minutes per time (including: 90 minutes of group discussion and 5-10 minutes of video-waring).
62626565|NCT04633993|NO_INTERVENTION|Usual Care|Routine care.
62626566|NCT05132647||Cerebellar ataxia and Healthy adults|We will not administer any intervention to the patients in this study
62626567|NCT01075919|ACTIVE_COMPARATOR|DHA-rich fish oil|1 g DHA-rich fish oil containing 450 mg DHA + 90 mg EPA
62626568|NCT01075919|ACTIVE_COMPARATOR|EPA-rich fish oil|1 g EPA-rich fish oil containing 300 mg EPA + 200 mg DHA
62626569|NCT01075919|PLACEBO_COMPARATOR|Placebo|1 g Olive oil
62626570|NCT05858866||Smartphone-addicted group|university sdudents
62626571|NCT05858866||non-smartphone-addicted group|university sdudents
62626572|NCT03026829|EXPERIMENTAL|CART sound therapy|
62062862|NCT05302557|EXPERIMENTAL|Interventional|"During the two weeks prior to the ileostomy closure procedure, daily stimulation of the efferent loop will be performed by irrigation with 500 ml of physiological saline or 500 ml of warm water, preferably bottled, associated with a nutritional thickener. The patient will be instructed by a stomatotherapy nurse. Stimulation will be performed up to the day before the intervention. Kegel exercises will be suggested.~Every surgeon will use his or her usual technique for all patients included in the study, regardless of the group assigned in the randomization.~All patients in both groups will receive the same antibiotic and antithrombotic prophylaxis. No antibiotic administration is expected during the postoperative period, following a Zero Surgical Infection (ZSI) protocol."
62062863|NCT05302557|NO_INTERVENTION|Control|"Direct standard surgery. Every surgeon will use his or her usual technique for all patients included in the study, regardless of the group assigned in the randomization.~All patients in both groups will receive the same antibiotic and antithrombotic prophylaxis. No antibiotic administration is expected during the postoperative period, following a Zero Surgical Infection (ZSI) protocol."
62062864|NCT00949884|EXPERIMENTAL|Olmesartan|Olmesartan 20 mg once daily for four weeks followed by 40mg one daily for four weeks.
62062865|NCT00949884|PLACEBO_COMPARATOR|Placebo followed by Olmesartan|Placebo capsule of olmesartan once daily for 2 weeks, followed by olmesartan 20 mg once daily for two weeks, followed by olmesartan 40 mg for 4 weeks
62626573|NCT01877668|EXPERIMENTAL|Tofacitinib 5 mgBID x 12 months|
62626574|NCT01877668|EXPERIMENTAL|Tofacitinib 10 mg BID x 12 months|
62626575|NCT01877668|ACTIVE_COMPARATOR|Adalimumab 40 mg q2 weeks x 12 months|
62626576|NCT01877668|PLACEBO_COMPARATOR|Placebo x3 months, then tofacitinib 5 mg BIDx 9 months|
62062866|NCT00949884|ACTIVE_COMPARATOR|Losartan|Losartan 50 mg once daily for four weeks, followed by losartan 100 mg once daily for four weeks
62062867|NCT03221101|NO_INTERVENTION|Long Term Oxygen Therapy alone|Long Term oxygen therapy is prescribed according to the guidelines
62062868|NCT03221101|ACTIVE_COMPARATOR|Non invasive ventilation|"Home non invasive ventilation is prescribed with the following settings~* PS mode~* IPAP according to clinical and hemodynamic tolerance~* EPAP according to air trapping~* RR around 12/ min.~* LOT for SaO2 \> 90%~* Monitoring with capnometry for settings validation"
62062869|NCT03992534|EXPERIMENTAL|LACTIN-V|"Name of Product: LACTIN-V (Lactobacillus crispatus CTV-05)~Dosage: LACTINV is a powder formulation of Lactobacillus crispatus CTV-05 provided in a prefilled vaginal applicator at a dose of 2 x 10\^9 CFU of L. crispatus CTV-05. Route of Administration: LACTIN-V powder is administered vaginally using a specially designed applicator.~Formulation: LACTIN-V is supplied as a pre-filled, single-use applicator. Each applicator contains LACTIN-V powder at a dose of 2 x 10\^9 CFU. The LACTIN-V powder formulation contains L. crispatus CTV-05 and a preservation matrix containing inactive excipients of non-animal origin."
62062870|NCT04705064||AI_AKI|Adults patients undergoing non-cardiac surgery
62626577|NCT01877668|PLACEBO_COMPARATOR|Placebo x 3 months, then tofacitinib 10 mg BID x 9 months|
62626578|NCT00587795|ACTIVE_COMPARATOR|StabilAir Wrist Brace|One study group will consist of patients treated with the StabilAir Wrist Brace.
62626579|NCT00587795|PLACEBO_COMPARATOR|Control|Study arm will consist of patients that are treated with placement of sugar tong splint or plaster cast.
62626580|NCT03339713|EXPERIMENTAL|Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1|Participants will receive intramuscular injection of 1\*10\^11 viral particles (vp) of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on 1 arm administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on the other arm at Day 1, and intramuscular injection of placebo on Day 29.
62626581|NCT03339713|EXPERIMENTAL|Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2|Participants will receive intramuscular injection of placebo administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on Day 1, and 1\*10\^11 vp of Ad26.RSV.preF on Day 29.
62626582|NCT00346762||1|HIV infected former commercial blood donors (FBDs) in Fuyang, Anhui Province
62626583|NCT00886366|EXPERIMENTAL|1|AZD6714 in 8 increasing oral single doses a-h given to 8 groups (3 on active and 1 on placebo in each group)
62626584|NCT00886366|EXPERIMENTAL|2|2 oral single doses d and g suspensions of AZD6714 given to 2 groups (3+1) together with food
62852378|NCT06231771|EXPERIMENTAL|Allogeneic mesenchymal stem cells (MSCs)|Peri-ulcer injection of Umbilical cord MSC (1.0 million cells/cm2 of the ulcer) will be administered at multiple sites (maximum of 30 sites) with intervals of 3 cm x 3 cm around the ulcer with total volume of 0.1 to 0.2 ml per injection. Whatever IMP is drawn into the syringe for administration to the wound must be completely dispensed and nothing should be left in the syringe. Number of injections and volume of each injection can be as per Investigator's discretion. The same to be recorded in the source notes and CRF.The injection will be done approximately using a 24G needle and 1 ml/3ml syringe approximately within 0.75 cm from the edge of the ulcer. The needle should enter the base of the ulcer from the edge. After injection, patients must be in a lying down position for at least one hour in daycare center at the site and monitoring of oxygen saturation will be done up to 2 hours ± 10 minutes after the administration of the product.
62062871|NCT03780374|ACTIVE_COMPARATOR|Sound Processing Principle 1|Sound Processing Principle 1 will be applied in the hearing aid.
62852379|NCT06231771|PLACEBO_COMPARATOR|Normal Saline|The blinded placebo group will be injected with normal saline (NSand the volume to be injected is similar to the area of ulcer (2 mL of normal saline per 1 cm2 of ulcer). each injection will be o.1 to 0.2 ml normal saline (maximum injection will be 30 injection peri ulcer)
62062872|NCT03780374|EXPERIMENTAL|Sound Processing Principle 2|Sound Processing Principle 2 will be applied in the hearing aid.
62062873|NCT03780374|EXPERIMENTAL|Sound Processing Principle 3|Sound Processing Principle 3 will be applied in the hearing aid.
62062874|NCT03970993|EXPERIMENTAL|Group 1a|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M 4 weeks apart and an optional booster vaccination 12 months after the third dose
62062875|NCT03970993|EXPERIMENTAL|Group 2a|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M at 0, 4 and 24 weeks, followed by CHMI by sporozoite challenge (mosquito bite) 4 weeks later. If protected from malaria, volunteers will receive an optional booster vaccination 28 days prior to malaria rechallenge
62450827|NCT01816477|ACTIVE_COMPARATOR|Thoracic epidural|Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
62450828|NCT01816477|EXPERIMENTAL|ON-Q soaker catheter system|"ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly."
62626585|NCT00886366|EXPERIMENTAL|3|Two increasing oral doses of AZD6714 and one placebo given to 2 groups with 3 type 2 diabetic patients.
62626586|NCT04110886|EXPERIMENTAL|HSK21542 single ascending doses|
62626587|NCT04110886|PLACEBO_COMPARATOR|Placebo single dose|
62626588|NCT03130959|EXPERIMENTAL|Module A|
62626589|NCT03130959|EXPERIMENTAL|Module B|
62626590|NCT00705341|ACTIVE_COMPARATOR|Low dose fluticasone for phase 2|For people with asthma, fluticasone at 250 mcg per day; phase 2 of study
62626591|NCT00705341|ACTIVE_COMPARATOR|High dose fluticasone for phase 2|For people with asthma, fluticasone at 1000 mcg per day; phase 2 of study
62626592|NCT00705341|NO_INTERVENTION|Nonasthmatic controls for phase 1|People without asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study
62626593|NCT00705341|NO_INTERVENTION|Asthmatic controls for phase 1|People with asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study
62626594|NCT05240807|EXPERIMENTAL|Clinical Coronary CTA Cohort|Subjects scheduled for a clinically indicated coronary CTA will receive a research contrast-enhanced coronary CT angiogram using photon-counting CT
62852380|NCT03300102||Patients with suspected or confirmed renal cell carcinoma|Patients with suspected or confirmed renal cell carcinoma who have consented will either donate tissue, or complete a structured questionnaire or a semi-structured interview. Not all patients will have all three interventions, each patient must have at least one.
62852381|NCT05003297||patients whom were hospitalized for 3 days or less|
62852382|NCT05003297||patients hospitalized for more than 3 days|
62852383|NCT06332872|EXPERIMENTAL|Oral ivermectin|For the treatment of head lice infestation, participants are receiving two single doses of oral ivermectin on days 0 and 7 of the experiment. (spaced 7 days apart)
62852384|NCT06332872|EXPERIMENTAL|Dimeticone liquid gel|For the treatment of head lice infestation, participants are receiving one application of 4% dimenticone liquid gel on day 0 of the experiment.
62626595|NCT05240807|EXPERIMENTAL|Clinical Nuclear Medicine or MRI Cardiac Stress Test Cohort|Subjects scheduled for a clinically indicated nuclear medicine or MRI cardiac stress test will receive a research contrast-enhanced coronary CT angiogram using photon-counting CT at rest and after administration of a cardiac stress agent
62626596|NCT01357395|EXPERIMENTAL|Amuvatinib|Amuvatinib 300 mg PO TID + standard-of-care platinum-etoposide
62626597|NCT01960465|EXPERIMENTAL|African Americans|138 Self identified African American
62062876|NCT03970993|EXPERIMENTAL|Group 3a|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M 4 weeks apart, followed by CHMI by sporozoite challenge (mosquito bite) 4 weeks later. If protected from malaria, volunteers will receive an optional booster vaccination 28 days prior to malaria rechallenge
62626598|NCT01960465|ACTIVE_COMPARATOR|non African Americans|53 Caucasians and 29 Other race (non African-Americans) Veterans.
62626599|NCT04676152|EXPERIMENTAL|Test subjects|All subjects enrolled had blood pressure measurements taken using the noninvasive blood pressure device.
62626600|NCT02798107||All patients treated with idarucizumab|
62626601|NCT03378245|EXPERIMENTAL|Telemedicine Intervention|Multidisciplinary telemedicine education of staff and providers on best practices for behavioral modification as well as education on best practices for pharmacologic therapies.
62626602|NCT06610643|EXPERIMENTAL|combination therapy|combination of 5-day remdesivir and 10-day Nirmatrelvir/Ritonavir
62626603|NCT06610643|ACTIVE_COMPARATOR|SOC|standard of care
62626604|NCT00593918||Toll-like Receptor 4 -2026/GG Genotype|Toll-like Receptor 4 (TLR4) -2026/GG Genotype of interest hypothesized to be associated with less inflammation during Respiratory Syncytial virus (RSV) infection
62626605|NCT00593918||Toll-like Receptor 4 -2026/AG and AA Genotypes|Toll-like Receptor 4 (TLR4) -2026/AG and AA control genotypes hypothesized to be associated with more inflammation during respiratory syncytial virus (RSV) infection
62626606|NCT03305692|EXPERIMENTAL|ECG Belt|Use ECG Belt body surface mapping system to optimize CRT programming.
62626607|NCT03305692|EXPERIMENTAL|Echocardiography|Use mitral inflow echocardiography to optimize CRT programming.
62626608|NCT04540328|OTHER|Non-surgical peridontal treatment|Patients with chronic periodontitis received non-surgical periodontal treatment, including scaling and root planing and polishing within 14 days under local anesthesia with manual and ultrasonic devices and standardized oral hygiene instructions including methods of tooth-brushing and interdental cleaning were also given to each one. A professional supragingival plaque control was applied on a regular basis every month.
62626609|NCT04663243|EXPERIMENTAL|Quasi experimental study|Before intervention and after intervention comparison
62626610|NCT01223937|EXPERIMENTAL|Desmopressin 25 μg|Participants took 1 orally disintegrating tablet of desmopressin 25 μg every night approximately 1 hour before bedtime for the entire duration of the 3-month treatment period.
62626611|NCT01223937|PLACEBO_COMPARATOR|Placebo|Participants took 1 orally disintegrating tablet of placebo every night approximately 1 hour before bedtime for the entire duration of the 3-month treatment period.
62852385|NCT06332872|NO_INTERVENTION|Permethrin shampoo|Participants are receiving two applications of 1% permethrin shampoo, which is the current drug of choice for Pediculosis capitis, on days 0 and 7. This group is defined as a control group.
62852386|NCT00643084|EXPERIMENTAL|1|patients will consume a low residue diet prior to surgery and have no routine bowel preparation
62852387|NCT00643084|OTHER|2|standard bowel preparation
62062877|NCT03970993|EXPERIMENTAL|Group 4a|Volunteers will receive 2 doses of 50μg R21/50μg Matrix-M 4 weeks apart and a 3rd fractional dose of 10μg R21/50μg Matrix-M at 24 weeks. This is followed by optional CHMI by sporozoite challenge (mosquito bite) 4 weeks later
62626612|NCT02360423|EXPERIMENTAL|CRE8 group|CRE8 sirolimus-eluting stent system
62626613|NCT02360423|ACTIVE_COMPARATOR|RESOLUTE group|RESOLUTE zotarolimus-eluting stent system
62626614|NCT04824937|EXPERIMENTAL|Telaglenastat + Talazoparib|"During 28 day study cycles, participants will receive:~* Telaglenastat 2x daily at a predetermined dose~* Talazoparib 1x daily at a predetermined dose"
62062878|NCT03970993|EXPERIMENTAL|Group 5|Volunteers will receive 2 doses of 10μg R21/50μg Matrix-M 4 weeks apart and a 3rd fractional dose of 2μg R21/50μg Matrix-M at 24 weeks. This is followed by optional CHMI by sporozoite challenge (mosquito bite) 4 weeks later
62626615|NCT04824937|EXPERIMENTAL|Telaglenastat + Talazoparib Staggered|If a beneficial response is seen with the Arm 1 Telaglenastat + Talazoparib combination, participants will receive telaglenastat alone 2x daily at a predetermined dose with the addition of talazoparib at 1x daily at a predetermined dose if the disease gets worse.
62626616|NCT00811980||Heathy Subjects|
62626617|NCT01666912|ACTIVE_COMPARATOR|6 week postpartum contraceptive implant|randomized to receive contraceptive implant at normal 6 week postpartum visit
62626618|NCT01666912|EXPERIMENTAL|Immediate postpartum contraceptive implant|randomized to receive contraceptive implant prior to leaving the hospital postpartum
62626619|NCT01620541||Preference, Ankle Arthrodesis|
62626620|NCT01620541||Preference, Ankle Arthroplasty|
62626621|NCT00624689|EXPERIMENTAL|1|Modified formula
62626622|NCT00624689|NO_INTERVENTION|2|Standard formula
62626623|NCT00624689|NO_INTERVENTION|3|Breastfed
62852388|NCT03826368||TBI Controls|Adult men and women between 18 and 55. No prior history of traumatic brain injury. Experienced taking hemp-derived botanicals.
62852389|NCT03826368||TBI HDS|Adult men and women between 18 and 55. History of traumatic brain injury. Experienced taking hemp-derived botanicals.
62626624|NCT05251116|OTHER|only one Arm is included in this study|This is a non-randomized, single arm study. All subjects will use the System. Results from the System will be compared to reference instrument.
62626625|NCT03326297|EXPERIMENTAL|Osteopathy manual therapy|Osteopathy manual therapy applying the following treatment: Technique for the treatment of parasympathetic innervation, Techniques for the treatment of sympathetic innervation of the digestive system, Functional visceral techniques.
62852390|NCT01873612|EXPERIMENTAL|Sedation with dexmedetomidine|Sedation with dexmedetomidine
62852391|NCT01873612|EXPERIMENTAL|Sedation with propofol|Sedation with propofol
62852392|NCT05437302|EXPERIMENTAL|interventional|prism spectacles prescribed
62852393|NCT05437302|ACTIVE_COMPARATOR|non interventional|presbyopia glasses prescribed
62852394|NCT03859947||Patients with acute bronchiolitis|
62852395|NCT03704636|EXPERIMENTAL|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00028 sensor.
62267541|NCT00401375|EXPERIMENTAL|MNTX 12 mg|Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) as an intravenous (IV) infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
62267542|NCT00401375|EXPERIMENTAL|MNTX 24 mg|Participants will receive MNTX 24 mg as an IV infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
62267543|NCT00401375|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to MNTX as an IV infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
62267544|NCT01806363|ACTIVE_COMPARATOR|Part A: Telmisartan, Chlorthalidone + Telmisartan|telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally
62267545|NCT01806363|ACTIVE_COMPARATOR|Part B: Chlorthalidone, Chlorthalidone + Telmisartan|telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally
62267546|NCT00762892|ACTIVE_COMPARATOR|Raltegravir|Raltegravir in combination with truvada (tenofovir and emtricitabine)
62267547|NCT00762892|ACTIVE_COMPARATOR|Atazanavir|Atazanavir, low dose ritonavir, and truvada (tenofovir and emtricitabine)
62450829|NCT02347670|ACTIVE_COMPARATOR|Group 1M- Community Site|"Participants randomized to Group 1-Main will attend follow-up visits at one of the four main community sites. A glaucoma specialist will perform the comprehensive eye examination and a ophthalmic technician will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.~Intervention: Efficacy-patient navigator to improve follow-up adherence"
62450830|NCT02347670|ACTIVE_COMPARATOR|Group 2- Office-Based|"Office-Based, Follow-Up Eye Care with Patient Navigation Protocol: Participants randomized to Group 2 will attend follow-up visits at the Wills Eye Hospital Glaucoma Research Center. A glaucoma specialist will perform the eye examination. Ophthalmic technicians will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.~Intervention: Efficacy-patient navigator to improve follow-up adherence"
62450831|NCT02347670|ACTIVE_COMPARATOR|Group 3- Office-Based|"Group 3- follow-up eye care at the Wills Eye Hospital. There will be no charge or co-pay for these visits. Those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire. These participants will receive a phone number to call and schedule their appointment and will receive a reminder phone call similar to the standard appointment-reminding procedure commonly used at the Wills Eye Hospital. Group 3 represents a realistic choice currently available for patients and thus will be used to compare with usual care and will have 2-3 visits over the one-year period depending on diagnosis.~Intervention: Office-Based Usual Care"
62450832|NCT02347670|ACTIVE_COMPARATOR|Group 1R- Community Site|"Participants randomized to Group 1-Randomized will attend follow-up visits at one of the four main community sites, these participants were randomized from the 40 community sites to the closest community location. A glaucoma specialist will perform the comprehensive eye examination. Ophthalmic technicians will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.~Intervention: Efficacy-patient navigator to improve follow-up adherence"
62062879|NCT03970993|NO_INTERVENTION|Group 6|They are infectivity control volunteers for the sporozoite challenge procedures: these volunteers are not vaccinated.
62450833|NCT00655642|ACTIVE_COMPARATOR|Ondansetron|Ondansetron 4 mg intravenous administration
62450834|NCT00655642|ACTIVE_COMPARATOR|Metoclopramide|Metoclopramide 10 mg intravenous administration
62450835|NCT00655642|ACTIVE_COMPARATOR|Promethazine|Promethazine 10 mg intravenous administration
62267548|NCT04473378||FreeStyle Libre sensor cohort|Patients with early stage breast cancer will have their blood glucose levels monitored by the Freestyle libre pro sensor.
62450836|NCT00655642|PLACEBO_COMPARATOR|Saline Placebo|Volume-matched saline placebo
62450837|NCT02309749||Naive cohort|
62450838|NCT02799602|EXPERIMENTAL|BAY1841788 /darolutamide (ODM-201)+standard ADT+Docetaxel|Co-administration of BAY 1841788 / darolutamide (ODM-201), standard ADT and docetaxel
62450839|NCT02799602|PLACEBO_COMPARATOR|Placebo + standard ADT + Docetaxel|Co-administration of Placebo matching BAY 1841788 / darolutamide (ODM-201) tablets, standard ADT and docetaxel
62450840|NCT00670956|ACTIVE_COMPARATOR|Active Study Group|STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart
62450841|NCT00670956|PLACEBO_COMPARATOR|Placebo Group|PLACEBO: IM x 2 doses 24 hours apart
62267549|NCT00945776|ACTIVE_COMPARATOR|Weekly phone calls|Will be called weekly to answer questions regarding usage.
62267550|NCT00945776|ACTIVE_COMPARATOR|Frequently asked questions|Providing written general answers to commonly asked questions.
62062880|NCT03970993|NO_INTERVENTION|Group 7|They are infectivity control volunteers for the sporozoite challenge procedures: these volunteers are not vaccinated.
62062881|NCT03970993|EXPERIMENTAL|Group 1b|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M, 4 weeks apart followed by an optional vaccination booster 12 months after the third dose.
62267551|NCT00945776|ACTIVE_COMPARATOR|Usual care|
62626626|NCT03326297|ACTIVE_COMPARATOR|Measures to support and education to the family|Measures to support and education to the family that consist on pedagogical intervention in parents, health education.
62626627|NCT03326297|NO_INTERVENTION|No specific intervention|No specific intervention, prescriptions by pediatrician
62626628|NCT00549549|ACTIVE_COMPARATOR|1|
62626629|NCT00549549|EXPERIMENTAL|2|
62626630|NCT00549549|EXPERIMENTAL|3|
62626631|NCT00549549|EXPERIMENTAL|4|
62626632|NCT03999359|NO_INTERVENTION|Control|"Participants allocated to the control group will receive treatment as usual for cardiac rehabilitation"
62626633|NCT03999359|ACTIVE_COMPARATOR|Intervention|"Participants allocated to the intervention group will receive treatment as usual for cardiac rehabilitation plus the home-based metacognitive therapy (Home-MCT)"
62626634|NCT03989336|EXPERIMENTAL|Manganese primed Sintilimab plus nPP chemotherapy|Subject received Manganese primed Sintilimab, nab-paclitaxel and platinum chemotherapy every 3 weeks until achieving a second assessable complete response or progressive disease, development of unacceptable toxicity, or withdrawal of consent.
62626635|NCT03989336|ACTIVE_COMPARATOR|Sintilimab plus nPP chemotherapy|Subject received Sintilimab, nab-paclitaxel and platinum chemotherapy every 3 weeks until achieving a second assessable complete response or progressive disease, development of unacceptable toxicity, or withdrawal of consent.
62626636|NCT01871077|EXPERIMENTAL|PRO-156|Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
62626637|NCT06224218|ACTIVE_COMPARATOR|Single Port Robotic Prostatectomy|Removal of the prostate using single port robot
62062882|NCT03970993|EXPERIMENTAL|Group 2b|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M at 0, 4 and 24 weeks.
62626638|NCT06224218|ACTIVE_COMPARATOR|Laser Enucleation of the Prostate|Enucleation of the prostate with laser surgery
62626639|NCT00546169||A|
62626640|NCT02641275|EXPERIMENTAL|Intervention|Structured self-management-training (incl. systemic analysis, coaching, teaching) in 4 sessions.
62626641|NCT02641275|NO_INTERVENTION|Control group|no intervention other than existing support (see exclusion criteria). However, intervention will be offered and studied secondary as well (after 1 1/2 year of no intervention).
62626642|NCT01932749|ACTIVE_COMPARATOR|bilateral repetitive transcranial magnetic stimulation|"Bilateral protocol:~Motor threshold 100% /LDLPFC/10Hz/5 second duration/10 second intertrain/ Motor threshold 120% /RDLPFC/1Hz/10 second duration/2second intertrain/"
62626643|NCT01932749|ACTIVE_COMPARATOR|unilateral repetitive transcranial magnetic stimulation|"Unilateral protocol:~Motor threshold 120% /RDLPFC/1Hz/10 second duration/2second intertrain"
62626644|NCT00826098|EXPERIMENTAL|1 (PRP)|Total knee replacement with PRP
62626645|NCT00826098|NO_INTERVENTION|2 (non-PRP)|Total knee replacement without PRP
62626646|NCT04408664|EXPERIMENTAL|Sodium Cromoglycate|Patients will take Sodium Cromoglycate (SCG) (Lomudal®) 4 times daily during 6 months: SCG 4X1 ampulla of 2 mL daily (by Omron pocket aerosol).
62626647|NCT04408664|PLACEBO_COMPARATOR|Sodium Chloride 0.9%|Patients will take Sodium Chloride 0.9% 4 times daily during 6 months: Sodium Chloride 4X1 ampulla of 2 mL daily (by Omron pocket aerosol).
62626648|NCT00594230|EXPERIMENTAL|Panobinostat 20 mg|Treatment with LBH589 (Panobinostat) 20 mg
62062883|NCT03970993|EXPERIMENTAL|Group 3b|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M 4 weeks apart.
62062884|NCT03970993|EXPERIMENTAL|Group 4b|Volunteers will receive 2 doses of 50μg R21/50μg Matrix-M 4 weeks apart and a 3rd fractional dose of 10μg R21/50μg Matrix-M at 24 weeks.
62062885|NCT04052191|EXPERIMENTAL|Low Dose|Low Dose of MCRcI® stem cells.
62626649|NCT00594230|EXPERIMENTAL|Panobinostat 30 mg|Treatment with LBH589 (Panobinostat) 30 mg
62626650|NCT05136079|EXPERIMENTAL|Prophylactic lymphaticovenous anastomosis|Intervention participants will undergo prophylactic lymphaticovenous anastomosis as an addendum to axillary or ilioinguinal lymphadenectomy for treatment of cutaneous malignancy.
62626651|NCT05136079|NO_INTERVENTION|Lymphadenectomy without lymphaticovenous anastomosis|Control participants will undergo axillary or ilioinguinal lymphadenectomy without lymphaticovenous anastomosis for treatment of cutaneous malignancy .
62626652|NCT05441553|EXPERIMENTAL|VGB-R04|Single intravenous (i.v.) infusion of VGB-R04 Intervention: Gene Therapy / Gene Transfer
62062886|NCT04052191|EXPERIMENTAL|Intermediate Dose|Intermediate Dose of MCRcI® stem cells.
62062887|NCT04052191|EXPERIMENTAL|High Dose|High Dose of MCRcI® stem cells.
62062888|NCT04802096|EXPERIMENTAL|Inspiratory muscle training combined pulmonary rehabilitation|
62626653|NCT05448742|EXPERIMENTAL|Main arm of the study|Six cadaveric lower limbs will have biplanar PSI slope-reducing MOWHTO performed on and accuracy of biplanar correction will be assessed.
62626654|NCT04577417||ADHD|Adolescents, male or female, ages 13-19, diagnosed with ADHD, all subtypes, based on the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and under treatment with a stimulant medication with the same drug and dosage for at least 12 months before their study participation date
62062889|NCT04802096|SHAM_COMPARATOR|Sham inspiratory muscle training combined pulmonary rehabilitation|
62626655|NCT04577417||Control|Adolescents, male or female, ages 13-19, with normal health status and development
62626656|NCT06302049|EXPERIMENTAL|esomeprazole group|patients in this arm will receive esomeprazole 20 mg once daily
62626657|NCT06302049|PLACEBO_COMPARATOR|Placebo group|patients in this arm will receive placebo once daily
62626658|NCT00289224|EXPERIMENTAL|1|Cholera Vaccine
62626659|NCT00289224|PLACEBO_COMPARATOR|2|Placebo
62626660|NCT02256917|EXPERIMENTAL|Human-cl rhFVIII|
62062890|NCT04236921|EXPERIMENTAL|Treatment A|1 x DopaSnap® tablet, administered under fasting conditions.
62062891|NCT04236921|ACTIVE_COMPARATOR|Treatment B|1 x RLD of CD-LD tablet administered under fasting conditions.
62267552|NCT04066972|EXPERIMENTAL|Single arm|
62626661|NCT02285075|OTHER|temocillin PK/PD in haemodialysis|Pharmacokinetic study measuring total and free temocillin concentrations in patients treated with haemodialysis receiving 1 gram temocillin for a 1 day interval, 2 gram temocillin for a two day interval and 3 gram temocillin for a 3 day interval to the next dialysis session
62626662|NCT01533961|EXPERIMENTAL|SCYX-7158|In each dose group (8 subjects) , 6 Healthy Volunteers receive SCYX-7158
62626663|NCT01533961|PLACEBO_COMPARATOR|Placebo of SCYX-7158|In each dose group (8 subjects) , 2 Healthy Volunteers receive placebo of SCYX-7158
62062892|NCT04236921|EXPERIMENTAL|Treatment C|Test - fed 1 x DopaSnap® tablet , administered under fed conditions.
62267553|NCT06192901||Study eye AT ELANA 841P|Subjects who underwent bilateral cataract surgery with the implantation of the IOL AT ELANA 841P in the first eye.
62267554|NCT06192901||Study eye AT LISA 839MP|Subjects who underwent bilateral cataract surgery with the implantation of the IOL AT LISA tri 839MP in the second eye.
62267555|NCT03981237|EXPERIMENTAL|Root canal treatment with laser-activated irrigation|In these patients, the root canals of the tooth are chemomechanically prepared. After shaping, irrigant activation is performed by means of a pulsed erbium laser. The canals are then dried and obturated.
62267556|NCT03981237|ACTIVE_COMPARATOR|Root canal treatment with ultrasonically activated irrigation|In these patients, the root canals of the tooth are chemomechanically prepared. After shaping, irrigant activation is performed by means of an ultrasonically driven instrument. The canals are then dried and obturated.
62267557|NCT02062788|EXPERIMENTAL|ORS group|Oral rehydration solution (ORS) treated group
62267558|NCT02062788|NO_INTERVENTION|Non-ORS group|Oral rehydration solution (ORS) untreated group
62626664|NCT01726465|EXPERIMENTAL|N-acetylcysteine|Patients were randomized to this arm will receive a bolus of N-acetylcysteine in an hour of 150 mg/kg after the beginning of the operation. After the bolus will start a 6-hour infusion of 50mg/kg/h of N-acetylcysteine.
62626665|NCT01726465|EXPERIMENTAL|Methylprednisolone|Patients were randomized to this arm will receive a bolus of methylprednisolone in an hour of 500 mg after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).
62626666|NCT01726465|PLACEBO_COMPARATOR|Placebo|Patients were randomized to this arm will receive placebo (Ringer's acetate) in an hour after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).
62626667|NCT06014996|EXPERIMENTAL|Pulsed Field Ablation|PVI using the PFA system (Insight Medtech).
62626668|NCT06014996|ACTIVE_COMPARATOR|Radiofrequency Ablation|PVI using the RFA system ((Biosense Webster).
62626669|NCT01763827|PLACEBO_COMPARATOR|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.
62626670|NCT01763827|PLACEBO_COMPARATOR|Placebo QM|Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.
62626671|NCT01763827|ACTIVE_COMPARATOR|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
62267559|NCT02877173|EXPERIMENTAL|Alprostadil Liposomes for Injection|Alprostadil Liposomes for Injection at low dose:20ug,once a day,continuous administration for 3 weeks; Alprostadil Liposomes for Injection at medium dose:40ug,once a day,continuous administration for 3 weeks; Alprostadil Liposomes for Injection at high dose:60ug,once a day,continuous administration for 3 weeks;
62267560|NCT02877173|ACTIVE_COMPARATOR|Alprostadil Injection|Alprostadil Injection:10ug,once a day,continuous administration for 3 weeks;
62267561|NCT02510027||Women aged 30-64 years old|Women aged 30 to 64 years who attend the Cervical Cancer Screening Program in 100 health centers in the state of Tlaxcala, Mexico
62267562|NCT05407584|EXPERIMENTAL|Cohort 1(1-3 prior line of chemotherapy)|Oregovomab and PLD is synergistic in PARPi-resistant recurrent ovarian cancer.
62626672|NCT01763827|ACTIVE_COMPARATOR|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
62626673|NCT01763827|EXPERIMENTAL|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
62626674|NCT01763827|EXPERIMENTAL|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
62626675|NCT03489980||Ambulatory consultation waiting room|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form before a medial consultation with hospital practitioner.
62626676|NCT03489980||Hemodialysis service|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form during hemodialysis.
62062893|NCT04236921|EXPERIMENTAL|Treatment D|DopaSnap® tablet administered at 0 and 4 hours post-first dose, for a total daily dose of CD/LD 50/200 mg.
62626677|NCT03489980||Day hospitalization service : psychiatry|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form during day hospitalization.
62062894|NCT04236921|EXPERIMENTAL|Treatment E|½ x DopaSnap® tablet administered at 0, 2, 4, and 6 hours post-first dose
62626678|NCT01904032|EXPERIMENTAL|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
62626679|NCT01904032|ACTIVE_COMPARATOR|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
62626680|NCT03139136|ACTIVE_COMPARATOR|MBS2320|
62626681|NCT03139136|PLACEBO_COMPARATOR|Placebo|
62626682|NCT03763201||rheumatoid arthritis|recently diagnosed rheumatoid arthritis patients in whom we measure Glucocorticoid-induced Tumour Necrosis Factor Receptor Related Protein (GITR) in their serum and synovial fluid (if clinically determined knee effusion)
62062895|NCT04219098|EXPERIMENTAL|Treatment|Butterfly IQ utilized to inject 10cc prior to surgery the remainder after incision
62062896|NCT04219098|ACTIVE_COMPARATOR|Control|Entire injection will be given after initial incision is made.
62267563|NCT05407584|EXPERIMENTAL|Cohort2 (>3prior line of chemotherapy)|Oregovomab and Paclitaxel show synergistic in PARPi-resistant recurrent ovarian cancer.
62267564|NCT03294031|EXPERIMENTAL|Pilates|The Pilates program covered a 12-week period, two weekly sessions. In one session, exercises were performed on a mat (Mat Pilates), and in the second session in standing and sitting position. The programme included warm-up exercises, the main part of the session and cooling activities.
62267565|NCT03294031|ACTIVE_COMPARATOR|Conventional Exercise|The conventional exercise programme covered a 12-week period, two weekly sessions. The programme aimed at improving aerobic capacity, muscular resistance, balance and flexibility. The program combined land-based and water-based exercise sessions.
62267566|NCT01074190|EXPERIMENTAL|Group 1|spinal fentanyl 15 micrograms plus bupivacaine 2.5 mg followed by a patient controlled epidural analgesia (PCEA) maintenance infusion of bupivacaine 1mg/mL
62852396|NCT02855918|OTHER|Blood sample for genetic purpose|"All the participants performed the same evaluations and blood analysis.~The study is composed of 3 groups :~* depressed patients with an history of suicide attempt~* depressed patients without any history of suicide attempt~* healthy controls without any history of psychopathology"
62852397|NCT05317091|EXPERIMENTAL|Laughter yoga practice|Laughter yoga for nurses The experimental group was divided into three groups as 18-17-16 people. Sessions 1st group Monday-Thursday between 12:00-13:00; 2nd group Tuesday-Friday between 17:00-18:00; The third group was held on Wednesday Saturday between 20:00-21:00.laughter yoga for nurses-Deep breathing exercises Deep breathing exercises (5 minutes), Warm-up exercises (10 minutes) laughter yoga for nurses-Childish games Childish games (10 minutes), Laughter exercises (15 minutes).
62852398|NCT05317091|EXPERIMENTAL|Laughter yoga session parts-1|Deep breathing exercises (5 minutes) Breathing is held for 4-5 seconds after deep inspiration. While the arms are brought to the normal position, exhale slowly and rhythmically. When expressing after deep inspiration, the lips can be pursed as if whistling or exhaled with laughter.
62852399|NCT05317091|EXPERIMENTAL|Laughter yoga session parts-2|Warm-up exercises (10 minutes) Rhythm of 1-2, 1-2-3 is added to increase the energy level even more and synchronize the movements of the group. After a few rhythmic clapping movements, another movement is added. Whisking hands left and right. Then an audible rhythm of ho, ho, ha-ha-ha is added to the clapping gesture. Make eye contact with people in the group and smile at them.
62852400|NCT05317091|EXPERIMENTAL|Laughter yoga session parts-3|"Childish games (10 minutes) Childlike games are used to help laugh without reason just like a child. The group is motivated by visualizing these games in their minds, raising the arms up in the form of a Y letter, and saying very good (applause), very good (applause), hey with palms facing the sky."
62062897|NCT04797182|EXPERIMENTAL|blank control|No intervention aiming at preventing thrombocytopenia will be taken after first cycle. Avatrombopag as salvage treatment will be administered to patients suffering from thrombocytopenia with nadir platelet count \< 50 × 109/L at a dose of 60mg/day until there is drug-withdrawal indication.
62267567|NCT01074190|EXPERIMENTAL|Group 2|spinal fentanyl 15 micrograms plus bupivacaine 2.5 mg spinal followed by a PCEA infusion of fentanyl 1 micrograms/mL plus bupivacaine 0.8 mg/mL
62267568|NCT01074190|ACTIVE_COMPARATOR|Group 3|spinal fentanyl 15 micrograms plus bupivacaine 2.5mg followed by a PCEA infusion of fentanyl 2 micrograms/mL plus bupivacaine 0.625 mg/mL
62267569|NCT03057236|NO_INTERVENTION|Standard of Care|This arm does not receive the behavioral intervention. Participants will complete HCV treatment per standard of care.
62267570|NCT03057236|EXPERIMENTAL|Cognitive Behavior Coping Skills|The CBCS intervention is a structured module-based group intervention involving 9, 2-hour sessions. Participants will participate in 4 weekly sessions before HCV treatment to learn and practice new cognitive behavioral skills, and 5 sessions during HCV treatment at weeks 2, 4, 6, 8, and 12.
62267571|NCT03716869|NO_INTERVENTION|Targeted Screening Arm (Current Process)|Students randomized to the targeted screening arm will complete their routine school-based health screenings. Students will be followed through the academic year for referrals to the Student Assistance Program (SAP). SAP currently exists in all Pennsylvania (PA) schools and functions like a triage service. If a student exhibits behavior concerning for MDD (raised by any contact, e.g. teachers, nurse, parent, peer, or even self-referral), SAP will triage the student and based on the initial assessment provide recommendations for school or community-based services.
62267572|NCT03716869|EXPERIMENTAL|Universal Screening Arm (Intervention)|"Students randomized to the universal screening arm will complete the Patient Health Questionnaire (PHQ-9) during the academic year. This screening tool includes nine close-ended questions with a scoring system ranging from 0 to 27. Scores \>10 are considered a positive screen. Students with a positive PHQ-9 result will then proceed to SAP triage as per the current process for those referred via the targeted screening arm."
62626683|NCT03763201||control group|age and sex matched healthy volunteers whom we measure Glucocorticoid-induced Tumour Necrosis Factor Receptor Related Protein (GITR) in their serum.
62267573|NCT06179771|ACTIVE_COMPARATOR|Interventional|Patients assigned to interventional arm will receive treatment with a cytokine adsorption device (HA 380) within 72 hours of being admitted to ICU. This is in addition to standard evidence based ICU care. Each patient will receive 2 treatments each lasting a maximum of 6 hours in a 24 hour period.
62267574|NCT06179771|NO_INTERVENTION|Standard care|Patients assigned to the standard care arm would receive evidence based standard ICU care.
62267575|NCT02486731||Noonan syndrome|Patients with Noonan syndrome
62267576|NCT02486731||LEOPARD syndrome|Patients with LEOPARD syndromes
62267577|NCT02486731||Controls|Healthy subjects
62267578|NCT00811772|ACTIVE_COMPARATOR|Bare metal stent|Implantation of one or more bare metal stent(s) to to treat coronary artery stenosis
62267579|NCT00811772|EXPERIMENTAL|Drug eluting stent|Implantation of one or more drug eluting stent(s) to treat coronary artery stenosis
62267580|NCT05567237|ACTIVE_COMPARATOR|Microcurrent alone (MC)|This group will receive a live microcurrent device and they will not be engaged in any resistance training exercises.
62626684|NCT00534638|EXPERIMENTAL|Cervarix/Engerix-B A Group|The A group includes subjects from communities where 70% of male and female adolescents were to be vaccinated with Cervarix vaccine. To achieve a Cervarix vaccination coverage of 70%, a 9:1 ratio was used to allocate study participants to receive Cervarix vaccine versus control Engerix-B vaccine (meaning 90% of vaccinated subjects were randomized to Cervarix). Finally, subjects from A group were either vaccinated with Cervarix, Engerix-B (control vaccine), or not vaccinated (enrolled control without vaccination). Vaccines were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
62626685|NCT00534638|EXPERIMENTAL|Cervarix/Engerix-B B Group|The B group includes subjects from communities where 70% of female adolescents were to be vaccinated with Cervarix vaccine. To achieve a Cervarix vaccination coverage of 70%, a 9:1 ratio was used to allocate female participants to receive Cervarix vaccine versus control Engerix-B vaccine (meaning 90% of vaccinated females were randomized to Cervarix). In this group, all male adolescents were to be vaccinated with Engerix-B control vaccine. Finally, subjects from B group were either vaccinated with Cervarix (females) or Engerix-B/not vaccinated (males and females). Vaccines were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
62626686|NCT00534638|ACTIVE_COMPARATOR|Engerix-B Group|In this control group, all adolescents were to be vaccinated with Engerix-B control vaccine. Finally, subjects from this group were either vaccinated with Engerix-B or not vaccinated. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
62626687|NCT01580826|NO_INTERVENTION|raw milk|Infants who were assigned to the raw group received fresh or thawed milk from their own mother, cultured weekly with a semi-quantitative analysis. Raw milk was withheld if it contained any Gram-negative organisms, S. aureus or enterococci.
62626688|NCT01580826|ACTIVE_COMPARATOR|pasteurized milk|Infants who were assigned to pasteurization received own mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
62626689|NCT02533583||symptomatic newborn|the symptomatic newborn cohort( symptomatic definition see detail),all of babies will referred for chest X-ray,and within 2 hours performing echocardiography to exclude critical and serious heart disease.All clinical assessment will do by attending doctor.
62626690|NCT02533583||Asymptomatic newborn|the asymptomatic newborn cohort will gave pulse oximetry and clinical assessment every 8 hours within 3 days.everybody have positive results will been preformed chest X-ray and echocardiography.All clinical assessment will do by attending doctor.
62626691|NCT05403840||MVRR: Patients due to undergo surgical MV repair/replacement|
62626692|NCT05403840||TMVI: Patients due to undergo transcatheter MV intervention|
62852401|NCT05317091|EXPERIMENTAL|Laughter yoga session parts-4|Laughter exercises (15 minutes) This section includes a variety of laughter exercises such as greetings, strawberry milk, conductor, bonus, hot soup, lion, aloha, bird, appreciation, laughter lotion, elevator, cream cake, and bursting balloon laughter.
62852402|NCT01758536|PLACEBO_COMPARATOR|Placebo Pills|"* 12 g each time, twice daily.~* 3 months"
62852403|NCT01758536|EXPERIMENTAL|Huatuo Zaizao Pills|"* 12 g each time, twice daily.~* 3 months."
62852404|NCT04903743|PLACEBO_COMPARATOR|group B|28ml of 0.25% bupivacaine and 2ml normal saline
62852405|NCT04903743|ACTIVE_COMPARATOR|group BM|received 28 ml of 0.25% bupivacaine and 2 ml magnesium sulfate 10%.
62852406|NCT05437705|EXPERIMENTAL|Neuromodulation using the optimal rTMS stimulation frequency|Through manipulation of brain state with a negative-affect task and using fMRI as the feedback signal, we aim to fine-tune repetitive Transcranial Magnetic Stimulation (rTMS) delivery to maximally impact the desired brain states in awake behaving study participants in a highly individualized manner (Visit 3: TMS/fMRI). The optimal rTMS stimulation frequency will be tested in a 3-day rTMS neuromodulation intervention.
62852407|NCT05437705|ACTIVE_COMPARATOR|Neuromodulation using the least optimal rTMS stimulation frequency|We will compare the results of the optimal rTMS frequency neuromodulation with a separate 3-day neuromodulation session using the least optimal rTMS frequency, as determined by Visit 3: TMS/fMRI.
62062898|NCT04797182|EXPERIMENTAL|primary prevention|"As the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy, Avatrombopag will be administered at a dose of 60mg/day on days -3\~-1 and 3\~9, for a total of 10 doses. On the condition that patients have platelet counts \<50 × 10 9 /L before next cycle, Avatrombopag will be administered at a dose of 60mg/day until there is drug-withdrawal indications. Platelet transfusions were administered to patients when the platelet count was less than 10×109 /L.~Drug-withdrawal indications:~PLT ≥ 100×109/L during salvage treatment or platelet count increases by 50×109/L, comparing with baseline level.~When platelet count is higher than 400×109/L during this study, researchers determine whether avatrombopag is discontinued"
62852408|NCT03373331|EXPERIMENTAL|Experimental Group|Participants in the experimental group will receive emotional processing training exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
62852409|NCT03373331|PLACEBO_COMPARATOR|Control Group|"Participants in the control group will meet with the examiner the same frequency and for the same duration as those in the experimental group.~They will receive placebo control exercises administered on a laptop computer.~."
62852410|NCT04483401|NO_INTERVENTION|Waitlist|"Waitlist Participants are first allocated to a waitlist condition. After the first MRI scan, participants wait for 12 weeks and have a second MRI scan."
62852411|NCT04483401|EXPERIMENTAL|Treatment arm|Upon completion on the waitlist time of 12 weeks, participants then are allocated to the treatment group. Participants are assessed by an independent occupational therapist (before and after intervention) and participate in 10 treatment sessions with a treating occupational therapist. Following the post-treatment assessment, participants have a third MRI scan.
62852412|NCT01484886|EXPERIMENTAL|Restrictive transfusion strategy|RBC will be transfused if the hemoglobin level falls below 7 for bi-ventricular repairs and under 9.0 for single ventricle palliations.
62852413|NCT01484886|EXPERIMENTAL|Liberal RBC transfusion strategy|RBCs will be transfused for Hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
62852414|NCT06311318|EXPERIMENTAL|Massage group|Patients in the experimental group received training and guidance from trained investigators regarding post-operative lower eyelid massage.
62062899|NCT02013596|NO_INTERVENTION|Control|Patients were given no TEAS
62062900|NCT02013596|EXPERIMENTAL|TEAS Pretreatment|Patients were given 30min of TEAS before pneumoperitoneum
62626693|NCT00184002|EXPERIMENTAL|DR-COP|"On cycle 1 patients receive Doxil 40 mg/m2 iv day 1 over a minimum of 60 min., Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min., Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum) and Prednisone 100 mg po days 1-5.~On cycle 2 until study completion patients receive Doxil 40 mg/m2 iv day 1, Rituxan 375 mg/m2 iv day 1, Cyclophosphamide 750 mg/m2 iv day 1, Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum) and Prednisone 100 mg po days 1-5~* 1 cycle = 21 days.~* Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles."
62626694|NCT02382315|EXPERIMENTAL|Intervention Group|Fear of Cancer Recurrence Intervention.
62626695|NCT02382315|NO_INTERVENTION|Wait-list Control Group|Patients assigned to this arm will be asked to wait 6 weeks before being offered the fear of cancer recurrence intervention.
62626696|NCT04726111|OTHER|Control patients|Control patients (negative serology and PCR)
62062901|NCT02013596|EXPERIMENTAL|TEAS Treatment|Patients were given 30min of TEAS during pneumoperitoneum
62267581|NCT05567237|ACTIVE_COMPARATOR|Microcurrent with exercise (MC + RT)|This group will receive a live microcurrent device and they will follow an exercise programme of 2 training sessions per week for 6 weeks (12 sessions in all)
62267582|NCT05567237|SHAM_COMPARATOR|Sham alone (SH)|This group will receive a sham microcurrent device and they will not be engaged in any resistance training exercises.
62267583|NCT05567237|SHAM_COMPARATOR|Sham with exercise (SH + RT)|This group will receive a sham microcurrent device and they will follow an exercise programme of 2 training sessions per week for 6 weeks (12 sessions in all)
62267584|NCT01783119|EXPERIMENTAL|Aloe Vera|Consume 200 ml of aloe vera gel per day over a period of three months
62267585|NCT01783119|PLACEBO_COMPARATOR|water|Consume 200 ml of placebo per day over a period of three months
62267586|NCT00385632||1|Participants following a drug conservation (DC) regimen in which ART was stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count was at least 350 cells/mm3, and then followed by episodic ART based on CD4 cell count
62267587|NCT00385632||2|Participants following a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count
62267588|NCT03376568||Narcolepsy with RBD & Control|Narcolepsy with REM sleep disorder lable(20) and Control subjects lable(20)
62450842|NCT00536575|EXPERIMENTAL|Intervention|The trial was designed as a single-arm Phase I/II study of sorafenib and bortezomib with dose optimization in initial patients. Phase I consisted of cohorts of 3 patients at each of three dose levels. Patients received bortezomib (Dose Level 1 - 1.3 mg/m2; Dose Level 2 - 1.6 mg/m2) by IV bolus on days 1, 8, 15, and 22 of each 5-week cycle with continuous oral dosing of sorafenib at 200 mg twice daily. Dose level 3 was planned as bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 with sorafenib 400 mg by mouth twice daily throughout each 5-week cycle.
62626697|NCT04726111|OTHER|asymptomatic patients|asymptomatic patients (PCR positive)
62626698|NCT04726111|OTHER|symptomatic patients|symptomatic patients (PCR positive)
62626699|NCT04726111|OTHER|Cured patients|cured patients who contracted the disease during pregnancy (positive serology in the 15 days preceding childbirth or history of positive PCR during pregnancy and negative PCR within 72 hours)
62626700|NCT02790918||Diagnosed Pulmonary Hypertension|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) and 6MWT.
62062902|NCT03821337|EXPERIMENTAL|rTMS|Participants will receive 18 sessions of active rTMS delivered at 120% rMT.
62626701|NCT02790918||Healthy Volunteer|Healthy Volunteer will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) and 6MWT.
62626702|NCT03643302||Therapy of bronchoalveolar lavage group|Patients with bronchiectasis exacerbations treat with fundamental treatment combining with the therapy of airway clearance and bronchoalveolar lavage.
62267589|NCT03376568||Narcolepsy with /without RBD|Narcolepsy with REM sleep disorder lable(20) and Narcolepsy without REM sleep disorderlable (20)
62267590|NCT03600662|EXPERIMENTAL|TriRec|Trileaflet Reconstruction of the Aortic Valve
62267591|NCT03600662|EXPERIMENTAL|Aortic valve replacement|Biological prosthesis, Device: St. Jude Medical Trifecta GT
62626703|NCT03643302||Fundamental treatment group|In the control group,fundamental treatment was adopted according to the guidelines
62626704|NCT05757752|OTHER|Intervention|Participants meeting eligibility criteria will participate in the Mind Body Program for Vascular Disease, working in-person or via telehealth with a study interventionist for an hour weekly in 6-8 week cycles learning problem-solving techniques targeting mood/distress and enhancing disease management strategies. Participants will be assessed at baseline, 3-months, and 6-months.
62062903|NCT03821337|PLACEBO_COMPARATOR|Sham TMS|Participants will receive 18 sessions of sham rTMS delivered through an inactive coil.
62062904|NCT00113360|EXPERIMENTAL|RAD001 plus Depot Octreotide|RAD001 at 5 or 10 milligrams orally once a day plus Octreotide Depot 30 milligrams intramuscularly once every 28 days.
62267592|NCT00586261|PLACEBO_COMPARATOR|Placebo|Placebo 30 mg daily for 6 months, nitroglycerin was given to check the brachial reactivity.
62267593|NCT00586261|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone 30 mg daily for 6 months, nitroglycerin was given to check the brachial reactivity.
62267594|NCT03969121|ACTIVE_COMPARATOR|Placebo + Endocrine therapy|Endocrine therapy for 16 weeks plus placebo
62267595|NCT03969121|ACTIVE_COMPARATOR|Palbociclib + Endocrine therapy|Endocrine therapy for 16 weeks plus Palbociclib
62267596|NCT02018731|EXPERIMENTAL|Metformin and Metformin & L-Citrulline|1500 mg/d metformin for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
62626705|NCT03785314|ACTIVE_COMPARATOR|injection under sitting position|saline injection under sitting position during thoracic epidural catheterization
62626706|NCT03785314|ACTIVE_COMPARATOR|injection under lateral decubitus position|saline injection under lateral decubitus position during thoracic epidural catheterization
62626707|NCT01925976|OTHER|Individualized dietetic intervention|Behavioral: Individualized dietetic intervention-eating habits.
62626708|NCT00722683|EXPERIMENTAL|Ultrasound Imaging|Ultrasound Imaging with Contrast
62626709|NCT04129112||Patients without body movements|Patient who, under general anesthesia without curare agents, during surgery has no body movements
62626710|NCT04129112||Patients with body movements|Patient who, under general anesthesia without curare agents, during surgery has any body movements that are no reflexes movements
62626711|NCT01826097|EXPERIMENTAL|Vibration|Whole body vibration applied to a group of 20 bladder cancer patients.
62450843|NCT04488575|EXPERIMENTAL|EDP1815|Patients will receive EDP1815 in addition to standard of care
62626712|NCT06257953|ACTIVE_COMPARATOR|Patients with a BMI of 18-24.9 kg/m2|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 15 ml of 0.25% bupivacaine was injected into the area. Then the block process will be applied to the other side in the same way. A total of 30 ml of 15 ml 0.25% bupivacaine will be injected.
62626713|NCT06257953|ACTIVE_COMPARATOR|Patients with a BMI of 25-29.9 kg/m2|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 15 ml of 0.25% bupivacaine was injected into the area. Then the block process will be applied to the other side in the same way. A total of 30 ml of 15 ml 0.25% bupivacaine will be injected.
62626714|NCT06257953|ACTIVE_COMPARATOR|Patients with a BMI of 30-40 kg/m2|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 15 ml of 0.25% bupivacaine was injected into the area. Then the block process will be applied to the other side in the same way. A total of 30 ml of 15 ml 0.25% bupivacaine will be injected.
62852415|NCT06311318|NO_INTERVENTION|Non-massage group|The control group receiving standard care without post-operative lower eyelid massage.
62852416|NCT03542032|OTHER|jaw-thrust|"the i-gel was inserted with triple airway maneuver (mouth opening, head extension and jaw thrust) This groups will record the insertion time of i-gel, number of trials, operative time, placement complications.~Recorded complications (blood, laryngospasm, etc.) during insertion and removal of supraglottic airway devices will be assessed.~Patients' postoperative sore throat will be questioned and recorded."
62062905|NCT00925821|EXPERIMENTAL|Allogeneic stem cell transplant|Second scheduled transplantation performed from an HLA-matched MRD or MUD after conditioning with treosulfan and fludarabine
62450844|NCT04488575|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo in addition to standard of care
62450845|NCT02382666|EXPERIMENTAL|Rolapitant Cohort 1|Investigational Product: Rolapitant Dose 1 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
62626715|NCT06236854||POD-Absent|The group of older-aged surgical patients who are not diagnosed with delirium as assessed for the following fives days post-surgery.
62626716|NCT06236854||POD-Present|The group of older-aged surgical patients who are diagnosed with delirium as assessed for the following fives days post-surgery.
62626717|NCT01300247|EXPERIMENTAL|Obinutuzumab + Fludarabine + Cyclophosphamide|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab (1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6), fludarabine (25 mg/m\^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6), and cyclophosphamide (250 mg/m\^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6).
62062906|NCT00925821|ACTIVE_COMPARATOR|High-dose melphalan chemotherapy|Second high-dose melphalan therapy followed by transplantation of peripheral blood stem cells
62626718|NCT01300247|EXPERIMENTAL|Obinutuzumab + Bendamustine|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab (1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6) and bendamustine (90 mg/m\^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6).
62626719|NCT01562652|EXPERIMENTAL|Research|
62626720|NCT06316596|ACTIVE_COMPARATOR|NEWBORN BORN AFTER EPIDURAL ANESTHESIA|Group epidural, 0.5% buvasin® will be applied epidural space in the lateral position after monitoring. The patient will be placed in the supine position and surgery will begin when the T5 spinal level is achieved. Pregnant heart rate, blood pressure and saturation values will be recorded at intervals and iv ephedrine will be administered when there is a 25% or more drop in blood pressure. When there is a 25% or more decrease in heart rate, iv atropine will be administered. A NIRS probe (infant,saturation sensor, Invos , Tullamore, Ireland) and pulse will be attached to the newborn by another anesthetist and the measurements will be recorded. Blood pressure will be taken from the umbilical vein. APGAR(activity,pulse,grimace,appearance,respiration), heart rate, SpO2 and umbilical vein saturation values of the newborn will be recorded. NIRS and spO2 values of the newborn will be checked intermittently.
62626721|NCT06316596|ACTIVE_COMPARATOR|NEWBORN BORN AFTER SPINAL ANESTHESIA|Group spinal, 0.5% buvasin® heavy will be applied spinal space in the lateral position after monitoring. Surgery will begin when the patient is placed in the supine position and T5 spinal level is achieved. Pregnant heart rate, blood pressure, and saturation values are recorded at regular intervals, and when there is a 25% or more drop in blood pressure, the patient will be given iv ephedrine. When there is a 25% or more drop in heart rate, iv atropine will be administered. A NIRS probe (infant,saturation sensor, Invos , Tullamore, Ireland) and pulse will be attached to the newborn by another anesthetist and the measurements will be recorded. Blood pressure will be taken from the umbilical vein. The newborn's APGAR(activity,pulse,grimace,appearance,respiration), heart rate, SpO2 and umbilical venous saturation values will be recorded. NIRS and spO2 values will be checked intermittently.
62626722|NCT02976246|ACTIVE_COMPARATOR|RenaKvit-vessel Active|One tablet of 360 micrograms vitamin K2 given once daily to examine the effect on vascular calcification
62626723|NCT02976246|PLACEBO_COMPARATOR|RenaKvit-vessel Control|One tablet of non-active drug given once daily
62626724|NCT02976246|ACTIVE_COMPARATOR|RenaKvit-bone Active|One tablet of 360 micrograms vitamin K2 given once daily to examine the effect on bone metabolism
62626725|NCT02976246|PLACEBO_COMPARATOR|RenaKvit-bone control|One tablet of non-active drug given once daily
62852417|NCT03542032|NO_INTERVENTION|classic group|"In the classic group, the index finger used as a guide, pushes the back of i-gel towards the hard palate, inserting it into the pharynx till a resistance is felt and the i-gel is then fixed it its place. This groups will record the insertion time of i-gel, number of trials, operative time, placement complications.~Recorded complications (blood, laryngospasm, etc.) during insertion and removal of supraglottic airway devices will be assessed.~Patients' postoperative sore throat will be questioned and recorded."
62626726|NCT03327285|EXPERIMENTAL|C-CAR011|The amount of cells received：1.0-5.0×10\^6 CAR+T cells/kg
62626727|NCT06611566|EXPERIMENTAL|VR-guided aerobic exercise then TV-guided aerobic exercise|Participants were randomised to VR-guided aerobic exercise followed by TV-guided aerobic exercise
62626728|NCT06611566|EXPERIMENTAL|TV-guided exercise then VR-guided aerobic exercise|Participants were randomised toTV-guided aerobic exercise followed by VR- aerobic guided exercise
62626729|NCT06611566|EXPERIMENTAL|VR-guided mindfulness exercise then TV-guided mindfulness exercise|5 minutes of VR-guided mindfulness exercise followed by 5 minutes of TV-guided mindfulness exercise
62626730|NCT06611566|EXPERIMENTAL|TV-guided mindfulness exercise then VR-guided mindfulness exercise|5 minutes of TV-guided mindfulness exercise followed by 5 minutes of VR-guided mindfulness exercise
62626731|NCT06014164||Patients using psychedelic substances|Adult patients self-administering psychedelic substances in psychiatric disorders
62626732|NCT03701438||Idelalisib|Participants currently enrolled in a Gilead-sponsored study, who are currently being treated with 100 or 150 mg of idelalisib twice daily for at least 7 consecutive days prior to receiving an influenza vaccine.
62626733|NCT01345214|EXPERIMENTAL|E|
62626734|NCT04135313|EXPERIMENTAL|Neoadjuvant chemotherapy|Patients receive 2 cycles of induction CapOx (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 per os bid days 1-14) chemotherapy, followed by chemoradiotherapy (54 Gy in 2 Gy fractions with concomitant capecitabine 825 mg/m2 per os bid on radiation days), then 2 cycles of consolidation CapOx chemotherapy, surgery (10-12 weeks following chemoradiotherapy) and 2 cycles of adjuvant CapOx chemotherapy
62626735|NCT04135313|ACTIVE_COMPARATOR|Chemoradiotherpy|Patients receive 54 Gy pelvic chemoradiotherapy in 2 Gy fractions with capecitabine 825 mg/m2 bid per os on radiation days and then surgery following 10-12 weeks. After surgery patients receive 6 cycles of adjuvant CapOx chemotherapy.
62626736|NCT03610880|EXPERIMENTAL|TG-2349 (400 mg) plus DAG181 (200 mg)|Dosing period 1 (Day 1 to 7): TG-2349 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181
62852418|NCT01876329||Rheumatoid Arthritis|Patients with seropositive or seronegative Rheumatoid Arthritis
62626737|NCT03610880|EXPERIMENTAL|DAG181 (200 mg) plus TG-2349 (400 mg)|Dosing period 1 (Day 1 to 7): DAG181 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181
62626738|NCT01957579|EXPERIMENTAL|MEDI-551|
62626739|NCT04633499|ACTIVE_COMPARATOR|dmPFC tDCS + Social Cognition tasks in older participants|Participants will receive either active or sham stimulation over the dmPFC while conducting two different social cognition paradigms: one regarding emotion recognition, one on visual perspective taking.
62626740|NCT04633499|EXPERIMENTAL|rTPJ tDCS + Social Cognition tasks in older participants|Participants will receive either active or sham stimulation over the rTPJ while conducting two different social cognition paradigms: one regarding emotion recognition, one on visual perspective taking.
62626741|NCT04633499|ACTIVE_COMPARATOR|Social cognition tasks in younger participants|Participants will conduct two different social cognition paradigms: one regarding emotion recognition, one on visual perspective taking but without tDCS stimulation.
62626742|NCT01770821|ACTIVE_COMPARATOR|Standard physical training & standard nutrition|Standard of care
62626743|NCT01770821|EXPERIMENTAL|Tailored physical training and sipdrink|Tailored physical training and sipdrink (Protein nutridrink, 200 ml x 2)
62626744|NCT01770821|EXPERIMENTAL|Tailored physical training and standard nutrition.|Standard physical training provided by the hospital and standard hospital nutrition
62626745|NCT01770821|EXPERIMENTAL|Standard physical training and sip drink|Standard physical training provided by the hospital and sipdrink (Nutridrink protein, 200 ml x2)
62626746|NCT01494272||Group CB (Caudal Before-study group)|This group will receive caudal ropivacaine and epinephrine after induction of general anesthesia prior to surgical incision
62626747|NCT01494272||Caudal After (CA)-control group|This group will receive caudal ropivacaine with epinephrine after completion of surgery but before emergence from anesthesia
62852419|NCT01876329||Autoimmune Thyroid Disease (AITD)|Participants with autoimmune thyroid disease without other known systemic or organ specific autoimmune illnesses.
62852420|NCT01876329||Control|Participants without Rheumatoid Arthritis, AITD, or other systemic or organ specific autoimmune illnesses
62852421|NCT01523275|EXPERIMENTAL|Mitomycin-C|Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial incisions and balloon dilation, as well as topical application of MMC in the radial incisions.
62852422|NCT01523275|PLACEBO_COMPARATOR|Saline|Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial incisions and balloon dilation, as well as topical application of isotonic saline in the radial incisions.
62852423|NCT01810614|EXPERIMENTAL|ADPKD Diet|All study participants will follow their regular diet for 8 days. After that, they will be asked to follow the ADPKD diet for a total of 4 weeks.
62852424|NCT00123669|NO_INTERVENTION|Control|Patient will not receive Inj Progesterone 500 mg
62852425|NCT00123669|EXPERIMENTAL|Treatment|An intramuscular injection of 500mg depot hydroxy-progesterone 5-14 days prior to surgery.
62852426|NCT05069870|EXPERIMENTAL|The DDI of SKLB1028 and Itraconazole|Eligible subjects received a single dose of SKLB1028 100 mg on Day 1, then took Itraconazole 200 mg twice-daily on Day 8 and 200 mg once-daily on Day 9 through Day 18, and took a single dose of SKLB1028 100 mg on Day 11.
62852427|NCT05069870|EXPERIMENTAL|The DDI of SKLB1028 and Gemfibrozil|Eligible subjects received a single dose of SKLB1028 100 mg on Day 1, then took Gemfibrozil 600 mg twice-daily on Day 8 through Day 19, and took a single dose of SKLB1028 100 mg on Day 12.
62852428|NCT05069870|EXPERIMENTAL|The DDI of SKLB1028 and Rifampicin|Eligible subjects received a single dose of SKLB1028 150 mg on Day 1, then took Rifampicin 600 mg once-daily on Day 8 through Day22, and took a single dose of SKLB1028 150 mg on Day 15.
62852429|NCT05776095|EXPERIMENTAL|Eyedeal® IOL|Eyedeal® Model PX65AS1 IOL
62852430|NCT02659748|EXPERIMENTAL|Milk fat|A 21-day low-fat (E%) experimental diet including milk fat with macronutrient and fatty acid class profiles differing only in type of fat and, thus, the proportion of single (bioactive) fatty acids.
62852431|NCT02659748|EXPERIMENTAL|Control Fat|A 21-day low-fat experimental diet. Eucaloric diet to Arm #1 with macronutrient and fatty acid class profiles differing only in type of fat and, thus, the proportion of single fatty acids. A control fat is used to replace dairy fats.
62450846|NCT02382666|EXPERIMENTAL|Rolapitant Cohort 2|Investigational Product: Rolapitant Dose 2 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
62626748|NCT01494272||Local Infiltration After (LIA) control group|This group will receive local infiltration of ropivacaine around the surgery site at the conclusion of surgery but before emergence from anesthesia
62626749|NCT03602703||chronic HCV|chronic HCV either treated or not with DAAs.Flow cytometry and Western Blot analysis for each subgroup
62626750|NCT03602703||Liver cirrhosis without HCC|Liver cirrhosis without HCC either received treatment or not.Flow cytometry and Western Blot analysis for each subgroup
62626751|NCT03602703||Liver cirrhosis with HCC|Liver cirrhosis with HCC either received treatment or not.Flow cytometry and Western Blot analysis for each subgroup
62626752|NCT03602703||Control group|Healthy subjects
62626753|NCT02293239|NO_INTERVENTION|Control Group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake \> 1.0 g/kg bodyweight)"
62626754|NCT02293239|EXPERIMENTAL|WB-EMS group|"physical exercise group regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake \> 1.0 g/kg bodyweight)"
62626755|NCT01315288|ACTIVE_COMPARATOR|Video presentation absolute risk|absolute risk
62626756|NCT01315288|ACTIVE_COMPARATOR|Video presentation absolute event-free survival|absolute event-free survival
62626757|NCT01315288|ACTIVE_COMPARATOR|Video presentation annualized absolute risk|annualized absolute risk
62626758|NCT01315288|ACTIVE_COMPARATOR|Video presentation relative risk|relative risk
62626759|NCT01315288|ACTIVE_COMPARATOR|Video presentation qualitative description|qualitative description
62852432|NCT03409887|EXPERIMENTAL|Intraorifice Group|Intraorifice barrier of GIC.
62852433|NCT03409887|EXPERIMENTAL|Base Group|Base of GIC
62852434|NCT03409887|ACTIVE_COMPARATOR|Control Group|Direct composite restoration
62852435|NCT04590846|EXPERIMENTAL|Constipation Health Education|"Health education leaflets are distributed once a week, and students are asked to bring it back to their parents to read. The activity of seeing leaflets, accumulating points, and redeeming prizes is adopted. a reply slip is designed in the weekly health education content, containing 3-5 test questions. Parents need to complete the answers and sign after reading the health education content. Those who have a high degree of correctness and fully paid in within 4 weeks will receive additional points. Students are required to keep a  Stool diary record sheet  every day, and it will be posted in the contact book. Children who have confirmed records and turned in will get 10 points a week, and those who turned in all 8 weeks without random answers can get extra points. The points of the parent health education receipt and the points of the children will be combined and calculated, and the weight will be set according to the total number of points for the draw."
62852436|NCT04590846|ACTIVE_COMPARATOR|General Health Course|"In order to correctly evaluate the effectiveness of health education intervention, only the parents of the experimental group will receive the health education leaflet during the intervention period. However, after the end of the trial, an electronic file of parental health education in the control group will be provided. Students are required to keep a  Stool diary record sheet  every day, and it will be posted in the contact book. Children who have confirmed records and turned in will get 10 points a week, and those who turned in all 8 weeks without random answers can get extra points. After the children's points are counted, a lottery will be drawn based on the total number of points. Since the experimental group and the control group have different benchmarks for points, the lottery will be drawn separately from each school. During the lottery process, the time will be announced in advance, and the number will be randomly selected by the computer in a live broadcast method."
62852437|NCT03870594||diabetic|patients suffer from diabetes mellitus
62852438|NCT03870594||non diabetic|patients free from diabetes with normal blood glucose level
62852439|NCT04954651||VAC|Vaccinated subject against Sars-Cov2
62852440|NCT02319629|EXPERIMENTAL|URSODIOL - URSODEOXYCHOLIC ACID|300 mg twice a day
62852441|NCT02319629|PLACEBO_COMPARATOR|placebo|placebo twice a day
62852442|NCT02815722|ACTIVE_COMPARATOR|SP2086 and Simvastatin|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.There were 5 days washout period between the two stages.The whole study needs 27 days.This group patient was given treatment from A stage to B stage.
62062907|NCT02428244|NO_INTERVENTION|Arm 1, Control|Standard of care intervention: All patients at the University as a standard of care receive informational materials about smoking cessation. They are referred to the patient resource center at our institution. Patients will be provided this, also they will be provided with a smoking cessation Quitline Brochure
62088025|NCT06312631|EXPERIMENTAL|Task handover model #8|"At each visit, the patient will perform the tasks with the gripping glove (A) or without the gripping glove (B).~The order of administration with then without the glove (AB) or without then with the glove (BA) is drawn at random for each patient.~The 8th model follows the following diagram:~Visit T1 = BA ; Visit T2 = BA ; Visit T3 = BA"
62450847|NCT02382666|EXPERIMENTAL|Rolapitant Cohort 3|Investigational Product: Rolapitant Dose 3 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
62450848|NCT02382666|EXPERIMENTAL|Rolapitant Cohort 4|Investigational Product: Rolapitant Dose 4 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
62450849|NCT02382666|EXPERIMENTAL|Rolapitant Cohort 5|Investigational Product: Rolapitant Dose 5 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
62450850|NCT02382666|EXPERIMENTAL|Rolapitant Cohort 6|Investigational Product: Rolapitant Dose 6 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
62626760|NCT03079167|EXPERIMENTAL|Erythropoietin|Erythropoietin (epoetin alfa) 1000 IU/kg birth weight (capped at 4000IU daily) IV infusion, on Days 1, 2, 3, 5 and 7 of age
62626761|NCT03079167|PLACEBO_COMPARATOR|Placebo|IV normal saline (equiv. volume), on Days 1, 2, 3, 5 and 7 of age
62626762|NCT01944644|ACTIVE_COMPARATOR|Active Low Field Magnetic Stimulation|LFMS will follow a previously published protocol for the treatment of a Major Depressive Episode (Rohan et al. 2004). Active Low Field Magnetic Stimulation treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain.
62626763|NCT01944644|SHAM_COMPARATOR|Sham Low Field Magnetic Stimulation|Sham Low Field Magnetic Stimulation will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
62626764|NCT03097432||ORALVAC COMPACT BÄUME|This non-interventional study was initiated to document the up-dosing period of children and adults with allergic rhinoconjunctivitis and/or allergic asthma treated with a SLIT containing purified, aqueous extracts of birch, alder, and hazel pollen. The following up-dosing schemes were freely selectable: scheme A consists of an up-dosing period of 12 days at the patient´s home using the standardized pollen extract in three different solution strengths to reach the maximum dose; scheme B performed only with the highest solution strength at the physician's office within 2 hours; and the new scheme C which is a regimen for initiation at the physician's office and continuation at the patient's home also exclusively using the highest solution strength and takes 4 days.
62626765|NCT02088892|EXPERIMENTAL|Group A|10 BCG-naïve subjects receiving intradermal BCG SSI at standard dose (2-8 x 10\^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
62852443|NCT02815722|ACTIVE_COMPARATOR|Simvastatin and SP2086|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.There were 5 days washout period between the two stages.The whole study needs 27 days.This group patient was given treatment from B stage to A stage.
62852444|NCT04193696|EXPERIMENTAL|radiotherapy plus PD-1|
62852445|NCT04626401|PLACEBO_COMPARATOR|Control diet during immobilisation|A 2 day controlled dietary intervention.
62852446|NCT04626401|EXPERIMENTAL|Branched chain amino acid restricted diet during immobilisation|A 2 day branched chain amino acid restricted dietary intervention.
62852447|NCT06060938|EXPERIMENTAL|Risk stratified arm|"The intervention consists of calculation and communication of personal risk together with recommendations for the subsequent interval between screening visits.~Women in the intervention arm are offered a risk measurement and risk stratified screening accordingly with stratification into four risk groups: Low, intermediate, elevated and high risk. Depending on the risk group the women will be offered a mammography every 1-4 years. The high risk group will also be offered tomosynthesis. The risk estimation is based on the risk model, BOADICEA, which is the most comprehensive model currently available for breast cancer risk prediction. The model incorporates the most up to date polygenic risk score for breast cancer, based on 313 single nucleotide polymorphisms (SNP), as well as familial breast cancer history, reproductive history, lifestyle/hormonal risk factors, height, weight and mammographic density, obtained from image analysis of the mammogram."
62852448|NCT06060938|ACTIVE_COMPARATOR|Control arm|In the control arm, participants are assigned to the standard national screening program with biennial screening.
62852449|NCT00700167|EXPERIMENTAL|1|"The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months.~The vaccines will be given during an outpatient visit. If for some reason, you happen to be in the hospital, you can still receive the vaccines. These visits should take no longer than 15-30 minutes."
62852450|NCT00145977|EXPERIMENTAL|Experimental|All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal. This group will also receive alendronate 70 mg once weekly, according to standard recommendations.
62852451|NCT00145977|ACTIVE_COMPARATOR|Control|All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal.
62852452|NCT00536913|EXPERIMENTAL|With Spacer|Budesonide/formoterol pMDI 40/2.25ug + spacer
62450851|NCT00198081|EXPERIMENTAL|Surgical Candidate|COX-2 Inhibitor 6-8 weeks prior to surgery
62450852|NCT00198081|EXPERIMENTAL|Medical Candidate|COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
62626766|NCT02088892|EXPERIMENTAL|Group B|10 BCG-naïve subjects receiving BCG Tice at standard dose (2-8 x 10\^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
62626767|NCT02088892|EXPERIMENTAL|Group C|10 BCG-naïve subjects receiving intradermal BCG SSI at high dose (6-24 x 10\^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
62626768|NCT02088892|EXPERIMENTAL|Group D|10 BCG-naïve subjects receiving intradermal BCG Tice at high dose (6-24 x 10\^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
62626769|NCT02088892|EXPERIMENTAL|Group E|8-12 BCG-naïve subjects receiving the optimal strain and dose of intradermal BCG identified from preliminary results obtained from Group A, B, C and D, followed by a punch biopsy at the challenge site 14 days later.
62626770|NCT00889915|ACTIVE_COMPARATOR|1|Participants will receive methylphenidate transdermal system.
62626771|NCT00889915|ACTIVE_COMPARATOR|2|Participants will receive lisdexamfetamine dimesylate.
62852453|NCT00536913|EXPERIMENTAL|Without Spacer|Budesonide/formoterol pMDI 40/2.25 ug
62852454|NCT02086006|OTHER|DESolve scaffold|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold. test arm, intervention
62852455|NCT04788368||Patients treated with TEM - transanala microsurgery|Early rectal cancer treated with TEM - full thickness resection
62088026|NCT02015663|EXPERIMENTAL|Arm 1|Tobramycin Inhalation Powder (112 mg) once daily during 168 days
62450853|NCT02666274||RK Group|participants colonised with Klebsiella spp. resistant to either 3GC or carbapenems (RK cohort of index carriers of Resistant Klebsiella)
62626772|NCT00889915|ACTIVE_COMPARATOR|3|Participants will receive osmotic-release oral system methylphenidate (OROS MPH).
62088027|NCT02015663|ACTIVE_COMPARATOR|Arm 2|Tobramycin Inhalation Powder (112 mg) twice daily on days 1-28, days 57-84 and days 113-140
62267597|NCT02018731|EXPERIMENTAL|L-Citrulline and Metformin & L-Citrulline|15 g/d L-citrulline for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
62626773|NCT00889915|ACTIVE_COMPARATOR|4|Participants will receive mixed amphetamine salts extended release.
62626774|NCT03426943|EXPERIMENTAL|CVVH using oXiris™ filter|"Patients included in this arm will have renal replacement therapy by performing Continuous Veno-Venous Hemofiltration (CVVH) using oXiris™ membrane.~They will also have arterial blood sampling and ultrafiltrate sampling during the CVVH."
62852456|NCT04788368||Patients treated with ESD|Early rectal cancer treated with the endoscopic treatment ESD - endoscopic submucosal resection
62852457|NCT04788368||Patients treated with EMR|Early rectal cancer treated with the endoscopic treatment EMR - endoscopic mucosal resection
62852458|NCT02567058|EXPERIMENTAL|3 groups of subjects|"3 groups:~* group I : healthy volunters~* group II : patient with an immobilisation (between 1 and 2 months)~* group III : patient with an antecedent of Achilles tendon breakage during the 10 past years~Each group have the same interventions : ultrasound exam, IPAQ questionnaire"
62852459|NCT03032380|EXPERIMENTAL|Cefiderocol|Participants will receive 2 g cefiderocol administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.
62267598|NCT02459795|EXPERIMENTAL|Test product|Ingenol Mebutate (Perrigo)
62267599|NCT02459795|ACTIVE_COMPARATOR|Reference product|Ingenol Mebutate (Reference)
62626775|NCT03426943|ACTIVE_COMPARATOR|CVVH using PrismafleX HF1400 filter|"Patients included in this arm will have renal replacement therapy by performing CVVH using a standard polysulfone filter (PrismafleX HF1400).~They will also have arterial blood sampling and ultrafiltrate sampling during the CVVH."
62267600|NCT02459795|PLACEBO_COMPARATOR|Placebo product|Placebo gel
62450854|NCT02105376|EXPERIMENTAL|Trigeminal Nerve Stimulation (TNS)|"TNS active group~TNS will be applied by the external simulator EMS400. The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 200 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia (approximately 0.5-2mA). The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed on the forehead just above the supraorbital foramen bilaterally."
62626776|NCT01517308|ACTIVE_COMPARATOR|Control Arm 24 weeks|PEG-IFN α2a 180 μg/week+ ribavirin 800 mg/die for 24 weeks
62626777|NCT01517308|EXPERIMENTAL|Active arm (48 weeks)|PEG-IFN α2a 180 μg/week + ribavirin 800 mg/die per 48 weeks
62626778|NCT02085928||Lateral epicondylitis|Patients with lateral epicondylitis with persistent pain for at least 3 months
62626779|NCT06585085|NO_INTERVENTION|A - Free PA practice|The women in group A (control group) will receive the usual care provided for any pregnancy, i.e. personalised information on physical activity and sedentary behaviour, with the provision of information booklets. They will be free to exercise during their pregnancy
62626780|NCT06585085|EXPERIMENTAL|B|In-person supervised PA sessions
62852460|NCT03032380|ACTIVE_COMPARATOR|Meropenem|Participants will receive 2 g meropenem administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.
62852461|NCT04976582|EXPERIMENTAL|interventional group|experimental group in which dry needling with conventional physical therapy treatment modalities including transcutaneous electrical nerve stimulation (TENS); electrical muscle stimulation (EMS); and interferential current (IFC). Physical agents including ultrasound, hot packs, and cold packs. Exercise including McKenzie exercises) will be administered.
62852462|NCT04976582|NO_INTERVENTION|control group|control group in which kinesiotaping with conventional physical therapy treatment (modalities including transcutaneous electrical nerve stimulation (TENS); electrical muscle stimulation (EMS); and interferential current (IFC). Physical agents including ultrasound, hot packs, and cold packs. Exercise including McKenzie exercises) will be administered.
62267601|NCT03927274|EXPERIMENTAL|Cleveland Multiport Catheter (CMC) + Topotecan|For predominantly enhanced tumors with volume of 8 cc or less, only 1 Cleveland Multiport Catheter (CMC) will be placed and convection-enhanced delivery (CED) will be performed over a 4-hour period within an MRI scanner, with the goal of complete tumor coverage (as evidenced by tracer distribution on MRI). The initial rate will be 1.20 ml/hour (5.0 microliters/minute/microcatheter) and infusion will be monitored by intermittent MRI imaging. The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent. Following completion of the 4-hour infusion, the CMC will be removed. The initial rate for each subsequent patient may be adjusted upwards in increments of up to 5 microliters/minute/microcatheter based upon the tumor coverage and safety characteristics of the previously treated patients.
62626781|NCT06585085|EXPERIMENTAL|C|Interactive videoconference PA sessions
62626782|NCT06585085|EXPERIMENTAL|D|In person and by videoconference (mixed format) PA sessions
62626783|NCT03628833|EXPERIMENTAL|Incontinence Management system|
62626784|NCT05018676|EXPERIMENTAL|ARX788|
62852463|NCT04232618||FIND cohort|Evaluation of biomarkers in serum samples from 500 people with suspected TB from non-African countries provided by FIND diagnostic biorepository.
62852464|NCT04232618||Phase 1|Evaluate the basic 3-marker multi-biomarker test (MBT) signature in 150 participants across three African sites. This will be used to lock down the final MBT signature to be used in the next phase of testing.
62852465|NCT04232618||Phase 2|Enrolment of 750 participants across three African sites using the locked down MBT signature from phase 1.
62852466|NCT03216434|EXPERIMENTAL|PTSD Diagnosed|Veterans exposed to combat and diagnosed with PTSD. MRI using DaTscan.
62062908|NCT02428244|EXPERIMENTAL|Standard of care + brief counseling|Patients who are randomized into this arm will receive the standard of care (outlined above). Additionally, patients will also receive a smoking education/counseling session. Patients will receive 10-30 minutes of guided discussion regarding the risks and benefits with regards to smoking and the healing of their traumatic injuries. The smoking educators, who will be trained in accordance with the guidelines provided by MdQuit.org will utilize motivational interviewing techniques to enhance interest in quitting. Patients will receive a description of the quitline, and the quitlined will be the recommended resource. If patients elect to enroll in the quitline, they will be consented using the standardized quitline protocols.
62852467|NCT03216434|EXPERIMENTAL|Designated Combat-Experienced Controls|Veterans exposed to combat, but never diagnosed with PTSD. MRI using DaTscan.
62062909|NCT02428244|EXPERIMENTAL|Standard of care + counseling/follow-up|"Patients who are randomized into this arm will receive the same intervention as patients in Arm 2, except when patients arrive for their follow-up, the smoking educator will check-in with their progress for approximately 5 minutes. The techniques utilized during this check-in visit will include repetition of previously described motivational interviewing, at this point patients who elect to be referred to the quitline will be given this opportunity."
62062910|NCT06264544|EXPERIMENTAL|zinc, selenium, and L-tyrosine supplementation|
62062911|NCT06264544|PLACEBO_COMPARATOR|placebo group|
62267602|NCT06403527|ACTIVE_COMPARATOR|Interventional arm|Ultrasound guided venous access during AF ablation
62267603|NCT06403527|NO_INTERVENTION|Control|Conventional venous puncture guided by palpation
62062912|NCT01726855||dorsal fascial flap|combined with standard modified Kessler technique and vascularized finger dorsal fascial flap pedicled with dorsal cutaneous branch of proper digital artery ,which is transported to finger palmar for placement of a mechanical barrier between flexor digitorum superficialis /profundus tendons.
62062913|NCT01726855||standard modified Kessler technique|
62062914|NCT03812861|EXPERIMENTAL|CAMDS bundle|25 surgical teams will manage 10 standardised simulated deteriorating ward patients with the help of a cognitive aid bundle
62852468|NCT01862692|ACTIVE_COMPARATOR|Developmental Awareness Skils|
62852469|NCT01862692|EXPERIMENTAL|Baby-Net condition|
62852470|NCT03684369|EXPERIMENTAL|Augmented TENS|Transcutaneous electrical nerve stimulation applied to each leg separately while participants perform steady submaximal contractions.
62062915|NCT03812861|NO_INTERVENTION|No bundle|25 surgical teams will manage 10 standardised simulated deteriorating ward patients without the help of a cognitive aid bundle
62062916|NCT00893347|ACTIVE_COMPARATOR|I|Treatment as usual
62062917|NCT00893347|EXPERIMENTAL|II|Treatment as usual + cognitive-behavioural therapy
62267604|NCT03914807|ACTIVE_COMPARATOR|Whole (3.25%) milk|
62267605|NCT03914807|ACTIVE_COMPARATOR|Reduced fat (1%) milk|
62267606|NCT04962022|EXPERIMENTAL|Period 1|PF-07321332/ritonavir orally
62267607|NCT04962022|EXPERIMENTAL|Period 2|Itraconazole + PF-07321332/ritonavir orally.
62267608|NCT00323440||Group 1|FMF patients in remission
62267609|NCT00323440||Group 2|FMF patients during attack
62267610|NCT00323440||Group 3|FMF patients without colchicine in remission
62267611|NCT00323440||Group 4|FMF patients without colchicine in attack
62267612|NCT02243085||photoselective vaporization|
62267613|NCT05458388|ACTIVE_COMPARATOR|Kimura-Takemoto classification|
62267614|NCT05458388|ACTIVE_COMPARATOR|EGGIM|
62267615|NCT04043546|EXPERIMENTAL|Exercise intervention|
62852471|NCT03684369|SHAM_COMPARATOR|Sham|Transient (10 s) application of transcutaneous electrical nerve stimulation applied to each leg separately while participants perform steady submaximal contractions .
62267616|NCT01417715||Crohn´s disease - active|Patients with Crohn´s disease in the active phase.
62852472|NCT00927914|EXPERIMENTAL|Ranirestat 80 mg|Two 80 mg Ranirestat tablets, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
62852473|NCT00927914|EXPERIMENTAL|Ranirestat 40 mg|One 40 mg tablet of Ranirestat and a matching placebo, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
62852474|NCT00927914|PLACEBO_COMPARATOR|Placebo|Two placebo tablets, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
62852475|NCT03666533|ACTIVE_COMPARATOR|Active tDCS|active tDCS plus gait training
62852476|NCT03666533|SHAM_COMPARATOR|Sham tDCS|sham tDCS plus gait training
62852477|NCT04264897|EXPERIMENTAL|Metformin|"The investigators use a ramp up dosing protocol in which the amount of metformin (Hunter Pharmacy) will begin at 500 mg/day in week 1, increase to 1000 mg/day in week 2, and then to 1500 mg/day in week 3, as tolerated. At week 3 and for the remaining 9 weeks, the dose will remain at 1500 mg/day, which is a standard clinical dose (1500-2000 mg/day). If a subject has gastrointestinal discomfort with 1500 mg/day the dose, the investigators will lower the dose to 1000 mg/day. The investigators will split the dose with 1/2 given in the a.m. and 1/2 in the p.m. and taken with meals to minimize GI discomfort."
62852478|NCT04264897|PLACEBO_COMPARATOR|Placebo|"Subjects assigned to the placebo group will receive visually identical pills (silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate).~The same dosing schedule will be followed as for metformin. The investigators use a ramp up dosing protocol in which the amount of placebo (Hunter Pharmacy) will begin at 500 mg/day in week 1, increase to 1000 mg/day in week 2, and then to 1500 mg/day in week 3, as tolerated. At week 3 and for the remaining 9 weeks, the dose will remain at 1500 mg/day. If a subject has gastrointestinal discomfort with 1500 mg/day the dose, the investigators will lower the dose to 1000 mg/day. The investigators will split the dose with 1/2 given in the a.m. and 1/2 in the p.m. and taken with meals to minimize GI discomfort."
62450855|NCT02105376|PLACEBO_COMPARATOR|Sham|"TNS sham~The placebo intervention will consist of an initial stimulation until a mild paresthesia is achieved, and then turn off the machine after 60 seconds, after which period there is a tendency of reduction natural feeling secondary to skin sensitization paresthesia."
62450856|NCT05132413|EXPERIMENTAL|treatment group|
62450857|NCT05132413|PLACEBO_COMPARATOR|Placebo group 1|
62450858|NCT05132413|PLACEBO_COMPARATOR|Placebo group 2|
62450859|NCT00836836|EXPERIMENTAL|1|Modified Atkins diet arm-In this arm, the children will start the modified Atkins diet after a 4-week baseline period, during which daily seizure log will be maintained. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided.
62450860|NCT00836836|NO_INTERVENTION|2|"No Intervention arm- After the 4-week baseline period, this group will receive their normal diet with no dietetic input, and remain on the same on-going antiepileptic medication for the 3 months. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided.~At the end of three months, patients in this arm will be offered the option of the modified Atkins diet treatment.~This group will not receive any dietetic input"
62450861|NCT02975089|NO_INTERVENTION|Control|A leaflet of healthy diet for elderly
62450862|NCT02975089|EXPERIMENTAL|Nutritional Intervention 1|"Multi-nutrient supplement"
62450863|NCT02975089|EXPERIMENTAL|Nutritional Intervention 2|"Multi-nutrient \& soy protein supplement"
62450864|NCT02975089|EXPERIMENTAL|Nutritional Intervention 3|Nutrition education on balanced diet \& food supplement
62450865|NCT03870997|EXPERIMENTAL|Diabetes Digital Intervention|
62450866|NCT03870997|EXPERIMENTAL|Generic Digital Intervention|
62450867|NCT03870997|NO_INTERVENTION|No Influenza Vaccination Intervention|
62267617|NCT01417715||Crohn´s disease - quiescent|Patients with Crohn´s disease in the quiescent phase.
62267618|NCT01417715||Ulcerative colitis - active|Patients with ulcerative colitis in the active stage.
62267619|NCT01417715||Ucerative colitis - quiescent|Patients with ulcerative colitis in the quiescent stage.
62450868|NCT01141725|EXPERIMENTAL|Treatment (combination chemotherapy)|Patients receive bendamustine hydrochloride IV on days 1-5 and idarubicin IV on days 1 and 2. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62450869|NCT04792528|EXPERIMENTAL|One training period|One training period of 30 minutes of daily adaptive training for 4-5 days a week up for 20- 25 trainings using computerized cognitive training.
62450870|NCT04792528|EXPERIMENTAL|Two training periods|Two training periods of 30 minutes of daily adaptive training for 4-5 days a week up for 20- 25 trainings using computerized cognitive training.
62450871|NCT04792528|ACTIVE_COMPARATOR|Active control|The generalized brain training group (Active control) will play solitaire 30 minutes daily for 25 sessions
62852479|NCT02135003|EXPERIMENTAL|Buddy arm, Standard of care arm|"Standard of care: Patients enrolled for pre-ART care received general health education, clinical monitoring, CD4 testing and other clinically indicated investigations, treatment of opportunistic infections, and cotrimoxazole prophylaxis.~Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. buddies attended at least two HIV health education. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments"
62852480|NCT02136888|EXPERIMENTAL|Group A|"Ponesimod will be administered orally, once daily for 22 days starting on Day 2, and will comprise the following multiple-dose up-titration: 3 days of 10 mg (Days 2 to 4), 3 days of 20 mg (Days 5 to 7), 5 days of 40 mg (Days 8 to 12), 3 days of 60 mg (Days 13 to 15), 3 days of 80 mg (Days 16 to 18), and 5 days of 100 mg (19 to 23).~Placebo matched for ponesimod will be given on Day -1. Placebo tablets matched for moxifloxacin will be administered on Days 1 and 24."
62852481|NCT02136888|EXPERIMENTAL|Group B|Placebo matched for ponesimod will be administered orally, once daily on Day -1 and on Day 2 through Day 23. In half of Group B subjects, 400 mg moxifloxacin will be administered orally on Day 1 and a matching placebo tablet on Day 24. In the other half of Group B subjects, a matching placebo tablet will be administered on Day 1 and 400 mg moxifloxacin on Day 24.
62267620|NCT05680909||SaCo VLM evaluation|"Prospective group of morbidly obese patients scheduled for elective bariatric procedure with the use of SaCo VLM for airway management.~The following features related to SoCo VLM use will be recorded: insertion of SaCo VLM, evaluation of ventilation parameters, attempt of endotracheal intubation via SaCo VLM's lumen under continuouis visualisation of entrance to larynx using videoscope intergatred system"
62267621|NCT04575558|EXPERIMENTAL|Hydroxychloroquine + Azithromycin|Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD, both for 7 days
62852482|NCT04012164|EXPERIMENTAL|Microbiological, anthropological and historical study|"30 adult participants will be recruited to self-report daily activities and contacts with domesticated and wild animals for a five month period. Following the five months of data collection, we will collect 5ml blood and 2g stool from each participant.~From the fifth month of investigation, an additional 30 adult participants will participate in oral anthropological, historical interviews to develop the socio-historical context of their changing activities and relations with selected domesticated and wild animals. No other intervention will be performed."
62852483|NCT05549921|EXPERIMENTAL|NY-ESO-1 TCR Specific T cell Therapy|This research is divided into two stages, Stage 1 and Stage 2, respectively. In Stage 1, 14 patients with advanced soft tissue sarcoma with positive expression of tumor antigen NY-ESO-1 and HLA-A\*02:01 genotype were enrolled. A further 42 patients will be enrolled in Stage 2, where the primary efficacy analysis will be performed at 3 months after the completion of cell reinfusion in the last subject, with a target ORR of 25%.
62852484|NCT03528499|EXPERIMENTAL|Scapular Movement Training|Orientation and scapular exercises, performed twice a week, for 8 weeks.
62852485|NCT03528499|ACTIVE_COMPARATOR|General Exercises|Scapulothoracic muscle stretching and strengthening exercises, performed twice a week, for 8 weeks.
62852486|NCT00548652|NO_INTERVENTION|1|standard nutrition counselling
62852487|NCT00548652|EXPERIMENTAL|2|MOVE -weight loss intervention
62852488|NCT00548652|EXPERIMENTAL|3|MOVE plus medical crisis counselling
62852489|NCT00548652|EXPERIMENTAL|4|MOVE plus methylphenidate
62852490|NCT00548652|EXPERIMENTAL|5|MOVE plus methyphenidate plus medical crisis counselling
62852491|NCT02937402|EXPERIMENTAL|Bronchoscopy with bronchoalveolar lavage|Patients undergo bronchoscopy with bronchoalveolar lavage over 45 minutes
62267622|NCT04575558|PLACEBO_COMPARATOR|Hydroxychloroquine + Placebo tablets|Hydroxychloroquine 400mg PO BID 2 times a day + Placebo, both for 7 days
62267623|NCT05194085|NO_INTERVENTION|Female SOC/Male SOC arm|Women will be provided the standard of care invitation letter for male partners for fast-track visit for HIV testing and laboratory HIV testing at enrollment and every 6 months until 6 months postpartum
62267624|NCT05194085|ACTIVE_COMPARATOR|Female intervention/Male SOC arm|Women will be provided the standard of care invitation letter for male partners for fast-track visit for HIV testing and POC VL tests for women at enrollment, delivery, and 6 months post-partum
62450872|NCT02672553|ACTIVE_COMPARATOR|EDWARDS INTUITY|EDWARDS INTUITY Valve System, Model 8300A
62450873|NCT02672553|ACTIVE_COMPARATOR|Stented Aortic Bioprostheses|Stented Aortic Bioprostheses
62450874|NCT04217278|ACTIVE_COMPARATOR|R1: Intermediate dose Cytarabine|First Randomisation (closed to recruitment) - control arm: Intermediate dose Cytarabine (1g/m\^2 administered by intravenous infusion over 2 hours on days 1-5 inclusive)
62450875|NCT04217278|EXPERIMENTAL|R1: Vyxeos|First Randomisation (closed to recruitment) - experimental arm: Vyxeos (29mg/65mg/m\^2 administered by intravenous infusion over 90 minutes on days 1 and 3)
62450876|NCT04217278|ACTIVE_COMPARATOR|R2: FB4|Second Randomisation - under 55 years - control arm: Fludarabine (40mg/m\^2 days -7, -6, -5, and -4), Busulphan (3.2mg/kg days -7, -6, -5 and -4)
62450877|NCT04217278|EXPERIMENTAL|R2: TBF|Second Randomisation - under 55 years - experimental arm: Thiotepa (5mg/kg day -7 and -6), Busulphan (3.2mg/kg days -5, -4 and -3), Fludarabine (50mg/m\^2 days -5, -4 and -3)
62626785|NCT00996034|EXPERIMENTAL|Healthy Smoker|There is only one arm to the study. All subjects will receive NicVax, \[123I\]5-I-A-85380,and Nicotine bitartrate.
62626786|NCT05586542|ACTIVE_COMPARATOR|Standard of Care (SOC)|"1. Wash and sharps debride the target diabetic foot ulcer to remove all non-viable tissue, callus, epibole at wound edges, slough, and debris (at the physician's discretion). The wound margins should be excised to healthy bleeding tissue.~2. Wash the wound once more with saline to remove remaining debris and confirm hemostasis is achieved, as needed.~3. Measure wound after debridement.~4. Place soft silicone contact layer dressing to cover over the wound, secured with adhesive strips.~5. Cover the contact layer with a hydroconductive wound dressing secured with kerlix gauze and adhesive tape.~6. Apply the Foot Defender® boot."
62450878|NCT04217278|ACTIVE_COMPARATOR|R3: FB2|Third Randomisation - 55 years and over (or under 55 with comorbidities) - control arm: Fludarabine (30mg/m\^2 days -6, -5, -4, -3 and -2), Busulphan (3.2mg/kg days -6 and -5)
62626787|NCT05586542|EXPERIMENTAL|Plasma Film|"1. Wash and sharps debride the target diabetic foot ulcer to remove all non-viable tissue, callus, epibole at wound edges, slough, and debris (at the physician's discretion). The wound margins should be excised to healthy bleeding tissue.~2. Wash the wound once more with saline to remove remaining debris and confirm hemostasis is achieved, as needed.~3. Measure wound after debridement.~4. Place an appropriately sized piece of Plasma Film onto the wound bed. The test agent should be cut to fit the interior of the wound with minimal overlap onto healthy skin.~5. Place soft silicone contact layer dressing to cover over the wound, secured with adhesive strips.~6. Cover the contact layer with a hydroconductive wound dressing secured with kerlix gauze and adhesive tape.~7. Apply the Foot Defender® boot."
62852492|NCT04398095|EXPERIMENTAL|Radiotherapy with hyperthermia in resectable sarcomas|12x 3 Gy (4 fractions per week) + hyperthermia (6x) + surgery
62062918|NCT01555801|EXPERIMENTAL|Submucosal injection combining with EUS|The enrolled patients will be accepted submucosal injection of saline,then ultrasonography will performed(EUS+SIS group).So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) or endoscopic submucosal dissection(ESD) or esophagectomy.
62267625|NCT05194085|ACTIVE_COMPARATOR|Female SOC/Male intervention arm|Women will be provided an invitation letter for male partners for wellness visits and laboratory-based HIV VL testing for women at enrollment, delivery, and 6 months post-partum
62267626|NCT05194085|ACTIVE_COMPARATOR|Female intervention/male intervention arm|Women will be provided an invitation letter for male partners for wellness visits and POC viral load testing for women at enrollment, delivery, and 6 months post-partum
62450879|NCT04217278|EXPERIMENTAL|Mini-TBF|Third Randomisation - 55 years and over (or under 55 with comorbidities) - experimental arm: Thiotepa (5mg/kg day -6), Busulphan (3.2mg/kg days -5 and -4), Fludarabine (50mg/m\^2 days -5, -4, and -3)
62450880|NCT00940056|EXPERIMENTAL|Endoscopic ablation of atrial fibrillation|
62852493|NCT04398095|EXPERIMENTAL|Radiotherapy with hyperthermia in non-resectable sarcomas|12x 3 Gy with simultaneous integrated boost 3.5 Gy (4 fractions per week) + hyperthermia (6x)
62062919|NCT01555801|PLACEBO_COMPARATOR|ordinary endosonography(EUS)|The enrolled patients will accept ordinary ultrasonography .So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) , endoscopic submucosal dissection(ESD) or esophagectomy.
62450881|NCT00940056|ACTIVE_COMPARATOR|Rate control|
62852494|NCT01886599|EXPERIMENTAL|Arm A: Subjects with normal renal function|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
62852495|NCT01886599|EXPERIMENTAL|Arm B: Subjects with end stage renal disease|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
62852496|NCT01886599|EXPERIMENTAL|Arm C: Subjects with mild renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
62062920|NCT03227016|EXPERIMENTAL|Combination Topo/Veli|Topotecan and Veliparib in increasing doses
62267627|NCT00725400|ACTIVE_COMPARATOR|1|Patients will receive a Cetuximab and Radiation Therapy.
62267628|NCT00725400|ACTIVE_COMPARATOR|2|Patients will undergo Surgery before or after Radiation Therapy.
62450882|NCT01349556|EXPERIMENTAL|Tretinoin pre-treatment|
62450883|NCT05611749|PLACEBO_COMPARATOR|control group receiving a placebo|The study medication (either placebo or Duloxetine) will be continued throughout the duration of hospitalization. The balance of the remaining pills will be provided to the patient as a discharge prescription to allow for 10 days total treatment.
62450884|NCT05611749|EXPERIMENTAL|treatment group receiving 60 mg Duloxetine|The study medication (either placebo or Duloxetine) will be continued throughout the duration of hospitalization. The balance of the remaining pills will be provided to the patient as a discharge prescription to allow for 10 days total treatment.
62450885|NCT05654909||PAU group|The PAU group were patients calling 1-1-2 assigned for the prehospital assessment unit,
62852497|NCT01886599|EXPERIMENTAL|Arm D: Subjects with moderate renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
62267629|NCT04683250|EXPERIMENTAL|TAS0953/HM06 Phase 1|Dose escalation and dose expansion until recommended Phase 2 dose determined
62267630|NCT04683250|EXPERIMENTAL|TAS0953/HM06 Phase 2|Treatment phase at recommended Phase 2 dose in three different populations
62267631|NCT01609907|EXPERIMENTAL|Sequence 1|
62267632|NCT01609907|EXPERIMENTAL|Sequence 2|
62267633|NCT01609907|EXPERIMENTAL|Sequence 3|
62852498|NCT01886599|EXPERIMENTAL|Arm E: Subjects with severe renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
62852499|NCT01368562|EXPERIMENTAL|Methylnaltrexone|Participants will receive single dose of MNTX 0.15 milligrams per kilogram (mg/kg) subcutaneously (SC). Subsequent dosing could be adjusted upward (to a maximum of 0.3 mg/kg) to achieve a desired clinical response or decreased to improve tolerability.
62450886|NCT05654909||non PAU group|The non PAU group were selected from the 1-1-2 calls (the European version of 9-1-1) EMS and were collected based on the same criteria as the patients assessed by the PAU. The control ratio was 1:10 for cases to increase power. Controls were matched on sex and age (within 5-year ranges). Matching was performed using incidence density sampling, where controls were selected for each case on the week of 1-1-2 call.
62450887|NCT06322927||Patient Interviews|Participants will be asked to take part in a 30-60 minute interview to understand their treatment preferences. Members of the research team will conduct this either in the clinic or over the phone, as per patient preference.
62450888|NCT02665897||Eclampsia|pregnant women with eclampsia will be diagnosed by the occurrence of seizures on top of preeclampsia.
62450889|NCT02665897||severe preeclampsia|pregnant women with severe preeclampsia will be diagnosed according to blood pressure ≥160/110 mmHg with proteinuria detection by boiling method +3,+4.
62450890|NCT02665897||healthy|matched normotensive pregnant women.
62450891|NCT02337465|EXPERIMENTAL|Diagnostic (KV-CBCT, ultrasound-guided radiation therapy)|Patients undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Patients also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.
62450892|NCT02946099|EXPERIMENTAL|Reciproc file|Reciproc files in reciprocating motion
62267634|NCT01609907|EXPERIMENTAL|Sequence 4|
62450893|NCT02946099|ACTIVE_COMPARATOR|ProTaper Next file|ProTaper Next files in continuous rotary motion
62450894|NCT03565549|EXPERIMENTAL|Mnemonic|Intervention group will receive a mnemonic aid to remember the CCHR
62450895|NCT03565549|ACTIVE_COMPARATOR|CCHR rule|The control group will receive the CCHR only
62450896|NCT04068142|NO_INTERVENTION|Clinical Personnel Safety Planning|Patients will complete a traditional written suicide safety plan with clinical personnel.
62450897|NCT04068142|EXPERIMENTAL|Peer Supporter Safety Planning|Patients will complete a traditional written suicide safety plan with peer supporters.
62450898|NCT01493765||Benchmarking|All resident study subjects will drill virtual temporal bones within the computer based system. The performance data will be used to validate the rating metrics and computer scoring process.
62852500|NCT03860818|NO_INTERVENTION|Control Arm|Usual Care
62450899|NCT00133770|EXPERIMENTAL|IV pantoprazole|The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
62450900|NCT01161251||Atrial fibrillation patients|Non-valvular atrial fibrillation (paroxysmal, persistent or permanent)
62852501|NCT03860818|EXPERIMENTAL|Intervention Arm|Technology-enabled pharmacist intervention
62267635|NCT01609907|EXPERIMENTAL|Sequence 5|
62267636|NCT01609907|EXPERIMENTAL|Sequence 6|
62267637|NCT05779462||patients with pelvic endometriosis|Patients referred for suspected pelvic endometriosis, with pelvic endometriosis on initial MRI
62267638|NCT05779462||patients without pelvic endometriosis|Patients referred for suspected pelvic endometriosis but without endometriosis found on diagnostic MRI.
62267639|NCT03269708|NO_INTERVENTION|Control|Participants receive standard care in cardiac rehabilitation program
62267640|NCT03269708|EXPERIMENTAL|Knowledge transfer group|Participants receive standard care in cardiac rehabilitation program plus education regarding telomere length
62267641|NCT05715970|EXPERIMENTAL|General population|25,000 subjects, divided between Sicily and Malta. Approximately 10,000 students aged between 12 and 18 will be enrolled in Malta and approximately 15,000 adults (\>18 years) will be enrolled in Sicily. These numbers are dictated by the need to obtain heterogeneous samples comparable with the subjects diagnosed in the previous ITAMA project (20,000). In Sicily, screening will be carried out in the GPs (Italian takers) clinics. In Malta the recruitment will be performed in the schools (Maltese takers). Furthermore, in Malta, a further extension of the results provides for the execution of the PoCT+questionnaire in the asymptomatic first-degree relatives of the pediatric subjects with an ascertained diagnosis of CD identified in the previous project.
62267642|NCT00736346|ACTIVE_COMPARATOR|1|
62267643|NCT00736346|ACTIVE_COMPARATOR|2|
62267644|NCT00736346|ACTIVE_COMPARATOR|3|
62267645|NCT00736346|NO_INTERVENTION|4|
62267646|NCT01859442|ACTIVE_COMPARATOR|Exercise group|6 week structured responsive interval exercise training programme
62267647|NCT01859442|SHAM_COMPARATOR|Control group|Negative, unsupervised, out of hospital control group
62267648|NCT03167996|EXPERIMENTAL|Group B/ HealthPals|"Group B have access to HealthPals app where they will coordinate with a trained health coach Group B patients will only come into SSATHI clinic to see their doctor for an initial visit and 6 month follow up, and they will have a telephone visit with their doctor at 3 months instead of an in-clinic visit~Lab testing is the same for both Group A/ control and Group B patients"
62450901|NCT03532009|EXPERIMENTAL|Sodium Zirconium Cyclosilicate (ZS)|Powder for oral suspension
62450902|NCT03532009|PLACEBO_COMPARATOR|Placebo|Powder for oral suspension
62852502|NCT01049542|EXPERIMENTAL|Astressin 2B|Healthy volunteers will receive incremental doses of intra arterial Astressin 2B (a selective and potent Urocortin 2 \& 3 antagonist). This serves as a dose finding Protocol for Astressin 2B, which will be used in subsequent protocols.
62852503|NCT05561205|EXPERIMENTAL|rTMS + methylphenidate|repetitive transcranial magnetic stimulation (rTMS) and methylphenidate
62852504|NCT05561205|EXPERIMENTAL|rTMS only|repetitive transcranial magnetic stimulation (rTMS) only
62062921|NCT06309238|EXPERIMENTAL|Intensive weight loss intervention|The intensive weight loss intervention (IWL) includes total dietary replacements, behavioural support, and weight loss medication. The intervention consists of three phases: induction, weight loss continuation, maintenance, and it will lasts two years in total.
62062922|NCT06309238|ACTIVE_COMPARATOR|Bariatric surgery|Bariatric surgery: Roux-en-Y Gastric Bypass (RYGB) or Sleeve Gastrectomy (SG)
62626788|NCT05586542|EXPERIMENTAL|DERMASEAL|"1. Wash and sharps debride the target diabetic foot ulcer to remove all non-viable tissue, callus, epibole at wound edges, slough, and debris (at the physician's discretion). The wound margins should be excised to healthy bleeding tissue.~2. Wash the wound once more with saline to remove remaining debris and confirm hemostasis is achieved, as needed.~3. Measure wound after debridement.~4. Place an appropriately sized piece of DERMASEAL onto the wound bed. The test agent should be cut to fit the interior of the wound with minimal overlap onto healthy skin.~5. Place soft silicone contact layer dressing to cover over the wound, secured with adhesive strips.~6. Cover the contact layer with a hydroconductive wound dressing secured with kerlix gauze and adhesive tape.~7. Apply the Foot Defender® boot."
62626789|NCT02799277|EXPERIMENTAL|Testosterone|14mg testosterone will be administered intranasally in a 1milliliter aqueous solution
62626790|NCT02799277|PLACEBO_COMPARATOR|Placebo|1ml blank (containing no drug) aqueous solution will be administered intranasally
62852505|NCT05094310|EXPERIMENTAL|Acupuncture group|Patients with breast cancer who experienced fatigue were measured by the Brief Fatigue Inventory(BFI) scale and other Fatigue related questionnaire. Breast cancer patients diagnosed with cancer related fatigue are included in our clinical study，and those patients will receive acupuncture treatment. The position of acupuncture refers to the principle of acupuncture treatment of traditional Chinese medicine. According to ICD-10-CD code R53.0, the diagnosis of CRF is determined by the experience of diminished energy or other physical and psychological symptoms every day or almost every day for two consecutive weeks in the past month. We collected patients' blood to detect fatigue related SNP.
62852506|NCT01947413|EXPERIMENTAL|iTBS group|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
62852507|NCT01947413|EXPERIMENTAL|cTBS group|In continuous theta burst stimulation (cTBS group), they received cTBS (80% of active motor threshold) on unaffected hemisphere.
62852508|NCT01947413|SHAM_COMPARATOR|sham TBS group|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
62852509|NCT06149247|EXPERIMENTAL|HyBryte (0.25 % hypericin)|HyBryte (0.25 % hypericin) ointment will be applied to CTCL lesions and treated with visible light 18-24 hours later starting at 6 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 12 weeks.
62852510|NCT06149247|ACTIVE_COMPARATOR|Valchlor (mechlorethamine)|Valchlor (0.016% mechlorethamine) gel will be applied to CTCL lesions once daily for 12 weeks.
62852511|NCT00718653|EXPERIMENTAL|1|lutein
62852512|NCT00718653|EXPERIMENTAL|2|Lutein plus green tea extract
62062923|NCT00621816|ACTIVE_COMPARATOR|1|Blinded nitroprusside infusion
62062924|NCT00621816|PLACEBO_COMPARATOR|2|Blinded placebo infusion
62062925|NCT05925634|ACTIVE_COMPARATOR|RPE (usual care)|Participants randomized to usual care (RPE) will not complete a GXT. They will instead be scheduled for an approximately 5-minute educational session (i.e., time/attention-matched control condition) where they will receive information about heart-healthy nutrition. This is standard care at both sites. Patients in the control group will follow standard exercise prescription protocols in CR. This will include a baseline exercise assessment on exercise equipment in the gym (e.g., treadmill, elliptical, rower, NuStep, and/or stationary bicycle) as appropriate. Based on exercise levels achieved on the first day, patients will be given exercise recommendations for their 2nd session of CR and so forth. Participants will be asked to exercise at a moderate intensity RPE level at both sites. As the patients progress in CR, patients will increase their time, intensity, and mode of exercise guided by RPE and clinical assessment.
62267649|NCT03167996|NO_INTERVENTION|Group A/ Control|"Group B will not have access to HealthPals app~Group A patients will come into SSATHI clinic to see their doctor for an initial visit, a 3 month follow up, and a 6 month follow up~Lab testing is the same for both Group A/ control and Group B patients"
62267650|NCT01926288|OTHER|HBeAg positive group|"Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks ."
62450903|NCT04924309||Patients undergoing assisted reproductive technology with donor sperm|
62450904|NCT04924309||Patients undergoing assisted reproductive technology with husband's semen due to male factor|
62626791|NCT01563731|OTHER|SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l|Highest SBP target. Higher LDL-C target. Control arm
62626792|NCT01563731|ACTIVE_COMPARATOR|SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l|"Intermediate SBP target. Higher LDL-C target~."
62626793|NCT01563731|ACTIVE_COMPARATOR|SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l|Lowest SBP target. Higher LDL-C target
62626794|NCT01563731|ACTIVE_COMPARATOR|SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l|Highest SBP target. Lower LDL-C target.
62626795|NCT01563731|ACTIVE_COMPARATOR|SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l|Intermediate SBP target. Lower LDL-C target.
62626796|NCT01563731|ACTIVE_COMPARATOR|SBP < 125 mmHg and LDL-C < 1.8 mmol/l|Lowest SBP target. Lower LDL-C target.
62626797|NCT00227019|EXPERIMENTAL|bevacizumab+ pemetrexed|pemetrexed (500 mg/m² IV) + bevacizumab (15 mg/kg IV). In addition to Vitamin B12 + Folate + Dexamethasone
62626798|NCT05576792||ranibizumab 0.2 mg|Intravitreal ranibizumab 0.2 mg for the treatment of ROP
62626799|NCT05164198|EXPERIMENTAL|Open-label reduced-dose TNFi|"Participants in the experimental arm will receive one of the intervention below according to the TNFi agent used at baseline:~1. Adalimumab 40mg subcutaneous every 3 weeks (Q3W) from week 0 to week 48.~2. Etanercept 50mg subcutaneous every 10 days (Q10D) from week 0 to week 48.~3. Golimumab 50mg (100mg if a participant's body weight ≥ 100kg) subcutaneous every 5 weeks (Q5W) from week 0 to week 48.~4. Remsima SC 120mg subcutaneous every 3 weeks (Q3W) from week 0 to week 48."
62626800|NCT05164198|ACTIVE_COMPARATOR|Open-label full-dose TNFi|"Participants in the comparator arm will receive one of the intervention below according to the TNFi agent used at baseline:~1. Adalimumab 40mg subcutaneous every 2 weeks (Q2W) from week 0 to week 48.~2. Etanercept 50mg subcutaneous every week (QW) from week 0 to week 48.~3. Golimumab 50mg (100mg if a participant's body weight ≥ 100kg) subcutaneous every 4 weeks (Q4W) from week 0 to week 48.~4. Remsima SC 120mg subcutaneous every 2 weeks (Q2W) from week 0 to week 48."
62626801|NCT04303416|EXPERIMENTAL|Patients|Patients before and after the treatment
62626802|NCT03413163|SHAM_COMPARATOR|control|"Peroperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.~Intervention: Other: Standard Pain Followup and Monitorization"
62626803|NCT03413163|EXPERIMENTAL|ESP block|"In addition to routine analgesic protocol; before anaesthesia induction; bilateral ultrasound guided erector spinae plane block (ESP) (intervention) will be performed via USG guidance at Th9 level.Standard Pain Followup and Monitorization will be performed.~Interventions:~Procedure: Ultrasound guided erector spinae plane block Other: Standard Pain Followup and Monitorization"
62852513|NCT01042041|EXPERIMENTAL|Arm I|Patients receive oral sorafenib tosylate twice daily. Beginning 2 weeks later, patients undergo chemoembolization with cisplatin, doxorubicin hydrochloride, and mitomycin C. Chemoembolization repeats once a month for up to 4 procedures in the absence of disease progression or unacceptable toxicity.
62626804|NCT03602196|EXPERIMENTAL|pregnant women|"pregnant women with one visit per trimester of pregnancy (14-18 weeks, 24-28 weeks and 34-38 weeks)~For the ancillary study: non-pregnant nulliparous women"
62852514|NCT03728283|ACTIVE_COMPARATOR|Conventional Implant placement|conventional implant placement following the manufacturer's instructions
62062926|NCT05925634|EXPERIMENTAL|GXT+ THHR (intervention)|Patients assigned to the intervention group will complete a GXT approximately one week later and ideally prior to the 4th cardiac rehabilitation session. Resting and peak heart rate from the GXT will be recorded and used to calculate a target heart rate range (THRR) using the Karvonen formula (60-85% Heart rate reserve). After the test, they will receive psychoeducational feedback (PF) about their test results and exercise performance. After the PF, we will discuss the THRR and how it will be used to guide exercise intensity in CR. Patients in the intervention group will use their THHR to adjust their exercise intensity. For the first 6 cardiac rehabilitation sessions, patients will receive feedback about heart rate from the PolarHR monitor, research staff and CR staff when available. The goal is for patients to exercise in THRR for the majority of each exercise session.
62062927|NCT01862952|ACTIVE_COMPARATOR|antiepileptic treatment as used in daily clinical practice|Antiepileptic treatment as used in daily clinical practice.
62062928|NCT01862952|NO_INTERVENTION|No medication|
62852515|NCT03728283|EXPERIMENTAL|Implant and Connective tissue grafting|implant placement in combination with connective tissue grafting
62062929|NCT01857622|EXPERIMENTAL|SRI 15mg|DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks.
62062930|NCT01857622|EXPERIMENTAL|Normal/MiRI low-dose group|DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors (body weight of ≤ 60 kg or the presence of concurrent treatment with quinidine or verapamil). DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors.
62062931|NCT01857622|EXPERIMENTAL|Normal/MiRI high-dose group|DU-176b was orally administered at a dose of 60 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors. DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors.
62062932|NCT04785664|EXPERIMENTAL|LLE- Long Live the Elderly!|"The group has been randomized among the Long Live the Elderly! (LLE) clients in two cities: Rome and Naples. The LLE central database includes all the participants to the program in Naples and Rome who have been administered the Functional Geriatric Evaluation (FGE) questionnaire."
62267651|NCT01926288|OTHER|HBeAg-negative group|"Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks ."
62852516|NCT05481476|EXPERIMENTAL|surufatinib combined with sintilimab and AG|
62267652|NCT05087550||Liver Transplantation patients|
62267653|NCT04261673|EXPERIMENTAL|Decompressive Craniectomy|After the evacuation of epidural hematoma, the bone flap should not be replaced at the end of the operation.
62267654|NCT04261673|EXPERIMENTAL|Craniotomy|After the evacuation of epidural hematoma, the bone flap must be replaced and fixed with an appropriate fixation system.
62852517|NCT01368224|PLACEBO_COMPARATOR|Maltodextrin|
62852518|NCT01368224|EXPERIMENTAL|Lactobacillus paracasei NCC 2461 (ST 11)|1x1010 CFU of Lactobacillus paracasei NCC 2461 (ST 11)
62852519|NCT01368224|EXPERIMENTAL|Lactobacillus paracasei+ Bifidobacterium longum|1x1010 CFU of Lactobacillus paracasei NCC 2461 (ST 11) + 1x1010 CFU of Bifidobacterium longum (NCC3001)
62852520|NCT06047119|EXPERIMENTAL|Mean arterial blood pressure above 60 mmHg during general anesthesia and 2 hours after|
62852521|NCT06047119|EXPERIMENTAL|Mean arterial blood pressure above 70 mmHg during general anesthesia and 2 hours after|
62852522|NCT06047119|EXPERIMENTAL|Mean arterial blood pressure above 80 mmHg during general anesthesia and 2 hours after|
62852523|NCT06047119|EXPERIMENTAL|Systolic blood pressure above 90% of baseline during general anesthesia and 2 hours after|
62626805|NCT03405168|EXPERIMENTAL|routine therapy plus moxifloxacin|Routine therapy (chemotherapy, endocrine therapy or target therapy) is according to physician's choice.
62852524|NCT06047119|EXPERIMENTAL|Positive end expiratory pressure 5 cm H20 during general anesthesia|
62852525|NCT06047119|EXPERIMENTAL|Positive end expiratory pressure 8 cm H20 during general anesthesia|
62852526|NCT06047119|EXPERIMENTAL|Positive end expiratory pressure 10 cm H20 during general anesthesia|
62852527|NCT06047119|EXPERIMENTAL|Tidal volume 5 ml/kg during general anesthesia|
62852528|NCT06047119|EXPERIMENTAL|Tidal volume 8 ml/kg during general anesthesia|
62267655|NCT02844556|OTHER|SMILE surgery|Small incision lenticule extraction (SMILE) has become a novel and effective method for the correction of myopia and myopic astigmatism. It is a micro-invasive and flapless refractive procedure that has been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
62852529|NCT06047119|EXPERIMENTAL|Tidal volume 10 ml/kg during general anesthesia|
62852530|NCT06047119|EXPERIMENTAL|Fraction of inspired oxygen 30% during general anesthesia and 2 hours after|
62852531|NCT06047119|EXPERIMENTAL|Fraction of inspired oxygen 80% during general anesthesia and 2 hours after|
62450905|NCT01173809|ACTIVE_COMPARATOR|Control|Patient will continue taking Amiodarone before, during and after catheter ablation (8 weeks post-ablation).
62626806|NCT05720429|EXPERIMENTAL|Primary care workers|"Primary care health personnel who will voluntarily join the psychoeducational program of their center.~All professional profiles working in primary care centers are eligible (ie primary care nurses, physiotherapists, family doctors, pediatricians, dentists, administrative staff, etc.). Groups of 10-15 people. Several groups can be established in the same center if the demand is high enough."
62852532|NCT02903459||Males|Evaluation of body mass index, determination of waist-to-hip ration and waist-to-height ration, using perimetry; evaluation of 7 skinfold according to the model 7-site-skinfold Equation, by Jackson and Pollock, and photogrammetry (to evaluate the lumbar lordosis degree) in males aged between 18 and 26.
62852533|NCT02903459||Young Adults|Evaluation of abdominal thickness, percentage of abdominal fat and photogrammetry (to evaluate the lumbar lordosis degree) in young adults females aged between 18-26.
62852534|NCT02903459||Adults|Evaluation of abdominal thickness, percentage of abdominal fat and photogrammetry (to evaluate the lumbar lordosis degree) in adult females aged between 40-60.
62852535|NCT02903459||Females|Evaluation of body mass index, determination of waist-to-hip ration and waist-to-height ration using perimetry, evaluation of 7 skinfold according to the model 7-site-skinfold Equation, by Jackson and Pollock, and photogrammetry (to evaluate the lumbar lordosis degree) in females aged between 18 and 26.
62852536|NCT03301116|EXPERIMENTAL|Healthy Moves|Home care aides (HCAs) will be trained to deliver Healthy Moves for Aging Well (Healthy Moves), a gentle physical activity program, to their clients. On the first home care visit after the training, HCAs will introduce the program, assess their clients' readiness for the activity and have their clients set personally meaningful goals, and teach the three chair-bound moves. Home care clients will be asked to do the three moves every day. HCAs remind clients of their activity as part of their regular home care visits throughout the 4-month intervention period.
62267656|NCT02844556|OTHER|FS-LASIK surgery|FS-LASIK surgery is femtosecond laser assisted- conventional refractive surgery and has also been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
62852537|NCT03301116|ACTIVE_COMPARATOR|Active Mind|Home care aides (HCAs) will be trained to deliver Active Mind for Aging Well (Active Mind), a gentle thinking activity program, to their clients. On the first home care visit after the training, HCAs will introduce the program, assess their clients' readiness for the activity and have their clients set personally meaningful goals, and teach the activity. Home care clients will be asked to do a word search puzzle every day. HCAs remind clients of their activity as part of their regular home care visits throughout the 4-month intervention period.
62852538|NCT02019485|EXPERIMENTAL|Treatment Sequence AB|Participants will receive single dose of new tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF) tablet and later, participants will receive single dose of current tapentadol prolonged-release formulation 2 (PR2) tablet without food. Administration of the study medications will be separated by a washout period (no treatment) of 7 to 14 days.
62267657|NCT01779973|EXPERIMENTAL|Remote Observed Dosing|Compliance with dosage observations of suboxone doses using remote observed dosing 4 days per week and 1 weekly in-office visit.
62267658|NCT03770585|ACTIVE_COMPARATOR|Group 1(Fluoroscopy guided group)|IN Fluoroscopy guided group, with x-ray beam, after cleaning and drapping and administration of local anesthesia, a22-g spinal needle is inserted in line till bony contact is felt under sterile conditions. Each facet joint is infiltrated with a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml (20mg) methylprednisolone acetate injected into the joint.
62450906|NCT01173809|ACTIVE_COMPARATOR|Study|Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
62450907|NCT03065309|EXPERIMENTAL|Single Arm|Patients will receive bolus dose of remifentanil before intubation
62450908|NCT01000753||Observational (specimen collection)|See Detailed Description
62450909|NCT05431868||the short AL group|Eyes with AL less than 22.50 mm were devided into the short AL group.
62450910|NCT05431868||the control group|Eyes with AL between 22.50 to 25.50 mm were devided into the control group.
62450911|NCT05431868||the long AL group|Eyes with AL more than 25.50 mm were devided into the long AL group.
62450912|NCT00450307|EXPERIMENTAL|3F8 and GM-CSF|One cycle has 5 days of 3F8 treatment. Each day, patients receive GM-CSF subcutaneously \~1.5 hr before the start 3F8 infusion. To limit side-effects, patients receive analgesics, antihistamines, and a small dose (IV, over \~5 minutes) of heat-modified 3F8. Cycles can be repeated after a 2-4 week interval, up to a total of two cycles.
62267659|NCT03770585|ACTIVE_COMPARATOR|Group2 (Ultrasound guided group)|In Ultrasound guided group, with Ultrasound guidance, , a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml(20mg) methylprednisolone acetate is administered intra-articular (until resistance was encountered) and injected around the posterior facet joint capsule.
62267660|NCT05512546||Aspirin Group|patients were prescribed 75 mg/day of either aspirin for 6 months
62267661|NCT05512546||Clopidogrel Group|75mg/day prescribed for 6 months
62267662|NCT03008356|EXPERIMENTAL|L-carnitine|Oral L-carnitine 1000mg twice daily
62267663|NCT03008356|EXPERIMENTAL|L-carnitine + health coaching|Oral L-carnitine 1000mg twice daily and weekly 10-15 minute health coaching calls
62267664|NCT03008356|PLACEBO_COMPARATOR|Placebo|Placebo capsules twice daily
62267665|NCT05231382|EXPERIMENTAL|Experimental group SALOX regimen|The therapeutic scheme was SLAOX regimens including oxaliplatin (130 mg/m2 infusion for 3 hours on day 1), Raltitrexed (2mg/m2 infusion for 30-60 minutes on day 1)
62267666|NCT05231382|ACTIVE_COMPARATOR|Control group FOLFOX regimen|The therapeutic scheme was modified FOLFOX6 regimens including oxaliplatin (130 mg/m2 infusion for 3 hours on day 1), leucovorin (200 mg/m2 from hour 3 to 5 on day 1) and Fluorouracil (400 mg/m2 in bolus, and then 2,400 mg/m2 continuous infusion 46 hours).
62267667|NCT03964961|EXPERIMENTAL|Functional massage|
62626807|NCT03536663|OTHER|Optiflux/Endexo|Optiflux (Active Comparator); Hemodialysis treatments on the Optiflux dialyzer (Optiflux Period) for 4 weeks - Visit 1 to 12 Endexo (Experimental); Subjects continue on Dialyzer with Endexo (Endexo Period) for 13 weeks - Visit 13 to visit 50
62852539|NCT02019485|EXPERIMENTAL|Treatment Sequence BA|Participants will receive single dose of current tapentadol PR2 tablet and later, participants will receive single dose of new tapentadol ER TRF tablet without food. Administration of the study medication will be separated by a washout period of 7 to 14 days.
62852540|NCT03663660||before the OIPP|Period 1 : Children hospitalized before the OIPP implementation
62852541|NCT03663660||after the OIPP implementation|Period 2 :Children hospitalized after the OIPP implementation
62852542|NCT00077467|EXPERIMENTAL|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62852543|NCT03284281|EXPERIMENTAL|Interventional arm|Active TVNS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 8 hours daily (4 hours twice daily) for 1-week post discharge.
62852544|NCT03284281|PLACEBO_COMPARATOR|Control arm|No stimulation will be performed.
62852545|NCT01893034|ACTIVE_COMPARATOR|Conservative treatment|Physiotherapy and activity modification
62852546|NCT01893034|ACTIVE_COMPARATOR|Surgical treatment|Arthroscopic treatment of femoroacetabular impingement
62852547|NCT04843683|EXPERIMENTAL|Stereotactic ablative radiotherapy (SBRT) Arm|Stereotactic ablative radiotherapy (SBRT) is a type of radiation treatment that delivers precise, high dose radiation to targeted areas. In this study, a single treatment of SBRT will be delivered to the abnormal area of a participant's heart that is causing dangerous heart rate and rhythm changes (arrhythmia).
62852548|NCT04843683|NO_INTERVENTION|Observational Arm|Potential participants who are eligible to be included in the study, but who choose not to have the SBRT procedure, can still receive standard medical treatment alone and be followed up with study visits and questionnaires.
62852549|NCT05260918|ACTIVE_COMPARATOR|Flotation-REST|Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event the participant needs assistance. Participants will undergo 60 minute sessions twice a week for 3 weeks.
62267668|NCT03964961|ACTIVE_COMPARATOR|Conventional massage|
62267669|NCT04788654|ACTIVE_COMPARATOR|Pharmacological group|Pharmacological analgesia will be performed
62267670|NCT04788654|EXPERIMENTAL|Pharmacologican and surgical group|Pharmacological and surgical analgesia will be performed.
62267671|NCT00441597|ACTIVE_COMPARATOR|1|first 3 day treatment placebo and 4 weeks later three day treatment with atorvastatin 80 mg
62267672|NCT00441597|ACTIVE_COMPARATOR|2|first 3 day treatment atorvastatin 80 mg and 4 weeks later three day treatment with placebo
62267673|NCT00441597|NO_INTERVENTION|3|3 days treatment with placebo twice
62267674|NCT05125237||Amiloride|Exposure group
62267675|NCT05125237||Triamterene|Reference group
62267676|NCT05033470|EXPERIMENTAL|Dabir Surface Mattress Overlay System|Eligible patients are treated with a mattress overlay system and standard of care (debridement, proper moisture balance, reduction of bacterial burden and nutritional counseling). Subjects will be seen weekly for 4 weeks. Patients who respond to the offloading device, may use the overlay for an additional 12 weeks with monthly follow-up visits in the clinic or their home. Subjects undergo study procedures on a weekly basis.
62267677|NCT03053297||Patients with EGFR mutation (+) NSCLC|Patients with EGFR mutation-positive locally advanced or metastatic NSCLC who have progressed while on or after receiving front-line EGFR-TKI therapy (e.g., gefitinib, erlotinib, afatinib, or icotinib).
62626808|NCT01014078|EXPERIMENTAL|Azithromycin Ophthalmic Solution, 1%|
62626809|NCT01014078|PLACEBO_COMPARATOR|Placebo|
62626810|NCT06251921|EXPERIMENTAL|Restorations 1|preheated resin-based composite
62626811|NCT06251921|EXPERIMENTAL|Restorations 2|room temperature resin-based composite
62852550|NCT05260918|PLACEBO_COMPARATOR|Nappod|Participants in this arm will be asked to lie comfortably in a special recliner called a Metro Nappod for the duration of a 60 minute session twice a week for 3 weeks. The chair is located in a quiet and dimly lit room to minimize interruptions. The pod is equipped with a privacy visor, built-in speaker, and a timer with an alarm.
62626812|NCT03259256|EXPERIMENTAL|Allogeneic transplantation of human islet|Each subject may receive 1-3 transplantations of allogeneic human islets we will inject the least dose of 3,000 IEQ/kg body weight of the recipient. Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml.
62852551|NCT01829880||Chronic heart failure patients|Patients with chronic heart failure who attend to internal medicine outpatient clinic.
62626813|NCT04788849||Women referred to colposcopy|Three sample types (urine, vaginal and cervical) will be collected from all enrolled women.
62626814|NCT00217581|EXPERIMENTAL|Docetaxel, Oxaliplatin & Bevacizumab|Must be administered 1st before Docetaxel \& Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
62062933|NCT04785664|NO_INTERVENTION|SoC- Standard of Care|No intervention will be carried out. The control group is selected by randomization from a pool of over-80s followed up by General Practitioners in the same cities who have been available to be involved in the study. Each GP provided a list of patients which 10 names have been selected from by randomization. The total pool consisted of approximately 8500 individuals. The sample was made up of 690 selected patients of which 83 (12.02%) refused to participate in the study.
62062934|NCT03017157||Anterior Myocardial Infarction|Patients who have suffered anterior myocardial infarction in our hospital
62062935|NCT00189592|EXPERIMENTAL|A|Percutaneous Fasciotomy
62626815|NCT05964985|PLACEBO_COMPARATOR|Normal saline in quadratus lumborum block|After the induction of anesthesia, normal saline is used for bilateral quadratus lumborum block in a volume of 20 mL of each side.
62626816|NCT05964985|ACTIVE_COMPARATOR|Ropivacaine in quadratus lumborum block|After the induction of anesthesia, 0.375% ropivacaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side.
62062936|NCT00189592|ACTIVE_COMPARATOR|2|Standard Fasciotomy
62062937|NCT04618263|EXPERIMENTAL|GATE-101, 5 mg IV, Single Dose|GATE-101, 5 mg IV, Single Dose, with follow up of 28 days
62062938|NCT04618263|EXPERIMENTAL|GATE-101, 15 mg IV, Single Dose|GATE-101, 15 mg IV, Single Dose, with follow up of 28 days
62062939|NCT04618263|EXPERIMENTAL|GATE-101, 50 mg IV, Single Dose|GATE-101, 50 mg IV, Single Dose, with follow up of 28 days
62626817|NCT05964985|ACTIVE_COMPARATOR|Compound lidocaine in quadratus lumborum block|After the induction of anesthesia, 0.6% compound lidocaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side.
62626818|NCT05964985|ACTIVE_COMPARATOR|Compound lidocaine and esketamine in quadratus lumborum block|After the induction of anesthesia, 0.6% compound lidocaine and 0.4 mg/kg esketamine are used for bilateral quadratus lumborum block in a volume of 20 mL of each side.
62852552|NCT02158429|ACTIVE_COMPARATOR|3 Dimensional ultrasound|an additional 5-10 minutes of ultrasound using three dimensional technique
62062940|NCT04618263|EXPERIMENTAL|GATE-101, 150 mg IV, Single Dose|GATE-101, 150 mg IV, Single Dose, with follow up of 28 days
62267678|NCT03053297||Patients newly diagnosed NSCLC|Patients newly diagnosed with locally advanced or metastatic NSCLC who are treatment naive or patients who were diagnosed at an earlier stage but have progressed to metastatic NSCLC during the selection period.
62626819|NCT02542137|EXPERIMENTAL|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
62852553|NCT02158429|ACTIVE_COMPARATOR|2 dimensional|an additional 5-10 minutes of ultrasound using standard two-dimensional technique
62062941|NCT04618263|EXPERIMENTAL|GATE-101, 450 mg IV, Single Dose|GATE-101, 450 mg IV, Single Dose, with follow up of 28 days
62267679|NCT01251367|EXPERIMENTAL|Dysport®|Dysport® is injected into lower limbs across 4 cycles of treatment, a minimum of 12 weeks between 2 injections. Doses vary from 1000 U to 1500 U.
62626820|NCT02723448|OTHER|Single Arm Study|Aclarubicin (6 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days (Days 2-5) of each 28 day cycle to each participant \[Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL) patients\]. There is no maximum number of cycles.
62626821|NCT06274619|EXPERIMENTAL|Healthy Volunteers|Healthy volunteers aged 65-75 years undergoing controlled human infection with RSV Memphis 37
62626822|NCT03475290|EXPERIMENTAL|Self-Efficacy and Perceived Social Support|
62267680|NCT03225053|EXPERIMENTAL|MEP® technique|G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
62267681|NCT02146612||Group Receiving Supplement|Amino acid supplement group
62267682|NCT04187768||Healthy Group|Healthy volunteers will donate a sample of blood to be used as controls
62267683|NCT04187768||NSCLC Group|Patients with advanced NSCLC will have blood collected prior to treatment and after completing 3 cycles of immune checkpoint therapy. . If a patient is noted to have progressive disease after 2 cycles of treatment, a sample will be collected after the 2nd cycle. If a patient is noted to have pseudoprogression (determined at the discretion of the treating physician), an additional sample may be collected after 3 cycles of therapy.
62626823|NCT03475290|EXPERIMENTAL|Perceived Social Support and Self-Efficacy|
62626824|NCT03475290|ACTIVE_COMPARATOR|Self-Efficacy|
62626825|NCT03475290|ACTIVE_COMPARATOR|Perceived Social Support|
62626826|NCT04329845|ACTIVE_COMPARATOR|open splenectomy for splenic injury in trauma|open splenectomy as a technique for removal of the spleen in case of injury to spleen
62267684|NCT01499420|EXPERIMENTAL|CSL112|
62626827|NCT04329845|ACTIVE_COMPARATOR|laparoscopic splenectomy for splenic injury in trauma|laparoscopic splenectomy as a technique for removal of the spleen in case of injury to spleen
62267685|NCT01499420|PLACEBO_COMPARATOR|Placebo|
62626828|NCT01940640|EXPERIMENTAL|DHA supplementation|mothers consuming 900 mg DHA/day and their neonates.
62852554|NCT02942225||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
62852555|NCT02942225||TD group|Typically development controls without lifetime diagnosis with ADHD
62852556|NCT04583137|EXPERIMENTAL|Buffered lidocaine|Each participant receives a single intranasal application of atomized 1 mL lidocaine 5% solution combined with bicarbonate 8.4% in a 1:10 ratio.
62852557|NCT04583137|EXPERIMENTAL|Plain lidocaine|Each participant receives a single intranasal application of atomized 1 mL lidocaine 5% solution.
62852558|NCT00335179|ACTIVE_COMPARATOR|Imiquimod cream|Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream Applied 3 times per week for 4 weeks
62852559|NCT00335179|PLACEBO_COMPARATOR|Vehicle cream|Vehicle cream 250 mg Applied 3 times per week for 4 weeks
62267686|NCT02481388||Weakness Group (WG)|Patients with heart failure and a maximum inspiratory pressure (MIP) \<70% of predicted MIP to age, considered as inspiratory muscle weakness. Following the recruitment process, these volunteers will be evaluated by spirometry and manovacuometry. Afterwards, volunteers will be also assessed in a maximal exercise ramp test. Before and after the ramp test, the optoelectronic pletysmography will be performed to analyse the chest wall tricompartmental distribution and the shortening velocities of rib cages muscles. Also a high-definition ultrasonography will be performed to measure the right diaphragmatic cupule thickness
62267687|NCT02481388||Control group (CG)|Patients with heart failure and do not have a maximum inspiratory pressure (MIP) \> 70% of predicted MIP to age, considered as inspiratory muscle weakness. Following the recruitment process, these volunteers will be evaluated by spirometry and manovacuometry. Afterwards, volunteers will be also assessed in a maximal exercise ramp test. Before and after the ramp test, the optoelectronic pletysmography will be performed to analyse the chest wall tricompartmental distribution and the shortening velocities of rib cages muscles. Also a high-definition ultrasonography will be performed to measure the right diaphragmatic cupule thickness
62267688|NCT05979298|ACTIVE_COMPARATOR|Gemcitabin|Gemcitabine 1000 mg/m2 days 1,8 every 3 weeks
62267689|NCT05979298|EXPERIMENTAL|Gemcitabine+Elenagen|GEM was supplemented with ELENAGEN (2.5 mg i.m. weekly)
62267690|NCT04009863|ACTIVE_COMPARATOR|HIFU on NMNG|The patients with non-toxic multinodular goiter are assigned to have high intensity focused ultrasound treatment.
62461439|NCT03127904|EXPERIMENTAL|Vein Fitness|"Lymphomiokinetic exercises will be performed during a 1 hour period, with the patients in a supine position, legs elevated and properly positioned on a carpet; the knees will be mildly flexed to a comfortable point. The patients will put feet on the pedals of ankle extension/flexion device. The frequency will be around 15 to 20 cycles/minute, while the amplitude will be individually adjusted according to the range of movement of each patient. During the exercises, study personnel will manually drain the lower members.~Compressive therapy will be applied as described in the control group arm.~Care of the wound will be delivered as described in the control group arm."
62461440|NCT03127904|ACTIVE_COMPARATOR|Control group|"Compressive therapy will be applied to both groups by properly trained personnel. Each layer of the compressive boot will have a 50% overlap, from the base to of the fingers to 3 cm bellow the popliteal fossa. The interface pressure used will be of at least 50mmHg in supine position.~Wound care will be delivered to every individual in both groups, 1 or 2 times each week by a nurse certified in wound management, following the principles of maintenance of a moisturized surface between the wound and its cover. The nurse will also carry out mechanical wound debriding and biofilm removal."
62461441|NCT02347501|EXPERIMENTAL|A|"Sitagliptin 100mg once daily orally or 50mg once daily for participants with moderate kidney disease for 24 weeks and narrowband ultraviolet-B (NBUVB) phototherapy.~NBUVB light therapy is continued until the participants' psoriasis clears (\<1% body surface area involved)."
62461442|NCT02347501|NO_INTERVENTION|B|"No additional treatment other than narrowband ultraviolet-B (NBUVB) phototherapy.~NBUVB light therapy is continued until the participants' psoriasis clears (\<1% body surface area involved)."
62852560|NCT01651806|ACTIVE_COMPARATOR|Females receiving a uniform dose of TA|Women receiving a single dose of 1 gram of TA--includes all women that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
62461443|NCT01374750|ACTIVE_COMPARATOR|m-TOR inhibitor free|Immunosuppressive drug
62461444|NCT01374750|EXPERIMENTAL|Sirolimus|Immunosuppressive drug
62062942|NCT04618263|EXPERIMENTAL|GATE-101, 15 mg IV, Single Dose, Lumbar Catheter|GATE-101, 15 mg IV, Single Dose, with Lumbar Catheter for collection of cerebrospinal fluid (CSF) PK samples, with follow up of 28 days
62626829|NCT01940640|ACTIVE_COMPARATOR|Control|follow on capsules without probiotics
62626830|NCT02821416|EXPERIMENTAL|Benralizumab|Benralizumab administered subcutaneously
62852561|NCT01651806|ACTIVE_COMPARATOR|Weighted dose of TA in female patients|Female patients receiving a weighted dose of TA. Will include all women that will get a weighted dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
62852562|NCT01651806|ACTIVE_COMPARATOR|Tranexamic acid weighted dose male|Male patients randomized to the weighted dose of TA. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
62852563|NCT01651806|ACTIVE_COMPARATOR|Uniform single dose TA male patient|Male patients receiving a single dose (1gram) of TA during TKA. Includes all men that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss. Patients will be randomized into one of these two groups.
62852564|NCT01651806|NO_INTERVENTION|Historical Cohort|"25 patients with no TA use in their surgical history.~A control group was established from a historical cohort of primary TKAs performed by the senior author (BL), none of which received TA. The most relevant Pubmed ID would be 24997651."
62852565|NCT01442844|ACTIVE_COMPARATOR|Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
62852566|NCT01442844|NO_INTERVENTION|No intervention|No intervention will be performed. Subject will receive dressings that are standard of care.
62852567|NCT00232791|EXPERIMENTAL|1|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
62852568|NCT00232791|ACTIVE_COMPARATOR|2|CYPHER™ Sirolimus-eluting Coronary Stent
62852569|NCT01687725||Renal denervation|Renal denervation using Symplicity Catheter system
62852570|NCT00149318||Patients with Fabry disease|
62852571|NCT03920644|EXPERIMENTAL|DPI-386 Nasal Gel|Receives Active Nasal Gel 2 times per treatment day
62852572|NCT03920644|PLACEBO_COMPARATOR|Placebo nasal gel|Receives Nasal Gel 2 times per treatment day
62461445|NCT02138669|OTHER|Intacs Device|INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
62852573|NCT03920644|ACTIVE_COMPARATOR|TDS Patch|Receives one patch per treatment.
62852574|NCT04787419|EXPERIMENTAL|probiotics|"2 sachets per day for 4 weeks.~1 sachet of probiotics (1gram) contains: Viable Counts 1 x 107 CFU/g living bacteria in dual pH dependent release coated (Lactobacillus acidophilus, Bifidobacterium longum, Streptococcus thermophilus), Vitamin C 10 mg, Vitamin B1 0.5 mg, Vitamin B2 0.5 mg, Vitamin B6 0.5 mg, Niacin 2 mg."
62461446|NCT01523626|OTHER|Conventional imaging|The control group will be evaluated with X-rays, ultrasonography and selective CT scanning.
62626831|NCT02821416|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously
62626832|NCT01841047|OTHER|Radiotherapy|Evaluation of the combination of radiotherapy with helical tomotherapy (54 Gy) followed by surgery in retro-peritoneal liposarcomas.
62852575|NCT04787419|PLACEBO_COMPARATOR|placebo|"2 sachets per day for 4 weeks.~1 sachet of placebo (1gram) contains: saccharum lactis"
62852576|NCT00605787|ACTIVE_COMPARATOR|Single group|Single group all treated similarly, outcome evaluated as changes within individuals during intervention
62062943|NCT04618263|EXPERIMENTAL|GATE-101, 50 mg IV, Single Dose, Lumbar Catheter|GATE-101, 50 mg IV, Single Dose, with Lumbar Catheter for collection of cerebrospinal fluid (CSF) PK samples, with follow up of 28 days
62062944|NCT04618263|EXPERIMENTAL|GATE-101 5 mg IV, Five Daily Doses|GATE-101 5 mg IV, Five Daily Doses, with follow up for 28 days from first dose
62062945|NCT04618263|EXPERIMENTAL|GATE-101 15 mg IV, Five Daily Doses|GATE-101 15 mg IV, Five Daily Doses, with follow up for 28 days from first dose
62062946|NCT04618263|EXPERIMENTAL|GATE-101 150 mg IV, Five Daily Doses|GATE-101 150 mg IV, Five Daily Doses, with follow up for 28 days from first dose
62062947|NCT04618263|PLACEBO_COMPARATOR|Placebo Comparator, Single Dose|Placebo Comparator, Single Dose, with follow up for 28 days
62461447|NCT01523626|OTHER|Immediate total body CT|The intervention group will receive a 'total body' CT scan from head to pelvis. Conventional radiography and FAST will be completely omitted.
62626833|NCT02575378|OTHER|Metronomic chemotherapy|Metronomic Chemotherapy for maintenance treatment with Capecitabine 300mg/m2 twice a day, everyday.
62626834|NCT02575378|EXPERIMENTAL|Metronimic chemotherapy plus Chinese Traditional Medicine|"Metronomic Chemotherapy for maintenance treatment with Capecitabine 300mg/m2 twice a day, everyday.~Chinese Traditional Medicine"
62626835|NCT04568798|ACTIVE_COMPARATOR|Sana Device|The Sana Device is an externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
62626836|NCT04568798|SHAM_COMPARATOR|Sana Sham Device|The sham treatment device is designed to copy the look and feel of the Sana therapy to a degree that it would be indistinguishable from the true treatment. The sham treatment delivers a series of Audio-Visual Stimulation (AVS) in the form of pulses of light (through closed eyelids) and sound, but that offer no therapeutic effect.
62626837|NCT00809536|OTHER|Cohort 1|This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults
62626838|NCT00809536|OTHER|Cohort 2|This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults
62062948|NCT04618263|PLACEBO_COMPARATOR|Placebo Comparator, Five Daily Doses|Placebo Comparator, Five Daily Doses, with follow up for 28 days from first dose
62267691|NCT04009863|ACTIVE_COMPARATOR|RAI on NMNG|The patients with non-toxic multinodular goiter are assigned to have radioactive iodine (i131) treatment.
62626839|NCT06371274|EXPERIMENTAL|ATRA+Toripalimab|Eligible participants are subjected to take all-trans retinoic acid orally at a dose of 150 mg/m2 per day, twice a day for three consecutive days per cycle (d0\~d2), and intravenous infusion of PD-1 monoclonal antibody at a dose of 240 mg on day 1 of each cycle (d1), with cycles repeated every 3 weeks until disease progression, death, loss to follow-up, intolerable toxicity, or meeting other withdrawal or termination criteria (whichever occurs first), for a maximum duration of 2 years.
62626840|NCT04536805|EXPERIMENTAL|Metformin + SBRT at total dose of 30 Gray (Gy)|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 6 Gy, (day 0 to day 10)"
62626841|NCT04536805|EXPERIMENTAL|Metformin + SBRT at total dose of 36 Gy|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 6 x 6 Gy (day 0 to day 12)"
62626842|NCT04536805|EXPERIMENTAL|Metformin + SBRT at total dose of 25 Gy|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 5 Gy (day 0 to day 10)"
62626843|NCT02573623||HIV-infected children with confirmed TB|Hospitalized children with TB confirmed by culture or GeneXpert
62626844|NCT02573623||HIV-uninfected children aged<5 years with confirmed TB|Hospitalized children aged\<5 years with TB confirmed by culture or GeneXpert
62626845|NCT02573623||HIV-uninfected children aged>4 years with confirmed TB|Hospitalized children aged\>4 years with TB confirmed by culture or GeneXpert
62626846|NCT02573623||HIV-infected control children|Children hospitalized in the surgery ward without any evidence of tuberculosis infection
62626847|NCT02573623||HIV-uninfected controls aged <5 years|Children \<5 years hospitalized in the surgery ward without any evidence of tuberculosis infection
62626848|NCT02573623||HIV-uninfected controls aged >4 years|Children \>4 years hospitalized in the surgery ward without any evidence of tuberculosis infection
62626849|NCT05421780|PLACEBO_COMPARATOR|Control biscuits group|For each MTT, subjects are to consume 90 g control biscuits as their breakfast within 15 mins.
62626850|NCT05421780|EXPERIMENTAL|autoclaved BSG-containing group|For each MTT, subjects are to consume 90 g autoclaved BSG-containing biscuits as their breakfast within 15 mins.
62626851|NCT05421780|EXPERIMENTAL|bio-transformed BSG-containing group|For each MTT, subjects are to consume 90 g bio-transformed BSG-containing biscuits as their breakfast within 15 mins.
62626852|NCT04076436||Fosfomycin cohort:|Cohort of patients with complicated urinary tract infection caused by Escherichia coli treated with intravenous fosfomycin
62626853|NCT04076436||Quinolones or beta-lactams cohort|Cohort of patients with complicated urinary tract infection caused by Escherichia coli treated with intravenous quinolones or beta-lactams.
62626854|NCT01731327|EXPERIMENTAL|Experimental Treatment A|A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
62852577|NCT04727489||Autism Spectrum Disorder|Probands with Autism Spectrum Disorder, (N=700), Diagnosis of ASD according to DSM-V criteria For all patients included in the study, core assessment carried out by either collaborating partners consists of diagnosis using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Patients with profound intellectual disability or with a known medical cause of autism, such as neurocutaneous syndromes, Fragile X, metabolic disorders, extreme prematurity, congenital rubella and other prenatal or postnatal neurological infections or gross dysmorphology, will be excluded.
62626855|NCT01731327|EXPERIMENTAL|Experimental Treatment B|A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
62062949|NCT01272960|ACTIVE_COMPARATOR|Interval Insertion|Will receive Mirena at 4-8 weeks post-partum after vaginal delivery.
62626856|NCT06091098|EXPERIMENTAL|Dynamic CO2 within Drive-Dependent OSA|During sleep, before \~30 distinct respiratory events, we will administer \~2% CO2 for \~3-4 breaths.
62626857|NCT06091098|ACTIVE_COMPARATOR|Dynamic CO2 within Classic OSA|During sleep, before \~30 distinct respiratory events, we will administer \~2% CO2 for \~3-4 breaths.
62062950|NCT01272960|EXPERIMENTAL|Post-Placental Mirena Insertion|Will receive Mirena insertion within 10 minutes of delivery of placenta
62062951|NCT02306122|EXPERIMENTAL|Default patient default doctor|Patient nonadherence information sent to physician; Pharmacist calls patient unless physician cancels call
62062952|NCT02306122|EXPERIMENTAL|Information patient default doctor|Patient nonadherence information sent to physician
62062953|NCT02306122|NO_INTERVENTION|Control patient default doctor|Control - no intervention
62267692|NCT01272700|EXPERIMENTAL|PCV|Peak airway pressure were set to deliver a tidal volume of 10 ml/kg of ideal body weight
62267693|NCT01272700|ACTIVE_COMPARATOR|VCV|After anesthetic induction, anesthesia maching were set to deliver a tidal volume of 10 ml/kg of ideal body weight
62267694|NCT00933075|EXPERIMENTAL|Dermacyd Silver Frutal (Lactic Acid)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also usedas a control sample.
62267695|NCT03111446|ACTIVE_COMPARATOR|Spinal Anesthesia|Spinal anesthesia will be used to anesthetize patients in this group for caesarian section
62626858|NCT06091098|SHAM_COMPARATOR|Sham CO2 within Drive-Dependent OSA|During sleep, Sham CO2 (air) will be administered for \~3-4 breaths before respiratory events.
62626859|NCT06091098|SHAM_COMPARATOR|Sham CO2 within Classic OSA|During sleep, Sham CO2 (air) will be administered for \~3-4 breaths before respiratory events.
62626860|NCT05937620|EXPERIMENTAL|Interventional arm|All patients will receive an injection of ICG and an injection of 99mTc nanocolloid albumin
62626861|NCT04531735||Group 1|COVID positive infants
62626862|NCT04531735||Group 2|RSV positive infants
62626863|NCT03226808|OTHER|Vivacit-E Liner|All subjects enrolled receive the study implant.
62461448|NCT04499170|EXPERIMENTAL|Muscle energy technique (G1)|Group Elderly (G1)
62626864|NCT04063501||Advanced stage unresectable Non-Small Cell Lung Cancer|Adult patients with a diagnosis of advanced stage unresectable Non-Small Cell Lung Cancer and indication for PD-1 blockade treatment (either as monotherapy or combined with chemotherapy)
62626865|NCT03705286|ACTIVE_COMPARATOR|PVC-ETT|Polyvinylchloride endotracheal tube
62626866|NCT03705286|EXPERIMENTAL|EVAC-PU-ETT|Continuous aspiration of subglottic secretions with polyurethane cuff endotracheal tube
62626867|NCT02385565|EXPERIMENTAL|high fat diet|10 % proteins, 30 % lipids, 60 % carbohydrates
62626868|NCT02385565|PLACEBO_COMPARATOR|Normal fat diet|10 % proteins, 45 % lipids, 45 % carbohydrates
62626869|NCT01858415|EXPERIMENTAL|Single arm|
62626870|NCT01852513|ACTIVE_COMPARATOR|QNASL nasal spray|QNASL 320 mcg once-daily administered as two sprays in each nostril; 2 weeks of treatment
62626871|NCT01852513|PLACEBO_COMPARATOR|Placebo nasal spray|Placebo nasal spray once-daily administered as two sprays in each nostril; 2 weeks of treatment
62626872|NCT05582876|ACTIVE_COMPARATOR|Group 1- patient of middle and high risk of prostate cancer|Patients with diagnosis or high probability of prostate cancer medium and high risk according to ISUP for which implementation is planned radical treatment \[i.e. PSA≥10 ng / ml or GS ≥ 7 (ISUP ≥2) or ≥cT2b\].
62626873|NCT05582876|ACTIVE_COMPARATOR|Group 2- patient after radical treatment, at relapse biochemical|Prostate cancer patients after radical treatment, with recurrence biochemical tests according to the criteria of the European Society of Urology (EAU, European Association of Urology) \[at least double measurement PSA ≥0.2 ng / ml not earlier than 6-13 weeks after radical prostatectomy or PSA≥0.1 with PSAdt (PSA doubling time) \<3 months or increase in PSA after radical radiotherapy\> 2 ng / ml above PSAnadir - the lowest PSA value found after the test treatment\] for whom further treatment is planned and the test result imaging / molecular imaging may alter the therapeutic decision
62626874|NCT04260074||Oral Cancer group|20 consecutive patients with oral squamous cell carcinoma referred to the Department of Otolaryngology - Head and Neck Surgery
62626875|NCT04260074||Healthy oral mucosa group|20 controls with normal buccal mucosa upon examination.
62852578|NCT04727489||Control without Autism Spectrum Disorder|Controls without Austim Spectrum Disorder, aged 6 to 40, N=2100 (300 adultes, 300 children) Healthy individuals with or without idiopathic surgical or urological conditions (e.g. orthopaedic conditions, hernia repairs, renal malformations, pre- or post-circumcision, phimosis, balanitis, scoliosis, congenital hip dislocation, adenoid or tonsil removal, dental procedures such as wisdom tooth extraction, cosmetic procedures such as removal of skin tags or cleft lip repairs, non-head injuries such as fractures, drainage of subungual or perichondrial haematomata).
62852579|NCT04727489||Relatives of probands with Autism Spectrum Disorder|"Relatives of probands with Autism Spectrum Disorder (N=1200 parents, N=600 siblings, N=300 other relatives)~* Without Autism Spectrum Disorder diagnosis according to DSM-V,~* With Autism Spectrum Disorder diagnosis according to DSM-V, and using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders"
62852580|NCT04727489||Relatives of controls|Relatives of controls without Autism Spectrum Disorder, N=400 first degree relatives
62852581|NCT03495778|EXPERIMENTAL|Test Granola|50.5 g Test Granola
62852582|NCT03495778|PLACEBO_COMPARATOR|Control Granola|54.3 Control Granola
62852583|NCT00422513|EXPERIMENTAL|methoxy polyethylene glycol-epoetin beta|120-360 micrograms (iv) monthly, starting dose
62852584|NCT00422513|ACTIVE_COMPARATOR|Epoetin Alfa|As prescribed, (iv), 3 times weekly
62852585|NCT01717599|EXPERIMENTAL|Diclofenac group|
62852586|NCT01717599|PLACEBO_COMPARATOR|Placebo(normal saline) group|
62852587|NCT06123351|EXPERIMENTAL|Denneroll protocol|orthotic will be placed under participants' neck. Treatment session time begin with 3 minutes then increase of 2-3 minutes until they reach 15 to 20 minutes in each session.
62852588|NCT06123351|ACTIVE_COMPARATOR|Traditional protocol|consists of one strengthening exercise for 10 repetitions in 3 sets each, and two stretching exercises with a hold for 20-30 seconds.
62852589|NCT06123351|ACTIVE_COMPARATOR|Dental management|formed soft occlusal splint will be individually designed for the upper arch of each participant.
62852590|NCT05704569||the outcome group|The composite endpoint included the presence of any of the following events: cardiovascular death, MI, stroke, hospitalization and/or application due to CHD, and transient ischemic attack
62852591|NCT05704569||no-outcome group|individuals who did not experience any events during the observation period
62062954|NCT02306122|EXPERIMENTAL|Choice patient choice doctor|Patient nonadherence information sent to physician; Pharmacist calls patient if physician requests call
62062955|NCT02306122|EXPERIMENTAL|Information patient choice doctor|Patient nonadherence information sent to physician
62626876|NCT06224998|EXPERIMENTAL|Schroth exercises|Schroth technique, one of these exercise approaches, is primarily based on isometric muscle contraction exercises that aim to rotate, lengthen and stabilize the spine. The key component of the Schroth method is autocorrection, defined as the patient's ability to reduce spinal deformity through active postural realignment of the spine in three dimensions. Automatic correction is achieved through self-extension and specific segmental corrections adapted to each curve pattern. The International Scoliosis Orthopedic Treatment and Rehabilitation Association considers automatic correction to be the most important element of scoliosis-specific exercise therapy.
62626877|NCT06224998|EXPERIMENTAL|Pilates exercises|Pilates exercise training improves flexibility and overall physical health by emphasizing strength, posture and coordination of respiratory-related movements. Pilates improves body awareness by working the body as a whole, using gravity and springs to increase resistance and assist in the execution of movements. Pilates, used in neuromuscular training and functional activity training in physiotherapy, is widely used for stimulation of blood circulation, development of flexibility, muscle endurance and strength, postural harmony and body awareness. Pilates has been reported to be an effective physical technique for pain, symptom management, and improving the Cobb angle in scoliosis. Pilates has been reported to be effective in improving scoliosis by correcting poor posture, strengthening the muscles necessary for postural correction, and maintaining body balance.
62626878|NCT04171193|EXPERIMENTAL|ISO|Patients not taking oral medications for depression. They will receive the study intervention consisting in general anesthesia with the volatile anesthetic gas Isoflurane until burst suppression is detected in electroencephalogram more than 80% of the time for 15 minutes.
62626879|NCT04171193|EXPERIMENTAL|ISOAD|Patients in treatment with oral medications for depression, will receive intervention consisting in general anesthesia with the volatile anesthetic gas Isoflurane until burst suppression is detected in electroencephalogram more than 80% of the time for 15 minutes
62852592|NCT02711917|EXPERIMENTAL|SP1- sevoflurane MAC 0.5|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.5. Propofol infusion is started to keep BIS between 40-60.
62852593|NCT02711917|EXPERIMENTAL|SP2- Sevoflurane MAC 0.75|In this group, patient of age 40-60 years, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen.Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.75. Propofol infusion is started to keep BIS between 40-60.
62852594|NCT02711917|EXPERIMENTAL|SP3 -Sevoflurane MAC 1.0|In this group, patient of age 40-60 years, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 1.0. Propofol infusion is started to keep BIS between 40-60.
62062956|NCT02306122|NO_INTERVENTION|Control patient choice doctor|Control - no intervention
62062957|NCT02306122|EXPERIMENTAL|Information patient information doctor|Patient nonadherence information sent to physician
62062958|NCT02306122|NO_INTERVENTION|Control patient information doctor|Control - no intervention
62062959|NCT02306122|EXPERIMENTAL|Information doctor|Physician receives nonadherence information, but there is no opportunity for pharmacist action
62062960|NCT02306122|EXPERIMENTAL|Choice doctor|Physician receives nonadherence information, and can choose to request pharmacist action
62626880|NCT04171193|EXPERIMENTAL|ISOPOT|Patients that where from ISO arm, that did not respond to intervention consisting in general anesthesia with the volatile anesthetic gas Isoflurane until burst suppression is detected in electroencephalogram more than 80% of the time for 15 minutes They will now, start taking sertraline as oral medication for depression to asset the enhancement of oral treatment after Isoflurane challenge.
62852595|NCT02711917|EXPERIMENTAL|SP4- Sevoflurane MAC 0.5|In this group, patient above 60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Propofol infusion is started to keep BIS between 40-60.
62852596|NCT02711917|EXPERIMENTAL|SP5- Sevoflurane MAC 0.75|In this group, patient above 60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.75. Propofol infusion is started to keep BIS between 40-60.
62852597|NCT02711917|EXPERIMENTAL|SE1- Sevoflurane MAC 0.5|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
62062961|NCT02306122|EXPERIMENTAL|Default doctor|Physician receives nonadherence information; pharmacist action will be triggered unless physician cancels action
62852598|NCT02711917|EXPERIMENTAL|SE2- Sevoflurane 0.75|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
62852599|NCT02711917|EXPERIMENTAL|SE3- Sevoflurane MAC 1.0|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
62062962|NCT03565068|EXPERIMENTAL|Panel A (Healthy Participants): MK-8189 Monotherapy 4-24 mg|Healthy participants will receive MK-8189 monotherapy orally once daily (QD) in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
62267696|NCT03111446|ACTIVE_COMPARATOR|General Anesthesia|Standardized General Anesthesia will be used to anesthetize patients in this group for caesarian section
62852600|NCT00574236|EXPERIMENTAL|A|
62852601|NCT01410344|OTHER|Allogeneic Transplant|One regimen from either reduced-intensity conditioning (RIC) (Fludarabine and Busulfan; or Fludarabine and Melphalan) or myeloablative conditioning (MAC) (Busulfan and Fludarabine; or Cyclophosphamide and Total Body Irradiation) will be administered prior to allogeneic hematopoietic cell transplantation (HCT).
62852602|NCT05715112||Experimental group|A convenience sample of older adults (65 and older).
62852603|NCT01906996||proximal row carpectomy|patients were treated with a proximal row carpectomy
62852604|NCT01906996||four corner fusion|patients were treated with a four corner fusion
62852605|NCT04193072||Obstetric brachial plexus palsy|
62852606|NCT04193072||Healthy|
62062963|NCT03565068|PLACEBO_COMPARATOR|Panel A (Healthy Participants): Placebo Monotherapy|Healthy participants will receive MK-8189 monotherapy matching placebo orally QD on Days 1-18.
62267697|NCT01564355|EXPERIMENTAL|Systemic Steroid Group|Will receive post-operative oral steroids for 10 days as per usual protocol.
62267698|NCT01564355|PLACEBO_COMPARATOR|Placebo|Will receive placebo pills for 10 days post-operatively
62267699|NCT00710073|EXPERIMENTAL|A|Combined sono-electro-magnetic therapy
62450913|NCT00376220|EXPERIMENTAL|1|"Drug: Riluzole Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) \< 12) the dose will not be increased further unless clinical symptoms recur.~Other Names:~• Rilutek"
62450914|NCT00376220|PLACEBO_COMPARATOR|2|Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS \< 12) the dose will not be increased further unless clinical symptoms recur.
62450915|NCT06460714|EXPERIMENTAL|Shock wave therapy, stretching and orthosis|Shortwave therapy, stretching and orthotics will be provided to Group A. Shock wave session will be provided for 20 minutes thrice a week. Five days in a week provided five minutes with 30 seconds sustained stretch will be provided and than orthotics will be used to obtained the sustained effect.
62450916|NCT06460714|ACTIVE_COMPARATOR|Stretching, strengthening and orthosis|In Group B spastic diplegic children just given stretching with strengthening and orthotics. We provide sustained 30 seconds stretch with 30 seconds rest for 5 minutes and followed with forty repetition of hip flexor and knee flexors and range will be maintained by applying orthosis.
62461449|NCT04499170|ACTIVE_COMPARATOR|Muscle energy technique (G2)|Group of young people (G2)
62852607|NCT03142685|EXPERIMENTAL|Arm B: Kub + Bowel US|Subjects clinical suspected of NEC whom are randomized into Arm B at time of consent will receive a bowel ultrasound q24 for 48 hours and a KUB q12 for 48 hours.
62852608|NCT03142685|NO_INTERVENTION|Arm A: KUB Only|Subjects clinical suspected of NEC whom are randomized into Arm A at time of consent will receive a KUB q12 for 48 hours. This is the current standard-of-care procedures.
62852609|NCT03278054|ACTIVE_COMPARATOR|Manual group|Root Canal Treatment with hand instruments:Root canal treatment was done with instrumentation using manual K files.
62852610|NCT03278054|ACTIVE_COMPARATOR|ProTaper group|Root canal treatment with Protaper instruments:Root canal treatment was done using ProTaper rotary files S1, S2, F1, and F2.
62852611|NCT03278054|ACTIVE_COMPARATOR|Hybrid group|Root canal treatment with hybrid instrumentation:Root canal treatment was carried out using ProTaper and Hyflex CM files.
62852612|NCT06460740|EXPERIMENTAL|4-7-8 breathing technique|4-7-8 breathing technique and stationary cycling
62852613|NCT06460740|ACTIVE_COMPARATOR|Stationary cycling|Stationary Cycling
62852614|NCT04972045|EXPERIMENTAL|CuminUP60®,then Curcumin capsules|Participants first received CuminUP60® 1600mg on the first day in a fasting state.After a washout period of 7days,they then received curcumin capsules 1600mg on the eighth day in a fasting state.
62852615|NCT04972045|EXPERIMENTAL|Curcumin capsules,then CuminUP60®|Participants first received curcumin capsules 1600mg on the first day in a fasting state.After a washout period of 7days,they then received CuminUP60® 1600mg on the eighth day in a fasting state.
62852616|NCT04211246|ACTIVE_COMPARATOR|Standard group|Fraction of inspired oxygen (FiO2) is titrated guided by SpO2.
62267700|NCT06421558|EXPERIMENTAL|Neubie Direct Current Electrical Stimulation Device|The experimental group subjects follow with 12 sessions of physical therapy over a 6-week period which include 30 min of various physical therapy exercises with the Neubie.
62852617|NCT04211246|EXPERIMENTAL|ORI group|Fraction of inspired oxygen (FiO2) is titrated guided by SpO2 and ORI
62852618|NCT01986556|EXPERIMENTAL|Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot A)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)
62852619|NCT01986556|EXPERIMENTAL|Lesinurad 400 mg Fed (Site 1 and Site 2, Lot A)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)
62852620|NCT01986556|EXPERIMENTAL|Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot B)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)
62852621|NCT01986556|EXPERIMENTAL|Lesinurad 400 mg Fed (Site 1 and Site 2, Lot B)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)
62062964|NCT03565068|EXPERIMENTAL|Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4-24 mg|Participants with Schizophrenia will receive MK-8189 monotherapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
62062965|NCT03565068|PLACEBO_COMPARATOR|Panel B (Schizophrenia Participants): Placebo Monotherapy|Participants with Schizophrenia will receive MK-8189 monotherapy matching placebo orally QD on Days 1-18.
62267701|NCT06421558|OTHER|Transcutaneous Electrical Stimulation|The control group subjects follow with 12 sessions of physical therapy over a 6-week period which include: a 30-min of various physical therapy exercises with TENS application.
62267702|NCT02639585|EXPERIMENTAL|Treatment arm|Daclinza and Sunvepra
62267703|NCT00513409|EXPERIMENTAL|Synflorix Booster Group|Subjects previously primed with Synflorix™ and receiving in the current study Havrix™ co-administered with Infanrix™ hexa (Dose 1) and Synflorix™ (Dose 2).
62062966|NCT03565068|EXPERIMENTAL|Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4-24 mg|In addition to background atypical antipsychotic (AAP) treatment, participants with Schizophrenia will receive MK-8189 add-on therapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
62062967|NCT03565068|PLACEBO_COMPARATOR|Panel C (Schizophrenia Participants): Placebo Add-on Therapy|In addition to background AAP treatment, participants with Schizophrenia will receive MK-8189 add-on therapy matching placebo orally QD on Days 1-18.
62062968|NCT03565068|EXPERIMENTAL|Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8-48 mg|Participants with Schizophrenia will receive MK-8189 monotherapy orally QD in escalating doses from 8 mg to 48 mg, as follows: Days 1-3: 8 mg, Days 4-6: 16 mg, Days 7-9: 24 mg, Days 10-12: 36 mg, Days 13-15: 48 mg, depending on safety and tolerability.
62062969|NCT03565068|PLACEBO_COMPARATOR|Panel D (Schizophrenia Participants): Placebo Monotherapy|Participants with Schizophrenia will receive MK-8189 monotherapy matching placebo orally QD on Days 1-15.
62062970|NCT06155383|ACTIVE_COMPARATOR|XELOX (capecitabine + oxaliplatin)|capecitabine with oxaliplatin arm
62267704|NCT00513409|EXPERIMENTAL|Synflorix Catch-up Group|Subjects previously primed with Havrix™ co-administered with Infanrix™ hexa and receiving in the current study Synflorix™ co-administered with Infanrix™ hexa (Dose 1) and Synflorix™ (Dose 2).
62267705|NCT03611855|EXPERIMENTAL|BCI Rehabilitation|Patients trained on use of BCI-controlled orthotic device are given a device for home use. Patients are asked to use the device an hour per day, 5 days per week, for 12 weeks. During device use, patients are instructed via pre-programmed instructions on a tablet paired with the device to either rest or vividly imagine moving their affected hand. The device receives signals from a scalp electrodes within a headset the patient dons prior to use. The device interprets these signals and closes the patient's hand during a successful rest trial, and opens the patient's hand during a successful move trial.
62267706|NCT03611855|ACTIVE_COMPARATOR|Range of Motion Therapy|Active and Passive Range-of-Motion (AROM, PROM) therapy strategies are commonly prescribed by physical therapists for at-home post-stroke motor deficit rehabilitation that can be performed independently. Patients practice movement with joints and limbs affected by the stroke, either by using the unaffected limb (or the assistance of a caretaker) to stretch the affected limb (PROM) or by actively moving the affected limb (AROM). Patients are asked to perform this therapy one hour per day, 5 days per week, for 12 weeks.
62267707|NCT02321436|ACTIVE_COMPARATOR|Treatment group|Dysport® 500U intramuscular injection
62267708|NCT02321436|PLACEBO_COMPARATOR|Placebo Group|Placebo intramuscular injection
62267709|NCT04925232|EXPERIMENTAL|One group|All participants will undergo 2 weeks (5 times each week) of repetitive TMS
62267710|NCT03927001|OTHER|Intervention|NeVa Stent Retrievers
62267711|NCT01650636|EXPERIMENTAL|Cognitive Behavioral Stress Management|
62267712|NCT01650636|ACTIVE_COMPARATOR|Health Information|
62267713|NCT05598099||Individual therapy over four consecutive days|Treatment will be delivered individually over four consecutive days
62267714|NCT05598099||Combined Individual and group therapy over four consecutive days|Treatment will be delivered in a mix of individual and group sessions over four consecutive days
62267715|NCT00940082||youth control group|healthy people which ages from 30 to 59
62267716|NCT00940082||youth diabetes group|type 1 and type 2 diabetes patients which ages from 30 to 59
62267717|NCT00940082||the elderly diabetes group|type 1 and type 2 diabetes patients which ages from 60 to 90
62450917|NCT03879200|NO_INTERVENTION|Standard Individual care|Historical controls Individual care follows standard individual Swedish antenatal care, i.e.8-9 30 minutes appointments with a midwife during a normal pregnancy including information and regular pregnancy check-ups. Women are offered classes (3 x 2 hours) that provide preparation for birth and parenthood according to the same guidelines. Obstetricians and general practitioners have a consultant role.
62450918|NCT03879200|EXPERIMENTAL|Group antenatal care|Group antenatal care will follow the same guidelines as for individual care but with tailored content provided in language supported group sessions.
62450919|NCT04375254||Intervention group|Medical students during psychiatry clerkship who received NbN psychopharmacology training
62450920|NCT04375254||Control group|Medical students during psychiatry clerkship who received standard psychopharmacology training
62450921|NCT03203148||CABG Surgical Patients|Patients undergoing coronary bypass grafting with cardiopulmonary bypass
62626881|NCT04241913|EXPERIMENTAL|Treatment|The treatment group receives the 10-week, group-based Mom Power intervention; intervention is provided to both mothers and children by trained providers. Treatment delivery will be consistent with the Mom Power manual.
62626882|NCT04241913|NO_INTERVENTION|Waitlist control|Participants randomized to waitlist control will not receive treatment during the experimental period; they will be offered treatment following completion of post- assessments.
62267718|NCT00940082||elderly control group|healthy people which ages from 60 to 90
62062971|NCT06155383|EXPERIMENTAL|Disitamab Vedotin + Toripalimab|Disitamab Vedotin with Toripalimab arm
62062972|NCT06155383|EXPERIMENTAL|Disitamab Vedotin + Toripalimab + XELOX|Disitamab Vedotin + Toripalimab + XELOX arm
62062973|NCT00644462||1|Asthmatic subjects
62062974|NCT00644462||2|Healthy subjects
62062975|NCT02956434|EXPERIMENTAL|Brief family intervention|Participants will receive the BFI in this arm of the study. The BFI is a 2-session intervention for family members of Veterans who are beginning PTSD treatment.
62450922|NCT01652365|EXPERIMENTAL|RDT Training and Subsidy Offered|Licensed drug shops within villages selected randomly to be in this arm will be invited to training on RDTs and offered access to subsidized RDTs available for purchase at a local wholesale pharmacy in Mbale, Uganda.
62450923|NCT01652365|EXPERIMENTAL|Information/Education Campaign|Community meetings describing RDTs and encouraging community members to be diagnosed prior to taking malaria treatment will be held in villages randomly assigned to this treatment arm.
62450924|NCT01652365|EXPERIMENTAL|RDT Training/Subsidy + Information/Education Campaign|Includes both the training and subsidy component and the information/education campaign component.
62062976|NCT02956434|NO_INTERVENTION|No intervention|Participants will not receive the BFI in this arm of the study. They will be eligible for any usual support or programming for the families of Veterans.
62852622|NCT05246085||Steroid|Subjects who take chronic swallowed topical steroids (i.e. budesonide or fluticasone) will be enrolled in the steroid cohort.
62852623|NCT05246085||Proton pump inhibitor|Subjects who take chronic proton pump inhibitors will be enrolled in the proton pump inhibitor cohort.
62852624|NCT05274295|EXPERIMENTAL|Cytori Celution System in Chronic Non-Healing diabetic Leg Ulcers|On the screening visit, the study physician will assign one eligible ulcer, as the target ulcer. Target ulcer will be treated and followed up during the whole study period. After liposuction investigational device will be applied on the target ulcer. After completion of Day1 visit all subjects enter the observation period and will come back to 3 on-site visits on day 7 day 14 and day 28
62852625|NCT02760225|EXPERIMENTAL|89Zr-Pembrolizumab PET imaging|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
62062977|NCT04615182|EXPERIMENTAL|OCS Preservation|
62267719|NCT00357500|EXPERIMENTAL|5-drug metronomic antiangiogenic regimen|Thalidomide: Start at 3 mg/kg (rounded to nearest 50 mg), increasing dose weekly by 50 mg as tolerated to 24 mg/kg (max 1,000 mg); Celecoxib: \< 20 kg at 100 mg; 20-50 kg at 200 mg; \> 50 kg at 400 mg; Fenofibrate: 90 mg/m2 (max 200 mg); Etoposide: 50 mg/m2; Cyclophosphamide: 2.5 mg/kg (max 100 mg); Patients receive oral etoposide once daily on days 1-21 and 43-63 (weeks 1-3 and 7-9) and oral cyclophosphamide once daily on days 22-42 (weeks 4-6). Patients also receive oral thalidomide once daily, oral celecoxib twice daily, and oral fenofibrate once daily in weeks 1-9. Treatment repeats approximately every 9 weeks for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients receive alternating etoposide and cyclophosphamide pulses (i.e., etoposide-cyclophosphamide-etoposide during courses 1 and 3 and cyclophosphamide-etoposide-cyclophosphamide during course 2).
62852626|NCT03041129||Untreated PCOS|PCOS per NIH criteria. Obese Lifestyle treatment only.
62852627|NCT03041129||Metformin PCOS-(Study arm not funded)|PCOS per NIH criteria. Obese Taking 1500 mg of metformin or more per day for at least 6 months.
62852628|NCT03041129||Oral Contraceptive PCOS-(Study arm not funded)|PCOS per NIH criteria. Obese Taking 30 mcg of ethanyl estradiol or more per day for at least 6 months.
62267720|NCT01560000|OTHER|fiber|
62267721|NCT02217605|EXPERIMENTAL|Fructose|Oral Fructose Challenge (75 g fructose in 500 ml water) followed by 75 minutes 31P MRS
62626883|NCT02997813||Cohort 1|All consecutive patients with complete set of data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and plerixafor
62852629|NCT03041129||Obese Control group-(Study arm not funded)|Obese Regular menses at least 18 months post-menarche Females only
62852630|NCT03708887|EXPERIMENTAL|Low dose group|Low-dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 1.5 grams per day for 1 year.
62852631|NCT03708887|EXPERIMENTAL|High dose group|High-dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 3 grams per day for 1 year.
62852632|NCT03708887|PLACEBO_COMPARATOR|Control group|Control drug, matching placebo capsules, 3 grams per day for 1 year.
62852633|NCT02457104||normal weight individuals not taking PPI|
62852634|NCT02457104||normal weight individuals taking PPI|
62852635|NCT02457104||obese individuals not taking PPI|
62852636|NCT02457104||obese individuals taking PPI|
62852637|NCT05813041|EXPERIMENTAL|Investigational Device|Single arm trial - healthy volunteers will all undergo an apheresis procedure using the BioCaptis device. No comparator will be used for this trial.
62062978|NCT06626100|EXPERIMENTAL|Exercise-themed game|The intervention includes an exercise-themed quiz game and monitored step count.
62062979|NCT06626100|ACTIVE_COMPARATOR|Diet-themed game|The intervention includes a diet-themed quiz game.
62062980|NCT05266963|ACTIVE_COMPARATOR|CREON|CREON is a pancreatic enzyme replacement
62062981|NCT05266963|PLACEBO_COMPARATOR|Placebo|Placebo
62062982|NCT04704154|EXPERIMENTAL|Regorafenib+Nivolumab|Parallel-cohort in adult participants with selected recurrent or metastatic tumors (HNSCC, ESCC, PDAC, BTC, and GBM/AA) who have been previously treated with one or more systemic therapy for the selected tumor indication.
62062983|NCT04207840|EXPERIMENTAL|Primatene Mist, E004|Participants who dosed with Primatene Mist.
62062984|NCT04207840|ACTIVE_COMPARATOR|Epinephrine Injection Auto-Injector (Generic of EpiPen)|Participants who were dosed with an Epinephrine Injection Auto-Injector.
62062985|NCT04207840|ACTIVE_COMPARATOR|Albuterol HFA|Participants who dosed with Albuterol HFA.
62062986|NCT00699140|EXPERIMENTAL|1 treatment group with IGIV3I Grifols|"Open label, non-randomized treatment group with IGIV3I Grifols~Each patient received a total dose of 2 g/kg IGIV3I Grifols, given intravenously over either 2 days or 5 days in divided doses."
62062987|NCT01378910|EXPERIMENTAL|Change of 3rd drug to maraviroc|Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
62062988|NCT04706533||Covid-19|Patients with confirmed SARS-CoV-2 infection presenting specifically for Covid-19
62062989|NCT05696314|EXPERIMENTAL|Outpatient Oropharynx Ultrasound|Transoral and/or Transcervical ultrasound of the oropharynx
62062990|NCT02118480|EXPERIMENTAL|cognitive remediation program: REHACOP|Cognitive rehabilitation program (REHACOP) including intervention in: attention, memory, processing speed, language, executive functioning and social cognition during 3 months, 3 times per week
62062991|NCT02118480|ACTIVE_COMPARATOR|Occupational Therapy|The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood) during 3 months, 3 times per week.
62852638|NCT04242641|EXPERIMENTAL|WW (formally Weight Watchers)|The intervention will consist of engaging with the WW programme for 12 weeks, including weekly attendance at a local WW workshop and access to digital tools. Only the parent will take part in the WW intervention. No modifications will be made to the current WW programme to support child weight loss.
62062992|NCT06546319|EXPERIMENTAL|Music Therapy|Participants will complete a series of questionnaires after enrolling, 15 days post hospital discharge, and 30 days post hospital discharge. Board-certified music therapists (i.e., MT-BC credential) will provide two music therapy sessions, not to occur on the same day, that include education and disease-specific content (e.g., harmonica exercises for respiratory health \[COPD\] or music-based breathing exercises \[HF\]) prior to patients' discharge and two virtual music therapy sessions that address music-assisted relaxation and imagery, additional techniques for managing psychosocial stressors, and gratitude exercises post-discharge.
62267722|NCT06035900|EXPERIMENTAL|10 normal healthy male volunteers|10 normal healthy male volunteers where each subject was given an identification code after signing the informed consent which was obtained according to APIC/PRU procedure of obtaining Consent form. The identification code consisted of the subject's initials, and a serial number.
62267723|NCT03539250|EXPERIMENTAL|IMRT with and without chemotherapy|Subdivision of the PTVnx into regions with different prescribed absorbed doses (PTVsv1,PTVsv2, PTVsv2 is the overlaps between PTVnx and temporal lobe) can be used in cases for which the PTVnx overlaps temporal lobe. When the volume of PTVsv2 is less than 0.2 cubic centimeter (cc), the prescribe dose for PTVsv2 is as the same as that of the PTVsv1, D1cc 63.1Gy, Dmax 72.9Gy for TL (32 fractions). When the volume of PTVsv2 is between 0.2 cc and 0.5cc, the prescribe dose for PTVsv2 is 66Gy, D1cc 63.1Gy, Dmax 72.9Gy for TL (32 fractions). When the volume of PTVsv2 is between 0.5 cc and 1cc, the prescribe dose for PTVsv2 is 66Gy, D1cc 65.8Gy, Dmax 75.2Gy for TL (32 fractions).
62267724|NCT02976870|EXPERIMENTAL|Ultrasound|Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
62267725|NCT05222256|EXPERIMENTAL|Group (L) levosimendan group|Patients in this group will receive levosimendan (0.1 μg/kg/min) during re-warming of the patients.
62267726|NCT05222256|ACTIVE_COMPARATOR|Group (A) Adrenaline group|Patients in this group will receive Adrenaline (0.05 μg /kg/min) during re-warming of the patients.
62267727|NCT00641251|ACTIVE_COMPARATOR|1|intensive medical management
62450925|NCT01652365|NO_INTERVENTION|Control|
62450926|NCT04238767||HIV-1-positive individuals|HIV-1-positive individuals eligible to receive a DTG-based ART regimen at enrolment.
62267728|NCT00641251|ACTIVE_COMPARATOR|2|Roux-en-Y gastric bypass with intensive medical management
62852639|NCT04242641|NO_INTERVENTION|Control|Participants randomised to the control group will receive no intervention during the 3 month period. Following final data collection control participants will receive 3 month complimentary access to WW.
62852640|NCT03833193|EXPERIMENTAL|Hypofractionated radiotherapy|The patients received daily accelerated radiotherapy with a total dose of 60Gy, delivered at 3Gy per fraction, five fractions per week, completed within 4 weeks.
62852641|NCT02997306|EXPERIMENTAL|Superior/Medial Running Sutures|In this cohort, the running sutures will be randomized to be oriented on Superior/Medial half of the scar, and the remaining half of the scar will be closed with simple interrupted sutures.
62852642|NCT02997306|EXPERIMENTAL|Inferior/Lateral Running Sutures|In this cohort, the running sutures will be randomized to be oriented on Inferior/Lateral half of the scar, and the remaining half of the scar will be closed with simple interrupted sutures.
62852643|NCT05197660||- cataract surgery|
62852644|NCT05197660||- hip arthoplasty|
62852645|NCT05197660||- knee arthoplasty|
62852646|NCT05197660||- coronary angioplasty|
62852647|NCT05197660||- definitive cardiac stimulation (pacemaker)|
62852648|NCT02199717||Boys with Hemophilia|Accelerometer use for 1 week.
62852649|NCT03711240|EXPERIMENTAL|bevacizumab+mFOLFOXIRI|
62852650|NCT04721587|NO_INTERVENTION|Standard of care|Office hysteroscopy performed as the standard of care of our Hospital
62852651|NCT04721587|EXPERIMENTAL|Virtual Reality|Office hysteroscopy with the use of VR environment (preprocedure and during procedure)
62852652|NCT06243562|ACTIVE_COMPARATOR|combined exercises and progressive muscle relaxation group|Participants in this group will be given combined exercises consisting of aerobic exercise, strengthening exercise and stretching exercise, as well as progressive muscle relaxation training. The studies will be carried out under the supervision of a physiotherapist.
62852653|NCT06243562|ACTIVE_COMPARATOR|combined exercises group|Participants in this group will be given combined exercises consisting of aerobic exercise, strengthening exercise and stretching exercise. They will rest for 10-15 minutes in a relaxation position only. The studies will be carried out under the supervision of a physiotherapist.
62267729|NCT04034862|EXPERIMENTAL|2DR|Switch from 3 drug regimen (DTG+ABC+3TC) to 2 drug regimen (DTG+3TC)
62450927|NCT03457909|EXPERIMENTAL|DS-MCE|outpatients who have esophagus symptoms will take DS-MCE and conventional endoscopy examination examination successively.
62450928|NCT04809181|EXPERIMENTAL|MRD positive AML/MDS patients after allogeneic hematopoietic stem cell transplantation|MRD positive AML/MDS patients after allogeneic hematopoietic stem cell transplantation
62450929|NCT04419337|EXPERIMENTAL|Active arm|metformin+pioglitazone+an SGLT2 inhibitor
62450930|NCT04419337|ACTIVE_COMPARATOR|Control arm|metformin + DPP4 inhibitors
62852654|NCT06055543|ACTIVE_COMPARATOR|Fortimel Energy|Control: high-energy ONS 1.5 Kcal/m 200ml for 90 days
62852655|NCT06055543|EXPERIMENTAL|Fortimel PlantBased|Intervention: high-energy ONS 1.5 Kcal/m 200ml for 90 days
62450931|NCT04442906|ACTIVE_COMPARATOR|group B|IGroup B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline
62852656|NCT02864862|ACTIVE_COMPARATOR|Immediate implant|Immediate implant alone
62852657|NCT02864862|ACTIVE_COMPARATOR|Immediate implant combined with SCTG|Subepithelial connective tissue graft (SCTG)
62852658|NCT02864862|ACTIVE_COMPARATOR|Immediate implant combined with ADM|Acellular dermal matrix (ADM)
62450932|NCT04442906|ACTIVE_COMPARATOR|group BD|. Group BD received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).
62450933|NCT04442906|ACTIVE_COMPARATOR|group BF|Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug).
62450934|NCT03231670||lobar pneumonia|Inpatient with lobar pneumonia will undergo a blood sampling during their hospitalization and after resolution of the infection (2 Months)
62626884|NCT02997813||Cohort 2|All consecutive patients with complete data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and cyclophosphamide
62267730|NCT04034862|NO_INTERVENTION|3DR|Continued 3 drug regimen treatment (DTG+ABC+3TC)
62267731|NCT05632185|NO_INTERVENTION|Control group|standard regular treatment modalities
62267732|NCT05632185|ACTIVE_COMPARATOR|Equine assisted intervention|patients will receive weekly equine-assisted therapy sessions over a period of 8 weeks in addition to their standard regular therapy
62267733|NCT02498639|ACTIVE_COMPARATOR|BAV without pacing|Patients undergo percutaneous balloon aortic valvuloplasty (BAV) without previous insertion of a temporary pacemaker lead in the right ventricle. Stabilization of the balloon during inflation is done without rapid pacing.
62267734|NCT02498639|ACTIVE_COMPARATOR|BAV with pacing|Patients undergo percutaneous balloon aortic valvuloplasty (BAV) after previous insertion of a temporary pacemaker lead in the right ventricle. Stabilization of the balloon during inflation is done under rapid pacing.
62267735|NCT03353571|OTHER|C3 PATIENT PARTICIPANTS|This single arm prospective study is designed to produce valid scientific evidence regarding safety and efficacy of the C3 in establishing urinary drainage and allowing the control of micturition when indwelling for up to 7 days in patients. The total study population will initially include 50 subjects with open enrollment of additional subjects.
62267736|NCT05424653|EXPERIMENTAL|Severe Symptomatic Aortic Regurgitation|Patients will be treated with transcatheter aortic valve system
62267737|NCT05573074|EXPERIMENTAL|tPBM Group|Visit 1: t-PBM at irradiance dose of 291.7 mW/cm2 (333s) Visit 2 - 18: randomized to receive active t-PBM of 291.7 mW/cm2 (333s) Visit 19: t-PBM at irradiance dose of 291.7 mW/cm2 (333s)
62267738|NCT05573074|ACTIVE_COMPARATOR|Sham Group|Visit 1: t-PBM at irradiance does of 291.7 mW/cm2 (333s) Visit 2 - 18: randomized to receive Sham of 0 mW/cm2 (333s) Visit 19: t-PBM at irradiance dose of 291.7 mW/cm2 (333s)
62450935|NCT00963157|EXPERIMENTAL|Group 1: 3.75 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
62450936|NCT00963157|EXPERIMENTAL|Group 5: 15 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
62450937|NCT00963157|EXPERIMENTAL|Group 4: 7.5 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
62450938|NCT00963157|EXPERIMENTAL|Group 2: 7.5 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
62450939|NCT00963157|EXPERIMENTAL|Group 3: 15 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
62450940|NCT04655599|EXPERIMENTAL|Olorinab, Then Placebo|Participants will first receive olorinab, followed by a washout period, and they then will receive placebo.
62450941|NCT04655599|PLACEBO_COMPARATOR|Placebo, Then Olorinab|Participants will first receive placebo, followed by a washout period, and they then will receive olorinab.
62450942|NCT00989261|EXPERIMENTAL|Cohort 1; ≥60 years of age|"Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission \<12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.~Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)~After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day."
62450943|NCT00989261|EXPERIMENTAL|Cohort 2; ≥18 years of age|"Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.~Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)~After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day."
62450944|NCT04303338|EXPERIMENTAL|Masotherapy with neural tension|The investigators are going to massage the patient´s upper limb applying a radial nerve neural tension. In order to the upper limb should be positioned lowering the scapula, elbow extended, internal rotation glenohumeral, forearm pronation, bend and cubital deviation of the wrist, fingers bended and thumb adduction, and finally glenohumeral abduction.
62450945|NCT04303338|ACTIVE_COMPARATOR|Masotherapy with non-neural tension|The investigators are going to practice a conventional upper limb massage
62450946|NCT03272256|EXPERIMENTAL|IM156, Dose escalation|
62450947|NCT02222766|EXPERIMENTAL|Parents and Tots Together Program|9-week group-based parenting program
62450948|NCT02222766|ACTIVE_COMPARATOR|Control|Minimal attention control- weekly mailed information on general child development for 9 weeks
62461450|NCT03613259|EXPERIMENTAL|Diagnostic (fluorothymidine F-18 PET)|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes 21 or less days prior to standard of care radiation therapy and 14 or less days prior to the standard of care surgery.
62461451|NCT03816371|ACTIVE_COMPARATOR|supine 0 degree head-of-bed elevation|0 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
62461452|NCT03816371|EXPERIMENTAL|30 degree head-of-bed elevation|30 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
62461453|NCT03816371|EXPERIMENTAL|45 degree head-of-bed elevation|45 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
62267739|NCT03724565||Endoscopic procedural area|air quality check of endoscopic procedural room
62267740|NCT03724565||Recovery area for patients|air quality check of recovery area for patients in endoscopic unit
62267741|NCT03724565||Cleansing area for equipments|air quality check of cleansing area for equipments in endoscopic unit
62267742|NCT05858619|EXPERIMENTAL|dupilumab treatment|Treatment with IL4RA inhibitor
62267743|NCT05352152||Patients with ascites infection|Patients who is confirmed with ascites infection or clinically diagnosed as ascites infection will be enrolled in this cohort.
62267744|NCT05342675|EXPERIMENTAL|Rapid Rollover|Participants will have their body re-positioned upon being transferred to the stretcher from the CT scanner table such that the biopsy site is down. Participants will be maintained in the same position for the post-biopsy CT scanner as well as in the post-procedure recovery area for a minimum of 2 hours.
62267745|NCT05342675|NO_INTERVENTION|Control|CT-guided lung biopsy will be performed per standard protocols
62267746|NCT03033875|EXPERIMENTAL|Tele-Savvy Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to participate in the Tele-Savvy program immediately.
62267747|NCT03033875|OTHER|Attention Control Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to participate in the Healthy Living Education Program. Persons in this group will be able to participate in the Tele-Savvy intervention after a delay of 6 months.
62626885|NCT01912859|EXPERIMENTAL|Nutrition/physical activity intervention|The intervention, Next Steps, comprises a network of community-led health maintenance programs offered to graduates of an initial intensive obesity course. These health maintenance programs will aim to help participants maintain and improve healthful behaviors and body mass indices.
62626886|NCT01912859|NO_INTERVENTION|Usual care|"Participants in the No Intervention arm will not have access to the Next Steps programs and will receive only usual care through their health care clinic."
62626887|NCT02225808|EXPERIMENTAL|CBT for anxiety in autism|Cognitive-behavioral therapy (CBT) teaches skills for coping with anxiety and consist of 12 weekly sessions. CBT is conducted with child and parent.
62626888|NCT02635256|EXPERIMENTAL|Hypofractionated Radiosurgery|5 fractions with 7 Gy, total dose 35 Gy
62626889|NCT04283253|EXPERIMENTAL|Robot + TTT Exercise|All participants will be enrolled in this group to receive the same 60 minute study intervention consisting of wrist and shoulder-elbow robot training and TTT arm exercises.
62852659|NCT02263352|EXPERIMENTAL|Lycored soft gels , Scaling and Rootplaning.|Systemic Lycored soft gels,(Jagsonpal Pharma) was given orally 8mgms/day for 2 months and Scaling and rootplaning (otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus) which was performed at baseline
62852660|NCT02263352|EXPERIMENTAL|Scaling and Rootplaning only.|Scaling and rootplaning(otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus) which was performed at baseline.
62267748|NCT03033875|NO_INTERVENTION|Usual Care Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to continue to receive care through whatever arrangement has been in place. Persons in this group will be able to participate in the Tele-Savvy intervention after a delay of 6 months.
62267749|NCT03586414|EXPERIMENTAL|A: 'MITOQUINOL MESYLATE then placebo|'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
62267750|NCT03586414|EXPERIMENTAL|B: Placebo then 'MITOQUINOL MESYLATE'|Placebo capsule administered twice daily for 4 weeks followed by a washout period, then 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'
62267751|NCT02090322|EXPERIMENTAL|Bevacizumab|"The treatment for Retinopathy of prematurity is Intravitreal bevacizumab. We want to compare two dosages (0.500 and 0.625mg) and demonstrate that 0.500mg there isn't lower in efficacy than 0.625mg.~When the baby have the diagnosis or Retinopathy of prematurity we are going to inyect the eye that have te problem, then we are going to explore until this illness disappear. It is only one intervention"
62267752|NCT03108313|EXPERIMENTAL|aloe vera toothpaste|aloe vera toothpaste isa will be administrated 2 times per day for 30 days and salivary bacterial count will be tested before the use of toothpaste the after 15 days and 30 days
62626890|NCT02930681|PLACEBO_COMPARATOR|Placebo|Four capsules of placebo to be taken 30 mins before each test meal at the investigator's site
62626891|NCT02930681|EXPERIMENTAL|Glucosanol 1000mg|Two capsules of placebo and two capsules of Glucosanol 500mg capsules to be taken 30 mins before each test meal at the investigator's site
62626892|NCT02930681|EXPERIMENTAL|Glucosanol 2000mg|Four capsules of Glucosanol 500mg to be taken 30 mins before each test meal at the investigator's site
62626893|NCT02213588|ACTIVE_COMPARATOR|AOX blend|Rosemary:Quercetin:Turmeric (300 mg total)
62626894|NCT02213588|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62626895|NCT03337620|ACTIVE_COMPARATOR|Bupivacaine|Bupivacaine is a local anesthestic that will be delivered to the SPG by the Tx360 device.
62626896|NCT03337620|PLACEBO_COMPARATOR|saline|Saline is being used as a placebo treatment that will be delivered to the SPG by the Tx360 device.
62852661|NCT04321447|EXPERIMENTAL|Clinical practice guideline (CPG) group|Implementation of an evidence-based clinical practice guideline and delivery of an educational programme
62852662|NCT04321447|NO_INTERVENTION|Usual care group|Usual care
62852663|NCT00505076|EXPERIMENTAL|MK-0777 8 mg|MK-0777 8 mg tablet by mouth twice daily for 4 weeks
62852664|NCT00505076|EXPERIMENTAL|MK-0777 3 mg|MK-0777 3 mg tablet by mouth twice daily for 4 weeks
62852665|NCT00505076|PLACEBO_COMPARATOR|Placebo|Placebo tablet by mouth twice daily for 4 weeks
62852666|NCT04741126|EXPERIMENTAL|Intervention Protocol|Hospital-based manually assisted cough technique for 4 weeks.
62852667|NCT00999193|ACTIVE_COMPARATOR|Conservative Treatment|
62852668|NCT00999193|EXPERIMENTAL|ORIF w. locking plate, no luxation|
62852669|NCT00999193|EXPERIMENTAL|Hemiarthroplasty, no luxation|
62852670|NCT03658096|ACTIVE_COMPARATOR|Healthy volunteer|
62852671|NCT03658096|ACTIVE_COMPARATOR|DRUJ instability patients|
62852672|NCT03365843|EXPERIMENTAL|Montage bone putty|Sternal closure with conventional wire cerclage plus Montage bone putty
62852673|NCT03365843|ACTIVE_COMPARATOR|Conventional Sternal Closure|Conventional wire cerclage sternal closure only -- standard care.
62852674|NCT01812447|EXPERIMENTAL|Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management.
62267753|NCT03108313|ACTIVE_COMPARATOR|fluoride toothpaste|fluoride toothpaste isa herbal toothpaste will be administrated 2 times per day for 30 days and salivary bacterial count will be tested before the use of toothpaste the after 15 days and 30 days
62626897|NCT02903810|EXPERIMENTAL|Mixed CAR-T Transfer|All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number
62062993|NCT06546319|NO_INTERVENTION|Control|No additional intervention will be conducted for this arm during their study participation. Participants will complete a series of questionnaires after enrolling, 15 days post hospital discharge, and 30 days post hospital discharge. Participants randomized to the control arm will be offered a single virtual music therapy session after 30 days post-discharge. No data will be collected during this music therapy session.
62267754|NCT05459831|ACTIVE_COMPARATOR|Pulmonary vein isolation with 50W energy setting|In this group of subjects, the initial pulmonary vein isolation procedure will be performed using 50W radiofrequency energy. This power setting will be used for all the ablation points.
62267755|NCT05459831|ACTIVE_COMPARATOR|Pulmonary vein isolation with 90W energy setting|In this group of subjects, the initial pulmonary vein isolation procedure will be performed using 90W radiofrequency energy. This power setting will be used for all the ablation points.
62626898|NCT06241885|EXPERIMENTAL|Intervention group I|Women in Intervention Group II will wear gynaecological shorts specially developed by the researchers before vaginal examination. These shorts will be made of disposable fabric and will be sewn by the researchers in four different sizes (S-M-L-XL) according to the weight of the women. The middle part of the shorts to be developed will be closed with a snap button, and the opening will be provided when the snap button is opened during vaginal examination. In addition, these shorts will be approximately knee-cap length for women.
62852675|NCT01812447|EXPERIMENTAL|Spiration Valve System, α-1|α-1 antitrypsin deficiency subjects will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management. There is no randomization for this group.
62626899|NCT06241885|NO_INTERVENTION|Control|The women in the control group will not be subjected to any additional hospital procedure during vaginal examination. Privacy curtains are routinely used in the hospital.
62062994|NCT02993939|ACTIVE_COMPARATOR|Interscalene block|Ultrasound guided Brachial plexus block injecting 20 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml, in the Interscalene groove.
62062995|NCT02993939|EXPERIMENTAL|Diaphragm-sparing block|Ultrasound guided combinated infraclavicular-Suprascapular block of the braquial plexus, injecting 20 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml dorsal to the axillary artery in the infraclavicular fossa plus an Ultrasound guided injection of 10 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml in the suprascapular fossa.
62267756|NCT06338956||>=50% LDL-C reduction|"LDL-C reduction \>=50%~Further divided by LDL \<55mg/dL 55\< LDL \< 70 mg/dL LDL \> 70 mg/dL"
62626900|NCT05420142|EXPERIMENTAL|Test meal incorporating the study groups innovative plant protein and fibre (variety 3) product.|The standardised test meal was prepared in a single dose using Knorr low sodium chicken stock cubes (9g = 1 stock cube), 65.64g of plant protein and fibre variety 3 (3.09g leucine), 28.6g butter, 5.12g cornflour, and 300ml water. The test meal is consumed in a single sitting in the morning following an overnight fast. Blood samples are acquired at baseline and at set intervals over the subsequent 3-hours to examine the net peripheral amino acid appearance.
62267757|NCT06338956||<50% LDL-C reduction|LDL-C reduction \<50%
62626901|NCT05420142|EXPERIMENTAL|Test meal incorporating the study groups innovative plant protein and fibre (variety 5) product.|The standardised test meal was prepared in a single dose using Knorr low sodium chicken stock cubes (9g = 1 stock cube), 67.78g of plant protein and fibre variety 3 (3.09g leucine), 27.79g butter, 4.63g cornflour, and 300ml water. The test meal is consumed in a single sitting in the morning following an overnight fast. Blood samples are acquired at baseline and at set intervals over the subsequent 3-hours to examine the net peripheral amino acid appearance.
62852676|NCT01812447|ACTIVE_COMPARATOR|Medical Management|The control group for this study will receive medical management. This medical management group will be evaluated and followed in the same manner as the treatment group, but without having a bronchoscopic procedure.
62626902|NCT05420142|EXPERIMENTAL|Test meal incorporating the study groups innovative plant protein and fibre (variety 6) product.|The standardised test meal was prepared in a single dose using Knorr low sodium chicken stock cubes (9g = 1 stock cube), 57.66g of plant protein and fibre variety 3 (3.09g leucine), 31.72g butter, 6.62g cornflour, and 300ml water. The test meal is consumed in a single sitting in the morning following an overnight fast. Blood samples are acquired at baseline and at set intervals over the subsequent 3-hours to examine the net peripheral amino acid appearance.
62626903|NCT05420142|ACTIVE_COMPARATOR|Test meal incorporating the control comparator (whey protein isolates), plus 10g of added pea fibre.|The standardised test meal was prepared in a single dose using Knorr low sodium chicken stock cubes (9g = 1 stock cube), 36.59g of unflavoured Optimum Nutrition gold standard 100% whey protein (3.09g leucine), 33.23g butter, 9.09g cornflour, and 300ml water. The test meal is consumed in a single sitting in the morning following an overnight fast. Blood samples are acquired at baseline and at set intervals over the subsequent 3-hours to examine the net peripheral amino acid appearance.
62626904|NCT03495297|NO_INTERVENTION|S-ICD Implant with defibrillation test|Patients undergoing de novo S-ICD implantation including induction of VF and defibrillation testing post-implant
62062996|NCT04146649|EXPERIMENTAL|Primary Osteoarthritis|Patients with native knees and effusions will participate in this arm.
62626905|NCT03495297|EXPERIMENTAL|S-ICD Implant without defibrillation test|Patients undergoing de novo S-ICD implantation without induction of VF and defibrillation testing post-implant
62062997|NCT04146649|EXPERIMENTAL|Primary TKA|Patients with total knee replacements will participate in this arm.
62450949|NCT03478059|EXPERIMENTAL|Mild Traumatic Brain Injury|"60 minute, 3 times per week, 6 week long Cognitive and Motor Dual-task Intervention program. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI.~Subjects with mTBI residuals will be gently progressed through exercise stations in an individually tailored fashion."
62626906|NCT05033925|PLACEBO_COMPARATOR|Placebo|receive a plasebo capsule 2 doses per day
62626907|NCT05033925|EXPERIMENTAL|FADA 800 mg/day|receive FADA capsules twice a day (each 400 mg)
62626908|NCT05033925|EXPERIMENTAL|FADA 2000 mg/day|receive FADA capsules twice a day (each 1000 mg)
62626909|NCT01670045||Rheumatoid Arthritis Participants|Participants with moderate to severe rheumatoid arthritis (RA) according to the American College of Rheumatology (ACR) criteria and the Disease Activity Score based on 28 Joint Count (DAS28) who were on tocilizumab treatment within 8 weeks prior to start of study will receive tocilizumab in accordance with the licensed label recommendations, and will be observed for 6 months. The study is designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication is required.
62626910|NCT03094884|EXPERIMENTAL|Pulsed Low dose radiation with Carboplatin/Paclitaxel|Pulsed Low Dose Radiation concurrent with Carboplatin and Paclitaxel
62626911|NCT01749046|EXPERIMENTAL|Remegal|Remegal 1500 mg
62852677|NCT05916599||Goal directed|The inferior vena cava collapse index IVC CI and lung ultrasound score (LUS) measurements and goal directed fluid therapy will be done.Patients in the group will be started with fluid replasment at an hourly rate of 2ml/kg/h and with ultrasound measurement the infused fluid will be evaluated and regulated.
62626912|NCT01749046|PLACEBO_COMPARATOR|Placebo|Placebo
62626913|NCT02721498|ACTIVE_COMPARATOR|Visit A|Rest period for 30-60 minutes
62626914|NCT02721498|ACTIVE_COMPARATOR|Visit B|Airway clearance session utilising the Active Cycle of Breathing techniques (ACBT) supervised by a specialist physiotherapist for 30-60 minutes.
62852678|NCT05916599||conventional|. Group applying zero balance liquid therapy to patients with conventional methods is planned. Crystalloid liquid infusion at a rate of 2ml/kg/hour will be administered to the patients in the group additional fluid replacement will be decided by monitoring bleeding and urinary output, zero balance is aimed at patients.
62852679|NCT00299611|ACTIVE_COMPARATOR|1|Levetiracetam
62626915|NCT02487537|PLACEBO_COMPARATOR|Non-sweetened soft drink|4-week-intervention with one liter of custom-made soft drink per day; soft drink does not contain glucose or any kind of sweet tasting substance
62852680|NCT00299611|PLACEBO_COMPARATOR|2|there is no active ingredient in the pills.
62852681|NCT06308705|OTHER|Sera|All sera available in our biobank and originating from the Strong Treat trial will be eligible for the study, based on the availability of the baseline and the 12-month follow up serum of each included case.
62852682|NCT02437110|EXPERIMENTAL|ALS|20 participants with ALS and a level of HERV-K:RPP30 greater than or equal to 13
62852683|NCT01571544|EXPERIMENTAL|Thermal suit|Randomly selected half of the patients will use thermal suit prior to anesthesia, during the surgery and post anesthesia care unit.
62852684|NCT01571544|ACTIVE_COMPARATOR|Conventional clothing|Randomly selected half of the patients will use conventional clothing prior to anesthesia, during the surgery and post anesthesia care unit.
62852685|NCT01311284|ACTIVE_COMPARATOR|Macintosh|
62852686|NCT01311284|ACTIVE_COMPARATOR|Mcgrath|
62852687|NCT01311284|ACTIVE_COMPARATOR|Airtraq Nasotracheal|
62062998|NCT06434714|ACTIVE_COMPARATOR|Bridge device|Bridge device placed in post-anesthesia care unit (PACU) and worn until end-of-life of the device (at 5 days) in addition to standard of care pain medications as per institutional policy
62062999|NCT06434714|SHAM_COMPARATOR|Sham device|Sham (non-functional) Bridge device placed in post-anesthesia care unit (PACU) and worn until 5 days post-delivery in addition to standard of care pain medications as per institutional policy
62063000|NCT06434714|NO_INTERVENTION|Standard of care|Standard of care pain medications only as per institutional policy
62063001|NCT04310917|OTHER|Lipoprotein a level|blood lipoprotein (a) test
62626916|NCT02487537|ACTIVE_COMPARATOR|Sweetened soft drink|4-week-intervention with one liter of custom-made soft drink per day, soft drinks contains an amount of sweetener, which is isosweet compared to 100 g of sucrose in one liter of beverage
62626917|NCT04542876|EXPERIMENTAL|Ayurveda|Guduchi Ghana is a unique Ayuvedic classical preparation prepared from aqueous extracts of Tinospora cordifolia stem.
62852688|NCT06163378|EXPERIMENTAL|RUBATO|patients will be asked to listen (using headphones to accommodate patients with hearing aid) to a minimum of 30 minutes per day of music (or a total of 3.5 hours per week), coming up to their scheduled reassessment appointments (every 6 to 12 weeks) using the RL music selection application while wearing an individual smart bracelet aimed to build their optimal music therapy profile;
62626918|NCT01787006|EXPERIMENTAL|Cetuximab, Cisplatin, 5-FU, Radiotherapy|"Cetuximab: Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total, IV~5-fluorouracil (5-FU): 1000mg/m2 per day as continuous infusion on day 8-11 and 36-39, 750mg/m2/day as continuous infusion on day 71-74 and 99-102~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle (day 8-11, 36-39, 71-74 and 99-102)~radiotherapy: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery."
62267758|NCT04820894||Observational (survey, medical records review)|Patients complete surveys over 30 minutes about sociodemographic information and perception of immunotherapy, over 10 minutes about expectations of cure, over 10 minutes about anxiety, over 10 minutes about depression, and over 30 minutes about physical well-being. Patients' medical records are reviewed.
62626919|NCT01787006|ACTIVE_COMPARATOR|Cisplatin, 5-FU, Radiotherapy|"5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 and 29-32, 750mg/m2/day as continuous infusion on day 64-67 and 92-95~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle (day 1-4, 29-32, 64-67 and 92-95)~radiotherapy: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery."
62626920|NCT01923324|EXPERIMENTAL|Physician telephone consultation|Received direct telephone consultation with pain physician about index patient
62267759|NCT02408471|OTHER|Ascension® MCP Finger Implant|Single arm study, patient treated with Ascension® PyroCarbon MCP implant.
62626921|NCT01923324|ACTIVE_COMPARATOR|Usual family physician care|Usual family physician care (without direct telephone consultation with pain physician)
62626922|NCT01990573|EXPERIMENTAL|methadone HCl 0.3 mg/kg|0.3mg/kg IV methadone HCl
62626923|NCT01990573|EXPERIMENTAL|methadone HCl 0.4 mg/kg|0.4mg/kg IV methadon HCl
62626924|NCT01990573|ACTIVE_COMPARATOR|control group|control no methadone, standard of care opioids.
62852689|NCT06163378|NO_INTERVENTION|STANDARD OF CARE|patients will continue to receive standard of care.
62626925|NCT03387969||meningitic group|Children suffering from fever , disturbed consciousnessand convulsion admitted in emergency department attending to assiut University Children Hospital aged between 2-18 years old
62626926|NCT03147950|ACTIVE_COMPARATOR|Prone-Flexed PCNL|Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)
62626927|NCT03147950|ACTIVE_COMPARATOR|Prone PCNL|Prone Position For Percutaneous Nephrolithotomy (PCNL)
62852690|NCT01429025|EXPERIMENTAL|rituximab, bendamustine and lenalidomide|Patients receive rituximab IV on day 1, bendamustine IV on days 1-2, and lenalidomide PO on days 1-10. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62852691|NCT02870933|EXPERIMENTAL|subject|this arm will receive Transepicardial with Transseptal CD 133+ Implantation
62267760|NCT00439946|EXPERIMENTAL|treprostinil|IV treprostinil continuous infusion via Crono Five infusion pump.
62267761|NCT02484911|EXPERIMENTAL|Olanzapine regimen|Olanzapine in combination with aprepitant ,palonosetron and dexamethasone.
62267762|NCT02484911|OTHER|Control regimen|Aprepitant in combination with palonosetron and dexamethasone
62267763|NCT01014832|EXPERIMENTAL|Uncontrolled diabetes|Uncontrolled diabetes
62852692|NCT02870933|NO_INTERVENTION|control|this arm will not receive Transepicardial with Transseptal CD 133+ Implantation
62267764|NCT00847912|EXPERIMENTAL|Arm 1: 5-fluorouracil|Group assigned to blinded 5-FU (5-fluorouracil) cream applied to face and ears twice daily for maximum of 56 doses
62267765|NCT00847912|PLACEBO_COMPARATOR|Arm 2: Placebo|Group assigned to blinded placebo, vehicle control cream applied to face and ears twice daily for maximum of 56 doses
62267766|NCT02762474|EXPERIMENTAL|nab-paclitaxel group|Weekly Regimens of paclitaxel Plus Cispaltin Combined With Concurrent IMRT
62626928|NCT04235322|EXPERIMENTAL|2LHERP® arm|2LHERP® treatment (6 months of treatment)
62626929|NCT04235322|PLACEBO_COMPARATOR|Placebo arm|Placebo treatment (6 months of treatment)
62626930|NCT06476704|EXPERIMENTAL|Hypofractionated radiotherapy + Liposomal Transcorcetin (L-TC)|
62626931|NCT06476704|ACTIVE_COMPARATOR|Hypofractionated radiotherapy alone|
62626932|NCT03959527|EXPERIMENTAL|zoliflodacin|Participant in this arm will receive a single dose of zoliflodacin.
62626933|NCT03959527|ACTIVE_COMPARATOR|ceftriaxone and azithromycin combination|Participant in this arm will receive a single dose of comparators combination (ceftriaxone and azithromycin).
62626934|NCT06178484||Functional treatment|Functional treatment combines the use of splints, rehabilitation and muscle strengthening
62852693|NCT01233232|PLACEBO_COMPARATOR|1|Placebo dose
62852694|NCT01233232|EXPERIMENTAL|2|Treatment arm AZD5069 50mg
62852695|NCT01233232|EXPERIMENTAL|3|Treatment arm AZD5069 80mg
62852696|NCT06119750|EXPERIMENTAL|MIS Solution|device under investigation
62852697|NCT06119750|PLACEBO_COMPARATOR|Saline|0.9%
62852698|NCT06119750|ACTIVE_COMPARATOR|Sodium Lauryl Sulfate|20%
62267767|NCT02022488|ACTIVE_COMPARATOR|midazolam and alfentanil|Midazolam 0.5mg/kg (oral) Alfentanil 10 microgram/kg (oral)
62626935|NCT06178484||Surgical treatment|Surgical treatment means ACL tear repair
62267768|NCT02022488|ACTIVE_COMPARATOR|midazolam and ketamine|Midazolam 0.5mg/kg (oral) Ketamine 2mg/kg (intranasal)
62267769|NCT02022488|PLACEBO_COMPARATOR|midazolam|Midazolam 0.5mg/kg
62852699|NCT04384133|OTHER|COPD group|Impulse oscillometric pulmonary function tests and spirometric pulmonary function test will be performed.To evaluate the degree of disease inflammation and phenotype, nitric oxide measurements will be made in the breath air with fractional exhaled nitric oxide (FENO) device. Blood eosinophil values will be examined. Thorax computed tomography will be performed to evaluate small airway dysfunction. To assess symptom control in patients with COPD, a dyspnea scale of mMRC will be administered. The COPD assessment test (CAT) will be applied to measure the quality of life. All participants will be followed for 1 year to record the number of exacerbations requiring emergency and hospital admissions for COPD.
62852700|NCT04384133|OTHER|Healthy control group with a history of smoking|Impulse oscillometric pulmonary function test, spirometric pulmonary function test and chest x ray will be performed.
62267770|NCT03528512|EXPERIMENTAL|IN ketamine|Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)
62852701|NCT04384133|OTHER|Healthy control group with no smoking history|Impulse oscillometric pulmonary function test, spirometric pulmonary function test and chest x ray will be performed.
62450950|NCT03478059|OTHER|Healthy Control|"60 minute, 3 times per week, 6 week long Cognitive and Motor Dual-task Intervention program. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI.~In addition to providing comparison data, the healthy control, athletic 18-34 year old subjects will be used to identify levels and intensity of progressions of dual-task training stations appropriate for highly trained athletes and military personnel recovering from concussion."
62450951|NCT05745298|EXPERIMENTAL|AFES and RMT Paraplegia Group|Patients with a diagnosis of paraplegia will receive co-treatment with abdominal functional electrical stimulation (AFES) and respiratory muscle training (RMT) for 2 weeks.
62626936|NCT05122455|EXPERIMENTAL|ASA baseline|Patients in chronic use of ASA
62267771|NCT03528512|ACTIVE_COMPARATOR|IN midazolam and fentanyl|Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
62267772|NCT06321107||Test group|Gensci094
62626937|NCT05122455|EXPERIMENTAL|ASA + Edoxaban|During this intervention phase, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days.
62626938|NCT05122455|EXPERIMENTAL|Clopidogrel|Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA).
62267773|NCT06321107||Control group|rFSH
62267774|NCT03246737||pregnant women|
62267775|NCT05182957|EXPERIMENTAL|Anti-PD-1 monoclonal antibody+Lenalidomide+Azacitidine|Anti-PD-1 monoclonal antibody plus Lenalidomide, Azacitidine
62267776|NCT04996121|EXPERIMENTAL|XZP-5955 tablets|XZP-5955 tablets
62267777|NCT02595450||Erlotinib|Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
62267778|NCT03976037|ACTIVE_COMPARATOR|Vaginal Misoprostol in combination with foley bulb|"Women in the vaginal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of misoprostol per vagina along with the insertion of a16F Foley catheter with a stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~Vaginal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
62063002|NCT05130814|ACTIVE_COMPARATOR|Control Group|"The Control Group will follow the standard treatment indicated three times a week for the 4 weeks of observation.~The standard treatment for 2° and 3° stage PU consists of: cleansing with saline or ringer's lactate, hyaluronic acid gauze plus polyurethane foam every 48 hours or as needed. In addition, zinc cream or hyaluronic acid sodium salt + metallic silver is applied to prevent and/or treat the skin maceration of the surrounding area, and eventual debridement of the lesion, application of topical treatment indicated for that stage of the lesion (as provided by the Protocol on pressure ulcers' dressing intended as the standard of care of the structure) and subsequent bandage (that generally consists of a polyurethane film -thin hydrocolloid plate or a pressure discharge system made with hydrocolloids and polyurethane foam, known as pressure relief system), are planned."
62626939|NCT05122455|EXPERIMENTAL|Clopidogrel + Edoxaban|Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days
62626940|NCT05122455|EXPERIMENTAL|Edoxaban|Finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered.
62626941|NCT02991963||Case|Malaria patient defined by positive RDT or blood smear
62626942|NCT02991963||Control|Non-malaria patient defined by negative RDT or blood smear
62626943|NCT02090283|EXPERIMENTAL|SD-101 Dermal Cream (6%)|All participants applied SD-101 dermal cream topically, once a day, to the entire body for the duration of the study.
62852702|NCT01453062||Patients with a diagnosis of CLL|Patients with a diagnosis of CLL
62852703|NCT04709133|EXPERIMENTAL|multi-ligament knee injures|A chart review will be performed to identify patients who underwent surgical treatment for multiligamentous knee injuries at Assiut University Hospital performed by one of sports medicine orthopaedic surgeons at Assiut arthroscopy and sport unit.
62267779|NCT03976037|ACTIVE_COMPARATOR|Buccal Misoprostol in combination with foley bulb|"misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
62267780|NCT01695473|EXPERIMENTAL|Neoadjuvant BKM120|Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in operating room (OR) scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
62626944|NCT01098162||Vimpat®|Routine treatment in accordance with the local marketing authorization for Vimpat® added to one Baseline antiepileptic drug.
62626945|NCT00762190|EXPERIMENTAL|TAK-559 32 mg QD + Insulin|
62626946|NCT00762190|ACTIVE_COMPARATOR|Insulin|
62626947|NCT00971490|EXPERIMENTAL|Group 1|
62626948|NCT00971490|PLACEBO_COMPARATOR|Group 2|
62626949|NCT00971490|SHAM_COMPARATOR|Group 3|
62626950|NCT04618991|EXPERIMENTAL|Adult patients with SAHOS for whom maxillary transversal surgery|Adult patients with SAHOS for whom maxillary transversal surgery is recommended.
62626951|NCT06598124|OTHER|Arm 1|Visit 1: Comparator Product; Visit 2: Investigational Product
62852704|NCT05082597|EXPERIMENTAL|ESWT|Receive low energy extracorporeal shock wave therapy
62626952|NCT06598124|OTHER|Arm 2|Visit 1: Investigational Product; Visit 2: Comparator Product
62626953|NCT06285071||Concizumab|Participants with haemophilia A or haemophilia B with inhibitors will be treated with commercially available Alhemo (Concizumab) according to routine clinical practice at the discretion of the treating physician. Recruitment will be completed after 4.5 years from the launch of Concizumab. The observation period for each participant is 2 years. Total duration of this study is about 6.5 years.
62626954|NCT03941145|EXPERIMENTAL|Exercise|Participants allocated to the intervention group will be asked to perform 2 exercise sessions per week for 6 weeks. Each session will involve 10 min of low-intensity cycling (25 W) interspersed with two 20-s 'all-out' cycle sprints against a resistance equivalent to 5% of body mass. The exercise intervention will be delivered on a commercially available cycle ergometer with software developed by CAR.O.L.
62852705|NCT03545425||Idiopathic Parkinson's Disease patients|Up to 30 Parkinson's Disease patients will be enrolled.
62852706|NCT03545425||Healthy Controls|Up to 30 Healthy Controls will be enrolled.
62852707|NCT03545425||LRRK2 G2019S - Manifesting|Up to 30 LRRK2 G2019S Manifesting carriers will be enrolled.
62852708|NCT03545425||LRRK2 G2019S - Non-Manifesting|Up to 30 LRRK2 G2019s Non-Manifesting carriers will be enrolled.
62626955|NCT03941145|NO_INTERVENTION|Control|The effects of the intervention will be compared to a no-intervention control group recruited from the same workplace settings.
62626956|NCT06483126||Persons with Parkinson's disease (PwPD)|Individuals with a diagnosis of Parkinson's disease
62626957|NCT06483126||Persons without Parkinson's disease|Healthy middle-aged and older adults
62626958|NCT01148264|EXPERIMENTAL|olanzapine|
62626959|NCT01148264|ACTIVE_COMPARATOR|metoclopramide|
62626960|NCT05851638||Healthy term neonates|"Inclusion criteria for participant selection are:~* Healthy infant on postnatal ward.~* Full term (gestational age ≥37 weeks).~* Anticipated stay in the hospital \> 1 day.~Exclusion criteria for participant selection are:~* Parent/guardian unable to/decline to participate in the study.~* Baby admitted to the Neonatal Unit.~* Presence of congenital cardiac anomalies (report of antenatal scans from patient electronic record chart)."
62626961|NCT03698539||Down syndrome who stutter|"This group consists of individuals with Down syndrome who stutter. They have a mild or moderate intellectual disability and are able to understand and produce a three word sentence.~Spontaneous hand gestures and stutter frequency are investigated in this group."
62626962|NCT03698539||Down syndrome who do not stutter|"This group consists of individuals with Down syndrome who do not stutter. They have a mild or moderate intellectual disability and are able to understand and produce a three word sentence.~Spontaneous hand gestures are investigated in this group"
62063003|NCT05130814|EXPERIMENTAL|EmoLED Group|"The Experimental Group will undergo, in addition to the standard treatment, treatment with Emoled three times a week for 4 consecutive weeks.~This treatment consists of irradiation with the blue light emitted by the device for one minute on the injured area. If the lesion has a greater extension than the irradiated area, multiple repeated applications will be performed, on adjacent areas, until the entire area is covered.~The treatment with EmoLED will be carried out in correspondence with the dressing change of the lesion."
62626963|NCT03698539||Typically developing children who stutter|This group consists of typically developing children who stutter. They function as a control group to the individuals with Down syndrome.
62063004|NCT05088889|EXPERIMENTAL|study arm|"Study treatments include SBRT (Stereotactic radiation therapy) to one primary/metastatic tumor (3 fractions of 8Gy) , and ipilimumab (1mg/kg every six weeks) + nivolumab (360mg every three weeks) .~Every 8 weeks patients will be assessed for response; responders will continue ipilimumab + nivolumab until disease progression, non-responders will receive very low dose radiation (2Gy single fraction to metastatic lesions of choice) prior to continuing ipilimumab + nivolumab ."
62267781|NCT02805777|EXPERIMENTAL|Washing procedure 1|this group will apply washing technique 1
62063005|NCT02836158|EXPERIMENTAL|R-IDARAM plus intrathecal chemotherapy|Patients will be treated with systemic R-IDARAM plus intrathecal immunochemotherapy
62267782|NCT02805777|EXPERIMENTAL|Washing procedure 2|this group will apply washing technique 2
62267783|NCT02325219|EXPERIMENTAL|Group 1|Participants will receive subcutaneous injection of CNTO 1959 50 milligram (mg) and placebo 100 mg at Week 0, 4 and then every 8 weeks thereafter.
62267784|NCT02325219|EXPERIMENTAL|Group 2|Participants will receive subcutaneous injection of CNTO 1959 100 milligram (mg) and placebo 50 mg at Week 0, 4 and then every 8 weeks thereafter.
62626964|NCT03698539||Typically developing children who do not stutter|This group consists of typically developing children who do not stutter. They function as a control group to the individuals with Down syndrome.
62626965|NCT05004792|ACTIVE_COMPARATOR|Intervention|Access to DermLoop Learn IT platform
62626966|NCT05004792|NO_INTERVENTION|Control group|No access to DermLoop Learn
62626967|NCT02164643|EXPERIMENTAL|Florbetapir (18F)|
62267785|NCT02325219|EXPERIMENTAL|Group 3|Participants will receive subcutaneous injection of placebo 50 mg and 100 mg at Weeks 0, 4 and 12. At Week 16, participants will be randomized in sub-group 3a to receive either CNTO1959 50 mg and placebo 100 mg at Week 16, 20 and then every 8 weeks thereafter or sub-group 3b to receive CNTO 1959 100 mg and placebo 50 mg at Week 16, 20 and then every 8 weeks thereafter.
62626968|NCT02164643|EXPERIMENTAL|Flutemetamol (18F)|
62626969|NCT04030676|EXPERIMENTAL|QuantiFERON Test|Patient with CytoMegaloVirus (CMV) infection will be included. They will have biopsies and blood samples, composite of QuantiFERON-CytoMegaloVirus (QF-CMV) assay.
62626970|NCT05743777|EXPERIMENTAL|Pembrolizumab + MET-4|
62626971|NCT05743777|ACTIVE_COMPARATOR|Pembrolizumab + Placebo|
62626972|NCT04640155|OTHER|Regular Diet|
62626973|NCT04640155|EXPERIMENTAL|Low FODMAP|
62626974|NCT02132728|NO_INTERVENTION|Control group|In the group with 11 volunteers, the control group did no change in normal food intake.
62626975|NCT02132728|EXPERIMENTAL|Flaxseed group|In this group with 14 volunteers, they received 50% carbohydrate, 31% fat, 19% protein and 60 g of flaxseed powder / day during the period of study.
62626976|NCT02132728|EXPERIMENTAL|Rice and low carb group|In this group with 13 volunteers, they received 35% carbohydrate, 46% fat, 19% protein and 60g of raw rice powder / day during the period of study.
62626977|NCT02132728|EXPERIMENTAL|Flaxssed and low carb group|In this group with 14 volunteers, they received 32% carbohydrate, 47% fat, 21% protein and 60 g of flaxseed powder / day during the period of study.
62626978|NCT05569369|EXPERIMENTAL|angioplasty with stenting|
62626979|NCT01897883||One Group|Full Analysis Set (FAS) will be the primary analysis set. All post ischemic stroke patients within 6-12 months from attack (i.e., with inclusion criterion No.2 fulfilled) except the screening failure patients, i.e., those who withdraw from the study once the informed consent is given, will be included in the FAS.
62626980|NCT06613009|EXPERIMENTAL|IBI3009|
62626981|NCT01237288|EXPERIMENTAL|Z-521|
62063006|NCT06624384|ACTIVE_COMPARATOR|Group 1: Drug group (topical cyclosporine 0.05% and Lifitgrast)|Group 1: In this group, cyclosporine 0.05% drops are poured into one eye and Lifitgrast drops are poured into the opposite eye.
62267786|NCT04145011|EXPERIMENTAL|COOLIEF Cooled Radiofrequency Probe|Cooled radiofrequency energy will be delivered to the study subjects' knee to ablate culprit sensory nerves and reduce knee pain
62267787|NCT04145011|ACTIVE_COMPARATOR|Conventional (Standard) Radiofrequency Probe|Standard (non-cooled) radiofrequency energy will be delivered to the study subjects' knee to ablate culprit sensory nerves and reduce knee pain
62852709|NCT03135119|ACTIVE_COMPARATOR|TF-CBT|Youth will receive standard Trauma-Focused Cognitive-Behavioral Therapy
62267788|NCT00498173|EXPERIMENTAL|Atomoxetine|Participants will receive flexibly dosed atomoxetine for 8 weeks. Dosage can be increased over the first 4 weeks of study participation and will then be held constant for the remainder of the 8-week trial.
62063007|NCT06624384|ACTIVE_COMPARATOR|Group 2: drug and placebo (cyclosporine 0.05%-Artlac)|Group 2: In this group, cyclosporine 0.05% drops are poured into one eye and artelac drops are poured into the opposite eye.
62063008|NCT06624384|ACTIVE_COMPARATOR|Group 3: drug and placebo (Lifitgrast-Artlac)|Group 3: In this group, Lifitgrast drops are poured into one eye and artelac drops are poured into the opposite eye.
62063009|NCT00227864|PLACEBO_COMPARATOR|Treatment as Usual|Participants are administered assessments at baseline, 1, 3 and 6 months
62063010|NCT00227864|EXPERIMENTAL|Intervention|Participants complete assessments at baseline, 1, 3 and 6 months, and receive a 2-session behavioral intervention at the baseline and 1-month study appointments.
62267789|NCT00498173|PLACEBO_COMPARATOR|Placebo|Participants will receive blinded, matched placebo for 8 weeks. Dosage can be increased over the first 4 weeks of study participation and will then be held constant for the remainder of the 8-week trial.
62267790|NCT05318456|EXPERIMENTAL|MoodElite T-4003-1|Participants will be instructed to take two capsules of MoodElite T-4003-1 once daily with water, after dinner without food starting on Day 0 for 42 days. If a dose is missed participants are instructed to take the dose as soon as they remember. Participants will be advised not to exceed 4 capsules daily.
62267791|NCT05318456|ACTIVE_COMPARATOR|Comparator|Participants will be instructed to take two capsules of comparator once daily with water, after dinner without food starting on Day 0 for 42 days. If a dose is missed participants are instructed to take the dose as soon as they remember. Participants will be advised not to exceed 4 capsules daily.
62267792|NCT05318456|PLACEBO_COMPARATOR|Placebo|Participants will be instructed to take two capsules of placebo once daily with water, after dinner without food starting on Day 0 for 42 days. If a dose is missed participants are instructed to take the dose as soon as they remember. Participants will be advised not to exceed 4 capsules daily.
62267793|NCT05561517|ACTIVE_COMPARATOR|Competition|Participation in a 5 K competition (running)
62063011|NCT02843802|EXPERIMENTAL|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
62063012|NCT02843802|ACTIVE_COMPARATOR|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
62063013|NCT05892666||Emergency department|ED care for acute ambulatory conditions by physicians unfamiliar with the patients.
62063014|NCT05892666||Walk-in clinics|In-person or virtual care in a walk-in clinic for acute ambulatory conditions by physicians unfamiliar with the patients. In-person and virtual care will be assessed together as part of the care offer in outpatient clinics, but separately as a sub-analysis.
62267794|NCT05561517|ACTIVE_COMPARATOR|Training|Performing a 5 K up-tempo training bout (running)
62267795|NCT03318146|EXPERIMENTAL|EXP-LP punctum plug|EXP-LP is a novel and innovative drug delivery system aiming to improve patient compliance and outcomes. EXP-LP punctum plug, is a non-invasive insert that replaces eye drops and provides sustained therapy for glaucoma, dry eye and other major eye diseases. EXP-LP is a combination of an ophthalmic prostaglandin drug (Latanoprost). The prostaglandin drug works by increasing the natural outflow of fluid from inside the eye
62267796|NCT03318146|ACTIVE_COMPARATOR|XALATAN®|XALATAN® (latanoprost ophthalmic solution) is an eye drop used to treat high eye pressure/intraocular pressure in people with open-angle glaucoma or ocular hypertension. XALATAN is administrated once a day
62267797|NCT05910866|EXPERIMENTAL|Left bundle branch area pacing (LBBAP)|Implant of the ventricular lead of the pacemaker in the left bundle branch area
62267798|NCT05910866|ACTIVE_COMPARATOR|Right ventricular pacing (RVP)|Implant of the ventricular lead of the pacemaker in a conventional site for pacing (apex/paraapical interventricular septum)
62267799|NCT02197676|EXPERIMENTAL|SGI-110|
62852710|NCT03135119|EXPERIMENTAL|TF-CBT+AAT|Youth will received Trauma-Focused Cognitive-Behavioral Therapy with Animal-Assisted Therapy as an adjunct.
62852711|NCT04760171||Group 1|Patients diagnosed with medullary thyroid cancer (MTC) who are undergoing standard surgical treatment for their disease. This will be either hemithyroidectomy or total thyroidectomy. Patients with laryngeal amyloidosis (LA) who are undergoing standard surgical treatment of this disease. This will be microlaryngoscopy \& biopsy/debulking
62267800|NCT01262521|EXPERIMENTAL|Dietary nitrate|150 ml tab water with 150 umol/kg sodium-nitrate
62267801|NCT01262521|PLACEBO_COMPARATOR|Water|150 ml Chapelle mineral water
62267802|NCT06063109|EXPERIMENTAL|Dapagliflozin|THP-00101 (Dapagliflozin) 10mg (18 Subjects): Tx A (5 days) -\> Tx B (5 days) Treatment A: THP-00101 (Dapagliflozin) 10mg/5 days Treatment B: THP-00101 (Dapagliflozin) 10mg/5 days + THP-00102 (Telmisartan) 80mg/5 days
62626982|NCT03295136|EXPERIMENTAL|Health Promotion Training for Women Employees|Groups of women employees will participate in a 20 session health promotion training course. The course will include health education and health promotion knowledge and skills, as well as leadership and project building skills, including empowerment, change process, recruiting partners and more. The first 15 sessions will be weekly session, while the remaining five will take place every couple of months throughout the following year.
62626983|NCT00765817|PLACEBO_COMPARATOR|1|
62267803|NCT06063109|EXPERIMENTAL|Telmisartan|THP-00102 (Telmisartan) 80mg (32 Subjects): Tx C (5 days) -\> Tx B (5 days) Treatment C: THP-00102 (Telmisartan) 80mg/5 days Treatment B: THP-00102 (Telmisartan) 80mg/5 days + THP-00101 (Dapagliflozin) 10mg/5 days
62626984|NCT00765817|EXPERIMENTAL|2|
62626985|NCT04120181||Control|The control group consists of 13 age- and gender-matched subjects who underwent CI surgery but showed no complications. The members of the control group were selected based on hospital records.
62626986|NCT03453814|EXPERIMENTAL|Interventional|Music therapy.
62626987|NCT03453814|NO_INTERVENTION|Comparison|No music therapy.
62626988|NCT02250963||DSE|Patients, who underwent Dobutamine Stress Echocardiography (DSE)
62626989|NCT02250963||CTCA|Computed tomography coronary angiography is going to perform with a 64-slice system (Brilliance 64, Philips Healthcare, Best, the Netherlands).
62626990|NCT04301739|EXPERIMENTAL|HLX10 + chemotherapy→ HLX10|HLX10 + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) → HLX10 + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery → HLX10 (9 cycles)
62063015|NCT05892666||Primary care practice|In-person or virtual care in a primary care clinic for acute ambulatory conditions (patients attached to a primary care practice, seen by their family physician or a colleague on a same-day appointment for urgent needs). In-person and virtual care will be assessed together as part of the care offer in outpatient clinics, but separately as a sub-analysis.
62267804|NCT02072811|OTHER|Induction, DAC|"The first stage of treatment.~First DAC induction cycle is common to all patients (regardless of risk group). After completion of induction I occurs early assessment of bone marrow on the +14 day after the start of treatment (+7 day after completion of chemotherapy)."
62267805|NCT02072811|OTHER|II early induction, CLAG|"Patients with blasts in the bone marrow in D14\> 10% receive early second induction (CLAG) which start form +16 day.~Patients with blasts in the bone marrow in D14 ≤ 10% do not receive early second induction and are qualified to assess the response times on +28 day or after full morphology recovery (if it occurs before the +28 day"
62267806|NCT02072811|OTHER|Consolidation, I HAM cycle|"I induction cycle starts after complete remission (CR).~- After I consolidation, patients from Intermediate I an Intermediate II group (ELN prognostic system):~If compatible donor is present - allogeneic HSCT qualification after I or II consolidation. If compatible donor for allogeneic HSCT is not present - attempt to CD34+ mobilization for autologous SCT after II consolidation~- After I consolidation, patients from Adverse risk group (ELN prognostic system):~If compatible donor is present - immediate qualification for allogeneic HSCT.~- Finding a donor should be initiated in all patients, at the latest after the end of I induction. In the first place, it should be checked whether the patient has a donor family, if not - searching start for an unrelated donor. For patients with no compatible donor for allogeneic HSCT - need to start searching for an alternative donor"
62450952|NCT05745298|EXPERIMENTAL|AFES and RMT Tetraplegia Group|Patients with a diagnosis of tetraplegia will receive co-treatment with abdominal functional electrical stimulation (AFES) and respiratory muscle training (RMT) for 4 weeks.
62450953|NCT02140450|ACTIVE_COMPARATOR|Timolol|Timolol eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
62450954|NCT02140450|ACTIVE_COMPARATOR|Brimonidine|Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
62626991|NCT04301739|PLACEBO_COMPARATOR|Placebo + chemotherapy→ Placebo|Placebo + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) → Placebo + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery → Placebo (9 cycles)
62626992|NCT05859308|ACTIVE_COMPARATOR|Boxing|Rock Steady Boxing
62450955|NCT02140450|ACTIVE_COMPARATOR|Acetazolamide|Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection
62626993|NCT05859308|EXPERIMENTAL|Virtual Reality Pixel Plucker|30 minutes of VR engagement
62626994|NCT03746405|ACTIVE_COMPARATOR|Repetitive TMS (rTMS)|excitatory rTMS applied over the medial prefrontal cortex (fMRI-guided)
62626995|NCT03746405|SHAM_COMPARATOR|Sham repetitive TMS (rTMS)|electrical sham coil applied over the medial prefrontal cortex (fMRI-guided)
62626996|NCT01738776||Cases|Hip fracture patients participating in a randomised controlled trial (RCT) of orthogeriatric care (ClinicalTrials.gov NCT01009268)
62626997|NCT01738776||Controls|A group of voluntary elderly persons without a history of hip fracture, recruited specifically for this purpose
62626998|NCT04118647|EXPERIMENTAL|Wu-Chu-Yu tang|
62626999|NCT04680247|ACTIVE_COMPARATOR|VA-LCP|Osteosynthesis with a VA-LCP system
62627000|NCT04680247|ACTIVE_COMPARATOR|NCB-PT|Osteosynthesis with a NCB-PT system
62627001|NCT06215482||"A-N group (Anxious-Non-anxious group)"|Upon admission, participants filled out a Anxiety Disorder Screening Scale, this group scored \<10 points
62627002|NCT06215482||"N-N group (Non-anxious-Non-anxious group)"|Upon admission, participants filled out a Anxiety Disorder Screening Scale, this group scored ≥10 points
62627003|NCT00972283|EXPERIMENTAL|IDeg OD|
62627004|NCT00972283|ACTIVE_COMPARATOR|IGlar OD|
62267807|NCT02072811|OTHER|II Consolidation HiDAraC|"Patients from all 5 risk group receive second after first consolidation \[Ara-C\] Patient from Very adverse risk receive Ara-C + CLA (Cladribine). If it is needed - more intensive consolidation treatment with 2-Cda.~Patients form Very adverse risk receive Maintenance treatment:~Decitabine 20 mg/m2 60 min infusion iv (Intravenous injection) for 5 days every 6 weeks.~Patients from Favorable, - Intermediate I an Intermediate II risk groups: CD34+ mobilization (HSCT qualification)."
62267808|NCT02072811|OTHER|Consolidation, III HiDAraC cycle|"Patients from Favorable, Intermediate I an Intermediate II risk groups receive III consolidation or autologous HSCT (depends on results of mobilization).~Patients from Adverse risk receive III Consolidation HiDAraC + Cladribina (CLA) If no CR: CLAG-M reinduction therapy and after CR - treatment according to protocol."
62267809|NCT00607308|EXPERIMENTAL|0.1 mg/kg|
62267810|NCT00607308|EXPERIMENTAL|0.5 mg/kg|
62267811|NCT00607308|EXPERIMENTAL|1 mg/kg|
62267812|NCT00607308|EXPERIMENTAL|5 mg/kg|
62267813|NCT00607308|PLACEBO_COMPARATOR|Placebo|
62267814|NCT00607308|EXPERIMENTAL|10 mg/kg|
62267815|NCT02335996|ACTIVE_COMPARATOR|patients with active hypercortisolism|
62267816|NCT02335996|ACTIVE_COMPARATOR|Patients in remission of their hypercortisolism after surgery|
62267817|NCT01220895|EXPERIMENTAL|ACT (mutlimer selection) plus standard therapy|Adoptive Cellular Therapy prepared using Multimer Selection in combination with standard best available antiviral drug therapy
62267818|NCT01220895|ACTIVE_COMPARATOR|Best available antiviral drug therapy|
62267819|NCT02890810|EXPERIMENTAL|Verum Electroacupuncture|Active Intervention
62267820|NCT02890810|PLACEBO_COMPARATOR|Placebo Electroacupuncture|Validated Control
62267821|NCT02690311|SHAM_COMPARATOR|LED with bluelight|Two types of smartphone were used. One type had a conventional LED display with the full range of blue light. The LED in the other type newly developed by Samsung Display was suppressed for the blue light portion of the spectrum (wavelength 450 \~ 470 nm). The smartphones were indistinguishable from each other with the naked eye, because other wavelengths mimicked blue light in the suppressed LED.
62267822|NCT02690311|EXPERIMENTAL|LED without bluelight|Two types of smartphone were used. One type had a conventional LED display with the full range of blue light. The LED in the other type newly developed by Samsung Display was suppressed for the blue light portion of the spectrum (wavelength 450 \~ 470 nm). The smartphones were indistinguishable from each other with the naked eye, because other wavelengths mimicked blue light in the suppressed LED.
62267823|NCT03829930|EXPERIMENTAL|Entinostat and Enzalutamide|Entinostat and Enzalutamide
62267824|NCT01962571|EXPERIMENTAL|Erythropoietin alfa|Recombinant human EPO (Epoetin alfa HEXAL®) will be given as an i.v. bolus injection on days 1, 2 and 3. The dosage per day will be 33.000 IU in accordance with previous trials.
62267825|NCT01962571|PLACEBO_COMPARATOR|Placebo|As matched placebo for this study, sterile normal saline (0.9% sodium chloride for i.v. administration) will be used. It will be given as a bolus injection in the same manner as EPO.
62267826|NCT02626507|EXPERIMENTAL|Gedatolisib ER+/HER2- Breast Cancer|"* Gedatolisib at escalating doses of 180, 215 and 260 mg via a 3-6 dose-escalation scheme is administered once weekly on the first day for each of the four weeks during the four 4-week cycles.~* Faslodex at 500 mg is administered IM into the buttocks slowly (over 1 - 2 minutes per injection) as two 5-mL injections, one in each buttock, on Days 1 and 15 of Cycle 1 and on Day 1 of the remaining three 4-week treatment cycles.~* Palbociclib at 125 mg is administered PO with food daily on Days 1-21 for each of the four 4-week cycles~* Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment."
62267827|NCT03712397|EXPERIMENTAL|nal-IRI in Head & Neck cancer|nal-IRI 80 mg/m2 for 90 minutes in sequence at day 1, every 14 days counted as one cycle
62267828|NCT04933929|EXPERIMENTAL|"Coronavirus disease Positive group Covid (+)"|Positive PCR test.
62267829|NCT04933929|ACTIVE_COMPARATOR|"Coronavirus disease Negative group Covid (-)"|Negative PCR test.
62267830|NCT04505098|ACTIVE_COMPARATOR|Intervention|
62267831|NCT04505098|NO_INTERVENTION|Usual Care|
62267832|NCT03113500|EXPERIMENTAL|Treatment (CHEP-BV)|"INDUCTION: Patients receive cyclophosphamide IV and doxorubicin IV on day 1, etoposide IV on days 1-3, and prednisone PO on days 1-5. Patients also receive brentuximab vedotin IV over approximately 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (or for up to 5 cycles for patients who received 1 cycle of CHOP-like or CHP-BV therapy prior to induction, per investigator's discretion) in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Between 30-60 days post-consolidative autologous stem cell therapy, post-consolidative radiation therapy, or after completing induction cycle 6 (cycle 5 for patients who qualify for receiving 5 cycles of CHEP-BV instead of 6), patients with objective response (complete response or partial response) receive brentuximab vedotin IV over approximately 30 minutes on day 1. Treatment repeats every 21 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity."
62267833|NCT01750112|EXPERIMENTAL|Macrolane VRF20|All subjects will receive treatment with Macrolane VRF20 to correct pectus excvatum deformity.
62267834|NCT04671849|EXPERIMENTAL|adult patients_Dose 1|
62267835|NCT04671849|EXPERIMENTAL|adult patients_Dose 2|
62267836|NCT04671849|EXPERIMENTAL|adult patients_Dose 3|
62267837|NCT04671849|EXPERIMENTAL|adult patients_Dose 4|
62267838|NCT04671849|EXPERIMENTAL|adult patients_Dose 5|
62267839|NCT04671849|EXPERIMENTAL|adult patients_Dose 6|
62267840|NCT04671849|EXPERIMENTAL|adult patients_Dose 7|
62267841|NCT04671849|EXPERIMENTAL|adult patients_Dose 8|
62267842|NCT02586168|EXPERIMENTAL|Gemcabene 900 mg|Gemcabene 900 mg
62267843|NCT02586168|PLACEBO_COMPARATOR|Placebo|Placebo
62267844|NCT02597946|EXPERIMENTAL|all patients|Part A: all enrolled patients will receive afatinib monotherapy. Part B: all eligible patients will receive afatinib combined with weekly paclitaxel.
62267845|NCT04317274|EXPERIMENTAL|High Cholesterol Good Video First|Participants see videos of a conversation around taking medications (statins) for high cholesterol. Patients see good video first and poor video second.
62267846|NCT04317274|EXPERIMENTAL|Colorectal Cancer Good Video First|Participants see videos of a conversation around screening for colorectal cancer. Patients see good video first and poor video second.
62852712|NCT05525598|EXPERIMENTAL|"Internet-delivered therapist-assisted treatment: One step at the time"|"One step at the times consists of 11 internet-delivered modules delivered over 14 weeks. Each module explores a different theme, primarily including elements from Cognitive Behavioral Therapy (CBT) for FSD, and includes FSD-related psychoeducation, various interactive exercises, and video and audio material. Interactions between patients and the therapist will take place via the telephone 3 times (start, mid-term, and end-of-treatment) and embedded messaging (therapist will respond to patients) approx. 2 times a week. The participating therapists are supervised every other week by specialized psychologists."
62063016|NCT02955472|OTHER|Group 1|"1. Period 1: GLA5PR GLARS-NF1 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~2. wash-out period: over 7 days.~3. Period 2: GLA5PR GLARS-NF3 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
62267847|NCT04317274|EXPERIMENTAL|High Cholesterol Poor Video First|Participants see videos of a conversation around taking medications (statins) for high cholesterol. Patients see poor video first and good video second.
62267848|NCT04317274|EXPERIMENTAL|Colorectal Cancer Poor Video First|Participants see videos of a conversation around screening for colorectal cancer. Patients see poor video first and good video second.
62627005|NCT04849624||ICU COVID-19 patients|COVID-19 patients that are admitted into the ICU and fulfilled the eligibility criteria
62627006|NCT04849624||ICU non-COVID-19 patients|Non-COVID-19 patients that are admitted into the ICU matched with ICU COVID-19 patients that are recruited and fulfilled the eligibility criteria
62627007|NCT03429621|EXPERIMENTAL|Simethicone|Each woman in the intervention group will be given Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery.
62267849|NCT00939900|EXPERIMENTAL|aclasta|aclasta group
62267850|NCT00939900|NO_INTERVENTION|control|control group
62267851|NCT03106623|EXPERIMENTAL|ONO-8577 Arm|Oral administration of ONO-8577 once a daily for 4 weeks
62267852|NCT03106623|ACTIVE_COMPARATOR|Active Comparator Arm|Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
62627008|NCT03429621|NO_INTERVENTION|No simethicone|The women will not be given Simethicone.
62627009|NCT04485663|EXPERIMENTAL|ALG-010133|Subcutaneous injections of ALG-010133 in HV or CHB subjects up to every 7 days for up to 12 weeks
62627010|NCT04485663|PLACEBO_COMPARATOR|Placebo|Subcutaneous injections of placebo in HV or CHB subjects up to every 7 days for up to 12 weeks
62627011|NCT01535443|EXPERIMENTAL|Bromfenac|Drug: Bromfenac ophthalmic solution 1 drop 4 times per day
62627012|NCT04716374||Patients with epithelial ovarian cancer|Patients with epithelial ovarian adenocarcinoma with archival tumor tissue available for analysis were identified through the Hellenic Cooperative Oncology Group (HeCOG)'s tumor repository. Patients had received treatment at HeCOG-affiliated institutions following standard international guidelines.
62627013|NCT02748057|EXPERIMENTAL|Ezetimibe 10 mg + Rosuvastatin 2.5 mg|1 Ezetimibe 10 mg tablet and 1 Rosuvastatin 2.5 mg capsule/tablet orally, once daily for 52 weeks. If participant does not achieve low-density lipoprotein- cholesterol (LDL-C) goal after Week 12, dosage of Rosuvastatin may be increased to 5.0 mg
62627014|NCT02748057|EXPERIMENTAL|Ezetimibe 10 mg + Rosuvastatin 5.0 mg|1 Ezetimibe 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules/tablets orally, once daily for 52 weeks.
62627015|NCT03360214|OTHER|Active PEMF + Treatment PIB|Participants will receive an active device (Pulsed Electromagnetic Field (PEMF) Device) and active drug (Bupivacaine Hydrochloride or Ropivacaine HCl).
62063017|NCT02955472|OTHER|Group 2|"1. Period 1: GLA5PR GLARS-NF3 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~2. wash-out period: over 7 days.~3. Period 2: ComparGLA5PR GLARS-NF1 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
62063018|NCT01373216|EXPERIMENTAL|Exenatide|Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving perioperatively i.v. exenatide on top of standard treatment
62267853|NCT03106623|PLACEBO_COMPARATOR|Placebo Arm|Oral administration of Placebo once a daily for 4 weeks
62267854|NCT06021080||CVVHD|Continuous Veno-Venous Hemosdialysis
62267855|NCT06021080||CVVH|Continuous Veno-Venous Hemofiltration
62267856|NCT01962233|EXPERIMENTAL|mesenchymal stem cells|Umbilical Cord Derived Mesenchymal Stem Cells at a dose of 100-800 million by intravenous infusion
62267857|NCT06020456||Variants Null|This group includes patients carrying a F8 variant with a major deleterious effect on the F8 gene (non-sense, intron 1 and 22 inversions, large deletions, small insertions/deletions leading to a frameshift and premature stop codon)
62267858|NCT06020456||Variants No Null|This group includes patients carrying a F8 variant with a mild effect on the F8 gene (missense, splice modification, small nucleotide deletion in the intron 13, and variant in the promoter)
62267859|NCT03685786|EXPERIMENTAL|Experimental: CART19 cell and auto-HSCT|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.
62267860|NCT04697485|EXPERIMENTAL|Low-Dose, Triple Polydiuretic Therapy (LDTPT)|Polydiuretic therapy will consist of bumetanide 0.5 mg + eplerenone 25 mg + dapaglifozin 5 mg once daily for 4 weeks.
62267861|NCT03707600|SHAM_COMPARATOR|Sham|The sham coil setting is designed to mimic the auditory artifact and scalp sensations evoked by the real coil without stimulating the brain.
62267862|NCT03707600|ACTIVE_COMPARATOR|TMS|Active TMS
62627016|NCT03360214|OTHER|Active PEMF + Sham PIB|Participants will receive an active device (Pulsed Electromagnetic Field (PEMF) Device) and placebo drug.
62063019|NCT01373216|NO_INTERVENTION|Control|Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving standard treatment
62267863|NCT03826550|EXPERIMENTAL|Diclofenac Sodium Gel3%|Diclofenac Sodium Gel 3%, dosed twice daily for 60 days.
62627017|NCT03360214|OTHER|Sham PEMF + Treatment PIB|Participants will receive a placebo device and active drug (Bupivacaine Hydrochloride or Ropivacaine HCl).
62627018|NCT03360214|OTHER|Sham PEMF + Sham PIB|Participants will receive placebo drug and placebo device.
62267864|NCT03826550|ACTIVE_COMPARATOR|Solaraze|Solaraze Gel dosed twice daily for 60 days.
62627019|NCT06156605|EXPERIMENTAL|Sidelying lumbar manipulation|Right sided lumbar manipulation
62267865|NCT03826550|PLACEBO_COMPARATOR|Placebo|Placebo Gel dosed twice daily for 60 days.
62627020|NCT06156605|ACTIVE_COMPARATOR|Sham ultrasound|Sham (non-therapeutic settings) ultrasound at the right PSIS
62627021|NCT03138577|OTHER|Dose Cohort 7|5 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
62627022|NCT03138577|OTHER|Dose Cohort 6|10 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
62267866|NCT05385861|EXPERIMENTAL|nal-IRI (ONIVYDE®) and Carboplatin|nal-IRI (ONIVYDE®) and Carboplatin
62627023|NCT03138577|OTHER|Dose Cohort 5|15 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
62627024|NCT03138577|OTHER|Dose Cohort 4|20 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
62852713|NCT05525598|ACTIVE_COMPARATOR|"Internet-delivered non-guided treatment: Get started"|"Get started is a non-guided self-help program, developed as an active control, that includes 4 modules consisting of FSD-related psychoeducation and guidance on making lifestyle improvements. Participants will have access to the Get started program for 14 weeks."
62852714|NCT05971706|EXPERIMENTAL|ozone|Gaseous ozone was applied immediately after non-surgical periodontal treatment
62852715|NCT05971706|ACTIVE_COMPARATOR|control|Only non-surgical periodontal treatment was applied
62852716|NCT01056302||Group 1|15 patients who underwent surgical repair of mandibular fractures at San Francisco VA Medical Center
62852717|NCT05500222|ACTIVE_COMPARATOR|Resmetirom|80 mg daily
62852718|NCT05500222|PLACEBO_COMPARATOR|Placebo|matching placebo daily
62852719|NCT00522236|EXPERIMENTAL|Arm 1|
62852720|NCT03546868|EXPERIMENTAL|Ulcerative Colitis|Patients with ulcerative colitis undergoing \[18F\]FSPG PET/CT scan
62063020|NCT01547026|ACTIVE_COMPARATOR|Psycho-education|Patients receive a 10 min. psycho-education on positive health effects of sports
62267867|NCT06417021|OTHER|Frontal position of Ultrasound machine (Ergonomic group)|Participants will simulate a CVC positioning keeping the ultrasound machine facing them
62267868|NCT06417021|OTHER|Lateral position (90°) of Ultrasound machine (No Ergonomic group)|Participants will simulate a CVC positioning keeping the ultrasound machine in a lateral position on the same side of the needle.
62627025|NCT03138577|OTHER|Dose Cohort 3|Supraclavicular Block: 25 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
62627026|NCT03138577|OTHER|Dose Cohort 2|30 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
62627027|NCT03138577|OTHER|Dose Cohort 1|35 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
62627028|NCT03621436|EXPERIMENTAL|TRVD Therapy|
62627029|NCT01227083||1|Asthma control test check AQLQ(Asthma Quality of Life Questionnaire)after being cAQOL(Computerized Asthma specific quality of life)
62627030|NCT01227083||2|Asthma control test check cAQOL(Computerized Asthma specific quality of life)after being AQLQ(Asthma Quality of Life Questionnaire)
62852721|NCT03546868|EXPERIMENTAL|Crohn's disease|Patients with Crohn's disease undergoing \[18F\]FSPG PET/CT scan
62852722|NCT05573269|EXPERIMENTAL|FOPE group|"Dietary supplement, Polyphenolic extract from pine bark (Oligopin® 100mg) and fish oil capsule contained EPA 350mg + DHA 250mg. This group will receive a nutritional supplement for a period of 6 months.~The participants will have a capsule of polyphenolic extract and a capsule of fish oil a day."
62852723|NCT05573269|ACTIVE_COMPARATOR|FO group|This group will have placebo capsule and fish oil capsule. Placebo capsule contained maltodextrin and magnesium stearate, while fish oil contained EPA 350mg + DHA 250mg. The participants will receive the supplements for a period of 6 months and have a capsule of placebo and a capsule of fish oil a day.
62063021|NCT04853732||Chronic Low Back Pain Cases|
62267869|NCT03313076|EXPERIMENTAL|n-3 PUFA (O3FA) + Vitamin D3|4g fish oil in 4 softgels (n-3 PUFA/O3FA) + 2000 IU Vitamin D3 in 1 capsule
62267870|NCT03313076|EXPERIMENTAL|n-3 PUFA (O3FA) Placebo + Vitamin D3|4g of corn/soy oil blend in 4 softgels + 2000 IU Vitamin D3 in 1 capsule
62267871|NCT03313076|EXPERIMENTAL|n-3 PUFAs (O3FA) + Vitamin D3 Placebo|4g fish oil in 4 softgels (n-3 PUFA/O3FA) + Vitamin D3 matching Placebo, an inert white powder placebo in 1 capsule
62267872|NCT03313076|PLACEBO_COMPARATOR|n-3 PUFA (O3FA) Placebo + Vitamin D3 Placebo|4g n-3 PUFA/O3FA Matching Placebo, a corn/soy oil blend in 4 softgels + inert white powder Vitamin D3 matching placebo in 1 capsule
62450956|NCT02140450|ACTIVE_COMPARATOR|Mannitol|Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
62627031|NCT01190189|EXPERIMENTAL|Cervarix Group|Healthy female subjects who received control vaccine in the primary study HPV-015 (NCT00294047), were administered three doses of Cervarix vaccine intramuscularly, according to a 0,1,6-month schedule.
62627032|NCT02833064||Acute Liver Failure|"* biological sampling~* MRI scanning for patients with paracetamol induced acute liver failure"
62627033|NCT02833064||Acute Liver Injury|- biological sampling
62627034|NCT02833064||Acute on Chronic Hepatic Injury|- biological sampling
62627035|NCT02833064||Stable Cirrhotics|- biological sampling
62852724|NCT00724711|EXPERIMENTAL|FTC/TDF (Truvada [TVD]) + PI/r|Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada \[TVD\]) for 48 weeks. The prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.
62852725|NCT00724711|ACTIVE_COMPARATOR|ABC/3TC + PI/r|Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.
62852726|NCT02030899|ACTIVE_COMPARATOR|Cage|Cage filled with autologous bone
62852727|NCT02030899|OTHER|Plate|Plate augmentation after iliac bone graft
62267873|NCT01081795|EXPERIMENTAL|Topiramate (JNS019) 50 mg|In titration period, topiramate 25 milligram (mg) tablet will be given once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and will be continued further for 18 weeks in the fixed dose period.
62852728|NCT04646434|EXPERIMENTAL|Supportive Care (brain and muscle monitoring, questionnaire)|Patients perform standard of care Kegel exercises while undergoing brain and muscle activity monitoring by UDS, EEG and EMG, respectively, before surgery, 6 weeks after surgery, and at 3, and 6 months after surgery. Patients complete questionnaires over 5-10 minutes about urinary function
62852729|NCT04136015||Dasatinib group|
62852730|NCT04136015||Imatinib group|
62852731|NCT02926521|NO_INTERVENTION|Dressing A|Dressing A: a nerve block catheter affixed with Pajunk anchor and covered with Tegaderm.
62852732|NCT02926521|ACTIVE_COMPARATOR|Dressing B|Dressing B: a nerve block catheter affixed with Pajunk anchor, skin treated with gum mastic liquid adhesive (Mastisol), all covered with Tegaderm
62852733|NCT02926521|ACTIVE_COMPARATOR|Dressing C|Dressing C: a nerve block catheter sealed with 2-octyl cyanoacrylate liquid adhesive (Dermabond), trailing catheter affixed with Pajunk anchor, all covered with Tegaderm
62852734|NCT02926521|ACTIVE_COMPARATOR|Dressing D|Dressing D: a nerve block catheter sealed with 2-octyl cyanoacrylate (Dermabond), trailing catheter affixed with Pajunk anchor, skin treated with gum mastic liquid adhesive (Mastisol), all covered with Tegaderm
62450957|NCT02140450|SHAM_COMPARATOR|Placebo|Artificial tears, 2 drops, 1-2 hours before intravitreal injection
62852735|NCT06449196|EXPERIMENTAL|Bolus Dosing|HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM) administered via bolus dosing
62852736|NCT06449196|EXPERIMENTAL|Fractionated Dosing|HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM) administered via fractionated dosing
62063022|NCT04853732||Chronic Pain-Free Controls|
62852737|NCT00363545|EXPERIMENTAL|Liquid Rotarix Group|Healthy male and female infants, between and including 6-12 weeks of age, who received two oral doses of the liquid formulation of the Rotarix™ vaccine, according to a 0, 2 month schedule.
62852738|NCT00363545|EXPERIMENTAL|Lyophilized Rotarix Group|Healthy male and female infants, between and including 6-12 weeks of age, who received two oral doses of the lyophilized formulation of the Rotarix™ vaccine, according to a 0, 2 month schedule.
62852739|NCT04944108|EXPERIMENTAL|Surfactant administration with less invasive surfactant administration (LISA) approach|Participants will be randomized to administer surfactant in a preterm manikin by using the LISA approach (thin catheter)
62852740|NCT04944108|ACTIVE_COMPARATOR|Surfactant administration with intubation (INSURE) approach|Participants will be randomized to administer surfactant in a preterm manikin by using the INSURE approach (tracheal tube)
62852741|NCT05282745||Women with high-grade squamous intraepithelial lesion (HSIL) in cervix|In the enrollment, women whose cervical histopathological results have been diagnosed as high-grade squamous intraepithelial lesion (HSIL) for the last 3 months with abnormal results will be included in this study. All participants will be followed up three times, at 6 months,12 months and 24 months.
62852742|NCT04672382|EXPERIMENTAL|Morphine|"During the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm) located 3 cm apart. Two areas will be treated with an intradermal injection of morphine (0.05 ml, 0.1 mg/ml), while two areas will be treated with injections of isotonic saline (0.05 ml, 0.9%) as vehicle. Fifteen minutes after the injections, the measurement of FLPI and wheal size will be conducted in one morphine and one saline treated area.~This measurement will be followed by application of histamine and cowhage in the four areas (two pre-treated with morphine and two pre-treated with vehicle)"
62063023|NCT02778126|EXPERIMENTAL|[¹⁴C]Prexasertib|170 milligrams (mg) of prexasertib containing approximately 50 μCi \[¹⁴C\] prexasertib radiotracer administered intravenously (IV) as a 1 hour continuous IV infusion.
62267874|NCT01081795|EXPERIMENTAL|Topiramate 100 mg|In titration period, topiramate 25 mg tablet will be given once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and will be continued further for 18 weeks in the fixed dose period.
62267875|NCT01081795|PLACEBO_COMPARATOR|Placebo|In titration period, matching placebo tablet will be given once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice orally from Day 22 to Day 28 and will becontinued further for 18 weeks in the fixed dose period.
62267876|NCT03405259|EXPERIMENTAL|Super Seal® Desensitizer|Professionally Applied
62267877|NCT03405259|SHAM_COMPARATOR|Acclean® Fluoride Varnish|Professionally Applied
62267878|NCT02261727|PLACEBO_COMPARATOR|Placebo|Placebo theophylline, one tablet twice daily, and Placebo prednisone, one tablet once daily
62267879|NCT02261727|ACTIVE_COMPARATOR|Low-dose theophylline arm|Theophylline 100 mg twice daily
62852743|NCT05768022|EXPERIMENTAL|Cura kinesio-taping|100 subjects (females and males) will receive kinesio taping from origin to insertion on the superficial muscles of Quadriceps femoris (VM,VL, RF).
62852744|NCT05768022|PLACEBO_COMPARATOR|Placebo|100 subjects (females and males) will receive placebo kinesio-taping across quadriceps.
62063024|NCT02778126|EXPERIMENTAL|Prexasertib|"105 milligrams per square meter (mg/m²) of prexasertib administered IV as a 1 hour continuous IV infusion once every 14 days (14 day cycles). Treatment may continue until discontinuation criteria are met.~Treatment for this arm was administered after ¹⁴C administration (¹⁴C was administered during first phase of the study)"
62063025|NCT02291484|EXPERIMENTAL|Comprehensive cardiac CT|"Tiered cardiac CT protocol:~1. CT calcium scan~2. CT angiography (if calcium scan positive or high pre-test probability)~3. CT perfusion (if \>50% stenosis on CTA, or cannot be ruled out)"
62267880|NCT02261727|ACTIVE_COMPARATOR|Theophylline and Prednisone arm|Theophylline 100 mg twice daily plus prednisone 5 mg once daily
62063026|NCT02291484|NO_INTERVENTION|Standard care|Standard diagnostic management of suspected CAD, using stress testing
62267881|NCT03420950|OTHER|Sedative first|Rapid sequence intubation: sedative first
62267882|NCT03420950|OTHER|Paralytic agent first|Rapid sequence intubation: paralytic first
62267883|NCT06144905||Anorexia nervosa (AN) group|Female in-patients with anorexia nervosa, age 16-50 years with BMI below 18.5 kg/m2.
62267884|NCT06144905||Heathy control (HC) group|Female healthy controls, age 16-50 with normal to mild overweight (18.5 ≤ BMI\< 27 kg/m2). .
62267885|NCT03828591|OTHER|Group A (intensive support)|Patients that receive standard and intensive psychological support during hospitalization
62267886|NCT03828591|OTHER|Group B (standard support)|Patients that receive only standard psychological support during hospitalization
62267887|NCT01133587|EXPERIMENTAL|admissions contract|"contract regarding patient-guided admissions"
62267888|NCT01133587|ACTIVE_COMPARATOR|wait list control|1 year on waiting list
62267889|NCT05285293|ACTIVE_COMPARATOR|Group 1 Control|PRF in intra-bony defects
62267890|NCT05285293|EXPERIMENTAL|Group 2 Experimental|PRF and Retinol in intra-bony defects
62267891|NCT00838331|EXPERIMENTAL|Fresh blood, then aged blood|
62267892|NCT00835237|EXPERIMENTAL|Boostrix Group|Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)
62267893|NCT00835237|ACTIVE_COMPARATOR|Decavac Group|Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)
62267894|NCT00927095|ACTIVE_COMPARATOR|Continuous OC (EE/DROS)|Continuous daily oral drospirenone (DROS; 3mg) + ethinyl estradiol (EE; 20ug)
62267895|NCT00927095|ACTIVE_COMPARATOR|Intermittent OC (EE/DROS)|Interrupted (21 days active - 7 days placebo) oral DROS (20ug)/EE(3mg)
62267896|NCT00927095|PLACEBO_COMPARATOR|Placebo|Continuous daily oral placebo
62450958|NCT00902551||1|Subjects underwent cervical sample DNA image cytometry
62450959|NCT00902551||2|Subjects underwent cervical sample conventional cytology
62852745|NCT01486082||Empirical OCA|This group will be treated with omeprazole, amoxicillin and clarithromycin without having a previous antibiogram.
62852746|NCT01486082||OCA after antibiogram|This group will be treated with omeprazole, clarithromycin and amoxicillin after an antibiotic susceptibility confirmation.
62852747|NCT03087617|ACTIVE_COMPARATOR|Usual Care|Usual Care includes a lung cancer screening CT exam. Following the screen, a radiologist will analyze the CT scan image and send the results to the patient's Primary Care Physician (PCP). If the scan is read as a category 1 or 2 in the Lung Reporting and Data System (Lung-RADS), patients are provided a letter in the mail with their results. If the scan is read as a category 3, 4A, 4B, or 4X in Lung-RADS the patient will be contacted by their primary care physician's office and told to schedule a follow up appointment. Either in the letter or at the follow up appointment, patients will be given a Quitline number created specifically for this trial and maintained for the duration.
62852748|NCT03087617|EXPERIMENTAL|Usual Care + Imbio Smoking Cessation Report|In this arm, patients will receive the Usual Care described above and will additionally be provided with the Report. In this arm, the Report will provide the Quitline number.
62627036|NCT02833064||Non-cirrhotic liver disease|- biological sampling
62852749|NCT03087617|ACTIVE_COMPARATOR|Usual Care + Counseling|In addition to the Usual Care described above, patients in this arm will participate in a 45 minute smoking cessation counseling session. Approximately three Tobacco Treatment Specialists will be trained to ensure consistent counseling methodology. Counselors will utilize a patient centered approach grounded in Motivational Interviewing skills to elicit perceived benefits for stopping smoking and to enhance self-efficacy for stopping. A major emphasis of a call is to enroll the caller in formal cessation programs and/or convince them to use FDA approved medication as part of a quit attempt. Study participants who desire further smoking cessation support after their session will be connected with the appropriate organization.
62627037|NCT05681832|EXPERIMENTAL|Intervention group|
62627038|NCT05681832|NO_INTERVENTION|Control group|
62627039|NCT01343537|EXPERIMENTAL|Monitoring|
62627040|NCT01229319|EXPERIMENTAL|cryo + imiquimod to Left|Cryotherapy alone to Right arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Left arm
62627041|NCT01229319|EXPERIMENTAL|Cryo + imiquimod to Right|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
62627042|NCT02861963|EXPERIMENTAL|Right ventricle outflow tract reconstruction|RVOT reconstruction used femoral allogenic vein valve conduit through ventricular fibrillation and without VSD closure
62627043|NCT02861963|ACTIVE_COMPARATOR|Systemic-to-pulmonary artery shunts|systemic-to-pulmonary artery shunts (modified Blalock-Taussig shunt)
62627044|NCT04438616|ACTIVE_COMPARATOR|dome magnetic attachment|"* A crestal incision is made using No. 15 c blade extending over the crest of anterior mandible and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge for implant installed.~* Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant in each group by the contra angle handpiece with special adaptor~* We connect magnetic attachment(dome) for each groups on complete denture by pick up procedure at day of implant installation"
62627045|NCT04438616|ACTIVE_COMPARATOR|flat magnetic attachment|"* A crestal incision is made using No. 15 c blade extending over the crest of anterior mandible and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge for implant installed.~* Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant in each group by the contra angle handpiece with special adaptor~* We connect magnetic attachment(flat) for each groups on complete denture by pick up procedure at day of implant installation"
62627046|NCT05871528||No hemorrhagic transformation|Patients with ischemic stroke treated with intravenous thrombolysis and no hemorrhagic transformation (IH1 or IH2 are allowed)
62627047|NCT05871528||Local hemorragic transformation|Patients with ischemic stroke treated with intravenous thrombolysis and hemorrhagic transformation PH1 or PH2
62627048|NCT05871528||Remote hemorrhage|Patients with ischemic stroke treated with intravenous thrombolysis and remote hemorrhage in areas without evident ischemia (rPH)
62627049|NCT02362737|EXPERIMENTAL|Active and Healthy Brotherhood (AHB)|16-week behavioral intervention
62627050|NCT02362737|NO_INTERVENTION|Control|Usual care.
62627051|NCT01533948|EXPERIMENTAL|Treatment (axitinib)|Patients receive axitinib PO BID. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62627052|NCT02384538|PLACEBO_COMPARATOR|Placebo|Placebo for ABT-981 every two weeks (Q2W) for 24 weeks.
62627053|NCT02384538|EXPERIMENTAL|ABT-981|ABT-981 200 mg every two weeks (Q2W) for 24 weeks.
62627054|NCT02264210|EXPERIMENTAL|Intervention group|Icotinib 125 mg three times daily (375 mg per day) orally for 12 months.
62627055|NCT02264210|NO_INTERVENTION|Observation group|Observation.
62627056|NCT05922514||Group 1 Baseline and 3 month Questionnaires|"170 participants with BERN imaging score with completion of baseline and 3 month questionnaires being : headache impact test (HIT-6), migraine disability assessment test (MIDAS), pain numerical rating scale (NRS), and spontaneous intracranial hypotension symptom severity scale (SIHSS).~Each participant will keep a daily headache diary for 90 days."
62852750|NCT03087617|EXPERIMENTAL|Usual Care + Imbio Smoking Cessation Report + Counseling|In addition to the Usual Care and Counseling described above, patients in this arm will also receive the Report.
62852751|NCT04531709||Recently diagnosed TGCT|
62852752|NCT04531709||Long-term survivors of TGCT|
62852753|NCT05611294|ACTIVE_COMPARATOR|Topography-Guided LASIK|Subjects receive Topography-Guided LASIK surgery on one eye.
62852754|NCT05611294|ACTIVE_COMPARATOR|Small Incision Lenticule Extraction|Subjects receive Small Incision Lenticule Extraction surgery on one eye.
62852755|NCT04444856||NovoSeven|Women with severe postpartum haemorrhage treated with NovoSeven
62852756|NCT04444856||Standard of care|Women with severe postpartum haemorrhage treated with standard of care
62852757|NCT06443645||Adjuvant scheme|Indication for anthracycline-based chemotherapy after first-line surgery
62852758|NCT06443645||Neoadjuvant scheme|Indication for anthracycline-based chemotherapy
62852759|NCT02668471|EXPERIMENTAL|Ultrasound guided|Radial artery catheters will be placed with the assistance of bedside ultrasound.
62852760|NCT02668471|ACTIVE_COMPARATOR|traditional method|Radial artery catheters will be placed by the palpation technique only.
62852761|NCT02750020||never smokers|Around 1667 never smokers will be required to answer a questionnaire via telephone.
62852762|NCT02750020||ex-smokers|Around 1667 ex-smokers will be required to answer a questionnaire via telephone.
62852763|NCT02750020||current smokers|Around 1667 current smokers will be required to answer a questionnaire via telephone.
62852764|NCT04679415|EXPERIMENTAL|Standard of care + hzVSF-v13 200 mg at D1, hzVSF-v13 100mg at D3 and D7 IV|Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
62852765|NCT04679415|EXPERIMENTAL|Standard of care + hzVSF-v13 400 mg at D1, hzVSF-v13 200mg at D3 and D7 IV|Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
62852766|NCT04679415|PLACEBO_COMPARATOR|Standard of care + 3 doses of the placebo (normal saline) IV|Drug: Placebo (Normal saline solution) Dosage form: 0.9% NaCl Solution Frequency Frequency: Dose at Day 1, 3, 7 Other names: 0.9% Normal saline
62852767|NCT00993226|EXPERIMENTAL|SABER-Bupivacaine Treatment 1a|double-blind
62852768|NCT00993226|PLACEBO_COMPARATOR|Placebo SABER-Bupivacaine Treatment 1b|double-blind
62852769|NCT00993226|ACTIVE_COMPARATOR|Bupivacaine HCl Treatment 1c|double-blind
62852770|NCT00993226|EXPERIMENTAL|SABER-Bupivacaine Treatment 2a|double-blind
62852771|NCT00993226|PLACEBO_COMPARATOR|Placebo SABER-Bupivacaine Treatment 2b|double-blind
62063027|NCT04078360|EXPERIMENTAL|Mobile-based intervention (AMBIT)|This arm will receive a mobile based program delivered over messages/IVR calls.
62063028|NCT04078360|ACTIVE_COMPARATOR|Face-to-face counselling|This arm will receive a brief counselling session from a trained health worker.
62063029|NCT04078360|ACTIVE_COMPARATOR|Active control|This arm will receive an educational BI leaflet.
62063030|NCT02343003|EXPERIMENTAL|Cooled radiofrequency|Cooled radiofrequency energy will be delivered to study subjects' knees to ablate culprit sensory nerves and reduce knee pain
62063031|NCT02343003|ACTIVE_COMPARATOR|Corticosteroid injection|Corticosteroid injections will be administered to study subjects' knees to reduce knee pain
62063032|NCT03040882|EXPERIMENTAL|cotton sock|
62852772|NCT00993226|ACTIVE_COMPARATOR|Bupivacaine HCl Treatment 2c|double-blind
62852773|NCT06466018|EXPERIMENTAL|Ocular rosacea group|
62852774|NCT06466018|EXPERIMENTAL|Pachychoroid group|
62852775|NCT06466018|OTHER|Control group|
62852776|NCT02526030|ACTIVE_COMPARATOR|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day, during study duration
62852777|NCT02526030|ACTIVE_COMPARATOR|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
62852778|NCT02526030|ACTIVE_COMPARATOR|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
62852779|NCT05176132||OBESE (BMI>30)|BMI above 30 kg/m2 and being 18 to 60 years of age. Since the initiative is open for the general obese population, the investigators did not define the size of the cohort, but expect around 500 referrals per year.
62852780|NCT05176132||CONTROL Normal weight (BMI 20-25)|100 persons with normal weight (BMI 20 - 25 kg/m2) 18 to 60 years of age
62852781|NCT05176132||CONTROL Overweight (BMI 25-30)|100 persons with overweight (BMI 25 - 30 kg/m2) 18 to 60 years of age
62852782|NCT01279941|NO_INTERVENTION|Testing Only|
62852783|NCT01279941|EXPERIMENTAL|Testing & Intervention|
62852784|NCT04795336|ACTIVE_COMPARATOR|Knee cohort|In the cohort of patients undergoing primary elective knee arthroplasty, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into intervention group. Intervention group will receive a 5mg Melatonin prescription for 14 days
62852785|NCT04795336|PLACEBO_COMPARATOR|Knee cohort control|In the cohort of patients undergoing primary elective knee arthroplasty, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into placebo group. Control group will receive a placebo pill for 14 days
62852786|NCT04795336|ACTIVE_COMPARATOR|Hip cohort|In the cohort of patients undergoing primary elective total hip, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into intervention group. Intervention group will receive a 5mg Melatonin prescription for 14 days
62852787|NCT04795336|PLACEBO_COMPARATOR|Hip cohort control|In the cohort of patients undergoing primary elective total hip, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into placebo group. Control group will receive a placebo pill for 14 days
62852788|NCT00336830|ACTIVE_COMPARATOR|Usual Care|Comparator without MD endorsement of Cardiac Rehabilitation
62852789|NCT00336830|EXPERIMENTAL|MD Endorsment of CR|Provided with MD endorsement of participation in Cardiac Rehabilitation
62852790|NCT03389048|EXPERIMENTAL|degenerative lumbar spine disease|patients who suffer from unilateral degenerative lumbar spine disease, undergo SLR test while being recorded by PMD-200
62852791|NCT00878761|EXPERIMENTAL|STX-100 (0.03mg/kg)|8 patients (6 active and 2 placebo)
62852792|NCT00878761|EXPERIMENTAL|STX-100 (0.1mg/kg)|8 patients (6 active and 2 placebo)
62627057|NCT05922514||Group 2 Baseline, 7 days and 3 month Questionnaires|"30 participants with BERN imaging score with completion of baseline and 3 month questionnaires being : headache impact test (HIT-6), migraine disability assessment test (MIDAS), pain numerical rating scale (NRS), and spontaneous intracranial hypotension symptom severity scale (SIHSS).~Each participant will keep a daily headache diary for 90 days."
62627058|NCT02235129|EXPERIMENTAL|6 minutes walking test|
62627059|NCT04335058|EXPERIMENTAL|Group A: Lactoferrin plus oral iron|Treated for 2 months regularly with oral administration of 100 mg Lactoferrin tablet twice a day before meals with oral administration of 100 mg of elemental iron capsules, one capsule twice daily on an empty stomach, at least 1 hour before or 2 hours after meals
62627060|NCT04335058|ACTIVE_COMPARATOR|Oral iron alone|Oral administration of 100 mg of elemental iron capsules, one capsule twice daily on an empty stomach, at least 1 hour before or 2 hours after meals
62627061|NCT00613392|EXPERIMENTAL|1|
62627062|NCT00613392|PLACEBO_COMPARATOR|2|
62627063|NCT01275794||1|Patients have an established diagnosis of T2D, Age 35 years and more, Experience of therapy with one OAD during the from 6 months to 5 years before the registration in the Program
62627064|NCT06180434||Proton group|Patients with grade 2 and 3 IDHmt glioma treated with proton therapy in Holland PTC, Maastro Clinic and UMC Groningen.
62627065|NCT06180434||Photon group|Patients with grade 2 and 3 IDHmt glioma treated with photon therapy in Erasmus MC, Haaglanden MC, LUMC, Amsterdam UMC locatie VUmc Site, Verbeeten Institute, Maastro Clinic, UMC Groningen, and Leuven University Hospital.
62627066|NCT04636502||Cohort|Participants who had treated with fSCIG (HyQvia) for not more than 27 months and SCIG 20% (Cuvitru) for not more than 35 months.
62627067|NCT04823390|OTHER|Anesthetist controlled group|15 patients undergoing cataract surgery will receive sedation given by the anesthetist together with local anesthesia according to the depth of sedation in the form of intravenous Midazolam and Fentanyl.
62627068|NCT04823390|OTHER|Patient-controlled group|15 patients undergoing cataract surgery under local anesthesia will administer sedation to themselves through a pump.
62852793|NCT00878761|EXPERIMENTAL|STX-100 (0.3mg/kg)|16 patients (12 active and 4 placebo)
62852794|NCT00878761|EXPERIMENTAL|STX-100 (1mg/kg)|16 patients (12 active and 4 placebo)
62063033|NCT03040882|ACTIVE_COMPARATOR|Elastic Compression Wraps|
62063034|NCT03299790|ACTIVE_COMPARATOR|training group 1: HIIT|high-intensity interval exercise training group (T2DM patients)
62267897|NCT01868048|EXPERIMENTAL|Sativex|"Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.~Subjects received study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg."
62627069|NCT01038102|ACTIVE_COMPARATOR|PUFA diet|Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%)
62852795|NCT06043544|EXPERIMENTAL|Treatment group|patients shoulder treated with Hymovis® 24mg/3ml.
62063035|NCT03299790|ACTIVE_COMPARATOR|training group 2: MIT|moderate-intensity exercise training group (T2DM patients)
62063036|NCT03299790|NO_INTERVENTION|Detraining period|Follow-up: detraining of group 1 and 2 (T2DM patients)
62063037|NCT03299790|NO_INTERVENTION|Healthy controls|
62267898|NCT01868048|PLACEBO_COMPARATOR|Placebo|Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
62267899|NCT03757208|NO_INTERVENTION|Fasting group|
62267900|NCT03757208|ACTIVE_COMPARATOR|Carbohydrate rich drink (CHD) group|
62627070|NCT01038102|ACTIVE_COMPARATOR|SFA diet|Diet high in saturated fat (15 E%)
62627071|NCT03287115|EXPERIMENTAL|Broccoli|Subjects will consume a dose of broccoli on day 11
62627072|NCT01738529|ACTIVE_COMPARATOR|CLE ileocolonoscopy on Crohn patients|Patients known with Crohn´s disease
62627073|NCT01738529|SHAM_COMPARATOR|CLE ileocolonoscopy on control patients|CLE ileocolonoscopy on patients without known IBD
62627074|NCT05007626||zero to six Exo|
62852796|NCT06043544|ACTIVE_COMPARATOR|Control group|patients shoulder treated with Corticosteroid.
62852797|NCT03406091||Poor Mobilizer (PM) in Multiple Myeloma (MM) patients|
62063038|NCT03355430||moderate keratoconus group|moderate keratoconus group underwent combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK) and accelerated corneal collagen cross-linking (CXL) after intracorneal ring segment (ICRS) implantation
62267901|NCT03178227|EXPERIMENTAL|Intervention|The intervention is a school-based intervention involving photoaging of the students selfies which takes 45 minutes total.
62852798|NCT02722057||Cohort 1 - Interventional|The Interventional cohort will not be utilized.
62852799|NCT02722057||Cohort 2 - Non Interventional|A Non-Interventional Cohort comprising pediatric (\<18 years of age) and adult R117H-CFTR patients treated with commercially-available Kalydeco.
62852800|NCT02722057||Cohort 3 - Historical|A Historical Cohort comprising data from an earlier time period for pediatric (\<18 years of age) and adult patients with the R117H-CFTR mutation who have never been exposed to Kalydeco and matched on age, gender, and lung function to patients in the Non-Interventional Cohort.
62852801|NCT03761862||Control|The control group with bilateral tubal ligation
62852802|NCT03761862||Neural Therapy|The treatment group
62627075|NCT05881031|NO_INTERVENTION|Standard of care|Standard of care is NiPPV initiation during a one-night, in-hospital PSG, during which NiPPV settings are titrated during the night by a PSG technologist to determine optimal settings according to current international guidelines. Once NiPPV equipment is obtained and NiPPV is used at home (time 0), NiPPV setting changes may occur at 1, 4, and 12 weeks when participants are contacted by the respiratory therapist. Additional titration of NiPPV settings may be guided by reported participant symptoms and comfort, as per standard of care.
62627076|NCT05881031|EXPERIMENTAL|Home Initiation of NiPPV|NiPPV settings will be titrated during an awake NiPPV trial by the respiratory therapist. Once NiPPV equipment is obtained and NiPPV is used at home (time 0), further titration of the NiPPV settings will occur on an outpatient basis guided by remote telemonitoring and home overnight oximetries at 1, 4, and 12 weeks. Additional titration of NiPPV settings may be guided by reported participant symptoms and comfort, as per standard of care. Participants will complete an in-hospital PSG after 12 weeks, during which NiPPV settings are titrated during the night by a PSG technologist to determine optimal settings according to current international guidelines.
62627077|NCT03734523||Pilot Group: 12 week study|"Premenopausal women between 18 and 52 who have been diagnosed with BV at least once within the past year will be invited to enroll. They will be followed longitudinally for 12 weeks. As this is an observational study, there is no control group.~Exclusions: pregnant women, those with allergies/sensitivities to product ingredients or to Diflucan or metronidazole, anyone who is immunocompromised, anyone with known vaginal infection other than BV or yeast, those who may be mentally/emotionally triggered by VSQ questions. We will exclude vulnerable populations: adults unable to consent, individuals too young to consent, prisoners, and pregnant women."
62627078|NCT03734523||Study Group: 6 month study|"Premenopausal women between 18 and 52 who have been diagnosed with BV at least once within the past year will be invited to enroll. They will be followed longitudinally for six months. As this is an observational study, there is no control group.~Exclusions: pregnant women, those with allergies/sensitivities to product ingredients or to Diflucan or metronidazole, anyone who is immunocompromised, anyone with known vaginal infection other than BV or yeast, those who may be mentally/emotionally triggered by VSQ questions. We will exclude vulnerable populations: adults unable to consent, individuals too young to consent, prisoners, and pregnant women."
62627079|NCT05926843|EXPERIMENTAL|Individuals with functionally complete/incomplete spinal cord injury|Individuals with functionally complete/incomplete spinal cord injury (ASIA grade A, B or C) who will undergo SCS for chronic pain
62627080|NCT06510907|EXPERIMENTAL|mindfulness-based stress reduction program on top of usual care|Mindfulness training will be delivered through a generic 8-week MBSR.
62627081|NCT06510907|NO_INTERVENTION|Usual Care|Since all participants have sub-optimal daytime BP control (grade I HT), they will be given an information sheet about lifestyle treatment for HT and be advised to adhere to these lifestyle changes at recruitment by the research assistant or research nurse (to participants in both arms). For grade I HT, it is the standard clinical practice to advise non-pharmacological treatment for a few months before increasing the doses of medications. (2) There is no additional intervention provided to the standard care group. The case doctors and the patients in the standard care arm will be informed not to amend drug treatment before the ABPM at the 8-week end-point (primary end-point in future definitive RCT). In Hong Kong, patients have unlimited access to publicly-funded primary care clinics and emergency departments for any health problem. This is not limited to participants in the trial.
62627082|NCT02665741|OTHER|Control|Standard colonoscopy - no distal colonoscope attachment will be used in this arm
62627083|NCT02665741|EXPERIMENTAL|Olympus transparent cap|The Olympus transparent cap will be attached to the distal end of colonoscope prior to starting the procedure
62852803|NCT03558568|ACTIVE_COMPARATOR|DBS off|
62852804|NCT03558568|ACTIVE_COMPARATOR|DBS on 60 Hz.|
62852805|NCT03558568|ACTIVE_COMPARATOR|DBS on 99 Hz.|
62852806|NCT03558568|ACTIVE_COMPARATOR|DBS on 130 Hz.|
62852807|NCT03558568|ACTIVE_COMPARATOR|DBS on 230 Hz.|
62852808|NCT00775047|EXPERIMENTAL|Pharmacy|Women receive their second and third depot-medroxyprogesterone acetate injections at the pharmacy by clinical pharmacists
62852809|NCT00775047|ACTIVE_COMPARATOR|Planned Parenthood clinic|Women receive their second and third depot-medroxyprogesterone acetate injections per usual care at their Planned Parenthood clinic.
62852810|NCT03625843|EXPERIMENTAL|Mindfullness exercises|Participate in mindfulness exercises prior to urodynamic studies (UDS). As a participant, you will be guided through a mindfulness meditation exercise by a licensed professional. During this exercise you will be asked to focus your attention on your breathing, physical sensations, and thoughts. This exercise will last for approximately 10 minutes.
62852811|NCT03625843|NO_INTERVENTION|Control|Sitting quietly in a room alone.
62852812|NCT02310334|EXPERIMENTAL|Unguided Pacing Strategy|Each participant will stay in the calorimeter (\~24 hrs) on 2 different occasions. During the first visit, the participant will partake in an unguided exercise session.
62063039|NCT03463915|ACTIVE_COMPARATOR|Bladder instillation WITH triamcinolone acetonide|Six weekly bladder instillations of standard cocktail plus triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).
62627084|NCT02665741|EXPERIMENTAL|Medivators Endocuff|The Medivators Endocuff will be attached to the distal end of colonoscope prior to starting the procedure
62852813|NCT02310334|EXPERIMENTAL|Guided Pacing Strategy|Each participant will stay in the calorimeter (\~24 hrs) on 2 different occasions. During the second visit, the participant will partake in a guided exercise session.
62852814|NCT02152280|EXPERIMENTAL|Danhong Injection|Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
62852815|NCT02152280|PLACEBO_COMPARATOR|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
62852816|NCT03060551|EXPERIMENTAL|SVF injection|SVF was obtained from lipoaspirates, using an automated processing system, and subsequently injected into the subcutaneous tissue of each finger in contact with neurovascular pedicles
62852817|NCT00682578|EXPERIMENTAL|Artekin|Dihydroartemisinin+ Paperaquine (DHA+PPQ, Artekin)
62852818|NCT00682578|ACTIVE_COMPARATOR|Standard treatment|"The standard treatment for uncomplicated falciparum and vivax malaria are as follows:~Uncomplicated falciparum: artesunate-sulphadoxin/pyrimethamine Vivax malaria: chloroquine"
62852819|NCT00296296|ACTIVE_COMPARATOR|Cyclosporin|Patients receive cyclosporin (dose-adjusted to pre-established targets) as immunosuppressive calcineurin inhibitor (CNI) and Diabetes Education / Management (therapeutic adjustment to target American Diabetes Association (ADA) criteria)
62852820|NCT00296296|ACTIVE_COMPARATOR|Tacrolimus|Patients receive tacrolimus (dose-adjusted to pre-established targets) as CNI and Diabetes Education / Management (therapeutic adjustment to target ADA criteria)
62852821|NCT00200356|EXPERIMENTAL|Edaravone|
62852822|NCT00200356|ACTIVE_COMPARATOR|Ozagrel|
62852823|NCT01848041|EXPERIMENTAL|RVL-1201 once daily|RVL-1201 0.1% ophthalmic solution dosed one full drop per eye in the morning; one full drop of vehicle (placebo) per eye approximately 8 hours after the morning dose
62627085|NCT04021498|PLACEBO_COMPARATOR|Placebo|"placebo~1 year"
62627086|NCT04021498|EXPERIMENTAL|Simvastatin|"40 mg~1 year"
62627087|NCT04877990|EXPERIMENTAL|Long-Term Extension Rollover Study: Deucravacitinib|
62627088|NCT01965314|PLACEBO_COMPARATOR|Traditional Training Group|These subjects will be offered multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
62627089|NCT01965314|ACTIVE_COMPARATOR|Simulation Training Group|In addition to traditional training the SG group will participate in a period of simulator based training. Following initial familiarization with the simulator these participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which these participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same simulator.
62627090|NCT05275582|EXPERIMENTAL|CARE-PACT|Brief (5 minute) meeting between the PACT medical provider and a behavioral health educator (in person or virtual using VA's VVC system) -followed by- 30 minute meeting alone with behavioral health educator (in person or virtual using VA's VVC system) 4 weeks of optional self monitoring using an app 2 optional 15-minute phone calls with behavioral health educator
62627091|NCT05275582|EXPERIMENTAL|CARE-PCMHI|30 minute meeting alone with behavioral health educator (in person or virtual using VA's VVC system) 4 weeks of optional self monitoring using an app 2 optional 15-minute phone calls with behavioral health educator
62627092|NCT05225389|EXPERIMENTAL|CT1812|Investigational Drug
62627093|NCT01139346|EXPERIMENTAL|oral darinaparsin|open label, single arm, dose escalation
62627094|NCT03444259||Atrial fibrillation|Patients with atrial fibrillation
62627095|NCT03444259||Coronary bypass|Patients undergoing coronary bypass
62627096|NCT03444259||Aortic valve replacement|Patients undergoing aortic valve replacement
62627097|NCT03444259||Mitral valve repair|Patients undergoing mitral valve repair
62627098|NCT03444259||Other|Patients undergoing cardiac surgery for indication other than above
62627099|NCT06414603|EXPERIMENTAL|Prospera Surveillance Cohort|"Subjects are required to undergo Prospera testing at times corresponding to the institution's graft surveillance schedule. Prospera test results will be provided to the clinical team. Prospera cfDNA level \< 0.15% will be interpreted as low risk for acute rejection (AR). Prospera cfDNA ≥ 0.15% will be interpreted as increased risk for AR and may be followed by EMB to rule out AR at the discretion of the treating clinicians. All other standard of care modalities for assessing AR can be used at the discretion of the treating clinicians at any time throughout the study.~As per standard of care, in subjects with clinical signs or symptoms of rejection, a for cause EMB can be done per the clinical team's discretion at any time during the study."
62063040|NCT03463915|PLACEBO_COMPARATOR|Bladder instillation WITHOUT triamcinolone acetonide|Six weekly bladder instillations of standard cocktail without triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
62627100|NCT06414603|NO_INTERVENTION|Endomyocardial Biopsy Surveillance Cohort|"Subjects will undergo surveillance EMB per the institution's standard clinical care. Biopsy interpretation will be per the institutional pathologist using international guidelines for grading of acute cellular or antibody-mediated rejection.~Subjects will also have Prospera testing performed at the time of surveillance EMB for the purpose of measuring concordance between dd-cfDNA surveillance testing and surveillance EMB; Prospera results will not be returned to investigators for subjects in the EMB surveillance group."
62627101|NCT04569604||Postsurgical hypoparathyroidism|Patients with hypoparathyroidism for 3 or more years after neck surgery
62627102|NCT04569604||Non-surgical hypoparathyroidism|Patients with hypoparathyroidism for 3 or more years without neck surgery
62627103|NCT04569604||Pseudohypoparathyroidism|Patients with the diagnosis of Pseudohypoparathyroidism
62627104|NCT04569604||Healthy controls|25 controls from the background population matched on age (±3 years), gender and level of education with the 25 patients with postsurgical hypoparathyroidism
62627105|NCT03800407||EFV-based ART|ART-naïve HIV-infected children aged 3 - 14 years who initiate EFV-based ART
62627106|NCT03800407||Concurrent EFV-based ART plus anti-TB therapy|ART-naïve HIV-infected children aged 3 - 14 years with TB coinfection who initiate EFV-based ART while receiving first-line anti-TB therapy
62627107|NCT03021629||primary open-angle glaucoma patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
62627108|NCT03021629||high myopia patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
62852824|NCT01848041|EXPERIMENTAL|RVL-1201 twice daily|RVL-1201 0.1% ophthalmic solution dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose
62627109|NCT03021629||age-matched people|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
62627110|NCT04995263|NO_INTERVENTION|Pre-intervention, control group|A basal measurement of primary and secondary outcomes of the target population, prior to the implementation the intervention. Estimated duration 3 months, n = 30.
62627111|NCT04995263|EXPERIMENTAL|Post-intervention, SUEÑA half bundle, active group 1|"Post-intervention, environmental and behavioral modifications in patient care interventions.~Implementation of components 1 through 4 of SUEÑA intervention in the entire PICU unit. All participants will be exposed to the intervention. Estimated duration: 3 months, n = 30."
62852825|NCT01848041|PLACEBO_COMPARATOR|RVL-1201 vehicle (placebo)|RVL 1201 ophthalmic solution vehicle (placebo) dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose
62852826|NCT03319745|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. About 4 weeks after treatment, patients then undergo radical cystectomy per standard of care.
62852827|NCT04455490||Delayed wound healing|Patients with delayed wound healing after Achilles tendon suture who were treated at Peking University Third Hospital
62063041|NCT02210793|ACTIVE_COMPARATOR|Transepithelial PRK|20 eyes to undergo a no touch , all-laser advanced surface ablation technique termed transepithelial PRK using the Amaris laser platform (Schwind eye-tech solutions Gmbh, Germany)
62627112|NCT04995263|EXPERIMENTAL|Post-intervention, randomization for SUEÑA half bundle plus, active group 2|"Randomization for full SUEÑA bundle: environmental and behavioral modifications in patient care interventions plus sleep informed treatment.~Participants will be randomized to receive SUEÑA components 1 through 5 Estimated duration: 6 months, n = 30"
62627113|NCT04995263|EXPERIMENTAL|Post-intervention, randomization for SUEÑA full bundle, active group 3|"Randomization for full SUEÑA bundle: environmental and behavioral modifications in patient care interventions plus sleep informed treatment and personalized psychoeducation.~. Participants will be randomized to receive SUEÑA components 1 through 6. Estimated duration: 6 months, n = 30"
62627114|NCT03828227|ACTIVE_COMPARATOR|"Candidate group OPTIMOX plus bevacizumab (Arm A)"|"Patients with :~* Serum albumin level ≥ 30g/L,~* ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).~Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles and then Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)"
62852828|NCT00947960|OTHER|Active/Placebo|Subjects receive 1-2 grams/kilogram body weight triheptanoin divided into 4 equal doses taken with meals and snack for 6 months crossing over to receive placebo vegetable oil at the same dose and frequency for the next 6 months during the randomization phase.
62852829|NCT00947960|OTHER|Placebo/Active|Subjects receive 1-2 grams/kilogram body weight placebo vegetable oil divided into 4 equal doses taken with meals and snack for 6 months crossing over to receive triheptanoin at the same dose and frequency for the next 6 months during the randomization phase.
62852830|NCT05401942|NO_INTERVENTION|Routine monitoring|patients with breast cancer who will receive adjuvant treatment and will be followed up during treatment with routine visits.
62852831|NCT05401942|ACTIVE_COMPARATOR|Tele-monitoring through mobile application|Patients with breast cancer who will receive adjuvant therapy and will be followed up during treatment through tele-monitoring with mobile application and CTCAE checklist for PRO.
62267902|NCT03178227|NO_INTERVENTION|Control|No intervention.
62852832|NCT00588068||1|Tumor and Marrow Markers
62852833|NCT06153004|EXPERIMENTAL|Healthy Activity Program (HAP)|HAP is a brief psychological treatment adapted from behavioral activation therapy, an empirically supported psychological treatment recommended by the World Health Organization.
62852834|NCT06153004|EXPERIMENTAL|Antidepressant medication (ADM)|Fluoxetine is a selective serotonin reuptake inhibitors (SSRIs) and one of the safest medications used to treat depression. It is a routinely used medication and part of the Essential Drug List (EDL) in India.
62063042|NCT02210793|ACTIVE_COMPARATOR|Conventional LASIK|20 eyes to undergo LASIK using a mechanical microkeratome (M2, Moria Surgical, Antony, France) and the Mel 80 excimer laser system(Carl Zeiss Meditec)
62063043|NCT02986490|OTHER|patient with antipsychotic/neuroleptic|Blood sample performed on patients requiring the establishment of treatment with antipsychotic / neuroleptic
62852835|NCT03594240|ACTIVE_COMPARATOR|intervention group|Intervention group included pediatric patients with diabetic nephropathy receiving oral vitamin B complex tablets( Neurorubine TM -Forte Lactab TM ) once daily.
62063044|NCT03609346||STEMI|Arm: STEMI Intervention: PCI with 1 or more BioFreedom stents in patients presenting with a STEMI. Medication according to hospital practice.
62063045|NCT00118261|EXPERIMENTAL|Erlotinib, modified FOLFOX6, and bevacizumab|
62063046|NCT06189404|EXPERIMENTAL|Cohort 1 (Periods 1-3), Cohort 2 (Periods 1-4)|Period 1: Single oral dose of theophylline (Day 1); Period 2: Once-daily oral doses of tigulixostat (Days 6 to 10); Period 3: Once-daily oral doses of tigulixostat (Days 11 to 13) and a single oral dose of theophylline (Day 11); Period 4: Single oral dose of tigulixostat (Day 19)
62063047|NCT05425511|EXPERIMENTAL|intervention group|The intervention group will have a longitudinal follow-up of seven months in total (a control period of 1 month, then 6 to 8 sophrology sessions during two months, then a 4-month follow-up).
62063048|NCT05425511|ACTIVE_COMPARATOR|control group|The control group will have a differed intervention (longitudinal follow-up of seven months in total beginning by a control period without intervention of 3 months, then 6 to 8 sophrology sessions during two months, then a 2-month follow-up).
62063049|NCT00840255|ACTIVE_COMPARATOR|Breif Behavioral Treatment of Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting \>1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
62852836|NCT03594240|PLACEBO_COMPARATOR|Control group|Placebo group or control patients received placebo that were similar in appearance to vitamin B complex tablets and the administered dose was as the same schedule as vitamin B complex .
62063050|NCT00840255|OTHER|Information Control|This arm of the study does not receive the Brief Behavioral Treatment for Insomnia. This arm will act as the control arm.
62063051|NCT00030420|EXPERIMENTAL|Celecoxib & Docetaxel|"Celecoxib: 400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.~Doctaxel: Day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days"
62063052|NCT05970302|EXPERIMENTAL|XELOX +Bev +Tislelizumab|"Every 3 weeks as a cycle:~1. Tislelizumab: 200mg, iv, d1;~2. Bevacizumab: 7.5mg/kg, iv, d1;~3. Oxaliplatin: 130mg/m2, iv, d1;~4. Capecitabine: 1000mg/m2, bid, po, d1-d14; Re-evaluate patients every two cycles. If the patient has been treated for more than 8 cycles, they will enter maintenance therapy, and the regimen is capecitabine + BEV combined with tislelizumab."
62063053|NCT02294630|ACTIVE_COMPARATOR|Dose Schedule I|Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:1
62063054|NCT02294630|ACTIVE_COMPARATOR|Dose Schedule II|Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:2
62267903|NCT03313427|EXPERIMENTAL|Intervention|Usual care Early physical therapy intervention at the UCIN and after discharge, at home; based on the family-centered model.
62267904|NCT03313427|OTHER|Control|Usual care
62852837|NCT03921645|EXPERIMENTAL|aerosol combined group|aerosol combined intravenous antibiotics group，amikacin 15mg/kg, qd
62852838|NCT03921645|NO_INTERVENTION|No intervention group|this group follow the usual treatment without any intervention
62852839|NCT04525885|EXPERIMENTAL|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).
62852840|NCT04525885|EXPERIMENTAL|Gefapixant 15 mg BID|Participants will receive a gefapixant 15 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).
62852841|NCT04525885|PLACEBO_COMPARATOR|Placebo|Participants will receive a matching placebo tablet BID during the 24-week main study period and during the 28-week extension period.
62852842|NCT00792571|EXPERIMENTAL|B.I.D|Beraprost Sodium Modified Release Tablets, 60mcg, b.i.d (twice a day dosing)
62852843|NCT00792571|EXPERIMENTAL|Q.I.D|Beraprost Sodium Modified Release Tablets, 60mcg, q.i.d (four times a day dosing)
62852844|NCT06313385|EXPERIMENTAL|Group 5 mg/mL|This group received 5 mg/mL concentration of Indocyanine Green (Aurogreen®, Aurolab, Tamil Nadu, India). Indocyanine Green (ICG) is being diluted with 5 mL dextrose 5%. The research assistant take 1 mL ICG using 1 mL syringe using filter that originated from the Aurogreen package.
62627115|NCT03828227|ACTIVE_COMPARATOR|"Candidate group - Capecitabine-bevacizumab (Arm B)"|"Patients with :~* Serum albumin level ≥ 30g/L,~* ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).~This treatment regimen will be given until disease progression (PD) or unacceptable limiting toxicity, as follows:"
62627116|NCT03828227|ACTIVE_COMPARATOR|"Non candidate group - Capecitabine-bevacizumab"|"Patients with:~* Serum albumin level \< 30g/L.~* And/ or ECOG PS 2 and mini GDS ≥ 1 (ie, depression).~This treatment regimen will be given until disease progression (PD) or unacceptable limiting toxicity, as follows:"
62627117|NCT01292707|ACTIVE_COMPARATOR|Control|Prescribing staff in control facilities will receive the standard package of RDT training that is being provided by NMCP in Tanzania
62063055|NCT02294630|ACTIVE_COMPARATOR|Dose Schedule III|Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:1
62627118|NCT01292707|ACTIVE_COMPARATOR|HW|Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial.
62627119|NCT01292707|ACTIVE_COMPARATOR|HWC|The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
62627120|NCT03869762|EXPERIMENTAL|Denosumab & Enzalutamide|"120mg subcutaneous injection on Day 1 of every four week cycle, for a maximum of 24 cycles, or until clinical disease progression, unacceptable toxicity, consent withdrawal or withdrawal for any other reason.~160mg PO daily; (4 x 40 mg capsules) until confirmed clinical disease progression, unacceptable toxicity, consent withdrawal or withdrawal for any other reason)"
62627121|NCT02778035|EXPERIMENTAL|60 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 60 min).
62063056|NCT02294630|ACTIVE_COMPARATOR|Dose Schedule IV|Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:2
62063057|NCT04895514|EXPERIMENTAL|Corneal tissue inlay|The treated cornea will be implanted with a thin disc of gamma-irradiated preserved corneal tissue
62063058|NCT05763784|EXPERIMENTAL|Pelvic Tightrope fixation|Theses patients will be treated with Tightrope for their traumatic pubic symphysis diastasis
62063059|NCT06326255|EXPERIMENTAL|Laughter Yoga Group|The intervention is a laughter yoga program consisting of 12 sessions, two 1-hour sessions per month.
62063060|NCT06326255|NO_INTERVENTION|wait-list-control group|Participants will receive the same intervention after the 3-Months Follow-up (T2).
62063061|NCT01421095|EXPERIMENTAL|Basal Testing|
62267905|NCT05007275|EXPERIMENTAL|Single arm, dose escalation|Experimental: Healthy Volunteers Biological/Vaccine: AZD1222 (1x10\^9 vp, 5x10\^9 vp and 1x10\^10 vp)
62063062|NCT04033263|PLACEBO_COMPARATOR|Placebo mouth rinse|Placebo: Deionized water (serving as negative control)
62267906|NCT02288507|EXPERIMENTAL|sorafenib & Yttrium-90 radioembolization|Sorafenib dose de-escalation starting at 400mg PO BID starting on Day1 Yttrium-90 radioemoblization on Day 14
62267907|NCT01972555|EXPERIMENTAL|Minimally invasive aortic valve replacement|Minimally invasive AVR with either ministernotomy or anterior right-sided minithoracotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.
62267908|NCT01972555|ACTIVE_COMPARATOR|Conventional aortic valve replacement|Conventional AVR through a standard median sternotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.
62267909|NCT01201135||Sickle cell disease|
62267910|NCT01201135||hereditary spherocytosis.|
62267911|NCT05526833|EXPERIMENTAL|Non-responders undergo rTMS of the right superior temporal sulcus (STS)|Non-responders to protocol #8116 will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will be administered 10 days (10 sessions) of MRI-guided 1 Hz rTMS delivered to the right superior temporal sulcus (STS). The rTMS parameters that will be used are a frequency of 1 Hz (1 pulse per second) at an intensity of 90% of the motor threshold (MT). Therefore, the investigators will deliver 1200 continuous pulses per session/day which adds up to 12,000 pulses in total for the whole treatment.
62267912|NCT05526833|EXPERIMENTAL|Partial responders undergo rTMS of the left temporo-parietal junction (TPJ)|Partial responders to protocol #8116 will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will be administered 10 days (10 sessions) of MRI-guided 1 Hz rTMS delivered to the original left temporo-parietal junction (TPJ) target. The rTMS parameters that will be used are a frequency of 1 Hz (1 pulse per second) at an intensity of 90% of the motor threshold (MT). Therefore, the investigators will deliver 1200 continuous pulses per session/day which adds up to 12,000 pulses in total for the whole treatment.
62267913|NCT05526833|NO_INTERVENTION|Complete responders undergo four follow-up clinical assessments|Complete responders to protocol #8116 will be offered followup clinical assessments at 1, 2, 4, and 8 weeks to assess sustainability of their response.
62852845|NCT06313385|ACTIVE_COMPARATOR|Group 2,5 mg/mL|This group received 2,5 mg/mL concentration of Indocyanine Green (Aurogreen®, Aurolab, Tamil Nadu, India). Indocyanine Green (ICG) is being diluted with 5 mL dextrose 5%. The research assistant take 0,5 mL ICG using 1 mL syringe using filter that originated from the Aurogreen package. The ICG in the syringe is added with 0,5 mL Dextrose 5%.
62852846|NCT06313385|ACTIVE_COMPARATOR|Group 0,5 mg/mL|This group received 2,5 mg/mL concentration of Indocyanine Green (Aurogreen®, Aurolab, Tamil Nadu, India). Indocyanine Green (ICG) is being diluted with 5 mL dextrose 5%. The research assistant take 0,1 mL ICG is taken using 1 mL syringe using filter that originated from the Aurogreen package. The ICG in the syringe is added with 0,9 mL Dextrose 5%.
62852847|NCT02878161|EXPERIMENTAL|A group|Infliximab plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
62852848|NCT02878161|EXPERIMENTAL|B group|Etanercept plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
62852849|NCT02878161|EXPERIMENTAL|C group|Adalimumab plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
62852850|NCT06428071|ACTIVE_COMPARATOR|Standard physical therapy program|All Patients in the three groups will receive supervised systematic exercise therapy that was performed effectively in previous work. This program consisted of lower limb static, dynamic, and flexibility exer¬cises that targeted the quadriceps, hamstrings, and gluteus muscles; and core strength training for 20 minutes per day. This program will be applied 3 times per week for 6 weeks
62063063|NCT04033263|ACTIVE_COMPARATOR|Elmex mouth rinse|Commercial mouth rinse used as gold standard in erosion studies: elmex® Erosion Protection solution (which contains 800 ppm Sn2+, as SnCl2, and 500 ppm F-, as NaF and AmF)
62063064|NCT04033263|ACTIVE_COMPARATOR|Fluoride mouth rinse|Fluoride solution similar to many other commercial mouth rinses containing sodium fluoride (NaF at 500 ppm F-)
62063065|NCT04033263|EXPERIMENTAL|Plant extract A|Plant Extract A
62063066|NCT04033263|EXPERIMENTAL|Plant extract A with fluoride|Plant Extract A + Fluoride
62267914|NCT02092194|ACTIVE_COMPARATOR|Standard Dose online HDF|Proposed target convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
62627122|NCT02778035|EXPERIMENTAL|30 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 30 min).
62063067|NCT04033263|EXPERIMENTAL|Plant extract B|Plant extract B
62063068|NCT04033263|EXPERIMENTAL|Plant extract B with fluoride|Plant Extract B + Fluoride
62063069|NCT04033263|EXPERIMENTAL|Plant extract C|Plant extract C
62063070|NCT04033263|EXPERIMENTAL|Plant extract C with fluoride|Plant Extract C + Fluoride
62063071|NCT01592149||Group 1|
62063072|NCT01833312|EXPERIMENTAL|Hypothermia|Best medical treatment + hypothermia 34-35°C for 24h
62063073|NCT01833312|NO_INTERVENTION|Control|Best medical treatment
62063074|NCT03114202|EXPERIMENTAL|Intervention group|Intensive nutritional counseling: once they are admitted to the study and once a week during radiotherapy
62627123|NCT02778035|EXPERIMENTAL|0 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 0 min).
62627124|NCT01304134|EXPERIMENTAL|Oxycodone i.v.|To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)
62063075|NCT03114202|OTHER|Control group|Standard care: when there is demand, usually 1 to 2 times during radiotherapy
62627125|NCT01304134|ACTIVE_COMPARATOR|Morphine i.v.|To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)
62063076|NCT04241692|EXPERIMENTAL|Application of Carnation Ambulatory Patch Monitoring System|The patient will wear a Standard Holter Monitor and the CAM Patch system simultaneously for 24 hours.
62063077|NCT04241692|EXPERIMENTAL|Application Conventional 24-Hour Holter Monitor Recorder|The patient will wear a Standard Holter Monitor and the CAM Patch system simultaneously for 24 hours.
62063078|NCT01897701|EXPERIMENTAL|Group A|High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 \& 21
62063079|NCT01897701|EXPERIMENTAL|Group B|Intermediate dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 \& 21
62267915|NCT02092194|EXPERIMENTAL|High Dose online HDF|Proposed target convection volume; 33-43 L/treatment (140-180 mL/min).
62267916|NCT00871312|ACTIVE_COMPARATOR|Topical Wound Oxygen Therapy|Subjects will receive four 90 minute treatments of two2 therapy per week
62267917|NCT00871312|PLACEBO_COMPARATOR|Placebo Therapy|Subjects will receive four 90 minute treatments of Placebo two2 therapy per week
62267918|NCT05919979|EXPERIMENTAL|Fasting, then fasting+exercise|
62267919|NCT05919979|EXPERIMENTAL|Fasting + Exercise, then fasting|
62267920|NCT03461757|EXPERIMENTAL|Arm 1: Rimegepant 75 mg|Participants were administered a single sublingual dose of 75 mg of rimegepant ODT on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
62267921|NCT03461757|PLACEBO_COMPARATOR|Arm 2: Placebo|Participants were administered a single sublingual dose of matching placebo for rimegepant (75 mg) ODT on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
62267922|NCT02019914||PTSD and OSA|Veterans diagnosed with Post Traumatic Stress Disorder (PTSD) and Obstructive Sleep Apnea (OSA), interested in a trial of CPAP therapy.
62267923|NCT01600443|EXPERIMENTAL|LoFric - SC - SCCM|Study period 1: LoFric Study period 2: SpeediCath Study period 3: SpeediCath Compact Male In each study period three catheterizations are made, separated by at least 2 hours.
62627126|NCT05680948||Enrolled patients exiting the ISS T-003 EF-UP study|No intervention - No intervention is foreseen in this Observational Study
62063080|NCT01897701|EXPERIMENTAL|Group C|Intermediate dose Monovalent Avian Influenza VLP (H7N9) and Low dose Adjuvant 1; IM; Day 0 \& 21
62063081|NCT01897701|EXPERIMENTAL|Group D|Low dose Monovalent Avian Influenza VLP (H7N9) and Low dose Adjuvant 1; IM; Day 0 \& Day 21
62063082|NCT01897701|EXPERIMENTAL|Group E|Intermediate dose Monovalent Avian Influenza VLP (H7N9) and High dose Adjuvant 1; IM; Day 0 \& 21
62627127|NCT04967157|PLACEBO_COMPARATOR|Placebo|Active ingredients: none
62627128|NCT04967157|ACTIVE_COMPARATOR|Cognizin®|Active ingredients: Citicoline
62627129|NCT02638974|EXPERIMENTAL|Medical Skin Camouflage|This arm will use medical skin camouflage for 6 weeks
62627130|NCT02638974|NO_INTERVENTION|Wait List Control|This arm will receive medical skin camouflage at the end of the study
62627131|NCT01853683|EXPERIMENTAL|Conservative Management|Children randomized to conservative management will be seen in the clinic 6-10 weeks after discharge and phoned to follow up every 3 month for a total follow-up of a year. Family will be instructed to come back to the hospital or call the treating physician if the child develops any abdominal pain or fever.
62063083|NCT01897701|EXPERIMENTAL|Group F|Low dose Monovalent Avian Influenza VLP (H7N9) and High dose Adjuvant 1; IM; Day 0 \& 21
62267924|NCT01600443|EXPERIMENTAL|LoFric - SCCM - SC|Study period 1: LoFric Study period 2: SpeediCath Compact Male Study period 3: SpeediCath In each study period three catheterizations are made, separated by at least 2 hours.
62267925|NCT01600443|EXPERIMENTAL|SC - SCCM - LoFric|Study period 1: SpeediCath Study period 2: SpeediCath Compact Male Study period 3: LoFric In each study period three catheterizations are made, separated by at least 2 hours.
62267926|NCT01600443|EXPERIMENTAL|SC - LoFric - SCCM|Study period 1: SpeediCath Study period 2: LoFric Study period 3: SpeediCath Compact Male In each study period three catheterizations are made, separated by at least 2 hours.
62627132|NCT01853683|ACTIVE_COMPARATOR|Operative Management|Children randomized to IA will be scheduled for an interval appendectomy 6-10 weeks after discharge, and will be seen in the clinic 6-8 weeks following the interval appendectomy and phoned for follow-up every 3 month for a total of one year.
62627133|NCT04346407|EXPERIMENTAL|Dronabinol|2.5mg of oral Dronabinol daily starting with pre-op cocktail and continued twice daily for three days after surgery
62627134|NCT04346407|PLACEBO_COMPARATOR|Placebo|Capsule with placebo daily starting with pre-op cocktail and continued twice daily for three days after surgery
62627135|NCT04727528|EXPERIMENTAL|Open-label correction phase (up to 48 hours)|"All eligible patients will receive SZC 10 g TID for up to 48 hours. Patients with POCT (Point-of-Care-Test) K+ ≥5.1 mmol/L after 24 hours will continue on SZC 10 g TID for another 24 hours. Patients who achieve normokalemia (defined as POCT K+ between 3.5 and 5.0 mmol/L inclusive) after receiving SZC 10 g TID for up to 48 hours will proceed to randomization.~Patients with POCT K+ \<3.5mmol/L at any time during the open-label phase will be withdrawn from study treatment and will be followed per protocol."
62627136|NCT04727528|EXPERIMENTAL|Randomized, placebo controlled phase (Day 2 or 3 to Day 29)|Patients will be randomized to SZC 10 g QD or placebo 10 g QD. The dose of SZC/placebo will be titrated by increasing or decreasing the dose by 5 g increments at 1-week intervals to between 5 g every other day (QOD) and 15 g QD of the randomized phase to maintain normokalemia by POCT K+.
62627137|NCT04445090|EXPERIMENTAL|Single Rising Dose part: BI 1569912|
62627138|NCT04445090|PLACEBO_COMPARATOR|Single Rising Dose part: Placebo|
62627139|NCT04445090|EXPERIMENTAL|Bioavailability and Food effect part: BI 1569912|This part follows the SRD part; open-label, randomised, single-dose, intraindividual, six-sequence, three-way crossover
62627140|NCT06077162|EXPERIMENTAL|What Can I Eat Diabetes Nutrition Education Classes Only|Participants will be enrolled in a 3 month, 5 session in-person diabetes nutrition education class, entitled What Can I Eat?, over the course of the 3 month intervention (4 \* 90 min in person classes weekly for a month, with 5th class at 3 months from baseline).
62627141|NCT06077162|EXPERIMENTAL|What Can I Eat Diabetes Nutrition Education Classes + Healthy Food Security Resource|Participants will be enrolled in a 3 month, 5 session in-person diabetes nutrition education class, entitled What Can I Eat?, over the course of the 3 month intervention (4 \* 90 min in person classes weekly for a month, with 5th class at 3 months from baseline). Additionally, patients will receive a $30.00 healthy food resource weekly for 12 weeks.
62627142|NCT06077162|EXPERIMENTAL|Healthy Food Security Resource Only|Patients will receive a $30.00 healthy food resource weekly for 12 weeks.
62627143|NCT03089645|EXPERIMENTAL|Part 1|MEDI5083 monotherapy followed by Durvalumab monotherapy in subjects with advanced solid tumors
62627144|NCT03089645|EXPERIMENTAL|Part 2|Sequential MEDI5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab in subjects with advanced solid tumors.
62627145|NCT03089645|EXPERIMENTAL|Part 3|Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel in subjects with IO refractory/relapsed 2/3L in NSCLC
62627146|NCT05782972|EXPERIMENTAL|dapagliflozin (Forxiga) treatment|The participants received oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks
62267927|NCT01600443|EXPERIMENTAL|SCCM - LoFric - SC|Study period 1: SpeediCath Compact Male Study period 2: LoFric Study period 3: SpeediCath In each study period three catheterizations are made, separated by at least 2 hours.
62267928|NCT01600443|EXPERIMENTAL|SCCM - SC - LoFric|Study period 1: SpeediCath Compact Male Study period 2: SpeediCath Study period 3: LoFric In each study period three catheterizations are made, separated by at least 2 hours.
62267929|NCT06448403||MCI|Recruitment according to relevant clinical assessment and ICD-criterias.
62627147|NCT02712918|EXPERIMENTAL|Brief Behavioral Activation Treatment for Depression|Behavioral treatment of depression. The study utilized the revised version of the Brief Behavioral Activation Treatment for Depression (BATD) protocol from 2011. The treatment was added to treatment as usual. Up to 10 sessions were administered.
62267930|NCT06448403||Mild AD|Recruitment according to relevant clinical assessment and ICD-criterias.
62627148|NCT02712918|PLACEBO_COMPARATOR|Standard care|Standard CARE (SC) at the inpatient unit. Mandatory: Therapeutic conversations with psychiatrist, psychologist or M.D, milieu therapy. Optional: Psychosomatic physiotherapy, therapeutic groups, psychopharmacological treatment.
62627149|NCT04731831||Patient with arthritis starting infliximab or adalimumab|Patients with Rheumatoid Artritis, Psoriatic Arthritis, Anchylosing Spondylitis starting treament with infliximab or adalimumab
62627150|NCT02118779|EXPERIMENTAL|Behavioural change intervention|Cognitive behavioural therapy (CBT) combined with exercise
62627151|NCT02118779|NO_INTERVENTION|Standard Patient Management|Standard care like usual (i.e. annual checks with neurologist, checks with cardiologist, if needed physical therapy)
62627152|NCT04273997|ACTIVE_COMPARATOR|Metronidazole Ointment|"Treatment Group A: Metronidazole 10% w/w ointment. A 2.5 cm strip of ointment (approximately 700 mg) will be administered topically to the wound together with suitable dressing, once daily.~One dose contains approximately 70 mg metronidazole in a formulation of white soft paraffin. The Investigator will demonstrate to the subject how to apply a 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape. Larger wounds may require additional amount of IMP to ensure sufficient cover of the wound"
62267931|NCT06448403||Control|Equivalent number of research participants as in the MCI and mild AD group.
62267932|NCT04319978|ACTIVE_COMPARATOR|Group A|Group A will receive single dose of dexamethasone IM 8mg 1 hour pre-operatively.
62267933|NCT04319978|ACTIVE_COMPARATOR|Group B|Group B will receive a single dose of dexamethasone IM 8mg immediately after surgery.
62267934|NCT05704478|ACTIVE_COMPARATOR|Intervention|Participants will be administered the drug vericiguat
62267935|NCT05704478|PLACEBO_COMPARATOR|Control|Participants will be administered a placebo
62267936|NCT01512303|EXPERIMENTAL|Sudarshan Kriya Yoga: SKY|SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment. All are soothing and present-focused. Participants will be encouraged to learn all the breathing exercises, and to utilize the exercises the ones that seems most appropriate for their needs. 8-day intensive group class (2.5 hours/day) followed by 4 weekly sessions (3 hours/session).
62267937|NCT01512303|EXPERIMENTAL|Mindfulness-Based Stress Reduction: MBSR|MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts, allowing the practitioner to calm his or her mind and come back to the present moment. The typical MBSR format will be adapted to match the SKY intervention. This intervention will include an 8-day intensive group class (2.5 hours/day) followed by 4 weekly sessions (3hrs/session).
62267938|NCT01512303|NO_INTERVENTION|Wait-List Control: WLC|Participants will undergo no intervention. These participants will have the option of receiving one of the two interventions at the conclusion of the study.
62627153|NCT04273997|PLACEBO_COMPARATOR|Placebo Ointment|"Treatment Group B: Placebo ointment. A 2.5 cm strip of ointment (approximately 700 mg) will be administered topically to the wound together with suitable dressing, once daily.~One dose of placebo ointment contains titanium dioxide and white soft paraffin. The Investigator will demonstrate to the subject how to apply a 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape. Larger wounds may require additional amount of IMP to ensure sufficient cover of the wound."
62627154|NCT06104566|ACTIVE_COMPARATOR|Arm 1|Combination therapy
62627155|NCT06104566|ACTIVE_COMPARATOR|Arm 2|mono therapy
62627156|NCT02830399|ACTIVE_COMPARATOR|active rTMS-ECT|5 active high frequency rTMS before 5 bilateral ECT
62627157|NCT02830399|PLACEBO_COMPARATOR|sham rTMS-ECT|5 sham rTMS before 5 bilateral ECT
62627158|NCT04058028|EXPERIMENTAL|Rozibafusp Alfa, Dose A|Investigational product solution in vial
62627159|NCT04058028|EXPERIMENTAL|Rozibafusp Alfa, Dose B|Investigational product solution in vial
62627160|NCT04058028|EXPERIMENTAL|Rozibafusp Alfa, Dose C|Investigational product solution in vial
62627161|NCT04058028|PLACEBO_COMPARATOR|Placebo for Rozibafusp Alfa|Placebo Investigational product solution in vial
62627162|NCT05615142|EXPERIMENTAL|LDRT+SBRT Combined with PD-1 Inhibitors|Dose escalation cohort. DOSE LEVEL: Low Dose Radiotherapy (LDRT) dose from 2 Gy to 6Gy (2 Gy/f) + partial stereotactic body radiation therapy (SBRT) dose at 10 Gy to 30 Gy (10 Gy/f) + PD-1 inhibitor (dose as recommended in the instruction manual).
62627163|NCT00940888||No treatment: ICD/CRTD-indicated|
62627164|NCT05524766|EXPERIMENTAL|BTL-785-7 Treatment|Subjects will be enrolled for an active treatment with BTL-785F device (BTL-785-7 applicator) for improvement of overall facial appearance and muscle tone in patients injected with botulinum toxin.
62627165|NCT05524766|NO_INTERVENTION|Control|Two (2) patients will be enrolled in the control group study and will not receive any treatment. Following the completion of the investigation, the control group patients will be offered the same treatment course as the active group.
62627166|NCT01792440||non-cystic fibrosis bronchiectasis|patients with non-cystic fibrosis bronchiectasis will be evaluated cross-sectionally
62627167|NCT01792440||healthy control subjects|healthy control subjects will be evaluated cross-sectionally
62627168|NCT04541329|EXPERIMENTAL|Tildrakizumab treatment|
62627169|NCT05458947|EXPERIMENTAL|pulsed wound irrigation (PWI)|The necrotic wound is irrigated with normal saline (0.9%) with an 8-12 pounds per square inch pressure (PSI) to provide a mechanical force to loosen necrotic tissue for wound healing
62627170|NCT05458947|EXPERIMENTAL|electrical stimulation (ES)|ES works to promote the migration of cells based on natural cell polarity known as galvanotaxis, enhancing and mimicking the natural current of injury. By recreating the natural electrical fields of the skin, ES attracts immune cells vital to healing to wound to facilitate wound closure
62627171|NCT05458947|EXPERIMENTAL|electrical stimulation (ES) and pulsed wound irrigation (PWI)|The necrotic wound is irrigated with normal saline (0.9%) with an 8-12 pounds per square inch pressure (PSI) to provide a mechanical force to loosen necrotic tissue for wound healing and ES to promote the migration of cells based on natural cell polarity known as galvanotaxis, enhancing and mimicking the natural current of injury. By recreating the natural electrical fields of the skin, ES attracts immune cells vital to healing to wound to facilitate wound closure
62627172|NCT06467747|EXPERIMENTAL|Music group|Listen music with earphone
62627173|NCT06467747|PLACEBO_COMPARATOR|Mute group|Keep mute under earphone
62627174|NCT06467747|NO_INTERVENTION|Control group|As usual anesthesia care without earphones
62627175|NCT01213446|EXPERIMENTAL|Biostate|
62627176|NCT02135016|EXPERIMENTAL|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
62063084|NCT01897701|EXPERIMENTAL|Group G|Placebo; IM; Day 0 \& 21
62063085|NCT04042116|EXPERIMENTAL|Phase 1b: Dose Escalation|- Up to 50 patients with advanced solid tumor
62063086|NCT04042116|EXPERIMENTAL|Phase 1b: Food Effect Cohort|- Approximately 16 evaluable patients with an advanced, metastatic solid tumor will be enrolled
62627177|NCT02135016|EXPERIMENTAL|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
62627178|NCT02135016|PLACEBO_COMPARATOR|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
62627179|NCT01085422|EXPERIMENTAL|Arm A|
62627180|NCT06130085|NO_INTERVENTION|Infants Continuing on amino acid based formula after 6 months elimination|
62627181|NCT06130085|ACTIVE_COMPARATOR|Infants receiving partially hydrolyzed formula after 6 months of elimination diet|
62627182|NCT06079996|EXPERIMENTAL|caffeine gum|The gum containing 200 mg of caffeine (CAF) were chewed for 10 minutes before test
62627183|NCT06079996|PLACEBO_COMPARATOR|placebo|The gum without caffeine (PLA) were chewed for 10 minutes before test
62627184|NCT04910581|ACTIVE_COMPARATOR|Experimental stimulation|Patients receive an inhibitor treatment of rTMS using activ coil (MCF B65 coil) for 30 minutes at 1Hz at 80% of the resting motor threshold (MagPro stimulator; MagVenture A / S, Farum, Denmark) onto the left laryngeal cortex located thanks to a neuronavigation device (Syneika one \[SYN1\], Syneika, Cesson-Sévigné, France).
62063087|NCT04042116|EXPERIMENTAL|Phase 2: Expansion Cohort - Endometrial Cancer|"* Recurrent endometrial carcinoma at least 1 prior platinum-based chemotherapy regimen~* Up to 10 patients who have progressed on treatment with 1 prior PD-(L)1 inhibitor administered as monotherapy will be allowed to enroll"
62063088|NCT04042116|EXPERIMENTAL|Phase 2: Expansion Cohort - Ovarian Cancer|"* Recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, of any histology excluding clear cell carcinoma~* At least 2 prior chemotherapy regimens which at least 1 must have been platinum-doublet chemotherapy~* Up to 10 subjects with recurrent ovarian, fallopian tube, or primary peritoneal cancer, of any histology excluding clear cell carcinoma who have progressed within 6 months after completing first-line platinum-based chemotherapy will be allowed to enroll"
62267939|NCT01512303|NO_INTERVENTION|Non-PTSD control|Baseline measures only will be collected from a group of 50 combat-exposed veterans without PTSD to assess group differences on these measures prior to treatment.
62267940|NCT06353451|EXPERIMENTAL|Intervention Group|Smartphone screen time should be reduced to less than 2 hours per day for 3 consecutive weeks. Screen time will be controlled by screenshots weekly.
62267941|NCT06353451|NO_INTERVENTION|Control group|Smartphone usage behavior should continue unchanged. Screen time will be measured by uploaded screenshots weekly.
62267942|NCT01343433||Control group|Chamber allocation will determine which patient receives bright light therapy. We selected four patient chambers at the Intensive Care Unit, each with the capacity of two patient beds. In two chambers patients will receive bright light therapy. Patients in the other two rooms are only exposed to environmental light
62627185|NCT04910581|PLACEBO_COMPARATOR|Sham stimulation|Patients receive a treatment of rTMS using placebo coil (MCF P B65 coil) for 30 minutes at 1Hz (MagPro stimulator; MagVenture A / S, Farum, Denmark) onto the left laryngeal cortex located thanks to a neuronavigation device (Syneika one \[SYN1\], Syneika, Cesson-Sévigné, France).
62627186|NCT00999310||Klinefelter syndrome|
62063089|NCT04042116|EXPERIMENTAL|Phase 2: Expansion Cohort - Clear Cell Cancer|"* Recurrent, metastatic clear cell carcinoma of ovarian, fallopian tube, primary peritoneal or endometrial origin~* At least 1 prior platinum- and taxane-based chemotherapy regimen"
62267943|NCT01343433||Treatment group (bright light therapy)|Chamber allocation will determine which patient receives bright light therapy. We selected four patient chambers at the Intensive Care Unit, each with the capacity of two patient beds. In two chambers patients will receive bright light therapy. During our study, light therapy will be applied with instrument 'Litepod' (manufactured by Goodlite, Donker Curtiusstraat 7/407, Amsterdam), which gives an intensity of 10000 lux at a distance of 22 centimetres.Patients will receive bright light therapy for three hours in the morning, from eight o'clock till eleven o'clock.
62627187|NCT00999310||Control men|
62627188|NCT00999310||Control women|
62627189|NCT00999310||parents of Klinefelter groupe|
62063090|NCT04042116|EXPERIMENTAL|Phase 2: Expansion Cohort - Cervical Cancer|"* Persistent or recurrent cervix cancer of squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma histology~* At least 1 prior regimen of platinum-based chemotherapy, with or without bevacizumab, for metastatic disease"
62063091|NCT02430701|EXPERIMENTAL|IRE Group|irreversible electroporation for Unresectable Esophageal Neoplasms
62267944|NCT03345108|EXPERIMENTAL|Test Denture Adhesive (Conventional Application)|Test denture adhesive will be applied to participants' dentures via conventional pattern of application.
62267945|NCT03345108|EXPERIMENTAL|Test Denture Adhesive (Continuous strip Application)|Test denture adhesive will be applied to participants' dentures via continuous strips pattern of application.
62267946|NCT03345108|OTHER|Negative Control|Participants will not apply any denture adhesive in this treatment arm.
62267947|NCT05996172|ACTIVE_COMPARATOR|CAMS Single Session Consultation (SSC)|CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients. The foundational brief intervention that all participants will receive includes 1 90-minute session of CAMS assessment and planning interview with follow-up care navigation.
62267948|NCT05996172|ACTIVE_COMPARATOR|CAMS SSC + Driver-Focused Skills Training|Specific skills are taught to youth based on CAMS drivers/case conceptualization of suicidality. Based on our pilot work, the common components of treatment include explicit coaching in skills informed by evidence-based treatments like Dialectical Behavior Therapy (DBT), Cognitive Behavioral Therapy (CBT), and Behavioral Activation (BA). Skills are drawn from the following 3 domains: emotion regulation and crisis survival skills (e.g., paced breathing, use of temperature and exercise to alter mood, Hope Box), behavioral activation strategies (e.g., goal-directed behavior, scheduling of activities, problem-solving) and communication skills (communication around suicidality, validation of self and others, making clear requests/DEAR MAN). Youth assigned to the Ongoing CAMS Intervention condition will receive three, 50-minute sessions that include the interim SSF and driver focused treatment encompassing skills instruction, in-session practice, and assigned homework.
62267949|NCT05996172|ACTIVE_COMPARATOR|CAMS SSC + Caregiver Skills Building|Caregivers will receive 3, 30-minute modules across 3 sessions that provide explicit coaching in several skills. Module content will include 1) psychoeducation on suicidality and the escalation cycle and creation of a communication plan related to responding to youth suicidality (i.e., Crisis Escalation and Communication Plan); 2) positive communication and relationship building strategies including reflective listening, validation, and how to implement regular teen-directed one-on-one time; and 3) setting up behavioral expectations, house rules, and using positive reinforcement based contingency management in the home (i.e., targeted praise, using rewards to promote more effective behaviors). All modules will include didactic skill building, role-play of skill use with the therapist, and a check-in with the youth and youth therapist to collaboratively problem-solve barriers to use of skills.
62461454|NCT05286957|EXPERIMENTAL|MRD-guided adjuvant tislelizumab and chemotherapy|"MRD+: Tislelizumab 200mg Q3W + chemotherapy 1-4 cycles and followed by Tislelizumab 200mg Q3W Up to 16 cycles or until PD or intolerable toxicity or withdrawal~MRD-: Adjuvant chemotherapy and surveillance the MRD status, the patient will receive treatment for MRD+ patient when MRD detected,"
62852851|NCT06428071|EXPERIMENTAL|knee Decompression|"The ACUTRAC AT270 Traction System device will be used for traction. The patient will assume the supine position with the hip of the treated limb in semi-flexion and the ipsilateral knee in 25-30º flexion. 15 minutes of continuous mechanical traction using 20% of the patient's weight will be used. The session will be 15 minutes, once a day, three-times a week for 6 weeks.~This group will receive decompression and standard physical therapy."
62852852|NCT06428071|EXPERIMENTAL|Decompression plus heating|this group will receive the standard physical therapy, the mechanical decompression and superficial heating using heat pad on the knee joint for 20 minutes while the patient receives the decompression session
62852853|NCT03800420|EXPERIMENTAL|BBT-401-1S|BBT-401-1S, Oral capsule, QD
62852854|NCT03800420|PLACEBO_COMPARATOR|Placebo|Placebo, Oral capsule, QD
62852855|NCT04469998|EXPERIMENTAL|AXR-270 Low Dose|AXR-270 Low Dose administered once daily
62852856|NCT04469998|EXPERIMENTAL|AXR-270 High Dose|AXR-270 High Dose administered once daily
62852857|NCT04469998|PLACEBO_COMPARATOR|AXR-270 Vehicle|AXR-270 Vehicle administered once daily
62852858|NCT05132114|NO_INTERVENTION|Control Group|LLETZ (without intraoperative Lugol's iodine)
62852859|NCT05132114|EXPERIMENTAL|Iodine group|LLETZ after the intraoperative application of Lugol's iodine
62852860|NCT03472846|ACTIVE_COMPARATOR|Group 1 - DMAB|postmenopausal women without type 2 diabetes mellitus treated with denosumab
62852861|NCT03472846|ACTIVE_COMPARATOR|Group 2 - TPTD|postmenopausal women with type 2 Diabetes mellitus treated with teriparatide
62852862|NCT03472846|ACTIVE_COMPARATOR|Group 3 - DMAB|postmenopausal women with type 2 diabetes mellitus treated with denosumab
62852863|NCT03472846|ACTIVE_COMPARATOR|Group 4 - TPTD|postmenopausal women without type 2 diabetes mellitus treated with teriparatid
62852864|NCT03720652|EXPERIMENTAL|8-Week Mindful Self-Compassion (MSC)|CNAs in Aim 1 will participate in the standardized, 8-week Mindful Self-Compassion course. Each 8-week session will last for 2.5 hours. Also included is a half day retreat, that CNAs may attend if they are able.
62852865|NCT03720652|EXPERIMENTAL|6-Week Mindful Self Compassion (MSC)|CNAs from both nursing homes in Aim 2 will participate in the 6-week Mindful Self-Compassion course, that was shortened and customized to fit the needs of health care staff. Each 6-week session will last for 1 hour.
62852866|NCT04020861|ACTIVE_COMPARATOR|PBM + TENS|The patients will be submitted to the active PBM and active TENS
62852867|NCT04020861|ACTIVE_COMPARATOR|PBM|The patients will be submitted to the active PBMT and placebo TENS
62852868|NCT04020861|ACTIVE_COMPARATOR|TENS|The patients will be submitted to the placebo PBMT and active TENS
62852869|NCT04020861|PLACEBO_COMPARATOR|Placebo|The patients will be submitted to the placebo PBMT and placebo TENS.
62063092|NCT02430701|NO_INTERVENTION|Control|The patients without treatment
62063093|NCT01254201||Dry Eye|Female patients over the age of 18 years with ocular complaints of dryness, grittiness, irritation, or related symptoms, without any identifiable cause.
62852870|NCT05813808|EXPERIMENTAL|chest x-ray and ultra-low-dose computed tomography|
62063094|NCT01254201||Fibromyalgia|Female patients over the age of 18 years diagnosed with Fibromyalgia.
62063095|NCT01254201||Healthy Control|Female patients over the age of 18 years with no symptoms of dry eyes and with no known diagnosis of Fibromyalgia.
62063096|NCT00553501|EXPERIMENTAL|Epratuzumab Plus Rituximab|"Induction Therapy (Month 1): Epratuzumab 360 mg/m\^2 by IV days 1, 8, 15 \& 22; Rituximab 375 mg/m\^2 by IV day 3, 8, 15 \& 22~Extended Induction (Weeks 12, 20, 28 \& 36) Epratuzumab 360 mg/m\^2 by IV weeks 12, 20, 28 \& 36; Rituximab 375 mg/m\^2 by IV weeks 12, 20, 28 \& 36"
62063097|NCT04005534|PLACEBO_COMPARATOR|Standard group|Patients from this group will undergo only ultrasound examination of the brachial plexus, two days before the surgery. On the day of surgery they will undergo ultrasound-guided brachial plexus blockade (interscale access; 15 ml 1% ropivacaine and sedation (midazolam 3 mg, fentanyl 50 µg and 15 mg ketamine.
62063098|NCT04005534|EXPERIMENTAL|Preemptive group|Patients from this group will undergo ultrasound-guided brachial plexus blockade, two days before the surgery. On the day of surgery they will undergo ultrasound-guided brachial plexus blockade (interscale access; 15 ml 1% ropivacaine and sedation (midazolam 3 mg, fentanyl 50 µg and 15 mg ketamine.
62063099|NCT01678014|EXPERIMENTAL|Anorexia|Anorexia patients
62267950|NCT05996172|ACTIVE_COMPARATOR|CAMS SSC + Lethal Means Safety|The CAMS Therapeutic Assessment incorporates low levels of lethal means restriction (see above). Experimental Intervention Component 4 will provide a high level of lethal means restriction that includes the evaluation of the need for a lock box, the provision of a lock box if needed, structured process for evaluating home safety in each room of the house, specific directives to accomplish, follow up with the clinician, and problem-solving barriers to lethal means restriction over two, 30-minute modules delivered across 2 sessions.
62267951|NCT05996172|ACTIVE_COMPARATOR|CAMS SSC + Driver Focused Skills Training + Caregiver training|This arm includes CAMS SSC, 3 sessions of youth facing driver focused skills, and 3 sessions of caregiver skills training.
62267952|NCT05996172|ACTIVE_COMPARATOR|CAMS SSC + Driver Focused Skills Training + Lethal Means Safety|This arm includes the CAMS single session intervention, 3 sessions of skills training for the youth, and lethal means safety for caregiver.
62063100|NCT06613529|EXPERIMENTAL|online mindfulness group|Patients in the experimental group received online mindfulness interventions at least once a week approximately 15-20 minutes each time.
62627190|NCT04617795|EXPERIMENTAL|Basal-Bolus (Group A)|"* 2 weeks standard therapy - using multiple daily injections (MDI) and Dexcom G6 Continuous Glucose Monitor (CGM), followed by:~* 4 weeks Omnipod 5 system use in Automated Mode with optional bolus, followed by:~* 4 weeks Omnipod 5 system use in Automated Mode with simplified bolus~* 6-month optional extension using Automated Mode"
62627191|NCT04617795|EXPERIMENTAL|Basal (Group B)|"* 2 weeks standard therapy - using basal injection only and Dexcom G6 Continuous Glucose Monitor (CGM), followed by:~* 2 weeks Omnipod 5 system use in Manual Mode with Dexcom G6 Continuous Glucose Monitor (CGM) - with fixed basal rate, no bolus, followed by:~* 4 weeks Omnipod 5 system use in Automated Mode with optional bolus, followed by:~  * If % time in range 70-180 mg/dL during Automated Mode is ≤50%, 4 weeks Omnipod 5 system use in Automated Mode with simplified bolus, OR~ * If % time in range 70-180 mg/dL during Automated Mode is \>50%, 4 weeks Omnipod 5 system use in Automated Mode with optional bolus~* 6-month optional extension using Automated Mode"
62852871|NCT03354507|EXPERIMENTAL|Sodium Bicarbonate|"Patients will receive sodium bicarbonate for 4 weeks, based on pre-calculated weight based doses. Patients are selected if they have metabolic acidosis at baseline.~\< 24 kg : 1/4 teaspoon bid. 24 - 42 kg : 1/2 teaspoon bid. \> 42kg : 3/4 teaspoon bid."
62063101|NCT01602757|EXPERIMENTAL|Synera|"Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3."
62063102|NCT06284317|EXPERIMENTAL|Durvalumab|Protocol treatment in the adjuvant phase consists of adjuvant durvalumab
62267953|NCT05996172|ACTIVE_COMPARATOR|CAMS SSC + Caregiver Skills Training + Lethal Mean Safety|The arm includes the CAMS single session intervention, 3 sessions caregiver skills training and lethal means safety.
62267954|NCT05996172|ACTIVE_COMPARATOR|CAMS SSC + Driver Focused Skills Training + Caregiver Skills + Lethal Means Safety|This arm includes the single session intervention, youth skills training, caregiver skills training and lethal means safety.
62267955|NCT02236520|ACTIVE_COMPARATOR|Spironolactone|50 mg capsule of Spironolactone administered orally 1 per day for 8 weeks
62267956|NCT02236520|ACTIVE_COMPARATOR|Chlorthalidone|25 mg capsule of Chlorthalidone administered orally 1 per day for 8 weeks
62267957|NCT02236520|ACTIVE_COMPARATOR|Diet|diet of 6 g salt per day for 8 weeks
62627192|NCT06157983||Index|Patient with atherosclerotic coronary artery disease and a measured plasma lipoprotein(a).
62627193|NCT06157983||Biological relative to index|First- or second-degree relative to the index with atherosclerotic coronary artery disease and a measured plasma lipoprotein(a)
62063103|NCT06284317|NO_INTERVENTION|Observation|Observation only
62852872|NCT03354507|NO_INTERVENTION|Control|Patients will not receive treatment if they do not have metabolic acidosis at baseline.
62852873|NCT01014910|ACTIVE_COMPARATOR|Continuous pulse oximetry monitoring|Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.
62852874|NCT01014910|ACTIVE_COMPARATOR|Intermittent pulse oximetry monitoring|Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
62852875|NCT01234935|EXPERIMENTAL|Arm I|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62063104|NCT04072341|EXPERIMENTAL|Propolis Period|Hemodialysis patients will be under regular treatment of their comorbidities and using Propolis.
62063105|NCT04072341|EXPERIMENTAL|Control Period|Hemodialysis patients will be under regular treatment of their comorbidities, but without using Propolis.
62267958|NCT02236520|PLACEBO_COMPARATOR|Placebo|placebo capsule administered orally 1 per day for 8 weeks
62267959|NCT00470600|PLACEBO_COMPARATOR|Normal Saline|250 milliliters normal saline as a placebo comparator was administered every 6 hours for a total of five doses over the first 24 hours. Those patients who received the initial five doses could continue to receive additional doses as needed every 6 hours through the 120-hour treatment period.
62267960|NCT00470600|EXPERIMENTAL|Intravenous ibuprofen|800 mg of intravenous ibuprofen diluted in 250 milliliters normal saline was administered every 6 hours for a total of five doses over the first 24 hours. Those patients who received the initial five doses could continue to receive additional doses as needed every 6 hours through the 120-hour treatment period.
62267961|NCT04469296|NO_INTERVENTION|control arm|In the control arm, patients will continue their usual diet without further recommendation.
62267962|NCT04469296|EXPERIMENTAL|"specific diet arm Ketogenic arm"|In the specific diet arms, the study diet will be calculated with a dietician, for the ketogenic diet, an iso-caloric ketogenic will be proposed and explained to the patient Each diet will be respected by the patient during 9 days +/- 1 day.
62267963|NCT04469296|EXPERIMENTAL|"specofoc diet arm protein restricted diet"|"In the specific diet arms, the study diet will be calculated with a dietician, for the protein restricted diet, a 20% protein restriction as compared to the usual diet will be calculated and the diet will be explained to the patient.~Each diet will be respected by the patient during 9 days +/- 1 day."
62267964|NCT05772260||Patients with autonomic dysfunction|Achalasia patients who have autonomic dysfunction in the heart rate variability test (HRV test) performed preoperatively.
62852876|NCT01234935|EXPERIMENTAL|Arm II|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15 and oral dasatinib once daily on days 1-28. Treatment repeats every 28 days for 6 courses\* in the absence of disease progression or unacceptable toxicity. NOTE: \*Courses with dasatinib repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.
62450960|NCT00878254|EXPERIMENTAL|R-MACLO/IVAM|"Four 21-day cycles, followed by Maintenance Therapy as follows:~* Cycles 1 and 3: Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Methotrexate, Leucovorin, and G-CSF per study protocol.~* Cycles 2 and 4: Rituximab, Cytarabine, Ifosfamide, Mesna, Etoposide, and G-CSF per study protocol.~* Maintenance Therapy: Rituximab: For study participants in complete remission. Every 6 months for up to 3 years, per study protocol."
62852877|NCT02763683||Parkinsons Disease|Individuals with Parkinsons Disease
62852878|NCT02763683||Healthy Controls|Individuals without Parkinsons Disease
62267965|NCT05772260||Patients with normal autonomic function|Achalasia patients without autonomic dysfunction in the heart rate variability test (HRV test) performed preoperatively.
62267966|NCT00109707|EXPERIMENTAL|CML-CP With Prior Imatinib Only|Imatinib-resistant / intolerant PH+ CML-CP patients
62267967|NCT00109707|EXPERIMENTAL|CML-AP With Prior Imatinib Onl|Imatinib-resistant / intolerant PH+ CML-AP patients
62267968|NCT00109707|EXPERIMENTAL|CML-CP|Imatinib-resistant / intolerant PH+ CML-CP patients
62267969|NCT01547455|EXPERIMENTAL|Atorvastatin|participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
62267970|NCT01547455|PLACEBO_COMPARATOR|Control|Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
62450961|NCT01904786|EXPERIMENTAL|Melatonin|Melatonin 40 mg every 8 hours for a total of six doses given over 48 hours orally (per nasogastric tube).
62852879|NCT01945918|ACTIVE_COMPARATOR|Self-management support education|Project staff will meet onsite with practice clinicians for a two-hour session to discuss what self-management support (SMS) is, why it is important, how primary care plays a role in this process, how others have approached it, and how it can be time and cost efficient for them to engage in SMS as part of standard diabetes care. Practices will have access to a website displaying general and local SMS resources. Discussion of the implementation of these resources into the practice will be facilitated. Two additional academic detailing visits will be made to check on progress on SMS adoption, provide additional information as needed, and answer questions. No input will be provided regarding how unique practice characteristics might be utilized for more effective implementation of SMS, and CTH will not be introduced.
62852880|NCT01945918|ACTIVE_COMPARATOR|Connection to Health Interactive Behavior Change Technology|Connection to Health (CTH) Arm: The number and length of staff visits to these practices will be the same as for the SMS Education Arm, but the content of the visits will center on the implementation and use of the CTH program as a way to implement SMS. Clinicians and selected staff members will be given hands-on experience using the system and will be provided with scenarios that will highlight the effective use of CTH as a tool for diabetes SMS. The practices will then implement CTH, using protocols selected from several suggested by the research team. Additional technical assistance with implementing CTH will also be provided as needed.
62627194|NCT04806321|EXPERIMENTAL|Project SOLVE|"This program is self-guided, digital, and approximately 30 minutes in length. Content is designed to help adolescents solve, rather than be overwhelmed by, everyday problems. The program includes: (1) An introduction to problem solving; (2) Testimonials from valued others (older adolescents; celebrities) describing their use of problem solving skills; (3) Evidence from studies that our brains are capable of problem solving and that problem solving can be helpful; and (4) Activities designed to enable adolescents to practice sequential problem solving using a few steps (SOLVE Steps)."
62627195|NCT04806321|ACTIVE_COMPARATOR|Project SUCCESS|"This program is self-guided, digital, and approximately 30 minutes in length. Content is designed to help adolescents improve their study skills. This program includes: (1) An introduction to study skills; (2) Testimonials from valued others describing their use of study skills; (3) Description of helpful and commonly used study skills (e.g., note-taking); and (4) Activities designed to encourage adolescents to practice these skills in their daily lives."
62267971|NCT02231554|EXPERIMENTAL|Feldenkrais|The Feldenkrais method is a self education method that uses the somatic sensory-motor learning to enhance the functions of people in daily life activities through the awareness of their motor habits and the experience of more efficient alternatives.
62267972|NCT02231554|ACTIVE_COMPARATOR|Back School|The Back School teaches the patient, with theoretical and practical knowledge, how to defend his own back from the pain and how to prevent their disease, considering awareness and education as important parts of the therapeutic process .
62627196|NCT05906654|EXPERIMENTAL|Intervention Group|Participants engage in walking and conversational reminiscence three times per week
62852881|NCT01945918|EXPERIMENTAL|Connection to Health plus Coaching|"Connection to Health plus Coaching (CTH+C) Arm: This arm adds practice coaching as described above to CTH. The active coaching phase focuses on meetings of the practice improvement team, scheduled every other week for approximately 40 minutes each. The improvement team will consist of 6 - 10 diverse representatives of the practice (e.g., front office, medical assistants, physicians). The coach will assist the team in developing a CTH adoption plan and then help them break it down into small bites for rapid cycle change using the Plan-Do-Study-Act quality improvement (QI) model. Active coaching will last for 3 months, followed by monthly calls by the coach to review data regarding the practice's use of CTH and brief booster coaching to deal with problems."
62852882|NCT03230019|ACTIVE_COMPARATOR|chest tube|VATS with chest tube placement
62852883|NCT03230019|EXPERIMENTAL|two-lumen catheter|VATS with two-lumen catheterization
62267973|NCT04417894|EXPERIMENTAL|dupilumab|Administered subcutaneously (SC) once every 2 weeks (Q2W), following a loading dose on Day 1
62627197|NCT06175039|EXPERIMENTAL|Telerehabilitation Exercise Group|
62852884|NCT03630770|NO_INTERVENTION|Control|This group receives no feeding supplement.
62852885|NCT03630770|EXPERIMENTAL|MCT Oil|This group is supplemented with MCT oil
62852886|NCT02704390|EXPERIMENTAL|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate oral capsule will be administered once daily in the morning for 24 months.
62852887|NCT00950820|EXPERIMENTAL|Panitumumab + XELOX|KRAS mutational status wild-type: Panitumumab plus Oxaliplatin and Capecitabine (XELOX)
62852888|NCT00950820|OTHER|XELOX (KRAS mutational status wt)|KRAS mutational status wild-type: Oxaliplatin and Capecitabine (XELOX)
62267974|NCT04417894|EXPERIMENTAL|Matching Placebo|Administered SC Q2W, following a loading dose on Day 1
62267975|NCT02189135|NO_INTERVENTION|Usual care|Usual care from physician/ doctor
62267976|NCT02189135|EXPERIMENTAL|Telemedicine|Mobile wireless glucometer with feedback from physicians
62450962|NCT01904786|PLACEBO_COMPARATOR|Placebo|Placebo consists of the solvent solution without melatonin. Solvent solution consists of 5 mL of saline/alcohol mixture in a ratio of 90:1
62450963|NCT01496040|EXPERIMENTAL|rAAV2/4.hRPE65|"3 cohortes of 3 patients each.~All the patients enrolled in the study will receive a single subretinal injection in one eye. The eye, that will be injected, will be the eye with the poorest visual acuity."
62627198|NCT06175039|OTHER|Control Group|
62627199|NCT06611969|EXPERIMENTAL|Inspiratory muscle training (IMT) plus conventional training group|IMT group will perform inspiratory muscle training in conjunction with the conventional marathon training plan
62852889|NCT00950820|OTHER|XELOX (KRAS mutational status mutant)|KRAS mutational status mutant: Oxaliplatin and Capecitabine (XELOX)
62267977|NCT01297335|EXPERIMENTAL|Intrathecal Clonidine|Subject will receive one time Clonidine injection via lower lumber interspace. Clonidine (Duraclon), 100 μg/ml, 1.5 ml will be diluted to 2 ml with preservative free saline, and total of 150 μg will be delivered. Supine and sitting blood pressures and heart rate will be measured at 10 minute intervals until 60 minutes after clonidine administration, then at 15 minutes for next 3 hours.
62267978|NCT01401634|OTHER|Intravenous Fluids|Intravenous fluids for patients with hyperglycemia is part of the standard protocol in our department
62627200|NCT06611969|ACTIVE_COMPARATOR|Conventional training group (not-IMT) group|The not-IMT group will follow only the conventional marathon training plan
62627201|NCT03285035||Non-operable esophageal cancer|Cryotherapy treatment
62267979|NCT01401634|EXPERIMENTAL|Oral Fluids|
62267980|NCT02670135|PLACEBO_COMPARATOR|triclosan free toothpaste|Control toothpaste with no triclosan ingredients in a 1450 ppm sodium fluoride/silica base - matching placebo
62627202|NCT00638469|OTHER|left/right|left or right body side
62627203|NCT03015298||Gastric cancer|Each patient will perform a PET/MRI examination,and in the next day,a PET/CT.All the examinations are performed before the operation.
62627204|NCT02964338|PLACEBO_COMPARATOR|Placebo|Participants received placebo via an approximately 1-hour intravenous infusion and as 3 subcutaneous injections at Week 0 followed by placebo administered as single subcutaneous injections at Weeks 4 and 8.
62627205|NCT02964338|EXPERIMENTAL|Fremanezumab 675/225/225 mg|Participants received placebo via an approximately 1-hour intravenous infusion and fremanezumab at 675 milligrams (mg) as 3 subcutaneous injections (225 mg/1.5 milliliters \[mL\]) at Week 0 followed by fremanezumab at 225 mg administered as single subcutaneous injections (225 mg/1.5 mL) at Weeks 4 and 8.
62267981|NCT02670135|ACTIVE_COMPARATOR|Triclosan containing toothpaste|Active formula containing 0.3% triclosan in a1450 ppm sodium fluoride/silica base
62267982|NCT00720109|EXPERIMENTAL|Treatment (enzyme inhibitor therapy and chemotherapy)|See Detailed Description
62267983|NCT04298983|EXPERIMENTAL|Abemaciclib + ADT+ RT|Abemaciclib at 150 mg by mouth twice daily, androgen deprivation therapy (ADT), and radiation therapy in conjunction with ADT.
62267984|NCT00586209|EXPERIMENTAL|L-glutamine|"L-glutamine group will be given at the following dosage:~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily \>66.7 at 15 g 2X daily"
62627206|NCT02964338|EXPERIMENTAL|Fremanezumab 900/225/225 mg|Participants received fremanezumab at 900 mg via an approximately 1-hour intravenous infusion and placebo administered as 3 subcutaneous injections at Week 0 followed by fremanezumab at 225 mg administered as single subcutaneous injections (225 mg/1.5 mL) at Weeks 4 and 8.
62267985|NCT00586209|PLACEBO_COMPARATOR|Placebo|"Maltodextrin group will be given at the following dosage:~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily \>66.7 at 15 g 2X daily"
62852890|NCT01181986|EXPERIMENTAL|Exenatide SC (Sub-study 1)|Study groups will be individuals with recent onset (\<3 years) or established (\>5 years) T2D. The plan is to achieve 40 complete studies of subcutaneous injection of exenatide BID (Byetta®, 5 or 10 µg) or identically looking Placebo SC for 10 days, separated by 14-day washout period. On the next day after each treatment phase, a single dose of the assigned medication will be injected just before a fat-enriched breakfast meal. A lunch meal of similar caloric and nutrient content will be administered 4 hours following the breakfast meal. Endothelial function will be measured just prior to the injection and every 2 hours during 8-hour post-breakfast period.
62267986|NCT01889290|EXPERIMENTAL|Methylnaltrexone|Pharmacokinetics of methylnaltrexone administered once daily
62627207|NCT05768997|EXPERIMENTAL|High dose IV iron plus ESA combination arm|
62450964|NCT03338361|EXPERIMENTAL|AAT active - VPT sham|Approach avoidance training active intervention and visual probe training sham intervention
62450965|NCT03338361|EXPERIMENTAL|VPT active - AAT sham|Visual probe training active condition and approach avoidance training sham condition
62627208|NCT05768997|ACTIVE_COMPARATOR|ESA monotherapy arm|
62627209|NCT01844817|EXPERIMENTAL|OGX-427|Three loading doses of OGX-427 at 600mg IV will be administered Days -9 to -1. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8, 15, and 22 of each 28 day cycle during the Treatment Phase.
62627210|NCT01844817|PLACEBO_COMPARATOR|Placebo|Three loading doses of placebo will be administered Days -9 to -1. Following the loading dose period, placebo will be administered weekly Days 1, 8, 15, and 22 of each 28 day cycle.
62627211|NCT05122377||GnRHa 3-month|Patients using GnRHa 3-month depot
62627212|NCT05122377||GnRHa 1-month|Patients using GnRHa 1-month depot
62627213|NCT01504139|EXPERIMENTAL|hCG in the late follicular phase + luteal phase|
62627214|NCT01504139|EXPERIMENTAL|hCG in the follicular phase + luteal phase|
62627215|NCT01504139|EXPERIMENTAL|LH in the luteal phase|
62450966|NCT03338361|EXPERIMENTAL|AAT active - VPT active|Approach avoidance training active condition and visual probe training active condition
62450967|NCT03338361|SHAM_COMPARATOR|AAT sham - VPT sham|Approach avoidance training sham condition and visual probe training sham condition
62627216|NCT01504139|ACTIVE_COMPARATOR|vaginal progesterone and estradiol in the luteal phase|
62627217|NCT04241016|ACTIVE_COMPARATOR|Endoscopic sinus surgery (ESS)|Endoscopic sinus surgery. Postoperative treatment consists of daily nasal douching, daily nasal steroid sprays, pain medication when necessary and at least one postoperative control visit including endoscopy two weeks after the operation. Additionally medical treatment including nasal corticosteroids, nasal douching and other allergy medication as necessary.
62267987|NCT06426355|ACTIVE_COMPARATOR|NMN intervention|Dietary Supplement: NMN intervention NMN capsules (total of 600mg/day) for 2-5 months
62267988|NCT06426355|PLACEBO_COMPARATOR|Placebo intervention|Placebo NMN-free placebo capsules for 2-5 months
62267989|NCT01240161||Patients with high grade gliomas|All subjects will have radiographically suspected or surgically proven de novo high grade gliomas. There are no control patients.
62267990|NCT05098795|EXPERIMENTAL|Peer-delivered Behavioral Activation|Adults 18 years or older on MOUD or referred to MOUD will receive Behavioral Activation (BA) an evidence-based intervention (EBI) by trained Peer Recovery Coaches (PRC)
62450968|NCT04963465||Before rupture of membranes|Vaginal swab collection prior to iatrogenic rupture of membranes
62450969|NCT04963465||After rupture of membranes|Vaginal swab collection after iatrogenic rupture of membranes
62450970|NCT03960697|EXPERIMENTAL|walk out from operating room|patients will return to the ward after surgery by walking
62267991|NCT04430244|EXPERIMENTAL|DALK using Dehydrated Corneas|Corneal transplantation of anterior lamellar grafts from dehydrated corneas.
62267992|NCT04430244|ACTIVE_COMPARATOR|DALK using Standard Organ Culture Stored Corneas|Corneal transplantation of anterior lamellar grafts from standard organ culture stored corneas.
62450971|NCT03960697|NO_INTERVENTION|leave operating room by transporting bed|patients will return to the ward after surgery by lying on the transporting bed
62461455|NCT05286957|ACTIVE_COMPARATOR|Non MRD-guided adjuvant tislelizumab and chemotherapy|patients in non MRD-guided arm receive adjuvant tislelizumab and chemotherapy
62627218|NCT04241016|NO_INTERVENTION|Control|Conservative treatment including nasal corticosteroids, nasal douching and other allergy medication as necessary.
62627219|NCT04127877|EXPERIMENTAL|CHRONIC HEMODIALYSIS PATIENTS, NICAS-ASSISTED MONITORING|Chronic hemodialysis patients, NICAS-assisted monitored
62627220|NCT04127877|NO_INTERVENTION|Control hemodialysis patients|Chronic hemodialysis patients, conventional clinical care and monitoring.
62627221|NCT04430088|EXPERIMENTAL|VVZ-149 Injections|
62627222|NCT04430088|PLACEBO_COMPARATOR|Placebo|
62627223|NCT04254081|EXPERIMENTAL|Buprenorphine 0.15mg + 1% lidocaine paracervical block|Paracervical block with 18mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate plus 0.15mg of buprenorphine
62627224|NCT04254081|PLACEBO_COMPARATOR|1% lidocaine paracervical block|Paracervical block with 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate
62627225|NCT03145103|EXPERIMENTAL|409M|CT ASPHINA 409M IOL
62627226|NCT01941784|EXPERIMENTAL|Supportive care (health education program)|See Detailed Description.
62627227|NCT04521478|EXPERIMENTAL|Treatment group 1|BI 1358894
62627228|NCT04521478|PLACEBO_COMPARATOR|Placebo group|Placebo
62627229|NCT04521478|EXPERIMENTAL|Treatment group 2|Quetiapine
62627230|NCT03517241||Geographic atrophy secondary to AMD|20 patients clinically diagnosed with geographic atrophy (GA) secondary to AMD.
62627231|NCT03517241||Stargards disease|20 patients clinically and genetically diagnosed with Stargards disease (STGD)
62627232|NCT03517241||Branch retinal artery occlusion|20 patients clinically diagnosed with branch retinal artery occlusion (BRAO)
62627233|NCT03517241||Full thickness macular hole|20 patients clinically diagnosed with acute full thickness macular hole (FTMH) before and after macular surgery
62627234|NCT03517241||Healthy controls|20 healthy control subjects. Visual acuity of 20/16- 20/32
62627235|NCT05935592|EXPERIMENTAL|Experimental Group|The experimental group will receive access to Intervention INC, a theory-guided interactive, family-centered web-based tool promoting healthy dietary behaviors.
62627236|NCT05935592|ACTIVE_COMPARATOR|Comparison Group|The comparison group will receive access to web-based newsletters focused on promoting healthy dietary behaviors.
62627237|NCT05002504|EXPERIMENTAL|Patients receiving craniosacral therapy|30 children without previous pathology receiving craniosacral therapy
62627238|NCT05002504|ACTIVE_COMPARATOR|Patients receiving balance and coordination therapy|31 patients without previous pathology receiving balance and coordination therapy
62627239|NCT05002504|PLACEBO_COMPARATOR|Patients receiving placebo|25 patients without previous pathology receiving placebo
62852891|NCT01181986|EXPERIMENTAL|Exenatide IV (Sub-study 2)|Study group will be individuals with recent onset (\<1 year) T2D on diet and impaired glucose tolerance. The plan is to achieve 35 complete studies. The intervention will include 3 randomly ordered visits with intravenous infusion of exenatide in the presence (v1) or absence (v2) of GLP-1 receptor inhibitor exendin-9, and a control test with Placebo IV without exendin-9 (v3). Endothelial function will be measured at baseline and 2 hours later during the final 15 minutes of the infusion cocktails. Study participants will remain fasting during the test visit (3 hours total).
62852892|NCT03820739||Cohort 1|Subjects who received an Ebola vaccine prime vaccination in EBOVAC-Salone are eligible for enrolment in this study. Adults are defined as participants 18 years of age or older at the time of prime vaccination, and children are defined as participants aged 1 to 17 years at the time of prime vaccination in EBOVAC-Salone.
62852893|NCT03820739||Cohort 2 (offspring)|Infants conceived by a female participant in EBOVAC-Salone during the 3 months following vaccination with Ad26.ZEBOV or during the 28 days following vaccination with MVA-BN®-Filo.
62852894|NCT03012126|EXPERIMENTAL|Clinically Based: Healthy Weight Clinic|All families referred to the Healthy Weight Clinic intervention arm will be scheduled for a 30-45 minute orientation clinic visit to orient the child and family to the program. During this visit, the family will meet with the community health worker who will provide a schedule of clinic visits and dietitian contacts. The community health worker will assess the child's social and environmental context to allow treatment tailoring. For the first 6 months, each family will be asked to attend two clinic visits per month and complete weekly 20-30 minute contacts with the dietitian via telephone. The program aims to deliver approximately 30 contact hours in the 6-month period. This will be followed by monthly visits to the Healthy Weight Clinic and monthly calls with their dietitian.
62627240|NCT02169843|EXPERIMENTAL|Sevoflurane & Dexmedetomidine|inhale Sevoflurane + intravenous pumping Remifentanil 0.1µg/kg/min + intravenous inject cisatracurium besilate 0.08mg/kg in fixed time interval + finally add sufentanil 0.15µg/kg,and intravenous pumping Dexmedetomidine 0.2µg/kg/h.
62267993|NCT01395394|EXPERIMENTAL|BH4 Non-Responders|Participants in this group have PKU and were deemed unresponsive to the drug. They will attend their first study visit, and proceed through the meal challenge without BH4. They will then take BH4 for 2 weeks. The second meal challenge will be performed with the participant's final dose of BH4.
62267994|NCT01395394|EXPERIMENTAL|Healthy Controls|Participants in this group match an enrolled PKU participant in terms of age, gender, and body mass index class. They will participate in a single study visit and will not be given BH4.
62627241|NCT02169843|ACTIVE_COMPARATOR|Sevoflurane & Placebo|inhale Sevoflurane + intravenous pumping Remifentanil 0.1µg/kg/min + intravenous inject cisatracurium besilate 0.08mg/kg in fixed time interval + finally add sufentanil 0.15µg/kg,and intravenous pumping Placebo(for Dexmedetomidine )0.05ml/kg/h.
62267995|NCT01395394|EXPERIMENTAL|BH4 Responders|Participants in this group will use their already prescribed BH4 with the meal challenge and be assessed at a single study visit. They will take their prescribed BH4 with the meal.
62627242|NCT05382429|EXPERIMENTAL|OWHTO|open wedge high tibial osteotomy group For the open wedge high tibial osteotomy group, Those who were randomly assigned to the OWHTO group, OWHTO Surgical procedure will be performed.
62627243|NCT05382429|EXPERIMENTAL|CWHTO|closing wedge high tibial osteotomy group For the closing wedge high tibial osteotomy group, hose who were randomly assigned to the CWHTO group, CWHTO Surgical procedure will be performed
62627244|NCT02413671|OTHER|Lupin Protein|Subjects received a test meal rich in carbohydrates and supplemented with lupin protein.
62627245|NCT02413671|OTHER|Whey Protein|Subjects received a test meal rich in carbohydrates and supplemented with whey protein.
62627246|NCT02413671|OTHER|Reference|Subjects received a test meal rich in carbohydrates not supplemented with any protein.
62267996|NCT06199388||SEER database|The model was trained using the Surveillance, Epidemiology, and End Results (SEER) Registry database. To identify specific tumor types, the International Classification of Diseases for Oncology, 3rd Edition codes (ICD-O-3) were used, including codes 9450, 9394, 9421, 9384, 9383, 9424, 9400, 9420, 9410, 9411, 9380, 9382, 9391, 9393, 9390, 9401, 9381, 9451, 9440, 9441, 9442, 9430, and 9380, covering astrocytic tumors, oligodendroglia tumors, oligoastrocytic tumors, ependymal tumors, and other gliomas. Inclusion criteria comprised all primary brain tumors (C71.0-C71.9, C72.3, C72.8, C75.3) diagnosed between 2000 and 2018, among patients under 21 years old, and meeting the third edition of the ICD-O-3 classification. Only patients with available survival time were included, and those with unknown or missing clinical features were excluded.
62627247|NCT05781087||Standard of care|Patients after ST-elevation myocardial infarction with non-culprit coronary artery disease.
62627248|NCT02435563|EXPERIMENTAL|Ticagrelor 180 mg|Single dose of 180mg ticagrelor administered orally
62627249|NCT02435563|EXPERIMENTAL|Ticagrelor adjusted dose+ritonavir 100mg|adpated dose of ticagrelor calculated after PK modelisation with the Simcyp® simulator administered simultaneously with 100 mg ritonavir
62627250|NCT05897372|ACTIVE_COMPARATOR|Standard of Care|Maximally tolerated dose of ACEi or ARB (but not both), SGLT2i, and finerenone. Blood pressure target \<130/80 mm Hg
62627251|NCT05897372|EXPERIMENTAL|Albuminuria-reduction protocol|"Maximally tolerated dose of ACEi or ARB (but not both), SGLT2i, and finerenone. Thereafter addition of semaglutide, pentoxifylline, hydrochlorothiazide, and baricitinib.~Blood pressure target \<130/80 mm Hg, but if still UACR \>300 further reduction in blood pressure will be attempted as tolerated."
62627252|NCT01689441|EXPERIMENTAL|Calcitriol|Calcitriol 2mcg IV x 1
62627253|NCT01689441|PLACEBO_COMPARATOR|Placebo|Normal saline 2cc IV x 1
62627254|NCT02363712|EXPERIMENTAL|APOS|APOS(All Phase Of Step)-shoe
62267997|NCT06199388||Chinese cohort|To assess the generalizability of the final model, an external validation cohort from China was used. This cohort consisted of 258 pediatric glioma patients diagnosed at Tangdu Hospital in Xi\&#39;an, China, between January 2010 and December 2018. These patients had complete clinical data and comprehensive follow-up records.
62450972|NCT04983121|EXPERIMENTAL|combine treatment group|This study adopts a single-arm, multi-center, open design. As per the initial plan, 30 stage II-III human epidermal growth factor receptor 2(HER2)-positive breast cancer patients who have received neoadjuvant therapy containing trastuzumab and pertuzumab and have been assessed as stable disease (SD) during the neoadjuvant treatment (an increase of 0-20%), disease progression (PD), inoperable or failing to meet the breast-conserving requirements will be enrolled to receive pyrotinib combined with Next-generation Site-specific HER2-targeting Antibody-drug Conjugate (ARX788) neoadjuvant therapy. The main purpose of the study is to observe the efficacy and safety of pyrotinib combined with ARX788 neoadjuvant treatment in stage II-III HER2-positive breast cancer.
62627255|NCT02363712|SHAM_COMPARATOR|Sham APOS|Sham APOS(All Phase Of Step)-shoe
62267998|NCT02247323||premenopausal women|premenopausal women with complex ovarian mass moderate for malignancy by risk of malignancy index score and low CA125.
62267999|NCT01478035|EXPERIMENTAL|phenytoin prophylaxis|Patients with suspected or proven pneumococcal meningitis are allocated to receive phenytoin prophylaxis or placebo to avoid seizures during the 10 days of antibiotic therapy starting after the antibiotic therapy
62627256|NCT01340729|EXPERIMENTAL|TPI 287|Starting dose TPI 287 of 125 mg/m2 intravenous (IV) for 3 weeks of 4 week schedule.
62627257|NCT03540069|EXPERIMENTAL|Cervical Cancer Screening Education|Context-specific multi-level peer education cervical cancer screening education curriculum is implemented by Care Groups. This is conducted through a cluster-randomized stepped wedge study. Cluster 1 (randomly selected) crosses to the intervention arm at Period 2, Cluster 2 (randomly selected) crosses over to the intervention arm at Period 3, and so on. By the end of the study, all clusters will cross over to the intervention arm (one-way), though in random order. At the end of the final time period, the outcome of interest is compared between the intervention and control periods within each cluster. Differences in service utilization and recommendation will be compared, whereby clusters serve as their own controls as they cross over from the control to intervention group.
62268000|NCT01478035|PLACEBO_COMPARATOR|placebo|placebo vials and pills labeled as phenytoin prophylaxis vials and pills
62268001|NCT03339921|EXPERIMENTAL|Botulinum toxin injections|Botulinum toxin injections for chronic compartment syndrome
62268002|NCT03339921|ACTIVE_COMPARATOR|surgical fasciotomy|surgical fasciotomy for chronic compartment syndrome
62450973|NCT02380846|OTHER|Rice|Control session - white rice (equivalent to 50g available carbohydrates)
62450974|NCT02380846|ACTIVE_COMPARATOR|Rice with chicken|Treatment 1 - White rice and steamed chicken breast (25g protein)
62450975|NCT02380846|ACTIVE_COMPARATOR|Rice with fish|Treatment 2 - White rice and steamed fish (25g protein)
62450976|NCT02380846|ACTIVE_COMPARATOR|Rice with egg white|Treatment 3 - White rice and egg white (25g protein)
62450977|NCT02380846|ACTIVE_COMPARATOR|Rice with beancurd|Treatment 4 - White rice and steamed beancurd (25g protein)
62627258|NCT03540069|NO_INTERVENTION|Control|No educational program is implemented for each cluster prior to crossover to intervention.
62627259|NCT01569945|ACTIVE_COMPARATOR|Tablets|Clomifen (5 days) followed by Ethinyl Estradiol (5 days)
62627260|NCT01569945|ACTIVE_COMPARATOR|human menopausal gonadotropins|Daily Injections
62627261|NCT00912132||Low risk singleton cohort|Women with singleton gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2009-2013) in this prospective cohort study. A sub-set of women with and without gestational diabetes were followed up to 6 weeks postpartum. Enrollment was based upon a predefined set of criteria including medical/reproductive history and pre-pregnancy body mass index. Women with a body mass index between 19.0-29.9 kg/m2 were in the low-risk cohort.
62627262|NCT00912132||Obese cohort|Women with singleton gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2009-2013) in this prospective cohort study. A sub-set of women with and without gestational diabetes were followed up to 6 weeks postpartum. Enrollment was based upon a predefined set of criteria including medical/reproductive history and pre-pregnancy body mass index. Women with a body mass index between 30.0-44.9 kg/m2 were in the obese cohort.
62627263|NCT03480594||Fatty Liver Patients|Hyperpolarized \[13C\] Pyruvate Injection in Fatty Liver patients
62627264|NCT03480594||Healthy Control Subjects|Hyperpolarized \[13C\] Pyruvate Injection in Healthy Control Subjects
62627265|NCT01727856||Rehabilitation Measurement Tool|This single arm consists of all subjects which will interact with the tool under invstigation.
62627266|NCT02741648||ELBW Infants with Prolonged Irradiation Storage Time|Extremely Low Birth Weight Infants whose Red Blood Cell (RBC) transfusion had prolonged Irradiation Storage Time (IST) being tested with metabolomics profile.
62268003|NCT02266992|EXPERIMENTAL|Fluenz Tetra|Live attenuated influenza vaccine- Fluenz tetra. Intra-nasal administration of 0.2ml (0.1ml in each nostril).
62268004|NCT05531175|EXPERIMENTAL|İntervention Group|A total of 10 sessions of reiki were applied to the patients in the intervention group twice a week for 5 weeks, lasting 40-45 minutes during dialysis. The scales were administered to the individuals in the intervention groups three times in total.
62627267|NCT02741648||ELBW Infants without Irradiation Storage|Extremely Low Birth Weight Infants whose Red Blood Cell (RBC) transfusion did not have Irradiation Storage being tested with metabolomics profile.
62268005|NCT05531175|NO_INTERVENTION|Control Group|No treatment was applied to the control group. The scales were administered to the individuals in the control groups three times in total.
62268006|NCT01232829|EXPERIMENTAL|Treatment (RO4929097)|"Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.~Patients may undergo tumor biopsy at baseline and on days 16 or 17 of course one for biomarker and other correlative studies. Blood samples may also collected at baseline and periodically during study for pharmacokinetic and angiogenesis marker studies."
62268007|NCT03687151||patients with a diagnosis of invasive or in situ cancer|patients with a diagnosis of invasive or in situ cancer living in the French Region Sud-Provence-Alpes-Côte d'Azur since 2005
62450978|NCT04566835|EXPERIMENTAL|Education Group|Taking the Health Promotion Program with cartoons and comics for Children with Asthma
62450979|NCT04566835|OTHER|Control Group|Taking standart care
62450980|NCT03697421||Local Evaluation|The SHR program intends to serves couples who are over 18 years of age, are in a romantic relationship, and have at least one child (biological or adopted) under the age of 18 residing in the home or are expecting.
62450981|NCT02101632|EXPERIMENTAL|Bee Venom|Bee Venom Ointment 0,0005%
62627268|NCT02741648||ELBW Infants with NEC|"Extremely Low Birth Weight Infants with Necrotizing Enterocolitis (NEC defined as Bell's Stage II or greater) and receiving Red Blood Cell (RBC) Transfusions being tested with Near Infrared Spectroscopy."
62627269|NCT02741648||ELBW Infants without NEC|Extremely Low Birth Weight Infants without Necrotizing Enterocolitis being tested with Near Infrared Spectroscopy.
62627270|NCT05600153|PLACEBO_COMPARATOR|primary breast approach|
62627271|NCT05600153|EXPERIMENTAL|axillary approach|
62627272|NCT01690195|EXPERIMENTAL|ABT-126|ABT-126 Open-label dose
62627273|NCT06121440|NO_INTERVENTION|Control Group|Routine tracheostomy care will be applied to the control group. No action will be taken.
62627274|NCT06121440|EXPERIMENTAL|Experimental Group|During the tracheostomy care process, the experimental group will listen to audiobook and play with musical-moving toy.
62627275|NCT03109626|ACTIVE_COMPARATOR|DHA administration|DHA 600 mg/day will be administered for 16 weeks to 5 patients in double blind
62627276|NCT03109626|PLACEBO_COMPARATOR|placebo administration|placebo will be made with the same colour and taste, in softgel as DHA, and will be administered for 16 weeks to 5 patients in double blind.
62627277|NCT01481883|EXPERIMENTAL|Raloxifene Hydrochloride 120mg oral per day|120mg raloxifene plus antipsychotic drug
62627278|NCT01481883|PLACEBO_COMPARATOR|Placebo tablet - one per day|Lactose pill plus antipsychotic medication
62268008|NCT00199563|ACTIVE_COMPARATOR|active drug|Viagra 100 mg / daily for 12 weeks.
62268009|NCT00199563|PLACEBO_COMPARATOR|Placebo|placebo/daily for 12 weeks
62450982|NCT02101632|PLACEBO_COMPARATOR|Vaseline|Vaseline ointment
62450983|NCT03197402|ACTIVE_COMPARATOR|Comparator group|Milk protein gel delivery system supplementation
62627279|NCT01113918||Obsity PCOS Women|"Polycystic ovary syndrome (PCOS) was diagnosed according to the European Society for Human Reproduction (ESHRE)/American Society of Reproductive Medicine (ASRM) case definition which requires presentation of signs and/or symptoms of a minimum of 2 of the following 3 criteria: polycystic ovary morphology (PCOM), oligomenorrhea or amenorrhea (Oligo-An), androgen excess (HA).~Body mass index (BMI) was defined as body weight in kilograms divided by body height in meters squared (kg/m2). Obesity was defined as BMI≥25 kg/m2, according to the Asia-Pacific definition."
62627280|NCT01113918||Non-obesity PCOS Women|The subjects BMI were less than ≥25 kg/m2 and out of criteria of PCOS by European Society for Human Reproduction (ESHRE)/American Society of Reproductive Medicine (ASRM).
62627281|NCT00988676||colonoscopy|
62627282|NCT02586311|EXPERIMENTAL|CKD-330 16/5mg + Amlodipine 5mg placebo|CKD-330 16/5mg + Amlodipine 5mg placebo, po, q.d.
62627283|NCT02586311|ACTIVE_COMPARATOR|CKD-330 16/5mg placebo + Amlodipine 5mg|CKD-330 16/5mg placebo + Amlodipine 5mg, po, q.d.
62268010|NCT01648127|EXPERIMENTAL|Ceftaroline|Ceftaroline intravenous 600 mg single dose
62268011|NCT01437774|ACTIVE_COMPARATOR|Concentric Thrombectomy Catheter|Control Arm
62268012|NCT01437774|EXPERIMENTAL|Reverse ReStore mechanical thrombectomy|Reverse ReStore Device mechanical thrombectomy Each arm will use either ReStore or Merci as the primary thrombectomy device
62268013|NCT05044156||Case group|vaginal candidiasis
62268014|NCT05044156||Control group|healty women
62268015|NCT01135498|EXPERIMENTAL|1|
62627284|NCT02717364||Population With Yervoy Exposure|Population With Yervoy Exposure
62450984|NCT03197402|EXPERIMENTAL|Leucine-enriched protein group|Leucine-enriched protein gel delivery system supplementation
62450985|NCT02368613|PLACEBO_COMPARATOR|placebo group|Placebo
62450986|NCT02368613|ACTIVE_COMPARATOR|test1 group|DW-3102 125mg
62627285|NCT01307878|EXPERIMENTAL|arm A|Pre-PTR, chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.
62627286|NCT01307878|NO_INTERVENTION|arm B|Upfront PTR, then chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.
62627287|NCT02608996|ACTIVE_COMPARATOR|Subcutaneous BNP|Patients will receive gradually increasing doses (10-25 µg/kg) of subcutaneously administered nesiritide (BNP) twice daily for two days, to determine the feasibility, safety and blood pressure lowering effect of BNP so as to identify the optimal dose.
62268016|NCT05224583||Simultaneous Liver-Kidney Transplant patients population at MDMC|Consecutive SLK transplant recipients who were transplanted at MDMC over a 6-year period (2015 to 2020).
62852895|NCT03012126|EXPERIMENTAL|Community Based: Healthy Weight & Your Child|All families referred to the Healthy Weight and Your Child intervention arm will be scheduled for a 60-minute family information session to orient the child and family to the program. During this visit, the family will receive information about the program and logistics such as program schedule and format and attendance. The program is delivered over 12 months, which includes 16 weekly sessions, followed by 4 sessions delivered every other week and concluding with 5 monthly sessions. Most sessions are 2 hours in length and include a group of about 8-15 children and their caregivers. The first hour is delivered in a classroom setting and the second hour in an additional area conducive for physical activity.
62852896|NCT03303664|EXPERIMENTAL|IMPROVE Protocol|The intervention is composed of 4 parts: 1) a multidisciplinary team that recommends, develops, approves, monitors the components of the intervention and training? 2) monitoring of medication sedation risk using established scale 3) restriction of medication dispensing via enhanced technology 4) health professional training on multimodality pain management including complementary and alternative therapies.
62627288|NCT02608996|PLACEBO_COMPARATOR|Subcutaneous placebo|Patients will receive subcutaneously administered placebo twice daily for two days for determination of the effect of BNP.
62627289|NCT00753298|EXPERIMENTAL|LoFric Primo (POBE) single-use urinary catheter|
62627290|NCT00753298|ACTIVE_COMPARATOR|LoFric Primo (PVC) single-use urinary catheter|
62268017|NCT01984268|EXPERIMENTAL|Four week ACTHAR treatment|Rheumatoid arthritis subjects with inadequate response to methotrexate will be randomized to receive twice a week dosing of ACTHAR for a period of four weeks.
62268018|NCT01984268|EXPERIMENTAL|Twelve week ACTHAR treatment|Rheumatoid arthritis subjects with inadequate response to methotrexate will be randomized to receive twice a week dosing of ACTHAR for a period of twelve weeks.
62268019|NCT00999531|EXPERIMENTAL|1|GS-9411 9.6 mg
62627291|NCT02499120|EXPERIMENTAL|Palbociclib plus Cetuximab|Palbociclib, 125 mg, orally once daily (QD) with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
62627292|NCT02499120|ACTIVE_COMPARATOR|Placebo plus Cetuximab|Placebo orally QD with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
62627293|NCT03328598|EXPERIMENTAL|Positive psychology therapy group|This arm will be given a positive psychological group intervention developed from an foreign psychotherapy.
62627294|NCT03328598|EXPERIMENTAL|Resilience promotion therapy group|This arm will be given a resilience group intervention developed from our pervious research results.
62627295|NCT03328598|ACTIVE_COMPARATOR|Controlled routine activity group|This arm will continue to participate in conventional community activities.
62627296|NCT05965427||PLHIV and Mpox coinfection|
62627297|NCT05965427||HIV negative PrEP users with Mpox infection|
62627298|NCT02017093|EXPERIMENTAL|Error Enhancement|Training of the upper extremity, using a robotic devise with error enhanced forces and traditional therapy.
62627299|NCT02017093|EXPERIMENTAL|Control treatment|Training of the upper extremity, using a robotic devise without forces applied and traditional therapy.
62268020|NCT00999531|EXPERIMENTAL|2|GS-9411 4.8 mg
62268021|NCT00999531|EXPERIMENTAL|3|GS-9411 2.4 mg
62268022|NCT00999531|PLACEBO_COMPARATOR|4|Saline Placebo
62268023|NCT01535729||Cohort|
62268024|NCT06536660|EXPERIMENTAL|Magnesium bone plate and screw fixation in jaw surgery|
62268025|NCT00634829|EXPERIMENTAL|T|Armstrong Albuterol HFA Inhalation Aerosol
62268026|NCT00634829|ACTIVE_COMPARATOR|R|2 inhalations Proventil-HFA Albuterol Sulfate, 108 mcg, prior to exercise
62268027|NCT00634829|PLACEBO_COMPARATOR|P|Placebo-HFA
62627300|NCT06612684|EXPERIMENTAL|Piezoelectric syndesmotomy of single-rooted teeth|Patients who need the extraction of a single-rooted hopeless tooth will be included in the intervention arm. The extraction of the tooth will be executed by piezoelectric syndesmotomy and by the use of forceps.
62627301|NCT06425211|EXPERIMENTAL|Erectile Dysfunction|"The therapy depends if patient is classified within muscular hyperactivity or muscular hypoactivity.~For muscular hypoactivity:~Pelvic Floor Physiotherapy assessment: session 1 Proprioceptive and Coordination Work: sessions 2-7 Muscle workout: sessions 8-15 Functional training: sessions 16-23 Final evaluation: Session 24~For muscular hyperactivity they will be given:~Pelvic Floor Physiotherapy assessment: session 1 Proprioceptive and Coordination Work: sessions 2-7 Muscle workout: sessions 8-15 Functional training: sessions 16-23 Final evaluation: session 24~These interventions include: Therapeutic exercises, Perineal electromyographic biofeedback, and Electrical stimulation"
62268028|NCT00717938|OTHER|A|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants.Used drugs=cisplatinum or carboplatin and e.g.etoposide.
62450987|NCT02368613|ACTIVE_COMPARATOR|test2 group|DW-3102 250mg
62627302|NCT06425211|EXPERIMENTAL|Premature Ejaculation|"Pelvic Floor Physiotherapy assessment: session 1 Proprioceptive and Coordination Work: sessions 2-15 Muscle workout: sessions 16-19 Functional training: sessions 20-23 Final evaluation: session 24~These interventions include: Therapeutic exercises, Perineal electromyographic biofeedback, and Electrical stimulation"
62627303|NCT06425211|EXPERIMENTAL|Premature Ejaculation + Erectile Dysfunction|"Pelvic Floor Physiotherapy assessment: session 1 Proprioceptive and Coordination Work: sessions 2-12 Muscle workout: sessions 13-20 Functional training: sessions 20-23 Final evaluation: session 24~These interventions include: Therapeutic exercises, Perineal electromyographic biofeedback, and Electrical stimulation"
62627304|NCT05171270||Psoriatic arthritis|Psoriatic arthritis Impact of Disease questionnaires (PsAID) used within routine clinic consultation.
62450988|NCT02368613|ACTIVE_COMPARATOR|test3 group|DW-3102 500mg
62450989|NCT04357275||ICU admissions due to COVID-19|
62450990|NCT03464136|EXPERIMENTAL|Group 1 (Ustekinumab)|Participants will receive intravenous (IV) infusion of ustekinumab (approximately 6 milligram/kilogram \[mg/kg\]) and 4 subcutaneous (SC) injections of placebo for adalimumab at Week 0, followed by 2 SC injections of placebo at Week 2. From Week 4 to Week 56, participants will self-administer one SC injection of ustekinumab 90 milligram (mg) every 8 weeks (q8w) starting at Week 8 and placebo adalimumab at the other designated every 2 weeks (q2w) dosing intervals.
62450991|NCT03464136|ACTIVE_COMPARATOR|Group 2 (Adalimumab)|Participants will receive IV infusion of placebo for ustekinumab and 4 SC injections of adalimumab (each 40 mg, total dose 160 mg) at Week 0, followed by 2 SC injections of adalimumab (each 40 mg, total dose 80 mg) at Week 2. From Week 4 to Week 56, participants will self-administer 1 SC injection of adalimumab 40 mg q2w.
62450992|NCT02627911|OTHER|Usual System (open-loop)|"In open loop, the patient will be provided with its usual pump and a CGM. To estimate rest and physical activity in patients being sedentary situation ( Centers : Caen, Nancy \& Strasbourg) or in situations of physical activity ( Centers : CHSF Marseille and Besancon ) , the usual system will be complemented by an accelerometer  ActiGraph  and a  ActiHeart  heart rate monitor."
62450993|NCT02627911|EXPERIMENTAL|DIABELOOP System (closed-loop)|In the closed loop, the patient's pump will be replaced by the Diabeloop system consisting of insulin pump Cellnovo driven by remote control augmented by Diabeloop software and connected to the CGM.
62450994|NCT03182179|EXPERIMENTAL|O-P sequence|Patients will receive of oral Ondansetron 4mg BD for 28 days followed by 28 days of placebo. It will be one week of washout between the two treatments.
62450995|NCT03182179|EXPERIMENTAL|P-O sequence|Patients will receive oral placebo for 28 days followed by Ondansetron 4mg BD for 28 days. It will be one week of washout between the two treatments.
62450996|NCT02531932|ACTIVE_COMPARATOR|Carboplatin alone|AUC 4 every 3 weeks as an IV infusion
62450997|NCT02531932|EXPERIMENTAL|Carboplatin + Everolimus|Carboplatin AUC 4 every 3 weeks IV infusion plus daily oral everolimus 5mg pill
62450998|NCT03674710|EXPERIMENTAL|Group A|"Patients assigned to group A will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, slow-pull, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
62450999|NCT03674710|EXPERIMENTAL|Group B|"Patients assigned to group B will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, wet suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
62451000|NCT03674710|EXPERIMENTAL|Group C|"Patients assigned to group C will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, standard suction, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
62451001|NCT03674710|EXPERIMENTAL|Group D|"Patients assigned to group D will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, wet suction, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
62451002|NCT03674710|EXPERIMENTAL|Group E|"Patients assigned to group E will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, standard suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
62451003|NCT03674710|EXPERIMENTAL|Group F|"Patients assigned to group F will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, slow-pull, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
62451004|NCT05320263|EXPERIMENTAL|contact aspiration first line thrombectomy|Patient randomized in this arm will have the first arm thrombectomy by contact aspiration
62451005|NCT05320263|SHAM_COMPARATOR|Stent retriever first line thrombectomy|Patient randomized in this arm will have the first arm thrombectomy by Stent retriever
62451006|NCT06484946|EXPERIMENTAL|Aquatic occupational therapy|Each child participated and experienced occupational therapy in the water.
62451007|NCT05705713|EXPERIMENTAL|Cases|48 participants with burn injuries associated with inhalation lung injuries were recruited from the burn department.
62451008|NCT05705713|ACTIVE_COMPARATOR|Control|10 participants with burn injuries NOT associated with inhalation lung injuries were recruited from the burn department.
62461456|NCT02218580|EXPERIMENTAL|Massage therapy & standard care|"Massage therapy will be provided by caregiver for 15 minutes at bedtime at home, every night, for a 2-week period.~Standard care will include medications routinely prescribed in the treatment of JIA, physiotherapy and occupational therapy exercises, splints, warmth application and acetaminophen."
62461457|NCT02218580|ACTIVE_COMPARATOR|Standard care|Standard care will include medications routinely prescribed in the treatment of JIA, physiotherapy and occupational therapy exercises, splints, warmth application and acetaminophen.
62627305|NCT01376973||group A|Not received any oral device (Control)
62627306|NCT01376973||Group B and Group C|Group B - Used Michigan Occlusal Splint (MOS); Group C - Used Planas Oral Appliance (POA).
62627307|NCT03420339|EXPERIMENTAL|Subjects on stimulant medication|All participants: Children and adolescents diagnosed with AD/HD, displaying disruptive behavior, and taking stimulant medication.
62627308|NCT06501807|OTHER|Biologic treatments available|Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval).
62627309|NCT01285778|EXPERIMENTAL|Panitumumab, mytomicin C, 5-FU, radiation|
62063106|NCT01933971|OTHER|Group 1: filgrastim 2.5 µg/kg/day for 7 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.~The sites, where the injections are to be performed, are planned as follows:~1. st injection: upper part of the upper arm, posterior surface~2. nd injection: upper part of the thigh~3. rd injection: abdomen with the exception of the umbilical area~4. th injection: upper part of the contra-lateral upper arm, posterior surface~5. th injection: upper part of the contra-lateral thigh~6. th injection: abdomen with the exception of the umbilical area~7. th injection: upper part of the same upper arm, posterior surface as for the 1st injection."
62451009|NCT01911494|EXPERIMENTAL|Intervention|"The CLIP intervention consists of (i) community engagement including community leaders, the women of the communities themselves, and their mothers, husbands, and mothers-in-law, regarding pre-eclampsia, its origins, symptoms, signs, and potential consequences, pre-permissions for maternal transport, and fundraising activities around transport and treatment costs; (ii) provision of HDP oriented antenatal care through CLIP visits and use of CLIP PIERS on the Move mHealth tool (for risk stratification), and (iii) use of the CLIP package for women with a CLIP 'trigger' (i.e., oral antihypertensive therapy (methyldopa) when indicated, intramuscular (i.m.) magnesium sulfate when indicated; and appropriate referral to an CEmOC facility when indicated)"
62451010|NCT01911494|NO_INTERVENTION|Control|Current standard of antenatal care
62451011|NCT03336541|EXPERIMENTAL|Ketamine group|Low-dose ketamine (0.5 mg/kg in 100 ml normal saline) is intravenously infused in 40 minutes after childbirth during cesarean delivery.
62451012|NCT03336541|PLACEBO_COMPARATOR|Placebo group|Placebo (100 ml normal saline) is intravenously infused in 40 minutes after childbirth during cesarean delivery.
62451013|NCT02879279|EXPERIMENTAL|Robotic rehabilitation|In the robotic rehabilitation group, both the distal and the proximal parts of the patients' upper arm will be treated by means of a multi-set of robotic and technological devices, i.e, Amadeo, Pablo, Diego and Motore. The aforementioned systems can be used to perform three-dimensional movements of the shoulder, planar movements of the shoulder and elbow, prono-supination movements of the forearm, flexion-extension movements of the wrist, bimanual movements, and flexion/extension movements of the fingers. A vibratory treatment will be applied, using the Amadeo, to increase the proprioception of the hand. Motor and cognitive tasks, comprising active, passive and active-assistive, will be performed during the treatment. Visual and auditory feedback will be provided to help the patients.
62451014|NCT02879279|ACTIVE_COMPARATOR|Conventional rehabilitation|In the conventional rehabilitation group, patients will undergo a conventional treatment. The therapeutic tasks will focus on sensorimotor reprogramming, hypertonus inhibition, functional improvement, including task-oriented exercises. Specifically, patients will perform passive, active and active assisted exercises on the three upper limb joints, to improve joint function, to prevent contractures, to inhibit hypertonus and to improve trophism and motor function.
62451015|NCT03916952||Healthy younger|All participants between 18 and 65 years of age that completed the test
62451016|NCT03916952||Healthy older|All participants \> 65 years of age that completed the test
62451017|NCT02889185|EXPERIMENTAL|Adaptative optics retinal camera|
62451018|NCT04042532|ACTIVE_COMPARATOR|Active group|Active group will receive active stimulation of standard intermittent TBS (iTBS) protocol.
62451019|NCT04042532|SHAM_COMPARATOR|Sham group|Sham group will receive sham stimulation of the same iTBS protocol with the coil set at 90 to the skull.
62451020|NCT04042532|NO_INTERVENTION|Cognitively normal control|Cognitively normal controls will be recruited for neuroimaging comparison.
62451021|NCT04695405||Treatment-Resistant Depression|Patients, who previously received intravenous ketamine, will be asked to provide genetic samples in order to assess relationships between response and genetic markers.
62451022|NCT00215319|EXPERIMENTAL|TSM Cage|Lumbar I/F with cage and pedicle screws
62451023|NCT03492359|ACTIVE_COMPARATOR|Normal Control|Participants with no diagnosis of respiratory disease between the ages of 0 and 80 whose breathing will be measured using Thora-3Di structured light plethysmography, body plethysmography and spirometry.
62451024|NCT03492359|ACTIVE_COMPARATOR|COPD Patients|Participants with chronic obstructive pulmonary disease between the ages of 0 and 80 whose breathing will be measured using Thora-3Di structured light plethysmography, body plethysmography and spirometry.
62451025|NCT02247479|EXPERIMENTAL|Lampalizumab Once in Every 4 Weeks (Q4W)|Participants will receive 10 milligrams (mg) dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
62451026|NCT02247479|EXPERIMENTAL|Lampalizumab Once in Every 6 Weeks (Q6W)|Participants will receive 10 mg dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
62451027|NCT02247479|SHAM_COMPARATOR|Sham Comparator|Participants will receive sham comparator Q4W or Q6W for 96 weeks.
62451028|NCT03562442|EXPERIMENTAL|Smokers|"Healthy caucasian smokers who are willing to quit smoking are investigated before cessation (Visit 1) and 6 weeks after cessation (Visit 2).~Intervention: Smoking cessation"
62451029|NCT03562442|NO_INTERVENTION|Never-Smokers|Healthy caucasian volunteers who never smoked are investigated once only (Visit 1)
62451030|NCT03082274||Men age 40-85 years with an initial negative prostate biopsy|Men age 40 - 85 years of age Previous negative prostate biopsy within 30 months.
62451031|NCT05256628|OTHER|Early Weightbearing|Patients randomized to early weightbearing will be permitted to begin immediate postoperative weightbearing as tolerated with crutches for additional stability.
62627310|NCT03214679|EXPERIMENTAL|Accessible Care|"Accessible Care for PWID is low-threshold care provided in the needle exchange programs, where they can comfortably access services without fear of the shame or stigma that often attends them in mainstream institutions.It includes features such as an informal, nonjudgmental atmosphere, availability of walk-in appointments, and a harm reduction framework to help them identify and pursue their own personal health goals. Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program."
62852897|NCT03303664|NO_INTERVENTION|Usual Care|Treatment of patients in the usual manner based on their diagnosis and resources available at that site.
62627311|NCT03214679|ACTIVE_COMPARATOR|Usual Care|Usual care represents the current process after someone tests positive for HCV antibody on site at the syringe exchange program. An on site care coordinator (not provided by study) assists with insurance and linkage to HCV medical provider at sites throughout NYC through the NYC Dept of Health Check Hep C program.
62627312|NCT03706664|OTHER|Training of machine learning algorithm|113 MR Enterography images labelled by Radiologists will be used to develop a machine learning algorithm to (1) localise the terminal ileum, (2) classify the terminal ileum as normal or abnormal.
62627313|NCT03706664|OTHER|Testing of machine learning algorithm|"113 MR Enterography images labelled by Radiologists will be used to test the accuracy of the machine learning algorithm to (1) localise the terminal ileum, (2) classify the terminal ileum as normal or abnormal compared to Radiologists opinion.~Cross Validation analysis will be used for data analysis."
62627314|NCT00905632|EXPERIMENTAL|BI 207127 low dose + SOC|BI 207127 low dose tid + SOC
62451032|NCT05256628|OTHER|Protected Weightbearing|Patients in the protected weightbearing group will be instructed to be touch weightbearing for a period of 6-weeks postoperatively before commencing to be weightbearing as tolerated.
62451033|NCT00446732|ACTIVE_COMPARATOR|1|
62451034|NCT00446732|NO_INTERVENTION|2|
62627315|NCT00905632|EXPERIMENTAL|BI 207127 middle dose +SOC|BI 207127 middle dose tid + SOC
62063107|NCT01933971|OTHER|Group 2: filgrastim 5 µg/kg/day for 7 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.~The sites, where the injections are to be performed, are planned as follows:~1. st injection: upper part of the upper arm, posterior surface~2. nd injection: upper part of the thigh~3. rd injection: abdomen with the exception of the umbilical area~4. th injection: upper part of the contra-lateral upper arm, posterior surface~5. th injection: upper part of the contra-lateral thigh~6. th injection: abdomen with the exception of the umbilical area~7. th injection: upper part of the same upper arm, posterior surface as for the 1st injection."
62627316|NCT00905632|EXPERIMENTAL|BI 207127 high dose+SOC|BI 207127 high dose tid +SOC
62063108|NCT01933971|OTHER|Group 3: filgrastim 10 µg/kg/day for 5 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.~The sites, where the injections are to be performed, are planned as follows:~1. st injection: upper part of the upper arm, posterior surface~2. nd injection: upper part of the thigh~3. rd injection: abdomen with the exception of the umbilical area~4. th injection: upper part of the contra-lateral upper arm, posterior surface~5. th injection: upper part of the contra-lateral thigh."
62063109|NCT02139657|EXPERIMENTAL|RIG-C|Single 20 IU/kg dose of RIG-C by intramuscular injection
62451035|NCT00439075|EXPERIMENTAL|CPAP|positive airway pressure
62451036|NCT00439075|ACTIVE_COMPARATOR|standard medical therapy|conventional oxygen therapy
62451037|NCT06546215|EXPERIMENTAL|digoxin test drug|digoxin tablet, 0.25mg, single dose
62451038|NCT06546215|ACTIVE_COMPARATOR|digoxin reference drug|digoxin tablet, 0.25mg, single dose
62627317|NCT00905632|PLACEBO_COMPARATOR|Placebo + SOC|Placebo tid +SOC
62627318|NCT01539746|EXPERIMENTAL|TAVI without predilation|
62451039|NCT02052245||Subject delivering preterm baby|
62451040|NCT02052245||Subject delivering term baby|
62451041|NCT06046664|OTHER|DCIS Test|
62451042|NCT01978678||Pulmicort|ICS and LABA - based on ACQ and FeNO
62451043|NCT04807842|OTHER|Active product|
62451044|NCT04807842|PLACEBO_COMPARATOR|Placebo|
62451045|NCT01699607|EXPERIMENTAL|amphetamine|There is only one arm to the study. All subjects will receive amphetamine at 0.5mg/kg prior to the second PET scan.
62627319|NCT01539746|ACTIVE_COMPARATOR|Standard TAVI procedure|
62627320|NCT03568383|EXPERIMENTAL|Arm A: Delamanid (DLM)|HHCs will receive delamanid (DLM) for 26 weeks.
62627321|NCT03568383|EXPERIMENTAL|Arm B: Isoniazid (INH)|HHCs will receive isoniazid (INH) and pyridoxine (vitamin B6) for 26 weeks.
62627322|NCT03748901||Full analysis set|Patients with recurrent or metastatic RCC who have initiated first line treatment between 1 January 2010 and 31 December 2015, with representative FFPE of nephrectomy surgical specimen which are suitable for assessment of PD-L1 expression
62627323|NCT04291118|OTHER|Medical Management and Sinus Surgery in private system|These patients will first receive medical management for their symptoms and then will undergo sinus surgery much earlier than the other group as they will include patients being operated in the private system.
62627324|NCT04291118|OTHER|Medical Management and Sinus Surgery in public system|These patients will first receive medical management for their symptoms, and then will undergo sinus surgery after a waiting period of at least 1 year since they are on the public wait-list.
62627325|NCT04291118|OTHER|Medical Management Only|These patients will only receive medical management for their symptoms as they will not require sinus surgery.
62627326|NCT03516162||Patients With Brain Tumors/AVMs|"Patients with a brain tumour/AVM scheduled for maximum safe resection via craniotomy.~Participants fulfilling all of the following inclusion criteria are eligible for the study:~* Consent of the patient~* Age: ≥18~* Fluent language skills in German~* Patient is capable to use a smartphone (based on the Google Android system) and uses a smartphone since at least 3 months~* Preoperative smartphone-assessed day-to-day behaviour can be recorded for at least 1 week (7 days)"
62627327|NCT03516162||Patients With Hydrocephalus|"Patients with hydrocephalus scheduled for VP-shunting~Participants fulfilling all of the following inclusion criteria are eligible for the study:~* Consent of the patient~* Age: ≥18~* Fluent language skills in German~* Patient is capable to use a smartphone (based on the Google Android system) and uses a smartphone since at least 3 months~* Preoperative smartphone-assessed day-to-day behaviour can be recorded for at least 1 week (7 days)"
62627328|NCT05504889||OPTIMOM residual samples|"Residual plasma samples collected in one of our prior studies monthly across pregnancy (OPTIMOM, NICHD 1U54HD085601-01, Clinical Trials.gov ID NCT02519790; K. Wisner, PI) will be evaluated for cholesterol and 4β-hydroxycholesterol.~These samples were obtained from women who gave their consent for use of their blood samples for future studies. All OPTI-MOM participants have been genotyped for variants in CYP3A5 using commercial allelic discrimination assays (ThermoFisher Scientific, Waltham, MA, with Taqman probes.)"
62627329|NCT05504889||Newly recruited subjects|Plasma samples will be collected from newly recruited subjects.
62451046|NCT05925790||Inflammatory phenotype|"Patients with the inflammatory phenotype of recurrent pericarditis exhibit signs indicating the presence of an inflammatory process during a recurrence. These signs may include one or more of the following:~* Fever~* Elevated C-reactive protein (CRP)~* Elevated white blood cell (WBC) count~* Elevated erythrocyte sedimentation rate (ESR)~* Pericardial late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR)~* Pericardial contrast enhancement on computed tomography (CT)"
62627330|NCT03017391|ACTIVE_COMPARATOR|algorithm 1 first metoclopramide|metoclopramide 10 mg tablets 3x daily orally and in those patients that cannot swallow tablets the medication will be substituted by suppositories 10 mg 3x daily rectally. In case of failure, granisetron patch 3.1mg/24 hours will be added to the treatment and a loading dose of 2 mg granisetron oral if the patient can swallow. In case of toxicity metoclopramide will be stopped. In case of failure of the combination (second step) or toxicity, an oral dose of dexamethasone 8 mg will be added daily.
62627331|NCT03017391|ACTIVE_COMPARATOR|algorithm 2 first granisetron|"granisetron patch 3.1 mg/24 hours will be offered to the patient, and a loading dose of 2 mg granisetron oral if the patient can swallow In case of failure, metoclopramide 10 mg tablets 3x daily orally will be added and in those patients that cannot swallow tablets the oral medication will be substituted with rectal suppositories 10 mg. The granisetron patch will only be withdrawn from patients that suffer from clinically relevant toxicity. Metoclopramide will then be administered.~In the case of secondary failure or toxicity, dexamethasone 8 mg orally daily will be added."
62627332|NCT05405764|EXPERIMENTAL|Porcine protein group|The patients will receive protein supplements twice daily (2x22g) for a period of 6 weeks during breakfast and lunch. The supplement will be delivered in powdered form.
62627333|NCT05405764|PLACEBO_COMPARATOR|Carbohydrate group|The patients will receive isocaloric carbohydrate supplements twice daily (2x21g) for a period of 6 weeks during morning and afternoon. The supplement will be delivered in powdered form.
62852898|NCT04494100|ACTIVE_COMPARATOR|CONTROL|Troncular blocks using a long-acting LA + Tourniquet
62852899|NCT04494100|EXPERIMENTAL|WALANT|Troncular blocks using a long-acting LA + WALANT technique using a short-term LA with epinephrine a vasoconstrictor agent
62852900|NCT02809040||Hypertensive Heart Disease|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
62451047|NCT05925790||Non-inflammatory phenotype|"Patients with the non-inflammatory phenotype of recurrent pericarditis do not exhibit any of the signs typically associated with an active inflammatory process during a recurrence. These patients present without:~* Fever~* Elevated CRP~* Elevated WBC count~* Elevated ESR~* Pericardial LGE on CMR~* Pericardial contrast enhancement on CT"
62451048|NCT06044181|NO_INTERVENTION|Peripheral avascular retina of ROP with no leakage.|If there is no active leakage detected by FFA, patients would be observed. The follow-up period: FFA will be done at the age of 18 months we will repeat FFA every 6 months and fundus examination with color photography every 3 months till the age of 3 years of children.
62852901|NCT02809040||Volunteer subjects|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
62852902|NCT02809040||Diagnosed Hypertension|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
62852903|NCT02885467|ACTIVE_COMPARATOR|Control|Standard total knee arthroplasty performed through medial parapatellar approach
62852904|NCT02885467|EXPERIMENTAL|Intervention|Total knee arthroplasty performed through medial parapatellar approach with identification, ligation, and burial of saphenous nerve branches
62451049|NCT06044181|ACTIVE_COMPARATOR|Peripheral avascular retina of ROP with active leakage.|If there is evidence of active leakage by FFA The confluent laser burns will be applied to the entire avascular retina from the ridge to the ora serrata for 360 through the transpupillary route.
62451050|NCT05130892|EXPERIMENTAL|Colchicine group|1 tablet (0.5mg) / time, once a day
62451051|NCT05130892|EXPERIMENTAL|Tranilast group|1 capsule (0.1g) / time, 3 times a day;
62451052|NCT05130892|EXPERIMENTAL|Oridonin group|2 tablets (0.5g) / time, 3 times a day
62451053|NCT05130892|NO_INTERVENTION|Non-intervention group|
62451054|NCT02287168|EXPERIMENTAL|dissemination of cancer cells|conversion of negative result of pre-gastrectomy peritoneal washing cytology to positive cytology after gastrectomy
62451055|NCT02287168|EXPERIMENTAL|elimination of cancer cells|elimination of peritoneal cancer cells occurred before (pre-gastrectomy peritoneal washing cytology) or after gastrectomy (post-gastrectomy peritoneal washing cytology) by intra operative peritoneal lavage ('post-lavage peritoneal washing cytology)
62627334|NCT05359952|EXPERIMENTAL|Starting the Conversation|"Participants are asked to watch an educational video along with an accompanying workbook (called Starting the Conversation). Participants are also asked to review a list of resources about sexual and menopausal health relevant to gynecologic cancer."
62461458|NCT00048958||No treatment|Samples as defined per the protocol for previously untreated patients with AML, ALL, MDS or MM will be submitted for analysis and within one month patients are required to register onto a CALGB treatment study.
62461459|NCT02911805|ACTIVE_COMPARATOR|Aerobic Exercise|Exercise 3 times a week
62852905|NCT05482750|EXPERIMENTAL|Resistance training in the fasted state|Subjects will maintain the standard diet and will perform resistance exercise sessions after overnight fasting (10 to 12 hours). Over the 12 weeks of intervention, participants will perform two sessions a week of resistance exercises.
62852906|NCT05482750|ACTIVE_COMPARATOR|Resistance training in the fed state|Subjects will maintain the standard diet and will perform resistance exercise sessions in the fed state, between 1 and 2 hours after consuming a carbohydrate-containing meal. Over the 12 weeks of intervention, participants will perform two sessions a week of resistance exercises.
62852907|NCT02284425|EXPERIMENTAL|Part A|Participants in Part A will consist of 4 sequential ascending dose cohorts. Each cohort will receive 1 of 4 ascending dose levels of study drug (REGN1193) or placebo.
62852908|NCT02284425|EXPERIMENTAL|Part B|Participants in Part B will consist of a single cohort and will receive three doses of study drug (REGN1193) or placebo.
62852909|NCT01832584|EXPERIMENTAL|RGC1|200 mg of Red Grape Cell (RGC) powder; daily oral dose
62852910|NCT01832584|EXPERIMENTAL|RGC2|1000 mg of Red Grape Cell (RGC) powder; daily oral dose
62268029|NCT00717938|EXPERIMENTAL|B|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
62627335|NCT05359952|ACTIVE_COMPARATOR|Sexual and Menopausal Health Resources Only|Participants are given the list of resources about sexual and menopausal health only.
62627336|NCT04200183|EXPERIMENTAL|iACTwithPain|
62627337|NCT04200183|EXPERIMENTAL|ACT-only intervention|
62627338|NCT04200183|NO_INTERVENTION|Wait list (inactive control)|
62627339|NCT02840474|EXPERIMENTAL|Part A: VRC01LS (40 mg/kg)|VRC-HIVMAB080-00-AB (VRC01LS) - (40 mg/kg) - administered intravenously (IV) at Day 0
62627340|NCT02840474|EXPERIMENTAL|Part B: VRC07-523LS (40 mg/kg)|VRC-HIVMAB075-00-AB (VRC07-523LS) - (40 mg/kg) - administered IV at Day 0
62627341|NCT06122285||Hepatis Delta|Bulevirtide (BLV) at a dose of 2 mg/day subcutaneously
62627342|NCT00836446|ACTIVE_COMPARATOR|Group 1|20 min. physical activity routine
62627343|NCT00836446|EXPERIMENTAL|Group 2|40 min. aerobic physical activity routine
62627344|NCT00766623|EXPERIMENTAL|High fat meal|A high fat milkshake containing 95g of fat
62627345|NCT00766623|EXPERIMENTAL|Control meal|Milkshake comparable with a normal breakfast
62627346|NCT00766623|EXPERIMENTAL|High fat meal 2|A high fat milkshake containing 95g of fat
62063110|NCT02955121|ACTIVE_COMPARATOR|Pharmacogenetic Results Available to Provider|Genotyping for CYP2C19 variants is performed. The test results are integrated into the electronic health record and alerts are displayed to the prescriber. The ultimate decision regarding antiplatelet therapy is left to the prescriber
62268030|NCT02606422|EXPERIMENTAL|Active HD-tDCS plus Speech-Language Therapy|Active HD-tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min.
62461460|NCT02911805|PLACEBO_COMPARATOR|Balance Training|Group balance training 3 times a week
62627347|NCT00766623|EXPERIMENTAL|High fat meal 3|A high fat milkshake containing 95g of fat
62627348|NCT00766623|EXPERIMENTAL|Control meal 2|Milkshake comparable with a normal breakfast
62627349|NCT00766623|EXPERIMENTAL|Control meal 3|Milkshake comparable with a normal breakfast
62627350|NCT01646840|EXPERIMENTAL|PF-04958242 capsule|
62627351|NCT01646840|ACTIVE_COMPARATOR|PF-04958242 oral solution|
62627352|NCT05912257|EXPERIMENTAL|NOSH|Multi-Targeted NOSH + Exercise (NOSH Regimen) Arm
62627353|NCT05912257|ACTIVE_COMPARATOR|Typical Regimen|Typical Regimen Arm
62852911|NCT01832584|PLACEBO_COMPARATOR|Placebo|1000 mg placebo to Red Grape Cell (RGC) powder; daily oral dose
62063111|NCT02955121|NO_INTERVENTION|Control Arm|No genotyping information is performed as part of clinical care. Standard therapy is followed. Genotyping will be performed at conclusion of study in control arm, and genotyping results will not be incorporated into electronic health record.
62627354|NCT01712048|ACTIVE_COMPARATOR|Submucosal Injection EMR|"For patients who are randomized to the submucosal injection arm polypectomy will be performed with selective saline injection to the layer of tissue underneath the polyp in order to create a safety cushion for resection."
62627355|NCT01712048|ACTIVE_COMPARATOR|Underwater EMR|"For patients who are randomized to the underwater arm polypectomy with water will be performed under full water emersion without the use of submucosal injection."
62627356|NCT00815997|SHAM_COMPARATOR|6-Fr TRI (transradial coronary intervention)|TRI will be performed using a 6-Fr guiding catheter.
62627357|NCT00815997|ACTIVE_COMPARATOR|4-Fr TRI|TRI will be performed using a 4-Fr guiding catheter.
62627358|NCT02091401|ACTIVE_COMPARATOR|IV|Women randomized into this treatment group will receive magnesium sulfate via an IV loading dose administered manually by study staff and an IV maintenance regimen.
62627359|NCT02091401|EXPERIMENTAL|Springfusor|Women randomized into this treatment group will receive magnesium sulfate via IV infusion (with the Springfusor® pump).
62627360|NCT05149261||Acute aortic syndrome|"patients admitted to the Georges Pompidou European Hospital via the SOS aorta network"
62627361|NCT00610779|ACTIVE_COMPARATOR|1|treatment with spray containing aromatic essential oils of some herbal plants.
62627362|NCT00610779|PLACEBO_COMPARATOR|2|spray containing placebo.
62627363|NCT05880667|EXPERIMENTAL|Adaptive Stereotactic Body Radiation|Simulation and treatment to be performed over 3-4 weeks per dose escalation
62627364|NCT01909973|EXPERIMENTAL|MedLink System|For 12 weeks, the patient who is newly prescribed antidepressant medication will receive a mobile phone and a GSM enable pill bottle in order to provide and receive feedback regarding medication adherence.
62627365|NCT01909973|NO_INTERVENTION|Treatment As Usual|Patients will continue to receive treatment as usual from their primary care doctor. Patients in this arm will also receive a free mobile phone for the 12 weeks of the intervention.
62627366|NCT04497532|NO_INTERVENTION|Control|
62627367|NCT04497532|EXPERIMENTAL|Diet|
62627368|NCT01155622|ACTIVE_COMPARATOR|32º Celsius|Endovascular Cooling was set at a target temperature of 32°C
62627369|NCT01155622|ACTIVE_COMPARATOR|34º Celsius|Endovascular Cooling was set at a target temperature of 32°C
62627370|NCT04794517|EXPERIMENTAL|IMP|Dapagliflozin 10 mg/die will be administered orally for six-weeks.
62627371|NCT04794517|PLACEBO_COMPARATOR|Placebo|Placebo, one tablet/die will be administered orally for six-weeks.
62627372|NCT05524649|EXPERIMENTAL|Experimental 1|Probiotic single strain formulation comprising Bifidobacterium longum CECT7894 in liquid format suspended in sunflower oil. This probiotic strain has Qualified Presumption of Safety (QPS) status by European Food Safety Authority.
62627373|NCT05524649|EXPERIMENTAL|Experimental 2|Probiotic single strain formulation comprising Pediococcus pentosaceus CECT8330 in liquid format suspended in sunflower oil. This probiotic strain has Qualified Presumption of Safety (QPS) status by European Food Safety Authority.
62627374|NCT05524649|PLACEBO_COMPARATOR|Placebo|Sunflower oil
62852912|NCT00847509|EXPERIMENTAL|FLT PET scan|Open label, nonrandomized, uncontrolled, single group assignment, multi-center clinical trial to evaluate \[F-18\] FLT as a PET imaging tool in cancer patients clinically scheduled for treatment with radiation or radiation - chemotherapy. Standard \[F-18\] FDG PET will be the active comparator.
62852913|NCT01656356|ACTIVE_COMPARATOR|A/17/turkey/Turkey/05/133 (H5N2)|
62852914|NCT01656356|PLACEBO_COMPARATOR|Placebo|
62451056|NCT02141100|EXPERIMENTAL|6-thioguanine, 6-mercaptopurine and methotrexate|"This is the only treatment arm; all eligible patients will receive standard methotrexate/6-mercaptopurine (6MP/MTX) maintenance therapy supplemented with 6-thioguanine (6TG).~Patients are enrolled when they have 12 to 3.5 months remaining of their maintenance therapy. After dose reduction in 6MP to 2/3 of the current dose 6TG therapy is initiated with a starting dose of 2.5 mg/m2/day. The 6TG dose will hereafter be increased at 2.5 mg/m2/day every 14 days until a max. of 12.5 mg/m2/day is reached or until the thiopurine metabolite profile (Ery-TGN/Ery-MeMP) has been increased by at least a factor 5."
62627375|NCT00418028|ACTIVE_COMPARATOR|A Cint|Capecitabine will be administered orally at a dose of 1250 mg/m2 twice-daily (in the morning and in the evening, the equivalent of a total daily dose of 2500 mg/m2) for 14 days, in 3 week cycles with a resting period of 7 days,until disease progression or severe toxicity. Dose adjustments were made in patients with grade 3 or greater diarrhea or hand and food syndrome.
62627376|NCT00418028|EXPERIMENTAL|B Ccont|Capecitabine 800 mg/m2 orally twice-daily (in the morning and in the evening the equivalent of one dose of 1600 mg/m2) for 21 days, in 3 week cycles without resting period, until disease progression or severe toxicity. Dose adjustments were made in patients with grade 3 or greater diarrhea or hand and food syndrome.
62852915|NCT02103153|EXPERIMENTAL|Picosure Laser System|
62451057|NCT05749627|EXPERIMENTAL|Neoantigen peptide vaccine/neoantigen-based DC treatment|Patients assigned to the neoantigen peptide vaccine/neoantigen-based DC treatment group will receive 5-6 subcutaneous injections of neoantigen peptide vaccine or neoantigen-based DC immune preparation within a 14-week treatment period.
62451058|NCT03972566||CREST with Calcinosis cutis|
62451059|NCT03972566||CREST without Calcinosis cutis|
62451060|NCT06496919||Gastric malignant tumor queue|
62451061|NCT06496919||Colorectal Malignant Tumor Queue|
62451062|NCT04721756|EXPERIMENTAL|18F-LY3546117 Scan Cohort 1|18F-LY3546117 PET scan at baseline and between 14-42 days after initiation of immune checkpoint therapy
62451063|NCT04721756|EXPERIMENTAL|18F-LY3546117 Scan Cohort 2|18F-LY3546117 PET scan at time of immune checkpoint therapy response
62451064|NCT01564433|EXPERIMENTAL|Gait trainer treatment|
62451065|NCT01564433|ACTIVE_COMPARATOR|Conventional group|
62852916|NCT03598517|EXPERIMENTAL|high dose chemoradiotherapy|all eligible patients receive image-guided intensity-modulated radiotherapy 60 Gy in 30 fractions over 6 weeks and concurrent weekly paclitaxel and cisplatin，followed by hyperfractionated intensity-modulated radiotherapy boost to residual metabolic disease concurrent with the same chemotherapy regimen, followed by adjuvant chemotherapy 6 weeks after completion of radiation therapy.
62451066|NCT05803018|EXPERIMENTAL|Study treatment|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62451067|NCT05292742|EXPERIMENTAL|A|Pyrotinib: 400 mg/day (once daily, orally at the same time every day), every 3 weeks for one year Capecitabine: 1000 mg/m2 orally twice daily every 3 weeks for 6 cycles Trastuzumab: Initial loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks. One year of trastuzumab treatment (including: neoadjuvant phase and adjuvant phase)
62451068|NCT05292742|ACTIVE_COMPARATOR|B|Patients in the control group will continue neoadjuvant targeted therapy, trastuzumab or trastuzumab in combination with pertuzumab. In case of neoadjuvant trastuzumab monotherapy, trastuzumab combined with pertuzumab targeted therapy is allowed in the adjuvant phase.
62451069|NCT02014974||Public Hospitals|Patients presenting and treated in public trauma centers in India.
62451070|NCT02014974||Private Hospitals|Patients presenting and treated in private trauma centers in India.
62451071|NCT02773836||Greek cohort|Participants recruited from Greece will receive a questionnaire at pre- and post- intervention
62451072|NCT02773836||German cohort|Participants recruited from Germany will receive a questionnaire at pre- and post- intervention
62451073|NCT02773836||Romanian Cohort|Participants recruited from Romania will receive a questionnaire at pre- and post- intervention
62451074|NCT02773836||Spanish Cohort|Participants recruited from Spain will receive a questionnaire at pre- and post- intervention
62451075|NCT02773836||Hungarian Cohort|Participants recruited from Hungary will receive a questionnaire at pre- and post- intervention
62451076|NCT02773836||Polish cohort|Participants recruited from Poland will receive a questionnaire at pre- and post- intervention
62063112|NCT02027480||Prospective Cohort|"The study will be a prospective cohort study of HIV-infected adults initiating ART at 4-8 health facilities in Nyanza Province, Kenya. Participants will be asked to take part in four visits over a 12 month period.~At each study visit, participants will be asked questions related to demographic characteristics, medical history, including history of/recent medical conditions, family medical history, TB history and smoking status. Participants will also have their height (at baseline visit only) and weight measured for calculation of BMI and blood pressure reading. Blood and urine specimens will be collected and stored at each study visit for future testing."
62063113|NCT04197011||Prosthesis users|Individuals with unilateral transfemoral amputation.
62063114|NCT04197011||Control|Individuals without unilateral transfemoral amputation.
62063115|NCT05324930|PLACEBO_COMPARATOR|Control group|After conventional therapy consisting of debridement, infection control and offloading, patients received a saline-moistened gauze dressing (control group) for wound care.
62451077|NCT00930865|ACTIVE_COMPARATOR|Bumetanide|
62451078|NCT00930865|ACTIVE_COMPARATOR|Dapagliflozin|
62451079|NCT00930865|ACTIVE_COMPARATOR|Bumetanide + Dapagliflozin|
62451080|NCT05718609|ACTIVE_COMPARATOR|Amoxicillin- and Clarithromycin-based BQT|rabeprazole 10mg bid, amoxicillin 1g bid, clarithromycin 500mg bid, colloidal bismuth 200mg bid for 14 days
62451081|NCT05718609|EXPERIMENTAL|Clarithromycin medication history-based BQT|The clarithromycin medication history will be asked before the treatment and the therapy will be performed as follows: with clarithromycin medication history: rabeprazole 10mg bid, amoxicillin 1g bid, furazolidone 100mg bid, colloidal bismuth 200mg bid for 14 days; without clarithromycin medication history: rabeprazole 10mg bid, amoxicillin 1g bid, clarithromycin 500mg bid, colloidal bismuth 200mg bid for 14 days.
62451082|NCT05718609|EXPERIMENTAL|Antimicrobial susceptibility tests-based BQT|Fecal molecular biology antimicrobial susceptibility tests will be performed before the treatment. The susceptibility of clarithromycin will be evaluated. The treatment regimen will be chosen according to the results of the antimicrobial susceptibility tests as follows: clarithromycin-sensitive: rabeprazole 10mg bid, amoxicillin 1g bid, clarithromycin 500mg bid, colloidal bismuth 200mg bid for 14 days; clarithromycin-resistant: rabeprazole 10mg bid, amoxicillin 1g bid, furazolidone 100mg bid, colloidal bismuth 200mg bid for 14 days.
62451083|NCT03706638|OTHER|Daily|Patients randomized to this arm will take ferrous sulfate 325 mg every day.
62451084|NCT03706638|OTHER|Intermittent (Every other day)|Patient's randomized to this arm will take ferrous sulfate 325 mg every other day.
62451085|NCT05042856|EXPERIMENTAL|PanOptix|All the patients will be bilaterally implanted with PanOptix IOL，one eye will be randomized selected for monocular analysis of each patient.
62451086|NCT03630666|ACTIVE_COMPARATOR|IADT|one injection of IADT. The overall duration of IADT will be six months.
62451087|NCT03630666|EXPERIMENTAL|IADT+ radiotherapy|One injection of IADT. The overall duration of IADT will be six months. Irradiation three months after injection of IADT. The overall duration of radiotherapy will be three months.
62451088|NCT01361126|EXPERIMENTAL|On-demand|The routine prophylactic therapy interval is targeted at every 7 days.
62451089|NCT01361126|EXPERIMENTAL|Prophylactic|On-demand subjects will receive rIX-FP only for the treatment of a bleeding episode.
62451090|NCT03286582|EXPERIMENTAL|AC-203|
62451091|NCT03286582|ACTIVE_COMPARATOR|Clobetasol|
62451092|NCT03890185|EXPERIMENTAL|A: Chemo+RT low dose|Chemo + Low dose RT: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1, Cisplatin (CDDP) 75mg/m2 IV D1 and radiation therapy (LDFRT) using 50 cGy of radiation per fraction BID on the day of chemotherapy and the day after during induction i.e. 50 cGy x 4 times per cycle given for a total of 2 cycles every 21 days.
62451093|NCT03890185|ACTIVE_COMPARATOR|B: Chemo alone|Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
62451094|NCT03340168|EXPERIMENTAL|Bisphenol-S kinetics - oral exposure|Six female volunteers will be exposed orally acute at the reference dose level(0.1 mg / kg bw). For the administration, the product will be dissolved in ethanol (100 mg / ml equivalent to 10 mg / 100 μl) and the solution will be deposited on a cookie (deposit of about 70 μl of solution on a cookie for an individual of 70 kg) and the ethanol is allowed to evaporate before giving each volunteer, with the subsequent consumption of 100 ml of water.
62451095|NCT03340168|EXPERIMENTAL|Bisphenol-S kinetics - dermal exposure|volunteers will be exposed dermally acute at a dose of 1 mg / kg bw. The solution will be applied to an area of 40 cm2 of the forearm and delimited by the indelible marker. The BPS will be added in suspension in an aqueous solution containing 1% of carboxymethylcellulose and administered in the form of drops (70 .mu.l for an individual of 70 kg). The treated area will be left uncoated and unwashed for a period of 4 hours. After 4 hours, the application area will be washed with water and soap. This type of application is therefore similar to an exposure of the general population via the skin (manipulation of cash receipts).
62451096|NCT06141096|EXPERIMENTAL|MB07133 600mg/m2/day|
62451097|NCT06141096|EXPERIMENTAL|MB07133 1200mg/m2/day|
62451098|NCT06141096|EXPERIMENTAL|MB07133 1800mg/m2/day|
62451099|NCT05103722|EXPERIMENTAL|Supportive Care|Patients with metastatic renal cell carcinoma (RCC) who are receiving immune-checkpoint inhibitor therapy
62451100|NCT05533346|EXPERIMENTAL|Experimental - with WISE|The experimental group will provide walking health education leaflets and exercise measurement wristbands for exercise monitoring, and will be given the intervention of the WISE program: three times a week, each time walking for at least 30 minutes, with a pace between 100-130 steps/ minutes, and then increase the number or time weekly according to personal ability.
62451101|NCT05533346|ACTIVE_COMPARATOR|Control - without WISE|The procedure of the control group will be the same as that of the experimental group, providing walking and health education leaflets and exercise measurement wristbands for exercise monitoring, but no intervention in the WISE program.
62451102|NCT06441435|EXPERIMENTAL|Intervention group|Low-protein diet strategies combined with AC-134 capsules
62451103|NCT06441435|ACTIVE_COMPARATOR|Control group|Low-protein diet strategies
62451104|NCT03917771|EXPERIMENTAL|Early lymphedema detection|Face-to-face consultation in Rehabilitation for early detection of lymphedema after surgery. Lower Limb measurement and care education
62627377|NCT05399147|OTHER|classic group (CL group)|20 patients will be enrolled to be intubated using the classic usual technique
62627378|NCT05399147|OTHER|tube 1st group (TF group)|20 patients will be enrolled to be intubated using the tube 1st technique
62627379|NCT02217852|EXPERIMENTAL|A1 nitrendipine|this arm will include Tibetan patients with hypertension whose BP is higher than 140/90mmHg but lower than 160/100mmHg and nitrendipine will be added (dose range 10mg-20mg bid).
62852917|NCT03453788|EXPERIMENTAL|Intervention group|Alternating follow-up visits by nurse and doctor. In the nurse-led consultations, the patients will be introduced to the smartphone LETSGOapp with access to information on cancer treatment and side effects, physical activity advice. Two-monthly assessment of 12 symptoms that may represent relapse through the app.The patients will fill in an electronic questionnaire package at baseline, 3, and 6 months after treatment.
62852918|NCT03453788|NO_INTERVENTION|Reference group|Regular hospital follow-up.The patients will fill in an electronic questionnaire package at baseline, 3, and 6 months after treatment.
62063116|NCT05324930|EXPERIMENTAL|Experimental group|After conventional therapy consisting of debridement, infection control and offloading, patients received the piscean collagen dressing (the study group) for wound care.
62268031|NCT02606422|SHAM_COMPARATOR|Sham plus Speech-Language Therapy|Sham HD-tDCS will be applied at the beginning of 45min speech-language therapy session.
62268032|NCT02111642|EXPERIMENTAL|Online risk calculator used|Online risk calculator tool for the development of postoperative de novo stress urinary incontinence used during preoperative counseling session.
62268033|NCT02111642|PLACEBO_COMPARATOR|Online risk calculator not used|Online risk calculator tool for the development of postoperative de novo stress urinary incontinence not used during preoperative counseling session.
62268034|NCT01335763|OTHER|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of \<=5.5mmol/L
62268035|NCT05392686|EXPERIMENTAL|Experimental: PD1 + PARP|"For the Induction Phase, participants receive 4 cycles:~PD1 200 mg, intravenous (IV) on Day 1 of each 21-day cycle PLUS carboplatin PLUS a taxane (either paclitaxel or nab-paclitaxel) for 4 cycles (21-day cycles). If the participant has a complete or partial response or stable disease to induction therapy, the participant to maintenance therapy.~For the Maintenance Phase, participants receive PD1 IV on Day 1 of each 21-day for up to 31 cycles PLUS maintenance oral PARP 100 mg twice daily. Until centrally verified progressive disease, physician decision or intolerable toxicity."
62268036|NCT02202629|PLACEBO_COMPARATOR|Cherry flavoured beverage 1|10floz cherry flavoured test article
62268037|NCT02202629|EXPERIMENTAL|Cherry flavoured beverage 2|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
62268038|NCT02202629|EXPERIMENTAL|Cherry flavoured beverage 3|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
62268039|NCT02202629|EXPERIMENTAL|Cherry flavoured beverage 4|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
62268040|NCT04586283|EXPERIMENTAL|Maternal Prone Position|Participants will initially be assessed in left-lateral position for 20 minutes. Participants will then be asked to lie in a prone position for 30 minutes supported by a specially designed pillow. Participants will then return to a left-lateral position for 20 minutes.
62451105|NCT03917771|ACTIVE_COMPARATOR|Usual follow-up|The usual follow-up will be carried out in GO consultation (0,1,6,12 months)
62268041|NCT05070767|EXPERIMENTAL|Neurolens|Our proprietary contoured prism lens design, commercially known as neurolens.
62268042|NCT05070767|PLACEBO_COMPARATOR|Control lens|A simple refractive error correction lens
62268043|NCT00659204|EXPERIMENTAL|nano-silver gel|
62268044|NCT00659204|ACTIVE_COMPARATOR|alcohol-based gel|
62451106|NCT06088771|EXPERIMENTAL|Non-small-cell lung cancer (NSCLC)|Participants will receive neoadjuvant subcutaneous Dupilumab 600mg and intravenous Cemiplimab 350mg on Day 1. Participants will proceed to standard of care surgery for early-stage, resectable NSCLC (within 7 days of Day 15), and will be observed for adverse events and dose limiting toxicities.
62268045|NCT06126432|EXPERIMENTAL|To evaluate the effects of probiotics consumption|Subjects consumed 2 bottles of probiotics-containing yogurt per day for 1 month
62268046|NCT00674050|EXPERIMENTAL|1|
62268047|NCT03559855|EXPERIMENTAL|Real Essentials|The Real Essentials curriculum is delivered in class to students by the Center for Relationship Education staff. It consists of 5 to 6 hours of healthy relationship education.
62451107|NCT06284525|EXPERIMENTAL|Gait training with exoskeleton resistance|Participants will complete 20-30 minutes of ankle resistance training on each visit. This will involve walking on a treadmill with stance phase ankle resistance and biofeedback.
62451108|NCT00218179||Cases|Lung cancer cases diagnosed prior to 2007 among baseline smokers in the PLCO
62451109|NCT00218179||Controls|Subjects without lung cancer among smokers at baseline in the PLCO study
62451110|NCT00514137|EXPERIMENTAL|Treatment (kinase inhibitor therapy)|Patients receive 37.5 mg oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62461461|NCT03749369|ACTIVE_COMPARATOR|SRP plus salvadora persica root|Subjects receiving salvadora gel in addition to scaling and root planing
62627380|NCT02217852|EXPERIMENTAL|A2 hydrochlorothiazide|this arm will include Tibetan patients with hypertension whose BP is higher than 140/90mmHg but lower than 160/100mmHg and hydrochlorothiazide will be added (dose range 12.5mg-25mg)
62852919|NCT01184950|EXPERIMENTAL|Trainer Curriculum|
62852920|NCT01184950|NO_INTERVENTION|No Curriculum|
62852921|NCT03336593|EXPERIMENTAL|QIV batch 1|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 1
62852922|NCT03336593|EXPERIMENTAL|QIV batch 2|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 2
62852923|NCT03336593|EXPERIMENTAL|QIV batch 3|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 3
62268048|NCT03559855|NO_INTERVENTION|Class as Usual|For the Class-as-Usual condition, there is no change in class content. Teachers offer what they typically offer.
62268049|NCT04647500|OTHER|22q11DS naive|22q11DS participants naive to methylphenidate
62268050|NCT04647500|OTHER|22q11DS consumer|22q11DS participants with a prolonged treatment of methylphenidate
62268051|NCT01112540|PLACEBO_COMPARATOR|Placebo Group|
62268052|NCT01112540|EXPERIMENTAL|Morphine|
62461462|NCT03749369|PLACEBO_COMPARATOR|SRP only|Subjects receiving scaling and root planing only
62852924|NCT03336593|ACTIVE_COMPARATOR|Trivalent Influenza Vaccine|1 dose of 0.5 ml of trivalent influenza vaccine
62063117|NCT05960370||"exposed or compaction group"|103 women with a decrease of ≥ 5% in endometrial thickness between the estrogenic phase (ovulation induction day) and the day of embryo transfer (7 days after ovulation induction).
62063118|NCT05960370||"non-exposed non-compaction group"|103 women with similar or greater endometrial thickness between the estrogenic phase (ovulation induction day) and the day of embryo transfer (7 days after ovulation induction).
62063119|NCT04195880|EXPERIMENTAL|Experimental VA Community Living Centers|Eight VA CLCs selected to receive the INTERACT intervention
62063120|NCT04195880|NO_INTERVENTION|Control VA Community Living Centers|Eight CLCs, matched to experiment CLCs, based on size, location to VAMC, and hospitalization rates, did not receive the intervention and continued care as usual
62063121|NCT06481852|EXPERIMENTAL|Drug group|PAH patients randomized to MTT with antibiotic preconditioning + fiber supplementation
62063122|NCT06481852|ACTIVE_COMPARATOR|Control 1|MTT with antibiotic preconditioning + placebo supplementation
62063123|NCT06481852|PLACEBO_COMPARATOR|Control 2|placebo + placebo supplementation.
62063124|NCT05869682|EXPERIMENTAL|Group I (Immediate BWL therapy)|Patients wear AYOpro BWL therapy glasses starting on day 1 of SOC ADT combination therapy for 12 months on trial.
62063125|NCT05869682|EXPERIMENTAL|Group II (Delayed BWL therapy)|Patients wear AYOpro BWL therapy glasses starting 6 months after the start of SOC ADT combination therapy for 6 months on trial.
62268053|NCT04889729||GENOMED4ALL - MDS patients|Information on targeted mutation screening (NGS including 60 genes related to MDS) from 13284 MDS patients
62627381|NCT02217852|EXPERIMENTAL|B1 captopril plus Hydrochlorothiazide|this arm will include Tibetan patients with hypertension whose BP is higher than 160/100mmHg and captopril plus Hydrochlorothiazide will be added (dose range：captopril 25mg-50mg tid, Hydrochlorothiazide 12.5mg-25mg qd).
62627382|NCT02217852|EXPERIMENTAL|B2 Beijing hypotensive No.0|this arm will include Tibetan patients with hypertension whose BP is higher than 160/100mmHg and Beijing hypotensive will be added (dose range：Beijing hypotensive No.0 one pile qd or less ).
62627383|NCT04566718||Group A|Obese women who have been treated with metformin for one year prior to the study.
62627384|NCT04566718||Group B|Obese women who have been treated with metformin for at least three years prior to the study.
62268054|NCT01548339|ACTIVE_COMPARATOR|Delayed|Laparoscopic cholecystectomy performed secondarily after an initial conservative treatment
62268055|NCT01548339|EXPERIMENTAL|Early|Laparoscopic cholecystectomy performed directly after the initial diagnosis
62268056|NCT04320238|EXPERIMENTAL|low-risk group|medical staff work in non-isolated general wards or laboratories, not directly contact with COVID-19 patients.
62268057|NCT04320238|EXPERIMENTAL|high-risk group|doctors and nurses work in isolated ward, directly contact with COVID-19 patients.
62268058|NCT06494137|ACTIVE_COMPARATOR|Psyllium|15g psyllium + 15 inulin dissolved in 250 ml water
62268059|NCT06494137|ACTIVE_COMPARATOR|Methylcelulose|15g methylcellulose +15 g inulin dissolved in 250 ml water
62268060|NCT06494137|PLACEBO_COMPARATOR|Maltodextrin|15g maltodextrin +15 g inulin dissolved in 250 ml water
62268061|NCT02300298|EXPERIMENTAL|Nintedanib plus Docetaxel|patients to receive backbone chemotherapy and nintedanib
62268062|NCT05711290|EXPERIMENTAL|Oxygen Nanobubble First|"In this arm, the oxygen nanobubbles will be provided as a drink first. The oxygen nanobubbles mixture will be mixed with water and oxygenated. This will be provided as a one-time 200ml drink 10 minutes before the start of the 6 minute walk test.~In this arm, the placebo will be provided as the second drink. This will be provided after atleast 2 hours after the first 6 minute walk test is completed. The placebo mixture will be mixed with water and oxygenated. This will be provided as a one-time 200ml drink 10 minutes before the start of the 6 minute walk test."
62268063|NCT05711290|PLACEBO_COMPARATOR|Placebo First|"In this arm, the placebo will be provided as a drink first. The placebo mixture will be mixed with water and oxygenated. This will be provided as a one-time 200ml drink 10 minutes before the start of the 6 minute walk test.~In this arm, the oxygen nanobubbles will be provided as the second drink. This will be provided after atleast 2 hours after the first 6 minute walk test is completed. The oxygen nanobubbles mixture will be mixed with water and oxygenated. This will be provided as a one-time 200ml drink 10 minutes before the start of the 6 minute walk test."
62268064|NCT02056483|EXPERIMENTAL|Screening-based nurse navigation|Based on systematic screening for psychological and physical symptoms as well as health behavior a nurse navigator will refer to and monitor use of appropriate rehabilitation programs
62268065|NCT02056483|NO_INTERVENTION|Usual care|Usual care
62461463|NCT04992052|ACTIVE_COMPARATOR|Treatment arm|This arm will have bone wax applied to the exposed cancellous surfaces of the bone.
62461464|NCT04992052|NO_INTERVENTION|Control Arm|This arm will serve as the control group. Bone wax will not be used in this group.
62461465|NCT00999037|EXPERIMENTAL|Renvela|Daily renvela with meals for 12 weeks
62461466|NCT00999037|PLACEBO_COMPARATOR|placebo|
62627385|NCT01963559|OTHER|Diabetic patients with MPP|
62627386|NCT01963559|OTHER|Diabetic patients without MPP|
62627387|NCT01788319|EXPERIMENTAL|lasertrabeculoplasty|
62627388|NCT04153955|EXPERIMENTAL|12-Hour Bed Rest|Subjects will be mobilized 12 hours after undergoing thrombectomy per usual care
62627389|NCT04153955|ACTIVE_COMPARATOR|24-Hour Bed Rest|Subjects will be mobilized 24 hours after undergoing thrombectomy per usual care
62627390|NCT03323827||Aim 2a|"Specific Aim 2. To determine how the cytosolic and mitochondrial protein acetylomes are regulated by muscle contraction in insulin sensitive and resistant human volunteers.~Protocol 2a. Subjects. Two groups (aged 21-65) will be studied: lean (BMI\<25), healthy insulin sensitive subjects, and obese (BMI\>30) nondiabetics 20 subjects will be enrolled"
62627391|NCT03323827||Aim 2b|"Specific Aim 2. To determine how the cytosolic and mitochondrial protein acetylomes are regulated by muscle contraction in insulin sensitive and resistant human volunteers.~Protocol 2b (muscle contraction and acetylation) Subjects. Two groups (aged 21-65) will be studied: lean (BMI\<25), healthy insulin sensitive subjects, and obese (BMI\>30) 32 subjects will be enrolled"
62063126|NCT02276066|EXPERIMENTAL|Inhospital group at day 14|This group of sepsis participants remain hospitalized at day 14. GFR assessment is performed at inpatient day 14 and again at 1 year follow up.
62627392|NCT03323827||Aim 3|"Specific Aim 3. To determine how acetylation of the mitochondrial inner membrane adenine nucleotide translocase ANT1 regulates protein structure and function.~Subjects. Two groups (aged 21-65) will be studied: lean (BMI\<25), healthy insulin sensitive subjects, and obese (BMI\>30) 20 subjects will be enrolled."
62627393|NCT03543176||UMEC/VI|The subjects in this arm had received, UMEC/VI as 62.5/25 microgram (mcg), which is an approved once-daily single inhaler dual LAMA/LABA therapy, given via Ellipta .
62627394|NCT03543176||FLUT/SAL|The subjects in this arm had received, FLUT/SAL as 250/50 mcg, which is an approved twice-daily single inhaler dual therapy ICS/LABA treatment, given via DISKUS.
62627395|NCT05518955|EXPERIMENTAL|Virtual reality combine with sleep promotion routine|Participants will receive virtual reality for 30 minutes before bedtime then will be placed on an eye mask and combine with the sleep promotion routine. The intervention duration need continues for two days or until discharge from ICU.
62852925|NCT03336593|EXPERIMENTAL|QIV (subjects 6-35 months)|2 dose of 0.25 ml of quadrivalent influenza vaccine
62852926|NCT03336593|EXPERIMENTAL|QIV (subjects 3-8 years)|2 dose of 0.5 ml of quadrivalent influenza vaccine
62852927|NCT03543787|ACTIVE_COMPARATOR|Health IT and Peer Support Intervention|Utilise electronic decision support, tracking of referral list and Peer facilitation for referral completion
62852928|NCT03543787|NO_INTERVENTION|Non intervention group|2014 - 2018 MoH referral protocol
62268066|NCT04766307|EXPERIMENTAL|experimental group|"Experimental group regimen:2H(Isoniazid)R(Rifampicin)Z(Pyrazinamide)E(Ethambutol)/4HR+Interleukin-2 （500000 units daily, subcutaneous injection in the first month）~Dosage: isoniazid 300mg(given once daily),rifampin 450mg(less than 50kg,given once daily) or 600mg(more than 50kg,given once daily),pyrazinamide 1500mg(less than 50kg,given once daily) or 30mg/kg(more than 50kg,given once daily),ethambutol 750mg(less than 50kg,given once daily) or 1000mg(more than 50kg,given once daily)."
62461467|NCT05179681||patients with non-intubated thoracic surgery|
62627396|NCT05518955|NO_INTERVENTION|control group|Participants will receive eye masks during their sleep for consecutive two days or until discharge from ICU.
62627397|NCT02591641|EXPERIMENTAL|Standard of Care First, then Liquicell|Subjects were secured on a standard ambulance stretcher, with a shear and pressure sensors attached to the body. Starting at 0 degrees head-of-bed (HOB) elevation, the ambulance traveled on a closed driver training course accelerating up to 30 mph and decelerating to a stop 5 times. Shear and pressure measurements were taken during the runs. The HOB was then elevated to 15 and 30 degrees respectively, and the procedure repeated. Subjects were asked to rate their comfort at each of the HOB elevations using a 0-10 scale. Following the first set of 15 runs, the course was repeated with the LiquiCell® ASMO.
62627398|NCT02591641|EXPERIMENTAL|Liquicell First, then Standard of Care|Subjects were secured on a standard ambulance stretcher with an anti-shear mattress overlay placed on top of the stretcher, with a shear and pressure sensor attached to the body. Starting at 0 degrees head-of-bed (HOB) elevation, the ambulance traveled on a closed driver training course accelerating up to 30 mph and decelerating to a stop 5 times. Shear and pressure measurements were taken throughout the runs. The HOB was then elevated to 15 and 30 degrees respectively, and the procedure repeated. Subjects were asked to rate their comfort at each of the HOB elevations using a 0-10 scale. Following the first set of 15 runs, the course was repeated without the LiquiCell ASMO.
62627399|NCT03104608|ACTIVE_COMPARATOR|Automatic Self Transcending Meditation|Participants in the ASTM group will undergo training in groups of 10 by certified teachers. Further, the following self-rated scales will be administered by a trained rater at the fourth ASTM session (week 0) as well as at weeks 4, 8, 12, and 24: Time Trade-off (TTO), Visual Function Questionnaire (VFQ-25), the Patient Health Questionnaire (PHQ-9), and Generalized Anxiety Disorder (GAD-7).
62852929|NCT05262062|EXPERIMENTAL|Strain Counter Strain Technique|"When general or local pain began to diminish, upper trapezius , levator scapulae and SCM was placed in a position of ease and was held for approximately 20 to 30 seconds.~Moderate digital pressure was applied to the identified MTrP as participants rated their level of pain on a scale ranging from 1 to 10.3. Ease was defined as the point at which a reduction in pain of at least 70% was achieved.Once the position of ease was identified, it was held for 20 to 30 seconds."
62852930|NCT05262062|EXPERIMENTAL|Muscle Energy Technique,|"After the ease position was maintained for 20 to 30sec an isometric contraction focused on the muscle fibers around the MTrP was performed.~Each isometric contraction was held for 7 to 10 sec and was followed by a soft-tissue stretch for 15 seconds and then relax for 30 seconds. Each stretch was held for 30 seconds, and it was repeated 3 times during the treatment session.~3. Treatment was performed on the 3 most painful areas between the upper border of the upper trapezius muscle, the SCM, the levator scapulae, and the SC muscle."
62852931|NCT05262062|EXPERIMENTAL|Integrated Neuromuscular Inhibition Technique|"1. Group c will receive Combination of exercise (strain counter strain , muscle energy \& ischemic compression. In ischemic compression patient will receive compression,2. After MTrPs identification, 3. Ischemic compression was applied in an intermittent manner for up to 2 minutes for each MTrP.~4. The pincer grasp (for the trapezius muscle and SCM) or direct digital pressure (for the levator scapulae and SC muscle) was used with the patients in either the supine position or sitting upright."
62063127|NCT02276066|ACTIVE_COMPARATOR|Discharged prior to 14 days|The group of patients were discharged before 14 days. GFR assessment at time of discharge and again at 1 year follow up.
62063128|NCT05515614|ACTIVE_COMPARATOR|Standard Fortification|Mother's breast milk will be fortified using Enfamil Liquid Human Milk Fortifier (LHMF) as per standard feeding protocol defined by LLUCH NICU.
62063129|NCT05515614|EXPERIMENTAL|Targeted Fortification|Mother's breast milk will be fortified with modular additives, namely Amino Acid powder, PolyCal, and safflower oil to meet the individual nutritional needs.
62063130|NCT03743896|NO_INTERVENTION|Control group|No intervention
62063131|NCT03743896|EXPERIMENTAL|Test group|single dose (2g), topical application of Transdermal Glucosamine Cream (containing 10% w/w of glucosamine sulfate)
62461468|NCT04971668|EXPERIMENTAL|Aromatherapy|Designated blend aromatherapy (ginger \& lavender) and patient will be asked to inhale deeply and simulate like chewing gum for 5 minutes.
62627400|NCT03104608|PLACEBO_COMPARATOR|Treatment as Usual|Participants will continue to receive their treatment as usual. The following self-rated scales will be administered by a trained rater at weeks 0, 4, 8, 12 and 24: TTO, VFQ-25, PHQ-9, and GAD-7.
62627401|NCT04468724|EXPERIMENTAL|IMMEDIATE|People who are included in the Immediate Arm receive the Makasi intervention right away or in a six-week time if they are not available on the spot
62627402|NCT04468724|OTHER|DIFFERED|People who are included in the Differed Arm receive the Makasi intervention three months after inclusion
62627403|NCT02232061|EXPERIMENTAL|Fingolimod|Fingolimod 0.5mg/day tablets taken orally.
62627404|NCT05035875||40 COPD patients|all participants were subjected to : history - clinical examination - spirometry - ultrasound evaluation of diaphragmatic function
62627405|NCT05035875||40 healthy individuals|all participants were subjected to : history - clinical examination - spirometry - ultrasound evaluation of diaphragmatic function
62627406|NCT06092034|EXPERIMENTAL|RP-A501|One planned dose of RP-A501 in cohorts of subjects with a confirmed diagnosis of Danon Disease.
62627407|NCT02483988|EXPERIMENTAL|NUsurface Meniscus Implant|All eligible patients will receive the NUsurface® Meniscus Implant.
62627408|NCT02787681|EXPERIMENTAL|NEMO Gauge|Measurement and adjustment of endotracheal tube position by stylet.
62627409|NCT05834127|EXPERIMENTAL|Aerobic exercises|Group A will receive aerobic exercises. Treatment will be given 3 times a week for 1 month. Total number of sessions will be 12
62627410|NCT05834127|ACTIVE_COMPARATOR|Yoga exercises|"Group B will receive yoga. Treatment will be given for 40 min, 3 times a week for 1 month.~Total number of sessions will be 12"
62627411|NCT03097926|ACTIVE_COMPARATOR|Standard BPD-DS|Standard BPD-DS with a 250-cm alimentary limb and 100-cm common channel
62627412|NCT03097926|EXPERIMENTAL|Long alimentary limb BPD-DS|BPD-DS with a 100-cm common channel, a 100-cm biliary limb, the remaining bowel as the strict alimentary channel
62627413|NCT03052920|EXPERIMENTAL|Cochlear Implantation|Cochlear implantation of the poor hearing ear
62627414|NCT03077607|EXPERIMENTAL|Arm A|Subjects will receive a 0.5 mg talazoparib and 100 mg itraconazole.
62627415|NCT03077607|EXPERIMENTAL|Arm B|Subjects will receive 1 mg talazoparib and 600 mg rifampin.
62627416|NCT05515510|ACTIVE_COMPARATOR|Control|"Oral health prevention recommendations (frequency of brushing, technique, diet counselling, fluoride use, etc.) will be provided as usual by the dentist (verbal/oral) according to the current German Ratgeber 2020 (KZBV,2029), which are implemented as standard oral health recommendation at the Department of Preventive and Pediatric Dentistry of Greifswald University.~Parents in the control group will be ask after the intervention, and at the recalls (between 2 and 12 weeks and 3 months), to answer a questionnaire in order to determine their knowledge, behaviour, attitudes and related oral health practices."
62627417|NCT05515510|EXPERIMENTAL|Test|"Oral health recommendations will be provided according to the current German Ratgeber 2020 (KZBV,2029), which are implemented as standard at the Department of Preventive and Pediatric Dentistry of Greifswald University. Test arm receives this information with a digital application (FU-APP) in addition to the established oral health recommendation/instruction according to the current German Ratgeber 2020 (KZBV,2020). After the intervention and at the recalls (between 2 and 12 weeks and 3 months), parents will be asked to answer two questionnaires in order to determine their FU-APP acceptance, knowledge, behaviour, attitudes and related practices."
62627418|NCT03456687|EXPERIMENTAL|Exenatide|This group will receive a weekly Exenatide 2mg injection for one year.
62852932|NCT01352403|OTHER|Psychotherapy-enhanced lifestyle intervention (PELI)|Intensive lifestyle intervention over 12 months including medically supervised dietary counseling and physical activity enhanced by a psychotherapeutic intervention
62627419|NCT02709837|ACTIVE_COMPARATOR|Poorly cooked meat-Good chewing|Meat cooked 10min at 75°C, chewing without appliance
62627420|NCT02709837|ACTIVE_COMPARATOR|Highly cooked meat-Good chewing|Meat cooked 45min at 90°C, chewing without appliance
62627421|NCT02709837|ACTIVE_COMPARATOR|Poorly cooked meat-Bad chewing|Meat cooked 10min at 75°C, chewing with appliance
62627422|NCT02709837|ACTIVE_COMPARATOR|Highly cooked meat-Bad chewing|Meat cooked 45min at 90°C, chewing with appliance
62627423|NCT04620070|NO_INTERVENTION|Conventional|In the Netherlands, out-of-hospital cardiac arrest (OHCA) is managed by paramedics. In this study, in the conventional arm, OHCA is managed by a physician of the Helicopter Emergency Medical Services (HEMS), but without the possibility of prehospital ECPR.
62627424|NCT04620070|EXPERIMENTAL|Intervention group|OHCA managed by the physician of the HEMS team, but with the possibility of prehospital ECPR.
62627425|NCT06478082|EXPERIMENTAL|Children with unilateral Cerebral Palsy|All children have unilateral cerebral palsy and are between 1-18 years old
62627426|NCT03671512|EXPERIMENTAL|Periodontal Structure Repair (PSR)|Periodontal pockets treated with PSR
62627427|NCT03671512|ACTIVE_COMPARATOR|Standard Root Planing (SRP)|Periodontal pockets treated with SRP
62627428|NCT03827694||Patients with possible PIFI|
62627429|NCT06481943||ACS|Adult patients who are undergoing a diagnostic angiography or revascularization procedure for the diagnosis or treatment of ischemia or acute coronary syndrome (ACS). Patients are further classified as having low, medium, and high risk for ACS.
62627430|NCT04437836|EXPERIMENTAL|Control arm|Participants will receive standard treatment of rifampicin
62627431|NCT04437836|EXPERIMENTAL|First High dose|Participants will receive 30mg per kg body weight of rifampicin
62627432|NCT04437836|EXPERIMENTAL|Second high dose|Particpants will receive 40mg per kg body weight of rifampicin
62627433|NCT06508060|EXPERIMENTAL|Tones combined with vibrotactile stimulation|The experimental group will receive treatment consisting of tones combined with vibrotactile stimulation delivered from a haptic wristband.
62627434|NCT06508060|OTHER|Tones alone|The control group will receive treatment consisting of tones alone, without the addition of vibrotactile stimulation from a wristband.
62627435|NCT05013580|EXPERIMENTAL|Open Wound|After horizontal bone grafting, the wound where the graft was attached to the bone will be filled with a type of tissue (the amnion-chorion membrane) taken from a placenta and will be left partially open to heal.
62627436|NCT05013580|ACTIVE_COMPARATOR|Closed Wound|After horizontal bone grafting, the wound where the graft was attached to the bone will be filled with collagen tissue and stitched closed while it heals.
62627437|NCT01133704|ACTIVE_COMPARATOR|sipuleucel-T (APC8015)|
62627438|NCT01133704|PLACEBO_COMPARATOR|Placebo|
62627439|NCT05227118|EXPERIMENTAL|MK-8189|Participants will be assigned to one of the following regimens: Titration 1: 4 mg x 2 tablets Days 1-3; 4 mg x 1 tablet \& 12 mg x 1 tablet Days 4-28 OR Titration 2: 4 mg x 2 tablets Days 1-3; 4 mg x 1 tablet \& 12 mg x 1 tablet Days 4-6; 12 mg x 2 tablets Days 7-28 OR Titration 3: 4 mg x 1 tablet Days 1-3; 4 mg x 2 tablets Days 4-6; 4 mg x 1 tablet \& 12 mg x 1 tablet Days 7-9; 12 mg x 2 tablets Days 10-28.
62627440|NCT05227118|PLACEBO_COMPARATOR|Placebo|Participants will be assigned to one of the following regimens: Titration 1: 2 tablets Days 1-28 OR Titration 2: 2 tablets Days 1-28 OR Titration 3: 1 tablet Days 1-3; 2 tablets Days 4-28.
62627441|NCT04668209|ACTIVE_COMPARATOR|Silmitasertib|Standard of care / supportive care in combination with Silmitasertib (CX-4945)
62627442|NCT04668209|NO_INTERVENTION|Standard of Care|Standard of care / supportive care
62627443|NCT03903250|PLACEBO_COMPARATOR|Sugar|100% soluble in liquid. 4 oz. taken in the morning of testing sessions.
62627444|NCT03903250|EXPERIMENTAL|A-GPC|100% soluble in liquid. 4 oz. taken in the morning of testing sessions.
62627445|NCT03372382|ACTIVE_COMPARATOR|ibuprofen plus acetaminophen|women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen
62627446|NCT03372382|EXPERIMENTAL|ibuprofen plus acetaminophen/hydrocodone|women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen/hydrocodone (Norco)
62627447|NCT00950729|ACTIVE_COMPARATOR|Driving with Running Shoes|
62627448|NCT00950729|ACTIVE_COMPARATOR|Driving with Plaster cast|
62627449|NCT00950729|ACTIVE_COMPARATOR|Driving with Aircast|
62627450|NCT02716779|EXPERIMENTAL|Pegylated Interferon (PEG-IFN) alfa-2a|Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
62627451|NCT02716779|PLACEBO_COMPARATOR|Placebo|Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
62627452|NCT02716779|EXPERIMENTAL|Ribavirin|Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
62627453|NCT02710019|EXPERIMENTAL|Psychoeducational video games|Participants in this group will play the Back to Reality Series video games: (1) Harry's Journey which delivers experiential knowledge about psychosis and marijuana use; (2) Harry's Journal which challenges their understanding of 12 psychiatric symptoms associated with psychosis and (3) the PathwaysToCare Map which uses colourful 3D images and voice-overs to depict actual mental health and addictions services for youth available in Hamilton. These in
62627454|NCT02710019|OTHER|Control video game|The control video game is a spelling/memory quiz involving with themes from pop culture. The control game will not provide any education about mental health and addictions issues It should be noted that all participants will play both sets of games during their initial and only visit. Participants are randomized to determine which game they will play first during this visit. This is not an RCT or a crossover design. There is no follow up or clinical assessments.
62627455|NCT04582201|EXPERIMENTAL|Dosage and Cohorts|"Cohort 1: 100 × 10\^6 iNKT cells; Cohort 2: 300 × 10\^6 iNKT cells; Cohorts 3 to 4: 1000 × 10\^6 iNKT cells~Dosage Frequency and Mode of Administration: agenT-797 will be administered to hospitalized participants as a single intravenous infusion."
62627456|NCT00478712||Families with Hirschsprung Disease|Individuals with Hirschsprung disease and their affected and unaffected relatives.
62627457|NCT06009679|EXPERIMENTAL|Intervention group|The intervention group will include patients with suspected postpartum RPOC that will receive treatment with Misoprostol, 600 microgram SL/PO/PV
62627458|NCT06009679|NO_INTERVENTION|Control group|The control group will include women with suspected postpartum RPOC per ultrasound examination that will undergo conservative follow-up with ultrasound for a period of 6-12 weeks postpartum
62627459|NCT02360488|EXPERIMENTAL|Telerehabilitation Therapy|The Telerehabilitation arm of this study will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During half of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
62852933|NCT01352403|OTHER|Roux-en-Y-gastric bypass (RYGB)|Laparoscopic Roux-en-Y gastric bypass surgery
62852934|NCT00229424|EXPERIMENTAL|1|Lafutidine group
62063132|NCT06285669|EXPERIMENTAL|kinesiotape|Kinesio taping was applied by a single physiotherapist to support the intercostal muscles,and, the diaphragm and facilitatory method was used on the respiratory muscles
62627460|NCT02360488|ACTIVE_COMPARATOR|In-Clinic Therapy|The in-clinic arm of this study will deliver half of the rehabilitation treatment sessions at a study site providing traditional outpatient therapy, continuously supervised by a licensed therapist. The unsupervised therapy sessions will take place in the patient's home, and will be guided by an individualized booklet generated and printed by the Treatment Therapist and distributed to the subject during the first in-clinic therapy visit. The content of the unsupervised therapy sessions will be matched to the same exercise and training components provided during the subject's in-clinic supervised therapy sessions. In addition, at the start of each of the unsupervised sessions, all subjects will receive 5 minutes of stroke education.
62852935|NCT00229424|ACTIVE_COMPARATOR|2|Famotidine group
62852936|NCT00229424|PLACEBO_COMPARATOR|3|Placebo group
62627461|NCT01205880|ACTIVE_COMPARATOR|vectical ointment and clobex spray|patients were assigned to apply vectical ointment first then clobex spray on one target lesion and also apply clobex spray first then vectical ointment on a different target lesion on the opposite side of the body.
62852937|NCT02160041|EXPERIMENTAL|BGJ398|BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
62852938|NCT02323100|ACTIVE_COMPARATOR|Ravicti low dose|Low dose Ravicti® oral liquid at 6ml (6.6 gm) by mouth or gastrostomy tube at 8 am, 5.5 ml (6.05gm) at 4pm and midnight for 7 days.
62852939|NCT02323100|ACTIVE_COMPARATOR|Ravicti high dose|Ravicti® oral liquid at 9ml (9.9 gm)at 8 am and 8.25ml (9.08 gm) at 4pm and midnight for 7 days.
62852940|NCT02323100|PLACEBO_COMPARATOR|Placebo|Matching placebo taken at 8am, 4pm and midnight for 7 days.
62063133|NCT06285669|NO_INTERVENTION|Control|This group didn't take kinesiotape application
62268067|NCT04766307|ACTIVE_COMPARATOR|Control regimen group|"The control group regimen: 2H(Isoniazid)R(Rifampicin)Z(Pyrazinamide)E(Ethambutol)/4HR~Dosage: isoniazid 300mg(given once daily),rifampin 450mg(less than 50kg,given once daily) or 600mg(more than 50kg,given once daily),pyrazinamide 1500mg(less than 50kg,given once daily) or 30mg/kg(more than 50kg,given once daily),ethambutol 750mg(less than 50kg,given once daily) or 1000mg(more than 50kg,given once daily)."
62268068|NCT00143455|EXPERIMENTAL|B|
62268069|NCT00143455|EXPERIMENTAL|A|
62268070|NCT00075504|EXPERIMENTAL|triapine, gemcitabine|Triapine IV over 4 hours followed by gemcitabine IV over 30 minutes on days 1, 8, and 15, repeat every 28 days
62268071|NCT05912842|EXPERIMENTAL|Medical Legal Partnerships|Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff together to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs of PLWH patients. Component 3 includes the provision of legal support through partnership with the Legal Clinic for the Disabled. Upon a positive legal needs screening, the case manager connects the patient to this attorney, at which point the patient, after signing a letter of engagement, becomes a client and can now address the identified legal issue(s) with legal representation.
62451111|NCT06322407|EXPERIMENTAL|Stellate Ganglion Block plus standardized drug treatment group|Besides orally topiramate plus ibuprofen as standardized drug treatment, patients will also receive SGBs plus standardized drug therapy; SGB will be performed once a week for 4 consecutive times in an individual series. The interval of each separate SGB procedure is 1 week. Every time patients with bilateral headache will be administered SGB alternately on each side at an interval of 40 min, and patients with unilateral headache will be administered SGB on the ipsilateral side;
62451112|NCT06322407|ACTIVE_COMPARATOR|standardized drug treatment group|The patients will only receive Topiramate plus ibuprofen as standardized drug treatment according to the guidelines for the treatment of CM.
62451113|NCT03627936|EXPERIMENTAL|Lorcaserin 20 mg manufactured at: Zofingen (A) + Kawashima (B)|Participants will receive a single oral dose of lorcaserin 20 milligram (mg) XR tablets manufactured at Zofingen (A) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Kawashima (B) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.
62451114|NCT03627936|EXPERIMENTAL|Lorcaserin 20 mg manufactured at: Kawashima (B) + Zofingen (A)|Participants will receive a single oral dose of lorcaserin 20 mg XR tablets manufactured at Kawashima (B) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Zofingen (A) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.
62451115|NCT03942523|EXPERIMENTAL|School Children|School children will be administered with behavioral change communication sessions as an intervention
62451116|NCT06526962||Group A|Patients who undergo outpatient hysteroscopic polypectomy using 5Fr bipolar electrode
62451117|NCT06526962||Group B|Patients who undergo outpatient hysteroscopic polypectomy using a conical optical 5Fr fibers for dual wave-length diode laser
62451118|NCT03862248|EXPERIMENTAL|High-Dose Isoniazid|New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg
62451119|NCT03862248|EXPERIMENTAL|High-Dose Rifampicin|New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg
62852941|NCT01386970|ACTIVE_COMPARATOR|HIV-negative|This group was used to compare intracellular ZDV- and 3TC-triphosphate concentrations to the HIV-infected group and in men versus women.
62852942|NCT01386970|ACTIVE_COMPARATOR|HIV-infected|This group was started on ZDV-3TC based therapy. Intracellular ZDV- and 3TC-triphosphate concentrations were compared in men versus women and the HIV-negative group.
62268072|NCT05912842|ACTIVE_COMPARATOR|Standard of Care|Comparison arm health organization will only receive the HIV standard of care (U.S. CDC HIV standard of care) and referral to legal aid.
62268073|NCT01471457|EXPERIMENTAL|Trimo-San group|Pessary wearers are instructed to apply one fingertip (approx 1 tablespoon) of Trimo-San gel inside the vagina or to the pessary (for women removing and cleaning pessary before reinsertion after cleaning) once nightly
62268074|NCT01471457|NO_INTERVENTION|Control group|Pessary wearers are informed on standard care of pessary, which includes topical estrogen application if they are using. Pessary wearers do not use Trimo-San gel
62268075|NCT05875675|EXPERIMENTAL|Drug group|Dietary Supplement: Pioglitazone 30 mg by mouth daily
62852943|NCT03708783|EXPERIMENTAL|No. 10 Lymph Node Dissection group|Patients with locally advanced upper or middle third gastric cancer will receive laparoscopic total gastrectomy and D2 lymphadenectomy with spleen-preserving No.10 lymph node dissections
62627462|NCT04637594|ACTIVE_COMPARATOR|Arm A (immune checkpoint inhibitor)|"CONTINUATION OF ICI TREATMENT:~Patients receive either pembrolizumab intravenously (IV) over 30 minutes on day 1, nivolumab IV over 30 minutes on days 1 and 15, atezolizumab IV over 30-60 minutes on day 1, durvalumab IV over 60 minutes on days 1 and 15, or avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 21 or 42 days for pembrolizumab, every 21 days for atezolizumab, and 28 days for nivolumab, durvalumab, and avelumab in the absence of disease progression or unacceptable toxicity."
62852944|NCT04067570|EXPERIMENTAL|SBRT post operative|"Stereotactic Body Radiotherapy (SBRT) 30 Gy in 5 fractions, once weekly to prostate bed~* / - 25 Gy in 5 fractions, once weekly simultaneously to pelvic lymph nodes~* / - 6-24 months of androgen deprivation therapy (ADT)"
62852945|NCT03614052|EXPERIMENTAL|tamsulosin hydrochloride|Tamsulosin hydrochloride 0,4 mg tablets by mouth per day for 5 days before ureteroscopy
62852946|NCT03614052|PLACEBO_COMPARATOR|Placebo oral tablet|Placebo oral tablets by mouth per day for 5 days before ureteroscopy
62852947|NCT00477516|EXPERIMENTAL|1|
62852948|NCT00576329|PLACEBO_COMPARATOR|A|
62852949|NCT00576329|EXPERIMENTAL|B|
62852950|NCT06365970|EXPERIMENTAL|Niraparib + Dostarlimab|"Niraparib: 300/200 mg daily (weight-based dosing\*)~Dostarlimab: 500 mg Q3 weeks~\*Weight-based dosing: Patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/mcL, the niraparib dose is determined to be 300 mg taken orally once daily continuously in combination with dostarlimab 500 mg every 3 weeks.~Patients weighing \<77 kg (\<170 lbs) OR with a platelet count \<150,000/mcL, the niraparib dosage will be 200 mg taken orally, once daily continuously in combination with dostarlimab 500 mg every 3 weeks (Q3W)"
62852951|NCT05647161|EXPERIMENTAL|Treatment Group|"Participants undergo 1st open heart surgery (first operation), and before closing the chest BAX602 will be sprayed on the surface of the heart and large vessels. Efficacy will be evaluated via adhesiolysis after re-do (2nd) open heart surgery.~Re-do open (2nd) heart surgery will be performed ≥3 month (90 days) to ≤12 months (360 days) after 1st open heart surgery. If the re-do open heart surgery is performed later than 12 months (360 days) after the 1st open heart surgery, serious adverse events should be collected until the end of the clinical trial (at the time of discharge after re-do surgery), all observations and endpoints will be collected, including primary endpoints, items related to secondary endpoints, safety endpoints, and other observational items whenever possible. The participants will be observed for safety up to discharge after re-do open heart surgery (up to 30 days)."
62063134|NCT04821635|EXPERIMENTAL|Rower|Single group of 35 traumatic paraplegic patients meeting the inclusion criteria will benefit from the FES-ROW protocol during 9 months
62451120|NCT03862248|ACTIVE_COMPARATOR|World Health Organisation (WHO) regimen|WHO levofloxacin-strengthened regimen (6EHRZLfx)
62268076|NCT05875675|PLACEBO_COMPARATOR|Control group|Dietary Supplement: Placebo
62268077|NCT02965807|EXPERIMENTAL|Bronchial Thermoplasty|Moderate bronchial asthma patients under the Bronchial Thermoplasty.
62268078|NCT00890565|EXPERIMENTAL|Treatment A: Sancuso® patch|Treatment A: Sancuso® patch (Day 1) and placebo IV (Day 3)
62451121|NCT02583620|OTHER|Emmetropic volunteers|Blood sample
62451122|NCT02583620|OTHER|High myopic volunteers|Blood sample
62451123|NCT03060005|EXPERIMENTAL|primary Sjögren's syndrome|The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.
62451124|NCT03060005|EXPERIMENTAL|secondary Sjögren's syndrome|The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.
62451125|NCT03060005|EXPERIMENTAL|meibomian gland dysfunction|The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.
62451126|NCT03060005|EXPERIMENTAL|control|the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.
62451127|NCT06132646|NO_INTERVENTION|Control group|Patients that had suffered a wrist fracture and are going to receive standard rehabilitation for the wrist.
62451128|NCT06132646|EXPERIMENTAL|Experimental group|Patients that had suffered a wrist fracture and are going to receive standard rehabilitation for the wrist.
62451129|NCT05640453|ACTIVE_COMPARATOR|Pregabalin group|Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.
62451130|NCT05640453|ACTIVE_COMPARATOR|Dexmedetomidine group|Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/h.
62451131|NCT06381063|EXPERIMENTAL|Ketoprofen|Ketoprofen 100 mg twice a day, during 48 after surgery, intravenous administration
62451132|NCT06381063|PLACEBO_COMPARATOR|Placebo|Placebo twice a day, during 48 h after surgery, intravenous administration
62451133|NCT06403865||PLWHIV|People living with HIV-1
62268079|NCT00890565|EXPERIMENTAL|Treatment B: IV Granisetron 10 mcg/kg|Treatment B: placebo patch (Day 1) and granisetron IV (Day 3)
62268080|NCT00890565|PLACEBO_COMPARATOR|Treatment C: Matching placebo patch|Treatment C: placebo patch (Day 1) and placebo IV (Day 3)
62268081|NCT00890565|ACTIVE_COMPARATOR|Treatment D: Oral Moxifloxacin 400 mg|Treatment D: placebo patch (Day 1) and oral moxifloxacin (Day 3).
62268082|NCT05464225|EXPERIMENTAL|COSD|Participants assigned to the COSD, will use the investigational device.
62268083|NCT05464225|ACTIVE_COMPARATOR|SOC|"Tongue depressors are the standard-of-care so the control group will use these instead of the investigational Colorado Oral Strengthening Device."
62451134|NCT05802966||Mindfulness-Based Cognitive Therapy + Treatment as usual|Patients receive Mindfulness-Based Cognitive Therapy (MBCT) and treatment as usual (TAU). Measurements are administered before, half-way and after MBCT.
62451135|NCT05802966||Wait-list control (Treatment as usual)|Patients in the wait-list controlled group receive treatment us usual (TAU) during their waiting-period. After their waiting period, they receive MBCT in a similar fashion compared to the intervention group. Measurements are administered before, half-way and after their waiting period. In addition, a fourth and fifth measurement will be administered half-way and after MBCT.
62451136|NCT01195259||metformin|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
62852952|NCT05647161|ACTIVE_COMPARATOR|Non-Treatment Group|"Participants undergo 1st open heart surgery (first operation) and the chest will be closed without spraying BAX602. Efficacy will be evaluated via adhesiolysis after re-do (2nd) open heart surgery.~Re-do open (2nd) heart surgery will be performed ≥3 month (90 days) to ≤12 months (360 days) after 1st open heart surgery. If the re-do open heart surgery is performed later than 12 months (360 days) after the 1st open heart surgery, serious adverse events should be collected until the end of the clinical trial (at the time of discharge after re-do surgery), all observations and endpoints will be collected, including primary endpoints, items related to secondary endpoints, safety endpoints, and other observational items whenever possible. The participants will be observed for safety up to discharge after re-do open heart surgery (up to 30 days)."
62852953|NCT03065972|ACTIVE_COMPARATOR|Surgical fistula creation from patient's anatomy|Patients randomized to surgical arteriovenous fistula will have a fistula surgically created from their anatomy to be used for hemodialysis access.
62063135|NCT02235363|EXPERIMENTAL|facelift|In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
62063136|NCT03941015||patients with renal desaturation|Patients who underwent a decrease of SrtO2 measurement from the baseline value for more than 20% lasting for more than 60 s.
62268084|NCT03976960|EXPERIMENTAL|Biological collection|"For all the patients include in the study :~samples of blood samples collected before or after surgery but also samples in paraffin-embedded tissue sections.~In parallel to this biological collection, standardized clinical data will be entered into a database"
62451137|NCT01195259||rosiglitazone|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
62451138|NCT00812253|EXPERIMENTAL|Intravenous Insulin|
62451139|NCT00812253|ACTIVE_COMPARATOR|Subcutaneous Insulin|Basal bolus insulin (4 injections per day)
62852954|NCT03065972|ACTIVE_COMPARATOR|Surgical graft implant|Patients randomized to surgical graft, will have a commercially available graft surgically implanted to be used for hemodialysis access.
62852955|NCT03014232|EXPERIMENTAL|SLED-f with HCO dialyzer|Online sustained low-efficiency diafiltration (online SLED-f) using novel high cut-off dialyzer which had larger pore size than standard high-flux dialyzer was assigned as the new intervention to compare the efficacy of cytokine removals with the control arm.
62852956|NCT03014232|ACTIVE_COMPARATOR|SLED-f with HF dialyzer|Online sustained low-efficiency diafiltration (online SLED-f) using standard high-flux dialyzer in septic acute kidney injury patients was assigned as the control group
62451140|NCT05017584|EXPERIMENTAL|Hyperbaric bupivacaine 10.5mg|
62451141|NCT05017584|EXPERIMENTAL|Hyperbaric bupivacaine 12mg|
62451142|NCT05017584|EXPERIMENTAL|Hyperbaric bupivacaine 13.5mg|
62451143|NCT05017584|EXPERIMENTAL|Hyperbaric bupivacaine 15mg|
62852957|NCT02561767|EXPERIMENTAL|MSCs group|"Allogeneic bone marrow-derived mesenchymal stem cells (10\^6/kg) from third party donors is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21.Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.~The third-party MSCs have no similar HLA alleles of kidney donors, and have no HLA alleles specific to preformed anti-HLA antibodies in recipients prior to KTx."
62852958|NCT02561767|PLACEBO_COMPARATOR|Control group|Placebo (saline) is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21. Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.
62852959|NCT03835793||Early-RRSO|"* RRSO before the age of 45 years~* RRSO was done 10 or more years ago"
62852960|NCT03835793||Late-/non-RRSO group|"* Natural menopause ≥ 50 years of age~* No RRSO ≤ age of 55~* No treatment-induced menopause ≤ 50 years of age"
62852961|NCT06180187|ACTIVE_COMPARATOR|Osseo-densification group|
62852962|NCT06180187|ACTIVE_COMPARATOR|Electrical mallet group|
62852963|NCT06179342||Cardiopulmonary healthy|Patients in whom there is no evidence of cardiopulmonary dysfunction in the course of diagnostics
62852964|NCT06179342||Idiopathic pulmonary fibrosis|idiopathic pulmonary fibrosis (IPF), confirmed according to the guidelines
62852965|NCT06179342||Chronic obstructive pulmonary disease|Chronic obstructive pulmonary disease (COPD) with/without emphysema
62852966|NCT06179342||Asthma bronchiale|
62852967|NCT00645450|EXPERIMENTAL|Propranolol|Weekly doses of short and long acting propranolol following recollection of traumatic memory
62852968|NCT00645450|PLACEBO_COMPARATOR|Placebo|Weekly doses of placebo following recollection of traumatic memory
62063137|NCT03941015||patients without renal desaturation|Patients who didn't undergo a decrease of SrtO2 measurement from the baseline value for more than 20% lasting for more than 60 s.
62063138|NCT00710372|EXPERIMENTAL|1|CYT006-AngQb
62063139|NCT00710372|PLACEBO_COMPARATOR|2|
62063140|NCT01001949|EXPERIMENTAL|Wheat Bran Extract|
62063141|NCT01001949|PLACEBO_COMPARATOR|placebo|
62063142|NCT06122220|EXPERIMENTAL|Pre-eclampsia|Subjects admitted with severe pre-eclampsia, based on the criteria by the American College of Obstetricians and Gynecologists (ACOG)
62063143|NCT06122220|ACTIVE_COMPARATOR|Control|Subjects admitted for normal labor, without any criteria of pre-eclampsia
62268085|NCT01968135|PLACEBO_COMPARATOR|Sugar Pill|Placebo Sugar Pill
62268086|NCT01968135|EXPERIMENTAL|Combined Oral Contraceptive Pill|150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
62268087|NCT04003233|EXPERIMENTAL|Spring Distraction System|The SDS device will be implanted during a scoliosis correction operation.
62461469|NCT04971668|EXPERIMENTAL|Gum Chewing|Patients will chew gum (sugar free) and inhale deeply with inert gauze for 5 minutes.
62852969|NCT02791568||Pilot Study|"1. Ultrasound Scan~2. MRI Scan~3. Blood/Urine collection"
62627463|NCT04637594|EXPERIMENTAL|Arm B (immune checkpoint inhibitor)|"DISCONTINUATION OF ICI TREATMENT:~Patients receiving ICI treatment will discontinue ICI treatment within 1 cycle length after randomization. Cycle length is determined by the ICI regimen the patient is receiving at randomization. At disease progression patients may restart the same ICI treatment they were receiving upon randomization at physician discretion."
62627464|NCT00869908||A|
62451144|NCT04078451|EXPERIMENTAL|the experimental group|"The experimental group operated by the left side of laparoscopic cholecystectomy preserving the main cystic artery.~The operation area of cystic artery dissection is moved from the traditional triangular area to the gallbladder neck plane, away from the hepatic duct and hepatic portal.Only the superficial and even more minute branches of the cystic artery were isolated and coagulated."
62852970|NCT02791568||Main Study- Control Group|"1. Ultrasound Scan~2. MRI Scan~3. Blood/Urine collection"
62852971|NCT02791568||Main Study- Study Group|"1. Ultrasound Scan~2. MRI Scan~3. Blood/Urine collection"
62852972|NCT02791568||Main Study- Ferumoxytol Group|"1. Ultrasound Scan~2. MRI Scan~3. Blood/Urine collection~4. Ferumoxtyol Infusion"
62852973|NCT04484571|EXPERIMENTAL|Robotic treatment|Patients receive 4 weeks of elbow rehabilitation treatment provided by the NEEM robotic elbow exoskeleton
62852974|NCT04484571|ACTIVE_COMPARATOR|Conventional treatment|Patients receive 4 weeks of elbow conventional rehabilitation treatment matched in time
62451145|NCT04078451|NO_INTERVENTION|the control group|treated with conventional laparoscopic cholecystectomy cutting the cystic artery
62451146|NCT02679482||Selective laser trabeculoplasty (SLT)|Patients who underwent to Selective laser trabeculoplasty
62852975|NCT05652088|EXPERIMENTAL|Patients with HIV Therapy|Subjects receiving therapies with the potential for HIV cure
62852976|NCT03278704|OTHER|RE training only|RE only - Progressive resistance exercise training only (leg extension, leg step up, chest press and pull down).
62852977|NCT03278704|EXPERIMENTAL|Concurrent RE + HIIT|RE + HIIT - Progressive resistance exercise training (leg extension, leg step up, chest press and pull down) followed by HIIT (10 x 1 min at 90% heart rate maximum).
62852978|NCT02820948|EXPERIMENTAL|Vitamin E ointment application|Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.
62852979|NCT02820948|NO_INTERVENTION|No Vitamin E ointment application|No vitamin E ointment was performed.
62852980|NCT05253391||Patients treated for asthma exacerbation|
62852981|NCT00597896|EXPERIMENTAL|Active pramipexole|Day 1: Random assignment to drug or placebo and dosage starting at 0.125 mg BID, which will be increased every week to a target dose of 1.5 mg/day. Targeted maximum dose of 1.5 mg/day is expected to be reached by week 4, however, dosing will be flexible based upon side effects reported. The maximum dose will be 1.5 mg/day.
62852982|NCT00597896|PLACEBO_COMPARATOR|Placebo pramipexole|Day 1: Random assignment to drug or placebo and dosage starting at 0.125 mg BID, which will be increased every week to a target dose of 1.5 mg/day. Targeted maximum dose of 1.5 mg/day is expected to be reached by week 4, however, dosing will be flexible based upon side effects reported. The maximum dose will be 1.5 mg/day.
62852983|NCT06092944|EXPERIMENTAL|continuous RISS group|Patients were given continuous RISS plane block in addition to patient controlled intravenous analgesia.
62088028|NCT05564182|EXPERIMENTAL|High intensity laser therapy + exercise|HILT will be applied to the patients five times a week for a period of three weeks and one session per day for a total of 15 sessions by a physical therapy technician who is experienced in using a laser device. (BTL-6000 high intensity laser 12 W, Stevenage, Hertfordshire, England). The laser device generates a maximum power of 12 W and emits a wavelength of 1064 nm (Nd: YAG laser). In the HILT group, it will be used in the rotator cuff muscles area in two stages, Phase I and Phase II. For analgesic effect in phase I. Phase II will also be applied for the biostimulation effect. Exercise program was applied in five sessions a week for three weeks, with a total of 15 sessions a day.
62451147|NCT02679482||Pattern laser trabeculoplasty (PLT)|Patients who underwent to Pattern laser trabeculoplasty
62451148|NCT04800653|EXPERIMENTAL|Stellate ganglion block|Before the operation, the left stellate ganglion block was performed, and 0.375% ropivacaine 5ml was injected into the stellate ganglion.
62451149|NCT04800653|NO_INTERVENTION|Control|Do nothing
62451150|NCT02285127|ACTIVE_COMPARATOR|Short nail implant|used to treat pertrochanteric fractures
62451151|NCT02285127|ACTIVE_COMPARATOR|Long nail implant|used to treat pertrochanteric fractures
62451152|NCT04901000||Carotid Endarterectomy under Local Anaesthetic Pre-CABG|Patients that underwent carotid endarterectomy under local anaesthetic prior to coronary artery bypass operations in staged fashion within 6 months.
62627465|NCT06544746||Bone level Implants|Marginal bone loss will be assessed according to the emergence profile in each system of implants. Standardized periapical radiograph that were captured after crown placement on implants will be compared with the new radiographs done after recalling the patient.
62852984|NCT06092944|EXPERIMENTAL|single RISS group|Patients were given single RISS plane block in addition to patient controlled intravenous analgesia.
62852985|NCT06092944|ACTIVE_COMPARATOR|PCIA group|Patients were given patient controlled intravenous analgesia.
62852986|NCT00548184|EXPERIMENTAL|Single Group Assignment|Lapatinib Trastuzumab Endocrine
62852987|NCT03211572|EXPERIMENTAL|Endocrine Therapy|Anastrozole 1 mg (postmenopausal) or tamoxifen 20mg (premenopausal) are to be taken orally each evening and would be started exactly 2 weeks prior to their surgery.
62852988|NCT02840617|EXPERIMENTAL|ICG injection group|ICG will be intravenously administered over a 10 second period immediately after the patient was anesthetized. The fluorescence will be performed during and after the surgery, respectively.
62852989|NCT03399201|ACTIVE_COMPARATOR|General Anesthesia|Standard General Anesthesia will be applied.The change of the pulmonary functions will be evaluated via spirometer.
62852990|NCT03399201|ACTIVE_COMPARATOR|Neuraxial Anesthesia|Neuraxial anesthesia will be applied. The change of the pulmonary functions will be evaluated via spirometer.
62852991|NCT05761717|EXPERIMENTAL|3+3|Neoantigen mRNA Personalised Cancer in combination with Stintilimab Injection. This study is a 3+3 dose escalation design.Participants will receive a total of 6 cycles of PCV every 21 days
62852992|NCT06362733|EXPERIMENTAL|Remote (Telehealth) Intervention Program|
62627466|NCT06544746||Tissue Level Implants|Marginal bone loss will be assessed according to the emergence profile in each system of implants. Standardized periapical radiograph that were captured after crown placement on implants will be compared with the new radiographs done after recalling the patient.
62627467|NCT03581916|EXPERIMENTAL|18F-JNJ-64326067|Participants will receive single intravenous (IV) bolus injection of 18F-JNJ-64326067 on Day 1.
62627468|NCT04091737|EXPERIMENTAL|CSL200|Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734
62627469|NCT05777837|ACTIVE_COMPARATOR|Laparoscopic Excision of Large Cesarean Scar Niche|
62063144|NCT04651400||COVID-19 patients who had received treatment with ATIII|Patient records of patients hospitalised for severe COVID-19 infection until 01.06.2020 that required oxygen therapy will be used to retrospectively gather baseline demographic data (age, gender, height, weight, ethnicity/race, blood group, rhesus factor) and comorbidities. Records will also be used to retrospectively gather information on routine coagulation and laboratory parameters measured as per local protocols (including where available: AT, aPTT, PT, Quick, INR, , fibrinogen, D-dimers, haemoglobin levels, and platelet count), and thromboembolic complications and bleeding events that occurred during the individual observational treatment period. Patients will be grouped into 2 cohorts; those that received treatment with ATIII and those that did not. ATIII was administered as per local guidelines at each institute.
62627470|NCT05777837|ACTIVE_COMPARATOR|Combined Hysteroscopic and Laparoscopic Repair without Excision of Large Cesarean Scar Niche|
62627471|NCT03315455|ACTIVE_COMPARATOR|Arm C (Control): No Prophylaxis, Then Emicizumab|Participants ≥12 years old with hemophilia A (with or without FVIII inhibitors) who are randomized to Arm C will not receive any prophylactic treatment for at least 24 weeks. After 24 weeks, participants will have the opportunity to switch to receive emicizumab prophylaxis at 3 mg/kg QW via SC injection for 4 weeks, followed by 6 mg/kg Q4W until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
62451153|NCT04901000||Carotid Endarterectomy under General Anaesthetic Pre-CABG|Patients that underwent carotid endarterectomy under general anaesthetic prior to coronary artery bypass operations in staged fashion within 6 months.
62451154|NCT04029675|EXPERIMENTAL|Study Group ( High dose vitamin C group )|They will receive 1.5 gm intravenous (IV) Vitamin C in 100 ml dextrose 5% (D5W) administered as an infusion over 30 to 60 minutes every 6 hours daily for 4 days or until ICU discharge.
62852993|NCT03653559|EXPERIMENTAL|"Home meals condition"|The recommendation consists of menus with examples of breakfast, lunch and dinner based on typical preparations plus a prescription of the number of portions of the food groups that provides 1200 kcal with a distribution of 50-60% carbohydrates, 15-20% protein and \< 30% lipids.
62088029|NCT05564182|ACTIVE_COMPARATOR|Exercise only|Exercise program was applied in five sessions a week for three weeks, with a total of 15 sessions a day.
62088030|NCT06696742|EXPERIMENTAL|GC+anti-PD1+Clostridium butyricum|"For Neoadjuvant therapy~* GC: gemcitabine (1.0 g/m2 on days 1 and 8) and cisplatin (70 mg/m2 evenly distributed over days 2 to 4) every 21 days for 3 cycles.~  * PD1: Tislelizumab 200mg every 21 days for 3 cycles. ③Clostridium butyricum: Clostridium Butyricum Tablets, 20mg, twice a day.~For Adjuvant Therapy:~①PD1: Tislelizumab 200mg every 21 days for 1-2 year.~②Clostridium butyricum: Clostridium Butyricum Tablets, 20mg, twice a day."
62268088|NCT04003233|EXPERIMENTAL|Minimal Invasive Deformity Correction system|The MID-C device will be implanted during a scoliosis correction operation.
62268089|NCT03692728||CC children|CC children were registered members of the Childhood Cataract Program of the Chinese Ministry of Health (CCPMOH). All of them were diagnosed with CC by two experienced pediatric ophthalmologists based on a comprehensive evaluation of the onset age (within one year after birth), morphological features of lens opacity, family history, and detailed medical records.
62451155|NCT04029675|ACTIVE_COMPARATOR|Control Group (Daily requirements vitamin C Group )|They will receive standard daily requirements of Vitamin C intravenously which is 75-90 mg in 100 ml dextrose 5% (D5W) administered as an infusion over 30 to 60 minutes daily for 4 days or until ICU discharge
62451156|NCT04281680||Pasireotide|Patients who received pasireotide perioperatively
62451157|NCT04281680||Octreotide|Patients who received perioperative octreotide
62627472|NCT03315455|EXPERIMENTAL|Arm A: Emicizumab Prophylaxis at 1.5 mg/kg QW|Participants ≥12 years old with hemophilia A (with or without FVIII inhibitors) who are randomized to Arm A will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 1.5 mg/kg via SC injection Q4W for at least 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
62852994|NCT03653559|ACTIVE_COMPARATOR|"Healthy meals condition"|"The recommendation consists of the educative graphic tool Eatwell plate plus a prescription of the same number of portions of the food groups for a isocaloric diet with the same macronutrient distribution as the home meals condition."
62852995|NCT00125606|ACTIVE_COMPARATOR|conditioning therapy with 12 Gy TBI / cyclophosphamide 120|
62852996|NCT00125606|EXPERIMENTAL|conditioning therapy with 8 Gy TBI / fludarabine 120|
62852997|NCT02291016|ACTIVE_COMPARATOR|Formoterol via DPI then Formoterol via nebulizer|"Group A: Received Formoterol 12 µg via DPI and placebo via nebulizer at treatment visit #1, and Formoterol 20 µg (solution form) via nebulizer and placebo via DPI at treatment visit 2.~Placebo: The placebo used will be sterile, preservative free, normal saline for nebulizer inhalation and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2."
62852998|NCT02291016|ACTIVE_COMPARATOR|Formoterol via nebulizer then Formoterol via DPI|"Group B: Received Formoterol 20 µg (solution form) via nebulizer and placebo via a DPI at treatment visit #1, and Formoterol 12 µg via a DPI with placebo via nebulizer at treatment visit 2.~Placebo: The placebo used will be sterile, preservative free, normal saline for nebulizer inhalation and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2."
62088031|NCT06696742|ACTIVE_COMPARATOR|GC+anti-PD1|"For Neoadjuvant therapy~①GC: gemcitabine (1.0 g/m2 on days 1 and 8) and cisplatin (70 mg/m2 evenly distributed over days 2 to 4) every 21 days for 3 cycles.~②PD1: Tislelizumab 200mg every 21 days for 3 cycles.~For Adjuvant Therapy:~①PD1: Tislelizumab 200mg every 21 days for 1-2 year."
62451158|NCT04281680||Control|Patients who received no additional medication in the timely cohort
62627473|NCT03315455|EXPERIMENTAL|Arm B: Emicizumab Prophylaxis at 6 mg/kg Q4W|Participants ≥12 years old with hemophilia A (with or without FVIII inhibitors) who are randomized to Arm B will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 6 mg/kg via SC injection Q4W for at least 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
62627474|NCT03315455|EXPERIMENTAL|Arm D: Emicizumab Prophylaxis at 1.5 mg/kg QW|Participants \<12 years old with hemophilia A and FVIII inhibitors who are enrolled to Arm D will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 1.5 mg/kg via SC injection QW for at least 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
62627475|NCT04966650|EXPERIMENTAL|Intervention group|For the intervention group, participants will receive a 5-mins brief nursing advice incorporating with Social Cognitive Theory (SCT). The protocol is about the relationship between exercise and mental health, the advantages of increase physical activity and regular exercise, and highlight the consequence if not deal with the depressive symptoms. At the 2nd month, participants will be assessed their depression symptoms via questionnaire, followed up their progress of physical activity changes and given a booster intervention. At 6th months, subjects will be assessed their depression symptoms and the level of physical activity changes via questionnaire.
62627476|NCT04966650|NO_INTERVENTION|Control Group|A wellbeing leaflet from CHP will be provided to each participant. At the 2nd month, subjects will be assessed their depression symptoms via questionnaire, followed up their progress of physical activity changes and given another wellbeing leaflets. At 6th months, subjects will be assessed their depression symptoms the level of physical activity changes via questionnaire.
62627477|NCT04420169||PRE implementation communication protocol|
62627478|NCT04420169||POST implementation communication protocol|
62627479|NCT06103071|ACTIVE_COMPARATOR|Sweeping group|Sweeping group include patients in which membrane sweeping started from 37 weeks and performed weekly till 40 weeks. Intervention is the sweeping of membranes from 37 weeks of gestational amenorrhea.
62852999|NCT01018810|EXPERIMENTAL|180 mg LY2525623|
62853000|NCT01018810|PLACEBO_COMPARATOR|Intravenous Placebo|
62627480|NCT06103071|NO_INTERVENTION|Non sweeping group|Non sweeping group include patients in which no sweeping of membranes done. No intervention done.
62627481|NCT04441788|PLACEBO_COMPARATOR|Placebo|Single-dose of placebo was administered by oral inhalation via nebulizer, once every week for up to 13 weeks.
62627482|NCT04441788|EXPERIMENTAL|ION-827359 37.5 milligrams (mg)|Single-dose of ION-827359 37.5 mg was administered by oral inhalation via nebulizer, once every week for up to 13 weeks.
62627483|NCT04441788|EXPERIMENTAL|ION-827359 75 mg|Single-dose of ION-827359 75 mg was administered by oral inhalation via nebulizer, once every week for up to 13 weeks.
62627484|NCT04555707|EXPERIMENTAL|Otezla + Enstilar|
62627485|NCT04694976||Sickle cell disease children from Lyon, France|Sickle cell disease children, followed in IHOPe (Institut d'Hématologie et d'Oncologie Pédiatrique) center, consulting their referring haematologist doctor or in emergency ward, with prescribed blood sample.
62853001|NCT01018810|PLACEBO_COMPARATOR|Subcutaneous Placebo|
62853002|NCT01018810|EXPERIMENTAL|3 mg LY2525623|
62853003|NCT01018810|EXPERIMENTAL|10 mg LY2525623|
62853004|NCT01018810|EXPERIMENTAL|30 mg LY2525623|
62088032|NCT05665309|EXPERIMENTAL|With 3D anatomical model|Surgery prepared using 3D anatomical model of the aneurysm
62451159|NCT01686841|EXPERIMENTAL|Fat Reduction|
62853005|NCT01018810|EXPERIMENTAL|90 mg LY2525623|
62451160|NCT05147051|EXPERIMENTAL|Reamberin group|Patients receive the investigational treatment (meglumine sodium succinate), 500 ml intravenously every 8 hours (up to 6 infusions).
62451161|NCT05147051|PLACEBO_COMPARATOR|Placebo|Patients receive a Placebo (Ringer's solution), 500 ml intravenously every 8 hours (up to 6 infusions).
62451162|NCT03012477|EXPERIMENTAL|cisplatin + AZD1775|"Treatment will consist of one cycle of cisplatin monotherapy (cisplatin 75 mg/m2 IV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days(1 cycle) later.~AZD1775 will be administered 200 mg as twice daily oral dosing predetermined dosing schedule, in combination with Cisplatin predetermined dosage every 21 days.~At least 10 patients will undergo a research biopsy within 5-48 hours after beginning cisplatin (Cycle 1 Day 1) and then again within 5-8 hours after the last dose of AZD1775 in cycle 2 (Cycle 2 Day 3)."
62853006|NCT01012219|EXPERIMENTAL|Period 1|In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).
62853007|NCT01012219|EXPERIMENTAL|Period 2|In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).
62627486|NCT06552403|EXPERIMENTAL|Modified 5:2 IF diet|The modified 5:2 IF diet involves 2 nonconsecutive fasting days (25%-30% of the total required daily energy intake based on ideal body weight) and 5 days of habitual intake (limited total energy intake according to ideal body weight) per week, as well as a 4-week run-in period and a minimum of 6,000 steps of physical activity per day.
62627487|NCT02946892|EXPERIMENTAL|Carvedilol|Study participants will receive carvedilol for 12 weeks
62627488|NCT02946892|EXPERIMENTAL|Placebo|Study participants will receive placebo (sugar pill) for 12 weeks
62627489|NCT05951361|ACTIVE_COMPARATOR|Kenacourt-A Orabase|"the patients in this group received steroid therapy Kenacourt-A Orabase three times daily for 4 weeks.~antifungal drug miconazole oral gel once daily for 1 week"
62627490|NCT05951361|ACTIVE_COMPARATOR|980nm Diode Laser|the patients received 980 nm diode laser treatment 300 mW, non-contact mode up to 10 sessions
62627491|NCT01951573|OTHER|Delefilcon A MF, then AOAMF|Delefilcon A multifocal contact lenses first, followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.
62627492|NCT01951573|OTHER|AOAMF, then Delefilcon A MF|Lotrafilcon B multifocal contact lenses first, followed by delefilcon A multifocal contact lenses. Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.
62627493|NCT03864523|EXPERIMENTAL|XAMNPIO|Pioglitazone 15 mg tablets 2/day during 2 years
62627494|NCT01369745|ACTIVE_COMPARATOR|Prednisolone|Prednisolone 2.7 mg daily for 12 weeks
62627495|NCT01369745|ACTIVE_COMPARATOR|dipyridamole|Dipyridamole 360 mg daily for 12 weeks
62627496|NCT01369745|ACTIVE_COMPARATOR|prednisone|Prednisone 5 mg daily for 12 weeks
62627497|NCT01369745|EXPERIMENTAL|Z102 (2.7/360)|Prednisolone 2.7 mg plus dipyridamole 360 mg daily for 12 weeks
62088033|NCT05665309|NO_INTERVENTION|Without 3D anatomical model|Surgery prepared without 3D anatomical model of the aneurysm (routine care)
62268090|NCT03692728||NV children|NV children were recruited from the Optometry Department of the ZOC as the control group. NV was defined as BCVA ≥0.3 (log MAR) in children between 3-5 years old or BCVA ≥0.15 (log MAR) in children older than 5 years. Children with strabismus and high refractive error (myopia or hyperopia: \>6.0 Diopters; astigmatism: \>3.0 Diopters) were excluded from NV group.
62627498|NCT01369745|PLACEBO_COMPARATOR|placebo|Placebo daily for 12 weeks
62627499|NCT02253888|EXPERIMENTAL|TPV/r - Room condition|
62627500|NCT02253888|EXPERIMENTAL|TPV/r - Refrigerated conditions|
62853008|NCT01012219|EXPERIMENTAL|Period 3|
62627501|NCT01297543|EXPERIMENTAL|Consolidation Group A|Low dose CLT-008 (human myeloid progenitor cells)
62627502|NCT01297543|EXPERIMENTAL|Consolidation Group B|Intermediate dose CLT-008 (human myeloid progenitor cells)
62627503|NCT01297543|EXPERIMENTAL|Consolidation Group C|Intermediate dose CLT-008 (human myeloid progenitor cells), no G-CSF
62627504|NCT01297543|EXPERIMENTAL|Consolidation Group D|High dose CLT-008 (human myeloid progenitor cells)
62627505|NCT01297543|ACTIVE_COMPARATOR|Induction Group A1 (cytarabine 7+3)|G-CSF
62627506|NCT01297543|EXPERIMENTAL|Induction Group A2 (cytarabine 7+3)|Intermediate dose CLT-008 (human myeloid progenitor cells)
62627507|NCT01297543|EXPERIMENTAL|Induction Group A3 (cytarabine 7+3)|High dose CLT-008 (human myeloid progenitor cells)
62627508|NCT01297543|ACTIVE_COMPARATOR|Induction Group B1 (cytarabine HIDAC)|G-CSF
62853009|NCT00475306|ACTIVE_COMPARATOR|Metoclopramide 20+diphenhydramine|Metoclopramide 20 mg + diphenhydramine, delivered intravenously over 15 minutes
62088034|NCT06133127|OTHER|single group assignment|Same assessments for all patients.
62088035|NCT04004793|EXPERIMENTAL|Dapagliflozin plus intensive lifestyle intervention|The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.
62088036|NCT04004793|PLACEBO_COMPARATOR|Placebo plus intensive lifestyle intervention|The treatment of placebo will be initiated and maintained at 10mg every morning until the completion of the study.
62268091|NCT04052659|EXPERIMENTAL|Treatment (sintilimab,chidamide and azacitidine)|"Sintilimab: 200 mg IV, Q3W, d1~Chidamid: 30 mg PO, BIW, d1, d4~Azacidine: 100 mg SC, Q3W, d1-7"
62268092|NCT04034160|EXPERIMENTAL|burger consumption group|Each participant will consume a burger with a whole wheat bun, lettuce, tomatoes, and vegan mayonnaise (free of cholesterol) for one meal. The burger patty will be 4 ounces. The beef patty (Beef Patty Chuck) will be 80% lean and 20% fat.
62627509|NCT01297543|EXPERIMENTAL|Induction Group B2 (cytarabine HIDAC)|Intermediate dose CLT-008 (human myeloid progenitor cells)
62627510|NCT01297543|EXPERIMENTAL|Induction Group B3 (cytarabine HIDAC)|High dose CLT-008 (human myeloid progenitor cells)
62853010|NCT00475306|ACTIVE_COMPARATOR|Metoclopramide 20+placebo|Metoclopramide 20 mg + placebo, delivered intravenously over 15 minutes
62853011|NCT00475306|ACTIVE_COMPARATOR|Metoclopramide 10 + placebo|Metoclopramide 10mg + placebo, delivered intravenously over 15 minutes
62853012|NCT00475306|ACTIVE_COMPARATOR|Metoclopramide 10+diphenhydramine|Metoclopramide 10 mg + diphenhydramine 25 mg, delivered intravenously over 15 minutes
62627511|NCT05024656|EXPERIMENTAL|AmnioExcel Plus Amniotic Membrane + Standard of Care|"AmnioExcel Plus is a human placental-based tissue consisting of dehydrated, tri-layer Placental (Amnion/Chorion/Amnion) Allograft Membrane (T-PAM) layers. T-PAM is a minimally manipulated placental membrane product made from tissues donated by pre-screened mothers during planned C-sections and is intended for use as a wound covering in the homologous use for the repair, reconstruction and replacement of skin at the direction of a physician. AmnioExcel Plus contains Human Cellular and Tissue Based Products (HCT/P) as defined by US FDA 21 CFR Part 1271.~Standard of care includes the following:~* Coban™~* Conforming gauze~* Optifoam® non-adhesive dressing~* Xtrasorb® for highly exudated wounds~* Cotton Gauze~* Normal saline (liquid or gel)~* Non-adhering dressings~* Steristrips~* Offloading boot, as appropriate"
62627512|NCT05024656|ACTIVE_COMPARATOR|Standard of Care|"* Coban™~* Conforming gauze~* Optifoam® non-adhesive dressing~* Xtrasorb® for highly exudated wounds~* Cotton Gauze~* Normal saline (liquid or gel)~* Steristrips~* Offloading boot, as appropriate"
62853013|NCT02125591|EXPERIMENTAL|Active PoNS CN-NINM|Active CN-NINM PoNS - Active cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
62853014|NCT02125591|SHAM_COMPARATOR|Sham PoNS CN-NINM|Sham CN-NINM PoNS - Sham cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
62853015|NCT00845091|EXPERIMENTAL|Exercise|moderate-intensity, low-impact, supervised, aerobic exercise
62853016|NCT00845091|ACTIVE_COMPARATOR|Heart Healthy Education|Educational topics on heart health (e.g., nutrition, smoking, sleep)
62853017|NCT02173093|EXPERIMENTAL|Treatment (IL-2, GM-CSF, GD2Bi-aATC)|Patients receive IL-2 SC daily on days -2 to 35, GM-CSF SC twice weekly x 5 weeks, and GD2Bi-aATC IV over 30 minutes twice weekly x 4 weeks for a total of 8 infusions. Laboratory evaluations of immune responses are obtained prior and after immunotherapy.
62853018|NCT00439738|EXPERIMENTAL|valsartan/HCTZ|
62853019|NCT00439738|ACTIVE_COMPARATOR|HCTZ +Amlodipine|
62853020|NCT02611596|EXPERIMENTAL|Ranolazine|Subjects will take one 500mg tablet twice daily (500mg BID) for seven days and then increase to two 500mg tablets twice daily (1000mg BID) for the remainder of the study, for a total of 24 weeks. Subjects taking moderate CYP3A4 inhibitors will not participate in upward titration and will remain on 500mg tablet twice daily (500mg BID) for the duration of the trial.
62853021|NCT02611596|PLACEBO_COMPARATOR|Placebo|Subjects will take one placebo tablet (identical to the 500mg Ranolazine tablet) twice daily (500mg BID) for seven days and then increase to two 500mg tablets twice daily (1000mg BID) for the remainder of the study, for a total of 24 weeks. Subjects taking moderate CYP3A4 inhibitors will not participate in upward titration and will remain on 500mg tablet twice daily (500mg BID) for the duration of the trial.
62853022|NCT05594745|ACTIVE_COMPARATOR|Xiidra|one drop BID for 9 months
62853023|NCT05594745|ACTIVE_COMPARATOR|Systane|One drop QID for 9 months
62853024|NCT01224951|ACTIVE_COMPARATOR|Qvar 100|"Patients will be randomized to receive either the active arm (3/4) or a SABA as rescue medication (1/4). The patient will be asked to take Qvar 100 (2puffs) in the morning and in the evening.~Daily dose (400 microgram)."
62853025|NCT01224951|NO_INTERVENTION|Control|Patients are allowed to use their SABA as rescue medication only. During the last 4 weeks, the patients will receive 400 microgram of Qvar.
62853026|NCT03117452|EXPERIMENTAL|visual training condition|Participants in the visual training condition will participate in the visual training (VT) group, during which they will complete computerized visual training that targets low- and mid-level visual processes. Each group will include a maximum of 3 participants and will meet 3 times a week over a period of 12-14 weeks.
62853027|NCT03117452|NO_INTERVENTION|control condition|Participants assigned to the control condition will receive standard Partial Hospital care without visual training.
62853028|NCT02883257|EXPERIMENTAL|Cognitive Behavioral Therapy|"* 20 individual 60-minute appointments over the course of 16 weeks~* Consistent with Beck, Rush, Shaw, and Emery (1979)"
62853029|NCT05785819|EXPERIMENTAL|VLX-1005|VLX-1005 200 mg given every 12 hours by intravenous infusion over 1 hour.
62853030|NCT05785819|PLACEBO_COMPARATOR|Placebo|Placebo given every 12 hours by intravenous infusion over 1 hour.
62853031|NCT00946140||Patients with ovarian cancer currently undergoing treatment|All of the patients will be treated per their treatment protocols by their physicians and they will be referred to this study for the DCE-MRI scans at baseline, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
62853032|NCT05677685|ACTIVE_COMPARATOR|Investigational Device|
62853033|NCT05677685|PLACEBO_COMPARATOR|Placebo|
62853034|NCT03196609|EXPERIMENTAL|Cohorte|"This cohort will consist of patients as described below:~* 15 patients with non-small cell lung cancer (NSCLC)~* 10 patients with hepatocellular cancer:~* 10 patients with colorectal cancer~* 10 patients with breast cancer~* 10 patients with prostate cancer~* 10 patients with glioblastoma"
62853035|NCT03309033||Observational (questionnaire, biospecimen collection)|Patients complete a short questionnaire regarding risk factors for HPV infection and undergo collection of blood samples for testing HPV16 and HPV18 levels on study.
62853036|NCT00640211||PIPET B|Participants in this study will be health care and other essential workers receiving long term neuraminidase inhibitor prophylaxis.
62853037|NCT00689117|EXPERIMENTAL|1|CT Gel
62853038|NCT00689117|ACTIVE_COMPARATOR|2|Clindamycin Gel (clindamycin)
62853039|NCT00689117|ACTIVE_COMPARATOR|3|Tretinoin Gel (tretinoin)
62853040|NCT00689117|PLACEBO_COMPARATOR|4|Vehicle Gel
62627513|NCT02422004|ACTIVE_COMPARATOR|Control|This constitutes the currently accepted regime and is therefore consider the control group (CTRL) with early range of motion and early weight bearing. The control group was allowed to have partial weight-bearing from day 0 and full weight-bearing from week 4. Furthermore, they were instructed in tendon strain exercise identical with the range of motion group.
62627514|NCT02422004|EXPERIMENTAL|Range of motion|Early range of motion and delayed weight bearing (ROM). The range of motion group was restricted completely from weight-bearing until week 6, allowed partial weight-bearing after 6 weeks and full weight-bearing after 8 weeks. In addition to this, the patients were instructed to perform tendon strain exercises, five times a day, from week 2. The exercises were performed by removing the foot from the brace and then perform light dorsal ankle movement, 25 repetitions/time, when sitting on a table.
62627515|NCT02422004|EXPERIMENTAL|Immobilization|Delayed weight-bearing or range of motion (IMMOB). The immobilization group was restricted completely from weight-bearing until week 6, allowed partial weight-bearing after 6 weeks and full weight-bearing after 8 weeks.
62627516|NCT01156909|EXPERIMENTAL|Rituximab|Rituximab induction using two infusions (500mg/m2, max 1000 mg) two weeks apart, followed by maintenance Rituximab infusions (500 mg/m2, max 1000 mg) after 3, 6, 10 and 15 months.
62627517|NCT05348044|EXPERIMENTAL|Res-ET intervention|Res-ET will include a 6-week remote (Zoom) home-group-delivered IMST exercise intervention of approximately 20 minutes a session consisting of a warmup and 3 bouts of 5 sets x 6 inspiratory maneuvers using an IMST training device (POWERBreathe) and 1 min recovery between each set (inspiration to rest ratio taken from Craighead 2021). The intensity of the IMST maneuvers will begin at 40% of MIP during week one, 50% of MIP during week two, and 60% of MIP during weeks three through six. Participants will remotely perform Res-ET intervention 4 times per week in a group setting (Zoom). During the intervention multiple opportunities to engage in a group training session will be available and a recording of an IMST session will be available for viewing if the participant is unable to attend a live group session. Each week the CEP will record participation rates and accelerometry data in REDcap. Group conversations and motivation will be encouraged during live training sessions.
62627518|NCT01344759|ACTIVE_COMPARATOR|Propofol|
62627519|NCT01344759|ACTIVE_COMPARATOR|Dexmedetomidine|
62268093|NCT04034160|ACTIVE_COMPARATOR|vegetarian burger consumption group|Each participant will consume a burger with a whole wheat bun, lettuce, tomatoes, and vegan mayonnaise (free of cholesterol) for one meal. The burger patty will be 4 ounces. The vegetarian patty (Impossible Burger) will be 18% fat.
62627520|NCT06111898||High-risk infants|
62627521|NCT06111898||Typically developing infants|
62627522|NCT04121676|EXPERIMENTAL|2-Week Monotherapy with AGEN2373|3+3 Dose escalation of AGEN2373 administered by IV.
62627523|NCT04121676|EXPERIMENTAL|3-Week Monotherapy with AGEN2373|3+3 Dose escalation of AGEN2373 administered by IV.
62627524|NCT04121676|EXPERIMENTAL|4-Week Monotherapy with AGEN2373|3+3 Dose escalation of AGEN2373 administered by IV.
62627525|NCT04121676|EXPERIMENTAL|Combination Therapy with 3-week AGEN2373 Monotherapy Lead-In Combination with 6-week Botensilimab|3+3+3 Dose escalation of AGEN2373. AGEN2373 and botensilimab administered by IV.
62627526|NCT04121676|EXPERIMENTAL|Combination Therapy with 3-week AGEN2373 in combination with 6-week Botensilimab|3+3+3 Dose escalation of AGEN2373. AGEN2373 and botensilimab administered by IV.
62853041|NCT01454778|EXPERIMENTAL|Paclitaxel|
62853042|NCT05519592|EXPERIMENTAL|Ropivacaine|Ropivacaine intramuscular injection
62627527|NCT01779063|EXPERIMENTAL|web based multimedia intervention|interactive,web based multimedia intervention
62853043|NCT05519592|PLACEBO_COMPARATOR|Control|Sodium Chlorure intramuscular injection
62627528|NCT01779063|ACTIVE_COMPARATOR|education booklet|printed educational booklet
62627529|NCT00665483|EXPERIMENTAL|1|Skin Prick Test
62853044|NCT05659537|EXPERIMENTAL|Dulaglutide|Participants will receive dulaglutide subcutaneously (SC)
62853045|NCT01068964|EXPERIMENTAL|0.03% Bimatoprost/0.5% Timolol in Same Bottle|Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
62853046|NCT01068964|ACTIVE_COMPARATOR|0.03% Bimatoprost and 0.5% Timolol in Separate Bottles|Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
62853047|NCT00185198|ACTIVE_COMPARATOR|Arm 1|
62853048|NCT00185198|PLACEBO_COMPARATOR|Arm 2|
62853049|NCT02356900|EXPERIMENTAL|Hyperoxic, Hyperbaric|Hyperoxic hyperbaric interval exercise training Six sessions of 30 min.of High-intensity interval training completed on a 3-times a week basis at 1.4 ATA of oxygen in a hyperbaric chamber.
62853050|NCT02356900|SHAM_COMPARATOR|Normoxic, Normobaric|Normoxic, normobaric, interval exercise training Six sessions of 30 min.of High-intensity interval training completed on a 3-times a week basis.
62853051|NCT02559700|EXPERIMENTAL|Brain training programme|Participants will complete a package of online brain training games focusing on reasoning and problem solving. The intervention will be accessed via a computer. There is no minimum or maximum dosage but participants will be recommended to complete the intervention five times a week. The package takes approximately 10 minutes to complete, depending on individual performance.
62088037|NCT00674492||Hepatitis C patients|patients who initiated antiviral treatment for hepatitis C
62268094|NCT05315921|EXPERIMENTAL|OsrhAAT 1 mg/kg IV|
62268095|NCT05315921|EXPERIMENTAL|OsrhAAT 3 mg/kg IV|
62627530|NCT05456243|EXPERIMENTAL|Low Dose Group|Adult kidney transplant recipients with subclinical rejection (biopsy-proven antibody-mediated and/or cellular rejection, including borderline rejection) will be administered one low dose of allogeneic A-MSC.
62853052|NCT01296399||Bare metal stent|patients, with a patent previously deployed intra coronary bare metal stent, receiving intra coronary bare metal stent, for de-novo stenosis
62853053|NCT01296399||Drug eluting stent|patients, with a patent previously deployed intra coronary bare metal stent, receiving intra coronary drug eluting stent, for de-novo stenosis
62853054|NCT00915499|ACTIVE_COMPARATOR|ASV mode|
62853055|NCT00915499|ACTIVE_COMPARATOR|CPAP mode|
62853056|NCT04332861||Prospective observational cohort|"For data analysis, the cohort will be subdivided as follows:~* Identification and Validation cohorts~* Patients with and without complicating factors~* Patients with and without measured inflammatory marker levels"
62063145|NCT04651400||COVID-19 patients who had not received treatment with ATIII|Patient records of patients hospitalised for severe COVID-19 infection until 01.06.2020 that required oxygen therapy will be used to retrospectively gather baseline demographic data (age, gender, height, weight, ethnicity/race, blood group, rhesus factor) and comorbidities. Records will also be used to retrospectively gather information on routine coagulation and laboratory parameters measured as per local protocols (including where available: AT, aPTT, PT, Quick, INR, , fibrinogen, D-dimers, haemoglobin levels, and platelet count), and thromboembolic complications and bleeding events that occurred during the individual observational treatment period. Patients will be grouped into 2 cohorts; those that received treatment with ATIII and those that did not. ATIII was administered as per local guidelines at each institute.
62627531|NCT05456243|EXPERIMENTAL|High Dose Group|Adult kidney transplant recipients with subclinical rejection (biopsy-proven antibody-mediated and/or cellular rejection, including borderline rejection) will be administered one high dose of allogeneic A-MSC.
62063146|NCT04651400||Non-COVID-19 patients who had received treatment with ATIII|"A control group will be used to gather comparative data in non-COVID-19 patients.~Data will be gathered retrospectively from patient records for severely ill patients who received oxygen therapy for non-COVID-19 infection until end 2019 (31.12.2019). Control group will also be grouped into 2 cohorts for those having received/ having not received ATIII treatment."
62853057|NCT01784822||Zenapro™ Hybrid Hernia Repair Device|Device to be used to reinforce or bridge the abdominal wall for the repair of ventral hernias.
62853058|NCT02291653|EXPERIMENTAL|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
62853059|NCT02291653|EXPERIMENTAL|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
62853060|NCT03868527||Hematological diseases|Cohort of patients followed for lymphoid malignant hemopathy in Lyon Sud Hospital
62853061|NCT02218892||Juvenil Idiopathic Arthritis|The group consists of children age 7-14 with an diagnosis of active Juvenile Idiopathic Arthritis.
62853062|NCT05738681|EXPERIMENTAL|NAC group|Tuberculosis patients who had standard regimen treatment, non-HIV, no severe co-morbidity, no chronic hepatitis B or C using NAC-long 1,200 mg/day for 8 weeks (NAC long group). Genetic test (acetylator status of NAT2), CBC, Cr, coagulogram were assessed at baseline. LFT were assessed at baseline, 2 weeks, 8 weeks and 24 weeks.
62853063|NCT05738681|NO_INTERVENTION|Non-NAC group|Tuberculosis patients who had standard regimen treatment, non-HIV, no severe co-morbidity, no chronic hepatitis B or C were using anti-TB alone (non-NAC group). Genetic test (Acetylator status of NAT2), CBC, Cr, coagulogram were assessed at baseline. LFT were assessed at baseline, 2 weeks, 8 weeks and 24 weeks.
62853064|NCT05382767|EXPERIMENTAL|CKDB-501A|
62853065|NCT05382767|ACTIVE_COMPARATOR|Botox®|
62853066|NCT02102711|EXPERIMENTAL|vitaminA drops|3000 IU/kg/die of Vitamin A oral drops, for 4 weeks.
62853067|NCT02102711|NO_INTERVENTION|control|Control of matched infants not supplemented with vitamin A ( beyond standard/routine needed)
62853068|NCT03029988|EXPERIMENTAL|Cohort 1|Subjects will receive 50 µg tilmanocept radiolabeled with 2.0 millicuries (mCi) Tc99m through a single IV injection.
62853069|NCT03029988|EXPERIMENTAL|Cohort 2|"Subjects will receive 200 µg tilmanocept radiolabeled with 2.0 mCi Tc99m through a single IV injection.~If it was determined that additional enrollment would not provide meaningful data, for example no metastatic liver lesions were visualized by Tc 99m tilmanocept for any of the subjects in the cohort, enrollment into Cohort 2 would begin and 3 subjects would be enrolled followed by a review of the imaging and safety data."
62853070|NCT02862353||patients with thrombocytopenia drug|
62853071|NCT04134546|EXPERIMENTAL|group with biliary injury|group for Early versus late intervention after biliary tract injury post cholecystectomy
62063147|NCT04651400||Non-COVID-19 patients who had not received treatment with ATIII|"A control group will be used to gather comparative data in non-COVID-19 patients.~Data will be gathered retrospectively from patient records for severely ill patients who received oxygen therapy for non-COVID-19 infection until end 2019 (31.12.2019). Control group will also be grouped into 2 cohorts for those having received/ having not received ATIII treatment."
62627532|NCT02595385|ACTIVE_COMPARATOR|RAP|Retrograde Autologous Prime of the bypass circuit. To remove 500-900ML of fluid.
62853072|NCT04273906|EXPERIMENTAL|End-range mobilization|End-range mobilization performed in end-position of the tibiofemoral joints' flexion and extension for 2\*3 min
62853073|NCT04273906|PLACEBO_COMPARATOR|Placebo|Hands-on treatment technique performed in end-range of the tibiofemoral joints' flexion and extension for 2\*3 min
62268096|NCT05315921|EXPERIMENTAL|OsrhAAT 10 mg/kg IV|
62268097|NCT05315921|EXPERIMENTAL|OsrhAAT 20 mg/kg IV|
62268098|NCT05315921|EXPERIMENTAL|OsrhAAT 40 mg/kg IV|
62627533|NCT02595385|ACTIVE_COMPARATOR|CS|Reinfusion of shed blood during the operation
62627534|NCT02595385|ACTIVE_COMPARATOR|RAP and CS|RAP and CS used in combination
62853074|NCT03232333||MIRODERM|Biologic wound graft
62853075|NCT04395053|EXPERIMENTAL|Treatment group TR|Intervention: Drug: SHR1459, new formulation; Intervention: Drug: SHR1459, old formulation.
62627535|NCT02595385|NO_INTERVENTION|Control|No intervention
62627536|NCT01280071|EXPERIMENTAL|dipyridamole, aminophylline|
62627537|NCT00704977|ACTIVE_COMPARATOR|1|Pterygium surgery using alcohol 20% + wound closure by bare sclera technique
62088038|NCT06140667|OTHER|LarysealTM Pro|
62627538|NCT00704977|ACTIVE_COMPARATOR|2|"Alcohol 20% for pterygium separation + wound closure by sliding flap technique.~The main steps of surgery are described below.Wound closure technique is as follows.~Disection of conjunctiva adjascent to the wound, bringing the dissected conjunctiva to the wound area and suturing by vicril 6/0 sutures"
62063148|NCT03219008|EXPERIMENTAL|Depression/underload 1|This group would be treated with fluoxetine from the minimum dosage.
62627539|NCT00704977|ACTIVE_COMPARATOR|3|"Alcohol 20 % for pterygium separation + using amniotic membrane and biological glue for wound closure.~The steps of surgery are as described below, wound closure technique is as follows.~Amniotic membrane is applied with its mesenchimal side to conjunctiva and glued by biological glue (main ingradients: calcium and thrombin)"
62853076|NCT04395053|EXPERIMENTAL|Treatment group RT|Intervention: Drug: SHR1459, old formulation; Intervention: Drug: SHR1459, new formulation.
62063149|NCT03219008|EXPERIMENTAL|Depression/underload 2|This group would be treated with fluoxetine combined with cognitive behavior treatment
62268099|NCT05315921|EXPERIMENTAL|OsrhAAT 60 mg/kg IV|
62268100|NCT01891487|ACTIVE_COMPARATOR|Track A|Those on active study medication
62268101|NCT01891487|PLACEBO_COMPARATOR|Track B|Those on placebo.
62268102|NCT01634555|EXPERIMENTAL|ramucirumab (IMC-1121B) and FOLFIRI|Treatment is sequential, Ramucirumab (IMC-1121B) will be administered before FOLFIRI ((Irinotecan + Folinic acid + 5-Fluorouracil). FOLFIRI will be administered each cycle and Ramucirumab (IMC-1121B) will be administered beginning from Cycle 2 (2-week cycle).
62268103|NCT03640923|EXPERIMENTAL|experimental group|Child with a proven infection of the mother or both biological parents known to HIV antenatal a swab of mucous membrane will be withdrawed
62268104|NCT04940910|EXPERIMENTAL|Black rice bran extract group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.52 g/day, Black rice bran extract 1 g/day)
62268105|NCT04940910|PLACEBO_COMPARATOR|Placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.52 g/day, Black rice bran extract 0 g/day)
62268106|NCT03452371|ACTIVE_COMPARATOR|Enhanced Traditional Care|Participants in this arm will receive usual care to help with smoking cessation offered to all patients who are smokers and some additional resources they can access for support.
62268107|NCT03452371|EXPERIMENTAL|Patient Navigation Intervention|Participants in this arm will meet with the trained patient navigator either in-person if she is available, or by telephone. They will receive up to ten hours of patient navigation over three months.
62268108|NCT00732303|EXPERIMENTAL|1|"* Pemetrexed (Alimta) 500mg/m\^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles~* Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.~The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks."
62268109|NCT03116932||Part A - high risk MSM|"Part A will consist of a descriptive analysis of the acceptability and knowledge on the topic of PrEP of the individuals that undergo routine HIV testing and counseling in study facilities or through outreach activities.~Part A will be focused only on high risk MSM. For this part of the study, 225 high risk will be interviewed to understand the knowledge and acceptability of PrEP in this population in Puerto Rico."
62268110|NCT02204150|EXPERIMENTAL|OFDI Capsule Imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI Imaging system.
62268111|NCT02551159|EXPERIMENTAL|Monotherapy|MEDI4736 monotherapy.
62268112|NCT02551159|EXPERIMENTAL|Combination Therapy|MEDI4736+Tremelimumab combination therapy
62268113|NCT02551159|ACTIVE_COMPARATOR|Standard of Care|Standard of Care treatment
62268114|NCT03743870||levobupivacaine cohort|125 pregnant patients that will have to undergo spinal anesthesia with Levobupivacaine for elective caesarean section.
62268115|NCT03743870||bupivacaine cohort|Historical control group made of 125 patients underwent spinal anesthesia with Bupivacaine for elective cesarean section during the period between April 2017 and April 2018.
62268116|NCT05914909|EXPERIMENTAL|Part A: AD-214 in Healthy Volunteers|
62268117|NCT05914909|PLACEBO_COMPARATOR|Part A: Placebo in Healthy Volunteers|
62268118|NCT05914909|EXPERIMENTAL|Part B: AD-214 in patients with ILD or CKD|
62268119|NCT05914909|PLACEBO_COMPARATOR|Part B: Placebo in patients with ILD or CKD|
62268120|NCT03241914|ACTIVE_COMPARATOR|MA|Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
62853077|NCT06458816|EXPERIMENTAL|Medial Non-Invasive Knee Distraction|medial aspect of knee with distraction device
62063150|NCT03219008|EXPERIMENTAL|Depression/underload 3|This group would be treated with fluoxetine and amfebutamone from the minimum dosage.
62063151|NCT03219008|EXPERIMENTAL|Depression/underload 4|This group would be treated with fluoxetine + physical treatment to help to cure depressive disorder.
62063152|NCT03219008|EXPERIMENTAL|Atypical 1|This group would be treated with fluvoxamine from the minimum dosage.
62063153|NCT03219008|EXPERIMENTAL|Atypical 2|This group would be treated with fluoxetine + cognitive behavior treatment
62268121|NCT03241914|EXPERIMENTAL|MA+LNG-IUS|Patients will receive MA (160mg po qd) plus LNG- IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
62268122|NCT04989855|EXPERIMENTAL|Fruquintinib plus Tislelizumab|Fruquintinib 5mg QD d1-d14, Q3W; Tislelizumab 200mg IV Q3W d1
62268123|NCT03834428|ACTIVE_COMPARATOR|No Text Message Control|Participants randomized to this arm will receive education about the ICOUGH protocol which includes the importance of ambulation.
62268124|NCT03834428|EXPERIMENTAL|Text Message Intervention|Participants randomized to this arm will receive daily text message reminders to ambulate in the hospital in addition to education about the ICOUGH protocol which includes the importance of ambulation.
62268125|NCT02789904||Chest pain patients in DEM|Recruitment done at SGH DEM. Blood taking will be done at 0, 1 and 2 hr.
62451163|NCT00423956|SHAM_COMPARATOR|Sham Comparator|One side is experimental and the opposite side is Sham control.
62461470|NCT04971668|OTHER|Placebo|Patient will simulate like chewing gum and inhale deeply with inert gauze for 5 minutes.
62461471|NCT02460159|EXPERIMENTAL|EZ 10 mg/Atorva 10 mg FDC|one EZ 10 mg/Atorva 10 mg fixed-dose combination (FDC) tablet orally with food once daily for 52 weeks.
62627540|NCT01377636|EXPERIMENTAL|Isoproterenol, BIS, forearm test|30 consecutive patients scheduled for EP studies under general anesthesia will participate in the study. Patients with neuromuscular disease precluding the use of succinylcholine will be excluded. The only other exclusions will be patient or cardiologist refusal. No attempts will be made to alter concurrent patient medication.
62627541|NCT00838617||Participants with ALS|Participants diagnosed with ALS.
62627542|NCT06173518|EXPERIMENTAL|AUTO1|
62627543|NCT00844662|EXPERIMENTAL|1|
62853078|NCT06458816|EXPERIMENTAL|Lateral Non-Invasive Knee Distraction|lateral aspect of knee with distraction device
62853079|NCT06458816|ACTIVE_COMPARATOR|Medial Manual Knee Distraction|medial aspect of knee with only manual distraction. no device.
62268126|NCT02069899|OTHER|Enrolled-04 Cohort|"Participants enrolled in Study NI-0501-04 (NCT01818492) will be invited to participate for long-term follow-up for 1 year either after haematopoietic stem cell transplantation (HSCT) or after the last administration of emapalumab.~In Study NI-0501-04, participants received emapalumab for 4 to 8 weeks. After the treatment period, participants could have undergone HSCT.~Participants for whom an appropriate donor was not identified by Week 8, or in a case where HSCT will be delayed for reasons unrelated to the administration of emapalumab, can continue receiving treatment with emapalumab beyond the foreseen 8 weeks in the current study (NI-0501-05, NCT02069899) at the request of the investigator, providing a favorable benefit/risk assessment of treatment is established.~The dose and timing was either carried forward from the last administered emapalumab dose as part of the parent protocol or an adjusted dose was administered, if necessary."
62268127|NCT02069899|NO_INTERVENTION|Enrolled-06 Cohort|"All participants who received at least 1 dose of emapalumab and were monitored for at least 4 weeks after the last drug administration in Study NI-0501-06 (NCT03311854) will be invited to participate for long-term follow-up for 1 year after the last administration of emapalumab.~Participants will not receive emapalumab in the current study (NI-0501-05, NCT02069899)."
62461472|NCT02460159|EXPERIMENTAL|EZ 10 mg/Atorva 20 mg FDC|one EZ 10 mg/Atorva 20 mg fixed -dose combination (FDC) tablet orally with food once daily for 52 weeks.
62461473|NCT01355081|EXPERIMENTAL|Vortioxetine 5 mg|Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.
62461474|NCT01355081|EXPERIMENTAL|Vortioxetine 10 mg|Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.
62627544|NCT00844662|ACTIVE_COMPARATOR|2|
62627545|NCT03072420|EXPERIMENTAL|Group no manual work or activity|Subject with an office or student job.
62627546|NCT03072420|SHAM_COMPARATOR|Group manual work|Subject working in a manual or predominantly manual.
62627547|NCT06118463||study group|Women aged 20-60; There is a definite pathological diagnosis of cervical cancer
62627548|NCT06118463||Healthy control group|Women aged 20-60; No tumors in the uterus or other parts of the body; No inflammatory disease; Blood routine and blood biochemical tests are normal.
62627549|NCT06277570|ACTIVE_COMPARATOR|conventional physiotherapy|"Demographic and medical information of the patients (age, gender, height and body weight, occupation, educational status, CV, family history and surgical history, medical history related to knee osteoarthritis) and pain level will be questioned. Conventional physiotherapy modalities will be applied in the group; exercise training, hotpack, ultrasound and transcutaneous electrical nerve stimulation (TENS). Patients will be treated for one hour, three days a week, for eight weeks.~The physical functions, muscle structure and knee joint cartilage thickness, quality of life and functional status of the patients will be evaluated before and after treatment."
62627550|NCT06277570|ACTIVE_COMPARATOR|NMES|"Demographic and medical information of the patients (age, gender, height and body weight, occupation, educational status, CV, family history and surgical history, medical history related to knee osteoarthritis) and pain level will be questioned. In addition to conventional physiotherapy methods, passive NMES treatment will be applied in the group.Patients will be treated for one hour, three days a week, for eight weeks.~The physical functions, muscle structure and knee joint cartilage thickness, quality of life and functional status of the patients will be evaluated before and after treatment."
62627551|NCT06277570|ACTIVE_COMPARATOR|superimposed NMES|"Demographic and medical information of the patients (age, gender, height and body weight, occupation, educational status, CV, family history and surgical history, medical history related to knee osteoarthritis) and pain level will be questioned. In addition to conventional physiotherapy methods, superimposed NMES treatment will be applied in the group. Patients will be treated for one hour, three days a week, for eight weeks.~The physical functions, muscle structure and knee joint cartilage thickness, quality of life and functional status of the patients will be evaluated before and after treatment."
62627552|NCT00271219|EXPERIMENTAL|Buprenorphine|Buprenorphine
62627553|NCT00271219|ACTIVE_COMPARATOR|Methadone|Methadone
62627554|NCT02785562|OTHER|Assessment of PDL1 expression|Other : assess clinical and pathological characteristics of PDL1 expression in Non Small Cell Lung Cancer patients.
62627555|NCT02290847|ACTIVE_COMPARATOR|In-Home Therapy|Cognitive Processing Therapy (CPT-C) will be delivered to participants face to face in their homes by a certified therapist.
62627556|NCT02290847|ACTIVE_COMPARATOR|In-Office Therapy|Cognitive Processing Therapy (CPT-C) will be delivered to participants face to face in a mental health clinic office setting by a certified therapist.
62627557|NCT02290847|ACTIVE_COMPARATOR|Telebehavioral Health|Cognitive Processing Therapy (CPT-C) will be delivered to participants over the internet using video conferencing software by a certified therapist.
62627558|NCT05490914||Experimental Group|COVID-19 case
62853080|NCT06458816|ACTIVE_COMPARATOR|Lateral Manual Knee Distraction|lateral aspect of knee with only manual distraction. no device.
62853081|NCT02894502|EXPERIMENTAL|Motivational interviewing only for patients|In this arm the interventions will be delivered only to patients
62853082|NCT02894502|EXPERIMENTAL|Motivational interviewing to patients and caregivers|In this arm the interventions will be delivered both to patients and caregivers
62063154|NCT03219008|EXPERIMENTAL|Atypical 3|This group would be treated with fluvoxamine + lithium from the minimum dosage.
62063155|NCT03219008|EXPERIMENTAL|Atypical 4|This group would be treated with fluvoxamine + lithium + physical treatment
62853083|NCT02894502|NO_INTERVENTION|Control group|This Group will receive the usual care
62063156|NCT03219008|EXPERIMENTAL|Anxiety/somatization 1|This group would be treated with mirtazapine/selective serotonin-norepinephrine reuptake inhibitors（SNRIs） from the minimum dosage.
62627559|NCT05490914||Control Group|Healthy population without COVID-19
62627560|NCT06494592|EXPERIMENTAL|Aerobic Exercise Group|
62627561|NCT06494592|ACTIVE_COMPARATOR|Balance Exercise Group|
62627562|NCT05947162|EXPERIMENTAL|smoking cessation combining with nicotine cue extinction training|Participants should stop smoking after 18:00 the night before the test. Combined with cue exposure therapy, nicotine addicts were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.
62627563|NCT05947162|PLACEBO_COMPARATOR|smoking cessation combining with neutral cue extinction training|Participants should stop smoking after 18:00 the night before the test, they are combined with cue exposure therapy, by repeatedly presenting neutral cue picture stimuli to nicotine addicts, and performing extinction training for 25 minutes.
62627564|NCT05947162|EXPERIMENTAL|smoking cessation combining with fasting and nicotine cue extinction training|Participants should stop smoking and eating food after 18:00 the night before the test. Combined with cue exposure therapy, nicotine addicts are repeatedly presented with nicotine cue picture stimuli for extinction training, which lasts for 25 minutes.
62627565|NCT05947162|PLACEBO_COMPARATOR|smoking cessation combining with fasting and neutral cue extinction training|Participants should stop smoking and eating food after 18:00 the night before the test. Combined with cue exposure therapy, nicotine addicts were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.
62627566|NCT05947162|SHAM_COMPARATOR|smoking cessation combining with early lifting of fast and nicotine cue extinction training|Participants should stop smoking and eating food after 18:00 the night before the test. After breakfast at 8:00 in the morning, they are combined with cue exposure therapy, by repeatedly presenting neutral cue picture stimuli to nicotine addicts, and performing extinction training for 25 minutes.
62627567|NCT05947162|NO_INTERVENTION|healthy control|Non-smoker healthy subjects matched with the smoking group in terms of age, gender, education level, etc. were used as the control group. Those healthy participants will finish fMRI scanning task.
62627568|NCT05165641|OTHER|segmental spinal anesthesia|thoracic spinal anesthesia at T 10 level
62627569|NCT04350645|ACTIVE_COMPARATOR|Tranexamic acid group|Tranexamic acid group will receive 1g slow bolus of tranexamic acid over 2 minutes at least 5 minutes before skin incision (at the end of spinal/general anaesthesia)
62627570|NCT04350645|PLACEBO_COMPARATOR|Control group|The placebo group will receive normal saline 0.9% (same amount as the tranexamic acid)
62627571|NCT00540670|EXPERIMENTAL|1|
62853084|NCT02365480|EXPERIMENTAL|Arm I (berberine chloride)|Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.
62627572|NCT00540670|EXPERIMENTAL|2|
62627573|NCT00540670|EXPERIMENTAL|3|
62461475|NCT01355081|PLACEBO_COMPARATOR|Placebo|Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.
62627574|NCT00540670|PLACEBO_COMPARATOR|4|
62627575|NCT01014195||Group 1|"Survivors of pediatric leukemia treated on Total Therapy Protocol XV (TOTXV) at St. Jude Children's Research Hospital (SJCRH), who are ≥ 8 years of age and ≥ 5 years from diagnosis.~Intervention: Neurocognitive and behavioral evaluation"
62627576|NCT03806517||Tremor dominant type group|Tremor dominant type (TDT) group will consist of the patients with tremor premotor symptoms.
62627577|NCT03806517||PIGD dominant type group|Postural instability and gait difficulty dominant type (PIGDT) group will consist of the patients with axial premotor symptoms.
62853085|NCT02365480|PLACEBO_COMPARATOR|Arm II (placebo)|Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.
62853086|NCT00593476|ACTIVE_COMPARATOR|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
62853087|NCT00593476|ACTIVE_COMPARATOR|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
62853088|NCT02872844|EXPERIMENTAL|Heat-stress|Each participant will undergo a 30-minute heat stress to one randomized ear. The participant will be reclined and the hot air caloric at 50°C applied by a licensed, unblinded audiologist for 30 minutes.
62063157|NCT03219008|EXPERIMENTAL|Anxiety/somatization 2|This group would be treated with mirtazapine/SNRIs + cognitive behavior treatment.
62088039|NCT06140667|OTHER|Ambu Aura Gain|
62461476|NCT03002779|EXPERIMENTAL|JNJ-53718678|
62461477|NCT05570903||Awake prone position Group|Patients in awake prone position will be included.
62627578|NCT03806517||Healthy control group|Healthy control group will consist of the subjects with same age and sex matched individuals in PD group.
62627579|NCT04418271|EXPERIMENTAL|Prehabilitation|Prefrail and frail patients receive prehabilitation (new form of care)
62627580|NCT04418271|NO_INTERVENTION|Standard of Care|Prefrail and frail patients receive no prehabilitation, but receive standard of care
62627581|NCT01048840||Subject with History of GERD|Children and adolescents ages 12-17 years, inclusive, seen at Children's Hospital, Boston or Massachusetts General Hospital between 1977 and 1990 for symptoms of GERD and also had biopsies and / or a pH probe that was positive for GERD.
62627582|NCT01048840||Controls with out GERD|Individuals that do not have a history of GERD or other GI problems prior to age 21 and whose date of birth are with in a year of a subjects
62627583|NCT00928850|ACTIVE_COMPARATOR|urethral irrigation but no fascial suturing, QOL forms|The anterior two-thirds of the urethra is divided exposing a Foley catheter that was placed at the beginning of the procedure. Irrigation of the urethra may prevent spread of prostate cancer cells to tissue that is not removed during surgery. The urethra is irrigated with 60 cc of sterile water as it is withdrawn from the patient to 'wash' the urethra.
62853089|NCT00566384|ACTIVE_COMPARATOR|Arm 1|
62853090|NCT00566384|PLACEBO_COMPARATOR|Arm 2|
62853091|NCT04863508||Low-risk hypertensive patients|Patients without diabetes, chronic kidney disease, hypertension-mediated organ damage, or established cardiovascular diseases
62853092|NCT04863508||With-risk hypertensive patients|Patients with diabetes, chronic kidney disease, hypertension-mediated organ damage, but without established cardiovascular diseases
62853093|NCT04863508||Hypertensive patients with cardiovascular diseases|Patients with established cardiovascular diseases
62627584|NCT00928850|ACTIVE_COMPARATOR|fascial suturing but no urethral irrigation, QOL forms|For patients undergoing fascial suturing only, after the initial placement of the suture through the urethra a second bite is taken deeply into the fascia of the lateral pelvic fascia.
62627585|NCT00928850|ACTIVE_COMPARATOR|both urethral irrigation and fascial suturing, QOL forms|
62627586|NCT00928850|ACTIVE_COMPARATOR|neither urethral irrigation nor fascial suturing, QOL forms|
62627587|NCT01528280|EXPERIMENTAL|Shiftwork|The comparison will consider nightworkers versus dayworkers.
62627588|NCT04225013||Control (no CIN)|Patients who receive contrast media but do not develop contrast-induced nephropathy
62627589|NCT04225013||Case (yes CIN)|Patients who receive contrast media and develop contrast-induced nephropathy
62627590|NCT01054495|ACTIVE_COMPARATOR|Acupuncture|Needle acupuncture at acupuncture point pericardium 6
62627591|NCT01054495|SHAM_COMPARATOR|Sham acupuncture|Non-penetrating sham needling at acupuncture point pericardium 6
62627592|NCT01054495|PLACEBO_COMPARATOR|Laser acupuncture|Laser stimulation at acupuncture point pericardium 6
62627593|NCT00873067|ACTIVE_COMPARATOR|ACVP plus roof line|Standard procedure for atrial fibrillation ablation, including pulmonary vein isolation plus roof line ablation. All ablation lines will be tested.
62627594|NCT00873067|ACTIVE_COMPARATOR|Additional CFAEs ablation|Atrial fibrillation ablation with pulmonary vein ablation and roof line. In addition, complex fractionated atrial electrograms ablation will be performed, lasting at most 30 minutes.
62627595|NCT01784276|NO_INTERVENTION|Control|Children assigned to Group A (control group) received usual care and therefore had no intervention before or during the return visit.
62627596|NCT01784276|EXPERIMENTAL|Video peer modeling|Video peer modeling (at home, the child watched a DVD recording of a typically developing child undergoing a dental visit);
62627597|NCT01784276|EXPERIMENTAL|Video goggles or portable DVD only|Video goggles/DVD (during the dental visit, the child watched their favorite movie using sunglass style video eyewear, or portable DVD player);
62853094|NCT03247452|ACTIVE_COMPARATOR|One-day low fiber diet|"Patients assigned to the active comparator will receive oral and written instructions about the same structured low fiber diet designed by an Endocrinologist but they will follow this diet only the day before colonoscopy.~2 liters of polyethylene glycol plus ascorbic acid will be administered"
62627598|NCT01784276|EXPERIMENTAL|Video peer modeling plus video goggles|Video peer modeling plus video goggles/DVD. At home, the child watched a DVD recording of a typically developing child undergoing a dental visit; During the dental visit, the child watched their favorite movie using sunglass style video eyewear, or portable DVD player.
62627599|NCT06612333||Patient|"Inclusion criteria:~* Aged between 12 and 30 years, included at the start of the social skills program.~* Patients with rare neurodevelopmental diseases~* Patients benefiting from the social skills program~* Appropriate level of verbal elaboration~* Patient with a family member or a friend also participating in the social skills program~Non-inclusion criteria :~* Opposition of the patient or, if a minor, of his/her parents to participation in the study~* Patient not psychiatrically stabilized: acute symptoms of anxiety, depression, psychotic disorders.~* Severe intellectual disability"
62853095|NCT03247452|EXPERIMENTAL|Three-day low fiber diet|"Patients assigned to the experimental group will receive oral and written instructions about a structured low fiber diet designed by an Endocrinologist. They must follow this diet three days before colonoscopy.~2 liters of polyethylene glycol plus ascorbic acid will be administered"
62063158|NCT03219008|EXPERIMENTAL|Anxiety/somatization 3|This group would be treated with mirtazapine + SNRIs from the minimum dosage.
62627600|NCT06612333||Family member or friend|"Inclusion criteria:~* be over 18 years~* be a close relative or friend of a patient and share in his or her daily life~* have taken or are taking the social skills program~Non-inclusion criteria :~- Opposition to participation in the study"
62627601|NCT01627743||COPD patients grade C and D|
62627602|NCT03397303|EXPERIMENTAL|patients with peripheral neuropathies|This project aims to understand how nerve mechanical properties are altered in patients with rare peripheral neuropathies . Stiffness of various peripheral nerves will be measured using ultrasound shear wave elastography. Patients will be compared with age-matched controls.
62627603|NCT03397303|OTHER|controls|
62627604|NCT00758381|EXPERIMENTAL|A|"Sorafenib 400 mg po bid, continuously~Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days."
62627605|NCT00758381|ACTIVE_COMPARATOR|B|Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days
62627606|NCT04121455|EXPERIMENTAL|Cohort 1: 200 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
62627607|NCT04121455|EXPERIMENTAL|Cohort 2: 400 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
62627608|NCT04121455|EXPERIMENTAL|Cohort 3: 600 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
62627609|NCT04121455|EXPERIMENTAL|Expansion group, Arm A: 600 mg Olaptesed pegol + Radiotherapy + 10 mg/kg Bevacizumab|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion, bevacizumab every two weeks for 26 weeks plus radiotherapy during weeks 1-6, incompletely or not resected patients
62627610|NCT04121455|EXPERIMENTAL|Expansion group, Arm B: 600 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6, completely resected patients
62627611|NCT04121455|EXPERIMENTAL|Expansion group, Arm C: 600 mg Olaptesed pegol + Radiotherapy + 200 mg Pembrolizumab|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion, pembrolizumab every three weeks for 26 weeks plus radiotherapy during weeks 1-6, incompletely resected patients
62627612|NCT04121455|EXPERIMENTAL|Expansion group, Arm D: 200 mg Olaptesed pegol + Radiotherapy + 10 mg/kg Bevacizumab|olaptesed pegol i.v. by continuous infusion, bevacizumab every two weeks plus radiotherapy during weeks 1-6, until progression or intolerable toxicity (patients with disease progression may continue treatment with all assessments if deemed appropriate by the investigator), incompletely resected patients
62627613|NCT04121455|EXPERIMENTAL|Expansion group, Arm E: 400 mg Olaptesed pegol + Radiotherapy + 10 mg/kg Bevacizumab|olaptesed pegol i.v. by continuous infusion, bevacizumab every two weeks plus radiotherapy during weeks 1-6, until progression or intolerable toxicity (patients with disease progression may continue treatment with all assessments if deemed appropriate by the investigator), incompletely resected patients
62627614|NCT04121455|EXPERIMENTAL|Expansion group, Arm F: 600 mg Olaptesed pegol + Radiotherapy + 10 mg/kgBevacizumab|olaptesed pegol i.v. by continuous infusion, bevacizumab every two weeks plus radiotherapy during weeks 1-6, until progression or intolerable toxicity (patients with disease progression may continue treatment with all assessments if deemed appropriate by the investigator), incompletely resected patients
62627615|NCT04121455|EXPERIMENTAL|Expansion group, Arm G: 600 mg Olaptesed pegol + Radiotherapy|olaptesed pegol i.v. by continuous infusion, bevacizumab every two weeks plus radiotherapy during weeks 1-6, until progression or intolerable toxicity (patients with disease progression may continue treatment with all assessments if deemed appropriate by the investigator), incompletely resected patients
62627616|NCT04121455|ACTIVE_COMPARATOR|Expansion group, Arm H: Standard of care - Temozolomide + Radiotherapy|oral treatment up to 35 weeks according to current SPC
62627617|NCT01996150|EXPERIMENTAL|Dilute bleach bath|Subjects will take a diluted bleach bath (0.005% Sodium hypochlorite) for 5-10 minutes twice a week for 12 weeks.
62627618|NCT02026596||aSAH patients|Patients suffering from aneurysmal subarachnoid haemorrhage
62853096|NCT01821976|ACTIVE_COMPARATOR|Ertl Procedure|Patients randomized to the Ertl Procedure Arm will receive an amputation very similar to the Burgess Procedure, except the surgeon will perform an additional step to make the cut end of the tibia bone heal to the cut end of the fibula bone with a bone bridge. This bone bridge connects the two bones together.
62853097|NCT01821976|ACTIVE_COMPARATOR|Burgess Procedure|Patients randomized to the Burgess Procedure Arm will receive a below the knee amputation where the bone is cut and skin and muscle from the back of the leg are rotated to cover the cut end of your bone. This provides good soft tissue padding to the bone and a good shape to the leg for later fitting of your prosthesis.
62853098|NCT05827536|OTHER|AB where A=standard of care and B=PKU GOLIKE|Patients will receive 3 daily self-administrations of their usual standard of care for 2 consecutive days in the first period followed by 3 daily self-administrations of PKU GOLIKE for 2 consecutive days in the second period.
62853099|NCT05827536|OTHER|BA where B=PKU GOLIKE and A=standard of care|Patients will receive 3 daily self-administrations of PKU GOLIKE for 2 consecutive days in the first period followed by 3 daily self-administrations of their usual standard of care for 2 consecutive days in the second period.
62853100|NCT05615025|EXPERIMENTAL|Sevoflurane arm|In this arm, anesthesia will be maintained by sevoflurane.
62853101|NCT05615025|EXPERIMENTAL|Propofol arm|In this arm, anesthesia will be maintained by propofol.
62853102|NCT06089096||MCI or SCI patient|At baseline: Cognitive tests, questionnaire, and Home Sleep Apnea Test will be done.
62853103|NCT04499313|ACTIVE_COMPARATOR|Group A: Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization, followed by a tapering dose according to the patient's condition.
62063159|NCT03219008|EXPERIMENTAL|Anxiety/somatization 4|This group would be treated with mirtazapine + SNRIs + physical treatment.
62063160|NCT03219008|EXPERIMENTAL|treatment as usual(TAU)|The investigators recommend therapy strategies according to accessible methods.
62853104|NCT04499313|ACTIVE_COMPARATOR|Group B: Methylprednisolone|Methylprednisolone Sodium Succinate at a dose of 0.5mg/kg (Injectable solution)
62063161|NCT06160739||group A|microcystic \& mixed lymphatic malformation
62063162|NCT06160739||group B|vascular malformation
62063163|NCT02294539|EXPERIMENTAL|Losartan 50mg/amlodipine 5mg|Once daily, 1T, PO medication
62063164|NCT02294539|EXPERIMENTAL|Losartan 100mg/amlodipine 5mg|Once daily, 1T, PO medication
62853105|NCT04904224|ACTIVE_COMPARATOR|PICE|Participants receive a panintestinal video capsule endoscopy (PICE)
62627619|NCT01141920|ACTIVE_COMPARATOR|3-month counseling induction: routine care|Participants assigned to this condition will receive routine stepped-care treatment at ATS. Participants will begin in Step 2 (one counseling session per week), and be advanced to higher intensity care based on missed counseling sessions and drug-positive urine samples. Participants advanced to Step 3 will be scheduled to attend 2 group counseling sessions per week (in addition to individual counseling), and those advanced to Step 4 will be scheduled to attend 8 group counseling sessions per week (in addition to individual counseling). Time of methadone dosing will be based on step of care.
62627620|NCT01141920|EXPERIMENTAL|3-month counseling induction: low threshold|Participants assigned to this treatment arm will receive low threshold counseling. These participants will be scheduled to attend one counseling session per month with their individual counselor for the first 3-months. Participants can attend more counseling sessions if they desire, and they can meet with program supervisors to address crisis situations. They can receive methadone dosing any time during the clinic hours (7:30 am-1:15 pm and 4:00 pm - 6:00 pm)
62627621|NCT05051891|EXPERIMENTAL|the experimental group|Orelabrutinib in Combinaion with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
62627622|NCT05051891|EXPERIMENTAL|The control group|R-CHOP
62627623|NCT03629145|EXPERIMENTAL|Live Music Therapy|Twenty minutes of live, preferred music played on guitar and voice
62853106|NCT04904224|ACTIVE_COMPARATOR|Colonoscopy|Participants receive an (Ileo-)Colonoscopy
62853107|NCT03039946|EXPERIMENTAL|Closed-loop GDFT|This group consists of patients undergoing laparoscopic and/or robotic abdominal surgery where fluid maintenance with Plasmalyte is carried out using a closed-loop system guided by the Clearsight non-invasive hemodynamic flow monitor.
62063165|NCT02294539|ACTIVE_COMPARATOR|Losartan50 mg/Hydrochlorothiazide12.5 mg|Once daily, 1T, PO medication
62063166|NCT02294539|ACTIVE_COMPARATOR|Losartan100 mg/Hydrochlorothiazide25 mg|Once daily, 1T, PO medication
62627624|NCT03629145|PLACEBO_COMPARATOR|Recorded Music|Twenty minutes of recorded music, also on guitar and voice, previously recorded by investigator
62627625|NCT02112409|EXPERIMENTAL|cell salvage and hemodilution technique|cell salvage technique throughout scoliosis corrective surgery; Acute normovolemic hemodilution technique commenced after induction of anaesthesia and prior the starting of surgery.
62627626|NCT02112409|ACTIVE_COMPARATOR|cell salvage|cell salvage technique throughout scoliosis corrective surgery
62063167|NCT05916092||Lateral-Oblique TransLoc 3D Screw(s)|Patients receiving the TransLoc 3D Screw(s) version will receive screw(s) placed lateral-obliquely into the intended SI joint.
62063168|NCT05916092||Lateral Oblique TransLoc 3D Screw with Posterior Device (Hybrid)|Patients receiving the TransLoc 3D Hybrid construct will receive one 3D-printed titanium screw placed lateral-obliquely and one 3D-printed titanium posterior device across the same sacroiliac joint.
62063169|NCT01655602|EXPERIMENTAL|upper edge trimming|Surgery: trichophytic closure The 1-millimetre trimming of upper edge of linear incision before wound closure
62627627|NCT00650338|EXPERIMENTAL|1|\<described in intervention\>
62627628|NCT00650338|EXPERIMENTAL|2|\<described in intervention\>
62627629|NCT00650338|EXPERIMENTAL|3|\<described in intervention\>
62853108|NCT03039946|ACTIVE_COMPARATOR|Restrictive fluid therapy|This group consists of patients undergoing laparoscopic and/or robotic abdominal surgery where fluid management is based on a restrictive (4ml/kg/h) Plasmalyte infusion.
62853109|NCT00740610|EXPERIMENTAL|Cohort 1|22 subjects to receive 1 mg GS-9450 for 4 weeks
62853110|NCT00740610|EXPERIMENTAL|Cohort 2|22 subjects to receive 5 mg GS-9450 for 4 weeks
62627630|NCT00650338|PLACEBO_COMPARATOR|4|\<described in intervention\>
62627631|NCT00650338|ACTIVE_COMPARATOR|5|\<described intervention\>
62853111|NCT00740610|EXPERIMENTAL|Cohort 3|22 subjects to receive 10 mg GS-9450 for 4 weeks
62853112|NCT00740610|EXPERIMENTAL|Cohort 4|22 subjects to receive 40 mg GS-9450 for 4 weeks
62853113|NCT00740610|PLACEBO_COMPARATOR|Cohort 5|22 subjects to receive placebo to match GS-9450 for 4 weeks
62853114|NCT02492932|EXPERIMENTAL|IJV_2nd|Ultrasonography examination of the patients who are assumed to take second attempt of internal jugular venous catheterization
62853115|NCT01951040||Oxytocin|Oxytocin was administered during labor
62063170|NCT01655602|EXPERIMENTAL|lower edge trimming|Surgery: trichophytic closure The 1-millimetre trimming of lower edge of linear incision before wound closure
62627632|NCT00328588|EXPERIMENTAL|1|7 days continuous infusion
62652911|NCT03539510|NO_INTERVENTION|Usual Care|"The standard of care for advance care planning at our institution is the Speak Up booklet and the Power of Attorney workbook from the Attorney General's Office - Ontario. Patients randomized to the Control arm will be asked to register on a separate research portal where participants will have electronic access to both of the booklets and a link to the Speak Up online Interactive workbook. There is no specific information on HF or HF treatments. Participants in the control arm will be asked to complete the ACP using the interactive workbook. Participants in the control arm will not receive any additional communication from the research team about their progress."
62853116|NCT01951040||No Oxytocin|Oxytocine was not administered during labor
62063171|NCT01655602|EXPERIMENTAL|Both edge trimming|Surgery: trichophytic closure The 0.5-millimetre trimming of both edge of linear incision before wound closure
62853117|NCT01136785|ACTIVE_COMPARATOR|Active CPAP therapy|7 days of treatment in the laboratory with active CPAP therapy.
62853118|NCT01136785|SHAM_COMPARATOR|Sham CPAP therapy|7 days of sham CPAP therapy in the laboratory.
62063172|NCT02923102|ACTIVE_COMPARATOR|Aloysia citriodora extract|Dietary Supplement: Aloysia citriodora extract
62853119|NCT02773953|EXPERIMENTAL|CPAP + T4PTelemonitoring device|T4P® (Telemonitoring device) is added to CPAP at home. Sleep lab technical staff are connecting to the web portal 2 X/ week. In case of air leaks, persistant significant apnea-hypopnea index, use \< 3h on three consecutive days, they have to call the patient .
62063173|NCT02923102|PLACEBO_COMPARATOR|Placebo Formulation|Dietary Supplement: Maltodextrin (no active ingredient)
62063174|NCT02880007|EXPERIMENTAL|ARM A|Dose Optimization in 3D Pulsed Dose Rate Brachytherapy
62627633|NCT05030532|EXPERIMENTAL|EVERYbody Project: Expert facilitator version|"This gender inclusive, dissonance-based body image program was created from focus group feedback. Based on the Body Project, the program retains key dissonance activities while expanding the inclusivity focus (e.g., expanding the gender focus, exploring diversity within appearance ideals, critically discussing the impact of limited diversity representation in cultural appearance norms).~Around 10% of content from the previous trial was modified to form the current intervention. Changes focused on enhancing diversity-focused content. College students with body image content interest completed two days (16 hours) of training on the program manual, group management, and conducting inclusive conversations. Post training, students self-assessed their facilitation readiness and were evaluated by two trainers on facilitation expertise. Peer leaders with sufficient expertise were invited to facilitate EVERYbody Project groups."
62627634|NCT05030532|ACTIVE_COMPARATOR|Video + Expressive Writing group|"Video + expressive writing groups were facilitated by a peer leader following a detailed script. This intervention was designed as an active but low-dissonance comparison condition. Participants viewed two separate documentary movies related to gender and/or appearance-related pressures (one during each session): (1) The Illusionists, and (2) The Mask You Live In. Participants engaged in a brief (10 minute) reflective writing exercise after each film. In order to keep dissonance low, participants were told that their reflections would not be shared with anyone and they were not turned in.~Peer facilitators received brief (1 hour) training on the video group manual."
62627635|NCT04387461|EXPERIMENTAL|Single Arm|"CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Day 1 to Week 6. If the patient shows persistent high-grade disease at Week 13, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 13 (e.g., complete response) then the patient will receive 3 weekly treatments.~Beginning at Week 25, patients will receive weekly x 3 treatments every 3 months through Week 49 then every 24 weeks thereafter.~Pembrolizumab will be given intravenous (IV) concurrently starting on Day 1 and continue every 6 weeks for up to 2 years."
62063175|NCT03485911|EXPERIMENTAL|BCX7353 110 mg once daily|BCX7353 administered as oral capsules once daily
62853120|NCT02773953|ACTIVE_COMPARATOR|CPAP standard care|After CPAP titration night, patients are instructed to use the device each night for the whole night. They receive written instruction and can reach the sleep unit (phone call, visit) how often they need, during week days, to resolve CPAP-related problems. A group educational session is scheduled 1 month after and a visit to the pneumologist 1.5 months after.
62627636|NCT00060606|EXPERIMENTAL|Prenatal Surgery Group|Fetal surgery to close spina bifida defect prior to 26 weeks of gestation with delivery by C-Section at approximately 37 weeks of gestation.
62627637|NCT00060606|ACTIVE_COMPARATOR|Postnatal Surgery Group|Standard postnatal closure of the spina bifida defect when the baby is medically stable, usually within 48 hours of birth by C-section.
62627638|NCT01537835|NO_INTERVENTION|Standard Scrubs|Participants will be randomized to one of three types of uniforms. This arm is the standard scrub arm. The participants will wear new standard scrubs.
62627639|NCT01537835|EXPERIMENTAL|Antimicrobial Scrubs 1|Participants will be randomized to one of three types of uniforms. In this arm, the participants will wear one of two types of antimicrobial uniforms. These are commercially available and registered with the Environmental Protective Agency.
62627640|NCT01537835|EXPERIMENTAL|Antimicrobial Scrubs 2|Participants will be randomized to one of three types of uniforms. In this arm, the participants will wear one of two types of antimicrobial uniforms. These are commercially available and registered with the Environmental Protective Agency.
62627641|NCT04428840|EXPERIMENTAL|on-day|Use of the self-measurement kiosk: measurement of vital signs + completion of short questionnaire
62853121|NCT00380042|ACTIVE_COMPARATOR|Active Stimulation|
62853122|NCT00380042|SHAM_COMPARATOR|Sham|
62853123|NCT04379128||patients with epilepsy|Attentional tasks : D2-R task and TAP battery (sustained attention, alertness, divided attention) executive task : digit span, incompatibility and flexibility task (TAP battery), verbal fluencies depression score (NDDI-E scale) and anxiety score (GAD-7 scale)
62853124|NCT04379128||Normal controls|Attentional tasks : D2-R task and TAP battery (sustained attention, alertness, divided attention) executive task : digit span, incompatibility and flexibility task (TAP battery), verbal fluencies depression score (NDDI-E scale) and anxiety score (GAD-7 scale)
62853125|NCT03370172|EXPERIMENTAL|Cohort 1|Cohort 1 participants will receive a single peripheral intravenous (IV) infusion of BAX 888 at a dose of 2.0\*10\^12 capsid particles per kilogram (cp/kg) on the day of dosing (Day 0).
62853126|NCT03370172|EXPERIMENTAL|Cohort 2|Cohort 2 participants will receive a single peripheral IV infusion of BAX 888 at a dose of 6.0\*10\^12 cp/kg on the day of dosing (Day 0).
62063176|NCT03485911|EXPERIMENTAL|BCX7353 150 mg once daily|BCX7353 administered as oral capsules once daily
62063177|NCT03485911|PLACEBO_COMPARATOR|Placebo|Matching placebo administered as oral capsules once daily
62063178|NCT05127798||Adult from 18 to 70 years old AML in first line|Patients \>/= 18 years old with recent diagnosis of AML who receive treatment with intensive chemotherapy according to our local guidelines.
62063179|NCT05713006|EXPERIMENTAL|Alectinib escalation dose|Alecensa 150 mg Roche
62063180|NCT03620422|OTHER|Healthy Controls|Mannitol-Induced Cough Challenges on Visit 2 and 3. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
62853127|NCT03370172|EXPERIMENTAL|Cohort 3|Cohort 3 participants will receive a single peripheral IV infusion of BAX 888 at a dose of 1.2\*10\^13 cp/kg on the day of dosing (Day 0).
62063181|NCT03620422|PLACEBO_COMPARATOR|Mild Allergic Asthmatics (Saline)|Mannitol-Induced Cough Challenges on Visit 2, 3 and 4. Nebulized placebo (Sodium Chloride 0.9% Inhl 3Ml) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
62063182|NCT03620422|ACTIVE_COMPARATOR|Mild Allergic Asthmatics (Salbutamol)|Mannitol-Induced Cough Challenges on Visit 2, 3 and 4. Nebulized salbutamol (5mg/mL) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
62063183|NCT06495541|OTHER|Pyrotinib|
62063184|NCT01656928|OTHER|Waiting-list control|Allocation to waiting-list Control. Receives intervention 6 months later.
62063185|NCT01656928|ACTIVE_COMPARATOR|Intervention|Allocation to intervention. Directly starts with nutritional intervention.
62063186|NCT01420432|EXPERIMENTAL|Human umbilical cord-derived MSCs and DMARDs|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated after three months and DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months
62063187|NCT01420432|NO_INTERVENTION|DMARDs|DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months
62063188|NCT05675852||Healthy participants|"Healthy participants aged from 1 to 75 years old. All experiments conducted in this study will make use of the electroencephalogram (EEG) recording technique. Healthy participants cannot participate if they suffer from dermatosis on the scalp. There is no other contraindication to the practice of an EEG, which simply consists of recording the electrical activity of the brain on a trace, after application of a conductive gel on the scalp where sensors connected to a recording device are placed.~We will collect the cerebral electrical response by the technique of steady state visual evoked potentials (SSVEP) which consists of presenting a visual stimulus periodically to interpret the EEG signal according to those variations."
62268128|NCT02069899|OTHER|Enrolled-CU Cohort|"In exceptional cases, at the spontaneous request of a treating physician, CU treatment will be granted to the participants who had exhausted all possible treatment options and who could not be enrolled in a clinical study. All participants who receive at least 1 dose of emapalumab under CU will be invited to participate for long-term follow-up for 1 year either after HSCT or after the last administration of emapalumab.~Participants can continue treatment in the context of the current Study (NI-0501-05, NCT02069899) while stem cell donor search is ongoing, or if the investigator assesses that continuation of treatment is beneficial."
62853128|NCT03373617||General anesthesia group|Patients in general anesthesia group are scheduled to undergo RIRS under general anesthesia.
62853129|NCT03373617||Spinal anesthesia group|Patients in spinal anesthesia group are scheduled to undergo RIRS under spinal anesthesia
62853130|NCT02082340|EXPERIMENTAL|Intervention arm|The intervention includes the following components: self-administered drug intake strategy, TB knowledge and socio-psychological counseling session, SMS text messages, phone calls, educational leaflet
62268129|NCT05093738|EXPERIMENTAL|Rehabilitation Group|Refugee Children taking cognitive rehabilitation
62268130|NCT05093738|NO_INTERVENTION|Control Group|Refugee Children not taking cognitive rehabilitation
62268131|NCT06495086|ACTIVE_COMPARATOR|NIV group|The NIV group received bilevel-positive airway pressure.
62853131|NCT02082340|NO_INTERVENTION|Control arm|patients included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by WHO
62853132|NCT01232036|ACTIVE_COMPARATOR|A|Reference
62853133|NCT01232036|EXPERIMENTAL|B|Test
62853134|NCT01232036|PLACEBO_COMPARATOR|C|Placebo
62853135|NCT05907941|EXPERIMENTAL|ciNPT|
62853136|NCT05907941|ACTIVE_COMPARATOR|Conventional tape dressings|
62853137|NCT04740138|EXPERIMENTAL|DBT Skills + Parent Training|
62853138|NCT00272662|EXPERIMENTAL|Cohort 1|Peginesatide starting dose of 0.1 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 3 weeks (Q3W) for a total of 4 doses.
62853139|NCT00272662|EXPERIMENTAL|Cohort 2|Peginesatide starting dose of 0.15 mg/kg administered SC Q3W for a total of 4 doses.
62853140|NCT00272662|EXPERIMENTAL|Cohort 3|Peginesatide starting dose of 0.2 mg/kg administered SC Q3W for a total of 4 doses.
62853141|NCT00272662|EXPERIMENTAL|Cohort 4|Peginesatide starting dose of 0.05 mg/kg administered SC Q3W for a total of 4 doses.
62853142|NCT01325337|EXPERIMENTAL|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
62853143|NCT01325337|EXPERIMENTAL|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
62853144|NCT01325337|EXPERIMENTAL|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
62627642|NCT04428840|NO_INTERVENTION|Off-day|No use of the self-measurement kiosk
62627643|NCT03701802||HIV-1 serodiscordant couples|Heterosexual couples in which one partner is infected with HIV-1 and the other partner is HIV-1 uninfected
62627644|NCT03701802||Concordant HIV-1 negative couples|Heterosexual couples in which both partners are HIV-1 uninfected
62627645|NCT06071546|EXPERIMENTAL|Main arm|"* one microperimetric examination with MAIA, one microperimetric examination with MAIA 2013 EDITION for agreement evaluation;~* one additional microperimetric examination with MAIA and one additional microperimetric examination with MAIA 2013 EDITION for repetability evaluation."
62627646|NCT05984433|EXPERIMENTAL|Electroauricular acupuncture|Immediately after Level 2 sedation is achieved, an enhanced auricular trauma protocol (ATP) will be administered on the ear ipsilateral to the operative side at 8 ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) as described by Cheng (2022). The original ATP was described by Helms (2011). Seirin L 0.2 x 30 mm needles will be placed at Hypothalamus and Shen Men points. Seirin J 0.18 x 15 mm needles will be placed at Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Vagus, and Insula points. Electrostimulation using an ITO ES 130 microstimulator at 30 HZ with Level 4 intensity, will be applied with the positive lead (red) on Hypothalamus and negative lead (black) at Shen Men for 60 minutes. All needles will be removed 1 hour after insertion.
62627647|NCT05984433|NO_INTERVENTION|No acupuncture|No acupuncture treatment given
62627648|NCT05263518|EXPERIMENTAL|AcrySof IQ toric IOL|patients who had cataract surgery with AcrySof IQ toric IOL implantation. The patients diagnosed age related cataract The patients' ages are over 50.
62627649|NCT05263518|EXPERIMENTAL|TECNIS toric IOL|patients who had cataract surgery with TECNIS toric IOL implantation. The patients are diagnosed age related cataract. The patients' ages are over 50.
62627650|NCT06262646|EXPERIMENTAL|FACT Group|Parents will receive 4-6 FACT consultation sessions, one weekly session, 45-60 mins per session. These sessions will be one-on-one, conducted face-to-face or via video conferencing.
62627651|NCT06262646|ACTIVE_COMPARATOR|Control Group|Parents will receive standard parenting advice about positive parenting tips recommended by the Child Assessment Services under the Department of Health.
62627652|NCT01044160||Oncology Group|The study will recruit from outpatient clinics with procedures designed to obtain a representative sample of research participants, in terms of diagnosis and time since diagnosis.
62627653|NCT01044160||Control Group|The study will first identify a large cohort of children who are willing to participate, and then call them back individually as they are found to match participants in the cancer group.
62627654|NCT02271217|PLACEBO_COMPARATOR|Placebo|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
62627655|NCT02271217|ACTIVE_COMPARATOR|dalfampridine-ER 7.5 mg|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
62853145|NCT01325337|PLACEBO_COMPARATOR|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
62268132|NCT06495086|ACTIVE_COMPARATOR|HFNC-30 group|HFNC-30 group received HFNC therapy at flow rates of 30 L/min.
62268133|NCT06495086|ACTIVE_COMPARATOR|HFNC-50 group|HFNC-50 group received HFNC therapy at flow rates of 50 L/min.
62627656|NCT02271217|ACTIVE_COMPARATOR|dalfampridine-ER 10mg|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
62627657|NCT03094793|EXPERIMENTAL|abnormal EEGs|
62627658|NCT03875196|EXPERIMENTAL|Biyofeedback|the patients underwent 16 sessions of biofeedback-assisted pelvic floor muscle training over 8 weeks for 20 minutes
62627659|NCT03875196|EXPERIMENTAL|Extracorporeal Magnetic Innervation|the patients underwent 16 sessions of biofeedback-assisted pelvic floor muscle training over 8 weeks for 20 minutes and the Extracorporeal Magnetic Innervation application was made for 20 minutes
62627660|NCT06346782|EXPERIMENTAL|I-PCIT|Participants in this study arm will receive an initial intake session with a cultural formulation interview (based on the Diagnostic and Statistical Manual (DSM-V), then will receive time-limited internet-based PCIT.
62627661|NCT06346782|ACTIVE_COMPARATOR|Waitlist Control|Participants in this study arm will begin the I-PCIT intervention after a waitlist of 5-6 months. The I-PCIT intervention will be parallel to that in the I-PCIT arm.
62627662|NCT03448523|EXPERIMENTAL|Right To Play's Positive Child and Youth Development program|Behavioural intervention
62627663|NCT03448523|NO_INTERVENTION|Control|No intervention; intervention to be offered after end line assessment
62627664|NCT04581408|EXPERIMENTAL|Orkambi|"Generic name: Lumacaftor/Ivacaftor~Dosage form: tablet~Dosage: each tablet contains 200 mg of Lumacaftor and 125 mg of Ivacaftor~Frequency: two tablets twice a day."
62627665|NCT02590991||Prebiotics group|No intervention since is a follow-up study
62627666|NCT02590991||Prebiotics & Probiotics group|No intervention since is a follow-up study
62627667|NCT02590991||Control group|No intervention since is a follow-up study
62627668|NCT05812053|EXPERIMENTAL|group 1: Tea Tree Oil- Eggshell Powder|30 primary molars will be treated with Eggshell Powder freshly mixed with Tea Tree Oil till reach suitable consistency (1:1 ratio by volume) to cover pulp stumps
62627669|NCT05812053|EXPERIMENTAL|group II: biodentine|30 primary molars will be treated with biodentine to cover pulp stumps
62853146|NCT01325337|ACTIVE_COMPARATOR|minoxidil 5% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
62853147|NCT05887583|EXPERIMENTAL|Intervention|The Rising New York Road Runners program: A School-based physical education curriculum with family engagement component.
62853148|NCT05887583|NO_INTERVENTION|Control|Standard school operating procedures
62268134|NCT00848055|EXPERIMENTAL|arm 1|AbGn168 cohort 1
62268135|NCT00848055|EXPERIMENTAL|arm 2|AbGn168 cohort 2
62268136|NCT00848055|EXPERIMENTAL|arm 3|AbGn168 cohort 3
62268137|NCT00848055|EXPERIMENTAL|arm 4|AbGn168 cohort 4
62268138|NCT00848055|EXPERIMENTAL|arm 5|AbGn168 cohort 5
62268139|NCT00848055|EXPERIMENTAL|arm 6|AbGn168 cohort 6
62268140|NCT00848055|EXPERIMENTAL|arm 7|AbGn168 cohort 7
62268141|NCT00848055|EXPERIMENTAL|arm 8|AbGn168 cohort 8
62268142|NCT05946369||Neutrophil to lymphocyte ratio less than 3|Patients are classified into 2 groups according to NLR \< or ≥ 3 and follow up the 2 groups for recurrence or regression of bladder urothelial tumor and documentation of BCG failure
62853149|NCT02221713||Group A: perforated diverticulitis|Patients with acute diverticulitis will be recruited from the A\&E department at King's, prior to commencement of antibiotics. Rectal swabs will be obtained from patients with a chief complaint of acute abdominal pain upon initial assessment, prior to initial antibiotics. All specimens will be initially frozen, but only patients specimens with an admitting diagnosis of acute diverticulitis and colonic imaging (CT imaging or visualization at surgery) will be analysed. This group will include patients with perforated diverticulitis (i.e., Hinchey III or IV).
62853150|NCT02221713||Group B: unperforated diverticulitis|Patients with acute diverticulitis will be recruited from the A\&E department at King's, prior to commencement of antibiotics. Rectal swabs will be obtained from patients with a chief complaint of acute abdominal pain upon initial assessment, prior to initial antibiotics. All specimens will be initially frozen, but only patients specimens with an admitting diagnosis of acute diverticulitis and colonic imaging (CT imaging or visualization at surgery) will be analysed. This group will include patients with unperforated diverticulitis (Hinchey I or II).
62853151|NCT02221713||Group C: asymptomatic diverticulosis|Patients with asymptomatic diverticulosis will be recruited from the 2-week wait (2ww) colorectal cancer pathway. Patients presenting with a chief complaint of fresh PR bleeding, with no other complaints, will be recruited prior to diagnostic imaging, either by CT, CT colonography, or endoscopy. They will provide a stool sample or rectal swab prior to bowel cleansing, if required for their evaluation, as that may alter the microbiome. Those patient samples with diverticulosis (and or haemorrhoids, as the other most common cause of fresh PR bleeding) will be analysed.
62268143|NCT05946369||Neutrophil to lymphocyte ration more than or equal 3|Patients are classified into 2 groups according to NLR \< or ≥ 3 and follow up the 2 groups for recurrence or regression of bladder urothelial tumor and documentation of BCG failure
62853152|NCT02221713||Group D: normal controls|Patients with or without haemorrhoids, and no other colonic pathology will be recruited from the 2ww colorectal cancer pathway. These will be the normal controls. Patients presenting with a chief complaint of fresh PR bleeding, with no other complaints, will be recruited prior to diagnostic imaging, either by CT, CT colonography, or endoscopy. They will provide a stool sample or rectal swab prior to bowel cleansing, if required for their evaluation, as that may alter the microbiome. Those patient samples with diverticulosis (and or haemorrhoids, as the other most common cause of fresh PR bleeding) will be analysed.
62627670|NCT05812053|ACTIVE_COMPARATOR|group III: mineral tri-oxide aggregate (MTA)|30 primary molars will be treated with MTA to cover pulp stumps
62627671|NCT05820243|EXPERIMENTAL|Antihistamine|The oral antihistamine condition will consist of fexofenadine (540mg) and famotidine (40mg). Commercially available pills (3 x 180mg fexofenadine and 2 x 20mg famotidine) will be placed within opaque capsules and administered to the participants upon arrival to the laboratory.
62461478|NCT05570903||Non awake prone position Group|Patients in non awake prone position will be included.
62627672|NCT05820243|PLACEBO_COMPARATOR|Placebo|The placebo condition will consist of dextrose in an identical number of opaque capsules as the antihistamine treatment. Total dextrose will be \<5g. The capsules will be administered to the participants upon arrival to the laboratory.
62627673|NCT04716621|EXPERIMENTAL|Early intervention|Three sites received the Pain Management Support System for Primary Care (PMSS-PC) integrated into the Electronic Health Record.
62268144|NCT03239821|SHAM_COMPARATOR|Placebo - deflated balloon|
62268145|NCT03239821|PLACEBO_COMPARATOR|Placebo - inflated balloon|
62268146|NCT03239821|ACTIVE_COMPARATOR|Codeine - delfated balloon|
62627674|NCT04716621|OTHER|Delayed intervention|Delayed wait-list control group. Three additional sites received the intervention 6 months after the first arm.
62853153|NCT05653453|EXPERIMENTAL|Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel|"Device: Tumor treating fields Subjects will use tumor treating fields each day~Drug: Gemcitabine hydrochloride and albumin binding paclitaxel 28 days is a cycle. On the 1st, 8th and 15th days of each cycle, 125 mg/m2 albumin binding paclitaxel will be administered intravenously，1000 mg/m2 gemcitabine hydrochloride will be administered immediately after the infusion of albumin binding paclitaxel."
62853154|NCT05653453|ACTIVE_COMPARATOR|Gemcitabine hydrochloride and albumin binding paclitaxel|Drug: Gemcitabine hydrochloride and albumin binding paclitaxel 28 days is a cycle. On the 1st, 8th and 15th days of each cycle, 125 mg/m2 albumin binding paclitaxel will be administered intravenously，1000 mg/m2 gemcitabine hydrochloride will be administered immediately after the infusion of albumin binding paclitaxel.
62853155|NCT05807165||HF-SRT|RT techniques and the dose schemes in the cohort of Hypofractionated Stereotactic Radiotherapy (HF-SRT)
62627675|NCT04241510|ACTIVE_COMPARATOR|Facilitation Tape|Diaphragm and Intercostal muscles will be taped with facilitation technique. After 30 minutes of application patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea.
62627676|NCT04241510|ACTIVE_COMPARATOR|Mechanical Correction Tape|Thorax will be taped with mechanical correction technique. After 30 minutes of application patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea.
62627677|NCT04241510|NO_INTERVENTION|No Tape|Patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea with no tape.
62268147|NCT03239821|ACTIVE_COMPARATOR|Codeine - inflated balloon|
62451164|NCT04390828|EXPERIMENTAL|Guided Imagery Meditation|the guided image meditation invention program of the intervention measures of this study include four important elements: 1) Meditation exercises: the exercises to adjust the body and mind through specific attention, so that people gradually feel the state of relaxation through practice; (2) Guided image: the simple visualization and use of mental images produced by imagination as a form of psychotherapy, images come from natural scenes (e.g., forests and mountains, streams and oceans), positive feelings and emotions are generated through psychological imagination to induce psychological and physiological relaxation state; (3) Music aids: reaching a relaxed state with comfortable and slow background music; (4) Breathing relaxation training: the patient is taught to take abdominal breathing to divert attention and stimulate the parasympathetic nervous system to achieve muscle relaxation. The entire intervention process takes about 15 to 20 minutes, 2 times a day.
62451165|NCT04390828|NO_INTERVENTION|Usual care|usual care
62451166|NCT03783208|EXPERIMENTAL|G-CSF|Patients in the G-CSF group will receive G-CSF once a day on hCG day, before hCG injection. The procedure involved the administration of G-CSF through slow infusion into the endometrial cavity using a soft embryo transfer catheter.
62627678|NCT02549664||LQT/HCM sedentary patients|LQT/HCM sedentary lifestyle
62627679|NCT02549664||LQT/HCM moderate/vigorous exercise|LQT/HCM participate in moderate or vigorous exercise
62268148|NCT00832507|EXPERIMENTAL|Cicletanine 150 mg QD|Cicletanine 150 mg administered once daily (QD)
62268149|NCT00832507|EXPERIMENTAL|Cicletanine 150 mg BID|Cicletanine 150 mg administered twice daily (BID)
62627680|NCT06263283|NO_INTERVENTION|Control Group|Standard care according to the modalities of each center (concomitant treatment prescription, psychological support, physiotherapy or dietetic are supports that can be proposed if needed)
62268150|NCT00832507|EXPERIMENTAL|Cicletanine 300 mg QD|Cicletanine 300 mg administered once daily (QD)
62268151|NCT00832507|PLACEBO_COMPARATOR|Placebo|Placebo to match cicletanine administered once daily
62268152|NCT04243863|EXPERIMENTAL|VNRX-7145|Oral dosing
62627681|NCT06263283|EXPERIMENTAL|Experimental Group|"Standard support with Daily realization of a session of Kine-Yoga supervised by a physiotherapist at J2, J3 and J4 of uterovaginal brachytherapy.~Possibility for the patient to practice this session in autonomy (using PEP tools given to the Shared Educational Check-up) according to her wish during the duration of the treatment and up to 15 days post treatment."
62627682|NCT01768559|EXPERIMENTAL|Lixisenatide|Lixisenatide 10 mcg once daily (QD) for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to Week 26 on top of insulin glargine with or without metformin.
62268153|NCT04243863|PLACEBO_COMPARATOR|Placebo|Oral dosing
62268154|NCT05398315|EXPERIMENTAL|Empathic Statements, MI, Male, No Backstory|Presence of empathic statements and MI techniques. Male narrator. No narrator backstory.
62268155|NCT05398315|EXPERIMENTAL|No Empathic Statements, No MI, Female, No Backstory|No empathic statements, MI techniques or narrator backstory. Female narrator
62268156|NCT05398315|EXPERIMENTAL|No Empathic Statements, No MI, Female, Backstory|No empathic statements or MI techniques. Presence of narrator backstory. Female narrator
62268157|NCT05398315|EXPERIMENTAL|Empathic Statements, MI, Female, Backstory|Presence of empathic statements, MI techniques and narrator backstory. Female narrator
62063189|NCT03654339|EXPERIMENTAL|experimental group|"Group A-15 patients were allocated to the microsurgical group for root coverage. following scaling and root planning, the laterally repositioned flap was done using the microsurgical approach~Group B-15 Patients were allocated to the conventional group for root coverage following scaling and root planning, the laterally repositioned flap was done using the macrosurgical approach"
62063190|NCT04860414|EXPERIMENTAL|Major Cognitive Impairment|
62853156|NCT05807165||HS-WBRT plus memantine|The course of hippocampus-sparing whole-brain radiotherapy (HS-WBRT) combined with the synergic use of the neuroprotective agent, memantine
62627683|NCT01768559|ACTIVE_COMPARATOR|Insulin Glulisine QD|Insulin glulisine QD from randomization up to Week 26 on top of Insulin glargine with or without metformin.
62853157|NCT02689921|EXPERIMENTAL|Neoadjuvant Biological Therapy|"Subjects will receive an aromatase inhibitor for the duration of the study \[exemestane (tablet, oral, 25 mg/day), letrozole (tablet, oral, 2.5 mg/day) or anastrozole (tablet, oral, 1 mg/day)\]. Premenopausal subjects will receive leuprolide acetate (11.25 mg, intramuscular injection, 3-month intervals).~Pertuzumab will be given by intravenous infusion in 3-week cycles until disease progression (Cycle 1 Day 0: 840 mg, infused over 60-90 minutes; subsequent cycles: 420 mg, infused over 30-60 minutes).~Trastuzumab will be given by intravenous infusion in 3-week cycles until disease progression (Cycle 1 Day 0: 8 mg/kg, infused over 60-90 minutes; subsequent cycles: 6 mg/kg, infused over 30-60 minutes)"
62853158|NCT02084251|EXPERIMENTAL|Exenatide analogue, Injection|PB-119 will be administered once weekly subcutaneously at dosage of 2μg、5μg、10μg、25μg、50μg、100μg、200μg or 400μg.
62063191|NCT04860414|EXPERIMENTAL|Minor Cognitive Impairment|
62063192|NCT04860414|ACTIVE_COMPARATOR|No Cognitive Impairment|
62063193|NCT00500240|NO_INTERVENTION|Conventional Care|Control Group: Conventional care using blood sugar management with regular human insulin.
62063194|NCT00500240|OTHER|Intensive Insulin|Intervention Group: Intense blood sugar management with Insulin Aspart + Insulin Glargine
62063195|NCT02002182|EXPERIMENTAL|Treatment-Vaccine Group|Two vaccinations with ADXS11-001 (ADXS-HPV) will be given at a dose of 1x10\^9 cfu intravenously. The drug will be given as a 500ml infusion over 60 minutes.
62063196|NCT02002182|NO_INTERVENTION|Control Group|Observational control group treated with standard of care therapy only
62063197|NCT05233943||Parkinson's patients|"The cognitive function of Parkinson's patients will be assessed using the Standardized Mini Mental Test  .~The spinal posture will be evaluated using IDIAG M360 Spinal Mouse  .~Parkinson's patients' spinal position sense will be assessed using a repositioning error test with J-TECH medical, Salt Lake City, USA Dual Digital Inclinometer.~Dynamic and static components of the balance function will be evaluated with 'four square step tests' and 'stand on one leg' tests respectively"
62853159|NCT01389661|EXPERIMENTAL|MSV treatment|MSV treatment: Mesenchymal stem cells from bone marrow expanded by GMP-compliant procedure in IBGM cell production unit in autologous plasma scaffold and implanted in maxillary bone cavities after cyst removal
62853160|NCT05772585||patients ALF and ACLF|patients with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) with hepatic encephalopathy
62063198|NCT05233943||Healthy control group|"The cognitive function of Parkinson's patients will be assessed using the Standardized Mini Mental Test  .~The spinal posture will be evaluated using IDIAG M360 Spinal Mouse  .~Parkinson's patients' spinal position sense will be assessed using a repositioning error test with J-TECH medical, Salt Lake City, USA Dual Digital Inclinometer.~Dynamic and static components of the balance function will be evaluated with 'four square step tests' and 'stand on one leg' tests respectively"
62063199|NCT01412190|OTHER|Untreated|
62063200|NCT01412190|ACTIVE_COMPARATOR|Restylane Vital Light|Restylane Vital Light administered at 3 treatment sessions 4 weeks apart
62063201|NCT06107764|ACTIVE_COMPARATOR|Intermittent theta burst stimulation (iTBS)|Participants complete MRI scanning and cognitive testing followed by rTMS (iTBS pattern) followed by repeat cognitive testing and MRI scanning
62268158|NCT05398315|EXPERIMENTAL|No Empathic Statements, No MI, Male, No Backstory|No empathic statements, MI techniques or narrator backstory. Male narrator
62268159|NCT05398315|EXPERIMENTAL|Empathic Statements, MI, Male, Backstory|Presence of empathic statements, MI techniques and narrator backstory. Male narrator.
62268160|NCT05398315|EXPERIMENTAL|No Empathic Statements, MI, Female, Backstory|Presence of MI techniques and narrator backstory. No empathic statements. Female narrator.
62853161|NCT06032013|EXPERIMENTAL|Cardiac Rehabilitation intervention|Outpatient intervention with participants after a cardiac event who fulfil the inclusion criteria.
62853162|NCT04609007|ACTIVE_COMPARATOR|Treatment as usual|The TAU condition consists of a single session of regular help-line telephone counselling
62063202|NCT06107764|ACTIVE_COMPARATOR|continuous theta burst stimulation (cTBS)|Participants complete MRI scanning and cognitive testing followed by rTMS (cTBS pattern) followed by repeat cognitive testing and MRI scanning
62063203|NCT06107764|SHAM_COMPARATOR|sham rTMS|Participants complete MRI scanning and cognitive testing followed by sham rTMS followed by repeat cognitive testing and MRI scanning
62268161|NCT05398315|EXPERIMENTAL|Empathic Statements, No MI, Male, No Backstory|Presence of empathic statements. No MI techniques or narrator backstory. Male narrator.
62268162|NCT05398315|EXPERIMENTAL|No Empathic Statements, MI, Male, Backstory|Presence of MI techniques and narrator backstory. No empathic statements. Male narrator.
62268163|NCT05398315|EXPERIMENTAL|Empathic Statements, No MI, Female, No Backstory|Presence of empathic statements. No MI techniques or narrator backstory. Female narrator.
62853163|NCT04609007|EXPERIMENTAL|Cognitive behavioral therapy|The experimental condition consists of a single session of regular help-line telephone counselling plus four therapist guided online CBT sessions.
62853164|NCT01789398|EXPERIMENTAL|BF2.649 (pitolisant)|BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules
62853165|NCT01789398|PLACEBO_COMPARATOR|placebo|Placebo of BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules
62853166|NCT02686008|EXPERIMENTAL|HPV negative tumors|10 patients with HPV negative tumors: Non-oropharyngeal tumors or p16 negative and HPV negative oropharyngeal tumors
62853167|NCT02686008|EXPERIMENTAL|HPV positive tumors|10 patients with HPV positive tumors: p16 positive and HPV positive tumors
62853168|NCT01643421|EXPERIMENTAL|Deep inspiration and expiratory positive airway pressure|The protocol of deep inspiration combined to expiratory positive airway pressure will be applied in asthmatic subjects.
62853169|NCT01643421|NO_INTERVENTION|Control|
62063204|NCT02459821|EXPERIMENTAL|Robot-assisted gait training group|The first group will be subjected to RAGT for 9 weeks (2 sessions/ week) with a total of 18 sessions by mean of GE-O System (9). During each session, the patients will practice 15 to 20 min of simulated floor walking followed by 5 to 10 min of repetitive simulated stair climbing up and down. Breaks will be optional, but uninterrupted training intervals of at least 5 min for simulated floor walking and 3 min of simulated stair climbing will be required. When the patient reaches the maximum amount of time, speed of gait will then be progressively increased. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
62063205|NCT02459821|ACTIVE_COMPARATOR|Conventional training group|The group will be subjected to conventional gait training for 9 weeks (2 sessions/week) with a total of 18 sessions. Each session will last altogether 50 minutes, the first 30 minutes will be dedicated to gait and stair climbing up and down training while the last 20 minutes to stretch the lower limb's muscles.
62268164|NCT05398315|EXPERIMENTAL|Empathic Statements, MI, Female, No Backstory|Presence of empathic statements and MI techniques. Female narrator. No narrator backstory.
62268165|NCT05398315|EXPERIMENTAL|No Empathic Statements, No MI, Male, Backstory|Presence of narrator backstory. No empathic statements or MI techniques. Male narrator.
62268166|NCT05398315|EXPERIMENTAL|Empathic Statements, No MI, Female, Backstory|Presence of empathic statements and narrator backstory. No MI techniques. Female narrator.
62268167|NCT05398315|EXPERIMENTAL|Empathic Statements, No MI, Male, Backstory|Presence of empathic statements and narrator backstory. No MI techniques. Male narrator.
62268168|NCT05398315|EXPERIMENTAL|No Empathic Statements, MI, Female, No Backstory|Presence of MI techniques. No empathic statements or narrator backstory. Female narrator.
62853170|NCT01089517|ACTIVE_COMPARATOR|Lucentis|
62627684|NCT01768559|ACTIVE_COMPARATOR|Insulin Glulisine TID|Insulin glulisine thrice daily (TID) from randomization up to Week 26 on top of Insulin glargine with or without metformin.
62627685|NCT01590901|OTHER|probucol in healthy male subjects|multiple oral doses of probucol in single group of healthy male subjects
62627686|NCT03207490|EXPERIMENTAL|Robot group|Receive 1 hour of AMADEO (robot-assisted therapy) for the hand and 1 hour of daily standard rehabilitation therapy
62627687|NCT04308876|EXPERIMENTAL|Manual therapy and strengthening exercises|Manual therapy and strengthening exercises were applied totally 15 sessions for 5 weeks 3 times a week in hospital by physiotherapist.
62627688|NCT04308876|ACTIVE_COMPARATOR|Strengthening exercises|Patients in this group performed the strengthening exercises given to the experimental group on their own at home with experimental group at the same time, frequency and dose.
62627689|NCT05208827|EXPERIMENTAL|Experimental group|Take two tablets once a day.Each tablet contains 800 units of vitamin D3, for a total of 1600 units taken orally daily
62627690|NCT05208827|PLACEBO_COMPARATOR|Control Group|The control group received the same packaged, similar-looking, similar-tasting placebo from the same manufacturer, containing starch, peanut oil (no pharmaceutical value)
62627691|NCT03470454||diabetics on linagelptin|Diabetic patients were given linagelptin for blood glucose control
62627692|NCT03470454||diabetics on other DPP4 inhibitors|Diabetic pateints were given other DPP4 inhibitors eg: vlidagliptin for blood glucose control
62627693|NCT04934163|EXPERIMENTAL|60 L/min arm|The flow rate of HFNC(high-flow nasal cannula) is set as 60 L/min after extubation.
62853171|NCT01089517|EXPERIMENTAL|E10030 low dose plus Lucentis|
62268169|NCT05398315|EXPERIMENTAL|No Empathic Statements, MI, Male, No Backstory|Presence of MI techniques. No empathic statements or narrator backstory. Male narrator.
62268170|NCT03286842|EXPERIMENTAL|Olaparib|Olaparib 150mg tablets administered orally twice daily continuously
62853172|NCT01089517|EXPERIMENTAL|E10030 high dose plus Lucentis|
62853173|NCT04580641||Subjects with migraine|No medical intervention. All included subjects will filled in the questionnaire concerning migraine characteristics and associated symptoms.
62853174|NCT05379010|EXPERIMENTAL|With L-PRF Block|
62268171|NCT04193163||Patients receiving ESOP 2 stem|
62268172|NCT00218491|EXPERIMENTAL|1200mg N-Acetylcysteine|1200mg N-Acetylcysteine
62853175|NCT05379010|ACTIVE_COMPARATOR|No L-PRF Block|
62853176|NCT05673798||training cohort|The investigators used the training cohort to develop the predictive nomogram with potential risk factors( initial response to chemotherapy)
62063206|NCT04321967|EXPERIMENTAL|Nitroglycerine paste|The randomized breast will receive Nitroglycerine paste and Dermabond.
62268173|NCT00218491|EXPERIMENTAL|2400mg N-Acetylcysteine|2400mg N-Acetylcysteine
62268174|NCT00218491|PLACEBO_COMPARATOR|Matching Placebo|Matching Placebo
62063207|NCT04321967|PLACEBO_COMPARATOR|Dermabond|The control breast will receive Dermabond only
62088040|NCT05419674|EXPERIMENTAL|groupA: dual therapy (vonoprazan+amoxicillin)|vonoprazan 20mg bid and amoxicillin 1000mg tid for 10 days
62268175|NCT02287727|EXPERIMENTAL|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62268176|NCT03378076|EXPERIMENTAL|FX006 32 mg|Two intra-articular (IA) injections of FX006 32 mg (total dose of 64 mg)
62268177|NCT03378076|ACTIVE_COMPARATOR|TAcs 40 mg|Two intra-articular (IA) injections of TAcs 40 mg (total dose of 80 mg)
62268178|NCT04947670|EXPERIMENTAL|Treatment Group|Renal denervation and maintenance of heart failure medications
62451167|NCT03783208|PLACEBO_COMPARATOR|Control group|Normal saline of 1 mL was infused into the endometrial cavity in the same way in patients in the control group
62627694|NCT04934163|EXPERIMENTAL|40 L/min arm|The flow rate of HFNC(high-flow nasal cannula) is set as 40 L/min after extubation.
62627695|NCT03809234|EXPERIMENTAL|Ondansetron with Tariquidar|The participants will receive an IV ondansetron infusion with tariquidar. Participants will receive either 8mg or 16 mg of iv ondansetron, with 4mg/kg tariguidar.
62627696|NCT03809234|PLACEBO_COMPARATOR|Ondansetron with Placebo|The participants will receive an IV ondansetron infusion with D5W as placebo. Participants will receive either 8mg or 16 mg of iv ondansetron.
62627697|NCT02780271|EXPERIMENTAL|Arm A|Subjects will receive in-person education plus e-communication AND subjects will receive control intervention
62627698|NCT02780271|EXPERIMENTAL|Arm B|Subjects will receive e-communication alone AND subjects will receive control intervention
62627699|NCT02780271|EXPERIMENTAL|Arm C|Subjects will receive in-person education alone AND subjects will receive control intervention
62627700|NCT02780271|ACTIVE_COMPARATOR|Arm D|Subjects will receive control intervention
62627701|NCT02029274|EXPERIMENTAL|BAF312 0.5mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 0.5 mg over a 10 day period. After, participants continued on 0.5 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
62627702|NCT02029274|EXPERIMENTAL|BAF312 2mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
62627703|NCT02029274|EXPERIMENTAL|BAF312 10 mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 10.0 mg over a 10 day period. After, participants continued on 10.0 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
62627704|NCT02029274|PLACEBO_COMPARATOR|Placebo|During period 1, participants received matching placebo daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
62627705|NCT03915626|EXPERIMENTAL|RLD patch|RLD rivastigmine patch (4.6 mg/24 hours); worn for 9 hours
62627706|NCT03915626|EXPERIMENTAL|generic patch|generic rivastigmine patch (4.6 mg/24 hours); worn for 9 hours
62853177|NCT05673798||validation cohort|The investigators used the validation cohort to verify the clinical utility and predictive ability
62627707|NCT03915626|EXPERIMENTAL|RLD patch with heat|RLD rivastigmine patch (4.6 mg/24 hours); worn for 9 hours; 90 min heat application
62268179|NCT04947670|SHAM_COMPARATOR|Control Group|Sham intervention, maintenance of heart failure medications with option for cross-over renal denervation treatment after 12 months
62627708|NCT03915626|EXPERIMENTAL|generic patch with heat|generic rivastigmine patch (4.6 mg/24 hours); worn for 9 hours; 90 min heat application
62268180|NCT01617278|EXPERIMENTAL|I-Scan 1|I-Scan 1 modality will be used by the endoscopist for the entire procedure
62268181|NCT01617278|EXPERIMENTAL|HD Colon|High definition white light modality will be used by the endoscopist for the entire procedure
62063208|NCT01431040|ACTIVE_COMPARATOR|Group A|Group A will have no bowel preparation and be permitted a regular diet the day prior to surgery until midnight.
62268182|NCT01617278|EXPERIMENTAL|I-scan 2|I-Scan 2 modality will be used by th endoscopist through out the procedure
62268183|NCT00505999||Questionnaire|Patients diagnosed with Multiple Myeloma and healthy controls.
62268184|NCT06208592||Anaconda Group|Use of Anaconda devide at any point during the initial follow up (7 days) additional of conventional intravenous sedation
62268185|NCT06208592||Non-Anaconda Group|Use on conventional intravenous sedation, not using Anaconda device
62268186|NCT01217021|EXPERIMENTAL|Assess [18F] MNI-558 and PET imaging|
62268187|NCT03033537||Verapamil|Intracavernosal injection of Verapamil
62853178|NCT06288464|EXPERIMENTAL|Intervention|Stoma feeding
62853179|NCT00827138|EXPERIMENTAL|DCC-2036|This is a single arm study
62853180|NCT03840434|OTHER|CCS group|Measurements by intramuscular punction and non invasive tool
62853181|NCT04143308|EXPERIMENTAL|Simultaneous training of walking and cognitive group|"1. Wearable technology (fitness wristband \& App)~2. SWATCH system (App \& controller)~3. 3 times a week (30 mins/ each time)~4. Lasts for 12 weeks~5. Simultaneous walking and cognitive training"
62853182|NCT04143308|ACTIVE_COMPARATOR|Cognitive training group|"1. Wearable technology (fitness wristband \& App)~2. SWATCH system (App)~3. 3 times a week (30 mins/ each time)~4. Lasts for 12 weeks~5. Cognitive training while sitting"
62853183|NCT04143308|ACTIVE_COMPARATOR|Treatment as usual group|1. Keep treatment as usual group at health care system.
62853184|NCT03495856|EXPERIMENTAL|Mindfulness Training For Chronic Pain|The intervention is adapted from the mindfulness-based stress reduction program. The adapted mindfulness training program consists of four, weekly 90 minute group sessions that focus on education on chronic pain and mindfulness, instruction and in-class mindfulness skills practice, and group discussion.
62853185|NCT04511377|EXPERIMENTAL|Digital Healthcare System Rehabilitation|Rehabilitation using Uincare Homeplus
62268188|NCT03033537||Phentolamine|Intracavernosal injection of Phentolamine to treat erectile dysfunction for a period of 2 wweks
62268189|NCT03279380|EXPERIMENTAL|Single-nucleotide polymorphisms (SNPs)|In the first part the Case-control study design will be used to estimate the association between multiple single-nucleotide polymorphisms (SNPs) and the endurance/power athlete status.
62268190|NCT03279380|ACTIVE_COMPARATOR|High Intensity Interval Training (HIIT)|"High intensity interval exercise on the cycling ergometer (Velodyn, Racermate ™, USA).~Protocol: 8 x 5 min at 80% PPO (between intervals 1.5 min at 75 W). Baseline measurements will include the V̇O2peak test and peak power output. Monitoring of physiological responses with spirometry and analysis of expired air (oxygen and carbon dioxide output) (Quark, Cosmed, Rim, Italy)."
62853186|NCT04511377|ACTIVE_COMPARATOR|Conventional Rehabilitation|Rehabilitation using Brochure
62451168|NCT00914888|EXPERIMENTAL|A|Tigecycline
62853187|NCT04664764|ACTIVE_COMPARATOR|degludec arm|Group A received insulin degludec,
62853188|NCT04664764|ACTIVE_COMPARATOR|glargine arm|group B received insulin glargine
62853189|NCT04664764|ACTIVE_COMPARATOR|NPH group|Group C received NPH insulin
62853190|NCT02921464||Group A|Group A - without known pre-existing SIHD
62853191|NCT02921464||Group B|Group B - with known pre-existing SIHD.
62451169|NCT00914888|ACTIVE_COMPARATOR|B|Ceftriaxone regimen
62451170|NCT04597086|EXPERIMENTAL|Group I (BWLT, best practice)|Patients receive BWLT over 30 minutes in addition to standard of care daily during hospital stay.
62451171|NCT04597086|ACTIVE_COMPARATOR|Group II (standard of care)|Patients receive standard of care during hospital stay.
62451172|NCT03997448|EXPERIMENTAL|Abemaciclib and Pembrolizumab|Abemaciclib 150mg days 1-21, and Pembrolizumab 200mg IV, Day 1
62627709|NCT02103699||Hepatitis C virus infected patients receiving simeprevir|
62627710|NCT03758599|EXPERIMENTAL|Climbing Exercise Group|At the beginning of each session, a standardized body-centered, mind-setting warmup of ten minutes will take place. The general warm-up will be followed by climbing specific warm-up, which will consist of bouldering (20-30 minutes). Afterwards the rope climbing session will start. Climbing sessions also contain several sport-specific skill-development training sessions to familiarize the participants with gear and rope management, to acquire footwork and route finding, and to locate good belay spots and resting positions while climbing. At the end of the climbing session a short cool-down of five minutes will be executed.
62627711|NCT03758599|EXPERIMENTAL|Aerobic Exercise Group|As the climbing exercise group, the aerobic exercise group will start with a ten minutes body-centered, mind-setting warm-up, followed by 60 minutes of Nordic walking and five minutes cool down. A physiotherapist or sport scientist will instruct and guide the group. Nordic walking will be performed at a moderate pace at varying paths.
62853192|NCT02198001|ACTIVE_COMPARATOR|tooth extraction and insertion of PRF|Experimental: Atraumatic tooth extraction with antibiotics( amoxicillin clavulanate combination) .Insertion of PRF membrane in tooth-extraction site.
62268191|NCT03279380|ACTIVE_COMPARATOR|Low Intensity Continuous Training|"Low intensity continuous exercise on the cycling ergometer (Velodyn, Racermate ™, USA).~Protocol: continuous 60 min cycling at 50% PPO. Baseline measurements will include the V̇o2peak test and peak power output. Monitoring of physiological responses with spirometry and analysis of expired air (oxygen and carbon dioxide output) (Quark, Cosmed, Rim, Italy)."
62268192|NCT06475014||Knee with OA|Underwent Total Knee replacement Surgery, using 3D printed PSI,
62268193|NCT02317666|EXPERIMENTAL|Medication Review|Structured 5-step multidisciplinary medication review (STRIP method) performed by the pharmacist in collaboration with the general practitioner.
62268194|NCT02317666|NO_INTERVENTION|Delayed Medication Review|Patients in the control group will not undergo a medication review during the study period (delayed medication review).
62853193|NCT02198001|PLACEBO_COMPARATOR|No PRF|Atraumatic extraction with antibiotic without PRF insertion
62853194|NCT01460511|PLACEBO_COMPARATOR|P - Placebo-HFA|Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
62268195|NCT01849302|EXPERIMENTAL|High protein/ High fat beverage|"Beverage based on milk protein: 1.8 MJ, 40 E% Protein, 42 E% fat~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
62268196|NCT01849302|EXPERIMENTAL|High protein/ Normal CHO beverage|"Beverage based on milk protein: 1.8 MJ, 40 E% Protein, 47 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
62268197|NCT01849302|EXPERIMENTAL|Low protein/ High fat beverage|"Beverage based on milk protein: 1.8 MJ, 9 E% Protein, 63 E% fat~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
62268198|NCT01849302|EXPERIMENTAL|Low protein/ High CHO beverage|"Beverage based on milk protein: 1.8 MJ, 9 E% Protein, 71 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
62268199|NCT01849302|EXPERIMENTAL|Normal protein/ Normal CHO beverage 1|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
62853195|NCT01460511|EXPERIMENTAL|T - E004 (Epinephrine Inhalation Aerosol) HFA-MDI|E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID
62853196|NCT02919358|EXPERIMENTAL|Music|Exposure to music, twice per day for the study period
62853197|NCT02919358|OTHER|Control|No intervention; standard care.
62853198|NCT00199043|EXPERIMENTAL|Only 1 arm|
62853199|NCT03608358|EXPERIMENTAL|Dapagliflozin 10 mg|Dapagliflozin 10 mg and dapagliflozin 5 mg placebo to match added to saxagliptin 5 mg and metformin
62853200|NCT03608358|EXPERIMENTAL|Dapagliflozin 5 mg|Dapagliflozin 5 mg and dapagliflozin 10 mg placebo to match added to saxagliptin 5 mg and metformin
62853201|NCT03608358|PLACEBO_COMPARATOR|Placebo|Dapagliflozin 5 mg placebo to match and dapagliflozin 10 mg placebo to match added to saxagliptin 5 mg and metformin
62853202|NCT01896206|EXPERIMENTAL|CNAP monitor|Subjects undergoing bariatric surgery and monitored using the CNAP monitor.
62853203|NCT02192333|NO_INTERVENTION|Arm I (usual care)|Participants receive usual care. After 12 months, participants may receive a survivorship clinic visit and boosters as in Arm II.
62853204|NCT02192333|EXPERIMENTAL|Arm II (survivorship care)|Participants attend a survivorship clinic visit that includes care plans, screening recommendations, physician coordination, health promotion education, symptom management and palliative care, late effects education, psychosocial and medical assessments, and referrals for services and care as appropriate. Participants also receive phone-based survivorship boosters over approximately 15-30 minutes at 4-8 weeks and 12-16 weeks after the initial clinic visit.
62853205|NCT03234569|EXPERIMENTAL|sonoHSG|This is the research procedure and it will be added onto the standard of care procedure for all subjects.
62853206|NCT01696682|EXPERIMENTAL|Narrow Gastric Conduit|The group in which narrowed gastric conduit will be performed during minimally invasive esophagectomy
62853207|NCT01696682|EXPERIMENTAL|Wide Gastric Conduit|The group in which widened gastric conduit will be performed during minimally invasive esophagectomy
62853208|NCT05083858|EXPERIMENTAL|Classical Physiotherapy Program + Cervical Stabilization Exercises|In addition to classical physiotherapy, Cervical Stabilization Exercises will be applied to the individuals in the 1st group.
62853209|NCT05083858|EXPERIMENTAL|Classical Physiotherapy Program + Oculomotor Exercises|In addition to classical physiotherapy, Oculomotor Exercises will be applied to the individuals in the 2nd group.
62853210|NCT05083858|ACTIVE_COMPARATOR|Classical Physiotherapy Program|Only the classical physiotherapy program will be applied to the individuals in 3rd group.
62853211|NCT00483756|ACTIVE_COMPARATOR|1|Treatment Arm 1 will also receive standard of care medications
62853212|NCT00483756|EXPERIMENTAL|2|Treatment Arm 2 will also receive standard of care medications
62853213|NCT00483756|EXPERIMENTAL|3|Treatment Arm 3 will also receive standard of care medications
62853214|NCT06491901|EXPERIMENTAL|Ultrasound group|Lung ultrasonography will be performed within 1 h of admission, followed by lung ultrasound scoring.
62853215|NCT06491901|ACTIVE_COMPARATOR|Control group|NRDS was diagnosed according to clinical criteria.
62853216|NCT00796523|EXPERIMENTAL|Happiest Baby videotape|videotape describing the Happiest Baby on the Block technique
62268200|NCT01849302|EXPERIMENTAL|Normal protein/Normal CHO beverage 2|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
62853217|NCT00796523|PLACEBO_COMPARATOR|control videotape|videotape with normal newborn instruction
62853218|NCT01370252||scope technique|
62451173|NCT05722600|EXPERIMENTAL|Hardaliye Group|Hardaliye Group consumed 250 ml/day of hardaliye (grape juice) for 28 days.
62451174|NCT05722600|PLACEBO_COMPARATOR|Placebo Group|Placebo Group consumed 250 ml/day of placebo drink for 28 days.
62627712|NCT03758599|ACTIVE_COMPARATOR|Social Contact Control Group|Patients allocated to the social contact control group will receive the same amount of social interaction as the exercise groups. A physiotherapist or sport scientist will be present while participants watch movies with relevant content to disease followed by interactive group discussions. This group is required to control for the impact of social contact/support on AD/PTSD and secondary outcomes.
62627713|NCT06483906|EXPERIMENTAL|VAH regimen combined with allo-HSCT|Eligible patients receive two cycles of the VAH chemotherapy regimen. If minimal residual disease (MRD) is negative after these two cycles, patients proceed to the transplantation process. If MRD remains positive, patients receive an additional two cycles of the VAH regimen. Upon achieving MRD negativity, they then proceed to the transplantation process.
62451175|NCT03593382||Female endurance athletes|Female endurance athletes recruited from Swedish and Danish national teams and competitive sport clubs
62451176|NCT02592148||Health subjects|Male and female
62451177|NCT05045209||Virtual rehabilitation|Virtual pulmonary rehabilitation will be provided by a tablet with connection to a physiotherapist for monitored exercise sessions with educational videos provided on the tablet.
62451178|NCT01415466|EXPERIMENTAL|R|multiple dose of Rosuvastatin 20mg
62627714|NCT06028854||High Neutrophil count|Patients with high neutrophil count in their preoperative complete blood count
62627715|NCT06028854||Low Neutrophil count|Patients with low neutrophil count in their preoperative complete blood count
62627716|NCT03999957|OTHER|Interventional Arm|Telehealth conferencing
62853219|NCT01370252||open technique|
62853220|NCT05847985|NO_INTERVENTION|Differences between LBDs patients and HC in regulation of language functions|In this study, 25 LBDs patients and 25 HC will undergo neuropsychological assessment, speech and writing recording, and MRI (structural T1 sequences, sentence comprehension fMRI task, neuromelanin-sensitive MRI sequence, and resting state measurement). The HC group will be matched to the LBDs patients with MCI for gender and age.
62627717|NCT00549796|ACTIVE_COMPARATOR|1|PCI performed at a hospital with co-located (on-site) cardiac surgery
62627718|NCT00549796|OTHER|2|PCI performed at a hospitals without co-located (on-site) cardiac surgery
62627719|NCT02583022|EXPERIMENTAL|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
62627720|NCT02583022|PLACEBO_COMPARATOR|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
62627721|NCT02583022|ACTIVE_COMPARATOR|Elidel cream 1%|Elidel cream 1%, Twice daily for 4 weeks
62451179|NCT01415466|EXPERIMENTAL|O|multiple dose of CS-866 40mg
62451180|NCT01415466|EXPERIMENTAL|R+O|multiple dose of the combination of Rosuvastatin 20mg and CS-866 40mg
62451181|NCT04371809||control subjects|
62451182|NCT04371809||subjects with Atrial Fibrillation|
62063209|NCT01431040|ACTIVE_COMPARATOR|Group B|Participants in this group will consume a clear liquid diet and perform 2 Fleets enemas in the late afternoon the day before surgery and nothing after midnight.
62063210|NCT05344261|ACTIVE_COMPARATOR|Control Arm|Standard Post-Amputation Surgical Care: Briefly, the transected nerves will be blindly tucked into surrounding bulky soft tissue to protect the nerve ends before the wound is closed.
62063211|NCT05344261|EXPERIMENTAL|Targeted Muscle Re-innervation|Briefly, each transected nerve is identified after amputation using 6-0 Prolene suture and is dissected proximally for length. With minimal dissection, a nerve stimulator is used to identify functional motor nerve branches. Near the point where the motor branch enters the muscle, the motor nerve branch is transected and an end-to-end coaptation is performed with a nearby tagged amputated nerve.
62063212|NCT05344261|EXPERIMENTAL|Regenerative Peripheral Nerve Interface|Briefly, a muscle graft (usually from the amputated limb) is wrapped around the clean ends of the transected nerve(s).
62063213|NCT03091647|EXPERIMENTAL|acupressure intervention|Practice acupressure at home and complete daily logs
62063214|NCT03091647|PLACEBO_COMPARATOR|usual care|Receive usual care and complete daily logs
62063215|NCT05529758|EXPERIMENTAL|Intervention Group|Receives internalized weight bias intervention along with standard behavioral weight loss program
62451183|NCT04371809||subjects with Acute Coronary Syndrome|
62063216|NCT06112223|EXPERIMENTAL|Gabapentin|Patients will receive oral gabapentin 600 mg 1 hour before the surgery.
62451184|NCT04371809||subjects with Acute Coronary Syndrome and Atrial Fibrillation|
62451185|NCT00769106|NO_INTERVENTION|B (control group)|regular treatment and follow up
62451186|NCT00769106|EXPERIMENTAL|A (CIK group)|cytokine-induced killer cell treatment plus regular treatment and follow up
62451187|NCT01617577|EXPERIMENTAL|G-CSF (filgrastim) first phase|Subjects assigned to this arm receive G-CSF for 5 days during the first phase of the study. At week 7 these subjects cross over to receive placebo injections for five days
62451188|NCT01617577|PLACEBO_COMPARATOR|Placebo first phase|Subjects assigned to this arm receive placebo injections daily for 5 days; after wk 7 they crossover to receive 5 daily injections of injections of G-CSF.
62451189|NCT03882320|EXPERIMENTAL|Sublingual Patient Controlled Analgesia (PCA)|Sufentanil Sublingual Patient Controlled Analgesia (PCA)
62627722|NCT03351088|OTHER|Preventive ligation|Preventive ligation of DVC is done after the opening of endopelvic fascia and before bladder neck dissection. DVC is ligated at the level of the apex with a 8-fashion single stich (1-0 Monocryl® CT-1 stich) trying to preserve puboprostatic ligaments and the muscle fibres of the rabdosphincter. DVC is then dissected at the end of prostatectomy before the section of the urethra.
62627723|NCT03351088|OTHER|Delayed ligation|Delayed ligation is done after the section of the urethra and once the prostatectomy is completed with a single stich (3-0 Monocryl® UR-6).
62627724|NCT01984957|OTHER|disease (ALS, SMA or SBMA)|muscle biopsy
62627725|NCT05934123||Intervention group|Infants admitted to the 11 EMNODN neonatal units
62627726|NCT04007510|EXPERIMENTAL|EPI-CAL mHealth data network|"This arm of the study involves the use of the mobile health technology (app) to measure outcomes within an early psychosis (EP) program."
62627727|NCT04007510|EXPERIMENTAL|DUP Evaluation|A subset of individuals will participate in interviews to validate a tool to determine the duration of untreated psychosis in community settings
62627728|NCT03476902|EXPERIMENTAL|Integrated Mobile Treatment|Individuals will receive 4 introductory sessions with a therapist followed by weekly phone calls. Participants will utilize nOCD application to assist with treatment protocol adherence.
62627729|NCT01601496|EXPERIMENTAL|FUSION Vascular Graft|All subjects who received a FUSION Vascular Graft at the baseline implant procedure.
62627730|NCT03388398||Mother-Infant Pairs|Mothers or caregivers (at least 16 years of age) and their infants who are 9 to 18 months of age at the time of their survey.
62627731|NCT03388398||Mothers or caregivers|Mothers or caregivers (at least 16 years of age) who are 19 to 36 months postpartum at the time of the survey.
62627732|NCT03388398||Healthcare staff|Healthcare staff (employed staff and volunteers at least 18 years of age) at all participating healthcare facilities.
62627733|NCT03388398||Providers|Health care providers (at least 18 years of age) at select participating healthcare facilities.
62627734|NCT03388398||Patients|Patients (at least 18 years of age) receiving care at select participating healthcare facilities.
62627735|NCT05450172||Consecutive patients scheduled for thoracic surgery|
62627736|NCT02837393||History of Kidney Stones|Participants with a history of kidney stones who will be undergoing kidney surgery.
62627737|NCT02837393||No History of Kidney Stones|Participants without a history of kidney stones who will be undergoing kidney surgery.
62627738|NCT03826537|OTHER|Honey substance|Honey substance containing 5.1 mg/kg tutin and 23 mg/kg hyenanchin. Subjects to receive single dose of test material such that each subject receives 1.8 mcg/kg body weight of tutin.
62627739|NCT00921583||1|Examination of dental implants 20 years in function
62627740|NCT00638092|EXPERIMENTAL|Iodine|This is the hypothetical active arm
62627741|NCT00638092|PLACEBO_COMPARATOR|Placebo|this is the hypothetical placebo
62627742|NCT02482883|ACTIVE_COMPARATOR|active Transcutaneous Electrical Nerve Stimulation|Arm A, treated by active stimulation of the trigeminovascular system after placement of the TENS device.
62627743|NCT02482883|SHAM_COMPARATOR|sham Transcutaneous Electrical Nerve Stimulation|Arm B, treated by non-active (sham) stimulation after placement of the TENS device. This absence of stimulation corresponds to the standard of care currently received by patients hospitalized for SAH due to ruptured aneurysm.
62627744|NCT04697290|EXPERIMENTAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for at least 2 days before infusion.
62627745|NCT04322084||Participants|Participants will be enrolled during induction therapy for ALL, before the first high-risk period of treatment, and will contribute data for two 5-day periods of continuous monitoring.
62627746|NCT04262193|PLACEBO_COMPARATOR|Suvorexant placebo|Placebo (inert) tablet
62627747|NCT04262193|EXPERIMENTAL|Suvorexant 20mg|Suvorexant 20mg tablet
62627748|NCT06612905||Housewife postmenopausal women|It will consist of 74 housewife postmenopausal women, at least 12 months after their last menstrual cycle.
62627749|NCT06612905||Worker postmenopausal women|It will consist of 74 worker postmenopausal women, at least 12 months after their last menstrual cycle.
62627750|NCT03665662|EXPERIMENTAL|Intervention|Patients in this arm will receive patient-selected music through headphones throughout their procedure.
62627751|NCT03665662|NO_INTERVENTION|Control|Patients will be wearing headphones during their procedure (for the purpose of blinding the care team), but will not receive any music, sounds or sound-cancelling effects through the headphones.
62627752|NCT03090061|EXPERIMENTAL|Light induced fluorescence intraoral camera|
62627753|NCT03090061|ACTIVE_COMPARATOR|Visual-tactile assessment method according to FDI criteria|
62627754|NCT05534568|EXPERIMENTAL|Treatment Group|The treatment group consists of women who have used alcohol, opioids, or other drugs during pregnancy and their children. Mothers who are randomly assigned to the treatment group will receive PCAP services through the work of highly trained, closely supervised case managers.
62627755|NCT05534568|NO_INTERVENTION|Control Group|The control group consists of women who have used alcohol, opioids, or other drugs during pregnancy and their children. Women in the control group will be provided with a service resource list and receive services as usual, but they will not be enrolled in PCAP.
62063217|NCT06112223|EXPERIMENTAL|Tramadol|Patients will receive oral tramadol 100 mg 1 hour before the surgery.
62627756|NCT06612450|ACTIVE_COMPARATOR|Coblation|patients will undergo turbinoplasty using coblation wand
62063218|NCT04686162|EXPERIMENTAL|Group using the smartphone application bae|Patients with personal history of suicide attempt or with suicidal ideation, will use the application during 6 months.
62451190|NCT03882320|ACTIVE_COMPARATOR|Intravenous Patient Controlled Analgesia (PCA)|Oxycodone Intravenous Patient Controlled Analgesia (PCA)
62627757|NCT06612450|ACTIVE_COMPARATOR|RaVoR|patients will undergo turbinate reduction using ravor radiofrequency
62627758|NCT03042351|OTHER|Unique arm|Magic Kegel app
62063219|NCT03399162|EXPERIMENTAL|PREHAB Group|"Patients in this arm will receive the usual standard of care prior to surgery, which includes a PREHAB workshop; consultations with a surgeon, anaesthesiologist, and nurse; referrals to diabetes counselling and/or smoking cessation, as appropriate; and the usual diagnostic work-up.~Patients in this group will also complete an 8-week PREHAB exercise program, with weekly exercise classes and a list of exercises to complete at home."
62063220|NCT03399162|ACTIVE_COMPARATOR|Standard of care group|Patients in this arm will receive the usual standard of care prior to surgery, which includes a PREHAB workshop; consultations with a surgeon, anaesthesiologist, and nurse; referrals to diabetes counselling and/or smoking cessation, as appropriate; and the usual diagnostic work-up.
62063221|NCT02187666||Lumbar|Patients undergoing lumbar spinal surgery
62451191|NCT06263322|EXPERIMENTAL|ROAMM-EHR|Patients will wear a smartwatch equipped with a smartwatch app before their surgery and for approximately a month after the surgery. Patients will be asked to wear the watch every day when awake. When wearing the smartwatch, patients will be asked questions about their symptoms following surgery and data will be sent to providers electronically and displayed in their EHR portal. Healthcare Providers will use this information along with patient medical history to decide on the next course of action. The study does not provide specific instructions about how to care for the patient. Those decisions are made by the provider team and their clinical judgement.
62627759|NCT02423811|EXPERIMENTAL|CCRT plus Fursultiamine|"Fursultiamine 100mg tid, po Radiotherapy 36Gy/18Fx Chemotherapy will include Cisplatin and 5-FU. Cisplatin 60-75 mg/m2 on days 1 and 29 with standard prehydration and antiemetic therapy.~5-FU 600-1000 mg/m2day administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1 through 4 and 29 through 32"
62627760|NCT06477705|NO_INTERVENTION|Control|Participants in this arm will receive no intervention
62627761|NCT06477705|EXPERIMENTAL|Recreational Football Training|Participants in this arm will participate in a football training session for 60 minutes. During the training the participans will execute the warm-up process, the part of soccer technical exercises and they will play a small-side-game.
62451192|NCT06263322|ACTIVE_COMPARATOR|Active Comparison|The active comparison patients will wear and respond to questions on the smartwatch. However, the information will not be viewable by their doctor and medical team. All standard of care procedures will remain.
62627762|NCT01865656|OTHER|4 intervention first referral units|"A Quasi-experimental intervention/control trial will be implemented to assess the impact of the following interventions on the outcome measures in a cluster of 4 intervention sites relative to a matched cluster of 4 control sites:~Refresher/simulation training to improve provider skills/knowledge Implementation of Emergency Obstetric Drills Revised Case sheets(for data collection and therefore part of both control and intervention sites), Mentoring and Supportive supervision, and Referral Strengthening"
62627763|NCT01865656|NO_INTERVENTION|Control Arm|
62627764|NCT02714036|EXPERIMENTAL|Regular|Participants will receive up to 100 mg /day MN-166 for 36 weeks. MN-166 dosing may vary based on individual tolerability.
62627765|NCT02714036|EXPERIMENTAL|Flexible|Participants will receive up to 100 mg /day MN-166 for 36 weeks. MN-166 dosing may vary based on individual tolerability. Participants will have all assessments except PET scans.
62627766|NCT01904968||Colon cancers in patients living the Cote D'or area|
62627767|NCT03625700||Hypoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation \<94 % irrespective of supplemental oxygen~Patients with chronic obstructive pulmonary disease: blood oxygen saturation \<88% irrespective of supplemental oxygen"
62627768|NCT03625700||Normoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation 94-98% in combination with supplemental oxygen OR blood oxygen saturation ≥94% without supplemental oxygen.~Patients with chronic obstructive pulmonary disease: blood oxygen saturation 88-92% in combination with supplemental oxygen OR blood oxygen saturation ≥88% without supplemental oxygen."
62627769|NCT03625700||Hyperoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation \>98% in combination with supplemental oxygen~Patients with chronic obstructive pulmonary disease: blood oxygen saturation \>92% in combination with supplemental oxygen"
62627770|NCT00411723|EXPERIMENTAL|1|
62063222|NCT02187666||Cervical|Patients undergoing cervical spine surgery
62627771|NCT00411723|PLACEBO_COMPARATOR|2|
62063223|NCT06371963||Elite Athletes|Senior Swedish male and female national team and recruiting squad athletes.
62627772|NCT02937740|OTHER|Naive patients - ARM 1|"NATESTO Testosterone Nasal Gel administered intranasally to patients with no prior TRT experience. Multiple-dose dispenser will be used for gel deposition into the nasal cavity. The dispenser is a finger-actuated, non-pressurized dispensing system designed to deliver 122.5mg of NATESTO (5.5mg testosterone) per actuation.~For BID administration, NATESTO 22 mg/day of testosterone. For the subset of patients that continue on TID, NATESTO 33 mg/day of testosterone."
62063224|NCT06371963||Gender and age matched controls|Healthy male and female non-elite athletic controls.
62063225|NCT03852966|EXPERIMENTAL|CBT-i/ADHD|Behavioral treatment for sleep problems in ADHD
62063226|NCT03749447|EXPERIMENTAL|Bardoxolone methyl|"Adult participants received bardoxolone methyl capsules, once daily (QD) at a starting dose of 5 milligrams (mg), followed by dose- escalation to 10 mg at Week 2 (Day 14 ± 3), and to 20 mg at Week 4 (Day 28 ± 3). Based on the eligibility UACR \>300 milligrams per gram (mg/g), the dose was increased to 30 mg starting from Week 6 (Day 42 ± 3) until the end of the study.~Participants under 18 years of age received bardoxolone methyl capsules at a starting dose of 5 mg every other day during the first week and QD during the second week of the study, followed by dose-escalation to 10 mg at Week 2 and to 20 mg at Week 4. Based on the eligibility UACR \>300 mg/g, the dose was increased to 30 mg starting from Week 6 until the end of the study."
62063227|NCT01086865|ACTIVE_COMPARATOR|Petivit BC|
62063228|NCT01086865|EXPERIMENTAL|Apetiviton BC|
62451193|NCT03769480||Study Group|Study Group=Athletes with Disability
62451194|NCT03769480||Control Group|Control Group=Healthy Athletes
62451195|NCT04790084||Healthy-Myopia-CSC|Cross-sectional study, no intervention, only collecting OCT,OCTA images and other eye parameters of patients.
62451196|NCT00617461|EXPERIMENTAL|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, 4 weeks treatment in either the first or second treatment period
62451197|NCT00617461|EXPERIMENTAL|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, 4 weeks treatment in either the first or second treatment period
62451198|NCT05131906|EXPERIMENTAL|People with Parkinson's disease on medication who freeze|We will be testing each of the 15 participants both with and without the removeable lasers on their shoes.
62451199|NCT04296357||IVF children|Children born from in-vitro fertilization
62451200|NCT04296357||IVM children|Children born from in-vitro maturation
62451201|NCT02234609|OTHER|adults with incisor dental caries lesion|modified ART class IV with glass ionomer cement
62451202|NCT03629925|EXPERIMENTAL|Sintilimab+ gemcitabine plus platinum|Sintilimab combination arm: Sintilimab in combination with gemcitabine plus cisplatin or carboplatin
62652912|NCT01399957||pwMS prescribed dalfampridine-ER|Anyone prescribed D-ER per usual clinical care was recruited into this observational study. All those willing to participate were consented and observed pre-drug and for a 14week period with two follow-up visits scheduled at 12 and 18months.
62451203|NCT03629925|PLACEBO_COMPARATOR|Placebo+gemcitabine plus platinum|Placebo combination arm: Placebo in combination with gemcitabine plus cisplatin or carboplatin
62451204|NCT00810368|ACTIVE_COMPARATOR|Carnosine treatment group|Carnosine treatment group
62627773|NCT02937740|OTHER|Non-naive patients - ARM 2|"NATESTO Testosterone Nasal Gel administered intranasally to patients who had prior TRT. Multiple-dose dispenser will be used for gel deposition into the nasal cavity. The dispenser is a finger-actuated, non-pressurized dispensing system designed to deliver 122.5mg of NATESTO (5.5mg testosterone) per actuation.~For BID administration, NATESTO 22 mg/day of testosterone. For the subset of patients that continue on TID, NATESTO 33 mg/day of testosterone."
62853221|NCT05847985|EXPERIMENTAL|Long-term effects of repeated sessions of home-based tDCS delivered via telepractice|The investigators will use a parallel-group, double-blinded, randomized, sham-stimulation-controlled design. Forty LBDs patients will be randomized into two parallel groups, n = 20 subjects in each arm. For the active group, the investigators will use the stimulation protocol with the anode over the left IFG (cathode over the right supraorbital area, 2mA, 20 minutes). Participants will undergo a baseline assessment (A0, as described in arm 1); 10 stimulation sessions (in a two-week period); a follow-up assessment immediately after tDCS treatment (A1), and follow-up assessments 8 weeks (A2) after the baseline assessment. Each assessment will consist of a brief neuropsychological assessment, speech and writing recording and MRI scanning.
62853222|NCT02756429|EXPERIMENTAL|atrial fibrillation|Patients with atrial fibrillation
62451205|NCT00810368|PLACEBO_COMPARATOR|Placebo control group|Placebo control group
62853223|NCT02756429|EXPERIMENTAL|Control|Patients without atrial fibrillation
62853224|NCT03034551|EXPERIMENTAL|Intervention Arm|Subjects in the treatment arm will be offered a $150 incentive to use the Wellth app each day to log one daily self-weighing and one medication check-in. If a sudden jump in weight is detected among any subjects receiving the Financial Incentive, Mobile Phone App, and Cellular Scale, a UMCPP physician or nurse will then call the patient to assess the patient's symptoms (i.e. increasing shortness of breath or decreases in exertional tolerance, medication and dietary adherence).
62853225|NCT03034551|NO_INTERVENTION|Standard of Care (Control) Arm|Patients randomized to the standard of care arm will not receive the Wellth app or scale. They will have the usual discharge instructions as prescribed by their health care team.
62088041|NCT05419674|EXPERIMENTAL|group B: dual therapy (rabeprazole+amoxicillin)|rabeprazole 10mg tid and amoxicillin 1000mg tid for 10 days
62451206|NCT04456361|EXPERIMENTAL|COVID-19 patients|Treatment consistsof Mesenchymal Stem Cells administered as a one-time, single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.
62451207|NCT01002690|EXPERIMENTAL|Etoricoxib|10-13 days treatment with etoricoxib
62451208|NCT04130789||patients with sepsis (cases)|patients who developed or were admitted with sepsis to the ICU (cases)
62451209|NCT04130789||patients without sepsis (controls)|patients who did not develop sepsis (controls).
62451210|NCT03842943|EXPERIMENTAL|Combination T-VEC/Pembrolizumab|"Pre-operative talimogene laherparepvec (T-VEC) with Pembrolizumab~T-VEC - intra-lesional injection into palpable lymph nodes every 3 weeks for 6 months, or until complete response of target tumors.~Pembrolizumab - administered intravenously every 3 weeks for 6 months, then every 3 weeks for one year in the adjuvant setting following complete lymph node dissection."
62451211|NCT05960864||Ankylosing spondylitis|Ankylosing spondylitis according to the modified New York criteria or with the clinical diagnosis of AS/r-axSpA fulfilling the ASAS Classification Criteria AND the mNY criteria plus having the indiaction for starting a bDMARD therapy according to the treating rheumatologist
62451212|NCT05960864||Non-radiographic axial spondyloarthritis|Patients with clinical characteristics of axial SpA but not fulfilling the modified New York criteria for which radiographic sacroiliitis is essential or with the clinical diagnosis of nr-axSpA fulfilling the ASAS Classification Criteria not fulfilling the mNY criteria and the indiaction for starting a bDMARD therapy according to the treating rheumatologist
62451213|NCT05960864||Juvenile spondyloarthritis|Patients with juvenile spondyloarthritis (juvenile ankylosing spondylitis, juvenile non-AS-spondyloarthritis).
62451214|NCT05960864||Crohn's disease|Patients with Crohn's disease
62451215|NCT05960864||Acute anterior uveitis|Patients with acute anterior uveitis
62451216|NCT05960864||Axial psoriatic arthritis|Patients with the clinical diagnosis of psoriatic arthritis with axial involvement (sacroiliac joints and/or spine) (axPsA)
62451217|NCT05960864||Reactive arthritis|Patients with reactive arthritis
62451218|NCT04604184|EXPERIMENTAL|BI 764198 treatment group|
62451219|NCT04604184|PLACEBO_COMPARATOR|Placebo|
62451220|NCT06157086||ofatumumab|MS adult patients who initiated ofatumumab as per neurologist practice and regardless of the study protocol
62451221|NCT06378619||Essential Tremor|Tris group will include 55 participants affected by essential tremor
62451222|NCT06378619||Parkinson Disease|Tris group will include 55 participants affected by Parkinson Disease
62451223|NCT01030965|EXPERIMENTAL|GSK573719 125mcg|125mcg once-daily via novel dry powder inhaler
62451224|NCT01030965|EXPERIMENTAL|GSK573719 250mcg|250mcg once-daily via novel dry powder inhaler
62451225|NCT01030965|EXPERIMENTAL|GSK573719 500mcg|500mcg once-daily via novel dry powder inhaler
62451226|NCT01030965|PLACEBO_COMPARATOR|Placebo|once-daily via novel dry powder inhaler
62451227|NCT03576391|EXPERIMENTAL|Control condition|Control condition to assess whether the repetition of a RAM task without fatiguing task in between 2 repetitions affects trunk motor control and cortical movement preparation.
62451228|NCT03576391|EXPERIMENTAL|Physical Fatigue condition|Fatigue condition to assess whether a physical fatiguing task in between 2 RAM tasks affects trunk motor control and cortical movement preparation for the 2nd RAM.
62451229|NCT03576391|EXPERIMENTAL|Cognitive Fatigue condition|Fatigue condition to assess whether a cognitive fatiguing task in between 2 RAM tasks affects trunk motor control and cortical movement preparation for the 2nd RAM.
62627774|NCT04215796|EXPERIMENTAL|ReX-C intervention|Subjects use ReX-C to receive CFTR modulators medications. Adherence data, side effects and response to treatment are monitored online in real time via ReX-C cloud.
62853226|NCT01952808|EXPERIMENTAL|Intervention Group|Participants randomly assigned to this group will receive the intervention immediately.
62063229|NCT03214081||Vonoprazan 10 mg or 20 mg|Usually, for adults, 10 mg of vonoprazan administered orally once daily. If that dosing proved insufficient, the dosage may have been increased up to 20 mg once daily. Participants received vonoprazan as part of a routine medical care.
62853227|NCT01952808|NO_INTERVENTION|Control Group|Participants randomly assigned to this group will not receive the intervention until one year after enrollment.
62853228|NCT05654077|EXPERIMENTAL|CAR-T Cell Injection|"A total of 24 patients with recurrent or refractory NPC received a single intravenous infusion of CAR-T cells at doses of 3.0 × 10\^6cells/kg, 9.0 × 10\^6cells/kg, and 1.5 × 10\^7cells/kg, respectively, and were enrolled according to the conventional 3+3 dose escalation."
62268201|NCT01849302|EXPERIMENTAL|Normal protein/Normal CHO beverage 3|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
62451230|NCT05283681|EXPERIMENTAL|Risankizumab Dose A|Participants will receive 1 Subcutaneous (SC) injection of risankizumab Dose A administered via Prefilled Syringe (PFS) at Day 1 and followed for 140 days
62627775|NCT05116254|OTHER|AZD1390|"The experimental oral drug AZD1390 (starting dose once daily 20 mg) will be combined with radiotherapy. Drug will be taken at same day as radiotherapy for 5 weeks at weekdays.~When starting dose of 20 mg is proven safe the next cohort will be 100 and thereafter 200, 400 mg"
62853229|NCT03068351|EXPERIMENTAL|RO6870810|Participants will be administered RO6870810 monotherapy at ascending-dose levels during the dose escalation phase followed by an expansion phase during which RO6870810 will be administered as monotherapy at the recommended dose. Participants will continue to receive study drug as long as they experience clinical benefit in the opinion of the Investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression, as determined by the Investigator after an integrated assessment of IMWG response criteria, biopsies/aspirate (if applicable), and clinical status, or withdrawal of consent.
62063230|NCT06363058|NO_INTERVENTION|Stage 1: Healthy people|To establish a baseline and ensure reliability, and to develop a training protocol for stage 3.
62063231|NCT06363058|EXPERIMENTAL|Stage 2: Short-term training SCA people|Short-term ES Cycling Training
62063232|NCT06363058|NO_INTERVENTION|Stage 2: SCA Control group|Control Group
62063233|NCT06363058|EXPERIMENTAL|Stage 3:Long-term training SCA people|Long-term ES Cycling Training
62063234|NCT06363058|NO_INTERVENTION|Stage 3: SCA Control group|Control group
62268202|NCT02587533|ACTIVE_COMPARATOR|Hypoxia without dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. No pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
62268203|NCT02587533|ACTIVE_COMPARATOR|Hypoxia with dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. Counteracting pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
62451231|NCT05283681|EXPERIMENTAL|Risankizumab Dose B|Participants will receive SC injections of risankizumab Dose B administered via PFS at Day 1 and followed for 140 days
62627776|NCT05116254|OTHER|AZD1390 + durvalumab|The experimental oral drug AZD1390 (starting dose once daily 20 mg) will be combined with radiotherapy and durvalumab (fixed dose 1500 mg Q4W, until surgery). Drug will be taken at same day as radiotherapy for 5 weeks at weekdays. The dose of AZD1390 in the AZD1390 plus durvalumab cohort will follow the dosing of the AZD1390 only cohort. When starting dose of 20 mg and the next dose of AZD1390 only has been proven safe, the next cohort will be 100 and thereafter 200, 400 mg.
62627777|NCT02155309|EXPERIMENTAL|Scopolamine|0.2 mg intranasal scopolamine, single dose
62627778|NCT02155309|PLACEBO_COMPARATOR|Placebo|placebo intranasal (0.1 mg per nostril), single dose
62627779|NCT06612788|OTHER|Sham/Active ExAblate Treatment Stage 1 and 2|Subject will undergo both Treatment 1 (sham) and Treatment 2 (with enhanced intensity). Subjects are blinded to the order of the sham vs active treatment.
62268204|NCT02587533|ACTIVE_COMPARATOR|Hyperoxia without dopamine|Nearly complete hemoglobin oxygen saturation. No additional pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
62268205|NCT02587533|ACTIVE_COMPARATOR|Hyperoxia with dopamine|Nearly complete hemoglobin oxygen saturation. Additional pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
62268206|NCT05761028|EXPERIMENTAL|CM310 high dose|CM310 is injected subcutaneously (SC) with a loading dose at the first dose, and then high dose thereafter, once every 2 weeks (Q2W) for a total of 26 doses.
62268207|NCT05761028|EXPERIMENTAL|CM310 low dose|CM310 is injected subcutaneously (SC) with a loading dose at the first dose, and then low dose thereafter, once every 2 weeks (Q2W) for a total of 26 doses.
62627780|NCT02406456|EXPERIMENTAL|Neurofeedback|
62627781|NCT05936021|OTHER|Standard of care|All patients placed on dialysis receive standard of care
62627782|NCT05936021|EXPERIMENTAL|Model-based Aranesp doses|On entering the study cohort, patients will begin receiving doses calculated by the algorithm instead of by the standard of care procedures. Model-based Aranesp doses will be computed at the same time that doses based on the dialysis anemia protocol are determined. The model-based doses will be administered instead of the protocol-based doses and in the same way and at the same time as the protocol-based doses would have been.
62627783|NCT04626258|ACTIVE_COMPARATOR|Active comparator: Fluconazol|Once a month one capsule Fluconazol 150 mg
62268208|NCT05761028|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection (SC), once every 2 weeks (Q2W) for a total of 26 doses.
62268209|NCT06053515|EXPERIMENTAL|Rosie the Chatbot Group|"Participants in the Rosie the Chatbot Group will be taking a pre-test health survey, mid-test health survey, and post-test health survey. In addition, they will be expected to actively use the chatbot app by asking questions related to maternal and infant health and selecting thumbs up or thumbs down to provide feedback for questions' response and using the features (video library, resources page, frequently asked questions (FAQ), and daily syllabus)."
62451232|NCT05283681|EXPERIMENTAL|Risankizumab Dose C|Participants will receive 1 SC injection of risankizumab Dose C administered via Auto-Injector (AI) at Day 1 and followed for 140 days.
62853230|NCT03068351|EXPERIMENTAL|RO6870810 + Daratumumab|Participants will be administered RO6870810 at ascending-dose levels in combination with daratumumab at the recommended dose during the dose escalation phase followed by an expansion phase during which both RO6870810 and daratumumab will be administered each at their recommended dose. Participants will continue to receive the study drugs as long as they experience clinical benefit in the opinion of the Investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression, as determined by the Investigator after an integrated assessment of IMWG response criteria, biopsies/aspirate (if applicable), and clinical status, or withdrawal of consent.
62451233|NCT05813587|EXPERIMENTAL|Meplazumab|First dose: 0.2 mg/kg - Day 1; second dose: 0.2 mg/kg - Day 8
62451234|NCT05813587|PLACEBO_COMPARATOR|Placebo|First dose: control - Day 1; second dose: control - Day 8
62451235|NCT03281499|EXPERIMENTAL|da Vinci Surgical System Model IS4000|Transoral robotic surgery, followed by tailored radiotherapy
62627784|NCT04626258|EXPERIMENTAL|L-Mesitran|The first month every day apply L-mesitran, the next five months apply L-mesitran every week on the vagina
62627785|NCT05996822||AcF injection|Patient having received an AcF injection 1 month after a DXM injection for the treatment of Diabetic Macular Edema or Uveitic Macular Edema
62627786|NCT02216279|EXPERIMENTAL|Pulmonary Hypertension Patients|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
62627787|NCT02216279|ACTIVE_COMPARATOR|Control Non-Smoking Participants|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
62268210|NCT06053515|NO_INTERVENTION|Book Club Group|Participants in the Book Club Group will be taking a pre-test health survey, mid-test health survey, and post-test health survey. In addition, they will receive a monthly children's book, which they are expected to read with baby if parenting or individually if pregnant.
62268211|NCT02419560|EXPERIMENTAL|ABT-199 and Ibrutinib Combination|Participants will take ABT-199 (dose 100-400 mg) and Ibrutinib (dose 280-560 mg).
62268212|NCT00919035|EXPERIMENTAL|Torisel|Single Agent Temsirolimus (Torisel®)
62268213|NCT01125280|EXPERIMENTAL|SBO score application|Acute strangulated SBO patients will receive a severity score at emergency admission. According to the score, they will be managed either conservatively or surgically. During surgery, the need of small bowel resection will be evaluated. The endpoint will be to correlate the type and success of treatment with the score in order to validate this new tool in SBO assessment.
62268214|NCT04642339|EXPERIMENTAL|Vaccine Gam-COVID-Vac|Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2 infection
62268215|NCT04642339|PLACEBO_COMPARATOR|Placebo|Placebo
62268216|NCT01866007|EXPERIMENTAL|Group 1|40 participants will receive a single subcutaneous (SC) injection of 100 mg guselkumab prepared from lyophilized formulation.
62063235|NCT02183935|NO_INTERVENTION|Lifestyle counseling, metformin|Age, gender and BMI matched controls will be managed by lifestyle counseling and metformin if indicated.
62627788|NCT03921476||Subjects on spironolactone for a diagnosis of acne vulgaris|Female subjects between 18 and 65 years of age currently taking spironolactone for a diagnosis of acne vulgaris
62627789|NCT03921476||Subjects on oral antibiotics for a diagnosis of acne vulgaris|Female subjects between 18 and 65 years of age currently taking oral antibiotics for a diagnosis of acne vulgaris
62627790|NCT04036591||Children under 24 months with ARIS|
62627791|NCT05156996||Treatment Group|
62627792|NCT05156996||Control Group|
62627793|NCT00666159|EXPERIMENTAL|1|
62627794|NCT00666159|ACTIVE_COMPARATOR|2|
62627795|NCT02843815|EXPERIMENTAL|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
62853231|NCT04122651|EXPERIMENTAL|Experimental Arm|Patients will be receiving a toric intraocular lens with either a 2.00 or 4.00 diopter (D) correction, depending on the degree of pre-operative astigmatism, and the astigmatic refractive error will be refined with the use of adjunctive limbal relaxing incisions LRIs and/or off axis rotation of the toric IOL (based on a standardized protocol) so the full amount of corneal astigmatism can be targeted for correction for each patient.
62268217|NCT01866007|EXPERIMENTAL|Group 2|40 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with UltraSafe Passive Delivery System (PFS-U).
62451236|NCT00806156|EXPERIMENTAL|NKTR-102 q14d|NKTR-102 was administered as an intravenous (IV) infusion over 90 ± 10 minutes, on Day 1 of each 2-week \[± 2 days\] cycle at a dose of 170 mg/m\^2 for the first 4 patients enrolled and at a dose of 145 mg/m\^2 for the remainder of the patients.
62063236|NCT02183935|ACTIVE_COMPARATOR|Duodeno - jejunal liner|Duodeno-jejunal liner (Endobarrier) will be implanted for the duration of 12 months. During this time subjects will be regularly monitored for investigated parameters. In addition, subjects will be carefully monitored upon device removal for additional 12 months.
62268218|NCT01866007|EXPERIMENTAL|Group 3|40 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with a prefilled syringe facilitated injection device (PFS FID).
62268219|NCT01866007|EXPERIMENTAL|Group 4|20 participants will receive a single intravenous (IV) infusion of 100 mg guselkumab prepared from liquid formulation.
62268220|NCT05243927|EXPERIMENTAL|Aerobic exercise group|Aerobic exercise will be performed under the supervision of a physiotherapist with a treadmill during 40-60 minutes, 3 days a week for 8 weeks.
62268221|NCT05243927|ACTIVE_COMPARATOR|Stabilization exercise group|Spinal stabilization exercises will be performed with a physiotherapist during 40-60 minutes, 3 days a week for 8 weeks.
62268222|NCT02227693|EXPERIMENTAL|avatrombopag 20-mg|20 mg avatrombopag (1 x 20 mg tablet and 2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
62627796|NCT02843815|ACTIVE_COMPARATOR|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
62627797|NCT05953155|OTHER|Control|The control group will be invited to attend 3 educational classes. In these sessions, participants will receive evidence-based information about self-management strategies and pain education.
62627798|NCT05953155|EXPERIMENTAL|Yoga|In addition to the invitation to attend the same 3 educational classes on evidence-based information about self-management strategies and pain education, the experimental group will participate in a 12-week, twice-weekly group-based yoga program.
62627799|NCT05900908|EXPERIMENTAL|surgical tumor removal and GammaTile therapy followed by adjuvant systemic therapy|surgical tumor removal and GammaTile therapy followed by adjuvant systemic therapy
62627800|NCT05900908|ACTIVE_COMPARATOR|surgical tumor removal followed by adjuvant systemic therapy|surgical tumor removal followed by adjuvant systemic therapy
62853232|NCT04122651|ACTIVE_COMPARATOR|Control Arm|The patient will receive a toric intraocular lens individually tailored to and ordered for each patients' precise degree of corneal astigmatism.
62853233|NCT05358613|EXPERIMENTAL|Immediate treatment|"The My Choices program will be offered immediately (maximum 10 working days from their first research interview) to the participants of this group.~The treatment will be dispensed as usual, wich means there are no special conditions that need to be respected specifically for the study."
62853234|NCT05358613|ACTIVE_COMPARATOR|Waiting list|"The My Choices program will be offered 3 months after the first research interview to the participants in this group.~The treatment will be dispensed as usual, wich means there are no special conditions that need to be respected specifically for the study."
62461479|NCT03619746|NO_INTERVENTION|Pre-Intervention|Current practice (unchanged). This arm of patients will cared for by physicians who have NOT received the POCUS Educational Intervention.
62627801|NCT05072210|EXPERIMENTAL|Mobile Intervention Group|One half of the participants will receive personalized automated alerts throughout their involvement.
62627802|NCT05072210|NO_INTERVENTION|Control Group|For 4 weeks, the other half of the participants will not receive personalized automated alerts. After 4 weeks, these alerts will be enabled.
62627803|NCT02263053|ACTIVE_COMPARATOR|Posterior Mobilization|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower lateral incisors and canines. Applies a force previous distraction grade III and performs oscillating for 1 minute.
62627804|NCT02263053|ACTIVE_COMPARATOR|Caudal Mobilization|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower molars of patients. Apply simultaneous flow and force the previous direction, and performs the degree of oscillation III for 1 minute.
62627805|NCT04758247|ACTIVE_COMPARATOR|Active|
62627806|NCT04758247|SHAM_COMPARATOR|Sham|
62627807|NCT01543802|EXPERIMENTAL|Pazopanib|
62627808|NCT04457362|EXPERIMENTAL|Experimental Cohort|Patients with clinically diagnosed wrist pathology undergoing wrist arthroscopy
62627809|NCT00200577|EXPERIMENTAL|TIL+IL2|TIL + IL2
62627810|NCT00200577|NO_INTERVENTION|control|Patients are not treated
62627811|NCT02027077|ACTIVE_COMPARATOR|Control group|Control group
62627812|NCT02027077|ACTIVE_COMPARATOR|Lifestyle counseling|Behavioral intervention group
62627813|NCT05027815|EXPERIMENTAL|cePolyTregs 100 x10^6 cells Open Label|single dose of 100 x 10\^6 cells by IV infusion
62627814|NCT05027815|EXPERIMENTAL|cePolyTregs 200 x10^6 cells Open Label|single dose of 200 x 10\^6 cells by IV infusion
62627815|NCT05027815|EXPERIMENTAL|cePolyTregs 400 x10^6 cells Open Label|single dose of 400 x 10\^6 cells by IV infusion
62627816|NCT02103660|ACTIVE_COMPARATOR|Depo-Medroxyprogesterone Acetate|Half of women will be randomized to receive Depo-Medroxyprogesterone Acetate injections every 13 weeks
62627817|NCT02103660|ACTIVE_COMPARATOR|Progestin Implant (Jadelle)|Half of women will be randomized to receive progestin implant.
62627818|NCT06202014|EXPERIMENTAL|Concurrent Radiotherapy With Envafolimab and Capecitabine|Concurrent radiotherapy with envafolimab and capecitabine, post-adjuvant envafolimab and capecitabine for locally advanced pancreatic cancer
62627819|NCT02541955|ACTIVE_COMPARATOR|40 Units|40 units of Acthar per week
62627820|NCT02541955|ACTIVE_COMPARATOR|80 Units|80 units of Acthar twice per week
62627821|NCT02797145|ACTIVE_COMPARATOR|Intensive Group|Dose adjusted digoxin by the recommended range for the serum digoxin: 0.5-0.9 nanogram/mL
62063237|NCT03635489|EXPERIMENTAL|Bevacizumab + Paclitaxel + Carboplatin|Participants will receive paclitaxel, carboplatin intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles. Bevacizumab IV infusion will start at Cycle 2 for 5 cycles, followed by maintenance therapy up to a maximum of 22 cycles or until disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.
62268223|NCT02227693|EXPERIMENTAL|avatrombopag 40-mg|40 mg avatrombopag (2 x 20 mg tablets and 1 x 20 mg matching placebo tablet) once daily on Days 1 through 5
62268224|NCT02227693|EXPERIMENTAL|avatrombopag 60-mg|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
62627822|NCT02797145|PLACEBO_COMPARATOR|Conventional|Use digoxin as recommended by the guidelines.
62627823|NCT04444765||Patients with bicarbonate-based intermittent dialysis|Dialysate is composed by electrolytes, including calcium, and bicarbonate. To avoid calcium carbonate precipitation, dialysate has to be supplemented with acids (citric acid, chloride acid or acetic acid).
62627824|NCT04444765||Patients with acetate free biofiltration dialysis|Acetate free biofiltration (AFB-K)is a technique that does not require dialysate acidification
62627825|NCT01400724|EXPERIMENTAL|Inofolic NRT|
62627826|NCT00371475|EXPERIMENTAL|Arm 1|
62627827|NCT00371475|OTHER|Arm 2|Historical Comparator: control data derived from the TAXUS IV and TAXUS V clinical trials
62627828|NCT05950880|EXPERIMENTAL|High intensity exercise + Conventional physical therapy|Patients in this group will receive High-intensity exercise + Conventional physical therapy
62627829|NCT05950880|ACTIVE_COMPARATOR|Conventional physical therapy|Patients in this group will receive Conventional physical therapy
62088042|NCT05419674|ACTIVE_COMPARATOR|group C: bismuth-containing quadruple therapy|rabeprazole 10 mg bid, colloidal bismuth pectin 200mg bid, amoxicillin 1000mg bid and clarithromycin 500mg bid for 10 days
62268225|NCT02227693|PLACEBO_COMPARATOR|placebo l|Placebo (3 x 20-mg matching placebo tablets) once daily on Days 1 through 5
62268226|NCT03382795|EXPERIMENTAL|EGFR retreat group|
62268227|NCT03469765||Group of patients after aortic surgery|with subanalysis of patients with/without supra-/infrarenal surgery
62268228|NCT00716755|EXPERIMENTAL|Dose Reduction|See Intervention
62268229|NCT03948828|OTHER|Conventional treatment group|GnRHa combained with reverse addition therapy
62268230|NCT03948828|EXPERIMENTAL|Conventional treatment and Autologous NK cells therapy|GnRHa combained with reverse addition therapy and NK cell combined treatment group
62268231|NCT00864435|EXPERIMENTAL|A|Carvedilol 12.5 mg Tablets, single dose
62268232|NCT00864435|ACTIVE_COMPARATOR|B|Coreg® 12.5 mg Tablets , single dose
62268233|NCT01739179||1|VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter
62627830|NCT02421419|ACTIVE_COMPARATOR|Corticosteroid alone (CS) Group|1 cc dexamethasone sodium phosphate (4mg/ml) injectable
62627831|NCT02421419|ACTIVE_COMPARATOR|Corticosteroid/Lidocaine (CSL) Group|1 cc dexamethasone sodium phosphate (4 mg/ml) injectable and 1 cc 1% Xylocaine (lidocaine) injectable
62627832|NCT02421419|ACTIVE_COMPARATOR|Corticosteroid/Saline (CSS) Group|1 cc dexamethasone sodium phosphate (4mg/ml) injectable and 1 cc 0.9% injectable Sodium Chloride (saline)
62627833|NCT06501599||Normal|"CT-0. Not consistent with pneumonia (including COVID-19). \[1,2\]~Enrollment number: 95"
62627834|NCT06501599||Mild|"СT-1. Ground glass opacities. Pulmonary parenchymal involvement =\<25% OR absence CT signs in typical clinical manifestations and relevant epidemiological history \[1,2\].~Enrollment number: 117"
62627835|NCT06501599||Moderate|"CT-2. Ground glass opacities. Pulmonary parenchymal involvement 25-50% \[1,2\].~Enrollment number: 117"
62627836|NCT06501599||Severe|"CT-3. Ground glass opacities. Pulmonary consolidation. Pulmonary parenchymal involvement 50-75%. Lung involvement increased in 24-48 hours by 50% in respiratory impairment per follow-up studies \[1,2\].~Enrollment number: 117"
62627837|NCT06501599||Critical|"CT-4. Diffuse ground glass opacities with consolidations and reticular changes. Hydrothorax (bilateral, more on the left). Pulmonary parenchymal involvement \>=75% \[1,2\].~Enrollment number: 117"
62627838|NCT03309228||Qualitative Research|Semi-structured interviews with patients, relatives and general practitioners.
62627839|NCT06503978|EXPERIMENTAL|Group A: Treatment (Dose 1)|"Part 1: Blinded Treatment (15 weeks)~Vancomycin, Miralax, Antacid, MTP-101P"
62627840|NCT06503978|EXPERIMENTAL|Group B: Treatment (Dose 2)|"Part 1: Blinded Treatment (15 weeks)~Vancomycin, Miralax, Antacid, MTP-101P"
62627841|NCT06503978|PLACEBO_COMPARATOR|Group C: Placebo|"Part 1: Blinded Placebo (15 weeks)~Placebo Vancomycin, Real Miralax, Real Antacid, Placebo MTP-101P"
62627842|NCT06503978|PLACEBO_COMPARATOR|Group D: Placebo|"Part 1: Blinded Placebo (15 weeks)~Placebo Vancomycin, Real Miralax, Real Antacid, Placebo MTP-101P"
62627843|NCT01211145|PLACEBO_COMPARATOR|1|Placebo
62627844|NCT01211145|EXPERIMENTAL|2|ZOMIG 0.5 mg
62627845|NCT01211145|EXPERIMENTAL|3|ZOMIG 2.5 mg
62627846|NCT01211145|EXPERIMENTAL|4|ZOMIG 5.0 mg
62627847|NCT06609291|EXPERIMENTAL|Experimental group|The intervention group, who will receive the intervention protocol. The psychological intervention will consist of 7 group sessions, conducted weekly, with a duration of approximately 60 minutes each.
62627848|NCT06609291|NO_INTERVENTION|Control group|The control group will receive the usual care, which consists of attending follow-up and follow-up appointments for pregnancy, resolving any doubts that may arise during the process with the midwives and attending prenatal preparation classes.
62268234|NCT01739179||2|VP Shunt Surgery for open insertion of the peritoneal catheter
62268235|NCT03499028|NO_INTERVENTION|Standard of Care Group|The Standard of Care Group will receive standard, routine medical care and will communicate with their surgeon and clinical care team through conventional methods such as phone.
62268236|NCT03499028|EXPERIMENTAL|Experimental (JointCOACH) Group|The Experimental Group will receive standard, routine medical care and utilize a web-based communication platform called JointCOACH to communicate with their care team via computer or smartphone throughout their episode of care. They will also receive information personalized to their treatment plan and will be asked to complete online questionnaires.
62268237|NCT03232086|SHAM_COMPARATOR|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
62268238|NCT03232086|ACTIVE_COMPARATOR|Concentrated PM2.5|Exposure to PM2.5 will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
62268239|NCT00369356|SHAM_COMPARATOR|1|Bare Metal Stenting
62627849|NCT02729480|EXPERIMENTAL|Continued Stimulation Group|Subjects randomized to this group will have the Halo Craniofacial Nerve Stimulator System activated immediately.
62627850|NCT02729480|ACTIVE_COMPARATOR|Delayed Continuation Group|Subjects randomized to this group with have the Halo Craniofacial Nerve Stimulator System activated after 90 days.
62627851|NCT04491981|EXPERIMENTAL|Encapsulated Glass Ionomer Cement|Repair of restorations in primary molars using a high viscosity glass ionomer cement (RIVA Self Cure - SDI)
62627852|NCT04491981|EXPERIMENTAL|Composite resin|Repair of restorations in primary molars using a composite resin (Filtek Bulk Fill- 3M ESPE)
62627853|NCT02666001|EXPERIMENTAL|Part 1 (BMS-663068+methadone)|Effect of multiple doses of BMS-663068, 600mg ER on the exposure of methadone
62627854|NCT02666001|EXPERIMENTAL|Part 2 (BMS-663068+buprenorphine and norbuprene)|Effect of multiple doses of BMS-663068, 600mg ER on the exposure of buprenorphine and norbuprenorphine
62627855|NCT04059289||Intraocular lens type I|Tecnis EYHANCE IOL (Johnson \& Johnson, New Brunswick/USA)
62627856|NCT04059289||Intraocular lens type II|Clareon IOL (Alcon Pharma. Freiburg/FRG)
62627857|NCT05515484|EXPERIMENTAL|Prone position with airbags|
62627858|NCT05515484|ACTIVE_COMPARATOR|prone position standard of care|
62627859|NCT04177992|EXPERIMENTAL|Servo control|"Automated control of oxygen. The oxygen saturation target range will be set to 93%.~Automated oxygen control can be over-ridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
62627860|NCT04177992|NO_INTERVENTION|Manual control|Standard practice. Oxygen adjustments will be made by clinical/nursing staff to maintain a target oxygen range of 90%-95%.
62627861|NCT05010317|EXPERIMENTAL|Group receiving the mindfulness and acceptance intervention|This group will under go four sessions of the mindfulness and acceptance based therapy. These sessions will be delivered in four weeks, utilizing 2 hours every week. This will be in addition to the standard of care (clinic based counselling).
62627862|NCT05010317|ACTIVE_COMPARATOR|Control group|This group will continue receiving the usual clinic based care (counselling) only.
62088043|NCT01290016|ACTIVE_COMPARATOR|Control 6-8 yrs|The group will receive information during the study about diet and exercise but will not receive the intervention till the end of the study protocol.
62627863|NCT02103023|EXPERIMENTAL|ID TIV + imiquimod|imiquimod ointment followed by intradermal influenza vaccine
62627864|NCT02103023|SHAM_COMPARATOR|ID sham + imiquimod|imiquimod ointment followed by sham intradermal influenza vaccine
62627865|NCT02103023|ACTIVE_COMPARATOR|IM TIV + aq|aqueous cream followed by intramuscular influenza vaccine
62627866|NCT02103023|ACTIVE_COMPARATOR|ID TIV + aq|aqueous cream followed by intradermal influenza vaccine
62627867|NCT02136901|EXPERIMENTAL|Investigational arm|The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
62268240|NCT00369356|ACTIVE_COMPARATOR|2|Stenting with DES
62627868|NCT02136901|ACTIVE_COMPARATOR|Control Arm|The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
62627869|NCT02675270|EXPERIMENTAL|Phonological, Orthographic, Untrained|
62853235|NCT03207763|EXPERIMENTAL|Cohort 1|Participating infants and children will receive Microneedle Formulation 1. At least 4 infants or children must complete Day 8 without halting criteria having been met before subjects will be enrolled into the next younger age group within a Cohort. At least the first 2 children will have a microneedle patch initially applied to the skin overlying the shoulder blade. If this site is well tolerated without halting criteria having been met additional microneedle patches may be applied to the same participants and in subsequent participants to the upper arm, forearm, wrist and/or thigh.
62853236|NCT03207763|EXPERIMENTAL|Cohort 2|Participating infants and children will receive Microneedle Formulation 2. At least 4 infants or children must complete Day 8 without halting criteria having been met before subjects will be enrolled into the next younger age group within a Cohort. At least the first 2 children will have a microneedle patch initially applied to the skin overlying the shoulder blade. If this site is well tolerated without halting criteria having been met additional microneedle patches may be applied to the same participants and in subsequent participants to the upper arm, forearm, wrist and/or thigh.
62627870|NCT02675270|EXPERIMENTAL|Semantic, Lexical, Untrained|
62627871|NCT05135936|EXPERIMENTAL|Hyperthermia Group|For the study, the method of passive whole-body hyperthermia is used. The IRATHERM®1000 system (Von Ardenne Institute for Applied Medical Research/Dresden) is used, in which the entire body is heated to a core body temperature above the physiological 37°C. The aim is to achieve a core body temperature of 38.5°C within the framework of mild whole-body hyperthermia. After this warm-up phase, a temperature plateau phase of about 60 minutes follows, in which an attempt is made to maintain the core body temperature of 38.5°C. In the temperature plateau phase, a slight increase in the body core temperature is usually observed. The total time required for a session is given as 1.5 to 2 hours, but this depends on the individual constitution and daily condition of the patient and can be subject to fluctuations.
62627872|NCT05135936|SHAM_COMPARATOR|Sham-Group|"Within the patient information, privacy policy, etc., there is talk of gentle hyperthermia and classic, mild hyperthermia. This serves to introduce the sham intervention as a control group compared to the patient. Lighting conditions, procedures, instructions and explanations are indistinguishable. Within the application, patients of the sham group will receive a hyperthermia application almost without overheating. In order to achieve this, the patients will be positioned on the IRATHERM®1000 in accordance with the Von Ardenne Institute's regulations. Due to the insulating blanket and the natural device and body heat, the patients of the sham group experience a gentle warmth, which is not the same as regular whole-body hyperthermia and an increase in the body core temperature of about 1.5 °C. In the sham setting, the core body temperature increases by about 0.3 to 0.4 °C within a 55-minute session."
62268241|NCT00369356|EXPERIMENTAL|3|Bare metal stenting and administration of prednisone
62627873|NCT04866082||ESICM and ESAIC members|questionnaire - Members of European Society of Intensive Care and European Society of Anaesthesiology and Intensive Care will obtain an electronic survey regarding their routine clinical practice of systemic corticosteroids administration among patients with COVID-19 ARDS
62627874|NCT05212584|EXPERIMENTAL|CD7 CAR T cells|Dose escalation phase: CD7 CAR T cells will be transduced with a lentiviral vector to express a CD7 CARs. with an escalation approach, 1 e6 to 7 e6 CAR-T cells/kg
62627875|NCT01136564|ACTIVE_COMPARATOR|Paricalcitol|
62627876|NCT01136564|PLACEBO_COMPARATOR|Placebo|
62853237|NCT00536393|ACTIVE_COMPARATOR|Doxorubicine|CHOP 8 courses every 21 days
62088044|NCT01290016|EXPERIMENTAL|2 servings dairy + exercise 6-8 yrs|Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.
62268242|NCT03174132|EXPERIMENTAL|Restylane Perlane Lidocaine|Restylane Perlane Lidocaine will be injected into one side of the nasolabial fold at day 1
62268243|NCT03174132|ACTIVE_COMPARATOR|Restylane Perlane|Restylane Perlane will be injected into the opposite side of the nasolabial fold on day 1
62268244|NCT03730155|EXPERIMENTAL|CCT intervention|CCT intervention. 8 weeks with 2 hours session every week. Homework approx. 25 min. of meditation daily.
62268245|NCT03730155|NO_INTERVENTION|Control waitlist|No treatment given. Participants only answer questionnaire packages.
62853238|NCT00536393|EXPERIMENTAL|Doxorubicine pegylated|CLOP 8 courses every 21 days
62853239|NCT04493892|EXPERIMENTAL|Educational Intervention|All participants receive educational information on the potential health risk of endocrine disruptor chemicals in hair care products, specifically phthalates. Provide information on how to reduce exposure.
62063238|NCT03635489|PLACEBO_COMPARATOR|Placebo + Paclitaxel + Carboplatin|Participants will receive paclitaxel, carboplatin IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles. Placebo IV infusion will start at Cycle 2 for 5 cycles, followed by maintenance therapy up to a maximum of 22 cycles or until disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.
62063239|NCT06342089||children with type I diabetes milletus|•Patient aged 8 to 14 years and diagnosed with type I diabetes milletus with erupted all 4 first permanent molars.
62853240|NCT01567449||the case group|The case group referred to SAH patients with aneurysm rebleeding
62853241|NCT01567449||the control group|the control group referred to SAH patients not with aneurysm rebleeding
62063240|NCT06062459|EXPERIMENTAL|Group A|MCE Group
62063241|NCT06062459|EXPERIMENTAL|Group B|BT Group
62063242|NCT06062459|EXPERIMENTAL|Group C|Combined MCE \& BT Group
62627877|NCT04996836|EXPERIMENTAL|BC diagnosis and Omics|"Participants will be offered:~1. Liquid biopsy of ctDNA and targeted NGS (BRCA1, BRCA2, CHEK2, PALB2, BRIP1, TP53, PTEN, STK11, CDH1, ATM, BARD1, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PMS1, PMS2, RAD50, RAD51C, RAD51D, NF1, EPCAM, SMARCA4, CDK12);~2. Whole-genome RRBS"
62063243|NCT06062459|OTHER|Group D|Control Group
62063244|NCT02062866|ACTIVE_COMPARATOR|Purse-String|Surgical wounds are healed via suturing.
62063245|NCT02062866|ACTIVE_COMPARATOR|Second Intent|Surgical wounds are allowed to heal without sutures.
62627878|NCT04996836|NO_INTERVENTION|BC diagnosis and standard of the care|Participants will not be offered targeted NGS or whole-genome RRBS but will receive their usual clinical care
62627879|NCT01768065|EXPERIMENTAL|Nasal Expiratory Positive Airway Pressure Devices|Nasal Expiratory Positive Airway Pressure Device
62853242|NCT01103024|EXPERIMENTAL|AIN457 300mg s.c every 2 weeks|
62853243|NCT01103024|EXPERIMENTAL|AIN457 300mg s.c every 4 weeks|
62063246|NCT00658138|EXPERIMENTAL|Adhesive A|
62063247|NCT00658138|ACTIVE_COMPARATOR|Adhesive B|
62063248|NCT05485610|EXPERIMENTAL|NMN intervention|3 months of NMN
62063249|NCT05485610|PLACEBO_COMPARATOR|Placebo|3 months of NMN-free placebo
62063250|NCT02913976|EXPERIMENTAL|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
62063251|NCT02913976|PLACEBO_COMPARATOR|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
62063252|NCT04632901||Testing of Visual Acuity (VA) Group|The same participants will undergo VA and CVA test with two different Landolt C charts under the same lighting conditions.
62063253|NCT04632901||Testing of Critical Visual Acuity (CVA) Group|The same participants will undergo VA and CVA test with two different Landolt C charts under the same lighting conditions.
62063254|NCT05603832|EXPERIMENTAL|F14 + Multimodal Analgesia|
62063255|NCT05603832|ACTIVE_COMPARATOR|Multimodal Analgesia|
62268246|NCT02611986|EXPERIMENTAL|McGrath MAC|tracheal intubation using the McGrath MAC
62268247|NCT02611986|EXPERIMENTAL|Macintosh Laryngoscope|tracheal intubation using the Macintosh Laryngoscope
62627880|NCT01768065|SHAM_COMPARATOR|placebo sham|A sham device
62853244|NCT01103024|EXPERIMENTAL|AIN457 150mg s.c every 4 weeks|
62853245|NCT01103024|PLACEBO_COMPARATOR|Placebo s.c every 2 weeks|
62853246|NCT01075308|EXPERIMENTAL|SB939|SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
62853247|NCT05346822|EXPERIMENTAL|integrated rehabilitation program for total knee arthroplasty|the intervention was performed in one KMUH affiliated facility
62853248|NCT05346822|NO_INTERVENTION|normal total knee arthroplasty clinical pathway|no integrated rehabilitatoin program for total knee arthroplasty patients with our conventional clinical pathway
62853249|NCT02265588|NO_INTERVENTION|Care as usual|Care as usual means receiving their regular medical care. This consists of the regular follow up visits at the gastroenterologist every 3 months.
62853250|NCT02265588|EXPERIMENTAL|Cognitive Behavioral Therapy|The intervention group receives regular medical care (care as usual) AND a cognitive behavioral therapy program called PASCET-PI. The therapy sessions will be performed by trained psychologist.
62853251|NCT03463005|EXPERIMENTAL|Royal jelly|The study subjects included healthy women who had husbands with male-factor infertility problems.
62853252|NCT03463005|ACTIVE_COMPARATOR|IUI group|The study subjects included in IUI group were healthy women who had husbands with male-factor infertility problems.
62853253|NCT00511394|ACTIVE_COMPARATOR|I|Infusion of 100 mL of 20% Albumin
62853254|NCT00511394|PLACEBO_COMPARATOR|II|100 mL Normal Saline
62853255|NCT02380768|EXPERIMENTAL|Ambu AuraGain|Subjects will receive the Ambu AuraGain size 1.5 or 2.0 based on manufacturer guidelines
62853256|NCT02380768|ACTIVE_COMPARATOR|LMA Supreme|Subjects will receive the Ambu AuraGain size 1.5 or 2.0 based on manufacturer guidelines
62268248|NCT00847483|ACTIVE_COMPARATOR|Latanoprost|
62853257|NCT06427135|EXPERIMENTAL|Exercise interventions|Adding exercise intervention therapy to existing medications
62853258|NCT06427135|NO_INTERVENTION|Conventional drug therapy|No exercise intervention, use of existing medication.
62853259|NCT02226445||ADHD medication and psychosocial counseling|
62088045|NCT01290016|EXPERIMENTAL|4 servings dairy + exercise 6-8 yrs|Subjects in this group will receive family based counselling to maintain the intake of 4 servings of dairy per day and also receive instruction on how to improve their physical activity.
62268249|NCT00847483|ACTIVE_COMPARATOR|Travoprost|
62451237|NCT00806156|EXPERIMENTAL|NKTR-102 q21d|NKTR-102 was administered as an IV infusion over 90 ± 10 minutes, on Day 1 of each 3-week \[± 2 days\] cycle at a dose of 170 mg/m\^2 for the first 6 patients enrolled and at a dose of 145 mg/m\^2 for the remainder of the patients.
62451238|NCT04491409||Observational (standard of care, medical chart review)|Patients undergo standard of care treatment and their medical records are reviewed at 30 days and at 1 year after surgery.
62451239|NCT04626999|ACTIVE_COMPARATOR|Synovial fluid COMP|Knee joint fluid is aspirated for ELISA COMP examination
62451240|NCT04626999|ACTIVE_COMPARATOR|MRI T2 Mapping|Affected knee is subjected to an MRI T2 mapping examination to see the condition of cartilage
62451241|NCT04626999|ACTIVE_COMPARATOR|Instability Examination|Lachmant Test, Pivot shift test and Rolimeter Measurement
62451242|NCT06021977|EXPERIMENTAL|Zanubrutinib|Each recruited subject will accept Zanubrutinib treatment.
62853260|NCT03496714|ACTIVE_COMPARATOR|PSYED-T|In PSYED-T (psychoeducation on trauma symptoms), participants will receive a psychoeducation handout and watch a related video on common reactions to trauma. Participants in this condition will also receive a rationale stating that both learning about the nature of trauma reactions and monitoring symptoms are important for preventing development of PTSD.
62853261|NCT03496714|EXPERIMENTAL|PSYED-T+SB|Participants in PSYED-T+SB (Combined psychoeducation on trauma reactions and safety behaviors) will receive psychoeducation handouts and videos on the nature of trauma symptoms and the nature of safety behaviors and how to fade them. Participants in this condition will also receive a rationale stating that learning about the nature of trauma reactions and safety behaviors, learning to fade safety behaviors, and monitoring symptoms are important in the prevention of PTSD.
62853262|NCT03496714|NO_INTERVENTION|Monitoring-only control|The third condition will be a monitoring-only control and thus will receive no psychoeducation information. Participants in the control condition will receive a rationale that monitoring symptoms is important in the prevention of PTSD development.
62853263|NCT00662298|EXPERIMENTAL|Severe Asthma|
62268250|NCT00847483|ACTIVE_COMPARATOR|Bimatoprost|
62268251|NCT00817531|EXPERIMENTAL|All subjects take open label Dasatinib|Dasatinib / Sprycel 100 mg
62853264|NCT03399396|EXPERIMENTAL|Web-Based Coaching|Web-based delivery of practice facilitation for HPV vaccine
62268252|NCT05801835|EXPERIMENTAL|Sequence A (T-R)|(cytarabine: daunorubicin) liposome for injection followed by Vyxeos
62268253|NCT05801835|EXPERIMENTAL|Sequence B (R-T)|Vyxeos followed by (cytarabine: daunorubicin) liposome for injection
62451243|NCT02419690|NO_INTERVENTION|Usual Care|The current standard of care in the clinic is a preventive care physical examination every 1-2 years and/or treatment for presenting medical conditions. The frequency and content of reproductive health is not standardized between clinicians, but it is expected that all clinicians will address sexuality during routine visits. Additionally, sexually active teens are encouraged to have urine screening tests for chlamydia, gonorrhea and pregnancy as indicated. Teens may also see a reproductive health educator at the clinic as well. Available contraceptive methods are oral contraceptive pills, contraceptive patches, Depo-Provera, diaphragms, condoms, implants and intrauterine devices (IUDs).
62451244|NCT02419690|ACTIVE_COMPARATOR|text message intervention|Subjects in the intervention arm will receive usual care plus text messages that have been developed to promote overall teen sexual health.
62451245|NCT04041609|EXPERIMENTAL|LYR-210 (Low Dose)|In-office bilateral placement of the LYR-210 drug depot (mometasone furoate low dose) in the middle meatus
62451246|NCT04041609|EXPERIMENTAL|LYR-210 (High Dose)|In-office bilateral placement of the LYR-210 drug depot (mometasone furoate high dose) in the middle meatus
62451247|NCT04041609|SHAM_COMPARATOR|Sham Procedure|In-office bilateral sham procedure
62451248|NCT05305274||2019 screening|34,400 schoolchildren with a 36-month follow-up from 2019 to 2021.
62451249|NCT05305274||2020 screening|34,400 schoolchildren with a 36-month follow-up from 2019 to 2021.
62451250|NCT05305274||2021 screening|34,400 schoolchildren with a 36-month follow-up from 2019 to 2021.
62063256|NCT02867514|ACTIVE_COMPARATOR|anodal tDCS on left DLPFC (F3)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 min for 10 sessions. Anode is placed on the scalp facing on left DLPFC and cathode on right DLPFC.
62063257|NCT02867514|SHAM_COMPARATOR|sham tDCS on left DLPFC (F3)|tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 min - 10 sessions). Anode is placed on the scalp facing on left DLPFC and cathode on right DLPFC.
62063258|NCT02867514|ACTIVE_COMPARATOR|anodal tDCS on right DLPFC (F4)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 min for 10 sessions. Anode is placed on the scalp facing on right DLPFC and cathode on left DLPFC.
62268254|NCT03506243|EXPERIMENTAL|Test group|Follitrope PFS
62268255|NCT03506243|ACTIVE_COMPARATOR|Control group|Gonal-F pen
62853265|NCT03399396|EXPERIMENTAL|In-Person Coaching|In-person delivery of practice facilitation for HPV vaccine
62853266|NCT01733303|EXPERIMENTAL|Exercise|Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality.
62268256|NCT03869359|EXPERIMENTAL|Group A|Gluten-free diet with placebo powder vs Gluten-free diet with gluten powder
62268257|NCT03869359|EXPERIMENTAL|Group B|Gluten-free diet with gluten powder vs Gluten-free diet with placebo powder
62627881|NCT05118035|EXPERIMENTAL|Intervention|"Patients randomized to intervention will have access to the screening tool. Once the AI-ECG indicates high risk of mortality, a warning message would be immediately triggered and sent to the corresponding attending physicians. Notifications appear in the recipient's smartphone message system for the prompt attention. The message notified the physician that, An ECG was received for patient X. An ECG indicates high risk of mortality. Please intensively attend to patient's conditions. If the physicians need to further identify the ECG, click on the following link to connect the ECG and the result of AI-ECG prediction. Of note, although we will actively send a warning message for high risk cases, the AI-ECG report for low risk cases still presented the degree of risk. Physicians can check the relative severity by access EHR for patients in the intervention group."
62627882|NCT05118035|NO_INTERVENTION|Control|Patients will continue routine practice.
62627883|NCT02146209|EXPERIMENTAL|Test Product Formula A|Metronidazole benzoate
62627884|NCT02146209|ACTIVE_COMPARATOR|Reference Product Formula B|Flagyl 125 mg/5 ml oral suspension
62853267|NCT03367468|ACTIVE_COMPARATOR|Physiotherapy group|Strengthening and stretching exercises,cross friction massage (supervised by physiotherapist) Mobilization techniques Daily usage of prescribed orthotic insole
62853268|NCT03367468|ACTIVE_COMPARATOR|Home exercise group|Strenthening and stretching exercises Daily usage of prescribed orthotic insole
62853269|NCT03367468|NO_INTERVENTION|Control group|Follow ups Daily usage of prescribed orthotic insole
62853270|NCT01437475|EXPERIMENTAL|Sci-B-Vac|The study involves only one, open label arm. Rate of immunization will be compared to results obtained using the ENGERIX B vaccine among HIV positive persons in formerly published, historical cohorts.
62853271|NCT03171753|EXPERIMENTAL|Music therapy|Listening prerecorded music through an individual headset for 30 min in before the induction of anesthesia
62853272|NCT03171753|ACTIVE_COMPARATOR|Control|patients wear headphones for 30 minuts without any sound
62268258|NCT03358888|ACTIVE_COMPARATOR|Standard of Care|
62268259|NCT03358888|ACTIVE_COMPARATOR|Multi-modal with as needed opioids|
62451251|NCT03778866|EXPERIMENTAL|Bicarbonate-buffered Medium|
62451252|NCT03778866|NO_INTERVENTION|HEPES-MOPS-buffered Medium|
62853273|NCT01326338|EXPERIMENTAL|Nitazoxanide Suspension|Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years
62853274|NCT01326338|PLACEBO_COMPARATOR|Placebo Suspension|Placebo Oral Suspension 5 ml for patients aged 1-3 years and Placebo Oral Suspension 10 ml for patients aged 4-11 years
62853275|NCT00961129||patients with colorectal cancer|patients with colorectal cancer in any stage or survivors
62268260|NCT03358888|ACTIVE_COMPARATOR|Multi-modal with one week of opioids offered|
62451253|NCT01060592|EXPERIMENTAL|Stoma Adjustment at Surgery|The first band adjustment will be made at surgery versus historical controls where the adjustment is not made for 3-4 weeks post-surgery. EndoFLIP device (FDA Device Listing Number : D091203)will be used to make the adjustment.
62627885|NCT02146209|ACTIVE_COMPARATOR|Reference Product Formula C|Flagyl 400 mg Tablets
62627886|NCT05095194|EXPERIMENTAL|High myopia patients who had cataract surgery with IOL and capsular tension ring implantation|The patients' axial length is over 26 mm and are diagnosed age related cataract The patients' age are over 50
62853276|NCT01872767||Cirrhotics/ Acute on chronic liver failure admitted to ICU|
62853277|NCT05282303||DIESPB|Dual injection of erector spinae plane block
62853278|NCT05282303||TPVB|Thoracic paravertebral block
62853279|NCT05282303||SAB|Serratus anterior plane block
62853280|NCT05282303||PIB|Parasternal ıntercostal block
62627887|NCT05095194|EXPERIMENTAL|High myopia patients who had cataract surgery with IOL implantation|The patients' axial length is over 26 mm and are diagnosed age related cataract The patients' age are over 50
62063259|NCT02867514|SHAM_COMPARATOR|sham tDCS on right DLPFC (F4)|tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 min - 10 sessions). Anode is placed on the scalp facing on right DLPFC and cathode on left DLPFC.
62627888|NCT06226337|NO_INTERVENTION|No intervention: control group|No intervention was applied to the control group other than routine practice.45 women were assigned to the control group
62268261|NCT03882814||Pethidine group / study group|Study group; patients given pethidine; The partogram was recorded during delivery. Cervical examination was performed at 2 hour intervals. Recorded in the file. 4 cm and greater cervical dilatation; 50 mg intramuscular (IM) injection was given to pethidine. 200 Montevideo units uterine contractions were reached. Maternal vital signs, maternal complications and neonatal APGAR scores were recorded by the clinician 0-5-15-30-45-60 minutes after pethidine injection.
62853281|NCT01117909|SHAM_COMPARATOR|"Laying of hands plus standard therapy"|Subjects will lie on their back as if they were receiving the joint mobilization treatment and the therapist will place their hands in a position as if to perform the mobilization but no movement will occur. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression
62268262|NCT03882814||control group|The patients who received placebo injection were included in the control group. Saline was given in placebo.
62063260|NCT01356316|EXPERIMENTAL|AdimFlu-S Influenza Vaccine|
62268263|NCT00861744|EXPERIMENTAL|Priorix 1 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 1) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
62627889|NCT06226337|EXPERIMENTAL|Experimental group|45 women to the experimental group. In the study, the experimental group Acemaşiran makam was played to the women as music during hysterosalpingography.
62627890|NCT01305772|EXPERIMENTAL|Surgery|Patients who underwent surgery after research PET/CT scans and subsequent radiation therapy with panitumumab administration
62853282|NCT01117909|EXPERIMENTAL|Standard therapy with joint mobilization|This group will receive three 60-second bouts of posterior joint mobilizations applied to the ankle joint during each treatment session, in addition to standard therapy. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression
62853283|NCT05984498||COPD group|People with a spirometry confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
62853284|NCT05984498||Healthy Controls|Older adults over the age of 55 who do not have COPD
62853285|NCT03050411|EXPERIMENTAL|Apatinib|Apatinib in combination with EGFR-TKIs
62853286|NCT04772677|EXPERIMENTAL|BEAM - Infant|BEAM Infant will be delivered via mobile application to mothers with a 6-17 month old child. It will include 15-30-minute lessons on mental health and parenting and a closed community forum. Mental Health videos will provide information and tools via The Unified Protocol, a best-practice program to address dysregulated emotions across mood and anxiety disorders. Parenting videos will help parents understand their children's challenging behaviours and teach proactive approaches to prevent negative interactions and promote a positive relationship. A closed online community forum will be facilitated by a mental health clinician and parent coach. Weekly Zoom meetings will be facilitated by clinicians where participants can meet with other participants, ask questions about the program content, or discuss the week's materials.
62063261|NCT03311763|ACTIVE_COMPARATOR|Counseling alone|Group 1: physical activity assessment, brief counseling session + physical activity wearable
62268264|NCT00861744|EXPERIMENTAL|Priorix 2 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 2) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
62268265|NCT00861744|EXPERIMENTAL|Priorix 3 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 3) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
62627891|NCT01305772|ACTIVE_COMPARATOR|Radiation Therapy|Patients who underwent radiation therapy only, in conjunction with panitumumab therapy.
62451254|NCT01060592|NO_INTERVENTION|Historic|Weight loss profile over time for 50 patients in the first 12 months after surgery as derived from historic control records. Band adjustments are made in a heuristic fashion during the year after surgery using the experience of surgeon alone
62627892|NCT00812942|ACTIVE_COMPARATOR|fobt|faecal occult blood test
62063262|NCT03311763|EXPERIMENTAL|Group exercise|Group 2: Group 1 intervention components + referral to a free, community-based, EIM practitioner led group exercise program (two, 1 hour classes/week for 8 weeks).
62627893|NCT00812942|ACTIVE_COMPARATOR|colonoscopy|colonoscopy screening
62063263|NCT04664725|EXPERIMENTAL|SHR3680+ Repaglinide, Bupropion|"* Experimental: Repaglinide, Bupropion and SHR3680~* Repaglinide and Bupropion QD on Day 1 and Day 21, SHR3680 240 mg once daily (QD) from Study Day 6 - 26"
62627894|NCT00195195||1|Sirolimus
62627895|NCT03639129|EXPERIMENTAL|Contrast-enhanced mammography (CME)|-Patients who meet eligibility criteria and consent to participate in this study will complete a CEM examination prior to or on the day that biopsy is scheduled. CEM must occur no later than 60 days after the diagnostic mammogram. The standard of care biopsy must occur no later than 30 days after CEM.
62627896|NCT00533221|ACTIVE_COMPARATOR|Somatotropin|subcutaneous application of somatotropin over 12 weeks followed by 8 weeks wash out period followed by 12 weeks subcutaneous placebo application
62627897|NCT00533221|PLACEBO_COMPARATOR|Placebo|12 weeks placebo subcutaneous application followed by 8 weeks wash out and 12 weeks subcutaneous application of somatotropin
62627898|NCT01461733|EXPERIMENTAL|amiodarone|standard dose amiodarone
62627899|NCT01461733|PLACEBO_COMPARATOR|placebo|
62853287|NCT04772677|EXPERIMENTAL|BEAM - Preschool|BEAM Preschool will be delivered via mobile application to mothers with a 18-36 month old child. It will include 15-30-minute lessons on mental health and parenting and a closed community forum. Mental Health videos will provide information and tools via The Unified Protocol, a best-practice program to address dysregulated emotions across mood and anxiety disorders. Parenting Videos will help parents understand their children's challenging behaviours and teach proactive approaches to prevent negative interactions and promote a positive relationship. A closed online community forum will be facilitated by a mental health clinician and parent coach. Weekly Zoom meetings will be facilitated by clinicians where participants can meet with other participants, ask questions about the program content, or discuss the week's materials.
62853288|NCT01317459|EXPERIMENTAL|Lifestyle counselling|
62853289|NCT01317459|EXPERIMENTAL|No intervention|Care as usual
62853290|NCT04276324|ACTIVE_COMPARATOR|Control Group|Only testing sessions
62853291|NCT04276324|EXPERIMENTAL|Resistance training group|Ten weeks of resistance training
62853292|NCT00578760|PLACEBO_COMPARATOR|2|placebo OD during course of chemotherapy
62853293|NCT00578760|EXPERIMENTAL|1|325mg ASA OD during course of chemotherapy
62853294|NCT05087992|EXPERIMENTAL|Phase 1a: BI 905711 + FOLFIRI + Bevacizumab|Phase 1a: Dose escalation in colorectal adenocarcinoma (CRC)
62853295|NCT05087992|EXPERIMENTAL|Phase 1b: BI 905711 + FOLFIRI|Phase 1b: Dose Expansion: Single arm cohort in 2nd line Pancreatic Ductal Adenocarcinoma (PDAC)
62853296|NCT05087992|EXPERIMENTAL|Phase 1b: BI 905711 + FOLFIRI + Bevacizumab|Phase 1b: Dose Expansion: Randomized cohort in 2nd line colorectal adenocarcinoma (CRC); Arm A.
62853297|NCT05087992|EXPERIMENTAL|Phase 1b: FOLFIRI + Bevacizumab|Phase 1b: Dose Expansion: Randomized cohort in 2nd line colorectal adenocarcinoma (CRC); Arm B.
62853298|NCT05184829|ACTIVE_COMPARATOR|systemic lymph node dissection group|systemic lymph node dissection group
62853299|NCT05184829|EXPERIMENTAL|selective lymph node dissection|selective lymph node dissection
62853300|NCT03124927|EXPERIMENTAL|Test Group|All subjects are enrolled into the test group and all subjects receive DCI pulse oximeter sensor.
62853301|NCT03629314|EXPERIMENTAL|Educational Pamphlet arm|Educational Pamphlet will be provided to all participants to review, questionnaire will be provided to complete before and after review of the pamphlets
62853302|NCT06455046|EXPERIMENTAL|AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection|The Combined Treatment Stage consists of AK104 at a dosage of 10 mg/kg, Pemetrexed at a dosage of 500mg/m2, Cisplatin with an AUC of 4-6 mg/mL/min, and Human Adenovirus 5 Injection. This treatment is administered every 3 weeks for a total of 4 cycles. Upon enrollment, the drugs are given in the following sequence on the first day of each combined treatment cycle: local injection of Human Adenovirus 5 Injection (d1-d5), intravenous infusion of AK104 (d1), intravenous infusion of Pemetrexed (d2), and intravenous infusion of Cisplatin (d2). The Maintenance Treatment Stage involves single-drug AK104 at a dose of 10 mg/kg every 3 weeks for a duration lasting up to two years.
62853303|NCT00553722|EXPERIMENTAL|Eplerenone|Administer Eplerenone, 25 mg, orally twice daily for 4 weeks.
62853304|NCT00553722|PLACEBO_COMPARATOR|placebo|Administer a placebo tablet orally twice daily for 4 weeks
62853305|NCT01332799|ACTIVE_COMPARATOR|Allopurinol|
62853306|NCT01332799|PLACEBO_COMPARATOR|Placebo (sugar pill)|
62853307|NCT02601261||Patients with some access to internet during stay|
62451255|NCT02259751|EXPERIMENTAL|KUC 7483 CL|
62627900|NCT01727817|EXPERIMENTAL|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in Control to Range (CTR) or in Safety Only mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct for hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
62627901|NCT01727817|NO_INTERVENTION|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. Subjects will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
62627902|NCT00591929|NO_INTERVENTION|1|No Continuous passive motion following ORIF of fractures around the knee
62853308|NCT02601261||Patients without access to internet during stay|
62627903|NCT00591929|ACTIVE_COMPARATOR|2|Continuous Passive Motion following ORIF of fractures around the knee
62268266|NCT00861744|ACTIVE_COMPARATOR|MMR-II Group|Subjects between 12 and 15 months of age at the time of study vaccination who randomly received one dose of one of three different commercially-available lot of M-M-R II (Merck and Co.) vaccine subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
62268267|NCT00774462|EXPERIMENTAL|1|
62627904|NCT03352492|EXPERIMENTAL|Bilateral iridotomy: Superior|Each subject in this single-arm study undergoes bilateral laser peripheral iridotomy surgery. Each participant will undergo superior laser peripheral iridotomy in one eye and temporal laser peripheral iridotomy in the fellow eye.
62627905|NCT03352492|EXPERIMENTAL|Bilateral iridotomy: Temporal|Each subject in this single-arm study undergoes bilateral laser peripheral iridotomy surgery. Each participant will undergo superior laser peripheral iridotomy in one eye and temporal laser peripheral iridotomy in the fellow eye.
62268268|NCT00286273|ACTIVE_COMPARATOR|citrate|regional anticoagulation with citrate
62268269|NCT00286273|ACTIVE_COMPARATOR|nadroparin|nadroparin is a low molecular weight heparin
62268270|NCT02699892||Rheumatoid arthritis participants|Participants who were on rituximab for rheumatoid arthritis and who will continue receiving rituximab treatment (at the discretion of treating physician) according to previous approved indication will be observed for a period of 72 weeks.
62268271|NCT04799886||Child and adolescent psychiatrist|
62268272|NCT02601521|EXPERIMENTAL|Internal coaching program|The internal coaching program uses a chronic disease management strategy to treat tobacco use and dependence. The program provides evidence-based treatment consisting of up to 12 months of services from a tobacco coach based at Partners HealthCare. The tobacco coach offers (1) repeated smoking cessation counseling delivered by proactive telephone calls, emails, and interactive voice response \[automated phone calls\] and (2) facilitated access to a new Partners HealthCare Inc., health insurance benefit that provides access to all FDA-approved smoking cessation medications without copay or prior approval.
62627906|NCT05285787|EXPERIMENTAL|EPN-701, 10mg orally daily over 14 days|Single arm
62627907|NCT00593424|ACTIVE_COMPARATOR|1|Low Fat/High Carbohydrate
62853309|NCT00305461|ACTIVE_COMPARATOR|1|Ciclesonide 160µg
62853310|NCT00305461|ACTIVE_COMPARATOR|2|Ciclesonide 320µg
62627908|NCT00593424|ACTIVE_COMPARATOR|2|High Monounsaturated Fat/Low Carbohydrate
62627909|NCT03472612|EXPERIMENTAL|CPAP withdrawal|Short-term withdrawal of CPAP therapy in moderate to severe OSA (intervention)
62627910|NCT01427270|EXPERIMENTAL|OXN|Oxycodone/Naloxone controlled-release tablets (OXN)
62627911|NCT01427270|ACTIVE_COMPARATOR|OXY|Oxycodone HCl controlled-release tablets (OXY)
62627912|NCT01427270|PLACEBO_COMPARATOR|Placebo|Placebo tablets to match OXN or OXY
62627913|NCT05176717|EXPERIMENTAL|QR-421a 180/60 µg|180 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter
62627914|NCT05176717|EXPERIMENTAL|QR-421a 60/60 µg|60 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter
62451256|NCT02259751|PLACEBO_COMPARATOR|Placebo|
62627915|NCT05176717|SHAM_COMPARATOR|Sham-procedure|Sham-procedure (no experimental drug administered) on Day 1, Month 3 and every 6 months thereafter
62627916|NCT01395810|EXPERIMENTAL|Prophylaxis, high dose (once weekly)|
62627917|NCT01395810|EXPERIMENTAL|Prophylaxis, low dose (once weekly)|
62627918|NCT01395810|EXPERIMENTAL|On-demand|
62627919|NCT01395810|EXPERIMENTAL|Prophylaxis, high dose (every second week)|
62627920|NCT00905567|EXPERIMENTAL|Test First|Topiramate 2 x 25 mg Tablet
62627921|NCT00905567|ACTIVE_COMPARATOR|Reference First|Topamax® Tablet 2 x 25 mg
62627922|NCT02317484||Ipragliflozin (SGLT2 inhibitor)|
62627923|NCT04621058|EXPERIMENTAL|D VITAMIN GROUP|"The administration of vitamin D will be carried out using the following treatment scheme:~If vitamin D deficiency (\< 30 ng/ml) treatment with 2 capsules of 0.266 mg If vitamin D deficiency (\< 40 ng/ml): treatment with 1 capsule of 0.266 mg~Blood levels of vitamin D will be determined on day 1, 4, 7 and 14. Based on the results from day 14, a new determination is recommended 4 weeks after starting treatment with the primary care physician who will decide whether to continue or interrupt the treatment. This phase will be carried out outside of the study.~In addition, the product should only be administered, if blood calcium and phosphorus levels are within normal limits, as well as if the creatinuria/calciuria ratio is within normal ranges."
62627924|NCT04621058|PLACEBO_COMPARATOR|PLACEBO GROUP|The procedure will be the same as in the experimental group but instead of the active component, patients will take placebo capsules exactly the same as above but without the active component.
62627925|NCT02028780|EXPERIMENTAL|Idarucizumab single doses|different infusion durations
62627926|NCT02028780|EXPERIMENTAL|Idarucizumab with dabigatran|short infusion with 2 capsules dabigatran
62627927|NCT00707980|EXPERIMENTAL|Vortioxetine|Vortioxetine 2.5 mg, 5 mg or 10 mg, encapsulated tablets, orally, once daily for up to 52 weeks. For the first week of treatment all participants received 5 mg/day vortioxetine, thereafter, the dose could be increased to 10 mg/day or decreased to 2.5 mg/day, based on participant's response and tolerability as judged by the investigator.
62627928|NCT03324477|EXPERIMENTAL|preload group|Patients will receive 4 ml/kg of hypertonic saline 3% via G14 cannula over 15-20 min before the induction of spinal anaesthesia.
62853311|NCT04189185|ACTIVE_COMPARATOR|K-wire tension band wiring|The patient is treated with 1.6 mm k-wires and 1 mm cerclage
62853312|NCT04189185|ACTIVE_COMPARATOR|Suture fixation|The fracture is reduced and fixed with 2.0 Orthocord suture.
62451257|NCT05348109||well fininshed cases|
62627929|NCT03324477|EXPERIMENTAL|coload group|Patients will receive 4 ml/kg of hypertonic saline 3% via G14cannula at the maximal possible rate at the time of identification of C.S.F .
62853313|NCT01059708||CO poisoned children|Children, ages 6-16, who have been poisoned by carbon monoxide
62853314|NCT04441580|EXPERIMENTAL|Artificial intelligence arm|Patients undergoing colonoscopy with artificial intelligence.
62853315|NCT04441580|ACTIVE_COMPARATOR|standard colonoscopy arm|Patients undergoing colonoscopy with standard colonscopy
62268273|NCT02601521|ACTIVE_COMPARATOR|External coaching program|The external coaching program consists of referral to the Massachusetts Tobacco Control Program's Smokers Helpline, a free program offering multi-session proactive telephone counseling for 3 months to individuals who are ready to quit smoking. Individuals in this arm also receive information about Partners HealthCare, Inc.'s new health insurance benefit that provides access to all FDA-approved smoking cessation medications without copay or prior approval.
62268274|NCT00525395|EXPERIMENTAL|A|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
62268275|NCT00525395|ACTIVE_COMPARATOR|B|Group B: 6 months non-stop treatment.
62268276|NCT02457455||Sick passangers|Passengers or cabincreew whom needed urgent medical supports during flights with completed medical records. (Aforementioned Flight Company records complaints, symptoms and diagnoses, demographic data, the mortality of those who request medical aid, whether medical treatment is performed by the cabin crew or by a medical professional on the plane, as well as those conditions which resulted in an emergency landing and dead). All ages are included.
62268277|NCT01055158|EXPERIMENTAL|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes.
62268278|NCT01055158|ACTIVE_COMPARATOR|Control|Enhanced Usual Care
62627930|NCT00406081||Participants with AD|Children with AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit (including a group of AD subjects with eczema herpeticum)
62627931|NCT00406081||Nonatopic controls|Children without AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit
62268279|NCT05312034|EXPERIMENTAL|Application of an antimicrobial stewardship program in ICUs|Application of an antimicrobial stewardship program in Brazilian ICUs using machine learning techniques and an educational model
62627932|NCT05605522|EXPERIMENTAL|Phase 1 Dose Escalation|
62627933|NCT05605522|EXPERIMENTAL|Phase 1 Dose Expansion|
62268280|NCT02018822|EXPERIMENTAL|All Participants|Participants who needed at least two tooth restorations
62268281|NCT02997761|EXPERIMENTAL|Treatment (ibrutinib, blinatumomab)|"INDUCTION THERAPY: Patients receive ibrutinib PO QD on days 1-49 of course 1 and days 1-42 of course 2, and blinatumomab IV on days 8-35 of course 1 and days 1-28 of course 2 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Patients with CR/CRi after Induction Therapy receive ibrutinib PO QD on days 1-42 and blinatumomab IV on days 1-28. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62268282|NCT02109484|EXPERIMENTAL|Cohort A P2-VP8 30 mcg|Cohort A toddlers (24-35 mo) receiving P2-VP8 Subunit Vaccine (30 mcg)
62268283|NCT02109484|PLACEBO_COMPARATOR|Cohort A Placebo|Cohort A toddlers (24-35 mo)
62268284|NCT02109484|EXPERIMENTAL|Cohort A P2-VP8 60 mcg|Cohort A toddlers (24-35 mo) receiving high dose P2-VP8 Subunit Vaccine (60mcg)
62268285|NCT02109484|EXPERIMENTAL|Cohort B P2-VP8 10mcg|Cohort B infants receiving P2-VP8 Subunit Vaccine (10mcg)
62268286|NCT02109484|PLACEBO_COMPARATOR|Cohort B placebo|Cohort B infants aged 6 to \< 8 weeks receiving placebo
62627934|NCT03549598|EXPERIMENTAL|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan, 18FDG PET/CT scan and 13NH3 PET/CT scan will be performed on each subject
62853316|NCT03800940|EXPERIMENTAL|Fistulography and trans-drain occlusion|Fistulography is performed to assess the condition of the fistula, and trans-drain occlusion is performed by injecting glue (NBCA and Lipiodol) through the drain to occlude the tract.
62853317|NCT03800940|SHAM_COMPARATOR|Fistulography|Fistulography is performed to assess the condition of the fistula, without trains-drain occlusion.
62853318|NCT01450852|EXPERIMENTAL|Strength Training|The strength training group completed 12 weeks of progressive, periodized resistance training 3d/wk.
62627935|NCT04031326|EXPERIMENTAL|LENA Home|Home visitors assigned to the intervention group will be trained to use and administer LENA Home in addition to the standard ECS curriculum during designated home visits beginning when the child is between 6- and 9-months old.
62853319|NCT01450852|NO_INTERVENTION|Active Control Group|The active control group was instructed to maintain normal activity and eating habits. They participated in all pre and post intervention measures.
62853320|NCT02802917|EXPERIMENTAL|SPF 50 Y49 091|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
62853321|NCT02802917|EXPERIMENTAL|SPF 50 X15 158|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
62853322|NCT02802917|EXPERIMENTAL|SPF 50 X15 160|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
62627936|NCT04031326|NO_INTERVENTION|Standard Practice|Home visitors assigned to the control group will administer the standard ECS curriculum only
62853323|NCT02802917|EXPERIMENTAL|SPF 50 X57 162|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
62268287|NCT02109484|EXPERIMENTAL|Cohort B P2-VP8 30mcg|Cohort B infants aged 6 to \< 8 weeks receiving P2-VP8 Subunit Vaccine (30mcg)
62268288|NCT02109484|EXPERIMENTAL|Cohort B1 P2-VP8 60mcg|Cohort B1 Infants aged 6 to \< 8 weeks receiving P2-VP8 Subunit Vaccine (60mcg)
62627937|NCT02182986||Subjects Enrolled Pre-Transplant|"Subjects (N=approximately 357) Enrolled Pre-Transplant~* Subjects with evidence of EBV infection prior to transplant~* Subjects without evidence of EBV infection prior to transplant, who are at risk of developing EBV infection after transplant"
62853324|NCT02917018|ACTIVE_COMPARATOR|Dexmedetomidine 1|patients will receive dexmedetomidine 1 mic/kg
62853325|NCT02917018|ACTIVE_COMPARATOR|Dexmedetomidine 0.75|patients will receive dexmedetomidine 0.75 mic/kg
62853326|NCT02917018|ACTIVE_COMPARATOR|Dexmedetomidine 0.5|patients will receive dexmedetomidine 0.5 mic/kg
62268289|NCT02109484|EXPERIMENTAL|Cohort A P2-VP8 10mcg|Cohort A toddlers (24-35 mo) receiving P2VP8 Subunit Vaccine (10mcg)
62268290|NCT03784066|ACTIVE_COMPARATOR|A|Durvalumab
62627938|NCT02182986||Subjects Enrolled Post-Transplant|"Subjects (N=approximately 588) Enrolled 3 Yrs Post-Transplant~* Subjects with evidence of EBV infection prior to transplant~* Subjects without evidence of EBV infection prior to transplant, who are at risk of developing EBV infection after transplant"
62627939|NCT01153009|PLACEBO_COMPARATOR|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
62627940|NCT01153009|EXPERIMENTAL|Vortioxetine 15 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 15 mg, encapsulated tablets, orally, once daily for 7 weeks, then placebo-matching capsules, orally, once daily for one week.
62627941|NCT01153009|EXPERIMENTAL|Vortioxetine 20 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 20 mg, encapsulated tablets, orally, once daily for 7 weeks, then placebo-matching capsules, orally, once daily for one week.
62853327|NCT03218800|ACTIVE_COMPARATOR|Intravenous Ertapenem|Patients with urinary tract infection will be treated with ertapenem by the intravenous route.
62853328|NCT03218800|EXPERIMENTAL|Subcutaneous Ertapenem|Patients with urinary tract infection will be treated with ertapenem by the subcutaneous route.
62853329|NCT05254847|EXPERIMENTAL|combined treatment group|Capecitabine combined with lenvatinib and tislelizumab: Lenvatinib,8mg po. qd.Tislelizumab,200mg iv. q3w. Capecitabine 1250mg/m\^2 bid.d1-d14 q3w
62853330|NCT04343924|EXPERIMENTAL|Diving Group|The subjects of this group daily dive, 5 days per week, for a total of 10 dives at a maximum depth of 6 meters for a maximum duration of 20 minutes in a swimming pool.
62853331|NCT04343924|ACTIVE_COMPARATOR|Virtual reality Group|The subjects of this group will follow virtual reality sessions recreating the environment in which the submarine diver of the GP+ group operates.
62853332|NCT04343924|NO_INTERVENTION|Control Group|The subjects of this group will be monitored and treated for PTSD and will not attend the dive discovery course or virtual reality sessions.
62268291|NCT03784066|ACTIVE_COMPARATOR|B|Durvalumab + Tremelimumab
62268292|NCT01273883|EXPERIMENTAL|Magnesium first, then placebo|Magnesium 532 mg daily for 25 days followed by 2 weeks of washout followed by 25 days of placebo.
62268293|NCT01273883|PLACEBO_COMPARATOR|Placebo first, then magnesium|Placebo daily for 25 days followed by 2 weeks of washout followed by magnesium 532 mg daily for 25 days.
62451258|NCT05647421|ACTIVE_COMPARATOR|The AcrySof™ IQ Vivity™ intraocular lens group|The AcrySof™ IQ Vivity™ will be implanted in 20 eyes of 10 patients (group 1)
62451259|NCT05647421|ACTIVE_COMPARATOR|TECNIS Synergy™ Intraocular Lens (Model ZFR00V ) group|The TECNIS Synergy™ Intraocular Lens (Model ZFR00V ) will be implanted in 20 eyes of 10 patients
62627942|NCT01153009|ACTIVE_COMPARATOR|Duloxetine 60 mg|Duloxetine 30 mg capsules, orally, once daily for one week then duloxetine 60 mg, capsules, orally, once daily for 7 weeks, then duloxetine 30 mg capsules, once daily, for one week.
62268294|NCT00631748|EXPERIMENTAL|Study Drug|Subjects randomized to the experimental arm of the study will be initially administered 50mg/day quetiapine fumarate (Seroquel XR) to be titrated up to 400mg/day by the end of the second week. Subjects will be stabilized at a dose of 400mg/day or alternatively 300, 200, 100, or 50mg/day or quetiapine fumarate as tolerated. During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
62063264|NCT01417611|EXPERIMENTAL|i-scan-CE/SE|Study Group using i-scan SE and CE mode: i-scan-CE/SE group was explored whole colon from the cecum to the rectum with i-scan-CE 2+ and SE 2+ mode. They had a chance to switch from i-scan to WL to perform polyp removal using cold biopsy or polypectomy
62063265|NCT01417611|EXPERIMENTAL|i-scan-CE/SE/TE-c|Study Group using i-scan SE \& CE mode as well as TE-c mode: i-scan-CE/SE/TE-c group was explored whole colon from the cecum to the rectum with i-scan CE2+, SE2+, TE-c mode. They had a chance to switch from i-scan to WL to perform polyp removal using cold biopsy or polypectomy
62627943|NCT00063804|EXPERIMENTAL|1|escalating single doses of AMD070 ranging from 1/4 to 1 times the maximum tolerated dose (MTD)
62627944|NCT00063804|EXPERIMENTAL|2|single dose of 200 mg AMD070 after eating a standardized meal
62627945|NCT00063804|EXPERIMENTAL|3|single dose of 200 mg AMD070 on Days 1, 3, and 17 and single dose of 100 mg ritonavir on Days 3 through 18
62627946|NCT06548646|EXPERIMENTAL|Thoracic Interfascial Plane Block|the Thoracic Interfascial Plane Block, which includes Pecto-Intercostal Fascial Plane Block and Serratus Intercostal Fascial Plane Block, is a peripheral nerve block that targets the intercostal nerve branches scattered throughout the chest and axilla
62627947|NCT06548646|ACTIVE_COMPARATOR|Erector Spinae Plane Block|Erector Spinae Plane Block (ESPB) is an anesthesia technique for providing effective analgesia during and after breast and abdominal surgery
62627948|NCT01067898|EXPERIMENTAL|200 000 IU vitamin D3 every three months|
62627949|NCT01067898|EXPERIMENTAL|100 000 IU vitamin D3 every three months|
62853333|NCT04354597|EXPERIMENTAL|Study Arm A (HCQ & AZ)|Subjects will receive weekly HCQ 400mg X 1 Day PO and AZ 500mg PO X 3 Days; weekly for 16 weeks.
62853334|NCT04354597|NO_INTERVENTION|Study Arm B (No treatment)|Subjects will receive no treatment in this group and will be serving as control.
62853335|NCT00642785||1|Patients with active oral or genital HSV skin lesions
62853336|NCT00642785||2|Patients with a history of recurrent oral or genital HSV but without an active lesion at the time of treatment
62853337|NCT00642785||3|Patients with active shingles/zoster
62853338|NCT00642785||4|Patients with post herpetic neuralgia
62063266|NCT04693936|ACTIVE_COMPARATOR|Nutraceuticals|Participants will receive a combination of nutraceuticals and will be instructed to follow a Mediterranean diet
62063267|NCT04693936|NO_INTERVENTION|Control|Participants will follow usual diet
62063268|NCT03253016|EXPERIMENTAL|cervicall cerclage|to test vaginal microbiome distribution in women with cervical cerclage due to cervical incompetence in weeks: 12 14 18 26 32
62461480|NCT03619746|EXPERIMENTAL|Post-Intervention|This arm of patients will cared for by physicians who have received the POCUS Educational Intervention.
62627950|NCT01067898|PLACEBO_COMPARATOR|placebo every three months|
62853339|NCT04316819|EXPERIMENTAL|Packed Promise Demonstration Benefits|Treatment households (n=2,143) received one food box per eligible child, per month, delivered to the household, which contained (1) shelf-stable foods, including 6 protein-rich items, 2 dairy items, 4 grain foods, 4 cans of fruit, and 12 cans of vegetables; (2) a nutrition education handout (e.g., a recipe); and (3) a $15 Fresh Check for frozen or fresh fruits and vegetables that participants could redeem at any of 38 Special Supplemental Nutrition Program for Women, Infants, and Children (WIC)-authorized stores or farmers' markets in the study counties.
62853340|NCT04316819|NO_INTERVENTION|Control Group|Control households (n=2,607) did not receive the treatment benefits but still could participate in other available nutrition assistance programs.
62853341|NCT00907179|EXPERIMENTAL|Dose escalation|"Phase I: Determine the highest and safest dosage of LBH589 (15 mg, 20 mg, and 30 mg). If the 15 mg dosage causes too many side effects, a back-up dosage of 10 mg will be used instead of the 15 mg.~Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given"
62853342|NCT01767142|EXPERIMENTAL|Outer Thigh CoolSculpting Treatment|Treatment with the CoolSculpting System and a modified belt applicator will be performed on one outer thigh; the remaining thigh is considered the untreated control. Subjects will receive one cooling cycle applied to the thigh area intended for treatment with a protocol-defined cooling rate and duration of 120 minutes.
62853343|NCT02766556|ACTIVE_COMPARATOR|arm 1|received ISB with 8mL of ropivacaine with 100 μg (1ml) of dexmedetomidine
62853344|NCT02766556|PLACEBO_COMPARATOR|arm 2|received ISB with 8mL of ropivacaine with 1ml of normal saline
62063269|NCT03253016|EXPERIMENTAL|vaginal progesterone|to test vaginal microbiome distribution in women treated with vaginal progesterone due to cervical shortening in weeks: 12 14 18 26 32
62063270|NCT03253016|NO_INTERVENTION|contol|to test vaginal microbiome during pregnancies without cerclage or progesterone
62063271|NCT06112730|ACTIVE_COMPARATOR|Standard pulmonnary rehabilitation group|Received routine pulmonnary rehabilitation
62063272|NCT06112730|EXPERIMENTAL|Nutritional supplementation intervention group|Received regular pulmonnary rehabilitation plus healthy dietary recommendations
62627951|NCT06088745|EXPERIMENTAL|Treatment main group|11500 subjects in treatment main group will receive 2 doses of LZ901 at D0 and D29. This group will be required to complete a 12 month safety follow-up after full immunization.
62627952|NCT06088745|PLACEBO_COMPARATOR|Placebo main group|11500 subjects in placebo main group will receive 2 doses of placebo at D0 and D29. This group will be required to complete a 12 month safety follow-up after full immunization.
62853345|NCT01168219|EXPERIMENTAL|Treatment (chemotherapy and transplant)|"REDUCED-INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3, busulfan IV over 45 minutes on days -6 to -3, and anti-thymocyte globulin IV over 4-10 hours on days -6 to -5 (matched sibling donor \[MSD\]) or -6 to -4 (matched unrelated donor \[MUD\]).~TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0 or on days 0-1.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus PO or IV on days -2 to 90 with taper on days 150-180. Patients also receive methotrexate IV on days 1, 3, 6 (MSD), and 11 (MUD).~CONSOLIDATION: Beginning on day 42, patients receive azacitidine SC or IV on days 1."
62268295|NCT00631748|PLACEBO_COMPARATOR|Placebo|Subjects randomized to the placebo arm of the study will follow the same titration and dosing procedure as the experimental arm but will receive matched placebo tablets. During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
62451260|NCT05451459|EXPERIMENTAL|Intervention Group|Participants in the intervention group will be offered four one-day group workshops (2-3 hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) Sports. The workshops will be offered online via Zoom and will be video recorded. The intervention group will also receive information (activity booklets via the Fit Families App) and physical education (physical activity)-related equipment, which will be mailed to them. At the end of the workshop parents will be instructed to practice the skills they learned with their child for the next 3 weeks (for at least 3 hrs per week).
62627953|NCT06088745|EXPERIMENTAL|Treatment immunization group|1500 subjects in treatment immunization group will receive 2 doses of LZ901 at D0 and D29. This group is designed to evaluate the batch-batch immunogenicity consistency among three different batches of LZ901, as well as the immunogenicity and immunogenicity persistence of the LZ901 at 36 months after full immunization.
62627954|NCT06088745|PLACEBO_COMPARATOR|Placebo immunization group|1500 subjects in placebo immunization group will receive 2 doses of placebo at D0 and D29. This group is designed to evaluate the batch-batch immunogenicity consistency among three different batches of LZ901, as well as the immunogenicity and immunogenicity persistence of the LZ901 at 36 months after full immunization.
62268296|NCT01234272|EXPERIMENTAL|ITM-IVPCA|ITM-IVPCA:intrathecal morphine and IV-fentanyl patient controlled analgesia
62627955|NCT02377583||Diabetic children|"* physical examination~* Glucocorticoid sensitivity index~* DNA sample~* Anxiety and depression questionnaires~* depression questionnaire~* MRI"
62627956|NCT02377583||Controls|"* physical examination~* Glucocorticoid sensitivity index~* DNA sample~* Anxiety and depression questionnaires~* depression questionnaire~* MRI~* Laboratory tests"
62627957|NCT04026750|EXPERIMENTAL|Pitolisant|
62627958|NCT04026750|PLACEBO_COMPARATOR|Matching placebo|
62627959|NCT06048393|EXPERIMENTAL|Group1|Single-dose:1 spray per side per time, 1ml/time Single-dose: 2 sprays per side per time, 2ml/time Multi-dose:1 spray per side per time, 1ml/time Multi-dose: 2 sprays per side per time, 2ml/time
62853346|NCT01630993|EXPERIMENTAL|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
62853347|NCT01630993|NO_INTERVENTION|Immediate Cord Clamping|At birth, the infant will be held at the level of the placenta and umbilical cord will be clamped within 10 seconds (routine practice).
62853348|NCT02463253||Phase 1|"A. OBJECTIVE: The objective of this phase of the study is to allow the clinical site to gain familiarity with patient recruitment, sample and data collection, and interpretation of the proteogenomic biomarker report provided, through retrospective analysis. This phase of the study will provide a platform for the transplant physicians to gain confidence with the format, logistics, and potential use of the biomarker tests on blood and tissue.~B. STUDY DESIGN: Enroll 20 subjects who are post-transplant and are undergoing kidney transplant biopsies at the UC Davis transplant center. Ten subjects will be enrolled who are receiving surveillance protocol biopsies and 10 subjects."
62268297|NCT01234272|ACTIVE_COMPARATOR|PCEA|PCEA:epidural PCA(patient controlled analgesia)
62627960|NCT06048393|PLACEBO_COMPARATOR|Group2|Single-dose: 1 spray per side per time Multi-dose: 2 sprays per side per time
62627961|NCT03435627||Norditropin® (naïve participants)|The treatment period of Norditropin® for naïve participants will be up to 208 weeks.
62627962|NCT03435627||Norditropin® (non-naïve participants)|The treatment period of Norditropin® for non-naïve participants will be up to 442 weeks.
62268298|NCT04704232|ACTIVE_COMPARATOR|ACD440|Subjects are simultaneously exposed to topical administration of ACD440 in a crossover design in separate locations from the placebo exposure.
62268299|NCT04704232|PLACEBO_COMPARATOR|Placebo|Subjects are simultaneously exposed to topical administration of placebo in a crossover design in separate locations from the ACD440 exposure.
62268300|NCT01156584|EXPERIMENTAL|Single arm|Toca 511 vector/ Toca FC prodrug
62268301|NCT00336973|EXPERIMENTAL|1|
62268302|NCT06017804|EXPERIMENTAL|MET Group|Received a muscle energy technique
62461481|NCT04910230|EXPERIMENTAL|nicotinamide plus usual care|
62461482|NCT04910230|NO_INTERVENTION|usual care|
62461483|NCT00324168|ACTIVE_COMPARATOR|1|
62627963|NCT02608242|EXPERIMENTAL|YH22189|YH22189 FDC tablet of Yuhan Corporation
62627964|NCT02608242|ACTIVE_COMPARATOR|Twynsta 80/10mg|Telmisartan/Amlodipine 80/10mg (FDC)
62627965|NCT02608242|ACTIVE_COMPARATOR|Crestor 20mg|Rosuvastatin 20mg
62627966|NCT03784313|EXPERIMENTAL|Perforators flaps (PF group)|
62627967|NCT03784313|SHAM_COMPARATOR|Secondary intention wound healing|
62627968|NCT01416077|NO_INTERVENTION|standard treatment|Fluid and inotropic drugs are given based on conventional parameters such as blood pressure and heart rate as judged by the individual anesthesiologists judgement.
62627969|NCT01416077|ACTIVE_COMPARATOR|goal-directed fluid treatment|Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised
62853349|NCT06286189|PLACEBO_COMPARATOR|Placebo|Placebo capsule 30 min before sleep
62063273|NCT04951674|EXPERIMENTAL|DIET|Participants will receive four individual, approximately 30-minute long dietary education sessions. The participants will receive detailed instructions (including meal plans, information on high fiber foods and serving sizes) on how to consume at least 30 grams of fiber per day.
62063274|NCT04951674|PLACEBO_COMPARATOR|CONTROL|No diet education. Group will spend same amount of time with study dietitian, but discussion is limited to review of current eating habits and minimal input on eating habits with referencing the standard food pyramid.
62853350|NCT06286189|EXPERIMENTAL|Trazodone|Trazodone capsule 30 min before sleep
62853351|NCT00439816|OTHER|Arm 1|
62853352|NCT05996302|ACTIVE_COMPARATOR|6-minute walk distance at 2840m|Participants will have 6-minute walk distance (6MWD) assessment near their resident altitude at 2840m
62063275|NCT04707196|EXPERIMENTAL|Abemaciclib + NSAI or Fulvestrant|Participants received abemaciclib 150 milligram (mg) orally twice daily, on days 1 through 28 of a 28-day cycle, for up to 6 cycles or less in case of disease progression, or any other discontinuation criterion is met, plus either NSAI (nonsteroidal aromatase inhibitors - anastrozole or letrozole) administered orally as per standard of care or fulvestrant administered intramuscularly as per standard of care.
62063276|NCT02410993||CABG surgery|Candidates for CABG surgery for left main disease, three-vessel disease or two-vessel disease with proximal LAD stenosis indicated by current practice guideline
62063277|NCT05363657||Renal tumor patiens|Patients with any renal tumor diagnosed with conventional imaging (computed tomography or magnetic resonance imaging) and undergoing to a clinical management in a hugh-volume center.
62853353|NCT05996302|EXPERIMENTAL|6-minute walk distance at sea level|Participants will have 6-minute walk distance (6MWD) assessment at sea level (0-30m)
62853354|NCT05902650||Group 1|diabetic patients with no diabetic retinopathy
62063278|NCT05377970|EXPERIMENTAL|Prehabilitation Intervention Program|Patients enrolled in this arm will receive the preabilitation intervention program prior to their surgery to complete
62063279|NCT02848716|ACTIVE_COMPARATOR|Standard of care arm|Standard chemoradiation based on FluoroDeoxyGlucose-Positon Emission Tomography (FDG-PET) imaging status of the pelvic nodes
62063280|NCT02848716|EXPERIMENTAL|Experimental arm|Pretherapeutic paraaortic lymphadenectomy followed by tailored chemoradiation. Pretherapeutic lymphadenectomy will be performed via the laparoscopic extraperitoneal or transperitoneal approach
62853355|NCT05902650||Group 2|diabetic patients with mild nonproliferative diabetic retinopathy
62853356|NCT05902650||Group 3|diabetic patients with moderate and severe nonproliferative diabetic retinopathy
62853357|NCT05902650||Group 4|diabetic patients with proliferative diabetic retinopathy
62063281|NCT02006875|EXPERIMENTAL|real rTMS|Experimental included the a daily real rTMS session for 15 mins followed by a physical therapy for 45 mins.
62063282|NCT02006875|SHAM_COMPARATOR|sham rTMS|the control interventions included a daily sham rTMS session for 15 minutes followed by a physical therapy for 45 minutes.
62063283|NCT03960671|EXPERIMENTAL|Anxiolytics|Pediatric patients treated with sedation using anxiolytics
62063284|NCT04251871|EXPERIMENTAL|Conventional medicines and TCMs granules|"Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.~Traditional Chinese Medicines (TCMs) granules: one bag, p.o, bid, for 14 days."
62461484|NCT00324168|PLACEBO_COMPARATOR|2|
62853358|NCT03123406|EXPERIMENTAL|Severe SHPT|Administer Cinacalcet HCL to subjects whose iPTH\>900 pg/ml from 1st to 32nd week.
62853359|NCT03123406|EXPERIMENTAL|Moderate SHPT|Administer Cinacalcet HCL to subjects whose 600≤iPTH\<900 pg/ml from 1st to 32nd week.
62853360|NCT03123406|EXPERIMENTAL|Mild SHPT|Administer Cinacalcet HCL to subjects whose 300≤iPTH\<600 pg/ml from 1st to 32nd week.
62063285|NCT04251871|ACTIVE_COMPARATOR|Conventional medicines|Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
62088046|NCT01290016|EXPERIMENTAL|4 servings dairy + exercise 9-12 yrs|Subjects in this group will receive family based counselling to maintain the standard recommended intake of 4 servings of dairy per day for 9-14 year olds according to the Canada's Food Guide and also receive instruction on how to improve their physical activity.
62268303|NCT06017804|ACTIVE_COMPARATOR|SMFR Group|Received a self-myofascial release technique using a foam roller
62461485|NCT06403761|EXPERIMENTAL|CagriSema|Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every 4 weeks in a 16-week dose escalation period until target dose of CagriSema is achieved and maintained for 12 weeks.
62461486|NCT06403761|EXPERIMENTAL|Semaglutide|Participants will receive once-weekly s.c injections of semaglutide at escalating doses every 4 weeks in a 16-week dose escalation period until target dose of CagriSema is achieved and maintained for 12 weeks.
62853361|NCT05646017||Type 1 diabetes patients|Type 1 diabetes patients using intermittently continuous glucose monitoring during the Spanish greatest heatwave in Castilla-La Mancha (Spain).
62853362|NCT02697344|EXPERIMENTAL|Treatment (AT-101, lenalidomide, and dexamethasone)|Patients receive R-(-)-gossypol acetic acid PO QD on days 1-21. Beginning in course 2, patients also receive lenalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, and 15 of courses 2-12. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
62853363|NCT04040322|PLACEBO_COMPARATOR|Placebo|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
62853364|NCT04040322|ACTIVE_COMPARATOR|Iloprost Injection, for intravenous use|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
62853365|NCT06445452|EXPERIMENTAL|SNAP-Ed|
62853366|NCT06445452|PLACEBO_COMPARATOR|No SNAP-Ed|
62853367|NCT04339842||Adults in quarantine due to the virus outbreak|Individuals over the age of 18 who spend most of their time at home in social isolation because of the Coronavirus to prevent the risk of contracting the virus
62853368|NCT05786742|EXPERIMENTAL|ultra hypo fractionation radiation therapy|comparative PRO's of 25 Gy in 5 daily fractions (Ultra hypo fractionation) administered to prostate and 1st centimeter of proximal seminal vesicle, starting mid week and ending mid following week.
62063286|NCT03077464|ACTIVE_COMPARATOR|behavioral nutrition education|Set of curricular nutrition education modules, previously developed and based on Social Cognitive Theory, for the HOP'N After-School program, with additional materials from MyPlate. Materials were employed to increase healthy eating behavioral capability, self-efficacy, attitudes, and enjoyment. Topics included: 1) nutrition label literacy; 2) drinking water; 3) eating colors of the rainbow; 4) healthful snacks; 5) benefits of fruit and vegetable consumption; 6) moving more and sitting less; and 7) taking healthy habits home.
62088047|NCT01290016|ACTIVE_COMPARATOR|Control 9-12 yrs|The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
62088048|NCT01807819||Heart Failure|Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
62088049|NCT01826903||depressed mother/child dyad - intervention|
62268304|NCT00290433|EXPERIMENTAL|HCVIDDOXIL Regimen|"Cycle 1: Cyclophosphamide by vein two times a day on Days 1,2, and 3. Mesna by vein nonstop over Days 1 through 3. Pegylated liposomal doxorubicin by vein over 1 hour on Day 2. Vincristine by vein on Days 4 and 11. Dexamethasone by mouth on Days 1 through 4 and 11 through 14.~Cycle 2: Methotrexate by vein over 2 hours on Day 1 and over 22 hours on day 1. Cytarabine by vein twice a day on Days 2 and 3."
62268305|NCT05089968||Patient from the first wave of COVID-19|57 Patients hospitalized in intensive care unit for pneumonia related to a Sars-Cov2 infection who required mechanical ventilatory support and developed microbiologically documented ventilator associated pneumonia during the 1st wave from January 24, 2020 to July 10, 2020
62853369|NCT05786742|ACTIVE_COMPARATOR|moderate hypo fractionation radiation therapy|PRO's of moderate hypo fractionation, 37,5 Gy in 15 or 36 Gy in 12 daily fractions administered 5 days per week.
62853370|NCT01610999|EXPERIMENTAL|Cohort A|0.24 mg/kg plerixafor on day 1
62853371|NCT01610999|EXPERIMENTAL|Cohort B|0.24 mg/kg plerixafor daily on days 1 \& 2
62853372|NCT01610999|NO_INTERVENTION|Cohort C|"Six control subjects will have research bloods drawn but receive no plerixafor."
62853373|NCT04232332|EXPERIMENTAL|3.75μg (pre test)|Single dose
62853374|NCT04232332|EXPERIMENTAL|7.5μg|Single dose
62853375|NCT04232332|PLACEBO_COMPARATOR|15μg single dose|Intramuscular injection once
62853376|NCT04232332|PLACEBO_COMPARATOR|30μg single dose|Intramuscular injection once
62853377|NCT04232332|PLACEBO_COMPARATOR|45μg single dose|Intramuscular injection once
62088050|NCT01826903||depressed mother/child dyad - no intervention|
62088051|NCT01826903||non-depressed mother/child dyad|
62461487|NCT06403761|EXPERIMENTAL|Cagrilintide|Participants will receive once-weekly s.c injections of cagrilintide at escalating doses every 4 weeks in a 16-week dose escalation period until target dose of CagriSema is achieved and maintained for 12 weeks.
62853378|NCT04232332|PLACEBO_COMPARATOR|60μg single dose|Intramuscular injection
62853379|NCT04232332|PLACEBO_COMPARATOR|75μg single dose|Intramuscular injection
62853380|NCT04232332|PLACEBO_COMPARATOR|90μg single dose|Intramuscular injection once
62853381|NCT04232332|PLACEBO_COMPARATOR|30μg multiple dose|The dosage will be adjusted according to the actual situation of the trial
62853382|NCT04232332|PLACEBO_COMPARATOR|45μg multiple dose|The dosage will be adjusted according to the actual situation of the trial
62853383|NCT05382442|EXPERIMENTAL|Part 1_Chemotherapy Regimen Selection Stage Group A(AK112+AK117+XELOX)|"AK112+AK117+XELOX~AK112 and AK117 and XELOX(Oxaliplatin 130 mg/sqm iv day 1, Capecitabine via oral, the total daily dose was 2000mg/sqm, day1-14)~If no progression occurs during AK112 plus AK117 plus XELOX, patients will receive maintenance capecitabine plus AK112 plus AK117 at the same dose used at the last cycle of the induction treatment. Capecitabine plus AK112 plus AK117 will be repeated every 3 weeks until disease progression, unacceptable toxicity or patient's refusal."
62853384|NCT05382442|EXPERIMENTAL|Part 1_Chemotherapy Regimen Selection Stage Group B(AK112+AK117+FOLFOXIRI)|"AK112+AK117+FOLFOXIRI~AK112 and AK117 and FOLFOXIRI(Irinotecan 150-165 mg/sqm iv day 1, Oxaliplatin 85 mg/sqm iv day 1, Leucovorin(LV) 400 mg/sqm iv day 1, 5-fluorouracil(5-FU) 2400-2800 mg/sqm 48 h-continuous infusion, starting on day 1)~If no progression occurs during AK112 plus AK117 plus FOLFOXIRI, patients will receive maintenance 5-FU/LV plus AK112 plus AK117 at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus AK112 plus AK117 will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
62063287|NCT03077464|EXPERIMENTAL|behavioral nutrition education plus skills|Set of curricular nutrition education modules, previously developed and based on Social Cognitive Theory for the HOP'N After-School program, with additional materials from MyPlate. Materials were employed to increase healthy eating behavioral capability, self-efficacy, attitudes, and enjoyment. Topics included:1) nutrition label literacy;2) drinking water;3) eating colors of the rainbow;4) healthful snacks;5) benefits of fruit and vegetable consumption;6) moving more and sitting less;and 7) taking healthy habits home. Designed to differ from behavioral nutrition education condition by devoting at least 15 minutes of each session to an additional behavioral skills training component. The behavioral skills component was designed to bolster behavioral capability, healthy eating attitudes, self-efficacy, and proxy efficacy with activities such as snack preparation sessions, role-playing games, fruit and vegetable tasting, and playing games that promoted healthier dietary behaviors.
62627970|NCT03709147|EXPERIMENTAL|FAME arm|"* cisplatin 75 mg/mq every three weeks OR carboplatin (CBDCA) at an area under the curve (AUC) of 5 every three weeks, up to a maximum of 4 cycles~* pemetrexed 500 mg/mq every three weeks~* pembrolizumab 200 mg flat dose every three weeks~* metformin hydrochloride up to a daily dosage of 1500 mg~* every-three week, 5-day Fasting-mimicking diet (FMD), up to a maximum of 4 cycles"
62627971|NCT03709147|EXPERIMENTAL|MERCY arm|"* cisplatin 75 mg/mq every three weeks OR carboplatin (CBDCA) at an area under the curve (AUC) of 5 every three weeks, up to a maximum of 4 cycles~* pemetrexed 500 mg/mq every three weeks~* pembrolizumab 200 mg flat dose every three weeks~* metformin hydrochloride up to a daily dosage of 1500 mg"
62627972|NCT03709147|NO_INTERVENTION|BORN arm|Standard clinical approach.
62063288|NCT01336621|EXPERIMENTAL|Retigabine IR|Open label flexible dose between 300 mg/day (Minimum) and 1200 mg/day (maximum).
62063289|NCT06340425||SDR group, main group will be evaluated within subject design|"* Patient characteristics: Children with spastic cerebral palsy, 5 to 16 years of age at time of SDR, both male and female. All children were diagnosed with bilateral involvement, Gross Motor Function Classification System level II or III.~* Intervention: All participants underwent an SDR procedure in terms of their clinical care, based on the clinical decision making of the attending physician. During the SDR procedure, 25-30% of the dorsal rootlets was cut, descending between L1 and S1. Children received an intensive one-year rehabilitation program after the procedure, of which two to three months of the rehabilitation was performed while the child was admitted to the hospital.~The effects within the SDR group will be compared to two control groups (see below)."
62063290|NCT06340425||Control groups|Additionally two reference databases, established during previous research, will be used to improve interpretation. A normative reference database of typically developing children will be used to calculate the three-dimensional gait analysis outcomes. This database consists of 87 typically developing children (aged between 4,5 and 18,5 years, 42 boys and 45 girls, weight range 17,6 and 92,5 kg, height range between 1,08 and 1,9 meter). A reference database of children with spastic CP without a SDR intervention will be used to qualitatively judge the muscle morphology of children with spastic CP with an SDR intervention. This database consists of 206 children with CP (aged between 0,6 and 17,4 years, 124 boys and 82 girls, weight range 5,8 and 82,0 kg, height range between 0,6 and 1,9 meter, 88 with unilateral and 118 with bilateral involvement, 104 with a GMFCS level 1, 63 with a level 2 and 39 with a level 3).
62268306|NCT05089968||Patient from the Second wave of COVID-19|211 Patients hospitalized in intensive care unit for pneumonia related to a Sars-Cov2 infection who required mechanical ventilatory support and developed microbiologically documented ventilator associated pneumonia during the 2nd wave from July 11, 2020 to January 8, 2021
62461488|NCT06403761|PLACEBO_COMPARATOR|Placebo|Participants will receive once-weekly s.c injection of placebo matched to semaglutide and cagrilintide for 28 weeks.
62627973|NCT00920504|EXPERIMENTAL|German PRO-SELF(c) Plus PCP|Group receives 10 weeks German PRO-SELF(c) Plus PCP intervention program
62627974|NCT00920504|ACTIVE_COMPARATOR|Standard Care|control group receives attention control and standard care
62627975|NCT01920724||wasting, obesity, stunting, normal|wasting (BMI for age Z-scores \< -2 SD), normal (-1 SD ≤ BMI for age Z-scores ≤ +1 SD), obesity (BMI for age Z-scores \> +2 SD), and stunting (HAZ \< -2 SD).
62627976|NCT03344146|OTHER|Group 1|Intake reminders followed by crossover to no intake reminders
62627977|NCT03344146|OTHER|Group 2|No intake reminders followed by crossover to intake reminders
62627978|NCT01033630|PLACEBO_COMPARATOR|Placebo|Image-matched placebo of active treatment
62627979|NCT01033630|ACTIVE_COMPARATOR|D&G 1g|Randomly allocated into three groups, D\&G capsule 1g/day
62627980|NCT01033630|ACTIVE_COMPARATOR|D&G 2g|Randomly allocated into three groups, D\&G capsule 2g/day
62627981|NCT00736294|EXPERIMENTAL|Ramipril|Inhibition Conversion Enzyme
62627982|NCT00736294|PLACEBO_COMPARATOR|Placebo|Placebo
62627983|NCT01883739|EXPERIMENTAL|Parental Presence at Handover Rounds|"Subjects will receive an educational document prior to transfer rounds introducing the concept of Patient and Family Centered Care and the role of a parent in transfer rounds. These parents will have the option of meeting with a parental peer support person for a coaching or training session prior to their participation in transfer rounds. During the transfer rounds parents will be actively included in discussion of their child's medical management plan upon discharge to the wards."
62652913|NCT06518213||Cohort receiving BIC/FTC/TAF as a rapid start, same-day initiation ART|All included subjects (one group, no control group) were started therapy with BIC/FTC/TAF (co-formulated in one tablet of Biktarvy® consisting of 50 mg of bictegravir, 200 mg of emtricitabine and 25 mg of tenofovir alafenamide) within 24 hours of inclusion in care and continued for 12 months.
62451261|NCT05451459|OTHER|Wait-list home-based group|The wait-list home-based group will serve as the control group (during intervention). This group will be instructed to continue their typical routines and activities for the duration of the 12-week intervention. At the end of the 12 weeks, they will be asked to complete the post-test surveys (same as questionnaires completed prior to randomization). Their participation in the research will be complete at this time. However, because the intervention has been shown to potentially benefit families, immediately following the post-test, participants in the wait-list home-based group will be offered the chance to complete the home-based intervention program (e.g., receiving the same intervention protocol and materials (physical education equipment and lesson plans/workbook) as described for the intervention group). No data will be collected for research from them during this time.
62627984|NCT03972384|EXPERIMENTAL|Post-ICU Problem Solving|The PIC-UPS intervention focuses on self-regulation activities and environmental cues to overcome problems with memory, planning and decision-making. The interventionist uses guided discovery, reviews progress, and emphasizes generalization and transfer to other patient-identified problems. This approach may be more acceptable to participants because they can see the relevance of tasks to everyday life. Activities such as goal-setting, self-evaluation and reflective thinking behaviors enhance self-efficacy and increase the likelihood that the individual will engage in self-management behaviors. The first session of PIC-UPS will be delivered after enrollment to those participants randomized to the intervention group. Weekly intervention sessions will be conducted by a trained interventionist and supplemented by telephone reminders to complete daily homework. Follow-up data collection will be conducted in the home by a blinded data collector three months post-enrollment.
62627985|NCT03972384|NO_INTERVENTION|Control Group|Participants in the control group will complete several surveys upon enrollment and randomization. Follow-up data collection will be conducted in the home for all participants control group by a blinded data collector three months post-enrollment.
62627986|NCT05201677|EXPERIMENTAL|High myopia with axial length between 26 mm and 28 mm|The patients' axial length is between 26 mm and 28 mm
62627987|NCT05201677|EXPERIMENTAL|High myopia with axial length more than 28 mm|The patients' axial length is more than 28 mm
62627988|NCT05476354|EXPERIMENTAL|Irbesartan/Amlodipine low|
62627989|NCT05476354|EXPERIMENTAL|Irbesartan/Amlodipine high|
62627990|NCT05476354|ACTIVE_COMPARATOR|Irbesartan|
62853385|NCT05382442|EXPERIMENTAL|Part 1_Expansion Stage Group A(AK112+Chemotherapy)|"AK112+Chemotherapy(Decided by Chemotherapy Regimen Selection Stage)~AK112 and XELOX or FOLFOXIRI(the same dosage, frequency and duration with Chemotherapy Regimen Selection Stage)"
62063291|NCT04755270|EXPERIMENTAL|vr-supported hypnofertility|Relaxation, visualization, imagination and affirmation and techniques based on the hypnofertility philosophy were applied to women in the experimental group in four stages
62627991|NCT00588705||focus group & questionaire|The group will discuss its views about how and when to talk about the risk of getting breast cancer. The focus group will be video recorded and the video recorded material will be later transcribed and carefully analyzed. In addition you will be asked to answer questions about yourself, such as education and marital status.
62627992|NCT06165237|EXPERIMENTAL|BR6001-1+BR6001-2|
62627993|NCT01005784|ACTIVE_COMPARATOR|fixed|
62268307|NCT02702037|EXPERIMENTAL|Intervention|"The participants will be supported to perform the sit-to-stand exercise at least four times per day during 12 weeks (7 days/week).~The participants will also be offered an oral protein-rich supplement (125 ml, 18 g protein (24% of RDI), 300 kcal) twice a day in conjunction with two of the four sit-to-stand exercises during 12 weeks (7 days/week)."
62627994|NCT01005784|EXPERIMENTAL|flexible|
62627995|NCT01481402|PLACEBO_COMPARATOR|Placebo-liothyronine|3 months of placebo followed by 3 months of Liothyronine treatment.
62627996|NCT01481402|OTHER|Liothyronine-Placebo|3 months of Liothyronine treatment followed by 3 months of Placebo treatment.
62627997|NCT01236625||No adhesiolysis|All patient undergoing elective laparotomy or laparoscopy with no need for adhesiolysis during the procedure.
62627998|NCT01236625||Adhesiolysis|All patient undergoing elective laparotomy or laparoscopy requiring adhesiolysis during the procedure.
62853386|NCT05382442|EXPERIMENTAL|Part 1_Expansion Stage Group B(AK112+AK117+Chemotherapy)|"AK112+AK117+Chemotherapy(Decided by Chemotherapy Regimen Selection Stage)~AK112 and AK117 and XELOX or FOLFOXIRI(the same dosage, frequency and duration with Chemotherapy Regimen Selection Stage)"
62853387|NCT05382442|EXPERIMENTAL|Part 2 cohort 1(AK112)|"Subjects receive AK112 until disease progression or unacceptable toxicity~AK112 (until disease progression, unacceptable toxicity or patient's refusal)"
62853388|NCT05382442|EXPERIMENTAL|Part 2 cohort 2(AK112+AK117)|"Subjects receive AK117 and AK112 until disease progression or unacceptable toxicity~AK112 and AK117 ( until disease progression, unacceptable toxicity or patient's refusal)"
62268308|NCT02702037|NO_INTERVENTION|Control|Standard care
62627999|NCT00944632|ACTIVE_COMPARATOR|Zk 245186 0.01% ointment|Active treatment, lowest dose
62628000|NCT00944632|ACTIVE_COMPARATOR|ZK 245186 0.03% ointment|Active comparator middle dose
62853389|NCT04510428|EXPERIMENTAL|OSIG-Eye Drop|Ocular Surface Immune Globulin (OSIG) eye drops 4 mg/ml (0.4%) four times a day for 8 weeks
62063292|NCT04755270|NO_INTERVENTION|Control|Any initiative was not applied to the control group
62853390|NCT04510428|PLACEBO_COMPARATOR|Placebo-Eye Drop|Normal Saline Eye Drops (0.9% NaCl) four times a day for 8 weeks
62063293|NCT03757234|EXPERIMENTAL|Omadacycline 200 iv/200 iv|On Day 1, participants received omadacycline 200 milligrams intravenously (iv). On Days 2 through 7, participants continued to receive omadacycline 200 milligrams iv. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes.
62451262|NCT04759508|ACTIVE_COMPARATOR|500 mg BD Flax Oil Capsule with Antihypertensive drug|Flax Oil Capsule 500 mg twice a day will be administered alongside antihypertensive drug in newly diagnosed hypertensive subjects
62063294|NCT03757234|EXPERIMENTAL|Omadacycline 200 iv/100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes.
62628001|NCT00944632|ACTIVE_COMPARATOR|ZK 245186 0.1% ointment|Active comparator highest dose
62628002|NCT00944632|PLACEBO_COMPARATOR|Vehicle ointment|Placebo comparator
62628003|NCT03338283|EXPERIMENTAL|Electromassage|"Electromassage and conservatory treatment. All subjects will be received a conservatory treatment (1h and 40 min) and electro-massage (10min).~The protocol will consist of six sessions, twice a week for three weeks. The duration will be 1 hour and 40 min for the conservatory treatment and 10 min for the electro-massage."
62628004|NCT03338283|ACTIVE_COMPARATOR|Conservatory Treatment|The control protocol will combine: (a) thermotherapy with infrared application; (b) active, self-assisted and isometric shoulder exercises, including Codman's pendulum exercises; (c) manual therapy, always in a pain-free range of movement; and (d) ultrasound in pulsatile mode over the acromium and scapulohumeral area.
62853391|NCT03181646|NO_INTERVENTION|control group|newborns with hypoxic ischemic encephalopathy grade 2/3 who will receive only supportive care
62063295|NCT03757234|EXPERIMENTAL|Omadacycline 200 iv/300 po or 100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv or omadacycline 300 milligrams per oral (po). All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
62451263|NCT04759508|PLACEBO_COMPARATOR|Placebo(Soya Oil) Capsule with Antihypertensive drug|No flax oil capsule,only placebo(soya oil) capsule will be administered alongside equivalent antihypertensive drug in newly diagnosed hypertensive subjects.
62628005|NCT03948971|OTHER|Venogram Group|Participants in this group have a scheduled clinically indicated a cerebral angiogram procedure and will undergo a Venogram.
62628006|NCT05977855|EXPERIMENTAL|Diary|
62628007|NCT05977855|NO_INTERVENTION|Standard Care|
62628008|NCT05333796|EXPERIMENTAL|Healthy children (5 to 12 years old)|
62628009|NCT01745614|EXPERIMENTAL|A (reference)/ B (test)|initial administration of reference and cross-over to test
62853392|NCT03181646|EXPERIMENTAL|study group|newborns with hypoxic ischemic encephalopathy grade 2/3 who will receive citicoline along with supportive care
62853393|NCT04687514|EXPERIMENTAL|Phase a (V1a-Ev2a): Dulaglutide first- Phase b (V1b-Ev2b) Placebo second|Dulaglutide is injected via pen s.c. once a week. The titration scale will be 1x 1.5mg in 0.5 ml in the first week and 2x 1.5 mg in 2x 0.5 ml once weekly for 3 further weeks. Dulaglutide or placebo weekly subcutaneously for 4 weeks; in random order, separated by washout period of at minimum 28 days.
62853394|NCT04687514|EXPERIMENTAL|Phase a (V1a-Ev2a): Placebo first- Phase b (V1b-Ev2b) Dulaglutide second|The Placebo will be injected via syringe and contains 0.5ml (only first injection) or 2x0.5ml (second to fourth injection) of 0.9% sodium chloride (0.9% NaCl). Dulaglutide or placebo weekly subcutaneously for 4 weeks; in random order, separated by washout period of at minimum 28 days.
62853395|NCT05912790|EXPERIMENTAL|Treated with the eyeTube|
62853396|NCT01642615|EXPERIMENTAL|Healing Phase: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg delayed-release capsules, orally, once daily for up to 8 weeks.
62628010|NCT01745614|EXPERIMENTAL|B (test)/ A (reference)|initial administration of test and cross-over to reference
62853397|NCT01642615|EXPERIMENTAL|Maintenance Phase: Dexlansoprazole 30 mg|Participants who are healed at Week 8 will be randomized to receive 30 mg dexlansoprazole delayed-release capsules, orally, once daily for up to 16 weeks.
62853398|NCT01642615|EXPERIMENTAL|Maintenance Phase: Placebo|Participants who are healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 16 weeks.
62853399|NCT03433612|OTHER|All Patients|"Estimates of the location of the L4-L5 intervertebral space will be done by the classic intercristal line technique and novel SAIL technique. Each technique will be performed by different randomly assigned investigators.~\* Both techiques will be assessed on all patients"
62853400|NCT06317129|EXPERIMENTAL|BariTon™ System implantation|
62268309|NCT05173064|EXPERIMENTAL|Machine learning-based exercise training system|Participants will join 6 individual exercise sessions (i.e., 20 minutes each session, once every two weeks) in our lab. During the exercise sessions, they will use the machine learning-based exercise training system to perform lower limb exercises. In addition, participants will receive an educational booklet on knee pain management. They will be encouraged to perform exercises at home at least 3 times per week over a 12-week period.
62088052|NCT02099032|EXPERIMENTAL|3g milk polar lipid fortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks.
62268310|NCT05173064|EXPERIMENTAL|Video-based exercise training system|Participants will join 6 individual exercise sessions (i.e., 20 minutes each session, once every two weeks) in our lab. During the exercise sessions, they will use the video-based exercise training system to perform lower limb exercises. In addition, participants will receive an educational booklet on knee pain management. They will be encouraged to perform exercises at home at least 3 times per week over a 12-week period.
62268311|NCT05173064|NO_INTERVENTION|Usual care|Participants will receive the same educational booklet as the other groups. They will be encouraged to perform exercises at home at least 3 times per week over a 12-week period. No other intervention will be provided.
62268312|NCT00585507|EXPERIMENTAL|single|fulvestrant 500mg
62451264|NCT02090608|EXPERIMENTAL|Paricalcitol|In patients identified by the inclusion criteria, data will be collected at baseline , during administration of oral Paricalcitol (PCT) (after 1, 3 and 6 months), and three months after PCT withdrawal. PCT will administered at dosage of 1 mcg/day; this dosage was chosen as it is not associated with excessive decline of parathyroid hormone (PTH) levels in most patients
62853401|NCT03162913|EXPERIMENTAL|Strawberry|Participants randomized into this arm of the study consume freeze-dried strawberry powder.
62268313|NCT01618942|EXPERIMENTAL|male subjects|grouped by gender and applied pressure pain test
62268314|NCT01618942|EXPERIMENTAL|female subjects|grouped by gender and applied pressure pain test
62268315|NCT01109888|ACTIVE_COMPARATOR|Cetrotide|
62268316|NCT00741416||Case|Those with a diagnosis of Coronary Artery Disease
62451265|NCT06011577|EXPERIMENTAL|REL-1017 25 mg|During the double blind treatment period (28 days), participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT)
62451266|NCT06011577|PLACEBO_COMPARATOR|Placebo|During the double blind treatment period (28 days), participants will take 1 tablet of placebo, orally, per day in addition to their ongoing antidepressant (ADT)
62451267|NCT05202704|EXPERIMENTAL|Experimental: Hidden conditioning procedure + Positive Expectation|Patients with chronic low back pain will receive verbal delivered positive instructions regarding manipulative therapy. Then, after the spinal manipulative therapy they will be submitted to a hidden conditioning procedure in which the pain threshold will be surreptitiously downgrade to conditioning pain decrease to manipulative therapy (G1).
62628011|NCT03155347|EXPERIMENTAL|Tocilizumab + MTX|Participants will receive tocilizumab SC injections Q2W along with MTX orally every week (QW) for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase, irrespective if they achieve or do not achieve DAS28 low activity (DAS28-ESR \<= 3.2).
62853402|NCT03162913|PLACEBO_COMPARATOR|Placebo|Participants randomized into this arm of the study consume a strawberry placebo powder.
62853403|NCT00561626|EXPERIMENTAL|A|
62853404|NCT00561626|EXPERIMENTAL|B|
62268317|NCT00741416||Control|Those who do not have Coronary Artery Disease (are healthy) but are matched to a Case participant by age, gender, and ethnicity.
62268318|NCT02731209|EXPERIMENTAL|catheter insertion for 2 weeks|50 randomized patients that will do urodynamic urinary examination and will be inserted urinary catheter for 2 weeks
62268319|NCT02731209|NO_INTERVENTION|follow up|50 randomized patients that will do urodynamic urinary examination and will be regularly followed by nephrologist
62853405|NCT01481532|EXPERIMENTAL|Cohort 3|The third cohort will include up to 24 patients with Crotoxin doses of 0.2 to 1.32 mg per m2 in which the dose escalation speed will be faster. Drug is administered over 3 + 4 day intervals using ambulatory infusion pumps; treating on an outpatient basis. Subjects will receive increasing doses over the course of 28 treatment days (8 dose levels). Dose escalation will continue if DLT is not established
62853406|NCT05867329|EXPERIMENTAL|Methylprednisolone|Methylprednisolone Intravenous (IV) 30 milligram (mg) twice a day (BID)
62853407|NCT05867329|EXPERIMENTAL|Methylprednisolone plus Upadacitinib|Methylprednisolone IV 30mg BID plus Upadacitinib 45mg every day.
62853408|NCT05867329|EXPERIMENTAL|Oral Upadacitinib|Upadacitinib 30 mg BID
62628012|NCT03155347|EXPERIMENTAL|Tocilizumab + Placebo Matched to MTX|Participants will receive tocilizumab SC Q2W along with placebo matched to MTX for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase. In the extension phase up to Week 48, participants who achieve DAS28 low activity (DAS28-ESR \<= 3.2) will remain on the same treatment they received in double-blind phase. Participants who do not achieve DAS28-ESR \<= 3.2 will receive treatment with tocilizumab 162 mg SC Q2W + MTX from Week 26 to Week 48.
62063296|NCT03757234|EXPERIMENTAL|Omadacycline 200 iv/450 po or 100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv or omadacycline 450 milligrams po. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
62063297|NCT03757234|ACTIVE_COMPARATOR|Levofloxacin 750 iv/750 po or iv|On Day 1, participants received levofloxacin 750 milligrams iv. On Days 2 through 7, participants received levofloxacin 750 milligrams iv or levofloxacin 750 milligrams po. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
62628013|NCT03155347|ACTIVE_COMPARATOR|Placebo Matched to Tocilizumab + MTX|Participants will receive placebo matched to tocilizumab along with MTX orally QW for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase. In the extension phase up to Week 48, participants who achieve DAS28 low activity (DAS28-ESR \<= 3.2) will remain on the same treatment they received in double-blind phase. Participants who do not achieve DAS28-ESR \<= 3.2 will receive treatment with tocilizumab 162 mg SC Q2W + MTX from Week 26 to Week 48.
62853409|NCT05867329|EXPERIMENTAL|Methylprednisolone then Cyclosporine|Methylprednisolone IV 30 mg BID Stage 1 and if determined to be a non-responder to Methylprednisolone, patient will receive rescue Cyclosporine (2milligram/kilogram (mg/kg) per day aiming for levels 200-400 nanograms per milliliter (ng/mL)) in addition to continuing Methylprednisolone for stage 2.
62063298|NCT06175585||traditional nursing group|
62268320|NCT02642133|OTHER|Intervention|All patients were in the same arm - this is a cohort study where the group serves as their own control. Patients who did not undergo the procedure were not included in this outcomes study.
62268321|NCT02258828|EXPERIMENTAL|Memantine|Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
62268322|NCT02258828|PLACEBO_COMPARATOR|Placebo|Patient received matched placebo
62853410|NCT05867329|EXPERIMENTAL|Methylprednisolone then Upadacitinib|Methylprednisolone IV 30mg twice a day Stage 1 and if determined to be a non-responder to Methylprednisolone, patient will receive rescue Upadacitinib 30mg BID in addition to continuing Methylprednisolone for stage 2
62853411|NCT05867329|EXPERIMENTAL|Oral Upadacitinib then Methylprednisolone|Oral Upadacitinib 30mg BID for stage 1 then for patients that are non-responders, add rescue Methylprednisolone IV 30mg twice a day in addition to continuing Upadacitinib for stage 2.
62063299|NCT06175585||narrative nursing group|
62063300|NCT04943042||Full-analysis set (FAS)|The FAS includes all enrolled patients. The FAS will be used for all analyses.
62451268|NCT05202704|ACTIVE_COMPARATOR|Active Comparator: Positive expectations|Patients with chronic low back pain will receive verbal delivered positive instructions regarding spinal manipulative therapy (G2) before the administration of a spinal manipulative therapy approach.
62853412|NCT05867329|EXPERIMENTAL|Oral Upadacitinib then Methylprednisolone plus cyclosporine infusion|Upadacitinib 30 mg BID for stage 1. If a patient is a non-responder to Upadacitinib 30 mg, then the study team will stop Upadacitinib and initiate Methylprednisolone IV 30mg twice a day plus Cyclosporine (2 milligram/kilogram (mg/kg) per day aiming for levels 200-400 nanograms per milliliter (ng/mL)) for stage 2.
62063301|NCT02260128|EXPERIMENTAL|Gum chewing|"This intervention group will receive chewing gum four times daily following surgery. Each of which they are encouraged to chew for 30 minutes.~Gum chewing is terminated when one of the primary end points occurs."
62063302|NCT02260128|NO_INTERVENTION|Control group|This group will receive the normal postoperative treatment. Occurence of primary end points are registrered.
62063303|NCT02459223|ACTIVE_COMPARATOR|Test Group|Treated with nutritional biscuits and khichadi. Nutritional biscuits providing 2.5 to 3 gm Protein and 90-100kcal/kg body Weight/day, as well as local food Khichadi (Rice and hulled split green gram cooked together with spices) for the three months period.
62268323|NCT03369964|EXPERIMENTAL|Atezolizumab + Emactuzumab|Participants will receive Atezolizumab and Emactuzumab on Day 1 of each 21- day cycle
62451269|NCT05202704|ACTIVE_COMPARATOR|Active Comparator: Neutral Expectations|Patients with chronic low back pain will receive verbal delivered neutral instructions regarding spinal manipulative therapy (G3) before the administration of a spinal manipulative therapy approach.
62451270|NCT02815878|EXPERIMENTAL|Group 1: Intervention with Disability|Participants with a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older receive Enhance Wellness for 6 months and complete pre and post outcome assessments.
62451271|NCT02815878|ACTIVE_COMPARATOR|Group 2: Intervention without Disability|Participants without a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older receive Enhance Wellness for 6 months and complete pre and post outcome assessments.
62268324|NCT03369964|ACTIVE_COMPARATOR|Atezolizumab + Emactuzumab + Obinutuzumab|"Participants will receive Atezolizumab, Emactuzumab, and Obinutuzumab on Day 1 of each- 21 day cycle (starting in cycle 2)~(Atezolizumab starting in cycle 2); and Obinutuzumab on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2-8."
62268325|NCT05758259|EXPERIMENTAL|combination vitamin D oral and topical cholecalciferol|combination topical vitamin D and supplementation Daily supplementation (1x/day, in the morning) and topical application (2x/day, in the morning and in the afternoon, minimum duration 4 hours on the skin) for 56 days Daily supplementation (1x/day, in the morning) and topical application (2x/day, in the morning and in the afternoon, minimum duration 4 hours on the skin) for 56 days
62268326|NCT05758259|ACTIVE_COMPARATOR|oral placebo and topical vitamin D|oral placebo and topical vitamin D Daily supplementation (1x/day, in the morning) and topical application (2x/day, in the morning and in the afternoon, minimum duration 4 hours on the skin) for 56 days
62063304|NCT02459223|ACTIVE_COMPARATOR|Control Group|Treated with only local food Khichadi (Rice and hulled split green gram cooked together with spices) for the three months period.
62063305|NCT02938169|EXPERIMENTAL|walking exercise group|"\*\*walking exercise with bracing exercise~* walking exercise: treadmill gait with tolerable gait speed~* bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this."
62063306|NCT02938169|EXPERIMENTAL|stabilization exercise group|"\*\* stabilization exercise with bracing exercise~* stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~* bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this."
62451272|NCT02815878|NO_INTERVENTION|Group 3: No intervention|Participants with a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older complete pre and post outcome assessments.
62853413|NCT05867329|EXPERIMENTAL|Methylprednisolone plus Upadacitinib then cyclosporine|Methylprednisolone IV 30mg BID and Oral Upadacitinib 45mg everyday stage 1 and then Cyclosporine 2 mg/kg per day aiming for levels 200-400ng/mL for stage 2.
62063307|NCT02938169|EXPERIMENTAL|walking and stabilization exercise group|"\*\*walking exercise, bracing exercise with stabilization exercise~* stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~* bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~* walking exercise:treadmill gait with tolerable gait speed"
62063308|NCT02938169|SHAM_COMPARATOR|flexibility exercise group|"\*\*Stretching exercise(control)~* Only educate the flexibility exercise(stretching exercise)~* Don't educate the walking exercise method and stabilization exercise method"
62451273|NCT00001337|EXPERIMENTAL|Arm A|EPOCH + Rituximab every 3 weeks for 6 cycles.
62063309|NCT01105806||cardiopulmonary resuscitation (CPR) video|This pilot study involves a two-arm parallel design comparing the effectiveness of a CPR video versus a CPR narrative script in advance directive (AD) completion over a 1 month time frame post intervention.
62063310|NCT01105806||cardiopulmonary resuscitation (CPR) narrative script|This pilot study involves a two-arm parallel design comparing the effectiveness of a CPR video versus a CPR narrative in advance directive (AD) completion over a 1 month timeframe post intervention.
62063311|NCT02856139||1 (MB- and VL-)|without mottled fluorescent band (MB) and vascular leakage (VL)
62063312|NCT02856139||2 (MB+ and VL-)|with mottled fluorescent band (MB), without vascular leakage (VL)
62451274|NCT01368523|EXPERIMENTAL|nilotinib|
62063313|NCT02856139||3 (MB-/+ and VL+)|with or without mottled fluorescent band (MB), with vascular leakage (VL)
62063314|NCT03139396|ACTIVE_COMPARATOR|inlay shaped inlay bridge design|The inlay shaped inlay bridge design preparation show three types of preparation, the inlay shaped, the tub shaped inlay bridge design and the proximal box shaped designs. Intracoronal preparation of the inlay retained prosthesis for the abutments (inlay shaped and tub shaped) should show the following criteria: The inlay shaped preparation should show an occlusal-proximal box preparation and to be designed with the line angles should be rounded, smooth and rounded corners, and rectangular flat floor with no beveling for the occlusal and gingival margins. The occlusal inlay preparation should have preparation depth allowed for a thickness of 2.0 mm for the material of the bridge. The occlusal reduction show 4 mm width with extension of 4 or 6 mm mesio distally for the posterior teeth.
62088053|NCT02099032|EXPERIMENTAL|5 g milk polar lipid fortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks.
62451275|NCT03086772|EXPERIMENTAL|Tai Chi|Individuals in the Tai Chi intervention group participated in a 12-week Tai Chi program.
62451276|NCT03086772|ACTIVE_COMPARATOR|Light Exercise|Individuals in the exercise control group performed a 12-week light exercise program.
62451277|NCT01286038|EXPERIMENTAL|Eltrombopag Treatment|Phase I: Dose Escalation
62451278|NCT01836848|EXPERIMENTAL|indocyanine green|in this arm we do the Intervention 'measuring cerebral perfusion by NIRS with ICG', the pat. gets before a CT-Scan with perfusion measurement a indocyanine green bolus i.v. and a measurement of cerebral perfusion with near-infrared-spectroscopy
62451279|NCT04659915|EXPERIMENTAL|Metformin + Prednison|"During one of the study periods, subjects receive Metformin 500 mg tablets p.o. for seven days (starting with a dose of 500 mg /d, then the dose will be increased by 500 mg the next days until 2000 mg /d is achieved).~Subjects also receive Prednisone 20 mg 1.5x/d tablets p.o. for seven days."
62451280|NCT04659915|PLACEBO_COMPARATOR|Placebo + Prednison|During the other study period, subjects receive the same dose of placebo tablets p.o instead of metformin. Subjects also receive Prednisone 20 mg 1.5x/d tablets p.o. for seven days.
62451281|NCT03875157|EXPERIMENTAL|IBI318 DL1|
62853414|NCT05867329|EXPERIMENTAL|Methylprednisolone plus Upadacitinib then increased Upadacitinib|Methylprednisolone IV 30mg BID and Oral Upadacitinib 45mg everyday stage 1 and if determined to be a non-responder to Methylprednisolone and 45 mg Oral Upadacitinib, patient will receive rescue Upadacitinib 30mg BID in addition to continuing Methylprednisolone for stage 2.
62853415|NCT03035487|EXPERIMENTAL|Micro-ultrasound|"Transrectal micro-ultrasound guided prostate biopsy, where images will be compared with images from standard of care modalities:~* Low resolution transrectal ultrasound examination (LR-TRUS)~* Multi-parametric MRI (mpMRI) examination performed according to the PI-RADS v2 protocol"
62853416|NCT00621062|ACTIVE_COMPARATOR|High Ligation of the GSV|
62853417|NCT00621062|ACTIVE_COMPARATOR|Endovenous Laser Ablation|
62853418|NCT00621062|ACTIVE_COMPARATOR|Radiofrequency ablation|
62451282|NCT03875157|EXPERIMENTAL|IBI318 DL2|
62451283|NCT03875157|EXPERIMENTAL|IBI318 DL3|
62451284|NCT03875157|EXPERIMENTAL|IBI318 DL4|
62451285|NCT03875157|EXPERIMENTAL|IBI318 DL5|
62451286|NCT03875157|EXPERIMENTAL|IBI318 DL6|
62451287|NCT03875157|EXPERIMENTAL|IBI318 DL7|
62451288|NCT03875157|EXPERIMENTAL|IBI318 DL8|
62451289|NCT03875157|EXPERIMENTAL|IBI318 DL7b|
62628014|NCT00041197|EXPERIMENTAL|Arm I (imatinib mesylate)|Patients receive oral imatinib mesylate (Gleevec; STI571) once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence during the year of initial treatment receive imatinib mesylate (Gleevec; STI571) at an increased dose. Patients who develop a recurrence after the year of initial treatment restart imatinib mesylate (Gleevec; STI571) and continue taking the drug at the discretion of the principal investigator.
62853419|NCT00621062|ACTIVE_COMPARATOR|Foam Sclerotherapy|
62451290|NCT03875157|EXPERIMENTAL|IBI318 DL8b|
62853420|NCT05506241|EXPERIMENTAL|Repetitive Visual Scanning Training|Participants will receive 30 minutes of their usual occupational therapy treatment and a 30 minute session of the Dynavision for 10 sessions for short stay inpatients (\~ 3 weeks) and 20 sessions for clients with longer 5-6 week stay.
62853421|NCT05506241|NO_INTERVENTION|Usual Treatment|Participants will receive the standard 60 minutes of occupational therapy treatment.
62853422|NCT03238170|EXPERIMENTAL|MR-Simulation|Patients will have 1 MRI scan appointment, using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan. The MR scan will be performed in the radiotherapy treatment position.
62853423|NCT03774056|EXPERIMENTAL|dose group|Drug name L:HC-1119 Dosage: 40 mg, 80 mg, 160 mg, and 200 mg
62853424|NCT03068091|OTHER|Pulmonary Assessment|All participants will undergo a Chest CT scan and pulmonary function testing
62853425|NCT00756535|EXPERIMENTAL|1|Group-based exercise training during hospitalization
62853426|NCT00756535|ACTIVE_COMPARATOR|2|Usual treatment and rehabilitation during hospitalization
62853427|NCT05546580|EXPERIMENTAL|Active arm|iadademstat and gilteritinib
62451291|NCT03875157|EXPERIMENTAL|IBI318 RP2D|
62853428|NCT06292611|ACTIVE_COMPARATOR|Battery operated toothbrush|Battery operated toothbrush
62853429|NCT06292611|ACTIVE_COMPARATOR|Manual toothbrush|Manual toothbrush
62853430|NCT05706051|OTHER|age-related hearing loss affected before hearing aid fitting|"patients aged 55 to 80 years old, undergoing posturography at diagnosis of ARHL and 3 months later before hearing aid fitting, within the role of control~same patients udergoing posturography at hearing aid fitting and 3 months after."
62853431|NCT04402255|EXPERIMENTAL|behcet group|this group includes 16 patients with behçet
62853432|NCT04402255|EXPERIMENTAL|fmf group|this group includes 16 patients with fmf
62853433|NCT04402255|ACTIVE_COMPARATOR|healty control|this group includes 16 healthy control
62088054|NCT02099032|PLACEBO_COMPARATOR|Unfortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks
62451292|NCT03554096|EXPERIMENTAL|2-HOBA|2-Hydroxybenzylamine acetate: 550mg dose
62451293|NCT01345032|EXPERIMENTAL|Home visits|Nutritional follow-up after discharge, conducted as nutritional counselling performed as in-person counselling in the participants homes
62628015|NCT00041197|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive oral placebo once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence at any time discontinue placebo and crossover to arm I. Treatment on arm I continues at the discretion of the principal investigator.
62628016|NCT04028791|EXPERIMENTAL|AS and AA|Participants will be submitted to 45 minutes of exercise on ergocycle.
62628017|NCT06144203|EXPERIMENTAL|Light-intensity aerobic exercise|
62628018|NCT06144203|EXPERIMENTAL|Moderate-intensity aerobic exercise|
62628019|NCT06144203|EXPERIMENTAL|High-intensity aerobic exercise|
62628020|NCT03308604|EXPERIMENTAL|Patients with locally advanced cervical cancer|
62628021|NCT04883151|EXPERIMENTAL|SOFUS pilot program|
62628022|NCT00671801|EXPERIMENTAL|Irinotecan + Lenalidomide|Irinotecan 200 mg/m\^2 intravenous once every 2 weeks on days 1 and 15; Lenalidomide orally 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
62628023|NCT02778022|EXPERIMENTAL|Immediate PriCARE|Parent-child dyads assigned to the immediate PriCARE group will receive the PriCARE intervention as soon as possible plus usual treatment. The intervention will last approximately 6-8 weeks. Each group will have approximately 4-13 participants and 2 facilitators and will meet 6 times for 1-2 hours per session. Parents are expected to practice the skills they learn with their children between sessions.
62628024|NCT02778022|NO_INTERVENTION|Delayed PriCARE|The delayed PriCARE group will not receive the PriCARE intervention until after their data collection for this study is complete (in 3-6 months). In addition, they will be immediately offered usual treatment. Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment and/or provided with a 1-2 page informational handout on child behavior problems from the CHOP patient care manual.
62628025|NCT04063735|EXPERIMENTAL|Experimental group|supplement was given for 3 months.
62628026|NCT04063735|PLACEBO_COMPARATOR|Placebo group|Placebo was given for 3 months.
62628027|NCT02831296||Affected Subjects <36 Mos. of Age|"Infants and children 36 months of age and younger at time of enrollment who have been genetically diagnosed with Spinal Muscular Atrophy (SMA)~The affected cohort will receive coordinated, multidisciplinary care including dietary intervention, respiratory monitoring, physical therapy, and genetic counseling. They will also undergo assessment of motor function, muscle action potential measurement, and body composition, as well as blood sample collection for DNA and biomarkers, and optional research skin biopsy."
62451294|NCT01345032|EXPERIMENTAL|Telephone consultation|Nutritional follow-up after discharge, conducted as nutritional counselling performed as telephone consultation
62451295|NCT01345032|NO_INTERVENTION|Control|No follow-up after discharge
62451296|NCT03363074|EXPERIMENTAL|Orthotic Insole|Device: Orthotic Insole 8-week follow-up with Orthotic Insole
62451297|NCT03363074|EXPERIMENTAL|Low-level Laser Therapy|Low-Level Laser 5-week follow-up
62628028|NCT02831296||Unaffected Subjects <36 Mos. of Age|"Infants and children 36 months of age and younger who are not affected with SMA~The unaffected group will undergo the same assessments as the affected group."
62628029|NCT02831296||Unaffected Family Members|"Parents and siblings of any age, without genetic diagnosis of SMA, who have family members enrolled in either of the Affected Infants/Children/Adults cohorts.~The unaffected siblings will undergo the same assessments as the affected group, where age-appropriate. Unaffected parents' participation will be limited to blood sample collection and optional research skin biopsy."
62628030|NCT02831296||Affected Subjects >36 Mos. of Age|"Children and adults \>36 months at time of enrollment who have been genetically diagnosed with Spinal Muscular Atrophy.~The older affected cohort will receive coordinated, multidisciplinary care including dietary intervention, respiratory monitoring, physical therapy, and genetic counseling. They will also undergo assessment of motor function, muscle action potential measurement, and body composition, as well as blood sample collection for DNA and biomarkers, and optional research skin biopsy. Where applicable, these participants will be considered Affected Control Subjects."
62628031|NCT00817908||1|Patients at high risk for CMV infection (CMV serostatus: D+/R-) who are expected to receive three months of antiviral prophylaxis.
62628032|NCT01054222|OTHER|Fesoterodine 4 mg|Dose determined as per previous drug regime in A0221045 and investigator's evaluation.
62628033|NCT01054222|OTHER|Fesoterodine 8 mg|Dose determined as per previous drug regime in A0221045 and investigator's evaluation.
62063315|NCT03139396|EXPERIMENTAL|tub shaped inlay bridge design|The tub-shaped reduction consist of an occlusal proximal inlay and prepared as the same geometry as the inlay shaped preparation, except that for the proximal box preparation which is not present in this preparation design.
62063316|NCT02924324|ACTIVE_COMPARATOR|Propofol First, then Propofol & Ropivacaine|1st Bone Marrow procedure (BM) Intervention A: propofol first. Then second BM procedure with propofol \& ropivacaine
62063317|NCT02924324|EXPERIMENTAL|Propofol and Ropivacaine First, then Propofol|1st BM procedure: Intervention B: propofol \& ropivacaine first. Then second BM procedure with propofol
62063318|NCT03134014|NO_INTERVENTION|Breakfast Skipping (BS)|The BS group will continue to skip breakfast.
62063319|NCT03134014|ACTIVE_COMPARATOR|Normal Protein Breakfast (NP)|The NP groups will be provided with the respective breakfast meals to consume, at home, between 6:00-8:00 am each day over the 4-mo intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The NP breakfasts will be 11% protein (10 g protein), 63% CHO, and 26% fat
62063320|NCT03134014|ACTIVE_COMPARATOR|High Protein Breakfast (HP)|The HP group will be provided with the respective breakfast meals to consume, at home, between 6:00-8:00 am each day over the 4-mo intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The HP breakfasts will be 34% protein (30 g protein), 40% CHO, and 26% fat.
62063321|NCT01370005|EXPERIMENTAL|BI 10773 low dose|BI 10773 low dose once daily
62063322|NCT01370005|EXPERIMENTAL|BI 10773 high dose|BI 10773 high dose once daily
62063323|NCT01370005|PLACEBO_COMPARATOR|Placebo|Placebo tablets matching BI 10773
62063324|NCT01148862|OTHER|Group A|Group A will wear the MiniMed Paradigm® X54 System with the Low Glucose Suspend (LGS) feature activated
62063325|NCT01148862|OTHER|Group B|Group B will wear the MiniMed Paradigm® X54 System with the Low Glucose Suspend (LGS) feature deactivated
62063326|NCT00633919|ACTIVE_COMPARATOR|Active|SLITone Dermatophagoides Mix
62063327|NCT00633919|PLACEBO_COMPARATOR|Placebo|SLITone Placebo
62063328|NCT05074355|EXPERIMENTAL|Azacitidine and Venetoclax|"A treatment cycle is 28 days long.~Azacitidine will be given by injection under the skin, once a day, for the first 6 days of every cycle.~Venetoclax will be given orally, once a day, as follows at the discretion of their study doctors:~Cycle 1:~* Day 1 - 100 mg~* Day 2 - 200 mg~* Days 3 to 28 - 400 mg~Cycle 2:~* Participants with a response to the study drugs will continue taking 400 mg from Days 1 to 21, with no study drug from Days 22 to 28 during Cycle 2.~* Participants who have not yet responded to the study drugs will continue taking 400 mg from Days 1 to 28 during Cycle 2.~Cycle 3 and subsequent cycles:~* Participants with a response to the study drugs will continue to take 400 mg from Days 1 to 21, with no study drug from Days 22 to 28.~* Participants whose disease has not worsened will continue taking 400 mg from Days 1 to 28.~* Participants have not responded to the study drugs will be withdrawn from the study."
62853434|NCT05901753|EXPERIMENTAL|Laryseal pro supra glottic device (SGD)|Laryseal pro SGD, the jaw will be lifted during insertion and the head will be extended, proper lubrication of both the front and back of the laryseal pro as if the patient's mouth is dry the laryseal pro ridges can get hung up on the back of the tongue during placement.
62853435|NCT05901753|EXPERIMENTAL|Laryngeal Mask Airway- Proseal™|The LMA-Proseal™ will be inserted using the digit method. The size will be determined according to the patient's weight and inserted according to the manufacture's recommendation with the use of an introducer.
62063329|NCT01921881|EXPERIMENTAL|St John's wort|"Subjects will undergo 3 oral glucose tolerance tests:~1. Without taking any St John's wort~2. After 3 weeks pretreatment with St John's wort~3. Minimum 6 weeks after last St John's wort ingestion"
62063330|NCT02473458|PLACEBO_COMPARATOR|Control|patients with acute ischemic stroke who received standard care plus placebo filled capsules,
62063331|NCT02473458|EXPERIMENTAL|450 mg licorice|patients with acute ischemic stroke who received standard care plus capsules filled with 450 mg of whole extract of licorice.
62063332|NCT02473458|EXPERIMENTAL|900 mg licorice|patients with acute ischemic stroke who received standard care plus capsules filled with 900 mg of whole extract of licorice.
62063333|NCT05549765|EXPERIMENTAL|Pharmacopucture on suboccipital muscles|"The Pharmacopucture group will recieve 3 sessions of Pharmacopucture on suboccipital muscles; on second, third, fourth day after hospitalization. A trained doctor of Korean medicine with at least 3 years of clinical experience are going to conduct the pharmacopucture.~The Pharmacopucture group will also be treated with other Korean medical treatment everyday: acupuncture, chuna and Korean herbal medicine."
62063334|NCT05549765|ACTIVE_COMPARATOR|Korean medical treatment|The control group will be received Korean medical treatment everyday after hospitalization: acupuncture(except on suboccipital parts), chuna, pharmacoacupuncture and Korean herbal medicine
62451298|NCT05719870|EXPERIMENTAL|Intervention group|Patients hospitalized in the Geriatric Unit aged 60 years or older, that living in the community setting and who will be discharged at home and with expected survival \>7 days.
62451299|NCT05719870|NO_INTERVENTION|Control group|"Patients hospitalized in the Geriatric Unit aged 60 years or older, that living in the community setting and who will be discharged at home and with expected survival \>7 days.~The control group will be discharged following standard care procedures, and will receive only appropriate corrections and clarifications in case mistakes in the comprehension of the medical recommendations."
62853436|NCT02416622|EXPERIMENTAL|Groups 1A and 1B|Subjects at least 18 y/o treated with a lower dose of rAAV2tYF-CB-hRS1 study drug.
62063335|NCT01862822|EXPERIMENTAL|upright position|Upright position during urine bag collection
62063336|NCT01862822|NO_INTERVENTION|usual position|
62063337|NCT05845476|EXPERIMENTAL|SOGI Data Collection Intervention|This single arm is an educational intervention for clinicians. After consent, they provide baseline survey fata, then the training intervention, then a post assessment.
62063338|NCT01423071||COPD with PH|COPD patients with confirmed diagnosis of PH.
62063339|NCT01423071||COPD without PH|COPD patients without confirmed diagnosis of PH
62063340|NCT01423071||PAH without COPD|PAH patients who do not suffer from COPD
62063341|NCT05830435|ACTIVE_COMPARATOR|TSST VR Friendly|
62063342|NCT05830435|EXPERIMENTAL|TSST VR Neutral|
62063343|NCT05830435|EXPERIMENTAL|TSST VR Unfriendly|
62063344|NCT04200079||COPD|Long term (at least 10 years) multidimensional (clinical, laboratory, physiological and radiological) follow up of chronic Obstructive Pulmonary Disease patients.
62853437|NCT02416622|EXPERIMENTAL|Groups 2 and 2A|Subjects at least 6 y/o treated with a middle dose of rAAV2tYF-CB-hRS1 study drug.
62063345|NCT02440802||Gonadoliberin antagonist treatment|Single arm study, all patients are treated the same way. Saliva sample collection for genetic analyses.
62853438|NCT02416622|EXPERIMENTAL|Group 3|Subjects at least 18 y/o treated with a higher dose of rAAV2tYF-CB-hRS1 study drug.
62853439|NCT02416622|EXPERIMENTAL|Group 4|Subjects at least 6 y/o treated with a maximum tolerated dose of rAAV2tYF-CB-hRS1 study drug determined for Groups 1A, 1B, 2 and 3.
62853440|NCT02814903||Planned cardiac surgery. POAF occurence or not|The ALDO-POAF study is an observational, 1-center and prospective pilot study that will enroll patients undergoing CABG ± aortic valve replacement. Patients who had emergency CABG, need for concomitant mitral surgery, left ventricular ejection fraction (LVEF) \< 50%, a history of AF or other atrial arrhythmia, unstable angina or heart failure, cardiogenic shock, atrioventricular block, hypothyroidism/hyperthyroidism, previous heart surgery, and off-pump or on-pump beating CABG will be excluded.
62853441|NCT02678559|EXPERIMENTAL|TEE monitory system|comparison between TEE and mini-invasive monitoring systems in accuracy of measurement of stroke volume variation during ARM.
62063346|NCT06310499||Primary fatal drowning|These patients are registered in the Danish Register of Causes of Death, with drowning as an underlying cause of death in the death certificate.
62853442|NCT02678559|EXPERIMENTAL|mini-invasive monitoring system|comparison between TEE and mini-invasive monitoring systems in accuracy of measurement of stroke volume variation during ARM.
62853443|NCT02706990|OTHER|Physica KR|Patients who have received a Physica KR total knee implant.
62853444|NCT02706990|OTHER|Physica PS|Patients who have received a Physica PS total knee implant.
62853445|NCT02686723|EXPERIMENTAL|ACL injury|Subjects who has ACL injury repaired and who were allowed to return to sport
62853446|NCT02686723|ACTIVE_COMPARATOR|Healthy subjects|Subjects who has never been injured in ACL and who practice sports with cutting task (soccer, handball)
62451300|NCT01912105|EXPERIMENTAL|treatment|Airway Medix Closed Suction System
62628034|NCT02820870|EXPERIMENTAL|Primary Care Intervention Group|"Primary care providers will receive a generated print-out of statin recommendations for patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant). Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the teamlets for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guidelines."
62628035|NCT02820870|NO_INTERVENTION|Usual Care Group|PACT teams that were not randomized to the intervention will serve as a usual care group and will be expected to follow the VA guidelines and HEDIS measures as part of the VA national roll-out.
62653130|NCT04832035|EXPERIMENTAL|"Standard psychotherapeutic care + coordinated and peer supported mental health care"|"Participants receive standard psychotherapeutic care in the public healthcare system. For participants and therapists in this group standard care and additional organisational support is available which is labeled coordinated and peer supported mental health care. This includes several additional organisational assistance components that are currently not part of the services of the public mental health care system, i.e. a coordination center, trained peers to support treatment utilisation, a support and training center for therapists, and an interpreter pool.This is Treatment as Usual plus coordination and peer support."
62853447|NCT02177799||gastroenteritis|
62853448|NCT01328405|EXPERIMENTAL|Air-Q LMA|Air-QⓇ intubating laryngeal mask (Mercury Medical, Clearwater, Fl.)
62853449|NCT01328405|EXPERIMENTAL|Proseal LMA|LMA-Proseal TM (LMA North America, San Diego, Ca.)
62853450|NCT01430169|EXPERIMENTAL|AA4500|"collagenase clostridium histolyticum (AA4500) contains purified collagenase AA4500 (clostridium histolyticum) consisting of two microbial collagenases in a defined mass ratio, Collagenase AUX-I and Collagenase AUX-II, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria.~2 injections of AA4500 0.58 mg were administered 24 hours apart."
62853451|NCT06272903|EXPERIMENTAL|Benzocaine 20% Topical Anesthesia Arm|"Participants will be assigned this arm either to their right or left hand side of their mouth. They will receive benzocaine 20% topical anesthesia prior to the placement of elastomeric orthodontic separators.~The topical anesthesia will be applied according to standard clinical practice. Pain and discomfort levels associated with the placement of separators will be assessed immediately after the procedure."
62853452|NCT06272903|PLACEBO_COMPARATOR|Placebo (Children's Toothpaste) Arm|"The other side of the mouth will receive a placebo, which consists of children's toothpaste, prior to the placement of elastomeric orthodontic separators.~The toothpaste will be applied according to standard clinical practice. Pain and discomfort levels associated with the placement of separators will be assessed immediately after the procedure."
62853453|NCT02568891|ACTIVE_COMPARATOR|Probiotic|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
62853454|NCT02568891|PLACEBO_COMPARATOR|Placebo|similar looking and tasting placebo without bacteria
62853455|NCT03941704|EXPERIMENTAL|Low Glycemic Index|Pulse-based diet
62853456|NCT03941704|ACTIVE_COMPARATOR|Moderate Glycemic Index|Regular diet
62853457|NCT05504239|EXPERIMENTAL|Teneligliptin 20 mg|Once daily for 24 weeks
62853458|NCT05504239|PLACEBO_COMPARATOR|Teneligliptin placebo|Once daily for 24 weeks
62853459|NCT04862221|EXPERIMENTAL|High-dose methylprednisolone|Intravenous methylprednisolone at an initial dose of 10 mg/kg/day for 3 days, 5 mg/kg/day on day 4.
62853460|NCT04862221|EXPERIMENTAL|Equine anti-thymocyte globulin|Intravenous equine anti-thymocyte globulin at a dose of 40 mg/kg/day for 4 days.
62853461|NCT04862221|PLACEBO_COMPARATOR|Supportive care|Supportive care will be administered as determined by the clinical team at participating clinical sites in accordance with their local practices and standards.
62063347|NCT06310499||Secondary fatal drowning|These patients are registered in the Danish Register of Causes of Death, with drowning as a contributory cause of death or drowning not registered in the death certificate.
62451301|NCT01912105|ACTIVE_COMPARATOR|control|standard closed suctioning systems
62451302|NCT00702065||1|
62451303|NCT00702065||2|
62853462|NCT04408560|ACTIVE_COMPARATOR|Groupe A with homéopathic treatment|Conventional treatment : paracetamol (drug analgesic class1) + Homeopathic drug : Rhus toxicodendron 9 CH et Ruta graveolens 5 CH
62063348|NCT04061590|EXPERIMENTAL|Cohort A (pembrolizumab)|Patients receive 200mg pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 4 weeks following study treatment.
62451304|NCT02476526|EXPERIMENTAL|Low Volume Contrast|Subjects in this arm will receive a single intravenous injection of low volume iso-osmolar non-ionic radio contrast medium, prior to undergoing 64-MDCT scanning. The use of low volume radio contrast medium constitutes the intervention. Both experimental and control groups receive a) acetylcysteine inhalation (Mucomyst) 1200 mg po BID x 48 hours starting the day prior to the CT scan; and b) isotonic Sodium Bicarbonate Solution 3ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan
62628036|NCT01635374|EXPERIMENTAL|Per-Oral Endoscopic Esophagomyotomy|Patients will have a standard pre-operative work-up that may include upper endoscopy (EGD), endoscopic ultrasound (EUS), upper GI X-rays, high-resolution manometry, pH, FLIP and impedance measurement studies. Once a diagnosis of esophageal motility disorder is confirmed, patients will be offered POEM or standard treatment. Patients undergoing POEM will review and sign the study consent prior to their procedure. Patients will return and be evaluated two weeks following their procedure. At this visit, any post-operative complications will be noted in the patient's medical record. Also, at this visit and at the preoperative visit, patients will complete a standardized Quality of Life assessment. Perceived pain levels and type and frequency of pain medications will be recorded in the patient's medical record. Patients will then return at 6 weeks post-op to complete a second set of questionnaires and have a high resolution manometry performed to assess residual LES pressure.
62628037|NCT05227443|NO_INTERVENTION|Control|The control group did not receive exercise training and the participants were informed to complete their medications provided by the treating physician.
62628038|NCT05227443|ACTIVE_COMPARATOR|Lower limb (LL) exercise training|All the participants in this modality of training were subjected to only lower limbs aerobic exercise training.
62628039|NCT05227443|ACTIVE_COMPARATOR|Upper, lower and breathing (ULB) exercise training|All the participants in this modality of training were subjected to upper and lower limb aerobic exercise training as well as breathing training.
62628040|NCT00617747|EXPERIMENTAL|1|
62853463|NCT04408560|SHAM_COMPARATOR|Groupe B without homeopathic treatment|Conventional treatment : paracetamol (drug analgesic class1)
62063349|NCT04061590|EXPERIMENTAL|Cohort B (pembrolizumab, cisplatin pemetrexed)|Patients receive 200mg pembrolizumab IV over 30 minutes and chemotherapy (cisplatin/pemetrexed) IV on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 4 weeks following study treatment.
62063350|NCT04194996||Operative|"Inclusion criteria:~1. ≥18 years old at time of treatment~2. Diagnosis of cervical deformity- must meet one or more of the following criteria:~   * C2-C7 sagittal kyphosis (Cobb \> 15o)~  * T1S-CL \> 35o~  * Segmental cervical kyphosis \> 10o between any 2 vertebra between C2-T1 or \> 15o across any 3 vertebra between C2-T1~  * Cervical scoliosis \> 10o (Cobb angle must include end vertebra within the cervical spine)~  * C2-C7 SVA \> 4cm~  * McGregor's slope \> 20 degrees or CBVA \> 25 degrees~3. Plan for surgical correction of cervical deformity in the next 6 months"
62063351|NCT05399095|EXPERIMENTAL|5 days supine positioning|Supine positioning for 5 days after DMEK with upright positioning for only 10 min every hour.
62628041|NCT00617747|PLACEBO_COMPARATOR|2|
62628042|NCT03199950|EXPERIMENTAL|Prophylactic Haloperidol arm|Patients will receive oral haloperidol 2dd1mg (08.00am \& 10.00pm)
62628043|NCT03199950|PLACEBO_COMPARATOR|No treatment|Patients will receive oral placebo 2dd (08.00am \& 10.00pm)
62853464|NCT02889029|EXPERIMENTAL|new 3D device|dedicated tailored stents wrought by 3D computer-assisted conception
62853465|NCT05744245|EXPERIMENTAL|Standard dose|"1 x 35 minute therapy session of Swallow Strength and Skill training per day, 5 days a week for 2 weeks. 10 sessions in total.~Plus usual care"
62451305|NCT02476526|SHAM_COMPARATOR|Control|Subjects in this arm will undergo 64-MDCT scanning without Radio Contrast Medium (RCM). Both experimental and control groups receive a) acetylcysteine inhalation (Mucomyst) 1200 mg po BID x 48 hours starting the day prior to the CT scan; and b) isotonic Sodium Bicarbonate Solution 3ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan
62451306|NCT05925153||College Students|
62461489|NCT01491880|EXPERIMENTAL|Child Anxiety Program by Telephone|The child anxiety program by telephone is an adaptation of Ron Rapee's Cool Kids Outreach Program (Lyneham and Rapee, 2006) for child anxiety, with appropriate adaptations made to meet the needs of rural Latino families (including a Spanish translation). This is a parent mediated program, where parents are taught how all the skills of cognitive behavior therapy (CBT) and how to apply these skills to these children's anxieties. Children are also expected to participate, however all direct contact that a therapist may have, is with the parent only.
62628044|NCT01909843|EXPERIMENTAL|ALX-0171 Oral inhalation|
62628045|NCT03327818||conservative surgery group|
62853466|NCT05744245|EXPERIMENTAL|High dose|"2 x 35 minute therapy therapy sessions of Swallow Strength and Skill training, per day, 5 days a week for 2 weeks. 20 sessions in total.~Plus usual care"
62063352|NCT05399095|ACTIVE_COMPARATOR|1 day supine positioning followed by usual physical activity for 4 days|Supine positioning for 1 days after DMEK with upright positioning for only 10 min every hour.
62628046|NCT03327818||hysterectomy group|
62628047|NCT02968459|EXPERIMENTAL|Umbilical cord MSCs Group|1\*10\^7 Umbilical cord MSCs
62628048|NCT02968459|PLACEBO_COMPARATOR|Placebo-Controlled Group|1ml of 0.9% saline
62853467|NCT05744245|NO_INTERVENTION|Usual care|Usual care
62628049|NCT03454087|EXPERIMENTAL|Enteral Dextrose Infusion|Critically-ill participants with sepsis enrolled in the interventional arm will receive a 24-hour infusion of dextrose solution by the enteral route to be initiated via an existing nasogastric or orogastric tube within the first 48 hours of meeting sepsis criteria.
62628050|NCT03454087|PLACEBO_COMPARATOR|Placebo|Critically-ill participants with sepsis in the placebo arm will receive a 24-hour enteral free water infusion via an existing orogastric or nasogastric tube within 48 hours of meeting sepsis criteria.
62628051|NCT05521074|EXPERIMENTAL|Active tDCS administered before extinction phase|The investigators will stimulate using 2mA of direct current during 20 min before the extinction phase of the fear conditioning and extinction paradigm.
62628052|NCT05521074|EXPERIMENTAL|Active tDCS administered during extinction phase|The investigators will stimulate using 2mA of direct current during 20 min during the extinction phase of the fear conditioning and extinction paradigm.
62628053|NCT05521074|EXPERIMENTAL|Active tDCS administered after extinction phase|The investigators will stimulate using 2mA of direct current during 20 min after the extinction phase of the fear conditioning and extinction paradigm.
62628054|NCT05521074|SHAM_COMPARATOR|Sham tDCS|Sham will consist of a ramp up and down of activity (from 0 to 2mA and back to 0mA) in the first 30sec and again in the last 30 sec of the 20min stimulation period (which will occur before/during/after the extinction phase). No active tDCS will occur.
62628055|NCT00472745|EXPERIMENTAL|WL|weight loss (WL) with nutrition/behavior modification counseling
62853468|NCT00450125||Six-Minute Walk Test|Two Six-minute walk tests where total distance walked measured. Tests performed within 15 days of an exercise stress test.
62063353|NCT03499015|NO_INTERVENTION|Ear without BET|ear without BET treatment works as control
62063354|NCT03499015|EXPERIMENTAL|BET ear|ear with BET treatment works as intervention arm
62063355|NCT00871884|ACTIVE_COMPARATOR|Treatment As Usual|
62628056|NCT00472745|ACTIVE_COMPARATOR|WM|Weight Maintenance (WM)
62628057|NCT00576524|EXPERIMENTAL|Sham Device first, ITD next|Subjects will be randomized to recieve sham device first, ITD next after washout of 7 days.
62628058|NCT00576524|EXPERIMENTAL|ITD first, sham device next|Subjects will be randomized to receive ITD first, sham device next, after washout of 7 days.
62628059|NCT05415462|EXPERIMENTAL|mRNA-1010|Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
62628060|NCT05415462|ACTIVE_COMPARATOR|Fluarix Tetra|Participants will receive a single dose of Fluarix Tetra by IM injection on Day 1.
62628061|NCT06612190|EXPERIMENTAL|TMS|
62628062|NCT06612190|SHAM_COMPARATOR|Control|
62628063|NCT03444805||NISSC-2|SSC patients treated with AHSCT
62628064|NCT01901042|EXPERIMENTAL|Symbiotic|Patients in this group received sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
62628065|NCT01901042|PLACEBO_COMPARATOR|Maltodextrin|patients in this group received sachets five grams of maltodextrin per sachet with identical casing and identical aspect to the product of the other arm group, and were instructed to proceed in the same way as those of the symbiotic group
62628066|NCT03207997|EXPERIMENTAL|Mild pulmonary fibrosis|mild pulmonary fibrosis (VFC\> 75% theoretical and DLCO / VA\> 55%) 2 additional unenhanced MR sequences
62628067|NCT03207997|EXPERIMENTAL|Moderate pulmonary fibrosis|moderate pulmonary fibrosis (VFC 50-75% and DLCO 36-55%) 2 additional unenhanced MR sequences
62628068|NCT03207997|EXPERIMENTAL|Severe pulmonary fibrosis|severe pulmonary fibrosis (VFC \<50% theoretical or DLCO / VA \<35%). 2 additional unenhanced MR sequences
62628069|NCT03207997|ACTIVE_COMPARATOR|Control group|2 additional unenhanced MR sequences
62628070|NCT00339833|EXPERIMENTAL|Salsalate|Salsalate (3g/day) for 7 days
62628071|NCT00339833|PLACEBO_COMPARATOR|Placebo|Placebo
62063356|NCT00871884|EXPERIMENTAL|Experimental|
62628072|NCT03255928||VAD-implanted patients|All patients receiving a VAD implant
62853469|NCT02296372|OTHER|SOFA <7|"Critically ill patients with a Sequential Organ Failure Assessment (SOFA) score \< 7 at first day of measurement.~Intervention: Measuring continuous glucose monitoring."
62853470|NCT02296372|OTHER|SOFA >7|"Critically ill patients with a Sequential Organ Failure Assessment (SOFA) score \> 7 at first day of measurement.~Intervention: Measuring continuous glucose monitoring."
62853471|NCT02290743|EXPERIMENTAL|Kinesio tape|Kinesio tape on quadriceps femoris
62268327|NCT05758259|PLACEBO_COMPARATOR|oral placebo and basic ingredient placebo topical vitamin D|Daily supplementation (1x/day, in the morning) and topical application (2x/day, in the morning and in the afternoon, minimum duration 4 hours on the skin) for 56 days
62268328|NCT02072655|NO_INTERVENTION|without socio-asthetic care|
62268329|NCT02072655|EXPERIMENTAL|with socio-aesthetic cares|
62628073|NCT03255928||VAD-patients suffering adverse events (AE)|VAD-patients sustaining a thromboembolic/bleeding complication over the course of support
62628074|NCT00770913|ACTIVE_COMPARATOR|1|
62628075|NCT00770913|EXPERIMENTAL|2|
62628076|NCT00770913|EXPERIMENTAL|3|
62628077|NCT06548633|EXPERIMENTAL|Vertebral Lumbar Mobilisations|Participants received the intervention.
62628078|NCT02998151|EXPERIMENTAL|All Study Participants|Participants received, in random order, a single dose of placebo, acamprosate, lovastatin, minocycline, or baclofen, with a two-week washout period between doses. Midway through the study (n=16) it was determined that acamprosate was undetectable in serum and this intervention was replaced by baclofen. Remaining participants (n=13) received baclofen and 5 participants were re-enrolled to receive baclofen or a second round of placebo, so investigators and participants would remain blinded to drug status during the baclofen visit. The second round of placebo was not analyzed.
62853472|NCT02290743|NO_INTERVENTION|Control|No intervention
62268330|NCT05279547|ACTIVE_COMPARATOR|Arm 1 (First constant-load then interval bed-cycling protocol)|"During Day 1, patients will be familiarized with the constant-load and interval bed-cycling exercise against no resistance. Patients will be also randomized in the two arms of the study before the determination of the appropriate exercise intensities to be subsequently use during the constant-load and interval bed-cycling protocols on Day 2 and Day 3. Exercise intensities will be determined so that the volume of training during the two protocols will be equal.~During Day 2, patients randomized to arm 1 will perform the constant-load bed-cycling protocol. During Day 3, patients who executed the constant-load bed-cycling protocol on Day 1 (arm 1) will perform the interval bed-cycling protocol."
62853473|NCT05364359|ACTIVE_COMPARATOR|Intervention group|The patients will receive a individual dietary counseling based on the taste-test
62853474|NCT05364359|PLACEBO_COMPARATOR|Standard dietary counseling|The patients will receive a individual standard dietary counseling not based on the taste-test
62853475|NCT04566887|EXPERIMENTAL|Acalabrutinib with R-CHOP chemotherapy|Acalabrutinib 100mg twice per day orally with standard of care R-CHOP chemotherapy by IV every 21 days for a maximum of six cycles.
62853476|NCT00529607||1|- patients with acute ST elevation myocardial infarction and consecutive percutaneous coronary intervention of the infarct-related artery
62853477|NCT00529607||2|- 30 patients with stable CAD (control group 1)
62853478|NCT00529607||3|- 30 healthy volunteers regarding cardiovascular diseases (control group 2)
62853479|NCT03222882|EXPERIMENTAL|RIF group|According to the histological dating and transcriptomic profile of endometrium of hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer . The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on day P＋7 in an HRT cycle. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy outcome of the FET cycle .
62853480|NCT06247189|EXPERIMENTAL|ICOPE Monitor Program|Evaluation at inclusion and re-evaluation monthly.
62853481|NCT03347292|EXPERIMENTAL|Dose escalation|The regorafenib starting dose will be 120 mg q.d.(once daily) 3 weeks on / 1 week off in combination with the recommended dose of pembrolizumab (200 mg Q3W). Pembrolizumab dose will not be escalated or de-escalated.
62853482|NCT03347292|EXPERIMENTAL|Dose expansion|Dose expansion cohorts will continue to be expanded until the sample size of 30-35 patients per cohort is reached.
62268331|NCT05279547|ACTIVE_COMPARATOR|Arm 2 (First interval then constant-load bed-cycling protocol)|"During Day 1, patients will be familiarized with the constant-load and interval bed-cycling exercise against no resistance. Patients will be also randomized in the two arms of the study before the determination of the appropriate exercise intensities to be subsequently use during the constant-load and interval bed-cycling protocols on Day 2 and Day 3. Exercise intensities will be determined so that the volume of training during the two protocols will be equal.~During Day 2, patients randomized to arm 2 will perform the interval bed-cycling protocol. On Day 3 they will perform the constant-load bed-cycling protocol."
62268332|NCT02728193|EXPERIMENTAL|RFA|Radiofrequency ablation
62268333|NCT02728193|EXPERIMENTAL|MWV|Microwave ablation
62268334|NCT02728193|EXPERIMENTAL|PEI|Percutaneous ethanol injection
62268335|NCT00678405|ACTIVE_COMPARATOR|WLm / WLnm|Best supportive care
62268336|NCT00678405|EXPERIMENTAL|FTm / FTnm|Breathlessness Intervention Service
62268337|NCT01212302|EXPERIMENTAL|aspirin, clopidogrel|If the treatment with aspirin and/or clopidogrel is insufficient (platelet function testing) the dose was increased or the drug was changed (clopidogrel to ticlopidine or prasugrel)
62268338|NCT03945708|EXPERIMENTAL|Treatment|Addition of whole blood adsorber to CPB circuit
62461490|NCT01491880|EXPERIMENTAL|Child Anxiety Program- Self Help|Families randomized to the Self-Help CBT condition will receive program materials along with instructions for completing weekly assignments. Specifically, they will receive the same materials as families in the telephone-based condition however in the self-help group, parents and children are expected to read the materials for that week and complete the workbook activities without planned therapist involvement. Instead they will be given the option to initiate a telephone call to the therapist, if they have questions or need extra support.
62268339|NCT03945708|NO_INTERVENTION|Control|Standard treatment
62268340|NCT00706134|PLACEBO_COMPARATOR|Placebo|
62268341|NCT00706134|EXPERIMENTAL|Aliskiren 75 mg|
62461491|NCT05613894|EXPERIMENTAL|Dose Escalation (Part 1)|Part 1 will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the MTD and/or recommended dose and schedule
62268342|NCT00706134|EXPERIMENTAL|Aliskiren 150 mg|
62268343|NCT00706134|EXPERIMENTAL|Aliskiren 300 mg|
62268344|NCT04247178||Patients undergoing elective orthopaedic surgery|
62268345|NCT04247178||Healthy Volunteers|
62268346|NCT03624322|ACTIVE_COMPARATOR|Period 1|Period 1 (n=36) assignment to 1 of 2 reference therapy treatment groups (Zyprexa 5mg IM or Zydis 10mg orally disintegrating wafer, 10mg) over 3 cohorts (single dose)
62853483|NCT01604356|EXPERIMENTAL|Electro-acupuncture|
62853484|NCT01809639|EXPERIMENTAL|Progesterone|400mg of oral micronized progesterone (Prometrium®) on days one, two, and three then 200mg on days four and five
62853485|NCT01809639|PLACEBO_COMPARATOR|Placebo|
62853486|NCT05061056|EXPERIMENTAL|Russian current 10%|Subjects will receive a interventions (Russian Current at 10% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
62853487|NCT05061056|EXPERIMENTAL|Russian current 20%|Subjects will receive a interventions (Russian Current at 20% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
62628079|NCT02131233|EXPERIMENTAL|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily plus placebo to raltegravir 1 tablet orally twice daily plus TRUVADA™ orally once daily for 96 weeks
62628080|NCT02131233|ACTIVE_COMPARATOR|Raltegravir|Raltegravir 400 mg tablet orally twice daily plus placebo to reformulated raltegravir 2 tablets orally once daily plus TRUVADA™ orally once daily for 96 weeks
62628081|NCT04783233||Packing with Gelfoam|Tympanoplasty surgery with fascia graft (either transcanal or post-auricular) will be preformed. The middle ear and external canal will then be packed with Gelfoam.
62628082|NCT04783233||Packing with Chitosan succinamide|The surgical intervention and tympanoplasty will be performed as normal. The middle ear and external canal will be packed Chitosan succinamide.
62628083|NCT00806208|ACTIVE_COMPARATOR|1|MEDI 507 and Methylprednisolone
62628084|NCT00806208|ACTIVE_COMPARATOR|2|MEDI-507 and Methylprednisolone
62628085|NCT00806208|ACTIVE_COMPARATOR|3|MEDI-507 and Methylprednisolone
62628086|NCT00806208|ACTIVE_COMPARATOR|4|MEDI-507 and Methylprednisolone
62628087|NCT00806208|PLACEBO_COMPARATOR|5|Placebo
62628088|NCT03992378|EXPERIMENTAL|Active Treatment|Patients will receive a single 4-hour session of active transcutaneous vagus nerve stimulation.
62628089|NCT03992378|SHAM_COMPARATOR|Sham Control|Patients will receive a single 4-hour session of sham transcutaneous vagus nerve stimulation.
62628090|NCT01440634|OTHER|supervised exercise|It consists of six months of supervised, intermittent track walking to near maximal leg pain or discomfort three days per week. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month.
62628091|NCT01440634|NO_INTERVENTION|Standard of Care|Patients will be observed during the time of the study, no intervention will be applied. Patients are allowed to do their regular activity at home.
62853488|NCT05061056|EXPERIMENTAL|Aussie current 10%|Subjects will receive a interventions (Aussie Current at 10% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
62628092|NCT01204086|EXPERIMENTAL|venlafaxine|
62628093|NCT01204086|EXPERIMENTAL|fluoxetine|
62628094|NCT00178217|EXPERIMENTAL|Music Therapy|The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
62628095|NCT00178217|NO_INTERVENTION|Standard Care Control|Subjects will receive standard care at control condition sessions, which includes the use of television, books, CD's, a child life specialist (when available) or other activities to help cope with the procedure.
62628096|NCT02693262|EXPERIMENTAL|CLS Mode on Biotronik CRT-D|All 15 patients will be randomized to this group. Their device will be set in the CLS mode for 1 week.
62628097|NCT02693262|ACTIVE_COMPARATOR|Accelerometer Mode on Biotronik CRT-D|All 15 patients will be randomized to this group. Their device will be set in the accelerometer rate responsive mode for 1 week.
62853489|NCT05061056|EXPERIMENTAL|Aussie current 20%|Subjects will receive a interventions (Aussie Current at 20% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
62628098|NCT04979416|NO_INTERVENTION|Control|No video message
62628099|NCT04979416|EXPERIMENTAL|Video message 1|
62628100|NCT04979416|EXPERIMENTAL|Video message 2|
62628101|NCT04979416|EXPERIMENTAL|Video message 3|
62853490|NCT04599530|OTHER|Biomechanical|All experimental tasks will be evaluated on biomechanical outcome measures
62853491|NCT04599530|OTHER|Psychological|All experimental tasks will be evaluated on psychological outcome measures
62853492|NCT04599530|OTHER|Physiological|All experimental tasks will be evaluated on biomechanical outcome measures
62853493|NCT04599530|OTHER|Performance|All experimental tasks will be evaluated on biomechanical outcome measures
62628102|NCT06612502|ACTIVE_COMPARATOR|Static Stretching group|The static stretching protocol comprised eight exercises, performed for 30 seconds per bilateral muscle group (with the exception of the sitting toe touch and butterfly stretch), and included the hip, knee, and ankle. Each subject completed each stretch before progressing to the subsequent one. The stretches were maintained until the subject experienced mild discomfort, but not pain.
62628103|NCT06612502|EXPERIMENTAL|short-time PMT group|The PMT was performed by the two physiotherapists using an OUTSO 06® Fascia Gun equipped with a 5 cm diameter soft attachment head. Throughout the PMT, the physiotherapists carefully maintained a consistent level of moderate pressure on the skin, and followed the direction of the muscle fibers. In the S-PMT group, the treatment was applied for 25minutes.
62628104|NCT06612502|EXPERIMENTAL|long-time PMT group|The PMT was performed by the two physiotherapists using an OUTSO 06® Fascia Gun equipped with a 5 cm diameter soft attachment head. Throughout the PMT, the physiotherapists carefully maintained a consistent level of moderate pressure on the skin, and followed the direction of the muscle fibers. In the L-PMT group, the treatment was applied for 40 minutes.
62628105|NCT01343979||positive|Patients with clinically suspected H1N1 infection confirmed by positive H1N1 PCR
62628106|NCT01343979||negative|Patients with clinically suspected H1N1 infection and negative H1N1 PCR
62628107|NCT04407702|EXPERIMENTAL|Control Group|The volunteers in this group will receive the same hygiene instructions as the other groups and will undergo both treatments, except that water will be used instead of the sealant and the laser device will be set to a power of 0 W. In other words, the same irradiation procedure will be performed but without the emission of light.
62628108|NCT04407702|EXPERIMENTAL|Sealant Group|The volunteers in this group will receive treatment with sealant (Permaseal - Ultradent), which is a photopolymerizable methacrylate-based resin.
62628109|NCT04407702|EXPERIMENTAL|Low-Level Laser Group|The volunteers in this group will receive irradiation with AsGaAl laser at a wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP, Brazil) with relative isolation.
62628110|NCT04407702|EXPERIMENTAL|Low Level Laser + Sealant Group|The volunteers in this group will receive the same irradiation administered to Low-level Laser Group. During the last session, these volunteers will also receive the same sealant applied in Sealant Group.
62628111|NCT02455453|EXPERIMENTAL|Diagnostic FFNP-PET/CT Scan|"* (2) 18F-FFNP-PET/CT scans~  * First one prior to estradiol challenge test~ * Second one immediately following one day of estradiol challenge test~* (1) FDG-PET/CT scan at screening~* The estradiol challenge test will consist of administering a total of 6 mg of estradiol dosed orally as three 2 mg tablets with each tablet being administered approximately 8 hours apart and within a 24 hour period. This estradiol medication will be provided to the patient by the study."
62628112|NCT02010905|ACTIVE_COMPARATOR|Losartan 150mg daily|Losartan: white film-coated biconvex tablet (50mg) with a diameter of 8mm. One time daily three tablets.
62628113|NCT02010905|PLACEBO_COMPARATOR|Placebo 150mg daily|Placebo: white film-coated biconvex tablet (50mg) with a diameter of 8mm. One time daily three tablets.
62628114|NCT04152083|EXPERIMENTAL|Eptinezumab|Participants will receive a single dose of eptinezumab 100 milligrams (mg) administered via intravenous (IV) infusion on Day 0.
62628115|NCT04152083|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo matching to eptinezumab administered via IV infusion on Day 0.
62628116|NCT04235504|ACTIVE_COMPARATOR|Control Arm|The Control Arm will use individual subject's current diabetes therapy (MDI+FGM or MDI+CGM) for 6 months during the Study Phase. During the Continuation Phase of 6 months Control Arm will start using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0
62628117|NCT04235504|EXPERIMENTAL|Treatment Arm|The Treatment Arm will use the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0 for 6 months during the Study Phase and other 6 months during the Continuation Phase.
62853494|NCT02340871||Genetic Neurological Diseases|The group consists of patients with a neurological disease that are tested for finding the genetic basis of their disease.The neurological signs and symptoms include ataxia, intellectual disability, seizures, movement disorders, migrational disorders, macrocephaly, microcephaly and various other signs and symptoms. The group consists of patients from 1-year-old until 90 years who are having a neurological disease as stated above or who are the parents or siblings of the affected patients. Blood specimens will be taken from them and DNA will be extracted for next generation studies like whole exome sequence or whole genome sequence. This process is called genetic testing. The current proposal will assist in diagnosing children and families with a neurological disease for genetic counseling.
62853495|NCT03896256|EXPERIMENTAL|Treatment Arm|Patients will be admitted to the hospital for a total of 5 full days from the time of admission until discharge. Ketamine infusion will be started on day 1. Adjustments to ketamine infusion will be made according to standard acute pain service protocol.
62853496|NCT05829785||overweight group|Subjects with a body mass index (BMI) ≥ 25
62853497|NCT05829785||normal weight group|Subjects with BMI \< 25
62853498|NCT02936661|EXPERIMENTAL|Tranexamic acid|Tranexamic acid 1 g（10ml） IV in 2 minutes after the baby delivered during ceasarean section
62628118|NCT01540981|ACTIVE_COMPARATOR|SOC - Standard of Care|Standard of care consists of pressure relief, creams, wound cleansing and dressings as needed
62628119|NCT01540981|ACTIVE_COMPARATOR|MIST Therapy with SOC|Standard of Care including pressure relief, wound cleansing, creams, and dressings as needed plus MIST Therapy daily for 5 days and then every other day for up to 7 more days
62628120|NCT00030628|EXPERIMENTAL|radiosurgery|"Patients undergo radiosurgery.~Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years."
62653131|NCT04832035|OTHER|"Standard psychotherapeutic care"|Participants receive standard psychotherapeutic care in the public healthcare system. For participants in this group no additional organisational support is available. This is Treatment as Usual.
62853499|NCT02936661|PLACEBO_COMPARATOR|placebo|NS 10ml IV in 2 minutes after the baby delivered during ceasarean section
62853500|NCT04865367||DEG n1: euploid medium|culture media derived from euploid embryos
62853501|NCT04865367||DEG n2: aneuploid medium|culture media derived from aneuploid embryos
62853502|NCT04865367||DEG n3: medium arrested embryos|culture media derived from arrested embryos
62853503|NCT04865367||DEG n4: control culture medium|pure culture media without contact to embryos
62853504|NCT05606029||Patients who underwent cholecystectomy for benign conditions|In those who underwent cholecystectomy for benign conditions, the histopathological analysis showed the malignancy.
62268347|NCT03624322|EXPERIMENTAL|Period 2|Period 2 (n=36) assignment to 1 of 3 IP treatment groups (INP105 of 5, 10, or 20mg or placebo) administered with the I231 POD® Device) over 3 cohorts (single dose)
62628121|NCT00030628|EXPERIMENTAL|radiosurgery + WBRT|"Patients undergo radiosurgery. Within 14 days, patients then undergo whole brain radiotherapy 5 days a week for 2.5 weeks.~Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years.~Patients are followed at weeks 6 and 12, every 3 months for 9 months, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter."
62628122|NCT05555576|EXPERIMENTAL|Vitamin C|1 000 mg vitamin C taken orally twice a day
62853505|NCT05884164|ACTIVE_COMPARATOR|Erector spinae group|Patients will receive erector spinae plane block after general anaesthesia .
62628123|NCT05555576|PLACEBO_COMPARATOR|Placebo|Matching placebo
62628124|NCT01960166|EXPERIMENTAL|Active distraction|Child will use Ipad as active distraction
62628125|NCT01960166|EXPERIMENTAL|Passive Distraction|Child will watch movie as passive distraction (control)
62628126|NCT04826471|EXPERIMENTAL|DermoRelizema ecofoam|DermoReizema ecofoam for 42 days, 2 times per day
62628127|NCT03767426|NO_INTERVENTION|Overnight sleep|Subjects are permitted a night of polysomnograph-recorded sleep before participating in training and testing sessions the next day
62628128|NCT03767426|ACTIVE_COMPARATOR|Sleep deprivation|Subjects sleep deprived before participating in training and testing sessions the next day
62628129|NCT03767426|EXPERIMENTAL|Daytime Nap|Subjects are trained and then retested after a daytime nap
62628130|NCT00585338|EXPERIMENTAL|Tandem 532/1064 nm Laser|Treatment of Vascular LesionsWith a Tandem 532/1064 nm Laser
62628131|NCT03258645||Acute ischemic stroke|Non-valvular atrial fibrillation patients hospitalized with an acute ischemic stroke
62628132|NCT01185002|EXPERIMENTAL|MgC boosts|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered MgC boosts."
62628133|NCT01185002|EXPERIMENTAL|Suprep boosts|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered Suprep boosts"
62628134|NCT01185002|EXPERIMENTAL|Suprep boosts - Reduced dose|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered a reduced dose of Suprep boosts"
62628135|NCT01912794|EXPERIMENTAL|Sensory Conditions|
62653132|NCT05545735|EXPERIMENTAL|4 Days of Antibiotics Group|Participants will receive 4 days of antibiotic therapy administered as per the standard of care for the treatment of early ventilator associated pneumonia (VAP).
62268348|NCT04077658|EXPERIMENTAL|HeartMath|
62268349|NCT04077658|ACTIVE_COMPARATOR|Waitlist Control|
62268350|NCT00236977|EXPERIMENTAL|Venofer|iron sucrose injection
62853506|NCT05884164|ACTIVE_COMPARATOR|Paravertebral block group|Patients will receive paravertebral plane block after general anaesthesia .
62853507|NCT02205840|EXPERIMENTAL|SI-614|
62853508|NCT02205840|PLACEBO_COMPARATOR|Placebo Vehicle|
62853509|NCT01711502||Female patients diagosed with metastatic breast cancer|
62853510|NCT06157788||Operated group|Patients were male individuals with anterior glenohumeral instability, who underwent preoperative fMRI, then surgical stabilization by 2 specialized shoulder surgeons, followed by a new fMRI one year postoperatively.
62268351|NCT00236977|ACTIVE_COMPARATOR|Ferrous Sulfate|oral iron
62268352|NCT04804254|EXPERIMENTAL|Monotherapy in Dose Escalation: ABBV-623|Participants with Relapsed/Refractory (R/R) B-cell malignancies will receive escalating doses of ABBV-623.
62853511|NCT06157788||Control Group|The control group consisted in healthy volunteers with no history of shoulder injury, instability, or hyperlaxity, the latter defined as more than 85° of external rotation elbow against waist, or hyperabduction over 105°, who had undergone fMRI at baseline.
62063357|NCT01287520|EXPERIMENTAL|LY2090314/pemetrexed/carboplatin|"Part A, Cycle 1 (28 days): Intravenous doses of LY2090314 starting at 10 milligram (mg) were given on Day 1 followed by 10 mg LY2090314, 500 milligram per square meter (mg/m\^2) pemetrexed (intravenous dose), and 5 or 6 area under the concentration-time curve (AUC) intravenous dose of carboplatin on Day 8.~Part A, Cycle 2 (21 days): Pemetrexed and carboplatin given on Day 1 at the same dose administered in Cycle 1.~Part A, Cycle 3 (21 days) and beyond: LY2090314, Pemetrexed and carboplatin were given on Day 1 at the same dose administered in Cycle 1. LY2090314 doses were escalated until the maximum tolerated dose (MTD) was reached.~Part B: Dose determined in Part A was administered. Participants were allowed to continue the combination treatment if they were receiving therapeutic benefit until they fulfilled one of the criteria for discontinuation."
62063358|NCT03798002|EXPERIMENTAL|Neuro-muscular exercise training Group|Neuro-muscular exercise training will be administer to Knee OA patients.
62063359|NCT03798002|ACTIVE_COMPARATOR|quadriceps training program|quadriceps stretching and strengthening exercises will be administer to Knee OA patients.
62063360|NCT04891796||Current smokers|Individuals who, at the time of the survey, smoke any forms of tobacco product either daily or occasionally.
62063361|NCT04891796||Ex-smokers|Individuals who were formerly smokers but, at the time of the survey, do not smoke at all.
62063362|NCT04891796||Never Smokers|Individuals who, at the time of the survey, have never smoked at all.
62628136|NCT02302040|EXPERIMENTAL|AIM2ACT|AIM2ACT uses existing mHealth technology developed by the study team to elucidate tailored intervention targets for each family. AIM2ACT then facilitates collaborative caregiver/adolescent asthma management by automatically guiding dyads through a structured process that includes the supportive behavioral management strategies of goal setting, contingency management, and problem solving communication. Skills-training videos for adolescents and caregivers provide guidance on how to complete each collaborative asthma management component.
62628137|NCT02302040|ACTIVE_COMPARATOR|Self-Guided|Participants in the self-guided control condition will be given general information on supportive behavioral management techniques they can use to target improvement in asthma self-management behaviors. The control condition will serve as an attention control and is designed to optimize recruitment and sustain interest while concurrently having a minimal impact on asthma management.
62628138|NCT02329782|EXPERIMENTAL|ARP intervention|Adherence counseling intervention
62628139|NCT02329782|NO_INTERVENTION|usual care|no intervention, standard care practices regarding adherence support
62853512|NCT01702636|ACTIVE_COMPARATOR|Tranexamic Acid|Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
62853513|NCT01702636|PLACEBO_COMPARATOR|Placebo|Intravenous placebo in 100 mL 0.9% NaCl over 10 minutes followed by 500 mL 0.9% NaCl infusion over 8 hours.
62853514|NCT03464292||Vehicle Patch|Control patch will be the same topical solution but will not contain capsaicin. The patch will applied to the hand for 30 - 60 min. Patients will be instructed to not touch or wash their hands during the course of the study to minimize spreading of the patch to other areas of the body. Subsequently, the patch will be immediately removed.
62853515|NCT03464292||Capsaicin Patch 8% or 0.1% Capsaicin Cream|8% capsaicin topical patch or 0.1% capsaicin cream. The patch will applied to the hand for 30 - 60 min. The cream will be applied similarly on a 3 cm2 area of the arm. Patients will be instructed to not touch or wash their hands during the course of the study to minimize spreading of the patch to other areas of the body. Subsequently, the patch will be immediately removed.
62853516|NCT04520529|OTHER|Patients with primary cutaneous lymphoma|
62853517|NCT02776618|EXPERIMENTAL|Polyglactin 910|One half of excision site will be randomly assigned superficial closure with polyglactin 910 suture
62853518|NCT02776618|EXPERIMENTAL|poliglecaprone 25|One half of excision site will be randomly assigned superficial closure with poliglecaprone 25
62853519|NCT01142804|EXPERIMENTAL|Enhanced Usual Care Group|Participants received weekly emailed tips of the week to provide support for walking.
62063363|NCT05288725|EXPERIMENTAL|Intra-articular injection with Bone Marrow Derived Mesenchymal Stem Cells (MSCs)|Participants will undergo a bone marrow aspirate procedure. Participants will receive a single intra-articular injection of NGRM-001 on treatment day.
62063364|NCT05288725|EXPERIMENTAL|Subchondral injection with Bone Marrow Derived MSCs|Participants will undergo a bone marrow aspirate procedure. Participants will receive a single subchondral injection of NGRM-001 on treatment day.
62628140|NCT03814902|EXPERIMENTAL|Electronic Tracking Device|Participants will be given a wearable electronic tracking device (ETD) to use for their child with autism spectrum disorder (ASD) for 6 weeks.
62628141|NCT05276206|ACTIVE_COMPARATOR|NSAID|The Control group will be given nothing and only non-steroidal anti-inflammatory drugs on need
62063365|NCT05288725|EXPERIMENTAL|Combined Intra-articular and Subchondral injection with Bone Marrow Derived MSCs|Participants will undergo a bone marrow aspirate procedure. Participants will receive a single combined intra-articular and subchondral injection of NGRM-001 on treatment day.
62063366|NCT05288725|ACTIVE_COMPARATOR|Corticosteroid injection|Subjects in the corticosteroid group will undergo a mock bone marrow aspirate procedure. Participants will receive a single intra-articular injection of corticosteroid on treatment day.
62063367|NCT00958022|EXPERIMENTAL|LBH589 and carboplatin with etoposide|"The main goal during the Phase I portion of this research study is to find out the highest and safest dose of LBH589 that can be given in combination with carboplatin with etoposide in subjects with lung cancer without causing severe side effects. The main goal of the Phase II portion of this study is to find how lung cancer responds to the LBH589 in combination with carboplatin and etoposide.~This study will also investigate how the body processes the combination of LBH589 and carboplatin with etoposide."
62088055|NCT03670745|EXPERIMENTAL|Pre-visit Planning Tool|To determine the effectiveness an electronic self-administered pre-visit planning tool allowing adolescents to list areas of concern to support shared decision-making during an office visit. Interviews will also explore approaches to implement and evaluate such a tool.
62628142|NCT05276206|ACTIVE_COMPARATOR|Nalufin|group will be given IV nalufin
62628143|NCT05276206|ACTIVE_COMPARATOR|local anesthetic group|the local anesthetic group will be given a S.C injection of local anesthetic in the wound
62628144|NCT05276206|ACTIVE_COMPARATOR|TAP block|Total abdominal plain block group will be given a TAP block
62628145|NCT06218771|EXPERIMENTAL|TQB3454 Tablets|TQB3454 Tablets, orally administered, 28 days as a treatment cycle.
62088056|NCT03670745|ACTIVE_COMPARATOR|control group|Will not be receiving an electronic self-administered pre-visit planning tool.
62853520|NCT01142804|EXPERIMENTAL|WalkLink Group|Participants received weekly emailed tips of the week, plus evidence-based online fitness walking program.
62853521|NCT01142804|EXPERIMENTAL|WalkLink+ Group|Participants received weekly emailed tips, plus evidence-based online fitness walking program, plus online/in-person social network intervention.
62853522|NCT05289518|EXPERIMENTAL|Intervention group|Subjects in the intervention group will recieve remote ischemic conditioning (RIC) treatment twice a day for 3 months.
62853523|NCT05289518|SHAM_COMPARATOR|Sham control group|Subject in the sham control group will recieve sham remote ischemic conditioning (Sham-RIC) treatment twice a day for 3 months.
62853524|NCT01149668|EXPERIMENTAL|PCI-24781|
62853525|NCT02984930|EXPERIMENTAL|PPI + mosapride group|After diagnosis(GERD), patient of this group will be taken proton pump inhibitor (40mg) plus mosapride for 4weeks. After then, patient of this group will be undergo upper endoscopy and scintigraphy.
62853526|NCT02984930|PLACEBO_COMPARATOR|PPI + placebo group|After diagnosis(GERD), patient of this group will be taken proton pump inhibitor (40mg) plus placebo drug of mosapride for 4weeks. After then, patient of this group will be undergo upper endoscopy and scintigraphy.
62268353|NCT04804254|EXPERIMENTAL|Monotherapy in Dose Escalation: ABBV-992|Participants with R/R B-cell malignancies will receive escalating doses of ABBV-992.
62628146|NCT04665973|EXPERIMENTAL|Oral semi-structured interview|The oral semi-structured interview uses the principles of motivational interviewing (partnership with the patient, no judgment, altruism, evocation) and follow the content of the booklet used in the control group.
62853527|NCT01601600|PLACEBO_COMPARATOR|Placebo|
62853528|NCT01601600|EXPERIMENTAL|BYM338|BYM338 active drug
62853529|NCT02005952||Spirometry, quality control, Pulmonary Function Laboratory|Performing spirometry, with control over the quality of the same, made from the pulmonary function laboratory of the Hospital de la Santa Creu i Sant Pau.
62853530|NCT02005952||Spirometry, quality control, software|Performing spirometry, with the support of software self-management quality of spirometry maneuvers incorporated therein
62268354|NCT04804254|EXPERIMENTAL|Combination in Dose Escalation|Participants with R/R B-cell malignancies will receive escalating doses of ABBV-623 and ABBV-992.
62268355|NCT04804254|EXPERIMENTAL|Monotherapy in Dose Expansion: ABBV-623|Participants with R/R B-cell malignancies will receive ABBV-623 at recommended Phase 2 dose (RP2D) determined in dose escalation phase.
62628147|NCT04665973|ACTIVE_COMPARATOR|Booklet|The information booklet was designed by the physiotherapists at Cliniques universitaires Saint-Luc and is specifically dedicated to raise patient's awareness about the benefits of physical activity (PA) in the context of cancer.
62853531|NCT02005952||Spirometry, quality control, control group|Performing spirometry in the way that is currently working in primary care (control group without any support).
62853532|NCT02147119||Patients post- cardiac catheterisation|
62853533|NCT05498415|ACTIVE_COMPARATOR|Education|Participants will receive basic education information on physical activity, sedentary behavior, and sleep for 8 weeks.
62853534|NCT05498415|EXPERIMENTAL|Education + Health Coaching + Activity Monitor|Participants will receive education information on physical activity, sedentary behavior and sleep plus health coaching plus a Fitbit activity monitor for 8 weeks.
62853535|NCT03393247|ACTIVE_COMPARATOR|infliximab and azathioprine at week 0|infliximab and azathioprine combination at week 0
62853536|NCT03393247|ACTIVE_COMPARATOR|infliximab and azathioprine at week 14|infliximab and azathioprine combination at week 14
62853537|NCT02543749|EXPERIMENTAL|DC vaccine|"Autologous DC pulsed with leukemia-associated peptides+adjuvant.~Ten vaccinations over 26 weeks with 10 x 106 freshly thawed DC Intradermal injections (1-2 ml volume)"
62853538|NCT01170533|ACTIVE_COMPARATOR|Omeprazole|prospective, open-label, two-sequence, three-period, randomized crossover study
62088057|NCT05248360|EXPERIMENTAL|Experimental group|Hydrogen-oxygen mixed gas(H2-O2, 66.6% hydrogen, 33.3% oxygen) inhalation, 900ml/min, 2h/d
62088058|NCT05248360|PLACEBO_COMPARATOR|Control group|Air inhalation, 900ml/min, 2h/d
62088059|NCT01593878|EXPERIMENTAL|TV|Test taken with TV on
62088060|NCT01593878|NO_INTERVENTION|Control|test taken in quiet
62268356|NCT04804254|EXPERIMENTAL|Monotherapy in Dose Expansion: ABBV-992|Participants with R/R B-cell malignancies will receive ABBV-992 at recommended Phase 2 dose (RP2D) determined in dose escalation phase.
62268357|NCT04804254|EXPERIMENTAL|Combination in Dose Expansion|Participants with R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) will receive ABBV-623 and ABBV-992 at recommended Phase 2 dose (RP2D) determined in dose escalation phase.
62268358|NCT02354937|EXPERIMENTAL|Subjects with renal impairment|Subjects with severe renal impairment will receive single oral dose of 744 30 mg
62628148|NCT03467542|EXPERIMENTAL|dAVF treatment|PHIL® Liquid Embolic System
62853539|NCT01170533|ACTIVE_COMPARATOR|Pantoprazole|prospective, open-label, two-sequence, three-period, randomized crossover study
62853540|NCT02150538|ACTIVE_COMPARATOR|Right ventricular stimulation|patients with conventional Right Ventricular Stimulation (only RV) with optimized algorithms for minimization of pacing
62853541|NCT02150538|EXPERIMENTAL|Biventricular Stimulation|Patients with biventricular stimulation (Right Ventricle and Left Ventricle)
62853542|NCT03011944||Quality Improvement Program|This group will consist of hospitalized and SNF, at-risk/malnourished patients being discharged to home health and outpatients at-risk/malnourished patients enrolled in home health.
62853543|NCT03011944||Control|This group will consist of historical controls, concurrent controls, and matched concurrent controls across other sites within the health system.
62853544|NCT02156271|ACTIVE_COMPARATOR|ramelteon|Subjects will take ramelteon 8mg one time daily 30 minutes before bedtime with approximately 8 ounces of water. Subjects have a 2 out of 3 chance of receiving ramelteon.
62853545|NCT02156271|PLACEBO_COMPARATOR|placebo|15 subjects will be randomized to receive the placebo
62853546|NCT04650451|EXPERIMENTAL|HER2-targeted dual-switch CAR-T cells|Subjects will receive one dose of BPX-603 on Day 1, followed by rimiducid IV infusion weekly (as tolerated) starting on Day 8 and continued until treatment discontinuation criteria are met.
62063368|NCT06625125|EXPERIMENTAL|Patients with ESRD receiving mindfulness-based intervention|"The mindful mediators are asked to act as neutral observers who quietly attend to, notice, and let go of internal and external stimuli (present experiences) such as thoughts, feelings, physical sensations, and sounds without reactions, evaluation, and judgments. (Smith, 2005).~The subjects in the mindfulness-based intervention (MBI) group will receive 30 minutes individually administered, guided, chairside interventions during their hemodialysis sessions, three times a week over eight weeks (Alhawatmeh et al., 2022; Thomas et al., 2017). Subjects in this group will receive their assigned intervention developed by the principal investigator (PI) according to the Smith's MBI protocol that will provide intervention instructions. During the eight weeks and at bedtime at night, the subjects will be optionally encouraged to practice the intervention at home."
62088061|NCT01648218|ACTIVE_COMPARATOR|Neutral protamine hagedorn (NPH) insulin|"Drug: Neutral protamine hagedorn (NPH) insulin~Other Names:~Humulin N, Novolin N~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 12 hours; for duration subjects are concurrently administered once-daily glucocorticoid."
62461492|NCT05613894|EXPERIMENTAL|Dose Expansion Cohort (Part 2)|Expansion Phase to assess identified MTD and schedule from Part 1.
62461493|NCT06129227|EXPERIMENTAL|Dual-task training|Mobility tasks performed in conjunction with cognitive tasks
62628149|NCT01610869|EXPERIMENTAL|Cyclophosphamide and BIBF-1120|Patients will receive oral BIBF 1120 (200mg bd) and cyclophosphamide (100mg) on a daily basis until disease progression or unacceptable toxicity.
62853547|NCT01978938|EXPERIMENTAL|Eravacycline|Eravacycline was administered IV at a dose of 1.5 mg per kilogram (kg) of body weight every 24 hours (q24h). At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 200 mg PO twice a day for a total therapy of 7 dosing cycles.
62853548|NCT01978938|ACTIVE_COMPARATOR|Levofloxacin|Levofloxacin (750 mg) was administered IV q24h. At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 750 mg PO once a day for a total therapy of 7 dosing cycles.
62853549|NCT02052713|EXPERIMENTAL|Sequence AB|Subjects will receive Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 1 and Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 2 orally once daily under fasted condition.
62853550|NCT02052713|EXPERIMENTAL|Sequence BA|Subjects will be randomized to receive Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 1 and Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 2 orally once daily under fasted condition.\[dutasteride 0.5 mg and tamsulosin HCl 0.4 mg) in period 2 orally once daily under fasted condition.
62853551|NCT01600625|EXPERIMENTAL|Minocycline treatment group|
62853552|NCT01093703|NO_INTERVENTION|Conventional Therapy|In the conventional therapy group, no medication changes other than the ones needed to achieve target awake average SBP will be undertaken. Time at which patients are taking their BP medications will be recorded.
62853553|NCT01093703|ACTIVE_COMPARATOR|Intensive Therapy|In the intensive therapy group, BP medications will be adjusted to both control awake average systolic BP to target and to cover the overnight period in an attempt to control nocturnal hypertension.
62853554|NCT03661567|EXPERIMENTAL|Methylprednisolone|Patients were treated with methylprednisolone after the first course of chest radiation and concurrent chemotherapy, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.
62853555|NCT03661567|ACTIVE_COMPARATOR|Observation|Observation after the first course of chest radiation, methylprednisolone can only be used for therapeutic purpose in the presence of grade≥2 radiation induced lung injury(NCI-CTC4.0).
62853556|NCT05412446|EXPERIMENTAL|HER2-positive patients|"Maximum 15 evaluable subjects with HER2-positive status in primary tumour before chemo/targeted therapy have to be enrolled in the study.~Subjects withdrawn from the study for any reason will be replaced."
62461494|NCT06129227|ACTIVE_COMPARATOR|Single-task training|Separate cognitive and mobility exercises
62461495|NCT06129227|ACTIVE_COMPARATOR|Control group|Upper limb strengthening and flexibility exercises
62461496|NCT02073604|OTHER|Healthy volunteers|Healthy volunteers
62461497|NCT02073604|OTHER|Congenital mirror movements|Patients presenting with congenital mirror movements
62628150|NCT01610869|PLACEBO_COMPARATOR|Cyclophosphamide and placebo|Patients will receive oral BIBF 1120 (200mg bd) and placebo capsules on a daily basis until disease progression or unacceptable toxicity.
62628151|NCT05822193||Individuals with COVID-19 diagnosis during the SARS-CoV-2 omicron wave in Brazil|
62628152|NCT04142905||Patients With Asthma|Subjects with sleep disordered breathing with asthma
62628153|NCT04142905||Patients Without Asthma|Subjects with sleep disordered breathing without asthma
62628154|NCT06007495|EXPERIMENTAL|Single-limb non-invasive ventilation with expiratory washout|In a random order, 30 minute period of non-invasive ventilation using the investigational mask, a vented full-face mask with expiratory washout
62628155|NCT06007495|ACTIVE_COMPARATOR|Single-limb non-invasive ventilation|In a random order, 30 minute period of non-invasive ventilation with a conventional vented full-face mask (RT077 or equivalent)
62628156|NCT06007495|ACTIVE_COMPARATOR|Dual-limb non-invasive ventilation|In a random order, 30 minute period of non-invasive ventilation with a conventional vented full-face mask (RT076 or equivalent)
62628157|NCT05174156|EXPERIMENTAL|biomarker study and treatment study|"All enrolled patients undergo biomarker study and treatment study.~* Biomarker study: the baseline tumor tissue will be collected and analyzed via NGS and mIHC~* Treatment study: SHR-1210 plus albumin-bound paclitaxel and platinum-based chemotherapy"
62628158|NCT01240902|EXPERIMENTAL|Extreme Risk: TAVI Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Iliofemoral Access
62853557|NCT05412446|EXPERIMENTAL|HER2-negative patients|"Maximum 15 evaluable subjects with HER2-negative status in primary tumour before chemo/targeted therapy have to be enrolled in the study.~Subjects withdrawn from the study for any reason will be replaced."
62853558|NCT04591678||SMA nusinersen adult cohort|"The nusinersen treatment will be given as standard of care. The treatment (which is NOT research, but the standard care) will be given by an injection into the cerebrospinal fluid (fluid in your spine) through a needle inserted into your lower back. Participants will receive a 12 mg (5 mL) dose during each administration/injection, which will occur on the following days: 1 (baseline), 15, 29, and 60. Following the 60 day treatment, participants will receive treatment every 4 months (6, 10, 14 etc.).~After the 60 day, 6 month, 10 month, 14 month, 18 month and 22 month treatments the study team will see each participant afterwards to collect information to evaluate your general health, function and response to the treatment for the study."
62853559|NCT06386016||patients with valvular heart disease|
62853560|NCT06386016||patients without valvular heart disease|
62853561|NCT03522623||IBD|Children and families with IBD will be surveyed
62853562|NCT01049009|ACTIVE_COMPARATOR|Nebivolol followed by Metoprolol XL|Subjects are randomized to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after cross over.
62853563|NCT01049009|ACTIVE_COMPARATOR|Metoprolol XL followed by Nebivolol|Subjects are randomized to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after cross over.
62853564|NCT03481179|EXPERIMENTAL|Experimental: hf rTMS and Physical therapy|High frequency TMS will be applied with an eight shaped coil angled at 45 degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1) injured. Forty stimulus trains will be provide at 10Hz over the injured hemisphere, at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 2000 pulses for approximately 20 minutes, with 120% of resting motor threshold (RMT). After TMS, patients will be submitted to 50 minutes of physical therapy protocol.
62063369|NCT06625125|ACTIVE_COMPARATOR|Patients with ESRD receiving progressive muscle relaxation|"The progressive muscle relaxation (PMR) group will receive the ABC version of PMR (Smith, 2005). This abbreviated version of PMR involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot.~As the MBI group, the subjects in the PMR group will receive 30 minutes individually administered, guided, chairside interventions during their hemodialysis sessions, three times a week over eight weeks. Subjects in this group will receive their assigned intervention developed by the principal investigator (PI) according to the Smith's PMR protocol that will provide intervention instructions. During the eight weeks and at bedtime at night, the subjects will be optionally encouraged to practice the intervention at home."
62063370|NCT06625125|NO_INTERVENTION|Patients with ESRD receiving the hospital traditional care|The control group will not receive any intervention from the study researchers
62268359|NCT02354937|ACTIVE_COMPARATOR|Subjects with normal renal function|Subjects with normal renal function will receive single oral dose of 744 30 mg
62268360|NCT03264300|ACTIVE_COMPARATOR|Development of advanced MRI methods|Subjects with brain tumor. Subjects may be scanned using a single time-point to permit development and optimization of advanced MRI methods. Subjects may be scanned up to two times, with both visits occurring within one month, to permit analysis of test-retest reliability/repeatability.
62268361|NCT03264300|ACTIVE_COMPARATOR|Validation of rCBV accuracy|64 subjects with primary glioma and 96 subjects with recurrent glioma. Subjects will be scanned using a single time-point to validate rCBV accuracy.
62628159|NCT01240902|EXPERIMENTAL|Extreme Risk: TAVI Non-Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Non-Iliofemoral Access
62628160|NCT01240902|EXPERIMENTAL|High Risk: TAVI|High Risk Surgical Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
62268362|NCT02105402|EXPERIMENTAL|Intervention Group - PROMPT therapy|Prompts for Restructuring Oral Muscular Phonetic Targets (PROMPT)
62628161|NCT01240902|ACTIVE_COMPARATOR|High Risk: SAVR|High Risk Surgical Patients: Surgical Aortic Valve Replacement (SAVR)
62853565|NCT03481179|SHAM_COMPARATOR|Control: Sham hf rTMS and Physical theraphy|In this group, the volunteer will start with sham TMS, will be the same parameters was used in experimental group, however, it will be performed using two coils, one connected to the magnetic stimulator, away from the patient's scalp and another uncoupled from the stimulator and positioned in the same way as in real stimulation. After, the volunteer will be submitted to 50 minutes of physical therapy protocol.
62853566|NCT02748382|ACTIVE_COMPARATOR|higher chloride solutions|higher chloride crystalloid (Normal saline) higher chloride albumin (5% Octalbin)
62628162|NCT00256932|PLACEBO_COMPARATOR|Placebo|
62853567|NCT02748382|ACTIVE_COMPARATOR|lower chloride solutions|lower chloride crystalloid (Ringer's lactate) lower chloride albumin (5% Plasbumin)
62853568|NCT05468047|EXPERIMENTAL|Ketamine administration|These individuals will be provided a personal ketamine-assisted therapy experience as part of an in-person training weekend within a psychedelic-assisted training program.
62268363|NCT02105402|NO_INTERVENTION|Waitlist or Delay Group|Participants in this group are on the waitlist for 10 weeks
62268364|NCT03288909||Early onset Parkinson's disease|Idiopathic Parkinson's disease within 1 year of symptom onset
62268365|NCT03288909||Idiopathic REM Sleep Behavior Disorder|Idiopathic REM Sleep Behavior Disorder
62268366|NCT03288909||Age-matched healthy controls|Age-matched healthy controls
62268367|NCT06126237|EXPERIMENTAL|CM313|CM313 injection, subcutaneous
62628163|NCT00256932|EXPERIMENTAL|Alvimopan 0.5 mg once daily|
62628164|NCT00256932|EXPERIMENTAL|alvimopan 0.5 mg twice daily|
62628165|NCT00652145|EXPERIMENTAL|Increase mesalamine dose by 2.4g/day|Increase dose of mesalamine by 2.4 gm per day
62628166|NCT00652145|NO_INTERVENTION|Maintain mesalmine dose|Maintain current mesalamine dose at 2.4 g/day
62628167|NCT04847583|EXPERIMENTAL|Telacebec (Q203) with COVID-19 standard of care (SoC)|
62628168|NCT04847583|ACTIVE_COMPARATOR|COVID-19 Standard of care (SoC)|
62628169|NCT04529239||Low to Moderate Risk|The CANRISK Canadian Diabetes Risk Questionnaire will be used for study group categorization to assess who is at risk of having prediabetes or type 2 diabetes. Participants will be categorized into one the following groups: i) low to moderate risk; ii) high risk, iii) very high risk.
62853569|NCT05468047|NO_INTERVENTION|No ketamine administration|These individuals will undergo the same psychedelic-assisted training program as those who receive the ketamine experience and will attend the same in-person training weekend; however, these individuals have opted out of ketamine administration by choice or due to contraindication and will not participate in the personal experience.
62853570|NCT03084380|EXPERIMENTAL|anti-GPC3 CAR-T|Transcatheter arterial chemoembolization (TACE) combine with GPC3-CART infusion
62853571|NCT05011201|EXPERIMENTAL|Experimental Group|Participants will undergo a single testing session of gait retraining using two variants of the dual joint visual feedback system (DJVF). The DJVF system uses IMU sensors to measure knee and hip joint motions and calculates the users foot position, relative to their pelvis. The relative foot position is represented in real time on a screen in front of the user with feedback designed to elicit increases in anteriorly located foot positions.
62853572|NCT04659811|EXPERIMENTAL|Treatment for recurrent meningioma (pembrolizumab, stereotactic radiosurgery)|Participants with recurrent grade II or III meningioma will receive stereotactic radiosurgery. in conjunction with pembrolizumab 200mg IV infusion on day 1 (to -1) of radiation and then every 3 weeks. Participants may be eligible for up to 17 additional cycles of pembrolizumab depending on disease status after completion of first course.
62853573|NCT05424640|NO_INTERVENTION|Baseline|Collection of baseline data 1 week before intervention
62853574|NCT05424640|EXPERIMENTAL|Dietary fiber 1|"15 g/day oat fiber 3 weeks intervention~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
62853575|NCT05424640|NO_INTERVENTION|Wash-out 1|"2 weeks~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
62853576|NCT05424640|EXPERIMENTAL|Dietary fiber 2|"15 g/day dietary fiber mix I 3 weeks intervention~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
62853577|NCT05424640|NO_INTERVENTION|Wash-out 2|"2 weeks~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
62628170|NCT04529239||High Risk|The CANRISK Canadian Diabetes Risk Questionnaire will be used for study group categorization to assess who is at risk of having prediabetes or type 2 diabetes. Participants will be categorized into one the following groups: i) low to moderate risk; ii) high risk, iii) very high risk.
62853578|NCT05424640|EXPERIMENTAL|Dietary fiber 3|"15 g/day dietary fiber 3 3 weeks intervention~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
62063371|NCT05301062||Radium-223 dichloride treatment|Castration-resistant prostate cancer (CRPC) patients with bone metastases for whom a decision has been made independently by the treating physician and the patient to treat with Radium-223.
62063372|NCT02130453|EXPERIMENTAL|ReSTE Cardiac Imaging|Echocardiography strain measurement performed taking about 10 minutes. After resting strain measurement done, first set of nuclear images performed. Once these images are completed, participant given Regadenoson 0.4 mg by vein over about 10 seconds. Within 2 to 4 minutes of receiving the Regadenoson, measurements repeated. These measurements will take about 2 minutes to complete.
62628171|NCT04529239||Very High Risk|The CANRISK Canadian Diabetes Risk Questionnaire will be used for study group categorization to assess who is at risk of having prediabetes or type 2 diabetes. Participants will be categorized into one the following groups: i) low to moderate risk; ii) high risk, iii) very high risk.
62628172|NCT02928523|EXPERIMENTAL|Autologous Fecal Microbiota Transplantation|Patients will receive autologous fecal microbiota transplantation (MaaT011- 150 mL rectal enema) - 2 administrations 24 hours apart.
62853579|NCT05424640|NO_INTERVENTION|Wash-out 3|"2 weeks~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
62853580|NCT05424640|EXPERIMENTAL|Dietary fiber 4|"15 g/day rye fiber 3 weeks intervention~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
62853581|NCT05424640|NO_INTERVENTION|Wash-out 4|"2 weeks~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
62853582|NCT02322853|ACTIVE_COMPARATOR|TAMOXIFEN|"Tamoxifen will be administered daily orally~Patients will receive study medication until disease progression or unacceptable toxicity"
62853583|NCT02322853|EXPERIMENTAL|TAMOXIFEN + LY2228820|"Tamoxifen will be administered daily orally LY2228820 dimesylate (Ralimetinib) will be administered orally~Patients will receive study medication until disease progression or unacceptable toxicity"
62853584|NCT05863000||Patients in Region H|The health care system in Region H consists of 10 hospitals, including Region H's Psychiatry which consists of 11 centers. The hospitals annually have around 3 million visits from outpatients
62853585|NCT02756806|EXPERIMENTAL|Picosecond Q-switched Laser|Treatment with investigational wavelengths of the Cutera enlighten laser for tattoo removal.
62853586|NCT00846183|ACTIVE_COMPARATOR|local ingury|In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed.
62853587|NCT00846183|NO_INTERVENTION|control|in 60 patients routine IVF are performed
62853588|NCT02867644|ACTIVE_COMPARATOR|standard care|
62853589|NCT02867644|EXPERIMENTAL|standard care+conversational hypnosis|
62063373|NCT02130453|OTHER|SPECT Cardiac Imaging|After resting strain measurement done, first set of nuclear images taken. Once these images are completed, participant given Regadenoson 0.4 mg by vein over about 10 seconds. Within 2 to 4 minutes of receiving Regadenoson, measurements repeated. These measurements take about 2 minutes to complete. At about 30 minutes after Regadenoson given, participant will have final images for the nuclear portion of the testing.
62063374|NCT01866163|EXPERIMENTAL|LEO 90100|LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
62628173|NCT01952899||Albert Schweitzer Hospital|
62628174|NCT01952899||Erasmus MC Academic Hospital|
62853590|NCT01112449|EXPERIMENTAL|Low dose selenized-yeast|200 µg/day of selenized-yeast (SY)
62628175|NCT01952899||Ikazia Hospital|
62628176|NCT01952899||IJsselland Hospital|
62628177|NCT01952899||Maasstad Hospital|
62628178|NCT01952899||Sint Franciscus Gasthuis Hospital|
62853591|NCT01112449|EXPERIMENTAL|selenomethionine|The second group will receive 200 µg/day of selenomethionine (SM)
62853592|NCT01112449|PLACEBO_COMPARATOR|Placebo|no active medication.
62063375|NCT01866163|PLACEBO_COMPARATOR|Vehicle|Aerosol foam vehicle
62063376|NCT00546325|EXPERIMENTAL|1|Rimonabant
62063377|NCT00546325|PLACEBO_COMPARATOR|2|Placebo
62063378|NCT03971708|OTHER|Ropivacaine|This is the control where patients will receive ropivacaine via the TAP block infusion post-operatively.
62853593|NCT01112449|EXPERIMENTAL|High dose selenized-yeast|The fourth group will receive 285 µg/day of selenized-yeast (SY).
62853594|NCT01802164|EXPERIMENTAL|1|Conventional abdominal wall closure with mesh implantation
62628179|NCT04849117||Systemic analgesia|Patients received only systemic analgesia : Acetaminophen, Ketoprofen, and Nefopam were administered systematically. Morphine was administered if necessary, according to our institutional pain management protocol.
62268368|NCT06126237|EXPERIMENTAL|CM313 + concomitant medication|CM313 injection, subcutaneous
62461498|NCT06030505||Case patients|Collection of medical data in a non-identifying way (demographic data, medical history, clinical data, microbiological data) to meet the objectives of the research.
62628180|NCT04849117||Bilateral TTMP block + systemic analgesia|Patients received the same protocol of systemic analgesia associated with a bilateral TTMP block performed during the first four hours after ICU admission, before tracheal tube removal.
62628181|NCT03464084|OTHER|bright light placebo|
62628182|NCT03464084|OTHER|bright light melatonin|
62628183|NCT03464084|OTHER|dim light|
62063379|NCT03971708|ACTIVE_COMPARATOR|Lidocaine|This is the study arm where patients will receive lidocaine via the TAP block infusion post-operatively.
62063380|NCT05354063|EXPERIMENTAL|Vaccine group 1|20μg dose of SYS6006 vaccine IM, on day 0 and day 21.
62268369|NCT01116908|NO_INTERVENTION|Control|
62461499|NCT06030505||Control patients|Collection of medical data in a non-identifying way (demographic data, medical history, clinical data, microbiological data) to meet the objectives of the research.
62628184|NCT04747249|EXPERIMENTAL|Psychological support|Monthly psychological support
62628185|NCT00753129|ACTIVE_COMPARATOR|1|Start with turning to prone position without head elevation, after 2 hours 30° head elevation, after 2 hours back to PP without head elevation.
62628186|NCT00753129|ACTIVE_COMPARATOR|2|Start with turning to prone position with 30° head elevation, after 2 hours PP without head elevation, after 2 hours back to 0° PP.
62628187|NCT02105194|EXPERIMENTAL|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
62628188|NCT04880668|NO_INTERVENTION|Control - No aerosol box|Participants will perform the AGMP without an aerosol box
62628189|NCT04880668|EXPERIMENTAL|Intervention - Aerosol box|Participants will perform the AGMP with an aerosol box
62063381|NCT05354063|EXPERIMENTAL|Vaccine group 2|30μg dose of SYS6006 vaccine IM, on day 0 and day 21.
62063382|NCT05354063|PLACEBO_COMPARATOR|Placebo|placebo IM, on day 0 and day 21 .
62063383|NCT03347747||Photoaged Male Subjects|45-80 year old males with visible photoaging and the desired exposure profile/driving history and who also has spent (or are spending) at least 30 minutes in a car per day (as the driver), 5 days per week for at least 15 years of their adult life to ensure they have the type of asymmetrical exposure required for hypothesis validation. This is an multi-center trial, and study sites will range from northern to southern latitudes in North America, Australia and potentially other international sites. Study Photography + Personal \& Medical History Collection via a study questionnaire will be obtained.
62063384|NCT03347747||Photoaged Female Subjects|45-80 year old females with visible photoaging and the desired exposure profile/driving history and who also has spent (or are spending) at least 30 minutes in a car per day (as the driver), 5 days per week for at least 15 years of their adult life to ensure they have the type of asymmetrical exposure required for hypothesis validation. This is an multi-center trial, and study sites will range from northern to southern latitudes in North America, Australia and potentially other international sites. Study Photography + Personal \& Medical History Collection via a study questionnaire will be obtained.
62063385|NCT02734680|EXPERIMENTAL|Concurrent chemoradiotherapy(CCRT) Group|Concurrent chemoradiotherapy(CCRT) (Total dose: 46 Gy; Single dose: 2 Gy; Frequency: 23; Gemcitabine(GEM), 300 mg/m2 weekly); Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)
62628190|NCT01380652|EXPERIMENTAL|rehabilitation with vibration training|
62628191|NCT01380652|NO_INTERVENTION|rehabilitation without vibration training|
62628192|NCT06192238||Adrenal Venous Sampling|Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.
62628193|NCT06361186|PLACEBO_COMPARATOR|Placebo|Placebo tablet, qd, oral administration for 28 days
62628194|NCT06361186|EXPERIMENTAL|test drug|Proximod Tablets, 6mg and 12mg, qd, oral administration for 28 days
62628195|NCT01275989|SHAM_COMPARATOR|21|sham acupuncture
62628196|NCT01275989|NO_INTERVENTION|15|Control
62853595|NCT01802164|NO_INTERVENTION|2|Conventional abdominal wall closure without mesh implantation
62268370|NCT01116908|ACTIVE_COMPARATOR|LifeStraw Family|
62268371|NCT01464502|ACTIVE_COMPARATOR|Standard CRT Implant|
62268372|NCT01464502|ACTIVE_COMPARATOR|Pressure-wire guided CRT Implant|
62628197|NCT01275989|ACTIVE_COMPARATOR|20|intervention
62853596|NCT03964428||periodontitis|
62063386|NCT02734680|EXPERIMENTAL|Stereotactic Radiotherapy(SBRT) Group|Stereotactic Radiotherapy(SBRT) (Total dose: 45 Gy; Single dose: 3 Gy; Frequency: 15) Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)
62628198|NCT01816932|EXPERIMENTAL|Home Visit|20 participants will be randomized to receive a home visit for the insertion of their implantable birth control rather than the standard office visit.
62628199|NCT01816932|PLACEBO_COMPARATOR|Office Visit|20 participants will be randomized to receive an office visit (standard of care).
62628200|NCT02589509|EXPERIMENTAL|Direct-Metacognitive|Direct attention training followed by metacognitive strategy training
62628201|NCT02589509|EXPERIMENTAL|Metacognitive-Direct|Metacognitive strategy training followed by direct-attention training
62628202|NCT04221360|EXPERIMENTAL|Group 1|"* Period 1: D390~* Period 2: CKD-375"
62628203|NCT04221360|EXPERIMENTAL|Group 2|"* Period 1: CKD-375~* Period 2: D390"
62628204|NCT06517745||Prone position group|Prone positioning sessions: at least 1 session per day session duration: at least 2 hours
62628205|NCT06517745||Control group|no prone positioning
62628206|NCT02412176|EXPERIMENTAL|Pacing site - right ventricular apex|The intervention will be the implantation of the lead into the right ventricular apex
62063387|NCT03545347|EXPERIMENTAL|Nandrolone Decanoate|Physical therapy with strength training, protein-rich nutritional supplement plus Nandrolone decanoate.
62268373|NCT02243215|EXPERIMENTAL|Offsite training|Access to a portable trainer for laparoscopic skills
62628207|NCT02412176|EXPERIMENTAL|Pacing site - septum|The intervention will be the implantation of the lead into the septum.
62628208|NCT05497765|EXPERIMENTAL|Compound silymarin|Dietary supplement: 4 tablets of compound silymarin twice a day for 12 weeks The active ingredient in each tablet: 81.6 mg of silibinin, mixed power of pueraria, schisandra and salvia miltiorrhiza
62628209|NCT05497765|ACTIVE_COMPARATOR|Silymarin|Dietary supplement: 4 tablets of silymarin twice a day for 12 weeks The active ingredient in each tablet: 81.6 mg of silibinin
62628210|NCT05497765|PLACEBO_COMPARATOR|Placebo|Dietary supplement: 4 tablet of placebo twice a day for 12 weeks Placebo Composition: corn dextrin
62628211|NCT06612489|EXPERIMENTAL|Intervention group|The intervention consist of 26 participants using biofeedback based dynamic-difficulty game for 15 mins each.
62628212|NCT06612489|OTHER|Control group|Twenty six participants in the control group played a serious game with a fixed difficulty level for 15 mins each
62628213|NCT01977768|EXPERIMENTAL|V7: Heat-inactivated M. vaccae pill|Daily pill of V7 together with standard tuberculosis therapy
62628214|NCT01977768|PLACEBO_COMPARATOR|Placebo pill|one pill of placebo pill once per day together with standard of care TB drugs
62853597|NCT03964428||periodontitis with T2DM|
62853598|NCT03964428||control|
62853599|NCT03876392|EXPERIMENTAL|magnetic resonance imaging|Detection of bone marrow metastases with magnetic resonance imaging
62853600|NCT01124864|EXPERIMENTAL|EGFR mutant patients|Patients with EGFR activating mutation tumors (Note: These patients must have progressed on one prior EGFR TKI containing regimen unless they have documented T790M activating mutation). Patients received AUY922 at 70 mg/m\^2 weekly infusions.
62853601|NCT01124864|EXPERIMENTAL|Kras mutant patients|Patients with KRAS mutant tumors. Patients received AUY922 at 70 mg/m\^2 weekly infusions.
62853602|NCT01124864|EXPERIMENTAL|EGFR and Kras wild type patients|Patients exhibiting both mutations were stratified to the KRAS mutation stratum. Patients received AUY922 at 70 mg/m\^2 weekly infusions.
62628215|NCT05297461|EXPERIMENTAL|Medication Review|The intervention group will receive medication review intervention which includes reviewing older adults' medications and identifying any drug-related problems.
62628216|NCT05297461|NO_INTERVENTION|Standard Care|The standard care includes the current existing care provided to patients in the community pharmacy.
62628217|NCT01121939|EXPERIMENTAL|1|combination of bevacizumab, pertuzumab, and sandostatin for patients with advanced neuroendocrine cancers
62628218|NCT05161026|OTHER|Patients with AML|Patients with AML
62628219|NCT05053971|EXPERIMENTAL|Treatment (entinostat, ZEN003694)|"PHASE I RUN-IN PERIOD: Patients receive ZEN003694 PO QD during days -14 to 1. Patients also undergo core needle biopsy within 30 days prior to starting therapy.~PHASE II RUN-IN PERIOD: Patients receive ZEN003694 PO QD or entinostat PO QW during days -14 to 1 based on the order to which they are enrolled to the study (e.g. every other patient starts by taking ZEN003694 alone for 14 days). Patients also undergo core needle biopsy within 30 days prior to starting therapy.~PHASE I \& II COMBINATION TREATMENT: Patients receive entinostat PO QW on days 1, 8, 15, and 22, and ZEN003694 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo core needle biopsy on day 1 of cycle 1, and on day 1 of cycle 14."
62628220|NCT02357056|ACTIVE_COMPARATOR|Wet Lab|Subjects in the wet lab group will perform dissections of the internal thoracic artery and placement of annuloplasty stitches in the mitral valve in pig models until time proficiency is reached based on the performance of our expert robotic surgeons.
62628221|NCT02357056|ACTIVE_COMPARATOR|Dry Lab|Subjects in the dry lab group will perform exercises form the fundamentals of laparoscopic surgery (FLS) program adapted for the daVinci robot. These exercises included, camera and clutching, peg transfer and intracorporeal knot tying. Participants will repeat these tasks until time proficiency is reached based on the performance of our expert robotic surgeons.
62628222|NCT02357056|ACTIVE_COMPARATOR|Virtual Reality|Subjects in the virtual reality group will perform exercises from a 9 task curriculum, on the daVinci Skills Simulator. These exercises included, camera and clutching, energy switching, peg board, energy dissection, matchboard, ringwalk, suture sponge, and vertical defect suturing. Participants will repeat these tasks all metrics are passed and an overall score is reached based on the performance of our expert robotic surgeons.
62628223|NCT02357056|NO_INTERVENTION|Control|The control group will receive no training after they complete the initial assessment and undergo randomization. They will be invited back after several weeks to complete the final assessment to control for any improvement in performance from the initial assessment alone and normal progression through surgical training outside of this project.
62063388|NCT03545347|PLACEBO_COMPARATOR|Placebo (Sodium Chloride)|Physical therapy with strength training, protein-rich nutritional supplement plus placebo.
62628224|NCT05598749|PLACEBO_COMPARATOR|Placebo|
62628225|NCT05598749|EXPERIMENTAL|Verum|
62628226|NCT01462864|ACTIVE_COMPARATOR|Intervention|Lifestyle education intervention
62628227|NCT01462864|NO_INTERVENTION|Control|The control group will receive an information leaflet which is generally distributed in our speciality clinic to patients with diagnosis of PCOS. The leaflet includes general information on PCOS, treatment options and advice on increasing physical activity.
62628228|NCT03126461|EXPERIMENTAL|SAbR plus ipilimumab plus nivolumab|SAbR/GRID plus ipilimumab 3mg/kg IV q3wk x 4 plus nivolumab 1 mg/kg IV q3wk x 4, followed by nivolumab 240 mg IV q 2wk until progression or intolerable toxicity
62628229|NCT00691288|EXPERIMENTAL|1|
62628230|NCT00691288|EXPERIMENTAL|2|
62628231|NCT04262063|EXPERIMENTAL|tell play do technique|Tell play do technique with a dental imitation toy and using euphemisms instead of demonstrating on a model or observing one. Tell play do technique provides a better explanatory concept of the dental procedure and can lead to more cooperation of the children patients which can influence the dental treatment in a good and positive way.
62628232|NCT04262063|ACTIVE_COMPARATOR|tell show do technique|Tell show do is the gold standard of the non-pharmacological behavior management techniques. It is based on the principle of learning theory and it is performed by the dentists themselves . It is the most important behavior modification technique practiced by dentists and it is commonly used for management of children anxiety in the first dental visit .
62628233|NCT00656175|ACTIVE_COMPARATOR|Immediate|Immediate switch of PI or NNRTI to Raltegravir
62628234|NCT00656175|ACTIVE_COMPARATOR|Delayed|Continue current therapy unchanged for 24 weeks, then switch PI or NNRTI to Raltegravir
62628235|NCT05739071|EXPERIMENTAL|Experimental (group 1)|This group will receive two sachets of JING SI HERBAL TEA a day (one in the morning and one in the evening).
62628236|NCT05739071|PLACEBO_COMPARATOR|Control (group 2)|This group will receive two sachets of placebo a day (same way as group 1).
62628237|NCT02943798|EXPERIMENTAL|Group A|Patients will be administered with etoposide plus carboplatin as first-line treatment.
62628238|NCT02943798|EXPERIMENTAL|Group B|Patients will be administered with paclitaxel plus carboplatin as first-line treatment.
62628239|NCT03984214|ACTIVE_COMPARATOR|Dronabinol|BX-1 contains 25 mg dronabinol/ml (2.5% delta-9-trans-tetrahydrocannabinol = THC), oral solution; three applications per day from 2.5 mg (3 x 1 droplet) up to 30 mg (3 x 12 droplets)
62628240|NCT03984214|PLACEBO_COMPARATOR|Placebo|Placebo: oral solution with cannabis flavor without active substance and otherwise identical to active comparator, three applications per day from 3 x 1 droplet up to 3 x 12 droplets
62628241|NCT05482503|EXPERIMENTAL|Atrial Fibrillation|
62628242|NCT05482503|EXPERIMENTAL|Premature beats|
62628243|NCT05482503|EXPERIMENTAL|Sinus Rhythm|
62628244|NCT00964379|ACTIVE_COMPARATOR|intraperitoneal colostomy|
62628245|NCT00964379|ACTIVE_COMPARATOR|extraperitoneal colostomy|
62063389|NCT05984316|EXPERIMENTAL|exercise group|
62063390|NCT02673710||Participants with metastatic colorectal cancer|Participants diagnosed with mCRC treated in first line with a combination of bevacizumab and chemotherapy for whom it is decided to continue the administration of bevacizumab beyond progression while changing CTR will be included in this study
62063391|NCT03354325|ACTIVE_COMPARATOR|Scheduled PCP follow-up|Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician (PCP) within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
62853603|NCT01124864|EXPERIMENTAL|Patients with EML4-ALK translocation|Patients with NSCLC who have tumors with an inversion in the short arm of chromosome 2 that results in the fusion of the echinoderm microtubule-associated protein-like 4 (EML4) gene with the ALK gene leading to the production of an EML4-ALK fusion tyrosine kinase. ALK is a transmembrane protein, which has a kinase domain and is not usually expressed in the lung. EML4 mediate ligand-independent dimerization, and therefore constitutive activity of the ALK tyrosine kinase domain. Patients received AUY922 at 70 mg/m\^2 weekly infusions.
62451307|NCT00027807|EXPERIMENTAL|Aldesleukin, Sargramostim & therapeutic autologous lymphocytes|Peripheral blood mononuclear cells (PBMC) for the generation of ATC will be collected using 1 or 2 phereses to obtain 8-20 × 109 PBMC for T cell expansion. The PBMC will be activated with OKT3 and expanded in IL-2 to generate from 20-320 ×109 ATC during a maximum of 14 days of culture. Three patients will be treated at each dose level. The dose levels for each infusion are: 5, 10, 20, and 40 billion. Each patient will receive a total of 8 doses of armed ATC given twice weekly for 4 weeks. If the patients encounter toxicities related to armed ATC, the dose and administration will be modified as delineated per the protocol. The patients will also receive subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion. GM-CSF (250μg/m2 twice per week) will given subcutaneously to start 3 days before the 1st armed ATC infusion and ending 7 days after the last dose of armed ATC.
62628246|NCT00420628|EXPERIMENTAL|Loteprednol/Tobramycin|0.5% loteprednol etabonate with 0.3% tobramycin opthalmic suspension
62451308|NCT02590861|EXPERIMENTAL|Dental implant|All participants will receive the same intervention, this is a single group study.
62628247|NCT00420628|PLACEBO_COMPARATOR|Vehicle|Vehicle
62628248|NCT01863615|EXPERIMENTAL|A(reference)/B(test)|initial administration of reference and cross-over to test
62628249|NCT01863615|EXPERIMENTAL|B(test)/A(reference)|initial administration of test and cross-over to reference
62628250|NCT04690634|EXPERIMENTAL|PCOS group|obese female patients with Polycystic ovary syndrome. All participants underwent laparoscopic sleeve gastrectomy (LSG)
62628251|NCT04690634|ACTIVE_COMPARATOR|control group|obese female patients without Polycystic ovary syndrome. All participants underwent laparoscopic sleeve gastrectomy (LSG)
62628252|NCT05767593||Depressed Adults|Adults with a current diagnosis of Major Depressive Episode
62451309|NCT01202006|EXPERIMENTAL|Intervention|General practitioners of patients in the intervention group will receive detailed instructions on uptitration of ACE-inhibitors and beta-blockers before the inclusion of participants.
62853604|NCT01124864|EXPERIMENTAL|Modified EGFR mutant patients|The modified EGFR stratum was defined as patients less heavily pretreated who had received one or two lines of prior therapy, with a documented response to a EGFR tyrosine kinase inhibitor (TKI) (complete response (CR), partial response (PR) or stable disease (SD) for ≥ 6 months), unless the patient had de novo resistance to EGFR TKI. Patients received AUY922 at 70 mg/m\^2 weekly infusions.
62853605|NCT02720354|EXPERIMENTAL|A single Intravenous bolus injection|A single Intravenous bolus injection of 11C\[DMDPA\]
62451310|NCT01202006|NO_INTERVENTION|Control|Patients in the control group receive care-as-usual. Their general practitioner will not be trained in applying the uptitration protocol.
62628253|NCT05767593||Healthy Controls|Adults without a current or past diagnosis of Major Depressive Episode
62628254|NCT03430908||Participants with an endotracheal tube|Participants undergoing general anesthesia with an endotracheal tube will have a gastric tube blindly inserted by an anesthesia provider.
62628255|NCT02335879|EXPERIMENTAL|Recombinant Human Follitropin|
62628256|NCT04964336||Multiple sclerosis|Patients with relapsing-remitting multiple sclerosis
62628257|NCT05118997|EXPERIMENTAL|Treatment Arm #1|IRRAflow with manual tPA administration followed by Active Fluid Exchange
62628258|NCT05118997|EXPERIMENTAL|Treatment Arm #2|IRRAflow with continuous infusion of tPA combined with Active Fluid Exchange
62853606|NCT04352972|ACTIVE_COMPARATOR|Hospital-based rehabilitation program|
62853607|NCT04352972|EXPERIMENTAL|Tele-monitored home exercise program|
62853608|NCT06019442|EXPERIMENTAL|Brief alcohol intervention (Health4Her-Automated) + lifestyle health promotion|"The intervention arm will receive:~* brief alcohol intervention~* lifestyle health promotion focused on physical activity and maintaining a healthy weight for reducing breast cancer risk.~Participants will receive an iPad and earphones to self-complete the intervention. Alcohol and lifestyle information will be delivered by way of an animation on an iPad, and self-completed activities to reinforce intervention content."
62853609|NCT06019442|OTHER|Lifestyle health promotion|"The control arm will receive:~* lifestyle health promotion focused on physical activity and maintaining a healthy weight for reducing breast cancer risk.~Participants will receive an iPad and earphones to self-complete the control intervention. Lifestyle information will be delivered by way of an animation on an iPad, and a self-completed activity to reinforce intervention content."
62063392|NCT03354325|EXPERIMENTAL|As needed PCP follow-up|At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician (PCP). Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
62063393|NCT04255342|EXPERIMENTAL|Implant Placement and Temporary Crown using AstraTech Implant System EV, Final Crown Delivery|
62628259|NCT05118997|ACTIVE_COMPARATOR|Treatment Arm #3|Standard EVD with manual tPA administration
62628260|NCT05207202|ACTIVE_COMPARATOR|EIT-PEEP strategy|Patients will receive PEEP titrated by EIT with a stepwise decrease PEEP trial
62853610|NCT01632267||Depression and anxiety|Subjects with a primary diagnosis of depression or anxiety disorder.
62063394|NCT01279330|NO_INTERVENTION|Control|Patients receive by mail the materials needed for stool samples.
62063395|NCT01279330|EXPERIMENTAL|Co-signed Letter|
62628261|NCT05207202|ACTIVE_COMPARATOR|ARDSNet-PEEP strategy|PEEP will be set according to the low FiO2-PEEP table to keep the oxygenation goals: SpO2 between 88% and 95%, and PaO2 between 55mmHg and 80mmHg.
62628262|NCT01691417|EXPERIMENTAL|Pneumatic Sleeves|
62628263|NCT01691417|EXPERIMENTAL|Congestive Heart Failure Patients|
62628264|NCT02090777|OTHER|Health Coach|Health Coach is conducted to see if it improves ophthalmic care for glaucoma patients.
62628265|NCT03970759||Stannous Fluoride Dentifrice|Twice daily brushing
62853611|NCT00183417|EXPERIMENTAL|1|Participants will receive cognitive behavioral therapy
62628266|NCT03970759||Positive Control Dentifrice|Twice daily brushing
62628267|NCT03970759||Negative Control Dentifrice|Twice daily brushing
62063396|NCT06365645|ACTIVE_COMPARATOR|App-based digital parenting education|App-based digital parenting education will be delivered through a smartphone app with similar features as M.Bapp, but the content delivered through this attention-matched control app will not contain any CBT modules or psychoeducation.
62088062|NCT01648218|EXPERIMENTAL|Regular or Aspart insulin|"Drug: Regular human insulin or Insulin Aspart~Other Names:~Humulin R, Novolin R, Novolog, NovoRapid~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before meals; Duration: 2 hours (Aspart) or 6 hours (Regular); for duration subjects are concurrently administered once-daily glucocorticoid."
62268374|NCT02243215|NO_INTERVENTION|Onsite training|Will be able practice on-site at Center of Clinical Education and at their local hospital.
62268375|NCT03030430|EXPERIMENTAL|BAT1706|BAT1706 injection
62268376|NCT03030430|ACTIVE_COMPARATOR|EU-sourced Avastin|EU-sourced Avastin
62628268|NCT01351090|EXPERIMENTAL|Ketorolac tromethamine (5%)|
62628269|NCT01351090|EXPERIMENTAL|Ketorolac tromethamine (15%)|
62628270|NCT01351090|PLACEBO_COMPARATOR|Placebo|
62268377|NCT03030430|ACTIVE_COMPARATOR|US-sourced Avastin|US-sourced Avastin
62268378|NCT05893927|EXPERIMENTAL|Intervention arm|Participants enrolled in the intervention arm will be given a 6-month access period to the diabetes education application designed by the study team. The web site will offer videos related to a specific areas of education concerning diabetes self-management. To encourage compliance, participant users will receive weekly notifications from the application that will guide them through viewing all videos in the series. Participants will continue routine follow-up appointments with their primary care physicians during the study period. There will be no restrictions on starting or stopping medications during the study period.
62451311|NCT05694468|OTHER|Control and Intervention group|In this non-random one-group repeated measures study with a mixed approach (quantitative and qualitative analysis), participants were tested on two occasions 4 weeks apart (baseline measure), and then engaged in the psychomotor relaxation program twice weekly for 8 weeks. Participants were tested again after the intervention program (post-test). The participants took part in a psychomotor relaxation program comprised by two 20-minute sessions per week for 8 weeks, with the whole class, and combined body awareness, muscle tone regulation and breathing exercises.
62451312|NCT03144687|EXPERIMENTAL|Cohort A|Participants with MF who were tolerating a ruxolitinib dose of less than 20 milligrams (mg) daily with no dose increase or no dose modification in the 8 weeks before screening visit received a combination of the itacitinib at the dose of 200 mg, orally, once daily (QD) and ruxolitinib, orally, twice daily (BID) at their previous stable dose (must had been \< 20 mg daily). Participants continued study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or other Protocol-specified criteria to stop treatment are met.
62628271|NCT02259205|EXPERIMENTAL|Enriched Yogurt|150 g yogurt enriched with approximately 0.5 g bioactive lipids extract from olive oil mill provided daily for 8 weeks
62628272|NCT02259205|PLACEBO_COMPARATOR|Plain Yogurt|150 g not enriched yogurt provided daily for 8 weeks
62628273|NCT02259205|NO_INTERVENTION|Control|No yogurt consumption
62628274|NCT06404359|EXPERIMENTAL|Exercise group|The investigators propose a 12-week intervention with therapeutic strength exercise in patients with colorectal cancer who are receiving chemotherapy treatment.
62628275|NCT06404359|ACTIVE_COMPARATOR|Control group|They will be provided with clear and concrete recommendations of activities for the user to perform the rest of the days of the week in order to increase their level of physical activity and increase weekly metabolic expenditure.
62628276|NCT06265337|EXPERIMENTAL|LAC|
62628277|NCT06265337|PLACEBO_COMPARATOR|CTR|
62628278|NCT03837457|EXPERIMENTAL|Cobomarsen|
62628279|NCT05853718|EXPERIMENTAL|TAF antiviral therapy group|Eligible hepatitis B pregnant women are given TAF antiviral therapy (25mg, oral, 1/day) from week 28-32 of gestation until delivery
62653133|NCT05545735|ACTIVE_COMPARATOR|7 Days of Antibiotics Group|Participants will receive 7 days of antibiotic therapy administered as per the standard of care for the treatment of early ventilator associated pneumonia (VAP).
62451313|NCT03144687|EXPERIMENTAL|Cohort B|Participants with MF who progressed after initial reduction in spleen with ruxolitinib treatment, progressed or discontinued for hematologic toxicities received treatment with itacitinib alone at the dose of 600 mg QD. Participants continued study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or other Protocol-specified criteria to stop treatment are met.
62063397|NCT06365645|EXPERIMENTAL|M.Bapp|M.Bapp contains the same app-based digital parenting education provided to the active comparator group as well as 9 additional interactive modules based on the MB cognitive behavioral therapy curriculum. M.Bapp contains interactive features and EMA-based voluntary daily assignments that provide the opportunity to receive additional final reimbursement. Those who complete all modules will receive a digital certificate of completion.
62063398|NCT06624592|ACTIVE_COMPARATOR|Isoflurane group|
62853612|NCT00183417|ACTIVE_COMPARATOR|2|Participants will receive supportive/expressive therapy
62853613|NCT00183417|ACTIVE_COMPARATOR|3|Participants will receive bibliotherapy
62853614|NCT00183417|NO_INTERVENTION|4|Participants in the control condition will receive no treatment
62853615|NCT02998957|EXPERIMENTAL|AcuTENS|"Stimulation using a portable TENS electrostimulation device at Dingchuan point using a biphasic rectangular wave with a frequency of 2Hz and a pulse width of 200 ms. The stimulation will be achieved using the highest intensity tolerated by the patient without pain during 40 minuts.~Once a day during 5 consecutive days."
62853616|NCT02998957|SHAM_COMPARATOR|Sham AcuTENS|"Stimulation using a modified portable TENS electrostimulation device at Dingchuan point with no electrical output, even though the screen will light up and display the same data as in the unmodified device during 40 minuts. Patients in this group will be informed that, due to the frequency of stimulation, it is unlikely that they will feel the electric stimulation.~Once a day during 5 consecutive days."
62063399|NCT06624592|ACTIVE_COMPARATOR|Sevoflurane group|
62063400|NCT02601716|EXPERIMENTAL|Group 1|"Group 1 subjects (n=15) will receive 4 doses of PfSPZ Vaccine (4.5 x 10\^5 PfSPZ/dose) every 2 days, followed by a single, boosting dose (same dose as before) given 16 weeks later, for a total PfSPZ dose = 22.5 x 10\^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by heterologous CHMI (7G8) Pf parasites at 28 and 40 weeks after the first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 4 priming immunizations and the boost scheduled for Group 1. Participants not protected after the first CHMI will be invited to receive a booster vaccination (4.5 x 10\^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week 40)."
62063401|NCT02601716|EXPERIMENTAL|Group 2|"Subjects (n=15) will receive 3 doses of PfSPZ Vaccine (9.0 x 10\^5 PfSPZ/dose) every 8 weeks, total PfSPZ dose = 27 x 10\^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by heterologous CHMI (7G8) Pf parasites at 28 and 40 weeks after first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 2. Participants not protected after the first CHMI will be invited to receive a booster vaccination (9.0 x 10\^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week 40)."
62088063|NCT01648218|EXPERIMENTAL|Insulin glargine|"Drug: Insulin glargine~Other Names:~Lantus~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 24 hours; for duration subjects are concurrently administered once-daily glucocorticoid."
62088064|NCT01241136|PLACEBO_COMPARATOR|Open traditional pilonidal cystectomy|traditional complete wide-excision pilonidal cystectomy
62451314|NCT02167295||Focus group|The focus groups will consist of 6 to 8 persons each (N = 32). The focus group discussions will last for about 60 to 90 minutes. The discussion topics will be based on previous literature and experience and will include reasons for betel quid chewing or for quitting, pros and cons of betel quid chewing, barriers to and facilitators of abstinence, health beliefs and experiences about betel quid chewing and other issues.
62628280|NCT01830933|EXPERIMENTAL|BreastCARE Intervention|"Intervention Clinic Patients: The RA will welcome the patient upon arrival at the clinic and again explain study procedures and field any questions. The RA will have the patient sign the HIPAA authorization form and then demonstrate how to enter information and answer questions on the tablet-PC and the patient will indicate their consent electronically before beginning the assessment.~Intervention Patient Report. Once the patient completes the BreastCare Computer survey, the program will immediately generate a personal feedback report containing information about her risk factors and recommendations to reduce her risk. This report will be printed and given to the patietns before she meets with her doctor."
62628281|NCT01830933|NO_INTERVENTION|BreastCARE Comparison|"Patients will be randomized into the intervention or comparison groups at the time of recruitment. Block-randomization will be used to assign patients to intervention or comparison groups.~Comparison Clinic Patients. Contact and baseline interview procedures will be the same for patients from the comparison clinics, however there will be no computer assessment at the time of their clinic visit. An RA will meet the patient 10 minutes prior to her appointment time to obtain written HIPAA authorization."
62853617|NCT04347668|ACTIVE_COMPARATOR|Usual Care|All residents are seen by a RN, with care by Registered Practical Nurse (RPN) and Personal Support Worker (PSW) staff 24/7. Residents supported by behavior support Ontario staff; include Behavior responsive team. Residents prior to admission have been assessed by the Geriatric program. Residents may receive psychotropic or cognitive enhancement medications. The residents are seen routinely seen once a week by the physician. Their Dementia is monitored weekly but the physician as well as daily by the registered staff. Quarterly or more frequently cognitive assessments are completed and referrals made to appropriate specialists. A day would include meals, engagement in scheduled and non-scheduled programs such as exercise, and activities, groups. Residents are supported in their activities of daily living, and social engagement. Specific interventions based on resident needs are supported in a Dementia capable environment.
62853618|NCT04347668|EXPERIMENTAL|Virtual Reality|"Virtual Reality (VR) is a scenario that simulates experiences. The immersive environment is similar to the real world, creating an experience. A person using virtual reality equipment is able to look around the artificial world, move around in it, and interact with virtual features or items. VR requires the user to use a multi-projected in their own room using BroomX to generate realistic images, sounds that simulate a user's physical presence in a virtual or imaginary environment. A library has been developed, set to music, as well, we will use library items already part of the BroomX. We will attempt to use BroomX in their own room or in a suitable room within the LTC home. The participants still get the immersive experience, and the projection device has automatic controls that conform the visuals to a 360 experience no matter what size the room is, or what chairs, window blinds, are in the room."
62853619|NCT01057641|EXPERIMENTAL|Spacer|"Implantation of a percutaneously implanted interspinous device (spacer)"
62853620|NCT01057641|OTHER|physiotherapy|The control group will receive at least physiotherapy and physical therapy (e.g. massage and fango). Under inpatient conditions therapy will last for seven days. After discharge physical therapy has to be continued for 5 weeks. A schedule will ensure the consistency of the physical therapy. The inpatient-treatment can be repeated every 6 months if necessary.
62853621|NCT02200198|ACTIVE_COMPARATOR|Inspiratory group|Inspiratory muscle training
62853622|NCT02200198|SHAM_COMPARATOR|Sham group|Sham training
62853623|NCT02200198|EXPERIMENTAL|Expiratory group|Expiratory muscle training
62853624|NCT01337037||standard VATS group|patients undergo standard VATS lobectomy using non-modified equipments,without limits of staples
62853625|NCT01337037||modified equipments group|patients undergo VATS lobectomy with modified VATS lobectomy equipments designed designed according to the experience of chinese lobectomy surgery: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.).
62853626|NCT01337037||less staples group|patients undergo VATS lobectomy with at most 4 staples used.
62853627|NCT01337037||open group|patients undergo lobectomy by thoracotomy approach
62088065|NCT01241136|EXPERIMENTAL|Minimal invasive pilonidal cystotomy|Using only Keyes Trephines to unroof and curette the pilonidal cyst cavity
62628282|NCT05038449|EXPERIMENTAL|Colchicine group|"The colchicine treatment includes an initial dose of 1 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 6 days and 0.5 mg every 24 hours until the completion of 10 days of total treatment.~+ standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)."
62853628|NCT00777153|EXPERIMENTAL|Cediranib 30mg|Cediranib 30mg
62853629|NCT00777153|OTHER|Cediranib 20mg + lomustine|Cediranib 20mg + lomustine
62853630|NCT00777153|ACTIVE_COMPARATOR|Lomustine and Placebo Cediranib|Lomustine and Placebo Cediranib
62853631|NCT05316935|EXPERIMENTAL|Non-obese EEC group (G)|20 non-obese EEC patients will be randomized to GnRHa + Letrozole group.Then every 12 weeks, an hysteroscope will be used to evaluate the endometrial condition, and the pathological findings will be recorded.
62853632|NCT05316935|EXPERIMENTAL|Non-obese EEC group (D)|20 non-obese EEC patients will be randomized to Diane-35 + metformin group.Then every 12 weeks, an hysteroscope will be used to evaluate the endometrial condition, and the pathological findings will be recorded.
62853633|NCT05316935|EXPERIMENTAL|Non-obese EAH group (G)|20 non-obese EAH patients will be randomized to GnRHa + Letrozole group.Then every 12 weeks, an hysteroscope will be used to evaluate the endometrial condition, and the pathological findings will be recorded.
62853634|NCT05316935|EXPERIMENTAL|Non-obese EAH group (D)|20 non-obese EAH patients will be randomized to Diane-35 + metformin group.Then every 12 weeks, an hysteroscope will be used to evaluate the endometrial condition, and the pathological findings will be recorded.
62088066|NCT06171048|EXPERIMENTAL|Group A|CM310 injection, Subcutaneous
62088067|NCT06171048|EXPERIMENTAL|Group B|CM310 injection, Subcutaneous
62628283|NCT05038449|PLACEBO_COMPARATOR|Standard therapy group|Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition).
62628284|NCT06361888|EXPERIMENTAL|Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine|
62088068|NCT01793246||pCLE for Discrete lung lesions|Patients undergoing bronchoscopy for the diagnosis of a lesion with probe based laser endomicroscopy (pCLE) imaging before biopsy
62088069|NCT01793246||pCLE for acute lung transplant rejection|Patients undergoing bronchoscopy for the detection of acute rejection of lung transplant with probe based laser endomicroscopy (pCLE) imaging before biopsy
62628285|NCT06361888|ACTIVE_COMPARATOR|Nab-paclitaxel Plus Gemcitabine|
62628286|NCT06361888|OTHER|Surufatinib with Nab-paclitaxel, and Gemcitabine|
62268379|NCT05893927|NO_INTERVENTION|Control arm|Participants in the control arm will not have access to the Diabetes Application. They will continue follow-up appointments according to the standard of care with their primary care physician, diabetic educators, etc. There are no restrictions on starting or stopping medications for patients within the control arm.
62268380|NCT04042779|ACTIVE_COMPARATOR|model-based WM training|In order to build the model-based WM training, existing tasks used to assess the different component of the Baddeley's model will be reviewed on their findings according to test-retest reliability and construct validity. For each component - phonological loop, visuospatial sketchpad, episodic buffer and central executive - the task with the highest reliability and validity will be chosen and then build the basis for the computerized training program. This procedure results in a model-based, adaptive, computerized training program for WM.
62628287|NCT05341791|NO_INTERVENTION|Standard administration of information notice|: During the standard study information administration, the participant will read though the written information notice which will be organized in sections. After each section, the study staff will explain to the participant the key information to understand. Throughout the process, participants will be allowed to ask study staff questions. We anticipate the time to administer consent by this standard approach will be approximately 45 to 60 minutes per participants.
62088070|NCT06492538||laser peripheral iridotomy/iridoplasty group|"based on angle closure mechanism, procedures were chosen LPI alone or combined with ALPIp.~LPI: laser peripheral iridotomy; ALPIp: argon laser peripheral iridoplasty."
62268381|NCT04042779|ACTIVE_COMPARATOR|single-task WM training|"The basis for the single-task training administered to the second group will be the widely used dual-n-back training paradigm suggested by Jaeggi et al. (2008). A complex dual n-back task including a visual and an auditory WM task will be implemented for tablet devices."
62268382|NCT04042779|ACTIVE_COMPARATOR|multiple-task WM training|Verbal WM tasks - particularly letter span and digit span tasks - and a visuospatial WM task are most commonly used (e.g. Dahlin et al., 2008; Klingberg et al., 2005; Westerberg et al., 2007). Therefore, a multiple-task training including these tasks will be administered to the third group.
62628288|NCT05341791|EXPERIMENTAL|video administration of information notice|The video will be 20-minutes long, and will consist of graphic depictions (in cartoon style) of the study information content presented in the same flow as the written notice, and explained by a voice-over in the background. The participant will view the video in a quiet room, on a tablet provided by the study staff. The participant will be able to pause the video or rewind it as needed, and view it at his/her desired pace. The video will have an embedded knowledge check at the end of each section, consisting of a background voice asking some questions, pausing (for the participant to think through the correct answers) and then providing the right answers.
62628289|NCT04232345|EXPERIMENTAL|Cohort 1 (Part 1): AZD4831 Dose 1|Randomized subjects will receive oral suspension of AZD4831 Dose 1 once daily in the morning for a period of 10 days
62628290|NCT04232345|EXPERIMENTAL|Cohort 2 (Part 1): AZD4831 Dose 2|Randomized subjects will receive oral suspension of AZD4831 Dose 2 once daily in the morning for a period of 10 days.
62628291|NCT04232345|EXPERIMENTAL|Cohort 3 (Part 1): AZD4831 Dose 3|Randomized subjects will receive oral suspension of AZD4831 Dose 3 once daily in the morning for a period of 10 days.
62628292|NCT04232345|EXPERIMENTAL|Cohort 4 (Part 2): AZD4831 Dose 2|Randomized subjects will receive oral suspension of AZD4831 Dose 2 once daily in the morning for a period of 10 days.
62628293|NCT04232345|EXPERIMENTAL|Placebo (Part 1)|Randomized subjects will receive oral suspension of placebo once daily in the morning for a period of 10 days.
62628294|NCT04232345|EXPERIMENTAL|Placebo (Part 2)|Randomized subjects will receive oral suspension of placebo once daily in the morning for a period of 10 days.
62628295|NCT00004067|ACTIVE_COMPARATOR|Arm 1: adriamycin + cyclophosphamide then taxol|
62628296|NCT00004067|EXPERIMENTAL|Arm 2: adriamycin + cyclophosphamide then taxol + herceptin|
62628297|NCT03943355||Nonoperative management protocol with angioembolization|The nonoperative management (NOM) protocol with angioembolization (AE) presents a trend in dealing with trauma patients with blunt splenic injury (BSI). This study was designed to explore the adverse events and associated risk factors before and after protocol-based NOM of BSI over a 12-year period.
62268383|NCT04042779|SHAM_COMPARATOR|sham intervention|Active control group that as well performs a training, however not based on WM. To exclude the involvement of WM, a motor training will be administered to the control group.
62628298|NCT03911076|EXPERIMENTAL|PVX-2|Prime: 3 mg pNGVL4a-Sig/E7(detox)/HSP70 DNA Boost: 0.1 mg TA-CIN protein
62628299|NCT03911076|PLACEBO_COMPARATOR|Placebo|Prime: PBS (Phosphate Buffered Saline) Boost: PGC (Phosphate Glycine Cysteine Buffer)
62628300|NCT05718674||ECP patient|Patients with chronic or acute GvHD after allogeneic haematopoietic stem cell transplantation undergoing extracorporeal photopheresis
62628301|NCT00578279|OTHER|A|subject randomized to 10ml of dehydrated alcohol
62628302|NCT00578279|EXPERIMENTAL|B|subject randomized to 20ml of dehydrated alcohol
62628303|NCT04626609||EoE group|Patients with confirmed eosinophilic esophagitis
62628304|NCT04626609||GERD group|Patients with gastro-esophageal reﬂux disease
62628305|NCT04626609||Control group|Individuals with no esophageal disease
62088071|NCT06492538||peripheral iridectomy based surgery combo|SPI combined with GSL or GSL+GT SPI: surgical peripheral iridectomy GSL:goniosynechialysis GT: goniotomy GSL and GT are both guided by surgical goniolens
62653134|NCT02641834|EXPERIMENTAL|Veg Group|Group that starts with the Vegetarian diet
62653135|NCT02641834|ACTIVE_COMPARATOR|Med group|Group that starts with the Mediterranean diet
62653136|NCT03583281|ACTIVE_COMPARATOR|Flax oil|Participants will consume capsules containing flax oil (4 grams alpha-linolenic acid \[ALA\] per day) for 4 weeks
62063402|NCT02601716|EXPERIMENTAL|Group 3|"Group 3 subjects (n=15) will receive 3 doses of PfSPZ Vaccine (18 x 10\^5 PfSPZ/dose) every 8 weeks for a total PfSPZ dose of 54 x 10\^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by CHMI with heterologous (7G8, NF135.C10) Pf parasites at 40 and 66 weeks after the first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 3. All participants will be invited to receive a booster vaccination (18 x 10\^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week66)."
62088072|NCT06492538||phacoemulsification and intraocular lens implantation based surgery combo|PEI: phacoemulsification and intraocular lens implantation surgery combo includes GSL alone or GSL+GT.
62628306|NCT06010602|ACTIVE_COMPARATOR|Quadratus lumborum block group|the patient In the lateral decubitus position, a subcostal area and above the iliac crest in the mid-axillary line, a convex ultrasound probe is placed under sterile conditions. Using an in-plane technique, the quadratus lumborum and psoas major muscles, as well as the transverse process of the L4 vertebra, are visualized. 22G, 100 mm peripheral block needle is used to perform the block. The needle is directed between the quadratus lumborum muscle and the psoas major muscle in the subfascial plane, following hydrodissection for proper needle placement. Then, 20 mL of 0.25% bupivacaine is injected slowly, aspirating every 5 cc to ensure proper spread. The injection is performed under ultrasound guidance, visualizing the local anesthetic pushing the fascia. The same procedure will be repeated for the other side.
62853635|NCT03817086|EXPERIMENTAL|Hand coordination and mental practice|In a total of 12 training sessions (days), 3 sessions per week over 4 weeks, participants practice physical in-phase and out-of-phase movement of both limbs for 40 minutes. Every 10 minutes, participants get a 2 minutes break during which the participants are asked to mentally imagine doing the task with an action observation of perfect performance.
62853636|NCT03817086|ACTIVE_COMPARATOR|Hand coordination and action observation|In a total of 12 training sessions (days), 3 sessions per week over 4 weeks, participants practice physical in-phase and out-of-phase movement of both limbs for 40 minutes. Every 10 minutes, participants get a 2 minutes break during which the participants are asked to observe a visual feedback of performance.
62853637|NCT05420909||Cohort 1|Participants diagnosed with metastatic colorectal cancer (mCRC) selected from the Flatiron Electronic Health Record database
62853638|NCT03449524|ACTIVE_COMPARATOR|75mg CXA-10|Once daily dosing of 75mg CXA-10 in the morning
62653137|NCT03583281|ACTIVE_COMPARATOR|Fish oil|Participants will consume capsules containing DHA-enriched fish oil (4 grams DHA per day + 0.8 grams EPA per day) for 4 weeks
62653138|NCT05043935|EXPERIMENTAL|L-PRF with antimicrobial photodynamic therapy|Application of L-PRF with antimicrobial photodynamic therapy in the defect
62653139|NCT05043935|ACTIVE_COMPARATOR|antimicrobial photodynamic therapy|Application antimicrobial photodynamic therapy in the defect
62653140|NCT02759640|EXPERIMENTAL|HS-10241|HS-10241 is administered orally starting at 100 mg/day.
62853639|NCT03449524|ACTIVE_COMPARATOR|150mg CXA-10|Once daily dosing of 150mg CXA-10 in the morning
62853640|NCT03449524|PLACEBO_COMPARATOR|Placebo|Once daily dosing in the morning
62853641|NCT01569217||respiratory muscle dysfunction patients|Neuromuscular patients
62853642|NCT01569217||diaphragmatic dysfunction|patients who present orthopnea, recruitment of accessory muscles, abdominal paradox, respiratory dysfunction or dyssynchronous movement
62628307|NCT06010602|ACTIVE_COMPARATOR|İlioinguinal-İliohipogastric nerve block group|the patient in the supine position, a linear ultrasound probe is placed over the spina iliaca anterior superior (SIAS) line, drawn from SIAS to the umbilicus. The probe is used to visualize the abdominal wall muscles, focusing on the fascial plane between the transversus abdominis and internal oblique muscles, where a flattened football-like appearance is seen. The iliohypogastric nerve is observed more laterally, and the ilioinguinal nerve is seen more medially. Using an in-plane technique with 22G, 100 mm peripheral block needle, local anesthetic is injected near the SIAS, between the transversus abdominis and internal oblique muscles. Again, 20 mL of 0.25% bupivacaine is injected slowly, aspirating every 5 cc, and the injection is visualized under ultrasound guidance, ensuring proper fascial spread. The same procedure will be repeated for the other side.
62628308|NCT01360008||Cryo ablation|Patients with first Ablation of atrial fibrillation treated by cryo ablation
62628309|NCT01360008||RF ablation|Patients with first Ablation of atrial fibrillation treated by Radio frequency ablation
62853643|NCT02473146|EXPERIMENTAL|Mylotarg Arm|"After randomization patients in the experimental arm are assigned to receive chemotherapy with:~Gemtuzumab Ozogamicin 3 mg/m2 (maximum dose: 5 mg) per IV, 60mn on Day 1 and 4 Cytarabine 200 mg/m2 per CIV over 24h on Day 1 to 7"
62063403|NCT02601716|EXPERIMENTAL|Group 4|"Subjects (n=15) will receive a single, priming dose of PfSPZ Vaccine (27 x 10\^5 PfSPZ/dose), followed by 2 additional immunizations (9.0 x 10\^5 PfSPZ per dose) every 8 weeks, total PfSPZ dose = 45 x 10\^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by CHMI with heterologous 7G8 and NF135.C10 Pf parasites at 40 and 66 weeks, respectively, along with 8 infectivity controls at each CHMI. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 4. All participants will be invited to receive a booster vaccination (9.0x10\^5 PfSPZ) 21 days prior to the second CHMI.~Subjects will be followed for 56 days beyond the final CHMI at (post-immunization week 66)."
62853644|NCT02473146|NO_INTERVENTION|Control Arm|After randomization patients in the control arm are assigned to receive chemotherapy with Idarubicin 12mg/m2 per IV, 30mn on Day 1,2,3 Cytarabine 200 mg/m2 per CIV over 24h on Day 1 to 7
62853645|NCT05213819|OTHER|Carpal tunnel syndrome|Patients with carpal tunnel syndrome were treated with phonophoresis, low level laser therapy and exercise.
62268384|NCT05480748||Group 1: 19>BMI<25 AND BMI>40|51 patients with BMI\>40 kg/m2 (morbidly obesity) and 51 patients with 19\<BMI\<25 kg/m2 (normal BMI), 18-75 aged, American Society of Anesthesiologists (ASA) physical status I-III scheduled for an elective surgical procedure requiring general anesthesia with endotracheal intubation.
62268385|NCT05480748||Normal body mass index and morbidly obese groups|51 patients with BMI\>40 kg/m2 (morbidly obesity) and 51 patients with 19\<BMI\<25 kg/m2 (normal BMI), 18-75 aged, American Society of Anesthesiologists (ASA) physical status I-III scheduled for an elective surgical procedure requiring general anesthesia with endotracheal intubation.
62268386|NCT01032811||Study Participants|St. Jude Children's Research Hospital patients from Leukemia, Neuro-Oncology, Radiation Oncology, and After Completion of Therapy (ACT) clinics.
62268387|NCT04160130|EXPERIMENTAL|SAPIEN 3 or SAPIEN 3 Ultra|Edwards SAPIEN 3 THV system Model 9600 TFX (20, 23, 26 and 29 mm) or SAPIEN 3 Ultra THV system Model 9750 TFX (20, 23, 26) with the associated transfemoral delivery systems.
62268388|NCT04160130|ACTIVE_COMPARATOR|any surgical bioprosthetic aortic valve|Any commercially available surgical bioprosthetic valve
62268389|NCT05197192|EXPERIMENTAL|GAVe-Arm|Acalabrutinib plus Venetoclax plus Obinutuzumab plus (GAVe)
62268390|NCT05197192|EXPERIMENTAL|GVe-Arm|Obinutuzumab plus Venetoclax (GVe)
62268391|NCT06359509|EXPERIMENTAL|SYS6020|Low, medium and high doses of SYS6020 will be given.
62268392|NCT01150539|EXPERIMENTAL|Overweight/obese women with PCOS|10 overweight/obese women with polycystic ovary syndrome
62628310|NCT05582629|EXPERIMENTAL|Arm 1|JT001 (VV116) Day 1: 0.6g, Q12H X 2 times Day 2-5: 0.3g, Q12H X 8 times Oral tablet
62628311|NCT05582629|PLACEBO_COMPARATOR|Arm 2|Placebo Day 1: 6 tablets, Q12H X 2 times Day 2-5: 3 tablets, Q12H X 8 times Oral tablet
62853646|NCT04516785||Intervention|FIT and urine VOC samples followed by colonoscopy
62853647|NCT04377113||RCC patients|"RCC patients (30 pts) will include patients with kidney cancer (renal cell cancer).~Investigators will collect and analyze:~* blood sample,~* urine sample,~* kidney tissue sample (healthy tissue, carcinomatous tissue and borderline tissue between them)."
62853648|NCT04377113||Healthy patients|"In this group (30 patients) will be recruiting healthy patients (volunteer).~Investigators will collect and analyze:~* blood sample."
62853649|NCT00665808||A|
62853650|NCT00665808||B|
62853651|NCT03085914|EXPERIMENTAL|Treatment Group A|Epacadostat + pembrolizumab + mFOLFOX6 (oxaliplatin, leucovorin, 5-fluorouracil)
62853652|NCT03085914|EXPERIMENTAL|Treatment Group B|Epacadostat + pembrolizumab + gemcitabine and nab-paclitaxel
62853653|NCT03085914|EXPERIMENTAL|Treatment Group C|Epacadostat + pembrolizumab + carboplatin and paclitaxel
62853654|NCT03085914|EXPERIMENTAL|Treatment Group D|Epacadostat + pembrolizumab + pemetrexed and investigators choice of platinum agent
62628312|NCT01973426||Children with limited control of their thumb|Children afflicted by hemiplegic stroke or hemiplegic cerebral palsy who have lost the ability to actively (and accurately) control the thumb.
62628313|NCT03864991|NO_INTERVENTION|Routine Care|This group will be followed up for routine care, maintaining a standard log book for documenting blood sugar and insulin dosages per advice and explanation by doctors, nurses and nutritionists.
62628314|NCT03864991|ACTIVE_COMPARATOR|e-device for step count (fit-bit)|This group will receive e-device for step count (fit-bit) in addition to routine care.
62628315|NCT03864991|ACTIVE_COMPARATOR|e-messages for log book|This group will receive daily e-messages for maintaining log book in addition to routine care.
62628316|NCT03864991|ACTIVE_COMPARATOR|e-messages for log book & fit-bit|This group will receive e-device for step count (fit-bit), daily e-messages for maintaining log book for blood sugar, insulin dosages and step count in addition to routine care.
62628317|NCT03234803|EXPERIMENTAL|poly-amide|poly-amide is a thermoplastic material recently introduced to be used as a complete denture material, that provide excellent aesthetics and flexibility.
62628318|NCT03234803|ACTIVE_COMPARATOR|poly-methyl methacrylate|poly-methyl methacrylate has been commonly used as a material for constructing complete dentures and proved to have high success rate and considered to be gold standard.
62628319|NCT02446548|EXPERIMENTAL|aliskiren - placebo - losartan|aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
62628320|NCT02446548|EXPERIMENTAL|losartan - placebo - aliskiren|aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
62628321|NCT03883763|EXPERIMENTAL|Hyperbaric Novabupi® 0.5% (bupivacaine S75:R25 + 8% glucose)|
62628322|NCT03883763|ACTIVE_COMPARATOR|Hyperbaric Neocaine® 0.5% (bupivacaine S50:R50 + 8% glucose)|
62063404|NCT02601716|OTHER|Infectivity Controls, CHMI (7G8)|Infectivity controls (n=24) will not receive any PfSPZ Vaccine. They will serve as infectivity controls for CHMI for all groups. 8 infectivity controls will undergo CHMI with each of two CHMIs (at 28 and 40) for Groups 1 and 2, and 8 infectivity controls will undergo CHMI with the 40 week CHMI for Groups 3 and 4. All CHMI will be conducted by exposure to the bites of 5 mosquitoes infected with heterologous (7G8) Pf parasites. Subjects will be followed for 56 days beyond the last CHMI at week 40 at the UMB site.
62268393|NCT00199862|EXPERIMENTAL|Radio-labeled huA33 Antibody|"Patients will receive a single I-V infusion of 4mCi-10mCi/10mg 124I-huA33 in 5-30 mL of 5% human serum albumin (HAS) in normal saline, over 5 minutes-4 hours. Patients will be studied with 124I-huA33 positron-emission tomography (PET) and ex-vivo quantitation of tumor uptake .~Blood samples will be obtained for pharmacokinetic analysis at 5, 15, 60, and 120 minutes after completion of IV, on and before or after PET scanning on subsequent days.~Surgery (or biopsy) will be scheduled to occur 8- 10 days after administration of 124I-huA33. The 8-10 day imaging session will be scheduled for the morning of surgery or biopsy, approximately 1-6 hours before the procedure."
62628323|NCT04719598|EXPERIMENTAL|intervention group is ( internet - based group) who will receive CBT sessions|study group ( group A)
62628324|NCT04719598|NO_INTERVENTION|control group ( group B)|researchers just answer their questions
62628325|NCT03060369||Established Shock (Cohort A)|"Meeting criteria i or ii, AND iii:~i. SBP ≤ 90mm Hg for greater than 30 minutes ii. Requirement for vasopressor or ionotrope to maintain SBP \> 90mm Hg iii. New dysfunction of at least one organ, including altered mental status, acute renal failure (increase from baseline in serum creatinine \>0.3 mg/dL or by 50%), oliguria (\<0.5 mL/kg/h for \>6h) , or hepatic injury (ALT, AST, or total bilirubin \>2xULN)suspected by the treating physician to be caused by organ hypoperfusion"
62853655|NCT03085914|EXPERIMENTAL|Treatment Group E|Epacadostat + pembrolizumab + cyclophosphamide
62853656|NCT03085914|EXPERIMENTAL|Treatment Group F|Epacadostat + pembrolizumab + gemcitabine and investigators choice of platinum agent
62853657|NCT03085914|EXPERIMENTAL|Treatment Group G|Epacadostat + pembrolizumab + investigators choice of platinum agent and 5-fluorouracil
62853658|NCT03725228|ACTIVE_COMPARATOR|Magnesium Sulfate|Continuous intravenous infusion of 15mg/kg/h of magnesium sulfate, starting just after spinal anesthesia infusion until the end of surgery
62628326|NCT03060369||Emerging Shock (Cohort B)|"Meeting criteria i or ii, AND iii:~i. New SBP ≤ 90mm Hg for greater than 30 minutes or recurrent shorter episodes, requiring use of or clinical anticipation of the need for fluid resuscitation or vasopressor/inotropic support to maintain SBP \> 90 mm Hg ii. New dysfunction of at least one organ (as defined above), including altered mental status, acute renal failure, oliguria, or hepatic injury not explained by a specific non-hemodynamic cause iii. Does not meet criteria for Established Shock"
62628327|NCT01049191||Fracture|Subjects experiencing a prior osteoporotic fracture.
62628328|NCT01049191||Control|These will be age and bone density matched controls to the fracture group.
62628329|NCT04391842|EXPERIMENTAL|Experimental: SAM ultrasound and diclofenac patch|Patients receive treatment from the SAM Ultrasonic Diathermy Device for 4 hours every day for 7 days combined with 1% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
62853659|NCT03725228|EXPERIMENTAL|Lidocaine|Continuous intravenous infusion of 1.5mg/kg/h of lidocaine, starting just after spinal anesthesia infusion until the end of surgery
62628330|NCT06267820|ACTIVE_COMPARATOR|TAP block with bupivacaine and ketorolac|Ultrasound guided TAP block with bupivacaine 0.25% (0.5 ml/kg) and ketorolac (0.5 mg/kg).
62628331|NCT06267820|ACTIVE_COMPARATOR|TAP block with bupivacaine|ultrasound guided TAP block with bupivacaine 0.25% (0.5 ml/kg).
62628332|NCT04961697|EXPERIMENTAL|PICU with diaries|"The main family member of a critically ill child will receive a diary upon PICU admission.~Except for the diaries intervention, this group of patients will be submitted to usual PICU routine care."
62628333|NCT04961697|NO_INTERVENTION|PICU without diaries|This group of critically ill patients and family members will not receive diaries, but will also be submitted to usual PICU routine care.
62628334|NCT02731274|EXPERIMENTAL|Motor memory consolidation|Subjects were divided in two groups: a control group and an experimental one. Before the intervention of physical exercise program, subjects performed a Tapping Pedal Test to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
62628335|NCT02731274|NO_INTERVENTION|Control|
62628336|NCT06054763|EXPERIMENTAL|Buyang Huanwu Decoction group|Oral administration of Buyang Huanwu Decoction (3 grams), two times in a day after breakfast and dinner, for 12 consecutive weeks
62628337|NCT06054763|PLACEBO_COMPARATOR|Placebo group|the same method as the treatment group, but taking Buyang Huanwu Decoction placebo (90% starch and 10% Buyang Huanwu Decoction)
62628338|NCT05883163|EXPERIMENTAL|Stimulation Group|The intervention group will receive non-invasive stimulation of the phrenic nerve for activation of the diaphragm.
62268394|NCT00882609|ACTIVE_COMPARATOR|TC-MDP Bone Scan|Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA \>10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan
62268395|NCT00882609|EXPERIMENTAL|F18-Fluoride PET/CT|Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA \>10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan
62628339|NCT05883163|NO_INTERVENTION|Control Group|The control group will not received intervention and will be treated with standard of care.
62628340|NCT02778152|EXPERIMENTAL|Laser depilation|Laser depilation to the natal cleft (pilonidal region) monthly for 5 treatments with either an 810nm of Nd:YAG laser dependent on Fitzpatrick skin type and tolerability.
62628341|NCT01923675|EXPERIMENTAL|color blocking tint|Spectacles with red-blocking tint subjects will wear glasses daily for 6 months and have
62628342|NCT01923675|OTHER|holographic diffuser|Spectacles with color neutral tint subjects will wear glasses daily for 6 months and have
62628343|NCT01923675|OTHER|diffuser & color blocking tint|Spectacles with holographic diffuser and red-blocking tint subjects will wear glasses daily for 6 months and have
62628344|NCT01923675|OTHER|holographic diffuser and neutral tint|Spectacles with holographic diffuser and color neutral tint subjects will wear glasses daily for 6 months and have
62628345|NCT05708040|ACTIVE_COMPARATOR|Closed loop system|Minimed 780G (Medtronic)
62628346|NCT05708040|EXPERIMENTAL|SmartPen|InPen (Medtronic)
62628347|NCT04245917||MNGIE Patients|Patients with mitochondrial neurogastrointestinal encephalomyopathy
62628348|NCT00527137|ACTIVE_COMPARATOR|rHuEPO|
62628349|NCT00527137|EXPERIMENTAL|darbepoetin alfa|
62628350|NCT03193229|EXPERIMENTAL|MapTrek|Patients in the intervention group receive a Fitbit and MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required prior to enrollment). Each week, patients are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. MapTrek also supports Street View on Google Maps, so patients can explore what they would see if they were in that location. Throughout each race, patients will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
62628351|NCT03193229|ACTIVE_COMPARATOR|Fitbit Only|Patients randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to MapTrek or simply by giving the patients a Fitbit.
62268396|NCT03733223||experimental group|The patients who were treated with Ateptidase had intracranial haemorrhage adverse reactions
62268397|NCT03733223||control group|The patients who were treated with Ateptidase did not have intracranial haemorrhage adverse reactions.
62628352|NCT01792765|NO_INTERVENTION|Control Arm|This arm will undergo ureteroscopy using conventional fluoroscopy to guide the procedure and visualize scope position, safety wire status, etc.
62628353|NCT01792765|EXPERIMENTAL|Ultrasound guidance|This arm will have intraoperative ultrasound guidance to determine safety wire position and for scope guidance.
62628354|NCT05084105||Cannabis Group|A total of 30 older (age 50-80 years) men and women who are using cannabis.
62628355|NCT05084105||Control Group|A total of 30 older (age 50-80 years) men and women who are not using cannabis.
62628356|NCT04219592||SSc|74 SSc patients aged 18 - 85
62628357|NCT04219592||Healthy controls|80 Healthy blood-donors aged 18 - 85
62628358|NCT01559610|NO_INTERVENTION|Control Group|Received preoperative guidance by a member of healthcare team with the aid of checklist
62628359|NCT01559610|OTHER|Group intervention|preoperative guideline by a nurse
62628360|NCT00426764|EXPERIMENTAL|Romidepsin|Participants received romidepsin 14 mg/m\^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.
62451315|NCT02167295||In-depth interviews.|We will conduct 15 one-to-one interviews, each lasts for about 45 to 60 minutes. Participants will be interviewed by a trained interviewer using a structured interview. The interview will be designed to collect information on socio-demographic background, current and/or former betel quid use, other substance use (smoking and/or alcohol consumption), as well as other variables including usage parameters, psychosocial and environmental influences on betel quid chewing, barriers to and interest in quitting, and knowledge of adverse effects on health.
62628361|NCT05139420|EXPERIMENTAL|lifestyle intervention plus phentermine-topiramate|Participants will be enrolled in a weight loss program based on lifestyle changes and the use of phentermine-topiramate to aid with weight loss
62628362|NCT05139420|EXPERIMENTAL|lifestyle intervention|Participants will be enrolled in a weight loss program based on lifestyle changes. They will be given a 6-month subscription to a calorie-reduced meal replacement program that also offers lifestyle coaching.
62628363|NCT06587633|EXPERIMENTAL|Endoscopic procedure|
62853660|NCT06275542|EXPERIMENTAL|Clinical extubation strategy without TOF monitoring|Extubation without TOF monitoring strategy: the administration of neostigmine reversal with a dose based on the degree of blockade without TOF monitoring, and extubation is performed at least 15 minutes after reversal if the patient can maintain SpO2 \> 95% for 3 minutes after receiving room air without oxygen supplementation.
62853661|NCT06275542|ACTIVE_COMPARATOR|Clinical extubation strategy with TOF monitoring|Extubation with quantitative TOF monitoring strategy: neostigmine reversal dosing is determined based on the degree of blockade observed through quantitative TOF monitoring, and extubation is performed when the measured TOF ratio is ≥ 0.90.
62853662|NCT01361204|EXPERIMENTAL|Theanine|Experimental Comparator, theanine Taking 4 tablets of theanine two times daily for 16 days Placebo Comparator, sucrose Taking 4 tablets of sucrose two times daily for 16 days
62853663|NCT04090372|ACTIVE_COMPARATOR|Control group|Control group will be assessed by standard preop planning using implants templates.
62853664|NCT04090372|ACTIVE_COMPARATOR|TraumaCad Group|TraumaCad Group will be assessed by preop planning using Traumacad
62853665|NCT06335745|EXPERIMENTAL|Arm 1: PediCARE + Usual Supportive Care Experimental|"Participants will be randomized in a 1:1 ratio and stratified according to treatment group and household material hardship (HMH) severity group and participant parents/guardians will complete:~* Remote baseline visit with introduction to PediCARE intervention by central study team~* Parent completion of baseline survey.~* Receipt of monthly PediCARE resource provisions x 6-months.~* Parent completion of 3-month follow-up survey.~* Parent completion of 6-month follow up survey and end of intervention period."
62853666|NCT06335745|NO_INTERVENTION|Arm 2: Usual Supportive Care Arm|"Participants will be randomized in a 1:1 ratio and stratified according to treatment group and HMH severity group and participant parent/guardians will complete:~* Remote baseline visit~* Parent completion of baseline survey.~* Receipt of site-specific routine supportive care x6-month study period~* Parent completion of 3-month follow-up survey~* Parent completion of 6-month follow-up survey"
62853667|NCT03053206|EXPERIMENTAL|ADE arm|"ADE arm~Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days"
62853668|NCT04475042|ACTIVE_COMPARATOR|Group A|Dapagliflozin - washout period - placebo
62853669|NCT04475042|ACTIVE_COMPARATOR|Group B|Placebo - washout period - Dapagliflozin
62628364|NCT01670383||Postresuscitation group|Adults (age over 16 years old) who have survived from nontraumatic cardiac arrest and admitted to ICU.
62853670|NCT01081418|EXPERIMENTAL|Standard care|Standard care comprised a treatment network consisting of open and closed inpatient wards, day-clinics, an outpatient centre, and eight private psychiatrists. Each patient was treated by a private psychiatrist or by a psychiatrist in the outpatient centre. Home visits were possible, but office visits were the general rule. Patients were allowed to use all treatment offers in the outpatient centre. Outside office hours, patients could refer themselves to the psychiatric hospital. Psychosocial treatments as supportive therapy, psychoeducation, psychotherapy, and family intervention were provided infrequently and in a less intensive and unsystematic way, and only in the minority of cases. This 'standard of care' definition is in accordance with other studies.
62853671|NCT03255083|EXPERIMENTAL|DS-1205c with osimertinib|Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 800 mg, 1200 mg) in combination with daily 80 mg oral dose of osimertinib
62853672|NCT04797624||Baseline group|The baseline group included the patients diagnosed with gastric cancer between January 1, 2019, and December 31, 2019, in the pandemic group at the Adana City Training and Research Hospital, Department of General Surgery, Divisions of Gastroenterological Surgery and Surgical Oncology. Gastric cancer surgery for adequate patients.
62853673|NCT04797624||Pandemic group|The pandemic group included the patients diagnosed with gastric cancer during the period between March 1, 2020, and December 31, 2020, in the pandemic group at the Adana City Training and Research Hospital, Department of General Surgery, Divisions of Gastroenterological Surgery and Surgical Oncology. Gastric cancer surgery for adequate patients.
62853674|NCT01131819|OTHER|1|The novel intervention we propose to use, the Wii Fit, will be introduced for a period of at least 20 minutes but not greater than 30 minutes per day to all the subjects in the study.
62853675|NCT03471624|EXPERIMENTAL|Tenofovir Alafenamide for 24 months|Participants on any antiviral treatment for chronic HBV who plan to be switched by their physician to be treated with TAF 25 mg for 24 months.
62628365|NCT01670383||Sepsis group|Adults (age over 16 years old) who satisfy the sepsis criteria (SIRS\>=2 and infection is suspected for a cause) and admitted to the ICU.
62628366|NCT03509181|EXPERIMENTAL|CBM|Cognitive Bias Modification for Interpretation delivered via smartphone
62628367|NCT03509181|ACTIVE_COMPARATOR|Symptom Tracking|Weekly symptom monitoring smartphone app with anxiety and depression symptom scores
62628368|NCT04482907|ACTIVE_COMPARATOR|Group receiving dill|They took 3 meals a day, 3x300 mg dry dill powder by mouth. They bought dry dill powder for 90 days.
62628369|NCT04482907|PLACEBO_COMPARATOR|Group receiving placebo|They took 3 meals a day and 3 cellulose placebo capsules by mouth. They took placebo capsules for 90 days.
62628370|NCT00878800|EXPERIMENTAL|Experimental: PXD101 and doxorubicin (BelDox)|5-day PXD101 IV schedule with dose escalation combined with 1 day doxorubicin dose escalation IV
62268398|NCT01710449|EXPERIMENTAL|Normal|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using either a disposable Mouthpiece without Bite blocks or Disposable oral-nasal (full Face) Non Invasive Ventilation with no Anti Asphyxia Vents no vent CAPA/NPPV Face mask and a standard Douglas Bag system.
62628371|NCT05640063|EXPERIMENTAL|Intervention Arm|Provision of Enhanced Delivery and Newborn Kits (CMWs and LHW program will continue to function as usual)
62628372|NCT05640063|NO_INTERVENTION|Control Arm|Standard Delivery Kits alone (CMWs and LHW program will continue to function as usual)
62628373|NCT06101147|EXPERIMENTAL|Vitamin D group|
62628374|NCT06101147|PLACEBO_COMPARATOR|Placebo group|
62628375|NCT02991248|EXPERIMENTAL|robotic training & stimulation|Device: robotic treadmill training paired with active spinal cord electrical stimulation, three times a week for 6 weeks.
62628376|NCT02991248|ACTIVE_COMPARATOR|robotic training & sham|Device: robotic training paired with sham spinal cord stimulation, three time a week for 6 weeks.
62628377|NCT02991248|PLACEBO_COMPARATOR|treadmill only|Device: treadmill Conventional treadmill training only, three time a week for 6 weeks.
62268399|NCT01710449|EXPERIMENTAL|Lung Disease|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using either a disposable Mouthpiece without Bite blocks or Disposable oral-nasal (full Face) Non Invasive Ventilation with no Anti Asphyxia Vents no vent CAPA/NPPV Face mask and a standard Douglas Bag system.
62268400|NCT02730884|EXPERIMENTAL|Rigosertib|Participants receive oral Rigosertib under fasting conditions twice a day on a continuous basis. Quality of life questionnaire completed on Day 1 of Cycle 1.
62628378|NCT02732288|EXPERIMENTAL|Melatonin, brain injured patients|Melatonin 3mg, orally, at 8pm, daily for 3 months
62628379|NCT02732288|EXPERIMENTAL|Healthy volunteers|Melatonin 3mg, orally, at 8pm
62853676|NCT02664623|EXPERIMENTAL|Dietary advice sheet|"Patients in this arm will receive a dietary advice sheet at the beginning of the study.~Intervention: Dietary advice sheet"
62853677|NCT02664623|EXPERIMENTAL|Dietary advice sheet + consults with dietician|"In addition to receiving a dietary advice sheet at the beginning of the study, patients randomized to this arm will have individual consultations with a dietician at inclusion, month 1 and month 3.~Intervention: Dietary advice sheet Intervention: Individual dietary consultations"
62853678|NCT05942781|EXPERIMENTAL|Vestibular activation training|A cross-over design will be used with group one receiving the training intervention for 7 days, a 6-day washout period, and a 7-day no-training period. Group two will follow the reverse sequence.
62268401|NCT01219010|EXPERIMENTAL|001|Siltuximab 15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
62628380|NCT01383018||AMS penile prosthesis receipients|Men for whom an AMS penile prosthesis is recommended
62628381|NCT04611022|EXPERIMENTAL|Patients Eligible for HPV Vaccine|
62853679|NCT05942781|NO_INTERVENTION|No training|
62628382|NCT01535313|ACTIVE_COMPARATOR|Manual (Hospital Systems TRAP Needle)|Bone marrow biopsy with a standard manual system
62628383|NCT01535313|EXPERIMENTAL|Powered|
62853680|NCT00003472|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62268402|NCT01661140|EXPERIMENTAL|Methotrexate (MTX) Tapering Dosage|At Week 0 participants will start open-label tocilizumab and open-label MTX for 24 weeks. At Week 24, participants achieving a good/moderate European League Against Rheumatism (EULAR) disease response will be randomized to the MTX Tapering group or MTX Maintenance group. In this arm participants will receive a double-blind MTX dose according to the MTX tapering scheme between Week 24 and Week 56. Participants will also continue to receive open-label tocilizumab between Week 24 and Week 56. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.
62628384|NCT01229215|EXPERIMENTAL|FCFD4514S|
62628385|NCT01229215|SHAM_COMPARATOR|sham|
62628386|NCT05695729|EXPERIMENTAL|PLYOMETRIC EXERCISE PROGRAM GROUP|"The Plyometric exercise group will receive 8 weeks of upper body plyometric exercise protocol. The session will last for 60 minutes 3 times per week.~Exercises will be done according to FIIT protocol."
62628387|NCT05695729|ACTIVE_COMPARATOR|CONVENTIONAL EXERCISE PROGRAM GROUP|"The conventional group will receive 8 weeks of upper body strength exercise protocol. The session will last for 60 minutes 3 times per week.~Exercises will be done according to FIIT protocol."
62628388|NCT01488552|EXPERIMENTAL|Gemcitabine & Abraxane Pancreatic Cancer|Gemcitabine+Nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin and Folfiri
62628389|NCT04686708||Pre-pandemic period|Patients managed in the pre-pandemic period
62628390|NCT04686708||Pandemic period|Patients managed in the pandemic period
62628391|NCT02954549|ACTIVE_COMPARATOR|Healthy control group|Subjects in this arm have a normal serum level of 25(OH)D, \>30 ng/mL. Subjects submit to blood draws and biometric tests (DXA, body composition, BP) and questionnaires on 3 occasions. They do not receive vitamin D3 supplementation.
62628392|NCT02954549|EXPERIMENTAL|Low dose supplementation group|Subjects in this group have been identified as having a level of 25(OH)D of \< 30 ng/mL and are randomized to receive vitamin D3 supplementation of 2000 IU daily for 3 months.
62628393|NCT02954549|EXPERIMENTAL|High dose supplementation group|Subjects in this group have been identified as having a level of 25(OH)D of \<30 ng/mL and are randomized to receive vitamin D3 supplementation of 5000 IU daily for 3 months.
62628394|NCT00679822||Heart Failure|Heart Failure Out Patients at OSU
62628395|NCT04162795|EXPERIMENTAL|Loratadine chewable tablet|Participants received one dose of loratadine chewable tablet to chew completely before swallowing.
62628396|NCT02403583|OTHER|Intervention- Home visits|Participants randomized to intervention arm receive 3 home visits conducted by one female and one male lay health worker.
62628397|NCT02403583|NO_INTERVENTION|Standard Care|Participants will receive current standard clinic-based services including the option for women and partners to return to the clinic for male partner HIV testing or CHCT.
62628398|NCT04079686|EXPERIMENTAL|Cephazolin|Patients will receive antibiotics (1g cephazolin) intravenously at the anesthestic induction and every 6 hours for 24 hours
62628399|NCT04079686|PLACEBO_COMPARATOR|Sterile saline|Patients will receive antibiotics (cephazolin) only at the anesthesia induction, and sterile saline intravenously every 6 hours for 24 hours
62628400|NCT02377609||Kidney or Liver Transplant Patients|adult kidney or liver Advagraf® (tacrolimus) recipients
62628401|NCT03697941||Surgical cut-down and arterial puncture under direct vision|
62628402|NCT03697941||Percutaneous arteriotomy closed with closure device|
62628403|NCT03559751|EXPERIMENTAL|VLN Cigarettes (A)|Subjects will smoke VLN cigarettes
62268403|NCT01661140|ACTIVE_COMPARATOR|Methotrexate (MTX) Maintenance Dosage|At Week 0 participants will start open-label tocilizumab and open-label MTX for 24 weeks. At Week 24, participants achieving a good/moderate European League Against Rheumatism (EULAR) disease response will be randomized to the MTX Tapering group or MTX Maintenance group. In this arm participants will continue to be administered a stable dose of MTX in a double-blind fashion between Week 24 and Week 56. Participants will also continue to receive open-label tocilizumab between Week 24 and Week 56. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.
62628404|NCT03559751|EXPERIMENTAL|Usual Brand Cigarettes (B)|Subjects will smoke their usual brand cigarettes
62628405|NCT03559751|EXPERIMENTAL|Nicotine Gum (C)|Subjects will chew nicotine gum
62628406|NCT00767221|EXPERIMENTAL|A|The patient is his own control. Endpoint variables are measured before, during and after treatment.
62628407|NCT02710487|EXPERIMENTAL|REM Sleep Awakening (REMSA)|The investigators will actively awaken each subject from nocturnal REM sleep in a sleep laboratory setting, in the hour preceding her/his habitual wake time.
62628408|NCT02710487|EXPERIMENTAL|NREM Sleep Awakening (NREMSA)|Awakening from the NREM sleep stage N2 will be the control intervention.
62628409|NCT04526600|NO_INTERVENTION|No fidget|
62628410|NCT04526600|EXPERIMENTAL|With fidget|The participant is given a specially designed fidget ball
62628411|NCT02197585|EXPERIMENTAL|Glue|Mesh fixation with glue
62628412|NCT02197585|ACTIVE_COMPARATOR|Suture|Mesh fixation with suture
62063405|NCT02601716|OTHER|Infectivity Controls, CHMI (NF135.C10)|Infectivity controls (n=8) will not receive any PfSPZ Vaccine. They will serve as infectivity controls for the second CHMI at week 66 for Groups 3 and 4. CHMI will be conducted by exposure to the bites of 3-5 mosquitoes infected with heterologous (NF135.C10) Pf parasites. Subjects will be followed for 56 days beyond the last CHMI at week 66 at the NMRC site.
62628413|NCT01455584|EXPERIMENTAL|HM781-36B|HM781-36B
62628414|NCT03885323|EXPERIMENTAL|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with RF-utilizing powered toothbrush
62628415|NCT03885323|PLACEBO_COMPARATOR|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
62628416|NCT03782181|ACTIVE_COMPARATOR|Whole body vibration plat|An arm type in which a group of patients with fibromyalgia receives an intervention based on the use of a whole body vibration platform, considered to be effective by clinical evidence.
62628417|NCT03782181|NO_INTERVENTION|Control group|No intervention arm
62628418|NCT04332926|ACTIVE_COMPARATOR|Own Brand Cigarette|
62628419|NCT04332926|EXPERIMENTAL|ECIG 30 Watts, 0 mg/ml nicotine|
62628420|NCT04332926|EXPERIMENTAL|ECIG 30 Watts, 8 mg/ml nicotine|
62628421|NCT04332926|EXPERIMENTAL|ECIG 30 Watts, 15 mg/ml nicotine|
62628422|NCT04332926|EXPERIMENTAL|ECIG 30 Watts, 30 mg/ml nicotine|
62628423|NCT03241329||Case : endometriosis|Infertile patients with endometriosis that is the only cause of their infertility
62628424|NCT03241329||Control : tubal factor|infertile patients with tubal factor that is the only cause of their infertility
62628425|NCT05816668|EXPERIMENTAL|Tranexamic Acid Group|Patients will receive an attack solution of 1,0 g of tranexamic acid 20 minutes before the surgery beginning, followed by a maintence dose of 1,0 mg/kg/h in pump surgery infusion
62628426|NCT05816668|PLACEBO_COMPARATOR|Placebo Group|Patients undergoinf to videolaparoscopic surgery will receive physcological saline as placebo under the same conditions of the tranexamic acid group.
62628427|NCT03583879|EXPERIMENTAL|Exoskeleton exercise|8-week exercise program using the exoskeleton
62628428|NCT03583879|ACTIVE_COMPARATOR|Standard exercise|8-week exercise program not using the exoskeleton
62628429|NCT03583879|PLACEBO_COMPARATOR|No exercise|8-weeks of no treatment (wait-list control)
62628430|NCT04819789|EXPERIMENTAL|Fermotein™ dry|Fermotein™ powder presented in the form of a porridge.
62628431|NCT04819789|EXPERIMENTAL|Fermotein™ wet|Fermotein™ wet presented in the form of a porridge.
62628432|NCT04819789|EXPERIMENTAL|Fermotein™ modified wet|Fermotein™ modified wet presented in the form of a porridge.
62628433|NCT04819789|ACTIVE_COMPARATOR|Mycoprotein|This mycoprotein product presented in the form of a porridge.
62063406|NCT03437590|EXPERIMENTAL|Part 1: JNJ-55308942 and [18F]-JNJ-64413739|Participants will first undergo a baseline positron emission tomography (PET)/ magnetic resonance (MR) scan with \[18F\]-JNJ-64413739 on Day 1. In Period 1 (on Day 2) and Period 2 (on Day 1), participants will receive oral dose of JNJ-55308942 (maximum dose 120 milligram \[mg\]). After approximately 4 hours of JNJ-55308942 dosing, participants will receive an intravenous (IV) injection of \[18F\]-JNJ-64413739, followed by a PET/MR scan. Doses will be selected based on the principal investigator's discretion. A wash-out period of at least 7 days will be maintained between the 2 doses of JNJ-55308942.
62268404|NCT05044676||patients with hepatocellular carcinoma|Patients with an indication for treatment with Atezolizumab / Bevacizumab for the management of an advanced disciplinary hepatocellular carcinoma in a multidisciplinary consultation meeting.
62628434|NCT04294199|ACTIVE_COMPARATOR|Immobilization|Patients in this group will be given a knee immobilizer to wear for 2 weeks and then receive outpatient physical therapy evaluation and treatment
62853681|NCT02886403|EXPERIMENTAL|Cohort 02|"This is a sub-study testing how the adhesion of two adhesives is influenced by exposure to real output.~There are two visits:~The first visit:~Two adhesive strips (standard adhesive strip) are applied to the peristomal skin and one of these strips is exposed to real output (contained in a sleeve) and the other strip is not.~The second visit:~Two adhesive strips (new adhesive strip) are applied to the peristomal skin and one of these strips is exposed to real output (contained in a sleeve) and the other strip is not."
62853682|NCT05002244|EXPERIMENTAL|Arm A|CTL0801 (Azilsartan) QD, 4days → CTL0801 (Azilsartan) + CTL0802 (Rosuvasatin) QD, 7days
62853683|NCT05002244|EXPERIMENTAL|Arm B|CTL0802 (Rosuvasatin) QD, 7days → CTL0801 (Azilsartan) + CTL0802 (Rosuvasatin) QD, 7days
62063407|NCT03437590|EXPERIMENTAL|Part 2: JNJ-55308942 and [18F]-JNJ-64413739|Participants will first undergo a baseline PET/MR scan with \[18F\]-JNJ-64413739 on Day 1. Participants will receive oral dose of JNJ-55308942 (maximum dose 120 mg) on Day 2, followed by two post-treatment scans, one obtained at Tmax (4 hours postdose) and one at 24 hours postdose. Doses will be selected based on the principal investigator's discretion.
62063408|NCT04122391||control|team will work in OR with volume of 85 dB
62063409|NCT04122391||intervention|team will work in OR with volume of 100 dB
62063410|NCT00987064|ACTIVE_COMPARATOR|Temperature controlled Laminar Airflow|Active treatment with Temperature controlled Laminar Airflow (TLA)
62063411|NCT00987064|PLACEBO_COMPARATOR|Placebo TLA|Placebo treatment with TLA (no filtration function)
62063412|NCT04525547||Ofev treatment|Korean patients diagnosed with idiopathic pulmonary fibrosis, systemic sclerosis associated interstitial lung disease or chronic fibrosing interstitial lung diseases with a progressive phenotype receiving Ofev (nintedanib 150milligrams (mg)/100mg twice a day (BID))
62063413|NCT03529448|EXPERIMENTAL|TN-TC11G, radiotherapy and Temozolomide Oral Product|"During Phase Ib, Four to seven weeks after surgical diagnosis, concurrent with radiotherapy (STUPP)~+ temozolomide (75mg/m2/day for 42 days) +TN-TC11G will be evaluated. During radiation therapy, temozolomide and TN-TC11G will be administered. This last, as the dose that have been selected previously, based on dose-titration period. Patient specific dose will remain until progresion of disease, unacceptable toxicity, non-compliance, consent withdrawal up to 2 years."
62853684|NCT04628455|OTHER|Inversion and Snaring|needlescopic inversion, snaring, and excision of the hernia sac using two Suture Grasper Sevice of Mediflex Company and a home made snare
62853685|NCT00580775||Placebo|Observing heart rate variability in placebo and active estrogen preparations
62853686|NCT00580775||Active estogen|Observing heart rate variability in placebo and active estrogen preparations
62853687|NCT05825157|ACTIVE_COMPARATOR|VLNT|Standard of care vascularized lymph node transfer
62853688|NCT05825157|EXPERIMENTAL|VLNT with Biobridge|Standard of care vascularized lymph node transfer plus BioBridge placement
62853689|NCT01368640||healthy adults|The study will cover 130 healthy adults. 65 men and 65 women in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
62853690|NCT05250544|EXPERIMENTAL|Stress ball group|For the adolescents in the stress ball group; Before the procedure, the adolescent's fear (with Childeren's Fear Scala (CFS)) will be evaluated and recorded by the adolescent, parent and observer. Then, the stress ball will be introduced to the adolescents and they will be asked to hold it in their desired hands. After explaining how to squeeze the stress ball, the PCR Test will start a few seconds after the adolescent starts to squeeze. As soon as the process starts, the stopwatch will be started, and when the process is finished, it will be stopped. When the PCR Test starts, the crying state of the adolescent will be observed and recorded. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
62063414|NCT05715359||Reconstruction of jaws.|Patients treated with free tissue transfer reconstruction of the jaws.
62268405|NCT04369365|ACTIVE_COMPARATOR|Arm A: Azithromycin|weekly oral azithromycin 1500mg for a maximum of 8 weeks
62268406|NCT04369365|PLACEBO_COMPARATOR|Arm B: Placebo|weekly oral placebo for a maximum of 8 weeks
62628435|NCT04294199|EXPERIMENTAL|Early range of motion|Patients in this group will be allowed to move the knee and start outpatient physical therapy and treatment immediately.
62628436|NCT05621447|EXPERIMENTAL|TAS-303, [14C]TAS-303|
62268407|NCT03428893|EXPERIMENTAL|Mobile Application Group|The mobile app group will receive physical therapy as determined by the physical therapist and agree to receive the home exercise prescription using a mobile app on their phone or personal tablet
62268408|NCT03428893|NO_INTERVENTION|Control|The control group will receive physical therapy as determined by the physical therapist based on clinical practice guidelines and will receive the home exercise program in the traditional way through paper exercise handouts
62268409|NCT04772261|EXPERIMENTAL|Lot-to-Lot Variability|Participants will be administered up to six different 13C-Spirulina test meal lots
62268410|NCT04772261|EXPERIMENTAL|Biological Variability|Participants will be administered the same 13C-Spirulina test meal lot on two different occasions
62628437|NCT03246022||Group l|SBP index was less than 30% of AHI
62628438|NCT03246022||Group 2|SBP index was less than 60% but more than 30%
62628439|NCT03103256|EXPERIMENTAL|YHP1701|PO, Once daily (QD), 8 weeks
62628440|NCT03103256|ACTIVE_COMPARATOR|YHR1703|PO, Once daily (QD), 8 weeks
62628441|NCT03103256|ACTIVE_COMPARATOR|YHR1704|PO, Once daily (QD), 8 weeks
62063415|NCT02760056|ACTIVE_COMPARATOR|Liothyronine (cytomel)|Subjects will be divided into 4 groups. The first group will take 25 mcg twice daily for one week. The second group will take 37.5 mcg twice daily for one week. The third group will take 50 mcg twice daily for one week. The firth group will take 75 mcg twice daily for one week
62268411|NCT05378438|EXPERIMENTAL|Intervention Arm|Participants allocated in this arm will be approached for a workshop related to microbe literacy. Using a microscope, live demonstration of the biological samples brought by the participants will be carried out by the team of researchers. Participants will be assisted to place biological materials under the microscope, manipulate the slides and discover the profusion of microbial life from the immediate environment. The session will be followed by question and answer round related to concurrent hygiene practices and basic sanitation to prevent infections including vaccines.
62628442|NCT01954238|ACTIVE_COMPARATOR|Rivaroxaban|Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease
62628443|NCT01954238|PLACEBO_COMPARATOR|Placebo|GCC-4401C matching placebo capsule
62628444|NCT01954238|EXPERIMENTAL|GCC-4401C|Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease. It is a novel molecule with a structural similarity to Rivaroxaban.
62628445|NCT01188668|EXPERIMENTAL|Aripiprazole + Desvenlafaxine SR|
62628446|NCT06153615|EXPERIMENTAL|Idiopathic Hypersomnia|
62628447|NCT06153615|ACTIVE_COMPARATOR|Narcolepsy type 1|
62628448|NCT06153615|ACTIVE_COMPARATOR|Healthy subject|
62628449|NCT02183012|EXPERIMENTAL|A: Ibuprofen extrudate, fed state|
62853691|NCT05250544|EXPERIMENTAL|Breathin exercise group|For the adolescents in the breathing exercise group; Before the procedure, the adolescent's fear (with Child's Fear Scala (CFS)) will be evaluated and recorded by the adolescent, parent and observer. Then, the breathing exercise will be introduced and applied to the adolescents. After explaining how to do the breathing exercise, the adolescent will be expected to complete the exercises. The PCR Test process will begin immediately after the exercise is complete. As soon as the process starts, the stopwatch will be started and will be stopped when the process is finished. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
62853692|NCT03213171|NO_INTERVENTION|Usual care|Usual care / Standard of care No intervention implemented
62853693|NCT03213171|EXPERIMENTAL|Intervention|Reception staff providing handout; Mobile tablet that provides the immediate opportunity for patients to register in the waiting room
62853694|NCT04150367||Study group|Patients with first diagnosed widespread destructive pulmonary tuberculosis with bacterial excretion, who receive intravenous treatment with Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment. Then group receives oral treatment of tuberculosis according to the known scheme.
62853695|NCT04150367||Control group|Patients with first diagnosed widespread destructive pulmonary tuberculosis with bacterial excretion, who receive oral forms of Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment. Then group receives oral treatment of tuberculosis according to the known scheme.
62853696|NCT01457352|EXPERIMENTAL|SPARC0921|
62063416|NCT02760056|PLACEBO_COMPARATOR|Placebo|Subject will take matching placebo twice a day for one week
62628450|NCT02183012|EXPERIMENTAL|B: Ibuprofen extrudate, fasted state|
62628451|NCT02183012|ACTIVE_COMPARATOR|C: Ibuprofen lysinate tablet, fed state|
62853697|NCT01457352|PLACEBO_COMPARATOR|Placebo0921|
62063417|NCT06445075|EXPERIMENTAL|Cohort 1|Apitegromab + incretin mimetic
62628452|NCT02183012|ACTIVE_COMPARATOR|D: Ibuprofen lysinate tablet, fasted state|
62628453|NCT02183012|ACTIVE_COMPARATOR|E: Ibuprofen tablet, fed state|
62628454|NCT02183012|ACTIVE_COMPARATOR|F: Ibuprofen tablet, fasted state|
62628455|NCT05339815||36 mm CoCrMo glenospheres|
62628456|NCT05339815||40 mm cross-linked UHMWPE glenospheres|
62628457|NCT04090346|EXPERIMENTAL|Clostridium difficile infection|Clostridium difficile infection (CDI) is due to a toxin-producing bacteria that causes a more severe form of antibiotic associated diarrhea. The disease ranges from mild diarrhea to severe colon inflammation that can even be fatal.
62628458|NCT03126786|ACTIVE_COMPARATOR|Active|Treatment will consist of IVT injection of Aflibercept followed by an SC injection of CLS-TA
62628459|NCT03126786|SHAM_COMPARATOR|Control|Treatment will consist of IVT aflibercept injection followed by a sham SC procedure
62628460|NCT05495386|EXPERIMENTAL|Hyposafe H02 Device|Hyposafe H02 Device will be used in the study
62063418|NCT06445075|PLACEBO_COMPARATOR|Cohort 2|Placebo + incretin mimetic
62063419|NCT05590546||Obese|No intervention, only performing cross-sectional analysis of pooled data collected in previous studies
62063420|NCT05590546||Control|No intervention, only performing cross-sectional analysis of pooled data collected in previous studies
62063421|NCT04534114|PLACEBO_COMPARATOR|Pooled Placebo|Participants received subcutaneous treatment with matching placebo.
62628461|NCT00537290|EXPERIMENTAL|Rituximab|All patients will receive 1000 milligrams of rituximab by intravenous infusion on Days 1 and 15.
62628462|NCT00547248|EXPERIMENTAL|Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group|Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.
62063422|NCT04534114|EXPERIMENTAL|40 mg BAY2976217|Participants received subcutaneous treatment with 40 mg BAY2976217.
62063423|NCT04534114|EXPERIMENTAL|80 mg BAY2976217|Participants received subcutaneous treatment with 80 mg BAY2976217.
62063424|NCT04534114|EXPERIMENTAL|120 mg BAY2976217|Participants received subcutaneous treatment with 120 mg BAY2976217.
62628463|NCT00547248|ACTIVE_COMPARATOR|Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group|Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.
62628464|NCT00547248|EXPERIMENTAL|Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group|Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.
62628465|NCT00547248|ACTIVE_COMPARATOR|Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group|Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix and Poliorix™ at 12-18 months of age.
62628466|NCT03205475|ACTIVE_COMPARATOR|A. Above Fidelity Phase 1 and Above Fidelity Phase 2|Alternating coaching and streamed or video feedback each week through phase 1, moves to video feedback only for phase 2.
62628467|NCT03205475|ACTIVE_COMPARATOR|B. Below Fidelity Phase 1 and Above Fidelity Phase 2|Receive weekly coaching in phase 1, move to video feedback only in phase 2
62628468|NCT03205475|ACTIVE_COMPARATOR|C. Above Fidelity Phase 1, Below in Phase 2- Add Refresher|Alternating coaching and streamed or video feedback each week through phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive a one week intensive in person refresher and then continue with weekly coaching and video feedback from the Senior Trainer (Enhanced Feedback plus intensive refresher course) for the final 12 weeks.
62853698|NCT00386542|EXPERIMENTAL|ID-JI-0.1|"Group ID-JI-0.1 (n = 16) - reduced 0.1 mL INF doses administered intradermally (ID) by needle-free jet injector (JI) (Biojector® 2000 subcutaneous syringe no. 2 \[green color code\], with 2 cm investigational spacer, Bioject Medical Technologies, Inc., Portland, OR, USA)"
62853699|NCT00386542|ACTIVE_COMPARATOR|IM-NS-0.1|"Group IM-NS-0.1 (n = 16) - reduced 0.1 mL INF doses administered intramuscularly (IM) needle-syringe (NS) (via 22-25 gauge needle, minimum 25 mm/1-inch length)"
62853700|NCT00386542|ACTIVE_COMPARATOR|IM-NS-0.25 control|"Group IM-NS-0.25 (controls) (n = 16) - full 0.25 mL INF doses administered intramuscularly (IM) by needle-syringe (NS) (22-25 gauge needle, minimum 25 mm/1-inch length)"
62853701|NCT03512457|EXPERIMENTAL|Intensive Intervention|Participants receive brochure, card advising how to make an appointment with dermatology, and reminder in one week to perform SSE.
62853702|NCT03512457|ACTIVE_COMPARATOR|Minimal Intervention|Participants receive brochure, card advising how to make an appointment with dermatology, and reminder in one week to perform SSE.
62853703|NCT03977311|EXPERIMENTAL|MR-HIFU|-The study team will determine the tumor volume to be treated per standard-of-care diagnostic MRI or CT imaging. An array of scans will be used to align the participant with the HIFU system, optimize heat delivery to the patients, and/or monitor aspects related to the participant such as motion. Vendor-provided software will be used with the participant in each position to create a customized treatment plan for heat delivery. The HIFU device will then be used to apply clinical levels (41-42°C) of heat to the tumor volume. Regions will be heated to the 41-42°C for up to 60 minutes in one session (either before or after radiation) on one day per five to ten standard radiation therapy fractions, with a maximum of 6 days of hyperthermia over the course of their standard, indicated radiation therapy treatment.
62853704|NCT02782858|EXPERIMENTAL|Dose 1 GNbAC1|Monthly IV repeated dose
62853705|NCT02782858|EXPERIMENTAL|Dose 2 GNbAC1|Monthly IV repeated dose
62853706|NCT02782858|EXPERIMENTAL|Dose 3 GNbAC1|Monthly IV repeated dose
62853707|NCT02782858|PLACEBO_COMPARATOR|Placebo|Monthly IV repeated dose
62853708|NCT06351384||Colorectal cancer arm|
62853709|NCT06351384||Healthy control arm|
62853710|NCT06351384||Intestinal polyp arm|
62628469|NCT03205475|ACTIVE_COMPARATOR|D. Above Fidelity Phase 1, Below in Phase 2- Add Peer|Alternating coaching and streamed or video feedback each week through phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive weekly coaching and video feedback from the Senior Trainer plus a weekly session paired with a local interventionist at fidelity (Enhanced Feedback plus peer support).
62628470|NCT03205475|ACTIVE_COMPARATOR|E. Below Fidelity Phase 1, Below in Phase 2- Add Refresher|Receive weekly coaching in phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive a one week intensive in person refresher and then continue with weekly coaching and video feedback from the Senior Trainer (Enhanced Feedback plus intensive refresher course) for the final 12 weeks.
62853711|NCT03361683|EXPERIMENTAL|High-flow nasal oxygen|Randomized patients will receive oxygen through a high flow nasal device capable of delivering humidified, heated air at an output rate of 40 L/min
62853712|NCT03361683|ACTIVE_COMPARATOR|Conventional oxygen|Randomized patients will receive oxygen through a Venturi mask at an air flow of 15 L/min
62853713|NCT02215018|EXPERIMENTAL|BI 44370 TA solution|
62853714|NCT02215018|EXPERIMENTAL|BI 44370 TA tablet|
62853715|NCT02215018|PLACEBO_COMPARATOR|Placebo solution|
62853716|NCT02215018|PLACEBO_COMPARATOR|Placebo tablet|
62853717|NCT04772833||Autopsy group|Patients with COVID-19 infection confirmed by PCR, whose death is related to active COVID-19 infection or its complications.
62853718|NCT00640692||1|
62853719|NCT00640692||2|
62853720|NCT00124046|ACTIVE_COMPARATOR|Surgical|
62853721|NCT00124046|ACTIVE_COMPARATOR|Medical Treatment|
62853722|NCT03079713|EXPERIMENTAL|Vibratory Anesthesia|Following administration of topical anesthetic and betadine, wearable vibrator will be triggered prior to and during the intravitreal injection
62853723|NCT03079713|SHAM_COMPARATOR|Standard Injection.|Following administration of topical anesthetic and betadine, wearable vibrator will be placed against the lower lid but NOT triggered prior to and during the intravitreal injection
62853724|NCT03079713|EXPERIMENTAL|Vibratory Anesthesia with Corneal/Conjunctival Sensation Test|Healthy patients not requiring intravitreal injection will be subjected to corneal and conjunctival aesthesiometry with and without the vibrator triggered while in contact with the lower eyelid of a single eye.
62853725|NCT04430595|EXPERIMENTAL|Multiple 4SCAR T cells to treat breast cancer|Multiple 4SCAR T cells to treat breast cancer
62268412|NCT05378438|NO_INTERVENTION|Control arm|Participants in this arm will be consented for the study and baseline data collection will be made but there will not be any intervention. Data will be collected for baseline as well as post interventional vaccination status among the studied population.
62628471|NCT03205475|ACTIVE_COMPARATOR|F. Below Fidelity Phase 1, Below in Phase 2- Add Peer|Receive weekly coaching in phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive weekly coaching and video feedback from the Senior Trainer plus a weekly session paired with a local interventionist at fidelity (Enhanced Feedback plus peer support).
62628472|NCT02421302|NO_INTERVENTION|Well-nourished HIV+ ART naive|These children aged between 6months-12years will be followed up for 12weeks to look at their nutrition, immune and pharmacological responses. They will receive routine nutritional and ART adherence counseling
62628473|NCT02421302|ACTIVE_COMPARATOR|Moderately-malnourished HIV+; RUTF|These children aged between 6months - 12years, ART naive or experienced, will be initiating ready-to-use-therapeutic(RUTF) food and will be followed up for 12 weeks to see the effect of nutrition supplementation on immune and pharmacological responses
62628474|NCT02421302|ACTIVE_COMPARATOR|Severely acute-malnourished HIV+; RUTF|These children aged between 6months - 12years, ART naive or experienced, will be initiating ready-to-use-therapeutic(RUTF) food and will be followed up for 12 weeks to see the effect of nutrition supplementation on immune and pharmacological responses
62628475|NCT03442244|EXPERIMENTAL|LEO 90100 foam|Each subject has each of the 2 investigational products applied at the same time on 2 sites on the back. The location on which the treatments are applied is randomised in a double-blinded manner LEO 90100 foam contains Calcipotriol hydrate 52.2 μg/g (equivalent to 50.0 μg/g calcipotriol) plus Betamethasone dipropionate 0.643 mg/g
62268413|NCT02820129|EXPERIMENTAL|Wallet Card Group|"The intervention arm is comprised of:~Patients from the TAPER study who receive a medication wallet card with their medications and medical conditions listed."
62268414|NCT02820129|PLACEBO_COMPARATOR|Control Group|"Standard of care as well as wait list control. These participants will receive a reminder wallet card which states, Remember to keep an up-to-date listing of your medications and bring your medications to your doctor's appointments."
62853726|NCT04989153||non-atrophic gastritis|No atrophic gastritis, The OLGA-0 group;OLGA :Operative Link on Gastritis Assessment)
62853727|NCT04989153||mild-moderate atrophic gastritis|The OLGA I-II group;OLGA :Operative Link on Gastritis Assessment)
62853728|NCT04989153||severe atrophic gastritis|The OLGA III-IV group;OLGA :Operative Link on Gastritis Assessment)
62853729|NCT04989153||gastric cancer|gastric cancer
62853730|NCT03278067||Vaccinated_Fluarix Tetra Group|Volunteered subjects who received GlaxoSmithKline's (GSK's) influenza vaccination (Fluarix Tetra) in 10 volunteer GP practices between 01 September and 30 November 2017.
62853731|NCT03278067||Vaccinated_Non GSK Group|Volunteered subjects who received non-GSK influenza vaccination in 10 volunteer GP practices between 01 September and 30 November 2017.
62853732|NCT03278067||Vaccinated_Unknown Group|Volunteered subjects who received influenza vaccination (GSK or non-GSK not known) in 10 volunteer GP practices between 01 September and 30 November 2017.
62063425|NCT01861522|EXPERIMENTAL|TAU-284|Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
62268415|NCT00657891|PLACEBO_COMPARATOR|1|Placebo Injection
62628476|NCT03442244|PLACEBO_COMPARATOR|Vehicle foam|"Each subject has each of the 2 investigational products applied at the same time on 2 sites on the back. The location on which the treatments are applied is randomised in a double-blinded manner.~Foam vehicle does not contain active ingredients"
62628477|NCT04845880|OTHER|SARS Cov_2 Incidence of Healthy Health Workers|
62628478|NCT04615078|EXPERIMENTAL|"Telemonitoring group"|Medical Telemonitoring in Non-Invasive Ventilation
62628479|NCT04615078|NO_INTERVENTION|"Standard of Care group"|Standard medical follow-up: standard home Non-Invasive Ventilation service, with transmission of their ventilator data without analysis leading to alerts
62628480|NCT05457179|EXPERIMENTAL|Intervention|PARCS is a park-based physical activity intervention including aerobic and resistance training adapted for adults with serious mental illness and led by certified peer counselors as part of peer group mental health recovery services.
62628481|NCT05457179|ACTIVE_COMPARATOR|Active Control|"The active control group will receive information about the importance of park-based PA and a map of local park locations but will not participate in structured park-based PA sessions. Participants in the control group will be invited to participate in park PA sessions after they have completed posttest.~Participants in both groups will receive usual care outpatient peer group treatment services, including routine counseling and health and wellness information/activities given by CPSs."
62628482|NCT01545141|NO_INTERVENTION|Surgery only|Surgical resection only, performed as standard of care for the disease
62853733|NCT01755026|ACTIVE_COMPARATOR|2 gram dose of cefazolin|2 gram dose of pre-operative cefazolin
62853734|NCT01755026|EXPERIMENTAL|4 gram Dose|4 gram dose of pre-operative prophylaxis
62853735|NCT02323607|EXPERIMENTAL|Cohort A (pacritinib, cytarabine, daunorubicin hydrochloride)|INDUCTION: Patients receive pacritinib PO on days 1-21, cytarabine IV every 24 hours on days 5-11, and daunorubicin hydrochloride IV every 24 hours on days 5-7. Treatment repeats every 28 days for 1-2 courses in the absence of disease progression or unacceptable toxicity.
62853736|NCT02323607|EXPERIMENTAL|Cohort B (pacritinib, decitabine)|"INDUCTION: Patients receive pacritinib PO on days 1-21 and decitabine IV every 24 hours on days 5-14. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients achieving CR will proceed with transplant evaluation (if appropriate). Transplant-ineligible patients will receive maintenance courses of pacritinib PO on days 1-21 and decitabine IV over 1 hour daily on days 1-5. Maintenance courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62268416|NCT00657891|EXPERIMENTAL|2|Xolair at 0.016 mg/kg/IgE(iu/ml)/4 wks
62268417|NCT03454022|ACTIVE_COMPARATOR|Usual care|"Participants receive an educational pamphlet from the National Kidney Foundation, Choosing a Treatment for Kidney Failure."
62063426|NCT01861522|PLACEBO_COMPARATOR|Placebo|Two placebo tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
62628483|NCT01545141|EXPERIMENTAL|Chemokin Modulatory Regimen (5 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 5 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
62628484|NCT01545141|EXPERIMENTAL|Chemokin Modulatory Regimen (10 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 10 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
62628485|NCT01545141|EXPERIMENTAL|Chemokin Modulatory Regimen (20 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
62628486|NCT02809950|EXPERIMENTAL|oral carbohydrate beverage group|
62628487|NCT02809950|PLACEBO_COMPARATOR|control group|
62853737|NCT03789279||Distal transradial arterial access|Patients undergoing invasive coronary angiography via the distal radial approach (anatomical snuffbox)
62853738|NCT05330104|EXPERIMENTAL|mEMA Arm|In this arm, participants will be using a mobile survey system to track the emergence of Chemotherapy-Induced Peripheral Neuropathy symptoms and fall risk over the course of the participant's chemotherapy.
62853739|NCT03137264||T790M positive|Patients determined to be T790M positive on cobas tissue and/or cobas plasma testing during Part 1 may be followed for clinical outcomes in Part 2, and will be treated in accordance with standard of care, which may include osimertinib.
62853740|NCT03137264||T790M negative|Patients determined to be T790M negative during Part 1 will not be followed for clinical outcomes in Part 2.
62853741|NCT06193122||Standard neoadjuvant treatments|Patients will be assessed using ultrasound imaging 3D and spectroscopy at the following intervals: once immediately prior to commencing neoadjuvant treatment. Once treatment begins, patients will be imaged at weeks 2, 4, 8, 12 and then prior to their surgery.
62853742|NCT00835029|ACTIVE_COMPARATOR|Clotrimazole varnish|Clotrimazole in a slow release varnish treatment
62853743|NCT00835029|ACTIVE_COMPARATOR|Clotrimazole troches|Clotrimazole troches 10 mgx5 day for treatment of denture associated candiad infection
62853744|NCT05315895||general population|general population in a specific area and specifc time range.
62853745|NCT00680394|EXPERIMENTAL|mifepristone+misoprostol|200 mg mifepristone+ 800 mcg buccal misoprostol
62853746|NCT00680394|EXPERIMENTAL|misoprostol|800 mcg buccal misoprostol+placebo
62853747|NCT03730792|EXPERIMENTAL|SHIFT Onboard Intervention|A 12-month onboarding process and social challenge supported with goal setting, computer-based training, self-monitoring, and group motivational interviewing.
62063427|NCT03768765||Long Term Medication Usage|Patients who have been on medication for over a year for benign prostatic hyperplasia (BPH)
62063428|NCT03768765||Short Term Medication Usage|Patients who have been on medication for under a year for benign prostatic hyperplasia (BPH)
62853748|NCT03730792|NO_INTERVENTION|Usual Practice Control|"Participants experience standard or Usual Practices in new employee onboarding processes at their workplace."
62853749|NCT04221776|EXPERIMENTAL|Intensive toilet training group|Intervention group was subjected to an intensive TT group session lasting 2-hours during 2 consecutive days in daycare centers.
62853750|NCT04221776|ACTIVE_COMPARATOR|Standard care toilet training group|Children participating in control group did not receive the intensive training, but parents got a leaflet and were encouraged to start TT their child at home, in their own manner.
62268418|NCT03454022|EXPERIMENTAL|DART|"Participants receive an educational pamphlet from the National Kidney Foundation, Choosing a Treatment for Kidney Failure. They also receive a link to access the web-based decision-aid program, Decision-Aid for Renal Therapy (DART). Participants may access this program using a computer at home throughout the duration of the trial. Those who do not have a computer with web access at home are assisted in watching the program in the clinic."
62268419|NCT01455688|EXPERIMENTAL|Early antiviral therapy|
62628488|NCT04399889|EXPERIMENTAL|Open Label infusion of hCT-MSC|The first 10 consecutive patients will all receive investigational product.
62853751|NCT03373903|PLACEBO_COMPARATOR|Placebo once daily for 16 weeks|
62853752|NCT03373903|EXPERIMENTAL|BEZ235 once daily for 16 weeks|
62063429|NCT03325543|EXPERIMENTAL|Intervention Group|The treatment program is based on the motor learning concepts of PFMs. The steps of learning a correct muscle contraction will be separate into four levels: 1. Understand 2. Search 3. Find 4. Learn. Feedback from the PF is mandatory. The intervention program will last four weeks, and will contain four outpatient consultations (1 session per week) lasting 60 minutes each session.
62063430|NCT03325543|ACTIVE_COMPARATOR|Control Group|The control group will receive only verbal instructions about the anatomy and function of the PFM, and to perform the contraction of the PFMs.
62063431|NCT05440383|EXPERIMENTAL|KLH-2109|Oral administration
62853753|NCT03373903|EXPERIMENTAL|BEZ235 twice daily for 16 weeks|
62853754|NCT03373903|EXPERIMENTAL|BEZ235 plus RAD001 once daily for 16 weeks|
62853755|NCT05514808|ACTIVE_COMPARATOR|Nutrition education intervention group|Each week, participants will learn about a topic related to nutrition, health and values-based ethics of clean sport. The intervention group will also receive information on dietary supplements, their benefits and their risks. Doping and body appreciation and their links to the use of dietary supplements will also be covered in this group. The duration of the intervention is 4 weeks; 1 module to be released every week.
62853756|NCT05514808|NO_INTERVENTION|Control group|No intervention to be received during the 4-week period.
62853757|NCT00601042|EXPERIMENTAL|1|Swedish snus ad libitum as a substitute for cigarettes
62063432|NCT05440383|ACTIVE_COMPARATOR|Leuprorelin|Subcutaneous administration
62628489|NCT04399889|EXPERIMENTAL|Randomized infusion of hCT-MSC|An interim analysis, for safety will be conducted and reviewed by the Data Safety and Monitoring Board (DSMB) after the first 10 patients have completed treatment and reached the 28 day endpoint. If there are no safety concerns, the trial will proceed with enrollment on the phase 2 portion of the study where the subsequent 40 patients will be randomized in a 1:1 fashion between treatment with MSCs and placebo. The investigational product will be further randomized to the MSCs manufactured by Duke or University of Miami. These products are considered to be comparable.
62628490|NCT04399889|PLACEBO_COMPARATOR|Randomized infusion of Placebo|An interim analysis, for safety will be conducted and reviewed by the Data Safety and Monitoring Board (DSMB) after the first 10 patients have completed treatment and reached the 28 day endpoint. If there are no safety concerns, the trial will proceed with enrollment on the phase 2 portion of the study where the subsequent 40 patients will be randomized in a 1:1 fashion between treatment with MSCs and placebo
62628491|NCT01668056|ACTIVE_COMPARATOR|Control|Patients will be stimulated according to the conventional flexible GnRH antagonist protocol for IVF. Alfa follitropin (150IU a day) will be started on the third day of the menstrual cycle. Treatment monitoring will be done with transvaginal ultrasound scans and serum determinations of estradiol and progesterone 5 days after the start of gonadotropins and every each day thereafter. Once the leading follicle reaches 13 mm in mean diameter 0,25mg of cetrorelix acetate will be administered daily. Once at least two follicles reach 18mm or more in mean diameter 250 micrograms of choriogonadotropin alfa will be administered and 36 hours latter patients will undergo follicle aspiration for IVF. Embryos will be cryopreserved (vitrification) on the third or fifth day of development. Two months after women will undergo uterine preparation for embryo transfer.
62628492|NCT01668056|EXPERIMENTAL|Ovulation induction|Patients will be monitored with daily transvaginal ultrasound scans from the tenth day of the menstrual cycle on. When the dominant follicle reaches a mean diameter of 16mm or more, patients will receive 250 micrograms of choriogonadotropin alfa subcutaneously. Daily transvaginal ultrasound scans will be done starting two days after the administration of the medication until a cohort of ovarian follicles between 4-6 mm is seen (follicular wave emergence). From this point on patients will undergo the same stimulation protocol as Controls, i.e., flexible GnRH antagonist protocol.
62853758|NCT00601042|PLACEBO_COMPARATOR|2|Tobacco-free, nicotine-free placebo snus ad libitum as a substitute for cigarettes
62853759|NCT00605956|EXPERIMENTAL|1|NatrOVA Creme Rinse - 1% Spinosad
62853760|NCT00605956|EXPERIMENTAL|2|NatrOVA Vehicle - no Spinosad
62063433|NCT01543412|EXPERIMENTAL|FOLFIRI|Folfiri consist of Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1and 2, 5-FU 400 mg/m2 iv bolus on day 1and 2, 5-FU 600 mg/m2 iv by ci for 22 hours on day 1 and 2, repeated every 2 wks The use of antiemetic prophylaxis was decided locally.
62063434|NCT01290211|EXPERIMENTAL|Cohort 1|Twice daily regimen
62063435|NCT01290211|EXPERIMENTAL|Cohort 2|Once daily regimen
62063436|NCT05447624|ACTIVE_COMPARATOR|Patients undergoing ablation of two of the genicular nerve branches|
62063437|NCT05447624|ACTIVE_COMPARATOR|Patients undergoing ablation of three of the genicular nerve branches|
62063438|NCT02152228|EXPERIMENTAL|Oral Parathyroid Hormone (1-34)|Oral administration of EnteraBio's Oral Parathyroid Hormone (1-34)
62063439|NCT05502419|ACTIVE_COMPARATOR|conventional physical therapy|
62063440|NCT05502419|EXPERIMENTAL|conventional physical therapy with slump stretching|
62063441|NCT01182935||participants in the 4th Tromsø study|
62451316|NCT02167295||Self-report questionnaire|This study is expected to enroll 30 participants who have smoking and betel nut chewing behaviors.Participants will complete 4 separate visits to CMUH, during which they will complete the same self-report questionnaire designed to measure withdrawal symptoms relating to betel quid chewing. To better measure betel quid withdrawal symptoms and to distinguish the 6 symptoms from those of smoking withdrawal, Participants will be required to attend one visit regular cigarette smoking and betel nut chewing behavior without restriction (as control), one visit after 12 hours of overnight betel quid deprivation (no cigarette deprivation), one visit after 12 hours of overnight cigarette deprivation (no betel quid deprivation), and one visit after 12 hours of both overnight betel quid and cigarette deprivation.
62063442|NCT04494438|NO_INTERVENTION|Steroid tapering.|
62628493|NCT01668056|EXPERIMENTAL|Dominant follicle aspiration|Patients will be monitored with daily transvaginal ultrasound scans from the tenth day of the menstrual cycle on. When the dominant follicle reaches a mean diameter of 16mm or more, patients will then undergo aspiration of the dominant and all follicles greater than 10mm in mean diameter. aspiration will be transvaginal ultrasound guided and under sedation, as for oocyte retrieval. Oocytes eventually obtained at this first aspiration will not be used for IVF. Daily transvaginal ultrasound scans will be done starting the day after the follicular aspiration until a cohort of follicles between 4-6 mm is seen (follicular wave emergence). From this point on patients will undergo the same stimulation protocol as Controls, i.e., flexible GnRH antagonist protocol.
62628494|NCT03868839|EXPERIMENTAL|Telmisartan Pill|Subjects will start telmisartan 40mg once a day during week 1; the dose will be increased to 80mg (target dose) or as tolerated during the remaining three weeks.
62628495|NCT00832988||Pacemaker patients|Patients who are implanted with a SJM Zephyr™ DR device for a standard pacing indication will be eligible
62628496|NCT02768402|EXPERIMENTAL|Treatment Arm|All eligible patients will be in the treatment arm for the 'Caisson TMVR System' (transcatheter mitral valve replacement) procedure. No control or comparator in this study.
62268420|NCT01455688|ACTIVE_COMPARATOR|Conventional therapy|
62853761|NCT00605956|PLACEBO_COMPARATOR|3|Blank Patch
62268421|NCT03166033||Case Group|"age between 41 and 70years. People in the case group with the symptom numbness and then were clinical and neural-electrophysiological diagnosed CTS. People in the control group would be exclude the symptom numbness. The case group included clinical diagnosed carpal tunnel syndrome which was divided into 4 parts every 10 years old age. The gender of the patients of the control group was matched to the case group and divided into 4 parts by age."
62268422|NCT03166033||Control Group|The present case-control study was based on the single medical center in Shanghai, China, in which more than 5000 CTS patients per year are treated. The hospital involved in the study is a university teaching hospital. Cases were recruited from the surgical wards and appropriate outpatient clinics, while the controls were recruited from the outpatient clinics. Both groups filled out a standardized questionnaire, and a standardized patient record was filled out by a hand surgeon. In addition, participants with jobs involving lifting and carrying of loads were interviewed.
62268423|NCT05195008|EXPERIMENTAL|Part A [Single Ascending Dose (SAD)]: BIIB113 Cohort 1|Participants aged 18 to 64 years will receive Dose 1 of BIIB113, orally, once daily (QD), on Day 1 of Part A of the study.
62451317|NCT03123822|EXPERIMENTAL|Single vision glasses|Typical glasses prescribed for children to correct only distance refractive error and to be worn all waking hours.
62451318|NCT03123822|EXPERIMENTAL|Single vision glasses with anti-glare coating|Typical glasses prescribed for children to correct only distance prescription with anti-glare coating and to be worn all waking hours.
62063443|NCT04494438|EXPERIMENTAL|Rituximab|Single administration of Rituximab 375 mg/mq at a rate of 0.5 to 1.5 ml/min over approximately 6 hours, following the infusion of 2.5-5 mg of intravenous chlorfenamine maleate (based on the local protocol and patient tolerance), methylprednisolone (2 mg/Kg) in normal saline and oral paracetamol (8 mg/kg).
62853762|NCT02941172|OTHER|[18F]FMPEP-d2 in warm conditions|PET scan is performed using PET radiotracer \[18F\]FMPEP-d2 in standard room temperature conditions.
62451319|NCT03123822|EXPERIMENTAL|Eyezen|Commercially available, low-powered, progressive addition lenses glasses with anti-glare coating to be worn all waking hours
62628497|NCT01363284|EXPERIMENTAL|Duloxetine|The first week of the treatment is the placebo treatment. The effect of placebo will be taken into consideration for further evaluation the duloxetine effect on clinical pain and descending pain inhibition capabilities.
62628498|NCT06355440|EXPERIMENTAL|Financial Navigation|"Participants will receive financial navigation service. During their hospitalization, participants will receive face-to-face information support with material booklets. Following discharge, weekly financial navigation information will be sent via WeChat for 1 month.~The financial navigation encompasses comprehensive information support:~* Strategies on patient-physician costs discussion~* Skills for inquiring and tracking treatment-related costs~* Basic knowledge about health insurance~* Guidance on accessing and applying for financial assistance~* Suggestions for returning to normal life and work~* Strategies for holding a financial-related family meeting"
62853763|NCT02941172|OTHER|[18F]FMPEP-d2 in cold conditions|PET scan is performed using PET radiotracer \[18F\]FMPEP-d2 during controlled cold exposure.
62853764|NCT02941172|OTHER|[18F]FDG in cold conditions|PET scan is performed using PET radiotracer \[18F\]FDG during controlled cold exposure.
62853765|NCT02671513|EXPERIMENTAL|SHR6390|Each subject will receive a single dose of SHR6390 and then repeat doses following a 3 week/1 week off regimen.
62853766|NCT00906737|EXPERIMENTAL|Ankle-Bot Training|Subjects in this group receive focused ankle training using the ankle-bot device.
62628499|NCT06355440|ACTIVE_COMPARATOR|Usual Care|Participants will receive usual care during hospitalization and regular follow-up after discharge. Participants have the freedom to utilize any financial resources, but financial navigators do not offer comprehensive information support. When participants actively inquire about cancer treatment-related costs or financial planning strategies, financial navigators will answer their questions.
62628500|NCT04008888|EXPERIMENTAL|A:Allogeneic Stem Cell Transplant Group|Fludarabine+Melphalan followed by Allogeneic SCT.
62628501|NCT04008888|EXPERIMENTAL|B:Autologous Stem Cell Transplant|Melphalan followed by Autologous SCT.
62628502|NCT04008888|EXPERIMENTAL|C:Non-Transplant|Consolidated Chemotherapy for Patients Unable to Receive Transplantation
62628503|NCT01964989|EXPERIMENTAL|aQIV|flu vaccine
62628504|NCT01964989|ACTIVE_COMPARATOR|non-adjuvanted comparator|flu vaccine
62853767|NCT00906737|ACTIVE_COMPARATOR|Conventional Therapy|Subjects in this group will receive conventional focused ankle physical therapy.
62853768|NCT00906737|NO_INTERVENTION|Control|Subjects in this group will not receive treatment; they will continue their usual care.
62853769|NCT02943304||Exposed|Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV
62853770|NCT02943304||Unexposed|Asymptomatic pregnant women with a negative RT-PCR ZIKV in serum and urine, and a negative specific serology for ZIKV at enrollment into the study and at the time of delivery
62853771|NCT05414357|EXPERIMENTAL|Patients with chemotherapy|
62853772|NCT05414357|ACTIVE_COMPARATOR|Patients without chemotherapy|
62853773|NCT05414357|ACTIVE_COMPARATOR|cancer-free volunteers|
62853774|NCT02834754|EXPERIMENTAL|Vedolizumab|Vedolizumab infusions at weeks 0, 2, and 6 weeks, then every 8 weeks for 52 weeks
62853775|NCT02834754|PLACEBO_COMPARATOR|placebo|Placebo infusions at weeks 0, 2, and 6 weeks, then every 8 weeks for 52 weeks
62853776|NCT01256294|EXPERIMENTAL|Sequence 1 - Branded Tacrolimus / Generic Tacrolimus|In Period 1 (Days 1-14) participants received branded tacrolimus (Prograf) orally twice a day and in Period 2 (Days 15 - 28) participants received generic tacrolimus (Sandoz) orally twice a day. Participants received the same stable dosage of tacrolimus they had been taking prior to enrollment (on a milligram for milligram basis).
62853777|NCT01256294|ACTIVE_COMPARATOR|Sequence 2 - Generic Tacrolimus / Branded Tacrolimus|In Period 1 (Days 1 - 14) participants received generic tacrolimus (Sandoz) orally twice a day and in Period 2 (Days 15 - 28) participants received branded tacrolimus (Prograf) orally twice a day. Participants received the same stable dosage of tacrolimus they had been taking prior to enrollment (on a milligram for milligram basis).
62853778|NCT06478381|EXPERIMENTAL|Dose Escalation|L218CAR19 is administered via infusion with ascending dose levels to determine the maximum tolerated dose (MTD)
62853779|NCT05605938|EXPERIMENTAL|Tenoten for children|1 tablet 3 times daily for 12 weeks. Route of administration: sublingual, the tablet should be held in the mouth until completely dissolved.
62853780|NCT05605938|PLACEBO_COMPARATOR|Placebo|As per the Tenoten for children dosing regimen.
62853781|NCT03180619|EXPERIMENTAL|Part A (Renal Impairment): Moderate or Severe Renal Impairment|Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and taking tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), will switch to tenofovir alafenamide (TAF) and receive TAF 25 milligram (mg) tablet once daily orally for 96 weeks.
62853782|NCT03180619|EXPERIMENTAL|Part A (Renal Impairment): End Stage Renal Disease|Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF and receive TAF 25 mg tablet once daily orally for 96 weeks.
62853783|NCT03180619|EXPERIMENTAL|Part B: Hepatic Impairment|Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF and receive TAF 25 mg tablet once daily orally for 96 weeks.
62853784|NCT05380479|EXPERIMENTAL|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night. This group will consist of 40 patients with anorexia in advanced cancer patients.
62268424|NCT05195008|EXPERIMENTAL|Part A (SAD): BIIB113 Cohort 2|Participants aged 18 to 64 years will receive Dose 2 of BIIB113, orally, QD, on Day 1 of Part A of the study
62628505|NCT04265261|PLACEBO_COMPARATOR|Group A|Participants will receive an oral dose of placebo matched to RG7774 once daily (QD)
62268425|NCT05195008|EXPERIMENTAL|Part A (SAD): BIIB113 Cohort 3|Participants aged 18 to 64 years will receive Dose 3 of BIIB113, orally, QD, on Day 1 of Part A of the study.
62628506|NCT04265261|EXPERIMENTAL|Group B|Participants will receive a low oral dose of RG7774 QD
62628507|NCT04265261|EXPERIMENTAL|Group C|Participants will receive a high oral dose of RG7774 QD
62628508|NCT05114187|EXPERIMENTAL|Education Intervention|
62628509|NCT05114187|ACTIVE_COMPARATOR|Education Control|
62628510|NCT04004260|EXPERIMENTAL|Experimental group|The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned.
62628511|NCT04004260|OTHER|Weekly check-in control group|The weekly check-in control group will be monitored weekly by means of the Tinnitus Handicap Inventory-Screening version (THI-S) and the Tinnitus Qualities Questionnaire (TQQ). Once the experimental group completes the ICBT intervention, the control group undertake the same ICBT intervention.
62628512|NCT00674206|EXPERIMENTAL|Gemcitabine and Oxaliplatin|All patients enrolled on clinical trial will receive Gemcitabine 1000mg/m\^2 on Day 1 and Oxaliplatin 100 mg/m\^2 intravenously over 2 hours on Day 2.
62063444|NCT04728334|EXPERIMENTAL|AK117 monotherapy|AK117 monotherapy intravenous (IV) infusion - Weekly doses
62268426|NCT05195008|EXPERIMENTAL|Part A (SAD): BIIB113 Cohort 4|Participants aged 18 to 64 years will receive Dose 4 of BIIB113, orally, QD, on Day 1 of Part A of the study.
62268427|NCT05195008|EXPERIMENTAL|Part A (SAD): BIIB113 Cohort 5|Participants aged 18 to 64 years will receive Dose 5 of BIIB113, orally, QD, on Day 1 of Part A of the study
62628513|NCT03620526|EXPERIMENTAL|Iloprost|patients received inhaled iloprost 10 mcg/mL x 1 dose after baseline and exercise test and then received measurements for hemodynamic data again for both baseline and after exercise test.
62853785|NCT05380479|ACTIVE_COMPARATOR|Megestrol Acetate|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night This group will consist of 40 patients with anorexia in advanced cancer patients.
62853786|NCT05090319||Viral Group|known viral infection
62853787|NCT05090319||Bacterial group|known bacterial infection
62853788|NCT01111396||Patient with ALL under chemotherapy|This group consists of patients with initial diagnosis of acute lymphatic leukemia (ALL), who are enrolled into the GMALL 2003 chemotherapy study. There is no change of the initial GMALL 2003 treatment protocol for the present study.
62628514|NCT03620526|PLACEBO_COMPARATOR|Placebo|patients received inhaled normal saline with the same amount x 1 dose after baseline and exercise test and then received measurements for hemodynamic data again for both baseline and after exercise test.
62628515|NCT02732392|EXPERIMENTAL|lymphadenectomy|
62628516|NCT02403804|OTHER|All subjects|"All 3 weeks will occur during luteal phase of menstrual cycle with a two-to-three week washout period between weeks.~Week 1: Phosphatidylcholine 3600 mg qam and 2700 mg qpm~Week 2: Betaine anhydrous 588 mg qam and 412 mg qpm~Week 3: Betaine anhydrous 1000 mg BID"
62853789|NCT02856152|EXPERIMENTAL|Treatment A Then B Then D Then C|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment A on Day 1 of first intervention period, followed by Treatment B on Day 1 of second intervention period, followed by Treatment D on Day 1 of third intervention period, and then Treatment C on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
62853790|NCT02856152|EXPERIMENTAL|Treatment B, Then C, Then A, Then D|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment B on Day 1 of first intervention period, followed by Treatment C on Day 1 of second intervention period, followed by Treatment A on Day 1 of third intervention period, and then Treatment D on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
62628517|NCT06491680|ACTIVE_COMPARATOR|Dapagliflozin group|Dapagliflozin group who consist of at least 20 breast cancer patients who receive 4 cycles of anthracyclines ( each cycle every 21 days ) with dapagliflozin 10 mg tablet once daily.
62628518|NCT06491680|NO_INTERVENTION|Control group|Control group who consist of at least 20 breast cancer patients who receive 4 cycles of anthracyclines ( each cycle every 21 days ) only.
62628519|NCT01082679|OTHER|methadone via specialty care|
62628520|NCT01082679|OTHER|Suboxone via specialty care|
62268428|NCT05195008|PLACEBO_COMPARATOR|Part A (SAD): BIIB113-Matching Placebo (Cohorts 1-5)|Participants aged 18 to 64 years will receive BIIB113-matching placebo, orally, QD, on Day 1 of Part A of the study.
62268429|NCT05195008|EXPERIMENTAL|Part B [Multiple Ascending Dose (MAD)]: BIIB113 Cohort 6|Participants aged 18 to 64 years will receive Dose 3 of BIIB113, orally, QD, up to Day 14 of Part B of the study.
62268430|NCT05195008|EXPERIMENTAL|Part B (MAD): BIIB113 Cohort 7|Participants aged 18 to 64 years will receive Dose 4 of BIIB113, orally, QD, on Days 1 to 14 of Part B of the study.
62268431|NCT05195008|EXPERIMENTAL|Part B (MAD): BIIB113 Cohort 8|Participants aged 18 to 64 years will receive Dose 6 of BIIB113, orally, QD, on Days 1 to 14 of Part B of the study.
62451320|NCT05391009|EXPERIMENTAL|PNF GROUP|PNF exercise twice daily five days per week for 8 weeks. D1 and D2 flexion and extension pattern for upper limb. In D1 Flexion-adduction -external rotation d1, extension -abduction-internal rotation and in D2 flexion-abduction-external rotation, extension-adduction-internal rotation
62628521|NCT01082679|OTHER|Suboxone via primary care|
62628522|NCT01396889|EXPERIMENTAL|Echinacea|0.5ml daily for children 1-2 years old and 2ml daily for children2-5 years old for 3 months
62628523|NCT01396889|PLACEBO_COMPARATOR|Placebo|Placebo
62628524|NCT03952962|EXPERIMENTAL|Randomized Discontinuation Period: OFF then ON DBS|"Subjects randomized to this arm are initially OFF DBS after the open label period then gradually decreased in their optimized setting's amplitude for 8 weeks and then ON DBS for 8 weeks."
62063445|NCT00770432|ACTIVE_COMPARATOR|Polyethylene glycol 3350 powder for solution|MiraLAX® (polyethylene glycol 3350 powder for solution)
62063446|NCT00770432|PLACEBO_COMPARATOR|Placebo|MALTRIN 500® M500 (maltodextrin 500)
62063447|NCT04947371|EXPERIMENTAL|Anlotinib Hydrochloride|Oral anlotinib 12 mg/d
62628525|NCT03952962|EXPERIMENTAL|Randomized Discontinuation Period: ON then OFF DBS|"Subjects randomized to this arm are initially ON DBS with optimized stimulation settings for 8 weeks after the open label period and then OFF DBS with gradually decreasing amplitude for 8 weeks."
62268432|NCT05195008|PLACEBO_COMPARATOR|Part B (MAD): BIIB113 Cohort 9|Participants aged 65 to 75 years will receive BIIB113, orally, QD, on Days 1 to 14 of Part B of the study. The calculated dose level will be adaptive by design based on review of the safety, tolerability, and PK data from Cohorts 1 to 7.
62268433|NCT05195008|PLACEBO_COMPARATOR|Part B (MAD): BIIB113-Matching Placebo (Cohorts 6 to 9)|Participants aged 18 to 75 will receive BIIB113-matching placebo, orally, QD, on Days 1 to 14 of Part B of the study.
62268434|NCT05195008|EXPERIMENTAL|Part C (OGA-PET SAD): BIIB113|Participants aged 20 to 64 will receive single dose of BIIB113, orally, QD, on Day 1 of Part C of the study, followed by a radiotracer specific to OGA (\[11\^C\]BIO-1819578), on Days 1 to 4 of Part C of the study.
62628526|NCT03373747|EXPERIMENTAL|Reliability of IET|In phase 1, the first of familiarization is to the participants understand the test and familiarize with the equipment after 24 to 48 hours, the participants will do the test applied twice at the same day with 10 minutes of rest. For realization of the IET the participants will be instructe to make the maximum effort as possible and mantain until they can't resiste. After one week the retest session will be doing. The order between the evaluators will be changed in the test and retest sessions.
62628527|NCT03373747|EXPERIMENTAL|Physiological analysis of IET|In phase 2, the participants will be submitted two sessions, familiarization session and test session. In the test session there is be two teste applied in the same day with approximately 20 minutes of rest. In the first test, thers is gas analysis during all the test until seven minutes after the test and blood lactat concentrate will be colected before the test with 10 minutes of rest, immediately after the teste and in the first, in the third, fifth and seventh minutes after the test. In the second test will be assess the muscular activation porcentage of lateral vastus muscle by means of twitch interpolation technique there is be performe before and after the test.
62628528|NCT00382785|EXPERIMENTAL|moderated online support|12-week online support led by a healthcare professional
62628529|NCT00382785|EXPERIMENTAL|peer-led support|12-week online support group in a peer-led format
62628530|NCT03711305|EXPERIMENTAL|SHR-1316 + carboplatin + etoposide|Participants will receive SHR-1316 intravenously in combination with carboplatin and etoposide during the induction phase (Cycles 1-4 or 6). Thereafter, participants will receive maintenance (after induction phase) SHR-1316 until persistent radiographic PD, intolerable toxicity or withdrawal of consent.
62628531|NCT03711305|ACTIVE_COMPARATOR|Placebo + carboplatin + etoposide|Participants will receive placebo intravenously in combination with carboplatin and etoposide during the induction phase (Cycles 1-4 or 6). Thereafter, participants will receive maintenance (after induction phase) placebo until persistent radiographic PD, intolerable toxicity or withdrawal of consent.
62268435|NCT05195008|EXPERIMENTAL|Part C (OGA-PET MAD): BIIB113|Participants aged 20 to 64 years will receive multiple doses of BIIB113, orally, QD, on Days 1 to 14 of Part C of the study, followed by a radiotracer specific to OGA (\[11\^C\]BIO-1819578) on Day 1 and either of Day 15, Day 16 or Day 17 of Part C of the study.
62268436|NCT06294457|EXPERIMENTAL|Intervention|"The total number of sessions to be conducted for each patient will be 10 sessions, spread over 5 weeks, which means a frequency of twice a week.~Each NESA microcurrent session will last 60 minutes. A maximum time of 15 minutes will be allowed for connecting the patient at the beginning and for removing the device at the end.~The directing electrode will be located throughout the treatment between the spinous processes of C6 and C7 to act generally on the individual, and in later sessions, the electrode will be placed d at T12-S3 to influence the sacral plexus.~The intensity will be set to Low (3 volts) in all sessions,. The other device parameters range between 100-900 microamperes and between 1.14 and 14.29 hertz, and are preset by each program."
62268437|NCT06294457|PLACEBO_COMPARATOR|Placebo|Non-active Non-Invasive Neuromodulation NESA
62268438|NCT00705211||Zetia monotherapy|Patients to be treated with Zetia alone (10-mg tablets,) for hypercholesterolemia
62268439|NCT00705211||Zetia combination therapy|Patients to be treated with Zetia (10-mg tablets,) in combination with other lipid-lowering drugs for hypercholesterolemia
62628532|NCT02532062|EXPERIMENTAL|Supplementation|Participants who are assigned to the Supplementation arm will receive a vitamin D supplement containing 4,000 units of vitamin D3 (cholecalciferol; capsule form) plus an oral multivitamin containing 400 units of vitamin D3 daily for a period of one year.
62628533|NCT02532062|ACTIVE_COMPARATOR|Placebo|Participants who are assigned to the Placebo arm will receive a placebo supplement plus an oral multivitamin containing 400 units of vitamin D3 daily for a period of one year.
62088073|NCT06492538||ab interno goniotomy|GT was performed in the nasal-inferior quadrant or nasal quadrant because the collector channels were mainly concentrated in the nasal quadrant, by inserting the tip of a microblade (TMH; Tanito Microhook, Inami \& Co., Ltd., Tokyo, Japan) into Schlemm's canal, and then the inner wall of Schlemm's canal and trabecular meshwork was incised over 120°
62268440|NCT04153188|EXPERIMENTAL|Pulsed Dye Laser & Oxymetazoline HCL 1% Cream|Once daily application of pea-sized amount to face of Oxymetazoline HCL 1% Cream for 4 weeks prior to 1st of 3 monthly Vbeam® Prima PDL treatments. Subjects will continue with once daily application of Oxymetazoline HCL 1% Cream during the 6-month post-baseline study with a 3-day washout of cream prior to each of the 3 PDL treatments.
62268441|NCT04153188|ACTIVE_COMPARATOR|Oxymetazoline HCL 1% Cream|Once daily application of pea-sized amount to face of Oxymetazoline HCL 1% Cream during the 6-month study.
62268442|NCT04055155||Staff/Provider end-users|Testing usability of a technology-enabled behavioral intervention for depression among provider end-users in primary care.
62268443|NCT04055155||Patient participants|Testing acceptability, feasibility, and preliminary effectiveness of a technology-enabled behavioral intervention for depression among patients with depression in primary care.
62063448|NCT03781830|EXPERIMENTAL|mHealth Intervention|Participants will receive the mHealth application either while they are an inpatient post-transplant, or at one of their post-transplant clinic visits. Study personnel will assist participants with downloading the mHealth application and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
62628534|NCT02501941|EXPERIMENTAL|Ketamine first|"Randomization to receive ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to other sedation after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring."
62628535|NCT02501941|EXPERIMENTAL|Other sedation (typically propofol) first|Randomization to receive sedative other than ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to ketamine after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring.
62853791|NCT02856152|EXPERIMENTAL|Treatment C, Then D, Then B, Then A|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment C on Day 1 of first intervention period, followed by Treatment D on Day 1 of second intervention period, followed by Treatment B on Day 1 of third intervention period, and then Treatment A on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
62853792|NCT02856152|EXPERIMENTAL|Treatment D, Then A, Then C, Then B|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment D on Day 1 of first intervention period, followed by Treatment A on Day 1 of second intervention period, followed by Treatment C on Day 1 of third intervention period, and then Treatment B on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
62853793|NCT05781880|EXPERIMENTAL|NBO group|Normobaric hyperoxia (NBO) oxygen group will be given 100% oxgen (10L/min for 4h) via a face mask.
62853794|NCT05781880|PLACEBO_COMPARATOR|Control group|Control group will be given nasal oxygen (2L/min for 4h）. All other therapy measures are the same as experimental group.
62853795|NCT01143701|EXPERIMENTAL|ADHD Collaborative Intervention|The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the American Academy of Pediatrics consensus recommendation for evidence-based ADHD care.
62853796|NCT01143701|NO_INTERVENTION|Typical ADHD care|Physicians in this group will provide typical ADHD care.
62628536|NCT06173388|EXPERIMENTAL|The structured exercise training program|Th study group received the structured exercise training program (composed of cervical stretching, strengthening and stabilizing exercises) plus the swallow resistance exercise.
62628537|NCT06173388|OTHER|The swallow resistance exercise|The control group: received only the swallow resistance exercise.
62628538|NCT02260219|ACTIVE_COMPARATOR|S2|Surgically Implant an Ahmed Glaucoma Drainage Device Model S2 in Neovascular Glaucoma Patients and evaluate the IOP evolution, complications and need for medication to control IOP
62063449|NCT02825134|EXPERIMENTAL|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
62063450|NCT02825134|ACTIVE_COMPARATOR|Surgical aortic valve replacement|Surgical aortic valve replacement
62063451|NCT04918368||Pregnant women between 18-45 years old, being in second and third trimester of a singleton pregnancy|
62063452|NCT01266694|EXPERIMENTAL|Cochicine|Colchicine arm: patient receiving 1 mg per day for 14 days
62063453|NCT01266694|PLACEBO_COMPARATOR|Placebo|patients placebo controlled
62063454|NCT04631705|EXPERIMENTAL|Group 1A (uninfected) - low dose|SARS-CoV-2-uninfected volunteers will receive a single dose of DZIF-10c by inhalation
62063455|NCT04631705|EXPERIMENTAL|Group 1B (uninfected) - mid dose|SARS-CoV-2-uninfected volunteers will receive a single dose of DZIF-10c by inhalation
62628539|NCT02260219|ACTIVE_COMPARATOR|M4|Surgically Implant an Ahmed Glaucoma Drainage Device Model M4 in Neovascular Glaucoma Patients and evaluate the IOP evolution, complications and need for medication to control IOP
62628540|NCT03166839||Region 1: Africa|Women living in and experiencing PPH in countries located in Africa.
62628541|NCT03166839||Region 2: Asia|Women living in and experiencing PPH in countries located in Africa.
62628542|NCT03166839||Region 3: Europe, NA, SA, Aus|Women living in and experiencing PPH in countries located in Africa.
62628543|NCT04793477|EXPERIMENTAL|K files (Dentsply Caulk, Milfors, DE, USA)|Instrumentation with manual files shall be performed with balanced forces (Roane) technique consist of placing the instrument as apically as it can go and then turning it clockwise (less than 180º). This is followed by a counterclockwise rotation (of at least 120º) with slight apical pressure. This is repeated until the desired working length is obtained.
62853797|NCT04608539|EXPERIMENTAL|Intravenous iron group|Single-dose intravenous infusion of 20 mg/kg body weight ferric derisomaltose/iron isomaltoside 1000 (MonoFer®)
62853798|NCT04608539|ACTIVE_COMPARATOR|Oral iron group|Oral therapy with 100 mg oral ferrous sulfate twice daily
62853799|NCT06173700|EXPERIMENTAL|Single Group Intervention|7-week web-based group with problem solving training
62853800|NCT02037555|EXPERIMENTAL|AT-III (Human)|"Single intravenous dose of AT-III (Human) sufficient to achieve an absolute increase of 20% (percentage points) above pretreatment AT levels according the following formula:~AT-III (Human) dose (IU) required = (20) × (subject weight in kg) / 1.4"
62451321|NCT05391009|EXPERIMENTAL|TRT GROUP|The duration of a TRT session Will be 60 min. Each session started with warm-up exercises for 10 min followed by 50 min of TRT. Each task will be repeated approximately 10 to 20 times, for 1 to 5 sets, or alternatively for 2 to 5 min. A 2 min rest period after every 15 min of practice will be allowed. Before commencing the exercise session, tasks will be demonstrated to each patient using the non-affected UE.
62451322|NCT00991848|EXPERIMENTAL|Lidocaine|Patients received 240 mg lidocaine diluted in 125 mL 0.9% saline. The solutions were infused over a period of 1 h, once a week, for 4 weeks (T1, T2, T3 and T4).
62451323|NCT01477359||CS screened as underlying etiology|"1. Patients with active Clinically Manifest CS~2. Patients diagnosed with extra-cardiac sarcoidosis and being screened for CS"
62451324|NCT01930461|EXPERIMENTAL|SLIT (A)|SLIT tablets of HDM allergen extracts, 3 different doses (A)
62628544|NCT04793477|EXPERIMENTAL|VDW.ROTATE (VDW, Munich, Germany).|Instrumentation with VDW.ROTATE files shall be performed with a glide path to WL using VDW.ROTATETM 15.04 until reaching working length (1.3cNm and 300-400 rpm), the next instrument in the sequence is VDW.ROTATETM 20.05 until reaching working length (2.1cNm and 300-400rpm). and finally instrument with VDW.ROTATETM 25.04 (2.3cNm and 300-400rpm)
62628545|NCT04793477|EXPERIMENTAL|Reciproc® blue (RCP, VDW, Munich, Germany)|Instrumentation with Reciproc blue files shall be performed with only one file and move it in a pecking motion (the amplitude will not exceed 3mm). All the instruments shall be cleaned after 3 pecks.
62853801|NCT02037555|PLACEBO_COMPARATOR|Placebo|Single intravenous administration of placebo at a volume equivalent to the volume for the calculated AT-III (Human) dose.
62853802|NCT02082938|EXPERIMENTAL|Bracing|Bracing: the patients began four weeks of training the gait with the brace, under the guidance and observation of the physiotherapist belonging to the group of authors of this study.
62853803|NCT05711758||PSAM Treatment Patients|Subjects having esophagogastroduodenoscopy (EGD) with Pylorus Sparing Antral Myotomy (PSAM) with standard of care lifestyle modification therapy.
62853804|NCT02076425|EXPERIMENTAL|PCIT-ED|Parent-Child Interaction Therapy - Emotional Development (PCIT-ED) is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
62628546|NCT01700257|OTHER|CT scan & Early CDT Lung test|Every study participant receives a CT scan \& Early CDT-Lung test (biomarker blood test) for lung cancer screening purposes.
62853805|NCT02076425|NO_INTERVENTION|Wait List|No intervention while subjects wait for PCIT-ED in the second phase of the study.
62853806|NCT00202475|ACTIVE_COMPARATOR|1|
62853807|NCT00202475|ACTIVE_COMPARATOR|2|
62853808|NCT00266058|ACTIVE_COMPARATOR|Lopinavir/ritonavir, artemethr/lumefantrine|Determination of the antimalarial drug levels artemether/lumefantrine in the absence and in the presence of co-administered antiretrovirals lopinavir and ritonavir.
62853809|NCT00266058|ACTIVE_COMPARATOR|efavirenz, artemether, lumefantrine|Determination of the antimalarial drug levels artemether/lumefantrine in the absence and in the presence of co-administered antiretroviral efavirenz.
62853810|NCT02117557|EXPERIMENTAL|Single incision laparoscopic surgery|Transumbilical single incision laparoscopic surgery will be performed for patients in this group.And addition of only one trocar through the stoma for drainage tube is allowed.
62853811|NCT02117557|ACTIVE_COMPARATOR|Conventional laparoscopic surgery|Conventional laparoscopic surgery for colorectal cancer will be performed for patients in this group.
62063456|NCT04631705|EXPERIMENTAL|Group 1C (uninfected) - high dose|SARS-CoV-2-uninfected volunteers will receive a single dose of DZIF-10c by inhalation
62628547|NCT06180161|EXPERIMENTAL|intervention grou[|Behavioral: multidomain intervention Dosage: a 2-hour session once a week for 12 weeks. Each multidomain intervention session includes 1 hour of combined physical (balance, strength and aerobic exercises) and cognitive (attention, memory, calculation, visual-spatial ability, processing speed and executive function) training and 1 hour of risk factor prevention and management strategies (nutrition, chronic disease management, oral health, fall prevention and transportation safety, psychosocial factors and sleep).
62628548|NCT06180161|NO_INTERVENTION|control group|Waiting for 12 weeks (waiting-list control group)
62628549|NCT02377492|EXPERIMENTAL|Paracervical & Intramyometrial|Vasopressin will be placed paracervically (8mL, 4 units) and intramyometrial (8mL, 4 units)
62628550|NCT02377492|ACTIVE_COMPARATOR|Intramyometrial|Vasopressin will be placed intramyometrial (16mL, 8 units)
62628551|NCT01826981|EXPERIMENTAL|Cohort 1,Group 1: LDV/SOF + RBV 12 wk (GT1 SOF retreatment)|LDV/SOF + RBV for 12 weeks in participants with genotype 1 HCV infection and who failed to achieve sustained virologic response (SVR) in a previous Gilead sofosbuvir study
62628552|NCT01826981|EXPERIMENTAL|Cohort 1,Group 2:SOF+Peg-IFN+RBV 12 wk (GT2,3 SOF retreatment)|SOF + PEG + RBV for 12 weeks in participants with genotype 2 or 3 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study
62628553|NCT01826981|EXPERIMENTAL|Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, liver disease)|LDV/SOF+RBV for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis
62628554|NCT01826981|EXPERIMENTAL|Cohort 2,Group 2: LDV/SOF+GS-9669 12wk (GT1 TE, liver disease)|LDV/SOF + GS-9669 for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis
62628555|NCT01826981|EXPERIMENTAL|Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)|LDV/SOF for 12 weeks in treatment-naive participants with genotype 3 HCV infection
62628556|NCT01826981|EXPERIMENTAL|Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)|LDV/SOF + RBV for 12 weeks in treatment-naive participants with genotype 3 HCV infection
62853812|NCT01923779||TG002 Subjects|Subjects previously randomised in study TG002
62853813|NCT02922699|EXPERIMENTAL|Omeprazole 40mg|Omez 40mg OD
62268444|NCT06500143||GLP-1RA agonists users|Participants presenting for elective surgery and taking once-weekly semaglutide or dulaglutide as part of their usual treatment with the last dose at least 7 days before surgery
62268445|NCT06500143||Control group|Participants presenting for elective surgery and not taking semaglutide or dulaglutide
62628557|NCT01826981|EXPERIMENTAL|Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)|LDV/SOF for 12 weeks in treatment-naive or treatment-experienced participants with genotype 6 HCV infection
62628558|NCT01826981|EXPERIMENTAL|Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)|LDV/SOF + RBV for 12 weeks in treatment-experienced participants with genotype 3 HCV infection
62063457|NCT04631705|EXPERIMENTAL|Group 2A (infected) - low dose|SARS-CoV-2-infected volunteers will receive a single dose of DZIF-10c by inhalation
62063458|NCT04631705|EXPERIMENTAL|Group 2B (infected) - mid dose|SARS-CoV-2-infected volunteers will receive a single dose of DZIF-10c by inhalation
62063459|NCT04631705|EXPERIMENTAL|Group 2C (infected) - high dose|SARS-CoV-2-infected volunteers will receive a single dose of DZIF-10c by inhalation
62268446|NCT06458803||El-treatment|patients receive oral eltrombopag at 25 to 75 mg once daily during the course.
62268447|NCT02464384|OTHER|cohort study|Collection of blood samples and ultrasound / MRI and x-ray examination.
62853814|NCT02922699|ACTIVE_COMPARATOR|Omeprazole 80 mg|Omez 80mg OD
62853815|NCT00783198|EXPERIMENTAL|SCH 39641 6 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 6 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
62853816|NCT00783198|EXPERIMENTAL|SCH 39641 12 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 12 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
62853817|NCT00783198|PLACEBO_COMPARATOR|Placebo|Participants receive placebo matching ambrosia artemisiifolia allergen extract, rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
62063460|NCT04631705|EXPERIMENTAL|Group 2D (infected)|SARS-CoV-2-infected volunteers will be randomized 1:1:1 to receive DZIF-10c by inhalation and infusion, DZIF-10c by inhalation and placebo by infusion, or placebo by inhalation and infusion
62063461|NCT04618822|EXPERIMENTAL|Teaching involving whole-body movements|
62268448|NCT02447588|OTHER|Group 1|Intrauterine insemination with sperm donor (IAD) at 36 hours post-hCG. Cases where the IAD is scheduled at 36 hours post-administration of hCG.
62268449|NCT02447588|EXPERIMENTAL|Group 2|Intrauterine insemination with sperm donor (IAD) at 24 hours post-hCG. Cases where the IAD is scheduled at 24 hours post-administration of hCG.
62628559|NCT01826981|EXPERIMENTAL|Cohort 3,Group 1: LDV/SOF 12 wk (GT1 cirrhotic CPT B)|LDV/SOF for 12 weeks in participants with genotype 1 HCV infection and Child-Pugh Turcotte (CPT) B cirrhosis
62628560|NCT01826981|EXPERIMENTAL|Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN noncirrhotic)|SOF+VEL (25 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
62628561|NCT01826981|EXPERIMENTAL|Cohort 4,Group 2:SOF+VEL 25mg+RBV 8 wk (GT3 TN noncirrhotic)|SOF+VEL(25 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
62853818|NCT02495038|NO_INTERVENTION|Intubating dose, Group I|"combined ED95 rocuronium and ED95 cisatracurium~ED95, dose causing on average 95% suppression of neuromuscular response."
62853819|NCT02495038|EXPERIMENTAL|10% reduction of combination of Esmeron® and Nimbex®, Group S|This arm reduced 10% of combined ED95 rocuronium and ED95 cisatracurium
62853820|NCT02495038|EXPERIMENTAL|20% reduction of combination of Esmeron® and Nimbex®, Group L|This arm reduced 20% of combined ED95 rocuronium and ED95 cisatracurium
62853821|NCT06533761|EXPERIMENTAL|Eganelisib|
62853822|NCT06533761|EXPERIMENTAL|Eganelisib in combination with cytarabine|
62853823|NCT03843671|EXPERIMENTAL|Group 1|Hyperbaric oxygen Hyperbaric chamber
62853824|NCT03843671|SHAM_COMPARATOR|Group 2|Sham for hyperbaric oxygen Hyperbaric chamber
62853825|NCT06269939|EXPERIMENTAL|Experimental group|The experimental group will receive memory techniques training administered twice a week for four weeks (8 training sessions).
62853826|NCT06269939|PLACEBO_COMPARATOR|Control group|The control group will receive memory exercises administered twice a week for four weeks (8 sessions).
62853827|NCT03635450|EXPERIMENTAL|First cohort of 3 subjects enrolled|The first cohort of three patients will receive a single dose in the first 48 postnatal hours.
62451325|NCT01930461|EXPERIMENTAL|SLIT (B)|SLIT tablets of HDM allergen extracts, 3 different doses (B)
62451326|NCT01930461|EXPERIMENTAL|SLIT (C)|SLIT tablets of HDM allergen extracts, 3 different doses (C)
62853828|NCT03635450|EXPERIMENTAL|Second cohort of 3 subjects enrolled|If there are no safety concerns after the first cohort of 3 subjects are infused then the second cohort of three patients will receive two doses, with the first dose given in the first 48 postnatal hours and the second dose given approximately two months after the first dose.
62853829|NCT02882750||Surgical Patients|Early stage NSCLC patients submitted to Surgical Resection
62853830|NCT02882750||SABR Patients|Early stage NSCLC patients submitted to SABR
62853831|NCT03159962|ACTIVE_COMPARATOR|Treated Group 1|Patient treated with bonded RME (Rapid Maxillary Expander) with a 13-mm screw. The acrylic splints of the bonded expander extended from the first deciduous molars through the first permanent molars.
62268450|NCT05550311|EXPERIMENTAL|Robot group|In addition to conventional treatment, an upper extremity robot-assisted rehabilitation program will be applied for 45 minutes a day, two days a week.
62268451|NCT05550311|ACTIVE_COMPARATOR|Control Group|Participants in this group will be included in a conventional rehabilitation program
62451327|NCT01930461|PLACEBO_COMPARATOR|Placebo|Placebo matching the SLIT tablets of HDM allergen extracts
62628562|NCT01826981|EXPERIMENTAL|Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN noncirrhotic)|SOF+VEL (100 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
62628563|NCT01826981|EXPERIMENTAL|Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN noncirrhotic)|SOF+VEL (100 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
62628564|NCT01826981|EXPERIMENTAL|Cohort 5,Group 1: LDV/SOF + RBV 24 wk (SOF retreatment)|LDV/SOF+RBV for 24 weeks in participants with genotype 1, 2, 3, or 6 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study
62853832|NCT03159962|ACTIVE_COMPARATOR|Treated Group 2|Patients treated with banded RME (Rapid Maxillary Expander) in the form of a butterfly palatal expander with a 13-mm screw cemented through bands on the second deciduous upper molars.
62451328|NCT02457858|EXPERIMENTAL|BMX-010 treated islets|Islet isolation using BMX-010
62628565|NCT01826981|EXPERIMENTAL|Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HBV coinfection)|LDV/SOF for 12 weeks in participants with genotype 1 HCV and hepatitis B virus (HBV) coinfection
62628566|NCT04600791|EXPERIMENTAL|BATwire Kit|Subjects will be implanted using the BATwire Implant Kit
62853833|NCT03159962|NO_INTERVENTION|Untreated Control Group|Matched untreated Class II control group prospectively evaluated after one year
62853834|NCT02184572|EXPERIMENTAL|INV_MMR|Subjects receive 1 dose of the study vaccine Priorix co-administered with Varivax and Havrix vaccines at Day 0. Subjects recruited in the US also receive Prevnar 13 at Day 0.
62853835|NCT02184572|ACTIVE_COMPARATOR|COM_MMR|Subjects receive 1 dose of the licensed vaccine M-M-R II or M-M-R VaxPro Lot 1 or Lot 2 co-administered with Varivax and Havrix vaccines at Day 0. Subjects recruited in the US also receive Prevnar 13 at Day 0.
62853836|NCT06247956|EXPERIMENTAL|SHR-8068 combined with adebrelimab and platinum-containing chemotherapy|
62063462|NCT04618822|EXPERIMENTAL|Teaching involving hand movements|i.e. arms and hands
62628567|NCT04855214||Body-powered Prosthesis User|Individuals who use a prosthesis that relies on a system of cables or harnesses which are operated using other parts of the body like the shoulders, chest, or elbows.
62063463|NCT04618822|ACTIVE_COMPARATOR|teaching involving minimal motor movements|i.e. seated on a chair using paper and pencil
62063464|NCT05057104||CK-SBRT with TACE group|
62063465|NCT05057104||Conversion hepatectomy after CK-SBRT plus TACE|
62268452|NCT02433652|EXPERIMENTAL|Trivalent dengue vaccine admixture + rDEN2Δ30-7169|Participants will receive the trivalent dengue vaccine admixture at Day 0 and the rDEN2Δ30-7169 vaccine at Day 180.
62268453|NCT02433652|EXPERIMENTAL|Placebo + rDEN2Δ30-7169|Participants will receive a placebo vaccine at Day 0 and the rDEN2Δ30-7169 vaccine at Day 180.
62268454|NCT02504021|EXPERIMENTAL|Family Consultation Condition|The family consultation will be one, 1-hour session conducted by trained, master's level therapists. The goals of the meetings are: a) Review patient and family understanding of events that caused the hospital admission; b) increase family awareness of the level of cognitive impairment that the patient is experiencing; c) discuss ways the family can get involved and help the patient with their medication and dialysis adherence; d) use motivational interviewing techniques as needed. This will be provided in addition to the usual care that inpatients receive in this unit.
62268455|NCT02504021|NO_INTERVENTION|Treatment as Usual Control Condition|Standard of care for the nephrology unit.
62451329|NCT03873480|ACTIVE_COMPARATOR|Intervention Arm|Participants randomized into the intervention group will receive an injection of 2.5 cc of 0.25% marcaine without epinephrine prior to the incision. The local anesthetic will be administered by the treating surgeon. All other aspects of the procedure will be kept in accordance with the standard of care for trigger thumb surgeries.
62628568|NCT04855214||Single degree-of-freedom (DOF) myoelectric prosthesis users|Individuals who use a myoelectric prosthesis that can perform only one movement.
62628569|NCT04855214||Multi-DOF myoelectric prosthesis users|Individuals who use a myoelectric prosthesis that can perform more than one movement.
62628570|NCT04855214||Sensory Augmentation|Individuals who experience augmented prosthesis sensory feedback through vibrating devices or pressure bladders, using electrical stimulation applied to the residual limb, or using neural implants.
62628571|NCT00829699|EXPERIMENTAL|1|Euinsulinemic (low insulin infusion) Euglycemic (normal blood glucose levels) glucose clamp with lipid (fat) infusion
62628572|NCT00829699|EXPERIMENTAL|2|Euinsulinemic Hyperglycemic (high glucose levels) glucose clamp with lipid infusion
62628573|NCT00829699|EXPERIMENTAL|3|Hyperinsulinemic (High dose insulin) euglycemic glucose clamp with lipid infusion
62628574|NCT00829699|EXPERIMENTAL|4|Hyperinsulinemic hyperglycemic (high glucose level) glucose clamp with lipid infusion
62628575|NCT05644288|EXPERIMENTAL|Intervention group|"The proposed intervention is a telephonic telenursing program aimed at managing social isolation in the elderly, the HELPeN (Help eNursing) program.~The operational part of the intervention will be carried out by volunteers nursing students from the University of Murcia enrolled in the academic years 2020-2023. To ensure homogeneity in the intervention carried out by the volunteers they will receive a 15-hour training oriented to ensure the acquisition of essential communication skills for the implementation of the intervention and to know the specific interventions of support and counseling for the elderly in social isolation."
62628576|NCT05644288|NO_INTERVENTION|Control group|No intervention will be performed in the control group and the subjects will be contacted on the same dates as the intervention group for data collection.
62628577|NCT03626701|EXPERIMENTAL|RECELL® Autologous Cell Harvesting Device|"RECELL + Telfa™ Clear and Xeroform™ dressings~Conventional autografting (only when indicated)"
62628578|NCT03626701|ACTIVE_COMPARATOR|Mepilex® Ag Wound Dressing|"Mepilex® Ag Wound Dressing~Conventional autografting (only when indicated)"
62628579|NCT05679453|ACTIVE_COMPARATOR|Etodolac|Etodolac, 400 mg tid per a day for four days
62628580|NCT05679453|ACTIVE_COMPARATOR|Lornoxicam|Lornoxicam, 8 mg twice per day for four days
62628581|NCT00410072|EXPERIMENTAL|TDF 0.5 mg|TDF=tenofovir
62628582|NCT00410072|EXPERIMENTAL|ETV 0.5 mg +TDF 300 mg|ETV=entecavir; TDF=tenofovir
62628583|NCT04444518|EXPERIMENTAL|VAX-MOM Intervention|
62063466|NCT02558361|OTHER|Open label, single arm|"Baseline visit:assess disease activity,synovial tissue biopsy of the knee with active synovitis \[target joint\] and punch skin biopsy of a target psoriatic plaque. Perform a similar punch skin biopsy on adjacent normal skin. Start apremilast (standard dosing). Perform venipuncture: blood samples will be obtained for routine studies, quantitative RT-PCR \& ex vivo cytokine production assays. UA/pregnancy test.~Month 1: assess disease active , monitor for AE's; repeat punch skin biopsy of target psoriatic plaque. Blood samples will be obtained for RT-PCR and ex vivo cytokine production assays.~Month 3: same as month 1; repeat synovial tissue biopsy from target knee joint and punch skin biopsy on target psoriatic plaque. Blood samples for RT-PCR ex vivo cytokine production assays and routine studies."
62063467|NCT03971838|EXPERIMENTAL|Intervention Arm|Women with a history of gestational diabetes will be offered 4-6 months of a diabetes prevention program.
62063468|NCT03290612|EXPERIMENTAL|Vitamin C then Placebo|Participants will receive a 1.5g dose of Ascorbic Acid upon wake for the first visit, and a placebo tablet on the second visit.
62628584|NCT04444518|ACTIVE_COMPARATOR|Standard of Care|
62628585|NCT00105989|EXPERIMENTAL|A|duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks
62628586|NCT00105989|PLACEBO_COMPARATOR|B|duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks
62628587|NCT01523834|EXPERIMENTAL|Panobinosat|"The treatment is divided in three phases: induction phase (course 1 to 6), consolidation phase (courses 7 to 12), maintenance phase (from course 13 until the end of therapy for any reason). The duration of a treatment course will be 28 days. The first dose of panobinostat in course 1 defines day 1 of the treatment cycle, and each cycle thereafter will begin 28 days later.~Treatment:~Panobinostat should be taken p.o. at the dose of 40 mg/day three-times every week (QW) (e.g., on Monday, Wednesday, and Friday or Tuesday, Thursday, and Saturday), as part of a 4 week (28 days) treatment cycle."
62853837|NCT06247956|ACTIVE_COMPARATOR|Adebrelimab combined with platinum-containing chemotherapy|
62853838|NCT02499445|ACTIVE_COMPARATOR|Remifentanil and propofol|remifentanil (0.75 mcg/kg/min) propofol (TCI effect-site concentration 0.8-1.5 mcg/ml)
62063469|NCT03290612|EXPERIMENTAL|Placebo then Vitamin C|Participants will receive a placebo tablet upon wake for the first visit, and a 1.5g dose of Ascorbic Acid on the second visit.
62063470|NCT05867719|NO_INTERVENTION|Normoxic|Participants will complete three flight simulator tasks at a normoxic (baseline) altitude. During the flight simulator, participants will need to accomplish three tasks: 1) Maintaining an altitude of 5,000 ft of elevation while performing a mental math test, 2) Flying the aircraft through the center of a series of 7 targets, and 3) Taking off and flying the aircraft a short distance to land on the center of an indicated target.
62063471|NCT05867719|EXPERIMENTAL|Simulated 8,000 feet hypoxic|Participants will complete three flight simulator tasks at a simulated 8,000 foot altitude. During the flight simulator, participants will need to accomplish three tasks: 1) Maintaining an altitude of 5,000 ft of elevation while performing a mental math test, 2) Flying the aircraft through the center of a series of 7 targets, and 3) Taking off and flying the aircraft a short distance to land on the center of an indicated target.
62451330|NCT03873480|NO_INTERVENTION|Non-Intervention Arm|Those that are not randomized into the intervention group will receive the standard of care for a trigger thumb release, which is administration of 2.5 cc of 0.25% marcaine without epinephrine following completion of surgery. The local anesthetic will be administered by the treating surgeon.
62451331|NCT05875688|EXPERIMENTAL|Group A|Filling the crown with cement up to margins.
62451332|NCT05875688|EXPERIMENTAL|Group B|Applying a cement layer on all fitting surfaces.
62451333|NCT05875688|EXPERIMENTAL|Group C|Applying a cement layer on all fitting surfaces except occlusal surface.
62063472|NCT05867719|EXPERIMENTAL|Simulated 12,000 feet hypoxic|Participants will complete three flight simulator tasks at a simulated 12,000 foot altitude. During the flight simulator, participants will need to accomplish three tasks: 1) Maintaining an altitude of 5,000 ft of elevation while performing a mental math test, 2) Flying the aircraft through the center of a series of 7 targets, and 3) Taking off and flying the aircraft a short distance to land on the center of an indicated target.
62451334|NCT02177084|EXPERIMENTAL|PTNS + conservative treatment|"PTNS consists in the insertion of a small electrode above the medial malleolus adjacent to the posterior tibial nerve. An adhesive surface electrode is placed under th arch of the foot. Both electrodes are connected to the neurostimulator that generates electricity. A neuromodulation session lasts 30 minutes.~The treatment plan includes 12 weekly sessions, followed by two sessions at 2-week intervals and the last one after one month. Two additional sessions of reinforcement (top-up) are provided at intervals of 6 months or earlier in case of worsening of symptoms"
62451335|NCT02177084|NO_INTERVENTION|conservative treatment|
62451336|NCT05764122|EXPERIMENTAL|Part 1: BIIB131 Low Dose|Participants will receive a single low dose of BIIB131 as an IV bolus followed by continuous IV infusion on Day 1. Based on the dose selection results from Part 1, participants may receive a single active dose of BIIB131 in Part 2.
62451337|NCT05764122|EXPERIMENTAL|Part 1: BIIB131 Medium Dose|Participants will receive a single medium dose of BIIB131 as an IV bolus followed by continuous IV infusion on Day 1. Based on the dose selection results from Part 1, participants may receive a single active dose of BIIB131 in Part 2.
62451338|NCT05764122|EXPERIMENTAL|Part 1: BIIB131 High Dose|Participants will receive a single high dose of BIIB131 as an IV bolus followed by continuous IV infusion on Day 1. Based on the dose selection results from Part 1, participants may receive a single active dose of BIIB131 in Part 2.
62268456|NCT04238390|EXPERIMENTAL|Ceftolozane-tazobactam|Participants will receive ceftolozane-tazobactam 3 grams (comprising ceftolozane 2 grams and tazobactam 1 gram) administered, every 8 hours, three times a day, intravenously over 60 mins
62268457|NCT04238390|ACTIVE_COMPARATOR|Meropenem|Participants will receive meropenem 1 gram, every 8 hours, three times a day, intravenously over 30 mins.
62853839|NCT02499445|ACTIVE_COMPARATOR|remifentanil and sevoflurane 1|remifentanil (0.75 mcg/kg/min) sevoflurane (end-tidal 0.8 vol%)
62063473|NCT05867719|EXPERIMENTAL|Ramp hypoxic exposure|Participants will complete three flight simulator tasks in a ramp exposure breathing at simulated 8,000 feet for five minutes before ascending to simulated 12,000 feet while flying in a flight simulator. During the flight simulator, participants will need to accomplish three tasks: 1) Maintaining an altitude of 5,000 ft of elevation while performing a mental math test, 2) Flying the aircraft through the center of a series of 7 targets, and 3) Taking off and flying the aircraft a short distance to land on the center of an indicated target.
62063474|NCT00486135|EXPERIMENTAL|1|Daily dosing for 21 days/7 days off
62063475|NCT00486135|EXPERIMENTAL|2|Continuous daily dosing
62268458|NCT05532774|NO_INTERVENTION|Ordinary defocusing frame glasses group|wear ordinary defocusing frame glasses
62268459|NCT05532774|EXPERIMENTAL|AI defocusing frame glasses group|wear defocusing frame glasses with artificial intelligence
62268460|NCT05433506|EXPERIMENTAL|Active Treatment: HU6 Tablet|
62268461|NCT05433506|EXPERIMENTAL|Active Treatment: HU6 Capsule|
62268462|NCT01709435|EXPERIMENTAL|Treatment (cabozantinib S-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62853840|NCT02499445|ACTIVE_COMPARATOR|sevoflurane 2 and sufentanil|sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (TCI effect site concentration 0.35-0.75 ng/ml)
62268463|NCT05846685||ED Patients Scheduled and Completed Falls Clinic Visit|Patients age 65 and Older identified by the automated system as being high-risk of future falls, and subsequently referred to the UW Health Mobility and Falls Clinic by the ED provider at discharge
62268464|NCT05846685||ED Patients Declined or Did Not Complete Falls Clinic Visit|Patients age 65 and Older identified by the automated system as being high-risk of future falls, and subsequently referred to the UW Health Mobility and Falls Clinic by the ED provider at discharge
62268465|NCT05846685||ED Patients Likely to be Discharged|Patients aged 65 and older who are in the emergency department and likely to be discharged.
62268466|NCT04453982||Human milk donors|
62268467|NCT05148923|ACTIVE_COMPARATOR|Rational energy algorithm|150 J, 360 J, 360 J biphasic DCCV
62268468|NCT05148923|ACTIVE_COMPARATOR|Maximum fixed energy algorithm|3x 360 J biphasic DCCV
62853841|NCT03717870|EXPERIMENTAL|Surgery|Laparoscopic enucleation of ovarian endometrioma (stripping of the peripheral capsule and coagulation using the lowest energy source available).
62063476|NCT00486135|EXPERIMENTAL|3|Continuous daily dosing
62063477|NCT03704532||Operative treatment|Patients having undergone an operative treatment of achilles tendon rupture
62268469|NCT01639677|EXPERIMENTAL|Laparoscopic gastric bypass|
62268470|NCT01639677|ACTIVE_COMPARATOR|Laparoscopic VBG|Laparoscopic vertical banded gastroplasty
62853842|NCT03717870|ACTIVE_COMPARATOR|Prolonged pituitary downregulation|Treatment with GnRH-a (triptorelin, goserelin, and leuprolide), with add-back therapy (combined oral contraceptive) for 3-6 months.
62853843|NCT00905645|EXPERIMENTAL|Primary Augmentation|Silimed Gel-Filled Mammary Implant
62853844|NCT00905645|EXPERIMENTAL|Revision-Augmentation|Silimed Gel-Filled Mammary Implant
62853845|NCT00905645|EXPERIMENTAL|Primary Reconstruction|Silimed Gel-Filled Mammary Implant
62268471|NCT02425826|EXPERIMENTAL|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
62268472|NCT02425826|PLACEBO_COMPARATOR|Placebo|Placebo tablets BID during Weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 36 weeks (from week 16 to week 52)
62063478|NCT03704532||Nonoperative treatment|Patients having undergone a nonoperative treatment with functional rehabilitation of achilles tendon rupture
62063479|NCT01595243|NO_INTERVENTION|control|patient with liver cancer in non-surgical treatment after discharge receive usual care
62063480|NCT01595243|EXPERIMENTAL|patient in experiment|patient in the experimental group will receive seven instances of telephone follow-up or face to face education
62063481|NCT05728567||Health control group|The participants without type 2 diabetes (T2DM) and mild cognitive impairment (MCI)
62063482|NCT05728567||T2DM group|The T2DM patients without MCI
62063483|NCT05728567||DCI group|The T2DM patients with MCI
62063484|NCT05779553||Group (1)(patient group):|"who are 50 newly diagnosed patient with colorectal cancer, who will be admitted at South Egypt Cancer Inistitute and Assiut University Hospital during 2023.~Patients group will be furtherly subclassified according to the American Joint Committee on Cancer Staging,TNM staging classification"
62063485|NCT05779553||Group (2) (control group)|40 apparently healthy individuals with matched age and sex are included in this study as a control group for comparison.
62063486|NCT04367038|EXPERIMENTAL|Warm Acupressure Procedure Group|"Latent phase Visual Analog Scale and Verbal Category Scale I given as pretest First venous blood sample taken Active phase The first warm acupressure procedure was performed for ten minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated three more times at one-hour intervals.~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second warm acupressure procedure was performed three times at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
62268473|NCT01515384|EXPERIMENTAL|Type 1 Diabetes|
62268474|NCT01515384|EXPERIMENTAL|Type 2 Diabetes|
62853846|NCT00905645|EXPERIMENTAL|Revision-Reconstruction|Silimed Gel-Filled Mammary Implant
62853847|NCT02600819|EXPERIMENTAL|E/C/F/TAF|Participants will switch their current antiretroviral regimen to E/C/F/TAF and receive treatment for 96 weeks. After Week 96, participants in the United States (US) who wish to participate in the open-label (OL) rollover extension will continue to take E/C/F/TAF FDC until the End of E/C/F/TAF Visit.
62853848|NCT02600819|EXPERIMENTAL|Open-Label Rollover Extension B/F/TAF|At Week 96 or the End of E/C/F/TAF Visit (whichever occurs last), participants will be given the option to receive open-label bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks.
62088074|NCT06492538||Schlemm canaloplasty|performed in the nasal quadrant by the collector channels were mainly concentrated in the nasal quadrant, by inserting the tip of a microblade (TMH; Tanito Microhook, Inami \& Co., Ltd., Tokyo, Japan) into Schlemm's canal, and then the inner wall of Schlemm's canal and trabecular meshwork was incised over 120°
62088075|NCT04807660||Prospective cohort|Middle ear fluid sample for each enrrolled children
62268475|NCT01515384|EXPERIMENTAL|Healthy Controls|
62268476|NCT04995081|ACTIVE_COMPARATOR|Allogeneic HB-adMSCs.|"Biological/Vaccine: Allogeneic HB-adMSCs~Allogeneic HB-adMSCs will be administered intravenously to study participants who qualify.~Other Names: Allogeneic Hope Biosciences adipose derived mesenchymal stem cells."
62853849|NCT05973721|EXPERIMENTAL|Phage treatment group|
62628588|NCT01473940|EXPERIMENTAL|Treatment (monoclonal antibody, chemotherapy)|"INDUCTION: Patients receive ipilimumab IV over 90 minutes in weeks 1, 4, 7, and 10 and gemcitabine hydrochloride IV over 30 minutes in weeks 1-7 and 9-11.~MAINTENANCE: Beginning in week 22, patients receive ipilimumab IV over 90 minutes once every 12 weeks and gemcitabine hydrochloride IV over 30 minutes once weekly for 3 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Treatment modifications may apply according to response."
62088076|NCT06102785||Fruquintinib combined with TAS102|Fruquintinib 4mg d1-21, q4w TAS102 35mg/m2，bid，d1-5，d15-19，q4w
62268477|NCT04995081|PLACEBO_COMPARATOR|Placebo|"Placebo will be administered intravenously to study participants who qualify.~Other Names: Sterile Saline Solution 0.9%"
62268478|NCT01457807|EXPERIMENTAL|1|AZD3241 300mg extended release formulation 1
62628589|NCT03241576|EXPERIMENTAL|Small portion size provision|Participants in this arm are served a small serving of a lunchtime food to eat (session 1).
62628590|NCT03241576|ACTIVE_COMPARATOR|Large portion size provision|Participants in this arm are served a large serving of a lunchtime food to eat (session 1).
62628591|NCT05394701|EXPERIMENTAL|RxOmega-3 soft gels (Enteric)|"Each participant receives their treatment of RxOmega-3 soft gel (Enteric) capsules at a total dose of 1260 mg Omega-3 Fatty Acids. Treatments are consumed with a glass of water (approx. 200 mL), followed by a standardized breakfast (diet-controlled condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours.~Participants are asked to arrive after an overnight fast (at least 9hrs). Each participant acts as their own control; there is no separate control group. A washout period of at least 14 days between each treatment will be used.~Adverse events are recorded throughout the study by direct questioning."
62268479|NCT01457807|EXPERIMENTAL|2|AZD3241 300mg extended release formulation 2
62628592|NCT05394701|EXPERIMENTAL|Omega-3 Complete soft gels (Non-Enteric)|"Each participant receives their treatment of Omega-3 Complete soft gel (Non-Enteric) capsules at a total dose of 1260 mg Omega-3 Fatty Acids. Treatments are consumed with a glass of water (approx. 200 mL), followed by a standardized breakfast (diet-controlled condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours.~Participants are asked to arrive after an overnight fast (at least 9hrs). Each participant acts as their own control; there is no separate control group. A washout period of at least 14 days between each treatment will be used.~Adverse events are recorded throughout the study by direct questioning."
62853850|NCT02857348|EXPERIMENTAL|Adventure video game|Physicians in this arm of the trial will be asked to play Night Shift, an adventure video game, for one hour.
62853851|NCT02857348|ACTIVE_COMPARATOR|Educational Module|Physicians in this arm of the trial will be asked to use myATLS, an app designed by the American College of Surgeons to serve as an adjunct to the ATLS course, and Trauma Life Support MCQ Review, an app designed to help students prepare for the ATLS exam. They will be asked to spend at least one hour on the combined tasks.
62853852|NCT05520892|EXPERIMENTAL|low-dose intravenous immunoglobulin|0.4g/kg.d, d1-5
62853853|NCT05520892|ACTIVE_COMPARATOR|high-dose intravenous immunoglobulin|1.0g/kg.d, d1-2
62853854|NCT03234283|EXPERIMENTAL|Study intervention group|All participants will be intubated with a video-laryngiscope by guiding the tracheal tube according to the highlighted Larynx on the Video Screen.
62268480|NCT01457807|PLACEBO_COMPARATOR|3|Placebo
62268481|NCT02566980||Pre-partum|130 pregnant women will be enrolled in first trimester. Healthy women or those with any degree of depressive symptoms are eligible. Blood samples and psychiatric assessments will take place once every trimester and once in the post-partum. At delivery placenta will be collected. Enrollment takes place at Spectrum Health Ob/gyn out-patient clinics in Grand Rapids, Michigan.
62268482|NCT02566980||Post-partum|50-100 women experiencing perinatal depression with and without suicidality will be enrolled from a partial hospitalization program, the Mother and Baby unit as well as outpatient clinics at Pine Rest Christian Mental Health Services, Grand Rapids, Michigan.
62268483|NCT04153721|EXPERIMENTAL|Digital Solution|The proposed digital solution aims to improve the patient's preparation for his colorectal surgery and follow his rehabilitation after surgery, by reinforcing his compliance with existing protocols and enriching it with complementary practices
62268484|NCT05841823|EXPERIMENTAL|Virtual reality exposure therapy (VRET)|In this group, each session of VRET will last 25 minutes and consists of three parts: 5 minutes of relaxation, 10 minutes of exposure to high-risk situation and 10 minutes of exposure to aversive situation. Each participants will receive 20 sessions of VRET, 5 sessions per week for 4 weeks.
62268485|NCT05841823|ACTIVE_COMPARATOR|Acceptance and commitment therapy (ACT)|In this group, participants will receive a 50-minutes ACT session per week for 4 weeks. Hence, a total of 4 sessions will be administered to each participant.
62268486|NCT05841823|NO_INTERVENTION|Treatment-as-usual control (TAU)|While for the control group, participants will receive non-specific ingredients of the psychotherapeutic approach schedule at a 50-minutes session per week for 4 weeks.
62268487|NCT06434311||Early knee Osteoarthritis|Patients who who have knee osteoarthritis categorized as 1 or 2 according to Kellgren - Lawrence
62268488|NCT06434311||Severe Knee Osteoarthritis|Patients who who have knee osteoarthritis categorized as 3 or 4 according to Kellgren - Lawrence
62268489|NCT00820521|EXPERIMENTAL|active|
62268490|NCT00820521|PLACEBO_COMPARATOR|placebo|
62088077|NCT05647369|EXPERIMENTAL|Experimental: Group 1|Experimental: Experimental group 1: patients, age 13-18, conventional brackets, Mastic mouthwash 15 patients, age 13-18,with conventional brackets,will get Mastic mouthwash
62853855|NCT04958460|EXPERIMENTAL|Probiotics group|"Probiotics~Candidates conditions excluded:~1. Patients with major mental or neurological diseases such as intellectual disability, autism group disorders, schizophrenia, severe depression, bipolar disorder, epilepsy, brain injury, etc.~2. Those who have serious gastrointestinal diseases, physiological diseases or genetic diseases that will affect the results of intestinal microflora assessment~3. Have received ADHD-related drug treatment (containing Methylphenidate or Atomoxetine) in the past month.~4. Have used antibiotics or edible probiotic-related products (including drops, tablets, capsules, bacterial powder) in the past month.~5. Participated in other clinical research in the past month.~6. Vegetarians or those currently undergoing special diet therapy.~7. Evaluation by the host is not suitable for entering the test."
62628593|NCT05394701|EXPERIMENTAL|Omega-3 LipoMicel® soft gels|"Each participant receives their treatment of Omega-3 LipoMicel® soft gel capsules at a total dose of 1260 mg Omega-3 Fatty Acids. Treatments are consumed with a glass of water (approx. 200 mL), followed by a standardized breakfast (diet-controlled condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours.~Participants are asked to arrive after an overnight fast (at least 9hrs). Each participant acts as their own control; there is no separate control group. A washout period of at least 14 days between each treatment will be used.~Adverse events are recorded throughout the study by direct questioning."
62628594|NCT05258253|EXPERIMENTAL|high intensity aerobics|"London bridges (8mins),Jumping lunges(8mins),Mountain climbers(8mins),Quadruped bent knee hip extension (8mins)"
62628595|NCT05258253|ACTIVE_COMPARATOR|pelvic clock exercises|Lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Subject begin with gentle movements from 12 to 6 o'clock, as instructed to move from 3 o'clock to 9 o'clock. Then move in a clockwise manner from 12 to 3 to 6 to 9 and then back to 12 o' clock.
62628596|NCT06415435|EXPERIMENTAL|Sylfirm X Treatment with Sunscreen|
62628597|NCT06415435|NO_INTERVENTION|No Treatment, Sunscreen Only|
62628598|NCT01254656|EXPERIMENTAL|LRV 500mg|
62628599|NCT01254656|EXPERIMENTAL|LRV 750mg +TVD|
62628600|NCT01254656|ACTIVE_COMPARATOR|EFV|
62628601|NCT01254656|EXPERIMENTAL|LRV 750mg+ DRV/r + OBT|
62628602|NCT01254656|EXPERIMENTAL|LRV 1000mg +DRV/r + OBT|
62628603|NCT01254656|ACTIVE_COMPARATOR|ETR|
62628604|NCT01678664|EXPERIMENTAL|embolization or chemoembolization plus everolimus|After 2 sessions of embolization with microsphere of 100 to 500 µm or chemoembolization with 100 mg of doxorubicine and 10 ml of lipiodol, administered every day, 10 mg of everolimus during 24 months or until progression (hepatic and other site).
62628605|NCT05419167|EXPERIMENTAL|STEP-COVID|Participants will participate online to the 6 sessions of the program addressing the psychological experience of pregnancy and supporting reflective capacities.
62628606|NCT05419167|NO_INTERVENTION|Usual prenatal cares|Participants of the comparison group will receive usual prenatal cares (ex. prenatal classes)
62628607|NCT01858207|ACTIVE_COMPARATOR|TACE+ RFA|"This arm will be conventional TACE(Transcatheter Arterial Chemoembolization) plus RFA(radiofrequency ablation.~use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor."
62628608|NCT01858207|ACTIVE_COMPARATOR|RFA|Recent advances in local ablation are aimed to expand the ablation size (\> 3cm in diameter) in a minimal session by utilizing the switching RF controller and simultaneous 2 or 3 RF electrodes placement. The procedure of RFA was according to manufacture algorithm. RFA was performed within 7 days after TACE because the embolization effect in reducing blood flow will be not evident afterwards.
62628609|NCT04156243|EXPERIMENTAL|CD19 CARvac T cells|CD19 CARvac T cells transduced with a lentiviral vector to express
62628610|NCT02809352||women tested positive for hrHPV|All women participating in START-HPV pilot program for cervical cancer screening and tested positive for hrHPV with the Hybrid Capture 2 test (Qiagen).
62628611|NCT00330694|EXPERIMENTAL|I|Implementation of ParkNet within 8 regions
62628612|NCT00330694|OTHER|II|Usual Care in 8 regions
62628613|NCT02899975|OTHER|Validation Swiss|20 german talking elderly and the non-professional caregiver will validate a Fitness and Information software
62628614|NCT02487797|EXPERIMENTAL|High dose oxytocin regimen|The oxytocin solution will be prepared using 90 units of oxytocin in 500 milliliters of normal saline (sodium chloride 0.9%). The oxytocin infusion will be initiated with a starting oxytocin concentration rate of 6 milliunits/minute (volume rate 2 milliliters/hour) that can be increased at increments of 6 milliunits/minute (volume rate 2 milliliters/hour) every 15-30 minutes until a labor pattern with uterine contractions every 2-3 minutes of moderate to strong intensity is established.
62628615|NCT02487797|ACTIVE_COMPARATOR|Low dose oxytocin regimen|The oxytocin solution will be prepared using 30 units of oxytocin in 500 milliliters of normal saline (sodium chloride 0.9%). The oxytocin infusion will be initiated with a starting oxytocin concentration rate of 2 milliunits/minute (volume rate 2 milliliters/hour) that can be increased at increments of 2 milliunits/minute (volume rate 2 milliliters/hour) every 15-30 minutes until a labor pattern with uterine contractions every 2-3 minutes of moderate to strong intensity is established.
62628616|NCT06391359|EXPERIMENTAL|Laparoscopic cholecystectomy|
62628617|NCT06391359|ACTIVE_COMPARATOR|Watchful waiting|
62628618|NCT01836146|EXPERIMENTAL|Renal Artery Ablation|
62853856|NCT04958460|PLACEBO_COMPARATOR|Control group|"Placebo~Candidates conditions excluded:~1. Patients with major mental or neurological diseases such as intellectual disability, autism group disorders, schizophrenia, severe depression, bipolar disorder, epilepsy, brain injury, etc.~2. Those who have serious gastrointestinal diseases, physiological diseases or genetic diseases that will affect the results of intestinal microflora assessment~3. Have received ADHD-related drug treatment (containing Methylphenidate or Atomoxetine) in the past month.~4. Have used antibiotics or edible probiotic-related products (including drops, tablets, capsules, bacterial powder) in the past month.~5. Participated in other clinical research in the past month.~6. Vegetarians or those currently undergoing special diet therapy.~7. Evaluation by the host is not suitable for entering the test."
62853857|NCT04270279|EXPERIMENTAL|Xueshuanxinmaining Tablet|"Patients were given Xueshuanxinmaining tablet orally 2 pills each time, 3 times daily for 8 weeks. And patients can take nitroglycerin tablets provided by the sponsor when angina attack.~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
62063487|NCT04367038|EXPERIMENTAL|Cold Acupressure Procedure Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous blood sample taken Active phase The first cold acupressure procedure was performed for ten minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated three more times at one-hour intervals.~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second cold acupressure procedure was performed three times at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
62063488|NCT04367038|EXPERIMENTAL|Conventional Acupressure Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous blood sample taken Active phase Conventional acupressure was performed for 30 minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated twice more at one-hour intervals.~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second conventional acupressure procedure was performed twice at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
62063489|NCT04367038|NO_INTERVENTION|Control Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous sample taken Active phase~No procedure other than the routine clinical practices were carried out. Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase No procedure other than the normal clinical routines was conducted Visual Analog Scale III and Verbal Category Scale III were performed. Second venous blood sample taken"
62628619|NCT00979095||Multiple hernia|Patients with more than 3 primary hernias
62628620|NCT00979095||Control group|Patients without hernias
62628621|NCT01635621|EXPERIMENTAL|OKZ 120 mg|
62628622|NCT01635621|EXPERIMENTAL|OKZ 240 mg|
62628623|NCT01635621|EXPERIMENTAL|OKZ 120 mg with 480 mg loading dose at Week 0|
62628624|NCT01635621|PLACEBO_COMPARATOR|Placebo|
62628625|NCT02858271|EXPERIMENTAL|AKB-9778|Single dose of \[14C\]-radiolabeled subcutaneous (SC) injection of AKB-9778 in the morning of Day 1
62268491|NCT06149780|EXPERIMENTAL|Fractional laser patients treated with laser|Laser with topical steroid and laser with vehicle.
62268492|NCT04082754|EXPERIMENTAL|CSL311 Cohort A1 (SAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a Single Ascending Dose (SAD)
62268493|NCT04082754|EXPERIMENTAL|CSL311 Cohort A2 (SAD Dose 2)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
62628626|NCT03122392|EXPERIMENTAL|AMS 800 Artificial Urinary Sphincter|"The AMS 800™ Urinary Control System is an implantable, fluid-filled, solid silicone elastomer prosthesis used to treat urinary incontinence due to reduced outlet resistance (intrinsic sphincter deficiency) following prostate surgery. The AMS 800 Urinary Control System simulates normal sphincter function by opening and closing the urethra, under patient control. When the cuff is closed, urine stays in the bladder.~When the patient wishes to void, he simply squeezes and releases the pump several times. This causes the fluid in the cuff to move into the pressure-regulating balloon . The cuff opens and urine passes through the urethra. The balloon then automatically re-pressurizes the cuff through the pump, within several minutes, the cuff again closes the urethra.~The control pump, which in implanted in the scrotum, is also designed to allow the clinician or patient to deactivate and activate the system without additional surgery."
62628627|NCT06135571||Cohort of left-sided colorectal cancer|Patients underwent curative surgery with dissection of No.253 Lymph node
62853858|NCT04270279|PLACEBO_COMPARATOR|Placebo|"Patients were given Xueshuanxinmaining tablet simulation orally 2 pills each time, 3 times daily for 8 weeks. And patients can take nitroglycerin tablets provided by the sponsor when angina attack.~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
62853859|NCT02366091|EXPERIMENTAL|Methotrexate|Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily
62853860|NCT02366091|EXPERIMENTAL|Colchicine|Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily
62853861|NCT02366091|EXPERIMENTAL|Methotrexate & Colchicine|Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily
62853862|NCT02366091|EXPERIMENTAL|Placebo|Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily
62853863|NCT01689194|EXPERIMENTAL|genexolPM + cisplatin|
62853864|NCT03712371|EXPERIMENTAL|Chitosan dose escalation|
62853865|NCT02280798||pilot study|"A total of 5 volunteers from our egg donation program were included in the study with 4 endometrial biopsies for each one after 4 diferente protocols~* Endometrial biopsy after Stimulated cycle~* Endometrial biopsy after Natural Cycle~* Endometrial biopsy after Natural modified cycle: the biopsy is taken seven days after the hCG~* Endometrial biopsy after Hormone Replacement Therapy Cycle"
62853866|NCT00630383|EXPERIMENTAL|1|Patients will receive 25 live hookworm larvae.
62063490|NCT01276561|ACTIVE_COMPARATOR|Single Incision Splenectomy|Patients will undergo splenectomy through a single incision in the umbilicus regardless of the technique or equipment used
62268494|NCT04082754|EXPERIMENTAL|CSL311 Cohort A3 (SAD Dose 3)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
62268495|NCT04082754|EXPERIMENTAL|CSL311 Cohort A4 (SAD Dose 4)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
62628628|NCT01749410||All participants|Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective medical record review.
62628629|NCT03791762|EXPERIMENTAL|WaveOne Gold|Root canal preparation with WaveOne Gold instrumentation system in a reciprocating manner
62853867|NCT00630383|PLACEBO_COMPARATOR|2|Patients will receive 0.01 % histamine solution.
62853868|NCT01782391|EXPERIMENTAL|0,75 Hz stimulation|slow transcranial oscillating stimulation (\~0,75Hz) during periods of Slow Wave Sleep
62853869|NCT01782391|SHAM_COMPARATOR|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
62853870|NCT02470988|ACTIVE_COMPARATOR|CBASP|Cognitive Behavioural Analysis System of Psychotherapy (CBASP) is a form of therapy specifically designed to treat individuals with chronic depression. CBASP combines a number of elements, with a focus on teaching the client to become aware of their interpersonal behaviour and its consequences.
62853871|NCT02470988|EXPERIMENTAL|CBASP Without DPI|In this arm CBASP will be delivered without Disciplined Personal Involvement (DPI) by the therapist.
62853872|NCT03911687|NO_INTERVENTION|Control Group|"Control data will be collected in the CONCERN CDS system that will be live in the EHR, but in silent release mode (e.g., not providing notification to clinicians)."
62853873|NCT03911687|EXPERIMENTAL|Intervention Group|"Experimental data will be collected in the CONCERN CDS system that will be live in the EHR in active release mode (e.g., providing CONCERN CDS system notification to clinicians)."
62268496|NCT04082754|EXPERIMENTAL|CSL311 Cohort A5 (SAD Dose 5)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
62268497|NCT04082754|EXPERIMENTAL|CSL311 Cohort A6 (SAD Dose 6)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
62628630|NCT03791762|EXPERIMENTAL|Reciproc Blue|Root canal preparation with Reciproc Blue instrumentation system in a reciprocating manner
62853874|NCT02717832|EXPERIMENTAL|Insulin Sensitivity|
62853875|NCT01209182|EXPERIMENTAL|Device image reading|Tissue images generated by the device are read by surgeons to determine if the tissue area under test has abnormal component or not. When Images generated by the device are read by surgeons as abnormal an additional margin of tissue is removed. The new margin is also imaged by the device to ensure complete tumor excision.
62853876|NCT03663400||Patients Treated with Tofacitinib|Microbiota profiling by 16S sequencing RNA-seq transcriptional profiling of the blood and biopsy samples Immunological profiling by multi-parameter flow cytometry
62268498|NCT04082754|EXPERIMENTAL|CSL311 Cohort A7 (SAD Dose 7)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
62268499|NCT04082754|EXPERIMENTAL|CSL311 Cohort A8 (SAD Dose 8)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
62268500|NCT04082754|EXPERIMENTAL|CSL311 Cohort B1 (MAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD
62268501|NCT04082754|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride solution administered intravenously
62628631|NCT03791762|EXPERIMENTAL|ProTaper Next|Root canal preparation with ProTaper Next instrumentation system in a rotating manner
62628632|NCT05935696||Tuberculous Pleural Effusion|"Tuberculous pleural effusion (TBE)~if any of the following criteria is presence:~* Histological evidence of caseating granuloma from pleural biopsy~* Microbiological evidence (positive growth of Mycobacterium tuberculosis culture, positive TB-PCR, positive Xpert MTB/RIF) from pleural fluid or pleural biopsy specimen~* In patients with positive sputum smear for acid fast bacilli, sputum positive for mycobacterium tuberculosis culture, sputum positive for Xpert MTB/RIF or TB-PCR with no apparent cause of an exudative pleural effusion~Patient without histological or microbiological evidence who demonstrated therapeutic response to anti-tuberculosis drugs will not be accepted as TBE in current study."
62628633|NCT05935696||Malignant Pleural Effusion (Control)|"Malignant pleural effusion (MPE)~if any of the following criteria is presence:~• Histological or cytological evidence of specific histopathological diagnosis of malignancy from pleural biopsy Patient without histological or cytological evidence or malignancy (para-malignant) will not be considered as MPE in the context of this study."
62628634|NCT05101759|OTHER|Geriatric Follow-up (Comprehensive Geriatric Assessment)|A systematic reassessment of geriatric parameters
62628635|NCT04117542||Overweight/Obesity Control|Adolescents who have overweight/obesity, but do not report loss of control eating.
62628636|NCT04117542||Overweight/Obesity Experimental|Adolescents who have overweight/obesity, and report loss of control eating.
62628637|NCT02163681|EXPERIMENTAL|Hyperpolarized Helium 3 MRI of the chest|Using hyperpolarized helium-3 as an inhaled contrast agent for MRI, we will assess the lung ventilation.
62628638|NCT03243305|EXPERIMENTAL|Interventional|This is a single-arm, open-label, Phase III study of AMPHORA , a non-hormonal contraceptive, at approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy.
62628639|NCT05873270||control group|
62628640|NCT05873270||Intervention group|
62628641|NCT05258734|EXPERIMENTAL|COVOS app|
62628642|NCT05258734|ACTIVE_COMPARATOR|Control Group|
62628643|NCT03210051|EXPERIMENTAL|RIC & ET|Remote ischemic conditioning paired with endovascular treatment. RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times. Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association. It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
62853877|NCT02194374|EXPERIMENTAL|ROR1R-CAR-T Cells|"Peripheral blood mononuclear cells (PBMC) collected via venipuncture and/or steady state leukapheresis at discretion of PI. Participants receive a cycle of lympho-depleting chemotherapy as chosen by treating physician 4 to 5 days before ROR1R-CAR-T cell infusion : Fludarabine, Cyclophosphamide, and Rituximab (FCR), Bendamustine and Rituximab (BR), or Fludarabine, Bendamustine, and Rituximab (FBR).~Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.~Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort."
62853878|NCT01250496|EXPERIMENTAL|Aminophylline|75 mg of intravenous aminophylline.
62268502|NCT04082754|PLACEBO_COMPARATOR|Placebo (2)|0.9% sodium chloride solution administered subcutaneously
62268503|NCT04082754|EXPERIMENTAL|CSL311 Cohort C1 (MAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously (SC)
62268504|NCT04082754|EXPERIMENTAL|CSL311 Cohort C2 (MAD Dose 2)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously
62268505|NCT04082754|EXPERIMENTAL|CSL311 Cohort C3 (MAD Dose 3)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously
62268506|NCT05304351|EXPERIMENTAL|Arm A|Investigational Vaccine
62268507|NCT05304351|EXPERIMENTAL|Arm B|Investigational Vaccine
62268508|NCT05304351|ACTIVE_COMPARATOR|Arm C & G|Active comparator
62628644|NCT05123352||Standard intensive chemotherapy|Patients with acute myeloid leukemia in this cohort will receive standard induction chemotherapy that combines seven days of cytarabine and three days of anthracycline (7+3 regimen).
62628645|NCT05123352||Bcl-2 inhibitor-based targeted therapy|Patients with acute myeloid leukemia in this cohort will receive Bcl-2 inhibitor-based targeted therapy, such as combination of bcl-2 inhibitor plus decitabine/azacitidine with or without sorafenib.
62628646|NCT00208260|ACTIVE_COMPARATOR|A|FOLFIRI
62628647|NCT00208260|ACTIVE_COMPARATOR|B|FOLFOX-4
62628648|NCT00208260|EXPERIMENTAL|C|FOLFIRI-HD
62628649|NCT00208260|EXPERIMENTAL|D|FOLFOX-7
62628650|NCT00208260|EXPERIMENTAL|E|FOLFIRINOX
62853879|NCT01250496|PLACEBO_COMPARATOR|Placebo|Matching normal saline placebo (sterile salt water).
62853880|NCT01612923|EXPERIMENTAL|midwife|Gynecological exam and ultrasound performed by midwife, medical abortion service provided by midwife,contraceptive advice provided by midwife. Follow-up visit provided by midwife
62853881|NCT01612923|NO_INTERVENTION|Physician|Gynecological exam and ultrasound and contraceptive advice provided by physician. Medical abortion service and follow-up visit provided by midwife
62268509|NCT05304351|EXPERIMENTAL|Arm D|Investigational Vaccine
62268510|NCT05304351|EXPERIMENTAL|Arm E|Investigational Vaccine
62268511|NCT05304351|EXPERIMENTAL|Arm F|Investigational Vaccine
62268512|NCT05288270|EXPERIMENTAL|Aramis Group|Consecutive patients, admitted to Sant' Anna Institute with diagnosis of stroke after hospital discharge that need motor and cognitive treatment and rehabilitation of neurological diseases.
62268513|NCT05288270|ACTIVE_COMPARATOR|Conventional Group therapy|Consecutive patients, admitted to Sant' Anna Institute with diagnosis of stroke after hospital discharge that need motor and cognitive treatment and rehabilitation of neurological diseases.
62628651|NCT01046331||Adult H1N1|Patients admitted to adult ICU with confirmed or suspected H1N1 Influence infection
62628652|NCT01046331||Pediatric H1N1|Patients admitted to pediatric ICU with confirmed or suspected H1N1 Influenza infection
62628653|NCT04744506|ACTIVE_COMPARATOR|Group 1: CG-TAD Group|US-guided clip insertion into suspicious ALNs pre-NAC Post-NAC, TAD removing SLNs and clipped LNs
62853882|NCT04178278|EXPERIMENTAL|Shuttle walking test group|Patients will performed shultte walking test.
62853883|NCT04178278|ACTIVE_COMPARATOR|Exercise stress test group|Patients will performed exercise stress test.
62853884|NCT04178278|ACTIVE_COMPARATOR|6 minutes walking test group|Patients will performed 6 minutes walking test.
62853885|NCT01395290|EXPERIMENTAL|cholecalciferol|cholecalciferol 20.000 IU per week
62853886|NCT04704947|EXPERIMENTAL|nonselective beta blocker group|Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to propranolol (Inderal®) 10 mg once daily titrated as patient's response.
62853887|NCT04704947|EXPERIMENTAL|cardio-selective beta blocker group|Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to bisoprolol (Concor®) 5 mg once daily titrated as patient's response.
62628654|NCT04744506|EXPERIMENTAL|Group 2: CN-LNM Group|US-guided CNSI injection to tattoo suspicious ALNs pre-NAC Post-NAC, TAD removing SLNs and carbon-marked LNs
62628655|NCT04744506|EXPERIMENTAL|Group 3: PCN-MAP Group|US-guided CNSI injection around primary tumor pre-NAC, additional US-guided clip placement for metastatic LN Post-NAC, TAD removing SLNs, carbon-marked LNs, and clipped LNs
62628656|NCT04602156|EXPERIMENTAL|Group T|Patients will be randomized to undergo PC catheter placement (8-French) using the trocar method under US guidance while receiving local anesthesia and opioid analgesic, in a bedside setting, either in the US room or in the ICU.
62853888|NCT04704947|PLACEBO_COMPARATOR|Control group|Ten patient with osteoporosis on alendronate sodium 70 mg (Fosamax®) once/week, vitamin D3 1 mcg once daily and calcium supplement 500 mg once daily.
62853889|NCT03476005|ACTIVE_COMPARATOR|Proficiently Trained interns -|Provided with proficiency based progression training supported by technology enhanced learning
62853890|NCT03476005|NO_INTERVENTION|Historical controls|no extra training provided
62063491|NCT01276561|ACTIVE_COMPARATOR|Laparoscopic Splenectomy|Patient will undergo standard laparoscopic splenectomy, port placement is surgeon dependent
62628657|NCT04602156|ACTIVE_COMPARATOR|Group S|Patients will be randomized to undergo PC catheter placement (8-French) using the Sellinger method under US guidance while receiving local anesthesia and opioid analgesic, in a bedside setting, either in the US room or in the ICU.
62628658|NCT01711255||Multiple Sclerosis|Subjects who have been diagnosed with clinically definite or probable multiple sclerosis as defined and recorded by board certified neurologist.
62628659|NCT01711255||Healthy controls|Adults age 18 and older who have not been diagnosed with any neurological, endocrine, or other chronic health condition. They must also be free of any recent acute illness that can impact inflammation/clotting.
62628660|NCT03822156||Cavitary Pulmonary Tuberculosis|The patients who are diagnosed with the cavitary pulmonary tuberculosis
62628661|NCT03822156||Endobronchial Tuberculosis|The patients who are diagnosed with the endobronchial tuberculosis
62628662|NCT05799430|EXPERIMENTAL|Intervention|The intervention group will receive a multidisciplinary medication review and a personalized therapeutic plan in the following 72 hours after hospital discharge. The intervention will be developed by a multidisciplinary team that includes a family physician (FP), a primary care nurse (PCN) and a primary care pharmacist (PCP). PCP is a pharmacist working in a full-time base for the Pharmacy Service in a Primary Care District in Andalusian Public Health Service.
62628663|NCT05799430|ACTIVE_COMPARATOR|Control group|The control group will receive usual care.
62628664|NCT02158377|ACTIVE_COMPARATOR|Tapered Screw-vent implants (TSV)|TSV implants to replace missing tooth/teeth
62628665|NCT02158377|EXPERIMENTAL|Trabecular Metal dental implants (TM)|TM dental implants to replace missing tooth/teeth
62628666|NCT03082469|ACTIVE_COMPARATOR|CytoSorb|CytoSorb therapy for 48h
62628667|NCT03082469|NO_INTERVENTION|Matched controls|60 matched controls with SAP and transpulmonary thermodilution monitoring
62628668|NCT04684134||experimental group|patients with colorectal polyps
62628669|NCT04684134||control group|patients without intestinal diseases
62628670|NCT01720524|PLACEBO_COMPARATOR|placebo|iv placebo of normal saline or 10% dextrose
62628671|NCT01720524|EXPERIMENTAL|sildenafil|Active study drug
62628672|NCT05556460|EXPERIMENTAL|Randomized - Device Group|The experimental group is allocated to use a novel tricuspid valve repair system for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd. and will continue to be managed on medical therapy, per physician discretion
62628673|NCT05556460|ACTIVE_COMPARATOR|Randomized - Control Group|Subjects will continue to be managed on medical therapy, per physician discretion
62628674|NCT03300440|EXPERIMENTAL|Intervention group|Probiotics and vitamin B7
62628675|NCT03300440|PLACEBO_COMPARATOR|Control group|Placebo and vitamin B7
62628676|NCT00677313|EXPERIMENTAL|1|
62853891|NCT00926029|PLACEBO_COMPARATOR|Fluoride control -A|Winterfresh Gel
62853892|NCT00926029|ACTIVE_COMPARATOR|Triclosan/Fluoride - B|Positive control (Total toothpaste)
62853893|NCT00926029|EXPERIMENTAL|Triclosan/fluoride/metal salt- C|test toothpaste
62853894|NCT04334577|EXPERIMENTAL|Attenuated Zoster Vaccine, Live|One shot of the vaccine (with live viruses titer \>=4.3 LgPFU per dose)
62853895|NCT04334577|PLACEBO_COMPARATOR|Placebo|one shot of placebo with no live virus
62853896|NCT04950296|ACTIVE_COMPARATOR|Group I: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
62853897|NCT04950296|ACTIVE_COMPARATOR|Group II: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
62628677|NCT02093416||Group 1: Control Group|BMI \<30 There are 20 controls in this group
62628678|NCT02093416||Group 2|BMI 30-35 There were 12 controls in this class
62628679|NCT02093416||Group 3|BMI 35-40 There were 9 controls in this clas
62628680|NCT02093416||Group 4|BMI \>40 There were 9 controls in this class
62628681|NCT01643447|ACTIVE_COMPARATOR|Diammonium glycyrrhizinate|Conventional drugs protect liver
62628682|NCT01643447|EXPERIMENTAL|Ulinastatin|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
62628683|NCT04616677|ACTIVE_COMPARATOR|Parts 1 and 2: Cohort 1 (JNJ-42847922)|Healthy participants with normal renal function \[estimated glomerular filtration rate (eGFR) greater than or equal to (\>=) 90 milliliter (mL)/minute (min)\] will receive single oral dose of JNJ-42847922 on Day 1.
62628684|NCT04616677|EXPERIMENTAL|Part 1: Cohort 2 (JNJ-42847922)|Participants with severe renal impairment (eGFR 15 to 29 mL/min) will receive single oral dose of JNJ-42847922 on Day 1.
62628685|NCT04616677|EXPERIMENTAL|Part 2 (Optional): Cohort 3 (JNJ-42847922)|Participants with moderate renal impairment (eGFR 30 to 59 mL/min) will receive single oral dose of JNJ-42847922 on Day 1.
62628686|NCT03866356|EXPERIMENTAL|Intervention group|The intervention group received care according to the SICP (Table 2). One of the researchers gave each participant one-on-one education in line with SICP. They were also provided with the booklet that had been prepared in accordance with SICP. The participants were phoned every week for eight weeks and offered counseling within the scope of SICP and then were reevaluated at the end of eight weeks (Post-intervention). The participants were followed from the eighth to the twelfth week without any intervention (4-week post-intervention).
62268514|NCT04495309|NO_INTERVENTION|Standard|Standard of care, i. e. no local radiotherapy in addition to standard systemic therapy (exception: palliative local treatment of symptomatic lesions where indicated)
62268515|NCT04495309|EXPERIMENTAL|Experimental|Standard of care (standard systemic therapy) + study intervention
62628687|NCT03866356|NO_INTERVENTION|Control group|The control group received no intervention during the eight-week intervention period. The control group received standard care. The women were given no educational materials.
62628688|NCT05917327|EXPERIMENTAL|MEX-CD1 Low volume CVVHD|"Patients enrolled in the treatment arm will receive MEX-CD1 treatment depending on the severity of their symptoms in addition to standard of care:~* Patients with moderate liver injury not requiring extracorporeal blood epuration therapies as standard of care: 5 treatments with MEX-CD1 on consecutive days~* Patients requiring extracorporeal blood epuration therapies as standard of care: 10 treatments with MEX-CD1 on consecutive days"
62628689|NCT03314883|EXPERIMENTAL|D-US ARF|Diaphragmatic evaluation, i.e thickening fraction (%) and excursion (millimeters), will be performed 3 times in the first two hours after acute hypoxic - hypercapnic respiratory failure (ARF) patients admission
62628690|NCT05661695|OTHER|RT's in ICU|We will collect ventilator pressure, flow, volume, oxygen and breathing pattern data, etc, as well as arterial blood-gas exchange and hemodynamic data of adults attached to ventilators. the RRT's will treat patients as normal without the assistance of the RT Assistant for the pre-intervention phase and will be observed collecting the same data and performing patient care with the assistance of the RT Assistant during the intervention phase. The RRTs will then be given a likert scale questionnaire on the use of the RT Assistant.
62628691|NCT05273723|EXPERIMENTAL|Intervention|Dose-finding study with 14 groups of 3 participants each. To identify the minimum effective dose (MED) to increase walking by 2,000 more steps per day between run-in and follow-up periods, the first group of 3 participants will receive a 5-week dose of the multi-BCT intervention. For the next subjects, the doses to administrate will vary between 1 and 10 weeks in length and will be determined using a modified version of the Time-to-Event Continual Reassessment Method (TiTE-CRM) according to the observed responses in the previous participants.
62628692|NCT02829658||Psychiatric patients group|Patient groups were composed with: BPD, other PD and assessed Psychologic test
62628693|NCT02829658||Control group|Matched controls (age, sex) composed the 3rd and 4th group (BPD control and other PD control). They were randomly chosen in the health database insurance previously used. They had no intervention.
62628694|NCT00995722|EXPERIMENTAL|Prednisone + Pyridostigmine|Corticosteroid
62088078|NCT05647369|PLACEBO_COMPARATOR|Control group: Group 2|Control group: Group 2 patients, age 13-18, conventional brackets, placebo mouthwash 15 patients, age 13-18,with conventional brackets,will get placebo mouthwash
62268516|NCT00746135|ACTIVE_COMPARATOR|A|Conventional Biventricular Stimulation: RV Apex and LV Lead Tip
62268517|NCT00746135|ACTIVE_COMPARATOR|B|"Anodal-Cathodal Biventricular Stimulation: cathodal LV Stimulation und anodal RVHis Stimulation = Anodal-cathodal Bi-V."
62628695|NCT00995722|PLACEBO_COMPARATOR|Placebo + Pyridostigmine|Matched, inactive substance
62268518|NCT00746135|ACTIVE_COMPARATOR|C|Anodal-Cathodal Tri-V Stimulation: RV-apex and LV and RV-His
62628696|NCT06333886||SCI patients with neuro-sacral dysfunction|450 patients with traumatic and non-traumatic acute SCI admitted to a level-1 trauma hospital in Montreal, Quebec, Canada
62628697|NCT00205660|OTHER|Stayers|Subjects are randomized to stay on their current antipsychotic.
62628698|NCT00205660|OTHER|Switchers|Subjects are randomized to switch to aripiprazole from their current antipsychotic.
62628699|NCT00324974|EXPERIMENTAL|Lansoprazole QD|
62628700|NCT00324974|PLACEBO_COMPARATOR|Placebo QD|
62628701|NCT05868681|EXPERIMENTAL|Study group|Proprioceptive training, which will be carried out 1 session lasting one hour twice per week for 5 weeks using Delos instrument with Riva method
62628702|NCT05868681|NO_INTERVENTION|Control group|Normal physiotherapy performed according to standard protocols.
62853898|NCT04950296|PLACEBO_COMPARATOR|Microcrystalline Cellulose|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
62853899|NCT03543072||exposure group|exposed to some factors
62853900|NCT03543072||control group|not exposed to some factors
62853901|NCT01798160|ACTIVE_COMPARATOR|DEB TACE|Drug eluting Beads (DC Beads) loaded with Doxorubicin
62451339|NCT05764122|PLACEBO_COMPARATOR|Part 1 and Part 2: Placebo|Participants will receive a single dose of BIIB131-matching placebo in Part 1 and Part 2, as an IV bolus followed by continuous IV infusion on Day 1.
62451340|NCT01966081|OTHER|Cases|
62451341|NCT01966081|OTHER|controls|
62853902|NCT01798160|EXPERIMENTAL|SIRT|Selective Internal Radiation Therapy using Yttrium 90 loaded resin beads (Sir Spheres)
62853903|NCT01212380|EXPERIMENTAL|Arm 1|Patients receive carfilzomib IV over 30 minutes once daily on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.Performance of pharmacology, pharmacodynamic and pharmacogenomic studies allow assessment of carfilzomib mechanism of action and also to understand how the variability of these different features correlate with clinical benefit/response and also toxicity.
62853904|NCT04267224||Early group|Patients receiving the loading dose of Ticagrelol 90 mg more than 60 minutes before PCI.
62853905|NCT04267224||Late group|Patients receiving the loading dose of Ticagrelol 90 mg less than 60 minutes before PCI.
62853906|NCT06089785||patients with liver cell failure|patients with liver cell failure and any complications
62853907|NCT03291093|EXPERIMENTAL|18F-Flutemetamol PET/MRI dynamic|"All included patients will be patients with a recent stroke and a significant carotid plaque.~The first 5 patients will undergo a slightly longer scan protocol to determine optimal scan time for the use of 18F-Flutemetamol in atherosclerosis imaging."
62088079|NCT01015183|EXPERIMENTAL|Intervention|Received Zinc Sulfate
62853908|NCT03291093|EXPERIMENTAL|18F-Flutemetamol PET/MRI CEA|10 patients will be selected from patients that will undergo carotid endarterectomy (CEA) and will undergo the the optimized (shorter) scan protocol with 18F-Flutemetamol. The decision for this operation is made by the surgeon and neurologist and based on clinical standards and is thus independent of study participation.
62853909|NCT03291093|EXPERIMENTAL|18F-Flutemetamol PET/MRI|The remaining 10 patients will undergo the optimized (shorter) scan protocol with 18F-Flutemetamol.
62853910|NCT02282293|ACTIVE_COMPARATOR|Daily TS + Monthly DP pregnancy|Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
62853911|NCT02282293|PLACEBO_COMPARATOR|Daily TS + DP Placebo pregnancy|Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
62853912|NCT04056377||Black boys|240 black boys were included in the study (mean age 7.5 years)
62088080|NCT01015183|PLACEBO_COMPARATOR|Control|Control group
62853913|NCT04056377||Black girls|339 black girls were included in the study (mean age 7.5 years)
62853914|NCT04056377||White boys|239 white boys were included in the study (mean age 7.4 years)
62853915|NCT04056377||White girls|224 white girls were included in the study (mean age 7.4 years)
62853916|NCT06505772|EXPERIMENTAL|The dexmedetomidine group|"Dexmedetomidine:~An initial dose of 0.5 mcg/kg of dexmedetomidine will be given over 10 minutes, starting 10 minutes after the initiation of anesthesia infusion.~Following the initial dose, a continuous infusion of dexmedetomidine will be administered at a rate of 0.4 mcg/kg/hour.~The infusion will be stopped before skin closure."
62853917|NCT06505772|PLACEBO_COMPARATOR|The Placebo group (the control group):|"Saline Solution (Placebo):~After the induction of anesthesia, a volume of saline solution equivalent to the volume of dexmedetomidine used in the experimental group will be administered using the same protocol."
62853918|NCT06431867||Older women|Women aged 70 years and older with a diagnosis of osteoporosis
62853919|NCT06431867||Primary healthcare professionals|Any healthcare professional working in a primary care setting e.g. general practitioner, pharmacist, physiotherapist
62853920|NCT01515644|EXPERIMENTAL|Intervention group I|Intervention group I: Powder based Infant formula with Inulin I
62628703|NCT05264909|EXPERIMENTAL|Transcranial Direct Current Stimulation TDCS|"Each subject will receive transcranial electrical stimulation at primary motor located in Cz based on the EEG 10-20 international system. The program include 18 sessions with a frequency of 3 times per week during 6 weeks. Therefore, during tDCS sessions, subjects will receive stimulation for 15 minutes with a current of 1.5 milliamp using 7x5 cm electrodes.~During the stimulation, the patient must simultaneously perform gait training for 30 minutes where the speed of each step is guided by the frequency of biaural rhythms and beats, constantly heard through hearing aids. Additionally, the length of the passage will be indicated by white stripes (50 cm long and 5 cm wide), placed perpendicular along a walkway of 6.5 m.~Thus, each session will be monitored on safety aspects of the subjects with emphasis on skin problems and other possible side effects of tDCS."
62628704|NCT05798143|EXPERIMENTAL|Active arTMS treatment|rTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with the Cool-B-70 figure-of-eight coil (MagVenture, Falun, Denmark).
62628705|NCT05205512|EXPERIMENTAL|Group I (telehealth exercise)|Patients participate in telehealth exercise intervention for 30 minutes per day, 3 days a week for 8 weeks.
62628706|NCT05205512|ACTIVE_COMPARATOR|Group II (delayed control)|Patients maintain current levels of physical activity for 8 weeks. Patients may then participate in telehealth exercise intervention for 8 weeks.
62853921|NCT01515644|EXPERIMENTAL|Intervention group II|Intervention group II: Powder based Infant formula with Inulin II
62853922|NCT01515644|PLACEBO_COMPARATOR|Intervention group III|Intervention group III: Powder based Infant formula without Inulin
62628707|NCT00868647|OTHER|Radiofrequency Ablation|
62628708|NCT00610272|EXPERIMENTAL|Single Site Radiation 4Gy Fraction|4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), \>4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after \> 4 weeks
62628709|NCT00610272|ACTIVE_COMPARATOR|Single Site Radiation 8Gy Fraction|8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), \>4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after \> 4 weeks
62628710|NCT00610272|ACTIVE_COMPARATOR|Multiple Sites Radiation 8Gy Fraction|8 Gy in a single fraction; retreatments \> 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
62628711|NCT00610272|EXPERIMENTAL|Multiple Sites Radiation 12Gy Fraction|12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments \> 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
62628712|NCT03307941|OTHER|Single arm (classic 3+3 design)|
62628713|NCT03252145|EXPERIMENTAL|Negative Pressure|PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb
62628714|NCT03252145|ACTIVE_COMPARATOR|Manual Lymph Drainage|Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb
62853923|NCT02212600||Population|We will include male and female patients who are over 50 years of age and who have an acute, displaced or undisplaced proximal humerus fracture caused by low energy trauma
62853924|NCT01494493|EXPERIMENTAL|rhBMP-2/ACS|
62853925|NCT01494493|ACTIVE_COMPARATOR|Autogenous Bone|
62853926|NCT03035474|OTHER|Direct & Digital|Health system engagement to improve local QI programs and patient engagement to improve self-management/medication adherence
62853927|NCT03035474|OTHER|Direct & Registry|Health system engagement to improve local QI programs and patient and control
62853928|NCT03035474|OTHER|Digital & Registry|Patient engagement to improve self-management/medication adherence and control
62853929|NCT03035474|NO_INTERVENTION|Registry|Control
62853930|NCT00920803|ACTIVE_COMPARATOR|5g SRT501|5.0 g of SRT501 will be administered once daily as an oral reconstituted powder, for 14 days at the same time each day. On Days 1 and 2, SRT501 will be administered approximately 15-30 minutes following the consumption of a standardized breakfast. On all other days, SRT501 will be administered approximately 15-30 minutes following the consumption of the evening meal. Following the course of SRT501 administration, subjects will undergo scheduled surgical removal of their metastatic liver disease as well as non-diseased tissue. Due to scheduling and surgical availability, subjects can receive SRT501 for a minimum of 10 days and a maximum of 21 days.
62853931|NCT00920803|PLACEBO_COMPARATOR|Placebo|Placebo will be administered once daily as an oral reconstituted powder, for 14 days at the same time each day. On Days 1 and 2, placebo will be administered approximately 15-30 minutes following the consumption of a standardized breakfast to allow for PK sample collection. On all other days, placebo will be administered approximately 15-30 minutes following the consumption of the evening meal. Following the course of placebo administration, subjects will undergo scheduled surgical removal of their metastatic liver disease as well as non-diseased tissue. Due to scheduling and surgical availability, subjects can receive placebo for a minimum of 10 days and a maximum of 21 days.
62853932|NCT01717833|EXPERIMENTAL|NEMS group|
62853933|NCT01717833|SHAM_COMPARATOR|Sham group|
62853934|NCT06365762|EXPERIMENTAL|C-KAD 2.6%|Administered four times a day (QID; no less than 3 hours apart) in both eyes for 120 days
62853935|NCT06365762|EXPERIMENTAL|C-KAD 1.3%|Administered four times a day (QID; no less than 3 hours apart) in both eyes for 120 days
62853936|NCT06365762|PLACEBO_COMPARATOR|Placebo|Administered four times a day (QID; no less than 3 hours apart) in both eyes for 120 days
62853937|NCT04143178|EXPERIMENTAL|Expressive Writing Group|Writing group participants has been asked to write for 3 consecutive days, 20 minutes each days, all the deepest emotions and feelings related to the disease, the transplant, and their best expectations after the operation.
62853938|NCT04143178|OTHER|Control Group|The control group participant has been asked to describe an objects in their room, in a neutral way, without mentioning emotions or feelings,for 3 consecutive days, 20 minutes each day.
62853939|NCT01051518|EXPERIMENTAL|CoreValve|
62853940|NCT02010151|EXPERIMENTAL|NAD-CPR|When dispatcher detects a patient with OHCA, the dispatcher activates trained neighborhoods by informing events nearby using short message service via cellular phone. The neighborhood within geographically accessible area who could perform effective CPR and defibrillation would be alerted with event of OHCA and the nearest AED.
62451342|NCT03574155|NO_INTERVENTION|Control- group|"It is composed of patients scheduled for surgical treatment by tumors of the uterine cervix, vulva, ovary or endometrium, who will receive preoperative and postoperative guidelines according to the usual routine for the perioperative period of the present institution. Patients and their followers of the control group will participate in a preoperative consultation with the surgeon to discuss the indication of the procedure and its risks, benefits and alternatives to the procedure being indicated, if any.~Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)"
62451343|NCT03574155|EXPERIMENTAL|Experimental Group|"Composed of patients scheduled for surgical treatment by tumors of the uterine cervix, vulva, ovary or endometrium who will receive preoperative counseling and education through a pre-defined protocol after preoperative consultation with the surgeon. The counseling session will take place with at least one companion. The purpose of this session is to supplement, re-emphasize and strengthen the perioperative guidelines. An illustration (explanatory folder) will be used to demonstrate the location of the surgery, how the scar will be and on which sites of the abdomen and organs the surgery will cover. All this counseling and education will be applied at the same time to the patient and her companion. At the end of the intervention, a space will be left open for both the patient and the companion to ask questions and questions.~Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)"
62451344|NCT05113056|EXPERIMENTAL|Non-randomized|All subjects will be ablated using the Acutus Medical Pulsed Field Ablation System (PFA System) in the management of their atrial fibrillation.
62853941|NCT02010151|NO_INTERVENTION|Conventional dispatcher assisted CPR|When dispatcher detects OHCA, they instruct the caller with CPR instructions. This is conventional dispatcher assisted CPR performed in Seoul.
62451345|NCT05330507||Wellinks Intervention|Following inpatient hospitalization for COPD exacerbation, participants will receive 16 weeks of access to Wellinks (i.e., connected spirometer and pulse oximeter, virtual respiratory therapist sessions with pulmonary rehabilitation, virtual health coaching sessions, mobile app access, COPD-related education). The 16-week period is comprised of a 30-day post-discharge program followed by a 12-week intensive period, which vary by frequency of contact with respiratory therapists/health coaches.
62853942|NCT02746224|OTHER|group 1A|the surgical technique initially dissects the inferior mesenteric vein (IMV).
62063492|NCT03880695|EXPERIMENTAL|Anlotinib+ Liposomal Doxorubicin|Anlotinib Hydrochloride Combined With Liposomal Doxorubicin Liposomal Doxorubicin 50mg/m2 Day 1 every-3-weeks (Q3W) and Anlotinib 12mg QD po at Day 8-21 Q3W and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
62088081|NCT04800835|ACTIVE_COMPARATOR|Group 1- Spatz3 adjustable balloon 12-month implantation;|A 12 month adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed
62628715|NCT02477358|EXPERIMENTAL|PRF Treated|Subjects will be randomized to either receive either left tooth platelet rich fibrin; right tooth implant alone, OR right tooth platelet rich fibrin; left tooth implant alone. Following treatment each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
62628716|NCT02477358|NO_INTERVENTION|Control|Subjects will be randomized to either receive either left tooth platelet rich fibrin; right tooth implant alone, OR right tooth platelet rich fibrin; left tooth implant alone. Following treatment each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
62628717|NCT05678439|EXPERIMENTAL|sesame extract|"Dietary supplement: sesame extract (contains sesamin 37-56mg per capsule)~This group will be given supplements for 8 weeks."
62628718|NCT05678439|PLACEBO_COMPARATOR|placebo|Placebo treatment ( identical capsules containing Lactose, Silica, Magnesium Stearate, Gelatin)
62628719|NCT06404749|EXPERIMENTAL|FB01|fungal fiber, 150 mg/day, oral capsules, 2 weeks
62628720|NCT06404749|ACTIVE_COMPARATOR|inulin|inulin, 3 g/day, oral capsules, 2 weeks
62628721|NCT03370965|EXPERIMENTAL|Patients with optic neuritis|
62853943|NCT02746224|OTHER|group 1B|the surgical technique initially dissects the inferior mesenteric artery (IMA).
62853944|NCT02746224|OTHER|group 2A|the patients will have a latero-terminal colorectal anastomosis
62853945|NCT02746224|OTHER|group 2B|the patients will have a termino-terminal colorectal anastomosis.
62853946|NCT04583722|OTHER|AX oleoresin|Raw AX oleoresin, 15 mg AX (in 4 pululan capsules)
62853947|NCT04583722|EXPERIMENTAL|AX-olive oil-PP emulsion|Microencapsulated AX (1%:2%:3% (AXO:OO:PP, %w/v ratio) + 0.15% maltodextrin). 15 mg AX (in 4 pululan capsules)
62853948|NCT05604378||EBV-positive gastric cancers|
62853949|NCT05604378||EBV-negative gastric cancers|
62853950|NCT05005039||Obese postmenopausal women who will undergo RYGB|
62853951|NCT05005039||Obese postmenopausal women who will undergo SG|
62853952|NCT04750616|EXPERIMENTAL|Oral niacinamide|
62853953|NCT04750616|PLACEBO_COMPARATOR|Matched placebo|
62853954|NCT03208582|OTHER|Single arm trial|Intervention : Risedronate Sodium (oral) Dosage: 1mg/kg/week Frequency: once/week Duration: 6 weeks
62628722|NCT01147718|EXPERIMENTAL|digoxin plus albiglutide|A single dose of 0.5mg digoxin administered on Day 1 followed by 5 weekly subcutaneous injections of albiglutide, followed by a further single dose of 0.5mg digoxin on Day 38.
62268519|NCT04889300|EXPERIMENTAL|Best Possible Self|Positive affect and optimism will be induced through the Best Possible Self (BPS) Intervention. In the optimism intervention, participants will be asked to imagine a future in which everything went well and in which all their wishes are fulfilled. This procedure is known to reliably generate positive affect and positive future expectations (Carrillo et al., 2019). Orientated at Flink et al. (2015) the BPS condition was adapted for a pain population.
62268520|NCT04889300|ACTIVE_COMPARATOR|Typical Day|In the control condition, participants are asked to describe and visualize a typical day (TD). We adapted the TD condition in order to take possible changes in participants´ TD due to the COVID-19 pandemic into account.
62268521|NCT01681264|ACTIVE_COMPARATOR|Morphine:Placebo|
62268522|NCT01681264|ACTIVE_COMPARATOR|Morphine:Guanfacine 1mg|
62268523|NCT01681264|ACTIVE_COMPARATOR|Morphine:Guanfacine 2mg|
62268524|NCT01681264|ACTIVE_COMPARATOR|Placebo:Guanfacine 2mg|
62268525|NCT01681264|PLACEBO_COMPARATOR|Placebo:Placebo|
62268526|NCT02723500|OTHER|MRI at baseline and over time|Patients with chronic lung disease will undergo pulmonary function tests, hyperpolarized Xenon MRI at each visit.
62268527|NCT01920347||Neurological Pupil index|The NPi will be measured during treatment
62268528|NCT03957837||Steep Trendelenburg|Patients undergoing elective laparoscopic prostatectomy in steep Trendelenburg position (25 degrees head down position)
62268529|NCT03957837||Healthy controls|Healthy awake volunteers undergoing steep Trendelenburg position (25 degrees head down position)
62268530|NCT00515801|EXPERIMENTAL|A|Glibenclamide 5 mg tablets
62451346|NCT05330507||Matched Controls|A matched control dataset will be extracted from electronic medical records of the participating healthcare system. Participants will be matched on an index COPD-related hospitalization and other key factors, utilizing propensity score matching (i.e., number of COPD-related hospitalizations in prior year, severity of COPD, age).
62451347|NCT03602768|EXPERIMENTAL|Goal Management Training|The online version of GMT with a therapist on the back-end monitoring progress and giving feedback throughout the program. Online GMT takes 5-9 weeks (self-paced) to complete 9 modules involving instructional video with interactive content, practice of cognitive strategies through games, and between-module exercises.
62628723|NCT06158035|EXPERIMENTAL|Norepinephrine group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62628724|NCT06158035|EXPERIMENTAL|Phenylephrine group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62628725|NCT03783377|EXPERIMENTAL|ARO-APOC3|
62268531|NCT00515801|PLACEBO_COMPARATOR|B|placebo capsules
62268532|NCT06036862|EXPERIMENTAL|Patients with severe rectal anastomotic stenosis|Focusing on Patients with severe rectal anastomotic stenosis, espically long length and ultra lower firbrotic stenosis
62268533|NCT05981833||Repair without DAA|repaired without dermal allograft augmentation (DAA).
62268534|NCT05656209|NO_INTERVENTION|Control group|The patient received conventional care after surgery, with no other interventions.
62268535|NCT05656209|EXPERIMENTAL|LA treatment group|The patient received conventional treatment and Lactobacillus acidophilus treatment for three months after surgery.
62268536|NCT05307029||Group A edentulous patients|edentulous patients rehabilitated with fixed full-arch prosthesis on 4 implants
62268537|NCT05307029||Group B edentulous patients|edentulous patients rehabilitated with fixed full-arch prosthesis on 6 implants
62268538|NCT04940143|EXPERIMENTAL|Botulinum toxin-A|Botulinum toxin-A (Onabotulinum toxin type-A) injection with electrical stimulation guidance will be administered to spastic ankle plantar flexor muscles. After the injection, the patients will be included in the comprehensive physiotherapy program.
62268539|NCT03720431|EXPERIMENTAL|TTAC-0001 and pembrolizumab|TTAC-0001 and pembrolizumab combination therapy will be administered.
62268540|NCT02500524|EXPERIMENTAL|10% Cocamide diethanolamine|10% Cocamide DEA aqueous lotion is applied directly to dry hair on a single occasion and is washed off with shampoo after 60 minutes.
62268541|NCT02500524|ACTIVE_COMPARATOR|1% permethrin creme rinse|1% permethrin creme rinse is applied to shampooed and towel dried hair on a single occasion and left in situ for 10 minutes, then rinsed off with clean water.
62268542|NCT00879229|EXPERIMENTAL|Ambrisentan|Participants were randomized to receive ambrisentan treatment at an initial dose of 5 mg for 4 weeks, followed by ambrisentan at the target dose of 10 mg for an additional 52 weeks
62268543|NCT00879229|PLACEBO_COMPARATOR|Placebo|Participants were randomized to receive placebo to match ambrisentan for 48 weeks, then transition to ambrisentan treatment at the initial dose of 5 mg for 4 weeks, followed by ambrisentan at the target dose of 10 mg for an additional 4 weeks.
62628726|NCT03783377|PLACEBO_COMPARATOR|Placebo|
62628727|NCT02058589|EXPERIMENTAL|GSK1437173A Group|Subjects, aged 18 years or older, received 2 doses of the GSK 1437173A vaccine, adjuvanted with AS01B at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
62628728|NCT02058589|PLACEBO_COMPARATOR|Placebo Group|Subjects, aged 18 years or older, received 2 doses of Placebo (lyophilised sucrose reconstituted with saline \[NaCl\] solution) at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
62628729|NCT06212986|EXPERIMENTAL|Experimental blended group|The experimental blended group (perform-up group) used the application Perform-UP Tennis on their own and also met up with a professional sports psychologist every 2 weeks for debriefing. Participants were asked to answer a series of questionnaires in two separate phases.
62628730|NCT06212986|NO_INTERVENTION|Control group|Participants were asked to answer a series of questionnaires in two separate phases, but they only carried out their classic technical training without integrating the mental training program with the app Perform-UP Tennis.
62628731|NCT04090385|EXPERIMENTAL|tDCS over M1 and DLPFC|Anodic transcranial direct current stimulation (tDCS) over left primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC). Duration: 20 minutes; Intensity: 2mA.
62853955|NCT04136782|EXPERIMENTAL|Trial group|55 cases of triple-negative breast cancer will be assigned into a trial group.
62451348|NCT03602768|EXPERIMENTAL|Memory & Aging Program|The online version of MAP with a therapist moderator on the course discussion pages. MAP takes 5-9 weeks (self-paced) to complete 8 modules involving instructional video with interactive content and practice of memory strategies through various exercises.
62451349|NCT03602768|PLACEBO_COMPARATOR|Cambridge Brain Sciences Training|This is a commercial and research brain training platform, composed of 7 games that are online adaptations of the standard measures of cognition including working memory and spacial planning.
62628732|NCT04090385|EXPERIMENTAL|tDCS over M1 and FPA|Anodic transcranial direct current stimulation (tDCS) over left primary motor cortex (M1) and left frontal polar area (FPA). Duration: 20 minutes; Intensity: 2mA.
62628733|NCT04090385|ACTIVE_COMPARATOR|tDCS over M1|Anodic transcranial direct current stimulation (tDCS) over left primary motor cortex (M1). Duration: 20 minutes; Intensity: 2mA.
62451350|NCT03602768|NO_INTERVENTION|Waitlist|Participants randomized to this arm will receive no additional information or access to intervention programs until after the follow up testing measures are collected, at which point they will be given access to the intervention of their choosing.
62628734|NCT06506058|EXPERIMENTAL|PD with FOG|"People with Parkinson's disease and freezing of gait:~n = 25 in experiments 1 and 2, 20 in experiments 3 and 4. (Up to 90 participants, if each participant only volunteers for one study, however, the investigators anticipate a significant overlap and that most participants will volunteer for multiple experiments)."
62628735|NCT06506058|EXPERIMENTAL|PD without FOG|n = 25 in experiments 1 and 2, 20 in experiments 3 and 4. (Up to 90 participants, as in Group 1.)
62628736|NCT06506058|ACTIVE_COMPARATOR|Old adults matched controls|(age- and sex-matched to the group with Parkinson's disease and freezing of gait): n = 25 in experiments 1 and 2, 20 in experiments 3 and 4. (Up to 90 participants, as in Group 1.)
62628737|NCT06506058|ACTIVE_COMPARATOR|young adults matched controls|Young adults (age 21-44) n = 25 in experiments 1 and 2, 20 in experiments 3 and 4. (Up to 90 participants, as in Group 1.)
62628738|NCT01857180|EXPERIMENTAL|Curriculum|Participants in the curriculum group took part in a structured, comprehensive curriculum consisting of a 1 hour didactic cognitive component, a 1 hour didactic non-technical (team-based skills) component, and 6 hours of structured technical skills practice in peg transfer, intracorporeal suture, and VR simulator tasks. Participants had the opportunity to ask questions and engage in discussion with experts after the didactic sessions, and received subjective feedback from circulating residents in addition to objective feedback in the technical skills tasks.
62628739|NCT01857180|NO_INTERVENTION|Self-directed|Participants in the control (self-directed) group took part in 8 hours of self-directed learning with written materials for cognitive and non-technical skills components and unstructured surgical simulation practice of technical skills with only objective feedback from the simulator for the VR tasks or time for the peg transfer and intracorporeal suture tasks.
62628740|NCT06355375|ACTIVE_COMPARATOR|exercise|aerobic exercise during pregnancy
62628741|NCT06355375|NO_INTERVENTION|no exercise|no recommendation regarding exercise
62853956|NCT04136782|ACTIVE_COMPARATOR|Control group|55 cases of triple-negative breast cancer will be assigned into a control group.
62628742|NCT03489252|EXPERIMENTAL|Device Feasibility (Fitbit Charge 3)|Participants wear the Fitbit Charge 3 device from the time of CT simulation for RT planning throughout the entire RT course.
62628743|NCT04820296|EXPERIMENTAL|Experimental group|Pregnant women in the experimental group will be given 4 sessions Solution-Oriented Approach program, starting at the 32th week of pregnancy. Pregnants in the experimental group will be administered the Wijma Birth Expectation/Experience Scale (W-DEQ-A) and Pregnancy Psychosocial Health Assessment Scale (PPHAS) before the intervention. After the program is completed, a training booklet will be provided for pregnant women and (W-DEQ-A) and PPHAS will be applied again. With pregnant women, 37-40. between gestational weeks, they will be contacted again, face-to-face interview method (W-DEQ-A) and PPHAS again will be evaluated. The pregnant women will inform the researcher by phone after the delivery and the researcher will visit the hospital within the first 24 hours after the delivery to evaluate the mothers' birth fear levels Scale (W-DEQ-B). At the end of the first postpartum week, the postnatal senses of security of the mothers will be evaluated by telephone follow-up counseling.
62628744|NCT04820296|NO_INTERVENTION|Control group|Pregnant women in the control group will only receive routine care. Pregnant women in the control group will be administered the same scales simultaneously with the experimental group.
62628745|NCT05995587|EXPERIMENTAL|MBCT (mindfulness teacher)|Participants in the MBCT (mindfulness teacher) group will receive mindfulness training from a certified mindfulness teacher.
62853957|NCT03618290||Acute ischemic stroke group|50 patients (expected) - Acute ischemic stroke (AIS)
62853958|NCT03618290||Non-neurological pathologies group|25 control subjects with non-neurological pathologies (Congestive heart failure (CHF), Chronic obstructive pulmonary disease ( COPD ) etc.)
62628746|NCT05995587|EXPERIMENTAL|MBCT (social workers)|Participants in the MBCT (social workers) group will receive mindfulness training from social workers (supervised by a certified mindfulness teacher).
62853959|NCT03618290||Non AIS-related brain injuries group|25 control subjects with traumatic or other non AIS-related brain injuries. These will include: Traumatic Brain Injury (TBI) defined as intracranial hemorrhage or contusion.
62853960|NCT01615276|PLACEBO_COMPARATOR|Protein ingestion|Protein ingestion directly after the contralateral leg received NMES
62853961|NCT01615276|EXPERIMENTAL|Protein ingestion after NMES|Ingestion of intrinsically labeled protein, directly after one hour of Neuromuscular electrical stimulation (NMES)
62853962|NCT03348436|EXPERIMENTAL|patients with atrioventricular nodal reentrant tachycardia|radiofrequency catheter ablation therapy
62853963|NCT03348436|EXPERIMENTAL|patients with atrioventricular tachycardia|radiofrequency catheter ablation therapy
62451351|NCT03680963|EXPERIMENTAL|Non-invasive strategy|Non-invasive strategy consisting of blood pressure monitoring by non-invasive automated cuff measurements
62451352|NCT03680963|OTHER|Control strategy|Usual strategy of systematic indwelling arterial catheter insertion in the early hours of acute circulatory failure
62628747|NCT05995587|NO_INTERVENTION|Care as usual group|The care as usual group will receive usual service provided in District Elderly Community Centres (DECC) and Integrated Community Centre for Mental Wellness (ICCMW).
62628748|NCT05906342|EXPERIMENTAL|20% fat meal|This meal will contain 15 kcal/kg of body weight and consist of 20% fat, 65% carbohydrates, and 15% protein.
62628749|NCT05906342|EXPERIMENTAL|40% fat meal|This meal will contain 15 kcal/kg of body weight and consist of 40% fat, 45% carbohydrates, and 15% protein.
62268544|NCT02645357|EXPERIMENTAL|computer reminders on clinical practice|on-screen, point-of-care computer reminders on clinical practice.
62268545|NCT02645357|OTHER|Control group|No on-screen, point-of-care computer reminders on clinical practice.
62268546|NCT00005613|EXPERIMENTAL|Autologous Transplant|autologous hematopoietic progenitor cell transplant
62628750|NCT05906342|EXPERIMENTAL|60% fat meal|This meal will contain 15 kcal/kg of body weight and consist of 60% fat, 25% carbohydrates, and 15% protein.
62268547|NCT00005613|EXPERIMENTAL|Allogeneic Transplant|allogeneic hematopoietic progenitor cell trasnplant
62268548|NCT03841929|EXPERIMENTAL|Study Arm|ELGANs recruited to the study group in addition to standard of care will have continuous cerebral NIRS monitoring for the initial 72 hours and TNE studies at definitive time frames and a hemodynamic report will be provided to the clinical team using the results of the multimodal monitoring and clinical data. The report will be a description of the hemodynamic status without any suggestions for management.
62268549|NCT03841929|NO_INTERVENTION|Standard Arm|ELGANs recruited into Standard arm will have the standard monitoring including cardiorespiratory monitoring. The invasive blood pressure monitoring, NIRS and TNE monitoring as per the clinical team's discretion - consistent with the current standard of care. No hemodynamic report will be provided routinely.
62853964|NCT02779322|ACTIVE_COMPARATOR|Minigastric bypass|Intervention(s): The patient will have done a Laparoscopic one anastomosis gastric bypass (minigastric bypass) at the time of the surgical procedure.
62088082|NCT04800835|ACTIVE_COMPARATOR|Group 2- 6-month non adjustable balloon implantation with additional 6 months follow-up|A 6-month non adjustable intragastric balloon for weight loss
62628751|NCT05906342|EXPERIMENTAL|80% fat meal|This meal will contain 15 kcal/kg of body weight and consist of 80% fat, 5% carbohydrates, and 15% protein.
62628752|NCT04136483|EXPERIMENTAL|CBT-I|
62628753|NCT06072118|EXPERIMENTAL|Adrenomedullin group|
62268550|NCT06433336||Effect of blood pressure on cardiovascular outcomes and recurrence after catheter ablation in patien|Atrial Fibrillation Recurrence Pulmonary Vein Isolation
62268551|NCT00689715|EXPERIMENTAL|EP|Single treatment arm
62628754|NCT01327248||affected patients|20 Patients suffering from bronchiolitis obliterans
62628755|NCT01327248||non-affected patients|20 matched controls not suffering from bronchiolitis obliterans
62088083|NCT01682707|ACTIVE_COMPARATOR|Laryngoscopy|Laryngoscopy Track Light teaqueal intubation
62088084|NCT01682707|ACTIVE_COMPARATOR|Track Light|
62268552|NCT04353180|ACTIVE_COMPARATOR|13 cis retinoic acid doses orally plus the standard therapy|Arm 1: infected patients will receive the standard therapy for COVID-19 (Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) and after three days of the standard therapy the infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days combined with the standard therapy . All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
62451353|NCT05702177|EXPERIMENTAL|Daridorexant 25 mg|Subjects will receive a daridorexant 25 mg tablet for oral administration.
62451354|NCT05702177|EXPERIMENTAL|Daridorexant 50 mg|Subjects will receive a daridorexant 50 mg tablet for oral administration.
62628756|NCT02741375||Brain Death Group (BD group)|Patients assessed as brain-dead at the first clinical evaluation by the OTBD committee were definitively diagnosed with BD through repeat clinical evaluation after 24 h or through CT angiography as a corroboratory test. Patients regarded as definitely brain-dead on the basis of this evaluation were classified as the BD group.
62628757|NCT02741375||Non-Brain Death Group (Non BD group)|Patients assessed as brain-dead at the first clinical evaluation by the OTBD committee were definitively diagnosed with BD through repeat clinical evaluation after 24 h or through CT angiography as a corroboratory test. Patients regarded as definitely not brain-dead on the basis of this evaluation were classified as the non-BD group.
62628758|NCT03084302||Pregnant women|Women in their first trimester of pregnancy, aged 18-45, who plan to receive their prenatal care from University of Pittsburgh Medical Center providers.
62853965|NCT02779322|ACTIVE_COMPARATOR|Gastric bypass|The patient will have a Laparoscopic Roux-en-Y gastric bypass at the time of the surgical procedure
62451355|NCT05702177|PLACEBO_COMPARATOR|Placebo|Subjects will receive a daridorexant-matching placebo tablet for oral administration.
62451356|NCT04682002|EXPERIMENTAL|OMT + multidisciplinary path|Patients in the experimental group will follow the obstetrician's and multidisciplinary path which provides osteopathic treatments, mindfulness, yoga, clinical nutrition, coaching and usual obstetric care.
62853966|NCT03596749|EXPERIMENTAL|Sevelamer Carbonate|Sevelamer carbonate will be given with fixed dose of 1600mg (p.o. b.i.d) with meals
62853967|NCT03596749|NO_INTERVENTION|Control|blank-control
62853968|NCT04153708|EXPERIMENTAL|Retrieval by phone call.|Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.
62268553|NCT04353180|ACTIVE_COMPARATOR|Aerosolized 13 cis retinoic acid plus the standard therapy|Arm 2: infected patients will receive the standard therapy for COVID-19 (Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) and after three days of the standard therapy the infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
62268554|NCT04353180|ACTIVE_COMPARATOR|13 cis retinoic acid doses orally|Infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
62268555|NCT04353180|ACTIVE_COMPARATOR|Aerosolized 13 cis retinoic acid|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
62268556|NCT04353180|SHAM_COMPARATOR|The standard therapy|Arm 3:infected patients will receive the standard therapy for COVID-19 for 14 days
62268557|NCT04372277|EXPERIMENTAL|Enstilar|Enstilar foam
62268558|NCT02590588|EXPERIMENTAL|Idelalisib|Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.
62628759|NCT03944863||POEM + Antibiotic prophylaxis|Cefazolin: 2g or Amoxicillin - clavulanic acid: 1g x 3 during 7 days
62628760|NCT03944863||POEM + No antibiotic prophylaxis|
62853969|NCT04153708|ACTIVE_COMPARATOR|Retrieval by mail letter|Patients assigned to strategy 2 will receive an invitation letter with an appointment with the hepatologist over a period of 14 days.
62853970|NCT01700309|NO_INTERVENTION|Control group|Treatment as usual
62853971|NCT01700309|EXPERIMENTAL|Young and Active|This arm will recieve web-based health counselling through the web-site Young and Active.
62853972|NCT02206789|ACTIVE_COMPARATOR|penetrating keratoplasty|"each arm will have two groups A and B.. Only on topical steroids(prednisolone acetate1%) group A On topical steroids + 2% cyclosporine Group B . Methodology of drug administration In both agroups 1. Schedule of topical steroid administration : 6 times for 2 weeks; 5 times for 2 weeks; 4 times for a month; 3 times for a month, and, subsequently twice-a-day until 1 year is completed . Topical steroids will be withdrawn at the end of ine year.Systemic steroids may be administered in the initial 2 weeks at the discretion of the investigators.~3. Patients randomized to receive 2% cyclosporine will receive the same 3 times a day for 2years~."
62853973|NCT02206789|ACTIVE_COMPARATOR|therapeutic keratoplasty|"each arm will have two groups A and B.. Only on topical steroids(prednisolone acetate1%) group A On topical steroids + 2% cyclosporine Group B . Methodology of drug administration In both agroups 1. Schedule of topical steroid administration : 6 times for 2 weeks; 5 times for 2 weeks; 4 times for a month; 3 times for a month, and, subsequently twice-a-day until 1 year is completed . Topical steroids will be withdrawn at the end of ine year.Systemic steroids may be administered in the initial 2 weeks at the discretion of the investigators. (For all patients with fungal keratitis topical steroids will be administered only after 2 weeks post keratoplasty.) Until then diclofenac sodium0.1% may be used 3. Patients randomized to receive 2% cyclosporine will receive the same 3 times a day for 2years~."
62853974|NCT05086211|EXPERIMENTAL|proprioceptive neuromuscular facilitation|"Each session including three PNF techniques:~Balance training exercises,participants will be treated for 20 minutes with PNF techniques that included;Rhythmic initiation, slow reversal techniques practiced with D1 and D2 pattern in lower limb,repeated contraction and Resisted PNF.The Technique will be performed for 3 days per week in same order on all subjects."
62853975|NCT05086211|EXPERIMENTAL|pertubation based balance training|Each session will include a 5-10min warm-up,voluntary tasks intended to induce internal perturbations,voluntary tasks combined with external perturbations and a 5-10mins cool down.The technique will be performed for 2 sets of 10 repetitions on all subjects.
62853976|NCT00927004|EXPERIMENTAL|Etoricoxib 60 mg|
62268559|NCT02234154|OTHER|TOPS System|Post Marketing Study
62268560|NCT06297746|ACTIVE_COMPARATOR|Subvastus approach|Patients indicated for total knee arthroplasty.
62268561|NCT06297746|ACTIVE_COMPARATOR|Medial Parapatellar approach|Patients indicated for total knee arthroplasty.
62268562|NCT01173991|EXPERIMENTAL|Carbohydrate counting|This group received carbohydrate counting training
62268563|NCT01173991|NO_INTERVENTION|Controls|This group received standard education
62268564|NCT05001321||Training Group|Based on the inclusion criteria, 2000 gastric cancer patients will be recruited in the analysis. And a model will be constructed based on deep learning.
62268565|NCT05001321||Internal Validation Group|Based on the inclusion criteria, 1000 gastric cancer patients will be recruited in this group to verify the sensitivity and specificity of the constructed model.
62451357|NCT04682002|OTHER|Usual care|Patients in control group will continue the routine obstetrical care as established by international guidelines
62451358|NCT01347788|EXPERIMENTAL|Cohort 1|Dose level 0: cabozantinib 40 mg daily
62853977|NCT00927004|PLACEBO_COMPARATOR|Sugar pill|
62853978|NCT06515795|NO_INTERVENTION|Control Session|Each participant will remain in a seated position, resting, for 40 minutes.
62268566|NCT05001321||External Validation Group|Based on the inclusion criteria, 300 gastric cancer patients from 5 other medical centers will be recruited in this group to verify the sensitivity and specificity of the constructed model.
62451359|NCT01347788|EXPERIMENTAL|Cohort 2|Dose level -1: cabozantinib 20 mg daily
62451360|NCT01347788|EXPERIMENTAL|Expansion cohort|Dose level 0: cabozantinib 40 mg daily
62628761|NCT05887700||ASD subjects|Patients with a confirmed diagnosis of Atrial Septal Defect (ASD) and implanted with the investigational device.
62853979|NCT06515795|EXPERIMENTAL|Isometric Handgrip Session|After remain in a seated position, resting, for 15 minutes, each participant will perform 4 repetitions of 2 minutes, alternating hands, maintaining the handgrip at a strength value of 30% of the maximal voluntary contraction (MVC) obtained in the initial test, with 1 minute of rest between each repetition. The exercise will be performed in a seated position. Participants will be encouraged to breathe normally and avoid the Valsalva maneuver.
62853980|NCT06515795|EXPERIMENTAL|Isometric Wall Squat Session|After remain in a seated position, resting, for 15 minutes, each participant will perform 4 repetitions of 2 minutes, maintaining the squat position with their back against the wall, with 2 minutes of rest (in a seated position) between each repetition. The knee joint angle will be defined using a fixed goniometer attached with Velcro to the thigh and leg. This angle corresponds to the knee position at 95% of the peak HR achieved during the initial incremental test. Participants will be encouraged to breathe normally and avoid the Valsalva maneuver.
62853981|NCT02122913|EXPERIMENTAL|Tumor patients_Dose 1|Adult patients with solid tumors receiving 50 mg of BAY2757556 once daily (dose escalation cohort).
62853982|NCT02122913|EXPERIMENTAL|Tumor patients_Dose 2|Adult patients with solid tumors receiving 100 mg of BAY2757556 once daily (dose escalation cohort).
62268567|NCT03410888|EXPERIMENTAL|popliteal approach|Blockade of the sciatic nerve at the level of the popliteal fossa.
62853983|NCT02122913|EXPERIMENTAL|Tumor patients_Dose 3|Adult patients with solid tumors receiving 100 mg of BAY2757556 twice daily (dose escalation cohort).
62853984|NCT02122913|EXPERIMENTAL|Tumor patients_Dose 4|Adult patients with solid tumors receiving 200 mg of BAY2757556 once daily (dose escalation cohort).
62853985|NCT02122913|EXPERIMENTAL|Tumor patients_Dose 5|Adult patients with solid tumors receiving 150 mg of BAY2757556 twice daily (dose escalation cohort).
62853986|NCT02122913|EXPERIMENTAL|Tumor patients_Dose 6|Adult patients with solid tumors receiving 200 mg of BAY2757556 twice daily (dose escalation cohort).
62853987|NCT02122913|EXPERIMENTAL|Tumor patients_Expansion|"Adults patients with solid tumors and neurotrophic tyrosine kinase (NTRK) genes or proteins of types 1 - 3 (dose expansion cohort).~Patients receive either the recommended or maximum tolerated dose of BAY2757556 as determined in the dose escalation part."
62268568|NCT03410888|ACTIVE_COMPARATOR|infragluteal approach|Blocking the sciatic nerve at the subgluteal level.
62268569|NCT05022797|EXPERIMENTAL|Glucarpidase, methotrexate, R-CHOP|Glucarpidase 2000Units per dose. IV. Bolus injection over 5 minutes. Administered 12 hours following after each HDMTX cycle, for a maximum of 3 cycles.
62268570|NCT04907760|EXPERIMENTAL|With a personalized care program|The strategy implemented is a personalized care pathway that includes participant follow-up by a nurse for 5 years with contact every 4 months for the first year, then every 6 months
62268571|NCT04907760|NO_INTERVENTION|Without a personalized care program|The comparison strategy does not include any specific management. The patient will not receive individualized management with the nurse coordinator.
62268572|NCT04027933|ACTIVE_COMPARATOR|Experimental|Education Based on Standard Patient Simulation was given to this group
62268573|NCT04027933|NO_INTERVENTION|Control|Control group
62268574|NCT01077843||Exposure|Ankylosing spondylitis patients currently exposed to anti-inflammatory treatments
62268575|NCT01077843||Non-exposure|Ankylosing spondylitis patients not currently exposed to anti-inflammatory treatments
62268576|NCT00120458|EXPERIMENTAL|1|Anxiolytic Therapy
62268577|NCT00120458|PLACEBO_COMPARATOR|2|Anxiolytic Therapy
62268578|NCT04667351|ACTIVE_COMPARATOR|5-fu 2400|
62451361|NCT05105698|EXPERIMENTAL|fasting conditions|A: A fixed dose combination of gemigliptin and dapagliflozin 50/10 mg film-coated tablet orally administered once without food (fasting conditions)
62451362|NCT05105698|EXPERIMENTAL|fed conditions|B: A fixed dose combination of gemigliptin and dapagliflozin 50/10 mg film-coated tablet orally administered once with food (fed conditions)
62268579|NCT04667351|EXPERIMENTAL|5-fu 1200|
62268580|NCT04584580|ACTIVE_COMPARATOR|Therapeutic dose low-molecular-weight heparin (LMWH)|Therapeutic dose low-molecular-weight heparin from admission until the end of hospital stay Enoxaparin 1 mg/kg subcutaneous every 12 hours
62451363|NCT06243211|ACTIVE_COMPARATOR|DMED|Dorsal myelotomy and expansive duraplasty (DMED) only.
62451364|NCT06243211|ACTIVE_COMPARATOR|DMED + ANGI|Dorsal myelotomy and expansive duraplasty (DMED) and supplemental autologous nerve graft implantation (ANGI).
62451365|NCT05241821||Conservative treatment|patients with periprocedural stroke after TAVI, treated conservatively
62451366|NCT05241821||Neuro-intervention|patients with periprocedural stroke after TAVI, treated with neuro-intervention
62451367|NCT01600209||Average risk patients|Subjects will be men and women, 50-84 years of age, inclusive, each with a screening colonoscopy resulting in normal findings.
62451368|NCT05259306|EXPERIMENTAL|Treatment-resistant Schizophrenia group|The subject will present for three baseline visits, followed by a treatment visit and subsequently follow-up visits at 24-hours, 48-hours, 1 week, 2 weeks, 1 month, and 3 months. Feasibility will be assessed as well as symptoms via detailed symptom rating scales at each visit. At the treatment visit itself, participants will undergo MR-guided low-intensity focused ultrasound of the MD thalamus.
62451369|NCT02470507||AKI with SIRS|Patients with AKI stage II or III and systemic inflammation without sepsis
62628762|NCT02033044|EXPERIMENTAL|cognitive remediation|Cognitive remediation programme in order to improve several cognitive domains.
62628763|NCT02033044|ACTIVE_COMPARATOR|Psychoeducation|Psychoeducation group in order to improve psychosocial functioning of patients.
62853988|NCT05266729|EXPERIMENTAL|AYP-101 1|0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.
62853989|NCT05266729|EXPERIMENTAL|AYP-101 2|0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.
62853990|NCT05266729|PLACEBO_COMPARATOR|Placebo|0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.
62628764|NCT06572163|OTHER|Surgical|containment, segmentation, and extraction of uterine tissue
62268581|NCT04584580|EXPERIMENTAL|D-dimer levels and weight adjusted low-molecular-weight heparin (LMWH)therapy|"from admission until the end of hospital stay. Patients will be stratified according to their body weight and D-dimer level and receive LMWH~D-Dimer level Body Weight LMWH dose~\<1 mg/dl \<100kg Enoxaparin 40mg OD 100-150kg Enoxaparin 40mg BD \>150kg Enoxaparin 60mg BD~1-3 mg/ dl \<100kg Enoxaparin 40mg BD 100-150kg Enoxaparin 80mg BD \>150kg Enoxaparin 120mg BD~\>3 mg/ dl Enoxaparin 80mg BD"
62628765|NCT04303195|EXPERIMENTAL|NG101 - 5 mg|NG101 5 mg, capsules, orally, QID (4 times a day) for up to 12 weeks
62628766|NCT04303195|EXPERIMENTAL|NG101 - 10 mg|NG101 10 mg, capsules, orally, QID (4 times a day) for up to 12 weeks
62628767|NCT04303195|EXPERIMENTAL|NG101 - 20 mg|NG101 20 mg, capsules, orally, QID (4 times a day) for up to 12 weeks
62853991|NCT03820440|EXPERIMENTAL|Treatment - hemodynamic tests|"Treatment - hemodynamic tests:~The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.~The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds"
62268582|NCT03659682|ACTIVE_COMPARATOR|semaglutide|Ozempic- 1.0 mg administered subcutaneously once weekly
62268583|NCT03659682|PLACEBO_COMPARATOR|placebo|Placebo, 1.0 mg administered subcutaneously once weekly
62268584|NCT01094769|EXPERIMENTAL|Moxonidine|
62268585|NCT01094769|PLACEBO_COMPARATOR|Placebo|
62268586|NCT05386615||Exablate|Observational study of Exablate treatment.
62628768|NCT04303195|PLACEBO_COMPARATOR|Placebo|Placebo-matching, capsules, orally, QID (4 times a day) for up to 12 weeks
62628769|NCT02587195|EXPERIMENTAL|Teriflunomide|Teriflunomide 14 mg Once Daily
62628770|NCT03749057|OTHER|rivaroxaban|15-20 mg rivaroxaban daily
62268587|NCT01652885|EXPERIMENTAL|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
62451370|NCT02470507||AKI without SIRS|Patients with AKI stage II or III and no systemic inflammation
62451371|NCT02470507||SIRS without AKI|Patients with systemic inflammation and normal renal function
62451372|NCT02470507||No SIRS and no AKI|Patients after major surgery who do not have an infection, SIRS or AKI
62451373|NCT04872322|ACTIVE_COMPARATOR|Standard Popliteal Nerve Block|Participants undergoing foot or ankle surgery will receive an initial injection of 0.5% ropivacaine as the initial anesthetic followed by continuous injection of 0.25% ropivacaine.
62451374|NCT04872322|ACTIVE_COMPARATOR|Partial Popliteal Nerve Block|Participants undergoing foot or ankle surgery will receive 0.25% ropivacaine initially followed by the usual continuous injection of 0.25% ropivacaine during surgery
62451375|NCT01769378|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously (SQ) once weekly for 24 weeks added to the participant's prescribed glimepiride dose.
62628771|NCT02195973|EXPERIMENTAL|Paclitaxel + LDE225|Patients will receive intravenous paclitaxel on days 1, 8, and 15 every 28 days (3 weeks on followed by one week off). This constitutes one cycle. in addition to the paclitaxel oral LDE225 will be taken daily. Dosages of each drug will vary according to the study cohort and phase. The study consists of six cycles of treatment followed by clinic visits every 2-3 months for up to two years.
62628772|NCT02537600|EXPERIMENTAL|Cobimetinib + Vemurafenib combination|"Every patients will be treated with :~Vemurafenib 1920 mg / day from day 1 to day 28 continuously Cobimetinib 60 mg / day from day 1 to day 21 One cycle = 28 days Intervention = Cobimetinib + Vemurafenib combination treatment. Only one arm."
62853992|NCT02679963|EXPERIMENTAL|Maintenance Olaparib|Olaparib (experimental arm): 600 mg daily (2 doses of 300 mg (2\*2 tablets of 150 mg) taken approximately 12 hours apart) po, administered until disease progression or toxicity requiring its interruption. Olaparib has to be started no later than 6 weeks after the last administration of induction chemotherapy, and no later than 3 weeks after the CT scan confirming response to induction chemotherapy
62853993|NCT02679963|PLACEBO_COMPARATOR|Placebo|Placebo (control arm): 2 doses of 300 mg per day (2\*2 tablets of 150 mg) taken approximately 12 hours apart
62268588|NCT03239574|EXPERIMENTAL|MightySat Test group|The subjects will be enrolled into the test group and will receive the MightySat investigational pulse oximeter.
62451376|NCT01769378|EXPERIMENTAL|Dulaglutide|Dulaglutide 1.5 milligram (mg) administered SQ once weekly for 24 weeks added to the participant's prescribed glimepiride dose.
62451377|NCT05969470|EXPERIMENTAL|Short intramedullary nails|The patients receives bone fixation with short intramedullary nails for extremity metastases.
62628773|NCT04721197|EXPERIMENTAL|Intervention|30-day egg vouchers, in addition to the standard of care.
62628774|NCT04721197|ACTIVE_COMPARATOR|Control group|Standard of care.
62628775|NCT02091414|EXPERIMENTAL|MMF, CsA, Corticosteroids|Participants received mycophenolate mofetil (MMF) 1.0 grams (g), orally (PO), twice daily (BID) from within 24 hours of transplantation through Week 24. Participants also received an initial loading dose of cyclosporine A (CsA) 4 to 6 milligrams per kilogram (mg/kg) within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 nanograms per milliliter (ng/mL) through Week 24. Participants also received corticosteroids as per the practice of each participating center.
62628776|NCT05830890|EXPERIMENTAL|Sentinel Lymph Node Biopsy|The fluorescence laparoscope was used to visualize and locate the sentinel lymph node, which was then removed.
62628777|NCT00960804|EXPERIMENTAL|Tanezumab 5 mg|
62628778|NCT00960804|EXPERIMENTAL|Tanezumab 10 mg|
62628779|NCT00960804|PLACEBO_COMPARATOR|Placebo|
62628780|NCT03198429|EXPERIMENTAL|Embedded fathering intervention|"This condition focuses on workers' practice with fathers who have been identified as perpetrators in cases of child exposure to domestic violence. Workers randomly assigned to this condition will receive:~1. a one-day training at the beginning of the study on the need to engage fathers as part of intervention in cases of child exposure to DV~2. access to a practice leader and consultant to respond to question and concerns about working with father perpetrators of DV~3. access to a 30-minute presentation, once a month, on issues of practice specific to working with this population In addition,~4. cases being assigned to ongoing service workers will be flagged by intake at the time they are opened to ongoing services as being a potentially appropriate referral to the Caring Dads program~5. clients who are then referred to CD as part of clinical service will be given access to this program at the earliest possible opportunity."
62268589|NCT04148131||Group 1, 0-5 months old|Children which is Obstetric brachial plexus palsy and 0-5 months old age have Naracas type 2 lesion.
62451378|NCT05969470|ACTIVE_COMPARATOR|Long intramedullary nails|The patients receives bone fixation with long intramedullary nails for extremity metastases.
62628781|NCT03198429|EXPERIMENTAL|Embedding mother-child intervention|"Workers in the MIM condition will receive additional training and facilitated referral to MIM for eligible clients. Specifically, workers randomly assigned to this condition will receive:~1. a one-day training at the beginning of the study on the impact of DV on mothers, mothering, and child development~2. access to a practice leader and consultant to respond to question and concerns about working with women victims of DV on parenting issues~3. access to a 30-minute presentation, once a month, on issues of practice specific to working with this population In addition,~4. cases judged by intake workers as being appropriate referrals to the MIM program (see Methods) and being assigned to these workers for ongoing service will be flagged at the time of transfer as being potentially appropriate referrals to the Mothers in Mind program~5. clients who are then referred to MIM as part of clinical service will be given access to this program at the earliest possible opportunity."
62628782|NCT03198429|EXPERIMENTAL|Combined intervention|A final group of workers will be randomly assigned to receive all the training, support, and referral opportunities associated with both the Embedded Mothers in Mind condition and the Embedded Caring Dads condition.
62628783|NCT03198429|NO_INTERVENTION|Treatment as usual|Workers in the service as usual condition will continue to provide in-home support to children and families in accordance with current practice. Workers will receive regular supervision from their supervisors. A review of practice reveals that, in general, workers make referrals to intervention programs in only a small minority of cases. Such referrals will continue under this study protocol - service will proceed as usual. This condition is not a placebo, families are continuing to receive the full child protection service that they would normally have received if this trail were not being run.
62628784|NCT01005901|EXPERIMENTAL|Glycopyrronium bromide|Glycopyrronium bromide 50µg delivered once daily via Single Dose Dry Powder Inhaler (SDDPI). At visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.
62063493|NCT05458258||Adults (age 60+) with Newly Diagnosed AML|This group will consist of participants age 60+ who will be assessed for malnutrition and sarcopenia. Participants in this group will undergo chemotherapy and/or receive cancer drugs (as part of standard care). Participants in this group will receive different assessments when they start induction therapy to measure their nutritional health and the severity of their sarcopenia.
62268590|NCT04148131||Group 2, 6-24 months old|Children which is Obstetric brachial plexus palsy and 6-24 months old age have Naracas type 2 lesion.
62451379|NCT05382923|EXPERIMENTAL|Bright Light Alone|Bright light administered with Re-Timer glasses for 1 hour on 3 consecutive days. Following the 8 hour delay of the light/dark and sleep/wake cycle in the laboratory, the light will be administered, on average at 5:30-6:30 pm, 7:00-8:00 pm, and 9:30-10:30 pm, respectively on these three days.
62268591|NCT04148131||Group 3, 25-36 months old|Children which is Obstetric brachial plexus palsy and 25-36 months old age have Naracas type 2 lesion.
62268592|NCT02363686|OTHER|FEES & Bedside Swallow Evaluation (BSE)|Subjects will receive a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), followed by a speech language pathologist (SLP) performing a bedside swallowing evaluation (BSE).
62268593|NCT03793712|EXPERIMENTAL|Lu AF11167 low dose|
62268594|NCT03793712|EXPERIMENTAL|Lu AF11167 high dose|
62268595|NCT03793712|PLACEBO_COMPARATOR|Placebo|
62268596|NCT01811251|EXPERIMENTAL|Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)|The aim of the study is to show a decrease in postoperative pain during the first postoperative mobilization surgery lumbar disc herniation through a co-analgesia with a single dose of dexamethasone, pregabalin, or a combination of these two products
62628785|NCT01005901|PLACEBO_COMPARATOR|Placebo|Placebo delivered once daily via SDDPI. At Visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.
62628786|NCT05077553|PLACEBO_COMPARATOR|Placebo sachet|
62628787|NCT05077553|EXPERIMENTAL|TCI999 probiotic sachet|
62628788|NCT04282629|EXPERIMENTAL|Milrinone|"milrinone group benefiting from an identical treatment to the standard care group and in addition, administration of milrinone (0.75 μg / kg / min, intravenous) from Day 4 to Day 14. In case of suspicion of vasospasm and after ineffective effect of medical measures (euvolemia and increase in mean arterial pressure), an endovascular treatment will be possible. The occurrence of vasospasm will be monitored closely with clinical examination and cerebral tissue oxygen pressure (PtiO2). From D4 to D14, general and biological data, clinical examination will be collected daily. Intensive care unit complications (neurologic, pulmonary, cardiac and septic complications) will be collected. At 1 month, the volume of DCI lesions will be measured on CT scan. Neurologic prognosis, quality of life and mortality will be studied at 1 month, 3 month, 6 month and 1 year. Adverse events will be monitored closely."
62628789|NCT04282629|PLACEBO_COMPARATOR|Standard Care|The standard care group will follow the recommended management of SAHa and will receive a placebo (intravenous glucose 5%) from Day 4 to Day 14. In case of suspicion of vasospasm and after ineffective effect of medical measures (euvolemia and increase in mean arterial pressure), an endovascular treatment will be possible. The occurrence of vasospasm will be monitored closely with clinical examination and cerebral tissue oxygen pressure (PtiO2). From D4 to D14, general and biological data, clinical examination will be collected daily. Intensive care unit complications (neurologic, pulmonary, cardiac and septic complications) will be collected. At 1 month, the volume of DCI lesions will be measured on CT scan. Neurologic prognosis, quality of life and mortality will be studied at 1 month, 3 month, 6 month and 1 year. Adverse events will be monitored closely.
62268597|NCT01811251|PLACEBO_COMPARATOR|Lactose (150mg), NaC1 0.9% (50ml)|The aim of the study is to show a decrease in postoperative pain during the first postoperative mobilization surgery lumbar disc herniation through a co-analgesia with a single dose of dexamethasone, pregabalin, or a combination of these two products
62268598|NCT01688154|ACTIVE_COMPARATOR|Product 1|35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)
62451380|NCT05382923|EXPERIMENTAL|Bright Light + Exercise + Melatonin|Bright light will be administered with Re-Timer glasses for 1 hour on 3 consecutive days. Following the 8 hour delay of the light/dark and sleep/wake cycle in the laboratory, the light will be administered, on average at 5:30-6:30 pm, 7:00-8:00 pm, and 9:30-10:30 pm, respectively on these three days. Exercise (1 hour at 65-75% heart rate reserve) will be administered on 3 consecutive, at 1:30-2:30 pm, 4:00-5:00 pm, and 6:30-7:30 pm on these days. Melatonin (0.5 mg) will be administered at 6 am, 8:30 am, and 11:00, on the 3 days.
62451381|NCT05382923|PLACEBO_COMPARATOR|Placebo Control|Dim red light will be administered with Re-Timer glasses for 1 hour on 3 consecutive days. Following the 8 hour delay of the light/dark and sleep/wake cycle in the laboratory, the light will be administered, on average at 5:30-6:30 pm, 7:00-8:00 pm, and 9:30-10:30 pm, respectively on these three days. Placebo tablets (0.5 mg) will be administered at 6 am, 8:30 am, and 11:00, on the 3 days.
62451382|NCT04574882||Case|Patients ages 30-74 with and without CHD (IICD 10: I63, I20-I25 ) within the last 5 years.
62451383|NCT04574882||Control|Patients aged 30-74 who have non-cardiovascular-related history
62451384|NCT01672190|EXPERIMENTAL|Yoga Therapy|Women in the Yoga Therapy Group will receive twice weekly yoga classes for 6 weeks.
62451385|NCT01672190|NO_INTERVENTION|Control|Women in the Control Group will wait 6 weeks before receiving a gift certificate for yoga classes at an external yoga studio in the San Francisco Bay Area
62451386|NCT02994056|EXPERIMENTAL|SOF/VEL+ RBV|SOF/VEL FDC plus RBV for 12 weeks
62451387|NCT05981625|EXPERIMENTAL|Giomer varnish containing surface pre-reacted glass fillers|Giomer-based varnish is a light-curable varnish/desensitizer. The surface pre-reacted glass (S-PRG) filler is a bioactive trilaminar structure with a multifunctional glass core embedded in resin matrix. It can release and recharge fluoride ions. When it becomes in contact with the oral fluids, it starts to bind to the collagen fiber and release six different types of ions like fluoride, calcium, phosphate that help in the formation of apatite crystals and seal the open dentinal tubules with a long-lasting effect Brand name: S_PRG (Shofu-Japan)
62451388|NCT05981625|ACTIVE_COMPARATOR|Bioactive Glass Air Polishing|Bioactive glass powder delivered by standalone air polishing system, is a bioactive material that reacts with saliva to deposit Hydroxycarbonate Apatite crystals (HCA), which is very strong and resilient. The continuous release of calcium ions promotes constant protection and long lasting seal of the tubules. Using the air polishing delivery system helps to provide a huge amount of calcium and phosphate particles at the exposed surface of the tooth. Moreover, the air pressure aids in pushing these particles inside the dentinal tubules to a considerable depth. Air polishing using such powder provides a bifunctional advantage of occluding the dentinal tubules. However, there is limited clinical trials testing the efficacy of the bioactive glass powder air polishing system in minimizing the dentin hypersensitivity
62451389|NCT06342921|EXPERIMENTAL|15 mg|15 mg of ADC189 tablets Once during the whole study.
62268599|NCT01688154|PLACEBO_COMPARATOR|Control product|2 empty capsules
62268600|NCT01032304|EXPERIMENTAL|Erdosteine|600 mg/day for 12 months
62268601|NCT01032304|PLACEBO_COMPARATOR|Placebo|Placebo for 12 months
62853994|NCT01264601|EXPERIMENTAL|Single Dose|This arm will receive TIV as 2 doses, the first of which will be normal saline administered at approximately 10% of the total age appropriate dose volume, followed 30 minutes later by the full age appropriate dose. For children receiving a 0.25ml dose, a 20%/80% split will be used for ease of administration in drawing up the dose.
62853995|NCT01264601|EXPERIMENTAL|Graded Challenge|Subjects in this arm will receive TIV by standard 10%/90% 2-step graded challenge split of the age appropriate dose, separated by 30 minutes. For children receiving a 0.25ml dose, a 20%/80% split will be used for ease of administration in drawing up the dose.
62063494|NCT05458258||Healthy Control Group: Adults with AML (age 60+) in Good Health|This group will also consist of participants age 60+ who will be assessed for malnutrition and sarcopenia. Participants in this group will undergo induction therapy and/or receive cancer drugs to treat their AML (as part of standard care). Participants in this group will also receive different assessments when they start induction therapy to measure their nutritional health and the severity of their sarcopenia. Participants in this group will receive the same assessment as participants in the first study group -- the only difference is that participants in this group have been determined to be healthier than those in the first study group according to clinical assessments.
62451390|NCT06342921|EXPERIMENTAL|45 mg|45 mg of ADC189 tablets Once during the whole study.
62628790|NCT01351454|ACTIVE_COMPARATOR|ACT HEALTHY|ACT HEALTHY is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, \& Hopko, 2001) and Life Steps, an HIV medication adherence intervention (Safren, Otto, \& Worth, 1999). ACT HEALTHY is based on the belief that the best way to improve mood, remain sober, increase medication adherence, and make long-term life changes is by changing and increasing one's activity level. Treatment includes 16 individual sessions over a 12-week period.
62628791|NCT01351454|PLACEBO_COMPARATOR|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, \& Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
62628792|NCT05676788|EXPERIMENTAL|Intersegmental plane identification by HSI and ICG|"Hyperspectral Imaging Intersegmental plane identification:~Defined as distance between intersegmental plane identification with Hyperspectral Imaging compared to near-infrared indocyanine green fluorescence."
62628793|NCT03059537|EXPERIMENTAL|Stimulation Test|Study meal plus chenodeoxycholic acid: 1,250 mg single dose stimulation
62628794|NCT05201326|EXPERIMENTAL|Treatment arm|irinotecan + bevacizumab + Re-radiotherapy
62628795|NCT00401193|EXPERIMENTAL|1|
62628796|NCT00401193|EXPERIMENTAL|2|
62628797|NCT00401193|PLACEBO_COMPARATOR|3|
62628798|NCT03153800|EXPERIMENTAL|Bronchial basal cells|
62628799|NCT02643433|EXPERIMENTAL|MR and JE coadministration group|Infants aged 8 months are vaccinated measles-rubella combined vaccine (MR) and Japanese Encephalitis alive vaccine (JE) in different sites at same time.
62628800|NCT02643433|ACTIVE_COMPARATOR|MR administration alone group|Infants aged 8 months are vaccinated measles-rubella combined vaccine alone
62628801|NCT06611579|EXPERIMENTAL|Treatment|Treatment with the inQB8 MonarQ Transcatheter Tricuspid Valve Replacement System
62451391|NCT06342921|PLACEBO_COMPARATOR|Placebo|Once during the whole study.
62451392|NCT00819247|EXPERIMENTAL|Degarelix 80/80 + 40|Loading doses of Degarelix 80 mg (20 mg/mL) on Days 0 and 3. Maintenance doses of 40 mg (20 mg/mL) given on days 28, 56, 84, 112 and 140.
62451393|NCT00819247|EXPERIMENTAL|Degarelix 40/40 + 40|Loading doses of Degarelix 40 mg (20 mg/mL) on Days 0 and 3. Maintenance doses of 40 mg (20 mg/mL) given on days 28, 56, 84, 112 and 140.
62451394|NCT00819247|EXPERIMENTAL|Degarelix 80 + 20|Loading dose of Degarelix 80 mg (20 mg/mL) on Day 0. Maintenance doses of 20 mg (10 mg/mL) given on days 28, 56, 84, 112 and 140.
62451395|NCT01673958|EXPERIMENTAL|Stair descending group|Stair descending exercise. Participants will carry out six weeks of stair descending training consisting of three exercise sessions per week.
62628802|NCT01916460|EXPERIMENTAL|Gastroparetic patient 19G|Endoscopic Ultrasound Fine Needle Aspiration of the gastric wall prior to surgical placement of gastric neurostimulator with 19-gauge fine core needle used for aspiration
62628803|NCT05693129|EXPERIMENTAL|Leniolisib|Leniolisib film-coated granules in 10, 15 and 20 mg strengths administered orally BID by body weight for 12 weeks for Part I and for 1 year for Part II.
62628804|NCT04947410|ACTIVE_COMPARATOR|OSAS Patients treated with CPAP|"Patients with OSAS will have 1 in 2 chance of being randomized into CPAP group"
62628805|NCT04947410|SHAM_COMPARATOR|OSAS Patients treated with nasal dilators|"Patients with OSAS will have 1 in 2 chance of being randomized into nasal dilators group"
62628806|NCT04947410|NO_INTERVENTION|Non OSAS Patients|Non OSAS Patients will be the parallel control group
62628807|NCT06328257|EXPERIMENTAL|Myofascial Release Training|The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Myofascial Release Training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 15-30 minutes. Each training session will be conducted approximately one hour prior to meals. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
62628808|NCT04002791|PLACEBO_COMPARATOR|Group 1: TR Band Arm|"Patients will receive hemostatic compression using the current standard of care TR band (Terumo Corporation, Japan). The band will be applied according to the instructions for use, with optimal pressure applied using Patent hemostasis protocol to achieve full hemostasis."
62853996|NCT01542567|ACTIVE_COMPARATOR|diclofenac|suppositories to prevent BCG side effects
62853997|NCT01542567|PLACEBO_COMPARATOR|placebo suppositories|
62853998|NCT01245569|EXPERIMENTAL|Foster®|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
62853999|NCT01245569|ACTIVE_COMPARATOR|Seretide® Accuhaler®|Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
62854000|NCT03374319|EXPERIMENTAL|Intervention group|Modified amputation procedure
62628809|NCT04002791|ACTIVE_COMPARATOR|Group 2: Vaso-band Arm|Patients will receive Vaso-band (VasoInnovations, Inc, USA), applied with ulnar balloon inflated with 15 ml of air, and the radial balloon inflated after the sheath is removed, to apply optimal pressure for obtaining full hemostasis. Ulnar balloon will be deflated after 60 minutes of radial artery hemostatic compression.
62628810|NCT02500823||CHD group|200 consecutive patients were recruited, who have diagnosed with coronary heart disease(CHD) by coronary angiography.
62628811|NCT02500823||Control group|The 200 healthy controls without previous CHD history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
62628812|NCT01360788||Healthy control subjects|Subjects with a significant smoking history (more than 10 pack-years) and a normal lung function.
62628813|NCT01360788||Asymptomatic GOLD stage I COPD patients|GOLD stage I COPD (post-bronchodilator forced expiratory volume in 1 second \[FEV1\] \> 80% predicted and FEV1/ forced vital capacity \[FVC\] \< 0.7 and a smoking history \> 10 pack-years) were recruited. A Medical Research Council (MRC) dyspnea score ≥ 2 was used to define the presence of symptoms (dyspnea). Concretely, this group did not present any respiratory symptoms, with a MRC dyspnea score of 1/5.
62628814|NCT01360788||Symptomatic GOLD stage I COPD patients|GOLD stage I COPD (post-bronchodilator forced expiratory volume in 1 second \[FEV1\] \> 80% predicted and FEV1/ forced vital capacity \[FVC\] \< 0.7 and a smoking history \> 10 pack-years) were recruited. A Medical Research Council (MRC) dyspnea score ≥ 2 was used to define the presence of symptoms (dyspnea) in this group.
62628815|NCT02590237|ACTIVE_COMPARATOR|Direct Laryngoscopy|The trachea will be intubated via direct laryngoscopy using a traditional straight blade (Miller) laryngoscope.
62628816|NCT02590237|EXPERIMENTAL|KingVision Video Laryngoscope|The trachea will be intubated using the Ambu KingVision Video Laryngoscope size 1 pediatric blade.
62628817|NCT03233815||Inhaled anesthesia (Sevoflurane)|Patients undergoing cardiovascular surgery with inhaled anesthesia with sevoflurane.
62628818|NCT03233815||Total Intravenous Anesthesia (Propofol)|Patients undergoing cardiovascular surgery with total intravenous anesthesia with propofol.
62628819|NCT02666989|ACTIVE_COMPARATOR|open placebo|8 weeks of open placebo treatment
62628820|NCT02666989|NO_INTERVENTION|waitlist group|4 weeks of waiting list followed by 4 weeks of open placebo treatment
62628821|NCT02762071|ACTIVE_COMPARATOR|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
62628822|NCT02762071|EXPERIMENTAL|Liposomal Bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
62628823|NCT02121548|PLACEBO_COMPARATOR|Outreach|Gets outreach materials and info on where to get screened by CHW.
62628824|NCT02121548|ACTIVE_COMPARATOR|CHW Outreach|Comprehensive CHW outreach including home visit, detailed 1:1 education, patient navigation
62628825|NCT02121548|ACTIVE_COMPARATOR|CHW Outreach and HPV Self-Sampling|Same as Arm 2 with a CHW outreach but also option of doing HPV home self-sampling
62628826|NCT06376708|EXPERIMENTAL|PEEK and PRF|maxillary sinus elevation using PEEK and platelet rich fibrin
62628827|NCT06376708|ACTIVE_COMPARATOR|PEEK alone|maxillary sinus elevation using PEEK alone
62628828|NCT06164483||Control|Healthy patients between 20 and 40 years
62854001|NCT04786834|ACTIVE_COMPARATOR|Traditional training group|Trainees in the Traditional trained group will be trained according to the traditional approach of 'See one, do one, teach one' principle. Trainees will have an e-learning didactic component (specifically on the anatomy \& physiology of the procedure, clinical aspects of the procedure, published evidence etc) which they must complete before training by a procedure expert. On completion of the e-learning module they will complete a summative assessment of their knowledge. They will then be shown how and then trained to suture and tie knots using the robot. The VUA will be demonstrated initially by an expert and who will then proctor the trainees in the same technique for repeated training trials., i.e., repeated practice for a period of time matched to the PBP group.
62628829|NCT06164483||MS group|Patient with Relapsing Remitting MS age between 20 and 40 years
62628830|NCT05013242|ACTIVE_COMPARATOR|group use GnRH|GnRH (zoladex 3.75mg) injection once every 4 weeks
62451396|NCT01673958|EXPERIMENTAL|Stair ascending group|Stair ascending exercise. Participants will carry out six weeks of stair descending training consisting of three exercise sessions per week.
62628831|NCT05013242|ACTIVE_COMPARATOR|Group use Visanne (dienogest 2mg) oral once daily for 12 weeks|Visanne (dienogest 2mg) oral once daily for 12 weeks
62451397|NCT06428708|EXPERIMENTAL|[18F] PSMA-1007 PET/CT|All patients enrolled undergo a \[18F\] PSMA-1007 PET/CT
62628832|NCT02191345|NO_INTERVENTION|10 minute break|Participants asked to take a 10 minute break as usual 3 times per week for 4 weeks
62628833|NCT02191345|EXPERIMENTAL|Guided Imagery|Participants listen to one of 6 pre-recorded guided imagery tracks 3 times per week for 4 weeks
62628834|NCT05290948|ACTIVE_COMPARATOR|investigate of the effect of intravitreal injection of bevacizumab with acetazolamide tablets|
62628835|NCT05290948|ACTIVE_COMPARATOR|Investigate the effect of intravitreal injection of bevacizumab alone|
62628836|NCT01564992||Parkinson disease|Identification of genes
62628837|NCT03166488|EXPERIMENTAL|Tricuspid Valvular Repair Patients|Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE) within 1 month preoperatively and as close to 6 months postoperatively as reasonably achievable.
62628838|NCT03948152|ACTIVE_COMPARATOR|Standard of Care|
62628839|NCT03948152|EXPERIMENTAL|Mask Advice Tool|
62628840|NCT05328453||Pregnant women at 15-24 gestation.|Routine fetal ultrasonography at 15-24 weeks. All sonographic measurements including 3D fetal thymus calculation was measured.
62628841|NCT01184170|EXPERIMENTAL|Metabolically Normal|"Subjects in this group are metabolically normal. They have low liver fat defined as less than five percent as determined by magnetic resonance spectroscopy.~Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits."
62628842|NCT01184170|EXPERIMENTAL|Metabolically Abnormal|"Subjects in this group are metabolically abnormal. They have high liver fat defined as at least ten percent as determined by magnetic resonance spectroscopy.~Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits."
62628843|NCT03929263|EXPERIMENTAL|Real-time fMRI neurofeedback|All participants will receive neurofeedback from the target region (no sham condition).
62854002|NCT04786834|EXPERIMENTAL|Proficiency based progression (PBP) training group: a new training methodology|Participants in the PBP trained group will follow the exact same e-learning didactic course as the Traditional trained group but the PBP group will be required to pass a test of procedure knowledge before continuing to the surgical training. Their knowledge will be assessed in a formative and summative fashion. After their initial VUA assessment, procedure-specific and validated procedure metrics will be used to teach the students the steps of the procedure, as well as the correct (and incorrect) way to perform the procedure. The metrics will be used to give them performance feedback with specific advice on how they might improve their performance, i.e., deliberate practice.
62854003|NCT02360683||patients with Parkinson's disease|Large population of Parkinson's patients who benefit from subthalamic stimulation
62063495|NCT02873819|EXPERIMENTAL|GL-0817|Subjects in active treatment will be vaccinated with GL-0817 with the adjuvants Poly-ICLC (Hiltonol®) and GM-CSF (Sargramostim, Leukine®) 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at Week 18. Patients will receive IV Cyclophosphamide 1 day prior to the first 3 vaccinations.
62063496|NCT02873819|PLACEBO_COMPARATOR|Placebo|Subjects in placebo arm will receive placebo to cyclophosphamide (normal saline solution) followed by Poly-ICLC/GM-CSF/placebo vaccine injections on the same schedule as the GL-0817 cohort.
62088085|NCT04610424|EXPERIMENTAL|Cooperative Parent Mediated Therapy|"Cooperative Parent Mediated Therapy (CPMT) is a targeted parent-mediated intervention focused on the ASD core symptoms (Bearss et al., 2015). CPMT is based on the most significant models of parent training for ASD, in the perspective of Naturalistic Developmental Behavioral Interventions-NDBI with specific attention to the promotion of cooperative interactions (Schreibman et al., 2016). The aim of CPMT is to improve parental skills, to enable parents promoting the following seven target skills in their child: socio-emotional engagement, emotional regulation, imitation, communication, joint attention, play and cognitive flexibility and cooperative interaction. An individualized treatment plan is designed for each child in order to determine his developmental level and treatment goals (Valeri et al., 2019)."
62628844|NCT03291951|EXPERIMENTAL|Resistance training group|Participants randomized to the resistance training (RT) group will receive an in-person and telephone-based intervention to promote home-based resistance training. The exercise intervention will begin by the 3rd adjuvant chemotherapy visit and continue exercise through the completion of post-operative chemotherapy. Participants will work with an exercise professional with expertise working with oncology patients.
62628845|NCT03291951|NO_INTERVENTION|Usual care group|Participants randomized to the usual care (U) group will be instructed to refer to their physician regarding what forms of exercise are safe for them, given their medical history. The U group will be told to continue whatever exercise program they have been undertaking up to enrolling in the study, but not to increase exercise or begin weight-lifting over the period of study participation.
62628846|NCT06132282|EXPERIMENTAL|Substance Use and Health Risk Intervention (SUHRI)|A technology-based application (administered via tablet) that addresses the interrelated topics of substance use and risky sex practices, within the context of personal relationships.
62628847|NCT04240223|EXPERIMENTAL|50 mg Brilacidin tablet|
62628848|NCT04240223|EXPERIMENTAL|100 mg Brilacidin tablet|
62628849|NCT04240223|EXPERIMENTAL|200 mg Brilacidin (2 x 100 mg Brilacidin tablets)|
62628850|NCT04240223|PLACEBO_COMPARATOR|Placebo tablet (replica of shape/size of 50 mg tablet)|
62628851|NCT04240223|PLACEBO_COMPARATOR|Placebo tablet (replica of shape/size of 100 mg tablet)|
62628852|NCT04240223|PLACEBO_COMPARATOR|Placebo (2 x replica of shape/size of 100 mg tablets)|
62628853|NCT00672633|EXPERIMENTAL|A , Experimental|Lovaza, 4 grams/day orally for 6 months
62628854|NCT00672633|PLACEBO_COMPARATOR|Corn Oil Pill|Corn Oil Pill, 4 pills/day orally for 6 months
62628855|NCT05265039|EXPERIMENTAL|Cognitive Processing Therapy (CPT)|
62628856|NCT05265039|ACTIVE_COMPARATOR|Relaxation Training (RT)|
62628857|NCT02521597|EXPERIMENTAL|Cellscope|The intervention for this study will be the use of a smartphone otoscope attachment called CellScope Oto.
62628858|NCT02521597|ACTIVE_COMPARATOR|Traditional otoscope|The control group will be using a classic otoscope
62628859|NCT06110598|EXPERIMENTAL|Arm A: Extended adjuvant therapy with capecitabine|"* Participants randomized to Arm A will take capecitabine (1000mg by mouth twice a day, 3-week cycle \[2 weeks on therapy, 1 week off\]) for up to 18 cycles, or until progression or intolerance to therapy develops.~* Participants who remain without disease recurrence at completion of 18 cycles of therapy who wish to continue therapy may do so at the discretion of their treating medical oncologist. Participants will be followed at standard 12-week intervals, where they will undergo routine cross-sectional imaging and labs."
62628860|NCT06110598|NO_INTERVENTION|Arm B: Active surveillance|"* Participants randomized to Arm B will undergo active surveillance, with no active treatment for the duration of their participation in the study.~* Participants in Arm B will undergo re-staging every 12 weeks (+/- 7 days), consisting of cross-sectional imaging (CT or PET-CT) and labs (CBC, chemistry panel, CA19-9 and blood draw for ctDNA). In addition to re-staging every 12 weeks, participants may be seen by their medical or surgical oncologist as clinically indicated. Participants who experience disease relapse may transition to palliative systemic therapy or best supportive care at the discretion of their treating medical oncologist."
62628861|NCT00758498|EXPERIMENTAL|1|armodafinil - dosage of 50 mg/day
62628862|NCT00758498|EXPERIMENTAL|2|armodafinil - dosage of 150 mg/day
62628863|NCT00758498|PLACEBO_COMPARATOR|3|matching placebo
62268602|NCT05858671|EXPERIMENTAL|Fenugreek Seed Tea|Fenugreek seeds will be delivered at a dose of 5g/day, drunk as a tea (2.5g/per tea bag), p.o. twice a day at a 12-hour interval) for 8 weeks (56 days). The tea bags will be brewed in a cup (200ml) of boiled hot water for 10 minutes before drinking. This will be self-administered by the subjects, twice a day at a 12-hour interval. The rationale for choosing the dose and intervention time course were based on the previous studies where metabolic effects have been detected. Literature reports from 12 human studies on diabetic and pre-diabetic subjects gave doses of fenugreek seed ranging from 1 to 100g/day, with the median treatment dose being 6.3g/day, to the participants; the intervention time course ranged from 1 week to 3 years, with the median treatment time being 60 days. The dose and duration in this study was designed as being similar to these studies where metabolic effects have been detected and where participant burden will not be too onerous.
62268603|NCT05858671|PLACEBO_COMPARATOR|Black Tea|Control group: A control black tea (2.5g/bag), self-administered by the subjects, twice in a day at a 12-hour interval. Black tea is a type of fermented tea that has been found to possess much less cardioprotective and lipid profile improving effect compared to green tea due to the different manufacture process. Consumption of black tea has been found not associated with a reduced risk of coronary heart disease in the United Kingdom. Therefore, we propose to use black tea as control tea for this study.
62268604|NCT02480127|EXPERIMENTAL|Endometrial injury|In the intervention group, endometrial sampling is obtained twice by Pipelle \[one in the follicular phase (during 8-9 or 11- 13 day in the beginning of buserelin cycle) and the last in the luteal phase (during 19-21 or 20-23 day) preceding the embryo transfer cycle preceding the embryo transfer cycle\]. Blood samples (5- 10 cc) are taken in the both groups twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).
62268605|NCT02480127|NO_INTERVENTION|Control|In the control group endometrial sampling will be done only in the luteal phase of the cycle preceding the embryo transfer cycle. Blood samples (5- 10 cc) are taken twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).
62268606|NCT01967550|EXPERIMENTAL|diclofenac diethylamine, DDEA 2.32% gel|diclofenac diethylamine, DDEA 2.32% gel
62268607|NCT01967550|PLACEBO_COMPARATOR|Placebo|Vehicle control
62268608|NCT05234632|EXPERIMENTAL|PICO 14 Any Wound|Any wound treated with PICO 14. For closed Surgical incisions this will be for 14 days post surgery and with a 30 day follow up. For chronic and dehisced wounds this will be for up to 28 days therapy and no follow-up.
62628864|NCT04616612|EXPERIMENTAL|SystemCHANGE (TM)|"SystemCHANGE™ focuses on using patients' already established and reliable systems to support medication-taking, rather than focusing on personal effort and remembering.When applied to medication adherence, the goal is to reduce medication-taking variability and move towards consistently taking medication with a 6-hour window of time (for daily medications like RAAS) and avoid missing medications. SystemCHANGE™ improvement cycles rely on efficient use of performance feedback in order to make decisions about whether system solutions work or if there is a need to select other solutions."
62628865|NCT04616612|ACTIVE_COMPARATOR|Attention Control|Participants in the attention control will receive educational materials about chronic kidney disease (CKD). The content will be focused on diet, exercise, and living with CKD.
62628866|NCT01816178|EXPERIMENTAL|communication training|Participants were instructed in the use of a voices output communication aid.
62628867|NCT02527174|EXPERIMENTAL|Study treatment arm|"Will receive volasertib combined with idarubicin plus cytarabine in a 3+7 schedule as induction chemotherapy. Volasertib dose will be given on day 4 in a dose escalation schedule over 3 dose levels (140 mg/m2, 170 mg/m2, 200 mg/m2) in successive cohorts.~Non-hematologic toxicity will be determined using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteria for adverse events. Hematologic toxicity will be determined by days to absolute neutrophil count (ANC) and platelet recovery."
62628868|NCT05849363|EXPERIMENTAL|Posterior fossa decompression|Posterior arch of atlas removal, reconstruction of cisterna magna, decompression of cerebellum, detection of magendie foramen.
62854004|NCT01588418|EXPERIMENTAL|Exenatide first, then Placebo|Exenatide 5mcg was injected subcutaneously 30 min before Oral Glucose Tolerance Test (OGTT)-PET study. The same subject was studied again a few weeks later with the same protocol with Placebo injection.
62854005|NCT01588418|EXPERIMENTAL|Placebo first, then Exenatide|Placebo was injected subcutaneously 30 min before OGTT-PET study. The same subject was studied again a few weeks later with the same protocol with injection of Exenatide 5mcg .
62854006|NCT00285389|EXPERIMENTAL|VAD Clorambucil Rituximab|
62854007|NCT02205489|EXPERIMENTAL|GZ402673 LEMTRADA|First course: Intravenous infusion for 5 consecutive days. Second course (will occur 12 months after the first course of treatment): Intravenous infusion for 3 consecutive days.
62854008|NCT00662675|EXPERIMENTAL|001|Pancrease MT 10.5 or MT 21 Pancrease MT capsules for maximum dose of 10 000 lipase units / Kg / day
62854009|NCT00662675|EXPERIMENTAL|002|Placebo for Pancrease MT 10.5 or MT 21 Capsules with Pancrease MT excipients without the active enzymes
62628869|NCT05849363|EXPERIMENTAL|Posterior Compression-Distraction-Reduction-Fixation|"After subperiosteal dissection, the facet joint was exposed. A 2-mm joint scraper with sharp edge was inserted into the joint capsule and rotated to remove the articular cartilage. A blunt-edged rotating distractor was then inserted into the joint space, and the facet was sequentially opened with larger and larger blunt rotating distractors. After distraction on one side, an appropriate-sized trial was placed into the contralateral facet, holding the distraction open. This was repeated back and forth with larger trials. These steps were repeated, and the facet joints were distracted up to the pre-planned distance of the odontoid tip above Chamberlain's line."
62628870|NCT06613191|ACTIVE_COMPARATOR|Aspirin only|Participants receiving aspirin only at time of the colonoscopy
62628871|NCT06613191|EXPERIMENTAL|P2Y12 inhibitor only|Participants receiving a P2Y12 inhibitor only at time of the colonoscopy
62854010|NCT05946356||Fibromyalgia patients|Participants will complete self-reported questionnaires to assess psychological wellbeing, physical activity, and disability.
62628872|NCT04392219|EXPERIMENTAL|EIDD-2801|EIDD-2801: Part 1: Participants were randomized to receive 50 to 1600 mg EIDD-2801 powder-in bottle (fasted); Part 2: Participants were randomized to receive two single 200 mg doses (fed or fasted); Part 3: Participants were randomized to receive twice daily doses of EIDD-2801 in an open-label manner.
62628873|NCT04392219|PLACEBO_COMPARATOR|Placebo|Placebo: Part 1: Participants were randomized to receive placebo (fasted); Part 3: Participants were randomized to receive placebo (fasted).
62628874|NCT03761485|EXPERIMENTAL|Dentifrice 750 ppm of NaF acidulated|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
62628875|NCT03761485|ACTIVE_COMPARATOR|Dentifrice 1.100 ppm of NaF neutral|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
62628876|NCT03761485|ACTIVE_COMPARATOR|Dentifrice 1.100 ppm of NaF acidulated|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
62628877|NCT02377232|ACTIVE_COMPARATOR|Usual Care Outreach for Colon Cancer Screening|Receives standard of care outreach concerning colon cancer screening.
62628878|NCT02377232|ACTIVE_COMPARATOR|Decision Aid for Colon Cancer Screening|Receives colon cancer screening decision aid intervention in addition to outreach.
62628879|NCT04570709|NO_INTERVENTION|Control|Patients in the control arm will receive standard of care and no intervention.
62628880|NCT04570709|EXPERIMENTAL|Intervention|Patients in the intervention arm will receive the PACT intervention provided by a multidisciplinary team of RNs, OTs, and PTs.
62628881|NCT02213380|OTHER|group GA|General anesthesia
62628882|NCT02213380|OTHER|group RA|Regional anesthesia
62628883|NCT02822521|EXPERIMENTAL|Mobile Application + Population Manager|This arm of the study will contain half the study population after randomization. The participants in this arm will receive the mobile application with daily questions after the first visit. A population manager will review patient-reported symptoms via a web-base dashboard and contact the subject based on pre-specified guidelines.
62628884|NCT02822521|NO_INTERVENTION|No Mobile Application|This arm of the study will contain half the study population after randomization. The participants in this arm will not receive the mobile application after the first visit. Although participants will be provided with the contact information of a study staff member, there will be no active contact with the subject unless he/she initiates.
62451398|NCT03244774|EXPERIMENTAL|Apatinib plus POF|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: apatinib 250 mg per day and POF. Cohort 2: apatinib 375 mg per day and POF. Cohort 3: apatinib 500 mg per day and POF. Cohort 4: apatinib 625 mg per day and POF. Cohort 5: apatinib 750 mg per day and POF.~A dose limiting toxicity (DLT) event is defined as any of the following events in the first 4-week period:~1. CTCAE Grade 4 event (except for neutropenia lasting for ≤ 5 days);~2. Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase)~If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
62854011|NCT01299545||a single group of patients -200 expected|polyarthrite rhumatoid patients
62854012|NCT02595632||Healthy|Healthy subjects with no apparent lung disease and normal lung function testing.
62854013|NCT00784342||Stable|Patients who are stable have not had a COPD exacerbation in the past 2 months.
62854014|NCT00784342||Exacerbation|Patients with an exacerbation have been diagnosed and started on treatment for an exacerbation within the past 3 days.
62451399|NCT02427607|EXPERIMENTAL|Perampanel|Participants started the study with the dose that they were receiving at the end of their participation in the previously participated Study E2007-G000-332 (Study 332) \[NCT02307578\]. Doses of perampanel were allowed to be adjusted based on clinical judgment. A minimum perampanel dose of 2 milligram (mg) per day was required to continue in the study. The maximum daily dose of perampanel permitted was 12 mg per day.
62451400|NCT03977584|EXPERIMENTAL|[^18F]GTP1 in Mutation Carriers: Crenezumab|Mutation-carrying participants receiving crenezumab in the main study NCT01998841 (GN28352) will receive up to three IV injections of \[\^18F\]GTP1 and will undergo a tau PET scan after each IV injection of \[\^18F\]GTP1.
62628885|NCT02943187|EXPERIMENTAL|Nutrition and Cognitive Training|The intervention includes a physician-directed diet, exercise, and nutritional supplementation regimen, combined with a 60-hour, clinician-delivered cognitive training program created by LearningRx.
62628886|NCT04808934||Non-Valvular Atrial Fibrillation (NVAF) Adults|Adult patients with NVAF newly treated with apixaban, dabigatran, rivaroxaban or VKAs between June 16, 2014 and December 31, 2018.
62628887|NCT04609020|EXPERIMENTAL|HArmonyCA, Juvederm, BOTOX|All treatments will be administered according to the respective label and according to an agreed upon treatment plan between the subject and Health Care Provider. If required: HarmonyCA Lidocaine will be administered at Visit 1, Juvéderm filler injections (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine and/or JUVÉDERM VOLUX with Lidocaine) will be administered at Visit 3, BOTOX will be administered at Visit 5. Touch-ups may be performed as required by subject's treatment plan after each study visit.
62628888|NCT00762034|EXPERIMENTAL|Pem/Carbo/Bev|Pemetrexed (Pem), carboplatin (Carbo) and bevacizumab (Bev) followed by pemetrexed and bevacizumab
62628889|NCT00762034|ACTIVE_COMPARATOR|Pac/Carbo/Bev|Paclitaxel (Pac), carboplatin (Carbo) and bevacizumab (Bev) followed by bevacizumab
62628890|NCT04839198|EXPERIMENTAL|Adaptive Treatment plus usual care|
62628891|NCT04839198|ACTIVE_COMPARATOR|Usual care|
62628892|NCT04284826|EXPERIMENTAL|mitomycin C injection group|A submucosal needle injection of 4mL of a MMC preparation (0.5mg/mL) into the tearing esophageal wall after esophageal bougie dilation on refractory benign esophageal stricture
62628893|NCT05802940|ACTIVE_COMPARATOR|Best practice alert (BPA) intervention group|An electronic health record best practice alert (BPA) will alert healthcare providers to recommend low dose aspirin for pregnant patients at high-risk for preeclampsia. This alert also allows the healthcare provider to order an over-the-counter-prescription for low dose aspirin and automatically documents LDA in the patient's medication list.
62628894|NCT05802940|NO_INTERVENTION|Standard care group|Healthcare provider's recommendation for aspirin in patients at high-risk for preeclampsia will be based on current practice (no alerts) and the healthcare provider's knowledge.
62628895|NCT04993079|EXPERIMENTAL|Clotild®|Subjects presenting an acute ischemic stroke due to M1 or middle cerebral artery (MCA) bifurcation occlusion, eligible for Endovascular Thrombectomy (EVT) based on neuro-interventionist and/or neurologist investigators' opinion will be eligible. Twenty (20) patients will be initially enrolled. Up to 42 patients will be enrolled following an analysis of the data of the first 20 enrolled patients by a data safety monitoring board (DSMB) and its' recommendation to proceed with the study. Clots will be retrieved and analysed in a group of participants for which Clotild® is used as neurovascular guidewire.
62628896|NCT03128619|EXPERIMENTAL|Arm A (copanlisib, letrozole)|PHASE II: Patients receive copanlisib (MTD) IV over 1 hour on days 1, 8, and 15 and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression, or unacceptable toxicity.
62268609|NCT05234632|EXPERIMENTAL|PICO 14 Closed Incisions|Any Closed incision treated with PICO 14, for closed Surgical incisions this will be for 14 days post-surgery and with a 30 day follow up.
62628897|NCT03128619|EXPERIMENTAL|Arm B (copanlisib, palbociclib, letrozole)|PHASE II: Patients receive copanlisib (MTD) IV over 1 hour on days 1, 8, and 15, palbociclib PO QD on days 1-21, and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62628898|NCT03128619|EXPERIMENTAL|Arm C (copanlisib, palbociclib, letrozole)|PHASE II: Patients receive palbociclib PO QD for days 1-14 of course 1 and letrozole PO continuously on days 1-14. Patients then undergo biopsy. Patients then receive copanlisib IV over 1 hour on days 1, 8, and 15 and letrozole PO continuously on days 1-28. Treatment with copanlisib (MTD) and letrozole repeats every 28 days for up to 3.5 courses in the absence of disease progression or unacceptable toxicity.
62854015|NCT03332680|EXPERIMENTAL|EmbryoGlue® (laboratory culture medium)|"laboratory culture medium~laboratory embryo culture medium, embryos are placed in this media prior to transfer into uterus via embryo transfer procedure to facilitate IVF. EmbryoGlue contains Hyaluronic acid."
62854016|NCT03332680|ACTIVE_COMPARATOR|Standard control medium|"laboratory culture medium~In standard procedure embryos are placed in a media prior to transfer into uterus via embryo transfer procedure to facilitate IVF."
62854017|NCT03071757|EXPERIMENTAL|Part 1A: Monotherapy Dose Escalation|Part 1A: ABBV-368 (various dose levels) intravenous administration every 2 weeks (Q2W). One cycle of treatment is 28 days, thus there will be 2 doses with ABBV-368 per cycle.
62854018|NCT03071757|EXPERIMENTAL|Part 2A: Monotherapy Cohort Expansion|Part 2A: Additional participants (triple negative breast cancer \[TNBC\]) will be enrolled in a dose expansion cohort that will further evaluate ABBV-368 (various dose levels) intravenous administration Q4W.
62088086|NCT04610424|ACTIVE_COMPARATOR|Control|Control group
62088087|NCT04517903|EXPERIMENTAL|exploratory phase|eye rubbing questionnaire at baseline and 15 days later
62268610|NCT05234632|EXPERIMENTAL|PICO 14 Chronic/Dehisced Surgical Wounds|Any Chronic/Dehisced Surgical wound treated with PICO 14, for chronic and dehisced wounds this will be for up to 28 days therapy and no follow-up.
62268611|NCT02745275|EXPERIMENTAL|Peer-led Health Education|A single 60 minute interactive workshop led by the trained health coach followed by a series of three one hour discussion groups
62451401|NCT03977584|PLACEBO_COMPARATOR|[^18F]GTP1 in Mutation Carriers: Placebo|Mutation-carrying participants receiving placebo in the main study NCT01998841 (GN28352) will receive up to three IV injections of \[\^18F\]GTP1 and will undergo a tau PET scan after each IV injection of \[\^18F\]GTP1.
62268612|NCT02745275|NO_INTERVENTION|Control|No intervention
62451402|NCT03977584|PLACEBO_COMPARATOR|[^18F]GTP1 in Non-carriers of Mutation: Placebo|Non-carriers of the mutation receiving placebo in the main study NCT01998841 (GN28352) will receive up to three IV injections of \[\^18F\]GTP1 and will undergo a tau PET scan after each IV injection of \[\^18F\]GTP1.
62451403|NCT05095909|EXPERIMENTAL|Cryo-compression|"Fitted with compression sleeve for the NICE Recovery SystemTM applied to the operative shoulder immediately post - operatively Minimum 6 hours treatment per day post-operatively. Utilize cyro-compression unit with a Medium compression level (inflate to 35 mmHg for 2 minutes and then deflate to 5 mmHg for 30 seconds) and Level 3 cooling (50F (10C)) for the first 24 hours. After that time, the compression and cooling levels will be up to the patients' discretion."
62451404|NCT05095909|ACTIVE_COMPARATOR|Cryo-therapy|Fitted with a standard gel ice pack with wrap immediately post-operatively. Minimum 6 hours treatment per day using gel ice packs.
62451405|NCT00803959|ACTIVE_COMPARATOR|No UDS|Women desiring surgery for diagnosed, uncomplicated predominant stress urinary incontinence (UI) who receive a basic office evaluation only.
62628899|NCT03128619|EXPERIMENTAL|Phase Ib (copanlisib, palbociclib, letrozole)|PHASE Ib: Patients with metastatic breast cancer receive copanlisib IV over 1 hour on days 1, 8, and 15, palbociclib PO QD on days 1-21, and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62628900|NCT03223155|EXPERIMENTAL|Sequential Arm|Patients will be randomized to either the Sequential Arm or the Concurrent Arm. Patients in the Sequential Arm will complete SBRT to 2-4 sites and then begin treatment with nivolumab/ipilimumab between 1-7 days after completion of SBRT.
62628901|NCT03223155|EXPERIMENTAL|Concurrent Arm|Patients will be randomized to either the Sequential Arm or the Concurrent Arm. Patients in the Concurrent Arm will begin treatment with nivolumab/ipilimumab first and must complete planned SBRT to 2-4 sites within 2 weeks (prior to second dose of nivolumab).
62628902|NCT04582279|EXPERIMENTAL|Receiving Ultrasound|Every patient will receive a lung ultrasound prior to each scheduled bronchoscopy until the study stops.
62854019|NCT03071757|EXPERIMENTAL|Part 2B: Combination Therapy Cohort Expansion|Part 2B: Additional participants (with Head and Neck carcinoma) will be enrolled in a dose expansion cohort that will further evaluate ABBV-368 (various dose levels) intravenous administration Q4W plus ABBV-181.
62268613|NCT05185271|EXPERIMENTAL|Dyad- focused strategy training intervention|"The dyad-focused strategy training intervention protocol will be developed to help dyads manage the needs that they have as transitioning to the community.~The following theoretical frameworks and guidelines will be used to guide the development of the intervention: (1) the strategy training guideline outlined by Skidmore et al; (2) Bodenmann's framework of dyadic coping; and (3) Self-efficacy theory."
62268614|NCT00977821|ACTIVE_COMPARATOR|fresh|Embryo transfer with fresh oocytes
62268615|NCT00977821|EXPERIMENTAL|Frozen|Embryo transfer with vitrified oocytes
62268616|NCT02982954|EXPERIMENTAL|ccRCC KPS ≥ 70%|Clear-Cell Renal Cell Carcinoma (ccRCC) with Karnofsky Performance Status (KPS) ≥ 70%
62854020|NCT03071757|EXPERIMENTAL|Part 3A: 18F-AraG Imaging Substudy in TNBC Participants|Part 3A: Additional participants (with TNBC) will be enrolled in 18F-AraG Imaging Substudy that will further evaluate ABBV-368 intravenous administration Q4W plus ABBV-181.
62854021|NCT03071757|EXPERIMENTAL|Part 3B: 18F-AraG Imaging Substudy in HNSCC Participants|Part 3B: Additional participants (with HNSCC) will be enrolled in 18F-AraG Imaging Substudy that will further evaluate ABBV-368 intravenous administration Q4W plus ABBV-181.
62854022|NCT00264758|ACTIVE_COMPARATOR|Conventional hemodialysis|Three times per week in-center hemodialysis
62063497|NCT06100055|ACTIVE_COMPARATOR|Low-volume rectal irrigation|This system consists of a small reservoir attached to a cone. Depending on the manufacturer, the reservoir can hold approximately between 110ml and 300ml of water. This reservoir is squeezed to inject water into the rectum. The regime will be such that participants will be asked to use rectal irrigation daily for two weeks. They will be restricted to not use rectal irrigation for more than once in a day. Every day they can use up to 300ml for irrigation. After two weeks participants can then adjust the number of irrigation days per week as well as volume used for irrigation but not exceeding irrigation therapy more than once a day and not more than 300ml per irrigation. Volume and frequency of rectal irrigation will be recorded by participant in participant journal. This will be used to check their compliance and average weekly irrigation sessions and volume used for satisfactory outcome.
62088088|NCT04517903|EXPERIMENTAL|Confirmatory phase|eye rubbing questionnaire at baseline and at 6 month follow-up
62088089|NCT02015195|EXPERIMENTAL|Acetic Acid 5%|Acetic Acid (5%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
62268617|NCT02982954|EXPERIMENTAL|Non-ccRCC, KPS ≥ 70%|Non Clear-Cell Renal Cell Carcinoma (nccRCC) with KPS ≥ 70%
62268618|NCT02982954|EXPERIMENTAL|RCC with non-active Brain Mets, KPS ≥70%|Renal Cell Carcinoma (RCC) with non-active Brain Metastases, with KPS ≥70%
62268619|NCT02982954|EXPERIMENTAL|any RCC with KPS 50%-60%|Renal Cell Carcinoma (RCC), regardless of any histology or existing non-active brain metastasis, with KPS 50%-60%
62268620|NCT05607875|EXPERIMENTAL|The Grow to Recovery train-the-trainer group|Professionals of the train-the-trainer group will receive an online training and then conduct a recovery group.
62268621|NCT05607875|OTHER|Control group|Professionals of the control group will not receive training.
62268622|NCT03157427|EXPERIMENTAL|CRYOBEAUTY MAINS|Cryotherapy medical device designed to treat solar lentigo on the randomized hand.
62268623|NCT03157427|NO_INTERVENTION|Control|The non randomized hand is not teated.
62268624|NCT01391000|EXPERIMENTAL|Laser CO2|
62628903|NCT05195216||individuals with cystic fibrosis|
62268625|NCT01391000|ACTIVE_COMPARATOR|TENS|
62268626|NCT02766738|NO_INTERVENTION|Control|All participants assigned to the control group will be given the option to engage in other activities that were offered by the facility during the 24-week intervention period. However, no specific resistance exercises were offered in these activities.
62268627|NCT02766738|EXPERIMENTAL|GrACE program|Participants in the exercise group will perform twice weekly training for 24 weeks. In brief, the program will include weight-bearing exercises and a range of seated, non-resisted upper- and lower-body dynamic and reaching movements. The following-weight bearing and resistance exercises: chair stands, chair dips, calf raises and hip flexor/abdominal lifts, trunk twists, and bicep curl and shoulder press. In total the sessions will be 45 minutes twice weekly.
62628904|NCT05195216||healthy individuals|
62854023|NCT00264758|EXPERIMENTAL|Frequent hemodialysis|Six times per week in-center hemodialysis
62854024|NCT06437444|EXPERIMENTAL|Asthma Care Pathway group|All the primary care and hospital pediatricians of the two Integrated Hospital Organizations (IHO) (Barakaldo-Sestao and Ezkerraldea-Enkarterri-Cruces) where the care pathway will be implemented. 83 participants in total.
62854025|NCT06437444|NO_INTERVENTION|Control|Primary care and hospital pediatricians of other IHOs where the care pathway is not implemented, but with similar characteristics to those in the experimental group, and with a proportion of 1:2. 166 participants in total.
62628905|NCT00858806|EXPERIMENTAL|Intermittent Imatinib|"Imatinib will be given with the following schedule:~* 1 week on / 1 week off for the 1st month(weeks 1-4)~* 2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)~* 1 month on / 1 month off from the 4th month thereafter (weeks 13 on)"
62628906|NCT02537665|OTHER|incidence of bleeding|the effect of the epidural catheter filled with heated or normal saline before inserting into epidural on the incidence of bleeding.
62628907|NCT02537665|PLACEBO_COMPARATOR|inserting time of catheter|record the time from beginning of catheter inserting to completing the placement of the catheter.
62628908|NCT03744403|EXPERIMENTAL|CS1001 monoclonal antibody|
62854026|NCT01528202|NO_INTERVENTION|Baseline placebo|measures taken before administration of placebo
62854027|NCT01528202|PLACEBO_COMPARATOR|Placebo|Placebo intervention given after 'baseline placebo' arm
62063498|NCT06100055|ACTIVE_COMPARATOR|High-volume rectal irrigation|The high-volume irrigation system consists of an irrigation bag connected to a tube. The water flows into the rectum, either by gravity or by using a pump. Some systems use balloon to hold the device in place during irrigation; others require the user to hold it in place. The mechanism of action is the same for all systems. Participants will start irrigation with 300ml and increase this by 100ml every 2 days until satisfactory defaecation is achieved, or the procedure becomes uncomfortable, up to a maximum of 1500ml. Initial frequency of irrigation is the same as for low-volume irrigation: i.e. once daily for two weeks followed by participant adjustment of number of irrigation days per week as well as volume used for irrigation but no more than 1500ml a day. Participants will be restricted to using high-volume irrigation to not more than once a day.
62063499|NCT01568502||DSE|Patients, who underwent Dobutamine Stress Echocardiography (DSE)
62063500|NCT01568502||DSCMR|Patients, who underwent Dobutamine Stress Cardiac Magnetic Resonance (DSCMR)
62628909|NCT00563914|EXPERIMENTAL|1|
62628910|NCT00563914|ACTIVE_COMPARATOR|2|
62451406|NCT00803959|ACTIVE_COMPARATOR|UDS|Women desiring surgery for diagnosed, uncomplicated predominant stress urinary incontinence (UI) who receive a basic office evaluation with preoperative urodynamic studies prior to surgery.
62451407|NCT00509964|ACTIVE_COMPARATOR|1|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
62451408|NCT00509964|ACTIVE_COMPARATOR|2|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and infusional 5-fluorouracil, on day 1 every 2 weeks.
62628911|NCT02143024|EXPERIMENTAL|Family-based depression intervention|The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker
62628912|NCT02143024|ACTIVE_COMPARATOR|Usual care plus educational materials|Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.
62628913|NCT04932096|EXPERIMENTAL|Melatonin|(melatonin doses of 3mg or 5mg based on patient size given nightly 1 hour prior to bedtime every night for 30 days)
62628914|NCT04932096|PLACEBO_COMPARATOR|Placebo|Placebo
62628915|NCT02562599|EXPERIMENTAL|drug:raltitrexed safety and efficacy|"To receive the safety and efficacy of raltitrexed-cisplatin neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with raltitrexed-cisplatin~Interventions:~Neochemotherapy (Induction Chemotherapy) Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles).~Concurrent Chemotherapy Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles) .~Radiation: Intensity-modulated radiotherapy (IMRT)"
62854028|NCT01528202|NO_INTERVENTION|baseline cherry juice|measures taken before the cherry juice intervention
62854029|NCT01528202|EXPERIMENTAL|cherry juice|trial where cherry juice is taken following the 'baseline cherry juice' arm
62854030|NCT03667898|EXPERIMENTAL|Active needle tip tracking|A needle tip tracking system is used when performing an ultrasound guided lumbar plexus block.
62854031|NCT03667898|OTHER|Inactive needle tip tracking|No needle tip tracking system is used when performing an ultrasound guided lumbar plexus block.
62854032|NCT03557840|EXPERIMENTAL|Temocillin treatment|Patients treated with temocillin and sampled as per the protocol
62854033|NCT06467136|EXPERIMENTAL|Condition 1|Condition 1 will have three phases: (A) no treatment; (B) speech therapy alone; (C) speech therapy plus MI-TEE (the home practice program).
62854034|NCT06467136|EXPERIMENTAL|Condition 2|Condition 2 will include two phases: (A) no treatment; (C) speech therapy plus MI-TEE (the home practice program).
62854035|NCT04084119|EXPERIMENTAL|hypopressive abdominal exercise|Participants will perform an hypopressive abdominal exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
62451409|NCT03698526|ACTIVE_COMPARATOR|Palliative care I|Palliative care
62451410|NCT03698526|ACTIVE_COMPARATOR|Control II|Patients with mamma carcinoma and (neo-) adjuvant radiotherapy
62451411|NCT03698526|ACTIVE_COMPARATOR|Control III|Patients before colonoscopy
62628916|NCT04984122|OTHER|Control|GA group intravenous 2-3 μ/kg fentanyl followed by 2 mg/kg propofol. were administered for anesthesia induction. After a laryngeal mask insertion anesthesia was maintained by inhalation of sevoflurane in an oxygen (60%) and nitrous oxide (40%) mixture to maintain a minimal alveolar concentration (MAC) of 0.8%-1.3%.
62451412|NCT00970281|EXPERIMENTAL|10 mg Olanzapine|
62628917|NCT04984122|OTHER|Study|In the LA group, after positioning of the patient, 50 mg of lidocaine spray (5 pumps, 10 mg in each pump) were applied to the ectocervix, then 2 mL bupivacaine hydrochloride was injected submucosally using a 27-gauge needle tip at the 3, 6, 9, and 12 o'clock locations in the ectocervix.
62854036|NCT04084119|ACTIVE_COMPARATOR|general strengthening exercise|Participants will perform a general strengthening exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
62628918|NCT05006599|EXPERIMENTAL|Humulin® R U-100|Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of Humulin® R U-100 (40 IU) four times daily for 3 weeks.
62628919|NCT05006599|PLACEBO_COMPARATOR|Placebo|Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of placebo (insulin diluent) four times daily for 3 weeks.
62628920|NCT02914535|EXPERIMENTAL|Filgotinib 200 mg (blinded dosing)|Filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 336 weeks
62628921|NCT02914535|EXPERIMENTAL|Filgotinib 100 mg (blinded dosing)|Filgotinib 100 mg + placebo to match filgotinib 200 mg for up to 336 weeks
62628922|NCT02914535|PLACEBO_COMPARATOR|Placebo (blinded dosing)|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 336 weeks
62628923|NCT02914535|EXPERIMENTAL|Filgotinib 200 mg (open-label)|Filgotinib 200 mg for up to 336 weeks
62628924|NCT02914535|EXPERIMENTAL|Filgotinib 100 mg (open-label)|Filgotinib 100 mg for up to 336 weeks
62628925|NCT02366299|ACTIVE_COMPARATOR|dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
62628926|NCT02366299|ACTIVE_COMPARATOR|propofol|Treatment of delirium by propofol i.v. infusion
62854037|NCT03209128||Irradiation prophyllactique cérébrale|
62854038|NCT05311644||Included|All participants that cesed VIT between 2005 and 2019, and did not withdraw his consent to participate to the study.
62854039|NCT04473742|EXPERIMENTAL|Patients exposed to silica|
62854040|NCT04473742|ACTIVE_COMPARATOR|Patients exposed to asbestos fibres|
62854041|NCT05834387|EXPERIMENTAL|Control group|
62451413|NCT00970281|PLACEBO_COMPARATOR|Placebo|
62451414|NCT01473966|NO_INTERVENTION|standard of care|patients receive standard care
62451415|NCT01473966|EXPERIMENTAL|Coffee orally|patients will receive standard of care plus coffee orally
62451416|NCT01473966|EXPERIMENTAL|coffee rectally|patients receive standard of care plus coffee rectally
62628927|NCT06458907|EXPERIMENTAL|TricValve® Device (Device) + Optimal medical therapy (OMT)|TricValve® Device (Device) + OMT
62628928|NCT06458907|ACTIVE_COMPARATOR|Optimal medical therapy (OMT) Alone|OMT can prevent heart attacks and heart failure with medications like blood thinners, cholesterol drugs, and blood pressure meds.
62628929|NCT06458907|EXPERIMENTAL|TricValve Single Arm Registry|Patients who fulfil any of the screening criteria to participate in a parallel singe-arm registry.
62628930|NCT03638141|EXPERIMENTAL|Durvalumab in combination with Tremelimumab (Cohort A dose)|"Starting at week 2, after initial DEB-TACE treatment, patients will receive Durvalumab in combination with tremelimumab, as specified per protocol (Cohort A dose).~Treatment will continue for up to 12 months, while receiving DEB-TACE. Repeat DEB-TACE will be provided Q8W if there is residual tumor that can be targeted."
62628931|NCT03638141|EXPERIMENTAL|Durvalumab in combination with Tremelimumab (Cohort B dose)|Starting at week 2, after initial DEB-TACE treatment, patients will receive Durvalumab in combination with tremelimumab as specified per protocol (Cohort B dose). Treatment will continue for up to 12 months, while receiving DEB-TACE. Repeat DEB-TACE will be provided Q8W if there is residual tumor that can be targeted.
62854042|NCT05834387|EXPERIMENTAL|Experimental group|
62451417|NCT00805298|ACTIVE_COMPARATOR|methylprednisolone|
62451418|NCT00805298|PLACEBO_COMPARATOR|placebo|
62451419|NCT00805298|ACTIVE_COMPARATOR|lidocaine|
62451420|NCT00805298|ACTIVE_COMPARATOR|bupivacaine|
62451421|NCT02779309||Development Cohort|437,000 home care recipients who received services from January 1, 2007 to December 31, 2012.
62451422|NCT02779309||Validation Cohort|122,000 home care recipients who received services from January 1, 2013 to December 31, 2013.
62451423|NCT01786447||Traumatic Brain Injury|Patients who present to the health care facility with mild or moderate traumatic brain injury (Glasgow Coma Scale 9-15) within 4 hours of injury
62451424|NCT01786447||Orthopedic Control|Patients who present to the health care facility with isolated extracranial orthopedic injury within 4 hours of injury
62628932|NCT05254340|EXPERIMENTAL|Healthy volunteers|Adults ages 18-75 years with no prior history of gastrointestinal diseases or symptoms.
62628933|NCT00096538|EXPERIMENTAL|valganciclovir|Patients receive oral valganciclovir twice daily for 3 weeks and then once daily for 21 weeks in the absence of disease progression or unacceptable toxicity. All patients are followed for 1 month after completion of therapy. Patients with responding disease are followed monthly for up to 1 year.
62628934|NCT03603119|ACTIVE_COMPARATOR|Group A|Dexamethasone-ondansetron
62628935|NCT03603119|EXPERIMENTAL|Group B|Midazolam
62628936|NCT02063594|PLACEBO_COMPARATOR|Saline Placebo|2 of 8 subjects in each dose cohort will receive normal saline as a single intravenous infusion
62628937|NCT02063594|EXPERIMENTAL|NCTX|6 of 8 subjects in each dose cohort will receive NCTX (PEGylated Liposomal Iodixanol Injection) as a single intravenous infusion
62628938|NCT01403571|EXPERIMENTAL|Salba supplement|30g/1000kal
62628939|NCT01403571|PLACEBO_COMPARATOR|Oat-bran based Control Supplement|36g/1000kcal
62628940|NCT04213092||ERCP+LC|Patients in this group underwent 2-stage ERCP+LC in a single setting. And, it was compared with our control group
62628941|NCT04213092||OC+CBD|This group with 2-stage OC+CBD exploration in a single setting approach was taken as a control group.
62628942|NCT02052297|OTHER|Part A|In Part A, up to 6 healthy subjects will be enrolled in order to determine the human radiodosimetry following administration of the PET radioligand.
62628943|NCT02052297|OTHER|Part B|In Part B, up to 8 healthy subjects will be recruited to provide sufficient PET data to quantify the uptake and distribution of GSK2634673F in healthy subjects.
62628944|NCT02052297|OTHER|Part C|In Part C, up to 20 IPF subjects will be recruited to provide sufficient PET data to quantify the uptake and distribution of GSK2634673F in IPF subjects and, if appropriate, potentially quantify the test/re-test variability.
62628945|NCT01634503|EXPERIMENTAL|1mg of GX-188E by electroporation|
62628946|NCT01634503|EXPERIMENTAL|2mg of GX-188E by electroporation|
62628947|NCT01634503|EXPERIMENTAL|4mg of GX-188E by electroporation|
62628948|NCT02335255|EXPERIMENTAL|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% (Taro Pharmaceuticals Inc.)
62451425|NCT06249399|EXPERIMENTAL|Aerobic Exercise Group|A behavioral treatment program will be applied to the patients. In addition, patients will be given submaximal aerobic exercise.
62628949|NCT02335255|ACTIVE_COMPARATOR|Naftin® Gel 2%|Naftin® (Naftifine Hydrochloride) Gel 2% (Merz Pharmaceuticals, LLC)
62628950|NCT02335255|PLACEBO_COMPARATOR|Placebo Topical Gel|Placebo Topical Gel (Taro Pharmaceuticals Inc.)
62628951|NCT00684164|EXPERIMENTAL|1|Subjects in the treatment group will receive standard medical treatment plus Conivaptan administered as a 20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
62628952|NCT00684164|PLACEBO_COMPARATOR|2|Subjects in the placebo control group will receive an equivalent volume loading dose of D5 followed by an infusion of D5 in the same manner as the experimental group.
62451426|NCT06249399|ACTIVE_COMPARATOR|Control group|A behavioral treatment program will be applied to the patients.
62451427|NCT00889590|EXPERIMENTAL|Zoledronic acid|Adjuvant zoledronic acid
62451428|NCT00889590|NO_INTERVENTION|Control|Standard care
62628953|NCT06371690||Medication errors during the application of high-risk drugs|Medication Errors During the Application of High-risk Drugs Before and After Using Web-Based Double-Eye Control Program
62628954|NCT06159543|EXPERIMENTAL|Mango added to habitual diet|Participants will be asked to consume 1.5 cups of mango per day for 12 weeks as part of their habitual diet.
62628955|NCT06159543|NO_INTERVENTION|Habitual diet without mango|Participants will be asked to refrain consuming mangos for 12 weeks while continuing their habitual diet.
62628956|NCT02454010|EXPERIMENTAL|Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101
62628957|NCT02454010|EXPERIMENTAL|2X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 2X the lowest dose
62628958|NCT02454010|EXPERIMENTAL|3X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 3X the lowest dose
62628959|NCT02454010|EXPERIMENTAL|4X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 4X the lowest dose
62628960|NCT02454010|EXPERIMENTAL|5X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 5X the lowest dose
62628961|NCT02454010|EXPERIMENTAL|Expansion Phase (Cohort 6), Ovarian|In the expansion phase, subjects in this cohort will be diagnosed with epithelial ovarian, peritoneal or fallopian tube carcinoma and will receive a dose of 25 mCi/m2 FF-21101(90Y)
62451429|NCT03122002||Patients With Ischemic Stroke|The patients with all types of ischemic stroke including TIA, small vessle diseases, MCAO, and ect. These patients will be recorded their emergency treatment, medical history, details about their drug therapy, results of their routine blood test and image scan, and whether they receive intravascular therapy in time or not.
62063501|NCT03715712|EXPERIMENTAL|Standard|Standardized blood pressure management with a target of mean blood pressure greater than 65mmHg and systolic blood pressure lower than 160mmHg
62063502|NCT03715712|ACTIVE_COMPARATOR|Individualized|Individualized blood pressure management of 20% within the preoperative ward blood pressure
62063503|NCT03579264|NO_INTERVENTION|Standard Arm|No use of My Viva Plan.
62063504|NCT03579264|EXPERIMENTAL|Intervention Arm|Use of My Viva Plan.
62063505|NCT02571322|EXPERIMENTAL|Whole Body Vibration training|Use of the HyperVibe Whole Body Vibration training device for 12 weeks 3 times per week crossover to aerobic exercise
62063506|NCT02571322|PLACEBO_COMPARATOR|Aerobic Exercise|Aerobic exercise training for 12 weeks 3 times per week crossover to use of the HyperVibe Whole Body Vibration training device
62063507|NCT06625541|EXPERIMENTAL|AJ302-IM|
62063508|NCT06625541|PLACEBO_COMPARATOR|Placebo|
62063509|NCT02337517|EXPERIMENTAL|Supportive care (vismodegib)|Patients receive vismodegib PO daily, every other day, every three days, or twice weekly for 6-12 months in the absence of disease progression or unacceptable toxicity.
62063510|NCT03392207||Health Care Professionals|Health care professionals receiving the seasonal influenza vaccine (2018) produced by Butantan Institute.
62451430|NCT03122002||Healthy Control|The patients admitted to hospital for symptoms like dizzness and headache, which later proved to be not related to cerebral vascular diseases, would be treated as control. Their medical history and the results of their routine blood test and image scan will be recorded.
62451431|NCT00570271|EXPERIMENTAL|1|
62451432|NCT00570271|EXPERIMENTAL|2|
62451433|NCT00570271|EXPERIMENTAL|3|
62451434|NCT00570271|EXPERIMENTAL|4|
62063511|NCT03392207||Elderly|Elderly (age 60 or more) receiving the seasonal influenza vaccine (2018) produced by Butantan Institute.
62063512|NCT01202487|EXPERIMENTAL|Pre-treatment with LET|Pre-treatment with Lidocaine Epinephrine Tetracaine solution at least 45 minutes prior to laceration repair with tissue adhesive
62063513|NCT01202487|PLACEBO_COMPARATOR|Pre-treatment with Placebo|Pre-treatment with Placebo solution at least 45 minutes prior to laceration repair with tissue adhesive
62063514|NCT00888901|EXPERIMENTAL|1|Patients on eltrombopag
62063515|NCT00888901|ACTIVE_COMPARATOR|2|Patients on corticosteroids
62063516|NCT00888901|NO_INTERVENTION|3|Untreated patients
62063517|NCT02696122|EXPERIMENTAL|Local Group|Local infiltration under general anesthesia via laryngeal mask
62063518|NCT02696122|EXPERIMENTAL|Spinal Group|Spinal anesthesia with 15 mg of 0.5% hyperbaric bupivacaine
62063519|NCT03996044|EXPERIMENTAL|Group 1|Thirteen patients who will receive treatment with teeth brushing, dental floss and tongue scraper.
62063520|NCT03996044|EXPERIMENTAL|Group 2|Thirteen patients who will receive treatment with teeth brushing, dental floss and antimicrobial photodynamic therapy applied to the back and middle third of the tongue.
62063521|NCT03996044|EXPERIMENTAL|Group 3|Thirteen patients who will receive treatment with teeth brushing, dental floss and probiotics.
62451435|NCT00570271|NO_INTERVENTION|5|
62628962|NCT02454010|EXPERIMENTAL|Expansion Phase (Cohort 7), Adv Tumors|In the expansion phase, subjects in this cohort will be diagnosed with triple negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), biliary cancer (cholangiocarcinoma or gall bladder carcinoma), pancreatic carcinoma, colorectal cancer and will receive a dose of 25 mCi/m2 FF-21101(90Y)
62628963|NCT03719495||Cohort 1|Pre-menopausal women as healthy controls will be recruited on Duke University Campus and Duke University Hospital.
62628964|NCT03719495||Cohort 2|Postmenopausal women as healthy controls will be recruited on Duke University Campus and Duke University Hospital.
62268628|NCT02766738|EXPERIMENTAL|GrACE + gait program|GrACE program as mentioned above plus focus on gait specific training will be one-hour training sessions for 24 weeks. Gait exercises will be a combination of exercises: heel and toe raises, stepping in different directions, single leg stand¬ing, step-ups, and task-specific balance work (e.g. reaching outward from the base of support while standing, sitting, and standing and turning). Gait exercises will be upgraded by: 1) reducing hand support and/or 2) narrowing the base of support, and/or 3) introducing a cognitive challenge (e.g. counting backwards while performing exercise) or perform¬ing exercise with the eyes closed.
62451436|NCT00570271|NO_INTERVENTION|6|
62451437|NCT02122081|EXPERIMENTAL|Treatment (OSMI, allogeneic transplant)|"CONDITIONING REGIMEN: Patients undergo organ-sparing marrow irradiation BID on days -6 to -4 and receive cyclophosphamide IV over 1-2 hours every 24 hours on days -3 to -2. Patients with an unrelated donor also receive anti-thymocyte globulin every 24 hours on days -4 to -2.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 and continuing for at least 6 months and methotrexate IV on days 1, 3, 6, and 11.~TRANSPLANT: Patients undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0."
62451438|NCT02072759|EXPERIMENTAL|Carnitine supplement|Carnitine supplement
62451439|NCT02072759|PLACEBO_COMPARATOR|Placebo|Placebo supplement
62451440|NCT02072759|NO_INTERVENTION|Healthy control|Healthy control group
62451441|NCT06261970|EXPERIMENTAL|Connect Community Level Enhancements|"Community Support Groups (CSGs)\*: Connect enhances Lishe Endelevu's to require at least four FTMs to be recruited into each CSG established. Connect enhances the CSG toolkit to include FTM focused content, including information on birth spacing and PPFP.~Home visits\*: the CHWs who facilitate the community support groups also conduct home visits to FTMs. CHWs are provided a job aid to counsel FTMs and their families on PPFP. Counseling addresses myths about FP, norms around fertility and spacing, and includes prompts to engage family and male partners when present. Counseling also integrates timely nutrition information from the support groups with PPFP information. CHWs can provide non-clinical FP methods (pills, condoms) and provide referrals for services at public health facilities"
62451442|NCT06261970|NO_INTERVENTION|Control|No additional Connect intervention. Lishe Endelevu Community Support Groups Operate per usual.
62451443|NCT03830528|EXPERIMENTAL|Part A-1|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
62451444|NCT03830528|EXPERIMENTAL|Part A-2|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
62451445|NCT03830528|EXPERIMENTAL|Part A-3|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
62451446|NCT03830528|EXPERIMENTAL|Part B|There will be one cohort of Japanese healthy men dosed with multiple doses of KW-6356 or placebo and one potential additional cohort (KW-6356 dose as determined in Part A or placebo)
62451447|NCT03830528|EXPERIMENTAL|Part C-1|There will be 2 cohort of Japanese and Caucasian healthy men dosed with multiple doses of KW-6356 (KW-6356 dose as determined in the previous studies)
62451448|NCT03830528|EXPERIMENTAL|Part C-2|There will be 2 cohort of Japanese and Caucasian healthy men dosed with multiple doses of KW-6356 (KW-6356 dose as determined in the previous studies)
62451449|NCT03830528|PLACEBO_COMPARATOR|Placebo|
62628965|NCT03719495||Cohort 3|Pre-menopausal women initiating tamoxifen after standard of care local-regional therapy after surgery +/- radiation.
62628966|NCT03719495||Cohort 4|Pre-menopausal women initiating ovarian suppression plus aromatase inhibition after surgery +/- radiation.
62628967|NCT03719495||Cohort 5|Postmenopausal women initiating endocrine therapy with aromatase inhibition after standard of care surgery +/- radiation.
62268629|NCT02263183|ACTIVE_COMPARATOR|red palm olein(labelled A)|red palm olein (labelled A)
62268630|NCT02263183|PLACEBO_COMPARATOR|palm olein(labelled B)(control)|palm olein(labelled B)(control)
62268631|NCT01329211||Gastroparesis Patients|
62268632|NCT01329211||Gastroparesis Patients' Caregivers|
62628968|NCT03064048|ACTIVE_COMPARATOR|Neo-ASA|During this arm the participant will receive a lozenge with nitric oxide as a dietary supplement twice daily.
62268633|NCT05332158|EXPERIMENTAL|Intervention arm|A single arm to administer questionnaires for patients barriers to adherence.
62268634|NCT00820651|PLACEBO_COMPARATOR|Placebo|
62268635|NCT00820651|EXPERIMENTAL|Diamel|
62268636|NCT04313127|EXPERIMENTAL|Low-dose Group|Subjects received one dose of 5E10 vp Ad5-nCoV at 18 to 60 years old
62451450|NCT03169959|EXPERIMENTAL|Cohort 1: Sequence 1 (ABC)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
62451451|NCT03169959|EXPERIMENTAL|Cohort 1: Sequence 2 (ACB)|"Subjects were randomized to treatment sequence 1 ACB:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
62451452|NCT03169959|EXPERIMENTAL|Cohort 1: Sequence 3 (BAC)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
62451453|NCT03169959|EXPERIMENTAL|Cohort 1: Sequence 4 (BCA)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
62451454|NCT03169959|EXPERIMENTAL|Cohort 1: Sequence 5 (CAB)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
62451455|NCT03169959|EXPERIMENTAL|Cohort 1: Sequence 6 (CBA)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5mg saxagliptin / 5mg dapagliflozin / 1000 mg metformin XR without food."
62628969|NCT03064048|PLACEBO_COMPARATOR|Placebo|During this arm the participant will receive a lozenge which will not contain nitric oxide as a dietary supplement twice daily.
62268637|NCT04313127|EXPERIMENTAL|Middle-dose Group|Subjects received one dose of 1E11 vp Ad5-nCoV at 18 to 60 years old
62268638|NCT04313127|EXPERIMENTAL|High-dose Group|Subjects received one dose of 1.5E11vp Ad5-nCoV at 18 to 60 years old
62268639|NCT02549209|EXPERIMENTAL|Investigational Treatment|"Subjects with no prior therapy:~* Pembrolizumab administered at 200 mg~* Paclitaxel administered at 175mg/m2~* Carboplatin administered at an AUC of 6~Subjects with prior external beam radiation therapy (XRT) and/or platinum-based chemotherapy must initiate paclitaxel and carboplatin at a reduced dose:~* Pembrolizumab administered at 200 mg~* Paclitaxel administered at 135mg/m2~* Carboplatin administered at an AUC of 5"
62268640|NCT01023971||Group A|Patients investigated with mfERG and MP-1
62268641|NCT01023971||Group B|Patients investigated by Laser Doppler Flowmetry
62063522|NCT03996044|EXPERIMENTAL|Group 4|Thirteen patients who will receive treatment with teeth brushing, dental floss, antimicrobial photodynamic therapy applied to the back and middle third of the tongue and probiotics..
62063523|NCT01164228|EXPERIMENTAL|Arm A (Sunitinib + Gemcitabine)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 22, and 29 and oral sunitinib malate once daily on days 1-14 and 22-35. Each cycle was 42 days (6 weeks) and was to be repeated for a total of one year.
62063524|NCT01164228|EXPERIMENTAL|Arm B (Sunitinib)|Patients receive oral sunitinib malate once daily on days 1-14 and 22-35. Each cycle was 42 days (6 weeks) and was to be repeated for a total of one year.
62268642|NCT03670953|ACTIVE_COMPARATOR|IR CD-LD - Dose Adjustment|Participants started on the same dose as the pre-study dosing regimen of IR CD-LD and then received dose adjusted IR CD-LD tablets daily orally, for a period of 3 weeks. If the participant was taking controlled release carbidopa-levodopa (CR CD-LD), the CR CD-LD was discontinued and substituted with a 1:1 milligram-equivalent dose of IR CD-LD.
62451456|NCT03169959|EXPERIMENTAL|Cohort 2: Sequence 1 (DEF)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
62628970|NCT05532384|EXPERIMENTAL|Early resumption of oral intake|Drink 30-50ML of normal temperature water after meeting the PACU transfer out standard. If the patient swallows successfully and does not cough, after returning to the ward, the medical staff of the ward will guide him or her to resume drinking and eating early: patient will resume drinking water within one hour after returning to the ward, a small amount of water for many times until the amount of drinking water reaches 300ml. If the patient does not have discomfort symptoms, he or she will resume eating according to normal drinking and eating habits.
62628971|NCT05532384|OTHER|Late resumption of oral intake|Drink 30-50ML of normal temperature water after 6h after the operation. A small amount of water can be used several times, and the amount of water can reach 300ml. If the patient does not have any discomfort symptoms, it can guide the patient to recover diet according to his/her normal eating habits.
62063525|NCT02204579|EXPERIMENTAL|NPSP795|intravenous
62063526|NCT04960553|EXPERIMENTAL|Device : Post Market Clinical Follow-up Investigation applying Exufiber® and Mepilex® Border Flex|Post Market Clinical Follow-up investigation : Up to 102 subjects with exuding chronic wounds deemed adequate by the Principle Investigator and Clinical Team for assigned treatment
62063527|NCT01218529|EXPERIMENTAL|Whole Brain Radiation Therapy (WBRT) + lapatinib|Whole Brain Radiation Therapy (30Gy in 10 fractions) and lapatinib 1250mg once daily for 2 weeks followed by lapatinib treatment 1500mg once daily for 4 weeks.
62063528|NCT03332641|EXPERIMENTAL|Citron peel Extract|Citron peel extract for 12 weeks
62063529|NCT03332641|PLACEBO_COMPARATOR|Placebo|Placebo for 12 weeks
62063530|NCT02225379|EXPERIMENTAL|Hypo-Sense (non invasive sensor)|Parallel measurements of capillary blood glucose using reference method and data generated by the non- invasive study device (Hypo Sense) during approximately 4 hours, in which a hypoglycemic event will be induced.
62063531|NCT02665702|EXPERIMENTAL|Endostar Combined With NVB and DDP|Endostar15mg/m2 NVB25 mg/m2 DDP75 mg/m2
62063532|NCT05496972||Telemedicine Visits|Participants are asked to fill out a survey about their experience.
62063533|NCT00310895|EXPERIMENTAL|Dose escalation|Treatment Schedule 3 will consist of dosing on Days 1, 4, 8, and 11 of each 21 day cycle (3 weeks equals 1 cycle) and Treatment Schedule 4 will consist of dosing on Day 1 of each 28 day cycle (4 weeks equals 1 cycle)
62088090|NCT02015195|EXPERIMENTAL|Sodium Bicarbonate Slurry (50%)|Sodium Bicarbonate Slurry (50%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
62088091|NCT02015195|EXPERIMENTAL|Papain Slurry (70%)|Papain Slurry (70%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
62628972|NCT00503347|EXPERIMENTAL|1|0.3 mg/kg
62628973|NCT00503347|EXPERIMENTAL|2|1 mg/kg
62628974|NCT00503347|EXPERIMENTAL|3|3 mg/kg
62628975|NCT00503347|EXPERIMENTAL|4|6 mg/kg
62063534|NCT05563792|EXPERIMENTAL|OPTIONS Intervention Coaching|Intervention participants will participate in a series of four coaching sessions focused on helping patients clarify their values and treatment goals, aligning these values and goals and their lifestyle with nonpharmacological treatment options, working on overcoming barriers to use and adherence of nonpharmacological treatment options (using motivational interviewing), and preparing patients to discuss these options with their primary care providers. A decision aid will be used during these coaching sessions.
62628976|NCT00616876|EXPERIMENTAL|1|Study group will receive 1% lactulose in all their feeds (human milk or preterm formula)
62628977|NCT00616876|PLACEBO_COMPARATOR|2|Control group will receive 1% dextrose placebo in all their feeds (human milk or preterm formula).
62628978|NCT02855801|EXPERIMENTAL|constant exercise without cryotherapy|constant exercise without cryotherapy
62628979|NCT02855801|EXPERIMENTAL|constant exercise with cryotherapy|constant exercise with cryotherapy
62628980|NCT02855801|EXPERIMENTAL|intermittent exercise, no cryotherapy|intermittent exercise without cryotherapy
62628981|NCT02855801|EXPERIMENTAL|intermittent exercise and cryotherapy|intermittent exercise with cryotherapy
62628982|NCT05705921|ACTIVE_COMPARATOR|Standard treatment|moderately hypofractionated radiotherapy 62 Gy in 20 fractions of 3.1 Gy
62628983|NCT05705921|EXPERIMENTAL|Experimental treatment|SBRT 5x7Gy with an iso-toxic integrated focal boost up to 50 Gy (Hypo-FLAME) in 15 days (2 fractions per week)
62628984|NCT01979523|EXPERIMENTAL|Arm A (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who experience objective disease progression may crossover to Arm B. (no patients will be enrolled to Arm B or Crossover therapy as of 11/6/2015)
62628985|NCT01979523|EXPERIMENTAL|Arm B (trametinib, Akt inhibitor GSK2141795)|Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62628986|NCT06319729|EXPERIMENTAL|Treatment group|During the 4-week intervention, participants are required to consume 4.7g of CDD-2105 granule (a Chinese herbal medicine formula containing four granular herbs) twice per day.
62063535|NCT05563792|NO_INTERVENTION|OPTIONS Waitlist Control|Participants randomized into waitlist control group will receive the intervention decision aid after completing the last survey at 9 months. Participants will also be offered the opportunity to have a brief 20-minute session with a member of the OPTIONS study staff to help walk them through this decision aid.
62628987|NCT06319729|PLACEBO_COMPARATOR|Placebo group|During the 4-week intervention, participants are required to consume 4.7g of placebo twice per day.
62628988|NCT02493452|ACTIVE_COMPARATOR|3.0 mg plecanatide|Plecanatide 3.0 mg dosed daily for 12 weeks
62628989|NCT02493452|ACTIVE_COMPARATOR|6.0 mg plecanatide|Plecanatide 6.0 mg dosed daily for 12 weeks
62628990|NCT02493452|ACTIVE_COMPARATOR|Matching placebo|Placebo dosed daily for 12 weeks
62628991|NCT02696486|EXPERIMENTAL|Exercise Training|
62628992|NCT00292253|EXPERIMENTAL|Rebif® with Rebiject™Mini|
62628993|NCT00292253|ACTIVE_COMPARATOR|Rebif® without Rebiject™Mini|
62628994|NCT04461548|EXPERIMENTAL|Experimental group 1: Best Possible Self|Participants are asked to think and write about their best possible future self and to imagine this positive future subsequently.
62063536|NCT04179981|OTHER|Conservative care (control arm)|Eligible OVS patients will receive conservative care/usual care with education about sleep apnea and sleep hygiene via handouts and video instructions. This is the control arm.
62268643|NCT03670953|EXPERIMENTAL|IPX203 - Dose Conversion|Participants received extended release (ER) CD-LD (IPX203) capsules orally, every 6 - 12 hours for a period of 4 weeks at a dose based on their most frequent stable dose of IR CD-LD in dose adjustment period. Participant with most frequent stable dose of 25-100 milligrams (mg) IR CD-LD received 70 - 280 mg IPX203 thrice daily (TID); \>25-100 - 37.5-150 mg IR CD-LD received 105-420 mg IPX203 TID; \>37.5-150 - 50-200 mg IR CD-LD received 140-560 mg IPX203 TID; \>50 - 200 mg IR CD-LD received 175-700 mg IPX203 TID. Participants who received a daily total dose of less than 125-500 mg IR CD-LD in dose adjustment received IPX203 every 12 hours. After initial dose conversion from IR CD-LD to IPX203 as per above mentioned dose conversion schedule, the dose of IPX203 could be further adjusted during the 4 week dose conversion period.
62451457|NCT03169959|EXPERIMENTAL|Cohort 2: Sequence 2 (DFE)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
62628995|NCT04461548|EXPERIMENTAL|Experimental group 2: Best Possible Self + next steps|Participants are asked to think and write about their best possible future self and what the next steps could be to reach that best possible future. Subsequently, participants are asked to imagine this positive future.
62063537|NCT04179981|ACTIVE_COMPARATOR|PAP therapy arm|PAP Therapy will be provided to eligible patients with OVS. This is the active therapy arm.
62063538|NCT05647551|EXPERIMENTAL|JUVÉDERM fillers and BOTOX/VISTABEL|At Visit 1, JUVÉDERM filler injections (Juvéderm VOLBELLA with lidocaine, Juvéderm VOLIFT with lidocaine, and/or Juvéderm VOLUMA with lidocaine) will be administered. At Visit 4, JUVÉDERM VOLBELLA with lidocaine, may be administered in the infraorbital hollow (IOH)/tear trough (TT) area. At Visit 6, participants will receive BOTOX/VISTABEL. Touch-ups may be performed as required based on investigator's assessment.
62063539|NCT02057003||DAA-based therapy against HCV|HIV/HCV-coinfected patients who start therapy against HCV including one or more DAA
62063540|NCT06624683|EXPERIMENTAL|intervation|Participants in the intervention group will immerse their feet up to 10 cm into water inside a collapsible plastic container, maintaining a temperature of 40°C for 30 minutes every night, one hour before usual bedtime (between 21:00 and 22:00), starting from the first day of the menstrual cycle (MC) and continuing for 28 days.
62628996|NCT04461548|EXPERIMENTAL|Experimental group 3: Self-compassion|Participants are asked to think and write about a self-compassion exercise and to imagine this content subsequently.
62063541|NCT06624683|NO_INTERVENTION|usual care|clinical usual care
62628997|NCT04461548|ACTIVE_COMPARATOR|Active control group|Participants are asked to think and write about a neutral task that is comparable to the experimental groups.
62628998|NCT04983290|EXPERIMENTAL|intervention|The participating subjects belonging to the experimental group, will receive at home a set of foods with modified textures that allow the patient to feed for the observation period of 4 months, will also be followed by the dietary service of the center and by personnel identified within the protocol in order to verify compliance, liability and information regarding the evaluation scales involved in the project.
62628999|NCT04983290|NO_INTERVENTION|control|The control group will continue with its own feeding for the entire observation period of the experimental group.
62629000|NCT05929989||active disease|
62629001|NCT05929989||control|
62629002|NCT05323877|EXPERIMENTAL|Investigational Device Arm (PerQseal+)|Large hole percutaneous arterial closure device - PerQseal+
62268644|NCT03670953|EXPERIMENTAL|IPX203 - Double-Blind Maintenance|Participants received IPX203 capsules orally, every 6 - 12 hours for 13 weeks at a stable dose established at the end of dose conversion period along with placebo matched to IR CD-LD.
62629003|NCT04506723|EXPERIMENTAL|Patients with urolithiasis|Patients with confirmed urolithiasis who is assigned to PCNL.
62063542|NCT01313546|ACTIVE_COMPARATOR|quadriceps|quadriceps muscular contraction
62063543|NCT01313546|ACTIVE_COMPARATOR|sartorius|stimulation of sartorius muscle through femoral nerve
62063544|NCT03485014|EXPERIMENTAL|Experimental: EXPAREL 4 mg/kg|Single dose of EXPAREL 4 mg/kg
62063545|NCT02070900|NO_INTERVENTION|Standard of Care|Sites implementing Option B+ for pregnant and lactating women according to the standard of care prescribed by the Ministry of health and Child Care national guidelines
62063546|NCT02070900|EXPERIMENTAL|POC Plus|Sites implementing Option B+ according to the standard of care prescribed by the Ministry of Health and Child Care, as well as programmatic mentoring and POC CD4 machines
62063547|NCT03848364|EXPERIMENTAL|Hip Hop Stroke 2.0 intervention group|"Students in 4th and 5th grade will receive the intervention, Hip Hop Stroke 2.0, disseminated and implemented by local Stroke Centers - uses a framework of Child-Mediated Health Communication to make children stroke literate and then empower these stroke literate students with the tools required to successfully communicate actionable stroke knowledge (recognition of stroke symptoms and the urgency of calling 911) to their parents and grandparents at home."
62063548|NCT06333834|ACTIVE_COMPARATOR|Traditional scorpion antivenom regimen|Active/placebo comparator
62629004|NCT04506723|ACTIVE_COMPARATOR|Patients without urolithiasis|Patients with renal tumor without urolithiasis in history who is assigned to partial or radical nephrectomy due to renal tumor.
62629005|NCT01514110|EXPERIMENTAL|RAD001|
62629006|NCT03295240|EXPERIMENTAL|BR-I in combination with VEN|The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered in combination with VEN (Venetoclax).
62629007|NCT04186624|EXPERIMENTAL|Supervised Exercise Program|The exercise program that applied at the hospital includes rotator cuff and scapular muscle strengthening, stretching and active-assistive range of motion exercises and proprioceptive neuromuscular facilitation exercises.
62629008|NCT04186624|ACTIVE_COMPARATOR|Home-based Exercise Program|The home-based exercise program given with a brochure that includes rotator cuff and scapular muscle strengthening, stretching and active-assistive range of motion exercises and proprioceptive neuromuscular facilitation exercises.
62063549|NCT06333834|EXPERIMENTAL|Serial dose of scorpion antivenom regimen|
62063550|NCT00735865|ACTIVE_COMPARATOR|1|
62063551|NCT00735865|ACTIVE_COMPARATOR|2|
62063552|NCT00735865|ACTIVE_COMPARATOR|3|
62063553|NCT00735865|ACTIVE_COMPARATOR|4|
62063554|NCT03131635|EXPERIMENTAL|Developmental Reciprocity Treatment Program (DRT-P)|Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.
62063555|NCT03131635|NO_INTERVENTION|Delayed Treatment Group (DTG)|
62063556|NCT02166437||Alendronate|Patients treated with alendronate
62063557|NCT02166437||Minodronate|Patients treated with minodronate
62063558|NCT02166437||Denosmab|Patients treated with denosmab
62063559|NCT03296709|ACTIVE_COMPARATOR|PPC m|
62063560|NCT03296709|EXPERIMENTAL|PPC z|
62629009|NCT05365815|EXPERIMENTAL|MGMC Intervention Group|"In the MGMC (intervention) group, pregnant women will participate in group prenatal care and have \~2-hour visits with the same two co-facilitators, a Black midwife and a Black care coordinator, along with 8-12 other Black women at a similar stage of pregnancy, for all prenatal and one postnatal care visits.~The care coordinator will proactively engage with women throughout pregnancy and up to 12 months postpartum. The care coordinator helps women make appointments, sends reminders, and follows-up to ensure care was received, understood, and was appropriate. In the 3rd trimester, women in MGMC will be introduced to a community-based postpartum doula. The doula will make home visits once before birth and within the first 2 weeks postpartum; they will have approximately 50 contact hours available for 12 months postpartum for primarily in-person support, but they will be available by phone and text."
62629010|NCT05365815|NO_INTERVENTION|Usual Care|In the usual care (comparator) group, pregnant women attend individually scheduled visits with a midwife or obstetrician for a physical assessment and counseling. Although this can vary by provider, continuity of care is rare and racial concordance is not a consideration. Referrals for medical or social services are given to the patient to complete in both prenatal and postnatal care.
62629011|NCT05150457|EXPERIMENTAL|Dose Escalation Phase, Dose Level 1|"Starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles.~Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles"
62629012|NCT05150457|EXPERIMENTAL|Dose Escalation Phase, Dose Level 2|3 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
62629013|NCT05150457|EXPERIMENTAL|Dose Escalation Phase, Dose Level 3|10 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
62629014|NCT05150457|EXPERIMENTAL|Dose Escalation Phase, Dose Level 4|30 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
62629015|NCT05150457|EXPERIMENTAL|Dose Escalation Phase, Dose Level 5|100 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
62063561|NCT03928002|EXPERIMENTAL|4DFlow magnetic resonance imagery|2D MRI, essential for diagnosis and monitoring of PAH, with an additional 8 minutes for 4D flow
62063562|NCT03928002|ACTIVE_COMPARATOR|Cardiac catheterization|cardiac catheterization procedure using the Fick method; gold standard
62268645|NCT03670953|ACTIVE_COMPARATOR|IR CD-LD - Double -Blind Maintenance|Participants received IR CD-LD tablets daily orally, for 13 weeks at a stable dose established at the end of dose adjustment period along with placebo matched to IPX203.
62268646|NCT03808727|EXPERIMENTAL|Massed Cognitive Processing Therapy (MCPT)|Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. MCPT will be delivered in an intensive outpatient setting (12 sessions in 5 days) composed of both group and individual sessions.
62268647|NCT03808727|ACTIVE_COMPARATOR|Standard Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Standard CPT will be delivered in 12 one-hour sessions over 6 weeks and involves only individual sessions.
62451458|NCT03169959|EXPERIMENTAL|Cohort 2: Sequence 3 (EDF)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
62629016|NCT05150457|EXPERIMENTAL|Dose Escalation Phase, Dose Level 6|200 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
62629017|NCT01083992|OTHER|Galvus + vitamin D|Galvus in combination with vitamin D
62629018|NCT01083992|OTHER|Galvus|vitagliptin as monotherapy
62629019|NCT04026230|EXPERIMENTAL|Atorvastatin|Capsules of atorvastatin. Daily dose of 80 mg for max. 10 years or until development of castration resistance.
62629020|NCT04026230|PLACEBO_COMPARATOR|Placebo|Identical capsules as in the atorvastatin arm, but including no active ingredient. Used daily for max. 10 years or until development of castration resistance
62629021|NCT00791427||AMD Patients|
62063563|NCT05975502||Pregnant women with positive syphilis serology|Pregnant women with blood TPHA/TPPA ≥ 80
62063564|NCT05975502||Children born with positive syphilis serology|Children born from mothers with syphilis during pregnancy and / or with blood TPHA/TPPA ≥ 80 at birth
62088092|NCT02015195|EXPERIMENTAL|Household ammonia (10%)|Ammonia (10%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
62268648|NCT00135668|ACTIVE_COMPARATOR|0.3 mcg/kg/min|Infusion of Sodium Nitroprusside began only after a 5-minute period of stable anesthesia or sedation (no changes in dosages). The infusion rate during the blinded study drug period was increased in a step-wise fashion to the full dose rate as follows: 5 ± 1 minutes at 1/3 of the full rate; 5 ± 1 minutes at 2/3 of the full rate; and 20 minutes at the full dose rate (ie, 30 minutes total). The full infusion rate was 0.6 mL/kg/hr; 2/3 of the full rate was 0.4 mL/kg/hr; and 1/3 of the full rate was 0.2 mL/kg/hr. After titration to the full dose of blinded study drug, blinded infusion dosage adjustments were not permitted during the blinded study drug administration period. The blinded infusion dosage continued for the 30 minutes unless clinical events demanded a change for safety reasons.
62629022|NCT02074293|EXPERIMENTAL|Splenius|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62629023|NCT02074293|EXPERIMENTAL|Scalene|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62629024|NCT02074293|EXPERIMENTAL|Sterno-cleido-mastoid|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62629025|NCT02074293|EXPERIMENTAL|Levator Scapulae|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62629026|NCT02074293|EXPERIMENTAL|Semispinalis|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62063565|NCT05512429||Stage-IV non small cell lung cancer (NSCLC)|Eighty-three patients with stage-IV NSCLC who received at least one cycle of platinum based chemotherapy (PBCT) or tyrosine kinase inhibitor (TKI) therapy and who underwent pre treatment fluorodeoxyglucose (FDG)-positron emission tomography (PET) /computed tomography (FDG PET/CT) from June 2012 to February 2019
62063566|NCT03595501||Hematology Analyzer - OLO|The investigational device is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening capillary or venous whole blood samples.
62629027|NCT02074293|EXPERIMENTAL|Trapezius|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62629028|NCT02074293|EXPERIMENTAL|Longissimus|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
62629029|NCT02074293|EXPERIMENTAL|Change from Baseline in Pain Frequency|Change from Baseline in Pain Frequency as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
62629030|NCT02074293|EXPERIMENTAL|Change from Baseline in Pain Intensity|Change from Baseline in Pain Intensity as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The severity on scales of 0(no pain) to 4(constant or extremely severe intensity).
62629031|NCT02074293|EXPERIMENTAL|Change from Baseline in CDSS|Change from Baseline in CDSS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The CDSS or Cervical Dystonia Severity Scale quantifies the severity of abnormal head positioning and was newly devised for this study. CDSS allots 1 point for each 5 degrees (or part thereof) of head deviation in each of the three planes of head movement (range of scores up to theoretical maximum of 54).
62088093|NCT02015195|EXPERIMENTAL|Lidocaine (4%)|Lidocaine (4%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
62268649|NCT00135668|ACTIVE_COMPARATOR|1 mcg/kg/min|Infusion of Sodium Nitroprusside began only after a 5-minute period of stable anesthesia or sedation (no changes in dosages). The infusion rate during the blinded study drug period was increased in a step-wise fashion to the full dose rate as follows: 5 ± 1 minutes at 1/3 of the full rate; 5 ± 1 minutes at 2/3 of the full rate; and 20 minutes at the full dose rate (ie, 30 minutes total). The full infusion rate was 0.6 mL/kg/hr; 2/3 of the full rate was 0.4 mL/kg/hr; and 1/3 of the full rate was 0.2 mL/kg/hr. After titration to the full dose of blinded study drug, blinded infusion dosage adjustments were not permitted during the blinded study drug administration period. The blinded infusion dosage continued for the 30 minutes unless clinical events demanded a change for safety reasons.
62268650|NCT00135668|ACTIVE_COMPARATOR|2 mcg/kg/min|Infusion of Sodium Nitroprusside began only after a 5-minute period of stable anesthesia or sedation (no changes in dosages). The infusion rate during the blinded study drug period was increased in a step-wise fashion to the full dose rate as follows: 5 ± 1 minutes at 1/3 of the full rate; 5 ± 1 minutes at 2/3 of the full rate; and 20 minutes at the full dose rate (ie, 30 minutes total). The full infusion rate was 0.6 mL/kg/hr; 2/3 of the full rate was 0.4 mL/kg/hr; and 1/3 of the full rate was 0.2 mL/kg/hr. After titration to the full dose of blinded study drug, blinded infusion dosage adjustments were not permitted during the blinded study drug administration period. The blinded infusion dosage continued for the 30 minutes unless clinical events demanded a change for safety reasons
62653141|NCT05303714|ACTIVE_COMPARATOR|Arm A (FOLFOX)|Patients randomized in the Arm A will undergo to 6 courses of systemic chemotherapy according to FOLFOX regimen, after these six courses of chemotherapy, radiologic restaging (CT scan) as well as a second staging laparoscopy will be performed. If a Progression Disease will be detected, the patient will end the trial and will undergo to II line chemotherapy regimen. If a stable disease or a partial response will be documented, after a multidisciplinary discussion, patient will undergo to either further 6 courses of chemotherapy or to cytoreductive surgery plus HIPEC.
62063567|NCT03595501||Hematology Analyzer - Predicate|The predicate device is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening patient populations found in clinical and reference laboratories.
62268651|NCT00135668|ACTIVE_COMPARATOR|3 mcg/kg/min|Infusion of Sodium Nitroprusside began only after a 5-minute period of stable anesthesia or sedation (no changes in dosages). The infusion rate during the blinded study drug period was increased in a step-wise fashion to the full dose rate as follows: 5 ± 1 minutes at 1/3 of the full rate; 5 ± 1 minutes at 2/3 of the full rate; and 20 minutes at the full dose rate (ie, 30 minutes total). The full infusion rate was 0.6 mL/kg/hr; 2/3 of the full rate was 0.4 mL/kg/hr; and 1/3 of the full rate was 0.2 mL/kg/hr. After titration to the full dose of blinded study drug, blinded infusion dosage adjustments were not permitted during the blinded study drug administration period. The blinded infusion dosage continued for the 30 minutes unless clinical events demanded a change for safety reasons
62268652|NCT00661115|EXPERIMENTAL|Arm 1|
62268653|NCT00661115|PLACEBO_COMPARATOR|Arm 2|
62451459|NCT03169959|EXPERIMENTAL|Cohort 2: Sequence 4 (EFD)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
62451460|NCT03169959|EXPERIMENTAL|Cohort 2: Sequence 5 (FDE)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
62451461|NCT03169959|EXPERIMENTAL|COhort 2: Sequence 6 (FED)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
62451462|NCT04529070|EXPERIMENTAL|Intervention + Standard of care|Nightmare Rescripting and Rehearsal: a 10 minute intervention for Primary Care plus Sleep Hygiene handout.
62451463|NCT04529070|ACTIVE_COMPARATOR|Standard of care|Standard of Care Sleep Hygiene handout alone.
62451464|NCT01269970||locally advanced esophageal carcinoma (cT2-3N0/+)|
62451465|NCT05329805|EXPERIMENTAL|interventional group|Job crafting intervention
62451466|NCT05329805|NO_INTERVENTION|control group|Regarding the control group, the participants will receive a simple educational booklet with one-session
62451467|NCT02928913||Sedentary|Predominantly engage in sedentary behaviours
62451468|NCT02928913||Non-sedentary|Predominantly engage in non-sedentary behaviours
62451469|NCT05140096|EXPERIMENTAL|Treatment AB|Participants will receive a single oral dose 100 mg acalabrutinib capsule on Day 1 of Period 1 (Treatment A) and later will receive single oral loading dose of 400 mg fluconazole tablets on Day 1, one hour prior to a single oral dose of 100 mg acalabrutinib in Period 2 (Treatment B).
62451470|NCT05140096|EXPERIMENTAL|Treatment AC|Participants will receive a single oral dose 100 mg acalabrutinib capsule on Day 1 of Period 1 (Treatment A), and later will receive oral dose of 200 mg iscavuconazole capsules three times daily (approximately every 8 hours apart) on Day 1, followed by 200 mg iscavuconazole capsule once daily from Day 2 to Day 5 with a single oral dose of 100 mg acalabrutinib capsule coadministered on Day 5 in Period 2 (Treatment C).
62451471|NCT03042676||ATLG group|ATLG treatment for GVHD prophylaxis.
62629032|NCT02074293|EXPERIMENTAL|Percent of Patients with Improved PGAS|Percent of Patients with Improved PGAS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The Physician Global Assessment Scale or PGAS is a 9 category scale scoring the physician's evaluation of the patients' status compared to baseline, ranging from -4 to +4 (very marked worsening to complete improvement), with 0 indicating no change from baseline and +1 slight improvement.
62629033|NCT02074293|EXPERIMENTAL|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62451472|NCT03042676||no ATLG group|No ATLG treatment.
62629034|NCT02074293|EXPERIMENTAL|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62629035|NCT02074293|EXPERIMENTAL|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62451473|NCT04471207|EXPERIMENTAL|Intelligent Biometrics - Prolonged Exposure (Therapist Guided).|"In the therapist-guided group, Study Therapists will virtually accompany patients during IVEs and use actionable biometric and subjective data during in vivo exposures (IVEs) (galvanic skin response \[GSR\], heart rate \[HR\], and subjective units of distress \[SUDS\]) to modify the assignments in real-time.~All participants receive at least 10 sessions of prolonged exposure therapy for posttraumatic stress disorder."
62629036|NCT02074293|EXPERIMENTAL|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62629037|NCT02074293|EXPERIMENTAL|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62629038|NCT02074293|EXPERIMENTAL|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62629039|NCT02074293|EXPERIMENTAL|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62629040|NCT02074293|EXPERIMENTAL|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62629041|NCT02074293|EXPERIMENTAL|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62268654|NCT02925156||Ghana|Participants in the Ghana cohort are located at or near the the village of Nkwantakese which is approximately 20 kilometers outside of Kwame Nkrumah University of Science and Technology in Kumasi.
62451474|NCT04471207|ACTIVE_COMPARATOR|Intelligent Biometrics - Prolonged Exposure (Record Only).|"In the record-only group, passive data collection will be utilized to collect and store biometric and behavioral data for future offline analyses to investigate predictors of outcome.~All participants receive at least 10 sessions of prolonged exposure therapy for posttraumatic stress disorder."
62268655|NCT02925156||South Africa|Participants in the South Africa cohort are located at or near Khayelitsha, the 3rd largest township in South Africa, which is an adjacent town to the city of Cape Town. The population of Khayelitsha is about 500,000 people.
62629042|NCT02074293|EXPERIMENTAL|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62268656|NCT02925156||Seychelles|Participants in the Seychelles cohort are located at or near The Republic of Seychelles, which is an archipelago with 81,000 inhabitants located approximately 1,500 km east of Kenya in the Indian Ocean and approximately 2,000 km north of the island of Mauritius.
62629043|NCT02074293|EXPERIMENTAL|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
62629044|NCT01065558|EXPERIMENTAL|Ecopipam 12.5 - 200 mg/day|Patients were administered ecopipam on an escalated dosing schedule over 11 days starting at 12.5 mg/day and increasing to the maximal tolerated dose or to 200 mg/day.
62629045|NCT05651386|OTHER|Six food elimination diet|The six food elimination diet will be performed in all subjects.
62629046|NCT04230343|EXPERIMENTAL|Self-benefit arm|
62629047|NCT04230343|ACTIVE_COMPARATOR|Social-benefit arm|
62629048|NCT00910845|EXPERIMENTAL|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
62629049|NCT00910845|OTHER|placebo/onabotulinumtoxinA|Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).
62629050|NCT05618288|ACTIVE_COMPARATOR|Standard of Care|Standard of care breastfeeding counseling. The ongoing antenatal, delivery and postnatal breastfeeding and lactation counseling that is provided by the Naivasha sub-County Referral Hospital.
62063568|NCT04305808||Recurrent Urinary tract infection|Menopausal women, with two or more documented, culture-positive infections in the last six months or ≥3 infections in the last year
62629051|NCT05618288|EXPERIMENTAL|mobile Health (mHealth)|Simple messaging service counseling intervention with healthcare providers. This arm will involve two-way messaging with healthcare providers Unstructured Supplementary Service Data application that provides session-based interaction with breastfeeding and lactation support content.
62629052|NCT00433433|ACTIVE_COMPARATOR|Favorable - Standard - any PET outcome|ABVDx3 cycles + Involved node RT (IN-RT) 30 Gy (+boost of 6Gy to residual lesions); FDG-PET after two cycles of ABVD for comparison with the experimental arm will be performed but no treatment adaptation will take place.
62268657|NCT02925156||Jamaica|Participants in the Jamaica cohort are located at or near Spanish Town, Jamaica which is an urban area 25 km from the center of Kingston. The population of Spanish Town in 1991 was estimated at 92,000 people.
62063569|NCT04305808||Healthy controls|Menopausal women, without prior history of UTIs or other urologic abnormalities.
62629053|NCT00433433|EXPERIMENTAL|Favorable - Experimental - PET negative|"ABVDx2 cycles; then FDG-PET evaluation:~PET negative: ABVDx2 without further RT (total of 4 cycles!)"
62629054|NCT00433433|EXPERIMENTAL|Favorable - Experimental - PET positive|"ABVDx2 cycles; then FDG-PET evaluation:~PET positive: presumed poor-risk: switch to escalated BEACOPPx2 + INRT30Gy (+boost 6Gy to residual lesions)."
62629055|NCT00433433|ACTIVE_COMPARATOR|Unfavorable - Standard - Any PET outcome|ABVDx4 cycles + IN-RT 30Gy (+boost 6Gy to residual lesions). FDG-PET after two cycles of ABVD for comparison with the experimental arm will be performed but no treatment adaptation will take place.
62629056|NCT00433433|EXPERIMENTAL|Unfavorable - Experimental - PET negative|"ABVDx2 cycles; then FDG-PET evaluation:~PET negative: ABVDx 4 cycles, without RT (total of 6 cycles)"
62629057|NCT00433433|EXPERIMENTAL|Unfavorable - Experimental - PET positive|"ABVDx2 cycles; then FDG-PET evaluation:~PET positive: presumed poor-risk: switch to escalated BEACOPPx2 + INRT 30Gy (+boost 6Gy to residual lesions)."
62629058|NCT02680171|EXPERIMENTAL|Prism adaptation treatment|Prism Goggles with ten-degree rightward deviating prism lenses will be used to implement prism adaptation treatment, in addition to standard care.
62629059|NCT02680171|SHAM_COMPARATOR|Sham prism adaptation treatment|Non-Shifting Goggles (sham) will be worn by patients in the control condition. These goggles do not shift the patients visual field.
62629060|NCT01655095|EXPERIMENTAL|PEG and Prucalopride|
62088094|NCT02015195|EXPERIMENTAL|Isopropyl Alcohol (70%)|Isopropyl Alcohol (70%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
62629061|NCT01655095|EXPERIMENTAL|Picosalax and Prucalopride|
62629062|NCT02953496|EXPERIMENTAL|vonapanitase|
62629063|NCT02603211||Women with Breast Tumors|Women with breast tumors.
62629064|NCT02895191|EXPERIMENTAL|Cohort 1|Cohort 1- Ulinastatin 4.8 million units per day
62629065|NCT02895191|EXPERIMENTAL|Cohort 2|Cohort 2- Ulinastatin 2.4 million units per day
62088095|NCT02015195|EXPERIMENTAL|Hot Water (40 degrees Celsius)|Hot Tap Water (40 degrees Celsius) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
62088096|NCT01473511|EXPERIMENTAL|Strongest Families Program + Usual care|50% randomized to receive Strongest Families intervention immediately as well as the usual care services available via the referring agency for the 22 month study period.
62629066|NCT02895191|EXPERIMENTAL|Cohort 3|Cohort 3- Ulinastatin 1.2 million units per day
62629067|NCT02895191|PLACEBO_COMPARATOR|control group|Placebo
62629068|NCT02589847|EXPERIMENTAL|RBX2660 Open-label|RBX2660 (microbiota suspension)
62629069|NCT02589847|OTHER|Historical control antibiotics|Retrospective Historical Control with standard of care
62629070|NCT06480019|OTHER|Intervention|Participants that receive psychotherapy
62629071|NCT06480019|NO_INTERVENTION|Waiting list|Participants that are waiting for intervention
62629072|NCT04283435|PLACEBO_COMPARATOR|estradiol valerate + placebo|preparation of the endometrium with Estradiol valerate 2mg/day (every 8 hours)(white tablets of cycloprogenova) .from the first day of the cycle till 12th day and we add placebo from the first day of the cycle till the day of start progesterone (we stop 3 days before embryo transfer).
62629073|NCT04283435|EXPERIMENTAL|estradiol valerate + Sildenafil citrate|We add Sildenfil citrate 50 mg daily from the first day of the period till the day of starting the progesterone. and stop 3 days before the embryo transfer.
62629074|NCT04642417|EXPERIMENTAL|Experimental|intervention give experience dietary fiber literacy
62629075|NCT04642417|NO_INTERVENTION|No Intervention|give standard education
62629076|NCT02006199|EXPERIMENTAL|relaxation with psychoeducation|after 8 weeks of relaxation with psychoeducation. subject take part in 8 weeks of the mindfulness meditation program
62629077|NCT02006199|EXPERIMENTAL|meditation|8 weeks of mindfulness meditation
62629078|NCT02635321||Patients with LGMD 2T|Four patients over 18 years old with genetically verified LGMD 2T.
62629079|NCT06274944||Infants|Infants admitted to the University of Minnesota Masonic Children's Hospital neonatal intensive care unit.
62629080|NCT03571776|ACTIVE_COMPARATOR|Surgery|Laparoscopic ovarian cystectomy
62629081|NCT03571776|ACTIVE_COMPARATOR|Sclerotherapy|US-aspiration and alcohol sclerosis
62629082|NCT03591224|ACTIVE_COMPARATOR|Intervention|Pharmacist optimizing antidepressant therapy using the patient's personalized pharmacogenomic report to make recommendations.
62629083|NCT03591224|PLACEBO_COMPARATOR|Control|Pharmacist optimizing antidepressant therapy based on standard of care
62629084|NCT03063619|PLACEBO_COMPARATOR|Arm A (placebo)|Patients apply placebo gel topically to each breast QD for up to 52 weeks.
62629085|NCT03063619|EXPERIMENTAL|Arm B (afimoxifene)|Patients apply afimoxifene gel topically to each breast QD for up to 52 weeks.
62629086|NCT02273362|EXPERIMENTAL|Prevention (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD for 7 days (depending on the date of surgery, treatment range may be 5-14 days).
62629087|NCT06171529|PLACEBO_COMPARATOR|Placebo - Saline|For patients who randomize to Saline: An unblinded IHTSC Fellow, nurse/PA, or OR staff will use a 3 or 5 cc syringe to draw up the saline. A 23 gauge needle will be used to inject the saline after arthroplasty and prior to closure of the capsule. 2cc of saline will be injected into each patient.
62629088|NCT06171529|EXPERIMENTAL|Treatment - CTM|For patients who randomize to CTM: An unblinded IHTSC Fellow, nurse/PA, or OR staff will use a 3 or 5 cc syringe to draw up the CTM Flow material. A 23, or 20 gauge needle will be used to inject the CTM after arthroplasty and prior to closure of the capsule. To draw up the injection: allow the particulate to settle to the bottom and withdrawal fluid into the 3 or 5 cc syringe. It is ok if some particulate is drawn up into the syringe. 2cc of CTM will be injected into each patient.
62629089|NCT00685867|EXPERIMENTAL|1|Rapid detection
61904694|NCT01458093||Colonoscopy patients|Consecutive colonoscopy outpatients referred to one of 29 endoscopy units in Italy
62629090|NCT00685867|OTHER|2|Enhanced infection control
62629091|NCT05090943||Quality of life questionnaires|
62629092|NCT04817267|EXPERIMENTAL|reSET-O + Treatment-As-Usual (TAU)|Participants randomly assigned to this group will receive the TAU plus the reSET-O app.
62629093|NCT04817267|NO_INTERVENTION|Treatment-As-Usual (TAU)|Participants randomly assigned to this group will receive the TAU only (no use of the reSET-O app).
62629094|NCT02627573|EXPERIMENTAL|Thymoglobulin|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -5 Busulfan 1 mg/kg po qid x 2 days Days -4 through -3 Thymoglobulin 2,5 mg/kg po qd x 2 days Days -1 through +30: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days -1 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration
27622731|NCT05710081|ACTIVE_COMPARATOR|Intervention|Bacterial Lysate - Broncho-Vaxom (OM-85) 3.5mg granules once daily for 10 days per month for 24 months
27622732|NCT05710081|PLACEBO_COMPARATOR|Placebo|Placebo - 3.5mg granules once daily for 10 days per month for 24 months
62629095|NCT02627573|EXPERIMENTAL|PTCy|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
62629096|NCT04736069|ACTIVE_COMPARATOR|Inpatient physical therapy program|The group received 21 sessions of physical therapy program including electrotherapy, superficial- deep heat applications and basic knee exercise program at inpatient clinic.
62629097|NCT04736069|ACTIVE_COMPARATOR|Outpatient physical therapy program|The group received the same physical therapy program including electrotherapy, superficial-deep heat applications and basic knee exercise program at outpatient clinic.
62629098|NCT02646319|EXPERIMENTAL|Treatment (nanoparticle albumin-bound rapamycin)|Patients receive nanoparticle albumin-bound rapamycin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
62629099|NCT02149563|ACTIVE_COMPARATOR|Treatment|One hundred participants will receive home treatment with oxygen-enriched air (40% O2) through a nasal tube during the night (7 hours) for one month.
62629100|NCT02149563|PLACEBO_COMPARATOR|Placebo|100 participants will receive regular air treatment (21% O2) through a nasal tube (identical to the procedure providing 40% O2) for one month
62629101|NCT04359498||LAR for rectal cancer|Retrospective chart review for surgical complications related to the LAR surgery, the stoma (diverting loop ileostomy) creation and the stoma reversal procedure after LAR for rectal cancer.
62629102|NCT06517095|ACTIVE_COMPARATOR|polished|The polished group did the improved capsular polishing.
62629103|NCT06517095|PLACEBO_COMPARATOR|control|The control group did not undergo improved polishing, the conventional I/A polishing the capsule instead.
62629104|NCT01151969|EXPERIMENTAL|New multicomponent intervention|
62629105|NCT01151969|NO_INTERVENTION|Usual Care|
62629106|NCT05681364||COPD and bronchiectasis patients with some metabolic profiling|The patients with stable COPD and bronchiectasis who meet the screening criteria and with some metabolic profiling according to the previous studies.
62629107|NCT05681364||COPD and bronchiectasis patients without the metabolic profiling|The patients with stable COPD and bronchiectasis who meet the screening criteria and without the metabolic profiling according to the previous studies.
62629108|NCT04201236|EXPERIMENTAL|Oropharyngeal exercises|Oropharyngeal exercises include soft palate, tongue and facial muscle exercises as well as stomatognathic function exercises. Training sessions were held once a day, 5 days a week for 12 weeks under the supervision of a mirror.
62629109|NCT04201236|EXPERIMENTAL|Inspiratory muscle training|The inspiratory muscle training group was administered for 12 weeks starting from 30% of maximal oral pressure, 7 days a week, 15 minutes twice a day. Patients came to the control once a week, mouth pressures were measured and training pressure was adjusted in 30% of the new value.
62629110|NCT04201236|NO_INTERVENTION|Control|This group was only monitorized without any rehabilitation intervention.
62629111|NCT05437445||Cases Data|subjects having abnormal plasma amino acid profiles with either one or more amino acid concentrations beyond (high or low) the locally defined age-specific reference ranges
62629112|NCT00384202|EXPERIMENTAL|1|
62629113|NCT05082337|EXPERIMENTAL|Guidewire|The SAVVY guidewire will be used in all TAVR procedures of patients included in the study
62629114|NCT05214209|EXPERIMENTAL|Intervention arm|Participants receiving the phone app together with a fitness tracker. All participants will receive the educational curriculum over a period of 4 weeks through the app. The mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve goals. The participant can use the app to log their food intake, weight, steps, exercise, in addition to participating in the peer support via the chat function. Participants will also receive regular care and follow up in community pharmacies for support.
62451475|NCT02921477|EXPERIMENTAL|Bosutinib Treatment Arm|Subjects will be administered the initial dose of bosutinib, with dosage progressively increased over the course of the study. The initial dose of bosutinib is 100 mg tablet, once per day. The dose will be increased as tolerated up to 300 mg per day. The dose will be increased by 100 mg each month if the lower dose is tolerated without significant side effects. That is to say, the subject will take 100 mg/day every day for the first month, 200 mg/day every day for the second month, and 300 mg/day every day for the third month and for the remainder of the study, provided that adverse reactions do not prohibit continuation at this dosage. Stopping and dose reduction rules for reported adverse reactions have been taken from the package insert of bosutinib. The duration of treatment is 1 year.
61904695|NCT05454449||symptomatic group|Individuals with patellar tendon pain last for 3 months Individuals age between 18-40 years old Victorian Institute of Sport Assessment (VISA) Questionnaire score ≦80
61904696|NCT05454449||asymptomatic group|Individuals without any lower extremity pain in past 3 months Individuals age between 18-40 years old Victorian Institute of Sport Assessment (VISA) Questionnaire score \>80
62268658|NCT02925156||United States|Participants in the United States cohort are located at or near Maywood, IL, which is an African-American working class community adjacent to the western border of Chicago, IL. The population of Maywood in 2010 was estimated at 24,090 people.
62451476|NCT02842697|EXPERIMENTAL|Single arm study|"Patients will receive CTA, Doppler ultrasound, HVPG measurement, and vHVPG per protocol.~Intervention: Procedure: HVPG measurement"
62268659|NCT00620412|ACTIVE_COMPARATOR|treatment|
62629115|NCT05214209|ACTIVE_COMPARATOR|Usual care arm|"The control group will be a usual care condition in which participants are free to seek any assistance for their medical care during the study period. Participants will be given physical tracking sheets to record their food intake, weight, steps and exercises."
62629116|NCT03825081|EXPERIMENTAL|Intervention|"Interventions will be the drugs:~* pilocarpine - 0.5%~* brimonidine - 0.2%~One drop of each of the study drugs will be placed in the non-dominant eye and patient will be evaluated for adverse events. At hour 1 and 3 vision will be measured for distance at 20 ft and reading at 14 inches; pupil size will be measured and patient will be evaluated for adverse events. At hour 6 vision will be measured for distance at 20 ft and reading at 14 inches; pupil size will be measured; patient will be evaluated for adverse events; and quality of life/satisfaction survey (NEI RQL-42) will be given to patient."
62629117|NCT02875795|EXPERIMENTAL|speech intelligibility|speech intelligibility is registered by an automatic speech processing tool
62629118|NCT01922258|PLACEBO_COMPARATOR|Placebo|Matching Placebo Once-Daily
62268660|NCT00620412|PLACEBO_COMPARATOR|placebo|
62451477|NCT03653195|OTHER|Pre-injury|Each participant will act as their own control. Pre-injury samples were collected.
62451478|NCT03653195|ACTIVE_COMPARATOR|Post-injury|Post-injury samples were collected at the same time and within 72 hours of injury.
62451479|NCT05629949|EXPERIMENTAL|QL1701+Docetaxel|Participants received intravenous infusion of QL1701 with docetaxel. The initial load dose of QL1701 was 8mg/kg, followed by 6mg/kg every three weeks; The recommended dose of docetaxel is 75mg/m2, given once every 3 weeks for a treatment cycle of 3 weeks.
62451480|NCT05629949|ACTIVE_COMPARATOR|Herceptin®+Docetaxel|Participants received intravenous infusion of Herceptin® with docetaxel. The initial load dose of Herceptin® was 8mg/kg, followed by 6mg/kg every three weeks; The recommended dose of docetaxel is 75mg/m2, given once every 3 weeks for a treatment cycle of 3 weeks.
62268661|NCT03142802|EXPERIMENTAL|Patients with testicular germ cell cancer|Patients with testicular germ cell cancer who have either been newly diagnosed, or have stage I cancer already on surveillance program will undergo conventional and low dose CT. Based on the imaging, they may undergo a surveillance program using low-dose CT.
62268662|NCT02192827|EXPERIMENTAL|Single Dose Dexamethasone|0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once
62268663|NCT02192827|EXPERIMENTAL|Two Dose Dexamethasone|0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once in the Emergency Department (ED), followed by another dose of dexamethasone at home, which will be prescribed from the ED. The second dose will be the same dosage, but will be prescribed and may be pill or liquid form.
62268664|NCT06495034|ACTIVE_COMPARATOR|control group|standard care: health education and routine functional exercise
62268665|NCT06495034|EXPERIMENTAL|experimental group|"1. standard care: health education and routine functional exercise;~2. airwave compression therapy"
62268666|NCT04952064|EXPERIMENTAL|200 mg group|Monosialoganglioside GM1, 200 mg/day, for 12-14 days
62268667|NCT04952064|EXPERIMENTAL|400 mg group|Monosialoganglioside GM1, 400 mg/day, for 12-14 days
62268668|NCT03921021|EXPERIMENTAL|Telomelysin (OBP-301)|All patients will receive Telomelysin (OBP-301) at 2x10\^12 viral particles (VP)/ tumor injection administered every two weeks x 4 injections as well as standard dose pembrolizumab 200 mg IV every 3 weeks. The tumor will be injected with OBP-301 four times (d1, d15, d29, d43). The preference is to inject the primary tumor endoscopically. Metastatic lesions may be injected on a case-by-case basis after discussion with the PI (Shah).
62629119|NCT01922258|EXPERIMENTAL|Brexpiprazole (flexible dose range 0.5 to 2 mg)|Titrate up from 0.25 mg/day brexpiprazole to 1 mg/day brexpiprazole. After achieving 1 mg/day target dose may be increased or decreased based on efficacy and tolerability. Allowable flexible doses will be 0.5 mg/day, 1 mg/day, or 2 mg/day.
62268669|NCT05450198|EXPERIMENTAL|Dose Escalation Panel A|Participants are randomized to low dose MK-6194 or placebo, administered every 2 weeks (q2w).
62268670|NCT05450198|EXPERIMENTAL|Dose Escalation Panel B|Participants are randomized to medium dose MK-6194 or placebo administered q2w.
62451481|NCT04716738||Irritable Bowel Syndrome with Sexual Dysfunction|We use Rome IV criteria, scale bristol and the female sexual fuction to establish IBS and sexual dysfunction diagnosis, and SF-36 to determinated quality of life.
62268671|NCT05450198|EXPERIMENTAL|Dose Escalation Panel C|Participants are randomized to high dose MK-6194 or placebo administered q2w.
62268672|NCT05450198|EXPERIMENTAL|Expansion Panel D|Participants are randomized to medium dose MK-6194 or placebo administered q2w.
62268673|NCT05450198|EXPERIMENTAL|Expansion Panel E|Participants are randomized to a dose less than or equal to high dose MK-6194 or placebo administered q2w.
62268674|NCT05450198|EXPERIMENTAL|Expansion Dose F|Participants are randomized to a dose less than or equal to high dose MK-6194 or placebo q2w.
62268675|NCT00858858|EXPERIMENTAL|Arm 1|All patients are treated with DCA and UDCA perfusion of the esophagus, one year apart, followed by 8 weeks of treatment with oral ursodeoxycholic acid 10 mg/kg qd. Then a final DCA perfusion of the esophagus.
62268676|NCT01411254|EXPERIMENTAL|1|
62268677|NCT01411254|EXPERIMENTAL|2|
62268678|NCT01411254|SHAM_COMPARATOR|3|
62451482|NCT04716738||Irritable Bowel Syndrome without Sexual Dysfunction|We use Rome IV criteria, scale bristol and the female sexual fuction to establish IBS and sexual dysfunction diagnosis, and SF-36 to determinated quality of life.
62451483|NCT03714295||Use of interdental brushes|The group use interdental brushes one time each day and wash teeth with a classical brush two times a day
62268679|NCT04042103|EXPERIMENTAL|Tapinarof (DMVT-505) cream, 1%|Tapinarof (DMVT-505) cream, 1% applied topically once daily
62268680|NCT05372029|EXPERIMENTAL|Approach Avoidance Training|"AAT condition, participants use a joystick to respond to the color of the border surrounding the stimulus images presented (i.e., pull for green, push for blue). The stimuli used are alcohol-related images and neutral beverage images. To experimentally manipulate automatic action tendencies, a contingency is set between alcohol stimuli and avoidance behaviors"
62629120|NCT04530929|ACTIVE_COMPARATOR|Group PROBIOTIC|The intervention factor was the SANPROBI BARRIER multi-strain probiotic (commonly available in pharmacies). Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
62629121|NCT04530929|PLACEBO_COMPARATOR|Group PLACEBO|Placebo created on the model of a probiotic capsule, specially for the needs of research, by Sanprobi Sp. z o.o.. Competitors used placebo for three months at a dose of 2x2 capsules daily.
62629122|NCT01218971|EXPERIMENTAL|Medisorb naltrexone 380 mg|Intramuscular (IM) injection administered once every 4 weeks for up to 48 weeks.
62629123|NCT01218971|EXPERIMENTAL|Medisorb naltrexone 190 mg|IM injection administered once every 4 weeks for up to 48 weeks.
62063570|NCT05619874|EXPERIMENTAL|HIFCT-S|For sessions 7 to 14, a concentrated circuit divided into four blocks of three exercises will be carried out, with a duration of 40 seconds per exercise with no rest between them. A rest of 120 seconds will be given at the end of each block, and a rest of the same time at the end of the first set. Two sets will be executed, which will result in a total time of 30 minutes including rest. For sessions 15 to 30, four blocks of two exercises will be performed, with a duration of 60 seconds per exercise, with no rest between them. The rest between blocks will be 120 seconds. Two sets will be performed, for a total time of 30 minutes including breaks. The exercises will be performed at speeds between 35 and 75 bpm. The intensity will be between 80% - 90% (8-9 RPE).
62268681|NCT05372029|SHAM_COMPARATOR|Sham Training|In the Sham participants use a joystick to respond to the color of the border surrounding stimulus images presented. There is no contingency between instruction type and pictures (i.e., non-training version of the task)
62451484|NCT03714295||No use of interdental brushes|The group wash teeth with a classical brush two times a day
62268682|NCT01049841|EXPERIMENTAL|perifosine + temsirolimus|This is a single arm, phase I study. Eligible patients will receive a loading dose of oral perifosine on the first day, followed by a maintenance dose starting on the second day until progression. Each patient is assigned to a group according to their body surface area (BSA). Temsirolimus will be combined with perifosine at four dose levels to determine the MTD for the combination therapy. Temsirolimus dosing will start on the same day as the perifosine load.
62268683|NCT04601987|ACTIVE_COMPARATOR|Counseling about the Maternal Benefits of Breastfeeding|Participants will review a slide deck while receiving scripted counseling designed to increase understanding of the maternal health benefits of breastfeeding.
62268684|NCT04601987|ACTIVE_COMPARATOR|Counseling about the benefits of Smoke-free Homes|Participants will review a slide deck while receiving scripted counseling designed to increase understanding of the health benefits of smoke free homes.
62268685|NCT06101056|EXPERIMENTAL|Code of Respect (X-CoRe) Multi-Level Sexual Assault (SA) and Harassment (SH) Prevention Program|
62268686|NCT06101056|OTHER|Control Condition|
62268687|NCT05511168|OTHER|Craniosynostosis patients|Craniosynostotic patients aged more than 3months
62451485|NCT06485414||central sensitization|Individuals who scored above 40 on the Central Sensitization Inventory for Koreans (CSI-K) assessment.
62451486|NCT05713591|EXPERIMENTAL|Transition care model|Patients in the experimental arm will receive the TC intervention which encompasses three main pillars that guided a standardized and structured clinical pathway to ensure an optimal transition from childhood care to adult care. Briefly, the first pillar was designed to improve the understanding of the clinical condition through tailored education. Healthcare providers delivered specific information and education strategies. The second pillar aimed to support the development of functional coping strategies by discussing with a counselor and/or a psychologist. The TC encompassed for this pillar both structured face-to-face discussions and counseling moments. The third pillar hoped to improve the engagement of CHD adolescents and their families.
62451487|NCT05713591|NO_INTERVENTION|Usual care|Patients in the control arm will receive a usual care approach without the high focus on standardization given by the experimental arm (e.g. without flyers and booklets or standardized moments of face-to-face counseling). Data collection will be performed using a consistent approach with the one described in the experimental arm: every three months in a year (T0, T1, T2, T3, and T4).
62451488|NCT02771665||Breast cancer women with known recurrences|Breast cancer women with known recurrences (locoregional recurrence and distant metastasis)
62451489|NCT02771665||Breast cancer women without recurrences|Breast cancer women without recurrences
62629124|NCT05205382|EXPERIMENTAL|Electronic cigarette pods (SREC or NJOY) with 5% nicotine concentration|Participants will complete a lab visit where they will use 5% nicotine electronic cigarette pods ad libitum for up to 60 minutes.
62629125|NCT05205382|EXPERIMENTAL|Electronic cigarette pods (NJOY) with 3% nicotine concentration|Participants will complete a lab visit where they will use 3% nicotine electronic cigarette pods ad libitum for up to 60 minutes.
62629126|NCT05205382|EXPERIMENTAL|Electronic cigarette pods (SREC) with 0% nicotine concentration|Participants will complete a lab visit where they will use 0% nicotine electronic cigarette pods ad libitum for up to 60 minutes.
62629127|NCT06038500|EXPERIMENTAL|Multicomponent Intervention in only one group of women at Risk of Sarcopenia|Quasi-experimental Pre-test/Post-test design - pilot
62629128|NCT00596050|ACTIVE_COMPARATOR|ketamine and midazolam|ketamine and midazolam
62629129|NCT00596050|ACTIVE_COMPARATOR|etomidate and fentanyl and lidocaine|etomidate and fentanyl and lidocaine
62629130|NCT01127048|EXPERIMENTAL|Prospan Hustenzäpfchen|
62629131|NCT01127048|PLACEBO_COMPARATOR|Placebo|
62268688|NCT04845828|EXPERIMENTAL|Sentinel lymph node mapping|The group composed of patients who undergo sentinel lymph node mapping
62268689|NCT04845828|ACTIVE_COMPARATOR|Routine lymph node dissection|The group composed of patients who undergo routine pelvic lymph node dissection
62268690|NCT02182687|OTHER|Arm A|Stereotactic Body Radiation Therapy (SBRT)
62268691|NCT02182687|OTHER|Arm B|Trans-Arterial Chemoembolization (TACE) Drug: Doxorubin
62451490|NCT02745951|EXPERIMENTAL|Heliox|Cardioplegia enriched with a 70:30 (Helium:Oxygen) Heliox mixture while the patient is on cardiopulmonary bypass
62451491|NCT02745951|ACTIVE_COMPARATOR|Standard of care|Cardioplegia enriched with a Nitrogen and Oxygen mixture while the patient is on cardiopulmonary bypass
62451492|NCT03720964||presbycusis affected patients|affected by a more severe age related hearing loss than expected according to the norm ISO 7029
62451493|NCT03720964||controls|not affected by age related hearing loss according to the norm ISO 7029
62268692|NCT03961503||Daptomycin (DAP)|DAP : Cohort of patients who received daptomycin as the first line treatment for at least 48 hours for the defined indication
62451494|NCT02380183|EXPERIMENTAL|Intervention|Civco needle guidance device will be used while the nerve block is performed.
62629132|NCT03297164||optimized group|the patients in this group have been given the suggestive treatment from guideline.
62268693|NCT03961503||Vancomycin (VAN)|VAN : Cohort of patients who received vancomycin as the first line treatment for at least 48 hours for the defined indication
62268694|NCT00841685|EXPERIMENTAL|1|Goldlock
62268695|NCT00841685|ACTIVE_COMPARATOR|2|Visicoil smallest size
62451495|NCT02380183|NO_INTERVENTION|Standard of Care|Needle guidance device will not be used while nerve block is performed; nerve block is performed by hand alone.
62451496|NCT05047406|EXPERIMENTAL|Probiotic|2 oral mini-bottles daily of Bacillus clausii probiotic liquid containing 2 billion spores/bottle for 2 weeks before living donor liver transplantation surgery In addition, patients will receive standard of care regarding immunosuppressants and antibiotic prophylaxis
62451497|NCT05047406|NO_INTERVENTION|Control (No Probiotic)|patients will receive standard of care regarding immunosuppressants and antibiotic prophylaxis
62451498|NCT04911959|ACTIVE_COMPARATOR|control group|patients receive transcatheter arterial chemoembolization (TACE) only.
62451499|NCT04911959|EXPERIMENTAL|Intervention group|patients receive transcatheter arterial chemoembolization (TACE) and lenvatinib 8mg per day.
62629133|NCT03297164||un-optimized group|the patients in this group have not been given the suggestive treatment from guideline.
62268696|NCT00841685|ACTIVE_COMPARATOR|3|Visicoil larger size
62268697|NCT00841685|ACTIVE_COMPARATOR|4|Bard goldmarker smallest size
62268698|NCT00841685|ACTIVE_COMPARATOR|5|Bard goldmarker larger size
62268699|NCT01452334|EXPERIMENTAL|Arm 1: BMS-936559|
62063571|NCT05619874|ACTIVE_COMPARATOR|HIFCT-P|"For sessions 7 to 14, a concentrated circuit divided into two blocks of six exercises will be carried out, with a duration of 60 seconds per exercise with no rest between them. A rest of 120 seconds will be given at the end of each block, and a rest of the same time at the end of the first set. Two sets will be executed, which will result in a total time of 30 minutes including rest.~For sessions 15 to 30, five blocks of two exercises will be performed, with a duration of 120 seconds per exercise, with no rest between them. The rest between blocks will be 120 seconds. The total time per block is four minutes, for a total time of 30 minutes including breaks. The exercises will be performed at speeds between 35 and 75 bpm. The intensity will be between 80% - 90% (8-9 RPE)."
62268700|NCT06190171|EXPERIMENTAL|Active respiratory muscle strength training|Enrolled heart transplant patients will undergo active preoperative respiratory strength training using two respiratory strength training devices from enrollment until they receive a heart transplant.
62268701|NCT06190171|SHAM_COMPARATOR|Sham respiratory muscle strength training|Enrolled heart transplant patients will undergo sham preoperative respiratory strength training using two respiratory strength training devices from enrollment until they receive a heart transplant. For individuals completing sham respiratory strength training, the spring will be removed from the devices as has been done in prior sham-controlled trials.
61904697|NCT05339867|NO_INTERVENTION|Mothers following Standard of Care|Participants randomized to this group will receive standard of Care for Postpartum. The standard of care control condition will be what women would typically get at hospital discharge (typically an Electronic Medical Record (EMR) generated document; a non-standardized, generalized brief review of how to care for self and the baby).
62063572|NCT04281433|EXPERIMENTAL|unilateral|
62063573|NCT04281433|EXPERIMENTAL|bilateral|
62268702|NCT03471702|EXPERIMENTAL|Single Arm Study|All subjects enrolled on study will utilize Aqueduct's Smart External Drain (SED) from the time of external drain implementation until end of study upon discharge of SED or switch to standard of care external drain.
62268703|NCT02995109|EXPERIMENTAL|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62268704|NCT04956380|EXPERIMENTAL|Joint Count + Early Inflammatory Arthritis Detection Tool|Rheumatologist reviews both the self-administered tender joint count (out of 68 joints on a homunculus) and self-administered Early Inflammatory Arthritis Detection Tool that were completed by the patient. Rheumatologist then uses the information provided in these tools by the patient to determine whether they should advance the urgency rating of the case.
62268705|NCT04956380|EXPERIMENTAL|Early Inflammatory Arthritis Detection Tool|Rheumatologist reviews both the self-administered Early Inflammatory Arthritis Detection Tool that was completed by the patient. Rheumatologist then uses the information provided in this tool by the patient to determine whether they should advance the urgency rating of the case.
62268706|NCT04956380|EXPERIMENTAL|Joint Count|Rheumatologist reviews both the self-administered Patient Tender Joint Count that was completed by the patient. Rheumatologist then uses the information provided in this tool by the patient to determine whether they should advance the urgency rating of the case.
62063574|NCT01754883|EXPERIMENTAL|Lithium Augmentation|Open-label trial - active treatment
62063575|NCT05613101|ACTIVE_COMPARATOR|Erector Spinae Plane Block|Erector Spina Plane Block was performed to the patients after coplition of total knee arthroplasty operation for postopetaive pain.
62268707|NCT04956380|NO_INTERVENTION|Control|Rheumatologist does not review any of the self-administered tools completed by the patient.
62268708|NCT01946321|OTHER|Post-amputation functional rehab|Patients will continue with their rehabilitation programme, as specified by their clinical team, following amputation. A series of functional outcome measures will be carried out at 3 or 4 time points during the first 3 months following delivery of their artificial limb.
62268709|NCT02820311|EXPERIMENTAL|TD-4208 175 mcg|double-blind
62268710|NCT02820311|EXPERIMENTAL|TD-4208 700 mcg|double-blind
62268711|NCT02820311|PLACEBO_COMPARATOR|Placebo for TD-4208|double-blind
62268712|NCT02820311|ACTIVE_COMPARATOR|Moxifloxacin 400 mg|open-label
62268713|NCT03304015|EXPERIMENTAL|Intervention: Behavioral Change Communications|
62268714|NCT03304015|NO_INTERVENTION|Control: No intervention|
62268715|NCT00639405||1|subjects who are diagnosed with parathyroid adenomas. There will be 6 subjects who have not had surgery and 25 subjects who have had surgery.
62268716|NCT03656679|ACTIVE_COMPARATOR|Pectoralis Blockade(PECs)|Participants undergo pectoralis nerve block (PEC II) will received anesthesia between the pectoralis major and minor in the chest while lying flat.
62268717|NCT03656679|ACTIVE_COMPARATOR|Paravertebral Blockade (PVB)|Participants undergoing paravertebral nerve block (PVB) consisting of receiving anesthesia in the back while sitting upright.
62268718|NCT00000414|EXPERIMENTAL|Arthritis Self-Management Program|small group self-management program
62268719|NCT00000414|EXPERIMENTAL|SMART Program|Self-Managed Arthritis Relief Therapy: mailed self management material
62268720|NCT05712044|NO_INTERVENTION|Basal|Samples will be taken to participants.
62268721|NCT05712044|EXPERIMENTAL|15 days folate suplementation|5mg tablets of folic acid will be given to participants every 8 hours for a period of 15 days, then samples are to be taken in duplicate for each individual.
62268722|NCT05712044|EXPERIMENTAL|30 days folate suplementatio|5mg tablets of folic acid will be given to participants every 8 hours fora a period of 30 days, then samples are to be taken in duplicate for each individual.
62268723|NCT05951608|EXPERIMENTAL|AK127 in combination with AK112|Subjects will receive AK127 in combination with AK112 by intravenous administration
62268724|NCT02429414|EXPERIMENTAL|Non-Video Double Lumen Tube (DLT) Group|Participants receive a non-video DLT for lung isolation before surgery. Once non-video DLT is in correct place, its final position before surgery checked with a fiberoptic bronchoscopy (FOB).
62268725|NCT02429414|EXPERIMENTAL|Video Double Lumen Tube (VDLT) Group|Participants receive a VDLT for lung isolation before surgery. Once VDLT is in correct place, its final position before surgery checked with the camera inside the tube.
62268726|NCT01534533|PLACEBO_COMPARATOR|Placebo|early atherosclerosis cases, received starch in hard shell gelatine capsules, once a day
62268727|NCT01534533|EXPERIMENTAL|Lutein group|early atherosclerosis cases, received 20mg lutein, once a day
62268728|NCT01534533|EXPERIMENTAL|Combination group|early atherosclerosis cases, received 20mg lutein plus 20mg lycopene, once a day
62268729|NCT01534533|EXPERIMENTAL|Normal lutein control group|20mg lutein for subjects free from atherosclerosis, once a day
62268730|NCT04241445||novice observers|who have practiced GMA sporadically (def.: \< = 2 GMA/week for \< = 2 years), have limited experience, and do not use GMA in clinical settings
62268731|NCT04241445||GMA experts|GMA tutors and individuals who have applied GMA regularly (def.: \> 2 GMA/week for \> 2 years)
62268732|NCT02128230|EXPERIMENTAL|Total Therapy 5b|Induction, optional bridging, first transplant, optional bridging, inter-therapy, optional bridging, second transplant, optional bridging, consolidation, maintenance
62268733|NCT04824508|ACTIVE_COMPARATOR|Conventional position (head position)|Leaderposition at the patient's head
62268734|NCT04824508|ACTIVE_COMPARATOR|Remote position|Leaderposition remote from patient and hands-off
62268735|NCT05667896||Remission|
62063576|NCT05613101|ACTIVE_COMPARATOR|Adductor Canal Block|Adductor Canal Block was performed to the patients after coplition of total knee arthroplasty operation for postopetaive pain.
62268736|NCT05667896||Non-remission|
62268737|NCT04454463||Adult patients with NAFLD|1500 patients 18 years and older at the time of enrollment.
62268738|NCT04454463||Pediatric patients with NAFLD|750 patients 2 years or older and up to 17 years old at the time of enrollment.
62268739|NCT01409785||LMA Supreme|
62268740|NCT01409785||LMA unique|
62268741|NCT05209100||Normal Liver|Individuals will have no evidence of steatosis or fibrosis.
62268742|NCT05209100||Steatosis Only|Individuals will have at least 5.6% liver fat as assessed by magnetic resonance imaging proton density fat fraction with no evidence of fibrosis as evidenced by magnetic resonance elastography.
62451500|NCT02006680||Children with Central Precocious Puberty|Children with Central Precocious Puberty will have hormonal testing of markers of puberty up to 30 days prior to placement of a Supprelin LA insert and 28-97 days after placement of the Supprelin LA insert.
62268743|NCT05209100||Fibrosis without Cirrhosis|Individuals will have any level of liver fat as assessed by magnetic resonance imaging proton density fat fraction with fibrosis up to level F3 as evidenced by magnetic resonance elastography.
62268744|NCT00730639|EXPERIMENTAL|Melanoma - BMS-936558 (MDX-1106)|
62268745|NCT00730639|EXPERIMENTAL|RCC - BMS-936558 (MDX-1106)|
62268746|NCT00730639|EXPERIMENTAL|mCRPC - BMS-936558 (MDX-1106)|
62268747|NCT00730639|EXPERIMENTAL|NSCLC - BMS-936558 (MDX-1106)|
62268748|NCT00730639|EXPERIMENTAL|CRC - BMS-936558 (MDX-1106)|
62451501|NCT06001632|EXPERIMENTAL|Krill oil capsules (LC n-3 PUFAs)|4 g/day krill oil (SuperbaBoostTM), with each 1g capsule containing 191mg EPA, 94mg DHA and 78mg choline.
62268749|NCT04382170|ACTIVE_COMPARATOR|20 mcg|Participants randomized to the 20mcg group will receive 20mcg of dexmedetomidine sublingual film every 30 minutes, if they continue to have agitation and do not meet any cardiovascular stopping criteria. The maximum dosing for this arm is 80mcg.
62268750|NCT04382170|EXPERIMENTAL|60 mcg|Participants randomized to the 60mcg group will receive 60mcg of dexmedetomidine sublingual film every 30 minutes, if they continue to have agitation and do not meet any cardiovascular stopping criteria. The maximum dosing for this arm is 240mcg.
62268751|NCT00949832|ACTIVE_COMPARATOR|Vitamin D + Calcium|Vitamin D and calcium supplementation
62451502|NCT06001632|PLACEBO_COMPARATOR|Vegetable oil capsules|4g/day of mixed vegetable oil (a mixture of olive oil (extra virgin, cold-pressed), maize oil (refined), palm kernel oil (refined) and medium-chain triglycerides, in the ratio 4:4:3:2).
62451503|NCT04400526|OTHER|Phase 1: A video competition for anti-drug abuse|Phase 1 aims to increase the public awareness of hazardous effects of drug abuses and existing resources available for drug abusers through a video competition. We will co-organize a video competition for anti-drug abuse with C.H.O.I.C.E. The competition will appeal to the participation of all children (aged 13-18) living in the four targeted districts.
62629134|NCT02609386|EXPERIMENTAL|Regimen 1|IRX Regimen with IRX-2, cyclophosphamide, indomethacin, zinc-containing multivitamin, and omeprazole as neoadjuvant and adjuvant therapy.
62629135|NCT02609386|ACTIVE_COMPARATOR|Regimen 2|Regimen 1 but without IRX-2
62063577|NCT00750100|ACTIVE_COMPARATOR|A|Patients undergo a standard antagonist protocol for in-vitro fertilisation, and are stimulated with recombinant gonadotropins.
62268752|NCT00949832|PLACEBO_COMPARATOR|Calcium|Calcium supplementation
62268753|NCT00949832|ACTIVE_COMPARATOR|Vitamin D2|Vitamin D2 response
62268754|NCT00949832|ACTIVE_COMPARATOR|Vitamin D3|Vitamin D3 response
62268755|NCT05530226|EXPERIMENTAL|Traditional Chinese medicine group|Traditional Chinese medicine, twice daily
62268756|NCT06290050|EXPERIMENTAL|Treatment A: Midazolam 2 mg|Midazolam 2 mg (1 milliliter \[mL\] of 2 milligram per milliliter \[mg/mL\]), syrup, orally, on Day 1 of Period 1.
62268757|NCT06290050|EXPERIMENTAL|Treatment B: Repaglinide 0.5 mg|Repaglinide 0.5 mg (1\*0.5 mg), tablets, orally, on Day 2 of Period 1.
62268758|NCT06290050|EXPERIMENTAL|Treatment C + Treatment A: TAK-279 Dose 1 + Midazolam 2 mg|TAK-279 Dose 1, capsules, orally, on Days 1 through 15 of Period 2 followed by Midazolam 2 mg (1 mL of 2 mg/mL), syrup, orally, on Day 14 of Period 2.
62268759|NCT06290050|EXPERIMENTAL|Treatment C + Treatment B: TAK-279 Dose 1 + Repaglinide 0.5 mg|TAK-279 Dose 1, capsules, orally, on Days 1 through 15 of Period 2 followed by Repaglinide 0.5 mg (1\*0.5 mg), tablets, orally, on Day 15 of Period 2.
62268760|NCT02215720|EXPERIMENTAL|Cetuximab + Temsirolimus|Cetuximab: 400mg/m² IV for 120 minutes Temsirolimus: 15mg IV for 60 minutes
62268761|NCT06548984|EXPERIMENTAL|Experimental group 1|diaphragmatic exercises
62268762|NCT06548984|EXPERIMENTAL|Experimental group 2|Respiratory muscle training
62268763|NCT06548984|NO_INTERVENTION|Control group|No intervention
62268764|NCT01430039||Crohn's, ulcerative colitis|Patients with diagnosed with Crohn's disease or ulcerative colitis who agreed to participate in the study and singed informed consent and answered a Crohn's disease activity index questioner for Crohn's disease or the ulcerative colitis activity index questioner for ulcerative colitis.
62268765|NCT01430039||No disease|Healthy subjects with no known inflammatory disease. For basal serum levels of syndecan 1
62268766|NCT05936450|EXPERIMENTAL|test group|placentrex gel + Open Flap Debridement
62268767|NCT05936450|ACTIVE_COMPARATOR|control group|Open Flap Debridement alone
62629136|NCT05982106|EXPERIMENTAL|TQ05105 Tablets (fasted)|TQ05105 tablets was administered on fasted state in the first cycle for Group A and the second cycle for Group B.
62629137|NCT05982106|EXPERIMENTAL|TQ05105 Tablets (fed)|TQ05105 tablets was administered on fed state in the second cycle for Group A and the first cycle for Group B.
62629138|NCT03020550||GERD Patients|Subjects with active GERD symptoms.
62629139|NCT04199377|EXPERIMENTAL|hip or knee replacement|total hip or knee replacement
62629140|NCT00482170|EXPERIMENTAL|1|Arm 1: Enbrel 50 mg Prefilled Syringe
62268768|NCT01258764|ACTIVE_COMPARATOR|Lisinopril|
62268769|NCT01258764|ACTIVE_COMPARATOR|Hydrochlorothiazide|
62268770|NCT04950257|ACTIVE_COMPARATOR|waiting list control group|Participants randomly allocated to this arm will be offered self-help components within a mobile phone app to target worry and rumination after a 6-week wait.
62268771|NCT04950257|EXPERIMENTAL|treatment group|Participants randomly allocated to this arm will be offered self-help components within a mobile phone app to target worry and rumination immediately.
62268772|NCT03610061|EXPERIMENTAL|Radiotherapy plus Durvalumab|"A minimum of 3 patients will initially be enrolled in each cohort of this arm. Patients will be allocated to a radiotherapy dose and site cohort from the schedule at registration. There will be no intra-patient dose or site escalations.~Cohorts will escalate in number of anatomical sites of radiotherapy and dose of radiotherapy given subject to safety. Durvalumab will be administered at a fixed dose every 4 weeks IV."
62268773|NCT03659019||ventilatory paralysis|dependence on mechanical ventilatory support
62629141|NCT00482170|ACTIVE_COMPARATOR|2|Arm 2 Enbrel 50 mg Autoinjector
62629142|NCT03777280|EXPERIMENTAL|peek framework Removable partial denture|polymer-based framework has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
62629143|NCT03777280|ACTIVE_COMPARATOR|cobalt chromium framework Removable partial denture|it's the gold standard framework which has many benefits such as they are used in thin sections and are less bulky,provide high strength and stiffness,and some disadvantages include hypersensitivity,metal display and oral galvanism,
62629144|NCT02629744|EXPERIMENTAL|Etrolizumab|Participants will self-administer single SC dose of etrolizumab using prefilled auto-injector, into the abdomen or the anterior thigh.
62629145|NCT05722743|EXPERIMENTAL|Harmony at HOME|Participants in this group will receive the Harmony at HOME intervention.
62629146|NCT05722743|ACTIVE_COMPARATOR|National Institute on Aging Program|Participants in this group will receive the National Institute on Aging education.
62629147|NCT03565003|EXPERIMENTAL|JAB-3068 (SHP2 inhibitor)|JAB-3068 will be administered orally in the morning following a fast of approximately 6 hours before on PK collection. Patients will continue to fast for approximately 2 hours after the administration of JAB-3068. On non-PK days patients will fast approximately 2 hours before JAB-3068 and continue to fast for approximately 2 hours afterwards.
62629148|NCT04411758|PLACEBO_COMPARATOR|Placebo Group|Patients will receive 4 capsules (400mg/day) containing magnesium stearate, silicon dioxide and microcrystalline cellulose for 2 months
62063578|NCT00750100|EXPERIMENTAL|B|Patients are undergo an antagonist protocol for in-vitro fertilisation and are stimulated with recombinant gonadotropins. When the patient has an estradiol value of 600 ng/L or more and when the patient has at least 6 follicles of 12 mm, the administration of gonadotropins is stopped and replaced by low dose human chorionic gonadotropins.
62063579|NCT02961114|EXPERIMENTAL|Microcannula Harvest Adipose|Acquisition of AD-tSVF via closed syringe microcannula harvest from subdermal fat deposits
62268774|NCT03659019||central hypoventilation|documented permanent or nocturnal hypoventilation
62268775|NCT04479111|EXPERIMENTAL|LISRH group|Following the principle of complete mesocolic excision(CME), Ileocecus-Sparing Right colectomy refers to the resection of the most portion of the ascending colon, hepatic flexure and mid to distal transverse colon. The extent of lymph node dissection and length of distal resection margin are similar to conventional right hemicolectomy. The length of proximal resection margin varies.
62268776|NCT05796635|EXPERIMENTAL|Herpecin L|Participants will use Herpecin L Everyday Protection lip balm.
62268777|NCT05796635|NO_INTERVENTION|Controlled Arm|Participants will not use any cold sore products or lip balms.
62629149|NCT04411758|EXPERIMENTAL|Propolis Group|Patients will receive 4 capsules (400mg/day) containing dry EPP-AF® green propolis extract for 2 months
62063580|NCT02961114|EXPERIMENTAL|Centricyte 1000|Autologous AD-tSVF via enzymatic isolation/concentration via Centricyte 1000 closed system to create AD-cSVF
62063581|NCT02961114|EXPERIMENTAL|IV Sterile Normal Saline|Re-suspension of AD-cSVF pellet in Normal Saline for deployment via IV
62063582|NCT02597907|EXPERIMENTAL|aprepitant plus palonosetron|aprepitant 80 mg palonosetron 0.075 mg
62063583|NCT02597907|ACTIVE_COMPARATOR|aprepitant plus ramosetron|aprepitant 80 mg ramosetron 0.3 mg
62063584|NCT04844437||Digital examination of fetal head decent in pregnant women|Pregnant women at 36 weeks or over gestational age in the active phase of the first stage or second stage of labor were examined by digital examination and fetal head station evaluated by two clinicians.
62268778|NCT01588717|EXPERIMENTAL|glycopyrrolate|glycopyrrolate 2 to 6 mg/day
62268779|NCT05272800|EXPERIMENTAL|BIS Group|Dry weight is evaluated monthly by clinical examination and biannually BIS-guided.
62268780|NCT05272800|ACTIVE_COMPARATOR|CE Group|Dry weight is evaluated monthly by clinical examination alone.
62063585|NCT04844437||Transperineal assessment of fetal head decent in pregnant women|Pregnant women at 36 weeks or over gestational age in the active phase of the first stage or second stage of labor were examined by transperineal ultrasound and fetal head station evaluated by two experienced clinicians.
62063586|NCT03931447|EXPERIMENTAL|Cohort 1: JNJ-72537634 Dose 1 or Placebo (Part 1 - SD)|Each participant will receive pretreatment with oral antibiotic; followed by a single day (SD) study intervention of JNJ-72537634 at dose 1 or placebo after overnight fast on Day 1.
62063587|NCT03931447|EXPERIMENTAL|Cohort 2: JNJ-72537634 Dose 2 or Placebo (Part 1 - SD)|Each participant will receive pretreatment with oral antibiotic; followed by a SD study intervention of JNJ-72537634 at dose 2 or placebo after overnight fast on Day 1.
62063588|NCT03931447|EXPERIMENTAL|Cohort 3: JNJ-72537634 Dose 1 or Placebo (Part 2 - MD)|Each participant will receive pretreatment with oral antibiotic; followed by a multiple day (MD) study intervention of JNJ-72537634 at dose 1 or placebo after overnight fast on Day 1 for 14 consecutive days.
62063589|NCT03931447|EXPERIMENTAL|Cohort 4: JNJ-72537634 Dose 2 or Placebo (Part 2 - MD)|Each participant will receive pretreatment with oral antibiotic; followed by a MD study intervention of JNJ-72537634 at dose 2 or placebo after overnight fast on Day 1 for 14 consecutive days.
62629150|NCT01475344|ACTIVE_COMPARATOR|Human Fibrinogen Concentrate|"Fibrinogen Concentrate will be administrated over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
62268781|NCT02750540|ACTIVE_COMPARATOR|Product A dose|Product A will contain tenofovir (TFV) 220 mg in 125 mL iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
62268782|NCT02750540|ACTIVE_COMPARATOR|Product B dose|Product B will contain tenofovir (TFV) \*660 mg in 125 mL iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
62268783|NCT02750540|ACTIVE_COMPARATOR|Product C dose|Product C will contain tenofovir (TFV) \*660 mg in 125 mL hypo-osmolar solution at half the osmolarity of iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
62268784|NCT02750540|PLACEBO_COMPARATOR|Take-home normal saline (NS) enema|The normal saline (NS) solution will be provided following administration of Product A which is iso-osmolar. The volume of NS enema (120 mL) was selected to approximately match that of Product A (125 mL)
62451504|NCT04400526|OTHER|Phase 2: Developing a community-based network|Phase 2 aims to develop a community-based network through training anti-drug ambassadors (ADAs). We target to recruit a total of 150 children aged 13 - 18 as ADAs through secondary schools and community centres in the four targeted districts by sending invitation letters. The content of the workshop will be designed by our expert panel. The content of the workshop will include (1) hazardous effects of drug abuse especially less psychotropic drugs such as Cannabis, (2) signs and symptoms of drug abuse particularly less psychotropic drugs like Cannabis, (3) alternatives to drug abuse, (4) community resources available, and (5) how to refer drug abusers. Besides, all children will be taught to use the AWARD model for referrals in the workshop.
62629151|NCT01475344|PLACEBO_COMPARATOR|Placebo|"Placebo administrated over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
62629152|NCT05621395|EXPERIMENTAL|E-OJ-01|1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
62268785|NCT02750540|PLACEBO_COMPARATOR|Take-home half normal saline (½ NS) enema|The ½ normal saline (½ NS) solution will be provided following administration of Product C which is hypo-osmolar. The volume of the ½ NS enema (120 mL) was selected to approximately match that of Product C (125 mL)
62629153|NCT05621395|PLACEBO_COMPARATOR|Microcrystalline cellulose|1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
62063590|NCT04396041||Patients treated for Pulmonary Arteriovenous Malformation|All participants in the study will be patients who have been treated for Pulmonary Arteriovenous Malformation using Microvascular Plugs, Amplatzer Vascular Plugs or Detachable coils.
62063591|NCT00638196|EXPERIMENTAL|1|placebo/active crossover
62629154|NCT03235323|EXPERIMENTAL|ECP group|Patients of ECP group are subjected to a standard ECP protocol one week postoperatively. A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
62629155|NCT03235323|NO_INTERVENTION|Control group|Patients of Control group received routine medicine treatment postoperatively
62063592|NCT01449240||No treatment|Approximately 5 adults (equal to or not less than 18yrs old) and 5 children (equal to or not over 18yrs old)
62063593|NCT02180438|EXPERIMENTAL|Open label prospective single arm study of Stribild|
62268786|NCT04156451|ACTIVE_COMPARATOR|Central Venous Pressure 8 - 10 mmHg|Furosemide deresuscitation or crystalloid loading until the CVP target 8-12 mmHg is reached
62268787|NCT04156451|EXPERIMENTAL|Central Venous Pressure 0 - 4 mmHg|Furosemide deresuscitation or crystalloid loading until the CVP target 0-4 mmHg is reached
62063594|NCT06333210|EXPERIMENTAL|bDMARDs and/or tsDMARD experienced subjects, BCD-180 group|Subjects in this arm will receive a fixed dose of BCD-180 infusions
62063595|NCT06333210|PLACEBO_COMPARATOR|bDMARDs and/or tsDMARD experienced subjects, Placebo group|Subjects in this arm will receive Placebo infusions till the assessment of the primary endpoint and then will be switched to BCD-180 infusions
62063596|NCT06333210|EXPERIMENTAL|bDMARDs and tsDMARD-naive subjects, BCD-180 group|Subjects in this arm will receive a fixed dose of BCD-180 infusions and subcutaneous injections of placebo to maintain blindness of adalimumab therapy till the assessment of the primary endpoint, thereafter subjects will receive only BCD-180 infusions
62268788|NCT02264990|EXPERIMENTAL|Veliparib + Carboplatin + Paclitaxel|"Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an area under the curve (AUC) of 6 mg/mL\*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.~After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."
62268789|NCT02264990|ACTIVE_COMPARATOR|Investigator's Choice Chemotherapy|"Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:~* Carboplatin AUC 6 mg/mL\*min + paclitaxel 200 mg/m²~* Cisplatin 75 mg/m² + pemetrexed 500 mg/m²~* Carboplatin AUC 6 or AUC 5 mg/mL\*min + pemetrexed 500 mg/m²~After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."
62629156|NCT05161845|EXPERIMENTAL|Experimental group|Participants randomized to receive one injections of 0.5 mL Measles, Mumps and Rubella Combined Vaccine, Live at Day 0.
62629157|NCT04369846|EXPERIMENTAL|Test drug group|The arm applies the test drug of GM-XANTHO
62629158|NCT04369846|PLACEBO_COMPARATOR|Placebo group|The arm applies the placebo
62063597|NCT06333210|PLACEBO_COMPARATOR|bDMARDs and tsDMARD-naive subjects, Placebo group|Subjects in this arm will receive Placebo infusions and subcutaneous injections of placebo to maintain blindness of adalimumab therapy till the assessment of the primary endpoint, thereafter subjects will be switched to BCD-180 infusions
62063598|NCT06333210|ACTIVE_COMPARATOR|bDMARDs and tsDMARD-naive subjects, Adalimumab group|Subjects in this arm will receive subcutaneous injections of adalimumab and infusions of placebo till the assessment of the primary endpoint, thereafter subjects will be switched to BCD-180 infusions
62063599|NCT01298921|ACTIVE_COMPARATOR|Continous Flow Oxygen|
62063600|NCT01298921|EXPERIMENTAL|Oxygen Demand Valve|
62268790|NCT04817111|OTHER|Open Label - MIB-626|MIB-626
62268791|NCT04854837||Hemodialysed patients received remdesivir|Remdesivir: day-1: 200 mg intravenously; day 2-5: 100 mg intravenously
62268792|NCT04854837||Hemodialysed patients not received remdesivir|Standard of care
62268793|NCT01409135|EXPERIMENTAL|AGS-22M6E-11-1 Dose Level 1|
62629159|NCT02119078|ACTIVE_COMPARATOR|ACE Service|Admission to the Acute Care for Elders (General Medicine Team 1) service. (See Intervention, below)
62629160|NCT02119078|NO_INTERVENTION|Standard care (other General Medicine teams)|Admission to one of the 4 non-ACE general medicine teaching teams at OHSU.
62268794|NCT01409135|EXPERIMENTAL|AGS-22M6E-11-1 Dose Level 2|
62268795|NCT01409135|EXPERIMENTAL|AGS-22M6E-11-1 Dose Level 3|
62451505|NCT04400526|OTHER|Phase 3: A mass promotional campaign|Phase 3 aims to engage the public to join the community-based network through anti-drug activities organized by anti-drug ambassadors. They are encouraged to design their own promotional activities for community members in the targeted districts.Types of activities can include but not limited to health talks, booths, outreaching activities, games, posters, leaflets and websites.
62451506|NCT01759290||Absorb Bioresorbable Vascular Scaffold|Subjects receiving the Absorb Bioresorbable Vascular Scaffold
62451507|NCT03781700|EXPERIMENTAL|Prednisolone|Prednisolone
62451508|NCT03781700|PLACEBO_COMPARATOR|Placebo|Placebo oral tablet
62451509|NCT04784195||Profesional acrobatics|Profesional Acrobatic Skyedivers as the cort group
62451510|NCT04784195||General active participations|Adults with meched caracteristics with the profesional acrobatics
62451511|NCT01171495|EXPERIMENTAL|Ensure Plus + Multivitamin/Counselling|
62451512|NCT01171495|ACTIVE_COMPARATOR|Multivitamin/Counselling|
62451513|NCT04849845|EXPERIMENTAL|Afrezza|The test product is defined as Afrezza \[insulin human\] inhalation powder administered using the Afrezza inhaler. In addition, subjects will take their personal basal insulin while enrolled in the study.
62451514|NCT05042141|EXPERIMENTAL|KOVIR|Standard dose, 3 capsules/time x 3 times/day x 14 days
62451515|NCT05042141|PLACEBO_COMPARATOR|Placebo|Placebo, 3 capsules/time x 3 times/day x 14 days
62629161|NCT05828368|NO_INTERVENTION|GROUP I: 40 systemically healthy subjects with healthy periodontium.|Systemically healthy subjects with healthy periodontium having probing pocket depth (PPD) ≤3mm, no clinical attachment loss (CAL=0) and bleeding on probing ≤ 10% of sites.
62629162|NCT05828368|EXPERIMENTAL|GROUP II: 40 periodontitis patients without coronary artery disease|Systemically healthy subjects with periodontitis having interdental clinical attachment loss ≥ 3-5mm (stage II/III periodontitis) and probing pocket depth (PPD) ≥5mm (stage II/III periodontitis) and bleeding on probing ≥10% of sites.
62629163|NCT05828368|EXPERIMENTAL|GROUP III: 40 coronary artery disease patients without periodontitis.|Patients diagnosed with coronary artery disease with healthy periodontium having probing pocket depth (PPD)≤3mm, no clinical attachment loss (CAL=0) and bleeding on probing ≤ 10% of sites (CAD).
62629164|NCT05828368|EXPERIMENTAL|GROUP IV: 40 periodontitis patients with coronary artery disease.|Coronary artery disease (CAD) patients with periodontitis having interdental clinical attachment loss ≥3-5mm (stage II/III periodontitis) and probing pocket depth (PPD) ≥5mm (stage II/III periodontitis) and bleeding on probing ≥ 10%.
62629165|NCT05207527|EXPERIMENTAL|Cardiovascular exercise|Cycloergometer
62268796|NCT01409135|EXPERIMENTAL|AGS-22M6E-11-1 Dose Level 4|
62268797|NCT01409135|EXPERIMENTAL|AGS-22M6E-11-1 Dose Level 5|
62268798|NCT01409135|EXPERIMENTAL|AGS-22M6E-11-1 Dose Level 6|
62268799|NCT01409135|EXPERIMENTAL|ASG-22CE Expansion Cohort 1|Breast Cancer
62268800|NCT01409135|EXPERIMENTAL|ASG-22CE Expansion Cohort 2|Bladder Cancer
62451516|NCT00454636|EXPERIMENTAL|Cisplatin / Capecitabine|Cisplatin, 80 mg/m2/day, intravenous (IV), every 3 weeks; capecitabine, 1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks.
62268801|NCT01409135|EXPERIMENTAL|ASG-22CE Expansion Cohort 3|Lung plus other solid tumor cancers
62451517|NCT00454636|EXPERIMENTAL|Epirubicin / Cisplatin / Capecitabine|Epirubicin, 50 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capecitabine, 625mg/m2, orally, twice daily per 3-week cycle. Study drugs were administered for at least 24 weeks.
62451518|NCT00454636|EXPERIMENTAL|Epirubicin / Oxaliplatin / Capecitabine|Epirubicin, 50 mg/m2/day, IV, every 3 weeks; oxaliplatin, 130 mg/m2/day, IV, every 3 weeks; capecitabine, 625mg/m2 orally, twice daily per 3-week cycle. Study drugs were administered for at least 24 weeks.
62451519|NCT00454636|EXPERIMENTAL|Docetaxel / Cisplatin / Capecitabine|Docetaxel, 60 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capecitabine, 825 mg/m2, orally, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks.
62451520|NCT00922974|EXPERIMENTAL|Radiosurgery/SBRT|
62063601|NCT01656837|EXPERIMENTAL|MST-BSF|MST-BSF integrates two models with empirical support for their effectiveness, MST-CAN for child maltreatment (Swenson, Schaeffer, Henggeler, Faldowski, \& Mayhew, 2012) and RBT for adult substance abuse (Tuten, Jones, Schaeffer, Wong, \& Stitzer, 2012) into one comprehensive treatment package. MST-BSF is intended to be comprehensive. The major interventions within the MST-BSF arm include safety planning and implementation, functional analysis of the abuse incident, cognitive behavioral interventions for PTSD symptomatology and low anger management, family communication and problem solving, abuse clarification, and Reinforcement Based Treatment for adult substance abuse. RBT is an incentive-based drug treatment program for adults who abuse opiates, cocaine, or other illicit drugs.
62063602|NCT01656837|EXPERIMENTAL|Comprehensive Community Treatment|Families randomized to the CCT condition receive an array of services consistent with existing DCF practices. Project Safe community providers offer individual, couples, and family therapy for substance abuse/dependence, early intervention groups, treatment for co-occurring disorders, gender-specific trauma/substance abuse groups, and relapse prevention groups. The DCF caseworker also is responsible for coordinating care for the behavioral and mental health needs of the children. Services include individual outpatient treatment, family therapy, intensive in-home treatment, extended day programs, intensive outpatient, partial and inpatient hospitalization, residential programs/temporary housing (safe homes, shelters), emergency mobile psychiatric services, and crisis stabilization.
62063603|NCT00615862||AUD+ and AUD-|AUD stands for alcohol use disorders. Patients with alcohol use disorders are assigned the label AUD+. Patients without alcohol use disorders are assigned the label AUD-.
62063604|NCT05767775||RA patients with BMI≥ 25 eligible to Tofacitinib|
62268802|NCT01290692|EXPERIMENTAL|TVI-Brain-1|All patients will receive the full TVI-Brain-1 treatment.
62063605|NCT05767775||RA patients with BMI<25 eligible to Tofacitinib|
62063606|NCT03395249|EXPERIMENTAL|SPR994, FI, F2, F3, F4 Oral Tablets|"SPR994 is active against multidrug-resistant Gram-negative and Gram-positive pathogens that cause serious and life-threatening infections, including extended spectrum beta-lactamase (ESBL) producers as well as strains resistant to levofloxacin and trimethoprim/sulfamethoxazole. SPR994 is administered in tablet form orally. Up to five different time released formulations of SPR994 will be studied in this protocol at 100 mg, 300 mg, 600 mg and 900 mg dosages.~SAD Cohorts: One dose (two for food effect cohort) MAD Cohorts: Twenty-seven (27) doses administered twice daily (BID) over a period of 14 days or forty doses administered three times daily (TID) over period of 14 days"
62268803|NCT04434391||QF-PCR for GBS screening|QF-PCR for vaginal-rectal samples in pregnant women
62268804|NCT03887897|ACTIVE_COMPARATOR|Airtraq|Airtraq laryngoscope
62268805|NCT03887897|ACTIVE_COMPARATOR|Macintosh|Macintosh laryngoscope
62268806|NCT00656955||Renal cancer patients|Renal cancer patients
62268807|NCT01075555|ACTIVE_COMPARATOR|sorafenib|sorafenib
62063607|NCT03395249|PLACEBO_COMPARATOR|Placebo Oral Tablet|"Placebo tablets (100, 300, and 600 mg) are pressed from a single placebo blend consisting of the same inactive ingredients; the active pharmaceutical ingredient (API) is replaced by Mannitol 200SD.~SAD Cohorts: One dose (two for food effect cohort) MAD Cohorts: Twenty-seven (27) doses administered BID over a period of 14 days or forty doses administered TID over a period of 14 days"
62063608|NCT03395249|OTHER|Optional Orapenem Open-Label Control|"A single, optional, open-label, control cohort that may enroll, in which all 8 subjects receive Orapenem.~SAD Cohort: One dose under fasted conditions and one dose under fed conditions."
62063609|NCT00792103|EXPERIMENTAL|NP101|sumatriptan iontophoretic transdermal patch
62268808|NCT01075555|EXPERIMENTAL|sorafenib + pravastatine|sorafenib + pravastatine
62451521|NCT00922974|ACTIVE_COMPARATOR|External Beam Radiation Therapy|
62451522|NCT06303999|ACTIVE_COMPARATOR|Nasogastric tube|The group was given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements.
62629166|NCT05207527|EXPERIMENTAL|Muscle strength|Strength exercises will be performed during the hemodialysis session.
62063610|NCT05386563|EXPERIMENTAL|Transcutaneous Auricular Vagal Nerve Stimulation (taVNS)|
62063611|NCT05386563|SHAM_COMPARATOR|Sham|
62063612|NCT05386563|NO_INTERVENTION|No Intervention (Control)|
62063613|NCT01892943||Patients with LHON|
62063614|NCT01683240|EXPERIMENTAL|Frimberger cholangioscope|Patients with need for cholangioscopy due to gallstones or histological evaluation of strictures
62063615|NCT03187015|OTHER|Midazolam|Treatment A: 2 mg of Midazolam administered - Period 1, Day 1 Treatment B: 2 mg of Midazolam with 5 mg Entinostat (after 14 day minimum washout from Period 1, Day 1) - Period 2, Day 1
62063616|NCT01629680|EXPERIMENTAL|Healthy subjects I|
62063617|NCT01629680|PLACEBO_COMPARATOR|Healthy subjects II|
62063618|NCT01849900|OTHER|Healthy Lifestyle|60 women randomly assigned to the control group
62063619|NCT01849900|OTHER|Knowing your body|60 women randomly assigned to intervention group
62268809|NCT02213809|EXPERIMENTAL|Case method education in COPD|Two hours of case method education in COPD are given two times within 3 months to the general practitioners at nine primary health care centers. The education covers examination, including interpretation av spirometry, and treatment of patients with COPD. The learning outcomes are predefined and are the same in both arms. The same person will teach at both times of education.
62629167|NCT05207527|EXPERIMENTAL|Mixed|Both aerobic and muscular strength exercises will be performed.
62268810|NCT02213809|ACTIVE_COMPARATOR|Traditional education in COPD|Two hours of traditional education in COPD are given two times within 3 months to the general practitioners at nine primary health care centers.The education covers examination, including interpretation av spirometry, and treatment of patients with COPD. The learning outcomes are predefined and are the same in both arms. The same person will teach at both times of education.
62268811|NCT06177756|EXPERIMENTAL|Intervention Arm|
62268812|NCT06177756|NO_INTERVENTION|Comparator Arm|
62451523|NCT06303999|EXPERIMENTAL|Intermittent Oro-esophageal Tube|The group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups
62063620|NCT00337662|EXPERIMENTAL|1|Olanzapine for Not Early Onset response (NEO) patients
62629168|NCT05207527|NO_INTERVENTION|Control|Conventional treatment or dyalisis usual care
62629169|NCT01556997|EXPERIMENTAL|XOMA 985|fixed-dose combination of perindopril arginine/amlodipine besylate(PERa/AMLb)
62063621|NCT00337662|ACTIVE_COMPARATOR|2|Risperidone for Not Early Onset response (NEO) patients
62063622|NCT00337662|ACTIVE_COMPARATOR|3|Risperidone for Early Onset response (EO) patients
62063623|NCT05507658|EXPERIMENTAL|Tislelizumab combined with XELOX|"1. Tirelizumab 200mg, iv.gtt, D1, Q3W;~2. Chemotherapy:~Oxaliplatin (130 mg/m2), iv.gtt, D1, Q3W; Capecitabine (1000mg/m2), P.O.B.I.D., D1-D14, Q3W."
62063624|NCT05893199|EXPERIMENTAL|Telemedicine|Patients in the intervention group (Telemedicine) will be followed up using the Ti.Care App in addition to the usual primary care follow-up.
62063625|NCT05893199|ACTIVE_COMPARATOR|Primary care|Patients in the control group will be followed up exclusively in primary care.
62063626|NCT04834778|EXPERIMENTAL|Cohort 1 - 25 mg|25 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
62063627|NCT04834778|EXPERIMENTAL|Cohort 2 - 50 mg|50 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
62063628|NCT04834778|EXPERIMENTAL|Cohort 3 - 100 mg|100 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
62268813|NCT06182332|EXPERIMENTAL|Screening (AI algorithm)|Patients' medical records are reviewed for consideration of palliative care consult using AI algorithm QW for 6 months.
62629170|NCT01556997|ACTIVE_COMPARATOR|Amlodipine Besylate (AMLb)|
62629171|NCT01556997|ACTIVE_COMPARATOR|Perindopril Erbumine (PERe)|
62629172|NCT00716807|EXPERIMENTAL|TMD 1|
62629173|NCT00716807|PLACEBO_COMPARATOR|TMD 2|
62629174|NCT00716807|EXPERIMENTAL|BMS 1|
62629175|NCT00716807|PLACEBO_COMPARATOR|BMS 2|
62629176|NCT05138978|EXPERIMENTAL|Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer|Toothpaste
62629177|NCT05138978|OTHER|Colgate Cavity Protection|Toothpaste
62063629|NCT04834778|EXPERIMENTAL|Cohort 4 - 200 mg|200 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
62063630|NCT04834778|EXPERIMENTAL|Cohort 5 - 400 mg|400 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
62268814|NCT05813912|EXPERIMENTAL|Insulin Icodec + Semaglutide|Participants will receive insulin icodec once weekly for 26 weeks in run-in period to ensure the dose optimization. Thereafter, participants meeting intensification criteria will proceed to the 26-week treatment period to receive once weekly semaglutide subcutaneously starting from 0.25 milligrams (mg) and dose increased up to 1 mg along with 700 units per milliliter (U/mL) insulin icodec therapy. There are no maximum or minimum insulin doses.
62268815|NCT01258907|EXPERIMENTAL|A|
62063631|NCT04834778|EXPERIMENTAL|Cohort 6 - 600 mg|600 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
62063632|NCT04834778|EXPERIMENTAL|Cohort 7 - 900 mg|900 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
62268816|NCT01258907|EXPERIMENTAL|B|
62268817|NCT01258907|PLACEBO_COMPARATOR|C|
62268818|NCT06087354|EXPERIMENTAL|Low Oxygen Concentration CAPA-IVM culture|Half of COCs were cultured in the CAPA step and IVM step in a low oxygen concentration (5%) and 6% carbon dioxide at 37 degree
62268819|NCT06087354|EXPERIMENTAL|Air Oxygen Concentration CAPA-IVM culture|Half of COCs were cultured in the CAPA step and IVM step in a air oxygen concentration (20%) and 6% carbon dioxide at 37 degree
62268820|NCT05008107|EXPERIMENTAL|Virtual Reality|Virtual reality (VR) will be provided to families of patients undergoing ambulatory pediatric surgery. VR will provide personalized education to patients and their families about the entire continuum of the child's surgical experience. This will range from the hospital registration, the peri-operative experience, including the separation of the child from the parent in the pre-operative area and the anesthetic induction process, and the post-operative hospital ward.
62268821|NCT05008107|NO_INTERVENTION|Control|Families will receive standard pre-operative instructions.
62268822|NCT02919436|EXPERIMENTAL|Tamsulosin|Subjects in this arm will receive tamsulosin 0.4 mg/day for five days prior to surgery and two days after surgery.
62268823|NCT02919436|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive a placebo capsule identical in appearance to the tamsulosin capsule, for five days prior to surgery and two days after surgery.
62268824|NCT06106464|EXPERIMENTAL|Aerobic exercise+6.5 h of prolonged sitting|Participants will sit 6.5 hours after 30 minutes of moderate intensity aerobic exercise.
62268825|NCT06106464|EXPERIMENTAL|Aerobic exercise+2 minutes of walking breaks every 30 minutes|Participants will break prolonged sitting with 2 minutes of walking every 30 minutes after 30 minutes of moderate intensity aerobic exercise.
62268826|NCT06106464|EXPERIMENTAL|Aerobic exercise+4 minutes of walking breaks every 1-h|Participants will break prolonged sitting with 4 minutes of walking every 1-h after 30 minutes of moderate intensity aerobic exercise.
62268827|NCT06106464|EXPERIMENTAL|Aerobic exercise+8 minutes of walking breaks every 2-h|Participants will break prolonged sitting with 8 minutes of walking every 2-h after 30 minutes of moderate intensity aerobic exercise.
62268828|NCT02981680|EXPERIMENTAL|RIPC|Patients in the remote ischemic preconditioning (RIPC) group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, surgery will be started. The entire pre-conditioning phase will last 30 minutes.
62268829|NCT02981680|SHAM_COMPARATOR|sham-RIPC|Patients in the sham-RIPC group will have the sphygmomanometer cuff placed on their right upper arm, but the cuff will not be inflated. Similar to patients in the RIPC group, patients in the sham-RIPC group will undergo the same 30 minute delay before starting surgery.
62268830|NCT03462407|EXPERIMENTAL|DAID|Trained assistants will help participants train their dog to engage in imitation based dog training, using positive reinforcement training (operant conditioning) focused on physical activities.
62268831|NCT03462407|ACTIVE_COMPARATOR|Dog walking|Trained assistants will help children train their dog to walk on a loose leash (eliminate pulling behavior) during this period using positive training techniques. The focus of this group will be on appropriate walking behavior to facilitate enjoyable independent dog-walking at home.
62268832|NCT03462407|NO_INTERVENTION|Control|This group will all own family dogs but will not participate in either intervention during year 1. All participants assigned to the waitlist will be offered the DAID intervention the subsequent summer.
62268833|NCT05776862|EXPERIMENTAL|UA and exercise in paraplegia group|Participants will take UA 4 capsules twice daily for 12 weeks while participating in an exercise program, 3 times per week.
62268834|NCT05776862|EXPERIMENTAL|UA in tetraplegia group|Participants will take UA 4 capsules twice daily for 12 weeks
62268835|NCT04357821|EXPERIMENTAL|Combination intervention arm|All volunteers will receive the combination intervention outlined above.
62268836|NCT02037737||RA patients on Abatacept IV|Rheumatoid Arthritis (RA) patients with inadequate response to one or more conventional DMARDs including Methotrexate and treated with Abatacept IV according to routine clinical practice in France
62268837|NCT04639180|EXPERIMENTAL|Treatment group (Camrelizumab Plus Rivoceranib (Apatinib))|Drug: Camrelizumab; Drug: Rivoceranib (Apatinib)
62268838|NCT04639180|NO_INTERVENTION|Control group (Active surveillance)|
62268839|NCT05826756||Patients|Individuals who have been diagnosed with lung cancer. Individuals with all stages of lung cancer and individuals who have reached no evidence of disease (NED).
62268840|NCT05826756||Caregivers|Family and friends who provide care for someone who has been diagnosed with lung cancer
62268841|NCT01391507|PLACEBO_COMPARATOR|Placebo|
62063633|NCT04834778|EXPERIMENTAL|Cohort 8 - 300 mg|300 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
62451524|NCT04800588|EXPERIMENTAL|Older participant group|We will evaluate the performance of healthy older participants (N = 300, age range 60 to 89 years) for three days at enrollment and then at 6-month intervals for three years thereafter. The goal is to characterize changes in performance to aging and task experience in a group of older subjects.
62451525|NCT04800588|EXPERIMENTAL|CCAB vs. manual test group|We will compare the performance of normal participants (N = 100, age range 18 to 89) on computerized and manually administered cognitive tasks.
62088097|NCT01473511|NO_INTERVENTION|Usual care|50% randomized will not receive Strongest Families Intervention during the 22 month study phase, but will receive the usual care services available via the referring agency. At the end of the 22 month study period study participants will be offered the Strongest Families Intervention services.
62088098|NCT03135132|PLACEBO_COMPARATOR|Control group|Usual dietary intake group
62451526|NCT04800588|EXPERIMENTAL|Test-Retest Reliability group|We will gather normative data from participants across the age range (N = 100, ages 18 to 89) for three days at enrollment, to better characterize test-retest reliability scores on Day 1 tasks.
62268842|NCT01391507|EXPERIMENTAL|20 mg COR-1|
62268843|NCT01391507|EXPERIMENTAL|80 mg COR-1|
62088099|NCT03135132|EXPERIMENTAL|LCD group|Low calorie diet (LCD) group (300kcal/day intake reduction)
62268844|NCT01391507|EXPERIMENTAL|160 mg COR-1|
62268845|NCT01281566|EXPERIMENTAL|001|Cisapride 0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
62268846|NCT01281566|PLACEBO_COMPARATOR|002|Placebo liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
62268847|NCT04753073|EXPERIMENTAL|NIPP|Treatment of the NIPP group with physical low-temperature plasma, subsequently within 8 weeks LEEP-Exzision
62268848|NCT04753073|NO_INTERVENTION|Controll|LEEP-Exzision
62629178|NCT02019550|EXPERIMENTAL|First Rebif Rebidose, Then Rebiject II|Subjects will self-inject Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using Rebif Rebidose self-injector device in Treatment Period 1 for 4 weeks followed by self-injecting Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebiject II self-injector device in Treatment Period 2 (4 weeks) for the next 4 weeks.
62451527|NCT04800588|EXPERIMENTAL|Health Disparities group|We will evaluate the performance of healthy older participants (N = 1200, age range 50 to 89 years) for three days at enrollment and then at 6-month intervals for three years thereafter. In the aim of better understanding health disparities in cognitive testing, this group will be divided into four cohorts: 300 African American participants; 300 Asian American participants; 300 Latino English-speaking participants; and 300 Latino Spanish-speaking participants, who will complete a Spanish translation of our computerized cognitive tests.
62451528|NCT01091025|OTHER|CF patients without known diagnose of CFRD|There is only one arm. All patients in the study had the same procedures (ie. an OGTT). Investigators used the screening criteria in parallel to this.
62451529|NCT00365352|EXPERIMENTAL|XP13512 600MG|XP13512 600MG ONCE DAILY
62451530|NCT00365352|EXPERIMENTAL|XP13512 1200MG|XP13512 1200MG ONCE DAILY
62451531|NCT00365352|PLACEBO_COMPARATOR|Placebo|PLACEBO ONCE DAILY
62451532|NCT02233348||ASD group|Subjects with DSM-IV ASD diagnosis
62451533|NCT02233348||Control group|Controls without lifetime ASD or a family history of ASD
62451534|NCT03741413|EXPERIMENTAL|Gain-frame SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can offer a helping hand to save their lives. Thank you for your support. were send to donors in this group."
62451535|NCT03741413|EXPERIMENTAL|Loss-frame SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can offer a helping hand to prevent them from death. Thank you for your support. were send to donors in this group."
62451536|NCT03741413|EXPERIMENTAL|Control SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can donate blood again. Thank you for your support. were send to donors in this group."
62451537|NCT03741413|NO_INTERVENTION|Control group|Donors in this group were not received SMS reminders.
62451538|NCT00846625|EXPERIMENTAL|1|Ranibizumab (0.5 mg)
62451539|NCT00846625|ACTIVE_COMPARATOR|2|Triamcinolone (4 mg/0.1 ml)
62451540|NCT02070744|EXPERIMENTAL|PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h|Participants received VX-661 50 milligram (mg) tablet plus Ivacaftor (IVA) 150 mg tablet every 12 hours (q12h) for 12 weeks.
62451541|NCT02070744|PLACEBO_COMPARATOR|PC Phase: VX 661 placebo q12h + IVA placebo q12h|Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.
62451542|NCT02070744|EXPERIMENTAL|PC Phase: VX-661 100 mg qd + IVA 150 mg q12h|Participants received two VX-661 50 mg tablets once daily (qd) plus IVA 150 mg tablet q12h for 12 weeks.
62451543|NCT02070744|PLACEBO_COMPARATOR|PC Phase: VX -661 placebo qd + IVA placebo q12h|Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.
62451544|NCT02070744|EXPERIMENTAL|OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h|Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.
62451545|NCT02978326|EXPERIMENTAL|Part A: SAGE-217 15/20 mg Oral Solution|Participants received SAGE-217, 15 milligrams (mg), oral solution, twice daily (BID) for first 2 days followed by SAGE-217, 15 or 20 mg, oral solution, BID, starting on Day 3 for up to 14 days as tolerated.
62451546|NCT02978326|PLACEBO_COMPARATOR|Part B: Placebo|Participants received SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.
62451547|NCT02978326|EXPERIMENTAL|Part B: SAGE 217 30 mg Capsules|Participants received SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.
62088100|NCT01899560|OTHER|Unique arm|Experimental and comparator
62088101|NCT01253915|EXPERIMENTAL|Carbon Dioxide|
62451548|NCT03481309|ACTIVE_COMPARATOR|anodal tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This anodal tDCS on the left motor cortex will be stimulated with 2mA for 10 minutes.
62451549|NCT03481309|ACTIVE_COMPARATOR|cathodal tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This cathodal tDCS on the left motor cortex will be stimulated with -2mA for 10 minutes.
62451550|NCT03481309|SHAM_COMPARATOR|sham tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). Sham stimulation with 2mA for 40 seconds will be applied.
62451551|NCT02494713|OTHER|ADT + chemotherapy|Patients will be treated with 4 monthly injections of degarelix along with two 8-week cycles of chemotherapy (doxorubicin and ketoconazole, weeks 1, 3, 5 and docetaxel and estramustine, weeks 2, 4, 6). Each cycle of chemotherapy will consist of 6 weeks of chemotherapy and 2 weeks of rest. In the absence of toxicity or disease progression, patients will receive 2 cycles of treatment prior to radical prostatectomy.
62451552|NCT01648010|EXPERIMENTAL|TC-3 gel|TC-3 gel group undergo intravesical instillation of the investigatory device
62063634|NCT02053545|EXPERIMENTAL|Conditioning Regimen & GVHD Prophylaxis|"Stratum 1 (Refractory disease, relapse after previous transplant): Clofarabine, Melphalan,Thiotepa, Cyclophosphamide, Mesna, Tacrolimus and mycophenolate mofetil (MMF)~Stratum 2 (Myeloid in remission): Busulfan, Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Tacrolimus, MMF~Stratum 3 (Lymphoid in remission): Fractionated total body irradiation (fTBI), Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Tacrolimus, MMF"
62063635|NCT05726682|EXPERIMENTAL|High risk AML and MDS|Participants with high risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic HSCT will receive 3 doses of SAR445419. A myeloablative conditioning (MAC) and a reduced intensity conditioning (RIC) cohort will be included.
62629179|NCT02019550|EXPERIMENTAL|First Rebiject II, Then Rebif Rebidose|Subjects will self-inject Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebiject II self-injector device in Treatment Period 1 for 4 weeks followed by self-injecting Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebif Rebidose self-injector device in Treatment Period 2 for the next 4 weeks.
62063636|NCT01395654|EXPERIMENTAL|Standard rechallenge, Slow rechallenge|
62063637|NCT02057601|EXPERIMENTAL|Infiltration group|The patients in this group will receive spinal anaesthesia with intrathecal bupivacaine 0.5% 2.0ml and will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
62063638|NCT02057601|NO_INTERVENTION|Non infiltration group|The patients in this group will receive spinal anaesthesia with intrathecal bupivacaine 0.5% 2.0 ml.
62063639|NCT02150837||5 & 2 & 2 Plan|MWCC members who used the Medifast 5 \& 2 \& 2 Meal Replacement Plan for weight loss.
62063640|NCT02150837||4 & 2 & 1 Plan|MWCC members who used the Medifast 4 \& 2 \& 1 Meal Replacement Plan for weight loss.
62063641|NCT00790114|EXPERIMENTAL|1|
62063642|NCT04488562||Patients with COVID-19|Patients with proven COVID-19 and abnormalities on chest X-Ray/HRCT, admitted at the hospital. Patients are included around the time of discharge from the hospital or at their regular outpatient clinic visit 6 weeks after discharge, depending on the clinical status of the patient at time of discharge.
62063643|NCT04649827||COVID-19|Patients with confirmed COVID-19 by RT-PCR or serological test
62063644|NCT01500564|SHAM_COMPARATOR|Sham tDCS and motor training: sham comparator|"Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).~Intervention: placebo tDCS Other: Motor Training"
62268849|NCT05479500|NO_INTERVENTION|Group 1|"Control group will consist of 12 patients with diagnosed Plantar Fasciitis, aged between 30-60 years. Only conventional physiotherapy program will be applied to this group.~Conventional treatment will consist of foot intrinsic muscles strengthening, plantar fascia, achilles and hamstring stretching exercises. The exercises will be performed as 10 repetitions and 3 sets. Participants will be treated for a total of 6 weeks, 2 days a week. Each treatment session will last 20-40 minutes."
62451553|NCT01648010|EXPERIMENTAL|MMC- gel|MMC gel group undergo intravesical instillation of the reverse thermal gelation device mixed with MMC
62451554|NCT05793736|EXPERIMENTAL|biofeedback + treatment as usual|The selected sample (n 10) will undergo 10 total Biofeedback Training sessions, twice a week. Each session will last 45 minutes. The total duration of the treatment will be 5 weeks, plus standard therapies (treatment as usual)
62268850|NCT05479500|EXPERIMENTAL|Group 2|Experimental group will consist of 12 patients with diagnosed Plantar Fasciitis, aged between 30-60 years. In addition to the conventional physiotherapy program, local release techniques will be applied to this group. Local Release Techniques will be applied as Gastro-solues trigger point myofascial release and Plantar fascia myofascial release. Participants will be treated for a total of 6 weeks, 2 days a week. Each treatment session will last 20-40 minutes.
62629180|NCT02239445|ACTIVE_COMPARATOR|chloral hydrate group|chloral hydrate 0.25 mg/kg oral solution diluted with oral syrup to 5 ml and 0.2 mL intranasal placebo (normal saline)
62268851|NCT05479500|EXPERIMENTAL|Group 3|"Experimental group will consist of 12 patients with diagnosed Plantar Fasciitis, aged between 30-60 years. In addition to the conventional physiotherapy program, myofascial chain release techniques will be applied to this group.~Myofascial release technique will be applied to the center of coordination points in the superficial back line myofascial chain of the body. Pressure will be applied to each point with 6 repetitions and lasting approximately 5-6 seconds.~Participants will be treated for a total of 6 weeks, 2 days a week. Each treatment session will last 20-40 minutes."
62268852|NCT05841043|EXPERIMENTAL|SHR8028 eye drops|
62268853|NCT05841043|PLACEBO_COMPARATOR|Vehicle|
62268854|NCT03954535|EXPERIMENTAL|Intervention|9 sessions and website with entertainment features and resources
62268855|NCT03954535|PLACEBO_COMPARATOR|Control|website with entertainment features and resources
62268856|NCT03571646|OTHER|Capnostream 20|Continuous monitoring of CO2
62268857|NCT03571646|OTHER|PM1000N-RR|Continuous monitoring of SpO2
62268858|NCT04396171||Probable bruxism(+)|
62268859|NCT04396171||Probable bruxism(-)|
62268860|NCT03259009||Patients with metastatic colorectal cancer|Rechallenge with an anti-EGFR monoclonal antibody in patients with metastatic colorectal cancer
62268861|NCT03847675|EXPERIMENTAL|Intervention|"The research assistant introduces the adapted 'Reach out and Read program and informs participants about the benefits of reading to children at an early age. A 4:50 minutes video clip would be shown during the initial visit. This video discusses the benefits of reading displaying practical tips for parents; it includes tips on how to read, pointing at the words.~A schematic pamphlet highlighting the importance of reading Arabic to children and the impact of such reading on children's brain development, vocabulary acquisition and behavior in addition to the impact on the parent child bond and relationship is given to the parents.~After each visit participants will receive an age appropriate book for their child.~Focus groups will be conducted by a qualitative researcher"
62268862|NCT03847675|NO_INTERVENTION|Control|The research assistant gives routine advice on child development including importance of reading and advice on nutrition and safety and gives parents a leaflet about early child development and complementary feeding
62629181|NCT02239445|EXPERIMENTAL|low dose dexmedetomidine Group|"Group L received intranasal dexmedetomidine at 1mcg/kg and 5 ml oral syrup~Undiluted preservative-free dexmedetomidine (AiBeiNing; Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) was prepared in a concentration of 100mcg/ml and dripped into both nostrils using a 1 mL syringe with the child in the Supine position."
62629182|NCT02239445|EXPERIMENTAL|high dose dexmedetomidine group|"Group H received intranasal dexmedetomidine at 2mcg/kg and 5 ml oral syrup~Undiluted preservative-free dexmedetomidine (AiBeiNing; Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) was prepared in a concentration of 100mcg/ml and dripped into both nostrils using a 1 mL syringe with the child in the Supine position."
62629183|NCT04293484|EXPERIMENTAL|Real tDCS - Real tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
62088102|NCT01253915|PLACEBO_COMPARATOR|Placebo|
62268863|NCT02173574|EXPERIMENTAL|Open-Label Single Arm Cohort|
62268864|NCT04772729|ACTIVE_COMPARATOR|Insulin Aspart|Patients will use the continuous subcutaneous insulin infusion of insulin aspart (Novo Rapid, Novo Nordisk) and RT-CGM for 4 weeks.
62268865|NCT04772729|EXPERIMENTAL|Insulin Fiasp|Patients will use the continuous subcutaneous insulin infusion of insulin faster aspart (Fiasp, Novo Nordisk) and RT-CGM for 4 weeks.
62268866|NCT03524859||Cystic fibrosis|Cystic fibrosis participants without experience on endurance or resistance training will be analyzed through a test battery and lung function test.
62268867|NCT03524859||Healthy Subjects|Healthy matched control group without experience on endurance or resistance training will be analyzed through a test battery.
62629184|NCT04293484|SHAM_COMPARATOR|Sham tDCS - Real tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
62088103|NCT03031028|OTHER|ketogenic diet|Ketogenic diet
62451555|NCT05793736|ACTIVE_COMPARATOR|treatment as usual|The control sample (n 10) will be treated only with standard therapies (treatment as usual) without the use of biofeedback training
62451556|NCT01506830|ACTIVE_COMPARATOR|Absolute isolation|Absolute isolation of the operatory field with rubber dam: Moisture control is provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
62451557|NCT01506830|EXPERIMENTAL|Relative isolation|Relative isolation of the operatory field with cotton rolls: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
62451558|NCT06095258|EXPERIMENTAL|Traditional Chinese medicine treatment group|Patients in this treatment group will receive individualized TCM syndrome differentiation treatment.
62451559|NCT06095258|ACTIVE_COMPARATOR|Western medicine control group|Patients in this control group will receive conventional Western medicine symptomatic treatment from general Western medicine practitioners.
62629185|NCT02210507|EXPERIMENTAL|White cassava gari|A single meal containing 400 gm of garified non-biofortified (white) cassava with retinyl palmitate reference dose.
62268868|NCT05454215|ACTIVE_COMPARATOR|Conventional settings first, modified settings second|"The control intervention (CON) is the conventional mode of a commercially available mechanical insufflator/exsufflator. The manoeuvre consists of 5 sets of 5 mechanical insufflations/exsufflations with individual pressure settings.~For the study, the same pressure settings will be used as during daily routine.~The study intervention (MOD) is a modified mode of a commercially available mechanical insufflator/exsufflator in which the active exsufflation of the last breath of each set will be omitted. The manoeuvre consists of 5 sets of 5 mechanical insufflations/exsufflations with individual pressure settings.~For the study, the same pressure settings will be used as during daily routine. This modified mode is already used in daily routine by a minority of subjects with NMD."
62268869|NCT05454215|EXPERIMENTAL|Modified settings first, conventional settings second|"The study intervention (MOD) is a modified mode of a commercially available mechanical insufflator/exsufflator in which the active exsufflation of the last breath of each set will be omitted. The manoeuvre consists of 5 sets of 5 mechanical insufflations/exsufflations with individual pressure settings.~For the study, the same pressure settings will be used as during daily routine. This modified mode is already used in daily routine by a minority of subjects with NMD.~The control intervention (CON) is the conventional mode of a commercially available mechanical insufflator/exsufflator. The manoeuvre consists of 5 sets of 5 mechanical insufflations/exsufflations with individual pressure settings.~For the study, the same pressure settings will be used as during daily routine."
62268870|NCT04002011|ACTIVE_COMPARATOR|Group VKA|"103 patients. First intake at postoperative day 1 or later when anticoagulation is secondary indicated.~Dosage adapted to INR = \[2.0-3.0\], parenteral (subcoutaneous low-weight molecular or intravenous unfractionated heparin) until INR \> or = 2.0.~Daily INR during hospital stay, then management by familial doctor. Duration: 3 months"
62268871|NCT04002011|ACTIVE_COMPARATOR|Group DOAC|"103 patients - One drug among the 4 DOAC according the morbidity of each patient (preoperative DOAC, oral nutrition recovery).~First intake at hospital discharge - parenteral (subcoutaneous low-weight molecular or intravenous unfractionated heparin) during hospital stay.~Regular daily dosages according the drug, its indication (atrial fibrillation/flutter or biological mitral replacement/repair or biological tricuspid replacement versus venous thromboembolism) and the morbidity of each patient (age, weight, creatinine ou its clearance).~Validation by one referent pharmacist. No biological monitoring. Duration: 3 months"
62451560|NCT01964664|EXPERIMENTAL|Mindfulness meditation training|6-week, one-on-one, mindfulness meditation intervention based on Mindfulness-Based Cognitive Therapy program
62451561|NCT01964664|ACTIVE_COMPARATOR|Audio Group|6 weeks of listening to podcasts daily (same length as guided meditations), and discussing podcast content with research assistant during weekly study visits
62451562|NCT04125654|EXPERIMENTAL|Patients with ascites enrolled for mNGS testing|Patients with ascites will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective clinical documents).
62629186|NCT02210507|EXPERIMENTAL|White cassava gari + red palm oil|A single meal containing 400 gm of garified non-biofortified (white) cassava with red palm oil.
62629187|NCT02210507|EXPERIMENTAL|Biofortified cassava gari|A single meal containing 400 gm of garified biofortified cassava.
62063645|NCT01500564|EXPERIMENTAL|Anodal tDCS and motor training: experimental|"Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).~Interventions:~* Device: anodal tDCS~* Other: motor Training during physiotherapy"
62063646|NCT01979731|EXPERIMENTAL|Job rotation|The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.
62629188|NCT05065294|EXPERIMENTAL|Psilocybin therapy|Participants will receive one or two doses of psilocybin in a monitored setting approximately three weeks apart, with preparation sessions before and integration sessions after.
62629189|NCT04955613|ACTIVE_COMPARATOR|Standard care|"12 sessions in total: sessions 1: Meeting with a doctor and physical therapist. sessions 2-11:Mirror therapy (standard care) for a total of 10 sessions over a period of 5 weeks (15-20 minutes per session).~sessions 12: Meeting with a doctor and physical therapist."
62629190|NCT04955613|ACTIVE_COMPARATOR|MyMove/VR system|"sessions 1: Meeting with a doctor and physical therapist. sessions 2-11:MyMove devices and VR gear for a total of 10 sessions over a period of 5 weeks 15-20 minutes per session.~sessions 12: Meeting with a doctor and physical therapist."
62629191|NCT05119075|EXPERIMENTAL|Dopaminergic ON-drug state first, dopaminergic OFF-drug state second|"The following examinations and assessments will be performed at visit 3 on regular treatment in dopaminergic ON-drug state and at visit 4 in dopaminergic OFF-drug state (overnight withdrawal of all antiparkinsonian drugs):~* MRI assessment,~* Cognitive, neuropsychiatric and neurological assessment,~* Robot-induced hallucinations through sensorimotor stimulation."
62063647|NCT01979731|ACTIVE_COMPARATOR|Guidelines Ergonomics|Manual material handling Orientation posture Orientation furniture Orientation in general
62063648|NCT03601455|EXPERIMENTAL|Regimen A (radiation therapy and durvalumab)|Participants receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Participants also undergo EBRT for 5 fractions beginning on day 8 of course 1.
62063649|NCT03601455|EXPERIMENTAL|Regimen B (radiation therapy, durvalumab, tremelimumab)|Participants receive tremelimumab IV over 60 minutes on day 1 for up to 2 courses and durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression of unacceptable toxicity. Participants also receive undergo EBRT for 5 fractions beginning on day 8 of course 1.
62268872|NCT03165097|EXPERIMENTAL|ACT-709478|"40 subjects will receive multiple doses of ACT-709478 at the planned dose levels of 30, 60, 100, and 200 mg.~Each dose level will be investigated in a new cohort of 10 healthy male and female subjects (4 male subjects on active drug and 1 on placebo, 4 female subjects on active drug and 1 on placebo) undergoing one treatment period with a once daily dosing scheme."
62268873|NCT03165097|PLACEBO_COMPARATOR|Placebo|Matched placebo administered accordingly
62268874|NCT03165097|OTHER|Midazolam|4 mg taken by mouth on Day 1 of the corresponding cohort
62268875|NCT03165097|EXPERIMENTAL|ACT-709478 combined with Midazolam|On Day 22 and Day 30, midazolam (4 mg) and ACT-709478 (60 mg or 100 mg) to be co-administered.
62451563|NCT05250414|OTHER|Study Procedure|
62629192|NCT05119075|EXPERIMENTAL|Dopaminergic OFF-drug state first, dopaminergic ON-drug state second|"The following examinations and assessments will be performed at visit 3 in dopaminergic OFF-drug state (overnight withdrawal of all antiparkinsonian drugs) and at visit 4 on regular treatment in dopaminergic ON-drug state:~* MRI assessment,~* Cognitive, neuropsychiatric and neurological assessment,~* Robot-induced hallucinations through sensorimotor stimulation."
62629193|NCT01116622|EXPERIMENTAL|Daily oral erlotinib and bexarotene capusles|Open label dose-ranging trial
62629194|NCT04054817|EXPERIMENTAL|Single Arm|
62629195|NCT03479008|OTHER|Healthy volunteers (iterative device development)|This phase will recruit healthy volunteers who will be vibrated with the prototype device using various vibration frequencies to determine which frequency produces the optimal physiologic response. Physiologic responses will be determined with a number of devices capable of measuring such things as tissue oxygenation, oxygen consumption, and muscle activity. Volunteers will be randomized to receive alternating 5 minute episodes of various vibration frequencies.
62063650|NCT03748017|PLACEBO_COMPARATOR|Placebo-Control Supplement|12 participants will receive a placebo-control supplement per daily oral feeding.
62063651|NCT03748017|ACTIVE_COMPARATOR|Streptococcus-Containing Probiotic Supplement|12 participants will receive a powdered probiotic containing 7.77 billion colony-forming units (CFU) of L. acidophilus, 8.25 billion CFU of B. lactis, and 2 billion CFU of S. salivarius bacteriocin-like inhibitory substance (BLIS) K12 per daily oral feeding.
62063652|NCT05398146|EXPERIMENTAL|Pre-Dressing|Information about the children and their parents who agreed to participate in the study was recorded on the 'Information Form' 5 minutes before the dressing procedure by the researcher.
62268876|NCT01556607|ACTIVE_COMPARATOR|Experimental: MDT-637|
62629196|NCT06248684|OTHER|prevention group|patients receive standardized perioperative care using Standard Operating Procedures (SOPs) in accordance with the guidelines of the professional societies for the prevention of postoperative delirium.
62629197|NCT05454020|EXPERIMENTAL|A (XG004)|XG004 in two dose level (5% or 10%) will be applied to the targeted knee
62063653|NCT05398146|EXPERIMENTAL|During Dressing|The first dressing of all children included in the study after appendectomy was performed by the doctor in the clinic. No distraction method was applied to the children in the control group during dressing. The children in the LM group were dressed while listening to music. The children in the BS group continued to squeeze the ball during the dressing. The children in the MO group were asked to perform mathematical operations given by the nurse. While the dressing was in progress, the pulse and oxygen saturation levels were recorded in the information form by the nurse. At the last stage of dressing, the children were asked to mark the level of pain they experienced during dressing on the VAS, immediately after the sticking plaster was placed on the surgical area. Parents and nurses assessed the pain level of the child during dressing through the VAS.
62268877|NCT01556607|PLACEBO_COMPARATOR|Placebo|
62629198|NCT05454020|PLACEBO_COMPARATOR|B (Placebo)|Placebo in all cohorts will be applied to the targeted knee.
62268878|NCT02493595||Cancer|Patients attending One-stop Symptomatic Breast Care clinics with suspicion of a breast lesion in one or both breasts.
62629199|NCT01465230|EXPERIMENTAL|lenalidomide|Maintenance treatment with lenalidomide following induction treatment with bendamustine and rituximab.
62629200|NCT04346160||Patients with bilateral conjunctivitis|Hospitalized patient affected by COVID-19 disease with bilateral conjunctivitis defined as red eyes (macroscopic signs of conjunctival congestion)
62629201|NCT04346160||Patients without conjunctivitis|Hospitalized patient affected by COVID-19 disease without any signs of conjunctivitis defined as red eyes (macroscopic signs of conjunctival congestion)
62629202|NCT04346160||Healthy control group|group of healthy patients considered as controls
62629203|NCT01290952|EXPERIMENTAL|Off-pump bypass surgery|Off-pump coronary artery bypass graft (OPCAB) using mandatory a stabilization device and advisable, but not mandatory, a heart positioner
62629204|NCT01290952|ACTIVE_COMPARATOR|On-pump bypass surgery|coronary artery bypass graft with cardiopulmonary bypass (CPB/CAB)
62268879|NCT03630328|EXPERIMENTAL|Cogni.Q|800 mg per day (Two 200 mg capsules in the morning and two 200 mg capsules in the evening) for 21 days
62268880|NCT03630328|PLACEBO_COMPARATOR|Placebo|Two capsules in the morning and two capsules in the evening for 21 days
62268881|NCT00896207|EXPERIMENTAL|Arm I|Participants complete an overnight fast of ≥ 10 hours, eat a high-fat (approximately 50% of total caloric content of the meal) and high-calorie (approximately 800-1,000 calories) meal, and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.
62268882|NCT00896207|EXPERIMENTAL|Arm II|Participants complete an overnight fast of ≥ 10 hours and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.
62268883|NCT00896207|EXPERIMENTAL|Arm III|Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol® self-emulsifying solid dispersion capsule formulation.
62268884|NCT00896207|EXPERIMENTAL|Arm IV|Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol®/vitamin E TGPS self-emulsifying solid dispersion capsule formulation.
62268885|NCT00896207|EXPERIMENTAL|Arm V|Participants receive a single dose of oral Akt inhibitor SR13668 in a vitamin E TGPS self-emulsifying solid dispersion capsule formulation.
62268886|NCT00896207|EXPERIMENTAL|Arm VI|Participants receive a single dose of oral Akt inhibitor SR13668 in a Myrj 53 self-emulsifying solid dispersion capsule formulation.
62629205|NCT03730376|NO_INTERVENTION|Control|Participants in the control group will be given a hypothetical scenario about carpal tunnel syndrome and asked to make a treatment decision for that hypothetical patient.
62268887|NCT02750033||Basal Cell Carcinoma (BCC)|Adult patients undergoing Mohs surgery to remove basal cell carcinoma (BCC) will have surgical margins assessed with multimodal optical spectroscopy (MMS) device, as well as standard histopathology evaluation.
62268888|NCT02750033||Squamous Cell Carcinoma (SCC)|Adult patients undergoing Mohs surgery to remove squamous cell carcinoma (BCC) will have surgical margins assessed with multimodal optical spectroscopy (MMS) device, as well as standard histopathology evaluation.
62268889|NCT03889977|EXPERIMENTAL|Exercise|Resistance exercise 45 min following breakfast
62268890|NCT03889977|NO_INTERVENTION|Control|No exercise (resting) following breakfast
62268891|NCT03223545|EXPERIMENTAL|Mindfulness-based cognitive therapy delivered by telephone|
61904698|NCT05339867|EXPERIMENTAL|Mother Using PM3 Intervention|Participants in this group will be using the PM3 intervention. PM3 is a maternal mortality prevention and optimal reproductive health promotion mobile app created based on formative work with Black women to ultimately increase postpartum comorbidity self-management, promote timely provider notification of postpartum-related complications, and ensure access to social support and community resources.
61904699|NCT01146457|PLACEBO_COMPARATOR|Placebo|
61904700|NCT01146457|ACTIVE_COMPARATOR|Morphine 25|
61904701|NCT01146457|ACTIVE_COMPARATOR|Morphine 50|
61904702|NCT01146457|ACTIVE_COMPARATOR|Morphine 75|
61904703|NCT01146457|ACTIVE_COMPARATOR|Morphine 100|
62268892|NCT03223545|PLACEBO_COMPARATOR|Usual Care (UC)|
62268893|NCT04559958||non-dialysis CKD group|Participants with estimated glomerular ﬁltration rate (eGFR) \<60 mL/min/1.73 m2 more than three months and without regular dialysis will be enrolled in non-dialysis CKD group.
62268894|NCT04559958||ESRD group|Participants with eGFR ≤15 mL/min/1.73 m2 and underwent regular dialysis will be recruited in ESRD group.
62268895|NCT04559958||control group|Participants with eGFR ≧60 mL/min/1.73 m2 and without evidence of kidney damage such as albuminuria or abnormal findings on renal imaging will be enrolled in control group.
62629206|NCT03730376|EXPERIMENTAL|Intervention|Participants in the intervetion group will be given a hypothetical scenario about carpal tunnel syndrome as well as information about the cost of treatment and asked to make a treatment decision for that hypothetical patient.
62629207|NCT06431529|EXPERIMENTAL|tumor neoantigen specific T cell|Tumor neoantigen specific T cells will be infused intravenously into patients. The number of T cells will be more than 1.0E9.
62629208|NCT01080092|EXPERIMENTAL|breathing technique group|technique as a stress management technique, reinforced by biofeedback
62629209|NCT01080092|PLACEBO_COMPARATOR|no breathing technique|the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
62629210|NCT05459337|EXPERIMENTAL|Intervention|"This arm will receive the MuST AKT intervention, which is a multidisciplinary, tailored person-centered behavioural intervention designed to help and enable the potential kidney transplant recipients to achieve what is required to receive a living donor kidney transplantation."
62629211|NCT05459337|NO_INTERVENTION|Usual Care (control)|In the usual care (control) condition, participants will go through the current standard of care, which is a social worker assessment.
62629212|NCT02565602|OTHER|Ca-41 & Sr-84 (isotope tracers) & vit D|Dosages: 3.7 kBq (100 nCi) Ca-41, 5 mg of Sr-84 and 400IU of vitamin D (daily)
62629213|NCT01298167|ACTIVE_COMPARATOR|Cyanoacrylate Superior/Inferior|This arm contains data from only the Cyanoacrylate used on superior ½ of wounds \& inferior ½ of wounds in randomized patients to determine the impact of Cyanoacrylate tissue glue versus Fast Absorbing Gut suture.
62629214|NCT01298167|ACTIVE_COMPARATOR|Fast Absorbing Gut Suture Superior/Inferior|This arm contains data from only the Fast Absorbing Gut Suture used on superior ½ of wounds \& inferior ½ of wounds in randomized patients to determine the impact of Cyanoacrylate tissue glue versus Fast absorbing gut suture.
62629215|NCT04868578|EXPERIMENTAL|PPI|the patient take PPI caps
62268896|NCT02282644|EXPERIMENTAL|CellSearch|
62063654|NCT05398146|EXPERIMENTAL|Post-Dressing|When the dressing was over, the application of distraction methods was terminated. After the dressing, the child's pulse and oxygen saturation levels were recorded in the information form by the nurse.
62268897|NCT03607838|EXPERIMENTAL|SI-6603|
62268898|NCT03607838|SHAM_COMPARATOR|Sham injection|
62268899|NCT05968573|ACTIVE_COMPARATOR|Persuasive Health Communication Intervention delivered in video format with captions|A video with captions created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
62268900|NCT05968573|ACTIVE_COMPARATOR|Persuasive Health Communication Intervention delivered in video format without captions|A video with captions created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
62268901|NCT05968573|ACTIVE_COMPARATOR|Persuasive Health Communication Intervention delivered by Health Educator|Healthcare provider educator getting patients screened for HIV/HCV.
62629216|NCT04868578|PLACEBO_COMPARATOR|PPI placebo|The patient take PPI placebo
62629217|NCT02637310|EXPERIMENTAL|N02RS1 1200mg|Combination of Broussonetia spp and Lonicera spp
62629218|NCT02637310|PLACEBO_COMPARATOR|Placebo|sugar pill
62629219|NCT01947842|EXPERIMENTAL|Smartphone App|The pharmacist will download and configure the Dosecast smartphone application to remind the patient to take their medication in addition to pharmacist counseling on the importance of adherence.
62629220|NCT01947842|NO_INTERVENTION|Counseling Alone|This arm will receive only counseling from the pharmacist with no other intervention.
62629221|NCT06613152|EXPERIMENTAL|HS-IT201 monotherapy|Adoptive transfer of 5x10\^9-4x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
62629222|NCT04940663|OTHER|Ecological Momentary Assessment|EMA collected daily (4x/day) for two weeks
62629223|NCT04970121|EXPERIMENTAL|Duloxetine arm|Chemotherapy regimens consisting of taxanes will be used according to treatment specifications. Subjects require therapeutic intervention for painful peripheral neuropathy will receive duloxetine 20 mg (orally, once daily) as the starting dose for 1 cycle of 7 days; the current dose will be maintained for effective pain control (NRS ≤ 3 points) and increased by 20 mg at the next cycle assessment for ineffective pain control (NRS \> 3 points) up to a maximum dose of 60 mg (orally, once daily). Duloxetine administration will be maintained until the uncontrolled pain (under the condition of treatment with duloxetine at its maximum dose), intolerable toxicity, completed antineoplastic therapy or subject loss of visit, death, withdrawal of informed consent, or other conditions occur. The administration of duloxetine is up to a maximum of 12 weeks.
62629224|NCT00977613|OTHER|life style counseling|Treated stage 2 and 3 colorectal cancer patients were counseled to exercise at least to the equivalent of 18 metabolic hours per week and were assessed over 6 months.
62629225|NCT02496364|OTHER|Observation|Clinical data analysis
62629226|NCT04561661|ACTIVE_COMPARATOR|Conservative treatment|Fracture treated with closed reduction, custom made orthosis and early mobilization.
62629227|NCT04561661|ACTIVE_COMPARATOR|Surgery|Fractures treated with closed reduction, percutaneous pinning (k-wires) and plaster.
62629228|NCT03571685|EXPERIMENTAL|Sustainable Early Episode Clinic Model of Care|The model of care given in the sustainable early episode clinic study, provides early intense intervention, with an ongoing maintenance phase in an outpatient setting.
62629229|NCT02258217|EXPERIMENTAL|Single arm|Acthar 80 units subcutaneously for five consecutive days.
62063655|NCT02798211|ACTIVE_COMPARATOR|Group 1|secukinumab 300mg s.c. injection
62063656|NCT02798211|ACTIVE_COMPARATOR|Group 2|secukinumab 150 mg s.c. injection
62063657|NCT02798211|PLACEBO_COMPARATOR|Group 3|Placebo s.c. injection
62063658|NCT06235658|NO_INTERVENTION|Control|Participants in the control group will not receive any intervention but will be provided with printed or electronic versions of the American Heart Association's 'Life's Essential 8' at baseline, which includes information on how to improve and maintain cardiovascular health.
62063659|NCT06235658|EXPERIMENTAL|Online Yoga Intervention|Participants in the intervention group will attend two virtual 60-minute gentle yoga sessions per week for 12 weeks.
62063660|NCT02508532|EXPERIMENTAL|Part 1 Avapritinib (formerly BLU-285) 30 mg QD|"Part 1: Patients received a starting dose of 30 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
62063661|NCT02508532|EXPERIMENTAL|Part 1 Avapritinib (formerly BLU-285) 60 mg QD|"Part 1: Patients received a starting dose of 60 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
62063662|NCT02508532|EXPERIMENTAL|Part 1 Avapritinib (formerly BLU-285) 90 mg QD|"Part 1: Patients received a starting dose of 90 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
62063663|NCT02508532|EXPERIMENTAL|Part 1 Avapritinib (formerly BLU-285) 135 mg QD|"Part 1: Patients received a starting dose of 135 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
62063664|NCT02508532|EXPERIMENTAL|Part 1 Avapritinib (formerly BLU-285) 200 mg QD|"Part 1: Patients received a starting dose of 200 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation. ."
62063665|NCT02508532|EXPERIMENTAL|Part 1 Avapritinib (formerly BLU-285) 300 mg QD|"Part 1: Patients received a starting dose of 300 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation. Patients that received at least one dose of avapritinib were included in the Part 2 analysis."
62063666|NCT02508532|EXPERIMENTAL|Part 1 Avapritinib (formerly BLU-285) 400 mg QD|"Part 1: Patients received a starting dose of 400 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation.~Patients that received at least one dose of avapritinib were included in the Part 2 analysis."
62063667|NCT02508532|EXPERIMENTAL|Part 1 Avapritinib (formerly BLU-285) 600 mg QD|"Part 1: Patients received a starting dose of 600 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
62063668|NCT02508532|EXPERIMENTAL|Part 1 and Part 2 Avapritinib (formerly BLU-285) 300 mg or 400 mg QD|"Part 1 and Part 2: Patients enrolled in Part 1 and Part 2 at a starting dose of 300 or 400 mg QD were included in the Part1/Part 2 safety and efficacy analysis.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
62063669|NCT06624865||patient with indication for small-intestine neuroendocrine tumor surgery|The target population for this study is consecutive patients with small-intestine neuroendocrine tumor for whom surgery is indicated
62063670|NCT05239910|EXPERIMENTAL|Tenalisib 400 mg BID and CHOP|
62063671|NCT05239910|EXPERIMENTAL|Tenalisib 800 mg BID and CHOP|
62088104|NCT05280535|EXPERIMENTAL|Study Protocol|All participants will receive all laboratory protocol components in a within-person randomized order across two sequential laboratory sessions.
62268902|NCT03173092|EXPERIMENTAL|Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 milligram (mg), capsules, orally, once, on Days 1, 8 and 15 and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22 of a 28-day cycle for a maximum of 39 cycles until PD or unacceptable toxicity, whichever occurs first for up to 3 years.
62268903|NCT04362280|EXPERIMENTAL|ReCHARGE|intervention intensity is increased through: the creation of family groups, greater involvement of school staff, separate lessons for females, health screeners will be home and families are invited to a nutrition counseling session with a registered dietitian.
62268904|NCT04362280|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|PE class as usual which consisted of choice time.
62451564|NCT04516850||Patients tested for COVID-19|The nasopharyngeal swabs taken from patients tested for Covid-19 who resulted infected and non-infected will be analyzed to evaluate the expression of receptors and activating proteases mediating SARS-CoV-2.
62629230|NCT01570257|NO_INTERVENTION|control group|These patients receive a shunt with the valve preset and fixed at a Performance level of 1.0, corresponding to an opening/closing pressure of 35-55 mm H2O.
62451565|NCT04516850||Patients with mild-moderate and severe SARS-CoV-2 infection|Formalin-fixed paraffin will be analysed to determine the association between polymorphism of the HSD3B1 gene and outcomes in COVID-19 affected patients
62629231|NCT01570257|EXPERIMENTAL|Intervention group|These patients receive a shunt with the valve preset at a Performance level (PL) of 2.5, corresponding to an opening/closing pressure of 135-155 mm H2O. The PL is allowed to be lowered until clinical improvement occurs.
62629232|NCT05281757||Ennovate® Complex|All patients who are treated with the Ennovate® Complex system in accordance with indications given in the instructions for use (IFU)
62629233|NCT00848757|EXPERIMENTAL|Intensive Life-Style Counseling|"Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the Diabetes Prevention Program (DPP) Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population."
62629234|NCT00848757|NO_INTERVENTION|Usual Care Control|Women with pre-diabetes randomized to usual care will be offered 30 minute appointments with a medical provider to review their diagnosis, risk for diabetes, and stress the importance of lifestyle changes to prevent diabetes, including weight loss and exercise and setting individual goals for these. Usual care participants will be encouraged to achieve goals equivalent to the ILI group: to reduce their weight by 7%, and to increase their physical activity to approximately 150 minutes moderate intensity exercise per week. They will be offered a consultation with an FHCHC nutritionist to achieve dietary/weight loss objectives. Participants are offered printed educational materials which are language and literacy-appropriate.
62629235|NCT05534243|ACTIVE_COMPARATOR|Before group|Mechanically ventilated emergency department patients receiving standard neuromuscular blockers prior to an educational initiative on the importance of ED-based targeted shorter acting neuromuscular blocker.
62629236|NCT05534243|EXPERIMENTAL|After group|Mechanically ventilated emergency department patients receiving neuromuscular blockers after an educational initiative aimed at improving use of shorter acting neuromuscular blocker practices in the ED.
62629237|NCT01710397|NO_INTERVENTION|Standard group, non-pregnant adults|Comparison group (prospective enrollment)
62629238|NCT01710397|NO_INTERVENTION|Standard group, pregnant women|Comparison group (retrospective record review)
62629239|NCT01710397|EXPERIMENTAL|Rapid group, non-pregnant adults|Rapid ART initiation
62629240|NCT01710397|EXPERIMENTAL|Rapid group, pregnant women|Rapid ART initiation
62629241|NCT03074604|EXPERIMENTAL|aortic no-touch OPCABG|aortic no-touch OPCABG
62629242|NCT03074604|EXPERIMENTAL|OPCABG with partial clamp applying carbon dioxide|OPCABG with partial clamp applying carbon dioxide
62451566|NCT05606393|EXPERIMENTAL|traditional speech therapy and additional virtual reality training group|Each participant received 1-hour traditional speech therapy(ST) and additional 30-minute VR training immediately after each session of traditional ST. All participants received 3 sessions of treatment every week for 3 weeks.
62451567|NCT05606393|ACTIVE_COMPARATOR|traditional speech therapy group|Each participant received 1-hour traditional speech therapy(ST) only for each session. All participants received 3 sessions of treatment every week for 3 weeks.
62451568|NCT04586621|EXPERIMENTAL|Atoldys/ Lexilens - SHAM|
62451569|NCT04586621|EXPERIMENTAL|SHAM- Atoldys/ Lexilens|
62451570|NCT00933751||Patients before emergent major abdominal surgery|
62451571|NCT01934296|EXPERIMENTAL|chronic brain recording|This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.
62629243|NCT03074604|ACTIVE_COMPARATOR|OPCABG with partial clamp|OPCABG with partial clamp
62629244|NCT00136214||Interferon Treated Group|Group treated with PEG-Interferon and ribavirin and undergoing MR brain and neuropsychiatric tests
62629245|NCT00136214||Non-treated cohort control|Group undergoing MR brain and neuropsychiatric tests
62629246|NCT00935077|EXPERIMENTAL|24 Month PPCM BP|A 24 month long physician/pharmacist collaborative intervention is implemented to manage hypertension
62629247|NCT00935077|EXPERIMENTAL|9 Month PPCM BP|A 9 month long physician/pharmacist collaborative intervention is implemented to manage hypertension
62629248|NCT00935077|SHAM_COMPARATOR|PPCM Asthma|A 9 month long physician/pharmacist collaborative intervention is implemented to manage asthma
62629249|NCT00935077|NO_INTERVENTION|BP Control Arm|No PPCM intervention
62629250|NCT01073163|EXPERIMENTAL|Bendamustine with Rituximab|Participants were administered bendamustine intravenous (IV) infusion at 90 mg/m\^2 on Days 1 and 2 of each 28-day cycle, and rituximab IV infusion at 375 mg/m\^2 on Day 1 of each 28-day cycle.
62629251|NCT06553404|ACTIVE_COMPARATOR|Single vision|Single vision glasses
62629252|NCT06553404|EXPERIMENTAL|myoslow|The Myoslow spectacle lens is based on the Defocus Incorporated Multiple Segments (DIMS) mechanism of action. This lens provides the same optical image as the Defocusing Incorporated Soft Contact Lens (DISC) without the drawbacks inherent with contact lens fitting.
62629253|NCT05204290|EXPERIMENTAL|Stereotactic Body Radiotherapy and Pembrolizumab Treatment|MRI scans of your spine (before treatment, 2 months after treatment, and 6 months after treatment) and immunotherapy with Pembrolizumab
62629254|NCT03293394|EXPERIMENTAL|Real tDCS|10 days anodal bilateral motor cortex and cathodal spinal tDCS
62629255|NCT03293394|PLACEBO_COMPARATOR|Sham tDCS|10 days sham bilateral motor cortex and sham spinal tDCS
62629256|NCT04094779|ACTIVE_COMPARATOR|Usual relational care|Isolate the patient from the group of other patients in order to propose to him a a relationship dual with the caregiver to the aim to calm the agitation
62629257|NCT04094779|EXPERIMENTAL|"Flash activity breath of fresh air"|Isolate the patient from the group of other patients in order to propose to him in a relationship dual with the caregiver a physical activity outside the service that promotes relaxation by focusing his attention to the environment during 15 minutes
62629258|NCT00848029|EXPERIMENTAL|1|
62629259|NCT01737411|ACTIVE_COMPARATOR|solifenacin|10 mg solifenacin per day for three months
62629260|NCT01737411|EXPERIMENTAL|cesa/vasa|repair of USL
62629261|NCT00696007|EXPERIMENTAL|1|A neoadjuvant chemotherapy (gemcitabine and cisplatin) regimen administered before surgery-nephroureterectomy for upper tract TCC
62629262|NCT00696007|OTHER|2|A retrospective cohort group (approximately 60 subjects) identified from an institutional cancer registry who have undergone a nephroureterectomy alone over the past five years
62629263|NCT00223665|EXPERIMENTAL|Intermittent Androgen Suppression (IAS)|"Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.~Flutamide dosed as 250mg orally three times a day for 14 days prior to the initiation of Leuprolide Acetate.~Leuprolide Acetate dosed as 7.5mg intramuscular (IM) injections once per month for a total of 9 months."
62629264|NCT01583790||no group|laparoscopic sleeve gastrectomy
62629265|NCT01263067|EXPERIMENTAL|Lifespan Integration Therapy (LI)|
62629266|NCT01263067|ACTIVE_COMPARATOR|Waitlist Control- Lifespan Integration|
62629267|NCT03238794|ACTIVE_COMPARATOR|Roux-En-Y Gastric Bypass (RYGB)|Participants will have elected to have RYGB surgery per standard of care.
62629268|NCT03238794|ACTIVE_COMPARATOR|Low-calorie Diet|Participants will have a low-calorie diet prescribed by a registered dietitian.
62629269|NCT00320788|EXPERIMENTAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q4|
62629270|NCT00320788|EXPERIMENTAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q12|
62629271|NCT00320788|EXPERIMENTAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q4|
62629272|NCT00320788|EXPERIMENTAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q12|
62629273|NCT00320788|EXPERIMENTAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 4.0mg q12|
62629274|NCT04591756|ACTIVE_COMPARATOR|N95 Filtering Facepiece Respirator|Subjects will wear the model of filtering facepiece respirator that they are currently approved to wear
62451572|NCT03085173|EXPERIMENTAL|EGFRt/19-28z/4-1BBL CAR T cells|Following enrollment, patients will undergo leukapheresis of peripheral blood for further T cell enrichment, activation and genetic modification using a retroviral vector encoding a CD19targeted CAR, the co-stimulatory ligand 4-1BBL and the EGFRt safety system (EGFRt/19-28z/4-1BBL). These T cells will be expanded and after the appropriate number of cells is generated, the modified T cells may be infused fresh or frozen for later use according to standard operation procedures. Modified T cell infusions will be administered 2-7 days following completion of the treating investigator's choice of conditioning chemotherapy. Serial sampling of blood and bone marrow will be performed following treatment to assess toxicity, therapeutic effects, and survival of the genetically modified T cells.
62451573|NCT05997056|EXPERIMENTAL|neuroendocrine tumors|Patients with well-differentiated neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas.
62451574|NCT02490488|EXPERIMENTAL|Masitinib & gemcitabine|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus gemcitabine 1000 mg/m² administered by 30 minutes infusion once a week during 3 weeks followed by 1 week without infusion.
62451575|NCT02490488|PLACEBO_COMPARATOR|Placebo & gemcitabine|Participants receive placebo (6 mg/kg/day), given orally twice daily, plus gemcitabine 1000 mg/m² administered by 30 minutes infusion once a week during 3 weeks followed by 1 week without infusion.
62451576|NCT04801966|EXPERIMENTAL|Treatment|"All participants will have an individualised treatment plan. The possible treatments that can be prescribed are as follows, they may be given as a single agent or in combination~* Trametinib 2 mg/day~* Cobimetinib 60 mg/day, on day 1-21 of each 28 day cycle (21 days on, 7 days off)~* Binimetinib 45 mg/ twice a day~* Alpelisib 300 mg/day~* Vemurafenib 960 mg twice a day~* Dabrafenib 150 mg twice a day~* Encorafenib 450 mg/day~* Palbociclib 125 mg/day, on day 1-21 of each 28 day cycle (21 days on, 7 days off)~* Ribociclib 600 mg/day, on day 1-21 of each 28 day cycle (21 days on, 7 days off~* Abemaciclib 150 mg twice a day~* Olaparib 300 mg twice a day~* Talazoparib 1 mg/day~* Nivolumab 240 mg IV once every two weeks~* Atezolizumab 1200 mg IV on day 1 of a 21 day cycle~* Pembrolizumab 200 mg IV on day 1 of a 21 day cycle"
62451577|NCT03473314|EXPERIMENTAL|Nitric Oxide gas at 160ppm|Nitric Oxide 160ppm for 50-80 minutes two -three times a day for 365 days
62451578|NCT04323670|OTHER|Selectra 3D|Guiding catheter to position the brady lead into a untypical heart position
62451579|NCT03415906|EXPERIMENTAL|sacubitril+valsartan|Combined angiotensin receptor and neprilysin inhibition
62451580|NCT03415906|ACTIVE_COMPARATOR|valsartan|Angiotensin receptor inhibition alone
62451581|NCT01788956||ICU Patients|80 subjects (male and female)
62451582|NCT05528016|ACTIVE_COMPARATOR|Skin-Only Blepharoplasty|Only the skin excision was performed for upper eyelid dermatochalasis.
62451583|NCT05528016|ACTIVE_COMPARATOR|Skin+Muscle Blepharoplasty|Skin plus muscle excision was performed for upper eyelid dermatochalasis.
62451584|NCT00669864|EXPERIMENTAL|BIAsp 30-30|Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 1000-2000mg, up to three times daily
62451585|NCT03876613|ACTIVE_COMPARATOR|Turkish music group|Rast makam
62451586|NCT03876613|ACTIVE_COMPARATOR|classical western music|Vivaldi
62451587|NCT03876613|ACTIVE_COMPARATOR|soft rock music|Elvis presley
62451588|NCT03876613|PLACEBO_COMPARATOR|control group|No music
62451589|NCT01623128|EXPERIMENTAL|Breastfeeding video|Participants randomized to this arm view the intervention video - Injoy Videos Better Breastfeeding video.
62268905|NCT03339661|EXPERIMENTAL|Group 1_ No proph treatment|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated will depend on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if γδ T cell expansion occurs, no secondary prophylaxis treatment will be introduce, and curative treatment stops.
62629275|NCT04591756|ACTIVE_COMPARATOR|Elastomeric Half-Mask Respirator with P100 filters|Subjects will wear the model of elastomeric half mask respirator that they are currently approved to wear.
62629276|NCT04949282||Lutathera|
62629277|NCT02208921||T2DM patients with Chronic Kidney Disease|T2DM patients with Chronic Kidney Disease
62629278|NCT01419535|EXPERIMENTAL|Mifepristone, then Placebo|Participants first received Mifepristone 50mg tablet every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days.
62268906|NCT03339661|EXPERIMENTAL|Group 2A_Proph treatment and γδ T cells expansion|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated depends on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if no γδ T cell expansion will occur, a secondary prophylaxis will be initiated during 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
62268907|NCT03339661|EXPERIMENTAL|Group 2B_Proph treatment and no γδ T cells expansion|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated depends on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if no γδ T cell expansion will occur, a secondary prophylaxis will be initiated during 3 months maximum. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
62629279|NCT01419535|EXPERIMENTAL|Placebo, then Mifepristone|Participants first received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Mifepristone 50 mg tablet every six hours for nine days.
62629280|NCT04183725|EXPERIMENTAL|Experimental group|Reduning injection +Oseltamivir phosphate granule simulants
62268908|NCT01765101|EXPERIMENTAL|customized insoles|"customized full-length lateral wedged shoe insoles~1 month and 3 months study the immediate, short-term and intermediate-term therapeutic effects"
62629281|NCT04183725|ACTIVE_COMPARATOR|Control group|Oseltamivir phosphate granules+ Reduning injection simulants
62629282|NCT04811859|EXPERIMENTAL|Study Group|In the study group, Inspiratory Muscle Training will be applied with Threshold IMT device (Respironics, USA) at 40% of the maximum inspiratory pressure value for eight weeks, every day of the week, twice a day for 15 minutes. The patients will come for a control once a week, the maximum inspiratory pressure will be measured again and the new training intensity will be determined at 40% of the new maximum inspiratory pressure.
62629283|NCT04811859|SHAM_COMPARATOR|Control group|In the control group, Inspiratory Muscle Training will be applied with Threshold IMT device (Respironics, USA) at 10% of the maximum inspiratory pressure value for eight weeks, every day of the week, twice a day for 15 minutes. The exercise workload will not be increased and will remain the same. It will run at 10% of maximum inspiratory pressure for eight weeks.
62629284|NCT03076996|EXPERIMENTAL|Online support group|Participants will be enrolled to receive six sessions from the Positive Connections curriculum through the m/eHealth intervention that will use Facebook to conduct online structured support groups.
62629285|NCT04478162|EXPERIMENTAL|Experimental|All phases of the FICare model have been implemented. Parents in the intervention group were included in a one-week training program within the scope of the Family Integrated Care model. A maximum of four couples attended the training in each session. A training program was also organized at weekend for those who could not attend it during the week. Training subjects consisted of the importance of breast milk, breastfeeding positions, hygienic care practices (eyes, nose, mouth, ears, skin, diaper change), bathing, nail clipping, kangaroo care, drug administration, first and emergency support, safe sleep, doctor check-up times, and vaccine follow-ups. Care practices were first shown on the model infant, and parents were asked to practice on the model. When the clinical stabilization of their infants was achieved, parents were asked to attend at least three caregiving sessions and stay in the hospital for an average of six to eight hours.
62629286|NCT04478162|NO_INTERVENTION|Control Groups|Individuals received usual care provided by nurses from the time the premature infant was admitted to the NICU until discharge. The usual care process is carried on between the nurse and the mother. Mothers are allowed to perform limited care practices (bottom cleaning, breastfeeding) that the nurse considers appropriate. Mothers of babies who are planned to be discharged start staying in the hospital approximately 2 days before. Fathers are not included in the care and process. They are not allowed to stay in the hospital. Fathers are only informed and not included in the care.
62629287|NCT05867134|EXPERIMENTAL|Activity as tolerated|"Instruction will be a treatment group return to activity as tolerated/comfortable and stop activity if pain present."
62629288|NCT05867134|NO_INTERVENTION|Standard Lifting Restrictions|"Instructions will be no lifting greater than 20lbs for 6 weeks for open surgery, 2 weeks for minimally invasive surgery."
62629289|NCT05892250|ACTIVE_COMPARATOR|Control group|Intervention will consist of a conventional physical therapy treatment program that includes manual therapy techniques and exercise
62629290|NCT05892250|EXPERIMENTAL|Experimental group|Intervention will consist of a conventional physical therapy treatment program that includes manual therapy techniques and exercise plus Dynamic Humeral Centering exercises
62629291|NCT03285945||PET3|Post-therapeutic FDG PET/CT performed after 3 days of steroid treatment
62629292|NCT03285945||PET10|Post-therapeutic FDG PET/CT performed after 10 days of steroid treatment
62063672|NCT02336919|EXPERIMENTAL|Txt2Prevent|The treatment group will receive all the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the Txt2Prevent text-messaging program. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living texts. There will be two streams, one for current/recent smokers and one for non-smokers. Texts will be sent out every 1-3 days for 60 days. All participants in the same stream will receive the same texts in the same order.
62629293|NCT04068831|EXPERIMENTAL|Talazoparib and Avelumab (VHL-deficiency) (Closed to Accrual)|All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles.
62629294|NCT04068831|EXPERIMENTAL|Talazoparib and Avelumab (FH- or SDH-deficiency)|All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles.
62629295|NCT04293497|EXPERIMENTAL|Pancreatic Cancer|This arm includes patients with pancreatic cancer. Cytology specimens will be obtained with endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic cancer. Cytology staining will be performed in the cytology specimens.
62629296|NCT03135509|EXPERIMENTAL|Treatment A (Reference)- CC-220 gelatin capsules|A single dose of 0.6 mg CC-220, administered as two 0.3-mg formulated CC-220 gelatin capsules.
62629297|NCT03135509|EXPERIMENTAL|Treatment B (Test)- CC-220 HPMC capsule|A single dose of 0.6 mg CC-220, administered as one 0.6-mg formulated CC-220 hydroxypropyl methylcellulose (HPMC) capsule.
62629298|NCT00293852|NO_INTERVENTION|Usual Care|
62629299|NCT00293852|EXPERIMENTAL|Collaborative Care|
62629300|NCT02758288||New Protocol to treat BK viremia or BKVAN|Adult kidney recipients who are determined to have BK viremia with a BK PCR viral load over 500 copy post-transplant treated with a new treatment protocol, prospective data collection approach
62268909|NCT01765101|PLACEBO_COMPARATOR|ready made insoles|"ready-made full-length lateral wedged shoe insoles at 1 and 3 months~study the immediate, short-term and intermediate-term therapeutic effects"
62063673|NCT02336919|NO_INTERVENTION|Usual Care|The usual care group will receive all standard discharge treatment, instructions and information for patients with acute coronary syndrome, but no text-messaging program. Nurses typically go over important information with patients before they leave as well as give them printed materials.
62451590|NCT01623128|PLACEBO_COMPARATOR|Sham video|Participants randomized to this arm view the sham video Injoy Videos Your Healthy Pregnancy: Prenatal Nutrition and Exercise video.
62063674|NCT02473861|EXPERIMENTAL|Immediate exercise arm|The length of the intervention for the immediate exercise group will be determined by treatment protocol and could range from 8 to 13 weeks. The intervention can begin up to one week before the first treatment and will continue until 2 weeks after the final taxane-containing treatment. The intervention will consist of thrice weekly supervised aerobic and resistance exercise training.
62451591|NCT03236857|EXPERIMENTAL|Venetoclax with or without chemotherapy|Venetoclax administered orally once daily (QD) with various doses and dosing regimens with or without chemotherapy at the discretion of the investigator. Allowed chemotherapy regimens as outlined in the study protocol.
62451592|NCT01766921|EXPERIMENTAL|aH5N1c - High dose|
62451593|NCT01766921|EXPERIMENTAL|aH5N1c - Low dose|
62451594|NCT04560881|EXPERIMENTAL|Inactivated SARS-CoV-2 vaccine, manufactured by BIBP|Intramuscular injection
62451595|NCT04560881|PLACEBO_COMPARATOR|Placeboof Inactivated SARS-CoV-2 vaccine, manufactured by BIBP|Intramuscular injection
62451596|NCT01659567||Chronic Hepatitis C|Participants with chronic hepatitis C, treated with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) according to the current standard of care and in line with current summaries of product characteristics/local labelling, will be observed for up to 96 weeks.
62451597|NCT00408902|EXPERIMENTAL|TandutinibTreatment|Patients receive oral tandutinib 500 mg twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62451598|NCT00442806|PLACEBO_COMPARATOR|Placebo|Placebo is injected
62451599|NCT00442806|EXPERIMENTAL|Treatment|ADRC's are injected
62451600|NCT02740608|OTHER|Liver transplantation|All Participants will receive liver transplantation using the OrganOx metra device
62451601|NCT03146091|EXPERIMENTAL|Outpatient nonantibiotic treatment|
62451602|NCT03146091|ACTIVE_COMPARATOR|Outpatient antibiotic treatment|
62451603|NCT04646057|EXPERIMENTAL|Treatment Arm|
62451604|NCT04646057|NO_INTERVENTION|Historical Control Arm|
62451605|NCT00212095|EXPERIMENTAL|docetaxel and ketoconazole|
62451606|NCT03166982|EXPERIMENTAL|laparoscopy|the tubo-ovarian abscess should be drained by interventional radiology, preferably by transvaginal or laparoscopic
62451607|NCT03166982|EXPERIMENTAL|ultrasound-guided puncture|The transvaginal echo guided puncture to replace the first laparoscopy because of its less invasive nature, this is a simple act, fast, possible under mild sedation, the cost is still lower than laparoscopy
62451608|NCT01153984|EXPERIMENTAL|Erlotinib|Participants will receive 150 milligrams (mg) erlotinib orally daily until disease progression, unacceptable toxicity, withdrawal due to any reason or death.
62451609|NCT05993338|EXPERIMENTAL|assess pulmonary hemodynamics in COVID-19 survivors|COVID-19 survivors from a moderate/severe COVID-19 pulmonary infection according to WHO COVID-19 clinical severity classification, ≥ 18 years, with residual symptoms and signs suggestive of pulmonary hypertension and not explained by other condition
62063675|NCT02473861|EXPERIMENTAL|delayed exercise arm|The delayed exercise group will begin an exercise intervention two weeks after completion of their last taxane-containing chemotherapy treatment that will last the length of their taxane chemotherapy plus two weeks. If participants in the delayed exercise group have a surgery planned during the intervention time that will require \>1 week off from exercise, the exercise intervention will be delayed until after the surgery. The intervention will consist of thrice weekly supervised aerobic and resistance exercise training.
62063676|NCT00509418|EXPERIMENTAL|A|Viusid, a nutritional supplement, in combination with controlled diet and exercise
62063677|NCT00509418|ACTIVE_COMPARATOR|B|Controlled diet and exercise
62063678|NCT02401373|EXPERIMENTAL|low dose|30 participants will be firstly recruited and assigned to receive the low dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).
62063679|NCT02401373|EXPERIMENTAL|High dose|After the safety of the low dose vaccination is confirmed, another 30 participants will be recruited and assigned to receive the high dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).
62063680|NCT06617104||schizophrenia|According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), individuals who meet the criteria for a diagnosis of schizophrenia.
62063681|NCT06617104||healthy individuals|No history of chronic illness in the past and no acute symptoms within the past month.
62063682|NCT01199159|ACTIVE_COMPARATOR|preoperative misoprostol|400mcg misoprostol given preoperatively
62063683|NCT01199159|PLACEBO_COMPARATOR|Placebo|
62063684|NCT05453747|EXPERIMENTAL|Ankle injury basketball player|Athletes included in the study; They were divided into two groups as those with and without ankle injury . The same exercise program was applied to the same group in both groups.
62063685|NCT05453747|ACTIVE_COMPARATOR|Basketball player|The same exercise program was applied to the same group in both groups.
62063686|NCT05029024|ACTIVE_COMPARATOR|Intervention group|Patients allocated to the intervention group received standard care plus a guided 30-minute mindful breathing session which consisted of four breathing exercises done consecutively in one-to-one manner. The four exercises included identifying the in-and out-breath, following the entire length of the breath, bringing the mind back to the body and relaxing the whole body. Each exercise lasted 7.5 minutes. Guidance was given by one of the two research assistants, who were medical doctors. They were trained by one of the co-investigators, who was a palliative care physician, certified in mindfulness training.
62063687|NCT05029024|PLACEBO_COMPARATOR|Control group|Patients in the control group received standard care alone.
62063688|NCT06302959||healthy controls|"For healthy controls, participation in this study lasts only one day. The following samples will be collected at three time-points on the same day (4 am, 12 pm, 8 pm):~Blood sampling: 80 mL citrated whole blood and 10 mL serum will be collected. Collection of spontaneous sputum: at least 5 ml of sputum are collected. Saliva collection: Saliva is also collected at all three time-points."
62063689|NCT06302959||mild-to-moderate asthma|"For patients with mild-to-moderate asthma, participation in this study lasts only one day.~The following samples will be collected at three time-points on the same day (4 am, 12 pm, 8 pm):~Blood sampling: 80 mL citrated whole blood and 10 mL serum will be collected. Collection of spontaneous sputum: at least 5 ml of sputum are collected. Saliva collection: Saliva is also collected at all three time-points."
62063690|NCT06302959||severe eosinophilic asthma|"Patients with severe eosinophilic asthma, will be monitored (i) before mepolizumab treatment, (ii) after 4 months of mepolizumab treatment, (iii) once they reach remission under mepolizumab treatment. Mepolizumab is already approved for the treatment of severe eosinophilic asthma and is not administered for study purposes but as a standard treatment.~On the day of participation, the following samples will be collected at three time-points (4 am, 12 pm, 8 pm):~Blood sampling: 80 mL citrated whole blood and 10 mL serum will be collected. Collection of spontaneous sputum: at least 5 ml of sputum are collected. Saliva collection: Saliva is also collected at all three time-points."
62451610|NCT04439656||Absence Seizures|Participants with absence seizures will have their eye movements compared to the EEG recording.
62063691|NCT04704453|EXPERIMENTAL|Experimental arm (A): capsaicin patch|
62063692|NCT04704453|OTHER|Standard arm (B): amitriptyline|
62063693|NCT05003388|EXPERIMENTAL|Treatment Group|Single intravenous infusion of 100 million cells
62063694|NCT04665622|OTHER|Fronto-temporal Dementia|10 subjects
62063695|NCT04665622|OTHER|Alzheimer's Dementia|20 subjects
62063696|NCT04665622|OTHER|Parkinson's Disease|20 subjects
62063697|NCT04665622|OTHER|Healthy volunteers|20 subjects
62063698|NCT05910086||patients having an accidental dural puncture during the installation of an epidural anesthesia|"patients having an accidental dural puncture during the installation of an epidural anesthesia will be included.~Analysis datas of medical record."
62063699|NCT02460263|PLACEBO_COMPARATOR|In-Center|Staff administered treatments in-center using the device
62063700|NCT02460263|EXPERIMENTAL|In-Home|Patient administered treatments in-home using the device
62063701|NCT04998162|EXPERIMENTAL|SVF injection|All patients with ankle osteoarthritis will be treated with a single injection of SVF, obtained from the patient's abdominal adipose tissue. All patients will be examined with a baseline clinical visit and will be followed-up with clinical evaluation at 1, 3, 6, 12 and 24 months.
62629301|NCT02758288||Standard Protocol to treat BK viremia or BKVAN|Adult kidney recipients who are determined to have BK viremia with a BK PCR viral load over 500 copy post-transplant treated with a traditional standard of care protocol, retrospective data collection approach
62063702|NCT02415777|EXPERIMENTAL|udca003|udca003
62268910|NCT04795557|EXPERIMENTAL|ADAPT232|"50 patients take ADAPT-232® oral solution in the daily dose of 60 ml ( 30 ml two times daily) for 14 days.~One mL of oral solution contains:~Schisandra chin. fructus native extract 10,0 mg DERnative 2,0-5,0:1 Eleutherococcus sent. radix native extract 2,6 mg DERnative 17-30:1 Rhodiola rosea radix native extract. 3,0 mg DERnative 2,0-5,0:1 Inactive excipients,"
62268911|NCT04795557|PLACEBO_COMPARATOR|Placebo|50 patients take Placebo oral solution in the daily dose of 60 ml ( 30 ml two times daily) for 14 days.
62451611|NCT05153122|EXPERIMENTAL|Investigational SenseGuard Device|Patients undergo SG monitoring at least twice daily before and after receiving treatment.
62629302|NCT05785039|EXPERIMENTAL|Study treatment|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62629303|NCT04498702|EXPERIMENTAL|APL-1202 treatment|
62629304|NCT03604848|EXPERIMENTAL|NGS-guided regimen: Regimen A|Regimen A: 9-month regimen for simple MDR-TB patients 4 months of pyrazinamide, amikacin ,moxifloxacin, prothionamide, and cycloserine , followed by 5months of pyrazinamide,moxifloxacin, prothionamide, and cycloserine
62629305|NCT03604848|EXPERIMENTAL|NGS-guided regimen: Regimen B|Regimen B: 12-month simple MDR-TB regimen for simple MDR-TB patients 6 months of pyrazinamide, amikacin ,moxifloxacin, prothionamide, and cycloserine , followed by 6 months of pyrazinamide,moxifloxacin, prothionamide, and cycloserine
62629306|NCT03604848|EXPERIMENTAL|NGS-guided regimen: Regimen C|"Regimen C : for complicated MDR-TB patients In regimen C, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol based on the drug susceptibility test results. The duration of treatment in the complicated MDR-TB group is consistent with control group, with 6 months of intensive phase and 18 months of consolidation phase."
62063703|NCT02415777|PLACEBO_COMPARATOR|placebo|placebo of udca003
62063704|NCT01583244||Patients with active rheumatoid arthritis|Patients aged 6 years and over who have moderate-to-severe active rheumatoid arthritis
62268912|NCT05275907|ACTIVE_COMPARATOR|A first, then B|6 weeks of drug A followed by a 2-week washout period completed with 6 weeks of drug B
62268913|NCT05275907|ACTIVE_COMPARATOR|B first, then A|6 weeks of drug B followed by a 2-week washout period completed with 6 weeks of drug A
62063705|NCT01215357|EXPERIMENTAL|Ecopipam|Ecopipam is a selective antagonist of one the classes of dopamine receptor.
62268914|NCT01871974|EXPERIMENTAL|low-dose group FK949E|oral
62268915|NCT01871974|EXPERIMENTAL|high-dose group FK949E|oral
62268916|NCT02573363|EXPERIMENTAL|selinexor, cytarabine, and mitoxantrone|"INDUCTION CHEMOTHERAPY: Patients receive high-dose cytarabine and mitoxantrone hydrochloride per standard of care on days 1 and 5, and selinexor PO on days 2, 4, 9, and 11.~CONSOLIDATION CHEMOTHERAPY: Patients receive high-dose cytarabine per standard of care on days 1, 3, and 5, and selinexor PO on days 2, 4, 9, and 11. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CHEMOTHERAPY: Patients achieving at least stable disease after consolidation chemotherapy may receive selinexor PO on days 1, 8, 15, and 22 at the discretion of principal investigator."
62451612|NCT02523456|EXPERIMENTAL|Introduce EWS and Training on EWS|The group of patients who admitted to a ward where the staff has trained on EWS and EWS has been introduced.
62451613|NCT02523456|NO_INTERVENTION|EWS not introduced|The group of patients who admitted to a ward where the staff has no special training on EWS and EWS has not been introduced.
62629307|NCT03604848|ACTIVE_COMPARATOR|WHO-approved MDR-TB regimen|6 months of pyrazinamide, amikacin,moxifloxacin, prothionamide , and cycloserine , followed by 18 months of pyrazinamide, moxifloxacin, prothionamide , and cycloserine
62063706|NCT01215357|PLACEBO_COMPARATOR|Placebo|Placebo given first week of the study.
62063707|NCT01433484|ACTIVE_COMPARATOR|Maintenance of Weight Loss--Control|The control arm will receive bi-monthly telephone contacts during the one-year maintenance phase.
62063708|NCT01433484|EXPERIMENTAL|Maintenance of Weight Loss--Experimental|The experimental arm will receive monthly telephone contacts for one year during the maintenance phase.
62063709|NCT04890795|EXPERIMENTAL|AL8326|Subject will received AL8326 once daily for 28-days cycle until intolerable toxicity or disease progression or death or voluntary withdrawal the end of this study.During treatment, subjects will be evaluated for anti-tumor efficacy and corresponding safety examinations every 2 cycles, and tumor disease status will be according to RECIST 1.1.
62063710|NCT01342692|ACTIVE_COMPARATOR|Azacitidine alone|
62063711|NCT01342692|EXPERIMENTAL|Azacitidine +Valproic acid|
62063712|NCT01342692|EXPERIMENTAL|Azacitidine +Lenalidomide|
62063713|NCT01342692|EXPERIMENTAL|Azacitidine + Idarubicine|
62063714|NCT00577538||1|
62063715|NCT00577538||2|
62063716|NCT04041050|EXPERIMENTAL|Part 1: Navitoclax Monotherapy|Participants will receive various doses of navitoclax once daily (QD).
62451614|NCT02873988||patients with COPD|patients with COPD
62451615|NCT02873988||patients without COPD|patients without COPD
62629308|NCT06039072||Subjects in the withdrawal group|Subjects received a combination of ACEI/ARB analogues, beta-blockers, MRA analogues, and diuretics during the standardized treatment phase, and after their cardiac function was restored, in order to avoid adverse effects on patients' cardiac function due to sudden withdrawal of drugs, the drugs were withdrawn according to a program to gradually stop the drug
62629309|NCT06039072||Subjects in the continuing medication group|Subjects received a combination of ACEI/ARB analogues, beta-blockers, MRA analogues, and diuretics during the standardized treatment phase, and were continued on the original regimen after their cardiac function recovered
62629310|NCT06234592|EXPERIMENTAL|Angiotensin II Infusion|Angiotensin II infusion commenced alongside standard care vasopressor therapy (norepinephrine). Angiotensin II up titrated in a protocolised manner to a target/maximum dose of 40 ng/kg/min whilst noradrenaline down titrated in order to achieve/maintain target mean arterial pressure (MAP) as directed by attending clinician.
62063717|NCT04041050|EXPERIMENTAL|Part 2: Navitoclax + Ruxolitinib Combination Therapy|Participants will receive various doses of navitoclax once daily (QD) in combination with ruxolitinib twice daily (BID).
62268917|NCT00916357|ACTIVE_COMPARATOR|Humalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20|A subcutaneous (SC) injection of 0.3- to 0.5-units per kilogram (U/kg) of Humalog alone for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout period), followed by a SC injection of the appropriate dose of Humalog. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog + 3.75 nanograms/kilogram (ng/kg) recombinant human hyaluronidase PH20 (rHuPH20). The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 ng/kg rHuPH20 following a 3 to 14 day washout period.
62063718|NCT04041050|EXPERIMENTAL|Part 3: Navitoclax Monotherapy|Participants will receive navitoclax once daily (QD).
62063719|NCT04041050|EXPERIMENTAL|Part 4: Navitoclax + Celecoxib|Participants will receive navitoclax once daily (QD) starting on Day 3. Participants will also receive celecoxib single dose on Day 1 and Day 7.
62063720|NCT04041050|EXPERIMENTAL|Part 5: Navitoclax + Ruxolitinib Combination Therapy|Participants will receive ruxolitinib BID and navitoclax QD for drug-drug interaction (DDI) assessment, followed by continued administration of navitoclax in combination with ruxolitinib.
62063721|NCT00460720||001|
62063722|NCT06624566|EXPERIMENTAL|The groups received a program of therapeutic physical exercise scheduled from Monday to Friday|"The program protocol consists of:~Monday and Wednesday: Aerobic circuit protocol (45').~* Warm-up 1-5 min: Global exercises, gentle stretching and range of motion exercises;~* Aerobic exercises 30 min, will consist of running a graded walk, step or stationary bike, each at a target heart rate of 70% FCR. If performed in a wheelchair, the aerobic exercises will consist of the use of different programs using the Motomed type motor-assisted kinesitherapy equipment, which will consist of doing exercises on a motorized bicycle.~* Return to calm for 5-10 min. Tuesdays and Thursdays: Strength circuit protocol (45')~* Warm-up 1-5 min: Global exercises, gentle stretching and range of motion exercises.~* Strength training 30 min: concentric and eccentric (hip extensors/flexors and adductors/abductors, knee flexors and extensors, dorsal and plantar ankle flexors).~Friday: Combined training (45'):~* 20min of aerobic protocol and 15 minutes of strength protocol.~* 5-10 min cool down."
62063723|NCT02235467|ACTIVE_COMPARATOR|ABA parent training|Applied Behavior Analysis parent training using videomodeling in 21 sessions
62268918|NCT00916357|ACTIVE_COMPARATOR|Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog alone for up to 3 dose finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 nanograms/kilogram (ng/kg) recombinant human hyaluronidase PH20 (rHuPH20). The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
62268919|NCT00916357|ACTIVE_COMPARATOR|Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog + 3.75 nanograms per kilogram (ng/kg) recombinant human hyaluronidase PH20(rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog alone. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
62451616|NCT05123937|EXPERIMENTAL|BOBATH technique|In group A (BOBATH) one session per day for three days lasting 1 hour for 3 months. Position transitions such as turning from supine to prone or from prone to supine from sitting to standing are facilitated according to the needs. Balance reflexes are attempted to stimulate by using a CP ball. Ambulation training appropriate to the child's motor development. Additionally, passive stretching of spastic muscle reduces spasticity and facilitates the motor function
62629311|NCT06234592|EXPERIMENTAL|Vasopressin Infusion|Vasopressin infusion commenced alongside standard care vasopressor therapy (norepinephrine). Vasopressin up titrated in a protocolised manner to a target/maximum dose of 0.04 IU/min whilst noradrenaline down titrated in order to achieve/maintain target mean arterial pressure (MAP) as directed by attending clinician.
62063724|NCT02235467|NO_INTERVENTION|ABA parent training control|
62063725|NCT05496621|EXPERIMENTAL|Musculoskeletal Diseas|Questionnaires will be asked for the validity of the Turkish version of the Keel Start Tool.
62629312|NCT06234592|ACTIVE_COMPARATOR|Norepinephrine Infusion|Standard care vasopressor therapy which recruited participants already receiving, titrated to achieve/maintain target mean arterial pressure (MAP) as directed by attending clinician.
62629313|NCT04919408|EXPERIMENTAL|Patients scheduled for cesarean section under spinal anesthesia|Patients scheduled for cesarean section under spinal anesthesia ASA I and II according to The ASA Physical Status Classification System
62629314|NCT05242536|EXPERIMENTAL|Nurse- led program|A nurse coordinated multidisciplinary program aiming to improve psychosocial problems has been developed and will be applied to the patients in the experimental group. This nurse-led program will start at discharge and continue for three months.
62629315|NCT05242536|NO_INTERVENTION|Routine follow-up group|The control group will be applied usual care. Patients in the control group will be discharged by receiving standard care and performing discharge trainings used in the routine care.
62063726|NCT01069081|ACTIVE_COMPARATOR|arm A|docetaxel and cisplatin chemotherapy
62063727|NCT01069081|EXPERIMENTAL|arm B|docetaxel and cisplatin chemotherapy combined with PPI 160mg per day.
62063728|NCT01069081|EXPERIMENTAL|arm C|docetaxel and cisplatin chemotherapy combined with PPI 200mg per day.
62629316|NCT04145206||experimental group|the experimental group is characterized by the practice of flamenco dance
62629317|NCT04145206||control group|not practice of flamenco dance
62629318|NCT01272908|EXPERIMENTAL|Single arm|
62063729|NCT06029556|ACTIVE_COMPARATOR|Mobility out of Bed|
62063730|NCT06029556|EXPERIMENTAL|Ergometry in Bed|
62063731|NCT04714801|ACTIVE_COMPARATOR|Infusion of 100 million ASC|Infusion of 100 million adipose derived mesenchymal stromal cells from healthy donors
62063732|NCT04714801|ACTIVE_COMPARATOR|Infusion of 200 million ASC|Infusion of 200 million adipose derived mesenchymal stromal cells from healthy donors
62063733|NCT04714801|PLACEBO_COMPARATOR|Infusion of placebo|Infusion of saline
62063734|NCT00640237|EXPERIMENTAL|1|Arm 1 - the patients will receive two large doses of vitamin D.
62063735|NCT00640237|NO_INTERVENTION|2|Arm 2 - the patients vitamin D status will be checked during the hospitalization and they will receive the recommendation to treat the vitamin D deficiency in the out-patient department.
62629319|NCT06431984|EXPERIMENTAL|Healthy subjects|"Participants are healthy volunteers selected by the investigating team. The size of the study is limited by the number of individuals authorised to board the aircraft.~The flying participants in the experiment will be the aircraft crew, i.e. volunteers from the research teams taking part in the parabolic flight.~Healthy volunteers over the age of majority will be included in the study."
62629320|NCT06099093|EXPERIMENTAL|18F-DCFPYL-PSMA PET|"Study procedures will be conducted as follows:~* Baseline screening visit with PSMA-PET/CT scan with Ga-PSMA-11.~* In-clinic visit with exam and PSMA-PET/CT scan with 18F-DCFPyl per standard institutional procedures.~* Standard of care therapy.~* Follow up every 3 months via chart review for 12 months, with the purpose of seeing how participants respond to 177Luvipivotide tetraxetan treatment."
62629321|NCT06142344|EXPERIMENTAL|Ho-166 radioembolization|Patients will undergo standard procedures for holmium radioembolization
62451617|NCT05123937|EXPERIMENTAL|Task training|In group B (task training) will be applied for 60 minutes per day, 3 times per week for 3 months the individual session lasted roughly 10 minutes for each activity. Standing from a seated situation; (ii) reaching for an object high up, which required ankle plantarflexion from the standing position, and go back to the starting position with the heel leaning on the floor; (iii) stepping on and off a bench; (iv) walking up and downstairs. (10) (v) Drinking water hold the cup stable and drink it by lifting it at an appropriate speed and power (vi) Moving a rubber ball, the task involved taking a 6.5 cm diameter rubber ball and placing it in a basket with a diameter of ten cm (the basket location was moved in various directions).
62629322|NCT00716768|ACTIVE_COMPARATOR|Laparoscopic Inguinal Hernia Repair|
62629323|NCT00716768|ACTIVE_COMPARATOR|Open Inguinal Hernia Repair|
62063736|NCT02760329||Chronic airways disease|Patients with suspected or primary diagnosis of asthma or COPD
62063737|NCT04887948|EXPERIMENTAL|Coadministration Group|Participants receive an injection of pneumococcal vaccine (20vPnC) and of COVID-19 vaccine (BNT162b2) at the same visit.
62063738|NCT04887948|ACTIVE_COMPARATOR|20vPnC-only Group|Participants receive an injection of pneumococcal vaccine (20vPnC) and of saline at the same visit.
62629324|NCT03677115|EXPERIMENTAL|dexmedetomidine group|a combination of ropivacaine and dexmedetomidine
62063739|NCT04887948|ACTIVE_COMPARATOR|BNT162b2-only Group|Participants receive an injection of COVID-19 vaccine (BNT162b2) and of saline at the same visit.
62063740|NCT04791202|EXPERIMENTAL|Dextrose Group|Injection for Group A: A 27-gauge needle to be inserted in the 1st CMC joint, at which time 0.5 ml of 15% dextrose mixed with 0.5 ml of 1% lidocaine solution is injected into intra and peri-articular area.
62451618|NCT06132035|EXPERIMENTAL|CG-P5 peptide eye drops|
62063741|NCT04791202|ACTIVE_COMPARATOR|Methylprednisolone Acetate Group|Injection for Group B: A 27-gauge needle to be inserted in the 1st CMC joint, at which time 0.5 ml of 40mg methylprednisolone acetate mixed with 0.5 ml of 1% lidocaine solution is injected into intra and peri-articular area.
62063742|NCT05046522|EXPERIMENTAL|Palmitoylethanolamide sold as Levagen +|Palmitoylethanolamide in capsule form - taken as a 700mg (2 x 350mg) dosage at onset of migraine and if unresolved at 2 hours post onset a second dose of 700mg (2 x 350mg)
62629325|NCT03112486||Cardiac Arrest cohort|adult patients (≥ 18 years of age) with non-traumatic out of hospital cardiac arrest
62629326|NCT03112486||Control cohort|matched control population will include hemodynamically stable patients who present to the ED with chest pain that is not of cardiac etiology (non-traumatic chief complaints).
62268920|NCT00916357|ACTIVE_COMPARATOR|Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then Humalog|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humulin-R + rHuPH20. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog following a 3- to 14-day washout period.
62268921|NCT00916357|ACTIVE_COMPARATOR|Humulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humulin-R + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humulin-R + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog alone. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
62268922|NCT00916357|ACTIVE_COMPARATOR|Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog|A subcutaneous (SC) injection of 0.3- to 0.5-units per kilogram (U/kg) of Humulin-R + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humulin-R + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog alone following a 3- to 14-day washout period.
62629327|NCT05750563|PLACEBO_COMPARATOR|Placebo|"Investigational food supplement placebo will be administered according to the same schedule provided for the active product:~* From day 1 to day 4: 1 tablet three times a day, before meals (breakfast, lunch and dinner)~* From day 5 to day 7: 1 tablet twice a day, before breakfast and dinner~* From day 8 to day 62: 1 tablet once a day, before breakfast"
62629328|NCT05750563|EXPERIMENTAL|Experimental|"The dosage will be the following:~* From day 1 to day 4: 1 tablet three times a day, before meals (breakfast, lunch and dinner)~* From day 5 to day 7: 1 tablet twice a day, before breakfast and dinner~* From day 8 to day 62: 1 tablet once a day, before breakfast"
62268923|NCT03730337|EXPERIMENTAL|ONO-7475 monotherapy|
62268924|NCT03730337|EXPERIMENTAL|ONO-7475 in combination with ONO-4538|
62268925|NCT04623983|EXPERIMENTAL|resilient bonding tray|Patients receiving resilient orthodontic bonding trays
62268926|NCT04623983|EXPERIMENTAL|rigid bonding tray|Patients receiving rigid orthodontic bonding trays
62268927|NCT02014636|EXPERIMENTAL|Part 1|Part 1 is a dose escalation phase in which subjects will receive pazopanib orally and the MK 3475 intravenously. Subjects will be evaluated for a minimum of 8 weeks before the next dose level cohort is enrolled.
62268928|NCT02014636|EXPERIMENTAL|Part 2|"Part 2 is a randomized phase in which subjects will be enrolled in each treatment arm:~Pazopanib monotherapy Pazopanib+MK-3475 MK-3475 monotherapy"
62268929|NCT00633659|EXPERIMENTAL|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
62451619|NCT06132035|PLACEBO_COMPARATOR|Placebo Eye drops|
62268930|NCT00633659|EXPERIMENTAL|Control|Voluven (HES 130/0.4)
62268931|NCT06108895|NO_INTERVENTION|Group C, control group|it will receive intrathecal 12.5 mg (2.5ml) hyperbaric bupivacaine 0.5%.
62268932|NCT06108895|ACTIVE_COMPARATOR|Group I|it will receive intrathecal 12.5 mg (2.5ml) hyperbaric bupivacaine 0.5% plus bilateral ultrasound guided IINB after surgery.
62268933|NCT06108895|ACTIVE_COMPARATOR|Group M|it will receive intrathecal 12.5 mg hyperbaric bupivacaine 0.5% plus 200 mcg morphine in 2.5ml solution.
62268934|NCT02858674|EXPERIMENTAL|Active Alerting Mechanism|Traditional Pop Up Alert used in Epic
62629329|NCT05075863|EXPERIMENTAL|Clomiphene Citrate|A total of 39 women were given clomiphene citrate, 100mg from 3 to 7 days of menstrual cycle. All patients underwent transvaginal scan (TVS) so that efficacy could be evaluated (ovulation occurs on 14 day of menstrual cycle after a treatment of 5 days of both groups. Induction of ovulation was assessed by TVS. If follicle of \>2cm is found on 12 days TVS and smaller/collapsed on 16 days TVS, ovulation induction was labeled.
62268935|NCT02858674|ACTIVE_COMPARATOR|Passive Alerting Mechanism|Noninterruptive alert that sits in the checklist
62451620|NCT06132035|ACTIVE_COMPARATOR|Intravitreal injection of Eylea®|
62451621|NCT05530356||Lean Controls (previously enrolled in the Renal HEIR Study)|
62451622|NCT05530356||Obese Youth without Type 2 Diabetes (previously enrolled in the Renal HEIR Study)|
62451623|NCT05530356||Obese Youth with Type 2 Diabetes (previously enrolled in the Renal HEIR Study)|
62451624|NCT02686216|EXPERIMENTAL|F-18 THK-5351|F-18 THK-5351 imaging
62451625|NCT06220799||The Study group (GI)|The Study group (GI) will include twenty five patients with chronic cervical radiculopathy with forward head posture (FHP) (CVA=less than 49° ).
62268936|NCT04083482|EXPERIMENTAL|Septic patients require CVVH|continuous venovenous hemofiltration. Continuous renal replacement therapy（CRRT）has become routine for patients with chronic renal failure ，AKI，fliud overload as well as oliguria in ICU .Continuous venovenous hemofiltration（CVVH）is the method of chioce for CRRT in critical ill .CVVH has significant beneficial effects on removing inflammatory cytokines ，improving oxygen index ，decreasing vasopressor requirements，increasing cardiac index and regulating immune dysfunction .
62268937|NCT01815307|EXPERIMENTAL|Gemcitabine group|1000mg/m2, day 1 every 2 weeks
62268938|NCT01815307|EXPERIMENTAL|S-1 group|80mg/m2/day, day 1-28, every 6 weeks
62268939|NCT02901808||NOMI|Patients suffering from NOMI
62268940|NCT02901808||No-NOMI|Patients not suffering from NOMI
62268941|NCT01295216|EXPERIMENTAL|Intervention|Pre-hypertensive subjects who receive mHealth support for 12 months
62268942|NCT01295216|NO_INTERVENTION|Control|Individuals who receive the usual primary health care
62268943|NCT06437808|EXPERIMENTAL|Training with Portable Force Plates Integration|
62268944|NCT06437808|OTHER|Standard Training|
62268945|NCT04269226|EXPERIMENTAL|Recruitment maneuver|Recruitment maneuver
62268946|NCT04269226|ACTIVE_COMPARATOR|No recruitment maneuver|No recruitment maneuver
62268947|NCT05175833|EXPERIMENTAL|Oral probiotics|oral gel containing Streptococcus salivarius K12 (2 billion live bacilli) and Lactobacillus brevis CD2 (4 billion live bacilli). During the trial, the oral gel was applied in the mouth every 8 hours for 7 days
62268948|NCT05175833|PLACEBO_COMPARATOR|Oral placebo|oral gel containing placebo. During the trial, the oral gel was applied in the mouth every 8 hours for 7 days
62268949|NCT06194890|NO_INTERVENTION|Control group|"When the patients are admitted, their written consent will be obtained and personal information forms and the Visual Comparison Scale (VAS) pain scale will be applied to all participants. VAS pain scale will be applied to both groups during the active phase of labor with 6-8 cm dilatation and 8-10 cm dilatation phases. At the end of the labor, the Birth Satisfaction Scale Short Form will be applied to both groups."
62268950|NCT06194890|EXPERIMENTAL|Intervention group|"When the patients are admitted, their written consent will be obtained and personal information forms and the Visual Comparison Scale (VAS) pain scale will be applied to all participants.~Women in the experimental group will watch a 15-20 minute video with comedy content during the active phase of the action (4-6 cm dilation), and no intervention will be made to women in the control group.~VAS pain scale will be applied to both groups during the active phase of labor with 6-8 cm dilatation and 8-10 cm dilatation phases. At the end of the labor, the Birth Satisfaction Scale Short Form will be applied to both groups."
62268951|NCT03260387||TPIAT|patients undergoing total pancreatectomy with islet autotransplant.
62268952|NCT06501404|EXPERIMENTAL|High dose of probiotic mixture|A daily high dose of a mixture of probiotics (Lactobacillus Fermentum CECT 5716 and Bifidobacterium breve CECT 7263), was given orally starting in the first 72 hours of life, until 36+6 weeks of postmenstrual age or discharge The total dose was 1x109 CFU of each of the strains
62268953|NCT06501404|EXPERIMENTAL|Low dose of probiotic mixture|A daily low dose of a mixture of probiotics (Lactobacillus Fermentum CECT 5716 and Bifidobacterium breve CECT 7263), was given orally starting in the first 72 hours of life, until 36+6 weeks of postmenstrual age or discharge The total dose was 1x106 CFU of each of the strains
62268954|NCT02369276||post SND within 3 months|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within 3 months, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
62451626|NCT06220799||The Control group (GII)|The Control group (GII) will include twenty five patients with chronic cervical radiculopathy without forward head posture (FHP)( CVA = more than 49).
62063743|NCT05046522|PLACEBO_COMPARATOR|A comparator placebo capsule - Maltodextrin and microcrystalline cellulose mix|A comparator capsule taken as a 700mg (2 x 350mg) dosage at onset of migraine and if unresolved at 2 hours post onset a second dose of 700mg (2 x 350mg)
62063744|NCT03492736|EXPERIMENTAL|Melatonin|30 days 10mg Melatonin taken nightly 1 hour before bed
62063745|NCT03492736|PLACEBO_COMPARATOR|Placebo|30 days placebo taken nightly 1 hour before bed
62063746|NCT05542563|EXPERIMENTAL|Mindfulness Intervention plus Standard of Care|The Foundations and Awareness modules of the HMP app require a minimum of 133 and 253 minutes, equating to less than 5 and less than 10 minutes per day on average, respectively. Date, duration, and content of usage will be recorded for each participant through the app. Participants will have access to the entire contents of the app for the full duration of the study.
62063747|NCT05542563|NO_INTERVENTION|Standard of Care|Control group receives standard of care only
62063748|NCT02254408|EXPERIMENTAL|Presatovir|Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
62451627|NCT02962128|EXPERIMENTAL|High Linoleic Acid (LA) Diet|European Americans (genotypes: TT, GT \& GG) and African Americans (genotypes: GT \& GG) at rs173537will be randomly assigned to a high LA diet (10% energy) based on a randomized block design with 5 strata defined by race and genotype combinations.
62063749|NCT02254408|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
62451628|NCT02962128|EXPERIMENTAL|Low Linoleic Acid (LA) Diet|European Americans (genotypes: TT, GT \& GG) and African Americans (genotypes: GT \& GG) at rs173537will be randomly assigned to a low LA diet (2.5% energy) based on a randomized block design with 5 strata defined by race and genotype combinations.
62063750|NCT05714605|EXPERIMENTAL|THRIVE Intervention|1 month intensive post discharge case management and care coordination.
62063751|NCT05714605|NO_INTERVENTION|Usual Care|Discharge to home without intensive post acute case management or care coordination.
62451629|NCT00892398|EXPERIMENTAL|ranibizumab|Trabeculectomy with mitomycin C associated with 2 subconjunctival injections of ranibizumab: 1 intraoperatively and 1 at 2 weeks post-operatively
62451630|NCT00892398|ACTIVE_COMPARATOR|standard care|Trabeculectomy with mitomycin C and standard post-operative care
62063752|NCT02761655|NO_INTERVENTION|Control Group|Patients in both experimental and control groups will receive educations on cognitive impairment, dementia, community resources, and related medication as well as health promotion for PWCIs. The teaching material will be derived from the online resources such as Alzheimer Disease International and Taiwan Alzheimer's Disease Association (TADA) and reviewed by the expert panel as well. Written information will be given to both groups (patients and FCGs), which will be suitable to general public and address issues of cognitive impairment and FCG involvement.
62088105|NCT00146640|EXPERIMENTAL|MR Prednisone|Participants will receive MR prednisone at bed time and placebo matching to IR prednisone in the morning. Total duration of double blind treatment will be 12 weeks.
62268955|NCT02369276||post SND within >3- 6months|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within \>3- 6months, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
62451631|NCT00399581|EXPERIMENTAL|HFOV-Lo|High Frequency Oscillatory Ventilation using lower mean airway pressures and higher FiO2s.
62451632|NCT00399581|EXPERIMENTAL|HFOV-Hi|High Frequency Oscillatory Ventilation using higher mean airway pressures
62629330|NCT05075863|EXPERIMENTAL|Letrozole|A total of 39 women were given letrozole, 5mg from day 3 to 7 of menstrual cycle. All patients underwent transvaginal scan (TVS) so that efficacy could be evaluated (ovulation occurs on 14 day of menstrual cycle after a treatment of 5 days of both groups. Induction of ovulation was assessed by TVS. If follicle of \>2cm is found on 12 days TVS and smaller/collapsed on 16 days TVS, ovulation induction was labeled.
62629331|NCT00952315|ACTIVE_COMPARATOR|Stonebreaker|Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
62629332|NCT00952315|ACTIVE_COMPARATOR|Lithoclast Select|Lithoclast Select will be used to breakup and remove kidney stone. Duration will be timed and documented.
62629333|NCT00952315|ACTIVE_COMPARATOR|Cyberwand|The dual probe Cyberwand device will be used to fragment and remove the kidney stone. Duration will be timed and documented.
62629334|NCT02980406|ACTIVE_COMPARATOR|Fructans|Fructans (FODMAP) are oligosaccharides containing fructose chains. Since the human body lacks hydrolases to break down these saccharides, fructans are poorly absorbed molecules in everybody. The fructan solution used in this study has a concentration of 38g/L.
62629335|NCT02980406|ACTIVE_COMPARATOR|Fructose|Fructose can be found in the diet as free fructose, in sucrose or as polymer structure in fructans. Absorption varies and occurs more rapidly in the presence of glucose than for free fructose because glucose cotransport is involved in the uptake of fructose. Therefore, when fructose is in excess of glucose, it is regarded as a FODMAP. The fructose concentration used in this study is 100g/L.
62629336|NCT02980406|ACTIVE_COMPARATOR|FODMAP mix|The FODMAP mix consists of 20g fructans, 10g galacto-oligosaccharides (GOS), 30g fructose, 10g sorbitol and 10g mannitol in one liter of tap water.
62629337|NCT02980406|PLACEBO_COMPARATOR|Glucose|Glucose is a carbohydrate that is not classified as FODMAP, and is therefore used as a control in this study. The concentration of the glucose solution in this study is 100g/L.
62629338|NCT03111277|EXPERIMENTAL|Experimental: ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's pain . The ExAblate uses ultrasound to heat a small spot in the brain. Ultrasound passes through the skin and skull and into the brain to focus on a spot the study investigator wants to treat.
62629339|NCT01973517||Relapsing Remitting MS|Patients with relapsing remitting multiple sclerosis will be imaged under high-field (7T) MRI prior to and following administration of gadolinium-based contrast (0.1 mmol/kg IV). Afterwards, they will be administered Feraheme 5mg/kg IV via slow push, and they will return 24 hours or later after pharmaceutical administration for post-Feraheme MR imaging.
62063753|NCT02761655|EXPERIMENTAL|Intervention Group|Patients in both experimental and control groups will receive educations on cognitive impairment, dementia, community resources, and related medication as well as health promotion for PWCIs. The teaching material will be derived from the online resources such as Alzheimer Disease International and Taiwan Alzheimer's Disease Association (TADA) and reviewed by the expert panel as well. Written information will be given to both groups (patients and FCGs), which will be suitable to general public and address issues of cognitive impairment and FCG involvement. The intervention group will further receive memory strategies training on encoding and retention, retrieval, as well as execution and monitoring.
62063754|NCT01455025|EXPERIMENTAL|Plerixafor granulocyte-colony stimulating factor|4 steps of plerixafor doses from 240 to 480 microgram/kg per day concomitant with GCSF and chemotherapy 3 to 6 evaluable patients will be enrolled at each dose level in a modified 3 + 3 design.
62268956|NCT02369276||post SND within 6 months -1 year|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within 6 months -1 year, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
62268957|NCT02369276||post SND within more than 1 year|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within more than 1 year, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
62629340|NCT06032585||Patients with parkinsonism|Parkinsonism incl. tremor, parkinsons, atypical parkinsons
62653142|NCT05303714|EXPERIMENTAL|Arm B (FOLFOX and PIPAC)|Patients randomized in the ARM B will undergo to 6 courses of systemic chemotherapy (FOLFOX regimen) plus PIPAC every two cycles of chemo (Fig.1). At least seven days should last between each PIPAC and the next chemotherapy course, and at least 14 days should last between the chemotherapy course and the next PIPAC. After six courses of chemotherapy and 3 PIPACs procedure, a radiologic restaging (CT scan) as well as a laparoscopic reassessment will be performed. If a Progression Disease will be detected, the patient will end the trial and will undergo to II line chemotherapy regimen. If a stable disease or a partial response will be documented, patient will be treated with cytoreductive surgery plus HIPEC.
62629341|NCT04832451|EXPERIMENTAL|Intervention Group|"The Beck Depression Inventory\[BDI\] (inclusion criteria) was applied face to face to the students who constituted the population (n=385). After the BDI scores were evaluated, the students who met the inclusion criteria were randomly assigned to the intervention and control groups.~In a preliminary interview held with the intervention group (n=10), they were informed about the subject of the research, the duration and content of the implementation process, session rules, and that sessions would be audio-recorded. Informed consent forms were obtained from them, and pre-tests (BDI, Coping Styles Inventory\[CSI\]) were applied.~A total of 21 90-minute Interpersonal Relational Role Analysis (IRRA) sessions (two sessions a week) were held with the intervention group.~21 sessions of IRRA were applied to the intervention group, once the sessions were completed, post-tests (BDI, CSI) were applied. Three months later, a follow-up test (BDI, CSI) was applied to intervention group."
62629342|NCT04832451|NO_INTERVENTION|Control Group|The students in the control group were informed about the research, informed consents were obtained from them, and pre-tests (Beck Depression Inventory, Coping Styles Inventory) were applied to them. No intervention was applied to the control group (n=10). Once the Interpersonal Relational Role Analysis sessions were completed, post-tests (Beck Depression Inventory, Coping Styles Inventory) were applied to the control group. Three months later, a follow-up test (Beck Depression Inventory, Coping Styles Inventory) was applied to control groups. After the follow-up test, the participants in the control group were referred to the psychological support unit of the university.
62629343|NCT02626663||aHUS|atypical Hemolytic Uremic Syndrome
62629344|NCT02626663||TTP|Thrombotic thrombocytopenic purpura
62629345|NCT02626663||MAHA|other microangiopathic hemolytic anemias
62629346|NCT01955746||Type 1 DM|
62629347|NCT04516967|ACTIVE_COMPARATOR|Experimental: Avatrombopag|Study is 3:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 12 weeks
62629348|NCT04516967|PLACEBO_COMPARATOR|Placebo Comparator:Placebo|Study is 3:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 12 weeks
62629349|NCT03363867|EXPERIMENTAL|Atezolizumab, Bevacizumab and Cobimetinib (ABC)|
62629350|NCT06517121|EXPERIMENTAL|Personalised tDCS group|Participants who are assigned to the personalised group will receive anodal tDCS over a individualized stimulation site.
62629351|NCT06517121|EXPERIMENTAL|Conventional tDCS group|Participants who are assigned to the Conventional group will receive anodal tDCS over F3.
62629352|NCT06517121|SHAM_COMPARATOR|Sham control group|Participants who are assigned to the Conventional group will receive sham tDCS. The active stimulation will be delivered for the first 30 seconds only.
62629353|NCT02229799||Stroke patients|
62629354|NCT01142947|OTHER|beclomethasone dipropionate (BD)|Patients who meet eligibility criteria will be treated with 6 weeks of beclomethasone dipropionate to assess change in pulmonary function and asthma control. These change will be used as phenotypes in a genetic association study. There is no placebo group.
62629355|NCT04403113|EXPERIMENTAL|Study Group (SG)|feeding and oral motor intervention strategies+structured neck and trunk stabilization exercises+caregiver training related to feeding (Study Group)
62629356|NCT04403113|PLACEBO_COMPARATOR|Control Group (CG).|feeding and oral motor intervention strategies+caregiver training related to feeding (Control Group)
62629357|NCT00882271|EXPERIMENTAL|1|Traditional Chinese Acupuncture
62629358|NCT00882271|PLACEBO_COMPARATOR|2|Placebo Acupuncture
62629359|NCT00789607|ACTIVE_COMPARATOR|MRI-guided FM|
62063755|NCT01964521|EXPERIMENTAL|Mepilex Transfer Ag|Mepilex Transfer Ag is a transfer dressing designed for low to high exuding wounds and used to prevent microbial growth. It is worn for up to two weeks at a time.
62629360|NCT00789607|ACTIVE_COMPARATOR|TRUS-guided FM|
62629361|NCT01075997|EXPERIMENTAL|A cell phone tips|This group will receive a cell phone and cell phone service for 1 year. This group will receive a daily video reminders and tips for the first 6 months of the study. For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent. The group will be instructed on how to use the cell phone. The group will be asked to check blood sugar on a schedule determined by their providers. The group will have blood sugars downloaded from from the glucometer by their providers at every visit and reviewed. The group will have the A1c measured. Also it will have this test repeated about every 3 months. They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
62653143|NCT05498727||Maternal Newborn and Child Health (MNCH) Clinics|Clients attending for routine service delivery at MNCH clinics.
62063756|NCT03320798||"group Bullous pemphigoid"|Patients consulting at dermatology department of Reims Teaching Hospital for bullous pemphigoid between 1997 and 2011.
62653144|NCT05498727||HIV Clinics|Patients attending for HIV clinic services
62063757|NCT02775422|EXPERIMENTAL|Pregnant women|Pregnant women
62063758|NCT06056622|OTHER|Combined Exercise Group|Multisensory stimulation with active range of motion movement, progressive Cawthorne-Cooksey exercises, and balance exercises with external perturbation on soft and hard surfaces while eyes are open or closed.
62063759|NCT06056622|OTHER|Control Group|A placebo exercise program consist of 10 minute reaction time game which requires mouse clicking on screen color changes will be used in control group.
62653145|NCT05498727||Tuberculosis (TB) Clinics|Patients attending TB clinic services.
62653146|NCT06275269|EXPERIMENTAL|Ultrasound-Guided Triamcinolone Injection Treatment Group|Ultrasound-Guided Triamcinolone Injection for the Treatment of Subglottic Stenosis
62629362|NCT01075997|ACTIVE_COMPARATOR|B no cell phone tips|This group will receive a cell phone and cell phone service for 1 year. For the second 6 months this group will be seen by their providers at least every 3 months. The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by their provider. The groups will have blood sugars downloaded from from the glucometer by their provider at every visit and reviewed. The group will have A1c measured. Also it will have this test repeated about every 3 months. They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
62629363|NCT03704831||IPACK group|IPACK group
62629364|NCT03704831||Surgical infiltration group|Surgical infiltration group
62629365|NCT02497508|EXPERIMENTAL|Nivolumab|Nivolumab will be administered 2 weekly by intravenous infusion in a dose of 3 mg/kg
62629366|NCT00215644|EXPERIMENTAL|Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab|
62629367|NCT00215644|ACTIVE_COMPARATOR|ECX Only|
62629368|NCT04408651|EXPERIMENTAL|Acceptance and Commitment Therapy|
62629369|NCT04408651|EXPERIMENTAL|Compassion-Focused Therapy|
62063760|NCT03317223|EXPERIMENTAL|CJ-12420/Clarithromycin/Amoxicillin|CJ-12420 50mg /Clarithromycin 500mg /Amoxicillin 1g
62063761|NCT03317223|ACTIVE_COMPARATOR|Lansoprazole/Clarithromycin/Amoxicillin|Lansoprazole 30mg /Clarithromycin 500mg /Amoxicillin 1g
62063762|NCT03402880|EXPERIMENTAL|Treatment (pembrolizumab, epacadostat)|Patients receive pembrolizumab IV on day 1 and epacadostat PO BID on days 1-21. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. Patients benefiting from treatment may continue for an additional 17 courses.
62268958|NCT02369276||without shoulder disability|20 Head and Neck Cancer(HNC) post SND without shoulder complication at the control group, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
62268959|NCT00577252||1|Adolescents with CF.
62629370|NCT05200377||Cerebral small vessel disease group|Patients with clinically and radiologically evidenced cerebral small vessel disease. Patients are grouped by severity of cerebral small vessel disease assessed by comprehensive MRI findings.
62629371|NCT01051557|EXPERIMENTAL|Treatment (temsirolimus and perifosine)|"PHASE I: Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and perifosine PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive temsirolimus and perifosine as in phase I. Some patients may also undergo cytoreductive surgery."
62629372|NCT04425681|EXPERIMENTAL|Osimertinib With Bevacizumab group|Osimertinib 80 mg oral daily; and bevacizumab 7.5 mg/kg intravenous every 3 weeks
62629373|NCT05641844|OTHER|Treatment arm|Subjects will undergo debridement of the fistula tract and suturing of internal opening, followed by a. water leak test. RD2 Ver.02 will be applied to the fistula tract in the operating room.
62629374|NCT05641844|OTHER|Control arm|Subjects will undergo debridement of the fistula tract and suturing of internal opening, followed by a. water leak test. Saline will be applied to the fistula tract in the operating room.
62629375|NCT05646732|EXPERIMENTAL|TMS-fMRI|Participants will undergo simultaneous TMS-fMRI as part of this study. There will be two locations stimulated: one control region and one target region. Participants will be randomized with respect to the order of receiving stimulation at the locations, but all participants will receive stimulation at both locations as part of the study. All participants will be considered as one group but order effects will be evaluated as an explanatory variable.
62629376|NCT02104882|EXPERIMENTAL|Intraoperative Radiotherapy|Following conventional frameless neuronavigation-guided microsurgical tumor resection, patients will receive IORT with 20-40 Gy (prescribed to the applicator surface). Not later than 4 weeks, radiochemotherapy (RCT) will be initiated, consisting of a total EBRT dose of 60 Gy (delivered in fractions of 2 Gy) and concomitant chemotherapy with temozolomide (50 mg/m2/d). Four weeks after RCT, cycling chemotherapy with temozolomide (150-200mg/m2/d/cycle) will be applied.
62629377|NCT04544059|EXPERIMENTAL|Lenalidomide|Lenalidomide orally 25 mg per day was administered on days 1 through 10 of each cycle and delivered concomitantly with standard dose R-CHOP-21 regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 or Liposome doxorubicin 30mg/m2, vincristine 1.4 mg/m2 \[capped at 2.0 mg\], all on day 1; prednisone 100 mg per day on days 1 through 5). All patients received aspirin 100mg per day prophylaxis throughout, unless they were on therapeutic dose warfarin or low molecular weight heparin for intercurrent conditions. The treatment continued for a maximum of six to eight cycles or until disease progression. Tumor lysis prophylaxis, antiemetics, and supportive care were standard of care.
62629378|NCT03871985|EXPERIMENTAL|Lavage combined with aspiration|Intermittent subglottic secretions lavage combined with aspiration
62629379|NCT03871985|ACTIVE_COMPARATOR|Pure aspiration|Intermittent subglottic secretions aspiration
62268960|NCT01359475|EXPERIMENTAL|Acetal crown|Clinical performance of acetal crowns for treatment of primary molars
62629380|NCT04560556||POC Testing Alone|POC HIV testing (the current standard of care) will be conducted for persons entering jail during the first two-month period.
62629381|NCT04560556||POC and 4th Generation Testing|POC plus 4th Generation HIV Testing will be conducted for persons entering jail during the second two-month period.
62629382|NCT04560556||4th Generation Testing Alone|4th Generation HIV Testing will be conducted for persons entering jail during the third two-month period.
62629383|NCT04319653|EXPERIMENTAL|Dynamic pelvic MRI|
62653147|NCT06275269|EXPERIMENTAL|Translaryngeal Endoscopic Mucosal Injection of Triamcinolone Treatment Group|Translaryngeal Endoscopic Mucosal Injection for the Treatment of Subglottic Stenosis
62629384|NCT05789212|EXPERIMENTAL|Personalized Trial ABCCBA|Participants in Arm 1 will receive a Personalized Trial comprised of three components delivered in a ABCCBA sequence over a total period of 12 weeks, where A-mindfulness, B-yoga, and C-guided walking. Participants in this arm will be prompted to complete 3 x 30-minute intervention sessions weekly during applicable treatment weeks. Interventions will be delivered by a virtual link to online videos recorded by an experienced wellness provider. Participants will be limited to three views of the study-provided intervention content each week.
62629385|NCT05789212|EXPERIMENTAL|Personalized Trial CBAABC|Participants in Arm 2 will receive a Personalized Trial comprised of three components delivered in a CBAABC sequence over a total period of 12 weeks, where A-mindfulness, B-yoga, and C-guided walking. Participants in this arm will be prompted to complete 3 x 30-minute intervention sessions weekly during applicable treatment weeks. Interventions will be delivered by a virtual link to online videos recorded by an experienced wellness provider. Participants will be limited to three views of the study-provided intervention content each week.
62451633|NCT06036511|EXPERIMENTAL|Ketamine Assisted Psychotherapy [KAP]|A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment, then within 24 hours, an integration session to take advantage of neuroplasticity for optimal therapeutic progress. Each participant will have two complete KAP sessions (preparation, treatment, and integration) followed by rsfMRI within approximately 24 hours, and again approximately two weeks after the completion of the second KAP session. Patients will also have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be correlated with changes in connectivity at each rsfMRI.
62451634|NCT06121453|EXPERIMENTAL|Single Arm: Adherence Intervention|Multicomponent Adherence Intervention
62629386|NCT05283265|EXPERIMENTAL|Intracranial patients|All participants with epilepsy undergoing intracranial monitoring for clinical purposes will be approached to participate in an experiment that is recording-only and an experiment that involves stimulation with simultaneous recording.
62629387|NCT01296139|EXPERIMENTAL|A|All subjects will receive 7.5 mg/kg Fe
62629388|NCT06512922|EXPERIMENTAL|adaptive cognitive training|The intervention lasted for 6 months. Participants will receive 30 minutes of training per day, at least five days per week. In each task, once a high accuracy (e.g. \>80%) is achieved, the task is automatically upgraded to the next difficulty level.
62629389|NCT06512922|ACTIVE_COMPARATOR|placebo cognitive training|The intervention lasted for 6 months. Participants will receive 30 minutes of training per day, at least five days per week. The tasks will be set to a fixed level of difficulty.
62063763|NCT03454425|EXPERIMENTAL|Exablate Subthalamotomy|Exablate treatment for Parkinson's Disease Motor Features
62063764|NCT03454425|SHAM_COMPARATOR|Sham ExAblate Subthalamotomy|
62063765|NCT00975052|ACTIVE_COMPARATOR|A|Sitagliptin alone
62451635|NCT04072588||Sacrospinous Ligament Fixation patients|Patients who underwent Sacrospinous Ligament Fixation for the treatment of vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
62451636|NCT04072588||lateral suspension surgery patients|Patients who underwent lateral suspension surgery for vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
62629390|NCT01460602|EXPERIMENTAL|Part 1: establish MTD|Part 1 consists of dosing to determine maximum tolerated dose (MTD) and dose limiting toxicity (DLT).
62629391|NCT01460602|EXPERIMENTAL|Part 2: The MTD from Part 1|During the Phase 2 part of the study, approximately 24 additional subjects will be enrolled in order to obtain a total of 30 response-evaluable subjects treated at the maximum tolerated dose.
62629392|NCT03905304|EXPERIMENTAL|Meditoxin|Meditoxin administered 200U\~300U, single-dose administration.
62629393|NCT03905304|ACTIVE_COMPARATOR|Botox|Botox administered 200-300U, single-dose administration.
62063766|NCT00975052|ACTIVE_COMPARATOR|B|Metformin alone
62063767|NCT00975052|EXPERIMENTAL|C|Sitagliptin and metformin concomitantly
62063768|NCT00975052|PLACEBO_COMPARATOR|D|Placebo
62063769|NCT05646199|ACTIVE_COMPARATOR|Metformin|Participants in this group will be given metformin
62653148|NCT03226587|EXPERIMENTAL|Blue light|Each subject will be undergo a whole body exposure to blue light (453 nm wavelength) for 30 minutes.
62653149|NCT03226587|PLACEBO_COMPARATOR|Control exposure|Each participant will also undergo a control examination, where the body will be covered with a light tight foil during blue light exposure for 30 minutes.
62653150|NCT01260909||Real-time kV/MV Prostate Imaging|
62653151|NCT01715298|EXPERIMENTAL|NVA237|NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
62653152|NCT01715298|PLACEBO_COMPARATOR|Placebo|Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
62653153|NCT03502798|EXPERIMENTAL|scanning a/LCI|
62063770|NCT05646199|ACTIVE_COMPARATOR|Semaglutide|Participants in this group with receive Semaglutide
62063771|NCT03833180|EXPERIMENTAL|Zilovertamab vedotin Schedule 1: Q1/3W|Participants will be administered escalating doses of zilovertamab vedotin at 0.50, 1.00, 1.50, 2.25, 2.50, 2.75, and 3.00 mg/kg IV on Day 1 of repeated 21-day cycles (Q1/3W).
62063772|NCT03833180|EXPERIMENTAL|Zilovertamab vedotin Schedule 2: Q2/3W|Participants will be administered escalating doses of zilovertamab vedotin at 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, and 2.25 mg/kg IV on Day 1 and 8 of repeated 21-day cycles (Q2/3W).
62063773|NCT03833180|EXPERIMENTAL|Zilovertamab vedotin Schedule 3: Q3/4W|Participants will be administered escalating doses of zilovertamab vedotin at 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, and 2.25 mg/kg IV on Day 1, 8, and 15 of repeated 21-day cycles (Q3/4W).
62629394|NCT04928456|EXPERIMENTAL|OMT Intervention Arm|"OMT will include:~1. Myofascial release of the thoracic inlet: gentle pressure applied to shoulders and neck to move the tissue in different directions with a gentle motion.~2. Pectoral traction: The armpit will be contacted with the finger pads of the doctor and each side will be gently grasped and have a slow pulling force applied towards the shoulders.~3. Diaphragm release with MFR: The doctor will touch below the ribs on each side and will apply gentle pressure and move the tissue from side to side.~4. Splenic pump: below the ribs on the left hand-side, the doctor will apply pressure and release pressure several times to create a vibration over the area just below the ribs.~5. Thoracic pump: The doctor will place their hands over the chest wall on each side and will apply pressure and release pressure several times to generate a pumping action of about 100 times in one minute.~Treatment will last 5 minutes with each technique lasting 1 minute."
62629395|NCT04928456|NO_INTERVENTION|Control|Participants in the control group will undergo the same assessments as the OMT intervention arm and will receive their vaccinations, but will not receive any OMT.
62629396|NCT04421352|EXPERIMENTAL|low-dose radiation+CS1001|low-dose radiation+CS1001
62629397|NCT00699023|EXPERIMENTAL|1|ezetimibe tablets 10 mg/die + simvastatin tablets 20 mg/die six weeks
62063774|NCT02304016|EXPERIMENTAL|Pelvic floor physical therapy|
62063775|NCT02304016|NO_INTERVENTION|Observatoin|
62629398|NCT00699023|PLACEBO_COMPARATOR|2|placebo + simvastatin tablets 20 mg/die six weeks
62629399|NCT00109746|ACTIVE_COMPARATOR|Chromium Picolinate|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
62629400|NCT00109746|NO_INTERVENTION|Placebo|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
62063776|NCT06155578|ACTIVE_COMPARATOR|Sodium metabisulfite cream|Sodium metabisulfite prepared in pediatric cold cream (water in oil emulsion) at a concentration of 25% to be applied on calcinosis topically twice daily.
62063777|NCT06155578|PLACEBO_COMPARATOR|Placebo cream|Pediatric cold cream (water in oil emulsion) to be applied on calcinosis topically twice daily.
62063778|NCT02489266|EXPERIMENTAL|Arm 1|Patients will receive cyclophosphamide and fludarabine followed by infusion of the AKTi-treated TIL, followed by high dose aldesleukin.
62451637|NCT02142244|EXPERIMENTAL|Near infra red sentinel node biopsy|Sentinel node biopsy adding indocyanine green injection at the tumor/biopsy site during the surgical procedure to the standard technique (blue die and lymph scintigraphy) and near infra red light for fluorescence. The indocyanine green saline solution - 5mg diluted in 10ml. will be injected in 4 points around the biopsy site - 4ml each - total 0.8mg - single procedure.Near infra red lens and camera will be used to detect the fluorescence and localize the sentinel node for biopsy.
62451638|NCT01170442|EXPERIMENTAL|vitamin D3 2000 IU|
62451639|NCT01170442|EXPERIMENTAL|vitamin D3 5000 IU|
62451640|NCT01170442|PLACEBO_COMPARATOR|Placebo|
62451641|NCT01921426|EXPERIMENTAL|GC4419|Open label, dose escalation study of GC4419 administered in 14 doses, corresponding to the first 14 doses of radiation therapy. Each dose will be given intravenously over 60 minutes. The possible doses which may be tested are: 15mg, 30mg, 50mg, 75mg, 112mg, and 170mg.
62451642|NCT03472729|EXPERIMENTAL|AGE-ON Workshop|Intervention participants will take part in a 6-week workshop to learn 1) basic features of the iPad; 2) how to use the internet; 3) how to take and view photos; 4) how to send and receive emails; and 5) other 'fun' functions.
62451643|NCT03472729|NO_INTERVENTION|Wait-list control|Wait-list control group to be offered workshops after the study is complete
62629401|NCT02198508|ACTIVE_COMPARATOR|DFX single treatment|a single oral dose of DFX 30 mg/kg once daily, (Exjade®, Novartis Pharmaceuticals Corporation, USA )
62629402|NCT02198508|ACTIVE_COMPARATOR|DFP single treatment|single oral dose of DFP 40 mg/kg/day twice a day, (Kelfer®, Cipla Ltd., India)
62629403|NCT02198508|EXPERIMENTAL|combination treatment|sequential oral doses of DFX 30 mg/kg/d, DFP 40 mg/kg/d and DFP 40 mg/kg/d (dosing interval: seven hours).
62629404|NCT04468893|EXPERIMENTAL|Positive Psychology Intervention with chat|Participants in this group will receive from 15 sessions of a Positive Psychology focused on the increase of wellbeing and sleep quality and decrease of anxiety and depression with the support of a chat service provided by therapists.
62629405|NCT04468893|ACTIVE_COMPARATOR|Positive Psychology Intervention without chat|Participants in this group will receive from 15 sessions of a Positive Psychology focused on the increase of wellbeing and sleep quality and decrease of anxiety and depression without the support of the chat service.
62063779|NCT01966315||Dexmedetomidine group|"Dexmedetomidine group is the patients who sedated with dexmedetomidine in intensive care unit. We will randomly allocate using www.randomizer.org.~They will sedate at the level of RASS -2. The dose of dexmedetomidine will be 0.2-0.7ug/kg/hr."
62063780|NCT01966315||Midazolam group|"Midazolam group is the patients who sedated with midazolam in intensive care unit. We will randomly allocate using www.randomizer.org.~They will sedate at the level of RASS -2. The dose of midazolam will be 0.05-0.1 mg/kg/hr."
62063781|NCT01316341|EXPERIMENTAL|BI10773 low dose Per Os(p.o.)|patient to receive a tablet containing low dose BI10773 Per Os(p.o.) plus one placebo
62629406|NCT05279495|OTHER|Loaded CANNAXR|"In a double-blinded fashion, 250 mg CANNAXR cream and 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks.~In a double-blinded fashion, 250 mg CANNAXR cream and 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks."
62629407|NCT03508349|EXPERIMENTAL|IST using RDT|Women presenting for their first ANC visit to facilities will be consecutively enrolled after providing informed consent. Women in the intervention group (IST+ routine care) will be tested for malaria at the health center during their ANC visits with an RDT. If positive, they will be treated with artemisinin-based combination therapy (ACT) in second or third trimester or quinine in the first trimester.
62629408|NCT03508349|NO_INTERVENTION|Routine Antenatal Care|Women presenting for their first ANC visit to facilities will be consecutively enrolled after providing informed consent. Women in the comparison group (routine care) will receive routine antenatal care services per the national guidelines. They will not be tested for malaria at each antenatal care visit unless they are symptomatic for malaria.
62629409|NCT01930916|OTHER|Not interventionnal|INR capillary measurement with INRatio 2 device antiphospholipid antibodies and lupus anticoagulant
62629410|NCT03974802|EXPERIMENTAL|somofilcon A (habitual) lens, then fanfilcon A (test) lens|Participants are habitual wearers of somofilcon A lens and refitted with fanfilcon A lens.
62629411|NCT00823602|EXPERIMENTAL|1|"GnRH antagonist ganirelix 0.25 mg fromm 6th ovarian stimulation"
62629412|NCT00823602|ACTIVE_COMPARATOR|2|GnRH agonist, suprefact, stimulation with a standard long protocol
62629413|NCT03162042||Squamous cell carcinoma|55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.
62629414|NCT03162042||Control group|55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.
62629415|NCT05929742|EXPERIMENTAL|experimental group|received early rehabilitation combined with VR training
62629416|NCT05929742|ACTIVE_COMPARATOR|comparison group|received only early rehabilitation
62629417|NCT01599169|EXPERIMENTAL|B-Back® verum|
62629418|NCT01599169|PLACEBO_COMPARATOR|B-Back® placebo|
62629419|NCT05820490||Dayshift workers|
62268961|NCT04742088|EXPERIMENTAL|Orthosis group|
62268962|NCT02881632||Healthy infants aged 0-2|Healthy infants aged 0-2 year with no respiratory diseases to provide a reference values. A structured light pattern (Structured Light Plethysmography (SLP) - Pneumscan) will be projected onto the chest and abdominal wall and the movement of this pattern as the patient breathes will be recorded for 2 min. The total period of testing per session should take approximately 30 minutes per person.
62268963|NCT02881632||Infants aged 0-1 with Bronchiolitis|Infants admitted to hospital within last 24hrs (AVB participants only). A structured light pattern (Structured Light Plethysmography (SLP) - Pneumscan) will be projected onto the chest and abdominal wall and the movement of this pattern as the patient breathes will be recorded for 2 min. The total period of testing per session should take approximately 30 minutes per person
62629420|NCT05820490||Nightshift workers|
62268964|NCT02004080||TBI admitted to ICU|Intensive Care treatment
62268965|NCT00252057|EXPERIMENTAL|Re-engineered hospital discharge|"Participants received the Re-Engineered Hospital Discharge, a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call 2-4 days after discharge by a clinical pharmacist."
62268966|NCT00252057|NO_INTERVENTION|Standard hospital discharge|Participants received the routine, standard hospital discharge.
62629421|NCT00512499|PLACEBO_COMPARATOR|Group 1|CONTROL GROUP (first year only; maximum 300 patients): patients seen by CHUS orthopedists at the Hotel-Dieu site, where no nurse coordinator is available for inclusion. This is random but not randomized.
62629422|NCT00512499|ACTIVE_COMPARATOR|Group 2|"MINIMAL INTERVENTION GROUP: 1/2 of patients, randomly selected.~INTERVENTION: A nurse coordinator will identify patients with fragility fractures and inform the patient about osteoporosis as the cause of the fracture, the benefit of treatment, and the options of treatment adapted to the individual patient. Written information will be sent to his/her family physician containing a presumed osteoporosis diagnosis, investigation to be performed, correct interpretation of any osteodensitometry results in the context of a fragility fracture, the options of treatment, and alternatives if the first prescriptions are not tolerated or stopped. Intervention"
62063782|NCT01316341|PLACEBO_COMPARATOR|Placebo|patient to receive two placebos
62063783|NCT01316341|EXPERIMENTAL|BI10773 high dose Per Os(p.o.)|patient to receive a tablet containing high dose BI10773 Per Os(p.o.) plus one placebo
62268967|NCT01079182||Ankylosing spondylitis|Participants with ankylosing spondylitis
62268968|NCT02189850|EXPERIMENTAL|BLI800 - Dose 1|BLI800 oral solution
62268969|NCT02189850|EXPERIMENTAL|BLI800 - Dose 2|BLI800 oral solution
62268970|NCT01857661|OTHER|control|hearing aid without an integrated sound generator
62653154|NCT01508000|ACTIVE_COMPARATOR|Arm A: modified FOLFOX6 and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
62063784|NCT05347966|OTHER|Brain Health PRO|
62063785|NCT04284839|ACTIVE_COMPARATOR|Direct Oral Anticoagulation (DOAC)|Patients in the intervention group will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
62063786|NCT04284839|PLACEBO_COMPARATOR|Vitamin K Antagonist|Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
62063787|NCT06227962||Retinoblastoma Survivors|Children and adults who survived retinoblastoma (8-35 years of age)
62063788|NCT06227962||Retinoblastoma Risk Carriers|Children and adults who (might) carry a genetic risk to develop retinoblastoma (8-35 years of age)
62063789|NCT06227962||Parents|Parents of Rb patients, Rb survivors, or Rb risk carriers (6 months-12 years of age)
62063790|NCT05810051|EXPERIMENTAL|Optimal medical therapy (OMT) plus a program of cardiac rehabilitation (CR)|The intervention group will receive cardiac rehabilitation in addition to lifestyle changes and pharmacological treatment.
62063791|NCT05810051|NO_INTERVENTION|Optimal medical therapy (OMT)|"The control group will be randomized to lifestyle changes and pharmacological treatment.~In the 7 to 14 days after randomization optimal medical therapy will be started."
62063792|NCT04330365|ACTIVE_COMPARATOR|Whole Health Team (WHT) Intervention Arm|The WHT intervention arm includes four core elements: 1) An interdisciplinary WHT collaborating with primary care; 2) Personalized Health Planning with prioritization of multi-modal non-pharmacological and CIH pain management approaches; 3) Whole Health Coaching sessions to assist patients in developing and implementing a Personalized Health Plan for chronic pain care; and 4) the web/mobile Whole Health Resource Directory provided to patient participants (in addition to their providers) to support non-pharmacologic/CIH chronic pain care.
62063793|NCT04330365|ACTIVE_COMPARATOR|Primary Care Group Education (PC-GE) Intervention Arm|Primary Care Group Education (PC-GE) iss the comparator arm, which is an abbreviated form of Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) adapted for group use in primary care.
62063794|NCT04330365|PLACEBO_COMPARATOR|Usual Primary Care (UPC) Arm|In VA, patient-aligned care teams (PACTs) or primary care is step 1 of VA's Stepped Care Model in the treatment of chronic pain. PCPs are expected to possess the requisite skill set for management of common chronic pain-causing conditions, which includes biopsychosocial assessment, multi-modal treatment, and coordination of specialty pain care after shared-decision making that incorporates patient preferences and values. Participants randomized to this arm will continue to have their PCP and PACT serve in this role.
62063795|NCT04740203|EXPERIMENTAL|CAR-T therapy|Administration of CD19 and CD22 CAR T-cells
62063796|NCT02812472|EXPERIMENTAL|treadmill training with functional electrical stimulation|Subjects in the experimental group received additional treadmill training with functional electric stimulation for 25 minutes per session, followed by 5 minutes cool down for 12 sessions.
62268971|NCT01857661|EXPERIMENTAL|sound generator|hearing aid with an integrated sound generator
62268972|NCT04411355|NO_INTERVENTION|control group patients|non intervention. only rutin care
62268973|NCT04411355|EXPERIMENTAL|intervention group patients|The intervention group was trained and monitored by a professional team in line with the components of the model. Life quality scale, hypertension information questions and chronic care assessment scale were applied to both groups at the beginning and in the sixth month of the study.
62268974|NCT01372904|EXPERIMENTAL|Dexamethasone|
62268975|NCT04697875|EXPERIMENTAL|Normobaric hypoxia (FiO2 15%)|
62268976|NCT04697875|SHAM_COMPARATOR|Placebo-ambient air (FiO2 21%)|
62268977|NCT02666573|EXPERIMENTAL|Photodynamic therapy protocol|In addition to scaling and root debridement, test sites received PDT according to manufacturer's instructions.
62268978|NCT02666573|OTHER|SRP|Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
62268979|NCT04538027|ACTIVE_COMPARATOR|6 weeks|Microdiscectomy was done at 6 weeks of starting symptoms
62268980|NCT04538027|ACTIVE_COMPARATOR|3 months|Microdiscectomy was done at 3 months of starting symptoms
62268981|NCT04538027|ACTIVE_COMPARATOR|6 months|Microdiscectomy was done at 6 months of starting symptoms
62268982|NCT04873752|EXPERIMENTAL|UDI-001|Four cycles with 8 administrations
62268983|NCT04234711||Conventional surgical group|Patients with total pulmonary venous connection undergo conventional surgical repair
62268984|NCT04234711||Sutureless surgical group|Patients with total pulmonary venous connection undergo sutureless surgical repair
62268985|NCT01146873|ACTIVE_COMPARATOR|Group 1: Lopinavir/ritonavir (LPV/r)|Participants are assigned to remain on their current LPV/r-based antiretroviral regimen. Ritonavir-boosted lopinavir syrup was given twice per day at 230 mg/m\^2 per dose. Children able to swallow tablets were given 1 tablet twice per day (200 mg lopinavir/50 mg ritonavir) if body surface area was less than 0.9m\^2 or 2 tablets twice per day if body surface area was 0.9m\^2 or higher.
62629423|NCT00512499|EXPERIMENTAL|Group 3|INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
62629424|NCT05797441|EXPERIMENTAL|EMPOWER|The goals of EMPOWER are to increase patients' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in TFT through the continued application of TFT skills, and encourage engagement in meaningful life activities. The program includes a Veteran workbook and four planned therapist contacts over the twelve weeks following TFT completion. The intervention includes: self-monitoring of symptoms, continued practice of TFT skills, engagement in meaningful activities, goal setting, and therapist support.
62629425|NCT05797441|ACTIVE_COMPARATOR|Treatment As Usual|The comparison condition will be TAU following completion of TFT. In the spirit of TAU, providers will not be restricted in the type or intensity of services offered. Depending on local clinic policy or norms, providers randomized to TFT may provide post-TFT treatment themselves or Veterans may be referred to other providers and/or back to the clinician who referred the Veteran to TFT. If providers would have typically discharged Veterans following TFT, that is also allowable.
62629426|NCT04825951|ACTIVE_COMPARATOR|CS 2000 appliance|treating growing skeletal Class III patients
62629427|NCT04825951|ACTIVE_COMPARATOR|Reversed Forsus Fatigue resistant appliance|treating growing skeletal Class III patients
62629428|NCT04825951|NO_INTERVENTION|Control|"A group of untreated skeletally growing class III patients will be recruited to account for the possible effects of growth in the treatment groups.~This group matches the treated groups in malocclusion, stages of skeletal maturation, and mean observation period. Those patients will be treated after the period of the study."
62629429|NCT03320174|ACTIVE_COMPARATOR|Tafenoquine 200 mg (2 x 100 mg tablets)|Tafenoquine 200 mg (2 x 100 mg tablets) daily for three consecutive days, followed by study treatment (tafenoquine 200 mg or placebo) once per week for 51 weeks
62629430|NCT03320174|PLACEBO_COMPARATOR|Placebo|Placebo daily for three consecutive days, followed by study treatment (tafenoquine 200 mg or placebo) once per week for 51 weeks
62629431|NCT00640419|EXPERIMENTAL|1|
62629432|NCT00640419|EXPERIMENTAL|2|
62629433|NCT00640419|PLACEBO_COMPARATOR|3|
62629434|NCT02420262|EXPERIMENTAL|IDegLira|
62629435|NCT02420262|ACTIVE_COMPARATOR|IGlar plus IAsp|
62629436|NCT00905424|EXPERIMENTAL|Active|Antidepressant + SPD489
62629437|NCT00905424|PLACEBO_COMPARATOR|Placebo|Antidepressant + placebo
62629438|NCT03218371||study group (Indentation)|Eyes (participants) for whom chandelier-assisted peripheral vitrectomy under air had been performed with scleral indentation. (Exposure)
62063797|NCT02812472|ACTIVE_COMPARATOR|treadmill training without functional electrical stimulation|Subjects in the control group received additional treadmill training without functional electric stimulation for 25 minutes per session, followed by 5 minutes cool down for 12 sessions.
62063798|NCT01457105|EXPERIMENTAL|ComVi biliary stent|
62063799|NCT04811599||deep learning algorithm group|Before patients going through colonoscopy or gastroscopy ,taking them tongue images and collecting basic information by mobile phone with Anymed.After examination,endoscopic report and histology analysis is collected .Categorizing the images by gastrointestinal diseases，developing and validating a deep learning algorithm for the diagnosis of digestive tract diseases depending on tongue images.Extracting tougue coating,gastric mucosa and stool DNA by high-throughput sequencing,and analyzing their composation,adundance and diversity.
62268986|NCT01146873|EXPERIMENTAL|Group 2: Efavirenz (EFV)|Participants are assigned to switch to an EFV-based antiretroviral regimen. Efavirenz was prescribed once daily in the evening at 200 mg for weights of 10 kg to 13.9 kg (22-30 lb) and 300mg for weights of 14 kg to 24.9 kg (31-55 lb). Efavirenz was available in 50-mg and 200-mg capsules. If children were unable to swallow capsules, caregivers were shown how to open the capsules and dissolve the contents in water.
62063800|NCT03324659|EXPERIMENTAL|Exercise and Meditation|The Exercise and Meditation group will practice mindfulness meditation immediately before walking treadmill exercise, five days per week for four weeks.
62268987|NCT01146873|ACTIVE_COMPARATOR|Group D: Stavudine (D4T)|Children are assigned to remain on their current antiretroviral regimen, which includes D4T. D4T was given at 1 mg/kg twice daily
62063801|NCT03324659|SHAM_COMPARATOR|Control|The Control group will listen to an audio book followed by quiet rest, five days per week for four weeks.
62268988|NCT01146873|EXPERIMENTAL|Group A: Abacavir (ABC)|Children stop taking D4T and switch to ABC. ABC was given at 8 mg/kg twice daily.
62268989|NCT05138081|EXPERIMENTAL|PNF Stretching: Group A|Routine physical therapy treatment
62629439|NCT03218371||control group (Non-indentation)|eyes (participants) for whom chandelier-assisted peripheral vitrectomy under air had been performed without scleral indentation.
62629440|NCT04727593|EXPERIMENTAL|Mindfulness Based Cognitive Therapy (MBCT)|Group intervention on Mindfulness-Based Cognitive Therapy classic program plus 4 monthly consolidation sessions of 90 minutes each.
62629441|NCT04727593|OTHER|Treatment as Usual (TAU)|TAU will be the control condition.
62629442|NCT02638987|EXPERIMENTAL|Dry needling|After the second computer task, a single dry needling session will be performed with the subject lying on the non painful side. After palpation of a taut band and detection of MTrP 2 in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the MTrP and will move the needle up and down in multiple directions. When local twitch responses are elicited, this will be repeated until the local twitch responses are extinct.
62629443|NCT02638987|NO_INTERVENTION|Rest|After the first computer task, participants will rest in sidelying position for 10 minutes.
62629444|NCT00925808||Unsuspected VTE|Prevalence of unsuspected VTE in oncology patients on routine staging CT scans of the thorax, abdomen and pelvis
62629445|NCT02155452||With ALA|Patients with malignant glioma. 25 patients will be provided the ALA for inducing fluorescence
62629446|NCT02155452||Without ALA|5 tumor tissue samples from ACTREC tumor tissue repository will be obtained. These would be malignant gliomas or other brain tumor samples where ALA is usually not administered and will be used as controls and for calibration purposes
62629447|NCT01052532||Mitral Regurgitation pre&post operation|Patients with severe Mitral Regurgitation without evidence of ischemia are tested prior to surgery and after valve repair.
62629448|NCT02232477|EXPERIMENTAL|Open-label treatment|laronidase 1.74 mg IT q 3 months for five years
62629449|NCT03887585|EXPERIMENTAL|Achilles tendon lengthening|Surgery of percutaneous Achilles tendon lengthening by triple hemisection
62629450|NCT04711694|EXPERIMENTAL|Early Mindfulness Intervention|The Early MBI group partake on the mindfulness intervention after first outcome assessment.
62629451|NCT04711694|PLACEBO_COMPARATOR|Late Mindfulness Intervention|"The Late MBI group partake on the mindfulness intervention after the second outcome assessment.~This groups is the control group for the Early MBI group.~After the second assessment, this group engage on the same intervention as the early group."
62629452|NCT01951118|EXPERIMENTAL|Donepezil Treatment & Atropine Challenge|Atropine nasal spray is administered at baseline for the atropine challenge which involves administration of the 40-item UPSIT immediately before and 45 minutes after atropine administration. Immediately after the atropine challenge, donepezil treatment is started and continues for 52 weeks.
62629453|NCT03382418|EXPERIMENTAL|Group 1: gp145 C.6980 (high dose)|Participants will receive 300 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
62629454|NCT03382418|EXPERIMENTAL|Group 2: gp145 C.6980 (low dose)|Participants will receive 100 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
62629455|NCT03382418|PLACEBO_COMPARATOR|Group 3: Placebo|Participants will receive placebo at Day 0 and Months 2 and 6.
62629456|NCT04687111|ACTIVE_COMPARATOR|Control|Valsartan 40mg bid titrated to maximum dose of 160mg bid
62629457|NCT04687111|EXPERIMENTAL|Intervention|Sacubitril/Valsartan 50mg bid titrated to maximum dose of 200mg bid
62629458|NCT04224532|EXPERIMENTAL|Group P|Pneumoperitoneum is induced before reverse Trendelenburg position.
62629459|NCT04224532|EXPERIMENTAL|Group RT|Pneumoperitoneum is induced after reverse Trendelenburg position.
62629460|NCT05789056|EXPERIMENTAL|QRX003, 4% QAM|Subjects will apply test article once daily in the morning (QAM) for 12 weeks
62629461|NCT05789056|EXPERIMENTAL|QRX003, 4% BID|Subjects will apply test article twice daily (BID) for 12 weeks
62629462|NCT00490919|EXPERIMENTAL|Double-blind BTDS 10 or 20|Buprenorphine transdermal system 10 or 20 mcg/h applied for 7-day wear
62629463|NCT00490919|PLACEBO_COMPARATOR|Double-blind Placebo TDS|Placebo transdermal system to match BTDS patches, applied for 7 days
62268990|NCT05138081|EXPERIMENTAL|Stabilization Exercises: Group B|Routine physical therapy treatment
62629464|NCT01738919|ACTIVE_COMPARATOR|Non-subluxated - splinting|Conservative treatment with splinting for 6 weeks.
62629465|NCT01738919|ACTIVE_COMPARATOR|Non-subluxated - operation|Operative treatment with extension block technique
62629466|NCT04559646||"Group A Haemoblock"|"100 patients. Haemostatic solution Haemoblock will be used after pocket formation during pacemaker implantation."
62629467|NCT04559646||"Group B Control"|100 patients. Saline solution will be used after pocket formation during pacemaker implantation.
62629468|NCT02983760|ACTIVE_COMPARATOR|Planar V/Q-based strategy|Control arm
62063802|NCT05667779|EXPERIMENTAL|QRL-101|Single-ascending doses of QRL-101 will be administered orally to healthy participants
62629469|NCT02983760|ACTIVE_COMPARATOR|CTPA-based strategy|Control arm
62629470|NCT02983760|EXPERIMENTAL|V/Q SPECT-based strategy|Experimental arm
62629471|NCT03365934|EXPERIMENTAL|ADHESIVE BANDAGE #1|bandage applied to wounded site.
62629472|NCT03365934|EXPERIMENTAL|ADHESIVE BANDAGE #2|bandage applied to wounded site.
62629473|NCT03365934|EXPERIMENTAL|ADHESIVE BANDAGE #3|bandage applied to wounded site
62629474|NCT03365934|EXPERIMENTAL|Antibacterial Bandage with 0.8% BZK|bandage with 0.8% Benzalkonium Chloride (BZK) applied to wounded site
62629475|NCT03365934|OTHER|Intact and No Bandage|This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
62629476|NCT03365934|OTHER|Wounded and No Bandage|This test site will be wounded and no bandage applied, serving as a positive control site.
62629477|NCT06296472|ACTIVE_COMPARATOR|Standard|
62629478|NCT06296472|EXPERIMENTAL|Experimental|
62629479|NCT04396600||Healthcare Workers Already Starting Peer Support Program|
62629480|NCT04396600||Healthcare Workers Starting Peer Support Program Later|
62629481|NCT04086121|EXPERIMENTAL|Spesolimab 600 mg|"600 milligrams (mg) solution for subcutaneous (SC) injection of BI 655130 (Spesolimab) were to administered subcutaneously every 4 weeks.~All patients will return 16 weeks post the last treatment for an End of Study (EOS) visit."
62629482|NCT02028507|EXPERIMENTAL|Cohort 1: Palbociclib plus Exemestane|- Cohort 1:Palbociclib 125 mg orally once daily on Day 1 to Day 21 followed by 7 days off treatment on every 28 days cycles in combination with Exemestane 25 mg orally once daily.
62629483|NCT02028507|ACTIVE_COMPARATOR|Cohort 1:Capecitabine|Cohort 1: Capecitabine, 1,250 mg/m2 twice daily for 2 weeks followed by a 1 week rest period, given as 3 weeks cycles. Capecitabine must be administered at a dose of 1,000 mg/m2 twice daily for 2 weeks followed by a 1 week of rest period, given as 3 weeks cycles, in patients over 70 years of age.
62629484|NCT02028507|EXPERIMENTAL|Cohort 2: Palbociclib plus Fulvestrant|- Cohort 2: Palbociclib 125 mg orally once daily on Day 1 to Day 21 followed by 7 days off treatment on every 28 days cycles in combination with Fulvestrant 500 mg on Days 1 and 15 of Cycle 1, and Day 1 of each subsequent 28 days Cycle.
62629485|NCT02028507|ACTIVE_COMPARATOR|Cohort 2:Capecitabine|Cohort 2:Capecitabine, 1,250 mg/m2 twice daily for 2 weeks followed by a 1 week rest period, given as 3 weeks cycles. Capecitabine must be administered at a dose of 1,000 mg/m2 twice daily for 2 weeks followed by a 1 week of rest period, given as 3 weeks cycles, in patients over 70 years of age.
62629486|NCT05448378|EXPERIMENTAL|D-chiro-inositol|Patients will take D-chiro-inositol. We will make two blood sampling, at the baseline and after one-month treatment
62629487|NCT06613113|EXPERIMENTAL|Fruquintinib Group|Participants will receive the combination of Fruquintinib and Adebrelimab within 3 weeks after completion of high and low dose radiotherapy on metastases until disease progression or intolerable toxicity occurred.
62629488|NCT01634308|EXPERIMENTAL|Novosis(bongros/BMP-2)|
62629489|NCT01634308|ACTIVE_COMPARATOR|Bio-oss|
62629490|NCT03545932|EXPERIMENTAL|Hydrogymnastics|Hydrogymnastics Program
62629491|NCT03984955|ACTIVE_COMPARATOR|Group A PRP injection|"Platelet-Rich Plasma injection Single therapeutic injection of Platelet-Rich Plasma performed under ultrasound guidance.~This group will also undergo a class-based physiotherapy intervention. This outcomes for this group will be compared to those receiving Sodium hyaluronate with mannitol (Ostenil Tendon) and those receiving the sham injection."
62629492|NCT03984955|ACTIVE_COMPARATOR|Group B Ostenil Tendon|Sodium hyaluronate with mannitol (Ostenil Tendon) Single therapeutic injection of sodium hyaluronate with mannitol (marketed under the device name Ostenil Tendon) under ultrasound guidance. This group will also undergo a class-based physiotherapy intervention.
62629493|NCT03984955|SHAM_COMPARATOR|Group C control group|Subcutaneous sham injection. This group will also undergo a class-based physiotherapy intervention. The outcomes for this group will be compared to those receiving Sodium hyaluronate with mannitol (Ostenil Tendon) and to those receiving PRP injection.
62629494|NCT03620149|EXPERIMENTAL|Denosumab|denosumab at reduced dose
62629495|NCT02440048|EXPERIMENTAL|HA ®Bond-apatite|10 extraction sockets will be preserved with Bond Apatite synthetic bone substitutes as test group
62629496|NCT02440048|ACTIVE_COMPARATOR|BioOss bovine bone substitute|10 extraction sockets will be preserved with BioOss particles bovine bone substitute as a positive control
62629497|NCT02440048|NO_INTERVENTION|extraction|10 extraction sockets with no use of bone substitute as negative control.
62629498|NCT06056635|EXPERIMENTAL|Karl Storz Curved or Straight Scope|A Karl Storz Curved (11508AAK) or Straight (11506AAK) Fetoscope will be used to provide visualization during in-utero (in the womb) diagnostic and interventional procedures. The curved scope will be used in patients with a placenta that sits at the front of their uterus. The straight scope will be used in patients with a placenta that sits at the back of their uterus.
62629499|NCT04948827|EXPERIMENTAL|Part A1 - Single-Dose (Active; 150 mg )|In Part A, cohorts of healthy nonsmokers were randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects were randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.
62629500|NCT04948827|EXPERIMENTAL|Part A3 - Single-Dose Food Effect (Active; 225 mg)|In this two-period food-effect cohort, each healthy nonsmoker subject received the randomly assigned treatment (SBP-9330 or placebo) under fasting conditions (Period 1). After a 7- to 14-day washout period, subjects received the same single dose of SBP-9330 or placebo in a fed state (Period 2) 30 minutes after the start of an FDA High-Fat and High-Calorie Breakfast. A sentinel group of 2 subjects were randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.
62629501|NCT04948827|EXPERIMENTAL|Part A2 - Single-Dose (Active; 300 mg)|In Part A, cohorts of healthy nonsmokers were randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects were randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.
62268991|NCT02129959||laparoscopy|laparoscopic cholecystectomy, laparoscopic gastrectomy, laparoscopic colectomy, laparoscopic appendectomy, laparoscopic assisted vaginal hysterectomy, robot-assisted laparoscopic radical prostatectomy
62629502|NCT04948827|EXPERIMENTAL|Part A4 - Single-Dose (Active; 450 mg)|In Part A, cohorts of healthy nonsmokers were randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects were randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.
62629503|NCT04948827|EXPERIMENTAL|Part A5 - Single-Dose (Active; 600 mg)|In Part A, cohorts of healthy nonsmokers were randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects were randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.
62629504|NCT04948827|PLACEBO_COMPARATOR|Part A - Single-Dose (Placebo; pooled)|In Part A, cohorts of healthy nonsmokers were randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects were randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.
62268992|NCT06050044|EXPERIMENTAL|Group A (hyperbaric bupivacaine)|Patients were injected intrathecally with 20 mg hyperbaric bupivacaine 0.5% solution.
62268993|NCT06050044|EXPERIMENTAL|Group B (Mixture of Hyperbaric and Isobaric Bupivacaine)|Patients received 10 mg hyperbaric bupivacaine and 10 mg isobaric bupivacaine 0,5 % solution.
62268994|NCT01550562|PLACEBO_COMPARATOR|Sham Stimulation|Sham subthreshold spinal cord stimulation therapy
62268995|NCT01550562|ACTIVE_COMPARATOR|Treatment 1|subthreshold spinal cord stimulation therapy
62629505|NCT04948827|EXPERIMENTAL|Part B1 - Multiple-Dose Active (150 mg)|In Part B, cohorts of healthy nonsmokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
62268996|NCT01550562|EXPERIMENTAL|Treatment 2|subthreshold spinal cord stimulation therapy
62268997|NCT01069822|EXPERIMENTAL|1|midazolam + AZD6765 IV solution
62268998|NCT01069822|ACTIVE_COMPARATOR|2|
62629506|NCT04948827|EXPERIMENTAL|Part B2 - Multiple-Dose Active (225 mg)|In Part B, cohorts of healthy nonsmokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
62268999|NCT05346705|EXPERIMENTAL|Tongue/soft palate muscle control function training group|In the sleep center, patients undergo a week of upper airway muscle training for 2 hours a day under the guidance of a doctor
62269000|NCT05346705|EXPERIMENTAL|Soft palate muscle group vocal resistance training group|In the sleep center, patients undergo a week of upper airway muscle training for 2 hours a day under the guidance of a doctor
62269001|NCT05346705|PLACEBO_COMPARATOR|Simple tongue extension, cheek drumming/voice training group|In the sleep center, patients undergo a week of upper airway muscle training for 2 hours a day under the guidance of a doctor
62629507|NCT04948827|EXPERIMENTAL|Part B3 - Multiple-Dose Active (300 mg)|In Part B, cohorts of healthy nonsmokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
62629508|NCT04948827|PLACEBO_COMPARATOR|Part B - Multiple-Dose Placebo (pooled)|In Part B, cohorts of healthy nonsmokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
62629509|NCT04948827|EXPERIMENTAL|Part C1 - Smoker Phase (Active; 150 mg)|In Part C, cohorts of healthy smokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
62629510|NCT04948827|EXPERIMENTAL|Part C2 - Smoker Phase (Active; 225 mg)|In Part C, cohorts of healthy smokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
62629511|NCT04948827|PLACEBO_COMPARATOR|Part C - Smoker Phase (Placebo; pooled)|In Part C, cohorts of healthy smokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
62269002|NCT03467464|EXPERIMENTAL|Intervention|EMDR treatment
62269003|NCT00105651|OTHER|Arm 1|
62269004|NCT05562544||Heading Group only|Subjects will perform a ball-passing task using their head
62269005|NCT05562544||Kicking Group then Heading Group|Subjects will perform a ball-passing task with their foot first, then will perform a ball-passing task using their head
62269006|NCT06072885||Laparoscopic pediatric surgery|Pediatric patients who are scheduled for laparoscopic surgeries in supine position (e.g. laparoscopic appendectomy, laparoscopic cholecystectomy, laparoscopic nissen fundoplication)
62451644|NCT03020121|EXPERIMENTAL|BD HPV assay on Viper LT|"The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.~Device: BD HPV assay on Viper LT The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test. Colposcopy/biopsy will be performed on all subjects."
62629512|NCT02953015|EXPERIMENTAL|Manipulative articulatory and myofascial techniques Group|Manipulative and myofascial techniques
62269007|NCT01014741|EXPERIMENTAL|Ibutilide arm|
62269008|NCT01014741|PLACEBO_COMPARATOR|Placebo arm|
62629513|NCT02953015|ACTIVE_COMPARATOR|Transcutaneous Electrical Nerve Stimulation Group|Electrical Nerve Stimulation
62629514|NCT01681238|OTHER|Protocol group 1|Using standard hemodynamic therapy
62629515|NCT01681238|EXPERIMENTAL|Protocol group 2|Using goal-directed therapy
62629516|NCT02512172|EXPERIMENTAL|Oral CC-486 & MK-3475|Oral CC-486 300 mg days 1-14 or 21 every 28 days + IV MK-3475 200 mg days 1 and 15 every 28 days
62629517|NCT02512172|EXPERIMENTAL|Romidepsin & MK-3475|Romidepsin 14 mg/m2 days 1, 8 and 15 + IV MK-3475 200 mg days 1 and 15 every 28 days
62629518|NCT02512172|EXPERIMENTAL|Oral CC-486 & Romidepsin & MK-3475|Oral CC-486 300 mg days 1-14 or 21 + romidepsin 7 mg/m2 (days 1, 8 and 15) + IV MK-3475 200 mg days 1 and 15 every 28 days.
62629519|NCT00168428|EXPERIMENTAL|botulinum toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
62629520|NCT00168428|PLACEBO_COMPARATOR|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
62269009|NCT02386150|EXPERIMENTAL|Group 1: 10 μg|10 μg RVEc is to be administered given in the volar surface of the forearm by ID injection (in alternate arms for each vaccination unless there is a medical reason not to alternate arms) with a needle and syringe (ID adapter may be used) (0.1 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
62269010|NCT02386150|EXPERIMENTAL|Group 2: 20 μg|20 μg RVEc is to be administered given in the volar surface of the forearm by ID injection (in alternate arms for each vaccination unless there is a medical reason not to alternate arms) with a needle and syringe (ID adapter may be used) (0.1 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
62063803|NCT05667779|PLACEBO_COMPARATOR|Placebo|Single-ascending doses of comparator placebo will be administered orally to healthy participants
62063804|NCT01654081|EXPERIMENTAL|Irinotecan|Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
62063805|NCT01068314|EXPERIMENTAL|Repetitive handgrip exercise|After baseline testing and randomization, subjects in this group are instructed to perform the intervention: daily repetitive handgrip exercise with upper arm compression band. Brachial artery endothelial function and venous compliance are tested at baseline and 6 weeks.
62063806|NCT01068314|NO_INTERVENTION|No arm exercise|Time control. Subjects do usual activities without any exercise intervention. Brachial artery endothelial function and venous compliance are tested at baseline and 6 weeks.
62269011|NCT00822107|EXPERIMENTAL|Thiazide Response|Hydrochlorothiazide 50 mg will be administered by mouth once.
62451645|NCT03054103|PLACEBO_COMPARATOR|Midazolam alone|Drug: Midazolam titrated 0.5-2.0 mg + normal saline placebo. Midazolam + Normal saline
62451646|NCT03054103|ACTIVE_COMPARATOR|Midazolam + Ketamine 5 mg|Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 0.5 ML. Midazolam + Ketamine 10 MG/ML: 0.5 ML
62269012|NCT01485757|EXPERIMENTAL|L-arginine|
62269013|NCT06022263|PLACEBO_COMPARATOR|Placebo|1.5 mL of Omnipaque mixed with water for injection
62269014|NCT06022263|EXPERIMENTAL|STA363|1.5 mL of STA363 (lactic acid, 120 mg/mL) mixed with Omnipaque
62269015|NCT01425151|ACTIVE_COMPARATOR|i-Gel|
62269016|NCT01425151|EXPERIMENTAL|ProSeal|
62451647|NCT03054103|ACTIVE_COMPARATOR|Midazolam + Ketamine 10 mg|Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 1 ML. Midazolam + Ketamine 10 MG/ML: 1 ML
62451648|NCT04502875|EXPERIMENTAL|Treatment Arm|Intracavernosal infusion of Platelet Rich Plasma
62451649|NCT04502875|ACTIVE_COMPARATOR|Control Arm|Intracavernosal infusion of Platelet Poor Plasma
62451650|NCT06120127|EXPERIMENTAL|chemotherapy with radiotherapy and immunotherapy|radiotherapy: SBRT of liver lesions; postoperative chemotherapy and immunotherapy: chemotherapy by investigators' choice with sintilimab for 18 weeks
62451651|NCT06120127|ACTIVE_COMPARATOR|chemotherapy|postoperative chemotherapy: chemotherapy by investigators' choice for 18 weeks
62451652|NCT06146257|EXPERIMENTAL|Dose Escalation of GLB-001 as a Monotherapy in Participants with R/R AML and R/R HR-MDS-Phase 1a|Part 1a (Dose Escalation) of the study will enroll R/R AML and R/R HR-MDS participants and will evaluate the safety, tolerability, PK, PD and preliminary efficacy of GLB-001 administered orally, and determine the maximum tolerated dose/maximum administered dose (MTD/MAD) in R/R AML or R/R HR-MDS patients who are eligible for dose limiting toxicity (DLT) evaluation.
62063807|NCT04199312|EXPERIMENTAL|Muscle Toning, Firming and Strengthening|The EMS device will be evaluated for muscle toning, firming and strengthening in the abdomen.
62269017|NCT02092571|EXPERIMENTAL|Treatment A|1 ring intravaginal for 7 days, produced from the new process
62269018|NCT02092571|EXPERIMENTAL|Treatment B|1 ring intravaginal for 7 days, produced from the legacy process
62269019|NCT02035995||Healthy volunteers|This group consisted of age matched non-pregnant healthy volunteers
62269020|NCT02035995||Healthy pregnant volunteers|This group consisted of age matched healthy pregnant volunteers
62269021|NCT00601068||Observational|Group of patients with osteochemonecrosis related to oral bisphosphonate use
62269022|NCT04697628|EXPERIMENTAL|Tisotumab vedotin|Tisotumab vedotin monotherapy
62451653|NCT06146257|EXPERIMENTAL|Dose Expansion of GLB-001 as a Monotherapy in Participants with R/R AML and R/R HR-MDS-Phase 1b|Part 1b (Dose Expansion) will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R AML and R/R HR-MDS participants.
62451654|NCT02268669|ACTIVE_COMPARATOR|Primary angioplasty|Patients assigned to this treatment will undergo cardiac catheterization within the time recommended by current guidelines. Double antiagregation will be used, vascular access wil be obtained and bivalirudin will be used as anticoagulation; all following current guidelines recommendations
62451655|NCT02268669|ACTIVE_COMPARATOR|Post-thrombolysis angioplasty|Patients will receive tenecteplase, enoxaparin, and double antiagreagation with clopidogrel or aspirin as recommended guidelines. Criteria of no reperfusion after fibrinolysis is defined as absence of ST-segment lowering \>50%, 90 minutes after fibrinolysis. If not reperfusion is achieved recue angiplasty will be performed inmmediately if reperfusion is achieved cardiac catheterization will be performed the mornig following the day of randomization
62063808|NCT04307706|EXPERIMENTAL|Intervention group|''Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group
62063809|NCT04307706|NO_INTERVENTION|Control group|Only data collection was carried out. No attempt was made by the researcher during the study.
62269023|NCT04697628|ACTIVE_COMPARATOR|Chemotherapy|Investigator's choice of one chemotherapy treatment (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)
62063810|NCT04903457|EXPERIMENTAL|Real stimulation before motor learning training|Patients receive five sessions of tDCS stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system immediately before sequential finger tapping task.
62063811|NCT04903457|ACTIVE_COMPARATOR|Sham stimulation before motor learning training|Patients receive five sessions of sham stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system immediately before sequential finger tapping task.
62063812|NCT01975220|EXPERIMENTAL|High dose, fasted|1 fixed dose combination (FDC) tablet vs. 3 single tablets under fasted conditions
62063813|NCT01975220|EXPERIMENTAL|High dose, fed|1 fixed dose combination (FDC) tablet vs. 3 single tablets under fed conditions
62629521|NCT00169104|ACTIVE_COMPARATOR|1|Subjects will receive ten doses of G-CSF at a dose of 5 mcgm/kg daily Monday through Friday for the first two weeks of the trial. All patients will also receive trastuzumab at 4 mg/kg week 1, and 2 mg/kg week 2 during the first two weeks of the trial. All patients will then receive 12 weeks of trastuzumab at 2 mg/kg IV weeks 3 through 14, vinorelbine at 25 mg/m2 IV weekly weeks 3,4,6,7,9,10,12,13 and G-CSF at 5 mcgm/kg SQ daily Monday through Friday weeks 3-14.
62629522|NCT00169104|PLACEBO_COMPARATOR|2|Subjects will receive ten doses of a placebo injection SQ daily Monday through Friday for the first two weeks of the trial. All patients will also receive trastuzumab at 4 mg/kg week 1, and 2 mg/kg week 2 during the first two weeks of the trial. All patients will then receive 12 weeks of trastuzumab at 2 mg/kg weeks 3-14, vinorelbine at 25 mg/m2 IV weekly weeks 3,4,6,7,9,10,12,13, and G-CSF at 5 mcgm/kg SQ daily Monday through Fridays weeks 3-14.
62629523|NCT03293017|EXPERIMENTAL|Baclofen 30 mg/day|baclofen 30 mg/day
62629524|NCT03293017|EXPERIMENTAL|Baclofen 60 mg/day|
62629525|NCT03293017|PLACEBO_COMPARATOR|Placebo|
62629526|NCT02859350|EXPERIMENTAL|Group 1a (PfSPZ Vaccine)|18-35 years; n= 20; 3 doses of 2.7x10\^6 PfSPZ Vaccine given eight weeks apart. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
62063814|NCT01975220|EXPERIMENTAL|Low dose, fasted|2 fixed low dose combination (FDC) tablets vs. 4 single tablets under fed conditions
62063815|NCT00110253|EXPERIMENTAL|S-Caine Peel|
62063816|NCT01615575|ACTIVE_COMPARATOR|Haemorrhoidal dearterialisation|Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and addiction of rectal mucopexy.
62063817|NCT01615575|ACTIVE_COMPARATOR|Stapler haemorrhoidopexy|Haemorrhoidopexy was performed with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA.)
62063818|NCT05670002|OTHER|Intervention|Taking milk supplement
62269024|NCT02386488|EXPERIMENTAL|Vortioxetine 10 mg single dose|8 men and 8 women
62269025|NCT02386488|EXPERIMENTAL|Vortioxetine 20 mg single dose|8 men and 8 women
62269026|NCT02386488|EXPERIMENTAL|Vortioxetine 10 mg multiple dose|8 men and 8 women
62269027|NCT02386488|EXPERIMENTAL|Vortioxetine 20 mg multiple dose|8 men and 8 women
62269028|NCT03764852|EXPERIMENTAL|outpatient laparoscopic|Patients will have laparoscopic outpatients. The procedure is identical to that performed in hospital. What changes is that the patient will return home at night if her condition allows it.
62269029|NCT03922009|EXPERIMENTAL|Virtual Reality group|The primary objective of this study was to evaluate the use of VR to reduce anxiety in spinal anesthesia patients compared with controls
62269030|NCT03922009|NO_INTERVENTION|control group|General routine care
62269031|NCT01309659|EXPERIMENTAL|Immediate Intervention Group|Subjects randomized to the immediate treatment group will be scheduled to begin treatment with IV iron infusion immediately (or within 2 business days). They will receive 200mg IV iron sucrose a week for 5 weeks followed by 19 weeks of follow up.
62269032|NCT01309659|EXPERIMENTAL|Wait List Control|Subjects randomized to the wait list control group will have an observation visit at week 6 and week 12. After that they will begin treatment with IV iron infusion. They will receive 200mg IV iron sucrose a week for 5 weeks followed by 7 weeks of follow up
62269033|NCT04599283|ACTIVE_COMPARATOR|Symptomatic|"1. You have to be a male patient.~2. You must have a smartphone (iPhone or Android).~3. You are at least 35 years old and have already been diagnosed with BPH or Overactive Bladder (OAB) condition OR you are presenting at least one of the following BPH / OAB symptoms:~1. Frequent or urgent need to urinate 2. Increased frequency of urination at night (nocturia) 3. Difficulty starting urination 4. Weak urine stream or a stream that stops and starts 5. Dribbling at the end of urination 6. Inability to completely empty the bladder 7. Experience urge incontinence - the involuntary loss of urine immediately following an urgent need to urinate"
62451656|NCT01024738|PLACEBO_COMPARATOR|Fluoride toothpaste|negative control toothpaste
62451657|NCT01024738|ACTIVE_COMPARATOR|Triclosan/Fluoride toothpaste|positive control toothpaste (Total toothpaste)
62451658|NCT01024738|ACTIVE_COMPARATOR|Chlorhexidine Oral Rinse|positive control oral rinse
62451659|NCT03050593||HFpEF group|clinical or radiographic evidence of heart failure and left ventricular ejection fraction \> 50% on transthoracic echocardiography
62629527|NCT02859350|PLACEBO_COMPARATOR|Group 1a (normal saline)|18-35 years; n=6; 3 doses of normal saline given 8 weeks apart. Volunteers will receive CHMI between 10 and 14 weeks post last dose of NS (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
62269034|NCT04599283|ACTIVE_COMPARATOR|Asymptmatic|"1. You have to be a male patient.~2. You must have a smartphone (iPhone or Android).~3. You are at least 18 years old and have not been diagnosed with BPH or OAB, and you are not presenting any of the above symptoms."
62269035|NCT04515693|EXPERIMENTAL|Maximal Assist group|Subjects with acute stroke who ambulate with Maximal assistance of 1.
62269036|NCT04515693|EXPERIMENTAL|Moderate Assist group|Subjects with acute stroke who ambulate with Moderate assistance of 1.
62269037|NCT04515693|EXPERIMENTAL|Minimal Assist group|Subjects with acute stroke who ambulate with Minimal assistance of 1.
62269038|NCT04515693|EXPERIMENTAL|Supervision/Modified Independence/Independence|Subjects who walk without physical assistance of a helper.
62451660|NCT03050593||HFrEF group|Clinical or radiographic evidence of heart failure and left ventricular ejection fraction \< 40% on transthoracic echocardiography
62451661|NCT03050593||Healthy control group|Asymptomatic controls (age and sex-matched) without known heart disease
62451662|NCT01925755||Group 1|
62451663|NCT03806036|ACTIVE_COMPARATOR|Vitamin D group|50 women will receive 300.000 I.U single dose of VIT D IM injection (Memphis company) , and in the next menstrual cycle induction done by clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day
62063819|NCT02213328|EXPERIMENTAL|Truvada|All participants will take Truvada, once daily by mouth for the first 12 weeks of the study. After Week 12 of the study, only participants who indicate a willingness to use Truvada PrEP and who do not have any medical reasons not to do so will continue to receive the Truvada tablets through Week 52.
62629528|NCT02859350|EXPERIMENTAL|Group 1b (PfSPZ CVac)|18-35 years; n=20; 3 doses of 1.0x10\^5 PfSPZ Challenge given every four weeks. Group 1b will start 8 weeks after Group 1a. Volunteers in Group 1b will receive their first immunization after the loading dose of chloroquine has been administered. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
62629529|NCT02859350|PLACEBO_COMPARATOR|Group 1b (normal saline)|18-35 years; n=6; 3 doses of normal saline given 4 weeks apart. Group 1b will start 8 weeks after Group 1a. Volunteers will receive CHMI between 10 and 14 weeks post last dose of NS (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
62269039|NCT02849366|EXPERIMENTAL|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62451664|NCT03806036|PLACEBO_COMPARATOR|Control group|50 women will receive clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day
62063820|NCT03383562||morning group|patients in the morning group are operated during 8:30 a.m. to 2:00 p.m.
62451665|NCT00944866||RA with drug|
62451666|NCT00944866||RA without drug|
62451667|NCT04723602|ACTIVE_COMPARATOR|cAd3-Marburg at 1 x 10^11 Particle Units (PU)|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10\^11 Particle Units (PU) vaccine.
62451668|NCT04723602|ACTIVE_COMPARATOR|cAd3-EBO-S at 1 x 10^11 PU vaccine|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10\^11 Particle Units (PU) vaccine.
62451669|NCT01909622|EXPERIMENTAL|Vitamin D-fortified milk|Skim milk fortified with 600 IU vitamin D3 / 250 mL
62063821|NCT03383562||afternoon group|patients in the morning group are operated during 2:00 p.m. to 8:00 p.m.
62063822|NCT03383562||night group|patients in the morning group are operated during 8:00 p.m. to 12:00 p.m.
62063823|NCT03104647|EXPERIMENTAL|VRP-Clinic|VRP-Clinic software on a virtual reality platform
62088106|NCT00146640|ACTIVE_COMPARATOR|IR Prednisone|Participants will receive IR prednisone in the morning and placebo matching to MR prednisone at bed time. Total duration of double blind treatment will be 12 weeks.
62088107|NCT02496494|EXPERIMENTAL|Tacrolimus conversion group|Cyclosprine was converted to tacrolimus in kidney transplant recipients.
62269040|NCT02849366|ACTIVE_COMPARATOR|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62269041|NCT05670587|EXPERIMENTAL|All participants|
62269042|NCT00605423|ACTIVE_COMPARATOR|1|Dose 0.2 ug/day Medidur implant
62269043|NCT00605423|ACTIVE_COMPARATOR|2|Dose 0.5 ug/day Medidur implant
62451670|NCT01909622|ACTIVE_COMPARATOR|Vitamin D-unfortified milk|Unfortified skim milk
62451671|NCT04956666|EXPERIMENTAL|Lyophilized S95014|"Lyophilized S95014 reconstituted was provided 5 mL of extractable volume with the concentration of 750 U/mL.~The vial of lyophilized powder (3.750 U/vial) was reconstituted with 5.2 mL of Sterile Water For Injection to obtain a 750 U/mL solution for single use."
62451672|NCT02593851|EXPERIMENTAL|Part 1: Cohort 1a|Participants (greater than or equal to \[\>=\] 6 months and less than or equal to \[\<=\] 24 months of age) will receive JNJ-53718678, 2 milligram per kilogram body weight (mg/kg) oral solution once daily on Day 1 to Day 7. Dose and/or dosing regimen may be adapted in subsequent cohorts based on the review of the safety/tolerability and full pharmacokinetic data from Cohort 1a.
62629530|NCT02859350|EXPERIMENTAL|Group 2 (PfSPZ Vaccine)|36-65 years; n=12; 3 doses of 2.7x10\^6 PfSPZ Vaccine given 8 weeks apart. Group 2 will start 3 weeks after Group 1a.
62269044|NCT03120286||Overweight and obesity|Women with BMI \>25
62269045|NCT03120286||Normal weight group|Women with BMI =18-24
62629531|NCT02859350|PLACEBO_COMPARATOR|Group 2 (normal saline)|36-65 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 2 will start 3 weeks after Group 1a.
62629532|NCT02859350|EXPERIMENTAL|Group 3 (PfSPZ Vaccine)|11-17 years; n=12; 3 doses of 1.8x10\^6 PfSPZ Vaccine given 8 weeks apart. Group 3 will start 3 weeks after Group 1a.
62629533|NCT02859350|PLACEBO_COMPARATOR|Group 3 (normal saline)|11-17 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 3 will start 3 weeks after Group 1a.
62629534|NCT02859350|EXPERIMENTAL|Group 4 (PfSPZ Vaccine)|6-10 years; n=12; 3 doses of 1.8x10\^6 PfSPZ Vaccine given 8 weeks apart. Group 4 will start 4 weeks after Group 1a.
62629535|NCT02859350|PLACEBO_COMPARATOR|Group 4 (normal saline)|6-10 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 4 will start 4 weeks after Group 1a.
62629536|NCT02859350|EXPERIMENTAL|Group 5 (PfSPZ Vaccine)|1-5 years; n=12; 3 doses of 1.8x10\^6 PfSPZ Vaccine given 8 weeks apart. Group 5 will start 7 weeks after Group 1a.
62629537|NCT02859350|PLACEBO_COMPARATOR|Group 5 (normal saline)|1-5 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 5 will start 7 weeks after Group 1a.
62629538|NCT02859350|EXPERIMENTAL|Group 6a (PfSPZ Vaccine)|6-11 months; n=3; 1 dose of 9.0x10\^5 PfSPZ Vaccine. Group 6a will start 7 weeks after Group 1a.
62629539|NCT02859350|EXPERIMENTAL|Group 6b (PfSPZ Vaccine)|6-11 months; n=12; 3 doses of 1.8x10\^6 PfSPZ Vaccine given 8 weeks apart. Group 6b will start 11 weeks after Group 1a.
62629540|NCT02859350|PLACEBO_COMPARATOR|Group 6b (normal saline)|6-11 months; n=4; 3 doses of normal saline given 8 weeks apart. Group 6b will start 11 weeks after Group 1a.
62629541|NCT06612892|EXPERIMENTAL|Immersive virtual reality|consisted of 30 patients and received procedure as immersive virtual reality program selected to enhance patient to use his upper limbs in order to interact with the show or game selected
62629542|NCT06612892|ACTIVE_COMPARATOR|Passive virtual reality|consisted of 3o patients and received procedure as passive virtual reality program as the patient just wear the headset with a view or show meant only to distract pain while following therapist commands to do active or active assisted upper limbs ROM ex.
62653155|NCT01508000|EXPERIMENTAL|Arm B: modified FOLFOX6 + Bevacizumab and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m2 2-h infusion~Hour 0: Folinic Acid 400 mg/m2 (DL form) or 200 mg/m2 (L form) 2-h infusion~Hour 2 (before 5-FU bolus): Bevacizumab 5 mg/kg IV over 90 minutes infusion\*.~Hour 3.5: 5-FU bolus 400 mg/m2 IV bolus over 2-4 minutes~Hour 3.5: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
62269046|NCT00436371|EXPERIMENTAL|1|Amisulpride 400-800mg per day on a twice-a-day regimen
62269047|NCT06323109||Healthy Controls|Age-matched healthy men with no lower urinary tract symptoms
62269048|NCT06323109||Known BPH/LUTS|Adult men diagnosed with BPH/LUTS
62269049|NCT02791061||Control|"Healthy Volunteers will undergo the following studying procedures:~Cardiovascular Magnetic Resonance Imagine (MRI) Cardiopulmonary exercise testing (CPET) Echocardiography"
62269050|NCT02791061||Congenital Disease|"Patients will undergo the following studying procedures:~Cardiovascular Magnetic Resonance Imagine (MRI) Cardiopulmonary exercise testing (CPET) Echocardiography"
62629543|NCT06190600|ACTIVE_COMPARATOR|Neoadjuvant chemotherapy with Standard Supportive Care|Patients aged 18 to 40 in good physical condition Eastern Cooperative Oncology Group (ECOG) scale 0-1, who are set to receive neoadjuvant chemotherapy will be selected. Criteria for entry into the study include proper liver, kidney and bone marrow function as well as heart ejection fraction of ≥ 50%. Treatment will be carried out according to 4 x AC regimen (doxorubicin 60 mg/ m2 cyclophosphamide 600 mg/ m2 i.v. every 21 or every 14 days + pegfilgastrim) followed by 12 x paclitaxel 80 mg/ m2 every 7 days and in the case of HER2 positive tumors trastuzumab ± pertuzumab (according to SPC).
62269051|NCT04499872||Patient/family Participant|Advance Care Plan with the Trajectory Touchpoint Technique
62063824|NCT03629860|ACTIVE_COMPARATOR|ascending ramus group|"* Local anesthesia will be given to the patient~* flap will be reflected to expose the facial wall of the maxilla then The ascending ramus is accessed.~* A disc bur will be used to make a rectangular osteotomy~* The block bone graft is removed from ascending ramus to recipient site the fixed by mini screws~* Doner site flap is closed by using interrupted internal sutures.~* after atrophic maxillary alveolar ridge augmentation,sub mucosal periosteal releasing cuts is done~* Post-operative medications will be prescribed as follows: amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, metronidazole 5 mg/kg every 8 hours for 7 days"
62063825|NCT03629860|ACTIVE_COMPARATOR|Chin Group|"* Local anesthesia will be given to the patient~* flap will be reflected to expose the facial wall of the maxilla then The chin is accessed.~* A disc bur will be used to make a rectangular osteotomy~* The block bone graft is removed from chin to recipient site the fixed by mini screws~* Doner site flap is closed by using interrupted internal sutures~* after atrophic maxillary alveolar ridge augmentation,submucosal periosteal releasing cuts is done~* Post-operative medications will be prescribed as follows: amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, metronidazole 5 mg/kg every 8 hours for 7days"
62063826|NCT06527664||Custom-made|Revision hip arthroplasty performed for non-oncological reasons, with Paprosky III bone loss
62063827|NCT01423981||Patients with keloid disorder.|All participants have a clinical diagnosis of keloid.
62629544|NCT06190600|EXPERIMENTAL|High Intensity Interval Training (HIIT)|"The group in which, concurrently with chemotherapy,IPA will be ordered, by means of supervised high intensity interval training twice a week.~During the course of chemotherapy, the intensity of physical activity will be increasing."
62063828|NCT03791502|EXPERIMENTAL|Pilates Method Exercises - lower volume|The prescription will consist of 18 exercises, performed in a single series of seven to 10 repetitions, 60 seconds rest between exercises. Each week the exercises will be changed and the same exercise can only be repeated every three weeks. The progression will occur increasing the resistance of the springs and the level of difficulty of the exercises, but without modifying the repetitions. Training intensity will be measured using Modified Borg's Perceived Effort Scale and then kept moderate throughout the program.
62063829|NCT03791502|EXPERIMENTAL|Pilates Method Exercises - higher volume|The participants will conduct a Pilates exercise program based on the recommendations of the American College Medicine of Sports. The prescription will consist of 12 exercises, performed in three sets of seven to ten repetitions and 60s of rest between sets. Every four weeks the exercises will be changed. The progression will occur increasing the resistance of the springs and the level of difficulty of the exercises. Training intensity will be measured using Modified Borg's Perceived Effort Scale and then kept moderate throughout the program.
62063830|NCT03791502|NO_INTERVENTION|Group control|The subjects allocated in the control group will remain with their usual activities, and after the reevaluation will be offered the intervention that presents the greater size of effect.
62269052|NCT03895866||Group A|High-risk HPV persistent infection more than half a year and reversion
62269053|NCT03895866||Group B|High-risk HPV non-infection
62269054|NCT01946607|ACTIVE_COMPARATOR|Citalopram|20 mg citalopram capsule, 1/ day, after breakfast (approximately 8am), for 7 days
62269055|NCT01946607|PLACEBO_COMPARATOR|Placebo|Placebo capsule 1/ day, after breakfast (approximately 8am), for 7 days
62269056|NCT01262365|PLACEBO_COMPARATOR|Placebo (Weekly infusion)|Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles
62269057|NCT01262365|EXPERIMENTAL|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
62063831|NCT06511999||Comatose participants resuscitated from cardiac arrest|Participants successfully resuscitated from cardiac arrest that are comatose (motor glasgow coma scale \<= 4) upon initial assessment will undergo jugular venous oxygen saturation (SjO2) monitoring with the study device \[TriOx PICC, ICU medical, San Clemente, CA\].
62063832|NCT03842462|ACTIVE_COMPARATOR|nCPAP|neonates assigned to the nCPAP group will be started on a pressure of 6 cmH2O( adjust range:6-8 cmH2O) by pure CPAP system , with FiO2 (0.21～0.40)adjusted to target SpO2 from 89% to 94%
62063833|NCT03842462|ACTIVE_COMPARATOR|NIPPV|neonates assigned to the NIPPV group will be started with the following parameters: a) positive end-expiratory pressure (PEEP) of 4 cmH2O (can be raised in steps of 1 cmH2O to max 8 cmH2O, according to the oxygenation).b)Peak Inspiratory Pressure (PIP) of15 cmH2O (can be raised in steps of 1 cmH2O to max 25 cmH2O, according to oxygenation,PaCO2 levels and the chest expansion); maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90-95%. c) inspiratory time (IT) will be 0.45 - 0.5 sec (according to clinicians'evaluation of leaks and the appearance of the pressure curve: a small pressure plateau is required and flow may be set accordingly) and rate will be started at30 bpm (can be raised in steps of 5 bpm to max 50 bpm, according to PaCO2 levels).
62629545|NCT02805946|OTHER|intravenous followed by oral|"* Start with posaconazole IV 300mg BID on the first day. Posaconazole will be infused over a period of 90 minutes.~* Days 2-7 patients will receive posaconazole IV 300mg QD.~* Days 8-12 patients will receive posaconazole PO 300mg QD.~* Days 13-16 patients will receive posaconazole PO 200mg QD.~* 3 PK curves will be determined on days 7, 12 and 16 (after the 7th, 12th and 16th dosage)."
62063834|NCT03842462|EXPERIMENTAL|NHFOV|"- neonates assigned to NHFOV will be started with the following boundaries, according to available physiological and mechanical data, as suggested elsewhere:~a) Paw of 10 cmH2O (can be changed in steps of 1 cmH2O within the range range 5- 16cmH2O); Paw will be titrated (within the range) according to open lung strategy, performing alveolar recruitment. Maximal allowed FiO2 will be 0.40 and SpO2 targets will be 89%-94%. b) frequency of 10Hz(can be changed in steps of 1Hz within the range 8-15Hz). c)Inspiratory time 50% (1:1).\[ d)amplitude 25 cmH2O(can be changed in steps of 5 cmH2O within the range 25-50 cmH2O); amplitude will be titrated according to PaCO2."
62063835|NCT05733962|EXPERIMENTAL|Use of the device DBL-4pen|After a 14-day baseline period during which the patient will use a Dexcom G6 Continuous Glucose Monitoring (CGM) and his current therapy (multiple daily injection), the patient will start a 42-day treatment period with the DBL-4pen system followed by an optional 42-day extension period.
62063836|NCT01502995|ACTIVE_COMPARATOR|With laser light|Trial of walking tasks using laser light on walker.
62063837|NCT01502995|ACTIVE_COMPARATOR|Without laser light|Trial of walking task without laser light on walker.
62063838|NCT05101135|EXPERIMENTAL|JT-001|Drug: JT-001
62063839|NCT05101135|PLACEBO_COMPARATOR|JT-001 Placebo|Drug: JT-001 Placebo
62063840|NCT02918500|NO_INTERVENTION|Placebo|Participants will receive 3 weeks of inactive NRT patches.
62451673|NCT02593851|EXPERIMENTAL|Part 1: Cohort 1b|Participants (\>= 6 months and \<= 24 months of age) will receive total daily dose of 6 mg/kg JNJ-53718678 oral solution or placebo \[either in once daily \[qd\] or twice daily \[bid\]) on Day 1 to Day 7.
62063841|NCT02918500|ACTIVE_COMPARATOR|Active|Participants will receive 3 weeks of active NRT patches
62063842|NCT03182140||Kyleena|Non-interventional, observational, uncontrolled study in women that have chosen Kyleena as their contraceptive method before entering the study
62063843|NCT01948180|EXPERIMENTAL|baltaleucel-T|"Treatment consists of 2 infusions of 2x10E7 cells/m2 given on Days 1 and 15 intravenously via a peripheral or central line over a 1 to 10 minute period.~Subjects who tolerate the study treatment well and who do not require treatment with an alternative chemotherapeutic agent will be eligible for up to 3 additional infusions of 2x10E7 cells/m2 administered at week 8, month 3 and month 6."
62063844|NCT00876460|EXPERIMENTAL|BIBF 1120 + docetaxel|Low, medium and high dose of BIBF 1120 and 60 mg/m2, 75 mg/m2 docetaxel every 3 weeks
62063845|NCT06439823|EXPERIMENTAL|Patient with neuromuscular disease or control subjects|Patients and controls will be examined by a neuropediatric or neurologist. they will perform upper and lower limb assessments in a walking laboratory. this study comprises a single session per patient/control subject.
62451674|NCT02593851|EXPERIMENTAL|Part 1: Cohort 1c|Participants (\>= 6 months and \<= 24 months of age) will receive total daily dose of 18 mg/kg JNJ-53718678 oral solution or placebo \[either in a qd or a bid regimen\] on Day 1 to Day 7.
62451675|NCT02593851|EXPERIMENTAL|Part 1: Cohort 1d|Participants (\>= 6 months and \<= 24 months of age) will receive JNJ-53718678 oral solution or placebo \[either in a qd or a bid regimen\] on Day 1 to Day 7. The cohort 1d is optional and may be included at the discretion of the sponsor.
62451676|NCT02593851|EXPERIMENTAL|Part 1: Cohort 1e|Participants (\>= 6 months and \<= 24 months of age) will receive JNJ-53718678 oral solution or placebo \[either in a qd or a bid regimen\] on Day 1 to Day 7. The cohort 1e is optional and may be included at the discretion of the sponsor.
62451677|NCT02593851|EXPERIMENTAL|Part 1: Cohort 2a|Participants (\>= 3 months and less than \[\<\] 6 months of age) will receive total daily dose of 1.5 mg/kg JNJ-53718678 oral solution \[either in a qd or a bid regimen\] on Day 1 to Day 7.
62451678|NCT02593851|EXPERIMENTAL|Part 1: Cohort 2b|Participants (\>=3 months and \< 6 months of age) will receive total daily dose of 4.5 mg/kg JNJ-53718678 oral solution or placebo \[either in a qd or a bid regimen\] on Day 1 to Day 7.
62629546|NCT02805946|OTHER|oral followed by intravenous|"* Start with posaconazole PO 300mg BID on the first day.~* Days 2-7: patients will receive posaconazole PO 300mg QD.~* Days 8-12: patients will receive posaconazole IV 300mg QD. Posaconazole will be infused over a period of 90 minutes.~* Days 13-16 patients will receive posaconazole IV 200mg QD.~* 3 PK curves will be determined on days 7, 12 and 16 (after the 7th, 12th and 16th dosage)."
62451679|NCT02593851|EXPERIMENTAL|Part 1: Cohort 2c|Participants (\>= 3 months and \< 6 months of age) will receive total daily dose of 13.5 mg/kg JNJ-53718678 oral solution or placebo \[either in a qd or a bid regimen\] on Day 1 to Day 7
62629547|NCT00618826|EXPERIMENTAL|Treatment Period|Treatment will be administered once every 2 weeks. One cycle of therapy will consist of 14 days. Paclitaxel is administered first after appropriate premedications. Gemcitabine is administered second and Avastin is administered after chemotherapy, all given on day 1 of each cycle.
62451680|NCT02593851|EXPERIMENTAL|Part 1: Cohort 2d|Participants (\>= 3 months and \< 6 months of age) will receive JNJ-53718678 oral solution or placebo \[either in a qd or a bid regimen\] on Day 1 to Day 7. The cohort 2d is optional and may be included at the discretion of the sponsor.
62063846|NCT04591977|EXPERIMENTAL|Self-Sampling Kit|Self-Sampling kit (Evalyn Brush) to collect samples for analysis for HPV/Cervical cancer screening.
62629548|NCT02407873||Cardiac surgery|
62629549|NCT03306095||Early refeeding group|Food Intake by patient with in 4 hours i.e \<4 hours after the EVL procedure
62451681|NCT02593851|EXPERIMENTAL|Part 1: Cohort 2e|Participants (\>= 3 months and \< 6 months of age) will receive JNJ-53718678 oral solution or placebo \[either in a qd or a bid regimen\] on Day 1 to Day 7. The cohort 2e is optional and may be included at the discretion of the sponsor.
62629550|NCT03306095||Delayed refeeding group|Food Intake by patient with in 4 hours i.e \> 4 hours after the EVL procedure
62629551|NCT02153125|EXPERIMENTAL|Eplerenone|25mg eplerenone given daily for a week, followed by 50mg given for a total of 3 months since commencement of treatment
62629552|NCT02153125|PLACEBO_COMPARATOR|Placebo|
62629553|NCT04305028||Experimental: Rivaroxaban [2.5 mg] + Aspirin|Drug: Rivaroxaban 2.5 mg twice daily, tablet Drug: Aspirin 75-100 mg once daily, tablet
62629554|NCT04305028||Active Comparator: Aspirin|Drug: Aspirin 75-100 mg once daily, tablet
62629555|NCT00983463||Obese, bariatric surgery, liver biopsy|Obese subjects approved and scheduled for bariatric surgery at Vanderbilt University Medical Center
62629556|NCT00983463||Normal BMI, abdominal surgery, liver biopsy|Normal weight subjects having elective abdominal surgery at Vanderbilt University Medical Center.
62629557|NCT00983463||Liver transplantation donors and recipients|All livers made available for implantation or explantation will be eligible.
62629558|NCT04957212|EXPERIMENTAL|TCHP regimen (trastuzumab, pertuzumab® (CinnaGen Co.), carboplatin, and docetaxel)|Study drugs are administered intravenously on a 3-weekly schedule and given consecutively on the same day in the following sequence: trastuzumab, followed by pertuzumab, carboplatin, and docetaxel. Trastuzumab is given at an initial dose of 8 mg/kg, followed by 6 mg/kg; pertuzumab® (CinnaGen Co.) is given at an initial dose of 840 mg, followed by 420 mg. Carboplatin is administered at a dose of AUC6 (area under the plasma concentration-time curve) and docetaxel is given at 75 mg/m2.
62629559|NCT04957212|ACTIVE_COMPARATOR|TCHP regimen (trastuzumab, Perjeta®, carboplatin, and docetaxel)|Study drugs are administered intravenously on a 3-weekly schedule and given consecutively on the same day in the following sequence: trastuzumab, followed by pertuzumab, carboplatin, and docetaxel. Trastuzumab is given at an initial dose of 8 mg/kg, followed by 6 mg/kg; Perjeta® is given at an initial dose of 840 mg, followed by 420 mg. Carboplatin is administered at a dose of AUC6 (area under the plasma concentration-time curve) and docetaxel is given at 75 mg/m2.
62629560|NCT06092463||Preterm infants|"Infants will be included just after birth after obtained consent based on written and verbal information. Fecal samples will be collected from day 1 of life and weekly for the following weeks until discharge to investigate the composition of the fecal microbiome in relation to the development of NEC and the effect of medical therapy.~In case of development of NEC with the need for surgery the affected intestine will be resected and stomas will be established. Samples of fecal content and tissue is collected from intestine proximal and distal to divided intestine. At time of reversal of stomas, again tissue will be collected both proximal and distal from division to investigate the development of the intestine during early life as well as potential nutritional effects on intestinal maturity. Infants who do not undergo surgery serve as controls, those who are treated for NEC with antibiotics only, will be included in a sub analysis comparing the microbiome of infants who need surgery."
62629561|NCT06092463||Newborn and children up to 1 year of age|Infants with congenital malformations will have to undergo scheduled surgery to resect and/or anastomose the affected area of the intestine and some will receive a stoma that needs later reversal. At primary surgery fecal samples and intestinal tissue will be collected proximal and distal to the pathology. In cases with a stoma, and when the child will undergo later reversal surgery, tissue samples from the proximal and distal ends of the intestine will be collected together with fecal samples.
62063847|NCT05827874|EXPERIMENTAL|Active Arm:|Participants will receive Nipocalimab loading dose intravenous (IV) infusion at Week 0 followed by tetanus, diphtheria, pertussis (Tdap) and pneumococcal polysaccharide vaccine (PPSV23) vaccine challenge as an intramuscular (IM) injection on Day 3 of Week 0 and additional doses of Nipocalimab IV at Week 2 and 4.
62629562|NCT01147562|OTHER|Lung Cancer Patients|Patients with a suspected or confirmed diagnosis of lung cancer, whether or not scheduled for lesion biopsy, thoracentesis or surgical resection of their tumor
62629563|NCT01438242|EXPERIMENTAL|Assay Guided Treatment - Genecept Asay|Subjects donate DNA sample for genetic testing and treatment decisions take genetic results into account. Genetic analysis is performed using the Genecept Assay, a genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
62629564|NCT01438242|EXPERIMENTAL|Clinician's utilizing Assay Guided Treatment in Psychiatry|Prescribing clinicians responsible for the treatment of patients age 18 and older with a primary diagnosis of Major Depressive Disorder or Generalized Anxiety disorder, and for whom the Genecept Assay has been utilized to perform genetic testing.
62629565|NCT06382129|EXPERIMENTAL|BL-B01D1|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62629566|NCT06382129|EXPERIMENTAL|Docetaxel|Participants receive Docetaxel as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62629567|NCT01296854|NO_INTERVENTION|Standard|The patients randomized into this arm of the study will not have spa therapy.
62629568|NCT01296854|EXPERIMENTAL|Spa Therapy|The patients randomized into this arm of the study will have 3 weeks of spa therapy
62629569|NCT01734057|EXPERIMENTAL|combinant treatment group|120 enrolled patients are randomly picked up to take Rituximab in combination with rhTPO at the indicated dose.
62063848|NCT05827874|OTHER|Control Arm:|Participants will receive PPSV23 and Tdap vaccine challenge as an IM injection on Day 3 of Week 0.
62063849|NCT03126864|EXPERIMENTAL|CD33-CAR-T cells - Adult Group|"After enrollment, steady state leukapheresis performed to collect apheresis material.~Fludarabine administered by vein on Days -5 to -3.~Cyclophosphamide administered by vein on Day -3.~CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found."
62629570|NCT01734057|ACTIVE_COMPARATOR|single treatment group|120 enrolled patients are randomly picked up to take dexamethasone at the indicated dose.
62629571|NCT05028829|EXPERIMENTAL|Group A: Atorvastatin 20 mg|Atorvastatin 20mg will be administered daily via oral route for 48 consecutive weeks on an outpatient basis.
62629572|NCT05028829|PLACEBO_COMPARATOR|Group B: Placebo to Match (PTM)|PTM will be administered daily via oral route for 48 consecutive weeks on an outpatient basis.
62629573|NCT03112226|ACTIVE_COMPARATOR|GnRHant + E2|Single dose of GnRH antagonist degarelix acetate for depot injection (80mg) Transdermal estradiol add-back; Climara patch, 0.075mg/day, weekly for 12 weeks
62629574|NCT03112226|PLACEBO_COMPARATOR|GnRHant + Placebo|Single dose of GnRH antagonist degarelix acetate for depot injection (80mg) Transdermal placebo patch, weekly for 12 weeks
62629575|NCT02757352|EXPERIMENTAL|Q2W Ixekizumab|"Participants received a starting dose of 80 or 160 milligram (mg) of ixekizumab given subcutaneously (SC) at week 0 followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 52 during the double-blind period.~Inadequate responders (IR) as determined by investigators could switch to ixekizumab 80 mg Q2W open label between week 16 and 44."
62063850|NCT03126864|EXPERIMENTAL|CD33-CAR-T cells - Pediatric Group|"After enrollment, steady state leukapheresis performed to collect apheresis material.~Fludarabine administered by vein on Days -5 to -3.~Cyclophosphamide administered by vein on Day -3.~CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found."
62063851|NCT03311425|ACTIVE_COMPARATOR|Local Depomedrol plus IV dexamethasone|Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone
62629576|NCT02757352|EXPERIMENTAL|Q4W Ixekizumab|"Participants received a starting dose of 80 or 160 mg of ixekizumab given SC at week 0 followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 52 during the double-blind period.~Inadequate responders as determined by investigators could switch to ixekizumab 80 mg Q2W open label week 16 and 44."
62063852|NCT03311425|PLACEBO_COMPARATOR|IV dexamethasone|Intraoperative systemic (IV) steroid (dexamethasone) only.
62629577|NCT02757352|PLACEBO_COMPARATOR|Placebo|"Participants received placebo as 2 SC injections Q2W to week 52 during double-blind period.~Inadequate responders as determined by investigators could switch to ixekizumab 80 mg Q2W open label between week 16 and 44."
62629578|NCT05385341|EXPERIMENTAL|Telerehabilitation (Tele RCV)|Experimental group (Tele-RCV): the treatment will consist of 20 home-based sessions monitored by the REMOTE-ACS device and containing 2 hours/day 5 days/7 of exercise training (the first session in center to form the patient) associated with 8 educative sessions.
62629579|NCT05385341|ACTIVE_COMPARATOR|Rehabilitation (RCV)|Group control (RCV) : 20 sessions of cardiac rehabilitation will be realized in a rehabilitation center containing exercise training during 2 hours/day 5 days/7 and educative program.
62629580|NCT05349019||Part A/Sub Cohort A1|15 healthy participants 18-35 years of age
62629581|NCT05349019||Part A/Sub Cohort A2|15 healthy participants 65-80 years of age
62629582|NCT05349019||Part A/Sub Cohort A3|Control group age and sex matched to the PD participants in Part B of the study
62063853|NCT01001481||001|
62063854|NCT02374632|OTHER|Low EBL|"Gastric bypass operated patients with low postoperative excess body weight loss (EBL) \<50%.~Interventions: Meal tests after saline/octreotide injection in a randomized order, sham feeding."
62063855|NCT02374632|OTHER|High EBL|"Gastric bypass operated patients with high postoperative excess body weight loss (EBL) \>70% matched with respect to age, gender and preoperative BMI in the LowEBL group.~Interventions: Meal tests after saline/octreotide injection in a randomized order, sham feeding."
62629583|NCT05349019||Part B|60 participants with a confirmed diagnosis of Parkinson's disease and a heterozygous G2019S mutation in the LRRK2 gene
62629584|NCT00179803|EXPERIMENTAL|high dose chemotherapy|
62629585|NCT02654158||Low-dose of Fuganlin Oral Liquid|"oral~less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day"
62063856|NCT04490135|EXPERIMENTAL|Carers group intervention|caregivers entered into the 8 week CARERS intervention (N=264) Group intervention, 8 x 2 hour sessions. Session 1-4 PST training, session 5-8 Simulation with standardized patients training Pre- post evaluations completed
62629586|NCT02654158||High-dose of Fuganlin Oral Liquid|"oral~less than 1 years old: 10mL each time and three times a day~1\~3 years old: 20mL each time and three times a day~4\~6 years old: 20mL each time and four times a day~7\~12 years old: 20mL each time and five times a day"
62629587|NCT02996890|EXPERIMENTAL|High dose - single shot|MV-ZIKA, high dose, one vaccination, day 0
62629588|NCT02996890|EXPERIMENTAL|Low dose|MV-ZIKA, low dose, two vaccinations, day 0 and day 28
62629589|NCT02996890|EXPERIMENTAL|High dose|MV-ZIKA, high dose, two vaccinations, day 0 and day 28
62629590|NCT02996890|PLACEBO_COMPARATOR|Placebo|Physiological saline, two treatments
62629591|NCT02506699||analgesic effect of rTMS|Observe the analgesic effect of rTMS, reference method of noninvasive stimulation of the motor cortex validated by data from the literature and current practice, after 5 separate sessions a week apart, patients with neuropathic pain chronic, refractory to first and second-line treatments proposed in a multidisciplinary center specializing in chronic pain Lower Normandy.
62629592|NCT06460454||Patients treated with 177Lu-PSMA for castration-resistant prostate cancer|Patients treated with 177Lu-PSMA for castration-resistant prostate cancer and who benefited from 68Ga-PSMA and 18FDG PET scans as part of the initial workup and treatment follow-up.
62629593|NCT01229969|EXPERIMENTAL|NeuroCom EquiTest® System|Measure balance assessment (test for Sensory Organization Test (SOT) and Limit of Stability (LOS).
62629594|NCT01229969|EXPERIMENTAL|Wii Fit|Determine if the Wii Fit is valid and feasible in detecting balance problems in older adults
62629595|NCT05279131|EXPERIMENTAL|Tirbanibulin (Klisyri®)|Participants will apply tirbanibulin ointment 1% once daily for 5 days beginning Day 1. Participants will be evaluated for safety, tolerability, and the presence of Actinic Keratosis (AK) lesions in the treatment field (TF) until completion of the response assessment period at Day 57.
62629596|NCT06484283|EXPERIMENTAL|Experimental Group|Researchers will inform mothers who apply to the unit and invite them to participate in the study. The informed consent form will be read to mothers who accept the study, and their written consent will be obtained. A simple randomization method will be used to control selection bias that may arise while determining research groups. All study participants (intervention and control groups) will be asked to complete the Introductory Characteristics Form, Spiritual Well-Being Scale, and Connor Davidson Resilience Scale Short Form. After this stage, mothers in the intervention group will be given a meditation application video, and the details of the application (how long and how to meditate) will be explained. After the implementation period, the mothers will be again administered the Spiritual Well-Being Scale and the Connor Davidson Resilience Scale Short Form
62629597|NCT06484283|NO_INTERVENTION|Control Group|No intervention will be made to the control group. To act ethically, after data is collected from the experimental and control groups, participants in the control group will be given the meditation video to practice.
62629598|NCT05017805|EXPERIMENTAL|3 doses of vaccine|Covid-19 vaccination on day 0, day 25±3, and 6 months after the second dose , respectively，and follow up one and half a year
62629599|NCT05017805|EXPERIMENTAL|1 dose of the third vaccination|One dose of COVID-19 vaccine and 1 year of follow-up
62451682|NCT02593851|EXPERIMENTAL|Part 1: Cohort 3a|Participants (greater than (\>) 1 month and \< 3 months of age) will receive total daily dose of 1 mg/kg JNJ-53718678 oral solution \[either in a qd or a bid regimen\] on Day 1 to Day 7.
62629600|NCT02334826|ACTIVE_COMPARATOR|PCI - BVS|percutaneous coronary intervention with the use of bioresorbable scaffolds (Absorb)
62629601|NCT02334826|ACTIVE_COMPARATOR|CABG|coronary artery bypass grafting
62451683|NCT02593851|EXPERIMENTAL|Part 1: Cohort 3b|Participants (\> 1 month and \< 3 months of age) will receive total daily dose of 3 mg/kg JNJ-53718678 oral solution or placebo \[either in a qd or a bid regimen\] on Day 1 to Day 7.
62451684|NCT02593851|EXPERIMENTAL|Part 1: Cohort 3c|Participants (\> 1 month and \< 3 months of age) will receive total daily dose of 9 mg/kg JNJ-53718678 oral solution or placebo \[either in a qd or a bid regimen\] on Day 1 to Day 7.
62451685|NCT02593851|EXPERIMENTAL|Part 1: Cohort 3d|Participants (\> 1 month and \< 3 months of age) will receive JNJ-53718678 oral solution or placebo \[either in a qd or a bid regimen\] on Day 1 to Day 7. The cohort 3d is optional and may be included at the discretion of the sponsor.
62629602|NCT06611826|EXPERIMENTAL|GEP|Gemcitabine, recombinant human endostatin and carrilizumab combined with high-low dose radiotherapy
62629603|NCT03025269||Relapsing MS patients treated with Ocrelizumab|30 patients diagnosed with relapsing forms of multiple sclerosis and newly beginning treatment with Ocrelizumab according to neurologists' orders
62629604|NCT01435759|EXPERIMENTAL|Antidepressant + SPD489 10 mg|
62629605|NCT01435759|EXPERIMENTAL|Antidepressant + SPD489 30 mg|
62629606|NCT01435759|EXPERIMENTAL|Antidepressant + SPD489 50 mg|
62629607|NCT01435759|EXPERIMENTAL|Antidepressant + SPD489 70 mg|
62269058|NCT01262365|EXPERIMENTAL|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles
62451686|NCT02593851|EXPERIMENTAL|Part 1: Cohort 3e|Participants (\> 1 month and \< 3 months of age) will receive JNJ-53718678 oral solution or placebo \[either in a qd or a bid regimen\] on Day 1 to Day 7. The cohort 3e is optional and may be included at the discretion of the sponsor.
62451687|NCT02593851|EXPERIMENTAL|Part 2: Cohort f|Participants of all age groups will receive daily dose of JNJ-53718678 oral solution or placebo, either in a qd or a bid regimen on Days 1 to 7.
62451688|NCT01725945|NO_INTERVENTION|Usual Care|Usual Care
62629608|NCT01435759|PLACEBO_COMPARATOR|Antidepressant + Placebo|
62451689|NCT01725945|EXPERIMENTAL|DASH Intervention|Dietary Approaches to Stop Hypertension dietary pattern. Usual care in combination with a DASH intervention consisting of 8 group and 3 individual sessions over 3 months, followed by 3 monthly phone consultations.
62629609|NCT01822210|EXPERIMENTAL|Botox|Injection of Botox in the tumor and surrounding stomach wall.
62269059|NCT00845455||1. Harm Avoidance|Personality type
62269060|NCT00845455||2. Reward Dependence|Personality type
62269061|NCT00845455||3. Novelty Seeking|Personality type
62269062|NCT00800501|EXPERIMENTAL|sNN0029|
62269063|NCT00800501|PLACEBO_COMPARATOR|Placebo|
62629610|NCT02594059|EXPERIMENTAL|Pulmonary idiopathic fibrosis|Patients with pulmonary idiopathic fibrosis according to ATS/ERS 2011's criteria
62063857|NCT04490135|NO_INTERVENTION|Wating list control|Caregivers waiting for entry into active arm of CARERS intervention.During this time usual care allowed with no other intervention. Study measures administered at intake and immediately prior to starting the CARERS group. (N=83)
62063858|NCT02659917|ACTIVE_COMPARATOR|Ketac Molar® (3M/ESPE) - Glass ionomer|Pit and fissure sealing using conventional glass-ionomer cement
62629611|NCT01176123|ACTIVE_COMPARATOR|CBT-I in person|Cognitive behavioral therapy for insomnia delivered in person
62269064|NCT02922062|EXPERIMENTAL|Low Carbohydrate Diet|Half of the participants will be randomly assigned to this diet arm. The macronutrient composition of the diet will be (PRO (protein):CHO (carbohydrate):FAT, 18:8:74). There are three diet phases within this arm that use different fats as the primary cooking oil either canola oil, palm oil or butter. Each diet phase lasts for 3 weeks. At the end of each diet phase the testing battery completed at baseline will be repeated followed by a 2 week washout where subjects revert back to their usual diets. Canola oil is the low saturated fat control diet and is administered first. Participants then randomly begin either the palm oil or canola oil diet phases.
62063859|NCT02659917|EXPERIMENTAL|Maxxion® (FGM) - Glass ionomer cement|Pit and fissure sealing using conventional glass-ionomer cement
62269065|NCT02922062|ACTIVE_COMPARATOR|High Carbohydrate Diet|Half of the participants will be randomly assigned to this diet arm. The macronutrient composition of the diet will be (PRO:CHO:FAT, 18:60:22). There are three diet phases within this arm that use different fats as the primary cooking oil either canola oil, palm oil or butter. Each diet phase lasts for 3 weeks. At the end of each diet phase the testing battery completed at baseline will be repeated followed by a 2 week washout where subjects revert back to their usual diets. Canola oil is the low saturated fat control diet and is administered first. Participants then randomly begin either the palm oil or canola oil diet phases.
62063860|NCT02659917|ACTIVE_COMPARATOR|Ketac Molar® (3M/ESPE) - Glass ionomer -|Restoration using conventional glass-ionomer cement
62269066|NCT05382351|EXPERIMENTAL|Entecavir group|Patients receive treatment with entecavir
62269067|NCT05382351|EXPERIMENTAL|Entecavir and Tenofovir Amibufenamide group|Patients will receive the treatment of entecavir combined with tenofovir amibufenamide
62269068|NCT00216411|EXPERIMENTAL|Dysport|
62269069|NCT00216411|PLACEBO_COMPARATOR|Placebo|
62063861|NCT02659917|EXPERIMENTAL|Maxxion® (FGM) - Glass ionomer cement -|Restoration using conventional glass-ionomer cement
62063862|NCT03926793|EXPERIMENTAL|Cohort 1|Patients will be randomized to receive inhaled GB002 or Placebo daily for 14 days
62063863|NCT03926793|EXPERIMENTAL|Cohort 2|Patients will be randomized to receive inhaled GB002 or Placebo daily for 14 days
62063864|NCT03926793|EXPERIMENTAL|Open Label Extension|Eligible subjects may participate in the Open Label Extension (OLE) study for a period of 24 weeks.
62269070|NCT04081363|EXPERIMENTAL|Swallowed Capsules Cohort|Participants swallowed two capsules of centanafadine (one containing a 50-milligram \[mg\] dose as extended release beads and other containing a 5-mg dose as immediate-release \[IR\] beads), total dose of 55 mg, orally in the morning of Day 1 following a minimum 8-hour fast.
62451690|NCT01827722|EXPERIMENTAL|Ozurdex Arm|Ozurdex intravitreal injection (combination with monthly sham injection) administered at a 16 week interval beginning on Day 1 and ending at Week 16.
62629612|NCT01176123|EXPERIMENTAL|CBT-I via telephone therapy|Cognitive behavioral therapy for insomnia delivered by telephone
62063865|NCT04647422|EXPERIMENTAL|AUD patients|Alcohol Use Disorder patients
62063866|NCT04647422|EXPERIMENTAL|AUD controls|Healthy control participants matched to group 1
62063867|NCT04647422|EXPERIMENTAL|First-degree relatives|Healthy first-degree relatives of AUD patients
62063868|NCT04647422|EXPERIMENTAL|First-degree controls|Healthy control participants matched to group 3
62063869|NCT05130255|EXPERIMENTAL|GD2-SADA:177Lu-DOTA Complex|"GD2-SADA IV. infusion followed by 177Lu-DOTA IV. infusion (The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA ).~1 treatment cycle in Part A, 2 treatment cycles in Part B and up to 5 treatment cycles in Part C"
62088108|NCT03911375|EXPERIMENTAL|Mindfulness Based Stress Reduction (MBSR)|Program of 30 hours of duration divided into 9 sessions with a weekly frequency of 2.5 h and an intensive session between week 6 and 7 of the program with a duration of 7.5 hours.
62269071|NCT04081363|EXPERIMENTAL|Sprinkled Onto Applesauce Cohort|Participants were administered centanafadine 55 mg, contents of 2 capsules (one containing a 50-mg dose as beads and other containing a 5-mg dose as IR beads) sprinkled on a tablespoon of applesauce, orally in the morning of Day 1 following a minimum 8-hour fast.
62063870|NCT03159897|EXPERIMENTAL|Comparator arm|Patients will receive 2 courses of standard ABVD (ABVD-28, d1, d15, cycles of 28 days) and then proceed to interim PET/CT evaluation. Those with a PET-2-negative scan (score 1-3 on 5PS) will continue with additional 4 ABVD courses while those with a PET-2-positive (score 4-5) scan will be diverted towards an intensification phase with either escalated BEACOPP or HDT plus ASCR, according to the preference of the centre. Upon completion of treatment, patients will be categorized for response (Lugano2014) by comparing actual PET/CT imaging with baseline, whether 6 ABVD cycles or ABVDx2 + intensification phase with BEACOPP or HDT/ASCR. A salvage rescue program will be planned for patients with Stable (\<PR) or Progressive Disease. ISRT 30 Gy will be delivered to complete responders (5PS score 1-2-3) on the initial bulky site(s), to focal rests in case of CR scoring 3 on 5PS with a residual size ≥ 2.5 cm and to focal rests uptakes in the event of PR scoring 4 or 5, whichever is the size.
62063871|NCT03159897|EXPERIMENTAL|Experimental arm|Dose-dense and dose-intense ABVD regimen (ABVD DD-DI: intercycle 21 days, d1, d11; doxorubicin 35 mg/m2 DD 1 and 11) is given in cycles 1 to 4 and dose-dense ABVD (ABVD DD: intercycle 21 days, D1 and D11; conventional doxorubicin dose, e.g. 25 mg/m2 DD 1 and 11) is given as cycles 5 and 6). The treatment is not PET-adapted, and only patients with no response or progressive disease at interim FDG-PET as defined by the Lugano Classification (e.g., score 4 or 5 on 5PS with no significant change or with increased uptake matched with baseline and/or new FDG-avid foci consistent with lymphoma) will be diverted to salvage therapy. ISRT 30 Gy will be delivered to responder patients (DS=3), on focal PET-positive rests with a residual size ≥ 2.5 cm and on patients in PR with uptake scoring 4 or 5, whichever is the size.
62063872|NCT05461105|EXPERIMENTAL|Cohort A: rencofilstat 75 mg|1 rencofilstat 75 mg softgel capsule, 75 mg daily dose, QD 120 days
62063873|NCT05461105|EXPERIMENTAL|Cohort B: rencofilstat 150 mg|2 rencofilstat 75 mg softgel capsules, 150 mg daily dose, QD 120 days
62063874|NCT05461105|EXPERIMENTAL|Cohort C: rencofilstat 225 mg|3 rencofilstat 75 mg softgel capsules, 225 mg daily dose, QD 120 days
62063875|NCT06365021|EXPERIMENTAL|Acceptance and Commitment Therapy|Participants in the clinical group will receive usual pharmacological treatment and undergo a protocol of 12 Acceptance and Commitment Therapy sessions, in group format, during 3 months. The intervention will be held weekly, with an estimated duration of 2 hours for each session, in addition to the participants' regular drug treatment. Scales are administered at the beginning and end of treatment, with follow-ups after 3 and 6 months.
62063876|NCT06365021|EXPERIMENTAL|Psychoeducation|Participants in the control group will usual pharmacological treatment and 3 sessions of Psychoeducation, in group format. Scales are administered at the beginning and end of treatment, with follow-ups after 3 and 6 months.
62063877|NCT03204084||the LTP group|Patients undergoing pterygium surgery with fibrin glue and conjunctival autografting and receiving Low-temperature Plasma Surgery System(LTP group),
62063878|NCT03204084||the control group|Patients undergoing pterygium surgery with fibrin glue and conjunctival autografting and receiving the conventional method using surgical micro knife and ophthalmic hemostasis(control group)
62063879|NCT05885919|EXPERIMENTAL|Edaravone Dexborneol group|Patients in this arm will be given Edaravone Dexborneol Concentrated Solution for injection twice a day for 10 to 14 days.
62629613|NCT03902470|EXPERIMENTAL|Thoracic epidural anaesthesia for vats|"Patients in thoracic epidural (TE) group will pre-medicated using midazolam 3-4 mg intravenous (IV)and fentanyl 50 mcg intravenously(i.v.). Then patients will placed in the lateral decubitus position. An epidural catheter will be inserted between T3-T4 and T4-T5 for all thoracic procedures except sympathectomy and thymectomy. A test dose (5 ml) of 2% lidocaine will be given, followed by 15-20 ml of bupivacain 0.5% and 50 mcg of fentanyl.~The objective is to achieve sensory and motor block between C7 and T7 levels. At this level diaphragmatic respiration is maintained. The anaesthesia level will be monitored by warm-cold discrimination."
62063880|NCT05885919|PLACEBO_COMPARATOR|Edaravone Dexborneol Placebo group|Patients in this arm will be given a placebo of Edaravone Dexborneol for injection twice a day for 10 to 14 days
62063881|NCT04244396||Drug refractory, symptomatic persistent atrial fibrillation|Asian population
62063882|NCT04479280||Covid19 positive patients|
62063883|NCT04479280||Covid19 negative patients|
62269072|NCT01222546|EXPERIMENTAL|CH5132799|
62269073|NCT00520364||History of chemotherapy|IVF after chemotherapy
62269074|NCT00520364||IVF without history of chemotherapy|IVF without history of prior chemotherapy
62629614|NCT03902470|ACTIVE_COMPARATOR|General anesthesia for vats|Patients will receive general anesthesia as follows, Premedication in the form of 3-4 mg midazolam (IV), induction of a anesthesia with propofol (2mg/kg) and fentanyl (1 mcg/kg). Tracheal intubation and double endotracheal tube insertion will be facilitated with cisatracurium 0.1 mg/kg. and confirmation of it is position will made by fiberoptic bronchoscopy, Anesthesia will be maintained with isoflurane (1-2 %) and cisatracurium (0.05 mg/kg per dose).After the end of the operation, anesthesia will be discontinued, the wound dressing will be applied, and extubation of the patient will be done after reversal of muscle relaxant by neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg) and extubation will be performed after complete neuromuscular recovery.
62629615|NCT00064103|EXPERIMENTAL|Treatment (Ad5CMV-p53 gene)|"Phase I: Patients receive Ad5CMV-p53 gene by intramucosal injection into the area of the lesion followed at least 2 hours later by Ad5CMV-p53 gene as an oral rinse on day 1. Patients then receive Ad5CMV-p53 gene as an oral rinse twice daily on days 2-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of Ad5CMV-p53 gene as an oral rinse until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Phase II: Patients receive treatment with intramucosal Ad5CMV-p53 gene as in phase I and Ad5CMV-p53 gene as an oral rinse at the MTD."
62629616|NCT04928144|EXPERIMENTAL|0.025% SHJ002|0.025% SHJ002 Sterile Ophthalmic Solution
62629617|NCT04928144|EXPERIMENTAL|0.080% SHJ002|0.080% SHJ002 Sterile Ophthalmic Solution
62629618|NCT04928144|EXPERIMENTAL|0.25% SHJ002|0.25% SHJ002 Sterile Ophthalmic Solution
62629619|NCT04928144|EXPERIMENTAL|SHJ002 - Maximum tolerated concentration|Maximum tolerated concentration of SHJ002
62629620|NCT05831124|EXPERIMENTAL|Low dose multivalent pneumococcal conjugate vaccine formulation A|Stage 1 - Participants will be randomized to receive a single injection.
62063884|NCT03311230|NO_INTERVENTION|Control|Participants in this arm will receive no other interventions during the 9 month study period
62269075|NCT00290615|EXPERIMENTAL|Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab|"Capecitabine - oral administration of 850 mg/m2 every 12 hours on days 1-14. Oxaliplatin - IV administration of 130 mg/m2 over 2 hours on day 1 of a cycle. Bevacizumab- IV administration of 7.5 mg/kg over 30-90 minutes on day 1 of a cycle.~Cetuximab at an initial dose of 400 mg/m2 over 120 minutes and subsequently 250 mg/m2 over 60 minutes on day 1 of a cycle.~Cycles are 21 days."
62063885|NCT03311230|EXPERIMENTAL|Supportive social incentive|Participants will identify a family member or friend to support them during a gamification intervention.
62269076|NCT05839054|EXPERIMENTAL|Roller Coasters, group 1|VR audio-visual users with Roller Coasters
62269077|NCT05839054|EXPERIMENTAL|Wild Dolphins, group 2|VR audio-visual users with Wild Dolphins
62629621|NCT05831124|EXPERIMENTAL|Low dose multivalent pneumococcal conjugate vaccine formulation B|Stage 2 - Participants will be randomized to receive a single injection.
62629622|NCT05831124|ACTIVE_COMPARATOR|Low dose of multivalent pneumococcal conjugate vaccine control|Primary control - Stages 1 and 2 - Participants will be randomized to receive a single injection.
62629623|NCT05831124|ACTIVE_COMPARATOR|Standard dose multivalent pneumococcal conjugate vaccine control|Control - Stages 1 and 2 - Participants will be randomized to receive a single injection.
62629624|NCT00597389|ACTIVE_COMPARATOR|1|oral solution of propranolol (propranolol HCL 20 mg/5 ml solution) or a liquid placebo twice daily for 10 days (and taper for 5 days; based on Pitman et al, 2002). Dose was calculated as determined by Famularo et al. (1988) to be 2.5 mg/kg/d with a maximum dose of 40 mg bid (Green, 2001).
62629625|NCT00597389|PLACEBO_COMPARATOR|2|A 25/5ml solution of placebo (a sugar solution that looks and tastes like the propranolol solution)
62629626|NCT03915483|EXPERIMENTAL|tDCS group|one session of computerized change detection attentional filter exercise (selective attention) combined with real tDCS
62629627|NCT03915483|SHAM_COMPARATOR|sham group|one session of computerized change detection attentional filter exercise (selective attention) combined with sham tDCS
62629628|NCT02950116|ACTIVE_COMPARATOR|Asthma|Asthmatic patients will perform three multiple breath nitrogen washout tests (N2-MBW-test)
62629629|NCT02950116|ACTIVE_COMPARATOR|Non-CF bronchiectasis|Patients with non-CF bronchiectasis will perform three multiple breath nitrogen washout tests (N2-MBW-test)
62629630|NCT02950116|ACTIVE_COMPARATOR|Cystic fibrosis|Patients with cystic fibrosis will perform three multiple breath nitrogen washout tests (N2-MBW-test)
62063886|NCT03311230|EXPERIMENTAL|Competitive social incentive|Participants will compete in a gamification intervention in groups of three.
62063887|NCT03311230|EXPERIMENTAL|Collaborative social incentive|Participants will collaborate in groups of three in a gamification intervention
62063888|NCT03149016|EXPERIMENTAL|Corticotomy-assisted Retraction|Corticotomy-assisted retraction will be performed in order to help in accelerating upper incisors' retraction
62063889|NCT03149016|NO_INTERVENTION|Conventional Retraction|Conventional retraction will be used in this group of patients by sliding mechanisms
62063890|NCT06225414|EXPERIMENTAL|Arm A: Enhanced Usual Care|Usual Care + Brief Educational Material
62063891|NCT06225414|EXPERIMENTAL|Arm B: Empower Latinx|"* PCP notifications of patients' LCS eligibility (addressing provider time constraints and barrier in identifying eligible patients);~* Patients' education (addressing knowledge barriers);~* Patients' referral to financial navigation resources (addressing health-related social risks)~* Patients' reminder to discuss LCS during PCP visit."
62063892|NCT04163887|OTHER|laparoscopic liver resection|Laparoscopy allows some surgical procedures to be performed through small incisions that enable the operator to access the abdominal cavity, often at the pubic area, and surgical instruments are introduced through these small incisions. This technique avoids large abdominal incisions and significantly reduces the duration of hospitalization.
62269078|NCT05839054|NO_INTERVENTION|group 3|did not use any additional equipment
62269079|NCT04359303|NO_INTERVENTION|CONTROL|Base WHO recommended treatment.
62269080|NCT04359303|EXPERIMENTAL|TREATMENT|Base WHO recommended treatment + Systemic indirect endovenous ozone therapy
62269081|NCT05383027|ACTIVE_COMPARATOR|Music Listening Control(MLC)|
62269082|NCT05383027|EXPERIMENTAL|Heart Focused Breathing|
62269083|NCT00775632|ACTIVE_COMPARATOR|Standard of Care|The current standard of care for GVHD prophylaxis at Princess Margaret Hospital is cyclosporine and Mycophenolate or cyclosporine and methotrexate.
62269084|NCT00775632|EXPERIMENTAL|Cyclosporine and Campath|The efficacy of experimental arm will be tested against standard of care for prevention of Chronic extensive GVHD.
62629631|NCT01515098|EXPERIMENTAL|Blueberry Group|37 grams of dehydrated blueberries daily for 6 months
62063893|NCT04163887|OTHER|open liver resection|standard of care
62269085|NCT05810220|EXPERIMENTAL|Hearing-Impaired Individuals who use Cochlear Implants or Auditory Brainstem Implant (ABI) Devices|"Two types of measurements will be obtained:~1. Perceptual: one or more sounds are presented and a behavioral response is collected (e.g., judgements of loudness, pitch or other differences between the sounds, or identifying the word or sentence that was said).~2. Physiological: noninvasive electrophysiological recordings of nervous system activity."
62269086|NCT04017260|EXPERIMENTAL|open and closed technique|treatment of pilonidal sinus by open and closed approach
62269087|NCT04017260|EXPERIMENTAL|Rhomboid flap technique|treatment of pilonidal sinus by Rhomboid flap
62269088|NCT04017260|EXPERIMENTAL|karydakis technique|treatment of pilonidal sinus by Karydakis
62269089|NCT04017260|EXPERIMENTAL|open technique|treatment of pilonidal sinus by open approach
62269090|NCT01093027|OTHER|15 - 30|The upper limb with tremor will be cooled with 15 degrees Celsius water for 10 minutes at Visit 1 and with 30 degrees Celsius water for 10 minutes at Visit 2.
62269091|NCT01093027|OTHER|30 - 15|The upper limb with tremor will be cooled with 30 degrees Celsius water for 10 minutes at Visit 1 and with 15 degrees Celsius water for 10 minutes at Visit 2.
62629632|NCT01515098|PLACEBO_COMPARATOR|Placebo Group|37 grams of dextrose powder daily for 6 months
62629633|NCT01515098|NO_INTERVENTION|Reference Group|No intervention
62629634|NCT06515626|EXPERIMENTAL|subject|
62629635|NCT04437914||Group 1 - Smartwatch - single lead (D1)|To obtain the automatic electrocardiographic diagnosis of the clock, two ECG tracings of 30 seconds will be obtained, in a calm environment, with the patient at rest, in the horizontal supine position. The device will be attached to the wrist on the left side with the use of the fingers of the right hand on the sensor button of the watch to complete the electrocardiographic DI derivation following the Einthoven triangle derivation criteria. The automatic diagnosis obtained must be the same in both plots to be validated. The specific results of the automatic diagnosis obtained by the watch will be: low beats with FC≤40 beats per minute (bpm); high beats with HR≥120bpm; sinus rhythm when interpreted as normal by the clock, atrial fibrillation, inconclusive and does not allow analysis due to poor technical quality and did not allow tracing.
62629636|NCT04437914||Group 2 - conventional ECG|The conventional ECG tracing will be obtained in the 12 leads of the frontal plane (DI, DII, DIII, aVR, AVL, AVF) and the horizontal plane (V1 to V6) and a 30-second rhythm trace in the DI lead. The diagnostic results of conventional ECG tracings will be: normal or abnormal; sinus rhythm, AF, atrial flutter or other non-sinus rhythm; intraventricular conduction disorder: left bundle branch block (BRE), right bundle branch block (BRD), right posteroinferior lower block (BDPI or left anterior superior (BDAS), isolated or associated; normal electrical axis, shifted to the right or shifted to the right) left, inconclusive and does not allow analysis due to poor technical quality.
62629637|NCT06611501|PLACEBO_COMPARATOR|Placebo|Placebo tablets orally daily for a total of 6 months of treatment.
62629638|NCT06611501|EXPERIMENTAL|Metformin|metformin hydrochloride 500 mg capsules daily for a total of 6 months of treatment
62629639|NCT04972799|EXPERIMENTAL|Treatment/Placebo|treatment sequence at day 0 and placebo sequence at 6 months
62629640|NCT04972799|EXPERIMENTAL|Placebo/Treatment|placebo sequence at day 0 and treatment sequence at 6 months
62629641|NCT04058457||STN DBS|Patients planned to undergo deep brain stimulation of the subthalamic nucleus
62629642|NCT04058457||GPi DBS|Patients planned to undergo deep brain stimulation of the globus pallidus interna
62629643|NCT04058457||VIM DBS|Patients planned to undergo deep brain stimulation of the ventral intermediate nucleus of thalamus.
62063894|NCT04609124||Intervention group:|Patients (n=35) fasting for 8 hours and received 10 mg metoclopramide intravenously diluted in 10 mL saline 0.9%.
62063895|NCT04609124||Control group:|Patients (n=35) fasting for 8 hours and received intravenous 10 mL saline 0.9% as placebo
62269092|NCT01779024|EXPERIMENTAL|ASA/Ghrelin|Intravenous acyl-ghrelin \[a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)\] was administered on the first ASA visit; Intravenous placebo \[packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor\] was administered on the second ASA visit.
62269093|NCT01779024|PLACEBO_COMPARATOR|ASA/Placebo|Intravenous placebo \[packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor\] was administered on the first ASA visit; Intravenous acyl-ghrelin \[a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)\] was administered on the second ASA visit
62063896|NCT00928759||peripubertal obese girls|Peripubertal obese girls, aged 8 - 16 years, who are obese (BMI-for-age percentile greater or equal to 95)
62629644|NCT01833585|EXPERIMENTAL|peripheral blood mononuclear cells|peripheral blood mononuclear cells will be injected to calf muscle of critical limb ischemia
62063897|NCT05822336|EXPERIMENTAL|Experimental arm|In this group, the duration of IM injections was 40 seconds. The drug was the same for both groups, Clindamycin 600 mg/4 ml intramuscularly.
62629645|NCT03576443|EXPERIMENTAL|Treatment arm|Idelalisib 150 mg x 2 p o, until progression
62629646|NCT02212925|EXPERIMENTAL|BI 14332 CL|
62629647|NCT02212925|PLACEBO_COMPARATOR|Placebo|
62629648|NCT05886088|EXPERIMENTAL|LID104|The patient must take 1 tablet of LID104 plus 1 tablet of placebo of dapagliflozin and 1 tablet of placebo of linagliptin once a day.
62629649|NCT05886088|ACTIVE_COMPARATOR|Dapagliflozin|The patient must take 1 tablet of dapagliflozin plus 1 tablet of placebo of LID104 and 1 tablet of placebo of linagliptin once a day.
62629650|NCT05886088|ACTIVE_COMPARATOR|Linagliptin|The patient must take 1 tablet of linagliptin plus 1 tablet of placebo of LID104 and 1 tablet of placebo of dapagliflozin once a day.
62629651|NCT05276583||Patients with depression like symptoms|Participants in this condition must indicate that they are currently suffering from a mental health illness and score at least 20 on the Becks Depression Inventory. These participants will undergo the motivate learning task and will study images associated with high and low rewards. After 24-hours participants will be tested on their memory for those images.
62629652|NCT05276583||Healthy controls without depression like symptoms|Participants in this condition must indicate that they do not currently suffer from a mental health condition and score less than 20 on the Becks depression inventory. These participants will also undergo the motivate learning task and will study images associated with high and low rewards. After 24-hours participants will be tested on their memory for those images.
62629653|NCT02141906|EXPERIMENTAL|Oncozene-DEB-TACE|"Screening Visit (procedures should be done within 28 days of treatment day):~Study visit assessments will be performed prior to Oncozene-DEB-TACE delivery (except pharmacokinetic blood draw).~Labs may be done within 3 days of the procedure. All visits can be completed +/- 10 days of planned visit day~Follow up after completion of treatment every 4-6 weeks:"
62629654|NCT04051697|NO_INTERVENTION|Usual Care arm|Participants allocated to the control group will receive their usual care. Healthcare professionals within the designated sites will deliver aftercare treatment as usual, with no changes to the patient's clinical care. Participants in this arm do not receive the self-management intervention (SEA CHANGE).
62629655|NCT04051697|EXPERIMENTAL|Intervention arm|Participants in the intervention group will receive usual care and will be offered access to the self-management intervention (SEA CHANGE). Healthcare professionals within the designated sites will deliver aftercare treatment as usual, with no changes to the patient's clinical care.
62629656|NCT02658669|EXPERIMENTAL|Cognitive-Behavioral Therapy for Insomnia|6-week manualized treatment designed to improve symptoms of chronic insomnia.
62629657|NCT02658669|ACTIVE_COMPARATOR|Sleep Education|6-week manualized treatment designed to provide information regarding traumatic brain injury and its relationship to sleep disturbance, which incorporates training in sleep hygiene to help improve nighttime sleep and daytime functioning.
62629658|NCT01965002|EXPERIMENTAL|MRgHIFU|The InSightec ExAblate 2000 magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system is a non-invasive device that is fully integrated with an MR imaging system and used for the ablation of soft tissue. The treatment process begins with the physician acquiring a set of MR images, identifying 1+ target volume(s) of fibroid tissue to be ablated, and drawing the treatment contours. The therapy planning software computes the type and number of sonications required to treat the defined volume while minimizing total treatment time. MR images taken during the sonication provide a diagnostic quality image of the target tissue and a quantitative, real-time temperature map overlay to confirm the therapeutic effect of the treatment. The transducer is then automatically moved to the succeeding treatment point and the process is repeated until the entire volume has been treated. About 100 individual sonications can be delivered over a 3-hour period to complete a treatment.
62629659|NCT04878939|EXPERIMENTAL|Anterior segment retraction using sliding mechanics (friction)|Power chain
62629660|NCT04878939|EXPERIMENTAL|Anterior segment retraction using segmental mechanics (frictionless)|T-loop
62629661|NCT03108066|EXPERIMENTAL|MK-3795|Participants receive 800 mg MK-3795 orally twice daily. Participants may continue to receive MK-3795 in the absence of unacceptable treatment related toxicity or unequivocal disease progression.
62629662|NCT03887182|EXPERIMENTAL|confirmed auditory processing disorders|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic
62088109|NCT03911375|NO_INTERVENTION|Control|Participants assigned to the control group will follow the usual treatment, according to their diagnosis.
62629663|NCT03887182|EXPERIMENTAL|suspected not confirmed auditory processing disorders|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic
62063898|NCT05822336|NO_INTERVENTION|Active arm|In this group, the duration of IM injections was 10 seconds. The drug was the same for both groups, Clindamycin 600 mg/4 ml intramuscularly.
62063899|NCT02607657|EXPERIMENTAL|Eplerenone 25 mg|Eplerenone 25 mg Tablet Oral Once daily
62063900|NCT02607657|EXPERIMENTAL|Eplerenone 50 mg|Eplerenone 50 mg Tablet Oral Once daily
62063901|NCT02607657|EXPERIMENTAL|Eplerenone 100 mg|Eplerenone 100 mg (2 tablets of 50 mg) Tablet Oral Once daily
62063902|NCT02607657|EXPERIMENTAL|Eplerenone 50 mg x 2|Eplerenone 50 mg Tablet Oral Twice daily
62063903|NCT02607657|EXPERIMENTAL|Eplerenone 25 mg x 2|Eplerenone 25 mg Tablet Oral Twice daily
62063904|NCT03290157|NO_INTERVENTION|Control group|Regular colonoscopy preparation paper based information provided
62063905|NCT03290157|OTHER|ColoprAPP group|Regular colonoscopy preparation paper based information provided plus usage of a downloaded SPA (ColoprAPP) as a reminder system for colonoscopy preparation
62063906|NCT00445198|EXPERIMENTAL|Phase 1 and Phase 2a|
62063907|NCT01907139|EXPERIMENTAL|Distributed constraint-induced therapy (dCIT)|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks.
62629664|NCT03887182|ACTIVE_COMPARATOR|healthy volunteers|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic, multidisciplinary consultation
62629665|NCT00834847|EXPERIMENTAL|Pravastatin fast|Test product under fasting conditions dosed in first period followed by either test or reference product dosed under fed conditions in second and third periods
62629666|NCT00834847|EXPERIMENTAL|Pravastatin|Test product under fed conditions dosed in first period followed by either test product dosed under fasting conditions or reference product dosed under fed conditions in second and third periods
62063908|NCT01907139|EXPERIMENTAL|Robot-assisted therapy (RT)|The ArmeoSpring (Hocoma AG, Switzerland) will be adopted in this study. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. The ArmeoSpring g provides weight support for the arm across a large 3D workspace, enabling naturalistic movement across approximately 66% of the normal workspace in the vertical plane and 72% in the horizontal plane. Its main structure consists of an arm exoskeleton with elastic bands that relieve the weight of the limb and provide a sense of arm flotation at all positions in the available workspace. A custom grip sensor consisting of a water-filled cylindrical bladder detects grip pressure and finger movement and allows incorporation of grasp and release practice into arm training.
62088110|NCT05826717|EXPERIMENTAL|Food product 1.|\[x\] gr apple containing 20 gr fructose as measured with an enzymatic method. Administered one time.
62088111|NCT05826717|EXPERIMENTAL|Food product 2.|\[x\] gr mashed apple containing 20 gr fructose as measured with an enzymatic method. Administered one time.
62063909|NCT01907139|ACTIVE_COMPARATOR|Dose-matched control therapy (DMCT)|The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening.
62063910|NCT01907139|EXPERIMENTAL|RT + dCIT|In this combination therapy group, the participants will received 2 weeks of RT using the ArmeoSpring and followed by 2 weeks of distributed CIT. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively. This combined intervention group may integrate proximal (shoulder and elbow) to distal (wrist and hand) training of the UL and help transfer from motor ability gained to functional performance improvement. That is, it appears to associate with the advantages/effects of each RT and dCIT intervention.
62063911|NCT00970125|EXPERIMENTAL|Cancer subjects|
62063912|NCT02090335|EXPERIMENTAL|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
62269094|NCT01779024|EXPERIMENTAL|fMRI/Ghrelin|Intravenous acyl-ghrelin \[a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)\] was administered on the first fMRI visit; Intravenous placebo \[packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor\] was administered on the second fMRI visit.
62269095|NCT01779024|PLACEBO_COMPARATOR|fMRI/Placebo|Intravenous placebo \[packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor\] was administered on the first fMRI visit; Intravenous acyl-ghrelin \[a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)\] was administered on the second fMRI visit
62269096|NCT03813537|NO_INTERVENTION|Standard of Care|The control will be discharged with standard of care follow-up instructions and scheduled for a standard follow-up clinic visit within 2-3 weeks post-op.
62269097|NCT03813537|EXPERIMENTAL|Phone Call|The experimental group will receive a phone call intervention 3 days post-op. During this phone call, the patient will be asked questions using a study questionnaire based on the most frequent indications for readmission post colorectal surgery. Based on the responses, patients will be advised to maintain the scheduled appointment, visit the clinic within 48 hours, or go to the Emergency Department immediately.
62269098|NCT05448911|EXPERIMENTAL|Experimental group|It uses minimally invasive small incisions, physiological access to the pelvis, and hollow screws for Pelvic and Acetabular fractures
62269099|NCT05448911|OTHER|Control Group|This approach typically requires extensive surgical exposure and large-scale soft-tissue dissection, which quickly leads to some serious complications, including increased rates of infection, poor wound healing, increased damage to large vessels or nerves, and heterotopic ossification
62269100|NCT03344302|EXPERIMENTAL|study group|100 women were assigned to receive an intravenous infusion of oxytocin 30 units in a rate 125 mL/hour minutes diluted into 500 mL of normal 0.9% sodium chloride) immediately after opening the visceral peritoneum just before incising the uterine wall during Cesarean section
62269101|NCT03344302|ACTIVE_COMPARATOR|Control group|100 women were assigned to an intravenous infusion of oxytocin 30 units in a rate 125 mL/hour diluted into 500 mL of normal 0.9% sodium chloride) immediately after clamping the umbilical cord during cesarean section
62629667|NCT00834847|ACTIVE_COMPARATOR|Pravachol®|Reference product under fed conditions dosed in first period followed by test product dosed under either fed or fasted conditions in second and third periods
62063913|NCT02090335|ACTIVE_COMPARATOR|Fitness Club Membership|Fitness club membership with education in using the exercise equipment.
62269102|NCT03267121|EXPERIMENTAL|Study Group|Apatinib Mesylate Tablets and Tegafur Gimeracil Oteracil Potassium Capsules administered as a daily oral treatment
62269103|NCT03522870|EXPERIMENTAL|Flash Glucose Monitoring System|People selected to this group will using flash glucose monitoring system continuously on Week 2-14 and Week 14-26.
62269104|NCT03522870|ACTIVE_COMPARATOR|SMBG|People selected to this group will using SMBG continuously on Week 2-14 and Week 14-26.
62629668|NCT02861664|EXPERIMENTAL|Test Dentifrice: Stannous fluoride (SnF2)|Participants were instructed to apply a strip of dentifrice containing 0.454% stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF) (1450 parts per million \[ppm\] fluoride in total) to cover the head of the toothbrush and brush their teeth for 1 timed minute, twice daily (morning and evening), following their normal routine. Participants were also permitted to rinse with tap water.
62629669|NCT02861664|ACTIVE_COMPARATOR|Negative Control Dentifrice: Sodium monofluorophosphate (SMFP)|Participants were instructed to apply a strip of dentifrice containing 1400ppm fluoride as sodium monofluorophosphate (SMFP) to cover the head of the toothbrush and brush their teeth for 1 timed minute, twice daily (morning and evening), following their normal routine. Participants were also permitted to rinse with tap water.
62629670|NCT02170857|NO_INTERVENTION|Open Curettage Only|patients will be treated by the conventional surgical method, i.e. open curettage without injecting any material.
62063914|NCT03461848|EXPERIMENTAL|CYPHP Evelina London Model|Practice clusters across Lambeth and Southwark have been randomised to introduce either the CYPHP Evelina London model of care, or Enhanced Usual Care.
62269105|NCT04027998||Carpal tunnel syndrome|group of carpal tunnel syndrome patients
62629671|NCT02170857|EXPERIMENTAL|Open Curettage with Hyaluronic Acid|Hyaluronic Acid injection will be employed in conjunction with the ordinary surgical procedure.
62063915|NCT03461848|ACTIVE_COMPARATOR|Enhanced Usual Care Model|Practice clusters across Lambeth and Southwark have been randomised to introduce either the CYPHP Evelina London model of care, or Enhanced Usual Care.
62629672|NCT00872612|EXPERIMENTAL|A|Endosonography arm
62629673|NCT00872612|ACTIVE_COMPARATOR|B|Conventional bronchoscopy arm
62269106|NCT04027998||Control group|group of healthy controls
62629674|NCT05205304|EXPERIMENTAL|Treatment group|Subjects will be treated with liquid carbon dioxide (D'oxyva) administered transdermally on the thumb after the Aortic Cross Clamp is removed
62269107|NCT02154386|EXPERIMENTAL|8-10 week healing group|dental implant placed (and bone core biopsy harvested) 8-10 weeks after tooth extraction/grafting
62269108|NCT02154386|ACTIVE_COMPARATOR|18-20 week healing group|dental implant placed (and bone core biopsy harvested) 18-20 weeks after tooth extraction/grafting
62269109|NCT04349527||RB Group|In this Group Patients receive round-block oncoplastic breast coserving surgery
62269110|NCT04349527||RG Group|In this Group Patients receive retrogladular oncoplastic breast coserving surgery
62269111|NCT00936208||Essential hypertensive men and women|
62269112|NCT01714427|ACTIVE_COMPARATOR|Dexamethasone|
62629675|NCT05205304|NO_INTERVENTION|Control group|Subject will not be treated with liquid carbon dioxide (D'oxyva)
62629676|NCT05516238|EXPERIMENTAL|Video group|Case management through video format
62629677|NCT05516238|ACTIVE_COMPARATOR|In-person|Case management through in person format
62451691|NCT01827722|EXPERIMENTAL|Ranibizumab Arm|Ranibizumab injection (combination with sham injections beginning on Day 1 and Week 16) administered at monthly intervals beginning Day 1 and ending at Week 20.
62063916|NCT03555825|ACTIVE_COMPARATOR|60 Minutes ArmeoSpring (1:1)|60 minutes of therapy 3x per week for 6 weeks working one-on-one with a clinician for duration of session.
62063917|NCT03555825|EXPERIMENTAL|60 Minutes ArmeoSpring (2:1)|60 minutes of therapy 3x per week for 6 weeks with one clinician supervising 2 participants.
62063918|NCT03555825|ACTIVE_COMPARATOR|30 Minutes ArmeoSpring (1:1)|30 minutes of therapy 3x per week for 6 weeks working one-on-one with a clinician for duration of session.
62063919|NCT03555825|EXPERIMENTAL|30 Minutes ArmeoSpring (2:1)|30 minutes of therapy 3x per week for 6 weeks with one clinician supervising 2 participants.
62063920|NCT00856661|EXPERIMENTAL|Desmoteplase|
62063921|NCT00856661|PLACEBO_COMPARATOR|Placebo|
62269113|NCT01714427|PLACEBO_COMPARATOR|Sterile isotonic saline|
62269114|NCT04204278|OTHER|Monovisc|
62629678|NCT02084017|ACTIVE_COMPARATOR|Current Standard|Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing applied under sterile conditions in the operating room following skin closure. Dressing changed post-operative day two and daily thereafter with daily inspection for infection by a physician.
62629679|NCT02084017|EXPERIMENTAL|Negative Pressure Wound Therapy|A negative pressure therapy (Kinetic Concepts, Inc, San Antionio, Tex) device will be applied under sterile conditions post-operatively and placed on suction (125-150 cm H2O). The device will be removed on post-operative day 4-7 depending on day of discharge.
62629680|NCT06612593|EXPERIMENTAL|Cilostazol Group|25 participants will receive the standard treatment and cilostazol at a dose of 50 mg twice daily for a month, then the dose will be increased to 100 mg twice daily for 5 months.
62629681|NCT06612593|ACTIVE_COMPARATOR|Control Group|25 participants will receive the standard treatment and the placebo twice daily for 6 months.
62629682|NCT05313399|ACTIVE_COMPARATOR|control group|the group have open bite caused by non-nutritive sucking habits and treat them with palatal crib.
62269115|NCT02655432||Spot photoscreener|Automated vision screener: Spot Vision Screener VS 100, Welch-Allyn. This photoscreener is a portable device, using an infrared light. It is built to detect amblyogenic risk factors. First of all, the spot photoscreener produces a sounds which attracts the child's attention and helps him shift his gaze towards the device, held at 1 meter in front him. The spot then evaluates for refractive errors, anisocoria, strabismus, ptosis and media opacity. The ophthalmologic evaluation consists of the measure of the visual acuity, ocular alignment, anterior and posterior segment. The patient will be cyclopleged with cycloplegic drops and will be refracted to obtain a cyclopleged refraction. This will determine his refractive error.
62269116|NCT04802993||All patients with pancreatic ductal adenocarcinoma aged 70 years and older|All patients in the registry aged 70 years and older with right-sided pancreatic ductal adenocarcinoma
62269117|NCT04802993||All patients with pancreatic ductal adenocarcinoma aged 70-79 years|All patients in the registry aged 70-79 years with right-sided pancreatic ductal adenocarcinoma
62269118|NCT04802993||All patients with pancreatic ductal adenocarcinoma aged 80 years and older|All patients in the registry aged 80 years and older with right-sided pancreatic ductal adenocarcinoma
62269119|NCT04802993||All patients resected with pancreaticoduodenectomy, all ages|All patients in the registry resected with pancreaticoduodenectomy during the study period
62269120|NCT04802993||All patients resected with pancreaticoduodenectomy, aged 70-79 years|All patients in the registry resected with pancreaticoduodenectomy during the study period, aged 70-79 years
62451692|NCT01827722|EXPERIMENTAL|Combination Ozurdex with Ranibizumab PRN|"Ozurdex intravitreal injection administered at 16 week intervals beginning on Day 1 and ending at Week 16 with an initial IV Ranibizumab injection administered at Day 1, then treated with Ranibizumab according to reinjection parameters assessed monthly (in combination with sham if reinjection parameters are not met).~Reinjection Parameters:~10 letter drop from best corrected visual acuity or a 100 µm increase in central retinal thickness according to optical coherence tomography (Spectralis HRA + OCT)."
62629683|NCT05313399|EXPERIMENTAL|experimental group|the group have open bite caused by by non-nutritive sucking habit and treat them with bonded spur.
62063922|NCT02617277|EXPERIMENTAL|Dose Schedule A|In Schedule A, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 1-5 and Days 15-19 of a 28-day cycle. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib).
62063923|NCT02617277|EXPERIMENTAL|Dose Schedule B|In Schedule B, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 15-17 and Days 22-24 of a 28-day cycle. In Schedule B there will be a 7-day AZD1775 (adavosertib) lead-in to enable serial PK measurements prior to initiating MEDI4736 on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
62451693|NCT00359086|EXPERIMENTAL|1|
62629684|NCT05514457|EXPERIMENTAL|remediation group 1|dyslexic children
62629685|NCT05514457|EXPERIMENTAL|remediation group 2|dyslexic children
62269121|NCT04802993||All patients resected with pancreaticoduodenectomy, aged 80 years and older|All patients in the registry resected with pancreaticoduodenectomy during the study period, aged 80 years and older
62269122|NCT02678390|EXPERIMENTAL|Healthy women|"Arm: Evaluation of MCT, aerobic exercise alone and MCT+ aerobic exercise on glucose/ketone/lipid/insulin metabolism in 4-hour visits with repeated blood sampling.~Interventions:~1. A control day with no MCT and no aerobic exercise.~2. A 5 day consecutive MCT intake of 30 g/day.~3. 30 minutes of aerobic exercise at 70% to 80% HRR of intensity.~4. A 5 day consecutive MCT intake of 30 g/day in combination with 30 minutes of aerobic exercise (70% to 80% HRR)/ day for the five days."
62269123|NCT02678390|EXPERIMENTAL|Women with prediabetes|"Arm: Evaluation of MCT, aerobic exercise alone and MCT+ aerobic exercise on glucose/ketone/lipid/insulin metabolism in 4-hour visits with repeated blood sampling.~Interventions:~1. A control day with no MCT and no aerobic exercise.~2. A 5 day consecutive MCT intake of 30 g/day.~3. 30 minutes of aerobic exercise at 70% to 80% HRR of intensity.~4. A 5 day consecutive MCT intake of 30 g/day in combination with 30 minutes of aerobic exercise (70% to 80% HRR)/ day for the five days."
62269124|NCT05681507|ACTIVE_COMPARATOR|Control group|Patients will benefit of our institutional intensive-care unit analgesia protocol
62269125|NCT05681507|EXPERIMENTAL|Intervention group|Patients will benefit of a transversus thoracic muscle plane block and our institutional intensive-care unit analgesia protocol
62269126|NCT04147104|ACTIVE_COMPARATOR|Standard-of-care plus invasive mechanical ventilation|Invasive mechanical ventilation for lung support and to facilitate exhalation via an endotracheal tube o tracheotomy.
62629686|NCT02313623||Patient Scheduled for Prostate Fusion Biopsies|For subjects with scheduled fusion biopsies, we propose a research plan to acquire additional biopsy cores for research purposes without impacting clinical protocol. After acquiring clinically-necessary biopsies, we propose taking an additional research biopsy to establish a matched-pair of clinical and research samples.
62629687|NCT06611293||Volunteers taking part in study|
62269127|NCT04147104|EXPERIMENTAL|ECCO2R plus invasive mechanical ventilation|Low-flow ECCO2R adjunct to standard-of-care and invasive mechanical ventilation.
62269128|NCT01780662|EXPERIMENTAL|Treatment (brentuximab vedotin, gemcitabine hydrochloride)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 15 more courses in the absence of disease progression or unacceptable toxicity. Patients with CR after any course may go off protocol therapy for stem cell transplant.
62269129|NCT01380431|EXPERIMENTAL|A|Subjects received the Par formulated product.
62269130|NCT01380431|ACTIVE_COMPARATOR|B|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
62269131|NCT01380431|ACTIVE_COMPARATOR|C|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
62269132|NCT06488131|EXPERIMENTAL|MTA Pulpotomy|Local anesthesia for pain control will be administered, followed by rubber dam isolation. Then, the tooth and surrounding rubber dam will be flushed with chlorhexidine solution for disinfection. After caries removal, a sterile bur will be used for access opening and complete deroofing of the pulp chamber. Coronal pulp tissue will be removed to the level of canal orifices using a sterile, sharp spoon excavator. A cotton pellet dampened with sodium hypochlorite will be applied on canal orifices to achieve hemostasis. This will be followed by MTA application and glass ionomer restoration. If necessary, the tooth will be restored with stainless steel crown after one week.
62451694|NCT00704795||1|Patients with type 1 diabetes mellitus
62629688|NCT05932771|EXPERIMENTAL|1.Trial for young male participants: Consuming hydrolyzed collagen (HC) with reistance exercise|Young male participants consumed one of three different HC doses (0 grams, 15 grams, or 30 grams) with 4 sets of 10 repetitions of barbell back squat exercise at 10-repetition maximum load in a random order and a seven-day wash-out period interspersed between each trial.
62629689|NCT05932771|EXPERIMENTAL|2.Trial for young female participant: Consuming hydrolyzed collagen (HC) with reistance exercise|The intervention procedure is exactly same as Arm 1 except for the number of visits. Young female participant was asked to visit the laboratory on four occasions during two consecutive months. Therefore, there were two trials in each month, where female participants' estrogen level was lower (i.e., onset of menses) or higher (i.e., ovulation). Dates for the trials were determined based on self-report of onset of menses and previous menstrual cycle length.
62629690|NCT05932771|EXPERIMENTAL|3.Trial for older male participants: Consuming hydrolyzed collagen (HC) with reistance exercise|The age range of older male participants was 40 - 65 years. The intervention procedure is exactly same as Arm 1
62629691|NCT05932771|EXPERIMENTAL|4.Trial for older female participants: Consuming hydrolyzed collagen (HC) with reistance exercise|The age range of older female participants was 40 - 65 years. The intervention procedure is exactly same as Arm 2
62451695|NCT00704795||2|Healthy control subjects matched for body mass index (BMI), age and gender.
62629692|NCT03683563|ACTIVE_COMPARATOR|4% citrate|dialysis catheter locked with 4% sodium citrate
62629693|NCT03683563|EXPERIMENTAL|30% citrate|dialysis catheter locked with 30% sodium citrate
62629694|NCT04608916|ACTIVE_COMPARATOR|Scalpel incision group|This group of patients will receive skin incision made with use of a scalpel blade.
62088112|NCT05826717|EXPERIMENTAL|Food product 3.|\[x\] ml apple juice containing 20 gr fructose as measured with an enzymatic method. Administered one time.
62088113|NCT05826717|EXPERIMENTAL|Food product 4.|20 gr of fructose powder dissolved in 300 ml of water. Administered one time.
62629695|NCT04608916|EXPERIMENTAL|Electrocautery incision group|This group of patients will receive skin incision made with use of electrocautery.
62629696|NCT01571141|EXPERIMENTAL|Monogin|
62269133|NCT06488131|ACTIVE_COMPARATOR|Root Canal Treatment|Local anesthesia for pain control will be administered, followed by rubber dam isolation. Then, the tooth and surrounding rubber dam will be flushed with chlorhexidine solution for disinfection. After caries removal, a sterile bur will be used for access opening and complete deroofing of the pulp chamber. Length of the root canal will be obtained using an apex locator. This will be followed by mechanical shaping using files, and irrigation with 2.5 percent sodium hypochlorite, followed by drying of the canals using paper points. Obturation will then be accomplished using gutta percha and sealer. Finally, the tooth will be restored with conventional glass ionomer restoration. If necessary, the tooth will be restored with stainless steel crown after one week.
62269134|NCT04426110||"Period 1 Control"|No Music. Wound stitches procedure conducted according to clinical practice.
62269135|NCT04426110||"Period 2 Music"|Music by headphones. Wound stitches procedure conducted according to clinical practice
62269136|NCT01681433|EXPERIMENTAL|Experimental: Arm A|OGX-427 + continuation of standard therapy with abiraterone acetate and prednisone
62269137|NCT01681433|ACTIVE_COMPARATOR|Control Arm: Arm B|Continuation of standard therapy with abiraterone acetate and prednisone
62269138|NCT04993404|EXPERIMENTAL|Cohort A：Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of Jaktinib Hydrochloride Tablets.
62269139|NCT04993404|EXPERIMENTAL|Cohort B：Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of Jaktinib Hydrochloride Tablets.
62269140|NCT04993404|EXPERIMENTAL|Cohort C：Normal Hepatic Function|Participants with normal hepatic function matched to participants with hepatic impairment in Cohorts A and B (matched with regards to age, sex, body mass index) will be administered a single oral dose of Jaktinib Hydrochloride Tablets.
62269141|NCT04993404|EXPERIMENTAL|Cohort D：Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 11, inclusive) will be administered a single dose of Jaktinib Hydrochloride Tablets.
62629697|NCT01571141|NO_INTERVENTION|No intervention|
62629698|NCT00826566|ACTIVE_COMPARATOR|1|500 mg caffeine capsules per day
62088114|NCT04313530|EXPERIMENTAL|fatigue in MSA Arm one|This arm will receive a total 10 sessions of TMS stimulation in two weeks. Pre and post intervention scales will be performed on week one, week 2 and week 4.
62269142|NCT02469285|EXPERIMENTAL|Modified pork|Pork with modified fatty acid composition, more unsaturated fat. 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
62269143|NCT02469285|ACTIVE_COMPARATOR|Normal pork|Normal pork 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
62629699|NCT00826566|PLACEBO_COMPARATOR|2|500 mg placebo capsules
62629700|NCT03099603|PLACEBO_COMPARATOR|0.5g|single dose of placebo to 2 healthy subjects or 0.5g HTD1801 to 6 healthy subjects
62629701|NCT03099603|PLACEBO_COMPARATOR|1.0g|single dose of placebo to 2 healthy subjects or 1.0g HTD1801 to 6 healthy subjects
62629702|NCT03099603|PLACEBO_COMPARATOR|2.0g|single dose of placebo to 2 healthy subjects or 2.0g HTD1801 to 6 healthy subjects
62629703|NCT03099603|PLACEBO_COMPARATOR|4.0g|single dose of placebo to 2 healthy subjects or 4.0g HTD1801 to 6 healthy subjects
62629704|NCT00361803|EXPERIMENTAL|All treated subjects|All subjects received Topotecan, administered intravenously over 30 minutes at 4 milligrams per meter\^2 weekly for 3 weeks every 28 days.
62629705|NCT00159952|ACTIVE_COMPARATOR|1|
62629706|NCT01150253|EXPERIMENTAL|probiotic fermented milk|
62629707|NCT01150253|PLACEBO_COMPARATOR|placebo|
62269144|NCT02469285|EXPERIMENTAL|Normal pork and berries|Normal pork and berries (strawberry, raspberry, wild blueberry, lingonberry, cloudberry, blackcurrant) 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
62269145|NCT02683200|EXPERIMENTAL|Treatment (MRI-guided Tri-60Co teletherapy SBRT)|Patients undergo MRI-guided Tri-60Co teletherapy SBRT 3-5 fractions over 1-2 weeks.
62629708|NCT00497146|EXPERIMENTAL|Paricalcitol|Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.
62629709|NCT00497146|PLACEBO_COMPARATOR|Placebo|Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.
62629710|NCT01734460||third trimester pregnant women|no intervention
62629711|NCT00627562|EXPERIMENTAL|1|robot assisted endoscopic head and neck surgery
62629712|NCT01966887|EXPERIMENTAL|MYDICAR-single intracoronary infusion|Genetic / AAV1 Serca2a (MYDICAR)
62629713|NCT01966887|PLACEBO_COMPARATOR|Placebo; single intracoronary infusion|Placebo comparator
62629714|NCT02812082|EXPERIMENTAL|video web-based patient education application|This is a single-arm design. Development of the web-based application will occur over a 6 month period. Patient accrual will not occur until development of the program is complete. Controlled usability testing during the development/design process of the computer program will not be employed as we do not aim to assess the mechanics of patient use, but rather overall time spent interacting with the application in an uncontrolled environment. Following completion of the tool, patient accrual will occur over a six month time period in order to meet our target sample size of up to 50 participants. Participants will be directed to complete a pre-test questionnaire at the time of accrual and will have 3 months to use the program before being directed to complete the post-test questionnaire.
62063924|NCT02617277|EXPERIMENTAL|Dose Schedule C|In Schedule C, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 8-10, Days 15-17, and Days 22-24 of a 28-day cycle. In Schedule C there will be a 7-day AZD1775 (adavosertib) lead-in to enable serial PK measurements prior to initiating MEDI4736 (durvalumab) on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
62063925|NCT02617277|EXPERIMENTAL|Dose Schedule D|In Schedule D, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) one time per day orally on Days 15-19, and Days 22-26 of a 28-day cycle. In Schedule D there will be a 9-day lead-in period with AZD1775 (adavosertib) being dosed on Days -9 to -5 to enable serial PK measurements prior to initiating MEDI4736 (durvalumab) on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
62063926|NCT05967182|EXPERIMENTAL|Pembrolizumab with Gemcitabine and Cisplatin|Participants will receive 4 cycles (21 days each) of the combined chemotherapy before and after your scheduled surgery. During the 9 months of chemotherapy treatment, participants will have clinic visits every 3 weeks or so. During the 2-4 year follow-up period, participants will come to the clinic every 3 months or so
62063927|NCT00594971|OTHER|B|90 terminally ill cancer patients will be referred to a specialist palliative care team at time of discharge.
62269146|NCT02137564|EXPERIMENTAL|Treatment (gamma secretase inhibitor PF-03084014)|Patients receive gamma secretase inhibitor PF-03084014 PO BID on days 1-21. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with PR, CR, or SD at the end of 4 courses may receive an additional 4 courses of gamma secretase inhibitor PF-03084014 in the absence of disease progression or unacceptable toxicity.
62269147|NCT05920876|EXPERIMENTAL|QLS32015|Dose escalation and does expansion of QLS32015 injection will be evaluated.
62269148|NCT04252846||Perampanel|Participants with a diagnosis of epilepsy (POS with or without SG or PGTCS associated with IGE) will initiate treatment with perampanel as first adjunctive treatment as per the clinical judgment of the treating physician as part of routine clinical care. All participants will be observed prospectively for up to 12 months after initiation of perampanel treatment.
62269149|NCT04623242|EXPERIMENTAL|Gantenerumab|
62269150|NCT04623242|EXPERIMENTAL|Solanezumab|
62269151|NCT04623242|PLACEBO_COMPARATOR|Matching placebo (Gantenerumab)|
62269152|NCT04623242|PLACEBO_COMPARATOR|Matching Placebo (Solanezumab)|
62451696|NCT03466190|EXPERIMENTAL|Custom made PEEK plate fixation|Open Reduction Internal Fixation using Custom made PEEK plates.
62451697|NCT03466190|ACTIVE_COMPARATOR|Titanium plate fixation|Open Reduction Internal Fixation using conventional titanium plating system.
62063928|NCT00594971|OTHER|C|90 terminally ill cancer patients will be discharged from hospital with extra effort put into improving the communication between the hospital and the primary sector.
62063929|NCT00594971|NO_INTERVENTION|A|90 terminally ill cancer patients will be discharged from hospital, receiving usual care.
62063930|NCT02716038|EXPERIMENTAL|MPDL3280A, Carboplatin, Nab-paclitaxel|"Subjects with advanced or recurrent cancers receiving:~* MPDL3280A every 21 days for up to 84 days~* Carboplatin every 21 days for up to 84 days~* Nab-paclitaxel every 7 days for up to 84 days"
62063931|NCT06534905|EXPERIMENTAL|E-cigarette switching|NJOY Ace e-cigarette (menthol or tobacco flavor, depending on patient preference) to be used ad libitum.
62063932|NCT06534905|ACTIVE_COMPARATOR|Standard brief advice to address tobacco use|"Patients will be exposed to a brief smoking cessation intervention (BI) based on long-standing tobacco treatment guidelines (Fiore, 2008) and recommendations in the newly revised 4th edition of the ASAM. If a patient reports wanting to stop smoking, they will be instructed to reach out to their medical provider at the treatment clinic. They will be given multiple state and federal resources for quitting smoking.~If the patient does not want to quit smoking during the brief intervention, we will check with them during the next session about their interest.~The brief smoking intervention will be delivered at each session to check on individuals who are attempting to quit and to possibly motivate those who aren't quitting to initiate a quit attempt."
62063933|NCT01320423|OTHER|surgery|
62063934|NCT06396416|EXPERIMENTAL|Virtual Weight Management Program|A maximum tolerated dose of semaglutide (Ozempic/Wegovy) will be administered once weekly subcutaneously, up to a dose of 2.0 mg. Participants will also receive nutritional and movement advice, as well as virtual coaching once every 4 weeks for 6 months.
62063935|NCT06396416|NO_INTERVENTION|Usual Care|Usual care participants will continue to receive the typical standard of kidney and diabetes care. They will not receive any study medication or coaching.
62063936|NCT02629055|EXPERIMENTAL|Respiratory EMG|Additional EMG measurements whilst on NIV will be used to guide the titration of NIV.
62063937|NCT02629055|NO_INTERVENTION|Care as usual|NIV will be initiated according to standard care protocol.
62063938|NCT03027063|EXPERIMENTAL|10,000 steps|"For the 10,000 steps group, participants will be asked to achieve a goal of 10,000 steps a day and to engage in 30 minutes of continuous exercise every day. Steps will be monitored with the under Armour fitness tracker which participants will receive.~For motivation, messages will be sent to study participants in this group via the messaging center in the Under Armor application three times a week. The frequency of messaging will be increased for participants who fail to meet their goals for three consecutive days. Study participants will also receive a weekly call to assess for side effects and provide additional encouragement."
62063939|NCT03027063|ACTIVE_COMPARATOR|Usual care|This will be the usual care group. Participants will also receive a fitness tracker to enable monitoring of steps and will be given a flyer that references the ACC/AHA guidelines for exercise and physical activity for the general population. Participants will not receive text messages or phone calls.
62063940|NCT04232046|EXPERIMENTAL|Intervention|Trigger point massage
62063941|NCT04232046|ACTIVE_COMPARATOR|Control|Treatment with standard drug Nortriptyline
62063942|NCT00877981|ACTIVE_COMPARATOR|Videoassited surgery|"In patients randomized to a video-assisted approach, the surgeon has the option to choose either the lateral- (VAPLA) or medial (MIVAP) techniques, both initiated with a 15 mm transverse skin incision. The lateral approach is performed as described by Henry.~The medial approach is performed using the gasless procedure developed by Miccoli."
62063943|NCT00877981|ACTIVE_COMPARATOR|Open surgery|Open surgery, a 15 mm transverse skin incision is made close to the site of the parathyroid adenoma indicated by sestamibi scintigraphy.
62063944|NCT01576718|EXPERIMENTAL|Fp MDPI 50 mcg|"Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
62063945|NCT01576718|EXPERIMENTAL|Fp MDPI 100 mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
62063946|NCT01576718|EXPERIMENTAL|Fp MDPI 200 mcg|"Fluticasone propionate (Fp) 200 mcg per dose twice a day (for a total daily dose of 400 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
62063947|NCT01576718|EXPERIMENTAL|Fp MDPI 400 mcg|"Fluticasone propionate (Fp) 400 mcg per dose twice a day (for a total daily dose of 800 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
62063948|NCT01576718|PLACEBO_COMPARATOR|Placebo MDPI|"Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
62088115|NCT04313530|SHAM_COMPARATOR|fatigue in MSA Arm two|This arm will receive a total 10 sessions of sham-TMS stimulation in two weeks. Pre and post intervention scales will be performed on week one, week 2 and week 4.
62451698|NCT04154748|EXPERIMENTAL|APC 90W / PPI 120mg|treatment with high-power argon plasma coagulation (90 Watt) followed by acid suppression with high-dose oral omeprazole (40 mg t.i.d)
62063949|NCT01576718|ACTIVE_COMPARATOR|Flovent Diskus 250mcg|"Fluticasone propionate (Fp) 250 mcg per dose twice a day (for a total daily dose of 500 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
62063950|NCT04047511|EXPERIMENTAL|Virtual Reality|"Twice a week, for a 4 consecutive weeks:~* 8 sessions of VRTierOne therapy ( 20 minutes each)~* 8 sessions of general fitness training (40 minutes each)"
62063951|NCT04047511|ACTIVE_COMPARATOR|Control|"Twice a week, for a 4 consecutive weeks:~* 8 sessions of group psychoeducation and relaxation (20 minutes each)~* 8 sessions of general fitness training (40 minutes each)"
62063952|NCT06422702|EXPERIMENTAL|intervention group|Implementation of a psychosomatic symptom intervention with a duration of three months.
62063953|NCT06422702|OTHER|control group|The control group implemented continuity of supportive care based on primary care
62063954|NCT01750736|EXPERIMENTAL|Augmented Exercise and Manual Therapy|Subjects will receive manual therapy according to clinical guidelines followed by instruction in a specific exercise to augment the specific manual treatment provided.
62629715|NCT02853526|EXPERIMENTAL|TIPS arm|Transjugular intrahepatic portosystemic shunt(TIPS) is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein. It is used to treat portal hypertension.TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (also called p-TIPS or modified TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.
62269153|NCT05405400||Treatment group|Families in the treatment group received one welcome visit, 12 visits from a community-based volunteer trained in the Sugira Muryango intervention over 3-4 months, as well as booster visits at 3 and 6 months. The primary caregiver, secondary caregiver if applicable, and any children ages 6-36 months participated in the sessions. Other family members were welcome to join as available.
62269154|NCT05405400||Control group|Usual childcare (no intervention)
62451699|NCT04154748|ACTIVE_COMPARATOR|APC 90W / PPI 40mg|treatment with high-power argon plasma coagulation (90 Watt) followed by acid suppression with standard dose oral omeprazole (40 mg q.d)
62269155|NCT04057274|EXPERIMENTAL|Exercise assessment|The exercise condition will involve venous blood samples being drawn immediately before and after a single bout of moderate-intensity aerobic interval exercise.
62451700|NCT04154748|ACTIVE_COMPARATOR|APC 60 W/ PPI 120mg|treatment with standard-power argon plasma coagulation (60 Watt) followed by acid suppression with high-dose oral omeprazole (40 mg t.i.d)
62451701|NCT01226056|EXPERIMENTAL|RAD001 in combination with sorafenib|
62451702|NCT02297009||Volunteers|30 volunteers, half men and half women Buccal swab
62063955|NCT01750736|ACTIVE_COMPARATOR|General Exercise and Manual Therapy|Subjects will receive manual therapy according to clinical guidelines followed by instruction in a general neck range of motion exercise.
62063956|NCT04143334||RAAB survey|We will examine 3700 Chaonan County residents aged 50 years and older, selected via a clustered, randomized sampling with probability proportional to size (PPS). The cluster will be at the village level, 50 subjects aged 50 years and older will be examined in each cluster includes Visual acuity, torch light, and fundus review, the major cause of blindness or visual impairment will be determined.
62063957|NCT04143334||conventional survey|All the recruited participants underwent ophthalmic examination according to the RAAB protocol and then 60% of them were re-examined with instruments in a mobile eye clinic set up in a village center on the same day. Examination in the mobile clinic included standardized visual acuity (VA) tests using logarithm of the minimum angle resolution charts, refraction, slit-lamp biomicroscopy, and dilated fundal examination with a binocular indirect ophthalmoscope.
62063958|NCT03993236|EXPERIMENTAL|Rosuvastatin/Ezetimibe 10/10mg|The experimental group is orally administered with rosuvastatin 10 mg plus ezetimibe 10 mg combination once daily for 90 days.
62063959|NCT03993236|ACTIVE_COMPARATOR|Rosuvastatin 20mg|The comparator group is orally administered with rosuvastatin 20 mg single agent once daily for 90 days
62063960|NCT03013218|EXPERIMENTAL|Evorpacept (ALX148)|The Part 1 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks.
62063961|NCT03013218|EXPERIMENTAL|Evorpacept (ALX148) + Pembrolizumab|The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab infusions.
62063962|NCT03013218|EXPERIMENTAL|Evorpacept (ALX148) + Trastuzumab|The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab infusions.
62269156|NCT04057274|NO_INTERVENTION|Resting assessment|The resting condition will involve venous blood samples being drawn before and after 60 minutes of seated rest.
62269157|NCT01484626|EXPERIMENTAL|Bendamustine|Bendamustine is combined with standard chemotherapy.
62451703|NCT01989520|EXPERIMENTAL|Treatment A|Phase IIb formulation
62451704|NCT01989520|EXPERIMENTAL|Treatment B|Putative phase III formulation
62451705|NCT01989520|EXPERIMENTAL|Treatment C|Slow dissolution variant 1
62451706|NCT01989520|EXPERIMENTAL|Treatment D|Slow dissolution variant 2
62451707|NCT01989520|EXPERIMENTAL|Treatment E|Optional treatment that may use one of 3 45 mg (intermediate dissolution variant) of AZD5069
62451708|NCT01055223||Type 2 diabetes subjects|Type 2 diabetes subjects
62451709|NCT03560375|EXPERIMENTAL|Circuit resistance training (CRT)|2-3 circuits \* 10 exercises \* 3 times per week
62451710|NCT03560375|EXPERIMENTAL|Empagliflozin 10 MG|10 mg once daily
62269158|NCT02554097||EST+LC group|Patients accept the management of endoscopic sphincterotomy and laparoscopic cholecystectomy.
62451711|NCT03560375|EXPERIMENTAL|Vegeterranean diet (V-Med diet)|The modified V-Med diet will be considered as ad-libitum (using fat sources), aimed for sufficient protein from animal and mainly plant-based sources with carbohydrates limitation.
62629716|NCT02853526|ACTIVE_COMPARATOR|conservative treatment arm|Conservative treatment including endoscopic therapy，non-selective beta blockers (propranolol)and anticoagulation therapy (warfarin).
62269159|NCT02554097||LCBDE+LC group|Patients accept the management of laparoscopic common bile duct exploration and laparoscopic cholecystectomy.
62629717|NCT04646187|EXPERIMENTAL|Intervention group|In patients treated with adalimumab, the dosing interval will be lengthened from 2 to 3 weeks. In patients treated with infliximab, the dosing interval will be lengthened from 8 to 12 weeks. Consists of two groups: Patients randomised to the intervention group and patients allocated to the intervention group based on preference.
62629718|NCT04646187|NO_INTERVENTION|Control group|Unchanged dosing interval. Consists of two groups: Patients randomised to the control group and patients allocated to the control group based on preference.
62629719|NCT01091870|PLACEBO_COMPARATOR|Placebo: soluble blue pigment|Soluble blue pigment for placebo controlling.
62629720|NCT01091870|EXPERIMENTAL|Sildenafil, 75mg daily|Sildenafil citrate, 75 mg daily divided in 3 doses. From third to 14th day after subarachnoid hemorrhage.
62269160|NCT02554097||LTCBDE+LC group|Patients accept the management of laparoscopic transcystic common bile duct exploration and laparoscopic cholecystectomy.
62269161|NCT05099471|EXPERIMENTAL|Venetoclax / Rituximab|"Cycle 1 (28-days cycle) Stepwise dose escalation of Venetoclax in all patients with a target dose of xy mg/d QD PO.~Day 1-7: Venetoclax xy mg/d QD PO Day 8-14: Venetoclax xy mg/d QD PO Day 15-28: Venetoclax xy mg/d QD PO~Cycle 2-12:~Day 1: Rituximab 375 mg/m2 IV Day 1-28: Venetoclax xy mg/d QD PO"
62269162|NCT05099471|ACTIVE_COMPARATOR|Dexamethasone / Rituximab / Cyclophosphamide|"Cycle 1-6:~Day 1: Dexamethasone 20 mg PO Day 1: Rituximab 375 mg/m2 IV Day 1-5: Cyclophosphamide 100 mg/m2 BID PO"
62451712|NCT04322175|EXPERIMENTAL|Single dose pharmacokinetic test|The 72 healthy subjects enrolled were admitted to the trial ward the day before the trial. On the day of dosing, the subjects were given 0.1% meloxicam eye drops once, 1 drop / time.
62451713|NCT04322175|EXPERIMENTAL|Multiple dose tolerance test|Eight healthy subjects were enrolled in the trial ward the day before the trial. 0.1% meloxicam eye drops were administered 4 times, 1 drop / time, and were administered at 8:00, 12:00, 16:00 and 20:00 daily for 3 consecutive days.
62629721|NCT01091870|EXPERIMENTAL|Sildenafil, 150 mg daily|Sildenafil citrate, 150 mg daily divided in 3 doses from third to 14th day after subarachnoid hemorrhage.
62629722|NCT00621257|ACTIVE_COMPARATOR|Treatment A|2,000 IU/day of ergocalciferol orally for 6 weeks (control arm)
62629723|NCT00621257|EXPERIMENTAL|Treatment B|2,000 IU/day of cholecalciferol orally for 6 weeks
62629724|NCT00621257|EXPERIMENTAL|Treatment C|50,000 IU of ergocalciferol once a week orally for 6 weeks
62629725|NCT00621257|ACTIVE_COMPARATOR|Maintenance A|400 IU/day of ergocalciferol orally over 2 years (control arm)
62629726|NCT00621257|EXPERIMENTAL|Maintenance B|2,000 IU/day of ergocalciferol orally from November 1 to April 30, and 1,000 IU/day of ergocalciferol orally for the remainder of the year over 2 years
62629727|NCT02664012|ACTIVE_COMPARATOR|Own Brand Menthol Cigarette|Own Brand Menthol Cigarette
62629728|NCT02664012|EXPERIMENTAL|Electronic Menthol Cigarette #1|VUSE® (menthol flavor, 14 mg nicotine)
62629729|NCT02664012|EXPERIMENTAL|Electronic Menthol Cigarette #2|VUSE® (menthol flavor, 29 mg nicotine)
62629730|NCT02664012|EXPERIMENTAL|Electronic Menthol Cigarette #3|VUSE® (menthol flavor, 36 mg nicotine)
62063963|NCT03013218|EXPERIMENTAL|Evorpacept (ALX148) + Rituximab|The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with rituximab infusions.
62063964|NCT03013218|EXPERIMENTAL|Evorpacept (ALX148) + Pembrolizumab + 5FU + Platinum|The Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab + 5FU + platinum infusions.
62063965|NCT03013218|EXPERIMENTAL|Evorpacept (ALX148) + Trastuzumab + Ramucirumab + Paclitaxel|The Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab + ramucirumab + paclitaxel infusions.
62629731|NCT02664012|ACTIVE_COMPARATOR|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
62063966|NCT00150995|EXPERIMENTAL|Tetrathiomolybdate|Patients will be started on a dose of 60mg Tetrathiomolybdate at bedtime and 40mg 3 times per day.
62269163|NCT05198271|EXPERIMENTAL|Management of risk factors|"-6 month program for reduction /correction of risk factors in patient with active RA :~1. Smoking cessation~2. weightloss~3. Increased physical activity~4. Periodontal treatment~5. Decreased anxiety"
62063967|NCT02066402|EXPERIMENTAL|Tedizolid Phosphate (Sivextro, BAY119-2631)|Participants received 200 mg Tedizolid Phosphate once daily intravenous (I.V.) infusion to oral for 6 days, followed by 4 days of placebo.
62269164|NCT01972750|EXPERIMENTAL|Dovitinib|IMP: Dovitinib (TKI258) Manufacturer: Novartis Dose: 500 mg/day Mode of application: orally Duration of treatment: 5 days / week (5 days on / 2 days off) of a 28-days cycle until progression of disease
62269165|NCT02086539|NO_INTERVENTION|Normal Letter|This arm will receive the recruitment letter in a business sized envelope. The letter states the participant will receive a $25 check upon enrollment into the study.
62629732|NCT04917354||hepatic lesion|
62629733|NCT04797429|EXPERIMENTAL|intervention group|The intervention group will receive antidiabetic therapy according to the current guidelines but with the additional opportunity to use the peer support IMS tool. Peer support and moderation of the intervention group will be provided by moderators. Moderators will be supervised by a dietitian.
62629734|NCT04797429|ACTIVE_COMPARATOR|control group|The control group receives the antidiabetic therapy according to the current guidelines, but without having access to the IMS tool. This means that participants receive medical treatment by their practitioner according to the Austrian recommendations.
62629735|NCT02750696|ACTIVE_COMPARATOR|Co/ Ac|Codeine/acetaminophen (30 mg/500 mg) analgesic association tablets. Patients in this group received one fixed-dose oral tablet of codeine/acetaminophen (30 mg/500 mg) every 4 hours for 3 days.
62063968|NCT02066402|ACTIVE_COMPARATOR|Linezolid|Participants received 600 mg Linezolid twice daily I.V. infusion to oral for 10 days.
62063969|NCT03352934|EXPERIMENTAL|Avelumab|10 mg/kg Avelumab every 2 weeks
62063970|NCT00299000|OTHER|Naglazyme, 1.0 mg/kg|Dose comparison
62063971|NCT00299000|OTHER|Naglazyme, 2.0 mg/kg|Dose Comparison
62063972|NCT06397274|EXPERIMENTAL|Stemchymal®|
62063973|NCT06397274|PLACEBO_COMPARATOR|Placebo|
62063974|NCT01919996|EXPERIMENTAL|Azithromycin|Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
62063975|NCT00813696|EXPERIMENTAL|A|cisplatin + gemcitabine
62629736|NCT02750696|EXPERIMENTAL|Tr/ Ac|Tramadol/acetaminophen (37.5 mg/325 mg) analgesic association tablets. Patients in this group received one fixed-dose oral tablet of tramadol/acetaminophen (37.5 mg/325 mg) every 4 hours for 3 days.
62269166|NCT02086539|EXPERIMENTAL|Large Envelope|This arm will receive the recruitment letter in an 8.5 x 11 inch envelope. The letter states the participant will receive a $25 check upon enrollment into the study.
62629737|NCT05621772|EXPERIMENTAL|Experimental group (Meridian Activation Remedy System for Parkinson's Disease)|Meridian Activation Remedy System for Parkinson's Disease (MARS-PD) treatment (16 times/8 weeks total, 2 times/week)
62629738|NCT05621772|NO_INTERVENTION|Control group (Usual Care)|Usual care (all participants will be allowed to continue their prescribed medication and treatment (except Korean Medicine therapy), and they will not receive any additional treatment or therapy in the research institute), and lifestyle advice (all participants will receive a smart band and application-based guidance about their lifestyle)
62629739|NCT05447845||Healthy|healthy volunteers with no known ocular condition
62063976|NCT00813696|ACTIVE_COMPARATOR|B|gemcitabine
62269167|NCT02086539|EXPERIMENTAL|Priority Mail|Group 3 will receive a recruitment letter shipped via USPS priority mail. The letter states the participant will receive a $25 check upon enrollment into the study.
62629740|NCT05447845||Patients|Subjects with diseases of the eye or the orbit
62629741|NCT05525000|EXPERIMENTAL|Participants aged over 35|Participants run through our validation protocol
62063977|NCT04381936|NO_INTERVENTION|Standard Care|Patient receives usual hospital care
62063978|NCT04381936|ACTIVE_COMPARATOR|Low dose corticosteroids|"First (main) randomisation part A~\[This arm is now closed to recruitment\]"
62629742|NCT03247088|EXPERIMENTAL|Treatment (sorafenib, busulfan, fludarabine, HSCT)|"PRE-STEM CELL INFUSION: Patients receive sorafenib orally PO QD or BID on days -24 to -5, busulfan IV over 3 hours on days -20 and -13 and -6 and -3, and fludarabine IV over 1 hour on days -6 to -3 in the absence of disease progression or unacceptable toxicity.~STEM CELL INFUSION: Patients receive allogeneic HSCT IV in the absence of disease progression or unacceptable toxicity.~POST-STEM CELL INFUSION: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, tacrolimus PO BID beginning day 5 for about 50 days, filgrastim SC on day 7 and sorafenib PO BID beginning between days +30 and +120 for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with matched unrelated donor receive mycophenolate mofetil PO TID or IV over 2 hours TID beginning on day 5 for up to 90 days for longer."
62269168|NCT02086539|EXPERIMENTAL|Amazon|This arm will receive a recruitment letter with the image of an Amazon gift card and told they will receive the $25 gift card if they enroll in the study.
62269169|NCT06047691|EXPERIMENTAL|Abbreviated, Intensive, Multi-Couple Group Cognitive-Behavioral Conjoint Therapy for PTSD|AIM-CBCT for PTSD is an abbreviated, intensive, multi-couple group version of cognitive-behavioral conjoint therapy for PTSD, an evidence-based treatment for PTSD delivered in a conjoint format.
62629743|NCT01431313|EXPERIMENTAL|Inhaled Nitrite|Sodium Nitrite Inhalation Solution (AIR001) 45mg dosage with one subsequent escalation dosage of 90mg based on tolerability.
62629744|NCT04639362|EXPERIMENTAL|Intensification|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are not in CR or who have detectable MRD after 15 cycles (3 cycles lead-in and 12 cycles induction) will continue with 6 intensification cycles ibrutinib in combination with obinutuzumab day 1, 2, 8, 15 for the first cycle and with obinutuzumab day 1 for the following 5 cycles.
62269170|NCT06047691|ACTIVE_COMPARATOR|Prevention and Relationship Education Program|PREP is an evidence-based relationship education program delivered in a multi-couple group format.
62629745|NCT04639362|EXPERIMENTAL|Observation|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are in CR or have no detectable MRD will be observed.
62629746|NCT06523049|EXPERIMENTAL|Combination treatment group|Participants in this group will receive vorolanib tablets, 200 mg orally once daily, plus sintilimab injection, 200 mg intravenously every three weeks.
62629747|NCT05283577|EXPERIMENTAL|Treatment Arm|Each participant will attend a total of 10 treatment visits (one visit per week), over the course of 10 weeks. Each EA session will be approximately 1 hour. Participants in the treatment arm will receive EA at 13 standardized acu-points that were chosen for their therapeutic effects.
62629748|NCT05283577|SHAM_COMPARATOR|Control Arm|Each participant in the control arm will attend a total of 10 treatment visits (one visit per week), over the course of 10 weeks. Participants in the control arm will receive electrical stimulation at non-disease related acu-points for approximately 1 hour per session.
62629749|NCT04742504||BENRA Treated Patients|Patients with severe eosinophilic asthma who will be treated with benralizumab (Fasenra®, Astra Zeneca) will be able to participate in a volunteer manner in the study after sing informed consent.
62629750|NCT04742504||Non BENRA TREATED PATIENTSP|patients with controlled severe asthma requiring high-dose inhaled corticosteroids plus long-acting beta agonists (with or without oral corticosteroids) but without request of benralizumab (Fasenra®, Astra Zeneca) treatment will be recruited
62629751|NCT01865721|ACTIVE_COMPARATOR|Continuous administration of Entonox|Patients randomized to this arm will be asked to inhale Entonox throughout the insertion phase of colonoscopy
62269171|NCT05298007|ACTIVE_COMPARATOR|real stimulation|Participants will receive active tDCS once daily for two weeks. The anode was placed over Fz with return electrodes placed at Fpz, Cz, F3 and F4. Fourteen2-mA sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 20 minutes each day over 14 consecutive sessions.
62269172|NCT05298007|SHAM_COMPARATOR|sham stimulation|Participants will receive sham tDCS once daily for two weeks. Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
62269173|NCT02933034|EXPERIMENTAL|Coronary Disease|Participant receive 2 cardiac MRI procedures: MEMRI and DEMRI.
62269174|NCT03336021|EXPERIMENTAL|Intervention|FAS program
62269175|NCT03336021|NO_INTERVENTION|Comparison|Comparison group
62269176|NCT04617951|EXPERIMENTAL|Ishige Okamurae extracts group|This group takes Ishige Okamurae extracts for 12 weeks.
62451714|NCT05115032|EXPERIMENTAL|Vestibular retraining with dynamic posturography|12 sessions, twice per week, of rehabilitation exercises last about 20 minutes, using CDP and interactive visual feedback
62451715|NCT05115032|ACTIVE_COMPARATOR|At-home rehabilitation exercises|Daily rehabilitation exercises involving nodding and shaking of the head
62629752|NCT01865721|ACTIVE_COMPARATOR|As required administration of Entonox|Patients randomised to this arm will be asked to use Entonox if and when they have pain
62653156|NCT01508000|EXPERIMENTAL|Arm C: modified FOLFOX6 + Panitumumab and Surgery|"Experimental: Arm B: modified FOLFOX6 + Bevacizumab and Surgery~6 cycles before and 6 cycles after surgery consisting in:~Hour - 1 (pre chemotherapy): Panitumumab 6 mg/kg IV over 60 minutes (≤ 1000 mg) or 90 minutes (\> 1000 mg) +/- 15 min. infusion\*.~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
62269177|NCT04617951|PLACEBO_COMPARATOR|Placebo group|This group takes placebo for 12 weeks.
62269178|NCT04595903|EXPERIMENTAL|Hemopurifier®|The Hemopurifier® will be placed within the extracorporeal circuit, all connections secured, treatment will utilize a blood pump at a flow rate of up to 200mL/min. The patients will be monitored for adverse events, device deficiencies and the development of hemodynamic instability. The treatment session will be for 4-6 hours once daily for 4 consecutive days.
62269179|NCT01665183|EXPERIMENTAL|ADI-PEG 20|arginine deiminase formulated with polyethylene glycol
62451716|NCT05251493|ACTIVE_COMPARATOR|Iron Isomaltoside/ferric derisomaltose|route: intravenous Dosage: 1000-1500 mg (100mg/mL), max dose 20mg/kg Frequency: max dose 1000 mg, if further doses required, must receive dosage divided Duration: one infusion or two infusions (dose dependent)
62451717|NCT05251493|ACTIVE_COMPARATOR|Iron Sucrose|Route: Intravenous Dosage: 100 mg/mL (maximum 300 mg per dose) Frequency: up to 3 doses per week or 1000 mg per week maximum Duration: until iron needs reached by simplified table
62451718|NCT00004109|EXPERIMENTAL|Doxorubicin + External-Beam RT|
62451719|NCT02034331|ACTIVE_COMPARATOR|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
62063979|NCT04381936|ACTIVE_COMPARATOR|Hydroxychloroquine|"First (main) randomisation part A~\[This arm is now closed to recruitment\]"
62063980|NCT04381936|ACTIVE_COMPARATOR|Lopinavir-Ritonavir|"First (main) randomisation part A~\[This arm is now closed to recruitment\]"
62063981|NCT04381936|ACTIVE_COMPARATOR|Azithromycin|"First (main) randomisation part A~\[This arm is now closed to recruitment\]"
62063982|NCT04381936|ACTIVE_COMPARATOR|Convalescent plasma|"First (main) randomisation part B~\[This arm is now closed to recruitment\]"
62269180|NCT02360020|EXPERIMENTAL|XLimus patients|participants must have symptomatic ischemic heart disease attributable to critical (that is, \>70% visual estimate) stenotic lesions of native coronary arteries. Inclusion criteria are 1) chronic total occlusion (CTO), 2) severe calcification, and 3) severe tortuosity. CTO is defined as the presence of TIMI 0 flow within the occluded segment and angiographic or clinical evidence of an occlusion duration of ≥3 months. Calcification is defined severe when larger than 3x vessel diameter, and comprising the vessel wall totally in two perpendicular views. Tortuosity is defined severe when: one or more bends \>= 90°, or three or more bends of 45-90° proximal to the diseased segment.
62269181|NCT01225484|ACTIVE_COMPARATOR|CFNB, periarticular infiltration|
62451720|NCT02034331|ACTIVE_COMPARATOR|Heat Application|For the provocation with heat, an insulated thermal heat pack (\~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
62063983|NCT04381936|ACTIVE_COMPARATOR|Tocilizumab|"Participants with progressive COVID-19 (as evidenced by hypoxia and an inflammatory state) may undergo randomisation between Tocilizumab and no additional treatment.~(Children with COVID-19 pneumonia are not eligible for this comparison).~\[This arm is now closed to recruitment\]"
62063984|NCT04381936|ACTIVE_COMPARATOR|Intravenous Immunoglobulin|"First (main) randomisation part A (children only)~\[This arm is now closed to recruitment\]"
62063985|NCT04381936|ACTIVE_COMPARATOR|Synthetic neutralising antibodies|"First (main) randomisation part B.~\[This arm is now closed to recruitment\]"
62269182|NCT01225484|ACTIVE_COMPARATOR|Intraarticular catheter, periarticular infiltration|
62451721|NCT02034331|EXPERIMENTAL|Insulin Iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
62063986|NCT04381936|ACTIVE_COMPARATOR|Aspirin|"First (main) randomisation part C~\[This arm is now closed to recruitment\]"
62063987|NCT04381936|ACTIVE_COMPARATOR|Colchicine|"First (main) randomisation part A~\[This arm is now closed to recruitment\]"
62063988|NCT04381936|ACTIVE_COMPARATOR|Baricitinib|"First (main) randomisation part D~\[This arm is now closed to recruitment\]"
62063989|NCT04381936|ACTIVE_COMPARATOR|Anakinra|"Randomisation for children only with PIMS-TS~(Children with COVID-19 pneumonia are not eligible for this comparison).~\[This arm is now closed to recruitment\]"
62063990|NCT04381936|ACTIVE_COMPARATOR|Dimethyl fumarate|"First (main) randomisation part A (UK adults only; early phase assessment)~\[This arm is now closed to recruitment\]"
62063991|NCT04381936|ACTIVE_COMPARATOR|High Dose Corticosteroids|First (main) randomisation part E
62063992|NCT04381936|ACTIVE_COMPARATOR|Empagliflozin|"First (main) randomisation part F~\[This arm is now closed to recruitment\]"
62063993|NCT04381936|ACTIVE_COMPARATOR|Sotrovimab|First (main) randomisation part J
62063994|NCT04381936|ACTIVE_COMPARATOR|Molnupiravir|"First (main) randomisation part K~\[This arm is now closed to recruitment\]"
62269183|NCT02913937|ACTIVE_COMPARATOR|Needle irrigation|Endodontic irrigation will be done using an endodontic needle.
62269184|NCT02913937|EXPERIMENTAL|Passive ultrasonic irrigation|Endodontic passive ultrasonic irrigation will be done using an endodontic needle followed by passive ultrasonic agitation.
62269185|NCT03467646|ACTIVE_COMPARATOR|Sleeve Gastrectomy|Patients undergo a laparoscopic sleeve gastrectomy as bariatric procedure
62451722|NCT02034331|PLACEBO_COMPARATOR|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
62063995|NCT04381936|ACTIVE_COMPARATOR|Paxlovid|"First (main) randomisation part L~\[This arm is now closed to recruitment\]"
62269186|NCT03467646|ACTIVE_COMPARATOR|Roux-en-Y gastric bypass|Patients undergo a laparoscopic Roux-en-Y gastric bypass as bariatric procedure
62451723|NCT00634907|EXPERIMENTAL|Pharmacogenetic-based warfarin dosing|"Pharmacogenetic-based warfarin dosing: Warfarin dosing based on formula that incorporates genetic testing results.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm, as noted above."
62269187|NCT03467646|EXPERIMENTAL|One-Anastomosis gastric bypass|Patients undergo a laparoscopic One-Anastomosis gastric bypass as bariatric procedure
62269188|NCT01192022|ACTIVE_COMPARATOR|TachoSil®|TachoSil® absorbable patches, applied topically, once, intraoperatively to stop bleeding. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
62269189|NCT01192022|ACTIVE_COMPARATOR|Surgicel® Original|Surgicel® Original absorbable patches, applied topically, once, intraoperatively to stop bleeding. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
62451724|NCT00634907|ACTIVE_COMPARATOR|Standard of care (control)|"Control or usual care warfarin dosing~NOTE: Standard of care (usual care) for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm, as noted above."
62451725|NCT02718495|PLACEBO_COMPARATOR|Part A|Part A consists of two treatment groups, SAD and MAD. Both treatment groups will consist of 3 cohorts. In SAD, subjects will receive a single dose of PTI-428 or placebo. In MAD, subjects will receive once daily dosing of PTI-428 or placebo for 7 days.
62451726|NCT02718495|PLACEBO_COMPARATOR|Part B|Part B will consist of 2 cohorts. Subjects will receive once daily dosing of PTI-428 or placebo for 28 days.
62451727|NCT02718495|PLACEBO_COMPARATOR|Part C|Part C will consist of 3 cohorts. Subjects will receive once daily dosing of PTI-428 or placebo for 28 days.
62451728|NCT02948270||Adolescents with ADHD|Adolescents who met diagnostic criteria in previous clinical/research assessment are invited to come back to SickKids to participate (ages 13-17)
62451729|NCT02948270||Adolescents without ADHD|Adolescent controls (ages 13-17) are tested through local high schools
62451730|NCT05424926||Patients|Patients
62451731|NCT02149303||Dabigatran|
62451732|NCT02433665|ACTIVE_COMPARATOR|Fixed dose|100 of the first 200 subjects will be randomized to a fixed dose of contrast material.
62451733|NCT02433665|ACTIVE_COMPARATOR|Customized dose|100 of the first 200 subjects will be randomized to a customized dose of contrast material based on the experimental algorithm. The second group of 300 subjects will receive a customized dose of contrast material based on the experimental algorithm.
62451734|NCT06079580||Patients with Lumbar spinal stenosis with balance disorders|According to the single-leg balance test, patients who maintain static balance for less than 10 seconds will be grouped as having impaired balance.
62451735|NCT06079580||Patients with Lumbar spinal stenosis with normal balance|According to the single-leg balance test, patients who maintain their static balance for more than 10 seconds will be grouped as having normal balance.
62451736|NCT05276284|EXPERIMENTAL|TEMPLE|Study drugs: Atezolizumab, 6-mercaptopurine and 6-thioguanine
62451737|NCT03923036||Metastatic colorectal cancer|"The French county Calvados registry of digestive cancers will allow to identify patients with a metastatic colorectal cancer diagnosed between 2004 and 2014.~Patients will be included if the cancer was diagnosed at the metastatic stage between 2004 and 2014 or non-metastatic before 2004 that became metastatic between 2004 and 2014 (synchronous and metachronous tumors)"
62451738|NCT02520271|ACTIVE_COMPARATOR|Depression|Behavioral activation only
62451739|NCT02520271|ACTIVE_COMPARATOR|Depression and SUD|Motivational interview and Behavioral activation
62451740|NCT03382366|OTHER|Sarcopenic Group|"This group is composed by 20 osteoporotic postmenopausal women, previously (pre-recruitment) classified as sarcopenic by the DXA.~This group will undergo the same evaluations/intervention of the second group."
62451741|NCT03382366|OTHER|Non-sarcopenic Group|"This group is composed by 20 osteoporotic postmenopausal women, previously (pre-recruitment) classified as non-sarcopenic by the DXA.~This group will undergo the same evaluations/intervention of the first group."
62451742|NCT02841774|ACTIVE_COMPARATOR|Moderate Intensity Group|pravastatin 40mg daily for 12 weeks
62451743|NCT02841774|EXPERIMENTAL|High Intensity Group|rosuvastatin 20 - 40 mg daily for 12 weeks
62451744|NCT01153048|EXPERIMENTAL|Specific education intervention with peer educators|
62451745|NCT01153048|NO_INTERVENTION|General education session in the health structure|
62451746|NCT03494595||Thrombosis|Patients who will develop thrombosis perioperatively
62451747|NCT03494595||No thrombosis|Patients who will not develop thrombosis perioperatively
62451748|NCT06461208|EXPERIMENTAL|Encapsulated FMT|
62451749|NCT06461208|PLACEBO_COMPARATOR|Placebo|
62451750|NCT04319666|EXPERIMENTAL|PCI to left main with IVL|
62653157|NCT03479905|SHAM_COMPARATOR|Salter nasal cannula|A Salter nasal cannula will be used at 4L/ minute during the colonoscopy. The FiO2 delivered to the patient at this rate has been shown to be equal to 36%
62063996|NCT04381936|ACTIVE_COMPARATOR|Baloxavir marboxil|Randomisation part G (influenza)
62629753|NCT04400149||1|amniotic fluid progesterone (this group will be evaluated by the amniotic fluid which was received via amniocentesis). This group consisted of pregnant women who had high risk in the antenal test and give consent to perform amniocentesis. Notwithstanding, amniocentesis detects chromosome abnormalities, neural tube defects, and genetic disorders for the fetuses. İn a routine amniocentesis, 1-2 ml amniotic fluid which was taken in the first place was discarded in order to prevent maternal contamination. Then 15-20 ml amniotic fluid was taken from all of the patients to diagnose genetic disorders of the fetuses. İn this study we evaluate the amniotic fluid progesterone in this 1-2 ml amniotic fluid which was discarded and throw away. Therefore, we are not performing an extra invasive procedure for pregnant women
62629754|NCT04400149||2|serum progesterone (this group consisted of the pregnant women who have amniocentesis procedure and blood samples were taken in the same procedure )
62269190|NCT05682027||Patients suspected of diaphragm dysfunction|"After inclusion, participants will be evaluated for diaphragm dysfunction with fluoroscopy, as in standard of care. Additionally, during the same hospital visit ultrasound will be performed.~The sonographer and the radiologist assessing the ultrasound and fluoroscopy, respectively, will be blinded to each other's' test results. Further assessment, and possible treatment, for diaphragm dysfunction is performed at the discretion of the treating physician.~The primary outcome is the concordance of diaphragm paralysis as determined by ultrasound compared with the construct for diaphragm paralysis based on traditional measurements."
62269191|NCT03124563|EXPERIMENTAL|Control group|Participants will wear a Fitbit Zip to record their daily activity data, which will be deidentified and aggregated with an online platform called Fitabase. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
62269192|NCT03124563|EXPERIMENTAL|Implementation Intention Condition|Participants will wear a Fitbit Zip to record their daily activity data, which will be deidentified and aggregated with an online platform called Fitabase. Participants in this arm will receive all components of the intervention: scheduling, maps, and activity goals.
62269193|NCT01799070||CHS|
62269194|NCT02982135|OTHER|group 1 direct bypass|direct bypass : patients recieve direct bypass treatment
62269195|NCT02982135|OTHER|group 2 indirect bypass|indirect bypass: patients recieve indirect bypass treatment
62269196|NCT01327157|PLACEBO_COMPARATOR|Visual Analog Scale (VAS)|"Initial consultation, dental cleaning and performing the visual analog scale. Consultation three months after achieving visual analog scale final~* VAS and dental cleaning at the first query.~* VAS at the last query. In the second period (91-180 days) that participants have been moved from the Placebo group (VAS) to the Experimental group(Occlusal Adjustment)."
62269197|NCT01327157|EXPERIMENTAL|Occlusal adjustment|In all consultations, was performed VAS and occlusal adjustment. Three sessions of intervention are doing. The Gnathostatic models were performed in the first and last query. To reach a terminal axis of rotation of the jaw the patient to perform the act of swallowing for 3 times, and after palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth and started the adjustment following the rules of Guichet with a cylindrical drill with a thin cut.. The rules to guide the occlusal adjustment selective grinding were in this sequence: Occlusal adjustment to the centric relation: with sliding towards anterior; with sliding towards the medium line; with sliding opposite to the medium line; No sliding.
62269198|NCT02590380|ACTIVE_COMPARATOR|treatment group (MESA)|Patients randomized to the treatment group will receive surgery with the MESA Rail Deformity System.
62629755|NCT05413226|EXPERIMENTAL|Amount of Celastrol Administered|Increasing doses of Celastrol to each of five male subjects
62629756|NCT05819879|ACTIVE_COMPARATOR|PENG group|
62629757|NCT05819879|ACTIVE_COMPARATOR|scaitico femoral block group|
62629758|NCT00553527|OTHER|1|Patient will receive standard of care humeral stem replacement. Only a data collection study. There will be no changes in standard of care for diagnosis.
62629759|NCT01956188|EXPERIMENTAL|EPA and DHA supplementation|EPA (1800mg/d) and DHA (1200mg/d) supplementation
62629760|NCT01956188|PLACEBO_COMPARATOR|Placebo|Soy oil (3000 mg/d)
62629761|NCT01648062|ACTIVE_COMPARATOR|Arousal reduction using guided imagery|Sleep Self-Regulation Using Mental Imagery: Participants in the arousal reduction condition were instructed to imagine wearing a backpack loaded with their worries, then putting the heavy backpack down, and then experiencing the relief and freedom from tension.
62629762|NCT01648062|ACTIVE_COMPARATOR|Mental simulation of sleep behavior|Sleep Self-Regulation Using Mental Imagery: Participants in this condition received instructions to visualize a specific behavioral plan designed to meet the goal of obtaining quality sleep each night through the practice of certain behaviors. To form the behavioral plan, participants visualised changing into comfortable clothes and taking time to relax prior to going to bed, the time they planned to go to sleep, where they planned to sleep, and the bedtime routine they follow to help them to get to sleep. At bedtime, they were instructed to mentally run through a checklist of these behaviors and then do any behaviors that they had not yet completed.
62063997|NCT04381936|ACTIVE_COMPARATOR|Oseltamivir|Randomisation part H (influenza)
62063998|NCT04381936|ACTIVE_COMPARATOR|Low-dose corticosteroids: Dexamethasone (influenza arm)|Randomisation part I (influenza)
62269199|NCT02590380|ACTIVE_COMPARATOR|control group (USS II)|Patients randomized to the control group will receive surgery with the DePuy Synthes USS II System.
62269200|NCT02285725|EXPERIMENTAL|Augmented Microdrilling Surgery|
62269201|NCT01988610|EXPERIMENTAL|Intervention Group|Open-label trial to assess the effects of Mifepristone on mood and cognition in people with a history of depression.
62269202|NCT02977195|EXPERIMENTAL|Dose escalation part, biological cohort and expansion Parts|Dose Escalation and Biological Cohort: NP137 was administrated in patients with locally advanced or metastatic solid tumors Expansion Parts: NP137 was administrated in patients with locally advanced or metastatic solid tumors (Expansion part 1) and in patients with RH+ endometrial cancers (Expansion part 2)
62269203|NCT01362036|EXPERIMENTAL|TXA127 sc injectable|All cohorts will recieve TXA127; Cohorts receive either 300, 600, or 900 ug/kg daily
62269204|NCT01409733|EXPERIMENTAL|Stage IV melanoma patients|
62269205|NCT04543994|EXPERIMENTAL|Remestemcel-L (150 million cells)|"Targeted endoscopic delivery of remestemcel-L at a dose of 150 million cells into the submucosal layer of the colon wall at baseline.~If at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 million MSCs (same dose at initial)."
62269206|NCT04543994|EXPERIMENTAL|Remestemcel-L (300 million cells)|"Targeted endoscopic delivery of remestemcel-L at a dose of 300 million cells into the submucosal layer of the colon wall at baseline.~If at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 300 million MSCs (same dose at initial)."
62269207|NCT04543994|PLACEBO_COMPARATOR|Placebo|"Direct injection of normal saline into the submucosal layer of the colon wall.~If not completely healed after 3 months, participants will then cross over to the treatment group to receive a direct injection of remestemcel-L at a dose of 150 or 300 million cells into the submucosal layer of the colon wall.~If at 6 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 or 300 million MSCs (same dose at initial)."
62629763|NCT01648062|ACTIVE_COMPARATOR|Combination|Sleep Self-Regulation Using Mental Imagery: Participants in this condition were asked to practice a combination of the guided imagery (for relaxation) and mental simulation imagery for sleep-related behaviour
62629764|NCT01648062|SHAM_COMPARATOR|Control|Sleep Self-Regulation Using Mental Imagery: Participants in this condition were asked to imagine a typical post work activity
62629765|NCT04352777|ACTIVE_COMPARATOR|Cohort 1|Fulvestrant plus abemaciclib
62629766|NCT04352777|ACTIVE_COMPARATOR|Cohort 2|Aromatase inhibitor plus abemaciclib (with or without ovarian suppression)
62629767|NCT05982197|ACTIVE_COMPARATOR|Curcuma longa oral gel group|
62629768|NCT05982197|ACTIVE_COMPARATOR|Standard treatment group|
62629769|NCT04032197|EXPERIMENTAL|Semaglutide|Semaglutide injected once-weekly. Standard dose escalations every 4 weeks will be applied, until the maximum dose of 1.0 mg semaglutide is reached.
62629770|NCT04032197|PLACEBO_COMPARATOR|Placebo|Placebo injected once-weekly. Standard dose escalations every 4 weeks will be applied, until the maximum dose of 1.0 mg placebo is reached.
62653158|NCT03479905|SHAM_COMPARATOR|Face mask group|A standard face mask will be used at 8L/minute during the colonoscopy. The FiO2 delivered to the patient at this rate has been shown to be equal to 60%.
62653159|NCT03479905|EXPERIMENTAL|High Flow Oxygen delivery|Oxygen will be delivered by using high flow nasal cannula
62269208|NCT00517829|ACTIVE_COMPARATOR|1- Docetaxel plus Oxaliplatin|Docetaxel as an intravenous (IV) infusion over 1 hour, followed by oxaliplatin IV over 2 hours
62269209|NCT00517829|ACTIVE_COMPARATOR|2- Docetaxel plus oxaliplatin plus cetuximab|Docetaxel 60 mg/m2 as an IV infusion over 1 ho ur, followed by oxaliplatin 130 mg/m2 IV over 2 hours, followed by cetuximab 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
62269210|NCT00087009|EXPERIMENTAL|Group I|Patients receive rituximab IV on days 1, 8, 15, and 22 and oral beta-glucan once daily on days 1-28 (days 8-28 of course 1). Treatment repeats every 42 days for 4 courses.
62269211|NCT00087009|EXPERIMENTAL|Group II|Patients receive rituximab IV on days 1, 4, 8, 15, and 22 and oral beta-glucan once daily on days 8-28. Beginning on day 42, patients with responding disease may receive monthly rituximab prophylaxis.
62269212|NCT05850221|EXPERIMENTAL|weight training|A prescribed 8-week training protocol
62269213|NCT05850221|NO_INTERVENTION|no prescribed weight training|no prescribed weight training
62451751|NCT01984242|EXPERIMENTAL|Atezolizumab and Bevacizumab|Atezolizumab 1200 milligrams (mg) and bevacizumab 15 milligrams per kilogram (mg/kg) will be administered as intravenous (IV) infusions every 3 weeks (q3w) on Day 1 and Day 22 of each 6-week cycle until disease progression.
62451752|NCT01984242|EXPERIMENTAL|Atezolizumab|Atezolizumab 1200 mg will be administered as IV infusion q3w on Day 1 and Day 22 of each 6-week cycle until disease progression. Upon disease progression, participants (except European Union \[EU\] participants) can crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.
62451753|NCT01984242|ACTIVE_COMPARATOR|Sunitinib|Sunitinib 50 mg will be administered orally once daily on Days 1 to 28 of each 6-week cycle until disease progression. Upon disease progression, participants can crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.
62269214|NCT02474342|EXPERIMENTAL|Autologous Adipose Tissue derived MSCs|
62269215|NCT04853784||Totally laparoscopic colon surgery|Totally laparoscopic colon surgery/intracorporeal anastomosis
62269216|NCT04853784||Laparoscopic-assited colon surgery|Laparoscopic-assited colon surgery/extracorporeal anastomosis
62269217|NCT03027700|ACTIVE_COMPARATOR|Health/Normal Controls|Health/normal control subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
62269218|NCT03027700|ACTIVE_COMPARATOR|F1/F2 fibrosis|Type 1 and 2 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
62451754|NCT03559387|EXPERIMENTAL|ANF-RHO™|Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg as a subcutaneous injection.
62451755|NCT03559387|ACTIVE_COMPARATOR|Neulasta®|Neulasta® will be administered to the subjects at a dose of 6.0 mg in 0.6 ml as a subcutaneous injection.
62451756|NCT04483700|EXPERIMENTAL|Filgotinib 200 mg (Main Study - Blinded)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg for up to 16 weeks.
62451757|NCT04483700|EXPERIMENTAL|Filgotinib 100 mg (Main Study - Blinded)|Participants will receive filgotinib 100 mg + PTM filgotinib 200 mg for up to 16 weeks.
62451758|NCT04483700|PLACEBO_COMPARATOR|Placebo (Main Study - Blinded)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg for up to 16 weeks.
62451759|NCT04483700|EXPERIMENTAL|Filgotinib 200 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 200 mg + PTM filgotinib 100 mg.~After study-wide unblinding, participants will receive filgotinib 200 mg."
62063999|NCT04381936|ACTIVE_COMPARATOR|Low-dose corticosteroids: Dexamethasone (pneumonia arm)|Randomisation part M (community-acquired pneumonia)
62064000|NCT03060564|EXPERIMENTAL|AC repair with tendon graft|acromioclavicular repair with tendon graft.
62064001|NCT03060564|ACTIVE_COMPARATOR|AC repair with no tendon graft|acromioclavicular repair without tendon graft/no intervention
62064002|NCT02909036|EXPERIMENTAL|Melphalan|Test Dose CE Melphalan 10mg/m2 with PK studies Day -12 to Day-3, CE Melphalan Dose of Target AUC 13 mg/L/h infused with PK studies Day -2, 3-10 x 10\^6 CD 34+ cells/kg reinfused Day 0, Pegfilgrastim 6mg injection Day +1
62064003|NCT01790360|ACTIVE_COMPARATOR|Patient Navigation (PN)|Behavioral Intervention: 'Patient Navigation (PN) Intervention' participants will receive support from navigators in choosing a provider and remembering to attend appointments
62064004|NCT01790360|EXPERIMENTAL|Financial Incentives (FI)|Behavioral Intervention: 'Financial Incentives (FI) Intervention' participants will receive gift cards and money for attending clinic visits
62064005|NCT06438653||Thoracic endovascular aortic repair|
62064006|NCT00538174|EXPERIMENTAL|Arm 1|2.5 mg
62269219|NCT03027700|ACTIVE_COMPARATOR|F3/F4 fibrosis|Type 2 and 3 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
62269220|NCT03027700|ACTIVE_COMPARATOR|Hepatic steatosis with fibrosis|Hepatic steatosis with liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
62269221|NCT05047809|EXPERIMENTAL|"Jingchuang Ointment(JCO) group"|"Ulcers were treated in this study using the four-step wound care guidelines, observation, rinsing, cleaning, and dressing, published by the Taiwan Food and Drug Administration. Besides, JCO was applied once a day on the wounds, last 3 months.~Jingchuang Ointment (JCO) is made by Chuang Song Zong Pharmaceutical Co., Ltd. (Taiwan)"
62269222|NCT05047809|OTHER|Regular treatment group|Ulcers were treated in this study using the four-step wound care guidelines, observation, rinsing, cleaning, and dressing, published by the Taiwan Food and Drug Administration.
62269223|NCT02543567|EXPERIMENTAL|Group 1|Ad26.ZEBOV 5\*10\^10 viral particles (vp) single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 1\*10\^8 Infectious Unit \[Inf. U.\] single dose IM injection on Day 57
62269224|NCT02543567|EXPERIMENTAL|Group 2|Ad26.ZEBOV 2\*10\^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5\*10\^7 Inf. U single dose IM injection on Day 57
62269225|NCT02543567|EXPERIMENTAL|Group 3|Ad26.ZEBOV 0.8\*10\^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5\*10\^7 Inf. U. single dose IM injection on Day 57
62451760|NCT04483700|EXPERIMENTAL|Filgotinib 100 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 100 mg + PTM filgotinib 200 mg.~After study-wide unblinding, participants will receive filgotinib 100 mg."
62451761|NCT04832113|EXPERIMENTAL|Patient Therapeutics Education (PTE)|Educational diagnosis prior radiotherapy and participation to Patient Therapeutics Education (PTE) in Adapted Physical Activity (APA) and dietetic sessions. In addition to conventional support (dietary and hydration advice).
62451762|NCT04832113|OTHER|Conventional support|Dietary and hydration advices
62451763|NCT02975271|EXPERIMENTAL|Serlopitant|Dose of experimental drug Serlopitant
62451764|NCT02975271|PLACEBO_COMPARATOR|Placebo|Matching dose of Placebo
62451765|NCT05102175||African American adults with poor sleep|Individuals with self-identified poor sleep quality and/or quantity
62451766|NCT00202449|EXPERIMENTAL|1|Prazosin
62451767|NCT00202449|ACTIVE_COMPARATOR|2|Paroxetine
62451768|NCT00202449|PLACEBO_COMPARATOR|3|Placebo
62451769|NCT06454006|PLACEBO_COMPARATOR|Placebo|"Placebo treatment will be delivered using Multi Radiance® Medical PhotOxyl photoceutical medical device emitting a light source that is sufficient to be indistinguishable from the active comparator but does not deliver any therapeutic energy, combined with standard of care therapy for a mechanically ventilated patient in the ICU.~The treatment administration protocol comprises one 7-minute treatment administration per day on each consecutive day for four consecutive weeks, for a maximum of 28 consecutive treatments over 28 consecutive days, or until the day of the subject's successful weaning from mechanical ventilation, or until the day of the subject's death, whichever occurs first."
62451770|NCT06454006|ACTIVE_COMPARATOR|Active|"Active treatment will be delivered using Multi Radiance® Medical PhotOxyl photoceutical medical device in active mode, combined with standard of care therapy for a mechanically ventilated patient in the ICU.~The treatment administration protocol comprises one 7-minute treatment administration per day on each consecutive day for four consecutive weeks, for a maximum of 28 consecutive treatments over 28 consecutive days, or until the day of the subject's successful weaning from mechanical ventilation, or until the day of the subject's death, whichever occurs first."
62451771|NCT06098846|PLACEBO_COMPARATOR|Placebo patch|Placebo transdermal patch daily
62451772|NCT06098846|ACTIVE_COMPARATOR|Dose Frequency 1|Active transdermal patch daily (actives could be alternated with placebo in a given sequence)
62451773|NCT06098846|ACTIVE_COMPARATOR|Dose Frequency 2|Active transdermal patch daily (actives could be alternated with placebo in a given sequence)
62451774|NCT06098846|ACTIVE_COMPARATOR|Dose Frequency 3|Active transdermal patch daily (actives could be alternated with placebo in a given sequence)
62653160|NCT03238131|ACTIVE_COMPARATOR|IVM annually (standard treatment)|The comparator (standard treatment) IVM 200 µg/kg body weight given at 0, 12 and 24 months plus vitamin pills at 6 and 18 months.
62064007|NCT00538174|EXPERIMENTAL|Arm 2|10 mg
62064008|NCT00538174|EXPERIMENTAL|Arm 3|20 mg
62064009|NCT00538174|PLACEBO_COMPARATOR|Arm 4|
62064010|NCT02504437|EXPERIMENTAL|pre-conditioned BMMSCs|autologous bone marrow mesenchymal stem cells (BMMSCs) with hypoxia pre-condition and endothelial pre-induction.
62064011|NCT02504437|ACTIVE_COMPARATOR|BMMSCs|autologous bone marrow mesenchymal stem cells (BMMSCs) without pre-condition.
62064012|NCT02504437|SHAM_COMPARATOR|Controls|standard therapy without autologous bone marrow mesenchymal stem cells (BMMSCs) infusion.
62653161|NCT03238131|EXPERIMENTAL|IVM plus ALB twice annually|IVM 200 µg/kg plus ALB 800 mg (regardless of weight) given at 0, 6, 12, 18, 24 months
62653162|NCT03238131|ACTIVE_COMPARATOR|IVM plus ALB once annually|IVM 200 µg/kg plus ALB 800 mg given at 0, 12, 24 months plus vitamin pills at 6 and 18 months.
62451775|NCT01054508|OTHER|Arm 1: Placebo (4 weeks) --> Placebo (12 weeks) --> Placebo (4 weeks) --> Tredaptive (12 weeks)|Placebo (4 weeks) --\> Placebo (12 weeks) --\> Placebo (4 weeks) --\> Tredaptive (12 weeks) There were two interventional periods of 12 weeks during which patients received either Placebo or Tredaptive (nicotinic acid/laropiprant). Patient who received Tredaptive were given dosages of 1g/20mg for 4 weeks followed by 2g/40mg for 8 weeks.
62451776|NCT01054508|OTHER|Arm 2: Placebo (4 weeks) --> Tredaptive (12 weeks) --> Placebo (4 weeks) --> Placebo (12 weeks)|Placebo (4 weeks) --\> Tredaptive (12 weeks) --\> Placebo (4 weeks) --\> Placebo (12 weeks) There were two interventional periods of 12 weeks during which patients received either Placebo or Tredaptive (nicotinic acid/laropiprant). Patient who received Tredaptive were given dosages of 1g/20mg for 4 weeks followed by 2g/40mg for 8 weeks.
62451777|NCT04962685|EXPERIMENTAL|Unilateral Posterior Crossbite|
62064013|NCT00116402|ACTIVE_COMPARATOR|1|will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID
62064014|NCT00116402|ACTIVE_COMPARATOR|2|salmeterol 50 mcg BID then crossover to combination therapy with fluticasone 220 mcg BID
62064015|NCT01007240|EXPERIMENTAL|soft liner with nano particles|the obturators of this patients will be relined with soft liner, with incorporated nano particles. after a week, the soft liner will be taken off, and will be checked for bacterial adhesion.
62269226|NCT02543567|EXPERIMENTAL|Group 4|Participants will receive intramuscular (IM) injection of Placebo (0.9% saline) once on Day 1 and Day 57
62451778|NCT04962685|NO_INTERVENTION|Normal occlusion|
62451779|NCT00417690|EXPERIMENTAL|A|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
62653163|NCT03238131|ACTIVE_COMPARATOR|IVM twice annually|IVM 200 µg/kg given 0, 6, 12, 18, and 24 months
62653164|NCT00088426||Control|Control group of Williams-Beuren (also known as Williams) syndrome
62064016|NCT05243381|OTHER|Immune non-responder patients|"* HIV viral load \< 50 copies/ml in the past 2 years~* CD4+ T-cell count \< 350 cells/mm3 on the last two tests"
62064017|NCT05243381|OTHER|Immune responder patients|"* HIV viral load \< 50 copies/ml in the past 2 years~* CD4+ T-cell count \> 500 cells/mm3 on the last two tests"
62269227|NCT02544308|ACTIVE_COMPARATOR|No further treatment|No further treatment
62269228|NCT02544308|EXPERIMENTAL|Lenalidomide + Dexamethasone|Lenalidomide 25mg orally daily on days 1-21 Dexamethasone 20mg orally on days 1, 8, 15 \& 22 Up to 9 cycles
62269229|NCT04640337|EXPERIMENTAL|Group E1: IPE applied, participants believe they are receiving IPE.|IPE will be applied following the standard protocol for PT. Participants will believe they are receiving IPE.
62269230|NCT04640337|PLACEBO_COMPARATOR|Group E2: IPE applied, participants believe they are receiving placebo.|IPE will be applied following the standard protocol for PT. Subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
62451780|NCT00417690|PLACEBO_COMPARATOR|P|One packet of oral granules administered three times daily for 2 weeks followed by one packet two times daily for two weeks
62451781|NCT05412498|EXPERIMENTAL|Training|Participants in this arm will perform five battle rope training exercises (acute bout per exercise) at two different conditions (30 and 45 seconds).
62451782|NCT05412498|NO_INTERVENTION|Control|Participants in this arm will receive no intervention.
62451783|NCT01819636|EXPERIMENTAL|Sparkling highly mineral bicarbonated sodium water|1.25 liter a day of sparkling highly mineral bicarbonated sodium water
62451784|NCT01819636|PLACEBO_COMPARATOR|Sparkling low mineralized water|1.25 liter a day of sparkling low mineralized water
62653165|NCT00088426||Family|Direct blood relatives (typically parents, and occasionally siblings of affected individuals) ofpatients with HPE are also eligible to participate.
62653166|NCT00088426||HPE|Patients with HPE
62629771|NCT05781022|ACTIVE_COMPARATOR|group (1) endoscopic group|"For patients in EG, we began with assessment of the site \& size of perforation . In this study, In this study, we used a fully covered stent (Mega stent, Taewoong Medical Industries, Gyeonggi-do, South Korea) ultra large and long (length: 24 cm, diameter: 36 mm) stent. We did not experience any complication with Mega stent, particularly migration, thanks to the design of Mega stent that fits well for the post-sleeve anatomy with reduction of migration.~Concurrently, the interventional radiology team subcutaneously drained the intraperitoneal free fluid using 2 intra-peritoneal tubes that were placed under US guidance in the sub-hepatic region and in the pelvis"
62629772|NCT05781022|NO_INTERVENTION|group (2) surgical group|surgical repair of perforation after adequate drainage
62064018|NCT03102125|EXPERIMENTAL|Nonspecific allograft dysfunction|Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
62269231|NCT04640337|PLACEBO_COMPARATOR|Group P1: IPE not applied, participants believe they are receiving IPE.|The needle will be inserted under the skin but the current will not be passing through. The subjects will see a shame video on the ultrasound screen so they will believe that the IPE is being performed.
62269232|NCT04640337|PLACEBO_COMPARATOR|Group P2: IPE not applied, participants believe they are receiving placebo.|The needle will be inserted under the skin, subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
62064019|NCT03102125|EXPERIMENTAL|Normal graft function|Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
62064020|NCT03102125|EXPERIMENTAL|Cardiac allograft vasculopathy|Patients with allograft dysfunction from known cardiac allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
62269233|NCT00471302||1|Healthy adults in a malaria endemic area in Mali
62629773|NCT02541409|ACTIVE_COMPARATOR|SOF+PEG+RBV|Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks
62064021|NCT03102125|EXPERIMENTAL|ACR/AMR|Patients with allograft dysfunction from prior episodes of acute cellular or antibody mediated rejection will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
62064022|NCT04266288|EXPERIMENTAL|Ketamine|Ketamine 0.5 mg/kg in 0.9% sodium chloride, total volume 50 mL via intravenous infusion over 40 minutes for one dose.
62064023|NCT04266288|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride, total volume 50 mL via intravenous infusion over 40 minutes for one dose
62269234|NCT02214238|ACTIVE_COMPARATOR|Market released PAP device|Use of a market released PAP device
62269235|NCT02214238|EXPERIMENTAL|Modified PAP device|Us of the modified PAP device
62269236|NCT01998828|EXPERIMENTAL|Momelotinib 100 mg PV|Participants with polycythemia vera will receive 100 mg of momelotinib.
62269237|NCT01998828|EXPERIMENTAL|Momelotinib 200 mg PV|Participants with polycythemia vera will receive 200 mg of momelotinib.
62269238|NCT01998828|EXPERIMENTAL|Momelotinib 100 mg ET|Participants with essential thrombocythemia will receive 100 mg of momelotinib.
62269239|NCT01998828|EXPERIMENTAL|Momelotinib 200 mg ET|Participants with essential thrombocythemia will receive 200 mg of momelotinib.
62269240|NCT02776488|EXPERIMENTAL|ELI Arm|Infusion of exogenous sodium lactate as supplemental fuel within 48 hours of TBI
62269241|NCT02776488|PLACEBO_COMPARATOR|Placebo|Placebo infusion of normal saline in Part 2 RCT
62269242|NCT03147729|OTHER|Radiofrequency in anal incontinence: a pilot study|It will be a single arm study with a group of anal incontinence with 10 women with anal incontinence
62269243|NCT03070847|EXPERIMENTAL|Very low dose|Will receive single bolus of Tranexamic acid. Dose: 5mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
62269244|NCT03070847|ACTIVE_COMPARATOR|Low dose|Will receive single bolus of Tranexamic acid. Dose: 10mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
62451785|NCT02551289||Patients|Patients newly diagnosed with Coeliac disease before starting treatment with a gluten free diet
62064024|NCT01624649||Patients with ADHD|Patients will receive methylphenidate hydrochloride or atomoxetine. The methylphenidate hydrochloride is available in three forms. 1) Immediate release 2) Extended release 3) Osmotic release oral system
62064025|NCT03528174|EXPERIMENTAL|Single Hormone closed loop|Subjects will have glucose managed using the Artificial Pancreas Control system (APC) using insulin only. Insulin will be infused through the Pacific Diabetes Technologies CGM Insulin Infusion system.
62269245|NCT04760561|NO_INTERVENTION|Control group (conventional care)|Patients randomized to this arm will receive the conventional positioning interventions provided by the critical care nurses, which will not include self-prone positioning.
62269246|NCT04760561|EXPERIMENTAL|Intervention group (prone position group)|Patients randomized to this arm will receive self-prone positioning.
62269247|NCT02735369|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62269248|NCT02735369|EXPERIMENTAL|2% OC-10X|2% OC-10X
62629774|NCT02541409|ACTIVE_COMPARATOR|SOF+RBV|Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks
62629775|NCT04165356|EXPERIMENTAL|Mouth-rinse with clorhexidine|Mouth-rinse with 0.12% clorhexidine + tooth brushing twice daily
62269249|NCT03760900|EXPERIMENTAL|infusion group|Autologous Umbilical Cord Blood Stem Cells Therapy
62451786|NCT02551289||Healthy volunteers|Participants who do not meet criteria for a clinical diagnosis of Coeliac disease as determined by screening blood sample.
62451787|NCT01152203|EXPERIMENTAL|Bendamustine + Bevacizumab|Bendamustine starting dose of 70 mg/m\^2 by vein on Days 1 and 2 of a 28 day cycle. Bevacizumab 10 mg/kg by vein on Days 1 \& 15 of every 28 day cycle.
62451788|NCT06496737|EXPERIMENTAL|Moderate-Intensity Interval Training (MIIT)|Moderate-Intensity Interval Training (MIIT) is developed by university badminton coaches
62451789|NCT06496737|EXPERIMENTAL|High-Intensity Interval Training (HIIT)|High-Intensity Interval Training (HIIT) is developed by university badminton coaches
62451790|NCT05249907|NO_INTERVENTION|Control|No application will be made this group
62269250|NCT03183193|PLACEBO_COMPARATOR|Control diet|A conventional and balanced diet based on American Heart Association (AHA) guidelines and lifestyle advice to achieve the objective of American Association for the Study of Liver Diseases (AASLD): loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation.
62269251|NCT03183193|EXPERIMENTAL|FLiO diet|A mediterranean dietary strategy based on macronutrient distribution (quantity and quality), antioxidant capacity, meal frequency, dietary behaviour and lifestyle advice to achieve the objective of AASLD: loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation.
62451791|NCT05249907|EXPERIMENTAL|VIBRATION GROUP|Vibration will be applied this group.
62451792|NCT05249907|EXPERIMENTAL|MASSAGE GROUP|Massage will be applied this group.
62629776|NCT04165356|ACTIVE_COMPARATOR|Mouth-rinse with bicarbonate isotonic solution|Mouth-rinse with isotonic solution with 1.5% sodium bicarbonate + tooth brushing twice daily
62629777|NCT04000126|ACTIVE_COMPARATOR|Control C|This group will be given induction anesthesia agents in standard doses (fentanyl 3mcg/kg, propofol 2mg/ kg, rocuronium 0,6mg/kg)
62269252|NCT01565070|ACTIVE_COMPARATOR|Biofreeze|
62269253|NCT01565070|PLACEBO_COMPARATOR|Placebo|Use of placebo ointment
62269254|NCT00636766|EXPERIMENTAL|1|
62629778|NCT04000126|EXPERIMENTAL|Lignocaine group L|This group will be given additionally 1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation
62629779|NCT04000126|PLACEBO_COMPARATOR|Placebo P|This group will be given additionally 100 ml 0,9% NaCl iv 10 min before intubation
62629780|NCT01853787|EXPERIMENTAL|Formoterol Fumarate|At study day n°1 the patients will be randomized to take either Salmeterol or Formoterol in a double blind way.
62629781|NCT01853787|ACTIVE_COMPARATOR|Salmeterol|The second study arm represents the crossing over arm. Every patient, at study day number 2 will take a different medication (Salmeterol 50 mcg or Formoterol 12 mcg) from that taken at the study day n° 1.
62629782|NCT02035553|PLACEBO_COMPARATOR|Placebo|Placebo, two tablets, once daily by mouth
62269255|NCT00371293|ACTIVE_COMPARATOR|1|Participants will receive CPAP therapy.
62269256|NCT00371293|ACTIVE_COMPARATOR|2|Participants will take part in a weight loss program.
62269257|NCT00371293|EXPERIMENTAL|3|Participants will receive CPAP therapy and take part in a weight loss program.
62451793|NCT00698100|EXPERIMENTAL|1|Patients will get human tyrosinase vaccination.
62451794|NCT00698100|EXPERIMENTAL|2|Patient will get mouse tyrosinase DNA vaccination.
62451795|NCT05855538||Paroxysmal AF|200 patients
62451796|NCT05855538||Persistent AF|200 patients
62451797|NCT05855538||Permanent AF|200 patients
62629783|NCT02035553|EXPERIMENTAL|Pimavanserin 40 mg|Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
62629784|NCT00807885|EXPERIMENTAL|Tegaderm-secured 24 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, Teflon angiocatheter secured with Tegaderm
62629785|NCT00807885|EXPERIMENTAL|Tape-secured 24 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, Teflon angiocatheter secured with a tape double chevron
62629786|NCT00807885|EXPERIMENTAL|Tegaderm-secured 24 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, polyurethane angiocatheter secured with Tegaderm
62629787|NCT00807885|EXPERIMENTAL|Tape-secured 24 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, polyurethane angiocatheter secured with a tape double chevron
62629788|NCT00807885|EXPERIMENTAL|Tegaderm-secured 20 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, Teflon angiocatheter secured with Tegaderm
62629789|NCT00807885|EXPERIMENTAL|Tape-secured 20 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, Teflon angiocatheter secured with a tape double chevron
62629790|NCT00807885|EXPERIMENTAL|Tegaderm-secured 20 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, polyurethane angiocatheter secured with Tegaderm
62629791|NCT00807885|EXPERIMENTAL|Tape-secured 20 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, polyurethane angiocatheter secured with a tape double chevron
62629792|NCT00807885|EXPERIMENTAL|SC button with 27 ga X 9 mm needle|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a button-type subcutaneous delivery system (with a 27-gauge, 9 mm long metal needle)
62629793|NCT01679392|EXPERIMENTAL|Ropivacaine|Unilateral transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
62629794|NCT05341050||patients with Ph+ CML-CP|
62629795|NCT04457700||Triple-negative and HER2 Positive breast cancer|Patients with triple-negative or HER2 Positive breast cancer, axillary lymph node metastasis who underwent NAC are eligible for this study. Axillary lymph node metastasis is confirmed by fine needle aspiration (FNA) or core needle biopsy (CNB) at initial diagnosis. CT-based radiomics will be uesd in evaluating the response and predicting pCR of metastatic lymph nodes after NAC in breast cancer patients.
62629796|NCT03311841|EXPERIMENTAL|End Stage Renal Disease|Participants requiring hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). A washout period of at least 14 days will separate dosings.
62629797|NCT03311841|EXPERIMENTAL|Severe Impairment|Participants with \<30 mL/min/1.73m\^2 estimated glomerular filtration rate (eGFR) not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
62269258|NCT06471400|OTHER|Patient relative/LAR interview|Study intervention: interview with patient relative/LAR
62064026|NCT03776994|EXPERIMENTAL|Group 1A 2 µg VEE Vaccine Alone|"Subgroup 1A, 2 µg VEE VLP Vaccine Alone Venezuelan equine encephalitis VLP Vaccine candidate~Vaccinations on Day 0, Day 28, and Day 140"
62629798|NCT03311841|EXPERIMENTAL|Moderate Impairment|Participants with 30 to \<60 mL/min/1.73m\^2 eGFR not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
62064027|NCT03776994|EXPERIMENTAL|Group 2A 10 µg VEE Vaccine Alone|"Venezuelan equine encephalitis VLP Vaccine candidate Subgroup 2A, 10 µg VLP Vaccine Alone~Vaccinations on Day 0, Day 28, and Day 140"
62064028|NCT03776994|EXPERIMENTAL|Group 3A 20 µg VEE Vaccine Alone|"Venezuelan equine encephalitis VLP Vaccine candidate Subgroup 3A, 20 µg VEE VLP Vaccine Alone~Vaccinations on Day 0, Day 28, and Day 140"
62064029|NCT03776994|EXPERIMENTAL|Group 1B 2 µg VEE Vaccine and Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 1B, 2 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)~Vaccinations on Day 0, Day 28, and Day 140"
62064030|NCT03776994|EXPERIMENTAL|Group 2B 10 µg VEE Vaccine with Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 2B, 10 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)~Vaccinations on Day 0, Day 28, and Day 140"
62629799|NCT03311841|EXPERIMENTAL|Mild Impairment|Participants with 60 to \<90 mL/min/1.73m\^2 eGFR not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
62064031|NCT03776994|EXPERIMENTAL|Group 3B 20 µg VEE Vaccine with Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 3B, 20 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)~Vaccinations on Day 0, Day 28, and Day 140"
62064032|NCT00709748|ACTIVE_COMPARATOR|1|Subjects in this study arm will receive treatment (fully active) Empi Select TENS devices.
62451798|NCT04255719|EXPERIMENTAL|Unilateral DBS of the subthalamic nucleus (STN)|To deliver unilateral STN DBS, bilateral stimulation will be turned off for three hours, and then turn on the unilateral STN DBS. The STN stimulation will be programmed as previous parameter configuration with optimal therapeutic benefits. Participants will be asked to complete a comprehensive set of assessments under unilateral STN stimulation in the off-medication state. 45 minutes after taking regular medication, participants need to complete the second set of assessments in the on-medication state.
62653167|NCT02354326||Diagnostic (VNC DECT)|Patients undergo CT scans. Additional images will be processed with virtual non-calcium (VNC) dual energy CT (DECT) information. Comparison will be made between images with and without addition of VNC.
62064033|NCT00709748|PLACEBO_COMPARATOR|2|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
62064034|NCT06512103||Experimental: 90 patients with apical periodontitis (AP group)|AP group was divided into 3 subgroups. The participants in the study group were divided into two subgroups: 35 patients with a PAI score of 3-4 (Group 2: mild-moderate AP), and 55 patients with at least one tooth with a severity of PAI 5 (Group 3: Severe AP).
62451799|NCT04255719|EXPERIMENTAL|Unilateral DBS of the globus pallidus interna (GPi)|To deliver unilateral GPi DBS, bilateral stimulation will be turned off for three hours, and then turn on the unilateral GPi DBS. The study protocol is identical to the intervention of unilateral STN DBS but it was done on a different day.
62064035|NCT06512103||Control: A healthy control group of 35 volunteers|A healthy control group of 35 volunteers without periodontal pathology as well as any acute/chronic disease (muscle-joint-bone diseases, inflammatory bowel disease, local or generalized infection, severe organ disease, cardiovascular disease and diabetes mellitus), were included in the control group. 35 healthy patients with a PAI score of 1-2 (Group 1: Control group) were included.
62451800|NCT02032368|EXPERIMENTAL|TACE group|Patients in TACE group receive transarterial chemoembolization (TACE) one month after resection.
62629800|NCT03311841|ACTIVE_COMPARATOR|Healthy Control|Participants with ≥90 mL/min creatinine clearance. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
62064036|NCT01023568|ACTIVE_COMPARATOR|Macintosh blade|Intubation with Macintosh blade laryngoscope
62064037|NCT01023568|ACTIVE_COMPARATOR|Glidescope|Intubation with Glidescope laryngoscope
62064038|NCT01023568|ACTIVE_COMPARATOR|Truview PCD|Intubation with the Truview PCD laryngoscope
62629801|NCT02251821|EXPERIMENTAL|Treatment (ruxolitinib, transplant)|Patients receive a ruxolitinib and undergo myeloablative or reduced-intensity conditioning followed by transplant and GVHD prophylaxis; see detailed description.
62629802|NCT03681899||Subjects aged of 65 years or older|Subjects aged of 65 years or older, taking at least one oral medication for two weeks or more.
62629803|NCT03635827|ACTIVE_COMPARATOR|NBTX-001|
62064039|NCT03353259|NO_INTERVENTION|SS-TG|Standard surgery using burr-hole procedure, irrigation and drainage.
62064040|NCT03353259|ACTIVE_COMPARATOR|SS-TXA-TG|Standard surgery using burr-hole procedure, irrigation and drainage combined withTranexamic acid (Cyklokapron) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day until complete hematoma disappearance.
62064041|NCT03353259|ACTIVE_COMPARATOR|SS-TXA-RoA|Standard surgery using burr-hole procedure, irrigation and drainage combined with Tranexamic acid (Cyklokapron) and Tocilizumab (RoActemra) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day combined with RoActemra subcutaneous injection of 162 mg once a week until complete hematoma disappearance.
62064042|NCT04502056|EXPERIMENTAL|AMA RI - B- B - R|Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will include information on the disproportionate impact on communities of color.
62064043|NCT04502056|EXPERIMENTAL|AMA RI - B - B - N|Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
62064044|NCT04502056|EXPERIMENTAL|AMA RI - W - W - R|Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will include information on the disproportionate impact on communities of color.
62451801|NCT02032368|NO_INTERVENTION|Control group|Patients in Control group receive no management.
62451802|NCT01157390|EXPERIMENTAL|Infant formula|The infants will be fed with Wondersun infant formula with high proportion of palmitic acid at the sn-2 position
62064045|NCT04502056|EXPERIMENTAL|AMA RI - W - W - N|Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
62064046|NCT04502056|EXPERIMENTAL|AMA DP - B- B - R|Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will include information on the disproportionate impact on communities of color .
62451803|NCT01157390|ACTIVE_COMPARATOR|Breast feeding|Complete breast feed within the first 3 month
62451804|NCT02259556|EXPERIMENTAL|anti-CD30 CAR T cells|Patients receive CART30 cell infusions with an escalation dose.
62451805|NCT01095510|EXPERIMENTAL|500 U CINRYZE (10-25 kg body weight)|Single IV dose of 500 U CINRYZE
62451806|NCT01095510|EXPERIMENTAL|1000 U CINRYZE (10-25 kg body weight)|Single IV dose of 1000 U CINRYZE
62451807|NCT01095510|EXPERIMENTAL|1000 U CINRYZE (>25 kg body weight)|Single IV dose of 1000 U CINRYZE
62451808|NCT01095510|EXPERIMENTAL|1500 U CINRYZE (>25 kg body weight)|Single IV dose of 1500 U CINRYZE
62451809|NCT03767192|EXPERIMENTAL|Active Stimulation|Device: The Ischemic Stroke System SPG stimulation and standard of care
62451810|NCT03767192|SHAM_COMPARATOR|Sham Stimulation|Device: Sham control Sham stimulation and standard of care
62629804|NCT03635827|PLACEBO_COMPARATOR|Placebo|
62629805|NCT03132415|EXPERIMENTAL|Get Connected|Get Connected is a brief intervention focused on resolving ambivalence about HIV prevention behaviors, increasing self-efficacy for change, and enhancing motivation moving toward action.
62629806|NCT03132415|ACTIVE_COMPARATOR|HIV Test Locator|Participants randomized to the control condition will receive the Get Connected testing site locator. Given the availability of search engines to locate HIV/STI testing sites, the test locator condition may be considered usual care.
62064047|NCT04502056|EXPERIMENTAL|AMA DP - B- B - N|Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
62064048|NCT04502056|EXPERIMENTAL|AMA DP - W- W - R|Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will include information on the disproportionate impact on communities of color.
62064049|NCT04502056|EXPERIMENTAL|AMA DP - W- W - N|Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
62064050|NCT04502056|PLACEBO_COMPARATOR|Control: AMA RI - B - B|"Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - No message on Covid-19 will be shown.~Acknowledgement Racial Injustice AMA: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.~African American Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA"
62064051|NCT04502056|PLACEBO_COMPARATOR|Control: AMA RI - W - W|"Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will also be white - No message on Covid-19 will be shown.~Acknowledgement Racial Injustice AMA: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.~White Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a white sender in acknowledgment of AMA"
62064052|NCT04502056|PLACEBO_COMPARATOR|Control: AMA DP - B - B|"Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - No message on Covid-19 will be shown.~African American Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA~AMA Acknowledgement Drug Pricing: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing"
62451811|NCT05152719|EXPERIMENTAL|Sprint Interval Training (SIT) Protocol|"Participants in the SIT group will start with a 5 minute warm-up jogging at around 70-80% of their heart rate max. The SIT protocol consists of 30 second intervals of all out shuttle runs, seperated by 2 minutes of low pace walking active rest. This will be repeated between 4 times during the first 2 weeks, 5 times during the second 2 weeks, and 6 times during the third 2 weeks. Participants will be instructed to sprint the greatest possible distance in 30 seconds, starting by running to the 5m marker and back, then to the 10m marker and back, then to the 15m marker etc. The SIT session will finish with 2 minutes walking at a pace 50% of their heart rate max."
62629807|NCT06128720|EXPERIMENTAL|Open Label|Participants will get Hyperbaric oxygen therapy for 20 days to determine best methods for full trial.
62629808|NCT06128720|EXPERIMENTAL|Active Hyperbaric Oxygen|Participants will get Hyperbaric oxygen therapy for 20 days.
62629809|NCT06128720|PLACEBO_COMPARATOR|Sham Hyperbaric Oxygen|Participants will get a Sham Hyperbaric oxygen therapy for 20 days
62629810|NCT05028816|OTHER|Group 1|"Side 1: Final layer dermal closure with poliglecaprone 25 suture (Monocryl ®, Ethicon, Inc. Bridgewater, NJ)~Side 2: Final layer closure with force modulating tissue bridges (FMTB) (Brijjit BP100-6, Brijjit Medical Inc., Marietta, GA)"
62629811|NCT05028816|OTHER|Group 2|"Side 1: Final layer closure with force modulating tissue bridges (FMTB) (Brijjit BP100-6, Brijjit Medical Inc., Marietta, GA)~Side 2: Final layer dermal closure with poliglecaprone 25 suture (Monocryl ®, Ethicon, Inc. Bridgewater, NJ)"
62629812|NCT05485480|EXPERIMENTAL|Opioid-sparing: Lidocaine, Ketamine, Magnesium, Clonidine, Fentanyl, Remifentanil, Propofol|"Ketamine: started at 5mg/h; continued until 30min before end of surgery, then reduced to 1mg/h until discharge from recovery.~Fentanyl: bolus of 50mcg before skin incision (in case of insufficient analgesia further boluses of 25mcg, upper limit is 100mcg).~Lidocaine: bolus of 1.5mg/kg of ideal body weight (IBW),(maximum 100mg) at induction of anaesthesia, then continuous infusion of 1.5mg/kg IBW/h (maximum 100mg/h) until discharge from recovery.~Magnesium: infusion of 2g/h for a maximum of 2h after induction of anaesthesia (maximum dose 4g). In case of bradycardia or hypotension, rate is reduced to 1g/h.~Clonidine: bolus of 15mcg if needed. Maximum amount 150mcg. Remifentanil: started at time of induction of anaesthesia until end of surgery."
62629813|NCT05485480|ACTIVE_COMPARATOR|Conventional group: Fentanyl, Remifentanil, Propofol|"Control Intervention:~Remifentanil: Remifentanil is given as a target controlled infusion using the Minto-model. It is started at the timepoint of induction of anaesthesia and given until the end of surgery.~Fentanyl: 2mcg/kg i.v. is given at the time of induction of anaesthesia and another 1-2mcg/kg is given prior to incision. Further fentanyl boluses (1-2mcg/kg boluses) are given in case there seems to be insufficient analgesia."
62629814|NCT05335655|ACTIVE_COMPARATOR|Group A|IV bolus of dexmedetomidine, blindly administered and tittered to 0.5mcg per kilogram (real weight), diluted in 10 ml of 0.9% saline solution during 15 minutes before the spinal block. Once the anesthetic effect is confirmed, the maintenance IV infusion, based on dexmedetomidine 100 mcg diluted in 100 ml of 0.9% saline solution tittered at 0.5 mcg per kilogram per hour (real weight), begins.
62629815|NCT05335655|PLACEBO_COMPARATOR|Group B|IV 10 ml initial bolus of 0.9% saline solution during the 15 minutes before the spinal block. Once de anesthetic effect is confirmed, the maintenance infusion of IV 0.9% saline solution (100 ml in equivalent dosage per hour) begins.
62629816|NCT06612957|EXPERIMENTAL|Cesarean Section + Uterine Diverticulum Repair Group|The original skin incision is used as the surgical incision. Tissues are sequentially separated until reaching the uterus. The original uterine incision'supper edge is used as the surgical incision for this procedure. The bladder is pushed down to fully expose the lower segment of the uterus. After the complete delivery of the fetus and placenta, the placental tissues are thoroughly cleaned, and the uterine scar diverticulum tissue in the lower segment is trimmed down to the original incision edge, making the lower edge of the incision normal uterine muscle tissue. The trimmed uterine scar diverticulum tissue is sent for pathological examination.
62629817|NCT06612957|NO_INTERVENTION|Conventional Surgery Group|Participants randomly assigned to the control group undergo the same preoperative preparations and surgical procedures as the intervention group, except for the specific steps involving the repair of the uterine diverticulum.
62653168|NCT04754295|EXPERIMENTAL|STANDARD|In this arm standard monitoring of vital signs will be used during operation.
62064053|NCT04502056|PLACEBO_COMPARATOR|Control: AMA DP - W - W|"Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will also be white - No message on Covid-19 will be shown.~White Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a white sender in acknowledgment of AMA~AMA Acknowledgement Drug Pricing: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing"
62064054|NCT02430363|ACTIVE_COMPARATOR|MK-3475|"Pembrolizumab (MK-3475) is a humanized monoclonal antibody. Information from these studies suggests that Pembrolizumab (MK-3475) may be beneficial in Glioblastoma / Gliosarcoma.~* Patients enrolling in phase 1 receive MK-3475 every 3 weeks, with the dose to be determined.~* MK-3475 will be given intravenously over the course of 30 minutes"
62064055|NCT02430363|EXPERIMENTAL|Suppressor of the PI3K/Akt pathways|"Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ. Patients will take the Pictilisib (capsules) orally with food. The dose should be taken every 3 weeks.~BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor. Inhibits ATR whileshown to be a poor inhibitor to Akt and PDK1.~Patients will take the BEZ235 (capsules) orally with food. The dose should be taken every 3 weeks.~Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 .~Patients will take the Ipatasertib (capsules) orally with food. The dose should be taken every 3 weeks.~The suggested dosage of inhibitors of the PI3K/Akt pathway orally as a single dose in capsule and Packed in plastic boxes, so that preparations can be taken at home"
62064056|NCT04718558||Patients aged between 3-24 month and undergoing cleft palate surgery|
62653169|NCT04754295|EXPERIMENTAL|GDT|A non-invasive hemodynamic monitor STARLINK™SV will be used in addition to standard monitoring.
62064057|NCT06625268||Women with suspected UTI|Adult women with suspected uncomplicated urinary tract infections
62269259|NCT01292642|EXPERIMENTAL|Treatment|Cognitive behavioral therapy (CBT) plus transdermal patch nicotine replacement therapy (NRT) to treat co-occurring nicotine and cannabis dependence during a 10-week study.
62629818|NCT03298997|EXPERIMENTAL|Ligation and Hemorrhoidopexy|"The patient will be placed in the Lloyd-Davies position. Provision of a sterile field, using a 10% povidone iodine solution. Rectal dilatation will be performed with a 10% xylocaine gel. Introduction of a proctoscope. Identification of the hemorrhoidal nodules (3rd, 7th, 11th hour). Confirmation of the hemorrhoidal artery location, through palpation. Ligation of the hemorrhoidal nodules using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Placement of a fixative suture in the hemorrhoidal nodule and then performance of hemorrhoidopexy Placement of a hemostatic gauze in the surgical field. Prior to operation, the patients will be submitted to pudendal nerve block. Using an atraumatic 25 Gauge (G) needle, a 20ml lidocaine solution (diluted with saline in a 1:1 rate) will be administered bilaterally, medially to the ischial tuberosity.~10 minutes before the operation, the patient will receive 1-2.5mg midazolam and 0.1-0.2 mg fentanyl."
62629819|NCT03298997|ACTIVE_COMPARATOR|Ultrasound Guided Ligation of Hemorrhoidal Arteries|"The patient will be placed in the Lloyd-Davies position. Provision of a sterile field, using a 10% povidone iodine solution. Rectal dilatation will be performed with a 10% xylocaine gel. Use of a proctoscope combined with a Doppler sensor. After the hemorrhoidal artery localization, Z ligations will be placed, using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~The proper artery ligation will be confirmed by the absence of the Doppler signal.~In the presence of residual hemorrhoidal tissue hemorrhoidopexy will be performed, by applying a continuous suture.~Placement of a hemostatic gauze in the surgical field. Prior to operation, the patients will be submitted to spinal anesthesia. Using an atraumatic 25 Gauge (G) needle, a levobupivacaine 5mg/ml and fentanyl 25mg solution, will be administered at the height of lumbar (L)2-L3 or L3-L4."
62629820|NCT03938363|EXPERIMENTAL|Cervical Dystonia (CD)|Patients with cervical dystonia
62629821|NCT03938363|PLACEBO_COMPARATOR|Healthy Control CD|CD age- and sex-matched healthy control subjects
62064058|NCT02895022|EXPERIMENTAL|Lidocaine 2% adrénalinée|The main objective is to determine the ED95 dose of 2% lidocaine with epinephrine injected into the epidural catheter for which it does not arise from failure to surgical anesthesia for cesarean during labor.
62629822|NCT03938363|EXPERIMENTAL|Blepharospasm (BS)|Patients with blepharospasm
62629823|NCT03938363|PLACEBO_COMPARATOR|Healthy Control BS|BS age- and sex-matched healthy control subjects
62629824|NCT02413632|OTHER|First period|"creation of a STIs score risk~pharyngeal swab+urinary collection+blood specimens+rectal Chlamydia trachomatis l Neisseria gonorrhoeae (CT/GC) testing"
62629825|NCT02413632|OTHER|Second period|"validation of a STIs score risk~pharyngeal swab+urinary collection+blood specimens+rectal Chlamydia trachomatis l Neisseria gonorrhoeae (CT/GC) testing"
62629826|NCT02187237|EXPERIMENTAL|Laser therapy|
62629827|NCT04069728|OTHER|Standard clinic appointment|Patients who undergo a routine clinic outpatient appointment using standard explanation of their fistula with words, diagrams and MRI images, as per Consultant preference
62629828|NCT04069728|EXPERIMENTAL|Clinic appointment with 3D model|Patients who undergo a routine clinic outpatient appointment using a 3D printed model to assist explanation of their fistula
62629829|NCT01955239|ACTIVE_COMPARATOR|Standard IMRT|Standard IMRT in which the mean dose to both whole parotid glands is minimized.
62629830|NCT01955239|EXPERIMENTAL|Stem-cell Sparing IMRT|Stem-cell Sparing IMRT in which the mean dose to the stem cell containing region of the parotid gland is minimized
62629831|NCT03143777|NO_INTERVENTION|Baseline|Standard physiotherapy and mobilisation
62629832|NCT03143777|EXPERIMENTAL|Sara Combilizer group|Ongoing care with the sara combilizer available for use
62629833|NCT01719991|EXPERIMENTAL|Nurse case management and self-management support|The first component of the intervention is the monitoring offered under the case management process. The second component of the intervention consists of group meetings (10-12 people) for self-management support in accordance with the stanford model. A sample of patients in each of the four FMGs (n = 126) will be recruited. These patients will receive the intervention for six months.
62629834|NCT01719991|NO_INTERVENTION|Control group|Patients in the control group (n = 121) will receive the usual care for six months and then the same intervention as the experimental group for the next five months (waiting list control group).
62064059|NCT04886427||Quickscan for patients and their kin|Patients and/or kin who are treated in the hospitals will be invited to fill in the quickscan.
62629835|NCT05765669|EXPERIMENTAL|Operative|Percutaneous screw fixation
62629836|NCT05765669|EXPERIMENTAL|Non-operative|Pain management and physical therapy advanced with weight bearing as tolerated.
62064060|NCT04886427||Quickscan for healthcare professionals|Healthcare professionals working in the hospitals will be invited to fill in the quickscan.
62629837|NCT01137097|ACTIVE_COMPARATOR|Lateral sentinel group|Lateral sentinel lymph node biopsy with radioisotope
62629838|NCT01137097|NO_INTERVENTION|No intervention for lateral neck|No lateral sentinel lymph node biopsy with radioisotope
62629839|NCT03758768|EXPERIMENTAL|Blue monochromatic light|Three consecutive mornings of one hour exposure to monochromatic light (20 lx, irradiance = 49.65 µW/cm2) with peak wavelength of 455 nm (blue light), with equal photon flux as the control condition.
62629840|NCT03758768|ACTIVE_COMPARATOR|Full spectrum light control condition|"Three consecutive mornings of one hour exposure to full spectrum light (2500 Kelvin, irradiance = 37.72 µW/cm2) with equal photon flux as the blue light.~We will adjust the light intensity to make sure that the photon energy is the same across the two conditions."
62269260|NCT06493955|EXPERIMENTAL|experimental arm|Patients with type 2 diabetes included in the adapted physical activity arm for 12 months
62269261|NCT06493955|ACTIVE_COMPARATOR|control arm|Type 2 diabetes patients with standard prescription for adapted physical activity (6 months)
62269262|NCT06273332|EXPERIMENTAL|AI-assisted registration|3D model registration will be carried out using artificial intelligence
62269263|NCT06273332|ACTIVE_COMPARATOR|Point-based registration|3D model registration will be carried out using point-based approach
62629841|NCT03101384||Patient with a diagnostic error|"Defined by one of :~1. Absence of prescribed test included in an accepted pulmonary diagnosis algorithm in the next 48h00 after the firts contact with a physician~2. Absence of prescribed test included in an accepted pulmonary diagnosis algorithm by the first contacted physician but the diagnostic is done before 48h00 because the patient went at the emergency room on his own initiative.~3. More than one doctor consulted before the diagnostic of pulmonary embolism (excluding the emergency physician if the patient was referred by the 1st contact doctor)"
62064061|NCT03717402|OTHER|Intervention Participants|Patients with advances cancer using opioids for chronic pain will be enrolled and asked to use the STAMP cancer pain management app for 4 weeks.
62269264|NCT01538654||'enteral protein tube feeding in obese|protein sparing modified fast with a defined enteral formula by tube
62269265|NCT06280482|EXPERIMENTAL|Treatment|
62629842|NCT03101384||Patient without a diagnostic error|Any patient that did not meet the criteria to define the diagnostic error
62629843|NCT02426008|EXPERIMENTAL|Culture media with growth factors and Cytokine|Growth factors and Cytokine adding to culture media to detect the deference and monitor the embryological outcome.
62629844|NCT02426008|PLACEBO_COMPARATOR|In Vitro culture media|culture media to monitor the embryological outcome as control group
62629845|NCT01347593|EXPERIMENTAL|ceftizoxime (cefizox) injection|ceftizoxime (cefizox) as single dose of 1 g at the interval of 30-60 minutes before the incision
62629846|NCT00006929|EXPERIMENTAL|Treatment (suramin, paclitaxel, carboplatin)|Patients receive suramin IV over 30 minutes on days 1 and 2. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62629847|NCT04504565|EXPERIMENTAL|99mTc-3PRGD2|intravenous injection of 0.3 mCi/kg of 99mTC-3PRGD2, patients underwent single-photon emission computed tomography/COMPUTED tomography (SPECT/CT) examination.
62064062|NCT02424591|ACTIVE_COMPARATOR|Ketamine|ketamine group will be infused after intubation and terminated at the start of skin closure
62269266|NCT05506189||Breast cancer survivors with over-weight or obesity|Breast cancer survivors with 25 and more than 25 of BMI will be supported with 6 months life style modification program using mobile application including human coach for reducing BMI.
62269267|NCT01426139|EXPERIMENTAL|Biotronik Orsiro DES|
62269268|NCT00896675||patients treated with EGFR inhibitors and/or VEGF inhibitor|
62269269|NCT00896675||NOT treated with EGFR inhibitors and/or VEGF inhibitor|
62269270|NCT06006793|EXPERIMENTAL|Dose-escalation and Dose-expansion|"In dose-escalation phase, SY-5933 tablets will be administrated orally, repeat daily, 28 days as a dosing cycle, in ascending doses.~In dose-expansion phase, RP2D of SY-5933 determined in dose-escalation phase will be administrated orally, repeat daily, 28 days as a dosing cycle."
62269271|NCT04015895||Patient with cancer|Patient with cancer will be included. They will have to answer at DEFCO tool.
62269272|NCT05343286|EXPERIMENTAL|APAP group: adapted and personalized physical activity|12 weeks of adapted and personalized physical activity
62269273|NCT05343286|ACTIVE_COMPARATOR|APA group: adapted physical activity|12 weeks of generic physical activity
62269274|NCT05343286|SHAM_COMPARATOR|Control group: no physical activity|no physical activity
62269275|NCT02222207|EXPERIMENTAL|Regorafenib [A]|Part A: Patients will receive Regorafenib eye drops
62629848|NCT00680849||1|Treatment condition from first study. This is a follow-up study.
62629849|NCT00680849||2|Control condition from first study.
62629850|NCT03610334|EXPERIMENTAL|SAD IFB-088 2.5mg|Cohort 1: A single daily dose of 2.5mg IFB-088 in oral capsule, is administered with 250 ml of water at room temperature, in the morning around 8:00am, in one intake
62629851|NCT03610334|PLACEBO_COMPARATOR|SAD Placebo 2.5mg|Cohort 1: A single daily dose of 2.5mg placebo in oral capsule, is administered with 250 ml of water at room temperature, in the morning around 8:00am, in one intake
62629852|NCT03610334|EXPERIMENTAL|SAD IFB-088 5.0mg|Cohort 2: A single daily dose of 5.0mg IFB-088 in oral capsule, divided in two doses of 2.5mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
62629853|NCT03610334|PLACEBO_COMPARATOR|SAD Placebo 5.0mg|Cohort 2: A single daily dose of 5.0mg placebo in oral capsule, divided in two doses of 2.5mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
62629854|NCT03610334|EXPERIMENTAL|SAD IFB-088 10.0mg|Cohort 3: A single daily dose of 10.0mg IFB-088 in oral capsule, divided in two doses of 5.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
62629855|NCT03610334|PLACEBO_COMPARATOR|SAD Placebo 10.0mg|Cohort 3: A single daily dose of 10.0mg Placebo in oral capsule, divided in two doses of 5.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
62629856|NCT03610334|EXPERIMENTAL|SAD IFB-088 20.0mg|Cohort 4: A single daily dose of 20.0mg IFB-088 in oral capsule, divided in two doses of 10.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
62629857|NCT03610334|PLACEBO_COMPARATOR|SAD Placebo 20.0mg|Cohort 4: A single daily dose of 20.0mg Placebo in oral capsule, divided in two doses of 10.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
62629858|NCT03610334|EXPERIMENTAL|SAD IFB-088 40.0mg|Cohort 5: A single daily dose of 40.0mg IFB-088 in oral capsule, divided in two doses of 20.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
62629859|NCT03610334|PLACEBO_COMPARATOR|SAD Placebo 40.0mg|Cohort 5: A single daily dose of 40.0mg Placebo in oral capsule, divided in two doses of 20.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
62064063|NCT02424591|PLACEBO_COMPARATOR|Placebo|placebo group will have standard of care rather than ketamine infusion
62064064|NCT02576158||Subjects will be women, 30-65 years of age|Patients who are at average risk of developing cervical intraepithelial neoplasia or cervical cancer who are eligible for cervical cancer screening will be asked to collect Cervical Exfoliated Cells sample for the HPV integration screening test and for the HPV testing and TCT. Subjects with HPV positive will undergo colposcopy within 90 days of enrollment.
62064065|NCT00771303||Ct scan|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer measurement, lower limb compression ultrasonography and multi-slice computed tomography.
62064066|NCT00041756|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62064067|NCT00041756|EXPERIMENTAL|25 mg PG-530742|25 mg PG-530742
62269276|NCT02222207|EXPERIMENTAL|Regorafenib [B1]|Part B: Regorafenib eye drops dose 1; plus sham IVT (Intravitreal therapy) once every 4 weeks
62269277|NCT02222207|EXPERIMENTAL|Regorafenib [B2]|Part B: Regorafenib eye drops dose 2; plus sham IVT (Intravitreal therapy) once every 4 weeks
62269278|NCT02222207|EXPERIMENTAL|Regorafenib [B3]|Part B: Regorafenib eye drops dose 3; plus sham IVT (Intravitreal therapy) once every 4 weeks
62064068|NCT00041756|EXPERIMENTAL|50 mg PG-530742|50 mg PG-530742
62064069|NCT00041756|EXPERIMENTAL|100 mg PG-530742|100 mg PG-530742
62064070|NCT00041756|EXPERIMENTAL|200 mg PG-530742|200 mg PG-530742
62064071|NCT03498222|EXPERIMENTAL|Dose Level -1|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 9mg/m2
62064072|NCT03498222|EXPERIMENTAL|Dose Level 1|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 18mg/m2
62064073|NCT03498222|EXPERIMENTAL|Dose Level 2|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 36mg/m2
62064074|NCT03203694|EXPERIMENTAL|Walking: Intervention arm in diabetics|The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
62064075|NCT03203694|EXPERIMENTAL|Walking: No intervention in diabetics|Subjects will be instructed to continue their usual lifestyle for 8 weeks.
62064076|NCT03203694|OTHER|Walking: Healthy cohort as reference controls|Subjects will be studied at one time only.
62064077|NCT03203694|EXPERIMENTAL|Lower body heating: Intervention arm in healthy subjects|This intervention consists of 60 minutes of lower body heating (40-42 degree C).
62064078|NCT03203694|EXPERIMENTAL|Lower body heating: Intervention arm in diabetics|This intervention consists of 60 minutes of lower body heating (40-42 degree C) 7 days per week for 7 days.
62064079|NCT03203694|OTHER|Lower body heating: Healthy cohort as reference controls|Subjects will be studied at one time only.
62064080|NCT04479722|EXPERIMENTAL|Microport CardioAdvance LAAC system|Subject implant Microport CardioAdvance LAAC system to occlude LAA through percutaneous intervention.
62064081|NCT04479722|ACTIVE_COMPARATOR|Watchman LAAC system|Subject implant Watchman LAAC system to occlude LAA through percutaneous intervention.
62064082|NCT06625957|EXPERIMENTAL|NTCB02-1|
62064083|NCT06625957|ACTIVE_COMPARATOR|NTCB-C|
62064084|NCT03193671||Benign|Benign tumors, pre-and postmenopausal
62629860|NCT03610334|EXPERIMENTAL|SAD IFB-088 60.0mg|Cohort 6: A single daily dose of 60.0mg IFB-088 in oral capsule, divided in two doses of 30.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
62064085|NCT03193671||Malignant|Malignant tumors, pre-and postmenopausal
62064086|NCT03193671||Borderline|Borderline tumors, pre-and postmenopausal
62064087|NCT03193671||Malignant+borderline|Malignant+borderline tumors, pre-and postmenopausal
62629861|NCT03610334|EXPERIMENTAL|SAD Placebo 60.0mg|Cohort 6: A single daily dose of 60.0mg Placebo in oral capsule, divided in two doses of 30.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
62629862|NCT03610334|EXPERIMENTAL|MAD IFB-088 15 mg|Cohort 7: subject taking 15.0mg of IFB-088 in oral capsule divided into 2 doses of 7.5mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
62064088|NCT03288896|EXPERIMENTAL|Alerta Alcohol|Intervention Group: The Experimental Group receives the Alerta Alcohol intervention, which consists of four sessions at school (baseline questionnaire, two sessions in three scenarios: at home, celebrations, and public places, and a final evaluation). The adolescents are provided with answers related to their views of each scenario; this information is used to provide highly specific feedback regarding their knowledge, risk perception, self-esteem, attitude, social influence (modelling, norms and social pressure), self-efficacy and action plans. In addition, two booster sessions are given at home to reinforce the contents of the three scenarios. Evaluation takes place after four months.
62269279|NCT02222207|EXPERIMENTAL|Regorafenib [B4]|Part B: Regorafenib eye drops dose 4; plus sham IVT (Intravitreal therapy) once every 4 weeks
62269280|NCT02222207|EXPERIMENTAL|Regorafenib [B5]|Part B: Regorafenib eye drops dose 5; plus sham IVT (Intravitreal therapy) once every 4 weeks
62629863|NCT03610334|PLACEBO_COMPARATOR|MAD Placebo 15 mg|Cohort 7: subject taking 15.0mg of placebo in oral capsule divided into 2 doses of 7.5mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
62629864|NCT03610334|EXPERIMENTAL|MAD IFB-088 30 mg|Cohort 8: subject taking 30.0mg of IFB-088 in oral capsule divided into 2 doses of 15.0mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
62629865|NCT03610334|PLACEBO_COMPARATOR|MAD Placebo 30 mg|Cohort 8: subject taking 30.0mg of Placebo in oral capsule divided into 2 doses of 15.0mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
62629866|NCT03610334|EXPERIMENTAL|MAD IFB-088 50 mg|Cohort 9: subject taking 50.0mg of IFB-088 in oral capsule divided into 2 doses of 25.0mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
62629867|NCT03610334|PLACEBO_COMPARATOR|MAD Placebo 50 mg|Cohort 9: subject taking 50.0mg of Placebo in oral capsule divided into 2 doses of 25.0mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
62629868|NCT04547140|EXPERIMENTAL|Liquid Alpha1-Proteinase Inhibitor + Standard Medical Treatment|Participants received the first intravenous (IV) infusion of liquid alpha1-proteinase inhibitor (human) 120 milligrams per kilogram (mg/kg), based on body weight on Day 1, followed by second liquid alpha1-proteinase inhibitor (human) dose of 120 mg/kg based on body weight, on Day 8 (second dose was not mandatory and was given at the principal investigator's \[PI\] discretion). Participants also received all standard of care interventions while hospitalized, from Day 1 to Day 29.
62629869|NCT04547140|PLACEBO_COMPARATOR|Placebo + Standard Medical Treatment|Participants received IV infusions of 0.9% normal saline of commensurate volume to that of liquid alpha1-proteinase inhibitor as placebo on Day 1 and Day 8 (Day 8 was not mandatory and was given at the PI's discretion). Participants also received all standard of care interventions while hospitalized, from Day 1 to Day 29.
62629870|NCT03576638|ACTIVE_COMPARATOR|Sinemet|Controlled Release 25/100
62269281|NCT02222207|EXPERIMENTAL|Regorafenib [B6]|Part B: Regorafenib eye drops dose 6; plus sham IVT (Intravitreal therapy) once every 4 weeks
62629871|NCT03576638|EXPERIMENTAL|AP CD/LD|
62629872|NCT01149031|ACTIVE_COMPARATOR|low level laser therapy, using a probe|"The treatment will be done by using a LLL-probe touching several areas of the vulvar vestibule, according to the selected protocol.~Every patient will be treated twice weekly for 6 weeks."
62629873|NCT01149031|PLACEBO_COMPARATOR|Placebo|The patients will be treated with placebo-probe, according to the same protocol
62629874|NCT00110357|ACTIVE_COMPARATOR|Group A|1-12 years old
62629875|NCT00110357|ACTIVE_COMPARATOR|Group B|13-18 years old
62629876|NCT05386290||UC patients|Patients who were diagnosed moderate-to-severe ulcerative colitis (UC) and intend to be treated by biological agents (infliximab or vedolizumab) or traditional drugs (glucocoticoid, immunosupressive drugs and/or mesalazine) will be enrolled.
62629877|NCT05386290||CD patients|Patients who were diagnosed moderate-to-severe Crohn's Disease (CD) and intend to be treated by biological agents (infliximab or ustekinumab) or traditional drugs (glucocoticoid, immunosupressive drugs and/or mesalazine) will be enrolled.
62269282|NCT02222207|ACTIVE_COMPARATOR|Ranibizumab|Ranibizumab IVT once every 4 weeks; plus placebo eye drops to match the regorafenib eye drop regimens
62269283|NCT01978288||Cohort 1 Newborns with asthmatic mothers|Infants born to mothers who have diagnosis of Asthma that were enrolled in study from 5/7/14 to 6/1/16.
62629878|NCT02252107|EXPERIMENTAL|Decitabine|Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.
62629879|NCT00985972||Intervention|Groups of school intervention that involves a combination of the physical activity and nutrition education in subjects 6 to 18 years of age
62629880|NCT00985972||Control|Groups included in the same school communities that serve as reference for individuals involved in intervention.
62629881|NCT00254423|EXPERIMENTAL|Arm A (once daily dasatinib)|Patients receive dasatinib PO QD for up to 15-18 years.
62629882|NCT00254423|EXPERIMENTAL|Arm B (twice daily dasatinib)|Patients receive dasatinib PO BID for up to 15-18 years.
62629883|NCT06183437|EXPERIMENTAL|Stop Group|This group will stop their heart failure medication(s) under the supervision of the study team. The investigators expect most participants in the STOP group to only be on beta-blockers and/or angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). The ACEi or ARB will be stopped first. The ACEi or ARB will be reduced by 50% every 7 days and stopped 7 days after 25% of maximal recommended dose for HF is reached. At this point (or at baseline if only on BB), the BB dose will be reduced by 50% every 7 days then stopped once 25% of the maximal dose is reached.
62629884|NCT06183437|NO_INTERVENTION|Standard of Care Group|This group with continue with their heart failure medication(s) for at least 1 year.
62629885|NCT03075189|EXPERIMENTAL|Protein supplement|"During hospitalization the intervention group will receive a protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.~Diet registration and testing at baseline, discharge and follow-up."
62629886|NCT03075189|NO_INTERVENTION|Standard treatment|"The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.~Diet registration and testing at baseline, discharge and follow-up."
62629887|NCT05841797|NO_INTERVENTION|Standard of Care (SOC)|"Standard of Care (SOC): For Arm 1 of the pilot trial, SOC will be implemented. SOC for PWLWH in Kenya is carried out according Kenyan National Guidelines and includes integration of antenatal care, HIV care, and HIV-exposed infant follow up within the maternal-child health clinic through 18-24 months postpartum. Provision of ART, HIV education, and adherence counseling is routinely provided. Psychosocial support is provided by either peer educators or lay health workers. WLWH who miss visits are followed up by phone and then traced in the community to encourage return to care.~PWLWH undergo routine VL testing six months after ART initiation or at confirmation of pregnancy if already on ART. VLs are performed every six months through breastfeeding.~Women with VL 200 copies/ml undergo enhanced adherence counseling with repeat VL in three months. While routine screening for IPV and depression are recommended per National Guidelines, they are incompletely implemented."
62629888|NCT05841797|EXPERIMENTAL|In-Person Program Management Plus (PM+)|For Arm 2, the investigators will implement the adapted PM+ utilizing the complete manual of operations and adaptation lessons learned in the non-clinical trial portion of the study. The investigators will train mentor mothers to serve as PM+ Helpers. In-person sessions will likely be delivered at home. Sessions will continue after the birth if not completed during pregnancy. PM+ Helpers will debrief regularly on the progress of participants with clinically trained supervisors - both for their own psychological well-being and to ensure that participants receive adequate care.
62629889|NCT05841797|EXPERIMENTAL|Mobile Program Management Plus (mHealth PM+)|For Arm 3, the investigators will implement the adapted PM+ utilizing the complete manual of operations and adaptation lessons learned in the non-clinical trial portion of the study. The investigators will train mentor mothers to serve as PM+ Helpers. In the mHealth delivered version of PM+, PM+ Helpers will conduct PM+ virtually after an initial meeting to create rapport. Sessions will be delivered by either 1) a PM+ Helper- initiated phone call or 2) a participant-initiated call via a call-in help line. Airtime will be provided so that participation will be free of charge. Sessions will continue after the birth if not completed during pregnancy. PM+ Helpers will debrief regularly on the progress of participants with clinically trained supervisors - both for their own psychological well-being and to ensure that participants receive adequate care.
62629890|NCT05355909|NO_INTERVENTION|controll group|Standard of care without preoperative fitness program
62629891|NCT05355909|EXPERIMENTAL|Interventional group|After randomisation the patients will obtain a two week personalised fitness program to improve the preoperative fitness
62629892|NCT03003702|EXPERIMENTAL|ETH|Overnight monitoring
62629893|NCT03003702|OTHER|CTH|Morning monitoring
62629894|NCT06266130|OTHER|Treatment Group|Digital Bonding Tray. Brackets will be bonded to each subject's teeth with a digital bonding tray.
62629895|NCT06266130|ACTIVE_COMPARATOR|Control Group|Direct bonding method. Brackets will be bonded to each subject's teeth by direct placement.
62629896|NCT06299449|EXPERIMENTAL|control group|conventional socket shield with conventional simultaneous implant placement
62629897|NCT06299449|EXPERIMENTAL|study group|computer guided implant placement combined with artificial intelligence-assisted socket shield.
62629898|NCT04712864|EXPERIMENTAL|Experimental LB1901|Drug: anti-CD4 CAR T cells anti-CD4 CAR T cells transduced with a lentiviral vector to express CD4 chimeric receptor domain on T cells.
62629899|NCT03099577|EXPERIMENTAL|radiochemotherapy 1|Patients will be treated with radiation therapy 64.8 Gy
62629900|NCT03099577|EXPERIMENTAL|radiochemotherapy 2|Patients will be treated with radiation therapy 69.6 Gy
62629901|NCT03099577|EXPERIMENTAL|radiochemotherapy 3|Patients will be treated with radiation therapy 74.4 Gy
62629902|NCT03099577|EXPERIMENTAL|radiochemotherapy 4|Patients will be treated with radiation therapy 79.2 Gy
62629903|NCT03099577|EXPERIMENTAL|radiochemotherapy 5|Patients will be treated with radiation therapy 84 Gy
62629904|NCT03099577|EXPERIMENTAL|radiochemotherapy 6|Patients will be treated with radiation therapy 88.8 Gy
62629905|NCT03099577|EXPERIMENTAL|radiochemotherapy 7|Patients will be treated with radiation therapy 93.6 Gy
62629906|NCT02749227|EXPERIMENTAL|Pasireotide LAR Therapy|Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed.
62629907|NCT03176641|ACTIVE_COMPARATOR|PRP group|30 patients will receive autologous platelet-rich plasma gel during meniscus repair surgery.
62629908|NCT03176641|PLACEBO_COMPARATOR|Control group|30 patients will receive meniscus repair surgery only.
62629909|NCT06473116|EXPERIMENTAL|Intervention group|Isoprenaline
62629910|NCT06473116|ACTIVE_COMPARATOR|Control group|Epinephrine (adrenaline)
62629911|NCT06611449|ACTIVE_COMPARATOR|The minimal flow group|As soon as mechanical ventilation begins, sevoflurane at a concentration of 3% and a fresh gas flow of 4 L/min with 40-45% oxygen will be used to maintain ventilation until the MAC value reaches 0.9-1.0 For patients in Group 1:the minimal flow group (n=16), maintenance anesthesia will be provided with 80-100% O2 and 3.5-4.5% sevoflurane at a fresh gas flow rate of 0.3-0.5 L/min(minimal fresh gas flow anesthesia) Near the end of the operation, the maintenance anesthetics will be discontinued, and the fresh gas flow will be increased to 6 L/min
62629912|NCT06611449|ACTIVE_COMPARATOR|The high flow group|As soon as mechanical ventilation begins, sevoflurane at a concentration of 3% and a fresh gas flow of 4 L/min with 40-45% oxygen will be used to maintain ventilation until the MAC value reaches 0.9-1.0 For patients in Group 2: the high flow group (n=16), maintenance anesthesia will be provided with a 40-45% oxygen-air mixture, 2-2,5% sevoflurane, and a fresh gas flow rate of 4 L/min (high fresh gas flow anesthesia) Near the end of the operation, the maintenance anesthetics will be discontinued, and the fresh gas flow will be increased to 6 L/min
62629913|NCT01743846||Major Surgery|Patients undergoing major surgery
62629914|NCT03295734|ACTIVE_COMPARATOR|Perindopril|4 mg qd titrated to 8 mg qd perindopril + aerobic exercise
62629915|NCT03295734|ACTIVE_COMPARATOR|Losartan|50 mg qd titrated to 100 mg qd losartan + aerobic exercise
62629916|NCT03295734|ACTIVE_COMPARATOR|HCTZ|12.5 mg qd titrated to 25 mg qd HCTZ + aerobic exercise
62629917|NCT01572714|ACTIVE_COMPARATOR|Social Support Program|The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.
62629918|NCT01572714|ACTIVE_COMPARATOR|Physical Activity Program|The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.
62269284|NCT01978288||Cohort 2 Newborns with asthmatic mothers|Infants born to mothers who have a diagnosis of Asthma with enrollment from June 2, 2016 going forward.
62269285|NCT01978288||Cohort 3 Newborns with healthy parents|Infants born to healthy parents without atopy (asthma, eczema, seasonal allergies) from June 2, 2016 going forward.
62269286|NCT06247943|EXPERIMENTAL|Lung Protective Ventilation Strategy Group|Use of lung-protective ventilation strategies
62269287|NCT06247943|OTHER|Control Group|Use of general ventilation strategies
62451812|NCT05152719|ACTIVE_COMPARATOR|Time Restricted Eating (TRE) Protocol|Participants will be asked to limit their food intake to the hours between 12pm to 8pm, and fast outside of these hours. During the fast, participants may consume zero calorie beverages with no caffeine or artificial sweetener. Participants are instructed to maintain their diet, with no restrictions on the type or amount of food consumed in the feeding window.
62451813|NCT05152719|ACTIVE_COMPARATOR|Combined Sprint Interval Training (SIT) and Time Restricted Eating (TRE) Protocol|Participants will be asked to abide by the same eating regimen as the Time Restricted Eating Protocol Arm. Additionally, participants in this arm will perform the SIT protocol, in the fasted state. The SIT protocol will be identical to that listed in the Sprint Interval Training Protocol Arm.
62451814|NCT02920411|EXPERIMENTAL|Combined dermatological treatment|"A combined treatment of two emollient products will be applied:~* Pediatopic treatment cream during acute stages of atopic dermatitis and~* Pediatopic body lotion during stable stages"
62451815|NCT02353130||Memantine-XR|Boys ages 8-12 with ASD treated with Memantine-XR daily for 8 weeks
62451816|NCT00927147|EXPERIMENTAL|BNCT plus cetuximab|Patients treated with BNCT followed by cetuximab administration
62451817|NCT02401542|ACTIVE_COMPARATOR|Vofatamab plus docetaxel|"IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of vofatamab, 25 mg/kg, on day one of each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.~Dosing with vofatamab and docetaxel will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor."
62451818|NCT02401542|PLACEBO_COMPARATOR|Placebo plus docetaxel|"IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of placebo on day one of each 21-day cycle.~One additional IV infusion of placebo given on Day 8 of Cycle 1. Dosing of docetaxel and placebo will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor"
62629919|NCT01572714|ACTIVE_COMPARATOR|Physical Activity Plus Fatigue|The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
62629920|NCT06611995||People with atrial persistent fibrillation but without ischemic stroke|
62629921|NCT06611995||People with atrial persistent fibrillation and ischemic stroke|
62629922|NCT04506931|EXPERIMENTAL|Short Message Service (SMS) survey|Participants will receive an SMS survey
62269288|NCT01806779|EXPERIMENTAL|Chantix|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
62629923|NCT04506931|EXPERIMENTAL|Interactive Voice Response (IVR) survey|Participants will receive an IVR survey
62629924|NCT04506931|EXPERIMENTAL|Computer Assisted Telephone Interviews (CATI) survey|Participants will receive a CATI survey
62629925|NCT04553614|ACTIVE_COMPARATOR|Exercise Referral Scheme|The active Sefton (AS_ERS) is a traditional exercise referral programme providing highly discounted access to council operated leisure centres and a number of partner gyms. Within this access patients will have access to gym and swimming facilities (£2 per visit) and exercises classes (£3 per visit). During the patients first meeting with their LDO a progressive personalised exercise programme will be developed. Following this the patient will attend their local gym or leisure centre for an induction with a staff member(£7 one off fee), enabling them to attend the centre at any time and complete the designed exercise programme. All exercise programmes will be different, but in general will include moderate intensity exercise on gym equipment (treadmill, ergometer etc.) and some basic resistance training. Patients may replace these gym sessions with exercises classes run by the facility. Patients will be encouraged to exercise 3-5 time per week.
62629926|NCT04553614|EXPERIMENTAL|Home-based HIIT|Participants will be instructed to complete each training session in a place of their choosing. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest. During the intervals participants will be advised to reach a heart rate of approx. 90% of their predicted maximum heart rate (220-age). The 1 minute interval will be split between 2 consecutive 30 second exercises. The research team have a library of 18 exercises, with 9 suggested exercise pairs. The participant will be advised to complete 4 intervals during weeks 1 and 2, with the number of intervals increasing by 1 every 2 weeks (maximum of 9 intervals). The participant will be advised to train 3x per week.
62269289|NCT01806779|EXPERIMENTAL|Chantix + Zyban|For the first 3 days after being switched from NRT (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus Zyban at a dose of 150mg once per day. Subsequently, the dose of Chantix will be 1 mg twice per day and the dose of Zyban will be 150 mg twice per day for the remainder of the 12-week active treatment duration.
62269290|NCT02505880|ACTIVE_COMPARATOR|1: General anesthesia|General anesthesia
62629927|NCT03557918|EXPERIMENTAL|Tremelimumab|Tremelimumab 750 mg IV Day 1 of each 28 day cycle. Up to 7 cycles.
62629928|NCT01526564|ACTIVE_COMPARATOR|ALC|ALC
62629929|NCT01526564|PLACEBO_COMPARATOR|Placebo|
62629930|NCT02030964|EXPERIMENTAL|DFMO, Celecoxib, Cyclophosphamide & Topotecan|Reconstituted DFMO powder by mouth for 14 days and celecoxib capsule by mouth daily in each cycle. Cyclophosphamide and Topotecan IV on days 8-12 in cycle 1 and days 1-5 of cycles 2-17. Patients may continue for up to 17 cycles as long as therapy is tolerated (no DLT) and disease progression does not occur (SD or better). \*Cycle 1 will include a 7 day lead-in with DFMO and celecoxib to deplete tumor polyamines.
62269291|NCT02505880|EXPERIMENTAL|2: Hypnosis|Hypnosis with local anesthesia
62269292|NCT04774835|ACTIVE_COMPARATOR|Standard aPS|Subjects receive standard assisted partner services from their local HIV testing services (HTS) counselor.
62269293|NCT04774835|EXPERIMENTAL|aPS + HIVST|Subjects receive standard assisted partner services from their local HIV testing services (HTS) counselor as well as the option to do HIV self-testing (HIVST) instead of testing at the local HTS location.
62269294|NCT02931721||MRI Positive|Men with sperm found in MD-TESE
62269295|NCT02931721||MRI Negative|Men with no sperm found in MD-TESE
62629931|NCT03677739|EXPERIMENTAL|Arm 1 Young melanoma Family Facebook focusing on skin cancer|Participants join a secret Young melanoma Family Facebook Group and view post messages focusing on skin cancer for 12 weeks.
62629932|NCT03677739|EXPERIMENTAL|Arm 2 Healthy Lifestyle Facebook focusing on healthy lifestyle|Participants join a secret Healthy Lifestyle Facebook Group and view post messages focusing on healthy lifestyle for 12 weeks.
62629933|NCT02763319|EXPERIMENTAL|Tafasitamab and bendamustine|Tafasitamab and bendamustine
62629934|NCT02763319|ACTIVE_COMPARATOR|Rituximab and bendamustine|Rituximab and bendamustine
62629935|NCT06185738|OTHER|WCM app|WCM app evaluation at baseline, upon completion of WCM program and 4 weeks after completion of WCM program, by completing PROMIS and Self Efficacy for managing disease scale questionnaires
62629936|NCT01341899|EXPERIMENTAL|stem cell transplantation|
62629937|NCT06392152|EXPERIMENTAL|TPT Group|Based on the WHO malaria treatment guidelines, a standard PQ regimen of 0.25 mg PQ base/kg body weight daily for 14 days was administered to eligible individuals through directly observed treatment (DOT) to ensure drug intake and monitor potential adverse effects during August-September 2019. The safety of each participant was monitored by follow-up blood testing using Hemocue's hemoglobin photometers to track changes in hemoglobin levels.
62629938|NCT06392152|NO_INTERVENTION|Non-TPT|To mitigate potential season effects, we included a crossover design to switch the two groups after nine months, when Group 2 (non-TPT) received focal PQ MDA in June-July 2020, while Group 1 served as control during this period.
62629939|NCT00872521|EXPERIMENTAL|bortezomib; doxorubicin; dexamethasone|PAD induction Open Label Treatment: Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1 4 8 \& 11) Doxorubicin 20 mg/m2 i.v. (D1 \& 4) Dexamethasone 20 mg p.o. (D1 2 4 5 8 9 11 \& 12)
62629940|NCT02260206|EXPERIMENTAL|Colchicine|Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
62629941|NCT02260206|NO_INTERVENTION|No intervention|No intervention
62629942|NCT03726801|EXPERIMENTAL|Stratum C|"N 32 C~Women who are going to be mastectomized, conservate surgery and ostomy who attend the health education together with their immediate family member prior to surgery"
62629943|NCT03726801|PLACEBO_COMPARATOR|Stratum E|"N 32 E~Patients who are going to be subjected to a mastectomized, conservate surgery and ostomy who come alone to the health education prior to surgery"
62269296|NCT02931721||Control group|No intervention, fertile
62269297|NCT01076855||Elderly with mild dementia|\>70 years old and presence of a carer
62269298|NCT01143753|EXPERIMENTAL|RO5212054: Continuous Dosing Cohort|Participants will receive RO5212054 in escalating dose levels.
62269299|NCT01143753|EXPERIMENTAL|RO5212054: New Formulation (F05) Bridging Cohort|Participants will receive RO5212054 as a single dose of new formulation (F05-150 mg film-coated tablet with different ratios of ingredients than F03 to increase bioavailability) and a single dose of current clinical Formulation (F03-150 mg film-coated tablet) in a cross-over manner. Participants will be alternately assigned to receive either F05 or F03 as their first dose, followed by the opposite Formulation as their second dose. Dose of RO5212054 will be decided based on the results of continuous dosing cohort.
62269300|NCT02198781||Cohort|Basic science study
62269301|NCT04938128|EXPERIMENTAL|CPAP treatment|This group will receive CPAP treatment
62451819|NCT02401542|EXPERIMENTAL|Vofatamab|"IV infusion vofatamab, 25 mg/kg on day one each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.~Dosing of vofatamab will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination."
62269302|NCT04938128|NO_INTERVENTION|Control|This group will receive Diet and Lifestyle advice only
62451820|NCT02029937|EXPERIMENTAL|Proflavine, high resolution imaging|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
62451821|NCT02029937|NO_INTERVENTION|Standard of care|No invention
62451822|NCT01683175|EXPERIMENTAL|Arm 1|Erlotinib 150mg daily oral up to 2 years
62451823|NCT01683175|ACTIVE_COMPARATOR|Arm 2|NP Chemotherapy for 4 cycles
62451824|NCT02120053|EXPERIMENTAL|Bone substitute material group|Immediate denture placement following extractions and alveolar sockets filling with bone substitute material
62451825|NCT02120053|ACTIVE_COMPARATOR|Conventional protocol|Immediate denture placement following the conventional protocol
62451826|NCT02161965|EXPERIMENTAL|Rivaroxaban|"Rivaroxaban (oral tablet) for patients with atrial fibrillation:~20 mg once daily for patients with GFR \> 49 ml per minute and 15 mg rivaroxaban once daily for patients with GFR of 15 to 49 ml.~Rivaroxaban (oral tablet) for patients with pulmonary embolism: 2 x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing"
62451827|NCT02161965|ACTIVE_COMPARATOR|vitamin K antagonists|Adjusted dose of warfarin or fluindione (oral tablet) titrated according to target international normalized ratio with a target range 2.0 to 3.0.
62451828|NCT04308577|EXPERIMENTAL|Ketogenic diet with MCT|Ketogenic Diet supplemented with MCT everyday for 6 weeks.
62451829|NCT00750659|EXPERIMENTAL|1|Nilotinib treatment
62451830|NCT05984056|EXPERIMENTAL|Intervention|Multidisciplinary lifestyle interventions will be provided weekly for 12 weeks after enrollment.
62451831|NCT05984056|NO_INTERVENTION|Control|No intervention. Periodic check-ups will be performed during the first 12 weeks, followed by monthly check-ins like the intervention arm.
62451832|NCT03990675|EXPERIMENTAL|FNA, FNB|
62451833|NCT01085344|EXPERIMENTAL|Factor VIII|escalating dose Factor VIII
62629944|NCT06312397|ACTIVE_COMPARATOR|Acupressure group|"After coronary angiography, acupressure will be applied for a total of 15 minutes. For the acupressure group, a total of three points will be applied: the heart meridian 7th point (HT7), the large intestine meridian 4th point (LI4), and the stomach meridian 36th point (ST36), which is deemed appropriate in the lower extremity.~The symmetry of the three selected different points will also be applied to the other extremity."
62269303|NCT02342002|EXPERIMENTAL|Mifepristone-misoprostol regimen|After a woman is determined eligible and signs the informed consent document, she will receive 200 mg mifepristone and advised to swallow the pill when they arrive at home. 24 hours after administration of the mifepristone, women will administer the four tablets of 200 mcg misoprostol sublingually.
62269304|NCT02342002|PLACEBO_COMPARATOR|Misoprostol alone regimen|After a woman is determined eligible and signs the informed consent document, she will receive a placebo (of same shape and size of mifepristone) and advised to swallow the pill when they arrive at home. 24 hours after administration of the mifepristone, women will administer the four tablets of 200 mcg misoprostol sublingually.
62269305|NCT03565627|EXPERIMENTAL|Exercise app|7 Minute Workout Challenge by Fitness Guide Inc.
62629945|NCT06312397|PLACEBO_COMPARATOR|Sham acupressure|In the acupressure application applied to the sham group, parallel pressure will be applied to the bone area and points where the HT7, LI4, ST36 meridians do not pass.
62269306|NCT03565627|EXPERIMENTAL|Running App|One You Couch to 5K by Public Health England
62269307|NCT02949180||AF|Five minutes puls wave recording will be performed in patients in atrial fibrillation at time of recruitment
62629946|NCT06312397|NO_INTERVENTION|Control group|With the control group, no intervention was conducted, and only standard care was given.
62629947|NCT04298580|ACTIVE_COMPARATOR|PVB before surgery|
62629948|NCT04298580|ACTIVE_COMPARATOR|PVB after surgery|
62629949|NCT01890759|EXPERIMENTAL|Meningococcal Diphtheria Toxoid Vaccine|Participants at age 9 to 17 months of enrollment will receive 2 doses on Menactra vaccine at 3 to 6 months apart
62629950|NCT01462110|EXPERIMENTAL|0.15% ethyl lauroyl arginate HCl-containing mouthrinse|Brush teeth as usual, followed immediately by rinsing with 20 mL of assigned 0.15% ethyl lauroyl arginate HCl-containing mouthrinse (19415-154-1) for 30 seconds - repeat twice daily for four weeks.
62629951|NCT01462110|SHAM_COMPARATOR|5% hydroalcohol mouthrinse|Brush teeth as usual, followed immediately by rinsing with 20 mL of assigned 5% hydroalcohol mouthrinse (W002194-0221P) for 30 seconds - repeat twice daily for four weeks.
62629952|NCT02804048|EXPERIMENTAL|Pelvic Floor Muscle Training|"superficial heat pelvic floor muscle intra vaginal manual therapy. PERFECT scale is applied in 5 sessions and based on the result of each assessment is performed the treatment plan with exercises of the pelvic floor muscles.~It is performed manual therapy in iliopsoas, diaphragm and piriformis. From the fourth session, initiate treatment with electromyographic biofeedback based on the result of PERFECT scale."
62629953|NCT02804048|PLACEBO_COMPARATOR|Low back|superficial heat low back Manual therapy in piriform, lumbar, iliopsoas and diaphragm.
62629954|NCT00436826|EXPERIMENTAL|Cladribine 3.5 mg/kg, IFN-beta (DB period)|Participants received cladribine tablets orally as cumulative dose of 0.875 mg/kg over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 milligram per kilogram (mg/kg) along with interferon (IFN)-beta therapy (Rebif® new formulation \[RNF\] 44 mcg three times a week, subcutaneously; Avonex® 30 microgram (mcg) every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during the Double blind period (DBP) of 96 weeks.
62629955|NCT00436826|PLACEBO_COMPARATOR|Placebo, IFN-beta (DB period)|Participants received matching placebo tablets orally over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during the DB period of 96 weeks.
62269308|NCT02949180||SR|Five minutes puls wave recording will be performed in patients in sinus rhythm at time of recruitment
62269309|NCT02008682|EXPERIMENTAL|Liraglutide 1.8 mg + metformin|2-week screening period, 26-week treatment duration, and a 1-week follow-up period
62269310|NCT02008682|ACTIVE_COMPARATOR|Sitagliptin 100 mg + metformin|2-week screening period, 26-week treatment duration, and a 1-week follow-up period
62269311|NCT00708578|ACTIVE_COMPARATOR|1|Administration of 4 mg of Glimepiride with Insulin Glargine
62064089|NCT03288896|NO_INTERVENTION|Control Group|Control Group: The Control Group just completes the baseline and the evaluation questionnaires and then they are allowed to receive the intervention as well (as a waiting list control condition). Evaluation takes place after four months from baseline
62269312|NCT00708578|ACTIVE_COMPARATOR|2|Administration of 1500 mg of Metformin with Insulin Glargine
62269313|NCT00708578|EXPERIMENTAL|3|Administration of a combination of 4mg Glimepiride plus 1000mg Metformin with Insulin Glargine
62064090|NCT05884229|NO_INTERVENTION|Standard opioid administration|
62064091|NCT05884229|EXPERIMENTAL|SPI-guided opioid administration|
62064092|NCT06133842||Enrolled Participants|"Patients above the age of 60 undergoing major non-cardiac surgery requiring invasive MAP monitoring as standard of care. They will be monitored intra-op using non-invasive EEG and CO monitors, which will be correlated with MAP.~They will also undergo baseline and followup assessment for post-operative delirium using the standardised CAM and MoCA tools administered by study staff."
62064093|NCT01372605|EXPERIMENTAL|Collaborative depression care|Measurement-Based Care: Decision support from paraprofessional to HIV medical provider around initiating and monitoring antidepressant treatment.
62064094|NCT01372605|OTHER|Enhanced usual care|Usual care. Enhanced through pre-study training of providers, provision of psychiatric diagnostic information at enrollment to HIV provider, and availability of best-practices guidelines for reference in clinic.
62064095|NCT02087501|OTHER|HORIZON AAA Stent Graft|All patients will received the HORIZON AAA Stent Graft
62064096|NCT00084643|EXPERIMENTAL|Treatment (GTI-2040, capecitabine, oxaliplatin)|Patients receive GTI-2040 IV continuously on days 1-14, oral capecitabine twice daily on days 2-15, and oxaliplatin IV over 2 hours on day 2 of the first course. In all subsequent courses, capecitabine is administered on days 1-14, oxaliplatin is administered on day 1, and GTI-2040 is administered as in course 1. Courses repeat every 21 days in the absence of disease progression and unacceptable toxicity.
62064097|NCT05982704|EXPERIMENTAL|tixagevimab/cilgavimab (Group 1)|tixagevimab/cilgavimab at a dose of 150+150 mg
62064098|NCT05982704|EXPERIMENTAL|tixagevimab/cilgavimab (Group 2)|tixagevimab/cilgavimab at a dose of 300+300 mg
62269314|NCT01029132|EXPERIMENTAL|non-responder group|patients who did not maintained or improved cognitive function
62269315|NCT01029132|EXPERIMENTAL|responder group|patients who maintained or improved cognitive function
62269316|NCT02751502|EXPERIMENTAL|Bimanual-to-unimanual device home training program|
62064099|NCT05982704|ACTIVE_COMPARATOR|regdanvimab group|regdanvimab at a dose of 40 mg/kg body weight
62064100|NCT03202095|EXPERIMENTAL|Open Label Treatment with Creatine|5 grams daily of oral creatine monohydrate powde
62064101|NCT01361373|ACTIVE_COMPARATOR|DOPAMINE|Sinemet up to 10 mg/kg/day
62269317|NCT02751502|NO_INTERVENTION|Conventional non-device home training program|Subjects receive 6 weeks of ongoing usual and customary care schedule of home physical and occupational therapy as usual and customary care independent of the study.
62269318|NCT02305862|EXPERIMENTAL|low dose group (5mg)|low dose Rosuvastatin
62269319|NCT02305862|EXPERIMENTAL|high dose group (20mg)|high dose Rosuvastatin
62269320|NCT04532060|EXPERIMENTAL|Antimicrobial Photodynamic Therapy|Patients treated with Antimicrobial Photodynamic Therapy
62064102|NCT01361373|PLACEBO_COMPARATOR|Placebo|placebo
62064103|NCT04313569|NO_INTERVENTION|Conservative treatment|Use of medications, like analgesic, muscle relaxants, non-steroidal anti-inflammatory drugs (NSAID) and local painkillers, depending on the patient condition, and physiotherapy, lifestyle and daily activity modification, patient education about positioning of the knee
62064104|NCT04313569|OTHER|Arthroscopic menisctomy|
62269321|NCT04532060|EXPERIMENTAL|Nystatin|Patients treated with Nystatin antifungal drug.
62629956|NCT00436826|EXPERIMENTAL|Cladribine 3.5 mg/kg, IFN-beta, Cladribine 3.5 mg/kg (OL Ext)|Participants who received cladribine 3.5 mg/kg initially and completed DB period entered in the open label (OL) extension (Ext.) period. In OL Ext. period, participant who met the eligibility criteria received OL oral cladribine 3.5 mg/kg over maximum of 48 weeks along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
62629957|NCT00436826|PLACEBO_COMPARATOR|Placebo, IFN-beta, Cladribine 3.5 mg/kg (OL Ext)|Participants who received placebo initially and completed DB period entered in the OL Ext. period. In OL Ext. period, participant who met the eligibility criteria received OL oral cladribine 3.5 mg/kg over maximum of 48 weeks along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
62629958|NCT00436826|EXPERIMENTAL|Cladribine 3.5 mg/kg, IFN-beta (Safety follow up)|Participants who received cladribine 3.5 mg/kg initially and completed DB period entered in the OL ext. safety follow up period. In this period, participants who did not meet eligibility criteria received only IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
62629959|NCT00436826|PLACEBO_COMPARATOR|Placebo, IFN-beta (Safety follow up)|Participants who received placebo initially and completed DB period entered in the OL ext. safety follow up period. In this period, participants who did not meet eligibility criteria received only IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
62629960|NCT00428480|EXPERIMENTAL|1|Daily reinforcement of walking speed
62629961|NCT00428480|ACTIVE_COMPARATOR|2|No reinforcement of walking speed
62629962|NCT01115777||Pediatric patients treated with radiotherapy|
62629963|NCT01775423|EXPERIMENTAL|BBI608|
62629964|NCT05358548|EXPERIMENTAL|Squamous Lung Cancer|"A Cycles consist of either:~* Paclitaxel Based: Carboplatin/Paclitaxel/Pembrolizumab OR~* nab-Paclitaxel Based: Carboplatin/nab Paclitaxel/Pembrolizumab These A Cycles will be given for up to four cycles (standard)~B Cycles consist of Pembrolizumab alone"
62629965|NCT05358548|EXPERIMENTAL|Non-Squamous Lung Cancer|"* A Cycles consist of Carboplatin/Pemetrexed/Pembrolizumab (up to four cycles standard)~* B Cycles consist of Pembrolizumab alone~Maintenance Cycles (Cycle 5 and beyond): Pemetrexed in combination with Pembrolizumab; Alternatively, Pembrolizumab alone, for up to 2 years since enrollment (standard)"
62269322|NCT03166293|EXPERIMENTAL|Immediate Group|Children will participate in intensive leg training with a physical therapist 1 hour/day, 4 days/week for 12 weeks. Children will continue to receive standard physical therapy care. Children will be followed for one year from the time of enrollment in the study.
62269323|NCT03166293|EXPERIMENTAL|Delay Group|Children will be monitored for 3 months with no intervention. Children will participate in intensive leg training with a physical therapist after the 3 month delay period. Training will be 1 hour/day, 4 days/week for 12 weeks. They will continue to receive standard care throughout. Children will be followed for one year from the time of enrollment in the study.
62269324|NCT06548061|EXPERIMENTAL|Spinal Laser Interstitial Thermal Therapy (sLITT)|Patients will undergo surgery utilizing the Visualase Thermal Therapy System (Medtronic) device.
62629966|NCT05358548|EXPERIMENTAL|Head and Neck Squamous Cell Carcinoma|"* A Cycles consist of Carboplatin/5-Fluorouracil/Pembrolizumab (up to six cycles standard)~* B Cycles consist of Pembrolizumab alone~Maintenance Cycles (Cycle 7 and beyond): Pembrolizumab alone, for up to two years since enrollment (standard)"
62269325|NCT03325673|EXPERIMENTAL|TrueTear|TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on contact lens (CL) wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.
62269326|NCT03325673|SHAM_COMPARATOR|TrueTear Sham Control|TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.
62629967|NCT06101186|NO_INTERVENTION|control group|Participants in the control group received standard nursing care provided by the institution where the research was conducted. After the study, we shared the materials developed for NPECP with the participants in the control group.
62269327|NCT03963635||Lyme Infected|Subjects presenting with suspected Lyme Disease
62269328|NCT03963635||Controls|Subjects with no known Lyme Disease, past or present
62269329|NCT05046509||COVID_Patients|"* Patients have been confirmed diagnosed with Covid-19 disease by PCR~* Patients aged 18 years and above"
62629968|NCT06101186|EXPERIMENTAL|Experimental group|Nursing education and counseling practice to be applied to the experimental group was based on NSM. In the implementation of NPECP, the women were first met, and after the meeting, their informed consent was taken and they were included in the study. It was stated that the women in the experimental group were told that four scheduled interviews would be conducted online in a period of approximately 4 weeks. The women were given a telephone number where they could contact the researcher so that they could receive telephone/online counseling and were included in the whatsapp group with their permission.
62064105|NCT05787158|EXPERIMENTAL|Group A|Group A: 20 patients were included in this group. This studygroup was assigned with basic treatment protocol with 15 minutes of TENS and thermal therapy for 10 minutes followed by muscle energy technique (Post facilitation stretching exercises). The intervention was given three days per weekfor six weeks. Each total session lasted for 45minutes. METs were applied for the weakened muscles.
62269330|NCT05572762|EXPERIMENTAL|Atraumatic Peribulbar Technique|a cannula is used to apply ophthalmic block
62451834|NCT06262711|EXPERIMENTAL|Vitamin C, then Placebo|Participants will first consume one 500mg vitamin C capsule daily for 6 weeks. After a 4-week washout period, participants will crossover and consume one placebo capsule daily for 6 weeks.
62629969|NCT03591601|ACTIVE_COMPARATOR|Manual therapy protocol|Treatment based on manual therapy with proven evidence.
62629970|NCT03591601|EXPERIMENTAL|Foam Rolling protocol|Treatment based on massage with a Foam Rolling
62269331|NCT05572762|ACTIVE_COMPARATOR|Conventional peribulbar block|a 24 or 25 gauge needle is used to provide regional o anesthesia to the study group
62269332|NCT03311711|EXPERIMENTAL|SPIRIT-in person|Patients and surrogates who participate in the SPIRIT intervention in person.
62269333|NCT03311711|EXPERIMENTAL|SPIRIT-remote|Patients and surrogates who participate in the SPIRIT intervention remotely, via teleconference.
62269334|NCT03311711|ACTIVE_COMPARATOR|Usual care|Patients and surrogates who receive the standard information about advance directives that is provided at the time of diagnosis.
62269335|NCT03428178|EXPERIMENTAL|rAAV2-ND4|A Single IVT of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4)（0.05ml).The dose is 1 × 10\^10 vg/0.05 mL for test groups.
62269336|NCT04888273|EXPERIMENTAL|All adolescents and parents who meet the eligibility criteria|The adolescents and parents will be invited to participate in a 5-component intervention that will hopefully empower and prepare the pair for the transition to adult care.
62269337|NCT04408690|EXPERIMENTAL|Rehabilitation and optional delayed ACL reconstruction|
62629971|NCT03591601|PLACEBO_COMPARATOR|Placebo Control|Placebo treatment based on the placement of the hands on the head without intention to treat.
62629972|NCT00963976|EXPERIMENTAL|Target systolic BP < 150 mmHg|Systolic blood pressure will be reduced to \<150 mmHg within 1 hour of randomization.
62629973|NCT00963976|ACTIVE_COMPARATOR|Target systolic BP < 180 mmHg|Systolic blood pressure will be reduced, to \<180 mmHg within 1 hour of randomization.
62629974|NCT04423133|EXPERIMENTAL|Online Family Literacy Program|The Ready and Healthy for Kindergarten program is a bilingual family literacy program that uses anticipatory guidance on health routines (e.g., physical activity) to introduce language and literacy skills to children and their families delivered via an online video conference format.
62629975|NCT06489314|EXPERIMENTAL|LEAD Intervention|LEAD consists of behavioral activation (BA) and motivational interviewing (MI), as well as discussions of masculinity and a family focus throughout to target father's depression symptoms and common comorbidities, like drinking. LEAD is guided by a manual (in Swahili and English). It includes five, 60-90-minute weekly sessions. LEAD was adapted for context based on formative work. Each session begins with MH assessment and review of activity completion and ends with homework to monitor activities. LEAD uses MI strategies to engage men in the treatment and increase commitment to addressing problems. MI strategies are then integrated throughout. (Session 1-5) to enhance father motivation to complete activities as well as to build self-efficacy (e.g., when reviewing homework, peer-father counselors reflect successes).
62629976|NCT06489314|NO_INTERVENTION|Waitlist Control|Those randomized to WL will complete assessments and be monitored at each timepoint; they will be offered LEAD following the last assessment. In a pilot, a control allows for a realistic examination of recruitment, randomization, implementation of LEAD, assessment procedures, and retention. If safety concerns arise, referrals and safety procedures will be implemented.
62629977|NCT01818973|EXPERIMENTAL|Single Arm|"Neoadjuvant chemotherapy with XELOX: Xeloda, po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning; Oxaliplatin, iv, 130mg/m2, day 1; and Bevacizumab, iv, 7.5 mg/kg, day 1, during the first cycle (each cycle has 3 weeks).~Followed by chemoradiotherapy, 50 Gy/25 fractions during 5 weeks plus 2 cycles XELOX and Bevacizumab: Xeloda, po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning; Oxaliplatin, iv, 100mg/m2, day 1; and Bevacizumab, iv, 7.5 mg/kg, day 1.~6-7 weeks from the last radiation therapy, Total Mesorectal Excision (TME) surgery will be performed.~3-4 weeks after operation, 3 cycles XELOX (the same as the neoadjuvant chemotherapy) and 2 cycles Xeloda (po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning) will be administered."
62629978|NCT01712139|ACTIVE_COMPARATOR|Avalide|irbesartan 300 mg and hydrochlorothiazide 25 mg tablet
62629979|NCT01712139|EXPERIMENTAL|Irbesartan and Hydrochlolothiazide|300 mg irbesartan and 25 mg hydrochlorothiazide tablet
62451835|NCT06262711|EXPERIMENTAL|Placebo, then Vitamin C|Participants will first consume one placebo capsule daily for 6 weeks. After a 4-week washout period, participants will crossover and consume one 500mg vitamin C capsule daily for 6 weeks.
62629980|NCT01222312|ACTIVE_COMPARATOR|Arm A cisplatin|Cisplatin 75 mg/m2, d1 Docetaxel 75 mg/m2, d1 every 3 weeks (d22) max. 6 cycles
62629981|NCT01222312|EXPERIMENTAL|Arm B oxaliplatin|Oxaliplatin 85 mg/m², d1 Docetaxel 50mg/m2, d1 every 2 weeks (d15) max. 8 cycles
62269338|NCT04408690|ACTIVE_COMPARATOR|Immediate ACL reconstruction + rehabilitation|
62451836|NCT03235778|EXPERIMENTAL|group1|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:11.78mg Volume:0.50ml Frequency:Once Duration:30min A total of 10 subjects, 2 subjects served as pre-test groups, given to the test drug；the remaining 8 subjects,6 received the test drug and 2 received the placebo.
62451837|NCT03235778|EXPERIMENTAL|group2|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:23.56mg Volume:1.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
62629982|NCT01308034|EXPERIMENTAL|association sunitinib radiotherapy|
62629983|NCT03269903|EXPERIMENTAL|Patients|Patients with malignant dysphagia treated with the HILZO stent
62629984|NCT02793219|EXPERIMENTAL|Sipuleucel-T then Docetaxel|Sipuleucel-T IV over 1-hour every 14 days for 3 doses; 28 day rest; 75 mg/m2 docetaxel IV over 1-hour every 21 days for 6 cycles
62629985|NCT04921800|EXPERIMENTAL|Wearable Sensor Applied|For these participants, the wearable ADAM sensor will be placed in the sternal notch to record anatomical data during the post-surgical period for up to 14 days
62629986|NCT05503459|EXPERIMENTAL|Bicycle learning|The protocol for this intervention group was a 2-week bicycle training program consisting of 10 sessions (five sessions per week, 60 mins per session) in a hall/gymnasium of each participating school and the Education University of Hong Kong. Each intervention session was conducted by a professional cycling instructor assisted by student helpers. The staff-to-participant ratio was 1:1.
62629987|NCT05503459|EXPERIMENTAL|Stationary cycling group|Participants were asked to ride on a stationary bicycle in the same format as that in the learning to bicycle group.
62629988|NCT05503459|NO_INTERVENTION|Active control group|Participants were asked to walk with their major caregivers for 20 minutes every day during the study period. After the study, they were taught how to ride a bicycle to recognize their contribution as controls.
62064106|NCT05787158|ACTIVE_COMPARATOR|Group B|Group B: 20 Patients of this group were given core stability exercises by the female physical therapist in three different levels. Each level continued for a duration of two weeks in which the patients were trained for the exercises. The patients were provided sessions thrice per week with 2 sets of 10 repetitions and a hold of 10 second after TENS for 15 minutes and thermal therapy for 10 minutes.
62064107|NCT04140500|EXPERIMENTAL|Part A: Single-Agent Dose Escalation|Participants will receive RO7247669 every 2 weeks (Q2W) or every 3 weeks (Q3W) up to the maximum tolerated dose (MTD) until disease progression, unacceptable drug toxicity, or withdrawal of consent, for up to 24 months.
62064108|NCT04140500|EXPERIMENTAL|Part B: Tumor Specific Expansion Cohorts|Participants with selected solid tumor indications will receive RO7247669 at a dose derived from Part A until disease progression, unacceptable drug toxicity, or withdrawal of consent, for up to 24 months.
62064109|NCT05528718||Experimental group|Participants assigned to this intervention arm in the main study will have been administered nitrous oxide at an inspiratory concentration of 50% with concurrent intravenous saline (100mL) for one hour.
62064110|NCT05528718||Placebo group|Participants assigned to this intervention arm in the main study will have been administered 50% oxygen with intravenous midazolam (0.02mg/kg in 100mL) for one hour.
62269339|NCT04268485||IPF patients|Patients with an MDT diagnosis of idiopathic pulmonary fibrosis. Patients will be observed over a 12 month period and have serial serum samples taken for KL-6 level.
62451838|NCT03235778|EXPERIMENTAL|group3|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:47.13mg Volume:2.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
62064111|NCT01486056||healthy patients, may have epilepsy|Subjects at least 12 years old and in general good health for Phase I, and at least 18 years old and in general good health for Phase II. It is desired, but not required, for subjects to have epilepsy and taking at least 1 antiepileptic medication.
62064112|NCT00094211||Low Walkability/Low Income|Participants reside in a low walkability, low income neighborhood
62451839|NCT03235778|EXPERIMENTAL|group4|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:94.25mg Volume:4.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
62451840|NCT03235778|EXPERIMENTAL|group5|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:164.92mg Volume:7.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
62269340|NCT04319107||Marfan Syndrome (MFS) patients|Patients who had a clinical diagnosis of MFS according to the revised Ghent criteria (ectopia lentis was not taken into account for the diagnosis), confirmed by FBN1 sequencing.
62269341|NCT04319107||Control patients|Relatives of MFS patients with none of the clinical features of MFS and in whom testing for the familial FBN1 mutation was negative.
62269342|NCT02481921|EXPERIMENTAL|MEDIC-HF|Group clinic or shared medical appointment of Education \& Intervention in Heart Failure
62269343|NCT02481921|NO_INTERVENTION|Usual Care|Usual care in heart failure
62269344|NCT04799392|EXPERIMENTAL|Persons tested with investigational device following PCR test|Persons tested with investigational device who previously tested positive or negative for COVID-19 with an emergency use authorized or FDA cleared COVID-19 test
62269345|NCT04799392|EXPERIMENTAL|Persons tested with investigational device following vaccination|Persons tested with investigational device who previously were vaccinated for COVID-19 with an emergency use authorized or FDA cleared COVID-19 vaccine
62269346|NCT02562560|EXPERIMENTAL|TGA|
62269347|NCT02562560|EXPERIMENTAL|Controls|
62269348|NCT06368713|EXPERIMENTAL|Exercise intervention group|The exercise intervention group will receive guidance for exercises and participate in remote exercise sessions monitored.
62269349|NCT06368713|NO_INTERVENTION|Control group|The control group will not receive exercise intervention.
62269350|NCT03899779|ACTIVE_COMPARATOR|Face-to-face hypnotherapy|12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)
62269351|NCT03899779|EXPERIMENTAL|Online hypnotherapy|12 weeks treatment with online hypnotherapy
62269352|NCT03899779|ACTIVE_COMPARATOR|Online psychoeducation|12 weeks treatment with online psychoeducation
62269353|NCT04675866|EXPERIMENTAL|camrelizumab+albumin-bound paclitaxel+S-1|camrelizumab+albumin-bound paclitaxel+S-1
62629989|NCT06047756|EXPERIMENTAL|Hippotherapy|Patients suffering with diplegic therapy will perform their exercise protocols on a stationary horse.The child is seat astride the horse wearing a helmet and was encouraged to perform various activities designed to emphasize movement in a forward and upward reaching direction to encourage active postural control, trunk strength, balance and trunk/pelvic dissociation.30 minutes to 1 hour with a frequency ranging from 4 sessions per week and the total duration of horseback riding 6 weeks.
62064113|NCT00094211||Low Walkability/High Income|Participants reside in a low walkability, high income neighborhood
62064114|NCT00094211||High Walkability/Low Income|Participants reside in a high walkability, low income neighborhood
62629990|NCT06047756|ACTIVE_COMPARATOR|Swiss Ball therapy|Children of second group will receive swiss ball therapy. Position the child to sit on the ball and giving extension rotation and flexion rotation to the child. This will facilitate trunk rotation by which the upper body is towards the weight bearing hip and away from the weight bearing hip.Training program 4 times per weeks with the treatment session of 30 minutes for 6 weeks duration
62629991|NCT03713671|OTHER|PHPT Group|Spatio-Temporal gait analysis and balance assessment of subjects with Primary Hyperparathyroidism
62629992|NCT03713671|OTHER|Control Group|Spatio-Temporal gait analysis and balance assessment of healthy subjects
62629993|NCT02541864|EXPERIMENTAL|Bismuth quadruple therapy|pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
62629994|NCT02541864|ACTIVE_COMPARATOR|Hybrid therapy|(pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
62629995|NCT05953402||Ozanimod-exposed participants with UC|Pregnant women with a diagnosis of UC who are exposed to ozanimod at any time during pregnancy
62629996|NCT05953402||Conventional therapy-exposed participants with UC|Pregnant women with a diagnosis of UC who are exposed to conventional therapies (aminosalicylates and/or thiopurines) but not exposed to ozanimod, other S1P therapies, or advanced therapies for UC (biologics and/or small molecules) at any time during pregnancy
62629997|NCT05953402||Advanced therapy-exposed participants with UC|Pregnant women with a diagnosis of UC who are exposed to advanced therapies for UC (biologics and/or small molecules) but not exposed to ozanimod or other S1P therapies at any time during pregnancy
62629998|NCT05837091|EXPERIMENTAL|Low Soduim Oxybate for Idiopathic Hypersomnia|Subjects prescribed with low sodium oxybate for idopathic hypersomnia will have a 24-hour polysomnography, wear an Axivity wristband and Nextsense EEG earbuds to evaluate total sleep time.
62629999|NCT02094638||Tanreqing|Inpatient using the Tanreqing Injection
62630000|NCT02824835||adenoma group|Patients with adenoma. Biopsies are taken before endoscopic resection.
62630001|NCT02824835||cancer group|Patients with colorectal cancer. Biopsies are taken before surgical resection.
62064115|NCT00094211||High Walkability/High Income|Participants reside in a high walkability, high income neighborhood
62630002|NCT02374424|EXPERIMENTAL|GA101_DHAP|"Patients receive: GA101-DHAP x 2, restaging, mobilization and collection of peripheral blood stem cells, + GA101-DHAP x 2, restaging with PET and CT and consolidation with BEAM and ASCT in patients in response (CR+PR).~During the treatment period of four cycles, all patients will receive a total of four 28-day courses of chemotherapy."
62630003|NCT06548854|EXPERIMENTAL|High dose group|The experimental drug was administered intravenously for 5 days
62630004|NCT06548854|EXPERIMENTAL|low dose group|The experimental drug was administered intravenously for 5 days
62630005|NCT06548854|PLACEBO_COMPARATOR|Placebo|Placebo infusion continued for 5 days
62630006|NCT02346877|NO_INTERVENTION|Standard of Care Cohort|The first 100 participants will be enrolled in the standard of care (control) cohort. These participants will receive treatment with Enbrel® (etanercept) in routine clinical practice and will complete a 52 week study period as per the investigator's standard of care.
62630007|NCT02346877|OTHER|Personalized Patient Counselling Cohort|Initiation of the personalized patient counselling cohort will begin after 75% of participants in the control cohort have been analyzed and shown not to have high persistence. Participants will receive Enbrel® (etanercept) therapy in routine clinical practice and personalized patient counselling based on the Information-Motivation-Strategy (IMS) model based on Beliefs about Medicines Questionnaire (BMQ) baseline results through a patient assistance program for patients on Enbrel (etanercept) therapy.
62630008|NCT00536770|PLACEBO_COMPARATOR|A|Placebo + gemcitabine
62630009|NCT00536770|PLACEBO_COMPARATOR|B|Placebo + gemcitabine + erlotinib
62630010|NCT00536770|ACTIVE_COMPARATOR|C|DN-101 + gemcitabine
62630011|NCT00536770|ACTIVE_COMPARATOR|D|DN-101 + gemcitabine + erlotinib
62451841|NCT03235778|EXPERIMENTAL|group6|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:259.16mg Volume:11.00ml Frequency:Once A total of 8 subjects,6 received the test drug and 2 received the placebo. Duration:30min
62269354|NCT03011346|ACTIVE_COMPARATOR|Symetis ACURATE neo/TF transfemoral TAVI system|Symetis ACURATE neo/TF transfemoral TAVI system: self-expandable transcatheter aortic bioprosthesis, support frame made of nitinol, supra-annular processed trileaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland)
62451842|NCT03235778|EXPERIMENTAL|group7|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:377.00mg Volume:16.00ml Frequency:Once A total of 8 subjects,6 received the test drug and 2 received the placebo. Duration:30min
62451843|NCT05870553|EXPERIMENTAL|CTP0301-A|Subjects who are randomized into this group will take CTP0301-A from the evening before colonoscopy to the morning of colonoscopy.
62451844|NCT05870553|EXPERIMENTAL|CTP0301-B|Subjects who are randomized into this group will take CTP0301-B before the morning of colonoscopy.
62451845|NCT05870553|ACTIVE_COMPARATOR|Cool prep|Subjects who are randomized into this group will take Cool prep from the evening before colonoscopy to the morning of colonoscopy.
62451846|NCT05111821|EXPERIMENTAL|Deferiprone|Patients receiving Deferiprone during 6 months. Oral deferiprone for 6 months at a dose of 30 mg/kg/d
62451847|NCT05111821|ACTIVE_COMPARATOR|Treatment As usual|Patients followed during 6 months according to standard care
62451848|NCT01191320|PLACEBO_COMPARATOR|Placebo|Placebo
62451849|NCT01191320|EXPERIMENTAL|Androxal 12.5 mg|12.5 mg/day
62451850|NCT01191320|EXPERIMENTAL|Androxal 25 mg|25 mg/day
62451851|NCT05635149||Fruquintinib and anti-PD-1 plus radiotherapy|"Fruquintinib is administrated as 4mg orally, once daily for 2 weeks on/1 week off.~anti-PD-1 antibody is administrated as 200mg once every 3 weeks. Patients with isolated or localized metastasis will receive radiotherapy."
62451852|NCT05635149||Fruquintinib and anti-PD-1 alone|"Fruquintinib is administrated as 4mg orally, once daily for 2 weeks on/1 week off.~anti-PD-1 antibody is administrated as 200mg once every 3 weeks."
62451853|NCT05596708|EXPERIMENTAL|Telitacicept treated group|
62451854|NCT02639949|EXPERIMENTAL|Group CBT|
62451855|NCT02639949|ACTIVE_COMPARATOR|Standard Care|
62451856|NCT01829009|NO_INTERVENTION|General Recommendations Group|General information about sarcopenia will be provided to the participants, as well as general recommendations of healthy habits. We will contact the participants weekly by phone to answer questions about sarcopenia, and remind them of their next appointment and about adverse events occured during this period of time. The frequent contact with the participants has also the purpose to prevent losses or rejections for future evaluations
62451857|NCT01829009|EXPERIMENTAL|Resistance Exercise Group|"An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.~Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24"
62451858|NCT05914103|EXPERIMENTAL|Intervention|
62451859|NCT05914103|NO_INTERVENTION|Control|
62451860|NCT01550588|PLACEBO_COMPARATOR|Medication|Anticoagulation, Antiplatelet agent
62451861|NCT01550588|ACTIVE_COMPARATOR|Device closure|Amplatzer PFO occluder device
62451862|NCT04117165|EXPERIMENTAL|SinnoTest® software|SinnoTest® is a therapeutic guidance device for patients suffering from chronic inflammatory rheumatism, in particular, rheumatoid arthritis. Prescription of bDMARD or their biosimilars is possible.
62451863|NCT04117165|ACTIVE_COMPARATOR|Patient Current care|Current care of patients with rheumatoid arthritis, based on the recommendations of the French Society of Rheumatology. Prescription of bDMARD or their biosimilars is possible.
62451864|NCT02492399|OTHER|myectomy by Morrow|"Procedure: myectomy by Morrow.~Will be included in a group of 30 patients with obstructive hypertrophic cardiomyopathy and mitral insufficiency. In the case of conservation SAM syndrome and mediated mitral insufficiency, the result will be read as unsatisfactory. Patients will perform advanced myoectomy. All patients who need to be supplemented by the operation extension myoectomy subsequently run out in the second group. When it is impossible to eliminate mediated mitral regurgitation without mitral valve replacement, patients performed myoectomy and mitral valve replacement. The result in this case is read as completely unsatisfactory. Upon reaching 15% replacement mitral valve study terminated.~Evaluation results will be made myoectomy as TEE and direct tensiometer."
62451865|NCT02492399|OTHER|extended myectomy|"Procedure: extended myectomy.~Will be included in a group of 30 patients with obstructive hypertrophic cardiomyopathy and mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy which supplemented resection and release of the papillary muscles. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. The result in this case will become engrossed in reading as completely unsatisfactory. At achievement of 15% prosthetics of the mitralny valve research stops.~Evaluation results will be made myoectomy as TEE and direct tensiometer ."
62451866|NCT05867160||Adult patients with focal-onset seizures starting a treatment with ASM as adjunctive therapy|"Adult patients having focal-onset seizures not adequately controlled despite a history of treatment with at least 2 ASM.~The patients should be eligible to start a treatment with ASM as adjunctive therapy.The patients will be prospectively observed up to 12 months after having completed the related titration."
62451867|NCT05091788|EXPERIMENTAL|Treatment Arm|All subjects will receive two coring treatments on the cheeks with the robotic coring device.
62451868|NCT02585466||BIS25|BIS 25 levels were subsequently maintained via propofol TCI 0.2 microg mL-1 TCI adjustments. Stable BIS values that showed no further decline and remained within BIS ±5 ofBIS 25 of the previous BIS value were considered an indicator of pseudo-steady state plasma effect-site equilibration
62630012|NCT03512353|EXPERIMENTAL|Carfilzomib Plus Dexamethasone|"Participants received carfilzomib administered as an intravenous (IV) infusion twice-weekly for up to six 28-day cycles followed by once-weekly for another six 28-day cycles. The carfilzomib dose was 20 mg/m² on days 1 and 2 of cycle 1, 56 mg/m² for the remaining days of cycle 1 (days 8, 9, 15, and 16) and then on days 1, 2, 8, 9, 15, and 16 of each cycle for cycles 2 to 6, and 70 mg/m² on days 1, 8, and 15 of each cycle for cycles 7 to 12.~Participants also received dexamethasone either orally or by IV infusion at a dose of 20 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1 to 6 and at a dose 40 mg once daily on days 1, 8, 15 of cycles 7 to 12."
62630013|NCT00822146|EXPERIMENTAL|1|
62451869|NCT02585466||BIS50|BIS 50 levels were subsequently maintained via propofol TCI 0.2 microg mL-1 TCI adjustments. Stable BIS values that showed no further decline and remained within BIS ±5 of either BIS 50 levels of the previous BIS value were considered an indicator of pseudo-steady state plasma effect-site equilibration
62451870|NCT00858910|EXPERIMENTAL|EG1: embedded MI|"Experimental group 1:~Participants receive motor imagery (MI) training included in 45min physiotherapy, 3 times per week for 2 weeks."
62451871|NCT00858910|EXPERIMENTAL|EG2: added MI|"Experimental group 2:~Participants receive a 15 minutes motor imagery (MI) training added to a 30 min physiotherapy session, 3 times a week for two weeks."
62451872|NCT00858910|PLACEBO_COMPARATOR|CG|"Control group:~Participants receive a 15 min control intervention added to their 30 min physiotherapy session, 3 times a week for two weeks."
62451873|NCT04740385||Lung cancer patients|Correct position of double lumen endotracheal tube will be assessed using lung sonography, routine chest auscultation and fiberoptic brochoscopy
62451874|NCT01255475|EXPERIMENTAL|Intervention|
62451875|NCT01255475|PLACEBO_COMPARATOR|Control|
62451876|NCT03896100||Element 2|Four clinical samples will be taken from each eligible subject and used to assess two clinical removal methods and two in vitro removal methods.
62451877|NCT03896100||Element 3|Four clinical samples will be taken from each eligible subject and used to assess three different storage methods.
62451878|NCT03896100||Element 4|Four clinical samples will be taken from each eligible subject and used to assess different ocular regions.
62451879|NCT00950157|EXPERIMENTAL|"Directive open question statement"|"Survey describes the surrogate outcome of the drug along with a directive warning (i.e., stating the issue and why it matters) for drugs shown to improve surrogate outcomes.~This directive warning mentions that it is not known whether the drug will help patients feel better, and that readers should ask their doctor if there is an available drug shown to improve patient outcomes."
62451880|NCT00950157|EXPERIMENTAL|Non-directive open question statement|"Survey describes the surrogate outcome of the drug along with a non-directive warning (i.e., stating the issue only) for drugs shown to improve surrogate outcomes.~This non-directive warning mentions only that it is not known whether the drug will help patients feel better."
62451881|NCT00950157|EXPERIMENTAL|No open question statement|Survey only describes the surrogate outcome of the drug.
62451882|NCT00821210|SHAM_COMPARATOR|2|
62451883|NCT00821210|ACTIVE_COMPARATOR|1|
62451884|NCT02877056||Colorectal Cancer|Participants undergo standard endoscopy before therapy. Tissue samples taken from the tumor and normal colorectal tissue.
62451885|NCT02774798||Rectal Intussusception and Prolapse|"AAR measurements will be taken from patients with suspected intra-rectal intussusception or rectal prolapse. Subgroup analysis will be performed after grading of rectal prolapse according to the Oxford Grading system. The subgroups will be:~1. Oxford Grades 1 \& 2 - intra-rectal intussusception~2. Oxford Grades 3 \& 4 - intra-anal intussusception~3. Oxford grade 5 - Overt Rectal Prolapse"
62451886|NCT01180595|OTHER|Modular|Trabecular Metal Modular Tibial Total Knee Component
62451887|NCT01180595|OTHER|Monoblock|Trabecular Metal Monoblock Tibial Total Knee Component
62451888|NCT03863678|EXPERIMENTAL|Neurodevelopmental therapy|Group 1 will only receive Neurodevelopmental therapy (NDT), for 12 sessions.
62451889|NCT03863678|EXPERIMENTAL|Neurodevelopemental therapy and dry needling therapy|Group 2 will receive Neurodevelopmental therapy (NDT) and dry needling therapy, for 12 sessions.
62451890|NCT05722067|EXPERIMENTAL|oocytes treated with calcium ionophore|Oocytes treated with a ready-to-use ionophore compound (GM508 CultActive, Gynemed) within 15 min after ICSI (or 18 min in IVF). After 15 min of incubation in GM508 CultActive and a thorough washing process, the oocytes subjected to AOA will transfer to the same time-lapse culture dish with the controlled sibling group.
62451891|NCT05722067|NO_INTERVENTION|oocytes undergo routine IVF/ICSI protocol|Untreated control oocytes will immediately place into the time-lapse imaging system, and the culture protocol was routine.
62451892|NCT01687686||All cohort|Initially healthy patients in General Practise Research Database (GPRD) meeting the inclusion criteria at any point between 1st January 2001 and 25th March 2010
62451893|NCT00988923|EXPERIMENTAL|group a: Hyperthermia (HT)|HT were treated for 20 minutes per session, a total of 8 sessions with device;
62451894|NCT00988923|NO_INTERVENTION|group b: No intervention|device was switched in off, only bolus was active
62451895|NCT02521207|EXPERIMENTAL|Part 1 OXP001|OXP001 formulation containing 800mg ibuprofen single dose
62630014|NCT02858635|EXPERIMENTAL|Suicide attempters|Clinical and neuropsychological assessment. Blood and saliva samples in order to answer objectives study.
62451896|NCT02521207|ACTIVE_COMPARATOR|Part 1 Ibuprofen control|Ibuprofen control 800mg single dose
62451897|NCT02521207|EXPERIMENTAL|Part 2 OXP001|OXP001 formulation containing 800mg ibuprofen three times per day
62451898|NCT02521207|EXPERIMENTAL|Part 2 Ibuprofen control|Ibuprofen control 800mg three times per day
62451899|NCT03594123|EXPERIMENTAL|Prior Brexpiprazole|Participants who received brexpiprazole in a previous double-blind phase 3 study (Trial 331-14-213 {NCT03548584}), received the same dose of brexpiprazole \[2 or 3 milligrams (mg)\], once daily (QD), orally, as they received during the previous study, for up to 12 weeks with dose adjustment.
62630015|NCT03560869|EXPERIMENTAL|Normal hydration then dehydration|Participants will consume water to maintain proper hydration for three days prior to testing (visit 1). Seven to 60 days later, participants will reduce water intake over three days and abstain from any water for the final 16 hours prior to testing (visit 2).
62630016|NCT03560869|EXPERIMENTAL|Dehydration than normal hydration|Participants will reduce water intake over three days and abstain from any water for the final 16 hours prior to testing (visit 1). Seven to 60 days later, participants will consume water to maintain proper hydration for three days prior to testing (visit 2).
62630017|NCT06344559|ACTIVE_COMPARATOR|Continuous theta burst stimulation|In a cross-over design, all participants will, in one session, receive continuous theta burst stimulation, to the right frontal eye field. Session order will be counter-balanced across participants, and stimulation protocol will be blinded to participants and the Investigator until after data collection is complete.
62630018|NCT06344559|ACTIVE_COMPARATOR|Intermittent theta burst stimulation|In a cross-over design, all participants will, in one session, receive intermittent theta burst stimulation, to the right frontal eye field. Session order will be counter-balanced across participants, and stimulation protocol will be blinded to participants and the Investigator until after data collection is complete.
62630019|NCT06344559|SHAM_COMPARATOR|Sham theta burst stimulation|In a cross-over design, all participants will, in one session, receive sham theta burst stimulation, to the right frontal eye field. Session order will be counter-balanced across participants, and stimulation protocol will be blinded to participants and the Investigator until after data collection is complete.
62630020|NCT03726073|EXPERIMENTAL|Intervention group|Electrical stimulation will be given 30min before anesthesia and during surgery, auricular acupressure will be given in postoperative 3 days
62630021|NCT03726073|SHAM_COMPARATOR|Non-intervention group|Usual care
62630022|NCT01449292|EXPERIMENTAL|Treatment plus Optimal Medical Therapy|Patients will be treated with the AeriSeal System and Optimal Medical Therapy
62630023|NCT01449292|ACTIVE_COMPARATOR|Optimal Medical Therapy|Patients will be treated according to Optimal Medical Therapy
62630024|NCT05311020|PLACEBO_COMPARATOR|Placebo drink|
62630025|NCT05311020|EXPERIMENTAL|Pitaya Ovule Extract Drink|
62630026|NCT02204644|EXPERIMENTAL|Flumatinib mesylate tablets|Flumatinib mesylate tablets 600mg qd for 12 months
62630027|NCT02204644|ACTIVE_COMPARATOR|Imatinib mesylate tablets|Imatinib mesylate tablets 400mg qd for 12months
62630028|NCT00005032|EXPERIMENTAL|Arm A|G3139 (3 mg/kg/day continuous IV infusion over 7 days every 21 days), Paclitaxel (150 mg/m2, 3 hr IV infusion on Day 6 of every 21 day cycle)
62630029|NCT03390595|EXPERIMENTAL|Avelumab plus gemcitabine/carboplatin|2 cycles of induction avelumab 10mg/kg every 2 weeks followed by 6 cycles of carboplatin/gemcitabine plus avelumab (carboplatin 5AUC day +1, gemcitabine 1000mg/m2 day +1 and +8 and avelumab 10mg/kg day +15) every 3 weeks followed by avelumab monotherapy 10mg/kg every 2 weeks until progressive disease or intolerance.
62630030|NCT03390595|ACTIVE_COMPARATOR|Gemcitabine/carboplatin alone|patients will receive 6 cycles of carboplatin/gemcitabine (carboplatin 5AUC day +1, gemcitabine 1000mg/m2 day +1 and +8) every 3 weeks.
62630031|NCT03630705|EXPERIMENTAL|Group 1: MenACYW Conjugate Vaccine (Mexico)|Participants aged 2 months (at the time of enrollment) received Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus toxoid (MenACYW) Conjugate vaccine at the age of Months 2, 6, and 12 along with Prevnar 13®, Hexacima®, vaccines at the age of Months 2, 4, 6 and 12; RotaTeq® vaccine at the age of Months 2, 4 and 6 and measles, mumps, rubella (MMR®II) vaccine at the age of Month 12.
62630032|NCT03630705|ACTIVE_COMPARATOR|Group 2: Menveo® (Mexico)|Participants aged 2 months (at the time of enrollment) received Menveo® vaccine at the age of Months 2, 4, 6, and 12 along with Prevnar 13®, Hexacima® vaccines at the age of Months 2, 4, 6 and 12; RotaTeq® vaccine at the age of Months 2, 4 and 6, and MMR®II vaccine at the age of Month 12.
62630033|NCT03630705|EXPERIMENTAL|Group 3: MenACYW Conjugate Vaccine (Russian Federation)|Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 3, 6, and 12 along with Prevnar 13® vaccine at the age of Months 2, and 4.5; Pentaxim® vaccine at the age of Months 3, 4.5, and 6; ENGERIX-B® vaccine at the age of Month 6 and MMR vaccine at the age of Month 12.
62630034|NCT03630705|OTHER|Group 4: Routine Pediatric Vaccines (Russian Federation)|Participants aged 2 months (at the time of enrollment) received Prevnar 13® vaccine at the age of Months 2, and 4.5; Pentaxim® vaccine at the age of Months 3, 4.5, and 6; ENGERIX-B® vaccine at the age of Month 6 and MMR vaccine at the age of Month 12.
62064116|NCT03968315|EXPERIMENTAL|Diagnostic (MRI, diaphragm fluoroscopy)|Patients undergo an MRI scan over 45-60 minutes and a diaphragm fluoroscopy 30 days before surgery.
62630035|NCT06608017|EXPERIMENTAL|Yupingfeng Powder with variation|Granules form, 2 times per day for 8 weeks
62630036|NCT06608017|PLACEBO_COMPARATOR|Placebo|Granules form, 2 times per day for 8 weeks
62630037|NCT05035745|EXPERIMENTAL|Patients with refractory solid tumors|Phase I will be carried out in a modified 3+3 dose escalation design, with a projected enrolment of patients with refractory solid tumors to determine the RP2D.
62630038|NCT06249607|EXPERIMENTAL|Group A: combined sleep hygiene and storytelling|
62064117|NCT05897801||Patients with a respiratory tract infection|Patients entering the emergency department of the sites, presenting with symptoms compatible with the diagnosis of respiratory tract infection.
62064118|NCT02646215|ACTIVE_COMPARATOR|Inspiratory muscle training group|Threshold inspiratory muscle training
62064119|NCT02646215|NO_INTERVENTION|Control group|No training
62064120|NCT04461795|EXPERIMENTAL|AJOVY (fremanezumab-vfrm)|Participants received 225 mg/1.5 mL solution via single-dose prefilled syringe administered subcutaneously once every 4 weeks in the abdomen, thigh, or upper arm for 12 weeks.
62630039|NCT06249607|EXPERIMENTAL|Group B: combined sleep hygiene and mindfulness breathing exercise group|
62630040|NCT06249607|OTHER|Group C: sleep hygiene group|
62630041|NCT04142671|EXPERIMENTAL|Individualised Gait Modification Intervention|"Patients will carry out several walking trials to test the efficacy of an individualised gait modification intervention.~Pre-intervention over ground walking, pre-intervention treadmill walking, intervention treadmill walking with real-time biofeedback on their knee loading, intervention treadmill walking with no feedback, and post-intervention over ground walking."
62630042|NCT03230435||Anorexia nervosa|Treatment settings as usual.
62630043|NCT03230435||Healthy controls|No interventions.
62630044|NCT03803163|EXPERIMENTAL|TransCon Treprostinil|
62630045|NCT06611930|PLACEBO_COMPARATOR|Placebo|
62630046|NCT06611930|EXPERIMENTAL|CK-0045 Dose level 1|
62630047|NCT06611930|EXPERIMENTAL|CK-0045 Dose level 2|
62630048|NCT02248168||Idiopathic Parkinson's disease patients|
62630049|NCT06574568|EXPERIMENTAL|YKST02|Participants will receive different doses of YKST02 in 21-day cycles via intravenous injection.
62630050|NCT01408212|EXPERIMENTAL|Acupuncture therapy|
62630051|NCT06490081|EXPERIMENTAL|Trilaciclib combined with concurrent chemoradiotherapy|Trilaciclib is used simultaneously before the first cycle of chemotherapy during radiotherapy for limited-stage small cell lung cancer
62630052|NCT03955159|EXPERIMENTAL|Experimental: Probiotic supplementation|The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.
62630053|NCT03955159|PLACEBO_COMPARATOR|Placebo comparator|The placebo that will be used in the present study is maltodextrin, which is a food supplement based on carbohydrate powder.
62630054|NCT06245421|EXPERIMENTAL|Investigational product|
62630055|NCT06245421|ACTIVE_COMPARATOR|Comparator|
62630056|NCT04549636||healthy COVID-19+|Individuals who recently recovered from COVID-19 and who have no history of lung disease
62630057|NCT04549636||asthmatic COVID-19+|Individuals who recently recovered from COVID-19 and who have asthma
62630058|NCT04549636||healthy COVID-19-|Individuals who have not been diagnosed with COVID-19 and who have no history of lung disease
62630059|NCT04549636||asthmatic COVID-19-|Individuals who have not been diagnosed with COVID-19 and who have asthma
62630060|NCT01406314|EXPERIMENTAL|Intervention|Intravenous infusion for approximately 48 hours followed by subcutaneous injection
62630061|NCT06612996|EXPERIMENTAL|Tramadol group|Intravenous Tramadol
62630062|NCT06612996|EXPERIMENTAL|Magnesium sulphate group|Intravenous Magnesium Sulphate
62630063|NCT06612996|PLACEBO_COMPARATOR|Control group|Saline
62630064|NCT04584840|NO_INTERVENTION|Group 1 (non-surgical treatment)|"* Soft diet.~* Suspension of the use of prostheses or intraoral devices.~* Oral hygiene guidelines.~* Topical antiseptics: in the form of mouthrinses with 0.12% chlorhexidine after every meal and clorhexidine gel over the exposed bone or fistula.~* Systemic antibiotics: for patients in stage 2 in which active acute infection is detected with Amoxicillin/Clavulanic Acid 875/125 mg every 8 hours for 2 weeks. Those allergic to penicillin will receive clindamycin 300 mg every 8 hours for 2 weeks or Levofloxacin 500 mg / day for 2 weeks. Systemic antibiotic treatment can be prolonged indefinitely until infection and symptoms are controlled."
62630065|NCT04584840|EXPERIMENTAL|Group 2 (surgical treatment)|"Same guidelines of conservative treatment plus surgical treatment according to the following protocol:~Specific protocol for surgical treatment:~* Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm.~* Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules.~* Secure a two layered waterproof closure without tension (simple or with local flaps).~* Samples will be sent for Pathological and microbiological analysis.~* Stitches removal after two weeks~* Postoperative systemic antibiotic following the mentioned protocol until stitches removal."
62630066|NCT00918593|EXPERIMENTAL|Electrochemotherapy|
62630067|NCT00918593|ACTIVE_COMPARATOR|radiotherapy|
62451900|NCT03594123|EXPERIMENTAL|Prior Placebo|Participants who received placebo in a previous double-blind phase 3 study (Trial 331-14-213 {NCT03548584}), received brexpiprazole following a titration schedule, to gradually increase their dose from 0.5 mg QD, in the starting to 2 or 3 mg QD, orally, for up to 12 weeks with dose adjustment.
62451901|NCT05034731|OTHER|Electric Only|
62451902|NCT05034731|OTHER|Aidable Residual Hearing|
62451903|NCT06217172|OTHER|Intervention Group|RHEUPP App follow-up
62451904|NCT06217172|OTHER|Control Group|Usual follow-up
62451905|NCT03679377|EXPERIMENTAL|Mandibular slotplate|Mandibular slotplates are placed during BSSO surgery and their clinical usefullness is tested. Afterwards the plates are removed and the osteotomy is fixated by three bicortical screws.
62451906|NCT01034319|EXPERIMENTAL|Diabetes Genetic Counseling|Subjects will have been genotyped and will received genetic counseling based on their results
62451907|NCT01034319|PLACEBO_COMPARATOR|No Genotyping or Counseling|Patients will not be genotyped and will therefore not receive genetic counseling
62451908|NCT04898062|ACTIVE_COMPARATOR|CRP-apheresis|Patients randomized to this group will undergo apheresis treatments with treatments every 24 ± 12 h each lasting 4-7 hours, until the CRP value does not rise to ≥ 30 mg/l within 96 h after the last treatment
62451909|NCT04898062|NO_INTERVENTION|Control|Patients randomized to this group will not undergo a apheresis treatments. They will be treated according to the current conventional treatment concept for covid-19 disease
62630068|NCT04042987||Historical Control Group|Retrospective chart review
62630069|NCT04042987||Prospective QIP Group|Participants that meet eligibility criteria will be prospectively enrolled into QIP including malnutrition screening, nutrition consultation, expedited provision of oral nutritional supplementation (ONS) and encouragement of ONS consumption.
62630070|NCT00402727|EXPERIMENTAL|Moxifloxacin|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
62630071|NCT00402727|ACTIVE_COMPARATOR|PIP/TAZ-AMC|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
62630072|NCT00929344|EXPERIMENTAL|Duloxetine|
62630073|NCT00929344|EXPERIMENTAL|Pregabalin|
62630074|NCT00929344|PLACEBO_COMPARATOR|Placebo|
62630075|NCT05543928|PLACEBO_COMPARATOR|Cohort 1 and Cohort 2 Placebo|
62630076|NCT05543928|EXPERIMENTAL|Cohort 1 and Cohort 2 CTAP101 Capsule|
62630077|NCT00726180|EXPERIMENTAL|Treatment arm|
62630078|NCT04324567||APR-open|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR) with laparotomy.
62630079|NCT04324567||APR-robot|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR) with laparoscopic robot assisted technique.
62630080|NCT00219427||1|
62630081|NCT04344652|EXPERIMENTAL|Photoscreening|Photoscreening of patients 0 to 10 years of age
62064121|NCT03285841||Cervical Sites|Imaging complete cervix from endocervical canal to transformation zone to ectocervix.
62064122|NCT03285841||Vulvar sites|Imaging vulvar lesions
62451910|NCT01029353|ACTIVE_COMPARATOR|Randomized Trial: Laparotomy|Under general anesthesia in the NICU or operating room, a laparotomy will be performed following standard procedures.
62451911|NCT01029353|ACTIVE_COMPARATOR|Randomized Trial: Peritoneal drain placement|Place a one-fourth inch Penrose drain in the lower abdomen with local anesthesia and sedation.
62451912|NCT01029353|ACTIVE_COMPARATOR|Preference Cohort: Laparotomy|Under general anesthesia in the NICU or operating room, a laparotomy will be performed following standard procedures.
62630082|NCT01361828||Patients with choroidal neovascularization|CNV due to Age-Related Macular Degenerations and Myopia were included.
62630083|NCT02895295|ACTIVE_COMPARATOR|Control|Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and will be provided with a list of resources available in the community to help them choose a prescription drug plan.
62630084|NCT02895295|EXPERIMENTAL|Expert Recommendation|"Participants randomized to the Expert Recommendation arm will receive access to a decision support tool that provides personalized expert scores for particular plans based on individual's likely annual out-of-pocket spending, including plan premiums and spending on prescription drugs, and the Medicare star ratings (a measure of customer satisfaction)."
62630085|NCT02895295|ACTIVE_COMPARATOR|Individual Analysis|"Participants randomized to Individual Analysis arm will receive access to a decision support tool that provides individualized cost information for each plan but not the expert scores for particular plans."
62630086|NCT03417752|EXPERIMENTAL|Exposure to firearm safety Public Service Announcement (PSA)|Exposure to the firearm safety PSA (approx. 2.5 minutes long) once per week for 3 weeks.
62630087|NCT03417752|EXPERIMENTAL|Exposure to a mix of PSAs|Exposure to a general health promotion video (approx. 2 minutes long) 1 week post-randomization followed by exposure to firearm safety PSA at 2- and 3-weeks post-randomization.
62630088|NCT03417752|ACTIVE_COMPARATOR|Active control|Exposure to the general health promotion video once per week for 3 weeks.
62451913|NCT01029353|ACTIVE_COMPARATOR|Preference Cohort: Peritoneal drain placement|Place a one-fourth inch Penrose drain in the lower abdomen with local anesthesia and sedation.
62451914|NCT05852847|EXPERIMENTAL|Low-dose baricitinib plus danazol|Oral baricitinib is given at a dose of 2 mg daily for 6 months. Danazol is given at a dose of 200 mg twice a day for 6 months. Treatment will be discontinued if very severe or life-threatening adverse events developed or at the patients' request.
62451915|NCT05852847|ACTIVE_COMPARATOR|Danazol|Danazol is given at a dose of 200 mg twice a day for 6 months. Treatment will be discontinued if very severe or life-threatening adverse events developed or at the patients' request.
62064123|NCT02676908|NO_INTERVENTION|4 weeks & EVLT|After endovenous laser therapy and avulsions, patients will wear compression socks for four weeks (usual care)
62064124|NCT02676908|NO_INTERVENTION|4 weeks & RFA|After radiofrequency ablation therapy and avulsions, patients will wear compression socks for four weeks (usual care)
62064125|NCT02676908|EXPERIMENTAL|2 weeks & EVLT|After endovenous laser therapy and avulsions, patients will wear compression socks for two weeks (trial group)
62064126|NCT02676908|EXPERIMENTAL|2 weeks & RFA|After radiofrequency ablation therapy and avulsions, patients will wear compression socks for two weeks (trial group)
62064127|NCT04084977||Sydenam Chorea (SC)|individuals with SC
62630089|NCT02992860|EXPERIMENTAL|Treatment Arm|JNJ-56022473 will be given intravenously to all subjects at a dose of 9 mg/kg once every 14 days for an initial treatment period of 3 months (6 infusions). Responders will then receive up to 20 additional infusions whereas for non-responders the initial treatment will be followed by a up to 9 months observation period without further JNJ-56022473 treatment. Thus, the individual study duration for a subject will be approx. 1 year. A follow up visit will be performed after 3 months after last study drug administration for all patients to track pregnancy status according to IB.
62630090|NCT06612723|EXPERIMENTAL|High frequency|Individuals will receive up to 18 visits of high-intensity gait training and activity coaching over 6 weeks
62630091|NCT06612723|ACTIVE_COMPARATOR|Low frequency|Individuals will receive up to 18 visits of high-intensity gait training and activity coaching over 12 weeks
62630092|NCT01290510|EXPERIMENTAL|hyaluronic acid sodium salt|
62630093|NCT03744936|EXPERIMENTAL|DA4Afib|Developing a tool to use during the encounter
62630094|NCT00511173|EXPERIMENTAL|Clinician dosing of warfarin|Warfarin dose based on clinician dosing without the use of warfarin pharmacogenetics
62630095|NCT02793947|EXPERIMENTAL|Peri-incisional injection|A 100 cc multimodal analgesic cocktail will be injected into the superficial and deep peri-incisional tissues after the completion of femur fracture fixation/instrumentation while the patient remains under general anesthesia and prior to wound closure. This cocktail includes 400 mg of 0.75% ropivacaine (53.33 mL), 0.6 mg of 1 mg/mL epinephrine (0.6 mL), 5 mg of 0.5 mg/mL morphine sulfate (10 mL), and 36.07 mL 0.9% sodium chloride solution. All infiltrations will be completed with a blunt trochar to minimize the risk of intravascular injection.
62630096|NCT02793947|NO_INTERVENTION|Control (no injection)|Femur fracture fixation/instrumentation will be completed per the standard of care. No peri-incisional injection will be completed.
62064128|NCT04084977||tonsilitis|children with tonsilitis in the past 3 months
62451916|NCT04114695||Non-CKD (eGFR >60 ml/min/1.73 m2)|Patients with renal function considered normal for age (eGFR \>60 ml/min/1.73 m2) without proteinuria or structural kidney disease.
62451917|NCT04114695||CKD stage 3a (eGFR 45-59 ml/min/1,73 m2)|Patients with CKD stage 3a (eGFR 45-59 ml/min/1,73 m2)
62451918|NCT04114695||CKD stage 3b (eGFR 30-44 ml/min/1,73 m2)|Patients with CKD stage 3b (eGFR 30-44 ml/min/1,73 m2)
62451919|NCT04114695||CKD stage 4 (eGFR 15-29 ml/min/1,73 m2)|Patients with CKD stage 4 (eGFR 15-29 ml/min/1,73 m2)
62451920|NCT04114695||CKD stage 5 (eGFR <15 ml/min/1,73 m2)|Patients with CKD stage 5 (eGFR \<15 ml/min/1,73 m2). 50% of these patients will be in dialysis, while the other 50% will be pre-dialysis patients.
62451921|NCT00678392|EXPERIMENTAL|Axitinib|
62451922|NCT00678392|ACTIVE_COMPARATOR|Sorafenib|
62451923|NCT01932034||Standard dosing|Vancomycin dosed and monitored according to standard practice
62451924|NCT01932034||BestDose Computer Software|Vancomycin dosed using BestDose computer software, targeting AUC rather than trough concentrations
62451925|NCT01932034||BestDose Computer Software 2|Vancomycin dosed using BestDose computer software, targeting AUC rather than trough concentrations and with computer-generated suggested optimal blood sampling times
62451926|NCT05959785|EXPERIMENTAL|intervention group|Assignment to the intervention group will be done by simple randomization of the sample. A random sequence of numbers will be generated using the statistical program SPSS v.28. Patients will be included in the intervention group of each subcategory if their subject number matches one of the random numbers generated.The intervention groups will receive an explanatory video where a study collaborator performs a series of abdominal or diaphragmatic breathing exercises, which are intended to assess their effectiveness in this clinical trial.
62064129|NCT04084977||control|children wit no tonsilitis
62088116|NCT04443920|ACTIVE_COMPARATOR|Tranexamic acid (TXA)|"All patients will receive 15 mg/kg Tranexamic acid (TXA) IV prior to skin incision. This arm will receive a second intravenous dose of 15 mg/kg of Tranexamic acid (TXA) before the release of the tourniquet. The medication is delivered from the pharmacy in a masked syringe labeled as study medication."
62269355|NCT03011346|ACTIVE_COMPARATOR|Edwards Sapien 3 Transcatheter Heart Valve|Edwards SAPIEN 3 Transcatheter Heart Valve system: balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)
62630097|NCT03093441|EXPERIMENTAL|Multimodal|Multimodal High-Intensity Interval Training Intervention. This group will train using multimodal exercises for 5 sets of 60 seconds of all out work, followed by 3 minutes of rest. Each session will have the same exercises within each set, but every session will be different than the others for movements utilized. There will be three movements used in each set. The first movement will be a strength movement for 4-6 repetitions. The second movement follows the first immediately and is a faster body weight or light implement power movement for 6-8 repetitions. The third movement follows the second immediately and is a very fast, sprint-like movement for the remainder of the 60 seconds. The intent of each set is to be completed with as much effort as possible across the full 60 seconds.
62451927|NCT05959785|PLACEBO_COMPARATOR|control groups|The patients belonging to the control groups of each subcategory will also receive an explanatory video with basic and light cervical mobilization exercises (Annex 12). This group of exercises will be made up of a series of cervical mobilization exercises that are performed without pain, smooth, controlled by the patients, and without forcing the angulations. They are performed seated, with the arms extended along the body and forearms and hands resting on the legs. The chair must be firm and comfortable. Head movements to the right and left, right and left lateral flexion of the cervical region, cervical flexion and extension will be performed. This exercise will be performed for 5 minutes 3 times a day and beginning in the first 24 postoperative hours.
62630098|NCT03093441|ACTIVE_COMPARATOR|Rowing|Multimodal High-Intensity Interval Training Intervention. This group will train using a rowing ergometer for 5 sets of 60 seconds of all out work, followed by 3 minutes of rest (a total of 20 minutes each session). Each training session will be the same across the 12 weeks. The intent of each set is to be completed with as much effort as possible across the full 60 seconds.
62630099|NCT03093441|NO_INTERVENTION|Control|Multimodal High-Intensity Interval Training Intervention. This group will be instructed to continue with any activity they were involved in prior to the study and to not begin any new exercise programs during the course of the study. To incentive participation in this group, the control group will be offered the MM-HIIT intervention the following semester at no cost.
62630100|NCT00536510|EXPERIMENTAL|1|laropiprant/niacin (MK0524A)
62630101|NCT00536510|PLACEBO_COMPARATOR|2|placebo
62630102|NCT01152996|EXPERIMENTAL|Vortioxetine|Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks.
62630103|NCT04423640||COVID Patients|Diagnosed patients with COVID-19 by PCR
62630104|NCT06050070|SHAM_COMPARATOR|Sham controlled feedback|Subjects will complete three visits with one or two fMRI sessions after initial assessment and training visit. The first session will be to introduce practice tasks using the mock scanner. In the second visit participants will have an fMRI. The study team will review the fMRI results to decide if participants will continue on the study (must exhibit a specific pattern of activation) and have the second fMRI at the third visit.
62630105|NCT06050070|EXPERIMENTAL|Real-time neurofeedback|Subjects will complete three visits with one or two fMRI sessions after initial assessment and training visit. The first session will be to introduce practice tasks using the mock scanner. In the second visit participants will have an fMRI. The study team will review the fMRI results to decide if participants will continue on the study (must exhibit a specific pattern of activation) and have the second fMRI at the third visit.
62630106|NCT05023538|NO_INTERVENTION|Usual care|No intervention
62269356|NCT03899766||Animal Assisted Intervention|children interact and play with the expert of Animal Assisted Intervention (AAI) and his/her trained dog in the waiting room and then, are accompanied by a parent (as standard care) and the AAI in the venipuncture room during and immediately after the procedure
62269357|NCT03899766||Clowns|children interact and play with hospital clowns in the waiting room and then, are accompanied by a parent (as standard care) and the clown in the venipuncture room during and immediately after the procedure
62269358|NCT03899766||Musicians|children interact and play with a musician in the waiting room and then, are accompanied by a parent (as standard care) and the musician in the venipuncture room during and immediately after the procedure
62269359|NCT03899766||Non-clinical Conversation|children are accompanied by a parent in the waiting room and then in the venipuncture room during the procedure, thus receiving standard care
62630107|NCT05023538|EXPERIMENTAL|Low-volume moderately-intense exercise|exercise at 50-65%VO2peak; 20-30min/training session, 3x/week, 6 months
62630108|NCT05023538|EXPERIMENTAL|High-volume moderately-intense exercise|exercise at 50-65%VO2peak; 20-50min/training session, 3x/week, 6 months
62064130|NCT02911350|EXPERIMENTAL|Hormone Suppressors, Paclitaxel & Radiation therapy|"Hormone Suppressors: Patients may take any of the following combinations for a period of 6 months:~1. Lupron / Flutamide~2. Zoladex/ Flutamide~3. Lupron/ Casodex~4. Zoladex/ Casodex~Paclitaxel: 30 mg/m2 twice a week administered as a one hour infusion either Monday \& Wednesday or Tuesday \& Thursday for eight consecutive weeks will be started within the first week of radiation therapy. Following the first 3 dose levels, the dose of Paclitaxel will be escalated to 35 mg/m2 (dose level IV), 40 mg/m2 (dose level V) \& 45 mg/m2 (dose level VI).~Radiation Therapy: 5 days a week for 8 weeks to a total dose of 66.6 to 73.8 Gray depending on when patient enter the study."
62451928|NCT05969197|EXPERIMENTAL|Group A - Match Play Training|15 participants will be in Match play training group giving the Match play exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
62451929|NCT05969197|EXPERIMENTAL|Group B - Plyometric Training|15 participants will be in Plyometric training group giving isotonic exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
62451930|NCT05069636|EXPERIMENTAL|Lymphatic OMM plus Moderna COVID-19 Vaccine regimen|Patients receive OMM treatments that will include thoracic inlet and outlet myofascial release, pectoral traction myofascial release, and Miller Thoracic Lymphatic Pump technique plus the Moderna COVID-19 Vaccine regimen.
62451931|NCT05069636|SHAM_COMPARATOR|Light Touch plus Moderna COVID-19 Vaccine regimen|Patients receive a series of light touch techniques plus the Moderna COVID-19 Vaccine regimen.
62451932|NCT02551445|EXPERIMENTAL|Gradual exposure to food stimuli|The intervention entails 2 sessions of psychoeducation and a clinical assessment including a discussion on learned food-related fears, role of food-related fears in the maintenance of anorexia nervosa, anxiety and its time course, avoidance, exposure and habituation, irrational fears and safety behaviors; and 8 sessions of in vivo exposure to foods, starting from the least scary food of a hierarchy of threatening foods created by each patient. Each session will involve exposure to a new food item and patients will be encouraged to confront their fear by looking at and touching the chosen food item. They will also be encouraged to eat the food and reflect on the consequences of eating and assessing those relative to their fears (e.g. checking whether they have lost control or changed shape after eating).
62064131|NCT05096468|EXPERIMENTAL|S-ketamine and pregabalin|
62630109|NCT05023538|EXPERIMENTAL|Low-volume high-intense exercise|exercise at 50-85%VO2peak; 20-30min/training session, 3x/week, 6 months
62630110|NCT06548503|EXPERIMENTAL|Intervention|Subject assumed the Si.Pi.Mi product as detailed in the protocol
62630111|NCT06548503|PLACEBO_COMPARATOR|Placebo|Subjects assumed the placebo as detailed in the protocol
62630112|NCT02511041|EXPERIMENTAL|1|This is a prospective exploratory study of nucleoside and monosaccharide supplement-ation and its effect on immunologic parameters in patients with evidence of altered glycosylation and immunologic abnormalities. Up to 50 subjects will receive escalating doses of oralmonosaccharide until a maximum tolerated dose is found and maintained for 6 weeks. Then nucleosidesupplementation will be added and the maximum tolerated dose will continue for 12 weeks. Parameters of interest will be assessed at NIH every 8 weeks. Themaximum participation time for each subject is 252 days. We will begin with PGM3 deficient patients, who will self-administer oral GlcNAc followed by dual supplementation with GlcNAc and Uridine. The remaining subjects will then receive these supplements following the same step-wise approach.
62630113|NCT01672268|ACTIVE_COMPARATOR|Standard TAVI procedure|Patients without Cardiac CT measures before TAVI
62630114|NCT01672268|EXPERIMENTAL|Cardiac CT scan before TAVI procedure|patients with cardiac CT measures before TAVI
62630115|NCT04519983|EXPERIMENTAL|Upfront TKI + Salvage SRT|Patients With Brain metastases of EGFR-mutant Non-small Cell Lung Cancer should receive Aumolertinib as upfront treatment. SRT(32Gy/4fx) is given to progressive or recurrent intracranial lesions as salvage therapy after intracranial failure.
62064132|NCT05096468|PLACEBO_COMPARATOR|Normal saline and placebo capsule|
62451933|NCT02068482|ACTIVE_COMPARATOR|1a USDD|Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
62451934|NCT02068482|NO_INTERVENTION|1b USDD|Patients control, no drug
62451935|NCT02068482|NO_INTERVENTION|Control group|Control Group, no disease, no drug
62064133|NCT06324721|EXPERIMENTAL|Breast cancer patients|Women and men diagnosed with breast cancer scheduled for surgery
62064134|NCT05040022|ACTIVE_COMPARATOR|Group pneumoperitoneum pressure 10|Pneumoperitoneum pressure at 10 mmHg
62064135|NCT05040022|PLACEBO_COMPARATOR|Group neumoperitoneum pressure 14|Pneumoperitoneum pressure at 10 mmHg
62064136|NCT03311932|ACTIVE_COMPARATOR|Cortef® Tablets - fasted|Single dose of 20mg Cortef® Tablets - fasted arm
62064137|NCT03311932|EXPERIMENTAL|Infacort® - fasted|Single dose of 20mg Infacort® - fasted arm
62451936|NCT02336737|EXPERIMENTAL|SiennaXP injection|"Single injection of SiennaXP in addition to comparator single dose of radioisotope (Technetium Tc99m Sulfur Colloid) and single dose of isosulfan blue dye.~Lymph node localization using the SentiMag handheld intraoperative localization system in addition to localization with standard of care handheld gamma probe."
62064138|NCT03311932|ACTIVE_COMPARATOR|Cortef® Tablets - fed|Single dose of 20mg Cortef® Tablets - fed arm
62064139|NCT03311932|EXPERIMENTAL|Infacort® - fed|Single dose of 20mg Infacort® - fed arm
62064140|NCT01686581||BOTOX®|BOTOX® (botulinum toxin Type A) administered according to physician prescription for the treatment of chronic migraine; all treatment decisions lie with the physician.
62451937|NCT06272409|EXPERIMENTAL|DEP114|DEP114 administered once (01) time a day, by morning, for 5 (+2) days.
62451938|NCT06272409|ACTIVE_COMPARATOR|DESLORATADINE|Desloratadine administered once (01) time a day, by morning, for 5 (+2) days.
62451939|NCT02237183|EXPERIMENTAL|Arm I (iloprost QID)|Patients receive iloprost via inhalation using a nebulizer QID for 60 days.
62451940|NCT02237183|PLACEBO_COMPARATOR|Arm II (placebo QID)|Patients receive placebo via inhalation using a nebulizer QID for 60 days.
62451941|NCT02237183|EXPERIMENTAL|Arm III (iloprost BID)|Patients receive iloprost via inhalation using a nebulizer BID for 60 days.
62451942|NCT02237183|PLACEBO_COMPARATOR|Arm IV (placebo BID)|Patients receive placebo via inhalation using a nebulizer BID for 60 days.
62451943|NCT04726202||Control arm|standard procedure of coding at hospital
62451944|NCT04726202||Precoding arm|Coding of the standard procedure will be reviewed and corrected
62630116|NCT03522818|ACTIVE_COMPARATOR|Normal|Group will use the alarm as provided by the manufacture.
62630117|NCT03522818|EXPERIMENTAL|Manual trigger|Group will use the same model but will be instructed to manually trigger the alarm 1-2 hours after the child falls asleep.
62064141|NCT04301440|ACTIVE_COMPARATOR|patients with anxious and / or depressive characteristics : treated group|patients with anxious and / or depressive characteristics, The device with the electromagnetic wave will be connected
62064142|NCT04301440|PLACEBO_COMPARATOR|patients with anxious and / or depressive characteristics : placebo group|The device with the electromagnetic wave will not be connected
62064143|NCT02018445|OTHER|Accell Evo3 DBM & Local Autograft|Accell Evo3 DBM (posterolateral gutter symptomatic side) and Local Autograft (posterolateral gutter contralateral non-symptomatic side)
62064144|NCT03202472|EXPERIMENTAL|Diagnostic (radiofrequency-guided localization)|Patients undergo mammogram or ultrasound for image-guided placement of the radiofrequency tag within 30 days of surgery and then undergo radiofrequency-guided localization during surgery.
62064145|NCT02653573|EXPERIMENTAL|Intervention|Telephone health coaching over 3 months with supporting education materials.
62064146|NCT01351025|EXPERIMENTAL|Arm A: atorvastatin / placebo|"At study entry (week 0), participants continued the entry boosted PI-based antiretroviral regimen (not provided by the study) and initiated atorvastatin at a daily dose of 10 mg for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, the dose of atorvastatin was increased to 20 mg daily at the week 4 visit. At week 20, atorvastatin was stopped for a 4-week washout period.~At week 24, placebo was started for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, the placebo dose was doubled at week 28. At week 44, the placebo was stopped to allow for another 4-week washout period."
62064147|NCT01351025|EXPERIMENTAL|Arm B: placebo / atorvastatin|"At study entry (week 0), participants continued the entry boosted PI-based antiretroviral regimen (not provided by the study) and initiated placebo for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, the dose of placebo was doubled at the week 4 visit. At week 20, the placebo was stopped for a 4-week washout period.~At week 24, atorvastatin was started at a daily dose of 10 mg for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, the dose of atorvastatin was increased to 20 mg daily at week 28. At week 44, atorvastatin was stopped to allow for another 4-week washout period."
62064148|NCT02300012|NO_INTERVENTION|Operation - No PBI|Patients requiring operation - baseline PBI data not seen by surgeon
62064149|NCT02300012|EXPERIMENTAL|Operation - PBI available|Patients requiring operation - baseline PBI data seen by surgeon pre-operatively
62064150|NCT02300012|NO_INTERVENTION|Non-operation|Patients with ACL rupture not requiring operation
62064151|NCT02300012|NO_INTERVENTION|Control|Healthy age matched volunteers - No operation
62064152|NCT04318093|EXPERIMENTAL|BMS-986259|
62064153|NCT04318093|PLACEBO_COMPARATOR|Placebo|
62064154|NCT06210503|ACTIVE_COMPARATOR|PENG group|The patient will undergo pericapsular nerve blockade with 0.5% ropivacaine based on 3 mg/kg ropivacaine using ultrasound scanning.
62064155|NCT06210503|ACTIVE_COMPARATOR|FICB group|The patient will undergo FICB with 0.5% ropivacaine based on 3 mg/kg ropivacaine using ultrasound scanning.
62269360|NCT03694496|EXPERIMENTAL|peer-led theory-based intervention group|2-6 students (depending on the headcount of the grade 2 students of the school) will be selected as peer leaders and they will receive oral health training first. After being trained and qualified, they will deliver oral health talks and workshops to their peers. The peer leaders will be requested to conduct six activities during 6 months, including health talks, workshops, information leaflets, etc.
62269361|NCT03694496|NO_INTERVENTION|Control group|Participants in the control group will continue their present practice, and no additional interventions will be given except oral health pamphlets delivery. We will record their present practice in detail. As the control group is in different schools, so they will have very low opportunity to get access to the peer-led activities conducted in the intervention group. Contamination will be quite minimum.
62630118|NCT01534416|EXPERIMENTAL|Bupivacaine|Subjects receive paracervical block with bupivacaine-epinephrine
62630119|NCT01534416|PLACEBO_COMPARATOR|Saline|Subjects receive paracervical injection of normal saline
62630120|NCT00856999|EXPERIMENTAL|Botox|Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
62630121|NCT02951624|EXPERIMENTAL|Control|Participants will spend 8 hours sedentary. Sedentary time will be spent sitting in a chair, restricted to sedentary behaviors (working on a computer, reading, watching TV, etc.) Participants will only be allowed to stand or walk to go to the toilet.
62630122|NCT02951624|EXPERIMENTAL|Breaker|Participants will spend a total of 7 hours and 12 min sedentary and a total of 48 min breaking sitting time with LPA. Sedentary time will be done in bouts of 18 min with 2 min of light walking.
62064156|NCT06071832|EXPERIMENTAL|Structured Play Condition|The following describes ONE intervention type with the following rationale. We chose to investigate shared book reading because it is a structured activity that is familiar, emotionally engaging, and supportive of general knowledge and language development. Adults report that shared reading is an important bonding activity that builds adult-child closeness through back- and-forth interactions. Importantly, the joint attention that occurs during shared book reading when adults and children share focus on the book may promote language and social emotional outcomes. Children are responsive and attentive during shared reading over video chat, but it is unknown whether a triadic interaction can be established during reading via video chat.
62630123|NCT02951624|EXPERIMENTAL|Intermediate|Total duration of sedentary time and LPA time will be the same as in Breaker. Sedentary time will be done in bouts of 54 min with 6 min of LPA between each bout.
62630124|NCT02951624|EXPERIMENTAL|Prolonger|Total duration of sedentary time and LPA time will be the same as in Breaker. Sedentary time will be done in bouts of 108 min with 12 min of LPA between each bout.
62630125|NCT01091246|EXPERIMENTAL|Q/LAIV (MEDI3250)|Q/LAIV (quadrivalent live attenuated influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10\^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 temperature sensitive, cold-adapted, attenuated, 6:2 resassortant influenza strains (A/H1N1 \[A/South Dakota/6/2007\], A/H3N2 \[A/Uruguay/716/2007\], B/Victoria \[B/Malaysia/2506/2004\], and B/Yamagata \[B/Florida/4/2006\]).
62630126|NCT01091246|EXPERIMENTAL|FluMist/B/Yamagata|FluMist/B/Yamagata (trivalent live attenuated influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10\^7.0 ± 0.5 FFU of each of 3 temperature sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 \[South Dakota/6/2007\], A/H3N2 \[A/Uruguay/716/2007\], and B/Yamagata \[B/Florida/4/2006\])
62630127|NCT01091246|EXPERIMENTAL|FluMist/B/Victoria|FluMist/B/Victoria (trivalent live attenuated influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10\^7.0 ± 0.5 FFU of each of 3 temperature sensitive, cold-adapted, attenuated, 6:2 reassortant influenza stains (A/H1N1 \[A/South Dakota/6/2007\], A/H3N2 \[A/Uruguay/716/2007\], and B/Victoria \[B/Malaysia/2506/2004\]).
62630128|NCT03810456|ACTIVE_COMPARATOR|iCBT|Patients in this arm will receive transdiagnostic CBT delivered in an intensive format over one weekend.
62630129|NCT03810456|ACTIVE_COMPARATOR|sCBT|Patients in this arm will receive transdiagnostic CBT delivered in a standard weekly format for 12 weeks.
62269362|NCT03115307|EXPERIMENTAL|Gonapeptyl|In the intervention group the patient will get the advice to using triptorelin (Gonapeptyl®) in the eight day after the injection of hCG (Pregnyl®) in the insemination cycle.
62269363|NCT03115307|NO_INTERVENTION|Control group|In the control group, there are no luteal phase medications in the insemination cycle.
62269364|NCT03224429|OTHER|Decisional Needs Assessment|Caregivers and patients with sickle cell disease will participate in a semi-structured open ended interview regarding treatment decision making.
62269365|NCT03224429|OTHER|Beta Testing|Caregivers and patients with sickle cell disease will review the web-based Sickle Cell Decision Aid.
62269366|NCT03891940||Patient receiving Anterior Cervical Spine Surgery|"1. Patients who fulfill the criteria of anterior cervical spine surgery under general anesthesia~2. Aged from 20-80 years old"
62269367|NCT03658486|OTHER|Exercise|12 weeks of progressive, home-based, moderate intensity, aerobic and strengthening exercise. Aerobic exercise will be completed 5 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous brisk walking at week 12. Strengthening exercises will involve whole body activities and commence with 1 set of each exercise (8-15 repetitions) and progress to 3 sets. The strengthening exercises will gradually progress in difficulty throughout the program.
62269368|NCT02534142||Completed followup|All members aged 50-74 who completed a fecal occult blood test between 1/1/2014 and 1/1/2015, who had a positive result and had a colonoscopy following the result.
62064157|NCT06071832|EXPERIMENTAL|Structured Reading Condition|The following describes ONE intervention type with the following rationale. For our structured play condition, we chose to investigate the activities of playing show and tell, imitating with objects, and drawing because these are common activities derived from lab-based video chat experiments with children, many of which are authored by the PI and Co-I.
62269369|NCT02534142||Did not complete followup|All members aged 50-74 who completed a fecal occult blood test between 1/1/2014 and 1/1/2015, who had a positive result and did not have a colonoscopy following the result.
62630130|NCT03810456|NO_INTERVENTION|TAU|Patients in this arm will not receive transdiagnostic CBT but will receive treatment as usual.
62064158|NCT06071832|EXPERIMENTAL|Control Condition|The control families will be asked to do video chat as usual, with no specific instructions.
62269370|NCT01224184|ACTIVE_COMPARATOR|Nutrition|Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
62269371|NCT01224184|EXPERIMENTAL|Young Women's|Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (Principal Investigator (PI): Dr. Wendee M. Wechsberg).
62269372|NCT03074474|OTHER|OviTex Permanent 1S|All subjects included in this post-market study had a ventral hernia repaired with OviTex 1S Permanent reinforced tissue matrix.
62269373|NCT00717171|PLACEBO_COMPARATOR|1|
62269374|NCT00717171|EXPERIMENTAL|2|
62630131|NCT04453020|EXPERIMENTAL|LHA DBS|Subjects will receive bilateral DBS of the LHA
62630132|NCT03176121|EXPERIMENTAL|Oxycodone treatment|"Patients will take either control-released oxycodone (OxyContin® 10mg and 20mg) or immediate-released oxycodone (OxyNorm® 5mg) or both for initial dose and used it to titrate his/her background dose.~After regular time assessment of the pain score (NRS), if the pain control is inadequate (NRS ≥ 4), a total daily dose in 24hrs will be summed up for the next dose titration until reach a stable dose (as defined as total daily dose is fixed for at least two weeks)."
62630133|NCT01499693|EXPERIMENTAL|Magnesium Pantoprazole 20mg|
62064159|NCT05389891|EXPERIMENTAL|Group 1|Experimental Group (n=54) The implementation phase was achieved through sessions within Feb-April2017 second semester of the academic year 2016/2017.Each session started by the objectives of the new session and summary of previous one. Motivation and reinforcement during session were used to enhance participation and sharing in this study. The researcher did the explanation of the questionnaire sheet to the pediatric student nurses to assess their awareness and attitude toward hemoglobinopathies. The researcher observed the pediatric student nurses 'practice during applying blood transfusion, subcutaneous medication administration, and oral medication administration using the observational checklist at faculty laboratory.
62451945|NCT04344418|ACTIVE_COMPARATOR|Usual care|The control arm will consist of usual care ie a combination of physical examination, lab tests and imaging. The need for a formal echocardiographic evaluation by a cardiologist or cardiac sonographer in patients assigned to the control arm will be at the discretion of the clinical teams, as is usual care at the Kenyatta National Hospital (KNH) and Aga Khan University Hospital Nairobi (AKUHN). A diagnosis will be selected based on the same pre-defined checklist and the time the diagnosis is made recorded.
62630134|NCT01499693|ACTIVE_COMPARATOR|Magnesium Pantoprazole 40mg|
62630135|NCT06043648||Constant monitoring|Intracuff pressure was monitored continuously throughout the surgery using the transducer of the invasive pressure monitoring device in patients undergoing elective non-head-neck surgical procedures under general anesthesia and orally intubated with a cuffed endotracheal tube.
62630136|NCT06043648||Intermittent monitoring|Intracuff pressure was monitored intermittently throughout the surgery using an analogue manometer in patients undergoing elective non-head-neck surgical procedures under general anesthesia and orally intubated with a cuffed endotracheal tube.
62630137|NCT06043648||None monitoring|After endotracheal intubation with a cuffed endotracheal tube, the cuff was inflated by the anesthesia provider using sealing pressure technique which involves slow inflation of the cuff until there is no audible gas leak while holding continuous positive airway pressure of 20 cmH2O with the head and neck in the neutral position. No other intracuff pressure monitoring or measurement was performed throughout the operation.
62630138|NCT03446976|EXPERIMENTAL|CT-P13 SC Auto-injector|CT-P13 SC Auto-injector
62630139|NCT03446976|EXPERIMENTAL|CT-P13 SC Pre-filled Syringe|CT-P13 SC Pre-filled Syringe
62630140|NCT04978337|EXPERIMENTAL|Treatment A: Rilematovir|Participants will receive oral dose of rilematovir 250 milligrams (mg), twice daily (bid) for 7 days.
62451946|NCT04344418|EXPERIMENTAL|Nurse-performed focused cardiac ultrasound (FoCUS)|The experimental arm will consist of nurse-performed FoCUS for patients with cardiorespiratory failure. A FoCUS-trained nurse will perform a FoCUS examination within 30 minutes of triage by the triage clinician. The Philips Lumify® handheld ultrasound device (HUD) with a phased array probe will be used and studies limited to a maximum of 10 minutes each. A presumptive diagnosis will then be selected by the nurse from a FoCUS checklist based on pre-defined thresholds for each FoCUS target condition and the time the diagnosis is made recorded. Additional imaging and lab tests may be requested at the discretion of the clinical team but the FoCUS nurses will be blinded to the results of these.
62451947|NCT01303562|PLACEBO_COMPARATOR|Placebo muffin made with no whole grains|
62630141|NCT04978337|PLACEBO_COMPARATOR|Treatment B: Placebo|Participants will receive oral dose of placebo matching to rilematovir, bid for 7 days.
62630142|NCT03523195|ACTIVE_COMPARATOR|Arm 0 (written information)|Participants wear Fitbit and receive written information on healthy exercise and diet recommendations.
62630143|NCT03523195|EXPERIMENTAL|Arm I (exercise program)|Participants complete exercise program including aerobic and resistance exercises over 60 minutes 3 times per week for 12 weeks. Exercise is supervised all 3 times during weeks 1-2. During weeks 3-12, exercise is supervised 2 times a week, with home-based coaching for an additional 60 minutes a week.
62630144|NCT06178042|EXPERIMENTAL|MI Paste Plus|Patients were instructed to use MI Paste Plus (GC Europe, Leuven, Belgium) according to manufacturers instructions.
62630145|NCT06178042|EXPERIMENTAL|Remin Pro|Patients were instructed to use (Remin Pro, VOCO GmbH, Cuxhaven, Germany) a pea-sized amount of the cream.
62630146|NCT06178042|ACTIVE_COMPARATOR|Control|Patients used a 1450 ppm fluoridated tooth paste (Colgate Sensitive Pro-Relief, Colgate-Palmolive, Swidnica, Poland) for conventional tooth brushing.
62630147|NCT05645302||Patients using Lidocaine Cataplasms|
62630148|NCT06611865|ACTIVE_COMPARATOR|Split-mouth group|It includes bilaterally indicated teeth. ILA and IANB were used on opposite sides in the same person; the second tooth was anesthetized only after the first extraction had completed and had been recorded.
62630149|NCT06611865|ACTIVE_COMPARATOR|Group 2 ILA|The patients in group 2, with unilateral extractions, that were only administered Intraligamentary anaesthesia.
62630150|NCT06611865|ACTIVE_COMPARATOR|Group 2 IANB|The patients in group 2, with unilateral extractions, that were only administered the Inferior Alveolar Nerve Block. In case of multiple unilaterally indicated teeth that were to be extracted under IANB, only the tooth best fitting all criteria was considered for the study.
62630151|NCT02388828||Subjects who have received lentiviral-based CARTmeso therapy|
62630152|NCT05959967|EXPERIMENTAL|Vestibular Rehabilitation Exercises (VRE)|The VRE arm will be engaged in vestibular exercises including gaze stabilization, balance, and gait training.
62630153|NCT05959967|ACTIVE_COMPARATOR|General Fitness Training (GFT)|The GFT arm will participate in general fitness exercises including cardiovascular, strength, and flexibility training.
62064160|NCT05389891|NO_INTERVENTION|Group 2|Control Group (n=54) The researcher did the explanation of the questionnaire sheet to the pediatric student nurses to assess their awareness and attitude toward hemoglobinopathies. The researcher observed the pediatric student nurses 'practice during applying blood transfusion, subcutaneous medication administration, and oral medication administration using the observational checklist at faculty laboratory.
62064161|NCT00133536|EXPERIMENTAL|1|100 subjects 45 mcg of influenza A/H5N1.
62630154|NCT02364583|ACTIVE_COMPARATOR|14 day dose regimen|0.5 mg/kg oral Primaquine administered daily for 14 days
62630155|NCT02364583|ACTIVE_COMPARATOR|7 day dose regimen|1.0 mg/kg oral Primaquine administered daily for 7 days
62630156|NCT02364583|ACTIVE_COMPARATOR|3.5 day dose regimen|1.0 mg/kg oral Primaquine administered twice daily (bd) for 3.5 days
62630157|NCT04346576|EXPERIMENTAL|Probiotics (LcS per 65 mL) prevent health problems in children|Probiotic test product was fermented milk containing 6.5 billion of LcS per 65 mL (108 CFU/mL), manufactured by Yakult Vietnam, Co., Ltd. The nutritional composition of the test product is 0.8 g of protein, \<0.1 g of fat, 12.4 g of carbohydrates, and the total energy is 52.7 kcal per bottle. Subjects were asked to drink one bottle of the test product per day after lunch for 12 weeks on consecutive days. The test products were stored in a refrigerator (\< 10°C), protected from direct sunlight, and used before their expiration date. Adherence to the intervention protocol was confirmed as follows; teachers at kindergartens or parents at home provided the probiotic drinks (1 bottle/day x 7 days/week) after lunch.
62630158|NCT04976439||Age|
62630159|NCT04976439||Grade|
62630160|NCT04976439||Tumor location|
62630161|NCT04976439||Stage|
62630162|NCT04976439||Lymphovascular invasion|
62630163|NCT06102720|EXPERIMENTAL|Colchicine Group|All patients in this arm will receive colchicine for 14 days in addition to standard medical care without clopidogrel (acetylsalicylic acid, lipid-lowering, antihypertensive, gastroprotective, hypoglycemic drugs if necessary, lifestyle recommendations, early rehabilitation activities).
62630164|NCT06102720|ACTIVE_COMPARATOR|Clopidogrel treatment group|All patients in this arm will receive standard treatment including clopidogrel.
62630165|NCT05707390|EXPERIMENTAL|Mild hepatic impairment|
62630166|NCT05707390|EXPERIMENTAL|Moderate hepatic impairment|
62630167|NCT05707390|EXPERIMENTAL|Severe hepatic impairment|
62630168|NCT05707390|EXPERIMENTAL|Healthy participants|
62064162|NCT00133536|PLACEBO_COMPARATOR|2|20 subjects saline placebo.
62630169|NCT06431945||People who inject drugs|
62630170|NCT04335084|EXPERIMENTAL|Medical Workers|Medical workers who are exposed to COVID-19 and as such are at higher risk for infection.
62630171|NCT04335084|PLACEBO_COMPARATOR|Placebo|Medical workers who are exposed to COVID-19 and as such are at a higher risk for infection
62630172|NCT06612216||healthy individuals and cancer patients|Comparing the microbiota characteristics of healthy individuals and cancer patients, revealing the differences in microbiota between healthy individuals and cancer patients.
62064163|NCT04758767|EXPERIMENTAL|Dose escalation cohort|Monotherapy CID-103. Priming dose will be given for first dose. Dose and duration of infusion dependent on dose cohort and tolerability.
62064164|NCT04758767|EXPERIMENTAL|Dose expansion cohort - pretreated|CID-103 monotherapy at the recommended phase 2 dose
62064165|NCT04758767|EXPERIMENTAL|Dose expansion cohort - Naïve|CID-103 monotherapy at the recommended phase 2 dose
62064166|NCT03170245||B thalassemia group|"Laboratory investigations :~* complete blood count~* renal and liver function tests~* serum ferritin~* lipid profile~* Interleukin -6~* HsC-RP~* Adiponectin level~Imaging :~* Abdominal ultrasound~* Echocardiography~* Carotid intima media thickness"
62269375|NCT06063200|OTHER|crossover 1: methylphenidate, placebo|methylphenidate (single dose, oral, 20 mg, immediate release) followed by placebo (single dose, oral)
62269376|NCT06063200|OTHER|crossover 2: placebo, methylphenidate|placebo (single dose, oral) followed by methylphenidate (single dose, oral, 20 mg, immediate release)
62630173|NCT06612216||Patients with different traditional Chinese medicine cancer toxicity syndrome types|According to the classification of traditional Chinese medicine cancer toxin syndrome types, compare the differences in microbiota between the heat toxin syndrome group, dampness toxin syndrome group, stasis toxin syndrome group, phlegm toxin syndrome group, wind toxin syndrome group, and cold toxin syndrome group in cancer patients, and explore the influence of different cancer toxin syndrome types on microbiota composition.
62630174|NCT06612216||Patients with different traditional Chinese medicine constitutions|According to the traditional Chinese medicine constitution classification, compare the differences in microbiota among tumor patients with qi stagnation constitution group, phlegm dampness constitution group, damp heat constitution group, blood stasis constitution group, qi deficiency constitution group, yang deficiency constitution group, yin deficiency constitution group, characteristic constitution group, and peaceful constitution group, and explore the influence of different constitution types on the microbiota composition of tumor patients.
62630175|NCT06612216||Patients with different tumor burden|Divide tumor patients into tumor bearing group and tumor free group, and explore their microbiota characteristics and differential patterns.
62630176|NCT06612216||Patients with different symptom burdens|According to the MDASI Anderson Symptom Scale, compare the differences in microbiota between individuals with mild and severe symptom burdens, and explore the impact of different symptom burdens on the microbiota composition of cancer patients.
62630177|NCT06612216||Patients with different treatment and outcome outcomes|Based on the application of different treatment methods and the resulting outcomes in cancer patients, compare the characteristic differences of microbiota between groups and explore the differential expression of microbiota.
62630178|NCT05038683|EXPERIMENTAL|HOT|Holbæk Obesity Treatment
62630179|NCT05038683|ACTIVE_COMPARATOR|COT|Conventional Obesity Treatment
62630180|NCT05736692|EXPERIMENTAL|Brief Sleep Intervention|1-session intervention designed to improve adolescent sleep quality and/or quantity.
62630181|NCT05736692|NO_INTERVENTION|Control|Care as Usual. Those in this condition will be asked to continue their scheduled/prescribed care until the next study assessment. Note that, to ensure that all participants (control and sleep intervention) are offered the current standard of care, all will get a simple handout on sleep hygiene and any who is not receiving follow-up care will be referred to the Brain Health and Wellness Center (the multidisciplinary program to which all PCSS care at Cincinnati Children's is routed).
62630182|NCT04687904|ACTIVE_COMPARATOR|Therapeutic education group|"The psychologist associated with the project takes care of the patient to receive a 1.5 hour therapeutic education interview (control group)."
62630183|NCT04687904|EXPERIMENTAL|Mindfulness meditation group|"The psychologist associated with the project takes care of the patient to receive training in mindfulness meditation twice (1.5 hours) (active group)"
62630184|NCT06607796|EXPERIMENTAL|Experimental group|intratumoral injection of toluenesulfonamide (PTS) to oligo lesions
62630185|NCT06607796|NO_INTERVENTION|Control subjects|follow-up observation of oligofocal lesions, no PTS intratumoral injection treatment, if progression can be oligofocal PTS intratumoral injection
62630186|NCT01735149|EXPERIMENTAL|Kochujang Pills|
62630187|NCT01735149|PLACEBO_COMPARATOR|Placebo|
62630188|NCT01647568||Control|Patients who are not on any anti-platelet/anti-coagulant therapy and present to our lab for a elective colonoscopy.
62630189|NCT01647568||Thienopyridine Users|Patients on Clopidogrel or prasugrel when they present for an elective colonoscopy.
62630190|NCT04832256||High Flow anesthesia|administered 4 L/min fresh gas flow during general anesthesia
62630191|NCT04832256||Low Flow Anesthesia|administered 1 L/min fresh gas flow during general anesthesia
62630192|NCT02155985|ACTIVE_COMPARATOR|Aspirin 300 mg + aspirin 100 mg placebo|At week 0, participants were prescribed aspirin 300 mg (one tablet) and placebo for aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study product tablets to allow for a 4-week washout period.
62630193|NCT02155985|ACTIVE_COMPARATOR|Aspirin 100 mg + aspirin 300 mg placebo|At week 0, participants were prescribed a placebo for aspirin 300 mg (one tablet) and aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study product tablets to allow for a 4-week washout period.
62630194|NCT02155985|PLACEBO_COMPARATOR|Aspirin 300 mg + aspirin 100 mg placebos|At week 0, participants were prescribed a placebo for aspirin 300 mg (one tablet) and placebo for aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study products tablets to allow for a 4-week washout period.
62630195|NCT04450693|EXPERIMENTAL|TTAX01|TTAX01 plus standard of care
62630196|NCT04450693|OTHER|Control|Standard care alone
62630197|NCT00847418|EXPERIMENTAL|Esketamine|
62630198|NCT01352273|EXPERIMENTAL|MEK162 + RAF265|
62630199|NCT01649115|NO_INTERVENTION|Usual Care|The Usual Care arm, will not be receiving the interactive nutrition education. They will be meeting with the Registered Dietitian twice in person after the participants are randomized in each arm, and once on the phone. The first meeting, they will be receiving pamphlets and handouts, which are typically given as part of usual care. The second meeting is a post-test assessment and Newest Vital Sign Assessment Tool. The second meeting and the follow-up phone call are both the same for usual care and the Healthy Lifestyles Passport arm.
62630200|NCT01649115|EXPERIMENTAL|Healthy Lifestyles Passport|The Healthy Lifestyles Passport arm will be receiving the intervention. They will be meeting with the Registered Dietitian twice in person after the participants are randomized into each arm, and once on the phone. The first meeting, they will be receiving the Healthy Lifestyles Passport, including the interactive nutrition education. The second meeting is a post-test assessment and Newest Vital Sign Assessment Tool.
62630201|NCT06508827|EXPERIMENTAL|Iron dextran 1000 mg IV|Iron dextran 1000 mg IV will be administered once, about 7 days prior to standard of care treatment.
62630202|NCT05062746|EXPERIMENTAL|MRT group|One session Matrix-Rhythm Therapy
62630203|NCT05062746|OTHER|Control group|One session routine, conventional physiotherapy and rehabilitation
62630204|NCT05454995|EXPERIMENTAL|Alucent VRS for Treatment of Atherosclerotic Lesions|Combination Product: VRS
62630205|NCT05660382|ACTIVE_COMPARATOR|Active group|Miconazole (2%) oil, administered as 5 drops per ear at \~30 mg per drop instilled into the external ear canal of the ear(s) affected by otomycosis, twice daily for 14 days.
62451948|NCT01303562|ACTIVE_COMPARATOR|Test muffin made with whole oats|
62451949|NCT01303562|ACTIVE_COMPARATOR|Test muffin made with whole barley|
62064167|NCT03170245||Control group|"Laboratory investigations :~* complete blood count~* renal and liver function tests~* serum ferritin~* lipid profile~* Interleukin -6~* HsC-RP~* Adiponectin level~Imaging :~* Abdominal ultrasound~* Echocardiography~* Carotid intima media thickness"
62064168|NCT05125523|EXPERIMENTAL|Sirolimus for Injection (Albumin Bound)|"Stage 1：Multiple doses of Sirolimus for Injection (Albumin Bound) will be administered intravenously.~Stage 2：RP2D of Sirolimus for Injection (Albumin Bound) as determined during stage 1 will be administered intravenously."
62064169|NCT02257905||AL Amyloidosis patients who received allo HSCT|
62451950|NCT02283775|EXPERIMENTAL|PomdeSAR|"Part A: Isatuximab (escalating dose) on Day 1, 8, 15, and 22, then Day 1 and 15 + pomalidomide 4 mg on Day 1 to 21 + dexamethasone 40 mg (20 mg in patients of 75 years or older) on Day 1, 8, 15, 22 in 28-day cycles up to disease progression~Part B: Isatuximab 10 mg/kg on Day 1, 8, 15, and 22, then Day 1 and 15 + pomalidomide 4 mg on Day 1 to 21 + dexamethasone 40 mg (20 mg in patients of 75 years or older) on Day 1, 8, 15, 22 in 28-day cycles up to disease progression"
62451951|NCT03445195|EXPERIMENTAL|Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin|
62451952|NCT03445195|PLACEBO_COMPARATOR|Placebo + Imipenem/Cilastatin|
62451953|NCT02974114|EXPERIMENTAL|Paracetamol and caffeine|Participants will be administered test product (containing 500 mg paracetamol and 65 mg caffeine). Two tablets will be taken orally once with 200 mL (milliliters) of water.
62451954|NCT02974114|EXPERIMENTAL|Paracetamol|Participants will be administered test product (containing 500 mg paracetamol). Two tablets will be taken orally once with 200 mL of water.
62451955|NCT02974114|PLACEBO_COMPARATOR|Placebo|Participants will be administered reference product (placebo to match Paracetamol 665mg sustained release tablets). Two tablets will be taken orally once with 200 mL of water.
62451956|NCT00128557|PLACEBO_COMPARATOR|Placebo|Supplement containing soybean oil with a small amount of vitamin E as an antioxidant
62451957|NCT00128557|ACTIVE_COMPARATOR|Vitamin A|15,000 ug retinol equivalents (50,000 International Units)
62451958|NCT04126681|EXPERIMENTAL|HQP1351 therapy cohort|HQP1351 40 mg, taken orally once every other day of a 28-day cycle
62451959|NCT04126681|ACTIVE_COMPARATOR|Best Available Therapy (BAT) cohort|Best available therapy (BAT) will be selected by the investigator for each participant.
62451960|NCT05147077|EXPERIMENTAL|Integrated rehabilitation group|This group will include 94 patients. On the basis of standard care, patients in this group will receive acupuncture, traditional Chinese medicine, repetitive transcranial magnetic stimulation.
62451961|NCT05147077|ACTIVE_COMPARATOR|Standard care group|The patients were recommended to take one oral tablet of escitalopram oxalate (10 mg) every morning after a meal for 4 weeks. Internal medicine includes lipid regulation, blood sugar control, anti-hypertension, anticoagulation, and other drugs. Moreover, general duty nursing and motor therapy are also needed.
62451962|NCT00674180||1|a workbook alone
62451963|NCT00674180||2|a workbook alone and the addition of computerized tailoring using onsite computer kiosks with touch screen monitors
62451964|NCT00674180||3|a workbook, the addition of computerized tailoring using onsite computer kiosks with touch screen monitors, and staff consultations.
62451965|NCT01399164|EXPERIMENTAL|Fortified Bread|A single serving of 14C-B12 fortified bread
62064170|NCT00544960|EXPERIMENTAL|1|AT-101 and docetaxel
62064171|NCT00544960|PLACEBO_COMPARATOR|2|placebo and docetaxel
62451966|NCT01038570|EXPERIMENTAL|Oxytocin|
62451967|NCT01038570|PLACEBO_COMPARATOR|Physiological serum|
62451968|NCT01583777|EXPERIMENTAL|Belinostat|Open Label
62451969|NCT04502069|EXPERIMENTAL|Open label opaganib|opaganib dosed at 500 mg Q12 hours
62451970|NCT05415566|NO_INTERVENTION|Routine Treatment Group|Inhaler treatment was applied according to the routine procedure in the emergency department.
62451971|NCT05415566|EXPERIMENTAL|Therapeutic Play Group|"Inhaler treatment was applied according to the Therapeutic Play Guide prepared by the researcher."
62451972|NCT03186066|ACTIVE_COMPARATOR|Standard Therapy|Buried Bumper Syndrome is treated by endoscopically dissecting the overgrown tissue with an endoscopic submucosal dissection knife.
62451973|NCT03186066|EXPERIMENTAL|Flamingo Device|The Flamingo device is used for treatment of Buried Bumper Syndrome.
62451974|NCT03070249||Emergency Department Healthcare Providers|This study will assess compassion fatigue among healthcare providers in a single emergency department (ED) using the Professional Quality of Life (ProQoL) scale.
62451975|NCT03520673|OTHER|Development of Clinical Decision Support Tool|All men will receive the same series of simple index tests which will be compared with the results of the urodynamics reference test to identify which index tests give the best prediction of the urodynamic results. The data from the first cohort will develop the clinical decision support tool.
62451976|NCT03947515|EXPERIMENTAL|cancer group|
62451977|NCT03947515|EXPERIMENTAL|control group|
62451978|NCT02844153||6 groups, for each CKD stage (1, 2, 3a, 3b, 4, 5)|All patients with type 2 diabetes seen for the first time by a nephrologist.
62451979|NCT02096419|NO_INTERVENTION|control group|Patients in this group will receive standard clopidogrel dose
62630206|NCT05660382|PLACEBO_COMPARATOR|Placebo group|Mineral oil, administered as 5 drops per ear instilled into the external ear canal of the ear(s) affected by otomycosis, twice daily for 14 days.
62630207|NCT02446444|EXPERIMENTAL|Enzalutamide|Enzalutamide 160 mg daily, by mouth, for 24 months from randomisation. All participants are treated with a LHRHA for 24 months from randomisation and external beam radiation therapy started approximately 16 weeks after randomisation (+/- brachytherapy boost)
62451980|NCT02096419|EXPERIMENTAL|interventional group|"Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).~They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.~On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity \>18U and \<18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if \>46U; not changed if 19-46U; decreased by 75 mg if \<19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients \>70 years 150 mg)"
62451981|NCT05868109|SHAM_COMPARATOR|Participants with Sham (no nitric oxide)|The mechanical ventilator circuit of the study participants are attached to the inhaled nitric oxide delivery device but nitric oxide is not delivered.
62451982|NCT05868109|EXPERIMENTAL|Participants with Nitric Oxide|The mechanical ventilator circuit of the study participants are attached to the inhaled nitric oxide delivery device and nitric oxide is delivered.
62451983|NCT04080583||Usual Care|People with a chronic lung condition who are physically inactive
62451984|NCT01628081|EXPERIMENTAL|Alga Dunaliella bardawil|After screen phase of maximum two weeks the subjects will be randomized to one of two treatments groups (1:1): Dunaliella or placebo.
62451985|NCT01628081|PLACEBO_COMPARATOR|Placebo|"Dosage Regimen and Treatment Groups~* Daily oral administration of:~* Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~* Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
62451986|NCT03665909|EXPERIMENTAL|Remote activity monitoring|"Receive the remote activity monitoring system (i.e., eNeighbor; see intervention description) over an 18-month period."
62451987|NCT03665909|NO_INTERVENTION|Control|Control participants do not receive the remote activity monitoring intervention.
62451988|NCT05105373|EXPERIMENTAL|Intervention-Parenting for Respectability|Randomisation in the cRCT will be conducted at the cluster level. PfR is a 16-session manualised programme starting with nine single sex sessions followed by seven mixed sex sessions, delivered once a week by two local facilitators who receive one week's training. Activities were developed specifically for PfR or adapted from other parenting programs, including Project H, Stepping Stones, Mema kwa Jamii, The International Child Development Programme and Parenting for Lifelong Health. The programme addresses four familial processes associated with GBV and VAC: poor parental bonding and child attachment; harsh parenting; inequitable socialisation by gender and parental conflict. A particular goal is to involve fathers, whom most parenting programmes find hard to recruit, and the first nine sessions are delivered in single-sex groups.
62451989|NCT05105373|ACTIVE_COMPARATOR|Control-Parenting for Respectability in a nutshell|Randomisation in the cRCT will be conducted at the cluster level immediately after baseline data collection. Parents allocated to the control arm will receive a two-hour structured lecture called Parenting in a Nutshell on parenting and partner relationships. Three topics will be covered: 1) child development; 2) positive parenting; and 3) resolving partner conflicts. Facilitators delivering this lecture will have same/similar expertise with the facilitators engaged in PfR. .
62451990|NCT02518113|EXPERIMENTAL|LY3039478 + Dexamethasone (Adult)|"Part A: 50 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~75 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~100 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~125 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression."
62451991|NCT02518113|EXPERIMENTAL|LY3039478 + Dexamethasone (Pediatric)|"Part B: LY3039478 administered orally TIW at escalating doses and dexamethasone administered orally twice a day (BID) on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~There were no participants enrolled to Part B of the study."
62451992|NCT02518113|EXPERIMENTAL|Phase 2: LY3039478 + Dexamethasone|"LY3039478 administered orally TIW and dexamethasone administered orally BID on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~There were no participants enrolled to Phase 2 of the study."
62451993|NCT02518113|PLACEBO_COMPARATOR|Phase 2: Placebo + Dexamethasone|"Placebo administered orally TIW and dexamethasone administered orally BID on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~There were no participants enrolled to Phase 2 of the study."
62630208|NCT02446444|ACTIVE_COMPARATOR|Conventional Non-steroidal Anti-androgen (NSAA)|"Conventional Non-steroidal Anti-androgen (NSAA), by mouth, for 6 months from randomisation.~All participants are treated with a LHRHA for 24 months from randomisation and external beam radiation therapy started approximately 16 weeks after randomisation (+/- brachytherapy boost)"
62630209|NCT04135755||vertebral compression fracture|No drugs intervention
62630210|NCT04135755||older adult without spinal deformity|No drugs intervention
62630211|NCT04135755||young adults|No drugs intervention
62064172|NCT03354728|EXPERIMENTAL|Supportive Care (multi-antigen CMV-modified vaccinia ankara)|Patients receive multi-antigen CMV-modified vaccinia ankara vaccine IM on days 28 and 56 post-HCT.
62269377|NCT06164379|EXPERIMENTAL|Finerenone group|After the induction period of two weeks, the patients with primary aldosteronism were randomized in an equal ratio to receive finerenone 10mg once daily. Patients received the initial dose (10mg, week 0) of drug for the first two weeks of randomized treatments period. Thereafter, the dose of finerenone would not be changed for the adequate blood pressure (BP) control and the normal serum potassium. For patients not meeting BP \< 140/90mmHg and the serum potassium ≥ 3.5 mmol/L, the dose of finerenone would be increased to 20mg once daily for the second 2 weeks later (week 2) and 30 mg 4 weeks later (week 4), respectively. The whole treatment period was 8 weeks. if blood pressure \> 160/110 mmHg during the clinical trial, amlodipine 5 mg once was added.
62451994|NCT04782726|PLACEBO_COMPARATOR|Control Arm|After consent and study enrollment the subject will be scheduled for CT simulation for radiation treatment planning. At the time of CT simulation, they will be immobilized by means of a thermoplastic mask. For patients in the control arm, the radiation treatment planning will proceed as normal. Treatment planning is performed on Pinnacle. The patient will return for validation of the radiation plan. Validation involves collecting on-table X-rays or cone beam CTs when the patient is in position for treatment, which is the standard of care. Most often, the date of validation will happen within 5 business days of the CT simulation.
62064173|NCT02176044|PLACEBO_COMPARATOR|Glucose infusion|Placebo infusion of sterile 5% glucose - 500ml infused over 4 hours.
62064174|NCT02176044|ACTIVE_COMPARATOR|Sodium Nitroprusside infusion|Sodium nitroprusside dissolved in 5% glucose solution. Infused at 0.5mcg/kg/min for 4 hours.
62630212|NCT01420250|EXPERIMENTAL|Cabazitaxel with Intensity Modulated Radiation Therapy (IMRT)|Weekly Cabazitaxel with concurrent IMRT
62064175|NCT04978545|EXPERIMENTAL|calciumhydroxide|Participants received calciumhydroxide as an intracanal medicament for a one week period
62630213|NCT00901615|EXPERIMENTAL|Lenalidomide and R-CHOP|Escalating Lenalidomide dose from 2.5 to 25 mg Lenalidomide and R-CHOP
62064176|NCT04978545|EXPERIMENTAL|chlorhexidine|Participants received chlorhexidine gel as an intracanal medicament for a one week period
62064177|NCT05252429|EXPERIMENTAL|Docetaxel plus pembrolizumab|Docetaxel 75mg/m2 plus pembrolizumab 200mg will be administered every 3 weeks intravenously for 6 cycles. Thereafter pembrolizumab 200mg every 3 weeks will be given as maintenance therapy until progression or up to 35 cycles.
62064178|NCT03472703|OTHER|Hungry|Her subjects will first have a break, then undergo all measurement and at the end of the study-day they will receive their lunch
62269378|NCT06164379|ACTIVE_COMPARATOR|Spironolactone group|After the induction period of two weeks, the patients with primary aldosteronism were randomized in an equal ratio to receive spironolactone 20mg once daily. Patients received the initial dose (20mg, week 0) of drug for the first two weeks of randomized treatments period. Thereafter, the dose of spironolactone would not be changed for the adequate blood pressure (BP) control and the normal serum potassium. For patients not meeting BP \< 140/90mmHg and the serum potassium ≥ 3.5 mmol/L, the dose of finernone would be increased to 40mg once daily for the second 2 weeks later (week 2) and 60 mg 4 weeks later (week 4), respectively. the whole treatment period was 8 weeks. if blood pressure \> 160/110 mmHg during the clinical trial, amlodipine 5 mg once was added.
62269379|NCT05182151||Patient|istradefylline 40mg daily over 12 week period
62630214|NCT01096381||Will receive bevacizumab|
62630215|NCT01096381||Will not receive bevacizumab|
62630216|NCT03893760||No Pulonary Hypertension|the presence of mean pulmonary pressures (PAPm) at the right heart catheterization \< 25 mmHg
62064179|NCT03472703|OTHER|Satiated|Her subjects will first receive their lunch, then perform all the tasks and last will have a break
62064180|NCT02707523|PLACEBO_COMPARATOR|Control|Placebo controlled (normal saline) daily for 3 days
62064181|NCT02707523|ACTIVE_COMPARATOR|Azithromycin (10 mg/kg)|10 mg/kg IV Azithromycin daily for 3 days
62269380|NCT03098823|EXPERIMENTAL|RAYOS®|
62064182|NCT02707523|ACTIVE_COMPARATOR|Azithromycin (20 mg/kg)|20 mg/kg IV Azithromycin daily for 3 days
62064183|NCT02067234|ACTIVE_COMPARATOR|Routine Care/Education|Patient will be assessed by MD and provided education by nurse
62269381|NCT03098823|ACTIVE_COMPARATOR|IR prednisone|
62269382|NCT02967471||ARDS group|
62269383|NCT02967471||control group|
62451995|NCT04782726|EXPERIMENTAL|Research Arm|After consent and study enrollment the subject will be scheduled for CT simulation for radiation treatment planning. At the time of CT simulation, they will be immobilized by means of a thermoplastic mask. For patients in the research arm, a theoretical plan will be created after physician's segmentation and will be used as a guide for the final plan. The patient will return for validation of the radiation plan. Validation involves collecting on-table X-rays or cone beam CTs when the patient is in position for treatment, which is the standard of care. Most often, the date of validation will happen within 5 business days of the CT simulation.
62630217|NCT03893760||Postcapillary Pulmonary Hypertension|PAPm ≥ 25 mmHg and postcapillary wedge pressure (PCWP) \>15 mmHg
62630218|NCT03893760||combined postcapillary/precapillary Pulmonary Hypertension|PAPm ≥ 25 mmHg, PAWP \>15 mmHg and diastolic peak gradient (DPG - diastolic pulmonary pressure - PCWP) ≥7 mmHg and/or pulmonary vascular resistence (PVR) \>3 WU, where available.
62064184|NCT02067234|EXPERIMENTAL|Psychoeducation/Coping Prevention|Patient will be assessed by MD and will meet with psychologist to obtain psychoeducation about coping, behavioral strategies, and sleep hygiene
62630219|NCT04929977|OTHER|Wearable device with smart mobile phone|20 mother/care provider-infant pairs practicing Kangaroo Mother Care, from a tertiary super-specialty hospital selected to wear the device ( few days in the hospital and for a week at home when discharged)
62630220|NCT02411279||Groupe 1: experimental group|Equiped group with telemedicine systems
62064185|NCT04481828||open gastrectomy|The first group (Group 1; n: 30) consisted of patients who underwent open surgery
62064186|NCT04481828||laparoscopic gastrectomy|The second group (group 2; n:30) consisted of patients who underwent laparoscopic gastrectomy
62064187|NCT02884414|EXPERIMENTAL|Cutaneous Stimulation|Cutaneous stimulation and/or feedback. This stimulation and/or feedback may be visual, auditory, tactile (e.g. vibratory, temperature), or haptic and is completely external.
62630221|NCT02411279||Groupe 2: control group|Non equiped group with telemedicine systems
62630222|NCT02207400|EXPERIMENTAL|Experimental Dentifrice|Participants were advised to brush their teeth with experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
62630223|NCT02207400|ACTIVE_COMPARATOR|Reference Dentifrice|Participants were advised to brush their teeth with reference dentifrice containing 1100ppm fluoride as sodium fluoride
62630224|NCT06248814|EXPERIMENTAL|Placebo, followed by BMS-986326 Dose A or Dose B|
62630225|NCT06248814|EXPERIMENTAL|BMS-986326 Dose A, followed by Placebo|
62630226|NCT06248814|EXPERIMENTAL|BMS-986326 Dose B, followed by Placebo|
62630227|NCT03738163|OTHER|Epaderm Cream|This is an open, non randomised single arm study.
62630228|NCT06437509|EXPERIMENTAL|Study treatment|Participants receive BL-B01D1 + PD-1 monoclonal antibody as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62630229|NCT04373317|ACTIVE_COMPARATOR|Pimavanserin 34mg|All participants assigned to pimavanserin will receive the FDA-approved dose of 34mg (equivalent to 40 mg pimavanserin tartrate) daily without titration; however, because pimavanserin is blinded to quetiapine, participants will undergo sham titration based on tolerability.
62630230|NCT04373317|ACTIVE_COMPARATOR|Quetiapine|"Quetiapine extended release will be titrated as shown in the following table. During the 8-week treatment phase, there is a maximum of 6 weeks for titration.~Titration Schedule~Visit/call Quetiapine Dose (Flexible)Quetiapine Notes Baseline visit (Visit 00)25 mg IR QHSAll participants must be up-titrated to at least 50 mg/day at week 1 Week 1 call (Visit 01)50 mg XR QHSUp-titration Week 3 visit (Visit 03)100 mg XR QHS (requiring two 50-mg quetiapine XR capsules)Up- or down-titration as appropriate based on psychosis symptoms and tolerability Week 5 visit (Visit 05)150 mg quetiapine XR QHSUp- or down-titration as appropriate based on psychosis symptoms and tolerability Week 6 call (Visit 06)200 mg quetiapine XR QHSUp- or down-titration as appropriate based on psychosis symptoms and tolerability"
62630231|NCT04034212|EXPERIMENTAL|Singing for Lung Health group|Once weekly attendance at a Singing for Lung Health group for 12 weeks.
62630232|NCT04034212|NO_INTERVENTION|Usual Care group|Usual care group, participants given advice on physical activity while continuing with usual care.
62064188|NCT01704911|EXPERIMENTAL|Transradial Coronary Intervention|Transradial Coronary Intervention
62064189|NCT01704911|EXPERIMENTAL|Transfemoral Coronary Intervention|Transfemoral Coronary Intervention
62064190|NCT05295914||Patient with chronic hepatitis B infection|Patient with chronic hepatitis B infection visited at liver and internal medicine clinic, Siriraj hospital between January 2015-2020
62064191|NCT00608725|OTHER|Patients|Patients with orthostatic intolerance
62064192|NCT00608725|OTHER|Healthy Control Subjects|"Healthy subjects to determine normal response"
62064193|NCT01052909|EXPERIMENTAL|Glimepiride|Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited
62064194|NCT01052909|ACTIVE_COMPARATOR|Amaryl|Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc
62064195|NCT03301090|EXPERIMENTAL|Cohort A|REGN3048+REGN3051 3 mg/kg (1.5 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
62064196|NCT03301090|EXPERIMENTAL|Cohort B|REGN3048+REGN3051 10 mg/kg (5 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
62064197|NCT03301090|EXPERIMENTAL|Cohort C|REGN3048+REGN3051 30 mg/kg (15 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
62064198|NCT03301090|EXPERIMENTAL|Cohort D|REGN3048+REGN3051 50 mg/kg (25 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
62630233|NCT04014218|EXPERIMENTAL|Inhalation sedation|
62630234|NCT04014218|ACTIVE_COMPARATOR|Propofol|
62630235|NCT02300870||Heart Transplant Rejection|Patients presenting with acute cellular rejection
62630236|NCT02300870||Heart Transplant Control|Patients presenting for routine office visit
62630237|NCT01268657|EXPERIMENTAL|Cognitive Behavioral Exposure Therapy|
62064199|NCT03301090|EXPERIMENTAL|Cohort E|REGN3048+REGN3051 100 mg/kg (50 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
62630238|NCT04575441|EXPERIMENTAL|Pilates Ball Exercises|Various exercises are conducted with using pilates ball. Sensory feedbacks like proprioception and vestibulation are given. Many physical fitness parameters like balance, coordination, speed and agility are used in this exercise program. Children are taken to the program for 40 min, twice a week during 6 weeks.
62630239|NCT04575441|NO_INTERVENTION|Without exercise|The children in this group are not included in any kind of exercise/sport program during 6 weeks.
62630240|NCT04233242|EXPERIMENTAL|Intervention|The viral load ≥400 c/mL before enrolment triggers genotypic resistance testing (GRT), followed by GRT-informed patient management and counselling. Onward treatment is informed by the resistance profile determined through GRT, with a GRT Expert Committee issuing a treatment recommendation.
62630241|NCT04233242|NO_INTERVENTION|Control|Standard of care according to national guidelines and recommendations of the World Health Organization: The viral load ≥400 c/mL before enrolment is followed by 3 sessions of enhanced adherence counselling and a follow-up viral load test. Onward treatment is informed by viral load testing.
62630242|NCT05957861|EXPERIMENTAL|web-based exercise|Participants will receive web-based aerobic exercise (AE) training three times per week for 16 weeks.
62630243|NCT05957861|NO_INTERVENTION|control group|control group without any intervention.
62269384|NCT06061861|EXPERIMENTAL|Financial Support and Free Delivery|The intervention group will receive monthly financial support for healthy food items along with free home delivery through the Instacart platform.
62269385|NCT06061861|EXPERIMENTAL|Free Delivery|The control group will receive only free home delivery through the Instacart platform.
62269386|NCT00684788|NO_INTERVENTION|No Intervention|Participants were offered depot naltrexone injections and were not required to take scheduled injections to work.
62269387|NCT00684788|EXPERIMENTAL|Employment-based reinforcement|Participants were offered depot naltrexone injections and were required to take scheduled injections to work.
62269388|NCT04320407|EXPERIMENTAL|Osia 2 System|Osia 2 Active Osseointegrated Implant System for Bone Conduction
62269389|NCT01178775|NO_INTERVENTION|1|control design
62630244|NCT03046953|EXPERIMENTAL|Avelumab|Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days.
62630245|NCT01429298|EXPERIMENTAL|Hydromorphone|2 mg of IV dilaudid will be administered over 2-3 minutes as initial dose.
62269390|NCT01178775|NO_INTERVENTION|2|education only group
62269391|NCT01178775|EXPERIMENTAL|3|education and education and walking program design
62630246|NCT01429298|ACTIVE_COMPARATOR|Usual care|The attending physician administers whatever IV opioid he/she deems appropriate in whatever dose he/she chooses for initial dosing
62269392|NCT02567487|ACTIVE_COMPARATOR|Group Levobupivacaine high volume|TAP block with levobupivacaine 0.25% of 0.5 ml/kg under general anesthesia
62269393|NCT02567487|ACTIVE_COMPARATOR|Group Levobupivacaine low volume|TAP block with levobupivacaine 0.25% of 0.25 ml/kg under general anesthesia
62269394|NCT02209077|EXPERIMENTAL|Healthy Volunteers|OCT performed to collect data from the back of the eye
62269395|NCT02209077|EXPERIMENTAL|Glaucoma group|OCT performed to collect data from the back of the eye
62269396|NCT03500432|ACTIVE_COMPARATOR|periprostatic group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+periprostatic block
62269397|NCT03500432|ACTIVE_COMPARATOR|PAT group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+periapical triangle (PAT) block
62269398|NCT03500432|EXPERIMENTAL|TPA switch group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+TPA switch (transperineal prostate biopsy local anesthesia switch) block
62630247|NCT05434663|EXPERIMENTAL|Treatment Group|
62630248|NCT02130388|OTHER|Renal Insufficiency|Based on creatinine clearance
62630249|NCT02130388|OTHER|Renal Sufficiency|Based on creatinine clearance
62653170|NCT00769561|EXPERIMENTAL|BFB-CBT|"Biofeedback-based cognitive-behavioral treatment:~The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits."
62630250|NCT04323384|EXPERIMENTAL|Biotene® followed by Sham|Recruited volunteers will each participate in two experimental sessions. Participants will be randomized into either Protocol A or Protocol B. In their first session, participants in Protocol A will undergo baseline mastication, swallowing, salivary, and oral health-related quality of life testing, then they will receive the experimental condition. For the experimental condition, participants will be instructed to apply Biotene® Oralbalance Moisturizing Gel according to package directions. Testing will then be repeated. In the second session, after baseline testing, participants will receive the sham condition (instead of the experimental condition). For the sham condition, participants will be instructed to rinse their mouth with room temperature distilled water. Testing will then be repeated.
62630251|NCT04323384|EXPERIMENTAL|Sham followed by Biotene®|Recruited volunteers will each participate in two experimental sessions. Participants will be randomized into two protocols: 1) Protocol A and 2) Protocol B. In their first session, participants in Protocol B will undergo baseline mastication, swallowing, salivary, and oral health-related quality of life testing, then they will receive the sham condition. Testing will then be repeated. In the second session, after baseline testing, participants will receive the experimental condition (instead of the sham condition). Testing will then be repeated.
62630252|NCT05926648|EXPERIMENTAL|Test Subjects|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVENSOR00061
62269399|NCT04212676|EXPERIMENTAL|PR+BAT Group|In addition to the PR program, the BAT will be administered to the experimental group by a physiotherapist with 5 years of experience in BAT for 8 weeks.
62630253|NCT05755646|EXPERIMENTAL|Ice Plant Intensive Cream plus Standard Care|This group receives a 30-minute nursing consultation on the standard treatment and on the use of the Ice Plant Intensive Cream for the prevention of hand-foot syndrome.
62630254|NCT05755646|ACTIVE_COMPARATOR|Standard Care|This group receives a 30-minute nursing consultation on the standard treatment for the prevention of hand-foot syndrome.
62630255|NCT02179047||stable angina, biomarker|patients with stable angina who received coronary angiography.
62630256|NCT02179047||placebo|healthy subject
62064200|NCT03301090|EXPERIMENTAL|Cohort F|REGN3048+REGN3051 150 mg/kg (75 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
62064201|NCT05957302|ACTIVE_COMPARATOR|Ketamine group|bolus of sedation for resuming sedation after sedation vacation
62064202|NCT05957302|ACTIVE_COMPARATOR|Fentanyl group|bolus of sedation for resuming sedation after sedation vacation
62064203|NCT05917223|EXPERIMENTAL|Milk protein ingestion|Consuming 20 g of Milk Protein dissolved in 350mL of water, one time at the experiment visit
62630257|NCT00193414|EXPERIMENTAL|Intervention|Chemotherapy-naïve patients with unresectable stage III/IV NSCLC received pemetrexed 500 mg/m2 IV and gemcitabine 1500 mg/m2 IV every 2 weeks for 8-12 cycles with restaging every 4 cycles. Patients also received supplemental folate/B12 therapy.
62630258|NCT02788721|EXPERIMENTAL|GLPG2451 single dose|Single dose of GLPG2451 oral suspension at up to 4 dose levels in ascending order
62064204|NCT05917223|EXPERIMENTAL|Corn protein ingestion|Consuming 20 g of Corn protein isolation dissolved in 350mL of water, one time at the experimental visit
62064205|NCT05917223|EXPERIMENTAL|Corn+Pea protein ingestion|Consuming 20 g of Corn+Pea protein isolation dissolved in 350mL of water, one time at the experimental visit
62064206|NCT05917223|EXPERIMENTAL|Non-protein, low energy|Consuming 20 g of carbohydrate dissolved in 350mL of water, one time at the experimental visit
62064207|NCT00737412|ACTIVE_COMPARATOR|1|The probiotic Bio-K+ CL1285 RX®
62269400|NCT04212676|ACTIVE_COMPARATOR|PR Group|Patients in the control groups will receive a 30-minute Pulmonary Rehabilitation (PR) program every day of the week for 8 weeks.
62064208|NCT00737412|PLACEBO_COMPARATOR|2|Placebo
62064209|NCT00365378|EXPERIMENTAL|1|HPV 16 L1 VLP vaccine
62064210|NCT00365378|PLACEBO_COMPARATOR|2|Placebo
62064211|NCT03180671|NO_INTERVENTION|Group 1 Control|Counselling with explanation of preventive procedures.
62269401|NCT03475459|EXPERIMENTAL|study drug|Study drug (NPC-15 and/or Placebo ) will be orally administered once with 200 ml of water at 20:00 on the first days of Period I, Period II and Period III.
62630259|NCT02788721|PLACEBO_COMPARATOR|Placebo single dose|Single dose of Placebo oral suspension
62630260|NCT05902871|EXPERIMENTAL|DSLT|Device study assessing safety and effectiveness of DSLT in Chinese Han participants
62630261|NCT05204914|OTHER|Supra glottic airway devices|
62630262|NCT05850702|EXPERIMENTAL|lidocaine|Intervention group
62630263|NCT05850702|PLACEBO_COMPARATOR|saline|control group
62630264|NCT05660252|EXPERIMENTAL|Collaborative request|The patient's relative is approached by the ICU team and an organ procurement coordinator together.
62630265|NCT05660252|NO_INTERVENTION|Routine request|The patient's relative is approached by the clinical team only.
62064212|NCT03180671|ACTIVE_COMPARATOR|Group 2 deprogramer Sliding Guide|Intervention using the Deprogrammer Sliding Guide for 12-15 minutes.
62630266|NCT00738426|ACTIVE_COMPARATOR|Erchonia ML Scanner (MLS)|Red diode low level laser light energy
62630267|NCT00738426|SHAM_COMPARATOR|Sham device|non-therapeutic sham light output
62630268|NCT04057378|ACTIVE_COMPARATOR|0.5 ms pulse width stimulus|Electroconvulsive therapy initiated with 0.5 ms pulse width stimulus
62064213|NCT03180671|ACTIVE_COMPARATOR|Group 3 deprogrammer Dawson B-Splint|Intervention using the Dawson B-Splint for 7 days with breaks for eating/drinking and oral hygiene procedures.
62269402|NCT03482414|ACTIVE_COMPARATOR|traditional wooden checkerboard|upper limb training with traditional wooden checkerboard
62630269|NCT04057378|ACTIVE_COMPARATOR|1.0 ms pulse width stimulus|Electroconvulsive therapy initiated with 1.0 ms pulse width stimulus
62064214|NCT03180671|ACTIVE_COMPARATOR|Group 4 deprogrammer Kois|Intervention using the Kois deprogrammer for 14 days with breaks for eating/drinking and oral hygiene procedures.
62088117|NCT04443920|PLACEBO_COMPARATOR|Placebo Normal Saline (NS)|"All patients will receive 15 mg/kg Tranexamic acid (TXA) IV prior to skin incision. This arm will receive a second intravenous dose of placebo (Normal Saline) in the volume calculated to be equal to the volume of 15 mg/kg of TXA. The medication is delivered from the pharmacy in a masked syringe labeled as study medication."
62088118|NCT00283738|ACTIVE_COMPARATOR|1|
62088119|NCT00283738|PLACEBO_COMPARATOR|2|Sham control
62088120|NCT03822624|EXPERIMENTAL|Probiotic group|
62088121|NCT03822624|PLACEBO_COMPARATOR|Placebo group|
62269403|NCT03482414|EXPERIMENTAL|gaming board with single-player games|upper limb training with a LED-based interactive gaming board equipped with single-player games
62630270|NCT01258478|EXPERIMENTAL|rehabilitation|Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
62630271|NCT01258478|SHAM_COMPARATOR|usual care|Usual care before surgery is provided
62630272|NCT04939649|EXPERIMENTAL|Ketamine|Participants will receive up to a four-week course of twice-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
62630273|NCT04939649|ACTIVE_COMPARATOR|Midazolam|Participants will receive up to a four-week course of twice-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
62630274|NCT00670722||A|
62630275|NCT00670722||B|
62630276|NCT00670722||C|
62630277|NCT00670722||D|
62630278|NCT01516489|NO_INTERVENTION|Stage 1 Control Group|In the FOBT kit, individuals will receive a card that asks them to complete and return their FOBT kit within 30 days.
62630279|NCT01516489|EXPERIMENTAL|$5 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $5 at PVAMC.
62630280|NCT01516489|EXPERIMENTAL|$10 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $10 at PVAMC.
62088122|NCT05439265||Prior to 11/01/2014|Group prior to the implementation of an electronic medical record order panel and pharmacy resident involvement
62269404|NCT03482414|EXPERIMENTAL|gaming board with two-player games|upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games
62269405|NCT06061549|EXPERIMENTAL|SRD-001 Gene Therapy|AAV1/SERCA2a 3E13 vg
62269406|NCT03490305||Combatants|Men 16-50 years old or combatants by own admission.
62630281|NCT01516489|EXPERIMENTAL|$20 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $20 at PVAMC.
62630282|NCT01516489|EXPERIMENTAL|$5 Voucher-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $5 at PVAMC.
62630283|NCT01516489|EXPERIMENTAL|$50 Lottery-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will have a 1 in 10 chance of being mailed a voucher that can be exchanged for $50 at PVAMC.
62630284|NCT01516489|EXPERIMENTAL|$500 Raffle-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be entered into a raffle in which 1 randomly chosen patient (out of about 100 patients) will be mailed a check in the amount of $500.
62630285|NCT01516489|NO_INTERVENTION|Stage 2 Control Group|In the FOBT kit, individuals will receive a card that asks them to complete and return their FOBT kit within 30 days.
62630286|NCT00000311|EXPERIMENTAL|1|Methadone + CM (contingency management)
62630287|NCT00000311|EXPERIMENTAL|2|methadone + VC (voucher control)
62630288|NCT00000311|EXPERIMENTAL|3|Buprenorphine + CM
62630289|NCT00000311|EXPERIMENTAL|4|Buprenorphine + VC
62630290|NCT04973657|EXPERIMENTAL|VK0214 Active 20mg|20mg QD
62630291|NCT04973657|EXPERIMENTAL|VK0214 Active 40mg|40mg QD
62630292|NCT04973657|PLACEBO_COMPARATOR|Placebo|Placebo QD
62630293|NCT06203158||High fucosylation group|Immunohistochemistry was used to detect the fucosylation level in the intestinal tissue biopsy of patients with Crohn's disease at baseline. The fucosylation level in the baseline intestinal tissue was higher than 50% of the total.
62630294|NCT06203158||Low fucosylation group|Immunohistochemistry was used to detect the fucosylation level in the intestinal tissue biopsies of patients with Crohn's disease at baseline. The fucosylation level in the baseline intestinal tissue was less than 50% of the total.
62630295|NCT05833919|EXPERIMENTAL|ARM A|Second line Eribulin 1.23 mg/m2 i.v. on day 1, 8 every 21 days followed by third line Capecitabine 1250 mg/m2 orally twice per day on days 1 to 14 every 21 days.
62630296|NCT05833919|EXPERIMENTAL|ARM B|Second line Capecitabine 1250 mg/m2 orally twice per day on days 1 to 14 every 21 days; followed by third line Eribulin 1.23 mg/m2 i.v. on day 1, 8 every 21 days.
62630297|NCT03112070|EXPERIMENTAL|Water aerobic exercise session (WATER)|A continuous session of dynamic water aerobic exercise which consist of a dynamic warm-up period (5 minutes), an active exercise period (35 minutes), and a cooldown period (5 minutes) to total 45 minutes. Heart rate (HR) will be continuously measured with heart monitors (Polar) to confirm the intensity of the WATER session. The WATER intensity will be calculated according to the formula proposed by Kruel for exercise in an aquatic environment18 as follows: HR for exercise = % x (HRmax - ΔHR); % is the intensity of exercise; HRmax is the maximum HR (estimated by 220 - age); ΔHR represents the difference between resting HR on land and resting HR in the water environment. Exercise intensities: 55-60% HRmax during warm-up; 70-75% HRmax during active exercise; and 55-60% HRmax during cooldown.
62630298|NCT03112070|NO_INTERVENTION|Control session (CONTROL)|A 45-min session with no exercise. During this session, participants will remain seated or standing as desired. They will read, talk, and drink water, but do nothing else.
62630299|NCT05438342|EXPERIMENTAL|synchronized hyperthermia autologous progenitor expansion -T (SHAPE-T)|Besides NCCN guideline recommended systemic anti-cancer treatment( chemotherapy /anti-PD-1 immmunotherapy/targeted therapy), combined with autoimmune cell therapy combined and noninvasive electromagnetic wave hyperthermia
62630300|NCT05438342|ACTIVE_COMPARATOR|systemic anti-cancer treatment plus Hyperthermia|BesidesNCCN guideline recommended systemic anti-cancer treatment( chemotherapy /anti-PD-1 immmunotherapy/targeted therapy), combined with noninvasive electromagnetic wave hyperthermia
62630301|NCT05438342|ACTIVE_COMPARATOR|systemic anti-cancer treatment|Only apply NCCN guideline recommended systemic anti-cancer treatment ( chemotherapy /anti-PD-1 immmunotherapy/targeted therapy)
62630302|NCT05430802|EXPERIMENTAL|Furmonertinib plus cisplatin/pemetrexed|furmonertinib 80mg/d for 9 weeks and cisplatin 75mg/m2 d1 iv + pemetrexed 500mg/m2 d1 iv at 21 day cycles for 3 cycles
62630303|NCT05324449|OTHER|treatment arm|open label treatment intervention
62630304|NCT04354818||People living with HIV|
62630305|NCT04354818||Recipients of Solid Organ Transplants|
62630306|NCT04354818||People Living with Cancer|
62630307|NCT04354818||People with acquired immunodeficiency|Patients with acquired immunodeficiency associated with other immunosuppressive therapy.
62630308|NCT04354818||People with primary immunodeficiency|
62630309|NCT05182801|PLACEBO_COMPARATOR|Placebo sachet|
62630310|NCT05182801|EXPERIMENTAL|Banana flower extract sachet|
62630311|NCT02494895|EXPERIMENTAL|Ticagrelor monotherapy|Ticagrelor monotherapy at 3 months after PCI
62630312|NCT02494895|ACTIVE_COMPARATOR|Ticagrelor with Aspirin|Ticagrelor with Aspirin DAPT(Dual Anti-platelet Treatment)
62630313|NCT02799017|EXPERIMENTAL|Intensive Phonology Treatment|"The participants in the experimental group will receive an hour of phonology treatment, an hour of group therapy, and an hour of reading. They will work on writing, generative naming during group time focusing on self-cueing with the sounds they learn during the individual session. They will be read to or read aloud depending on their level.~The participants in the experimental group will be taught all consonants and vowels over the course of 16 weeks."
62630314|NCT02799017|ACTIVE_COMPARATOR|Intensive SFA Treatment|The participants in the control group will receive an hour of individual therapy, an hour of reading and an hour of group therapy in a traditional setting. They will work on writing, generative naming during group time following the semantic feature analysis to retrieve the name.They will be read to or read aloud depending on their level.
62269407|NCT03490305||Civilians|Children \<16 years, all women and men ≥50 years.
62630315|NCT06605846|EXPERIMENTAL|Otago exercise training|This group included 52 patients receive Otago exercise training for 45 minutes after each session with routine medical care for prostatic cancer patients
62630316|NCT06605846|SHAM_COMPARATOR|control|This group included 52 patients receive routine medical care for prostatic cancer patients.
62630317|NCT03273920|EXPERIMENTAL|Robotic gastrectomy|Robotic distal gastrectomy with D2 nodal dissection
62630318|NCT03273920|ACTIVE_COMPARATOR|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 nodal dissection
62630319|NCT02989402|EXPERIMENTAL|Rivastigmine patch|15 cm\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day
62630320|NCT03944213||MDD patients|
62630321|NCT03944213||Healthy controls|
62630322|NCT04543175||Chemotherapy breast cancer patients|Newly diagnosed breast cancer patients (clinical stages IA, IIA, IIB, IIIA and IIIB) before and after chemotherapy with the following drugs (Doxorubicin + Cyclophosphamide (DC) or Paclitaxel + Carboplatin (PC) or Docetaxel were followed until they complete four cycles of chemotherapy.
62630323|NCT01451918|ACTIVE_COMPARATOR|Resveratrol|
62630324|NCT01451918|PLACEBO_COMPARATOR|Placebo|
62064215|NCT05487430|EXPERIMENTAL|Intervention Group|"Self-affirmation audio recording included 40 positive sentences in order to increase the sensation of well-being of the patients. Some examples are:~1. Now I have decided to think more positively.~2. I am in control of my thoughts.~3. I am completely relaxed.~4. I am strong, and I am aware of my strength.~5. I can be comfortable and positive in any situation.~6. I love myself as I am and accept myself for who I am.~7. I know very well how to relax.~8. All my muscles relax with every deep breath I take.~9. I leave myself in peace.~10. I am a relaxed, joyful, and happy person.~11. I am calm at all times and in all situations.~12. I know that everything that happens in my life happens for my own good.~13. I am very good at relaxing.~14. My life energy is rising.~15. I am surrounded by positive energy.~In the background of the recording there were sounds of birds crowing and river-like flowing water together for increasing the effect of relaxation."
62064216|NCT05487430|NO_INTERVENTION|Control Group|The participants of the control group only received the conventional care given in the inpatient clinic.
62064217|NCT03648125|OTHER|Rowing training session|"Power tests, balance and tonicity tests are performed eyes opened and eyes closed :~* with artificial occlusal disturbance and~* without artificial occlusal disturbance"
62064218|NCT02230436|EXPERIMENTAL|Early drain removal|Removing drain(s) on postoperative day 3 (n = 72)
62064219|NCT02230436|EXPERIMENTAL|Late drain removal|Removing drain(s) on postoperative day 4 or later (n = 72)
62269408|NCT02883946||hairy-cell leukemia|Patients with hairy-cell leukemia.
62630325|NCT05060991|EXPERIMENTAL|Immunosuppression reduction|Reduction of immunosuppression before and after administration of a third dose of SARS-CoV-2 mRNA vaccine
62630326|NCT05060991|NO_INTERVENTION|Standard of care|No change to immunosuppression before or after receipt of a third dose of SARS-Co-2 mRNA vaccine
62630327|NCT04410471||Liver transplant patient after having Covid19|Adult Liver transplant patient who had survived to Covid19 in the first wave of the disease in Spain (disease until june 30th), in all the liver Transplant Units in Spain (24).
62630328|NCT04410471||No immunosuppressed patient with previous Covid19|Not immunosuppressed patient who had survived to Covid19 in the first wave of the disease. These patient have been diagnosed and treated in the Hospital Gregorio Marañón (Madrid), before 30th June
62630329|NCT00956332|EXPERIMENTAL|MGA - Low therapeutic dose|
62630330|NCT00956332|EXPERIMENTAL|MGA - Intermediate therapeutic dose|
62064220|NCT04731415|OTHER|Healthy pregnant women|Optical coherence tomography and Optical coherence tomography angiography using Optovue® were performed in each trimester and at 6 weeks after childbirth.
62064221|NCT03746184||Knee osteoarthritis|Treatment course
62064222|NCT05441618||Lyoplant®|Lyoplant® is a pure collagen implant obtained from bovine pericardium. The membrane is used for the replacement and extension of connective tissue structures in neurosurgery.
62064223|NCT03446300||college student population|
62064224|NCT03446300||working population|
62064225|NCT03446300||aged more than 50 years old population|
62088123|NCT05439265||After 11/30/2014|Group after implementation of an electronic medical record order panel and pharmacy resident involvement
62088124|NCT00185367|EXPERIMENTAL|Arm 1|
62088125|NCT00185367|ACTIVE_COMPARATOR|Arm 2|
62269409|NCT06428578|EXPERIMENTAL|FBM-In person|
62269410|NCT06428578|EXPERIMENTAL|FBM-Virtual|
62269411|NCT06428578|ACTIVE_COMPARATOR|home delivered food|
62630331|NCT03958188||Patients|"Patients who have undergone pre-operated computerized tomography (CT) imaging for a subsequently operated Neuro-endocrine tumor (NET).~Clinical data collected for each patients:~* Age~* Sex~* Symptomatology (abdominal pain, diarrhea, carcinoid flush, digestive bleeding, weight loss, occlusive syndrome)~* Blood Chromogranine A and urinary 5-hydroxyindoleacetic acid (5-HIAA)~* Carcinoid valvulopathy"
62630332|NCT06007846|EXPERIMENTAL|Arm 1|
62630333|NCT02908984|EXPERIMENTAL|Specific neck rehabilitation|The intervention includes specific neck rehabilitation as described by Jull and Falla over a period of 4 weeks and recommendations for further training.
62630334|NCT02908984|ACTIVE_COMPARATOR|Standard primary health care|This represents individualized therapy administered by the primary physician.
62630335|NCT03905941|EXPERIMENTAL|Metformin then oral combined hormonal contraceptives|Subjects will take metformin 2000 mg/day for the first 6 months, followed by 6 months of oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg.
62630336|NCT03905941|ACTIVE_COMPARATOR|Oral combined hormonal contraceptives then metformin|Subjects will take oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg for the first 6 months, followed by 6 months of metformin 2000 mg/day.
62630337|NCT04649086|EXPERIMENTAL|Eccentric group|The experimental group (eccentric) will perform 5 habituation sessions: the initial power of the exercise will be set to 10 Watts and then increased by 10% each session, depending on the muscle tolerance. The training power must correspond to 3 times that of the control group to obtain a similar metabolic stimulation and will be adapted according to the pain felt at the end of the session.
62064226|NCT03274154|EXPERIMENTAL|Pre-Hyaluron 465 Innēov|43 caucasian female subjects have taken during a meal, for the first 4 months of trial,1 capsule and 1 tablet/die of the food supplement composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese) .
62064227|NCT03274154|NO_INTERVENTION|Untreated group|23 caucasian female subjects untreated
62064228|NCT04082520|EXPERIMENTAL|Treatment (gallium Ga 68-DOTATATE PET/MRI, Lutathera)|Patients receive gallium Ga 68-DOTATATE IV and undergo a PET/MRI or PET/CT before cycles 1 and 4. Patients then receive lutetium Lu 177 dotatate IV over 30-40 minutes. Treatment repeats every 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo MRI on study and during follow-up, as well as blood sample collection and possible SEPCT/CT dosimetry on study.
62088126|NCT03664323||Group 1 Sequential strategy|Patients for whom anti-PD-1 therapy was stopped with the introduction of a new treatment line (19 patients, 63%).
62630338|NCT04649086|ACTIVE_COMPARATOR|Concentric group|The control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test. The power will be adjusted weekly to stay within the target heart rate range.
62630339|NCT02482142|PLACEBO_COMPARATOR|phosphorus alone|Effect of phosphorus (500mg) ingestion alone. No meal. Needed to determine the impact of phosphorus alone on DIT
62630340|NCT02482142|PLACEBO_COMPARATOR|high CHO meal alone|Ingestion of placebo tablets with the high carbohydrate meal
62630341|NCT02482142|ACTIVE_COMPARATOR|High CHO meal plus phosphorus|Effect of phosphorus (500mg) tablets ingestion of DIT of the high carbohydrate meal
62088127|NCT03664323||Group 2 Concomitant strategy|Patients for whom a combination of CT with anti-PD-1 therapy was initiated (11 patients, 37 %).
62088128|NCT00394511|EXPERIMENTAL|Arm I|Radiotherapy. Irradiation of the prostatic bed using megavoltage equipment with effective photon energies of greater than 4 MV.
62088129|NCT00394511|NO_INTERVENTION|Arm II|No further treatment.
62630342|NCT02482142|ACTIVE_COMPARATOR|High protein meal plus phosphorus|Effect of phosphorus (500mg) tablets ingestion of DIT of the high protein meal
62630343|NCT02482142|PLACEBO_COMPARATOR|High protein meal alone|Ingestion of placebo tablets with the high protein meal
62630344|NCT05973461|EXPERIMENTAL|Cycle Ergometer and Virtual Reality|30 min ride on cycle ergometer while viewing neighborhood scenes using virtual reality
62630345|NCT05973461|EXPERIMENTAL|Cycle Ergometer|30 min ride on cycle ergometer
62630346|NCT06215066|ACTIVE_COMPARATOR|Modified Progressive Muscle Relaxation Group (MPMR)|
62630347|NCT06215066|ACTIVE_COMPARATOR|Virtual Reality Group (VR)|
62088130|NCT03637595|ACTIVE_COMPARATOR|Positive Control Group|Acupuncture
62088131|NCT03637595|SHAM_COMPARATOR|Negative Control Group|Sham Intervention
62630348|NCT01854697|EXPERIMENTAL|Arm A: 3-DAA + RBV in GT1a|ABT-450/r/ABT-267 150 mg/100 mg/25 mg once daily (QD) and ABT-333 250 mg twice daily (BID) and weight-based RBV for 12 weeks (3 direct-acting antivirals \[DAAs\] with RBV in GT1a)
62630349|NCT01854697|ACTIVE_COMPARATOR|Arm B: TPV/PR in GT1a|Telaprevir (TPV) 750 mg every 8 hours (q8h) and pegIFN 180 µg/week and weight-based RBV (PR) for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1a)
62630350|NCT01854697|EXPERIMENTAL|Arm C: 3-DAA + RBV in GT1b|ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID and weight-based RBV for 12 weeks (3 DAAs with RBV in GT1b)
62630351|NCT01854697|EXPERIMENTAL|Arm D: 3-DAA in GT1b|ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID for 12 weeks (3 DAAs without RBV in GT1b)
62630352|NCT01854697|ACTIVE_COMPARATOR|Arm E: TPV/PR in GT1b|Telaprevir 750 mg q8h and pegIFN 180 µg/week and weight-based RBV for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1b)
62630353|NCT05138601|NO_INTERVENTION|Usual Care with Education|The participant will be provided with educational material and a home BP monitor. Control participants will continue to see their physicians for their usual care for BP management (their BP data will not be reviewed by pharmacists and the patients will not have support from vCCC pharmacists)
62630354|NCT05138601|EXPERIMENTAL|Virtual Collaborative Care Clinic|Participants will partake in the virtual collaborative care clinic
62630355|NCT05772676|EXPERIMENTAL|Aprepitant|Aprepitant (80 or 125 mg) + Ondansetron 8 mg + Metoclopramide 10 mg + Dexamethasone 8 mg
62630356|NCT05772676|PLACEBO_COMPARATOR|Placebo|Placebo + Ondansetron 8 mg + Metoclopramide 10 mg + Dexamethasone 8 mg
62630357|NCT05513846||Meditation|This is the group that will have learned at least Shamhbavi Mahamudra Kriya before they are enrolled in the study.
62630358|NCT05513846||Control|This is the group that will not have learned Shambhavi Mahamudra Kriya before they are enrolled in the study. They will be invited to the study by the Meditation group.
62630359|NCT01013714|ACTIVE_COMPARATOR|Routine Care + Cardiac Sympathetic Denervation (CSD)|"Patients in this arm receive routine care and undergo cardiac sympathetic denervation. The procedure must be scheduled to occur within one month of randomization.~Follow-up Visits~* Follow up at 4 weeks after optimization of medical therapy and surgery~* All patients are followed at the ICD clinic at 7 months or as needed.~* Information regarding ICD therapy and arrhythmias will be obtained from ICD interrogations at the follow up visits.~* Monthly phone calls will be used to determine for interval events, including presence of side-effects.~VT Ablation is permitted in both arms for ICD shock after optimization."
62088132|NCT03637595|EXPERIMENTAL|Energy Medicine (EM) Intervention|Energy Medicine by an energy medicine practitioner
62630360|NCT01013714|PLACEBO_COMPARATOR|Routine Care|"Patients in this arm remain on prescribed drug regimen and will not undergo CSD.~Follow-up Visits~* Medical follow up at 4 weeks after optimization of medical therapy.~* All patients are followed at the ICD clinic at 7 months or as needed.~* Information regarding ICD therapy and arrhythmias will be obtained from ICD interrogations at the follow up visits.~* Monthly phone calls will be used to determine for interval events, including presence of side-effects.~VT Ablation is permitted in both arms for ICD shock after optimization."
62630361|NCT03416192|EXPERIMENTAL|MCO-HD|Hemodialysis with Medium Cut-Off filter
62630362|NCT03416192|ACTIVE_COMPARATOR|High-flux HDF|Hemodiafiltration with standard high-flux filter
62630363|NCT02581488|EXPERIMENTAL|Santyl|Collagenase ointment applied topically once per day for up to six weeks.
62630364|NCT02581488|ACTIVE_COMPARATOR|Product containing silver|Products containing silver will be applied per Investigator instructions and instructions for use/package insert for up to six weeks.
62630365|NCT03019991|EXPERIMENTAL|PK Group (Danoprevir,Ritonavir)|Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14;100mg BID on day 5 -day 13; Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13;
62630366|NCT03019991|PLACEBO_COMPARATOR|Placebo Group|ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13; Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13 for 14 days;
62630367|NCT04611568|EXPERIMENTAL|Prevention (health educational campaign)|"MEDIA CAMPAIGN: Participants view digital media strategies.~PRIMARY CARE PROVIDERS AND PROFESSIONALS: Primary care providers and professionals who see skin and potential melanomas receive online based curriculum on melanoma. Participants also complete a survey to assess knowledge and confidence before and after receiving the curriculum.~MELANOMA COMMUNITY REGISTRY VOLUNTEERS: Melanoma Community Registry volunteers in Oregon receive educational and training materials on melanoma. Participants also complete a survey before and after receiving educational material.~HIGH SCHOOL STUDENTS: High school students receive an educational lecture over 1 hour on sun-safety and early detection of melanoma practices. Participants also complete a survey before and after the educational lecture."
62088133|NCT05696418|EXPERIMENTAL|Mobile Bearing Design TKA|Patients who were randomized to receive the PFC Sigma Mobile Bearing TKA system
62088134|NCT05696418|EXPERIMENTAL|Fixed Bearing Design TKA|Patients who were randomized to receive the PFC Sigma Fixed Bearing TKA system
62630368|NCT06079749||Simultaneous BTKA|Simultaneous BTKA
62630369|NCT06079749||Staged BTKA|Staged BTKA
62630370|NCT03571607|EXPERIMENTAL|13-valent pneumococcal conjugate vaccine|
62088135|NCT01365520|EXPERIMENTAL|N8|
62630371|NCT03215875|EXPERIMENTAL|Fed- 60mg ER Torsemide|Adult healthy subjects will be given standardized high-fat, high-calorie meal prior to dosing
62630372|NCT03215875|EXPERIMENTAL|Fasting- 60mg ER Torsemide|Adult healthy subjects will fast overnight (at least 10h) prior to dosing
62630373|NCT05450913|OTHER|patients with unilateral hip and leg pain|"Musculoskeletal system examination, neurological examination, visual analog scale (VAS) score and DN4 (Douleur Neuropathique 4 Questions) of patients presenting with unilateral hip and/or leg pain, 3 tests frequently used in the diagnosis of priformis (Freiberg test, Pace sign, FADIR) ) will be applied.~Patients with suspected priformis syndrome will be given an intramuscular injection If the pain intensity decreases by 50% or more after the intramuscular injection, the diagnosis of piriformis will be made."
62630374|NCT01228656|EXPERIMENTAL|-mometasone furoate associated with salicylic acid|
62088136|NCT00401466|EXPERIMENTAL|1|Prolonged follow-up intervals every 12 months
62630375|NCT01228656|ACTIVE_COMPARATOR|-mometasone furoate|
62088137|NCT00401466|ACTIVE_COMPARATOR|2|Standard follow-up intervals of 3 months
62088138|NCT00798395|EXPERIMENTAL|Treatment 1|
62088139|NCT00798395|EXPERIMENTAL|Treatment 2|
62088140|NCT00798395|PLACEBO_COMPARATOR|Treatment 3|
62088141|NCT00798395|ACTIVE_COMPARATOR|Treatment 4|
62088142|NCT04374617||Venous thromboembolism|Patients at risk of venous thromboembolism (deep venous thrombosis and/or pulmonary embolism)
62088143|NCT00911963|EXPERIMENTAL|Part A|This will be a 4 dose escalation study comparing VCH-222 to placebo treatment.
62630376|NCT00907023||SOT|Patients that have had a solid organ transplant
62088144|NCT00911963|EXPERIMENTAL|Part B|VCH-222 + peginterferon alfa-2a + ribavirin (12 weeks) followed by peginterferon alfa-2a + ribavirin for 36 weeks
62451996|NCT02200965|ACTIVE_COMPARATOR|Received a letter on 3 occasions|"My Diabetes, My Information, My Plan Document:~To deliver a structured, understandable, well designed, user friendly, user developed and approved document / letter to all people with diabetes that contains all information about their key care processes in diabetes to promote self-awareness, patient activation and process completion of their own diabetes outcomes.~This communication (3 mailings per patient (at 0 and 3 and 6 months) will be distributed to the 50% of the whole epidemiological base of people with diabetes (n=\>16,000) with the non-interventional group (that will receive the same document once at 3 months) acting as control."
62451997|NCT02200965|ACTIVE_COMPARATOR|Received letter on 1 occasion|"My Diabetes, My Information, My Plan Document:~To deliver a structured, understandable, well designed, user friendly, user developed and approved document / letter to all people with diabetes that contains all information about their key care processes in diabetes to promote self-awareness, patient activation and process completion of their own diabetes outcomes.~This communication (3 mailings per patient (at 0 and 3 and 6 months) will be distributed to the 50% of the whole epidemiological base of people with diabetes (n=\>16,000) with the non-interventional group (that will receive the same document once at 3 months) acting as control."
62630377|NCT06312800|EXPERIMENTAL|Acamprosate|Commercially available Acamprosate 333 mg tablets will be administered three times daily. Subjects will be started with one tablet with breakfast for 3 days, then one tablet with breakfast and dinner for 3 days, then one tablet 3 times a day for the next 15 days. Intervention order of medication trials will be determined by biostatistician.
62630378|NCT06312800|ACTIVE_COMPARATOR|Placebo|Placebo tablets are not available from the manufacturer for either of these drugs which are marketed as white tablets about the size of an aspirin tablet. Custom made placebo tablets will be purchased that are about that size. While not ideal , the extent of disguising the drug identity should be adequate with this. The placebo tablets will be administered three times daily. Subjects will be started with one tablet with breakfast for 3 days, then one tablet with breakfast and dinner for 3 days, then one tablet 3 times a day for the next 15 days. Intervention order of medication trials will be determined by biostatistician
62630379|NCT06312800|EXPERIMENTAL|Methazolamide|Commercially available methazolamide 50 mg tablets will be administered three times daily. Subjects will be started with one tablet with breakfast for 3 days, then one tablet with breakfast and dinner for 3 days, then one tablet 3 times a day for the next 15 days. Intervention order of medication trials will be determined by biostatistician
62630380|NCT04443647|EXPERIMENTAL|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
62630381|NCT04443647|PLACEBO_COMPARATOR|Placebo|Saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
62630382|NCT04195178||Anesthesia Providers|Clinically active anesthesia providers
62630383|NCT02894814|ACTIVE_COMPARATOR|Basic intervention|Elements of One-Stop Dispensing (use of own medication, placed in bedside locker, partly or self-administration of medication during hospitalization)
62630384|NCT02894814|ACTIVE_COMPARATOR|Extended intervention|Elements of One-Stop Dispensing and focused dialogue with the patients about their medication during the hospitalization.
62630385|NCT02894814|NO_INTERVENTION|Observational part of the study|Data collection on patients under the traditional medication system
62630386|NCT04878055|EXPERIMENTAL|Reparixin|Reparixin oral tablets, 1200 mg three times daily (TID) (2 tablets 600 mg each, TID) for up to 21 days or until decision of discharge from the hospital, on top of standard supportive care
62630387|NCT04878055|PLACEBO_COMPARATOR|Placebo|placebo, 2 tablets TID (identical to Reparixin tablets) for up to 21 days or until decision of discharge from the hospital, on top of standard supportive care.
62630388|NCT06612619|NO_INTERVENTION|One-on-one instruction to simulation-based training|The usual instruction with one instructor instructing the trainee in simulation-based training in osteosynthesis of proximal femoral fractures
62630389|NCT06612619|ACTIVE_COMPARATOR|Dyad instruction|Dyad or two-on-one instruction, where two trainees are instructed by an instructor at the same time and with the same time usage as in the non-intervention arm.
62451998|NCT03777033|NO_INTERVENTION|Control Group|Patients after thyroidectomy will be managed as usual. Oral or IV supplements of Calcium will be giver on demand and recorded according to the clinical picture or the biochemical hypocalcaemia.
62451999|NCT03777033|EXPERIMENTAL|Study group|Intervention: the patients will be given prophylactically ca and vit D. Patients after thyroidectomy will be given systematically from the day of operation a scheme with oral calcium in the form of 1000ca++mg/tab and oral alfacalcidol in the form of 0.5 micrograms/tb Intervention: The patients will receive one tablet three times a day oral calcium (3g/d) and 2 tablets , two times a day alfacalcidiol (2 micrograms/d) for the first 5 days. Afterwards they will be taking 2 tablets a day of oral calcium ( 2g) and 2 tablets a day alfacalcidiol (1micrograms/d) for another 10 days ( total 15 days)
62452000|NCT05510648|ACTIVE_COMPARATOR|High-intensity laser therapy|A total of 15 sessions of hotpack, TENS and exercise program will be applied to the patients for three weeks, 5 days a week, 1 session a day. The hotpack, which is used as a superficial heater, is applied to the knee area for 30 minutes, wrapped in two layers of towels. As analgesic current, conventional TENS is applied to the knee area for 30 minutes with 4 electrodes at 80 Hz frequency, 200 ms current duration. Flow intensity is adjusted according to the patient's tolerance, and the current intensity is increased as the patient's sense of current decreased in the following periods. HILT is applied in analgesic mode for 3 sessions every other day in the first week, and 6 sessions every other day in the biostimulant mode for the next two weeks, for a total of 9 sessions for three weeks.
62630390|NCT01773603|NO_INTERVENTION|Conventional incubation|Five-day embryo culture in conventional incubators
62630391|NCT01773603|ACTIVE_COMPARATOR|Embryoscope|Five-day embryo culture in embryoscope which is an incubator with a built-in camera
62630392|NCT05947669|ACTIVE_COMPARATOR|Standard of care - Methylprednisolone|Subjects are hospitalised Day 1 and for at least 4 days. It is accepted that participating centres handle the subjects on an outpatient basis as long as all study requirements are met. Methylprednisolone 80 mg intravenously (body weight 40-80 kg; methylprednisolone 1 mg/kg if body weight \< 40 or \> 80 kg) will be administered from Day 1 until mCTCAE ir-colitis/diarrhoea grade ≤ 2 and hereafter converted to oral prednisolone. During tapering, if ir-colitis/diarrhoea increases from grade 2 to ≥ grade 3, or from grade \< 2 to ≥ grade 2, re-assessment including diagnostic workup will be performed, and the patient will be evaluated for rescue infliximab.
62630393|NCT05947669|EXPERIMENTAL|Treatment with infliximab|Infliximab will be administered Day 1 or latest Day 2 (within 48 hours). Infliximab infusion is handled as standard by skilled staff. A second dose of infliximab will be administered if ir-colitis/diarrhoea has not resolved to grade ≤ 2 on Day 7. Methylprednisolone 80 mg (body weight 40-80 kg; methylprednisolone 1 mg/kg if body weight \< 40 or \> 80 kg) intravenously is co-administered from Day 1 until mCTCAE ir-colitis/diarrhoea grade ≤ 2 and hereafter converted to oral prednisolone. Initial dosage of infliximab is 5 mg/kg. Dosage of infliximab for subjects referred to a second dose of infliximab will be left to the discretion of the treating physician. In the event of failure of infliximab, second line biological immunosuppressant treatment will also be left to the discretion of the treating physician.
62630394|NCT06311461|EXPERIMENTAL|Acupuncture|Participants in the acupuncture group will receive a standardized Traditional Chinese Medicine (TCM) point prescription. Acupuncture will be administered 2 times per week for 5 weeks for a total of 10 treatments.
62630395|NCT06311461|ACTIVE_COMPARATOR|Attention Control Group|The attention control group will view non-pain related TED talk videos over 5 weeks approximately equal to 10 hours of treatment for the acupuncture group.
62630396|NCT01004978|EXPERIMENTAL|Arm I (sorafenib tosylate and TACE)|Patients receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of sorafenib tosylate is reached, patients undergo TACE comprising doxorubicin hydrochloride, mitomycin C, and cisplatin (closed to accrual as of 10/1/2010); conventional chemoembolization comprising doxorubicin hydrochloride only; or chemoembolization comprising doxorubicin-eluting beads. Treatment with TACE repeats approximately every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI on study.
62630397|NCT01004978|ACTIVE_COMPARATOR|Arm II (placebo and TACE)|Patients receive placebo PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of placebo is reached, patients undergo TACE as in Arm I. Patients also undergo CT and MRI on study.
62630398|NCT02710084|EXPERIMENTAL|Oxytocin|The first phase of the study will follow a double-blind, placebo-controlled design. Participants randomized to the experimental group will receive intranasal oxytocin in doses of 24 IU, two times daily, for a total of 48 IU. Doses may be reduced by 8 IU/day if safety concerns emerge. During the second phase of the study, all participants will receive oxytocin, in identical doses.
62630399|NCT02710084|PLACEBO_COMPARATOR|Saline|During the first phase, patients randomized to the placebo group will receive intranasal saline solution in doses of 24 IU two times daily, for a total of 48 IU. During the second phase of the study, all participants will receive oxytocin, in identical doses.
62630400|NCT01968811|EXPERIMENTAL|Avance foam, abdominal dressing kit|
62630401|NCT02912312|EXPERIMENTAL|Arm I: Hypofractionated Regional Nodal Irradiation (RNI)|Patients undergo hypofractionated RNI in 15 fractions 5 consecutive days a week for 3 weeks. Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
62630402|NCT02912312|ACTIVE_COMPARATOR|Arm II: Standard Regional Nodal Irradiation (RNI)|Patients undergo standard RNI in 25 fractions 5 consecutive days a week for 5 weeks. Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
62286842|NCT01868984|ACTIVE_COMPARATOR|Standard Therapy Plus Paclitaxel|"Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (\>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).~For this treatment group, Paclitaxel solution treatment of each lesion encountered from proximal to distal will be attempted until the 20 mg Paclitaxel dose limit is met."
62630403|NCT04179279||Pilot|
62630404|NCT04179279||Pivotal|
62630405|NCT06452602|EXPERIMENTAL|Induction Immunochemotherapy|
62286843|NCT05107167|EXPERIMENTAL|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve.
62286844|NCT02849756||older in intensive care unit|older (age superior at 85 years) hospitalized in intensive care unit. A follow-up until 6 months after hospitalization will determine the evolution of the quality of life and others secondary outcomes.
62452001|NCT05510648|SHAM_COMPARATOR|Sham high-intensity laser therapy|Hotpack, TENS and exercise program applications will be applied to the patients in the same way as in the HILT group, 5 days a week, 1 session a day, a total of 15 sessions for three weeks. HILT is administered as a placebo for three weeks, 3 sessions a week, every other day, for a total of 9 sessions.
62452002|NCT02035709|ACTIVE_COMPARATOR|TCI-PCA|Intravenous Patient-Controlled Analgesia with Target-Controlled Infusion
62452003|NCT02035709|ACTIVE_COMPARATOR|PCA|Intravenous Patient-Controlled Analgesia
62452004|NCT03601663|EXPERIMENTAL|Group 1|Participants in the main experimental group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity, a wearable activity tracker to support self-monitoring, and autonomy-support delivered through weekly emails to help enhance motivation for physical activity.
62452005|NCT03601663|ACTIVE_COMPARATOR|Group 2|Participants in this comparison group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity, and a wearable activity tracker to support self-monitoring. They will not receive any specific support to enhance motivation for physical activity.
62452006|NCT03601663|ACTIVE_COMPARATOR|Group 3|Participants in this information-only comparison group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity.
62452007|NCT05838066|EXPERIMENTAL|KN026+HB1801|Subjects will receive an intravenous (IV) infusion of KN026 plus HB1801. All subjects are required to receive study treatment as planned until investigator-assessed loss of benefit, toxic intolerance, withdrawal of consent, loss to follow-up, or death, whichever occurrs first.
62452008|NCT05838066|ACTIVE_COMPARATOR|Trastuzumab + Pertuzumab + Docetaxel|On Day 1 of each 21-day cycle, patients will receive an intravenous (IV) infusion of Pertuzumab 840 mg loading dose followed by 420 mg per cycle, IV, D1, Q3W, in combination with trastuzumab 8 mg/kg loading dose followed by 6 mg/kg per cycle, IV, D1, Q3W and docetaxel 75 mg/m\^2. All subjects are required to receive study treatment as planned until investigator-assessed loss of benefit, toxic intolerance, withdrawal of consent, loss to follow-up, or death, whichever occurred first.
62452009|NCT02957656|EXPERIMENTAL|Group 1: H7N9 pLAIV + AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of approximately 10\^7.0 FFU of H7N9 pLAIV at study entry (Day 0). They will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at Day 84.
62452010|NCT02957656|EXPERIMENTAL|Group 2: AS03-adjuvanted H7N9 pIIV + AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at study entry (Day 0) and one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at Day 84.
62452011|NCT02957656|EXPERIMENTAL|Group 3: AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at study entry (Day 0).
62452012|NCT02957656|EXPERIMENTAL|University of Rochester URMC 13-001 Participants|Participants received one dose of 10\^7 FFU of H7N9 pLAIV at study entry (Day 0), one dose of 10\^7 FFU of H7N9 pLAIV at Day 28, and one dose of 30 µg of unadjuvanted H7N9 pIIV at Day 84.
62452013|NCT02957656|EXPERIMENTAL|Johns Hopkins School of Public Health CIR293 Participants|Participants received one dose of 10\^7 FFU of H7N9 pLAIV at study entry (Day 0), one dose of 10\^7 FFU of H7N9 pLAIV at Day 28, and one dose of 30 µg of unadjuvanted H7N9 pIIV at Day 84.
62452014|NCT05713409||Adult patients with an established diagnosis of CD going through ileocecal resection|
62452015|NCT03526965|EXPERIMENTAL|Yoga Chikitsa|YC group were given traditional combination of yoga therapy including loosening movements, physical postures, breathing, relaxation and yoga counselling.
62452016|NCT03526965|ACTIVE_COMPARATOR|Usual Care|Usual care were given exercise moves of necks, pain medications prescribed by physicians.
62452017|NCT00944697|PLACEBO_COMPARATOR|Tablets|A placebo tablet to match the active reference treatment
62452018|NCT00944697|ACTIVE_COMPARATOR|Tablet|Oxycodone Naloxone tablets
62452019|NCT03263299|ACTIVE_COMPARATOR|cabergoline group|received cabergoline in addition to aspirin. Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer. Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
62452020|NCT03263299|ACTIVE_COMPARATOR|Aspirin group|Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
62452021|NCT03263299|ACTIVE_COMPARATOR|GnRH Group|Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.
62630406|NCT03832829|EXPERIMENTAL|Indirect restorations with SR Nexco|Large posterior defects with at least one or more cuspal coverage in molars will be restored using the materials listed (SR Nexco). Procedures will be done using local anesthesia. The procedure, starts with removal of caries or defective restorations and coronal relocation of the the margins using flowable composite with maximum thickness 1 to 1.5 mm and followed by resin composite build-up. Defined principles of morphology driven preparation technique will be followed Impression making, fabrication of indirect restoration with SR Nexco and adhesive cementation will be completed according to manufacturer's instructions.
62630407|NCT02108977|EXPERIMENTAL|Videoconferencing Genetic Consultation|Patients will travel to CBOC and receive genetic counseling session via videoconferencing
62630408|NCT02108977|ACTIVE_COMPARATOR|Teleconferencing Genetic Consultation|Patients will receive genetic counseling session via telephone (usual treatment)
62630409|NCT03651817|ACTIVE_COMPARATOR|6ml/kg volume|Patients ventilation will provided with a tidal volume of 6ml/kg
62630410|NCT03651817|ACTIVE_COMPARATOR|8ml/kg volume|Patients ventilation will provided with a tidal volume of 8ml/kg
62630411|NCT02298426|EXPERIMENTAL|health management and product|"We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.~Meanwhile, we use dietary supplement products of SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS® to help balance the constitution of participants."
62630412|NCT02298426|EXPERIMENTAL|general management and product|"We provide general information about health. Information is provided through telephones and materials.~Meanwhile, we use dietary supplement products of SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS® to help balance the constitution of participants."
62630413|NCT02298426|EXPERIMENTAL|health management and placebo|"We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.~Meanwhile, we use placebo to replace the dietary supplement products."
62630414|NCT02298426|PLACEBO_COMPARATOR|general management and placebo|"We provide general information about health. Information is provided through telephones and materials.~Meanwhile, we use placebo to replace the dietary supplement products."
62630415|NCT03510975|SHAM_COMPARATOR|Verbal Behavioral Therapy|All children and their parents were instructed only a verbal behavioral therapy
62630416|NCT03510975|EXPERIMENTAL|Check-list|All participants were instructed a behavioral therapy with a written formed check-list for parents to complete
62630417|NCT03510975|ACTIVE_COMPARATOR|Desmopressin plus verbal therapy|All children in Group III received desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) plus verbal behavioral therapy.
62630418|NCT02045186|OTHER|Assessment of Oral HPV Infection|Oral HPV infection will be assessed 14 times, once prior to starting CRT, weekly during CRT, and then serially post-treatment: 4-8 weeks, 3 months, 6 months, 12 months, 18 months, 24 months. Patients will provide samples of their saliva and exfoliated epithelial cells at these timepoints. Samples will be collected with supplies provided by and analyzed by OralDNA Labs.
62630419|NCT01128400||rs1761667- AA genotype|subjects carrying the CD36 genotype rs1761667, i.e. a Single Nucleotide Polymorphism that significantly reduces CD36 level and has a minor allele frequency of 38-48%.
62630420|NCT01128400||rs1761667-GG genotype|subjects who are homozygous of CD36 genotype rs1761667-G allele.
62452022|NCT01840189|ACTIVE_COMPARATOR|Cortef|Treatment A is oral hydrocortisone replacement( Cortef 5 mg)with weight-adjusted doses as suggested by Mah et al , will take 2 months
62630421|NCT01128400||rs1761667-AG genotype|Heterozygous of CD36 gene rs1761667-A genotype.
62630422|NCT01325545||Cryptogenic stroke|Patients with stroke of unknown cause after comprehensive conventional evaluation
62630423|NCT01325545||Stroke of known cause|Patients with stroke of known cause determined by comprehensive conventional evaluation
62630424|NCT06453733|EXPERIMENTAL|Crainio|Acquisition of cerebral PPG signals from Crainio's probe stuck to the patient's forehead, alongside concurrent invasive ICP measurements in patients with traumatic brain injury
62630425|NCT02915172|EXPERIMENTAL|Lenvatinib + Capecitabine|"Phase 1 Study Escalation: Group consists of participants with various solid tumors.~Dose of Lenvatinib received depends on when joining study. First group of participants receive lowest dose level of Lenvatinib. Each new group receives a higher dose of Lenvatinib than the group before it, if no intolerable side effects were seen. This continues until highest tolerable dose of Lenvatinib found.~All participants receive the same dose of Capecitabine.~Phase 2 Study Expansion: Group consists of participants with advanced breast cancer and any solid tumors with confirmed FGFR abnormalities.~Participants receive Lenvatinib at the highest dose that was tolerated in Dose Escalation Phase.~All participants receive the same dose of Capecitabine."
62630426|NCT01344239|EXPERIMENTAL|Limb RIPC|The limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
62630427|NCT01344239|NO_INTERVENTION|convention|Adult patients undergoing elective open abdominal aortic aneurysm repair received no treatment after induction of anaesthesia
62630428|NCT02517736|EXPERIMENTAL|sorafenib at a dose of 800 mg / day|
62630429|NCT05381454|EXPERIMENTAL|MitoQ|Treatment group
62630430|NCT05381454|NO_INTERVENTION|Control group|Control group
62630431|NCT06491355|EXPERIMENTAL|mfolfox6 and hlx04 regimen induction therapy followed by combined treatment with slulimumab|Induction therapy: mFOLFOX6 regimen + bevacizumab. lasting 2 cycles. Combination therapy: mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody. Every 2 weeks is a cycle.
62630432|NCT06491355|ACTIVE_COMPARATOR|mfolfox6 and hlx04 regimen treatment|"mFOLFOX6+ HLX04 (bevacizumab). The mFOLFOX6 regimen is: oxaliplatin, calcium leucovorin, 5-fluorouracil, bevacizumab, One cycle is every 2 weeks, lasting 2 cycles.~During treatment, the drug was administered continuously, and tumor response was assessed by imaging every 8 weeks."
62630433|NCT06346041|EXPERIMENTAL|Oncolytic Virus injection(IDOV-SAFETM)|"Intravenous administration of IDOV-SAFETM as single agent for patients with advanced solid tumors.~Dose cohorts: 1x10\^9 pfu、3x10\^9 pfu、1x10\^10 pfu and 3x10\^10 pfu"
62630434|NCT02849080|EXPERIMENTAL|Semaglutide flexible dosing (3, 7 or 14 mg)|
62630435|NCT02849080|ACTIVE_COMPARATOR|Sitagliptin 100 mg|
62630436|NCT00206427|EXPERIMENTAL|Intervention|Intervention/Lapatinib (GW572016)
62630437|NCT06487715|EXPERIMENTAL|Albumin-bound paclitaxel plus S1 and sintilimab in combination with Bevacizumab|Intraperitoneal period: Albumin-bound paclitaxel plus S-1 combined with sintilimab (200 mg, d1) and bevacizumab (7.5 mg/m2, d1) intraperitoneally, 3-week cycle, 2 cycles; Maintenance period: Albumin-bound paclitaxel plus S-1 combined with sintilimab (200 mg, d1) and bevacizumab (7.5 mg/m2, d1) intravenously, 3-week cycle
62630438|NCT03000985|EXPERIMENTAL|Psychoeducation|6 session of a psychoeducation program with the family. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
62630439|NCT03000985|NO_INTERVENTION|Control|Treatment as usual
62630440|NCT01466413|EXPERIMENTAL|Restylane|"Patients with an even subject identification number (SIN) (02, 04, 06, 08, 10, 12, 14, 16) will have ELAPR to the right arm and the control to the left, where patients with an odd subject identification number (01, 03, 05, 07, 09, 11, 13, 15) will have the ELAPR to the left arm and the control to the right.~Patients will receive either device ELAPR002c or ELAPR002e. This will alternate to minimise bias between the right and left arms.~The first group of eight patients (01 - 08) will have their biopsy performed at day 169. The second group of eight patients (09 - 16) will have their biopsy at day 85."
62630441|NCT02812641|EXPERIMENTAL|BPF-CCRT (Run-in Phase)|"Neoadjuvant CCRT with Bevacizumab, Cisplatin and 5-fluorouracil~Chemotherapy:~Bevacizumab(B): 10 mg/kg on day 1~Cisplatin(P): 75 mg/m2 on day 1~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
62630442|NCT02812641|EXPERIMENTAL|BPF-CCRT (Randomized Phase)|"Neoadjuvant CCRT with Bevacizumab, Cisplatin and 5-fluorouracil~Chemotherapy:~Bevacizumab(B): 10 mg/kg on day 1~Cisplatin(P): 75 mg/m2 on day 1~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
62630443|NCT02812641|ACTIVE_COMPARATOR|PF-CCRT (Randomized Phase)|"Neoadjuvant CCRT with Cisplatin and 5-fluorouracil~Chemotherapy:~Cisplatin(P): 75 mg/m2 on day 1~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
62630444|NCT05293860|EXPERIMENTAL|Connective tissue manipulation|Connective tissue manipulation will be applied to participants' back for 5-20 minutes, 3 times a week for 4 weeks in this group.
62630445|NCT05293860|SHAM_COMPARATOR|Superficial massage with the head of the therapeutic ultrasound device|Superficial massage with the head of the therapeutic ultrasound device will be applied to participants' back for 15 minutes, 3 times a week for 4 weeks in this group.
62630446|NCT02085265|EXPERIMENTAL|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
62630447|NCT02085265|ACTIVE_COMPARATOR|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
62630448|NCT01351207|ACTIVE_COMPARATOR|pork sausages and hash brown potatoes plus eggs|
62630449|NCT01351207|PLACEBO_COMPARATOR|pork sausages and hash brown potatoes plus egg-free pudding|
62630450|NCT01351207|PLACEBO_COMPARATOR|pork sausages and hash brown potatoes|
62630451|NCT04680533|EXPERIMENTAL|TENS device|The device is worn on the upper calf right below the knee and secured by an elastic band. The device is controlled by an App and alternates between treatment periods and rest periods. Participants will be asked to wear the device 7-8 hours per day alternating legs.
62630452|NCT06279195|EXPERIMENTAL|Idiopathic Pelvic Pain|Participants with Idiopathic Pelvic Pain must: 1. Self-report an average non-menstrual pelvic pain rating of ≥ 4/10 (on a 0 to 10 Numeric Rating Scale) over the past 6 months. 2. Not have received a prior diagnosis attributed to a secondary cause (e.g., leiomyoma, endometriosis). Participants will be instructed to start taking Relugolix-combination therapy (40 mg of relugolix, 1 mg of estradiol, and 0.5 mg of norethindrone acetate) within 7 days of their period starting, at the same time every day for the next 6 months.
62630453|NCT06279195|EXPERIMENTAL|Endometriosis:|Participants with Endometriosis: 1. Must self-report an average non-menstrual pelvic pain rating of ≥ 4/10 (on a 0 to 10 Numeric Rating Scale) over the past 6 months. 2. Have a previously confirmed surgical diagnosis of stage III-IV endometriosis, indicating potential remission. Participants will be instructed to start taking Relugolix-combination therapy (40 mg of relugolix, 1 mg of estradiol, and 0.5 mg of norethindrone acetate) within 7 days of their period starting, at the same time every day for the next 6 months.
62630454|NCT00385918|EXPERIMENTAL|Lokomat training|Subjects will receive active exercise treatment in the Lokomat device 3 times per week for 3 months. Each session will last approximately 45 minutes.
62630455|NCT00385918|ACTIVE_COMPARATOR|Home stretching then Lokomat training|Patients will participate in a home stretching program for 3 months. They will then be crossed over to an active Lokomat treatment for a subsequent 3 months.
62630456|NCT02423083|EXPERIMENTAL|Treatment arm|
62630457|NCT05132660|EXPERIMENTAL|Sinemet|25 mg carbidopa/100 mg levodopa
62630458|NCT05132660|PLACEBO_COMPARATOR|Placebo|Placebo pill of similar size/shape
62630459|NCT05132660|NO_INTERVENTION|follow-up|Follow-up testing on participants previously prescribed levodopa
62630460|NCT06612983|EXPERIMENTAL|IASTM|This arm of the study received treatment on day one and walking treatment on day two.
62630461|NCT06384027|NO_INTERVENTION|Spontaneous breathing|The volunteer will remain lying down for a period of 5 minutes in spontaneous breathing and after this period the diaphragmatic and inferior vena cava ultrasound outcomes will be evaluated.
62630462|NCT06384027|ACTIVE_COMPARATOR|CPAP|When using CPAP, these same outcomes will be evaluated at three different PEEP levels, namely: 5, 10 and 15 cmH2O after 5 minutes of use.
62630463|NCT06384027|ACTIVE_COMPARATOR|Bilevel|During the use of Bi-level, we will maintain the PEEP value at 5cmH2O and modify the pressure support (PS) ventilation values, establishing the following values: 5, 7 and 10 cmH2O of PS, with all outcomes also being evaluated at the same time. end of 5 minutes.
62630464|NCT01869088|ACTIVE_COMPARATOR|TACE Only|TACE with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
62630465|NCT01869088|EXPERIMENTAL|TACE Plus Adenovirus|After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0\*1011vp：0.5ml\*3） will be first infused through the target artery of HCC patient and followed with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg) and lipiodol emulsion or/and polyvinyl alcohol particles(dependent on the tumor size) Procedure: TACE (Transcatheter arterial chemoembolization)
62630466|NCT00962676||immunocompromised group|
62630467|NCT00962676||non-immunocompromised group|
62630468|NCT04714190|EXPERIMENTAL|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
62630469|NCT04714190|ACTIVE_COMPARATOR|Physician's Choice|Participants will receive physician choosed chemotherapy from the following options: Paclitaxel Injection or Irinotecan Hydrochloride Injection or Apatinib Mesylate Tablets oral.
62630470|NCT03556969||Propofol sedation after SA|Participants who undergo propofol sedation after spinal anesthesia
62064229|NCT05885282|ACTIVE_COMPARATOR|Control Exercise Group|Lumbar spinal stabilization exercises will be given. Lumbar spinal stabilization exercises; diaphragmatic breathing, and contraction of the transversus abdominis and multifidus muscles will be taught in the supine position. Activation of these muscles will be studied in different positions (prone, crawling, sitting, and sitting on different surfaces). The focus will be on increasing kinesthetic awareness. It will be desirable to ensure and maintain the activation of these muscles during subsequent exercises. Exercises will be continued according to the patient's functional status and individual needs. Advancement of exercises; extremity movements on dynamic surfaces, narrowing of support surfaces, reciprocal movements, increasing the number of resistance and repetitions. The duration of a session will be 40 minutes.
62064230|NCT05885282|ACTIVE_COMPARATOR|Paraspinal Vibration Group|In addition to lumbar spinal stabilization exercises, LV will be applied to the cervical and lumbar paraspinal muscles. Spinal stabilization exercises will be as in the control group. The duration of a session will be 50 minutes, with spinal stabilization exercises 40 minutes and LV 10 minutes.LV will be applied before the exercises. LV will be applied to the cervical paraspinal muscles for a total of 5 minutes (2.5 minutes on the right side, 2.5 minutes on the left side) while the patients are in a sitting position. LV will be applied to the lumbar paraspinal muscles for a total of 5 minutes (2.5 minutes on the right side, 2.5 minutes on the left side) while the patients are lying in the prone position. LV application will be made with Vibrasens © device and vibration frequency 80 Hz amplitude 1 mm will be selected.
62269412|NCT04517487|ACTIVE_COMPARATOR|VMT recipients|"In order to prevent transfer of pathogens, sperm, or antibiotic-resistant commensals we will establish a vaginal fluid bank in which samples from suitable donors will be kept for future use:~* Donors will be screened using a questionnaire addressing risk factors for potentially transmissible infections, undergo screening for cervico-vaginal infections, cervical cytology screening, and serology analysis for transmittable infections {see detailed screening in Lev-Sagie et al. Nat Med. 2019;25(10):1500-1504. doi: 10.1038/s41591-019-0600-6.}~* The collected samples for VMT will be examined for bacteria,viruses and sperm.~Before transplantation, patients will be treated with intravaginal antibiotics. A frozen specimen will be thawed at room temperature and will be placed in the patient's vagina.~Following VMT, patients will be evaluated every 14 days for the first 2 months, then every month for additional 10 months."
62630471|NCT05530486|PLACEBO_COMPARATOR|Comparador de placebo: CC + curativo|The group will receive placebo LASER application associated with Helianthus annuus oil dressing.
62630472|NCT05530486|ACTIVE_COMPARATOR|Comparador ativo: LG1 + curativo|The group will receive application of LASER Gallium Arsenide (GasAs) 660 nm 4 J/cm² associated with Helianthus annuus oil dressing.
62630473|NCT05530486|ACTIVE_COMPARATOR|Comparador ativo: LG2 + curativo|The group will receive application of LASER Gallium Arsenide (GaAs) 660 nm 8 J/cm² associated with Helianthus annuus oil dressing.
62630474|NCT05530486|ACTIVE_COMPARATOR|Comparador ativo: LG3 + curativo|The group will receive application of LASER Gallium Arsenide (GaAs) 660 nm 12 J/cm² associated with Helianthus annuus oil dressing.
62630475|NCT03284853|EXPERIMENTAL|Netarsudil/Latanoprost 0.02%/0.005%|PG324 Ophthalmic Solution (netarsudil 0.02% / latanoprost 0.005%) one drop daily to each eye for 180 days.
62630476|NCT03284853|ACTIVE_COMPARATOR|GANFORT®|GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.
62630477|NCT01492192|EXPERIMENTAL|RCC Patients Antiangiogenic treatment|
62630478|NCT06248307|EXPERIMENTAL|Barrita experimental|Two bars to be consumed before lunch and before dinner
62630479|NCT06248307|PLACEBO_COMPARATOR|Barrita placebo|Two bars to be consumed before lunch and before dinner
62630480|NCT01676012||five types of bronchoscopy|"Bronchoscopy will be performed in a standardized order using five different imaging modes.~1. Standard white light videobronchoscopy (WLB)~2. High Definition -Bronchoscopy~3. HD-bronchoscopy + surface enhancement (iScan-surface)~4. HD-bronchoscopy + tone enhancement (iScan-tone)~5. Auto Fluorescence Bronchoscopy (AFB - SAFE3000) in dual video mode"
62630481|NCT06462898|ACTIVE_COMPARATOR|Omega-3 Fortified Protein Smoothie|Participants will receive a shaker bottle containing 1 tbsp omega-3 powder and 1 scoop protein powder mixed with water, after morning physical training, five days a week, for eight weeks.
62630482|NCT06462898|PLACEBO_COMPARATOR|Non-Fortified Protein Smoothie|Participants will receive a shaker bottle containing 1 scoop protein mixed with water, after morning physical training, five days a week, for eight weeks.
62630483|NCT03997396||the DGM group|The subject recruitment was implemented in the obstetrics department of the First People's Hospital of Chongqing Liangjiang New Area, China. 255 pregnant women diagnosed with GDM by IADPSG2010 standard and their children will be enrolled into the GDM group.
62630484|NCT03997396||the Non-GDM group|In the obstetrics department of Chongqing First People's Hospital of Liangjiang New Area,China,the healthy pregnant women and delivery children in the same period were enrolled into the non-GDM group in a 1:1 ratio.
62630485|NCT03894839|ACTIVE_COMPARATOR|glutaraldehyde disinfection and microwave application|%2 glutaraldehyde, solution form,duration time 1 minute and 1 time in a day by patients and 3 minutes 650 watt microwave energy application by dentists at each control session
62630486|NCT03894839|ACTIVE_COMPARATOR|Chlorhexidine gluconate disinfection and microwave application|%2 chlorhexidine gluconate, solution form, duration time 1 minute and 1 time in a day by patients and 3 minutes 650 watt microwave energy application by dentists at each control session
62630487|NCT03894839|ACTIVE_COMPARATOR|Sodium hypochlorite disinfection and microwave application|%5 sodium hypochlorite, solution form,duration time 1 minute and 1 time in a day by patients and 3 minutes 650 watt microwave energy application by dentists at each control session
62630488|NCT03894839|ACTIVE_COMPARATOR|glutaraldehyde disinfection and ozone therapy|%2 glutaraldehyde, solution form,duration time 1 minute and 1 time in a day by patients and 15 minutes ozone therapy at each control session by dentists
62630489|NCT03894839|ACTIVE_COMPARATOR|Chlorhexidine gluconate disinfection and ozone therapy|%2 chlorhexidine gluconate, solution form, duration time 1 minute and 1 time in a day by patients and 15 minutes ozone therapy at each control session by dentists
62630490|NCT03894839|ACTIVE_COMPARATOR|Sodium hypochlorite disinfection and ozone therapy|%5 sodium hypochlorite, solution form,duration time 1 minute and 1 time in a day by patients and 15 minutes ozone therapy at each control session by dentists
62630491|NCT06474572|ACTIVE_COMPARATOR|Direct laryngoscope and table at xiphoid level|Participants will be required to intubate the manikin with a direct laryngoscope and table at xiphoid level
62630492|NCT06474572|ACTIVE_COMPARATOR|Videolaryngoscope and table at xiphoid level|Participants will be required to intubate the manikin with a video laryngoscope and table at xiphoid level
62630493|NCT06474572|ACTIVE_COMPARATOR|Direct laryngoscope and table at umbilical level|Participants will be required to intubate the manikin with a direct laryngoscope and table at umbilical level
62630494|NCT06474572|EXPERIMENTAL|Videolaryngoscope and table at umbilical level|Participants will be required to intubate the manikin with a video laryngoscope and table at umbilical level
62630495|NCT05575739||Male factor|Couples that have just the male factor as cause of infertility
62064231|NCT05885282|ACTIVE_COMPARATOR|Gastrosoleus Muscle Complex Vibration Group|In addition to lumbar spinal stabilization exercises, LV will be applied to the gastrosoleus muscle complex. Spinal stabilization exercises will be as in the other 2 groups. The duration of a session will be 50 minutes, with spinal stabilization exercises 40 minutes and LV 10 minutes.LV application will be applied sequentially, bilaterally, to the gastrosoleus complex. LV will be applied before the exercises. LV will be applied for a total of 10 minutes (5 minutes each on the right and left) while the patients are lying in the prone position. LV application will be made with Vibrasens © device and vibration frequency 80 Hz amplitude 1 mm will be selected.
62064232|NCT04588233|EXPERIMENTAL|Administration of Melatonin|
62630496|NCT05575739||Other causes of infertility|diminished ovarian reserve polycystic ovarian syndrome unexplained infertility tubal factor
62630497|NCT06447701|EXPERIMENTAL|Tocilizumab group|Intravenously for more than 1 hour.
62630498|NCT06447701|PLACEBO_COMPARATOR|Control group|Intravenously for more than 1 hour.
62630499|NCT06612749|EXPERIMENTAL|Integrative medicine intervention|Healthcare providers were treated for 30 minutes with integrative medicine based on manual and mind-body modalities
62630500|NCT02082171|NO_INTERVENTION|Control group|
62452023|NCT01840189|ACTIVE_COMPARATOR|Solu-cortef|This is the treatment B by continuous subcutaneous hydrocortisone infusion. Solu-cortef infusion will be given as Solu-Cortef Act-o-Vial 50mg/ml, , produced by Pfizer. Pump designed for subcutaneous insulin infusion can be used for subcutaneous administration.
62630501|NCT02082171|EXPERIMENTAL|Intervention group|Comprehensive geriatric assessment followed by multi-domain preventive intervention
62064233|NCT04588233|PLACEBO_COMPARATOR|Administration of Placebo|
62064234|NCT02995902|EXPERIMENTAL|FLT-PET/MRI|
62630502|NCT06613373|EXPERIMENTAL|experimental|"Dalpiciclib combined with AI,28 days as one cycle.~Dalpiciclib: 150 mg (p.o.) was given once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~Letrozole: 2.5mg, p.o., once a day, continuous administration."
62630503|NCT05316181|EXPERIMENTAL|HIPEC|Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) followed by physician-choice chemotherapy until disease progression.
62630504|NCT05316181|NO_INTERVENTION|No HIPEC|Physician-choice chemotherapy from enrollment until disease progression.
62630505|NCT05042752|NO_INTERVENTION|No intervention arm|Standard care of AHF on a patient admitted on a HAH unit consists in physical examination and basic complementary tests
62064235|NCT04990141||Cases group|Women recruited between 9 and 14 gestational weeks diagnosed with preeclampsia or other complication at the end of pregnancy
62630506|NCT05042752|EXPERIMENTAL|Experimental arm|Clinical ultrasound on HAH admitted patient. Clinical handheld Ultrasound consists of inferior vena cava diameter measurement and lung ultrasound protocol in order to guided Diuretic Therapy
62630507|NCT03162406|EXPERIMENTAL|Vitamin D|Procedure: SRP Dietary Supplement: Vitamin D3 Oral supplementation 25000 IU once per week for 6 months Other Name: Cholecalciferol
62064236|NCT04990141||Control group|Women recruited between 9 and 14 gestational weeks without diagnosis of preeclampsia or other complication at the end of the pregnancy
62269413|NCT04517487|PLACEBO_COMPARATOR|Placebo|"Vaginal fluid of all recipients will be collected before initiation of the study using the same protocol, will be clearly labeled and will be kept frozen in similar conditions. These samples will be used in the placebo arm for autologous vaginal fluid transplantation.~Before transplantation, patients will be treated with intravaginal antibiotic.~Following Placebo, patients will be evaluated every 14 days for the first 2 months, then every month for additional 2-4 months.~After 4-6 months, patients who initially received placebo will be offered a VMT in case they are still symptomatic and fulfill inclusion criteria, in an open-label phase."
62269414|NCT02777671|EXPERIMENTAL|Group A|Period 1 - BIA 2-093 + Gliclazide Period 2 - Gliclazide
62269415|NCT02777671|EXPERIMENTAL|Group B|Period 1 - Gliclazide Period 2 - BIA 2-093 + Gliclazide
62269416|NCT05138809|EXPERIMENTAL|Exercise|Use online exercise platform
62452024|NCT02999035||corneal sensitivity measurement|"Air jet aesthesiometry and liquid jet aesthesiometry:~All patients will receive the same intervention of corneal sensitivity measurement with air jet aesthesiometry and liquid jet aesthesiometry.~Thresholds represent the intensity of air / liquid jet that can just be perceived by the patients."
62452025|NCT02313103|OTHER|Lofexidine HCl|End Stage Renal Disease (ESRD) subjects will be dosed with 400 micrograms of lofexidine HCl with 240 mL water after their hemodialysis session.
62452026|NCT02313103|OTHER|Matched Control|normal renal function subjects (enrolled to match each End Stage Renal Disease subject) will be dosed with 400 micrograms of lofexidine HCl with 240 mL water at the same clock time as ESRD subjects.
62452027|NCT06071013|EXPERIMENTAL|Nintedanib + gefitinib/erlotinib/afatinib|Nintedanib will administered orally twice per day Gefitinib will administered orally once daily Erlotinib will administered orally once daily Afatinib will administered orally once daily
62452028|NCT03130764|EXPERIMENTAL|Durvalumab/Tremelimumab|Patients with resected stage IB-IIIA NSCLC who have completed standard adjuvant therapy (as recommended by the treating physician) to receive durvalumab-tremelimumab will be enrolled. Patients will receive durvalumab (20 mg/kg) intravenously every 4 weeks for 1 year and tremelimumab (1 mg/kg) intravenously every 4 weeks for 4 doses.
62452029|NCT06194474||Delirium Group|
62452030|NCT06194474||No Delirium Group|
62452031|NCT03791749|EXPERIMENTAL|Breastfeeding Support|Home visits will be conducted at 2-3 and 6-8 weeks post-delivery. Mothers will be asked to perform a simple technique while breastfeeding at least once a day.
62452032|NCT03791749|NO_INTERVENTION|Standard Care|Home visits will be conducted at 2-3 and 6-8 weeks post-delivery. No intervention will be administered.
62452033|NCT05395000|EXPERIMENTAL|"Parents group"|Parent or primary caregiver of a child or adolescent (\<18 years old) diagnosed with type 1 diabetes.
62452034|NCT05395000|EXPERIMENTAL|"School workers group"|"Any adult who works or will work in a school or daycare setting who is likely to administer glucagon to a child or adolescent with type 1 diabetes (e.g. teachers, facilitators, teacher candidates, etc.). This individual must not meet the criteria for the parent group."
62452035|NCT04552574|EXPERIMENTAL|Intervention group|All subjects will intake HMR(Home meal replacement)-type omega-3-balanced-diet for 4 weeks.
62452036|NCT04552574|NO_INTERVENTION|Control group|No intervention for 4 weeks.
62630508|NCT03162406|PLACEBO_COMPARATOR|Placebo|Procedure: SRP Dietary Supplement: Placebo Oral supplementation once per week for 6 months
62630509|NCT02820519|EXPERIMENTAL|Loxapine|Loxapine Capsules 10 mg Day 1- 14: 10 mg b.i.d Day 15-28: 10 mg t.i.d Day 29-42: 20 mg b.i.d. Day 43-56: 20 mg t.i.d. Dosages will be escalated according to analgesic efficacy and tolerability.
62452037|NCT02324972|EXPERIMENTAL|AQX-1125|1 x AQX-1125 Capsule daily
62452038|NCT02324972|PLACEBO_COMPARATOR|Placebo|1 x placebo capsule daily
62452039|NCT06396520||Typically developing infants|Born after gestational week 37, Uneventful birth, No known history of brain injury, No known neurological disorders
62452040|NCT06396520||High Risk for Cerebral Palsy|"Recruitment through CP-EDIT (Clinical trials.gov ID: NCT05835674), inclusion criteria.~'Newborn-detectable risk-pathway'. Preterm birth with gestational age below 32 or birth weight below 1500 g and clinical concern, Moderate to severe brain injury (Papile grade 3 to 4 intraventricular haemorrhage, cystic periventricular leukomalacia, neonatal stroke, term hypoxic-ischaemic encephalopathy (≥35 weeks gestation at birth) or other significant neurological condition), History (e.g. neonatal seizures, Extra Corporal Membrane Oxygenation, meningitis, kernicterus, severe hypoglycemia) or neurological risk factors (brain malformation, increased tone), Parental concern and one of the factors above~'Infant detectable risk-pathway'. Inability to sit independently by age 9 months, Hand function asymmetry or crawl asymmetry, Inability to take weight through the plantar surface of the feet, History (as above) or neurological risk factors, Parental concern and one of the factors above."
62452041|NCT05927285|EXPERIMENTAL|VeXUS group|The VExUS group was considered the intervention group, where in addition to all the above, the decision for decongestant treatment was guided by the VExUS score until reaching a score that VExUS considered noncongestive, which was grade 0.
62452042|NCT05927285|ACTIVE_COMPARATOR|Control group|The control group is considered the conventional approach, where the treatment was guided by improvement in clinical data, imaging, or laboratory studies during the daily evaluation until categorized as decongested.
62452043|NCT00012714|OTHER|Arm 1|
62452044|NCT05198804|EXPERIMENTAL|ZN-c3 and Niraparib|ZN-c3 in combination with Niraparib
62452045|NCT05198804|EXPERIMENTAL|ZN-c3|ZN-c3 Monotherapy
62452046|NCT02448771|EXPERIMENTAL|Palbociclib in Combination with Bazedoxifene|"Palbociclib 125 mg Oral on days 1-21 per cycle Bazedoxifene 40 mg Oral on days 1-28 per cycle~One cycle is 28 days."
62452047|NCT01627275|EXPERIMENTAL|DLI from HLA-identical donor|Naive T Cell Depleted Donor Lymphocyte Infusion from HLA matched family member donor or 8/8 HLA matched unrelated donor.
62630510|NCT04871152||Patients with chronic migraine|In the same group of patients, the response to triptans will be analyzed at 3 different times with respect to the start of treatment with onabotulinumtoxinA: before treatment, after 4 months and after 7 months of treatment.
62064237|NCT06625450|ACTIVE_COMPARATOR|Tofacitinib|Mesalamine will be withdrawn while tofacitinib will be continued during maintenance of remission of the disease
62630511|NCT03140163|EXPERIMENTAL|Subjects suffering from pneumonia|CXR ULD-CT
62630512|NCT04124380|EXPERIMENTAL|Imaginal Exposure First, then Alcohol Skills|Imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault. After imaginal exposure, alcohol skills targeting alcohol misuse after sexual assault.
62630513|NCT04124380|EXPERIMENTAL|Alcohol Skills First, then Imaginal Exposure|Alcohol skills targeting alcohol misuse after sexual assault. After alcohol skills training, imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault.
62630514|NCT04124380|ACTIVE_COMPARATOR|Supportive Counseling/Telehealth|Internet-based intervention focusing on providing support.
62630515|NCT04124380|EXPERIMENTAL|Alcohol Skills First, no additional treatment|Alcohol skills targeting alcohol misuse after sexual assault only. No additional treatment.
62630516|NCT04124380|EXPERIMENTAL|Imaginal Exposure First, no additional treatment|Imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault. No additional treatment.
62269417|NCT03991351||Men aged 18-34|Participants will be males aged 18-34. Each individual will be exposed to images of men with either a muscular, skinny or overweight physique or the control images of landscapes.
62452048|NCT05405998|EXPERIMENTAL|Experimental group : proactive course|"The strategy is based on the implementation of an optimized proactive care pathway, combining elements that promote city-hospital coordination in setting up the pump and elements that promote patient education."
62630517|NCT04084002||Patients with subacute chronic stroke|Patients with subacute chronic stroke
62630518|NCT04084002||Control group|Healthy control group age and sex matched
62630519|NCT02869477||Patients with cardia cancer diagnosis|
62630520|NCT00844402|EXPERIMENTAL|Atorvastatin|Atorvastatin 10 mg per day for 48 weeks
62630521|NCT02010112|EXPERIMENTAL|Initial Diagnosis Cohort|Subjects with clinical indication of H.pylori infection will undergo breath test compared to routine clinical standard of care- endoscopy
62630522|NCT02968108|EXPERIMENTAL|Group1: Ustekinumab Dose Regimen 1|Subjects will receive a single intravenous (IV) induction dose of 3 milligram per kilogram (mg/kg) for subjects less than \< 40 kilogram (kg) or 130 milligram (mg) for subjects greater than or equal to \>= 40 kg at Week 0 followed by subcutaneous (SC) maintenance dose of 2 mg/kg for subjects \< 40 kg or 90 mg for subjects \>= 40 kg at week 8.
62064238|NCT06625450|ACTIVE_COMPARATOR|Tofacitinib plus mesalamine|Both mesalamine and tofacitinib will be continued during maintenance of remission of the disease
62269418|NCT00964977|NO_INTERVENTION|no irradiation|Patients within this arm only receive curative intended radical surgery
62269419|NCT00964977|ACTIVE_COMPARATOR|Radiation|Patients receive radiation within 6 weeks after curative intended radical surgery.
62269420|NCT02803944||Cystic fibrosis patients taking azithromycin|Cystic fibrosis patients taking azithromycin continuously for two years.
62269421|NCT03072056|EXPERIMENTAL|Extensive Metabolizers, 4 mg|subjects will receive 32 mL of MIN-101 as a 0.125 mg/mL oral solution
62269422|NCT03072056|EXPERIMENTAL|Extensive Metabolizers, 8 mg|subjects will receive 32 mL of MIN-101 as a 0.25 mg/mL oral solution
62269423|NCT03072056|EXPERIMENTAL|Extensive Metabolizers, 16 mg|subjects will receive 32 mL of MIN-101 as a 0.5 mg/mL oral solution
62269424|NCT03072056|EXPERIMENTAL|Poor Metabolizers, 4 mg|subjects will receive 32 mL of MIN-101 as a 0.125 mg/mL oral solution
62269425|NCT03072056|EXPERIMENTAL|Poor Metabolizers, 8 mg|subjects will receive 32 mL of MIN-101 as a 0.25 mg/mL oral solution
62269426|NCT03072056|EXPERIMENTAL|Poor Metabolizers, 16 mg|subjects will receive 32 mL of MIN-101 as a 0.5 mg/mL oral solution
62269427|NCT00343421|EXPERIMENTAL|Group 1|PEDIACEL co-administered with Prevenar
62269428|NCT00343421|ACTIVE_COMPARATOR|Group 2|Infanrix-IPV+Hib co-administered with Prevenar
62269429|NCT06168032|EXPERIMENTAL|Vaccinated group|Any booster doses(without limitations in the subtypes or brands of the vaccines) recommended or approved by Chinese government will be administered once in the 6th months after latest confirmed COVID-19 infection and during the following 6 months, any conditions including repeated COVID19 infection, critical and/or severe conditions and all-cause death will be recorded.
62269430|NCT06168032|NO_INTERVENTION|Non-vaccinated group|Patients unwilling to get vaccination will be allocated into these group, but any events including recurrent COVID19 infection, critical and/or severe conditions and all-cause death will be recorded in the following six months.
62269431|NCT03380689|EXPERIMENTAL|SIRB2|Biweekly combination therapy with S-1, Irinotecan, and Bevacizumab
62269432|NCT01960621|EXPERIMENTAL|2|
62269433|NCT02585505|ACTIVE_COMPARATOR|Intravenous|stem cells will be injected through intravenously in the subjects
62269434|NCT02585505|ACTIVE_COMPARATOR|superior pancreaticoduodenal|stem cells
62269435|NCT02585505|ACTIVE_COMPARATOR|splenic artery|stem cells will be injected through splenic in the subjects
62269436|NCT05956795||BWH stage T2a tumors in patients who are on chronic immunosuppression|Patient's whose cutaneous squamous cell carcinoma is BWH stage T2a and also have a history of organ transplant, hematologic malignancy, autoimmune disease. After these participants are diagnosed, the participants are entered into the study without any further imaging or sentinel lymph node biopsy. The participants will have ultrasound surveillance every 6 months and regular visits every 3 months throughout the duration of the study (2 years).
62452049|NCT05405998|NO_INTERVENTION|Control group : optimized medical treatment|At the end of the inclusion visit (see previous chapter), the patient will be invited to come to the hospital two weeks later for pump placement.
62452050|NCT01431924||Adolescent and adult patients with asthma|Adolescents and Adults age 12-65 with an ICD-9 code for asthma and a prescription for an inhaled corticosteriod or a corticosteriod/salmeterol combination
62452051|NCT01224132|NO_INTERVENTION|Probiotics|
62452052|NCT01224132|NO_INTERVENTION|skim milk powder, dextrose|
62630523|NCT02968108|EXPERIMENTAL|Group2: Ustekinumab Dose Regimen 2|Subjects will receive a single Intravenous (IV) dose of 9 mg/kg for subjects \<40 kg or 390 mg for subjects \>= 40 kg at Week 0 followed by SC maintenance dose of 2 mg/kg for subjects \<40 kg or 90 mg for subjects \>= 40 kg at week 8.
62630524|NCT02640313|EXPERIMENTAL|18F-choline PET-MR imaging|"Intervention: 18F-choline PET-MR imaging.~Drug: 18F-choline, dosis 4 MBq/kg body-weight (maximum 360 MBq), administered intravenously as a single dose.~Procedure: dynamic and static 18F-choline PET-MR."
62630525|NCT03635762|EXPERIMENTAL|Be In Charge|behavioral + nutrition education program
62630526|NCT05418907||Patients with confirmed paraganglioma|10 patients with confirmed PGL who have undergone CT, somatostatin receptor (SSTR) PET/CT and 18F-FDG PET/CT (as standard diagnostic procedures) and are scheduled for surgery.
62630527|NCT05477004||Open label ketamine|Patients who receive a ketamine infusion for the treatment of chronic pain in the course of usual clinical care
62630528|NCT05927077||healthy study participants who undergo planned surgeries for weight reduction from Central Europe|The investigators will take benefit of planned surgeries for weight reduction to collect study material that allows to determine the chemical exposome of the participants
62630529|NCT05927077||healthy study participants who undergo planned surgeries for weight reduction from North America|The investigators will take benefit of planned surgeries for weight reduction to collect study material that allows to determine the chemical exposome of the participants
62630530|NCT05927077||healthy study participants who undergo planned surgeries for weight reduction from South Korea|The investigators will take benefit of planned surgeries for weight reduction to collect study material that allows to determine the chemical exposome of the participants
62630531|NCT03646747|EXPERIMENTAL|MRI scan|"10 healthy participants will be asked to undergo two baseline OE-MRI scans with either nasal cannula or facial mask to breathe air and oxygen throughout.~Following this initial pilot, OE-MRI will be tested in 30 patients with solid head and neck tumours."
62630532|NCT03239067||ticagrelor group|patients prescribed with ticagrelor
62630533|NCT03239067||clopidogrel group|patients prescribed with clopidogrel
62630534|NCT01148394|NO_INTERVENTION|Traditional|Involves traditional management of patients with preoperative mechanical bowel preparation, no preoperative education, nasogastric tube, delayed feeding and mobilisation, use of drains
62630535|NCT01148394|ACTIVE_COMPARATOR|Multimodal rehabilitation|Involves preoperative patient education, no preoperative mechanical bowel preparation, no nasogastric tube, early oral feeding and mobilisation, physiotherapy
62630536|NCT01659840|OTHER|Red laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
62064239|NCT02344537|EXPERIMENTAL|Meditation Group Therapy|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
62630537|NCT01659840|OTHER|Infrared laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
62088145|NCT06071884|EXPERIMENTAL|Bridge Percutaneous Nerve Field Stimulator|The case group (n = 15) will receive an activated Bridge device after surgery and continuing wearing the device until post-operative day (POD) 7.
62630538|NCT03908554|EXPERIMENTAL|intervention|The WHPP was applied to the intervention group in the workplace for two times a week for five weeks. During the first 5 minutes of the session, breathing exercises, 20 minutes, PMR and 10 minutes, posture exercises were performed. PMR has progressed gradually to every session. The program is under control with a follow-up chart of what the participants do every day, and the participants were supported with various reminders (i.e., graphical leaflets on PMR techniques which also can be used as a guide while practicing at home).
62630539|NCT03908554|NO_INTERVENTION|Control|Participants of the control group rested in a room for 40 minutes and were told that they could read every session.
62630540|NCT04900454|EXPERIMENTAL|DVX201 infusion|"Subjects will enroll and the MTD and/or the recommended phase 2 dose of DVX201 will be determined utilizing a modified 3+3 enrollment schema.~This study will enroll a minimum 3 subjects who each receive a single dose of DVX201 and who are evaluable for toxicities at each dose level. Depending on the occurrence of DLTs and the number of dose levels evaluated, additional subjects may be enrolled (approximately 3-15 additional subjects). All subjects will be followed for 28 days post infusion of DVX201."
62630541|NCT04405323|EXPERIMENTAL|Lu AG06466 - Sequence 1|Dosing on Days 1 and 8 will be following an overnight fast, and dosing on Days 3 and 10 will be following a standard high-fat breakfast.
62630542|NCT04405323|EXPERIMENTAL|Lu AG06466 - Sequence 2|Dosing on Days 1 and 8 will be following, a standard high-fat breakfast and dosing on Days 3 and 10 will be following an overnight fast.
62630543|NCT03560453|NO_INTERVENTION|Control|Attend assigned high school for 9 months
62452053|NCT04393506|OTHER|Inductive therapy|Inductive therapy with Camrelizumab and Apatinib, followed by radical surgery and post-operative radiotherapy/chemoradiotherapy.
62452054|NCT02437149|EXPERIMENTAL|Video and Brochure|Real stories video presentation and a brochure with information about distracted driving will be given to the participant.
62452055|NCT02437149|EXPERIMENTAL|Power Point and Brochure|Brief power point presentation and a brochure with information about distracted driving will be given to the participant.
62452056|NCT02437149|EXPERIMENTAL|Brochure Only|Only a brochure with information about distracting driving will be given to the participant.
62630544|NCT03560453|EXPERIMENTAL|Project SEARCH plus ASD Supports|Attend Project SEARCH plus ASD Supports for 9 months
62630545|NCT05291130||Plasmafit® Vitelene® Vitamin E ceramic femoral heads|Plasmafit® Acetabular Cup System with Vitelene® is a highly crosslinked polyethylene stabilized with vitamin E and bioceramic femoral heads
62630546|NCT05291130||Plasmafit® Vitelene® Vitamin E metal femoral heads|Plasmafit® Acetabular Cup System with Vitelene® is a highly crosslinked polyethylene stabilized with vitamin E and metal femoral heads
62630547|NCT05291130||Plasmafit® polyethylene metal femoral heads|Plasmafit® Acetabular Cup System with polyethylene and metal femoral heads
62630548|NCT01007604|ACTIVE_COMPARATOR|Exercise and lifestyle counselling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
62064240|NCT02344537|NO_INTERVENTION|Wait-List Controls|The wait-list group will not take part in study treatment (daily meditation or stretching) during the study wait of 8 weeks in order for us to compare change related to the study intervention to change associated with no active treatment ( treatment-as-usual). (After completing 8 weeks of no study treatment as part of the wait-list group, these patients will be offered the opportunity to receive 8 weeks of treatment.)
62064241|NCT01215214|EXPERIMENTAL|midazolam|period 1: midazolam administration alone period 2: ketoconazole 400 mg PO for 4 days administration, midazolam iv single administration period 3: rifampicin 600 mg PO for 9 days administration, midazolam iv single administration
62064242|NCT03237520|EXPERIMENTAL|Virtual Reality Therapy|Intervention: Virtual Reality therapy(VRT) reinforcing modified Constraint Induced Movement therapy(mCIMT) VRT will be administered using computer based program. mCIMT will be administered using the physical rehabilitation protocol.
62064243|NCT03237520|ACTIVE_COMPARATOR|mCIMT|Intervention: Modified Constraint Induced Movement Therapy Only mCIMT will be administered using the physical rehabilitation protocol.
62064244|NCT01535742|EXPERIMENTAL|Ambu Aura-i size 1.5|patients will receive either the Ambu Aura-i size 1.5 or air-Q ILA 1.5 based on manufacturer recommendations of body weight
62064245|NCT01535742|EXPERIMENTAL|air-Q size 1.5|patients will receive either the Ambu Aura-i size 1.5 or air-Q ILA 1.5 based on manufacturer recommendations of body weight
62064246|NCT01535742|EXPERIMENTAL|Ambu Aura-i size 2|patients will receive either the Ambu Aura-i size 2 or air-Q ILA 2 based on manufacturer recommendations of body weight
62064247|NCT01535742|EXPERIMENTAL|air-Q size 2|patients will receive either the Ambu Aura-i size 2 or air-Q ILA 2 based on manufacturer recommendations of body weight
62064248|NCT03135561|EXPERIMENTAL|pedometer-plus-email|
62064249|NCT03135561|ACTIVE_COMPARATOR|pedometer-only|
62064250|NCT02799225||Enterobacteria|
62452057|NCT05823090|EXPERIMENTAL|Bright light therapy|Eligible participants were provided a light box and an actigraphy wrist-watch and given instructions on the use of each. The light therapy dosing protocol was planned as follows: Weeks 0-2, 50 lux dim red light (DRL) x 15 30 minutes/day; weeks 3-4, 10,000 lux x 15 minutes/day; weeks 5-6, 10,000 lux x 30 minutes/day; weeks 6-8, 10,000 lux x 45 minutes/day. At week 2, the study coordinator dispensed the 10,000 lux BLT unit (and picked up the DRL box) and the actigraphy watch. Participants and their parent/guardian met with 2 study clinicians at the end of each 2-week period. One study clinician, who was blinded to the participant's light box use, conducted a brief interview regarding mood, safety and functioning and side effects. The other study clinician subsequently met with the participant to review safety, side effects and response and made recommendations on duration and timing of light box use based on level of improvement and any barriers to use.
62452058|NCT04297280|EXPERIMENTAL|TACE in combination with sintilimab|One-session TACE treatment starts at day 0. Sintilimab will be initiated on day 14 after TACE. Sintilimab will be administered every three weeks (200mg fixed dose IV) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62452059|NCT01890915||Tetraplegia|Persons with spinal cord injury, level of injury C4-T1, American Spinal Injury Association (ASIA) impairment levels A-B and duration of injury greater than 1 year. Ages 18-65 years old.
62452060|NCT01890915||Control|Age and gender-matched able-bodied controls. Ages 18-65 years old.
62452061|NCT03785236||Tx-group|T1D patients that received islet of Langerhans transplantation (Tx) at least 3 months earlier
62452062|NCT03785236||Control group|T1D patients that await islet of Langerhans transplantation
62452063|NCT05053165|EXPERIMENTAL|A (LB-P6)|Healthy volunteers will be administered once daily orally
62452064|NCT05053165|EXPERIMENTAL|B (LB-P8)|Healthy volunteers will be administered once daily orally
62452065|NCT05053165|EXPERIMENTAL|C (Placebo)|Healthy volunteers will be administered once daily orally
62452066|NCT03526939||HIV negative from RDS round 1|HIV negative PWID subjects from RDS round 1
62064251|NCT06257355|EXPERIMENTAL|CSB-001 QID|One drop CSB-001 four times daily for 14 days in the study eye
62452067|NCT03526939||HIV negative from RDS round 2|HIV negative PWID subjects from RDS round 2
62452068|NCT03526939||HIV negative from RDS round 3|HIV negative PWID subjects from RDS round 3
62452069|NCT01820039|EXPERIMENTAL|FertiScreen|all patients between 18 and 38 years, consulting their general practitioner for infertility will be asked to use FertiScreen.
62452070|NCT02986763||Professional pesticides|A specific questionnaire with professional information about pesticide uses is added for this arm Questionnaire to collect domestic pesticide use, diet, household characteristics Dust sampling Blood sampling Urine sampling Hair sampling
62452071|NCT02986763||Volunteers|Questionnaire to collect domestic pesticide use, diet, household characteristics Dust sampling Blood sampling Urine sampling Hair sampling
62452072|NCT02540356|EXPERIMENTAL|Single-Route Arm|BAX69 administered weekly by intraperitoneal (IP) infusion only
62452073|NCT02540356|EXPERIMENTAL|Double-Route Arm|BAX69 administered weekly by intravenous (IV) infusion + intraperitoneal (IP) infusion
62452074|NCT05376046||Sickle cell disease|"Confirmed sickle cell disease withHaemoglobin profile was determined by high performance liquid chromatography (HPLC) (Variant II Biorad, California, United States), by capillary electrophoresis on Capillarys 3 Octa® (Kit hydragel hémoglobine Sebia, Lisses, France) and iso-electrofocalisation.~Patients were included during injury evaluation in our tertiary centre."
62064252|NCT06257355|EXPERIMENTAL|CSB-001 TID|One drop CSB-001 three times daily for 14 days in the study eye
62064253|NCT04035200|EXPERIMENTAL|V117957 1 mg|V117957 tablets taken orally at bedtime
62064254|NCT04035200|EXPERIMENTAL|V117957 2 mg|V117957 tablets taken orally at bedtime
62064255|NCT04035200|PLACEBO_COMPARATOR|Placebo|Placebo to match V117957 tablets taken orally at bedtime
62064256|NCT02893306|EXPERIMENTAL|DMT1+MSCs|type 1 diabetic patients receiving a single dose of allogeneic ex vivo expanded mesenchymal stem cells
62064257|NCT02565121|EXPERIMENTAL|Olfactory disorder after brain trauma|Recruited from 250 patients with moderate to severe traumatic brain injury in the Hodeskadeprosjektet (TBI) cohort. Treatment with (first) corticosteroids and (second) olfactory stimulation.
62064258|NCT01934998||SCA6 and control|SCA6 and control
62064259|NCT01934998||SCA6 or controls|Twelve SCA6 patients and 8 controls to be studied
62064260|NCT04402658|EXPERIMENTAL|Physical performance test|After performing measurements of lung function by spirometry, participants will inhale either salbutamol or placebo. After 15 minutes of rest, a second spirometry will be performed before the participants warm-up by 10 minutes cycling. The exercise protocol will consist of 60 minutes of cycling at 70% of maximal oxygen consumption (VO2max) on the cycle ergometer followed by an all-out sprint. Several times during the exercise test, 30-second Wingate tests will be conducted. Participants will be blinded to feedback such as power (W), distance covered, and heart rate. Strong verbal encouragement will be given to each participant for them to perform their best. Measurements of lung function (spirometry), heart rate, arterial oxygen saturation and Borg ratings of perceived exercising will be recorded throughout the trials, as well as capillary blood sampled for analysis of \[La-\] and \[Glucose\].
62064261|NCT05745428||First group with aortic dissection|19 patients admitted to our Department of Cardiovascular Sciences with a radiological diagnosis of AD within 14 days of the onset of symptoms
62064262|NCT05745428||Control Group|19 healthy outpatient or inpatient controls at our Department with another diagnosis and no evidence of AD, matched for demographic and clinical characteristics.
62064263|NCT00002537|EXPERIMENTAL|Arm I|Beginning on day 1, patients receive topotecan IV continuously for 3-6 weeks and thoracic radiotherapy 5 days a week for 2, 3, or 6 weeks. Cohorts of 4-6 patients receive escalating doses of topotecan and thoracic radiotherapy until the maximum tolerated dose (MTD) of each therapy is determined. The MTD is defined as the dose preceding that at which 2 of 4 or 6 patients experience dose-limiting toxicity. Six additional patients are treated at the MTD. Patients who fail to achieve complete remission (CR) and continue to have measurable disease at 4-6 weeks after completion of radiotherapy receive topotecan IV continuously on days 1-21 at 1 dose level preceding the MTD as determined by the ongoing Protocol NYU-9123. Treatment continues every 4 weeks in the absence of unacceptable toxicity.
62064264|NCT06389097||Cohort A|Patients with advanced prostate cancer planning to undergo treatment with Radium-223
62064265|NCT06389097||Cohort B|Patients with advanced cancer undergoing treatment with 177Lu-DOTATATE or 177Lu-PSMA-617
62064266|NCT04586413||Non-hospitalised post-COVID-19 patients|This cohort will have had a confirmed positive test for COVID-19 or antibody test confirming they had COVID-19 but they were not hospitalised for this
62064267|NCT04586413||Hospitalised post-COVID-19 patients|This cohort will have a confirmed diagnosis of COVID-19 and been hospitalised but were not in an Intensive Care Unit
62064268|NCT04586413||Intensive care post-COVID-19 patients|This cohort will have a confirmed diagnosis of COVID-19 and been hospitalised in an Intensive Care Unit
62064269|NCT00284141|EXPERIMENTAL|aflibercept 4.0 mg/kg|Participants with metastatic non-small-cell lung adenocarcinoma administered 4.0 mg/kg Aflibercept every 2 weeks until a study withdrawal criterion was met.
62064270|NCT01356953|EXPERIMENTAL|Aerobic Exercise|
62452075|NCT05376046||Healthy|25 healthy controls matched on age and gender
62452076|NCT00873054||1 ESWL|In this procedure,scope will be placed inside bladder and a plastic tube (stent) will be left to drain the kidney on the affected side in a routine manner. Next the patient will be transferred to a separate room and sound waves will be aimed at the center of the stone until the stone is broken into pieces.
62630549|NCT01007604|EXPERIMENTAL|PCD with peristaltic pulse waveform|Daily use for two hours
62630550|NCT01388933|EXPERIMENTAL|TU-100|15g TU-100 (oral, daily) for 8 consecutive weeks (administered as 5g three times daily)
62630551|NCT01388933|PLACEBO_COMPARATOR|Matching placebo|Matching placebo given 5g three times daily orally for 8 consecutive weeks
62630552|NCT01938846|EXPERIMENTAL|BI 860585|Multiple ascending doses of BI 860585 administered continuously in a 28-day cycle, including food interaction cohorts
62630553|NCT01938846|EXPERIMENTAL|BI 860585 + paclitaxel|Multiple ascending doses of BI 860585 in combination with fixed dose paclitaxel
62452077|NCT00873054||2 PCNL|In this procedure,scope will be placed inside bladder and a plastic tube (stent) will be left to drain the kidney on the affected side in a routine manner. Next, a small (1cm) cut will be made in the back and a tube will be placed into the kidney. Through this tube a small camera will be placed inside the kidney and break the stone into many pieces and remove them through the same tube. All fragments that can be seen will be removed. A different plastic tube (drain) will be placed through the cut and into the kidney and left in place for 5-7 days.
62064271|NCT03276637|EXPERIMENTAL|Healthy Active-Duty Airmen Cohort|Whole exome sequencing (WES) will be performed on 75 ostensibly healthy, active-duty Airmen (patient-participants) who receive medical care in military Primary Care, Internal Medicine and/or Family Practice settings who in their baseline survey expressed interest in receiving WES. Military healthcare providers who have received brief genomics training will return results to the patient-participants and the WES reports will be permanently integrated into their electronic medical record.
62452078|NCT00587574||I|Chronic graft-versus-host disease
62064272|NCT03276637|NO_INTERVENTION|Healthcare Provider Cohort|The Healthcare providers who provide medical care in military Primary Care, Internal Medicine and/or Family Practice settings and enroll participants. Military healthcare providers have received a brief genomics training and will return results to the patient-participants
62452079|NCT00587574||II|No chronic graft-versus-host disease
62452080|NCT01393236||patients|patient characteristics are specified in H-2-2010-011
62452081|NCT01393236||controls|age matched to patients described in protocol H-2-2010-011
62630554|NCT01938846|EXPERIMENTAL|BI 860585 + exemestane|Multiple ascending doses of BI 860585 in combination with fixed dose exemestane
62630555|NCT03360019|ACTIVE_COMPARATOR|Residents in memory care or skilled nursing Facility|
62630556|NCT03360019|ACTIVE_COMPARATOR|Resident in independent living setting|
62630557|NCT03360019|OTHER|Care Partners|
62630558|NCT06451666|EXPERIMENTAL|Pilocarpine HCl Ophthalmic Solution|
62630559|NCT06451666|PLACEBO_COMPARATOR|Vehicle|
62064273|NCT05674890|OTHER|Group A: HFA followed by SSVR|Patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with both the Humphrey HFA-III perimeter and the SmartSystem VR headset on the same clinic visit, spaced roughly 10-15 minutes apart. The sequence in which each patient undertakes the two tests will be randomized. Group A includes participants who tested using the HFA, followed by a 15 minute rest period, then tested with the SSVR.
62064274|NCT05674890|OTHER|Group B: SSVR followed by HFA|Patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with both the Humphrey HFA-III perimeter and the SmartSystem VR headset on the same clinic visit, spaced roughly 10-15 minutes apart. The sequence in which each patient undertakes the two tests will be randomized. Group B includes participants who tested using the SSVR, followed by a 15 minute rest period, then tested with the HFA.
62064275|NCT00737880|ACTIVE_COMPARATOR|1|In situ organ perfusion using HTK solution during pancreas procurement
62064276|NCT00737880|ACTIVE_COMPARATOR|2|In situ perfusion using UW solution during pancreas procurement
62064277|NCT03809884|EXPERIMENTAL|Dietary Counselling|All enrolled patients will undergo a 1:1 counselling with a registered dietitian (with possible inclusion of family members, as appropriate). The dietitian will undertake an assessment of the comorbidities (e.g. diabetes), dietary intake, dietary habits (e.g. eating out, food preparation, socio-cultural aspects) and provide an individually tailored strategy to increase potassium in the diet. Secondly, on a weekly basis, the dietitian will contact the patient by telephone, or electronically (as preferred by the patient) to reinforce the advice and provide support/advice as necessary.
62064278|NCT03809884|ACTIVE_COMPARATOR|Potassium Citrate Supplement|Patients who are not able to successfully increase their potassium intake at 4 weeks with dietary counselling will receive potassium citrate supplements. They will receive oral potassium supplementation in the form of 50 to 100 mmol of potassium citrate (as 25 to 50 ml of the liquid solution).
62064279|NCT04099602|EXPERIMENTAL|Massage group|Twice a day after the birth of the baby was massaged by the researcher for 5 days. Bilirubin levels were measured twice daily by the transcutaneous bilirubin meter before the morning massage and 2 hours after the evening massage for 5 days. In the morning (between 07:00-09:00 am) and in the evening (between 19:00-21:00 pm) twice a day, 15-20 minutes baby massage was applied.
62630560|NCT00959283||Ancillary-correlative|Patients undergo peripheral blood collection periodically for biomarker analysis. Samples are analyzed for GATA1 mutations by real-time PCR, polymorphisms, cytogenetics, and K-RAS mutations, gene expression, drug sensitivity patterns, and minimal residual disease by flow cytometry.
62630561|NCT02332941|EXPERIMENTAL|Single Arm|This is a pilot study. It will be an interventional, prospective, observational, clinical study that seeks to evaluate the effect of intravitreal rituximab over a period of one month.
62064280|NCT04099602|NO_INTERVENTION|Control group|The control group who were administered standard care and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days
62064281|NCT04170686|EXPERIMENTAL|Immediate Treatment|Participants will have immediate access to the self-help app. They will take 8 weeks to work through the content at their own pace.
62064282|NCT04170686|NO_INTERVENTION|Waitlist Control|"Participants in the waitlist will receive no intervention for 8 weeks, other than a few check in emails from study personnel. At the end of 8 weeks, they will be crossed over to the active treatment group and will be given access to the app."
62064283|NCT05365711||Pregnant women|Microbiological samples are collected from the pregnant women in the mid-pregnancy and during the delivery. Patient records of these women and newborns are investigated for any infections or complications during and after the delivery.
62064284|NCT05365711||Partners|Partners of the pregnant women will be studied to understand the household transmission of studied bacteria and possible risk factors for carriage.
62064285|NCT04954586|EXPERIMENTAL|Pain Informed Movement|This will be an 8-week in-person group exercise program held twice weekly, in which participants will receive pain Informed movement (60 minutes), with instructions provided for a third home session. Home sessions will be facilitated by exercise handout sheets. Pain education will be delivered through weekly access to videos. The pain informed movement component has been developed by a team member and will be delivered by an experienced yoga teacher.
62064286|NCT02094521|EXPERIMENTAL|NNC0113-0987|
62064287|NCT04438902|EXPERIMENTAL|osimertinib combined with anlotinib|
62064288|NCT01545180||HTPcap in IC|HTPcap active and passive in a population of stable patients with heart failure (left ventricular ejection fraction impaired or preserved) and / or valvular disease who received a left right heart catheterization as part of their care.
62064289|NCT02468102||Rivaroxaban / Cohort 1|Patients who have filled a prescription for rivaroxaban in any pharmacy in Sweden during the study period.
62064290|NCT02468102||Standard of care drugs / Cohort 2|Patients who have filled a prescription for standard of care drugs (warfarin, aspirin, clopidogrel, ticlopidine, prasugrel or ticagrelor) in any pharmacy in Sweden during the study period.
62630562|NCT02372383|EXPERIMENTAL|Fasting|"Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes~* Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~* Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~* Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
62064291|NCT04257708||normal uterine cavity|
62269437|NCT05956795||BWH stage T2b|Participants whose cutaneous squamous cell carcinoma is BWH stage T2b. Participants will initially undergo CT imaging of the nodal basin immediately after diagnosis. If the CT is positive, the participants will be excluded from the study. If the CT is unremarkable, patients will undergo sentinel lymph node biopsy (SLNB), which has a higher sensitivity to detect occult micro-metastases. If the SLNB is negative, the participants are entered into the study. The participants will have ultrasound surveillance every 6 months and regular visits every 3 months throughout the duration of the study (2 years).
62452082|NCT04906577|EXPERIMENTAL|VIZOLF|visual stimulus (photograph of the child) and olfactory stimulus ad libitum, with a minimum of 6 stimulations per day, to the body odour emitted by the child during the first 5 days of life
62452083|NCT04906577|EXPERIMENTAL|VIZ|visual stimulus (photograph of the child) and olfactory stimulus ad libitum, with a minimum of 6 stimulations per day, to a neutral odour during the first 5 days of life
62452084|NCT04500522|EXPERIMENTAL|INH|3 vaginal tablet of isonicotinic acid hydrazide (INH) 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.
62064292|NCT04257708||abnormal uterine cavity|
62064293|NCT00815035|ACTIVE_COMPARATOR|Peanut OIT|Subjects randomized to receive active treatment with peanut protein flour.
62064294|NCT00815035|PLACEBO_COMPARATOR|Placebo|Subjects randomized to receive placebo in the form of oat flour.
62064295|NCT03454464|SHAM_COMPARATOR|Conventional operation group|Conventional operation group,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure.
62064296|NCT03454464|EXPERIMENTAL|central neck dissection first group|central neck dissection first group,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
62269438|NCT05956795||BWH stage T3|Participants whose cutaneous squamous cell carcinoma is BWH stage T3. Participants will initially undergo CT imaging of the nodal basin immediately after diagnosis. If the CT is positive, The participants will be excluded from the study. If the CT is unremarkable, patients will undergo sentinel lymph node biopsy (SLNB), which has a higher sensitivity to detect occult micro-metastases. If the SLNB is negative, the participants are entered into the study The participants will have ultrasound surveillance every 6 months and regular visits every 3 months throughout the duration of the study (2 years).
62269439|NCT04469413||standard IV intermittent bolus infusion group|
62064297|NCT04235582|EXPERIMENTAL|Outcomes Group|"During the intervention period, the Outcomes group will receive incentives for abstaining from drug use. Patients in this group will receive the same services and urine drug-test schedule as standard of care and a similar mobile app and debit card as the Inputs group. However, the app will prompt patients in this group to submit saliva drug tests through their mobile phones on a random schedule (averaging three tests per week). Patients will receive immediate financial rewards in exchange for submitting drug-negative samples. Saliva tests typically have a window of detection between 24-48 hr after drug use."
62088146|NCT02782429|EXPERIMENTAL|Ketamine|This group received ketamine in a dose 0.5 mg / in anesthesia, in addition to other drugs used for induction, which will be standardized.
62269440|NCT04469413||continuousIV intermittent bolus infusion group|
62269441|NCT03014401|EXPERIMENTAL|Stem Cells|Fat pad harvest with stem cell transplantation and standard arthroscopic debridement.
62269442|NCT03014401|ACTIVE_COMPARATOR|Placebo|Standard arthroscopic debridement with fat pad harvest WITHOUT stem cell transplantation
62630563|NCT02372383|EXPERIMENTAL|Food/Enzymes|"Subjects with CF will be given the antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).~* Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~* Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~* Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
62630564|NCT02372383|ACTIVE_COMPARATOR|Healthy Controls|"Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes~* Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~* Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~* Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
62630565|NCT03758157||Temperature Measurement|Each subject will have his or her temperature measured by both the welloStationX Automated Non-Contact Thermometer and the Welch Allyn SureTemp Oral Thermometer.
62064298|NCT04235582|EXPERIMENTAL|Inputs Group|"Will receive incentives for behaviors that are inputs to abstaining from drug use. Patients in this group will receive the same services and urine drug-test schedule as standard of care. Additionally, patients will be registered for a mobile phone app provided by DynamiCare Health and provided with a linked debit card. The app will prompt patients to complete actions that are inputs to abstinence an average of three times per week. These actions will be tailored to the patient's individual needs, and may include:~* Drug adherence to prescribed SUD pharmacotherapy~* Attendance at individual and group psychotherapy sessions"
62064299|NCT04235582|EXPERIMENTAL|Combination Group|"Will receive interventions from both Inputs and Outputs groups, as well as standard of care therapy services and urine drug tests an average of three times per week, total. Interventions include incentives for:~* Drug adherence to prescribed SUD pharmacotherapy~* Attendance at individual and group psychotherapy sessions~* Random saliva tests"
62630566|NCT01873118|NO_INTERVENTION|Usual Care Control hospital unit|This study involves implementation of interventions across entire hospital units. This arm is a usual care control unit paired to the intervention unit.
62630567|NCT01873118|EXPERIMENTAL|implementation unit|"3 implementation protocols implemented sequentially:~1. RN-RHDS: implementation of discharge readiness assessment by the discharging nurse~2. RN-RHDS+PT-RHDS: implementation of discharge readiness assessment by the discharging nurse which is informed by patient self-assessment of discharge readiness~3. RN-RHDS+PT-RHDS+NIAF: implementation of discharge readiness assessment by the discharging nurse which is informed by patient self-assessment of discharge readiness followed by documentation of nurse actions initiated in response to the assessment. Nurse are instructed that action must be taken if any assessment item scores less than 7 ( on a 10 point scale)."
62064300|NCT00793221|OTHER|Sirolimus-eluting stent|Implantation of sirolimus-eluting coronary stent
62269443|NCT06206174|EXPERIMENTAL|TGRX-814|TGRX-814 monotherapy for Dose escalation study; oral, once daily administration.
62630568|NCT06005753|EXPERIMENTAL|Group A|Surgical intervention group
62630569|NCT02235025|OTHER|Asymptomatic mild COPD|Subjects of this group have GOLD grade I COPD (post-bronchodilator FEV1 \> 80% predicted and FEV1/FVC \< 0.7). They also have a modified Medical Research Council (mMRC) score equal to zero and are free of respiratory symptoms including chronic cough and/or chronic expectoration and/or chronic wheeze.
62630570|NCT02235025|OTHER|Symptomatic mild COPD|Subjects of this group have GOLD grade I COPD (post-bronchodilator FEV1 \> 80% predicted and FEV1/FVC \< 0.7). They also have a modified Medical Research Council (mMRC) score \> 0.
62064301|NCT00793221|ACTIVE_COMPARATOR|Everolimus-eluting stent|Implantation of everolimus-eluting coronary stent
62269444|NCT01531920|OTHER|alcohol + placebo|Part A alcohol + placebo
62064302|NCT03861806|EXPERIMENTAL|PAS true|Participants will receive paired associative stimulation therapy with a modulatory inter-stimulus interval.
62269445|NCT01531920|OTHER|alcohol + perampanel|Part A : alcohol + perampanel
62064303|NCT03861806|SHAM_COMPARATOR|PAS sham|Participants will receive paired associative stimulation therapy with a non modulatory inter-stimulus interval.
62269446|NCT01531920|OTHER|perampanel + alcohol|Part B: perampanel + alcohol
62269447|NCT01531920|OTHER|placebo + alcohol|Part B: placebo + alcohol
62269448|NCT05059314|EXPERIMENTAL|Interventional group|"1. Warm up and cool down~2. Brisk walk (30 mintues each session per week 5 days)~3. Week 1 to 6"
62269449|NCT05059314|NO_INTERVENTION|Control group|Routine activity
62269450|NCT01595776|EXPERIMENTAL|single arm: autologous EPCs|
62064304|NCT05272670|EXPERIMENTAL|Experimental group|A 4-week digital foot self-management program will be provided to the participants in experimental group.
62064305|NCT05272670|NO_INTERVENTION|Control group|The control group received routine care that are required to attend the education sessions in the diabetes clinic according to their scheduled appointments. Routine care included routine check-ups and foot care education.
62064306|NCT03892629|EXPERIMENTAL|Baduanjin exercise group|Participants in this group received Baduanjin exercise
62064307|NCT03892629|ACTIVE_COMPARATOR|Instrument rehabilitation group|Participants in this group received rehabilitation by using tri-ball respiratory trainer
62269451|NCT04699487|EXPERIMENTAL|Patient receiving Photobiomodulation|
62630571|NCT02235025|OTHER|Healthy controls|Healthy controls have normal baseline spirometry (FEV1 \> 80% predicted, FEV1/FVC \> 0.7). They don't have any health problems, including cardiovascular, metabolic, neuromuscular, musculoskeletal, or respiratory diseases that could contribute to breathlessness or exercise limitation. They have a mMRC score equal to zero and do not complain any respiratory symptoms including chronic cough and/or chronic expectoration and/or chronic wheeze and/or chronic respiratory related medication.
62269452|NCT01060085||Breast Cancer|Women shown to have DCIS or invasive breast cancer by fine needle aspiration cytology and/or core needle biopsy.
62269453|NCT00832728|ACTIVE_COMPARATOR|ELAD|ELAD Therapy + Standard of Care
62269454|NCT00832728|OTHER|Standard of Care|Hospital based standard of care for acute liver failure
62269455|NCT05405179|EXPERIMENTAL|Simultaneous dental implantation|To perform dental implantation simultaneously in free vascularized flap during jaw reconstruction
62269456|NCT04962360|EXPERIMENTAL|Nutritional standardized supplementation formula.|Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake.
62269457|NCT04962360|PLACEBO_COMPARATOR|Placebo|Low caloric formula (Powder added to water) without added vitamins and minerals
62630572|NCT05050305|EXPERIMENTAL|Marizomib plus pomalidomide and dexamethasone|"A safety run-in using a modified 3+3 dose de-escalation design with relapsed/refractory multiple myeloma (RRMM) cohort, expanded to a total of 16 participants once recommended phase 2 does (RP2D) has been identified.~* Marizomib (MRZ) at a pre-determined dose on Days 1, 8, 15, 22 of a 28 day study cycle~* Pomalidomide (POM) at a daily predetermined dose on Days 1-21 of a 28 day study cycle~* Dexamethasone (DEX) at a daily predetermined dose on Days 1, 2, 8, 9, 15, 16, 22, 23 of a 28 day study cycle~Simultaneously, relapsed/refractory multiple myeloma (RRMM) with central nervous system (CNS) involvement cohort will receive an identical modified 3+3 dose de-escalation design and expanded to an efficacy-evaluable total of 30 patients once recommended phase 2 does (RP2D has been identified"
62630573|NCT06144112|ACTIVE_COMPARATOR|fresh frozen plasma|according to the Thromboelastography (TEG) test, CK r-time prolongation, fresh frozen plasma transfusion (FFP) is performed
62452085|NCT04500522|PLACEBO_COMPARATOR|Placebo Comparator|3 vaginal tablet of Placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
62452086|NCT00532337|PLACEBO_COMPARATOR|P|
62630574|NCT06144112|EXPERIMENTAL|prothrombin complex concentrate|according to the Thromboelastography (TEG) test, CK r-time prolongation, prothrombin complex concentrate (PCC) is administered
62630575|NCT05632263||EHMRGscore|validation of the EHMRG score for hospitalized patients with acute heart failure in the emergency department
62269458|NCT04360902|NO_INTERVENTION|Standard of Care Group|Subjects in the standard of care group will continue to receive anemia management in the same way they normally do as part of their routine dialysis care. For the purposes of this study, this means the use of the clinic's established Mircera® anemia management algorithm. Participation in this study will not affect the anemia management of subjects in the control group.
62452087|NCT00532337|EXPERIMENTAL|E1|
62452088|NCT00532337|EXPERIMENTAL|E2|
62452089|NCT00532337|EXPERIMENTAL|E3|
62630576|NCT03727841|EXPERIMENTAL|1/Arm 1 Marizomib|Marizomib at days 1, 8, and 15 of each 28-day cycle
62630577|NCT03727841|NO_INTERVENTION|P/Pregnancy Evaluation|Data collection on pregnancy, birth and Health of Child
62064308|NCT03892629|ACTIVE_COMPARATOR|Baduanjin Exercise and Instrument Rehabilitation|Participants in this group received both instrument rehabilitation and Baduanjin exercise
62064309|NCT03892629|NO_INTERVENTION|No Intervention|Participants in this group only received routine drug-treatment
62064310|NCT02852122|EXPERIMENTAL|C-11 choline|
62064311|NCT00780182|EXPERIMENTAL|1|All subjects will receive three 40mg doses of CMX001 as 1)solution fasted, 2)tablet fasted and 3)tablet following a high-fat breakfast. The order in which each subject receives each of the doses will be determined by a randomization code.
62064312|NCT01920425|OTHER|Hand-written diary first|Participants in this group will use the hand-written diary for the first two week and switch to Kinesia HomeView and the electronic diary for the second two weeks.
62088147|NCT02782429|PLACEBO_COMPARATOR|Placebo|This group received the equivalent volume of saline, in addition to other drugs used for induction, which will be standardized.
62452090|NCT00532337|ACTIVE_COMPARATOR|A|
62630578|NCT03356600|EXPERIMENTAL|Apatinib plus radiotherapy|"Apatinib:~Within 1 week before radiotherapy, the dose of Apatinib were 500mg/daily .During radiotherapy,the dose of Apatinib were 250mg/daily.~After radiotherapy, if the subject did not have a level 3 or above adverse reaction, investigators consider increasing doses to 500mg.~Radiotherapy:~The subjects with 1 to 4 metastases receive stereotactic radiosurgery or stereotactic radiation therapy ,and the subjects with more than 4 metastases receive stereotactic radiosurgery plus whole-brain radiation therapy."
62630579|NCT02606240||Mild to Moderate ARDS on PRISMALUNG|Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device in patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS).
62064313|NCT01920425|OTHER|Kinesia HomeView first|Participants in this group will use Kinesia HomeView and the electronic diary for the first two week and switch to the hand-written diary for the second two weeks.
62064314|NCT05591625|NO_INTERVENTION|Control|Participants who exhibit symptoms of PTSD and are randomised to the control group, will receive usual care offered by their hospital.
62064315|NCT05591625|EXPERIMENTAL|Eye Movement Desensitisation and Reprocessing|Participants who exhibit symptoms of PTSD and are randomised to the intervention group, will receive EMDR plus usual care offered by their hospital. EMDR will be delivered by trained and accredited psychological therapists, employed by National Health Service community mental health teams.
62064316|NCT05591625|NO_INTERVENTION|Observation|Participants who do not exhibit symptoms of PTSD will receive usual care offered by their hospital and repeat the psychological assessment at 12-months post-hospital discharge.
62452091|NCT01690442|EXPERIMENTAL|Couples Based HIV/STI Risk Reduction Intervention (CHSR)|The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
62452092|NCT01690442|ACTIVE_COMPARATOR|Renaissance Wellness Promotion (WP)|This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
62630580|NCT00807365|EXPERIMENTAL|GHRH|Growth Hormone-Releasing Hormone
62630581|NCT00866957||Patients with liver cancer|Patients diagnosed with liver cancer
62630582|NCT01523145|EXPERIMENTAL|Intervention|
62630583|NCT01523145|EXPERIMENTAL|Control gruop|
62630584|NCT04887350|EXPERIMENTAL|Student-Senior Isolation Prevention Partnership (SSIPP)|The Student-Senior Isolation Prevention Partnership is a phone administered talk therapy.
62630585|NCT04887350|ACTIVE_COMPARATOR|Problem Solving Therapy (PST)|Problem Solving Therapy is a phone administered talk therapy.
62064317|NCT03221010|EXPERIMENTAL|Motivational Interviewing|Intervention Group: in this group, composed of 6 randomized Basic Health Units, the professionals who coordinate the smoking groups will receive the training for the use of the Motivational Interviewing as an additional resource to the work of motivation and cognitive-behavioral approach usually performed in the groups, however , With an approach based on Motivational Interviewing.
62064318|NCT03221010|ACTIVE_COMPARATOR|Traditional cognitive-behavioral approach|Control Group: in this group composed of the remaining 6 Randomized Basic Health Units, professionals will use only the traditional cognitive-behavioral approach advocated by the Brazilian Ministry of Health's smoking program.
62064319|NCT04344041|EXPERIMENTAL|Intervention group|High dose of vitamin D3
62064320|NCT04344041|ACTIVE_COMPARATOR|Comparator group|Standard dose of vitamin D3
62064321|NCT05966935|EXPERIMENTAL|fenugreek cumin powder|Overweight and Obese adults in this group will receive fenugreek cumin powder daily twice a day before morning and evening meals for 8 weeks
62064322|NCT05966935|NO_INTERVENTION|Control group|Overweight and obese participants in this group will not receive fenugreek and cumin powder or any intervention for 8 weeks
62064323|NCT06383702|EXPERIMENTAL|Experimental: pregabalin sustained-release tablets|
62064324|NCT06383702|PLACEBO_COMPARATOR|Placebo Comparator|
62452093|NCT01209052|EXPERIMENTAL|COHORT 1|Interlocking design with Cohort 2. Single dose; treatment period over 2 days such that two subjects will receive GSK1325756 and at least one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK1325756 from 10mg, to 50mg, and 200mg, will be administered over the 6 week long treatment period allowing adequate washout period between doses.
62630586|NCT04887350|OTHER|Wait List Control (WLC)|Participants in the WLC will continue with their regular treatments for the 12 week study period but not receive any study related intervention during this 12 weeks. Following completion of all study assessments WLC participants will self-select either SSIPP or PST. Participants in WLC will not complete study assessments after week 12.
62064325|NCT03027414|EXPERIMENTAL|Substudy 1 Active and Sham|HVs that receive TMS over the right dlPFC
62064326|NCT03027414|EXPERIMENTAL|Substudy 2 Active and Sham|HVs that receive TMS over the right dlFPC
62064327|NCT03027414|EXPERIMENTAL|Substudy 3 Active and Sham|HVs will receive offline TMS to the lest IPS (FPN)
62088148|NCT03591965|EXPERIMENTAL|ATG-008|To enroll approximately 40 hepatitis B virus (HBV) positive, unresectable HCC subjects who have previously received at least one prior line of systemic therapy. Among which, approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg, once daily (QD) and another approximately 20 subjects will receive oral ATG-008 at an initial dose of 20 mg, twice daily (BID). The pharmacokinetic (PK) samples will be collected from 10 subjects each in the two dose groups.
62064328|NCT05582980|EXPERIMENTAL|HD-tDCS (active)|Stimulation will be applied by a battery-operated device (NeuroConn DC Stimulator Plus) via 5 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration). To target the left DLPFC, the central electrode (anode) will be placed over International 10-20 electrode position F3, with return peripheral electrodes at Fp1, Fz, C3 and F7. Stimulation will be applied at an intensity of 2 milliamp (mA), 8-sec fade in and 5-sec fade out, for 20 min, two times daily, on 5 consecutive weekdays (total 10 sessions). During each session, the subject has to perform a computerized working memory task (i.e., 2-back task). The two times daily sessions will be separated by at least 2 hours.
62064329|NCT05582980|SHAM_COMPARATOR|HD-tDCS (sham)|In sham stimulation, the electrode montage and protocol will be the same as the active stimulation, except the 2 mA current will be turned on for 30 sec and then ramped down to 0 mA through the remainder of the 20-min time.
62064330|NCT01934413|ACTIVE_COMPARATOR|Technology-Enhanced TPC|In addition to receiving usual palliative care service in the hospital setting, Technology-Enhanced Transitional Palliative Care patients will receive Transitional Care from the Palliative Care consulting team beginning in the hospital within 24 hours of study enrollment and continuing post discharge for eight weeks in their homes in rural locations by means of video visits with the Palliative Care consulting team.
62064331|NCT01934413|OTHER|Usual standard of care|The control group will receive only the current standard palliative care service in the hospital setting, which includes standard in-hospital palliative care consultation and standard discharge planning.
62064332|NCT03614962|EXPERIMENTAL|Warmth + TENS group|All participants will be offered a hat device that elicits warmth and TENS.
62064333|NCT03614962|ACTIVE_COMPARATOR|Warmth + placebo-TENS group|All participants will be offered a hat device that elicits warmth and placebo-TENS.
62064334|NCT03614962|ACTIVE_COMPARATOR|Warmth group|All participants will be offered a hat device that elicits warmth only.
62269459|NCT04360902|EXPERIMENTAL|Intervention Group|"For subjects randomized into the intervention group, our erythropoiesis model will be used to identify each subject's individual values for several physiological determinants of erythropoiesis based on his/her sex, body height and history of body weights, Hgb concentrations and Mircera® administrations over the preceding 150 to 180 days.~For subjects in the intervention group, their current method of anemia management will be discontinued. From this point on, Mircera® dose recommendations will be generated by the Anemia Controller software based on our erythropoiesis model and each subject for the duration of their 26-week participation in this study. The Anemia Controller computes the Mircera® doses required to attain the target Hgb level of 10.5 g/dL. Controller-generated Mircera® recommendations will be communicated to the respective clinics' anemia managers on a standardized report."
62452094|NCT01209052|EXPERIMENTAL|COHORT 2|Interlocking design with Cohort 1. Single dose; treatment period over 2 days such that two subjects will receive GSK1325756 and at least one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK1325756 from 25mg, to 100mg, and 400mg, will be administered over the 6 week long treatment period allowing adequate washout period between doses.
62064335|NCT03614962|ACTIVE_COMPARATOR|TENS group|All participants will be offered a hat device that elicits TENS only.
62064336|NCT03614962|SHAM_COMPARATOR|control group|All participants will be offered a hat device that without warmth or TENS output.
62064337|NCT05453175|EXPERIMENTAL|Interrupting sitting|Participants will engage in low intensity physical activity every thirty minutes up to 120 minutes
62064338|NCT05453175|NO_INTERVENTION|Control|Participants will remain seated for the entire 120 minutes
62064339|NCT02456805|ACTIVE_COMPARATOR|Infant Formula 1|A standard commercial milk-based infant formula
62452095|NCT01209052|EXPERIMENTAL|COHORT 3|Placebo controlled, 14-day, once daily, repeat-dose evaluation with one selected dose of GSK1325756 in 14 subjects. Dose selection based on review of safety and tolerability data from cohorts 1 and 2.
62630587|NCT04399369|EXPERIMENTAL|SDF|38% silver diamine fluoride solution
62064340|NCT02456805|EXPERIMENTAL|Infant Formula 2|A standard commercial soy-based infant formula.
62630588|NCT04399369|ACTIVE_COMPARATOR|NaF|5% sodium fluoride varnish
62630589|NCT04194983|EXPERIMENTAL|Fish oils and dairy fats|
62630590|NCT04194983|PLACEBO_COMPARATOR|Fish oils and plant fats|
62064341|NCT01712243|ACTIVE_COMPARATOR|Dim light|15 minutes of very dim (\<1 lux) light during the night
62064342|NCT01712243|ACTIVE_COMPARATOR|Room light|15 minutes of normal room light (\~100 lux) during the night
62064343|NCT01712243|EXPERIMENTAL|Colored light|15 minutes of colored light during the night
62269460|NCT00745563|EXPERIMENTAL|A|
62630591|NCT04799262|EXPERIMENTAL|Tofacitinib+Prednisone|Tofacitinib was given at the dose of 10mg daily through the 24 weeks. Prednisone (or equivalent oral GCs) of 15 mg daily at baseline willed be tapered to 2.5 mg or less within 20 weeks. Unless specifically considered by patients and physicians, the GC will be tapered followed the predefined taper regimen depending on the response to treatment judged by PMR-AS. The PMR-AS will be determined every two weeks; if\<10 the GC daily dosage was decreased by 2.5mg; if\>17, the GC daily dosage was increased to the previous dosage; if 10≤PMR-AS≤17, the GC daily dosage was maintained at the previous stable dose.
62064344|NCT02206308|EXPERIMENTAL|single arm|Three escalating single-dose groups of chimeric anti-CD20 monoclonal antibody(SCT400) : 250 mg/m2 , 375 mg/m2，500 mg/m2, once a week for 4 doses;
62064345|NCT02786264||Propofol-dominant Sedation|Patients receiving propofol infusion for TAVR as the primary drug for sedation.
62269461|NCT05543473|EXPERIMENTAL|patients|patients with brain radiological findings that affect balance functions
62269462|NCT06296862|EXPERIMENTAL|Dietary Approaches to Stop Hypertension Diet|
62630592|NCT03183115|EXPERIMENTAL|RFA group|"Balloon type RFA (12J/cm2, 1 application) will be applied for the entire speckled esophageal mucosa at the 3 months after complete ESD.~Oral prednisolone 30mg/day will be prescribed at day 3 after RFA procedure and continue for 28 days to prevent the post-RFA stenosis."
62269463|NCT06296862|NO_INTERVENTION|Usual Diet|
62630593|NCT03183115|NO_INTERVENTION|Control group|No intervention; surveillance endoscopy alone
62630594|NCT02824224|EXPERIMENTAL|Tamoxifen|Tamoxifen 10mg tablet by mouth twice daily for 7 days
62630595|NCT02824224|PLACEBO_COMPARATOR|Placebo|Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
62630596|NCT02899247|EXPERIMENTAL|No Surface Sealant|Resin composite only
62630597|NCT02899247|ACTIVE_COMPARATOR|With surface Sealant|Resin composite with surface sealant application
62630598|NCT04367662|EXPERIMENTAL|Patient with COVID-19 infection|Patient with COVID-19 infection hospitalized in a COVID unit
62064346|NCT02786264||Dexmedetomidine-dominant Sedation|Patients receiving dexmedetomidine infusion for TAVR as the primary drug for sedation.
62630599|NCT04819139|ACTIVE_COMPARATOR|Thumb exercises +orthosis|"Participants will be instructed to perform daily exercises grouped in 3 sets of 10 repetitions in the absence of pain for 4 weeks. If the patient experienced pain, the number of repetitions dropped sequentially until the exercise was performed pain free. Exercises consisted of active - resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle. Each participant will also engaged in a one month re-education/joint protection program for thumb use during ADL's and completed a weekly record sheet for monitoring purposes.~In addiction, they will received a thumb whale orthosis to wear at night and during ADL's as needed for pain."
62630600|NCT04819139|EXPERIMENTAL|Thumb exercises +orthosis+ proprioceptive program exercises|"Participants will be instructed to perform daily exercises grouped in 3 sets of 10 repetitions in the absence of pain for 4 weeks. If the patient experienced pain, the number of repetitions dropped sequentially until the exercise was performed pain free. Exercises consisted of active - resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle. Each participant will also engaged in a one month re-education/joint protection program for thumb use during ADL's and completed a weekly record sheet for monitoring purposes.~In addiction, they will received a thumb whale orthosis to wear at night and during ADL's as needed for pain. In addiction, patients will received a proprioceptive program exercises using also a online program with a laptop."
62630601|NCT04000971|ACTIVE_COMPARATOR|Integrated Stroke Practice Unit (ISPU)|ISPU personnel will continue with care provided under the Joint Commission-certified CSC/PSC design, including a 30-day clinic visit post-discharge. This will be supplemented by a more integrated model designed to increase coordination through team-based initiatives across the continuum of care for stroke - from acute and in-hospital care through 12 months post-discharge. Care teams will follow patients in their home or rehabilitation/skilled nursing facility monthly for 12 visits to assess recovery, manage risk factors, increase understanding, and build positive behavior change for patients and caregivers. Primary outcomes will be assessed by phone at 3, 6, and 12 months; secondary outcomes will be assessed at 3, 6, and 12 months.
62064347|NCT03154372|OTHER|deliberate practice|expert supervised practice with validated metrics
62064348|NCT03154372|OTHER|self-guided practice|self guided practice with validated metrics
62269464|NCT00276172|EXPERIMENTAL|Natalizumab|Open-label natalizumab
62269465|NCT00872105|OTHER|Non-operative treatment|The first treatment strategy will involve conservative (nonoperative) management of the clavicle fracture.
62269466|NCT00872105|ACTIVE_COMPARATOR|Operative treatment|The second treatment strategy will involve operative fixation (i.e. ORIF) of the fracture with a plate and screws.
62269467|NCT02173743|EXPERIMENTAL|PRP group|PRP during barbotage
62269468|NCT02173743|OTHER|Control group|Regular barbotage
62269469|NCT00202735|ACTIVE_COMPARATOR|Immobilization in internal rotation|"Immobilization in internal rotation:All patients in this group are immobilized with the arm in internal rotation.~The arm is immobilized with a normal collar and cuff device."
62269470|NCT00202735|EXPERIMENTAL|Immobilization in external rotation.|Immobilization in external rotation (ER. All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling ER, 15˚ version.To control the position, a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed
62269471|NCT03828929|EXPERIMENTAL|Vitamin C and Thiamine|IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
62269472|NCT03828929|PLACEBO_COMPARATOR|Placebo|50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
62269473|NCT01266863|EXPERIMENTAL|E test method|
62269474|NCT05837637||Parkinson's disease patients|Parkinson's disease patients attend the Parkinson and Movement disorder clinic at Ho Chi Minh University Medical Center
62269475|NCT05837637||healthy control|The participants including hospital staffs and relatives of patients that matched age and gender
62269476|NCT02755857|EXPERIMENTAL|Lozanoc|65 mg, capsules, at least 2 capsules twice a day
62064349|NCT02041923|PLACEBO_COMPARATOR|Attention Control|Mothers received equal amount of attention from the team. Attention consisted of additional teaching regarding premature infant care.
62630602|NCT04000971|ACTIVE_COMPARATOR|Comprehensive or Primary Stroke Center (CSC/PSC)|CSC/PSC personnel will continue with care provided under the Joint Commission-certified CSC/PSC design, including a 30-day clinic visit post-discharge, follow-up clinic visits as recommended by their outpatient provider, and other clinic visits initiated by the patient when issues arise. Primary outcomes will be assessed by phone at 3, 6, and 12 months; secondary outcomes will be assessed at 3, 6, and 12 months.
62630603|NCT03679143|EXPERIMENTAL|ZSP1273(single dose)-100 mg(Cohort 1)|ZSP1273 100 mg /Placebo
62630604|NCT03679143|EXPERIMENTAL|ZSP1273(single dose)-200 mg(Cohort 2)|"ZSP1273 200mg/Placebo~Enrollment into Cohort 2 will begin upon assurance of tolerance for Cohort 1."
62269477|NCT04686630||Single group|Only observational study
62630605|NCT03679143|EXPERIMENTAL|ZSP1273(single dose)-400 mg(Cohort 3)|"ZSP1273 400mg/Placebo~Enrollment into Cohort 3 will begin upon assurance of tolerance for Cohort 2."
62630606|NCT03679143|EXPERIMENTAL|ZSP1273(single dose)-600 mg(Cohort 4)|"ZSP1273 600 mg/Placebo~Enrollment into Cohort 4 will begin upon assurance of tolerance for Cohort 3."
62630607|NCT03679143|EXPERIMENTAL|ZSP1273(single dose)-900 mg(Cohort 5)|"Drug:ZSP1273 900 mg/Placebo 900mg；~Enrollment into Cohort 5 will begin upon assurance of tolerance for Cohort 4."
62630608|NCT03679143|EXPERIMENTAL|ZSP1273(single dose)-1200 mg(Cohort 6)|"ZSP1273 1200 mg/Placebo~Enrollment into Cohort 6 will begin upon assurance of tolerance for Cohort 5."
62064350|NCT02041923|EXPERIMENTAL|H-HOPE Intervention|H-HOPE was administered twice daily by the mother.
62269478|NCT02877342||Pre-intervention|All injured patients arriving by ambulance (to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority category will be eligible for inclusion. Patients arriving without notification buy ambulance service
62630609|NCT03679143|EXPERIMENTAL|ZSP1273(Food Effect)-Cohort 7|"Drug:ZSP1273 /Placebo； Period 1 (Day1 to Day5): Subjects receive ZSP1273/Placebo under the fasting or fed condition ,respectively on Day1.~Period 2 (Day 8 to Day12): Subjects receive ZSP1273/Placebo under the fed or fasting condition, respectively on Day 8."
62630610|NCT03679143|EXPERIMENTAL|ZSP1273(multiple doses)-Low Dose(Cohort 8)|"while fasted or fed according to the results of Cohort FE~ZSP1273 /Placebo for 5 Days."
62630611|NCT03679143|EXPERIMENTAL|ZSP1273(multiple doses)-Median Dose(Cohort 9)|"while fasted or fed according to the results of Cohort FE~ZSP1273/Placebo for 5 Days."
62630612|NCT03679143|EXPERIMENTAL|ZSP1273(multiple doses)-High Dose(Cohort 10)|"while fasted or fed according to the results of Cohort FE~ZSP1273/Placebo for 5 Days."
62630613|NCT04156893|EXPERIMENTAL|RH genotype matched red cell transfusions|Subjects will receive RH genotyped matched red cell units for transfusion in addition to standard serologic C, E, and K antigen matching and being hemoglobin S negative, which is our institutional standard of care for patients with Sickle Cell Disease.
62064351|NCT03328143|EXPERIMENTAL|Treatment with Lavender|Lavender (Lavandula angustifolia) aromatherapy will be administered at regular intervals using a nasal inhaler.
62269479|NCT02877342||Post-Intervention|All injured patients arriving by ambulance, and allocated to a red (1st) or yellow (2nd) priority category will be eligible for inclusion. Patients arriving with and without notification by the ambulance service using the pre-hospital notification application.
62269480|NCT03821857|EXPERIMENTAL|Women|18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology
62269481|NCT05182554|NO_INTERVENTION|Control|No intervention in this arm; the study team will examine publicly available county- and zip code-level outcomes in this group.
62630614|NCT01707628|ACTIVE_COMPARATOR|Early group after rituximab|"Patients who received rituximab last dose 3-6 months before influenza vaccination will be the early group."
62630615|NCT01707628|ACTIVE_COMPARATOR|Late group after rituximab|"Patients who received rituximab last dose 9-12 months before influenza vaccination will be the late group."
62269482|NCT05182554|EXPERIMENTAL|Treatment 1: Direct|Facebook users in the area receive ads which include videos of health professionals telling them to get vaccinated. The health professionals answer common questions about Covid-19 vaccines (e.g. are they safe / are they free).
62269483|NCT05182554|EXPERIMENTAL|Treatment 2: Friends|Facebook users in the area receive ads which include videos of health professionals encouraging them to help their friends to get vaccinated. There is also a link in the ad to a website build by the study team. This website hosts videos which answer common questions about vaccination (the same videos which are directly served to Facebook users in Treatment 1).
62269484|NCT05182554|EXPERIMENTAL|Treatment 3: Gossips|Facebook users in the area receive ads which include videos of health professionals encouraging them to nominate their most influential friends to help their friends get vaccinated. The difference from Treatment 2 is that the health professionals call on Facebook users to get their most influential friends to do the convincing about the vaccine. There is also a link in the ad to a website built by the study team. This website hosts videos which answer common questions about vaccination (the same videos that are directly served to Facebook users in Treatment 1).
62269485|NCT03373604|EXPERIMENTAL|Cognitive impairment|Alzheimer's disease (mild cognitive impairment or mild stage Alzheimer's disease dementia)
62269486|NCT03373604|ACTIVE_COMPARATOR|No cognitive impairment|Healthy controls
62269487|NCT03044340|EXPERIMENTAL|erythermalgia patient|patient will be measured chlorine ions impedance with the SUDOSCAN and evaluation on pain du to temperature with the THERMOTEST
62452096|NCT01209052|EXPERIMENTAL|COHORT 4|Placebo controlled, 14-day, once daily, repeat-dose evaluation with a higher selected dose of GSK1325756 in 14 subjects. Dose selection based on review of safety and tolerability data from cohort 3.
62269488|NCT05011708|EXPERIMENTAL|Test (I-DROP MGD)|"Part I of this study is a contralateral eye design, accordingly patient would receive either I-DROP MGD (Test) or Thealoz Duo (Control) in either eye.~Part II, patients shall receive either only I-DROP MGD"
62269489|NCT05011708|ACTIVE_COMPARATOR|Control - Thealoz Duo|"Part I of this study is a contralateral eye design, accordingly patient would receive either I-DROP MGD (Test) or Thealoz Duo (Control) in either eye.~Part II, patients shall receive either only I-DROP MGD"
62269490|NCT00283595|ACTIVE_COMPARATOR|1|Treatment with rHGH
62269491|NCT00283595|PLACEBO_COMPARATOR|2|Treatment with Placebo
62269492|NCT00397826|OTHER|MK0733,simvastatin|20 patients with total cholesterol ≧ 240 mg/dL or LDL-C \> 160 mg/dL for primary hypercholesterolemia; LDL-C ≧ 130 mg/dL for secondary hypercholesterolemia with identifiable risk factors will be enrolled into study to receive simvastatin 40 mg once daily for 12 weeks.
62269493|NCT00338871|EXPERIMENTAL|study|home exercise
62269494|NCT00338871|NO_INTERVENTION|control|regular therapy
62269495|NCT01891331|EXPERIMENTAL|VT-1161 300mg QD|
62269496|NCT01891331|EXPERIMENTAL|VT-1161 600mg QD|
62269497|NCT01891331|EXPERIMENTAL|VT-1161 600mg BID|
62269498|NCT01891331|ACTIVE_COMPARATOR|Fluconazole 150mg|
62452097|NCT06496087|EXPERIMENTAL|Deprexil Group|The trial group will be administered 1 capsule of DEPREXIL orally every 8 hours for 6 months of treatment.
62452098|NCT04078048|EXPERIMENTAL|Vitamin C Group|Tablet Vitamin C 500 mg Once a day
62452099|NCT04078048|EXPERIMENTAL|Vitamin E Group|Tablet Vitamin E 600 I U Twice daily
62452100|NCT04078048|PLACEBO_COMPARATOR|Placebo Group|Capsule Paraffin oil 500 mg Once a day
62452101|NCT04111770|EXPERIMENTAL|IVUS guided PCI|Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.
62452102|NCT04111770|ACTIVE_COMPARATOR|QCA guided PCI|QCA will be used to determine lesion characteristics
62452103|NCT02619799|ACTIVE_COMPARATOR|GROUP A(MAGNESIUM GROUP)|MAGNESIUM GROUP received 50 mg(0.1 ml) of intrathecal magnesium sulphate diluted to 1 ml with 0.9% normal saline combined with 14-16 ml of epidural 0.75% ropivacaine as a part of combined spinal epidural technique at L2-L3/L3-L4 interspace.
62452104|NCT02619799|ACTIVE_COMPARATOR|GROUP B(MIDAZOLAM GROUP)|MIDAZOLAM GROUP received 1mg(0.2ml) of intrathecal midazolam diluted to 1ml with 0.9% normal saline combined with 14-16 ml of epidural 0.75% ropivacaine as a part of combined spinal epidural technique at L2-L3/L3-L4 interspace.
62452105|NCT06308874|EXPERIMENTAL|Amg dose Group|Amg dose administration group
62452106|NCT06308874|PLACEBO_COMPARATOR|Amg dose Group- Placebo|Amg dose administration group- Placebo
62452107|NCT06308874|EXPERIMENTAL|Bmg dose Group|Bmg dose administration group
62452108|NCT06308874|PLACEBO_COMPARATOR|Bmg dose Group- Placebo|Bmg dose administration group- Placebo
62452109|NCT05876195|PLACEBO_COMPARATOR|Group 1: Saline 0.9% (placebo) primary dose|IM saline 0.9% (placebo) day 0, followed by multi-dose ID subunit KLH (0 mcg (saline), 1 mcg, 3 mcg, 10mcg, 30mcg, 100mcg) day 28
62452110|NCT05876195|ACTIVE_COMPARATOR|Group 2: subunit KLH 1000mcg primary dose|IM dose subunit KLH 1000 mcg day 0, followed by multi-dose ID subunit KLH (0 mcg (saline), 1 mcg, 3 mcg, 10mcg, 30mcg, 100mcg) day 28
62452111|NCT05876195|ACTIVE_COMPARATOR|Group 3: subunit KLH 1000mcg plus aluminium hydroxide adjuvant 900mcg primary dose|IM dose subunit KLH 1000 mcg plus aluminium hydroxide 900mcg day 0, followed by multi-dose ID subunit KLH (0 mcg (saline), 1 mcg, 3 mcg, 10mcg, 30mcg, 100mcg) day 28
62064352|NCT01068301|OTHER|Second Allogeneic Transplant Procedure Recipient|"Participants with Acute Lymphoblastic Leukemia (ALL); Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Chronic Myeloid Leukemia (CML); Juvenile Myelomonocytic Leukemia (JMML); Non-Hodgkin lymphoma (NHL) with evidence of bone marrow disease, receiving a second allogeneic transplant procedure.~Intervention: Plerixafor"
62064353|NCT01540994|EXPERIMENTAL|SBRT|Stereotactic Body Radiation Therapy
62064354|NCT00628836|ACTIVE_COMPARATOR|SE group|surface stimulation
62064355|NCT00628836|EXPERIMENTAL|BE group|BION stimulation
62064356|NCT05626764||Immune checkpoint inhibitors|Any immunotherapy by immune checkpoint inhibitor molecule in combination or monotherapy, associated or no with any other cancer treatment such as chemotherapy, targeted therapy, radiotherapy, etc.
62064357|NCT05626764||CAR-T cells|Transplantation of recombined autologous immune T-cells
62269499|NCT05183750|OTHER|Adult with isolated medial compartmental knee osteoarthtitis|
62630616|NCT01707628|ACTIVE_COMPARATOR|Control group|Healthy individuals will be receive vaccination with influenza vaccine and will serve as controls.
62630617|NCT03559283|EXPERIMENTAL|Walking and Record Cortical Activity|A sensor placement will be performed on the patient's forehead to record brain activity when walking, when performing a mental task, and when performing both tasks at the same time. In parallel, walking will be on a carpet that will record the spatio-temporal parameters of walking.
62630618|NCT03666247|EXPERIMENTAL|HealthMindr Application|Participants in this study arm will have access to the mobile messaging platform (HealthMindr) for 3 months.
62630619|NCT03666247|OTHER|Waitlist|Participants in this study arm will not have access to the mobile messaging application during the course of the study. After the Month 9 follow up assessment participants in this study arm will be offered access to HealthMindr.
62630620|NCT01718392|EXPERIMENTAL|Training|24 weeks combined exercise programme (supervised)
62630621|NCT01718392|NO_INTERVENTION|Control|sedentary/habitual lifestyle
62630622|NCT06202703|EXPERIMENTAL|pneumococcal vaccination arm|the participants will receive a registered pneumococcal vaccine according to manufacturers instructions
62630623|NCT04356287|EXPERIMENTAL|One infusion of UCMSC|Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of placebo at month 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A. Each placebo infusion will consist of a similar volume of PlasmaLyte A.
62630624|NCT04356287|EXPERIMENTAL|Two infusions of UCMSC|Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of UCMSC at month 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A.
62452112|NCT05876195|ACTIVE_COMPARATOR|Group 4: subunit KLH 1000mcg plus Montanide ISA-51 primary dose|IM dose subunit KLH 1000 mcg plus Montanide ISA-51 day 0, followed by multi-dose ID subunit KLH (0 mcg (saline), 1 mcg, 3 mcg, 10mcg, 30mcg, 100mcg) day 28
62630625|NCT04356287|PLACEBO_COMPARATOR|Placebo infusions|Patients receive intravenous placebo infusions at months 0 and 3. Each placebo infusion will consist of 50 ml of PlasmaLyte A.
62630626|NCT01996111|EXPERIMENTAL|• Group 2:|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension
62630627|NCT01996111|EXPERIMENTAL|• Group 3:|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension
62064358|NCT00744263|PLACEBO_COMPARATOR|Placebo|
62064359|NCT00744263|EXPERIMENTAL|13-valent pneumococcal conjugate vaccine|
62064360|NCT03622879|EXPERIMENTAL|MT + TENS|The subject will adopt a semi-seated position on a bed while the mirror board is positioned between the legs perpendicular to the subject's midline. The paretic leg will be positioned behind the mirror, with the intact leg facing the reflective surface. All subjects will be reminded to focus on the image in the mirror during MT training. All subjects will receive concurrent TENS stimulation over the common peroneal nerve while practising bilateral lower limb exercises. After 15 minutes of priming with TENS + MT, all subjects will perform 60 minutes of lower limb task-oriented training.
62064361|NCT03622879|PLACEBO_COMPARATOR|Placebo-MT+TENS|In the Placebo-MT+TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group, except that the reflecting surface of the angle-adjustable mirror was covered with paper. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
62064362|NCT03622879|PLACEBO_COMPARATOR|MT+placebo-TENS|In the MT+placebo-TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group. The only difference is that placebo stimulation will be applied to the paretic limb from identical-looking TENS devices with the electrical circuit disconnected inside. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
62064363|NCT03622879|SHAM_COMPARATOR|control training|All subjects will perform 60 minutes of lower limb task-oriented training only.
62064364|NCT01865305|EXPERIMENTAL|Trial part 1|
62064365|NCT01865305|EXPERIMENTAL|Trial part 2|
62064366|NCT03735160||Nasal intubation with pressure sensor|anesthetized patient with nasotracheal intubation
62064367|NCT02692911||Women with gallstones|Women aged 50-74 with gallstones
62064368|NCT03209414||Stable coronary artery disease|Patients with stable effort angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
62269500|NCT01796405|EXPERIMENTAL|Low-Risk|Multifocal or Low-Risk Multi System Clofarabine, Low Dose, Two Cycles
62269501|NCT01796405|EXPERIMENTAL|High-Risk|High-risk Multi System Clofarabine, Standard Dose, Two Cycles
62269502|NCT05220527|EXPERIMENTAL|Study group|triamcinolone plus hyruan injection
62269503|NCT05220527|ACTIVE_COMPARATOR|Experimental|vitagen plus hyruan injection
62269504|NCT05220527|PLACEBO_COMPARATOR|Placebo|normal saline plus hyruan injection
62269505|NCT05337254|EXPERIMENTAL|STS101 5.2 mg|STS101 (dihydroergotamine nasal powder), 5.2 mg
62269506|NCT05337254|EXPERIMENTAL|STS101 7.0 mg|STS101 (dihydroergotamine nasal powder), 7.0 mg
62452113|NCT05876195|ACTIVE_COMPARATOR|Group 5: subunit KLH 10mcg primary dose|IM dose subunit KLH 10 mcg day 0, followed by multi-dose ID subunit KLH (0 mcg (saline), 1 mcg, 3 mcg, 10mcg, 30mcg, 100mcg) day 28
62452114|NCT05876195|ACTIVE_COMPARATOR|Group 6: subunit KLH 10mcg plus aluminium hydroxide adjuvant 900mcg primary dose|IM dose subunit KLH 10 mcg plus aluminium hydroxide 900mcg day 0, followed by multi-dose ID subunit KLH (0 mcg (saline), 1 mcg, 3 mcg, 10mcg, 30mcg, 100mcg) day 28
62630628|NCT01996111|EXPERIMENTAL|• Group 4:|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension
62630629|NCT01996111|PLACEBO_COMPARATOR|• Group 1|• Injection of 1.0 cc of 0.9% Saline
62269507|NCT05337254|EXPERIMENTAL|STS101 8.6 mg|STS101 (dihydroergotamine nasal powder), 8.6 mg
62269508|NCT05337254|ACTIVE_COMPARATOR|DHE intramuscular injection|Dihydroergotamine mesylate
62269509|NCT05337254|ACTIVE_COMPARATOR|DHE nasal spray|Dihydroergotamine mesylate
62452115|NCT05876195|ACTIVE_COMPARATOR|Group 7: subunit KLH 10mcg plus Montanide ISA-51 primary dose|IM dose subunit KLH 10 mcg plus Montanide ISA-51 day 0, followed by multi-dose ID subunit KLH (0 mcg (saline), 1 mcg, 3 mcg, 10mcg, 30mcg, 100mcg) day 28
62452116|NCT05876195|NO_INTERVENTION|Group 8: Blood-sample only group (non-randomised)|No challenge agent, blood sampling only.
62452117|NCT03048162|ACTIVE_COMPARATOR|sodium chloride|0.9% isotonic sodium chloride, 500 ml, one package in 30 minutes
62452118|NCT03048162|ACTIVE_COMPARATOR|Hydroxyethylstarch|6% hydroxyethylstarch, 500 ml, one package in 30 minutes
62452119|NCT03048162|ACTIVE_COMPARATOR|Ringer-Lactate Infusion Solution Bag|Ringer's lactate, 500 ml, one package in 30 minutes
62452120|NCT04908566|EXPERIMENTAL|PD-1 antibody combined with FOLFIRINOX regimen|
62452121|NCT04908566|ACTIVE_COMPARATOR|PD-1 antibody combined with SOX program|
62452122|NCT05132309||Chronic pancreatitis without pancreatic external insufficiency|
62452123|NCT05132309||Chronic pancreatitis with mild pancreatic external insufficiency|
62452124|NCT05132309||Chronic pancreatitis with severe pancreatic external insufficiency|
62452125|NCT05132309||Chronic pancreatitis with severe pancreatic external insufficiency who underwent pancreatic surger|
62452126|NCT00392639|EXPERIMENTAL|1-2|Comparison of 2 cooling procedures
62452127|NCT03774238|EXPERIMENTAL|COPD patients|FMD analysis Endothelial progenitors Exercise test Exercise training
62452128|NCT03774238|EXPERIMENTAL|Healthy subject|FMD analysis Endothelial progenitors Exercise test
62452129|NCT03868137|PLACEBO_COMPARATOR|Placebo|3 doses of placebo identical to study drug will be given to patients starting 1 day before IUD insertion
62452130|NCT03868137|EXPERIMENTAL|Ibuprofen|3 doses of Ibuprofen 800 mg will be given to patients starting 1 day before IUD insertion. Patient will take 800 mg Ibuprofen at noon and 8 PM day before IUD insertion and at 8 AM on the day of IUD insertion.
62452131|NCT01456182|OTHER|Dose arm 1|
62452132|NCT01456182|OTHER|Dose arm 2|
62452133|NCT01456182|OTHER|Dose arm 3|
62452134|NCT01456182|OTHER|Dose arm 4|
62452135|NCT01456182|OTHER|Dose arm 5|
62452136|NCT06257108|EXPERIMENTAL|Restorative group|Class II restorations using chlorhexidine-containing bonding agent in Primary molars in children aged between 5-9 years.
62452137|NCT06257108|ACTIVE_COMPARATOR|Control Group|Class II restorations using standard bonding agent in Primary molars in children aged between 5-9 years.
62452138|NCT02248077|ACTIVE_COMPARATOR|AutoloGel|AutoloGel consists of platelet-rich plasma (PRP) gel produced from the patient's own peripheral blood and pharmaceutical additives including calcium chloride, thrombin and ascorbic acid. The AutoloGel product is obtained by processing the patient's own blood using the AutoloGel System. After the final AutoloGel formulation is produced it is used immediately for patient's specific ulcer care.
62452139|NCT02248077|OTHER|Usual and Customary Care (UCC)|Standard of care
62452140|NCT01521442|EXPERIMENTAL|Arm 1|12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
62452141|NCT01521442|OTHER|Arm 2|12-week delay before beginning Mindful Yoga Therapy treatment which will consist of 12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
62269510|NCT02692066||Healthy Controls|Healthy Children ages 6 months-21 years who have not received varicella vaccine and who do not have prior varicella or zoster will receive Varivax. We will then measure 1) markers of humoral immunity at baseline and 4 weeks post vaccination and 2) markers of cell mediated immunity at baseline, 1 week, and 4 weeks post vaccination
62452142|NCT00966953|PLACEBO_COMPARATOR|Fluoride Toothpaste|fluoride control
62452143|NCT00966953|ACTIVE_COMPARATOR|Total/Whitening|positive control
62452144|NCT00966953|EXPERIMENTAL|antibacterial plant extract 1|Honokiol
62452145|NCT00966953|EXPERIMENTAL|antibacterial plant extract 2|magnolol
62452146|NCT02369809|EXPERIMENTAL|Neovasculgen®|Single group prospective treatment
62452147|NCT02369809|ACTIVE_COMPARATOR|standard care|
62452148|NCT01963039|ACTIVE_COMPARATOR|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement (PMMA) is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
62452149|NCT01963039|SHAM_COMPARATOR|Sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the bone cement(PMMA) is prepared to simulate the odor associated with mixing of polymethacrylate , but the needle is not placed and cement is not injected.
62452150|NCT02114697|ACTIVE_COMPARATOR|Lifestyle modification|Lifestyle modification is tailored to each participant and includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake.
62452151|NCT02114697|EXPERIMENTAL|Statin therapy|Participants will receive statin medication along with instruction about regular exercise.
62630630|NCT05748574|EXPERIMENTAL|"Sleep Well Sachet Treatment"|"Sachet of Sleep Well direct granulate (2.0 g)~1 sachet contains: 190 mg standardized dry extract of Melissa officinalis leaf , 75 mg dried pressed juice of fresh Lactuca sativa herb, 0.41 g Magnesiumdicitrate, 0.12 g L-Tryptophan, excipients and natural flavors."
62630631|NCT04986774|EXPERIMENTAL|Rescue Intracranial Stenting (RIS)|RIS in Acute Ischemic Stroke caused by intracranial large vessel occlusion
62630632|NCT06612411|ACTIVE_COMPARATOR|B. subtilis intervention|
62064369|NCT03209414||Unstable coronary artery disease|Patients with unstable angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
62630633|NCT06612411|PLACEBO_COMPARATOR|Placebo capsules|
62269511|NCT02692066||Children with Chronic Liver Disease|Children with chronic liver disease ages 6 months-21 years who have not received varicella vaccine and who do not have prior varicella or zoster will receive Varivax. We will then measure 1) varicella DNA in the blood and saliva at enrollment, 1 week, 2 weeks, 3 weeks, 4 weeks post vaccination 2)markers of humoral immunity at baseline and 4 weeks post vaccination and 3) markers of cell mediated immunity at baseline, 1 week, and 4 weeks post vaccination
62269512|NCT03119792|EXPERIMENTAL|Investigational|An education intervention will be implemented for 600 children from the original cohort (300) and comparable cohort (300) over a four month period at community centers. These sessions will occur twice a month on the weekends. The education intervention will help increase the children's knowledge of attitudes, and habits of healthy lifestyles.
62452152|NCT05445128|EXPERIMENTAL|Part A: Single Day Dosing/Apheresis|Single dose of MGTA-145 in combination with plerixafor followed by apheresis
62630634|NCT03166501|EXPERIMENTAL|Treatment|Lanicemine 100mg Intravenous
62452153|NCT05445128|EXPERIMENTAL|Part B: 2-Day Dosing/Apheresis|MGTA-145 in combination with plerixafor followed by apheresis on two consecutive days
62630635|NCT03166501|PLACEBO_COMPARATOR|Placebo|Normal saline Intravenous
62630636|NCT02651844|EXPERIMENTAL|Mifepristone|Tablets of Mifepristone 200 mg p.o. once a day during 14 days between biopsy and surgery after confirming inclusion criteria
62064370|NCT03209414||Non-ST elevation myocardial infarction|Patients with non-ST elevation myocardial infarction wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
62064371|NCT03209414||ST-elevation myocardial infarction|Patients with ST elevation myocardial infarction wil be enrolled. In majority of patients primary percutaneous coronary intervention will be performed. Based on coronary angiography, heart team will decide on further medical treatment, percutaneous angioplasty, or bypass grafting.
62064372|NCT03729024|EXPERIMENTAL|Light adjustable lens (LAL) and Light Delivery Device (LDD)|
62630637|NCT05827692|EXPERIMENTAL|Forest Bath Intervention group A|The intervention consists of 2 sessions of approximately 2 hours duration and fortnightly frequency. In this context, it is guaranteed that patients will receive the care, visits and treatments usually used in people who have presented their clinical situation. The only difference between participating or not in the intervention is the participation in the practice of forest baths and the performance of some additional assessments, i.e. not routinely performed, which are part of this project. The investigators will be responsible for providing an overview of the study to eligible patients interested in participating. Before proceeding to start the intervention, an informed consent will be given to the patients, in which a description of the characteristics of the sessions will be provided.
62064373|NCT05477147|EXPERIMENTAL|Treatment Group|Patients undergoing catheter ablation that qualify after initial screening.
62064374|NCT04670003||users|users of web-application
62064375|NCT06152016|OTHER|BE-FAST|
62064376|NCT06152016|OTHER|FAST|
62064377|NCT04380532|EXPERIMENTAL|V-SARS recipients|Single arm having at least 20 volunteers administered once-per-day pill of V-SARS
62064378|NCT03966222|ACTIVE_COMPARATOR|Open vein harvest|For the standard open conventional technique, the saphenous vein will be exposed by a longitudinal leg incision starting from the medial malleolus and ending at the upper medial thigh at the sapheno-femoral junction. The saphenous vein will be dissected free from its perivascular fat pedicle and visible side branches will be ligated and divided.
62064379|NCT03966222|EXPERIMENTAL|Endoscopic vein harvest|We will use the Terumo VirtuoSaph® Plus Endoscopic Vessel Harvesting System for all endoscopic vein extractions, which is an open carbon dioxide (CO2) system. Approximately 6 l/min of CO2 will be continuously insufflated in the subcutaneous tunnel.
62269513|NCT03119792|ACTIVE_COMPARATOR|Control|The control group will consist of 600 children from the original cohort (300) and comparable cohort (300). The control group will meet twice a month for four months at community centers. During these sessions, investigators will teach a curriculum that is not related to knowledge, attitudes, and habits towards healthy lifestyles.
62064380|NCT03788460||childrens population with lack of Factor VI|"We will check PT levels, we will concentrate the data in the table, along with personal information such as age and gender.~We will try to conduct a statistical relationship between the PT values and Factor VII levels, to look for statistical significance, we will try to find a model for predicting the level of factor VII based on PT"
62064381|NCT00267696|EXPERIMENTAL|Gemcitabine/carboplatin/bevacizumab|A regimen consisting of gemcitabine(1000 mg/m2)/carboplatin(AUC 3) / bevacizumab(Avastin®)(10mg/kg) will be administered on day 1 and day 15 of a 28 day cycle.
62269514|NCT02107586|ACTIVE_COMPARATOR|Biceps tenodesis|32 subjects in the study will receive biceps tenodesis as a surgical intervention
62269515|NCT02107586|ACTIVE_COMPARATOR|Biceps tenotomy|32 subjects in the study will receive biceps tenotomy as a surgical intervention
62269516|NCT01197326||Group 1|Patients who triggered MET/RRT calls prior to the use of the MP5 EWS patient monitor.
62269517|NCT01197326||Group 2|Patients who triggered MET/RRT calls after the use of the MP5 EWS patient monitor.
62630638|NCT05827692|EXPERIMENTAL|Forest Bath Intervention group B|The intervention consists of 2 sessions of approximately 2 hours duration and fortnightly frequency. In this context, it is guaranteed that patients will receive the care, visits and treatments usually used in people who have presented their clinical situation. The only difference between participating or not in the intervention is the participation in the practice of forest baths and the performance of some additional assessments, i.e. not routinely performed, which are part of this project. The investigators will be responsible for providing an overview of the study to eligible patients interested in participating. Before proceeding to start the intervention, an informed consent will be given to the patients, in which a description of the characteristics of the sessions will be provided.
62630639|NCT06358118|EXPERIMENTAL|experimental group|Take Buyuan Zhixiao Formula granules
62269518|NCT01051427|ACTIVE_COMPARATOR|Nasal catheter|In this arm will be the patients with epistaxis that cannot be stopped with anterior nasal packing and are randomized not to put Surgiflo. So they receive the usual treatment with a nasal catheter balloon into the nose.
62064382|NCT02775318|OTHER|Stellate Ganglion Block|After diagnosis of vasospasm patients were administered ultrasound guided Stellate Ganglion block using 10 cc of 0.5% Inj Bupivacaine on the same side of vasospasm or the side contralateral to the focal neurological deficit.Patients were then assessed using transcranial Doppler and digital subtraction angiography after 30 minutes
62064383|NCT05309538|ACTIVE_COMPARATOR|Group A|Control group
62064384|NCT05309538|EXPERIMENTAL|group B|experimental group
62064385|NCT00528476||1|Patients, who were treated because of recurrent (2 or more urinary tract infections per year) pyelonephritis or cystitis.
62064386|NCT00528476||2|Patients with nonrecurrent urinary tract infections (patients who had no history of more than one urinary tract infections in last year).
62064387|NCT01406002|EXPERIMENTAL|Treatment arm 1|darexaban, wash-out, rifampicin + darexaban
62088149|NCT06029361|EXPERIMENTAL|SELFIT device group|25 patients in experimental group will receive 15 minutes with the SELFIT system during the 45 minutes of physical therapy
62452154|NCT04634448|OTHER|Interval appendectomy|For all patients presenting with a periappendicular abscess, an interval appendectomy is planned at 2 to 3 months after initial conservative treatment, which is considered mandatory for all patients over 35 years of age. If a patient is under 35 and asymptomatic and does not want to undergo surgery, a follow-up MRI at 1 year will be performed.
62630640|NCT06358118|PLACEBO_COMPARATOR|control group|Take a placebos
62630641|NCT06488898|EXPERIMENTAL|Allogeneic adipose tissue-derived mesenchymal stem cells|"Allogeneic adipose tissue-derived mesenchymal stem cells and expanded, which are considered an advanced therapy medicinal product according to European regulation (Regulation (EC) No 1394/2007)."
62630642|NCT02801825|EXPERIMENTAL|Axillary artery.|Cannulation of the axillary artery.
62064388|NCT05596513|ACTIVE_COMPARATOR|control group|received intensive motor-learning approaches that focuses on training of the affected hand (motor-learning approaches such as - constraint-induced movement therapy (CIMT) and hand-arm bimanual intensive training (HABIT) provide an alternative).
62064389|NCT05596513|EXPERIMENTAL|study group|received the intensive motor-learning approaches of the control group but from a vertical surface
62064390|NCT04930744|ACTIVE_COMPARATOR|Standard Tuberculosis Medicine|Participants will have a chance to be put on standard tuberculosis medicines (Isoniazid, Rifampicin, Ethambutol and Pyrazinamide) only. It is a combination pill pack that will be taken by mouth daily. The combination pack includes Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide which they will take for 2 months. They will only take Isoniazid and Rifampicin for the last 4 months.
62630643|NCT02801825|EXPERIMENTAL|Femoral artery.|Cannulation of the femoral artery.
62630644|NCT00357877|PLACEBO_COMPARATOR|Placebo Dental Coating|Dental coating with all ingredients except Chlorhexidine topically applied by dental professional supragingivally to the full dentition
62630645|NCT00357877|ACTIVE_COMPARATOR|Active Dental Coating|10% w/v chlorhexidine acetate coating FDA IND #45466. Dental coating with all ingredients including Chlorhexidine topically applied by dental professional supragingivally to the full dentition
62630646|NCT02309970||Conservative|patient will get treatment with Antiplatelets or Anticoagulant depending on their clinical status/etiology
62088150|NCT06029361|ACTIVE_COMPARATOR|Control Group|45 minutes of conventional physical therapy
62088151|NCT06305507||Focussed therapy|laser application in focussed mode
62088152|NCT06305507||Shower laser application|laser application in shower or sweep mode
62630647|NCT02309970||IV tPA|patient will receive intravenous thrombolysis treatment
62630648|NCT02309970||Endovascular treatment|patient who will receive endovascular treatment
62064391|NCT04930744|EXPERIMENTAL|Standard TB Medicines and Metformin|Participants will have a chance to be put on standard tuberculosis medicines (Isoniazid, Rifampicin, Ethambutol and Pyrazinamide) only. It is a combination pill pack that will be taken by mouth daily. The combination pack includes Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide which they will take for 2 months. They will only take Isoniazid and Rifampicin for the last 4 months. For this arm, they will also take Metformin hydrochloride one 500 mg tablet daily starting one week after the initiation of tuberculosis medicines, then increasing to one 500 mg table twice daily through study week-12 for a total 11 weeks of metformin exposure.
62630649|NCT06611462|EXPERIMENTAL|Prehabilitation|"Intervention (the STRONG programme): At least six counselling sessions (around one per week) prior to surgery as an integrated prehabilitation programme tailored to the individual patient's need for risk reduction at surgery based on a baseline screening for risky SNAP factors. It is delivered via the surgical Engage in the process of change. The smoking cessation intervention follows the Gold Standard Programme and a similar structure has been used for alcohol cessation, physical exercise, and nutrition interventions. All participants in the intervention group will receive immunonutrition in the days before surgery."
62630650|NCT06611462|NO_INTERVENTION|Treatment as usual|Treatment as usual in the preoperative period in the included hospital departments, e.g. brief counselling/advice regarding smoking cessation and weight loss, and handing out the national folders on smoking and surgery. Participants are free to access support to lifestyle changes in the community.
62630651|NCT00570336|EXPERIMENTAL|2.5 milligram (mg) CTS-1027|2.5 mg CTS-1027
62630652|NCT00570336|EXPERIMENTAL|5 mg CTS-1027|5 mg CTS-1027
62630653|NCT00570336|EXPERIMENTAL|10 mg CTS-1027|10 mg CTS-1027
62630654|NCT00570336|EXPERIMENTAL|30 mg CTS-1027|30 mg CTS-1027
62630655|NCT00570336|PLACEBO_COMPARATOR|Placebo|Placebo
62630656|NCT02646683|OTHER|Early Crohn's disease|"VEDOLIZUMAB 300 mg at week 0,2,6, (10), 14, 22, 30,(34), 38, (42), 46, (50)~week 10 = only required for subjects not responding week 34, 42 and 50- only required for subjects who have no endoscopic improvement at week 26"
62630657|NCT02646683|OTHER|Late Crohn's disease|"VEDOLIZUMAB 300 mg at week 0,2,6, (10), 14, 22, 30,(34), 38, (42), 46, (50)~week 10 = only required for subjects not responding week 34, 42 and 50- only required for subjects who have no endoscopic improvement at week 26"
62630658|NCT04173416|EXPERIMENTAL|Youth Opioid Recovery Support (YORS)|"The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.~The specific components of YORS will be refined and adapted based on feedback from interviews and focus groups with various stakeholders. However, the basic framework outlined above is expected to persists."
62630659|NCT04173416|NO_INTERVENTION|Treatment As Usual|TAU will contain patients who will be receiving treatment for opioid use disorder through their usual venues without the family engagement, assertive outreach, contingency management, and home delivery of medication. This often includes a referral and warm hand off to intensive outpatient SUD services and/or mental health care.
62630660|NCT06133998|EXPERIMENTAL|incentive spirometry with aerobic exercises|"Group A: Aerobic exercise (running, jugging, cycling, walking) will be given to the group A for the checking the effect of incentive spirometer~* In sitting position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung.~* This schedule will be following supervised exercise training for a minimum 60 minutes 3 days a week in moderate patient,75 minutes in moderate to vigorous patients and 150 minutes in healthy patients~* We will check the dyspnea of the patient by the borage scale~* We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~* We will check the quality of life by the questionnaire."
62630661|NCT06133998|ACTIVE_COMPARATOR|incentive spirometry without aerobic exercises|"Group B: In group B we will check the effects of incentive spirometer without the aerobic exercise.~* In aerobic exercise following treatment protocol will be involve~* In sitting position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung.~* We will check the dyspnea of the patient by the borage scale~* We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~* We will check the quality of life by the questionnaire.~* We will check the chest expansion by measuring tap."
62630662|NCT04784078|EXPERIMENTAL|dTRA group|
62630663|NCT04784078|ACTIVE_COMPARATOR|cTRA group|
62064392|NCT04676490|NO_INTERVENTION|Usual Discharge Care|Usual ED discharge care
62064393|NCT04676490|EXPERIMENTAL|RECORD-ED Card|Usual care, plus a physical greeting card-style card with audio discharge instructions (English or Spanish) recorded on it
62269519|NCT01051427|EXPERIMENTAL|Surgiflo|In this arm will be the patients with epistaxis that cannot be stopped with anterior nasal packing and are randomized to put into the nose Surgiflo.
62269520|NCT01121393|EXPERIMENTAL|Arm A BIBW 2992|Patients receive a tablet of BIBW 2992 daily until progression or unacceptable toxicity
62269521|NCT01121393|ACTIVE_COMPARATOR|Arm B Chemotherapy|Patients receive Gemcitabine and Cisplatin, maximum is 6 courses
62269522|NCT00878371|OTHER|morphine|All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
62269523|NCT03824808|ACTIVE_COMPARATOR|Treatment group|Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution
62269524|NCT03824808|PLACEBO_COMPARATOR|Control group|0.9% Sodium Chloride Injection
62269525|NCT00525655|EXPERIMENTAL|Multimedia Intervention|
62269526|NCT04464161|EXPERIMENTAL|Arm 1|The treatment arm will receive 6 week supply of daily Ensure protein drinks, while the control arm will be instructed to continue their current diet. This includes 2 weeks pre-operatively and 4 weeks post-operatively.
62269527|NCT04464161|NO_INTERVENTION|Arm 2|The control group will be instructed to continue to their regular diets.
62269528|NCT04356560||healthcare workers|Actively working at Department of Otorhinolaryngology Head and Neck Surgery \& Audiology, Rigshospitalet University Hospital of Copenhagen, Denmark. During 2020 COVID 19 pandemic
62269529|NCT04356560||Patients|Patients presenting with complications to upper respiratory tract infections and patients undergoing surgery involving airway mucosa During 2020 COVID 19 pandemic
62269530|NCT02742038|EXPERIMENTAL|Fluoride varnish plus education|Biannual fluoride varnish every 6 month/ 24 months plus educational component
62269531|NCT02742038|PLACEBO_COMPARATOR|Placebo varnish plus education|Biannual placebo varnish every 6 month/ 24 months plus educational component
62269532|NCT06044688|EXPERIMENTAL|Phoropter|Refraction performed by an eye care professional using a phoropter.
62269533|NCT06044688|ACTIVE_COMPARATOR|VisionCheck|Self-administered refraction performed using the EyeQue VisionCheck device.
62269534|NCT02698735|EXPERIMENTAL|Gentamicin|Gentamicin antibiotic
62269535|NCT02698735|PLACEBO_COMPARATOR|Placebo|Vehicle control
62269536|NCT01445028|EXPERIMENTAL|Primary, high-risk retinal detachment|Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
62269537|NCT01445028|EXPERIMENTAL|Recurrent RD associated with PVR|Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
62269538|NCT00723970|EXPERIMENTAL|A|Use of quetiapine, flexible dose (150-300 mg/day) for 8 weeks, following a 2-week placebo lead-in phase
62269539|NCT02019407|EXPERIMENTAL|CTI group|CTI(Cavo-Tricuspid Isthmus)
62269540|NCT02019407|PLACEBO_COMPARATOR|Non CTI group|Non CTI (Cavo-Tricuspid Isthmus)
62269541|NCT02428257|EXPERIMENTAL|hypobaric|continuous spinal anesthesia with 2,5 mg boluses of hypobaric bupivacaine, prepared diluting each 1 ml of 0.5% isobaric bupivacaine with 1 ml of sterile water.
62269542|NCT02428257|ACTIVE_COMPARATOR|isobaric|continuous spinal anesthesia with 2,5 mg boluses of 0.5% isboaric bupivacaine
62269543|NCT00375726|EXPERIMENTAL|1|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10\^3 PFU dose) into the deltoid region of either arm.
62269544|NCT00375726|EXPERIMENTAL|2|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10\^5 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
62269545|NCT00375726|EXPERIMENTAL|3|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10\^1 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
62269546|NCT00375726|PLACEBO_COMPARATOR|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
62064394|NCT04676490|EXPERIMENTAL|RECORD-ED Patient Portal|Usual care, plus access to audio-recorded discharge instructions (English or Spanish) through the patient portal
62064395|NCT04156997||Patients with extreme lipid phenotypes|Adult patients (age 18 years or older) diagnosed with any lipid or metabolic disorder including hyperlipidemia, dyslipidemia, hyperlipoproteinemia, low HDL levels and deranged lipoprotein metabolism
62269547|NCT02911480|EXPERIMENTAL|oxytocin intravenous 0.1 IU|single dose of 0.1 International Units (IU) intravenous (IV) oxytocin
62269548|NCT02911480|EXPERIMENTAL|oxytocin intravenous 1 IU|single dose of 1 IU IV oxytocin
62630664|NCT05837286|EXPERIMENTAL|Experimental Group with Cortisone Injection of affected digit(s) and nighttime orthosis|The experimental group will consist of receiving a PIP joint on the day they receive their cortisone injection. The Oval-8 ® will be issued to the subject by an Occupational Therapist to ensure correct fit and comfort as well as given written instructions for night use. The orthosis will be worn at night for 6-week duration. Participants will have 1 follow up phone call or email at the 6-week mark and then 1 follow up phone call or email at the 12 week mark by a member of the research team from the time they received their cortisone injection where the time for resolution of trigger finger symptoms, VAS (Visual Analogue Scale), subjective questionnaire and QuickDASH scores will all be recorded in their medical research file.
62630665|NCT05837286|ACTIVE_COMPARATOR|Control Group-No Orthosis|The control group will be identical to the experimental group except without the use of a nighttime orthosis. Participants will have 1 follow up phone call or email at the 6-week mark and then 1 follow up phone call or email at the 12 week mark by a member of the research team from the time they received their cortisone injection where the time for resolution of trigger finger symptoms, VAS (Visual Analogue Scale), subjective questionnaire and QuickDASH scores will all be recorded in their medical research file.
62630666|NCT06609200|EXPERIMENTAL|Electroacupuncture group|"The WHO Standardized Acupuncture Points Location \[2\] will be used to identify the location of these acupoints, Tianshu(ST-25), Daheng(SP-15), Daimai(GB-24), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), and Sanyinjiao(SP-6). After sterilizing the skin, sterile adhesive pads will be pasted on acupoints first, and then needles of size 0.30\*75 mm will be inserted into the acupoints to a depth of 50 mm outward and upward slightly. Needles will be lifted, thrust, and twirled evenly 3 times to achieve de-qi. Paired electrodes of the EA apparatus will be attached transversely to the acupoint respectively with a continuous wave of 50 Hz and a current intensity of 1-5 mA (preferably with the skin around the acupoints shivering mildly without pain) for 30 min. Patients will be treated with electroacupuncture 2 sessions per week over 8 consecutive weeks, 16 sessions for each patient."
62630667|NCT06609200|SHAM_COMPARATOR|Sham acupuncture group|The sham electro-acupuncture group (SEA) penetrates acupuncture on non-acupuncture points (1 cm away from the acupuncture point and meridian). The same type of acupuncture needles will be used for SEA with the exact skin sterilization method. All acupuncture points will be needled perpendicularly with a guide tube. Insertion depth will be approximately 50 mm, depending on the location of individual points. Each point will be connected to a sham electro-stimulator (showing a continuous wave at a frequency of 30 Hz but without actual stimulation). All needles will be removed after 30 min of needle retention. Patients will be treated with sham electroacupuncture 2 sessions per week over 8 consecutive weeks, 16 sessions for each patient in total.
62630668|NCT04837287|ACTIVE_COMPARATOR|Static Stretching Exercise for 10 Seconds|After the participants are given one session of training, the participants do the exercises themselves at home.
62630669|NCT04837287|ACTIVE_COMPARATOR|Static Stretching Exercise for 30 Seconds|After the participants are given one session of training, the participants do the exercises themselves at home.
62630670|NCT03977987||The treatment group|Pregnant women with high HBV DNA level \> 2\*10\^6 IU/ml who agree to receive the antiviral treatment during the late pregnancy.
62630671|NCT03977987||The control group with high HBV DNA level|Pregnant women with high HBV DNA level \> 2\*10\^6 IU/ml who decline to receive the antiviral treatment during the late pregnancy.
62630672|NCT03977987||The control group with low HBV DNA level|Pregnant women with high HBV DNA level \< 2\*10\^6 IU/ml
62269549|NCT02911480|EXPERIMENTAL|oxytocin intravenous 10 IU|single dose of 10 IU IV oxytocin
62064396|NCT04156997||Healthy volunteers|Healthy adult volunteers with normal lipid metabolism will be recruited for the purpose of comparison
62064397|NCT01822067||Normal weight- Non Maternal obesity|Full-term neonates at 2 weeks of age born to normal weight mothers
62064398|NCT01822067||Obese- Obese Mothers|Full-term neonates at two weeks of age born of obese mothers
62269550|NCT02911480|EXPERIMENTAL|oxytocin tablet 20 IU|single dose of 20 IU tablet oxytocin
62269551|NCT02911480|EXPERIMENTAL|oxytocin tablet 200 IU|single dose of 200 IU tablet oxytocin
62064399|NCT06129201||Training group|Experimental group: population of initially diagnosed nasopharyngeal carcinoma \[600 people\]; Control group: 2400 healthy individuals+nasopharyngeal disease patients+other tumors.
62269552|NCT05874973|EXPERIMENTAL|Time-Controlled Adaptative Ventilation (TCAV)|"APRV mode set with:~* a Phigh at Plateau Pressure of the VCV mode~* a Tlow set to terminate the expiration at 75% of the maximal expiratory flow~* a Plow set at 0 cmH2O.~* a Thigh set to achieve adequate decarboxylation."
62269553|NCT05874973|ACTIVE_COMPARATOR|Volume Control Ventilation (VCV)|"Ventilation with the VCV mode set with:~* a tidal volume (VT) at or below 6 ml/kg of predicted body weight~* a positive end-expiratory pressure (PEEP) set at least at 5 cmH2O~* a driving pressure lower than 15 cmH2O."
62269554|NCT04670640|EXPERIMENTAL|Breath Focus|Participants receiving the breath focus study intervention.
62630673|NCT04874818||lymphopenia|lymphocyte counts (\<1.0 x10e9/L)
62630674|NCT04874818||normal lymphocyte numbers|lymphocyte counts ((1.0 - 3.5 x10e9/L))
62064400|NCT06129201||Validation group|Validation group: Experimental group: Nasopharyngeal cancer population \[400 people\]; Control group: 1600 healthy individuals+patients with nasopharyngeal diseases+other tumors.
62269555|NCT04670640|EXPERIMENTAL|Vibration|Participants receiving the vibration study intervention.
62064401|NCT03184896||Hip Fracture|
62064402|NCT02961374|EXPERIMENTAL|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO once weekly. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
62064403|NCT01619332|EXPERIMENTAL|LEZ763|Part I- Healthy volunteers enrolled into 6 single-ascending dose cohorts Part II- Healthy volunteers enrolled into 5 multiple-ascending dose cohorts. Part III- LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
62064404|NCT01619332|PLACEBO_COMPARATOR|Placebo|Part I : Healthy volunteers enrolled in 6 single ascending dose cohorts to receive matching placebo of LEZ763. Part II: Healthy volunteers enrolled in 5 multiple ascending dose cohorts to receive matching placebo of LEZ763. Part III- Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
62064405|NCT01619332|ACTIVE_COMPARATOR|Sitagliptin|Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
62064406|NCT05536102|EXPERIMENTAL|Experiment group|Pegylated Liposomal Doxorubicin + Oxaliplatin + Capecitabine + Tislelizumab; reapt every 21 days.
62064407|NCT04244435|EXPERIMENTAL|Thoracic epidural analgesia|CABG and thoracic epidural analgesia will be used for perioperative analgesia postoperative period
62269556|NCT04670640|EXPERIMENTAL|Vibration With Breath Focus|Participants receiving the vibration with breath focus study intervention.
62269557|NCT04670640|EXPERIMENTAL|Screens Free|Participants receiving the screens free study intervention.
62630675|NCT04693780|EXPERIMENTAL|Structured guide with pre-appraisal content|Once logged into the website, participants in the intervention group will navigate health information through an annotated structured guide to health evidence which is designed to inform participants where to find specific health information but it will also provide information to understand why such content is more valuable than other content. This structured annotated guide to evidence will also outline the value of pre-appraisal and will help them navigate to products produced for them. These products have been produced by the research team and include a collection of web resource ratings, evidence summaries and blog posts modelled after those developed and presented on the McMaster Optimal Aging Portal. The topics of this citizen content match the scope of the IMAGINE Network.
62064408|NCT04244435|ACTIVE_COMPARATOR|Opioids|CABG and opioids will be used for perioperative analgesia
62064409|NCT04244435|ACTIVE_COMPARATOR|CABG|coronary artery bypass grafting with and without cardiopulmonary bypass
62064410|NCT01262443|EXPERIMENTAL|Therapy Cool Flex catheter group|Therapy Cool Flex Catheter . No more available data
62064411|NCT04466215|ACTIVE_COMPARATOR|Miricorilant|900 mg (6 x 150 mg) tablets daily taken orally for two weeks
62064412|NCT04466215|PLACEBO_COMPARATOR|Placebo|Six placebo tablets taken orally for two weeks
62064413|NCT04963361||fear of movement group|The score of fear of movement scale was more than 37
62064414|NCT04963361||non-fear of movement group|The score of fear of movement scale was no more than 37
62064415|NCT04215263||Geriatric patient underwent general anesthesia procedure|geriatric patients (≥60 years) ware assessed for cognitive impairment after general anesthesia for non-neurologic noncardiac surgery.
62064416|NCT03889613|EXPERIMENTAL|all patients|All enrolled patients- prospective observation (all patients are followed using videocapsule)
62064417|NCT01734434||Pregnant women|24 weeks or more of gestation
62064418|NCT04903223|NO_INTERVENTION|Baseline Mevalonate and MRI Imaging|
62064419|NCT04903223|EXPERIMENTAL|Mevalonate Change After Rosuvastatin|
62064420|NCT01635075|EXPERIMENTAL|Exercise|1-mile treadmill walk
62269558|NCT00751777|EXPERIMENTAL|Group 1: 37.5 µg LT patch|80 subjects will receive a two vaccination regimen with a LT patch.
62269559|NCT00751777|PLACEBO_COMPARATOR|Group 2: 0 µg LT patch (placebo)|40 subjects will receive a two vaccination regimen with a placebo patch.
62269560|NCT01420237|OTHER|Restoration ADM X3 Device|Restoration ADM X3 Device in total hip replacement.
62269561|NCT03645993||Early-Onset Alzheimer's disease|Patients ages 45-60 with Early-Onset Alzheimer's disease
62630676|NCT04693780|PLACEBO_COMPARATOR|Listing without pre-appraisal content|Once logged into the website, participants in the control group will navigate health information through a structured one-page guide (see Appendix 1) that does not include pre-appraisal information. Instead it will list the main organizations in the field that produce citizen content with descriptions of the type of content they produce with links to their individual websites. This will be presented to participants when they login to the platform. None of the citizen content produced specifically for the study will be provided to them prior to crossing-over.
62630677|NCT05505383|EXPERIMENTAL|Backward walking training group|This group will participate in a backward walking training program (8-week, 3 times weekly, and 30-min each time) and conventional gait training program (8-week, 3 times weekly, and 45-min each time).
62269562|NCT03645993||Negative Control|Family members of patients with Early-Onset Alzheimer's disease who have consented to the study.
62630678|NCT05505383|ACTIVE_COMPARATOR|Conventional gait training|This group will participate in a conventional gait training program (8-week, 3 times weekly, and 45-min each time).
62269563|NCT01383837|EXPERIMENTAL|STYLEnS|Multifamily Group HIV/STI Prevention intervention or Single Family Dyad (youth and a parent)
62269564|NCT01383837|ACTIVE_COMPARATOR|Health Promotion|Health Promotion Intervention - Adolescents only
62269565|NCT01872520||the Injection of DanShenDuoFenSuanYan|Patient who use the Injection of DanShenDuoFenSuanYan
62269566|NCT05422807|ACTIVE_COMPARATOR|Psychological intervention|Families randomized to the intervention group will receive 12 sessions of Behavioral Family Systems Therapy for Teens with type 2 diabetes (BFST-DM2) over 6 months.
62269567|NCT05422807|NO_INTERVENTION|Control group|The participants assigned to the control group will receive their standard medical care for diabetes.
62269568|NCT01175109|EXPERIMENTAL|Escalating doses of imatinib and LBH589|"Study will incorporate a 3+3 dose escalation design."
62269569|NCT05266235|EXPERIMENTAL|Withings WBS08 and 12-lead reference ECG|The electrodes of the 12-lead ECG will be set up on the participants, before they step on withings WBS08 to have ECGs simultaneously recorded by the study device and the control device
62269570|NCT05378386||TPVR|Transcatheter Pulmonary Valve Replacement
62269571|NCT03065348|EXPERIMENTAL|Intervention|"1. Around 2 to 4 weeks before surgery:~   * Fried frailty score~  * CARE score assessment~  * NRS Kondrup assessment~  * Plasma albumin and CRP values~  * Start with daily oral whey protein administration until evening before surgery45~2. Around 5-7 days before surgery:~   - Start with immunonutrition~3. Evening before surgery:~   * CARE score assessment~  * NRS Kondrup~  * CERAD cognition test assessment~  * Plasma albumin and CRP values, urine specific gravity~  * Carbohydrate loading~  * If urine specific gravity is \>1.020 then additional tap water drinking will be encouraged~4. Day of surgery:~   * Carbohydrate loading~  * Start anesthesia with spinal anesthesia (continuous)~5. POD 7:~   * CARE assessment~  * CERAD assessment~  * Plasma albumin and CRP values~6. POD14:~   * CARE assessment~  * Plasma albumin and CRP value~7. POD 30:~   * CARE assessment~  * NRS Kondrup~  * CERAD assessment~  * Plasma albumin and CRP values~8. POD 90:~   * CARE assessment~  * NRS Kondrup~  * CERAD assessment"
62269572|NCT06416904|EXPERIMENTAL|arch wire stopper mesial to the maxillary first molar group|In postpubertal female patients with maxillary dentoalveolar protrusion, canine retraction after the extraction of the maxillary first premolars with archwire stoppers mesial to the maxillary first molars.
62630679|NCT01630018|ACTIVE_COMPARATOR|Topotecan|Topotecan
62630680|NCT01630018|ACTIVE_COMPARATOR|Camtobell|Belotecan
62630681|NCT04126044|ACTIVE_COMPARATOR|Reference: bevacizumab - EU|
62630682|NCT04126044|EXPERIMENTAL|Test: PF-06439535 (CN)|
62630683|NCT04085718||Study arm|All included patients will undergo FDGPET/CT scan
62630684|NCT01898052|EXPERIMENTAL|multimodal drug injection|Multimodal drug injection Levobupivacaine 150 mg, epinephrine(1:1000) 0.6 mL(0.6 mg), morphine sulfate 5 mL(5 mg), ketorolac 1 mL (30 mg) and mixed with normal saline up to 100 mL
62630685|NCT01898052|ACTIVE_COMPARATOR|Single anaesthetic drug|Single anaesthetic drug levobupivacaine 150 mg and epinephrine (1:1000) 0.6 ml (0.6 mg)
62630686|NCT03003169||ambulatory surgery description|
62630687|NCT00027885|ACTIVE_COMPARATOR|Docetaxel|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
62630688|NCT00027885|EXPERIMENTAL|Combine bevacizumab and docetaxel.|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
62630689|NCT05701280|EXPERIMENTAL|DBS+Rehab|Active-DBS combined with motor rehabilitation
62630690|NCT05701280|ACTIVE_COMPARATOR|Rehab|Control-DBS combined with motor rehabilitation
62269573|NCT06416904|ACTIVE_COMPARATOR|maxillary first molar indirectly anchored to the inter-radicular mini-screw group|In postpubertal female patients with maxillary dentoalveolar protrusion, canine retraction after the extraction of the maxillary first premolars, with the maxillary first molars indirectly anchored to the inter-radicular mini-screw.
62269574|NCT04141332||Group 1|80 Patient
62064421|NCT01635075|PLACEBO_COMPARATOR|Passive|20 min inactivity
62064422|NCT01129635|EXPERIMENTAL|CRT Candidate|"Patients with NYHA Class III or IV heart failure; EF ≤ 30% and QRS duration ≥ 120 ms, who are scheduled for CRT surgery.~Intervention: Cardiac Resynchronization Therapy (CRT) implantation"
62064423|NCT00891306|EXPERIMENTAL|Treatment arm|Gene Therapy
62064424|NCT05819814|EXPERIMENTAL|Intervention|Participants will receive their high polygenic risk result for coronary artery disease.
62269575|NCT04141332||Group 2|80 Control subject
62269576|NCT02431572|EXPERIMENTAL|Metastatic Melanoma to the Brain (Cohort A)|"* Assess Inflammation (PBR PET)~* Immunotherapy~* Assess Inflammation (PBR PET)"
62269577|NCT02431572|EXPERIMENTAL|Primary Brain Tumor (Cohort B)|"* Assess Inflammation (PBR PET)~* Immunotherapy~* Assess Inflammation (PBR PET)"
62452155|NCT04634448|OTHER|Follow-up MRI|For all patients presenting with a periappendicular abscess, an interval appendectomy is planned at 2 to 3 months after initial conservative treatment, which is considered mandatory for all patients over 35 years of age. If a patient is under 35 and asymptomatic and does not want to undergo surgery, a follow-up MRI at 1 year will be performed.
62452156|NCT01945138|NO_INTERVENTION|Control|Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.
62630691|NCT06360965|ACTIVE_COMPARATOR|Improved warm meridians and relieve pain plaster group|Use an improved warm meridians and relieve pain plaster (about 7cm wide, 10cm long, and 0.5mm thick) to apply to the navel.
62269578|NCT02431572|EXPERIMENTAL|Primary Brain Tumor (Cohort C)|"* Chemoradiation~* Assess inflammation (PBR PET)~* Follow Patients"
62269579|NCT05766995|EXPERIMENTAL|Manual toothbrush and water flosser with standard jet tip|Brush with a standard ADA manual toothbrush twice daily followed by water flossing once in the evening
62269580|NCT05766995|EXPERIMENTAL|Manual toothbrush and water flosser with targeted jet tip|Brush with a standard ADA manual toothbrush twice daily followed by water flossing once in the evening
62269581|NCT05766995|ACTIVE_COMPARATOR|Manual toothbrush and dental floss|Brush with a standard ADA manual toothbrush twice daily followed by dental flossing once in the evening
62269582|NCT02398591|EXPERIMENTAL|JNJ 53718678 250 milligram (mg)|Participants will receive either single oral dose of 250 mg of JNJ 53718678 or matching placebo on Day 1.
62269583|NCT02398591|EXPERIMENTAL|JNJ 53718678 500 mg|Participants will receive either single oral dose of 500 mg of JNJ 53718678 or matching placebo on Day 1.
62452157|NCT01945138|EXPERIMENTAL|Closed Loop Insulin|Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
62452158|NCT01580878|EXPERIMENTAL|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% (Taro Pharmaceuticals, Inc.)
62452159|NCT01580878|ACTIVE_COMPARATOR|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) (Schering Plough HealthCare Products Inc.)
62452160|NCT01580878|PLACEBO_COMPARATOR|Butenafine Vehicle|Butenafine Cream vehicle (Taro Pharmaceuticals Inc.)
62452161|NCT00747188|EXPERIMENTAL|2|
62452162|NCT00747188|NO_INTERVENTION|A, 2, III|
62452163|NCT04438057|NO_INTERVENTION|Standard of Care|Patient will receive standard of care therapy.
62064425|NCT05819814|NO_INTERVENTION|Control|Participants will receive standard of care, and disclosure of high polygenic risk result will be deferred until study completion.
62064426|NCT05208853|EXPERIMENTAL|Anti CD30 CAR T cells|"Patients receive anti CD30 CAR-T cells on day 0 after lymphodepleting treatment.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to anti CD30 CAR-T cells infusion."
62064427|NCT00529919|ACTIVE_COMPARATOR|1|MCT oil consumption
62064428|NCT00529919|PLACEBO_COMPARATOR|2|Olive oil consumption
62064429|NCT04591535|EXPERIMENTAL|WD-1603 (tablet strength 1) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 1) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
62269584|NCT02398591|EXPERIMENTAL|JNJ 53718678 1000 mg|Participants will receive either single oral dose of 1000 mg of JNJ 53718678 or matching placebo on Day 1.
62269585|NCT03431155|EXPERIMENTAL|Experimental group|Nursing intervention
62269586|NCT03431155|NO_INTERVENTION|Control Group|- Receive routine nursing care
62269587|NCT05095207|EXPERIMENTAL|Participants with Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer|Abemaciclib in Combination with Bicalutamide
62269588|NCT06089642|NO_INTERVENTION|Control|Usual care
62452164|NCT04438057|ACTIVE_COMPARATOR|Treatment Arm|Patient will receive convalescent plasma
62653171|NCT00769561|ACTIVE_COMPARATOR|Occlusal Splint (OS)|"Dental treatment with occlusal splints:~Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment."
62064430|NCT04591535|EXPERIMENTAL|WD-1603 (tablet strength 2) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 2) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
62064431|NCT04591535|EXPERIMENTAL|WD-1603 (tablet strength 3) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 3) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
62269589|NCT06089642|EXPERIMENTAL|Virtual Reality therapy|Patients receive virtual reality therapy in the form of active distraction or focussed attention (randomized between those two)
62452165|NCT01144663|EXPERIMENTAL|Nimenrix 3 Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 3 primary doses of Nimenrix™ vaccine at 2, 3 and 4 months of age, followed by a booster dose of Nimenrix™ vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 3, 4 and 12 months of age.
62630692|NCT06360965|ACTIVE_COMPARATOR|Traditional warm meridians and relieve pain plaster group|Select Angelica sinensis, Ligusticum chuanxiong, Cinnamon, Sichuan pepper, Corydalis yanhusuo, Fructus Evodiae, Paeonia lactiflorus, Artemisia argyi, Cyperus, Zelan, and Muxiang, mix in a ratio of 1.5:1:1.8:1.5:1.2:0.5:1.5:0.8:1.5:1.5, and use a grinder to grind and sieve; Take an appropriate amount of Vaseline and mix thoroughly with the above-mentioned powder in a 1:1 ratio. Take an appropriate amount of medication and place it in the center of the acupoint patch (8cm x 8cm). Press the medication evenly into a circular hole with a diameter of about 4cm and a depth of about 3mm, and align the patch.
62630693|NCT06360965|PLACEBO_COMPARATOR|Placebo plaster group|Take an appropriate amount of Vaseline and mix thoroughly with 1% of the original ingredient, starch, and pigment. Take an appropriate amount of medication and place it in the center of the acupoint patch (8cm x 8cm). Press the medication evenly into a circular hole with a diameter of about 4cm and a depth of about 3mm, and align the patch.
62630694|NCT05203601|EXPERIMENTAL|SIBP-03(Recombinant anti-HER3 humanized monoclonal antibody injection)|"Stage 1: dose escalation stage Injection, first dose 2mg/kg, then 5mg/kg until the dose are no longer met the requirements of continuing the trial or up to 40 mg/kg.~Stage 2: joint extension stage:~① Group of advanced head and neck squamous cell carcinoma ：SIBP-03 \& Cetuximab 5mg/kg dose level: Sibp-03, 5 mg/kg, Q3W Cetuximab, 400 mg/m2 (week 1), 250 mg/m2 (weekly follow-up), QW 10mg/kg dose level: Sibp-03, 10 mg/kg, q3W Cetuximab, 400 mg/m2 (week 1), 250 mg/m2 (weekly follow-up), QW~② Group of breast cancer：SIBP-03 \& Trastuzumab \& Docetaxel 5mg/kg dose level: Sibp-03, 5 mg/kg, Q3W Trastuzumab, first dose 8 mg/kg, maintenance dose 6 mg/kg, q3w+ Docetaxel 75mg/m2 q3w.~10mg/kg dose level: Sibp-03, 10 mg/kg, q3W Trastuzumab, first dose 8 mg/kg, maintenance dose 6 mg/kg, q3w+ Docetaxel 75mg/m2 q3w."
62630695|NCT01957423|EXPERIMENTAL|Whey protein|Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
62064432|NCT04591535|EXPERIMENTAL|WD-1603 (tablet strength 4) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 4) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
62064433|NCT01083641|EXPERIMENTAL|Estrogen Therapy|Estrogen therapy
62064434|NCT02462850|EXPERIMENTAL|CL-108|CL-108 Hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
62269590|NCT00746252|EXPERIMENTAL|1|risperidone
62269591|NCT00746252|EXPERIMENTAL|2|aripiprazole
62653172|NCT06551753|EXPERIMENTAL|virtual reality app|virtual reality app
62064435|NCT02377037|EXPERIMENTAL|Sitting|Remain seated in a chair, with hands placed on top of the thighs for 10 minutes, remaining motionless in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured minute by minute.
62269592|NCT02289222|EXPERIMENTAL|Pomalidomide, Dexamethasone & MK-3475|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days and dexamethasone is given at 40 mg orally weekly. MK3475 will be given as an intravenous infusion at 200 mg every 2 weeks (days 1 and 14).
62269593|NCT02004665||acute coronary syndrome and delirium|patients with acute coronary syndrome and delirium
62452166|NCT01144663|EXPERIMENTAL|Nimenrix 2 Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 2 primary doses of Nimenrix™ vaccine at 2 and 4 months of age, followed by a booster dose of Nimenrix™ vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 4 and 12 months of age.
62269594|NCT03713164|ACTIVE_COMPARATOR|Pomegranate Juice (PJ)|single dose of 8oz Pomegranate Juice (PJ)
62269595|NCT03713164|ACTIVE_COMPARATOR|Ellagic Acid (EA)|500 mg Ellagic Acid (EA) capsules
62269596|NCT01464307|EXPERIMENTAL|IncobotulinumtoxinA (Xeomin) 400 Units|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
62269597|NCT01464307|PLACEBO_COMPARATOR|Placebo Comparator Arm|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
62269598|NCT05561660|EXPERIMENTAL|PFO closure|
62269599|NCT05561660|SHAM_COMPARATOR|Shame procedure|
62064436|NCT02377037|EXPERIMENTAL|Standing|Remain in an upright position (standing) with hands placed on the thighs for 10 minutes, remaining motionless in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured minute by minute.
62064437|NCT02377037|EXPERIMENTAL|Transitions sit/stand|The participant will perform one sit-to-stand followed by a stand-to-sit transition, every minute in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured.
62064438|NCT06266091|EXPERIMENTAL|M701 group|M701 will be administered via intra-peritoneal infusion following sufficient drainage of malignant ascites. The treatment regimen consists of a leading dose of 50μg on Day 1, followed by three infusions of the full dose of 400 μg M701 on Days 4, 11, and 18. If well tolerated, patients will continue to receive M701 infusions every 2 weeks as maintenance treatment. Additionally, these patients will receive systemic therapy as determined by the investigator.
62064439|NCT06266091|ACTIVE_COMPARATOR|Control group|Patients in the control group will undergo paracentesis on Day 1 and Day 18. If necessary, they may receive additional paracentesis during this period. Additionally, these patients will receive systemic therapy as determined by the investigator.
62064440|NCT02966002|EXPERIMENTAL|Intervention: aspirin|650 mg. Twice a day for 8 weeks
62630696|NCT01957423|ACTIVE_COMPARATOR|Soy protein|Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
62630697|NCT02252302|ACTIVE_COMPARATOR|Resting in diesel exhaust following salbutamol inhalation|Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of 400ug of salbutamol.
62630698|NCT02252302|PLACEBO_COMPARATOR|Resting in diesel exhaust following placebo inhalation|Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of a placebo.
62064441|NCT05852028||selinexor-based regimens|This study is a real-world study to explore the safety and efficacy of selinexor-based therapy in patients with lymphoma. It is planned to enroll 250 patients with lymphoma, including 150 patients with diffuse large B-cell lymphoma and 100 patients with peripheral T and NK/T-cell lymphoma.
62064442|NCT05797792|EXPERIMENTAL|Intraarterial alteplase|All the patients will be given a 15 minutes IA infusion of alteplase (Actylise®) at a drug concentration of 1.0 mg/ml. At 15 minutes of IA treatment onset, the infusion will be stopped and the angiographic score assessed. Study drug will be prepared according to the following steps: 1/ Dilute 2 vials of 10 mgs (rt-PA) in 20 cc of sterile water for injection (SWI), to attain a 20 ml solution at a concentration of 1mg/ml; 2. Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225). A patient of 89 Kgs or more will receive 20.0 cc of infusion for 15 min, totaling a dose of 20.0 mg of rt-PA.
62064443|NCT05797792|NO_INTERVENTION|No intervention|Patients allocated to this arm will receive a similar care to patients allocated to IA alteplase except the thrombolytic
62064444|NCT06622720||Residents|Individuals undergoing elective colorectal resection due to cancer performed by residents between January 2022 and December 2023.
62064445|NCT06622720||Colorectal surgeons|Individuals undergoing elective colorectal resection due to cancer performed by experienced colorectal surgeons between January 2022 and December 2023.
62064446|NCT00314067|EXPERIMENTAL|1|
62064447|NCT00314067|EXPERIMENTAL|2|
62064448|NCT00314067|ACTIVE_COMPARATOR|3|
62064449|NCT06006845||A|Tumor patients infected with COVID-19
62064450|NCT01226914|PLACEBO_COMPARATOR|Placebo|For subjects in the placebo group, saline was drawn into the applicator and aerosolized in a similar fashion; it was allowed to remain in the wound during closure.
62269600|NCT00730938|ACTIVE_COMPARATOR|1|
62630699|NCT02252302|ACTIVE_COMPARATOR|Cycling in diesel exhaust following salbutamol inhalation|Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of 400ug of salbutamol.
62269601|NCT00730938|PLACEBO_COMPARATOR|2|Saline placebo
62269602|NCT04986462||patients with bursal-side partial-thickness rotator cuff tears|Patients with bursal-side partial-thickness rotator cuff tears who underwent arthroscopic surgery and was followed up at Peking University Third Hospital.
62269603|NCT05700162|EXPERIMENTAL|Photograph|As soon as the mother starts to express her milk, she will be asked to look at the photo of her baby sent to her on whatsapp for 5 minutes.
62269604|NCT05700162|EXPERIMENTAL|Video|As soon as the mother starts to express her milk, she will be asked to watch the 5-minute video of her baby sent to her on whatsapp.
62269605|NCT05700162|EXPERIMENTAL|Live Broadcast|As soon as the mother starts to express her milk, she will be asked to watch the 5-minute live video of her baby with the call sent to her from WhatsApp.
62269606|NCT05700162|EXPERIMENTAL|Control Group|The mother will be asked to express both breasts for 15 minutes every 3 hours. No additional application will be made.
62630700|NCT02252302|PLACEBO_COMPARATOR|Cycling in diesel exhaust following placebo inhalation|Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of a placebo
62064451|NCT01226914|EXPERIMENTAL|Evicel|For subjects in the treatment group, Evicel was applied in the usual manner by study personnel, with 5mL of each component drawn into a two-barrel syringe device and aerosolized using a pedal-controlled inert gas supply.
62064452|NCT04113681|EXPERIMENTAL|Geniculate Artery Embolization Arm|Single-arm prospective study of geniculate artery embolization for symptomatic knee osteoarthritis
62269607|NCT04480177|OTHER|insole group|the control group receives insole only.
62269608|NCT04480177|EXPERIMENTAL|exercise group|the experimental group receives exercise and insole.
62269609|NCT02257983|ACTIVE_COMPARATOR|EPI-743|EPI-743 400 mg P.O. TID
62269610|NCT02257983|PLACEBO_COMPARATOR|Placebo|Sesame Oil, NF in sealed gelatin capsules to match the test product
62269611|NCT02636088|EXPERIMENTAL|Cetuximab|Cetuximab is administered once a week. The initial dose is 400 mg/m2 body surface area. First Cetuximab infusion should start day 15 in cycle 1.The subsequent weekly doses are 250 mg/m2.
62269612|NCT02108431|EXPERIMENTAL|balloon catheter for transurethral bladder-drainage|intraoperatively placement of transurethral catheter after robot-assisted radical prostatectomy
62269613|NCT02108431|ACTIVE_COMPARATOR|balloon catheter for suprapubic bladder-drainage|intraoperatively placement of suprapubic catheter after robot-assisted radical prostatectomy
62269614|NCT02698488|ACTIVE_COMPARATOR|Embryo Selection by Morphology|Embryos will be morphologically evaluated according to the number and regularity of blastomeres and fragmentation degree. Only embryo culture media of good quality embryos (embryos with ≥6 cells with no fragmentation) will be included in the study
62630701|NCT02252302|SHAM_COMPARATOR|Resting in filtered air following salbutamol inhalation|Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of 400ug of salbutamol.
62269615|NCT02698488|ACTIVE_COMPARATOR|Embryo Selection by Morphology and Mass Spectroscopy|Embryos will be morphologically evaluated according to the number and regularity of blastomeres and fragmentation degree. Only embryo culture media of good quality embryos (embryos with ≥6 cells with no fragmentation) will be included in the study. After dilution, embryo culture media will be analyzed by electrospray ionization quadrupole time-of-flight (ESI-QTOF) MS. The spectra will be collected in the negative ion mode. Abundance of ions in each spectrum will be further analyzed.
62269616|NCT03389971|ACTIVE_COMPARATOR|multi-sidehole catheter|
62269617|NCT03389971|EXPERIMENTAL|USAT catheter|
62269618|NCT05091398|ACTIVE_COMPARATOR|Group I|ultrasound-guided erector spinae block on T4 and T6 levels after the anesthesia induction and turning the patient in the lateral position
62269619|NCT05091398|ACTIVE_COMPARATOR|Group II|ultrasound-guided paravertebral block on T4 and T6 levels after the anesthesia induction and turning the patient in the lateral position
62269620|NCT05091398|ACTIVE_COMPARATOR|Group III|ultrasound-guided intercostal nerve block on T4 and T6 levels after the anesthesia induction and turning the patient in the lateral position
62269621|NCT05799456||Bladder cancer|
62269622|NCT05799456||No evidence of disease|
62269623|NCT01505621||Young|Healthy adults 18-30 years old
62269624|NCT01505621||Elderly|Healthy adults greater than 65 years old
62269625|NCT04309227|EXPERIMENTAL|Traditional High-Intensity Training|Participants will perform their training at \~70% of their 1-repetition maximum, as traditionally advocated in strengthening literature. Each of the diagnoses (RA, OA, myositis) will have a High-Intensity arm.
62630702|NCT02252302|PLACEBO_COMPARATOR|Resting in filtered air following placebo inhalation|Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of a placebo.
62064453|NCT04313959|ACTIVE_COMPARATOR|Local anesthetic|Patients assigned for local anesthetic group will receive a single-shot ultrasound-guided erector spine plane block with 25 mL of 0.2% of ropivacaine
62064454|NCT04313959|ACTIVE_COMPARATOR|Local anesthetic + steroid|Patients assigned for local anesthetic + steroid group will receive a single-shot ultrasound-guided erector spine block plane with 25 mL of 0.2% of ropivacaine with 5 mg dexamethasone
62452167|NCT01144663|ACTIVE_COMPARATOR|Menjugate Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 2 primary doses of Menjugate® vaccine at 2 and 4 months of age, followed by a booster dose of Menjugate® vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 4 and 12 months of age.
62653173|NCT03470077|EXPERIMENTAL|Group A|40 randomly allocated Patients undergoing repair of rupture globe will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.
62064455|NCT01516411|ACTIVE_COMPARATOR|Cognitive app|Cognitive app promotes behavior change via goal setting, feedback, and problem solving
62064456|NCT01516411|ACTIVE_COMPARATOR|Social app|Social app promotes behavior change via social relationships and feedback
62630703|NCT02252302|SHAM_COMPARATOR|Cycling in filtered air following salbutamol inhalation|Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of 400ug of salbutamol.
62630704|NCT02252302|PLACEBO_COMPARATOR|Cycling in filtered air following placebo inhalation|Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of a placebo
62630705|NCT02022046||2/study, control|Study group: children aged\<18 years with chronic kidney disease Control group: children aged\<18 years without chronic kidney disease Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
62630706|NCT01707888||major lung resection|Patients undergo major lung resection by thoracoscopy/VATS.
62064457|NCT01516411|ACTIVE_COMPARATOR|Affect app|Affect app promotes behavior change via game-like elements including the use of a bird avatar as a visual representation of one's activities and operant conditioning
62064458|NCT01516411|ACTIVE_COMPARATOR|Nutrition app|Nutrition app promotes behavior change bvia tracking of food consumption
62064459|NCT04923295|EXPERIMENTAL|Pre Treatment and post treatment|Patients on Peritoneal Dialysis will be evaluated by PET and transport status Patients on Peritoneal Dialysis will be evaluated by PET after treatment with Dapagliflozin
62064460|NCT03940508|EXPERIMENTAL|MCI + IPT-A|Participants will receive the Making Connections Intervention (MCI) in addition to IPT-A for depression.
62269626|NCT04309227|EXPERIMENTAL|Low Intensity plus Blood Flow Restriction Training|Participants will perform their training at \~30% of their 1-repetition maximum, and will have blood flow partially occluded (60-70%) to the training limb. Each of the diagnoses (RA, OA, myositis) will have a Low-Intensity plus Blood Flow Restriction arm.
62269627|NCT04309227|NO_INTERVENTION|Control|Each of the diagnoses (RA, OA, myositis) will have a control arm. The control groups will be evaluated at time 0, 4 weeks, and 8 weeks but will not receive intervention.
62630707|NCT06442722|ACTIVE_COMPARATOR|DDH with capsulorrhaphy|one group will undergo capsulorrhaphy, a surgical procedure to tighten the hip capsule
62064461|NCT03940508|ACTIVE_COMPARATOR|IPT-A Only|Participants will receive IPT-A for depression.
62064462|NCT05156463|NO_INTERVENTION|Control|Participants will receive standard follow-up survivorship care, an accelerometer to measure physical activity and NCCN (National Comprehensive Cancer Network) patient materials.
62064463|NCT05156463|EXPERIMENTAL|Treatment|Participants will receive same materials as standard of care group. In addition participants will use PAI Activity tool, Garmin activity tracker and exercise logs, and also receive periodic exercise coaching.
62064464|NCT00811447|EXPERIMENTAL|1|Administration of docetaxel 60 mg/m² on Day 1, Cisplatin 60 mg/m² after the end of the docetaxel infusion and 5-fluorouracil (5-FU) 600 mg/m²/day from Day 1 after the end of the cisplatin infusion to Day 5.
62269628|NCT02733666|EXPERIMENTAL|Absorbable screw group|One absorbable screw was used for fixation in the experimental group
62269629|NCT02733666|NO_INTERVENTION|K-wires group|two 1.8-mm K-wires were used for the fixation in the control group. The K-wires were the most common used by the orthopaedic surgeon.
62630708|NCT06442722|ACTIVE_COMPARATOR|DDH without capsulorrhaphy|group has no tightness of the hip capsule
62064465|NCT00811447|ACTIVE_COMPARATOR|2|Cisplatin 75 mg/m² on Day 1, 5-FU 600 mg/m²/day from Day 1 after the end of the cisplatin infusion to Day 5.
62064466|NCT04322006|EXPERIMENTAL|TJ004309 injection Monotherapy or Combination with Toripalimab|TJ004309 will be dose escalated in a 3+3 design in Monotherapy or combination with Toripalimab
62064467|NCT02692690|EXPERIMENTAL|before-after|TENS stimulation neck and thigh
62064468|NCT01782742|ACTIVE_COMPARATOR|Bexarotene treatment Arm|"75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.~Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)"
62269630|NCT04994119|EXPERIMENTAL|BIA 5-1058|Treatment Period 1: Subjects were admitted to the clinical unit on Day 1. Subjects received a single oral dose of BIA 5-1058 400 mg (4 x 100 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay.
62630709|NCT04646018|EXPERIMENTAL|Lumbar Manipulation Group|Group that receives experimental lumbar non-thrust manipulation
62630710|NCT04646018|SHAM_COMPARATOR|Sham Manipulation Group|Group that receives sham lumbar non-thrust manipulation
62630711|NCT05510414|EXPERIMENTAL|PCI group|intervention based on psychological capital model
62630712|NCT05510414|NO_INTERVENTION|Control group|routine psychological counseling
62269631|NCT04994119|EXPERIMENTAL|Warfarin|Treatment Period 2: Subjects were admitted to the clinical unit on Day 1. Subjects received a single dose of racemic warfarin (Coumadin® 5 x 5 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay. Subjects were required to return for out patient visits.
62630713|NCT03014271|EXPERIMENTAL|Sources of Strength Suicide (SOS)|Receive Sources of Strength Suicide (SOS) Prevention Program
62630714|NCT03014271|ACTIVE_COMPARATOR|SOS Waitlist Control|Delayed implementation of Sources of Strength Suicide Prevention Program after 16 months.
62630715|NCT04203212||Endometriosis Group|20 premenopausal women with surgically verified endometriosis who will receive goserelin 1 injection per month for 6 months. Subsequently goserelin will be discontinued and patients will be monitored for another 6 months after menstrual restoration.
62630716|NCT04203212||Control Group|20 age- and BMI-matched premenopausal, health women who will receive no treatment and be monitored for 6 months.
62269632|NCT04994119|EXPERIMENTAL|BIA 5-1058 and Warfarin|Treatment Period 3: Subjects were admitted to the clinical unit on Day 1. Subjects received a single concomitant dose of BIA 5-1058 400 mg (4 x 100 mg tablets) and racemic warfarin (Coumadin® 5 x 5 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay. Subjects were required to return for out patient visits.
62630717|NCT05394285|EXPERIMENTAL|hetrombopag Olamine tablets|"The first chemotherapy cycle (single center, open label, randomized controlled):~When platelets were \<50\*109/L, oral hetrombopag 7.5 mg/day was started. When the platelet count is \>100\*109/L, the administration is suspended.~2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days."
62630718|NCT05394285|OTHER|rhTPO|"The first chemotherapy cycle (single center, open label, randomized controlled):~Start using rh-TPO 15000 units/day (subcutaneous injection) when platelets are less than 50\*109/L. When the platelet count is more than 100\*109/L, the administration is suspended.~2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days."
62630719|NCT02532257|EXPERIMENTAL|Treatment (lenalidomide, rituximab, ibrutinib)|Patients receive lenalidomide PO on days 1-21, rituximab IV over 4-6 hours on days 1, 8, 15, and 22 of cycle 1 and day 1 of all subsequent cycles, and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62630720|NCT01345656|EXPERIMENTAL|Arm 1|
62630721|NCT01345656|EXPERIMENTAL|Arm 2|
62630722|NCT01345656|EXPERIMENTAL|Arm 3|
62630723|NCT01345656|EXPERIMENTAL|Arm 4|
62630724|NCT01345656|PLACEBO_COMPARATOR|Arm 5|
62630725|NCT01345656|ACTIVE_COMPARATOR|Arm 6|
62630726|NCT05680077||Positive group|Esophageal carcinoma and high-grade intraepithelial neoplasia patients.
62653174|NCT03470077|EXPERIMENTAL|Group B|40 randomly allocated Patients undergoing repair of rupture globe.will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.
62269633|NCT04607200|EXPERIMENTAL|Monotherapy|AGEN2034 - dose of 3 mg/kg IV every 2 weeks for up to 24 months
62269634|NCT04607200|EXPERIMENTAL|Combination Therapy|AGEN2034 - dose of 3 mg/kg IV every 2 weeks + AGEN1884 - dose of 1 mg/kg IV every 6 weeks (following AGEN2034 infusion), for up to 24 months
62269635|NCT01178060|ACTIVE_COMPARATOR|Personalized Risk Information|Patients received personalized stroke and heart attack risk assessment information.
62452168|NCT01144663|ACTIVE_COMPARATOR|NeisVac-C Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 2 primary doses of NeisVac-C™ vaccine at 2 and 4 months of age, followed by a booster dose of NeisVac-C™ vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 4 and 12 months of age.
62452169|NCT01004172|EXPERIMENTAL|carboplatin, bevacizumab, trastuzumab (if HER2+)|"Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days.~carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle~bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle~trastuzumab\*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only~\*8mg/kg loading dose in cycle 1 for some participants~HER-2: human epidermal growth factor receptor 2"
62452170|NCT03841032|EXPERIMENTAL|Sunscreen Lotion|Subjects with rosacea will apply the test sunscreen lotion to the face for 4 weeks
62452171|NCT06547580|EXPERIMENTAL|Group-based PFMT|A group-based Pelvic floor muscle training was practiced under the supervision of an experienced physiotherapist, 2 sessions a week, 30-45 minutes each, for 12 weeks.
62630727|NCT05680077||Negative group|Patients with other digestive malignancies (including gastric cancer, colorectal cancer, liver cancer, pancreatic cancer,Cholangiocarcinoma, etc.) and patients with non-digestive malignant tumors (including thyroid cancer, lung squamous cell carcinoma, cervix Cancer, endometrial cancer, breast cancer, prostate cancer, etc.), Patients with benign digestive disorders (including esophagitis, gastritis, enteritis, appendicitis, gastric polyps, colorectal polyps, etc.).
62630728|NCT01326247|NO_INTERVENTION|0.9% NaCl solution|
62630729|NCT02235181|NO_INTERVENTION|Standard Treatment|Women will be allocated to standard treatment, currently this is no treatment.
62630730|NCT02235181|ACTIVE_COMPARATOR|Arabin pessary|The Arabin cervical pessary will be inserted between 18 and 20+6 days gestation and removed between 35 and 36+6 weeks gestation unless Labour occurs sooner.
62630731|NCT02879955|EXPERIMENTAL|10 gastric bypass operated patients|4 different carbohydrate loads ingested at separate study days will be tested against each others ability to induce GLP-1 secretion.
62630732|NCT02879955|EXPERIMENTAL|10 healthy control subjects|4 different carbohydrate loads ingested at separate study days will be tested against each others ability to induce GLP-1 secretion.
62630733|NCT03821766||Heart failure|Patients suffering from heart failure regardless to the etiology will undergo cardiac catheterization according to their medical condition. the SCG and BCG signals will be recorded along with the intracavitary pressure profiles detected invasively with the cardiac catheterization.
62630734|NCT03131726|EXPERIMENTAL|Simvastatin|simvastatin 40 mg daily for 6 months
62630735|NCT03131726|NO_INTERVENTION|No treatment|No treatment
62630736|NCT00734708|EXPERIMENTAL|A|positive drug (0.3% Trafermin contained)
62064469|NCT01782742|PLACEBO_COMPARATOR|Placebo|"1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.~Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)"
62630737|NCT00734708|PLACEBO_COMPARATOR|P|control
62064470|NCT02750176|EXPERIMENTAL|CERCT|Closed chain exercises
62064471|NCT02672384|EXPERIMENTAL|patients in ICU|"Dental examination will be performed to diagnose CP based on the Centre for Diseases Control definition.~A point of care P. gingivalis test (Denka Seiken Co (Japan) ) on saliva and detection of antibodies against P. gingivalis in sera will be performed.~In case of discrepancies between both diagnoses methods, RT-PCR for identification of P. gingivalis and other pathogens will be performed on samples of periodontal pocket performed in routine."
62088153|NCT02748239|ACTIVE_COMPARATOR|MEDIAS 2 CT|The MEDIAS CT is a newly developed education program for the initiation of a conventional insulin therapy in type 2 diabetic patients.
62630738|NCT03212859|EXPERIMENTAL|Coach2Move Intervention Group|Coach2Move Intervention Group
62630739|NCT03212859|ACTIVE_COMPARATOR|Usual Care|Usual care physiotherapy among older adults
62630740|NCT02299388|ACTIVE_COMPARATOR|Liraglutide|All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
62064472|NCT03696797|ACTIVE_COMPARATOR|Treatment Group|Will have a Unit of blood (two cups, the same amount donated at the Red Cross) drawn. This involves having a needle inserted into a vein in your arm. Prior to taking the blood, staff will measure your blood count to be sure you are not anemic, and blood pressure to be sure no dehydration. During or after donation, a sports drink is provided to replace the fluid loss. Phlebotomy
62269636|NCT01178060|OTHER|Standard Education|Patients received general risk information on heart attack and stroke.
62269637|NCT02779374|EXPERIMENTAL|Autologous bone marrow transplantation|autologous bone marrow will be given by intravenous infusion. the intervention will be preceded by a period of 6 months of follow up the a period of 12 months follow up
62452172|NCT06547580|EXPERIMENTAL|Individualized PFMT|Individualized Pelvic floor muscle training with Electromyography Biofeedback was practiced under the supervision of an experienced physiotherapist, 2 sessions a week, 30-45 minutes each, for 12 weeks.
62630741|NCT02299388|PLACEBO_COMPARATOR|Placebo|All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
62630742|NCT00595543|ACTIVE_COMPARATOR|1|
62630743|NCT00595543|ACTIVE_COMPARATOR|2|
62630744|NCT00595543|ACTIVE_COMPARATOR|3|
62630745|NCT05704270|EXPERIMENTAL|Adaptive cognitive training|This arm is the intervention arm. Participants randomized to this arm will use a tablet to receive the multi-domain adaptive cognitive training, which will be delivered 30 minutes at least 5 times a week for 12 weeks.
62630746|NCT05704270|ACTIVE_COMPARATOR|Active control|This arm is the control arm. Participants randomized to this arm will use the same tablet to receive the cognitive training of low difficulty level with no adaptive change. The intervention dosage will be the same, which is 30 minutes each time, at least 5 times a week for 12 weeks.
62630747|NCT03225677||Patients with Cirrhosis|Patients with a diagnosis of cirrhosis will have a blood draw and muscle biopsy will be performed.
62630748|NCT03225677||controls|control group should have serum ALT and AST within normal range and a blood draw and muscle biopsy will be performed
62630749|NCT04530669|EXPERIMENTAL|study group|"in the active arm patients will receive high tone power therapy in addition to the physical therapy conventional selected exercise program"
62630750|NCT04530669|SHAM_COMPARATOR|control group|"the sham arm will receive the same physical exercise program with sham high tone power therapy."
62630751|NCT03580161||18-F FDG PET/CT|Patients receiving routine diagnostic scan
62630752|NCT03580161||Ga-68 PSMA PET/CT|Patients receiving routine diagnostic scan
62064473|NCT03696797|SHAM_COMPARATOR|Control Group|Will not donate blood, but will have a needle inserted into a vein in your arm. Both groups will not know which group assignment they have been randomized. Sham Phlebotomy
62064474|NCT03724396|EXPERIMENTAL|Novel Executive Function Training - NEXT|Same as BWL with some additional strategies targeted at improving executive function to help adherence to BWL skills.
62088154|NCT02748239|PLACEBO_COMPARATOR|Current CT program|This program is currently used for the initiation of conventional insulin therapy in type 2 diabetic patients.
62630753|NCT03580161||68-Ga Dotatate PET/CT|Patients receiving routine diagnostic scan
62630754|NCT03580161||99mTc Pertechnetate Thyroid Scan|Patients receiving routine diagnostic scan
62630755|NCT03580161||99mTc DMSA(III) Renal Scan|Patients receiving routine diagnostic scan
62630756|NCT03580161||99mTc MAG3 Renal Scan|Patients receiving routine diagnostic scan
62630757|NCT03580161||99mTc MDP/HDP Bone Scan|Patients receiving routine diagnostic scan
62630758|NCT00532532|EXPERIMENTAL|1|AV650 low dose
62630759|NCT00532532|EXPERIMENTAL|2|AV650 high dose
62630760|NCT00532532|EXPERIMENTAL|3|Placebo
62653175|NCT04243278|EXPERIMENTAL|PO LD-ASA|Study participants who are assigned to the oral aspirin arm of the study will receive 81mg oral aspirin. Over-encapsulated 81mg aspirin tablets will be used. Study participants in this arm will take 81mg aspirin daily for 6 months.
62630761|NCT05646030|OTHER|Subjects with known elevated serum CEA|"Before the start of sample collection questionnaire A on paper will be filled in by all study subjects. The order of sample collection will be: automated capillary sampling, lancet capillary sampling and venipuncture. Herein automated and lancet capillary sampling will be performed by the study subjects themselves whereas the venipuncture will be performed by the study personnel. After all sampling has been completed, the subject is asked to complete questionnaire B which will evaluate pain, burden, ease of use and preference.~For subjects in arm A and C this entails the end of the study"
62064475|NCT03724396|ACTIVE_COMPARATOR|Behavioral Weight Loss - BWL|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
62630762|NCT05646030|OTHER|Subjects currently undergoing colorectal cancer related follow-up|The subjects of arm B are requested to perform automated capillary and lancet capillary sampling at home following their next two outpatient visits. During these outpatient visits, a reference value blood CEA measurement will be obtained using venipuncture by the personnel of the clinical laboratory of Erasmus MC. The required materials will be sent to the home address of the patient. Sampling will be performed at home and by the subjects themselves. Subjects will have access to the tutorial videos for automated and lancet capillary sampling.
62630763|NCT05646030|OTHER|Volunteers|"Before the start of sample collection questionnaire A on paper will be filled in by all study subjects. The order of sample collection will be: automated capillary sampling, lancet capillary sampling and venipuncture. Herein automated and lancet capillary sampling will be performed by the study subjects themselves whereas the venipuncture will be performed by the study personnel. After all sampling has been completed, the subject is asked to complete questionnaire B which will evaluate pain, burden, ease of use and preference.~For subjects in arm A and C this entails the end of the study"
62064476|NCT01047722|ACTIVE_COMPARATOR|Patient drinks aspirin in Gatorade.|Patient drinks Gatorade containing 325 mg aspirin. Bleeding Volume Test is done one hour later.
62269638|NCT01773109|EXPERIMENTAL|Eligible patients will receive etirinotecan pegol at a dose of|single-arm, open-label study is designed to investigate the efficacy and safety of etirinotecan pegol in patients with metastatic or recurrent NSCLC after failure of 2nd line therapy. Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Patients will be followed clinically every week for the first cycle with laboratory parameters (section 6.2.1) and physical exam. Response will be determined with RECIST version 1.1 after 2 cycles of therapy. Patients with Stable disease (SD), partial response (PR) or complete response (CR) will continue on additional therapy for up to six cycles. In the absence of disease progression in subjects completing six full cycles, further treatment beyond cycle #6 will be left to the discretion of the treating physician and his/her staff. Patients with progressive disease will be taken off study and will be followed for OS
62630764|NCT01588158|ACTIVE_COMPARATOR|Vicodin 5/325 mg|Half of the patients will be randomized to Vicodin
62630765|NCT01588158|ACTIVE_COMPARATOR|Acetaminophen 325 mg|Half of the patients will be randomized to Acetaminophen
62630766|NCT02454348|ACTIVE_COMPARATOR|Norepinephrine and vasopressin|Norepinephrine (0.05 to 0.5 mcg/kg/min) and vasopressin (0.04 units/min) will be given by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg).
62630767|NCT02454348|ACTIVE_COMPARATOR|Norepinephrine|Norepinephrine (0.05 to 0.5 mcg/kg/min) will be given by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg).
62630768|NCT03503110|EXPERIMENTAL|dMRI and electrocorticography|Direct measurements of cortical electrical properties of patients operated on awake surgery for a brain tumor, using electrocorticography (ECoG), based on the dMRI tractography data previously acquired for each patient.
62630769|NCT05587894|EXPERIMENTAL|Nirmatrelvir/r 5 days alone|
62630770|NCT05587894|EXPERIMENTAL|Nirmatrelvir/r 10 days alone|
62630771|NCT05587894|EXPERIMENTAL|Nirmatrelvir/r 5 days + remdesivir s.d|
62630772|NCT05587894|EXPERIMENTAL|Nirmatrelvir/r 10 days + remdesivir s.d|
62630773|NCT03576274|EXPERIMENTAL|Technology Enhanced Home Exercise only|Participants in TEHE group will receive a combined technology and home exercise program. Participants will schedule an online meeting with the research team for exercise goal setting and preference. Participants will receive a daily symptoms survey. They will receive, reminder, motivation message and physical performance feedback though the mobile phone application.
62630774|NCT03576274|EXPERIMENTAL|Technology Enhanced Home Exercise plus|"In additional to the TEHE program, participants will receive auricular point acupressure (APA) training on how to locate the ear points, place the seeds and apply the pressure on the seed.~Participants will be instructed to press the tape and seeds covering each ear point for 3 minutes per time with a 2-second pause in between pressing, three times daily (morning, afternoon and evening: 9 minutes total).~The tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day."
62653176|NCT04243278|PLACEBO_COMPARATOR|PO Placebo|A standard placebo pill, the same size, shape and color of the oral aspirin will be used. The placebo pills will be over-encapsulated in the same manner as the aspirin tablets. The placebo will be administered to the participants randomized to placebo group in the same manner the oral aspirin would be administered - they will take the pill daily for 6 months.
62064477|NCT01047722|PLACEBO_COMPARATOR|Gatorade Placebo|Patient ingests Gatorade and one hour later a Bleeding Volume Test is performed
62064478|NCT01007968|EXPERIMENTAL|HDACi|
62064479|NCT04402528|EXPERIMENTAL|mehealth portal with integrated behavioral tools|Patients in this arm will use the mehealth for ADHD web-based software and have access to a module that allows parents and teachers/childcare providers to develop and implement behavioral interventions such as daily report cards online.
62064480|NCT00685321|EXPERIMENTAL|1|deep TMS treatment
62064481|NCT00685321|SHAM_COMPARATOR|2|inactive treatment
62088155|NCT00056290|ACTIVE_COMPARATOR|1|VEGF
62088156|NCT00056290|PLACEBO_COMPARATOR|2|Placebo
62269639|NCT04621370|ACTIVE_COMPARATOR|Arm A|"* Durvalumab 1500mg IV over 60 minutes, starting in the week prior to day 1 of radiotherapy, and continuing every 4 weeks until completion of FOLFOX chemotherapy~* Short course radiotherapy (25Gy delivered in 5 fractions) starting on day 1~* FOLFOX chemotherapy will be given every 2 weeks, starting approximately 1-2 weeks after radiotherapy and continuing for 6 cycles in total~* Assessment of response will be at approximately 16-18 weeks after day 1 of RT. If the patient is proceeding to surgery, this will be performed at approximately 18-20 weeks after day 1 of RT where possible."
62630775|NCT03576274|EXPERIMENTAL|Technology Enhanced Home Exercise-Mindfulness intervention|"In addition to the TEHE program, the TEHE+MBI group will receive a audio-recording of a mindfulness-based body scan.~During the weekly study visit: Participants will be instructed to listen to the recorded mindfulness-based body scan in the morning and before bedtime.~At home: Participants will be asked to listen to this audiotape daily in the morning and before bedtime."
62630776|NCT03576274|NO_INTERVENTION|Control (usual care)|The control group will receive instructions on how to use the physical activity tracker and mEMA application. Participants will be asked to meet with a research team member weekly to discuss their fatigue experience and receive general information about fatigue management.
62630777|NCT03576274|ACTIVE_COMPARATOR|Auricular Point Acupressure only|"Participants will receive auricular point acupressure (APA) training on how to locate the ear points, place the seeds and apply the pressure on the seed.~Participants will be instructed to press the tape and seeds covering each ear point for 3 minutes per time with a 2-second pause in between pressing, three times daily (morning, afternoon and evening: 9 minutes total).~The tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day."
62630778|NCT01265394|EXPERIMENTAL|(18F) Flutemetamol|
62630779|NCT01680809|EXPERIMENTAL|Compression stocking 15-20mmHg|Compression stocking 15-20mmHg
62630780|NCT01680809|EXPERIMENTAL|Compression stocking 20-30mmHg|Compression stocking 20-30mmHg
62630781|NCT03156257||Self-reported healthy males and females|The investigators are interested in sampling a wide variety of individuals from varying ethnic groups, sex, and age range.
62630782|NCT04265222|OTHER|Conventional Fluoroscopy|Participants undergoing femoroplasty with conventional treatment
62630783|NCT04265222|EXPERIMENTAL|HipCheck|Participants undergoing femoroplasty with Stryker HipCheck System
62630784|NCT01104883|EXPERIMENTAL|Adductor-Canal-Blockade|Adductor-Canal-Blockade with ropivacaine
62630785|NCT01104883|PLACEBO_COMPARATOR|Adductor-Canal-blockade with saline|Adductor-Canal-blockade with isotonic saline
62064482|NCT02405364|EXPERIMENTAL|Front line therapy|Induction: 4 cycles of 28 days of Carfilzomib/Lenalidomide/Dexamethasone Stem Cell Harvest+Intensification Consolidation 4 cycles of 28 days of Carfilzomib/ Lenalidomide/Dexamethasone Maintenance: Lenalidomide 13 cycles of 28 days
62452173|NCT01789320|EXPERIMENTAL|triamcinolone acetonide (Triesence®)|TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) in a total volume of 100 uL administered via microneedle directly to the suprachoroidal space (SCS)
62630786|NCT03425318|EXPERIMENTAL|Single arm|Patients with ARDS will be placed inside of a Continuous Negative Abdominal Pressure Device. Negative pressure will be applied to the abdomen as an adjunct to positive pressure ventilation
62630787|NCT02665819||Pediatric cancer women survivors|Women diagnosed for a cancer between 01/01/87 and 31/12/99 before the age of 15 years old living in Rhône-Alpes, will incur a blood taking for DNA tests (hormone tests) to see their fertility capacity.
62064483|NCT06040996|EXPERIMENTAL|IPSA|A new parent training program for parents with ADHD
62064484|NCT06040996|OTHER|Continued Routine Services|Continued Routine Services
62064485|NCT01327118|PLACEBO_COMPARATOR|Isoton sodium chloride|
62064486|NCT01327118|ACTIVE_COMPARATOR|Prostaglandin F2alpha|
62064487|NCT06625788||Patients with 10 or more colorectal adenomas|patients with 10 or more cumulative colorectal adenomas histologically confirmed
62452174|NCT04173936||Tai Chi|All participants enrolled in a 12 week community-based tai chi program.
62630788|NCT05423457|EXPERIMENTAL|Vegan diet|"Participants were provided with and instructed to eat these foods:~* flaxseed meal,~* walnuts,~* pecans,~* extra-virgin olive oil,~* Brazil nuts~* Taiwanese purple laver (also known as hong-mao-tai or Bangia atropurpurea, and was selected to test for its vitamin B12 bioavailability).~Each Participant has three group sessions and three individual nutrition counseling with a dietitian."
62630789|NCT05423457|ACTIVE_COMPARATOR|MyPlate (Taiwanese version)|Each Participant has three group sessions and three individual nutrition counseling with a dietitian.
62653177|NCT04130841|EXPERIMENTAL|Spontaneous ILM peeling|
62653178|NCT04130841|ACTIVE_COMPARATOR|Active ILM peeling|
62653179|NCT04130841|NO_INTERVENTION|No ILM peeling|
62088157|NCT00699543|EXPERIMENTAL|C|Coroflex Please stent implantation
62088158|NCT00699543|ACTIVE_COMPARATOR|T|Taxus stent implantation
62088159|NCT05023720||Regorafenib group|Patients were given only regorafenib orally
62630790|NCT02370511|EXPERIMENTAL|Native mitral valve with severe MAC|Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.
62630791|NCT02370511|EXPERIMENTAL|Valve-in-Ring|Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).
62630792|NCT02370511|EXPERIMENTAL|Valve-in-Valve|Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).
62630793|NCT02404402|EXPERIMENTAL|Active LED|Active LED Treatment
62630794|NCT02404402|SHAM_COMPARATOR|Sham LED|Inactive (sham) LED Treatment
62064488|NCT01396395|EXPERIMENTAL|Standard treatment plus nicorandil|The subjects will receive nicorandil 5 milligram (mg ) tablet orally three times daily for a period of 12 weeks along with one of the standard antianginal therapies (such as aspirin, beta-blockers, lipid lowering statins and angiotensin-converting enzyme inhibitors \[(ACEIs\] as permitted by disease condition /as per standard local practices/prescribed per discretion of investigators).
62064489|NCT01396395|OTHER|Standard treatment|
62064490|NCT02408237|ACTIVE_COMPARATOR|tDCS Ambulatory & Sham|Active tDCS Ambulatory: 1 mA of current of active tDCS applied for 20 minutes, single session of stimulation. Sham tDCS Ambulatory: applied for 20 minutes, single session of stimulation.
62064491|NCT02408237|ACTIVE_COMPARATOR|tDCS home use & Sham|Active tDCS home use: 11 active tDCS sessions: single session in the hospital and the remaining 10 in the subject's home, with duration of each active tDCS session of 20 min. Sham tDCS home use: 11 sessions of tDCS: single session in the hospital and the remaining 10 in the subject's home, with duration of each sham tDCS session of 20 min.
62064492|NCT00596596|ACTIVE_COMPARATOR|1|0,5 mg prucalopride
62064493|NCT00596596|ACTIVE_COMPARATOR|2|1 mg prucalopride
62064494|NCT00596596|ACTIVE_COMPARATOR|3|2 mg prucalopride
62064495|NCT00596596|PLACEBO_COMPARATOR|5|Placebo arm
62630795|NCT02576977|EXPERIMENTAL|Pembrolizumab+Pomalidomide+Dexamethasone|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W) PLUS pomalidomide 4 mg orally (PO) on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
62630796|NCT02576977|ACTIVE_COMPARATOR|Pomalidomide+Dexamethasone|Participants receive pomalidomide 4 mg PO on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
62630797|NCT04298827|ACTIVE_COMPARATOR|Unimodal|Patients will be randomized at their pre-surgical consultation. Patients will undergo a physical therapy evaluation prior to surgery and at 4 and 8 weeks post-op. Their preoperative visits will be as close to 4 weeks before surgery as possible but given the urgency of some of these surgeries and diagnoses, treatment will not be delayed to complete the components of this study. The patient will also be asked to complete a quality of life assessment at the beginning and end of the study as well as an anonymous survey at the conclusion of the study evaluating her satisfaction with the experiment.
62630798|NCT04298827|ACTIVE_COMPARATOR|Trimodal|Patients will be randomized at their pre-surgical consultation. Patients will undergo a physical therapy evaluation, nutritional counseling and group therapy, prior to surgery and at 4 and 8 weeks post-op. Their preoperative visits will be as close to 4 weeks before surgery as possible but given the urgency of some of these surgeries and diagnoses, treatment will not be delayed to complete the components of this study. The patient will also be asked to complete a quality of life assessment at the beginning and end of the study as well as an anonymous survey at the conclusion of the study evaluating her satisfaction with the experiment. Patient nutritional assessments will be obtained with Patient Generated Subjective Global Assessment questionnaires as well as targeted questioning by the dietician.
62653180|NCT02171624|EXPERIMENTAL|dabigatran etexilate|quinidine run-in, followed by dabigatran+quinine and dabigatran alone in randomized order
62064496|NCT00596596|ACTIVE_COMPARATOR|4|4 mg prucalopride
62064497|NCT02629211|EXPERIMENTAL|NaviAid™ AB|NaviAid™ AB device procedure
62630799|NCT04870021|EXPERIMENTAL|Intervention Arm|"After birth, one cc of intravenous blood was drawn from the peripheral veins of healthy newborn. The blood was immediately centrifuged, and serum was put in a plastic container, labeled with a unique identification number. The serum containers were frozen and then sent using a cold chain container, to Pakistan Medical Research Council laboratory at Jinnah Postgraduate Medical Center Karachi. The serum was tested for anti-hepatitis B surface antigen antibody on Enzyme Immunoassay (EIA) kit DS-EIA-Anti-HBsAg, manufactured by DSI S.r.I (Italy).~After obtaining a blood sample, infants born to mothers in the intervention group were administered GSK's ® recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs. This birth dose of hepatitis B was followed by zero dose oral polio vaccine as per hospital policy. Infants born to mother in the control group were given oral polio vaccine as per the hospital policy."
62630800|NCT04870021|OTHER|Control Arm|"In this arm of the study, after birth, one cc of intravenous blood was drawn from the peripheral veins of healthy newborn. The blood was immediately centrifuged, and serum was put in a plastic container, labeled with a unique identification number. The serum containers were frozen and then sent using a cold chain container, to Pakistan Medical Research Council laboratory at Jinnah Postgraduate Medical Center Karachi. The serum was tested for anti-hepatitis B surface antigen antibody on Enzyme Immunoassay (EIA) kit DS-EIA-Anti-HBsAg, manufactured by DSI S.r.I (Italy).~After obtaining a blood sample, infants born to mothers in the control group were given oral polio vaccine as per the hospital policy. Subsequent vaccinations were administered as per the expanded program on immunization schedule in Pakistan."
62630801|NCT04655326|EXPERIMENTAL|Treatment Group|Each participant receives a customized probiotic based on the results of the test of their microbiota
62630802|NCT05851573|EXPERIMENTAL|Psychosocial intervention|
62630803|NCT02633943||Subjects with Transfusion-Dependent β-Thalassemia|Long-term follow-up for participants treated with ex vivo gene therapy product in applicable bluebird bio-sponsored parent clinical trials and who agreed to participate in this study. Participants will be followed in this study for 13 years (for a total of 15 years of follow-up after drug product infusion in the parent studies)
62269640|NCT04621370|ACTIVE_COMPARATOR|Arm B|"* Durvalumab 1500mg IV over 60 minutes, starting in the week prior to day 1 of radiotherapy, and continuing every 4 weeks until completion of FOLFOX chemotherapy~* Long course chemoradiotherapy (50Gy to boost volume, 45Gy to elective volume delivered in 25 fractions) starting on day 1~* FOLFOX chemotherapy will be given every 2 weeks, starting approximately 1-2 weeks after radiotherapy for 4 cycles~* Assessment of response at approximately 16-18 weeks after day 1 of RT. If the patient is proceeding to surgery, this will be performed at approximately 18-20 weeks after day 1 of RT where possible."
62269641|NCT03033355||Pre- BTX-A injection|Female patients with confirmed diagnosis of Multiple Sclerosis referred to our Neurourology clinic with neurogenic lower urinary tract dysfunction prior to receiving intradetrusor injection of Botulinum Toxin-A.
62269642|NCT03033355||Post- BTX-A injection|Female patients with confirmed diagnosis of Multiple Sclerosis referred to our Neurourology clinic with neurogenic lower urinary tract dysfunction who receive intradetrusor Botulinum Toxin-A.
62064498|NCT02387996|EXPERIMENTAL|Nivolumab|Nivolumab intravenous infusion as specified
62269643|NCT06461260|EXPERIMENTAL|Amygdala TI|Right amygdala Temporal Interference (TI) stimulation with 100 frequency difference, 20 minutes per day for 5 days.
62269644|NCT04116112|EXPERIMENTAL|Higher Systolic Blood Pressure (SBP) Target|Lower systolic blood pressure to ≤180 mmHg and maintain for 24 hours. If anti-hypertensive medication used, then maintain ≥160 mmHg.
62269645|NCT04116112|EXPERIMENTAL|Lower SBP (<160 mmHg) Target|Lower systolic blood pressure to \<160 mmHg and maintain for 24 hours. If anti-hypertensive medication used, then maintain \>140 mmHg.
62269646|NCT04116112|EXPERIMENTAL|Lower SBP (<140mmHg) Target|Lower systolic blood pressure to \<140 mmHg and maintain for 24 hours. If anti-hypertensive medication used, then maintain \>110 mmHg.
62269647|NCT05694351|EXPERIMENTAL|Families with type 2 diabetes|Families (n=25) of at least two family members - minimum one adult and one child per family unit (appx. 100 individuals in total) will be included. A convenient study sample will be composed with no restriction to family types - traditional nuclear families, same-sex parenting families, single-parent families, or blended/ step-parent families). Balanced representation of different geographical areas within Region Zealand will be attempted.
62630804|NCT00787163|EXPERIMENTAL|1|amnioinfusion
62630805|NCT00787163|NO_INTERVENTION|2|expectant management
62630806|NCT04398940|EXPERIMENTAL|TQ-B3139 capsules|TQ-B3139 capsules administered orally.
62630807|NCT05205499|EXPERIMENTAL|IBS|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System
62630808|NCT02196298|EXPERIMENTAL|Lokomat|16 sessions in total, 30 minutes each plus set-up time followed by 5 minutes of overground walking. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
62630809|NCT02196298|ACTIVE_COMPARATOR|Physiotherapy|16 sessions, 35 minutes. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
62630810|NCT01218815|EXPERIMENTAL|Culprit lesion IRA Revascularization|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
62630811|NCT01218815|ACTIVE_COMPARATOR|Complete IRA revascularization|Primary PCI of culprit lesion in IRA with DES stent
62064499|NCT06481579|EXPERIMENTAL|IVX-A12 Vaccine|Participants will receive a single dose of IVX-A12, 300 micrograms (mcg), intramuscular (IM) injection on Day 1.
62064500|NCT06481579|ACTIVE_COMPARATOR|Licensed RSV Vaccine|Participants will receive a single dose of licensed RSV vaccine IM injection on Day 1.
62630812|NCT03602716|EXPERIMENTAL|HD-tDCS group|This HD-tDCS group will be stimulated by active HD-tDCS.
62630813|NCT03602716|SHAM_COMPARATOR|Sham HD-tDCS group|This sham HD-tDCS group will have a sham stimulation with HD-tDCS.
62630814|NCT02503241|EXPERIMENTAL|PEEP_Titration_INCREMENTAL|"The investigators will compare 3 levels of PEEP (BASELINE versus PEEP INCREMENTAL versus PEEP DECREMENTAL). Baseline PEEP is based in the standard of care PEEP used in the participant units. PEEP incremental value is based in transpulmonary pressure.~Intervention : PEEP INCREMENTAL"
62630815|NCT02503241|EXPERIMENTAL|PEEP_Titration_DECREMENTAL|"The investigators will compare 3 levels of PEEP (BASELINE versus PEEP INCREMENTAL versus PEEP DECREMENTAL). Baseline PEEP is based in the standard of care PEEP used in the participant units. PEEP decremental value is based in lung recruitment maneuver followed by a best compliance curve during PEEP decrements.~Intervention :PEEP DECREMENTAL"
62630816|NCT02933398|ACTIVE_COMPARATOR|Laparoscopic Assisted Partial Nephrectomy|Current standard for partial nephrectomies.
62064501|NCT03921346|EXPERIMENTAL|Arm A (mobile device app)|"Paramedics preparing drugs with the help of the mobile device app PedAMINES™.~Each paramedic will have to prepare sequentially 4 direct IV emergency drugs with the help of the mobile device app PedAMINES™."
62064502|NCT03921346|ACTIVE_COMPARATOR|Arm B (conventional preparation method)|"Paramedics preparing drugs with the help of conventional method.~Each paramedic will have to prepare sequentially 4 direct IV emergency drugs with the help of conventional method"
62064503|NCT01775514||Participants With Cancer|Participants from Turkey with non-small cell lung, colon cancer, breast cancer, gastric cancer and malignant melanoma will be included.
62630817|NCT02933398|ACTIVE_COMPARATOR|Robotic Assisted Partial Nephrectomy|Possible new standard for partial nephrectomies.
62630818|NCT03320265|EXPERIMENTAL|PC-mAb|Phosphorylcholine human monoclonal antibody, i.v. infusions
62630819|NCT03320265|PLACEBO_COMPARATOR|Placebo|Placebo to PC-mAb, i.v. infusions
62630820|NCT01653457|PLACEBO_COMPARATOR|Placebo|
62630821|NCT01653457|ACTIVE_COMPARATOR|Memantine|
62630822|NCT04211012|EXPERIMENTAL|Treatment Arm|
62630823|NCT05807035|EXPERIMENTAL|Radvax|This is a single arm study where all participants will get active Radvax autologous tumour vaccine weekly for 4 weeks and then monthly thereafter
62630824|NCT05572021|EXPERIMENTAL|Prospective|Participants enrolled to ventral hernia repair with Fortiva mesh
62269648|NCT04864665|EXPERIMENTAL|Formula fed|0 - 6 months: a formula with prebiotics and milk fat (Stage 1); \>6 - 12 months: a formula with prebiotics and milk fat (Stage 2); \>1 - 2 years: a formula with prebiotics and milk fat (Stage 3)
62630825|NCT05572021|ACTIVE_COMPARATOR|Retrospective|Retrospective participants with ventral hernia repair using Strattice mesh
62452175|NCT03617692||Oral Cannabis|This is an observational study of individuals who have already decided to try cannabis for their cancer treatment-related symptoms. A research assistant will provide information on the range of edible cannabis products and basic information about their various cannabinoid profiles, approximate prices, and nearby locations where participants may choose to purchase their product. Participants will then initiate use of an orally administered product they have selected and obtained. Participants will take the product as they see fit, without any frequency or dosing instructions from study staff, for two weeks.
62630826|NCT00622102|EXPERIMENTAL|1|50% of the consenting subjects will take part in the lottery and use the Med-eMonitor as a device to monitor adherence
62630827|NCT00622102|OTHER|2|50% of the consenting subjects will use only the Med-eMonitor as a device to monitor adherence
62630828|NCT00673257|EXPERIMENTAL|Pharmacokinetics of Daunorubicin chemotherapy patients|Patients receiving a chemotherapy regimen including daunorubicin hydrochloride administered as an infusion of any duration \< 24 hours on a 1 or a 2 day schedule. Pre-study evaluations no greater than 14 days prior to daunomycin administration. If patients have had significant intercurrent illness or treatment that might affect organ function, laboratory work should be performed at an appropriately closer interval to daunomycin administration. A complete history and physical examination including height, weight and body surface area. Patients should be weighed with only light clothing; shoes must be removed before weight is measured. Patients height should be measured using a stadiometer after removing shoes. Laboratory evaluation: a) CBC with differential and platelet count. b) ALT, AST, bilirubin, creatinine, total protein, albumin, alkaline phosphatase, GGT.
62630829|NCT00301457|EXPERIMENTAL|1|6 years adjuvant anastrozole therapy
62269649|NCT03730116||the patients with HT and concomitant stable CAD|
62269650|NCT04008407|ACTIVE_COMPARATOR|ESD|Lesion with overt stigmata of SMIC or those with high risk (=\> 10%) for covert SMIC.
62630830|NCT00301457|EXPERIMENTAL|2|3 years adjuvant anastrozole therapy
62630831|NCT02141191|EXPERIMENTAL|HS/sham|Subjects will utilize inhaled hypertonic saline (7%) delivered using the tPAD device during one session and perform a sham treatment with the tPAD during the other. The order will be randomized.
62630832|NCT02141191|EXPERIMENTAL|sham/HS|Subjects will utilize inhaled hypertonic saline (7%) delivered using the tPAD device during one session and perform a sham treatment with the tPAD during the other. The order will be randomized.
62630833|NCT03030677|OTHER|Interventional Without Dissectioin|confirming insertion of B Braun Catheter Kit Contiplex with 18 Gauge needle using ultrasound without injecting 10 ml of lidocaine 1% as a dissecting solution
62088160|NCT05023720||Joint group|The patient was treated with regorafenib orally and in combination with other medications
62269651|NCT04008407|ACTIVE_COMPARATOR|EMR|Lesion with no overt or a low risk for (\<10%) for covert SMIC
62269652|NCT02474966|EXPERIMENTAL|Real-Sham dTMS|This arm will be treated before with real deep Transcranial Magnetic Stimulation (dTMS) (the first day) and after with sham dTMS (the second day)
62269653|NCT02474966|EXPERIMENTAL|Sham-Real dTMS|This arm will be treated before with sham deep Transcranial Magnetic Stimulation (dTMS) (the first day) and after with real dTMS (the second day)
62269654|NCT04197115|NO_INTERVENTION|Phase 1|Septic patients admited to ICU whick will be treated as specified in current guidelines.
62452176|NCT04437342||Maternal Group|Pregnant women in labour (vaginal delivery or caesarean section) that are admitted to the hospital. Pre-labour 3 different questionnaires are administered to evaluate depression, general anxiety disorder and the association to the covid-19 pandemic. 40 days post delivery via telephone contact 2 questionnaires are administered, one in order to assess the postpartum disorder the other to assess depression.
62452177|NCT02697409|EXPERIMENTAL|Intervention group|The intervention group receives two school-based modules taking less than two hours each delivered by medical students in the schools.
62653181|NCT02171624|EXPERIMENTAL|quinidine|quinidine run-in, followed by dabigatran+quinine and dabigatran alone in randomized order
62630834|NCT03030677|OTHER|Interventional With Dissectioin|confirming insertion of B Braun Catheter Kit Contiplex with 18 Gauge needle using ultrasound after injecting 10 ml of lidocaine 1% as a dissecting solution
62630835|NCT04959409||Exposed Cohort|Children receiving topical analgesia
62630836|NCT04959409||Control / Unexposed Cohort|Children who do not receive topical analgesia
62630837|NCT01945983|ACTIVE_COMPARATOR|Early norepinephrine|Norepinephrine 4 mg in 5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour, adjusted according to patient's body weight to achieve norepinephrine 0.05microgram/kg/min Continuous drip for 48 hours.
62630838|NCT01945983|PLACEBO_COMPARATOR|Placebo|5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour. Adjust rate of infusion according to patient's body weight to achieve dosage of norepinephrine comparable to 0.05 microgram/kg/min Continuous drip for 48 hours.
62630839|NCT04407039||Glioma molecular subtype: G-CIMP-low|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
62630840|NCT04407039||Glioma molecular subtype: G-CIMP-high|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
62269655|NCT04197115|ACTIVE_COMPARATOR|Phase 2|"Septic patients admitted to ICU which will be treated as specified in current guidelines adding:~Vitamin C Hydrocortisone B complex (Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg)"
62269656|NCT03132337||Stem Cell Transplant|Serial Blood Draws
62269657|NCT00915681|EXPERIMENTAL|Legalon SIL|Silibinin: loading dose of one hour infusion of 5 mg/kg, followed by 20 mg/kg/day infused continuously via pump
62269658|NCT00546052|EXPERIMENTAL|1|Losartan (MK0954) / Losartan + HCTZ (MK0954A)
62269659|NCT02975544|EXPERIMENTAL|Intervention group|Received CRECES programme during 5 weeks as part of the extracurricular plan
62630841|NCT04407039||Glioma molecular subtype: codel|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
62630842|NCT04407039||Glioma molecular subtype: classic-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
62630843|NCT04407039||Glioma molecular subtype: mesenchymal-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
62630844|NCT04407039||Glioma molecular subtype: LGM6-GBM|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
62269660|NCT02975544|NO_INTERVENTION|Control group|Continued with their habitual school routine
62269661|NCT05088304||The normal FFMI group|The FFMI was calculated as follows: FFMI = fat-free mass (kg)/height squared (m2). FFMI cut-off values (derived from BIA measurements, \</≥15 kg/m2 for females and \</≥17 kg/m2 for males). Patients with esophagogastric cancer were then divided into the normal FFMI group (FFMI ≥17 kg/m2 for male and FFMI ≥15 kg/m2 for female).
62269662|NCT05088304||The low FFMI group|The FFMI was calculated as follows: FFMI = fat-free mass (kg)/height squared (m2). FFMI cut-off values (derived from BIA measurements, \</≥15 kg/m2 for females and \</≥17 kg/m2 for males). Patients with esophagogastric cancer were then divided into the low FFMI group (FFMI \<17 kg/m2 for male and FFMI \<15 kg/m2 for female).
62269663|NCT00209378|ACTIVE_COMPARATOR|heparin|Citrate regional anticoagulation is compared with standard systemic heparinization.
62452178|NCT02697409|NO_INTERVENTION|Control group|
62452179|NCT04568681||Patients with dystonia|Patients with dystonia who have clinically been deemed candidates for DBS surgery.
62630845|NCT04407039||Glioma molecular subtype: PA-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
62630846|NCT00873717|EXPERIMENTAL|Dentary|Intervention: trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.
62630847|NCT00873717|EXPERIMENTAL|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
62630848|NCT00873717|EXPERIMENTAL|Dentary + nutrition|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed) associated with control of the administration of dietary prescriptions, incitement to eat.
62630849|NCT00873717|NO_INTERVENTION|Control|usual care
62630850|NCT02437994|EXPERIMENTAL|Pulmonary Rehabilitation|The rehabilitation program will be multidisciplinary and will include supervised exercise training (interval exercise and resistance exercises), breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability.
62630851|NCT02437994|NO_INTERVENTION|Control|In addition, a control group (Group C) which will not participate in the rehabilitation program (usual care) will be include at the same time as patients in Group A and B so as to be able and independently address study objectives 2 and 3 and 4. Group C will also randomized to those into paper-pencil version and electronic version.
62630852|NCT03560011|NO_INTERVENTION|Rituximab (375 mg/m²)|Single infusion of rituximab (375 mg/m²)
62064504|NCT06623201|EXPERIMENTAL|Blue-Light Photodynamic Therapy and Sonidegib|All subjects will receive Sonidegib (ODOMZO) 200mg by mouth every day on an empty stomach (1 hour before or 2 hours after a meal) for 3 months, and PDT with topical application of ALA for a total of 3 sessions. PDT will be first administered at Visit 3 (Day 7), Visit 4 (Day 30), and Visit 5 (Day 90).
62064505|NCT04034459|ACTIVE_COMPARATOR|FOLFOXIRI plus bevacizumab|"One cycle (cycle duration 14 days) consists of:~* Irinotecan 150 mg/m² iv, 30 - 90 min. day 1~* Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1~* Oxaliplatin 85mg/m² day 1~* 5-FU 3000 mg/m² iv over 48 h days 1-2~* Bevacizumab 5 mg/kg BW iv over 30 to 90\* min day 1 \*1st administration 90 min.; in case of good tolerability, second administration 60 min.; further administrations 30 min.~Repeat administration every 2 weeks for a maximum of 12 cycles~* Dose adaptation at the treating physician's discretion.~* Switch to the recommended maintenance treatment with fluoropyrimidine and bevacizumab after the 8th cycle (following 2nd staging after baseline) is possible at the treating physician's discretion if response according to RECIST 1.1 (CR or PR) has been achieved."
62064506|NCT04034459|EXPERIMENTAL|FOLFOXIRI plus cetuximab|"One cycle (cycle duration 14 days) consists of:~* Irinotecan 150 mg/m² iv, 30 - 90 min. day 1~* Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1~* Oxaliplatin 85mg/m² day 1~* 5-FU 3000 mg/m² iv over 48 h days 1-2~* Cetuximab initially 400 mg/m² with infusion rate of ≤5 mg/min., subsequently 250 mg/m² iv with infusion rate of ≤10 mg/min. days 1+8~Repeat administration every two weeks up to a maximum of 12 cycles.~* Dose adaptation at the treating physician's discretion.~* Switch to the recommended maintenance treatment with 5-FU and cetuximab or irinotecan and cetuximab after the 8th cycle (following 2nd staging after baseline) is possible at the treating physician's discretion if response according to RECIST 1.1 (CR or PR) has been achieved."
62064507|NCT05834036|EXPERIMENTAL|Healthy Controls|Healthy controls
62269664|NCT00209378|ACTIVE_COMPARATOR|Citrate|regional anticoagulation with citrate containing replacement solution
62269665|NCT01347151|EXPERIMENTAL|Glide scope|
62452180|NCT01107002|EXPERIMENTAL|Day 5 embryo transfer group|Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
62630853|NCT03560011|EXPERIMENTAL|Rituximab followed by 5 injections of immunoglobulin IV|Rituximab (375 mg/m²) followed by 5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g). Treatment duration : 6 months
62630854|NCT01673178|PLACEBO_COMPARATOR|Placebo Arm|
62630855|NCT01673178|EXPERIMENTAL|25 mg|
62630856|NCT01673178|EXPERIMENTAL|50 mg|
62064508|NCT02339896||WHO category 2|Children patient who have experienced WHO category II exposure will receive rabies vaccine (SPEEDA) 0.1 ml intradermal two site for 4 times
62064509|NCT02339896||WHO category 3|Children patient who have experienced WHO category II exposure will receive rabies vaccine (SPEEDA) 0.1 ml intradermal two site for 4 times with ERIG
62088161|NCT01798082|NO_INTERVENTION|Standard counseling|
62269666|NCT01347151|EXPERIMENTAL|Pentax airway scope|
62269667|NCT03326843|EXPERIMENTAL|Avatrombopag 60 mg|Open-label: oral avatrombopag
62269668|NCT04434495|EXPERIMENTAL|PRP group|mock embryo transfer and PRP injection
62269669|NCT04434495|NO_INTERVENTION|control group|only mock embryo transfer
62269670|NCT02342015|EXPERIMENTAL|Atorvastatin|Atorvastatin 40 mg/day for three months
62269671|NCT02284282|ACTIVE_COMPARATOR|Spinal injection|Patients receive spinal injection Bupivacaine/Morphine
62269672|NCT02284282|PLACEBO_COMPARATOR|Subcutaneum injection|Placebo subcutaneum injections
62269673|NCT00362089|ACTIVE_COMPARATOR|Marinol|Intervention group with Marinol D40 fish oil capsules
62269674|NCT00362089|NO_INTERVENTION|Nutrition counseling|Control group
62269675|NCT04887493|EXPERIMENTAL|Sublingual misoprostol|Sublingual misoprostol group will receive misoprostol 25µg by sublingual routes; the dose will be given repeatedly every 4 hours by sublingual route till there is labour pain or contraction or to a maximum of 6 dosages.
62630857|NCT01673178|EXPERIMENTAL|100 mg|
62630858|NCT01673178|EXPERIMENTAL|150 mg|
62630859|NCT03289988||Normal group|Normal group(control group): patients with negative colonoscopy findings (n= 238).
62630860|NCT03289988||Low risk adenoma group|Low risk adenoma group: patients having at least one low risk adenoma (n=250).
62630861|NCT03289988||High-risk adenoma group|High-risk adenoma group: patients having at least one of following criteria (more than 1 cm in size, villous or tubulovillous histologic type, high-grade dysplasia findings) (n=316).
62630862|NCT03289988||Colon cancer|Colon cancer: histologically confirmed colon cancer patients (n=160).
62630863|NCT00968955|ACTIVE_COMPARATOR|Local infiltration with ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
62630864|NCT00968955|PLACEBO_COMPARATOR|Local infiltration with saline|Local infiltration with saline (150 ML) (placebo)
62452181|NCT05265182|EXPERIMENTAL|Semi-CAVE|The Semi-CAVE (Figure 2) will use two screens positioned at a corner of the room, each with a ceiling-mounted short throw projector in front. The user will sit in the middle of the area, giving them a viewing angle of roughly 180 degrees. The user will interact with the system through motion sensors positioned at the corners of the area. To one side of the area will be a sufficiently powerful computer running the software. The projectors will be connected to this computer via HDMI cables or similar. The Semi-CAVE may be offered as a solution for rehabilitation centers.
62452182|NCT05265182|EXPERIMENTAL|Head-mounted display or HMD|The HMD will be a commercially available device that uses handheld controllers in addition to the head mounted apparatus, to control movement while in the VE. This device could provide a cheaper, more practical alternative to patients with mobility issues and environmental limitations brought about by the pandemic, since this can be used at home. Any patient, with supervision from their caregivers, will be able to use the applications using only the HMD system.
62630865|NCT06149572|EXPERIMENTAL|Lateral (L) Position group|Parturients will be put for spinal punctures at the lateral position
62064510|NCT02844491||Cohort A|"In Cohort A, patients will be included either in the group sustainable responseor in the short / refractory response group.~- sustainable response group : patient with NHL diffuse large B cells, and persistent complete response for at least 6 months after first-line treatment with Rituximab OR patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstrom's disease in complete response or partial stable response for at least 1 year after first line treatment with Rituximab~short / refractory response group : patient with NHL diffuse large B cells, refractory or relapsed in less than 6 months after at least one line of treatment with Rituximab OR patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstrom's disease refractory or relapsed / progression within less than 1 year after at least one line of treatment with Rituximab"
62064511|NCT02844491||Cohort B|"For Cohort B patients will be included either in the group B hematologic therapeutic abstention or in the group any blood disease not treated with anti-CD20 antibodies.~B hematologic therapeutic abstention group : patient with hematological malignancy whatever the initial expansion stage~any blood disease not treated with anti-CD20 antibodies group : patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstorm disease without treatment criteria at diagnosis and with stable disease for at least 6 months"
62269676|NCT04887493|EXPERIMENTAL|Vaginal misoprostol|Vaginal misoprostol group will receive misoprostol 25µg by per vaginal routes; the dose will be given repeatedly every 4 hours by per vaginal route till there is labour pain or contraction or to a maximum of 6 dosages.
62269677|NCT02562742||SOF+REB|Adult patients with genotype 2 chronic HCV infection with or without compensated cirrhosis who take SOF+REB as part of routine clinical care at a participating clinical site.
62269678|NCT01298115||Stage 5 chronic kidney disease|Incident patients commencing renal replacement therapy or conservative care
62452183|NCT00757601|EXPERIMENTAL|15 mg MK1006/Placebo/45 mg MK1006/60 mg MK1006/Placebo (Fed)|Participants received 15 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by placebo to MK1006 taken with food (Fed state) in Period 5.
62452184|NCT00757601|EXPERIMENTAL|Placebo/30mg MK1006/45mg MK1006/60mg MK1006/30mg MK1006 (Fed)|Participants received placebo to MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
62452185|NCT00757601|EXPERIMENTAL|15mg MK1006/30mg MK1006/Placebo/60mg MK1006/30mg MK1006 (Fed)|Participants received 15 mg MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
62630866|NCT06149572|ACTIVE_COMPARATOR|Sitting (S)position group|Parturients will get spinal punctures at the Sitting position as comparison
62630867|NCT01084057|EXPERIMENTAL|Arm I (Cohort A)|Patients receive oral vorinostat once daily on days 1-14 and ixabepilone IV over 3 hours on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62064512|NCT00647101|EXPERIMENTAL|Latanoprost group|
62064513|NCT06625489|EXPERIMENTAL|Part A: GSK3915393|Participants from Chinese, Japanese, and European ancestries will be randomized to receive GSK3915393 under fasting condition.
62630868|NCT01084057|EXPERIMENTAL|Arm II (Cohort B)|Patients receive oral vorinostat once daily on days 1-7 and 15-21. Patients also receive ixabepilone IV over 3 hours on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62630869|NCT06092528|EXPERIMENTAL|Pulmonary Rehabilitation Group|Pulmonary rehabilitation practices (inspiratory muscle training, aerobic exercise training, resistance exercise training) will be performed 3 sessions a week for 6 weeks under the supervision of a physiotherapist to the training group.
62452186|NCT00757601|EXPERIMENTAL|15mg MK1006/30mg MK1006/45mg MK1006/Placebo/30mg MK1006 (Fed)|Participants received 15 mg MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
62452187|NCT00757601|EXPERIMENTAL|60mg MK1006 / Placebo / 100mg MK1006 / 120mg MK1006 / Placebo|Participants received 60 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by placebo to MK1006 in Period 5.
62452188|NCT00757601|EXPERIMENTAL|Placebo/ 80mg MK1006/ 100mg MK1006/ 120mg MK1006/ 140mg MK1006|Participants received placebo to MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by 140 mg MK1006 in Period 5
62452189|NCT00757601|EXPERIMENTAL|60mg MK1006/ 80mg MK1006/ Placebo/ 120mg MK1006/ 140mg MK1006|Participants received 60 mg MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.
62452190|NCT00757601|EXPERIMENTAL|60mg MK1006/ 80mg MK1006/ 100mg MK1006/ Placebo/ 140mg MK1006|Participants received 60 mg MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.
62452191|NCT00757601|EXPERIMENTAL|140mg MK1006 / Placebo / 200mg MK1006 / 230mg MK1006 / Placebo|Participants received 140 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by placebo to MK1006 in Period 5.
62452192|NCT00757601|EXPERIMENTAL|Placebo/170mg MK1006/ 200mg MK1006/ 230mg MK1006/ 260mg MK1006|Participants received placebo to MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.
62452193|NCT00757601|EXPERIMENTAL|140mg MK1006/170mg MK1006/ Placebo/ 230mg MK1006/ 260mg MK1006|Participants received 140 mg MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by 260 mg MK1006 in Period 5
62452194|NCT00757601|EXPERIMENTAL|140mg MK1006/170mg MK1006/ 200mg MK1006/ Placebo/ 260mg MK1006|Participants received 140 mg MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.
62452195|NCT02388178|PLACEBO_COMPARATOR|Fluoride free, silica based toothpaste|Control toothpaste containing no anti-cavity ingredients
62452196|NCT02388178|EXPERIMENTAL|fluoride + amino acid in a silica toothpaste|Experimental toothpaste containing fluoride and amino acid (arginine)
62630870|NCT06092528|SHAM_COMPARATOR|Control Group|Control group will be given breathing exercises as a home program for 6 weeks.
62630871|NCT00837967|EXPERIMENTAL|First Symbicort, then Terbutaline|Symbicort Turbuhaler 160/4.5μg for 3 days First , then Terbutaline Turbuhaler 0.4 mg for 3 days
62653182|NCT06147674||VQm PHM™|Non-invasive measurements obtained with the VQm PHM™ compared to current standard of care.
62064514|NCT06625489|PLACEBO_COMPARATOR|Part A: Placebo|Participants from Chinese, Japanese, and European ancestries will be randomized to receive placebo under fasting condition.
62064515|NCT06625489|EXPERIMENTAL|Part B: Nintedanib followed by Nintedanib plus GSK3915393|Male participants will be randomized to receive Nintedanib in Period 1 followed by co-administration of Nintedanib and GSK3915393 in Period 2 under fed conditions. There will be a washout period of minimum 5 days post last dose between Period 1 and Period 2.
62064516|NCT06625489|EXPERIMENTAL|Part B: Nintedanib plus GSK3915393 followed by Nintedanib|Male participants will be randomized to receive co-administration of Nintedanib and GSK3915393 in Period 1 followed by Nintedanib in Period 2 under fed conditions. There will be a washout period of minimum 5 days post last dose between Period 1 and Period 2.
62064517|NCT03185832||CRT-D Cohort|Number of participants with first appropriately treated ventricular arrhythmia
62064518|NCT03185832||ICD Cohort|Number of participants with first appropriately treated ventricular arrhythmia
62064519|NCT03185832||Pacing (PM / CRT-P) Cohort|All cause mortality
62630872|NCT00837967|EXPERIMENTAL|First Turbuhaler, then Symbicort|Terbutaline Turbuhaler 0.4 mg for 3 days First, then Symbicort Turbuhaler 160/4.5μg for 3 days,
62269679|NCT04937556|ACTIVE_COMPARATOR|Probiotic: Lactobacillus salivarius + Vit D + Zinc|Lactobacillus strain during 28 days, approximately 1\*10E9 colony forming unit (CFU) of L. salivarius in 1 capsule per day.
62630873|NCT04110314|ACTIVE_COMPARATOR|Gain-framed portal reminders + Pre-commitment Prompts|Participants receive gain-framed reminder/recall messages regarding influenza vaccination via the patient portal and a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
62630874|NCT04110314|ACTIVE_COMPARATOR|Gain-framed portal reminders + No pre-commitment prompt|Participants receive gain-framed reminder/recall messages regarding influenza vaccination via the patient portal and no pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
62630875|NCT04110314|ACTIVE_COMPARATOR|Loss-framed portal reminders + Pre-commitment prompt|Participants receive loss-framed reminder/recall messages regarding influenza vaccination via the patient portal and a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
62630876|NCT04110314|ACTIVE_COMPARATOR|Loss-framed portal reminders + No pre-commitment prompt|Participants receive loss-framed reminder/recall messages regarding influenza vaccination via the patient portal and a no pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
62630877|NCT04110314|ACTIVE_COMPARATOR|No portal reminder + Pre-commitment prompt|Participants do not receive any reminder/recall messages regarding influenza vaccination via the patient portal but do receive a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
62630878|NCT04110314|NO_INTERVENTION|No portal reminders + No pre-commitment prompt|Participants do not receive any reminder/recall messages regarding influenza vaccination via the patient portal and do not receive a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
62064520|NCT03185832||Non-device Cohort|All-cause mortality in the subject cohort with 2 to 5 predefined SCD driving risk factors
62064521|NCT01478711|ACTIVE_COMPARATOR|Intervention|A clinical decision support tool for the care and management of premature infants will be embedded into the electronic health record.
62269680|NCT04937556|PLACEBO_COMPARATOR|Placebo|Placebo supplement in 1 capsule per day during 28 days.
62269681|NCT01514227|EXPERIMENTAL|Short-term DAPT (6 months) group|6 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
62269682|NCT01514227|EXPERIMENTAL|Long-term DAPT (18 months) group|18 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
62269683|NCT01069562|ACTIVE_COMPARATOR|MANUAL|In the manual group isoflurane was administered using Tech 7 vapouriser. The dial setting was controlled by the anesthesiologist to achieve and maintain a BIS of 50 during anesthesia.
62630879|NCT05844332||LUTATHERA|patients treated with LUTATHERA Injection
62630880|NCT02872233|EXPERIMENTAL|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
62630881|NCT02477878|EXPERIMENTAL|BPX-501 and Rimiducid|"All subjects will receive 3 cycles of BPX-501 T cell infusions at escalating dose levels (DL). DL1 on Day 0, DL2 on Days 30 and 60. The first dose of BPX-501 T cells will occur ≥30 days after hematopoietic stem cell transplant (HSCT).~Two doses of Rimiducid ( 0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion."
62064522|NCT01478711|NO_INTERVENTION|No Intervention|No intervention, No clinical decision support tool will be used for non-intervention sites.
62064523|NCT06096324|EXPERIMENTAL|Intervention|Job announcements plus educational sessions, mentoring, a micro-grant, and behavioral economic text messages.
62064524|NCT06096324|OTHER|Control|Job announcements only
62269684|NCT01069562|EXPERIMENTAL|IAADS group|In this group, liquid isoflurane was injected into the circuit using a syringe pump controlled by the IAADS system.The IAADS system has the algorithm to regulate the rate of infusion of isoflurane such that BIS is achieved and maintained at 50 during anesthesia.
62269685|NCT02870309|EXPERIMENTAL|Alpha-1 MP|Participants received 8 IV infusions of 60 mg/kg Alpha-1 MP administered weekly at an infusion rate not exceeding 0.08 mL/kg/min over approximately 15 minutes, up to Week 8.
62269686|NCT00753870|EXPERIMENTAL|A|Otherwise healthy smokers
62269687|NCT04476303|EXPERIMENTAL|SAD (#6 Cohort)|Drug: BEY2153 or placebo subjects will receive single ascending dose of BEY2153 or placebo once.
62452197|NCT02388178|ACTIVE_COMPARATOR|1450 ppm fluoride in a silica base toothpaste|Fluoride toothpaste containing fluoride as the anti-cavity ingredient
62630882|NCT04666545|EXPERIMENTAL|Intervention|"This arm will receive the MuST AKT intervention, which is a multidisciplinary, tailored person-centered behavioural intervention designed to help and enable the potential kidney transplant recipients to achieve what is required to receive a living donor kidney transplantation."
62630883|NCT04666545|NO_INTERVENTION|Usual Care (control)|In the usual care (control) condition, participants will go through the current standard of care, which is a social worker assessment.
62630884|NCT02546128|EXPERIMENTAL|intervention|"rehabilitation + active-dose ESWT (extra-corporeal shockwave therapy)"
62630885|NCT02546128|PLACEBO_COMPARATOR|control|"rehabilitation + placebo-dose ESWT (extra-corporeal shockwave therapy)"
62269688|NCT04476303|EXPERIMENTAL|SAD (#1 Cohort) - Food effect evaluation|Drug: BEY2153 or placebo subjects will receive single ascending dose of BEY2153 or placebo for two periods at 7 days interval, with both fasting and after high fat meal.
62269689|NCT04476303|EXPERIMENTAL|MAD (#4 Cohort)|Drug: BEY2153 or placebo subjects will receive multiple ascending dose of BEY2153 or placebo for 7 days.
62630886|NCT05116371||Group 1: Same day initiation option|1) ENG implant with initiation of concurrent COC use for bleeding control at time of insertion
62630887|NCT05116371||Group 2: Delayed initiation option|"2) ENG implant alone with option for delayed initiation of COC if bleeding concerns develop"
62630888|NCT01566422|EXPERIMENTAL|Vancomycin powder|80 randomized patients will be given vancomycin powder in the surgical sites prior to closure following spinal surgery.
62630889|NCT01566422|NO_INTERVENTION|Control|80 participants who were not randomized to receive Vancomycin powder will receive no intervention at the conclusion of their surgery.
62630890|NCT03507985||The exposed group|The exposed group where patients receive morphine analgesia The patient will realise two tests evaluating memory and attention, for the first at the inclusion visit after giving his consent, and in a second time during the follow up visit 15 days or 1 month later.
62630891|NCT03507985||The unexposed group|"The unexposed group where patients receive 1 +/- 2-stage analgesia is non-opioid analgesics.~The patient will realise two tests evaluating memory and attention, for the first at the inclusion visit after giving his consent, and in a second time during the follow up visit 15 days or 1 month later."
62630892|NCT02227784|EXPERIMENTAL|Atorvastatin + Evacetrapib|Atorvastatin 40 milligrams (mg) orally once daily for 28 days during lead in period. Atorvastatin 40 mg plus evacetrapib 130 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
62630893|NCT02227784|ACTIVE_COMPARATOR|Atorvastatin 80 mg|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 80 mg orally with placebo for blinding once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
62630894|NCT02227784|ACTIVE_COMPARATOR|Atorvastatin + Ezetimibe|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 40 mg plus ezetimibe 10 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
62630895|NCT02227784|ACTIVE_COMPARATOR|Atorvastatin 40 mg|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 40 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
62630896|NCT05018416|EXPERIMENTAL|2 REACT injections|Cohort 1 subjects will receive 2 REACT injections in the biopsied and non-biopsied contralateral kidneys 3 months apart (+60 days).
62630897|NCT05018416|EXPERIMENTAL|1 REACT Injection|Cohort 2 subjects will receive 1 REACT injection into the biopsied kidney and if a pre-defined trigger is met, will undergo a second REACT injection into the contralateral kidney.
62630898|NCT01137487|OTHER|residual gastric volume|
62630899|NCT01137487|OTHER|residual gastric volume not monitored|
62630900|NCT01330550|EXPERIMENTAL|high fiber sugar free biscuit.|High fiber sugar free biscuit will regulate Blood sugars.
62630901|NCT04473872|ACTIVE_COMPARATOR|Neurodevelopmental treatment program group|"When applying NGT, which is described as a problem solving approach, the treatment program appropriate for their functional levels will be determined for each patient, taking into account the individual needs and wishes of the patient. Principles to be considered while applying the treatment program:~* Inhibition of normal / ineffective movements~* Facility of normal / effective movements Sensory-motor stimulation~* Correct placement of body segments Neurodevelopmental treatment physiotherapy session for 5-days in a week, over 6-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities."
62630902|NCT04473872|EXPERIMENTAL|diaphragmatic breathing|The group will have a neurodevelopmental treatment program (BOBATH treatment approach) and diaphragmatic breathing exercises. Diaphragmatic breathing; To give the patient a supine position, a pillow is placed under his knees and head. The patient is asked to place his right hand on the upper abdomen and his left hand on the upper part of his chest. The patient is told to take a slow and deep breath through the nose until four counts, and to hold the air in for the time it has inhaled, and then the patient shrinks her lips like a whistle and exhales from using her breath for a long time. Exercises are performed two hours after meals, in short, 2-3 minutes in the beginning, in 10 of the patients, on average 30 minutes per day.
62269690|NCT00825500|PLACEBO_COMPARATOR|Inhaled Placebo|Inhaled Staccato Placebo (0 mg)
62269691|NCT00825500|ACTIVE_COMPARATOR|Inhaled Loxapine 1.25 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
62269692|NCT00825500|EXPERIMENTAL|Inhaled Loxapine 2.5 mg|Inhaled Staccato Loxapine 2.5 mg, single dose
62269693|NCT00489567||Group A|Children hospitalised with community-acquired severe RV GE and children acquiring nosocomial severe RV GE.
62269694|NCT06330038|EXPERIMENTAL|TIVA group|The TIVA group will receive propofol for both induction and maintenance of general anesthesia.
62452198|NCT00349947|ACTIVE_COMPARATOR|1|Participants will take part in an exercise program.
62452199|NCT00349947|NO_INTERVENTION|2|Participants will take part in a usual activity group.
62269695|NCT06330038|ACTIVE_COMPARATOR|GAS group|The GAS group will receive one or more volatile anesthetics (sevoflurane, desflurane, or isoflurane) for induction and maintenance of anesthesia during the surgery. For GAS group, propofol, midazolam, remimazolam, etomidate, or ketamine can be used with inhalation agents as co-induction agents under the discretion of the attending anesthesiologist.
62452200|NCT05822401|EXPERIMENTAL|Blood flow restriction (BFR)|Blood flow restricted training (BFR) integrated into the daily work tasks for 8 weeks.
62653183|NCT00819039|EXPERIMENTAL|Part 1: Oral Aprepitant|In Study Part 1, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.
62653184|NCT00819039|EXPERIMENTAL|Part 2: Oral Aprepitant|In Study Part 2, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.
62653185|NCT00819039|ACTIVE_COMPARATOR|Part 2: Intravenous Ondansetron|In Study Part 2, participants aged 6 months to 17 years received a single intravenous dose of ondansetron on Day 1.
62064525|NCT05661721|OTHER|"Intervention first, control after (Sweet then salty)"|"This arm will be divided into the following periods:~Run-in period: 7 days without any licorice intake Intervention period: 14 days with sweet licorice intake First wash-out period: 14 days without any licorice intake Control period: 14 days with salty licorice intake Second wash-out period: 14 days without any licorice intake."
62269696|NCT05683444|OTHER|Healthy participant 1|
62269697|NCT05683444|OTHER|Healthy participant 2|
62269698|NCT01584479||Low Risk Experimental Group|"1 visit - Low Risk~\~1200 subjects~- Low Risk Experimental Group = 1 visit intervention, no history of periodontitis, non-smoker, non-diabetic, IL-1 genotype (-)"
62269699|NCT01584479||Low risk Control Group|"2 visits - Low Risk~\~1200 subjects~- Low risk Control Group = 2 visit intervention, no history of periodontitis, non-smoker, non-diabetic, IL-1 genotype (-)"
62269700|NCT01584479||High Risk Experimental Group|"1 visit - High Risk~\~800 subjects High Risk Experimental Group = 1 visit intervention, one or more of the following risk factors: history of periodontitis, smoker or diabetic, IL-1 genotype (+)"
62630903|NCT04473872|EXPERIMENTAL|respiratory muscle training with the THRESHOLD IMT device|The group will have a neurodevelopmental treatment program (BOBATH treatment approach) and respiratory muscle training with the THRESHOLD IMT device. T-IMT is an instrument that provides the same pressure in each breath for the strength and endurance of the inspiratory muscles, regardless of the patient's rapid or slow breathing. This device provides a constant pressure in inspiration with its flow-free one-way valve. It also has an adjustable device pressure. The tool consists of pressure section, mouthpiece and nose clip. During application, constant pressure is applied to the inspiration phase. The training group is started from 40% of MIP and inspiratory muscle training is given. In practice, patients are asked to sit in a loose position on the upper chest and shoulders. After eight breathing cycles, 1-2 respiratory controls are requested
62269701|NCT01584479||High Risk Control Group|"2 visits - High Risk~\~800 subjects High Risk Control Group = 2 visit intervention, one or more of the following risk factors: history of periodontitis, smoker or diabetic, IL-1 genotype (+)"
62269702|NCT05080465|EXPERIMENTAL|Treatment Arm|A single dose of 0.5 to 1 x 10\^6/kg autologous BM MSCs (Total volume: 30 - 50 ml) will be infused via peripheral venous access.
62269703|NCT05534360||Tenecteplase|All consecutive patients with an arterial acute ischemic stroke treated with intravenous thrombolysis with tenecteplase.
62269704|NCT00873522||Community acquired pneumonia|
62269705|NCT00873522||Health-Care-Associated pneumonia|
62269706|NCT05990673|EXPERIMENTAL|remimazolam|remimazolam is given for anesthesia induction
62269707|NCT05024955||Observational (interview, discussion)|Participants attend an interview over 45-60 minutes and/or a focus group over 1.5 to 2 hours.
62269708|NCT05568511|EXPERIMENTAL|Home-based, digitally delivered exercise training program|
62269709|NCT05568511|ACTIVE_COMPARATOR|Standard care control group|
62630904|NCT06325891||Gastric cancer group|"* Adult patients (≥18 years of age) and undergoing esophagogastroduodenoscopy~* Patients with pathological diagnosis of high-grade dysplasia or gastric cancer"
62630905|NCT06325891||Control group|"* Adult patients (≥18 years of age) and undergoing esophagogastroduodenoscopy~* Patients with no or minimal upper GI symptoms and current EGD appear normal or minimal gastritis"
62630906|NCT03762577|EXPERIMENTAL|Training Group|Training group will attend ground-based walking training under the supervision of a physiotherapist for 2 days and 30 minutes a week. Patients will walk for 1-2 days in a week without supervision.
62269710|NCT01509963||patients candidates for the SN procedure|The study will focus on patients candidates for the SN procedure as recommended by Saint-Paul de VENCE initially in 2005 but modified in 2009.
62269711|NCT02916940|EXPERIMENTAL|Diprophos|Patients having had a sprain of the long fingers, within 2 weeks of consultation. This group will receive a single injection of corticoids.
62064526|NCT05661721|OTHER|"Control first, intervention after (Salty then sweet)"|"This arm will be divided into the following periods:~Run-in period: 7 days without any licorice intake Control period: 14 days with salty licorice intake First wash-out period: 14 days without any licorice intake Intervention period: 14 days with sweet licorice intake Second wash-out period: 14 days without any licorice intake."
62064527|NCT03315936|PLACEBO_COMPARATOR|Placebo matching BI 894416 (SRD Part)|Single Rising Dose (SRD) Part
62064528|NCT03315936|EXPERIMENTAL|BI 894416 3 milligram (mg)|SRD Part
62269712|NCT02916940|NO_INTERVENTION|Control group|Patients having had a sprain of the long fingers (Eaton classification type I and II), within 2 weeks of consultation. This group will receive the standard of care treatment, without injection of corticoids.
62269713|NCT04788355|ACTIVE_COMPARATOR|Control Group standard treatment|Patients will be treated only with standard hospital treatment
62269714|NCT04788355|EXPERIMENTAL|Group Hydroxychloroquine|Patients will be treated with Hydroxychloroquine associated with standard hospital treatment
62269715|NCT04788355|EXPERIMENTAL|Group Hydroxychloroquine e Apixaban|Patients will be treated with Hydroxychloroquine associated with apixaban and standard hospital treatment
62269716|NCT04788355|EXPERIMENTAL|Group Apixabana|Patients will be treated with apixaban associated with standard hospital treatment
62269717|NCT03637933|ACTIVE_COMPARATOR|India ink tattooing|Experimental group includes patients undergone to preoperative endoscopic tattooing with Sterile Carbon Particle Suspension.
62269718|NCT03637933|EXPERIMENTAL|Sterile Carbon Particle Suspension tattooing|Control group includes patients undergone to preoperative endoscopic tattooing with India Ink.
62269719|NCT02905474|EXPERIMENTAL|eKidneyCare|The eKidneyCare mobile app has an active interface with the renal clinic pharmacy system to allow for updated medication profiles to be sent directly to the patient's smartphone for the renal clinic pharmacy information system.
62269720|NCT02905474|ACTIVE_COMPARATOR|My MedRec (Commercial App)|My MedRec is a commercially available mobile app which allows a user to have a personal health record along with keeping track of their medications. The My MedRec mobile app allows users to track blood pressure and medication information through manual data entry with the app. It is a stand alone mobile app which stores specified medical information on the native smartphone device and does not connect to any other servers or databases.
62269721|NCT00866307|EXPERIMENTAL|Arm I (HR-average)|See Detailed Description.
62269722|NCT00866307|EXPERIMENTAL|Arm II (HR-high)|See Detailed Description.
62452201|NCT05822401|ACTIVE_COMPARATOR|Usual care (control)|Will continue their work as usual
62269723|NCT06275503|OTHER|Systematic screening group|Individuals aged 75/76 randomized to systematic screening are invited through a centralized screening facility to participate in prolonged ECG screening.
62269724|NCT06275503|OTHER|Opportunistic screening group|Individuals aged 75/76 randomized to opportunistic screening are invited to participate when they visit their primary care facility to prolonged ECG screening.
62269725|NCT03021642|EXPERIMENTAL|First Tepotinib Test, Then Tepotinib Reference|
62269726|NCT03021642|EXPERIMENTAL|First Tepotinib Reference, Then Tepotinib Test|
62269727|NCT00883376||1|OSAS patients
62269728|NCT00883376||2|no OSAS patients
62269729|NCT05028400|EXPERIMENTAL|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded automatically intraoperatively in each patient before, during, and after ICGA and/or FA in the same surgical field of view to guarantee comparability of the methods.
62269730|NCT05712512||Infant siblings of children with autism spectrum disorder|
62269731|NCT03355300|EXPERIMENTAL|Cannabidiol Oral Solution|Cannabidiol Oral solution, dose as assigned in INS-17-103.
62269732|NCT01895322|EXPERIMENTAL|OPC-41061|
62269733|NCT02868242|EXPERIMENTAL|LDV/SOF|Participants will receive LDV/SOF 90/400 mg fixed dose combination (FDC) (1x 90/400 mg tablet or 4 x 22.5/100 mg tablets based on swallowability assessment during screening) for 12 weeks.
62269734|NCT05061173|EXPERIMENTAL|Aerobic exercise training Group|
62064529|NCT03315936|EXPERIMENTAL|BI 894416 10 mg|SRD Part
62064530|NCT03315936|EXPERIMENTAL|BI 894416 20 mg|SRD Part
62064531|NCT03315936|EXPERIMENTAL|BI 894416 30 mg|SRD Part
62269735|NCT05061173|EXPERIMENTAL|Resistance Exercise Training Group|
62269736|NCT05061173|EXPERIMENTAL|Combined Exercise Training Group|
62269737|NCT04312490|EXPERIMENTAL|patients|all patients with myocarditis
62269738|NCT04683965|EXPERIMENTAL|Pemetrexed + TAS-102 + Bevacizumab|Pemetrexed 500 mg/m2 d1+ TAS-102, capsule, 35mg/m2, bid,po, d1\~5, d8\~12 + Bevacizumab 5 mg/kg d1, d14; Repeated every 4 weeks
62269739|NCT02922140|NO_INTERVENTION|control group|will receive standard care by physician in attendance
62269740|NCT02922140|ACTIVE_COMPARATOR|intervention group|will be supplied by clinical pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.
62452202|NCT01328275||1|long-term follow-up of HIV-infected patients on ART
62452203|NCT01775020|EXPERIMENTAL|L-arginine|L-arginine
62630907|NCT03762577|NO_INTERVENTION|Control Group|Patient education will be given and no intervention will be made.
62269741|NCT02914262|EXPERIMENTAL|Experimental:Cohort 1-6 Experimental|Intervention AKB 4924 Six subjects per cohort will receive single doses of 20 to up to 480 mg of AKB 4924 orally in a dose escalation format
62653186|NCT05225740|ACTIVE_COMPARATOR|Control|General stress reduction based on stress management training to help people cope with feelings of anxiety, used as an active control condition
62630908|NCT05359211|EXPERIMENTAL|Treatment (lymphodepletion, liso-cel, NKTR-255)|Patients receive standard of care lymphodepletion therapy consisting of cyclophosphamide and fludarabine on days -5 to -3 followed by liso-cel CAR-T cell infusion on day 0. Patients then receive NKTR-255 IV over 30 minutes every 3 weeks starting on day 10 or 14 for up to 3 doses in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray and ECHO or MUGA during screening. Patients undergo bone marrow biopsy and aspiration, LP for CSF sample collection during screening, on the study and during follow-up as clinically indicated. Patients also undergo PET/CT throughout the trial. Additionally, patients undergo blood sample collection and may optionally undergo tissue biopsy throughout the trial.
62630909|NCT04232644|ACTIVE_COMPARATOR|Treatment A|crushed d-amphetamine IR tablets
62630910|NCT04232644|EXPERIMENTAL|Treatment B|manipulated ADAIR IR capsules
62630911|NCT04664101|EXPERIMENTAL|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT) The intervention consists of high intensity interval training, consisting of a 30-minute exercise session that includes 10 x 1-minute intervals of high intensity 3x/week (e.g., Monday, Wednesday, Friday) and supplemented with 2 sessions per week of strength, balance, and mobility exercises (e.g., Tuesday, Thursday). Exercise will be supported by an activity tracker, which will allow study personnel to track patient heart rates during exercise on a daily basis, allowing them to provide individualized feedback and coaching.
62064532|NCT03315936|EXPERIMENTAL|BI 894416 40 mg|SRD Part
62630912|NCT04664101|OTHER|Comparator|Patients randomized to the control arm will receive the same technology platform and education on exercise options, including HIIT, but will return home to exercise as they see fit without personalized instruction and coaching. They will be remotely monitored, but will not receive feedback unless any adverse events are noted
62630913|NCT02565316|ACTIVE_COMPARATOR|Nepeta menthoides Boiss & Bohse freeze dried extract capsule|
62269742|NCT02914262|PLACEBO_COMPARATOR|Placebo:Cohort 1-6|"Intervention Placebo:~Two subjects per cohort will receive single oral doses of placebo"
62630914|NCT02565316|ACTIVE_COMPARATOR|Sertraline capsule|
62630915|NCT01354197||All ICU admission patients|All ICU admission to surgical intensive care unit at cohort time
62630916|NCT02047370|EXPERIMENTAL|Diaphragm stretching|30 Patients with asthma are included in this group. They will receive a diaphragm stretching technique
62630917|NCT02047370|PLACEBO_COMPARATOR|Placebo group|Ultrasound disconnected in same position and with the same duration.
62630918|NCT00719160|PLACEBO_COMPARATOR|Esomeprazole|
62630919|NCT00719160|ACTIVE_COMPARATOR|Placebo|
62630920|NCT05122624|EXPERIMENTAL|Score intervention arm|The PredicTB score will be implemented in this arm.
62064533|NCT03315936|EXPERIMENTAL|BI 894416 54 mg|SRD Part
62064534|NCT03315936|EXPERIMENTAL|BI 894416 70 mg|SRD Part
62064535|NCT03315936|EXPERIMENTAL|BI 894416 10mg tb / 10mg PfOS / 40mg tb|"BI 894416 10 mg tablet (tb) / BI 894416 10 mg powder for oral solution (PfOS) / BI 894416 4\*10 mg tablets.~Relative bioavailability (rel BA) part"
62064536|NCT03315936|EXPERIMENTAL|BI 894416 10mg PfOS / 10mg tb / 40mg tb|"BI 894416 10 mg powder for oral solution (PfOS) / BI 894416 10 mg tablet (tb) / BI 894416 4\*10 mg tablets.~Relative bioavailability (rel BA) part."
62064537|NCT06017830|EXPERIMENTAL|Patients with low back pain|
62064538|NCT06230614|ACTIVE_COMPARATOR|Colistin 1 MU in normal saline 1 ml|1 MU of colistin in a total volume of 6 ml, diluted with a 1:1 ratio in normal saline (0.9%)
62269743|NCT00589446|EXPERIMENTAL|1|Embryoscopy will be evaluated in women with at least two previous miscarriages, after confirmation of missed abortion by ultrasound. Embryoscopy will only be performed in patients in whom curettage is clinically indicated, and will only be added to the D\&C if there is a possibility of visualizing embryonic tissue, i:e. from approximately 5½ weeks onwards when there is an embryonic pole detected on ultrasound.
62269744|NCT04806607|ACTIVE_COMPARATOR|19Gauge Fine Needle Biopsy|19Gauge Fine Needle
62630921|NCT05122624|NO_INTERVENTION|Control arm|The standard of care will be conducted in this arm.
62630922|NCT04224025|EXPERIMENTAL|exercise and respiratory therapy|Rehabilitation program for three weeks in-Hospital and continuation at home
62630923|NCT03592836|ACTIVE_COMPARATOR|Continuous infusion of loop diuretics|Furosemide continuous infusion: 125 or 250 mg die
62630924|NCT03592836|ACTIVE_COMPARATOR|Intermittent infusion of loop diuretics|Furosemide bolus intermittent: 125 or 250 mg die
62630925|NCT00810069|EXPERIMENTAL|Early Intervention|Escitalopram 10 milligrams per day for 4 weeks (one 10 milligram \[mg\]-capsule) followed by Duloxetine flexible dose (60 or 120 mg daily) for 12 weeks.
62630926|NCT00810069|EXPERIMENTAL|Delayed Intervention|Escitalopram 10 mg per day for 4 weeks (one 10 mg-capsule) followed by Escitalopram 10 to 20 mg per day for 4 weeks (one or two 10 mg capsule\[s\]). Then, non-responders switched to Duloxetine 60 or 120 mg per day for 8 weeks , and responders continued on Escitalopram 10 to 20 mg per day for 8 weeks.
62630927|NCT04881214|NO_INTERVENTION|Control|Patients in this arm will receive standard of care
62630928|NCT04881214|EXPERIMENTAL|Pulmonary Rehabilitation|Patients will undergo a 12-weeks Pulmonary rehabilitation program. It will include 3 sessions of supervised exercise per week, as initially proposed on COPD patients. Patients will exercise on electromagnetically braked cycle ergometers for 45 min by alternating 30-s exercise intervals at 100% of peak-work rate estimated during the initial incremental test, with 30-s rest periods. Total workload will be increased (by 5%) on a weekly basis. Strength training of lower and upper limbs, will also be included.
62630929|NCT01562717|EXPERIMENTAL|Ibuprofen|
62630930|NCT01562717|PLACEBO_COMPARATOR|Placebo|
62630931|NCT03519126|EXPERIMENTAL|vaginal|Group of volunteers who will be treated with vaginal electrostimulation
62630932|NCT03519126|EXPERIMENTAL|posterior tibial nerve|Group treated with transcutaneous electrostimulation of the posterior tibial nerve
62630933|NCT03519126|NO_INTERVENTION|control|Group of volunteers who will not be treated
62269745|NCT04806607|ACTIVE_COMPARATOR|22 Gauge Fine Needle Biopsy|22Gauge Fine Needle
62630934|NCT01457417|EXPERIMENTAL|75 milligram (mg) DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
62630935|NCT01457417|EXPERIMENTAL|150 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
62269746|NCT04755634|EXPERIMENTAL|Single Arm|This is a prospective, single-arm, single-center study
62452204|NCT04242771|EXPERIMENTAL|Experimental group|Participants will utilize a daily sleep program available within a widely used smartphone app, which includes seven soundtracks (10-15min each) for guided mindfulness practice at bedtime. Techniques include breathing exercises, mental imagery, awareness of body and mind, and muscle and body relaxation.
62653187|NCT05225740|ACTIVE_COMPARATOR|Standard Exposure|Psychoeducation about exposure therapy and anxiety sensitivity, interoceptive exposure therapy modeling and practice, and completion of questions about the exercises and the large-group aspect
62653188|NCT05225740|EXPERIMENTAL|Enhanced Exposure|Psychoeducation about exposure therapy and anxiety sensitivity, interoceptive exposure therapy modeling and practice, and post-exposure processing aimed at emphasizing harm expectancy violation
62653189|NCT01082419|OTHER|Group A|healthy volunteers
62064539|NCT06230614|EXPERIMENTAL|Colistin 1 MU in normal saline 2 ml|1 MU of colistin in a total volume of 12 ml, diluted with a 1:2 ratio in normal saline (0.9%)
62630936|NCT01457417|EXPERIMENTAL|300 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
62653190|NCT01082419|OTHER|Group B|patients with supposed disease free liver (normal hepatic and pancreatic biochemistry)
62269747|NCT06417619|EXPERIMENTAL|Patients|Mindfulness-based psychoeducation will be implemented in the experimental group in the form of group sessions once a week for a total of 8 weeks. Post-tests will be administered immediately after the completion of psychoeducation sessions for the experimental group, and a follow-up test will be conducted 3 months after the post-test.
62269748|NCT06417619|NO_INTERVENTION|Depression Patients|No intervention will be applied to the control group other than routine treatment. For the control group, no intervention will be made, and post-tests will be administered 8 weeks after the pre-test, followed by a follow-up test 3 months after the post-test.
62269749|NCT05966285||suture group|Patients ≥65 years who underwent urgent surgical groin hernia repair from January 2015 to June 2022 were included.
62269750|NCT05966285||mesh repair|Patients ≥65 years who underwent urgent surgical groin hernia repair from January 2015 to June 2022 were included.
62269751|NCT01459458|EXPERIMENTAL|Clinics trained in brief intervention|Female clients ages 16-29 seeking care in 11 reproductive health clinics in Western Pennsylvania where clinic providers are trained to implement the brief partner violence/reproductive coercion intervention.
62269752|NCT01459458|NO_INTERVENTION|Control sites providing standard of care|Female clients ages 16-29 seeking care in 14 reproductive health clinics in Western Pennsylvania where clinic providers are providing standard domestic violence screening per usual standard of care.
62269753|NCT04957771|EXPERIMENTAL|Regular exercise group|
62269754|NCT04957771|NO_INTERVENTION|non-regurlar exercise group|
62452205|NCT04809246|NO_INTERVENTION|Standard of care|The first group (n=240) of participants enrolled in the study will be assigned to the control period to receive the standard of care.
62452206|NCT04809246|EXPERIMENTAL|'One-stop-shop' intervention|Following the control period, the second group (n=300) of participants enrolled in the study will be assigned to the intervention period to receive the 'one-stop-shop' intervention.
62452207|NCT01608581|EXPERIMENTAL|exposure to multi-media campaign|A multimedia campaign highlighting dangers of gasoline and fire was delivered to an intervention region in the state of Queensland
62452208|NCT01827007|EXPERIMENTAL|Study arm, elevation of PEEP|
62452209|NCT01779622|EXPERIMENTAL|1|Healthy volunteers are ingesting a mixed meal either rapidly or slowly
62452210|NCT01124851|EXPERIMENTAL|Arm 1|ABT-652 Dose 1 vs placebo capsules administered orally once daily for 7 days
62452211|NCT01124851|EXPERIMENTAL|Arm 2|ABT-652 Dose 2 vs placebo capsules administered orally once daily for 7 days
62452212|NCT01124851|EXPERIMENTAL|Arm 3|ABT-652 Dose 3 vs placebo capsules administered orally once daily for 7 days
62452213|NCT02756312|OTHER|Intravenous anesthesia|Patients will receive total intravenous anesthesia undergoing brain tumor resection.
62452214|NCT02756312|OTHER|Inhalation anesthesia|Patients will receive volatile inhalational anesthesia undergoing brain tumor resection.
62452215|NCT05749133|EXPERIMENTAL|Anti-GPRC5D CAR-T|Subjects who meet the enrollment conditions will receive intravenous infusion of Anti-GPRC5D CAR-T Cells Injection, doses of 1.0\~6.0×10\^6 /kg±20% CAR-T cells, after lymphodepleting therapy.
62452216|NCT00510510|EXPERIMENTAL|NVA237 100 µg|
62452217|NCT00510510|EXPERIMENTAL|NVA237 200 µg|
62452218|NCT00510510|PLACEBO_COMPARATOR|Placebo|
62653191|NCT01082419|OTHER|Group D|patients with cirrhosis
62653192|NCT01082419|OTHER|Group E|patients with liver tumour and surgery indication
62064540|NCT01231841|EXPERIMENTAL|rATG + Cyclosporine|Patients receive anti-thymocyte globulin IV daily over 4-24 hours on days 1-5. Beginning on day 6, patients receive oral cyclosporine twice daily for 6 months followed by a taper. Treatment continues in the absence of disease progression or unacceptable toxicity
62064541|NCT04888247|EXPERIMENTAL|Treatment|Trans-septal mitral valve replacement
62452219|NCT03129919|EXPERIMENTAL|Orthodontic patients treated with brackets Carriere SLX®|Subjects requiring orthodontic treatment and will be treated with passive self-ligating braces Carriere SLX®
62452220|NCT03129919|ACTIVE_COMPARATOR|Orthodontic patients treated with brackets Empower®|Subjects requiring orthodontic treatment and will be treated with interactive self-ligating braces Empower®
62452221|NCT02282436||COPD exacerbation|No specific intervention for this study
62452222|NCT04865107|EXPERIMENTAL|MSCs Arm|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
62452223|NCT04865107|PLACEBO_COMPARATOR|Placebo Arm|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
62452224|NCT00760058|EXPERIMENTAL|1|AcrySof® IQ intraocular lens
62452225|NCT00760058|ACTIVE_COMPARATOR|2|Tecnis® Aspheric intraocular lens
62452226|NCT00760058|ACTIVE_COMPARATOR|3|Akreos® MI60 intraocular lens
62452227|NCT00499798||patients on temozolimide for brain cancer|
62630937|NCT01457417|EXPERIMENTAL|600 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
62630938|NCT01457417|EXPERIMENTAL|300 mg DKN-01 Part B|Dose Confirmation: Once the MTD had been established or the highest planned dose level completed, 300 mg of DKN-01 was administered as IV on days 1 and 15 of every 28 day cycle.
62452228|NCT03540056||Boys without varicocele|Boys thoroughly examined but without diagnose of varicocele
62452229|NCT03540056||Boys with a varicocoele|Boys with a diagnosed varicocele of any stage possible.
62088162|NCT01798082|EXPERIMENTAL|Standard counseling, pelvic organ prolapse decision aid|In addition to standard counseling at the time of the initial new patient visit, the patients randomized to the experimental arm will recieve a pelvic organ prolapse decision aid prior to their initial visit.
62452230|NCT05431881|PLACEBO_COMPARATOR|Control|A silent state (a wave file made without sound) is applied for at least 20 minutes from 20 minutes before arrival to the operating room. The sound generator is a smartphone device, set the volume (at a volume corresponding to 60 dB in the experimental group), and hang it on the transport bed. Upon arrival in the operating room, before anesthesia, the volume is adjusted to 0.
62452231|NCT05431881|EXPERIMENTAL|Binaural beat|In the experimental group, the binaural sound, which was produced by the beat of 2Hz difference, is applied for 20 minutes from 20 minutes before arrival to the operating room. The sound generator is a smartphone device, set the volume corresponding to 60 dB, and hang it on the transport bed. Upon arrival in the operating room, before anesthesia, the volume is adjusted to 0.
62452232|NCT00561730||Pantoprazole|All patients enrolled
62452233|NCT06355245||Patients with unspecific symptoms|Patients referred to the Diagnostic Center at Danderyd Hospital (DC DS), a multidisciplinary diagnostic center referral pathway for patients with radiological findings suggestive of metastasis without known primary tumor or suspicion of serious but unspecific symptoms.
62452234|NCT03558308|EXPERIMENTAL|Brain+ with clinical support|Intervention: Computer based cognitive rehabilitation. This group will train with the programme 'Brain+' and receive continuous support from a clinician during the intervention period.
62452235|NCT03558308|EXPERIMENTAL|Cogmed with continuous support|Intervention: computer based cognitive rehabilitation. This group will train with the programme 'Cogmed' and receive continuous support from a clinician during the intervention period.
62452236|NCT03558308|EXPERIMENTAL|Brain+ without support|Intervention: computer based cognitive rehabilitation. This group will train with the programme 'Brain+' but receive no support during the intervention period.
62452237|NCT03558308|SHAM_COMPARATOR|Sham-training group|Intervention: Sham computerized gaming. This group will train computerized solitaire and other computerized games which are thought to be generally cognitive stimulating but with a very limit load on executive functions. This group will receive continuous support during the intervention period.
62452238|NCT01637038|NO_INTERVENTION|Control Group|no intervention
62452239|NCT01637038|EXPERIMENTAL|RIPC group|Those undergoing remote ischemic postconditioning
62452240|NCT04040920|EXPERIMENTAL|Ozone therapy|Ozone application before pits and fissure sealants
62630939|NCT01560026||ovarian preservation|endometrial cancer with ovarian preservation
62452241|NCT04040920|ACTIVE_COMPARATOR|Pits and fissure sealants|
62452242|NCT03413631|EXPERIMENTAL|Prenatal mentalization intervention|The intervention group participants were offered three mentalization-focused 4D interactive ultrasounds at 24, 30 and 34 gestational weeks and a mentalization-focused week-by-week pregnancy diary combined with three prenatal sessions and option for one session after delivery in addition to obstetric care as usual (see Prenatal obstetric treatment as usual).
62452243|NCT03413631|ACTIVE_COMPARATOR|Prenatal obstetric treatment as usual|The control group received obstetric care as usual in a tertiary setting. The comprehensive treatment as usual was conducted at the hospital antenatal outpatient clinic, including regular obstetric ultrasounds. The multidisciplinary treatment team, consisting of an obstetrician, a midwife, a social worker and a psychiatric nurse, assess and support health and psychosocial situation of the pregnant woman. The pregnant woman was referred to addiction and psychiatric treatment when needed.
62064542|NCT04568967|EXPERIMENTAL|intervention arm|"The intervention arm for this trial consists of HIV patients with TB testing performed regardless of presence of TB symptoms. Testing will be done on expectorated sputum, stool and concentrated urine with Ultra, and urine with AlereLAM.~To fulfil exploratory objectives, we will also collect and store 2x tongue swabs for molecular TB diagnostic assay (Xpert Ultra and/or LumiraDx) testing, blood for testing with CRP, and urine samples which will be stored for retrospective FujiLAM testing and analysis."
62064543|NCT04568967|NO_INTERVENTION|control arm|"The control arm for this trial will consist of patients managed according to the current WHO recommended TB testing practices for HIV positive inpatients (as of Q1 2020).~TB testing will be done as follows:~Sputum Ultra performed whenever the patient has cough, fever, weight loss over night sweats and/or Ultra performed on any tissue (including lymph nodes) from patients with clinical suspicion of extrapulmonary TB.~and/or: Urine Alere TB-LAM performed if patients have signs and symptoms of TB (pulmonary and/or extrapulmonary), or with advanced HIV disease, or who are seriously ill, or else irrespective of signs and symptoms of TB, but combined with a CD4 cell count of less than 200 cells/mm ."
62630940|NCT01560026||oophorectomy|endometrial cancer without ovarian preservation
62064544|NCT02691195|PLACEBO_COMPARATOR|group control|group control :Before induction of intravenous anesthesia, patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
62064545|NCT02691195|EXPERIMENTAL|group SPB|group SPB:Before induction of intravenous anesthesia, patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
62064546|NCT02390427|EXPERIMENTAL|Arm A|"Arm A~- Taselisib with Trastuzumab emtansine (also called T-DM1)~* Taselisib administered orally, daily in each treatment cycle (3 weeks).~* Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks)."
62064547|NCT02390427|EXPERIMENTAL|Arm B|"Arm B~-Taselisib with T-DM1 and Pertuzumab~* Taselisib is administered oral, daily or every other day per treatment cycle (3 weeks).~* Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks).~* Pertuzumab- administered once via IV per treatment cycle (3 weeks)."
62064548|NCT02390427|EXPERIMENTAL|Arm C|"Arm C:~* Taselisib with Pertuzumab and Trastuzumab~* Cohort C will not open without additional authorization from Genentech~  * Taselisib is administered oral, daily in each treatment cycle (3 weeks).~ * Trastuzumab administered once via IV per treatment cycle (3 weeks).~ * Pertuzumab- administered once via IV per treatment cycle (3 weeks)."
62064549|NCT02390427|EXPERIMENTAL|Arm D|"Arm D~* Taselisib with Pertuzumab, Trastuzumab, and Paclitaxel~* Cohort will not be opened without additional authorization from Genentech~  * Taselisib- administered oral, daily in each treatment cycle (3 weeks).~ * Pertuzumab- administered once via IV per treatment cycle (3 weeks).~ * Trastuzumab administered once via IV per treatment cycle (3 weeks).~ * Paclitaxel- administered via IV, weekly for 3 weeks within each cycle."
62064550|NCT06481254|EXPERIMENTAL|Hawthorn Vinegar Group|"Before starting the study (pre-test/0. week), Patient Information Form, OAG and OHQoL-UK were administered to all group participants to evaluate the level of oral mucositis in patients. In addition to routine oral mucositis treatment, patients with DM in the hawthorn vinegar group gargled with 1 tablespoon (10 cc) of diluted hawthorn vinegar (mixed with 40 cc water) for 1 minute 15-20 minutes before meals 3 times a day for 14 days. OAG and OHQoL-UK were administered again on the 7th day (interim-measurement) and 14th day/end of the study (post-test)."
62064551|NCT06481254|EXPERIMENTAL|Black Mulberry Syrup Group|"Before starting the study (pre-test/0. week), Patient Information Form, OAG and OHQoL-UK were administered to all group participants to evaluate the level of oral mucositis in patients. In addition to routine oral mucositis treatment, patients with DM in the black mulberry syrup group gargled with 1 tablespoon (10 cc) of pure black mulberry syrup for 1 minute 15-20 minutes before meals 3 times a day for 14 days. OAG and OHQoL-UK were administered again on the 7th day (interim-measurement) and 14th day/end of the study (post-test)."
62064552|NCT06481254|EXPERIMENTAL|Green Tea Group|"Before starting the study (pre-test/0. week), Patient Information Form, OAG and OHQoL-UK were administered to all group participants to evaluate the level of oral mucositis in patients. In addition to routine oral mucositis treatment, patients with DM in the green tea group gargled with 50 cc green tea for 1 minute 15-20 minutes before meals 3 times a day for 14 days. OAG and OHQoL-UK were administered again on the 7th day (interim-measurement) and 14th day/end of the study (post-test)."
62088163|NCT02724072|EXPERIMENTAL|Thoraflex™ Hybrid Device.|Plexus™ 4 and Ante-Flo™ configurations will be included in this study.
62269755|NCT03194373|EXPERIMENTAL|Palbociclib and Carboplatin|"Treatment with Palbociclib and Carboplatin for up to 6 cycles:~Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days Carboplatin (IV), dose= AUC 5, day= 1, cycle length: 21 days~Maintenance Palbociclib after 6 cycles Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days"
62630941|NCT01409187|EXPERIMENTAL|Ipilimumab + Interferon + Interleukin-2|Ipilimumab starting dose 2 mg/kg intravenous (IV) day 1 only; IFN alfa-2b at 5 million U/m2 subcutaneously daily for 5 days starting day 1; IL-2 at 9 million IU/m\^2 daily IV continuous infusion for 4 days on days 2-5.
62630942|NCT05242302|EXPERIMENTAL|reverse end to side nerve transfer|
62630943|NCT05242302|ACTIVE_COMPARATOR|end to end nerve transfer|
62630944|NCT05242302|ACTIVE_COMPARATOR|nerve decompression|
62630945|NCT04069676||Autism Spectrum Condition (ASC)|Adults males and females with a formal autism diagnosis, without intellectual disability
62630946|NCT04069676||Typically developped (TD)|Adults males and females without any neurodevelopemental issue (or health issue which could impaired task performances)
62630947|NCT03350490|ACTIVE_COMPARATOR|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (\> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62630948|NCT03350490|ACTIVE_COMPARATOR|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
62630949|NCT03350490|EXPERIMENTAL|Combination therapy|"In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(\>2cm),then drink QilishengImmunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
62630950|NCT03350490|NO_INTERVENTION|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62630951|NCT05194345|EXPERIMENTAL|Autism Eats nutrition intervention|Autism Eats intervention lessons (10 lessons + 2 booster sessions) integrate ASD-specific feeding strategies such as repeated exposures, food chaining, and making regular mealtime routines and behaviorally-focused nutrition content and activities utilizing goal setting, healthy meal planning, monitoring progress, strategies to overcome barriers, and creating healthy home food environment. The early intervention (EI) providers will be trained to implement the lessons. EI providers are well-trained to use personalized intervention and coaching approach in their EI services, which will be applied to Autism Eats activities as well. Each intervention lesson will take 25-30 minutes within one hour EI services, and parent-child dyads will participate in the intervention as part of their regular EI services. The Autism Eats lesson manual will be provided to the EI providers and the parent handbook will be distributed to the parent participants.
62064553|NCT06481254|NO_INTERVENTION|Control Group|"Patients in the control group received no any treatment other than routine oral mucositis treatment and data collection tools. Patient Information Form, OAG and OHQoL-UK were administered to the patients before the study (pre-test/0th week) and OAG and OHQoL-UK were administered again on the 7th day (mid-measurement) and 14th day/end of the study (post-test)."
62088164|NCT05547802||Heterologous vaccination cohort|Subjects with two doses of BBIBP-CorV vaccine and third (second booster) dose of the BNT162b2 vaccine.
62630952|NCT05194345|ACTIVE_COMPARATOR|We Can! enhanced usual care control|Enhanced usual care (EUC) control group materials are from the evidence-based materials that are already developed and available online (in both English and Spanish): https://www.nhlbi.nih.gov/health/educational/wecan/index.htm. We will download one to two handouts and email early intervention providers to distribute them to parent-child dyads. Materials will be distributed each week for 10 weeks and additional monthly handouts for two months after the first 10 weeks (parallel to the intervention schedule).
62630953|NCT03842904|EXPERIMENTAL|Trimbow pMDI|Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation solution.
62630954|NCT03842904|ACTIVE_COMPARATOR|Fostair pMDI|Fostair 100/6 micrograms per actuation pressurised inhalation solution.
62630955|NCT03560063|EXPERIMENTAL|Corin OPS arm|Total hip replacement with use of Corin Optimised Positioning System to guide implant positioning
62630956|NCT03560063|ACTIVE_COMPARATOR|Standard care arm|Total hip replacement with standard templating to guide implant positioning
62088165|NCT05547802||Homologous vaccination cohort|Subjects receiving three doses of BNT162b2 vaccine.
62088166|NCT00503828|ACTIVE_COMPARATOR|naproxen|Naproxen 500 mg/day for 4 weeks
62088167|NCT00503828|EXPERIMENTAL|Derris Scandens Benth|Derris Scandens Benth
62088168|NCT05953961|ACTIVE_COMPARATOR|Therasphere Transarterial Radioembolization|Two-phase treatment including mapping angiogram with personalized dosimetry followed by complete treatment of the tumor angiosome with 90-Yittrium glass microsphere infusion.
62088169|NCT05953961|ACTIVE_COMPARATOR|Microwave Ablation|Ablation performed with a high powered, gas cooled multi-antenna system targeting an ablative margin \> 5mm.
62630957|NCT03701542||Group of 22 patients|Group of 22 patients who underwent vitrectomy due to macular hole
62630958|NCT00329693|PLACEBO_COMPARATOR|1|Daily Tablets Dosing
62630959|NCT00329693|EXPERIMENTAL|2|Daily Tablets Dose
62630960|NCT00329693|EXPERIMENTAL|3|Daily Tablets Dosing
62630961|NCT00329693|EXPERIMENTAL|4|Daily Tablets Dosing
62653193|NCT01082419|OTHER|Group F|patients with reversible liver diseases and with acute left cardiac insufficiency
62653194|NCT01082419|OTHER|Group C|patients with non cirrhotic hepatopathy
62630962|NCT00130689|OTHER|Cetuximab|Patients received cetuximab at an initial dose of 400 mg/m2 administered IV over 120 min, followed by weekly infusions at 250 mg/m2 administered IV over 60 min. Once cycle was 4 weeks of therapy. Patients received treatment until disease progression or unacceptable toxicity.
62630963|NCT02128659|EXPERIMENTAL|SHE Project|Receives SHE Project Intervention during Week 1 of enrollment
62630964|NCT02128659|ACTIVE_COMPARATOR|Wait-List Control|Receive SHE Project intervention during Week 2 of Enrollment
62630965|NCT05186584|EXPERIMENTAL|MAITLAND'S ANTEROPOSTERIOR(AP) MOBILIZATION|Patients in this group will receive Maitland's Antero-Posterior Mobilization.
62630966|NCT05186584|EXPERIMENTAL|MAITLAND'S LATERAL MOBILIZATION|Patients in this group will receive Maitland's Lateral Mobilization.
62630967|NCT05013957||Retrospective analysis|Methylome of existing neuroendocrine tumor samples from the biobank of Basel University Hospital will be evaluated
62064554|NCT00659984|EXPERIMENTAL|Ultratrace™ Iobenguane I 131|"Eligible patients received a diagnostic imaging dose of Ultratrace™ Iobenguane I 131 (1-5 mCi) within 7 days of study enrollment, followed by three dosimetry scans over 3-6 days. If the imaging dose demonstrated normal biodistribution and tumor uptake, then the patient received a therapeutic dose within 7-28 days of the diagnostic imaging dose, followed by a single imaging scan on Day 7 post therapy. As per protocol, therapeutic dosing was to begin at 12.0 mCi/kg and escalate to 15.0, 18.0, and 21.0 mCi/kg until the MTD was established or the 21.0 mCi/kg dose level was reached. Actual doses administered ranged from 8.8 to 18.6 mCi/kg. Based on actual doses administered, patients were grouped into 3 mean dose groups: 11.2, 15.5, and 18.2 mCi/kg.~The dosimetry dose was administered over a period of 1-3 minutes by injection; the therapeutic dose was diluted in up to 25 mL normal saline and infused intravenously over 30 to 60 minutes."
62064555|NCT03046511|EXPERIMENTAL|Intraperitoneal|One single dose of intraperitoneal Cefazolin 1000 mg via the recently inserted peritoneal catheter
62064556|NCT03046511|ACTIVE_COMPARATOR|Intravenous|One single dose of intravenous Cefazolin 1000 mg one hour before catheter insertion
62064557|NCT04297618|EXPERIMENTAL|Xiidra treatment|Each participant will use the same study drops, Xiidra, over the course of the 12-week study.
62064558|NCT04456335||Caries-free|Caries-free children
62064559|NCT04456335||Early childhood caries|Children with early childhood caries
62064560|NCT02964455|EXPERIMENTAL|Docetaxel + Nedaplatin + Radiotherapy|Docetaxel and nedaplatin 5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation.
62064561|NCT02177539|ACTIVE_COMPARATOR|Cyclopentolate|
62269756|NCT03535753|EXPERIMENTAL|Decitabine and R-GDP|ALL patients will be treated with Decitabine and R-GDP
62269757|NCT00953758|EXPERIMENTAL|1|
62269758|NCT02918864|EXPERIMENTAL|ION-ASD|ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training).
62064562|NCT02177539|EXPERIMENTAL|Cyclopentolate+tropicamide+phenylephrine|
62064563|NCT05975437||Care as usual|Participants who are included during care as usual, before the hospital's transition to personalized follow-up. Care as usual is organized as 'one-size fits all' and does not take individual differences in prognoses and needs into account. For the majority of hospitals follow-up includes annual mammography and physical examination combined with discussing of the results of the mammogram and sometimes also the patient's needs.
62269759|NCT02918864|ACTIVE_COMPARATOR|Facilitated Play|The active comparison condition is a facilitated play therapy group.
62269760|NCT05291494|EXPERIMENTAL|WeChat group|The patients in this group will be first assessed by a researcher on admission about anxiety and sleep (base on the State-Trait Anxiety Inventory (STAI) scale and the sleep quality scale (SQS)). Once the assessment completed, the patients are required to follow the WeChat public platform to watch the education videos when they are free. The content of the videos covers all aspects of surgery, anesthesia, and perioperative care. The videos are presented in an easy-to-understand pattern to ensure participants of all ages and levels of education comfortably understand the content.
62630968|NCT05013957||Prospective analysis|Methylome analysis of tumor samples of neuroendocrine tumor patients undergoing an operation or biopsy will be prospectively evaluated
62630969|NCT01952418|NO_INTERVENTION|"Standard monitor (24)"|"Endoscopists in this arm will perform colonoscopy using the standard size video monitor (24)."
62630970|NCT01952418|ACTIVE_COMPARATOR|"Large monitor (32)"|"Subjects randomized to this group will perform colonoscopy while viewing a large video monitor (32)."
62630971|NCT04041921||Chronic coronary occlusion patients|≥3 months chronic total occlusion on coronary angiography
62630972|NCT06161714|EXPERIMENTAL|Right mandibular molar|Articaine 4% with 1:100,000 epinephrine
62630973|NCT06161714|EXPERIMENTAL|Left mandibular molar|Lidocaine 2% with 1:100,000
62630974|NCT00305669|EXPERIMENTAL|GM-CSF before surgery|GM-CSF dose prior to surgery- Cohort 1-GM-CSF 250mcg/m2 for 2 weeks Cohort 2-GM-CSF 250mcg/m2 for 3 weeks Cohort 3-GM-CSF 250mcg/m2 for 4 weeks Cohort 4-GM-CSF 125mcg/m2 for 4 weeks
62630975|NCT02794688||Ductal lavage group|The patients will receive ductal lavage therapy every other day for two weeks, and will be followed up for one year.
62630976|NCT04252885|EXPERIMENTAL|Group A-Standard treatment+lopinavir/ritonavir|In group A, 50 cases are given ordinary treatment plus a regimen of lopinavir (200mg) and ritonavir (50mg) (oral, q12h, every time 2 tablets of each, taking for 7-14 days).
62653195|NCT01082419|OTHER|Group G|patients with reversible liver diseases and with biliary cholestasis
62630977|NCT04252885|ACTIVE_COMPARATOR|Group B-Standard treatment+arbidol|In group B, 50 cases are given ordinary treatment plus a regimen of arbidol (100mg) (oral, tid, 200mg each time, taking for 7-14 days).
62630978|NCT04252885|NO_INTERVENTION|Group C-Standard treatment|In group C, 25 cases are only given ordinary treatment.
62630979|NCT02187003|EXPERIMENTAL|Rivipansel Treatment Arm|
62630980|NCT02187003|PLACEBO_COMPARATOR|Placebo Treatment Arm|
62452244|NCT02444403|OTHER|Police Education Program (PEP)|The entire police force mandated for periodic refresher training will be assigned to classes which receive one PEP course over 2 years.
62452245|NCT03726463||polycystic kidney disease|patients with polycystic kidney disease who receive kidney transplantation at Asan Medical Center
62452246|NCT02841709|EXPERIMENTAL|Sequence 1|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D4, D2, D3, D1 and P, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
62452247|NCT02841709|EXPERIMENTAL|Sequence 2|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D2, P, D4, D3 and D1, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
62452248|NCT02841709|EXPERIMENTAL|Sequence 3|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D3, D1, D2, P and D4, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
62452249|NCT02841709|EXPERIMENTAL|Sequence 4|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: P, D4, D1, D2, D3, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
62452250|NCT02841709|EXPERIMENTAL|Sequence 5|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D1, D3, P, D4 and D2 with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
62452251|NCT04819971|EXPERIMENTAL|TTC|
62452252|NCT03556371|EXPERIMENTAL|N-acetylcysteine Treatment|Oral administration of two capsules, containing 600 milligrams (mg) of N-acetylcysteine each one, twice day (10.00 and 20.00 hours; Total = 2400 mg/day) for four weeks.
62452253|NCT03556371|PLACEBO_COMPARATOR|Placebo oral capsules|Oral administration of two capsules, containing 600 milligrams (mg) of Placebo each one, twice day (10.00 and 20.00 hours; Total = 2400 mg/day) for four weeks.
62452254|NCT02001558|EXPERIMENTAL|Microcyn|Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily.
62452255|NCT02001558|ACTIVE_COMPARATOR|Sterile saline|Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily.
62452256|NCT06404411|EXPERIMENTAL|intervention group|
62452257|NCT06404411|ACTIVE_COMPARATOR|control group|
62452258|NCT05559203|EXPERIMENTAL|Intervention group|Digital music and movement resources.
62630981|NCT02962232|EXPERIMENTAL|LEGFLOW OTW group|in the LEGFLOW OTW group the subject will be treated by the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW)
62630982|NCT02962232|ACTIVE_COMPARATOR|AMPHIRION DEEP group|in the AMPHIRION DEEP group the subject will be treated by PTA catheter (AMPHIRION DEEP)
62630983|NCT00720070|EXPERIMENTAL|Arm I|Patients receive standard concurrent chemoradiotherapy (CRT). Patients undergo PET/CT scan at 9-13 weeks after completion of CRT. Patients with complete response of primary site undergo neck dissection within 4 weeks.
62630984|NCT00720070|ACTIVE_COMPARATOR|Arm II|Patients undergo neck dissection and receive standard concurrent CRT. Patients undergo PET/CT scan at 9-13 weeks after completion of CRT.
62452259|NCT06484959|OTHER|Horticultural therapy 1st session|What is horticultural therapy?: the scope of horticultural therapy, information will be given in the nursing home conference room. The training will be done with a power point presentation.In terms of the suitability of the caregivers, the training will be carried out by dividing into 3 groups of 10 people. Training will last 40 minutes. This training will be on Monday
62088170|NCT03417973||complex regional pain syndrome|Chronic regional pain of lower limb(s) patients medically indicated to have dorsal root ganglion (DRG) stimulation for control of pain. DRG stimulator will be implanted for trial of 3-4 days and then permanently, if patient find acceptable levels of pain control with trial.
62269761|NCT05291494|PLACEBO_COMPARATOR|Regular group|Patients in this group were also assessed by the same researcher on admission for anxiety and sleep (base on State-Trait Anxiety Inventory (STAI) scale; sleep quality scale (SQS) scale). Upon completion of the assessment, they received oral instruction from the ward nurse covering the same contents as above instead of the education video.
62269762|NCT03468855|EXPERIMENTAL|ATI-50002 Topical Solution|ATI-50002 topical solution, high dose active, twice-daily, 24 weeks
62269763|NCT03353870||qualitative interview|This study has only one arm
62269764|NCT02887391||Conventional Hemodialysis|Control group 4 hours of hemodialysis 3x per week (12 hours hemodialysis/week)
62269765|NCT02887391||In-Centre Nocturnal Hemodialysis|8 hours of hemodialysis 3x per week (24 hours hemodialysis/week)
62269766|NCT03439865|EXPERIMENTAL|standard of care treatment + ivacaftor|topical nasal steroid spray and culture-directed antibiotics + ivacaftor 150 mg tablet
62269767|NCT03439865|PLACEBO_COMPARATOR|standard of care treatment|topical nasal steroid spray and culture-directed antibiotics
62269768|NCT03807713|OTHER|Minimally Invasive Ponto Surgery|Surgical method for installation of a bone anchored hearing system for hearing rehabilitation
62269769|NCT03728309|EXPERIMENTAL|JUVÉDERM® VOLITE™|Participants received an initial treatment of JUVÉDERM® VOLITE™ XC injectable gel, intradermally up to 4 milliliters (mL) on Day 1 followed by an optional touch-up treatment up to 2 mL on Day 30, if applicable. Participants were eligible to receive repeat treatment up to 4 mL at Month 6, if applicable.
62452260|NCT06484959|OTHER|Horticultural therapy 2st session|Horticultural therapy garden design and principles?: Within the scope of horticultural therapy, information will be given in the nursing home conference room. The training will be done with a power point presentation.In terms of the suitability of the caregivers, the training will be carried out by dividing into 3 groups of 10 people. Training will last 40 minutes. This process will take place with the soil sample sent to agricultural engineering.This training will be on Tuesday
62452261|NCT06484959|OTHER|Horticultural therapy 3st session|The relationship between soil, plants and water: information will be provided by the landscape architect involved in the research. The scope of horticultural therapy, information will be given in the nursing home conference room. The training will be done with a power point presentation.In terms of the suitability of the caregivers, the training will be carried out by dividing into 3 groups of 10 people. Training will last 30 minutes.This process will take place with the soil sample sent to agricultural engineering.This training will be on Wednesday
62452262|NCT06484959|OTHER|Horticultural therapy 4st session|Introduction and characteristics of plants: This information will be provided by the landscape architect involved in the research. The scope of horticultural therapy, information will be given in the nursing home conference room. The training will be done with a power point presentation.In terms of the suitability of the caregivers, the training will be carried out by dividing into 3 groups of 10 people. Training will last 30 minutes. This training will be on Thursday
62452263|NCT06484959|OTHER|Horticultural therapy 5st session|Care and watering techniques: This information will be provided by the landscape architect involved in the research. The scope of horticultural therapy, information will be given in the nursing home conference room. The training will be done with a power point presentation.In terms of the suitability of the caregivers, the training will be carried out by dividing into 3 groups of 10 people. Training will last 30 minutes. This training will be on Friday.
62452264|NCT06484959|OTHER|Horticultural therapy 6st session|Survey analysis in gardens: Samples will be taken from the soil, analyzed, soil examination will be made, and the substances to be fertilized will be determined. This process will take place with the soil sample sent to agricultural engineering.This was done when the caregivers were informed.
62452265|NCT06484959|OTHER|Horticultural therapy 7st session|Preparing the area in the garden for planting was done when the caregivers were informed. The garden created with the drawings made within the scope of the work plan was prepared. Soil is prepared for planting by hoeing and fertilizing.
62452266|NCT06484959|OTHER|Horticultural therapy 8st session|Planting seedlings and seeds in gardens: The information about horticultural therapy, the plants were planted by the caregivers. This process has been achieved by implementing the training and information provided by the researchers.
62452267|NCT03151239|PLACEBO_COMPARATOR|Placebo|
62452268|NCT03151239|EXPERIMENTAL|NMN supplementation|
62452269|NCT02366221||All subjects|Subjects with a history of complex arm trauma
62630985|NCT06597292|EXPERIMENTAL|Vision improvement|
62630986|NCT00667485|EXPERIMENTAL|Weekly Rapamcyin|Rapamycin (liquid) taken weekly and Bevacizumab (IV infusion ) once every 3 weeks
62630987|NCT00667485|EXPERIMENTAL|Daily Rapamycin|Daily oral rapamycin (tablets) and Bevacizumab (IV infusion)once every 3 weeks
62630988|NCT02990130||Study Group|This is a pilot observational study involving patients enrolled in the Seattle VA Bone Marrow Transplant Unit (BMTU) for treatment of their hematologic malignancy. Measurements of patient fitness, body composition, and inflammatory milieu will be performed at visits before HCT, and 30 days (+/- 10 days) after HCT. For patients that continue to receive care at the Seattle VA, additional visits (not exceeding 6 total) may be requested periodically for up to 2 years after HCT.
62630989|NCT04351165|EXPERIMENTAL|Arm 1|"Period 1:~100 mg oral dose of IMP4297 (5 capsules, 20 mg/capsule);~Period 2:~100 mg oral dose of IMP4297 (10 capsules, 10 mg/capsule);~Each treatment sequence will consist of 2 periods, separated by a washout period of at least 7 days between each Dose."
62630990|NCT04351165|EXPERIMENTAL|Arm 2|"Period 1:~100 mg oral dose of IMP4297 (10 capsules, 10 mg/capsule);~Period 2:~100 mg oral dose of IMP4297 (5 capsules, 20 mg/capsule);~Each treatment sequence will consist of 2 periods, separated by a washout period of at least 7 days between each Dose."
62630991|NCT04366154||Patients|
62630992|NCT04366154||Caregivers|
62630993|NCT01407263|EXPERIMENTAL|Lymphadenectomy vs. no lymphadenectomy|In patients randomized to standard, only the nodal packet under the external iliac vein and above the obturator nerve will be dissected. For patients randomized to the modified template, the external iliac, hypogastric and obturator fossa nodal groups will be removed.No lymph nodes will be removed in patients randomized to the no PLND arm.
62630994|NCT01407263|EXPERIMENTAL|Transverse versus vertical closure of the port site incision (Closed as of 9/30/2021)|
62630995|NCT01407263|EXPERIMENTAL|One vs. three days of antibiotic prophylaxis (Closed as of 9/30/2021)|
62630996|NCT01407263|EXPERIMENTAL|Hemostatic agent vs. no hemostatic agent|
62630997|NCT04888494|EXPERIMENTAL|Hippocampus-stimulation|Active high-frequency rTMS (20 Hz pulse trains)
62630998|NCT04888494|EXPERIMENTAL|Sham-stimulation|Sham rTMS
62630999|NCT03002636|EXPERIMENTAL|Morbid Obesity group|Morbid Obesity group(n=300)
62631000|NCT03002636|EXPERIMENTAL|severe Obesity group|severe Obesity group (n=300)
62631001|NCT03002636|OTHER|non-Obesity group|non-Obesity group(n=300)
62631002|NCT02921945|EXPERIMENTAL|SCT800|
62631003|NCT06473831|EXPERIMENTAL|Magnet System, DI Biofragmentable|GT Metabolic Solutions Magnet System, DI Biofragmentable (MagDI System)
62631004|NCT01695005|EXPERIMENTAL|LY3039478 - Dose Escalation|Part A: LY3039478 administered orally three times per week (TIW) at escalating doses (2.5 milligrams \[mg\] to 100 mg) for two 28 day cycles. Participants receiving benefit may continue until disease progression
62631005|NCT01695005|EXPERIMENTAL|LY3039478 - Cohort Expansion|Part B, C, D and E: LY3039478 administered orally three times per week (TIW) at a fixed dose determined in Part A for two 28 day cycles. Participants receiving benefit may continue until disease progression.
62631006|NCT01695005|EXPERIMENTAL|Dose 1 LY3039478 + Prednisone|Part F1: LY3039478 administered orally TIW for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only (28 day cycles). Participants receiving benefit may continue until disease progression.
62631007|NCT01695005|EXPERIMENTAL|Dose 2 LY3039478 + Prednisone|Part F2: LY3039478 administered orally TIW (twice a week in cycle 1) for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only. Participants receiving benefit may continue until disease progression.
62631008|NCT01409980||Triphalangeal Thumb|A search will be performed using CPT code 26587 (reconstruction of a supernumerary digit) at both Primary Children's Hospital and Shriners to identify all patients who Dr. Wang and Hutchinson operated on with a delta phalanx.
62631009|NCT04133597|EXPERIMENTAL|Interventional|Two experimental steps: baseline skin conductance measurements (step 1, three minutes) and measurements of SC after social media stimulation with Line messages or calls (step 2, three minutes). With a 5-minute rest period after these two steps completed, then each participant fill out questionnaires for assessing anxiety and problematic smartphone use.
62631010|NCT03364036|EXPERIMENTAL|Mavenclad®|
62088171|NCT03417973||Chronic pelvic pain|Chronic pelvic or urological pain patients medically indicated to have dorsal root ganglion (DRG) stimulation for control of pain. DRG stimulator will be implanted for trial of 3-4 days and then permanently, if patient find acceptable levels of pain control with trial.
62631011|NCT03100656|OTHER|Anorexia nervosa I|Anorexia nervosa with BMI \<=17.5 kg/m² or BMI \>17.5 kg/m² with regular binge-purge episodes
62631012|NCT03100656|OTHER|Anorexia nervosa II|Anorexia nervosa with BMI \> 18.5 kg/m² for at least 12 months.
62631013|NCT03100656|OTHER|Controls|Healthy control women
62631014|NCT01635517||Tolvaptan|Tolvaptan administration
62631015|NCT05468983|OTHER|BioHpp hybrid prosthesis( fixed )|4 implants were placed in the mandibular arch by a surgical guide, after 3 months the final prosthesis was constructed by using a digital workflow( CAD-CAM )
62631016|NCT05468983|OTHER|BioHpp bar supported and retained overdenture|4 implants were placed in the mandibular arch by a surgical guide, after 3 months the final prosthesis was constructed by using a digital workflow( CAD-CAM )
62631017|NCT01909141|ACTIVE_COMPARATOR|arm 1:letrozole-pioglitazone -metformin group|Arm 1 will receive letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.
62631018|NCT01909141|ACTIVE_COMPARATOR|arm 2: clomiphene citrate-pioglitazone-metformin|Arm 2 will receive clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.
62631019|NCT01100723|EXPERIMENTAL|Computer directed dosing decisions|This study will be an open-label, non-randomized, single arm design. Patients will have their mineral and bone disorders managed by the computer directed algorithm. The computer algorithm will make recommendations for dosing active vitamin D and cinacalcet. The doses of these medications recommended by the algorithm will then be prescribed to the subjects participating in the study unless overridden by the patients primary attending nephrology for other clinical or safety concerns. At any time in the study, subjects may be on neither, one, or both of these medication depending on their laboratory results and the output recommendations of the algorithm.
62631020|NCT00289094|ACTIVE_COMPARATOR|1|P.F.C.® Sigma™ Rotating Platform (RP) Cruciate Retaining Knee System
62064564|NCT05975437||Personalized care|Participants who are included after the hospital's transition to personalized follow-up. After this transition, personalized follow-up becomes the standard form of care for all patients, regardless of their participation in this study. Participants of this group receive personalized follow-up, which is based on individual prognoses and needs. Personalized follow-up will be provided by the use of personalized surveillance (PSP) and personalized aftercare plans (PAP).
62631021|NCT00289094|ACTIVE_COMPARATOR|2|P.F.C.® Sigma™ Fixed Cruciate Retaining Knee System
62631022|NCT02719002|EXPERIMENTAL|OCT C-scan|
62631023|NCT01320241|ACTIVE_COMPARATOR|novel radiation stent|"Patients undergo placement of a novel biliary stent loaded with 125I seeds on day 1.~Intervention: Device: self-expandable 125I radioactive seeds-loaded-stent"
62631024|NCT01320241|EXPERIMENTAL|conventional stent|"Patients undergo placement of a conventional nitinol SEMS on day1.~Intervention: Device: self-expandable biliary nitinol alloys stent"
62631025|NCT05490355|ACTIVE_COMPARATOR|Perineural Steroid Injections Alone|"Participants assigned to this study arm will receive only Perineural Steroid Injections per clinical standards.~Participant will also complete a joint function questionnaire at 4 time points, pre-procedure, 2 weeks post procedure, 3 months post procedure, and 6 months post procedure."
62064565|NCT06461819|EXPERIMENTAL|Prostate cancer patient, candidate of definitive radiation treatment|A single institution with a single group, a phase II study, Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.
62064566|NCT05553847|NO_INTERVENTION|Usual oxygen dose|A Glittre-ADL tests will be performed and the patients will use their usual fixed dose of oxygen. Pulse rate and saturation will continuously be registered during the test. Before, and after the Glittre-ADL, the patients will be asked the rate their level of dyspnea using Borg Dyspnea Scale
62064567|NCT05553847|EXPERIMENTAL|Automated oxygen dose|A Glittre-ADL tests will be performed and the patients will use automated oxygen titration set at an SpO2-target of 90 to 94 % and an oxygen flow of 0 - 8 liters/min. Pulse rate, oxygen flow rate and saturation will continuously be registered during the test. Before, and after the Glittre-ADL, the patients will be asked the rate their level of dyspnea using Borg Dyspnea Scale
62064568|NCT01222429|ACTIVE_COMPARATOR|diet following American Diabetes Association guidelines|Participants will follow diets based on ADA guidelines. This group will also receive weekly nutrition classes.
62064569|NCT01222429|EXPERIMENTAL|vegan diet|Participants in the intervention group will follow a low-fat, vegan diet for 20 weeks, and will attend nutrition classes in the form of a weekly support group.
62269770|NCT03728309|EXPERIMENTAL|Control Group: No Treatment Then Optional JUVÉDERM® VOLITE™|Participants received no treatment for up to 30 days and then received an optional JUVÉDERM® VOLITE™ XC injectable gel initial treatment intradermally up to 4 mLs and an optional touch-up treatment up to 2 mL 30 days later, if applicable.
62269771|NCT04642755||Group 1|LTBI+ and severe to moderate malnutrition
62631026|NCT05490355|EXPERIMENTAL|Perineural Steroid Injections Plus Radiofrequency Ablation|"Participants assigned to this study arm will receive Perineural Steroid Injections plus Radiofrequency Ablation per clinical standards.~Participant will also complete a joint function questionnaire at 4 time points, pre-procedure, 2 weeks post procedure, 3 months post procedure, and 6 months post procedure."
62631027|NCT03520712|EXPERIMENTAL|valoctocogene roxaparvovec Open Label|Single administration of BMN270 at a dose of 6E13 vg/kg
62631028|NCT04684563|EXPERIMENTAL|NHL Dose Level 1a (DL1a)|3x10\^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push
62631029|NCT04684563|EXPERIMENTAL|NHL Dose Level -1 (DL-1)|7x10\^5 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 1a.
62631030|NCT04684563|EXPERIMENTAL|NHL Dose Level 1b (DL1b)|3x10\^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
62631031|NCT04684563|EXPERIMENTAL|NHL Dose Level 2 (DL2)|7x10\^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
62269772|NCT04642755||Group 2|LTBI+ and uncontrolled DM
62631032|NCT04684563|EXPERIMENTAL|NHL Dose Level 3 (DL3)|3x10\^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
62631033|NCT04684563|EXPERIMENTAL|NHL Dose Level 4 (DL4)|7x10\^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
62631034|NCT04684563|EXPERIMENTAL|NHL Dose Level 5 (DL5)|3x10\^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
62088172|NCT00415493|EXPERIMENTAL|Order 1|Cold-dry air provocation followed (on a separate day) by Warm-moist air provocation
62269773|NCT04642755||Group 3|LTBI+ and helminth infection
62653196|NCT02687672|EXPERIMENTAL|Stem Cell Transplantation|Injection of leukapheresis-derived, purified, autologous CD34+and CD133+ stem cells
62631035|NCT04684563|EXPERIMENTAL|CLL Dose Level 1b (DL1b)|3x10\^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 2.
62064570|NCT02543320|EXPERIMENTAL|Supportive care (neurofeedback)|Beginning at weeks 4 and 5 or 5 and 6 of radiotherapy, patients undergo neurofeedback training QID TIW for up to 6 treatments. Patients also complete questionnaires over 10 minutes at baseline and after neurofeedback training.
62064571|NCT01736501|NO_INTERVENTION|Baseline1-demographics|Baseline survey- demographics only
62064572|NCT01736501|OTHER|Baseline1 w/genetics|Genetics education, baseline interest in genome screening - 1
62269774|NCT04642755||Group 4|LTBI+ with more than one of the above conditions (severe to moderate malnutrition, DM, helminth infection)
62269775|NCT04642755||Group 5|"Healthy LTBI+ controls who are negative for all of the above conditions (severe to moderate malnutrition, DM, helminth infection)"
62269776|NCT04642755||Group 6|Healthy LTBI negative controls with none of the above conditions (severe to moderate malnutrition, DM, helminth infection).
62269777|NCT01180660|ACTIVE_COMPARATOR|Lidocaine|Lidocaine infusion
62269778|NCT01180660|PLACEBO_COMPARATOR|Placebo|Placebo Normal Saline Infusion
62452270|NCT02153398|EXPERIMENTAL|Group 1: D961H sachet 10 mg|Age: ≥1 year Weight: \<20 kg
62452271|NCT02153398|EXPERIMENTAL|Group 2: D961H capsule 10mg|Age: ≥1 year to 11years Weight: ≥20 kg
62452272|NCT02153398|EXPERIMENTAL|Group 3: D961H capsule 20 mg|Age: ≥1 year to 11years Weight: ≥20 kg
62452273|NCT02153398|EXPERIMENTAL|Group 4: D961H capsule 10 mg|Age: 12 to 14 years Weight: ≥20 kg
62452274|NCT02153398|EXPERIMENTAL|Group 5: D961H capsule 20 mg|Age: 12 to 14 years Weight: ≥20 kg
62452275|NCT05362448|ACTIVE_COMPARATOR|80 Hz|Stimulation with a frequency of 80 Hz
62452276|NCT05362448|ACTIVE_COMPARATOR|130 Hz|Stimulation with a frequency of 130 Hz
62452277|NCT05362448|ACTIVE_COMPARATOR|180 Hz|Stimulation with a frequency of 180 Hz
62631036|NCT04684563|EXPERIMENTAL|CLL Dose Level 2 (DL2)|7x10\^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
62064573|NCT01736501|OTHER|Baseline2-demographics|Baseline survey- demographics only
62064574|NCT01736501|OTHER|Baseline2 w/genetics|Genetics education, baseline interest in genome screening - 2
62064575|NCT00984321|EXPERIMENTAL|Psychoeducational Intervention Group|
62064576|NCT00984321|EXPERIMENTAL|Expressive Writing Intervention|
62064577|NCT00984321|ACTIVE_COMPARATOR|Control Group|
62064578|NCT05326763|ACTIVE_COMPARATOR|platelet rich plasma group|Preparing 2 mL of PRP with concentration of 4-6 times the average normal values, 20mL of blood will be first collected from the patient's upper limb cubital vein using an 18G needle.
62064579|NCT05326763|ACTIVE_COMPARATOR|dextrose group|4 ml of PRP + 4 ml of 0.9% saline -h 2 ml of 1% lidocaine (10-ml syringe).
62064580|NCT05326763|NO_INTERVENTION|Placebo (the control group)|
62064581|NCT01765595|EXPERIMENTAL|DDI+|DDI+ Incorporated in routine ambulatory practice
62064582|NCT01765595|NO_INTERVENTION|Control|Standard care
62064583|NCT03233178||SGLT2|Patients initiating SGLT2 inhibitors
62064584|NCT03233178||Liraglutide|Patients initiation liraglutide
62064585|NCT03233178||Sitagliptin|Patients initiating sitagliptin
62269779|NCT05399537|EXPERIMENTAL|Prismocitrate 18|
62269780|NCT05912465|EXPERIMENTAL|Treatment-Naive Lung Cancer Patients|This arm includes 150 treatment-naive lung cancer patients. Assessments include medical history, physical exams, lab tests, and imaging. Objective: investigate cancer cachexia, stress, and metabolic changes. Cachexia criteria: weight loss, reduced food intake, inflammation markers. Stress assessment: questionnaires, biomarkers. Metabolic changes measured by PET-CT scans analyzing FDG uptake in organs/lesions. Data will uncover the relationship between cancer cachexia, stress, and metabolic changes in treatment-naive lung cancer patients, leading to improved interventions/outcomes.
62269781|NCT02289183|EXPERIMENTAL|Totally laparoscopic distal gastrectomy|The totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy will be performed for the treatment of patients with distal gastric cancer assigned to this group.
62269782|NCT02289183|ACTIVE_COMPARATOR|Laparoscopy-assisted distal gastrectomy|The laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis will be performed for the treatment of patients with distal gastric cancer assigned to this group.
62064586|NCT03233178||Control Group|Patients who did not initiate any new anti-hyperglycemic treatment
62064587|NCT04803617||Patient's group|geriatric patients with interstitial lung disease
62452278|NCT05362448|SHAM_COMPARATOR|DBS off|Absence of stimulation
62452279|NCT04975399|EXPERIMENTAL|Administration of CC-92328|CC-92328 administered intravenously in 28-day cycles
62452280|NCT06105983|EXPERIMENTAL|Treatment A|Part 1: Sisunatovir without rabeprazole
62452281|NCT06105983|ACTIVE_COMPARATOR|Treatment B|Part 1: Sisunatovir with 40 mg rabeprazole
62452282|NCT06105983|ACTIVE_COMPARATOR|Treatment C|Part 2: Sisunatovir suspension without rabeprazole
62452283|NCT06105983|EXPERIMENTAL|Treatment D|Part 2: Sisunatovir suspension with 20 mg rabeprazole
62452284|NCT06105983|EXPERIMENTAL|Treatment E|Part 2: Sisunatovir suspension with 40 mg rabeprazole
62653197|NCT02687672|EXPERIMENTAL|Stem Cells|Injection of bone marrow-derived, purified, autologous CD34+and CD133+ stem cells.
62631037|NCT04684563|EXPERIMENTAL|CLL Dose Level 3 (DL3)|3x10\^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
62631038|NCT04684563|EXPERIMENTAL|CLL Dose Level 4 (DL4)|7x10\^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
62631039|NCT04684563|EXPERIMENTAL|CLL Dose Level 5 (DL5)|3x10\^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
62064588|NCT04803617||Control group|healthy volunteers selected from the geriatric population
62064589|NCT02553811|EXPERIMENTAL|intervention|accuracy diagnostic in carpal tunnel syndrome = evaluation and comparison ultrasonography X electromyography
62064590|NCT05008029|EXPERIMENTAL|In situ immobilization|Immobilization without reducing the radius fracture and above-elbow casting.
62064591|NCT05008029|ACTIVE_COMPARATOR|Reduction under general anesthesia|Radius closed reduction under general anesthesia and above-elbow casting. Percutaneous fixation with K-wires, a sugar tong splint immobilization, and a nerve block if needed.
62064592|NCT04508296|EXPERIMENTAL|GEDVI-oriented de-escalation|Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT. In the case of GEDVI \> 650 mL/m2 the primary goal of de-escalation is to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI \< 650 mL/m2 he target fluid balance is in the range of 0 to +3000 mL
62064593|NCT04508296|EXPERIMENTAL|EVLWI-oriented de-escalation|Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT. In the case of EVLWI \> 10 mL/kg the primary goal of de-escalation is to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of EVLWI \< 10 mL/kg, the target fluid balance is in the range of 0 to +3000 mL
62064594|NCT02708433|ACTIVE_COMPARATOR|Buffered 1% lidocaine|"In week one each subject would receive either anesthetic (Buffered 1% lidocaine with 1/100,000 Epinephrine) or (Non-Buffered 2% lidocaine with 1/100,000 Epinephrine) to block the inferior alveolar, lingual, buccal nerves.~In week two the alternate anesthetic would be administered.~Mandibular molar and canine tested for pulpal anesthesia"
62064595|NCT02708433|ACTIVE_COMPARATOR|Non-Buffered lidocaine|"In week two each subject would receive the alternate anesthetic (Buffered 1% lidocaine with 1/100,000 Epinephrine) or (Non-Buffered 2% lidocaine with 1/100,000 Epinephrine) to block the inferior alveolar, lingual, buccal nerves.~Mandibular molar and canine tested for pulpal anesthesia"
62064596|NCT01616576|EXPERIMENTAL|Control first, then Experimental (Group A)|Initial subject use of Control Sound Processing Strategy for the first week, followed by subject use of Experimental (HiRes™ Optima) Sound Processing Strategy for the HiResolution™ Bionic Ear System for the second week.
62064597|NCT01616576|EXPERIMENTAL|Experimental first, then Control (Group B)|Initial subject use of Experimental (HiRes™ Optima) Sound Processing Strategy for the first week for the HiResolution™ Bionic Ear System, followed by subject use of the Control Sound Processing Strategy for the second week.
62064598|NCT02385019|EXPERIMENTAL|Administration of 0.5 x 10ˆ6 donor Treg/kg|First group of 5 patients will receive a total of 0.5 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
62064599|NCT02385019|EXPERIMENTAL|Administration of 1.0 x 10ˆ6 donor Treg/kg|Second group of 5 patients will receive a total of 1.0 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
62269783|NCT05574205|EXPERIMENTAL|High Quality Protein|Participants will consume four high-quality protein containing meals per day (amounting to 1g/kg/day of protein) over a 10-day period. Each meal will contain 75:25 animal:plant protein with most of the animal protein from supplemental high-quality protein powder.
62631040|NCT04684563|EXPERIMENTAL|ALL Dose Level 1b (DL1b)|3x10\^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 2.
62631041|NCT04684563|EXPERIMENTAL|ALL Dose Level 2 (DL2)|7x10\^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
62631042|NCT04684563|EXPERIMENTAL|ALL Dose Level 3 (DL3)|3x10\^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
62631043|NCT04684563|EXPERIMENTAL|ALL Dose Level 4 (DL4)|7x10\^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
62631044|NCT04684563|EXPERIMENTAL|ALL Dose Level 5 (DL5)|3x10\^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
62631045|NCT05027438|EXPERIMENTAL|COAST + Deprescribing|CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
62631046|NCT03189212|ACTIVE_COMPARATOR|Usual Care Visit|
62631047|NCT03189212|EXPERIMENTAL|Telemedicine Visit|
62631048|NCT03072290|EXPERIMENTAL|low dose steroid|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
62631049|NCT03072290|ACTIVE_COMPARATOR|comparator|ultrasound-guided steroid injection using 1ml of 40 mg (40mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
62631050|NCT03540732|NO_INTERVENTION|1. Control|"* Standard physiotherapy~* Empiric formula directed feeding (daily caloric requirement calculated by 25 kcal/kg/day)"
62631051|NCT03540732|ACTIVE_COMPARATOR|2. Intervention|"* Up to 60 minutes of cycle ergometry daily in addition to standard physiotherapy sessions.~* Indirect calorimetry directed feeding (use of indirect calorimetry to calculate daily caloric requirement)"
62631052|NCT01221558|EXPERIMENTAL|6mg lycopene|
62631053|NCT01221558|EXPERIMENTAL|15mg lycopene|
62631054|NCT01221558|PLACEBO_COMPARATOR|placebo|
62631055|NCT01745562|EXPERIMENTAL|A(reference)/B(test)|initial administration of reference and cross-over to test
62631056|NCT01745562|EXPERIMENTAL|B(test)/A(reference)|initial administration of test and cross-over to reference
62631057|NCT04330417|EXPERIMENTAL|EMG Glove Group|A total of 12 sessions of robot-assisted hand training for 6 consecutive weeks.
62631058|NCT04330417|ACTIVE_COMPARATOR|Control Group|A total of 12 session of standard hand therapy sessions in 6 consecutive weeks.
62631059|NCT04967105||elderly patients following liver resection|elderly patients (aged ≥60 years) scheduled for any type of liver resection due to benign or malignant hepatobiliary diseases
62064600|NCT02385019|EXPERIMENTAL|Administration of 2.0-3.0 x 10ˆ6 donor Treg/kg|Third group of 5 patients will receive a total of 2.0-3.0 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
62064601|NCT02385019|EXPERIMENTAL|Administration of MTD of donor T reg|Preliminary Phase 2 study will include another 5 to 10 patients at the MTD identified in the Phase 1 study
62452285|NCT02192099|EXPERIMENTAL|Rapastinel (225 mg/450 mg IV administration) prefilled syringe|Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
62631060|NCT03096561|OTHER|Hypothermia related cardiac arrest|blood draw from three different vessels punctured in the emergency room (central vein, peripheral vein, artery) and comparison of potassium rate and other biological values between the different sites of blood draw and two different measuring techniques (laboratory vs. blood gas analyser)
62631061|NCT00003471|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62631062|NCT05505292|PLACEBO_COMPARATOR|Lifitegrast Ophthalmic Solution Vehicle|
62631063|NCT05505292|EXPERIMENTAL|Lifitegrast Ophthalmic Solution 5%|
62631064|NCT01360346|EXPERIMENTAL|Enteral Sedation (EN)|Melatonin, Hydroxyzine, and Lorazepam. At every work shift, it will be checked the possibility to decrease the Lorazepam and then the Hydroxyzine dosage to quickly obtain and continuously maintain a RASS level = 0
62631065|NCT01360346|ACTIVE_COMPARATOR|Intravenous Sedation (IV)|Intravenous propofol or midazolam administration at the ICU admission to discharge at the compatible lowest level with harsh ICU environment. At every shift nurses are requested to give intravenous lowest dosage to obtain RASS=0
62631066|NCT06612164|EXPERIMENTAL|Kefir Consumption Group|Commercial lactose-free kefir (Altinkilic, Turkey) beverage, which is produced from cow milk with 3.1% fat and 7.5% protein content and stored in appropriate conditions, was used in this study. The kefir (intervention) group was provided with 250 mL of plain lactose-free kefir containing at least 107-1010 probiotic bacterial strains (Lactobacillus, Lactic acid, Streptococcus, Acetic acid bacteria sp) and yeasts (Kluyveromyces marxianus, Torulaspora delbrueckii, Saccharomyces cerevisiae, Candida). The participants were asked to consume 250 mL of plain lactose-free kefir daily for 6 weeks. Any particular time was not specified for kefir consumption. Kefir consumption routine of participants was followed up by regular phone calls every week and evaluated by examining their consumption records.
62631067|NCT06612164|NO_INTERVENTION|Control Group|Short Physical Activity Assessment Tool was used for evaluating physical activity levels of the participants, mental health status by The Warwick-Edinburgh Mental Well-Being Scale (WEMWBS). Gastrointestinal system symptoms were evaluated by using the Gastrointestinal Symptom Rating Scale (GSRS), sleep quality by the Pittsburg Sleep Quality Index (PSQI) and diet quality by the Healthy Eating Index-2015 (HEI-2015). Measurements were recorded prior to kefir intervention (initial measurement) and post kefir intervention (final measurement) for kefir and control groups.
62631068|NCT03407001|EXPERIMENTAL|Screening (US, CEUS, Lumason)|Within 30 days of routine MRI, participants undergo non-contrast ultrasound of the abdomen. Participants then receive Lumason IV and undergo contrast-enhanced ultrasound of the abdomen over 1 hour in the absence of disease progression or unacceptable toxicity.
62064602|NCT03342053|EXPERIMENTAL|RO7234292 Monthly|RO7234292 is administered every 28 days intrathecally for 14 months.
62064603|NCT03342053|EXPERIMENTAL|RO7234292 Bimonthly|RO7234292 is administered every 56 days intrathecally for 14 months following 2 monthly doses to serve as a loading dose.
62064604|NCT01876641|EXPERIMENTAL|Study Treatment|In Cohorts 1-4, a subcutaneous dose of decitabine will be administered three times/week over a 2 week period. Cohorts 5 and 6 will receive decitabine two times a week for 8 weeks and Cohorts 7 and 8 will receive decitabine three times a week for 8 weeks. Patients will start treatment with decitabine initially at the cohort in which they enter the study. Patients will remain in the cohort in which they were initially enrolled for the entire treatment course. Vemurafenib + Cobimetinib will be given continuously for subjects in Cohorts 5, 6, 7 and 8. Vemurafenib will be given on a 28-day cycle at the standard dose of 960 mg p.o. BID. Cobimetinib will be given on a 21-day cycle with a 7-day rest between cycles. Decitabine will be given for 2 cycles only. Each cycle will be 28 days long. Vemurafenib + Cobimetinib will be continued indefinitely until disease progression.
62064605|NCT02601898|EXPERIMENTAL|Lipoic acid|vaginal capsules of lipoic acid (10 mg, one capsule per day)
62064606|NCT02601898|ACTIVE_COMPARATOR|Progesterone|Vaginal soft gel of progesterone (200 mg, two capsules per day)
62631069|NCT04769232|ACTIVE_COMPARATOR|Standard Imaging|In 20 randomly assigned patients, the area of endoscopically highest activity will be biopsied as determined by standard imaging. A total of 10 biopsies will be taken in 4 sets: 1 = one single biopsy at best guess of highest activity; 2 = one single biopsy at second best guess of highest activitiy, 3 = 4 biopsies in proximal esophagus with presumed activity, 4 = 4 biopsies in distal esophagus with presumed activity. Overall qualitative (eosinophilic inflammation present vs. absent) and semi-quantitative (estimation of the number of eosinophilic neutrophils according to the following categories 1: 0, 2: 1-6, 3. 7-14, 4. 15-50, 5. :50-100, 6. \> 100, together with an estimation of an absolute number of eosinophilic neutrophils) inflammatory activity will be rated for the presumed localization of maximal histologic activity and subsequently for all other 10 biopsies using this imaging modality by endoscopist.
62653198|NCT06237179|EXPERIMENTAL|Exercise Training Intervention|The exercise program (ET) is tailored to each participant depending on his initial functional capacity, cardiorespiratory fitness and strength, to achieve ≥150 moderate to vigorous physical activity
62064607|NCT00199498|EXPERIMENTAL|Septal RV lead placement|patient randomized to Septal RV lead placement
62064608|NCT00199498|ACTIVE_COMPARATOR|Apical RV lead placement|patient randomized to Apical RV lead placement (current standard placement)
62452286|NCT02156648|OTHER|Feasibility study|All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
62452287|NCT03805230||Cohort A|all patients admitted to participating hospitals during 7 consecutive days
62653199|NCT06237179|ACTIVE_COMPARATOR|Healthy Living Education Control|Educational modules delivered remotely (or manual and telephone call) in a group-based setting to approximately match contact frequency and structure with the ET arm.
62452288|NCT03805230||Cohort B|30 sequential patients with a single additional inclusion criterion
62064609|NCT05138159|EXPERIMENTAL|Experimental: Donafenib + S-1|Donafenib: 200mg po bid； S-1 capsule: According to the body surface area \<1.25m2 40mg/d, 1.25 \~ 1.5 m2 50 mg/d, \> 1.5m2 60mg/d po bid, taking 14 days, stopping for 7 days, 21 days for 1 cycle.
62064610|NCT00951262|EXPERIMENTAL|life review|a life review program includes 3-session life review and formulation of a life review book as a gift for advanced cancer patients.
62064611|NCT00951262|NO_INTERVENTION|controlled group|the subjects in the controlled group do not receive the life review program
62452289|NCT04170881||CHILDREN|Children from involved daycares (Paris region)
62452290|NCT04170881||WORKERS|workers in involved daycares (Paris region)
62452291|NCT02586103||MRI|Patients who undergo simulated practice MRI on the day of or prior to their scheduled MRI.
62452292|NCT05327166|NO_INTERVENTION|Usual Care|Participants assigned to this arm will receive usual care.
62452293|NCT05327166|EXPERIMENTAL|ED-LINC Intervention|Patients assigned to the ED-LINC intervention will receive 1) overdose education, 2) brief bedside intervention targeting motivation to engage in outpatient care, 3) a patient-centered approach to MOUD using a treatment decision support tool, 4) longitudinal and proactive care management and 5) weekly caseload supervision allowing for stepped-up care targeting opioid use and comorbidity.
62452294|NCT02374918|EXPERIMENTAL|mTBI wavelength-1 bright light|30 minutes daily light exposure for 6 weeks
62631070|NCT04769232|EXPERIMENTAL|High Magnification Imaging|In 20 randomly assigned patients, the area of endoscopically highest activity will be biopsied as determined by high magnification imaging. A total of 10 biopsies will be taken in 4 sets: 1 = one single biopsy at best guess of highest activity; 2 = one single biopsy at second best guess of highest activitiy, 3 = 4 biopsies in proximal esophagus with presumed activity, 4 = 4 biopsies in distal esophagus with presumed activity. Overall qualitative (eosinophilic inflammation present vs. absent) and semi-quantitative (see above) inflammatory activity will be rated for the presumed localization of maximal histologic activity and subsequently all other 10 biopsies using this imaging modality by endoscopist.
62631071|NCT05895357|EXPERIMENTAL|Music Therapy|The patients were asked about the type of music they wanted to listen to. Especially in the last meta-analyses, it was determined that listening to the music that patients chose was more effective (Witten 2020). For this reason, after the intervention group is asked about the music they want to listen to, the music they want will be played from the music application.
62631072|NCT05895357|NO_INTERVENTION|No intervention|The patients in the control group will not listen to music, and routine procedures will performed in the clinic without additional intervention. Anxiety, pain, and comfort assessments will made in the control group patients before and after the procedure.
62064612|NCT00724139|EXPERIMENTAL|1|patients (aged 50-75) with Symptomatic knee OA for at least 6 months, fulfilled American College of Rheumatology clinical criteria for OA of the knee and radiographically assessed osteoarthritis of the knee graded 1-2 according to the Kellgren \& Lawrence scale.
62631073|NCT02318888|EXPERIMENTAL|Surgery and Icodextrin|Icodextrin 4% instilled every 30 minutes during surgery and 1000 ml instilled before closure of abdomen
62631074|NCT02318888|ACTIVE_COMPARATOR|Surgery|No instillations during surgery
62631075|NCT04097769|OTHER|HX009|Study treatment: HX009 administered every 2 weeks (14 \[±1\] days) via intravenous infusion.
62631076|NCT02983890|ACTIVE_COMPARATOR|Arm of study1|Dicloxacillin tablets.
62064613|NCT03107819||Pediatric patients undergoing EGD|Subjects ages 2-18 years undergoing upper endoscopy (EGD) will submit a blood and urine specimen for plasma and urine metabolomics profiling.
62064614|NCT05458596|EXPERIMENTAL|Screen-based simulation|Screen-based simulation about intimate partner violence against women prepared by researchers will apply to nursing students.
62064615|NCT05876611||Using the new type of self stabilizing atlantoaxial fusion cage|Use the new type of self stabilizing atlantoaxial fusion cage to treat atlantoaxial dislocation.
62631077|NCT02983890|PLACEBO_COMPARATOR|Arm of study 2|No treatment
62631078|NCT05143632|NO_INTERVENTION|Intermittent NIBP monitoring|Oscillometric intermittent (3 mins) noninvasive blood pressure monitoring
62064616|NCT05876611||Using other fusion systems|Use screw and plate system or other existing models of fusion cages.
62064617|NCT00874432|ACTIVE_COMPARATOR|Chronic Kidney Disease-ACE-I|ace inhibitor
62064618|NCT00874432|PLACEBO_COMPARATOR|Chronic Kidney Disease|
62064619|NCT00874432|ACTIVE_COMPARATOR|Age matched control-ACE-I|ace-inhibitor
62064620|NCT00874432|PLACEBO_COMPARATOR|Age matched control|Placebo
62064621|NCT02670252|EXPERIMENTAL|BUCY|For standard-risk ALL undergoing HLA-matched allo-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
62064622|NCT02670252|ACTIVE_COMPARATOR|TBICY|For standard-risk ALL undergoing HLA-matched allo-HSCT，TBICY conditioning regimen was 4.5 Gy TBI/day on days -5 and -4；CY 60 mg/kg/day on days -3 and -2.
62064623|NCT05007561|EXPERIMENTAL|Naltrexone|50mg naltrexone HCL once daily for seven days by mouth
62064624|NCT05007561|PLACEBO_COMPARATOR|placebo|sugar pill once daily for seven days by mouth
62064625|NCT01657630||Accu-Chek Combo|15 type 1 young patients under 6 years old who begin to use the Accu-Chek Combo System
62064626|NCT02186080|EXPERIMENTAL|Gemigliptin|Gemigliptin 50mg qd added to subjects current diabetes treatment
62064627|NCT02186080|PLACEBO_COMPARATOR|Placebo|Placebo (identical in appearance to gemigliptin)
62064628|NCT02901145|EXPERIMENTAL|progressive/relapsed solid tumors|patient with progressive/relapsed solid tumors who failed first line therapy
62064629|NCT02757924|EXPERIMENTAL|Infant formula supplemented with prebiotics|infant formula powder, feed ad libitum
62064630|NCT01547299|EXPERIMENTAL|Enzalutamide alone|Enzalutamide 160 mg, orally, once daily
62269784|NCT05574205|EXPERIMENTAL|Low Quality Protein|Participants will consume four low-quality protein containing meals per day (amounting to 1g/kg/day of protein) over a 10-day period. Each meal will contain 25:75 animal:plant protein with most of the plant protein from supplemental low-quality protein powder.
62064631|NCT01547299|EXPERIMENTAL|Enzalutamide & Leuprolide & Dutasteride|Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily
62064632|NCT02413463|ACTIVE_COMPARATOR|Augmented recession|The medial rectus muscle will be exposed and hooked through a limbal approach. The muscle will then be secured with 6-0 polyglactin sutures. The medial rectus muscles will then be recessed using standard tables with the surgical dose targeting the average of the largest and smallest angles
62064633|NCT02413463|ACTIVE_COMPARATOR|Faden|Medial rectus muscle recession will be performed as described above with the surgical dose targeting the smallest pre-operative angle. The muscle will then fixated to the sclera using 6/0 polyester sutures placed in a mattress like with the anterior and the posterior sutures passing through both the edge of muscle and the sclera 12 mm and 14 mm from the muscle insertion, respectively.
62269785|NCT04473456|NO_INTERVENTION|Serial arm|In the serial group, all colonoscopies will be performed by the same endoscopist. EGDs are performed by the attending endoscopist on the day of the procedure.
62064634|NCT04268992|EXPERIMENTAL|Long-term exercise|Supervised exercise training three times a week for three months.
62452295|NCT02374918|PLACEBO_COMPARATOR|mTBI wavelength-2 bright light|30 minutes daily light exposure for 6 weeks
62452296|NCT02374918|EXPERIMENTAL|HC wavelength-1 bright light|30 minutes of light exposure
62452297|NCT02374918|PLACEBO_COMPARATOR|HC wavelength-2 bright light|30 minutes of light exposure
62631079|NCT05143632|EXPERIMENTAL|ClearSight|Continuous non invasive hemodynamic monitoring
62064635|NCT04268992|NO_INTERVENTION|Usual care|Patients are not offered supervised exercise.
62064636|NCT03735563|EXPERIMENTAL|Ketamine|Individuals needing the LISA will receive premedication as follows: caffeine (in case of gestational age \<32 weeks and not already given), glycopyrrolate, and randomly either ketamine or fentanyl.
62064637|NCT03735563|EXPERIMENTAL|Fentanyl|Individuals needing the LISA will receive premedication as follows: caffeine (in case of gestational age \<32 weeks and not already given), glycopyrrolate, and randomly either ketamine or fentanyl.
62064638|NCT04399551|EXPERIMENTAL|Participants with HIV infection|HIV-infected participants will receive CAB LA + RPV LA regimen for a month of oral lead in (OLI) at Day 1 followed by CAB LA + RPV LA injections at Months 1 and 2 and every 2 months (Q2M) thereafter.
62064639|NCT04399551|OTHER|Staff study participants (SSP)|Staff study participants will be randomized to receive standard implementation support (Arm-S; through visit(s) with the medication lead in their country, education on the medication, and patient and staff education/support materials) or through enhanced implementation support (Arm-E; through the addition of continuous quality improvement during the study).
62064640|NCT01078662|EXPERIMENTAL|1|Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose recommended by Investigator. Full dose: 300 mg twice daily (bid) or Reduced doses: 200 mg twice daily (bid) or 100 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions.
62064641|NCT02578914|EXPERIMENTAL|NS2 Ophthalmic Drops (0.5%)|NS2 Ophthalmic Drops (0.5%)
62064642|NCT02578914|SHAM_COMPARATOR|NS2 Ophthalmic Drops Vehicle (0.0%)|NS2 Ophthalmic Drops Vehicle (0.0%) control
62064643|NCT02006121|ACTIVE_COMPARATOR|Apomorphine hydrochloride|Apo-go® Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
62064644|NCT02006121|PLACEBO_COMPARATOR|Placebo|Placebo: saline infusion
62064645|NCT03495804|ACTIVE_COMPARATOR|mannitol|Participants are given a minimum of 1500 mL of a preparation of mannitol as oral contrast agent over an hour prior to the examination.
62064646|NCT03495804|EXPERIMENTAL|polyethylene glycol|Participants are given a minimum of 1500 mL of a preparation of polyethylene glycol as oral contrast agent over an hour prior to the examination.
62064647|NCT06307119|EXPERIMENTAL|Occupational Therapy and Relaxation Group|MOHO Based Intervention and Jacobson's Progressive Muscle Relaxation method
62064648|NCT06307119|EXPERIMENTAL|Relaxation Group|Jacobson's Progressive Muscle Relaxation method
62064649|NCT06307119|NO_INTERVENTION|Control Group|No İntervention
62064650|NCT04596137|EXPERIMENTAL|İnfant pain management|Kangaroo mother care was applied to the infants during heel prick. With kangaroo mother care, the pain of infants was reduced.
62269786|NCT04473456|ACTIVE_COMPARATOR|Simultaneous arm|In the simultaneous group, all colonoscopies will be performed by the same endoscopist. EGDs are performed by the attending endoscopist on the day of the procedure.
62631080|NCT03018275|EXPERIMENTAL|1|"Vials of lyophilized R mucosa (103, 104, or 105 CFU)"
62631081|NCT01146535|EXPERIMENTAL|Interferon-alpha|"Interferon-alpha~150 IU lozenges bid for 5 days"
62064651|NCT00997737|EXPERIMENTAL|DB, VI and FV|Breathing exercises
62064652|NCT01160484|EXPERIMENTAL|DVD-R single arm|"Dose schematic of Dexamethasone + Bortezomib + Pegylated Liposomal Doxorubicin + Lenalidomide (DVD-R) Therapy:~Dexamethasone\*- 40 mg IV Bortezomib\*\*- 1.0 mg/m2 IV Push Pegylated Liposomal Doxorubicin\*- 4.0 mg/m2 IV Lenalidomide\*\*\*- 10 mg PO~Per 28 Day Cycle~* Intravenous infusion (IV) Days 1, 4, 8 and 11 \*\* Intravenous push (IVP) Days 1, 4, 8 and 11 \*\*\* Per Orem (PO) Days 1-14"
62064653|NCT03548116|SHAM_COMPARATOR|Group 1|Individuals will receive sham non-imaging mode ultrasound (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
62452298|NCT01056549|EXPERIMENTAL|exenatide subcutaneous injection|Study A: lipoprotein turnover following subcutaneous exenatide administration, under conditions of pancreatic clamp. Study B: lipoprotein turnover study following subcutaneous placebo administration, under conditions of pancreatic clamp.
62631082|NCT01146535|PLACEBO_COMPARATOR|maltose|"maltose~200 mg maltose lozenges bid for 5 days"
62631083|NCT02163889||Candida Positive Patients|Symptomatic adult patients, confirmed via blood culture with species identification to be positive for Candida
62653200|NCT02020642|EXPERIMENTAL|Intervention Group|A baseline polysomnography (PSG) is performed at inclusion (before renal transplantation, Tx), followed by a post-Tx PSG 6 months after transplantation
62653201|NCT02020642|NO_INTERVENTION|Control Group|A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG at 6 months if the patient is not already transplanted
62064654|NCT03548116|EXPERIMENTAL|Group 2|Individuals will receive half-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
62064655|NCT03548116|EXPERIMENTAL|Group 3|Individuals will receive full-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
62064656|NCT03548116|SHAM_COMPARATOR|Group 4|Individuals will receive sham non-imaging mode ultrasound (control group) delivered to the lower, middle, and upper spleen based on the spleen's size.
62064657|NCT03548116|EXPERIMENTAL|Group 5|Individuals will receive half-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
62064658|NCT03548116|EXPERIMENTAL|Group 6|Individuals will receive full-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
62064659|NCT03548116|SHAM_COMPARATOR|Group 7|Individuals will receive sham non-imaging mode ultrasound with a disconnected probe (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
62269787|NCT06193590|EXPERIMENTAL|Carevix|suction cervical stabilizer utilized for intrauterine procedures
62269788|NCT06193590|ACTIVE_COMPARATOR|Tenaculum|standard of care cervical stabilization device
62452299|NCT00508170||Patients with Oropharyngeal Cancer|
62064660|NCT01336959|EXPERIMENTAL|Open Label - BCT197 Part A|10mg single dose of BCT197
62064661|NCT01336959|EXPERIMENTAL|BCT197 Part B|Single dose of 50mg BCT197
62064662|NCT01336959|PLACEBO_COMPARATOR|BCT 197 Placebo Part B|Single dose of matching placebo to 50mg BCT197
62064663|NCT01291316|EXPERIMENTAL|clobazam|
62064664|NCT01291316|ACTIVE_COMPARATOR|clonazepam|
62064665|NCT01291316|PLACEBO_COMPARATOR|tolterodine|
62064666|NCT05600725|EXPERIMENTAL|Pacing intervention|A novel atrial pacing approach will be delivered using the subject's already implanted pacemaker, ICD or BiV/ICD while the subject is in a semi-recumbent position and while hemodynamic and symptom data is collected. This will be repeated once daily, 3d/wk over 4 weeks.
62064667|NCT05600725|SHAM_COMPARATOR|Sham pacing|Subjects in this arm will be treated identically to the subjects in the pacing intervention arm but their already implanted pacemaker, ICD or BiV/ICD will have programming changes simulated but not actually implemented.
62064668|NCT03177889|SHAM_COMPARATOR|Usual treatment|oral mucolytics \[ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid\]
62064669|NCT03177889|ACTIVE_COMPARATOR|TCM treatment|"Traditional Chinese Medicine plus oral mucolytics (described above);~Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g"
62088173|NCT00415493|EXPERIMENTAL|Order 2|Warm-moist air provocation followed (on a separate day) by Cold-dry air provocation
62452300|NCT00508170||Patients with Non-Oropharyngeal Cancer|
62452301|NCT01729130||Group 1 Pancreas/kidney transplant|Group 1 of patients with End Stage Renal Disease (ESRD) and Diabetes Mellitis who will receive a pancreas and kidney transplant. An adipose tissue biopsy and blood samples are collected at time of transplant surgery. A repeat adipose tissue needle biopsy and blood samples are collected between 3-12 months post transplant.
62452302|NCT01729130||Group 2 DM with kidney transplant|Group 2 are patient with DM and ESRD and who will receive only a kidney transplant.
62452303|NCT01729130||Group 3 No DM and kidney transplant|Group 3 will be patients who do not have DM but do have the diagnosis of ESRD and will receive only a kidney transplant.
61978552|NCT02366845|EXPERIMENTAL|Algorithm Dosing|"Admitted University of Colorado Hospital or Denver Health bleeding patients with chronic liver disease determined to receive fresh frozen plasma (FFP) for clinical indications as determined by hospital clinician. This group will receive plasma doses based on the study dosing algorithm table.~A pre-transfusion INR (before transfusion) and a target post-transfusion INR (after transfusion) will be used to determine dose of FFP. The study table will reveal the dose in (ml/kg) of FFP to be transfused. INR measurements will be performed before (pre) and after (post) transfusion of plasma has been administered. Primary and secondary outcome measures will be collected. No other transfused blood component,crystalloid or colloidal fluid will be infused between the first and second INR studies except plasma."
62452304|NCT06237075|EXPERIMENTAL|tDCS stimulation|2-milliamp stimulation for 5\~15 min
62452305|NCT06424899|EXPERIMENTAL|neoadjuvant: adebrelimab combined with platinum-based chemotherapy|Adebrelimab 20mg/kg combined with platinum-based chemotherapy, q3w, MDT after 3 cycles, if the patient is suitable for surgery, surgery will be performed, and Adebrelimab adjuvant therapy will be performed for 35 cycles after surgery or until the disease recurrence or toxicity is difficult to tolerate as indicated by imaging; If the patient is not eligible for surgery after evaluation,, radical chemoradiotherapy will be performed, followed by Adebrelimab consolidation therapy for 35 cycles or until radiographically indicated disease recurrence or toxicity is difficult to tolerate.
62631084|NCT03973541|EXPERIMENTAL|Virtual Reality Exposure Therapy|VRET will include 360° videos with three scenarios a) riding a bus, b) going to a school cafeteria and c) a job interview. These scenarios were chosen based on clinical experience and frequently reported difficult situations in the literature . The order of the scenarios is jointly decided by the patient and therapist. In the videos the patients can make choices which determine the further course of the exposure scenario. For example, in the bus scenario the information system is out of order. Therefore, the patient has to ask the driver to announce, when they are at a particular stop. Depending on whether or not the patient decides to do so, the video will skip to one of two alternative continuations of the scenario. During the exposures the therapist will also motivate the patient towards acting in ways they consider unacceptable to provoke fear of ridicule, and make the patient act against him or her excessively rigid rules for social interaction to observe the consequences.
62631085|NCT03973541|ACTIVE_COMPARATOR|In Vivo Exposure Therapy|In vivo exposure consists of role-playing and guided exposure either inside or outside the therapist's office with active modelling from the therapist in early sessions. Staff members are called upon to conduct exposure. Similarly to the VRET during in vivo exposure the therapist will motivate the patient towards acting in ways they consider unacceptable.
62631086|NCT03973541|PLACEBO_COMPARATOR|Virtual Reality Relaxation Therapy|VR relaxation therapy will consist of a VR scenario of swimming with dolphins, created by the dolphin swim club (www.thedolphinswimclub.com). Swimming with real wild dolphins has been shown to have a positive effect on anxiety, although not specifically on SAD
62631087|NCT02196857|EXPERIMENTAL|Azacytidine + Sorafenib|Azacitidine 75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) daily for 7 days per 28 day cycle. Sorafenib administered orally at a dose of 400 mg twice daily every day continuously.
62631088|NCT03002545|PLACEBO_COMPARATOR|Placebo|identically tasting and looking Placebo
62631089|NCT03002545|ACTIVE_COMPARATOR|Magnesium|Supplementation with 400 mg Magnesium from Magnesium citrate once daily
62631090|NCT02038179|EXPERIMENTAL|Allopurinol, Then Placebo|Participants will be asked to take 4 weeks of allopurinol (300 mg oral per day), then will crossover (after 2-4 week washout period) and take placebo for an additional 4 weeks.
62653202|NCT02167672||Consumers|Women who have had a Hysterectomy in the previous 2 years
62653203|NCT02167672||Doctors|Obstetricians and Gynaecologists
62064670|NCT02322814|EXPERIMENTAL|Cohort I: Cobimetinib, Paclitaxel|Participants will receive a combination of cobimetinib plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
62452306|NCT06424899|ACTIVE_COMPARATOR|radical chemoradiotherapy and adebrelimab consolidation for 38 cycles|Consolidation therapy with adebrelimab , 20mg/kg, q3w, d1, was started within 1 to 42 days after radical chemoradiotherapy. The infusion time of adebrelimab was 60 minutes or more, and the treatment lasted for 38 consecutive cycles or until the disease recurred or the toxic reaction was difficult to tolerate as indicated by imaging.
62631091|NCT02038179|EXPERIMENTAL|Placebo, Then Allopurinol|Participants will be asked to take 4 weeks of placebo, then will crossover (after 2-4 week washout period) and take allopurinol (300 mg oral per day) for an additional 4 weeks.
62064671|NCT02322814|PLACEBO_COMPARATOR|Cohort I: Placebo, Paclitaxel|Participants will receive a combination of cobimetinib placebo plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
62064672|NCT02322814|EXPERIMENTAL|Cohort II:Cobimetinib,Paclitaxel,Atezolizumab|Participants will receive cobimetinib plus paclitaxel plus atezolizumab in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
62064673|NCT02322814|EXPERIMENTAL|Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab|Participants will receive cobimetinib plus nab-paclitaxel plus atezolizumab until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
62064674|NCT05707611|EXPERIMENTAL|Running|Running on treadmill in moderate intensity for 30 minutes
62064675|NCT05707611|EXPERIMENTAL|Cycling|Cycling on ergometer in moderate intensity for 30 minutes
62064676|NCT05707611|EXPERIMENTAL|Swimming|Swimming in moderate in tensity for 30 minutes
62631092|NCT03106883|EXPERIMENTAL|Affective training|"One happy and three sad faces selected from the NimStim Set of Facial Expressions~Five five-minute blocks separate by 90-second rest periods"
62064677|NCT01716143|OTHER|catheter ablation|
62064678|NCT03462134||Survey amongst orthopaedic surgeons|Selected of 20 patients from the Escape trial (NCT01850719)
62064679|NCT01069575|EXPERIMENTAL|URLC10-CDCA1-KIF20A 1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A\*2402-restricted URLC10 peptide (1mg), CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
62064680|NCT01069575|EXPERIMENTAL|URLC10-CDCA1-KIF20A 2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A\*2402-restricted URLC10 peptide (2mg), CDCA1 peptide (2mg) and KIF20A peptide(2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
62064681|NCT01069575|EXPERIMENTAL|URLC10-CDCA1-KIF20A 3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A\*2402-restricted URLC10 peptide (3mg), CDCA1 peptide (3mg) and KIF20A peptide(3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
62064682|NCT03133104||antenatal corticosteroids|Women who received a rescue dose of steroids
62064683|NCT03133104||No antenatal corticosteroids|Women who did not received a rescue dose of steroids
62064684|NCT05244811|PLACEBO_COMPARATOR|use of placebo in treatment of functional ovarian cyst|trial the effect of placebo in treatment of functional ovarian cyst
62064685|NCT05244811|ACTIVE_COMPARATOR|use of cocs in treatment of functional ovarian cyst|trial of the effectiveness of cocs in the treatment of functional ovarian cyst
62064686|NCT05244811|ACTIVE_COMPARATOR|use of progesterone in treatment of functional ovarian cyst|comparison between the effect of progesterone in the treatment of functional ovarian cyst with the effect of cocs
62064687|NCT01811979|ACTIVE_COMPARATOR|oral sucrose solution|local anesthetic eye drops (Alcaine 0.5% drop) and a pacifier, plus 0.5 cc/kg of 24% sucrose, to relieve pain associated with eye examinations for retinopathy of prematurity will be given
62064688|NCT01811979|PLACEBO_COMPARATOR|steril water|steril water 0,5 cc/kg plus topical anesthetics (Alcaine %0.5 damla) before eye examination will be given
62064689|NCT03579290|EXPERIMENTAL|CBT4CBT program|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:~Understanding and changing patterns of drug use, Coping with craving, Substance refusal skills, Seemingly irrelevant decisions, Planning for emergencies, and Problem-solving skills. Staying Safe"
62064690|NCT06104514|EXPERIMENTAL|Lift the upper lip and improve the peri-oral rhytids|
62064691|NCT05106114|EXPERIMENTAL|Intensive gait training rehabilitation protocole|"* Functional gait training~* Strengthening interventions~* High intensity interval training"
62064692|NCT05480670|EXPERIMENTAL|Berberine arm|Participants in this group will receive an oral 550 mg Berberine supplement tablet BDS for 3-months as an add-on to the changes in the diet/life-style for 3-months. The changes in the diet/life-style include limiting fat and carbohydrate intake and improve dietary behavior without the application of a calorie-restricted diet program. Exercise will also be recommended to include 30 min/day of moderate to intense activity.
62064693|NCT05480670|NO_INTERVENTION|Control arm|Participants in this group will undergo changes in their diet/life-style.
62064694|NCT05768724|EXPERIMENTAL|İntervention group|METAbolic Syndrome REduction in NAvarra (RESMENA) diet was applied to adolescents with PCOS
62452307|NCT00084084|EXPERIMENTAL|Agalsidase alfa (Cohort 1)|Cohort 1: Patients who completed TKT023.
62631093|NCT03106883|SHAM_COMPARATOR|Sham training|"Neutral, non-affective, non-social photos of objects (i.e., cars)~Five five-minute blocks separate by 90-second rest periods"
62631094|NCT06477081|ACTIVE_COMPARATOR|FemtoLASIK|For the FS-LASIK technique, the following steps will be followed: application of topical anesthesia to mitigate discomfort and pain throughout the procedure, and the patient will be covered with a sterile drape. Subsequently, the patient will be aligned to artificially flatten the entire corneal surface, ensuring head stability with a slight tilt to optimize surgical access and avoid nasal interference. The femtosecond laser system use will be the ATOS operating system (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), which is responsible for creating a corneal incision to create the flap, with controlled precision to ensure proper separation of corneal layers. The excimer laser will be the Amaris (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), responsible for performing refractive correction on the cornea through selective photoablation. Following photoablation, the flap will be carefully repositioned, and upon completion
62631095|NCT06477081|ACTIVE_COMPARATOR|Keratorefractive lenticule extraction|For the KLEx technique, the following steps will be followed: after topical anesthesia, a sterile drape is placed over the patient, and a speculum is inserted into the eye, centered, and aligned with a curved interface cone before applying suction. The laser used will be the ATOS operating system (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), which performs photo-dissection starting from the posterior surface of the refractive lenticule, followed by the creation of the lenticule edge. The anterior surface of the refractive lenticule is formed by extending beyond the posterior diameter of the lenticule by 0.5 mm to form the anterior flap, followed by a peripheral cut. Specific FS laser parameters are employed for each patient. Subsequently, the suction is released, and a Siebel spatula is used to separate and reflect the flap. Finally, the refractive lenticule is extracted using toothless forceps through the small incision. Once the procedure is complet
62631096|NCT00558012|EXPERIMENTAL|Active Medication Group|One-time dose: Intravenous Zoledronic Acid 5.0 mg; Vitamin D (800 IU/daily); Calcium 1200 mg/daily (supplement plus diet)
62631097|NCT00558012|PLACEBO_COMPARATOR|Placebo|One-time dose: intravenous saline; Vitamin D (800 IU/daily); 1200 mg calcium (supplement plus diet)
62631098|NCT05677425|EXPERIMENTAL|Temperature measurement group|Temperature measurement in the renal pelvis during ureteroscopic laser stone disintegration. Temperature measurement will be performed using different laser power settings.
62631099|NCT04307862|EXPERIMENTAL|ZEP-3Na 0.1%|The ZEP-3Na 0.1% cream will be applied topically twice daily
62631100|NCT04307862|EXPERIMENTAL|ZEP-3Na 1%|The ZEP-3Na 1% cream will be applied topically twice daily
62631101|NCT04307862|PLACEBO_COMPARATOR|Vehicle Control|The Vehicle Control cream will be applied topically twice daily
62064695|NCT05768724|EXPERIMENTAL|conrol group|American Heart Association (AHA) guidelines based diet was applied to adolescents with PCOS
62064696|NCT01622543|ACTIVE_COMPARATOR|Folfox plus Bevacizumab and Reolysin|
62631102|NCT04403555|EXPERIMENTAL|Ivermectin|Ivermectin plus standard of care treatment Dose 2 tablets 12mg per day for 3 days
62631103|NCT04403555|NO_INTERVENTION|Standard of care|Standard of care treatment
62452308|NCT00084084|EXPERIMENTAL|Agalsidase Alfa (Cohort 2)|Cohort 2: Treatment-naive patients.
62631104|NCT03953521|EXPERIMENTAL|navigated|Positioning of the coil according to neuronavigation (Mylius et al., 2013, Definition of DLPFC and M1 according to anatomical landmarks for navigated brain stimulation: Inter-rater reliability, accuracy, and influence of gender and Age, NeuroImage 78, 224-232).
62064697|NCT01622543|ACTIVE_COMPARATOR|Folfox plus Bevacizumab|
62064698|NCT02601937|EXPERIMENTAL|Dose Escalation Level 1|"Pediatric patients with select R/R rhabdoid tumors, INI1- SMARCA4-negative tumors, or synovial sarcoma who participated in the dose escalation portion of the study.~Participants received 240 mg/m\^2, open-label, oral tazemetostat twice daily (BID) in continuous 28-day cycles"
62452309|NCT02743702|EXPERIMENTAL|GROUP RECEIVING RESPIRATORY PHYSIOTHERAPY|Respiratory Physiotherapy sessions were held once a week by the physiotherapist, and four times more for the family at home, for one year. The sessions have a duration between 30 and 45 minutes, varying according to the level of patient cooperation. The exercise program should be repeated in three cycles, although younger children took longer than older in performing them.
62452310|NCT02743702|EXPERIMENTAL|GROUP RECEIVING THEIR USUAL THERAPIES|This group received no approach of their respiratory difficulties by Physiotherapy. Only continued their usual therapies.
62631105|NCT03953521|ACTIVE_COMPARATOR|F3|Positioning of the coil according to EEG (electroencephalography) electrode Position F3 (marking this Position on a head cap).
62631106|NCT04659863|EXPERIMENTAL|Inclisiran|Year 1 - inclisiran sodium 300 mg subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 450 and 630)
62064699|NCT02601937|EXPERIMENTAL|Dose Escalation Level 2|"Pediatric patients with select R/R rhabdoid tumors, INI1- SMARCA4-negative tumors, or synovial sarcoma who participated in the dose escalation portion of the study.~Participants received 300 mg/m\^2, open-label, oral tazemetostat twice daily (BID) in continuous 28-day cycles"
62064700|NCT02601937|EXPERIMENTAL|Dose Escalation Level 3|"Pediatric patients with select R/R rhabdoid tumors, INI1- SMARCA4-negative tumors, or synovial sarcoma who participated in the dose escalation portion of the study.~Participants received 400 mg/m\^2, open-label, oral tazemetostat twice daily (BID) in continuous 28-day cycles"
62064701|NCT02601937|EXPERIMENTAL|Dose Escalation Level 4|"Pediatric patients with select R/R rhabdoid tumors, INI1- SMARCA4-negative tumors, or synovial sarcoma who participated in the dose escalation portion of the study.~Participants received 520 mg/m\^2, open-label, oral tazemetostat twice daily (BID) in continuous 28-day cycles"
62064702|NCT02601937|EXPERIMENTAL|Dose Escalation Level 5|"Pediatric patients with select R/R rhabdoid tumors, INI1- SMARCA4-negative tumors, or synovial sarcoma who participated in the dose escalation portion of the study.~Participants received 700 mg/m\^2, open-label, oral tazemetostat twice daily (BID) in continuous 28-day cycles"
62064703|NCT02601937|EXPERIMENTAL|Dose Escalation Level 6|"Pediatric patients with select R/R rhabdoid tumors, INI1- SMARCA4-negative tumors, or synovial sarcoma who participated in the dose escalation portion of the study.~Participants received 900 mg/m\^2, open-label, oral tazemetostat twice daily (BID) in continuous 28-day cycles"
62064704|NCT02601937|EXPERIMENTAL|Dose Escalation Level 7|"Pediatric patients with select R/R rhabdoid tumors, INI1- SMARCA4-negative tumors, or synovial sarcoma who participated in the dose escalation portion of the study.~Participants received 1200 mg/m\^2, open-label, oral tazemetostat twice daily (BID) in continuous 28-day cycles"
62064705|NCT02601937|EXPERIMENTAL|Dose Expansion Cohort 1|"Pediatric patients with atypical teratoid rhabdoid tumor (ATRT) who participated in the dose expansion portion of the study.~Patients received 1200 mg/m\^2 open-label, tazemetostat BID orally in continuous 28-day cycles."
62064706|NCT02601937|EXPERIMENTAL|Dose Expansion Cohort 2|"Pediatric patients with malignant rhabdoid tumor (MRT)/ rhabdoid tumor of kidney (RTK)/select tumors with rhabdoid features who participated in the dose expansion portion of the study~Patients whose disease was without central nervous system (CNS) involvement received 520 mg/m\^2 open-label, tazemetostat BID orally in continuous 28-day cycles. Patients whose disease had CNS involvement received 1200 mg/m\^2 open-label, tazemetostat BID orally in continuous 28-day cycles."
62631107|NCT04659863|PLACEBO_COMPARATOR|Placebo|Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 360, 450, and 630)
62631108|NCT05128266||Endodontical Retreatment|non-surgical retreatment of teeth with broken file instrument into the canal using ultrasounds, microscope and a modified spinal needle
62631109|NCT01967004|EXPERIMENTAL|Functional Assessment|Participant will be asked to perform a series of tasks involving their prosthesis. These tasks can involve switching grips as well as moving objects.
62631110|NCT05737901|NO_INTERVENTION|Standard care group|The standard discharge training of the clinic was carried out in the patient's room on the day of discharge in an average of 5 minutes, in the form of verbally explaining the information deemed important by the physician and/or nurse to the patient. No intervention was made in this group.
62064707|NCT02601937|EXPERIMENTAL|Dose Expansion Cohort 3|"Pediatric patients with INI-negative tumors who participated in the dose expansion portion of the study.~Patients whose disease was without central nervous system (CNS) involvement received 520 mg/m\^2 open-label, tazemetostat BID orally in continuous 28-day cycles. Patients whose disease had CNS involvement received 1200 mg/m\^2 open-label, tazemetostat BID orally in continuous 28-day cycles."
62064708|NCT02601937|EXPERIMENTAL|Dose Expansion Cohort 4|"Pediatric patients with one of the tumor types defined in Cohorts 1 through 3 or synovial sarcoma with SS18-SSX rearrangement.~Patients received 800 mg/m\^2 tazemetostat three times daily (TID) orally in continuous 28-day cycles."
62064709|NCT04374396|SHAM_COMPARATOR|Group 1|patients in this group will receive sham ipsilateral ultrasound-guided single shot erector spinae block at L2 after induction of anaesthesia and before the start of surgery without injection of local anesthetics
62064710|NCT04374396|EXPERIMENTAL|Group 2|patients in this group will receive real ipsilateral ultrasound-guided single shot erector spinae block at L2 after induction of anaesthesia and before the start of surgery with injection of 0.3 ml/kg of 0.25% of plain bupivacaine.
62064711|NCT04764292|EXPERIMENTAL|Contrast-enhanced mammography|Women who meet criteria for supplemental screening MRI, but who are unable to have MRI for medical/access/cost reasons, will be invited to have screening with contrast-enhanced mammography. Women will also have standard-of-care mammography/tomosynthesis per usual clinical practice.
62064712|NCT04318730|EXPERIMENTAL|Arm 1|
62064713|NCT06002191|EXPERIMENTAL|Flourish + Questionnaires|Participants will be onboarded to Flourish by a research study clinician, following which they will receive a text messaging program for 4 weeks as well as an accompanying resources website. As part of the text messaging program, participants will receive brief questionnaires evaluating their online experiences once every 3 days.
62064714|NCT06002191|ACTIVE_COMPARATOR|Questionnaires Alone|Participants will be onboarded to a text message program that solely will send participants brief questionnaires evaluating their online experiences once every 3 days.
62064715|NCT03503539|EXPERIMENTAL|Mini percutaneous nephrolithotomy|All operations were performed or supervised by the same surgeon. Right after the patients in mini-PNL group were placed a 5F ureteral catheter with general anesthesia, they were had a prone position and the access was performed by choosing the optimal calyx to reach the stone following the contrast agent was given. The guide wire was then placed and the stones were broken with a laser lithotripter using a 12F nephroscope (Modular minimally invasive PCNL system, Karl Storz, Tuttlingen, Germany) following the dilatation using an one step dilator with a 16.5F access sheath. When necessary, stones were removed using the stone removal forceps. Right after a 14-Fr nephrostomy tube was inserted and an antegrade pyelography was taken, the operation was terminated.
62064716|NCT03503539|ACTIVE_COMPARATOR|Retrograde intrarenal surgery|Following the general anesthesia performed, a safety guide wire was placed and semirigid ureteroscopy (9.5 / 11.5F) was performed. Stones were fragmented using a 270 micron meter laser fiber with the help of 7.5-F fiber optic flexible ureterorenoscope after the placement of ureteral access sheat (9.5 / 11.5 F). Stone fragmentation was accomplished using a laser energy of 0.5-1.5 J and a rate of 5-15 Hz and adjusting this range according to stone hardness. 4.7F JJ stent was routinely placed at the end of the operation because of worries about possible edema etc. due to access sheath. In this group, access sheath could not be placed in 2 patients due to the small diameter of the ureter, and JJ stent was placed, and 2 weeks later, the procedure was performed as it was in the others.
62064717|NCT04100512|ACTIVE_COMPARATOR|Incentive spirometry|Each patient will be instructed on how to use the respiratory therapy device, either IS or OPEP, by research personnel and respiratory therapists. Participants will be instructed to record their compliance with the RT protocol in their respective patient diaries. Patient diaries will be collected upon discharge for analysis.
62064718|NCT04100512|EXPERIMENTAL|Oscillating Positive Expiratory Pressure Device|Each patient will be instructed on how to use the respiratory therapy device, either IS or OPEP, by research personnel and respiratory therapists. Participants will be instructed to record their compliance with the RT protocol in their respective patient diaries. Patient diaries will be collected upon discharge for analysis.
61978553|NCT05587205|EXPERIMENTAL|Treatment at time of surgery|EO2002 intracameral injection
61978554|NCT05587205|EXPERIMENTAL|Treatment post surgery|EO2002 intracameral injection
61978555|NCT05587205|ACTIVE_COMPARATOR|Treatment at time of or post surgery|EO2002 intracameral injection
62064719|NCT01616875|EXPERIMENTAL|Cabazitaxel + Cisplatin chemotherapy|Cabazitaxel 15mg/m2 Intravenous (IV)followed by Cisplatin 70mg/m2 IV on day 1 of each 21 day cycle for 4 cycles
62064720|NCT00439829|EXPERIMENTAL|1|Initiation of ovarian stimulation therapy on day 1 (i.e., first day of menses)
62064721|NCT00439829|ACTIVE_COMPARATOR|2|Initiation of ovarian stimulation therapy on day 4 (day 1= first day of menses)
62064722|NCT04953338||Cases|Patients with a confirmed diagnosis of Vitiligo within the study period will be included as cases for analysis.
62064723|NCT04953338||Controls|The controls will be defined by matching cases with people who have never been diagnosed with vitiligo either prior to or during the study period, by age and sex, at General Practice level.
62064724|NCT00054925|ACTIVE_COMPARATOR|Personal contact (PC)|The Personal Contact (PC) intervention offers one-on-one guidance and support in maintaining weight loss.
62064725|NCT00054925|ACTIVE_COMPARATOR|Interactive technology (IT)|Utilizes internet and automated phone technology to enhance the frequency and timeliness of feedback.
62064726|NCT03179813|EXPERIMENTAL|Hydrocortisone group|Intraoperative topical use of hydrocortisone as a irrigation solution in third molar surgery.
62064727|NCT03179813|PLACEBO_COMPARATOR|Control Group|Intraoperative irrigation with saline solution.
62064728|NCT02640391||Quiescent UC|Patients with quiscent UC who will undergo colonoscopy for surveillance or mucosal healing check up
62064729|NCT04204213||8 Section Brocade Tai Chi Therapy|Subject participants with end stage osteoarthritis knee were enrolled into a customised multidisciplinary education program that consisted of one hour healthcare education seminars followed by another hour of 8 Section Brocade (Baduanjin) sitting Tai Chi classes for 4 consecutive weeks.
62064730|NCT06273358||Over 45 year old|"Before surgery All preoperative patients will have Preoperative Stop Bang, Pittsburghb Sleep Quality Index, and Mini Mental tests for sleep quality and consciousness monitoring. This will be based on sleep the day before surgery and mini-mental exams before surgery.~The intraoperative phase Our clinical approach is to admit patients under general anesthesia after regular assessment and monitoring. The following parameters will be recorded intraoperatively.~After surgery As usual, patients are brought to the PACU after awakening. It will be measured Pittsburghb Sleep Quality Index on 3 days, QoR-15 on the last day, and 3D CAM or ICU-CAM for 3 days postoperatively. Patients will stay in the ward and intensive care unit for 72 hours and be called for 72 hours after release."
62064731|NCT06273358||Over 65 year old|"Before surgery All preoperative patients will have Preoperative Stop Bang, Pittsburghb Sleep Quality Index, and Mini Mental tests for sleep quality and consciousness monitoring. This will be based on sleep the day before surgery and mini-mental exams before surgery.~The intraoperative phase Our clinical approach is to admit patients under general anesthesia after regular assessment and monitoring. The following parameters will be recorded intraoperatively.~After surgery As usual, patients are brought to the PACU after awakening. It will be measured Pittsburghb Sleep Quality Index on 3 days, QoR-15 on the last day, and 3D CAM or ICU-CAM for 3 days postoperatively. Patients will stay in the ward and intensive care unit for 72 hours and be called for 72 hours after release."
62064732|NCT04045210|NO_INTERVENTION|No Intervention|
62064733|NCT04045210|EXPERIMENTAL|Doula|
62064734|NCT06320925||Study Subjects|Patients who have undergone a surgical procedure (per product indications for use) using the Stryker implants who meet all of the following criteria will be screened and enrolled by participating Investigators.
62064735|NCT03881319|ACTIVE_COMPARATOR|Conventional Gynecologic Treatment group|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
62064736|NCT03881319|EXPERIMENTAL|Low dose acupuncture group|Acupuncture has fewer acupuncture points.
62064737|NCT03881319|EXPERIMENTAL|High dose acupuncture group|Acupuncture has more acupuncture points.
62269789|NCT05207007||posterior polar cataracts|"Phacomulsification lens removal cataract surgery with Intraocular lens(IOL) implantation were performed in these patients.~Drug: Subconjunctival dexamethasone and general anesthesia All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia."
62269790|NCT05207007||posterior lenticonus|"Phacomulsification lens removal cataract surgery with Intraocular lens(IOL) implantation were performed in these patients.~Drug: Subconjunctival dexamethasone and general anesthesia All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia."
62269791|NCT05409261|EXPERIMENTAL|Ad26.COV2.S|Single dose (0.5mL) of SARS-CoV-2 vaccine Ad26.COV2.S.
62269792|NCT02436876|EXPERIMENTAL|Cohort 1|Single, intra-wound local administration of MBN-101; dosage = 0.5 µg/cm2; randomized 3:1 with placebo
62269793|NCT02436876|EXPERIMENTAL|Cohort 2|Single, intra-wound local administration of MBN-101; dosage = 1.5 µg/cm2; randomized 3:1 with placebo
62269794|NCT02436876|EXPERIMENTAL|Cohort 3|Single, intra-wound local administration of MBN-101; dosage = 5.0 µg/cm2; randomized 3:1 with placebo
62269795|NCT04315519|EXPERIMENTAL|Blood Flow Restricted Aerobic (BFRA)|Low intensity Aerobic exercise with Blood Flow Restriction
62269796|NCT04315519|EXPERIMENTAL|Moderate Aerobic Exercise (MAE)|moderate intensity aerobic exercise
62452311|NCT02281578|EXPERIMENTAL|Combination prevention|Community-based, combination HIV prevention intervention package
62064738|NCT06624917|EXPERIMENTAL|Green Breast Surgery|"Preoperative assessment:~Counsel patients before admission.~* Encourage 1 month of no alcohol and smoking before surgery.~* Recommend weight loss for BMI \> 30 with exercise.~Operative assessment:~* Admit to Day Surgery Unit.~* Allow clear liquids until 2 hours before surgery.~* Give maltodextrin 2 hours prior to surgery.~* Prescribe antibiotic prophylaxis if needed.~* Prescribe post-op anti-nausea/vomiting medication.~* Use Awake Breast Surgery Protocol with Peripheral Nerve Blocks (ESP or PECS1).~* Follow Intercollage Green Theatre checklist.~* Post-operative assessment:~Apply personalized DVT prophylaxis.~* Allow food and water shortly after surgery.~* Encourage mobilization a few hours post-surgery.~* Use telemedicine for first follow-ups and later as needed.~* Scheduled Time Frame pain (NRS scale) and quality of life (PSQ-18, SF-36, QoL, Breast-Q, TSQ-WT) assessment~* Check for complications 30 days after surgery."
62064739|NCT06624917|NO_INTERVENTION|Conventional Surgery|"Preoperative assessment:~Counsel patients before admission.~* Encourage 1 month of no alcohol and smoking before surgery.~* Recommend weight loss for BMI \> 30 with exercise.~Operative assessment:~* Admit to surgical unit according to the surgeon preference~* Allow clear liquids until 2 hours before surgery.~* Give maltodextrin 2 hours prior to surgery.~* Prescribe antibiotic prophylaxis if needed.~* Prescribe post-op anti-nausea/vomiting medication.~* Intraoperative management according to Surgeon and Anesthesiologist~Post-operative assessment:~* Apply personalized DVT prophylaxis.~* Allow food and water shortly after surgery.~* Encourage mobilization according to the intraoperative managment.~* Use telemedicine for first follow-ups and later as needed.~* Scheduled Time Frame pain (NRS scale) and quality of life (PSQ-18, SF-36, QoL, Breast-Q, TSQ-WT) assessment~* Check for complications 30 days after surgery."
62064740|NCT06134323|EXPERIMENTAL|medication-combined transcutaneous vagus nerve stimulation|Participants will receive anti-anxiety medication and transcutaneous vagus nerve stimulation
62064741|NCT06134323|PLACEBO_COMPARATOR|medication-combined sham stimulation group|Participants will receive anti-anxiety medication and sham stimulation
62269797|NCT00820898|EXPERIMENTAL|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62269798|NCT02065752|EXPERIMENTAL|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 100 mg, and 2 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
62269799|NCT02065752|EXPERIMENTAL|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
62452312|NCT02281578|ACTIVE_COMPARATOR|Standard of care|Locally run standard of care HIV prevention, treatment and care services
62631111|NCT05737901|EXPERIMENTAL|Education Booklet Group|Discharge training was given by the researcher the day before the surgery in an average of 60 minutes in the meeting room of the clinic through the booklet.
62269800|NCT02065752|EXPERIMENTAL|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
61978556|NCT05587205|SHAM_COMPARATOR|Sham injection at time of or post surgery|Sham injection
62269801|NCT04210609|EXPERIMENTAL|VHT treatment|Patients will be treated with VHT for 55 minutes at a minimum frequency of 2 times per week
62269802|NCT05733871|EXPERIMENTAL|Active group|Participants use the innovative line of products intended for body weight reduction, that represent a meal replacement for weight management
62452313|NCT02553369||Enrolled patients|Patient randomly enrolled in the study within a cohort of patient followed for HIV infection.
62452314|NCT04365751|EXPERIMENTAL|Percutaneous microwave ablation group|MWA (Microwave) is an ultrasound-guided, minimally invasive technique that implants ablation electrodes into target tissue to rapidly generate high temperatures and rapidly develop coagulative necrosis in tumor tissue, thereby achieving the goal of local tumor treatment.
62631112|NCT05737901|EXPERIMENTAL|Mobile Application Group|The mobile application was introduced to the patient by the researcher the day before the surgery. During the presentation phase, the patient was informed about the titles and contents of the training videos, and after explaining the technical features related to turning the tablet on and off, raising and lowering the volume, logging into the account using the username and password for training, using the buttons on the main screen and the keyboard, the patient was asked to apply them. All these stages took an average of 20 minutes. In addition, information about logging in, such as how to switch on and off the device, the patient's user name and password, were added to the back of the tablet in writing.
62631113|NCT04761757|ACTIVE_COMPARATOR|Control Arm|
62269803|NCT05733871|ACTIVE_COMPARATOR|Active control|Participants use the standard line of products intended for weight reduction that represent a meal replacement for weight management with already proven clinical effectiveness (positive control).
62269804|NCT05733871|NO_INTERVENTION|Control group|Participants receive personalized advice on proper nutrition for a reduction diet in which they use common food.
62452315|NCT04365751|OTHER|Laparoscopic hepatectomy|Laparoscopic hepatectomy is a widely used surgical technique in the treatment of benign (malignant) liver diseases
62269805|NCT05301946||Stroke patients|The created-ICF Core Set for Stroke including activitiy, participation, and environmental factors was used show the meaningfulness of the clinical outcome measurements. The correlation of the created-ICF Core Set for Stroke's items and the outcome measurements were analyzed through Spearman or Pearson correlation analysis.
62269806|NCT00425386|EXPERIMENTAL|Erlotinib and Sunitinib|"Drug: erlotinib hydrochloride Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;~1. 100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;~2. 150 mg/day, continuous daily~Drug: sunitinib malate Will be administered at 50 mg daily, 4 weeks on, 2 weeks off"
62452316|NCT02030184|EXPERIMENTAL|Topotecan and Rhenium Re 188 P2045|In the phase II portion of this study, patients will be screened using Technicium Tc99m. Eligible, consented patients will receive Topotecan treatment for three days, at doses of either 1.0 mg/m2 or 1.5 mg/m2. They will then receive a single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
62452317|NCT04464135|EXPERIMENTAL|WE+AA group|Water containing 1% of AA was used during insertion of colonoscopy using water exchange method.
62452318|NCT04464135|ACTIVE_COMPARATOR|WE group|Water exchange colonoscopy was used for standard screening or surveillance colonoscopy.
62452319|NCT05658887|PLACEBO_COMPARATOR|Placebo|Preoperative tylenol, preoperative celecoxib, preoperative gabapentin placebo
62452320|NCT05658887|EXPERIMENTAL|Intervention|Preoperative tylenol, preoperative celecoxib, preoperative gabapentin
62452321|NCT04322071||Lower risk of long term complications|Young people with diabetes who have HbA1c \<58mmols/mol, and family members.
62631114|NCT04761757|ACTIVE_COMPARATOR|Intervention Arm|
62631115|NCT06412848||Urothelial Carcinoma Cohort|This is a single cohort study enrolling Participants with Urothelial Carcinoma (UC), who are prescribed treatment with avelumab as first line maintenance therapy after a platinum-based chemotherapy (PBCT).
62269807|NCT00971945|EXPERIMENTAL|Paclitaxel|
62452322|NCT04322071||Higher risk of long term complications|Young people with diabetes who have HbA1c ≥75mmols/mol and \<100mmols/mol, and family members.
62631116|NCT02342392|ACTIVE_COMPARATOR|treatment group|intralesional ranibizumab injected
62631117|NCT02342392|NO_INTERVENTION|control group|no intralesional ranibizumab injected.
62631118|NCT00640939|ACTIVE_COMPARATOR|A|Topical diclofenac sodium patch
62452323|NCT04496635|NO_INTERVENTION|Baseline phase|Patients included in the VINCat program, and operated on colorectal surgery between 2007 and 2015 in Catalonia
62631119|NCT00640939|PLACEBO_COMPARATOR|B|Topical patch identical in appearance to active comparator
62452324|NCT04496635|EXPERIMENTAL|Implementation phase|Patients included in the VINCat program, and operated on colorectal surgery between 2016 and 2018 in Catalonia
62452325|NCT01471483||patient will receive a phone call from nurse|The proposed study will be a prospective longitudinal feasibility study of 50 older adults with a recent diagnosis of stage II, III or IV ovarian cancer who will receive standard first line chemotherapy and surgery over approximately a six-month period. Half of the 50 patients receive a weekly telephone call from geriatric nurse practitioner (NP); the remaining 25 patients would receive standard oncology care alone (randomization).
62452326|NCT01471483||patients will not receive a phone call from nurse|The proposed study will be a prospective longitudinal feasibility study of 50 older adults with a recent diagnosis of stage II, III or IV ovarian cancer who will receive standard first line chemotherapy and surgery over approximately a six-month period. Half of the 50 patients receive a weekly telephone call from geriatric nurse practitioner (NP); the remaining 25 patients would receive standard oncology care alone (randomization).
62631120|NCT01675492|EXPERIMENTAL|wave-front guided LASIK|
62269808|NCT05360056|EXPERIMENTAL|Dexcom CGM|
62631121|NCT05714540|PLACEBO_COMPARATOR|Control group|The patients will receive 20 ml 0.9% saline soaked pharyngeal pack inserted in the posterior pharyngeal wall after induction of anesthesia and endotracheal intubation .
62631122|NCT05714540|ACTIVE_COMPARATOR|ketamine group|The patients will receive ketamine soaked 50 mg ketamine in 20 ml normal saline soaked pharyngeal pack inserted in the posterior pharyngeal wall after induction of anesthesia and ETT insertion
62631123|NCT05714540|ACTIVE_COMPARATOR|Magnesium group|The patients will receive 20 mg/kg magnesium sulfate soaked pharyngeal pack inserted in the posterior pharyngeal wall after induction of anesthesia and ETT
62631124|NCT05171114|EXPERIMENTA